id|nct_id|intervention_type|name|description
215031605|NCT03830437|OTHER|Evaluation of newborn stress|Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.
215031606|NCT03830437|OTHER|Evaluation of body weight trend|Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life
215031607|NCT03769350|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
215031608|NCT02882347|DRUG|Somatostatin|
215031609|NCT04596722|DIETARY_SUPPLEMENT|Pomella|"Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts"
215031610|NCT04596722|OTHER|Placebo|"White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts"
215031611|NCT05725031|DRUG|Ephedrine|70 μg/kg as pretreatment
215031612|NCT05725031|DRUG|Rocuronium 0.6|0.6 mg/kg
215031613|NCT05725031|DRUG|Rocuronium 0.8|0.8 mg/kg
215031614|NCT05725031|DRUG|Rocuronium 1.2|1.2 mg/kg
215031615|NCT06263816|DRUG|Experimental group: Patients will be treated with carvedilol.|Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.
215031616|NCT06263816|OTHER|Control group: Patients will receive a placebo.|Patients will receive the number of pills of placebo corresponding to the dose determined during the titration period (either one pill in the morning or 1 pill twice a day: 1 in the morning and 1 in the evening).
215031617|NCT03525262|RADIATION|30Gy (Gray) planning target volume (PTV)|PTV1\_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
215031618|NCT05634174|DRUG|Mirabegron|Single dose, 100mg oral mirabegron
215031619|NCT04030650|OTHER|Functional analyses|2-minute walking test 200-metre walking test
215031620|NCT04030650|OTHER|3D analysis of walking and balance|Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb
215031621|NCT04030650|OTHER|Functional analyses|400-metre walking test 200-metre walking test
215031622|NCT06004232|BEHAVIORAL|Prenatal Yoga to Prevent Postpartum Depression (PRY-D) intervention|The PRY-D curriculum is a mindfulness-based prenatal yoga intervention which utilizes techniques to build both embodiment and mindfulness, and has previously been shown to reduce depression in a small sample of pregnant women with clinical depression.
215031623|NCT06004232|BEHAVIORAL|Treatment as Usual (TAU)|TAU involves routine prenatal care, during which time all patients are given information on the importance of physical activity during pregnancy.
215031624|NCT01697371|RADIATION|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
215031625|NCT01697371|RADIATION|Proton Radiation|
215031626|NCT04551495|DRUG|Entrectinib|Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles
214281058|NCT02342327|OTHER|switch to non-menthol cigarettes prior to cessation attempt|
214281059|NCT02342327|OTHER|continue smoking menthol cigarettes prior to cessation attempt|
214469573|NCT04141371|DRUG|Molar Sodium Lactate|daily 3-hour infusion of sodium molar lactate during the vasospasm period
214469574|NCT04141371|DRUG|physiological serum|daily saline infusion over 3 hours during the vasospasm period
214469575|NCT06214559|DEVICE|Sérum VERRUPRO|To be applied twice a day
215031627|NCT04551495|DRUG|Letrozole|Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles
215031628|NCT04551495|DRUG|Goserelin|Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
215031629|NCT03514368|OTHER|Patients treated with immune checkpoint blockade|"Tumor biopsy specimens and blood samples will be collected at different time points:~* Baseline~* before the 3rd ICB administration (blood samples only)~* before the 5th ICB administration (blood samples only)~* at the time of treatment permanent discontinuation (blood samples only)~* at the time of progression (tumor biopsy specimens only)~* after the last dose of ICB treatment (blood samples only taken twice per year until study termination)"
215031630|NCT04472117|OTHER|usual care|Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.
215031631|NCT04472117|OTHER|Educational video|Watch an educational video created by the research team and.will also complete the post-video survey. Those randomized to view the video must complete the post-video survey (Appendix 3), and all patients must complete the Post-Op Survey with the Patient Experience and Decision Regret Scale (Appendix 5) to be evaluable. If not completed, they will be replaced.
215031632|NCT05894629|BEHAVIORAL|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|12-week program consisting of PNE and TE
215031633|NCT05894629|BEHAVIORAL|Active Comparator: Usual treatment|12-week program consisting of home exercises, performed 3 days/week.
215057133|NCT03171519|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
215057134|NCT03171519|BEHAVIORAL|Acupuncture|The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
215057135|NCT02841683|BEHAVIORAL|Tabac Info Service|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
214281060|NCT00758212|BIOLOGICAL|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
214281061|NCT03053193|DIAGNOSTIC_TEST|MammaPrint, BluePrint, and Full-Genome Testing|Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
214281062|NCT06361342|BEHAVIORAL|General decrease in smartphone use|Subjects will decrease their time on smartphone in general.
214281063|NCT06361342|BEHAVIORAL|Avoiding Social Media Apps|Subjects will avoid use of social media apps on the smartphone which includes Twitter, Facebook, Tik Tok, Instagram, and Pinterest.
214281064|NCT03355521|OTHER|Nordic Walking|Nordic walking Training the total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
214281065|NCT03355521|OTHER|Free Walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
214281066|NCT03985631|OTHER|Rehabilitation intervention|Rehabilitation sessions based on Tai Chi through telerehabilitation
214281067|NCT01114425|DRUG|raltegravir (Isentress)|raltegravir (Isentress) 400 mg bid
214281068|NCT01114425|DRUG|Truvada®|
215031634|NCT05109325|BEHAVIORAL|IntERact|The IntERact intervention includes: (1) three remotely delivered Health Coach therapist sessions that integrate behavioral therapy (motivational interviewing \[MI\] + cognitive behavioral therapy \[CBT\] and strengths-based care management (CM); as well as, (2) an APP supporting and enhancing the therapist intervention by: (a) conducting automated daily assessments; (b) delivering daily MI/CBT messages tailored by the daily surveys; (c) delivering GPS-enabled alert notifications and immediate one-touch pro-social support; (d) providing access to reminders regarding goals/strengths from the ED session, CBT tools/skills (e.g., infographics, coping strategies, harm reduction strategies), and other psychoeducation (e.g., safe storage); (e) facilitating one-touch contact with pro-social support, including the health coach and others; (f) providing easy linkage to care management resources (web links, phone numbers, contact information).
214281069|NCT06243991|DEVICE|in vivo Corneal Confocal Microscopy|CCM was performed using the Heidelberg Retinal Tomograph 3 with the Rostock Cornea Module (HRT3-RCM, Heidelberg Engineering GmbH, Germany) under topical anesthesia. A viscous gel (Viscotears, Novartis Pharmaceuticals UK) served as a coupling agent between the cornea and the applanation cap. The subjects were instructed to focus on the fixation light with the unexamined eye to ensure proper positioning. Five high-quality images of the SNP were selected and analyzed using the automated tracing of nerve fibers program (ACCMetrics, M.A. Dabbah, Imaging Science and Biomedical Engineering, Manchester, England).
214281070|NCT06243991|DIAGNOSTIC_TEST|Corneal Sensitivity|Corneal sensitivity was evaluated using a Cochet-Bonnet esthesiometer (Luneau Ophtalmologue, Chartres, France), comprising a nylon filament measuring 60 mm in length and 0.12 mm in diameter. Participants were instructed to maintain a forward gaze while the esthesiometer gently made perpendicular contact. The procedure involved gradually decreasing the filament length in 5 mm increments, starting from 60 mm, until the initial response from the subject was detected.
214469576|NCT06128655|OTHER|Participation in PFCC-IR|PFCC-IR with the critical care team is standard practice in ICU but it doesn't usually include family members. The intervention for this study is interdisciplinary patient care rounds that include one family member of the patient.
215031635|NCT06429930|DRUG|L608 Liposomal inhalation solution|Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
215031636|NCT06429930|DRUG|Placebo Solution|Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
215031637|NCT05125172|OTHER|Focus of Attention|Focus of attention instruction and feedback. Focus of attention refers to what people are thinking about during motor tasks. An external focus refers to thinking about an outside outcome or target. An internal focus of attention refers to thinking about how someone is moving their body.
215031638|NCT03977155|DRUG|BOS-589|oral tablets
215031639|NCT03977155|DRUG|Placebo|oral tablets
215031640|NCT04531579|DRUG|Valproic Acid Solution|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
215031641|NCT04531579|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
215031642|NCT00936936|DRUG|Gemcitabine|1800 mg/m\^2 IV over 3 hours on Days -5 to Day -2.
215031643|NCT00936936|DRUG|Docetaxel|Docetaxel 300 mg/m\^2 IV over 2 hours on Day -5.
215031644|NCT00936936|DRUG|Melphalan|50 mg/m\^2 IV over 15 minutes on Days -4 to Day -2.
214281071|NCT06243991|DEVICE|Non invasive tear break up time|Noninvasive tear break-up time (NI-TBUT) was assessed using a Sirius Scheimpflug camera (CSO, Florence, Italy) and the device automatically provided the average NI-TBUT value
214303141|NCT01123109|PROCEDURE|3-D Endoanal Ultrasound|The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
214303142|NCT03409926|DIETARY_SUPPLEMENT|Acacia Gum|dietary supplement will be added to the participant's usual diet
214303143|NCT01027481|DRUG|Lucentis|intravitreally administration of 0.05 ml Lucentis
214469577|NCT03669523|DRUG|Denosumab-nivolumab combination|"* Denosumab: 120 mg every 4 weeks subcutaneously~* Nivolumab: 240mg intravenously on day 1 every 2 weeks"
214469578|NCT05790304|DRUG|Camizestrant|Camizestrant 75 mg tablets. Experimental drug.
214469579|NCT04642352|DRUG|superior laryngeal nerve block|A unilateral injection of 2 cc of a 1:1 mixture of 0.25% bupivacaine and Kenalog-40 via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) on the side which exhibited most discomfort/tenderness/cough on palpation. If neither side was uncomfortable, the right side will be used.
214281072|NCT06243991|DIAGNOSTIC_TEST|Ocular Surface Disease Index Qestionnaire|The Ocular surface disease index (OSDI) questionnaire consists of a total of 12 questions categorized into three subscales as follows: ocular symptoms, vision-related function, and environmental triggers. Each patient is asked to rate the symptoms on a 5-point scale ranging from never (0 score) to always (4 score) for every question in the questionnaire. The fourth and fifth questions in the first section, concerning blurred vision and reduced vision symptoms, were excluded from the questionnaire as these symptoms may already be present in patients with keratoconus disease. The total OSDI score was calculated according to the formula: OSDI = \[(sum of scores for all questions answered) × 100\] / \[(total number of questions answered) × 4\].
214281073|NCT06243991|DEVICE|Corneal tomography|Scheimpflug-tomography device (Pentacam, OCULUS, Wetzlar, Germany) was used for measurement of keratometric values.
214281074|NCT00671697|DRUG|Arsenic Trioxide|
214281075|NCT00671697|DRUG|Decitabine|
214281076|NCT02857543|OTHER|Plant-Based Diet|
214281077|NCT02857543|OTHER|American Heart Association Diet|
214281078|NCT02857543|OTHER|Mediterranean Diet|
214281079|NCT05255068|BEHAVIORAL|OPTIMAL|A person-centered mealtime care intervention
214281080|NCT04121377|OTHER|Resistance training|"Weekly sessions introducing resistance exercises and monitoring the patients acceptability. The exercises are isometric contractions, seated heel-rise and elastic band. The patient register the amount of exercise in a home exercise journal. To protect the tendon while doing range of motion of the foot, dorsiflexion is restricted beyond neutral (0 degrees of dorsiflexion). The load on the strength exercises will progress from isometric contraction without external load to strengthening exercises with 10-20 RM (RM: Repetition Maximum). Each strength exercise can progress with added weight or stronger elastic band. The Borg scale is used to guide the patient to progress or regress the load in each exercise. The recommended level being easy to hard (2-5/10). It is emphasised that the exercises must not cause sudden or severe pain in the tendon, but muscle soreness is to be expected."
214281081|NCT04388189|DRUG|Duloxetine|FDA approved antidepressant
214281082|NCT04388189|DRUG|Bupropion|FDA approved antidepressant
214281083|NCT05300620|DEVICE|Custom Foot Orthotics EVA|these are custom foot orthotics made out of Ethyl Vinyl Acetate material
214281084|NCT05300620|DEVICE|Original Liner|these are original shoe liners
214281085|NCT05300620|DEVICE|Custom Foot Orthotics PU|these are custom foot orthotics made out of Expanded Poly Urethane Material
214281086|NCT05300620|DEVICE|Custom Hybrid Foot Orthotics|these are custom foot orthotics made out of a combination of Ethyl Vinyl Acetate and Expanded Poly Urethane Material
214281087|NCT01561365|BEHAVIORAL|Ottawa ankle rules|Ottawa ankle rules implementation
214281088|NCT05033860|OTHER|Read leaflets containing knowledge of COVID-19 and vaccination.|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and participants are asked to read the leaflets.
214281089|NCT05759676|DEVICE|Cre8™/Cre8™ EVO drug-eluting stent|Patient with CAD who undergoing PCI with Cre8™/Cre8™ EVO drug-eluting stent
214281090|NCT01548521|DRUG|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
214281091|NCT03919214|OTHER|Automated Messaging|This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg.
214281092|NCT00872534|DRUG|acetylsalicylic acid|325mg once a day for 7 days
214281093|NCT04440202|BEHAVIORAL|Conventional sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional sea bream fillets and will be asked to consume them twice weekly for 1 month. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
214281094|NCT04440202|BEHAVIORAL|Enriched sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 enriched sea bream fillets and will be asked to consume them twice weekly for 1 month. Enriched sea bream fillets will be produced by a fish farming company from fish bread with a diet enriched with a fraction of bioactive polar lipids extracted from olive oil by-products. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
214281095|NCT00000105|BIOLOGICAL|Intracel KLH Vaccine|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
214281096|NCT00000105|BIOLOGICAL|Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
214281097|NCT00000105|DRUG|Montanide ISA51|Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
214469580|NCT06011577|DRUG|REL-1017|REL-1017 tablet
214469581|NCT06011577|DRUG|Placebo|Placebo tablet
214657237|NCT04963413|BIOLOGICAL|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
214281098|NCT00000105|BIOLOGICAL|Tetanus toxoid|Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
215031645|NCT00936936|DRUG|Carboplatin|"Cycle 1: 333 mg/m\^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m\^2 IV over 2 hours on Days -6 to -3."
215031646|NCT00936936|DRUG|Mesna|3,000 mg/m\^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
214281099|NCT03281486|DEVICE|HA formulation Oral Spray|It is an HA formulation of FDA listed ingredients
214469582|NCT05467735|OTHER|Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
214844153|NCT02677662|OTHER|Diesel Exhaust|Dilute diesel exhaust
215031647|NCT00936936|DRUG|Ifosfamide|3,000 mg/m\^2 IV over 6 hours on Days -6 to -3
214844154|NCT02677662|OTHER|Filtered air|Filtered air
215031648|NCT00936936|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours, every 12 hours on Days -6 to -4.
214281100|NCT03281486|DEVICE|Placebo|Placebo formulation without the active ingredients
214281101|NCT04922008|DRUG|capecitabine and trastuzumab|In IRIS-C cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
214281102|NCT04922008|DRUG|vinorelbine and trastuzumab|In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
214281103|NCT06060288|DIAGNOSTIC_TEST|Diagnosis by mobile phone imaging|"The photographs will be taken with a smartphone iPhone 14 Pro in a one-year period. Imaging will follow the recommendations regarding intraoral photography in oral mucosal screening set by (Lin et al., 2021).~Personal data and a brief description of the present illness concerning the main complaint will be informed by the patients and recorded in a diagnosis chart of the Oral medicine department Cairo University. Complete intraoral physical examination will be performed by the main investigator under supervision of the main supervisor and the co-supervisor using dental equipment with artificial light."
214281104|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
214844155|NCT03180528|DRUG|Remetinostat|Applied topically under bandage occlusion
214844156|NCT02856087|DRUG|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
214844157|NCT02856087|DRUG|Naloxone|naloxone infusion
214844158|NCT02856087|DRUG|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
215031649|NCT00936936|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
215031650|NCT03670472|OTHER|smear of nasal fossae|1 smear of nasal fossae during a usual or scheduled visit
214844159|NCT02856087|DRUG|Normal Saline|normal saline infusion
214844160|NCT02999451|DEVICE|snare-assisted POEM|"POEM is performed by using a snare which is retracted into the sheath to expose the tip, leaving a 1-2mm length for operation.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a snare in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a snare.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a snare.~4. The mucosal incision is closed with endoclips."
214844161|NCT02999451|DEVICE|knife-assisted POEM|"POEM is performed by using a conventional endoscopic knife.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a knife in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a knife.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a knife.~4. The mucosal incision is closed with endoclips."
214844162|NCT05746130|BEHAVIORAL|Plastic-free diet program|"Applying the plastic-free diet as four meals (three main meals, one snack) in pension kitchen. Promoting of glass water bottle giving and daily use.~Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample."
215031651|NCT06477770|PROCEDURE|Clorhexidine soap|surgical wound will be washed with saline solution and 10 ml of chlorhexidine soap
215031652|NCT06477770|OTHER|Sucrose|75 g of sucrose will be administered to the surgical wound at 8:00 am every day, once a day, and then it will be covered with sterile gauze.
215031653|NCT00931541|DRUG|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
214844163|NCT05746130|BEHAVIORAL|Plastic-free diet education program|"Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample"
214844164|NCT05746130|BEHAVIORAL|BPA exposure feedback|Feedback about BPA levels in theirs urinary sample
214844165|NCT04455971|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a form of meditation that increases bodily awareness during structured, partnered female genital stimulation over a 15-minute period.
214844166|NCT06467201|DRUG|KSHN001126 150mg|6 subjects will receive single oral dose of 150mg
215031654|NCT00931541|DRUG|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
215031655|NCT06565312|DIETARY_SUPPLEMENT|Flora Power Probiotic Vaginal Suppository|The suppository contains Microcrystalline Cellulose, Ascorbic Acid, Vitamin C, Gelatin Capsule, Vaginal Probiotic Blend (Lactobacillus fermentum LF61, Lactobacillus acidophilus LA85, Lactobacillus plantarum Lp90), Magnesium Stearate, and Silicon Dioxide.
215031656|NCT01714674|DIETARY_SUPPLEMENT|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
215031657|NCT01714674|DIETARY_SUPPLEMENT|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
215031658|NCT06140225|BEHAVIORAL|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
215031659|NCT06140225|BEHAVIORAL|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
215031660|NCT06140225|BEHAVIORAL|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
215031661|NCT06140225|BEHAVIORAL|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
215031662|NCT06140225|BEHAVIORAL|"JEFIT APPLICATION"|It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.
215031663|NCT06140225|BEHAVIORAL|"FITBIT-FLEX APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
215031664|NCT06140225|BEHAVIORAL|"MEIZU BONG 2S APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
215031665|NCT02733094|DRUG|Secukinumab|
215031666|NCT04185779|DIAGNOSTIC_TEST|Colonoscopy|Diagnostic colonoscopy
215031667|NCT03733548|BEHAVIORAL|RELAX|Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly, 90-minute sessions delivered (60 minutes of parents and adolescents meeting separately, 30 minutes of a combined meeting) in a group format. RELAX equips adolescents with emotion regulation and conflict management skills. This program includes a parent involvement component designed to help parents support adolescents' use of these skills. Each week skills will be discussed and practiced in group, and a skills rehearsal homework activity will be assigned. Following the program, an 8-week follow-up review session will be offered. Additionally, a single 60 minute focus group will be held following the review session to solicit parent and adolescent feedback on the intervention.
215031668|NCT02771301|BIOLOGICAL|dendritic cells|Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
215031669|NCT02101463|DEVICE|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
215031670|NCT01373281|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
215031671|NCT01373281|BIOLOGICAL|Placebo: Sodium chloride (NaCl) 0.9%|0.5 mL, Subcutaneous
215031672|NCT03620396|PROCEDURE|Scaling and root planing|After the serum collection is done from the patient for the assessment of trefoil factor 3, Non surgical periodontal therapy is carried out.
215031673|NCT06141928|OTHER|Functional recovery analysis|Functional recovery analysis with force evaluator \& tester
215031674|NCT03262961|DRUG|Sildenafil 20 MG|
215031675|NCT03262961|DRUG|Placebo Oral Tablet|
214469583|NCT05727670|PROCEDURE|exposure of the tooth crown|surgical exposure of the crown of a retentive tooth
215031676|NCT00137592|BEHAVIORAL|small media, group education (multicomponent)|
214469584|NCT03812549|DRUG|Sintilimab|Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.
214469585|NCT03812549|RADIATION|stereotactic body radiation therapy|Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f
215031677|NCT02829372|DRUG|CD3/HER2 bispecific monoclonal antibody|Increasing doses, IV on day 1 and 15 of each 28 day cycle
215031678|NCT03943277|OTHER|No intervention, observational study|No intervention observational study
215031679|NCT05791344|DEVICE|ECG monitoring|Intra-procedural ECG changes during TAVR
215031680|NCT05334238|DRUG|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
215031681|NCT02804620|BEHAVIORAL|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
215031682|NCT02550002|DRUG|Aflibercept|Intravitreal injection
215031683|NCT06839053|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215031684|NCT06839053|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215031685|NCT06839053|PROCEDURE|Computed Tomography|Undergo CT
215031686|NCT06839053|PROCEDURE|Gastrointestinal Endoscopy|Undergo endoscopy
215031687|NCT06839053|BIOLOGICAL|Rituximab|Given IV
215031688|NCT06839053|DRUG|Sonrotoclax|Given PO
215031689|NCT06839053|DRUG|Zanubrutinib|Given orally (PO)
214469586|NCT03812549|RADIATION|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
215031690|NCT02433964|OTHER|Grupo LED|
215031691|NCT02433964|OTHER|Placebo|ledterapia off + price
215031692|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
215031693|NCT01444781|BIOLOGICAL|DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
215031694|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine|0.5 mL (each), Intramuscular each into the right and left deltoid muscle
215031695|NCT01871649|DRUG|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
215031696|NCT01871649|DRUG|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
215031697|NCT01331759|DEVICE|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
215031698|NCT06318676|DRUG|Mezigdomide|Specified dose on specified days
215031699|NCT05311397|DRUG|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
215031700|NCT06579508|OTHER|Cycle ergometer|"The initial part will last 5 minutes at low intensity, corresponding to easy by the RPE.~The main part will be performed at the intensity of training zone 3 (100-110% of the Lan), lasting 5 minutes with a rest of 2.5 minutes between exercises. The intensity will be controlled by HR and RPE.~The final part will last 3 minutes at low intensity, corresponding to easy by the RPE.~The load progression occurred during the first four weeks, starting with 3 sets and adding 1 set per week.~The intensity of each effort is 100-110%HRAnTh."
215031701|NCT04432779|OTHER|no intervention|no intervention
215031702|NCT06571864|DRUG|Anti-CD38 Monoclonal Antibody|Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)
215031703|NCT06571539|DEVICE|AR-assisted EVD placement|Cfr. arm description
215031704|NCT06571539|PROCEDURE|Freehand EVD placement|External ventricular drain (EVD) placement using the conventional freehand technique. This intervention covers the matched, non-concurrent control group, retrospectively obtained without active enrollment to receive study treatment.
215031705|NCT01300637|DRUG|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
215031706|NCT01300637|DRUG|placebo|identical-appearing pill of placebo
215031707|NCT04197232|OTHER|clinical evaluation|\- In children: general clinical evaluation, birth weight, APGAR, ECG, admission to ICU, hospital admissions in perinatal age, presence of malformations; complete blood count, inflammatory index, complement, antibiotic treatment, brain ultra-sound, presence of infection, presence of sepsis, presence of necrotizing enterocolitis, growth curve, presence of recurrent infections, developmental milestones, response to vaccines, admission to hospital in the first year of life.
215031708|NCT04277130|BEHAVIORAL|Intervention with active video games|Participants in intervention group were paired up by their teachers. Each participant had a classmate playing with him/her, and the waiting time is minimal because Xbox 360 Kinect allowed double play mode. The intervention group was provided with an AVG, the Xbox 360 Kinect technology (Kinect Sports Seasons I \& II, including bowling, soccer, boxing, track and field, table tennis, beach volleyball, golf, tennis). The AVG intervention consisted of two 30-min sessions per week, for a total of 12 weeks. Participants either played in PE classes and/or recess. They had no other specific routing of activities but straight played the AVG during the intervention. They could free to choose games they like in the Xbox 360. The AVGs of Xbox 360 chosen was of moderate to vigorous intensity (3-6 METs) and no matter what games they chose, their PA level would be between moderate and vigorous intensity.
215031709|NCT02167776|BEHAVIORAL|Church-based teaching|In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
215031710|NCT04253600|BEHAVIORAL|Risk profile screening questionnaire|Families will be asked to complete a LimeSurvey questionnaire that aims at evaluating general risk profiles associated with DLD (e.g., no elevated risk, behavioral risk, environmental risk, familial risk), as well as our exclusion criteria (e.g., hearing deficit).
215057136|NCT06156657|OTHER|subcostal TAP block|Comparison between subcostal TAP block and opioids for postoperative pain after laparscopic sleeve gastrectomy
214281105|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
214281106|NCT05186064|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing will be performed on tumor material after re-resection per standard of care
214281107|NCT01479673|DIETARY_SUPPLEMENT|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
215057137|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Enhanced Parent Involvement|
215057138|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Minimal Parent Involvement|
215057139|NCT04343430|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
214281108|NCT01002703|DRUG|Lenalidomide, Bendamustine, Prednisone|During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
214281109|NCT06001424|OTHER|physical therapy|Frenkel's exercises for lower limb, Proprioceptive neuromuscular facilitation for upper limb in the form of rhythmic stabilization
214281110|NCT06001424|OTHER|life kinetic exercises|A multimodal training that combines coordinative, cognitive and visual tasks.
214281111|NCT02674529|DRUG|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
214281112|NCT02674529|DRUG|Placebo|Placebo
214281113|NCT02674529|BEHAVIORAL|Real-time Neurofeedback fMRI task pre- and post-RCT|Placebo experiment during an fMRI scanning session
215031711|NCT04253600|PROCEDURE|Investigation of the neural correlates of DLD using Magnetic Resonance Imagery (MRI)|MRI data acquisition will take place during natural sleep in infants aged from 6 to 12 months. First, families will have to complete a security questionnaire to make sure that neither the children nor the accompanying parent have any known contraindication preventing the MRI session and that none of them is wearing any ferro-magnetic elements. Then, families will be welcomed in a calm and child-friendly environment where we will propose them some preparatory games known to facilitate sleep in children. MRI protocol will comprise structural and functional images and won't exceed 30 minutes.
215031712|NCT04253600|BEHAVIORAL|Online investigation of predictive factors associated with DLD and LANCOM app development|Parents will be asked to complete a series of online questionnaires every six months. Questionnaires will be created on LimeSurvey and will include different questionnaires, scales, and observations that aim at evaluating children's development, and especially language development, as well as parental and environmental characteristics.
215031713|NCT04253600|BEHAVIORAL|Individual behavioral and cognitive assessment|Individual cognitive and behavioral assessment will be scheduled once a year, around the child's birth date, and will comprise an extensive battery of standardized evaluation appropriate for the child's age. This individual evaluation will focus on several developmental aspects including language, psychomotor, behavioral and cognitive development, as well as executive and socio-emotional functioning, depending on the age of the children. Evaluations will be adapted to each child's specific profile, while respecting the following administration rules: (1) we will prioritize language development testing, (2) testing sessions will be adapted to each child's pace and possibilities, (3) if a child does not want to take part in the assessment, feels tired, or does not seem to be comfortable with the investigator, tests won't be administered.
215031714|NCT04253600|BEHAVIORAL|Automated analysis of language development and environment|"Following the individual assessment, families will be asked to record their child's language environment over a 2-days' timeframe using the LENA® device, a small wearable device allowing for large-scale all-day audio recording and automated vocal analyses of speech segments. An automatic analysis of the recordings, performed by the LENA pro software algorithms, will provide amongst others, a direct and natural measure of the child's number of vocalizations, adult word counts, conversational turns, duration of exposure to electronic media versus to meaningful language. Data acquisition will take place once a year following our sample selection, with a required recording time per day ranging from 12 to 16 hours."
215031715|NCT02075060|PROCEDURE|IPOI (pre-operative)|
215031716|NCT02075060|PROCEDURE|IPOP (post-operative)|
215057140|NCT04343430|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
215057141|NCT04343430|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
214281114|NCT02891850|DRUG|Riociguat (Adempas, BAY63-2521)|Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
214281115|NCT02891850|DRUG|Sildenafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
214281116|NCT02891850|DRUG|Tadalafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
214281117|NCT06069245|DIETARY_SUPPLEMENT|MitoQ|80mg of MitoQ taken in one dose on one occasion.
214281118|NCT06069245|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
214281119|NCT06397014|PROCEDURE|D-type stoma lateral hernia repair|underwent D-type stoma lateral hernia repair
214281120|NCT04349670|PROCEDURE|GPOEM - gastric per-oral endoscopic myotomy|Endoscopic section of the pyloric muscle with submucosal tunnel technique.
214281121|NCT04445922|DRUG|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
214281122|NCT04445922|DRUG|reference-anastrozole tablet|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
214281123|NCT01974583|PROCEDURE|regrafted with thin split-thickness skin graft|Group A (the treatment group) were regrafted with thin split-thickness skin graft
214281124|NCT01974583|PROCEDURE|covered with the occlusive hydrocellular dressing|group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith \& Nephew)
214281125|NCT01974583|PROCEDURE|covered with paraffin gauze|Group C covered with paraffin gauze
215057142|NCT04343430|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
214281126|NCT06141590|DRUG|administration of UI068|Test
214281127|NCT06141590|DRUG|administration of UIC202205, UIC202206|Reference
214281128|NCT02049281|DRUG|Vintafolide|Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
214281129|NCT02129725|DRUG|Sildenafil citrate|Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months
214281130|NCT02129725|DRUG|Placebo Oral Capsule|placebo capsules, 1 capsule po three times a day for 3 months
214281131|NCT03440710|PROCEDURE|BET|Balloon Eustachian Tuboplasty
214281132|NCT04441021|OTHER|Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
214303144|NCT05164900|PROCEDURE|pterygium excision with sutures fixed conjunctival auto-graft|Pterygium excision with vicryl 8/0 fixed conjunctival auto-graft under local anesthesia. During the follow up period, indicators of ocular irritation were assessed.
214281133|NCT04546438|DEVICE|miraDry®|"MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands.~In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions)."
214281134|NCT01191229|DEVICE|Tecnis one-piece MF IOL|25 patients to be implanted after cataract surgery
214281135|NCT01191229|DEVICE|Crystalens AO|25 patients that are previously implanted
214281136|NCT04506372|DRUG|Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers|Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
214281137|NCT04506372|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
214281138|NCT04506372|BEHAVIORAL|Diary to register drug adherence|To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
214281139|NCT04506372|BEHAVIORAL|Quality of life questionnaire|Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
214281140|NCT04506372|BEHAVIORAL|WHODAS questionnaire|Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
214281141|NCT06111300|DRUG|Dexmedetomidine|Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery. Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.
214281142|NCT02532491|DRUG|Aripiprazole|Initial dose: 10 mg.
214281143|NCT02532491|DRUG|Risperidone|Initial dose: 2 mg.
214281144|NCT01104506|PROCEDURE|fMRI|
214281145|NCT01104506|PROCEDURE|mTMS|
214281146|NCT04953377|BEHAVIORAL|PFMT educational intervention|an educational intervention to learn about the pelvic floor and how to train it
214281147|NCT03880071|BEHAVIORAL|DBT+ACT|\- The experimental group (DBT+ ACT) will have: 25 therapy group sessions (1 sessions of 2 hours once a week) 25 individual interview sessions (1 sessions of 1 hour once a week) will receive 25 group sessions and 25 individual ones during 6 months.
214281148|NCT03880071|BEHAVIORAL|DBT|"The control group (DBT) will have:~50 therapy group sessions (1 session of 2h30 once a week) 50 individual interview sessions (1 sessions of 1 hour once a week)"
214281149|NCT00331682|DRUG|alvocidib|Given IV
214281150|NCT00331682|DRUG|docetaxel|Given IV
214281151|NCT02732704|DEVICE|JenaValve Pericardial TAVR System|TAVR with JenaValve Pericardial Valve and Delivery System
214281152|NCT00573469|DRUG|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
214281153|NCT00573469|DRUG|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
214281154|NCT00573469|DRUG|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
214281155|NCT02916108|OTHER|Reading EEG|EEG recording for 5 minutes (not an intervention)
214281156|NCT01294657|BEHAVIORAL|Health Education|Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
214281157|NCT01294657|BEHAVIORAL|MAPS|12 counseling phone calls over 1 year, lasting about 20-30 minutes.
215057143|NCT04343430|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
214281158|NCT03761277|DEVICE|Medtronic SynchroMed™ II infusion system|Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).
214281159|NCT03761277|DRUG|Preservative-free morphine sulfate (PFMS)|The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
214281160|NCT00004978|DRUG|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
214281161|NCT01384253|OTHER|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
214281162|NCT01384253|BIOLOGICAL|trastuzumab|4 mg/kg.
214281163|NCT00109798|DRUG|temozolomide|Patient will take drug on day 1-5 of 28 day schedule
215057144|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
215057145|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
214281164|NCT00109798|DRUG|topotecan hydrochloride|Patient will have IV on days 2-6 on a 28-day schedule
214281165|NCT01541124|DRUG|Opioid|10 mg/pill, po, each 6h, during 6m
214281166|NCT06243263|DRUG|Bupivacain|At the end of the surgery, after wound closure, an inferior alveolar nerve block with 2ml bupivacaine 0,5 % will be realized.
214281167|NCT02052284|OTHER|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
214281168|NCT02554669|BEHAVIORAL|postprandial and postabsorptive physical activity on treadmill|
214281169|NCT05443789|BEHAVIORAL|Proton pump inhibitor education|A 15 minutes (preferable) one-on-one educational visit about deprescription of proton pump inhibitor
214281170|NCT05443789|BEHAVIORAL|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
214469587|NCT05299723|BEHAVIORAL|BLT Intervention|BLT will be administered via a Luminette 3 light therapy visor. The Luminette 3 is a visor worn above the eyes containing light emitting diode (LEDs) emitting a blue-enriched white light reflecting to the retina at 1,000 lux via a holographic system in order to ensure correct penetration into the eye without impeding vision. This range of light and intensity is sufficient to synchronize the circadian clock.
214844167|NCT06467201|DRUG|KSHN001126 300mg|6 subjects will receive single oral dose of 300mg
215057146|NCT01285570|DRUG|5% dextrose in water|Placebo
215057147|NCT00788931|DRUG|IV LBH589|
215057148|NCT00788931|DRUG|Oral LBH589|
215031717|NCT02722785|BEHAVIORAL|Aerobic and Resistance Exercise Training|Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum \[1-RM\] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
215031718|NCT06420700|PROCEDURE|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty in the treatment of adults with obesity
215031719|NCT03934294|OTHER|Specific acupuncture group|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G."
215031720|NCT03934294|DRUG|Metoclopramide 10mg|Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.
215031721|NCT03934294|OTHER|Non-specific acupuncture group|Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related conditions, and are not reported to improve digestive function.
215031722|NCT05750784|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
215031723|NCT06378840|RADIATION|Nab-paclitaxel/Platinum, Sintilimab|Sintilimab Combined With Concurrent Nab-paclitaxel/Platinum-based Chemoradiotherapy
215031724|NCT05175157|OTHER|Gut Fellings questionnaire|Answer the Gut Fellings questionnaire
215031725|NCT05701826|DRUG|HRS3797|HRS3797 for injection, low dose
215031726|NCT05701826|DRUG|HRS3797|HRS3797 for injection, medium dose
215031727|NCT05701826|DRUG|HRS3797|HRS3797 for injection, high dose
215031728|NCT01302886|DRUG|BHQ880|
215031729|NCT03842397|DEVICE|Kephalios Device 1|The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
215031730|NCT04370886|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
215031731|NCT03033784|DRUG|8 International Units (IU) of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 8IU.
215031732|NCT03033784|DRUG|24IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 24IU.
215031733|NCT03033784|DRUG|48IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 48IU.
215031734|NCT03033784|DRUG|Placebo|Participants will receive an intranasal placebo to match the oxytocin doses.
215031735|NCT03130049|PROCEDURE|Popliteal plexus block|10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
215031736|NCT01312298|PROCEDURE|General anesthesia|Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml
214657238|NCT05812716|BEHAVIORAL|resiLIR Healthcare Professionals|"Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life."
215031737|NCT01312298|PROCEDURE|Regional anesthesia|Patients will receive intrathecal anesthesia
215031738|NCT03332056|DRUG|Belladonna and Opium|
215031739|NCT03332056|OTHER|Placebo suppository|
215031740|NCT06344247|DRUG|RAS inhibitors：Losartan®️/Valsartan®️|Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.
215031741|NCT06344247|DRUG|dapagliflozin：Forxiga®️|Forxiga®️ : titrated to the target dose (10 mg qd).
215057149|NCT00788931|DRUG|trastuzumab|
215057150|NCT00788931|DRUG|paclitaxel|
215057151|NCT01278238|DRUG|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
215057152|NCT01278238|DEVICE|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
215057153|NCT01278238|OTHER|Placebo|Neither phenylephrine nor lower limb bandaging
215057154|NCT00692614|DRUG|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
215057515|NCT03563755|OTHER|Cognitive Bias Modification|CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
215057516|NCT04212715|RADIATION|Pelvic SABR with intra-prostatic SABR|SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
214281171|NCT04044235|BEHAVIORAL|PrEP Cohort|AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
214281172|NCT03998033|BIOLOGICAL|ET140202 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140202 expression construct
214281173|NCT00001995|DRUG|Rifabutin|
214281174|NCT01508650|BEHAVIORAL|Usual care|Usual care control group
214281175|NCT01508650|BEHAVIORAL|Rehabilitation intervention|Multi-domain rehabilitation intervention
214281176|NCT04165434|OTHER|Concurrent Training|Strength training and interval aerobic training in the same training session
214281177|NCT02064894|DRUG|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
214281178|NCT02064894|DRUG|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
214281179|NCT02064894|DRUG|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
214281180|NCT02760199|DRUG|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
214281181|NCT02760199|DEVICE|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
214281182|NCT01682057|DEVICE|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
214281183|NCT01682057|DEVICE|ROX Anastomotic Coupler System (ACS)|
214281184|NCT01793675|PROCEDURE|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
214281185|NCT04522960|DIAGNOSTIC_TEST|MEG+hdEEG+MRI|"We will perform several tests:~* Neuropsychological testing to evaluate evolution of cognition during our study.~* Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~* MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls"
214281186|NCT01996293|DRUG|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
214281187|NCT04449900|OTHER|This is observational study with the examination of OCTA|This is observational study with the examination of OCTA
214281188|NCT05199012|DIETARY_SUPPLEMENT|Black pepper extract|Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1
214281189|NCT00002098|DRUG|Lentinan|
214281190|NCT00002098|DRUG|Didanosine|
214281191|NCT03184831|PROCEDURE|sinus lift, implant placement, sole bovine bone|sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
214281192|NCT03184831|PROCEDURE|sinus lift, implant placement, injectable PRF + bovine bone|sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
214281193|NCT02084654|DRUG|Exenatide 5 and 10 mcg 2 times a day|
214281194|NCT02084654|DRUG|placebo|
214281195|NCT02864498|DRUG|DS107|
214281196|NCT02864498|DRUG|Placebo|
214281197|NCT04309539|PROCEDURE|Fascia iliaca block|"A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia."
214469588|NCT05299723|BEHAVIORAL|BLB Intervention|BLB will be administered via orange lenses that filter out short-wavelength blue light, while allowing the other visible spectrum light to pass. The BLB lenses result in a reduction in melanopic irradiance (i.e., the light that affects sleep) of about 85%. The BLB lenses only make the overall light environment about 30% dimmer. Therefore, the BLB lenses are effective in blocking out most of the blue light in the visible environment that impacts sleep, but do not result in drastic overall dimming/darkening of the light environment.
215031742|NCT06344247|DRUG|simagliptin：Forxiga®️|Semaglutide®️ : titrated to the target dose (1 mg qw).
214281198|NCT04309539|PROCEDURE|combined LFCN block with PENG block|With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
214281199|NCT06506383|OTHER|No Intervention as this is an ecological study|No Intervention as this is an ecological study
214281200|NCT03425877|DEVICE|MS Band 2|Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
214281201|NCT03425877|BEHAVIORAL|Emotion Assessment|The subjects will be subjected to the viewing of 21 video clips depicting 6 different emotional states belonging to the FilmStim database validated by Schaefer's studio and collaborators (Schaefer, Nils, Sanchez, \& Philippot, 2010). When viewing the clip, subjects will wear the Microsoft ® Band 2 .and after each movie clip of an evaluation of the stimulus value and activation level perceived by the Self-Assessment Manikin (Bradley \& Lang, 1994) questionnaire). The presentation of movie clip is randomized and does not follow a fixed effect. Between the presentation of each clip a fixed interval of 15 seconds has been inserted in order to induce artifacts and overlap of physiological signals among different emotional valence video clips.
215031743|NCT04132297|BEHAVIORAL|Asthma Academy|The Asthma Academy is a one hour virtual training that includes providing information about asthma, asthma medications, communicating with healthcare providers and navigating healthcare resources.
214469589|NCT05299723|BEHAVIORAL|Sleep Hygiene Education|The sleep hygiene education will consist of watching a sleep education video (background on the regulation of sleep, the impacts of insufficient sleep on mental and physical health, etc.) and a sleep hygiene video (providing overview of sleep hygiene approaches).
214281202|NCT03425877|BEHAVIORAL|Single Task|The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).
215031744|NCT04132297|BEHAVIORAL|Telehealth Visit|The telehealth Visit will be conduct by a trained Doctor of Nurse Practice (DNP) student via a scheduled meeting through zoom on the participant's smart phone or computer. The visit will last about one hour wherein participant will be asked about their asthma knowledge and will be given information about asthma.
215031745|NCT00525863|DRUG|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to \~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
215031746|NCT05310357|DIAGNOSTIC_TEST|Testing for chromosomal instability (CIN)|The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment.
215031747|NCT00851084|DRUG|aflibercept|administration: IV infusion
215031748|NCT00851084|DRUG|oxaliplatin|administration: IV infusion
215031749|NCT00851084|DRUG|5-FU|administration: IV infusion
215031750|NCT00851084|DRUG|Folinic Acid|administration: IV infusion
215031751|NCT02997007|DEVICE|active tDCS|Participants will receive active tDCS over the angular gyrus on five consecutive days
215031752|NCT02997007|DEVICE|sham tDCS|Participants will receive sham tDCS over the angular gyrus on five consecutive days
215031753|NCT03236883|DRUG|Gemcitabine|Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
215031754|NCT03236883|OTHER|GPBSC|immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)\*10\^8/kg,once a month,repeated every 4weeks,three times in all.
215031755|NCT03650023|DIETARY_SUPPLEMENT|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
215031756|NCT03650023|DIETARY_SUPPLEMENT|White egg|White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
215031757|NCT00734032|DRUG|SB480848 40mg EC Tablet|1 tablet once a day
215031758|NCT00734032|DRUG|SB480848 80mg EC Tablet|1 tablet once a day
215031759|NCT00734032|DRUG|SB480848 160mg EC Tablet|1 tablet once a day
215031760|NCT00734032|DRUG|SB480848 Placebo Tablet|1 tablet once a day
215031761|NCT04973319|DRUG|Pyrotinib|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment.
215031762|NCT04973319|DRUG|Trastuzumab|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
215031763|NCT06500507|DRUG|QLS4131 Injection|Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.
215031764|NCT05903235|BEHAVIORAL|Virtual Reality-based Mirror Therapy (VR+MT)|In this VR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb simultaneously while observing the animated hand as mirroring reflection of the affected hand within the immersive environment, which presented on the goggle via the VR+MT system.
214469590|NCT06315335|DRUG|UCB9741|Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
214469591|NCT06315335|DRUG|Placebo|Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
214469592|NCT06659952|OTHER|HIV-positive heart transplant|Receipt of heart from HIV-positive deceased donor only as part of this study
214469593|NCT03581773|DRUG|Folic Acid|5 mg pr day for 12 weeks
214469594|NCT03581773|DRUG|Placebo Oral Tablet|1 placebo pill pr day for 12 weeks
214469595|NCT05181020|BEHAVIORAL|Maternal Voice Exposure|Main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.
214469596|NCT05582785|DIAGNOSTIC_TEST|Hyperfine MRI|Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
214469597|NCT03220035|OTHER|Laboratory Biomarker Analysis|Correlative studies
214469598|NCT03220035|DRUG|Vemurafenib|Given PO
215031765|NCT05903235|BEHAVIORAL|Mixed Reality-based Mirror Therapy (MR+MT)|In the MR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb concurrently meanwhile watching the real-time mirroring image reflection of the non-affected upper limb's movements of the patients captured, transformed, and superimposed on the affected upper limb, which projected to the screen from the front side via the MR+MT system.
214469599|NCT00696111|DRUG|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
215057517|NCT05100771|OTHER|Pediatric brain MRI|Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)
215057518|NCT02176200|DRUG|Berodual® Respimat®, low inspiratory flow rate|
214281203|NCT03425877|BEHAVIORAL|Dual Task|This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
214281204|NCT03425877|BEHAVIORAL|Rest|At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
214281205|NCT01595932|DIETARY_SUPPLEMENT|α-galactosidase|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
214281206|NCT01595932|DIETARY_SUPPLEMENT|Placebo|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
214281207|NCT02027896|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
214281208|NCT00246155|BIOLOGICAL|Botulinum toxin type A|
214281209|NCT01292616|DRUG|therapy with disease-modifying anti rheumatic drugs (DMARD)|DMARD drug and dosage is chosen by the treating physician without restriction by the study
214469600|NCT05490680|DRUG|Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg|Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose
214469601|NCT05490680|DRUG|Placebo|Placebo Oral Film
214469602|NCT03639883|DRUG|AIV001|Intradermal injection
214469603|NCT06065215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that uses powerful magnets and radio waves to generate detailed images of the body's internal structures. The MRI intervention includes using a specialized MRI machine and lung imaging protocol.
214469604|NCT06065215|DIAGNOSTIC_TEST|Echocardiogram|"An echocardiogram, often called an echo, is a non-invasive medical test that uses high-frequency sound waves (ultrasound) to create real-time images of the heart's structure and function. It provides valuable information about the heart's size, shape, and function."
214281210|NCT03312270|BEHAVIORAL|Multimodality information comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
214281211|NCT05948020|BIOLOGICAL|CBT102-A capsule|"Orally CBT102-A will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with 1.25×10\^11 live cell. The shelf life is 6 months.~Subjects receive oral dose of 1 capsule CBT102-A (1.25 x 10\^11 live cell) before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule CBT102-A (2.5 x 10\^11 live cell) before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule CBT102-A (5 x 10\^11 live cell) before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule CBT102-A (1 x 10\^12 live cell) before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
214469605|NCT06065215|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound is a non-invasive imaging technique that employs high-frequency sound waves (ultrasound) to visualize the structures and conditions of the lungs. It is particularly valuable for diagnosing and monitoring lung-related conditions, such as pneumonia, pleural effusions, and pulmonary edema. The lung ultrasound intervention involves using an ultrasound machine equipped with a specialized probe gently placed on the chest to capture detailed images of the lungs and adjacent structures.
214469606|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
214469607|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.1%)|ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
214469608|NCT03162783|DRUG|ADX-102 Ophthalmic Lipid Solution (0.5%)|ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
214469609|NCT03595787|PROCEDURE|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
214469610|NCT03649880|DRUG|¹⁸F-Fluoromisonidazole|Given IV
214469611|NCT03649880|PROCEDURE|Computed Tomography|Undergo PET/CT
214469612|NCT03649880|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI or PET/CT
214469613|NCT03649880|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
214469614|NCT03649880|PROCEDURE|Oxygen Therapy|Receive supplemental oxygen
214469615|NCT06227338|DRUG|Indocyanine green|"Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg)."
214469616|NCT05739864|BIOLOGICAL|FMT|This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT
214469617|NCT05739864|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
214469618|NCT06093997|OTHER|Massage treatment|The patient sits upright and the neck naturally relaxes. The doctor uses techniques such as pressing and kneading to relax the soft tissues of the neck, and massages points such as FengMen, FengChi, JingJiaji, JianJing,Tianzong and so on. The focus is on using muscle relaxation techniques around the soft tissues of spasms and pain areas to relax the patient's neck and shoulders. All procedures were performed from mild to severe, once a week for 15 minutes each time, for a total of 4 weeks of treatment.
215031766|NCT05903235|BEHAVIORAL|Traditional Mirror Therapy (MT)|In the traditional MT group, patients will be instructed to perform the unilateral movements of the non-affected upper limb at the same time while watching the mirror of a mirror box placed in front of the patient's midsagittal plane, in which the illusory reflection of the non-affected upper limb appears as if it were the another affected upper limb.
215031767|NCT06559319|DIAGNOSTIC_TEST|blood sampling|Venous blood is collected, and sIgE and BAT will be detected using whole blood and serum, respectively.
215031768|NCT06247748|DRUG|Exendin-4 Fc fusion protein (JY09) injection|D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29, D36, D43, D50, D57, D64, D71, and D78 subjects returned to the study center to receive a subcutaneous abdominal injection of 2.4 mg of JY09 injection(total of 8 administrations).All doses were to be administered within 3 min.
215031769|NCT06247748|DRUG|Metformin Hydrochloride tablet|D1 to D4 continuous oral administration of 0.5 g metformin hydrochloride tablets twice daily (D4 was administered only in the morning, with a total of 7 administrations) for a washout period of 96 h;0.5 g metformin hydrochloride tablets orally twice a day continuously from D85 to D88 (D88 was given only in the morning, for a total of 7 doses).
215031770|NCT06247748|DRUG|Rosuvastatin calcium tablets|D8 received a single oral administration of 10 mg of Rosuvastatin calcium tablets in the morning, with a washout period of 168 h,and 10 mg Rosuvastatin calcium tablets orally at 72 h ± 0.5 h (D95) after JY09 administration.
215031771|NCT06247748|DRUG|Digoxin tablet|D15 received a single oral administration of 0.25 mg digoxin tablets in the morning, with a washout period of 168 h,oral 0.25 mg digoxin tablets 72 h±0.5 h after JY09 administration (D102)
215031772|NCT03828604|BEHAVIORAL|Stress; Trier Social Stress Task|Standardized acute psychosocial stressor
215031773|NCT03828604|BEHAVIORAL|Placebo Trier Social Stress Task|Active control version of the TSST
215031774|NCT05379530|DIAGNOSTIC_TEST|Thromboelastography (TEG)|Thromboelastography (TEG) is a type of Viscoelastic testing (ROTEM is another example) and is a validated point of care method of dynamically assessing intraoperative coagulopathy via functional assay.
215031775|NCT05379530|OTHER|Anesthesia Provider Survey|Pre-operative and post-operative provider surveys will be distributed to anesthesiologists caring for study subjects to assess knowledge, practice, and attitudes about TEG.
215031776|NCT04144920|BEHAVIORAL|CS: Continuous sitting|Participants were asked to sit continuously throughout the duration of the lab visit.
215031777|NCT04144920|BEHAVIORAL|HFLD: HIgh frequency, low duration standing breaks|Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
215031778|NCT04144920|BEHAVIORAL|LFHD: Low frequency, high duration standing breaks|Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
214281212|NCT05948020|OTHER|Placebo capsule|"Orally placebo will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with Lactose powder filler. The shelf life is 6 months. The color, condition, smell and other appearances are exactly the same as CBT102-A.~Subjects receive oral dose of 1 capsule placebo before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule placebo before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule placebo before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule placebo before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
214281213|NCT01812174|DEVICE|17mm aortic valve (On-X )|Heart aortic valve replacement surgery: 17mm Aortic
214469619|NCT06093997|OTHER|Cupping|Use a 4-5cm diameter suction cupping for cupping. The treatment area is coated with glycerol, and the cupping is aspirated and adsorbed on the skin. The cupping is slowly pushed along the patient's neck, along the urinary bladder channel of Foot-Taiyang and governor's meridians from top to bottom, repeating back and forth 9 times. Once a week, for a total of 4 weeks of treatment.
214469620|NCT06093997|OTHER|Bloodletting|the doctor takes JianZhongShu, one on the left and one on the right, with a total of 2 acupoints. After disinfecting with 75% alcohol cotton balls, the patient is quickly pricked 5 times with a blood collection needle, and cupping is performed at the needle hole. After 5 minutes, remove the jar, wipe the blood clean, and disinfect the needle hole. Once a week, for a total of 4 weeks of treatment.
214469621|NCT03504683|BEHAVIORAL|Early TRE|Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
214469622|NCT03504683|BEHAVIORAL|Mid-day TRE|Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
214281214|NCT01812174|DEVICE|23mm mitral valve (On-X)|Heart mitral valve replacement surgery: 23mm Mitral
214281215|NCT02509273|DRUG|Clonidine|
214281216|NCT02509273|DRUG|Midazolam|
214281217|NCT04950998|BEHAVIORAL|Moving Up - A|Moving Up - A is a physical activity smartphone app for persons with mild cognitive impairment or mild forms of dementia. The app includes a personally tailored set of messages, tips, strategies, and tasks designed to increase physical activity levels and disrupt extended periods of sedentary time. Users also have the ability to track their steps and and sedentary behavior time as well as their progress towards activity goals.
214469623|NCT03504683|BEHAVIORAL|Control Schedule|Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
214469624|NCT06047509|PROCEDURE|Focal Laser Ablation|Removal of cancerous tissue through the direct application of laser energy
214469625|NCT00248807|DRUG|1.25 mg enalaprilat IV|an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)
214469626|NCT00248807|OTHER|Head up tilt (HUT)|45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
214657239|NCT02906514|DRUG|Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)|1000mL used for cardiopulmonary bypass priming
214469628|NCT06083753|DRUG|PIPE-307 Dose A|Subjects will receive daily oral doses of PIPE-307
215031779|NCT04669067|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
215031780|NCT04669067|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
215031781|NCT03809000|RADIATION|Radiation Therapy|daily fractions
215031782|NCT03809000|DRUG|Enzalutamide|tablet
215031783|NCT03809000|DRUG|Bicalutamide|tablet
215031784|NCT03809000|DRUG|GnRH analog|Injection
215031785|NCT01798225|DRUG|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
215031786|NCT01798225|DRUG|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
215031787|NCT00751231|DRUG|clopidogrel|Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
215031788|NCT00751231|DRUG|PRT060128|80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
214469629|NCT06083753|DRUG|PIPE-307 Dose B|Subjects will receive daily oral doses of PIPE-307
214469630|NCT06083753|DRUG|Placebo|Subjects will receive daily oral matching dose of Placebo
214469631|NCT04063592|PROCEDURE|Residual limb revision|Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
214469632|NCT06402669|OTHER|Packed Red Blood Cell Administration|Difference in occurrence of mortality in patients transferred versus directly admitted who have packed red blood cell administration in the first four hours of arrival to the hospital.
214469633|NCT03501576|BIOLOGICAL|Inactivated Influenza Vaccine|Given seasonal inactivated influenza vaccine IM
214469634|NCT05715268|DEVICE|WeB|"Participants will be given WeB devices and trained on the use of these devices for home therapy, including the associated mobile applications. Participants will be given home programs and given a schedule to use the WeB devices at home on their own time. At their standard visit participants will have their WeB device use checked and progressed as the therapist deems appropriate.~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
214469635|NCT05715268|OTHER|Standard pelvic floor physical therapy|"Baseline will consist of a standard PFPT evaluation. Regular visits (tele-video visits or in-person depending on the patients preference) will be scheduled every week for the first 4 weeks and then every other week at the discretion of the therapist. A total of 8-10 visits will be scheduled over the 12 weeks of the study. Participants will be given home exercise programs (as per standard PFPT).~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
214469636|NCT05702749|PROCEDURE|Microsurgical resection of VS|Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.
214469637|NCT05702749|RADIATION|Stereotactic radiosurgery|Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.
214469638|NCT05702749|OTHER|PREHAB|A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).
214469639|NCT05583006|DRUG|tenofovir alafenamide (TAF)|TAF switch therapy in CHB patients who are unsatisfied to ETV therapy.
214469640|NCT06851650|OTHER|Rehabilition protocol after rotator cuff repair surgery|adding early scapular strengthening (lower trapezius and serratus anterior) exercise in Rehabilition program after rotator cuff repair surgery
214469641|NCT05725655|OTHER|Thermotherapy|Hot baths directly after an exercise session
214469642|NCT06493955|OTHER|Adapted physical activity for 12 months|6 additional months of adapted physical activity after the 6 first months
214469643|NCT06493955|OTHER|Adapted physical activity for 6 months|standard 6-month prescription for adapted physical activity
214469644|NCT06192485|OTHER|proactive balance training|20 participants will receive a proactive balance training program
214469645|NCT06192485|OTHER|Reactive balance training|20 participants will receive a Reactive balance training program
214469646|NCT05098899|GENETIC|MyGeneMyDiet® Recommendations for Weight Management|This group will receive Nutrition and Lifestyle recommendation based on SNPs known to have an impact to body weight and body composition, and responses to physical activity and dietary fat intake
214469647|NCT05098899|OTHER|Usual Standard of Care for Weight Management|This group will receive the conventional and standard nutrition lifestyle recommendation for weight management
214469648|NCT04829188|BEHAVIORAL|Structured Telephone Support (STS)|Structured telephone support (STS) consists of post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care within seven days post-discharge.
214281218|NCT03370601|DRUG|Infliximab|Infliximab 10mg/kg every 8 weeks
214281219|NCT03370601|DRUG|Mercaptopurine|6-mercaptopurine 1 à 1,5 mg/kg
214281220|NCT03370601|DRUG|Azathioprine|Azathioprine 2 à 2.5mg/kg/j
214281221|NCT03370601|DRUG|Infliximab|Infliximab 5mg/kg every 8 weeks
214281222|NCT01829373|BIOLOGICAL|vaccine 1650-G|
214281223|NCT01333254|PROCEDURE|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
214469649|NCT04829188|BEHAVIORAL|Low-intensity Remote Patient Monitoring (RPM-Low)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
214469650|NCT04829188|BEHAVIORAL|High-intensity Remote Patient Monitoring (RPM-High)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
214469651|NCT04829188|BEHAVIORAL|Standard Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' PCP or specialist to coordinate care and ensure timely follow-up.
214657240|NCT02906514|DRUG|Sodium Chloride 0.9% (Fresenius)|1000mL used for cardiopulmonary bypass priming
214657241|NCT06399406|COMBINATION_PRODUCT|Medi-TBS|The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.
214657242|NCT04788992|OTHER|Intervention group|Dementia care training consists of dementia care e-books, dementia virtual reality activity and peer support program.
214281224|NCT03105895|PROCEDURE|Mesh group|An onlay PDVF mesh will be placed as abdominal wall reinforcement
215057519|NCT02176200|DRUG|Berodual® Respimat®, medium inspiratory flow rate|
215057520|NCT02176200|DRUG|Berodual® Respimat®, high inspiratory flow rate|
214281225|NCT04964375|DRUG|ABSK043 oral capsule|ABSK043 is a novel, oral small molecule inhibitor of PD-L1
215031789|NCT03360344|DEVICE|Kinesio 12 inch Tape|Kinesio Tape approximately 12-inch strip will be applied to the dorsal surface of the forearm of the affected side for three-day increments over three weeks of the study.
215031790|NCT03360344|DEVICE|Kinesio 4 inch Tape|Kinesio Tape for the control group will be a 4 inch Kinesio Tape applied to the scapular spine for three day increments over three weeks of the study.
215031791|NCT03360344|DEVICE|Cock up Splint and Lumbrical exercises|A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
215031792|NCT01145183|DRUG|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
215031793|NCT01145183|DRUG|Placebo|Matched placebo daily dosing
215031794|NCT04196621|DEVICE|High viscous artificial tears|Instillation of one drop high viscous artificial tears
215031795|NCT04196621|DEVICE|Low viscous artificial tears|Instillation of one drop low viscous artificial tears
214281226|NCT03346915|BEHAVIORAL|WoW and BNI|The Text/web based health information technology system, WoW, will provide educational resources for participants and their families to learn more about HPV vaccination and cervical cancer screening. WoW will be tailored to the participant and will be based on the participant's cancer screening and HPV vaccine health needs; It will then send custom text messages based their concerns and will remind them to schedule and attend their doctor's appointment. The brief negotiated interview will encourage and empower participants to have positive behavioral changes in regards to their health.
214281227|NCT00807378|OTHER|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
214281228|NCT04883931|DRUG|Normal Saline|0.5 ml 0.9% normal saline will drop on both eyes twice in a day.
214281229|NCT04883931|BIOLOGICAL|Breast milk|0.5 ml breast milk from all infant's own mother will drop both eyes twice in a day
214281230|NCT02396485|OTHER|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
214281231|NCT02837601|DEVICE|AirSeal® Insufflation System (AIS)|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
214281232|NCT06413563|DIAGNOSTIC_TEST|Complete blood count|"Complete blood count will be done for all patients and then will search about CD4, CD8 T lymphocyte cells surface markers~* CD56 Natural killer cells surface marker~* CD19 Lymphocyte cells surface marker"
214281233|NCT03948711|DEVICE|Near-infrared spectroscopy (NIRS) monitoring of cerebral oxygenation|Monitoring before anesthesia to hospital admission. No treatment decisions made based on monitoring.
214281234|NCT03266965|DRUG|Carbidopa|All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
214281235|NCT03266965|DIETARY_SUPPLEMENT|L-Histidine|Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
214281236|NCT06199895|DRUG|Paclitaxel Polymeric Micelles for Injection|300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
214281237|NCT05084378|DRUG|Povidone-Iodine Lavage Solution|0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.
214281238|NCT05084378|DRUG|Chlorhexidine Lavage Solution|0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.
214281239|NCT05084378|DRUG|Topical Antibiotic|2 grams Vancomycin powder
214281240|NCT05084378|DRUG|Saline Lavage Solution|1 litre of sterile isotonic saline
214281241|NCT00257543|PROCEDURE|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
214281242|NCT05288920|PROCEDURE|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
215031796|NCT04576754|DEVICE|WB001|The WB001 treatment consists of PPD-specific psychoeducational lessons and CBT-specific skills or tools. The lessons teach PPD-specific information to normalize and contextualize postpartum experiences, as well as provide information on effective mood management and mental health promotion in the context of having recently given birth. Patients complete up to 30 psychoeducational lessons. In addition, patients access and apply core CBT-based tools upon endorsing a negative mood. These tools are core to CBT and are considered transdiagnostic. Examples include thought challenging, behavioral activation, mindfulness, and self-care.
215031797|NCT04576754|DEVICE|Educational|The Comparison Condition provides educational only material about various mental and physical topics, delivered in an interactive smartphone application that is accessible anytime of day.
215031798|NCT04446052|DRUG|GM-CSF priming|
215031799|NCT04446052|DRUG|Placebo|Placebo
215031800|NCT02753972|BEHAVIORAL|Mindful Eating and Living|8 week mindfulness skills intervention
214281243|NCT05288920|DRUG|Transforaminal injection of Steroids alone|Transforaminal injection of Steroids alone
214281244|NCT00977860|RADIATION|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
214281245|NCT04269096|OTHER|Protocol Compliance|Compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol
214657243|NCT04788992|OTHER|Control group|Dementia care training consists of dementia care e-books and peer support program without dementia virtual reality activity
214469652|NCT04829188|BEHAVIORAL|Enhanced Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives.
214469653|NCT05715125|DRUG|Dose A VTX958|Dose A VTX958
214469654|NCT05715125|DRUG|Dose B VTX958|Dose B VTX958
214469655|NCT05715125|DRUG|Placebo|Placebo
214469656|NCT06751485|DRUG|JSKN003|Experimental drug
214469657|NCT06751485|DRUG|Doxorubicin|Active Comparator
214469658|NCT06751485|DRUG|Paclitaxel|Active Comparator
214469659|NCT06751485|DRUG|Topotecan|Active Comparator
214469660|NCT04263597|DRUG|2'-fucosyllactose|2FL powder will be provided to participants randomized to receive 2FL in packets. They will be instructed to drink this daily by adding the required amount to food or drink. It may also be mixed in standard feeds or mixed with water and administered by enteral tube, whenever applicable.
214469661|NCT06479148|DEVICE|enVista® Aspire™|Eyes will receive enVista® Aspire™ lenses
214469662|NCT06479148|DEVICE|An IOL with a slightly extended depth of focus|Eyes will receive lenses with a slightly extended depth of focus
214469663|NCT06479148|DEVICE|MX60E|Eyes will receive MX60E lenses
214469664|NCT05871372|DEVICE|Brain Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care, respectively, The depression cohort will also have deep brain stimulation (DBS) leads implanted as part of their trial. We will deliver stimulation via the DBS and sEEG electrodes. We will adhere to well known safety parameters.
214469665|NCT05871372|DEVICE|sEEG Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care. We will deliver stimulation via the sEEG electrodes. We will adhere to well known safety parameters.
214469666|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
214469667|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
214469668|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
214469669|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
214469670|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
214469671|NCT04447040|DRUG|Placebo|Placebo tablets administered as a single two-tablet dose.
214469672|NCT06348680|OTHER|Video assisted episiotomy repair training|Midwifery Intervention The 'video recording' prepared by researchers specialized in the field of midwifery to increase the episiotomy repair skills of midwifery students will be used as training material. The content of the video recording is as follows: control before episiotomy repair, episiotomy repair, subcutaneous suturing, skin suturing, suturing techniques (Continuous, Simple Intermittent, Mattress). After the video recording is completed, it will be restarted and shown to the students in the experimental group continuously throughout the application period. At the end of the application period, students will be re-evaluated.
214469673|NCT05622968|DEVICE|Foley catheter|Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water
214469674|NCT05622968|DRUG|Intravaginal prostaglandin E2|Insertion of intravaginal Dinoprostone
214469675|NCT06393062|DIAGNOSTIC_TEST|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.
214469676|NCT06191900|BIOLOGICAL|Autologous tumor infiltrating lymphocyte injection（GT201）|GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
214469677|NCT03808831|DEVICE|Fall detection and prevention system|The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
214469678|NCT03808831|DEVICE|Sham fall detection and prevention system|The sham system with record but no alert function
214469679|NCT04076618|DEVICE|Vest|Weighted Vest worn \> or = 8 hours per day
214469680|NCT04076618|BEHAVIORAL|Resistance Exercise Training|Structured exercise training 3 days a week
214469681|NCT04076618|BEHAVIORAL|weight loss program|a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
214469682|NCT04978480|OTHER|no intervention|There is no intervention. We are only collecting standard of care data.
214469683|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
214469684|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
214469685|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
214469686|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
214469687|NCT05943665|DRUG|MDMA|medication and therapy combined
214469688|NCT04903678|DRUG|Melphalan|Melphalan is performed for intrathecal chemotherapy
214469689|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 1)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 800 MBq/m²"
214844168|NCT06467201|DRUG|KSHN001126 600mg|6 subjects will receive single oral dose of 600mg
214844169|NCT02092883|DRUG|ACTH|PK PET scan before and after ACTH treatment
215057521|NCT02176200|DRUG|Berodual® HFA-MDI, low inspiratory flow rate|
215031801|NCT02753972|BEHAVIORAL|Active Weight Loss Control|8 week active weight loss control group
215031802|NCT00133705|DRUG|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
215031803|NCT00133705|DRUG|Inert Capsule|sugar pill
215031804|NCT01418105|PROCEDURE|Videofluroscopic swallow study (VFSS)|Barium, radiation
215031805|NCT01418105|PROCEDURE|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
215031806|NCT01418105|PROCEDURE|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
215031807|NCT04164719|DRUG|TNX-102 SL|Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
215031808|NCT00400101|BIOLOGICAL|Virosome-formulated synthetic peptides (malaria vaccine)|
215031809|NCT00824954|PROCEDURE|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
215031810|NCT03840967|DRUG|Niraparib|Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
215031811|NCT01993732|PROCEDURE|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
215031812|NCT00246103|DRUG|Valproic acid|Beginning Dose, Level 1: 15 mg/kg/day.
215031813|NCT00246103|DRUG|Epirubicin|Beginning Dose, Level 1: 75 mg/m\^2.
215031814|NCT00246103|DRUG|5-fluorouracil|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m\^2.
215031815|NCT00246103|DRUG|Cyclophosphamide.|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m\^2.
214469690|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 2)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 1600 MBq/m²"
215031816|NCT03320005|OTHER|Resistance training group|Resistive exercises for legs and arms
215031817|NCT05077423|DRUG|CD33*CD3 BsAb|CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
215031818|NCT04023058|PROCEDURE|Mitral surgery|Guidelines approved mitral surgery
215031819|NCT04881058|DEVICE|RF Non-Invasive Treatment|Self-controlled single-arm group using the PicoSure device.
215031820|NCT03906409|OTHER|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
215031821|NCT03906409|OTHER|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
215031822|NCT01795157|DEVICE|CCADSS|Questionnaire is transferred wireless to the physician's PC
215031823|NCT01795157|DEVICE|pen-paper|Questionnaire completed and transferred to the physician using standard methods
215031824|NCT01855984|DIETARY_SUPPLEMENT|Oral mixed tocotrienols|200mg per day
215031825|NCT01855984|DIETARY_SUPPLEMENT|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
215031826|NCT01342666|DIETARY_SUPPLEMENT|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
215031827|NCT01342666|DIETARY_SUPPLEMENT|Cucumber consumption|Daily consumption of 300g of cucumber.
215031828|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
215031829|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement|(List No- P968/Z0)
215031830|NCT02523027|OTHER|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
215031831|NCT00175500|DEVICE|Large Diameter Femoral Head|
215031832|NCT05481684|OTHER|Normal Progesterone group|No progesterone supplementation
215031833|NCT05481684|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, vaginal pills (Lutinus 2\*1) or SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day. Progesterone supplementation was discontinued if there was no pregnancy. Progesterone supplementation at the same dose was continued until 10 gestational weeks for viable pregnancies.
215031834|NCT04114825|BIOLOGICAL|RV001V|RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
215031835|NCT04114825|OTHER|Placebo|Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
215031836|NCT05012579|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
215031837|NCT05938686|OTHER|Home_Based Digital Mindful Dance Program|Home\_Based Digital Mindful Dance Program including warm up, dance and cool down for 60 minute with 12 weeks.
215031839|NCT04033640|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|"The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product."
215031840|NCT04033640|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
215031841|NCT04033640|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
215031842|NCT04033640|DIAGNOSTIC_TEST|Complete blood count (CBC)|In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
215057522|NCT02176200|DRUG|Berodual® HFA-MDI, medium inspiratory flow rate|
214281246|NCT01538043|OTHER|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
214281247|NCT03338374|DEVICE|Biventricular pacemaker|All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
214281248|NCT00851747|DRUG|Phosphatidylcholine Deoxycholate|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
214281249|NCT00851747|DRUG|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
214281250|NCT03431428|PROCEDURE|transanal surgery|Transanal surgery could Preserve anus to reduce trauma and improve the quality of life
214281251|NCT03431428|PROCEDURE|Miles surgery|Miles surgery cut off the anus, enlarge the trauma and reduce the quality of life.
214281252|NCT03431428|DRUG|Preoperative chemoradiotherapy|After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
214281253|NCT06558032|DRUG|Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia)|One tablet of the test drug was given orally under fasting condition
214281254|NCT06558032|DRUG|Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)|One tablet of the test drug was given orally under fasting condition
214281255|NCT00543504|DRUG|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
214281256|NCT00543504|DRUG|Sorafenib|200 mg By Mouth Daily for 28 Days
214281257|NCT00543504|DRUG|Erlotinib|50 mg By Mouth Daily for 28 Days.
214281258|NCT00543504|DRUG|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
214281259|NCT00543504|DRUG|Lapatinib|250 mg By Mouth Daily for 21 Days.
214281260|NCT00543504|DRUG|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
214281261|NCT00543504|DRUG|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
214281262|NCT02215512|DRUG|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
214281263|NCT02407353|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
214469691|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 3)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 2700 MBq/m²"
214469692|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 4)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 4000 MBq/m²"
214469693|NCT05796167|DRUG|Pimavanserin|Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
214281264|NCT02407353|DRUG|Placebo|Placebo which will be dosed as oral suspension, single doses to match PF-06648671
214281265|NCT01264900|BEHAVIORAL|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
214281266|NCT04873505|DIETARY_SUPPLEMENT|troches|Take one troche after each meal.
214281267|NCT05601284|BEHAVIORAL|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
214281268|NCT05601284|BEHAVIORAL|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
214281269|NCT05863832|DRUG|Ciprodiazole|Ciprofolxacin 500 mg / Metronidazole 500 mg
214281270|NCT05863832|DRUG|Ciprofloxacin Tablets & Metronidazole tablets|Ciprofolxacin 500 mg + Metronidazole 500 mg
214281271|NCT04884854|DEVICE|Efferon LPS|Efferon LPS is a single-use therapeutic device for extracorporeal blood purification using direct hemoperfusion. Detoxification is carried out by selective adsorption of lipopolysaccharides (bacterial endotoxins) and non-selective removal of cytokines by internal porous structure. It is a cylindrical polycarbonate casing filled with spherical granules of LPS-selective polymeric adsorbent mesoporous beads and isotonic sodium chloride solution. The device is registered in Russia as a medical device RZN 2019/8886.
214469694|NCT05218889|DRUG|surufatinib + camrelizumab + nab-paclitaxel + S-1|"phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40mg bid, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1"
214281272|NCT06506786|OTHER|Garden-fresh Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables harvested from their gardens.
214469695|NCT05218889|DRUG|nab-paclitaxel + gemcitabine|nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
215031843|NCT06329219|DEVICE|water-filtered Infrared-A radiation|The water-filtered Infrared-A radiation device is designed for self-administered home treatments. The regimen prescribes 30-minute sessions, five times weekly, spanning 12 weeks.
215031844|NCT05872412|DRUG|Doxorubicin|60 mg/m2 IV bolus on day 1 every three weeks for four cycles.
215031845|NCT05872412|DRUG|Cyclophosphamide|600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.
215031846|NCT05872412|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour weekly for 12 weeks
214281273|NCT06506786|OTHER|Supermarket Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables purchased from a supermarket.
214281274|NCT02024815|RADIATION|External Beam radiotherapy|External Beam radiotherapy
214281275|NCT02458040|DRUG|Drug selected in the study|
214281276|NCT00039975|DRUG|Indinavir sulfate|
214281277|NCT00039975|DRUG|Ritonavir|
214281278|NCT00039975|DRUG|Amlodipine|
214281279|NCT00039975|DRUG|Diltiazem HCl|
214281280|NCT01051323|DRUG|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
214281281|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
214281282|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
214281283|NCT01109043|DRUG|Bisoprolol or bisoprolol + HCTZ|Film-coated tablets containing 5 mg or 10 mg of bisoprolol hemifumarate or film-coated tablets containing 5 mg of bisoprolol fumarate (2:1) and 12.5 mg of HCTZ were given
214469696|NCT05752071|DEVICE|Gastric electrical stimulation|Mounting of a temporary gastric pacemaker
214469697|NCT03920358|DEVICE|FRED, FRED Jr and FRED X|Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm
214469698|NCT02270814|DRUG|nab-paclitaxel|
214469699|NCT02270814|DRUG|Cisplatin|
214469700|NCT02270814|DRUG|Carboplatin|
214469701|NCT02270814|BIOLOGICAL|Cetuximab|
215031847|NCT05872412|DRUG|Carboplatin|Area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles
215031848|NCT00600340|BIOLOGICAL|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
215031849|NCT00600340|BIOLOGICAL|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
214281284|NCT04905485|BEHAVIORAL|VIOME Precision Nutrition Program|Precision diet and supplement recommendations based on participants' microbiome results.
214281285|NCT05890872|DEVICE|Aliya Pulsed Electric Fields (PEF)|Percutaneous or Endobronchial PEF
214281286|NCT04873804|OTHER|Transcranial Direct Current Stimulation|The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
214281287|NCT02627105|BEHAVIORAL|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
214469702|NCT01928394|BIOLOGICAL|Nivolumab|
214469703|NCT01928394|BIOLOGICAL|Ipilimumab|
214469704|NCT01928394|DRUG|Cobimetinib|
214469705|NCT05782075|OTHER|Remote biological monitoring by a heart failure nurse|Review of biological results by a nurse (IDE) trained in heart failure monitoring, alongside the cardiologist, at S1, S2, M1, M2 and M3.
214469706|NCT02342613|BIOLOGICAL|Activated PTCy-MILs|The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
214469707|NCT04433208|DIETARY_SUPPLEMENT|Complex oligosaccharide|Complex oligosaccharide concentrate
215031850|NCT06549335|DRUG|Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)|"Induction therapy:~The ZGR regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 28 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-28;~2. Obinutuzumab, 1000mg, ivgtt, day 1/8/15 (C1), day1 (C2-6);~3. Lenalidomide, 25 mg qd, po, day 2-11.~Maintenance therapy:~1. Obinutuzumab, ivgtt,1000mg, every 3 months for 2 years;~2. Lenalidomide, 25mg, PO, during 1-10 days in every 28 days for 6 cycles."
215031851|NCT05754125|DIETARY_SUPPLEMENT|Di-Leucine Supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
215057523|NCT02176200|DRUG|Berodual® HFA-MDI, high inspiratory flow rate|
215057524|NCT03973112|DRUG|HLX10 3mg/kg|anti-PD-1
214281288|NCT02627105|BEHAVIORAL|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
214281289|NCT04770662|OTHER|Questionnaires|"Administered Questionnaires:~* Dutch version of Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS, Goodman W.K. e.a.)~* Dutch version of Eating Disorder Inventory-3 (EDI-3, David M. Garner)~* General Questionnaire: demografic , scholar and social information and child psychiatric history~* Dutch version of the Child Behavior Checklist (CBCL, T.M. Achenbach)~* Anorectic Behavior Observation Scale (ABOS, Vandereycken W., Universitair Centrum Kortenberg, 1992)"
214281290|NCT02978430|DEVICE|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
214281291|NCT02978430|OTHER|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
214281292|NCT02146898|OTHER|Position|
214469708|NCT04433208|DIETARY_SUPPLEMENT|Probiotic|Probiotic
214469709|NCT04433208|OTHER|PPI|Over-the-counter proton pump inhibitor (PPI)
214469710|NCT04433208|OTHER|H2 Blocker|Over-the-counter H2 blocker
214281293|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 0 to 7 days
214657244|NCT05053646|PROCEDURE|Meniscal repair|The meniscus is trimmed with an arthroscopic punch followed by an electric shaver to expose the margins of the tear and remove damaged tissue. Vertical sutures are made using TRUESPAN™ Meniscal Repair System (DePuy Synthes) to approximate both the femoral and tibial surfaces of the torn meniscus.
215031852|NCT05754125|DIETARY_SUPPLEMENT|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
214281294|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 8 to 14 days.
215031853|NCT05754125|DIETARY_SUPPLEMENT|Collagen Supplement|Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
214281295|NCT05202652|DIETARY_SUPPLEMENT|HealthSpan|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the oral capsule containing the active ingredients, for three consecutive months.
214281296|NCT05202652|DIETARY_SUPPLEMENT|Placebo|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the placebo, for three consecutive months.
214281297|NCT01778218|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
214281298|NCT02655796|DEVICE|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
214281299|NCT05805410|BEHAVIORAL|robotic hippotherapy|A custom designed cable-driven robotic system that mimics horseback movement during walking was used in this study.
214281300|NCT05805410|BEHAVIORAL|Conventional physical therapy|Stretching of trunk and leg muscles, followed by sitting and standing balance training, and conventional treadmill walking.
214281301|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Single pill
214281302|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg|Single pill
214469711|NCT03208049|BEHAVIORAL|Behavioral Therapy (BT)|Behavioral Therapy will regulate time spent in bed based on information collected from sleep diaries during evaluation and treatment. Behavioral therapy is designed to improve sleep quality by matching opportunity for sleep to the amount of average total sleep calculated from sleep diaries. Once the quality of sleep has improved, sleep quantity is gradually increased by slowly increasing sleep opportunity. Stimulus control will strengthen the bed/sleep association by eliminating non-sleep activities from the bedroom.
214281303|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg|oral tablet
214281304|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg|oral tablet
214281305|NCT04518293|DRUG|Telmisartan 20 mg/indapamide 1.25 mg|oral tablet
214281306|NCT04518293|DRUG|telmisartan 40 mg/indapamide 2.5 mg|oral tablet
214281307|NCT04518293|DRUG|Amlodipine 2.5 mg/indapamide 1.25 mg|oral tablet
214469712|NCT03208049|BEHAVIORAL|Cognitive Therapy (CT)|Cognitive Therapy is designed to identify maladaptive beliefs about sleep, challenge their validity, and replace them with more adaptive thinking patterns. This therapy aims to reduce sleep-related worry, anxiety, and fear. The treatment phase of the study lasts six weeks. During treatment, you will meet with a study therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
214469713|NCT05492825|OTHER|Yoga|Each yoga class will follow a standardized structure, allowing participants to easily re-join if they miss classes. Yoga classes will be adapted to the abilities and limitations of each study participant, for example, using a chair for sitting exercises rather than the floor and to assist with balance. Postures (asanas) will target back pain and include mindfulness, relaxation, and breathing practices integral to hatha yoga, with focus on breath-based movement throughout. Each group will have 1-2 yoga instructors and no more than 5 participants per yoga instructor (up to 10 participants/group).
214469714|NCT05492825|OTHER|Physical Therapy|The assessment at the second screening visit by the Physical Medicine \& Rehabilitation physician/Physical Therapy staff will be available to physical therapists in the Electronic Health Record and will guide the type of exercises, to focus on stabilization (strengthening core trunk muscles) and flexion or extension exercises. Sessions are divided into 30 minutes of working directly with a physical therapist and 30 minutes of supervised aerobic exercise (on treadmill or recumbent bike). Participants will receive a guidebook for guiding and recording home practice, based on Saper's guidebook and modified based on feedback from experts and stakeholders for clarity and cultural appropriateness.
214657245|NCT05053646|PROCEDURE|Marrow venting procedure|After meniscal repair, a bone marrow venting procedure will be performed: a 45° micro-fracture awl is repeatedly penetrated through the bone of the intercondylar notch at the PCL origin until marrow elements are seen to enter the joint.
215031854|NCT00679614|DRUG|tramacet, naloxone|Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.
215057525|NCT03973112|DRUG|HLX04 5mg/kg|anti-VEGF, a biosimilar to Avastin
215057526|NCT03973112|DRUG|HLX04 10mg/kg|anti-VEGF, a biosimilar to Avastin
215057527|NCT04178928|DRUG|Levothyroxine|investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
215057528|NCT05597540|DRUG|Short antibiotic treatment|7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
214281308|NCT04518293|DRUG|amlodipine 5 mg/indapamide 2.5 mg|oral tablet
214281309|NCT01278979|DEVICE|"Objective measurements of perineal tears with Peri-Rule"|"Four measurements will be used in this study.~1. Depth of tear, from the fourchette into the greatest depth of the perineal body.~2. Length of tear, from the fourchette to the apex of the vaginal tear.~3. Length of tear, from the fourchette along perineal skin towards the anus.~4. Length of the perineal body, from the fourchette to outer margin of anus."
214281310|NCT01278979|OTHER|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
215031855|NCT00679614|DRUG|tramacet|Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.
215031856|NCT00679614|DRUG|Acetaminophen|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
215031857|NCT00722670|BEHAVIORAL|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
215031858|NCT00722670|BEHAVIORAL|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
215031859|NCT03884673|DRUG|DTG+ 3TC|It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
215031860|NCT05530304|DEVICE|Triple inner branched arch stentgraft|New findings regarding treatment planning and management of patients with aortic arch pathologies.
215031861|NCT00181246|DRUG|Transdermal Fentanyl|
215031862|NCT01524406|DRUG|HPP593|Oral, twice a day.
215031863|NCT01524406|DRUG|Placebo|Oral, twice a day.
215031864|NCT03847519|DRUG|ADXS-503|A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
215031865|NCT03847519|DRUG|Pembrolizumab|a programmed death receptor-1 (PD-1)- blocking antibody.
215031866|NCT04403776|DRUG|tofacitinib MR 11 mg|Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
215031867|NCT04403776|DRUG|tofacitinib IR 5 mg|Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
215031868|NCT05827341|OTHER|No intervention|No intervention needed
215031869|NCT01228032|OTHER|Care team|The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
215031870|NCT03787147|DEVICE|Google Cardboard|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
215031871|NCT03787147|DEVICE|Oculus|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
215031872|NCT03787147|DRUG|Lidocaine Hydrochloride|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
215031873|NCT03787147|DRUG|Bupivacaine|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
215031874|NCT01652157|BIOLOGICAL|ULTRESA|pancreatic enzyme replacement therapy
214281311|NCT01369758|DEVICE|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
215031875|NCT01652157|BIOLOGICAL|PANCREAZE|pancreatic enzyme replacement therapy
215031876|NCT01652157|BIOLOGICAL|CREON|pancreatic enzyme replacement therapy
215031877|NCT01652157|BIOLOGICAL|ZENPEP|pancreatic enzyme replacement therapy
215031878|NCT01652157|BIOLOGICAL|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
215031879|NCT01652157|BIOLOGICAL|PERTZYE|pancreatic enzyme replacement therapy
215031880|NCT01652157|OTHER|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
215031881|NCT02712203|BIOLOGICAL|MMR vaccine / MMRV vaccine|Subcutaneous injection, two doses
215031882|NCT03347669|DEVICE|Sudoscan®|Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
215031883|NCT01687062|OTHER|FeSO4|
215031884|NCT01687062|OTHER|reduction of phytate|
215031885|NCT01687062|OTHER|NaFeEDTA|
215057529|NCT05597540|DRUG|Usual antibiotic treatment|14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
215031886|NCT00798408|DIETARY_SUPPLEMENT|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
215031887|NCT00798408|DIETARY_SUPPLEMENT|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
215031888|NCT01928056|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
215031889|NCT01238887|DIETARY_SUPPLEMENT|Microcrystalline Cellulose placebo pill|Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
215031890|NCT01238887|DIETARY_SUPPLEMENT|Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
215031891|NCT01238887|DIETARY_SUPPLEMENT|Garcinia Cambogia derived Hydroxycitric Acid|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
215031892|NCT01738412|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
214281312|NCT06504706|PROCEDURE|Matcha Tea|Japanese tea rich in antioxidants and Catechins
214281313|NCT06504706|PROCEDURE|Green Tea|Green tea rich in catechins
214281314|NCT02066246|DEVICE|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
215031893|NCT02089204|RADIATION|FMISO-PET/CT|Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
215031894|NCT02089204|RADIATION|FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
215031895|NCT02089204|RADIATION|contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
215031896|NCT05255666|DRUG|Pembrolizumab|400 mg intravenously
215031897|NCT05255666|DRUG|Liposomal Irinotecan|Starting at 50 mg/m\^2. The dose may be increased to 70 mg/m\^2 if tolerated or dose reduced to 35 mg/m\^ if treatment-emergent severe adverse event (TESAE) occurs.
215031898|NCT02314923|BIOLOGICAL|V920 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.
215031899|NCT02314923|OTHER|Placebo|0.9% Saline
215031900|NCT00725985|DRUG|Cladribine|Cladribine tablets were administered until CDMS conversion, whichever occur first.
214479431|NCT04889066|DRUG|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
215031901|NCT00725985|DRUG|Placebo|Placebo matched to cladribine tablets were administered.
215031902|NCT00725985|DRUG|Rebif® new formulation (RNF)|Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
215031903|NCT03419819|DIETARY_SUPPLEMENT|PKU Sphere|PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria.
215031904|NCT03548129|DRUG|phosphomycin|Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
215031905|NCT03548129|DRUG|Culture specific antibiotic therapy|Culture-specific antibiotic treatment for 5 days
215031906|NCT03548129|DIAGNOSTIC_TEST|Pre-treatment Urine Culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
214281315|NCT02066246|DEVICE|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
214281316|NCT03385512|BEHAVIORAL|OPEN High Touch|This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.
214281317|NCT03385512|BEHAVIORAL|OPEN High Tech|The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
214281318|NCT03385512|BEHAVIORAL|ASK Poster in Exam Rooms|This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
215031907|NCT03548129|DIAGNOSTIC_TEST|Antimicrobial sensitivity testing|Susceptibility of urinary pathogens to various antimicrobials
215031908|NCT03548129|DIAGNOSTIC_TEST|Post-treatment urine culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
215031909|NCT04476784|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
215031910|NCT04476784|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
215031911|NCT04476784|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
215031912|NCT02020226|DRUG|TH-302|480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
215031913|NCT02551783|PROCEDURE|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
214281319|NCT05451225|BEHAVIORAL|Targeted Educational Campaign|"Correction Officers will be exposed to the Targeted Educational Campaign (TEC) with the aim to increase their knowledge about the early symptoms of psychosis, and how to make a referral to the Correction Health Services staff, their self-efficacy to detect symptoms of psychosis and make referrals, and their expectations about their ability to be successful in making that referral (and for referrals to result in beneficial outcomes).~Correction Officers will be approached and recruited during roll call and in the staff canteen where they take their meal breaks, or at a time/location agreed upon by the Department of Correction, to complete brief surveys at three different times; pre-exposure, after 6 months, and after 12 months from the beginning of the TEC."
214281320|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
214281321|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
214281322|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
215031914|NCT02551783|PROCEDURE|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
215031915|NCT06637189|DRUG|Ganirelix|Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).
215031916|NCT06637189|DRUG|Medroxyprogesterone Acetate 10 MG|Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
215031917|NCT01515371|DRUG|IncobotulinumtoxinA|"Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.~For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection."
215031918|NCT01515371|DRUG|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
215031919|NCT00054262|DRUG|T900607|
214281323|NCT01764672|DRUG|Methylphenidate|Oral dose 40mg (2 x 20mg)
214281324|NCT01764672|OTHER|Placebo|Oral intake of 2 placebo tablets
214281325|NCT00016887|BIOLOGICAL|filgrastim|
214281326|NCT00016887|BIOLOGICAL|recombinant interferon alfa|
214281327|NCT00016887|DRUG|carmustine|
214281328|NCT00016887|DRUG|cyclophosphamide|
214281329|NCT00016887|DRUG|cytarabine|
214281330|NCT00016887|DRUG|dexamethasone|
214479432|NCT06863987|DRUG|Valsartan Oral Solution|"Valsartan oral solution, taken by mouth, once daily. It is recommended that the medication be administered at the same time each day (e.g., in the morning).~The dose administered is based on the subject's weight at the V1 visit:~Halve dose:~\<35 kg: 7 mL (equivalent to valsartan 20 mg);~* 35 kg: 13 mL (equivalent to valsartan 40 mg).~Full dose:~\<35 kg: 13 mL (equivalent to valsartan 40 mg);~* 35 kg: 27 mL (equivalent to valsartan 80 mg)."
214657246|NCT05948176|OTHER|The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition|It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years
214281331|NCT00016887|DRUG|etoposide|
214281332|NCT00016887|DRUG|melphalan|
214281333|NCT00016887|PROCEDURE|bone marrow ablation with stem cell support|
214281334|NCT00016887|PROCEDURE|peripheral blood stem cell transplantation|
214281335|NCT00016887|RADIATION|radiation therapy|
214281336|NCT03571425|OTHER|Oral Placebo|A placebo beverage will be consumed orally
215031920|NCT03748550|BEHAVIORAL|Aerobic exercise|All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.
214281337|NCT03571425|OTHER|Oral Protein|A protein beverage will be consumed orally
214281338|NCT03571425|OTHER|Enteral Protein|A protein beverage will be consumed via a naso-gastric feeding tube
214281339|NCT05964205|OTHER|Electronic clinical decision support tool|Electronic clinical decision support tool
214469715|NCT05492825|OTHER|Treatment As Usual|Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians. Those patients who receive on-site medical care have the opportunity to address nonpharmacological and pharmacological treatment with onsite physicians and physician assistants, and to receive referral to specialty care including physical therapy and orthopedics at multiple Montefiore locations throughout the Bronx.
214469716|NCT02658253|BIOLOGICAL|PRIMVAC|3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
214469717|NCT02658253|BIOLOGICAL|GLA-SE|2.56 µg of GLA content
214469718|NCT02658253|BIOLOGICAL|Alhydrogel|0.85 mg og Aluminium content
214469719|NCT02658253|BIOLOGICAL|Placebo|0.9% Na cl
214479433|NCT06863987|DRUG|Placebo|"placebo, taken by mouth, once daily. It is recommended that the medication be administered at the same time each day (e.g., in the morning).~The dose administered is based on the subject's weight at the V1 visit:~Full dose:~\<35 kg: 13 mL ;~* 35 kg: 27 mL .~Placebo dosing during elution phase:~\<35 kg: 7 mL;~* 35 kg: 13 mL."
215031921|NCT06637410|DEVICE|High intensity laser therapy|HILT was performed by a single physiotherapist experienced in using a laser device. During HILT application, the patients were seated comfortably on chairs and their shoulders were in neutral position. The wavelength of the laser light used was 1064 nanometers. In the HILT group, the device was used on the rotator cuff muscles in two stages: phase I and phase II. Pulse method was used in phase I for analgesic effect. A standard frequency of 25 Hz is applied. During the first four therapy sessions, it was aimed to provide an analgesic effect by using 8 W power and 12 J/cm dose. The rays were applied to the rotator cuff muscles area in a circle from outside to inside for 2.5 minutes, for a total energy of 300 J, on an area of 25 cm2. For the biostimulation effect, the continuous wave method was used in phase II. n the next five sessions, biostimulation effect was applied using 7W power. A dose of 100 J/cm was applied longitudinally to the rotator cuff muscles.
215031922|NCT06637410|DEVICE|Ultrasound therapy|US therapy was performed by a single physiotherapist experienced in using US device. Calibration and control of the device are performed regularly. During US therapy, the patients were seated comfortably on chairs and their shoulders were in neutral position. The standard US dose was 1.2 W/cm2. The duration of ultrasound was 8 minutes. Using slow circular movements, the physiotherapist applied the transducer head of US device over the shoulder joint on an area of 25 cm2. US device was used in pulsed mode at a frequency of 1 MHz. The therapeutic ultrasound pulse cycle was 50%.
215031923|NCT06637410|OTHER|Therapeutic Exercise|ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set underCalibration and control of the device are performed regularly.
215031924|NCT06638489|OTHER|High-Intensity-Focused-Electromagnetic-Therapy (HIFEM)|The HIFEM stimulation was administered using an Emsella instrument (manufactured by BTL Industry Inc., Boston, MA). The frequency ranged between 50 and 60Hz, and the intensity was as high as the patient could tolerate, which was usually up to 100%.
215031925|NCT06638489|OTHER|Pelvic-Floor-Muscle-Training (PFMT)|The PFMT protocol was that outlined by previous study. The participants were instructed to execute 5 rapid contractions over a span of 3 seconds and 10 prolonged contractions, each lasting between 3 to 8 seconds, with intervals of 10 seconds for relaxation in between, all while in a crook-lying position.
215031926|NCT06640673|DIAGNOSTIC_TEST|Hd-EEG|Subjects undergo a clinical and neuropsychological assesment, then a Hd-EEG both during resting state and execution of tasks, and structural Magnetic Resonance Imaging
215031927|NCT06641531|OTHER|Screening pap smear test|"The patient put in dorsal lithotomy position and place the feet in stirrups or on foot rests . then, the physician will insert a cusco speculum into the vagina to hold vaginal wall open . The specimens will be collected as follows; firstly, the speculum will be inserted without lubricant. Any mucous, discharge or blood will be removed with dry cotton. A wooden spatula will be used for sampling ectocervix which will be rotated 360 degrees. For sampling endocervix, A brush or a swab will be rotated only 90 degrees as the circumferential bristles will be in contact with the entire surface the moment the brush is inserted.~The samples will be applied to the slides which will be encoded and immediately fixed in 95% ethanol and the samples will be transferred to pathology department to be stained by the standard Papanicolaou stain"
215031928|NCT04789941|DRUG|Cis Platinum + Irinotecan|Studying the efficacy and safety of neoadjuvant cisplatin and irinotecan use in treatment of locally advanced cancer cervix.
215031929|NCT06015516|DRUG|Minoxidil Tablets|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
214281340|NCT01637272|DRUG|SOM230|Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 \& 60 mg of pasireotide (as free base) \& solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
214657247|NCT05340309|BIOLOGICAL|Atezolizumab and Recombinant Human Hyaluronidase|Given SC
215031930|NCT06015516|DRUG|Minoxidil topical solution 20 mg/ml|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
215031931|NCT06639230|DEVICE|laser therapy|Laser-treated group (test group): This group consisted of ten patients treated using diode lasers. The diode laser was operated in continuous wave mode with an output power of 3 W in contact mode to excise the pyogenic granuloma. The tip was moved around the base of the lesion in circles. The base of the lesion was cut precisely till the whole mass was entirely excised.
215031932|NCT06639230|DRUG|Sclerotherapy|Sclerotherapy-treated group (control group): This group consisted of ten patients treated with injections of sclerosing agent. After anaesthetizing the surgical site with a local anesthetic agent, The lesion was injected with a 2.5% concentration until it leaked out from the surface, leading to necrosis and spontaneous detachment of the lesion.
215031933|NCT05812690|OTHER|This is a non intervention - observation only study|This is non intervention study
215031934|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally. Electroacupuncture (EA) was applied to the BL32 and BL54 acupoints at a frequency of 2/100Hz. Each treatment lasting for 30 minutes. Patients received five acupuncture treatments per week for two consecutive weeks
215031935|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6). The acupuncture and EA procedure for the lumbosacral acupoints was the same as in Group A. After 30 minutes of treatment, abdominal and lower limb acupoints were selected for an additional 30 minutes treatment.Each treatment lasting for 60 minutes.Patients received five acupuncture treatments per week for two consecutive weeks
215031936|NCT05332704|DRUG|ONO-4685|-Part A: Single ascending doses of ONO-4685 as a single IV dose (Cohort A1-A5).
215031937|NCT05332704|DRUG|Placebo|-Part A: Single ascending doses of placebo as a single IV dose (Cohort A1-A5).
215031938|NCT05332704|DRUG|ONO-4685|-Part B: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort B1 and B2)
215031939|NCT05332704|DRUG|Placebo|-Part B: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort B1 and B2).
215031940|NCT05332704|DRUG|ONO-4685|-Part C: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort C1 and C2).
215031941|NCT05332704|DRUG|Placebo|-Part C: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort C1 and C2).
215031942|NCT06462404|DRUG|E2086|E2086 oral tablets.
215031943|NCT06462404|DRUG|E2086 Placebo|E2086 matching placebo tablet.
215031944|NCT06462404|DRUG|Active Comparator|Active comparator oral tablets.
215031945|NCT06462404|DRUG|Active Comparator Placebo|Active comparator matching placebo tablet.
215031946|NCT06563986|DRUG|Systemic treatment (FTD-TPI and bevacizumab)|"Systemic treatment (FTD-TPI and bevacizumab) administration is according to standard clinical practice. Each treatment cycle will be 28 days in duration.~One treatment cycle consists of the following:~* Days 1-5: oral intake of FTD-TPI and bevacizumab IV infusion on day 1~* Days 8-12: oral intake of FTD-TPI~* Day 15: bevacizumab IV infusion~Bevacizumab 5.0mg/kg i.v. is repeated every 2 weeks. If toxicity occurs, dose modifications and dose delays should be administered and applied according to standard practice."
215031947|NCT06563986|DEVICE|Radioembolization with 166-Ho microspheres|"Individualized 166Ho radioembolization will be performed via a catheter during angiography. Before the treatment, a scout procedure will be performed to determine individualized 166Ho dose of the treatment. Dosimetry-based treatment planning will be individualized using Q- Suite software.~In case of bilateral disease, patients will be treated in two procedures to each hemi-liver, separated by 1 month. Before the first procedure, a scout procedure will be performed in which the individualized 166Ho dose of the first and second procedure will be calculated."
215031948|NCT03413800|DRUG|Lenalidomide-Dexamethasone-DLI|Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
215031949|NCT00863304|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
214844170|NCT03441139|OTHER|Cryotherapy + Medical analgesics|"Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion"
215031950|NCT00863304|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
215031951|NCT00863304|DRUG|naproxen|naproxen 1000 mg daily for 16 weeks
215031952|NCT00863304|OTHER|placebo|placebo to match tanezumab and naproxen dosing
215031953|NCT01008826|DIETARY_SUPPLEMENT|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
215031954|NCT03921567|DRUG|Lidocaine Hydrochloride|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
214281341|NCT05196204|OTHER|Trunk-oriented task training combined with functional electrical stimulation|Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
214657248|NCT05340309|OTHER|Survey Administration|Ancillary studies
214469720|NCT04627246|BIOLOGICAL|Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)|"SOC: Subgroup1: intravenous mFOLFIRINOX for twelve 14-day cycles. Subgroup2: intravenous gemcitabine twice, on days 1 and 8, and oral capecitabine for 14 days of 21-day cycles, for eight cycles.~PEP-DC vaccine: At least 5 subcutaneous vaccinations starting on cycle 8 (subgroup1) or cycle 5 (subgroup2) of chemotherapy: Subgroup1: every 4 weeks, on day 3 of every second 14-day cycle, and then every 4 weeks starting from the first nivolumab administration. Subgroup2: Every 3 weeks, on day 9 of each 21-day cycle, and then every 4 weeks starting from the second nivolumab administration.~Nivolumab for a maximal duration of 2 years: intravenous, starting after the last chemotherapy cycle. Administered as flat dose of 240mg every 2 weeks during 14 weeks, then as flat dose of 480 mg every 4 weeks until the last vaccination. Then, as a maintenance therapy at 480 mg every 4 weeks until appearance of new lesions or unacceptable toxicity."
215031955|NCT03921567|DRUG|Lidocaine Hydrochloride and Ketamine|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
215031956|NCT03921567|DRUG|Placebo|will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
215031957|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
215031958|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
215031959|NCT05819957|OTHER|Therapeutic Education Program (TEP)|the TEP lasts 12 months, being structured into 6 modules.
215031960|NCT01505088|DRUG|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
215031961|NCT01505088|DRUG|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
215031962|NCT01505088|DRUG|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
215031963|NCT01505088|DRUG|Placebo Eyedrops|Placebo Eyedrops
215031964|NCT04871620|DIAGNOSTIC_TEST|>15% SV increase during fluid challenge|The stroke volume will be measured before and after 15 minutes fluid challenge with crystalloids
215031965|NCT01868412|DEVICE|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
215031966|NCT01868412|DEVICE|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
215031967|NCT00285051|DRUG|inhaled delta-8-THC 300mcg or 600mcg per dose|"drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC"
215031968|NCT02806661|PROCEDURE|Vagus nerve-preserving Robot-assisted Gastrectomy|
215031969|NCT02806661|PROCEDURE|Conventional Robot-assisted Gastrectomy|
215031970|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 12|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12
215031971|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 3|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3
215031972|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 6|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
215031973|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 24|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24
214479434|NCT06865404|PROCEDURE|PIFPB block|The ultrasound probe will be positioned parallel and 2-3 cm lateral from the midline in the 4th or 5th intercostal space. The needle will be inserted in-plane in a cauda-cranial direction until the tip of the needle reaches the plane of the fascia between the pectoralis major muscle and the external intercostal muscles. A 20 ml volume of bupivacaine 0.25% will be injected on each side.
214657249|NCT06828588|DRUG|ABY-025 Loading Dose|Subjects will receive a loading dose (400 micrograms) of ABY-025 prior to the \[68Ga\]Ga-ABY-025 infusion.
214844171|NCT03441139|DRUG|Medical Analgesics|Best analgesic therapy at investigator's discretion
215031974|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 21|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21
215031975|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 18|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
215031976|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 15|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
215031977|NCT04670809|DRUG|Clevidipine Butyrate Injection|Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
214281342|NCT05196204|OTHER|Trunk-oriented task training alone|"The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises."
214281343|NCT02493140|DIETARY_SUPPLEMENT|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
214281344|NCT02493140|DIETARY_SUPPLEMENT|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
214281345|NCT03024060|DRUG|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
214281346|NCT03024060|DRUG|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
214281347|NCT03024060|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
214281348|NCT03024060|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
214281349|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrencePrognosticScore|Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling
214281350|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrenceDiagnosticScore|Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
214281351|NCT02968797|DEVICE|SafeSed|Monitor respiratory parameters
214281352|NCT01399515|DRUG|Valproic Acid|One 500mg tablet by mouth daily
214281353|NCT04534361|OTHER|CBCT measurements|No intervention will be performed on patients for this study. Based on the CBCTs already done previously of the patients in the sample, linear measurements will be taken in order to assess dimensional changes of the alveolar ridge at 1, 3, 5 and 7 mm from the bone crest in the CBCTs taken before and after implant explantation, 4-6 months apart.
214281354|NCT01350297|PROCEDURE|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
214281355|NCT02600572|OTHER|Isometric exercises|Subjects will perform one session of isometric exercises at the end of Day 1
214281356|NCT02600572|OTHER|Eccentric exercises|Subjects will perform one session of eccentric exercises at the end of Day 2
214281357|NCT01496612|DRUG|Buspirone|
214281358|NCT01496612|DRUG|Placebo|
214281359|NCT05032560|DRUG|ABX464|Drug: ABX464 ABX464 is a new anti-inflammatory drug
214281360|NCT05032560|DRUG|Placebo|Drug: Matching Placebo placebo matching with ABX464
214281361|NCT00358371|DRUG|flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
214281362|NCT00358371|DRUG|flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
214281363|NCT06557005|OTHER|Facilitated Transition to Primary Care|The intervention includes default PCP visit scheduling, tailored nudge messages to patients, ongoing care recommendations sent to the PCP, and a summary of recommendations after pregnancy given to the patient.
214281364|NCT04194034|BIOLOGICAL|TG6002|"Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient."
214281365|NCT04194034|DRUG|Flucytosine (5-FC)|"Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between."
214281366|NCT04235985|COMBINATION_PRODUCT|Chlorhexidine Gluconate with HUBS|4% CHG soap will be applied to HUBS following manufacturers recommendation and applied to skin for different application times as dictated by the randomization of the marked sites on the forearm. Followed by a HUBS moistened with water.
214281367|NCT05658146|DRUG|Mavacamten Capsule 1|Specified dose on specified days
214281368|NCT05658146|DRUG|Mavacamten Capsule 2|Specified dose on specified days
214281369|NCT05658146|DRUG|Mavacamten Capsule 3|Specified dose on specified days
214281370|NCT03675100|PROCEDURE|colonoscopic mucosal biopsy|colonoscopic mucosal biopsy was undertaken for every participant
214281371|NCT01146418|BIOLOGICAL|Corifollitropin alfa|Single injection of 150 μg corifollitropin alfa administered under protocol P06029
214281372|NCT01146418|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH 300 IU administered under protocol P06029.
214281373|NCT06201741|RADIATION|[131I]/[18F]/[68Ga]ZT-111|\[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose
214281374|NCT02885103|DEVICE|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
214281375|NCT02885103|DEVICE|Nebulizer|Inhalation will be done will Nebulizer and via mouth
214281376|NCT00358852|OTHER|No intervention|This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
214281377|NCT00356291|BEHAVIORAL|Skill-Building (SB) plus Motivational Interviewing|SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
214281378|NCT00356291|BEHAVIORAL|Skill-Building (SB)|SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
214281379|NCT04489563|DEVICE|i-ACT|Performing exercises with an adapted motion detection device (i.ACT) for 20-30 minutes.
214657250|NCT06828588|DRUG|[68Ga]Ga-ABY-025|Subjects receive a tracer dose of \[68Ga\]Ga-ABY-025 and will receive a PET/CT scan a few hours after the injection.
215031978|NCT04670809|DRUG|Ncardipine Hydrochloride Injection|Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
215031979|NCT06121752|PROCEDURE|Endoscopic submucosal dissection|Endoscopic resection is recommended for the management of small DNETs measuring ≤10 mm. Various endoscopic techniques have been utilized for the resection of DNETs including endoscopic mucosal resection (EMR), band ligation assisted EMR, endoscopic submucosal dissection (ESD). However, the published studies report a high rate of histologically incomplete resection even with ESD. More recently, device assisted endoscopic full thickness resection (EFTR) has emerged as a safe and effective resection modality in cases with upper and lower gastrointestinal (GI) mucosal as well as submucosal lesions. There is limited data on the outcomes of EFTR in cases with DNETs.
215031980|NCT06121752|DEVICE|EFTR|"Initially, the lesion will be marked circumferentially using the FTRD probe available with the device (Forced Coag, E1, 20W). Subsequently, wire guided balloon dilatation of the pyloric channel will be performed.~The device will be mounted over a therapeutic channel gastroscope and negotiated across the cricopharynx over the guidewire with or without assistance of dilating balloon available with the device.~After reaching the target site, the lesion will be pulled withing the FTRD cap with the help of grasping forceps and gentle suctioning.~The clip will be fired after ensuring the entry of the lesion inside the cap, the premounted snare closed and electrocautery activated to cut the grasped tissue (HighCut 200W, Effect 4)."
215031981|NCT06464770|DRUG|Chlorhexidine Gluconate|Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds
215031982|NCT05882370|DRUG|Cadonilimab|Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
215031983|NCT05882370|PROCEDURE|transjugular intrahepatic portosystemic shunt (TIPS)|transjugular intrahepatic portosystemic shunt (TIPS)
215031984|NCT05987137|OTHER|No intervention is being administered.|No intervention is being administered.
215031985|NCT06130540|DRUG|Secukinumab|Intravenous (i.v.) doses of Secukinumab at Week 0, Week 4 and Week 8
215031986|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt
215031987|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
215031988|NCT02507934|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
214281380|NCT05856032|DEVICE|Acapella device|Acapella is one of the Oscillatory Positive Expiratory Pressure (OPEP) device used in mobilization of peripheral secretions to the central trachea. It consists of a mouth piece and metal strip that is attached to a magnet which oscillates upon exhalation of the patient into the device results in oscillations. This helps in generating positive expiratory pressure (PEP) and oscillations of the magnetic ball assist in mucus collection and expectoration. Pulmonary functions are greatly reduced in patients undergone CABG surgery due to prolong effects of anaesthesia and muscle relaxants administered prior to surgery.
214281381|NCT05856032|OTHER|Conventional Treatment|Conventional chest physiotherapy techniques
214281382|NCT05106283|PROCEDURE|Deep block and Combined Block|Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
215031989|NCT02507934|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
215031990|NCT03298737|BEHAVIORAL|Covert Spatial Attention|"During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar."
215031991|NCT05393180|DEVICE|Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF|"Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. This will be done endocardially using an irrigated endocardial ablation catheter.~Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation. ."
215031992|NCT05992909|PROCEDURE|Lymphovenous bypass procedure|Participants will return to the clinic 14 days, 6 months, 12 months, 18 months, and 24 months after your surgery for measurements of your legs to see if there are changes over time
214469721|NCT06080113|RADIATION|Focal Brachytherapy|Targeted focal brachytherapy is an image-guided technique, where the radioactive source is placed only, and directly into the cancerous area of the prostate. The aim is to preserve the normal surrounding prostate gland tissue to limit treatment-related side effects to the adjacent anatomical structures. A multiparametric prostate MRI is used to identify, localize, and delineate the intraprostatic PCa tumour lesion and plan treatment. A specialized MRI-ultrasound image-fusion software combines the MRI-images with dynamic ultrasound performed in the operating room and is used to focally guide the placement of the radioactive source in the prostate cancer (PCa) tumour focus based on focal dosimetry calculations. A safety margin around the tumour is applied where it is possible to account for MRI tumour volume underestimation, microscopic spread, and treatment uncertainties.
214469722|NCT06503497|BIOLOGICAL|chemotherapy sequential CAR-NK cell infusion|In each chemotherapy cycle, patients received 2 intravenous infusions of CAR-NK on days 2 and 3 after each chemotherapy was discontinued.
214469723|NCT00005095|OTHER|Ca-125|Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
214469724|NCT00005095|OTHER|screening questionnaire administration|Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
214469725|NCT00005095|PROCEDURE|Surgery|Subjects will be assessed for high risk factors.
214469726|NCT05779969|OTHER|Chest CT scan|Comparison of structural damage to the manubriosternal joint (MST) between a population of patients with radiographic axSpA and a control population free of chronic inflammatory rheumatism on chest CT.
214469727|NCT05910775|BEHAVIORAL|Pre and Post Treatment Presentations|A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance
214469728|NCT02398656|DRUG|Tenecteplase|TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
214469729|NCT02398656|DRUG|Antiplatelet treatment|Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
214469730|NCT02520713|GENETIC|Genetic testing and GAIN report|All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
214469731|NCT03941405|DRUG|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
214469732|NCT06448299|PROCEDURE|TAPB|Patients will receive ultrasound guided bilateral oblique subcostal TAPB using 25 mL bupivacaine 0.25% in each side
214469733|NCT06448299|BIOLOGICAL|ESPB|Patients will receive ultrasound guided bilateral ESPB at T8 level using 25 mL bupivacaine 0.25% in each side
214469734|NCT06394271|DEVICE|EVAR|Catheter based insertion of aortic endograft via iliac or femoral arteries
214469735|NCT06335849|BIOLOGICAL|LYB004 25µg|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
214469736|NCT06335849|BIOLOGICAL|LYB004 50µg|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
214469737|NCT06335849|BIOLOGICAL|SHINGRIX|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
214469738|NCT05811494|DEVICE|Lexo|Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.
214469739|NCT05811494|DEVICE|Lokomat|Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.
214469740|NCT05811494|DEVICE|C-Mill|C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.
214469741|NCT05811494|DEVICE|Body-weight support treadmill|Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
214469742|NCT02019004|DRUG|Onabotulinum Toxin A|
214469743|NCT02019004|DRUG|Incobotulinum Toxin A|
214469744|NCT04299464|DRUG|Placebo|Participants will receive oral placebo for approximately 12 weeks.
214469745|NCT04299464|DRUG|RO7017773|Participants will receive oral RO7017773 for approximately 12 weeks.
214469746|NCT05821816|DEVICE|tDCS|Use of Transcranial direct current stimulation for 20 minutes per day, 5 days a week, at 2mA
214469747|NCT05821816|OTHER|Conventional rehabilitative treatment|Physiotherapy treatment consisting in two treatments per day of 40 minutes each
214469748|NCT03231085|DRUG|Ferrous fumarate or ferrostrane|Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
214469749|NCT03950570|DRUG|Abraxane|In patients with relapsed. metastatic breast cancer, ORIN1001 will be administered in combination with Abraxane administered by intravenous infusion.
214469750|NCT03950570|DRUG|ORIN1001|ORIN1001 will be administered as a table as a monotherapy in the dose escalation phase in patients with advanced solid tumors or in combination with Abraxane in patients with relapse, refractory breast cancer
214469751|NCT06005571|PROCEDURE|composite restoration repair by traditional acid etch treatment procedure and adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid and adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
214469752|NCT06005571|PROCEDURE|Composite restoration repair by acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
214469753|NCT06005571|PROCEDURE|Composite restoration repair by sandblasting first, then acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed, the old restoration surface were sandblasted, and the tooth and restoration surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was added to repair the old restoration and restore the carious cavity.
214469754|NCT05679375|DRUG|Intrathecal ketamine|Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine
215031993|NCT01930500|BEHAVIORAL|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
215031994|NCT01930500|BEHAVIORAL|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
215031995|NCT06443853|DIAGNOSTIC_TEST|Dental plaque scoring and dental plaque coated tooth surface measuring|"The Turesky Modified Quigley Hein Plaque Index of anterior teeth of the volunteers' was recorded using clinical visual examination.~Intraoral photographs of the volunteers were taken by using a digital camera and 3D images were recorded by an intraoral scanner. The plaque-covered area and the total surface area of the teeth were marked in the manual mode of the Image J program and the areas were measured in square pixels. The correlation between clinical visual scoring, dental plaque areas on images were compared."
215031996|NCT06847256|PROCEDURE|Heat Challenge|Participants will be asked to arrive well-hydrated and to refrain from exercise, alcohol, caffeine, and smoking for 24 hours prior to the visit. Height, weight, blood pressure, and body fat percentage will be measured. Blood (15.5 ml) and urine will be collected. Participants will wear a heart rate monitor and sit in a heat chamber at 62-63 degrees Celsius for 45 minutes. Heart rate will be measured continuously. Body temperature and a self-report of their comfort (1-4 scale) and thermosensation (1-7 scale) will be measured before the challenge, every 15 minutes during the challenge, and after the challenge. During the challenge, a sample of sweat will be collected to measure electrolyte loss. Participants will consume 16 ounces of water at their own pace during the 45 minutes. If they become too uncomfortable to continue or their body temperature rises above 39 degrees Celsius, the challenge will be stopped. All baseline measures except body fat percentage will be measured again.
215031997|NCT04511494|DIETARY_SUPPLEMENT|Peanut (bamba)|OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
215031998|NCT04547556|DIAGNOSTIC_TEST|BioFire|"A molecular rapid syndromic testing platform, using the following panels:~* BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)~* BioFire FilmArray Pneumonia Panel plus (PP)"
215031999|NCT03528902|DRUG|Tamoxifen|Tamoxifen 20 mg po daily for 24 weeks.
215032000|NCT03528902|DRUG|Placebo Oral Tablet|Placebo
215032001|NCT06035562|BEHAVIORAL|PVSET|6, one-hour sessions of individual therapy, consisting of Positive Valence System Enhancement Treatment for Anxiety and Depression (PVSET), which will consist of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
215032002|NCT05463133|DRUG|Sirolimus|Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
215032003|NCT05463133|DRUG|Cyclophosphamide|Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
215032004|NCT05463133|DRUG|Alemtuzumab|Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
215032005|NCT05463133|DRUG|Busulfan|Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
215032006|NCT05463133|BIOLOGICAL|Pheripheral blood stem cells|Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
215032007|NCT05463133|DRUG|Emapalumab-Izsg|Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
215032008|NCT05463133|DRUG|Tociluzumab|Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
215032009|NCT05463133|DRUG|Total Body Irradiation|Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
215032010|NCT06367413|DIETARY_SUPPLEMENT|Placebo|Participants will receive three servings of carbohydrate per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of maltodextrin per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of maltodextrin per kg of body weight in the pre-sleep serving (1.1 gr maltodextrin/kg BW/day).
215032011|NCT06367413|DIETARY_SUPPLEMENT|NAC|Participants will receive three servings of N-acetylcysteine per day during the 4-day experimental period. In specific, they will be supplemented with 13.33 mg of N-acetylcysteine per kg of body weight per serving (40 mg NAC/kg BW/day).
215032012|NCT06367413|DIETARY_SUPPLEMENT|NAC + Whey Protein|Participants will receive three servings of N-acetylcysteine + whey protein per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the pre-sleep serving (1.1 gr Whey protein + 40 mg NAC /kg BW/day).
215032013|NCT05030766|DRUG|Nicotine Replacement Therapy|6 weeks of Nicotine replacement patches
214281383|NCT02828696|DEVICE|"No prep treatment of worn dentition with CAD-CAM composite"|Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
214281384|NCT05865067|OTHER|Yoga Therapy|The intervention sessions will consist of 12 yoga therapy sessions, each one approximately 30 to 45 minutes long, it will be given once a week (on Saturdays) in a room in the building of the School of Health Professions in the Campus of Medical Sciences from the University of Puerto Rico.
214281385|NCT05865067|OTHER|Exercise|The wait-list control group will be motivated to exercise at home (except for Yoga).
214281386|NCT05191771|DEVICE|Neovis Total Multi|1 drop in each eye, 4 times per day
214281387|NCT05191771|DEVICE|Systane Balance|1 drop in each eye, 4 times per day
214281388|NCT01117831|OTHER|Epidemiological intervention|An analysis of 600 diabetic patients in the Island of PR to evaluate metabolic control.
214281389|NCT01499056|BIOLOGICAL|stem cell injection|intra articular inection of mesenchymal stem cell
214281390|NCT03789474|DEVICE|HUNTLEIGH FLOWTRON ACS900|
214281391|NCT02171520|DRUG|Dabigatran etexilate generation I|
214281392|NCT02171520|DRUG|Dabigatran etexilate generation II|
214281393|NCT02457260|DRUG|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
214281394|NCT02544360|BEHAVIORAL|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
214281395|NCT03889444|DRUG|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
214281396|NCT03708328|DRUG|Lomvastomig|Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
214281397|NCT06292520|OTHER|Portage Guide Protocol|Portage Guide Protocol will be given to this group The study will follow the Randomized control trial study design and a purposive sampling technique will be used. Data will be collected from a special education centre BASES (Behaviour and special education services), Lahore. Children with autism spectrum disorder with mild to moderate severity level will be included in the study. The age range of the children will be from three years to seven years. Children with other neurological disorders or any comorbid conditions will be excluded from the study. The consent form will be filled out by parents of children who meet the inclusion criteria. The autism screening tool will apply by the speech and language pathologist. Half of the total number of children will receive therapeutic intervention under ABL
214281398|NCT06292520|OTHER|ABLLS-R protocol|ABLLS-R protocol will be given to this group
214281399|NCT05016999|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion)
214281400|NCT02605824|DRUG|n-acetylcystine|NAC is a mucolytic drug.
214281401|NCT02605824|DRUG|0.9% saline|Normal saline is a placebo agent.
214281402|NCT02955160|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
214281403|NCT02955160|BIOLOGICAL|Tdap|Tetanus, diphtheria, and pertussis vaccine
214281404|NCT00066885|DRUG|calcitriol + docetaxel|
214281405|NCT01989897|DRUG|saline with 1mg/ml Histamine base|
214281406|NCT01989897|DRUG|diluent, saline with HSA--phenol|
214281407|NCT01796080|OTHER|Mueller manoeuvre|
214281408|NCT01796080|OTHER|Inspiratory threshold|
214281409|NCT01796080|OTHER|Expiratory apnoea|
214281410|NCT01796080|OTHER|Steady state normal breathing|
214281411|NCT05824793|COMBINATION_PRODUCT|A-PRF+|A-PRF+ contributes to accelerating the healing process, more rapid revascularization, and reducing the risk of inflammation at the graft site. It leads to a decrease in the severity of postoperative complications. Many authors have mentioned platelet concentrates as an effective adjunction that improves the healing of hard and soft tissue and decreases pain, swelling, and trismus. However, there are still some controversial results in the literature. Recently, it has been demonstrated that the production of PRF with lower centrifugal force and lower centrifugal time has more potential to release several growth factors and facilitate more favorable healing at the site of the application when compared to standard PRF. Promoting the healing process after tooth extraction using A-PRF+ aims to manage patient discomfort as well as postoperation complications.
214281412|NCT00283452|BEHAVIORAL|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
214281413|NCT01944592|BEHAVIORAL|Gynaecology Teaching Associates (GTA's)|Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
214281414|NCT01944592|BEHAVIORAL|Manikin (conventional) training|Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
214281415|NCT00496808|DRUG|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
214281416|NCT01691209|DEVICE|Phoenix (BAY81-2996)|Topical formulation applied to the skin
214281417|NCT01691209|DRUG|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
214281418|NCT04963335|BEHAVIORAL|Exergame Training|The individualized exergames were designed for a pressure sensitive plate connected to a personal computer and a frontal screen. The pressure-sensitive plate allows a precise analysis of the user's movements. This concurrent motor-cognitive training aims to improve motor and cognitive functions in an ecological valid setting. The cognitive functions are triggered by specific stimuli in the game scenarios. The video games are controlled via specific (whole body) movements as steps, weight shifting, jumps, and arm movements. The training focus is mainly on multi-tasking, balance and coordination as well as executive functions and attention. Furthermore, the meaningful games (colorful and appealing visuals) were designed to motivate the players to move. As the exergame will automatically adapt (individual progression) during play time, participants are challenged at their individual motor and cognitive level.
214469755|NCT05679375|DRUG|Intravenous ketamine|Patients will receive IV Ketamine 0.25mg/kg after spinal
214469756|NCT05384756|DRUG|Alemtuzumab|Given IV
214281419|NCT01256801|BIOLOGICAL|cytokine|interleukin 2 2 million unit every week
214281420|NCT04345809|PROCEDURE|MESH WHIT OMEGA-3|Mesh placement with Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
214281421|NCT04345809|PROCEDURE|MESH WITHOUT OMEGA-3|Mesh placement without Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
214281422|NCT04528381|PROCEDURE|Laparoscopy|Laparoscopic orchiopexy
214469757|NCT05384756|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
214469758|NCT05384756|RADIATION|Intensity-Modulated Radiation Therapy|Undergo TMLI
214469759|NCT05384756|DRUG|Sirolimus|Medication to prevent the development of graft-versus-host disease (GVHD)
214469760|NCT04254627|DRUG|Etanercept|Etanercept 50 mg weekly injection
214469761|NCT04254627|DRUG|Mifepristone|Mifepristone 300 mg pill
214469762|NCT04728334|DRUG|AK117|An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal
214469763|NCT05328154|OTHER|Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care|"* Inclusion medical consultation~* Inclusion clinical examination~* Calculation of Kauppila score at one year~* Imaging procedures (DXA) at 1 year~* Magnesium dosage: Visit 1: Day 0 and Visit 3: Day 0+1 year~* Samples for biological collection and microbiota analysis Visit 1: Day 0 and Visit 3: Day 0+1 year~* Genotyping in Visit 1: Day 0~* Serum CTX dosage in Visit 3: Day 0+1 year~* Cardiovascular investigations (FMD, RHI, FLD, PWV) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of sarcopenia (SARC-F, SPPB, muscle strength and body composition) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of pain (NPS, BPI, sensitivity/pain thresholds, CPM) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Quality of life component questionnaires (PSQI, HADs, SF-36) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Follow-up diary to be completed at months 1 and 12 of the study"
214469764|NCT05328154|DRUG|Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation|"* Inclusion medical consultation~* Inclusion clinical examination~* Calculation of Kauppila score at one year~* Imaging procedures (DXA) at 1 year~* Magnesium dosage: Visit 1: Day 0; Visit 2: Day 0+9 months and Visit 3: Day 0+1 year~* Samples for biological collection and microbiota analysis Visit 1: Day 0 and Visit 3: Day 0+1 year~* Genotyping in Visit 1: Day 0~* Serum CTX dosage in Visit 3: Day 0+1 year~* Cardiovascular investigations (FMD, RHI, FLD, PWV) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of sarcopenia (SARC-F, SPPB, muscle strength and body composition) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of pain (NPS, BPI, sensitivity/pain thresholds, CPM) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Quality of life component questionnaires (PSQI, HADs, SF-36) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Magnesium intake for 1 period of 3 months~* Phone call~* Follow-up diary to be completed at months 1, 10, 11 and 12 of the study"
214469765|NCT06349772|DRUG|Zynrelef|Zynrelef will be injected at the 12mm port site
214844172|NCT04703855|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
214469766|NCT06349772|DRUG|Exparel|Exparel will be injected at the 12mm port site
214469767|NCT04261686|DEVICE|Covera Vascular Covered Stent|This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent
214469768|NCT05911724|OTHER|Group I Healthy|Healthy Subjects
214469769|NCT05911724|DRUG|CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study|Group II: Stable Angina Patients
214469770|NCT05911724|DRUG|HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study|Group III: Heart Failure Patients
214469771|NCT06840327|OTHER|Blood and tissue samples|Blood samples will be taken from catheters placed for the purpose of surgery (arterial and venous catheters), or during routine venipunctures. (D-1 pre-op). Tissue samples will be taken from surgical waste generated by the surgery. They will therefore not require any additional incisions or surgical procedures.
214469772|NCT06840327|OTHER|walking test|The study includes a walking test between D5 and D7.
214469773|NCT06837974|OTHER|AI guided TIPS|The TIPS procedure will be conducted under the guidance of AI model which was constructed based on the pre-operation enhanced CT images and intra-operation DSA images.
214469774|NCT06837974|OTHER|Artificially blinded TIPS|The TIPS procedure will be conducted based on the experience of operators.
214469775|NCT03676192|DRUG|CT-P16|15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
214469776|NCT03676192|DRUG|Avastin|15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
214469777|NCT02838316|DRUG|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|Autologous muscle derived stem cells
214844173|NCT01556152|DRUG|GRC 17536 (Medium Dose)|1 BD for 28 days
214844174|NCT01556152|DRUG|GRC 17536 (Low Dose)|1 BD for 28 Days
214844175|NCT01556152|DRUG|Placebo|Matching Placebo for 28 Days
214844176|NCT04628936|DRUG|KZR-616|Subcutaneous 30 mg for 1 week, then 45 mg weekly
214844177|NCT04808349|OTHER|no intervention|no intervention
215032014|NCT05030766|BEHAVIORAL|Mindfulness Training Smoking Cessation Intervention|Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.
214281423|NCT00453622|DEVICE|Cardiac Resynchronization Therapy-Defibrillator|Implantation of a CRT-D device
214281424|NCT00065403|DEVICE|Acupuncture|
214844179|NCT05695755|DIAGNOSTIC_TEST|ECHO, Serum electrolytes|echocardiography, serum electrolytes and cortisol level for all patients
214844180|NCT02786719|DRUG|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
214844181|NCT02786719|DRUG|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
214844182|NCT02786719|DRUG|Cisplatin|Cycle 3+5 (given daily x 4 days)
214844183|NCT02786719|DRUG|Etoposide|Cycle 3+5 (given daily for 3 days)
214844184|NCT02786719|DRUG|Vincristine|Cycle 4+6 (given daily for 3 days)
215032015|NCT05030766|BEHAVIORAL|Contingency Management Smoking Cessation Intervention|Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.
215032016|NCT00645658|DRUG|Testim, 1% testosterone gel|Subjects apply contents of gel packet (Testim, 1% testosterone gel) to skin daily.
215032017|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR
214469778|NCT06839118|DRUG|Botox 200 UNT Injection|A concentration of 50U/mL BTX-A is prepared using saline in four syringes: one with 1 mL, one with 0.8 mL, one with 0.7 mL, one with 0.6 mL. This equals a total administration dose of 155U. A total of 155U BTX-A will be injected at day 1 (first day in week 1) by subcutaneous injections according to the PREEMPT protocol.
215032018|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
215032019|NCT04483778|DRUG|Pembrolizumab|SCRI-CARB7H3(s)x19 plus pembrolizumab
215032020|NCT06004063|DIETARY_SUPPLEMENT|Enteral nutrition (EN)|Given by Nasogastric Tube
215032021|NCT06004063|OTHER|Standard care parenteral nutrition (PN)|Given by PO or Given by IV (vein)
215032022|NCT02947048|DRUG|L1-79|
215032023|NCT02947048|DRUG|Placebo|
215032024|NCT06636955|OTHER|biobank|"* nasopharyngeal swab collection~* nasopharyngeal nasal washes collection, during hospitalization, if any"
215032025|NCT06636955|OTHER|follow up|\- one year follow up: after 1 month, 3 months, 6 months et 12 months
215032026|NCT06637046|DIAGNOSTIC_TEST|Diagnostic procedures|A 30-gauge 1-inch needle was inserted adjacent to, but not within, the CFN. The infiltrate was delivered at the level of the fibular neck just proximal to where the CPN coursed beneath the deep fascia of the peroneus longus. This was immediately adjacent to the first known anatomical site of compression of the CPN. 0.3cc of the drug was delivered.
215032027|NCT06637046|DIAGNOSTIC_TEST|Lidocaine HCl|This study compares the vasodilatory effects of lidocaine to papaverine after diagnostic infiltration of the Common Peroneal Nerve in patients with demonstrated motor weakness of the EHL (extensor hallucis longus).
215032028|NCT06642025|BIOLOGICAL|CAR-T Cell Injection|"Conditioning chemotherapy: Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before intraperitoneal infusion.~On the day of administration, premedication with 500mg of acetaminophen orally and 20mg of promethazine intramuscularly or intravenously (or other non-steroidal anti-inflammatory drugs and antihistamines) should be given 30 minutes before intraperitoneal infusion.~The therapeutic dose of CAR-T cells is defined as intravenous injection of 1.0E6 CAR-T cells/kg as the initial standard dosage."
214469779|NCT01957735|DRUG|BP31510 monotherapy|
214469780|NCT01957735|DRUG|BP31510 in combination with chemotherapy|
214469781|NCT06835101|OTHER|Music intervention|"The music group will receive music beginning 20 minutes before spinal anesthesia until the end of surgery."
214469782|NCT06835101|DRUG|Midazolam (sedative)|"The midazolam group will receive increments of midazolam beginning 20 minutes before spinal anesthesia."
214469783|NCT06558227|BIOLOGICAL|ZG005 for Injection|10 mg/kg or 20 mg/kg administered intravenously Q3w
214469784|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
214469785|NCT06558227|BIOLOGICAL|Sintilimab|200 mg administered intravenously Q3w
214469786|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
214469787|NCT06837168|DEVICE|Stainless steel fixed retainer|The Stainless steel fixed orthodontic retainer is fabricated from a 0.0215-inch, five-stranded stainless steel wire
214469788|NCT06837168|DEVICE|3D printed CAD/CAM Chrome cobalt fixed lingual retainers|CAD/CAM Chrome cobalt retainers; will be digitally designed by the dental technician using EXOCAD software. Then, they will be printed by DMP Flex100 metal 3D printer and then will be polished. Also, a projection like extensions will be added at the ends of the retainers to avoid slippage in addition to gingivally directed V notch shaped bend in the retainer to increase the retention in the anterior region
214469789|NCT05268510|DRUG|Pembrolizumab|400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
215032029|NCT06638034|DRUG|68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
215032030|NCT06637956|DRUG|Nitroglycerin (NTG)|Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation
215032031|NCT06640309|DRUG|Nicotinamide Tablet|Nicotinamide is anti-inflammatory and antioxidant.
215032032|NCT06640309|DRUG|conventional synthetic antirheumatic drugs|methotrexate- leflunomide- sulfasalazine- hydroxychloroquine
214469790|NCT05268510|DRUG|Olaparib|300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
214469791|NCT05268510|DRUG|mFOLFOX-6|Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles
214469792|NCT05268510|DRUG|CapOX|Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
214469793|NCT04194268|RADIATION|Carbon Ion|12 x 4 Gy (RBE)
214469794|NCT02912078|OTHER|Pocket-warming|Pocket-warming of epidural medication
214469795|NCT02912078|OTHER|Standard of Care Labor Epidural|Labor epidural medication administered per standard of care; no pocket warming.
214844185|NCT02786719|DRUG|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
214844186|NCT02786719|DRUG|Doxorubicin|Cycle 4+6 (given daily for 3 days)
215032033|NCT06638528|OTHER|Walking apnea at High Lung Volume|Walking apnea at High Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
215032034|NCT06638528|OTHER|Walking normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
215032035|NCT06642883|DIETARY_SUPPLEMENT|Prolife|randomized in a 1:1 ratio to treatment :1 vial/day for 60 days.
215032036|NCT06642883|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 vial/day for 60 days.
215032037|NCT06644703|OTHER|Cryotherapy|The pulpotomy area was irrigated with 2 °C saline solution for 5 minutes in cryotherapy group.
215032038|NCT05653999|DEVICE|Hearing Aids|Hearing aids will be used by infants with a diagnosed sensorineural hearing loss.
215032039|NCT03605693|BEHAVIORAL|Written Exposure Therapy|Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
214281425|NCT05780229|PROCEDURE|Conservative treatment|The rehabilitation is based on restoring the balance of the shoulder joint. Aiming to diminish pain and restore function, pain control and inflammation are addressed during the firsts 3-6 weeks. Before week 3, pendulum movements are allowed to initiate mobilization of the shoulder joint. Aiming to gain (almost) complete shoulder joint mobility, a passive and active mobility exercise program is carried out. Lastly, the focus is on muscle reinforcement, performing a series of active exercises with weights or bands to exercise different muscles of the shoulder or the shoulder girdle.
214281426|NCT05780229|PROCEDURE|Arthroscopic Decompression Surgery|Arthroscopic decompression surgery of the rotator cuff tear consists of cleaning the subacromial space. The procedures that are sometimes performed to diminish pain may include, removing the inflamed bursa, releasing the long head of the biceps (if injured), or lightly burring the acromion bone under which the tendons slide.
214281427|NCT05780229|PROCEDURE|Reverse Prosthesis|The reverse prosthesis consists of shoulder articular joint replacement. The humeral head is sectioned, and, on the scapular side, a metal tray is placed, which is fixed with screws, and a metal half-sphere fixed to the metal tray. On the humeral side, a metal stem with a concave plastic component is placed to articulate with the metal half-sphere, allowing shoulder mobility without the need of rotator cuff muscles.
214281428|NCT05780229|DRUG|Pain-Relief Medication|In the reverse prosthesis procedure and arthroscopic decompression surgery, the pain-relief medication plan is a standard regimen for all patients, which can be modified as needed. This plan is based on 50mg of dexketoprofeno, 1g of paracetamol, and 100mg of tramadol.
214281429|NCT05780229|DEVICE|Reverse Prosthesis Device|In the reverse prosthesis procedure, a Delta III reverse shoulder prosthesis is applied. The original design was developed by Grammont in 1980's, and has 2 components: 1) a metal tray fixed with screws, and a metal half-sphere fixed to the metal tray, and 2) a concave polyethylene component.
214281430|NCT02716428|DRUG|Faldaprevir|
214281431|NCT02716428|DRUG|TD-6450|
214281432|NCT02716428|DRUG|Ribavirin|
214281433|NCT06248632|OTHER|Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)|Expression of inflammatory markers obtained from circulating monocytic cells of XLH
214844187|NCT02786719|DRUG|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
214844188|NCT00820508|DRUG|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
214844189|NCT04867811|OTHER|conventional therapy|conventional therapy
214844190|NCT04867811|OTHER|cupping therapy|cupping therapy
214844191|NCT04867811|DEVICE|TENS|transcutaneous electrical nerve stimulation
214844192|NCT04867811|OTHER|TENS and cupping therapy|TENS and cupping therapy
214844193|NCT00705315|DRUG|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
214844194|NCT00705315|DRUG|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
214844195|NCT00705315|DRUG|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
214844196|NCT04529876|DRUG|Tofacitinib|Tofacitinib claim is used as the reference group.
214844197|NCT04529876|DRUG|Abatacept|Abatacept claim is used as the exposure group.
214844198|NCT01989676|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
214844199|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
214844200|NCT01989676|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
214844201|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
214844202|NCT03941834|DRUG|Rimegepant|BHV3000 (rimegepant) 75mg tablet
214844203|NCT03941834|DRUG|Placebo|Placebo
214844204|NCT03911596|DEVICE|Smart Autofocusing Eyeglasses|The smart eyeglasses system is meant to be a next generation alternative technology which replaces the generic eyeglasses used for correction of refractory defects in human vision. These smart eyeglasses do not fix any internal eye problems. They just externally compensate for the loss of eye focusing functions caused by presbyopia. This system is a medical assistive device which is meant to improve the quality of life of presbyopic patients.
214844205|NCT01877694|DRUG|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
214844206|NCT01877694|DRUG|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
214844207|NCT03458143|DRUG|Ketamine 150 ng/ml|conscious sedation in TCI-mode
215032040|NCT04753619|DRUG|Niclosamide Oral Tablet|"* NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\]~* If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding."
215032041|NCT03047044|OTHER|Optimizing basal infusion (B.I)|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 8 hr: 2 - 4 ml, 8-24 hr: 1 - 3 ml, 24 hours \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 0.5 ml).
215032042|NCT03047044|OTHER|Conventional PCA mode|Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
215032043|NCT01467856|PROCEDURE|PAP Device Procedure|"Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP \> 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic."
215032044|NCT01851798|OTHER|Home sleep test administered to all enrolled subjects|
215032045|NCT01066299|DRUG|Syntocinon®|single dose of OXT (24 IU)
215032046|NCT01066299|DRUG|inactive nasal spray|single dose (24 IU)
215032047|NCT03112928|DEVICE|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~1. Pain evaluation~2. Placement of the electrodes and fiducial marker~3. Practice of motor execution in Augmented Reality (AR)~4. Gaming using phantom movements~5. Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
215032048|NCT03112928|DEVICE|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
215032049|NCT06289764|OTHER|Bergamot Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
215032050|NCT06289764|OTHER|Grapefruit Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
215032051|NCT06289764|OTHER|Sweet almond oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles
215032052|NCT04258631|DRUG|Hydromorphone|Given IT
215032053|NCT04258631|PROCEDURE|Laparotomy|Undergo laparotomy
215032054|NCT04258631|DRUG|Liposomal Bupivacaine|Drug
214469796|NCT06252402|BIOLOGICAL|CMV/HIV-CAR T Cells|Eligible participants will temporarily interrupt their ART regimen for 4 days prior to leukapheresis to prevent residual cell drug levels that could inhibit lentiviral transduction of the T cells during CAR T cewll manufacturing. Participants will resume their ART regimen immediately after leukapheresis. Once the final cell product is released, participants will receive a single intravenous (IV)infusion of autologous CMV/HIV-CAT T cells (defined as Day 0). Up to three doses of CMV/HIV-CAR T cewlls may be explored.
215032055|NCT04258631|OTHER|Questionnaire Administration|Ancillary studies
214281434|NCT01802931|DRUG|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
214281435|NCT01802931|DRUG|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
214281436|NCT00779285|DRUG|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
214469797|NCT03924414|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
214469798|NCT03924414|OTHER|Placebo|Normal Saline 100 ml (placebo) IV infusion
214844208|NCT03458143|DRUG|Remifentanil|conscious sedation in TCI-mode
215032056|NCT03093415|DRUG|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
215032057|NCT05805189|PROCEDURE|pulmonary vein (PV) isolation|The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
215032058|NCT03895372|DRUG|PF-06826647 or Placebo|Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
215032059|NCT03895372|DRUG|PF-06826647|Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
215032060|NCT05883709|DRUG|Tafasitamab Injection|The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
215057530|NCT01872585|BEHAVIORAL|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
215057531|NCT00000553|DRUG|simvastatin|
214281437|NCT06237998|DEVICE|Telemedicine|Patients receive equipment for report of vital signs and patient reported experience measures (PREMS), automatically transmitted via smartphone/bluetooth for six months (possible extension to 12 months in case of instability). A digital smartphone application is used for registration and transmission of data, including modes for asynchronous (chat) communication with the healthcare provider. Planned titration to OMT or diuretic adjustments may be done remotely depending on clinical assessment. The digital sensors include an electronic scale, pulse and blood pressure monitor for daily measurements by the patient.
215032061|NCT05589025|PROCEDURE|pulpotomy technique with formocresol|The pulpotomy procedure performed was a modification of that described by Pinkham et al; 2005 where pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. After the completion of the access cavity, coronal pulp was extirpated using a sharp excavator. Any residual coronal pulpal tissue was removed using a sterile round bur in a slow-speed handpiece to a depth of few millimeters below the free gingival margin. Hemostasis was achieved with a water-dampened cotton pellet. If hemostasis was not achieved after the initial application of the cotton pellet, the case was eliminated from the study. Following hemostasis, a cotton pellet, moistened with formocresol was applied for 3 minutes and removed. A zinc- oxide and eugenol base was placed over the amputation site. Thereafter, a glass ionomer base was applied.
215032062|NCT05589025|PROCEDURE|pulpectomy technique with zinc oxide and eugenol|The pulpectomy procedure used herein was a modification of that described by Payne et al;1993 Pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. An initial endodontic K-file fitting snugly in the canal was introduced inside it. In most cases, the pulp tissue was removed completely on the first attempt. If the first attempt was unsuccessful, the procedure was repeated and canals were generally enlarged three sizes past the initial file to eliminate the organic remnants. Copious irrigation with a light flow of sterile 0.9% NaCl-solution was used throughout the procedure. At the end, the canals were dried and filled with zinc-oxide \& eugenol.
215032063|NCT06109324|OTHER|Robotic Rehabilitation of the upper limb|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
215032064|NCT06109324|OTHER|Conventional Rehabilitation of the upper limb|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
215032065|NCT06565117|DRUG|White yu green skin lotion|Group A: Systemic emollient was applied twice daily for 8 weeks Group B: Continue applying skin lotion twice daily in locally affected skin areas or in areas previously affected by AD for 8 weeks
215032066|NCT00304161|DRUG|Atomoxetine|40 to 80 mg orally once daily for 8 weeks
215032067|NCT00304161|DRUG|Placebo|40 to 80 mg orally once daily for 8 weeks
215032068|NCT03331354|BEHAVIORAL|Distant vocational learning|use of hybrid distance learning to facilitate successful employment outcomes
215032069|NCT03331354|OTHER|Basic vocational services|self-help manual
215032070|NCT06435026|DRUG|FTC/TDF 200mg/300mg|Standard Dose
214281438|NCT04891952|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|Functional precision medicine test to predict response to candidate chemotherapeutic agents
214281439|NCT01623583|OTHER|Enhanced Needle Phobia Intervention|"The enhanced intervention will include the standard intervention, with two enhancements:~* The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch~* Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity."
214281440|NCT01623583|OTHER|Standard Needle Phobia Intervention|"The standard intervention will include the following components:~1. Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.~2. Basic training on relaxation breathing~3. Brief video of a patient overcoming needle phobia~4. Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle"
214281441|NCT03036696|OTHER|Pregnant Mothers Interview|"Pregnant mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection and preferences for methods related to non-invasive sample collection.~Data collection for pregnant mothers includes Clinical Health Update (3rd trimester) and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
214469799|NCT05846334|DEVICE|mindfulHeart|'mindfulHeart' is an interactive, self-guided and patient-oriented mHealth intervention for the reduction of stress in patients with IHD and includes automated feedback via visualization of changes in patient reported outcome measures (PROMs).
214469800|NCT03403257|OTHER|No interventions|No intervention
214469801|NCT05257759|OTHER|Usual care|Standard management offered in the intensive care unit
214844209|NCT03458143|PROCEDURE|Oocyte retrieval|Oocyte retrieval for In Vitro Fertilization
215032071|NCT06435026|DRUG|FTC/TDF 300mg/450mg|150% Standard Dose
215032072|NCT06435026|DRUG|FTC/TDF 400mg/600mg|200% Standard Dose
215057532|NCT00000553|DRUG|niacin|
215057533|NCT00000553|DRUG|antioxidants|
214469802|NCT05257759|OTHER|Electrostimulation|The patients included will receive throughout their stay, in addition to the standard care offered in the department, electrical nerve stimulation. The ES will be applied to the tibial nerve to allow contraction of the plantar flexors. The protocol will be applied twice a day, 5-7 days a week and will have the following characteristics: stimulation frequency 100Hz, pulse width 1ms, intensity allowing the development of 5-10% of the maximum tetanic force obtained during the force-frequency relation, contraction time 20s, recovery time 20s, for a total of 25 contractions per session.
214469803|NCT05257759|OTHER|Evaluation of the neuromuscular system|"Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~* electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~* maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~* MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~* Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition."
214469804|NCT04079218|DRUG|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
214469805|NCT03643107|DRUG|Irofulven|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
214469806|NCT03643107|COMBINATION_PRODUCT|Prednisolone 10 mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
214469807|NCT05744024|DEVICE|Virtual Reality system|The intervention group 1 will be wearing the 'SyncVR' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, a controller, and a headphone. The SyncVR Relax \& Distract Application (SyncVR R\&D) will be used.
214469808|NCT05744024|OTHER|Headphones|Headphones with audio. The patients will be hearing their preferred audio, chosen by patient to relaxing and to offer distraction, through headphones during wound care.
214469809|NCT06505187|DRUG|Celecoxib|200mg every 12 hours
214469810|NCT06505187|DRUG|Tylenol|650mg q6h
214469811|NCT06505187|DRUG|Oxycodone|5mg every 6 hours as needed
214469812|NCT06505187|DRUG|placebo|every 12 hours
214469813|NCT04200391|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
215032073|NCT06296225|DEVICE|Vibration|"Grip strenght measurement will always be done in the same way : for each series, 3 measurements of maximum strength will be taken for each side. Participants will receive verbal encouragement.~After initial both sides grip strength evaluation, all participant will first experiment the vibration situation using the device Vibramoov Physio (TechnoConcept, Manosque, France): the vibrations had a frequency of 100Hz, with an amplitude of 2mm, they will be applied to the anterior part of the forearm for 10 minutes, 3 times. At the end of each 10 minutes vibration session, handgrip strength will be assessed.~* Participants then have a one-hour rest period.~* Control situation: participants will have 4 series of grip strength measurements every 10 minutes.~At the end of the 2 hours, the patient will be discharged from the study protocol."
215032074|NCT02816814|OTHER|Diet rich in omega-3 fatty acids|A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause
214469814|NCT06237218|BEHAVIORAL|COTID program|COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.
214469815|NCT02694822|DRUG|Zalifrelimab|An anti-CTLA-4 monoclonal antibody.
214469816|NCT02424617|DRUG|Erlotinib|Participants received erlotinib 150 mg for the 21-day cycle.
214469817|NCT02424617|DRUG|Bemcentinib|Participants received bemcentinib 600 mg on Days 1 and 2 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
214469818|NCT02424617|DRUG|Bemcentinib|"Participants received starting loading dose of bemcentinib 600 mg (200 mg on Days 1, 2 and 3) and bemcentinib 100 mg as daily maintenance dose for the 21-day cycle.~Depending on tolerability and DLT, the loading dose of bemcentinib was escalated to 800mg (400 mg on Days 1 and 2) and bemcentinib 100 mg as daily maintenance for the 21- day cycle and to 1200 mg daily (600 mg on Days 1 and 2, or 400 mg on Days 1, 2 and 3) and bemcentinib 200 mg as daily maintenance for the 21- day cycle)."
214469819|NCT02424617|DRUG|Bemcentinib|Participants received bemcentinib 400 mg on Days 1, 2 and 3 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
214469820|NCT03841773|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
214469821|NCT03841773|DRUG|Placebo SL Tablets|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
214469822|NCT06415955|OTHER|None, pure observationnal study|None, pure observationnal study
214469823|NCT01722812|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
214469824|NCT01722812|DRUG|Placebo|Twice daily topical treatment for 14 days
214479435|NCT06865404|PROCEDURE|PIRSB Block|After the PIFPB is performed with the same position and probe, a bilateral posterior rectus sheath block (PRSB) will be conducted. The probe will be placed 2-3 cm next to the xiphoid in the epigastric region and parallel to the costal margin. The needle will be inserted into the plane between the rectus abdominal muscle and its posterior sheath. After verifying needle placement, 10 ml of bupivacaine 0.25% will be injected on each side.
214844210|NCT03458143|DRUG|Ketamine 200 ng/ml|conscious sedation in TCI-mode
214844211|NCT04372719|DRUG|H3N2|
214844212|NCT00130234|DRUG|Xolair® (Omalizumab)|
215057534|NCT00995436|DEVICE|Extraoral anchorage|Extra oral anchorage
215032075|NCT02816814|OTHER|Diet with extra virgin olive oil|A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
215032076|NCT06441305|BEHAVIORAL|SWITCH intervention package|"* Addition of digital monitoring \& supervision by CHA~* Digitized registration of households by CHPs every 6 months~* Digital reminders to CHP to conduct home visit if a child has never been visited in 3 mo.~* Digital reminder for timely training to family MUAC of all family members through home visit by CHP when child turns 6 months of age.~* Platform for 2-ways messaging: biweekly SMS reminders to caregivers through the CHP's app; feedback by caregiver~* Community level screening based on weight and weight-for-age (WAZ) led by CHP every other month (aligned with Community Action Days),~* Digital calculation of WAZ.~* CHP and Growth Monitoring and Promotion refer to health facility if WAZ\<-3 to check on WHZ eligibility~* At the end of every wasting treatment consultation, compilation of the list of defaulters and non-respondents, for immediate transmission by CHA to relevant CHP through digital task of an instruction for immediate follow-up."
215032077|NCT04466839|OTHER|Questionnaire and interview|The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).
215032078|NCT05593289|OTHER|telerehabilitation|Physical activity that is planned, structured with repeated muscle movements with the aim of relearning motor skills, resistance of neck muscles and postural correction.
215032079|NCT01370044|DRUG|Carbogen|3 minutes administration of carbogen
215032080|NCT01370044|DRUG|Placebo|3 minutes administration of oxygen
215032081|NCT05342168|DIAGNOSTIC_TEST|Using a swallowed expanding sponge (Cytosponge TM) to obtain sampling of the esophageal musosa|A gelatin capsule containing the collapsed mesh sponge is swallowed with an attached string fixed to the cheek. After 8 minutes the gelatin capsule will have dissolved and the expanded soft mesh sponge can be with drawn sampling the surface of the esophagus on the way out. The sponge then will be spun and the supernant fixed, processed and stained.
215032082|NCT03119220|DEVICE|Fitbit One|Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
214844213|NCT05829850|DEVICE|SYNOLIS VA 40/80|Three 2mL injections of SYNOLIS VA 40/80, one week apart
214281442|NCT03036696|OTHER|Breastfeeding Mothers Interview|"Breastfeeding mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection, and preferences for methods related to non-invasive sample collection.~Data collection for breastfeeding mothers includes Clinical Health update (post-natal), Infant Feeding, and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
215032083|NCT04618276|OTHER|Photodynamic Therapy|PDT with two different photosensitizers
215032084|NCT05941429|DRUG|Nano-Silver Fluoride|NSF is a varnish which has been introduced as experimental formulation . the laboratory synthesis of NSF was carried out in a nano techonolgy center .
215032085|NCT05941429|DRUG|Silver diamine fluoride|38% silver diamine fluoride
215032086|NCT00796458|DRUG|docetaxel|Given IV
214281443|NCT04729270|PROCEDURE|Physiotherapy treatment with physium device.|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
215032087|NCT00796458|DRUG|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
215032088|NCT04552054|DEVICE|Mixed Reality+ 3D printing guided localization|Researchers project a three-dimensional reconstructed image of the patient's chest through MR glasses, then overlay the virtual chest with the actual chest. Finally, researchers put the three-dimensional printing navigational template on the surface of the body to guide for percutaneous lung puncture localization.
214281444|NCT04729270|PROCEDURE|Conventional physiotherapy treatment.|The intervention for this group consisted of 10 sessions with Electrical Nerve Stimulation (TENS) for a month.
214281445|NCT01666496|BEHAVIORAL|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
214281446|NCT01666496|BEHAVIORAL|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
214844214|NCT00000302|DRUG|Buprenorphine|
214844215|NCT02656316|DEVICE|Active tDCS|In this group subjects will receive 20 min of treatment.
214844216|NCT02656316|DEVICE|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
214844217|NCT02857387|BIOLOGICAL|blood sample withdrawn|
214844218|NCT05565261|DEVICE|complete denture|Bite force was measured with a bite force measuring device. Quality of life and patient satisfaction were evaluated with questionnaires.
215032089|NCT04552054|DEVICE|Computerized Tomography guided localization|CT-guided percutaneous lung puncture staining marker localization.
215032090|NCT01655277|PROCEDURE|Ultrasound Guided Adductor Canal Block|
215032091|NCT01655277|PROCEDURE|Ultrasound Guided Femoral Nerve Block|
215032092|NCT04316416|PROCEDURE|T7 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T7 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T7 spinous process.~After imaging of erector spina musceles and transvers process of 7 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
214469825|NCT05912634|PROCEDURE|Conservative TAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
214844219|NCT01114997|DRUG|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
215032093|NCT04316416|PROCEDURE|T9 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T9 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T9 spinous process.~After imaging of erector spina musceles and transvers process of 9 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
215032094|NCT04316416|DRUG|control group|24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
215032095|NCT04331275|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.
215032096|NCT06089993|OTHER|Exercise|"The total volume of exercise is 40 repetitions of each of the 4 exercises. The participant is instructed to perform a maximum of 10 repetitions each set, with 1'30'' rest between sets and between exercises. The researcher provides instructions and verbal encouragement. The total duration of the exercise bout is between 1 hour and 1 hour and 15 minutes.~Part 1: Before and after the exercise condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
215032097|NCT06089993|OTHER|Rest|"The participant remains in sedentary activities such as reading or using a laptop.~Part 1: Before and after the rest condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
215032098|NCT02992730|BEHAVIORAL|No Intervention|No Intervention
215032099|NCT01208766|DRUG|Bortezomib, Melphalan, Prednisone (VMP)|"* Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11,22,25,29,32~* Melphalan \_ 9 mg/m² \_ p.o. \_ days 1-4~* Prednisone \_ 60 mg/m² \_ p.o. \_ days 1-4"
215032100|NCT01208766|DRUG|1 or 2 cycle(s) HDM (High Dose Melphalan)|"\- Melphalan \_ 100 mg/m² \_ i.v. rapid infusion \_ -3, -2\*~\*Patients with renal insufficiency 100 mg/m2 only at day -3~If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR."
215032101|NCT01208766|DRUG|2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)|"* Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11~* Lenalidomide \_ 25 mg \_ p.o. \_ days 1-21~* Dexamethasone \_ 20 mg \_ p.o. \_ days 1,2,4,5,8,9,11,12"
215032102|NCT03885700|BEHAVIORAL|Educational program for 2 months|"The intervention was suggested based on the recommendations for adolescents' healthy diet and physical activity, it was derived from the 2008 Physical Activity Guidelines for Americans and Dietary Guidelines for Americans, 2010 by the U.S. HHS, Physical activity guidelines for children and adolescents by CPS 2012. The Food Guide Pyramid by the USDA, Nutrition \&Healthy Eating by Mayo clinic \& CDC website. The program was modified according to the age of the child. This plan was typically pursued in a School-based Intervention to Promote Healthy Lifestyles in Sousse, Tunisia, by Harrabi et al. The 1st month covered the healthy diet \& the 2nd month covered the physical activity as follow:~* 1st \& 5th week: A 60-minutesession in health education.~* 2nd \& 6th week: Group counselling.~* 3rd \& 7th week: Students were divided into 8 groups \& each group was asked to make presentation about a task related to the topic.~* 4th \& 8th week: Discussing the presentation."
215032103|NCT01968122|DEVICE|intravascular stent therapy|Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (\<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
215032104|NCT01206127|OTHER|Postoperative positioning: Bed rest|Patients in this group should be lying down facing up 2 hours postoperatively
215032105|NCT01206127|OTHER|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperative
215032106|NCT06634784|OTHER|Bone Conduction Implant (BCI)|Improvement in hearing using BCI.
215057535|NCT00995436|DEVICE|Miniscrews|Intraoral skeletal anchorage using mini screws
215057536|NCT00995436|DEVICE|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
215057537|NCT00319202|DRUG|Candesartan|32 mg/d for 6 months
215057538|NCT00319202|DRUG|Placebo|Placebo administration for 6 months
215032107|NCT05071326|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
215032108|NCT05150678|PROCEDURE|removal of ceserean section scar|we will remove the previous scar in group A
215032109|NCT05150678|PROCEDURE|non removal of cesearean section scar|we will open in the previous cesearean scar in group B
215032110|NCT06636578|DRUG|dexmedetomidine|will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
215032111|NCT06636578|DRUG|ropivacaine|will receive 30 ml of 0.25% of plain ropivacaine for each side.
215032112|NCT06636578|DRUG|fentanyl|will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
215032113|NCT06635122|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. The TIPS-dedicated stent (Gore, Arizona, USA)was emplaced within the liver and gradually expanded utilizing a balloon with a diameter ranging from 6 to 10 millimeters, aiming for a decrease in portal-venous pressure gradient to less than 12 mmHg or achieve a reduction of 25 to 50% relative to the baseline pressure.
215032114|NCT06635122|PROCEDURE|Endoscopic treatment|Endoscopic variceal ligation, endoscopic injection sclerotherapy, endoscopic variceal histoacryl injection therapy , or a combination of several methods were selected according to the location, size, and shape of the patient's varicose veins.Treatment failure can be transferred to TIPS therapy.
215032115|NCT06632171|BEHAVIORAL|Cognitive Behavioral Therapy- Based and Motivational Interviewing-Supported Psychoeducation|The aim of this study is to examine the effects of cognitive-behavioral-based and motivational interview-supported psychoeducation on emotional eating and psychological resilience in obese individuals. The study will be conducted in a randomized controlled experimental design. The sample of the study will consist of 102 obese individuals in total, 51 in the experimental group and 51 in the control group, who meet the inclusion criteria. A cognitive-behavioral and motivational interview-supported psychoeducation program will be applied to the experimental group. All patients will be evaluated at three time points: pretest (baseline), posttest (8 weeks), and follow-up test (3 months after the posttest). No intervention will be applied to the control group.
215032116|NCT06632080|DRUG|Substance P|The participants will receive a continuous intravenous infusion of 20 mL of substance P (1.5 pmol/kg/min) over 20 minutes.
215032117|NCT06632080|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
215032118|NCT03896633|DRUG|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
215032119|NCT03896633|DRUG|Azopt 1%|Azopt 1%, RLD
214844220|NCT01114997|DRUG|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
215032120|NCT06519565|DRUG|PRG-1801|PRG-1801 is a chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA. Participants will undergo leukapheresis to collect mononuclear cells for PRG-1801 manufacturing. Prior to infusion, patients receive lymphodepletion with cyclophosphamide (250-300 mg/m2/day) and fludarabine (25-30 mg/m2/day) for 3 days. PRG-1801 is then administered as a single intravenous infusion at one of three dose levels: 35×10\^6, 100×10\^6, or 300×10\^6 CAR-T cells. Premedication with antipyretics and antihistamines is given 30-60 minutes before infusion. The infusion rate is 2-5 ml/min. Patients are monitored for safety and efficacy for up to 24 months post-infusion. Some patients may be eligible for a second infusion if they respond initially but later relapse.
215032121|NCT02420509|DRUG|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
215032122|NCT04047355|DRUG|Propranolol|Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
215032123|NCT04315922|DIAGNOSTIC_TEST|Microbiome and Plasma Characterisation|Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
215032124|NCT04320199|DIETARY_SUPPLEMENT|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
215032125|NCT04320199|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
215032126|NCT05617326|OTHER|AAA screening by a GP|The GPs included in the experimental group will be trained in AAA screening with an ultra-portable ultrasound machine and will keep an ultrasound machine available (Butterfly iQ+ model). Their patients will be able to be screened by the GP in the office or at home. In case of positive screening, the GP will be able to refer the patients to the radiologist for diagnostic confirmation..
215032127|NCT05617326|OTHER|AAA screening by a radiologist|General practitioners in the control group will refer their patients to the radiologist for AAA screening.
215032128|NCT06680661|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) is one part of the conditioning regimen. 50 mg/kg beginning on day -6.
215032129|NCT06680661|DRUG|Fludarabine|Fludarabine (Flu) is one part of the conditioning regimen. 150 mg/m2 (30 mg/m2 per day on days -6 to -2)
215032130|NCT06680661|DRUG|Thiotepa|Thiotepa (Thio) is one part of the conditioning regimen.10 mg/kg (5 mg/kg per day on days -5 and -4)
215032131|NCT06680661|RADIATION|Total Body Irradiation|400 cGy (200 cGy per day on days -2 and -1).
215032132|NCT06680661|BIOLOGICAL|Double Umbilical Cord Transplant|Cord blood is a regulated biologic. Selection of cord blood units will be based on published guidelines.
215057539|NCT03544593|DEVICE|Revolve System|Fat grafting system
214844221|NCT01114997|DRUG|Lidocaine + Esmolol (Combo)|"Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)~Maintenance Infusion rate after Induction:~Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
214844222|NCT05315245|OTHER|AGI|no intervention, only observation
214844223|NCT00472953|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
214844224|NCT00472953|DRUG|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
214281447|NCT02695329|DEVICE|KneeAlign 2|Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
214281448|NCT02887638|OTHER|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:~* Analysis of the sitting-posture profile:~  o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~* Analysis of the dural profile before and after the provoking task:~  o Determination of the dural sensitivity by the use of the slump-test~* Analysis of the pain profile before and after the provoking task:~  * Determination of pressure pain sensitivity by the use of pressure algometry~ * Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
214281449|NCT04324775|OTHER|Exercise + Manual Lymphatic Drainage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes
214844225|NCT05672745|DEVICE|WB-LIFE|WB-LIFE is a mobile application program grounded in validated psychotherapies (including cognitive behavioral therapy, interpersonal, and dialectical behavioral therapy), that enlists the relational agent Woebot to guide users in managing their mood. The user experience is driven by artificial intelligence and centers around mood tracking, evidence-based tools, and goal-oriented, tailored conversations.
214281450|NCT04324775|OTHER|Exercise + Swedish massage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
214281451|NCT03721744|DRUG|GB201|GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine
214281452|NCT03721744|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 will be administered intravenously starting on Day 1 of Cycle 1. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle
214281453|NCT03721744|DRUG|Gemcitabine|Low-dose gemcitabine 600 mg/m\^2 will be administered intravenously following completion of paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle.
214281454|NCT03721744|OTHER|Standard of care treatment options|Patients will receive one of the standard of care treatment options assigned by the Investigator for each patient prior to starting protocol treatment, including Gemcitabine, capecitabine, 5-FU/LV, Onivyde plus 5-FU/LV (if Onivyde is available in the country/region) or best supportive care (BSC).
214281455|NCT00384566|DRUG|Carvedilol|anit hypertensive medication
214281456|NCT00384566|DRUG|Metoprolol|Anti hypertensive medication
214281457|NCT02213367|DRUG|Bilastine|20mg (8 weeks)
214281458|NCT02213367|DRUG|Bilastine|40mg
214281459|NCT02213367|DRUG|Bilastin|80mg
214281460|NCT02366052|BEHAVIORAL|Nutritional Counseling|Nutritional counseling by a trained nutritionist for 12 weeks.
214281461|NCT02366052|DIETARY_SUPPLEMENT|Lactobacillus casei shirota (LCS)|The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
214281462|NCT02366052|OTHER|Nutritional Counseling and LCS|Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
214281463|NCT04425915|BIOLOGICAL|Convalescent Plasma|Dose-250 ml Frequency - 2 doses on consecutive days Duration -Start by day 3 of symptom onset (of severe COVID-19 as in inclusion criteria) in eligible patients
214281464|NCT04425915|OTHER|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
214281465|NCT06467474|BEHAVIORAL|PEG-D program|PEG-D will be carried out in person, open format, for six consecutive weeks lasting 90 minutes each. An approximate group of 6 to 10 participants will be led by a team of experienced psychologists and psychiatrists. Each group will have a main therapist and a co-therapist to ensure effective support and guidance for participants. Before the start of the group, participants received a booklet containing the content of the sessions.
214281466|NCT06467474|DRUG|TAU|The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\&#39;s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the patient will proceed to augmentation with the aforementioned medications and if there is no improvement of at least 25%, the patient will be considered drop-out. Associations with Lorazepam if necessary will be allowed in any phase of the study.
214281467|NCT00160628|DRUG|Levetiracetam|
214281468|NCT05446805|DRUG|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
214281469|NCT05446805|DRUG|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
214281470|NCT03198247|OTHER|Usual care|"The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
214281471|NCT03198247|OTHER|PNE + CST|The PNE and CST program will be divided in 3 individual sessions.
214281472|NCT03123718|DRUG|Intrathecal methotrexate|Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
214281473|NCT03123718|DRUG|High-dose intravenous methotrexate|"Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~\* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged \>70 years."
214281474|NCT01032837|DRUG|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
214281475|NCT01032837|DRUG|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
214281476|NCT01032837|DRUG|Placebo|Matching placebo provided as capsules and as a suspension.
214281477|NCT00674245|DRUG|Pantoprazole|40 mg once daily for 4 weeks
214281478|NCT00674245|DRUG|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
214281479|NCT00674245|DRUG|placebo|40 mg once daily for 4 weeks
214281480|NCT01351922|OTHER|No treatment given|Patients will fill out a questionaire by interview.
214281481|NCT00843024|DRUG|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
214281482|NCT00843024|DRUG|Placebo|Placebo to match
214281483|NCT05948397|DIAGNOSTIC_TEST|Combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and quality of life scale|A combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and quality of life scale would be given to all patients. The sum of the responses for the third, fourth and fifth questions and quality of life scale scores will be recorded.
214281484|NCT05948397|DIAGNOSTIC_TEST|Bladder diary|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance
214281485|NCT05948397|DIAGNOSTIC_TEST|Pad test|"One-hour pad test.~* the test is started by putting one pre-weighted pad without patient voiding, -patient drinks 500 ml of sodium-free liquid in \<15 min- then sits or rests,~* patient walks for 30 min, including climbing one flight of stairs (up and down),~* patient performs the following activities: standing up from sitting (10 ), coughing vigorously (10 ), running on the spot for 1 min, bending to pick up an object from the floor (5 ), and washing hands in running water for 1 min (this activity program may be modified according to the patient's physical fitness),~* the total amount of urine leaked is determined by weighing the pad. In the analysis of 1-hr pad test, an increase of 1-10 g is classified as representing mild incontinence, 11-50 g moderate and \>50 g severe incontinence. The values for 24-hr pad test are classified as follows: Mild (4-20 g/ 24 hr), moderate (21-74 g/24 hr), and severe (\>75 g/24 hr) incontinence"
214281486|NCT01741597|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
214281487|NCT01741597|OTHER|pharmacological study|Correlative studies
214281488|NCT01741597|BIOLOGICAL|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
214281489|NCT02840500|OTHER|No intervention|No intervention
214281490|NCT04113005|DRUG|Desmopressin|To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
214469826|NCT05912634|PROCEDURE|Extensive TAAD- R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
214469827|NCT05419687|BEHAVIORAL|Training in de-escalating violence|"* Individual educational component through a de-escalating violence training for health care workers (verbal and non-verbal de-escalating techniques)~* Refreshment training in the form of collaborative learning"
214844226|NCT00813345|OTHER|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
214281491|NCT03839979|DIAGNOSTIC_TEST|BIOLINE HCV kits|We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.
214281492|NCT03839979|DIAGNOSTIC_TEST|ACCU-CHEK kits|For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.
214281493|NCT03839979|DIAGNOSTIC_TEST|ErKameter 3000 mercury manometer|For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.
214281494|NCT02643680|DEVICE|The novel biocellulose wound dressing|The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
214469828|NCT05419687|BEHAVIORAL|Code of conduct delivered via a warning board|A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals
214469829|NCT01868997|DRUG|teprotumumab|
214469830|NCT01868997|DRUG|normal saline|
214469831|NCT05603819|DEVICE|EDIT-B|To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.
214469832|NCT05433662|BEHAVIORAL|Pandemic Acceptance and Commitment Therapy (Pan-ACT)|Pan-ACT is a 10-session, closed group, transdiagnostic intervention for older adults.
214844227|NCT00813345|OTHER|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
215057540|NCT02487147|OTHER|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
214281495|NCT02643680|DEVICE|Bactigras|Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
214281496|NCT01008488|DRUG|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
214281497|NCT03265769|OTHER|radial access site|radial route
214281498|NCT03265769|OTHER|femoral access site|femoral route
214281499|NCT02216734|BEHAVIORAL|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
214281500|NCT00804544|DEVICE|SPECT/CT|SPECT/Low-Dose MultiSclice CT
214281501|NCT02801383|DRUG|Yallaferon®， the recombinant human interferon α-2b gel|
214281502|NCT02801383|OTHER|gel without active ingredient|
214281503|NCT03123913|DRUG|Testosterone Enanthate|Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
214281504|NCT03123913|DRUG|Somatropin|Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
214281505|NCT01523262|PROCEDURE|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
214281506|NCT01523262|PROCEDURE|Normal surgery, with sham intervention without inflating arm cuff|
214281507|NCT03108183|DIAGNOSTIC_TEST|x-rays|To get further and actual information about periapical lesions, different x-rays will be done (panoramic radiographic, small picture ray, cone beam computed tomography). Furthermore a periodontal status will be performed.
215032133|NCT06680661|DRUG|Tacrolimus|Tacrolimus will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. Tacrolimus will continue at least until day 180 and then be tapered off.
215032134|NCT06680661|DRUG|Mycophenolate Mofetil|MMF will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. MMF will continue until day 30.
215032135|NCT06680661|DRUG|Abatacept|Abatacept at a dose of 10mg/kg will be given on days T-1, T+5, T+14 and T+28.
214281508|NCT02439138|DRUG|GS-1101|Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
214281509|NCT00394368|DRUG|beclomethasone dipropionate plus formoterol fumarate combination|
214281510|NCT00394368|DRUG|fluticasone propionate plus salmeterol xinafoate combination|
214281511|NCT02517567|DEVICE|Delefilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
214281512|NCT02517567|DEVICE|Narafilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
214281513|NCT02517567|DEVICE|Somofilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
214281514|NCT02023606|DRUG|SPN-810M|
214281515|NCT06037447|PROCEDURE|3-steps standardized repair-oriented strategy|3-steps standardized repair-oriented strategy, including subvalvular apparatus rehabilitation (leaflet plication if chordae absent on leaflet margin, mal-connected chordae resection if chordae mal-connected to leaflet body, papillary muscle splitting if short chordae or dysplastic or fused papillary muscle etc.), leaflets repair (leaflets plication if functional leaflet prolapse, leaflet cleft closure and patch augmentation for anatomical leaflet defect, etc.) and annuloplasty (posterior annuloplasty for annular dilatation and shallow leaflet coaptation, etc.)
214281516|NCT00052481|PROCEDURE|quality-of-life assessment|
214281517|NCT02920372|DRUG|EPOETIN ALFA|
214281518|NCT00006237|BIOLOGICAL|interleukin-2|Given IV
214281519|NCT00006237|BIOLOGICAL|filgrastim|Given subcutaneously
214281520|NCT00006237|BIOLOGICAL|interferon alfa|Given IV and subcutaneously
215032136|NCT06271057|DRUG|golcadomide|golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166
215032137|NCT06576687|OTHER|Physical Rehabilitation|Exercises include (1) single-limb hops to stabilization, (2) hop to stabilization and reach, (3) unanticipated hop to stabilization, (4) single-limb stance activities, and (5) continuous choice-reaction hopping.
215032138|NCT06235801|DRUG|Gilteritinib|Given by PO
215032139|NCT06235801|DRUG|Momelotinib|Given by PO
215032140|NCT03090165|DRUG|ribociclib|400mg PO
215032141|NCT03090165|DRUG|ribociclib|600mg PO
214281521|NCT00006237|DRUG|cisplatin|Given IV
214281522|NCT00006237|DRUG|dacarbazine|Given IV
214281523|NCT00006237|DRUG|vinblastine|Given IV
214281524|NCT02301000|BIOLOGICAL|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
214281525|NCT02301000|DRUG|Metronidazole|Peroral metronidazole 400 mg t.i.d. for ten days
214281526|NCT05829304|OTHER|MTA based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
214281527|NCT05829304|OTHER|Collagen based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
214281528|NCT00585247|DRUG|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
214281529|NCT00585247|OTHER|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
215032142|NCT03090165|DRUG|Bicalutamide|150mg PO
215032143|NCT01928537|DRUG|rigosertib sodium|
215032144|NCT05269082|OTHER|No intervention|This is a non-interventional study.
215032145|NCT01405664|OTHER|Weight-Bearing as Tolerated|WBAT immediately after surgery
215057541|NCT02487147|OTHER|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
215032146|NCT04289493|OTHER|Language and functional communication therapy|17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.
214281530|NCT04821115|DEVICE|Low intensity choc waves therapy (active applicator)|At each of the 4 sessions, 4000 shockwaves will be delivered at level 8 (EFD = 0.133 mJ/mm2), over a period of 15 to 20 minutes. The probe will be applied directly to the plaque, on the flaccid penis. The device will stop automatically after the 4000 shock waves.
214281531|NCT04821115|DEVICE|Sham (sham applicator)|At each of the 4 sessions, a sham applicator will be used. The sham applicator has an internal foam pad that disperses the shockwave energy, but is not visible from the outside. The sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted.
215032147|NCT04283175|OTHER|Posturological examination on KPlates and AMTI platforms|By an unique evaluator
215032148|NCT04283175|OTHER|Berg Balance Scale (BBS)|Falls and fera of falling, motor and sensory impairments
215032149|NCT03008408|DRUG|Everolimus|Given PO
215032150|NCT03008408|DRUG|Letrozole|Given PO
215032151|NCT03008408|DRUG|Ribociclib|Given PO
215032152|NCT03044054|DEVICE|ECHOPULSE|HIFU Under ultrasound guidance
215032153|NCT05805800|DRUG|5HT3RA+Olanzapine|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner."
215032154|NCT05805800|DRUG|5HT3RA+Olanzapine+Dexamethasone|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner. On first day, dexamethasone is given orally within 30 minutes before cisplatin/adriamycin/cyclophosphamide administered."
215032155|NCT05530655|DRUG|Lisinopril Tablets|This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.
214281532|NCT01846416|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
215032156|NCT06138782|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Our protocol consists of five treatments of inhibitory continuous TBS (cTBS) to the R OFC lasting three minutes delivered every hour over the course of 10 days (2 weeks) for a total of 50 treatments.
215032157|NCT01277185|DIETARY_SUPPLEMENT|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
215032158|NCT01277185|DIETARY_SUPPLEMENT|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
215032159|NCT03275831|DEVICE|PluroGel|Surfactant based gel
215032160|NCT03275831|DEVICE|Intrasite gel|Hydrogel
214469833|NCT03194971|OTHER|Tumor samples from patients treated with TTFields at initial diagnosis.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
214844228|NCT05571033|BEHAVIORAL|Spinal reflex conditioning|Each participant will serve as their own control. The intervention is 30 sessions. The first 6 sessions are baseline measures of reflexes. The remaining sessions will engage participants in learning how to decrease their reflex activity in their calf muscle on the more-affected leg. Each intervention visit will involve 20 trials in which participants do not get visual feedback about their performance, then 225 trials with visual feedback.
215032161|NCT06501105|DEVICE|WOUNDCHEK Bacterial Status|Lateral flow point of care test for the qualitative detection of bacterial protease activity in wound fluid.
215032162|NCT04817436|OTHER|physical activity program (APA)|adapted physical activity program (APA)
215032163|NCT01443312|GENETIC|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
215032164|NCT05870072|OTHER|Dual task training|In addition to balance exercises, random name-word generation, counting the days of the week forward and backward, counting the months of the year forward and backward, subtracting 3 by 3 numbers from 300 to 900 starting from a random number, adding 7 from 1 to 100 and adding 100 Cognitive tasks such as counting tasks by subtracting 7 will be given. While testing dual-task performance, subjects will be asked to perform both tasks without prioritizing and do their best, and will be warned not to stop thinking. In dual-task training, the additional task to be assigned to the motor task will initially be of low complexity and novelty, and will progress to a high degree of complexity and novelty in the training process.
215032165|NCT05870072|OTHER|Kinesthetic motor imagery training|Kinesthetic motor imagery training will be planned according to the PETTLEP model. In our study, a single standard motor imagery frame will be created for the subjects. Before starting the motor imagery sessions, individuals will be given an introductory motor imagery session. How to visualize from first-person and third-person perspectives will be explained practically. Motor imagery training will be done in a quiet environment with the door and window closed in order to minimize the external factors that will distract the individual and prevent him from focusing, and the individual will be asked to sit in the motor imagery training sessions. a comfortable chair in the position they feel most comfortable in. Individuals will have their eyes closed throughout the entire motor imagery training. At the beginning of the session, approximately 5 minutes of relaxation exercise will be performed to maximize attention during motor imagery.
215032166|NCT05870072|OTHER|Balance exercises|Balance exercises will begin with approximately 5 minutes of warm-up exercises and will end with approximately 5 minutes of cool-down exercises at the end of each session. Balance exercises; Static standing on flat ground for 30 seconds with feet together, standing in tandem position for 30 seconds, standing on one leg for 30 seconds, and toes for 30 seconds, one foot airborne backwards, one foot airborne knee flexion slightly squat, one foot airborne knee extension slightly squat, going on the toes, turning with the heel, and multi-directional stretching exercises with eyes open and closed on one leg on the balance board. Each exercise will be performed with 10 repetitions for both lower extremities. Exercises will be applied once a day, 3 days a week for 6 weeks. The exercise program will be accompanied by a physiotherapist and groups of 6-10 people with similar suitability will be formed for the session hours.
214281533|NCT04835532|PROCEDURE|guided bone gereration|"guided bone generation: GBR is a procedure that uses barrier membranes with or without particulate bone grafts or/and bone substitutes.~tenting screws: Screws are implanted in the surgical area to prevent the barrier membrane from collapsing.~A-PRF/I-PRF: Obtained by autologous blood centrifugation."
214281534|NCT03290092|DRUG|Taselisib (GDC0032)|The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
214281535|NCT03290092|DRUG|Taselisib (GDC0032)|The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
214281536|NCT01065285|BIOLOGICAL|Evaluation of vaccines against flu|evaluate efficacy and tolerance
214281537|NCT03794271|PROCEDURE|Pupilometer guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
214281538|NCT03794271|PROCEDURE|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
214281539|NCT06268002|DIETARY_SUPPLEMENT|Vernonia cinerea|Vernonia cinerea is an herb that is claimed in many Thai medicinal formulas. In traditional medicines, they use this herbal to treat diseases such as hypertension, asthma, fever, hepatitis, gallstones, including use to help smoker quit smoking.
214281540|NCT06268002|DIETARY_SUPPLEMENT|Placebo|Sweetener
214281541|NCT00533598|DRUG|MK0557|
214281542|NCT03409835|DRUG|Ramosetron|Ramosetron 0.3 mg is administered after induction of general anesthesia.
214281543|NCT03409835|DRUG|Normal saline|Normal saline 2 ml is administered after induction of general anesthesia.
214281544|NCT01487200|DRUG|FX006 10 mg|single 3 mL IA injection
214281545|NCT01487200|DRUG|FX006 40 mg|single 3 mL IA injection
214469834|NCT03194971|DEVICE|Tumor samples from patients treated with TTFields at tumor recurrence.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
214281546|NCT01487200|DRUG|FX006 60 mg|single 3 mL IA injection
214469835|NCT03802799|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
214469836|NCT03658343|DIAGNOSTIC_TEST|T2* Imaging|T2\* imaging sequences for MRI
214469837|NCT05682560|BIOLOGICAL|REGENECYTE|HPC, Cord Blood
215032167|NCT05889468|DRUG|Aspirin 81Mg Ec Tab|Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.
214469838|NCT05682560|BIOLOGICAL|Placebo|Normal Saline
214469839|NCT03825107|OTHER|patching|covering the fellow eye with an eyepatch to force use of the amblyopic eye
214469840|NCT03825107|OTHER|Dichoptic videos|watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
214281547|NCT01487200|DRUG|TCA IR 40|single 1 mL IA injection
214281548|NCT03638297|DRUG|PD-1 antibody + cox inhibitor|"BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."
214281549|NCT06306781|DRUG|HCL001 cell (homologous allogeneic hepatocytes) injection|The patient will undergo a DSA procedure in the hospital's operating room before infusion. A catheter will be inserted into the femoral artery and guided to the hepatic artery. Upon confirmation through imaging, HCL001 cell injection will be slowly infused through the catheter. During the infusion, the cells should be continuously agitated to prevent clumping. The infusion can be administered as a single dose or multiple doses, and after infusion, the patient will be closely monitored for at least one week.
214281550|NCT02837783|DRUG|Linaclotide|Oral, once daily
214469841|NCT05926739|DEVICE|Electrical stimulation and biofeedback with Phenix Liberty medical device|"12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.~The patient will undergo 12 therapeutic functional reeducation sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used. The patients will complete questionnaires at the end of the care.~Overall, the functional rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 12 sessions between 6 and 8 weeks~* 1 end visit, within the week after the 12th session"
214469842|NCT06568432|DEVICE|CRP+SAA POCT|CRP+SAA POCT will be provided in 20 village clinics in the intervention group
215032168|NCT05889468|DRUG|Placebo|Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.
214281551|NCT02837783|DRUG|Placebo|Oral, one daily
214281552|NCT01962896|DRUG|Erlotinib|
214281553|NCT01962896|DRUG|Sirolimus|
214281554|NCT05759247|DEVICE|BORA Band (wristband)|Wristband collecting patient vital signs and activity
214281555|NCT00115102|DRUG|fentanyl|
214281556|NCT00115102|DRUG|S-ketamine|
214469843|NCT06506734|OTHER|Questionnaires|"*  Psychosocial Impact of Dental Aesthetics Questionnaire  PMID 24280547~*  Orofacial Esthetic Scale  PMID 30856637~*  Orofacial Esthetic Scale  PMID 34231057~* A photograph of the patient's smile will be sent to 2 dentists who will also assess the presence or absence of dental dyschromia."
214469844|NCT05712759|OTHER|Influenza-like illness group|"Each patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing.~ILI is defined by fever \> 37,8°C or/and cough or sore throat."
214469845|NCT06384404|OTHER|Questionnaire|PROMIS questionnaire
214281557|NCT05309642|BEHAVIORAL|Intermittent calorie restriction|Recipes will be provided with suggestions of meals that would not exceed the calorie restriction. For the remaining 5 days of the week, they will receive instructions and recipes that follows the Korean Dietary Reference Intakes (KDRIs), with an intake limit of 2,000 kcal/day for women and 2,500 kcal/day for men. The percentage of energy (E%) from different macronutrients in the recipes will be 45-60 E% carbohydrates, 25 E% fat and 10-20 E% protein.
214281558|NCT05309642|BEHAVIORAL|Standard of care|They will receive individualized guidance from a hepatologist on how to choose a healthy diet, to reduce the intake of sweets and saturated fatty acids, increase sources of unsaturated fat, avoid large portions, and to regularly eat 3 meals per day. Each participant will be provided a written summary of the dietary advice.
214281559|NCT02158403|OTHER|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
214281560|NCT00920712|DRUG|Weiqi decotion|Decoction ,two times a day
214281561|NCT02792725|DRUG|Abemaciclib|Administered orally
214281562|NCT06504940|DRUG|Orelabrutinib combined with bendamustine and rituximab|they will receive three cycles of Orelabrutinib combined with bendamustine and rituximab (BR: bendamustine 70mg/m\^2 on days 1-2; rituximab 375mg/m\^2 on day 0). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 21 cycles, each cycle 28 days).
214281563|NCT06504940|DRUG|Orelabrutinib combined with obinutuzumab|they will receive six cycles of Orelabrutinib combined with obinutuzumab (G 1000mg iv on days 1, 8, 15 of cycle 1, and day 1 of cycles 2-6; Orelabrutinib 150mg once daily). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 18 cycles, each cycle 28 days ).
214281564|NCT04013204|OTHER|Endothelial function guided therapy|To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
214281565|NCT03641443|DEVICE|Non-invasive measurement of intracranial pressure|Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
214281566|NCT00040482|DRUG|Cyclophosphamide|
214281567|NCT00040482|DRUG|ATG|
214281568|NCT00040482|DRUG|MESNA|
214281569|NCT00040482|PROCEDURE|Radiation therapy|
214281570|NCT03072992|DRUG|Curcumin|Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
214281571|NCT03072992|DRUG|Paclitaxel|Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
214281572|NCT03072992|DRUG|Placebo|Placebo i.v. solution, once weekly for 12 weeks
214281573|NCT05325671|PROCEDURE|transarticular multimodal drug infiltration|as described previously
214469846|NCT06569095|OTHER|Detection of MDS-SC using MFC|The aim of this study is to investigate the predictive values of MDS-SC determined by MFC for patients with MDS-EB who underwent allotransplantation.
214844229|NCT05247333|OTHER|Minor ailment service|The service had several components: agreed standard operational procedures between community pharmacists and primary care physicians for 31 minor ailments, IT based consultation protocol and training before and during the study for the pharmacists. Practice change facilitators were used to confirm the fidelity of the intervention.
214844230|NCT00441233|DEVICE|Silicone hydrogel contact lens|
214281574|NCT06505876|BEHAVIORAL|Basic treatment|including anti-infection therapy, blood pressure and blood glucose control
214844231|NCT03034161|DEVICE|Thermal imaging|Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.
214281575|NCT06505876|DEVICE|Oral Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214281576|NCT06505876|DEVICE|Nasogastric Tube Feeding|The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214281577|NCT05375370|OTHER|circulating tumor DNA dosage|blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
214281578|NCT03980002|DRUG|FCR and Ibrutinib|"Induction treatment:~Patients \<65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count \<10×10\^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~1. FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~2. Ibrutinib:420mg/d"
214281579|NCT03980002|DRUG|BR and Ibrutinib|"Induction treatment:~Patients ≥65y and ≤75 y or \<65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10\^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d"
215032169|NCT01309230|BIOLOGICAL|Vigil™|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
215032170|NCT05985135|PROCEDURE|Muscle Biopsy|Needle muscle biopsy of the outer thigh muscle
215032171|NCT05985135|OTHER|Jell-O with Amino acids|An amino acid mixture containing 13C6 Lysine isotope label
215032172|NCT05985135|DIETARY_SUPPLEMENT|Dextrose|Intravenous form of sugar
215032173|NCT05468918|DEVICE|Phonak Audeo previous generation hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
215032174|NCT05468918|DEVICE|Phonak Audeo Lumity hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
215032175|NCT00796263|DRUG|HAART|"1 (lamivudine) or 2 (lamivudine + abacavir) nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications once daily~plus~dolutegravir(DTG) 50 mg orally once daily"
215032176|NCT04481685|DRUG|ATI-450|50 mg (as determined from Phase I study) per dose. (100 mg per day). Up to a maximum of 14 days while inpatient. Patients discharged home or transferred to the intensive care unit (ICU) will be discontinued off drug permanently.
215032177|NCT04481685|DRUG|Placebo|Placebo pill will be taken twice daily preferably spaced 12 hours apart.
215032178|NCT02565394|OTHER|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
215032179|NCT04611243|BIOLOGICAL|third dose vaccination with CoronaVac vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine
215032180|NCT04611243|BIOLOGICAL|third dose vaccination with BionTech vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine
215032181|NCT04611243|BIOLOGICAL|Vaccination with Coronavac vaccine|Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart
215032182|NCT04611243|BIOLOGICAL|Vaccination with BionTech Vaccine|Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
214281580|NCT03980002|DRUG|Ibrutinib and Thalidomide|"Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy."
214281581|NCT02634671|OTHER|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
215032183|NCT06006286|DRUG|Atezolizumab|Given by IV (vein)
215032184|NCT06006286|DRUG|Bevacizumab|Given by IV (vein)
215032185|NCT06006286|DRUG|ADI-PEG 20|Given by Injection (inj)
215032186|NCT06570746|DRUG|Sedative|Sedation is applied before the procedure
215032187|NCT06570174|DIETARY_SUPPLEMENT|oral protein supplements|Participants in this group received an oral protein supplement providing 18g of protein per day. The supplement was administered postoperatively and continued throughout the study period. The goal was to assess the impact of protein supplementation on protein intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed. These outcomes were measured at three specific time points: before surgery, at discharge, and during the outpatient visit.
215032188|NCT06570174|GENETIC|placebo|Participants in this group received a placebo supplement containing carbohydrates instead of protein, which was identical in appearance and taste to the protein supplement to maintain the study's double-blind design. The placebo was administered postoperatively and continued throughout the study period. The aim was to serve as a control to evaluate the effects of the protein supplement on outcomes including nutrient intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed, measured at three key time points: before surgery, at discharge, and during the outpatient visit.
215032189|NCT06569459|DRUG|Trilaciclib Injection [Cosela]|Chemoradiotherapy and immunotherapy with Trilaciclib in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
215032190|NCT06569459|DRUG|Placebo|Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
215032191|NCT06557811|DRUG|Semaglutide|After randomization, each patient will receive four blisters of 3 mg tablets (semaglutide or placebo) and four blisters of 7 mg tablets (semaglutide or placebo), to be taken before breakfast. After 60 days, the patient will receive a 14 mg dose (a total of 16 blisters with 7 tablets each). The possibility of maintaining the 14 mg dose of the study drug or reducing it to 7 mg will be evaluated depending on side effects and tolerability.
215032192|NCT05513365|DRUG|Goserelin 10.8 mg|Goserelin injection (10.8 mg) once per 3 months until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
214281582|NCT02634671|OTHER|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
214281583|NCT02634671|OTHER|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
214281584|NCT00867724|DEVICE|Aer-O-Scope Colonoscopy|Screening Colonoscopy
214281585|NCT06411197|OTHER|Hypertonic saline injection|Injection with hypertonic saline (7%)
214281586|NCT06411197|OTHER|Isotonic saline injection|Injection with isotonic saline (0.9%)
214281587|NCT03601975|DRUG|Gemcitabine/Cisplatin|gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
215032193|NCT05513365|DRUG|Bicalutamide 50 mg|Bicalutamide tablets (50 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
215032194|NCT05513365|DRUG|Dutasteride 0.5 mg|Dutasteride capsules (0.5 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
215032195|NCT04535297|OTHER|exposure|Exposure to social distancing due to COVID-19
214281588|NCT06242158|PROCEDURE|arthroscopic assisted mini-open 5 step repair|"First step Identifying the tear size , quality and if reducible on the foot print . minimal removal of the bursa and pulling of the tendon with a grasper to reach the foot print area with gentle mobilization of the tendon .~Step two Acromioplasty Using a probe, the LHBT was palpated and mobilized, looking for any signs of degeneration and fraying or instability . The LHBT was inspected either through the tear by the subacrominal portal or through the glenohumeral portal .~Step three Antero-lateral mini-open approach was used through a longitudinal 4 cm skin incision Step four Transosseous repair using the giant needle was used. 3 to 4 number two fiber wire sutures was passed equidistance through the tendon Step five The subarominal bursa was used for biological augmentation of the repair"
214281589|NCT01316796|DRUG|Sodium Nitrite Cream|
214281590|NCT01190345|DRUG|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
214281591|NCT01190345|DRUG|no bevacizumab|no bevacizumab
214281592|NCT02313792|DRUG|Palifermin|
214281593|NCT01239004|DRUG|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
214469847|NCT06168825|OTHER|Mind Over Matter (MOM)|"Each participant's involvement in the study will include:~* Attending a Pre-Program Orientation which will be held a week before the first MOM Session.~* Completing 5 weekly sessions of MOM~* Completing 2 surveys; one will be given before the start of the intervention (a pre-test) and the other will be given after the last MOM Session (a post-test)~Participants will also have the option to participate in an optional Focus Group session which will occur a week after the last MOM Session ends~Participants will spend about 6 weeks in this study. If they decide to participate in the optional session, they will spend about 7 weeks in this study.~Please note, this entire Intervention will be offered online. There will be no in-person sessions or visits."
214281594|NCT01239004|DRUG|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
214281595|NCT01910025|DRUG|ADI-PEG 20|
214469848|NCT06569056|DRUG|HRS-8427|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
214469849|NCT06569056|DRUG|Imipenem and Cilastatin Sodium|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
214469850|NCT06569056|DRUG|HRS-8427 placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
214469851|NCT06569056|DRUG|Imipenem and Cilastatin Sodium placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
214469852|NCT03027102|BIOLOGICAL|DNT cells|DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
214469853|NCT05872204|DRUG|Abemaciclib|150 mg tablet twice daily
214469854|NCT05872204|DRUG|Letrozole|2.5 mg tablet once daily
214469855|NCT02852538|BEHAVIORAL|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
214281596|NCT02275468|DRUG|Fu-zheng-qu-zhuo (FZQZ) oral liquid|FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
214281597|NCT00843947|PROCEDURE|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
214281598|NCT02714582|BEHAVIORAL|Bedside shift report|Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson \& Mangino 2006).
214281599|NCT04933877|PROCEDURE|Fascial plane block|Serratus anterior plane block
214281600|NCT00003997|DRUG|irofulven|
214281601|NCT04356391|PROCEDURE|Connective Tissue Graft Technique|For the sites receiving the control technique (Connective Tissue Graft), the technique described by Langer B. and Langer L. will be started with a sulcular incision followed by a partial thickness flap. A CTG is then harvested according to the technique described by Bruno, the first incision is perpendicular to the 2nd premolar and 1st molar and is 2-3mm apical to their gingival margin as wide as the recipient site, followed by a second incision parallel to the for mentioned teeth, 1-2mm apical to the first incision, then the CTG is raised by periosteal elevator and released from apical and lateral attachments by sharp incision when needed. The graft is then prepared to have a homogenous thickness of 1.5-2mm. The donor CTG is stabilized to the underlying connective tissue interproximally using 4-0 Vicryl sutures. The recipient flap is repositioned coronally, to cover as much as possible of the graft with no tension, 2mm coronal to the CEJ, then sutured with 4-0 Vicryl sutures.
214303145|NCT02389998|OTHER|Placebo Suspension|The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
214469856|NCT05256940|BEHAVIORAL|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, that is delivered in three sessions in person, virtually, or by telephone.
214469857|NCT05256940|OTHER|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
214469858|NCT02622217|BEHAVIORAL|Sleep deprivation|
214469859|NCT02052882|BIOLOGICAL|romiplostim|
214469860|NCT05613478|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
214469861|NCT05613478|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
214281602|NCT04356391|PROCEDURE|Pinhole Surgical Technique|For the sites receiving the test technique (Chao Pinhole Surgical Technique) the surgery starts with a small pinhole opening in the alveolar mucosa apical to the mucogingival junction of the affected tooth, the flap is then undermined using special instruments to create a full thickness pouch, followed by extending the pouch horizontally and coronally to undermined the adjacent papilla without incising it and free the flap for its coronal displacement. Then multiple 2x12mm strips of collagen resorbable membrane material (Bio-Gide, Geistlich Pharma AG) are packed under the papilla to secure the flap in a coronal direction. Gentle pressure is applied for 5 minutes to minimize the thickness of the blood clot after each of the procedures. The patients are advised to brush all teeth and sites except the buccal surfaces of the operated-on teeth, which are to be cleaned with 0.12% Chlorhexidine mouth rinse.
214469862|NCT05613478|PROCEDURE|Radical surgery|Radical surgery
214469863|NCT05613478|PROCEDURE|Preoperative TACE treatment|TACE treatment before preoperative camrelizumab combined with apatinib mesylate
214469864|NCT05613478|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (at least 6 cycles) after radical surgery
214281603|NCT02216591|DEVICE|Active Cognitive Training (ACT)|
214281604|NCT02216591|DEVICE|Control (CON)|
214281605|NCT02207244|DRUG|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
214281606|NCT02207244|DRUG|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
214281607|NCT02207244|DRUG|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
214281608|NCT02207244|DRUG|Placebo for adalimumab|Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
214281609|NCT02406716|OTHER|Biospecimen retention|
214281610|NCT02256020|OTHER|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
214281611|NCT02256020|OTHER|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
214281612|NCT01184300|GENETIC|Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers|Patients found to carry the CYP2C19\*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
214281613|NCT00039130|BIOLOGICAL|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC\>5000/ul courses II-VII
214281614|NCT00039130|BIOLOGICAL|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV \& VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
214281615|NCT00039130|DRUG|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
214281616|NCT00039130|DRUG|cytarabine|1 g/sq m/day IV infusion Days 4 \& 5, courses II, IV, VI
214469865|NCT05613478|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (at least 6 cycles) after radical surgery
214469866|NCT05713942|DIAGNOSTIC_TEST|The Sport Concussion Assessment Tool 5th Edition (SCAT5)|The SCAT5 is a standardized tool for use by healthcare professionals in the evaluation of individuals 13 years old or older, who are suspected of having sustained a sports-related concussion. It comprises a neuropsychological test battery that assesses attention and memory function through 8 different domains 1) Symptom number, 2) Symptom severity, 3) Orientation, 4) Immediate memory, 5) Concentration, 6) Neurological examination, 7) Balance errors, 8) Delayed recall.
214469867|NCT05713942|DIAGNOSTIC_TEST|The Immediate Post-Concussion Assessment and Cognitive Testing tool version 4 (ImPACT)|The ImPACT is a computer-based neurocognitive test battery that provides an objective measure of neurocognitive functioning as an assessment aid in the management of concussion in individuals ages 12-80 years
214469868|NCT05305495|DRUG|Empagliflozin 25 MG|Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (≤120 mg) and urine output will be monitored for three hours. Those with a urine output \< 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.
214469869|NCT05267873|DRUG|Duloxetine, Vortioxetine|Medications for major depressive disorder
214844232|NCT01560819|DRUG|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
214844233|NCT06307041|DEVICE|Dental floss+Gengigel|0.2% Hyaluronic Acid Gel-Impregnated Dental Flosses
214844234|NCT06307041|DEVICE|Dental Floss|Dental Flosses
214844235|NCT04500132|DRUG|EC-18|EC-18 QD
214281617|NCT00039130|DRUG|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
214281618|NCT00039130|DRUG|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 \& 5 courses III,V, VII
214281619|NCT00039130|DRUG|etoposide|80 mg/sq m/day IV infusion Days 4 \& 5 courses II, IV, VI
214281620|NCT00039130|DRUG|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
214281621|NCT00039130|DRUG|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX \<10nM, courses II-VII
214281622|NCT00039130|DRUG|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
214281623|NCT00039130|DRUG|prednisone|60 mg/sq m PO/day Days 1-7 course I
214281624|NCT00039130|DRUG|vincristine sulfate|2 mg IV push Day 1 courses II-VII
214281625|NCT00039130|DRUG|Allopurinol|300 mg/day PO Days 1-14, course I
214281626|NCT04920019|PROCEDURE|Thoracic continuous epidural analgesia|"Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M\&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)"
214281627|NCT00908713|DRUG|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
214281628|NCT00908713|DRUG|Placebo|Sodium chloride 0.9% 10 mL every 12 h for 5 days
214281629|NCT00745836|DRUG|statin|
214281630|NCT06505434|PROCEDURE|Cataract surgery|Phaco + IOL Implantation
214844236|NCT04500132|DRUG|Placebo EC-18|Placebo EC-18 QD
214281631|NCT00139698|DRUG|olmesartan alone or in combination with hydrochlorothiazide|
214281632|NCT03147560|BIOLOGICAL|Sabin IPV+ bOPV+ bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
214281633|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
214281634|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + Sabin IPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
214281635|NCT05651997|PROCEDURE|MACT|"* A biopsy of healthy cartilage is taken from a non-weight bearing area of the knee joint during an arthroscopic procedure.~* The biopsy is processed in the GMP accredited laboratory to isolate and amplify chondrocytes.~* The cells are seeded and cultured on a collagen matrix (Chondro-Gide®, Geistlich Pharma)~* The membrane is implanted and sutured onto the injured site."
214281636|NCT05651997|PROCEDURE|AMT|This treatment combines the microfracture procedure with the application of a bilayer matrix of porcine type I/III collagen (Chondro-Gide, Geistlich Pharma) and the supplementation of autologous bone.
214281637|NCT01866930|BIOLOGICAL|Pegylated Interferon Lambda-1a|
214281638|NCT01866930|DRUG|Daclatasvir (DCV)|
214281639|NCT01866930|DRUG|Ribasphere (RBV)|
214281640|NCT05119452|OTHER|Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)|The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline
214281641|NCT00750815|DRUG|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
214281642|NCT00750815|DRUG|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
214281643|NCT03834597|DEVICE|conventional Macintosh laryngoscope|After closure of surgical, anesthesiologist will perform the conventional Macintosh laryngoscope to assess post-thyroidectomy vocal cord mobility.
214281644|NCT03834597|DEVICE|GlideScope®|Patient will be left for a while until hemodynamic stabilization then examination with GlideScope® will be commenced to assess postthyroidectomy vocal cord mobility by another experienced anesthesiologist
214281645|NCT00279305|DRUG|Anti-CD20 (rituximab)|
214281646|NCT00279305|DRUG|Placebo Comparator|Placebo intravenous infusion
214281647|NCT00270868|PROCEDURE|Double guide wire technique|
214281648|NCT00270868|PROCEDURE|Standard bile duct cannulation|
214303146|NCT02389998|DRUG|Hyoscyamine|While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
214303147|NCT04071730|DIETARY_SUPPLEMENT|Immulina Dietary Supplementation|Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
214303148|NCT05089682|DEVICE|DBS Stimulation during sleep|Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
214303149|NCT02909452|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
214303150|NCT02909452|DRUG|Pembrolizumab|A selective humanized monoclonal antibody (mAb)
214303151|NCT00706979|OTHER|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
214303152|NCT00706979|BEHAVIORAL|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
214303153|NCT02709031|DRUG|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
214303154|NCT02709031|DRUG|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,
214281649|NCT01212315|DEVICE|Triclosan coated sutures|Subcutaneous and cutaneous sutures coated with triclosan (Vicryl Plus / Monocryl Plus) are used to close the incisions after vein harvesting and sternotomy. All wounds are inspected before discharge from hospital and the patients are instructed to contact the study coordinator if any suspected infection occurs. In addition, all patients are controlled after thirty days by a nurse and contacted by telephone sixty days after surgery to assess postoperative infections by a predefined questionnaire. Infection symptoms are graded according to the Asepsis score and the CDC classification. Patient records including bacterial cultures and antibiotic treatment are collected for all patients with suspected infections.
214281650|NCT03081988|OTHER|chemoradiotherapy|concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
214281651|NCT05745571|OTHER|Blood sample|The study foresees a phase of patient recruitment, in which, in the hours immediately following the blood sampling, the isolation of the PBMCs, their incubation and cytofluorimetric analysis will be carried out and the conservation of the material to be analyzed subsequently by molecular biology and immunochemistry.
215032196|NCT02891356|DEVICE|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
215032197|NCT03900650|BEHAVIORAL|High provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
215032198|NCT03900650|BEHAVIORAL|Low provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
215032199|NCT03900650|BEHAVIORAL|Alcoholic beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
215032200|NCT03900650|BEHAVIORAL|Non-alcoholic beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
215032201|NCT02835105|DRUG|Surotomycin|A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
215032202|NCT02835105|DRUG|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
215032203|NCT05919498|OTHER|Individual semi-directive interview|"This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour."
215032204|NCT05919498|OTHER|Focus groups|"This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours."
215032205|NCT02577809|DRUG|Morphine100|100mcg added to the spinal anaesthetic
215032206|NCT02577809|DRUG|Morphine50|50mcg added to the spinal anaesthetic
214281652|NCT03428724|DRUG|Standard Preparation|standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
214281653|NCT03428724|DRUG|Individualized Preparation|individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age\>65, neurologic comorbidities)
214281654|NCT00456014|DRUG|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
214281655|NCT00456014|DRUG|Desipramine|Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
214303155|NCT04950569|DRUG|levosimendan|On the basis of standard conventional anti-heart failure treatment, levosimendan was used for 24 hours. The first load was 12 μg/kg, intravenous injection for 10 minutes, followed by intravenous infusion of 0.1 μg/Kg/min for 24 hours.
214303156|NCT05584150|OTHER|Deep Cleansing Gel|daily use
214303157|NCT01996826|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
215032207|NCT02577809|DRUG|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
215032208|NCT02577809|DRUG|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
215032209|NCT02577809|DRUG|Indomethacin|100mg Indomethacin suppository
215032210|NCT06017557|DIAGNOSTIC_TEST|Artificial Intelligence|With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, it would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumors can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.
215032211|NCT03508583|OTHER|Participation|"The mpoc 56 and mpoc 20 will be field-tested with a sample of 300 parents of children with disabilities residing in the Turkey.~Professionals working with children with disabilities will be assessed with MPOC SP questionnaires"
215032212|NCT02899403|OTHER|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
215057542|NCT05129163|BEHAVIORAL|Exercise|The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
214469870|NCT05219175|DRUG|MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (\~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (\~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (\~80 mg MDMA) to 140 mg MDMA HCL (\~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (\~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (\~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (\~100 mg MDMA) to 180 mg MDMA HCL (\~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (\~280 mg MDMA) to 500 mg MDMA HCL (\~435 mg MDMA)"
215032213|NCT03403179|OTHER|Functional Remediation|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
214469871|NCT06766890|BEHAVIORAL|WeJoy+WeHop|School-based CBT (WeJoy) comprises six weekly sessions on psychoeducation, cognitive restructuring, behavioural activation, emotional regulation, and self-monitoring. Exergaming on the interactive floor (WeHop) can gain a sense of autonomy, competence, and relatedness to help them regulate their emotions and maintain positive behaviours according to the Self-Determination Theory. Children participate in the interactive floor games by stepping on various targets and moving in response to the game's rules. Combining task division, cooperation, and taking turns constitutes the collaboration mechanism.
214844237|NCT05538637|DIAGNOSTIC_TEST|Echocardiography|"Mitral velocity time-integral variability measurement before and after passive leg raising.~Mitral velocity time-integral variability measurement after fluid loading in preload-responsiveness patients."
214844238|NCT04869371|DRUG|Docetaxel injection|75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
215032214|NCT04279587|BEHAVIORAL|Residential camp|Intensive education at a residential camp.
215032215|NCT00370578|DEVICE|repeated thrombus aspiration during primary PCI|
215032216|NCT00427700|DRUG|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
215032217|NCT00427700|DRUG|raloxifene|100mg PO on days 5-9 of the menstrual cycle
215032218|NCT05664529|DIAGNOSTIC_TEST|Chatoor Feeding Scale|Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
215032219|NCT05444387|OTHER|Upper limb loading|1 lb. external weight will be wrapped around both wrists during partial body weight support treadmill training. The partial body weight support treadmill training will be given for a maximum of 30 minutes and will finish earlier if the child asked to stop, or if the child stopped stepping. Body weight support will be systematically reduced, walking speed will be progressively increased over the training period, upright standing posture will be emphasized and normal kinematic components of the gait cycle will be facilitated during the training session. The training protocol for the current study will consist of 2 training sessions per weeks with at least one day in between and will last for 6 weeks.
215032220|NCT06388629|DEVICE|Rook Epicardial Access Kit|Access the epicardial surface of the heart via a subxiphoid approach with the subject device to facilitate guidewire placement into the pericardium.
215032221|NCT02423694|DEVICE|electro-acupuncture|"8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.~Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5\~1.0 mA"
215032222|NCT02423694|DRUG|escitalopram oxalate tablets|escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
215032223|NCT03477422|DRUG|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
215032224|NCT03477422|DRUG|Meropenem|Meropenem was the Comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg.Patients were given either Meropenem or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Drug) was given at 8th hour from first dose, third dose (Placebo) at 12th hour from first dose and the fourth dose (Drug) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
215032225|NCT01379690|OTHER|HBA1C|Used level of HBA1C as a reflection of glycaemic control of the cases and controls
215032226|NCT04581395|OTHER|non-pretreated Succinylcholine|no pretreatment
215032227|NCT04581395|DRUG|succinylcholine 1 minute after rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
215032228|NCT04581395|DRUG|succinylcholine 2 minutes following rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
215032229|NCT05681949|OTHER|ADBoard|Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
215032230|NCT05417906|OTHER|Standard care|Oral prednisolone for 5 days
215032231|NCT05417906|OTHER|Eosinophil-directed care|Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10\^3/µL, or 3 days if eosinophil is \< 0.300 x 10\^3/µL
214844239|NCT04869371|DRUG|Triptorelin Pamoate for Injectable Suspension|15mg every 12 weeks
214844240|NCT04869371|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone, once daily
214844241|NCT02625506|DRUG|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
215032232|NCT06119217|COMBINATION_PRODUCT|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
215032233|NCT06119217|COMBINATION_PRODUCT|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
215032234|NCT06119217|COMBINATION_PRODUCT|Nab-Paclitaxel and gemcitabine|Dose and schedule per protocol
215032235|NCT06252415|BIOLOGICAL|foetal amniotic fluid sample|At the inclusion visit, during the foetal samples taken for the CMA/ES as part of the care.
215032236|NCT06252415|BIOLOGICAL|blood samples|2 x 5ml blood EDTA tubes for both parents
215032237|NCT06252415|OTHER|semi-structured online interviews|25 included couples will be invited to take part in 2 semi-structured online interviews (by telephone or videoconference)
215032238|NCT05945225|DEVICE|Sonicare DiamondClean 9000 Philips®|Brush teeth with the electric toothbrush daily during 3 months
215032239|NCT05945225|DEVICE|HydroSonic Easy Curaden®|Brush teeth with the hydrosonic toothbrush daily during 3 months
215032240|NCT05945225|DEVICE|Manual toothbrush Oral-B 123|Brush teeth with the manual toothbrush daily during 3 months
215032241|NCT05945225|DEVICE|Manual toothbrush Curaprox CS 5460|Brush teeth with the manual toothbrush daily during 3 months
215032242|NCT03560388|OTHER|Acupuncture and touch/relaxation|Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
215032243|NCT06564688|DIAGNOSTIC_TEST|Swallowing function test|"The oral function score assesses the oral functional performance of chewing in all participants.~The Functional oral feeding Scale (FOIS) was used to assess the ability of all participants to eat.~The standardized swallowing assessment (SSA) was used to assess the global swallowing function of all participants."
215032244|NCT06272578|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
214303158|NCT01996826|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
214303159|NCT02248350|BEHAVIORAL|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
214303160|NCT02248350|BEHAVIORAL|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
214303161|NCT00729027|DRUG|25 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
214303162|NCT00729027|DRUG|50 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
214303163|NCT00729027|DRUG|placebo|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
214303164|NCT04564456|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test oproduct in one study period
214303165|NCT04564456|DRUG|ADVAIR DISKUS® 500/50|2 inhalations Reference product in one study period
214303166|NCT02734979|DEVICE|Biobridge and lymph node transfer|Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
214303167|NCT00739544|OTHER|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
214303168|NCT06267079|OTHER|core stability exercise|Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).
214303169|NCT03016247|BEHAVIORAL|TRUST Intervention|The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.
214303170|NCT03016247|BEHAVIORAL|Enhanced Usual Care|Single meeting with a Nutritionist for physical activity and eating counseling.
214303171|NCT00441844|DRUG|Simvastatin|
214303172|NCT04911283|OTHER|Brucella serology test|MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.
214303173|NCT04911283|OTHER|Medical history for brucellosis|Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
214303174|NCT02255981|OTHER|Acupuncture and massage|"Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself."
214303175|NCT05890040|OTHER|questionnaire|assessment of anxiety
214303176|NCT00518323|DRUG|Paliperidone ER|3 mg or 6 mg tablet once daily for 6 weeks
214303177|NCT00518323|DRUG|Placebo|Once daily for 6 weeks
214303178|NCT00518323|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
214303179|NCT00518323|DRUG|Paliperidone ER|6 mg or 12 mg tablet once daily for 6 weeks
214303180|NCT00005010|DRUG|Irbesartan|
214303181|NCT00005010|DRUG|Pravastatin|
214303182|NCT02428660|GENETIC|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
214303183|NCT02428660|OTHER|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
214303184|NCT02428660|OTHER|MTM|Medication Therapy Management
214303185|NCT06250985|OTHER|Timing of reimplantation|Patients will be rendomized 1:1 by computer to recieve either standart care or intervention prior to removal of infected system
214303186|NCT04056442|DRUG|Cannabidiol , synthetic form|Cannabidiol ( synthetic form)
214303187|NCT04056442|DRUG|Placebo|Olive Oil Solution, 5%
214281656|NCT05173805|DRUG|YL-15293|After enrollment, patients will receive oral YL-15293 twice a day until disease progression, unacceptable adverse events, concurrent diseases prevent further study treatment, the investigator decides to withdraw the patient, the patient withdraws consent, the patient is pregnant, or for administrative reasons. After treatment, the patients will continue to be followed up for 30 days. Patients who permanently stop the study treatment for reasons other than disease progression will be followed up for disease evaluation after treatment until the start of new anti-cancer treatment, withdrawal of consent, loss of follow-up, death or until the sponsor stops the study, whichever comes first.
214281657|NCT05165901|DEVICE|Scrambler Therapy|LG Medipain is a type of non-invasive neuromodulation.
214281658|NCT03886805|OTHER|Dual task with variable- and fixed-priority instructions|The participants were asked to perform dual-task activities focused, interchangeable or simultaneously, on balance (motor tasks) and on cognitive tasks performance, according to the instructional priority established by the physical therapist.
214281659|NCT03886805|OTHER|Dual-task with variable-priority instructions|The participants were asked to spend half the session focused on balance (motor tasks) and half the session focused on cognitive tasks performance, according to the instructional priority established by the physical therapist.
214281660|NCT05106686|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan group|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
214281661|NCT05106686|DIETARY_SUPPLEMENT|placebo group|Placebo 300 mg/day for 12 weeks
214281662|NCT04008576|BEHAVIORAL|Group Blended Transdiagnostic treatment|The treatment combines group face-to-face and Internet-delivered psychotherapy: 7 group sessions delivered every 3 weeks plus the use of an online treatment platform between sessions. Its goal is to learn and practice adaptive regulation strategies from a mechanistically transdiagnostic approach, with a focus on both negative and positive affectivity. Each group session will focus on one of the following core components: the first group session will focus on CBT traditional strategies such as motivation for change and psychoeducation about emotions; sessions 2 to 5 will focus on strategies to down-regulate negative affect: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, and interoceptive and situation-based emotion exposure; session 6 will focus on strategies to regulate positive affect; the final session will teach relapse prevention techniques. All the treatment components are delivered in 16 online treatment modules.
214281663|NCT04481854|PROCEDURE|cricoid pressure|cricoid pressure during laryngoscopy
214281664|NCT04481854|PROCEDURE|left paratracheal pressure|left paratracheal pressure during laryngoscopy
214281665|NCT03534960|DEVICE|High Flow Nasal Oxygen Therapy|Nasal cannula flows of 3 to 8 lpm via systems approved to provide increased humidification and warmth to inspired gas
214281666|NCT03534960|DEVICE|Nasal CPAP|"Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O"
214281667|NCT02657291|DRUG|Ropivacaine|Local anesthetic
214281668|NCT02657291|DEVICE|Ultrasound|Ultrasound guided block
214281669|NCT03378232|DIETARY_SUPPLEMENT|Placebo Olive Oil|Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
214281670|NCT03378232|DIETARY_SUPPLEMENT|High EPA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
214281671|NCT03378232|DIETARY_SUPPLEMENT|High DHA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
214281672|NCT03303365|RADIATION|stereotactic radiosurgery (SRS)|"All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.~In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).~Dose prescription to the PTV for target lesions will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
214281673|NCT04956367|PROCEDURE|Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma|Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
214281674|NCT04956367|DEVICE|CO2 laser with PRP|CO2 laser with PRP
214281675|NCT04956367|DEVICE|CO2 laser with placebo|CO2 laser with placebo
214281676|NCT00171353|DRUG|valsartan|
214281677|NCT04158115|OTHER|Entire Spine Mobilization|8 sessions of Following: -Entire Spinal Mobilization of all spinal segment from C0 to C1 to L5 to S1 (10 reps × 3 sets), - Moist heat: 10 to 15 minutes, - Soft tissue Mobilization, - Exercises : (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
214281678|NCT04158115|OTHER|Segmental Mobilization|"8 sessions of following -Segmental Mobilization: All lumbar segment from L1 to L2 to L5 to S1 (10 reps × 3 sets) - Moist heat: (10 to 15 minutes), -Soft tissue Mobilization~\- Exercises: (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)"
214281679|NCT03930797|BEHAVIORAL|Intimacy Enhancement|The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
214281680|NCT03930797|BEHAVIORAL|Living Healthy Together|The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
214281681|NCT00078442|DRUG|Pegylated interferon alfa-2a|Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
214844242|NCT02625506|DRUG|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
214281682|NCT01322139|DRUG|Placebo spray and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
214281683|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
214281684|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
214281685|NCT01322139|DRUG|Placebo spray and moxifloxacin|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
214281686|NCT00701675|DRUG|sertraline 50 mg daily|50 mg daily
214281687|NCT00701675|DRUG|sertraline 100 mg daily|100 mg daily
214281688|NCT00701675|DRUG|Placebo 50 or 100 mg|50mg or 100mg matching placebo
214281689|NCT01156870|DRUG|SAR566658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
214281690|NCT06049862|BEHAVIORAL|MaRiTensi App|"MaRiTensi is a mobile health-based hypertension self-management application used on Android smartphones.~MariTensi provides facilities for recording blood pressure, BMI, activity, examination results, education about hypertension, consultations, reminders and community chat."
214281691|NCT01261910|BEHAVIORAL|Intensive initial education|Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
214281692|NCT01939652|PROCEDURE|Restrictive VS Standard Fluid Regime|
214281693|NCT01939652|DRUG|Drag: Crystalloids and Colloids|
214281694|NCT01375556|DRUG|Ethanol|
214281695|NCT06464068|DRUG|Durvalumab|"All drugs will be administered intravenously. Induction treatment will be administered on a 21-day cycle for four cycles and will consist of:~* etoposide 80-100 mg/m² (administered on days 1-3 of each 21-day cycle);~* investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m² (administered on day 1 of each cycle);~* durvalumab 1500 mg every 3 weeks in combination with chemotherapy (induction phase) followed by maintenance phase with durvalumab 1500 mg every 4 weeks. Patients will continue treatment until disease progression per investigator assessment, unacceptable toxicity, or other discontinuation criteria were met for a maximum of 24 months. Continuation of study treatment after disease progression will be permitted if there is evidence of clinical benefit for a maximum 24 months."
214281696|NCT02019329|OTHER|Placebo|Oral daily administration from Days 1-12
214281697|NCT02019329|DRUG|RO5545965|Oral daily administration from Days 1-12
214281698|NCT02019329|DRUG|risperidone|13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
214281699|NCT00317356|DRUG|OPC-6535(Tetomilast)|
214281700|NCT00273871|DRUG|Cyclosporin or tacrolimus|
214281701|NCT00079898|PROCEDURE|Acupuncture|
214281702|NCT00870792|BEHAVIORAL|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
214281703|NCT04433221|BIOLOGICAL|Multiple sarcoma-specific CAR-T cells and sarcoma vaccines|1 infusion, CART 1x10\^6\~1x10\^7 cells/kg via IV and vaccines 1-5x10\^6 irradiated cells via subcutaneous injection
214281704|NCT02154243|DRUG|Midodrine|10 mg, p.o., once, on day of surgery after first physical therapy session
214469872|NCT04613505|BEHAVIORAL|Semi-structured interview|Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.
214281705|NCT02154243|OTHER|Intravenous fluid bolus|15 cc/kg, once, on day of surgery after first physical therapy session
214469873|NCT04613505|BEHAVIORAL|Same day consent questionnaire|A questionnaire (yet to be developed) will be administered to participants.
214469874|NCT06765343|DEVICE|Plaque disclosing agent|Dye agent binding to oral biofilm and plaque for visual detection
214281706|NCT05457764|DEVICE|Virtual reality headset|"The VR headset was a Pico G2, Pico Interactive, San Fransisco, USA, offering a choice from 60 erotic videos each of 10-30 minutes duration. The men were allowed to watch any and as many of these video clips as they wished. The No VR arm, donors used the computer monitor available in the donation rooms."
214281707|NCT00176228|DRUG|Lamotrigine|"It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg."
214281708|NCT03931538|DIAGNOSTIC_TEST|Guidance 4.0 PCR test|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
214281709|NCT03931538|DIAGNOSTIC_TEST|Urine Culture|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
214281710|NCT01833013|OTHER|live birth date and quality of life assessment|
214281711|NCT00323921|DEVICE|dermatological infrared laser|
214281712|NCT04212650|DRUG|Losartan|Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.
214281713|NCT04212650|OTHER|Placebo|Appearance-matched microcrystalline cellulose placebo
214281714|NCT00634374|DEVICE|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
214281715|NCT02099994|BIOLOGICAL|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10\^10 vp or saline placebo
214469875|NCT06765343|DEVICE|Guided Biofilm Therapy|Utilisation of a air-polishing device conveying a jet of air, water and erythritol powder for plaque debridement on dental surfaces, followed by calculus removal with an ultrasonic scaler
214469876|NCT06765343|DEVICE|Ultrasonic debridement and polishing|Removal of plaque and calculus with an ultrasonic scaler, followed by surface polishing with a rubber cup and abrasive paste
214469877|NCT06348251|BEHAVIORAL|FoodSteps|Participants will get access to the FoodSteps digital intervention with coaching for 16 weeks and receive a weekly stipend benefit to aid with implementing health behavior changes
214469878|NCT04070469|DRUG|Amoxicillin|dosage of plasma concentration of amoxicillin
214469879|NCT06053619|OTHER|GaitTrainer and Virtual Reality|"Realization of Gait Trainer-assisted robot walking rehabilitation sessions without and with the addition of an immersive VR device. The proposed virtual stage will be a natural space (i.e. forest) of 360°. The subject will be able to explore the environment without moving. The created scene represents a straight path crossing a landscape composed of different natural elements. A fluid movement is obtained with the help of two sensors (trackers) of the HTC Vive device, placed at the level of the subject's feet. Moreover, thanks to these sensors the individual has a virtual representation of his lower limbs.~Post-stroke patients will perform 3 conventional sessions (Gait Trainer alone) and 3 sessions with the immersive VR device (Gait Trainer + VR)."
214469880|NCT02294435|DEVICE|Visceral Manifold and Thoracic Bifurcation|Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
214469881|NCT02294435|DEVICE|Unitary Manifold|Unitary Manifold Endovascular stent graft system
214469882|NCT04778397|DRUG|Magrolimab|Administered intravenously (IV).
214469883|NCT04778397|DRUG|Venetoclax|Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).
214469884|NCT04778397|DRUG|Azacitidine|Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).
214469885|NCT04778397|DRUG|Cytarabine|"Induction: administered continuous infusion, 100 or 200 mg/m\^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).~Consolidation: administered IV, 1500 or 3000 mg/m\^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles."
214469886|NCT04778397|DRUG|Daunorubicin|Administered IV peripherally (IVP), 60 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
214469887|NCT04778397|DRUG|Idarubicin|Administered IV, 12 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
214469888|NCT04778397|DRUG|Steroidal Eye Drops|Administered per institutional standard during consolidation.
214469889|NCT05752461|DRUG|SHR-2004 injection|low dose subcutaneous injection once
214469890|NCT05752461|DRUG|SHR-2004 injection|medium dose subcutaneous injection once
214469891|NCT05752461|DRUG|SHR-2004 injection|high dose subcutaneous injection once
214469892|NCT05752461|DRUG|Enoxaparin sodium injection|40 mg administered as subcutaneous injection once daily
214469893|NCT04433260|OTHER|Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
214469894|NCT04433260|OTHER|Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
214469895|NCT04433260|OTHER|Informed consent|Participants will need to give their consent to participate to the survey after reading PIS
214469896|NCT04466488|BEHAVIORAL|Choice Architecture|"1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach, including an ink stamp or pre-printed sticker for quick entry of the ART prescription along with TPT and cotrimoxazole.~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
214469897|NCT06517654|DEVICE|EMG-Biofeedback|The Neurotrac® Simplex device will be used for EMG-Biofeedback treatment. As in the muscle strength assessment procedure, the EMG reference electrode will be placed on the patient\&#39;s forearm, and 2 adhesive electrodes in the EMG channel will be placed on the patient\&#39;s perineal muscles. The patient will be asked to contract and relax the pelvic floor muscles at certain intervals in accordance with the visual and auditory stimuli made on the device screen or computer screen. The pelvic floor muscle contraction and rest period will last 5 seconds each. The program will continue for 2 days a week, 25 minutes per session and 8 weeks and will be performed in a clinical environment. During the treatment, the treatment will be visualized for the patient with different imagery. At the end of the games played, the patients'; scores (%), the lowest and highest EMG values will be recorded in mV. The treatment will be applied to the patients in two sessions per week.
214469898|NCT06517654|OTHER|Rebound Therapy|The program will be performed in a clinical environment for 8 weeks, 2 days a week, each session will be 30 minutes. The correct breathing pattern will be taught to the patient before starting the exercises. O2 saturation and maximum heart rate will be checked during the rest periods during the exercises. The maximum heart rate will be calculated with the formula (HRmax = 208 - 0.7 × age), and the exercise will be paused when it exceeds 80%. The patient will be asked to contract the pelvic floor muscles during the exercise. Necessary warnings regarding the preservation of posture will be made throughout the exercises. The exercise intensity will be increased progressively in order to ensure the patient's adaptation to the exercises.
214281716|NCT02099994|BIOLOGICAL|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10\^8 pfu or saline placebo
214281717|NCT02099994|BIOLOGICAL|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
214281718|NCT02099994|BIOLOGICAL|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
214281719|NCT03919799|DRUG|Belumosudil (KD025)|ROCK-2 Inhibitor
214281720|NCT03919799|DRUG|Placebo|Inactive substance
214469899|NCT06517654|OTHER|Home Exercise Program|Home Exercise Program In addition to EMG-Biofeedback Therapy in Group 1, in addition to Rebound Therapy in Group 2, and in Group 3, only a home exercise program will be applied to patients 5 days a week. The exercise program consists of diaphragmatic breathing, piriformis stretching exercise, adductor stretching exercise, gluteal stretching exercise, cat-camel exercise, happy baby position, deep squat exercise, trunk rotator stretching exercises. Each exercise will be repeated 5 times on the right and left, and 20 seconds will be waited for each repetition.
214469900|NCT04870307|OTHER|Dissemination and Implementation Research|Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D\&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
214469901|NCT04385264|DRUG|Hydroxychloroquine|Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
214469902|NCT04385264|DRUG|Mannitol|Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD
214469903|NCT02442115|OTHER|Treatment of Functional Constipation by|The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
214469904|NCT05906784|OTHER|group acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
214469905|NCT05906784|OTHER|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
214469906|NCT04605445|PROCEDURE|1 visit root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
214469907|NCT04605445|PROCEDURE|2 visits root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be started, or performed in another visit, lasting 2 visits. In the first visit cleaning and shaping is performed and a medication is put in place in the canals, and the tooth is temporized until the next visit at least one week apart. In the second visit the tooth is root filled and temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
214469908|NCT04142866|DEVICE|Anodal transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the active tDCS condition, stimulation continues for the first 20 minutes of the 60-minute treatment session, and then ramps back down to 0 milliamps (mA).
214281721|NCT01175252|OTHER|Database analysis|Review and collect data from database
214469909|NCT04142866|DEVICE|Sham transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
214281722|NCT01530568|OTHER|Xpert|This arm receives the GeneXpert test
214281723|NCT01530568|OTHER|Smear|This arm receives smear microscopy
214281724|NCT03004027|OTHER|Self help leaflet|Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
214281725|NCT05948696|BEHAVIORAL|Horticultural group therapy.|Estimated 10 persons with schizophrenia who attend to a 12-week horticultural group therapy will be assessed for their experience about the program.
214281726|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
214281727|NCT00330746|DRUG|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
214281728|NCT00330746|DRUG|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
214281729|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
214281730|NCT02717585|DEVICE|Continuous Positive Airway Pressure Therapy (CPAP)|Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
214281731|NCT03973710|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
214281732|NCT03973710|DIETARY_SUPPLEMENT|Placebo controls|placebo with a similar appearance to probiotics supplement
214281733|NCT06584552|DIETARY_SUPPLEMENT|Lactobacillus Paracasei LPB27|Probiotic
214281734|NCT06584552|OTHER|Maltodextrin|Placebo
214281735|NCT05405309|DRUG|RP-3500|RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.
214469910|NCT04142866|BEHAVIORAL|Speech-Language Therapy (SLT)|Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
214469911|NCT06011213|BEHAVIORAL|Issuing health risk warning for a heat waves or cold spells|Whenever a health risk warning for a heat waves or cold spells is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
214469912|NCT06011213|DEVICE|A digital heat or cold health risk early warning tool|A WeChat mini-program provides real-time updates on early warnings and health advisories.
215032245|NCT05634343|OTHER|experimental group 1|Laughter therapy, also called therapeutic laughter, is used to relieve pain and stress and to promote a general sense of well-being. Laughter therapy is simply a method of 'laughing for no reason' in which the person interacts in a group setting with improvisation or pantomime-like exercises and childish games without humour, jokes or funny events. The aim is thus to benefit from laughter.
214281736|NCT05405309|DRUG|Olaparib|Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate.
214281737|NCT01087138|BEHAVIORAL|exercise|exercise class 3x's/week
214281738|NCT01087138|BEHAVIORAL|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
214281739|NCT06977256|OTHER|Sensory-Based Exercises|Participants in the Sensory-Based Intervention Group received weekly 40-minute face-to-face sessions for 8 weeks, involving structured exercise and sensory-based activities tailored to individual needs, with caregiver feedback and home programs provided after each session.
214281740|NCT06977256|OTHER|Telerehabilitation and Based Sensory Intervention|Participants in the Telerehabilitation-Based Sensory Intervention Group received 8 weeks of in-person sessions followed by 8 weeks of weekly 30-minute telerehabilitation sessions, combining individualized sensory-based activities with caregiver coaching and home-based implementation via Zoom. Sessions were personalized, progressively structured, and conducted in a stable virtual environment to support continuity and engagement.
214281741|NCT07131410|OTHER|Group hialuronyc|Patients will receive the container with cream for application on both feet after thoroughly washing and drying them. It is recommended to use an amount the size of a hazelnut for each foot, spreading it in a thin layer over the entire foot, excluding the interdigital area. The application will be done every night for twelve months. The product will be massaged into the foot for 15 seconds. During the study, participants will not be allowed to use any other topical product (cream, emulsion, gel, lotion, or oil) on their feet and/or nails.
214281742|NCT07133126|DEVICE|Acumen monitoring|Patient undergoing a thoracic surgery or an aortic surgery will be monitored as usual using the CE marked medical device ACUMEN with the intelligent HPI system.
214281743|NCT07131631|DIAGNOSTIC_TEST|Cardiac MRI|Clinically indicated baseline CMR study with contrast up to 90 days before TEER procedure, including KCCQ questionnaire. At 6 months, participants will return for repeat of KCCQ, CMR study and a transthoracic echocardiogram. Blood samples, done as standard clinical care for hemotocrit for ECV calculation, will be obtained.
214281744|NCT07131319|OTHER|Spatially Fractionated Radiotherapy (SFRT)|Several spherical volumes (with a diameter of 1 cm) are selected within the hypoxic area of the primary tumor. The distance between each spherical volume is 1.5 - 2 cm, and a high-dose radiotherapy of 12 Gy × 1F is delivered.
214281745|NCT07131319|DRUG|Tislelizumab, Carboplatin, Pemetrexed|For adenocarcinoma, pemetrexed (500 mg/m², day 1) + carboplatin (AUC 5, day 1) is used.
214281746|NCT07131319|DRUG|Tislelizumab, paclitaxel, Carboplatin|For NSCLC with pathological types other than adenocarcinoma, nab-paclitaxel (100 mg/m² on day 1 and day 8) + carboplatin (AUC 5, day 1) is used.
214281747|NCT07132515|DRUG|Enoxaparin, warfarrin, or apixaban|Enoxaparin, warfarrin, or apixaban
214281748|NCT07131306|DRUG|ucMSC and Standard medical treatment|umbilical cord Mesenchymal stem cell1 million/kg will be given once a week for 4 week . 250 ml normal saline will be infused 30 minutes prior to ucMSCs infusion. All patients will receive the standard medical treatment.
214469913|NCT06011213|DEVICE|Self-monitoring blood pressure and ECG device|Devices for self-monitoring blood pressure and ECG
214844243|NCT00114231|DRUG|capecitabine|
214281749|NCT07131306|OTHER|Standard medical treatment|Standard medical treatment
214281750|NCT07131683|BIOLOGICAL|Human umbilical cord mesenchymal stem cell derived exosomes|Nasal spray of hUC-MSC-Exo (low dose: 2.5×10\^10 particles, mid-dose: 5.0×10\^10 particles, high-dose: 1.0×10\^11 particles), once per day for 7 days, then once per week for 3 weeks
214281751|NCT07131683|OTHER|Placebo Control|Nasal spray of placebo control, once per day for 7 days, then once per week for 3 weeks
214281752|NCT04841590|OTHER|Intervention of the experimental group (EG)|Treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
214281753|NCT04841590|OTHER|Control Group (CG)|Subjects in the control group (CG) will not receive any treatment
214281754|NCT05505201|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
214281755|NCT05505201|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
214281756|NCT06535945|DRUG|Albumin administration|when albumin serum concentration is at 30 g/L or below
214281757|NCT06630728|DRUG|Reduced Nicotine Content Cigars|Participants will smoke a very low nicotine content filtered little cigar containing 0.50mg nicotine per gram of tobacco
214281758|NCT06630728|DRUG|Normal nicotine content cigar|Participants will smoke a normal nicotine content filtered little cigar containing 5.17mg nicotine per gram of tobacco
214844244|NCT00114231|DRUG|oxaliplatin|Given IV
215032246|NCT05634343|OTHER|experimantal group 2|Mindfulness is purposefully drawing attention in the desired direction so that we can stay in the present moment without judgment. It is also defined as a conscious understanding of what is happening in the moment we live in with an open and loving attitude. According to another definition, mindfulness includes paying attention to what is happening in the present moment, noticing the quality of this attention, and accepting what is noticed without judgment. With conscious awareness, the individual discovers how to live in harmony with all the events that take place in the present moment, place and time, without any evaluation, rather than the sorrows and regrets of the past, the anxieties and worries of the future. Mindfulness helps us to relate to our experiences by enabling us to see the positive-negative, good-bad experiences we have had objectively.
214469914|NCT06011213|BEHAVIORAL|Perform daily self-monitoring of their BP and ECG|Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
214469915|NCT03664700|DEVICE|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
214469916|NCT04027140|DEVICE|M/L Taper with Kinectiv Technology Stems and Necks|Patients that have been implanted with a M/L Taper with Kinectiv Technology Stem and/or neck to repair hip malfunction/disease.
214469917|NCT00595049|DRUG|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
214469918|NCT06079775|DRUG|Xeruborbactam Oral Prodrug|Experimental
214469919|NCT06079775|DRUG|Ceftibuten|Experimental
214469920|NCT06079775|DRUG|Xeruborbactam Oral Prodrug Placebo|Placebo Comparator
214469921|NCT06079775|DRUG|Ceftibuten Placebo|Placebo Comparator
214469922|NCT05640479|DRUG|Pregabalin|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
214469923|NCT05640479|DRUG|Dexmedetomidine|patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
214469924|NCT01957722|PROCEDURE|Microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
214469925|NCT01957722|BIOLOGICAL|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
214469926|NCT04736121|DEVICE|Resin microspheres containing yttrium-90 (Y-90)|Biocompatible resin microspheres are an injectable permanent implant and preferentially placed into the distal microvascular supply of tumors to provide direct irradiation of tissue and destruction of the microvascular bed. Spheres contain yttrium-90 (Y-90) and are a size between 20 and 60 microns in diameter.
214469927|NCT04832854|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of each 21-day cycle.
214469928|NCT04832854|DRUG|Tiragolumab|Tiragolumab 600 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
214469929|NCT04832854|DRUG|Carboplatin|Carboplatin at initial target area under the concentration curve (AUC) of 5 or 6 mg/mL/min will be administered by IV infusion on Day 1 of each 21-day cycle.
214469930|NCT04832854|DRUG|Cisplatin|Cisplatin at 75 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
215032247|NCT04452916|OTHER|Buchinger fasting|Caloric intake of \< 250 kcal/d for 5 days
215032248|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection (prefilled syringe)|MG-K10 Humanized Monoclonal Antibody Injection
214469931|NCT04832854|DRUG|Pemetrexed|Pemetrexed at 500 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
214469932|NCT04832854|DRUG|Gemcitabine|Gemcitabine at 1000 or 1250 mg/m\^2 will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
214844245|NCT00114231|PROCEDURE|neoadjuvant therapy|Undergo surgery
215032249|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection（Penicillin bottle）|MG-K10 humanized monoclonal antibody injection (single injection)
215032250|NCT05500521|DIAGNOSTIC_TEST|Caloric irrigation|In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.
214281759|NCT06630728|DRUG|Usual brand cigar|Participants will smoke their usual brand filtered little cigar
214281760|NCT06985446|OTHER|Study Group:Black stain-positive|In children with black stains (BS+), we evaluated DMFT, dft, plaque index (Silness-Löe), gingival index (Löe-Silness), salivary pH, salivary flow rate, salivary buffering capacity, and body mass index (BMI).
214469933|NCT04832854|DRUG|Paclitaxel|Paclitaxel at 175 or 200 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
215032251|NCT05500521|DIAGNOSTIC_TEST|vHIT|This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.
215032252|NCT05500521|DIAGNOSTIC_TEST|VEMP|Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).
215032253|NCT04049513|BIOLOGICAL|WZTL002-1 (1928T2z CAR-T cells)|WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
215032254|NCT04049513|DRUG|Cyclophosphamide and Fludarabine lymphodepleting chemotherapy|Cyclophosphamide 500 mg/m\^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m\^2 IV on days -5 to -3, inclusive
214469934|NCT05128903|DRUG|[18F]DPA714|"Intravenous injection~* Before or within 2 weeks of starting radiation therapy~* Before starting chemotherapy~* 1 year after the start of radiation therapy Timing cont.~* 1.5 to 2 years after the start of radiation therapy"
214844246|NCT00114231|RADIATION|radiation therapy|Undergo radiotherapy
214844247|NCT04065061|DIETARY_SUPPLEMENT|Erinacine A-enriched Hericium Erinaceus Mycelia|
214844248|NCT04065061|DIETARY_SUPPLEMENT|Placebo|Placebo supplement was given to the participants.
215032255|NCT06563817|DRUG|Rapamycin|All enrolled patients receive treatment with sirolimus (rapamycin)#The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.
215032256|NCT06519526|DRUG|SHR-0302|SHR-0302 will be administered orally as tablets.
215032257|NCT06519526|DRUG|SHR-2554|SHR-2554 will be administered orally as tablets.
215032258|NCT06417060|DRUG|Caudal block anesthesia|Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
215032259|NCT06417060|DRUG|Dorsal penile block anesthesia|Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.
215032260|NCT00843960|BEHAVIORAL|behavioral adaptation and symptom management|behavioral adaptation and symptom management
215032261|NCT06563687|DEVICE|Dexcom ONE+|In all the neonates recruited CGM sensor and transmitter will be placed soon after study enrollment. The sensors will be inserted in the lateral thigh and continuous measurements will be recorded for all the duration of therapeutic hypothermia.
215032262|NCT04541927|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
215032263|NCT01296204|DRUG|BB4 antibody-Iodine 131|Injection of an antibody after labelling with Iodine 131
215032264|NCT03049644|PROCEDURE|Mechanical Diagnosis and Therapy|Identification of directional preference.
215032265|NCT03049644|PROCEDURE|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
215032266|NCT06059898|DEVICE|GBR surgery including membrane placement|After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured
215032267|NCT06059898|PROCEDURE|Biopsy|After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration
215032268|NCT05313490|DIETARY_SUPPLEMENT|Beetroot Juice|7 days of 140 mL per day of beetroot juice
215032269|NCT05313490|OTHER|Placebo Beetroot Juice|7 days of 140 mL per day of placebo beetroot juice
215032270|NCT04539288|OTHER||There is no intervention in this study.
215032271|NCT04794504|DRUG|Botox 100 UNT Injection|Botox will be injected intramuscularly into the masseter and temporalis muscles bilaterally to investigate if it can supplement postoperative analgesia in orthognathic surgery patients
215032272|NCT04794504|OTHER|0.9% Saline Injection|As a placebo control to the 100 UNT Botox injection, 0.9% saline will be injected intramuscularly into the masseter and temporalis muscles bilaterally
215032273|NCT04597801|DRUG|Alcon|Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
215032274|NCT00356187|DRUG|Propranolol|
215032275|NCT04190472|DIAGNOSTIC_TEST|IOP HPV test|Immediately after the LEEP, a cervical sample was taken for the IOP-HPV test
215032276|NCT05358223|OTHER|Music|A standard music determined by us for the 1st and 4th groups will be played during the process.
215032277|NCT05358223|DEVICE|TENS|TENS device will be connected to the 3rd and 5th groups during the process and the process will be done in this way.
215032278|NCT03898427|DEVICE|Wrist Actigraphy Devices|A watch-like wearable sensor
215032279|NCT03898427|DEVICE|Polysomnography|Sleep Monitor
215032280|NCT03898427|DEVICE|Videography|Thermal Camera
215032281|NCT03960944|OTHER|Yoga|30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
215032282|NCT06003504|OTHER|First aid training with blended learning approach|"The content of the first aid blended learning training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of 2 consecutive parts:~1. First aid theory is learned independently in a mobile application followed by an online test to ob-tain an admission ticket for the subsequent in-class training;~2. First aid skills are practiced during a 1-day in-class training facilitated by a certified first aid instructor of the Rwanda Red Cross.~Participants get at least 10 days to learn in the mobile application and obtain the admission ticket."
215032283|NCT06003504|OTHER|First aid training with face-to-face approach|"The content of the first aid face-to-face training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of a 3-days in-class training with lectures and practical exercises on first aid the-ory and skills, facilitated by a certified first aid instructor of the Rwanda Red Cross."
215032284|NCT00815633|DRUG|Alefacept|15mg intramuscular injection weekly for 12 weeks
215032285|NCT02978495|DRUG|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
215032286|NCT02978495|DRUG|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
215032287|NCT02978495|DRUG|Paclitaxel|80mg/m2 weekly for 12 weeks
215032288|NCT02978495|DRUG|Cyclophosphamide|600mg/m2 4 cycles each 21 days
214281761|NCT06985446|OTHER|Control Group: Black stain-negative|In healthy children without black stains (BS-), we assessed DMFT, dft, plaque index (Silness-Löe), gingival index (Löe-Silness), salivary pH, salivary flow rate, salivary buffering capacity, and body mass index (BMI).
214281762|NCT04415008|DRUG|HAD induction with intermediate dose cytarabine|daunorubicin,cytarabine,homoharringtonine
214281763|NCT05284656|DRUG|combination of Pentoxifylline 400 MG and Folic Acid|drugs used to delay progression of chronic kidney disease
214281764|NCT05284656|DRUG|folic acid|drugs used to delay progression of chronic kidney disease
214281765|NCT05284656|DRUG|Pentoxifylline 400 MG|drugs used to delay progression of chronic kidney disease
214281766|NCT06164418|PROCEDURE|Dental restoration|Each patient will receive a cervical restoration using the corresponding group adhesive and restorative material
214281767|NCT06992791|BEHAVIORAL|Prenatal Education on Childbirth|"Starting at 30 weeks, participants will be given access to Tinyhood, an online educational service aimed at perinatal education. Text reminders will be sent periodically throughout the third trimester to encourage interaction with educational videos and written materials, which will be tracked for number of interactions via the Tinyhyood interface. The videos include: Pregnancy Milestones, Physically and Mentally Preparing for Labor, Finding Support During Labor, Deciding Birth Preferences and Self-Advocacy, Signs Labor Is Approaching, Contractions, Signs of Preterm Labor, Going to the Hospital, Baby's Positioning, Stages of Labor, Induction of Labor, Managing Pain, Pain Options in Labor, Relaxation Techniques for Labor,  Breathing Techniques, Labor Positions and several handouts highlighting common obstetrical emergencies and possible interventions."
214281768|NCT06992310|DEVICE|Hearing Aid with standard noise reduction (NR_1)|"Each participant will be fitted with the 3 different noise reduction (sound changing) principles on the same hearing aid, saved to 3 manual programs (ensures exact same hearing loss compensation for each intervention).~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort.~The active comparator condition is the state of the art Noise Reduction principle to mimic the natural directivity of the outer ear."
214281769|NCT06992310|DEVICE|Hearing Aid with NR_2|"Each participant will be fitted with the 3 different noise reduction (sound changing) principles on the same hearing aid, saved to 3 manual programs (ensures exact same hearing loss compensation for each intervention).~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort.~The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
214281770|NCT06992310|DEVICE|Hearing Aid with NR_3|"Each participant will be fitted with the 3 different noise reduction (sound changing) principles on the same hearing aid, saved to 3 manual programs (ensures exact same hearing loss compensation for each intervention).~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort.~The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
214281771|NCT06997120|BEHAVIORAL|Bodhi AIM (intervention group)|"AIM (Action In Mindfulness) is a smartphone app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations."
214281772|NCT06997120|BEHAVIORAL|HIB (control group)|"HIB (Health In Balance) is a smartphone app that is matched to AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in AIM. Like AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts."
214281773|NCT06994962|DEVICE|Alcohol-related mobile health technologies|Participants will be asked to use the mobile technologies as they choose while drinking for a four-week period.
214281774|NCT06994962|BEHAVIORAL|Motivational interview and psychoeducation on blood/breath alcohol concentration|Brief 25/30-minute motivational interview and psychoeducation on blood/breath alcohol concentration that includes both personalized and standardized information.
214281775|NCT06994962|BEHAVIORAL|Lower tech facilitation|Study staff will review instructions for technology use closely with participants and guide them in use of existing phone technologies as reminders for use of the three moderate drinking technologies during drinking situations.
214281776|NCT06994962|BEHAVIORAL|Higher tech facilitation|Participants will use an app developed during the study, SmartSip, that will provide protective behavioral strategies and reminders for use of the three moderate drinking technologies during drinking situations.
214281777|NCT06994962|BEHAVIORAL|Alcohol Education|Brief 25/30-minute psychoeducation on generalized alcohol use providing information about alcohol and its effects, adapted from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Rethinking Drinking resources
214281778|NCT06994962|DEVICE|Alcohol Education Technology|Participants will be able to prompt text messages which will provide them one-off trivia facts using information provided during the attention control psychoeducation session
214281779|NCT07001436|DRUG|Azvudine tablets|On the first day of the study, a single oral dose of 3 mg ( 3 tablets ) of Azvudine tablets is taken orally on an empty stomach.
214281780|NCT07001085|DIAGNOSTIC_TEST|Tumor Tissue Collection and NGS|Tumor tissue is collected during surgery and used for DNA extraction. Next-Generation Sequencing (NGS) is performed to identify oncogenic mutations.
214281781|NCT07001085|OTHER|Blood Collection for Plasma ctDNA|Blood is collected at three time points: one day before surgery, one month, and six months after surgery. Plasma is separated and used for further molecular analysis or storage.
214469935|NCT05541029|BEHAVIORAL|Live music|Live Music. A board-certified music therapist will provide live music (singing with instrument accompaniment) of child preferred songs, per caregiver report, with the tempo entrained to the child's respiratory rate at intervention start and decreased as needed to facilitate relaxation, with a target tempo of 60-80 beats per minute (BPM). Song choices will be based on patient preferences, per caregiver report, and performed with relaxing characteristics (steady rhythm and volume)
214844249|NCT03965728|DRUG|BAY1830839|Tablet, oral.
214844250|NCT03965728|DRUG|Placebo|Tablet, oral.
214844251|NCT03965728|DRUG|Midazolam|For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
214844252|NCT03965728|DRUG|Methotrexate|Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
214469936|NCT05541029|BEHAVIORAL|Recorded music|Recorded Music. MP3 players will be loaded with a recorded music playlist of the child's preferred songs, per caregiver report, and connected to two small speakers that are to be placed at either side of the head of the bed. Speakers will be tested with sound level meter and volume control set at 50-60 decibels. A member of the study team will stay at bedside throughout the recorded music condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
214469937|NCT05541029|OTHER|Usual care|Usual Care. A pharmacologic approach to ameliorating stress and pain in MV children is standard of care in CHP's PICU. CHP provides weight-based guidelines to aid clinical decisions on medications for sedation and analgesia. Bedside nurses assess the child's sedation and pain scores once an hour and administered PRN medications as needed, based on clinical judgement, using CHP's PICU weight-based guidelines. For example, if a child has a pain score of \>1-2 above goal, guidelines suggest providing a fentanyl dose of 0.5 mcg/kg and assessing again in 1 hour. We will include usual care as a third condition to explore how our selected biomarkers vary over 20 min. without the addition of any musical stimuli. A member of the study team will stay at bedside throughout the usual care condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
214469938|NCT04970446|DRUG|Antibiotics|All patients will receive a one week course of antibiotic therapy.
214469939|NCT04970446|DIETARY_SUPPLEMENT|Dietician designed diet|All patients will be recommended dietary modification 3 weeks prior to, and during, the study.
214469940|NCT04970446|DRUG|FMT|Anaerobically prepared stool. Dosing will vary according to mode of administration.
214469941|NCT04970446|OTHER|Placebo|Placebo will contain food colourant, 0.9% normal saline and glycerol.
214469942|NCT05725564|BEHAVIORAL|FAST (Functional Activity Strength Training)|Daily exercise intervention including functional resistance exercises and personalized coaching.
214469943|NCT05725564|BEHAVIORAL|Band Together|3 times weekly group exercise over Zoom featuring strength and balance exercises for 45 minutes
214469944|NCT05725564|BEHAVIORAL|Behavioral Change Technique|Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence
214469945|NCT02608359|DRUG|Abiraterone Acetate|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
214281782|NCT07001085|DIAGNOSTIC_TEST|ctDNA Mutation Analysis via ddPCR|Circulating tumor DNA (ctDNA) is isolated from plasma samples. Mutations previously identified by NGS are quantitatively analyzed using droplet digital PCR (ddPCR).
214281783|NCT07001566|OTHER|There was no intervention. Only assessment procedure will be performed.|There was no intervention. Only assessment procedure will be performed.
214281784|NCT07002177|DRUG|FWD1802|orally QD with 28 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
214281785|NCT07002177|DRUG|Palbociclib 125mg|Dose: 125 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break (3-weeks-on/1-week-off), constituting a 28-day cycle
214469946|NCT03325296|DRUG|LEO 124249|Ointment containing LEO 124249
214469947|NCT03325296|OTHER|Ointment vehicle|Ointment without active ingredients
214469948|NCT06565793|DEVICE|Non Complex PCI|The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).
214469949|NCT06565793|DEVICE|Complex PCI|The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved complex percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).This designation is applied to angioplasty procedures that meet at least one criterion for complexity. The complex angioplasty involved patients with unprotected left coronary common trunk (UT-PCI), the use of rotablator rotary atherectomy (ARota-PCI), the angioplasty of chronic coronary occlusion (CCO-PCI), or the angioplasty of a bifurcation lesion (CBL-PCI).The highly intricate angioplasty procedure was conducted on patients who met at least two criteria indicative of complexity.
215032289|NCT00721110|DRUG|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
214281786|NCT07002177|DRUG|Ribociclib 200Mg Oral Tablet|Dose: 600 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break, constituting a 28-day cycle
214281787|NCT07002177|DRUG|Abemaciclib 150 MG|Dose: 150 mg Route: Orally Frequency: BID Schedule: Everyday
214281788|NCT07002177|DRUG|Everolimus 10 mg|Dose: 10 mg Route: Orally Frequency: QD Schedule: Everyday
214281789|NCT07132684|DRUG|Daunorubicin/Idarubicin|Daunorubicin/Idarubicin is used in Induction Therapy and Maintenance Therapy.
214281790|NCT07132684|DRUG|Cytarabine|Cytarabine is used in Induction Therapy, Consolidation Therapy and Maintenance Therapy.
214281791|NCT07132684|DRUG|Azacitidine|Azacitidine is used in VA regimen
214281792|NCT07132684|DRUG|Venetoclax|Venetoclax is used in VA regimen
214281793|NCT07133152|OTHER|Adverse events|During patient follow-up (hospitalisation + 6 months post-hospitalisation), adverse events will be collected from the patient's computerised medical record (available at the hospital) and by means of a questionnaire carried out by telephone with the patient at 3- and 6-months post-hospitalisation.
214281794|NCT07014813|PROCEDURE|Sub pectoral fixation|Subpectoral biceps tenodesis via mini-open incision. Biceps tendon prepared with Krackow sutures, press-fit into bony tunnel using harvested bone plug. Stability checked post-fixation.
214469950|NCT06568094|DRUG|HRS-5041 tablets|HRS-5041 tablets
214469951|NCT06568094|DRUG|Abiraterone Acetate tablets（II）|Abiraterone Acetate tablets（II）
214469952|NCT06568094|DRUG|Prednisone Acetate tablets|Prednisone Acetate tablets
214469953|NCT06568094|DRUG|Docetaxel Injection|Docetaxel Injection
214469954|NCT06568094|DRUG|HRS-1167 tablets|HRS-1167 tablets
214469955|NCT06568094|DRUG|SHR2554 tablets|SHR2554 tablets
214281795|NCT07015645|PROCEDURE|Gamma Knife Radiosurgery|Patients received gamma knife radiosurgery (GKRS) treatment for pituitary adenomas.
214281796|NCT07015333|DRUG|pembrolizumab and cetuximab|Treatment of betel nut-induced oral cancer with pembrolizumab and cetuximab
214281797|NCT07014839|PROCEDURE|Endovascular Aortic Intervention|This intervention involves EVAR or TEVAR for the treatment of abdominal or thoracic aortic aneurysms, respectively. The procedures were performed using commercially available stent-grafts via a transfemoral approach under standard perioperative protocols. The study specifically focuses on the systemic inflammatory response following these interventions, with close monitoring of laboratory parameters including IL-6, neutrophil-to-lymphocyte ratio (NLR), CRP, leukocyte count, and procalcitonin during the early postoperative period. No adjunctive anti-inflammatory or immunomodulatory therapies were administered.
214281798|NCT07014878|BIOLOGICAL|TCR-T cells|"Dose escalation will follow the standard 3+3 design. Patients will receive a single infusion of DCTY1102 injection. Exploration of higher, lower, or intermediate dose levels may be considered based on emerging safety and tolerability data. Dose escalation will proceed sequentially."
214281799|NCT07015320|BEHAVIORAL|urotherapy|prompted and scheduled voiding, regular sleep timing, fluid and caffeine restriction and avoiding the cellular phones 2 hours before bedtime. If the child had constipation, it should be treated. In addition, alarm therapy was performed in the form of awaking the child every night by his parents after 1-2 hours from deep sleep to void then continue the sleep. The parents should be informed about the importance of their psychological support to their child by avoiding any punishment or embarrassment. Furthermore, the parents were asked to monitor their child's response by documenting the number of wet nights within the last month
214281800|NCT07015320|BEHAVIORAL|no intervention|no intervention
214281801|NCT07014462|DRUG|Dexamethasone plus Venetoclax-based Low-Intensity Therapy|Participants will receive standard low-intensity therapy (LIT) regimens for newly diagnosed AML, which may include venetoclax combined with either azacitidine, decitabine, or low-dose cytarabine, per treating physician's discretion. In addition, participants will receive dexamethasone administered orally at 10 mg twice daily on days 1-3 of cycles 1 and 2, and 20 mg orally on day 1 of cycles 3 through 6. This intervention is being studied to evaluate whether the addition of dexamethasone improves tolerability and clinical outcomes in patients unfit for intensive chemotherapy.
214281802|NCT07015931|DRUG|retinoic acid cream 0.025%|half finger tip unit
214281803|NCT07015931|DRUG|adapalene cream 0.1%|half finger tip unit
214281804|NCT07015073|DEVICE|Pulsed dye laser (PDL)|Treatment with a pulsed dye laser (PDL) at 595 nm using the VBeam Prima® system (Candela Medical). Parameters: 10 mm spot size, 7-9 J/cm² fluence, 0.5-3 ms pulse duration. Cryogen spray cooling is applied. No anesthesia is used. This intervention will be applied to one of the three defined regions of each participant's port-wine stain.
214281805|NCT07015073|DEVICE|Potassium titanyl phosphate (KTP) laser|Treatment with a KTP laser at 532 nm using the DermaV® system (Lutronic Medical Systems). Parameters: 10 mm spot size, 8-11 J/cm² fluence, 10 ms pulse duration. Cryogen spray cooling is applied. No anesthesia is used. This intervention will be applied to a second anatomically comparable region of the port-wine stain.
214281806|NCT07015073|DEVICE|Sequential KTP + PDL laser treatment|Sequential treatment of the same region with two lasers: first with KTP (532 nm, DermaV® system), then with PDL (595 nm, VBeam Prima® system). Each laser will be applied using its standard parameters: KTP (10 mm spot, 8-11 J/cm², 10 ms), followed by PDL (10 mm spot, 7-9 J/cm², 0.5-3 ms). Cryogen spray cooling is used before each pass. No anesthesia is applied. This treatment is administered to a third region of the port-wine stain.
214281807|NCT07015060|PROCEDURE|cutaneous biospy|cutaneous biospy
214281808|NCT07016360|DRUG|Topical Adapalene Gel 0.1%|Topical adapalene is a retinoid that helps in epidermal changes. Cryotherapy is a liquid nitrogen applied to affected parts for 6 months
214281809|NCT07016360|PROCEDURE|Topical Liquid Nitrogen application|Liquid Nitrogen will be applied to affected parts.
214281810|NCT06680050|DRUG|Durvalumab (MEDI4736)|Durvalumab will be administered via IV infusion at a dose of 1500 mg on day 8 Q4W until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
214281811|NCT06680050|DRUG|Ceralasertib|Ceralasertib dose will be administered orally, 240mg BID, approximately 12 ± 2 hours apart, days 1 to 7 q28 (Q4W), up to progression or unacceptable toxicity.
214281812|NCT06680050|RADIATION|radiotherapy|Loco-regional recurrences of the primary tumor and regional lymph node metastases will be treated with a total dose of 36 to 50 Gy in daily fractions with a dose of 2 to 3 Gy per fraction. Two weeks from the last dose of radiotherapy, a systemic treatment with durvalumab and ceralasertib will be started.
214281813|NCT07015892|RADIATION|Thoracic Radiotherapy 45 Gy BID|45 Gy delivered in 30 fractions of 1.5 Gy twice daily over three weeks, with 95% of the planning target volume (PTV) receiving at least 95% of the prescribed dose.
214281814|NCT07015892|RADIATION|Thoracic Radiotherapy 60 Gy BID|60 Gy delivered in 40 fractions of 1.5 Gy BID. A minimum dose of 54 Gy will be accepted if organ-at-risk tolerance is exceeded.
214281815|NCT07015892|RADIATION|Thoracic Radiotherapy SIB 45-54 Gy BID|45 Gy in 30 fractions (1.5 Gy BID) to PTV and 54 Gy in 30 fractions (1.8 Gy BID) to high-risk CTV. Both delivered simultaneously using 3D conformal planning.
214281816|NCT07016061|OTHER|Motor İmagery Group|Participants will engage in a motor imagery exercise program consisting of 5 minutes of warm-up, 20 minutes of motor imagery, and 5 minutes of cool-down, totaling 30 minutes. The intervention will be administered in three sessions per week for one week.
214469956|NCT05748015|DIAGNOSTIC_TEST|quantification of sensory and autonomic small nerve fibers by punch skin biopsy|We'll perform a punch skin biopsy of 3mm from thigh, leg and fingertip and we'll quantify peripheral sensory and autonomic nerve fibers.
214469957|NCT05748015|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
214844253|NCT06457620|BEHAVIORAL|Conventional Physiotherapy|Each participant received conventional physiotherapy at the clinic as a part of their management plan. Group A exercise was five times a week for thirty minutes, beginning on the third day after total knee arthroplasty (TKA). The program aimed to improve leg strength, core stability, balance, and overall performance through exercise instructions. The baseline evaluation was completed one day before the TKA, and the posttest was completed four weeks after the TKA.
215032290|NCT00721110|DRUG|Placebo|Placebo boluses and infusions will be substituted
214469958|NCT05748015|OTHER|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: COMPASS 31 autonomic symptoms scale; Small Fiber Neuropathy Symptom Inventory Questionnaire (SFN-SIQ), the Pain Detect Questionnaire and the Total neuropathy score
214469959|NCT05647564|DIAGNOSTIC_TEST|F-fluorodeoxyglucose positron emission tomography (FDG PET)|Imaging scan
214469960|NCT05647564|DIAGNOSTIC_TEST|prostate-specific membrane antigen positron emission tomography (PSMA PET)|Imaging scan
214469961|NCT04858009|DRUG|Cisplatin|Given via HIPEC
214469962|NCT04858009|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with mitomycin and cisplatin
214469963|NCT04858009|DRUG|Nab-paclitaxel|Given via HIPEC
214469964|NCT04858009|PROCEDURE|Computed Tomography|Undergo CT scan
214469965|NCT04858009|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214281817|NCT07016061|OTHER|Action Observation Group|Participants will receive an action observation training program delivered by researchers, including 5 minutes of warm-up, 20 minutes of action observation, and 5 minutes of cool-down, totaling 30 minutes. The intervention will be administered in three sessions per week for one week.
214281818|NCT07016061|OTHER|Exercise Group|Participants will perform a standard physical exercise program. The session will last 30 minutes, including warm-up, exercise, and cool-down phases. The intervention will be administered in three sessions per week for one week.
214281819|NCT07016061|OTHER|Combined Group (Motor Imagery + Action Observation+Exercise)|articipants will engage in a combined motor imagery and action observation program for a total of 30 minutes, incorporating elements of both interventions. The intervention will be administered in three sessions per week for one week.
214281820|NCT07016217|BEHAVIORAL|Early Plain Portrait and Letter|"In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns.~The Portraits provide data of individual prescribing along with evidence-based benchmarks or targets. The plain Portrait includes the main message, prescriber's data (compare to optimal prescribing, with or without information on BC mean/median). Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a standalone publication that details the evidence for the recommended practice in a brief and practical manner, with references."
214281821|NCT07016217|BEHAVIORAL|Early Complete Portrait and Letter|"In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns.~The Portraits provide data of individual prescribing along with evidence-based benchmarks or targets. The complete Portrait includes the main message, prescriber's data (compare to optimal prescribing, with or without information on BC mean/median) and a series of self-reflection questions. Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a standalone publication that details the evidence for the recommended practice in a brief and practical manner, with references."
214281822|NCT07016217|BEHAVIORAL|No intervention|To measure the impact of the interventions, Arm C (Group 3) will receive no intervention in the Early mailing and Arm B (Group 2) will receive no intervention in the Delayed mailing.
214281823|NCT07016217|BEHAVIORAL|Delayed Plain Portrait and Letter|"Delayed plain Portrait and Letter (as described)"
214281824|NCT07016217|BEHAVIORAL|Delayed Complete Portrait|"Delayed complete Portrait and Letter (as described)"
214281825|NCT07014943|DRUG|High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy|Gemcitabine (2.5 g/m²) (Days -9 and -3), Busulfan (3.2 mg/kg) (Days -9 to -7), and Thiotepa (5 mg/kg) (Days -5, -4, and -3) were all administered intravenously. Peripheral stem cells were infused on Day 0.
214281826|NCT03793127|OTHER|Maximal oxygen consumption (V02 max)|Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.
214469966|NCT04858009|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214469967|NCT03949725|BEHAVIORAL|Hans Kai Program|In Hans Kai, first, participants attend a 2-month Health School to develop the skills necessary to improve their health and wellbeing. The Health School includes sessions on health indicators; nutrition, grocery shopping and meal planning; physical activity; stress, coping, and health (sleep); and primary care through the years. After participants complete the Health School, they form Hans Kai groups (of 3 or more adults) and begin to meet regularly (at least once a month) independently of facilitators, in a self-sustaining model.
214469968|NCT05738408|BEHAVIORAL|Financial Incentives (FI) and Nicotine Replacement Therapy (NRT)|: In the intervention condition, patients will receive both NRT plus a 12-week program of monetary incentives for verified smoking abstinence that will be implemented by our clinic staff
214469969|NCT03726047|BEHAVIORAL|Exercise|Subjects will complete 5 minutes of exercise on an ergometer to examine the effects of exercise on retention of a newly learned walking pattern.
214469970|NCT06419855|DEVICE|Human collagen matrix graft|Is a porous cross-linked human collagen Matrix or Sponge, used as a scaffold in the repair and restoration of dura mater defects, following craniotomy, laminectomy or in general when there is intentional (surgical procedure) or accidental damage to the dura mater.
214469971|NCT06419855|DEVICE|Bovine collagen matrix graft|Is a porous type 1 collagen matrix derived from bovine Achilles tendon, this matrix is absorbed after 8 weeks and is used for the repair and restoration of dura mater defects.
214469972|NCT02523222|DIETARY_SUPPLEMENT|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
214469973|NCT04491617|OTHER|Standard opioid prescribing|Patients are routinely prescribed opioid medications in addition to non-opioids.
214469974|NCT04491617|OTHER|Restrictive opioid prescribing|Patients are prescribed non-opioid pain medications, and will be prescribed opioids only if they request them.
215032291|NCT00721110|DRUG|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
215032292|NCT00721110|DRUG|Ketamine + Lidocaine|both Ketamine and Lidocaine will be given
215032293|NCT00416507|DRUG|fluorouracil|
214469975|NCT04904146|DIAGNOSTIC_TEST|Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.|The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.
214469976|NCT05125783|OTHER|questionnaire|Completion of the questionnaire by the patient after consultation with the practitioner.
214281827|NCT03793127|OTHER|Brown adipose tissue (BAT) imaging|Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2\* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.
214281828|NCT03793127|OTHER|Muscle function testing|This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
214281829|NCT06762561|PROCEDURE|Prophylactic retromuscular mesh reinforcement|Prophylactic retromuscular mesh placement involves reinforcing the abdominal wall during closure after open abdominal aortic aneurysm (AAA) repair to prevent incisional hernias. This technique creates a retro-muscular space by carefully dissecting the rectus abdominis muscles from the posterior rectus sheath. A self-gripping polyester mesh or composite mesh is placed in this space, extending 4 cm beyond the midline on each side, ensuring tension-free coverage. The mesh is secured at key points, and the rectus sheaths are closed with continuous sutures. This approach leverages the anatomical integrity of the abdominal wall to reduce hernia risk without increasing postoperative complications.
214469977|NCT06536491|DRUG|EC-104 high dose|Intravitreal injection
214469978|NCT06536491|DRUG|EC-104 low dose|Intravitreal injection
214469979|NCT06536491|DRUG|Dexamethasone intravitreal implant|Marketed product intravitreal injection
214469980|NCT04036253|BIOLOGICAL|Erythropoietin alfa|Prefilled syringes of erythropoietin
214469981|NCT05949281|DRUG|Colchicine 0.5 MG Oral Tablet|Colchicine 0.5 mg once-daily
214469982|NCT05949281|DRUG|Placebo|Placebo tablet once-daily
214469983|NCT06338709|DEVICE|BariClip® Device Treatment|Device Administration (Implantation)
214469984|NCT05690685|DEVICE|Silver I Alginate Non-Woven Dressing (Hydro-Alginate)|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver I Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change up-to six-week follow-up period."
214469985|NCT06368479|DEVICE|iStatis HBsAg Test|Capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples to be tested on the iStatis HBsAg Test at the point of care setting.
214469986|NCT06450561|OTHER|cardiovascular event|In this single group observational trial the exposure of interest is a cardiovascular event.
214469987|NCT04128761|BEHAVIORAL|Scarcity Narrative|Participants are presented with a hypothetical scarcity narrative and asked to listen and consider the scenario.
214469988|NCT04128761|BEHAVIORAL|Neutral Narrative|Participants are presented with a hypothetical neutral narrative and asked to listen and consider the scenario.
214469989|NCT06068946|BIOLOGICAL|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist
214469990|NCT06068946|BIOLOGICAL|Placebo|Placebo comparator
214469991|NCT06799429|BEHAVIORAL|Supervised in-person group|Individually prescribed and directed/supervised by a fitness trainer in-person, multi-mode exercise 2 x a week for 30-60 minutes The fitness trainer is with the participant while they exercise.
214469992|NCT06799429|BEHAVIORAL|Monitored distance group|Individually prescribed ulti-mode exercise 2 x a week for 30-60 minutes. Written plan/feedback and support by phone/text or email is provided by a fitness trainer who is not present with the participant when they exercise.
214281830|NCT06895096|DEVICE|Pit Fissure Sealant|Flowable composite is being used for the purpose of sealing pits and fissures which require etching and bonding before application whereas self etch sealants are self adhesive and do not require etching and sealing.
214281831|NCT05159492|DEVICE|PVI using PEF|PVI using PEF
214281832|NCT05159492|DEVICE|PVI using CFRF|PVI using CFRF
214469993|NCT05193929|DEVICE|OptiPulse™|TheOptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an off loader and shin pumping unit, and the other acts as pressure reducing footwear.Both active and non-active footwear should be worn to give balanced gait
214469994|NCT05193929|DEVICE|Standard of Care offloading device|CAM boot
214469995|NCT01346540|DRUG|BIBF 1120|VEGF inhibitor
214469996|NCT01346540|DRUG|Placebo|BIBF 1120 placebo
214469997|NCT05297201|DRUG|CPL500036 - low dose|CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
214469998|NCT05297201|DRUG|CPL500036 - high dose|CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
214469999|NCT05297201|DRUG|Placebo|Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
214470000|NCT05061069|DIAGNOSTIC_TEST|cervical vestibular evoked myogenic potentials (cVEMP)|cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
214470001|NCT05821686|DRUG|Human Interleukin-2 (IL-2) (Proleukin)|All the recruited participants will receive 4 intralesional injections of Interleukin-2 with a dose of 500,000 international units (IU) per mm width of tumor to max dose of 10 million IU.
214470002|NCT06640166|DRUG|encorafenib + cetuximab + FOLFIRI|"encorafenib plus cetuximab beyond progression in combination with irinotecan-based doublet chemoterapy (FOLFIRI) as follows:~* encorafenib 300 mg (75 mgx4 hard capsules) orally once daily;~* cetuximab 500 mg/sqm iv every 14 days;~* FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours)."
214470003|NCT03893682|DRUG|CG-806|CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
215032294|NCT00416507|DRUG|gemcitabine hydrochloride|
215032295|NCT00416507|DRUG|liposomal cisplatin|
215032296|NCT00000222|DRUG|Buprenorphine|
214470004|NCT06318949|PROCEDURE|blood sampling|If the patient does not object to participating in the study, a blood sample is taken at each visit (an additional tube may be added to a routine blood sample taken for standard care), or a residual blood sample is reused after routine tests have been performed, and data is collected from the medical record.
214470005|NCT06606197|OTHER|Having sex with other men|Having sex with other men
214470006|NCT06528665|DRUG|ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults|"ZEPOSIA®~* Titration is required for treatment initiation.~* The recommended maintenance dosage is 0.92 mg orally once daily.~* If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned."
214281833|NCT06618586|BEHAVIORAL|TodaysBaby|The TodaysBaby intervention is comprised of: 1) Text message-delivered, short educational videos in the first 2 months after birth, with each video timed to match content addressing anticipated barriers and facilitators to adhering to guidelines (e.g. parental concerns that infant will choke while supine). Participants will also have access to a web portal where intervention videos will be maintained. 2) Text queries regarding safe sleep practices, which collect data on sleep practices in near real-time and provide reinforcement of adherence. Mothers will receive 1-2 text message questions weekly that assess sleep practices in near real-time .
214281834|NCT07087600|OTHER|Automatic lateralization therapy|Program the bed to vary angle and time continuously during the intervention
214281835|NCT07087600|OTHER|Supine Positioning|In this intervention, participants will be positioned in the supine position with the head of the bed elevated at 30°
214281836|NCT07111858|OTHER|Watchful waiting with supportive care|Usual care is Pavlik Harness Treatment. Watchful waiting with ongoing ultrasound scans is the intervention in this study to determine whether the hip matures without the use of the Pavlik Harness
214281837|NCT07125976|BEHAVIORAL|peer support|This intervention is a one-week, structured peer support program for patients in the first six months of hemodialysis treatment.
214281838|NCT04774471|DIAGNOSTIC_TEST|Evaluation of BIT-Motion software|Software program to discern benign versus malignant breast lesions.
214281839|NCT07127211|BEHAVIORAL|Suspension and Stable Push-Up Training at Multiple Angles|"Participants will perform push-ups under three suspension conditions: (1) no suspension (hands and feet on a stable surface), (2) hands suspended using TRX straps, and (3) feet suspended using TRX straps. Each condition will be performed at five different body angles relative to the floor: +30°, +15°, 0°, -15°, and -30° (0° defined as shoulder joints aligned with ankle joints when arms are extended).~For each angle, participants will complete five repetitions, with 3-5 minutes of rest between angles and at least 48 hours of rest between suspension conditions to minimize fatigue effects. All exercises will be conducted under supervision to ensure correct form and safety.~Surface electromyography (EMG) will record muscle activity from the pectoralis major, anterior deltoid, triceps brachii, upper trapezius, and serratus anterior. EMG data will be processed as root mean square (RMS) and normalized to maximal voluntary isometric contraction (%MVIC).~This intervention is designed to dete"
214281840|NCT07131904|OTHER|non-alcoholic, fiber-enriched beer (FEB)|500 ml FEB consumed once during a test day in a randomized crossover design. Postprandial blood glucose is monitored for 120 minutes using a continuous glucose monitor (FreeStyle Libre 3).
214281841|NCT07131904|OTHER|conventional, non-alcoholic beer|500 ml conventional non-alcoholic beer consumed once during a test day in a randomized crossover design. Postprandial blood glucose is monitored for 120 minutes using a continuous glucose monitor (FreeStyle Libre 3).
214281842|NCT07131904|OTHER|glucose solution|Glucose solution containing 12.5 g glucose in 500 ml water, consumed once during a test day in a randomized crossover design. Postprandial blood glucose is monitored for 120 minutes using a continuous glucose monitor (FreeStyle Libre 3).
214281843|NCT07132008|DRUG|Tislelizumab|200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.
214281844|NCT07132008|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
214281845|NCT07132008|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
214281846|NCT07132944|OTHER|CTraC-FIT|"The intervention is designed to support Veterans at high risk of readmission with comprehensive transitional care that includes:~Structured Follow-Ups: Regularly scheduled follow-up calls to monitor the patient's progress, address any issues, and provide ongoing support.~Health Coaching: Personalized coaching to help Veterans manage their health conditions, adhere to treatment plans, and make lifestyle changes that can improve their overall health.~Care Coordination: Assistance with navigating the healthcare system, facilitating appointments, and ensuring that the Veteran receives all necessary post-discharge services.~The intervention arm aims to improve functional abilities and reduce hospital readmissions by providing tailored support based on the unique needs of each participant. The CTraC NCM will follow a standardized protocol to ensure consistent and effective delivery of the intervention across all participants in this group."
214303188|NCT06397352|OTHER|ShotBlocker®|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors.It is positioned onto the skin before an injection is made. After positioning the ShotBlocker® and ensuring that the contacts were in contact with the children's skin, the injection was made through the central hole by the nurse. The ShotBlocker® was cleaned with 70% alcohol before use on another child.
214470007|NCT06821412|DEVICE|ASTERISK System|This intervention uses an experimental socket fabricated by a certified prosthetist. The electronics within the experimental socket are set up with the ASTERISK system, which sends information collected from the EMG sensors to the prosthetic hand wirelessly rather than the current available method of wired control.
214470008|NCT06821412|DEVICE|Wired Configuration|This intervention uses the same experimental socket that is used for the ASTERISK intervention. The prosthesis is set-up with wired EMG control, which is the current available method for EMG-controlled prostheses.
214470009|NCT04260243|OTHER|Experimental-Myofascial + Respiratory rehabilitation|6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
214470010|NCT04260243|OTHER|Sham Myofascial + Respiratory rehabilitation|6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
214470011|NCT06446817|DEVICE|LuxHighAdd IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
214470012|NCT06446817|DEVICE|LuxGood IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
214470013|NCT04718896|DRUG|bimekizumab|Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
214470014|NCT06144762|BIOLOGICAL|Biological/Vaccine: Blood sample and tissue sample|"During the surgery :~Tissus sample : primary tumor and metastasis blood sample : 3 EDTA tubes ex vivo MRI data"
214470015|NCT06295913|DIETARY_SUPPLEMENT|Group 1, hydroxytyrosol-rich extract capsule|Following a two-week washout period, the subjects will receive a bottle containing capsules (Group 1). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol apart from that provided by the capsule.
214470016|NCT06295913|DIETARY_SUPPLEMENT|Group 2, capsule of placebo|Following a two-week washout period, the subjects will receive a bottle containing capsules (Placebo) (Group 2). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol.
214470017|NCT05663047|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
214470018|NCT05663047|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
214281847|NCT07132944|OTHER|Enhanced Usual Care|"The Enhanced Usual Care (EUC) arm involves participants receiving the standard care provided by their assigned Veterans Affairs Boston Healthcare System (VABHS) inpatient and outpatient teams. This includes routine medical evaluations, treatments, and follow-up appointments as typically recommended by their healthcare providers. In addition to receiving standard care, participants in the EUC group will undergo baseline, endpoint, and 3-month follow-up assessments as part of the study protocol.~For participants with intermediate functional ability (SPPB score of 7-9), no additional intervention will be provided after randomization to the control group. However, for participants with low functional ability (SPPB score of 0-6), a safety protocol will be activated to notify their assigned inpatient medical team (e.g., hospitalist, social worker) about the participant's risk of functional decline, ensuring that appropriate support and referrals are provided if needed."
214281848|NCT07132931|BEHAVIORAL|Mindful Leadership Intervention|Mindful leadership training program focusing on contemplative practices, mindfulness exercises, and leadership skill development.
214281849|NCT07132931|BEHAVIORAL|Management Skills Training|Standard management skills training including organizational techniques, communication skills, and leadership fundamentals.
214281850|NCT07132125|BEHAVIORAL|Default-style LLM chatbot|A large language model chatbot (GPT-4o) that delivers tailored persuasive messages to parents about HPV vaccination, using the model's default style with longer, structured responses. Participants engage in a three-minute, multi-turn conversation, with responses personalized to their top-rated vaccine concern identified in a pre-intervention survey.
214281851|NCT07132125|BEHAVIORAL|Conversational-style LLM chatbot|A large language model chatbot (GPT-4o) that delivers tailored persuasive messages to parents about HPV vaccination in a conversational style, with short responses. Participants engage in a three-minute, multi-turn conversation, with responses personalized to their top-rated vaccine concern identified in a pre-intervention survey.
214470019|NCT06167304|OTHER|Technology-implemented exercise therapy|Therapy plans are performed at home overseen by a remote physical therapist via SimpleTherapy.
214470020|NCT06167304|OTHER|Traditional Physical Therapy|Traditional physical therapy per Standard of care.
215032297|NCT05177380|PROCEDURE|Personalized rehabilitation program of facial involvement in systemic sclerosis|Personalized rehabilitation program of facial involvement in systemic sclerosis
215032298|NCT05177380|OTHER|Delivery of a standard prescription for facial rehabilitation|Delivery of a standard prescription for facial rehabilitation
215032299|NCT01554904|DEVICE|Facial-Flex|Oral exercise device
214470021|NCT05951660|BEHAVIORAL|Educational intervention|"Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~* What is sexuality?~* How psychopharmacology influences sexuality~* What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences."
214470022|NCT06822764|OTHER|observational|observational
215032300|NCT00517790|DRUG|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
215032301|NCT00517790|DRUG|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
214281852|NCT07132125|BEHAVIORAL|Public health informational materials|Official public health informational materials on HPV vaccination from the Centers for Disease Control and Prevention (U.S.), National Health Service (U.K.), or Public Health Agency of Canada, matched to the participant's country of residence. Materials are 589-680 words in length, cover HPV risks and benefits of vaccination, and are presented for three minutes before participants proceed.
214281853|NCT06935227|OTHER|Use Steri-Strip in post-surgery + standard care|Steri-strip will be maintained for 8 days postoperatively.
214281854|NCT06935227|OTHER|Standard care|Postoperative care recommendations.
214281855|NCT05179798|DEVICE|mobile app|Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
214281856|NCT06943820|DRUG|AK129(dose 1)|IV infusion
214281857|NCT06943820|DRUG|Pemetrexed|IV infusion;500mg/m2
214281858|NCT06943820|DRUG|Paclitaxel|IV infusion;175mg/m2
214281859|NCT06943820|DRUG|Carboplatin|IV infusion;AUC 5
214281860|NCT06943820|DRUG|AK129(dose 2)|IV infusion
214281861|NCT06943820|DRUG|Docetaxel|IV infusion;75mg/m2
214281862|NCT06943820|DRUG|Cis-platinum|IV infusion;100 mg/m2
214281863|NCT06943820|DRUG|5-FU (5-fluorouracil)|IV infusion;1000 mg/m2
214281864|NCT06943820|DRUG|Cetuximab|IV infusion;400mg/m2/ 250mg/m2
214281865|NCT06943820|DRUG|Paclitaxel|IV infusion;80mg/m2
214281866|NCT06943820|DRUG|Docetaxel|IV infusion;35mg/m2
214281867|NCT06943820|DRUG|Chemotherapy|IV infusion
214281868|NCT06943820|DRUG|AK129(RP2D)|IV infusion
214281869|NCT06943820|DRUG|Penpulimab|IV infusion;200mg
214281870|NCT03320954|BEHAVIORAL|Anomia treatment|Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
215032302|NCT06131190|BEHAVIORAL|mindfulness training|it focuses on attention and has gained empirical support as a complementary or alternative intervention
215032303|NCT01940055|BEHAVIORAL|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
214281871|NCT01839851|DRUG|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
214281872|NCT01839851|DRUG|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
214281873|NCT05102006|DRUG|LBL-007 Injection|LBL-007 Injection; dose A or dose B; Q3W
214281874|NCT05102006|DRUG|Toripalimab Injection|Toripalimab Injection; dose C; Q3W
214281875|NCT06246578|DEVICE|Continuos glucose monitoring and blood glucose measurement|The individuals who use Dexcom G 7 sensors for continous glucose monitoring is in addition applied a Libre 2 sensor and asked to wear both sensors for 14 days. In case of a Dexcom glucose value \< 5 mmol/l, the participants is aked to measure a blood glucose as well uising fingerprick and Contour Next One
214281876|NCT04710056|DRUG|REGN4461|
214281877|NCT04316676|DIAGNOSTIC_TEST|PET-MPI Protocol|Patients with suspected CAD who are referred to a clinical PET-MPI will undergo the standard clinical protocol applied in the Emory Nuclear Medicine department.
214281878|NCT04316676|DIAGNOSTIC_TEST|CT-MPI|"For the CT-MPI, dynamic volume CT myocardial perfusion applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium. The dynamic shuttle mode consists of an image acquisition during rapid, yet smooth back-and-forth movement of the CT scanner table, so that contrast media bolus passage can be evaluated within the entire left ventricle in a time-resolved fashion. This scan acquisition will be performed during pharmacologically induced stress and during rest conditions. CT-MPI studies will be contrast medium enhanced by 50-70 ml of iodinated contrast agent, administered at a flow rate of 5 mL/s. The CT examinations are scheduled within 90 days of the standard clinical PET examination."
214281879|NCT04316676|DIAGNOSTIC_TEST|CT-FFR|Coronary CT angiography (CCTA) will be performed for delineation of the coronary arteries, detection of potential coronary stenosis and FFR calculation. CCTA will be performed at rest following administration of intravenous contrast agent (50-70 mL of iodinated contrast material at a flow rate of 4-5 mL/s). A total radiation dose of approximately 8 millisievert (mSv) has expected to be administered with the stress/rest protocol to the patient. The total amount of contrast agent will not exceed 140 ml. The CT examinations are scheduled within 90 days of the standard clinical PET examination.
214281880|NCT04316676|DRUG|Regadenoson|Pharmacological stress testing for the CT-MPI scan will be performed with a single injection of 0.4 mg of regadenoson (Lexiscan).
214281881|NCT03734055|BEHAVIORAL|Peer Mentoring|Manualized peer mentorship program designed to provide modeling and reinforcement by peers (mentors) to other African American women with SLE (mentees) to encourage them to engage in activities that promote disease self-management.
214281882|NCT03734055|BEHAVIORAL|Social Support Group|Social support controls will participate in a lupus support group created for this project, on the same schedule as peer mentoring sessions.
214281883|NCT06526052|BEHAVIORAL|Mindfulness Program|Online, coached mindfulness training program
214281884|NCT06526052|BEHAVIORAL|Active Comparator|Remote meetings with a supportive coach
214470023|NCT03449264|BIOLOGICAL|biological collection|"* Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~* Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out."
214470024|NCT06433739|OTHER|standardized algorithm|standardized algorithm for the correct selection of peripheral venous catheters
214303189|NCT06397352|OTHER|Buzzy® Group|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors. Vibrations started 30 seconds before the procedure and continued until it was completed. The device was cleaned with 70% alcohol before use on another child
214470028|NCT06286722|OTHER|Progressive, individualized and structured exercise program|See description under Arms
214470029|NCT06331338|BEHAVIORAL|Decision Cycle for Person-Centered Glycemic Management|It is defined as a purposefully designed holistic care intervention that improve self-management .
214470030|NCT06331338|OTHER|Traditional diabetes self-management education|Traditional diabetes self-management education content focuses more on teaching relevant knowledge and some skills.
214470031|NCT06270550|OTHER|Dynamic Movement Intervention|Dynamic movement intervention is a physical therapy approach for infants suffering abnormal developmental motor evolution caused by a known or unknown non-degenerative syndrome affecting the central nervous system
214470032|NCT06822595|DEVICE|Blood flow restriction (BFR) training|Both groups followed an identical 8-week isokinetic training protocol twice weekly. The BFR group performed exercises with arterial occlusion pressure set to 80% of the measured occlusion pressure.
214470033|NCT06822595|DEVICE|Isokinetic training|Both groups followed an identical 8-week isokinetic training protocol twice weekly.
214470034|NCT06823700|DEVICE|SQ-Kyrin Transcatheter Mitral Valve Repair System|To percutaneously repair the mitral valve via the femoral vein and atrial septum, offering a treatment for symptomatic functional mitral regurgitation through edge-to-edge valve clipping.
214470035|NCT05663359|PROCEDURE|EVLA 1940 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1940 nm
214470036|NCT05663359|PROCEDURE|EVLA 1470 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1470 nm
214470037|NCT05442359|DRUG|Nano-bio fusion gingival gel|Thin coat applied to cover the palate after free gingival graft harvest. A stent will be placed to retain its effect. Patients will receive the gel to be used at home twice daily till 3rd week and once in the 4th week
214470038|NCT05442359|DEVICE|stent|Applied as a palatal stent for palatal wound
214470039|NCT06311175|BEHAVIORAL|Dietary Tracking Prescription|Dietary tracking prescriptions to follow during a digital weight loss intervention.
214470040|NCT06078761|BEHAVIORAL|Healthy Eating Active Lifestyle (HEAL) Program|Evidence-based lifestyle medicine program for cancer survivors
214470041|NCT05147116|OTHER|Sleeping in a tent|Participants will spend 10 consecutive nights of sleeping in a tent
214470042|NCT06816797|OTHER|Cog Fun Ageing intervention|Cog Fun Aging is a group-based intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 10 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
214470043|NCT06816797|OTHER|Cog-Fun Aging Crossover|"In the initial phase of the study (between T0 and T1) this group will receive usual care. Participants are users of regional services where activities for healthy older adults are available. This group will continue going to activities as normal during the initial phase and then participate in the Cog-Fun Aging intervention."
214470044|NCT05263297|OTHER|control group|no intervention will be made.
214470045|NCT05826652|OTHER|Single injection subcostal transversus abdominis plane block|Single injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 20 ml between tranvers and rectus abdominis muscle immediately next to the linea semilunaris.
214470046|NCT05826652|OTHER|Multiple injection subcostal transversus abdominis plane block|Multiple injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 5 ml between transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volume lateral to this point near the subcostal margin.
214470047|NCT05826652|PROCEDURE|Without Block|The patients in this group will not receive block
214470048|NCT05182255|DEVICE|Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered|To aid in maintaining patency of the esophagus in cases of obstruction of the esophagus caused by an esophageal disease and to seal tracheoesophageal fistula.
214470049|NCT06821438|PROCEDURE|Laparoscopy|Endoscopy
214470050|NCT06454344|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-I is a structured program with a robust empirical evidence supporting its efficacy for improving sleep quality and quantity. The cognitive component of CBT-I teaching individuals how to recognize and change the beliefs they hold about sleep that negatively impact sleep, such as negative thoughts and emotions. The behavioral component includes several strategies to help improve sleep, including: improved sleep hygiene, improving the sleep environment, relaxation training, stimulus control therapy (consistent wake/sleep times, using the bed only for sleep, etc), and sleep restriction. Sleep restriction consists of reducing the time spend in bed initially to increase sleep drive in subsequent nights. Once sleep has improved, the time in bed is gradually increased again.
214470051|NCT03127631|BEHAVIORAL|Nutrition|Standardized advice on healthy diet practices.
214470052|NCT03127631|BEHAVIORAL|Exercise|Standardized advice on exercise including strength training and resistance training exercises.
214470053|NCT03127631|BEHAVIORAL|Smoking cessation|Advice to quit smoking, if applicable, and on available aids to quit smoking,
214470054|NCT03127631|DRUG|Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
214470055|NCT03127631|DRUG|ACE inhibitor|Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater \>130mmHg, or other blood pressure lowering medication as applicable.
214470056|NCT05473676|DEVICE|Robotic Training Period|Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.
214470057|NCT05319821|BEHAVIORAL|Receive ECHO training|Active Intervention
214470058|NCT05319821|BEHAVIORAL|Offered ECHO training in year 5|Delayed Intervention
214470059|NCT05049239|BEHAVIORAL|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.
214470060|NCT05049239|BEHAVIORAL|Physical training combined with cognitive support.|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.~The cognitive support consists of person centred individual occupational therapy with focus on daily time management skills and planning and organisation in daily life, i.e. make time for physical exercise. The number of session during the intervention period depend on the participants needs and is estimated to 4-6 sessions."
214470061|NCT06823596|DRUG|Efavirenz 600mg|"Efavirenz induces pyroptosis of HIV expressing cells via the CARD8 inflammasome. In contrast to most ART drugs, and in addition to its anti-retroviral effect, EFV also induces intracellular Gag-Pol dimerization and premature HIV protease activation, causing cleavage of the inflammasome protein CARD8. CARD8 activation results in the production of effector molecules that rapidly kill virus-infected cells by pyroptosis. This effect of EFV has been called TACK or T cell activator of cell killing. We aim to harness this effect to reduce residual nonsuppresible viremia (NSV) in people on stable antiretroviral therapy (ART). Participants in this study will receive EFV in addition to their stable ART regimen for two months, during and after which we will monitor plasma HIV RNA and markers of viral persistence and immune activation."
214470062|NCT06823830|DRUG|Jinfeng Pill|Jinfeng pills were compared with Diane-35 group and Jinfeng pills combined with Diane-35 group were compared with Diane-35 alone.
214470063|NCT03843190|BEHAVIORAL|Take of Pounds Sensibly (TOPS)|Dietician-facilitated classes
214470064|NCT03843190|OTHER|Waitlist Control|At end of study, offered peer-led classes to attend.
214470065|NCT04696757|DRUG|Capecitabine|Capecitabine without surgery
214844254|NCT06457620|OTHER|Traditional Physical Preatment|Each participant got traditional physical treatment during a video conference as part of telerehabilitation. The physiotherapy assistant contacted Group B to arrange a virtual follow-up clinic appointment via Zoom or WhatsApp, along with a 4-week program. We inquired about the patient's level of satisfaction with their TKR procedure. The patient was informed that clinical photos were taken, and the video call was to be recorded. Before the virtual clinic, each patient's verbal agreement was acquired. With workout instructions, the program pursued to enhance leg strength, core stability, balance, and overall performance. The posttest was conducted four weeks after the TKA, and the baseline assessment was finished one day before the procedure.
214844255|NCT01241682|BIOLOGICAL|DC + CTX|3x 50x10e6 DC + cyclophosphamide
214470068|NCT04449198|DRUG|Resveratrol|500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
214470069|NCT04449198|OTHER|Placebo|placebo for 12 weeks
214470070|NCT06357962|OTHER|Semi-permanent acupuncture|These are sessions that last approximately one hour. The selection of points will be based on the energy diagnosis made during the first visit. In some cases, a point may be changed depending on progress. During the session, an interrogation will be conducted to assess symptoms and signs of the condition, and to evaluate if there have been any adverse reactions to the previous session. At the end of the visit, semi-permanent acupuncture will be applied to the selected points.
214470071|NCT06357962|OTHER|Sham of semi-permanent acupuncture|A simulated semi-permanent acupuncture session will be conducted, consisting of specific placebo materials without needles and without stimulation for a few minutes. These points will not correspond to any acupuncture point and will be located on the hands, feet, and back. Stickers without pins will be applied, but never in critical points related to contraction stimulation or cervical ripening.
214470072|NCT06547541|BEHAVIORAL|Exercise|A body weight based resistance training.
214470073|NCT06822634|OTHER|Observational single centre feasibility study|Patients scheduled to undergo standard of care neo. adjuvant radiotherapy prior to surgery.
214470074|NCT04197336|DEVICE|Bariatric Embolization of Arteries with imaging visible Embolics|bariatric embolization will be performed using tiny (100-200 μm), radiopaque (visible on X-ray) beads (referred to as BTG-001933) in order to suppress the body's signals for feeling hungry, which we predict will lead to weight loss.
214470075|NCT06701136|DRUG|Sudapyridine|In Study A, Cycle 1 (D1-D10): Participants will take Sudapyridine (WX-081) 300 mg once daily after breakfast. Cycle 2 (D11-D14): Participants will take Sudapyridine 300 mg once daily after breakfast with itraconazole 200 mg daily; an additional itraconazole dose (200 mg) will be given after dinner on D11. In Study B, Cycle 1 (D1): Participants will take Sudapyridine 450 mg as a single dose after breakfast. Cycle 2 (D22): Participants will take Sudapyridine 450 mg with rifampin 600 mg daily (D15-D27). In Study C, Cycle 1 (D1): Sudapyridine 450 mg will be given fasting; Cycle 2 (D15): after a high-fat breakfast.
214470076|NCT06701136|DRUG|Itraconazole|In Study A: Participants will receive itraconazole capsules at 200 mg orally once daily after breakfast during Cycle 2 (D11-D14). An additional dose of itraconazole (200 mg) will be administered after dinner on D11.
214470077|NCT06701136|DRUG|Rifampin|In Study B: Participants will receive rifampin capsules at 600 mg orally once daily under fasting conditions during Cycle 2 (D15-D27).
214470078|NCT06731413|DRUG|Reduced Dose of Chemotherapy and Immunotherapy|Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135 mg/m2 intravenous (IV) every 21 days. Participants with non-squamous histology will receive carboplatin AUC 3 IV every 21 days and pemetrexed 375 mg/m2 IV every 21 days (collectively, induction chemotherapy). Both groups will receive pembrolizumab 200 mg IV every 21 days for a total of up to 35 cycles (Cycles ≥5 are collectively the maintenance portion of treatment) or until disease progression or unacceptable toxicity.
214470079|NCT05248191|BIOLOGICAL|Capsule fecal microbiota material (cap-FMT)|Cap-FMT consists of Lyophilized FMT administered at 5 x 10\^11 bacteria per capsule daily for five days, for a total dose of 2.5 x 10\^12 bacteria.
214470080|NCT05248191|BIOLOGICAL|Colonoscopic fecal microbiota material (colo-FMT)|Colo-FMT consists of rehydrated Lyophilized FMT material administered as a single dose of 2.5 x 10\^12 bacteria as liquid.
214470081|NCT06817135|OTHER|scapular stabilization exercises|Cools exercise using the Thera-Band, including sidelying external rotation, side-lying forward flexion, prone horizontal abduction with external rotation, and prone extension exercises to promote lower trapezius and middle trapezius activity with minimal activation of the upper trapezius part.
214470082|NCT06817135|OTHER|Muscle Energy Technique|Muscle Energy Technique for the 1.sternocleidomastoid 2. levator scapulae 3. upper trapezius 4. pectoralis major Through mild isometric contractions, it uses the intrinsic energy of a muscle to lengthen it and induce relaxation through autogenic inhibition.
214470083|NCT06817135|OTHER|Advice about the right the breastfeeding ergonomic.|The patients sit with their backs supported with pillows. Don't lean over the infant. Keep the arms supported and feet on the ground.
214470084|NCT06822218|DEVICE|high tone power therapy|patients will be assigned into 2 groups with pre and post treatment protocol application. all patients will be thoroughly evaluated before and after treatment protocol application.
214470085|NCT06822218|DEVICE|TENS|These patients will receive TENS with applied frequencies range from 2 to 120 Hz. for 3 times per week for 30 minutes every session during 3 months of intervention in addition to medications.
214470086|NCT06656910|BEHAVIORAL|Self Compassion Group|"A 7-week self-compassion Programme:~Course 1:~Detective Warm-Up Game, Explaining the application of compassion/self-compassion.~Course 2:~Draw and Tell Warm-up Game, Breath Awareness Exercise, Mindful Eating Activity.~Course 3:~Walking Warm-Up, Body Scan Meditation, How Do You Treat Your Friend Activity.~Course 4:~Random Cards warm-up game, Compassion Meditation, Just Like Me Exercise.~Course 5:~Break, Self-compassionate letter writing.~Course 6:~Tree Drawing Warm-Up Game, Mountain Meditation, Recognize Your Inner Bully, Three Calming Breathing Exercises.~Course 7:~Considering the process with participants, Implementation of final tests, Tender farewell."
214470087|NCT06512922|DEVICE|adaptive cognitive training|The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.
214470088|NCT06512922|DEVICE|placebo cognitive training|They received cognitive training tasks of fixed difficulty.
214470089|NCT06510998|BEHAVIORAL|isometric wall exercise|Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)
214470090|NCT06510998|BEHAVIORAL|passive stretching|A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used
214470091|NCT02084381|DEVICE|MCO-Ci 400|hemodialysis
214470092|NCT02084381|DEVICE|Revaclear 400|hemodialysis
214470093|NCT00178932|PROCEDURE|genetic analysis|genetic assay of blood sample drawn with patient's consent
214470094|NCT00178932|PROCEDURE|genetic assay|genetic assay of blood sample drawn with patient's consent
214470095|NCT04585815|DRUG|Sasanlimab Prefilled syringe|prefilled syringe
214470096|NCT04585815|DRUG|Encorafenib|capsules
214470097|NCT04585815|DRUG|Binimetinib|tablets
214470098|NCT04585815|DRUG|Sasanlimab|solution supplied in vials
214470099|NCT04585815|DRUG|Axitinib|tablets
214470100|NCT04585815|DRUG|SEA-TGT|solution in vials
214470101|NCT05826288|OTHER|BioIntelliSense BioButton Rechargable|This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.
214470102|NCT05826288|OTHER|Memora Health two-way patient engagement platform provided by RC|The Memora Health platform is designed to automate complex care workflows, making them simple for patients and clinicians to navigate. It utilizes a multi-modal communications system that primarily relies on two-way text messaging and artificial intelligence.
214470103|NCT03753347|BIOLOGICAL|2018-19 quadrivalent inactivated influenza vaccine|A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
214470104|NCT06302504|BEHAVIORAL|Nature-based mindfulness program|only one arm is included in this study
214470105|NCT03926052|DRUG|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
214470106|NCT03926052|DRUG|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
214470107|NCT05287594|BEHAVIORAL|Integrated Exercise Program|"Neuromuscular warm-up: Each participant will perform a series of dynamic stretches, core stability, balance, and medicine ball exercises. The dynamic stretches include 8 repetitions of 6 stretches targeting the hip and thigh musculature, followed by 3 core stability isometric exercises (curl-up, side bridge, and bird dog). Participants will then perform 2 sets (per leg) of hop-to-stabilization (with a reach) balance exercises, followed by 3 separate medicine ball exercises emphasizing explosive full-body movements.~High Intensity Interval Training (HIIT): HIIT will include a series of high intensity exercise bouts on a stationary bike that includes a 1:1 work-to-rest ratio. Training intensity will be determined from the peak power output obtained during the baseline VO2 peak assessment and progressively increased by the number of bouts and intensity. The number of work bouts will increase from 5 to 8 bouts and the intensity will increase from 90 to 110% of peak power output."
214470108|NCT06462820|DEVICE|Active SAINT Stimulation|"Participants who are randomly assigned to this group will receive active SAINT targeted to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
214844256|NCT05965791|DIAGNOSTIC_TEST|Phalen's wrist flexion test|The Phalen's test will be performed at different wrist flexion angles from 0 to 90 degrees.
214844257|NCT00368316|BIOLOGICAL|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
214281885|NCT03997110|RADIATION|Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
214844258|NCT04159181|OTHER|Lactulose|Oral solution lactulose (20g lactulose/200mL water).
214844259|NCT04159181|OTHER|Picoprep|Cathartic to accomplish an evacuation of the colonic content.
214844260|NCT04159181|OTHER|Placebo (water)|oral administration of Water (200mL).
214844261|NCT03297086|PROCEDURE|cataract surgery|cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
214281886|NCT03997110|RADIATION|Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
214281887|NCT02976428|PROCEDURE|Sensor Guided Soft Tissue Balancing|Primary TKR with soft tissue balancing with a sensor guided device.
214281888|NCT02976428|PROCEDURE|Standard Soft Tissue Balancing|Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
214281889|NCT00215332|DEVICE|CHARITE|Lumbar Total Disc Replacement
214303190|NCT05328128|BEHAVIORAL|Toilet training|As the training model, Brazelton's child-oriented toilet training method was taken as the basis in study group. In addition, literature studies on toilet training in Turkey were scanned and the final form of training to be given to mothers was created. In the control group, families manage training process themselves.
214303191|NCT04015245|DRUG|Stronger Neo-Minophagen C|intravenous injection after TACE
214303192|NCT06530342|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in all athletes.
214303193|NCT05301296|DIAGNOSTIC_TEST|Clinical examination of the breast for early detection of Cancer|Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
214303194|NCT03382119|DEVICE|Ultrasound with ARFI (acoustic radiation force impulse)|This technology uses sound waves to measure the stiffness of tissue.
214303195|NCT03382119|DEVICE|Ultrasound with backscatter imaging|This ultrasound tool gathers data from the waves returning from imaged tissue.
214303196|NCT03622346|PROCEDURE|Semi-constrained total knee arthroplasty|Semi-constrained total knee arthroplasty
214303197|NCT05096845|BIOLOGICAL|Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|"Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively.~Storage condition: store at 2\~8°C protected from light Expiry date: 24 months after production date"
214303198|NCT05096845|OTHER|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
214303199|NCT01514760|OTHER|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
214303200|NCT05185960|OTHER|ALLSWEET®|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be diluted in water.
214303201|NCT05185960|OTHER|ALLSWEET® and sucrose|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be added to sucrose (table sugar) and diluted in water.
214303202|NCT05185960|OTHER|Sucrose|Table sugar. It will be consumed by diluting it in water.
214303203|NCT02092662|OTHER|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
214303204|NCT02092662|OTHER|Healthy controls|no treatment
214470109|NCT06462820|DEVICE|Sham SAINT Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation targeted to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
214470110|NCT03164278|BEHAVIORAL|Independent Transfer Training|Independent Transfer Training Program: ITTP training starts with an overview and self-evaluation using the transfer assessment instrument questionnaire (TAI-Q) followed by three core modules: wheelchair setup, body setup, and flight/landing. Wheelchair setup includes factors such as the angle and distance of the wheelchair to the transfer surface, removing barriers, applying the brakes, and height of the transfer. Body setup involves positioning one's body for an optimal transfer and covers foot, hip, arm and hand positions. Flight/landing discusses how to achieve a smooth and controlled transfer, the head-hips relationship, use of transfer device, and safe landing.
214470111|NCT03757689|DRUG|Pembrolizumab|Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.
214470112|NCT03757689|PROCEDURE|Wide Excision and Sentinel Lymph Node (SLN) Biopsy|Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
214470113|NCT03099135|DRUG|No Treatment|No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
214470114|NCT05368974|DRUG|Direct Acting Antivirals|Direct-acting antiviral exposure during documented pregnancy
214470115|NCT06035445|BEHAVIORAL|In-person adolescent-friendly service (iPAS) intervention|Monthly visits take place in a group setting with sessions led by peer educators. Clinical staff and peer educators are trained in care of adolescents using the Right to Care training materials. During their clinic visit, adolescents are evaluated individually by a healthcare provider and receive their supply of ART. In addition, adolescents participate in scheduled group team-building activities including dancing, sports, music and receive group counseling facilitated by peer educators. Nine group counseling sessions will discuss the topics of: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. The half-day sessions will end with the provision of a meal. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
214470116|NCT06035445|BEHAVIORAL|mHealth (InTSHA) intervention|The InTSHA intervention is based on Got Transition elements (two-way messaging between adolescents and healthcare providers) and the SMART model. The SMART model focuses on modifiable factors of transition preparation through content delivery, facilitated discussions, online meet ups and consultation with the healthcare team. The intervention consists of 9 modules delivered monthly by group chat. The topics of the modules are: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. Outside of scheduled group chat sessions, adolescents have access to the chat group to check in with members, review content of the sessions, or to comment or ask additional questions. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
214281890|NCT05131698|COMBINATION_PRODUCT|Tislelizumab and Lenvatinib|"TACE therapy: For transarterial infusion chemotherapy before or after TACE embolization, each drug will generally be diluted with 0.9% sodium chloride solution or 5% dextrose solution 150-250 mL and injected slowly into the target artery for ≥20 min. Subsequent TACE therapy will be administered on an as-needed basis as assessed by the clinician, with each treatment interval exceeding 6 weeks and no more than 6 treatments in total.~Lenvatinib: The starting dose of lenvatinib will depend on the patient's baseline weight: if baseline weight ≥ 60 kg, patients will receive 12 mg of lenvatinib administered once daily; if baseline weight \< 60 kg, patients will receive 8 mg of lenvatinib once daily. TACE therapy will be given 3 days apart.~Tirelizumab: Tirelizumab 200 mg , intravenous infusion on the same day as the first dose of lenvatinib, once every three weeks.~Translated with www.DeepL.com/Translator (free version)"
214281891|NCT04388709|DRUG|Peginterferon Lambda-1A|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
214281892|NCT00318110|PROCEDURE|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
215032304|NCT01940055|BEHAVIORAL|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
214470117|NCT06035445|BEHAVIORAL|Standard of Care|Adolescents in standard of care are seen every three months by clinicians and collect medication monthly at an on-site pharmacy during regular weekdays. Individual counseling delivered by counselors or social workers is available when necessary. Staff at all clinics receive training in adolescent-friendly services (AFS) through the Right to Care training materials.
214470118|NCT06024746|DRUG|Finerenone|Oral finerenone.
214470119|NCT06024746|DRUG|Empagliflozin|Oral empagliflozin.
214844262|NCT05533099|OTHER|Observational study|Observational study of a device implanted in a previous clinical study
214844263|NCT01976728|DRUG|Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump|
214844264|NCT01976728|DRUG|Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump|
214281893|NCT04773483|DIETARY_SUPPLEMENT|Quorn Foods products|180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)
214281894|NCT04773483|DIETARY_SUPPLEMENT|Meat/fish products|Standard meat/fish products matched to Quorn group for protein intake
214281895|NCT02255604|DRUG|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
214281896|NCT02255604|DRUG|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
214281897|NCT02255604|DRUG|0.1 ml Isoton saline|4 injection into a lymphnode
214470120|NCT06480383|DRUG|ITI-1284 10 mg|ITI-1284 10 mg tablet, taken once daily, sublingual administration.
214470121|NCT06480383|DRUG|ITI-1284 20 mg|ITI-1284 20 mg tablet, taken once daily, sublingual administration.
214470122|NCT06480383|DRUG|Placebo|Matching placebo tablet, taken once daily, sublingual administration
214470123|NCT05118074|DIAGNOSTIC_TEST|Creatinine, eGFR|Compare diagnostic tests to reference methods
214470124|NCT04182815|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
214470125|NCT00866684|DRUG|Sirolimus|Treatment arm Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day
214470126|NCT00866684|DRUG|Azathioprine|control arm Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
214470127|NCT00866684|DRUG|Mycophenolate|Control arm Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
214470128|NCT00866684|DRUG|Ciclosporin|Control arm Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
214470129|NCT00866684|DRUG|Tacrolimus|Control arm Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
214844265|NCT01976728|DRUG|Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump|
214470131|NCT03808961|DIETARY_SUPPLEMENT|Niacin|100mg tablets twice daily
214470132|NCT03808961|DIETARY_SUPPLEMENT|Niacinamide|100mg tablets twice daily
214470133|NCT03808961|OTHER|Placebo|Placebo tablet twice daily
214470134|NCT04817774|BIOLOGICAL|TX200-TR101|TX200-TR101 is an autologous gene therapy medicinal product composed of Treg cells (CD4+/CD45RA+/CD25+/CD127low/neg) that have been ex vivo expanded and transduced with a lentiviral vector encoding for a CAR to recognize HLA-A\*02. Treatment will be given via an IV infusion at a pre-defined timepoint several weeks after transplant. Four, single ascending dose cohorts of TX200-TR101 are planned and an additional expansion cohort.
214470135|NCT04531917|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) teaches patients about complex pain mechanisms known to be of importance in pain following breast cancer such as malfunctioning of the endogenous analgesic system and pain memories.
215032305|NCT05417178|OTHER|myStrength Macropersonalization Enginge|An onboarding process that utilizes the PHQ-9, GAD-7, and WHO-5 that leads to a user of the digital program's clinical focus and primary, secondary, and tertiary intervention recommendations.
214470136|NCT04531917|OTHER|Behavioural Graded Activity|"Patients in the experimental group will receive a behavioural treatment integrated within the concepts of operant conditioning. The purpose of Behavioural Graded Activity (BGA) is to increase the level of physical activity in the patient's daily lives in a time-contingent manner. On top of that, a healthy behaviour will be positively reinforced to consequently create a withdrawal of the attention towards pain behaviour, which is seen as an unreliable alarm sign in chronic pain patients. The implementation of BGA after PNE is described in the guideline reported by the International Association for the Study of Pain."
214470137|NCT04531917|OTHER|Usual care|The content of the leaflet has a biomedical approach in explaining pain and providing information on the different pain medication classes. This leaflet is mostly available in waiting rooms of oncology centres and units of the Flemish part of Belgium.
214470138|NCT06585566|PROCEDURE|Cortical-shell graft|Retromolar cortical shell graft technique for SABG
214470139|NCT04004065|DRUG|Vesleteplirsen|Vesleteplirsen injection, for IV use
214470140|NCT06241976|OTHER|Glucose drink|75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)
214844266|NCT01976728|DRUG|Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)|
214281898|NCT02466178|DEVICE|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
214281899|NCT02531906|DRUG|Gabapentin|Given PO
214844267|NCT06617533|OTHER|PCF model|PCF practices practices receive (1) a per-beneficiary-per-month prospective payment that depends on the average health of their attributed Medicare beneficiaries; (2) a Flat Visit Fee for primary care visits, subject to a geographic adjustment factor, and (3) a Performance-based Adjustment (PBA). The PBAs depend on practices' performance on several quality measures in addition to their performance in reducing beneficiaries' use of inpatient care or total cost of care, relative to national and regional benchmarks. Practices must meet a limited set of care delivery requirements and can use the PCF Model's flexible use of payments to invest in strategies that best suit their practices' unique patient population and resources. In return, practices take on limited financial risk in exchange for performance-based payments that reward participants that meet certain performance and quality benchmarks for selected outcomes.
214844268|NCT04344132|PROCEDURE|Scalp Block|standard practice of controll the pain after surgery. Block of the nerve emergences.
214281900|NCT02531906|DRUG|Methadone Hydrochloride|Given PO
214470141|NCT06241976|OTHER|Pure orange juice|300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket
214470142|NCT03167216|DRUG|Cromolyn Sodium|Mast cell stabilizer
214470143|NCT03167216|DRUG|Cetirizine Hydrochloride|Histamine receptor antagonist
214844269|NCT04703517|DIAGNOSTIC_TEST|Point of care ultrasound|Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
214281901|NCT02531906|DRUG|Oxycodone Hydrochloride|Given PO
214281902|NCT02531906|OTHER|Quality-of-Life Assessment|Ancillary studies
214281903|NCT02531906|OTHER|Questionnaire Administration|Ancillary studies
214470144|NCT03876964|DEVICE|Transcatheter Aortic Valve Replacement|Minimally invasive replacement of the aortic valve through a catheter.
214470145|NCT03690115|DRUG|Ponatinib 30 MG|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
214470146|NCT05540262|DRUG|Edaravone|Edaravone injection 30mg three times a day
214470147|NCT04540107|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
214470148|NCT04540107|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214470149|NCT04540107|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
214470150|NCT06063395|PROCEDURE|open surgery on the abdominal aorta by laparotomy|Laparotomy aortic surgery for the management of an abdominal aortic aneurysm has several distinct stages which will not be altered by the performance of this study. The patient arrives in the operating room and is taken care of by the anesthetic team. The patient is then placed in the correct position for optimal surgical management and a skin cleansing procedure is carried out. A sterile drape is applied and the preoperative checklist in force in the establishment is completed. Initial dissection of the aneurysm and its proximal and distal control is left to the discretion of the principal surgeon. Once the aortic aneurysm has been controlled, the main surgeon places self-static retractors and then prepares to clamp the aorta. The surgeon initiates aortic clamping to create the aorto-biliac or bifemoral bypass. Once the bypass has been created, the operation is completed by closing the surgical approach and the skin incision. The bandage is then applied.
214470151|NCT05795816|DRUG|Testofen|Twice daily dose of 1 capsule (300mg per capsule Testofen)
214844270|NCT02430415|DEVICE|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
215032306|NCT03965117|DRUG|Norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is \> 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
215032307|NCT02553096|DEVICE|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
215032308|NCT01605097|RADIATION|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
215032309|NCT05504434|DEVICE|Single-use gastroscope|Adults patients are treated with a single use gastroscope instead of a reusable gastroscope
215032310|NCT02554955|DRUG|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
215032311|NCT02554955|DRUG|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
215032312|NCT02554955|DRUG|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
215032313|NCT00924274|DIETARY_SUPPLEMENT|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
215032314|NCT00924274|DIETARY_SUPPLEMENT|sunflower oil|sunflower oil
214281904|NCT00630396|DRUG|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
214470152|NCT05795816|DRUG|Microcrystalline cellulose|Twice daily dose of 1 capsule
214470153|NCT05064891|PROCEDURE|Ultrasound guided injection|Subdeltoid bursa injection, suprascapular nerve block, or posterior glenohumeral joint injection. The participants should only receive one type of the injection mentioned above.
214470154|NCT03714360|DRUG|Tranexamic Acid|patients with ASA(American Society of Anesthesiologists grades) 1 to 2, scheduled to undergo lumbar decompressive surgery at Middelfart Hospital. Patients were randomized, in blocks of 10, to two groups: TXA or placebo. Anticoagulation therapy was discontinued 2-7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10mg/kg), or an equivalent volume of saline solution (placebo).
214844271|NCT02430415|DEVICE|traditional lightwand intubation|traditional lightwand intubation
214844272|NCT01185028|DRUG|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
214844273|NCT03063424|DIAGNOSTIC_TEST|Eucapnic voluntary hyperventilation|
214844274|NCT03063424|DIAGNOSTIC_TEST|Exercise challenge on a cycle ergometer|
215032315|NCT04250701|OTHER|Body Posture Assessment|Application of three evaluations above at a one time.
215032316|NCT02305992|PROCEDURE|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
215032317|NCT02305992|PROCEDURE|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
215032318|NCT02305992|PROCEDURE|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
215032319|NCT03531580|DEVICE|Magnetic Resonance Imaging|Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
215032320|NCT04190264|DEVICE|Thermal Rehabilitation Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
215032321|NCT04190264|OTHER|Cold Water Immersion|Whole-body immersion in cold water.
215032322|NCT04179617|OTHER|5% nicotine content JUUL pod|JUUL pods that contain 5% nicotine
215032323|NCT04179617|OTHER|3% nicotine content JUUL pod|JUUL pods that contain 3% nicotine
215032324|NCT02699411|DEVICE|Dry needling|dry needling Travell and Simons
215032325|NCT02699411|OTHER|Stability and propioception|Start excursion balance test, WOMAC; ROM, EVA.
214281905|NCT00279591|DEVICE|Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device|Continuous blood pressure monitoring of patients during med flight to hospital
214281906|NCT00279591|DEVICE|Standard of care blood pressure monitoring|Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
214281907|NCT06102239|DIAGNOSTIC_TEST|Bilirubin level sodium level c reactive protein level|detect level of bilirubin,sodium \&c-reactive protein as indicator of complicated appendicitis
214281908|NCT04413396|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
214281909|NCT06498999|BEHAVIORAL|4-STEP-Training Program for Social Media Addiction (4-STEP-TPS)|"4 Modules with 1 Module being delivered in 1 weekly session of approximately 90 minutes. The details of each module/step is described as follows:~Step 1 (Module 1): S = Screening, Assessment and Psychoeducation: Involves screening and assessment of the problem, interpretation of the results, feedback and psychoeducation, identifying and breaking the resistance, motivation, and conceptualization.~Step 2 (Module 2): T = Treatment Conceptualization and Planning: Involves pattern identification, distortion identification, as well as pattern and distortions modifications.~Step 3 (Module 3): E = Effective Management Strategies: Involves management strategies to treat the earlier identified patterns as well as the implementation and confirmation of activities via a Pattern Schedule Chart.~Step 4 (Module 4): P = Prevention (Lapse-Relapse): Involves self-reflection and support building, monitoring and dependency check and slip plans and support additions"
214281910|NCT02314611|DEVICE|PROFEMUR® Gladiator HA Coated Modular Femoral Stem|Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
214281911|NCT01672697|BEHAVIORAL|Physical Therapy (PT) and Behavioral Therapy (BT)|"1. Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.~2. Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment."
214281912|NCT03006497|OTHER|Exercise program based on motor learning principles|The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
214281913|NCT04822454|OTHER|Night shift shadowing program|Our population, made up of 70 students, was divided into two randomly randomized groups: 31 (44.3%) had five night shift shadowing duty prior to their first official night shifts, and 39 (55.7%) did not participate in the shadowing program.
214844275|NCT01569347|OTHER|Interviews|Interviews
214281914|NCT04617509|DRUG|Formulation A GS-248|Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
214281915|NCT04617509|DRUG|Formulation B GS-248|Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
214281916|NCT00090480|BIOLOGICAL|HyperAcute - Breast cancer vaccine|Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
214281917|NCT00790023|DRUG|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
214281918|NCT00790023|DRUG|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
214281919|NCT00790023|DRUG|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
214281920|NCT01338792|DRUG|oxaliplatin|Given IV
214281921|NCT01338792|DRUG|pemetrexed disodium|Given IV
214281922|NCT01338792|OTHER|questionnaire administration|Ancillary studies
214281923|NCT01338792|OTHER|laboratory biomarker analysis|Correlative studies
214281924|NCT01338792|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
214281925|NCT01338792|GENETIC|polymorphism analysis|Correlative studies
214281926|NCT03269383|DRUG|Bupivacaine|Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine
214281927|NCT03269383|OTHER|Saline|Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
214281928|NCT05739097|DIAGNOSTIC_TEST|iron deficiency, coagulation abnormalities|avoid transfusions, where possible
214281929|NCT04286321|OTHER|Zero hard-boiled egg at 0 h|No eggs will be consumed on test day along with spinach consumption
214281930|NCT04286321|OTHER|One hard-boiled egg at 0 h|One egg will be consumed on test day along with spinach consumption
214281931|NCT04286321|OTHER|Two hard-boiled eggs at 0 h|Two eggs will be consumed on test day along with spinach consumption
214281932|NCT04286321|OTHER|Three hard-boiled eggs at 0 h|Three eggs will be consumed on test day along with spinach consumption
214281933|NCT04286321|OTHER|One hard-boiled egg at 3 h|One egg will be consumed on test day three hours after spinach consumption
214281934|NCT04286321|OTHER|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
214281935|NCT04286321|OTHER|Two egg whites at 0 h|Two egg whites will be consumed on test day along with spinach consumption
214281936|NCT04286321|OTHER|Vegetable oil at 0 h|9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption
214281937|NCT03517956|DRUG|Rogaratinib (BAY1163877)|"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
214281938|NCT03517956|DRUG|Copanlisib (BAY80-6946)|"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
214844276|NCT01569347|OTHER|Blood sample|Blood sample
214844277|NCT01569347|OTHER|Hair sample|Hair sample
214844278|NCT03389256|DRUG|Apatinib|Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
215032326|NCT01715116|DEVICE|Enhanced ICD programming|"* VT monitor: \> 166/min~* fVT: \> 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~* VF: \> 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~* SVT/VT discrimination is turned on, high rate time out is OFF~* SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~* SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~* T wave-oversensing and lead noise discrimination is turned on in all devices."
214281939|NCT04512404|DRUG|HMG-CoA Reductase Inhibitor|
214281940|NCT00336063|DRUG|Azacitidine|Given SC
214281941|NCT00336063|OTHER|Laboratory Biomarker Analysis|Correlative studies
214281942|NCT00336063|OTHER|Pharmacological Study|Correlative studies
214281943|NCT00336063|DRUG|Vorinostat|Given PO
214281944|NCT01044862|DRUG|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
214281945|NCT01044862|DRUG|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
214281946|NCT01044862|DRUG|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
214281947|NCT01652703|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
215032327|NCT03107845|BEHAVIORAL|Cognitive Behavior Therapy|Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
214281948|NCT01652703|OTHER|Placebo|Administered by subcutaneous injection
214281949|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 65-70
214281950|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 85 or greater
214281951|NCT02521636|OTHER|Antibiotic therapy randomization|
214281952|NCT02521636|OTHER|Serum PCT dosage|
214281953|NCT04051723|DRUG|The dexamethasone plus ropivacaine|The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
214281954|NCT04051723|DRUG|The ropivacaine|The local infiltration solution containing 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
214281955|NCT04078113|OTHER|Pupillometer|Measurements of pupillary dilatation with pupillometer to administer or not analgesia
214281956|NCT04775459|DRUG|Surfactant administration until 2020|Surfactant is administrated if Fi02 \>30% among the Guidelines of 2019
214281957|NCT04775459|DRUG|Surfactant administration since 2021|Surfactant is administrated if Fi02 \>30% OR if score LUS \>8/18 among the literature
214281958|NCT05832385|RADIATION|IMRT|anal cancer: chemoradiotherapy, radiation dose\>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
214281959|NCT02790528|DRUG|Atorvastatin|20mg QD
214281960|NCT02790528|DRUG|Placebo|Placebo drug will be administered.
214281961|NCT03167840|BEHAVIORAL|Physical and Cognitive Training|Physical Exercise and Cognitive Training
214281962|NCT03167840|BEHAVIORAL|Physical Training|Physical training alone
214281963|NCT03167840|BEHAVIORAL|Cognitive training|Cognitive training alone
214281964|NCT05123768|DIAGNOSTIC_TEST|NGS|A genetic panel of more than 100 genes, associated with CP spectrum disorders, will be assessed using NGS
214281965|NCT01786798|DEVICE|Transvaginal sonography|"Transvaginal sonography will be performed to:~* measure the endometrial thickness~* detect the endometrial pattern"
214281966|NCT06127277|BEHAVIORAL|Next4You|Youth in the intervention arm will have access for four continuous weeks to a mobile intervention that covers topics related to communication, relationships, sexual wellness, contraception, respecting self and partners, and building wealth and wellness.
214281967|NCT02927522|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
214281968|NCT02927522|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
214281969|NCT04497688|DRUG|PEG-rhG-CSF|Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
214281970|NCT02314897|DEVICE|LV pacing|Left ventricular pacing lead implanted via the coronary sinus.
214281971|NCT02314897|DEVICE|RV pacing|Conventional right ventricular pacing.
214281972|NCT01604174|OTHER|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
214281973|NCT01604174|OTHER|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
214281974|NCT02155608|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
214470155|NCT03714360|DRUG|Sodium Chloride 0,9%|Sodium Chloride 0,9%
214470156|NCT05584540|BEHAVIORAL|UNTIRE App|Digital therapeutic application
214470157|NCT04107181|DEVICE|"Introducer calla device"|The research introducer will be used after the patient consents prior to the annual pap smear.
214470158|NCT04107181|BEHAVIORAL|Interviews only|Healthy volunteer interviews
214470159|NCT06068244|OTHER|3D printed crowns|3D printed crowns
214470160|NCT06068244|OTHER|Zirconia crowns|Nu smile zirconia crowns
214470161|NCT05523856|PROCEDURE|Active Surveillance|It consists on monitoring the cancer with regular tests including PSA, blood test and digital rectal examination every 6 months, a magnetic resonance imaging and prostate biopsy at the first year, and based on clinical decision thereafter. If there was a change on the results, the patient is considered for treatment.
214470162|NCT05523856|PROCEDURE|Robot-Assisted Radical Prostatectomy|It consists on the removal of the prostate gland and seminal vesicles with neurovascular preservation whenever anatomically and oncologically possible, with the Da Vinci procedure. Access is made through 5 or 6 small incisions, less than 1 cm. An extended pelvic lymph node dissection is performed when the risk estimation of node involvement is above the 5%. After surgery, the patient will be hospitalized for about 3 days and will probably resume his work activity between 3 and 5 weeks.
214470163|NCT05523856|RADIATION|Intensity-Modulated Radiotherapy|Patients in this group undergo volumetric modulated arc therapy under daily image-guided radiation therapy in the supine position. Radiation is delivered in 2-3 Gy daily fractions, 5 days per week, with a prescription dose of 60-70 Gy to the prostate.
214470164|NCT05523856|RADIATION|Real-time brachytherapy|Patients in this group receive I125 permanent seeds (low dose rate). The images are obtained with a transrectal ultrasound probe and are transferred to a planning system for calculating the number and position of the seeds. The prescrption dose is 145 Gy to the reference isodose (100%).
214470165|NCT05672108|PROCEDURE|Computed Tomography|Undergo CT
214281975|NCT02155608|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
214281976|NCT03346785|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
214281977|NCT03346785|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
214281978|NCT03346785|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
214281979|NCT02329353|DRUG|Lactobacillus brevis CD2 Lozenges|Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
214281980|NCT06159530|PROCEDURE|dental implants|4 dental implants placed in the mandible according to all-on 4 concept
214281981|NCT06159530|PROCEDURE|peek framework|peek framework screwed to multi-unit abutments of 4-implants
214281982|NCT06159530|PROCEDURE|visio-lign nano composite|peek framework veneered with nano composite (visio-lign) as an occlusal material
214281983|NCT06159530|PROCEDURE|zirconia crowns|peek framework covered with zirconia crowns as an occlusal material
214281984|NCT02097576|OTHER|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
214281985|NCT02097576|OTHER|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
214281986|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Induction Phase|To each of two test sites, approximately 20 μl/cm\^2 of the Butenafine HCl 1% was applied directly to the skin and covered with a 25 mm Hilltop chamber with a Webril pad (2 cm in diameter, within an area of approximately 3 cm\^2), and tape was applied over the chamber to secure the occlusive patch to the skin. On the next day, the chambers were removed and both test sites were lightly wiped. Approximately 2 μl/cm\^2 of Butenafine HCl 1% was reapplied directly to the skin and lightly spread over the treated irradiated test site. The treated non-irradiated test site did not receive a similar reapplication. Between 5 and 15 minutes after application, the treated irradiated test site was irradiated with two times the subject's Minimal Erythema Dose (MED). Evaluation of the test sites occurred two days after the irradiation. This procedure was repeated two times per week for three consecutive weeks for a total of 6 induction exposures per test site.
214470166|NCT05672108|DRUG|Ethiodized Oil|Given IA
214470167|NCT05672108|DRUG|Mitomycin|Given IA
214470168|NCT05672108|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
214844279|NCT03389256|DRUG|EGFR-TKI|Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po
214470169|NCT05672108|DEVICE|Tris-acryl Gelatin Microspheres|Given IA
214470170|NCT04587453|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to human interleukin-13 (IL-13) and blocks the interaction with IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
214470171|NCT04587453|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
214470172|NCT04587453|OTHER|Topical corticosteroids (TCS)|TCS administered as needed.
214470173|NCT04381429|DRUG|A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
214844280|NCT05303935|DRUG|Quetiapine 50 MG|A single dose of 50mg of quetiapine taken at bedtime for one night.
214844281|NCT05303935|DRUG|Placebo|A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
214844282|NCT04910828|OTHER|Common foods of varying glycemic indices|Examples of foods of varying glycemic index to be tested include bread, rice, breakfast cereals, starchy vegetables, legumes, fruit and dairy products.
214844283|NCT00966381|OTHER|Exercise and weight loss intervention|randomized control trial, stratified by parity
214470174|NCT04381429|DRUG|F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
214470175|NCT06313853|BEHAVIORAL|COACH-Cog|Oncology clinician intervention components: 1) a brief training video (completed once during the duration of the study following enrollment and randomization), 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments Patient/Care partner dyad intervention components: 1) Care partners (and patients if able) will participate in a one-time communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
214470176|NCT05775562|DIAGNOSTIC_TEST|Pre and post dive examinations|"Performing pre-dive examinations:~\- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Measurement of circulating bubbles~* ECG~* Venous blood sampling (biological collection)~* Water balance (Δweight/water intake)~* EFR by plethysmography cabin~* Weight measurement~Realization of the examinations the day after the dive:~* Venous blood sample (biological collection)~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Weight measurement"
214470177|NCT05591326|PROCEDURE|i-PRF application procedure|Local anesthesia will be applied to the area with gingival recession. Before the procedure, the venous blood taken from the patient will be centrifuged at 700 RPM for 3 minutes in glass and non-addition tubes to obtain i-PRF. i-TZF will be taken into a 2 cc injector. In 2020, Özsağır et al. Decortication, that is, microneedling, will be performed with insulin needle tips according to the protocol defined by Dr. Then the prepared i-PRF will be infected to the apical mucogingival junction of the keratinized gingival area. This process will be repeated once a month for 3 months. After the 3rd month, the horizontal and vertical gingival recession values will be evaluated and recorded at the end of 6 months and 1 year.
214470178|NCT04929483|DRUG|BIO89-100|Subcutaneous injection
214470179|NCT04929483|DRUG|Placebo|Subcutaneous injection
214470180|NCT03857945|OTHER|Preoperative mobility device(s) training|Patients in Group 1 (the intervention, that is the mobility device training group group) will receive training on the mobility device(s) with the physical therapy visit during their standard pre-operative care.
214470181|NCT05169723|BEHAVIORAL|Exertional respiratory activities|participants will perform a series of exertional respiratory activities
214470182|NCT06344741|BEHAVIORAL|Accepted in latent phase|Participants admitted to the delivery room in the latent phase will be included. Routine procedures will be performed.
214470183|NCT06344741|BEHAVIORAL|Accepted in active phase|Participants admitted to the delivery room in the active phase will be included. Routine procedures will be performed.
214470184|NCT05880199|DEVICE|Body surface gastric mapping device|A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.
214470185|NCT03125070|OTHER|Best Practice and Internet site with links to existing resources|Receive usual care
214844284|NCT04445064|BIOLOGICAL|IO102|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
214844285|NCT04445064|BIOLOGICAL|IO103|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
215032328|NCT03107845|BEHAVIORAL|CBT plus Feedback|Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI \& OQ-30), interpersonal functioning (IIP-32 \& OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
215032329|NCT03107845|BEHAVIORAL|CBT plus Feedback plus CST|"Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation."
215032330|NCT02038647|DRUG|Alisertib|Alisertib tablets
215032331|NCT02038647|DRUG|Placebo|Placebo matching tablets
214470186|NCT03125070|OTHER|Internet, Mobile app and Telehealth Intervention|Receive INSPIRE and survivorship care plan
214470187|NCT03125070|OTHER|Survey Administration|Ancillary studies
214470188|NCT06556823|OTHER|CLNDT+ Conventional PT in Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
214844286|NCT03176355|PROCEDURE|Canaliculo- Dacryocystorhinostomy|Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa
214844287|NCT04421092|PROCEDURE|Superior laryngeal nerve block|Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
215032332|NCT02038647|DRUG|Paclitaxel|Paclitaxel intravenous injection
215032333|NCT02259803|DRUG|Telmisartan/amlodipine fixed-dose combination (FDC) tablet|
215032334|NCT02259803|DRUG|Telmisartan|
215032335|NCT02259803|DRUG|Amlodipine|
215032336|NCT02962661|OTHER|Best Practice|Given standard of care
215032337|NCT02962661|OTHER|Laboratory Biomarker Analysis|Correlative studies
215032338|NCT02962661|DRUG|Mesenchymal Stem Cell Transplantation|Given IV
215032339|NCT02962661|DRUG|Mesenchymal Stem Cell Transplantation|Given transendocardially
215032340|NCT03809533|DRUG|sofosbuvir/velpatasvir|12-week, oral, fixed-dose
214470189|NCT06556823|OTHER|CLNDT+ Conventional PT in non Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
214470190|NCT06556823|OTHER|SMWLM+ Conventional PT in Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
214470191|NCT06556823|OTHER|SMWLM+ Conventional PT in non Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
214470192|NCT04200274|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
214470193|NCT04534218|DRUG|Regorafenib|"* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle."
214470194|NCT04534218|DRUG|Cyclophosphamide|50 mg per os, daily, for 6 months
214470195|NCT04534218|DRUG|Capecitabine|625mg/m²/orally twice daily continuously for 6 months
214470196|NCT04534218|DRUG|Aspirin|75 mg orally and daily until progression
214470197|NCT05861336|DRUG|Losartan|Losartan will be administered at the dose of 25 mg PO qd starting on Cycle 1 Day 1. If this dose will be tolerated during week 1, escalation to 50 mg PO qd at Cycle 1 Day 8
214470198|NCT05861336|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days
214470199|NCT05861336|DRUG|Nab paclitaxel|nab-paclitaxel 125 mg/m2 on days 1, 8, and 15
214844288|NCT04421092|PROCEDURE|Injection of placebo (saline)|Superior laryngeal nerve block using 1mL of saline as the injection.
214844289|NCT04421092|PROCEDURE|Injection of steroid-lidocaine mixture|Superior laryngeal nerve block using 1mg 1:1 triamcinolone 40mg: 1% lidocaine with 1:200000 epinephrine as the injection.
215032341|NCT02881827|RADIATION|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
215032342|NCT02881827|OTHER|Placebo|Simulation of treatment with the device switched off
214470200|NCT05861336|RADIATION|Stereotactic Body Radiation Therapy|7 consecutive fractions for a total dose of 35-42 Gy
214470201|NCT04288635|BIOLOGICAL|Whole blood samples|Whole blood samples at admission, from day one to three after admission
214470202|NCT03897361|GENETIC|"CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)"|Peripheral blood autologous CD34+ enriched cell fraction transduced with lentiviral vector, pCCL-CTNS or pCDY.EFS.CTNS.T260I, that contains the human CTNS complementary deoxyribonucleic acid (cDNA) sequence.
214470203|NCT05318898|OTHER|Vegetal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetal protein sources
214470204|NCT05318898|OTHER|Animal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
214470205|NCT06405321|DRUG|Conversion or neoadjuvant therapy.|Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.
214470206|NCT05866861|DRUG|CUG252|CUG252 will be administered by subcutaneous injection.
214470207|NCT05866861|DRUG|Placebo|Placebo will be administered by subcutaneous injection.
214470208|NCT04141891|BEHAVIORAL|Driving Decision Aid|Healthwise DDA
214470209|NCT04141891|BEHAVIORAL|Older Drivers Website|National Institute on Aging (NIA) Older Drivers Website
214470210|NCT05205512|OTHER|Exercise Intervention|Maintain current levels of physical activity
214470211|NCT05205512|OTHER|Questionnaire Administration|Ancillary studies
214470212|NCT05205512|OTHER|Telemedicine|Participate in telehealth exercise intervention
214470213|NCT04966585|DRUG|Posaconazole Delayed Release Oral Tablet|Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
214844290|NCT03782480|DRUG|Intrarosa|Prasterone intravaginal inserts
214470214|NCT04966585|DRUG|Matching Placebo Tablet|Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
214470215|NCT04179539|DIAGNOSTIC_TEST|V/Q PET/CT|Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired
214470216|NCT04179539|DIAGNOSTIC_TEST|CTPA|CTPA will be done according to the usual protocol in the radiology department of the investigator center
214470217|NCT05349240|DEVICE|C2 CryoBalloonTM Ablation System.|Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
214470218|NCT06290921|OTHER|Ovulation triggering|Ovulation triggering when women only 2 dominant follicles as opposed to the clinic's standard of 3 follicles or more
214470219|NCT06162715|DRUG|Tirzepatide|Tirzepatide will be initiated 12 months after patients undergo Roux-en-Y Gastric Bypass. Patients will be started on the lowest dose of 2.5 mg and the dose increased every 6 weeks following an adaptive maximum dose titration protocol. Patients will then complete a final 4 weeks of the study drug.
214470220|NCT06162715|OTHER|Standard of Care post-gastric bypass|Patients randomized to the control arm will receive the standard of care for weight maintenance after gastric bypass including dietary guidance provided by the Vanderbilt Surgical Weight Loss handbook. This includes recommendations for 64 oz of fluids per day, ≥60 grams of protein/day, and daily bariatric multivitamins. Patients will continue to have access to dedicated bariatric dietitians, advanced practice providers, and surgeons on an ad hoc basis per patients' request.
214470221|NCT03134755|DRUG|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
214470222|NCT06281080|PROCEDURE|En-Bloc Resection of Bladder Tumours|Patients underwent En-Bloc Resection of Bladder Tumours using Agilis Robotic System.
214470223|NCT03801876|DRUG|Carboplatin|Given IV
214470224|NCT03801876|PROCEDURE|Esophagectomy|Undergo esophagectomy
214470225|NCT03801876|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214281987|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Challenge Phase|5 μl/cm\^2 of the Butenafine HCl 1% was applied directly to each of the two virgin sites (treated sites) adjacent to the induction patch sites and covered with Hilltop chambers with Webril pad and tape was applied over the chambers to secure the occlusive patches to the skin. Two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Sites were at least 2.5 cm apart. The patches were removed 24 hours later and the sites were lightly wiped. Test sites were evaluated. Butenafine HCl 1% (2 μl/cm\^2) was applied to the treated irradiated site. After 15 minutes, the treated irradiated site and the untreated irradiated site were irradiated with 0.5 MED of UVA/UVB irradiation followed by 10 Joules/cm\^2 of UVA from a xenon arc solar simulator equipped with a Schott WG345 to eliminate UVB radiation. The remaining sites served as the treated non-irradiated site and untreated non-irradiated site.
214281988|NCT06000098|OTHER|Restrictive fluid therapy|"0,5 ml/hour fluid administration during prostatic anastomosis.~After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down)."
214470226|NCT03801876|DRUG|Paclitaxel|Given IV
214844291|NCT03782480|DRUG|Placebos|Placebo intravaginal inserts
214844292|NCT01119807|DEVICE|Intravenous access during OHCA|First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
214281989|NCT04353076|OTHER|Simulated heatwave exposure|Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.
214281990|NCT04353076|OTHER|Simulated heatwave exposure with mid-day cooling|Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
214281991|NCT02487693|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
214281992|NCT02487693|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
214281993|NCT02599129|DRUG|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
214470227|NCT03801876|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
214470228|NCT03801876|OTHER|Quality-of-Life Assessment|Ancillary studies
214470229|NCT03801876|OTHER|Questionnaire Administration|Ancillary studies
214470230|NCT03801876|DRUG|FOLFOX regimen|Folinic acid, flurouracil and oxaliplatin
214470231|NCT03801876|DRUG|CAPOX regimen|Capecitabine combined with oxaliplatin
214470232|NCT03801876|DRUG|Docetaxel|Chemotherapy
214470233|NCT03801876|DRUG|5FU|Chemotherapy
214470234|NCT06186830|OTHER|Validity and reliability analyses|Validity and reliability analyses will be performed using Cognitive Exercise Therapy Approach Biopsychosocial Questionnaire, Patient Health Questionnaire-9, Patient Health Questionnaire-15, Generalized Anxiety Disorder-7, Short Form-36, Craniomandibular Pain and Disability Inventory, and Mandibular Function Impairment Questionnaire.
214470235|NCT06505356|PROCEDURE|Prostate biopsy|Transrectal prostate biopsy
214470236|NCT02658825|DRUG|JNJ-63623872 2400 milligram (mg)|Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
214470237|NCT02658825|DRUG|JNJ-63623872 3000 mg|Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
214470238|NCT02658825|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
214470239|NCT02658825|DRUG|Moxifloxacin|Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
214470240|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 2400 mg)|Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
214470241|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 3000 mg)|Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
215032343|NCT02881827|OTHER|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
215032344|NCT05576649|OTHER|Task difficulty adaptation according to Arvaneh et al. (2019)|The task difficulty in the P300 speller training will be adapted according to Arvaneh et al. (2019).
215032345|NCT05576649|OTHER|Random task difficulty|The task difficulty in the P300 speller training is chosen randomly.
214281994|NCT02599129|DRUG|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
214281995|NCT02515058|DEVICE|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
214281996|NCT02515058|DEVICE|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
214470242|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 Dose)|Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
214470243|NCT02658825|DRUG|Placebo (Matching with Moxifloxacin)|Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
214470244|NCT05199454|OTHER|Exercise training|Aerobic exercise training using a treadmill or a bike for 12 weeks, 3 times per week, 60 minutes per session.
214470245|NCT05287633|DRUG|Esomeprazole|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
214844293|NCT01119807|DEVICE|Humeral IO insertion|First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
214844294|NCT01119807|DEVICE|TIbial IO insertion|First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
214844295|NCT04130178|DRUG|Nerve block|block of the digital nerves in rheumatoid arthritis patient
214844296|NCT04130178|DRUG|Saline injection|subcutaneous saline injection
214844297|NCT01124695|DRUG|tamoxifen|PO
214844298|NCT04632524|DRUG|MgSO4|Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
214844299|NCT05403619|DIAGNOSTIC_TEST|Diagnostic test|Cardiac Ultrasound in order to explore the causes of shortness of breath
214844300|NCT01284855|DRUG|Antivenom|Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
214844301|NCT02668822|DRUG|ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)|Medicated vaginal ring
214844302|NCT02668822|DRUG|Placebo vaginal ring|Placebo vaginal ring
214844303|NCT02668822|DRUG|Ibuprofen|Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
214844304|NCT05707455|OTHER|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
214844305|NCT01358539|BEHAVIORAL|Pain education|Patients receiving pain education
214844306|NCT00970255|PROCEDURE|Lingual Frenulum frenotomy|Clipping the lingual frenulum with scissors
215032346|NCT05576649|OTHER|Task difficulty adaptation according to iterative learning controller|The task difficulty in the P300 speller is determined by an iterative learning controller.
214281997|NCT03808493|DRUG|TAK-438 OD|TAK-438 OD tablet
214281998|NCT03808493|DRUG|TAK-438|TAK-438 tablet
214281999|NCT01125865|DEVICE|SEMS insertion|Self-expandable metallic stent will be inserted for malignant hilar obstruction.
214282000|NCT01125865|DEVICE|DLS insertion|DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
214282001|NCT06146452|OTHER|Not|Not
214470246|NCT05287633|DRUG|Placebo|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
214844307|NCT00970255|PROCEDURE|Sham frenotomy|Sham Clipping the lingual frenulum with scissors
214844308|NCT05633914|DRUG|Tucidinostat|20mg, po., biw, q3w
214844309|NCT05633914|DRUG|nab-paclitaxel|125mg/m2, d1, iv.drip, q7d
214844310|NCT01477814|BEHAVIORAL|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
214470247|NCT06470243|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214470248|NCT06470243|PROCEDURE|Bone Scan|Undergo bone scan
214470249|NCT06470243|DRUG|Cabazitaxel|Given IV
214844311|NCT01477814|BEHAVIORAL|chart reminder, educational mat'ls, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
214844312|NCT01477814|BEHAVIORAL|CR,ed mat'ls, FIT, phone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
214282002|NCT02743559|DEVICE|Mechanical Stimulation using whole body vibration|All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
214282003|NCT05711940|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
214282004|NCT00070278|DRUG|cyclophosphamide|
214282005|NCT00070278|DRUG|epirubicin hydrochloride|
214282006|NCT00070278|DRUG|gemcitabine hydrochloride|
214470250|NCT06470243|DRUG|Carboplatin|Given IV
214470251|NCT06470243|PROCEDURE|Chest Radiography|Undergo chest x-ray
214844313|NCT05389709|DRUG|Iberogast (STW5-II, BAY98-7410)|Survey without any intervention assigned in the study.
215032347|NCT05632393|DRUG|Daridorexant|Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
215032348|NCT02757430|PROCEDURE|Cardiac Ablation|
215032349|NCT03986892|BEHAVIORAL|Physical Activity|Physical Activity
215032350|NCT06570265|DEVICE|GBR membrane|GBR procedure is a technique often used in conjunction with dental implants to enhance the success and stability of the implant. This technique involves using barrier membranes to protect the bone graft or defect site from the rapid proliferation of surrounding soft tissues. In this clinical investigation resorbable, collagen membrane will be used.
215032351|NCT05454865|DIETARY_SUPPLEMENT|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack PO bid for 2 treatment cycles (1 cycle = 3 weeks)
215032352|NCT05454865|DIETARY_SUPPLEMENT|Placebo|Placebo 1 1pack PO bid for 1 treatment cycle (1 cycle = 3 weeks) and followed by Jin Si Herbal Tea 1 pack PO bid for the 2nd treatment cycle
215032353|NCT03469895|DRUG|ibrutinib ou idelalisib|treatment by ibrutinib or idelalisib for autoimmune cytopenia
215032354|NCT00473174|DRUG|Ramipril|Dosing on awakening versus bedtime
215032355|NCT00473174|DEVICE|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
215032356|NCT05910424|OTHER|collection of saliva, gum fluid and/or dental plaque samples|Non-invasive sampling of dental plaque, crevicular fluid and/or saliva, using an examination probe, paper tips and saliva swabs
215032357|NCT04817956|DRUG|Atezolizumab|drugs used outside indication, based on biomarker
215032358|NCT03196778|RADIATION|Low Dose Radiotherapy|Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks
215032359|NCT00892866|OTHER|Cytology Specimen Collection Procedure|Correlative studies
215032360|NCT00892866|OTHER|Laboratory Biomarker Analysis|Correlative studies
215032361|NCT01256047|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
215032362|NCT06040398|BEHAVIORAL|JUMPSTART exercise program|The intervention is an early mobilization protocol (JUMPSTART). Four interactive exercise videos, at different intensity levels, include a variety of stretches and exercises designed to improve the full body mobilization of post-TAVR patients. Videos have been developed in consultation with a physiotherapist and cardiac rehabilitation specialist and have been piloted for initial acceptability by patients at the Hamilton General Hospital. The videos will be freely accessible to all eligible patients and their caregivers (regardless of participation in the research study) online (www.hhscebi.ca/projects/jumpstart). A written version of the exercise program, with photographs and detailed instructions, will also be made available. Additional exercise videos will be developed based on patients' needs and feedback received.
215032363|NCT01516372|DRUG|GEn 1200mg|1200 mg of Gen administered as a single dose
215032364|NCT01516372|DRUG|Gen 6000 mg|6000 mg of Gen administered as a single dose
215032365|NCT01516372|DRUG|GEn Placebo|Placebo to match GEn Tablets
215032366|NCT01516372|DRUG|Moxifloxacin Placebo|Placebo to match Moxifloxacin
214282007|NCT00070278|DRUG|paclitaxel|
214282008|NCT00070278|GENETIC|comparative genomic hybridization|
214282009|NCT00070278|GENETIC|microarray analysis|
214282010|NCT00070278|GENETIC|mutation analysis|
214282011|NCT00070278|PROCEDURE|conventional surgery|
214282012|NCT00070278|PROCEDURE|neoadjuvant therapy|
214282013|NCT02464462|DIETARY_SUPPLEMENT|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
214282014|NCT02464462|OTHER|Placebo|Rice powder pills
214282015|NCT04167202|PROCEDURE|Hydrogen-rich water|Hydrogen-rich water (one hydrotherapy every 4 hours)
214282016|NCT04167202|PROCEDURE|RICE|RICE protocol
214282017|NCT00846430|DRUG|Peg-Interferon alpha-2b|age and weight dependant
214282018|NCT00846430|DRUG|Celecoxib (Celebrex)|age and weight dependant
214282019|NCT00846430|DRUG|Temozolomide (temodar)|age and weight dependant
214282020|NCT00846430|DRUG|Vincristine Sulfate (Oncovin)|age and weight dependant
214470252|NCT06470243|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214470253|NCT06470243|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214470254|NCT06470243|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214470255|NCT06470243|DRUG|Prednisone|Given PO
214844314|NCT01522950|DRUG|Nebivolol|5 mg daily or 10 mg daily
214844315|NCT01522950|DRUG|atenolol|25 mg daily or 50 mg daily
214844316|NCT01522950|DRUG|placebo|one tablet daily
214844317|NCT03109119|DRUG|Sevoflurane|The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
214844318|NCT03109119|DRUG|Propofol|These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
215032367|NCT01516372|DRUG|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
215032368|NCT06268106|BEHAVIORAL|Graphic novel visualization|Patients in interventional group do receive and visualize graphic novel, which is more informative than standard informed consent.
215032369|NCT01933763|DRUG|REGN1193|
215032370|NCT01933763|OTHER|Placebo|
214282021|NCT00084721|DRUG|celecoxib|
214470256|NCT04433338|OTHER|14-day Low Calorie Diet|"Participants will be asked to:~* Use 4 (women) or 5 (men) Modifast meal replacements per day.~* Daily consume a minimum of 250 grams of (raw) vegetables without dressing.~* Daily consume 100 grams of lean meat/fish/meat analogues.~* Daily consume two spoons of liquid oil~* Daily drink at least 2.0 litres of water, coffee or tea without added sugar or milk, bouillon or sugar-free drinks."
214470257|NCT03173235|DIAGNOSTIC_TEST|Plasma level of vitamin D|messurement of plasma level of vitamin D
214470258|NCT05492175|OTHER|robotic practice|According to the group assignment, participants will start from the BMT proximal mode (i.e., forearm pronation-supination movement), and then the distal mode (i.e., wrist flexion-extension movement), and vice versa. Each participant is expected to complete approximately 400 to 600 repetitions of the proximal mode session (i.e., forearm movements) and another 400 to 600 repetitions of the distal mode session (i.e., wrist movements), respectively.
214470259|NCT05492175|OTHER|kinetic exergaming|All of the participants in experimental and comparison groups will practice on the exergaming for 30 minutes per session. To avoid fatigue, the four domains of programs will be provided alternately. Each program will be executed for approximately 5 minutes with warm-up, followed by a 2-minute break between programs, and cool-down. The games will be selected and adapted according to the personal capacity, the occupational role, and the rehabilitation goal of each participant. The investigators will illustrate and guide the participants to play the games and stand next to them to prevent falls from occurring. To increase security, we will place a handrail in front of the participant for support as needed.
214470260|NCT05492175|OTHER|conventional therapy|Participants in control group will receive 30 minutes of therapist-mediated conventional therapy per session. The training protocols of the conventional therapy will use occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their personal needs. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The content of the functional tasks will be decided together by participants and therapists, such as picking up and putting down items in a box, lifting two soft drink bottles, and so on.
214470261|NCT06769282|BEHAVIORAL|Experimental: Intervention (SPARE) plus Treatment as Usual|5 components: (1) Social skills training, including selecting healthy friends and partners, (2) Problem solving with emphasis on positive outcomes of nonaggressive solutions, (3) Awareness of domineering behavior in self and conflict resolution skills, (4) emotion Regulation, and (5) psycho-education on ACEs and trauma. Each session will include 30 minutes of didactic instruction on the component with developmentally engaging activities to illustrate concepts and an individually tailored 15-minute narrative and mindfulness activity, which may address a traumatic memory depending on youth need and receptivity.
214470262|NCT06769282|BEHAVIORAL|Treatment as Usual (TAU)|Treatment As Usual consists of individual, family, occupational, and art therapy, social skills and emotion regulation groups, and therapeutic milieu. All staff and clinicians are trained in the Incredible Years Parenting Program, which aims reduce behavioral problems, enhance children's social and emotional competence, and improve child-parent interactions. Children also receive individualized treatment tailored for their needs (e.g., sleep interventions). Behavioral health needs staff (BHS) facilitate children's skill acquisition and generalization, implement individualized behavior contingency programs, and assist caregivers with parenting strategies via daily check-ins
214470263|NCT06111365|DEVICE|CHLOE|"the system will provide to the user a CHLOE™ score, which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5"
214470264|NCT05198635|DEVICE|local cerebral oxygen saturation|minimum SctO2, SctO2 drop/rise defined by different thresholds, and area under/above the threshold
214470265|NCT05152628|DRUG|Tacrolimus granules|Oral
214470266|NCT05152628|DRUG|Tacrolimus granules|Oral
214470267|NCT05801068|DRUG|Factor Xa Inhibitor|Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
214470268|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
214844319|NCT01795079|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
214844320|NCT00978913|BIOLOGICAL|DC vaccine|DC vaccination, one vaccine biweekly
214844321|NCT02287324|PROCEDURE|Manipulation|
214282022|NCT00084721|DRUG|irinotecan hydrochloride|
214282023|NCT03258489|DEVICE|Transcutaneous nervous electric stimulation (TENS)|TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.
214844322|NCT02287324|PROCEDURE|Manual Contact|
214844323|NCT04953078|BIOLOGICAL|Baiya SARS-CoV-2 Vax 1|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
214282024|NCT03258489|DEVICE|Interferential electrical stimulation (IES)|The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)
214282025|NCT03258489|DEVICE|TENS and IES Placebo|Same protocol without electrical output.
214282026|NCT05571540|BIOLOGICAL|U-CAR-T Cells (LstCAR019)|"LstCAR019 will be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one: 1×10\^6 cells/kg;Dose level two: 2×10\^6 cells/kg;Dose level three: 5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of LstCAR019 at the best dose verified in the first portion."
214282027|NCT00661882|OTHER|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
214282028|NCT00661882|OTHER|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
214282029|NCT00661882|OTHER|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
214282030|NCT00661882|PROCEDURE|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
214282031|NCT01029795|DRUG|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
214282032|NCT01029795|DRUG|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
214282033|NCT01029795|DRUG|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
214282034|NCT03684811|DRUG|FT-2102|FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
214282035|NCT03684811|DRUG|Azacitidine|Azacitidine will be administered per the site's standard of care.
214282036|NCT03684811|BIOLOGICAL|Nivolumab|Nivolumab will be administered per the site's standard of care.
214282037|NCT03684811|DRUG|Gemcitabine and Cisplatin|Gemcitabine and cisplatin will be administered per the site's standard of care.
214282038|NCT02190357|DRUG|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
214282039|NCT03445338|DRUG|K0706|Study
214282040|NCT03445338|DRUG|K0706|Study
214282041|NCT03445338|DRUG|K0706|Study
214282042|NCT02177305|DRUG|0.02 mcg tiotropium solution|
214282043|NCT02177305|DRUG|0.04 mcg tiotropium solution|
214282044|NCT02177305|DRUG|0.08 mcg tiotropium solution|
214282045|NCT02177305|DRUG|0.16 mcg tiotropium solution|
214282046|NCT02177305|DRUG|0.28 mcg tiotropium solution|
214282047|NCT02177305|DRUG|0.40 mcg tiotropium solution|
214906697|NCT03512769|DEVICE|Restful Jaw Device|The Restful Jaw device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. If needed, the dental assistant also holds the jaw in a slightly forward position to maintain an open airway. This device replicates the dental assistant in holding the jaw during dental procedures.
214282048|NCT02177305|DRUG|Placebo solution|
214282049|NCT05864001|BEHAVIORAL|STAR-C mobile app|Digital coaching intervention for healthy lifestyle
214282050|NCT03591198|BEHAVIORAL|Qigong Training|Eight-Section Brocades
214282051|NCT03591198|BEHAVIORAL|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
214282052|NCT03425123|OTHER|Regenerative Endodontic Procedure (REP)|Regenerative Endodontic Procedure (REP) involves disinfection of the root canal with the use of acombination of three antibiotics including ciprofloxacin, metronidazole, minocycline. At the second visit, the patient is evaluated for resolution of signs or symptoms of an acute infection and if none then bleeding is induced, the site covered with a plug and the patient is evaluated at follow up.
214282053|NCT03398681|DRUG|Ferric carboymaltose|Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]
214282054|NCT03398681|DRUG|Placebo (Normal saline)|Normal saline (0.9% weight/volume (w/v) NaCl)
214282055|NCT03398681|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Cardiac magnetic resonance including T2\* and T1-mapping sequences
214282056|NCT03862820|DIAGNOSTIC_TEST|dynamic ultrasound|move abdomen with ultrasound probe to predict intraabdominal adhesions
214906698|NCT04412967|DEVICE|Dynamic ultrasound-guided short-axis needle tip navigation|placement of peripheral venous catheters using ultrasound guided technique
214470269|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:~* For children \>/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~* For children \< 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~* Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols\*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
214470270|NCT00619879|OTHER|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
214470271|NCT00619879|RADIATION|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.~Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) \< 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:~* Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count~* Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
214470272|NCT05105009|DRUG|Furosemide Injection|"* Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~* Oral creatinine load using 5 grams of creatinine"
214470273|NCT05105009|DRUG|Creatinine Powder|5g of creatinine (Sigma) in 250 ml of water was taken orally
214470274|NCT05105009|DRUG|Iohexol|5 ml iohexol (Omnipaque) intravenously
214470275|NCT05920863|PROCEDURE|TACE|TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.
214470276|NCT05920863|DRUG|Tislelizumab, Lenvatinib|Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight \<60kg, 8mg/day; weight ≥60kg, 12mg/day.
214470277|NCT06108076|DRUG|Ketone Monoester (KE)|Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits
214470278|NCT03822312|DEVICE|DBT-TOBI|The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through
214470279|NCT03822312|DEVICE|MRI-TOBI|The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
214470280|NCT05233150|BEHAVIORAL|PriCARE/CARIÑO|PriCARE/CARIÑO is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE/CARIÑO uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE/CARIÑO includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. CARIÑO is the culturally adapted version of PriCARE for Spanish speaking participants.
214470281|NCT05409872|DIETARY_SUPPLEMENT|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
214470282|NCT05409872|OTHER|Placebo|The subject takes the placebo twice a day for three months.
214470283|NCT05928052|DEVICE|Transcutaneous Biopac Electrical Stimulator|A transcutaneous electrical stimulator sends low levels of electrical current through surface hydrogel electrodes directly to the spinal cord to improve function.
214470284|NCT05825768|DEVICE|Breast MRI|Breast Magnetic Resonance Imaging prior to breast conserving surgery with and without intravenous contrast agent.
214470285|NCT05825768|DIAGNOSTIC_TEST|standard breast imaging|The control group that receives standard preoperative imaging only (breast ultrasound and mammography)
214470286|NCT05086796|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~1. Triage~2. Engage, Assess, and Plan~3. Treat~4. Communicate and Coordinate~5. Follow up~6. Monitor"
214844324|NCT06260020|BEHAVIORAL|Comprehensive module for management of sleep disorders[Behavioral and pharmacological therapy]|"Development of module by Delphi method:components of Module include Behavioural intervention Modifying stimulus by change in location,using bedtime stories. Giving schedules to activities which interfere with sleep before bedtime. Using a bedtime pass to allow child to make a prefixed number of requests for parental attention while in bed.~Giving sleep items like cuddle toys to replace parental presence. Gradually delaying the bedtime so the child feels urge to sleep. Sleep hygiene by providing suitable environment to sleep, proper bedtime routine, sleep wake schedules Providing rewards for following good bedtime routine as positive reinforcement. Pharmacological intervention Sleep disorders due to underlying ENT, pulmonary conditions, to be treated as per standard protocol Usage of melatonin if required for sleep onset difficulty An 80%agreement over an intervention will be included in the module"
214844325|NCT05567939|OTHER|Natural course of disease|Sample and questionnaire collection
214906699|NCT04412967|OTHER|Standard technique of placing a PVC|Standard technique with palpation or Visual inspection of the pvc placement site
214282057|NCT06831812|BIOLOGICAL|AV-1959R (Abeta vaccine)|AV-1959R is an investigational adjuvanted vaccine designed to induce a targeted immune response against beta-amyloid (Aβ) to support the primary prevention of Alzheimer's disease and the treatment of asymptomatic preclinical Alzheimer's disease. It is administered intramuscularly (IM) at doses of 100 µg or 300 µg on Weeks 0, 4, and 14, in combination with the adjuvant.
214470287|NCT04813055|PROCEDURE|Therapeutic EUS|"1. EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~2. EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~3. EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~4. EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~5. EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~6. EUS-guided pancreatic duct drainage"
214470288|NCT04813055|PROCEDURE|Percutaneous Procedures|Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)
214470289|NCT04813055|PROCEDURE|Surgical Interventions|Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)
214470290|NCT04813055|PROCEDURE|non-EUS-based endoscopic procedures|Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
214470291|NCT05195281|PROCEDURE|Fine Needle Biopsy or Aspiration|A new sampling of the tumor will be performed after 4-6 months of neoadjuvant chemotherapy
214470292|NCT02795858|DRUG|Ramucirumab|
214470293|NCT02795858|DRUG|Somatostatin Analog|
214470294|NCT06242756|PROCEDURE|Bladder catheterization|Patients placed in the catheterized group will have an indwelling catheter placed after anesthetic has been administered. It would be removed at 12 hours post cesarean section.
214470295|NCT06096103|DIETARY_SUPPLEMENT|placebo|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
214470296|NCT06096103|DIETARY_SUPPLEMENT|Botanical Extract Standardized for Iron + Vitamin C|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
214470297|NCT06096103|DIETARY_SUPPLEMENT|Botanical Extract Standardised for Iron|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
214470298|NCT02573779|OTHER|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
214470299|NCT04947124|DRUG|QLS-101ophthalmic solution 1%|QLS-101ophthalmic solution 1.0%
214470300|NCT04947124|DRUG|QLS-101ophthalmic solution 2%|QLS-101ophthalmic solution 2.0%
214470301|NCT06547216|DRUG|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
214844326|NCT05535439|PROCEDURE|EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle|Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle
214470303|NCT04231331|DRUG|Ertugliflozin|Ertugliflozin 5mg qd for 12 months
214470304|NCT04231331|DRUG|Placebo|Placebo qd for 12 months
214844327|NCT01052324|DRUG|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5\~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
214282058|NCT02618889|BEHAVIORAL|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
214282059|NCT00429273|DRUG|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
214282060|NCT00429273|DRUG|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
214470305|NCT05295732|DRUG|TMB-001|Topical TMB-001 0.05% QD/BID
214470306|NCT05295732|DRUG|Matching Vehicle|Topical Vehicle
214470307|NCT03760406|PROCEDURE|Opti-VIM targeting in DBS surgery|DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). The VIM coordinates will be calculated with the probabilistic model that have been developed.
214470308|NCT05665881|DRUG|Ephedrine|vasopressor
214470309|NCT05665881|DRUG|Phenylephrine|vasopressor
214470310|NCT05665881|DRUG|Norepinephrine|vasopressor
214470311|NCT05236647|DRUG|Morphine|Intravenous morphine infusion compared to subcutaneous morphine infusion
214470312|NCT06112054|DEVICE|Clotild Smart Guidewire System (CSGS)|In the current study, a commercially available CE marked guidewire will be used to direct a catheter through blood vessels while the Clotild® Smart Guidewire (study device) will only be used to perform electrophysiological measurements (via its sensors) in the blood vessels during peripheral endovascular procedures. It is thus designed for use as an adjunct to conventional angiographic procedure
214470313|NCT05090683|BEHAVIORAL|Mind-body mobile application|Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
214470314|NCT04750252|BIOLOGICAL|StroMel|Autologous MSC
214282061|NCT01438957|DRUG|Dexmedetomidine hydrochloride|Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
214282062|NCT01438957|DRUG|Placebo|
214282063|NCT01186679|PROCEDURE|laminectomy|surgical laminectomy with glial scar resection
214282064|NCT01186679|PROCEDURE|Intrathecal|direct into the CSF through lumbar puncture
214282065|NCT00374790|DRUG|Ferrous sulfate|
214282066|NCT06055647|GENETIC|immunohistochemical approach|Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.
214282067|NCT02115789|BEHAVIORAL|Visual Analog Scale|"Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being normal skin and 10 being the worst scar imaginable."
214282068|NCT01506167|DRUG|Bevacizumab|Bevacizumab was administered as part of standard first-line treatment
214282069|NCT01506167|DRUG|Capecitabine/Oxaliplatin|Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
214282070|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Oxaliplatin|Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
214282071|NCT01506167|DRUG|Capecitabine|Capecitabine was administered along with bevacizumab as part of standard first-line treatment
214282072|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Irinotecan|Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
214282073|NCT01506167|DRUG|Fluorouracil +/- Folinic Acid|Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
214282074|NCT02603614|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
214282075|NCT02603614|DRUG|Placebo|Placebo control
214282076|NCT05240053|OTHER|enhanced recovery programe|Early postoperative analgesia , early oral intake , early mobilization , early removal of nasogastric tube \& drains if any. The patients in this group started clear fluid once they awaked from anesthesia , a full liquid diet on first postoperative day , normal diet on second day provided that there was no vomiting or abdominal distension. The patients in this group were instructed for early ambulation \& encouraged to stay out of the bed for 4 hours on first day postoperative , 6 hours in following day , 8 hours on subsequent days. Also they were encouraged to walk the length of 3 meters once on first day postoperative , twice on day 2 \& three times on subsequent days. Regarding analgesia in this group postoperatively , they were received fentanyl via an epidural catheter.
214282077|NCT04752150|OTHER|Analgesia management; group ESPB and RIB|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
214282078|NCT02632955|DRUG|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
214282079|NCT02632955|PROCEDURE|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
214282080|NCT00144963|DRUG|Vincristine Sulfate Liposomes Injection|Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
214282081|NCT00144963|DRUG|Dexamethasone|Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
214844328|NCT05685524|DIAGNOSTIC_TEST|DNA methylation test|Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.
214282082|NCT04897932|DEVICE|RS - WP06|Ad hoc use of handheld urinal
214282083|NCT02615587|DRUG|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
214282084|NCT05790629|PROCEDURE|endo-sequence putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
214282085|NCT05790629|PROCEDURE|neo-MTA putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
214282086|NCT02495168|DRUG|Generic Budesonide/Formoterol Fumarate Dihydrate|Oral inhalation, generic formulation of the brand-name product.
214282087|NCT02495168|DRUG|Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)|Oral inhalation, brand-name product.
214282088|NCT02495168|DRUG|Placebo|Oral inhalation, no active ingredient.
214282089|NCT01410786|PROCEDURE|Conventional Instrumentation|Standard Oxford surgical instruments
214282090|NCT01410786|PROCEDURE|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
214282091|NCT05090137|OTHER|Diuretics|As per group descriptions
214282092|NCT05867745|OTHER|Interview|As previously specified
214282093|NCT05867745|OTHER|Survey|As previously specified
214844329|NCT02860819|DRUG|Veliparib|Veliparib 250mg BID, continuously
214844330|NCT02860819|DRUG|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
214844331|NCT02860819|DRUG|Carboplatin|Carboplatin AUC = 4, day 1
214282094|NCT05867745|OTHER|Letter to a friend (autoethnography)|As previously specified
214282095|NCT06281600|DIETARY_SUPPLEMENT|Human milk oligosaccharide|5g daily dose of HMOs.
214282096|NCT06281600|DIETARY_SUPPLEMENT|Maltodextrin placebo|5g daily dose of maltodextrin.
214282097|NCT05921305|DRUG|MTX|MTX (5mg/m\^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
214470315|NCT06440395|BEHAVIORAL|Behavioural: Small Steps for Big Changes Diabetes Prevention Program|The 4-week behaviour change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 4-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the YMCA). The supervised session will include brief behavioural counselling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
214470316|NCT05698355|OTHER|Telerehabilitation Treatment|Telerehabilitation includes self-massages for pelvic floor muscle, sex education, breathing, myofascial releasing with wand, and pelvic floor relaxing exercises.
214470317|NCT06534372|PROCEDURE|Open cardiac surgery with sternotomy|Factors affecting the occurrence of chronic pain in patients undergoing open cardiac surgery with sternotomy will be investigated.
214470318|NCT06799572|OTHER|massage|"Hands will be washed with hand soap and rubbed with disinfectant before the procedure.~* The head of the bed is raised by 30°-45° in the incubator.~* The baby is placed face down.~* Vaseline is applied to the hands.~* The 15 minute session will consist of three 5 minute phases. Phase 1 will be tactile stimulation phase, Phase 2 will be kinesthetic stimulation and Phase 3 will be I Love You technique.~* In the tactile stimulation phase, the infant is turned to the prone position and a stroking motion (12 strokes in approximately 5 seconds) will be applied with moderate pressure in 1-minute intervals, from the top of the head to the neck and back to the top of the head, from the neck to the shoulder, from the neck to the shoulder, from the upper back to the waist and back to the upper back, from the thigh to the foot and both legs, from the shoulder to the hand and from both arms to the shoulder.~* In the kinesthetic stimulation phase, the infant is placed in the supine position and eac"
214470319|NCT05022342|OTHER|alpelisib plus fulvestrant|Prospective observational study. There is no treatment allocation. Patients administered alpelisib plus fulvestrant, that have started before inclusion of the patient into the study will be enrolled.
214470320|NCT06300281|BEHAVIORAL|Neuromuscular Exercise|A Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization
214470321|NCT06300281|BEHAVIORAL|Aquatic Exercise|The exercise program will begin with a 10-minute warm-up period, including straight, sideways, back walking, cycling without equipment on the parallel bar, lower extremity strength exercises, standing on tiptoes and pressing on the heels, weight transfer, resistant exercises with auxiliary devices, calisthenic exercises, hamstring and quadriceps femoris stretching. It will end with a cooling period including exercises.
214470322|NCT06601101|DRUG|Insulin|Insulin eye drops in the postoperative prescription for corneal crosslinking
214470323|NCT06601101|DRUG|Placebo eye drops of 0.5% Methylcellulose|Placebo eye drops of 0.5% Methylcellulose in the postoperative prescription for corneal crosslinking
214470324|NCT03085719|DRUG|Pembrolizumab|Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells
214470325|NCT03085719|RADIATION|Radiation|Radiation is used to shrink the cancer
214470326|NCT06503406|DEVICE|SupraSDRM®|SupraSDRM® Bidegradable Matrix Wound Dressing is a tri-polymber, Biodegrable dermal covering manufactured by PolyMedics Innovations, GmbH.
214470327|NCT06503406|DEVICE|NovoSorb® BTM|NovoSorb® BTM absorbable synthetic wound dressing, PolyNovo Biomaterials, K172140
214470328|NCT04032847|BIOLOGICAL|ATL001|ATL001 infusion
214470329|NCT04032847|DRUG|Pembrolizumab|Checkpoint inhibitor
214282098|NCT05921305|DRUG|Corticosteroid|Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
214282099|NCT00934830|DRUG|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
214282100|NCT00934830|OTHER|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
214470330|NCT06620770|OTHER|questionnaires|Morisky and SF12 Questionnaires delivery at inclusion, 6, 12 and 18 months
214470331|NCT05055648|RADIATION|Photon Radiotherapy|nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
214470332|NCT05055648|RADIATION|Proton Radiotherapy|nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
214470333|NCT03213665|DRUG|Tazemetostat|Given PO
214470335|NCT02831959|DEVICE|NovoTTF-200M device|
214470336|NCT02831959|OTHER|Best Standard of Care|
214470337|NCT05892744|DRUG|Sertraline|50-200mg/day
214470338|NCT03056573|DEVICE|Transaortic TAVR Implant|Transaortic TAVR implant
214282101|NCT04339439|DEVICE|Vessel loop (FDA product code FZZ)|The intervention will be a vessel loop placed below sutures to raise the sutures from the skin of the palm.
214282102|NCT03294902|DEVICE|Pedra Tissue Perfusion Monitor|This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
214282103|NCT00727025|DEVICE|wound closure device (Steri-Strip™)|wound closure with steri-strip S
214282104|NCT01785927|OTHER|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
214470339|NCT03056573|DEVICE|Subclavian /Axillary TAVR implant|Subclavian /Axillary TAVR implant
214470340|NCT06158607|BEHAVIORAL|Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders|Provision of PrEP information through 4 counseling sessions, prevention navigation, and nurse practitioner prescribed PrEP in an addiction treatment setting.
214470341|NCT06158607|OTHER|Standard of care treatment|Participants in substance use treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
214470342|NCT02698579|GENETIC|No interventional drug product utilized in this follow-up study|"Participants received a single IV infusion of Lenti-D Drug Product (also known as elivaldogene autotemcel or eli-cel) in either parent Study ALD-102 or ALD-104.~The objectives of this long-term follow-up study are to assess long-term safety and efficacy following completion of participation in parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant are conducted in this study."
214470343|NCT06000657|DRUG|Vemliver tablet|Chronic Hepatitis B Patients Who Pretreated with Entecavir switching to Vemliver tab (Tenofovir Alafenamide Hemitartrate)
214470344|NCT06000657|DRUG|Baracross Tablet|Chronic Hepatitis B Patients Who Pretreated with Entecavir continuting treatement with Baracross Tablet
214470346|NCT05296005|DRUG|Capecitabine|Given PO
214470347|NCT05296005|DRUG|Docetaxel|Given IV
214470348|NCT05296005|DRUG|Fluorouracil|Given IV
214470349|NCT05296005|DRUG|Leucovorin|Given IV
214470350|NCT05296005|DRUG|Oxaliplatin|Given IV
214470351|NCT05296005|RADIATION|Radiation Therapy|Undergo radiotherapy
214470352|NCT05296005|PROCEDURE|Surgical Procedure|Undergo surgical resection
214470353|NCT05715229|DRUG|Nivolumab|Immunotherapy
214470354|NCT05715229|DRUG|Ipilimumab|Immunotherapy
214282105|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
214282106|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
214470355|NCT05715229|DRUG|Carboplatin|Chemotherapy
214470356|NCT05715229|DRUG|Paclitaxel|Chemotherapy
214844332|NCT05171764|DEVICE|Additional Gemstone Spectral Imaging (GSI) cardiac scan|After the subject undergoes the clinically prescribed cardiac Computed Tomography (CT) scan for their diagnostic purposes, the investigational Gemstone Spectral Imaging (GSI) scan will be conducted following the diagnostic CT scan utilizing the same contrast administration.
214470357|NCT05715229|DRUG|Pemetrexed|Chemotherapy
214470358|NCT02658279|DRUG|Pembrolizumab|
214470359|NCT04946032|OTHER|Epidural catheter|The epidural catheter length will vary, either 4 cm or 5 cm into the epidural space.
214470360|NCT03598894|OTHER|Ambulatory blood pressure measurements|Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
214470361|NCT06110273|BEHAVIORAL|Fit for Duty-mobile|Fit for Duty-mobile participants will receive self-regulatory support and behavior change techniques via an initial core intervention delivered through a native smartphone app (includes connected device data, 10 weekly lessons, weekly tailored feedback) and 4 coaching calls (weeks 1, 4, 8, and 16). App based tailored feedback and messaging will continue through 2 years. Optional 4-week refresher e-campaigns are offered every 6 mos. after the initial core intervention. Participants choose to follow either a Small Changes approach or a Large Changes approach and may choose to switch approaches over the 2 years, if desired.
214470362|NCT06110273|BEHAVIORAL|m-Health Control|Participants receive digital tools and education on weight gain prevention behaviors at baseline.
214470363|NCT03776253|BEHAVIORAL|Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components)|Attend CFS
214470364|NCT03776253|OTHER|Questionnaire Administration|Ancillary studies
214844333|NCT02524184|DRUG|sildenafil|sildenafil 100 mg per day for 7 days.
214282107|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
214282108|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
214282109|NCT00549965|DRUG|Risedronate Sodium|
214282110|NCT06178939|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.
214470365|NCT06138470|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
214470366|NCT06138470|DIETARY_SUPPLEMENT|Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
214470367|NCT06138470|DIETARY_SUPPLEMENT|Saffron and Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
214470368|NCT06138470|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Food supplements are taken during 6 weeks by healthy volunteers
214470369|NCT06244992|DRUG|PTT-936|Eligible patients will receive single-agent PTT-936 administered per orally (PO).
214470370|NCT06244992|DRUG|Combination of PTT-936 and anti-PD-1/L1 therapy|Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).
214470371|NCT04689256|DEVICE|MR-010|MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat.
214470372|NCT04867278|PROCEDURE|External Beam Radiation (XRT)|Patients that undergo surgical fixation of an acetabular fracture will receive debridement and a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery.
214470373|NCT04867278|PROCEDURE|Debridement|Gluteus minimus debridement in the OR
214470374|NCT04939688|RADIATION|Conventional dose AND ultra low-dose CT scanning in the search for cranial lesions|As well as undergoing the usual, conventional radiation dose CT scan, these patients will also undergo ultra low-dose CT scanning in the search for cranial lesions.
214470375|NCT05981040|DRUG|ZYIL1 capsules 25 mg and 50 mg Placebo|ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
214470376|NCT05981040|DRUG|ZYIL1 capsules 50 mg and 25 mg Placebo|ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
214470377|NCT05981040|DRUG|ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg|ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
214470378|NCT05981040|DRUG|Matching placebo 25 mg and Matching placebo 50 mg|Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
214470379|NCT06095375|DRUG|Regorafenib|Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.
214470380|NCT06095375|DRUG|Temozolomide|"Following a 3+3 design, in cohort A three patients will be administered temozolomide 150-200 mg/m2 for 5 consecutive days every 28 days until 6-12 cycles and regorafenib daily for 21 days, with a 1-week washout period at dose of 80 mg (level 1), 120 mg (level 2), or 160 mg (level 3) (regorafenib 40 mg- level -1). As a general rule, one cycle will last 28 days (day 1-28); however, in the event of treatment prolongation, the cycle period will be extended.~In cohort B,During concomitant therapy phase: temozolomide 75 mg/m2/die for 42 (max 49 days) consecutive days (concomitant with radiation therapy)."
214470381|NCT06224712|BEHAVIORAL|Arogya Sangama|Using human-centered design, the investigators will work wit the community to develop a prototype Arogya Sangama model to identify methods to bring GPTF and HWC service providers to create ideas, systems, processes, services, and delivery strategies for the GPTFs. They will help identify and prioritize interventions and address barriers to usability. There will also be capacity building of GPTFs to implement the interventions identified.
214470382|NCT05401838|BEHAVIORAL|Group Brief Cognitive-Behavioral Therapy (G-BCBT)|G-BCBT comprises 12, 90 minute sessions organized in three phases: (1) emotion regulation, (2) cognitive flexibility, and (3) relapse prevention. The first session will be a tailored individual session focusing on person-specific crisis response planning and developing the participant's suicide mode. Sessions 2 through 5 feature treatment goal setting, followed by teaching skills in stimulus control, mindfulness, relaxation, a reasons for living task, and survival kit. Sessions 6 through 10 provide opportunities for improving cognitive flexibility via cognitive-behavioral exercises such as ABC worksheets, challenging questions, patterns of problematic thinking worksheets, coping cards, and activity planning. The third phase of treatment focuses on relapse prevention, and encompasses the last two sessions of treatments where group participants demonstrate mastery of the skills learned in treatment and practice successfully navigating a future stressful situation.
214470383|NCT05401838|BEHAVIORAL|Dialectical Behavior Therapy (DBT) Skills Group|DBT comprises 24 weekly group therapy sessions each lasting 90 minutes. DBT sessions include worksheets and skills practice activities. The DBT protocol entails three phases as follows. Phase I (8 weeks) covers a two-week mindfulness orientation and a six-week distress tolerance module. Distress tolerance skill building includes paired muscle relaxation, distraction, and radical acceptance. Phase II (nine weeks) entails a two-week mindfulness module followed by seven weeks of emotion regulation skill building. Emotion regulation content includes a model of describing emotion and a pleasant events checklist. Phase III (7 weeks) includes two-week mindfulness and orientation module, followed by five weeks of interpersonal effectiveness training. Interpersonal effectiveness training approaches include clarifying goals in interpersonal situations, guidelines for keeping relationships, and self-respect. Mindfulness, cutting across modules, addresses review of concepts such as Wise Mind.
214470384|NCT05104463|DRUG|CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107|CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
214470385|NCT04004442|DRUG|Avelumab|Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)
214470386|NCT04004442|DRUG|AVB-S6-500|AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)
214282111|NCT06178939|PROCEDURE|intervention group|For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
214282112|NCT02352402|DRUG|Ticagrelor|
214470387|NCT01885689|DRUG|clofarabine|Given IV
214282113|NCT02352402|DRUG|Placebo|
214282114|NCT04106960|OTHER|No Intevention Used|N/A as in the study does not have intervention in place. It is exploring the relationships between the social and physical features of the environment and participation through using standardized outcome measures.
214282115|NCT04013334|DRUG|MTG201|MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
214282116|NCT04013334|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 480 mg by IV infusion every 4 weeks
214282117|NCT02269241|DRUG|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
214282118|NCT01487551|DRUG|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
214470388|NCT01885689|DRUG|melphalan|Given IV
214470389|NCT01885689|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
214470390|NCT01885689|DRUG|tacrolimus|Given IV or PO
214470391|NCT01885689|DRUG|sirolimus|Given PO
214282119|NCT03556150|OTHER|Manual Therapy protocol|"This protocol consists of:~* Six minutes of joint's mobilisation (two minutes of each technique).~* Nine minutes of ischemic pressure . Three minutes per muscle in this order: temporal muscle, masseter muscle and lateral pterygoid. Choosing the two most painful trigger points.~* Three minutes of trigemino's nerve stretching."
214282120|NCT03556150|OTHER|Effleurage|"The protocol consists of:~* Five minutes in temporal muscle.~* Ten minutes superficial massage in the neck and cheek of the most painful joint.~* Five minutes of effleurage in the cheek, with the index finger inside the mouth and the thumb outside."
214282121|NCT02270957|BIOLOGICAL|Abatacept|
214282122|NCT02270957|OTHER|Placebo|
214282123|NCT00136656|DRUG|antibiotic|cephalosporine by oral route : cefixime
214282124|NCT00136656|DRUG|antibiotics|cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
214282125|NCT04305262|DEVICE|Wireless continuous vital parameter monitoring|The patients included in this study will have continuous, wireless monitoring of vital parameters during the first four days of acute admission
214282126|NCT03466697|OTHER|Glucose injection/Normal saline injection|Before each PET scan, subject will be injected either glucose or normal saline.
214282127|NCT02302001|DEVICE|Silicone Implant|
214282128|NCT03018821|DRUG|Standard - Yinchengao Decoction plus Ganlu Detoxification Pill|Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.
214282129|NCT03018821|DRUG|Entecavir or Tenofovir|Western drug for anti-HBV such as Entecavir and Tenofovir
214282130|NCT03018821|DRUG|Standard - Ge Xia Zhu Yu Decoction|Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
214282131|NCT03018821|DRUG|Advanced - Supplemented Taohong Huazhuo Decoction|Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
214470392|NCT01885689|OTHER|Pharmacological Study|Correlative studies
214470393|NCT04484428|DRUG|K-285|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
214470394|NCT04484428|DRUG|Menthol|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
214470395|NCT05267470|DRUG|Bemarituzumab|Intravenous (IV) infusion
214282132|NCT03018821|DRUG|Standard - Chaihu Shugan San|Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
214282133|NCT03018821|DRUG|Advanced - Soothe the liver and regulate qi Decoction|Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
214282134|NCT03018821|DRUG|Standard - Xiaoyao powder|Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
214470396|NCT05267470|DRUG|Docetaxel|IV infusion
214470397|NCT05267470|DRUG|Pembrolizumab|IV infusion
214470398|NCT05267470|DRUG|Carboplatin|IV infusion
214470399|NCT05267470|DRUG|Paclitaxel|IV infusion
214470400|NCT05267470|DRUG|Nab-paclitaxel|IV infusion
214844334|NCT02524184|DRUG|placebo|an identical placebo per day for 7 days
214844335|NCT01059721|PROCEDURE|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
214282135|NCT03018821|DRUG|Advanced - Supplemented Ganbi Decoction|Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
214282136|NCT03018821|DRUG|Standard - Yiguan Decoction|Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
214282137|NCT03018821|DRUG|Advanced - Supplemented Zimu Dan|Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
214282138|NCT03018821|DRUG|Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus|Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
214282139|NCT03018821|DRUG|Advanced - Guifu Erxian Decoction|Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
214282140|NCT03018821|DRUG|Advanced - Supplemented Ganji Decoction|Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
214282141|NCT01694030|OTHER|Attachment security priming|
214470401|NCT04967248|OTHER|Alpelisib|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
214470402|NCT04967248|OTHER|Fulvestrant|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
214470403|NCT05796154|DEVICE|ear blood pressure monitor|The ear blood pressure monitor is a biometric monitoring device that collects blood pressure non-invasively from the ear.
214470404|NCT06026488|OTHER|Other|real world treatment and survival of DLBCL patients in China
214470405|NCT04480736|DRUG|Placebo|Matching placebo will be administered orally.
214470406|NCT04480736|DRUG|JNJ-64281802 High dose|JNJ-64281802 high dose will be administered orally.
214470407|NCT04480736|DRUG|JNJ-64281802 Medium dose|JNJ-64281802 medium dose will be administered orally.
214470408|NCT04480736|DRUG|JNJ-64281802 Low dose|JNJ-64281802 low dose will be administered orally.
214470409|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen X|JNJ-64281802 dosing regimen X will be administered orally.
215032371|NCT04244734|OTHER|Usual care treatment|"All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
214282142|NCT01125683|DRUG|AZD1446|Capsule, oral single and multiple dose
214282143|NCT01125683|DRUG|Donepezil|Capsule, oral and single dose
214282144|NCT01125683|DRUG|Placebo|Capsule, oral and single dose
214282145|NCT00292266|DRUG|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
214282146|NCT00292266|DRUG|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
214282147|NCT05261074|OTHER|No intervention|No intervention (retrospective study)
214282148|NCT00859053|DRUG|BMS-790052|Capsules, Oral, 30 mg, single dose, one day
214282149|NCT01679860|PROCEDURE|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:~* CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~* HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~* Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
214282150|NCT01679860|DRUG|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:~* CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
214282151|NCT02130973|DRUG|Standard Clinical Practice Regimen|Standard Clinical Practice Regimen
214282152|NCT02130973|DRUG|Experimental Cyclic Regimen|Experimental Cyclic Regimen
214282153|NCT02302820|OTHER|Advance Care Planning Intervention|"ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids."
214282154|NCT02459353|DRUG|Dapagliflozin|
214470410|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Y|JNJ-64281802 dosing regimen Y will be administered orally.
214470411|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Z|JNJ-64281802 dosing regimen Z will be administered orally.
214470412|NCT06181357|PROCEDURE|Endoscopic lung volume reduction in 2 stages|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the experimental group, patients will be treated according to Limoges' treatment algorithm (2 stages)
214282155|NCT02459353|DRUG|Placebo|
214282156|NCT00157534|DRUG|Celgosivir|
214282157|NCT00489541|DEVICE|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
214282158|NCT01898611|DRUG|Ghrelin|Ghrelin
214282159|NCT01898611|DRUG|Placebo|Saline will be used as a placebo
214282160|NCT02221947|DRUG|Bryostatin 1|25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
214470413|NCT06181357|PROCEDURE|Endoscopic lung volume reduction in 1 stage|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the control group, the entire lobe will be treated during one procedure
214470414|NCT06730022|DRUG|MTX-001 (Dermacyte Liquid)|Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.
214282161|NCT02221947|DRUG|Placebo|Placebo, single dose via intravenous infusion over 1 hour.
214282162|NCT06298500|DEVICE|hernia repair surgery|In recent years, atraumatic mesh fixation with tissue adhesive has increasingly become the method of choice. It is the recommended mesh fixation method by the International Hernia Society Guidelines. In this study patients with inguinal hernia are treated by placing a prosthetic mesh in one of the layers of the abdominal wall to cover the weakness, the mesh is fixed by Histoacryl LapFix,
214282163|NCT06576674|DIETARY_SUPPLEMENT|Dietary Fiber + Green Tea Extract|10g fiber + 750mg green tea supplement will be administered at experimental arm
214282164|NCT06576674|OTHER|Alcohol|alcohol administered up to a target BAC 60mg% during lab sessions
214282165|NCT06576674|OTHER|Aspartame Placebo Supplement|Aspartame sweetener mixed with water + aspartame capsule
214282166|NCT02359760|PROCEDURE|Piezocision|Flapless corticotomies
214282167|NCT04673422|DRUG|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
214470415|NCT03825588|BEHAVIORAL|ASAP (As Safe As Possible)|ASAP (As Safe As Possible) is a brief intervention for adolescents hospitalized for suicide risk that focuses on the development of a safety plan, teaching emotion regulation and distress tolerance skills, along with 1-2 post-discharge follow-up calls to encourage adherence to use of the safety plan and to outpatient treatment.
214470416|NCT03825588|BEHAVIORAL|BRITE smart phone app|BRITE is a smart phone app that aims to support daily emotion regulation and a safety plan that is personalized to the needs and preferences of each adolescent.
214470417|NCT03825588|BEHAVIORAL|TAU (treatment as usual)|TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.
214470418|NCT03576612|BIOLOGICAL|AdV-tk|Given IT
214470419|NCT03576612|DRUG|Valacyclovir|Given PO days 1-14; 1-3 days post surgery
214470420|NCT03576612|RADIATION|Radiation|Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks
214470421|NCT03576612|DRUG|Temozolomide|Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)
214470422|NCT03576612|BIOLOGICAL|Nivolumab|day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks
214470423|NCT03576612|OTHER|Laboratory Biomarker Analysis|correlative studies
214470424|NCT05810012|DRUG|PENG block|10ml of 0.125% isobaric bupivacaine injected
214470425|NCT05810012|DRUG|FICB Block|20ml of 0.125% isobaric bupivacaine injected
214470426|NCT07063550|OTHER|exposure to microplastic|Microplastic content in cancerous and paracancerous tissues
214470427|NCT07063355|OTHER|Stripping Massage Technique:|"* The back of the neck and shoulder were uncovered.~* Controlled and steady pressure was administered using the thumb along the entirety of the tense trapezius muscle, moving from origin to insertion and perpendicular to the muscle fibers, for approximately 3 minutes, twice weekly over a period of 4 weeks.~* The pressure was progressively raised with each subsequent stroke, based on tolerance level."
214470428|NCT07063355|OTHER|Post-Isometric Relaxation (PIR)|"* During the PIR intervention, the patients rested in a supine position with their necks tilted to the side, away from the affected side, placing the upper trapezius muscle fibers in a stretched position.~* A moderate isometric contraction, around 75% of the patient's maximum effort, was performed by the upper trapezius and maintained for 5 seconds, followed by a 3-second relaxation phase.~* The therapist then gently mobilized the cervical spine to a new range of motion barrier.~* This sequence was repeated four times per session."
214470429|NCT07062536|DRUG|Oxaliplatin, 5FU, leucovorin|Administered as a single regimen every 2weeks
214470430|NCT07062536|DRUG|Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,|Administered alternately every 2weeks
214470431|NCT07062146|OTHER|reiki|Reiki sessions for 30 minutes, on Day-7 before the surgery and on D15 after the surgery
214470432|NCT07062146|OTHER|Sham (No Treatment)|Sham sessions for 30 minutes, on D-7 before the surgery and on D15 after the surgery,
214470433|NCT07062939|OTHER|postural drainage with ACBT|postural drainage and ACBT for 2 times a day for 30 min for 4 weeks.
214470434|NCT07062939|OTHER|flutter with ACBT|flutter with active cycle breathing technique for 30 min. for 4 week and 2 times a day.
214470435|NCT06783933|DIAGNOSTIC_TEST|surgical or interventional validation|surgical or interventional validation
214470436|NCT07063121|BEHAVIORAL|Shadow's Edge mobile app|A mobile application adapted for Colombian youth that uses interactive storytelling, journaling, and emotional regulation activities to promote subjective well-being and resilience.
214470437|NCT07063121|BEHAVIORAL|Guide to Self-Awareness (GSEA)|A printed guide developed to promote emotional insight, mindfulness, self-awareness, and social-emotional skills through structured reflection activities. Designed to be used alongside the Shadow's Edge app.
214470438|NCT07062302|DEVICE|photobiomodulation|"The output of the photobiomodulation device is listed as below:~* Irradiation size: 15 cm × 10 cm~* Dual-wavelength: 660 nm + 850 nm~* Optical power density: 10 - 15 mW/cm2~* Dose density: 6J/cm2"
214470439|NCT07063108|DRUG|Esketamine hydrochloride|Intravenous infusion of esketamine: after induction, a single dose of 0.25 mg/kg before skin incision，and continuous 0.125 mg/kg/h until 30 min before surgery was stopped.
214470440|NCT07063108|DRUG|Saline|after induction, a single intravenous infusion of an equal amount of 0.9% saline before skin incision, followed by a continuous infusion at the same rate as the test group until 30 min before surgical cessation.
214470441|NCT07062523|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga- FAPI will be used to image lesions of Sjögren's syndrome by PET/ CT.
214470442|NCT07063524|DEVICE|Electrical stimulation|Electrical stimulation with controlled heat during the intervention
214470443|NCT07062016|OTHER|Non-Interventional Study|Non-interventional study
214844336|NCT04310306|DEVICE|Thrombectomy using EmboTrap II|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, using a stent retriever, contact aspiration EmboTrap II. The number of thrombectomy attempts is at the operator's discretion. Combination of balloon guide catheter or intermediate catheter is recommended.
214282168|NCT04673422|DRUG|Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
214470444|NCT07062263|DRUG|Trastuzumab|Inj Trastuzumab given in a dose of 8mg/kg intravenously over 90 mins as first dose and subsequent doses at a dose of 6mg/kg intravenously over 30-60 minutes in 3 weekly cycle along with standard of care chemotherapy
214470445|NCT07062263|DRUG|Chemotherapy|Gemcitabine + cisplatin OR Gemcitabine-cisplatin-Nab-Paclitaxel given as a standard of care, chemotherapy as per the institutional guidlines
214470446|NCT04230681|DRUG|Hydromorphone|Patients will be randomized to one of two opioids for the treatment of post-operative pain.
214470447|NCT04230681|DRUG|Fentanyl|Fentanyl
214844337|NCT05184699|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Patients with psoriatic disease will be randomized to receive food supplement Endocalyx for 4 months.
214844338|NCT05184699|DIETARY_SUPPLEMENT|Placebo|Patients with psoriatic disease will be randomized to receive placebo for 4 months.
214844339|NCT03264820|DEVICE|Laser Doppler|\- Laser measurements at the level of each finger at 47 °C and at ambient temperature
214844340|NCT03264820|DEVICE|Laser speckle|\- Laser measurements at the forearm
214844341|NCT03264820|BEHAVIORAL|pain evaluation|Visual scale assesment pain
214282169|NCT04390191|DEVICE|Continuous Positive Airway Pressure|CPAP at fixed pressure (8-10cm H20) for 72 hours continuously (except for daily activities such as eating, personal activities and breaks for ambulation etc).
214282170|NCT04669652|DEVICE|Piezo-ICSI|During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjection of a sperm with less psychical stress applied on the oocytes than by the conventional technique.
214282171|NCT02321878|DRUG|liraglutide|"Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given."
214282172|NCT01867437|DRUG|Placebo|Sterile solution (vehicle) for subcutaneous infusion
214282173|NCT01867437|DRUG|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
214282174|NCT04927260|DRUG|Patient treated by Avapritinib in real life|"The patients included are treated with Avapritinib as part of their care. There is no change in treatment associated with this study.~Patients must regularly complete various questionnaires: FACT-G, FACT-COG, and a neuropsychiatrist or a trained physician will give them the MoCA."
214282175|NCT03336671|PROCEDURE|Endoscopic Sinus surgery|Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.
214282176|NCT03336671|PROCEDURE|Adenoidectomy|Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
214282177|NCT02781597|DRUG|Tranexamic Acid|Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
214282178|NCT02781597|DRUG|Placebo|Patients will receive 0.9% normal saline
214282179|NCT01616667|PROCEDURE|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
214282180|NCT01774604|DRUG|Indomethacin|100 mg Indomethacin PR x 1
214282181|NCT01774604|DRUG|Placebo|
214282182|NCT00509015|DRUG|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S\&25mg P/20 kg, 1 day, single dose
214282183|NCT00509015|DRUG|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
214282184|NCT00509015|DRUG|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
214282185|NCT00509015|DRUG|placebo tablets|3 days of lactose tablets (160mg) albochin
214470448|NCT06844526|OTHER|Hoping Exercise|Week 1 Hopping to the sides on two legs (hands-free) 3 × 10 repetitions Hopping to front and back on two legs (hands-free) 3 × 10 repetitions Hopping to the front on two legs (hands-free) 3 × 10 repetitions Week 2 Hopping to the sides on two legs (hands on the chest) 2 × 15 repetitions Hopping to front and back on two legs (hands-free) 2 × 10 repetitions Hopping to the sides on one leg (hands-free) 5 × 4 repetitions Week 3 Hopping to the sides on one leg (hands on the chest) 3 × 10 repetitions Hopping zig-zag on two legs (hands-free) 2 × 10 repetitions Week 4 Hopping zig-zag on one leg (hands-free) 2 × 10 repetitions Hopping through squares on two legs (hands-free) 2 × 10 repetitions Week 5 Hopping in 8-shape on two legs (hands-free) 2 × 10 repetitions Hopping through squares on one leg (hands-free) 2 × 10 repetitions Week 6 Hopping through squares on one leg (hands on the chest) 2 × 10 repetitions Hopping in 8-shape on one leg (hands-free) 2 × 10 repetitions
214844342|NCT03264820|OTHER|Blood pressure and heart rate|Measurement of blood pressure and heart rate
214282186|NCT03384095|DRUG|Hyaluronic Acid (HA)|Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks
214282187|NCT03384095|OTHER|Placebo|Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks
214844343|NCT01188265|DRUG|Valproate|
214844344|NCT01188265|DRUG|Dextromethorphan 60 mg per day|VPA plus dextromethorphan 60 mg per day
214844345|NCT01188265|DRUG|Placebo|VPA plus placebo
214844346|NCT01188265|DRUG|Dextromethorphan 30 mg|VPA \& Dextromethorphan 30 mg per day
214844347|NCT03235609|DRUG|Fentanyl|fentanyl used with propofol for sedation
214282188|NCT02954731|BEHAVIORAL|UP-CBT|"Psychotherapy in groups based on the Unified Protocol a third generation CBT-type psychotherapy"
214282189|NCT02954731|BEHAVIORAL|Standard-CBT|Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
214844348|NCT03235609|DRUG|Ketamine|ketamine used with propofol for sedation
214844349|NCT06200428|OTHER|sleep support pillow|A sleep support pillow will be used in this study.
214282190|NCT05806281|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
214282191|NCT00564772|DRUG|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
214282192|NCT01312272|DRUG|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
214282193|NCT01312272|DRUG|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
214282194|NCT05927506|BEHAVIORAL|Other|Observational study of behavior cognitive and motor control
214282195|NCT02034214|BEHAVIORAL|Life skills education|The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
214282196|NCT02034214|OTHER|Reproductive health services|All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
214282197|NCT02034214|BEHAVIORAL|Economic livelihoods|The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
214282198|NCT04281810|DEVICE|transcutaneous electric diaphragm stimulation|The electrodes were placed on the parasternal region beside the xiphoid process; and the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was set as biphasic waves, frequency of 30 Hz, pulse width of 400 μs, and rise time of 0.7s.
214282199|NCT03978832|DRUG|PERSERIS|PERSERIS is an extended-release SC injectable suspension administered once-monthly
214282200|NCT03978832|DRUG|Risperidone|Oral risperidone
214282201|NCT01752998|BEHAVIORAL|Treating Opioid Patients' Pain and Sadness (TOPPS)|
214282202|NCT01752998|BEHAVIORAL|Health Education|
214282203|NCT01727297|DEVICE|REVEAL Implantable Cardiac Monitor|
214282204|NCT02042183|DRUG|Lubiprostone|12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
214282205|NCT02042183|DRUG|Placebo|0 mcg soft capsules of placebo for oral administration
214282206|NCT03609632|OTHER|Dietary Supplement: Glucose|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
214282207|NCT01615185|DRUG|full-dose amisulpride|amisulpride 800mg/d
214282208|NCT05823129|BEHAVIORAL|Tele-rehabilitation caregiver empowerment enhanced post- discharge rehabilitation directive|The intervention group will receive an implemented TUG test-based telerehabilitation program. The TUG test-based telerehabilitation involves patients routinely doing two TUG tests by themselves twice daily. Each patient will be provided with a unique link to the TUGstopwatch, a prerecorded video outlining instructions on how to properly conduct a TUG test, and support and guidance for patients and caregivers throughout the study period.
214282209|NCT05574790|OTHER|annual follow up|Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality
214282210|NCT04080401|DEVICE|Game-based rehabilitation exercise|4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
214282211|NCT04080401|OTHER|Conventional brochures of rehabilitation exercise|4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
214282212|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
214282213|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
214282214|NCT01192516|BEHAVIORAL|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
214282215|NCT01192516|BEHAVIORAL|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
214282216|NCT03874247|DRUG|pelubiprofen 45mg|bid for 3 days after meal
214282217|NCT03874247|DRUG|pelubiprofen placebo|bid for 3 days after meal
214282218|NCT01256008|BEHAVIORAL|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
214282219|NCT01256008|BEHAVIORAL|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
214282220|NCT03641430|OTHER|Supportive care with OCT product|Participants will apply over-the-counter product for a certain period with or without light challenge. We will perform clinical assessments of the skin associated with product application as well as assess these changes with and without light challenge. Skin biopsies will be obtained following standard medical practice and will be used to analyze skin markers related to photoaging, pigmentation, oxidative stress, and other dermatologic conditions.
214282221|NCT06652334|PROCEDURE|Spinal anesthesia|20 patients undergoing spinal anesthesia
214282222|NCT06652334|PROCEDURE|Erector spinae plane block|20 patients undergoing erector spinae plane block
214282223|NCT02846311|DEVICE|Flu Test|
214282224|NCT00318630|DRUG|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
214282225|NCT00318630|DRUG|Placebo|Subjects will also receive placebo oral tablet.
214282226|NCT05458843|PROCEDURE|Fluid replacement|Participants will drink Gatorade Zero ad libitum, up to 1 cup every 15 minutes.
214282227|NCT05458843|PROCEDURE|No fluid replacement|Participants will not be permitted to drink.
214282228|NCT02244606|DRUG|SCY-078|
214282229|NCT02244606|DRUG|Fluconazole|
214282230|NCT02244606|DRUG|Micafungin|
214282231|NCT00285454|PROCEDURE|Retrograde coronary venous delivery of cells.|
214282232|NCT04483271|DIETARY_SUPPLEMENT|300 mg of omega3-FA|"The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.~Baseline and follow-up serum levels of IL-1,IL-6, and TNF will be measured."
214282233|NCT02256189|DRUG|Sitagliptin|Sitagliptin 100 mg daily
214282234|NCT02256189|DRUG|Placebo|Placebo one tablet daily
214282235|NCT00119626|DRUG|NXY-059|
214282236|NCT02248103|PROCEDURE|Periosteal pedicle graft|Autogenous pedicle graft harvested from the periosteum
214282237|NCT02248103|BIOLOGICAL|Bioresorbable collagen membrane|Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
214282238|NCT02824952|DRUG|Tagrisso|taking orally everyday for 6 or 12 weeks.
214282239|NCT01905813|DRUG|INCB040093|Escalating doses starting at 100 mg every day (QD)
214282240|NCT01905813|DRUG|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
214282241|NCT01685034|BIOLOGICAL|"Allergy immunotherapy (allergy shots)"|
214282242|NCT00036712|PROCEDURE|management of therapy complications|
214282243|NCT00036712|PROCEDURE|pain therapy|
214282244|NCT01292434|BEHAVIORAL|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
214282245|NCT00378378|DRUG|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
214282246|NCT00378378|DRUG|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
214282247|NCT05698030|OTHER|Food allergy|Oral immunotherapy to pistachio
214282248|NCT05527340|DRUG|Iberdomide|Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO)
214282249|NCT05527340|DRUG|Dexamethasone|Dexamethasone 40 mg (PO) (or 20 mg (PO) if patient ≥ 75 years old) should be administered on the days 1, 8, 15 and 22 of every 4-week cycle.
214282250|NCT05527340|DRUG|Daratumumab|Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days).
214282251|NCT04902794|DEVICE|Light Emitting Diode|Blue light-emitting diode applied to the female genital region for eight minutes, for five sessions, one per week
214282252|NCT04902794|DEVICE|Sham Light Emitting Diode|Sham Blue light-emitting diode turned off applied to the female genital region for eight minutes, for five sessions, one per week
214282253|NCT00263601|BIOLOGICAL|Allergovit 6-grasses|Subcutaneous injections
214282254|NCT00263601|OTHER|Placebo|Subcutaneous injections
214282255|NCT03485339|DIAGNOSTIC_TEST|genome testing|blood sampling via venipuncture
214282256|NCT01084369|DRUG|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
214282257|NCT02295488|PROCEDURE|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
214282258|NCT02295488|BIOLOGICAL|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
214282259|NCT05884905|PROCEDURE|short hydration|NSS infusion prior to and following cisplatin administration within 6 hours
214282260|NCT05884905|PROCEDURE|conventional hydration|NSS infusion prior to and following cisplatin administration over 24 hours
214282261|NCT00407797|DRUG|Pregabalin|150 to 600 mg/day during 21 weeks
214282262|NCT01013376|DRUG|MC-1101|MC-1101 1.0%
214282263|NCT01013376|DRUG|Vehicle|Vehicle
214282264|NCT03803397|BIOLOGICAL|PV-001-DC|Patient-specific cellular therapeutic for cancer immunotherapy
214282265|NCT02535117|PROCEDURE|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
214282266|NCT02535117|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
214282267|NCT05722483|OTHER|Virtual Intensive Outpatient Program|Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
214282268|NCT04481932|DRUG|Trastuzumab combined with Pyrotinib and chemotherapy|"Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth"
214282269|NCT03612505|BEHAVIORAL|Mother groups using principles of UNICEF/World Health Organization's Care for Child Development|"The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~* Introduction (10 minutes)~* Lesson on \*Early Childhood Development\* topic (20 minutes)~* Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~* Observe caretakers one-on-one in play role with the child (25 minutes)~* Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future"
214282270|NCT00865696|DRUG|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
214282271|NCT00865696|DRUG|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
214282272|NCT00016185|DRUG|alvocidib|
214282273|NCT00016185|DRUG|docetaxel|
214282274|NCT00428311|DRUG|Metformin|
214282275|NCT00428311|DRUG|Ethynyl-estradiol plus cyproterone acetate|
214282276|NCT01437072|OTHER|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
214282277|NCT04332562|OTHER|dietary restriction (salt restriction)|salt restriction for one week after being diagnosed with hypertension
214282278|NCT03198117|DRUG|Huaier Granule|a Chinese traditional medicine
214282279|NCT03198117|OTHER|placebo|placebo
214282280|NCT05823961|DEVICE|Cross-linked hyaluronic acid eye drops|Cross-linked hyaluronic acid (CLHA)-based eyedrops
214282281|NCT01783301|DRUG|FSH|
214282282|NCT00169598|PROCEDURE|positron emission tomography|
214282283|NCT04478539|DEVICE|Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter|"Admitted patients will receive at least 1 cycle of extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (Baxter, IL, USA). The number of cycles of blood purification is determined based on multiple biochemical, immunological, coagulation parameters, radiological imaging and overall clinical condition.~The patient is connected to the Prismaflex® oXiris® system via a double lumen catheter placed in the femoral vein or vena subclavia.~Flow rates will be maintained as follow; effluent dose 35 mL/Kg/h, dialysate 14 - 16 mL/Kg/h, blood 150 mL/min, replacement 16 -18 mL/Kg/h; patient fluid removal is tailored to the individual's volume status, ≈ 100 - 250 mL/h.~The oXiris® extracorporeal and organ support modality will be chosen according to the patient's kidney function; continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) or slow continuous ultrafiltration (SCUF)."
214282284|NCT04987346|OTHER|Walking on an instrumented treadmill|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
214282285|NCT04987346|OTHER|Walking on an instrumented treadmill while dual-tasking|Participants aged between 6 and 17 years will be asked to walk at comfortable walking speed while playing either a cognitive (Stroop Color and Word Test) or motor (requiring arm swing) game.
214282286|NCT04849598|OTHER|Oxygen therapy|Oxygen therapy during ESWTs and Stair Walking Test: one test using the prescribed constant oxygen flow and one using an automatic oxygen titration system. SpO2 target range: 90 - 94%
214282287|NCT00553644|DRUG|Bortezomib|Given IV
214282288|NCT00553644|OTHER|Laboratory Biomarker Analysis|Correlative studies
214282289|NCT00553644|DRUG|Lenalidomide|Given PO
214282290|NCT02205112|DRUG|Nemonoxacin|
214282291|NCT02205112|DRUG|Levofloxacin|
214282292|NCT01980368|OTHER|Educational Intervention|Receive readings and attend book club
214282293|NCT01980368|BEHAVIORAL|Exercise Intervention|Receive Tai Chi Easy class, DVD, and exercise manual
214282294|NCT01980368|OTHER|Questionnaire Administration|Ancillary studies
214282295|NCT01795209|DRUG|Ranibizumab|"Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg~Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
214282296|NCT01795209|DEVICE|Sham injection|"Three monthly sham injections followed by retreatment (sham injections) as needed~Stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
214282297|NCT01795209|PROCEDURE|Rescue laser|"In the Lucentis group: performed if BCVA \< 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA \< 20/40 or CFT ≥ 350um from Month 3"
214282298|NCT02073552|DRUG|Polyethylene glycol 4000|\- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
214470449|NCT06844526|OTHER|Core Stability Exercises|Week 1 Bridging in face-down position 3 × 20 s Bridging in the supine position 3 × 20 s Side bridging (right and left) 3 × 20 s Week 2 Lifting the leg in supine position (knee bent) 3 × 20 repetitions Rising opposite hand and foot in quadriceps 3 × 20 repetitions Cross-crunch abdominal muscles 3 × 20 repetitions Week 3 Bridging on a physioball 3 × 20 repetitions Cobra exercise on a physioball 3 × 20 repetitions Superman exercise 3 × 20 repetitions Week 4 Sit-up on a physioball 3 × 20 repetitions Rotating the trunk in a sitting position using a physioball 3 × 20 repetitions Week 5 Lunge exercise with trunk rotation using a medicine ball 3 × 20 repetitions Bridging on a physioball (leg raising alternately) 3 × 10 repetitions on each leg Week 6 Lunge exercise (back leg on a physioball) 3 × 10 repetitions on each leg Superman exercise (alternately) 3 × 10 repetitions on each side
214470450|NCT01266096|DRUG|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
214470451|NCT07061938|DRUG|ACE1831|ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.
214470452|NCT07061938|DRUG|Lymphodepleting chemotherapy|Subjects assigned to receive lymphodepleting preconditioning (LDC) will receive chemotherapy cyclophosphamide ahead of ACE1831 administration.
214470453|NCT06149338|DEVICE|Macintosh laryngoscope|Macintosh laryngoscope has been the gold standard for endotracheal intubation since the middle of 20th century. During laryngoscopy and direct vision of the vocal cords, an endotracheal tube is passed into the trachea, establishing the airway.
214470454|NCT06149338|DEVICE|Vie Scope|Vie Scope is a laryngoscope, whose function is relied on Seldinger technique. Firstly, bougie is passed through the translucent barrel of Vie Scope under direct vision between the vocal cords and into the trachea. Then, Vie Scope is removed and an endotracheal tube is passed over the bougie, which will be finally removed. The inflation of the endotracheal tube's cuff is followed by ventilation and confirmation of the tube placement.
214470455|NCT06682130|DRUG|Group A：Patients with PR or ctDNA positivity after salvage treatment|"1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group A: 2.5mg day8~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6; Patients in Group A who intend to receive Glofitamab+ASCT will receive Glofitamab 2.5mg on day8 and start ASCT pretreatment on day15."
214470456|NCT06682130|PROCEDURE|Group B: Patients with CR and ctDNA negative after salvage treatment|Group B patients initiated ASCT treatment directly after evaluating the efficacy of salvage treatment
214470457|NCT06682130|DRUG|Group C: Patients with SD/PD after posterior treatment|"1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group C: cycle1 2.5mg day8, 10mg day15 cycle2 30mg day21~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6;~After two treatment cycles with Glofitamab, patients in group C had a PET-CT to assess efficacy. Those with partial remission proceeded to ASCT consolidation, those with complete remission chose between ASCT or Glofitamab maintenance, and those with stable disease or progressive disease exited the trial."
214470458|NCT05727761|DRUG|pioglitazone-metformin|Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks
214470459|NCT06554847|DRUG|611|subcutaneous injection
214470460|NCT06554847|DRUG|Placebo|subcutaneous injection
214470461|NCT06554847|DRUG|Topical corticosteroid|Topical
214470462|NCT06904612|DIETARY_SUPPLEMENT|Micronutrient fortified iodized salt|addition of folic acid, B12 and iron to iodized salt to be consumed daily and assess rise in serum levels.
214470463|NCT06934642|DRUG|Tirzepatide|The drug is being studied to better understand the biological effects of tirzepatide on MASLD.
214470464|NCT04362644|DRUG|PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714|Study participants will undergo PET/CT with the glucose analogue \[F-18\]FDG and the translocator protein (TSPO) ligand \[F-18\]DPA-714 in two separate imaging sessions.
214470465|NCT06628778|DRUG|Dalteparin|Dalteparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge
214470466|NCT05619367|DRUG|Odronextamab|
214470467|NCT05623787|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
214470468|NCT06249815|COMBINATION_PRODUCT|Misoprostol 200mcg Tab|ranscervical Foley catheter (silicone, size 20F with 30ml balloon)+Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
214282299|NCT02073552|DRUG|Macrogol 3350 plus ascorbic acid|\- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
214282300|NCT03782792|DRUG|Spesolimab|Solution for infusion
214282301|NCT03782792|DRUG|Placebo|Solution for infusion
214470469|NCT06249815|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
214470470|NCT06618014|DRUG|Toripalimab|Toripalimab was given 240 mg intravenously on day 1 of each 21-day cycle for 6 cycles.
214470471|NCT06618014|DRUG|Docetaxel|Docetaxel was administered at a dose of 75 mg/m2 on day 1 of each 21-day cycle for 6 cycles.
214282302|NCT06354595|DEVICE|Multidimensional Rehabilitation in the Metaverse|Using the multidimensional rehabilitation space in the metaverse, evaluate the platform after use.
214282303|NCT00919919|DRUG|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
214470472|NCT06618014|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 4 on day 1 of each 21-day cycle for 6 cycles.
214470473|NCT05172843|PROCEDURE|Surgical knee arthroplasty|"Surgery will be performed 3 months from inclusion in the trial (at week 13). The procedure and type of prosthesis and postoperative program will be at the discretion of the involved surgeon and the participating department.~Post-surgical care and rehabilitation will follow current clinical standards."
214470474|NCT05172843|BEHAVIORAL|Supervised weight loss|"The supervised intensive dietary weight loss program will be initiated 3 months from inclusion in the trial (at week 13) and lasts for 12 weeks.~The program includes full meal replacement by a standard liquid energy intake in a supervised dietary program. Participants will attend the nutrition department weekly. They will be weighed on a decimal scale, given nutritional and dietetic instructions by an experienced dietitian and formula diet products are handed in sessions of 1-2 h. The participants will be taught to make diet plans.~Following the 12 weeks intensive dietary weight loss program participants will be scheduled for two booster follow-up sessions with a dietician at weeks 39 and 51."
214470475|NCT03428646|DRUG|Dupilumab|Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.
214470476|NCT06230861|DIETARY_SUPPLEMENT|Quercetin|Quercetin tablets 500mg 1 x per day
214470477|NCT06230861|OTHER|Placebo|Placebo control 1 x blinded placebo tablet per day
214470478|NCT06778031|DRUG|SHR-A1811|SHR-A1811.
214470479|NCT06778031|DRUG|SHR-1316|SHR-1316.
214470480|NCT06778031|DRUG|SHR-8068|SHR-8068.
214470481|NCT05789394|BIOLOGICAL|Allogeneic Adipose-derived Mesenchymal Stem Cells|Receive IT
214470482|NCT05789394|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214470483|NCT05789394|PROCEDURE|Craniotomy|Undergo craniotomy
214470484|NCT05789394|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214470485|NCT05789394|PROCEDURE|Ommaya Reservoir Tap|Undergo Ommaya reservoir placement for collection of CSF
214470486|NCT05956314|DRUG|KM-001 cream 1% 12 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
214470487|NCT05956314|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort):~* The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~* Symptom-directed physical examinations will be performed at all other trial visits.~* Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination."
214282304|NCT00919919|DRUG|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
214470488|NCT05956314|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort. Vital signs will be measured in supine position after at least 5 minutes of rest.
214470489|NCT05956314|DIAGNOSTIC_TEST|Serum chemistry|Approx. 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments during screening, and on Days 1 (baseline), 7, 84 112, 140 or at an ET visit - where applicable, per cohort. Serum chemistry will include assessments of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.
214470490|NCT05956314|DIAGNOSTIC_TEST|Hematology|Approx. 5 mL whole blood will be collected for complete blood count (CBC) during screening, and on Days 1 (baseline), 7, 84, 112, 140 or at an ET visit - where applicable, per cohort. The CBC assessments will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute \[abs.\]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
214282305|NCT05273918|OTHER|cognitivo-comportmental therapy|15 workshops once a week during 90 minutes
214470491|NCT05956314|DIAGNOSTIC_TEST|Serology|Approx. 5 mL whole blood will be collected for serology assessments during screening. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
214282306|NCT05273918|OTHER|body mediation|15 workshops once a week during 90 minutes
214282307|NCT00645060|OTHER|high performance liquid chromatography|Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
214282308|NCT00645060|OTHER|pharmacological study|Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
214470492|NCT05956314|DIAGNOSTIC_TEST|Urinalysis|General urinalysis will be performed, by dipstick, during screening, and on Days 1 (baseline), 7, and 84, 112, and 140, or at an ET visit - where applicable, per cohort. At least 7 to 10 mL of urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
214906700|NCT00553839|DRUG|ketamine hydrochloride|Open label pharmacokinetic study to be conducted in infants and children presenting for medical procedures (eg., surgery or cardiac catheterization). After the start of the procedure, a 0.5 cc preload blood sample (T0) will be drawn from an IV line. Then a 2 mg/kg IV bolus of Ketamine will be administered over 5 minutes. Timed 0.5 ml blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus.
214282309|NCT00645060|PROCEDURE|radionuclide imaging|1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
214282310|NCT00645060|PROCEDURE|single photon emission computed tomography|2 days and 3-5 days post antibody infusion
214282311|NCT00645060|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
214282312|NCT01250275|OTHER|traditional canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
214282313|NCT01250275|OTHER|high oleic canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
215032372|NCT04244734|OTHER|New Treatment Protocol-MotoMED®|"Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
214282314|NCT01250275|OTHER|soybean oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.
214282315|NCT01250275|OTHER|high linoleic safflower oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.
214282316|NCT01250275|OTHER|coconut oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
214282317|NCT01250275|OTHER|traditional canola oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.
214282318|NCT01250275|OTHER|safflower oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
214282319|NCT05776498|PROCEDURE|immediate implant placement with particulate bone graft using the dual zone technique.|Tooth extraction and immediate implant placement as mentioned, then particulate bone graft will be packed in the gap between the implant and the buccal plate of bone and the tissue (dual zone), then will be covered by a customized healing abutment.
215032373|NCT02082977|DRUG|GSK2816126|GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
215032374|NCT02009787|DRUG|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 months
215032375|NCT02009787|DRUG|placebo tablets|2000 IU placebo tablets were taken daily for 6 months
215032376|NCT01535482|BEHAVIORAL|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
214282320|NCT05776498|PROCEDURE|immediate implant placement with connective tissue grafting|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supraperiosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
214282321|NCT03137290|DRUG|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
214906701|NCT02684864|OTHER|Non-interventional|
214906702|NCT01965756|DRUG|Metformin|
214906703|NCT01965756|DRUG|Placebos|
214906704|NCT02245399|BEHAVIORAL|A canola oil enriched mediterranean diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.
214906705|NCT02245399|BEHAVIORAL|A high wheat fiber diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants
214906706|NCT01898507|OTHER|Low nicotine cigarettes|15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.
214906707|NCT00425932|BIOLOGICAL|Rituximab|At Week 24 or any time up to Week 48 if the Patient DAS 28 \> 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
214906708|NCT00259870|DRUG|SB-773812|
214906709|NCT00259870|DRUG|Olanzapine|
214906710|NCT03340597|DRUG|F901318|F901318 tablet
214906711|NCT01659983|PROCEDURE|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
214906712|NCT05915663|OTHER|nasogastric tube and orogastric tube|nasogastric tube in period 1 and orogastric tube in period 2
214906713|NCT05915663|OTHER|orogastric tube and nasogastric tube|orogastric tube in period 1 and nasogastric tube in period 2
214282322|NCT03137290|DRUG|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
214282323|NCT01201018|DRUG|Oshadi D, Oshadi R|Oral administration
214282324|NCT01095783|PROCEDURE|physiotherapeutic intervention|Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
214282325|NCT01095783|PROCEDURE|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
214282326|NCT04004715|DIETARY_SUPPLEMENT|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
214282327|NCT04004715|DIETARY_SUPPLEMENT|Whey Protein|commercially available whey protein isolate
214282328|NCT04004715|DIETARY_SUPPLEMENT|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
214282329|NCT00772291|DRUG|pregabalin|pregabalin 150-600mg/day during 8 weeks
214282330|NCT00772291|DRUG|placebo|placebo drug during 8 weeks
214282331|NCT04022993|DRUG|Lantus Solostar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
214282332|NCT04022993|DRUG|Insulin RinGlar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
214282333|NCT04639375|BIOLOGICAL|Vaccinated with polio vaccine (IPV)|poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States
214282334|NCT04866225|DRUG|Oral [14C]PF-06865571|Oral radiolabeled PF-06865571
214282335|NCT04866225|DRUG|Oral PF-06865571|Oral PF-06865571
214282336|NCT04866225|DRUG|IV [14C]PF-06865571|IV radiolabeled PF-06865571
214282337|NCT05509920|OTHER|S-PRG barrier coat|S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
214282338|NCT03533868|DIAGNOSTIC_TEST|Point-of-care viral load monitoring test|For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
214282339|NCT00425295|BEHAVIORAL|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
214282340|NCT00814164|DRUG|clofarabine|IV
214282341|NCT00814164|DRUG|daunorubicin hydrochloride|IV
214282342|NCT00814164|GENETIC|cytogenetic analysis|Correlative study
214282343|NCT00814164|GENETIC|protein expression analysis|Correlative Study
214282344|NCT00814164|OTHER|immunologic technique|Correlative Study
214844350|NCT06436352|PROCEDURE|Capsulotomy and fixation|"Firstly, Guide wire insertion passing anterior to the GT and the neck is done. then passing a pointed Schanze 5 or 6 ± scalpel, under X-ray in AP-lateral views until reaching the capsule (intra trochanteric line). Aspiration of hematoma with suction was done.~Then we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
214282345|NCT00814164|OTHER|pharmacological study|Correlative Study
214282346|NCT00136799|DRUG|Fluvastatin|
214282347|NCT05336812|DRUG|Acalabrutinib|Given PO
214282348|NCT05336812|BIOLOGICAL|Obinutuzumab|Given IV
214282349|NCT05336812|DRUG|Venetoclax|Given PO
214282350|NCT00675493|DRUG|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
214282351|NCT01815593|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
214282352|NCT04395443|OTHER|medication reconciliation|the emergency clinical pharmacists will start medication reconciliation with the admitted patients and a full diseases and preadmission medications history will be taken.A comparison between the accuracy and completeness of drug history lists already presented in the profile and drug history taken by the clinical pharmacists to detect the medication discrepancies
214906714|NCT01704495|DRUG|AZD5069|AZD5069 oral capsules self-administered twice daily.
214282353|NCT06113809|DRUG|Palbociclib|"Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab"
214906715|NCT01704495|DRUG|Placebo|Placebo oral capsules self-administered twice daily.
214282354|NCT06113809|DRUG|Pembrolizumab|"Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)"
214282355|NCT02321800|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
214470493|NCT05956314|DIAGNOSTIC_TEST|ECG test|A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84, 112, and at day 140 (for Cohort 2), or at an ET visit - Where applicable. The measurement will be taken after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTc interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
214470494|NCT05956314|DIAGNOSTIC_TEST|Pharmacokinetics Assessments|"Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit.~* Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable.~* Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2."
214470495|NCT05956314|DIAGNOSTIC_TEST|Clinical global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator during screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort).~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
214470496|NCT05956314|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS) pain scale|"The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The score will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, 140, and at an ET visit - where applicable, per cohort).~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
214470497|NCT05956314|DIAGNOSTIC_TEST|Peak pruritus-numerical rating scale (PP-NRS)|"The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The scores will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort).~The PP-NRS was designed to measure peak pruritus, or worst itch, over the previous 24 hours based on the following question: On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?"
214470498|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows:~Since the start of the trial, my overall status has:~from, 1= very much improved to 7= very much worse"
214470499|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe"
214470500|NCT05956314|DIAGNOSTIC_TEST|Lesion photography|"High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022)."
214906716|NCT03886610|OTHER|Healthy controls|individuals without spinal cord injury
214906717|NCT03886610|OTHER|Subacute SCI patients|individuals with spinal cord injury ≥ 2 weeks
214906718|NCT03886610|OTHER|Chronic SCI patients|individuals with spinal cord injury ≥ 24 months
214906719|NCT06283381|DRUG|Esomeprazole|oral administration, tablets, 40 mg
214906720|NCT02338323|DRUG|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
215032377|NCT01535482|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
215032378|NCT00400140|DEVICE|Hyperopic lens|+3 D glasses
214282356|NCT02321800|DRUG|Imipenem/cilastatin|1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
215032379|NCT00001382|BIOLOGICAL|PROSTVAC|
215032380|NCT00945087|OTHER|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
214282357|NCT00982878|DRUG|Maraviroc|150mg twice daily
215032381|NCT04637061|COMBINATION_PRODUCT|intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis|Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.
214282358|NCT00064116|BIOLOGICAL|rituximab|Rituximab 375 mg/m² i.v. day 1
215032382|NCT04637061|DIAGNOSTIC_TEST|Air Leak test|This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.
214282359|NCT00064116|DRUG|CHOP regimen|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
214282360|NCT05536986|OTHER|Stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
215032383|NCT04637061|DIAGNOSTIC_TEST|Evaluation of the anastomotic rings|The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete
215032384|NCT04839640|OTHER|Bredent denture teeth|composite resin denture teeth
214282361|NCT03722966|DRUG|Varenicline|All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.
214282362|NCT03722966|DRUG|Oral Nicotine Replacement Therapy (NRT)|Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
214282363|NCT03722966|BEHAVIORAL|Medication Reminders|Half of study participants will be randomly assigned to receive automated medication reminders via their smartphones.
214282364|NCT03722966|BEHAVIORAL|Tobacco Cessation Counseling|All participants will be offered 6 weekly tobacco cessation counseling sessions with a Tobacco Treatment Specialist.
214282365|NCT01746745|DRUG|[^14C]-LY2940680|Administered as solution by mouth
214282366|NCT03132220|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive therapy is a 16 in-person hours intervention. The intervention in this population is designed to reduce symptoms of PTSD and BOS and increase resiliency scores.
214282367|NCT03132220|BEHAVIORAL|Book Club Active Control Intervention|Participants randomized to the book club active control intervention will meet for 16 in-person hours that are broken into sessions. Books will be assigned to read during homework time and discussions regarding the books will occur during the sessions. The time involved will be similar to the MBCT intervention.
214282368|NCT01169493|DEVICE|VVI-40|Pacing mode set to VVI-40, RV only pacing
214282369|NCT01169493|DEVICE|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
214282370|NCT01169493|DEVICE|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
214470501|NCT05956314|DRUG|KM-001 cream 1% 16 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
214470502|NCT05819710|DRUG|TS-142|Single dose of 5 mg of TS-142
214282371|NCT00791856|DRUG|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
214282372|NCT00791856|DRUG|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
214282373|NCT06127953|PROCEDURE|intermediate cleft rhinoplasty|intermediate cleft rhinoplasty using open approach and combined techniques of Tajima, Dibbell and Potter's Rhinoplasty
214282374|NCT05228132|DEVICE|Pristine™ Long-Term Hemodialysis Catheter|Placement of the Pristine™ Long-Term Hemodialysis Catheter Placement.
214282375|NCT05499312|DRUG|HKIIM-KU formula|Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
214282376|NCT05499312|DRUG|Placebo|Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
214282377|NCT01753271|OTHER|thoracic mobilization & shoulder mobilization & exercise|
214282378|NCT01753271|OTHER|shoulder mobilization & exercise|
214282379|NCT04144244|OTHER|MicroFluidic Sperm Sorting Chips|sperm selection of IUI treatment
214282380|NCT04144244|OTHER|Gradient-Density Centrifugation|sperm selection of IUI treatment
214282381|NCT02277756|DEVICE|thermode|thermal stimulation with test thermode
214282382|NCT01336764|BEHAVIORAL|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
215032385|NCT00741377|DRUG|BHQ880|
214282383|NCT01336764|BEHAVIORAL|Control|Unguided listening to radio/music.
214282384|NCT01357733|OTHER|Early interim FDG PET/CT after 1 cycle of R-CHOP|FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
214470503|NCT05819710|DRUG|TS-142|Single-dose of 10 mg of TS-142
214470504|NCT05819710|DRUG|Zopiclone|Single-dose of 7.5 mg of zopiclone
214470505|NCT05819710|DRUG|Placebo|Single-dose of placebo
215032386|NCT00741377|DRUG|Zoledronic acid|
215032387|NCT03464201|DRUG|Enzalutamide 40 MG|Enzalutamide 160 mg p.o. every day
215032388|NCT04355832|DRUG|Glucagon-like peptide-1|Infusion of Glucagon-like peptide-1
215032389|NCT04355832|DRUG|Placebos|Infusion of normal saline solution that will mimic Glucagon-like peptide-1
215032390|NCT06507722|DIAGNOSTIC_TEST|Timing of OGTT|In Aim 1, timing of oral glucose tolerance test will be altered.
215032391|NCT06507722|BEHAVIORAL|Timing of Standardized Meal|In Aim 2, timing of a standardized meal will be altered.
214282385|NCT05374434|OTHER|Conventional irrigation|The participant will be treated by manual irrigation with sodium hypochlorite NaOCl.
214282386|NCT05374434|DEVICE|Inertial cavitation|The participant will be treated by inertial cavitation-generating device, that generates hydraulic cavitation to clean root canals deeper and more effectively than other existing systems.
215032392|NCT03989284|BEHAVIORAL|Community-based depression interventions|We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
215032393|NCT00708981|OTHER|Multifactorial Intervention|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~1. BP control of \<130/80mmHg and renal protection with reduction of proteinuria to \<0.5g/day using therapy with ACE inhibitors and/or ARBs.~2. Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~3. Use of hypolipidemic therapy to achieve targets of LDL \< 70 mg/dl, HDL \> 40/50 mg/dl (M/F)and TG \< 200 mg/dl.~4. Patient enhanced self-management provided by combined diabetes-renal education curriculum.~5. Behavior and social intervention~6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
215032394|NCT02624479|DRUG|Sodium thiosulfate|oral administration of thiosulfate
215032395|NCT02689557|OTHER|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
215032396|NCT05852340|DRUG|Ritlecitinib|"ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)"
215032397|NCT05026801|DRUG|Azithromycin plus hydroxychloroquine|All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
215032398|NCT05694611|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
215032399|NCT05694611|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
215032400|NCT01955356|PROCEDURE|Scratching|Endometrial biopsy
215032401|NCT05363683|PROCEDURE|Squat Biofeedback|The intervention group will complete bilateral squats with each limb on a separate portable force plate. They will receive real-time visual feedback on a 32-inch screen during all squats. Biofeedback conditions will be progressed from simplest (ground reaction force only) to most complex (ground reaction force plus center of pressure). This intervention will be included in additional to standard care post-operative physical therapy.
215032402|NCT05363683|PROCEDURE|Standard Care|The intervention group will receive standard care post-operative physical therapy.
215032403|NCT04212923|BEHAVIORAL|Medical Dashboard based self-management intervention|Before the start of the intervention, chronic kidney disease patients and care providers will receive a face-to-face training session on the use of Medical Dashboard. To avoid contamination, Medical Dashboard will only be made accessible for participants in the intervention group via a secure password-protected registration process.
215032404|NCT05942040|OTHER|Tailored Palliative Care Information|This study test feasibility and acceptability of implementing tailored informational materials into clinician's discussions about CBPC with MA plan members who are eligible for the service.
215032405|NCT01903863|BIOLOGICAL|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
214470506|NCT02759172|BEHAVIORAL|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
214282387|NCT00113620|DRUG|Neurodex|
214470507|NCT04812093|DEVICE|Spectroscopic otoscope measurements|Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
214282388|NCT02837445|DEVICE|PHC ON|Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
214470508|NCT05322239|DEVICE|Intermittent Theta Burst Stimulation|iTBS parameters. A series of 20, 10 s trains will be presented over the course of the \~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
214470509|NCT05322239|DEVICE|Continuous Theta Burst Stimulation|cTBS parameters. A single 600 pulse cTBS train will be delivered during each stimulation session. The train will consist of 50 Hz bursts, repeated at intervals of 200 ms (5 Hz) for 40 sec.
214282389|NCT02837445|DEVICE|PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
214282390|NCT05883449|DRUG|AFM13|anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion
214282391|NCT05883449|DRUG|AB-101|NK cell therapy, intravenous infusion
214282392|NCT05883449|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy, intravenous infusion
214470510|NCT03142802|DIAGNOSTIC_TEST|Low-dose computed tomography (LDCT)|"In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance:~1. Normal LDCT:~   \- Patient continues on the study (i.e. continued surveillance)~2. Suspicious LDCT:~   \- Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study~3. Elevated serum tumour markers or other evidence of metastatic disease:~   * Patient goes off study"
214470511|NCT02773810|OTHER|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
214470512|NCT06428786|OTHER|Female Sexual Function Index|As part of the study, data on the socio-demographic characteristics of the individuals is collected by means of personal interviews using a questionnaire. The results of laboratory tests required for the diagnosis of PCOS will be taken from hospital records. The Female Sexual Function Index (FSFI), the Beck Depression Inventory and the KF-36 quality of life assessment form will be completed in person and the total scores will be analyzed taking into account four different PCOS phenotypes.
214470513|NCT06289166|DRUG|STSP-0601 for Injection|A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.
215032406|NCT04261985|BEHAVIORAL|healthy weight behaviors supported by web-based mobile phone application|Chorus is a mobile phone platform that provides texting, a web application, and an online community for mHealth interventions.Content is created using existing templates to insert text, images, pictures, audio, video clips, or any combination of these. Users interface with Chorus by clicking a hyperlink embedded in a text message sent to their phone to then access web-based interactions via prompts and clicks. Content was created in English and Spanish.
214470514|NCT05624125|OTHER|Beetroot juice|Two 70 ml beetroot juice drinks daily for 4 months.
214470515|NCT05624125|OTHER|Placebo|Two 70 ml placebo drinks daily for 4 months.
214470516|NCT02433379|DEVICE|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
214470517|NCT05656261|GENETIC|Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys|On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.
214470518|NCT06259305|OTHER|Creation of a memory track combined with the baby's heartbeat|This is as described above
215032407|NCT06570850|DRUG|Colistin Sodium Methanesulfonate|Intravenous colistin (colistinmethate soidum) 5 mg/kg/day intravenous (dosage will be adjusted according to creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
214470519|NCT06552299|OTHER|Laypersons|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
214470520|NCT06552299|OTHER|Health-Care Providers|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
214470521|NCT03996772|DRUG|Apixaban Oral Tablet|Factor Xa Inhibitor
214470522|NCT03996772|DRUG|Dabigatran|Direct Thrombin Inhibitor
214470523|NCT03996772|DRUG|Edoxaban Tablets|Factor Xa Inhibitor
214470524|NCT03996772|DRUG|Rivaroxaban|Factor Xa Inhibitor
214470525|NCT05433454|OTHER|Outreach From Navigators|Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.
214470526|NCT06543628|DRUG|Tadalafil 5mg|Participants will take tadalafil once daily at a dose of 5 mg for 6 months.
214470527|NCT06543628|DEVICE|LIPUS (Low Intensity Pulsed Ultrasound)|Participants will receive LIPUS treatment applied twice a week for 4 weeks, with the cycle repeated after a 4-week interval without treatment.
214470528|NCT06633835|BIOLOGICAL|protein subunit: Novavax COVID-19 vaccine|Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.
214470529|NCT06633835|BIOLOGICAL|Pfizer mRNA COVID-19 vaccine|Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.
214470530|NCT05727618|DRUG|Pituitrin|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
215032408|NCT06570850|DRUG|Colistin Sodium Methanesulfonate plus Fosfomycin|Intravenous colistin(dosage is same as colistin group) plus intravenous fosfomycin(dosage will be adjusted according to MIC and creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
215032409|NCT00220077|PROCEDURE|Endoscopy|
215032410|NCT04928638|BEHAVIORAL|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
215032411|NCT04928638|BEHAVIORAL|Written educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
214470531|NCT05727618|DRUG|normal saline|Intravenous infusion of normal saline at the same dose and speed
214470532|NCT06230848|PROCEDURE|Multisensory Early Oral Administration of Human Milk (M-MILK)|M-MILK is implemented as droplets, at day 3 of life, after every hands-on care, and during the beginning of a full gavage feeding. The infant may be supportively positioned in bed, held skin-to-skin by caregiver, or held/cradled by nurse or caregiver. The nurse draws up 1 mL of milk into the 1-mL syringe from a prepared bottle or enteral feeding syringe. The nurse then proceeds to implement M-MILK while observing the infant's responses closely. The nurse talks to the infant with a soft calm voice while providing gentle touch throughout the intervention. The nurse begins M-MILK by first placing 1-2 drops of milk onto the infant's upper lip, allowing the infant to feel and smell the milk. The nurse gently strokes the infant's lips with a pacifier/swab or infant's fingers. M-MILK will be provided based on infants' responses and cues. M-MILK is concluded if the infant is no longer engaged or has finished the 1 mL of milk.
214470533|NCT06291493|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingerstick blood draws.
214470534|NCT03541512|BEHAVIORAL|Mindfulness + Education|"Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
214470535|NCT03541512|BEHAVIORAL|Education|"Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
214470536|NCT06852547|DIETARY_SUPPLEMENT|protein|protein
215032412|NCT06617806|OTHER|Follow-up by the Advanced Practice Nurse|"At each follow-up (FU), the recommendations of an APN may include :~* Referral to a specialized memory assessment in case of cognitive impairment~* Psychological FU in the event that APN detects any mood complaints~* Ophthalmological and/or ear, nose, and throat consultation if any auditory or visual difficulties is observed~* Compression stockings use if orthostatic hypotension is present~* Nutritional counseling, with particular emphasis on the intake of protein, in combination with long-term assessment of weight~* Supplementation with vitamin D and calcium based to prevent osteoporosis in older adults, especially those at risk of recurrent falls~* Proposal of a standardized and personalized physical activity program~* Evaluation of medication therapies, especially antipsychotics, blood pressure medication or broad anticholinergics. The STOPPFall tool will be also proposed and coordinated by APN in accordance with the patient's physician~* A comprehensive social evaluative approach"
215032413|NCT03790956|PROCEDURE|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
215032414|NCT04112368|DRUG|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
215032415|NCT04112368|DRUG|Oral Micronized Progesterone 200mg|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)
215032416|NCT04112368|DRUG|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
215032417|NCT04112368|DRUG|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
215032418|NCT04501718|DRUG|Apatinib Combined With Temozolomide and Etoposide Capsules|"Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator."
215032419|NCT06676085|DRUG|Nafamostat|Nafamostat combined with unfractionated heparin for anticoagulation
215032420|NCT06676085|DRUG|Heparin|unfractionated heparin for anticoagulation
215032421|NCT06609304|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel at 2.0×10\^6/Kg
215032422|NCT06679478|PROCEDURE|Enhanced Recovery After Surgery (ERAS) Early Mobilization Protocol|The intervention is applied from the first day after surgery until discharge. (including the day of discharge).
215032423|NCT07006025|DRUG|Decitabine|Oral tetrahydrouridine and oral decitabine capsule
215032424|NCT06675318|OTHER|Cross training for quadriceps muscle of contralateral lower limb|An isokinetic exercise program consisting of 20 sessions conducted five days a week. The program begins with five repetitions at a speed of 60°/s, followed by sets of 5-15 repetitions with incremental increases of 30°/s. Rest periods of 30 seconds were included between sets.
215032425|NCT06675318|OTHER|Quadriceps isometric exercises, along with hot pack and TENS for painful knee|10 repetitions of quadriceps isometric exercises in 3 sets, along with hot pack and TENS treatments for painful knee
215032426|NCT06674239|BEHAVIORAL|Patient Follow-up and Evaluation Form, Patient Information Form Healthy Lifestyle Behaviors Scale Education Booklet|"In the experimental phase of the study, an informed consent form, patient information form, healthy lifestyle behaviors scale, patient follow-up and evaluation form and education booklet were used.~Patient Information Form: This form was developed by the researchers. Healthy Lifestyle Behaviors Scale: The scale, which measures the health-promoting behaviors associated with the individual's healthy lifestyle, consists of a total of 52 items.~Patient Follow-up and Evaluation Form: Metabolic value tests are routinely requested in the institution.~Education Booklet: An education booklet was created based on the literature and the opinions of three experts.~Data collection method: Individualized education was given to the experimental group. Then, the Patient Information Form and the Healthy Lifestyle Behaviors Scale were applied as pre-test and post-test. The laboratory values of the patients were examined and recorded in the Patient Follow-up and Evaluation Form."
214282393|NCT05883449|DRUG|Fludarabine|Lymphodepleting chemotherapy, intravenous infusion
215032427|NCT06674434|OTHER|Mobilization with Movement|Mobilization with Movement (MWM) is a manual therapy technique that combines active, patient-directed movements with passive joint mobilization to treat tennis elbow. To find joint restrictions or dysfunctions, a comprehensive patient assessment is the first step in the process. While the patient was in a supine position with the elbow fully extended and the forearm pronated, the therapist applied a sustained lateral glide of the forearm and stabilized the distal portion of the arm. While the patient asked to make a fist, the therapist kept up the lateral glide. Each session included three sets of movement-based mobilizations, each with ten repetitions. The entire course of treatment consists of twelve sessions.
214470537|NCT04839224|DRUG|carbogen|Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
214470538|NCT04839224|DRUG|phenylephrine|Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
215032428|NCT06674434|OTHER|Sustained Stretch|The basic concept of stretching involves lengthening the tendon during a state of relaxation. To stretch the Extensor Carpi Radialis Brevis tendon, the following position should be adopted: the elbow should be extended, the forearm in a pronated position, the wrist flexed, and the wrist should also be ulnar deviated, based on the patient's comfort level. This position should be maintained for 30 to 45 seconds and repeated three times before and after exercises in each treatment session, with a 30-second rest period in between.
215032429|NCT06673576|DIAGNOSTIC_TEST|Complete crown technique for superimposition|the complete crown technique, the crown of the tooth corresponding to the gingival margin under evaluation will be selected using the paint method and circular selection tool. The same selection process will be applied to the moving model.
215032430|NCT06673576|DIAGNOSTIC_TEST|Gold standard technique for superimposition|the gold standard technique, adjacent intact teeth and a portion of the palatal gingiva will be selected. Superimpositions will be executed utilizing the software's iterative closest point algorithm (ICP).
214282394|NCT05883449|DRUG|Interleukin-2|Immune cytokine, subcutaneously
214470539|NCT03839498|DRUG|Axitinib|"Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered."
214470540|NCT06560281|OTHER|Motion Minder Therapy (MoMT)|Motion Minder Therapy (MoMT) total duration is 1 hour a day, 5 days a week for 4 weeks. The treatment is a carefully planned sequence of exercises intended to help children with spastic hemiplegic cerebral palsy develop their fine motor abilities. Activities includes Sticker Sorting, Beads on Parade, Pegboard Activities, Sensory Bins, Sculpture Building, Finger Painting \& Drawing with Different Tools, Musical Instrument Play. Smartwatches that have tactile sensations and auditory indications are used strategically during certain tasks to enhance proprioception and give real-time feedback, making the rehabilitation process vibrant and interesting.
214470541|NCT06198816|OTHER|ultrasound accelerated thrombolysis and venoplasty|IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).
214470542|NCT06309433|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|Patient will undergo periodic (6-12-24m) dexa scans on the periprosthetic bone
214282395|NCT04799431|DRUG|Neoantigen Vaccine with Poly-ICLC adjuvant|"Neoantigen Vaccine with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22. 2 to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
214282396|NCT04799431|DRUG|Retifanlimab|500 mg will be administered as a 30 minute IV. Infusion (-5 min/+15min) on Day 1 of each 28 day cycle every 4 weeks.
214470543|NCT04579900|PROCEDURE|Endoscopy and duodenal biopsy and sampling|All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
214470544|NCT04169243|BEHAVIORAL|New Nordic Diet|The New Nordic Diet conforms with the Nordic Nutrition Recommendations and incorporates environmental sustainability and planetary health. It includes rapeseed oil, whole grain bread, wild fish, seafood and game, potatoes, root vegetables, cabbages, Nordic fruits and berries. A two-week menu including all daily meals has been created to ensure dietary goals of the New Nordic Diet intervention: fish and shellfish intake ≥ 3 times/w (fatty fish at least once per week), ≥ 500 g fruit, berries, vegetables and legumes daily (legumes as main protein source at least twice per week), whole-grain cereal products, rapeseed oil for cooking/dressing and three table spoons of nuts and seeds per day.
214470545|NCT04169243|OTHER|Control|The control women receive diet advice according to usual care, which may be a short meeting with the regular midwife or a short meeting with a dietician. From the study, they will receive a gift certificate that can be used in grocery stores.
214470546|NCT03937362|DIAGNOSTIC_TEST|First clinical response evaluation (CRE-1)|Consisting of: endoscopy with bite-on-bite biopsies
214470547|NCT03937362|DIAGNOSTIC_TEST|Second clinical response evaluation (CRE-2)|Consisting of: PET-CT, endoscopic bite-on-bite biopsies,EUS with FNA
214470548|NCT04765696|OTHER|No intervention is administered|No intervention is administered, the cohort is followed in order to evaluate the impact of housing and relocation on active ageing outcomes.
214470549|NCT01293214|PROCEDURE|Limb transplantation|
214282397|NCT01044771|DRUG|change from tenofovir to raltegravir|Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
214282398|NCT04357132|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora Application
214282399|NCT04357132|OTHER|VR-Distraction|Participants will be instructed to use one of four applications
214282400|NCT01906008|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
214282401|NCT01906008|DRUG|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
214282402|NCT01906008|BEHAVIORAL|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
214282403|NCT01906008|BEHAVIORAL|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
215032431|NCT07011394|DIAGNOSTIC_TEST|FeNO|FeNO will be measured before the bronchial provocation test using a FeNO VIOX device
215032432|NCT07011394|DIAGNOSTIC_TEST|Blood eosinophil count|a blood test will be performed om the day of bronchial provocation test
215032433|NCT07011069|PROCEDURE|ESP block group|ESP blocks are performed for patients undergoing VATS.
215032434|NCT07011069|PROCEDURE|RISS block group|RISS blocks are performed for patients undergoing VATS.
215032435|NCT07010172|DEVICE|cognitive rehabilitation with computer software|3-5 sessions per week, 4 weeks cognitive rehabilitation with computer software
215032436|NCT07010640|OTHER|Video Instrctions|Video instructions of rehabilitation techniques and movements to help with adherence and compliance to treatment.
215032437|NCT06674044|GENETIC|Atorvastatin|Atorvastatin 10mg once a day for 1 month
215032438|NCT07010445|OTHER|Naïve: epilepsy first diagnosis, anti-epileptic drugs; DRE-surgery: resective surgery; DRE-VNS: vagal nerve stimulation; DRE-KD: ketogenic diet.|Anti-epileptic drugs, resective surgery, vagal nerve stimulation or ketogenic diet.
215032439|NCT07010510|DIAGNOSTIC_TEST|CMR, stress ECG, Holter, BnP|"This study involves no experimental intervention. All data were collected retrospectively from patients with repaired Tetralogy of Fallot (TOF) who underwent standard clinical follow-up. As part of routine care, patients received comprehensive multimodal functional assessment, including:~Cardiac Magnetic Resonance Imaging (CMR) with feature-tracking strain analysis~Transthoracic Echocardiography~Exercise stress testing (treadmill ECG using Bruce protocol)~12-lead ECG and 24-hour Holter monitoring~Laboratory evaluation including NT-proBNP levels~NYHA functional class assessment"
215032440|NCT07011355|OTHER|Stress Ball|"Targeted Sensory Stimulus Type - Proprioceptive Input Based Mechanism:~Stress ball application is aimed at regulating the nervous system, especially through proprioceptive and tactile (tactile) stimuli. In this respect, it differs from methods such as aromatherapy, music therapy or breathing exercises, which are more effective through the sensory, emotional or autonomic nervous system."
215032441|NCT03267849|OTHER|wearing swimming goggles or having laser suturelysis|Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the interventions
215032442|NCT05156528|BIOLOGICAL|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine|Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.
215032443|NCT05156528|BIOLOGICAL|Placebo|Single intramuscular dose contains 0.15\~0.25 mg of aluminum ion
215032444|NCT06687447|OTHER|Oxycotin Massage Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed, verbal and written consent will be obtained from women who want to participate in the study, and pre-test data will be collected by the researcher. The pre-test data of the research were it will be collected by face-to-face interview technique in approximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured by the researcher. At this stage, the patient will receive an oxytocin massage for 10 minutes while in a sitting position. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again by the researcher. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again by the researcher and uterine involution and physiological parameters will be evaluated.
215032445|NCT06687447|OTHER|Reflexology Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed women who want to participate in the study, and pre-test data will be collected. The pre-test data of the research were it will be collectedapproximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured. In practice; The foot is first relaxed and warmed up with passive movements, then the sole of the foot is scanned with the thumb walking crawling technique. The application will be applied first to the right foot for 10 minutes and then to the left foot for a total of 20 minutes. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again and uterine involution and physiological parameters will be evaluated.
215032446|NCT06687447|OTHER|Control Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed, verbal and written consent will be obtained from women who want to participate in the study, and pre-test data will be collected by the researcher. The pre-test data of the research were it will be collected by face-to-face interview technique in approximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured by the researcher. Patients in the control group will not undergo any intervention and will receive their routine care. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again by the researcher. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again by the researcher and uterine involution and physiological parameters will be evaluated.
215032447|NCT03035214|DRUG|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
215032448|NCT03436667|DIAGNOSTIC_TEST|Spirometry|Lung volumes will be measured using spirometry.
215032449|NCT03436667|DIAGNOSTIC_TEST|Reaction Time|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
215032450|NCT05950438|PROCEDURE|Esophagectomy|Esophagectomy is a complex surgical procedure performed to treat various esophageal disorders. The surgery involves the removal of all or part of the esophagus and reconstruction using other parts of the gastrointestinal tract.
215032451|NCT05898594|PROCEDURE|Low-dose Computed Tomography|Per standard care
215032452|NCT01263210|BIOLOGICAL|Prevenar|
215032453|NCT04361500|DEVICE|Seraph 100|Seraph 100 therapy during a COVID-19 infection
215032454|NCT02953431|DEVICE|CPAP|CPAP will be administered with a CPAP machine
215032455|NCT03491176|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215032456|NCT03491176|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
215032457|NCT03491176|OTHER|Quality-of-Life Assessment|Ancillary studies
215032458|NCT03491176|OTHER|Questionnaire Administration|Ancillary studies
215032459|NCT04227587|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
215032460|NCT04227587|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
215032461|NCT00913822|DRUG|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
215032462|NCT00913822|DRUG|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
215032463|NCT01397253|OTHER|Automated communication tools|"Automated communication tools will include:~* PCP notification of patient admission and location~* Data on medications begun on admission~* Automated alerts on changes in patient status and location while the patient is hospitalized~* Links to the EMR and to hospital physician contact information on all email alerts~* Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~* Automatic reporting to PCPs of test results pending at discharge~* Electronic delivery of final discharge summaries"
215032464|NCT04523025|DIAGNOSTIC_TEST|NLR-ratio|The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation
215032465|NCT05640557|OTHER|Physical Exercises|An original, noninvasive exercise program
214282404|NCT01230632|DIETARY_SUPPLEMENT|high fat overfeeding|Dietary Supplement:3 days overfeeding
214282405|NCT04775875|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory wave form confirmation of cerebral arteries, and optical tracking technology (eg, AntNeuro Visor2 system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
214282406|NCT02491203|OTHER|Telerehabilitation system|Usual care plus home-based virtual reality telerehabilitation system.
214282407|NCT05251974|DIAGNOSTIC_TEST|Quest beta blocker assay|Blood assay to detect presence of beta blocker medications
214282408|NCT01888237|DRUG|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
214282409|NCT01888237|DRUG|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
214282410|NCT01033968|PROCEDURE|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
214282411|NCT00730132|DRUG|Ezetimibe|Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
214282412|NCT00730132|DRUG|Statin|Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
214282413|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (high)|High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
214282414|NCT03956732|DIETARY_SUPPLEMENT|Vitamin D|One daily tablet containing 20 μg of vitamin D3, cholecalciferol.
214282415|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (medium)|Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
215032466|NCT03290521|PROCEDURE|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
215032467|NCT03290521|PROCEDURE|No washing|no washing
215032468|NCT00404911|BEHAVIORAL|MFG therapy|MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
214282416|NCT04007718|BEHAVIORAL|Interpretation bias training|Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
214282417|NCT03059602|OTHER|No specific treatment based intervention-health measurement instrument|Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
214282418|NCT01626391|DRUG|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
215032469|NCT00404911|BEHAVIORAL|Standard of Care|Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
215032470|NCT01937702|OTHER|0.9% NaCl (sodium chloride)|
215032471|NCT05585294|BEHAVIORAL|Exercises|Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
215032472|NCT02295865|DRUG|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
215032473|NCT02295865|DRUG|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
215032474|NCT02295865|DRUG|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
215032475|NCT02295865|DRUG|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
214470550|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
215032476|NCT01651988|DRUG|Ketamina-Propofol Combination|"After randomization to the study group, the patients were given:~Procedures \< 10 minutes~1. Ketamine-Propofol Combination KETOFOL 1:1~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~2. Ketamine-Propofol Combination KETOFOL 1:2~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures \> 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min"
215032477|NCT01892189|DRUG|Ketamine|Ketamine intravenous administration.
215032478|NCT01892189|DRUG|TAK-063|TAK-063 tablets
215032479|NCT01892189|DRUG|TAK-063 Placebo|TAK-063 placebo-matching tablets
215032480|NCT05975424|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
215032481|NCT03622606|DIAGNOSTIC_TEST|Right Language screening test (R-LAST)|Validation of the Right Language screening test in acute and subacute phase of right stroke
215032482|NCT03960736|OTHER|ESP block (Group A)|US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.
215032483|NCT03960736|OTHER|TEA group (Group B)|Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
214282419|NCT01626391|DRUG|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
214282420|NCT02624908|DRUG|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
214282421|NCT02624908|DRUG|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
214282422|NCT02596308|BIOLOGICAL|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
215032484|NCT01110512|DRUG|Flavonid|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day."
215032485|NCT01110512|DRUG|Daflon|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day"
215032486|NCT03247101|DRUG|Miyarisan-BM (Clostridium Butyricum Miyairi)|40mg po tid x 6months
215032487|NCT03247101|DRUG|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
215032488|NCT03247101|DRUG|Biotase group|Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
215032489|NCT03378960|DRUG|Omeprazole 20mg|
215032490|NCT00808873|OTHER|socio-educational intervention|brief mental health education and 6 follow-up visits
215032491|NCT03362671|DEVICE|Implant Supported Mandibular Advancement Oral Appliance|This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
215032492|NCT03362671|DEVICE|Orthodontic Mini Implant|Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
215032493|NCT05549544|DEVICE|Left bundle branch area pacing|Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.
214282423|NCT00772343|BIOLOGICAL|0.9% Normal Saline|0.5 mL, intramuscular on Days 0, 7, and 28
214470551|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
214470552|NCT02038777|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
214470553|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
214470554|NCT02038777|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
215032494|NCT05549544|DEVICE|Biventricular pacing|Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
215032495|NCT05737979|OTHER|Study chart review|Evaluation of the IVF cycle using the prescribed medication
214282424|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
214282425|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine with adjuvant|0.5 mL, intramuscular on Days 0, 7, and 28
214282426|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
214282427|NCT01218568|DRUG|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
214282428|NCT01218568|DRUG|Lactulose|Lactulose 30-60 ml in two or three divided doses.
214282429|NCT02220205|OTHER|PelvicSim|
214282430|NCT02220205|DEVICE|Manufacturer model|
214282431|NCT04580953|DEVICE|CardiaCareTM RR2|Treatment with CardiaCareTM RR2
214470555|NCT02038777|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
214470556|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
214470557|NCT02038777|DRUG|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
214470558|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
214470559|NCT02038777|DRUG|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
214282432|NCT00937625|BIOLOGICAL|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
214282433|NCT00081640|DRUG|PRO 2000/5 Gel (P)|
214470560|NCT03493425|DRUG|Carboplatin|Given IV
214470561|NCT03493425|DRUG|Cisplatin|Given IV
214470562|NCT03493425|DRUG|Docetaxel|Given IV
214470563|NCT03493425|RADIATION|Image Guided Radiation Therapy|Undergo image guided IMRT
214470564|NCT03493425|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image guided IMRT
214470565|NCT03493425|OTHER|Laboratory Biomarker Analysis|Correlative studies
214470566|NCT03493425|OTHER|Questionnaire Administration|Ancillary studies
214470567|NCT03493425|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214470568|NCT04903223|DRUG|Rosuvastatin 10mg|Rosuvastatin will be administered to all participants on Study Day #2
214470569|NCT04223765|DRUG|CAR.k.28|Three dose levels will be evaluated: Dose level 1 (5x10\^5 cells/kg), Dose level 2 (1x10\^6), and dose level 3 (2x10\^6 cells/kg).
214470570|NCT04223765|DRUG|Fludarabine|30 mg/m\^2/day IV for 3 consecutive days
214470571|NCT04223765|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for 3 consecutive days
214470572|NCT04223765|DRUG|Bendamustine|70 mg/m\^2/day administered over 3 consecutive days.
214470573|NCT04234113|DRUG|Nanrilkefusp alfa|A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15
214470574|NCT04234113|DRUG|Pembrolizumab|A humanized IgG4 monoclonal antibody with high specificity of binding to the PD-1 receptor
214470575|NCT06298461|DRUG|KleanLyte|Laxative for colonoscopy bowel preparation
214470576|NCT06298461|DRUG|Bi-PegLyte|Laxative for colonoscopy bowel preparation
214906721|NCT02338323|DRUG|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
214906722|NCT04735523|DRUG|Dabigatran|Dabigatran dispensing claim is used as the exposure group
214906723|NCT04735523|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
214906724|NCT05533593|DRUG|Aminoglycoside|Inpatients using aminoglycoside
214906725|NCT04369144|OTHER|Dynamic Scapular Recognition exercise|The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session
214906726|NCT01967966|DRUG|GDC-0032|Single oral dose
214906727|NCT01967966|DRUG|GDC-0032|Single IV dose
214906728|NCT05936060|BIOLOGICAL|INMUNOCEM|Mesenchymal Stromal Cell suspension intraarticularly injected
214906729|NCT05936060|DRUG|PLACEBO COMPARATOR|Administration of plasmalyte as a vehicle for MSC
214906730|NCT00802230|DRUG|Terbutaline Infusion|
214906731|NCT05780125|DRUG|FibCLOT|30 mg/kg of FibCLOT (rounded up to the nearest 2 or 3 grams) after protamine administration
214906732|NCT05780125|DRUG|RiaSTAP|30 mg/kg of RiaSTAP (rounded up to the nearest 2 or 3 grams) after protamine administration
214906733|NCT03426618|OTHER|Non-interventional|Non-interventional
214906734|NCT06254118|DRUG|Polyunsaturated Fatty Acids|1000mg omega-3 fatty acids taken once daily with meals for 12 months
214906735|NCT06254118|DIETARY_SUPPLEMENT|olive oil|1000mg olive oil taken once daily with meals for 12 months
214906736|NCT03328507|DRUG|BLI4900|BLI4900 Bowel Preparation
214906737|NCT03328507|DRUG|PEG Control|Polyethylene glycol-based bowel preparation
214906738|NCT02328313|BEHAVIORAL|Walk with Ease Program|The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
214906739|NCT02262715|DRUG|VX-787|Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.
214906740|NCT02262715|DRUG|Oseltamivir|Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.
214906741|NCT02262715|OTHER|Placebo|Participants will receive placebo matching to VX-787 either two times a day or or once a day.
214906742|NCT00997373|DRUG|Letrozole|2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
214906743|NCT05209867|DRUG|CBD oil|"* Each participant will be provided two 30mL(Milliliters) bottles (2000mg CBD per bottle) with a syringe dropper during their initial (baseline) visit with instructions to administer the solution under the tongue (0.5 cc \~1/2 dropper) twice per day (BID) 8-12 hours apart (morning and evening) at the prescribed daily dosage (63mg/day).~* The investigators plan to collect samples from five patients over three time points: baseline (no CBD), and after one and two months of CBD-administration"
214906744|NCT06155929|BEHAVIORAL|Flight|The participants are flying to turkey and back home. The flights are the intervention.
214906745|NCT01129063|DRUG|Clopidogrel|"Pharmaceutical form : tablet~Route of administration: oral"
214906746|NCT00566241|DRUG|recombinant human IGF-1|rhIGF-1
214906747|NCT00566241|DRUG|Placebo|Placebo
214906748|NCT04835662|BEHAVIORAL|Complementary feeding promotion|The intervention engaged fathers through community meetings, religious services, and mobile phone text and voice messages. Mothers received home visits from community health extension workers (CHEWs), which fathers also could attend. Social behavior change communication materials included TV and radio messages, sermon guides, counseling cards, pamphlets, posters, and feeding bowls.
215032496|NCT00691626|BEHAVIORAL|CBT for Insomnia plus Imagery Rehearsal|patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
215032497|NCT00691626|BEHAVIORAL|CBT for Insomnia plus psychoeducation|patients receive standard CBT for insomnia combined with psychoeducation
215032498|NCT01519479|OTHER|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
215032499|NCT01519479|OTHER|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
215032500|NCT02167711|DRUG|SIRT Yttrium-90|
215032501|NCT03440411|DRUG|Pomalidomide|4 mg/daily as oral administration (PO) on days 1-21.
215032502|NCT03440411|DRUG|Cyclophosphamide|50 mg every other day as oral administration (PO) on days 1-28
215032503|NCT03440411|DRUG|Dexamethasone|40 mg as oral administration (PO) on days 1, 8, 15, 22.
215032504|NCT02793960|DRUG|topical BPM31510 3.0% Cream|Application of drug to lesions of epidermolysis bullosa
215032505|NCT00932607|DRUG|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
215032506|NCT04910620|DRUG|Placebo|Placebo only
215032507|NCT04910620|DRUG|TCI378|TCI378 (Lactobacillus plantarum TCI378)
215032508|NCT04910620|DRUG|TCI507|TCI507 (Lactobacillus plantarum TCI507)
215032509|NCT03716648|DIAGNOSTIC_TEST|DISE-assisted titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
215032510|NCT03716648|DIAGNOSTIC_TEST|PSG-guided titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
215032511|NCT03716648|DEVICE|subjective titration|Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
214470577|NCT06760715|BEHAVIORAL|an interactive m-health self-management|Description: The experimental group will undergo a lifestyle intervention based on the Transtheoretical Model (TTM), utilizing the MOSAC cloud platform. This intervention focuses on self-management to facilitate behavior changes aimed at weight loss and improving Obstructive Sleep Apnea (OSA) of T2DM patients. Key components include self-monitoring, tracking, real-time feedback, and customized weight loss plans, all enhanced by gamification features. The intervention emphasizes a healthy approach to weight loss, promoting a balanced diet, moderate calorie reduction, and increased physical activity, such as step counts. Each stage of the intervention outlines specific objectives, processes, and measures for achieving behavioral change and supporting healthy weight loss.
214470578|NCT06760715|BEHAVIORAL|In the control group|Description: In the control group, standard medical care will continue to be provided along with written educational pamphlets on weight loss and sleep hygiene. The interactive m-health cloud platform will not be offered. However, the results of the three questionnaires administered to each participant will be individually explained, and any questions will be addressed immediately. After the activity concludes, participants may choose to receive the same intervention as the experimental group, if they wish.
214470579|NCT06229574|OTHER|virtual reality glasses|The breastfeeding software developed will be applied in this group.
214470580|NCT06322667|OTHER|No Intervention|This is a non-interventional study.
215032512|NCT04461886|DRUG|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
215032513|NCT02957838|DIETARY_SUPPLEMENT|C18:0|Receives 24g of C18:0 in a low-fat banana milkshake.
215032514|NCT02957838|DIETARY_SUPPLEMENT|mock|Low fat banana milkshake without C18:0 supplement.
215032515|NCT05136716|OTHER|Traditional Physical Therapy|Stretching for tight muscles, strengthening for weak muscles, postural reactions training, proprioceptive training, and walking training were all part of the neurodevelopmental treatment plan.
215032516|NCT05136716|DEVICE|Hyperbaric oxygen therapy|HBO2 therapy at a pressure of 1.7 atm For 60 minutes, participants breathed 100% O2.
215032517|NCT03859011|OTHER|Acupuncture|"Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion."
215032518|NCT03859011|OTHER|Usual Care|Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
215032519|NCT02903485|OTHER|nurses perform presurgical assessement and surveillance during surgery|
215032520|NCT02903485|OTHER|the anesthetic team performs presurgical assessement and surveillance during surgery|
215032521|NCT04778202|DIAGNOSTIC_TEST|blood sample collection|blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
215032522|NCT01139515|DRUG|Eletriptan commercial tablet|20 mg tablet, single dose
215032523|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
214470581|NCT06834269|DEVICE|Transcranial magnetic stimulation (tSMS)|Transcranial static magnetic stimulation (tSMS) will be delivered simultaneously to both hemispheres, at the motor cortex (M1), via magnets housed in a helmet.
214470582|NCT06836700|PROCEDURE|Mini PCNL|90 Participants underwent MINI PCNL in MIN PCNL arm and 90 Participants underwent Standard PCNL in Standard PCNL arm.
214844351|NCT06436352|PROCEDURE|Fixation only|"we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
214470583|NCT06840652|DRUG|Baclofen|Safety and effectiveness of baclofen as a treatment for alcohol withdrawal in patients with chronic liver disease. The investigators will administer baclofen in increasing doses up to a maximum dose of 10 mg every 8 hours, evaluating the drug's tolerance and its effectiveness in achieving alcohol abstinence. Baclofen will be administered during the patient's hospitalization for decompensation of their liver disease, in patients followed up as outpatients in hepatology clinics, and in those managed as outpatients by psychiatrists specializing in addiction
214470584|NCT06259279|BEHAVIORAL|High intensity high impact exercise intervention|"Patients in the intervention group will receive a 32-week exercise-based intervention that includes:~\- Supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes."
215032524|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
214844352|NCT02384291|DEVICE|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
214470585|NCT03743532|BEHAVIORAL|E-cigarette Switching|Participants provided with e-cigarette device and nicotine pods and advised to switch from combustible cigarettes to e-cigarettes.
214470586|NCT03743532|BEHAVIORAL|Financial Incentives|Participants earned incentives for carbon monoxide-verified combustible cigarette abstinence.
215032525|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
215032526|NCT05349604|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
215032527|NCT05349604|DIETARY_SUPPLEMENT|Placebo|One intake in total
215032528|NCT01659294|BEHAVIORAL|Nurse Case Management|
215032529|NCT01659294|BEHAVIORAL|standard diabetologist care|routine care by diabetologist \& team
215032530|NCT00569179|DEVICE|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
215032531|NCT03890211|DEVICE|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
215032532|NCT01512576|OTHER|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
215032533|NCT01512576|BEHAVIORAL|relaxation|1 treatment session of 30 minutes
215032534|NCT03747692|PROCEDURE|study group|local anesthesia by mepicaine hydrochloride by intracervical local injection using 10 mm syringe.
215032535|NCT03747692|PROCEDURE|control group|each patient receives one tablet of NSAIDs (diclofenac sodium 50 mg) and 5ml of a placebo in form of normal saline are injected intracervical 5 minutes before the procedure using 10 mm syringe.
215032536|NCT04803565|DEVICE|Custom-made shoe insole|Subjects will receive a custom-made shoe insole designed on the patient's foot and shoes. The subjects should wear the insole for at least 6 hours per day.
215032537|NCT04803565|DEVICE|Sham conventional Insole|Subjects will receive a conventional insole without any specific property (sham insole)
215032538|NCT03146260|PROCEDURE|Conventional TESE|usual procedure for sperm extraction
215032539|NCT03146260|PROCEDURE|Microdissection TESE|Procedure of extraction is performed under the operating microscope
215032540|NCT02834364|DRUG|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
214470587|NCT05869539|DRUG|Combination of Tumor-infiltrating lymphocyte transfer with ANV419|"The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10\^9 and up to 2x 10\^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419."
214470588|NCT02766322|OTHER|Oral Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
214844353|NCT02384291|DEVICE|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
214844354|NCT00298740|DEVICE|Aventis U-400 Insulin|
214844355|NCT03684031|BEHAVIORAL|Cognitive Control Training|A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
214844356|NCT03684031|BEHAVIORAL|Sham Cognitive Control Training Program|A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
215032541|NCT02834364|DRUG|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
215032542|NCT00005835|DRUG|buthionine sulfoximine|Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
215032543|NCT00005835|DRUG|melphalan|The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
215032544|NCT00005835|PROCEDURE|Peripheral blood stem cell infusion|Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.
215032545|NCT00005835|OTHER|Filgrastim|5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC \>/= 1500 mm3 for three consecutive days.
215032546|NCT03904485|RADIATION|cardiac magnetic resonance(CMR) T2 mapping|T2 value before transplant，3 month and 6month after transplant
215032547|NCT00358878|DRUG|Satavaptan|oral administration once daily
215032548|NCT00358878|DRUG|placebo|oral administration once daily
215032549|NCT03022721|OTHER|No interventions are planned for this study.|No interventions are planned for this study, it is purely observational.
214470589|NCT02766322|OTHER|Oral Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
214844357|NCT04199884|BEHAVIORAL|Active IU-focused Psychoeducation Intervention|This paradigm was an IU-focused psychoeducation intervention wherein participants were provided psychoeducation about the nature of IU and anxiety, given strategies to cope with fear of uncertainty, and provided examples and information as to how they can expose themselves to uncertainty.
214844358|NCT04199884|BEHAVIORAL|Health-focused Psychoeducation Intervention|This intervention is a health-focused psychoeducation intervention wherein participants learn ways to engage in healthy behaviors, such as getting adequate sleep, eating healthier, and exercising regularly.
214844359|NCT04778306|PROCEDURE|Transoral Laser Surgery|Remove of the laryngeal tumour via diode laser
214470590|NCT02766322|OTHER|Intravenous Alcohol Challenge Test (Clamp)|Subjects will be evaluated with an alcohol clamp (i.e. alcohol will be infused intravenously until reaching 60mg/dl and this blood alcohol concentration will be kept constant for two hours). We will record subjective responses to alcohol throughout different times of the clamp.
214844360|NCT06051604|DEVICE|Mi-Helper|The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
214844361|NCT04651322|DEVICE|upper robot Robot assisted upper arm training(RAT)|"The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~\*Robot Assisted Arm training + Conventional occupational therapy"
214844362|NCT04651322|BEHAVIORAL|Conventional therapy|The control group received the usual conventional therapy \*Only Conventional occupational therapy
214844363|NCT05357859|DIETARY_SUPPLEMENT|solubilized vitamin D3|solubilized vitamin D3
214844364|NCT05357859|DIETARY_SUPPLEMENT|medium chain triglyceride|MCT with same amount
214844365|NCT03767699|BEHAVIORAL|Medical Nutrition Therapy|MNT was offered every 2-4 weeks to all pregnant women with T2DM and GDM. Women. MNT is offered as a mandatory part of their prenatal visit and/or hospital stay. The MNT provides an individual food plan with the following recommendations: total calories should be calculated as 30 kcal/kg based on pregestational BMI for an ideal weight. Of the total energy intake 40-45% is provided by carbohydrates, a maximum of 40% is provided by lipids and the remaining percentage by proteins providing moderate-to-low glycemic index foods and fiber consumption, glucose self-monitoring, participating in 15-30 min of daily physical activity after prior authorization of the treating physician, and meeting the minimal energy requirements of pregnancy (never \< 1,500 kcal).
214844366|NCT05062915|DIAGNOSTIC_TEST|HINTS|HINTS (Head Impulse, Nystagmus, test of skew) V-HIT (Head impulse test google assisted) MRI: 3-4 MRI of the brain including the posterior fossa Vestibular rehabilitation for all patients with a vestibular deficit.
214844367|NCT04894084|DEVICE|CP321|The primary objective is to evaluate the system performance of the test product. This is done by asking subjects to answer questions throughout the study
214844368|NCT02591563|OTHER|procedures|Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
214844369|NCT01345318|BIOLOGICAL|PF-04236921|Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
214844370|NCT01345318|BIOLOGICAL|PF-04236921|Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
214844371|NCT02063308|DIETARY_SUPPLEMENT|Oxaloacetate (OAA)|
214844372|NCT01247779|PROCEDURE|gynecologic surgery - standard coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
214844373|NCT01247779|PROCEDURE|gynecologic surgery - robot assisted coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
214844374|NCT00317642|DRUG|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m\^2 / day up to 3 cycles
214844375|NCT00317642|DRUG|placebo|placebo (sodium Chloride) 1-hour IV infusion
214844376|NCT00317642|DRUG|cytarabine|cytarabine IV infusion 1g/m\^2/day for up to 3 cycles
214844377|NCT02921503|OTHER|mobile topical corticosteroid app|app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
214844378|NCT04305379|PROCEDURE|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction including a Medial Umbilical Ligament Sling plus Intussusception
214844379|NCT04305379|PROCEDURE|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction with Intussusception Only
214844380|NCT01602471|DRUG|[F-18]RDG-K5|Approximately fifteen (15) patients with carotid artery stenosis \> 69% will undergo an endarterectomy and will be imaged under PET/CT with \[F-18\]RGD-K5
214844381|NCT03648619|DIAGNOSTIC_TEST|Semi whole-body MRI|Single semi-automatic, semi whole-body MRI protocol (Dot engine)
214844382|NCT03022669|BEHAVIORAL|Text Message|Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
214844383|NCT03022669|BEHAVIORAL|Mobile Application|
214844384|NCT03022669|OTHER|Website|American Heart Association patient education website
214844385|NCT05491239|PROCEDURE|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
215032550|NCT02323048|DRUG|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
215032551|NCT02323048|DRUG|placebo|Placebo (sugar pill)
215032552|NCT03906214|OTHER|Web-based Survey|"Participants will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and uneventful use of possibly risky medication. If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of Medications of Interest and report current or past use."
214470591|NCT02766322|OTHER|Intravenous Alcohol Self-administration Test|"Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit."
214470592|NCT05814159|DRUG|Anakinra|sub cutaneous daily injection
214470593|NCT05814159|DRUG|Placebo|sub cutaneous daily injection
215032553|NCT01447992|DEVICE|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
214470594|NCT06521866|DRUG|Serplulimab|IV 3 mg/kg on Day 1, q2w
215032554|NCT03474276|DRUG|Azythromycin|Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
215032555|NCT03474276|DIETARY_SUPPLEMENT|Inuline and fructo-oligosaccharides|Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.
215032556|NCT03474276|DRUG|Albendazole|Administration of Albendazole at inclusion of the child : 200mgs, one administration
215032557|NCT03474276|DIETARY_SUPPLEMENT|Fortified blend flour|"Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day~Compostion of the fortified blend flour per 100 grams : either :~Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g"
215032558|NCT04484857|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
215032559|NCT06204783|OTHER|Pressure volume (PV) loop measurement|Pressure volume (PV) loop measurement using a conductance catheter
214470595|NCT06521866|DRUG|Chemotherapy|"Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours"
215032560|NCT03855904|DEVICE|TC-325|TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.
215032561|NCT03359161|COMBINATION_PRODUCT|sc2Wear Furosemide Infusor|Subcutaneous furosemide for the treatment of fluid overload
215032562|NCT03580954|DEVICE|Transcranial Magnetic Stimulation|Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
215032563|NCT04101773|PROCEDURE|RBL versus sutured mucopexy versus haemorrhoidectomy.|All 3 interventions are part of Dutch usual care, and serve as each other's control.
215032564|NCT00757016|DRUG|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
215032565|NCT00757016|DRUG|Saline solution|Saline solution
214470596|NCT06521866|RADIATION|SABR|SABR: 25-60 Gy/5 Fx
214470597|NCT06521866|DRUG|Targeted therapy|Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly ; Bevacizumab: 5 mg/kg IV on Day 1
215032566|NCT00738127|PROCEDURE|Open reduction and internal fixation|Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
215032567|NCT02350452|PROCEDURE|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
215032568|NCT02350452|PROCEDURE|Bipolar coagulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
215032569|NCT06634498|OTHER|real rTMS on the dlPFC|During real rTM session, participants will perform the regulation of craving (ROC). In the rest phase, participants need to relax and rest. In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
215032570|NCT06634498|OTHER|Sham (No Treatment)|During the sham rTMS session, participants will perform the regulation of craving (ROC). In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
214470598|NCT04742075|DRUG|Olaparib + durvalumab + UV1|The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
214470599|NCT03592693|DRUG|Combined Vitamin C and Stress-Dose Hydrocortisone|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
214470600|NCT03592693|DRUG|Placebo plus placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
214470601|NCT03943004|DRUG|DFP-14927|DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
214470602|NCT06789315|DRUG|Mycophenolate Mofetil|MMF at a dose of 750 mg twice daily for a period of 28 days,
214470603|NCT06789315|DRUG|Prednisone|Prednisone at a dose of 40 mg for 28 days.
214470604|NCT04533737|BIOLOGICAL|Brodalumab|Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection
214282434|NCT06471452|DEVICE|Interaktor|"In the app (Interaktor), the patients will report frequency and distress on common symptoms and concerns.~Free text comments will also be possible to make to cover the patients' other potential needs. Information about the concerns will be included in the app containing; a) general information about why they have the side effects and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents, web pages or YouTube videos.~Supportive Care delivered from a study-specific nurse. During the health dialogues with a nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and needs and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patient's journal."
214282435|NCT05484622|DRUG|Vorasidenib|Administered orally as tablets.
214282436|NCT05484622|DRUG|Pembrolizumab|Administered as IV infusion.
214282437|NCT00856154|BIOLOGICAL|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.~1. Gag150 RLLNAWVKV~2. Gag433 FLGKIWPV~3. Env 67 NIWATHACV~4. Pol606 KLGKAGYVV~5. Vpu66 ALVEMGHHV~6. Vif101 GLADQLIHL~7. Vif23 SLVKHHMYV~8. Gag298 KRWIILGLNKIVRMY~9. gp41 VWGIKQLQARVLAVERYLKD~10. Padre AKXVAAWTLKAAA"
214282438|NCT00518986|DRUG|armodafinil|200 mg/day
214282439|NCT00518986|DRUG|placebo|placebo
214282440|NCT02088047|DEVICE|ProFoveate|ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
214282441|NCT05788081|DRUG|golcadomide|BMS-986369 is an orally administered Cereblon-modulating compound
214282442|NCT05788081|DRUG|Nivolumab 10 MG/ML|Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.
214470605|NCT04533737|OTHER|Placebo|The placebo solution is similar to the active guselkumab (Dummy 1) or brodalumab (Dummy 2) solution except that it does not contain any active substance
214470606|NCT04533737|BIOLOGICAL|Guselkumab|Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection
214282443|NCT05788081|DRUG|Rituximab|Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions
214282444|NCT01021046|PROCEDURE|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
214282445|NCT01021046|PROCEDURE|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
214282446|NCT00002916|BIOLOGICAL|human papillomavirus 16 E7 peptide|
214282447|NCT00002916|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
214282448|NCT00002916|PROCEDURE|adjuvant therapy|
214282449|NCT00002916|PROCEDURE|surgical procedure|
214282450|NCT00002916|RADIATION|radiation therapy|
214282451|NCT00006097|DRUG|CC-1088|
214282452|NCT03647033|DEVICE|iStent implantation|The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
214282453|NCT05290415|DIAGNOSTIC_TEST|DNA methylation testing|DNA CDO1 and CELF4 methylation testing
214282454|NCT04332146|BEHAVIORAL|Mindfulness-based program (MBI-p-R)|The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.
214282455|NCT04332146|BEHAVIORAL|Booklet-based psychoeducation|The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
214470607|NCT04273594|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
214282456|NCT04901468|OTHER|No Intervention|This is an observational study
214470608|NCT04942626|DRUG|Kineret 100 MG in 0.67 ML Prefilled Syringe|Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.
214470609|NCT04942626|DRUG|Capecitabine|Capecitabine will be administered using a 3+3 dose escalation design (500 mg/m2 bid, 650 mg/m2 bid and 825 mg/m2 bid po, respectively) from day 1 to day 40 of RT including weekends.
214470610|NCT04942626|RADIATION|Radiotherapy|PTV: 1.8 Gy to 45 Gy (#28 fractions) to the primary tumor and pelvic lymph nodes; followed by a sequential boost of 1.8 Gy to 9 Gy (#5 fractions) to the gross tumor volume
214470611|NCT04942626|PROCEDURE|Watch and Wait (cCR) or TME surgery (non-cCR)|Restaging to evaluate tumor response will be conducted 10 weeks after completion of CRT. For patients achieving a clinical complete response (cCR), a Watch and Wait (W\&W) option with close follow-up is scheduled. In case of non-cCR, immediate total mesorectal excision (TME) surgery is recommended. According to the current German S3-guidelines, adjuvant chemotherapy is optional.
214470612|NCT06528184|DIAGNOSTIC_TEST|Self-sampled HPV DNA testing|Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)
214470613|NCT06528184|DIAGNOSTIC_TEST|Clinician-sampled HPV DNA test|Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)
215032571|NCT05858814|BIOLOGICAL|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
215032572|NCT01358734|DRUG|Azacitidine|Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7
215032573|NCT01358734|DRUG|Lenalidomide|Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
215032574|NCT01358734|OTHER|Best Supportive Care (BSC)|"The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support"
214282457|NCT03712072|DEVICE|Magnetoencephalography (MEG)|The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.
214282458|NCT03712072|DEVICE|Electroencephalography (EEG)|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp.
214282459|NCT03712072|DEVICE|Transcranial Magnetic Stimulation (TMS)|The device will be used for motor mapping. Motor threshold is operationally defined as minimum machine output necessary to elicit a response from the abductor pollicis brevis right (APB), contralateral to the stimulated hemisphere, of 50 microvolts, on \>50% of trials. Upper limb motor mapping is conducted at 110% abductor pollicis brevis motor threshold in each hemisphere, or at 100% machine output (MO). Lower limb motor mapping is conducted at a fixed machine output corresponding to the magnitude sufficient to elicit reliable tibialis anterior (TA) motor evoked potentials (MEPs). Single pulse TMS is performed while motor evoked potentials are recorded bilaterally from the APB, deltoid, and TA using surface electromyography (EMG).
214470614|NCT06051227|DRUG|Fentanyl Citrate|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
214470615|NCT06051227|DRUG|Esketamine|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
214470616|NCT05705518|DRUG|Systane Complete PF|3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product
215032575|NCT02300545|DRUG|Pazopanib|
215032576|NCT01892566|OTHER|mHealth Intervention|See arm description
215032577|NCT01731782|DRUG|bupivacaine|
215032578|NCT01731782|DRUG|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
214470617|NCT05705518|DRUG|Refresh Relieva PF|3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product
214470618|NCT05705518|DRUG|Refresh Optive Mega-3 PF|3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
214470619|NCT05705518|DRUG|CVS Health Lubricant Eye Drop (PG 0.6%)|3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product
214470620|NCT06410755|DEVICE|Monitoring system using a insole-type gait analyzer|The researcher provides feedback over the phone once a week in accordance with the subjects' amount of exercise and walking level collected only to the experimental group using the insole-type gait analysis system. Check the stability of data collection, and if an abnormality occurs, take action and record it by phone or in person
215032579|NCT02295462|OTHER|Person-centered Care|Medication Review + Person-centered Care
215032580|NCT02295462|OTHER|Optimised Treatment|Medication Review only
214282460|NCT00616395|DEVICE|No intervention|
214282461|NCT04258384|OTHER|survey application|Data collection tools used in the study; Demographic Data Form, Mcgill and Melzack Pain Questionnaire, Short Form-36 (SF-36), Vanderbilt Multidimensional Pain Coping Inventory (VMPCI), Pain Coping Inventory (PCI), Pain Coping Scale were used.
214282462|NCT00005589|BIOLOGICAL|filgrastim|
214282463|NCT00005589|BIOLOGICAL|rituximab|
214282464|NCT00005589|DRUG|carmustine|
214282465|NCT00005589|DRUG|cyclophosphamide|
214282466|NCT00005589|DRUG|cytarabine|
214470621|NCT06132685|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214470622|NCT06132685|PROCEDURE|Computed Tomography|Undergo CT scan
214470623|NCT06132685|DRUG|Dexamethasone|Given dexamethasone or IV
214470624|NCT06132685|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214470625|NCT06132685|OTHER|Questionnaire Administration|Ancillary studies
214470626|NCT06094062|OTHER|App-based treatment support|The intervention includes a smartphone app that patients will download on their smartphones. Medication intake, symptom course and well-being will be tracked over treatment duration. If symptoms worsen, the pharmacist will contact the patients and counsel them based on their adherence and well-being data. Patients who still have symptoms after the 30 days of treatment will receive a final counseling by the pharmacy, and if necessary will be forwarded to the treating physician.
215032581|NCT05890209|DEVICE|Continuous Glucose Monitoring device|A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
215032582|NCT04542681|DRUG|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo/normal saline
215032583|NCT04542681|DRUG|MANP - 1st Cycle|Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
215032584|NCT04542681|DRUG|MANP - 2nd Cycle|Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
215032585|NCT06397092|PROCEDURE|transapical beating-heart septal myectomy|The patients with hypertrophic cardiomyopathy undergoing TA-BSM
215032586|NCT02476227|PROCEDURE|Ablation using CARTO system|automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
215032587|NCT06412887|DEVICE|Virtual reality headset|Meta-Quest 2 virtual reality headset was used in this study
215032588|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid|Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
214470627|NCT06568731|DRUG|Danuglipron|Danuglipron oral tablets
215032589|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid (Revised)|The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
215032590|NCT03044145|BEHAVIORAL|Treatment as usual|Standard mental health treatment at FHMC
215032591|NCT00732888|DRUG|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
215032592|NCT00732888|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
215032593|NCT01093131|OTHER|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
215032594|NCT01093131|DRUG|Oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
215032595|NCT01093131|OTHER|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
215032596|NCT01093131|DRUG|Intravenous sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
215032597|NCT04419246|OTHER|interscalene block|ultrasound guided ultrasound guided interscalene block 30 minutes before operation. 30 minutes before operation.
215032598|NCT04419246|DRUG|tranexamic acid|10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
215032599|NCT04419246|OTHER|general anesthesia|general anesthesia will be applied in accordance with standard procedures
215032600|NCT01195597|DEVICE|E-Cigarette 7.2 mg nicotine|"Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges (Original cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer"
215032601|NCT05892107|PROCEDURE|Toy Group|After meeting the children in the toy group, the toy will be given to the children to play 1 minute before the procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
215032602|NCT05892107|PROCEDURE|Mask group with cartoon characters|The nurse who will open the vascular access with the children in the cartoon character mask group will meet the child 1 minute before the procedure with a cartoon character mask on his/her face.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
215032603|NCT05892107|PROCEDURE|Control group|In the control group, the nurse who will open the vascular access will meet the child 1 minute before the procedure with a white mask on her/his face. Children in the control group will be subjected to routine procedures before blood collection.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
215032604|NCT06228950|BEHAVIORAL|Mindfulness-Based Stress Reduction|A therapeutic approach called mindfulness-based stress reduction, or MBSR, aims to reduce emotional and behavioral problems by fostering mindfulness, which is an impartial awareness of the present moment. MBSR will be an 8-week training course for students with visual impairment. MBSR training, translated and adapted in Urdu language that includes 8 audios and worksheets corresponding to each week. Worksheets to record home practice will be filled upon receiving oral feedback from the students with visual impairment. Face-to-face group-based sessions will be conducted weekly.
215032605|NCT03974061|BEHAVIORAL|Brief Acceptance and Commitment Therapy|Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
215032606|NCT03974061|BEHAVIORAL|Brief Alcohol Intervention|The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
214282467|NCT00005589|DRUG|etoposide|
214282468|NCT00005589|DRUG|melphalan|
214470628|NCT05091879|GENETIC|Multigene pharmacogenomics test|This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
214470629|NCT05111613|DEVICE|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
214470630|NCT05111613|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
215032607|NCT06188195|DRUG|Dexamethasone|ACS intervention were used in the experimental group
215032608|NCT03641287|OTHER|Exercise Counseling|Meet with exercise physiology
215032609|NCT03641287|OTHER|Aerobic Exercise|Receive prescription for moderate aerobic exercise
215032610|NCT03641287|OTHER|Physiological Support|Receive motivational support via telephone care
215032611|NCT03641287|OTHER|Quality-of-Life Assessment|Ancillary studies
215032612|NCT03641287|OTHER|Questionnaire Administration|Ancillary studies
215032613|NCT03641287|OTHER|Best Practice|Undergo habitual level of physical activity
215032614|NCT03322566|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
215032615|NCT03322566|DRUG|Epacadostat|Epacadostat administered orally twice daily.
215032616|NCT03322566|DRUG|Platinum-based chemotherapy|Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
215032617|NCT03322566|DRUG|Placebo|Matching placebo administered orally twice daily.
215032618|NCT05104060|PROCEDURE|pectoralis minor intervention group|The subjects in pectoralis minor group will received manual therapy for pectoralis minor by physical therapist, the technique including stretch and soft tissue mobilization. The subjects asked to perform the scapular control exercise and shoulder strength exercise.Subjects will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
215032619|NCT05104060|PROCEDURE|shoulder strengthening group|The subjects in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
215032620|NCT06487520|OTHER|group watching hot environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Peaceful mountain snow image was shown. This image includes a cold winter day.~Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
215032621|NCT06487520|OTHER|group watching cold environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Deep space relaxation image was shown. This image contains a hot environment image with explosions in space.Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
215032622|NCT00603681|DRUG|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
215032623|NCT00603681|DRUG|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
215032624|NCT05870345|DEVICE|Butterfly IQ|Butterfly IQ is a pocket sized ultrasound device. Each participant will undergo a ultrasound exam of both elbows using a pocket sized ultrasound device.
215032625|NCT00841139|DRUG|Perhexiline|100mg o bd
215032626|NCT00841139|DRUG|Placebo|1 tablet bd
215032627|NCT00986882|DRUG|SAF312A|
215032628|NCT00986882|DRUG|Placebo|
215032629|NCT00986882|DRUG|Ibuprofen|
215032630|NCT05291910|DRUG|Inetetamab|Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
214470631|NCT06780748|PROCEDURE|Identification rate of sentinel lymph node|To evaluate the identification rate of sentinel lymph nodes (SLNs). The study will compare the identification rates based on different localization techniques for SLN mapping
214282469|NCT00005589|PROCEDURE|bone marrow ablation with stem cell support|
214282470|NCT00005589|PROCEDURE|peripheral blood stem cell transplantation|
214470632|NCT06780241|DIAGNOSTIC_TEST|CMR|CMR (with contrast at baseline and non-contrast at follow-up)
214470633|NCT06780241|OTHER|Quality of Life Questionnaire|Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire
214470634|NCT04294641|DRUG|Ibrutinib|140 mg capsules for a dose of 420 mg daily by mouth for up to 12 months.
214470635|NCT04294641|DIAGNOSTIC_TEST|ECG|At screening.
214470636|NCT04294641|DIAGNOSTIC_TEST|PFT's|"Participants should have PFTs if not performed ≤3 months prior to start of study treatment and Cycle 7, Day 1 (6 months).~Optional at Cycle 12, Day 28 (12 months) and Cycle 24, Day 28 (24 months)."
215032631|NCT05291910|DRUG|Toripalimab|240mg intravenously every 3 weeks
215032632|NCT05291910|DRUG|Albumin-Bound Paclitaxel|130mg/m2, IV , D1, D8, q3w
215032633|NCT01569412|BIOLOGICAL|Ertumaxomab|trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
215032634|NCT05187234|OTHER|Education|Experimental: intervention group Education and training booklet based on the Roy adaptation model was given to the patients. The training was repeated at the first welcome and after the first month.
215032635|NCT01252680|BIOLOGICAL|Healive+Healive|Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
215032636|NCT01252680|BIOLOGICAL|Healive+Havrix|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
215032637|NCT01252680|BIOLOGICAL|Havrix+Havrix|Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
214282471|NCT04661384|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given ICV
214282472|NCT04171531|DRUG|Botox® injection|Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.
214282473|NCT04171531|DEVICE|Mid-urethral sling|"Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Mini-sling and single-incision sling will not be allowed due to potential risk for higher failure rate."
214282474|NCT04947319|DRUG|Tirabrutinib|Part A: Tirabrutinib 480 mg, taken orally, once a day on an empty stomach. Tirabrutinib treatment may be continued until disease progression or clinically unacceptable toxicity is observed.
214282475|NCT04947319|DRUG|Tirabrutinib|"Part B, Arm 1 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an MTR induction regimen. Tirabrutinib with MTR treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment."
214282476|NCT04947319|DRUG|Tirabrutinib|"Part B, Arm 2 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an R-MPV induction regimen. Tirabrutinib with R-MPV treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment."
214282477|NCT05540652|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community."
214282478|NCT05707910|BIOLOGICAL|EBV immunological agent|Low-dose group:2\*10\^7 Medium-dose group:5\*10\^7 High-dose group:2\*10\^8
215032638|NCT01252680|BIOLOGICAL|Havrix+Healive|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
214282479|NCT05833152|PROCEDURE|total knee arthroplasty|To observe the postoperative functional outcome of patients with knee extension lag at different angles
214282480|NCT06249126|PROCEDURE|Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)|Definitive fixation by joint fusion
214282481|NCT06249126|PROCEDURE|Open Reduction Internal Fixation (ORIF) only|Definitive fixation with plates and screws
214470637|NCT04294641|DIAGNOSTIC_TEST|CT|Non-contrast CT at baseline and later during the study if clinically indicated.
215032639|NCT00164580|BEHAVIORAL|Community-Level Intervention|
215032640|NCT02736071|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
215032641|NCT02736071|DRUG|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
215032642|NCT02736071|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
214282482|NCT06188923|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
214282483|NCT06188923|DRUG|Placebo|Same as active comparator, except placebo dispensed
214470638|NCT04294641|DRUG|Steroid pulse (prednisone)|0.5-2mg/kg/day allowed for clinical disease stabilization during first 4 weeks after starting Ibrutinib.
214470639|NCT04294641|DRUG|Voriconazole|At any dose.
214470640|NCT04294641|DRUG|Posaconazole|"As clinically indicated. At doses less than or equal to suspension 200 mg twice a day (BID) if ibrutinib dose modified to 280 mg once daily.~OR Posaconazole suspension 200 mg three times a day (TID) or 400 mg BID if Ibrutinib dose modified to 140 mg once daily.~OR Posaconazole injection intravenous (IV) injection 300 mg once daily; or delayed-release capsules 300 mg once daily if Ibrutinib dose modified to 140 mg once daily.."
214470641|NCT04294641|DRUG|Azithromycin|Treat or prevent bronchiolitis obliterans.
215032643|NCT02736071|DRUG|Placebo 2|Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
215032644|NCT05375630|DIETARY_SUPPLEMENT|Placebo|Placebo
215032645|NCT05375630|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2
214470642|NCT04294641|DRUG|Montelukast|Treat or prevent bronchiolitis obliterans.
214470643|NCT04294641|DRUG|Budesonide|Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).
215032646|NCT05809700|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|"This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded."
215032647|NCT01370148|DRUG|conivaptan hydrochloride|Intravenous
215032648|NCT03656354|DEVICE|Seismocardiography|Seismocardiography recording
215032649|NCT03551093|DEVICE|ISS SPG stimulation|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
214282484|NCT04704921|GENETIC|ABBV-RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
214282485|NCT04704921|GENETIC|ABBV-RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
215032650|NCT00376558|BEHAVIORAL|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
215032651|NCT06334796|DIAGNOSTIC_TEST|Virtual Assistant|Stage 1 focused on safety, using only medical information from clinical records for the virtual assistant. In Stage 2, which evaluated accuracy, participants interacted with the virtual assistant post-medical stabilization. Additionally, participants also provided initial symptom details for Chat-GPT input. Nine neurologists specializing in emergency participated in the study. In Stage 1, they assessed the virtual assistant's performance using clinical history information. In Stage 2, they analyzed the results from participant interactions with the assistant and performed a comparative evaluation of Chat-GPT. The virtual assistant functioned as a chatbot on WhatsApp and Telegram, using Spanish and incorporating advanced algorithms, decision trees, and large language models for interaction. For comparison, we utilized Chat-GPT versions 3.5 and 4, employing two prompt types in natural Spanish: one incorporating clinical record data and the other based on participant narratives.
215032652|NCT02546323|DRUG|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
215032653|NCT02546323|DRUG|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
215032654|NCT03765931|DRUG|Doxycycline|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
215032655|NCT03765931|DRUG|Amoxicillin|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
215032656|NCT04087642|DIAGNOSTIC_TEST|Intraoperative Crede manoeuver|In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
215032657|NCT04087642|DIAGNOSTIC_TEST|Preoperative prolapse reduction cough stress test|In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
215032658|NCT02578082|DRUG|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
215032659|NCT00195780|DRUG|Divalproex Sodium (Depakote ER)|
215032660|NCT03323255|DEVICE|repeated transcranial magnetic stimulation continuous theta-burst stimulation|cTBS
215032661|NCT03323255|DEVICE|SHAM repeated transcranial magnetic stimulation|SHAM stimulation
215032662|NCT04957589|DIETARY_SUPPLEMENT|Very Low Calorie Diet|"A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day."
214282486|NCT04704921|BIOLOGICAL|Ranibizumab (LUCENTIS®)|0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
214282487|NCT04741828|DRUG|Vi-DT Typhoid Conjugate Vaccine|Typhoid Conjugate Vaccine
214282488|NCT05517083|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
214282489|NCT03569553|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
214282490|NCT04545502|DEVICE|Gelsoft Plus Vascular Graft|Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.
214282491|NCT04545502|DEVICE|Vascular Bypass Graft|Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.
214282492|NCT04545502|DEVICE|Cardiovascular Patch|Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.
214282493|NCT04545502|DEVICE|Gelweave Vascular Graft|The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.
214282494|NCT04545502|DEVICE|Gelweave Valsalva Vascular Graft|This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.
214282495|NCT04862585|DRUG|Cimetidine|Given IV and/or PO
214282496|NCT04862585|DRUG|Dexamethasone|Given IV and/or PO
214282497|NCT04862585|DRUG|Diphenhydramine|Given IV and/or PO
214282498|NCT04862585|DRUG|Famotidine|Given IV and/or PO
214282499|NCT04862585|DRUG|Paclitaxel|Weekly or every 14 day dosing
214282500|NCT04862585|OTHER|Quality-of-Life Assessment|Ancillary studies
214282501|NCT04862585|DRUG|Ranitidine|Given IV and/or PO
214282502|NCT03959839|PROCEDURE|ESD|Rectal Endoscopic Submucosal Dissection
214282503|NCT03959839|PROCEDURE|TAMIS|Transanal Minimally Invasive Surgery
214282504|NCT03959839|PROCEDURE|TEO|Transanal Endoscopic Operation
214282505|NCT05127265|OTHER|Video Monitoring|continuous video monitoring
214282506|NCT05127265|OTHER|Accelerometer Monitoring|continuous accelerometer monitoring of patient movements
214282507|NCT05127265|OTHER|Noise Level Monitoring|continuous environmental noise monitoring
214282508|NCT05127265|OTHER|Light Level Monitoring|continuous environmental light monitoring
214282509|NCT05127265|OTHER|Air Quality Monitoring|continuous environmental air quality monitoring
214282510|NCT05127265|OTHER|EKG Monitoring|continuous EKG monitoring
214282511|NCT05127265|OTHER|Vitals Monitoring|continuous vitals monitoring (heart rate, oxygen saturation)
214470644|NCT04294641|DRUG|Beclomethasone|Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).
215032663|NCT04957589|OTHER|High Intensity Interval Training|The HIIT training will consist of a five-exercise approach across three movements (star jumps, standing squats, on-the-spot-sprinting, standing squats and star jumps), which are collectively described as a cycle in this context. Each exercise is performed for 60 seconds with a 90 seconds recovery period. Each training session will begin with a two minute warm-up and cooldown (on-the-spot-jogging) followed by five minutes of static stretching. Volunteers would aim to exceed the initial number of star jumps and standing squats in the subsequent attempt per cycle. A total of three training sessions per week are to be completed, preferably non-consecutive but may be consecutive on no more than two training sessions per week. Progression is through a gradual increase in volume (repetitions of star jumps and standing squats) on a per-session basis.
215032664|NCT04621578|DEVICE|HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)|"Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point."
215032665|NCT01943760|DRUG|tramadol|The volume of the solution was adequate to maintain the concentration of 2% tramadol
215032666|NCT01943760|DRUG|0.9% saline|
214282512|NCT05127265|OTHER|Biosample Collection|blood and urine samples collected once on Day 1 and once on Day 2
214282513|NCT05127265|OTHER|Delirium Motor Subtyping Scale 4 (DMSS-4)|done daily on delirious patients to subtype delirium
214282514|NCT03366337|DRUG|Bardoxolone methyl capsules|Bardoxolone 5 mg capsules
214282515|NCT06274918|DEVICE|Personalized Body-Worn Alcohol Dispenser|This is an alcohol dispenser that will be worn on the Anesthesia Providers scrub pants, near the hip. It will be worn by both the attending physician and the resident physician/CRNA/SRNA. The device is produced by Georgia-Pacific.
214282516|NCT05618652|BEHAVIORAL|Equity Focused and Trauma-Informed Communication Intervention|Clinician communication intervention that includes didactic training and real-time feedback on communication behaviors during clinical encounters.
214282517|NCT00390065|DRUG|Nitric Oxide|Early low dose (5ppm) NO inhalation Placebo
214282518|NCT04755569|DEVICE|ODOCOR II CCM LEADS|ODOCOR II CCM LEADS Implantation
214282519|NCT00356473|DRUG|Atorvastatin|
214282520|NCT01217359|DRUG|Interferon Alfa-2b|Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
214282521|NCT00896571|DRUG|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
214282522|NCT00247897|DRUG|Skin antisepsis|See Detailed Description
214282523|NCT01804283|PROCEDURE|ischemic postconditioning|"multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest."
214282524|NCT01804283|PROCEDURE|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
214282525|NCT01804283|DEVICE|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
214282526|NCT01804283|DEVICE|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
214282527|NCT04505462|OTHER|Therapeutic diet|A special healthy diet for dialysis patients
214282528|NCT01581645|DEVICE|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
214282529|NCT05379738|OTHER|6 sessions of adapted physical activity after stem cell transplant|"physical assessement before and after stem cell transplant:~* weight loss~* brachial muscle circumference~* grip strength evaluation~* short physical battery test~psychometric assessment before and after stem cell transplant:~* quality of life questionary~* physical activities questionary"
214282530|NCT05229406|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
214282531|NCT03849196|DRUG|2L PEG-Asc|PEG-Asc powder
214282532|NCT03849196|DRUG|Bisacodyl 10Mg Suppository|bisacodyl 10 mg suppository
214282533|NCT03849196|DRUG|1L PEG-Asc|PEG-Asc powder
214470645|NCT04294641|OTHER|Filgrastim|Neutrophil growth factor permitted per institutional policy
214470646|NCT04294641|OTHER|Pegfilgrastim|Neutrophil growth factor permitted per institutional policy.
214470647|NCT04294641|OTHER|Erythropoietin|Red cell growth factor permitted per institutional policy.
214282534|NCT02973698|OTHER|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
214282535|NCT02973698|OTHER|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
214282536|NCT02973698|OTHER|Control|No intervention will do
214282537|NCT00689234|PROCEDURE|diaphragm plication 6 months after inclusion|thoracotomy
214282538|NCT00689234|PROCEDURE|diaphragm plication at time of inclusion|thoracotomy
214906749|NCT06187012|OTHER|Hypertensive pregnancy|Participants will attend one visit lasting approximately 3-4 hours on a single day or split over multiple visits to complete all measures. Participants will first be asked to provide written informed consent for the study. Participants' anthropometric measures (waist-to-hip ratio, height and weight, hip and waist circumference and left arm circumference and resting blood pressures will then be taken. After this, the participants will undergo cardiopulmonary exercise testing, followed by magnetic resonance imaging, echocardiography, retinal imaging and vascular imaging of the ear. The study visit will conclude with participants being provided with a wrist-worn physical activity monitor to wear for 7-9 days following the visit. These monitors will provide objective measures of physical activity while people go about their normal activities.
214282539|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-carb)|Receive dietary guidelines and recipes and consume a low-carbohydrate diet
214282540|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-fat)|Receive dietary guidelines and recipes and consume a low-fat diet
214282541|NCT03785808|BEHAVIORAL|Special Diet Therapy (USDA control)|Receive dietary guidelines and recipes and consume USDA control diet
214282542|NCT05015244|PROCEDURE|3T (Tesla) Magnetic Resonance Imaging (MRI)|Neurological evaluation using MRI and neuropsychological tests
214282543|NCT01486732|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
214282544|NCT01486732|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
214282545|NCT01486732|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
214282546|NCT00574132|DRUG|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
214282547|NCT00574132|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
214282548|NCT00574132|DRUG|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions
214282549|NCT05292846|DRUG|Direct-acting oral anticoagulation|Apixaban Dabigatran Edoxaban Rivaroxaban
215032667|NCT02589288|PROCEDURE|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
215032668|NCT02589288|PROCEDURE|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
214282550|NCT03863249|PROCEDURE|SCALE AND ROOT PLANING|"SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA)."
214282551|NCT03863249|DRUG|ADJUNTIVE ANTIBIOTICS|"The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN."
214282552|NCT03863249|DIAGNOSTIC_TEST|MICROBIAL SAMPLING|"1. Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~2. The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy."
214282553|NCT06407167|DIAGNOSTIC_TEST|DN4 (Douleur Neuropathique 4 Questions) questionnaire|DN4 includes a series of ten questions consisting of both sensory descriptors and signs related to bedside sensory examination
214282554|NCT05812898|OTHER|exercises|strengthening of the gluteus maximus and medius, calf muscles stretching for calf and hamstring muscles
214282555|NCT05812898|OTHER|myofascial release|myofascial release using instrument assisted soft tissue mobilization
214282556|NCT02337257|DRUG|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
214282557|NCT02337257|DRUG|Placebo|subjects will receive placebo one pill per day for 16 weeks
214282558|NCT00459953|DRUG|Extended treatment|All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
214282559|NCT06076265|PROCEDURE|Radical Gastric Cancer Surgery|Laparoscopic (robotic) radical surgery for gastric cancer
214282560|NCT03789344|OTHER|acupuncture|Acupuncturists apply the seven-days' electro-acupuncture treatment on the acupoints of Neiguan points and Daling points for 30min per day.
214282561|NCT03789344|OTHER|Psychotherapy|Subjects in psychotherapy group would be accepted 20mins- psychotherapy per day.
214282562|NCT03789344|OTHER|blank control|Blank control subjects would be observed only during this investigation.
214282563|NCT02741180|OTHER|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
214282564|NCT02741180|OTHER|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
214282565|NCT00496470|DRUG|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
214282566|NCT00496470|DRUG|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
214282567|NCT05704062|PROCEDURE|Diffusion Weighted Imaging|Undergo DW-MRI
214282568|NCT05704062|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
215032669|NCT03963284|PROCEDURE|cardiac surgery|pediatric cardiac surgery with cardiopulmonary bypass
215032670|NCT03963284|DEVICE|NephroCheck test|Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test
215032671|NCT06561802|DIAGNOSTIC_TEST|GCF and saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Also, 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips and put into propylene tube. Tubes were stored at -80ºC until the day of analysis.
215032672|NCT06424639|DRUG|Luspatercept|Luspatercept (dose of 1.0 mg/kg, subcutaneous injection every 3 weeks) Cyclosporine (3-5mg/kg/day)
215032673|NCT06424639|DRUG|cyclosporine|Cyclosporine (3-5mg/kg/day)
215032674|NCT00006167|DRUG|oxandrolone|
215032675|NCT00006167|BEHAVIORAL|Progressive Resistance Training|
214282569|NCT02054260|DRUG|Surgicel|
215032676|NCT03578055|DRUG|BDD with UDCA|Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
214282570|NCT04556695|OTHER|Questionnaire survey|Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)
214282571|NCT04556695|DEVICE|Accelerometer study|Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.
214282572|NCT04556695|OTHER|Semi-structured interview study|Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
214282573|NCT02837575|BIOLOGICAL|VCL-HB01|Investigational Product
214282574|NCT02837575|OTHER|Phosphate-buffered saline|Placebo
215032677|NCT03578055|DRUG|Placebo|Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
215032678|NCT00453492|DRUG|risedronate sodium|
215032679|NCT01055028|DRUG|Bevacizumab|15 mg/kg, IV every 21 days x 6 cycles.
215032680|NCT01055028|DRUG|Paclitaxel|"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"
215032681|NCT01349478|DEVICE|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
215032682|NCT05181345|OTHER|Sleep recording (at home)|Before both heat exposures, the sleep-wake rhythm will be measured at home for 7 days using actigraphy and a sleep diary that will have been given to him/her during the inclusion visit.
214282575|NCT04418453|OTHER|Integration of telemedicine for MOUD in primary care|Patients with opioid use disorder in rural primary care settings may be referred to receive telemedicine for medication treatment for opioid use disorder
214282576|NCT04006574|OTHER|Exercises|Core stabilization
214282577|NCT06526650|OTHER|'Ai Pono|"Hands-on Cooking and Cultural Lessons These lessons will be widely advertised. Each 2-hour presentation will involve hands-on cooking demonstrations and tastings, accompanied by lessons on the cultural significance of featured food items. Demonstrations will link the consumption of vegetables (e.g., sweet potato, breadfruit, kalo) to Native Hawaiian (NH) history and traditional beliefs to help participants rediscover their heritage through the meals they prepare."
214282578|NCT05594784|DRUG|Olverembatinib|a third-generation TKI
215032683|NCT05181345|OTHER|Heat exposure|"The subjects will be exposed twice (2 different visits) to heat (45°C; 60-70% humidity rate) for 3 hours in a climate chamber.~The subjects will be equipped with various external sensors allowing the continuous recording of core temperature, mean skin temperature (9 skin measurement points), heart rate, cerebral electrical activity, cerebral oxygenation, skin vascular conductance (blood flow by laser-doppler), blood pressure and skin conductance.~Neurophysiological and cognitive exploration (NPCE) includes the Stroop test, the Psychomotor Vigilance Task (PVT) and the odd-ball test."
215032684|NCT05181345|OTHER|Normal sleep|"The night before one of the two heat exposures (first visit for the Normal sleep first group and second visit for the Reduced sleep first group), the participants will have a normal night at home. The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
215032685|NCT05181345|OTHER|Sleep restriction|"The night before one of the two heat exposures (first visit for the Reduced sleep first group and second visit for the Normal sleep first group), the participants' sleep will be restricted. The sleep restriction will correspond to a reduced sleep period with a bedtime of 3 hours (04:00 - 07:00). This night of sleep restriction will be carried out in a sleep apartment (at the lab). The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
215032686|NCT03763630|DRUG|House dust-mite SLIT|received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day. Normal saline was administered to the placebo group. 11 µg of HDM allergen (equal parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered twice daily as oral drops.
215032687|NCT03763630|DRUG|Normal saline|Normal saline administered in same frequency and manner as intervention
214282579|NCT05594784|DRUG|Venetoclax|a selective inhibitor of B-cell lymphoma 2 (Bcl-2)
215032688|NCT02848131|DRUG|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
214282580|NCT05594784|DRUG|prednisone|Glucocorticoids
214282581|NCT05594784|DRUG|Vincristine|Anti-tumor alkaloids
214282582|NCT06108739|DRUG|Cyclophosphamid|A total of 10mg/kg ATG was administered, and two doses of 14.5 mg/kg Cy were given on days 3 and 4 post-HCT in ATG-PTCy cohort.
214282583|NCT06108739|DRUG|ATG|A total of 10mg/kg ATG was administered.
214282584|NCT06258642|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, Q2W, iv
214282585|NCT06258642|DRUG|Anlotinib|12 mg, qd, po for 2 consecutive weeks and then discontinued for 1 week.
215032689|NCT02848131|DRUG|Group 2: Quercetin|Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
215032690|NCT06494995|DRUG|Cadonilimab|a PD-1/CTLA-4 dual antibody
215032691|NCT06494995|RADIATION|Low-dose radiotherapy|Low-dose radiation
215032692|NCT06494995|RADIATION|SBRT|selected leisions to treat with stereotactic radiotherapy
215032693|NCT06494995|DRUG|Capecitabine|Capecitabine metronomic chemotherapy
215032694|NCT06469021|OTHER|Conservative Approach|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the individuals. In a one session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises and 10 minutes of balance training will be applied. The exercises will start from an easy level and the level of difficulty will be gradually increased. The assessments will be evaluated in three stages: at the beginning of treatment, at the third month of treatment and at the end of treatment (sixth month).
215032695|NCT06469021|OTHER|Rehabilitative Game Therapy|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the patients and will be applied to the patients with a conventional approach. In a one-session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises, and 10 minutes of balance training will be applied in the clinical setting. Home exercises will be performing with the SmartPose system differently from the control group. The SmartPose system is a special software system that enables the user to perform movements with a tablet or phone without the need for any sensors.
215032696|NCT05719246|BEHAVIORAL|Yoga|The yoga video set that the participants will follow is a brief, at-home, 6-week twice per week Standardized Yoga \& Meditation Program for Stress Reduction (SYMPro-SR) program. The videos feature Sydney Topfer guiding the participants through different yoga poses.
215032697|NCT05499702|BEHAVIORAL|Caloric Restriction|"Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from Nutritional Guidelines after Bariatric Surgery. Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake"
215032698|NCT05499702|DRUG|Hyperglycemic clamp|Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism
215032699|NCT05059327|DRUG|Basimglurant with crossover to Placebo|Basimglurant with crossover to Placebo
215032700|NCT05059327|DRUG|Placebo with crossover to Basimglurant|Placebo with crossover to Basimglurant
215032701|NCT01419730|DRUG|Vitamin D3|Vitamin D3 50,000 IU
215032702|NCT01419730|BEHAVIORAL|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
215032703|NCT00518869|DRUG|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
215032704|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
215032705|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
214282586|NCT02672826|PROCEDURE|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
214282587|NCT00654680|DRUG|Vardenafil (Levitra, BAY38-9456)|5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
214282588|NCT00654680|DRUG|Placebo|Matching placebo
214282589|NCT03530969|BEHAVIORAL|Self-Efficacy Assessment|"Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training."
214282590|NCT03530969|BEHAVIORAL|UCLA Geriatrics Attitudes Scale|The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
214282591|NCT03530969|BEHAVIORAL|Course Evaluations|The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
215032706|NCT06643325|DIAGNOSTIC_TEST|Gastric ultrasound|Serial, gastric sonography
215032707|NCT06413914|BEHAVIORAL|Cognitive behavioral Therapy|"Cognitive behavioral therapy is the psychological approach in this study. It is associated with better outcomes of rehabilitation for long-term pain in general, reduced pain intensity and less use of medication and health services, sustaining factors that provide an understanding of how thoughts and feelings affect the experience of pain. An important aim is also a reduction in pain-related rumination and worry and changed metacognition that maintains inhibiting behavior and thought patterns.~A workbook for pain has been developed. It contains knowledge about pain and pain management, describes measures and homework from session to session. The treatment consists of 8 sessions with 7 weekly sessions + 1 booster session 2 months after the end of treatment.~."
215032708|NCT06567782|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
215032709|NCT06567782|DRUG|CAPEOX|CAPEOX chemotherapy consisting of capecitabine and oxaliplatin will be administered.
215032710|NCT06152835|OTHER|Data and breast milk samples collection|Breast milk samples and, clinical, anamnestic and lifestyle data collection
215032711|NCT06800846|PROCEDURE|Intraosseous Morphine|Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation
215032712|NCT06800846|PROCEDURE|Periarticular Injection|Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.
215032713|NCT02063256|DIETARY_SUPPLEMENT|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
215032714|NCT02063256|OTHER|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
215032715|NCT05793086|DIAGNOSTIC_TEST|Ultrasound|Using shear wave elastography and gray scale analysis of ultrasound.
214282592|NCT03530969|BEHAVIORAL|The Consultation and Relational Empathy (CARE) questionnaire|The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
214282593|NCT03530969|BEHAVIORAL|Consumer Assessment of Health Care Providers and Systems Program (CAHPS)|"Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)"
214282594|NCT03530969|BEHAVIORAL|Patient activation measure (PAM) scale|The PAM scale contains 22 items that assess patient engagement in their care process.
214282595|NCT06297577|PROCEDURE|Albumin Platelet Rich Fibrin (Alb-PRF) combined with minimally invasive surgical technique (MIST)|Albumin-PRF will be placed into intrabony defect
214282596|NCT06297577|PROCEDURE|Minimally invasive surgical technique (MIST)|MIST will be the surgical access for treatment of Intrabony defect
214282597|NCT01114256|PROCEDURE|FNA Biopsy|
214282598|NCT04966039|OTHER|No intervention.|There was no intervention.
214282599|NCT05806073|PROCEDURE|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
214282600|NCT05806073|PROCEDURE|Therapeutic neck dissection|patient underwent Therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
214282601|NCT00386178|DRUG|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
215032716|NCT05793086|DIAGNOSTIC_TEST|Electrical impedance myography|Measurement of localized bioimpedance of muscle
215032717|NCT05793086|DIAGNOSTIC_TEST|Excitability testing|Electrical studies of myofiber excitability
215032718|NCT05731245|DRUG|Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
215032719|NCT05689099|DRUG|Semaglutide B, 1.34 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
215032720|NCT05689099|DRUG|Semaglutide B, 0.68 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
215032721|NCT03559530|DRUG|Antimicrobial|Antimicrobial therapy according to A. baumannii susceptibility profile
215032722|NCT03058874|DEVICE|Extra-vascular lung water measurements by ultrasound|Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
215032723|NCT03058874|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
215032724|NCT06469242|DEVICE|Serafilcon A multifocal contact lenses|Investigational multifocal soft contact lenses
215032725|NCT06469242|DEVICE|Senofilcon A multifocal contact lenses|Commercially available multifocal soft contact lenses
215032726|NCT06469242|DEVICE|CLEAR CARE® Cleaning & Disinfecting Solution|Hydrogen peroxide-based contact lens cleaning and disinfection system
215032727|NCT04626726|DRUG|CD19 CAR-T|CD19 CAR-T infusion for patients with CD19 positive tumor cells
215032728|NCT04626726|DRUG|CD22 CAR-T|CD22 CAR-T infusion for patients with CD22 positive tumor cells
215032729|NCT04626726|DRUG|CD19+CD22 CAR-T|CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
215032730|NCT04626726|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
215032731|NCT04626726|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
215032732|NCT01657331|DRUG|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
215032733|NCT01657331|DRUG|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
215032734|NCT01657331|DRUG|Neulasta|(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
215032735|NCT01664715|BEHAVIORAL|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
215032736|NCT01664715|BEHAVIORAL|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
215032737|NCT01664715|BEHAVIORAL|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
215032738|NCT04924933|DIAGNOSTIC_TEST|Computerised associative memory task using abstract words and landscape photographs|Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
215032739|NCT00997763|DEVICE|XIENCE V|everolimus-eluting stent
215032740|NCT00997763|DEVICE|CYPHER|sirolimus-eluting stent
215032741|NCT02261792|PROCEDURE|24 hours Trendelenburg position|Trendelenburg position
215032742|NCT02261792|PROCEDURE|24 hours bed rest|24 hours bed rest after EBP
215032743|NCT02261792|PROCEDURE|EBP|Autologous Epidural Blood Patch
215032744|NCT03801590|DEVICE|Crosslinking with Riboflavin and UV-A|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.
215032745|NCT05032378|BEHAVIORAL|Kinesthetic Awareness Training|One physical or occupational therapy session per week for 8 weeks during which the participant with disordered movement will attempt to perform desired movements while wearing the KAT device
215032746|NCT05032378|BEHAVIORAL|Provision of KAT-assisted physical or occupational therapy|Physical or occupational therapy professionals will provide one KAT-assisted therapy session per week for 8 weeks to one or more participants with movement disorder.
214282602|NCT05027100|DRUG|Anlotinib Tislelizumab Irinotecan|Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
214470648|NCT04294641|OTHER|Transfusions|According to institutional policy.
215032747|NCT05793502|DEVICE|Solia S and Selectra 3D Developed by BIOTRONIK|LBBaP with Solia S and Selectra 3D Developed by BIOTRONIK
214282603|NCT04904562|DRUG|Angiotensin II|Angiotensin II started at 5 ng/kg/min and titrated in 5-10 ng/kg/min increments every 5 minutes up to 80ng/kg/min to achieve target arterial pressure (MAP)
214282604|NCT04904562|DRUG|Placebo|Placebo
214282605|NCT03972332|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
214282606|NCT04141592|PROCEDURE|Bariatric Surgery|Already clinically indicated surgical procedures
214282607|NCT06233617|DRUG|0.9% Sodium Chloride Injection|biliteral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
214282608|NCT06233617|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|biliteral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
214282609|NCT06233617|DRUG|Dexmedetomidine injection|biliteral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
214282610|NCT03209596|DIETARY_SUPPLEMENT|Orange juice (1L/d)|The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
214282611|NCT03209596|DIETARY_SUPPLEMENT|Control drink (1L/d)|The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
214282612|NCT00837642|DIAGNOSTIC_TEST|Transthoracic echocardiography|Full transthoracic echocardiography will be performed.
214282613|NCT00002105|DRUG|Doxorubicin hydrochloride (liposomal)|
214282614|NCT00002105|DRUG|Bleomycin sulfate|
214282615|NCT00002105|DRUG|Vincristine sulfate|
214282616|NCT00615511|DIETARY_SUPPLEMENT|placebo pregnenolone|Sugar pill, taken twice a day
214282617|NCT00615511|DIETARY_SUPPLEMENT|pregnenolone|500mg in tablet form taken orally twice a day
214282618|NCT05097989|DRUG|ALXN2050|Oral tablets
214282619|NCT05097989|DRUG|Placebo|Oral tablets
214282620|NCT05108155|PROCEDURE|Cemented THA|THA with cement fixation
214282621|NCT05108155|PROCEDURE|Unemented THA|THA with uncemented / pressfit fixation
214282622|NCT06968195|BIOLOGICAL|Anti-GPC3-CAR Autologous T Lymphocytes|Given IV
214906750|NCT03819972|DIETARY_SUPPLEMENT|Dose response of Capolac®|Capolac® (milk minerals high in calcium) dose is manipulated
215032748|NCT02652247|PROCEDURE|molecular analysis of exhaled breath condensate|
215032749|NCT02652247|PROCEDURE|molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate|
214906751|NCT00287534|DRUG|Anastrozole|oral
215032750|NCT02652247|PROCEDURE|molecular analysis of bronchoalveolar lavage (BAL) aspirate|
215032751|NCT03380273|BEHAVIORAL|Implementation of the AO Trauma SSI Prevention Bundle|"AOT SSI Prevention Bundle~Preventive measure~1. Antibiotic prophylaxis~2. Perioperative antibiotics~3. Oxygen administration~4. Patient temperature~5. Surgeon protective wear~6. Patient operative skin preparation~7. Suction drains~8. Blood glucose level~9. Red cell transfusion~10. Dressing changes"
215032752|NCT01362790|DRUG|Pentostatin|Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m\^2 or 2 mg/m\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on days 1 and 5 of 25 day cycle
215032753|NCT01362790|DRUG|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
215032754|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
214906752|NCT00287534|DRUG|Tamoxifen|oral
215032755|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles"
215032756|NCT03452930|RADIATION|Radiation Therapy|Undergo RT
215032757|NCT03452930|DRUG|Tinostamustine|Given IV
215032758|NCT02457065|BEHAVIORAL|"Melanoma Survivor plaque"|The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
215032759|NCT04830085|PROCEDURE|Hysterectomy|Hysterectomy (abdominal, vaginal or laparoscopic)
215032760|NCT05896241|OTHER|non-interventional study|non-interventional study
215032761|NCT06467409|DRUG|Placebo|patient-controlled analgesia(PCA) administration
215032762|NCT06467409|DRUG|morphine hydrochloride injection|patient-controlled analgesia(PCA) administration
215032763|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
215032764|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
215032765|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
215032766|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
215032767|NCT02600650|DIETARY_SUPPLEMENT|Testosterone boosting supplement|Proprietary formulation of Testosterone boosting supplement administered daily
215032768|NCT02600650|DIETARY_SUPPLEMENT|Placebo Comparator|Daily administration of Placebo Comparator
215032769|NCT05044767|DEVICE|total hip arthroplasty|hip replacement surgery
214282623|NCT06968195|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214282624|NCT06968195|PROCEDURE|Computed Tomography|Undergo CT
214282625|NCT06968195|DRUG|Cyclophosphamide|Given IV
214282626|NCT06968195|PROCEDURE|Echocardiography Test|Undergo ECHO
214282627|NCT06968195|DRUG|Fludarabine|Given IV
214282628|NCT06968195|PROCEDURE|Leukapheresis|Undergo leukapheresis
214282629|NCT06968195|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214282630|NCT06968195|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214282631|NCT05096897|OTHER|Self-administrated questionnaires|GOHAI, IBD-Q, IBD-disk
214282632|NCT00820560|DRUG|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
214282633|NCT01257087|DRUG|Insulin|All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
214282634|NCT03258268|DEVICE|Standard of Care with EASY DSS|"The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
214282635|NCT03258268|OTHER|Standard of Care without EASY DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
214282636|NCT03533764|BEHAVIORAL|ASMA|ASMA, grounded in social cognitive theory and utilizing motivational interviewing techniques, guides adolescents in their transition to being consumers and teaching them to navigate the health system, including overcoming challenges to health care access. Briefly, it consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
214282637|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(High dose 2g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins \& vitamin C 500 mg (2 g-daily in 4 divided doses) started one day before operation till the end of hospital stay or development of post operative atrial fibrillation
215032770|NCT01969214|DEVICE|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day"
215032771|NCT00279695|PROCEDURE|high frequency ultrasound examination|high frequency ultrasound examination of the eye
215032772|NCT01117246|DEVICE|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
215032773|NCT03324841|DIAGNOSTIC_TEST|Caris MI Profiling|Customized comprehensive biomarker testing
215032774|NCT03429140|DRUG|Gel-One|an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
214282638|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(Low-dose 1g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins, vitamin C 500 mg (1 g-daily in 2 divided doses) and also received 2 capsules containing starch to be completely equivalent in frequency to the other groups. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
214282639|NCT06074367|DRUG|placebo capsules|A sixty CABG Patients commenced on maximum tolerated dose of b-blocker, statins and placebo capsules containing starch mimic vitamin C capsules was taken every 6 hrs. The placebo capsules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
214282640|NCT04813198|BEHAVIORAL|TIPSTART|TIPSTART is a multimodal, cognitive behavior-based therapy integrating peer-sharing, technology, aerobic and resistance training.
214282641|NCT05894083|PROCEDURE|Surgery|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
214282642|NCT05894083|COMBINATION_PRODUCT|Chemoradiation|Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV\_High and PTV\_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV\_High in 2 Gy per fraction.
214282643|NCT05894083|OTHER|Observation|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
214282644|NCT05894083|RADIATION|Post-operative radiation|Patients will receive adjuvant radiation based on pathologic features.Total radiation treatment doses and prescriptions will include 36 Gy in 18 fractions, 50 Gy in 25 fractions and 60 Gy in 30 fractions.
214282645|NCT00232024|DRUG|Tegaserod|
214282646|NCT03863054|DEVICE|NATROX™ Topical Oxygen Therapy System|"A small battery-powered electrochemical oxygen generator to concentrate atmospheric oxygen and feed to wound site through a dressing-like oxygen distribution system"
214282647|NCT02817256|DIETARY_SUPPLEMENT|Vitamins and Minerals|Multivitamins and Minerals supplementation
214282648|NCT01412515|DRUG|everolimus|everolimus per os 10mg per day
214282649|NCT03258437|DIETARY_SUPPLEMENT|DA-9401|
214282650|NCT03258437|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
215032775|NCT03429140|OTHER|Saline Placebo|a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery
215032776|NCT00763828|DEVICE|Life Recovery Systems ThermoSuit|Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
215032777|NCT05887336|DEVICE|Walther System|Walther System providing INMEST treatment
215032778|NCT05887336|DEVICE|Sham Walther System|Walther System not providing INMEST treatment, but otherwise behave as the active comparator.
215032779|NCT05887336|DRUG|Non preserved ocular lubricants|"* Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)"
215032780|NCT05887336|PROCEDURE|Eye lid procedure|Lid hygiene, warm eye bag, lid massage and Omega 3
215032781|NCT03510689|DIAGNOSTIC_TEST|echocardiography|Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.
215032782|NCT03510689|OTHER|Cardiopulmonary Exercise Testing|A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.
215032783|NCT03510689|OTHER|Blood Collection|We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.
215032784|NCT01173744|DEVICE|Gamma-3 Nail|Gamma-3 Nail (stryker)
215032785|NCT01173744|DEVICE|DHS|DHS (Zimmer)
215032786|NCT00219726|DRUG|Imatinib mesylate|
215032787|NCT06007157|BEHAVIORAL|Hypersodic/Hyposodic diet|Participants will undergo a dietary intervention consisting of a week of high-sodium diet (4800 mg/day), followed by a week of low-sodium diet (1200 mg/day).
215032788|NCT05885750|BEHAVIORAL|Unprocessed|Participants will consume unprocessed or minimally processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
215032789|NCT05885750|BEHAVIORAL|Mildly processed|Participants will consume mildly processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
215032790|NCT05885750|BEHAVIORAL|Heavily refined|Participants will consume heavily refined processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
215032791|NCT05805150|DEVICE|Control Lens (stenfilcon A)|One week wear
215032792|NCT05805150|DEVICE|Test Lens (senofilcon A)|One week wear
215032793|NCT01530958|BEHAVIORAL|CKD Registry|"Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~* identify patients with CKD~* notify PCPs of a patients' CKD status~* provide PCP outreach with NKDEP guidelines and patient educational materials"
215032794|NCT01530958|BEHAVIORAL|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
215032795|NCT01530958|BEHAVIORAL|Usual care|"Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care."
215032796|NCT02114645|DRUG|Leuprolide acetate|in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
215032797|NCT02114645|DRUG|vaginal progesterone|crinone gel is applied till fetal heart beat is detected
215032798|NCT02114645|DRUG|4 mg oral estradiol valerate|estrofem is given twice a day
214282651|NCT06504849|BEHAVIORAL|Receiving LSM messages.|"* LSM messages via instant messaging applications~* Chat-type support messages via instant messaging applications"
215032799|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)|Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
215032800|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)|Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
215032801|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)|Nasal continuous positive airway pressure alone
215032802|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)|nasal continuous positive airway pressure alone
215032803|NCT02659085|DRUG|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
215032804|NCT02659085|PROCEDURE|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
215032805|NCT01666366|PROCEDURE|Coronary artery bypass grafting|
215032806|NCT02260232|OTHER|exercise training|
215032807|NCT02124980|BEHAVIORAL|Recovery Line|
215032808|NCT00516308|DEVICE|NightHawk|
215032809|NCT06179537|DRUG|BLU-5937|Single and multiple doses assessment
215032810|NCT01061788|DRUG|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~   Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~   Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
215032811|NCT02688439|OTHER|Sciatic Nerve block|
215032812|NCT02688439|OTHER|Leg raised 30°|
214282652|NCT06504849|BEHAVIORAL|Receiving brief pre-HTN messages.|"* A flyer with brief pre-HTN information which is distributed during the recruitment phase~* Brief pre-HTN messages via instant messaging applications"
214282653|NCT05665478|OTHER|Dose prediction using population pharmacokinetic models|Dose prediction using population pharmacokinetic models.
214282654|NCT03844646|DEVICE|CGM|Intermittent use of a continuous glucose monitor (CGM)
214282655|NCT03844646|OTHER|Dietitian|Monthly meetings with a dietitian
214282656|NCT01378949|DRUG|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
214282657|NCT01378949|DRUG|Morphine|Morphine 1 mg/cc
214282658|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
214282659|NCT00621153|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
214282660|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
214282661|NCT00753415|BIOLOGICAL|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).
214282662|NCT00753415|BIOLOGICAL|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
214282663|NCT00653575|BEHAVIORAL|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
214282664|NCT00653575|BEHAVIORAL|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
214282665|NCT06341842|DRUG|Dapagliflozin 10mg Tab|Dapaglifloziin 10 mg 1 tab daily
214470649|NCT04294641|PROCEDURE|Oral/Skin biopsy|Optional. Baseline, Cycle 7, Day 1 (6 months), Cycle 12, Day 28 (12 months) and Cycle 24, Day 28.
214844386|NCT05491239|PROCEDURE|Continuous regional paravertebral block|"The PVB catheter is placed under general anaesthesia at the beginning of the VATS procedure under direct thoracoscopic vision. The level of the PVB catheter placement is chosen at the intercostal space of the largest incision (mostly thoracic level 4 or 5). Under direct thoracoscopic vision, the surgeon inserts a Touhy needle. The tip of the needle is observed beneath the pleural surface thoracoscopically. Injection of about 2 mL ropivacaine 7.5mg/mL will create subpleural hydrodissection to reach the adequate paravertebral plane for placement of the catheter. The PVB catheter is subsequently placed under direct thoracoscopic vision and left next to the sympathetic chain in the paravertebral space. Next, a bolus of ropivacaine (total amount 20 mL including the given amount for hydrodissection) is given through the catheter.~Postoperatively, a ropivacaine 2 mg/mL pump for continuous infusion is given with an infusion rate of 8-14 ml/hour."
214282666|NCT02784808|DRUG|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
214282667|NCT02784808|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
214282668|NCT00003993|BIOLOGICAL|aldesleukin|
214282669|NCT00003993|DRUG|bryostatin 1|
214282670|NCT04235114|DRUG|50 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 50 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
214282671|NCT04235114|DRUG|1 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 1 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
214282672|NCT04255602|DRUG|Ticagrelor 60mg|Ticagrelor 60mg plus Aspirin 100mg for experimental group
214282673|NCT04255602|DRUG|Ticagrelor 90mg|Ticagrelor 90mg plus Aspirin 100mg for active comparator group
214282674|NCT03548909|DIAGNOSTIC_TEST|VITROS Immunodiagnostic Products|NT-proBNP II assay
214282675|NCT04239144|PROCEDURE|Bilateral sympathectomy|Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.
214282676|NCT04239144|PROCEDURE|Catheter ablation|Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
214282677|NCT00042900|DRUG|pyroxamide|
214282678|NCT00241215|DRUG|Botulinum toxin serotype A|
214282679|NCT00440713|DRUG|Aripiprazole|
214282680|NCT00440713|BEHAVIORAL|Interpersonal Therapy|
214470650|NCT05669612|DIETARY_SUPPLEMENT|Dairy based protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
214470651|NCT05669612|DIETARY_SUPPLEMENT|Mixed protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
214470652|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 1|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
214470653|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 2|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
215032813|NCT02688439|OTHER|Distal tourniquet placed on the lower part of the leg|
215032814|NCT02688439|OTHER|Leg in a neutral position|
214282681|NCT03570021|PROCEDURE|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|"total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association \[American Thyroid Association Surgery Working Group, Thyroid 2009\]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery \[French Society of Otolaryngology Head and Neck Sugery\].~\- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection \[Hartl DM, Ann Surg 2012\], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons \[Hartl DM, World J Surg 2012\]."
214282682|NCT03570021|PROCEDURE|total thyroidectomy alone without neck dissection|This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
214282683|NCT04804475|OTHER|Exercise Trainig|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
214282684|NCT01787487|DRUG|Azacitidine|Given SC or IV
214282685|NCT01787487|OTHER|Laboratory Biomarker Analysis|Correlative studies
214282686|NCT01787487|DRUG|Ruxolitinib Phosphate|Given PO
214282687|NCT06464848|OTHER|Narrative identity task|All participants will be asked to develop five personal narratives in response to different types of questions: trauma, transgression, negative memory, self-definition, and turning point. For each story, participants will be asked to provide details of where they were, who they were with, what happened and how they and others reacted, what happened, how they reacted and how others reacted (if at all).
214282688|NCT06975878|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214470654|NCT04179773|OTHER|Current care study|"Observational study in two parts:~1. Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~2. Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject."
214470655|NCT04817761|DRUG|Calaspargase pegol (S95015)|"Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2.~Patients aged 40 to \< 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2."
214470656|NCT04892940|DEVICE|Virtual Reality (VR) technique|"The PICO G2 4k helmet from the Chinese manufacturer Pico which is an autonomous virtual reality helmet will be used.~The sessions proposed last 20 minutes with a child pain protocol. The teenager will be able to choose his universe (forest, beach, mountain, aquatic, space), the voice that accompanies him (man, woman, none), the sound environment of music therapy (6 to choose from).~Each patient in the experimental group benefits from a virtual reality program including two daily sessions during their stay in the continuing care unit from the first post-operative day until the third post-operative day. Each session is proposed by a nurse anesthetist from the pain team and trained in the proper use of the equipment.This virtual reality program will be added to the standard analgesic protocol for the experimental group."
214470657|NCT04892940|DRUG|Analgesic protocol|"Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively."
214470658|NCT06485479|BEHAVIORAL|Intervention ads|The ads will be on topics to encourage quitting smoking, formatted as multi-color text with graphic elements. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.
214470659|NCT06485479|BEHAVIORAL|Control ads|The ads will be on topics unrelated to quitting smoking, formatted as black text on a white field. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.
214844387|NCT05491239|PROCEDURE|Single shot intercostal nerve block|At the end of the surgery a single shot ICNB will be placed at 9 levels (thoracic level 2 to 10) with 2-3mL local anaesthetics per intercostal space under direct thoracoscopic vision. The injection site will be chosen just lateral from the sympathetic trunk. This group will have no analgesic catheters for continuous analgesia. No mobility restrictions are instructed in this group.
215032815|NCT04116684|DEVICE|Withings Digital Blood Pressure Monitor|This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
215032816|NCT00834782|PROCEDURE|IOP measurement|Measuring IOP
214282689|NCT06975878|BIOLOGICAL|Vaxneuvance vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214282690|NCT06975878|BIOLOGICAL|Hexyon vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214282691|NCT06975878|BIOLOGICAL|M-M-RvaxPro vaccine|Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
214282692|NCT06975878|BIOLOGICAL|Varivax vaccine|Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
214282693|NCT05930483|BEHAVIORAL|¡Vida! program|Participate in ¡Vida! program
214282694|NCT05930483|BEHAVIORAL|¡Vida! Plus [¡Vida! + Experiential Learning (EL)]|Participate in ¡Vida! Plus program
214282695|NCT05930483|BEHAVIORAL|Health Coaching|Receive health coaching
214282696|NCT05930483|BEHAVIORAL|Mailed Toolkits|Receive a mailed toolkit of health items
214282697|NCT06001840|BEHAVIORAL|Promotion factors|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
214282698|NCT06001840|BEHAVIORAL|Mitigation strategies|"Health Communications. The first narrative describes a person unknown to the participant who purchases from the illegal market and experiences negative life outcomes (e.g., ill health from contaminants). The second narrative incorporates cognitive biases of social proof (i.e., portraying a choice as the opinion of the majority).~Availability of Nicotine Replacement Therapies (NRT): Transdermal NRT will be available in the LETM at two different prices. In one condition, transdermal NRT will be available at a 50% subsidy in the form of coupons. In the other condition, a five-day supply of NRT will be available for free.~Penalties: Penalties will be presented in different fine magnitudes along with a description of the consequences of illegal purchases (i.e., a criminal record)."
214282699|NCT05913843|DEVICE|Take photo|We will use the camera to take 2 front and side images of the participant, and select one of the better images to upload to the facial analysis system (GestaltMatcher Database) for analysis.
214282700|NCT03886246|DRUG|Spesolimab|Solution for infusion
214282701|NCT03886246|DRUG|Spesolimab|Solution for injection
214282702|NCT06272695|BIOLOGICAL|Volagidemab|Administered by SC injection once weekly for 6 weeks
214282703|NCT03076697|DIAGNOSTIC_TEST|Fundus photography|Fundus photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing disease along with the stage of disease. Several ophthalmologists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
214282704|NCT05226117|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is a humanized monoclonal antibody (mAb) with a hydrolyzable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors while reducing systemic toxicity. SN-38 is the active metabolite of irinotecan. Sacituzumab govitecan is administered at 7.5 mg/kg as an IV infusion on days 1 and 8 of a 21- day cycle till progression, toxicity or withdrawal of consent
214282705|NCT04519879|OTHER|Clinical Observation|Undergo clinical observation
214282706|NCT04519879|OTHER|Patient Observation|Undergo active surveillance
214282707|NCT04519879|OTHER|Questionnaire Administration|Ancillary studies
214282708|NCT04519879|DRUG|White Button Mushroom Extract|Given PO
214282709|NCT03752827|DEVICE|Adipose Derived Regenerative Cells|Adipose-derived regenerative cells isolated with the Transpose Ultra system
214282710|NCT03752827|DRUG|Corticosteroid|Corticosteroid injection into subacrominal space
214282711|NCT03385993|DEVICE|Technology based guided meditation and relaxation|Subjects will be guided through a mediation and relaxation exercise on a tablet or virtual reality headset for up to an hour each day.
214282712|NCT05370365|PROCEDURE|Below elbow cast|Patients will be stay with a below elbow cast for 4 or 6 weeks
215032817|NCT00261339|DRUG|Pantoprazole|
214282713|NCT05735431|DRUG|Administration of investigation drug|Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
214282714|NCT05735431|DRUG|Administration of comparator|Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
214282715|NCT00659997|DRUG|Albendazole|Single oral dose of 400mg
214282716|NCT00659997|DRUG|Levamisole|Single oral dose of 2.5mg/kg
214282717|NCT02592356|PROCEDURE|Computed Tomography|Correlative studies
214282718|NCT02592356|PROCEDURE|Dual X-ray Absorptiometry|Correlative studies
214282719|NCT02592356|PROCEDURE|Physical Examination|Correlative studies
214844388|NCT01049412|DRUG|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
215032818|NCT00044785|DRUG|triacetyluridine|
215032819|NCT00044785|DRUG|fluorouracil|
215032820|NCT00044785|DRUG|leucovorin|
215032821|NCT00044785|DRUG|camptosar|
215032822|NCT01862354|PROCEDURE|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
215032823|NCT01862354|PROCEDURE|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
214282720|NCT02592356|OTHER|Quality-of-Life Assessment|Ancillary studies
214282721|NCT02592356|OTHER|Questionnaire Administration|Ancillary studies
214282722|NCT02592356|DRUG|Cabozantinib|
214282723|NCT02592356|DRUG|Lenvatinib|
214282724|NCT04849143|OTHER|Stingless bee honey ( Kelulut honey)|"The honey will be acquired from Brainey Sdn Bhd, a company that provides stingless bee honey certified with Good Manufacturing Practice (GMP), ISO 22000, and Halal.~As the honey used is not medical-grade honey, sterilization with 25kGy gamma-ray irradiation will be done for safety purposes to eradicate any potential life-threatening infection such as spores from Clostridium botulinum."
214282725|NCT04849143|OTHER|Gel dressing|Smith-Nephew's Intrasite gel
214282726|NCT00580684|BIOLOGICAL|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
214470660|NCT03643744|DRUG|Celecoxib 200mg|14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
214470661|NCT03643744|DRUG|Placebo|14 placebo capsules taken 1 in the morning and 1 in the evening.
214470662|NCT04895033|BEHAVIORAL|Responsibility condition|During the fMRI scan, participants will complete alcohol purchase task paradigm for hypothetical alcohol rewards under two conditions. In the next-day responsibility condition, we will present a vignette describing a drinking scenario in which participants have a significant activity the next day (e.g., a work, family, or academic obligation the next morning) and participants are asked to imagine they are deciding how much they want to drink in this situation. The control condition will use a vignette describing a typical drinking scenario with no explicit responsibilities the next day
214470663|NCT03125928|DRUG|Atezolizumab|Monoclonal antibody
215032824|NCT00670644|OTHER|questionnaire administration|Completed self-report form
215032825|NCT00670644|OTHER|survey administration|Completed self-report form-other
215032826|NCT00670644|PROCEDURE|quality-of-life assessment|Completed self-report form qol
215032827|NCT03598348|DRUG|Apatinib+Capecitabine|Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
215032828|NCT03598348|DRUG|Apatinib|Apatinib 250mg po Qd
215032829|NCT06052592|OTHER|Milk|Newborns will be fed with breast milk, formula milk or postbiotic formula milk
215032830|NCT05006664|DRUG|Adcetris 50 MG Injection|Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.
215032831|NCT05006664|DRUG|Endoxan|Treatment by study drug Cyclophosphamide (Endoxan) in combination.
215032832|NCT05006664|DRUG|Doxorubicin|Treatment by study drug Doxorubicin in combination.
215032833|NCT05006664|DRUG|Etoposide|Treatment by study drug Etoposide in combination.
215032834|NCT05006664|DRUG|Prednisone tablet|Treatment by study drug Prednisone in combination.
215032835|NCT00002930|PROCEDURE|positron emission tomography|
215032836|NCT00002930|RADIATION|fludeoxyglucose F 18|
215032837|NCT06571435|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST), and Posterior Shoulder Endurance Test|"The modified closed kinetic chain upper extremity stability test is reliable and is performed in an individualized manner by placing the hands on the floor at shoulder level. The evaluation process is the same as the original test; the total number of touches in 15 seconds is noted by lifting one hand, touching the other and placing it back. A total of 3 measurements are taken with a 45-second rest interval. The endurance capacity of the muscle group is an important factor for sports performance as it requires specific sports movements repeated in a certain period of time.~For posterior shoulder endurance test participants will lie with their face down. While the shoulder is hanging from the stretcher, individuals will be asked to lift the dumble calculated with the weight appropriate for their weight to 90 degrees abduction in accordance with the 60 bpm metronome. Their duration in seconds will be noted. 1 measurement will be made with each arm."
215032838|NCT03903783|OTHER|Cefotaxime|"Patients with C3G antibiotic therapy will receive cefotaxime. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
215032839|NCT03903783|OTHER|Ceftriaxone|"Patients with C3G antibiotic therapy will receive ceftriaxone. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
215032840|NCT00693147|PROCEDURE|Total Thyroidectomy|Late postoperative course of patients with mini Video Assisted Thyroidectomy (miVAT) versus classic Thyroidectomy (T)
215032841|NCT03935347|DRUG|Cyclophosphamide|Given IV
215032842|NCT03935347|DRUG|Fludarabine|Given IV
215032843|NCT03935347|DRUG|Fludarabine Phosphate|Given IV
215032844|NCT03935347|BIOLOGICAL|Pembrolizumab|Given IV
215032845|NCT03935347|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
215032846|NCT03935347|BIOLOGICAL|Aldesleukin|Given IV
215032847|NCT03817580|DRUG|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
215032848|NCT03817580|DRUG|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
215032849|NCT03817580|DRUG|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
214470664|NCT03125928|DRUG|Paclitaxel|Chemotherapy
214470665|NCT03125928|DRUG|Trastuzumab|Monoclonal antibody
214470666|NCT03125928|DRUG|Pertuzumab|Monoclonal antibody
214470667|NCT05021497|OTHER|Global Positional Re-education|A series of gentle active movements and postures aimed at realigning joints and stretching shortened muscles. GPR includes 8 therapeutic postures in lying, sitting and standing.
214470668|NCT05021497|OTHER|Conventional Physical Therapy Program|Axial traction will be given for 5 minutes, followed by mobilization of the muscle fascia along with static stretching of the scalene, levator scapulae, upper trapezius, sternocleidomastoid and pectoralis minor muscles.
214470669|NCT06504836|OTHER|Gait training with biofeedback|Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
214470670|NCT06504836|OTHER|Gait training without biofeedback|Gait training include treadmill and overground walking.
214470671|NCT06265688|DRUG|CX-2051|Investigational drug monotherapy
214282727|NCT06667544|DRUG|RNK08954-01|Once daily oral treatment for a 3 week cycle
214282728|NCT06650800|DRUG|Psilocybin|Single-dose psilocybin administration: oral ingestion of one 25 mg capsule
214282729|NCT06650800|OTHER|MRI|1.5 hour brain MRI before and after psilocybin administration
214282730|NCT06978270|BEHAVIORAL|Healthy Eating: Provider and Parent Components|Healthy Eating intervention for child care providers: Peer coaching using brief MI online, tailored materials, coach-led online support groups for FCCP and children's tableware and food toys; 2) Brief training on using and scheduling messages within the Classtag App; 3) Posters for the FCCH. Also for parents, healthy eating encoragement and communication from childcare providers including via the Classtag App, newsletters, videos and tableware/food toys focused on child diet at home.
214282731|NCT06978270|BEHAVIORAL|Healthy Start: Reading Readiness Childcare Proiver and Parent Materials|Reading readiness intervention for child care providers: Peer coaching using brief MI online, tailored materials, coach-led online support groups for FCCP and children's books; 2) Brief training on using and scheduling messages within the Classtag App; 3) Posters for the FCCH. Also for parents, reading readiness encoragement and communication from childcare providers including via the Classtag App, newsletters, books focused for use at home.
214282732|NCT07133165|OTHER|standard biometric ultrasound|In this study, biometric measurements were systematically performed for each patient using both manual methods and an artificial intelligence (AI) system (Live View Assist, Samsung). The AI system provided real-time guidance by identifying anatomical landmarks and assisting in the measurement of key biometric parameters, including Femur Length (FL), Abdominal Circumference (AC), Head Circumference (HC), and Biparietal Diameter (BPD). This dual approach ensured that both manual and AI-assisted methods were applied uniformly as part of routine clinical care.
214282733|NCT06577727|OTHER|Gold standard blood test|Blood test will measure haemoglobin and other parameters
214282734|NCT06577727|OTHER|Imaging and videography of anatomical sites|Images and videos of anatomical sites will be collected for AI to estimate iron status
214282735|NCT05977647|DRUG|Tamsulosin Oral Capsule|Patient will be enrolled in one of study arm through randomization.
214282736|NCT06988566|OTHER|Intervention Group|The intervention were connected to the ECM response and coordination centre (RCC) which provided the participants with 24/7/365 access to assistance from certified RCC staff who were supported by eDoctors. Patients self-tracking activities (saturation, pulse, lung function, temperature and report on increased sputum, coughing, and shortness of breath) were monitored dayly by the RCC whoom would contact them in the event of signs of deterioration. The RCC staff together with the participant would make informed decisions, via phone or video call, on how to best manage the change in condition guided by the previous measures evaluated with graphs, including plotted trends. If there was a need for medical treatment, a treatment plan was drawn up with fixed follow-ups and a course plan.
214282737|NCT07002281|DRUG|[14C]Azvudine suspension|A single oral dose of 3 mg/100 μCi of \[14C\]Azvudine suspension is given orally on an empty stomach.
214282738|NCT07000474|OTHER|Omics|Multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.
214282739|NCT07001007|DIAGNOSTIC_TEST|Coronary Computer Tomography (CCTA)|Use of standard equipment for usual care
214470672|NCT04443530|DRUG|Ultimaster™ Tansei™ stents|Patients receiving Ultimaster™ Tansei™ stents
214470673|NCT02851095|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
214470674|NCT02851095|DRUG|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
214282740|NCT07001007|OTHER|Laser Doppler Vibrometry and single-lead ECG|Physiological data acquisition equipment
214282741|NCT07001007|DEVICE|Echocardiography|GE Vivid E95
214282742|NCT07001007|DEVICE|Pulse Wave Velocity|Arteriograph, Tensiomed, Hungary
214282743|NCT07002190|OTHER|Watching an animation video|education
214470675|NCT02851095|DRUG|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
214470676|NCT05724433|OTHER|Virtual HF Care|Patients will receive virtual visits for 3 months following hospitalization / emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.
214282744|NCT06603844|DRUG|CRB-601 monoclonal antibody|CRB-601
214470677|NCT05724433|OTHER|Routine HF Care|Care as determined by the treating physician
214470678|NCT04487860|DRUG|AS012|oral administration
214470679|NCT04487860|DRUG|Placebo|oral administration
214470680|NCT04469712|PROCEDURE|SASI Bipartition|SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus.
214470681|NCT04469712|PROCEDURE|Gastric bypass|A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler.
214470682|NCT06483035|DEVICE|Intensive Visual Simulation (IVS)|The IVS system initially makes a video-recording of the intact body part (arm or leg) executing a set of specific movements. These video recordings will be digitally reversed and projected onto a large screen in front of the patient. On the screen, the patient will monitor an intact, life-like extremity in place of the amputated extremity. This digital extremity will then execute the recorded movements in a pre-planned manner. Simultaneously, the patient will follow the digital virtual limb moving on the screen with his/hers amputated arm/leg, which is hidden below the screen. Hence, IVS therapy comprises elements of both movement perception, motor planning, motor execution and visual feedback of two intact limbs moving which are distinctive from classical Mirror-Therapy.
214844389|NCT01049412|DRUG|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
214844390|NCT01944787|OTHER|Routine|IV Hydration at 125 cc hour
214282745|NCT06603844|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD(L)-1 used as per label
214282746|NCT07131930|OTHER|Caregiver Burden, Psychological Resilience, Sleep Quality|Informal caregivers who provide daily care for bedridden patients are evaluated in this study. The exposure involves physical, emotional, and financial caregiving responsibilities such as assistance with feeding, mobility, and emotional support. The impact of caregiving on sleep quality and psychological resilience is assessed using validated questionnaires (Zarit Burden Interview, Pittsburgh Sleep Quality Index, Resilience Scale).
214282747|NCT07132463|RADIATION|Long-course chemoradiotherapy|45-50.4 Gy in 25-28 fractions to the pelvis on Days 1-5 each week. Capecitabine at a dose of 825 mg/m², taken orally twice daily (bid), 5 days per week during radiotherapy.
215032850|NCT02852707|BEHAVIORAL|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
214282748|NCT07132463|DRUG|Tislelizumab combined with the CAPOX regimen|"Tislelizumab 200 mg IV on Day 1 of each 21-day cycle. Capecitabine: 1000 mg/m² orally twice daily (bid) on Days 1-14 of each 21-day cycle.~Oxaliplatin: 130 mg/m² IV on Day 1 of each 21-day cycle."
214282749|NCT07132463|DRUG|CAPOX regimen|"Capecitabine: 1000 mg/m² orally twice daily (bid) on Days 1-14 of each 21-day cycle.~Oxaliplatin: 130 mg/m² IV on Day 1 of each 21-day cycle."
214282750|NCT03557099|DRUG|Hetrombopag Olamine|once daily
214282751|NCT06870812|PROCEDURE|Surgical management|"Following randomization into the surgical arm, a competency-trained neurosurgeon will perform the MIPS for clot evacuation with strict adherence to the Surgical Manual of the CSG. Image interpretation, patient position, anesthetic plan, stereotactic navigation registration, exoscopic positioning, access, optics, resection, and hemostasis are detailed in the Surgical Manual of the CSG.~The OR arrival time should occur \<24 hours from the last known normal (LKN) with a goal of arrival in less than 8 hours from the last known normal."
214470683|NCT06483035|OTHER|Usual Care (UC)|"After allocation to UC, the participants continue with their normal treatment as prescribed by their medical doctor or other health professionals. All control participants are offered to complete IVS treatment after the end of the study period. The participants in the control group will therefore be placed on a fictitious waiting list during the study period."
214470684|NCT05434949|DIAGNOSTIC_TEST|Blood test|"Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00."
214470685|NCT05434949|OTHER|Analyses of samples|C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
214470686|NCT04246671|BIOLOGICAL|TAEK-VAC-HerBy|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).
214470687|NCT06045416|PROCEDURE|venous blood puncture|"Venous blood puncture performed at first hospital contact, and at 28 days, 3 month, and 6 months after hospital admission.~Lumbar puncture and joint puncture for the study will be performed if it is indicated due to diagnostic or therapeutic reasons."
214470688|NCT05295602|RADIATION|CT scan|CT of lower leg
215032851|NCT02852707|BEHAVIORAL|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
215032852|NCT02852707|BEHAVIORAL|Not exposed|People not engaged in regular sports competition/exercise training.
215032853|NCT06322901|PROCEDURE|Flap|Different flap designs for implant placement
215032854|NCT06254625|OTHER|Fecal Microbiome|Fecal microbiome transplantation from a healthy donor.
215032855|NCT06254625|OTHER|Placebo|Place capsules
215032856|NCT03254810|BIOLOGICAL|SYN060|a single subcutaneous 0.57 mg/kg dose of SYN060
214470689|NCT06292728|DEVICE|ENDOPLY System|One endoscopic procedure where the ENDOPLY System is used for endoscopic gastric plication.
214470690|NCT05157282|DEVICE|TESS|Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
214470691|NCT05157282|OTHER|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
214470692|NCT05157282|OTHER|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
214470693|NCT05157282|DEVICE|sham-TESS|Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
214470694|NCT06131281|PROCEDURE|E-TORe|The E-TORe utilizes ESD in addition to APC prior to endoscopic suturing. In this approach, a standardized solution of normal saline or hetastarch mixed with methylene blue and epinephrine is injected into the gastric rim of the GJA outlet. The mucosa is then carefully incised to expose the underlying muscular layer for a width of approximately 1cm around the GJA circumference. Following ESD, APC is then applied to the inner and outer mucosal margins of the ESD tract. Finally, endoscopic sutures are then placed in purse string fashion and cinched closed around a 6mm TTS balloon.
214844391|NCT01944787|OTHER|IV Hydration at 250cc hour|IV Hydration at 250 cc hour
214844392|NCT06685159|PROCEDURE|Laparoscopic Surgery|Laparoscopic surgery (with controlled pneumoperitoneum) in the Trendelenburg position
214844393|NCT00111462|DRUG|Darbepoetin alfa|
215032857|NCT03254810|BIOLOGICAL|Adalimumab North American source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
215032858|NCT03254810|BIOLOGICAL|Adalimumab European source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
215032859|NCT06310486|OTHER|Drowning-related OHCA|These patients were involved in a drowning incident (submersion or immersion in liquid) and experienced out-of-hospital cardiac arrest (OHCA), defined as being unconscious and not breathing normally at any time in the prehospital setting. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).
214470695|NCT06131281|PROCEDURE|c-TORe|The c-TORe will be completed utilizing APC prior to endoscopic suturing. In this approach, the gastric rim of the anastomosis is circumferentially ablated using APC (forced APC, flow of 0.8 L/min and power of 30-70 watts) extending an average of 1-2 cm from the outlet. Following ablation, endoscopic sutures are placed in a purse string fashion within the ablated area and the outlet cinched closed over a 6mm through-the scope (TTS) balloon.
214470696|NCT06085547|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include rural-targeted information
215032860|NCT06310486|OTHER|Drowning-related non-OHCA|These patients were involved in a drowning incident (submersion or immersion in liquid) but did not experience an OHCA. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).
215032861|NCT04715126|OTHER|Oxyjun|One capsule to be taken after breakfast with water.
215032862|NCT04715126|OTHER|Placebo|One capsule to be taken after breakfast with water.
215032863|NCT03156114|DRUG|BI 754111|Day 1 of 3 week cycle
215032864|NCT03156114|DRUG|BI 754091|Day 1 of 3 week cycle
215032865|NCT00822380|DIETARY_SUPPLEMENT|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
215032866|NCT00822380|DIETARY_SUPPLEMENT|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
215032867|NCT00822380|DIETARY_SUPPLEMENT|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
215032868|NCT00822380|DIETARY_SUPPLEMENT|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
215032869|NCT00822380|DIETARY_SUPPLEMENT|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
215032870|NCT05271006|BEHAVIORAL|Exercise|The mHealth platform to be used by the exercise group is Down Dog, which has a suite of apps for yoga, HIIT, barre, and running workouts. Down Dog has agreed to provide free memberships for one year to all participants in the study. To ensure participant de-identification on the Down Dog platform, each participant will receive a Participant ID which will be pre-registered by the study coordinator on the Down Dog platform. Randomized participants will be provided instructions for downloading the apps onto their phone or a link to the website to be used on their computer. Following randomization, participants in the exercise group will be asked to engage in physical activity (using any if the Down Dog apps), 4 days a week for 20 minutes a day for 12 weeks.
214470697|NCT06085547|BEHAVIORAL|Rural-Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a two and a half minute video based messaging adjunct meant to enact a rural-targeted framing of health information presented to White rural individuals.
215032871|NCT04172220|DRUG|Midazolam|1-2 mg of Midazolam as premedication.
215032872|NCT04172220|PROCEDURE|PECS|"Loco-regional anesthesia: PEC I and serratus plane block with an echoguided technique.~For the PEC I: infiltration of 10 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of the pectoralis major muscle and the small pectoralis muscle at the height of the third rib on the anterior axillary line.~For the serratus plane block: identification of the fifth rib on the average axillary line and infusion of about 20 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of large dorsal muscle and of the anterior serratus muscle."
215032873|NCT04172220|PROCEDURE|Opioid-free general anesthesia|"Induction with Propofol 1.5-2 mg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in Target-Controlled Infusion (TCI) of 6 mcg/ml, subsequently modified to maintain a Bispectral Index (BIS) value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
215032874|NCT04172220|PROCEDURE|General anesthesia|"Induction with Propofol 1.5-2 mg/kg; Fentanyl 1μg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in TCI of 6 mcg/ml, subsequently modified to maintain a BIS value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
214282752|NCT06870812|OTHER|Medical Management|"Following randomization into the medical arm patients will be treated following the Medical Manual of the CSG. The Medical Manual has been adapted by the REACH Executive Committee (REC) from the current American Heart Association (AHA) and American Stroke Association (ASA) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Whenever clinically feasible, the CSG should be followed as it represents a template for the care of these subjects.~The Medical Manual details specialty level of care, including intensive care placement, blood pressure control, hemostasis and coagulopathy, anemia, deep venous thrombosis and pulmonary embolism prophylaxis/treatment, glucose management, temperature management, seizure prophylaxis, intracranial pressure monitoring and management, intraventricular hemorrhage (IVH)/obstructive hydrocephalus management, cerebral edema, decompressive hemicraniectomy, nutritional support, respiratory support, and comfort care."
215032875|NCT04172220|PROCEDURE|Postoperative analgesia|Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS\>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
215032876|NCT05202782|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given IV
215032877|NCT05202782|OTHER|Quality-of-Life Assessment|Ancillary studies
214282753|NCT07012616|OTHER|Supraclavicular brachial plexus block|Patients will receive an ultrasound-guided supraclavicular brachial plexus block.
214282754|NCT07015970|OTHER|No Intervention: Observational Cohort|No intervention
214282755|NCT07015580|OTHER|16S rRNA sequencing|Clinical data including medical history, clinical symptoms, imaging examination, laboratory examination will be collected. 3-5ml saliva sample of every patients will be collected for 16S rRNA sequencing of oral microbiota.
214282756|NCT06396741|OTHER|The quadriceps muscle will be punctured with ultrasound control|With the subject in the supine position, the quadriceps muscle will be shown by ultrasound. Subsequently, a dry needling technique will be performed at the most hyperalgesic point using ultrasound control.
214282757|NCT05910242|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
214282758|NCT05910242|PROCEDURE|Sham remote ischemic conditioning|Sham-RIC is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
214282759|NCT06880354|DRUG|CLL1 and CD38 Dual-Target CAR-T Cell Injection|This product is a lentiviral gene-modified autologous chimeric antigen receptor T-cell product that targets both CLL1 and CD38.
214282760|NCT06719531|DEVICE|Continuous Glucose Monitoring|CGM and frequent sample testing
214282761|NCT06634095|BEHAVIORAL|Moulage group|The experimental group is trained with a moulage-supported standardized patient simulation. Participants in the experimental group practice during the specified moulage-supported standardized patient simulation. Moulage-supported simulations regarding pressure ulcers will be created and training will be provided.
214282762|NCT01594983|DRUG|LCQ908|
214282763|NCT01594983|DRUG|Fenofibrate|Fenofibrate once daily 12 weeks
214282764|NCT01594983|DRUG|Fish Oil|Fish Oil once daily for 12 weeks
214282765|NCT01594983|DRUG|Placebo of LCQ908|Matching placebo of LCQ908
214282766|NCT01594983|DRUG|Placebo of fenofibrate|Matching placebo of fenofibrate
214282767|NCT01594983|DRUG|Placebo of fish oil|Matching placebo of fish oil capsule
214282768|NCT07073365|OTHER|Local Therapy (Surgery or Radiotherapy)|Patients will receive local therapy, either surgical resection or radiotherapy, to the primary lung tumor following disease control after first-line treatment with osimertinib plus platinum-based chemotherapy (FLAURA2 regimen). The specific modality (surgery or radiotherapy) will be determined based on tumor characteristics, patient condition, and multidisciplinary team assessment.
214282769|NCT04419714|DEVICE|TatchSleep|Wearable measurement device
214282770|NCT07122427|PROCEDURE|Graft collection|Sampling of superior venous and arterial grafts (internal mammary artery, great saphenous vein) after coronary artery bypass surgery.
214282771|NCT07133204|OTHER|Investigator developed cream infused with HuangQin extract|A water in oil emulsion with consistency similar to cold cream. Infused with organic extract of scutellaria baicalensis.
214282772|NCT05263206|DRUG|Dupilumab|Injection solution subcutaneous
214282773|NCT05263206|DRUG|Placebo|Injection solution SC
214282774|NCT05263206|DRUG|Fexofenadine (loratadine if not available)|Tablet or capsule Oral
214282775|NCT05048979|OTHER|Exercise|Telehealth-facilitated supervised exercise program. Veterans with PAD will be enrolled in a 12-week, 3 day a week, aerobic training program in a self-selected location.
214282776|NCT05992311|DRUG|Montelukast|This group will receive the montelukast treatment.
214282777|NCT05992311|OTHER|Placebo|This group will receive a placebo pill instead of montelukast
214282778|NCT05799729|DRUG|Ketamine|CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.
214470698|NCT05534945|DRUG|Programmed intermittent epidural bolus 5 ml|patients in this group will receive a programmed epidural intermittent bolus of 5 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
214282779|NCT05231954|OTHER|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
214282780|NCT06347484|BEHAVIORAL|EHR-informed Recruitment Method of Contact|The intervention being studied here is the method of contact (patient portal vs. email vs. postal mail) after being identified in the EHR
214282781|NCT06347484|BEHAVIORAL|Educational Text-Messages and Connection to Cardiovascular Research Opportunities|All participants who enroll in CONNECT, regardless of method of contact, will receive educational text messages and connection to cardiovascular research opportunities. Text messages will be tailored and include content on cardiovascular health promotion and research participation.
214282782|NCT04312126|DEVICE|MRI system|MRI system - GE Discovery MR750 3T
214282783|NCT04312126|DEVICE|MEG system|MEG system The CTF MEG 275 Magnetoencephalography (MEG) scanner system
214282784|NCT06362733|BEHAVIORAL|Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth|This is a 12-week intervention program (1 hour/week) of treatment to target insistence on sameness in youth with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of combination of parent-training and parent-mediated intervention with the child.
214282785|NCT05947643|DRUG|theophylline|capsules dissolved in intranasal irrigation
214282786|NCT05947643|DRUG|Placebo|identical-appearing lactose capsules dissolved in intranasal irrigation
214282787|NCT04023526|DRUG|Azacitidine|Azacitidine SC or IV will be administered at a standard dose of 75 mg/m\^2 on days 1-7 of each cycle.
214282788|NCT04023526|DRUG|Cusatuzumab|Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.
214282789|NCT02940977|OTHER|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
214282790|NCT05857735|OTHER|Observational registry with no intervention.|No intervention
214282791|NCT01373437|DEVICE|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
214282792|NCT02371551|OTHER|Blood/urine sampling|Routine chemistry profile
214282793|NCT02371551|OTHER|Conventional routine CT examination|Standard diagnostic examination
214282794|NCT02371551|OTHER|Contrast-enhanced renal ultrasonography (CEUS)|Study-specific diagnostic examination
214470699|NCT05534945|DRUG|Programmed intermittent epidural bolus 6 ml|patients in this group will receive a programmed epidural intermittent bolus of 6 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
214282795|NCT02371551|OTHER|Functional MRI|Study-specific diagnostic examination
214282796|NCT00015301|DRUG|Methylphenidate|
214282797|NCT05346471|DEVICE|Multimodal neuromonitoring|Multimodal neuromonitoring accounts for intraparenchymatous ICP probe, brain tissue oxygen probe and/or cerebral microdialysis device
214282798|NCT03631472|DEVICE|RheOx|RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
214282799|NCT05952063|DIAGNOSTIC_TEST|Digital Psychological Test: Schema Scale|Thirty-five questionnaire, 5-point likert scale
214282800|NCT02197715|BEHAVIORAL|Computer-adaptive SAFE|
214282801|NCT02197715|BEHAVIORAL|Face-to-face SAFE|
214282802|NCT02197715|BEHAVIORAL|Usual Care|
214282803|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 10 mg administered once daily in the morning
214282804|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 15 mg administered once daily in the morning
214282805|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 20 mg administered once daily in the morning
214282806|NCT03217487|PROCEDURE|Corneal epithelial autograft|Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
214470700|NCT05534945|DRUG|Programmed intermittent epidural bolus 7 ml|patients in this group will receive a programmed epidural intermittent bolus of 7 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
214470701|NCT05534945|DRUG|Programmed intermittent epidural bolus 8 ml|patients in this group will receive a programmed epidural intermittent bolus of 8 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
214906753|NCT01592786|DRUG|Memantine Hydrochloride (HCl)|Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
215032878|NCT05202782|OTHER|Questionnaire Administration|Ancillary studies
214470702|NCT05534945|DRUG|Programmed intermittent epidural bolus 9 ml|patients in this group will receive a programmed epidural intermittent bolus of 9 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
214282807|NCT03217487|PROCEDURE|Limbal conjunctival autograft|A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
214470703|NCT05534945|DRUG|Programmed intermittent epidural bolus 10 ml|patients in this group will receive a programmed epidural intermittent bolus of 10 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
215032879|NCT05202782|DRUG|Zanubrutinib|Given PO
215032880|NCT03719859|OTHER|Physical Therapy|"Subjects who will participate in the physical therapy intervention group will attend therapy 4-6 days after discharge from the hospital, and continue in therapy approximately once a week for three months. The physical therapy progression will follow the standard of care developed at Duke Sports Medicine Physical Therapy for rehabilitation following RSA. Some of the patients in the PT intervention cohort may have physical therapy at an institution outside of Midwest Orthopaedics at Rush. All patients, whether in the Rush system or outside, will be given a prescription with the identical instructions for physical therapy, status post (R/L) reverse total shoulder arthroplasty, 1-2 x per week x 12 weeks."
214470704|NCT02368041|DEVICE|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
214470705|NCT04110522|OTHER|Direct to patient PsA Screening Questionnaire|Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST ≥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.
214470706|NCT06184984|DIETARY_SUPPLEMENT|Metabolic availability of methionine in mung beans|Each participant will randomly receive 7 different levels of methionine provided as free amino acids and cooked mung beans.
214470707|NCT06850935|OTHER|Centella asiatica extracellular vesicle formulation|Water-based formulation containing purified Centella asiatica extracellular vesicle as main active ingredient. Applied twice daily at two drops per use to the face after face cleansing for 28 consecutive days.
215032881|NCT03719859|OTHER|Home Therapy|The surgeon/Nurse Practitioner/Physician Assistant will advance rehabilitation exercises and activity guidelines at customary scheduled postoperative appointments for this surgical procedure: 2 weeks (+/- 5 days), 6 weeks (+/- 1 week), 3 months and 6 months (+/- 1 month), and 1 and 2 years (+/- 2 months).
215032882|NCT03157895|BEHAVIORAL|Connecting|Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
215032883|NCT02895555|PROCEDURE|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested allograft.
215032884|NCT02895555|PROCEDURE|Allograft|Approx 50 g of allograft bone in the fused site
215032885|NCT05642338|DIAGNOSTIC_TEST|WATS3D|the WATS3D brush samples the esophagus by abresing the tissue. the brush is directed through the workingchanel of endoscope into the oesophagus
215032886|NCT01272258|DRUG|PRO 140|SC injection
215032887|NCT01272258|DRUG|Placebo|SC injection
215032888|NCT01506726|DRUG|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
215032889|NCT01506726|DRUG|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
214282808|NCT03217487|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
215032890|NCT01825863|DRUG|Ropivacaine|
215032891|NCT01825863|DRUG|Saline 9%|
215032892|NCT02001519|DRUG|AC4-CDDP4|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
215032893|NCT02009826|RADIATION|[18F]-PBR111 Positron Emission Tomography (PET)|\[18F\]-PBR111 radioligand to assess binding to TSPO
215032894|NCT02009826|BEHAVIORAL|Cognitive and psychomotor tasks|Cognitive and psychomotor tasks on digitizing tablet
214282809|NCT03217487|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
214282810|NCT03019822|DRUG|LSD|100ug per os, single dose
214282811|NCT03019822|DRUG|MDMA|125mg per os, single dose
214282812|NCT03019822|DRUG|Amphetamine|40.3mg per os, single dose
214282813|NCT03019822|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs
214282814|NCT00147810|PROCEDURE|Telephone outreach to enhance asthma care|
214282815|NCT05035953|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis
214282816|NCT05035953|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to thrombolysis
214282817|NCT00000383|BEHAVIORAL|Trauma-Focused CBT|Structured skills, exposure, trauma-specific interventions
214282818|NCT00000383|BEHAVIORAL|Child-Centered Therapy|Client-directed supportive interventions
214282819|NCT00122668|DRUG|non-nucleoside reverse transcriptase inhibitors|
215032895|NCT02009826|BIOLOGICAL|Blood sampling|Blood sampling for peripheral inflammatory and neurotoxicity markers
215032896|NCT01468155|DRUG|dabigatran|30 days pre ablation and 90 days post ablation
215032897|NCT00616720|BIOLOGICAL|aldesleukin|
215032898|NCT00616720|BIOLOGICAL|idiotype-pulsed autologous dendritic cell vaccine APC8020|
215032899|NCT00616720|BIOLOGICAL|recombinant interferon gamma|
215032900|NCT00616720|GENETIC|polymerase chain reaction|
214282820|NCT00122668|DRUG|nucleoside reverse transcriptase inhibitors|
214282821|NCT00122668|DRUG|protease inhibitor|
214282822|NCT04624568|DEVICE|PAPILOCARE|"Papilocare® is a self-administered vaginal gel. Its single-dose cannula contains hyaluronic acid and pre-biotics (Coriolus Versicolor) that would improve the re-epithelialization of the uterin cervix. By creating a protective film on the cervix, this gel could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus.~The specific approach related to our study would be to apply Papilocare® vaginal gel for 6 months for the treated group.~Smear and HPV test will be perform by all patients at 6 and 12 months."
214282823|NCT05815940|BEHAVIORAL|Mobile Application|a mobile application was developed that can be used by children with urinary incontinence and their parents.
214282824|NCT03709160|DRUG|Bumetanide 1 MG|all patients will be taking the treatment recommended by heart failure guidelines
214282825|NCT00540514|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
214282826|NCT00540514|DRUG|Paclitaxel|Administered by intravenous infusion.
214282827|NCT00540514|DRUG|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
214282828|NCT02076880|OTHER|Caloric restriction|"Caloric restriction of 1000 kcal per day compared to the usual food intake.~* usual breakfast of the patient (possibly limited in quantity)~* midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened"
214470708|NCT06852989|OTHER|Shared book reading intervention|The study group participated in a parent training program focusing on shared interactive reading practices and attended nine read-aloud meetings with their children under the supervision of a trained librarian.
214470709|NCT06851221|DIAGNOSTIC_TEST|beta3 expression|the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor
214470710|NCT06851975|OTHER|blood sampling|36ml of blood will be taken during a blood sampling performed in standard practice
214470711|NCT06847984|DIETARY_SUPPLEMENT|Curcumin|"Participants were instructed to rinse with 10 mL of mouthwash for~1 minute, once daily for 1 week of each month. This regimen will be repeated monthly for a period of 1 year."
214470712|NCT06847984|OTHER|Chlorohexidine|Participants were instructed to rinse with 10 mL of mouthwash for 1 minute, once daily for 1 week of each month. This regimen will be repeated monthly for a period of 1 year
214470713|NCT05066854|PROCEDURE|integron research|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Urine samples will be sent to the laboratory for culture and integron PCR according to routine practice.~Results of the integron search will be given to the investigator. Patients in the experimental group with a positive or uninterpretable PCR will also receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.~Patients in the experimental group with a negative PCR will receive a treatment with SXT at the recommended dose."
214470714|NCT05066854|PROCEDURE|usual practice|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Patients in the control group will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
214470715|NCT06851247|DRUG|Toripalimab|"Fixed dose: 240mg/ time, add 100ml normal saline, intravenous infusion for 30 minutes (not less than 20 minutes, not more than 60 minutes).~The first course of induction chemotherapy (D1) is used on the first day of each cycle, and every 21 days is a course of treatment up to 18 courses or one year.~After intravenous infusion of triplelizumab, GP regimen induction chemotherapy was administered at an interval of 30-60 minutes."
214470716|NCT06851247|DRUG|Anlotinib|"Oral administration before breakfast, 10mg/ time/day, once a day (d1-14), repeated every 3 weeks, using three courses, one week before radiotherapy discontinuation.~Use on the day the first course of induction chemotherapy begins (D1)."
214844394|NCT04232657|DRUG|Romosozumab|39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
215032901|NCT00616720|GENETIC|reverse transcriptase-polymerase chain reaction|
214282829|NCT02076880|OTHER|No caloric restriction|No change in eating habits to patients in this arm
214282830|NCT03275662|BEHAVIORAL|Dietary Fiber|
214470717|NCT06851247|DRUG|Gemcitabine|"1000mg/m2, D1, D8, add 0.9% normal saline 500ml, intravenous infusion. Every 21 days is a treatment cycle. If the recovery of toxicity in the subject is not sufficient for the next course of chemotherapy, the start of the next course of chemotherapy may be appropriately delayed, but the delay cannot exceed 21 days.~The treatment was continued for 3 courses."
214470718|NCT06851247|DRUG|Cisplatin|"Induction Chemotherapy: 80mg/m2, D1, add 1000ml 0.9% normal saline, intravenous infusion for 3 hours.~Concurrent Chemoradiotherapy100mg/m2, add 5% glucose 500ml, intravenous drip. Use on the first day of each cycle, every 21 days for a treatment cycle"
214470719|NCT06851247|RADIATION|radiation|IMRT, 33Fx
214470720|NCT06417853|BIOLOGICAL|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) Injection
214470721|NCT06417853|COMBINATION_PRODUCT|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA)|12 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
215032902|NCT00616720|OTHER|flow cytometry|
215032903|NCT00616720|OTHER|laboratory biomarker analysis|
214282831|NCT03275662|BEHAVIORAL|Fermented Foods|
214282832|NCT02501473|DRUG|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
214282833|NCT02501473|DRUG|Pembrolizumab|PD-1 Inhibitor
214282834|NCT02501473|DRUG|Rituximab|Rituximab (anti-CD20 antibody)
214470722|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)|25 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
214470723|NCT06417853|BIOLOGICAL|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) with MF59® Injection
214470724|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant)|12 mcg Influenza A (H7N9) with 4 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
215032904|NCT05279560|BIOLOGICAL|autologous PRP (platelet rich plasma)|The required volume of PRP will be extracted from 60 ml of the patient's peripheral blood. Injecting PRP into the ovaries will be performed likewise to the standard operating procedure of oocyte retrieval. After centrifugation of the whole blood, 5ml PRP will be injected in each ovary intra-medullar and subcortical using a 17-gauge single lumen needle under sedation und under transvaginal ultrasound monitoring.
214282835|NCT05348070|PROCEDURE|Laparoscopy/Laparotomy|All patients included in the study were operated patients.
214282836|NCT03846596|BIOLOGICAL|Additional blood tube|Additional blood tube during care
214470725|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant)|12 mcg Influenza A (H7N9) with 8 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
215032905|NCT05279560|OTHER|Saline solution (NaCL) Injection|Injecting NaCL into the ovaries will be performed likewise to the standard operating procedure of oocyte retrieval. NaCL will be injected in each ovary intra-medullar and subcortical using a 17-gauge single lumen needle under sedation und under transvaginal ultrasound monitoring.
215032906|NCT06563557|OTHER|Hemodynamic changes between epidural and paravertebral during esophagectomy|The thoracic epidural technique remains the gold standard for perioperative pain management for this procedure. The placement of a paravertebral catheter homolateral with the thoracic incisions is strongly recommended. A goal directed fluid therapy is proposed to guide fluid management and limit postoperative complications. Few studies suggested less side effects in the paravertebral group. The vasoplegia due to the epidural can cause significant hypotension especially as reverse Trendelenburg position is required during surgery. The aim is to bring more light to the hemodynamic changes caused by two different locoregional techniques. An algorithm for fluid and vasopressor management has been proposed. We defined hypotension as 20% of decrement of the median arterial pressure during anesthesia. To reduce bias, the locoregional techniques is performed by an experienced anesthesiologists and the rest of the perioperative management is conducted by another blinded anesthesiologist.
215032907|NCT01413815|DIETARY_SUPPLEMENT|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
215032908|NCT01413815|OTHER|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
215032909|NCT06052891|DEVICE|CHAMP Application|Children's Mercy Kansas City's CHAMP application was developed for data transfer of pediatric cardiac population vitals from home to the healthcare team in March 2014. CHAMP provides families and the clinical team with a new model of care leveraged by a remote patient monitoring (RPM) platform. CHAMP has been used in over 1000 patients, 28 states, and across 12 pediatric hospitals in pediatric cardiology. The CHAMP application is available in 11 languages for families to use on mobile devices (Apple and Android).
215032910|NCT03271775|OTHER|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
215032911|NCT03271775|OTHER|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
215032912|NCT03863574|DRUG|Saroglitazar Magnesium 2mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.
215032913|NCT03863574|DRUG|Saroglitazar Magnesium 4mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.
215032914|NCT03863574|DRUG|Placebos|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
215032915|NCT05443321|OTHER|Health Information Exchange (HIE) platform|An improved health information exchange (HIE) platform will be developed at the start of the study with key stakeholder input. This platform will be implemented for use after baseline data collection, and will allow for improved data exchange between transferring and accepting hospital. We will allow for a 6-month wash-in period prior to intervention data collection.
214282837|NCT05592964|DIETARY_SUPPLEMENT|Fasting|Standard fasting
214282838|NCT05592964|DIETARY_SUPPLEMENT|Water|In Group S, water was given 1 hour before the operation.
214282839|NCT05592964|DIETARY_SUPPLEMENT|Carbohydrate fluid|In Group K, carbohydrate fluid was given 1 hour before the operation.
214282840|NCT02313181|OTHER|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
214282841|NCT02313181|OTHER|Standard Care|Continue exclusive breastfeeding unless otherwise directed by a health care provider
214282842|NCT06463210|DEVICE|Virtual reality as a distraction technique|A 360º relaxing video with music was displayed through a VR headset
214282843|NCT03157778|OTHER|Obese men|Biological measures before, just before, and after lunch, in obese men
214282844|NCT03157778|OTHER|Normal-weight men|Biological measures before, just before, and after lunch, in normal-weight men.
214282845|NCT04369521|OTHER|low free sugar diet|low free sugar diet with nutrition and exercise recommendation
214282846|NCT02324569|DRUG|SYR-472|SYR-472 tablets
214282847|NCT02324569|DRUG|Placebo|Placebo tablets
214282848|NCT00819221|DRUG|AZD2281|capsules, oral, bd, 2 months
214282849|NCT00819221|DRUG|liposomal doxorubicin|once every 4 weeks at 40mg/m2
214282850|NCT02559193|OTHER|Observational study, data collection only trial.|Data collection only trial design.
214282851|NCT00911820|DRUG|Bevacizumab|
214282852|NCT00911820|DRUG|Cisplatin|
214282853|NCT00911820|DRUG|Irinotecan|
214282854|NCT00911820|DEVICE|Docetaxel|
215032916|NCT05712681|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet after the meal
215032917|NCT05712681|DRUG|JP-1366 20mg tablet|R : JP-1366 20mg tablet under fasting condition
214282855|NCT05554705|BEHAVIORAL|Intensive Lifestyle intervention|12 week therapeutic lifestyle change program
214282856|NCT00785668|DRUG|AER 001|10 mg dry powder administered using a handheld device
214282857|NCT01652898|DRUG|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
214282858|NCT01652898|DRUG|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
214282859|NCT01652898|DRUG|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
214282860|NCT00023634|BIOLOGICAL|KLH|100 mcg w/EGFRvIII
214282861|NCT00023634|BIOLOGICAL|GMCSF|arm 1: 100 mcg w/EGFRvIII
214282862|NCT01929278|DRUG|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
214282863|NCT01929278|OTHER|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
214282864|NCT01929278|OTHER|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril \[approximately 2 cm x 2 cm\]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
214282865|NCT02559245|OTHER|Descurainia Sophia|
214282866|NCT02559245|OTHER|Ficus carica|
214282867|NCT06289608|OTHER|No intervention|No dental intervention was made. Only a clinical examination
214282868|NCT05519540|DRUG|Xevinapant (Debio 1143)|All participants (Japanese and non-Japanese) received a single oral dose of 200mg xevinapant (Debio 1143) on Day 1 under fasted condition.
214282869|NCT06259266|OTHER|Anti-reflux valve for dialysis catheter|
214282870|NCT04755803|PROCEDURE|Penoplasty|"Modified penoplasty technique:~1. Degloved the penile skin and excise the inner prepuce.~2. Advanced penoscrotal skin to cover penile shaft~3. Fixed the penis base and reconstructed the penoscrotal angle"
214282871|NCT00218465|DRUG|GW468816|Pharmacotherapies for Relapse Prevention
214282872|NCT00218465|DRUG|Placebo Comparator: Placebo|
214282873|NCT06799494|BIOLOGICAL|Gardasil-9|"The 9-valent HPV VLP vaccine is a sterile liquid suspension prepared by combining the adsorbed VLPs of each HPV type and additional amounts of the aluminum-containing adjuvant and the final purification buffer. The 9-valent HPV vaccine, or Gardasil-9, is a sterile suspension for intramuscular administration. Each 0.5-mL dose of the vaccine also contains approximately 500 mcg of aluminum (provided as AAHS), 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 mcg of polysorbate 80, 35 mcg of sodium borate, \<7 mcg yeast protein, and water for injection. The product does not contain a preservative or antibiotics.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap. After thorough agitation, GARDASIL 9 is a white, cloudy liquid."
214282874|NCT06799494|DRUG|Lidocaine injection|Lidocaine 1% will be injected intradermally and subcutaneously into the margin of the lymph node to be sampled to numb the area. To confer local anesthesia, 1-2% will be injected into the tissue surrounding the area where the bone marrow will be removed.
214282875|NCT06799494|DRUG|Lorazepam|Lorazepam, an FDA-approved benzodiazepine, will be administered as an anxiolytic before the bone marrow aspirate procedure per the clinician who will perform the procedure. If needed, lorazepam will be administered sublingually per manufacturer dosing recommendations.
214282876|NCT03275051|OTHER|Safety and Efficacy assessments|Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
214282877|NCT05975021|DRUG|Istaroxime|IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 0.5 µg/kg/min for 42 hours. Total duration 48 hours.
214282878|NCT05975021|DRUG|Placebo|IV infusion via a syringe pump. Total duration 48 hours.
214282879|NCT00079118|DRUG|docetaxel|
214282880|NCT00079118|DRUG|irinotecan hydrochloride|
214282881|NCT02486432|DRUG|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
214282882|NCT01372137|DRUG|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
214282883|NCT01372137|OTHER|Glucose 5%|Placebo
214282884|NCT02114814|BEHAVIORAL|Diabetes self-management program for Hispanics and their families|The intervention group received an 8-weekly culturally tailored diabetes self-management and family support education program delivered in Spanish
214282885|NCT02114814|BEHAVIORAL|General health educational program for Hispanics and their families|The attention control group received 8-weekly education program on general health information
214282886|NCT01007084|DRUG|Propranolol|40 mg
214282887|NCT01007084|DRUG|Propranolol ER|120 mg twice per day
214282888|NCT01007084|DRUG|Sugar pills|sugar pill
214282889|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
214282890|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
214282891|NCT00766337|DRUG|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
214282892|NCT02546804|PROCEDURE|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
214282893|NCT02546804|PROCEDURE|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
214282894|NCT02546804|PROCEDURE|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
214282895|NCT05385731|OTHER|Nordic Walking (NWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
214282896|NCT05385731|OTHER|Free Walking (FWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
214282897|NCT05385731|OTHER|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
214282898|NCT05119205|DIAGNOSTIC_TEST|Bone marrow biopsy and compete blood count|Bone marrow biopsy and compete blood count will be done for follow up in patients with multiple myeloma
214282899|NCT03098550|BIOLOGICAL|Nivolumab|Specified dose on specified days
214282900|NCT03098550|BIOLOGICAL|Daratumumab|Specified dose on specified days
214282901|NCT02804932|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g/day) for 8 weeks
214282902|NCT02804932|OTHER|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 8 weeks
214282903|NCT01927237|OTHER|HLR|
214282904|NCT01927237|OTHER|EHR|
214282905|NCT00664872|OTHER|proactive psychosocial intervention by care managers|A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
214282906|NCT00664872|BEHAVIORAL|case management|
214282907|NCT03825315|BIOLOGICAL|DAXI 80 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)
214282908|NCT03825315|BIOLOGICAL|DAXI 120 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
214282909|NCT03825315|OTHER|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
214282910|NCT00819611|BEHAVIORAL|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
214282911|NCT00819611|BEHAVIORAL|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
214844395|NCT04232657|DRUG|Denosumab|Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
214282912|NCT00125294|DRUG|Methadone|
214282913|NCT04654130|OTHER|Neurofeedback|"NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks."
214282914|NCT00854477|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
214282915|NCT04758780|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
214282916|NCT00319865|DRUG|Velcade|
214282917|NCT00319865|DRUG|Thalidomide|
214282918|NCT00319865|DRUG|Adriamycin|
214282919|NCT00319865|DRUG|Dexamethasone|
214282920|NCT04540601|OTHER|Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)|"We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday."
214282921|NCT01693653|DRUG|Tocilizumab|Intravenous infusions every 4 weeks for 3 doses.
214282922|NCT04655391|DRUG|Bosutinib Monohydrate|Given PO
214282923|NCT04655391|DRUG|Decitabine|Given IV
214282924|NCT04655391|DRUG|Enasidenib Mesylate|Given IV
214282925|NCT04655391|DRUG|Gilteritinib Fumarate|Given PO
214282926|NCT04655391|DRUG|Glasdegib Maleate|Given PO
214282927|NCT04655391|DRUG|Ivosidenib|Given PO
214282928|NCT04655391|DRUG|Venetoclax|Given PO
214282929|NCT01204853|DRUG|Sitaxentan|sitaxentan sodium 100 mg
214282930|NCT05433805|OTHER|Fasting-mimicking diet (FMD) and physiotherapy|"FMD is a diet held monthly during five days with the restriction of calories to less than 1000 kcal, glucose and proteins.~Physiotherapy will be organized as home-based exercises explained by the physiotherapeutist at the beginning of the study."
214282931|NCT03304743|DIAGNOSTIC_TEST|Dental panoramic radiograph|"If not performed within the previous 12 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.~OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints."
214282932|NCT01304316|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
214282933|NCT05524038|DRUG|Bupivacaine Hydrochloride|20mg of Bupivacaine hydrochloride as local anesthetic will be used in (QL) group and (ESB) group
214282934|NCT05524038|DEVICE|Ultrasound device|high-frequency linear probe covered with sterile sheath Active Array L12-4 (8-13MHz) of an ultrasound machine (Philips clear vue350, Philips Healthcare, Andover MA01810, USA) for performing the blocks .
214282935|NCT05524038|DRUG|Dexamethasone|injection of 4mg dexamethasone in each block
214282936|NCT05524038|DEVICE|echogenic needle|22- gauge, 50 mm echogenic needle (Stimuplex D; B Braun, Germany) for performing the blocks .
214282937|NCT01213745|OTHER|Intervention|
214282938|NCT01213745|OTHER|Attention|
214282939|NCT01213745|OTHER|Control|
214282940|NCT02937909|OTHER|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
214282941|NCT04700371|DEVICE|Interwoven stent|Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
214282942|NCT04700371|DEVICE|Laser-cut stent|Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
214282943|NCT04397107|DRUG|IL-2|Patients were received low dose recombinant human Interleukin-2
214282944|NCT05625087|DRUG|Alpelisib|Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days
214282945|NCT05625087|DRUG|Ribociclib|Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
214282946|NCT02563444|DEVICE|Ultrasound fusion guiding system - TUS A-500 (Aplio 500)|
214282947|NCT04109794|PROCEDURE|E-CTG|Envelope connective tissue graft
214844396|NCT04232657|DRUG|Placebo|Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
214282948|NCT02936570|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)"
214282949|NCT05276401|DRUG|5% Bisphosphocin Topical Gel|Topical Gel
214282950|NCT05276401|DRUG|Placebo Topical Gel|Topical Gel
214282951|NCT05276401|DRUG|10% Bisphosphocin Topical Gel|Topical Gel
214282952|NCT03284944|DEVICE|Small-Volume|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
214282953|NCT03284944|DEVICE|Standard-Volume|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
214282954|NCT04334031|GENETIC|Biobanking with genetic analysis|Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
214282955|NCT04334031|OTHER|SF-12 questionnaire|Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
214282956|NCT00607971|DRUG|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
214282957|NCT05415839|DEVICE|Laser|Laser
214844397|NCT02044250|DRUG|Clopidogrel|Clopidogrel 75mg 1tab P.O. daily
214282958|NCT05607277|PROCEDURE|Endovascular Repair of abdominal aortic aneurysms|Femoral artery access
214282959|NCT02050529|DRUG|Labetalol|Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
214282960|NCT02050529|DRUG|Hydralazine|Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
214282961|NCT04184869|DRUG|Belinostat|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
214282962|NCT04184869|DRUG|Atazanavir|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir) Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
214470726|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant)|20 mcg Influenza A (H7N9) with 3.3 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
214282963|NCT01411774|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
214282964|NCT01411774|DRUG|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (\~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (\~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
214282965|NCT01411774|DRUG|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
214282966|NCT04410211|DRUG|Sevoflurane|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator"
214282967|NCT04410211|DRUG|Midazolam injection|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator."
214282968|NCT05954013|BEHAVIORAL|PD_Pal intervention|The PD\_Pal intervention will be delivered by a nurse that is specifically trained to deliver the PD\_Pal intervention, i.e. the PD\_Pal nurse. In the PD\_Pal intervention, the patient, family caregiver and PD\_Pal nurse complete four steps wherein they discuss and compose a: 1) Individual care plan; 2) Proactive care plan; 3) Quality of life and end-of-life plan and; 4) Coordination and revision plan. Together these steps lead to the Parkinson Support Plan. To facilitate patients in taking these steps, all patients receive a Parkinson Support Plan workbook. This workbook consists of information and questions aligned with the four steps. Patients can utilize this workbook before, during, or after the conversations with the PD\_Pal nurse.
214282969|NCT02403492|DEVICE|cPAP|All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
214282970|NCT02403492|DEVICE|cPAP, Continuation|Participants will be randomized to continue cPAP for a 2 week period
214282971|NCT02403492|DEVICE|cPAP, Discontinuation|Participants will be randomized to discontinue cPAP for a 2 week period
214282972|NCT00056316|BEHAVIORAL|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
214282973|NCT00056316|BEHAVIORAL|Behavioral Skills Training: Experimental|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
214282974|NCT05813951|DRUG|Linezolid|linezolid either continues infusion or standard intermittent dose
214282975|NCT04766580|BEHAVIORAL|Placebo and nocebo effect|The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
214282976|NCT00231075|DRUG|Paraplatin|
214282977|NCT00231075|DRUG|Paclitaxel|
214282978|NCT02038023|DRUG|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
214282979|NCT04847362|BEHAVIORAL|Experimental|education group
214282980|NCT05798650|BEHAVIORAL|facial dissatisfaction|"Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs."
214282981|NCT00712127|OTHER|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
214282982|NCT00712127|OTHER|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
214282983|NCT04467060|DRUG|Anaprazole Sodium|2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg，fasting oral administration.
214282984|NCT04467060|DRUG|Placebo|single dose, fasting oral administration
214282985|NCT01456247|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
214282986|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
214282987|NCT01456247|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
214282988|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
214282989|NCT01456247|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
214282990|NCT01456247|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
214470727|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant)|20 mcg Influenza A (H7N9) with 6.7 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
214470728|NCT06417853|DEVICE|Microarray Patch Delivery System|Vaccine free Microarray Patch Delivery System (VXS-1219U)
214844398|NCT02044250|DRUG|Aspirin|Aspirin 100\~200mg 1\~2tab P.O. daily
214844399|NCT06240364|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 84 days.
214470729|NCT06189508|DRUG|NXT007|In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
215032918|NCT03884257|DEVICE|Passeo-18 Lux treatment group|Percutaneous endovascular angioplasty with the Passeo-18 lux
215032919|NCT03884257|DEVICE|IN.PACT Admiral treatment group|Percutaneous endovascular angioplasty with the IN.PACT Admiral
215032920|NCT06162351|DRUG|PLX038|"Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection).~Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death."
215032921|NCT06065046|DRUG|Baricitinib 4 MG|Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days
215032922|NCT06065046|OTHER|Standard treatment|Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.
215032923|NCT04347538|OTHER|Saline Nasal Irrigation|Saline nasal irrigation BID
215032924|NCT04347538|OTHER|Saline with Baby Shampoo Nasal Irrigation|Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.
215032925|NCT02135133|DRUG|Idelalisib|150 mg BID Oral Daily
215032926|NCT02135133|DRUG|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
215032927|NCT06614543|DIETARY_SUPPLEMENT|Meal Replacement|These meal replacements provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.
215032928|NCT04891198|DRUG|Envafolimab|Subcutaneous injection
214282991|NCT03150615|OTHER|Early enteral nutrition|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament. Standard enteral diet, administered through a nasojejunal tube, is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.~After PD, enteral nutrition liquid regimen will be used step by step from postoperative day 1 to postoperative day 7.Patients are targeted to receive calories for 25 kcal/kg/day. Meanwhile, oral food intake was not restricted."
214282992|NCT03150615|OTHER|Saline|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament.~After PPPD,Only Normal Saline were given through nasojejunal tube. Entral nutrition was not administrated. Patients intake food orally at will."
214282993|NCT03150615|DEVICE|nasojejunal tube insertion|
214470730|NCT04530032|OTHER|ketogenic/modified Atkins diet|ketogenic/modified Atkins diet use
214470731|NCT04530032|OTHER|Standard diet|standard (normal) diet use
214470732|NCT06849739|DRUG|biologic therapy(eg:IFX,ADA,UST,VDZ)|This study compares the detection of blood samples from IBD patients after biologic therapy(eg:IFX,ADA,UST,VDZ) using different methods
215032929|NCT06077357|OTHER|MMSE Test|Mini Mental State Examination (MMSE), is a brief mental test used to assess individuals' cognitive functions. This test evaluates basic cognitive abilities such as memory, attention, calculation, language, orientation, and problem-solving. MMSE is commonly used for monitoring and assessing mild cognitive impairments, dementia, and other neurological conditions. This test is typically scored out of 30, with higher scores indicating better cognitive function.
215032930|NCT06077357|OTHER|PASE Test|"The PASE test stands for Physical Activity Scale for the Elderly. This scale is used to assess the physical activities undertaken by elderly individuals in their daily lives. The PASE test allows for the evaluation of both daily activities such as walking, climbing stairs, and household chores, as well as exercise routines. It is used to determine the level of physical activity in elderly individuals and support the process of healthy aging."
215032931|NCT06077357|OTHER|The PRISMA-7 Frailty Scale|The PRISMA-7 Frailty Scale is a tool used to assess the level of frailty in elderly individuals. This scale evaluates signs of frailty such as physical activity, fatigue, weight loss, and difficulties with vision and hearing. PRISMA-7 is employed in determining the risk of frailty in the elderly and aids in identifying appropriate treatment and support methods.
215032932|NCT06077357|OTHER|TAMPA Test|"The TAMPA test, abbreviated from Tampa Scale for Kinesiophobia, is a scale used to assess fears related to pain. This scale is employed to evaluate the fear of pain and avoidance behaviors associated with it. By measuring individuals' attitudes and fears towards pain, the TAMPA test helps identify their emotional and behavioral responses in this area."
214282994|NCT03150615|OTHER|Oral intake|Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.
214282995|NCT05611398|PROCEDURE|Orthopedic Surgery|A complete retrospective chart review was performed for all the patients' records and included all patients aged 18 years or higher who presented to Arrowhead Regional Medical Center with long bone fractures with Injury Severity Score \<16 and their repair and lactate levels at the time of surgery
214470733|NCT03627728|DRUG|Regorafenib|regorafenib/placebo
214470734|NCT03627728|OTHER|placebo|regorafenib/placebo
214470735|NCT06852040|DEVICE|Intraoral induction electrical stimulation therapy|Intraoral induction electrical stimulation therapy (specific method\[13\]: hand-held electrode rods were used to stimulate the mandibular hyoid muscle, digastric muscle, anterior abdomen, and other muscles of the three groups. Parameter setting: the frequency is 80Hz, the wave width is 1ms, the intensity is set to the muscle contraction, each electrical stimulation is 3s, intermittent 10s, 20min/time, 1 time/day, 5 days/week, 4 weeks is limited.
214470736|NCT06852040|DEVICE|tDCS treatment|tDCS treatment (specific method: microcurrent stimulator, stimulation electrode (3 cm×4 cm gelatin sponge), anodic stimulation site is the pharyngeal sensorimotor cortex area (between C3/T3 on the left\[14\], between C4/T4 on the right); the supraorbital area is the site of cathodic stimulation. The direct current intensity is 2.0 mA (20 min/time, 2 times/day) for two treatments (respectively, yin and yang alternating treatment), with an interval of at least 1 h, 5 days/week, and 4 weeks.
214282996|NCT06334510|BIOLOGICAL|One dose of quadrivalent influenza virus split vaccine was administered|"Safety observation: All 4900 vaccine recipients participated in the safety observation after vaccination, and were followed up for adverse events (AE) within 30 minutes and 0-30 days after vaccination, and SAEs within 6 months after vaccination.~In addition to 1050 recipients aged 18-59 years who were included in the first layer test, 350 recipients aged 3-17 years and 350 recipients aged ≥60 years were randomly selected from each group. Blood samples were collected before and 30 days after vaccination for influenza virus HI antibody detection."
214282997|NCT06081257|DIETARY_SUPPLEMENT|"KB-120 small molecular nutrient and vitamin E"|"The experimental group was given oral KB-120 small molecular nutrients, once a day, once a bag (30ml), and vitamin E100mg orally twice a day for a total of 3 menstrual cycles"
214282998|NCT06081257|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles
214282999|NCT03021122|DEVICE|PedAMINES™ / Conventional Method|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• PedAMINES™ (Period 1) and then Conventional Method (Period 2)"
214283000|NCT03021122|DEVICE|Conventional Method / PedAMINES™|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Conventional Method (Period 1) and then PedAMINES™ (Period 2)"
214283001|NCT01087190|DRUG|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
214283002|NCT05377983|OTHER|Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes|During the hospitalization period after CABG surgery, 2% lavender oil (Lavandula angustifolia) inhalation will be applied to the intervention group three times a day.
214283003|NCT01748032|BEHAVIORAL|Cognitive training|20 minutes/day for 5 sequential working days
214470737|NCT06852040|DEVICE|tDCS combined with intraoral induction electrical stimulation|tDCS combined with intraoral induction electrical stimulation. The patients were first treated with tDCS (the method is the same as that of the control group B) for 20 people twice a day and then given intraoral induction stimulation (the specific method is the same as that of the control group A) for 20 minutes, once a day, for 4 weeks.
214283004|NCT00585728|PROCEDURE|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
214283005|NCT04673162|DRUG|Methylprednisolone, Placebo|iv administration
214283006|NCT04370405|DRUG|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
214283007|NCT04014712|DRUG|Tetrahydrobiopterin|Oral, Single dose
214283008|NCT04014712|DRUG|Placebo oral tablet|Single dose
214470738|NCT05803473|DEVICE|Dexcom G6 Continuous Glucose Monitoring System (Dexcom Inc., San Diego, USA)|"For CGM-arm subjects, glucose data are obtained by the CGM Dexcom G6 which via an iPhone SE 3 transmits data to the in-hospital diabetes team stations to be displayed on an iPad 9 10.2."
214470739|NCT05803473|DEVICE|FreeStyle Precision Pro Glucometer for glucose POC testing|For the POC-arm subjects, glucose assessment is done by standard ward glucometer.
214470740|NCT06851468|DRUG|Keverprazan|Keverprazan ：Dosage form: tablet；dose：20mg；dosage: 2 times a day；duration: 14 days
214470741|NCT06851468|DRUG|Esomeprazole|Esomeprazole：Dosage form: capsule；dose：40mg；dosage: 2 times a day；duration: 14 days
214283009|NCT02990910|DRUG|Individualized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
214283010|NCT02990910|DEVICE|conventional opioid analgesia|(b) all received 25μg/kg morphine
214283011|NCT02893514|OTHER|Screening Only (SO) condition|Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.
214283012|NCT02893514|OTHER|SUSIT Condition|Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
214283013|NCT05272020|DIAGNOSTIC_TEST|CPET, 6MWT, QOL assessment|Preoperative and postoperative (6 months + 18 months) assessment
214283014|NCT02741024|DRUG|Amodiaquine-Artesunate (ASAQ)|Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home
214283015|NCT02741024|DRUG|Artemether-Lumefantrine (AL)|Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
214470742|NCT06851468|DRUG|Amoxicillin|Amoxicillin：Dosage form: capsule；dose：1g；dosage: 3 times a day；duration: 14 days。
214844400|NCT06240364|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 84 days.
214844401|NCT02358551|DEVICE|Placement of electrode lead through axillary vein puncture|
214844402|NCT02358551|DEVICE|Placement of electrode lead through subclavian vein puncture|
214844403|NCT06420609|OTHER|Go-TAD|The participants will receive a medical visit that will include the 4 open-ended questions comprising the Go-TAD intervention
214844404|NCT05045469|DRUG|dian dao san|dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks
214844405|NCT03868046|DRUG|Treatment with immune checkpoint inhibitors.|Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
214283016|NCT00851500|DRUG|K-604|K-604 is given for 26 weeks
214844406|NCT03868046|DIAGNOSTIC_TEST|Blood tests.|Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
214844407|NCT03332251|DEVICE|Posture Correction Girdle|Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
215032933|NCT06077357|OTHER|(JAMAR) Muscle Test|The JAMAR Muscle Test is a widely used clinical assessment tool for evaluating hand grip strength. It involves using a device called a dynamometer to measure the force exerted by a person's hand when squeezing the instrument. This test provides valuable information about an individual's upper body strength, which can be important in various medical and rehabilitative contexts. The JAMAR Muscle Test is often utilized in physical therapy, sports medicine, and other healthcare fields.
214283017|NCT00851500|OTHER|Placebo|placebo tablets are given for 26 weeks
214283018|NCT05000060|OTHER|Timing/1 week|Time of restart of antiplatelet therapy is one week after injury
214283019|NCT05000060|OTHER|Timing/3 weeks|Time of restart of antiplatelet therapy is left to treating clinician discretion
215032934|NCT06077357|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale (FSS) is a self-report questionnaire used to assess the severity of fatigue in individuals. It consists of nine items that measure the impact of fatigue on various aspects of daily life, such as physical functioning, motivation, and mental clarity. The FSS is commonly used in clinical settings and research studies to quantify the level of fatigue experienced by individuals with various medical conditions, including chronic illnesses, neurological disorders, and mental health conditions. It provides valuable information for healthcare professionals in understanding and managing fatigue-related symptoms.
215032935|NCT06393738|DRUG|ARV-393|Oral dose of ARV-393 at a specified dose schedule will be taken in 28-day cycles
215032936|NCT06634303|DEVICE|Brain cooling|Brain cooling intervention in acute ischemic stroke patients post mechanical thrombectomy
215032937|NCT05081843|BEHAVIORAL|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
214283020|NCT01937728|DRUG|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA \< 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
214283021|NCT01937728|DRUG|B: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks."
214283022|NCT01937728|DRUG|C: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
214844408|NCT06462144|DRUG|IMPT-514 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
214283023|NCT01937728|DRUG|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
214283024|NCT01937728|DRUG|E: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
214283025|NCT01937728|DRUG|F: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks."
214844409|NCT06616805|DEVICE|treadmill|Treadmill JAGUAR treadmill:( T900, China) motorized treadmill model (T900) motor power (6.OHP) input voltage (AC220-240 V, 50Hz) speed range (1-20KM/H), inclination range (1-15%) was used for exercise treatment
214844410|NCT05853809|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement to guide anti-inflammatory asthma treatment
214844411|NCT04504006|PROCEDURE|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
214844412|NCT00258505|PROCEDURE|Procedure: intracranial monitoring up to 9 days after injury|
214844413|NCT06674694|DRUG|Brexpiprazole long-acting injection|A single injection was administered.
215032938|NCT05081843|BEHAVIORAL|Usual health education curriculum|The schools' regular health education curriculum includes classroom lectures, hands on activities and group work.
215032939|NCT05918354|DEVICE|Skin Prick Automated Test|Detection of sensitisation to specific allergens via the skin prick automated test.
215032940|NCT03985527|DEVICE|Transvenous nerve stimulation|Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
214283026|NCT00583778|DRUG|ipratropium|0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
214283027|NCT00179114|DRUG|Botulinum Toxin Type A|
214283028|NCT00179114|DRUG|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
214283029|NCT00635596|BIOLOGICAL|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
214283030|NCT03775655|DRUG|Dexmedetomidine|10μg dexmedetomidine will be added to the injectate to be injected intrathecally
214283031|NCT05622084|DEVICE|Inperia Advance|Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device
214283032|NCT03410550|DEVICE|Exoskeleton Training|Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
214283033|NCT04143321|DRUG|Empagliflozin 25 MG|after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
214283034|NCT01916213|PROCEDURE|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
214283035|NCT01446900|DRUG|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
214283036|NCT01446900|DRUG|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
214283037|NCT00413127|DRUG|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
214283038|NCT00413127|DRUG|NaCl 0,9%|Administration of placebo i.v.
214283039|NCT00114036|BEHAVIORAL|Quality improvement strategies|
214283040|NCT00848705|BEHAVIORAL|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
214283041|NCT04489680|OTHER|Educational|Teaching session
214283042|NCT01513161|DRUG|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
214283043|NCT01513161|DRUG|Placebo|
214283044|NCT02287272|DRUG|CHF 5993 pMDI|4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
214283045|NCT02287272|DRUG|Cimetidine plus CHF5993 pMDI|Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
214283046|NCT00059982|DRUG|perifosine|
214283047|NCT02716454|PROCEDURE|Ileocaecal resection|laparoscopic ileocaecal resection with primary anastomosis
214283048|NCT05136768|DRUG|Sintilimab|Sintilimab: 200mg, administered by intravenous infusion on the first day of each cycle, one cycle every 3 weeks (Q3W), with the maximum cycle of 17. Suspension of Sintilimab administration: patients's request, disease progression, researcher-evaluated SAE
214283049|NCT05136768|RADIATION|SBRT|"At least one metastatic lesion is suitable for SBRT. If applicable, all metastatic lesions were allowed to be irradiated.~Recommended dose: BED ≥ 80Gy. Dose fractionation is determined as per physician's discretion, generally depending on the location of irradiated lesion and the distance to surrounding OARs.~Timing of SBRT: After completing at least 2 platinum-containing chemotherapy plus sintilimab treatments, SBRT can be started after assessing that there is no AE ≥ G2."
214283050|NCT05136768|DRUG|Platinum based chemotherapy|Platinum based single or doublet chemotherapy, one cycle every 3 weeks (Q3W), 4-6 cycles.
214283051|NCT01053884|DRUG|Anidulafungin|"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC \> 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."
214283052|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
214283053|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
214283054|NCT05708287|DEVICE|HFNC|The patients with mild hypoxemia, defined as the need for conventional oxygen therapy (COT) using nasal cannula at 4-5 liters per minute (LPM) to maintain O2 Saturation \>90%, were commenced on HFNC therapy
214283055|NCT01975753|DRUG|Morphine|
214844414|NCT03419104|DIAGNOSTIC_TEST|preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
214283056|NCT01975753|DRUG|Fentanyl|
214283057|NCT02503553|BEHAVIORAL|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
214283058|NCT02503553|BEHAVIORAL|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
214283059|NCT04201002|PROCEDURE|Resection plus intraoperative radiotherapy|En-bloc resection plus intraoperative radiotherapy
214283060|NCT05769881|PROCEDURE|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
214844415|NCT03270592|OTHER|Service dog|Use of a individualized certified service dog
214844416|NCT06083636|OTHER|Single extra blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
214283061|NCT05769881|PROCEDURE|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
214844417|NCT06083636|OTHER|Single blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
214283062|NCT04153240|DEVICE|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA)|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) has been developed for adult patients with positional OSA, and snorers. Worn on the back of the neck, it begins to vibrate when the patient starts to sleep in the supine position and increases in intensity until the patient changes.
214283063|NCT01525537|DRUG|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
214283064|NCT01525537|DRUG|sufentanil|sufentanil was given at standard practise
214283065|NCT02338440|DRUG|lipoprostaglandin E1|Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
214283066|NCT00573911|PROCEDURE|Endoscopy and pH study|endoscopy and PH study done one time
214283067|NCT00903695|DRUG|Memory XL|An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, \& acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
214283068|NCT00903695|DRUG|placebo|placebo comparator
214283069|NCT03633682|BEHAVIORAL|Headspace - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
214283070|NCT03633682|BEHAVIORAL|Stop, Breathe, & Think - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, \& Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
214283071|NCT04882540|DRUG|brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 100 mg tablets~* Route of administration: Oral use"
214283072|NCT03983291|BEHAVIORAL|FaReWell Depression|Facial massage and force exercise
214283073|NCT01785732|PROCEDURE|Renal Denervation|Sympathetic renal denervation via renal arteries
214283074|NCT06840366|OTHER|Lokomat intervention|The intervention will consist of an 8-week motor rehabilitation program, with 3 weekly sessions of 60 minutes each. In the first weeks, joint mobilization and postural control in a sitting position will be worked on, followed by muscle strengthening and balance re-education in a standing position. Subsequently, coordination exercises and assisted walking on different surfaces will be incorporated. In the final phase, independent walking and the integration of functional movements in daily life activities will be encouraged. The program will be adapted to the individual needs of each patient to optimize recovery and improve quality of life.
214283075|NCT02817191|DRUG|Hylo-Comod eye drop|The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
214283076|NCT02817191|DRUG|Tears Naturale Forte eye drop|The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
214283077|NCT01082120|DRUG|AZD1656|Tablets orally, twice daily for 10 days
214283078|NCT01082120|DRUG|Pioglitazone|Tablet oral single dose for 10 days
215032941|NCT04281940|DEVICE|Transcatheter implantation of chordal repair system|Implantation of anchor via transcatheter delivery system to delivery chordal repair system tethering the mitral leaflets to the ventricle
214283079|NCT02466360|BEHAVIORAL|Back Belief questionnaire|
214283080|NCT02466360|BEHAVIORAL|QUEBEC scale|
214283081|NCT02466360|BEHAVIORAL|Fear Avoidance beliefs questionnaire|
214283082|NCT02466360|BEHAVIORAL|Visual analog scale|
214283083|NCT02466360|BEHAVIORAL|individual interviews|
214283084|NCT02466360|BEHAVIORAL|Focus groups|
214283085|NCT02108353|DRUG|Melatonin 2mg|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
214283086|NCT02108353|DRUG|Placebo|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
214283087|NCT01285674|DRUG|Intra-tympanic Cisplatinum|Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
214283088|NCT02662296|DRUG|Ibrutinib|Given PO
214283089|NCT02662296|DRUG|Idelalisib|Given PO
214283090|NCT00543140|DEVICE|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
214283091|NCT05404295|OTHER|Umbilical cord blood platelel lysate gel|For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
214283092|NCT01906502|DEVICE|Sensimed Triggerfish|
214283093|NCT02663323|DEVICE|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
215032942|NCT02531191|DRUG|peficitinib|oral
214283094|NCT02584673|DEVICE|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
214283095|NCT00873223|DRUG|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
215032943|NCT02303821|DRUG|Carfilzomib|
215032944|NCT02303821|DRUG|Dexamethasone|
215032945|NCT02303821|DRUG|Mitoxantrone|
215032946|NCT02303821|DRUG|PEG-asparaginase|
215032947|NCT02303821|DRUG|Vincristine|
215032948|NCT02303821|DRUG|Intrathecal (IT) Methotrexate|
214283096|NCT00873223|DRUG|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
214283097|NCT01975545|DRUG|Fluor varnish|Dental varnish will be applied to one anterior superior teeth in a random side.
214283098|NCT01975545|DRUG|Fluor varnish with nanoparticles|Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
214283099|NCT03141476|DRUG|Cefuroxime 1,5g|Patients with BMI of \<30kg/m\*m: 1,5 g Cefuroxime
214283100|NCT03141476|DRUG|Cefuroxime 3g|Patients with BMI of 30-50kg/m\*m: 3g Cefuroxime
214283101|NCT03141476|DRUG|Cefuroxime 4,5g|Patients with BMI of \>50kg/m\*m: 4,5 g Cefuroxime
214283102|NCT04847492|PROCEDURE|Traditional corticotomy|A full-thickness mucoperiosteal flap will be elevated including the interdental papilla, and extended from the distal side of the second premolar on the right side to the same position on the left side without performing any vertical releasing incisions. Then, one vertical incision between the roots of upper anterior teeth and two vertical incisions in the site of first premolar extraction will be made by the piezosurgery knife.
214283103|NCT04847492|PROCEDURE|Flapless corticotomy|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva by using a blade N.15. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
214283104|NCT01827397|BIOLOGICAL|EN41-UGR7C HIV vaccine|
215032949|NCT02303821|DRUG|Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|
215032950|NCT02303821|DRUG|6-Mercaptopurine|
214283105|NCT01827397|BIOLOGICAL|NaCl|
214283106|NCT00861432|OTHER|additive homeopathic treatment|These patients receive additive homeopathic treatment
214283107|NCT01036841|DRUG|desmopressin tablet|Administration of desmopressine tablet
214283108|NCT01036841|DRUG|desmopressin MELT formulation|Administration of desmopressine MELT formulation
214283109|NCT06231160|PROCEDURE|Systematic Therapy Combined With Microwave Ablation|Patients with unresectable pancreatic cancer were included for laboratory examination, and quality of life and pain scores were recorded. The experimental group underwent microwave ablation first, followed by chemotherapy according to the guidelines; The control group received the same chemotherapy. Record the use of chemotherapy drugs and the occurrence of adverse events. Follow up will be conducted at 30 days, 90 days, and 180 days after chemotherapy to evaluate pancreatic function and quality of life.
214283110|NCT03902574|DRUG|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
214283111|NCT03902574|DRUG|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
214283112|NCT03902574|DRUG|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
214283113|NCT06243809|DRUG|Linagliptin 5 mg Oral Tablet|Linagliptin 5 mg Oral Tablet
215032951|NCT02303821|DRUG|Cyclophosphamide|
214283114|NCT06243809|DRUG|Trajenta 5 MG Oral Tablet|Linagliptin 5 mg Oral Tablet (Trajenta )
214283115|NCT01945957|DRUG|Oxytocin|"For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin."
214283116|NCT06436508|BEHAVIORAL|Early mobilization protocol|"* Step 1 - Day 1: Bed rest, elevation of the head end to 30°~* Step 2 - Day 2: Bed rest, elevation of the head end to 60°~* Step 3 - Day 3: Bed rest, elevation of the head end to 80°~* Step 4 - Day 4: Sitting on the edge of the bed~* Step 5 - Day 5: Sitting in a chair, standing up~* Step 6 - Day 6: Walking with or without assistance~* Step 7 - Day 7: Walking with or without assistance from today"
214283117|NCT06436508|BEHAVIORAL|Standard care|During standard care, early mobilization does not take place in the intensive care unit; the patient receives only standard supportive care in bed rest.
214283118|NCT02322567|OTHER|medical records|review of medical records
214283119|NCT00799240|DRUG|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
214283120|NCT00799240|DRUG|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
214283121|NCT02801292|DRUG|Ketamine|Single bolus of Ketamine .25 milligrams per kilogram of weight.
214283122|NCT05219084|DRUG|hip denervation|Lidocaine 2% 2ml was injected into each genicular nerve
214283123|NCT05219084|DRUG|intra-articular hydration|10 ml; of normal; saline were injected inside the hip joint
214283124|NCT05219084|DRUG|Combined group|hip denervation and intra-articular hydration were conducted together
214283125|NCT05219084|DRUG|Control group|Normal; saline was injected subcutaneously
214906754|NCT06234839|DIETARY_SUPPLEMENT|L. reuteri (DSM 17938 and ATCC PTA 5289) in form of oral tablets|Each subject of the experimental group was instructed to dissolve inside the mouth two tablets per day (in the morning and before going to bed at night), during the experimental period of 30 days. The tablets were provided by BioGaia ProDentis® (Stockholm, Sweden). The tablets contained two strains of L. reuteri (DSM-17938 and ATCC PTA 5289), at a dose of 2 x 108 CFU/tablet.
214906755|NCT00108264|BIOLOGICAL|Tumor RNA transfected dendritic cells|
214906756|NCT06308458|OTHER|Breather Exerciser Trainer|Gradual intensity from 2-3 rate of perceived exertion (RPE) up to reach 5-7 RPE, with gradual frequency; 1st week 8 sets of 5 repetitions '1 minute rest', 2nd week be 9 sets, and 3rd week reach 10 sets of 5 repetitions. then from 4-8 weeks 'end of study protocol' will be 10 sets of 6 repetitions with 1 minute rest between sets.), along with conventional breathing exercises (Diaphragmatic breathing, Pursed-up breathing, and Exercise connected with respiration), for 5 sessions per week for eight weeks
214906757|NCT06308458|OTHER|Conventional Breathing Exercise|Diaphragmatic breathing; place one hand on upper chest and the other on belly. Patient Breathe in slowly through nose, letting the air in deeply towards lower belly then patient is asked to tighten abdominal muscles and let them fall inward during exhalation through pursed lips Pursed-up breathing; by inhales through nose and exhales over 4 and 6 seconds in a whistling position Exercise connected with respiration; repetitive bilateral shoulder flexion then repetitive bilateral shoulder abduction, synchronized with breathing
214906758|NCT02183558|OTHER|OGTT by randomization|
214906759|NCT02183558|OTHER|OGTT by indication|
214283126|NCT05773430|BEHAVIORAL|Targeted Neurocognitive Training|Only two cognitive domains will be targeted for training (10 hrs of training in each, for a total of 20 hours). Two or more cognitive exercises may be employed within a cognitive domain. These exercises provide both immediate and intermittent feedback and are customized to the participants' individual ability; the difficulty and/or complexity of each game are systematically decreased/increased based on participants' performance to always be challenging, but not overly frustrating. Typically, in an hour session, one exercise (e.g., Mental Map) will be engaged at a time (20-30 minutes) before switching to another exercise (e.g., Hawkeye) in another domain for 20-30 minutes. This helps the participant remain engaged but avoid fatigue.
214283127|NCT04777500|DEVICE|Auricular transcutaneous electrical nerve stimulation device|We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.
214906760|NCT03034447|OTHER|Questionnaire|Children and parents are going to inform data regarding socioeconomical status, asthma and rhinitis diagnosis, asthma and rhinitis control, medications, sleep complaints, and sleep habits
214906761|NCT03034447|OTHER|Lung Function Test|Children are going to blow in a machine that measures how the lung is working
214283128|NCT04613960|DRUG|Magnesium sulfate|MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
214283129|NCT04613960|DRUG|normal saline|Placebo treatment
214283130|NCT06497933|PROCEDURE|Atrial fibrillation ablation|Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
214283131|NCT01437462|DRUG|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
214283132|NCT01437462|DRUG|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
214283133|NCT01603056|BIOLOGICAL|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
214283134|NCT01603056|BIOLOGICAL|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
214283135|NCT02198066|OTHER|Dry Sterile Dressing|Described in Arm Description.
214283136|NCT02198066|OTHER|Metallic Silver Dressing|Described in Arm Description.
214283137|NCT02198066|OTHER|Ionic Silver Dressing|Described in Arm Description.
214283138|NCT00786500|DIETARY_SUPPLEMENT|Gynostemma pentaphyllum tea|3 grams twice daily, orally
214470743|NCT06851273|BEHAVIORAL|Guided Self Help Family Based Therapy (GSH FBT)|Each family will participate in ten virtual sessions of GSH FBT with a trained GSH practitioner local to their provincial study site. Parents will meet their coach for a 60-minute onboarding session where the parents/caregivers are familiarized with the video platform used in treatment. Then, the treatment consists of ten virtual 20-minute sessions over 6 months. In GSH FBT, the parents weigh the adolescent patient prior to the session, on the same day as the session, and report the weight to the coach. Throughout treatment, parents have access to an online platform with a series of videos that outline the core components of FBT: the urgency to act, parental empowerment, medical complications, strategies to use during and after mealtime, and how to externalize the illness. In line with GSH approaches, coach-therapists direct parents to watch or review videos and text content rather than directly affecting behavioral change.
214470744|NCT06850194|PROCEDURE|vertical ramus osteotomy with iliac graft|in the VRO group all patient will undergo vertical ramus osteotomy surgery with iliac graft to correct the sever mandibular defficiency
214470745|NCT06850194|PROCEDURE|bilateral sagittal splitting osteotomy|all patients in this group will undergo to bilateral sagittal split osteotomy to correct the sever mandibular deficiency
214470746|NCT06568406|PROCEDURE|Physiotherapy|Examination by a physiotherapist: the first check-up with an examination and a therapeutic intervention with the patient is performed within 24-72 hours after delivery. This is followed by two regular outpatient check-ups by a physiotherapist for the purpose of therapy and education. The second check takes place after 6-8 weeks. And the third check occurs after 10-14 weeks after childbirth. In these three checks, data collection is carried out simultaneously (in order to complete the secondary objective). The patients are examined and monitored by the same physiotherapist.
214470747|NCT06568406|DIAGNOSTIC_TEST|Urogynaecology|Examination by a urogynaecologist this is carried out in the period of 14-18 weeks after childbirth in order to complete the primary objective. Data collection in order to complete the primary objective is done in the period of 14-18 weeks and 12-14 months after delivery (the online method without the need for a physical visit is preferred).
214470748|NCT06017414|BEHAVIORAL|Systemic Psychotherapy-informed Growth Path|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention aims to support members to explore their relationships, situations, and goals.
214470749|NCT06017414|BEHAVIORAL|Systemic Psychotherapy-informed Listener Training|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention encourages listeners to explore their relationships, situations, and goals and think about how they would support members working through their own relationships, situations, and goals.
214470750|NCT06850948|OTHER|Qualitative|Interviews collected with participants concerning their experience of gender identity healthcare
214470751|NCT06852885|OTHER|Meals|The intervention of the Solid'Africa Gemura selective feeding program will be administered as usual for study participants in the two intervention sites. Eligible hospital inpatients will receive three meals a day during their hospital stay, as prescribed by hospital nutritionists for their specific conditions and ordered from Solid'Africa. The Solid'Africa team will prepare the ordered meals in their off-site kitchen in Rusororo and deliver them daily to the hospitals where the meals will be distributed to the study participants. Meal caloric and nutritional content information is standardized except upon request. The normal meal is 575g of food consisting of 2300kCal with 300g of carbohydrates, 175g of protein, and 100g vitamins/minerals. In addition, Solid'Africa will adjust meal content per nutritionist request for specific needs like low salt/sugar, etc.
214906762|NCT03034447|OTHER|Home Sleep Study|Children are going to sleep at home with a device that tells if they stop breathing during sleep
214906763|NCT00597662|DEVICE|polylactide-caprolactone-trimethylenecarbonate copolymer|Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
214283139|NCT00786500|DIETARY_SUPPLEMENT|Placebo tea|3 grams twice daily, orally
214283140|NCT03192111|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
214283141|NCT04231864|BIOLOGICAL|Durvalumab|Given intravenously (IV)
214283142|NCT04231864|DRUG|Epacadostat|Given orally (PO)
214283143|NCT04144205|OTHER|Change of the fraction of inspired oxygen|"After the stabilization of cardiopulmonary bypass, in the first half of patients, fraction of inspired oxygen would be set at 0.5 and maintained for 5 minutes (T0), then it would be changed to 1.0 and maintained for 5 minutes (T1). Again, fraction of inspired oxygen would be resumed to be 0.5 and maintained for 5 minutes (T2).~In the other half of patients, the direction of change in fraction of inspired oxygen will be reversed as follows. It will be set at 1.0 and maintained for 5 minutes (T0), then changed to 0.5 and maintained for 5 minutes (T1), and finally to 1.0 and maintained for 5 minutes (T2)."
214283144|NCT02468115|DRUG|VIS410|Single fixed IV dose of VIS410
214283145|NCT02468115|DRUG|Placebo|Single IV dose of placebo
214283146|NCT00679315|DRUG|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
214283147|NCT00679315|DRUG|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
214283148|NCT05325554|BEHAVIORAL|Multimodal rehabilitation|Multimodal rehabilitation
214283149|NCT01221571|DRUG|AFM 13|Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
214283150|NCT01708733|DRUG|KSY|Chinese herbal formula
214283151|NCT02506140|DRUG|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
214283152|NCT02506140|DRUG|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
214283153|NCT00328757|BEHAVIORAL|Regular diet as the first postoperative meal|
214283154|NCT03017547|DRUG|IC14|Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS
214283155|NCT03017547|OTHER|Placebo|sterile normal saline for infusion
214283156|NCT05802121|DRUG|Apple Cider Vinegar|"Each patient will be instructed to take 1 caplet (equivalent of 143 mg/caplet containing 36% acetic acid) per day for 3 months (NPN: 80078433)~https://www.jamiesonvitamins.com/products/apple-cider-vinegar-chromium?srsltid=AfmBOoqdVBFe83\_5JM9BmkomQM1LqsJYSFTiP\_78cnmehfzVg-4T4Z6o"
214283157|NCT03569514|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
214283158|NCT05147350|DRUG|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 (Oral) in combination with FOLFIRI (IV)
214283159|NCT04604223|DRUG|Pioglitazone 45 mg|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
214283160|NCT04105101|DEVICE|Industrial passive shoulder exoskeleton|Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.
214283161|NCT00723983|DRUG|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
214470752|NCT05244278|DEVICE|Medtronic-GI genius (CADe system for detecting colorectal polyps)|Medtronic-GI genius: AI will provide real-time feedback throughout each colonoscopy procedure and alert endoscopists to the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.
214470753|NCT06851637|BEHAVIORAL|PoET|Participants in the PoET group completed two online training sessions (3 hours each) via Zoom. Group size was about 25-30 people. The sessions included the following positive psychology constructs: happiness, humour, optimism, loving kindness and gratitude on the first day, and hope, self-efficacy, meaningfulness, forgiveness and resilience on the second day.
214470754|NCT06231706|OTHER|Prebiotic-like nut and seed mix|A mixture of nuts, seeds and other plant based ingredients.
214283162|NCT00723983|DRUG|NP101 Study Patch|NP101 study patch 4 hour application
214283163|NCT00735410|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
214283164|NCT00942253|OTHER|Dopamine Agonist and Exercise|Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
214283165|NCT05576870|OTHER|Plant based toddler nutrition|Plant based toddler nutrition fed daily ad libitum
214283166|NCT05576870|DIETARY_SUPPLEMENT|Dairy based toddler nutrition|Commercially available toddler nutrition fed daily ad libitum
214283167|NCT05700097|DRUG|Dengzhanxixin Injection|Experimental arms for low, and high dose for the standard protocol
214283168|NCT05700097|DRUG|Placebo injection|placebo control arm for the standard protocol
214283169|NCT00577681|DRUG|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
214283170|NCT00923338|DEVICE|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
214283171|NCT04955197|DIAGNOSTIC_TEST|exfoliated cytology|Micronuclei (MN) are small chromatin bodies in the cytoplasm formed by chromosome fragments or whole chromosomes that fail to be included in the nuclei during cell division. They are considered as a sensitive indicators of genetic damage. They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation. Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions. Consequently, detection of micronuclei in exfoliated cells indicates an increased risk for cancer
214470755|NCT06231706|OTHER|Bread Crouton|A commercially available bread crouton product.
214470756|NCT06231706|DIETARY_SUPPLEMENT|Probiotic capsule|Contains the single strain Lactobacillus rhamnosus GG at 15 billion CFUs per capsule.
214470757|NCT06231706|OTHER|White bread and low fat spread|Consists of 3 slices of bread (providing approx. 55-60g CHO; 3g fibre) + low fat spread (10-15g)
214470758|NCT03703167|DRUG|Ibrutinib|Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).
214470759|NCT03703167|DRUG|Lenalidomide|Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 \& 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).
214470760|NCT03703167|DRUG|Rituximab|Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
214470761|NCT06484140|BEHAVIORAL|Financial Navigation|During hospitalization, participants will receive needs assessment, and one-on-one cost-related health education with a material booklet. Resource and service referral will be delivered face-to-face or by phone when the navigator identifies unaddressed problems. Within three months after discharge, participants will receive monthly follow-up phone calls and personalized counseling via WeChat.
214470762|NCT06484140|OTHER|Usual Care|Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
214470763|NCT04783766|DRUG|CK-3773274|CK-3773274- Tablets
214470764|NCT04783766|DRUG|Placebo|Placebo- Tablets
214470765|NCT00140322|BEHAVIORAL|Exercise, fall risk reduction|
214844418|NCT04197128|DEVICE|Resorbable Collagen membrane with bone graft for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision. Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, bovine bone graft will be place with overlying resorbable collagen membrane. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted Vicryl 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)"
214844419|NCT04197128|DEVICE|Ribose cross linked collagen matrix for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision.~Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, ribose cross linked collagen matrix will be cut and adapted to the buccal wall and ridge around the buccal aspect of healing abutment. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)."
214844420|NCT01254461|DRUG|AZD1981|100 mg per oral, twice daily for 8 days
214283174|NCT04052347|BEHAVIORAL|Shared decision-making with a Decision-aid|A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9
214283175|NCT04052347|BEHAVIORAL|routine shared decision-making|control group
214283176|NCT00113984|BIOLOGICAL|PROSTVAC-V/TRICOM|
214470766|NCT03818620|DEVICE|Barco digital dermatoscope device images|Images of skin lesion taken with the Barco dermatoscope by site team member
214470767|NCT03818620|DEVICE|Reference standard dermatoscope device images|Images of skin lesion taken with a standard dermatoscope device (as part of standard care)
214283177|NCT00113984|BIOLOGICAL|PROSTVAC-F/TRICOM|
214283178|NCT00113984|DRUG|MDX-010|
214283179|NCT00113984|DRUG|Sargramostim|
214470768|NCT04170881|OTHER|Exposed/non exposed - Epidemiology|visit of daycares and environmental measurement will be performed
214470769|NCT03079921|DRUG|Phentolamine|Physiologic receptor blockade (α1-receptor).
214283180|NCT03537105|PROCEDURE|Skin biopsies|Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
214470770|NCT03079921|DRUG|Propranolol|Physiologic receptor blockade (β2-receptor).
214283181|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
214470771|NCT03079921|DRUG|Placebo|100mL bag of Normal Saline Solution (NSS).
214470772|NCT02482337|PROCEDURE|POEM|POEM procedure in the OR
214470773|NCT04805658|DIAGNOSTIC_TEST|Clinical examinations|Clinical examinations
214470774|NCT05325099|DRUG|Azacitidine|azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times
214470775|NCT05325099|DRUG|Placebo|Placebo (subcutaneous injection) QOD x 3 times
214470776|NCT05163496|DRUG|Psilocybin (Usona Institute)|PAP + psilocybin 25 mg
214470777|NCT05163496|DRUG|Active placebo|PAP + niacin 250mg
214844421|NCT01254461|DRUG|AZD1981|4x100 mg per oral, twice daily for 8 days
214283182|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
214470778|NCT06201390|BEHAVIORAL|Sleep consistency|Participants will be asked to maintain a consistent bed- and wake-time.
214470779|NCT05807048|DRUG|Daratumumab and Hyaluronidase-fihj|DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection for subcutaneous use. Supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL.
214470780|NCT05807048|DRUG|Pre-Intervention Medication|"The following pre-medications will be administered 1-3 hours before each dose of DARZALEX FASPRO:~* Acetaminophen 650 to 1,000 mg orally~* Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously~* Montelukast 10mg PO prior to DARZALEX FASPRO®.~* Methylprednisolone 100 mg (or equivalent) orally or intravenously"
214283183|NCT03012165|DRUG|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
214283184|NCT02454491|DRUG|Heparin|intraradial administration of heparin 5000 ui
214283185|NCT02454491|DRUG|Verapamil|intraradial administration of verapamil 5 mg
214844422|NCT01254461|DRUG|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
214283186|NCT05521789|DRUG|ESB Thoracic|Erector spinae thoracic block with bupivacaine
214283187|NCT02744690|DRUG|Mitomycin-C (MMC)|Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
215032952|NCT02303821|DRUG|Cytarabine|
214283188|NCT03824613|DIAGNOSTIC_TEST|Urinary miRNA|MiRNA detection in urine
214283189|NCT02362061|RADIATION|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
214283190|NCT02770560|DEVICE|Urokinase locking solution|On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
214283191|NCT05230303|DIETARY_SUPPLEMENT|Caffeine supplementation|Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
214283192|NCT05230303|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
214283193|NCT00935571|DRUG|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
214283194|NCT01131754|OTHER|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
214283195|NCT02294591|DRUG|N-acetylcysteine|Add-on treatment of NAC
214283196|NCT02294591|DRUG|Placebo|Add-on treatment of placebo
214283197|NCT04302298|DEVICE|Virtual Reality|A machine which immerses the participant in a simulated environment where they can perform a procedure.
214283198|NCT04071561|OTHER|Posterior retroperitoneal adrenalectomy (PRA)|Minimally invasive adrenalectomy procedure
214283199|NCT04071561|OTHER|Lateral transperitoneal adrenalectomy (LTA)|During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
214283200|NCT02486497|BIOLOGICAL|hENT1|hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
214283201|NCT02627144|DRUG|Bevacizumab|Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
214283202|NCT02627144|DRUG|Interferon alpha-2a|Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
214283203|NCT04019574|DRUG|CR845 0.5 mcg/kg IV|0.5 mcg/kg IV CR845
214283204|NCT04019574|DRUG|CR845 3 mcg/kg IV|3 mcg/kg IV CR845
214283205|NCT04019574|DRUG|Moxifloxacin 400 mg Oral Tablet|400 mg Oral Moxifloxacin
214283206|NCT04019574|OTHER|Placebo|IV Placebo as a bolus injection
214283207|NCT02429544|BEHAVIORAL|Residential Program|Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
214283208|NCT02429544|BEHAVIORAL|Questionnaires|Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
214844423|NCT04090879|OTHER|Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)|1\) Altering the nicotine content of the tobacco research cigarette
214844424|NCT04090879|OTHER|E-Cigarettes|1\) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
214844425|NCT06327737|DIAGNOSTIC_TEST|Capnography|This is non-invasive follow-up method to the management of DKA and the reduction of the frequency of invasive procedures was investigated in patients diagnosed with diabetic ketoacidosis (DKA) in the pediatric emergency department and followed up with capnography.
214283209|NCT02429544|DEVICE|Electroencephalogram (EEG)|EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
214283210|NCT02429544|OTHER|Saliva Testing|Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
214283211|NCT02429544|BEHAVIORAL|Study Diary plus Actigraph|For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
214906764|NCT00597662|DEVICE|Icodextrin 4%|1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
214906765|NCT04202120|OTHER|Age-related stereotyping priming|The priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
215032953|NCT02303821|DRUG|Daunorubicin|
215032954|NCT05087342|DRUG|Semaglutide 2.4mg|The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
215032955|NCT05087342|DRUG|Placebo|A placebo will be given to the control group per the schedule outlined in the armed description.
215032956|NCT06644248|DIAGNOSTIC_TEST|Colposcopy|The intervention involves the use of colposcopy, a diagnostic procedure to visually examine the cervix using a colposcope. The procedure includes the application of saline, acetic acid, and iodine solutions to enhance the visualization of cervical tissues and identify abnormalities. The dosage form includes applying these solutions directly to the cervical area. The frequency of the intervention is typically a single session per patient, with the duration of the procedure lasting approximately 10-15 minutes. This study aims to utilize an AI model to analyze the colposcopic images obtained during the procedure to improve the accuracy and efficiency of cervical cancer detection.
215032957|NCT05625802|PROCEDURE|Erector Spinae Plane Block (ESPB)|Up to 30 Cubic Centimeter (cc) of 0.5% ropivacaine administered by local injection into the erector spinae plane under ultrasound guidance
215032958|NCT05625802|DRUG|Ropivacaine|0.5% ropivacaine
215032959|NCT03408262|BIOLOGICAL|Ad4-EnvCN54|Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
215032960|NCT03408262|BIOLOGICAL|MVA-CN54|Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
215032961|NCT03408262|BIOLOGICAL|CN54gp140/MPLA|Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
215032962|NCT05974787|BEHAVIORAL|Emergency department cancer patients interview|The interview focuses on several parts of the (pre-)admission process: The first part is regarding the barriers and facilitators encountered during the (pre-)admission process. The second part will focus on the timeline that led to an emergency department (ED) visit. It will be established when and which symptoms were first detected. The third part is regarding the number and type of health care workers that were contacted before visiting the ED. The fourth part will be about the actions and considerations taken before the ED visit.
215032963|NCT02070211|DIETARY_SUPPLEMENT|omega-3 PUFAs|4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.
215032964|NCT02070211|OTHER|Standard care|Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.
215032965|NCT02070211|DIETARY_SUPPLEMENT|placebo|4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
215032966|NCT03246412|DIAGNOSTIC_TEST|Nevus doctor clinical decision support|The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
214844426|NCT00232479|DRUG|trastuzumab, docetaxel and carboplatin in dose dense regimen|trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
214844427|NCT03052114|DEVICE|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
215032967|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
215032968|NCT05410223|DRUG|IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
214844428|NCT06392542|BEHAVIORAL|Whole Selves|Whole Selves is a brief online self-guided intervention addressing transgender/nonbinary young adults' experiences with alcohol use and romantic relationships. The intervention is delivered in a single session of approximately 40 minutes. Whole Selves employs principles of technology-adapted motivational interviewing (e.g., eliciting and strengthening participants' internal reasons for behavior change through interactive activities) as well as personalized feedback on participants' self-reported alcohol use and romantic relationship experiences. The intervention incorporates text and video narratives from transgender/nonbinary people sharing their own experiences with alcohol use and romantic relationships. Content will be tailored based on participants' current alcohol use and romantic relationship experiences.
214844429|NCT04119024|PROCEDURE|Biopsy|Undergo biopsy
214283212|NCT05780658|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
214283213|NCT02088710|BEHAVIORAL|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
214283214|NCT03118258|BEHAVIORAL|'Pap smear' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility."
214283215|NCT03118258|BEHAVIORAL|'Self-collected vaginal swab for HPV testing + pap smear triage' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
214283216|NCT03332654|OTHER|Determine prevalence of stress urinary incontinence|
214283217|NCT04971122|OTHER|Trendeleburg -5 degree,-10 degree,-15 degree|Use a -5 or -10 or -15 degree trendelenburg position
214283218|NCT04547569|BEHAVIORAL|Speech adaptation|Sensorimotor adaptation in speech
214283219|NCT04547569|BEHAVIORAL|Vibrotactile Discrimination|Vibrotactile Discrimination
214283220|NCT04547569|OTHER|fMRI|fMRI measurement of brain activity
214283221|NCT04547569|BEHAVIORAL|Speech production|Speech production task
214283222|NCT06379412|OTHER|observational study, no intervention|observational study, no intervention
214283223|NCT00094744|DEVICE|Eye patch|adhesive eye patch used to cover the sound eye
214283224|NCT05817825|BEHAVIORAL|Smart IOP Intervention|Smart IOP is a remotely delivered IOP program in operation since 2016, allowing patients to complete addiction treatment entirely online. The original program, consisting of 72 video modules across 8 different topics, will be adapted and tailored to hospitalized patients with serious infections from injection drug use. Participants will watch video content asynchronously, and will be required to correctly answer knowledge questions to proceed to the next module. The whole treatment program will require approximately 4 weeks to complete. Participants are also asked to answer questions about how to apply the knowledge to their own personal circumstances. The answers to these are reviewed by the peer recovery coach during weekly encounters. Videos can be viewed at a time that is most convenient to the participants. T
214283225|NCT05817825|BEHAVIORAL|Peer Recovery Coach|Peer recovery coach, an individual in sustained recovery (\>5 years) and certified to be a coach, will meet weekly with the participant to review progress, answer questions about the videos, review answers to questions, and encourage continuation of treatment after discharge. These meetings will occur in-person or remotely.
214283226|NCT02008201|DIETARY_SUPPLEMENT|vitamin D|
214283227|NCT06133205|OTHER|Catgut Embedding at acupoints|Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
214283228|NCT00903591|OTHER|questionaire, blood or saliva sample|Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
214283229|NCT05168527|DRUG|Fruquintinib,Albumin Paclitaxel,Gemcitabine|The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
214283230|NCT00888368|PROCEDURE|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
214283231|NCT00888368|PROCEDURE|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
214283232|NCT05820685|DRUG|Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol)|Participants will receive acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, and gabapentin 300 mg every eight hours. Participants will also receive Oxycodone 5 mg or Tramadol 50 mg every six hours as needed for breakthrough pain. Providers will have the ability to adjust this pain regimen based on clinical judgement.
214844430|NCT04119024|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214844431|NCT04119024|PROCEDURE|Computed Tomography|Undergo CT scan
214844432|NCT04119024|DRUG|Cyclophosphamide|Given IV
214844433|NCT04119024|DRUG|Fludarabine Phosphate|Given IV
214844434|NCT04119024|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
214844435|NCT04119024|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given IV
214844436|NCT04119024|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214844437|NCT04119024|PROCEDURE|Positron Emission Tomography|Undergo PET scan
215032969|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd."
215032970|NCT05410223|DRUG|IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
215032971|NCT04245189|OTHER|Endoscopic ultrasound for detection of Chronic pancreatitis|Presence of Chronic pancreatitis in alcoholic cirrhosis patients.
214283233|NCT05820685|DRUG|Dronabinol|Participants will receive Dronabinol 10 mg every 12 hours scheduled. Providers will have the ability to adjust this pain regimen based on clinical judgement.
214283234|NCT03181334|BEHAVIORAL|Branch I|FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
214283235|NCT03181334|BEHAVIORAL|Branch II|"FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week."
214283236|NCT03181334|BEHAVIORAL|Branch III|"FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks."
214283237|NCT03181334|BEHAVIORAL|Branch IV|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive."
214283238|NCT03181334|BEHAVIORAL|Branch V|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive."
214283239|NCT05477810|DRUG|Treatment A (investigational drug) followed by Treatment B (reference drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
214283240|NCT05477810|DRUG|Treatment B (reference drug) followed by Treatment A (investigational drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
214283241|NCT02285790|DEVICE|Reflectance confocal microscopy|
214283242|NCT02285790|PROCEDURE|Punch biopsy|
214283243|NCT02285790|PROCEDURE|Surgical excision|Excision of the suspected basal cell carcinoma lesion under local anesthetics
214283244|NCT04564937|DRUG|SCT510A|SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
214283245|NCT04162639|BIOLOGICAL|Skin allograft|Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
214283246|NCT00420927|BIOLOGICAL|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
214844438|NCT06450873|DRUG|Coriolus Versicolor Extract|Dietary Supplement Given PO
214283247|NCT00420927|DRUG|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
214283248|NCT00420927|BIOLOGICAL|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
214283249|NCT04383795|DRUG|Antithyroid Drug|Administration of antithyroid Drug for 6 months
214283250|NCT01220622|DRUG|Nimodipine|Administration of nimodipine 30mg tid for 6 months
214283251|NCT01220622|DRUG|Placebo|Administration of placebo 30mg tid for 6 months
214844439|NCT06450873|OTHER|Questionnaire Administration|Ancillary studies
214844440|NCT05894148|DRUG|Genakumab injection|Group 1: 120mg Q4W，group 2: 200mg Q4W
214844441|NCT05894148|DRUG|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
214844442|NCT01040273|DRUG|Bupivacaine|
214844443|NCT01040273|DRUG|Placebo|
214844444|NCT04628481|DRUG|Ladarixin|Oral ladarixin twice a day for 13 cycles
214844445|NCT04628481|DRUG|Placebo|Oral placebo twice a day for 13 cycles
215032972|NCT02903147|BEHAVIORAL|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
215032973|NCT02903147|BEHAVIORAL|The employer's training|
215032974|NCT05720104|DEVICE|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
215032975|NCT05720104|OTHER|Standard oral hygiene instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
215032976|NCT00553969|DRUG|carvedilol phosphate|Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
215032977|NCT00553969|DRUG|lisinopril|tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
215032978|NCT00553969|DRUG|carvedilol phosphate and lisinopril|carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
215032979|NCT00553969|DRUG|placebo and placebo|capsule once daily for 9 months; dosage unknown
214283252|NCT05157854|BEHAVIORAL|Active in My Home (AiMH)|"AiMH starts with two workshops for staff to introduce them to the intervention and the contributions expected from them. Their task is to participate in a couple of the sessions, inspire the course participant to stick to strategies developed during the sessions and support activity in general between the occupational therapy sessions.~AiMH consists of eight sessions, five individual ones and three in a group. Each session has a theme, such as: activity and health, and is built up with short lessons, using one's senses such as smell or touch, testing a simple activity, and setting goals for an activity one wants to test between sessions. The participants are given around 25 USD to try out that activity."
214283253|NCT01115101|DRUG|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
214283254|NCT01115101|DRUG|Piritramid|"Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded."
214283255|NCT04605484|BIOLOGICAL|Posoleucel (formerly known as ALVR105) cells|Infusion
214283256|NCT04605484|BIOLOGICAL|Placebo (visually identical to Posoleucel)|Infusion
214283257|NCT02454296|DRUG|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
214283258|NCT02454296|DRUG|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
214283259|NCT02782975|DRUG|aducanumab|
214283260|NCT05727215|BIOLOGICAL|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
214283261|NCT06398574|OTHER|Real dry needling|With the subject lying supine, a dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made
214283262|NCT06398574|OTHER|Sham dry needling|With the subject lying supine, a sham dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made, simulating the real technique
214283263|NCT06091748|DRUG|68Ga-DOTATOC|Detection of somatostatin positive lesions in GEP-NETs
214283264|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)|Given via ICT delivery
214283265|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)|Given via ICT/ICV dual delivery
214283266|NCT05854069|BEHAVIORAL|FAMS-T1D|"FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.~Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly."
214283267|NCT05854069|BEHAVIORAL|Digital resources for diabetes|Quality digital resources about diabetes management provided upon enrollment and during the study.
214283268|NCT06278779|DRUG|Esketamine group|"The recommended dosing for Spravato is:~Weeks 1-4:~Starting Day 1 dose:~\< 65 years: 56 mg~≥ 65 years: 28 mg~Subsequent doses:~28 mg (≥ 65 years), 56 mg or 84 mg twice weekly~Weeks 5-8:~28 mg (≥ 65 years), 56 mg or 84 mg once weekly~From Week 9:~28 mg (≥ 65 years), 56 mg or 84 mg every 2 weeks or once weekly"
214283269|NCT06278779|DRUG|Racemic ketamine|"Typically, dosing will begin at the standard dose of 0.5 mg/kg and adjusted as needed using an ascending dose titration schedule:~1. 0.5 mg/kg~2. 0.6 mg/kg~3. 0.75 mg/kg~4. 0.9 mg/kg~5. Further increments by 0.1-0.2 mg/kg, up to max 1.5 mg/kg"
214283270|NCT06628128|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
214283271|NCT03201835|DRUG|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
214283272|NCT03201835|DRUG|Sativex|spray X 4 actuations
214283273|NCT03201835|DRUG|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
214283274|NCT03201835|DRUG|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
214844446|NCT00020358|BIOLOGICAL|aldesleukin|
215032980|NCT03458572|DEVICE|Seirin Pyonex press needle acupuncture|Acupuncture
215032981|NCT04219020|OTHER|Co-created intervention|
214470781|NCT05807048|DRUG|Post-Intervention Medication|"The following post-medications will be administered:~* Methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO®.~* Patients with a history of chronic obstructive pulmonary disease will be prescribed short and long-acting bronchodilators and inhaled corticosteroids.~* Antiviral prophylaxis for herpes zoster reactivation must be initiated within one week of daratumumab hyaluronidase-fihj administration and continued for 3 months following the end of treatment."
214283275|NCT03201835|DRUG|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
214283276|NCT05873387|DEVICE|Use of Eko DUO stethoscope (paired ECG/PCG)|Auscultation of heart sounds using electronic stethoscope
214283277|NCT00885430|DRUG|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
214283278|NCT00821353|PROCEDURE|RF catheter ablation|RF catheter ablation
214283279|NCT00821353|DRUG|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
214283280|NCT04318795|PROCEDURE|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
214283281|NCT04318795|PROCEDURE|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
214283282|NCT02912910|OTHER|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
214283283|NCT02912910|OTHER|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
214283284|NCT04443270|DRUG|Chloroquine phosphate|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
214283285|NCT00905697|PROCEDURE|Living donor lung transplantation|Living donor lung transplantation
214844447|NCT00020358|BIOLOGICAL|gp100 antigen|
214283286|NCT00725569|DRUG|Bellis perennis and Staphysagria (C6)|homeopathic remedy
214283287|NCT00725569|DRUG|Bellis perennis and Staphysagria (C30)|Homeopathic Remedy
214283288|NCT00725569|DRUG|Placebo|Placebo remedy, identical in size, shape and taste to treatment remedies
214283289|NCT06205004|OTHER|Questionnaires|In the present study, the investigators aim to investigate the prevalence and effects of IA on the psychosocial well-being among adults in Hong Kong by measuring the level of Internet use, depression, anxiety, sleep quality, QOL together with basic demographic data in the current situation of COVID with popularity of Metaverse.
214283290|NCT05292040|DRUG|LY3857210|Administered orally.
214283291|NCT01057342|DRUG|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
215032982|NCT00582296|BEHAVIORAL|questionnaires, telephone interview, optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
214283292|NCT01057342|DRUG|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
214283293|NCT01057342|DRUG|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
214283294|NCT05686551|DRUG|Tominersen 60 mg|60 mg tominersen administered intrathecally every 16 weeks (Q16W).
214283295|NCT05686551|DRUG|Placebo|Matching placebo administered intrathecally Q16W.
214283296|NCT05686551|DRUG|Tominersen 100 mg|100 mg tominersen administered intrathecally Q16W.
214283297|NCT02862444|OTHER|Culturally Appropriate Intervention|Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
214283298|NCT04512716|DRUG|131-I Apamistamab|Patients will receive 131-I apamistamab 5-7 days prior to a single infusion of 1x10\^6 19-28z CAR T-cells/kg for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL. 131-I apamistamab may be administered inpatient or outpatient at the discretion and judgment of the treating investigators.
214283299|NCT04512716|BIOLOGICAL|CAR T-cell|19-28z CAR T-cells will be administered inpatient as a single infusion of 1x10\^6 19-28z CAR T-cells/kg, for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL cohort. Patients will be observed inpatient for a minimum of 7 days (longer as clinically indicated and at the discretion of the treating physician).
214283300|NCT06251648|DRUG|Lenalidomide|Patients exposed to LEN
214283301|NCT06332781|DRUG|Gentamicin|administered via bladder
214283302|NCT06332781|DRUG|Nitrofurantoin|administered PO
214283303|NCT00262574|DRUG|Nesiritide,|PCI
214283304|NCT02680080|DRUG|Moxifloxacin|a single 400 mg tablet of Moxifloxacin
214283305|NCT02680080|DIETARY_SUPPLEMENT|Grapefruit group|one liter of fresh pink-grapefruit juice
214283306|NCT01370356|DRUG|Varenicline Tartrate|Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
214283307|NCT01370356|DRUG|Placebo|Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
214283308|NCT03748186|DRUG|STRO-002|intravenous antibody drug conjugate
214283309|NCT06088953|DIAGNOSTIC_TEST|VRB test|"V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise.~V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation."
214844448|NCT00020358|BIOLOGICAL|incomplete Freund's adjuvant|
214844449|NCT00020358|BIOLOGICAL|tyrosinase peptide|
215032983|NCT00582296|BEHAVIORAL|questionnaires, telephone interview and optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
215032984|NCT02475993|OTHER|SMART app|Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
214283310|NCT06317181|DEVICE|Collection of elastography data|patients who are scheduled for an elastography for clinical reasons usually receive an ultrasound scan in which the b-mode images of the liver tissue are collected. In this study additional radiofrequency data is collected through a software access.
214283311|NCT06317181|DEVICE|Collection of ultrasonic raw data|Patients who are transferred to the ultrasound departement due to suspicious focal lesions receive an ultrasonic investigation including the acquisition of raw data and extracting a definitive diagnose from the following clinical routine investigation, depending on the standards of the participating center
214283312|NCT00131118|DRUG|Zoledronic Acid|
214283313|NCT06331416|DEVICE|Telemonitoring|Patients will be asked to carry out one measurement (arterial pressure, oxygen saturation, body temperature, heart rate, spirometry) every 24 hours for 90 days. The system will be supplied by the company Vivisol. The telemonitoring data will be read once a day and the principal investigator will be alerted in case of alteration of any parameter. If vital parameters remain stable, a phone call will be performed every 5 days. In case of compromise of any parameter, the patient will be offered a phone call within the same day. In case of new occurrence of any respiratory or non-respiratory symptoms, the patient must contact the principal investigator and he will be offered a phone call or a video-assisted call within the same day. If the alterations or symptoms persist for 24 hours, or in any case upon decision of the investigator in charge, the patient will be offered an in-person evaluation in the same day. If deemed necessary according to usual care, the patient will be hospitalized.
214283314|NCT05012488|OTHER|Comparison of gait and foot pressure|The spatio temporal gait parameters of the patients will be evaluated with Zebris (Zebris Medical Limited , Germany) FDM (Force Distribution Measurement ) treadmill system. The system has production of 3D motion analysis and force measurement technologies for biomechanics. When the treadmill is in static and dynamic condition, strong pressure distribution measurement will be taken.
214283315|NCT00499577|BIOLOGICAL|CMV pp65 peptide|Given intramuscularly
214283316|NCT00499577|BIOLOGICAL|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
214283317|NCT00499577|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
214283318|NCT00499577|BIOLOGICAL|survivin Sur1M2 peptide vaccine|Given subcutaneously
214283319|NCT05385952|DEVICE|GATT-Patch (currently named ETHIZIA)|"GATT-Patch (currently named ETHIZIA) is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
214283320|NCT05385952|DRUG|TachoSil|"TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge.~TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical."
214283323|NCT00040664|DRUG|ritonavir|ritonavir oral capsules or oral solution
214283324|NCT00040664|DRUG|fosamprenavir|fosamprenavir oral suspension or tablet
214283325|NCT02611557|PROCEDURE|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
214283326|NCT02925494|DRUG|Estradiol/Norethindrone Acetate|capsules
215032985|NCT04116489|OTHER|Forest walk|Participants will be provided with an educational program about the forest and take a guided forest walk.
215032986|NCT04116489|OTHER|Wildlife rehabilitation|Participants will be provided with education on wildlife rehabilitation and assist with wildlife care such as feeding baby animals.
215032987|NCT04116489|OTHER|Wildlife sanctuary observation|Participants will be provided an educational program on wildlife care and accompany park game keepers during animal feeding and will observe iconic wildlife.
215032988|NCT04116489|OTHER|Bird feeding and watching|Participants will learn about bird identification and safe bird feeding. Bird feeders will be provided at the Soldier On facility for home bird feeding after study conclusion.
214283327|NCT02925494|DRUG|Elagolix|film-coated tablets
214844450|NCT04763096|DRUG|Advagraf|"Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks."
214844451|NCT00502658|BEHAVIORAL|Dietary supplement containing vitamins, minerals, and herbs|
214844452|NCT00502658|BEHAVIORAL|Shakes with nutrients and herbs|
214844453|NCT00502658|BEHAVIORAL|Control dietary supplement|
214844454|NCT00502658|BEHAVIORAL|Isocaloric, isonitrogenous control shakes without herbs|
214844455|NCT00502658|BEHAVIORAL|Personal energy tracking tool|
214844456|NCT00160888|DRUG|sodium nitroprusside, bradykinin, acetylcholine|
214844457|NCT03562949|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
214844458|NCT03562949|DRUG|Reference Product|QVAR® 40 mcg (Beclomethasone Dipropionate HFA)
214844459|NCT03562949|DRUG|Placebo|Placebo Product
214844460|NCT04623528|DIAGNOSTIC_TEST|T1 and T2 relaxometry of the liver parenchyma|Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
214844461|NCT04205162|DEVICE|Verafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
214844462|NCT04205162|DEVICE|Etafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
214844463|NCT04245293|DEVICE|Ainara|Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
214844464|NCT04245293|DEVICE|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
214844465|NCT03649945|DRUG|Docetaxel|75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
214844466|NCT03649945|DRUG|Nedaplatin|80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
214844467|NCT03649945|DRUG|Endostar|7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
214844468|NCT01889472|DEVICE|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
214844469|NCT02666924|DIETARY_SUPPLEMENT|Chinese-canadian specific cooking classes|Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
214844470|NCT02666924|OTHER|Diabetes educational classes|Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
214844471|NCT01011556|DRUG|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
214844472|NCT01011556|DRUG|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
214844473|NCT04010734|PROCEDURE|Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography|"The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH)."
214844474|NCT02078011|DEVICE|High Intensity Focused Ultrasound|The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
214844475|NCT00640458|DRUG|Sildenafil 100 mg|
214283328|NCT05929014|DEVICE|Bilateral-Transcranial direct current stimulation (bilateral-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal and anodal electrodes will be applied over the right and left primary motor areas, respectively.
214283329|NCT05929014|DEVICE|Sham bilateral-tDCS|Sham bilateral-tDCS
214283330|NCT06963736|BEHAVIORAL|Blue light|Blue light blocking glasses use and discouraged late night eating.
214283331|NCT06963736|BEHAVIORAL|Eating|Encouraged not to eat past 8pm.
214844476|NCT00640458|DRUG|Placebo|
214844477|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Knowledge Intervention|Counseling scripts assessing and addressing vaccination-related knowledge gaps
214844478|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Reminders|Reminders of upcoming vaccination due dates, sent to the mother's mobile phone
214844479|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Incentives|Conditional incentives for timely vaccination, tailored to each child's vaccination schedule
214283332|NCT06963736|BEHAVIORAL|Standing|Encouraged to stand for 10 minutes per hour each out from 5pm to bed time.
214283333|NCT04210687|PROCEDURE|trapeziometacarpal limited excision|Narrow pseudarthrosis CMC1
214283334|NCT04210687|PROCEDURE|Trapeziectomy|Simple trapeziectomy
215032989|NCT06560307|DEVICE|Enterra Therapy System|The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
215032990|NCT04231019|OTHER|self-administered questionnaire|"Self-administered questionnaires with plain language statements and brief description of the clinical features and photographs of MIH were used to determine the knowledge, awareness and perception regarding the prevalence, severity, etiology and treatment modalities of molar-incisor hypomineralization (MIH) among Egyptian fifth year dental students, general dental practitioners and dental specialists.~There were two routes for delivering the questionnaire either as online questionnaire sent to the participants by email or as a hard copy that is hand delivered."
215032991|NCT02370147|BEHAVIORAL|Smoking reduction intervention|Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
215032992|NCT02370147|BEHAVIORAL|Exercise and diet advice control|Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
215032993|NCT06316570|DRUG|Early Dual Antiplatelet Therapy|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose;~Days 2-7: Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
215032994|NCT06316570|DRUG|Placebo|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose;~Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
215032995|NCT03734536|DEVICE|REGENETEN™ Bioinductive Implant|The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.
215032996|NCT03734536|DEVICE|Arthroscopic repair of the high-grade (>50%) partial-thickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
215032997|NCT05064618|DRUG|Am80|medicine taken internally
215032998|NCT05064618|DRUG|Gemcitabine|Administered intravenously at a dose of 1000mg/m2
215032999|NCT05064618|DRUG|nab-Paclitaxel|Administered intravenously at a dose of 125mg/m2
215033000|NCT02248493|DRUG|Paracetamol|
214283335|NCT03636061|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
214283336|NCT03636061|DRUG|Placebo (vehicle) nasal spray|Placebo
214470782|NCT04314778|BEHAVIORAL|social incentive-based gamification|At the beginning of each week, starting from postoperative day 3, the participant receives 70 points (10 points for each day that week). If the participant does not meet their daily step goal, they lose 10 points from their balance. This leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. At the end of each week if the participant has at least 40 points, they will move up a level (levels from lowest to highest: blue, bronze, silver, gold, platinum). If not, the participant will drop a level. All participants begin at the silver level. Each week, participants get a fresh set of 70 points. Participants will receive daily feedback for the step counts, and weekly feedback for their levels. Participants in the intervention arm will be asked to identify a family member or friend to be their support sponsor. A weekly report will be sent to this person with the participant's performance (points and level).
214470783|NCT06104605|OTHER|Institutional interventions|Intervention will include, but not be limited to, the following: adding a referral option to chiropractic care in the electronic health record (EHR), optimizing referral option, e.g., creating a list of preferred providers. Additional strategies may be added depending on community health center staff engagement prior to implementation.
214470784|NCT06104605|OTHER|PCPs interventions|"Two one-hour interactive grand rounds/lunch seminars that allow for inter-professional learning for PCPs with optional continuing education credits for PCPs.~Short teaching cases involving clinical vignettes developed with local doctors of chiropractic (DCs), information about DCs (e.g., evidence-base for treatments), and logistics of the referral process (e.g., geographic location of community-based DCs who accept Medicaid) sent to participating providers unable to attend the seminars. Additional strategies may be added depending on primary care provider engagement prior to implementation."
214844480|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Service notifications|Service notifications (e.g., related to stockouts or service non-availability), sent to the mother's mobile phone
214844481|NCT01899196|BIOLOGICAL|blood sampling,|
215033001|NCT02248493|DRUG|Placebo (for paracetamol)|
215033002|NCT02248493|DRUG|Ketoprofen|
215033003|NCT02248493|DRUG|Tramadol|Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
215033004|NCT02248493|DRUG|Morphine|administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
214283337|NCT06149247|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
214283338|NCT06149247|DRUG|Mechlorethamine Topical Gel|Valchlor is an FDA-approved drug for the treatment of CTCL.
214283339|NCT05853419|DEVICE|Robotic-assisted PCI|Robotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer
214283340|NCT06851767|GENETIC|Plerixafor|Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
214283341|NCT06851767|DRUG|Filgrastim|Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
214470785|NCT06104605|OTHER|Patient interventions|Printed and electronic educational materials (e.g., brochures) written at a sixth grade reading level in English and Spanish that present chiropractic as a safe and effective evidence-based treatment for LBP. These materials will be written, reviewed, and revised by the researchers with CHC patient input. Additional strategies may be added depending on patient engagement prior to implementation.
214283342|NCT06851767|DRUG|Palifermin|Mucositis prophylaxis: As is standard practice prior to busulfan conditioning, IV infusion of keratinocyte growth factor (palifermin) will be administered at 60 micrograms/kg/day for 3 days before initiation of busulfan (days -6 to -4), as well as for the 3 days following study agent administration (days 1 to 3).
214470786|NCT05161117|BEHAVIORAL|Virtual reality simulation app for caregiver education|"Using a virtual reality headset/goggles, caregivers will engage with an interactive app experience to identify and mediate fall risk hazards in the inpatient care environment. The app will present a hospital bedroom and bathroom laden with fall risks. As the caregiver progresses through the experience, the caregiver will ambulate (virtually) through the environment with the goal of identifying fall risks inherent within that inpatient setting. Fall risks will be targeted and identified using the app sighting function and after focusing on the fall risk for the allotted marking time, will self-resolve."
214283343|NCT06851767|DRUG|Busulfan|Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). For this study, busulfan is administered once daily (3 mg/kg) x 2 days, targeting a daily busulfan AUC of 4500-6500 micromol\*min/L or a cumulative AUC of 9000 micromol\*min/L (for the 2 days of therapy if levels are available. Busulfan will be infused over 3 hours each day as per standard clinical practice.
214283344|NCT06851767|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. A one-time dose \>5(SqrRoot) 10\^6 base-edited cells/kg body weight will be administered to each participant. The exact dosage depends on the number of viable cells that are repaired, cryopreserved, and thawed. The study agent will be administered by IV infusion in a volume of approximately 50 mL over about 15-30 minutes, in accordance with NIH CC DTM infusion policy.
215033005|NCT06428188|BIOLOGICAL|BCMA/CD19 CAR-T cells|"The intervention in this clinical trial involves a novel approach using BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/CD19 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, BCMA/CD19 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial BCMA/CD19 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
215033006|NCT04727151|BIOLOGICAL|TAC01-HER2|"TAC01-HER2 and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide"
215033007|NCT04727151|BIOLOGICAL|TAC01-HER2 plus pembrolizumab|"TAC01-HER2 plus pembrolizumab and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide"
215033008|NCT05025605|DRUG|BXCL501 80 Micrograms|Sublingual film containing 80 Micrograms BXCL501
215033009|NCT05025605|DRUG|Placebo Film|Matching Sublingual Placebo film
214283345|NCT06182059|PROCEDURE|continuous peripheral nerve block|continuous regional anesthesia in total knee replacement
214283346|NCT05182125|BIOLOGICAL|AdC6-HIVgp140|"The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB)."
214283347|NCT05182125|BIOLOGICAL|AdC7-HIVgp140|"The products is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.6 mL for AdC7-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC7-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the IB."
214283348|NCT05182125|BIOLOGICAL|CH505TF gp120|"CH505TF gp120 is formulated in 20 mM sodium phosphate, 150 mM NaCl, 0.02% polysorbate 80 (PS80), pH 6.5, supplied as a frozen liquid in 2 mL glass vials. Each 2 mL vial contains 0.75 mL of formulated gp120 at a concentration of 0.8 mg/mL and is stored at ≤ -65°C.~The study product is described in further detail in the IB."
214283349|NCT05182125|BIOLOGICAL|GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])|The GLA-SE adjuvant will be provided as vials containing 20 mcg/mL GLA in a 4% oil-in-water emulsion. Each sterile, single use vial contains 0.4 mL of product. Product appears as a milky-white liquid. GLA-SE must be stored at 2° to 8°C and must not be frozen. The study product is described in further detail within the IB.
214283350|NCT05182125|BIOLOGICAL|Placebo|Placebo will be Sodium Chloride for Injection, 0.9%, will be used as the placebo. It must be stored as recommended by the manufacturer.
215033010|NCT05025605|DRUG|BXCL501 120 Micrograms|Sublingual film containing 120 Micrograms BXCL501
215033011|NCT05025605|DRUG|BXCL501 60 Micrograms|Sublingual film containing 60 Micrograms BXCL501 Europe Only
215033012|NCT05478876|RADIATION|carbon ion radiation therapy CIRT|"CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.~The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.~Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol."
215033013|NCT03886857|DEVICE|transcutaneous spinal cord stimulation|noninvasive electrical stimulation of the human lumbar spinal cord
215033014|NCT05803772|DRUG|APHD-012|Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
215033015|NCT05803772|DRUG|APH-012P|Distal jejunal-release placebo beads
214283351|NCT06174610|DIAGNOSTIC_TEST|Measurement of Renal Resistive Index|"The kidneys are preliminarily visualized in a 2D projection, followed by identifying interlobar or arcuate vessels using color Doppler. Flow measurements in these vessels are performed using pulsed-wave Doppler. Renal Resistive Index is determined over three cardiac cycles (five in the case of atrial fibrillation) in two different arteries, each in a different kidney section. Subsequently, measurements from each artery are averaged. If possible, the examination should be conducted bilaterally.~The investigators do not have access to previous measurements (each study is recorded on a separate card)."
214283352|NCT01086085|DRUG|Adefovir|Adefovir 10 mg po once daily for 36 weeks
214283353|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
214283354|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
214283355|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
214283356|NCT00519402|OTHER|tonsillar examination and questionnaire completion|
214283357|NCT01218243|DEVICE|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
214470787|NCT05161117|BEHAVIORAL|online fall prevention education module|Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.
214470788|NCT05263583|DRUG|Sepantronium Bromide|continuous intravenous infusion
214470789|NCT00540657|DRUG|CCX282-B|250mg capsule, twice daily, 13 weeks
214283358|NCT05978804|OTHER|Computerized Cognitive Training|Computerized Cognitive training (BrainHQ or Constant Therapy)
214283359|NCT05978804|DEVICE|Active tDCS (tDCS) on DLPFC|Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
214470790|NCT00540657|DRUG|Placebo|Placebo capsule, twice daily, 13 weeks
214470791|NCT05977621|OTHER|Transrectal ultrasound (TRUS)|Transrectal ultrasound (TRUS) images of the female pelvis
214283360|NCT04234178|DRUG|Epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
214283361|NCT04234178|DRUG|Intrathecal+Epidural|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
215033016|NCT03797807|PROCEDURE|MINST|A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
215033017|NCT03797807|PROCEDURE|MIST|A minimally invasive surgical treatment protocol, named MIST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
215033018|NCT03797807|DIAGNOSTIC_TEST|GTI subgroup (Geometrical/Thermal Imaging)|Geometrical/Thermal Imaging
215033019|NCT04862403|PROCEDURE|Umbilical cord clamping distance|Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).
215033020|NCT04796805|OTHER|Topical essential oil application|We applied black pepper essential oil to the participants in experimental group before the catheter insertion procedure
215033021|NCT04089696|DEVICE|ExSprion|The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
214470792|NCT05099874|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
214470793|NCT04428541|OTHER|Questionnaire for visual function assessment of preverbal children|18 items questionnaire
214283362|NCT01003288|BIOLOGICAL|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)~\* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
214470794|NCT06016764|DEVICE|Continuous Theta Burst in Transcranial Magnetic Stimulation|This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia, intellectual disability, and social-emotional impairment in autism
215033022|NCT00723632|BIOLOGICAL|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
215033023|NCT00723632|DRUG|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants \<65 kg, 1000 mg/day for participants \>65 to \<85 kg, and 1200 mg/day for participants \>=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
215033024|NCT03924284|DIAGNOSTIC_TEST|PB2 gene RT-PCR; NS gene RT-PCR|PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus
215033025|NCT02756585|RADIATION|ct perfusion|computed tomography perfusion of the head
215033026|NCT01678365|DRUG|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
215033027|NCT00311831|BEHAVIORAL|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
215033028|NCT00311831|BEHAVIORAL|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
215033029|NCT03092193|DRUG|Naproxen|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
214283363|NCT06321783|OTHER|Assessment|Evaluation of cervical proprioception, hand-eye coordination, postural control and endurance of cervical muscles
214283364|NCT01926236|OTHER|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
214470795|NCT05841004|DEVICE|Investigational device|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
214470796|NCT05841004|DEVICE|Comparator device|Hollister Infyna Chic, single-use compact catheter.
215033030|NCT03092193|DRUG|Naproxen-esomeprazole|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
215033031|NCT03078231|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
215033032|NCT03078231|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
215033033|NCT01346592|BIOLOGICAL|Trivalent split influenza vaccine (TIV)|
215033034|NCT01346592|BIOLOGICAL|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
215033035|NCT01346592|BIOLOGICAL|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
215033036|NCT04964752|DEVICE|continuous glucose-monitoring|Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.
215033037|NCT05686980|DRUG|ABBV-552|Oral Capsule
215033038|NCT02679274|DRUG|Placebo|Intermittent intramuscular injections of saline (males and females).
215033039|NCT02679274|DRUG|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
215033040|NCT03694730|OTHER|Exercise Treatment|Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
215033041|NCT03694730|OTHER|Pain- Guided Activity Modification|Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
215033042|NCT06810440|BEHAVIORAL|Sumadhur|Sumadhur is a 4-month intervention with weekly sessions that last about 1.5 hours. Newly married women, their husbands and mothers-in-law gather with other household triads (5 households per group for a total of 15 people per group).
215033043|NCT06810440|DIETARY_SUPPLEMENT|Multiple micronutrient supplement MMS|Multiple micronutrient supplement MMS provided in 180 pill bottles
215033044|NCT06570356|DIAGNOSTIC_TEST|Geriatric Depression Scale - 15|a validated screening tool designed to identify depression in older adults. It consists of 15 simple yes/no questions that assess depressive symptoms.
215033045|NCT06570980|DRUG|sulfonylurease with metformin, DPP4 inhibitors with Metformin|Oral hypoglycemic agents
215033046|NCT03596554|OTHER|Descriptive study|Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).
215033047|NCT03207347|DRUG|Niraparib|Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
215033048|NCT02208765|DEVICE|Stress Single Photon Emission Computed Tomography|
215033049|NCT04154163|DIAGNOSTIC_TEST|Dried blood Spot (DBS)|Dried Blood Spot filter paper and sponges
215033050|NCT04154163|DIAGNOSTIC_TEST|Venous blood sampling|Venous blood
215033051|NCT00974272|DRUG|Exenatide|Single subcutaneous injection (10 μg)
215033052|NCT00974272|OTHER|Normal Saline|Single subcutaneous injection
215033053|NCT03272321|DRUG|Oxytocin|Syntocinon nasal spray
215033054|NCT03272321|DRUG|Placebo|Placebo nasal spray
215033055|NCT05905198|DEVICE|Programming|programming the implanted DBS device to adjust the parameter and switch stimulation mode between Variable-Frequency settings and High-Frequency settings.
215033056|NCT03290677|PROCEDURE|Cryoablation|This involves passing a special needle into the body (cryoprobe) to freeze tumor and kill a small part (not all) of the cancer. The immune system will respond to the damage caused by freezing part of the tumor.
214283365|NCT01926236|DRUG|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
214283366|NCT01926236|DRUG|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
214283367|NCT01926236|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
214283368|NCT02941198|DEVICE|GyneFix|The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
214283369|NCT02941198|DEVICE|Cu T380 A|Cu T380 A will be inserted into the uterus
214283370|NCT05262127|BEHAVIORAL|Flash Version of EMDR|EMDR and the inclusion of a positive engaging focus generated autonomously by participant
214470797|NCT04024020|OTHER|lumbar puncture|Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
214470798|NCT06196424|OTHER|study questionnaire to investigate family history|Participants will be given a specific study questionnaire (paper-based) to fill at home, which was specifically designed to collect family history information
214283371|NCT02147236|BEHAVIORAL|Social Skills Training|
214283372|NCT00450281|GENETIC|chromogenic in situ hybridization|
214283373|NCT00450281|GENETIC|gene expression analysis|
214283374|NCT00450281|GENETIC|mutation analysis|
214283375|NCT00450281|GENETIC|polymerase chain reaction|
214283376|NCT00450281|GENETIC|polymorphism analysis|
214283377|NCT00450281|OTHER|fluorescent antibody technique|
215033057|NCT03290677|PROCEDURE|Biopsy|Removing a small piece of the affected area to confirm cancer
215033058|NCT05594186|DRUG|Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.|Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.
215033059|NCT05605197|DRUG|U87 CAR-T|Subjects will be pretreated with cyclophosphamide 250\~500 mg/m2( body surface area) for 3 days prior to Intravenous injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2. Researchers can perform intratumoral injection based on their judgment.This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3\~6 patients.
215033060|NCT04431284|OTHER|Questionnaires|The two groups (23 patients per group) will be contacted by phone or e-mail to participate to the CIO study. Once their agreement received, each patient will be asked to complete the same set of online questionnaires : weight, HAD (Hospital Anxiety and Depression scale), BES (Binge Eating Scale), YFAS (Yale Food Addiction Scale), DEBQ (Dutch Eating Behavior Questionnaire), IPAQ (International physical activity questionnaire), COVID 19 questionnaire Penn State, items from the Do-It questionnaire, general questions on the lifestyle during the lockdown (custom questionnaire), COVID stress evaluation (custom questionnaire)
215033061|NCT02330003|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
215033062|NCT02330003|BIOLOGICAL|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
215033063|NCT05119868|OTHER|Nutritional intervention based on Mediterranean Diet|A personalized nutritional counseling and a tailored diet, according to Mediterranean dietary pattern, designed on the pre-pregnancy weight, height and trimester of pregnancy provided by certified dietitians.
215033064|NCT02731560|DRUG|Rituximab|"Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.~This was done either by a specialist nurse or a trained doctor."
215033065|NCT03519880|DEVICE|Custom Mask Interface|Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
215033066|NCT01260779|DRUG|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
215033067|NCT05544409|DEVICE|MAKv1|1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
215033068|NCT02659371|DIETARY_SUPPLEMENT|Low energy diet|
215033069|NCT04463355|BEHAVIORAL|Video discharge instructions|Short video (2 minutes) including information about clinical features, management and follow up of pediatric patients with acute gastroenteritis
215033070|NCT06205069|DEVICE|Tissue flossing|While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.
215033071|NCT03249649|BEHAVIORAL|Comprehensive Healthcare Needs Assessment|Questionnaire focused on existing healthcare communication, treatment and services plus community needs in those three areas.
215033072|NCT06398184|OTHER|Exercise + motor imagery and action observation|A total of 8 sessions of 4 sets of knee extension exercises will be performed. During the breaks between each series, participants will perform a progressive protocol of action observation and motor imagery.
215033073|NCT06398184|OTHER|Exercise|A total of 8 sessions of 4 sets of knee extension exercises will be performed.
214283378|NCT00450281|OTHER|immunohistochemistry staining method|
214283379|NCT00450281|OTHER|laboratory biomarker analysis|
214283380|NCT00450281|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
214283381|NCT00450281|OTHER|study of socioeconomic and demographic variables|
214283382|NCT00450281|PROCEDURE|study of high risk factors|
214283383|NCT03295812|OTHER|standard therapy|standard therapy,non-interventional study
214283384|NCT03727347|DEVICE|InSeca Stylus|Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
214283385|NCT02200562|DRUG|ipilimumab and dabrafenib|
214283386|NCT02186990|DRUG|propofol|2,5 mg/kg
214283387|NCT02186990|DRUG|etomidate|0,3 mg/kg
214283388|NCT02186990|DRUG|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
214283389|NCT03615378|DIETARY_SUPPLEMENT|5000 IU D3|Daily
214283390|NCT03615378|DIETARY_SUPPLEMENT|1000 IU D3|Daily
214283391|NCT03615378|DIETARY_SUPPLEMENT|Placebo|lactose/sugar tablet
214283392|NCT01421004|DRUG|TKI258|
214283393|NCT04063930|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Sodium zirconium cyclosilicate (a hyperkalemia treatment)
214283394|NCT04063930|DRUG|Placebos|Matching placebo
214283395|NCT03200860|DRUG|Empagliflozin 10 MG|10 mg daily, oral, 30 days
214283396|NCT03200860|DRUG|Placebo Oral Tablet|Matching Placebo, 10 mg daily, oral, 30 days
214283397|NCT02418364|OTHER|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
214283398|NCT02418364|OTHER|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
214283399|NCT04199910|OTHER|There is no intervention, only research blood samples are collected|Research blood samples collected
214283400|NCT00217594|DRUG|Alemtuzumab (Campath)|
214470799|NCT06429163|PROCEDURE|Infiltration of the anterior abdominal wall|Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.
214283401|NCT00000208|DRUG|Buprenorphine|
214283402|NCT00980382|DRUG|S-1, Docetaxel|"* Phase I study~  * S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~* Phase II study~  * S-1 (80mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (35 mg/m2) iv : Days 1, 8"
214283403|NCT02764060|DEVICE|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
214283404|NCT02764060|DEVICE|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
214283405|NCT01744197|DRUG|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
214283406|NCT02872194|DRUG|BAY987516, Y55-170|10 uL in one eye
214283407|NCT02872194|DRUG|BAY987516, X72-151|10 uL in one eye
214283408|NCT02872194|DRUG|BAY987516, Y49-034|10 uL in one eye
214283409|NCT02872194|DRUG|Standard shampoo mixture (control)|10 uL in one eye
214283410|NCT05686811|OTHER|Myofascial release therapy therapy|Group A was treated with myofascial release therapy and routine physical therapy. For routine physical therapy subjects will first applied TENS, hot pack and neck isometric exercises then myofascial release therapy will be given. For myofascial release therapy subjects was in the supine or possibly sitting position, the examiner was seated at the head of the table, the examiner was used his right thumb to palpate (using flat palpation) the upper trapezius muscles from medial to lateral to establish if any MTrPs are present. The entire mass of the upper trapezius muscle is lifted by the supraspinatus muscle and grasped with a pincer grasp. The muscles at this point rotate between the thumb and forefinger to detect the delicate location of the trigger point. Treatment session longs for 10 minutes of myofascial release on each side
214283411|NCT05686811|OTHER|Post isometric relaxation technique|This group will receive routine physical therapy with myofascial release therapy.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
214283412|NCT05482724|BEHAVIORAL|Super Skills for Life|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández.~The intervention was administered by a trained clinical psychologist in SSL. Sessions were held after school hours once a week for eight weeks, with each session lasting approximately one hour. The contents of the program were covered through playful activities in groups of 4 to 6 children"
214283413|NCT01031927|DRUG|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
214283414|NCT04342897|DRUG|LY3127804|Administered IV
214283415|NCT04342897|DRUG|Placebo|Administered IV
214283416|NCT02551965|OTHER|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
214283417|NCT01831050|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
214283418|NCT01831050|BIOLOGICAL|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
214283419|NCT01831050|BIOLOGICAL|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
214283420|NCT01831050|BIOLOGICAL|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
214283421|NCT01831050|BIOLOGICAL|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
214283422|NCT01831050|BIOLOGICAL|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India \[SII\]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
214283423|NCT04166175|PROCEDURE|botox injection in intersphincteric space|injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position
214283424|NCT04166175|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy under GA in lithotomy position
214283425|NCT06266000|DRUG|Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
214283426|NCT06266000|DRUG|Commercial Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
214283427|NCT06266000|DRUG|Palm Oil capsule|Palm oil capsule
214283428|NCT02223897|DRUG|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
214283429|NCT02223897|DRUG|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
214283430|NCT03568734|OTHER|Fecal transplant|At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
214283431|NCT04374773|DRUG|Dronabinol|2.5 mg PO administered once prior to and once after 1 week of hormone therapy
214283432|NCT00886574|DRUG|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
214283433|NCT00886574|DRUG|Aspirin|100 mg once a day
214283434|NCT01849198|DEVICE|accelerometry m. trapezius and m. adductor pollicis|
214283435|NCT02970422|OTHER|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
214283436|NCT00282594|DRUG|Novolin R (human recombinant Insulin)|
214283437|NCT03779724|OTHER|exercises|
214283438|NCT00803725|DRUG|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
214283439|NCT00803725|DRUG|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
214283440|NCT02959307|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
214283441|NCT02959307|DEVICE|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
214283442|NCT01311479|PROCEDURE|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
214283443|NCT00231205|PROCEDURE|Revascularization|
214283444|NCT03159624|OTHER|Biodesign™ SIS graft|2x3 cm Biodesign™ SIS perforated mesentery graft
214283445|NCT03159624|OTHER|Doyle silastic sheet|Doyle silastic sheet
214283446|NCT04532944|DIAGNOSTIC_TEST|imaging of energy dysfunction|7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
214283447|NCT02344277|DEVICE|S-ICD System (implantable defibrillator)|"The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.~Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system."
214470800|NCT06429163|PROCEDURE|Upper hypogastric plexus blockade|At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.
215033074|NCT02085720|DEVICE|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
215033075|NCT05382130|DIAGNOSTIC_TEST|Test all|"In the test all arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results."
215033076|NCT03275337|DEVICE|Transcranial Direct Current Stimulation|tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
215033077|NCT06565299|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery about congenital heart defects with cardiopulmonary bypass
215033078|NCT01295047|DRUG|Atenolol|
215033079|NCT01295047|DRUG|VERAPAMIL|240 MG SR
215033080|NCT01295047|DRUG|Perindopril|4 MG
215033081|NCT00689884|DRUG|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
214283448|NCT01325584|DRUG|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
214283449|NCT00887978|DRUG|UT-15C SR|treprostinil diolamine sustained release tablets
214283450|NCT00887978|DRUG|Placebo|
214283451|NCT05416593|BEHAVIORAL|General exercise prescription (FITT)|The (1) control group (FITT) will receive a preexercise evaluation and 3 individualized training sessions based on the ACSM and FITT principles (ACSM, 2021). These are the procedures commonly used for apparently healthy individuals that start to exercise in health clubs.
214283452|NCT05416593|BEHAVIORAL|Affective regulation (AFFECT)|As for the (2) experimental group (AFFECT), the focus will be given to exercise intensity assessment and manipulation. The same preexercise evaluation, number of individualized sessions, and methodological approach (i.e., FITT) will be made. However, individual preferences and experiences regarding exercise intensity will be assessed in the preexercise evaluation. These will be used to select the exercise sessions' initial intensity. Moreover, intensity self-selection guidance and affective response assessments will be made throughout the session for continuous intensity adjustments (aiming for pleasurable feelings).
214283453|NCT06823713|DRUG|RTX001|RTX001 is an autologous engineered regenerative macrophage cell therapy
214283454|NCT01104350|OTHER|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~* Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~* Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~* Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
214283455|NCT06064604|OTHER|Control|The stroke survivors will serve as their own control group. The participants will complete the required tasks without an exoskeleton device.
214283456|NCT06064604|DEVICE|Hip Exoskeleton|The Georgia Tech Hip Exo is a wearable robotic device for hip extension/flexion assistance. This device will be used to study the lower limb movement and how to effectively assist users. It makes use of a responsive controller that considers information such as joint angles to understand the user's state and assists with the appropriate level of power accordingly.
214283457|NCT06064604|DEVICE|Ankle Exoskeleton|The Dephy Exoboot is a lower limb exoskeleton which attaches to the user below the knee through a cuff at the proximal calf and a provided shoe. This investigational device is used to make it easier for able-bodied and impaired individuals to walk and run under a variety of conditions. The exoskeleton provides assistance at the ankle joint during movement. The purpose is to assist the user in lower limb movements such as ground level walking, climbing stairs/ramps, and sit-to-stand.
214283458|NCT04170153|DRUG|M1774|M1774 will be administered orally throughout the study.
214283459|NCT04170153|DRUG|Niraparib|Niraparib will be administered orally throughout the study.
214283460|NCT02947503|DRUG|Metformin TEVA 850 mg|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
214283461|NCT06444464|OTHER|Aerobic exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of aerobic exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
214283462|NCT06444464|OTHER|Isometric exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of isometric exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
214283463|NCT06293053|DRUG|Dupilumab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous"
214470801|NCT05646355|BEHAVIORAL|Proactive CRC Screening Outreach|Proactive approach that incorporates a mailed outreach invitation to screen with fecal immunochemical testing (FIT), followed by active assistance to colonoscopy completion if preferred or indicated by FIT test result.
215033082|NCT05591365|OTHER|Structured In-Patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
215033083|NCT05591365|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
214470802|NCT05646355|BEHAVIORAL|Usual Care|Participants will not receive additional outreach from the study team regarding CRC screening.
214470803|NCT04304651|DIAGNOSTIC_TEST|Limited cancer screening|"The limited cancer screening will include: 1) a complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin); and 4) chest X-ray.~In women, a breast examination, Pap smear/pelvic examination (if \< 70 years old and previously sexually active) and mammogram will be performed, if not conducted in last year.~In men, similarly, prostate examination and PSA testing will be performed, if not conducted in the last year.~All patients will undergo colon cancer screening as per local practice."
214470804|NCT04304651|DIAGNOSTIC_TEST|Limited cancer screening + FDG PET/CT|The limited cancer screening (as described above) in combination with a FDG PET/CT.
214470805|NCT06392230|DRUG|Oral [14C] PF-06821497|A single oral dose of \[14C\] PF-06821497 will be administered as an extemporaneous suspension in Period 1
214470806|NCT06392230|DRUG|Oral PF-06821497|A single oral dose of PF-06821497 will be administered as an extemporaneous oral suspension in Period 2
214470807|NCT06392230|DRUG|IV [14C] PF-06821497|A single IV infusion of \[14C\] PF-06821497 will be administered at the Tmax after administration of the unlabeled oral dose of PF-06821497 in Period 2
214470808|NCT05928013|DIAGNOSTIC_TEST|Neurothesiometer|The 'gold standard' device for Vibration Perception Threshold testing
214470809|NCT05928013|DIAGNOSTIC_TEST|NERVE|The experimental device for Vibration Perception Threshold testing developed by the project team
214470810|NCT03676894|DEVICE|Sham Fotona SP Dynamis|Female patients with SUI will be treated with non-ablative Er:YAG laser with Fotona SP Dynamis with sham handpiece.
214470811|NCT03676894|DEVICE|Intravaginal Fotona SP Dynamis|Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis
214470812|NCT03676894|DEVICE|Intraurethral Fotona SP Dynamis|Female patients with SUI will be treated intraurethraly with non-ablative Er:YAG laser with Fotona SP Dynamis
214470813|NCT04738591|DEVICE|DIABE-TEXT|Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
214470814|NCT03768960|DRUG|Daratumumab|Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
214470815|NCT03541889|DRUG|FLT imaging and TK1 blood measurements|F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
215033084|NCT02038036|DRUG|Best Available Therapy|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
215033085|NCT02038036|DRUG|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
214470816|NCT05482932|DIAGNOSTIC_TEST|Health-related physical fitness assessment|Participants will complete several questionnaires and perform multiple health-related physical fitness tests
214470817|NCT06683391|BEHAVIORAL|Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment|The intervention in the REMODAL trial involves administering specific amounts of oral carbohydrates (CHO) at different glucose thresholds to evaluate the effectiveness of proactive versus reactive hypoglycemia management strategies in adults with Type 1 diabetes using continuous glucose monitoring (CGM). Participants will undergo three distinct interventions, each designed to test a different amount and timing of CHO intake.
214470818|NCT05362435|BEHAVIORAL|Physical activity-based wellness programs|Each MKS+ program has 20-25 participants and consists of the following: 12 Week INTENSE PHASE: 1) pre-program information and orientation session, and data collection/testing; 2) core weekly programming with the following three components: a) 45-60 minute exercise class, b) 15-20 minute nutrition and wellness education, and c) 15-30 minute sharing circle; 3) end of program celebration; 4) urban poling sessions; 5) introduction to local healthcare providers as identified as relevant for the group; 6) ongoing online support via private Facebook group; 7) daily pedometer tracking to provide immediate motivational feedback to participants. 6-12 Week FOLLOW-UP PHASE: 1) Program Facilitator contacts participants weekly to encourage healthy activities, address concerns as needed, and record weekly step counts; 2) encourages continued engagement in private Facebook group; 3) 15-30 minute nutrition and wellness education, and c) 15-45 minute sharing circle.
214470819|NCT05422274|DEVICE|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .
214470820|NCT06089837|DRUG|EC5026 oral tablet|"2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)"
215033086|NCT04029779|BIOLOGICAL|I-PRF|Local anaesthesia was administered and mucoperiosteal flap was reflected. Atraumatic tooth extraction was performed. Socket was curetted to remove the granulation tissue present in the socket with the help of curettes. The socket was well irrigated with saline. Implant osteotomies wasl performed with sequential drilling with standardized drills.I-PRF was freshly prepared 600rpm for 7 min(50g). 1ml of the i-PRF was applied in to the osteotomy site and the implant surface will be thoroughly coated followed by placing of the implant. The surgical site was thoroughly irrigated and debrided. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
215033087|NCT03265184|DIETARY_SUPPLEMENT|green coffee extract|Patients in treatment group take 400 mg GCE supplements twice a day for tow month
215033088|NCT02476448|DRUG|Normal saline|Used to distend the bladder for cystoscopic evaluation
215033089|NCT02476448|DRUG|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
215033090|NCT02476448|DRUG|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
215033091|NCT02476448|DRUG|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
214283464|NCT03730181|DRUG|Rifapentine|Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.
215033092|NCT04262479|DRUG|recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel|3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
215033093|NCT04262479|DRUG|Vitamin D|1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
215033094|NCT06641739|DEVICE|laser assisted SPPF|A full-thickness flaps were elevated. In the test sites after the SPPF access will be performed, root surface debridement will be meticulously performed, followed by intra-marrow penetrations (IMPs), on the defect walls using a 0.25 mm wide half round bur, mounted on a slow-speed handpiece. Following this, low-level laser biostimulation of the defect will be effected with an 940 nm diode laser at 3 W power, with an uninitiated 0.6mm optical fiber tip. The defects will be irradiated for 20 seconds in a continuous noncontact mode and then retracted for 8 seconds. This will be repeated for 3 times so that the defects were effectively lased for about 60 seconds.
215033095|NCT06641739|PROCEDURE|Platelet Rich Plasma|In the second group, following the SPPF, the defect will grafted with particulated PRF, which will be overlaid with a PRF membrane, without any adjunctive defect management measures. PRF will be prepared by collecting Intra-venous blood (from the antecubital vein) in a 10-ml sterile glass tube without anticoagulant and immediately centrifuged in a centrifugation machine at 3000 rpm for 10 minutes. It will result in the separation of blood into a structured fibrin matrix in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma (platelet poor plasma) at the top. PPP will be discarded. PRF will be easily separated from the red corpuscles base using sterile tweezers and scissors.
215033096|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of short term study (7 days) of stevia leave powder 1000 mg/day in diabetic subjects
215033097|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of long term study (60 days) of stevia leave powder 1000 mg/day in diabetic subjects
215033098|NCT06637241|BEHAVIORAL|Risk stratification care|In this group, Taiwanese adolescent baseball players are categorized into high-risk, medium-risk, and low-risk groups based on injury risk from a previous study. High-risk players receive sports protection education and physician referrals for shoulder and elbow assessments, with further imaging if necessary. Common issues like Little League shoulder and elbow are managed with conservative treatments. The sports protection education includes the Modified Yokohama Baseball-9 (mYKB-9), a program that significantly reduces injuries with exercises targeting shoulder and elbow health. Medium-risk players receive mYKB-9 education only, while low-risk players are observed without changes to their training methods.
215033099|NCT04174586|BIOLOGICAL|microtransplantation|HLA mismatched donor cord blood infusion
215033100|NCT04952714|DEVICE|Oxiris|Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.
215033101|NCT00937105|DEVICE|lotrafilcon A contact lenses|FDA approved soft contact lenses
215033102|NCT00937105|DEVICE|Renu Multiplus|
215033103|NCT00937105|DEVICE|Clear Care|
215033104|NCT00000354|DRUG|Lofexidine|
215033105|NCT00002256|DRUG|Zalcitabine|
215033106|NCT02682251|OTHER|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
215033107|NCT04280588|DRUG|Fingolimod 0.5 mg|Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
214283465|NCT03730181|DRUG|Isoniazid|Isoniazid. 25mg/kg
215033108|NCT03537508|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
214283466|NCT05403450|DRUG|Tolinapant|Capsule for oral administration
214283467|NCT05403450|DRUG|Decitabine + Cedazuridine|Tablet for oral administration
214283468|NCT04566380|DRUG|ONO-4538|IV infusion over 30 minutes
214283469|NCT04566380|DRUG|oxaliplatin|IV infusion over 2 hours
214283470|NCT04566380|DRUG|S-1|Administered orally twice daily
214283471|NCT04566380|DRUG|capecitabine|Administered orally twice daily
214283472|NCT04566380|DRUG|bevacizumab|IV infusion over 30 minutes
214283473|NCT04566380|DRUG|temozolomide|Administered orally once daily for 5 days every 28 days
214283474|NCT03291730|BEHAVIORAL|Breathing and journaling exercise|May help reduce anxiety of receiving chemotherapy
214283475|NCT03291730|OTHER|Art-therapy|May help reduce anxiety of receiving chemotherapy
214283476|NCT03996252|DRUG|Calcipotriene 0.005% Foam|Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
214283477|NCT03996252|DRUG|Efudex 5% Topical Cream|Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
215033109|NCT03537508|BIOLOGICAL|MenACYW-135 conjugate vaccine|Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
215033110|NCT03537508|BIOLOGICAL|DTaP-IPV//Hib vaccine|DTaP-IPV//Hib vaccine at 2, 4, 6 and 12 to 15 (Group 1a)/15-18 (Group 1b and Group 2) months of age Intramuscular
214470821|NCT06089837|DRUG|Placebo oral tablet|2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
214470822|NCT05058924|DRUG|Prophylactic low molecular weight heparin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.
215033111|NCT03537508|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
215033112|NCT03537508|BIOLOGICAL|Pentavalent rotavirus vaccine|Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
215033113|NCT03537508|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
215033114|NCT03537508|BIOLOGICAL|Measles, mumps, rubella (MMR) vaccine|MMR vaccine at 12 months of age, Subcutaneous
215033115|NCT03537508|BIOLOGICAL|Varicella vaccine|Varicella vaccine at 12 months of age
215033116|NCT03537508|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine at 15 to 18 months of age
215033117|NCT01972659|DRUG|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
215033118|NCT01972659|DRUG|Magnesium Sulphate|"Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion"
215033119|NCT01972659|DRUG|sugammadex|4 mg/kg iv bolus at the end of the surgery
215033120|NCT02399228|DRUG|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
215033121|NCT04983979|DRUG|Sodium Zirconium Cyclosilicate|sachets of 5g or 10g given OD titrated to serum potassium
215033122|NCT04983979|DRUG|Placebo|matched placebo given titrated according to potassium at a dose to 5 or 10g
215033123|NCT04144517|DRUG|Nemvaleukin Alfa|Nemvaleukin alfa IV infusion.
214283478|NCT05044546|BEHAVIORAL|Behavioral Activation Therapy|Participate in BA counseling
215033124|NCT04144517|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
215033125|NCT06811285|OTHER|Kinesiological Taping|The Kinesiological Taping group will receive two parallel I-shaped kinesiological taping applications.
215033126|NCT06811285|OTHER|Foot Massage Group|The Foot Massage Group will receive foot massage for 20 minutes.
215033127|NCT03292978|DIETARY_SUPPLEMENT|probiotics intervention|The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
215033128|NCT03292978|DIETARY_SUPPLEMENT|non-probiotic control|The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
215033129|NCT01003964|DRUG|IP|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
214283479|NCT05044546|PROCEDURE|Discussion|Participate in focus group
214283480|NCT05044546|BEHAVIORAL|Health Education|Participate in health and wellness education counseling
214283481|NCT05044546|OTHER|Questionnaire Administration|Ancillary studies
214283482|NCT05044546|OTHER|Tobacco Cessation Counseling|Participate in smoking cessation counseling
214283483|NCT05615610|DEVICE|tSCS|The participants in Group A will receive tSCS (Burst mode, 9 pulses per burst, pulse frequency = 160 Hz, burst frequency = 2 Hz) with upper limb exercises. The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Two 7.5 × 12.6 cm electrodes will be attached between C6 and T5 level on each side of spinal column and with 2 cm from the spine. Intensity of TENS will be individually selected by the participants according to tolerance levels.
214283484|NCT05615610|DEVICE|tVNS|The participants in Group B will receive tVNS (pulse frequency = 25Hz, pulse duration = 0.3 ms) on the cymba conchae of left outer ear with upper limb exercises.The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Intensity of tVNS will be individually selected by the participants according to tolerance levels. Previous studies showed that it was effective to improve the upper limb motor function in people with stroke and cognitive function in people with mild cognitive function.
214283485|NCT05615610|DEVICE|Control|The participants in Group C will receive placebo tSCS and tVNS with upper limb exercises, where the stimulation will be delivered by placebo-TENS device with disconnected electrical circuit.
215033130|NCT01003964|DRUG|GP|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
215033131|NCT05307094|BEHAVIORAL|Improving Parents as Communication Teachers|A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.
215033132|NCT03067636|BEHAVIORAL|Physical Exercise|Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
214470823|NCT05058924|DRUG|Low molecular weight heparin and low-dose aspirin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.
214470824|NCT03523572|DRUG|Trastuzumab deruxtecan|The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
215033133|NCT03067636|BEHAVIORAL|Stress management training A|Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
215033134|NCT03067636|BEHAVIORAL|Stress management training B|Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
215033135|NCT06267417|DEVICE|Laser therapy|\- Laser will be applied with the specified wave length using Diode laser (Sirrolaser Blue ™, USA) device over 5 consecutive days from start of chemotherapy cycle beside the standard preventive protocol applied in the hospital
215033136|NCT06267417|DEVICE|Mock treatment|The exact repetition of the treatment modality but without any laser emission beside the standard preventive protocol applied in the hospital
215033137|NCT05147142|DEVICE|Low Intensity Focused Ultrasound|Brainsonix BX Pulsar 1002
215033138|NCT03664544|DRUG|MCI-186|30 mg MCI-186 will be administered intravenously over 60 minutes.
215033139|NCT06656572|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
215033140|NCT06656572|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
215033141|NCT06658236|OTHER|Proprioceptive Neuromuscular Facilitation|Group A will follow a PNF-based training protocol to enhance strength, flexibility, and coordination. The exercises include two main movement patterns: flexion-abduction-external rotation with the elbow extended and extension-adduction-internal rotation with the elbow extended. These patterns target the muscles around the shoulder and upper chest. A yellow Thera-Band adds light resistance, increasing muscle engagement. The protocol also employs the reversal of antagonists technique, alternating between opposing muscle groups for balanced development and improved coordination. Participants will complete three sets of ten repetitions per session, with a 60-second rest between sets. The program spans 12 weeks, with three weekly sessions, allowing for consistent progress and muscle recovery. This structured approach aims to improve functional mobility and the performance of activities involving similar movements, offering a comprehensive training strategy through PNF and resistance.
215057543|NCT05129163|BEHAVIORAL|Nutrition activities|The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
214283486|NCT06526273|BEHAVIORAL|PILI 'Āina|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker. At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks).
214470825|NCT03523572|DRUG|Nivolumab|Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
214470826|NCT04845893|OTHER|Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
214470827|NCT06040125|BEHAVIORAL|Supervised Circuit Training|16-week, multicomponent exercise intervention comprised of sessions supervised by certified exercise oncology trainer and home-based, self-directed aerobic exercises. Stationary bike and accelerometer (activity/heart rate monitor) will be provided.
214470828|NCT06418100|PROCEDURE|The recto intercostal fascial plane block|After ensuring aseptic conditions, the high-frequency linear ultrasound probe was used to detect the rectus abdominis muscle and the 6-7th costal cartilage as described by Tulgar et al. After rotating and shifting the transducer, 6-7th costal cartilages, the rectus abdominis muscle, and intercostal muscles between the cartilages were confirmed. The primary investigator (B.C.) directed the needle tip caudad in the cephalic direction in-plainly, and 20 ml 0,25% bupivacaine was injected bilaterally into the plane between the costal cartilage and the rectus abdominis muscle following negative aspiration.
214470829|NCT05269966|BIOLOGICAL|Injection Brolucizumab|"Single-chain antibody fragment (scFv)~Brolucizumab 6 mg was administered by Intravitreal (IVT) injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) were performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing."
214470830|NCT05110508|BEHAVIORAL|Text Based Behavioral Intervention for Physical Activity|Text intervention messaging will be sent through an automated text messaging service programmed by the CM Informatics team, which has been approved by the institution. Participants will be asked to wear Garmin physical activity monitor to provide physical activity information throughout the intervention. The Garmin is worn like a wristwatch. The device is small and non-intrusive. The Garmin device is a consumer wearable that will automatically detect and track activity such as walking, running, and cycling. The text messages incorporate information from the Garmin monitor to support physical activity.
214470831|NCT05575219|DRUG|Clonidine (without protocolized initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
214470832|NCT05575219|DRUG|Clonidine (protocolized initiation)|"* Observe participants without initiating clonidine with dexmedetomidine infusion time of 72-119 hours. To wean off dexmedetomidine, decrease the infusion by 25% of the starting dose every 6 hours.~* Begin clonidine at 1 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of 120-144 hours.~* Begin clonidine at 1.5 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion times of 145-167 hours.~* Begin clonidine at 2 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of \>/= 168 hours or with infusion time of 120-167 hours at doses \>/= 1.1 mcg/kg/min.~* If clonidine is started decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours)."
214283487|NCT06526273|OTHER|Control|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker based on previously tested materials and protocols. At 3 months, participants randomized to the control group will receive monthly untailored health education information and links to community resources from the community health worker via United States Postal Service or electronic messaging. Examples include information on food assistance programs, farmers' markets, cultural events, and physical activity events.
214470833|NCT03967002|PROCEDURE|Test group with corticotomy surgery|"The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~* the second premolars and first premolars,~* the first lower premolars and canines,~* the canines and lateral incisors,~* the lateral incisors and central incisors, and,~* the two lower central incisors."
214283488|NCT07124221|DRUG|Cabergoline tablets|Cabergoline tablets will be administered for 14 weeks.The allowed dose range is from 0.25 mg (1 tablet) QW to 1mg (4 tablets) QW. Dosage adjustments are made based on the serum PRL level.
214283489|NCT07124221|DRUG|Bromocriptine mesylate tablets|Bromocriptine mesylate tablets was administered for 14 weeks.The dose is 1.25 mg (0.5 tablet) QD to 7.5mg 3 tablets) QD. Dosage adjustments are made based on the serum PRL level.
214283490|NCT06979297|BEHAVIORAL|Web-based physical activity and diet intervention|Participants receive access to a theory-driven, web-based intervention for 12 weeks that provides interactive information on diet and physical activity, including goal setting, diet and activity tracking, tailored information on healthy eating and increasing exercise, and videos on topics of healthy eating and physical activity.
214283491|NCT06979297|OTHER|Wait-list control arm|Participants in the wait-list control will complete all the same measures as the intervention group for the first 12 weeks, then will receive access to the Internet-based intervention for another 12 weeks.
214283492|NCT07131670|OTHER|Electronic Patient-Reported Outcome Monitoring|Participants complete the MDASI-LC and EQ-5D questionnaires electronically on a weekly basis during CRT and for 12 weeks after CRT. The data are used to evaluate symptom burden, symptom clusters, and symptom trajectories.
214283493|NCT07131059|DRUG|Ivosidenib|500mg d1-28
214283494|NCT07131059|DRUG|Gilteritinib|120mg d1-28
214283495|NCT07131059|DRUG|Venetoclax|400mg d1-21 ; 400mg d1-7;400mg d1-28; 600mg d1-21
214283496|NCT07131059|DRUG|Avapritinib|200mg d1-28.
214283497|NCT07131059|DRUG|Daunorubicin|45mg/m2/d d1-2;
214283498|NCT07131059|DRUG|Cytarabine|100mg/m2/d d1-5
214283499|NCT07131059|DRUG|Idarubicin|10mg/m2/d d1-2
214283500|NCT07131059|DRUG|MTZ|8mg/m2/d d1-2
214283501|NCT07131059|DRUG|HHT|2mg/m2/d d1-5
214283502|NCT07131059|DRUG|Azacitidine|75mgd/m2 d1-7.
214283503|NCT06813092|OTHER|Whole-Body Electromyostimulation|20 min of WB-EMS (bipolar, 85 Hz, 350 µs, 6s impulse - 4s impulse break)
214283504|NCT06813092|OTHER|Resistance exercise|High-intensity/high velocity multiple set resistance exercise
214283505|NCT06985108|PROCEDURE|nazotracheal intubation|intubation tube will be placed from nasal orifice through nazopharyngeal pathway to place into trachea
214283506|NCT01844440|PROCEDURE|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
214283507|NCT06607432|DEVICE|Transcranial Interference Stimulation (tIS)|Field strength dose of 0.30 - 0.40 V/m
214283508|NCT06607432|OTHER|Sham tIS|Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.
214283509|NCT06074133|PROCEDURE|Blood collection|Undergo blood draw
214283510|NCT06074133|PROCEDURE|Chest Computed Tomography|Undergo standard of care chest Computed Tomography
214283511|NCT06990464|DRUG|SIBP-A19|"SIBP-A19 formulation for injection. Strength: 1.0, 2.0, 3.2, 4.0, 4.8, 5.6, 6.4 and 8.0 mg/kg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle. The dose escalation stage, 1mg/kg and 2mg/ kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one participant. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored. The third stage will use RP2D for further exploration."
214283512|NCT06608823|DEVICE|Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System|Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device
214283513|NCT06608823|DEVICE|SAVR|SAVR using commercially available surgical prosthetic valves.
214283514|NCT05766852|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
214283515|NCT06614894|DRUG|Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day|Ambroxol Hydrochloride 30 mg oral pill/tablet - 9 mg/kg/day
214283516|NCT06614894|DRUG|Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day|Ambroxol Hydrochloride 30 mg oral pill/tablet - 18 mg/kg/day
214283517|NCT06614894|DRUG|Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day|Ambroxol Hydrochloride 30 mg oral pill/tablet - 27 mg/kg/day
214283518|NCT05513859|PROCEDURE|Craniotomy|Undergo craniotomy
214283519|NCT05513859|DEVICE|Quantitative Oblique Back-Illumination Microscopy|Undergo intraoperative microscopy utilizing qOBM
214283520|NCT06999226|BEHAVIORAL|RENEW-AI|AI assisted health coaching using the LLM-driven chat functionality.
214283521|NCT06587399|OTHER|Manual therapy treatment|"Joint mobilization techniques will be applied to the shoulder joint complex, adapted to the subjects' degree of irritability.~The muscular trigger points of the shoulder muscles will be treated using a pressure release technique applied for 60 seconds.~In addition, the subjects will carry out a 12-week home-based therapeutic exercise program."
214283522|NCT06587399|OTHER|Radial shock wave treatment|"The treatment will be carried out with 1 session per week for 6 weeks. For this purpose, a radial shock wave generator will be used, at a frequency of 8 to 12 Hz, 2000 pulses/session and with a pressure of 2.5 to 4.0 bar.~Between 3 and 5 points will be treated per session: insertion of the supraspinatus muscle, dorsolateral area under the acromion and a maximum of 3 trigger points of the rotator cuff muscles.~In addition, the subjects will carry out a 12-week home therapeutic exercise program."
215033142|NCT06658236|OTHER|Chest Expansion Exercises|Group B participants followed a breathing-coordinated exercise protocol using a yellow Thera-Band to improve upper extremity function. The protocol began with subjects breathing generally at rest. They were then instructed to synchronize their movements with their breathing: performing upper extremity flexion, abduction, and external rotation during inhalation, followed by extension, adduction, and internal rotation during exhalation. This coordination between breathing and movement aimed to enhance muscle activation and control. Each session included three trials of ten repetitions for each exercise, with a 1-minute rest between trials. The protocol was conducted three times per week over 12 weeks. This approach was designed to promote strength, flexibility, and coordination in the upper body while integrating breath control, which may also support relaxation and better movement efficiency. The structured schedule ensures consistent practice and gradual improvement over the 12 weeks
215033143|NCT05472818|DRUG|[11C]APP311|For each \[11C\]APP311 (UCB-J) PET scan, up to 20 mCi of \[11C\]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two \[11C\]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third \[11C\]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
215033144|NCT06824493|OTHER|no interventions|no intervention as this is an observational studies
215033145|NCT06824493|OTHER|None-placebo|Observational study with no interventions
215033146|NCT06824493|OTHER|No Intervention: Observational Cohort|no intervention because of observational studies
215033147|NCT06605820|OTHER|None - Interview Only|None - Interview Only
215033148|NCT05336357|DEVICE|Goal-Directed Therapy|"Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 65 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell."
214470834|NCT04685135|DRUG|MRTX849|21 day cycles
214844482|NCT03928535|DEVICE|High-FlowNasal Cannula|High-flowoxygenwas applied immediately after extubation through specific nasal cannula. Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%. After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.
214844483|NCT03928535|DEVICE|Noninvasive Ventilation|Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation. Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation \[SaO2\] 92%, with pH of 7.35). The FIO2 was adjusted to maintain SPO2 at less than 92%. Sedatives to increase tolerance to NIV were not allowed.
215033149|NCT01622478|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
214470835|NCT04685135|DRUG|Docetaxel|21 day cycles
214844484|NCT00660088|OTHER|Ketasyn|10g for 7 days, 20g for 7 or 14 days
214844485|NCT00263887|DRUG|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
214844486|NCT00263887|DRUG|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
214844487|NCT00022841|DRUG|Pamidronate|
215033150|NCT01622478|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
215033151|NCT01622478|PROCEDURE|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
215033152|NCT01622478|PROCEDURE|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
215057544|NCT00276068|DRUG|topical lidocaine + oral desipramine, and/or placebo|
215057545|NCT05808582|DRUG|chidamide，fulvestrant|chidamide combined with fulvestrant
215057546|NCT01740258|RADIATION|Radiation Therapy|
215057547|NCT01740258|DRUG|Temozolomide|
215057548|NCT01740258|DRUG|Bevacizumab|
215057549|NCT02112539|OTHER|platelet aggregation measurement|
215057550|NCT00771927|DRUG|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
214470836|NCT05896033|BEHAVIORAL|Non-Menthol Cigarettes|Ppts will be randomly assigned to a group that receives non-menthol cigarettes
214470837|NCT05896033|BEHAVIORAL|Tobacco Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives tobacco flavored e-cigarettes
214470838|NCT05896033|BEHAVIORAL|Menthol Cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored cigarettes
214470839|NCT05896033|BEHAVIORAL|Menthol Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored e-cigarettes
214470840|NCT06508632|BEHAVIORAL|Mandala group|Individual mandala activity will be carried out in all sample groups after admission to the clinic where they come to receive outpatient chemotherapy and when they start taking medication. Children will color (paint).
214470841|NCT05832307|OTHER|Existing Influenza Vaccination Practices|Usual care is defined as the existing inpatient influenza vaccination practices that currently exist at a given site.
214470842|NCT05832307|OTHER|Standardized inpatient influenza vaccination program|Intervention A: The basic intervention is the inpatient influenza vaccination program Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative
214470843|NCT05661604|OTHER|No Intervention|This is an observational study to assess the incidence and key disease characteristics of symptomatic acute respiratory viral infections in a high-risk population at risk for poor outcomes. Duration of each participant will be up to 12 months.
214470844|NCT05709249|DRUG|XLJDOD compound granule|Treatment will begin within 3 months after standard adjuvant chemotherapy and compliance will be continuously monitored. XLJDOD will be taken twice a day, infused with warm water, 1 hour after lunch and dinner. One course of treatment will take 28 days in 1 month, and 2- to 3-day rest. Treatment will continue for 6 courses.
214470845|NCT05709249|DRUG|placebo (XLJDOD mimetic agent)|The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.
214470846|NCT05507905|BEHAVIORAL|Music|Music associated with dance forms in dance classes.
214470847|NCT05507905|BEHAVIORAL|Dance Classes|Four Different dance forms taught for 6 weeks each
214470848|NCT05566470|DIAGNOSTIC_TEST|Assessment of Central Neuromuscular Dysfunction, Shoulder Physical Functionality and Psychological Factors|Each of the 2 groups will be evaluated in terms of functional level and psychological factors; American Shoulder and Elbow Surgeons evaluation form (ASES), Connor-Davidson Psychological Resilience Scale (CDPRS) and the Depression, Anxiety, Stress-21 Scale (DASS-21) will be used to evaluate these factors. Furthermore, the corticospinal excitability of the deltoid muscle will be assessed with Transcranial Magnetic Stimulation (TMS). Both deltoid muscles of the patient will be evaluated by saving motor evoked potentials signals that respond to TMS, and motor excitability will be compared between the affected arm and the unaffected arm. In addition, the control group will also be assessed in terms of functional level and psychological factors with TMS, ASES, DASS-21 and CPDRS.
214470849|NCT03519178|DRUG|PF-06873600|PF-06873600 tablet for oral dosing
214470850|NCT03519178|DRUG|Endocrine Therapy 1|Endocrine Therapy 1
214470851|NCT03519178|DRUG|Endocrine Therapy 2|Endocrine Therapy 2
214470852|NCT05427253|DRUG|C106 solution|selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
214470853|NCT05427253|DRUG|Placebo|Placebo for C106 solution
214470854|NCT02315703|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
214470855|NCT02315703|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
214470856|NCT02315703|BIOLOGICAL|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
214470857|NCT02315703|BIOLOGICAL|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
214470858|NCT02315703|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
214470859|NCT02240238|DRUG|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
214470860|NCT02240238|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
214470861|NCT04901078|DRUG|KNX100|KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
214470862|NCT05496036|DRUG|Pembrolizumab|400mg IV
214470863|NCT02932176|DEVICE|Non-invasive vascular testing|Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm
214470864|NCT02932176|DEVICE|machine-learning algorithm|
214470865|NCT04734080|DRUG|Dronabinol 5mg Cap|Dronabinol is a synthetic tetrahydrocannabinol (THC) agent approved for nausea and vomiting with chemotherapy and as an appetite stimulant in AIDS patients.
214470866|NCT04734080|OTHER|Placebo oral tablet|Non-active placebo
214470867|NCT04661397|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.
214470868|NCT04661397|DRUG|Darunavir|Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.
214470869|NCT04661397|DRUG|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.
214470870|NCT04661397|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.
214470871|NCT06233253|OTHER|Best Practice|Receive usual care
214470872|NCT06233253|OTHER|Medical Chart Review|Ancillary studies
214470873|NCT06233253|BEHAVIORAL|Online Mindfulness Meditation|Receive an online mindfulness intervention
214470874|NCT06233253|OTHER|Survey Administration|Ancillary studies
214470875|NCT04073498|DRUG|SerpinPC|Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
214283523|NCT07002229|DRUG|Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days."
214470876|NCT04073498|DRUG|Placebo|Matching placebo administered by SC injection according to cohort dosing instructions.
214906766|NCT04202120|OTHER|Non age-related stereotype priming|he priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
214470877|NCT06155604|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily
214470878|NCT06155604|DRUG|Standard maintenance therapy|Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
214470879|NCT05586061|DRUG|Disitamab vedotin|Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, (every 3 weeks) Q3W
214470880|NCT05586061|DRUG|Tislelizumab|Tislelizumab: 200mg, d1, ivdrip, (every 3 weeks) Q3W
214470881|NCT05586061|DRUG|S1|S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.
214906767|NCT00607074|DRUG|Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
214906768|NCT00607074|DRUG|Anti-Giardia treatment only (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
214906769|NCT00607074|DRUG|Control group (placebo)|Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
214906770|NCT02659410|OTHER|Heat stress (21)|4h exposure to heat (WBGT of 21°C), no solvent
214906771|NCT02659410|OTHER|Heat stress (25)|4h exposure to heat (WBGT of 25°C), no solvent
214906772|NCT02659410|OTHER|Heat stress (30)|4h exposure to heat (WBGT of 30°C), no solvent
214906773|NCT02659410|OTHER|Heat Stress (21) +TOL|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV)
214906774|NCT02659410|OTHER|Heat stress (25) + TOL|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV)
214906775|NCT02659410|OTHER|Heat stress (21) + TOL|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV)
214906776|NCT02659410|OTHER|Heat stress (21) + ACE|4h exposure to heat (WBGT of 21°C) + Acetone (concentration = TLV)
214906777|NCT02659410|OTHER|Heat stress (25) + ACE|4h exposure to heat (WBGT of 25°C) + Acetone (concentration = TLV)
214906778|NCT02659410|OTHER|Heat stress (30) + ACE|4h exposure to heat (WBGT of 30°C) + Acetone (concentration = TLV)
214906779|NCT02659410|OTHER|Heat stress (21) + DCM|4h exposure to heat (WBGT of 21°C) + Dichloromethane (concentration = TLV)
214906780|NCT02659410|OTHER|Heat stress (25) + DCM|4h exposure to heat (WBGT of 25°C) + Dichloromethane (concentration = TLV)
214906781|NCT02659410|OTHER|Heat stress (30) + DCM|4h exposure to heat (WBGT of 30°C) + Dichloromethane (concentration = TLV)
214906782|NCT02659410|OTHER|Heat stress (21) + TOL (dermal)|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
214906783|NCT02659410|OTHER|Heat stress (25) + TOL (dermal)|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
214906784|NCT02659410|OTHER|Heat stress (30) + TOL (dermal)|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
214906785|NCT03966417|OTHER|Exercise training|Continuous exercise training 2 times per week for a period of 12 weeks.
214906786|NCT05342194|DRUG|Toripalimab|240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
214906787|NCT05342194|DRUG|Lenvatinib mesylate capsules|8 mg orally (po) once daily (QD)
214906788|NCT05342194|DRUG|Placebo IV|Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
214906789|NCT05342194|DRUG|Oral placebo|Oral placebo po QD continuously
214906790|NCT05342194|DRUG|Oxaliplatin for injection|85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles
214906791|NCT05342194|DRUG|Gemcitabine hydrochloride|1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
214906792|NCT05342194|DRUG|Cisplatin|25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
214906793|NCT05182632|BEHAVIORAL|Group pelvic floor telerehabilitation|Multimodal group physiotherapy: 12 weeks of weekly group physiotherapy treatments including education and pelvic floor muscle exercises delivered online + home exercise program
214906794|NCT02199964|DRUG|Cyclosporin 0.05% emulsion|Topical therapy for dry eye
214906795|NCT02199964|DRUG|Endura, Refresh artificial tears|Over the counter therapy for dry eye, used 4 times a day
214906796|NCT00328497|DRUG|Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
214906797|NCT02172664|PROCEDURE|Self etch enamel etching|The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.
214470882|NCT05540353|DEVICE|Transvaginal photobiomodulation|Low light laser therapy applied transvaginally using a small vaginal wand with sterile disposable wand covers. The intervention last 3-5 minutes based on a surface area calculation performed at the beginning of the intervention, and involves a gentle in and out motion of the wand to deliver light energy to the muscles of the pelvic floor.
215033153|NCT05293314|DIAGNOSTIC_TEST|An exhaled breath test|All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant. Breath sample detection was based on the HPPI-TOFMS platform.
214906798|NCT02172664|PROCEDURE|selective etch protocol|Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.
215033154|NCT06248710|DRUG|Oxytocin nasal spray|Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant
215033155|NCT06248710|OTHER|Animal-Assisted Intervention|The dogs involved in the study are trained and used to work with different people in animal-assisted interventions. The dog will be familiarized with the room and the material as well as the staff of the study. The dog will be specifically trained for this study. The dog will be involved for a maximum of 3 sessions per day (approx. 20 minutes in total) and 2 days per week.
215033156|NCT06248710|DRUG|Placebo|The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
214906799|NCT02172664|DEVICE|Adhese Universal|the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
214906800|NCT03608631|DRUG|Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|Given IV
214906801|NCT05835310|BIOLOGICAL|Anifrolumab|Participants will receive a single dose of Anifrolumab via IV infusion.
214906802|NCT05835310|DRUG|Placebo|Participants will receive matching placebo via IV infusion
214906803|NCT05849493|BEHAVIORAL|Metacognitive Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
214906804|NCT05849493|BEHAVIORAL|Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
214906805|NCT06976242|PROCEDURE|Elastic Resistance Training|The type of resistance exercises in which the participants use the Thera Band of yellow and red colours (weight about 2-2.5 kg with full elongation) for resistance training
214906806|NCT06976242|PROCEDURE|Free Weight Exercises|The type of resistance exercises in which the participants use weight cuffs (weight 2-2.5 kg) tied to their lower leg for resistance training
214906807|NCT06976242|PROCEDURE|Conventional Training|The conventional training includes side-lying hip abductions, standing weighted abductions, and lateral step-ups exercises.
214906808|NCT03285152|OTHER|Ketogenic Diet (KD)|specially-formulated very low carbohydrate meals (KD)
214906809|NCT03285152|OTHER|Standard Diet (SD)|counseling on maintaining adequate nutritional intake from a normal diet (SD)
214906810|NCT06974656|DRUG|Dexmedetomidine|Patients will receive 1 μg/kg of intravenous dexmedetomidine over 10 min followed by an intravenous infusion of n 0.3-0.5 μg/kg/h.
214906811|NCT06974656|DRUG|Lidocaine|Patients will receive a bolus of intravenous lidocaine 1.5mg/kg over 10 min followed by a continuous infusion of lidocaine 1.5-2 mg/kg/h.
214906812|NCT06572384|BIOLOGICAL|Belimumab|Belimumab will be administered.
214906813|NCT06572384|OTHER|Placebo|Placebo will be administered.
214906814|NCT06443502|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
214906815|NCT06443502|DRUG|Concomitant Antibiotic Therapy|Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.
214906816|NCT06730555|BEHAVIORAL|ACCESS Intervention|Participants will receive the ACCESS intervention with funding, consisting of up to 16 hours of practice facilitation per month in person and/or virtually. Practice facilitation is training and support on implementation of routine HIV/HCV screening.
214906817|NCT06730555|BEHAVIORAL|Control Group|Participants will receive a link to the CDC compendium of evidence-based interventions for HIV prevention.
214906818|NCT05064709|DEVICE|Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.
214906819|NCT05064709|DEVICE|OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
214906820|NCT06023602|DRUG|Generic cetrorelix acetate|Generic cetrorelix acetate (0.25 mg SC)
214906821|NCT06023602|DRUG|Reference cetrorelix acetate|reference cetrorelix acetate (0.25 mg SC)
214906822|NCT05112705|DIAGNOSTIC_TEST|Proximal lower limb ultrasound|Twice weekly proximal lower limb ultrasound
214906823|NCT05700942|DEVICE|High Dose Intervention-tsDCS|Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)
214906824|NCT05700942|DEVICE|Low Dose Intervention-tsDCS|Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
214906825|NCT02883816|OTHER|assessment of lung function|measurement of lung volumes and flow rates of bronchial
214906826|NCT05445102|PROCEDURE|autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect|after extraction of tooth it will be grinded using hand bone mill and demineralized and placed in intrabony defect
214283524|NCT07002229|DRUG|Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days."
215033157|NCT06611306|RADIATION|DE-iPTV|Dose-escalated VMAT-based radiotherapy, as previously described in our planning study
215033158|NCT06257394|DRUG|Dasatinib(Sprycel) arm|"▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~ 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~     * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib."
215033159|NCT06257394|DRUG|Non-Dasatinib(Sprycel) arm|"▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~ 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3‡ → Allogeneic HSCT~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab"
215033160|NCT00835367|DRUG|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
215033161|NCT00835367|DRUG|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
214283525|NCT07002229|DRUG|Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days."
214283526|NCT07001072|DEVICE|Smartshoes with haptic vibration feedback|wearable smartshoe with capability‬ to deliver haptic/vibration feedback to assess effect on freezing of gait
214283527|NCT07002463|DEVICE|Luna EMG|Participants receive additional upper limb rehabilitation using the Luna EMG robotic system. Each session includes 4 EMG-triggered exercises (shoulder flexion, external rotation, elbow extension, and forearm supination), with 50 repetitions per movement. The intervention is delivered 5 days per week for 6 weeks alongside a standard rehabilitation program.
214283528|NCT07002463|BEHAVIORAL|Therapist-assisted upper limb training|Participants receive additional upper limb rehabilitation with a physiotherapist performing assisted movements equivalent to the robotic training protocol. Each session includes 4 assisted exercises (shoulder flexion, external rotation, elbow extension, and forearm supination), with 50 repetitions per movement. The intervention is delivered 5 days per week for 6 weeks alongside a standard rehabilitation program.
214470883|NCT05540353|DEVICE|Sham therapy|Use of the same vaginal wand as active arm, but without activation of the machine. The intervention last 3-5 minutes, and involves a gentle in and out motion of the wand to massage the muscles of the pelvic floor, without delivery of light therapy.
214470884|NCT06244654|DEVICE|Oculus Quest 2 VR virtual reality glasses and wired over-ear headphones|After the VR group comes to the preoperative area and is evaluated, they will be asked to wear VR glasses and headphones. VR glasses and headphones were worn on the patient during peripheral nerve block applications and the operation. At the end of the operation, the VR glasses and headphones were removed and they were taken to the postoperative recovery room.
214470885|NCT06244654|OTHER|No VR|After evaluation of the patients taken to the preoperative area, routine peripheral nerve block application was performed without the use of VR glasses. VR glasses were not worn during the operation, as is the routine protocol. At the end of the surgery, they were taken to the postoperative recovery room.
214470886|NCT05739955|OTHER|Sani24|24-hour continuously acting quaternary ammonium salt disinfectant
214470887|NCT05739955|OTHER|Standard EPA-registered disinfectant|Standard EPA-registered disinfectant
214470888|NCT05739955|OTHER|Routine Disinfection|Routine disinfection at the study hospital
214470889|NCT05861921|OTHER|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.
214470890|NCT03291652|DIAGNOSTIC_TEST|DSA/3DRA|DSA/3DRA
214470891|NCT03878407|OTHER|Monitoring of ARCH variants|Blood samples will be tested for mutations, before patients are given Standard of Care chemotherapy/radiation or after given Standard of Care chemotherapy/radiation. Another testing is done after 3 months and after 1 year if positive for ARCH.
214470892|NCT05199051|COMBINATION_PRODUCT|Gemtuzumab ozogamicine - Cytarabine - Gilteritinib|See Arms description paragraph
214470893|NCT06145620|OTHER|Physiotherapy|The intervention involves the visualization of different videos explaining the performance of lumbar strengthening exercises, measures for back care, and neuroscience pain education.
214470894|NCT05941182|OTHER|online questionnaires|Before and after online questionnaires
215033162|NCT04111601|DEVICE|Blue light imaging|Advanced virtual chromoendoscopy
215033163|NCT06606275|DRUG|Apixaban|Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa, playing a crucial role in preventing blood clot formation. It is commonly prescribed for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) and for treating and preventing venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
214283529|NCT07000903|OTHER|Exposure and immune profiles|The exposure and immune profiles will be determined in HBM blood and urine samples collected prospectively during the first SOC visit.
214283530|NCT07001787|DRUG|Drug：HS-10510；|Drug：HS-10510 Description：Subjects will receive HS-10510 orally as a single and multiple ascending dose.
214283531|NCT07001787|DRUG|Drug：Placebo|Drug：Placebo Description：Subjects will receive placebo matching the HS-10510 dose orally as a single and multiple ascending dose.
214283532|NCT07001787|DRUG|Drug： Rosuvastatin|Drug：Rosuvastatin Description：Subjects will receive rosuvastatin orally.
214283533|NCT07002099|DRUG|Selinexor + High-dose Methotrexate + Rituximab + WBRT|"Rituximab 375 mg/m² intravenously on Day 0 of each 21-day cycle~High-dose Methotrexate (HD-MTX) 3.5 g/m² intravenously over 4 hours on Day 1 of each cycle~Selinexor 80 mg orally once weekly (on Days 1, 8, and 15) during each cycle~Treatment is administered every 21 days for up to 6 cycles. Tumor response will be evaluated every 3 cycles.~Patients who achieve a partial response (PR) or better will undergo consolidative low-dose whole-brain radiotherapy (WBRT) at 23.4 Gy in 13 fractions."
214283534|NCT07000942|OTHER|Electrical cardioversion (ECV)|Electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure
214283535|NCT07001397|DRUG|EPAG-pfos|The initial dose of EPAG-pfos is 150mg/d orally. The dose is adjusted according to hematological indicators, with a maximum dose of 150mg/d until hematological remission is achieved
214283536|NCT07000461|PROCEDURE|Group Non-pulsatile perfusion|Non-pulsatile group in pump blood flow
214283537|NCT07001683|DEVICE|VR SHINECON VIRTUAL REALITY GLASES|"Unity program; It is a game engine that is used for the development of 2D, 3D, virtual reality and augmented reality applications and also has mobile support. 3D objects and animations necessary to develop the application have been prepared. These objects and animations; It was developed in the Autodesk 3ds Max program, where 3D modeling and animations are made.~The virtual reality aspect of the application is integrated into the Google VR SDK (Google Virtual Reality Software Development Kit). Interactions in the virtual environment and 360° viewing operations in the virtual world are provided through this Google VR SDK. The development process was completed by writing application codes in C#, one of the languages supported by the Unity program, using the methods included in the SDK."
214283538|NCT07002424|BEHAVIORAL|Therapeutic - Psychological|The intervention uses a transdiagnostic model that incorporates aspects of peer support, psychoeducation, trauma-informed cognitive behavioural therapy (CBT), Compassion focused therapy (CFT) models of distress. It also aligns itself to the Dual Processing Model of coping with bereavement (Stroebe \& Schut, 2010) and Tonkin's model of grief (Tonkin, 1996).
214283539|NCT07002619|PROCEDURE|Routine cholangiography|Intraoperative cholangiography attempted regardless of indication and anatomy
214283540|NCT07002619|PROCEDURE|Selective cholangiograpy|Intraoperative cholangiography only attempted in case of uncertainty regarding anatomy
214283541|NCT07001839|DRUG|QLS4131 for Injection.|Eligible participants will be assigned to 1 of the 9 dose groups ranging from 0.06 μg/kg to 600 μg/kg.
214283542|NCT07001514|BEHAVIORAL|Calming digital content|Participants watch a curated selection of soothing documentaries narrated by Sir David Attenborough for 30-60 minutes each evening during one hour before bedtime.
214283543|NCT07001514|BEHAVIORAL|Exciting Digital Content|Participants engage with the interactive word-based game Ruzzle for 30-60 minutes each evening during one hour before bedtime, designed to provide mental stimulation.
214283544|NCT07001514|BEHAVIORAL|Non-digital book reading|Participants read a non-fiction book of their choice for the same duration, avoiding all digital screens during one hour before bedtime before bedtime.
214283545|NCT07002151|OTHER|educational kinesiology training program intervention for study group|The Educational kinesiology program were included : (Cross crawl) Sit or stand and with the right-hand elbow touch the left knee and vice versa. (The owl) Bring one hand up to the opposite shoulder and hold a pinch around the trapezius muscle between the neck and shoulder. the thumb should be on one side of the muscle and the other fingers clasping around the other side. Turn the head to the same side as thehand is gripping and take a deep breath. Slowly exhale as bringing the head gently around to the other side. Repeat this movement one more time. (The arm activation) Hold one arm next to the ear. Exhale gently while activating the muscles by pushing the arm against the other hand in four directions (front, back, in and away). (The Energizer) Place the head on the desk in front exhale and inhale while coming up and try to hyperextend the neck carefully. (cook's hook-up) put the left ankle over your right knee. Next, hook the right hand around the left ankle.
214283546|NCT07002151|OTHER|conventional upper extremities coordination training for both arms experimental and comparator (study and control) groups|Bimanual coordination,Hand-arm coordination ,Drinking \& Strength training
214283547|NCT07002385|BEHAVIORAL|control group|The control group received standard psychiatric care, which involved physician-led management following clinical guidelines for geriatric disease treatment, including routine medication prescriptions based on diagnostic results. At diagnosis, healthcare providers informed caregivers about the confirmed disease entity, clinical status, and necessary precautionary measures. Monthly mental health lectures were conducted for all patients, covering topics such as common psychological symptoms and coping strategies. Post-discharge, monthly outpatient follow-ups included blood pressure and glucose monitoring. Medication dosages were adjusted if patients reported changes in somatic symptoms.
214470895|NCT06451627|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) will be infused at a speed of 0.3mg / kg / h during surgery .
214470896|NCT06451627|DRUG|saline|Saline will be infused at a speed of 0.3mg / kg / h during surgery .
215033164|NCT06606275|DRUG|Warfarin|Warfarin is a vitamin K antagonist widely used as an anticoagulant to prevent thromboembolic events, particularly in conditions like atrial fibrillation, venous thromboembolism, and in patients with mechanical heart valves. It inhibits the enzyme vitamin K epoxide reductase, thereby reducing the activation of vitamin K-dependent clotting factors (II, VII, IX, X) and regulatory proteins C and S. Due to its narrow therapeutic index, warfarin requires regular monitoring of the International Normalized Ratio (INR) to optimize anticoagulation while minimizing the risk of bleeding. Warfarin's pharmacokinetics and pharmacodynamics can be influenced by genetic polymorphisms, diet, and drug interactions, necessitating individualized dosing strategies.
215033165|NCT06606158|OTHER|Exercises program|Strength, mobility, and balance exercises described within the standardized Physiotherapy plan.
215033166|NCT06606158|OTHER|App exercises program|A strength, mobility, and balance exercise program delivered through a mobile app.
214906827|NCT03835923|BEHAVIORAL|lifestyle intervention|"intervention phase 1 (baseline - month 6): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity. The intervention is accompanied by regular oral and written feedback.~intervention phase 2 (month 6 - month 12): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity without additional oral or written feedback."
215033167|NCT06121856|DEVICE|VerioVue Enhancements BGMS|Blood glucose monitoring system
214906828|NCT03835923|BEHAVIORAL|usual care|Recommendation for lifestyle intervention at baseline and after 6 months (e.g. salt reduction, restricted alcohol consumption and smoking cessation, 10,000 steps/day, 150 minutes/week moderate intensity exercise)
214906829|NCT05863663|OTHER|questionnaire|cross sectional questionnaire
214906830|NCT04752852|DRUG|Dexamethasone|8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
214906831|NCT04752852|DRUG|Placebo|2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
214906832|NCT04083638|DIAGNOSTIC_TEST|IFAB|Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
214906833|NCT04079647|DRUG|Immunotherapy|Patients receive immunotherapy for cancer treatment
214906834|NCT04935879|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
214906835|NCT04935879|DRUG|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
214906836|NCT06983184|OTHER|MC-synced NTP|Menstrual cycle-synced neuromuscular training program
214906837|NCT06983184|OTHER|Blinded NTP|Blinded neuromuscular training program
214906838|NCT03440229|OTHER|Emulsifier-containing diet|CMC is one of many synthetic dietary emulsifiers that are incorporated into a variety of processed foods. We have recently shown that, in mice, consumption of P80 and CMC, alters microbiota composition, have pro-inflammatory potential and promote microbiota encroachment into the colonic mucosa, low-grade inflammation, and metabolic syndrome. However, it is not known whether these compounds have similar effects in humans. We would like to study these effects in the human gut microbiota.
214906839|NCT00126750|BEHAVIORAL|VA MI Plus Interactive|The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
214906840|NCT01400490|DIETARY_SUPPLEMENT|EPA-DHA Study|6 weeks of dietary supplementation
214906841|NCT01087125|DRUG|No Interventions|No Interventions
214906842|NCT00486785|DRUG|Alfuzosin|Alfuzosin 10mg Once Daily for 24 weeks
214906843|NCT05963191|DEVICE|Colorectal cancer screening with CAD EYE colonoscopy|"The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa.~In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis."
214906844|NCT06661629|DEVICE|Nerve stimulation|The intervention is testing the effect of unilateral versus bilateral hypoglossal nerve stimulation on upper airway collapsibility during drug-induced sleep endoscopy
214906845|NCT05238298|DEVICE|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
214906846|NCT03585569|BIOLOGICAL|Abobotulinumtoxin A|Treating Patients with Multiple Sclerosis with lower extremity spasticity using Dysport (Abobotulinumtoxin A)
214906847|NCT03839069|PROCEDURE|minor salivary gland transplantation|The investigators will harvest the autologous labial salivary gland tissue and transplant to the upper and lower conjunctival fornix of the lesion eye.
214906848|NCT03811691|DIAGNOSTIC_TEST|MRI exam|Pacing system safety and stability under MRI scan environment
214906849|NCT04899180|DRUG|99mTc-PYP|Radioisotope used by SPECT/CT imaging
214906850|NCT06162598|OTHER|Ventriloquist Puppet|one day preparation intervention applied by researcher for children under the inhaler treatment. Preparation will be 30 minutes long
214906851|NCT05263245|OTHER|Light breakfast|Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
214906852|NCT06864585|DRUG|Avibactam sodium/Ceftazidime hydrate|The recommended adult dosage is 2.5 g (0.5 g of avibactam and 2 g of ceftazidime) administered by intravenous infusion over a period of 2 hours 3 times daily. For peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess, Zavicefta should be co-administered with a metronidazole injection.
214906853|NCT06864351|OTHER|OptiThyDose|"OptiThyDose is an iterative mathematical model applied at each patient visit, consisting of three components: (i) a disease-specific pharmacometrics (PMX) model, (ii) an empirical Bayesian estimation (EBE) component, and (iii) an optimal control theory (OCT) component. It calculates the optimal LT4 or CMZ/MMZ dose to maintain Free Thyroxine (FT4) levels within the upper half of the age-specific reference range, integrating past clinical and lab data.~Dosing follows international guidelines, with physicians able to consult OptiThyDose for individualized dosing within recommended ranges. At each outpatient visit, the physician can either (A) prescribe a dose within OptiThyDose's suggested range or (B) choose a dose based on personal experience."
214906854|NCT05382793|DIETARY_SUPPLEMENT|Control|No iodine
214906855|NCT05382793|DIETARY_SUPPLEMENT|Iodide (150 μg/day)|A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide
214906856|NCT05382793|DIETARY_SUPPLEMENT|Iodine (300 μg/day)|Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide
214906857|NCT05429372|GENETIC|PF-06939926|All participants will receive a single dose of PF-06939926 on Day 1.
214283548|NCT07002385|COMBINATION_PRODUCT|Intervention group|The intervention group received a structured biopsychosocial program delivered by a multidisciplinary team. Geriatricians adjusted medications biweekly; rehabilitation therapists led Baduanjin sessions and monitored daily exercises via smart wristbands. Nurses provided CBT-I manuals, and psychologists offered weekly video support. Psychological care included biweekly mindfulness sessions and daily app-guided exercises, with monthly life review activities. Social support involved community events, volunteer roles, and weekly caregiver workshops. Adherence (≥70%) was tracked via app; non-compliance triggered reminders and tailored support. Exercise intensity was regulated by heart rate; patients with ≥5-point HAMD-17 increases were referred. Monthly reviews ensured ongoing quality improvement.
214283549|NCT05782361|DRUG|Tepotinib|Tepotinib hydrochloride hydrate will be supplied as film coated tablets. The 250 mg oval, white-pink film-coated tablets contain the excipients mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry II pink. All formulations are intended for oral administration. Refer to pharmacy manual for formulation and strength information.
214470897|NCT06223451|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that can alter the excitability of the motor area by generating a magnetic field through a coil. Low-frequency stimulation (\<1 Hz) applied with rTMS has inhibitory effects. Repetitive transcranial magnetic stimulation has a neurorehabilitative role as it can modulate the excitability of targeted brain areas. Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation.Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.
215033168|NCT06497946|BEHAVIORAL|SlimTrack Plataform|SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available
215033169|NCT06497946|BEHAVIORAL|Diet prescription|Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
215033170|NCT05145816|DRUG|Belantamab mafodotin 2.5 mg/kg (8 weeks)|2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
215033171|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (8 weeks)|1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
215033172|NCT05145816|DRUG|Belantamab mafodotin 1.4 mg/kg (12 weeks)|1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
215033173|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (12 weeks)|1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
215033174|NCT05145816|DRUG|Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages|Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
215033175|NCT05145816|DRUG|Belantamab mafodotin 1.0 mg/kg (12 weeks)|1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
214283550|NCT05782361|DRUG|Pembrolizumab|"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
214283551|NCT07001774|BEHAVIORAL|Vitalis Cardio|Participants receive five free health coaching sessions with a trained student health coach, access to two health education videos, and a free wrist worn activity monitor to keep track of their physical activity and sleep behaviors.
214283552|NCT07002346|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706: 5 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 2 years.
214283553|NCT07002346|DRUG|Bevacizumab|Bevacizumab : 15 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 22 cycles.
214283554|NCT07002346|DRUG|carboplatin|Carboplatin: AUC=5, intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 6 cycles
214283555|NCT07002346|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 6 cycles
214283556|NCT07132190|RADIATION|Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV|Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
214283557|NCT07132827|DRUG|SHR-1905 Injection|SHR-1905 Injection
214283558|NCT07132827|DRUG|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
214283559|NCT07132164|OTHER|biobank sample collection|"At inclusion, patients will benefit from blood testing for biobank establishment, and stool sample collection for gut microbiota analysis will be organized depending on the center.~The 12-month visit (M12) will also include an additional blood sample collection as part of the biobank, as well as stool sample collection"
214283560|NCT07133113|OTHER|We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).|"The patients will be identified via the French Nationwide Multidisciplinary Team Meetings for Autoimmune encephalitis, which are conducted on a bi-monthly basis. All patients with newly diagnosed NMDAR, LGI1, CASPR2, IgLON5, GFAP or GAD65 encephalitis and treated for less than 8 weeks will be included. Treatment protocols at the initiation of therapy will be stratified into: 1) first-line only; 2) rituximab without cyclophosphamide; 3) rituximab combined with cyclophosphamide; 4) others.~The referral clinicians will be contacted by email and the data will be collected using standardized questionnaires, which will be sent at baseline (visit 1, V1) and 4 months after the initiation of therapy (visit 2, V2). The questionnaires will be structured into 7 sections:~* 1 Demographics~* 2 Symptoms~* 3 Cognitive screening tests (MMSE, MoCA, and/or others)~* 4 Level of dependence (ADL, I-ADL, mRS, CASE) and impact on social life~* 5 Diagnostic tests (brain MRI, brain PET, CSF, and EEG findings)"
214283561|NCT06618313|DRUG|JCXH-213,an mRNA-LNP based in vivo CAR therapy|JCXH-213 infusion
214470898|NCT06223451|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
214470899|NCT04088838|OTHER|Pain tracking app|In this study no clinical interventions are made. Patients scheduled for surgery will be treated according to the standard of care. All patients enrolled will have an application installed to track their pain symptoms through short daily and weekly questionnaires.
215033176|NCT06675409|OTHER|Education|The effectiveness of two different training methods with virtual patients for improving the critical decision-making skills of paramedic students will be compared between two groups: one receiving expert-guided training and the other following a self-directed approach
215033177|NCT06674317|BEHAVIORAL|Internet Delivered Cognitive Behavioral Therapy for Insomnia in Persons with Inflammatory Rheumatic Diseass|"Cognitive behavioral therapy for insomnia (CBTi) is considered a first-line treatment for insomnia. Access to this treatment option is limited therefore we have been developing an internet delivered cognitive behavioral therapy for insomnia (I-CBTi) to help overcome accessibility barriers.~The purpose of this study is to pilot test a tailored internet-delivered cognitive behavioral therapy for insomnia (I-CBTi) intervention for persons with Inflammatory Rheumatic Diseases showing symptoms of insomnia."
215033178|NCT06675422|DRUG|JY231 injection|Dose escalation was carried out using the 3+3 principle and the mode of administration was intravenous.
215033179|NCT06674005|OTHER|Cucurbita pepo L. Flowers Extract|2 mg twice per day for 1 month
215033180|NCT06674005|OTHER|Placebo|2 mg twice per day for 1 month
214470900|NCT06166680|OTHER|Sleep quality assessment|"The following item will be assessed in all subjects (n=420):~1\. Sleep, through the Pediatric Sleep Questionnaire."
215033181|NCT06598761|COMBINATION_PRODUCT|Immunotherapy+radiotherapy|"Adjuvant Immunotherapy: Immunotherapy drug of choice is tirilizumab, which has received national recommendations in metastatic uroepithelial cancer. Tirelizumab 200mg Q3w; the duration of immunotherapy is recommended for at least 1 year.~Adjuvant radiotherapy can be given concurrently or sequentially with adjuvant immunotherapy; it is recommended that radiotherapy can be started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT), daily image-guided radiotherapy (Daily IGRT) techniques are used."
215033182|NCT06598761|OTHER|surveillance alone|Patients recieve surveillance alone without any adjuvant interventions until any disease progression endpoints occur.
215033183|NCT02549820|DEVICE|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
215033184|NCT06266351|DEVICE|This is observational IOP measurement|IOP measurement of patients having LASIK with both CATS and GAT
215033185|NCT06279130|DRUG|botensilimab|Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)
215033186|NCT06279130|DRUG|balstilimab|Anti programmed cell death protein-1 (anti-PD1)
215033187|NCT07004296|DRUG|HDM2005|HDM2005 will be administered via IV infusion.
214283562|NCT07002437|OTHER|Augmented Acute Intermittent Hypoxia (aAIH)|"aAIH (augmented acute intermittent hypoxia) consists of 3, 5-minute episodes of low oxygen (9-13% O2), interspersed with 3-min room air intervals.~Each study participant will complete one session of augmented AIH (aAIH), which consists of 3, 5-minute exposures. Each exposure involves a 5-minute hypoxic episode (9-131% inspired O2), with a 3-min interval of room air breathing (21% O2). Gas mixtures will be delivered via Douglas bags (pre-filled with desired gas mixture) that are coupled to a non-rebreathing valve and facemask. A manual-control valve allows seamless gas mixture switching. Participant safety will be continuously monitored in real-time using non-invasive sensors and LabChart software. For instance, inspired and expired concentrations of O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, tidal volume, heart rate, and blood pressure) will be continuously monitored."
214283563|NCT07002437|OTHER|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|"AIHH consists of 1-min episodes of low oxygen (9% O2) and elevated carbon dioxide (5% CO2), interspersed with 1.5 min room air.~Each participant will complete one session of AIHH exposure, which consists of 15, 1-minute hypercapnic hypoxic episodes (4-5% inspired CO2, 9-131% inspired O2), with 1.5-minute intervals of room air breathing (21% O2). Gas mixtures will be delivered in the same manner described for AIH intervention. Participant safety will be continuously monitored in real-time using LabChart software. For instance, inspired and expired concentrations of CO2 and O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, heart rate, and blood pressure) will be monitored."
214283564|NCT07002437|OTHER|Sham AIH|"A single session of sham AIH with episodes of normal room air (21% O2).~Sham experiments will use methods identical to AIH/AIHH protocols except that normoxic gas (21% inspired O2) will be delivered. Since the timing and intervals vary with each protocol, the sham will use a distinct protocol involving 5, 3-min episodes with 2 min intervals between each episode. The valve on the non-rebreathing mask will be turned to deliver these episodes, but 21% O2 will be delivered throughout."
214283565|NCT07001709|DRUG|Oxycodone oral capsule 15 mg|Single dose of 15 mg oxycodone direct release (both arm 1 and arm 2)
214470901|NCT06166680|OTHER|Anthropometry|"The following items will be assessed in all subjects (n=420):~2\. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate (with the Quick Tongue-Tie assessment tool)"
214470902|NCT06166680|OTHER|Tongue strength assessment|"The following items will be assessed in all subjects (n=420):~3\. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing.~4\. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 sec. of tongue elevation.~5\. Tongue peak pressure during 3 sec. of tongue protrusion."
215033188|NCT03592264|DRUG|OBI-3424|liquid formulation for Intravenous infusion
215033189|NCT07004608|BEHAVIORAL|Aalana Palana|Alan Palana is a facilitated video viewing intervention which promotes responsive and sensitive parenting, early learning opportunities and desired nutritional practices for young children and pregnant women. The content not only describes 'WHAT' behaviours caregiver should adopt, 'HOW' they could include these behaviours in their routines but also 'WHY' a particular behaviour is important for their child's development.
215033190|NCT06919471|OTHER|Fitbit|Wear it on wrist
214283566|NCT07001709|DRUG|Abiraterone Acetate Tablets 500 mg|Abiraterone group: 1000 mg abiraterone acetate (at steady state)
214283567|NCT07131254|BIOLOGICAL|GT719 Injection|GT719 Injection
214283569|NCT07133061|DIAGNOSTIC_TEST|Wingate test|During the test, 1s power, 5s power, 30s power, speed, heart rate, the value of lactate and other parameters are determined.
214470903|NCT06166680|OTHER|Tongue endurance assessment|"The following items will be assessed in all subjects (n=420):~6\. The tongue endurance (i.e., the time to task failure in maintaining a pressure equal to 50%Pmax against the IOPI bulb) during tongue elevation.~7\. The tongue endurance during tongue protrusion."
214283570|NCT07133061|DIAGNOSTIC_TEST|Dynamometry|The test determines the strength of the handshake by right and left hand separately.
214283571|NCT07133061|DIAGNOSTIC_TEST|Rebound plate|The test determines the height of the jump from the right lower limb and from the left lower limb separately.
214283572|NCT07133061|DIAGNOSTIC_TEST|Blood lactate test|Measurement of volume of lactate in the blood.
214283573|NCT07131124|BEHAVIORAL|Mindful Self-Compassion program|"The MSC self-compassion program will be delivered by instructors trained by the LBCM Organization, certified Qualiopi and affiliated to the ADM (accredited training organization).~The MSC program consists of 8 weekly sessions, each 2.5 hours long, plus an additional half-day of supplementary practice ."
214470904|NCT06166680|OTHER|Orofacial praxis assessment|\- The following item will be assessed in a subset of subjects (n=31): 8. Orofacial praxis through the Motricité Bucco-Linguo-Faciale (MBLF) test.
214470905|NCT05364307|OTHER|Prescreener database|Identify and characterize participants with reported memory complaints and/or cognitive impairment to determine the probability of randomization into a therapeutic AD clinical trial.
214283574|NCT07131124|BEHAVIORAL|Treatment As Usual (TAU) program|"Current treatment strategies for Alcohol Use Disorders (AUD) rely on a combination of pharmacological and psychotherapeutic treatments (Schuckit, 2009). The three specialized outpatient centers participating in our study provide comprehensive and up-to-date addiction care that meets international and national recommendations (HAS, 2023; SFA, 2023).~The services offered, in addition to standard care, include:~Brief interventions, Psychoeducation sessions, Motivational interview, Individual and group therapies for patients (cognitive-behavioral therapies, cognitive remediation, relaxation techniques), Individual and group therapies for families, Psychosocial interventions, including social support and strengthening of psychosocial skills, Peer support groups (peer helpers, expert patients, former user groups)"
214283575|NCT07001631|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|The Dutch version of the standard EMDR protocol with age-specific adaptations for children and adolescents will be used. The eight phases consist of history taking, preparation, assessment, desensitization, installation, body scan, closure, and re-evaluation. During an EMDR session, the child focuses on emotionally disturbing memories (images, thoughts, emotions, and sensations) while simultaneously focusing on an external distracting stimulus (e.g., eye movements). This process facilitates accessing and desensitizing the traumatic memory network, so information processing is enhanced, and new associations can be made between the traumatic memory and more adaptive memories and information. As a result, the traumatic memory representation will be less intense and emotionally disturbing. After the intake session (week 1), including case conceptualization and treatment plan, a maximum of 6 weekly EMDR sessions with a duration of 1 hour per session will be offered.
214470906|NCT06031610|PROCEDURE|carotid artery stenting|Patients were monitored for at least 24 h after surgery, with control for hyperperfusion syndrome, dual antiplatelet therapy was continued for 4-6 weeks, and the postoperative patients have the final residual stenosis of less than 30%, thrombolysis in Myocardial Infarction (TIMI) grade 3, and no dissection or thrombosis. Any surgery-related complications were recorded.
214470907|NCT06031610|DRUG|drug therapy|Carotid artery stenosis requires taking antiplatelet aggregation drugs and statin lipid-lowering drugs. It can inhibit platelet aggregation, stabilize plaque, reduce vascular inflammatory factors, and prevent further development of atherosclerosis.
214470908|NCT06105190|DEVICE|Implantation of premium monofocal IOL, LuxSmart (device under investigation)|Patients will be implanted with study IOL in both eyes
214470909|NCT06105190|DEVICE|Implantation of monofocal IOL, LuxGood (control device)|Patients will be implanted with Control IOL in both eyes
214470910|NCT03325946|BEHAVIORAL|ACQUIRE Therapy|Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
214283576|NCT03905668|OTHER|Video Monitoring|Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
214283577|NCT03905668|OTHER|Accelerometer Monitoring|Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
214283578|NCT03905668|OTHER|Electromyographic Monitoring|Patients may have electromyographic monitoring for up to seven days while in the ICU.
214283579|NCT03905668|OTHER|Noise Level Monitoring|Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
214283580|NCT03905668|OTHER|Light Level Monitoring|Patients may have light level monitoring for up to seven days while in the ICU.
214283581|NCT06596031|BEHAVIORAL|Health coaching|The core belief in coaching is that people are resourceful and that the participant knows what is best for themselves. If the participants are assigned to the health coaching group, they will have access to a health coach with a physiotherapist background. Instead of offering physiotherapy advice, however, the health coaching will work with the participant to come up with ideas that work the best for them to manage their health and wellness to prepare for surgery, including addressing some difficulties the participant are facing when using the online resource.
214470911|NCT06527664|DEVICE|custom-made acetabular implant|custom-made acetabular implant produced with additive manufacturing, to fill the bony loss in Paprosky III bone defects
214470912|NCT03411096|PROCEDURE|Quadratus lumborum block using ropivacaine|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with 0.75% ropivacaine (20cc) under ultrasound guidance.
214283582|NCT06596031|BEHAVIORAL|Digital toolkit|This intervention provides, via a website, self-management support of preoperative rehabilitation for hip or knee replacement based on NICE guidelines Joint replacement (primary): hip and knee. This includes guidance for patients to undertake a strengthening programme that will aid recovery, lifestyle behaviours including weight management, diet and smoking cessation, and maximising functional independence and quality of life before surgery.
215033191|NCT06919471|OTHER|MySnackTracker App|App to track your dietary intake
214283583|NCT02048605|BEHAVIORAL|Psycho-social CBT based training|Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.
214283584|NCT02048605|BEHAVIORAL|Unspecific group training|Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
214283585|NCT07015593|OTHER|interview|30 for Qualitative interview and 750 for quantitative survey
215033192|NCT06675032|BIOLOGICAL|PCV24 formulation 1|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
215033193|NCT06675032|BIOLOGICAL|PCV24 formulation 2|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
215033194|NCT06675032|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|"13-Valent Pneumococcal Polysaccharide Conjugate Vaccine:Dosage form: Injection Specification:0.5 mL/strip Dosage: The preferred site for infants is the anterolateral thigh (lateral femoral muscle), and for toddlers and children, the deltoid muscle of the upper arm.~Dosing schedule:6 weeks months: 4 doses, one dose each of basic immunization at 2, 4, and 6 months of age, and one dose of booster immunization at 12-15 months of age, with the earliest of the first dose being given at 6 weeks of age. The first dose should be given at 6 weeks of age at the earliest."
215033195|NCT06675032|BIOLOGICAL|Sodium Chloride Injection|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
215033196|NCT06675266|DIAGNOSTIC_TEST|Development of AI algorithm for early detection of fetal brain anomalies in the second trimester screening scan|Development of AI algorithm for early detection of fetal brain anomalies in the second trimester of pregnancy
215033197|NCT06674148|DRUG|Qifangfeixian granules|The experimental group was treated with Qifangfixian granules
215033198|NCT06674148|OTHER|Placebo|The control group was treated with placebo
215033199|NCT06674252|OTHER|Jiawei Bufei Tang granules|"Jiawei Bufei Tang is a traditional Chinese medicine formula applied by Professor Li Pingping to patients with lung cancer and qi yin deficiency syndrome. It consists of Huangqi, Codonopsis pilosula, Schisandra chinensis, Rehmannia glutinosa, Ziyuan, Mulberry bark, Snake berry, Half branch Lotus, White Hedyotis diffusa, etc. Bu Fei Tang is derived from the Yuan Dynasty's Yong Lei Ling Fang and consists of six ingredients: ginseng, astragalus, schisandra, Radix Rehmanniae, Ziyuan, and mulberry bark. It is mainly used to treat cough caused by lung qi deficiency. Jiawei Bufei Tang adds white Hedyotis diffusa, Scutellaria barbata, and snake berry to the original formula. White Hedyotis diffusa is more effective in dispelling carbuncles and detoxifying, Scutellaria barbata is more effective in dispelling phlegm and diuresis, and snake berry is more effective in dispelling scrofula and dispersing nodules, increasing the effect of clearing heat and detoxifying. This formula is particularly e"
215033200|NCT06674252|DRUG|Placebo|placebo
214283586|NCT00534430|DRUG|busulfan|
214283587|NCT00534430|DRUG|cyclosporine|
214470913|NCT03411096|PROCEDURE|Quadratus lumborum block with normal saline|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with normal saline (20cc) under ultrasound guidance.
214283588|NCT00534430|DRUG|etoposide|
214283589|NCT00534430|DRUG|mycophenolate mofetil|
214283590|NCT00534430|PROCEDURE|allogeneic bone marrow transplantation|
214283591|NCT00534430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214283592|NCT00534430|PROCEDURE|peripheral blood stem cell transplantation|
214283593|NCT00534430|RADIATION|total-body irradiation|
214470914|NCT06184997|OTHER|INTAKE OF ISOTONIC DRINK|Intake of natural isotonic drink based on 20% Atlantic sea water, mixed with lemon and stevia.
214470915|NCT06184997|OTHER|PLACEBO|Intake of natural mineral water
214283594|NCT06872671|OTHER|Experimental: Breathing Exercise Group|Eyes will be closed first. Head and neck will be relaxed. Breathing will be taken through the nose for three seconds. Then the breath will be held for three seconds. In the last step, breath will be exhaled through the mouth for three seconds. The patient will be instructed to take five normal breaths between each breathing exercise. The patient will be asked to count to three and will be told that he/she can count by using his/her fingers. The exercise will be started two minutes before the catheterisation procedure and the patient will be instructed to perform the breathing exercise twice. The patient will be asked to continue doing the breathing exercise until the PIC application process is completed.
214283595|NCT06872671|OTHER|Valsalva Manoeuvre Group|The valsalva manoeuvre will be performed by blowing into a plastic tube connected through a sphygmomanometer. Patients will be allowed to raise the manometer by 30 mmHg for at least 20 seconds. Care will be taken to ensure that the PIC procedure is performed by the same nurse for the patients in the Valsalva manoeuvre group. The nurses performing the PIC procedure will be informed about the research subject and will be told that the patients will start the valsalva manoeuvre before the PIC procedure. Patients who can perform the valsalva manoeuvre by the researcher will be included in the study. Haemodynamic variables (blood pressure, pulse, saturation) of the patients will be recorded before the valsalva manoeuvre. Afterwards, the researcher will instruct the patients to blow into the plastic tube for 20 seconds after a deep breath to create 30 mmHg pressure.
214283596|NCT06930534|DEVICE|Swoop Plus Mk2.0|portable brain MRI scanner
214283597|NCT06418724|DRUG|Cetuximab|Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR). EGFR is over-expressed in many human cancers, including colorectal cancers.
214283598|NCT06418724|DRUG|Cemiplimab|Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Engagement of PD-1 with its ligands PD-L1 and PD-L2, which are expressed by antigen presenting cells and may be expressed by tumour cells and/or other cells in the tumour microenvironment, results in inhibition of T cell function such as proliferation, cytokine secretion, and cytotoxic activity. Cemiplimab potentiates T cell responses, including antitumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.
214283599|NCT06781255|DRUG|Kamuvudine-9|96 mg tablets taken twice a day for 24 weeks
214283600|NCT07124429|OTHER|Reformer Pilates|Reformer pilates is a form of exercise that uses a specialized machine with a sliding carriage and springs to provide resistance. It is highly effective for improving core strength, flexibility, and muscle tone while also promoting better posture and balance.
214283601|NCT07124429|OTHER|conservative treatment|Conservative physiotherapy is a treatment approach that aims to manage pain and improve function using non-surgical methods. This treatment often includes methods like applying hot packs to relax muscles and increase circulation, and using a TENS (Transcutaneous Electrical Nerve Stimulation) device to help relieve pain.
214470916|NCT03760588|DRUG|Sacubitril/valsartan|Target dose 97/103 mg b.i.d .
214470917|NCT05997953|OTHER|Edinburgh Postnatal Depression Scale|Edinburgh Postnatal Depression Scale used as screening tool for postpartum depression
214470918|NCT02740634|DRUG|F-18 AV 1451|Tau binding agent
215033201|NCT06673732|OTHER|Muscle Energy Technique with Stationary Bi-Cyclying|"MET for post-isometric relaxation of the Achilles, calf, quads, hamstrings, and ankle, position each muscle at resistance, just short of pain. The patient contracts (10-20% effort) for 5-10 seconds while the therapist resists. After relaxing and exhaling, the therapist gently stretches the muscle to the new barrier. Repeat this process 2-3 times, gradually increasing the stretch with each repetition.~For PFS MET of the Achilles tendon, calf, quads, hamstrings, and ankle, contract the muscle maximally for 5-10 seconds while the therapist resists. Afterward, the muscle is relaxed, and the therapist quickly stretches it to the new barrier, holding for 10 seconds. Following a 20-second rest, repeat the process 3-5 times. For Reciprocal Inhibition MET, the muscle is placed mid-range, the patient pushes against resistance, then relaxes while the therapist stretches the muscle. This is repeated 3-5 times. Stationary cycling complements the routine."
215033202|NCT06673732|OTHER|Muscle Energy Technique without Stationary Cycling|MET for post-isometric relaxation of the Achilles, calf, quads, hamstrings, and ankle, position each muscle at resistance, just short of pain. The patient contracts (10-20% effort) for 5-10 seconds while the therapist resists. After relaxing and exhaling, the therapist gently stretches the muscle to the new barrier. Repeat this process 2-3 times, gradually increasing the stretch with each repetition. Post FS MET of the Achilles tendon, calf, quads, hamstrings, and ankle, contract the muscle maximally for 5-10 seconds while the therapist resists. Afterward, the muscle is relaxed, and the therapist quickly stretches it to the new barrier, holding for 10 seconds. Following a 20-second rest, repeat the process 3-5 times. For Reciprocal Inhibition MET, the muscle is placed mid-range, the patient pushes against resistance, then relaxes while the therapist stretches the muscle. This is repeated 3-5 times without Stationary Cycling
215033203|NCT06673719|RADIATION|99mTc-pertechnetate SPECT/CT|This procedure is similar to standard Meckel's diverticulum scan, with the addition of SPECT/CT acquisition to measure gastric volume.
215033204|NCT06673719|PROCEDURE|Combined High-Resolution Manometry-Nutrient Drink Test|Proximal gastric high-resolution manometry was done concurrently with nutrient drink test to measure proximal gastric function.
215033205|NCT04175015|OTHER|Smartie© sweet/candy|one chocolate sweet/ chocolate candy
215033206|NCT06675747|OTHER|Ultrasound imaging|To investigate the mechanism of action of occlusal splints, a routinely applied treatment method for myogenic temporomandibular disorders, ultrasound images will be taken from all patients before and after treatment, and measurements will be conducted based on these images.
214470919|NCT02740634|DRUG|C-11 PiB|Amyloid binding agent
214470920|NCT06145646|DEVICE|Muscle warm-up|Passive heating of the vastus lateralis of the right quadriceps will be performed using a microwave device. The device will be set at a power of 150 W and a distance of 10-15 cm from the skin surface for 20 minutes with the purpose of increasing local muscle temperature to 40 ºC.
214470921|NCT06006013|BIOLOGICAL|Pembrolizumab|Given IV
214470922|NCT06006013|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214470923|NCT06006013|DRUG|Cabozantinib S-malate|Given PO
214470924|NCT06006013|PROCEDURE|Computed Tomography|Undergo CT
214470925|NCT06006013|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214470926|NCT03476343|DEVICE|GE OPTIMA MR430s with HDx/GE Electronics|MRI scan
214470927|NCT03088878|DRUG|Cirmtuzumab (2-16 kg/mg) plus Ibrutinib|Participants will receive escalating doses of cirmtuzumab (2-16 mg/kg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily, starting at week 4.
214470928|NCT03088878|DRUG|Cirmtuzumab (300mg) plus Ibrutinib|Participants will receive cirmtuzumab (300 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
214470929|NCT03088878|DRUG|Cirmtuzumab (600 mg) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
214470930|NCT03088878|DRUG|Cirmtuzumab (RDR) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily
214470931|NCT03088878|DRUG|Cirmtuzumab plus ibrutinib|Arm A: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
215033207|NCT06673654|DRUG|Ruxolitinib Topical Cream 1.5%|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
215033208|NCT06673654|DRUG|OPZELURA (Ruxolitinib) Cream|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
215033209|NCT06673654|DRUG|Placebo|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
215033210|NCT06674551|PROCEDURE|Suprascapular nerve block and Axillary nerve block|A linear ultrasound probe will be placed in a sagittal plane at the superior medial border of the scapula. The probe will be moved laterally and then placed parallel to the scapular spine. when the needle tip contacts the bone just medial to the spinoglenoid notch and after confirmation of absence of vascular structure by color Doppler, 10 ml of 0.5% bupivacaine will be injected with aspiration every 3 ml to avoid intravascular injection and the spread of the local anaesthetic
215033211|NCT06674551|PROCEDURE|Interscalene Nerve Block|The ultrasound probe will be placed in the supraclavicular fossa in a transverse orientation, aimed caudad into the thoracic cavity, to visualize the brachial plexus near the subclavian artery. Once identified, the plexus will be followed cephalad where it is found within the brachial plexus fascial sheath in the interscalene groove.
215033212|NCT06681012|DEVICE|Gelsectan®|Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
215033213|NCT06681012|DRUG|Placebo|Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
215033214|NCT06680648|PROCEDURE|addition of oxygeninsufflation via working channel of flexible scope|addition of oxygeninsufflation via working channel of flexible scope in order to improve visibility when advancing the flexible scope
215033215|NCT06680648|PROCEDURE|no-oxygen insufflation|no-oxygen insufflation added to the flexible scope while advancing it
215033216|NCT03598829|DIAGNOSTIC_TEST|Tryptase, Serum test|Blood draw lab test which measures concentration of Tryptase in the sample. Tryptase is the one of the primary secretions of active mast cells and is used as a measure of inflammatory activity. Normal Reference Value: \&lt;11.5 ng/mL
214470932|NCT03088878|DRUG|Ibrutinib alone|Arm B: Participants will receive ibrutinib (420 mg) orally once daily
214470933|NCT03831256|DIAGNOSTIC_TEST|Traditional integrated prenatal screening|biochemical prenatal screening with or without nuchal translucency by US
214470934|NCT03831256|DIAGNOSTIC_TEST|Second-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS after a positive traditional prenatal screen
214470935|NCT03831256|DIAGNOSTIC_TEST|First-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS at first trimester
214470936|NCT03831256|DIAGNOSTIC_TEST|Invasive prenatal testing for fetal aneuploidy|amniocentesis or chorionic villi sampling (CVS)
214470937|NCT02657005|DRUG|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
214470938|NCT06278753|DIAGNOSTIC_TEST|carbon dioxide cystoscopy|Using carbon dioxide medium for filling bladder
214470939|NCT06794853|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|All patients were treated with Transjugular Intrahepatic Portosystemic Shunt (TIPS).
214470940|NCT04506866|DEVICE|InterStim Micro|Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use
214470941|NCT06821516|PROCEDURE|Evaluation of the postoperative analgesic effectiveness of PENG block in participants undergoing total hip arthroplasty under spinal anesthesia|Evaluation of the postoperative analgesic effectiveness of PENG block in participants undergoing total hip arthroplasty under spinal anesthesia
214470942|NCT06821516|PROCEDURE|Evaluation of the postoperative analgesic effectiveness of lumbar erector spinae block in participants undergoing total hip arthroplasty under spinal anesthesia|Evaluation of the postoperative analgesic effectiveness of lumbar erector spinae block in participants undergoing total hip arthroplasty under spinal anesthesia
214906858|NCT04524533|BEHAVIORAL|Experimental smoking cessation video|Participants who are randomized to the intervention group will watch an educational video that includes tips on quitting smoking during a dental cleaning. The video is approximately 10 minutes long and tailored to readiness to quit at the time of the dental visit.
214906859|NCT04524533|BEHAVIORAL|Control video|Participants randomized to the control group will watch a 10 minute video.
214906860|NCT04524533|OTHER|Brochure of smoking cessation EBTs|All participants will receive identical print materials on EBTs consistent with smoking cessation standard clinical care.
214906861|NCT04524533|BEHAVIORAL|Tailored text message program|Participants randomized to the intervention group will be enrolled in a 4-week tailored text message program which includes assessment questions in addition to text messages geared towards motivating and facilitating EBT utilization for individuals ready to quit smoking and individuals who are not ready to quit smoking.
214906862|NCT04524533|OTHER|Assessment text messages|Participants randomized to the control group will be enrolled in a different 4-week text message program that includes only assessment questions.
214906863|NCT07001410|OTHER|Age group|Observation of the outcomes by age groups.
214906864|NCT02792010|DEVICE|Hip cartilage MRI|Hip cartilage MRI
214906865|NCT07003295|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214906866|NCT07003295|PROCEDURE|Computed Tomography|Undergo PET/CT
214906867|NCT07003295|BIOLOGICAL|Glofitamab|Given IV
214906868|NCT07003295|BIOLOGICAL|Obinutuzumab|Given IV
214906869|NCT07003295|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214906870|NCT06676098|PROCEDURE|IANBD 3D guided approach|The IANBD will be used to administer the dental anesthetic 2mm medial to the lingula
214906871|NCT07004556|DIAGNOSTIC_TEST|Preoperative blood sampling for determining Phoenixin 14 levels|In addition to routine blood draws for pre-operative preparations, 5 ml of blood will be collected.
214906872|NCT07004556|DIAGNOSTIC_TEST|Postoperative blood sampling for determining Phoenixin 14 levels|In addition to routine blood draws for postoperative controls, 5 ml of blood will be collected.
214906873|NCT01555749|DRUG|NNC172-2021|One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
214906874|NCT01555749|DRUG|placebo|One injection administered subcutaneously (s.c., under the skin)
214906875|NCT02583451|DRUG|Placebo tablet matching lemborexant|Tablet form taken orally at bedtime.
214906876|NCT02583451|DRUG|Placebo tablet matching zopiclone|Tablet form taken orally at bedtime.
214906877|NCT02583451|DRUG|Zopiclone 7.5 mg|7.5 mg tablet taken orally at bedtime.
214906878|NCT02583451|DRUG|Lemborexant 2.5 mg|2.5 tablet taken orally at bedtime.
214906879|NCT02583451|DRUG|Lemborexant 5 mg|5 mg tablet taken orally at bedtime.
214906880|NCT02583451|DRUG|Lemborexant 10 mg|10 mg tablet taken orally at bedtime.
214906881|NCT06589570|DEVICE|Removable Partial Denture|A removable partial denture (RPD) is a dental prosthesis designed to replace one or more missing teeth in the mouth. Unlike full dentures, which are used when all teeth are missing, an RPD is specifically made for patients who still have some of their natural teeth remaining. It restores both function and aesthetics, allowing patients to chew, speak, and smile with greater confidence.
214906882|NCT04300062|PROCEDURE|Rebiopsy|Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.
214906883|NCT07007793|DRUG|Baxdrostat|Baxdrostat tablet administered orally, once daily (QD).
214906884|NCT07007793|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
214906885|NCT05556772|PROCEDURE|Biospecimen Collection|Collection of blood; urine; cervical, anal, vaginal samples
214906886|NCT05556772|OTHER|Interview|Attend interview
214906887|NCT06864780|OTHER|Posture Correction Exercises|This intervention focuses on improving forward head posture (FHP) through a series of corrective exercises aimed at enhancing cervical alignment, reducing muscle strain, and reinforcing proper posture habits. The exercises include chin tucks, cervical retraction with resistance bands, shoulder blade squeeze, and wall posture alignment. Participants will receive hot pack therapy (15-20 mins) for cervical muscle relaxation and TENS (10 mins) for pain relief before and after exercises. These exercises target deep cervical flexors and postural stabilizers to help retrain the neck and upper back muscles, promoting long-term postural correction. The intervention will be performed 3 times per week for 6 weeks under supervision, with a focus on maintaining correct postural alignment during daily activities.
214906888|NCT06864780|OTHER|Strengthening and Stretching Exercises|This intervention aims to address muscle imbalances associated with forward head posture (FHP) by incorporating stretching of tight muscles (upper trapezius, levator scapulae) and strengthening of weak postural muscles (deep neck flexors, scapular stabilizers). The exercises include upper trapezius stretch, levator scapulae stretch, deep neck flexor strengthening, and scapular retraction with resistance bands. Participants will undergo hot pack therapy (15-20 mins) for cervical muscle relaxation and TENS (10 mins) for pain relief before and after exercises. The stretching exercises will help release tension in overactive muscles, while strengthening exercises will restore muscular balance, improving posture and reducing neck discomfort. The intervention will be conducted 3 times per week for 6 weeks with supervised sessions to ensure proper technique and progressive improvement in flexibility and strength.
214906889|NCT01019343|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
214906890|NCT01019343|DEVICE|Eye-tracking Device|The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
214906891|NCT01019343|DEVICE|Pulsed vibrator|This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
214283602|NCT07132372|OTHER|Birth Memories and Recall scale|The data collection tools were applied to the participants by the researcher through face-to-face interviews. At the outset, the purpose of the study was explained to the participants. It was stated that participation in the study was completely voluntary and that they could withdraw from the study at any time. Then, their written and verbal consent was obtained.Participants who agreed to participate in the study, had no condition that would prevent communication, and had babies between the ages of 0 and 1 were included in the study.Data were collected using a personal information form, BIMF, PMBAS, and BirthMARQ.
214470943|NCT05613218|DRUG|Oxygen|"Patients will have nasal cannula or oxygen mask placed as the usual standard of care.~Patients will be screened and randomized in the emergency department to either liberal or restrictive oxygenation after providing informed written consent and oxygen is titrated to the prespecified target range using an automated feedback device (O2MATIC). Consented patients will be randomly allocated to study groups via the web-based system within REDCap. The allocation will be concealed. Time at randomization will be considered as study time zero (T0). All patients will receive usual standard of care except for their O2 management. The intervention will last for 24 h. After 24 h, patients will be switched over to usual care for oxygen therapy. If the treating physician thinks, that the patient need another oxygenation target and it is thought to be harmful to continue with the allocated target, the intervention-phase can be stopped prematurely."
214283603|NCT07133009|OTHER|Intentional Relationship Model (IRM) Training|"1 Theory: Brief introduction to the Intentional Relationship Model, therapeutic self-awareness, and explanation of therapeutic styles.~1. Practice: Students share their existing knowledge and thoughts about therapeutic styles, and discuss the practical implications of therapeutic styles that may be relevant to them.~2. Theory: Information about defining interpersonal characteristics and getting to know our clients~2 Practice: Sources of differences in client profiles in the client-therapist relationship, structuring questions appropriately, and practices for getting to know our clients better 3 Theory: Information about potential difficulties that may arise in the therapeutic process 3 Practice: Scenarios are played out about what can be done to address difficulties that may arise in the client-therapist relationship 4 Theory: Information about interpersonal reasoning skills and coping with difficulties 4 Practice: Strategies that can be used to create an appropriat"
214283604|NCT06508125|DRUG|cross-linked hyaluronic acid|cross-linked hyaluronic acid injection with physical therapy
214283605|NCT06508125|DRUG|non-cross-linked hyaluronic acid|non-cross-linked hyaluronic acid injection with physical therapy
214283606|NCT04122898|OTHER|Pelvic Floor Muscle Training|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the gymnasts in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (inward lift of the pelvic floor assessed with suprapubic 2D ultrasound) and instructions on how to perform the training program. The athletes will be offered at least one individual follow-up session with the same physiotherapist during the intervention period. The program will consist of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The athletes will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 3 months and the exercises will take approximately 10 minutes per day to perform.
214283607|NCT02113605|OTHER|Cognitive behavior therapy|Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
214283608|NCT04541940|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
214283609|NCT04541940|OTHER|In-person Rehabilitation Therapy|Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
214283610|NCT00968994|DEVICE|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
214470944|NCT06644716|DIAGNOSTIC_TEST|[18F]F-FAPI PET-CT|Each patient will receive a FAPI PET-CT.
215033217|NCT04180722|DEVICE|aTouchAway™ platform|Participants will receive multi-component Virtual Transition Intervention. The four components of the intervention comprise: (1) routine virtual clinic visits scheduled at the same frequency as usual care; (2) virtual care plan and action plan for respiratory infection/deterioration and management of ventilator issues; (3) remote, weekly and monthly monitoring of ventilator and cough assist metrics, VAI symptoms, and oxygen saturations; and (4) as needed clinical consultations triggered by identification of abnormal parameters or requested by the VAI or family caregiver.
215033218|NCT07011212|DIAGNOSTIC_TEST|BL-Predicter|To Clinically validate the BL-Predictor toll by a randomised conytrolled ttrial
215033219|NCT06674291|DRUG|No intervention (observational study)|This is an observational registry conducted in the real world clinical setting and there is no intervention in this study. Treatment of MDR-END Regimen and the follow-up of subjects will be conducted in the clinical judgment of the investigator.
215033220|NCT07009795|BEHAVIORAL|Rise & Renew Hybrid Grief Support Program|"The Rise \& Renew Hybrid Grief Support Program is a culturally responsive, multi-component behavioral intervention designed specifically for Black women aged 40 and older who have experienced the loss of a spouse, parent, or child. It integrates wellness practices, grief support, spiritual care, and community healing in a hybrid format that includes both an in-person and virtual component.~This intervention is distinguished by its cultural tailoring for middle-aged and older Black women, co-facilitation by both a trained facilitator and a faith-based leader, and its combination of expressive arts, spiritual guidance, and practical wellness strategies delivered in a hybrid format. It addresses grief holistically through emotional, physical, spiritual, and social dimensions, and emphasizes culturally relevant healing practices often overlooked in conventional grief programs."
215033221|NCT06675669|OTHER|Reflective thinking method|It will be applied to students in the initiative group for 1 hour per week for 7 weeks.
214283611|NCT00968994|DEVICE|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
214283612|NCT04998786|DRUG|Ixazomib|Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
214470945|NCT06007898|BEHAVIORAL|Parent self-help psychological resource|A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet.
214470946|NCT02333825|PROCEDURE|Medial patellofemoral ligament reconstruction surgery|Medial patellofemoral ligament reconstruction surgery using hamstring autograft
214470947|NCT02333825|OTHER|Physical therapy and rehabilitation|A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
214470948|NCT05214222|DRUG|Anlotinib/Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Anlotinib: once a day, 1 capsule each time (10mg for body weight \<60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~* Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
214283613|NCT04998786|DRUG|Iberdomide|Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
214283614|NCT04998786|DRUG|Dexamethasone Oral|Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
214283615|NCT01545986|BEHAVIORAL|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
214283616|NCT04247360|DEVICE|cuff pressure|maintaining cuff pressure according the groups
214283617|NCT04256070|BEHAVIORAL|education and tele-consultation|education and tele-consultation based on Watson's Human Care Theory
214283618|NCT04488900|DRUG|CKD-508 Capsule|Investigational drug
214283619|NCT04488900|DRUG|Placebo Capsule|Placebo
214283620|NCT04488900|DRUG|CKD-508 Tablet|Investigational drug
214283621|NCT04488900|DRUG|Placebo Tablet|Placebo
214283622|NCT04949477|DRUG|Dexmedetomidine|the patient will receive intranasal dexmedetomidine at a dose of 1 μg/kg to the patient 45 min. before the procedure.
214283623|NCT04949477|DRUG|paracetamol|the patient will receive paracetamol orally \[Rx paracetamol 250 mg/ml\] at a dose of 20 mg/kg given to the patient 45 min before the procedure by drinking.
214283624|NCT03937310|DIAGNOSTIC_TEST|Next-generation sequencing of swabs collected during surgery|Traditional swabs for culturing as well as swabs for NGS testing will be collected
214283625|NCT01499745|BEHAVIORAL|Pulmonary Rehabilitation|"Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation"
214283626|NCT03733795|OTHER|TCD|Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
214283627|NCT05329974|OTHER|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
214283628|NCT02998593|DRUG|Bahman capsules|Oral Use of Bahman capsules for 3 months by patients.
214283629|NCT02998593|DRUG|Placebo|Oral use of placebo capsules by patients for 3 months.
214283630|NCT02067169|BIOLOGICAL|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
214283631|NCT04250870|DIAGNOSTIC_TEST|Senior Fitness Test|"Chair stand test:The number of full stands performed on a seated position that can be completed within 30 seconds was recorded.~Arm curl test: The participants were asked to lift weights starting with a full elbow extension and then full flexion.~2-minute step test: The participant was asked to begin stepping as quickly as possible to reach the marked height for two minutes.~Chair sit-and-reach test:The participant could extend right or left knee to a full extension, heel on the floor and ankle in a neutral position of 90 degrees. Then, the participant was asked to reach to the toes.~Back-scratch test:The participant was asked to stand up and place his/her preferred hand over the same shoulder, palm down and fingers extended, and reach down the middle of the back as far as possible.~8-foot up and go test:The participant was asked to get up from a chair without any arm support and walk a distance of 2.44 meters; then turn around a cone and come back to sit down on the chair."
214283632|NCT01011634|DRUG|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
214906892|NCT01019343|OTHER|Gait Trainer Treadmill (GTT)|The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
214906893|NCT01019343|OTHER|Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA|Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
214283633|NCT05544357|OTHER|Short set configuration resistance training|Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
214470949|NCT05214222|DRUG|Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks Post-progression genetic testing, continued treatment: Anlotinib,Penpulimab Anlotinib: Once daily, one capsule per time (10mg for weight \<60KG, 12mg for weight ≥60KG), administered from day 1 to day 14 of each cycle. Two consecutive weeks of treatment followed by one week off, 3 weeks per treatment cycle.~Penpulimab: 200mg, administered on day 1 of each cycle, every 3 weeks."
214283634|NCT05544357|OTHER|Long set configuration resistance training|Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
214283635|NCT00751829|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
214283636|NCT00751829|DRUG|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
214283637|NCT03147014|BIOLOGICAL|Maternal hyperoxygenation|approximately 10-15 minutes of maternal hyperoxygenation
214283638|NCT00309387|DIETARY_SUPPLEMENT|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
214283639|NCT00309387|OTHER|Placebo|placebo tablets manufactured to mimic Centrum tablets.
214283640|NCT01357187|OTHER|Scheduled removal of posterior instrumentation with AmnioFix|
214283641|NCT01357187|OTHER|Scheduled removal of posterior instrumentation without AmnioFix|
214283642|NCT00616200|OTHER|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
214283643|NCT01450436|OTHER|Peapod assessment|"EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old)."
214283644|NCT04498013|DRUG|Cyclodynon|Cyclodynon 1 tablet a day during 6 menthes period.
214283645|NCT04498013|BEHAVIORAL|Lifestyl modification|Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
214470950|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go (TUG single-task)|The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
214470951|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go dual-task (TUGdt)|Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
214906894|NCT01019343|DEVICE|iMobility|This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
214283646|NCT02483520|BEHAVIORAL|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
214283647|NCT05360381|DRUG|HLX35|A Recombinant Human Anti-EGFR and Anti-4-1BB Bispecific Antibody, HLX35 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
214283648|NCT01713972|DRUG|dabrafenib|Given PO
214283649|NCT01713972|DRUG|pazopanib hydrochloride|Given PO
214283650|NCT01713972|OTHER|Correlative studies|"Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
214283651|NCT01382953|DEVICE|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
214283652|NCT01356472|DRUG|Imipenem/cilastatin|the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
214283653|NCT00613249|DRUG|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
214283654|NCT00613249|DRUG|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
214283655|NCT00613249|DRUG|HEC-based Placebo Gel|intravaginal gel, dosed daily
214283656|NCT01633333|OTHER|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
214283657|NCT01633333|OTHER|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
214283658|NCT00786682|DRUG|docetaxel|
214283659|NCT00786682|DRUG|hydroxychloroquine|
214283660|NCT06306040|DRUG|Nalbuphine Versus Magnesium Sulfate|"Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions."
214283661|NCT02835807|BEHAVIORAL|Health Chat including Indoor Tanning|Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.
214283662|NCT02835807|BEHAVIORAL|Health Chat excluding Indoor Tanning|In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
214283663|NCT04492618|DRUG|Ruxolitinib|Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
214283664|NCT00338689|DIETARY_SUPPLEMENT|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
214283665|NCT01948622|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
214283666|NCT01948622|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
214283667|NCT03152851|PROCEDURE|Pressure stimulus group|
214283668|NCT02079181|RADIATION|fluorine F 18 d-FMAU|Given IV
214283669|NCT02079181|PROCEDURE|positron emission tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
214283670|NCT02079181|PROCEDURE|computed tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
214283671|NCT00789139|DEVICE|ICM Implantation|Sub cutaneous implantation of the ICM
214283672|NCT06045767|DRUG|Pembrolizumab 50 MG Injection [Keytruda]|Chemo-immunotherapy combination
214283673|NCT05551559|PROCEDURE|bariatric surgery|bariatric surgery
214283674|NCT02689388|PROCEDURE|Femoral Nerve Block|Use of femoral nerve block as part of general anesthesia
214470952|NCT05893524|DIAGNOSTIC_TEST|Clinical functional assessment|The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
214283675|NCT01401283|DEVICE|measurement of cardiac output and pulse pressure variation|hemodynamic optimization according to cardiac index and pulse pressure variation
214283676|NCT02968407|OTHER|Peer- and self-rating|Participants will be given a print and a e-mail of the modified OSATS global rating scale and will be introduced to how the rating scale is used to rate technical performance. The participant will receive a USB stick each allowing the participant to see a video of his/her own performance and two videos from previous post-test performances from participants enrolled in the course. One video is a video of a participant who performed poorly,the other is from a participant who performed well. The participants will be asked to watch and rate the videos of their peers' performance first and afterwards watch and rate the participants own video performance. The investigators choose to let the participants rate their peers' performances before their own, so the participants will have the best opportunities to self-rate. Participants will be asked to email the results of their ratings to the principal investigator within 3 days. And expert in surgery will also rate the videos using OSATS.
214283677|NCT03012906|OTHER|the prevalence of ischemic events|
214283678|NCT02181023|DRUG|Aclidinium Bromide|Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
214283679|NCT02181023|DRUG|Glycopyrronium Bromide|Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
214283680|NCT03571269|PROCEDURE|Optical coherence tomography-guided reperfusion strategy|Optical coherence tomography will be used to detect the detailed characteristics of culprit lesion and to decide and optimize the reperfusion strategy according to the established algorithm in the protocol.
214470953|NCT05822635|DEVICE|SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System|Observational, prospective study for the clinical utility of the SpyGlass Discover Digital Catheter and the SpyScope DS Catheter during an intraoperative endoscopy procedure.
214470954|NCT03899636|DRUG|Modified FOLFIRINOX Regimen|Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
214470955|NCT03899636|DEVICE|NanoKnife System|IRE using NanoKnife System
214470956|NCT05191264|OTHER|EQ5D (EuroQol 5 Dimensions)|The evaluation of the quality of life was conducted with the EQ5D (EuroQol 5 Dimensions) score (min 0: bad health and max:100 good health).
214470957|NCT05191264|OTHER|Numerical Rating Scale (NRS)|the type and intensity of pain will be evaluated by Numerical Rating Scale (NRS) from 0 to 10 in different positions and in different activities (e.g. background pain, general maximum/minimum pain, pain of the site treated by the procedure, pain at rest, in lying position, in sitting position, in standing position, at bearing weight, in walking, description of painful irradiations, nocturnal awakenings).
214283681|NCT04183595|DRUG|(N1, N3-bis(2- mercaptoethyl)isophthalamide)|600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
214283682|NCT04183595|OTHER|Excipients microcrystalline cellulose, silica and magnesium stearate|6 Capsules will be administered every 24 hours for 14 days.
214283683|NCT00399854|DEVICE|Dhermia® - Industra Mecânica Fina Ltda|
214283684|NCT01288495|DIETARY_SUPPLEMENT|supplemental L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
214283685|NCT01288495|DIETARY_SUPPLEMENT|Metamucil|Subjects will consume the placebo prior to eating fructose-containing foods.
214283686|NCT01829334|OTHER|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
214283687|NCT01829334|OTHER|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
214283688|NCT01829334|OTHER|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
214283689|NCT01829334|OTHER|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
214470958|NCT05191264|OTHER|evaluated the consumption of analgesics|the consumption of analgesics by step and by dosage will be evaluated.
214283690|NCT02396433|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle.
214283691|NCT02396433|DRUG|Eribulin|Eribulin will be given on days 1 and 8 of each cycle.
214283692|NCT02396433|DRUG|E7449|E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
214283693|NCT03991715|BEHAVIORAL|Activity Tracker|Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
214283694|NCT02111772|BIOLOGICAL|Rhinovirus|
214283695|NCT00372125|DRUG|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
214283696|NCT04648956|OTHER|Standard treatment|Participants shall fill the ICOAP-Ar questionnaire three times within one month in addition to other questionnaires including the KOOS/HOOS, and the Global Rating of Change Scale (GRoC). The first two times will be within a time frame of 48-72 hours. The third time will be after one month.
214283697|NCT06164223|DEVICE|VR Baby Pump|VRBaby-Pump application is a video application specially prepared with virtual reality glasses and a milking pump placed inside a toy doll. In the video content, the mother is breastfeeding her baby on an armchair in the baby room prepared for a newborn baby.
214283698|NCT03723759|DRUG|Faster Aspart 200 U/mL|A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
214470959|NCT06315842|OTHER|Levels of Diagnostic and Therapeutic Intervention tool by Fontecha and col.|During the intervention periods, participating physicians will integrate into their usual clinical practice a tool for adjusting diagnostic and therapeutic intensity designed by Fontecha-Gómez and colleagues. The tool for adjusting the level of diagnostic and therapeutic intensity classifies patients' profiles into 5 groups based on the recommended level of adjustment.
214470960|NCT06315842|OTHER|Usual clinical practice|The participating physicians will carry out the standard clinical practice currently performed in the study centers. This means that during this period, the diagnostic and therapeutic adjustment tool or any similar tool will not be introduced into routine clinical practice.
214470961|NCT06801548|PROCEDURE|Esthetic crown lengthening surgery|Esthetic crown lengthening surgery using mock-up based guide
214470962|NCT06801548|PROCEDURE|Esthetic crown lengthening surgery using Digital guide|Esthetic crown lengthening surgery using digital guide based on DSD and CBCT
214470963|NCT04465344|DEVICE|Implantation of trifocal IOL, Isatis TF (device under investigation)|Patients will be implanted with study IOL in both eyes
214470964|NCT04465344|DEVICE|Implantation of monofocal IOL, Isatis (control device)|Patients will be implanted with Control IOL in both eyes
214470965|NCT04275869|OTHER|Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
214470966|NCT04001543|DIETARY_SUPPLEMENT|Immunomodulating oral supplementation|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
214283699|NCT03723759|DRUG|Faster aspart 100 U/mL|A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
214283700|NCT04190615|DIAGNOSTIC_TEST|thromboelastometry test (TEM test)|TEM test from the whole blood sample
214283701|NCT02845544|OTHER|Pilates-based exercises|
214283702|NCT01366690|BEHAVIORAL|Peer Support|A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
214283703|NCT03505762|DRUG|Cyclophosphamide|Given IV
214283704|NCT03505762|DRUG|Doxorubicin Hydrochloride|Given IV
214283705|NCT03505762|OTHER|Laboratory Biomarker Analysis|Correlative studies
214283706|NCT03505762|DRUG|Prednisone|Given PO
214283707|NCT03505762|OTHER|Quality-of-Life Assessment|Ancillary correlative
214283708|NCT03505762|OTHER|Questionnaire Administration|Ancillary studies
214283709|NCT03505762|BIOLOGICAL|Rituximab|Given IV
214283710|NCT03505762|DRUG|Vincristine Sulfate|Given IV
214283711|NCT03026101|OTHER|Nitroglycerin|Intra-arterial adminstration to dilate external carotid artery branches to replicate migraine pain
214470967|NCT04001543|DIETARY_SUPPLEMENT|Sip feed control|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
214470968|NCT05366712|DEVICE|Stryker Trident® II HA coated cementless acetabula component|New acetabula component.
215033222|NCT07010588|DEVICE|non-contrast abbreviated MRI (NC-AMRI)|Non-contrast abbreviated MRI (NC-AMRI) examination include T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI), which takes 10 minutes approximately.
214283712|NCT02941978|BEHAVIORAL|Motivational interview|Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge
214283713|NCT02941978|BEHAVIORAL|Control|Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
214283714|NCT05590013|DRUG|Pectointercostal and ESP block|Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
214283715|NCT05225766|OTHER|bupivacaine|used for peripheral block
214283716|NCT06054698|DRUG|HRS9531 injection|HRS9531 injection , QW，36 weeks
214283717|NCT06054698|DRUG|HRS9531 injection Placebo|HRS9531 injection Placebo，QW，36 weeks
214283718|NCT05163600|OTHER|Blod flow restriction training|includes one strength and one endurance training
214283719|NCT05285982|DRUG|Nintedanib (Ofev®)|Nintedanib (Ofev®) soft capsules
214283720|NCT01484847|DRUG|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
214283721|NCT02847832|OTHER|Standardized transvaginal ultrasound examination|
214283722|NCT06499077|DIAGNOSTIC_TEST|Sampling of exhaled breath|Exhaled breath of all participants is collected following our standardized procedure
214283723|NCT06433869|DRUG|serplulimab|Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.
214283724|NCT06433869|DRUG|Bevacizumab|Intraperitoneal injection of bevacizumab is added to PD-1 inhibitor or rmhTNF-NC.
214283725|NCT06433869|DRUG|rmhTNF-NC|Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.
214283726|NCT04517812|OTHER|Exercise-based games via the VirtualRehab platform|A 12-week exercise-based home rehabilitation intervention delivered via the VirtualRehab platform. A personalised exercise-based rehabilitation plan will be created for each participant.
214283727|NCT02487602|DEVICE|Gelesis100|Gelesis100 capsules
214283728|NCT02487602|OTHER|Placebo|Sucrose (sugar) capsules
214283729|NCT01024634|BEHAVIORAL|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
214283730|NCT03651921|BEHAVIORAL|CTS-BC-CH|"CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants.~Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making."
214283731|NCT02789709|PROCEDURE|Surgery|Segmental resection for colon cancer and anterior resection in patients with rectal cancer
214283732|NCT02376361|DEVICE|Transonic|"Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).~1. Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines~2. Recirculation, access flow will be performed according to HD03 Manual.~3. Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist."
214283733|NCT02101060|OTHER|exercise|16-week progressive aerobic and resistance exercise training
214283734|NCT03733002|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
214283735|NCT03733002|DRUG|Placebo of AngongNiuhuang pill|This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
214283736|NCT03733002|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke.
214283737|NCT06102759|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
214283738|NCT02302027|DEVICE|platinium IRC9LXO2AWQ|high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 \* 67 \* 36 cm
214470969|NCT06823622|BEHAVIORAL|Stepstones transition program|"The STEPSTONES transition program is an 8-component intervention designed to support adolescents with chronic conditions transitioning to adult care. It includes: a transition coordinator (TC), education about the condition, phone support, guidance on transitioning to adult care, parental guidance, peer meetings, a personalized transition plan, and the actual transfer to adult care. The intervention is implemented in five steps, starting with outpatient visits and culminating in the transfer to adult care. Delivered via the Mitt vårdmöte digital platform, the program includes the HEADDDSS adolescent health interview and is conducted by trained specialized nurses."
214470970|NCT04911296|OTHER|Mock-RP|Standard 000 capsule filled with potato starch, enteric-coated with colorant and lubricious coating.
214283739|NCT03604380|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
214283740|NCT03604380|OTHER|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
214283741|NCT00736684|DEVICE|Proximal Femoral Nail AntirotationTM (PFNA)|intramedullary nailing
214283742|NCT00736684|DEVICE|Gamma Nail 3TM (Gamma3)|intramedullary nailing
214283743|NCT00949897|DEVICE|Biofoam|Device
214283744|NCT00949897|OTHER|Iliac Crest Allograft with locked plate|
214283745|NCT03829982|BEHAVIORAL|Exposure to bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
214283746|NCT03829982|BEHAVIORAL|Exposure to dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
214283747|NCT03761160|OTHER|Mobile Health App|mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit
214283748|NCT03761160|OTHER|Usual care|Usual care per hospital guidelines
214283749|NCT01880398|OTHER|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
214283750|NCT05033353|DIAGNOSTIC_TEST|Monitoring of regional cerebral oxygenation|Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
214283751|NCT00859404|DRUG|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
214283752|NCT06211478|DRUG|Vitamin E|Vitamin E will be taken for 6 months for gaucher disease patients who have oxidative stress and vitamin E defecient
214283753|NCT03988985|OTHER|Patient-targeted feedback|The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
214283754|NCT03988985|OTHER|GP-targeted feedback|The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
214283755|NCT03291054|DRUG|Pembrolizumab|Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
214283756|NCT03291054|DRUG|Epacadostat|Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
214283757|NCT02321644|DRUG|CC-90001|CC-90001 Active-ingredient-in-capsule and formulated tablet
214283758|NCT06304194|OTHER|Analysis of biological samples|"The collected biological sample will be isolated and the specific nucleic acid (DNA/RNA/cfDNA) extracted for molecular analysis for understanding the reproducibility of the analysis and thus the feasibility of centralization:~* hot spot on DNa (ddPCR/Sanger)~* fusion genes on RNA (target resequencing)~* Known mutation analysis by liquid biopsy (cfDNA) for somatic mutations with a mutation frequency of less than 10%~* Tumor type-associated gene sequence analysis by Sanger sequencing and NGS"
214283759|NCT04246008|OTHER|Neuromuscular training|The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.
214283760|NCT04246008|OTHER|Conventional strength training|The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes
214283761|NCT01246401|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
214283762|NCT00048555|DRUG|IDEC-114|Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions
214283763|NCT03462082|OTHER|Asymmetric STN-DBS|Asymmetric deep brain stimulation
214283764|NCT04540224|DIAGNOSTIC_TEST|Flow-Cytometric analysis|Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33
214283765|NCT02931487|BEHAVIORAL|Attentional Bias Modification|Computerized
214283766|NCT02931487|BEHAVIORAL|Sham Comparator|Computerized
214283767|NCT02031107|DEVICE|cTBS|
214283768|NCT02031107|DEVICE|cathodal tDCS|
214283769|NCT02031107|DEVICE|sham stimulation|
214283770|NCT04380168|PROCEDURE|Modified pec11 trunk block|Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
214283771|NCT00637481|DRUG|atorvastatin calcium|Given orally
214283772|NCT00637481|OTHER|laboratory biomarker analysis|Correlative studies
214283773|NCT04077983|DRUG|combined therapy using nab-paclitaxel and gemcitabine chemotherapy|"1. Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~2. Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~3. Three weeks is a course of treatment with a total of 4 courses."
214283774|NCT00925912|PROCEDURE|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
214283775|NCT00925912|PROCEDURE|Perianal block|0.25% bupivacaine injected at perianal region
214283776|NCT01705639|DRUG|Melatonin|All subjects receive the same dose of melatonin
214283777|NCT00166114|DRUG|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
214283778|NCT00166114|DRUG|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
214283779|NCT02093832|OTHER|There are no specific Intervention|are no specific Intervention
214283780|NCT05496257|OTHER|direct pulp capping in primary molars|caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
214283781|NCT02335294|DRUG|TRV130|Rescue: Ibuprofen, oxycodone
214283782|NCT02335294|DRUG|Morphine|Rescue: Ibuprofen, oxycodone
214283783|NCT02335294|DRUG|Placebo|Rescue: Ibuprofen, oxycodone
214283784|NCT00545168|DRUG|Spinosad|10 minute topical application of product, followed by a complete rinse off.
214283785|NCT00545168|DRUG|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
214283786|NCT00545168|DRUG|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
214283787|NCT01218204|DRUG|10mg atorvastatin|10mg
214283788|NCT01218204|DRUG|80mg atorvastatin|80mg
214283789|NCT01218204|DRUG|GSK1292263 Placebo|Placebo
214283790|NCT01218204|DRUG|100mg GSK1292263|100mg
214283791|NCT01218204|DRUG|300mg GSK1292263|300mg
214283792|NCT01218204|DRUG|800mg GSK1292263|800mg
214283793|NCT01218204|DRUG|10mg ezetimibe|10mg
214283794|NCT01218204|OTHER|Washout|No interventions - washout period
214283795|NCT00335673|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
214283796|NCT04012775|BIOLOGICAL|Insulin Humulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
214283797|NCT04012775|BIOLOGICAL|Insulin Rinsulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
214283798|NCT05615272|BIOLOGICAL|Bio-PRF|Intervention group
214283799|NCT05615272|DRUG|Alveogyl|Control group
214283800|NCT03516994|BEHAVIORAL|Respecting Choices First Steps|Advance Care Planning Approach
214283801|NCT03516994|BEHAVIORAL|Five Wishes Form|Advance Care Planning Approach
214283802|NCT06436482|DEVICE|Optical Coherence Tomography|Placing the probe of OCT in RB10c through the working channel of bronchoscope for real time dynamic scanning and collecting OCT parameters from participants in different groups.
214283803|NCT02122250|BEHAVIORAL|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
214283804|NCT02122250|BEHAVIORAL|Static web-based materials|Static web-based materials
214283805|NCT04554667|BEHAVIORAL|Exercise Intervention|Heavy Lifting Strength Training
214283806|NCT03251768|DRUG|rHSA-GCSF 2.4mg|Human Serum Albumin GCSF 2.4mg at day 3 and day 7
214283807|NCT03251768|DRUG|GCSF|GCSF 5 mcg/kg/day
214470971|NCT03979924|BEHAVIORAL|Trismus rehabilitation|"The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,…) in order to strengthen the stretching."
214470972|NCT05336682|PROCEDURE|Lesion Sterilization and Tissue Repair with radicular instrumentation|Coronal and accessible radicular pulp tissue are extirpated using rotary files. After proper drying, the paste is placed in the cavity and the canals.
214470973|NCT05336682|PROCEDURE|Lesion Sterilization and Tissue Repair without radicular instrumentation|Only the coronal pulp is removed, the pulpal floor is covered with triple antibiotic paste with propylene glycol mix.
214470974|NCT05336682|PROCEDURE|Conventional pulpectomy|Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of ZOE.
214283808|NCT00799604|DRUG|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (\<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
214283809|NCT02838303|OTHER|Organophosphate|Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
214283810|NCT02838303|OTHER|Placebo|Multineem, WHO Class U: Unlikely to present acute hazard in normal use
214283811|NCT02216188|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
214283812|NCT02216188|OTHER|Control|Untreated control group
214283813|NCT04348773|PROCEDURE|Dehydration|Dehydration of the natural tooth by tooth isolation
214283814|NCT04348773|PROCEDURE|Rehydration|Rehydration
214283815|NCT00960778|DRUG|nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
214283816|NCT00960778|OTHER|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
214283817|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing=no|
214283818|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing = yes|
214283819|NCT00127660|BEHAVIORAL|Menu: calories=no, value pricing = no|
214283820|NCT01919125|DRUG|IDX719|IDX719 supplied as 50 mg tablets.
214283821|NCT00775424|BIOLOGICAL|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
214283822|NCT00775424|BIOLOGICAL|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
214283823|NCT00775424|BIOLOGICAL|PLACEBO|PLACEBO
214283824|NCT00775424|BIOLOGICAL|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
214283825|NCT02685085|DRUG|Misoprostol ( Prostaglandin E2)|
214283826|NCT02685085|DEVICE|Foley's catheter|
214283827|NCT02427893|DRUG|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
214283828|NCT02427893|DRUG|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
214906895|NCT01019343|DEVICE|QMAT|The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
214283829|NCT03763214|DEVICE|Stenting with PTFE-coated stent (HILZO)|Placing a metal stent in the biliary tract by duodenoscopy
214283830|NCT01987505|DRUG|Rituximab|1400 mg will be injected subcutaneously (SC).
214283831|NCT00035334|DRUG|NC-503 (Anti-amyloidotic (AA) Agent)|
214283832|NCT04829396|OTHER|placebo|Powder consisting of 13 g of digestible carbohydrates with similar appearance as the investigational fibre mixture.
214283833|NCT04829396|DIETARY_SUPPLEMENT|Fibre mixture|The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day.
214283834|NCT05506891|BEHAVIORAL|Physical therapy group|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
214283835|NCT05506891|DRUG|Astragalus|After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
214283836|NCT04224649|DEVICE|HARA Filler(Hyaluronic acid Filler)|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
214283837|NCT04224649|DEVICE|Restylane® Lidocaine|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
214470975|NCT06123962|PROCEDURE|Collect peripheral blood and bronchoalveolar lavage fluid|"Peripheral venous blood will be collected and stored from the study participants at a total of five time points: Day 0, Day 1, Day 2, Day 3 after admission to the ICU, and the day of ICU discharge/death. The collection will be conducted after assessing the patients' eligibility for ARDS diagnosis. Each time point will involve the collection of one tube of peripheral venous blood, totaling 5 mL per sample.~Within 24 hours after patients' admission to the ICU and meeting the assessment criteria for ARDS diagnosis, bronchoalveolar lavage fluid (BALF) will be collected and retained, totaling 10 mL."
214470976|NCT03171545|BEHAVIORAL|Patient Activation|Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
214470977|NCT03171545|BEHAVIORAL|Provider Education|Staff in clinics assigned to this group will receive team training and a checklist.
214470978|NCT06357169|DEVICE|Venus Glow|two treatments over a one week period. At the first visit they will complete an initial questionnaire regarding current scalp care practices, skin type, and hair type. An initial baseline scalp swab and HairMetrix photography in the two swab sites will be taken at the beginning of this visit. Treatment with the Venus Glow™ device will also occur. To treat, the scalp will be divided into four quadrants. Swab samples will be collected at the first baseline and concurrent treatment session, second treatment session and 3-6 days after the last treatment when participants have returned to their usual cleansing routine.
214470979|NCT06823427|DRUG|9MW2821|a nectin-4 ADC with MMAE payload
214283838|NCT05735015|DRUG|encaleret|Oral administration, twice a day
214283839|NCT04617002|DRUG|ONC201 (dordaviprone)|ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist.
214283840|NCT04930016|BEHAVIORAL|Quality of life diagnosis and therapy during the completed RCT DIQOL|Quality of life measurement, diagnosis, and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
214283841|NCT05131646|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
214283842|NCT02988531|OTHER|PET/MR scan|Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
214283843|NCT03132207|OTHER|Non interventionel study|Only one questionnaire will be done for women and professional
214283844|NCT06299826|DRUG|AZD5462|Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.
214283845|NCT06299826|DRUG|Placebo|Participants will receive matching doses of film-coated tablets of Placebo OD orally.
214283846|NCT06513949|BIOLOGICAL|Atibuclimab|monoclonal antibody against human CD14
214283847|NCT06513949|OTHER|Placebo|Sterile normal saline for injection
214283848|NCT06220201|DRUG|CC-97540|Specified dose on specified days
214283849|NCT06220201|DRUG|Fludarabine|Specified dose on specified days
214283850|NCT06220201|DRUG|Cyclophosphamide|Specified dose on specified days
214470980|NCT06823427|DRUG|Toripalimab (JS001 )|anit-PD-1 antibody
214470981|NCT06823869|OTHER|musical book|The child will indicate that he wants to play with the musical book. The child will play with toys for 5 minutes before treatment. Once the child is ready, inhaler medication will begin and the treatment will last 10 minutes. The treatment is terminated at the end of the 10th minute. The child's playing time with the toy is approximately 15 minutes.
214283851|NCT03030924|DEVICE|Solace|Noninvasive physiologic monitor
214283852|NCT03266107|DEVICE|Intracept|Radiofrequency ablation of the basivertebral nerve using the Intracept System
214283853|NCT01503151|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
214283854|NCT01503151|BEHAVIORAL|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
214283855|NCT01503151|BEHAVIORAL|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
214283856|NCT01503151|BEHAVIORAL|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
214283857|NCT06064006|DRUG|NNC0487-0111|NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
214283858|NCT06064006|DRUG|Placebo (NNC0487-0111)|Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
214470982|NCT06823869|OTHER|musical piano|The child will indicate that he wants to play with the musical piano. The child will play with toys for 5 minutes before treatment. Once the child is ready, inhaler medication will begin and the treatment will last 10 minutes. The treatment is terminated at the end of the 10th minute. The child's playing time with the toy is approximately 15 minutes.
214283859|NCT06089291|DEVICE|Persona IQ|"Persona IQ is a system comprised of the following subsystems:~1. RTM utilizing mymobility® patient application and care team dashboard,~2. PPK System with~3. CTE Extension Implant and Instrumentation,~   1. Surgical Base Station System,~  2. Home Base Station System,~  3. Canary CDMP,~  4. Canary CMGP software module, and~4. The ZBEdgeTM Connected Artificial Intelligence data platform.~The system combines physical components, electronics, software, and user interfaces to collect, store, analyze, transmit, and display patient data for use by both physicians and patients."
214470983|NCT06823869|OTHER|sham|The child will not play with toys during treatment. Before the treatment, the researcher demonstrates the process on himself with a nebul mask. Treatment begins after the child is ready. The process will take 10 minutes.
214283860|NCT03454997|OTHER|training including in-person and online|training, motivational interviewing practice
214283861|NCT03454997|OTHER|organizational strategy meetings|meetings with leadership to optimize implementation of evidence-based practices
214283862|NCT03454997|OTHER|performance coaching|to enhance ability to deliver the weight management intervention
214283863|NCT03784729|OTHER|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. For the bilateral BL25, sterile disposable steel needles (Huatuo, Suzhou, China; 0.3 mm×75 mm) will be inserted to a depth of 50-70mm until until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Huatuo, Suzhou, China; 0.3 mm×40 mm) will be inserted to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi. It should be noted that the needle at KI3 will be inserted at an angle of 45°obliquely downward. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session."
214283864|NCT03784729|OTHER|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm .No manipulation of needles without deqi will be conducted. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
214283865|NCT01191801|DRUG|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
214283866|NCT01191801|DRUG|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
214283867|NCT00740805|DRUG|Cyclophosphamide|Given IV
214283868|NCT00740805|DRUG|Doxorubicin Hydrochloride|Given IV
214283869|NCT00740805|OTHER|Laboratory Biomarker Analysis|Correlative studies
214283870|NCT00740805|OTHER|Pharmacological Study|Correlative studies
214283871|NCT00740805|DRUG|Veliparib|Given PO
214283872|NCT03348956|DIAGNOSTIC_TEST|EPR Oximetry|Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
214283873|NCT03731780|OTHER|Personalized Treatment|Targeting individual caries risk factors
214283874|NCT03731780|OTHER|Chlorhexidine and Remineralization|chlorhexidine mouth wash and remineralizing agent
214283875|NCT03731780|OTHER|Control|Control is standard preventive measures (tooth brushing, fluoride tooth paste, interdental cleaning)
214283876|NCT00934973|DRUG|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
214283877|NCT00934973|DRUG|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
214283878|NCT00934973|DRUG|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
214283879|NCT00934973|BEHAVIORAL|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
214283880|NCT00934973|BEHAVIORAL|No website|No CBT website
214283881|NCT00934973|BEHAVIORAL|CBT website with minimal support|
214283882|NCT00694993|DRUG|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
214283883|NCT00694993|DRUG|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
215033223|NCT07010588|DEVICE|enhanced abbreviated MRI (E-AMRI)|E-AMRI examination (using gadoxetic acid disodium) including T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI)and hepatobiliary phase (HBP) images, which takes 15 minutes approximately.
214283884|NCT05220202|BEHAVIORAL|Behavioral Intervention Group (MOTIVATE)|Behavioral: Behavioral Intervention Group (MOTIVATE) The behavioral intervention is designed for older Veterans with musculoskeletal pain and depression and will include 8 individual telephone sessions delivered by health coaches (for up to 5 months total), accounting for additional time between sessions (if needed).
214283885|NCT05068102|DRUG|BI 765063|BI 765063
214283886|NCT05068102|DRUG|Ezabenlimab|Ezabenlimab
214283887|NCT05068102|DRUG|[89Zr]Zr- BI 765063|\[89Zr\]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)
214283888|NCT05068102|DRUG|BI 770371|BI 770371
214283889|NCT05068102|DRUG|[89Zr]Zr- BI 770371|\[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET
214283890|NCT00114101|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
214283891|NCT00114101|OTHER|Laboratory Biomarker Analysis|Correlative studies
214283892|NCT00114101|DRUG|Lenalidomide|Given PO
214283893|NCT00114101|DRUG|Melphalan|Given IV
214283894|NCT00114101|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
214283895|NCT00114101|OTHER|Placebo Administration|Given PO
214283896|NCT06517693|DRUG|PGT121.414.LS|Administered SC in the thigh
214283897|NCT06517693|DRUG|VRC07-523LS|Administered SC in the thigh
214283898|NCT03210376|DRUG|Deep Neuromuscular Blockade (NMB)|Deep Neuromuscular Blockade (NMB) given during surgery.
214283899|NCT03210376|DRUG|Moderate Neuromuscular Blockade (NMB)|Moderate Neuromuscular Blockade (NMB) given during surgery.
214283900|NCT03210376|DRUG|Sugammadex|4 mg/Kg, intravenously as a single bolus injection after surgery.
214283901|NCT03210376|DRUG|Neostigmine|70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
215033224|NCT07010237|DRUG|Dose-attenuated IST and Hetrombopag|Porcine-ATG : 15 mg/kg/day IV ×5 days. Cyclosporine : 3-5 mg/kg/day (adjusted to trough 100-200 μg/L). Hetrombopag: 15 mg daily for 24weeks.
214283902|NCT03210376|BEHAVIORAL|Pain Assessment|Pain assessment done at about 15, 45, and 90 minutes after surgery.
214283903|NCT06421428|OTHER|LEI Interview|"In accordance with the IPA (Interpretative phenomenological analysis) methodology, a semi-structured interview outline will be defined, aimed at understanding the lived experiences of women (lived experience) during their coexistence with urinary incontinence and during the treatment process.~The screwdriver questions were formulated starting from the scientific literature and with reference to the Theoretical Domains Framework (TDF), created and validated by Michie et al. (2005) and later updated by Cane et al. (2012). The interview questions will be discussed in a focus group composed of a uro-gynecologist, two midwives, a nurse, an expert in qualitative methodology. The final screwdriver questions resulting from the focus group will be tested on a small group of women."
215033225|NCT07010211|OTHER|Gait Video Recording and Analysis|Participants undergo a 6-minute walk test (6MWT) while being recorded on video. The footage is later analyzed using artificial intelligence algorithms to assess gait parameters.
215033226|NCT07010185|BEHAVIORAL|home based exercise|warm-up Exercises (5 minutes), dynamic Stretching (5 to 10 repetitions), strengthening exercises focused on lower limb muscles, such as bridging, clamshells, and various leg exercises (5-10 repetitions across 2-3 sets, based on patient tolerance)
215033227|NCT06681974|BEHAVIORAL|CONTROL:Information form with hygienic-dietary measures or sleep hygiene guidelines is provided and explained.|"* Establish a regular sleep schedule~* Do not stay in bed longer than our regular sleep schedule.~* Avoid naps during the day~* Do not perform exciting activities and/or activities that demand physical or mental energy in the 3 hours prior to going to bed.~* Avoid the use of mobile screens, as well as exposure to intense light in the 3 hours prior to going to bed.~* Follow a healthy bedtime routine~* Healthy lifestyle habits: avoid tobacco, alcohol and other toxic substances."
215033228|NCT06681974|BIOLOGICAL|EXPERIMENTAL: program of exercises that will be composed of 4 blocks|the first is the work of the soft palate (retropalatine level), the second is the work of the functionality of the tongue (retroglossus level), the third is the work of the position of the hyoid bone (hypopharyngeal level), and the fourth is work on anterior head tilt and craniocervical extension (anterior head posture).
215033229|NCT06690879|DEVICE|Smartphone application AI Posture Evaluation and Correction System (APECS)|Mobile application APECS v. 6.2.0. is used to assess upper body posture during standing from back side and right side.
215033230|NCT06690320|BEHAVIORAL|IMPLEMENTATION OF A PLANNED EDUCATION PROGRAM ON HEALTH BELIEF MODEL AND FATUALIST TENDENCIES IN WOMEN AT HIGH RISK OF BREAST CANCER|Description: By examining the parameters of the health belief model and fatalism scales, 6 targets were determined for these scale parameters. The targets were prepared to gain early diagnosis behaviors in breast cancer. By using the breast model, the behavior will be demonstrated in practice
215033231|NCT06626126|OTHER|ApoB-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets
215033232|NCT06626126|OTHER|LDL-C-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.
215033233|NCT06418282|DEVICE|Dayspring|NPCD
215033234|NCT06630767|PROCEDURE|ERAS|Enhanced recovery after surgery (ERAS) programs are a combination of evidenced-based perioperative care approaches that work synergistically to improve recovery after surgery. The core elements of ERAS protocols are preoperative advice, optimization of diet, systematic analgesic and anesthetic regimes, and early mobilization.
215033235|NCT06630767|PROCEDURE|Conventional|Conventional care for patients subjected for laparoscopic common bile duct exploration
215033236|NCT06686472|DRUG|TL-925|TL-925 is an eye drop.
215033237|NCT06686472|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
215033238|NCT06690671|DRUG|Golidocitinib in combination with anti-PD-1|Golidocitinib 150/75 mg once daily (QD) with anti-PD-1 （200 mg IV Q3W），21 days in one cycle.
214283904|NCT06421428|OTHER|LEI Survey|Some sociodemographic data identified from the reference literature will be collected in paper form immediately at the end of each interview, for the description of the sample. The data will concern: age, nationality, marital status, level of education, number of children, menopause, social relationships, level of information, period of onset of symptoms, type of symptomatology, frequency of episodes of urinary incontinence, quantity of urinary leakage, uro-gynecological pathological history.
214283905|NCT03332797|DRUG|GDC-9545|GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
214283906|NCT03332797|DRUG|Palbociclib|Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
214283907|NCT03332797|DRUG|LHRH Agonist|The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
214283908|NCT05311618|DRUG|NGM438|NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
214283909|NCT05311618|DRUG|Pembrolizumab (KEYTRUDA ®)|Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
214283910|NCT06147739|OTHER|Temporary Anchorage Devices|intrusion
214283911|NCT06209177|DRUG|ARO-CFB|ARO-CFB for sc injection
214283912|NCT06209177|DRUG|Placebo|sterile normal saline (0.9% NaCl for sc injection)
214283913|NCT04394286|GENETIC|SHP648|Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
214283914|NCT06266078|DEVICE|Innovative PPE|The healthcare workers will perform tasks using innovative personal protective equipments, such as LightWeight Powered Air-Purifying Respirator (PAPR) or other type of PAPR and a Sealed coverall
214283915|NCT06266078|DEVICE|Traditional PPE|The healthcare workers will perform tasks using usual personal protective equipments, such as N95 mask plus Faceshield and waterproof apron.
214283916|NCT05695352|DRUG|Levonorgestrel 1.5mg|oral synthetic progesterone agonist
214470984|NCT06821529|BIOLOGICAL|ICA07 therapy|4 million iPSC-DAPs will be administrated into the putamen on each side of the brain
214470985|NCT06438965|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|MSOT scans will be obtained from two muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patient with neuromuscular diseases.
214283917|NCT05695352|DRUG|Meloxicam 15 mg|Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
214283918|NCT05695352|OTHER|Placebo|Each tablet contains Calcium Carbonate 1000 mg
214283919|NCT04856371|DRUG|CYH33|Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
214283920|NCT04856371|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
214283921|NCT04856371|DRUG|Letrozole|Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
214283922|NCT04856371|DRUG|Palbociclib|Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
214283923|NCT00116467|BIOLOGICAL|GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|
214283924|NCT03487263|BIOLOGICAL|IC14|chimeric monoclonal antibody against human IC14
214283925|NCT00484874|DRUG|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
214283926|NCT03607162|DIAGNOSTIC_TEST|DIAFEVER algorithm|PCT rapid test-based predictive algorithm
214283927|NCT00811798|BIOLOGICAL|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
214283928|NCT02279537|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
214283929|NCT03374397|DRUG|Surgiguard|Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
214283930|NCT00238004|DRUG|Nicotinic acid|
214283931|NCT02530593|BEHAVIORAL|There is no intervention, only observation|
214283932|NCT04047745|DRUG|Liposomal bupivacaine|interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine
214283933|NCT04047745|DRUG|Ropivacaine injection|interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
214283934|NCT02709733|BEHAVIORAL|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
214283935|NCT02490332|DEVICE|Ventilation tube treatment|Tympanostomy
214283936|NCT01980394|PROCEDURE|Esophageal Stump Washout|a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
214283937|NCT06239454|DEVICE|interleaving stimulation|ILS consists of two rapid and alternate stimulation programs with different contacts, amplitudes, and pulse width but the same frequency up to a maximum of 125Hz. Contact selection is determined by postoperative stereotactic computed tomography and clinical evaluation to achieve a balance between motor improvement and tolerable side effects. For example, ILS is successfully applied for PD motor symptoms (stimulation of subthalamic nucleus) as well as dyskinesia (additional stimulation of zona incerta).
214283938|NCT06239454|DEVICE|empirical stimulation|Patients are settled with simple polar stimulation with combined parameters adjustment (monopolar mode, 60\~90µs pulse width, 130\~185Hz frequency and varied voltage) during the follow-up.
214283939|NCT05009615|DIETARY_SUPPLEMENT|Green coffee extract|150 mg polyphenols from green coffee, twice daily
214283940|NCT05009615|DIETARY_SUPPLEMENT|Beta glucan|2.5 g BG twice daily
214283941|NCT05009615|DIETARY_SUPPLEMENT|Green coffee + beta-glucan|150 mg polyphenols from green coffee + 2.5 g BG, twice daily
214283942|NCT06077318|OTHER|Keyhole repair|The keyhole technique involves placing a mesh with a slit in the central hole around the intestinal ring, allowing facilitating the passage of the intestine through the central slit.
214283943|NCT06077318|OTHER|Sugarbaker repair|The modified Sugarbaker technique uses a mesh to place a patch on the lateralized intestine, effectively preventing herniation of abdominal contents through the stoma.
214283944|NCT01280175|PROCEDURE|charcoal block|
214283945|NCT01280175|DEVICE|Aerochamber Plus spacer|
214283946|NCT01280175|DRUG|pMDI standard actuator|
214283947|NCT04937673|DRUG|Camrelizumab+Albumin bound paclitaxel+Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
214283948|NCT04937673|DRUG|Camrelizumab+ Paclitaxel+ Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
214283949|NCT01927874|PROCEDURE|Infiltration|injection of local anesthetic, associated with general anesthesia
214283950|NCT01927874|PROCEDURE|Spinal block|injection of anesthetic
214283951|NCT01927874|DRUG|Bupivacaine|10ml 0.5% bupivacaine.
214283952|NCT01927874|DRUG|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
214283953|NCT05746949|PROCEDURE|oxygenization techniques|to compare the effects of high-flow nasal oxygen and jet ventilation on oxygenation in patients who will receive general anesthesia for endolaryngeal surgery.
214283954|NCT00217295|DRUG|Avonex and Topamax|
214283955|NCT05740397|OTHER|Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm|"The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect"
214283956|NCT05195580|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
214470986|NCT06823895|DRUG|Maixuekang capsule|"Single dose group: Participants will be given Maixuekang capsules once, 1g, orally.~Multiple dose group: Participants will receive 1g of Maixuekang capsules orally for 3 days, 3 times a day."
214470987|NCT06805500|DEVICE|REACTION|Combination of a exoskeleton and gait trainer
214283957|NCT05038423|BEHAVIORAL|5R Shared Leadership Program|"The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., \& Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., \& Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176"
214470988|NCT06805500|DEVICE|ABLE Regain|Exoskeleton
214283958|NCT05038423|BEHAVIORAL|12-week structured walking program|Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
214283959|NCT01007097|DRUG|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
214283960|NCT01007097|DRUG|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
214283961|NCT01007097|DRUG|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
214283962|NCT01007097|DRUG|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
214283963|NCT01007097|DRUG|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
214283964|NCT01007097|DRUG|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
214283965|NCT01007097|DRUG|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
214283966|NCT00299975|DRUG|MaZiRenWan (MZRW) Low dose|Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
214283967|NCT00299975|DRUG|MaZiRenWan (MZRW) Median dose|Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
214283968|NCT00299975|DRUG|MaZiRenWan (MZRW) High dose|Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
214283969|NCT02590367|DRUG|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks."
214283970|NCT02590367|DRUG|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
214283971|NCT02590367|DRUG|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
214283972|NCT02825056|DRUG|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
214283973|NCT02825056|DRUG|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
214283974|NCT06340750|BIOLOGICAL|LMY-920|CAR T Therapy
214470989|NCT06805500|DEVICE|GABLE Core|Gait trainer
214283975|NCT02300688|DRUG|Treatment A|administration of 1 time administration of the test drug (Treatment A)
214283976|NCT02300688|DRUG|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
214283977|NCT04101461|DRUG|Iron|PharaFerro27; Devart Lab Company, Egypt
214283978|NCT04101461|DIAGNOSTIC_TEST|Complete blood count|to assess the anemia
214283979|NCT04101461|DIAGNOSTIC_TEST|Serum ferritin|to assess the anemia
214283980|NCT04101461|DIAGNOSTIC_TEST|Serum hepcidin|to assess the iron abosrption
214470990|NCT04666688|DRUG|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
214283981|NCT04101461|DIAGNOSTIC_TEST|Serum Iron|to assess the anemia
214283982|NCT04101461|DIAGNOSTIC_TEST|Serum total iron binding capacity|to assess the anemia
214470991|NCT04666688|DRUG|Tislelizumab|anti-PD-1 monoclonal antibody
214470992|NCT04666688|DRUG|Gemcitabine/nab-paclitaxel|chemotherapy
214470993|NCT06606353|BEHAVIORAL|Talk-To-Jo|"Participation begins with the completion of a socio-demographic questionnaire. Next, participants test the Talk-to-Jo intelligent digital health companion on a tablet: first, a member of the research team explains the tool to the dyad (person with a neurocognitive disorder and their caregiver). The person with the disorder then interacts with Talk-to-Jo, possibly with the help of their caregiver. An observer is present, but does not intervene unless there are questions or technical problems. At the end of the test, health recommendations are given. Questions focus on the participant's memory and depression.~Next, a 30-minute interview is conducted with a member of the research team to gather impressions of the tool, digital skills, barriers and facilitators to using AI, as well as your expectations of Talk-to-Jo.~An additional individual interview can be arranged if required."
214470994|NCT05005819|DRUG|[18F] APN-1607|Subjects will undergo PET imaging using \[18F\]APN-1607.
214470995|NCT06821646|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|18F-N-((2-(2-(fluoro-18f)ethoxy)phenyl)methyl)-N-(4-phenoxy-3-pyridinyl) acetamide
214470996|NCT06821646|DIAGNOSTIC_TEST|transcranial magnetic stimulation and electroencephalography(TMS-EEG)|single pulse and paired pulse
214470997|NCT04788823|DRUG|Prednisone|Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
214470998|NCT04083170|DRUG|Fludarabine|Given IV
214470999|NCT04083170|DRUG|Cyclophosphamide|Given IV
214471000|NCT04083170|DRUG|Thiotepa|Given IV
214471001|NCT04083170|RADIATION|Total-Body Irradiation|Undergo TBI
214283983|NCT04964531|OTHER|speckle tracking echocardiography|before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
214283984|NCT03469375|DRUG|modified-FOLFIRINOX|LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
214283985|NCT01193868|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
214283986|NCT01193868|OTHER|laboratory biomarker analysis|Correlative studies
214283987|NCT01193868|OTHER|pharmacological study|Correlative studies
214283988|NCT06373991|BIOLOGICAL|ATHENA CAR-T|Phase 1 dose escalation (3+3): dose 1 and dose 2.
214283989|NCT06373991|DRUG|Fludarabine|Intravenous injection of fludarabine.
214471002|NCT04083170|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
214471003|NCT04083170|BIOLOGICAL|Dilanubicel|Given IV
214471004|NCT06488248|PROCEDURE|Endoscopic third ventriculostomy (ETV)|The procedure is performed using an endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent). The intervention is carried out under general anesthesia, with the procedure typically lasting around 60 minutes.
214471005|NCT06488248|PROCEDURE|Ventriculoperitoneal shunt (VPS)|The procedure entails the insertion of a catheter into both the ventricular system and the peritoneal cavity, connected to a programmable valve that regulates cerebrospinal fluid flow. The choice of programmable valve (Codman Hakim or Codman Certas Programmable Valves, Integra, Plainsboro, USA; Strata valve, Medtronic, Minneapolis, USA; Sophysa, Orsay, France; Miethke proGAV, Aesculap, Tuttlingen, Germany) is at the surgeon's discretion. The preoperative valve setting is preset to a pressure level between 85 - 135 mmH2O. The VPS procedure is conducted under general anesthesia and typically lasts approximately 90-120 minutes.
214471006|NCT03094312|PROCEDURE|Dynamic Spectral Imaging (ISD)|cerebral stimulation: dynamic spectral imaging (ISD)
214471007|NCT01221948|DEVICE|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
214471008|NCT06191159|DEVICE|Scalpel and standard electrocautery or PEAK PlasmaBlade|Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.
214471009|NCT06191159|DEVICE|PEAK PlasmaBlade|PEAK PlasmaBlade for entire surgery.
214471010|NCT06191159|DEVICE|Standard Electrocautery|Standard Electrocautery for entire surgery.
214471011|NCT04989556|OTHER|Interview|Participate in interview
214471012|NCT04989556|OTHER|Palliative Therapy|Receive standard symptom management by palliative care team
214471013|NCT04989556|OTHER|Palliative Therapy|Receive provider initiated remote contact
214471014|NCT04989556|OTHER|Quality-of-Life Assessment|Ancillary studies
214471015|NCT04989556|OTHER|Questionnaire Administration|Complete questionnaire
214471016|NCT00746096|DRUG|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
214283990|NCT06373991|DRUG|Cyclophosphamide|Intravenous injection of cyclophosphamide.
214283991|NCT05538702|DEVICE|IQOS 3.0 DOU with bland taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
214283992|NCT05538702|DEVICE|IQOS 3.0 DUO with menthol taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
214283993|NCT05538702|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
214283994|NCT05538702|DEVICE|IQOS 3.0 DUO turned off with a bland taste unit|Placebo device
214471017|NCT00746096|DRUG|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
214471018|NCT04059185|OTHER|Triple P-Level 2|Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.
214471019|NCT04059185|OTHER|Play Nicely|"Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes."
214471020|NCT04059185|OTHER|Usual care|"Our usual care control group participants receive a resource and referral list for local social services"
214471021|NCT03756662|DEVICE|ARGOS-SC suprachoroidal pressure sensor|The sensor device is intended to be permanently implanted suprachoroidal in the human eye during non-penetrating glaucoma surgery.
214471022|NCT05174637|DRUG|FDA018-ADC|FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
214471023|NCT04283045|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the TA.
214283995|NCT02444520|BEHAVIORAL|Integrated GP Care|"The overall aims of the intervention are to help the patient:~1. develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;~2. understand factors that may be maintaining the problem;~3. learn how to modify the behavioral and cognitive responses which may be maintaining the problem;~4. adopt a healthy sleep routine which can promote healthy living.~Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed."
214283996|NCT01428544|DRUG|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
214283997|NCT03326765|OTHER|Questionnaires|"* Epworth sleepiness scale~* Pittsburgh sleep quality Index (PSQI)~* EQ-5D Adults~* Pediatric Daytime Sleepiness scale (PDSS)~* Sleep disturbance Scale for Children (SDSC~* EQ-5D Children~* Sleaping diary"
214283998|NCT03326765|PROCEDURE|electroencephalogram (EEG)|is an electrophysiological monitoring method to record electrical activity of the brain
214283999|NCT03326765|PROCEDURE|polysomnography|type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
214284000|NCT03326765|PROCEDURE|Actigraphy|type of sleep study based on bracelet around the wrist
214284001|NCT05965154|DRUG|Carrilizumab, bevacizumab,capecitabine|"1. Carrilizumab: 200mg/ cycle, three weeks as a treatment cycle, the first day of each cycle, intravenous drip;~2. Bevacizumab: 7.5mg/kg, intravenous infusion on the first day of each cycle, every 3 weeks for 1 cycle (Q3W);~3. Capecitabine: 1250mg/m2, three weeks as a treatment cycle, oral twice a day (once in the morning and once in the evening; Stop the drug for 1 week after 2 weeks of treatment."
214284002|NCT03706105|BEHAVIORAL|Cardiac Rehabilitation|3 x week \~1 hour of exercise + education
214284003|NCT00530309|DRUG|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
214284004|NCT00530309|DRUG|Placebo|Subjects will also receive placebo.
214284005|NCT06497413|DEVICE|Transcranial Photobiomodulation|The transcranial photobiomodulation will be delivered through the Neuradiant 1070 Plus-Programmable 4-Quadrant Photobiomodulation System. This is a commercially available helmet that will be purchased from a commercially available source.
214284006|NCT06497413|DEVICE|Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered|In this condition the participants will wear the Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus); however, the light will not be administered.
214284007|NCT04982809|DRUG|Betamethasone, Dexamethasone, Prednisolone|Corticosteroids
214284008|NCT01386827|BIOLOGICAL|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml \> 2 years later
214284009|NCT01386827|BIOLOGICAL|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml \> 2 years later
214284010|NCT01386827|BIOLOGICAL|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
214284011|NCT01386827|BIOLOGICAL|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
214284012|NCT03321123|DRUG|MB-CART19.1|Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
214284013|NCT02905552|OTHER|No intervention|
214284014|NCT05864872|PROCEDURE|axillary brachial plexus block|conventional group, 3 to 6 mL of bupivacaine was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior ultrasound group:1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
214284015|NCT00090974|PROCEDURE|quality-of-life assessment|
214284016|NCT02495805|PROCEDURE|Continuous proximal adductor canal block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
214284017|NCT02495805|PROCEDURE|Continuous femoral nerve block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
214284018|NCT01815515|DRUG|18F-DCFBC|"18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push."
214284019|NCT00171730|DRUG|Pasireotide|
214284020|NCT01717261|RADIATION|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
214284021|NCT05025241|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
214284022|NCT01655706|DRUG|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
214284023|NCT01655706|DRUG|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
214471024|NCT04283045|BEHAVIORAL|JASPER Plus+|"JASPER Plus+ refers to direct instruction of social communication targets of pointing to share, showing gesures, and give to share gestures, and play targets at the child's target play level.~JASPER Plus+ will occur at a table top with repeated trials of instruction until the child can produce the desired behavior on their own."
214284024|NCT01753791|DRUG|80 mg PF-06473871|80 mg of PF-06473871 or placebo
214284025|NCT01753791|DRUG|160 mg PF-06473871|160 mg of PF-06473871 or placebo
214284026|NCT01753791|DRUG|320 mg PF-06473871|320 mg of PF-06473871 or placebo
214284027|NCT01753791|DRUG|480 mg PF-06473871|480 mg of PF-06473871 or placebo
214284028|NCT01053221|DRUG|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
214284029|NCT01053221|DRUG|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
214284030|NCT05510804|COMBINATION_PRODUCT|ALISA|assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance
214284031|NCT05311540|DRUG|Zinc Sulfate|
214284032|NCT05349994|OTHER|Extended physiotherapy|At admission to the surgical ward after ICU care, participants received an individual rehabilitation plan developed in collaboration with the participants and the ward-based physiotherapist. The rehabilitation plan included specified exercises for 1- 2 sessions of approximately 30 minutes a day. For example breathing exercises, practicing transfer in and out of bed and from sitting to standing, stairclimbing, and walking with or without walking aids.
214284033|NCT06460220|BEHAVIORAL|Safe Alternatives for Teens and Youth - Parent (SAFETY-P)|The parent component of SAFETY focuses on enhancing parents' skills in supporting youth safety and managing parental distress during a suicidal crisis, ideal content to adapt for web-based delivery for parents. Specifically, parent information includes psychoeducation about suicide risk and protective factors, lethal means restriction, development of a parent distress tolerance plan (i.e., Parent Safety Plan), parent self-care and sources of support, strengthening the youth/parent relationship, and focus on care linkage for the youth. The SAFETY-P asynchronous parent intervention module will include text, interactive handouts, vignettes, and short video examples. The SAFETY-P module will allow for parents to access information and skills training on their own time, with the opportunity and encouragement to ask informed questions of their child's clinician; this will provide clinicians the opportunity to utilize their check-ins with parents more effectively to address youth safety.
214284034|NCT06460220|BEHAVIORAL|Treatment As Usual (TAU)|TAU will consist of treatment and case management as usual in the NCH Critical Assessment and Treatment (CATC) program. This may include individual and group therapy sessions for the youth, family therapy, medication management, and case management/discharge planning. Frequency of these services varies by availability and care linkage to ongoing outpatient care. We will track the number, type and length of all treatment and case management services provided as part of TAU in CATC to control for time spent in by parents and youth in TAU across study conditions. Additionally, the Child and Adolescent Services Assessment (CASA), a services use measure, will be utilized to capture any additional treatments and parents' involvement in those treatments.
214284035|NCT06279091|BEHAVIORAL|Diaphragmatic Breathing|apply breathing exercises to evaluate the effectiveness on anxiety reduction
214284036|NCT06279091|BEHAVIORAL|Bubble Blower Breathing|apply breathing exercises by using bubble blower to evaluate the effectiveness on anxiety reduction
214284037|NCT06279091|BEHAVIORAL|Tell Show Do|apply basic behavioral management technique as control group
214284038|NCT06158594|BEHAVIORAL|Summer day camp|The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
214284039|NCT03107936|BEHAVIORAL|smokeSCREEN game|smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
214284040|NCT03465202|DRUG|Capecitabine|
214284041|NCT04168060|PROCEDURE|Crura dissection|The diaphragmatic crura, one of two tendon structures below the diaphragm, will be removed during the laparoscopic sleeve gastrectomy.
214284042|NCT04168060|PROCEDURE|Sleeve gastrectomy|Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
214284043|NCT04168060|PROCEDURE|Hiatal hernia repair|This involves tightening the opening in your diaphragm with stitches to keep your stomach from bulging upward through the opening in the muscle wall.
214284044|NCT02266225|OTHER|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
214284045|NCT02600702|OTHER|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
214284046|NCT02600702|OTHER|Physical modalities|
214284047|NCT04394260|BEHAVIORAL|Savvy Caregiver Program via Remote Learning|The SCP program is comprised of four pre-recorded Savvy Caregiver videos (each 1 hour and 45 minutes in length). Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of enjoyable involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
214471025|NCT04049851|DRUG|Moxidectin 2 MG Oral Tablet|One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.
214471026|NCT04049851|DRUG|Ivermectin 3Mg Tab|3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.
214471027|NCT04049851|DRUG|Placebo oral tablet|Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
214906896|NCT01019343|DIAGNOSTIC_TEST|Treadmill Test|Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
214844488|NCT05631535|OTHER|Intensive lifestyle change program with a very-low-energy diet|The intervention will consist of two phases. In the first phase, the participants receive weekly visits for two months. During these visits, a nutritionist will take the participants' weight and abdominal circumference measurements, and each one will receive a meal plan with a very low-energy diet (800 kcal/d). The second phase will implement in the third and fourth months, and nutritional counseling will continue to be provided every week in the third and biweekly in the fourth month. In this second phase, a gradual reintroduction to low-energy dietary meal plans (1200-1800 kcal/d) will perform. In addition, a specially adapted Diabetes Prevention Program for a very low-energy diet will implement.
214844489|NCT05631535|OTHER|Intensive lifestyle change program with a low-energy diet|The structure (frequency of nutritional counseling, number of sessions, time of sessions, etc.) in this group will be the same as that of the intervention group, and a modified Diabetes Prevention Program will also provide. From the beginning of the study will recommend meal plans with a low-energy diet (1200-1800 kcal).
214844490|NCT00779402|OTHER|Control|Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
214844491|NCT00779402|BIOLOGICAL|Sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
214844492|NCT04143282|DRUG|Metformin plus chemotherapy|determine the effect of metformin along with standard chemotherapy
214844493|NCT04143282|DRUG|Chemotherapy|standard chemotherapy
214844494|NCT01953887|DRUG|EC905|Oral
214844495|NCT01953887|DRUG|solifenacin|oral
214844496|NCT01953887|DRUG|tamsulosin|oral
214844497|NCT00693225|DRUG|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
214844498|NCT01315028|OTHER|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley \& Schwannauer, 2006).
214844499|NCT01315028|OTHER|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
214844500|NCT00538655|DRUG|modafinil|400mg vs. 200mg (PO) daily
214844501|NCT03353298|DRUG|Allopurinol 300 mg|Allopurinol oral tablets 300 mg given to participants once daily for 9 months
214844502|NCT03353298|DRUG|Placebo Oral Tablet|placebo oral tablets given to participants once daily for 9 months
214844503|NCT04281732|DEVICE|Virtual Reality Headset based tests|Visual task tests based on Oculus Rift
214844504|NCT03128736|DRUG|Esomeprazole group|Esomeprazole 40mg qd
214844505|NCT03128736|DRUG|Dexlansoprazole group|Dexlansoprazole 60mg qd
214844506|NCT03282539|DEVICE|LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
214844507|NCT03282539|DEVICE|LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
214844508|NCT06678009|DEVICE|the isokinetic training group with blood flow restriction|The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions.
214844509|NCT06678009|DEVICE|the isokinetic training group without blood flow restriction|The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions.
214844510|NCT05535192|BEHAVIORAL|THRIVE|"The THRIVE Intervention will involve:~1\) one in-person exercise sessions, followed by twice-weekly, home-based exercise sessions, supervised remotely through telehealth, and 2) a remotely delivered dietary assessment and recommendations to support protein intake throughout the study"
214844511|NCT05535192|BEHAVIORAL|Health Education Support Program|Participants will receive a tablet with information and resources regarding mediation, stretching and gentle movement, relaxation and creative arts during chemotherapy
214844512|NCT02572791|DRUG|Chlorhexidine|
214844513|NCT02572791|DRUG|Mupirocin|
214844514|NCT02572791|BEHAVIORAL|Household cleaning|
214844515|NCT04192929|DEVICE|Narrow band imaging|Blue light is used during withdrawal phase instead of the regular white light to highlight surface changes
214844516|NCT04192929|OTHER|Chromoendoscopy|Indigo carmine will be sprayed during withdrawal phase of colonoscopy
214844517|NCT04192929|OTHER|High definition white light endoscopy|High definition equipment will be used to perform colonoscopy
214844518|NCT04832334|OTHER|Kinesthetic and Visual Imagery Questionnaire, Box and Block Test, Hand Lateralization Test.|Imagery ability was determined.
214844519|NCT04832334|OTHER|Berg Balance Scale, Functional Reach Test|Balance level was determined.
214844520|NCT04832334|OTHER|Timed Up and Go Test, Functional Independence Scale|Functionality was evaluated.
214844521|NCT00391534|DRUG|modified release formulation of oxcarbazepine (OXC MR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
214284048|NCT04394260|BEHAVIORAL|Focus group|After watching the Savvy Caregiver videos participants will take part in a focus group to discuss their experience with the SCP and how the course material applies to them as a LGBT caregiver. The semi-structured discussion will include, but not be limited to the following questions: 1) Can you tell me about your role as a caregiver? (Probes: living situation, experiences, challenges). 2) What went well with the SCP, and what could be improved? 3) How relevant to your situation as an LGBT caregiver were the course materials? 4) How well did the questionnaire reflect your experiences with discrimination due to sexual orientation and/or gender identity? (Probe about when working with your care recipient's health care providers, in-home aides/visiting nurses, adult day care staff, respite, etc? 5) What are some of the additional caregiver challenges that should be considered in these questionnaires? (Probes: mental health, physical health, and social life strain, Quality of life, stress).
214284049|NCT00280631|DRUG|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
214284050|NCT03981211|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
214284051|NCT03981211|DRUG|Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
214284052|NCT06279962|OTHER|Survey questionnaire|The intervention is being assigned to one of the 8 different versions of the survey vignette.
214284053|NCT04620993|OTHER|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position."
214284054|NCT04620993|OTHER|Evaluation of navıcular drop|The amount of navicular drop of both feet will be measured
214284055|NCT04620993|OTHER|Evaluation of plantar pressure distrubution|The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
214284056|NCT05079139|PROCEDURE|surgical technique of Musset|"The one-stage rectovaginal fistula cure according to Musset is an intervention indicated in the treatment of simple post-obstetrical or simple post-surgical rectovaginal fistulas.~The procedure consists in performing a perineal section to the perineal section to the fistula pathway in order to perform local excision followed by a repair plane by plane with rectal and anal closure, then of the external sphincter of the anus, and interposition of the deep and superficial transverse elevator and perineal muscles before closing the vagina and perineum."
214284057|NCT05786820|DIETARY_SUPPLEMENT|Pycnogenol|daily consumption of a pycnogenol-containing capsule
214844522|NCT00391534|DRUG|immediate release formulation of oxcarbazepine (OXC IR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
214284058|NCT05786820|DIETARY_SUPPLEMENT|Placebo|Daily consumption of a placebo capsule
214284059|NCT01465997|DRUG|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
214284060|NCT01465997|DRUG|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
214284061|NCT05152589|DIAGNOSTIC_TEST|hearing test|Auditory Brainstem Response (ABR) Test
214284062|NCT04873791|DIAGNOSTIC_TEST|Assessment of geriatric individuals living in home environment and nursing home.|Assessments explained in the arm section were made as described in one session in both group
214284063|NCT02246660|DRUG|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
214284064|NCT02246660|DRUG|Placebo|Placebo will be taken orally for 6 months.
214284065|NCT03032146|PROCEDURE|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
214284066|NCT03018704|DRUG|Topiramate|anticonvulsant medication. The medication was dosed twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
214284067|NCT03018704|DRUG|placebo|inactive medication. the doses of placebo were titrated the same as the active intervention.
214284068|NCT00440219|DRUG|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
214284069|NCT00440219|DRUG|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
214284070|NCT04851249|PROCEDURE|Hallux Valgus - chevron osteotomy, lapidus procedure|The purpose is to compare the preoperative clinical features (previous medical history, age, BMI, occupational status etc), PROMs (Manchester-Oxford Foot and ankle questionnaire, SF-36, VAS activity scale) and radiological parameters (both two and three dimensional) with the postoperative PROMs (+ likert scale) and the postoperative radiological parameters.
214844523|NCT00658034|PROCEDURE|Acupuncture|Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
215033239|NCT06691737|OTHER|Whole Body Vibration|"Whole body vibration consists of 3-minute vibrations with a 30-second break. Participants were asked to step onto the platform barefoot and position their feet 3 from the center of the platform, with feet pointing forward, knees slightly bent, and upper limbs along the body. The training was divided into two parts: week 1 with a frequency of 20 Hz, and a constant amplitude of 3 mm."
215033240|NCT06691815|DIAGNOSTIC_TEST|Triptorelin (GnRH agonists)|"1. Triptorelin test. A baseline blood sample will be taken to determine LH, FSH, Estradiol/Testosterone, AMH, and Inhibin B. Then, Triptorelin Acetate 100 ug/m² of body surface area will be administered subcutaneously, maximum dose 0.1 mg (Decapeptyl Daily prefilled syringe of 0.1 mg for subcutaneous administration. Three hours later, a new sample will be taken to determine LH and FSH. The patient may return home and lead a normal life. An appointment will be made the following day to perform the last sample of this test 24 hours after the subcutaneous administration of Triptorelin Acetate, with the determination of LH, FSH, Estradiol/Testosterone, and Inhibin B.~2. GnRH Infusion: This consists of determining LH and FSH in baseline blood samples, 15, 30, 45, 60 and 120 minutes after slow infusion of GnRH. GnRH 0.83 μg/min during the 120 minutes that the study lasts (Luteoliberin 100 μg)"
215033241|NCT04275284|BIOLOGICAL|PCV10|0.5 ml injection
215033242|NCT04275284|BIOLOGICAL|PCV13|0.5 ml injection
215033243|NCT00863590|DRUG|odanacatib|\[Intervention Name: odanacatib (Panel A)\] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
215033244|NCT00863590|DRUG|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
215033245|NCT00863590|DRUG|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
215033246|NCT00863590|DRUG|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
215033247|NCT02495883|OTHER|Ethanol|50ml of 40% Ethanol
215033248|NCT02495883|DRUG|Propranolol|Beta blocker
215033249|NCT00470223|DRUG|cisplatin|
215033250|NCT00470223|DRUG|doxorubicin hydrochloride|
215033251|NCT00470223|DRUG|etoposide|
215033252|NCT00470223|DRUG|ifosfamide|
215033253|NCT00470223|DRUG|methotrexate|
215033254|NCT00470223|DRUG|zoledronic acid|
215033255|NCT00470223|PROCEDURE|conventional surgery|
215033256|NCT05039307|BEHAVIORAL|Educational and motivational strategy|The intervention will focus on the following topics A) Healthy diet: food pyramid, a healthy plate distribution, type of carbohydrates and fats, healthy cooking techniques and healthy oils. B) Physical activity: definition, types of physical activity, advantages and benefits, examples, active physical activity sessions. C) Weight control: strategies, benefits and healthy weight gain during pregnancy. D) Knowledge and awareness of T2DM and GDM: definition, prevention, management and complications. These topics will be delivered through individualized education, group sessions and focus groups. Participants will be provided with printed material at baseline and also during the individual education sessions at the household containing a brief summary of the topics covered. The motivational components of goal setting and the use of a pedometer will be incorporated explained during the individual education sessions. The intervention will be primarily delivered by trained peer educators.
215033257|NCT06257420|DRUG|Rapamycin|Once weekly oral rapamycin
215033258|NCT06691568|DEVICE|Air purifier|Purifiers were turned on for the active group and off for the placebo
215033259|NCT06690632|OTHER|water preparation|ingestion of 1.5L of water 30min prior MRE acquisition
215033260|NCT06690632|OTHER|polyethylene glycol preparation|ingestion of 1.5L of water diluted PEG 45 min prior MRE acquisition (standard protocol)
215033261|NCT00420706|DRUG|SCA-136|
215033262|NCT00666042|DRUG|Vigamox - administration in spray form|Vigamox will be administered in a spray form
215033263|NCT00666042|DRUG|Vigamox eye drops|Vigamox eye drops
215033264|NCT00217802|BEHAVIORAL|six-session telephone counseling program|
215033265|NCT05505500|BEHAVIORAL|Interview|Concept Elicitation Interviews are used to create tools followed by Cognitive Debrief Interviews that are used to review created tools.
215033266|NCT03085290|OTHER|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
215033267|NCT03085290|OTHER|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
215033268|NCT04293432|DRUG|Drugs, Generic|All drugs having ≥10 TdP cases reported in the FAERS database
215033269|NCT00069550|DRUG|dextromethorphan|
215033270|NCT00069550|DRUG|donepezil hydrochloride|
215033271|NCT03268278|DRUG|Buprenorphine|Buprenorphine plus local anesthetic
215033272|NCT03268278|DRUG|Sterile saline|Placebo 1,8 ml
215033273|NCT03268278|DRUG|lidocaine, epinephrine (Local anesthetic)|2% lidocaine 1:100,000 epinephrine
215033274|NCT01442571|DEVICE|Hyaluronic Acid Injection|
215033275|NCT01442571|DRUG|Saline Injection|
215033276|NCT04809805|DRUG|BAY2666605|One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
214284071|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T)|"This is a 36-hour group training involving 4 theoretical + 11 practice online sessions using video-feedback, the core component of MISC original trainings.~Session 1: MISC presentation; Session 2: Bases of the interaction and MISC culture-context components; Session 3: The emotions in the interaction and MISC emotional components; Session 4: MISC cognitive components and implications for learning; Session 5: Practice with you-tube examples of interaction; Session 6: Practice with trainer's examples of video-feedback. Sessions 7 to 14: Practice with participants' video-recordings. Session 15: End of the intervention, last video-feedback training and preparing for post-assessment."
214471028|NCT06621849|PROCEDURE|erector spinae plane block|In the erector spinae plane block (group E), an ultrasound-guided block will be performed on the ipsilateral side of the surgery while the patient is in lateral position 3-5 cm from the midline (10). Moving cephalic from the sacrum, we will identify the L5, L4, and L3 transverse processes and erector spinae muscles posteriorly. A 21 G and 70mm length needle will be directed in-plane, and the needle tip will be positioned anterior to the erector spinae muscle at the corner of the transverse process. After the initial saline injection, dissection of the plane will be observed by injecting a total volume of 20 ml composed of 10 micrograms dexmedetomidine in 2ml of normal saline and 18 ml of bupivacaine 0.25%, which is far from the toxic dose (10). Correct placement is defined as the spread of local anesthetic cranially and caudally from the injection point, dissecting the plane between the transverse processes and erector spinae muscles.
214471029|NCT06621849|DRUG|Morphine|patients will receive 5 ml of subcutaneous lidocaine 1% then 3.5 ml of bupivacaine 0.5% and 0.1 mg of morphine in 0.25 ml of normal saline intrathecal
214471030|NCT06106646|DIETARY_SUPPLEMENT|No active intervention in this protocol (previously randomized to Vitamin C)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
214471031|NCT06106646|OTHER|No active intervention in this protocol (previously randomized to Placebo)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
214471032|NCT05778838|DRUG|Midodrine Oral Tablet|Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.
214471033|NCT04618315|DEVICE|Hearing Aids|Receiver-in-the-ear hearing aids.
214471034|NCT05332561|DRUG|Atezolizumab 1200 mg in 20 ML Injection|Arm 1
214471035|NCT05332561|DRUG|Inavolisib|Arm 2
214471036|NCT05332561|DRUG|Ipatasertib|Arm 3
214471037|NCT05332561|DRUG|Olaparib|Arm 4
214471038|NCT05332561|DRUG|Sacituzumab govitecan|Arm 5
214471039|NCT05332561|DRUG|Trastuzumab/pertuzumab|Arm 6
214471040|NCT06278285|OTHER|Blood GLP1|On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues
214471041|NCT06278285|OTHER|Blood No treated GLP1|On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.
214471042|NCT02211859|DRUG|BI 2536|
214471043|NCT05444881|BEHAVIORAL|Mindfulness-based Intervention (Headspace TM)|"A commercially available mindfulness mobile phone application (HeadspaceTM) will be used. The use of HeadspaceTM in the current protocol is approved by NYSPI Information Technology Services.~An mHealth mindfulness program such as Headspace provides self-paced, guided mindfulness meditations through a website or mobile app (iOS and Android). The program consists of basic meditation courses as well as courses targeting stress management, anxiety, depression, and parenting. Based on the qualitative interviews with parents in Phase I, psychoeducation will be included on mindfulness practice and mental health, emphasizing basic meditation courses, and asking parents to complete daily assignments of 10 to 20 min a day during the 6-week period. As an engagement strategy, every week participants in the intervention group will receive a call or an email or text message (depends on preference; partisans may opt out to receive email/text messages)."
214471044|NCT05338606|DRUG|Bimatoprost Sustained Release Implant|Intraocular Implant
214471045|NCT06149663|DRUG|LP352|LP352 will be administered as a liquid either orally or through a G-tube or Percutaneous Endoscopic Gastrotomy (PEG) tube.
214471046|NCT06127459|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma).
214471047|NCT06127459|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
214471048|NCT04566237|PROCEDURE|Objective Scatter Index (OSI)|On Optical Quality Analysis System (OQAS) device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
214471049|NCT04566237|PROCEDURE|Average Lens Density (ALD)|on IOLMaster® 700 device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
214471050|NCT01926080|OTHER|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
214284072|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 36-hour individual training involving 25-weekly online, individual, self-administered 50' sessions (21h) + 4 online 1.5-hour group meetings with a supervisor (6h) and 9h of between sessions work (readings, video-recordings for later video-feedback, reflection exercises). Session 1 (Supervisor): Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC: Session 9 (Supervisor): Summary, online group exercises and keys for forward recordings; Sessions 10-11 (Christmas Homework): Recording daily life interactions; Sessions 12-17 (SA): guided reflection with video-feedback; Session 18 (Supervisor): Control session for doubts and video-feedback group training. Sessions 19-28 (SA): guided reflection with video-feedback. Session 29 (Supervisor): Final online video-feedback group training.
214284073|NCT06150313|OTHER|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|This is an equivalent 36-hour online self-administered training involving 27 x 45' individual online sessions (20.25h), mostly based on reflection exercises around brief readings, animated shorts, or pills, but not video-feedback. This is complemented with 2 x 1.5h online group face-to-face sessions with a supervisor (3h) and 13h of between-sessions work based on looking for new information, adult-child activities (but not for video-feedback) or out-of-line guided reflective exercises. Session 1 (Supervisor): group meeting for program presentation; Sessions 2-28 (Self-Administered): Online self-administered sessions doing readings or watching pills; Session 29 (Supervisor): Final doubts session to close de course.
214471051|NCT06584721|OTHER|Anti-pronation taping (Low dye taping) + Conventional therapy|"They would be receiving treatment as follow:~Anti-pronation taping (Low dye taping) Applied on alternate days. 3 days / week for 4 weeks.~Conventional Therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsxset1, 10sec hold) 3sessions/ week."
214284074|NCT03598985|DIAGNOSTIC_TEST|"Smartphone MyAnkle balance application"|"Balance will be assessed simultaneously using MyAnkle application and the Biodex balance system. The smartphone will be fixed to the middle of the shin with an armband. Participants will assume a single leg stance on each side under two conditions: eyes opened and closed. Testing will be done at three levels of difficulty; least difficult (level 8), moderate (level 6) and severe difficult (level 4). A conditioning trial for each level will be given for 30 seconds. Further, a 2-minute rest between tests will be given. During the testing, participants should not touch the ground or stance limb by other limb nor to grasp the handrail. Participants will repeat the same testing in two separate sessions, with one-week interval in between."
214284075|NCT00327249|DRUG|imexon|
214284076|NCT04040114|DEVICE|Molemap Skin Cancer Triage Artificial Intelligence Device|This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
214284077|NCT02397785|DEVICE|ApexM|Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
214284078|NCT02397785|DEVICE|Sham Device|Identical to ApexM but will not deliver any electrical stimulation
214284079|NCT00642460|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (patients\>=30kg) or 12mg/kg (patients \<30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
214284080|NCT00642460|DRUG|Placebo|iv every 2 weeks for 12 weeks
214284081|NCT00642460|DRUG|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
214471052|NCT06584721|OTHER|Short Foot Exercises + Conventional PT|"They would be receiving treatment as follow:~Short foot exercises are used to reduce the foot pronation: Frequency: 30 reps x 1 set, 30 sec hold and 10 sec relaxation for 4 weeks. 3 session/ week).~Short foot Exercises includes a four-week plan, 1- Shortening of foot in Anterior-posterior direction, 2- Increase medial longitudinal arch, 3- Balanced loading in standing, 4- Approximating Head of first, second meta-tarsal and calcaneus with patient in standing (single leg).~Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsx1set, 10sec hold) 3sessions/ week."
214284082|NCT00642460|DRUG|methotrexate|as prescribed
214284083|NCT00642460|DRUG|corticosteroids|orally, as prescribed
214284084|NCT00320411|DRUG|lapatinib|Lapatinib 1500mg QD
214284085|NCT01947205|DRUG|paracetamol|
214284086|NCT01947205|DRUG|dexketoprofen trometamol|
214284087|NCT01947205|DRUG|suction curettage|
214284088|NCT01947205|DRUG|suction curettage|
214284089|NCT01947205|OTHER|without drug|
214284090|NCT01110434|DRUG|Topiramate|Topiramate (200 mg daily)
214284091|NCT01110434|DRUG|Placebo|Placebo (daily)
214284092|NCT01348503|DRUG|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
214284093|NCT01348503|DRUG|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
214471053|NCT06585228|DIAGNOSTIC_TEST|Cardiac Computed Tomography|Cardiac CT acquired during the acute stroke imaging protocol
214471054|NCT06585228|DIAGNOSTIC_TEST|Transesophageal echocardiography|Ultrasound through the oesophagus to assess cardiac structures.
214284094|NCT00439842|BEHAVIORAL|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
214284095|NCT02317185|DEVICE|genex bone graft with bone graft|
214471055|NCT06585228|DIAGNOSTIC_TEST|Repeated Cardiac Computed Tomography|A second cardiac CT performed after the TEE.
214471056|NCT04985955|DRUG|Tofacitinib|Tofacitinib tablet will be administered orally.
214284096|NCT02317185|OTHER|autogenous bone graft|
214284097|NCT02656979|DRUG|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
214471057|NCT02538809|OTHER|measurement of tumor mRNA concentration in urine|bed-side test of tumor mRNA concentration in urine
214284098|NCT00700960|DRUG|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
214479436|NCT06865404|PROCEDURE|PIEOB block|After the PIFPB is performed with the same position and probe, an external oblique block will be used to place the linear array ultrasound probe between the midclavicular line and the anterior axillary line at the level of the 6th rib, with the direction mark pointing to the cephalad. The probe will be rotated on the slightly medial cranial end, and the caudal end will be lateral to produce a mesial sagittal oblique view and a short-axis view of the ribs. The following structures will be identified from superficial to deep layers: subcutaneous tissue, external oblique muscle, intercostal muscles, pleura, and lung. After determining the thoracic fascial space between the external oblique muscle and the intercostal muscles, bupivacaine 20 mL will be slowly injected into the space with a nerve block needle at the head side of the 6th rib horizontally near the mid axillary line. The block will be repeated in the same way on the other side.
214284099|NCT03085420|DIAGNOSTIC_TEST|Echocardiogram|A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
214284100|NCT03233503|DIAGNOSTIC_TEST|Basic taste, fat sensation and texture perception|"This is an observational Sensory study methodologically similar to Astringency and bitterness perception clinicalTrials.gov identifier NCT03171402 Participants are first involved in sensory training sessions that train how they recognise between different basic tastes and differentiate perceived intensity in solutions and foods. After 6 months of training, the trained participants are involved in tasting a wide array of commonly consumed foods. At this study phase, participants will rate for the foods' taste, fat sensation perception and texture"
214284101|NCT05260788|PROCEDURE|Cystoscopy|Standard of care cystoscopy procedure
214284102|NCT06072729|OTHER|comparison of magnesium sulphate versus cold compression|This study will involve a total of 70 participants who will be divided into two groups. One group will receive magnesium sulphate, while the other group will receive cold compression. The severity of phlebitis will be assessed in both groups using a visual phlebitis (VIP) rating scale.
214284103|NCT02557646|BIOLOGICAL|Peginterferon alfa-2a|Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
214284104|NCT02557646|DRUG|Ribavirin|Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
214284105|NCT04013139|DIAGNOSTIC_TEST|CPET|CPET
214284106|NCT01094223|BEHAVIORAL|Mindfulness Based Relapse Prevention|Meditation based therapy group incorporating relapse prevention skills training
214284107|NCT01094223|BEHAVIORAL|Health Education|Psychoeducation group focused on various topics pertaining to physical health
214284108|NCT01703949|DRUG|Brentuximab Vedotin|Given IV
214284109|NCT01703949|OTHER|Laboratory Biomarker Analysis|Correlative studies
214284110|NCT01703949|BIOLOGICAL|Nivolumab|Given IV
214284111|NCT01786044|BEHAVIORAL|MasterMed|An online interactive educational program
214284112|NCT01786044|BEHAVIORAL|Usual Care|
214284113|NCT00089154|BIOLOGICAL|apolizumab|Given IV
214284114|NCT00089154|OTHER|laboratory biomarker analysis|Correlative studies
214284115|NCT00089154|OTHER|pharmacological study|Correlative studies
214284116|NCT04448171|DEVICE|Active TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an active setting.
214284117|NCT04448171|DEVICE|Sham TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an inactive setting.
214284118|NCT03740711|PROCEDURE|Left atrial venting|The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.
214284119|NCT04287816|OTHER|Zero hard-boiled egg at 0 h|No eggs will be consumed on test day along with spinach consumption
214284120|NCT04287816|OTHER|One hard-boiled egg at 0 h|One egg will be consumed on test day along with spinach consumption
214284121|NCT04287816|OTHER|Two hard-boiled eggs at 0 h|Two eggs will be consumed on test day along with spinach consumption
214284122|NCT04287816|OTHER|Three hard-boiled eggs at 0 h|Three eggs will be consumed on test day along with spinach consumption
214284123|NCT04287816|OTHER|One hard-boiled egg at 3 h|One egg will be consumed on test day three hours after spinach consumption
214284124|NCT04287816|OTHER|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
214284125|NCT04287816|OTHER|Two egg whites at 0 h|Two egg whites will be consumed on test day along with spinach consumption
214284126|NCT04287816|OTHER|Vegetable oil at 0 h|9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption
214284127|NCT06578338|OTHER|Physical height measurement|Physical height will be measured and images will be collected for AI to estimate the height
214284128|NCT02761278|PROCEDURE|Endometrial biopsy|
214284129|NCT00660309|DRUG|Aliskiren|Aliskiren 300 mg tablets
214284130|NCT00660309|DRUG|Irbesartan|Irbesartan 300 mg tablets
214284131|NCT00660309|DRUG|Captopril|Captopril 25 mg tablet
214284132|NCT03005314|PROCEDURE|chemotherapy|chemotherapy before surgery
214284133|NCT03005314|PROCEDURE|Surgery|chemotherapy after surgery
214284134|NCT01010490|PROCEDURE|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
214471058|NCT03911141|BEHAVIORAL|Gamification|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
214471059|NCT03911141|BEHAVIORAL|Financial|"Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
214284135|NCT01010490|PROCEDURE|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
214471060|NCT06320171|DEVICE|Non-Invasive neuromodulation|Direct stimulation of the autonomic nervous system was achieved using Program 7 (P7) of the device, with a directional electrode positioned at the level of the C7 spinous process. P7 delivered a biphasic polarity current with oscillatory frequencies ranging from 1.92 to 14.29 Hz and variable intensities between 0.1 and 0.9 mA.
214284136|NCT01010490|PROCEDURE|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
214284137|NCT03103568|DRUG|Nitisinone in Arm A|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
214284138|NCT03103568|DRUG|Tolbutamide|A 500 mg tablet is given as single oral dose 2 weeks apart.
214284139|NCT03103568|DRUG|Metoprolol|A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
214284140|NCT03103568|DRUG|Chlorzoxazone|A 250 mg tablet is given as single oral dose 2 weeks apart.
214284141|NCT03103568|DRUG|Furosemide|A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
214284142|NCT03103568|DRUG|Nitisinone in Arm B|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
214284143|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
214284144|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
214284145|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
214284146|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
214284147|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
214284148|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
214471061|NCT06320171|OTHER|Placebo|The placebo group followed the same procedure, except that no current was applied during their 20-minute session.
214471062|NCT04100408|OTHER|Biospecimen Collection|Undergo saliva or buccal mucosa collection
214471063|NCT04100408|OTHER|Laboratory Biomarker Analysis|Correlative studies
214471064|NCT04100408|OTHER|Questionnaire Administration|Ancillary studies
214471065|NCT06100666|BEHAVIORAL|Observational Tests|The Sustainable and Healthy Eating Behaviors Scale will be used to assess sustainable eating behaviors, one-day food consumption records will be collected with the 24-hour Dietary Recall method, the International Diet Quality Index and EAT-Lancet Diet Score will be used to assess diet quality, and body weight, height, waist circumference and neck circumference will be measured to determine nutritional status.
214479437|NCT05255133|OTHER|Liquid biopsies|Blood sampling will be done at regular intervals
214479438|NCT05255133|OTHER|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
214479439|NCT06203106|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
214284149|NCT01308775|BEHAVIORAL|SIS.NET, Routine Follow-up|"* SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.~* Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit."
214284150|NCT00160290|DRUG|Lactulose|15 mL / 12 hours
214284151|NCT00160290|DRUG|Plantago ovata|3,5 g / 12 hours
214284152|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg）|
214284153|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg）|
214284154|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg）|
214284155|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg） and vaccine|
214284156|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg） and vaccine|
214284157|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg） and vaccine|
214284158|NCT02559921|BIOLOGICAL|placebo and vaccine|
214284159|NCT01116011|DRUG|AZD7268|Capsule, Oral, BID
214284160|NCT01116011|DRUG|Placebo|Capsule, Oral, BID
214284161|NCT06485167|DEVICE|HIFEM- chair|The intervention consists of pelvic floor training combined with high-intensity electromagnetic energy treatment (HIFEM®). This includes six HIFEM® treatments (each lasting 28 minutes) with one session per week over six weeks. The woman completes a voiding diary before treatment and one week (±7 days) after treatment. She sits fully clothed on the HIFEM chair.
214284162|NCT02573311|DRUG|tamsulosin hydrochloride|
214284163|NCT05660551|OTHER|Demostration|This group will be demonstrated on a model after the theoretical training. The maneuvers used in the management of shoulder dystocia will be shown to the students on the model, respectively.
214471066|NCT05333393|BEHAVIORAL|DİABOT (mobile application robot )|Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type 1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet.
214471067|NCT02070549|DRUG|Trametinib|Given PO
214471068|NCT04819334|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
214471069|NCT06487208|OTHER|Use of a digital cognitive aid in order to anticipate a critical situation|Use of a digital cognitive aid in order to anticipate a critical situation
214471070|NCT06487208|OTHER|Placebo|No intervention
214284164|NCT05660551|OTHER|Telesimulation|After the theoretical training for this group, telesimulation will be applied. A scenario will be created for the telesimulation experience and a video will be shot with this scenario. These videos will be watched by the students in groups of 4 on Microsoft Teams and a case discussion will be made through this scenario.
214284165|NCT05660551|OTHER|Kahoot Game|Kahoot, a game-based program, will be applied to this group one week after the theoretical training. The game will be organized according to the learning objectives and achievements related to shoulder dystocia.
214284166|NCT00603889|BIOLOGICAL|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
214284167|NCT05494333|OTHER|no intervention|NO intervention
214471071|NCT03295721|DRUG|HTX-011|HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
214471072|NCT03295721|DRUG|Saline Placebo|Saline placebo by instillation
214471073|NCT03295721|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg by injection
214471074|NCT03295721|DEVICE|Luer-lock applicator|Applicator for instillation
214471075|NCT03295721|DEVICE|Vial access device|Device for withdrawal of drug product
214471076|NCT05616247|BEHAVIORAL|ECALC|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention
214284168|NCT04089384|OTHER|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
214284169|NCT04089384|OTHER|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
214284170|NCT04089384|OTHER|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
214284171|NCT05022108|BIOLOGICAL|Alpha bisabolol gel|Using alpha bisabolol gel with a concentration of 0.5%, 2,5% or 5% to treat sensitized area with histamine.
214284172|NCT02914899|BEHAVIORAL|Surveys|"Intake surveys recorded demographics, workplace profile, financial profile, health care access, cancer screening behavior, medical history, etc.~Exit surveys asked whether drivers received shared decision making (SDM) counseling, completed LCS (low-dose computed tomography \[LDCT\] scan), had barriers, felt satisfied, etc."
214284173|NCT02914899|BEHAVIORAL|Navigation|CHWs facilitated SDM and LCS for drivers, providing navigation ( finding a PCP, scheduling appointments, assisting with insurance, etc.), following up on results and next steps.
214284174|NCT02914899|BEHAVIORAL|Focus groups|Gained drivers' perspectives on adapting the community health worker (CHW) model to facilitate lung cancer screening (LCS).
214284175|NCT02914899|BEHAVIORAL|In-depth interviews|"Interviews with Chinese livery bases elicited perspectives on adapting the CWH model for the drivers' occupational environment.~Interviews with PCPs, clinic directors, etc. serving Chinese communities provided insight into adapting the CHW model within the health care context."
214284176|NCT04774640|DEVICE|MaterniT GENOME|
214284177|NCT06629818|DRUG|Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)|qw cycle 1-2, q2w cycle 3-6, q4w cycle 7-12
214284178|NCT06629818|DRUG|Venetoclax|400mg po qd for 1 year
214284179|NCT06629818|DRUG|Dexamethasone|Dexamethasone 20mg po qw for the first 6 months, then 10mg po qw for the next 6 months
214471077|NCT05616247|BEHAVIORAL|ECALC Plus Weekly Boosters|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention Plus Weekly Booster Content Delivered by Mobile Device
214284180|NCT06069102|DRUG|Usual care|The usual care group will be given anti-hypertensive medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's BP consistently exceeds 150/100 mmHg consistently.
214284181|NCT06069102|DRUG|Tight blood pressure control|The intervention group will be initiated on blood pressure medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's hospital BP consistently exceeds 140/90 mmHg or home BP consistently exceeds 135/85 mmHg.
214284182|NCT05683249|DRUG|NRCT-101-SR|NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects \< 50kg LBM receive a total of four 375 mg tablets per day.
214284183|NCT05683249|DRUG|Placebo|Matching placebo
214284184|NCT05148052|DEVICE|Virtual reality exergames|Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
214284185|NCT05148052|BEHAVIORAL|Conventional occupational therapy|Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
214471078|NCT04752657|OTHER|Delayed administration of survey modules|The intervention consists in delaying the administration of the physical function, physical activity, and events survey modules by 2 weeks
214471079|NCT04752657|OTHER|Regular administration of survey modules|The physical function, physical activity, and events survey modules are administered according to the regular pattern
214284186|NCT06133270|DRUG|NNC0560-0004|NNC0560-0004, Oral administration (taken through the mouth)
214284187|NCT06133270|DRUG|Placebo (NNC0560-0004)|Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
214471080|NCT06799325|BEHAVIORAL|acceptance and commitment therapy based stress management program|The Stress Management Program Based on Acceptance and Commitment Therapy will be applied to the intervention group, consisting of 6 sessions, 1 session per week, and each session lasting 45 minutes.
214471081|NCT06455241|OTHER|HABIT (Hand Activities Behavior Intervention)|A Novel Occupational Therapy Intervention for Enhancing Daily Hand-Use of the affected upper extremity Among Individuals post Stroke.
214471082|NCT06757036|BEHAVIORAL|Laughter Yoga|the group where Laughter Yoga is performed
214471083|NCT06422793|PROCEDURE|No NG tube gastric decompression|Participants in this group will not undergo gastric decompression following orthognathic surgery at our institution.
214471084|NCT06799975|OTHER|Education|"Patients in the education group will have a meeting with a physiotherapist at the end of the T1 evaluation, which will take place in a suitable room that ensures privacy is maintained. During this meeting, the physiotherapist will provide the patient with advice regarding their return home and will suggest simple exercises to activate/maintain the abdominal and lower back muscles, to be performed at home until the next visit, one month after the surgery. These exercises are part of standard clinical practice and should be routinely performed by patients who undergo lumbar spinal fusion in the period following the surgery. Additionally, the patient will have the opportunity to communicate, via email or phone, with the physiotherapist until the follow-up appointment with the spine surgeon (scheduled for one month later)."
214471085|NCT06799975|OTHER|Usual Care|The usual discharge procedures consist of a brief interview with the neurosurgeon during which instructions are provided on how to manage the first month after the surgery.
214471086|NCT06349109|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test (CPET), the gold standard for the assessment of cardiorespiratory fitness, will be used. The Modified Bruce/half Bruce protocol with will be used. In addition, dyspnoea, leg fatigue and general fatigue will be recorded every three minutes at rest, during the test and during the post-test recovery phases using the Modified Borg Scale and blood pressure will be recorded with a sphygmomanometer. The test will be continued until individuals reach the end of the protocol or until the last point at which they wish to stop the test. The test will be terminated if the patient wishes to terminate the test, severe breathlessness, leg fatigue or general fatigue, loss of coordination, progressive chest pain, ST segment elevation or depression of more than 2 mm, oxygen saturation of 80% or less, reaching 85% or more of the predicted heart rate. Oxygen consumption (VO2peak) will be used as the primary outcome measure for cardiorespiratory fitness.
214479440|NCT06343051|DEVICE|USCOM|Device that measures how much blood is being pumped in and out of the heart.
214479441|NCT06610890|DRUG|Hemay005|One 15mg tablet, four tablets at a time
214284188|NCT06647407|BIOLOGICAL|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
214479442|NCT06610890|DRUG|Midazolam maleate|One 15mg tablet, one tablet at a time
214284189|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection in vial Route of administration: Intramuscular (IM)
214284190|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Powder and solvent for injectable solution in a pre-filled syringe Route of administration: Intramuscular (IM)
214284191|NCT06647407|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
214284192|NCT06647407|DRUG|Paracetamol|Pharmaceutical form:Suspension-Route of administration:oral
214284193|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
214284194|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
214284195|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Oral solution in tube Route of administration: oral
214284196|NCT06647407|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
214284197|NCT06647407|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
214284198|NCT00265798|DRUG|Sorafenib Tosylate|
214284199|NCT03503305|DEVICE|adipose-derived stem cell injection|5 ml injection of adipose derived stem cells
214471087|NCT06349109|OTHER|Atrial-Ventricular Strain Analysis|Atrial-Ventricular strain will be evaluated by a specialist physician using Speckle Tracking Echocardiography. During the evaluation, standard echocardiographic measurements will be made with transthoracic echocardiography. With these measurements, images suitable for strain analysis will be obtained. Deformation analysis will be performed using the speckle tracing method for the appropriate images obtained and hemodynamic parameters obtained by the analysis will be recorded.
214471088|NCT06349109|OTHER|Arterial Stiffness Measurement|Arterial stiffness will be assessed using the pulse wave velocity (PWV) technique with the Mobile-O-GRAPH (TG) (LE.M., Stolberg, Germany), an oscillometer-based device. After the patients have rested sufficiently, measurements will be taken in an upright sitting position in a quiet and sufficiently bright environment at room temperature, with the device manso placed 2-3 cm above the chiibital fossa in the non-dominant upper limb and the arms raised to the level of the heart. Pulse propagation velocity will be calculated in m/sec with the help of a computer. A high velocity data indicates a high level of arterial stiffening and a low velocity data indicates a low level of arterial stiffening.
214471089|NCT06349109|OTHER|Physical Activity Level|Physical activity level will be assessed with the Child Physical Activity Questionnaire.
214906897|NCT01019343|DEVICE|Arm Intellistretch Device|The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
214284200|NCT03503305|DRUG|Corticosteroid injection|5 ml injection of corticosteroid
214284201|NCT01401582|OTHER|Implementation of Dementia Care Manager|"Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers."
214284202|NCT05798897|DRUG|MT-601|Multi-antigen specific CD4+ andCD8+ T cells
214284203|NCT05637710|DRUG|Administration of investigation of Eurofarma drug|Participants randomized to this group will receive one (01) film-coated tablet of the investigational drug + one (01) levocetirizine placebo tablet, once a day, for seven (07) days.
214284204|NCT05637710|DRUG|Administration of Comparator|Participants randomized to this group will receive one (01) levocetirizine 5mg tablet (Zina® 5mg) + one (01) FDC placebo tablet, once daily, for seven (07) days.
214284205|NCT04015622|DRUG|Enzalutamide|Enzalutamide 160 mg PO OD
214284206|NCT04015622|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks
214284207|NCT05487989|OTHER|Clinical examen|MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
214284208|NCT04603183|DRUG|Abemaciclib|Patients will receive abemaciclib 150 mg orally twice daily (BID) (300 mg daily, administered as six 50 mg tablets) during each 28 day cycle combined with either letrozole or fulvestrant.
214284209|NCT04603183|DRUG|Paclitaxel|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
214284210|NCT04603183|DRUG|Letrozole|Patients will receive 2.5 mg letrozole, orally administered and taken daily during each 28-day cycle combined with abemaciclib.
214284211|NCT04603183|DRUG|Fulvestrant|Patients will receive 500 mg fulvestrant, by intramuscular \[IM\] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter combined with abemaciclib.
214284212|NCT05860647|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
214284213|NCT04774393|DRUG|Decitabine and Cedazuridine|Given PO
214284214|NCT04774393|DRUG|Enasidenib|Given PO
214284215|NCT04774393|DRUG|Ivosidenib|Given PO
214284216|NCT04774393|DRUG|Venetoclax|Given PO
214284217|NCT05288062|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspirate/biopsy
214471090|NCT06349109|OTHER|Physical Activity Barriers Assesment|"Physical Activity Outcome Expectancies (child survey) and Physical Activity Home Environment Scale (Child) will be used in children, while  Physical activity barriers (Parent) will be used in family members."
214479443|NCT03003533|GENETIC|SPK-8011|A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene
214479444|NCT06503679|DRUG|LY4100511 (DC-853) Dose 1|Administered orally
214284218|NCT05288062|DRUG|Dexamethasone|Given orally
214284219|NCT05288062|DRUG|Lenalidomide|Given orally
214284220|NCT05288062|DRUG|Pomalidomide|Given orally
214284221|NCT06384209|DRUG|Fluoxetine|The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 20mg Fluoxetine. The nurse will then dispense the antidepressants for two weeks. As the study population comprises patients with more severe forms of depression, the investigators don't expect a relevant response to this starting dose. Therefore, after two weeks, which corresponds to the third FB counselling session, the nurse will increase to 40mg Fluoxetine.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Fluoxetine will be increased to 60mg, reassured and encouraged that the goals they set can be achieved.
214284222|NCT06384209|DRUG|Sertraline Pill|The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 50mg Sertraline for all breastfeeding women instead of Fluoxetine. The nurse will then dispense the antidepressants for two weeks. As the study population comprises patients with more severe forms of depression, the investigators don't expect a relevant response to this starting dose. Therefore, after two weeks, which corresponds to the third FB counselling session, the nurse will increase to 100mg Sertraline if breastfeeding.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Sertraline will be increased to 150mg.
214479445|NCT06503679|DRUG|LY4100511 (DC-853) Dose 2|Administered orally
214844524|NCT00658034|PROCEDURE|Placebo Acupuncture|"Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.~Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture."
214844525|NCT01020617|DIETARY_SUPPLEMENT|Ls-33|10\~10 CFU/day
214844526|NCT05453708|OTHER|Survey|One 15-20-minute survey
214844527|NCT02359864|RADIATION|5 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
214844528|NCT02359864|RADIATION|10 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
214844529|NCT00725764|DRUG|GSK1363089 (foretinib)|Multitargeted tyrosine kinase inhibitor
214844530|NCT03953664|OTHER|Experimental-Exercise training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.
214844531|NCT00003808|DRUG|theophylline|
214844532|NCT04937738|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
214844533|NCT04937738|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
214844534|NCT04937738|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
214844535|NCT04937738|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
214844536|NCT04937738|DRUG|Capecitabine|1000 mg/m² two times per day (BID), d1-14
214844537|NCT04937738|DRUG|Oxaliplatin|130 mg/m² d1 i.v. every 3 weeks
214844538|NCT00361387|DRUG|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
214844539|NCT03853499|OTHER|No intervention (observational study)|No intervention (observational study)
214844540|NCT01788709|OTHER|preparation cleaning solution|
214844541|NCT05580887|DRUG|mFOLFIRINOX|every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1 Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
214844542|NCT05580887|DRUG|Doxorubicin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
214844543|NCT05580887|DRUG|Cyclophosphamid|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
214844544|NCT05580887|DRUG|Paclitaxel|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
214844545|NCT05580887|DRUG|Carboplatin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
214844546|NCT05040737|DEVICE|PS membrane versus PMMA membrane,|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
214844547|NCT01360437|DRUG|Prasugrel|Prasugrel 10mg/day
215033277|NCT01554358|BEHAVIORAL|Lifestyle intervention|"The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake \<30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~\--------------------------------------------------------------------------------"
215033278|NCT02477033|DIETARY_SUPPLEMENT|Butyricicoccus pullicaecorum 25-3T|
214479446|NCT06503679|DRUG|LY4100511 (DC-853) Dose 3|Administered orally
214479447|NCT06503679|DRUG|Midazolam|Administered orally
214844548|NCT01360437|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
214844549|NCT02625337|DRUG|Pembrolizumab|
214844550|NCT02625337|DRUG|Dabrafenib|
214844551|NCT02625337|DRUG|Trametinib|
214844552|NCT02625337|PROCEDURE|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
214844553|NCT02625337|PROCEDURE|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
214844554|NCT01928615|DRUG|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
214844555|NCT01928615|DRUG|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
214844556|NCT01928615|DRUG|Chemotherapy|Standard chemotherapy for early breast cancer.
214844557|NCT05476133|OTHER|Executive functions training-elementary and Promoting executive function in in the classroom|evidence based practice that target executive function skills in early elementary years.
214844558|NCT01223209|DRUG|LTX-315|0.25-2.0 mg/ML, maximum 5 injections during 36 days.
214844559|NCT00709137|DRUG|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
214844560|NCT00709137|DRUG|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
214844561|NCT00828828|BIOLOGICAL|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
214844562|NCT01239498|PROCEDURE|Injection of Saline + Lidocaine/Adrenaline|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.~Injection of Saline + Lidocaine 1%"
214844563|NCT01239498|PROCEDURE|Lidocaine/Adrenaline only|Injection of Lidocaine/Adrenaline only
215033279|NCT02477033|OTHER|Maltodextrin|
215033280|NCT04528186|DIAGNOSTIC_TEST|Maternal thyroid volume|Maternal thyroid volume measurement
215033281|NCT04847037|PROCEDURE|Connected tools|Use of connected tools in postoperative bariatric follow-up vs no use of connected tools.
215033282|NCT06032390|OTHER|AI assisted mammography screening interpretation|Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in a consensus meeting. Examinations with an AI score of \>9.8 will be selected for the consensus meeting by default. AI risk scores and image markings are provided to the readers only in the consensus meetings. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).
215033283|NCT06032390|OTHER|Standard mammography screening interpretation|Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in a consensus meeting, and the radiologists will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system retrospectively but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.
215033284|NCT06262659|OTHER|Doppler Ultrasonography Assessment|"Preoperative data will be collected from the latest available data within the last month. Preoperative Doppler ultrasonography venous mapping for all patients will be performed by experienced Radiology Specialists.~AVF flow measurement will be performed intraoperatively and at the 6th week postoperatively using Doppler ultrasonography (B-Mode and duplex ultrasound on the LOQIC; GE Healthcare Technologies, Milwaukee, Wisconsin, United States). For each patient, AVF flows will be recorded by taking at least 3 measurements of AVF flow, depth, and vascular diameters at 2, 5, 10, and 15 cm proximal to the AVF anastomosis, and arithmetic averages will be calculated. AVF flow will be expressed in ml/min, and the vascular structure diameters and the distance of AVF from the skin will be indicated in mm. AVF depth will be calculated as the distance from the skin to the anterior wall of the AVF."
215033285|NCT04070209|DRUG|Darolutamide (BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
215033286|NCT04070209|RADIATION|SBRT|SBRT will consist of 2-5 fractions of highly targeted radiation therapy delivered every other day. The radiation component will be completed in 4-10 days.
215033287|NCT05040776|DRUG|EP-7041 Injection|EP-7041 infusion
215033288|NCT05176587|OTHER|Follow-up of patients undergoing bariatric surgery : integrated pathway|Integrated pathway : multidisciplinary, pre- and post-operative, care course for patients undergoing bariatric surgery
215033289|NCT05785208|DRUG|Osimertinib|Osimertinib will be administered at a dose of 80 mg daily until disease progression
215033290|NCT02639689|DEVICE|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
215033291|NCT06193707|OTHER|the Remote Intervention|Remote health intervention refers to the use of big data, artificial intelligence and 5G technology to provide healthcare services and interventions to individuals at a distance. This approach allows healthcare providers to deliver medical care, monitor patients' health, offer consultations, provide education, and offer support without the need for in-person interaction.
215033292|NCT06193707|OTHER|the Traditional Intervention|Ultrasound follow-up review is recommended. If there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
215033293|NCT04410861|PROCEDURE|Micropulse laser photostimulation|In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.
215033294|NCT05928988|DRUG|SHR8554；Itraconazole|Drug: SHR8554 Administered as specified in the treatment arm Drug: Itraconazole Administered as specified in the treatment arm
215033295|NCT02185183|DRUG|Alequel|Alequel
215033296|NCT04164381|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
215033297|NCT03589274|BEHAVIORAL|I-FS-CBT|12 manual-guided sessions of I-FS-CBT
215033298|NCT03589274|BEHAVIORAL|G-FS-CBT|12 manual-guided sessions of G-FS-CBT
215033299|NCT05702307|OTHER|Glucose as reference food|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
215033300|NCT05702307|OTHER|Tagliatella control|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from tagliatella control, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
215033301|NCT05702307|OTHER|5% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 5% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
214471091|NCT06230380|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PTGs during surgery. The surgical field will be visualized with AF as a minimum of two times during surgery on each side of the neck: First upon exposing the undersurface of the thyroid gland, and secondly before removal of a pathological PTG. Also, removed PTGs will be examined ex vivo to document AF pattern.
214284223|NCT06384209|BEHAVIORAL|Friendship Bench Intervention- Problem Solving Therapy|The Friendship Bench Problem-solving therapy is an evidence-based intervention for depression delivered by Lay Health Workers according to an established manual. Patients are encouraged to come up with a list of their problems, to select one problem they want to tackle, brainstorm for solutions, identify the best solution, and develop an action plan to implement it until the next session. Each session consists of four stages, namely kuvhura pfungwa (opening the mind), kusimudzira (uplifting), kusimbisa (strengthening) and kusimbisisa (re-strengthening). The LHW helps patients to recognize potentially dysfunctional problem-solving and develop a realistic plan for the successful resolution of the prioritized problem. Participants are reassured and encouraged that the goals they set can be achieved. The sessions will be delivered approximately one week apart
214284224|NCT03381482|DIAGNOSTIC_TEST|CSF drawing during spinal anaesthesia|4mL of CSF by lumbar puncture
214284225|NCT03381482|DIAGNOSTIC_TEST|Fasting blood sample|6x5 mL of fasting blood sample
215033302|NCT05702307|OTHER|16% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
215033303|NCT05702307|OTHER|16% sunflower penne|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower penne, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and samples from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
215033304|NCT05702307|OTHER|16% sunflower fusilli|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower fusilli, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
215033305|NCT00791648|DRUG|atorvastatin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
215033306|NCT00791648|DRUG|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
215033307|NCT05209035|DRUG|Trazodone|Trazodone 50mg daily
215033308|NCT05209035|OTHER|Placebo|Starch 50mg
215033309|NCT00317265|PROCEDURE|Coronary bypass surgery|
215033310|NCT04976777|DEVICE|Updated DEX PS DDS Applicator|Intravitreal Administration
215033311|NCT04976777|DEVICE|Approved DEX PS DDS Applicator|Intravitreal administration
215033312|NCT04976777|DRUG|Dexamethasone|Dexamethasone 0.7 mg in a solid polymer drug delivery system
215033313|NCT00462826|BIOLOGICAL|ziv-aflibercept|
215033314|NCT05114928|PROCEDURE|Transepithelial Corneal Collagen Cross-linking|Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
215033315|NCT05114928|DIAGNOSTIC_TEST|Scheimpflug camera|Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
215033316|NCT03944395|OTHER|Assisted Partner Notification Services|Three options for partner Notification services; contract referral, provider referral and dual referral
215033318|NCT06956391|DRUG|18F-FDG|Participants will be injected with 18F-FDG and imaged for up to 3 hours on a PET scanner
215033319|NCT03983330|BEHAVIORAL|Brief Motivational Interviewing (i-BMI)|"The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
215033320|NCT03983330|BEHAVIORAL|Control|Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
214284226|NCT03381482|DIAGNOSTIC_TEST|Lumbar puncture|10 mL of CSF by lumbar puncture
214284227|NCT04038502|DRUG|Carboplatin|Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
215033321|NCT04319757|DRUG|ACE1702|ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously
215033322|NCT04319757|DRUG|Cyclophosphamide|Lympho-conditioning agent
215033323|NCT04319757|DRUG|Fludarabine|Lympho-conditioning agent
214284228|NCT04038502|DRUG|Olaparib|Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
214284229|NCT05765266|DEVICE|ACP Max™|Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
214284230|NCT05765266|DEVICE|Depo-Medrol®|Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
214284231|NCT03350581|PROCEDURE|FAM 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by FAM alone.
215033324|NCT05291650|DRUG|Glucocorticoids|The product of the glucocorticoid is betamethasone injectable suspension and the dosage is 1 ml. To alleviate the discomfort on local tissues, the suspension injected into the infrapatellar fat pad will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine. That is, the total amount of the drug injected into the infrapatellar fat pad for the glucocorticoid group will be 2.0 ml.
214471092|NCT04072783|DIAGNOSTIC_TEST|MRI,DTI, functional MRI|"1. Patients will undergo testing with Pre- and and post-surgical MRI. The protocol will be Sagittal T1, Axial inversion recovery, T2, fluid-attenuated inversion recovery, susceptibility weighted image, diffusion weighted images, diffusion tensor imaging, resting state fMRI, sagittal 3D GRE / FFE or 3D T1 VIBE and tractography.~2. Once patients are identified, surgery is planned.The standard of care procedures fall into two categories based on age of presentation, clinician judgement and family preference all other things being equal. Both the endoscopic-assisted craniectomy and open CVR are standard of care procedures. Patients self-select into these groups. None of the surgery nor any aspect of it is experimental.~3. Patients are routinely examined for neurodevelopment pre- and post-operatively as part of American Cleft Palate Craniofacial Association guidelines.The Vineland Adaptive Behavior Scales are used up to and including age 4."
214471093|NCT06517394|BEHAVIORAL|Recovering Together after Cardiac Arrest|The intervention will teach resiliency skills (mindfulness, coping, etc.) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person or on Zoom/telephone, depending on the participant's preference and access to technology.
214471094|NCT06185413|OTHER|Participatory system dynamics approach|First, local health profiles of children will be collected and used to engage key leaders and stakeholders from intervention communities and municipal administrations in participatory processes. These will be used to develop a systems map of drivers of PA behaviour in schoolchildren aged 6-12 years in the local communities. Second, based on the systems map, stakeholders from the civic and private sectors will be involved in developing and implementing actions to promote healthy PA behaviour through system changes.
214471095|NCT06374225|DEVICE|Automated Titration (O2matic)|The patient will receive supplemental oxygen titrated using an autonomous oxygen titration device. The patient will be monitored and vital signs documented by the site's usual SpO2 assessments, but oxygen titration will occur automatically through the O2matic PRO100 device during the intervention period, unless there is a safety concern. The SpO2 range programmed into the PRO100 is 92-94%. The acceptable SpO2 range for the protocol is 90-96%. If a patient requires \>15lpm or other signs of advancing respiratory failure, they will be taken off the autonomous oxygen and transitioned to higher flow oxygen devices or mechanical ventilation per usual clinical care. If the patient is not receiving any supplemental oxygen per the autonomous titration, the clinical team may remove the oxygen delivery device from the patient, but the patient should remain connected to the PRO100 for the duration of the intervention period for data collection and to monitor for new supplemental oxygen needs.
214471096|NCT04966299|DIETARY_SUPPLEMENT|Eryhtritol|"Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks~EryClot-Pilot:~Erythritol 50g dissolved in 300mL water administered once per visit~EryClot:~Erythritol 50g dissolved in 300mL water administered once per visit"
214471097|NCT04966299|DIETARY_SUPPLEMENT|Sucrose|Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
214471098|NCT04966299|DIETARY_SUPPLEMENT|Glucose|Glucose 75g dissolved in 300mL water administered once per visit
214471099|NCT04966299|DIETARY_SUPPLEMENT|Fructose|Fructose 25g dissolved in 300mL water administered once per visit
214471100|NCT04966299|DIETARY_SUPPLEMENT|Xylitol|Xylitol 33.5g dissolved in 300mL water administered once per visit
214471101|NCT04966299|DIETARY_SUPPLEMENT|Water|300mL water administered once per visit
214479448|NCT06503679|DRUG|Repaglinide|Administered orally
214479449|NCT06503679|DRUG|Digoxin|Administered orally
214479450|NCT06503679|DRUG|Rosuvastatin|Administered orally
214479451|NCT04564209|OTHER|Info Viz for Health|During the intervention, health care providers provide HIV-related health education using a mobile app that contains a bilingual database of relevant infographics.
214479452|NCT06667336|PROCEDURE|intermittent suction|This suction was applied only as needed to clear secretions
215033325|NCT05291650|DRUG|Saline|A total of 2.0 ml drug including 1.5 ml saline and 0.5 ml lidocaine will be injected into the infrapatellar fat pad for the placebo group.
215033326|NCT05291650|DRUG|Hyaluronic acid|After completing the process of infrapatellar fat pad injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space.
215033327|NCT06789588|DRUG|pharmacogenetic algorithm|The dose predictor algorithm proposed in this work aims to maintain and quality treatment in an individualized and effective manner. In the routine use protocol, warfarin is prescribed based only on the INR collected within 5 days. The proposed intervention protocol is based on the patient's clinical and genetic factors, such as genetic polymorphisms, age, weight, height, race, use of amiodarone, statins, antifungals or antibiotics, tobacco use, clinical indication and what the RNI target.
215033328|NCT06789588|DRUG|Clinical treatment|Patients with AF indicated for OAC therapy guided by institutional protocol.
215033329|NCT05975242|BEHAVIORAL|Smartphone diabetes management application|The intervention is a smartphone diabetes management application that is combined with structured blood glucose testing.
215033330|NCT06441162|DRUG|Nebulized 3% sodium chloride solution|Standardized dose of nebulized 3% sodium chloride will be provided from 4 mL vial and administered be every 6 hours.
214284232|NCT03350581|PROCEDURE|FAM-CT 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by the integration of the FAM with CT or MRI.
214284233|NCT06459245|BEHAVIORAL|Resistance training|Bend the dumbbell, holding one dumbbell in each hand, on the side of the body, bend the arm to lift the dumbbell, front wall and upper arm as close as possible, pause for a moment, and then slowly lower the dumbbell until both arms are completely straight The second section of the dumbbell side flat, straight back, feet standing, arms perpendicular to the side of the body, hands grasp the dumbbell, to the side above the shoulder level, elbow slightly bent, and then put back in place The third section of the dumbbell rowing, feet stand straight, hold the dumbbell, the arm as far back as possible, can feel the upper arm and the waist back is stretched, and then straight back into the preparatory position Section 4: Lift the dumbbell flat in front of you, with your feet open, hold the dumbbell with both hands, extend your arms naturally in front of you, lift the dumbbell to the elbow above shoulder height, stay for 1-2 seconds.
214284234|NCT03286335|RADIATION|Proton Radiation|Radiation treatment
214284235|NCT03886480|DEVICE|SaeboVR|Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
214284236|NCT02742610|BEHAVIORAL|Mindfulness with Contingency Management|
214284237|NCT02742610|BEHAVIORAL|Active Control|
214284238|NCT00880828|OTHER|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
214284239|NCT00880828|OTHER|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
214284240|NCT00880828|DRUG|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
214471102|NCT06334991|BIOLOGICAL|CD19 t-haNK|"CD19t-haNK erived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).~Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM."
214471103|NCT03325985|BEHAVIORAL|Nurse-led telephonic case management|Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
214471104|NCT03325985|BEHAVIORAL|Facilitated,outpatient specialty palliative care|In-person or telehealth palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
214471105|NCT06395779|BEHAVIORAL|Neuromuscular Exercise Group|A 12-week Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization, balance training, muscle strength, breathing, and functional movement patterns will be created for the participants in Group 1.
214471106|NCT06395779|BEHAVIORAL|Dance Therapy Group|Participants in Group 2 will be given dance training by a dance instructor in the gym for 1 hour a day, 2 days a week, for a total of 12 weeks. In dance therapy practices, simple and basic movements are appropriate to the level of the participants, and special attention will be paid to the rhythm of the music not being fast. Latin dances were applied to the participants; selected rumba, merengue, bachata, and salsa movements. Dance therapy will start with a warm-up exercise (10 minutes), then dance exercises will be applied and the activity will end with a cool-down exercise (10 minutes).
214471107|NCT04321551|DRUG|Testosterone Cyp 200Mg/Ml Inj (in Oil)|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.
214471108|NCT04321551|DRUG|Letrozole|Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1- ylmethylene)dibenzonitrile. Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C. Letrozole is available as 2.5 mg tablets for oral administration.
214471109|NCT05811585|DEVICE|ADEPT|Adhesion Reduction Solution (4% icodextrin solution)
214471110|NCT06444295|BEHAVIORAL|Activity scheduling|"Participants will engage in activity scheduling in the app (i.e., Activities module). On the first day of using the app, users will create a list of valued/important and avoided activities (e.g., spending time with friends, going to the gym), and then have the option to add alcohol protective behavioral strategies (e.g., adding ice to drinks, alternating alcoholic and nonalcoholic beverages) to activities that the user identifies as being likely to involve drinking. On subsequent days, users will be encouraged to complete at least one activity from their list."
214471111|NCT06444295|BEHAVIORAL|Cognitive restructuring|"Participants will engage in cognitive restructuring in the app (i.e., Thoughts activities). Users first go through an activity involving the identification of maladaptive cognitions and create a list of their maladaptive cognitions. On subsequent days, they engage in a guided in-app activity involving cognitive restructuring of maladaptive cognitions from their list."
214479453|NCT06667336|PROCEDURE|continuous suction|The suction catheter was inserted at the start of laryngoscopy and maintained in the oropharynx until the moment of ETT delivery.
214479454|NCT03873402|BIOLOGICAL|Nivolumab|Specified dose on specified days
214479455|NCT03873402|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214471112|NCT06444295|BEHAVIORAL|Coaching calls|Participants will receive 10-20 minute weekly coaching calls during the app use period (4 total, including coaching provided in the enrollment call). All coaching calls will, at minimum, include a check-in, troubleshooting of technical issues, check-in about experience with symptom self-monitoring, and offers of referrals. Coaching calls in conditions involving activity scheduling will involve assistance with the Activities module. Coaching calls in conditions involving cognitive restructuring will involve assistance with the Thoughts module.
214471113|NCT06444295|BEHAVIORAL|Non-core intervention components|"All participants, regardless of condition, will receive the following non-core THRIVE components.~* 21 days of brief self-report surveys in the app assessing their PTSD symptoms and alcohol use in the prior 24 hours.~* A banner in their app displaying rotating non-personalized encouraging messages from other users. All app users will have the option of submitting encouraging statements to be displayed to all other users. Statements will be vetted by study staff before posting.~* Lists of referral options specific to each recruitment site via the Resources section of the app.~* Answers to frequently asked questions about the study, the study consent form, and contact information for the study team via the Information section of the app.~* One call with a study point person within the first week following randomization to ensure they were able to access the app and troubleshoot access issues"
214284241|NCT06498401|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
214284242|NCT04103853|DRUG|Proxalutamide|Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
214284243|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 1. Group 1 receives treatment A\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B\*\* was applied to group 1 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
214284244|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 2. Group 2 receives treatment B\*\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A\* was applied to group 2 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
214284245|NCT06384768|OTHER|Video training|A 4 week support program consist of videos for fear of childbirth
214284246|NCT03624894|OTHER|impression|common polyvinylsiloxane oral impression
214284247|NCT02579044|DRUG|Everolimus and lonafarnib|
214471119|NCT06559007|DRUG|HRS-5041 dose level 1|Single dose of HRS-5041 orally administered
214284248|NCT06039930|BEHAVIORAL|Tele PROTECT|Tele-PROTECT is a behavioral intervention delivered virtually over nine 45-minute sessions for depressed elder abuse (EA) victims. It is designed to work in synergy with EA resolution services that provide safety planning, support services, and links to legal services.
214284249|NCT06039930|BEHAVIORAL|Depression Education|DepEd is designed as an intervention delivered virtually over nine 45-minute sessions with active therapeutic ingredients (education, support, empathy). It is designed to be what a good clinician providing education would do with an individual with depression.
214471120|NCT06559007|DRUG|HRS-5041 dose level 2|Single dose of HRS-5041 orally administered
214471121|NCT06423339|PROCEDURE|Ultrasound guided Genicular nerve block|Ultrasound guided genicular nerve block
214471122|NCT06423339|PROCEDURE|Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee|Ultrasound guided Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee
214471123|NCT06423339|PROCEDURE|Adductor canal block|Ultrasound guided sub-sartorial Adductor canal block
214471124|NCT06423339|DRUG|Bupivacaine Hydrochloride|Pupivacaine 0.5% in 20 ml vial
214471125|NCT05052255|DRUG|RVU120|RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
215033331|NCT06441162|DEVICE|Chest percussion cups|The chest percussion cup is a small, flexible cup made of vinyl that is used to provide gentle chest wall vibrations to assist with airway clearance and is utilized in patients of all ages with sputum production, such as those with acute bronchiolitis. Administered every 6 hours while on supplemental oxygen therapy.
214471126|NCT02821351|DEVICE|Radio frequency (RF) Cardiac ablation|Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
214471127|NCT05032092|DIAGNOSTIC_TEST|Next Generation Sequencing|Molecular analysis of liquid biopsy.
214471128|NCT05032092|DIAGNOSTIC_TEST|Next Generation Sequencing|Molecular analysis of tissue biopsy.
214284250|NCT01217814|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214471129|NCT05032092|GENETIC|Biomarker Monitoring|Biomarker Monitoring of study patients receiving matched therapy.
214471130|NCT05100212|BIOLOGICAL|cord blood-RBC concentrates|Patients in the experimental arm are candidates to receive CB-RBC units until the completion of 29 weeks of postmenstrual age (29+6). In case of unavailability of an ABO/Rh matched CB-RBC unit, patients receive adult -RBC (standard transfusions).
214471131|NCT05100212|BIOLOGICAL|adult donor RBC concentrates|Patients in the comparator arm are candidates to receive adult donor-RBC units
214471132|NCT06310252|DIAGNOSTIC_TEST|Opthalmic assessments|"The participants will undergo the following assessments:~1. Pupil size measurement~2. Manifest refraction (no autorefraction)~3. Monocular in both eyes and binocular uncorrected visual acuity (photopic):~   * Distance (4 m)~  * Intermediate (80 cm)~  * Near (40 cm)~4. Monocular best corrected visual acuity (photopic):~   * Distance (4 m)~  * Near (40 cm)~  * Distance-corrected near (40 cm)~5. Monocular and binocular mesopic (with and without glare) and photopic (without glare) contrast sensitivity testing (subgroup)~6. Slit lamp examination~7. Tear breakup time~8. Placido Corneal topography, keratometry and pachymetry~9. Optical coherence tomography including epithelium mapping (subgroup)~10. Applanation intraocular pressure~11. Cycloplegic refraction~12. Dilated fundus examination~13. Wavefront aberrometry (subgroup)~14. Adverse events"
214471133|NCT04593615|PROCEDURE|ICG near-infrared imaging|Indocyanine green tracer is used to guide laparoscopic D2 lymph node dissection for gastric cancer
214471134|NCT06296368|BEHAVIORAL|Preference Reporting to Improve Management and Experience (PRIME)|PRIME is a decision support tool that uses best-worst scaling to provide a personalized report to providers and patients of their most important treatment priorities
214471135|NCT05975697|OTHER|Experimental group to be applied FES|"In the first 24 hours after the thrombectomy procedure, the relatives of the patients in the experimental and control groups who meet the inclusion criteria will be informed by the researcher and their consent will be obtained.~FES treatment to the deltoid, triceps, extensor carpi radialis muscles for a total of 10 sessions, 30 minutes twice a day (in the morning and in the evening), for 5 days after the first 24th hour after the thrombectomy procedure in the experimental group patients (Program duration is 15 minutes and resting time is 15 minutes). minutes) will be applied.Patient information form (Appendix 1), Fugl-meyer upper extremity motor assessment scale (Appendix-2) and Quick DASH (Arm, Shoulder and Hand Injury Questionnaire Short Form) (Appendix-3) were given to both groups within the first 24 hours after the thrombectomy procedure. ) will be applied. All patients will be re-evaluated before and on the 5th day after treatment."
214471136|NCT05662865|DRUG|SGLT2 inhibitor|SGTL2i (15 mg) once daily
214471137|NCT05662865|OTHER|Controlled, Adaptive Study Diet|An adaptive study diet combined with SGLT2i, which consists of four sequential, 7-day long phases in which dietary carbohydrates are gradually reduced (50% carbs, 30% carbs, 20% carbs, and 10% carbs) based on safety and tolerability to achieve moderate ketosis. All diet phases are isocaloric. All meals are provided on an inpatient unit.
214471138|NCT01976182|DRUG|Methotrexate|methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
214471139|NCT01976182|DRUG|Cyclophosphamide|cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
214471140|NCT02470728|OTHER|New Clinical Pathway|
214471141|NCT06350175|COMBINATION_PRODUCT|Nicotine Replacement Therapy Agent|The NRT Agents-- 21mg nicotine patches (x14) and 2 mg nicotine lozenges (\~210).
214471142|NCT06350175|OTHER|West Virginia Quit Line|Instructional Pamphlets and contact information for the WV QL. A telehealth line set up to assist people of WV to quit smoking.
214471143|NCT05906589|DIETARY_SUPPLEMENT|Inulin|The participant will take inulin twice daily over a 14 day period.
214471144|NCT05906589|DIETARY_SUPPLEMENT|Psyllium|The participant will take psyllium twice daily over a 14 day period.
214471145|NCT05906589|DIETARY_SUPPLEMENT|Maltodextrin|The participant will take maltodextrin twice daily over a 14 day period.
214284251|NCT01217814|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214284252|NCT01217814|DRUG|Golimumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214471146|NCT04047602|RADIATION|Reduced Dose SRS|Subjects will receive SRS treatment at a reduced dose based on the brain tumor size
214471147|NCT02684227|DRUG|Carboplatin|Given IV
214471148|NCT02684227|DRUG|Enzalutamide|Given PO
214471149|NCT02684227|OTHER|Laboratory Biomarker Analysis|Correlative studies
214284253|NCT01217814|DRUG|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
214284254|NCT01217814|DRUG|Folic/folinic acid|"Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard."
214284255|NCT02421276|OTHER|Phlebotomy|White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
214284256|NCT03256916|DRUG|Nelfinavir|Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.
214471150|NCT02684227|DRUG|Paclitaxel|Given IV
214471151|NCT02684227|OTHER|Pharmacological Study|Correlative studies
214471152|NCT06406075|DEVICE|Lab demo 1.0|During the intervention, transcutaneous spectral data are collected continuously with the Lab demo. Up to 20 whole blood glucose reference values are also collected, as well as interstitial fluid glucose values using a continuous glucose monitoring device. Some participants will attend multiple measurement sessions.
214471153|NCT06509984|DRUG|Apremilast treatment|treatment of apremilast
214471154|NCT03606408|DRUG|osilodrostat|osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
214471155|NCT05390268|BEHAVIORAL|Mobile app-assisted behavioral treatment|"The app-assisted training group has access to a newly developed app in which they are taught how to handle tics. A new app session is released at each new treatment session and the content of the app videos is comparable to the information and training at face-to-face individual treatment, as defined by the manual Niks to Tics\["
214471156|NCT05390268|OTHER|Mobile app-assisted psychoeducation|The app-assisted educational group has access to a newly developed app in which they receive psychoeducation on tics.
214471157|NCT05356962|BEHAVIORAL|StOP?-protocol|The StOP?-protocol is an intra-operative briefing initiated by the responsible surgeon. When performing a StOP?-protocol, the surgeons inform the team present in the operating room about the Status (St) of the operation, the Objectives (O) of the operations, the potential problems (P) they may meet and encourage the team to ask questions or voice concerns (?). The responsible surgeon announces at the team timeout when they plan to perform the StOP-protocol(s).
214471158|NCT05995496|OTHER|Fasting state|16 hours of fasting
214471159|NCT05995496|OTHER|Fed state|Fed a standardized meal
214471160|NCT05995496|OTHER|Magnetic Resonance Imaging|Neuroimaging with computational modeling
214471161|NCT04218318|DEVICE|phototherapy|Phototherapy will be commenced for neonates in both groups according to AAP guidelines.Neonates will be treated with intensified overhead blue LEDs phototherapy if they have a TSB level at or above phototherapy threshold. Neonates will be started on intensified 360◦ LED phototherapy if they have TSB level within 50µmol/L below the exchange threshold. The administration of IVIG is indicated in infants with isoimmune hemolytic disease if TSB lies within 34 to 51 micromol/L of the threshold for exchange transfusion and not responding to initial intensified phototherapy.Infants with a TSB concentration above the thresholds for exchange should have immediate intensified 360◦ LED phototherapy, and preparation for exchange transfusion will be started.Infants showed clinical signs of acute bilirubin encephalopathy will have an immediate exchange transfusion.
214471162|NCT01593241|DRUG|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
214471163|NCT01593241|RADIATION|Involved node RT|Involved node RT
214471164|NCT03556293|BEHAVIORAL|AKI Prevention Toolkit|AKI Prevention Toolkit. Intervention: All sites will receive the AKI Prevention Toolkit including 3 core interventions: 1. Standardized order sets; 2. IV and oral fluids; and 3. Reduced contrast volume. The interventions adhere to the KDIGO guidelines and add interventions developed and tested in our pilot intervention to implement AKI preventive strategies.
214471165|NCT03556293|BEHAVIORAL|Technical Assistance (TA)|Technical Assistance (TA). Intervention: TA will be offered to the 8 teams randomized to the TA condition and will receive the AKI Prevention Toolkit plus monthly technical calls independently. TA arms will include TA with and without automated surveillance reporting (ASR).
214471166|NCT03556293|BEHAVIORAL|Virtual Learning Collaborative (VLC)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 8 teams and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator \[CAC\] and Systems Redesign). VLC arms will include VLC with and without automated surveillance reporting (ASR).
214471167|NCT03556293|BEHAVIORAL|Automated Surveillance Reporting (ASR)|Automated Surveillance Reporting (ASR). Intervention: The ASR will be offered to 8 teams. In addition to either TA or VLC, ASR teams will receive automated monthly reports in the form of an dashboard focused on AKI outcome and preventative measures overtime. The ASR report will be customized to each team and each individual operator and linked to their national VA-CART registry.
214471168|NCT05122793|BEHAVIORAL|Prevention offer|Improvement of outcomes through lifestyle changes and improved health literacy
214471169|NCT06196203|DRUG|AK117|AK117 IV injection
214471170|NCT06196203|DRUG|Placebo|Placebo IV injection
214471171|NCT06196203|DRUG|Azacitidine|Azacitidine SC injection
214471172|NCT04246138|PROCEDURE|alignment types|types of alignment mechanical versus kinematic of TKA to be studied
214471173|NCT03822793|DRUG|Placebo|Patient will receive an intravenous perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 9 minutes, starting at the time of surgical incision.
214471174|NCT03822793|DRUG|Group 1: perfusion of 300 mg Exacyl|Patient will receive an intravenous perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
214471175|NCT03822793|DRUG|Group 2: perfusion of 500 mg Exacyl|Patient will receive an intravenous perfusion of 500 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
214471176|NCT03822793|DRUG|Group 3: perfusion of 1000 mg Exacyl|Patient will receive an intravenous perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
214471177|NCT03822793|DRUG|Group 4: perfusion of 3000 mg Exacyl|Patient will receive an intravenous perfusion of 3000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
214471178|NCT05204329|BIOLOGICAL|MSC Secretome Eye Drops|MSC Secretome eye drop will be dispensed.
214471179|NCT03223090|BEHAVIORAL|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
214471180|NCT03223090|BEHAVIORAL|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
214471181|NCT05203835|DRUG|Acebilustat|By mouth, once a day, 100 mg capsule
214471182|NCT05203835|DRUG|Placebo|Placebo to match acebilustat by mouth, once a day
214471183|NCT00661141|DRUG|Antizol|
214471184|NCT00661141|DRUG|Placebo|
214471185|NCT00661141|OTHER|Ethanol|oral dose of ethanol (0.5 g/kg)
214471186|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 1|Our current hearing aids which will be programmed to our standard frequency response curve.
214284257|NCT03256916|DRUG|Cisplatin|Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.
214284258|NCT03256916|RADIATION|Pelvic EBRT and Brachytherapy|Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 45- 50Gy/23-25 #/5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
214284259|NCT02382393|OTHER|Brain Performance Test (BPT, Lumos Labs, Inc)|A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
214284260|NCT02382393|OTHER|Computerized Assessment|a validated, computerized cognitive assessment tool
214284261|NCT05962697|OTHER|SA controller|Novel controller to be tested
214284262|NCT05962697|OTHER|TA controller|original controller to be tested
214284263|NCT05962697|OTHER|SA controller early testing|Novel controller to be tested early testing
214284264|NCT06562751|OTHER|Questionnaire|Online questionnaire designed by the investigatory team.
214284265|NCT06562751|OTHER|Focus group|Online focus group
214284266|NCT06562751|OTHER|Interview|Online semi-structured interview
214284267|NCT06562751|OTHER|Workshop|Online and face to face co-production workshops
214471187|NCT05828017|DEVICE|Hearing Aid - Variation #1 under Program 1|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
214471188|NCT05828017|OTHER|Hearing Aid - Variation #2 under Program 5 - Streaming Only|Our current hearing aids which will be programmed to our standard frequency response curve.
214471189|NCT05828017|OTHER|Hearing Aid - Variation #3 under Program 5 - Streaming Only|Hearing aids that will have the frequency response curve #3 adjusted and fit to the participant's hearing loss.
214471190|NCT05828017|OTHER|Hearing Aid - Variation #4under Program 5 - Streaming Only|Hearing aids that will have the frequency response curve #4 adjusted and fit to the participant's hearing loss.
214471191|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 2|Our current hearing aids which will be programmed to our standard frequency response curve.
214471192|NCT05828017|OTHER|Hearing Aid - Variation #1 under Program 2|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
214471193|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 3|Our current hearing aids which will be programmed to our standard frequency response curve.
214471194|NCT05828017|OTHER|Hearing Aid - Variation #1 under Program 3|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
214471195|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 4|Our current hearing aids which will be programmed to our standard frequency response curve.
214471196|NCT05828017|OTHER|Hearing Aid - Variation #1 under Program 4|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
214284268|NCT03875651|DEVICE|SYNERGY 4.50 mm and 5.0 mm Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
214284269|NCT00437307|DRUG|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
214284271|NCT00810030|DRUG|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
214471197|NCT05828017|OTHER|Unaided|No hearing aids worn at all and participants tested as is.
214471198|NCT05005416|BEHAVIORAL|GOALS Intervention|Weekly treatment sessions are comprised of a graded activity program focused on goal setting in 4 treatment domains: therapeutic exercise, aerobic activity, functional activity, and pain coping skills. Instruction in cognitive behavioral coping skills for pain include: explaining pain (pain neuroscience education), pacing, soliciting positive social support, cognitive restructuring, present mindedness, and symptom self-management planning.
214471199|NCT05005416|BEHAVIORAL|Usual Care Physical Therapy|Usual care will be characterized by extracting the following variables from participants' electronic health record: date of physician referral to physical therapy for neck or low back pain diagnosis (index referral), attendance of at least one PT visit (adherence), dates of first and last PT visits for index referral (duration of care), number of PT visits attended across an 8-week episode of care for the index referral (number of visits), clinic where PT services were provided (service location), and CPT billing codes issued during the episode of care for the index referral (type and frequency of treatments provided).
214471200|NCT05095727|DRUG|mRNA-3745|Sterile frozen liquid dispersion for injection
214471201|NCT05012163|BEHAVIORAL|Reminder|Letter, short message service (SMS) text, phone, and/or email
214471202|NCT05012163|BEHAVIORAL|Financial incentive|Letter, SMS, phone, and/or email
214471203|NCT05012163|BEHAVIORAL|Lottery|Letter, SMS, phone, and/or email
214471204|NCT06412263|PROCEDURE|Routine root canal treatment/ retreatment|It is a routine clinical procedure involving root canal treatment/ retreatment and pain assessment after the treatment
214479456|NCT03873402|OTHER|Ipilimumab placebo|Specified dose on specified days
214471205|NCT04260867|OTHER|Essential Oil|Those randomized to the treatment group will have containers filled with the essential oil of their choice.
214471206|NCT04260867|OTHER|No Essential Oil|Those randomized to the control group will then be given empty single-use handheld aromatherapy containers containing no essential oil.
214471207|NCT04896580|BEHAVIORAL|Nature based exercise|Participants will engage in three months of moderate intensity PA, consisting of three 50-minute walking sessions per week (5-minute warm-up, 40 minute walk, 5 minute cool-down and stretch) with an exercise physiologist for 12 weeks.
214471208|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Sulfasalazine enteric-coated tablets Cohort A: PBC treatment group: (1) PBC patients with poor response to UDCA after treatment: 30 patients continued to take UDCA(13-15mg/kg), 30 patients took UDCA(13-15mg/kg)+SASP (0.5g orally three times a day), 30 patients took SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected. (2) Newly treated PBC patients: 30 patients took UDCA(13- 15mg/kg) and 30 patients took UDCA(13-15mg/kg)+SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
214471209|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Cohort B:60 cases with hepatitis B cirrhosis were collected from each group, 30 cases continued the current treatment, and 30 patients were taking SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
214471210|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Cohort C：Patients with HCV were treated with sulfasalazine Cohort C: 60 cases with hepatitis C cirrhosis were collected，30 cases continued the current treatment(people with hepatitis C cirrhosis continue to take antivirals), and30 patients were taking SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
214471211|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Cohort D：Patients with alcoholic liver fibrosis/cirrhosis were treated with sulfasalazine 60 cases with alcoholic cirrhosis were collected , 30 cases continued the current treatment and 30 patients were taking SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
214471212|NCT03914300|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214471213|NCT03914300|DRUG|Cabozantinib S-malate|Given PO
214471214|NCT03914300|PROCEDURE|Computed Tomography|Undergo CT
214471215|NCT03914300|BIOLOGICAL|Ipilimumab|Given IV
214471216|NCT03914300|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214471217|NCT03914300|BIOLOGICAL|Nivolumab|Given IV
214471218|NCT06170437|BEHAVIORAL|Smoke-free home resident intervention|Study staff delivered intervention on how to adopt a smoke free home using a pamphlet
214471219|NCT06170437|BEHAVIORAL|Lay Health Worker coaching|Brief tobacco cessation coaching by lay health worker housing staff with residents within 2 weeks of the smoke-free home resident intervention, and on a monthly schedule as part of their routine encounters with residents (total 6 sessions).
214471220|NCT06204900|DEVICE|Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
214471221|NCT05933863|DRUG|PD-(L)1 antibody immunotherapy|The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
214471222|NCT05311085|DRUG|Cytisine|"Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)"
214471223|NCT05311085|DRUG|Nicotine delivered via an e-cigarette|Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
214471224|NCT05311085|COMBINATION_PRODUCT|Cytisine plus nicotine delivered via an e-cigarette|"Cytisine: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)~Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco"
214471225|NCT05703191|DEVICE|Nitric Oxide Generator and Delivery System|Initial at 20ppm is recommended by guidelines. The concentration is adjusted based on actual condition of subjects.
214471226|NCT06387329|DRUG|Nitrofurantoin 100 MG|No additional information
214844564|NCT06291454|DIAGNOSTIC_TEST|Routine periodontal examination|In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness \& Löe, 1964), Löe-Sillness's gingival index (GI)(Löe \& Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo \& Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.
214479457|NCT04155710|BIOLOGICAL|IOV-2001|Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
214844565|NCT01100905|OTHER|Iron-containing food product|
214471227|NCT06805357|OTHER|Chest Physiotherapy by Rib Cage Compressions (RCC)|Bimanual Rib Cage Compressions (RCC) applied to the thorax only, with patients in a standardized position (supine with the head of the bed elevated to 35 degrees). The intervention is standardized in terms of the direction of force (posterior and downward) and the characteristics of the compression (brief and vigorous compressions at the beginning of expiration).
214471228|NCT05062330|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days
214471229|NCT05062330|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days
214284272|NCT00810030|DRUG|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is \>25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height \[m\] x height \[m\].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
214284273|NCT04658953|OTHER|Ultrasound guided infiltration|In the patient in prone position, an infiltration guided by ultrasound will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
214284274|NCT04658953|OTHER|Fluoroscopy guided infiltration|In the patient in prone position, an infiltration guided by fluoroscopy will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
214284275|NCT03725098|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
214471230|NCT05105906|DIAGNOSTIC_TEST|cognitive tests performed|cognitive tests performed
214471231|NCT05451875|DEVICE|Non-invasive monitoring|Comparison of VitalTracer monitoring devices with invasive and/or non-invasive gold standard reference
214471232|NCT05716763|DRUG|Tramadol Hydrochloride 5 MG/ML Oral Solution|50mg (10mL) single dose
214471233|NCT05716763|DRUG|Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))|50mg (20 drops) single dose
214471234|NCT05785546|OTHER|usual care|For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.
214471235|NCT06033599|OTHER|MORE and MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.
214471236|NCT06033599|OTHER|MORE and No MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.
214471237|NCT06033599|OTHER|Support Group and MI and NRT|Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.
214471238|NCT06033599|OTHER|Support Group and No MI and NRT|Eight group support group sessions and and nicotine replacement therapy.
214471239|NCT05493241|BEHAVIORAL|Behavioral Activation for Independence in Older Veterans (ACTIVaTE)|6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.
214471240|NCT05493241|OTHER|Usual care|"In this study, both arms will have access to usual care as part of their routine clinical care. Recognizing the heterogeneity of primary care services provided to patients at risk for functional decline, we will minimally standardize the usual care arm by providing a booklet of educational information on maintaining activity to support independence in aging (e.g., an NIH handout Participating in Activities you Enjoy as you Age and information on VA and community recreation programs to stay active) that will be mailed to participants after randomization."
214284276|NCT03725098|DEVICE|FLOSEAL|The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
214471241|NCT03414242|OTHER|Cervical spine musculature|Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
214471242|NCT06457594|OTHER|Questionnaire|EORTC QLQ-INFO25 EORTC QLQ - H\&N43 and EORTC QLQ-C30
214471243|NCT05695222|OTHER|This is not an interventional study|This is not an interventional study
214471244|NCT04572295|DRUG|E7090|E7090 oral tablet.
214471245|NCT04572295|DRUG|Fulvestrant|Fulvestrant intramuscular injection.
214471246|NCT04572295|DRUG|Exemestane|Exemestane oral tablet.
214471247|NCT04446351|DRUG|GSK6097608|GSK6097608 will be administered as an IV infusion.
214471248|NCT04446351|DRUG|Dostarlimab|Dostarlimab will be administered as an IV infusion.
214471249|NCT04446351|DRUG|Cobolimab|Cobolimab will be administered as an IV infusion.
214471250|NCT04446351|DRUG|Belrestotug|Belrestotug will be administered as an IV infusion.
214471251|NCT02567409|DRUG|Berzosertib|Given IV
214471252|NCT02567409|DRUG|Cisplatin|Given IV
214471253|NCT02567409|DRUG|Gemcitabine Hydrochloride|Given IV
214284277|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
214471254|NCT05740839|BEHAVIORAL|HIIT Exercise Program|Exercise program with stationary bike via the Zoom platform.
214471255|NCT05740839|BEHAVIORAL|Control Group|Usual Activities
214471256|NCT06787209|BEHAVIORAL|Program to improve lumbopelvic function.|"Each individual will receive a weekly session log at the start of the intervention, allowing them to record the total number of sessions performed between in-person visits and the perceived exertion.~In the strengthening phase, both compound and isolated exercises will be performed. These exercises will be of low intensity and maintained for prolonged periods until the patient reaches fatigue or can no longer perform the repetitions correctly. If the patient reaches 40 repetitions, the exercise will be progressed in difficulty. The patient will have one minute of rest after each set.~Each session will include a total of 4 sets focused on the gluteal muscles The speed of execution for each repetition will be between 4-6 seconds. After the strengthening phase, three unilateral static stretches targeting the hip flexors will be performed, each lasting one minute.~The entire program will be performed using bodyweight exercises and adapted exercises that can be done at home."
214471257|NCT06787209|BEHAVIORAL|generic health care|"The patients will receive 10 physiotherapy sessions at the health center throughout 4 weeks.They will be taught active exercises and undergo passive therapies to address their low back pain. Each session will last approximately 30 minutes.~The intervention will therefore be variable depending on the assigned physiotherapist, as there is no standardized protocol for action."
214284278|NCT01087645|DRUG|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
214284279|NCT01087645|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
214284280|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
214471258|NCT04132518|DEVICE|Sculptra|Initial injection and optional 3 injections with Sculptra in Midface.
214471259|NCT04047290|DRUG|AK112|AK112 is a PD1/VEGF bispecific antibody.
214471260|NCT03092453|BIOLOGICAL|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.
214471261|NCT03092453|DRUG|Cyclophosphamide 300mg/m^2|administered prior to subject's first DC dose
214471262|NCT03092453|DRUG|Pembrolizumab|administered 7-8 weeks after subject's last DC dose
214471263|NCT05144555|OTHER|Fixed orthodontic treatment with stainless steel brackets|"Stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
214284281|NCT01087645|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo
214471264|NCT05144555|OTHER|Fixed orthodontic treatment with ceramic brackets|"Ceramic brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
214471265|NCT06487104|DEVICE|TrachPhone HME|"Use of TrachPhone HME for humidification of inhaled air in tracheostomized patients.~The TrachPhone HME is an HME specifically designed for tracheostomy patients."
214471266|NCT06487104|DEVICE|External Humidifier (Usual Care)|Usual care routines using an External Humidifier for humidification of inhaled air in tracheostomized patients.
214471267|NCT06835062|BEHAVIORAL|Recommendations for Enhancing General Well-Being|"* Wear comfortable clothing and lie on your back. Place one hand on your abdomen. As you inhale through your nose, direct your breath towards your hand, and exhale through your mouth.~* In the same position, place one hand on your abdomen, inhale through your nose, and expand your belly under your hand. As you exhale through your mouth, purse your lips and blow out the air from your lungs.~* Engage in brisk walking at least three times a week.~* Perform stretching exercises similar to yoga; try forward bends while standing and sitting.~* Stay active throughout the month; you can dance, swim, or ride a bike.~* Reduce your intake of tea and caffeine.~* Increase your consumption of milk.~* Drink plenty of water.~* Reduce your intake of sugar-rich snacks such as chocolate.~* Prioritize foods rich in calcium, as well as vitamins A, B, and E."
214479458|NCT04155710|DRUG|Low dose IL-2|6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
214479459|NCT04155710|DRUG|High dose IL-2|6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
214479460|NCT04155710|DRUG|IL-2|6 doses of IL-2 will follow the infusion of IOV-2001
214284282|NCT04664166|OTHER|Alpena Otago Telehealth Program|"A physical therapist will use video visits to evaluate the participants and provide exercise instructions from Week 1 to Week 4. Each participant will use the Blue Marble Health in Motion app from a mobile tablet to complete the exercise guided by an avatar at their own pace after receiving the exercise instructions from the physical therapist. Participants are encouraged to exercise three days a week and 30 minutes each day using the app for 6 months. The exercise protocol based on the evidence-based Otago program includes warm up, strengthening, and balance exercise.~3.5. Research Study Design and Data Analyses:"
214284283|NCT03474770|DRUG|BIS-001ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
214284284|NCT03926169|DRUG|Risankizumab|Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
214284285|NCT03926169|DRUG|Placebo for risankizumab|Placebo for risankizumab is administered as a SC injection in PFS
214284286|NCT02392143|OTHER|Printed Education Material|The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test \[18\]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
214479461|NCT04007055|DIAGNOSTIC_TEST|Point of care screening for HPR|HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234
214471268|NCT06835062|OTHER|Clinical Pilates|"In addition to the general well-being recommendations, the Clinical Pilates Group participated in a total of 16 face-to-face, clinically based Pilates exercise training sessions over eight weeks, with two sessions per week, each lasting 50 minutes. The exercise training started at the end of the menstrual cycle.~The clinical Pilates-based exercise program applied to the group was designed by the researcher. The number of repetitions, levels, and variations of the exercises were progressively adjusted by the researcher according to the participants' conditions.~During the first session, the principles of clinical Pilates were explained, following the BASI Pilates method as described by Isacowitz. Participants were taught alignment, breathing, and core engagement techniques."
214471269|NCT05843877|BIOLOGICAL|Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy|Islet cells are isolated from patients healthy pancreatic tissue. Following total pancreatectomy, these autologous cells are injected into the portal vein, to implant in the liver and produce insulin.
214471270|NCT05843877|PROCEDURE|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)|As a standard procedure, the tumor-affected region of the pancreatic head with surrounding tissue and lymph nodes is removed during surgery. Reconstruction is performed by pancreaticojejunostomy.
214471271|NCT06833619|DEVICE|Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique|Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique
214479462|NCT04007055|DRUG|Ticagrelor 90mg|Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
214284287|NCT02392143|OTHER|Academic Detailing|Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
214284288|NCT02392143|OTHER|Academic Detailing+Telephone Education|PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
214284289|NCT00316849|OTHER|pharmacological study|
214284290|NCT00316849|PROCEDURE|adjuvant therapy|
214284291|NCT00316849|RADIATION|3-dimensional conformal radiation therapy|
214284292|NCT00316849|RADIATION|intensity-modulated radiation therapy|
214284293|NCT00316849|DRUG|temsirolimus|Given IV
214284294|NCT00316849|DRUG|temozolomide|Given orally
214284295|NCT05810883|DIAGNOSTIC_TEST|Blood Tests; Serum Fasting Insulin and Glucose|"Laboratory results of blood samples, for high-density lipoprotein (HDL), low-density protein (LDL), triglycerides, and total cholesterol (TC) will be evaluated for this study. Fasting Insulin and fasting glucose levels will be used to calculate IR.~Insulin Resistance will be calculated using Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (FPG (mmol/L) × FPI (mU/L)/22.5) \[21\] and defined as HOMA-IR ≥ 3.4"
214284296|NCT06136793|BEHAVIORAL|HomeStyles-China|2-arm \~10 week educational intervention
214284297|NCT03591991|DRUG|Empagliflozin|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.
214284298|NCT03591991|OTHER|placebo|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg placebo . After admission, patients were treated with 10 mg placebo once daily for 3 mouths.
214284299|NCT05071469|OTHER|Kinesiotaping|KT was applied.
214284300|NCT05071469|OTHER|Mulligan Mobilization Technique|MMT was applied
214284301|NCT00634530|BEHAVIORAL|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
214284302|NCT01730469|DRUG|AT1001 150 mg|AT1001 150mg is available as a capsule
214284303|NCT00844896|BEHAVIORAL|DEF-only|"The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise."
214284304|NCT00844896|BEHAVIORAL|DEF + COPE|"All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks."
214284305|NCT00580190|DRUG|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
214284306|NCT00580190|OTHER|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
214284307|NCT00580190|DRUG|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
214284308|NCT00004915|DRUG|raloxifene|
214284309|NCT03955744|OTHER|3D translabial ultrasound|All patients will undergo 3D translabial ultrasound with vaginal manometry
214284310|NCT02590614|DIETARY_SUPPLEMENT|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
214284311|NCT02590614|DIETARY_SUPPLEMENT|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
214471272|NCT05127980|OTHER|Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments)|Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).
214284312|NCT03129984|DEVICE|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
214471273|NCT05127980|OTHER|Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin)|Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).
214284313|NCT05052762|OTHER|Group A: Elastic resisted training for Gluteus Maximus strength|"Subjects attended physical therapy two times per week for a total of 10 visits. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) are added. Each exercise was performed for 10 repetitions. Elastic resistance was Added to the fire hydrant, hip extension in prone and deadlift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
214284314|NCT05052762|OTHER|Group B: Weight resisted training for Gluteus Maximus strength|Subjects attended p two times per week for a total of 10 visits. The participants performed PHEKF in 90° knee flexion with 30° hip abduction and 10° hip extension to increase the muscle activity of the gluteus maximus. In the prone position, the participant performed 10° hip extension until the posterior knee reached the horizontal bar. The participants maintained 90° knee flexion with 30° hip abduction and 10° hip extension in the prone position against the resistance. Sandbags (3 kg) will be used to provide resistance on the ankle through a rope and pulley. Each subject performed three sets with three repetitions of five seconds each. 1-minute break is allowed between each set.
214284315|NCT02233647|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
214284316|NCT02233647|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
214284317|NCT04774328|DRUG|CA-008 (vocacapsaicin)|Single administration of CA-008 (vocacapsaicin) versus placebo
214284318|NCT04774328|DRUG|Placebo|Single administration of CA-008 (vocacapsaicin) versus placebo
214284319|NCT02129400|DRUG|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
214284320|NCT02129400|DRUG|Aer medicinalis Linde 100%|
214284321|NCT05148598|DEVICE|ADRCs|Adipose Derived Regenerative Cells (ADRCs) processed with Celution System
214284322|NCT05148598|OTHER|Standard Care|Standard care
214284323|NCT05148598|OTHER|Placebo|Placebo visually indistinguishable from ADRCs
214284324|NCT01652612|OTHER|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
214284325|NCT02174250|DRUG|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
214284326|NCT02174250|DRUG|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
214284327|NCT00686933|DRUG|ABT-089|Subjects will take up to 80 mg daily for 24 months
214284328|NCT01858298|OTHER|Conservative treatment: pulpectomy and composite resin crown|
214471274|NCT05127980|OTHER|Data collection: Patient reported outcome (Fatigue questionnaires)|Data collection: Patient reported outcome (Fatigue questionnaires) at 6 and 12 months.
214284329|NCT01858298|OTHER|Non-conservative treatment: Tooth extraction|
214284330|NCT04906291|OTHER|Toothpaste use|Brushing three times a day
214284331|NCT05337228|DRUG|IN-C006 Peri inj.|IN-C006 peri inj. will be injected continuously for 3 days.
214284332|NCT05337228|DRUG|RPN301|RPN301 will be injected continuously for 3 days.
214284333|NCT03570645|DRUG|Dexmedetomidine Group|combination of ropivacaine and dexmedetomidine 100 ug every time
214284334|NCT03570645|DRUG|dexamethasone group|combination of ropivacaine and dexamethasone 10mg every time
214284335|NCT03570645|DRUG|control group|block with only ropivacaine
214284336|NCT00603668|BIOLOGICAL|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
214284337|NCT03808532|OTHER|Cura+ Moisturizing Cream|Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily for six months.
214284338|NCT05367401|DRUG|Sabatolimab|Solution for intravenous infusion
214284339|NCT05367401|DRUG|Magrolimab|Solution for intravenous infusion
214284340|NCT05367401|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
214284341|NCT00350909|BEHAVIORAL|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
214284342|NCT03992001|BIOLOGICAL|Blood component A|PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs
214284343|NCT03992001|BIOLOGICAL|Blood component B|PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
214284344|NCT03699098|DIAGNOSTIC_TEST|TSH, T3, T4 and thyroid gland DVH|measuring thyroid functions and DVH parameters of thyroid gland
214284345|NCT01814514|DRUG|Timolol-trusopt|
214284346|NCT01814514|DRUG|placebo|
214284347|NCT02080949|RADIATION|4fx x 5Gy|It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
214284348|NCT00401453|BEHAVIORAL|Diet: carbohydrate days. (Name: oatmeal.)|Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
214284349|NCT04333797|OTHER|Risk and Protective Factors Assessment|First assessment at baseline (T0) - 17 y.o. Follow-up 2 years later (T1) - 19 y.o.
214284350|NCT00130936|DRUG|Epirubicin|
214284351|NCT00130936|DRUG|Carboplatin|
214284352|NCT00130936|DRUG|Capecitabine|
214284353|NCT02091492|DRUG|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
214284354|NCT02091492|DRUG|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
214284355|NCT03910374|PROCEDURE|Dural closure|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
214284356|NCT03792698|OTHER|Aidcube digital app-based platform|Use of customizable, patient-specific mHealth home rehabilitation plan
214284357|NCT05952011|PROCEDURE|Left stellate ganglion block|patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.
214284358|NCT05952011|DRUG|Topical Nitroglycerine|Application of topical Nitroglycerin solution to the LIMA pedicle graft during dissection of the vessel in both study arms.
214284359|NCT05142943|OTHER|Visual illusion|the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes.
214284360|NCT05142943|OTHER|Physical exercise|"* General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~* Gross mobility and coordination: ball games.~* Fine mobility and coordination: writing tasks, puzzles, abacus ...~* Strength exercises: shoulder, elbow, wrist, fingers.~* Stretching."
214284361|NCT05142943|OTHER|Sham Visual illusion|only the placebo visual illusion
214479463|NCT05296122|DEVICE|TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.|The main purpose with the study is to investigate safety and feasibility of the TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation together with SmartTwist™ MR Hand Drill with the SmartTip™ MR Drill Kit for MR-guided laser thermal ablation of brain lesions.
214284362|NCT01154790|DRUG|CG100649|6 subjects: study drug 2 subjects: placebo
214284363|NCT01154790|DRUG|Placebo|6 subjects: study drug 2 subjects: placebo
214479464|NCT05152472|DRUG|Atezolizumab 1200 mg|(Intravenous administration)
214284364|NCT01154790|DRUG|Naproxen|6 subjects: study drug 2 subjects: placebo
214284365|NCT05914298|DIAGNOSTIC_TEST|blood and buccal swab genetic test|blood samples and buccal swabs will be obtained from patients with HME in order to analyze the genotype (EXT1 or EXT2 mutations) and correlate the genotypic pattern with the phenotypic presentation
214284366|NCT05914298|DIAGNOSTIC_TEST|PUL|measurement of ulnar length with anthropometer and patient's height
214284367|NCT05914298|DIAGNOSTIC_TEST|Range of motion|measurement of range of motion of elbow, forearm and wrist
214284368|NCT01699204|DIETARY_SUPPLEMENT|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
214284369|NCT01699204|OTHER|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
214471275|NCT06840067|RADIATION|carbon ion radiotherapy (CIRT)|1.CIRT: GTV: Primary tumor visible on imaging and clinical examination, and involved regional lymph nodes identified by CT/MRI (≥1.0 cm) or PET/CT scan. CTV: GTV plus 5mm margin, include posterior peritoneal plexus area and elective node irradiation around the pancreas (ENI). PTV: CTV plus 2.5-5mm margin (depending on the system error of each unit; When pancreatic head cancer is close to the stomach and intestines, the gastrointestinal direction does not expand). ITV: delineated on 4D-CT considering the influence of respiratory activity. Prescription dose: Stratification by measuring the nearest distance between PTV and gastrointestinal tract (≥5mm or \< 5mm); Pancreatic head cancer (distance \< 5mm) : 52.8Gy(RBE)/4.4Gy/12Fx; Pancreatic head, body and tail cancer (≥5mm) : 57.2Gy(RBE)/4.4Gy/13Fx. CIRT was once a day, four or five times a week. 2.Chemotherapy:Gemcitabine 1000mg/m2, intravenous infusion, dl, d8; Q3w . 3.Targeted therapyNituzumab injection 400mg, Qw，at least 4-6 cycles.
214284370|NCT01699204|OTHER|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
214284371|NCT04552847|DRUG|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
214284372|NCT04552847|DEVICE|PET/CT|Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
214284373|NCT04552847|DEVICE|PET/MR|Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
214284374|NCT00691418|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
214284375|NCT00691418|DIETARY_SUPPLEMENT|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
214284376|NCT04587232|DIAGNOSTIC_TEST|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire (Mini-OAKHQoL) was derived from the Turkish version of OAKHQoL questionnaire, which was developed to assess the quality of life (QoL) in subjects with lower limb osteoarthritis. It includes five subscales: physical activities, mental health, pain, social support, social functioning; with three additional independent items addressing sexual life, professional life, and fear of being dependent. The numerical rating scales in the items range from 0 (worst) to 10 (best). Scores were obtained by computing the means of the item scores in each subscale. The last three items' score (independent items) becomes the corresponding score.
214284377|NCT04587232|DIAGNOSTIC_TEST|Nottingham Health Profile|Standardized questionnaire to investigate the health-related quality of life. NHP is a general is used to measure health problems perceived by the patient. It comprises 6 sections. The sum of the items within each section ranges from 0 to 100, and the total score ranges from 0 to 600. The higher score shows a worse quality of life.
214284378|NCT04587232|DIAGNOSTIC_TEST|Short form 36|Standardized questionnaire to investigate the general health-related quality of life. The SF-36 questionnaire is a generic quality of life questionnaire and consists of 8 subscales, with 36 items. The scores ranges from 0 to 100 and the high score indicates good health.
214284379|NCT04587232|DIAGNOSTIC_TEST|Western Ontario and McMaster|Standardized questionnaire to investigate the health status of patients with osteoarthritis. The WOMAC OA index assesses the symptomatic severity and disability with pain, stiffness, and physical function domains. Each subscale was summated to a maximum score of 20, 8, and 68, respectively, with the higher scores corresponding worst health status.
214284380|NCT03174834|OTHER|Bladder Stimulation technique|The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
214284381|NCT04061213|DIAGNOSTIC_TEST|Tc-99m-DPD scintigraphy|Myocardial scintigraphy
214284382|NCT04334070|DRUG|Lamprene®/Clofazimine|All participants will receive Lamprene/clofazimine 50 mg capsules. The recommended dose of clofazimine for this program is 100 mg once daily, administered orally, preferably with meals. Duration of treatment will be decided by the treating physician. When considering clofazimine for the treatment of NTM infection, clofazimine is to be administered as part of a multi-drug regimen.
214284383|NCT04991415|OTHER|Manual Therapy|
214284384|NCT00795106|DRUG|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
214479465|NCT05152472|DRUG|Imatinib 400 MG|(Per os)
214284385|NCT00795106|DRUG|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
214284386|NCT05200091|OTHER|Combined explosive strength and specific balance training group|"Training will consist to perform one hour of combined ankle explosive strength training and specific balance training using randomized perturbations.~Explosive strength training: Participants will perform only 2 sets of 3 min (12 contractions for each set) for both lower limbs and both ankle plantar- and dorsiflexion movements.~Balance specific training: Participants will be standing, secured by an adjusted harness, which do not support the weight but is strictly there to prevent a fall. They will have online visual feedback of their CoP via an avatar on the screen in front of them. Each training session will consist of 10 sequences of 3 min, including the 5 different conditions:~* Forward tilt of base of support;~* Backward tilt of base of support;~* Translation forward;~* Translation backward;~* Without moving their feet, participants will have to move their avatar to reach different targets placed around them on the screen, at different distance from the center."
214284387|NCT05985577|OTHER|Without any intervention|There were no special interventions for the two groups.
214284388|NCT05363644|BIOLOGICAL|BioDFence G3|Placement of a sheet of BioDFence® G3 will be applied to the neurovascular bundle on participants undergoing an elective Full Nerve Sparing Radical Prostatectomy for primary treatment of prostate cancer.
214284389|NCT05416398|OTHER|Aerobic Exercise, High Intensity Interval Training|Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.
214284390|NCT06013670|PROCEDURE|Endoscopy+NSBBs|Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure\>90mmHg and heart rate\>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
214284391|NCT06013670|PROCEDURE|Transjugular intrahepatic portosystemic shunt|TIPS group: All TIPS procedures are completed by a professional liver disease intervention treatment team.
214284392|NCT06260085|OTHER|Relatives vioce record|In the study, it was emphasized that the messages to be played to the patient should be 3-5 minutes and simple terms should be used in a way that can be understood by individuals with low education level. Written informed consent was obtained from the patient and the patient's relatives before the application. In the message recorded by a patient's relative decided by the patient's family members, the patient's relative said what he/she wanted to say to the patient and recorded it using a voice recorder. The researcher had a preliminary interview with the patient's relative before the voice recording was taken about the use of the voice recorder and the content of the message (Table 1) in order to prevent the messages from negatively affecting the patient. The voice recording created by the patient's relative was played to the patient by the researcher using a music pillow. After the patient listened to the audio recording, it was erased under the witness of the patient's relative.
214284393|NCT00382278|PROCEDURE|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
214284394|NCT00119054|BEHAVIORAL|In Home Health Messaging Device|
214284395|NCT06045897|DEVICE|EEG 64 channels|64-channel EEG in wake and resting conditions for 1h30, with oculogram, electromyogram and electromyogram and electrocardiogram. Five minutes of eyes closed will be used for microstate analysis. 1h30 will be used for the sensorimotor task.
214284396|NCT06045897|DEVICE|Polysomnography 19 electrodes|Overnight polysomnography with 19 EEG channels and ventilatory polygraphy.
214284397|NCT06045897|BEHAVIORAL|Light hypnosis|Healthy controls will undergo a 5 min light hypnosis exercise that will be focused on proprioception.
214284398|NCT06045897|BIOLOGICAL|Biological sampling|Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.
214284399|NCT06045897|BEHAVIORAL|Virtual reality|Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.
214284400|NCT06045897|DEVICE|Voice recording|A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.
214284401|NCT06117657|DRUG|Low dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^11 vg/kg.
214284402|NCT06117657|DRUG|Middle dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10\^11 vg/kg.
214284403|NCT06117657|DRUG|High dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^12 vg/kg.
214284404|NCT00467571|DRUG|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
214471276|NCT05332262|DIAGNOSTIC_TEST|Assessment of platelet reactivity|Assessment of platelet reactivity and HPR status will be performed post-PCI. Platelet reactivity will be measured by VerifyNow P2Y12 and HPR status will be defined using a cut-off value of platelet reactivity units (PRU)\>208.
214471277|NCT05332262|DIAGNOSTIC_TEST|Troponin measurement|Measurement of high sensitivity troponin for the assessment for the presence of myocardial infarction/myocardial injury will be performed post-PCI.
214284405|NCT02108470|OTHER|Dental consultation using OHIP|The S-OHIP\[M\] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
214284406|NCT02737293|OTHER|Control Diet|4-week intake of Control Diet 5 day rotating menu
214284407|NCT02737293|OTHER|Med Diet|4-week intake of Med Diet 5 day rotating menu
214284408|NCT02737293|OTHER|Med Diet + Whole Egg|4-week intake of Med Diet plus Whole Egg 5 day rotating menu
214471278|NCT05524402|BEHAVIORAL|TOR-C 1|TOR-C 1 is an active intervention, adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program with weekly sessions and home practice.
214284409|NCT01835587|DRUG|CC-486|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
214284410|NCT01270776|DRUG|2% aqueous chlorhexidine|A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
214284411|NCT01270776|DRUG|2% Chlorhexidine 70% isopropyl alcohol|single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
214284412|NCT01190774|BEHAVIORAL|Information to health provider without patient knowledge|The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
214284413|NCT01190774|BEHAVIORAL|dentist behaviour and patient expectancy|patient give information about their dental anxiety to the dentist
214284414|NCT00112320|PROCEDURE|PVR plus RV remodeling|PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
214284415|NCT00112320|PROCEDURE|Standard PVR|PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
214284416|NCT04360915|DRUG|ASK120067|Take ASK120067 tablets orally in first day at 160 mg in fast condition.
214284417|NCT04360915|DIETARY_SUPPLEMENT|ASK120067 in fed condition|Take ASK120067 tablets orally in first day at 160 mg in fed condition.
214284418|NCT05221528|DIAGNOSTIC_TEST|Measurement of lipid profiles|Measured: total cholesterol, high-density lipoprotein cholesterol, and triglyceride Calculated: low-density lipoprotein
214284419|NCT06129071|PROCEDURE|US guided block of maxillary nerve|Extraoral ultrasound-guided block of the maxillary nerve will be performed in the examined group using an ultrasound device and local anesthetic levobupivacaine (0,5%, 2 mL) combined with triamcinolonacetonid (2mL).
214284420|NCT06123845|BEHAVIORAL|static CPAP 8 cmH2O|Set static CPAP or PEEP pressure level at 8 cmH2O
214284421|NCT06123845|BEHAVIORAL|static CPAP 5 cmH2O|Set static CPAP or PEEP pressure level at 5 cmH2O
214284422|NCT06254703|DIAGNOSTIC_TEST|VexLUS (venous excess lung ultrasound)|IVC, hepatic veins (HVs), portal veins (PVs) and intrarenal veins (IRVs), and lung ultrasound
214284423|NCT03951402|DRUG|100 mg CG5503 (tapentadol hydrochloride) PR tablet|100 mg CG5503 (tapentadol hydrochloride) PR tablet.
214284424|NCT03951402|DRUG|Placebo matching CG5503 PR tablet|Matching placebo tablet to CG5503 PR tablet.
214284425|NCT03951402|DRUG|Placebo matching moxifloxacin capsule|Matching placebo capsule to moxifloxacin capsule.
214284426|NCT03951402|DRUG|400 mg Moxifloxacin tablet (overencapsulated)|Overencapsulated 400 mg Moxifloxacin tablet.
214471279|NCT05524402|BEHAVIORAL|TOR-C 2|TOR-C 2 is an active intervention teaching educational information on key modifiable factors relating to recovery after concussion, such as return to activity, the role of nutrition and sleep, and the relationship between concussion and anxiety. The format is a 4-week program delivered over live video with weekly sessions.
214284427|NCT06177600|BEHAVIORAL|Interactive educational digital platform for transgender and gender-diverse (TGD) young adults and caregivers|"Investigators will develop a free mobile- and web-enabled platform for TGD young adults and their caregivers that combines educational modules with high-quality, evidence-based information and interactive features. At the time of account creation, users will complete an intake survey that will be used to personalize platform features. Young adults will be asked about their goals; mental health; access to health care; degree of caregiver support; and sociodemographic characteristics. Caregivers will be asked about their goals and self-assessed level of supportiveness of their young adults.~Users will be assigned educational modules that build knowledge and skills related to improving mental health and navigating relationships and communication with others. Both exposure to and completion of modules will be tracked."
214284428|NCT03501069|DRUG|TAK-418|TAK-418 capsules.
214284429|NCT03501069|DRUG|TAK-418 Matching Placebo|TAK-418 matching placebo capsules.
214284430|NCT04943185|DEVICE|XEN gel microstent implantation|"Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention"
214284431|NCT03199274|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo standard of care Y-90 radioembolization
214284432|NCT03199274|DRUG|Perflutren Protein-Type A Microspheres|Given IV.
214284433|NCT03199274|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
214284434|NCT05412511|BEHAVIORAL|MB-TB|Training exercises with throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
214284435|NCT05412511|BEHAVIORAL|MB-NTB|Training exercises without throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
214284436|NCT00766480|DRUG|cisplatin|Given IV
214284437|NCT00766480|DRUG|fluorouracil|Given IV
214284438|NCT00766480|RADIATION|radiation therapy|Patients undergo radiotherapy
214284439|NCT06049680|DRUG|SMOFlipid® (lipid injectable emulsion)|"SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated."
214284440|NCT00602342|DRUG|Terbinafine|
214284441|NCT02530489|DRUG|Atezolizumab|Given IV
214284442|NCT02530489|DRUG|Nab-paclitaxel|Given IV
214284446|NCT02591589|OTHER|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 \> 70 mmHg or oxygen saturation greater than or equal to 92%.
214284447|NCT02591589|OTHER|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
214284448|NCT02846779|OTHER|Low intensity|Low intensity telepharmacy outreach
214284449|NCT02846779|OTHER|Moderate intensity|Moderate intensity telepharmacy outreach
214284450|NCT02846779|OTHER|High intensity|High intensity telepharmacy outreach
214284451|NCT02180152|BEHAVIORAL|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
214284452|NCT00227695|BIOLOGICAL|rituximab|comparing two maintenance schedules of Rituximab
214284453|NCT00404677|OTHER|deep inhalation|deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
214471280|NCT04760470|OTHER|Technology-assisted upper extremity rehabilitation|Subjects get 6 weeks of technology-assisted upper extremity rehabilitation
214284454|NCT02288052|BEHAVIORAL|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
214284455|NCT02288052|BEHAVIORAL|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
214284456|NCT06968624|DRUG|Intravenous Ketamine Infusions|The patients received a single intravenous infusion of esketamine (0.2 mg/kg), which was added to 50 ml of normal saline and administered via a micro-infusion pump over 40 minutes.
214284457|NCT06968624|DRUG|Intravenous normal saline|The patients received a single intravenous infusion of 50 ml normal saline via a micro-infusion pump over 40 minutes
214284458|NCT06968624|DRUG|Oral Duloxetine 60mg|Patients received 60 mg/day of oral duloxetine as maintenance therapy for depression.
214284459|NCT04076176|DIETARY_SUPPLEMENT|CGMP protein substitute|PKU sphere is a powdered, low phenylalanine protein substitute, containing a balanced mix of casein glycomacropeptide (CGMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals, trace elements and the omega-3 long chain polyunsaturated fatty acid (LCP); docosahexaenoic acid.
214284460|NCT04076176|DIETARY_SUPPLEMENT|L-amino acid protein substitute|Patient may choose from a list of products, specified in the protocol, that are nutritionally comparable to PKU Sphere.
214284461|NCT06971731|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
214284462|NCT06971731|DRUG|JNT-517 Tablet|JNT-517: 150 mg BID
214284463|NCT06971731|DRUG|Placebo Tablet: BID|Placebo Tablet: BID
214471281|NCT04093167|DRUG|Pembrolizumab|Per current Product Monograph/U.S. Drug Label and/or local guidelines.
214284464|NCT02458820|PROCEDURE|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
214284465|NCT06969963|DRUG|Lepsiramp, 0.5 Mg/mL Oral Suspension|Test product
214471282|NCT06839638|PROCEDURE|100% Trichloroacetic Acid (TCA)|Patients in this group will receive 100% TCA application to xanthelasma lesions using the dipstick method. The surrounding skin will be protected with white soft paraffin to prevent chemical spillage. Post-treatment, Fusidic acid 2% will be applied twice daily for one week. Treatment efficacy will be assessed after six weeks.
214284466|NCT06969963|DRUG|Fycompa, 0.5 Mg/mL Oral Suspension|Reference product
214284467|NCT06969638|BEHAVIORAL|Black Ads|Food ads that feature Black individuals
214284468|NCT06969638|BEHAVIORAL|White Ads|Food ads that feature White individuals.
214284469|NCT06969638|BEHAVIORAL|Many Likes|"Food ads that have many likes"
214284470|NCT06969638|BEHAVIORAL|Few Likes|"Food ads that have few likes"
214284471|NCT01794884|DRUG|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
214284472|NCT01794884|DRUG|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
214471283|NCT06839638|PROCEDURE|Cryotherapy (Liquid Nitrogen)|Patients in this group will receive cryotherapy using liquid nitrogen. A single freeze-thaw cycle will be performed until a narrow halo of white ice forms around the lesion. Post-treatment care will include Fusidic acid 2% applied twice daily for one week. Treatment efficacy will be assessed after six weeks.
214471284|NCT04180202|DEVICE|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
214471285|NCT04590196|DRUG|Longvida curcumin|longvida curcumin verdure sciences formulation
214471286|NCT04590196|OTHER|placebo|"Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide"
214284473|NCT05193968|OTHER|Sympathoexcitatory stressors|Muscle sympathetic nerve activity will be measured continuously at baseline and in response to sympathoexcitatory stressors, including a Valsalva maneuver, isometric handgrip exercise, a cold pressor test, and stepped hypercapnia.
214284474|NCT05193968|DRUG|Sodium Nitroprusside|Sodium nitroprusside, used to test endothelium-independent vasodilation, will be infused through a brachial artery catheter at 0.25, 0.5, 1.0 and 2.0 ug/100ml tissue/min.
214284475|NCT05193968|DRUG|Acetylcholine|Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
214284476|NCT05193968|DRUG|Terbutaline|Terbutaline, a β2-Adrenergic selective agonist, will be infused through a brachial artery catheter at 0.1, 0.5, 1.0, and 2.0 μg/100ml tissue/min.
214284477|NCT05193968|DRUG|Norepinephrine|Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
214284478|NCT04080492|OTHER|QOL Survey|The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
214284479|NCT06922708|DIAGNOSTIC_TEST|Integrated PRS-Enhanced Breast Cancer Risk Assessment (CanRisk model)|Standard genetic counseling followed by a blood draw (0.5 mL) for DNA extraction. The sample is processed using a high-throughput SNP genotyping platform, and the PRS, based on 313 SNPs, is calculated and integrated into the CanRisk model for refined breast cancer risk stratification.
214284480|NCT03685578|DEVICE|EmboTrap® Revascularization Device|EmboTrap® Revascularization Device
214284481|NCT03685578|DEVICE|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
214284482|NCT03685578|DEVICE|CEREGLIDE 71 Intermediate Catheter|CEREGLIDE 71 Intermediate Catheter
214284483|NCT07131514|DRUG|HRS-4642+AG +Adebrelimab|HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab will be administrated per dose level in which the patients are assigned.
214284484|NCT06931938|OTHER|Awake Prone Positioning|The clinical intervention in the Intervention Group is Awake Prone Positioning, a standard therapy in intensive care units worldwide in ARDS care. The intervention should not be started later than 24 hours after randomization. An earlier start, as soon as possible, after randomization is strongly recommended. In patients in the intervention group standard Awake Prone Positioning for at least 10 hours/day for a length of 72 hours should be applied. The reach the targeted 10 hours / day (per 24 hours), it is strongly recommended to use blocks of a longer time period (e.g. multiple 3-5 hours blocks) within the 24h period to reach the anticipated APP goal. It is recommended that the APP therapy within the targeted intervention for 10 hours/day (per 24 h period) is not interrupted for more than 2 hours till reaching the goal of 10 hours / day (per 24 h). It is further strongly recommended that one APP session should last at least 3 hours. (...) For more information please see the protol.
214284485|NCT06096857|DRUG|Roseomonas mucosa (RSM2015) and Cardamom seeds|Freeze dried packet to be reconstituted in water
214284486|NCT06096857|DRUG|Placebo (sucrose)|Freeze dried packet to be reconstituted in water
214471287|NCT06533150|OTHER|multiomic profiling|2 aliquots of patients-derived bone tissue specimens (collected as surgical waste from routinely surgeries) will be collected and exploited from proteins and metabolites isolation according to standardized protocol. Then, samples will be digested using Filter-aided sample preparation digestion protocol and analysed by Liquid Chromatography Tandem Mass Spectrometry. Peptides will be loaded on the PepMap 100 C18 trap cartridge, and subsequently separated on an EASY Spray C18 analytical column. The mass spectrometer, equipped with a nanoESI spray source, operates in positive ion polarity and MS/MS mode. Also metabolites will be assessed by LC-MS/MS and will be separated by HPLC. Obtained results will be analyzed by integrated pathway analysis (IPA) to achieve the multiomic profiling of each patient thus identifying druggable targets to be exploited in drug design. The selected biomolecules will be then tested in patient cells using the developed bioink-nanoparticle complex.
214284487|NCT06205238|OTHER|CGA|"CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up."
214284488|NCT02751996|DRUG|SB 9200|SB 9200
214284489|NCT02751996|DRUG|Placebo|
214284490|NCT02751996|DRUG|Tenofovir|
214284491|NCT03713970|PROCEDURE|celtra duo press|celtra duo press ingot
214284492|NCT03713970|PROCEDURE|IPS e.max press|IPS e.max press ingot
214284493|NCT05342545|OTHER|Alert-based computerized decision support|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
214284494|NCT04106856|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214284495|NCT04106856|DRUG|Losartan|Given PO
214284496|NCT04106856|DRUG|Losartan Potassium|Given PO
214284497|NCT04106856|OTHER|Quality-of-Life Assessment|Ancillary studies
214284498|NCT04106856|OTHER|Questionnaire Administration|Ancillary studies
215033332|NCT05939141|DEVICE|Genio System|"All participants have previously been implanted with a Genio® system implantable stimulator. This research is observational in nature (long term safety follow-up) and participants will not be exposed to additional procedures.~The Genio System comprises of a bilateral Implantable Stimulator (IS), which is implanted via a minimally invasive surgery procedure and positioned over the genioglossus muscle with its electrodes positioned over both the left and right hypoglossal nerve branches. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway. The Implantable Stimulator receives energy pulses transmitted via the DP placed under the patient's chin and connected to the Activation Chip (AC), which contains the patient's stimulation parameters and contain a battery that provides energy."
214284499|NCT06539728|DIAGNOSTIC_TEST|Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces|Participants will drop a saline solution with proteins onto the testing device. They will wait for it to dry and then report on the tactile sensation and overall feel of the surface. Feedback will include comparisons with the two reference surfaces. The primary goal is to determine the presence of mock COVID antigen in synthetic saliva using the device, which aligns with the goals of diagnostic testing.
214284500|NCT06539728|DIAGNOSTIC_TEST|Biomechanical Measurements|Participants may have biomechanical measurements recorded, such as placing samples on a scale to measure downward force or using medical tape with a flexible wire to track finger motion. These measurements are likely aimed at objectively assessing how participants interact with the surfaces and their physical responses to tactile stimuli.
214284501|NCT06539728|BEHAVIORAL|Psychophysical Tasks|Participants may alternatively be asked to perform standardized psychophysical tasks, such as Two Alternative Forced Choice tests, Odd-Man Out tests, or Magnitude Estimation tests. These tasks will provide structured comparisons and quantitative data on participants' perception and preferences regarding tactile qualities. The tasks are designed to evaluate participants' perception and preferences regarding tactile qualities, which involves behavioral responses to sensory stimuli.
214284502|NCT03894462|BEHAVIORAL|Attempted Suicide Short Intervention Program|ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan.
214284503|NCT03894462|BEHAVIORAL|Zero Suicide Usual Care|Participants will have access to outpatient treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged.
214284504|NCT04761289|OTHER|Multimodal Exercise and Functional Rehabilitation Program|"1. Prescription of multimodal physical exercise.~2. Reeducation of Activities of Daily Living (ADL).~3. Prescription of support products and adaptations of the environment."
214284505|NCT00040937|BIOLOGICAL|filgrastim|PBSC collection: 10 mcg/kg SQ days 1-10
214284506|NCT00040937|BIOLOGICAL|sargramostim|"PBSC collection: 500 mcg/m2 SQ day 1 through last apheresis~1st and 2nd trans: 500 mcg SC or IV days 6-WBC recovery"
214284507|NCT00040937|DRUG|cyclophosphamide|PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
214284508|NCT00040937|DRUG|dexamethasone|40 mg/d PO days 1-4, 9-12, 17-20
214471288|NCT04428203|DRUG|Epidiolex Oral Liquid Product|600 mg Oral solution
214471289|NCT04428203|DRUG|Epidiolex Oral Liquid Product|800 mg oral solution
215033333|NCT01701388|DEVICE|Ekso exoskeleton|The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
214284509|NCT00040937|DRUG|melphalan|"1. st trans: 140 mg/m2 IV over 20 mins day -1~2. nd trans: 200mg/m2 IV over 20 mins day -1"
214284510|NCT00040937|DRUG|prednisone|maint: 50 mg/d PO every other day until progression
214284511|NCT00040937|DRUG|thalidomide|ind: 50 mg increased by 50 mg every week to max 400 mg PO qhs for 35 days maint: 50 mg/d increased by 50 mg every week to 200 mg PO daily until progression
214284512|NCT00040937|PROCEDURE|peripheral blood stem cell transplantation|2-4 x 10\^6/kg IV day 0
214284513|NCT03151837|DIETARY_SUPPLEMENT|Greenyn Momordica charantia extracts|Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)
214284514|NCT03151837|DIETARY_SUPPLEMENT|Placebo control|Starch
214284515|NCT00806390|DRUG|Metoprolol|Metroprolol tartrate titrated up
214284516|NCT02267811|OTHER|Orthodontic Treatment|Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
214284517|NCT02267811|DEVICE|OrthoPulse™|Participants carry out daily OrthoPulse™ treatments at home.
214284518|NCT02239978|BEHAVIORAL|Postural perturbation|Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
214284519|NCT00018837|BEHAVIORAL|Community Re-Entry Program: What is Schizophrenia|
214284520|NCT03158376|DRUG|Gabapentin|
214284521|NCT03158376|DRUG|Placebo|
214284522|NCT00602953|OTHER|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
214284523|NCT05127005|PROCEDURE|Trapeziectomy|Surgical excision of trapezoideum
214284524|NCT05127005|PROCEDURE|Sham|Skin incision only
214284525|NCT01822431|RADIATION|metaiodobenzylguanidine scintigraphy|
214284526|NCT03731611|PROCEDURE|Umbilical Cord Milking|Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
214471290|NCT04428203|DRUG|Epidiolex Oral Liquid Product|800 mg oral solution
214471291|NCT03703908|DRUG|CCX140-B|Orally administered tablet
215033334|NCT05503082|DRUG|Ubrogepant 50 MG [Ubrelvy]|Ubrogepant 50 MG \[Ubrelvy\]
215033335|NCT05503082|DRUG|Ubrogepant 100 MG [Ubrelvy]|Ubrogepant 100 MG \[Ubrelvy\]
214284527|NCT02498314|OTHER|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
214284528|NCT02498314|OTHER|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
214284529|NCT02498314|OTHER|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
214284530|NCT01004627|PROCEDURE|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
214284531|NCT02289040|PROCEDURE|cardiac surgery|cardiac surgery with extracorporeal circulation for congenital heart disease
214284532|NCT02407821|DRUG|Escitalopram|Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
214284533|NCT02407821|DRUG|Placebo|The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
214284534|NCT00352560|DRUG|Irbesartan|Tablets, Oral, 300 mg, once daily, 30 days.
214284535|NCT00352560|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 30 days.
214284536|NCT05463575|DRUG|Ketohexokinase inhibition|participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
214284537|NCT05463575|OTHER|Placebo|participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
214284538|NCT03883620|BIOLOGICAL|Dengushield 1 mg/kg (Cohort 1) intravenous|Participants will be administered Dengushield 1 mg/kg as slow intravenous injection.
214284539|NCT03883620|BIOLOGICAL|Dengushield 3 mg/kg (Cohort 2) intravenous|Participants will be administered Dengushield 3 mg/kg as slow intravenous infusion.
214284540|NCT03883620|BIOLOGICAL|Placebo 3 mg/kg (Cohort 2) intravenous|Participants will be administered Placebo 3 mg/kg as slow intravenous infusion.
214284541|NCT03883620|BIOLOGICAL|Dengushield 7 mg/kg (Cohort 3) intravenous|Participants will be administered Dengushield 7 mg/kg as slow intravenous infusion.
214284542|NCT03883620|BIOLOGICAL|Placebo 7 mg/kg (Cohort 3) intravenous|Participants will be administered Placebo 7 mg/kg as slow intravenous infusion.
214284543|NCT03883620|BIOLOGICAL|Dengushield 12 mg/kg (Cohort 4) intravenous|Participants will be administered Dengushield 12 mg/kg as slow intravenous infusion.
214284544|NCT03883620|BIOLOGICAL|Placebo 12 mg/kg (Cohort 4) intravenous|Participants will be administered Placebo 12 mg/kg as slow intravenous infusion.
214284545|NCT02581449|DIETARY_SUPPLEMENT|omega-3|dietary supplement
214284546|NCT02581449|OTHER|empty soft gelatin capsules|empty softgels of matched size, shape and color
214284547|NCT06083116|DRUG|Hydrochlorothiazide、Henagliflozin Proline|Hydrochlorothiazide and Henagliflozin Proline
214284548|NCT04567225|DRUG|Early Glargine|A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion
214284549|NCT04567225|DRUG|Late Glargine|A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.
214284550|NCT04567225|OTHER|IV insulin infusion|Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
214284551|NCT04567225|OTHER|IV fluid and electrolytes replacement|The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
214284552|NCT00345345|BIOLOGICAL|Alemtuzumab (Campath)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
214284553|NCT05184140|PROCEDURE|Sentinel node detection|"Injection of the radiotracer to infundibulo-pelvic and utero-ovarian ligament in patients with high suspicion of malignancy adnexal mass. Injection of green indocyanine r to infundibulo-pelvic and utero-ovarian stumps only in case of malignancy after the adnexectomy.~Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer diagnosis."
214284554|NCT01740986|DRUG|SA09012 Low dose|Tablet, b.i.d
214284555|NCT01740986|DRUG|SA09012 High dose|Tablet, b.i.d
214284556|NCT01740986|DRUG|Placebo|Tablet, b.i.d
214284557|NCT03630172|PROCEDURE|Dry needling|Using a thin, filiform needle to penetrate a muscle and its trigger point to produce a local twitch response
214284558|NCT02016560|DRUG|florbetapir F 18|
214284559|NCT02016560|DRUG|Flortaucipir F18|
214284560|NCT02016560|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
214284561|NCT05778747|OTHER|Heart to Heart Yoga|The Heart to Heart Yoga intervention is a therapeutic and standardized form of yoga intervention that is adapted from MediYoga designed to fit the needs of patients with HF and family caregivers who have physical limitations and depressive symptoms and to fit cultural and social norms in Kentucky. The intervention will use a gradual, physical/ psychological yoga adaptation approach, and it will be delivered two times per week (40 -60 minutes per session) via videoconference technology for 12 weeks (total 24 sessions). Real-time, face-to-face, video conferencing technology is used.
214284562|NCT01943292|DRUG|Defactinib|
214284563|NCT06226753|PROCEDURE|Type of anaesthesia used|Spinal anaesthesia will be used for closure of loop ileostomy
214284564|NCT05659095|OTHER|autologous hair follicle derived mesenchymal stem cell suspension|Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point. The follow-up duration was 9 months.
214471292|NCT04134910|PROCEDURE|Physical Therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
214284565|NCT04719754|DIAGNOSTIC_TEST|Vaginal swab|The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.
214284566|NCT05871294|DEVICE|Acoustic stimulation|The sound used for treatment is selected based on the patient's tinnitus frequency and loudness. Patients receive 90 minutes of acoustic stimulation therapy every day (at least 5 days per week). The entire treatment period is 3 months.
214471293|NCT06019962|DEVICE|digital pelvic inclinometer|It is a reliable and valid instrument for measuring pelvic tilt angle
214471294|NCT06394388|BEHAVIORAL|Cuidando juntos|"Caregiver TLC program will be culturally tailored by including a focus on addressing cultural values to promote social connectedness and translated into Spanish (Cuidando Juntos).~Cuidando Juntos consists of 8 modules: stress management; behavioral activation; building resilience; building self-care skills; managing difficult emotions; reducing isolation; and two on understanding and responding to difficult behaviors of the PLWD."
214284567|NCT05871294|DEVICE|Repetitive transcranial magnetic stimulation|The course of repeated transcranial magnetic stimulation therapy is 4 weeks, with 5, 5, 4, and 3 treatments per week, each lasting 90 minutes (including rest time)
214471295|NCT05025865|DRUG|Sodium Hyaluronate|Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
214471296|NCT05025865|DRUG|Placebo|A placebo will be given in capsule form to study participants.
214471297|NCT06851546|PROCEDURE|Nasal 180° Selective Laser Trabeculoplasty (SLT)|The Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
214471298|NCT06851546|PROCEDURE|Inferior 180° Selective Laser Trabeculoplasty (SLT)|The Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
214284568|NCT04492202|OTHER|Survey|The survey will be sent to health professionals via online link.
214284569|NCT02194205|DRUG|COMBIVENT HFA|
214284570|NCT02194205|DRUG|Placebo HFA|
214284571|NCT02194205|DRUG|COMBIVENT CFC|
214284572|NCT02194205|DRUG|Placebo CFC|
214284573|NCT04182360|DRUG|Carbetocin|Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.
214284574|NCT05605314|OTHER|Cyclosporine|eye drop
214284575|NCT05990972|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation (FMT) is a therapeutic method to transplant the microbiota from the feces of healthy people into the intestinal tract of patients. This treatment aims to improve a range of diseases associated with the gut microbiota by restoring the balance of the gut microbiota.
214284576|NCT04723745|BEHAVIORAL|V-TRACTS Assessment/Feedback|The proposed V-TRACTS assessment strategically targets emotional, cognitive and behavioral functions that we have determined are highly predictive of long-term outcome in Veterans. The assessment targets domains of head injury, psychological trauma, depression, suicidality, anxiety, chronic pain and sleep, substance use and activity level. This assessment will, in most cases, be completed online using the Qualtrics platform and online using telehealth or other approved platform for the clinical interview. Once the assessment is complete, the clinical team will convene a consensus meeting to review the case and determine a course of recommended additional assessment and/or rehabilitation action. After a consensus is reached, a V-TRACTS psychologist/supervised fellow will provide comprehensive feedback encompassing the entire assessment battery and offer rehabilitation options that would be targeted to the individual veteran's needs via VA telehealth or other approved online service.
214284577|NCT04723745|BEHAVIORAL|OPTIONAL Brief Assessment of Thinking|A neuropsychological/cognitive assessment will be conducted to gather information about functioning in the areas of memory, attention, and thinking. This assessment is designed to be done online in a single session, and it will take approximately 45-90 minutes to complete. The test battery is designed to focus on the specific cognitive abilities thought to be impacted by blast, mTBI, PTSD, etc. This battery is not intended to be an exhaustive assessment of all neuropsychological functions.
214284578|NCT04723745|BEHAVIORAL|OPTIONAL STEP-Home-Brief|STEP-Home-Brief is a condensed version of the 12-week experimental program STEP-Home that will target four core skills (problem solving, emotional regulation, attention training, and health and wellness). It will be individualized to Veterans' problems: vocation/career, community reintegration, psychoeducation to destigmatize barriers to mental health, substance misuse, anger management, and family and intimate partner relationships. STEP-Home-Brief will include 1-3 sessions using the same treatment modules as the 12-week program in a condensed, targeted format.
214844566|NCT01424098|BEHAVIORAL|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
214844567|NCT06551948|DIETARY_SUPPLEMENT|psyllium|15 g psyllium
214284579|NCT04723745|BEHAVIORAL|OPTIONAL At-home Exercise Program|This is a 5-week, full-body exercise program that can be done in the convenience of the Veteran's home, using only bodyweight as resistance and with household items as equipment. Given the online delivery of this program, they will receive access to instructional videos and materials that demonstrate how to perform each exercise safely and correctly. Participants will be contacted by study staff weekly over the phone to maintain interest and monitor adherence during the study.
214284580|NCT04723745|BEHAVIORAL|OPTIONAL Referral to 12-week STEP-Home|Referral to the experimental 12-week STEP-Home workshop research study (VABHS IRB #3210).
214284581|NCT04723745|BEHAVIORAL|OPTIONAL Clinical Referral|Clinical referrals to VABHS clinical services based on assessment and patient-directed primary problem/complaint.
214284582|NCT00638378|DRUG|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
214284583|NCT01852110|DRUG|MK-7622|MK-7622 capsule
214844568|NCT06551948|DIETARY_SUPPLEMENT|methylcellulose|15 gm methylcellulose
214284584|NCT01852110|DRUG|Placebo|Matching placebo to MK-7622 capsule
214284585|NCT01852110|DRUG|AChEI|"One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally"
214284586|NCT00153075|DEVICE|Berodual Respimat|
214284587|NCT00153075|DEVICE|Berodual HFA-MDI|
214284588|NCT01675271|OTHER|individual exercise|individual exercise and dietary prescription
214284589|NCT01675271|OTHER|general exercise|general exercise counselling
214284590|NCT01776333|BEHAVIORAL|video decision aid|
214284591|NCT01717807|OTHER|C11-Erlotinib PET/CT|
214284592|NCT00102726|DRUG|SB497115|SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
214284593|NCT00102726|OTHER|Placebo|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
214284594|NCT03529916|OTHER|isolation of endothelial cells precursors in blood|Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
214284595|NCT00759031|DRUG|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
214284596|NCT00759031|DRUG|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
214284597|NCT00369616|BIOLOGICAL|CYT002-NicQb|
214844569|NCT06551948|DIETARY_SUPPLEMENT|maltodextrin|15 g maltodextrin
214844570|NCT06551948|DIETARY_SUPPLEMENT|inulin|15g inulin
214844571|NCT05567627|BIOLOGICAL|Genetic: GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
214844572|NCT02396927|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
214844573|NCT02396927|DEVICE|2D HD laparoscopy|Placebo
214844574|NCT02627274|DRUG|RO6874281|RO6874281 will be administered as per the schedule specified under arm description.
214844575|NCT02627274|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified under arm description.
214284598|NCT02430311|DRUG|Olaparib|Tablet-150mg, Oral
214284599|NCT02430311|DRUG|Paclitaxel|Injection
214284600|NCT02430311|DRUG|Olaparib|Tablet-100mg, Oral
214284601|NCT04180488|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214284602|NCT04180488|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214284603|NCT04180488|DRUG|non sedating H1-antihistamine|Pharmaceutical form:Tablet Route of administration: oral administration
214284604|NCT00286169|DRUG|Amrubicin Hydrochloride|
214284605|NCT00471068|DRUG|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
214284606|NCT00471068|DRUG|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
214284607|NCT00471068|DRUG|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
214284608|NCT06037395|BIOLOGICAL|CT-P41|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
214284609|NCT06037395|BIOLOGICAL|US-licensed Prolia|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
214844576|NCT02627274|DRUG|Cetuximab|Cetuximab will be administered as per the schedule specified under arm description.
214844577|NCT04692857|PROCEDURE|supra inguinal fascia iliaca block|injection of 30,40 or 50 ml of 0.2 ropivacaine .
214844578|NCT02190786|DRUG|KUX-1151|
214844579|NCT00178724|OTHER|No Treatment Given|Intervention is not given.
214844580|NCT03837158|PROCEDURE|early loading|two TiZr implants on SLA surface
214844581|NCT03837158|PROCEDURE|immediate loading|four TiZr implants on SLA surface
214844582|NCT04491734|DIETARY_SUPPLEMENT|maltosyl-isomalto-oligosaccharides (MIMO)|Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.
214844583|NCT01723917|DIETARY_SUPPLEMENT|PhytoSERM tablet|
214844584|NCT01723917|DIETARY_SUPPLEMENT|placebo|
215033336|NCT06177431|DRUG|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
214284610|NCT03912155|OTHER|Multi-scale analysis of physiological brain networks|It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
214284611|NCT02656784|BEHAVIORAL|Cognitive Therapy|Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
214284612|NCT02656784|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
214284613|NCT04113304|BEHAVIORAL|Parenting Young Children Check-up (PYCC)|The PYCC intends to motivate parents to learn behavioral parenting strategies to reduce child disruptive behavior.
214284614|NCT00281255|DRUG|Allopurinol|
214284615|NCT00281255|DRUG|Dobutamine|
214284616|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
214284617|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
214284618|NCT01842698|DEVICE|ultrasoundguided paravertebral catheter|
214284619|NCT01393704|DRUG|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
214284620|NCT05830591|OTHER|Characterization of the microbiome in oral and fecal samples|The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.
214471299|NCT06851286|BEHAVIORAL|Laughter Therapy|A laughter yoga session; It is approximately 30 minutes and consists of four parts. These sections; hand clapping and warm-up exercises, deep breathing exercises, childish games and laughter exercises. In each laughter yoga session, the first three parts are the same, but the laughter exercises in the fourth part vary. In the first session of each new group, the introduction of laughter yoga, its purpose and objectives will be discussed. 10 minutes will be allocated for this section in the first session of each group. Therefore, the first session is planned to be 40 minutes in each group and all subsequent sessions are planned to be 30 minutes.
214844585|NCT04371263|OTHER|Emotional Change of Nursing Manpower in Emergency and Critical Unit After Keen Election And What's The Influence of Emotional Change|use the emotion regulation questionnaire (ERQ) to realize the influence in duty work
214284621|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with short hamstring graft technique|ACL and short hamstring graft
214284622|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with a standard hamstring graft technique|ACL with standard hamstring graft
214284623|NCT03458273|PROCEDURE|Zero fluoroscopy ablation|Catheter ablation for the treatment of atrial and ventricular arrhythmia - no fluoroscopy guidance
214284624|NCT03458273|PROCEDURE|Conventional ablation without 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance only. 3D system (Every Ensite/Carto) is not allowed
214284625|NCT03458273|PROCEDURE|Conventional ablation with 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance + 3D system support (Ensite/Carto)
214284626|NCT06194565|DRUG|99mTc-ABH2|Each patient will receive an intravenous injection of 99mTc-ABH2, and undergo a SPECT/CT scan within specified time.
214284627|NCT04684498|DRUG|Oseltamivir phosphate capsules|Treatment group vs. Control group
214284628|NCT03675698|OTHER|Nasotracheal Intubation|side of nostril and size of endotracheal tube estimation for nasotracheal intubation will be done based on radiological imaging ( CT/MRI head)
214844586|NCT01745081|DRUG|20% mannitol bolus administration|
214844587|NCT01745081|DRUG|Hypertonic saline 3% bolus administration|
214284629|NCT05822713|DRUG|Amisulpride|5mg/2ml
214284630|NCT05822713|DRUG|Amisulpride Placebo|2ml
214284631|NCT02877615|DRUG|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
214284632|NCT02877615|DRUG|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
214284633|NCT02877615|DRUG|Placebo|Two sachets of placebo twice a day
214284634|NCT01804296|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
214284635|NCT01023230|DRUG|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
214284636|NCT01023230|DRUG|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
214284637|NCT00948987|DRUG|Aspirin|325 mg enteric coated single dose p.o.
214284638|NCT02091544|OTHER|Lifestyle intervention|
214471300|NCT06199089|DRUG|CM313 Injection|"Intravenous CM313 administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to experimental group were treated with CD38 monoclonal antibody (CM313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
214471301|NCT06199089|DRUG|Placebo Injection|"Intravenous Placebo administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to placebo comparator group were treated with placebo of CM313 once a week for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of placebo of CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after placebo administration."
214284639|NCT03866005|DIETARY_SUPPLEMENT|Diabetes Visual Function Study (DiVFuSS) softgels|The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).
214471302|NCT04674826|DRUG|Tralokinumab administered as 1 × X mL with Device A|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
214471303|NCT04674826|DEVICE|Tralokinumab administered as 2 × Y mL with Device B|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
214471304|NCT06849804|PROCEDURE|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|Group E (n=25): Erector spinae plain block group will receive 0.5 ml/kg of 0.25%bupivacaine.
214471305|NCT06849804|PROCEDURE|Caudal Block Anesthesia|Caudal block group will receive 1 ml/kg of 0.25% bupivacaine
214471306|NCT06849804|PROCEDURE|Local infiltration in the wound|Local Infiltration Group will receive 0.2 ml/kg 0.25% bupivacaine
214284640|NCT03866005|OTHER|canola oil placebo softgels, 2 per day|Placebo containing canola oil, 2 softgels per day
214471307|NCT05995054|DRUG|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 110 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
214471308|NCT04180462|OTHER|Practice Facilitation|Practice facilitation to support quality improvement methods to effect practice change to develop a sustainable HPV vaccine delivery system.
214471309|NCT04180462|OTHER|Education|An educational video to increase the provider's knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13.
214844588|NCT06453837|OTHER|Mentha Suaveolens extract incorporated into a food supplement|Each subject of this group takes 1 capsule of the food supplement per day, with lunch, for 84 consecutive days.
214284641|NCT04159025|DEVICE|CoreDx Pulmonary Mini-Forceps|Manufactured by Boston Scientific
214284642|NCT02612324|BEHAVIORAL|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
214284643|NCT02612324|BEHAVIORAL|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
214471310|NCT04180462|OTHER|Audit and Feedback|Audit and feedback of vaccine coverage to increase motivation to engage in practice change.
214471311|NCT04180462|OTHER|Communication Strategy|A communication strategy to improve the provider's communication skills and their self-efficacy to address parental hesitation.
214471312|NCT04724499|BEHAVIORAL|High-Intensity Intervals Training|16 week exercise program with stationary bike.
214471313|NCT04724499|OTHER|Attention Control|16 week stretching program.
214844589|NCT06453837|OTHER|Placebo product|Each subject of this group takes 1 capsule of comparator product per day, with lunch, for 84 consecutive days.
215033337|NCT05264727|DRUG|Dextrose|Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes
215033338|NCT05264727|DRUG|Clinisol 15%|Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
214284644|NCT00381095|DRUG|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
214284645|NCT00381095|DRUG|Placebo|Placebo
214284646|NCT03374878|OTHER|no oral contraceptive and training|10 weeks of training in a group of oral contraceptive users
214284647|NCT03374878|OTHER|oral contraceptive and training|10 weeks of training in a group of users of oral contraceptives
214284648|NCT05397821|PROCEDURE|UNC technique|In general, UNC techniques can be divided in being either intravesical or extravesical and refluxing or non-refluxing
214284649|NCT04054388|BEHAVIORAL|LINE re-education|
214284650|NCT03653650|COMBINATION_PRODUCT|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
214284651|NCT03653650|COMBINATION_PRODUCT|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
214284652|NCT03653650|COMBINATION_PRODUCT|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
214471314|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with a Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with a connective tissue graft harvested from the palate.
214471315|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with micro Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with multiple micro connective tissue graft harvested from the palate.
214471316|NCT06030947|DEVICE|Division of the Connective Tissue Graft into multiple micro Connective Tissue Grafts|The harvested connective tissue graft is divided in multiple micro connective tissue grafts with a scalpel blade before being placed on the recipient site.
214284653|NCT06030791|DIAGNOSTIC_TEST|MRI|MRI of operated knee
214471317|NCT06651021|DRUG|balcinrenone/dapagliflozin|"Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition.~Each participant will be involved in the study for up to 35 days."
214471318|NCT06649708|DRUG|HX044|Conventional dose-escalation design with 3+3 cohort size. All administered on a Q3 weekly basis. Dose escalation will be based on the absence of DLTs during the 21-day DLT evaluation after a review of safety data by the Safety Review Escalation Committee. Subjects will continue on study treatment until the subject develops an intolerable toxicity, withdraws consent, develops progression of disease, death, lost to follow-up, start of new anticancer treatment or up to study treatment duration of 24 months, whichever comes first.
214471319|NCT06650579|DRUG|Abiraterone Acetate|Given abiraterone acetate
214471320|NCT06650579|DRUG|Bicalutamide|Given PO
214471321|NCT06650579|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214471322|NCT06650579|PROCEDURE|Computed Tomography Angiography|Undergo CCTA
214471323|NCT06650579|DRUG|Leuprolide|Given IM or SC
214471324|NCT06650579|DRUG|Prednisone|Given prednisone
214471325|NCT06650579|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
214471326|NCT06650579|DRUG|Relugolix|Given PO
214471327|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple palatal micro connective tissue grafts|The connective tissue graft will be harvested from the palate.
214471328|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple tuberosity micro connective tissue grafts|The connective tissue graft will be harvested from the maxillary tuberosity.
214471329|NCT06651489|DRUG|Guselkumab|Subcutaneous injection of 100 mg at Weeks 0, 4, 12, and 20
214284654|NCT03620240|BEHAVIORAL|Sleep Education|Assessing the effectiveness of a Sleep Education Program in improving sleep behaviors in secondary school students.
214284655|NCT01102400|DRUG|MEDI-575|MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
214284656|NCT01310621|DRUG|Bovine surfactant|"* Dose of diluted surfactant : 20ml/kg~* Type :Bovine surfactant~* Phospholipid concentration: 5 mg/ml~* Number of lavages to be given: 2 (10ml/kg each)"
214284657|NCT03608449|OTHER|questionnaires|questionnaire about mental health status during psychotherapy
214284658|NCT00670683|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214284659|NCT05666492|OTHER|Platelet rich plasma|Platelet-rich plasma will be placed on the olfactory epithelium topically.
214471330|NCT05342493|DRUG|Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution|The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
214471331|NCT06167200|OTHER|No intervention, study is observational|No intervention, study is observational
214471332|NCT04954677|OTHER|AI-box|Automatic quality-control system（AI-box）could real-time measure endoscopic inspection completeness, evaluate gastric cleanliness.
214471333|NCT06757881|BIOLOGICAL|Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group)|Different dose groups
214284660|NCT05666492|OTHER|Saline|Saline will be placed on the olfactory epithelium topically.
214284661|NCT04070950|OTHER|Questionnaires|Two self-questionnaires
214471334|NCT06757881|BIOLOGICAL|Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group)|Different dose groups
214284662|NCT06476262|BEHAVIORAL|This research has only one arm. The intervention focuses on occupational issue|During the post-stroke consultation, each participant is invited to complete questionnaires on occupational gaps, mood disorders, fatigue, cognition, and quality of life.
214284663|NCT01104493|BIOLOGICAL|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
214284664|NCT01104493|OTHER|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
214284665|NCT04459091|DIETARY_SUPPLEMENT|Amino Essential Acid|8 gr die in two administration
214284666|NCT04459091|DIETARY_SUPPLEMENT|placebo|8 gr die in two administration
214284667|NCT00208091|DRUG|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
214471335|NCT06757881|BIOLOGICAL|Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）|Different dose groups
214471336|NCT04621643|BEHAVIORAL|digital cognitive behavioral therapy (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
214471337|NCT04621643|BEHAVIORAL|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
214471338|NCT05942924|PROCEDURE|Repeated tactile stimulation|See arm
214471339|NCT05942924|PROCEDURE|Selective tactile stimulation|See arm
214471340|NCT06356558|OTHER|Educational intervention (VISACT)|The intervention is an implementation strategy called VISACT: VISuAl aids, Coach providers in communication, and Train organizations in health literacy. This strategy will be delivered to patients, providers, and organizations through a novel interactive response platform.
214471341|NCT06772922|OTHER|Exercise|effect of exercise after three months (comparison of the patient with himself)
214284668|NCT03029377|OTHER|Posture Study, Autonomic Function Tests, and a Stress Test|Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
214284669|NCT01342796|BIOLOGICAL|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
214471342|NCT06496945|OTHER|Adult day program use|Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
214471343|NCT06496945|OTHER|Other community care (non-attendees)|Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
214471344|NCT06093217|DEVICE|Artificial Intelligence|AI technology will generate a report with relevant key slice imaging identifying the presence of an acute pulmonary embolism and RV:LV ratio measurements to the radiologist
214471345|NCT03368625|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery before surgical resection of brain mets.
214471346|NCT04687865|OTHER|Biobank|"For each patient included in the study the following samples will be collected at the indicated time points after transplantation:~* Serum samples and plasma sample: Day1, Month 1, Month 3, Month 6, Month 12, month 60, month 120 and at the time of each allograft biopsy.~* Urines samples: Month 3 and Month 12 and at the time of each allograft biopsy.~* Peripheral Blood Mononuclear Cell (PBMC): for each organ allograft biopsy.~* Allograft biopsies: systematically at Month 3, and Month 12, and for cause in case of allograft dysfunction."
214284670|NCT01342796|BIOLOGICAL|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
214284671|NCT01599234|DRUG|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
214284672|NCT01599234|DRUG|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
214284673|NCT02248155|DRUG|Pramipexole|
214284674|NCT03916328|DRUG|B/F/TAF|A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
214284675|NCT03916328|DRUG|TDF/3TC/EFV or DTG or NVP|A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.
214284676|NCT03916328|OTHER|DMPA|Two thirds of the women will be on DMPA for contraception.
214284677|NCT05104892|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
214284678|NCT05104892|DRUG|placebo|Pharmaceutical form: Tablet Route of administration: Oral
214284679|NCT03764189|PROCEDURE|microosteoperforation|small holes made using large round bur
214284680|NCT04190394|OTHER|Intermittent retraining program.|Patient benefits from an intermittent retraining program for 8 weeks, with three 45-minute sessions per week.
214284681|NCT00080977|BIOLOGICAL|aldesleukin|
214284682|NCT04893967|DEVICE|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
214284683|NCT04893967|DEVICE|kinesiology tape|Kinesiology Tape is applied without creating any tension over low back
214284684|NCT01717404|DRUG|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
214284685|NCT01934530|PROCEDURE|Soft Tissue Grafting|"All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement."
214284686|NCT04425161|OTHER|Fluid challenge (0.9 % NaCl)|500 ml Fluid challenge of (0.9 % NaCl) will be given
214284687|NCT00107471|BIOLOGICAL|filgrastim|Given PO
214284688|NCT00107471|DRUG|topotecan hydrochloride|Given IV
214284689|NCT00107471|RADIATION|radiation therapy|
214284690|NCT05809401|BEHAVIORAL|Pragmatic Rehabilitation|A series of behavioral activities to improve specific pragmatic abilities in patients
214284691|NCT05809401|BEHAVIORAL|Neuropsychological Rehabilitation|A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
214284692|NCT03140553|DRUG|TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)|TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
214471347|NCT05037461|RADIATION|High-dose-high precision MR-guided radiotherapy|MR-guided radiotherapy as described in the group information
214471348|NCT04382079|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
214471349|NCT04382079|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
214471350|NCT03899649|DRUG|SOC|Standard of Care treatment
214471351|NCT03899649|DEVICE|NanoKnife System|Irreversible Electroporation
214471352|NCT03500731|BIOLOGICAL|CD3/CD19 negative hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation
214471353|NCT03500731|DRUG|Rituximab|Transplantation Conditioning
214471354|NCT03500731|DRUG|Alemtuzumab|Transplantation Conditioning
214471355|NCT03500731|DRUG|Fludarabine|Transplantation Conditioning
214471356|NCT03500731|DRUG|Thiotepa|Transplantation Conditioning
214471357|NCT03500731|DRUG|G-CSF|Transplantation conditioning
214471358|NCT03500731|DRUG|Hydroxyurea|Transplantation Conditioning
214471359|NCT06821750|BIOLOGICAL|PF-07314470|subcutaneous injection
214471360|NCT06821750|BIOLOGICAL|Placebo for PF-07314470|subcutaneous injection
214844590|NCT02275754|BEHAVIORAL|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
214844591|NCT02275754|BEHAVIORAL|PN Only|Participants will be navigated by PN on request
214284693|NCT04497506|BEHAVIORAL|Wise Intervention (Self-affirmation and Incremental theory of personality)|The intervention designed to promote prosocial behavior and reduce online risks is based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes two components: a self-affirmation activity and an ITP intervention. The SA component includes a list of values so that they could choose the two or three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component includes activities such as reading scientific information about social behavior and its role in people's well-being, the meaning and value of online risk behaviors through stories and videos of the experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change.
214284694|NCT04497506|BEHAVIORAL|Standard preventive intervention|It consists of an educational intervention that provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
214284695|NCT00033215|DRUG|S-3304|
214284696|NCT02889484|PROCEDURE|Lumbar disc hernia surgery|
214284697|NCT06163170|DRUG|Nivolumab +/- ipilimumab|Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma
214284698|NCT06163170|DRUG|Nivolumab|Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma
214284699|NCT01114178|OTHER|questionnaire|self completed questionnaire supervised by a technician
214284700|NCT00869895|DRUG|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
214284701|NCT04021004|OTHER|Survey Questionnaire|Survey Questionnaire
214284702|NCT01549444|OTHER|presence of maternal risk factor for hypertension|
214284703|NCT03007576|BIOLOGICAL|RegStem|RegStem, 1.5 ml, one injection
214284704|NCT00812890|DEVICE|semi-quantitative pregnancy test|
214284705|NCT02433483|DRUG|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
214471361|NCT06806631|OTHER|Video assisted discharge training|The researchers developed a training content by utilizing various sources and consulting expert opinions. DISCERN (quality criteria for consumer health information) tool was used to evaluate the information quality of the educational content and 5 expert opinions were obtained and the educational content was finalized in line with the suggestions. The training content included the problems that patients may experience in the postoperative period, postoperative interventions (movement, breathing and cough exercises), control times, nutrition, do's and don'ts and other nursing care issues. The content of the training video prepared according to the DISCERN scale was found to be sufficient. The training content was then converted into a video training given by the nurse researcher.
214471362|NCT04415866|BEHAVIORAL|Paced Auditory Serial Addition task (PASAT)|Single and double digits are presented at intervals between 2 and 3 seconds and the participant must add each new digit to the one immediately prior to it. The participants will be asked to indicate by electronic button press whether the sum of the addition is 13 or not. The duration of the PASAT will be two 12-min tasks.
214471363|NCT05333029|BIOLOGICAL|Allogeneic mesenchymal stromal cells (MSCs)|Treatment dose 2 x10\^6 cells/kg (+/- 20%)
214471364|NCT05333029|BIOLOGICAL|Extracorporeal photopheresis (ECP)|Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant
214471365|NCT03501524|DEVICE|VATS evacuation|the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax
214471366|NCT03501524|DEVICE|thoracostomy tube|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
214471367|NCT02812524|DRUG|Intratumoral Ipilimumab|Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
214471368|NCT05191121|BEHAVIORAL|FTP Alone|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins).
214284706|NCT02433483|DRUG|Intrathecal Triples|given IT.
214471369|NCT05191121|BEHAVIORAL|FTP+Con-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing conventional parameter FES.
214471370|NCT05191121|BEHAVIORAL|FTP+WPHF-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing wide pulse, high frequency parameter FES.
214471371|NCT05259150|BEHAVIORAL|Health for Hearts United Planning for Health|Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, \& Move Around More) and plan for their health ministry and cardiovascular health program to congregants.
214471372|NCT05259150|BEHAVIORAL|Health for Hearts United Preparing for Health|Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool \& Recognition.
214471373|NCT05259150|BEHAVIORAL|Health for Hearts United Delivery of Health|The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).
214471374|NCT05259150|OTHER|Health for Hearts United Comparison Group Health Ministry Development|Participants (health leaders) have meetings to develop the health ministry. Research participants (church congregants) do not receive cardiovascular health program.
214471375|NCT06807736|DRUG|Cabotegravir long-acting|3ml intramuscular injection containing 600mg of Cabotegravir
214471376|NCT06807736|DRUG|Tenofovir emtricitabine|Oral tablet taken daily to PrEP HIV infection.
214471377|NCT06807736|DRUG|Dapivirine containing vaginal ring|Intra-vaginal silicone ring containing slow-release Dapivirine, replaced every 28 days
214284707|NCT02433483|BIOLOGICAL|HPC-A|Given IV.
214284708|NCT02835508|DRUG|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
214471378|NCT04564183|OTHER|Sample collection|Blood, Urine, Nail, Hair, Saliva, optional Stool
214284709|NCT02835508|DRUG|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
214284710|NCT02835508|DRUG|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
214471379|NCT04564183|OTHER|Questionnaires|SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire
214471380|NCT04564183|RADIATION|High resolution CT scan of the chest|Upon enrollment, all participants will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.
214284711|NCT01647815|PROCEDURE|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
214284712|NCT03489720|BEHAVIORAL|Prescribed Exercise Program|"Brief cardiovascular exercise training (\>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~* Walking quickly or running up and down stairs~* Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~* Walking up an incline on a treadmill~* Jogging or running on a treadmill or elliptical~* Stationary cycling or rowing"
214284713|NCT03489720|BEHAVIORAL|Usual Exercise Program|Usual exercise activity for 8 weeks
214284714|NCT06160154|OTHER|no intervention|all patients undergoing minimally invasive distal pancreatectomy, no intervention, no randomization
214284715|NCT04271891|DEVICE|WBPC|The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks.
214284716|NCT04271891|DEVICE|Without WBPC|Not treat with WBPC
214284717|NCT01138553|DRUG|Mifepristone|200mg capsules daily for 5-28 days
214471381|NCT04564183|DIAGNOSTIC_TEST|Pulmonary Function Test|All recruited participants will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.
214471382|NCT06174181|DEVICE|Preservative-free ophtalmic lubricant emulsion|Use of a preservative-free ophtalmic lubricant emulsion continous during 6 months
214471383|NCT06174181|OTHER|Routine treatment|Use of a preservative-free ophtalmic lubricant emulsion after each intravitreal injection during few days
214471384|NCT06657079|DRUG|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
214471385|NCT06657079|DRUG|Placebo|Saline inhaler
214471386|NCT04939038|PROCEDURE|Revascularization|Depending on the condition of the patients, patients will have either endovascular or surgical revascularization
214471387|NCT04939038|PROCEDURE|Standard wound care|Standard wound care according to guidelines
214471388|NCT04959552|DEVICE|FreeStyle Libre 2|The FreeStyle Libre 2 Flash Glucose Monitoring
214471389|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (in a single-dose vial)-Route of administration:Intramuscular (IM) injection
214284718|NCT00031863|DRUG|rofecoxib|
214284719|NCT00031863|PROCEDURE|adjuvant therapy|
214284720|NCT03780907|DRUG|E2007|1 mg of E2007 was administered by mouth once daily.
214284721|NCT03780907|DRUG|E2007|2 mg of E2007 was administered by mouth once daily.
214284722|NCT03780907|DRUG|Placebo|Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
214284723|NCT01760707|BEHAVIORAL|exercise training|
214284724|NCT01760707|BEHAVIORAL|usual care|
214284725|NCT02818686|DRUG|TD-1473|
214284726|NCT02818686|DRUG|Placebo|
214284727|NCT04806854|DRUG|LUM-201|Administered orally once daily
214284728|NCT01923701|BEHAVIORAL|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
214284729|NCT04734223|DIAGNOSTIC_TEST|Neuroimaging Findings in Patients With COVID-19|MR and BT Imaging
214471390|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (powder or cake in a single dose glass vial and a clear and colourless solvent in a pre filled syringe for reconstitution-Route of administration:Intramuscular (IM) injection
214471391|NCT02369406|DRUG|Nevirapine|
214471392|NCT02369406|DRUG|Kaletra|
214471393|NCT02369406|DRUG|Lamivudine|
214284730|NCT04006249|DIAGNOSTIC_TEST|dental probes|Measurement of the depth of the periodontal pockets and clinical loss
214284731|NCT02338661|DEVICE|SBG hip stem|
214284732|NCT06038084|DRUG|Bronpass Tab.|Twice a day
214284733|NCT06038084|DRUG|Placebo of Erdos capsule|Three times a day (It is for the masking.)
214284734|NCT06038084|DRUG|Erdos capsule|Three times a day
214284735|NCT06038084|DRUG|Placebo of Bronpass Tab.|Twice a day (It is for the masking.)
214284736|NCT03446183|BEHAVIORAL|Smoking cessation workshops|All the participants took part in smoking cessation workshops. The comparison of metabolic aspects was made between the smokers and non-smokers
214284737|NCT03342690|DRUG|Eplerenone|"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."
214284738|NCT05898555|DEVICE|Skiin garment and pods|"Participants will be asked to wear a Skiin smart garment over their own clothes.~Small motion capture markers will be placed on their body and pressure-sensitive insoles placed into their shoes to measure the pressure underneath their feet during the study tasks.~Once the sensors are ready for collection, participants will be asked to complete 5 tasks associated with their daily activities: 1. Locomotion; 2. Lower limb strength - repeated sit-to-stand-to-sit transitions; 3. Lower limb strength and locomotion - Timed Up and Go; 4. Free walking during a 2min walk; 5. Standing balance, postural control."
214284739|NCT05803057|DEVICE|TMS stimulation treatment|Using the TMS treatment coli to stimulation with high frequency
214284740|NCT05803057|DEVICE|TMS stimulation sham-treatment|Using the TMS sham-treatment coli to stimulation with high frequency
214284741|NCT01352689|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
214284742|NCT01352689|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
214284743|NCT02309879|DRUG|Remifentanil infusion|Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
214284744|NCT02309879|DRUG|Lidocaine infusion|Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
214284745|NCT02309879|DRUG|Magnesium sulphate infusion|Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
214284746|NCT02309879|DRUG|Magnesium sulphate and Lidocaine infusion|Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
214471394|NCT02369406|DRUG|Zidovudine|
214471395|NCT06567548|OTHER|control group|An absorbable gelatin sponge is a sterile hemostatic agent primarily composed of purified porcine-derived gelatin. It is widely utilized in surgical procedures to control bleeding
214471396|NCT06567548|OTHER|Platelet-rich fibrin (PRF)|Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.
214471397|NCT06567548|OTHER|Albumin Platelet Rich- Fibrin|is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
214471398|NCT06346470|OTHER|Web-based breast self examination education|Students in this group will receive web-based breast self-examination education for 6 hours .
214471399|NCT03308877|BEHAVIORAL|BMI|Four 45-minute, brief motivational sessions for substance use
214471400|NCT03308877|BEHAVIORAL|Stadard Care (SC)|Standard procedures at pretrial program + assessement
214471401|NCT02219633|DRUG|LEO 39652 cream|Applied for 21 days
214471402|NCT06283719|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
214471403|NCT05823922|BEHAVIORAL|Clinician Delivered CBT|Clinicians teach cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety and depression. Participants will attend weekly sessions with their clinician for 6 weeks.
214471404|NCT05823922|BEHAVIORAL|Supplemental MAYA App|"The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.~Participants will attend weekly sessions with their clinician as well as using the MAYA application for at least 20 minutes twice a week"
214471405|NCT05823311|DRUG|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.
214471406|NCT05823311|DRUG|Gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
214844592|NCT00002633|DRUG|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
214844593|NCT00002633|DRUG|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
214844594|NCT00002633|DRUG|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
214844595|NCT00002633|DRUG|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
214844596|NCT00002633|DRUG|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
214844597|NCT00002633|DRUG|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
214844598|NCT00002633|PROCEDURE|orchiectomy|Optional orchiectomy
214844599|NCT00002633|RADIATION|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
214844600|NCT04785911|DRUG|Antiemetic Combinations|Evaluation of response to treatment of hyperemisis gravidarum (antiemetics and other methods ) by PUQE score
214844601|NCT01913054|DRUG|Fentanyl Injection|
214844602|NCT01913054|DRUG|Etomidate Fat Emulsion Injection|
214844603|NCT01913054|DRUG|Propofol Injection|
214844604|NCT04592653|BIOLOGICAL|Nemvaleukin alfa|IV infusion over 30 minutes
214844605|NCT04592653|BIOLOGICAL|Pembrolizumab|IV infusion over 30 minutes
214844606|NCT02811341|DRUG|Scopolamine Hydrobromide|
214844607|NCT02811341|DRUG|normal saline|
214844608|NCT01107327|PROCEDURE|FDG-PET/CT|"The study is focused on two goals, both of which use a new imaging test called PET/CT. PET/CT combines a special radioactive scan with a CT scan. PET/CT is most commonly used in medical practice to evaluate cancer. Abnormal areas such as cancer light up on the PET/CT scan. However, many doctors, including us, have noticed that PET/CT also lights up in areas of blood clot formation as well. In this study, PET/CT will be used to evaluate the two goals of this project."
214844609|NCT01638273|DRUG|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
214844610|NCT01638273|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
214844611|NCT06251960|PROCEDURE|socket preservation with completely demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
214844612|NCT06251960|PROCEDURE|socket preservation with partially demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
214844613|NCT04850027|PROCEDURE|TME+Lateral lymph node dissection.|TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
214844614|NCT00000680|DRUG|Zidovudine|
214284747|NCT05922150|RADIATION|low level laser therapy|LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function
214284748|NCT05922150|DRUG|ozone gel|ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects
214284749|NCT04219631|DEVICE|expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate.|women enrolled in WINNER-FLOW-URO-MG group will freely use the expiratory mouthpiece device during all their childbirth process.
214284750|NCT03219294|DRUG|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
214844615|NCT00000680|DRUG|Aldesleukin|
214844616|NCT04245358|DEVICE|Ainara|1g of gel per administration
214844617|NCT04859140|OTHER|Psychometric ratings (Likert-scale)|Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)
214844618|NCT04859140|BEHAVIORAL|Range of motion measures|Sit-and-reach and toe touch tests
214844619|NCT04859140|BEHAVIORAL|Mental calculation task|Iterated substractions (for 2 minutes)
214284751|NCT03219294|DRUG|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
214284752|NCT01373801|DEVICE|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
214284753|NCT01373801|DEVICE|Control|Standard packing gauze roll bandage.
214284754|NCT03224572|DRUG|high-dose vitamin C 30gm|High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
214284755|NCT03224572|OTHER|normal saline|500ml normal saline, once per week, and total 4-week treatment
214284756|NCT01160250|DRUG|vismodegib (GDC-0449)|Oral repeating dose
214284757|NCT04912050|DEVICE|Tablo Hemodialysis System|Renal Replacement Therapy between 12\< to ≤ 24 hours.
214284758|NCT06043089|DIETARY_SUPPLEMENT|Beetroot juice supplementation or placebo|Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
214284759|NCT02050360|DRUG|Sildenafil 40 mg|
214284760|NCT02050360|DRUG|Sildenafil 80 mg|
214284761|NCT02050360|DRUG|Placebo|
214284762|NCT06049745|DRUG|Misoprostol 400 Microgram Oral Tablet|S.L misoprostol 400 mcg
214284763|NCT05548725|OTHER|Reguired field|Investigations to know relationship between acute kidney injury and mineral bone disease
214284764|NCT03273192|DRUG|Adalimumab|A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
214471407|NCT04804293|DEVICE|FDA approved ultrasound system with shear wave elastography capability|The investigators will acquire at least 4 acquisitions for each of 2 locations on the wrist. The objective is to correlate SWE measurements with patient-reported measures of symptom severity and functional status scores and severity of pre-operative electrodiagnostic tests (EDX). Evaluate the treatment response to surgical decompression or corticosteroid injection, using quantitative SWE and correlate the results to repeated patient reported outcomes with Boston CTQ, and objective clinical improvement with Semmes-Weinstein monofilament evaluation for recovery of sensibility, and grip and lateral pinch strength.
214284765|NCT01901237|BEHAVIORAL|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
214284766|NCT05321732|DRUG|DWP16001|DWP16001 A mg
214284767|NCT05321732|DRUG|DWP202010|DWP202010 B mg
214284768|NCT01788332|DRUG|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
214844620|NCT04859140|DEVICE|Resting-state electroencephalography|Alpha and beta oscillation power (4 minutes recordings)
214284769|NCT01788332|OTHER|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water
214284770|NCT02157467|DRUG|BMS-955176|
214284771|NCT02157467|DRUG|Ortho Cyclen|
214284772|NCT02058667|RADIATION|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
214284773|NCT04416594|OTHER|Data collection|Only data collection
214284774|NCT00453297|DRUG|MF101|
214284775|NCT05985889|OTHER|Robot|You have to walk with a robot mounted on your lower limb. To move, to change direction.
214284776|NCT05985889|OTHER|Fizio|Patients do state-funded physical therapy.
214284777|NCT05985889|OTHER|EXE1|Patients undergo intensive virtual reality therapy once a day.
214284778|NCT05985889|OTHER|EXE2|Patients undergo intensive virtual reality therapy twice a day.
214284779|NCT05985889|OTHER|EXE+ROB|The patients intensively performed 1 virtual reality therapy and 1 robotic therapy every day.
214284780|NCT04626297|DRUG|Lebrikizumab|Given SC
214284781|NCT04626297|DRUG|Placebo|Given SC
214284782|NCT04350489|OTHER|Non-surgical periodontal treatment|Conventional non-surgical periodontal treatment were performed
214284783|NCT04804878|PROCEDURE|Collection of blood, tissue, and other biological samples.|Behavioral health assessments, including quality of life.
214284784|NCT04804878|OTHER|Medical Chart Review|Health data abstracted directly from patient's health records
214284785|NCT03167411|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
214284786|NCT03167411|DRUG|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
214284787|NCT03962010|DRUG|GX-G6|long acting anti-diabetic drug
214284788|NCT03962010|DRUG|Control|Control
214284789|NCT02637739|DEVICE|hysteroscope|Women of PUL with β-hCG \> 1000 IU/L or abnormal β-hCG trend (increase \< 66% or decrease \< 15%) were offered HSC.
214284790|NCT02602496|OTHER|Fruits and Vegetables|5 servings of fruits or vegetables
214284791|NCT02602496|OTHER|Whole Grain|3 servings of whole grain
214284792|NCT02602496|OTHER|Control|3 servings of refined grain
214284793|NCT05501730|DIAGNOSTIC_TEST|Quantra QPlus System|Coagulation monitoring system
214284794|NCT03524898|DRUG|Nab-Paclitaxel|150 mg/m2 / 125 mg/m2
214284795|NCT03524898|DRUG|gemcitabine|1000 mg/m2
214284796|NCT06236178|DRUG|Corticosteroid|1 ml of 40 mg methylprednisolone acetate
214284797|NCT06236178|DRUG|Autologous Blood|1 ml of autologous venous blood
214284798|NCT06236178|DRUG|Local Anesthetic|1 ml of 2% prilocaine HCl
214284799|NCT04983654|DIAGNOSTIC_TEST|patients with limb ulcers|"For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis ( sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks,~* Analysis of cytokine and metalloproteases in the wound fluid,~* Assessment of healing according usual treatment"
214284800|NCT04983654|DIAGNOSTIC_TEST|For patients without limb ulcers|"For patients without limb ulcers : at inclusion visit only~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis (sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks"
214284801|NCT04185545|BIOLOGICAL|Rotavirus RV3 Vaccine (Bio Farma)|Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains \> 5x10\^6 fcfu/mL rotavirus vaccine strain RV3
214284802|NCT04185545|OTHER|Placebo|Each 1 mL dose of placebo contains 30% of sucrose in DMEM
214284803|NCT02137174|OTHER|Home and school visits|Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
214284804|NCT00802139|DRUG|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
214284805|NCT00802139|DRUG|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
214284806|NCT03618498|PROCEDURE|ILM flaps insertion techniques or free ILM flaps.|The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
214284807|NCT02020330|DRUG|Artemether-lumefantrine 3 days|One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
214284808|NCT02020330|DRUG|Artemether-lumefantrine 5 days|One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
214284809|NCT03749070|DIETARY_SUPPLEMENT|Silymarin|It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
214284810|NCT05101005|DEVICE|Drug-Coated Balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions.
214284811|NCT05101005|DEVICE|Sirolimus-Eluting Stent|Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.
214284812|NCT06304220|DRUG|Cerazet|Comparation of the utilization of two distinct progestogens for pituitary suppression
214284813|NCT05351125|PROCEDURE|cardiac catheterization|catheterization in critical congenital heart disease requiring atrial septostomy or balloon valvuloplastyor PDA stenting
214284814|NCT05685966|OTHER|no intervention|no intervention
214284815|NCT04993092|OTHER|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
214284816|NCT04993092|OTHER|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
214284817|NCT04957693|BEHAVIORAL|vegan diet and lifestyle changes|vegan diet and lifestyle changes
214284818|NCT06359067|OTHER|Treated by bispecific antibodies, teclistamab or elranatamab in usual care|Treated by bispecific antibodies, teclistamab or elranatamab in usual care
214284819|NCT06359067|OTHER|Not treated by bispecific antibodies in usual care|Not treated by bispecific antibodies in usual care
214471408|NCT05806021|DRUG|Triamcinolone Acetonide|Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
214471409|NCT03787173|DEVICE|Optimized|Inspiratory trigger and Expiratory trigger settings optimized by investigator
214284820|NCT04921371|OTHER|Colgate® Cavity Protection Toothpaste|Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
214284821|NCT04921371|OTHER|Listerine® Cool Mint®|Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
214284822|NCT04921371|OTHER|Concept Curve Winter Series Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
214284823|NCT04921371|OTHER|5% Hydroalcohol Mouthrinse|Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
214284824|NCT04921371|OTHER|Mouthrinse Prototype 1|Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
214284825|NCT04921371|OTHER|Mouthrinse Prototype 2|Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
214284826|NCT03091634|DRUG|xue-fu-zhu-yu capsule|participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
214284827|NCT03091634|DRUG|xue-fu-zhu-yu capsule simulated agent|participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
214284828|NCT01318304|OTHER|Vaginal lavage specimen|Collection of 3cc of saline used in the vagina to collect innate immunity markers
214284829|NCT05285813|DRUG|Vibecotamab|Given by vein (IV)
214284830|NCT05285813|DRUG|Dexamethasone|Given by vein (IV) over about 60 minutes before the dose
214284831|NCT05285813|DRUG|Acetaminophen|Given by mouth (PO) about 30-60 minutes before the dose
214284832|NCT05285813|DRUG|Diphenhydramine|Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose
214471410|NCT03787173|DEVICE|Automated|Inspiratory trigger and Expiratory trigger settings automatized
214471411|NCT06536647|DIAGNOSTIC_TEST|Contactless measurement of patient vital signs using the VitalsTM system|Contactless measurement of the patient blood pressure, heart rate, respiratory rate, body temperature and SpO2 will be carried out using the VitalsTM platform based on facial video data.
214471412|NCT03397706|COMBINATION_PRODUCT|VRx-3996 and valganciclovir|second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)
214471413|NCT06107361|DEVICE|B. Braun 6.35cm 20 gauge ultralong intravenous catheter|B Braun Medical Inc, 6.35cm 20 gauge ultralong intravenous catheter
214844621|NCT04859140|DEVICE|Resting-state galvanic skin resistance measures|Skin conductance during the resting state period
214471414|NCT06107361|DEVICE|BD 5.71 cm 20 gauge Accucath|Bard Access Systems, Inc, BD 5.71 cm 20 gauge ultralong intravenous catheter with guide wire
214844622|NCT05856058|DRUG|SHR0302|SHR0302 oral solution 1 time, SHR0302 tablets 1 time
214844623|NCT03114358|OTHER|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
214844624|NCT05522634|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
214844625|NCT01659034|DRUG|Thienopyridine for 3 months|
214844626|NCT04073134|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
214844627|NCT04073134|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
214844628|NCT00239824|BEHAVIORAL|Strength training of the pelvic floor muscles|"Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.~Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist."
214844629|NCT00239824|BEHAVIORAL|strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist|
214844630|NCT00361686|DRUG|tramadol|
214844631|NCT00361686|DRUG|remifentanyl|
214844632|NCT00361686|DEVICE|patient contolled analgesia|
214844633|NCT02111109|DEVICE|Side Stream Dark Field Microscopy|
214844634|NCT03895151|DIETARY_SUPPLEMENT|Milk supplementation|Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.
214844635|NCT03895151|OTHER|Food Based Recommendation (FBR) nutrition education|Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
214844636|NCT01845753|OTHER|Observation|Observation
214844637|NCT00090753|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
214844638|NCT00090753|DRUG|Epoetin alfa|Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
214844639|NCT00090753|DRUG|Epoetin beta|Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
214844640|NCT00090753|DRUG|Darbepoetin alfa|Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
214844641|NCT00535353|DRUG|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
214844642|NCT00535353|DRUG|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
214844643|NCT02767947|DRUG|Luliconazole Cream 1%|Luliconazole cream will be applied per schedule specified in the arm.
214844644|NCT02767947|DRUG|Vehicle Cream|Vehicle cream will be applied per schedule specified in the arm.
214844645|NCT04221594|PROCEDURE|Invasive Cardiac Catheterization (ICA)|Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.
214844646|NCT04221594|PROCEDURE|Coronary Computed Tomographic Angiogram (CCTA)|Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate \~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.
214471415|NCT04748380|OTHER|CRC decision aid pamphlet|A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise
214284833|NCT03342183|OTHER|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation).
214284834|NCT03342183|OTHER|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
214284835|NCT04578431|DIETARY_SUPPLEMENT|Artificial sweeteners (acesulfame-potassium, sucralose, saccharine, cyclamate)|The intervention is found in light products ingested by millions of people on a daily basis worldwide
214284836|NCT04696315|DIAGNOSTIC_TEST|Multiple features extraction|"In the present study, the gold standard of preclinical AD is amyloid PET. SCD with positive amyloid is the target population for early AD intervention. The investigators aim to extract the diagnostic features from multiple parameter MRI, genetic, blood and clinical data using Max-Relevance and Min-Redundancy (mRMR) algorithm. Then, based on support vector machine (SVM), random forest (RF) and multi-kernel learning (MKL) classification methods, the investigators will construct predicted diagnostic model of preclinical AD."
214284837|NCT03740945|DRUG|Placebo|Daily administration of one placebo vaginal ovule at bedtime
214284838|NCT03740945|DRUG|Prasterone (DHEA)|Daily administration of one prasterone vaginal ovule at bedtime
214284839|NCT04086862|PROCEDURE|Therapeutic ultrasound|A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm\^2 and 100% duty cycle sequentially to each masseter muscle.
214471416|NCT04748380|OTHER|Home Safety Pamphlet|The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
214471417|NCT05742399|DRUG|Hyaluronic acid NanoGel|Hyaluronic acid nanoparticles (2%)
214471418|NCT05742399|DRUG|Placebo gel|conventional gel having the same color, form and packaging
214471419|NCT06271382|OTHER|Acupressure Group|"In the research, the participant in the acupressure group will receive acupressure application 3 times a week for 2 weeks, a total of 6 times.~Depending on the preparation and pressure time on the 5 selected points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes."
214471420|NCT06271382|OTHER|Sham Acupressure Group|"Depending on the preparation and pressure time on the 5 selected sham points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.~Patients in the sham acupressure group will receive acupressure 6 times in total, 3 times a week for 2 weeks. The practitioner will do the first acupressure at the Family Health Center, and the person with type 2 diabetes will do the others at home. Ankle Brachial Index evaluation will be performed by the researcher at the Family Health Center a total of 3 times before the intervention, 1 week after the intervention and 2 weeks after the intervention."
214471421|NCT06271382|OTHER|Foot Ankle Exercise Group|Exercise will be performed regularly for 2 weeks, 3 days a week for a maximum of 30 minutes.
214471422|NCT06505512|DIAGNOSTIC_TEST|No intervention|No intervention
214471423|NCT06413654|DRUG|B001|The subjects will receive IV dose of B001 on Day 1 and Day 15 of RCP
214471424|NCT06413654|OTHER|Placebo|The subjects will receive IV dose of placebo matched to B001 on Day 1 and Day 15 of the RCP
214471425|NCT06527235|DRUG|ultrasound-guided betamethasone infiltration of the meniscal wall|The perimeniscal injections will be guided by ultrasound with an 18 megahertz (MHz) linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of lidocaine injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
214471426|NCT06527235|DRUG|ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wall|The perimeniscal injections will be guided by ultrasound with an 18 MHz linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of isotonic saline injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
214471427|NCT03976154|OTHER|Thoracic Epidural Catheter Fixation Techniques|"All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms."
214471428|NCT04098874|DRUG|Bupropion Extended Release Oral Tablet|12 weeks postpartum of blinded study medication
214471429|NCT04098874|DRUG|Placebo oral tablet|12 weeks postpartum of blinded placebo
214471430|NCT06851832|BIOLOGICAL|Recombinant zoster vaccine(CHO cell)(low adjuvant)|The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 50 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
215033339|NCT04996667|DRUG|inhaled nitric oxide (iNO)|"Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
214471431|NCT06851832|BIOLOGICAL|Recombinant Zoster Vaccine (CHO cell)|"The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle.~Vaccination Schedule 1: A total of two doses will be given, with the second dose administered 30 days after the first dose.~Vaccination Schedule 2: A total of two doses will be given, with the second dose administered 60 days after the first dose \[only applicable to the Phase II Experimental Vaccine Group B2\]."
214471432|NCT06851832|BIOLOGICAL|Zoster Vaccine, Live|"The dosage for each administration is 0.5 mL, containing not less than 4.3 lg PFU of varicella-zoster live virus, administered subcutaneously at the attachment site of the lower edge of the deltoid muscle on the outer side of the upper arm.~A total of one dose will be given. To maintain blinding, the positive control group A1 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 30. The positive control group A2 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 60."
214471433|NCT06851832|BIOLOGICAL|Recombinant Zoster Vaccine (CHO cell)|The dosage for each administration is 0.5 mL, containing 50 μg of gE and the AS01B adjuvant system \[QS-21 (50 μg), MPL (50 μg), DOPC (1 mg), and cholesterol (0.25 mg)\], administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 60 days after the first dose.
214471434|NCT06851832|BIOLOGICAL|Recombinant Zoster Vaccine (CHO cell) (Adjuvant control)|The dosage for each administration is 0.5 mL, containing 0.25 mL of MF59 and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
214471435|NCT06851832|BIOLOGICAL|Normal Saline|"The dosage for each administration is 0.5 mL, containing 0.5 mL of NaCl solution, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose (applicable to Phase I clinical trial).~To maintain blinding, subjects in the positive control A1 and positive control A2 groups will receive a placebo on Day 0 (applicable to Phase II clinical trial)."
214471436|NCT06388434|BEHAVIORAL|Protective Arm Balance Response Training|Participants will be trained in the reach to grasp arm balance response while being exposed to unpredictable balance perturbations
214844647|NCT04221594|PROCEDURE|Dynamic Cardiac Positron Emission Tomography (dPET)|Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
214844648|NCT00776568|PROCEDURE|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
214844649|NCT00776568|DRUG|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
214844650|NCT01256060|DRUG|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
214844651|NCT05577494|OTHER|Questionnaire online|"Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual."
214844652|NCT00579631|BEHAVIORAL|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
214844653|NCT00786630|BEHAVIORAL|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
214844654|NCT00786630|BEHAVIORAL|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
214844655|NCT01889550|BEHAVIORAL|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
214844656|NCT01889550|BEHAVIORAL|Access to the website www.ouh.dk|Access to the usual information from the hospital website
214844657|NCT01401335|BEHAVIORAL|Questionnaires|questionnaires at entry, month 4, 8 and 12
214844658|NCT03394716|RADIATION|Radiotherapy|standard radiotherapy treatment with 1-3 extra MRIs
214844659|NCT01466036|DRUG|Cabozantinib|60 mg QD orally in cycles of 28 days
215033340|NCT05153772|DRUG|AlphaMedix|212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
215033341|NCT06627049|OTHER|Focus group|Focus group to evaluate the facilitators and barriers to the use of virtual reality.
214471437|NCT06346067|DRUG|Naporafenib|Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor
214471438|NCT06346067|DRUG|Dacarbazine|Dacarbazine IV - Day 1
214471439|NCT06346067|DRUG|Temozolomide|Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle
214471440|NCT06346067|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
214284840|NCT04242303|PROCEDURE|Total knee replacement|"Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts."
214471441|NCT05089877|DEVICE|Surgical Ablation|The AtriCure cryoICE® cryoFORMTM cryoablation probe is used in the cryosurgical treatment of cardiac arrhythmias by freezing target tissues, creating an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway.
214284841|NCT03659812|OTHER|MACS technique|MACS is a technique that allow us to tag and detect apoptotic spermatozoa. These apoptotic spermatozoa have phosphatidylserine in their membranes, so we add magnetic beads with Annexin V, which binds specifically to phosphatidylserine. The spermatozoa are then tagged and can be retained in a magnetic field, allowing us to collect just the non-apoptotic spermatozoa.
214284842|NCT00729651|DRUG|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
214284843|NCT00729651|DRUG|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
214284844|NCT00729651|DIETARY_SUPPLEMENT|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
214284845|NCT01119391|BEHAVIORAL|There was no intervention; this was a survey only study|There was no intervention; this was a survey only study
214284846|NCT02275871|OTHER|MRI|High risk screening MRI will be performed as part of the patient's routine care.
214471442|NCT04359654|DRUG|Dornase Alfa Inhalation Solution [Pulmozyme]|Nebulised Dornase alfa 2.5mg bd for 7 days
214471443|NCT05591547|RADIATION|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
214471444|NCT06845748|OTHER|Physical activity Group|"This intervention consists of a 48-week structured physical activity program designed to counteract age-related muscle decline. Participants assigned to this group will engage in a home-based exercise program, including muscle-strengthening exercises (bodyweight exercises targeting major muscle groups; progressive difficulty based on individual capacity; designed for feasibility in daily life, requiring no specialized equipment) and aerobic exercise (moderate-intensity cardiovascular activity (e.g., brisk walking, cycling); target heart rate between 65-75% of the estimated maximum heart rate).~The program follows guidelines from the American College of Sports Medicine (ACSM) and aims to improve muscle strength, function, and quality of life. It is distinct from other studies as it specifically targets preventing sarcopenia and muscle loss through a practical, home-based, and scalable intervention.~Participants will be monitored through periodic assessments."
214471445|NCT05912608|PROCEDURE|Conservative TAAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
214844660|NCT05704673|DRUG|nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study.|investigate the effect of Iv nalbuphine on postoperative nausea and vomiting and pain with intrathecal morphine on inguinal hernia repair surgery.
214284847|NCT02275871|OTHER|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
214284848|NCT02399826|DEVICE|Offloading|"Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement"
214284849|NCT02399826|PROCEDURE|Dressing Application|Application of a non adherent dressing, and a multi-layer compression dressing
214284850|NCT02018588|DIETARY_SUPPLEMENT|tryptophan|graded levels of tryptophan will be given to each subject
214284851|NCT06843564|OTHER|Remote Enhanced Assessment for Care at Home (REACH) Kit|"Families of 6 month old infants will receive tele-device kits that include thermometers, pulse oximeters, and tele-otoscopes and respiratory swab tests, which families will then have the option to use when they schedule telemedicine visits with their usual primary care practice.~Note that the investigators are not studying the devices themselves; the investigators are instead studying health care use and experiences when these devices are made available."
214284852|NCT06430528|DRUG|Osilodrostat|Add methylprednisolone to osilodrostat therapy after first dose and continue during osilodrostat titration.
214284853|NCT06072313|OTHER|Monopolar electrical diathermy plus therapeutic exercise|The Experimental Group will undergo two sessions per week of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device and one session of therapeutic neck exercise per week.
214284854|NCT06072313|OTHER|Therapeutic Exercise|The exercise program will consist of standing, seated and supine postures, starting with simple postures and moving on to more complex ones. Participants will be asked to focus on their posture, joint positions and muscle tension in each exercise posture.
214284855|NCT02250781|DRUG|Oral ONC201|Given PO
214284856|NCT00545662|DRUG|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
214844661|NCT01397266|PROCEDURE|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
214844662|NCT01397266|PROCEDURE|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
214284857|NCT00545662|DRUG|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
214284858|NCT01734356|OTHER|Skin biopsies|
214284859|NCT05751902|OTHER|Arabic version of OHIP questionnaire|Translated Arabic version of Oral Health Impact Profile questionnaire
214284860|NCT05050604|DRUG|Choline Alfoscerate 400mg|Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
214284861|NCT05050604|DRUG|Placebo of Choline Alfoscerate 400mg|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
214284862|NCT03556774|BEHAVIORAL|'WeChat WeQuit' smoking cessation training program|Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
214284863|NCT06153329|DRUG|THDB0206 injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
214284864|NCT06153329|DRUG|Humalog®|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
214284865|NCT06153329|DRUG|BC222insulin lispro injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
214284866|NCT05011565|OTHER|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function
214284867|NCT01862900|BIOLOGICAL|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
214284868|NCT05680896|BIOLOGICAL|inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV|the protection of COVID-19 vaccines on breakthrough infection
214284869|NCT01218711|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
214471446|NCT05912608|PROCEDURE|Extensive TAAAD-R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total hemiarch) or reimplantation of the innominate trunk only (partial hemiarch).
214471447|NCT06128915|OTHER|vaccine|Vaccination against 20 serotypes of S. pneumoniae
214471448|NCT05561439|OTHER|Dosimetric monitoring|Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
214471449|NCT06852937|DEVICE|da Vinci SP Surgery System|da Vinci SP Surgery System
214284870|NCT00592943|DRUG|armodafinil|tablet, taken by mouth, once each study day
214284871|NCT05004870|DEVICE|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
214284872|NCT02984709|BEHAVIORAL|Positive Psychology Intervention|Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period) Small gift ($5 gift card code sent every 2 weeks for 8 weeks)
214284873|NCT02984709|BEHAVIORAL|Education|Health Behavior Contract - Baseline visit Education Packet - Baseline visit
214284874|NCT02575937|BEHAVIORAL|low glycemic diet|nutrition education-based low glycemic diet intervention
214284875|NCT05329610|DIETARY_SUPPLEMENT|Beta-alanine|Slow-release beta-alanine.
214284876|NCT05329610|DIETARY_SUPPLEMENT|Placebo|Taste and appearance-matched placebo (tapioca starch).
214284877|NCT06461364|PROCEDURE|Assessment of cuspal deflection of bulk-fill restorations|To assess the performance of bulk-fill restorations on premolar teeth in class II cavities using some selected FDI criteria, a total sample size of 30 (10 for each group test) will be sufficient to detect: an effect size of 1.22 at a power (1-β error) of 0.8 and using a two-sided hypothesis test and a significance level (α error) 0.05 for data. Two teeth will be added to each group to compensate drop out samples.
214284878|NCT02560532|DRUG|Clazosentan|Concentrated solution for intravenous injection
214471450|NCT06851897|OTHER|perforated 3D printed metal fixed retainer|The key of modification is digitally designing fixed metal retainer which will be custom made for each patient, and 3D metal printing of the fixed retention wire using Metal printer instead of using generic metal wire for all patients.
214471451|NCT06851897|OTHER|conventional fixed retainer|Conventional fixed metal retainer will be used. Multi strand wire will be used
214284879|NCT02067871|OTHER|Laser Therapy|Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.
214284880|NCT02067871|OTHER|Electrical Stimulation|Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
214284881|NCT00035516|DRUG|Epothilone|
214284882|NCT02893943|DIETARY_SUPPLEMENT|Probiotics|
214284883|NCT02893943|DIETARY_SUPPLEMENT|Placebo|
214284884|NCT00496821|DRUG|ALN-RSV01|
214284885|NCT04938804|DEVICE|Low-dose computed tomography|The Low-dose computed tomography is conducted according to the guideline suggested by American College of Radiology.
214284886|NCT04039698|OTHER|Telemedicine|Telemedicine monitoring and teleconsultation by video calls
214471452|NCT06096623|BEHAVIORAL|Weekly Survey|Subjects will respond to Electronic patient-reported outcome (ePRO) every week for 8 weeks.
214471453|NCT04821141|DRUG|Bazedoxifene and Conjugated Estrogens|BZA (20 mg) plus CE (0.45 mg) taken together once daily
214471454|NCT05870046|PROCEDURE|Power training in women older than 65 years with pre-sarcopenia|resistance training based on muscle power training, perform the exercises at high speed.
214471455|NCT05870046|PROCEDURE|Multimodal and nonspecific exercises in women older than 65 years with pre-sarcopenia|different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
214471456|NCT04267120|DRUG|Lenvatinib|Lenvatinib will be provided by Merck.
214471457|NCT04267120|DRUG|Pembrolizumab|Merck will provide pembrolizumab
214471458|NCT04267120|PROCEDURE|Research blood collection|-Within 2 weeks prior to first dose of study drug, cycle 4 day 1, and at the off-treatment assessment
214284887|NCT04039698|DRUG|Velpatasvir/Sofosbuvir|Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
214471459|NCT01805609|BEHAVIORAL|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture \& discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff \& that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
214471460|NCT01805609|BEHAVIORAL|questionnaires|
214471461|NCT05309616|DRUG|Taltz|Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
214471462|NCT06156072|DIAGNOSTIC_TEST|Ultrasound-guided venipuncture|Venipuncture will be performed using ultrasound to identify the most appropriate vessel and guide the puncture
214471463|NCT04524416|DEVICE|Minimally invasive glaucoma surgery (MIGS)|MINIject implant placed into supraciliary space. The implantation was done in a previous study in which patient participated and is not part of this study.
214471464|NCT05112809|DEVICE|Cochlear Stimulation System (CSS)|Cochlear stimulation with surround sound and noise cancellation
214471465|NCT03935971|DRUG|Dupilumab|See arm/group description
214471466|NCT05863156|DIAGNOSTIC_TEST|Right side lying position|In the study, 60 participants were placed in the right side lying position (intervention 1)
214471467|NCT05863156|DIAGNOSTIC_TEST|Semi Fowler|In the study, 60 participants in the semi-sitting position (intervention 2)
214284888|NCT05388331|OTHER|No intervention|No intervention
214471468|NCT05863156|DIAGNOSTIC_TEST|left side lying position|In the study, 120 participants in the left side lying position (control group).
214471469|NCT03433742|OTHER|Blood levels drawn|The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
214471470|NCT05197465|OTHER|Questionnaires|Participants will complete pain and quality of life questionnaires. Opioid consumption will also be assessed using validated questionnaires.
214844663|NCT04491695|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 71.5 hours.
214844664|NCT04491695|DRUG|Oral antiplatelet|Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.
214844665|NCT05622994|DRUG|Rimonabant|Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
214844666|NCT05014880|BEHAVIORAL|ICR (Intensive Cardiac Rehabilitation)|Participants in this arm will not have to adopt a 10-hour eating window while taking part in UCSD's 9-week ICR program.
215033342|NCT06627049|OTHER|Implementing facilitating strategies|Implement strategies to facilitate the integration of virtual reality into rehabilitation sessions.
214284889|NCT00365729|BEHAVIORAL|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
214284890|NCT01018966|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
214284891|NCT00810238|BIOLOGICAL|C-Cure|Intraventricular injection
214284892|NCT00680706|DRUG|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
214284893|NCT00680706|DRUG|Placebo|D5W (50 ml)
214284894|NCT05079282|DRUG|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed
214284895|NCT06042452|GENETIC|Genetic|A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing their recommendations. The Global Screening Array (GSA) will be used.
214284896|NCT00080470|DEVICE|bion|battery powered microstimulator
214284897|NCT01950741|DRUG|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
214284898|NCT05037071|DEVICE|Upper body graduated compression sleeve|An over the counter light compression sleeve will be worn during game training
214284899|NCT06266169|OTHER|making artificial intelligence based decisions of gamete, embryo and endometrial potential|The method of Raman spectroscopy is based on the registration of inelastic scattering of photons. Each compound has its own spectral pattern when using a certain type of monochromatic radiation (laser). With this method, it is possible to obtain metabolic fingerprints from the objects being studied. Luminescent spectroscopy is a type of spectroscopy used to register emission from objects that occurred after absorbing the exciting (primary) radiation. Spectrophotometry is the detection of radiation in the visible area of the spectrum. Raman spectroscopy is used for the spent medium and semen to build artificial intelligence model and make prognosis of function for each object. For endometrium, luminescent spectroscopy and spectrophotometry are used to build the model and test its clinical relevance
214284900|NCT02521870|DRUG|SD-101(1)|SD-101 administered intratumorally at escalating doses (up to 11 doses).
214284901|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
214284902|NCT02521870|DRUG|SD-101(2)|Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
214284903|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
214471471|NCT04466865|OTHER|Best Case/Worst Case communication tool training|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of kidney disease. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning the intervention is designed to lead to a discussion of participants preferences and consideration of outcomes.~The nephrologist verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The nephrologist also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
214284904|NCT02521870|BIOLOGICAL|SD-101(3)|Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
214471472|NCT03505723|DRUG|Tranexamic Acid|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
214471473|NCT03505723|DRUG|Placebo (Saline)|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
214471474|NCT03505723|OTHER|Perioperative hypotension-avoidance strategy|"Perioperative hypotension-avoidance strategy includes:~1. Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~2. Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~3. Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery."
214471475|NCT03505723|OTHER|Perioperative hypertension-avoidance strategy|Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
214471476|NCT03170206|DRUG|Binimetinib|Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
214471477|NCT03170206|DRUG|Palbociclib|It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
214471478|NCT05831072|BEHAVIORAL|Mindfulness-cognitive oriented group program|Mindfulness-cognitive oriented group program is a 4-week program based on the theory of mindfulness-based cognitive therapy (MBCT). The main elements of MBCT such as mindfulness breathing, raisin meditation for mindful eating, body scan and mindfulness walking are included. In addition to the weekly intervention, participants are also required to do the mindfulness practice at home.
214471479|NCT04680715|RADIATION|Per-Operative Radiotherapy technique by Papillon +TM|20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
214471480|NCT01725763|OTHER|Cardiac MRI|
214471481|NCT05888025|BEHAVIORAL|Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)|MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
214471482|NCT06074120|DEVICE|Low-level laser therapy|Low-level laser therapy would be introduced via a vaginal probe (gain medium: Gallium-Aluminum-Arsenide, wavelength 660nm) for 30 minutes per treatment, once a week, for 8 courses.
214471483|NCT06143215|BEHAVIORAL|4 weeks revision|In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 4-8-12 weeks revision times could change diabetic foot reulceration rate.
214471484|NCT02905422|BEHAVIORAL|H.E.A.L.T.H. II Intervention|12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
214471485|NCT01130025|DRUG|Warfarin|Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.
214471486|NCT01130025|DRUG|Innohep®|Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
214471487|NCT04622683|PROCEDURE|Ultrasound|To determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels. To also determine whether porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
214471488|NCT04136132|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
214471489|NCT04898075|BEHAVIORAL|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
215033343|NCT06627049|OTHER|Focus group|Evaluate the strategies used to facilitate VR implementation.
214284905|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
214284906|NCT04051073|DEVICE|Continuous non-invasive blood pressure monitoring|Continuous non-invasive blood pressure monitoring using CNAP
214284907|NCT02877381|PROCEDURE|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
214284908|NCT02877381|PROCEDURE|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
214284909|NCT04336085|PROCEDURE|caudal block|Caudal block will be performed using ultrasound guidance, the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the two cornua. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
214284910|NCT04336085|PROCEDURE|pericapsular nerve group block|In PENG group, the patient will be placed in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
214284911|NCT00920998|DRUG|Z-338|oral
214284912|NCT04400591|BIOLOGICAL|Nonconforming Lisocabtagene Maraleucel|Nonconforming lisocabtagene maraleucel is lisocabtagene maraleucel that does not meet the commercial release specifications, however is deemed acceptable to administer as an investigational product in the Expanded Access Protocol setting.
214284913|NCT00739791|BEHAVIORAL|exercise intervention|
214284914|NCT00739791|GENETIC|gene expression analysis|
214284915|NCT00739791|GENETIC|polymerase chain reaction|
214471490|NCT04898075|OTHER|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
214471491|NCT05216406|DIETARY_SUPPLEMENT|5-HTP|CLEANMOOD is an organic 5-Hydroxytryptophan (5-HTP) ingredient.
214471492|NCT05216406|OTHER|Placebo|Maltodextrin capsule
214471493|NCT02578550|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
214471494|NCT02578550|DRUG|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
214471495|NCT02578550|DRUG|Darunavir|A single tablet containing darunavir 800 mg will be administered.
214471496|NCT02578550|DRUG|Cobicistat|A single table containing cobistat 150 mg will be administered.
214471497|NCT03617445|DRUG|FMT oral capsule|FMT oral capsules, single dose of 5 capsules
214471498|NCT03617445|DRUG|Oral Vancomycin|Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
214471499|NCT03617445|DRUG|FMT oral placebo|Placebo oral capsules, single dose of 5 capsules
214471500|NCT03617445|DRUG|Oral Vancomycin placebo|Placebo oral vancomycin capsules every 6 hours for 14 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
214471501|NCT05485584|DRUG|rSIFN-co Nasal Spray|8 million IU (16 μg)/day; Once daily
214284916|NCT00739791|GENETIC|proteomic profiling|
214471502|NCT05485584|DRUG|rSIFN-co Nasal Spray|16 million IU (32 μg)/day; Twice daily
214284917|NCT00739791|GENETIC|reverse transcriptase-polymerase chain reaction|
214284918|NCT00739791|OTHER|laboratory biomarker analysis|
214284919|NCT00739791|OTHER|medical chart review|
214471503|NCT05485584|DRUG|Placebo Nasal Spray|Once daily
214844667|NCT05014880|BEHAVIORAL|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|Participants in this arm will adhere to a daily, consistent 10-hour eating window while undergoing UCSD's 9-week ICR program to see if there is an improvement on cardiometabolic parameters.
214844668|NCT03002480|OTHER|Thromboelastography-Guided Treatment Regimen|"The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate."
214284920|NCT00739791|OTHER|questionnaire administration|
214284921|NCT00739791|PROCEDURE|psychosocial assessment and care|
214284922|NCT00739791|PROCEDURE|quality-of-life assessment|
214284923|NCT00739791|PROCEDURE|support group therapy|
214284924|NCT00739791|PROCEDURE|therapeutic dietary intervention|
214471504|NCT05485584|DRUG|Placebo Nasal Spray|Twice daily
214471505|NCT04266431|BEHAVIORAL|EMPOWER|Behavioral weight loss intervention
214471506|NCT04690582|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
214471507|NCT04690582|BEHAVIORAL|Crisis Response Plan (CRP)|The crisis response plan (CRP) is a collaborative, patient-centered intervention that is typically handwritten on an index cards and focuses on several key components: (1) warning signs, (2) self-regulatory strategies, (3) reasons for living, (4) sources of social support, and (5) professional and crisis services.
214471508|NCT04690582|BEHAVIORAL|Safety Planning Intervention (SPI)|The safety planning intervention (SPI) is a suicide-focused intervention typically handwritten on a pre-printed form that includes the following sections: (1) warning signs, (2) internal coping strategies, (3) people and social settings that provide distraction, (4) people who can offer help, (5) professionals or agencies they can contact during a crisis, and (6) making the environment safe.
215033344|NCT06627049|OTHER|Interviews|Interviews to evaluate the facilitators and barriers to the use of virtual reality.
215033345|NCT06627049|OTHER|Interviews|Evaluate the strategies used to facilitate VR implementation.
214284925|NCT00519831|BIOLOGICAL|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
214284926|NCT00519831|DRUG|vinflunine|Vinflunine 320 mg/m² every 21 days
214284927|NCT02150317|PROCEDURE|TACE+Sorafenib|TACE followed by Sorafenib
214284928|NCT02150317|PROCEDURE|TACE|TACE alone
214284929|NCT05081973|OTHER|A model for predicting extubation success based on extubation readiness estimator and lung ultrasonography score|"Parameters to be recorded before and after extubation to create a new dual extubation model from all babies who met the extubation criteria included in the study:~1. Lung ultrasound score: Lung ultrasound will be performed prior to the extubation and after the extubation. Lung aeration will be scored based on three chest areas for each side (upper anterior, lower anterior and lateral) and a score of 0 to 3 points will be given for each area (Total score ranges from 0 to 18 points).~2. Probability of Successful Extubation: It will be calculated by extubation readiness estimator provided by the website named http://extubation.net/.~This parameter will be calculated only 1 hour prior to the scheduled extubation time."
214284930|NCT02854631|DRUG|Selonsertib|18 mg tablet administered orally once daily
214284931|NCT02854631|DRUG|Prednisolone|40 mg (4 x 10 mg tablets) administered orally once daily
214471509|NCT04690582|BEHAVIORAL|Narrative Assessment|"The narrative assessment is a patient-centered assessment approach in which the clinician invites the patient to share the story of a recent crisis or period of intense emotional distress. Patients are asked to identify the thoughts, emotions, and physical sensations experienced in the time leading up to this crisis, as well as the contextual and environmental characteristics surrounding the crisis. Information obtained from the narrative assessment is then used to help formulate a crisis response plan."
214471510|NCT06051760|BIOLOGICAL|NV-001|NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.
214471511|NCT04869631|OTHER|The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.|We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.
214471512|NCT03711474|DRUG|Dexamethasone|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
214471513|NCT03711474|DRUG|Saline|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
214471514|NCT05487404|DRUG|ADX-629|3 oral doses of ADX-629 600 milligrams
214471515|NCT05487404|DRUG|Placebo|3 oral doses of placebo
214284932|NCT02854631|DRUG|Placebo|Selonsertib placebo tablet administered orally once daily
214284933|NCT01740947|DRUG|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
214284934|NCT04232995|OTHER|Balance Training|Balance enhancing exercises
214471516|NCT06813846|PROCEDURE|Mid-Crestal Sulcular Incision|A long incision over the crest and midway between buccolingual aspect through the gingiva from the site of the distal implant in mesial direction with intra-sulcular incisions in the teeth adjected to the implant site · Following a full or partial thickness flap is raised to establish access to cover screw.
214471517|NCT06813846|PROCEDURE|Split-Finger Procedure|"The surgical technique first designs 3 interlacing fingers over and adjacent to each implant site and will be extended around each adjacent tooth. · A sulcular incision will be made 2 to 3 mm to the palatal side from each tooth with a loop design (at least 2.0-2.5 mm) adjacent to the implant location. · The incisions will then be joined facially with a semicircular incision at the preplanned free tissue margin of the implant crown. · The facial fingers will be elevated to the desired interimplant height for the papillae. The middle palatal finger will then be split and reflected to the respective mesial and distal sides (each is at least 2.0-2.5 mm wide). · The soft tissue maintains its elevated position with a permucosal extension or a final prosthetic abutment that is extended through the soft tissue. · A modified vertical mattress suture will then be used to suture each papilla using 4-0 or 5-0 Gut or Vicryl sutures."
214471518|NCT06813846|PROCEDURE|"I shaped incision"|A Labial horizontal incision with a #15c blade will be performed mesiodistally 0.5-1.0 mm inside from the labial border of the implant. A horizontal incision will also be performed, parallel to the buccal side, on the palatal side, which is in contact with the palatal border line of the implant different from the labial side. Another incision will be done bucco-lingually over the implant midline perpendicular to the horizontal incision lines performed on the labial and palatal sides. The flap will be reflected with care and the implant will be exposed to remove the cover screw. The healing abutment will be connected and both flaps will be folded up alongside the healing abutment intending them to heal without suture.
214284935|NCT04232995|OTHER|General Exercises|General Exercises
214284936|NCT01022229|DIETARY_SUPPLEMENT|Compound Natural Health Product|"* 15-35 mg zinc citrate~* 150-350 mg magnesium lactate~* 30-70 mg pyridoxine hydrochloride~* 150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
214284937|NCT01022229|DIETARY_SUPPLEMENT|Placebo|Placebo
214284938|NCT03748888|BEHAVIORAL|Exercise group|"An antenatal physical activity (APA) programme will be designed for participants in the exercise group.~The APA will last for 20-24 weeks. Participants in the EG must enrol in the APA between their 12-16 weeks of gestation.~The APA programme has a frequency of three times a week, which involves aerobic, strength and stretching exercises. The intensity of the APA programme is individually calculated for each participant based on their pre-pregnancy fitness level. Single sessions of the APA programme last 50-60min."
214284939|NCT03390816|OTHER|Nutritional assessment|Observational
214284940|NCT04653961|DEVICE|DreaMed Advisor Pro DSS-MDI algorithm|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
214284941|NCT04662125|DRUG|caffeine, paracetamol tablet|oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
214471519|NCT04889716|DRUG|mosunetuzumab|1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.
214471520|NCT04889716|DRUG|glofitamab|2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12
214471521|NCT04889716|DRUG|obinutuzumab|1000 mg IV on Cycle 1 Day 1.
214471522|NCT05507814|BEHAVIORAL|Episodic Future Thinking (EFT)|Participants will generate descriptions of vivid positive future events.
214471523|NCT05507814|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive future events.
214284942|NCT04662125|DRUG|Oral prednisolone|patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
214284943|NCT04662125|DRUG|oral pregabalin|patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
214471524|NCT06016062|DRUG|RC148 Monotherapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
214471525|NCT06016062|DRUG|RC148+docetaxel Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
214471526|NCT06016062|DRUG|RC148+RC48 Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle； RC48 will be administered as an IV infusion on Day 1 of each 2-week cycle.
214471527|NCT06016062|DRUG|RC148+RC88 Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle.
214284944|NCT03544658|PROCEDURE|Dental prophylaxis|Professional dental prophylaxis including dental scaling and dental polishing with prophylactic paste
214471528|NCT06016062|DRUG|RC148/Bevacizumab+RC88 Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle; Bevacizumab will be administered as an IV infusion on Day 1 of each 3-week cycle
214471529|NCT04823923|OTHER|blood sampling for ITK dosage|Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)
214471530|NCT03845790|OTHER|Blood and microdialysis samples|Blood and microdialisys pharmacocinetic samples on one of the two antibiotics prescribed in routine use
214471531|NCT06823089|DEVICE|ReNew Hip Implant|Surgical Intervention
214471532|NCT05834712|DEVICE|mobile platform or not mobile platform|Intervention using WeChat
214471533|NCT04220684|DRUG|Cytarabine Hydrochloride|Given IV
214471534|NCT04220684|DRUG|Fludarabine|Given IV
214471535|NCT04220684|BIOLOGICAL|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given via infusion
214471536|NCT06529393|PROCEDURE|SHAC block|with the patient in a beach-chair position and with the arm in extension, the subscapularis muscle is stretched posteriorly and becomes easily visible. With external rotation and abduction, the coracobrachialis and the biceps brachii muscles are displaced, allowing the visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia.Once the injection into the fascial space is achieved, the investigators can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle. By injecting the pericapsular space, the investigators reach the terminal articular branches indistinctly from their origin. Furthermore, through the Weitbrecht foramen, a natural capsular foramen between the upper and middle glenohumeral ligaments, the investigators also reach the intra-articular space .
214471537|NCT06529393|PROCEDURE|suprascapular nerve block|Patients will be placed in lateral position by using A high - frequency linear ultrasound probe will be placed approximately 2 cm medial to the medial border of the acromion and about 2 cm cranial to the superior margin of the scapular spine until supraspinatus or infraspinatus muscle contractions were elicited. Following negative aspiration,A 21G 10-cm needle will be inserted using an in-plane approach .The tip of the needle will be placed at the floor of the supraspinatus fossa where the nerve has passed .A volume of 15 mL of a mixture of 2% lidocaine (5 mL) and 0.5% levobupivacaine (10 mL) was injected.
214284945|NCT03544658|PROCEDURE|Tooth color assessment by the participant|Tooth color assessment using the VITA Classical shade guide. Assessment will be done with normal light conditions and with a light correcting device
214284946|NCT03544658|PROCEDURE|Tooth color assessment by the investigator|Tooth color assessment using the VITA Classical shade guide and the VITA Toothguide 3D Master. Assessment will be done with normal light conditions and with a light correcting device
214471538|NCT03836066|DRUG|Atezolizumab-Bevacizumab|Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
214471539|NCT06446193|DEVICE|NDTx-01|NDTx-01 intervention: Run 'NDTx-01' application on a smartphone 5 times a week, for 6 weeks, 30 sessions in total.
214471540|NCT06446193|BEHAVIORAL|TAU|TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education
214471541|NCT06822309|PROCEDURE|External Oblique Intercostal Plane Block|The block is performed before skin incision by a specialized anesthetist. With the patient positioned in the supine position with their ipsilateral arm abducted, the skin was sterilized, using the high frequency linear probe (M-Turbo HF 38 transducer 13- 6 MHz) of Fujifilm Sonosite ultrasound is placed over the sixth rib medial to the anterior axillary line approximately in midclavicular line in a parasagittal orientation. A 20-guage needle is inserted in a cephalocaudal direction, and the external oblique intercostal plane was hydro dissected with saline. After hydro dissection, the needle is advanced 1 to 2 cm, and 20 mL of 0.25% bupivacaine (Sunny Pharmaceutical) with 4 mg dexamethasone as an additive was administered. The same procedure will be done at the other side (bilateral external oblique intercostal plane block).
214284947|NCT03544658|PROCEDURE|Tooth color assessment with SpectroShade|Tooth color assessment using SpectroShade (dental spectrophotometer). Color will be registered in VITA Classical and VITA Toothguide 3D Master and CIELab parameters
214284948|NCT00268593|DRUG|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
214284949|NCT00268593|DRUG|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
214284950|NCT00268593|DRUG|prednisone|5 mg twice a day orally
214284951|NCT04945005|PROCEDURE|Transesophageal guidance of lead implantation|In patients undergoing lead implantation including transesophageal echocardiography for clinical reasons (e.g. intraprocedural cardioversion), echocardiography was also used for guidance of lead implantation to reduce lead-leaflet interactions
214284952|NCT02473432|PROCEDURE|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
214284953|NCT02473432|PROCEDURE|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
214284954|NCT02473432|PROCEDURE|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
214284955|NCT03854305|DRUG|PRV-6527|Treatment
214284956|NCT03854305|DRUG|Placebo|Comparator
214284957|NCT00388778|DRUG|Doxycycline|
214471542|NCT06822309|DEVICE|Patient controlled analgesia|Patients in group will receive intravenous patient controlled analgesia device 100 ml (Accuafuser 100 mL, basal rate 4 mL/hr., bolus 0.5 mL/time, and lock time 15 minutes) for postoperative pain management that will contain 30 mg morphine (loading dose0.1mg/kg) will be given by infusion over 10 minutes then accuafuser will be connected),8 mg dexamethasone and 8 mg ondansetron diluted in 100 ml saline.
214471543|NCT05270005|DIAGNOSTIC_TEST|Ultrasound-based flow imaging|Ultrasound-based flow imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
214471544|NCT05270005|DIAGNOSTIC_TEST|Ultrasound-based strain imaging|Ultrasound-based strain imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
214471545|NCT05270005|DIAGNOSTIC_TEST|Conventional duplex|Conventional duplex measurements of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
214471546|NCT05156320|DRUG|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 was administered every 4 weeks by intravenous (IV) infusion.
214471547|NCT05156320|DRUG|Placebo|Placebo was administered every 4 weeks by intravenous (IV) infusion.
214471548|NCT03382938|DRUG|Dexmedetomidine|WOUND INFILTRATION IN CESAREAN SECTION
214471549|NCT03382938|DRUG|Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
214471550|NCT03382938|DRUG|Dexmedetomidine - Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
214471551|NCT03382938|OTHER|0,9% saline|placebo WOUND INFILTRATION IN CESAREAN SECTION
214471552|NCT03004547|OTHER|Measuring sodium content|Sodium MRI measurement of sodium content in the tissues of all participants
214471553|NCT06823505|OTHER|structured questionnaire|Using the Depression Scale (CES-D), Cancer Self-Efficacy Scale (CASE), Family Peer Relationship Questionnaire (FPRQ), Family Resilience Scale (FRAS) and Parent-Child Relationship Quality Scale
214471554|NCT06823453|BEHAVIORAL|Peer Harm Reduction Support Champion Intervention|This intervention will recruit non-substance-using friends and family members of people who use opioids and live on the West side of Chicago, educate them on harm reduction (HR) tools and services, and train them to become peer HR support champions. They will be asked to recruit one friend or family member who uses opioids to the study, who will also be provided with an educational training on overdose risk reduction and available HR tools and services. The intervention will then facilitate a counselor-led initial conversation between peer HR support champions and their friend or family member who uses opioids, to help establish HR-related support, and will provide all participants with naloxone and fentanyl test strip kits. This intervention will not only provide another mechanism through which people who use opioids can access HR tools and services, thereby reducing logistical barriers to access and preventing overdose, but it should also reduce stigma and increase social support.
214471555|NCT00179465|DRUG|Tiagabine|Up to 36 mg daily
214471556|NCT00179465|DRUG|Placebo|Placebo
214471557|NCT06086951|BEHAVIORAL|Pai.ACT Group|The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors. The app also offers 4-6 video-based individual ACT sessions with a dedicated counseling team and a referral system for intensive psychological support, all underpinned by empirical evidence from a previous ACT trial in Hong Kong.
214471558|NCT06086951|OTHER|Control Group|Both the Pai.ACT group and the control group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
214471559|NCT06760455|DRUG|BPR-30221616 Injection|BPR-30221616 will be administered by subcutaneous (SC) injection
214284958|NCT05551039|OTHER|Retrospective patient chart review|Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).
214284959|NCT04974385|DRUG|Liposomal bupivacaine|Validate the analgesic efficacy of admixed LB + bupivacaine compared with plain bupivacaine when injected for ISNB for total shoulder arthroplasty.
214284960|NCT04974385|DRUG|Bupivacaine|Active comparator as standard of care.
214284961|NCT00257101|BEHAVIORAL|self-medication monitoring|
214284962|NCT02426437|OTHER|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
214284963|NCT02426437|OTHER|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
214284964|NCT01064713|DRUG|Tesetaxel|"Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days."
214284965|NCT04557878|DRUG|Hypertonic Dextrose Solution|Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
214284966|NCT04557878|BIOLOGICAL|Liquid Phase Concentrated Growth Factor (LPCGFs)|Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
214284967|NCT02300532|OTHER|No intervention|
214284968|NCT01952275|PROCEDURE|Collection of biological samples|
214471560|NCT06760455|DRUG|Sodium Chloride Injection|Sodium Chloride Injection will be administered by SC injection
214471561|NCT05911308|DRUG|Durvalumab|1,500 mg Durvalumab IV infusion will be given on day 1 of each cycle for 3 cycles.
214471562|NCT05911308|DRUG|Carboplatin|Carboplatin IV infusion will be given on day 1 of each cycle for 3 cycles. The dose will be AUC 5.
214471563|NCT05911308|DRUG|Abequolixron|100 or 120 mg Abequolixron will be administered by mouth twice a day for 5 days followed by 2 days off throughout your treatment (5 days a week for up to 9 weeks).
214284969|NCT02837198|DRUG|FYU-981|
214471564|NCT05911308|DRUG|Abraxane|100 mg/m2 Abraxane will be given by IV infusion on days 1, 8, and 15 of each cycle for 3 cycles.
214471565|NCT05911308|DRUG|Pemetrexed|500 mg/m2 pemetrexed will be given by IV infusion on day 1 of each cycle for 3 cycles.
214284970|NCT02837198|DRUG|Topiroxostat|
214284971|NCT04372030|OTHER|Online questionnaire|this is an online questionnaire collecting retrospective data on health care use and non-use
214471566|NCT05738005|OTHER|Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)|Amyloidosis patients will use MyFitnessPal application to track dietary intake and use of herbal/alternative supplements in from week 2-9. Patient's usage of the application and questionnaires completed by the patient at the start, Week 2 and Week 10 will determine feasibility.
214471567|NCT05615389|DRUG|Medicinal Cannabis - C12T12|"Participants randomised to receive C12T12 Ruby Balanced Oil will commence with 0.008ml/kg/day (0.1 mg/kg/day THC) in two divided doses, and titrate up in four steps (increase by 0.008ml/kg/day every four days) over 16 days up to a maintenance dose of 0.04ml/kg/day (0.5mg/kg/day THC) in two divided doses, with a ceiling dose of 2ml/day (25mg/day THC) for participants weighing 50kg or more. The maintenance dose will then be continued from day 17 until day 42.~Down-titration will occur for 16 days after the end of study visit, in the reverse of the up-titration period."
214471568|NCT05615389|DRUG|Medicinal Cannabis - C20T5|Participants randomised to the C20T5 Ruby CBD Oil will receive a matched volume to the C12T12 arm during the up-titration, maintenance, and down-titration phases.
214471569|NCT06126224|DRUG|KarXT|KarXT 20/2 mg (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)
214284972|NCT01900704|DRUG|SER120 750 ng|SER120 750 ng
214284973|NCT01900704|DRUG|SER120 1500 ng|SER120 1500 ng
214284974|NCT01900704|DRUG|Placebo|Placebo
214284975|NCT06214338|DIETARY_SUPPLEMENT|Low dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 2.5, separated by 1 hour and 15 min.
214284976|NCT06214338|DIETARY_SUPPLEMENT|High dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 5 separated by 1 hour and 15 min.
214284977|NCT06139432|DEVICE|Active tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* The stimulation level is 2mA for 20 minutes.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
214284978|NCT06139432|DEVICE|Sham tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
214471570|NCT06126224|DRUG|Placebo|Placebo Capsules
214471571|NCT05409573|OTHER|double monitoring of EtO2|"A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~* In the pharynx (via a nasopharyngeal catheter) for the needs of the study~* On the facemask (as the practice in the OR)"
214471572|NCT06823687|OTHER|Virtual reality glasses|Virtual reality glasses Beginning 1-2 minute before the start of the procedure, the patients will be watched (5-10 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product.
214471573|NCT06822270|PROCEDURE|open surgery|open surgical methods for treating Pelvi-ureteric Junction Obstruction
214471574|NCT06822270|PROCEDURE|Laparoscopic Pyeloplasty|minimally invasive laparoscopic techniques.
214284979|NCT03418415|DEVICE|Renal denervation|multi-electrode catheter-based renal denervation
214284980|NCT03274505|OTHER|Questionnaires|"* Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~* Clinical evaluation~* Routine neuropsychological evaluation (for stroke patients)~* Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) \> 10)"
214284981|NCT05805904|DRUG|BMS-986278|Specified dose on specified days.
214284982|NCT05805904|DRUG|Placebo|Specified dose on specified days
214471575|NCT03625115|BEHAVIORAL|Family Navigator (FN)|The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.
214471576|NCT06821763|DRUG|Calcium Hydroxide Intracanal medication|non setting calcium hydroxide(CH) mixed with normal saline and placed as intra canal medicament during first visit of root canal treatment. effectiveness measured after 48hrs, 72hrs and 96hrs
214471577|NCT06821763|DRUG|triple antibiotic paste (TAP)|mix metronidazole, ciprofloxacin and minocycline in ratio 1:1:1 with normal saline and placed as intra canal medicament during first visit of root canal treatment.
214471578|NCT06535828|DEVICE|AI and mechanic modeling|The data collected from research tests on your blood and tumor samples will be used to develop an AI model for treatment selection.
214471579|NCT06823414|OTHER|Video assisted mastectomy|Nipple Skin sparing mastectomy assisted by endoscopic or robotic
214471580|NCT06823258|DRUG|HS-10365|HS-10365 administered orally once at D1
214471581|NCT05815745|DEVICE|Pacemaker - Physiological pacing|The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
214471582|NCT05815745|DEVICE|Pacemaker - Right Ventricular pacing|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
214471583|NCT06823102|OTHER|tDCS|Transcranial direct current stimulation
214471584|NCT06609642|BEHAVIORAL|Art application|"First, participants will complete questionnaires that will provide us with their socio-demographic information, their level of knowledge in visual arts and music, as well as their level of eco-anxiety.~Second, participants will use the application on a touchscreen tablet:~1. A member of the research team will give a brief explanation of the application.~2. The participant will use the application on the touchscreen tablet.~3. A member of the research team will be present in the room during the test as an observer.~Third, the participant will answer questions from a member of the research team: impressions of the tool, digital skills and abilities, enablers and barriers to the use of the tool, expectations, needs, and interests in the application."
214471585|NCT06822556|DIETARY_SUPPLEMENT|Placebo|14 days of supplementation with 25 mg/day hemicellulose crystalline
214284983|NCT00359060|BEHAVIORAL|Physical activity|
214284984|NCT00197132|DRUG|Avandia|
214284985|NCT02882009|DRUG|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
214284986|NCT02882009|DRUG|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
214284987|NCT03181581|BIOLOGICAL|acoustic coupling fluid|ultrasound images obtained with both ACF and Ringer's acetate
214284988|NCT03181581|BIOLOGICAL|Ringer's acetate|ultrasound images obtained with Ringer's acetate only
214284989|NCT04423237|DRUG|Deferasirox|DEFERASIROX administered as per clinical practice and according to technical note
214284990|NCT00465205|DRUG|Valacyclovir|500mg oral twice daily
214284991|NCT00465205|DRUG|Matching Placebo|500 mg oral twice daily
214284992|NCT04359550|BIOLOGICAL|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
214471586|NCT06822556|DIETARY_SUPPLEMENT|Tetraselmis chuii|14 days of supplementation with 25 mg/day tetraselmis chuii
214471587|NCT03016156|OTHER|CRADLE|"A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.~The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts."
214471588|NCT03016156|OTHER|Red reflex testing|Traditional red reflex testing for leukocoria using a direct ophthalmoscope on routine eye examination. Red reflex testing via direct ophthalmoscope will be performed before dilation, using the ophthalmoscope held close to the examiner's eye, focused on the pupil, viewed at 12 to 18 inches from the patient's eyes, with the room lights dimmed, in accordance with the American Academy of Pediatrics guidelines.
214471589|NCT05377957|OTHER|Quality of life questionnaires|Collection of patient-reported outcomes concerning general and health-related quality of life and impact of uveal melanoma diagnosis
214471590|NCT05377957|OTHER|Discrete choice experiment|Assessment of patient preferences for outcomes of proton therapy and enucleation
214471591|NCT05377957|OTHER|Shared decision-making analysis|Assessment of shared decision-making from the perspective of the patient (by questionnaire), physician (by questionnaire) and a neutral observer (by audiotape), combined with patient-reported satisfaction and regret of the treatment decision (by questionnaire)
214284993|NCT04359550|OTHER|placebo|placebo
214284994|NCT04656691|DRUG|bamlanivimab|Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.
214284995|NCT02421523|PROCEDURE|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of \~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
214471592|NCT05377957|OTHER|Impact of side-effects analysis|Assessment of the impact of side-effects by questionnaire
214471593|NCT06281834|DRUG|Rifapentine|Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children \<2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.
214284996|NCT02421523|PROCEDURE|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of \~30% of the subject's MVC. Subjects will be asked to perform \~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (\~50% MVC). Similarly, if no damage has occurred at \~50% MVC, four more subjects exercise at \~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
214284997|NCT02421523|PROCEDURE|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
214284998|NCT00230997|DRUG|Galantamine|
214284999|NCT04540211|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
214471594|NCT06281834|DRUG|Dolutegravir|All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention
214471595|NCT04098250|DRUG|Erenumab|a CGRP receptor monoclonal antibody
214471596|NCT04098250|OTHER|Placebo|Placebo
214471597|NCT03221309|OTHER|Evaluate model of care for HCV-infected adults with on-going opioid misuse|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
214471598|NCT06313957|BIOLOGICAL|LUCAR-20SP cells|Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
214471599|NCT05015348|OTHER|fish oil with omega-3 PUFA|3.6g per day fish oil with omega-3 PUFA (EPA+DHA)
214471600|NCT05015348|OTHER|placebo|palm oil as placebo
214471601|NCT04170283|DRUG|Zanubrutinib|Participants will receive zanubrutinib at a dose of 160 mg twice daily (for a total daily dose of 320 mg), or the last dose level received in the BeiGene parent study.
214471602|NCT04170283|DRUG|Tislelizumab|Patients in Australia who participated in a parent study that involved combination therapy of zanubrutinib and tislelizumab will receive tislelizumab at a dose of 200mg every 3 weeks..
214471603|NCT04101357|DRUG|BNT411|intravenous
214471604|NCT04101357|DRUG|Atezolizumab|intravenous
214471605|NCT04101357|DRUG|Carboplatin|intravenous
214471606|NCT04101357|DRUG|Etoposide|intravenous
214471607|NCT05868382|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214471608|NCT05868382|BIOLOGICAL|mRNA-1010.4|Sterile liquid for injection
214471609|NCT05868382|BIOLOGICAL|mRNA-1010.6|Sterile liquid for injection
214471610|NCT05553353|DEVICE|repetitive transcranial magnetic stimulation--Active|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
214471611|NCT05553353|DEVICE|repetitive transcranial magnetic stimulation--Sham|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.
214471612|NCT03574649|DRUG|Nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214285000|NCT04540211|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.
214285001|NCT04540211|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
214285002|NCT04540211|DRUG|Cisplatin|Cisplatin 60-80 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
214471613|NCT03574649|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
214471614|NCT03574649|DRUG|5Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214471615|NCT03574649|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214471616|NCT03574649|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
214471617|NCT03574649|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
214471618|NCT03574649|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
214471619|NCT03574649|BIOLOGICAL|GI-4000|RAS yeast vaccine
214471620|NCT03574649|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
214471621|NCT03574649|DRUG|Aldoxorubicin|INNO-206
214471622|NCT03574649|DRUG|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
214471623|NCT03574649|DRUG|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
214471624|NCT03574649|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
214471625|NCT03574649|DRUG|Docetaxel|Docetaxel
214471626|NCT03574649|DRUG|carboplatin|carboplatin
214471627|NCT05940558|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
214471628|NCT04421222|DRUG|EPI-7386 (QD)|Once daily oral dose of EPI-7386
214471629|NCT04421222|DRUG|EPI-7386 (BID)|Twice daily oral dose of EPI-7386
214471630|NCT04421222|DRUG|Abiraterone acetate|Once daily dose of abiraterone acetate
214471631|NCT04421222|DRUG|Apalutamide|Once daily dose of apalutamide
214471632|NCT05485727|OTHER|The Lokomat® Pro Hocoma USA & Conventional physical therapy|Lokomat Consists of robotic gait orthosis and an advanced body weight support system, combined with a Treadmill. (used for gait training) and Conventional Physical Therapy
214471633|NCT05485727|OTHER|Conventional Physical Therapy|Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
214471634|NCT02497950|DEVICE|HeartMate 3|Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
214471635|NCT06310551|DRUG|Oral VH4524184|VH4524184 to be taken orally.
214471636|NCT06310551|DRUG|VH4524184 Formulation A SC|Low (\<1mL) starting dose of VH4524184 LAI Formulation A administered subcutaneously.
214471637|NCT06310551|DRUG|Placebo Formulation A SC|Starting dose of Placebo Formulation A administered subcutaneously.
214471638|NCT06310551|DRUG|rHuPH20|Dose of rHuPH20 administered subcutaneously.
214471639|NCT06310551|DRUG|VH4524184 Formulation B SC|Starting dose of VH4524184 LAI Formulation B administered subcutaneously.
214471640|NCT06310551|DRUG|Placebo Formulation B SC|Starting dose of Placebo Formulation B administered subcutaneously.
214471641|NCT06310551|DRUG|VH4524184 Formulation C SC|Starting dose of VH4524184 LAI Formulation C administered subcutaneously.
214471642|NCT06310551|DRUG|Placebo Formulation C SC|Dose of Placebo Formulation C administered subcutaneously.
214471643|NCT06310551|DRUG|VH4524184 Formulation A IM|Starting dose VH4524184 LAI Formulation A administered intramuscularly.
214471644|NCT06310551|DRUG|Placebo Formulation A IM|Dose of Placebo Formulation A administered intramuscularly.
214471645|NCT06310551|DRUG|VH4524184 Formulation B IM|Starting dose VH4524184 LAI Formulation B administered intramuscularly.
214471646|NCT06310551|DRUG|Placebo Formulation B IM|Dose of Placebo Formulation B administered intramuscularly.
214471647|NCT01236781|DEVICE|Screening Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
214471648|NCT01236781|DEVICE|Diagnostic Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
214471649|NCT05951023|DRUG|Eszopiclone 2 mg|Eszopiclone tablet (encapsulated)
214471650|NCT05951023|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Eszopiclone
214471651|NCT05377281|PROCEDURE|Peripheral Nerve Tissue Implantation|At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed. From the biopsied section, the epineurium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the substantia nigra.
214285003|NCT04540211|DRUG|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
214285004|NCT04540211|DRUG|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
214285005|NCT00600483|DRUG|gentamicin-collagen sponge dipped in saline|100-cm2 sponge
214471652|NCT05590689|DRUG|Gliolan|A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)
214471653|NCT05590689|RADIATION|Radiodynamic therapy|Radiotherapy will be performed in combination with Gliolan administration
214471654|NCT05394935|OTHER|High-Intensity Exercise|Acute, low-volume HIIT 12x (1min:1min) Working intensity: \>85% heart rate reserve Resting intensity: Active rest
214471655|NCT05394935|OTHER|Moderate-Intensity Exercise|Continuous, MISS 50mins Working intensity: 50-60% heart rate reserve
214471656|NCT06255288|OTHER|SNAK intervention|The intervention consists of structured dialogue, patient information, and a protein supplement. The structured dialogue part of the intervention consists of an A3 poster with illustrations and keywords which will be hanging in the outpatient clinics. The poster will be utilized by nurses, patients, and their relatives to facilitate a dialogue regarding nutrition and wound healing. The patient information part of the intervention consists of a leaflet with easy-to-read information, which patients and their relatives can bring home after their visit to the outpatient clinic. The leaflet will consist of general information as well as food categories and recipes they can use to enhance their daily protein intake. For the protein supplement part of the intervention, the patients will have access to protein supplement beverages while they are in the outpatient clinic waiting room. Furthermore, they will receive prescriptions for protein drinks, that they can pick up at their local pharmacy.
214471657|NCT06082323|DRUG|LT-002-158/Placebo oral tablet(s)|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
214471658|NCT04028284|DEVICE|HoloLens-guided epidural|To determine whether using the HoloLens tool increases the success of epidural insertion.
214471659|NCT04028284|OTHER|US-guided epidural|traditional thoracic epidural procedure
214471660|NCT00949598|DRUG|letrozole|Given orally
214471661|NCT00949598|DRUG|tamoxifen citrate|Given orally
214471662|NCT03190538|OTHER|No intervention|There will be no specific intervention to these paediatric NASH patient
214285006|NCT04208698|DRUG|CIN-102 Dose 1|Deuterated domperidone (deudomperidone)
214471663|NCT05229822|DIAGNOSTIC_TEST|LBP|Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
214471664|NCT05229822|DIAGNOSTIC_TEST|sCD14-ST|Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
214471665|NCT05229822|DIAGNOSTIC_TEST|16s rRNA|Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.
214471666|NCT06077214|DRUG|Treatment with liposomal bupivacaine|Patients will randomly be treated with either liposomal bupivacaine (study drug) after undergoing bariatric surgery.
214471667|NCT06077214|DRUG|Treatment with standard bupivacaine|Patients will randomly be treated with standard bupivacaine after undergoing bariatric surgery.
214471668|NCT04075461|PROCEDURE|Arthroplasty|Arthroplasty is commonly used for a displaced femoral neck fracture.
214471669|NCT04075461|PROCEDURE|Internal fixation|Internal fixation is commonly used for undisplaced femoral neck fracture
214285007|NCT04208698|DRUG|CIN-102 Dose 2|Deuterated domperidone (deudomperidone)
214471670|NCT05176470|DRUG|Cyclophosphamide|Given IV
214285008|NCT04208698|DRUG|Placebo for CIN-102|Placebo
214285009|NCT01262053|OTHER|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
214285010|NCT01262053|OTHER|Active Intervention|"The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function."
214285011|NCT01262053|OTHER|Control|Parallel control with no intervention
214285012|NCT05074212|OTHER|Factorial Assignment|At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
214285013|NCT03092609|BEHAVIORAL|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
214471671|NCT05176470|DRUG|Fludarabine|Given IV
214285014|NCT03092609|BEHAVIORAL|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
214285015|NCT05048940|BIOLOGICAL|Janssen vaccine|0.5 ml millilitre(s) Intramuscular use
214285016|NCT05048940|BIOLOGICAL|Spikevax (Moderna) vaccine|0.5 ml millilitre(s) Intramuscular use
214285017|NCT01990404|DRUG|Premixed 50% nitrous oxide and oxygen|Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
214285018|NCT01990404|DRUG|Medical Air|Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
214285019|NCT01482884|DRUG|tralokinumab|2 sc injections of every 2 weeks for 12 weeks.
214285020|NCT01482884|DRUG|placebo|2 sc injections of every 2 weeks for 12 weeks.
214285021|NCT01408004|DRUG|Pazopanib|Tablet 800mg qd til progression
214471672|NCT05176470|BIOLOGICAL|Lifileucel|Given by IV infusion
214471673|NCT05176470|BIOLOGICAL|Pembrolizumab|Given IV
214471674|NCT05176470|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214471675|NCT06045299|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine+Brimonidine combination ophthalmic solution
214471676|NCT06045299|DRUG|Aceclidine ophthalmic solution|Aceclidine ophthalmic solution
214471677|NCT06045299|DRUG|Placebo (Vehicle) ophthalmic solution|Placebo (Vehicle) ophthalmic solution
214471678|NCT03915262|BIOLOGICAL|Search for exocrine pancreatic insufficiency at week 0 and 12|"We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin.~We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease.~We will gather the total caloric and fat intake with a diet record."
214471679|NCT05469789|OTHER|No Intervention|As it is an observational study, no intervention is administered in this study.
214471680|NCT06536517|DRUG|Methadone|Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
214471681|NCT06541184|DRUG|Ziconotide [Prialt]|Intrathecal injection of ziconotide, using an internal pump, surgically inserted by a trained neurosurgeon or anesthesiologist, under general anesthesia.
214471682|NCT01804985|DRUG|Imatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
214471683|NCT01804985|DRUG|nilotinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
214471684|NCT01804985|DRUG|dasatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
214471685|NCT03314688|BEHAVIORAL|Dietary/Physical Activity intervention|Motivational counseling to follow established dietary and exercise guidelines.
214285022|NCT01408004|DRUG|Everolimus|tablet 10 mg qd til progression
214285023|NCT01408004|DRUG|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
214285024|NCT01408004|DRUG|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
214285025|NCT01408004|DRUG|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
214285026|NCT01408004|DRUG|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
214471686|NCT03314688|BEHAVIORAL|Usual Care|Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
214471687|NCT05165810|BEHAVIORAL|Same-day ART initiation [experimental]|Participants assigned to same-day ART initiation will be offered standard, first-line ART on the day of trial enrollment. Participants, will be provided with focused counseling and instructions on where to follow-up for ongoing HIV care (either community-based HIV care or government-based HIV care, depending on randomization).
214471688|NCT05165810|BEHAVIORAL|Standard ART initiation [usual care]|Participants randomized to standard ART initiation will not initiate ART on the day of trial enrollment, but only after linking to their assigned source of HIV care (either community-based HIV care or government-based HIV care, depending on randomization). In standard ART initiation, patients typically, complete an intake visit at the HIV clinic, with baseline laboratory testing, and return to the clinic approximately 2 weeks later to begin ART.
214471689|NCT05165810|OTHER|Community-based HIV care [experimental]|Participants randomized to community-based HIV care will be referred to PWID-focused integrated care centers (ICCs) for ongoing HIV clinical management - a prototype of decentralized HIV care in India. ICCs will provide free HIV care that will adhere closely to Indian HIV treatment guidelines and, when relevant, to local HIV treatment standards.
214471690|NCT05165810|OTHER|Government-based HIV care [usual care]|Participants randomized to government-based HIV care will be referred to government-based HIV clinics for ongoing HIV clinical management. Government-based clinics provide free HIV care that adheres closely to Indian HIV treatment guidelines
214471691|NCT05165810|BEHAVIORAL|Enhanced adherence support [experimental]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.
214471692|NCT05165810|BEHAVIORAL|Routine adherence support [usual care]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months
214471693|NCT00179400|DRUG|Pioglitazone|This was a randomized placebo-controlled crossover study in which subjects received both agents in random order, separated by a wash-out period. Following 10 or 21 days' intervention, subjects underwent a pancreatic clamp study.
214471694|NCT00179400|DRUG|Placebo|This was a randomized placebo-controlled crossover study in which subjects received both agents in random order, separated by a wash-out period. Following 10 or 21 days' intervention, subjects underwent a pancreatic clamp study.
214471695|NCT00179400|PROCEDURE|Pancreatic Clamp Study|During the clamp procedure, glucose (a sugar) and insulin were infused with an IV catheter, and blood samples were collected periodically throughout the procedure to measure blood sugar levels and the levels of several hormones that are found in the body and are related to glucose metabolism.
214471696|NCT03765619|DRUG|Aspirin|250 patients will be randomized to receive postoperative Aspirin.
214471697|NCT05675735|BEHAVIORAL|Clinic-Level Multidimensional Intervention|The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.
214471698|NCT05772520|DRUG|TLL018 tablets|oral tablets administered 20 mg BID and 40 mg BID for 12 weeks
214285027|NCT03308734|BEHAVIORAL|Reduced-Exertion High-Intensity Interval Training|The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
214285028|NCT01480050|DRUG|temozolomide|standard of care drug
214285029|NCT01480050|OTHER|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
214285030|NCT01480050|OTHER|pharmacological study|
214285031|NCT01480050|DRUG|Mibefradil|
214285032|NCT04267198|BEHAVIORAL|Intention Treatment for Anomia|Word retrieval treatment for aphasia that engages right hemisphere intention mechanisms using a left-hand circular gesture.
214471699|NCT05572684|DRUG|NC410|NC410 will be given intravenously (IV) every 2 weeks
214285033|NCT02324062|OTHER|Questionnaires|These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
214285034|NCT02324062|OTHER|Blood Draw and Baseline Questionnaire|Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
214471700|NCT05572684|DRUG|pembrolizumab|Pembrolizumab 400mg will be given IV every 6 weeks.
214285035|NCT04344925|DEVICE|Aerosol-reducing Mask|Patient will be put on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
214285036|NCT04344925|DEVICE|Standard Mask|Patient will be put on BIPAP using the standard mask
214285037|NCT02059486|BEHAVIORAL|Teen Choice|The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
214285038|NCT05195125|PROCEDURE|Direct Peritoneal Resuscitation|Direct peritoneal resuscitation involves the abdominal infusion and drainage of a peritoneal dialysate in high-risk liver transplant patients, for up to 24 hours after surgery.
214471701|NCT06288360|DRUG|Camrelizumab|200 mg, intravenously, 20-60 min. 2 times, every 21 days
214471702|NCT06288360|DRUG|Paclitaxel-albumin|260 mg/m² over 30 min, 3 times, every 21 days
214471703|NCT06288360|DRUG|Cisplatin|4 h, 75-80 mg/m², 3 times, every 21 days
214471704|NCT06288360|PROCEDURE|radical surgery|Radical hysterectomy + pelvic lymphadenectomy 士 para-aortic lymphadenectomy
214471705|NCT04979377|OTHER|Clinical hyperandrogenism assessment|Modified Ferriman-Gallwey scale
214471706|NCT04979377|DIAGNOSTIC_TEST|Total testosterone (ng/dL)|Circulating total testosterone (LC-MS/MS or IQL-CDC method) at follicular phase
214285039|NCT01234298|DRUG|SPD489 Low-Dose|SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
214285040|NCT01234298|DRUG|SPD489 High-Dose|SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
214471707|NCT04979377|DIAGNOSTIC_TEST|A1c (%)|High Performance Liquid Chromatography (HPLC)
214471708|NCT04979377|DIAGNOSTIC_TEST|Total cholesterol|Determined by enzymatic methods
214471709|NCT04979377|OTHER|Body mass index (BMI) (kg/m2)|Defined as body weight divided by the square of body height, and expressed in kg/m2
214471710|NCT04979377|DIAGNOSTIC_TEST|Frequency of chronic vascular complications [n (%)]|Retinopathy, nephropathy, neuropathy, and macrovascular disease.
214471711|NCT04979377|DIAGNOSTIC_TEST|Polycystic ovary morphology|Sonographic assessment
214471712|NCT04979377|DIAGNOSTIC_TEST|Cardiovascular autonomic reflex tests (CARTs)|Cardioautonomic function assessement by Vital scan HW7-HW6T:
214471713|NCT04979377|DIAGNOSTIC_TEST|Sex hormone-binding globulin (SHBG) (nmol/L)|Circulating SHBG (IQL) at follicular phase
214471714|NCT04979377|DIAGNOSTIC_TEST|Dehydroepiandrosterone-sulphate (IQL) (ng/mL)|Circulating DHEAS (IQL) at follicular phase
214471715|NCT04979377|OTHER|Waist circumference (cm)|Waist circumference measurement made at the top of the iliac crest
214471716|NCT04979377|OTHER|Waist-to-hip ratio|Waist circumference divided by hip circumference (measurement should be taken around the widest portion of the buttocks)
214471717|NCT04979377|OTHER|Body composition|Vital Scan HW7-HW6T
214471718|NCT04979377|DIAGNOSTIC_TEST|Mean glucose (mg/dL)|Continuous glucose monitoring (GCM) records
214285041|NCT01234298|DRUG|Placebo|Placebo capsule taken once-daily for up to 26 weeks
214285042|NCT04051866|PROCEDURE|Non-surgical periodontal treatment: Scaling and root planing (SRP)|Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.
214285043|NCT04051866|OTHER|Oral hygiene instructions|Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
214285044|NCT03589872|DIAGNOSTIC_TEST|Fine motor dexterity test, nine hole peg test|The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
214285045|NCT02956421|BIOLOGICAL|RABIPUR®|Biological rabies vaccine
214471719|NCT04979377|DIAGNOSTIC_TEST|Time in target range (hours)|Continuous glucose monitoring (GCM) records
214471720|NCT04979377|DIAGNOSTIC_TEST|Time in hyperglycemia (hours)|Continuous glucose monitoring (GCM) records
214471721|NCT04979377|OTHER|Insulin dose (UI/Kg)|Daily insulin dose divided by body weight
214471722|NCT04979377|OTHER|Insulin sensitivity|Equation that relies on routine clinical measures: A1c, presence of hypertension, and waist circumference
214471723|NCT04979377|DIAGNOSTIC_TEST|High-density lipoprotein (HDL) (mg/dL)|Enzymatic methods after precipitation of serum with phosphotungstic acid and Mg2+
214471724|NCT04979377|DIAGNOSTIC_TEST|Low-density lipoprotein (LDL) (mg/dL)|Estimated by the Friedewald's equation.
214471725|NCT04979377|DIAGNOSTIC_TEST|Triglycerides (mg/dL)|Determined by enzymatic methods
214471726|NCT06402851|DRUG|Anticoagulant Oral|Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
214471727|NCT05874453|OTHER|eye care protocol|The lower conjunctiva of the eye to be treated is opened, 1-2 drops of gel are applied, the eye is closed. Cleaning eye secretions is done with sterile distilled water. A gel containing trehalose, hyaluronic acid and carbomer will be applied every 2-4 hours in accordance with intensive care eye care protocol. In order to determine the exposure keratopathy, staining with Fluorescein Sodium will be performed by the ophthalmologist on days 0, 5 and 10, and a blue light pen will be used for evaluation. In order to determine the degree of dry eye, the Schirmer I test will be performed on the 0th and 10th days
214471728|NCT06153966|DRUG|ION717|ION717 will be administered by IT injection.
214471729|NCT06153966|DRUG|Placebo|Placebo-matching ION717 will be administered by IT injection.
214285046|NCT02956421|BIOLOGICAL|PIKA rabies vaccine|Biological rabies vaccine
214471730|NCT04243070|DIAGNOSTIC_TEST|3-channel Holter ECG recording|3-channel Holter ECG recording for patients undergoing an EPS
214471731|NCT04243070|DIAGNOSTIC_TEST|12-channel Holter ECG recording|12-channel Holter ECG recording for patients undergoing a routine follow-up
214285047|NCT05813015|DRUG|Docetaxel|Docetaxel 40mg/m2，every 21 days，6 cycles.
214285048|NCT05813015|DRUG|Tegafur-Gimeracil-Oteracil|S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.
214471732|NCT06235190|DEVICE|Felix NeuroAI Wristband|The Felix NeuroAI Wristband (Felix) is a wrist-worn, noninvasive, transcutaneous neurostimulation system. Using a proprietary artificial intelligence (AI) algorithm, stimulation will be automatically adapted to patient's needs with the goal to provide full day relief of upper limb tremor.
214471733|NCT06235190|DEVICE|Sham Device|The sham device has the same exterior appearance and components as the Felix device and is used the same way (without delivering the treatment).
214471734|NCT05772884|OTHER|Supervised Exercise Intervention|Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.
214471735|NCT01009788|DRUG|ABT-888|Capsules (30-40 mg) taken orally twice a day on days 1-7 of each 28 day cycle
214471736|NCT01009788|DRUG|temozolomide|Capsules (150 mg/m\^2 initially, and 200 mg/m\^2 starting cycle 2 if tolerated) taken orally once a day on days 1 through 5 of a 28 day cycle
214471737|NCT06258681|OTHER|Incentive spirometer|The incentive spirometry group will continue training with Volumetric Triflo. It is asked to exhale at first and then hold their breath for at least 3 seconds after taking as deep a breath as possible.
214285049|NCT05024591|DEVICE|Lunit INSIGHT MMG CADe/x for medical imaging|• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis
214285050|NCT05545930|PROCEDURE|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
214471738|NCT06258681|OTHER|Individualized respiratory training group|Participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle.
214471739|NCT06350669|DEVICE|Vestibular rehabilitation phone application|The standard vestibular rehabilitation process, with the support of a phone app throughout the process
214471740|NCT04731376|OTHER|Best Practice|Receive standard peri-operative care
214471741|NCT04731376|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214471742|NCT04731376|OTHER|Questionnaire Administration|Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
214471743|NCT04731376|DRUG|Testosterone Cypionate|Given IM
214471744|NCT06051383|OTHER|Self management|"patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes~Session 1 :~* Introduction to the concept of self-management.~* Education/reassurance~* Managing fluid intake.~* Caffeine abstinence~* Alcohol advice~Session 2 :~* Adjusting medications~* Constipation advice.~* Strategies for dribbling. pelvic floor exercise.~* Double-voiding.~* Bladder re-training.~Session 3:~• Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months"
214285051|NCT05545930|DEVICE|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
214285052|NCT05899608|BIOLOGICAL|Ivonescimab Injection|Subject will receive ivonescimab and chemotherapy as an IV injection
214285053|NCT05899608|BIOLOGICAL|Pembrolizumab Injection|Subject will receive pembrolizumab and chemotherapy as an IV injection
214285054|NCT03365687|DIETARY_SUPPLEMENT|Vitamin D|2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
214285055|NCT03365687|DIETARY_SUPPLEMENT|Placebo|2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
214285056|NCT04102020|DRUG|Venetoclax|Tablet: Oral
214285057|NCT04102020|DRUG|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
214285058|NCT04102020|DRUG|Azacitidine|Oral Tablet
214285059|NCT06117709|BEHAVIORAL|I-STAMP|A patient-facing smartphone application that hosts participants' analgesic and laxative medications, provides pain-specific psychoeducation, collects patient reported outcomes, and provides feedback to participant symptoms.
214285060|NCT03898362|OTHER|pneumatically powered wheelchair or scooter|a wheelchair or scooter powered by compressed air will be used for 6 months. Compressed air is a novel power source and no batteries are used in these devices.
214285061|NCT03898362|DEVICE|battery powered wheelchair or scooter|a wheelchair or scooter powered by a battery will be used for 6 months. These are conventional mobility devices that the participants are using or in the process of obtaining
214285062|NCT03853616|BIOLOGICAL|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
214471745|NCT06514963|DRUG|HRS-9813|Specified dose on specified days
214471746|NCT06514963|DRUG|Placebo|Specified dose on specified days
214285063|NCT04216875|PROCEDURE|Best Practice Diabetes Management in Primary Care|Practice adherence to best practice guidelines treating diabetes patients in different primary care practices is shown in this before- and after observational study
214285064|NCT04216329|DRUG|Selinexor|Selinexor will be administered orally at an initial dose of 80 mg. The first dose will be given on day 2 of radiation and will thereafter be administered weekly on the second day of weekly radiation on weeks 1, 2, 4, and 5. If this dose level is tolerated, the dose will be escalated to 60 mg twice a week (days 1 and 4) on weeks 1,2,4,5. The third and final dose level will also be 60mg administered twice weekly for 6 weeks starting on days 1 and 4 radiation.
214285065|NCT04216329|DRUG|Temozolomide|Temozolomide will begin on the first day or evening prior of radiation and be administered orally daily at a dose of 75 mg/m\^2 during the radiation treatment. Temozolomide will continue until the completion of radiation and then will be stopped. Beginning 1-month post-radiation therapy (RT), the adjuvant temozolomide will be given per standard of care.
214285066|NCT04216329|RADIATION|Generic Radiation therapy (RT)|Radiation therapy (RT) will be administered daily (Monday to Friday)
214285067|NCT04216329|OTHER|Selective serotonin receptor (5-HT3) antagonists|Anti-emetic for breakthrough nausea.
214285068|NCT04216329|OTHER|Olanzapine|2.5mg to 5mg once a day if weight loss is rapid.
214285069|NCT04216329|DIETARY_SUPPLEMENT|Salt tablets|To treat hyponatremia, add salt tablets to participants diet per institutional guidelines.
214285070|NCT04216329|OTHER|Anti-diarrheal|Treat diarrhea with an anti-diarrheal per institutional guidelines
214285071|NCT06805565|DRUG|ONO-1110|ONO-1110 tablets once a day
214285072|NCT06805565|DRUG|Placebo|Placebo tablets once daily
214285073|NCT06457178|BEHAVIORAL|Acceptance and Commitment Therapy-Based Intervention for Oncology Patients|An intervention program was prepared for oncology patients aiming to reduce psychological distress and increase participation in normal life.
214285074|NCT06457178|BEHAVIORAL|Psychoeducation for Oncology Patients|A program was prepared to support oncology patients in physical and psychological symptom management.
214471747|NCT03927768|DIAGNOSTIC_TEST|Predictive Model|Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
214471748|NCT03927768|DIAGNOSTIC_TEST|Breast Imagers|Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
214285075|NCT01333826|BEHAVIORAL|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
214285076|NCT06648473|DIAGNOSTIC_TEST|MRI Scan|Subjects will begin the MRI with T1-pre, T2w, and volumetric 3D FLAIR images being obtained. The subject will be brought out of the MRI magnet and moved into a seated position and will then have a standard Brain Tumor Imaging Protocol MRI scan.
214285077|NCT03857321|DRUG|Insulin|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly \& Company)
214285078|NCT03857321|OTHER|Placebo|Matching placebo (sterile saline) to 20 IU Humulin® R U-100
214285079|NCT03857321|DEVICE|intranasal nebulizer-like device|Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.
214285080|NCT05542576|DRUG|AMDX2011P|AMDX2011P single bolus injection intravenous for diagnostic review
214285081|NCT05076630|OTHER|Air pollutants|Particulate matter and gaseous pollutants
214285082|NCT00704054|DRUG|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
214285083|NCT06360562|BEHAVIORAL|Resilience Training|Behavioral group-based intervention delivering mindfulness, metallization, and self-compassion skills.
214285084|NCT05733221|DEVICE|3D Printed Model|3D Printed Model generated pre-operatively of the patients mandible.
214471749|NCT04210947|OTHER|30 rolls per minute(30RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 2 secs. Then comeback from insertion to origin with 2 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
214471750|NCT04210947|OTHER|15 rolls per minute(15RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 4 secs. Then comeback from insertion to origin with 4 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
214471751|NCT04210947|OTHER|self-determined|Participants will start using foam roller from muscle origin to insertion with self determined-speed. Then comeback from insertion to origin with same pace. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
214471752|NCT05361941|DEVICE|EP Granules with Tobramycin|EP Granules with Tobramycin is a Ca-salt resorbable intended for orthopedic applications as a bone void filler for bone gaps or voids and in cases where risk of post-operative infection is high, such as the first stage of a 2-stage or 1.5 stage revision of an infected total joint.
214471753|NCT05361941|DEVICE|empty voids|Voids are left empty
214471754|NCT06335888|DRUG|AzaFol|AzaFol-PET/CT imaging
214471755|NCT06335888|DRUG|FDG|FDG-PET/CT imaging
214471756|NCT05253586|PROCEDURE|Laparoscopic|Surgeon
214471757|NCT05253586|PROCEDURE|Robotic|Versius system
214471758|NCT05326386|BEHAVIORAL|HTN and Medication Adherence|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
214471759|NCT05832047|DRUG|Plasma solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
214471760|NCT05832047|DRUG|Lactated Ringer solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
214471761|NCT05832047|DRUG|8-hour aggressive hydration|If patients experienced postprocedural abdominal pain Numerical Rating Scale (NRS score\>3) or a worsening of abdominal pain compared with the pain before ERCP, the administration of study fluid continues until 8 hours (3 mL/kg/hr ) regardless of the results of serum amylase/lipase within 4 hours after ERCP because serum amylase/lipase within 4 hours after ERCP may have a result approximately 1-2 hours (5 hours-6 hours after ERCP) after blood sampling
214471762|NCT01988883|DRUG|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
214471763|NCT01988883|DRUG|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
214471764|NCT01988883|DRUG|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
214471765|NCT05383196|DRUG|Onvansertib|oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.
214285085|NCT05980182|BEHAVIORAL|mHealth Application|Self-directed application (app) that is downloaded to the participant's personal device. The app contains five informational videos, that provide an orientation to the content on the app, and discuss what colorectal cancer is, and the type of CRC screening tests that are available as well as a video with a personal history. There is a a National Cancer Institute (NCI) risk calculation tool, and a family history infographic. Once the videos have been viewed participants have the option to indicate if they wish to receive a call from the healthcare clinic to discuss scheduling an appointment for screening.
214471766|NCT05383196|DRUG|Paclitaxel|once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle
214471767|NCT06451835|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
214471768|NCT05348395|OTHER|Experimental diet|Participants that successfully complete the run-in phase will participate in the experimental diet for 8 weeks of feeding. The Participants' adherence will be monitored using direct observation, written daily food diaries, and food waste inventory (i.e., participants are trained to estimate portion of uneaten foods). Participants will be asked to eat one meal onsite 2-3 weekdays (e.g., Monday, Wednesday, and Friday), at which time they will receive meals and snacks for the remainder of that day and enough until the next scheduled visit.
214471769|NCT03403465|OTHER|FDG PET scan|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
214844669|NCT06149091|DRUG|Tranexamic Acid；|Tranexamic acid (TXA) is an antifibrinolytic drug that competitively inhibits the activation of plasminogen. After its efficacy and safety were confirmed in several randomized controlled trials, both systemic and topical administration of TXA have been widely used for hemostasis in trauma and various surgical settings.
214844670|NCT06149091|DRUG|Adrenalin|In diagnostic bronchoscopy, one of the most commonly used topical hemostatic agent is epinephrine. The primary mechanism of epinephrine is vasoconstriction, leading to reduced blood flow and hemostasis.
214471770|NCT05408975|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
214471771|NCT05408975|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
214471772|NCT05298748|OTHER|Womb sound recordings|"Womb sounds will be chosen from commercially available (Amazon) womb recordings using a recording that most closely resembles the womb including maternal heart rate, fetal heartbeat, respiratory sounds, bowel popping sounds and frequency spectra as described by Parga, Daland 2018 et al."
214471773|NCT04308681|OTHER|BMS-986278 Placebo|Specified Dose on Specified Days
214471774|NCT04308681|DRUG|BMS-986278|Specified Dose on Specified Days
214471775|NCT05664217|DRUG|NKTR-255 at 1.5 µg/kg|NKTR-255 at 1.5 µg/kg
214471776|NCT05664217|DRUG|NKTR-255 at 3.0 μg/kg|NKTR-255 at 3.0 μg/kg
214471777|NCT05664217|DRUG|NKTR-255 at 3.0/6.0 μg/kg|NKTR-255 at 3.0/6.0 μg/kg
214471778|NCT05664217|OTHER|Placebo Comparator|Commercially available 0.9% Sodium Chloride Solution for Injection (USP)
214471779|NCT03844750|PROCEDURE|Hepatectomy|Undergo liver resection.
214471780|NCT03844750|BIOLOGICAL|Pembrolizumab|Given IV
214471781|NCT03844750|DRUG|Vactosertib|Given orally
214471782|NCT05517811|DIAGNOSTIC_TEST|TEG indices|Blood samples
214285086|NCT06436547|DEVICE|Subiculum-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are biliteral subiculum.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
214285087|NCT03107780|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214285088|NCT03107780|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214285089|NCT03107780|DRUG|Navtemadlin|Given PO
214471783|NCT05565820|OTHER|Vamousse Spray 'n' Go|Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).
214471784|NCT05565820|DRUG|Nix Creme Rinse Lice Treatment|1% permethrin lotion for topical application.
214471785|NCT06281041|DRUG|Antiplatelet Agents|Aspirin or clopidogrel
214471786|NCT03209609|DEVICE|VEST|External support for vein grafts, cobalt chrome braid
214285090|NCT03107780|RADIATION|Radiation Therapy|Undergo radiation therapy
214285091|NCT05318963|BIOLOGICAL|LCAR-AIO cells product|before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
214285092|NCT04375033|DRUG|Sublingual buprenorphine with naloxone|The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit through Week 48.
214285093|NCT04375033|DRUG|Injectable subcutaneous buprenorphine|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit through Week 48.
214285094|NCT06533059|DRUG|ALTA2618|Oral ALTA2618 tablets will be administered at protocol-defined dose
214285095|NCT06105554|DRUG|Belumosudil mesylate|Given by PO
214285096|NCT03771677|DRUG|Nucleotide Analog|such as Entecavir,entecavir 0.5mg per day
214285097|NCT03771677|DRUG|Interferon Alfa-2A|Peginterferon alfa-2a 180ug per week
214285098|NCT05725902|DRUG|Etavopivat|The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
214471787|NCT03209609|PROCEDURE|Coronary artery bypass vein grafts|Bypass coronary arteries with autologous saphenous vein grafts
214471788|NCT06021353|DEVICE|UV fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
214471789|NCT06021353|DEVICE|IR fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
214471790|NCT06021353|PROCEDURE|LASIK|Laser-assisted in situ keratomileusis (LASIK) surgery
214471791|NCT06430333|BEHAVIORAL|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|Mindfulness-based sleep program for pregnant women.
214471792|NCT06430333|OTHER|Treatment-as-usual (TAU)|Usual practices from real-world care experiences.
214844671|NCT06149091|DRUG|Hemagglutinase|Thrombin injection (Batroxobin) is an enzymatic hemostatic agent refined from the venom of the Brazilian lancehead snake. It promotes clot formation at the bleeding site, characterized by rapid and effective hemostasis and high safety. It is now widely used for clinical prevention and treatment of perioperative bleeding and oozing. Multiple randomized controlled studies have evaluated the safety and efficacy of intravenous/topical application of thrombin in various trauma and surgical settings.
214285099|NCT07132905|BEHAVIORAL|"Mpata Yathu (Our Space)"|Mpata Yathu is a church-based, lay counselor-delivered psychological intervention adapted from the Friendship Bench problem-solving therapy (PST) model. Designed for adolescent girls and young women in Zambia with a history of gender-based violence and elevated mental health symptoms, the intervention includes six weekly individual PST sessions delivered in private spaces within Catholic churches. Lay counselors are trained in trauma-informed, survivor-centered care and offer optional referrals to mental health, HIV, or GBV-related services. Mpata Yathu maintains the core structure of Friendship Bench but was adapted through community-partnered participatory research to meet the sociocultural needs of Zambian youth.
214285100|NCT07131605|OTHER|Before bariatric surgery, both blood and biological samples (stool and urine) will be collected. Patients will also undergo a cardiology examination|This study includes a comprehensive set of laboratory and clinical investigations to evaluate the cardiovascular and metabolic impact of obesity and its modulation after bariatric surgery. Multiple biological samples (blood, urine, stool, and omental adipose tissue) will be collected at baseline and during follow-up.
214285101|NCT06193499|PROCEDURE|Platelet rich plasma (PRP)|Intra-articular injection of platelet rich plasma (PRP)
214285102|NCT06193499|OTHER|Placebo|Intra-articular Saline injection (0,6-1ml)
214844672|NCT04418531|BIOLOGICAL|Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
214844673|NCT01808248|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
214285103|NCT06977841|DRUG|Tegoprazan|50 mg twice daily (BID), d1-14, administered 30 minutes before morning and evening meals.
214285104|NCT06977841|DRUG|Amoxicillin 250Mg Cap|750 mg four times daily (QID), d1-14, administered immediately after breakfast, lunch, dinner, and bedtime snack.
214285105|NCT06977841|DRUG|Tetracycline 500 Mg|500 mg three times daily (TID), d1-14, postprandial after breakfast, lunch, and dinner.
214285106|NCT06977841|DRUG|Bismuth|220 mg BID, d1-14, administered 2-3 hours after tetracycline doses at lunch and dinner
214285107|NCT07124975|BEHAVIORAL|Comparison of the treatment data with other patients|In this group, feedback will be provided as in the routine treatment data feedback group. In addition to this information, aggregated results for all participants (proportion of days with CPAP usage ≥4 hours per day and average daily usage time) and the participant's ranking based on these aggregated data will also be provided as feedback.
214285108|NCT07124975|BEHAVIORAL|CPAP data feedback|Participants will receive monthly feedback on their CPAP therapy treatment data (usage time and the proportion of days with \>4 hours of use) via mail or email for 6 months.
214285109|NCT07132112|BIOLOGICAL|GT719 Injection|GT719 Injection
214285110|NCT07131202|DRUG|FL115+PD-1|Combined treatment
214285111|NCT07131423|DEVICE|Standard extracorporeal shock wave therapy|ESWT was performed using the Swiss DolorClast Master ESWT device in accordance with the guidelines of the International Society of Medical Shockwave Therapy. The treatment was carried out by a physical therapist with at least 5 years of ESWT experience. The patient sat with the shoulder abducted at 45°, the elbow flexed at 90°, and the forearm supinated. The shock waves were delivered in a circular motion, targeting the 2-3 most painful tender points within a 3 cm radius centered on the lateral epicondyle. A total of 2,500 pulses were administered per session (0.2 to 2 bar, 8 Hz, 2,500 pulses, with intensity adjusted according to the patient's tolerance). All patients received a total of 4 ESWT sessions, once every 5 days, over a period of 3 weeks.
214285112|NCT07131423|DEVICE|CC points shock wave therapy|The assessment was conducted by a 5-year or more experienced FM therapist, following the standard procedure of the FM organization. The process included conducting interviews, filling out assessment forms, performing movement checks, and conducting palpation. Four CC points covering the entire upper limb, including the shoulder area, were selected. The points were ranked based on the severity of the dense touch. The blackboard pen was used to mark the points on the patient's body. The same ESWT therapist as in Group A used the same shock wave treatment instrument to treat the four CC points. The most severe point received 800 shocks, the second most received 700 shocks, and the remaining two points each received 500 shocks. A total of 2,500 pulses (with an intensity of 0.2 to 2 bar, a frequency of 8 Hz, and the intensity adjusted according to the depth of the point and the patient's tolerance) were administered. This treatment was performed once every 5 days for 3 weeks.
214285113|NCT07131423|DEVICE|Shock wave therapy for the CC points and the lateral epicondyle|Carry out the same process as Group B, but only select the three most severe CC points for shock therapy. Also, rank them according to the severity of the touch examination-induced densification. The most severe point receives 600 pulses, the second most severe receives 500 pulses, and the third most severe receives 400 pulses. At the same time, treat the lateral epicondylitis pain area in the same way as Group A. Apply 1000 pulses to the pain area. The total number of shocks for all treatments is 2500 (with an intensity of 0.2 to 2 bar, a frequency of 8 Hz, and the intensity is adjusted according to the depth of the point and the patient's tolerance). The therapist performing the treatment is the same as those in Group A and Group B. The treatment is carried out once every 5 days for 3 weeks.
214285114|NCT07132021|DEVICE|Active taVNS|Protocol uses a 25 Hz frequency with 500 μs pulse width in biphasic configuration, operating at a 1:1 duty cycle with current intensity set to the maximum tolerable level without inducing pain. The total stimulation duration is 60 minutes. The stimulation is combined with physical therapy focused on upper extremity function.
214285115|NCT07132021|DEVICE|Sham taVNS|Physical therapy focused on upper extremity function with masking for transcutaneous vagus nerve stimulation
214285116|NCT07132723|OTHER|Time in minutes from admission to closed reduction|Time in minutes from admission to closed reduction measured as: From arriving time in the emergency department until the start of surgery in the operating theater.
214844674|NCT01808248|DRUG|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
214285117|NCT07132424|PROCEDURE|Assesment|Foot posture, toe muscle strength and balance assesment
214285118|NCT07132658|RADIATION|MR-Guided SBRT|MR-Guided SBRT
214471793|NCT06190223|PROCEDURE|Anterior cruciate ligament (ACL) reconstruction with a periost-patellar-tendon-bone (PPTB) autograft and a tibial press-fit technique|A longitudinal incision will be performed starting from the central part of the patella. A ruler will be used to mark a tendon thickness of 10mm from the middle of the patellar tendon. Superiorly, the patellar periosteum will be marked with a length of 30-40mm and a width of 10mm. Inferiorly, the tibial tubercle will be marked in a trapezoidal shape with a length of approximately 35mm, a superior narrow base of 10mm and an inferior wider base of 12mm. After extraction, the superior part of the graft will be prepared with reinforced sutures in a whipstitch pattern, while the bone block will be shaped according to the planned tunnel width. After adequate preparation, the femoral end of the graft will be shuttled in with an adjusted fixation device, while the tibial end will be hammered in with a small mallet, in a press-fit fashion, stopping short of the joint surface, but tensioned appropriately. The femoral adjustable device will then be tensioned to ensure proper graft sitting.
214471794|NCT00898638|OTHER|biologic sample preservation procedure|
214285119|NCT07131709|OTHER|AI Generated Summary|Summary of the doctor's appointment generated by AI (either with or without the Next Steps Plan, depending on the arm participants are allocated to).
214471795|NCT00898638|OTHER|medical chart review|
214471796|NCT02393885|DEVICE|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
214471797|NCT06210802|OTHER|Korean version of Defense and Veterans Pain Rating Scale|Defense and Veterans Pain Rating Scale translated into Korean
214471798|NCT03805477|DRUG|Nintedanib|Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
214471799|NCT03387761|DRUG|Ipilimumab|"For Cohort 1:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~* Day 1: Ipilimumab 1 mg/kg~* Days 22: Ipilimumab 1 mg/kg"
214471800|NCT03387761|DRUG|Nivolumab|"For Cohort 1:~* Day 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~* Days 1 and 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~\- Days 1, 22 and 43: Nivolumab 3 mg/kg"
214471801|NCT06799312|DEVICE|Ipsilesional high frequency rTMS combined with physiotherapy|As mentioned in details in arms description.
214471802|NCT06799312|DEVICE|Contralesional Continuous Burst Theta rTMS (cTBS) + Physiotherapy|As mentioned in details in arms description.
214471803|NCT06799312|DEVICE|Sham rTMS + Physiotherapy|As mentioned in details in arms description.
214471804|NCT06482268|COMBINATION_PRODUCT|Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)|"Investigational PET agents will be synthesized at UCSD and administered to subjects according to the local institutional guidelines. IND applications for these agents are linked with the IND application for the study product, CT1-DAP001. The IND applications for the PET radiopharmaceuticals contains the manufacturing method, specifications, quality testing, clinical usage, and safety and efficacy information for individual PET agents.~Investigational Cell Injector Suniviion needle: The investigational instrument will be used to administer dopaminergic progenitors into the putamen. After aspirating cells, the instrument will be attached to a Leksell stereotactic frame to administer the cells into the brain."
214471805|NCT06798779|DEVICE|Glasses|The patients will have had their vision corrected with glasses that may contain both spherical and cylindrical corrections. The glasses prescription that offers the best subjective correction of vision are being recorded.
214471806|NCT06798779|DIAGNOSTIC_TEST|Corneal topography|This is a scan of the cornea (front of the eye). This gives us information on how the cornea is refracting light for the patient.
214471807|NCT05076513|DRUG|Niraparib|"In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~* For patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~* For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily."
214471808|NCT05076513|RADIATION|Radiation therapy|Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.
214471809|NCT05983770|DRUG|AT-1501|IV infusions of AT-1501 20 mg/kg over 1 hour.
214471810|NCT05983770|DRUG|Tacrolimus|Tacrolimus will be administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter.
214285120|NCT06393751|BIOLOGICAL|Bevacizumab|Given IV
214285121|NCT06393751|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214285122|NCT06393751|PROCEDURE|Computed Tomography|Undergo CT
214285123|NCT06393751|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214471811|NCT02951130|DRUG|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo
214471812|NCT02951130|DRUG|Placebo (5% Dextrose)|The study intervention is an intravenous infusion of milrinone or placebo
214471813|NCT00429364|DRUG|Losartan Potassium|Losartan .3 - 1.4 mg/kg
214471814|NCT00429364|DRUG|Atenolol|Atenolol .5 - 4 mg/kg
214471815|NCT05584553|DEVICE|ToggleLoc 2.9 mm soft tissue device|The ToggleLoc 2.9 mm Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
214285124|NCT06393751|DRUG|Paclitaxel|Given IV
214285125|NCT06393751|DRUG|Tolinapant|Given PO
214285126|NCT07131917|DEVICE|Miniaturized Intracavitary Monitoring Probe|A sterile, miniaturized, biocompatible monitoring probe (≤1.5 mm diameter) is temporarily introduced into the cavity of an infected walled-off pancreatic necrosis (WOPN) during standard percutaneous drainage. The device is designed to measure local microenvironmental parameters in situ, such as acidity and related indicators, without interfering with fluid evacuation. Measurements are performed intermittently or continuously for up to 72 hours and are used solely for observational purposes. This intervention is distinct from standard WOPN management, as it allows real-time assessment of local physicochemical conditions, which are not accessible through systemic biomarkers or imaging alone.
214285127|NCT07131761|OTHER|Tai chi|Yang style of Tai Chi (24 form)
214471816|NCT05584553|DEVICE|JuggerLoc soft tissue device|The JuggerLoc Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
214471817|NCT04871529|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214471818|NCT04871529|DRUG|Avelumab|Given IV
214471819|NCT04871529|DRUG|Gemcitabine Hydrochloride|Given IV
214471820|NCT04871529|DRUG|Carboplatin|Given IV
214471821|NCT06771479|BIOLOGICAL|MVA strain monkeypox attenuated live vaccine (low dose)|Low dose MVA strain monkeypox attenuated live vaccine
214471822|NCT06771479|BIOLOGICAL|MVA strain monkeypox attenuated live vaccine (high dose)|High dose MVA strain monkeypox attenuated live vaccine
214471823|NCT06771479|OTHER|Placebo|Vaccine excipient
214471824|NCT06565481|OTHER|Measurement Properties (Reliability and Validity) of a Set of Assessments evaluating Physical Function in adult Participants with Hemophilia|"This study evaluates the reliability (Test-Retest) of six health related instruments that assess physical function in people with hemophilia: Short Physical Performance Battery, Unipedal Stance Test, Four Square Step Test, Timed up and Go, 1 kg Arm Lift Test, 30 Second Chair Stand Test. This study is needed to determine the psychometric properties of these six assessments. Validity of these test will be determined with the Short Form 36, the Hemophilia Activities List and the Hemophilia Joint Health Score Methodology: Reliability (Test re-test study and validity (cross sectional study) of the six tests reported in patients with hemophilia.~This intervention contains physiotherapie assessments, however, no drugs nor medical devices."
214471825|NCT06772506|PROCEDURE|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|non-surgical technique plus splint and ultrasonic device with 200 mg Tetracycline
214471826|NCT06772506|PROCEDURE|Minimally invasive non-surgical technique with mini five and after five minimally invasive instrument plus splint|minimally invasive instruments, with mini five and after five minimally invasive instrument ultrasonic scaler device, conventional radiographic device and periodontal instruments with post-operative 1 gram penicillin for 3 days regulatory Statement: This study does not include an FDA-regulated device intervention, as the tools utilized are not the subject of investigation but are instead employed as part of routine clinical
214471827|NCT03408665|RADIATION|SBRT|3 sessions at least, up to 6. Neither specifc device is imposed.
214285128|NCT07131761|OTHER|Moderate-Intensity Combined Exercise (MICE)|start from warm up (5 minute )repetitions in circuit in the exercises bent row with elastic band, bodyweight squats, adapted push-ups (on the wall or on the counter), deadlifts with an elastic band, presses with an elastic band and an abdominal band on the floor or adapted on the chair and cool down in the end
214285129|NCT07131761|OTHER|Control ( No Exercise )|The CON session will last 60 minutes and will be conducted only sitting. Participants will be told not to sleep and will not be allowed to use reading materials or any electrical gadgets during the CON session.
214285130|NCT07131475|DRUG|PBR28 TSPO PET|Each SEAL participant will undergo brain imaging with PBR28 translocator protein (TSPO) positron emission tomography (PET) at study enrollment and at 1-year follow up.
214471828|NCT06431750|OTHER|Secukinumab|This is an observational study, there is no treatment allocation.
214471829|NCT04145375|DRUG|ZEN003694|Up to 120mg
214471830|NCT04145375|DRUG|Enzalutamide|160mg
214471831|NCT04872855|DEVICE|patient with knee arthroplasty|patient with HLS KneeTec cementless and hybrid fixation prosthesis
214471832|NCT04351906|DEVICE|ECCO2R|ECCO2R integrated into the multiFiltrate device
214285131|NCT07132242|DRUG|SHR-A1811 4.0mg/kg|SHR-A1811 4.0mg/kg, IV, Day 1, Q3W
214471833|NCT05584683|DRUG|Amoxicillin potassium clavulanate|LP-001 will be reconstituted and administered as a single dose
214471834|NCT05584683|DRUG|Amoxicillin potassium clavulanate (Augmentin ES-600)|Augmentin ES-600 will be reconstituted and administered as a single dose
214285132|NCT07132242|DRUG|Pyrotinib 240mg|Pyrotinib 240mg, po, QD, from Day 8 to Day 21,Q3W
214285133|NCT07132242|DRUG|SHR-A1811 4.8mg/kg|SHR-A1811 4.8mg/kg, IV, D1, Q3W
214285134|NCT07132242|DRUG|Pyrotinib 320mg|Pyrotinib 320mg, po, QD, from Day 8 to Day 21, Q3W
214285135|NCT07132099|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|This is a brief, structured, patient-centered therapy consisting of three to four face-to-face sessions. Each session typically lasts between 60 to 90 minutes. A fourth session may be added if clinically necessary.
214471835|NCT02088658|BEHAVIORAL|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
214471836|NCT05650190|DEVICE|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
214471837|NCT05650190|DEVICE|Spectacle lenses|Single vision, impact resistant spectacle lenses
214471838|NCT04070573|DRUG|acetylsalicylic acid|High risk pregnant women will be treated with daily aspirin during pregnancy.
214471839|NCT06628024|OTHER|Milk|Milk
214471840|NCT06628024|OTHER|Yoghurt|Yoghurt
214471841|NCT06804668|DEVICE|tDCS|The intervention involves a home-based, self-administered application of network-targeted, multifocal transcranial direct current stimulation (tDCS) using the Neuroelectrics® StarStim Home-tES device. Participants will apply the tDCS for 20 minutes each day over seven consecutive days. The device is specifically programmed to target a brain network associated with motor symptom improvement in Parkinson's Disease, based on recent research identifying this network through deep brain stimulation studies.
214844675|NCT01808248|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214844676|NCT03690167|OTHER|Concentrated Growth Factor (CGF)|CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)
214285136|NCT07132099|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"This intervention uses the ACT for Life protocol, which is designed to maximize recovery after suicidal crises. It consists of three components delivered over three to six individual sessions. The average number of sessions is four to five, with each session lasting approximately 60 minutes."
214285137|NCT07132099|OTHER|Treatment as Usual (TAU)|Treatment as usual (TAU) is not a structured intervention within this study. It may include standard outpatient or inpatient services, pharmacotherapy, or no structured treatment, depending on individual circumstances.
214285138|NCT07132359|OTHER|The Body Understanding Measure for Pregnancy Scale|During the study, the purpose of the study was explained to the pregnant women, and it was stated that participation in the study was completely voluntary and that they could leave the study at any time, and their written and verbal consent was obtained (Informed Consent Form). Pregnant women who agreed to participate in the study filled out the data collection forms individually.
214285139|NCT06853925|BEHAVIORAL|Radioactive Iodine Support (RAI Support)|RAI Support consists of multimedia content (images, videos, text, audio, and infographics across different website pages) that is written at an 8th grade reading level. RAI Support uses patient materials that are visually diverse to appeal to patients from different racial and ethnic backgrounds and inclusion of all genders. RAI Support users can access short (\~3 minutes or less) clinician-approved symptom management education videos and follow clinician-led video-guided activities such as nutrition management for dry mouth. In addition, RAI Support contains infographic pages about specific symptoms of RAI (e.g., salivary, lacrimal, and nasal symptoms with strategies for symptom management) and a resources page consisting of a printable treatment summary and survivorship plan to bring to provider appointments and access to evidence-based stress-management resources such as relaxation recordings.
214285140|NCT06853925|OTHER|Treatment as Usual (TAU)|The American Cancer Society (ACS) website on Radioactive Iodine (Radioiodine)Therapy for Thyroid Cancer is the TAU comparison. This website is a reputable and trusted source of information about cancer, with relevant content and web availability. Using the ACS website allows participants in both groups to receive information (addressing ethical concerns) through a website (similar delivery mode for information).
214285141|NCT05011422|DEVICE|Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus|Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product
214285142|NCT06981325|DRUG|Cemiplimab|Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for up to 12 months (max. 17 cycles).
214285143|NCT05448560|BEHAVIORAL|Multi-level Intervention of shared model of survivorship care|1\) Patient survivorship education via telehealth with the cancer center- The research registered nurse (RN) will discuss the contents of the survivorship care plan and coordination between the cancer center and PCP clinic. 2) Ongoing patient-tailored education program by MyChart within the EHR patient portal- Patients will be asked to select survivorship topics of interest from a panel (e.g. school issues, fertility, fatigue, physical activity, single kidney health, emotions/coping) that will then be sent over 1 year. 3) Structured interactive phone communication between the research RN at the cancer center and community PCP clinic- The discussion will explain the patient's cancer history, tumor recurrence monitoring schedule, individualized risk of late effects and surveillance schedule, psychosocial challenges, health behaviors, and coordination between the cancer center and PCP clinic. 4) In-person visit with the PCP clinic for survivorship care.
214285144|NCT05448560|OTHER|Comparison Group|Participants will be contacted by study staff at their cancer center to schedule an in-person visit at the survivorship clinic that will include a comprehensive history focused on cancer-related medical and psychosocial issues, physical examination, ordering of recommended surveillance for late effects, and delivery of hard copy of their survivorship care plan.
214285145|NCT06978673|PROCEDURE|Splanchnic nerve neurolysis - 5 ml of absolute alcohol (100%)|Splanchnic neurolysis will be performed with 5 ml of absolute alcohol on each side at the level of the eleventh thoracic vertebra.
214285146|NCT06978673|PROCEDURE|Celiac Plexus Neurolysis - 5 ml of absolute alcohol (100%)|Celiac plexus neurolysis will be performed with 5 ml of absolute alcohol on each side at the level of the first lumbar vertebra.
214285147|NCT06983041|DEVICE|vaginal cooling device|medical grade polymer capsule filled with inert fluid (15 cc's)
214285148|NCT04309604|BIOLOGICAL|IC14|monoclonal antibody directed against CD14
214285149|NCT05479474|BIOLOGICAL|Platelet rich plasma|"Patients will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.~* On the third month after the testicular PRP procedure, a TESE will be performed~* If the procedure is successful a new IVF cycle using the sperm procured from the procedure will be done."
214285150|NCT06986785|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214285151|NCT06986785|DRUG|Lenvatinib|8mg (body weight \< 60kg), or 12mg (body weight ≥60kg), QD.
214285152|NCT05923866|DRUG|ONO-2808|Oral administration of ONO-2808 at low, middle or high doses once a daily for 24 weeks
214285153|NCT05923866|DRUG|Placebo|Oral administration of placebo once a daily for 24 weeks
214285154|NCT06607458|DRUG|Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab|Trifluridine-tipiracil plus Bevacizumab Alone
214285155|NCT06607458|DRUG|Trifluridine-tipiracil plus Bevacizumab Alone|Trifluridine-tipiracil plus Bevacizumab Alone
214285156|NCT05304988|OTHER|Testing of the EFT|Our team will develop specific questions in EFT. Then, subject will be invited to fill in a set of questionnaires covering demographic characteristics, EFT items and a numerical rating scale for pain scores. The physiotherapists will rate the subject with the most appropriate level of physical activity.
214844677|NCT03690167|OTHER|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)
214844678|NCT03690167|OTHER|Control|Nothing applied after extraction
214844679|NCT00110734|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
214844680|NCT04385095|DRUG|SNG001|SNG001 via inhalation
214471842|NCT06804629|BEHAVIORAL|Moderate-to-High Intensity Resistance Exercise Training|Resistance exercise training was designed in accordance with World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed such that moderate-to-high intensity participants could achieve two sets of 8-12 repetitions of the eight exercises before volitional fatigue, a deterioration in lifting form, or failure to complete a repetition, using loads of approximately 70-80% of their estimated one-repetition maximum. Completed in the following order, the exercises were: barbell back squat, barbell bench press, hexagon bar deadlift, barbell bent over row, dumbbell lunges, seated dumbbell lateral raises, weighted or unweighted abdominal crunches, and seated dumbbell bicep curls. There was one minute of rest between each set, and two minutes of rest between each exercise. If participants could complete two sets of 12 repetitions, load was increased gradually by approximately 5% in the following session.
214471843|NCT06804629|BEHAVIORAL|Low Intensity SHAM Resistance Exercise Training Attention Control|The low intensity SHAM condition was matched all features of engagement with the moderate-to-high intensity intervention apart from load, and load progression. Low intensity SHAM participants completed the same program with loads of approximately 20% of their estimated one-repetition maximum. To maintain low intensity, repetitions completed on the main, heavier lifts (i.e., back squat, bench press, deadlift, bent over row) were increased from 10 in one session to 12 in the next; load was then increased by approximately 10% in the following session, and 10 reps were performed again. On the remaining lighter, assistance lifts, eight repetitions were performed per set, then one repetition was added to both sets in each session, and load was increased by the smallest increment possible when two sets of 12 repetitions were performed. Borg's 6-20 rating of perceived exertion scores were used to monitor intensity, such that if scores exceeded 11, load and reps were not progressed.
214471844|NCT06804694|BEHAVIORAL|TECC-T1D3 Program|The TECC-T1D3 program is a twelve-week virtual care intervention designed to support individuals with Type 1 Diabetes (T1D) and Diabetes Distress. The program includes a health coach (HC) and a virtual care team (VCT) of T1D, mental health experts and peer support, offering comprehensive care through various communication channels, including WebEx, phone calls, and text messaging. The program aims to: i. Provide T1D specific mental health and wellbeing support, ii. Provide guidance on how to communicate with others about T1D, manage stigma and ask for help with diabetes management and iii. Facilitate connections with T1D communities. Participants can choose topics of discussion based on their needs and will be directly supported by the HC and indirectly monitored by VCT.
214471845|NCT06804694|OTHER|Education Intervention|The Education Intervention is a low-intensity, education-focused intervention consisting of 10 automated emails over 12 weeks, providing generalized educational messages with links to resources for mental health support and well-being for individuals living with T1D.
214471846|NCT05674357|BEHAVIORAL|Individualized Evidence-Based Therapy in Cancer (Patients)|"The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~* Cognitive Behavioral Therapy (CBT)~* Acceptance Commitment Therapy (ACT)~* Mindfulness-Based Cognitive Therapy (MBCT)~* Mindfulness-Based Stress Reduction (MBSR)~* Meaning-Centered Psychotherapy (MCP)~* Cognitive Behavioral Therapy for Insomnia (CBT-I)~* CBT for pain~* CBT for fatigue~* CBT for nausea"
214471847|NCT05674357|BEHAVIORAL|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
214844681|NCT04385095|DRUG|Placebo|Placebo via inhalation
214285157|NCT06590285|BEHAVIORAL|App-based Educational Intervention|"The program's educational content is designed to engage patients in the science of sleep and recovery. Segments like The Sleep Adventure demystify complex neurobiological processes in an accessible format, aligning with emerging trends in patient education that focus on engagement and knowledge empowerment. Concurrently, the program's physical activity component is meticulously crafted, offering safe, supportive exercises that correspond with the treatment stages of alloHSCT patients. This aspect draws upon evidence highlighting the importance of sustained physical activity during intensive treatments to enhance overall recovery and quality of life. Additionally, the program comprehensively addresses sleep disturbances, prevalent in HSCT patients, through in-depth exploration and evidence-based, non-pharmacologic management strategies, reflecting the significant impact of sleep quality on patient recovery and long-term health outcomes."
214285158|NCT06345781|BEHAVIORAL|Abdominal Functional Electrical Stimulation|Functional electrical stimulation electrodes will be applied to the abdomen during a bowel program to assess effects of stimulation on bowel management time.
214285159|NCT04715997|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
214285160|NCT04715997|DRUG|Placebo|Normal saline
214285161|NCT06993142|BEHAVIORAL|Increase of physical activity volume and intensity with the use of a motivational smartphone application|A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting moderate-to-vigorous physical activity (MVPA) relative to baseline level).
214285162|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR)|The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
214844682|NCT00196820|DRUG|Capecitabine|
214471848|NCT04251481|RADIATION|PET/MRI with FDG|For the PET/MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for both the MRI and PET portions of the examination. The dye for the PET portion will be 18F-fluorodeoxyglucose (FDG). FDG is an FDA-approved radioactive substance (isotope) that contains chemicals that can be traced by PET/MRI. The dye for the MRI portion will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
214471849|NCT04251481|RADIATION|MRI scan without contrast|MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner to scan the neck ; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
214285163|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up|"Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted."
214285164|NCT06668571|DRUG|Ketamine|The subjects will receive 1:1 single IV racemic ketamine (dosed @0.5 mg/kg actual body weight) (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
214471850|NCT04251481|RADIATION|MRI with gadolinium|For the MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for MR scans. The dye for the MRI will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
214471851|NCT05236062|BEHAVIORAL|Exercise|aerobic and resistance exercise
214471852|NCT05236062|BEHAVIORAL|Attention control|stretching
214471853|NCT06039852|OTHER|Novel Postural Management Night-time Intervention|"Essential elements and components of PMN-TI:~* Safe and comfortable position to enable sleep~* Positioning to enable UAD overnight~* Quiet breathing unobstructed by base of tongue (i.e. stertor), vocal cords (i.e. stridor) or pooled secretions~* Postural support in lying to achieve comfort, promote symmetry of posture and maximum loadbearing~* Stomach contents reduced or emptied overnight to minimize reflux and associated aspiration risk."
214471854|NCT04003246|RADIATION|Thoracic RT and Durvalumab|1500mg every 4 weeks \[Q4W\] intravenous \[IV\], first dose within 3 days of RT initiation
214471855|NCT04003246|DRUG|Consolidative Durvalumab|1500mg every 4 weeks \[Q4W\] intravenous \[IV\] up to one year
214471856|NCT06805708|BEHAVIORAL|Sleep hygiene training programme|"A programme focusing on cognitive-behavioural counselling. The programme will be delivered in 12 sessions of 30 minutes each (intensive phase: 1 session per week for 3 weeks; maintenance phase: 1 session every 2 weeks). After each meeting, the research group members will provide a short-written report reflecting the main discussion topics, the degree of participation, and the group's position in the participatory action research cycle. The discussion topics will be:~1. Management of sleep hygiene in schoolchildren, families and teachers:~   * Surveys (quantitative approach)~  * Focus groups (qualitative approach)~  * The study will identify the health assets~2. Educational elements"
214471857|NCT06804967|DEVICE|virtual reality relaxation headset|No headset will be used
214471858|NCT06804772|OTHER|Investigational Facial Serum #3|Investigational Facial Serum #3 is a placebo comparator
214471859|NCT06804772|OTHER|Investigational Facial Serum #1|Investigational Facial Serum #1 is made with Activated Silk™ 27P-α.
214471860|NCT06804772|OTHER|Investigational Facial Serum #2|Investigational Facial Serum #2 is made with an active comparator.
214471861|NCT06805682|OTHER|Usual Care|Children will be followed using each CPS participating center's usual practices
214471862|NCT06577259|DRUG|BMS-986435|Specified dose on specified days
214471863|NCT01386138|BEHAVIORAL|Psycho-education|Receive RBT education and peer-support in a group format.
214471864|NCT01386138|BEHAVIORAL|Experimental|Receive RBT education and a pro-active counseling method
214471865|NCT06805812|DRUG|Palbociclib|Administered in combination with endocrine therapy
214844683|NCT00535080|DRUG|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
214471866|NCT06805812|DRUG|Ribociclib|Administered in combination with endocrine therapy
214471867|NCT06805812|DRUG|Abemaciclib|Administered in combination with endocrine therapy
214471868|NCT05453838|DIETARY_SUPPLEMENT|oral intake of one serving of the original and new product|1\) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
214906898|NCT01019343|PROCEDURE|Transcranial Sonography (TCS)|Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2-inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.
214471869|NCT06578117|DEVICE|Vision Training and Learning Task|"Participants will be seated at a computer, and will be shown a random-noise visual stimulus drifting in one of eight directions. Participants will be instructed to indicate the direction of motion they perceive using a Sony Access Controller or a computer keyboard. Sound cues during stimulus presentation will also be used to ensure participants are aware of stimulus onset during the training task.~After several repetitions of this visual training, a second set of visual cues will be presented to evaluate participant's learning of the program. Responses will be provided in the same manner by input from the controller or the keyboard."
214285165|NCT06668571|DRUG|Normal Saline|The subjects will receive 1:1 single IV normal saline/placebo (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
214285166|NCT04196842|DEVICE|Telemonitoring devices|Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
214285168|NCT07001527|DEVICE|Chlorhexidine|dressing impregnated
214285169|NCT07001527|DEVICE|Chlorhexidine|COmmon dressing
214285170|NCT07000565|OTHER|Eye Care with Artificial Tears|Every 2 hours, the artificial tear solution was gently applied to the designated eye for 5 days. The artificial tear product (REFRESH®) contains 5.6 mg of polyvinyl alcohol and 2.4 mg of povidone per mL and is used to maintain ocular surface moisture and reduce irritation.
214471870|NCT03914742|DRUG|PARP Inhibitor BGB-290|Given PO
214471871|NCT03914742|DRUG|Temozolomide|Given PO
214471872|NCT03914742|PROCEDURE|Therapeutic Conventional Surgery|resection surgery
214471873|NCT06336902|BIOLOGICAL|Balstilimab|Given IV
214471874|NCT06336902|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214471875|NCT06336902|BIOLOGICAL|Botensilimab|Given IV
214471876|NCT06336902|PROCEDURE|Computed Tomography|Undergo CT scan
214471877|NCT06336902|OTHER|Dietary Intervention|Undergo FMD
214471878|NCT06336902|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214471879|NCT06336902|DIETARY_SUPPLEMENT|Vitamin C|Given IV
214844684|NCT01503463|PROCEDURE|Home telemonitoring of patients with CHF|"Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified."
214844685|NCT02851719|OTHER|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
214844686|NCT02851719|OTHER|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
214285171|NCT07000565|OTHER|Eye Care with Normal Saline|Every 2 hours, the saline solution(Bio-Fleks brand) was gently applied to the designated eye for 5 days.
214844687|NCT03066895|DEVICE|BabyGentleStick|Experimental device.
214844688|NCT03066895|DEVICE|Standard Lancing Device|HMC standard of care.
214844689|NCT03028623|PROCEDURE|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
214844690|NCT03028623|PROCEDURE|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
214844691|NCT04181164|OTHER|Microindentation|Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
214844692|NCT04181164|OTHER|High resolution peripheral quantitative computed tomography (HRpQCT)|HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
214285172|NCT07000812|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants in the intervention arm receive 12 weekly sessions of individual CBT. Therapy includes exposure and response prevention, cognitive restructuring, psychoeducation, and relapse prevention strategies.
214285173|NCT07001904|OTHER|Enzyme-linked immunosorbent assay (ELISA)|The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum
214471880|NCT06627413|DRUG|Lumateperone Capsule|Lumateperone 42 mg capsule, oral administration
214471881|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E2 IM injection
214844693|NCT04181164|BIOLOGICAL|Biochemical analysis of different bone markers.|Measurement of different bone markers by biochemical analysis of blood samples.
214471882|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E3 IM injection
214471883|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X2 IM injection
214844694|NCT06678802|OTHER|Blood sampling|blood sampling from peripheral vein
214471884|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X5 IM injection
214471885|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
214471886|NCT06804070|OTHER|Botanical Moisturizer + Unscented Soap|"The intervention includes the use of 2 products:~1. A botanical moisturizer~2. An unscented bar of soap"
214844695|NCT02715232|DRUG|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
214844696|NCT02715232|DRUG|Lynestrenol|2-3 tablets/day, if menstruation still occurs
214844697|NCT02715232|DRUG|Cyproterone Acetate|25mg daily
214844698|NCT02715232|DRUG|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
214844699|NCT02715232|DRUG|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
214844700|NCT04079582|OTHER|Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
214844701|NCT04079582|OTHER|Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
214844702|NCT00761176|DEVICE|The Provant Therapy System|The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
214285174|NCT07001969|PROCEDURE|Massoud-Goel Technique and Theory|Percutaneous Trans-facet Fixation Massoud-Goel Technique and Theory for Treatment of Degenerative Spine
214285175|NCT07001969|PROCEDURE|Percutaneous Trans-facet Fixation for Treatment of Degenerative Spine|Percutaneous Trans-facet Fixation (Developmental of Dr Atul goel technique of transfacet fixation by open surgery using Magrel technique) Massoud-Goel Technique and Theory for Treatment of Degenerative Spine
214285176|NCT07001163|DIETARY_SUPPLEMENT|Probiotic|Probiotic sachets contained 1× 109 colony-forming unit of Bifidobacterium Animalis subsp.lactis BB-12), were given via orogastric tube twice daily.
214285177|NCT07001995|DRUG|limertinib|limertinib 80 mg
214285178|NCT07001995|DRUG|etoposide and carboplatin|etoposide 100 mg/m² IV D1-3 + carboplatin AUC 5-6 IV
214285179|NCT06676904|PROCEDURE|Higher Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 50 x 10\^9/L during postnatal days 1-7, and then for a platelet transfusion threshold of 35 x 10\^9/L at 8 or more postnatal days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
214285180|NCT06676904|PROCEDURE|Lower Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 25 x 10\^9/L during postnatal days 1-7, and then for a platelet transfusion threshold of 20 x 10\^9/L at 8 or more postnatal days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
214285181|NCT07002450|DIAGNOSTIC_TEST|Cardiac computed tomography angiography|Patients will undergo CCT according to the following protocol. A non-contrast enhanced prospective ECG-triggered image will be acquired followed by a contrast-enhanced prospective ECG-triggered image using a tri-phasic contrast protocol. Delayed CT images 60 seconds after the initial contrast-enhanced CT scan will be obtained. Cardiac CT image interpretation will be performed according to routine clinical practices in a pragmatic fashion. The LA will be assessed for filling defects and characterized based upon attenuation values. If LA thrombus cannot be excluded, filling defects will be assessed on the delay images. Increases in attenuation would be consistent with pseudo-thrombus from 'slow flow' and 'incomplete opacification'. Areas where attenuation does not change significantly (persistent filling defect) will be diagnosed as thrombus. If the CCT shows no LA thrombus then the ED physician will be able to perform electrical and/or chemical cardioversion at their discretion.
214285182|NCT07002450|OTHER|Standard of care management|"Patients in the standard of care arm may undergo any combination of the following management strategies in the emergency department (ED) at the discretion of their treating physician:~1\. Transesophageal echocardiogram (TEE) facilitated cardioversion; 2. Rate control; 3. Consultation with inpatient cardiac specialist for assessment/management and consideration of hospital admission; 4. cardioversion after 3 weeks of anticoagulation; and/or 5. Outpatient referral to cardiac specialist or general practitioner for further management."
214285183|NCT07000695|DRUG|Pelacarsen|Patients receive Pelacarsen
214285184|NCT07000643|RADIATION|Intensity-Modulated Proton Therapy (IMPT)|"This is the experimental arm intervention. Patients receive Intensity-Modulated Proton Therapy (IMPT) for primary nasopharyngeal carcinoma.~The subjects are patients with histologically confirmed, previously untreated, non-metastatic (M0) nasopharyngeal carcinoma.~Radiotherapy target volumes and doses: GTV (gross tumor volume of primary tumor and metastatic lymph nodes); CTV70Gy (GTVp + 0-5mm margin, GTVn + 0-3mm margin, reducible near organs at risk) at a dose of 69.6-70Gy; CTV50-54Gy (GTVp + 8-10mm margin + entire nasopharyngeal mucosa + adjacent high/intermediate risk structures and intermediate-risk subclinical lymph node regions) at a dose of 50-54Gy, delivered at 2Gy/(RBE) per fraction. The protocol notes that proton therapy does not use a PTV (Planning Target Volume).~The systemic therapy plan is formulated according to clinical guidelines."
214285185|NCT07000643|RADIATION|Intensity-Modulated Radiotherapy (IMRT)|"This is the control arm intervention. Patients receive Intensity-Modulated Radiotherapy (IMRT) for primary nasopharyngeal carcinoma; IMRT is one of the current standard and widely used treatment techniques.~The subjects are patients with histologically confirmed, previously untreated, non-metastatic (M0) nasopharyngeal carcinoma.~Radiotherapy target volumes and doses: GTV (gross tumor volume of primary tumor and metastatic lymph nodes); CTV70Gy (GTVp + 0-5mm margin, GTVn + 0-3mm margin); PTV70 (CTV70 + 3-5mm margin, reducible near organs at risk) at a dose of 70Gy; CTV50-54Gy (GTVp + 8-10mm margin + entire nasopharyngeal mucosa + adjacent high/intermediate risk structures and intermediate-risk subclinical lymph node regions); PTV50-54 (CTV50-54 + 3-5mm margin, reducible near organs at risk) at a dose of 50-54Gy, delivered at 2Gy/(RBE) per fraction.~The systemic therapy plan is formulated according to clinical guidelines."
214285186|NCT07000539|DIAGNOSTIC_TEST|Indocyanine Green Angiogram|Three different doses of indocyanin green will be compared (5 mg, 7.5 mg, and 10 mg). These doses are within the range of currently recommended doses by the International Society for Fluorescence Guided Surgery (ISFGS) for bariatric surgery.
214844703|NCT04035382|PROCEDURE|Labor induction|The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
214844704|NCT05091216|OTHER|Traditional Chinese Medicine mouthwash|The mouthwash used in this test is based on the records of past traditional Chinese medicine classics and the existing antibacterial experimental evidence. The selected medicinal materials are honeysuckle, scutellaria, peppermint, licorice, and rhizome.
214844705|NCT05091216|OTHER|Dilute 50 times of Traditional Chinese Medicine mouthwash|Dilute 50 times of traditional Chinese medicine mouthwash.
214844706|NCT05681416|DIAGNOSTIC_TEST|Panel sequencing, whole exome sequencing, whole genome sequencing|Besides the mutation positive men (group 2), all will receive multigene panel analysis in a patient care setting and if negative, whole exome sequencing (WES), whole genome sequencing and transcriptome analyses. In PCA-affected men (group 3), additional mutational analysis will be performed on formalin-fixed paraffin embedded (FFPE) - and fresh frozen (FF) tumor tissue from biobanked radical prostatectomy specimens using FFPE panel analysis (like TruSightOncology 500) or WES if FF samples are available.
214844707|NCT03398590|BEHAVIORAL|self-regulation theory-based mHealth behavior intervention|Participants will receive a self-regulation theory-based mHealth behavior intervention (5 biweekly group sessions, 60 minutes /session). An experienced Certified Diabetes Educator from the Joslin Diabetes Center and PI (Dr. Zheng) who has been trained using self-regulation for weight loss will co-facilitate group sessions. The intervention combines diet modification and increased physical activity with a weekly weight loss goal as well as focuses on improving participants' three typical self-regulation strategies - self-monitoring, self-evaluation and self-reinforcement. Intervention duration will last 2 months with subsequent 1-month follow.
214285187|NCT07002242|DRUG|Azvudine tablets(FNC) and Aluvia|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC+ Aluvia: FNC 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days. Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days; Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days."
214285188|NCT07002242|DRUG|Azvudine tablets(FNC) and Aluvia|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ Aluvia: FNC 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days. Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days; Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days."
214285189|NCT07002242|DRUG|Azvudine tablets(FNC) and Aluvia|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ Aluvia: FNC 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days. Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days."
214844708|NCT06429514|DIETARY_SUPPLEMENT|Ganoderma lucidum spore powder|One bag at a time, 2 times a day, 2g / bag
214844709|NCT06429514|OTHER|placebo|One bag at a time, 2 times a day, 2g / bag
214844710|NCT05530941|BEHAVIORAL|Online suicide prevention campaign|The online prevention campaign consists of two campaign videos, a website with information about suicide prevention and mental health tailored to men, and testimonials of men who struggled with their mental health.
214844711|NCT01836614|DRUG|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
214844712|NCT01418950|OTHER|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
214844713|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
214285190|NCT07002398|DRUG|VG801|Administered as specified in the single treatment arm. Study Cohort: Low dose, medium dose and high dose cohort
214844714|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
214844715|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
214844716|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
214844717|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
214844718|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
214844719|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
214844720|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
214844721|NCT03549455|BEHAVIORAL|Exposure Therapy and Self Distancing|Weeks 1 and 2 will be introductory sessions (background, rationale, motivational enhancement); Weeks 3 \& 4 will have Exposure therapy with Self-Distancing; Weeks 5 \& 6 will have Exposure therapy only; Weeks 7 \& 8 will have Exposure therapy with Self-Distancing;
214844722|NCT00109850|BIOLOGICAL|cetuximab|400mg/m\^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m\^2 maintenance dose, IV over 60 min, Days 8 \& 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
214844723|NCT00109850|DRUG|cisplatin|30mg/m\^2, bolus intravenous (IV), on Days 1 \& 8 of each cycle.
214844724|NCT00109850|DRUG|irinotecan hydrochloride|65mg/m\^2, intravenous (IV) over 30 min, on Days 1 \& 8 of each cycle.
214844725|NCT00109850|RADIATION|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
214844726|NCT01614184|DRUG|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
214844727|NCT00476593|DRUG|Diclofenac|"Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
214844728|NCT00476593|DRUG|Dexamethasone|"Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
214285191|NCT07001488|DRUG|Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days; RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
214285192|NCT07001488|DRUG|Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10consecutive days; FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days; RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
214285193|NCT07001488|DRUG|Azvudine tablets (FNC) and Rilpivirine Tablets (RPV)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days."
214285194|NCT07000825|DIETARY_SUPPLEMENT|Intervention with yerba mate extract or placebo|The standardized extract of yerba mate (Ilex paraguariensis) will be supplied by Sustentec. It is a dry extract of the plant's green, powdered leaves, obtained through aqueous extraction. The extract was obtained by infusing the dried leaves of the plant and the drying process was carried out using a spray-dryer (ratio 6/1 leaves/extract). The extract will be encapsulated containing 250 mg each. Administration Intervention group: 2,250 mg of standardized yerba mate extract will be administered in 9 capsules, 3 times a day, just before the main meals. This amount will provide approximately 980 mg of caffeoylquinic acids/day, which was defined based on the estimated usual intake of caffeoylquinic acids by individuals in a municipality in the southern region of the country, from traditional drinks made with yerba mate (chimarrão and tereré) (Gebara et al., 2017). Placebo group: 9 capsules containing maltodextrin will be administered 3 times a day, just before the main meals.
214285195|NCT07132957|DRUG|14C-labeled AL8326|Oral, About 60mg (200μCi) of 14C-labeled AL8326
214285196|NCT07132255|DEVICE|R-One assisted tele-PCI|Surgeons perform operations using R-One vascular interventional navigation control system from remote control center via 5G. robotic slave executes at procedure site.
214285197|NCT07132255|DEVICE|R-One assisted on-site PCI|Surgeons perform operations by controlling robot from local console .
214285198|NCT07132203|DEVICE|Laser interstitial thermal therapy|The LITT procedure was performed using the LS1 laser ablation system and SR1 stereotactic robotic system (Sinovation, Beijing, China). The ablation system was equipped with a 980-nm laser with a maximum of 15 W of power, a core silica fiber optic with a 1.8-mm diameter cooling catheter, and a cooling pump to make saline flow into and out through the catheter. The optic and catheter approaches were planned with the preoperative simulation software (Sinovation, Beijing, China) using the preoperative T1-weighted MRI scan, and passing through important cerebral vascular and functional zones was avoided。. The catheter was implanted by neurosurgeons under stereotactic guidance, and a laser probe was inserted through the catheter. After LITT, a T1-weighted intraoperative MRI scan was performed to confirm the effect of ablation. The ablation rate was calculated by another neurosurgeon who did not participate in the study.
214844729|NCT03430011|BIOLOGICAL|JCARH125|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).
214844730|NCT03430011|BIOLOGICAL|JCARH125 + anakinra|Participants will undergo leukapheresis to isolate PBMCs for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by two doses of anakinra administered subcutaneously and one dose of JCARH125 administered IV. Subjects receive anakinra for 5 consecutive days following JCARH125 infusion.
214844731|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot A|
214844732|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot B|
214844733|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot C|
214285199|NCT07132879|OTHER|No intervention - Prospective cohort study|No intervention - Prospective cohort study
214285200|NCT07132320|BIOLOGICAL|Pressure Ulcer Nursing AI Application Training|Clinical nurses receive training and guidance via an AI application designed for pressure ulcer nursing based on a clinical judgment model.
214285201|NCT07132320|BIOLOGICAL|Traditional Pressure Ulcer Nursing Education|Clinical nurses receive conventional pressure ulcer nursing education not involving the developed AI application.
214844734|NCT00489099|BIOLOGICAL|V232 Current Process Hepatitis B Vaccine|
214844735|NCT01228227|DRUG|ATORVASTATIN 80 mg|reload of Atorvastatin 80 mg before the procedure
214844736|NCT01228227|DRUG|ROSUVASTATIN 40 mg|reload of rosuvastatin 40 mg before the procedure
214844737|NCT03330860|OTHER|Twelve clips regarding maternal and neonatal health topics|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
214844738|NCT03330860|OTHER|Control Clip|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
214844739|NCT06440863|PROCEDURE|Total Knee Arthroplasty|Patients undergoing total knee arthroplasty
214844740|NCT06440863|PROCEDURE|Total Hip arthroplasty|Patients undergoing total hip arthroplasty
214844741|NCT06678750|DEVICE|TKA using computer navigation|TKA using Exactech GPS Newton Knee protocol
214844742|NCT06678750|PROCEDURE|TKA|TKA using manual instrumentation
214285202|NCT07132502|OTHER|ctDNA MRD|"Definition and Essence: ctDNA MRD involves detecting DNA fragments released by tumor cells into the bloodstream through highly sensitive techniques to determine the status of minimal residual disease in cancer patients.~Detection Methods: Technologies such as digital PCR and next-generation sequencing (NGS) are employed to achieve precise detection of low-frequency ctDNA mutations.~Clinical Significance: It is utilized for evaluating the prognosis of cancer patients and providing crucial evidence for the formulation of personalized treatment plans."
214285203|NCT07131215|OTHER|Home-based multimodal exercise|Mobile Applications
214285204|NCT07131215|OTHER|Supervised multimodal exercise program|In laboratory
214285205|NCT07131215|OTHER|Education|Menopause education
214844743|NCT05647616|OTHER|Strengthening exercises|Participants in group A will be required to complete 12 sessions in 4 to 6 weeks. Resistance-Bands will be used to do ankle plantar flexion and eversion (3 sets of 10 repetitions). Participants will have to be seated on the floor with the knee extended and instructed to perform the movement at the ankle joint without allowing extraneous movement at hip and knee. The resistance band will be doubled and securely attached to the base of a table. The training resistance will be determined by calculating 70% of the resting length of the resistance band and adding this distance to the resting length of the resistance band. Using this calculated distance, the examiner will place a mark to which the resistance band will be stretched during exercise performance on the floor. Each week a study investigator will track each participant's completion. Participants will be instructed to move through their entire range of motion for the direction of each exercise.
214285206|NCT07131618|OTHER|cryocompression|"Cryocompression induces vasoconstriction in the applied area, thereby reducing blood flow. As a result, the delivery of the chemotherapeutic agent to peripheral nerves is limited, and it is aimed to protect nerve tissue from toxic effects. At the same time, low temperature slows down nerve conduction and cellular metabolism, helping to prevent damage to nerve cells.~30 minutes after the start of the paclitaxel infusion, cryocompression will be applied using ice gel gloves for the hands and socks for the feet, lasting 30 minutes. After paclitaxel ends, carboplatin will be infused intravenously in 250 cc isotonic solution over 1 hour. Cryocompression will again be applied 30 minutes after the start of the carboplatin infusion using the same method, for 30 minutes. This intervention will be performed weekly during each cycle of the 6-week carboplatin/paclitaxel protocol, for a total of 60 minutes per session."
214285207|NCT07002515|OTHER|Health education|Randomized controlled studies that explain behavior change as a process through health education aimed at promoting healthy behaviors in individuals with digital game addiction.
214285208|NCT07002021|COMBINATION_PRODUCT|Health education|The intervention group will receive a health education intervention focused on dengue prevention and campus environmental governance, while the control group will continue with their standard school health education without any additional intervention. An health education including the knowledge of dengue fever, harm of mosquitoes, and measures of mosquito control, will be developed and reviewed by an expert group. The campus environmental governance includes organizing campus environmental cleaning once a week, focusing on removing mosquito breeding places such as water containers.
214285209|NCT07131111|RADIATION|CT aortography|"Performed before and after stenting using a multidetector CT scanner (device model and parameters to be specified).~Analysis will include:~* Evaluation of aortic arch geometry (normal / gothic / crenel).~* Measurement of residual stenosis at the site of coarctation.~* Aortic diameter measurements at predefined anatomical levels:~Ascending aorta (AA), Proximal descending thoracic aorta (PDA), At the level of the diaphragm (DA), Abdominal aorta (AbAo).~\- Aortic tortuosity. All CT data will be interpreted by two independent observers blinded to clinical outcomes"
214285210|NCT07131111|RADIATION|CMR|"CMR examinations will be performed using a commercially available 1.5 Tesla whole-body scanner (Ingenia, Philips Healthcare, release 4.1.3.0). In pediatric or uncooperative patients, free-breathing sequences were used when breath-holding was not feasible.~Brachial blood pressure was measured in the right arm in the supine position immediately before image acquisition using automated oscillometric devices.~Cine steady-state free precession (SSFP) sequences were obtained in multiple views including the short axis of the ascending aorta (AAO) and descending aorta (DAO), as well as the aortic root to evaluate aortic valve morphology (bicuspid vs tricuspid).~Left ventricular (LV) and left atrial (LA) functional parameters were assessed by standard volumetric analysis. The following CMR-derived parameters were collected:~Left ventricular ejection fraction (LVEF) Left ventricular strain Left ventricular mass index (LVMI) Left atrial volume Left atrial strain LV and LA strain were analyzed usi"
214285211|NCT07132671|RADIATION|Brachytherapy and MR-Guided SBRT|HDR Brachytherapy followed by MR-guided SBRT
214285212|NCT03686657|DRUG|Metformin|1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks
214285213|NCT03686657|DRUG|Val, Cel and Met XR Low|500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
214285214|NCT03686657|DRUG|Val, Cel and Met XR High|1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
214285215|NCT04600921|DRUG|Ertugliflozin 5 mg|The subject will receive Ertugliflozin 5mg orally once daily for 52 weeks.
214285216|NCT04600921|DRUG|Placebo 5mg|The subject will receive Placebo 5mg orally daily for 52 weeks.
214285217|NCT02429557|OTHER|Abdominal compression|Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
214285218|NCT02429557|OTHER|Sham abdominal compression|Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
214285219|NCT02429557|DRUG|Placebo pill|Placebo pill given 1 hour before the second heat up tilt
214285220|NCT02429557|DRUG|midodrine|Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
214285221|NCT06607484|DRUG|SR-878|Intravenous infusion
214285222|NCT06607484|DRUG|Placebo|Intravenous infusion
214285223|NCT06871410|DRUG|Autologous Anti-CD83 CAR T-cells|Given IV
214844744|NCT04126343|DRUG|Padsevonil|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period"
214844745|NCT04126343|DRUG|Moxifloxacin|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive moxifloxacin once during the Treatment Period"
214844746|NCT04126343|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding"
214844747|NCT02389699|RADIATION|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
214844748|NCT02389699|RADIATION|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
214844749|NCT00084799|BIOLOGICAL|monoclonal antibody hu3S193|
214844750|NCT01885351|BEHAVIORAL|MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
214844751|NCT01885351|BEHAVIORAL|MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
214844752|NCT01672047|DRUG|Vitamin D2|25（OH）D level \<12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， \>116.75nmol/L stopped.
214844753|NCT00736398|PROCEDURE|Spinal fusion|Spinal fusion
214844754|NCT02890225|PROCEDURE|3 days after|in 3 days after RIRS.
214844755|NCT02890225|PROCEDURE|10days after|in10 days after RIRS.
214285224|NCT06871410|PROCEDURE|Biospecimen Collection|Undergo bone marrow aspiration blood sample collection
214844756|NCT02890225|PROCEDURE|EPVL performed in30days after RIRS|Patients in Group C undergo EPVL in630days after RIRS.
214844757|NCT05352282|PROCEDURE|Serratus Anterior Plane Block|SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.
214285225|NCT06871410|PROCEDURE|Chest Radiography|Undergo chest x-ray
214285226|NCT06871410|PROCEDURE|Computed Tomography|Undergo CT
214285227|NCT06871410|DRUG|Cyclophosphamide|Given IV
214285228|NCT06871410|PROCEDURE|Echocardiography|Undergo ECHO
214285229|NCT06871410|DRUG|Fludarabine Phosphate|Given IV
214285230|NCT06871410|DRUG|Hydroxyurea|Given hydroxyurea
214844758|NCT05352282|PROCEDURE|Lumbar Intrathecal Fentanyl Injection|Patients will receive 25 microgram intracthecal fentanyl immediately preoperative.
214844759|NCT06525857|OTHER|LTOT|Patients with newly prescribed LTOT will be monitored for physiological changes
214844760|NCT03617120|DEVICE|Ergonomic Brace vs hard brace|"Visit 1:~1. Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~2. Pressure measurement of participant wearing their hard brace~Visit 2:~1. Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~2. 3D body scanning (before wearing the Ergonomic Brace)~3. Fitting of the Ergonomic Brace~4. Pressure measurement of participant wearing the Ergonomic Brace (instant)~5. Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~6. 3D body scanning (after wearing the Ergonomic Brace for 2 hours)~7. Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~1. Standing in-brace radiograph of the Ergonomic Brace~2. Doctor consultation"
214285231|NCT06871410|PROCEDURE|Leukapheresis|Undergo leukapheresis
214285232|NCT06871410|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214285233|NCT06871410|PROCEDURE|Positron Emission Tomography|Undergo PET
214285234|NCT06871410|OTHER|Questionnaire Administration|Ancillary studies
214285235|NCT06684743|BIOLOGICAL|RSV prefusion F protein-based vaccine|For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used
214285236|NCT06626334|DEVICE|Bright Blue Light|Bright blue light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#132, Medium Blue) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
214285237|NCT06626334|DEVICE|Bright Full-Spectrum (White) Light|Bright full-spectrum (white) light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#211 0.9 ND) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
214844761|NCT04039048|DEVICE|cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
214844762|NCT04039048|DEVICE|Sham cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
214844763|NCT04039048|OTHER|Balance training|Balance training will be performed through the Biodex Balance System for 20 minutes.
214844764|NCT01571726|DRUG|Fluciclatide|7mCi
214844765|NCT03712124|DRUG|CNSA-001|CNSA-001 Powder for Suspension
214844766|NCT03712124|DRUG|Placebo|Placebo Suspension
214844767|NCT01332721|DRUG|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
214844768|NCT00533806|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
214844769|NCT00533806|BEHAVIORAL|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
214844770|NCT02084927|BIOLOGICAL|HBOT|HBOT of 2 ATA for 90 minutes, for 60 treatments
214844771|NCT06388031|DRUG|Immune checkpoint inhibitor|"Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg."
214844772|NCT04314843|DRUG|Cyclophosphamide|Administered according to package insert
214844773|NCT04314843|DRUG|Fludarabine|Administered according to package insert
214844774|NCT04314843|BIOLOGICAL|Lenzilumab|Administered as an IV infusion
214844775|NCT04314843|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously.
214285238|NCT06626334|DEVICE|Usual Ambient Light|"Across all arms, the usual ambient light in the inpatient room will not be modified.~For the Bright Blue Light and Bright Full-Spectrum (White) Light arms, light will be added to the environment using a Day-Light Classic Plus Light Therapy Lamp as specified in the corresponding intervention descriptions.~For the Usual Ambient Light arm, a Day-Light Classic Plus Light Therapy Lamp mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended) will be positioned at a 12-14 inches from eye level with the on/off switch in the off position. The lamp will be positioned in this manner for 4 hours daily during the morning/early afternoon hours, for up to 3 days."
214285239|NCT06326463|DRUG|Fludarabine|40mg/m2, Day -4, -3 and -2
214285240|NCT06326463|DRUG|Cyclophosphamide|"Day -3 and Day-2~REST DAY, -1"
214844776|NCT04409587|DRUG|Aspart|"A population of well controlled patients with type 1 diabetes who are experienced in the use of both Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitor (CGM) was chosen in order to assess the effect of the change in glycemic profile using two different methods of basal insulin delivery. Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses.~Replacing basal insulin delivery by CSII with a single daily injection of degludec will add minimal, if any, treatment burden which will be offset by potential therapeutic benefits. These benefits include the potential for reduced glycemic variability and the elimination of the risk of hyperglycemia and DKA with basal insulin interruption which can occur with infusion set occlusion or disgorging inherent to Continuous Subcutaneous Insulin Infusion."
214844777|NCT02335957|RADIATION|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
214844778|NCT03110016|DEVICE|Smartphone Application|The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
214844779|NCT02390310|DEVICE|Shang Ring|Comparison of healing times at 7 day and more than 7 days after circumcision.
214844780|NCT02390310|DRUG|injectable anesthesia (lidocaine 1%)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
214844781|NCT02390310|DRUG|topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
214844782|NCT00055718|DIETARY_SUPPLEMENT|silymarin|
214844783|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
214844784|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
214285241|NCT06326463|DRUG|CD70-CAR T cell infusion (Autologous)|Day 0 or +1
214844785|NCT05595122|DEVICE|EUS-CDS|EUS-CDS with FCSEMS through LAMS
214285242|NCT06326463|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide
214285243|NCT06630455|DIETARY_SUPPLEMENT|Meu-cinn|Meu-cinn 250 mg/day for 8 weeks
214285244|NCT06630455|DIETARY_SUPPLEMENT|Placebo|Placebo 250 mg/day for 8 weeks
214844786|NCT04005963|DIAGNOSTIC_TEST|13N-NH3 PET cardiac blood flow perfusion rest and load imaging|"Immediately after the bedside injection of 13N-NH3 370 MBq, dynamic 2D collection of heart images 10 min, scanning 1 bed; , a total of 6 min), 3min bedside injection 13N?NH3 370-540 MBq immediately after the dynamic 2D collection of heart image 10 min. Both rest and load imaging are corrected for CT attenuation.~Image reconstruction is carried out by the method of maximum expectation of an ordered subset, the dynamic image is divided into the early phase of the first 2 min and the late phase of the last 8 min, the captured image is replayed (VIP replay) of the volume image protocol and the gated data is reconstructed."
214844787|NCT00551616|DRUG|CDB-2914|Single dose
214844788|NCT00551616|DRUG|Levonorgestrel|Single dose
214844789|NCT04282655|OTHER|Treatment Guardian Milk Warmer (Medela TM)|Infants were randomized to receive prepared syringes of breast milk via the continuous milk warmer (treatment arm)
214844790|NCT04282655|OTHER|Control|Standard warming procedure of breast milk in syringe prior to feeding.
214844791|NCT04825002|DIAGNOSTIC_TEST|Urinary multimarker sensor|We will develop a urinary multimarker sensor, able to measure trace amounts of biomarkers from naturally voided urine.
214844792|NCT03605823|DEVICE|Express Mini shunt|Implantation of Express Mini shunt through pars plana in vitrectomized eyes
214844793|NCT00578838|OTHER|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
214844794|NCT00578838|OTHER|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
214844795|NCT00280969|DRUG|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
214844796|NCT00280969|DRUG|efavirenz|Patients are treated with efavirenz 300mg along with Epzicom.
214285245|NCT07034768|DRUG|EDG-7500|Single dose of EDG-7500
214285246|NCT07131579|DRUG|Normal Saline|equal volume of normal saline
214285247|NCT07131579|DRUG|Dexmedetomidine|0.5 mcg/kg of dexmedetomidine
214285248|NCT07132866|BEHAVIORAL|ADAPT|The ADAPT intervention consists of three group sessions (of 75-90 min), with 6-8 8th grade students in each group, administered over three consecutive weeks, plus one interactive parent component (of 45 min) administered during the three weeks (separate from the student sessions).
214285249|NCT07132437|DRUG|ZKY001 EYE DROPS|"On the 1st postoperative day (Day1), ZKY001 eye drops were dropped into the experimental eyes (the operative eyes were taken as the experimental eyes). ZKY001 eye drops were given at 8:00 am ±1h from Day1 to Day5. 4 times a day, 1 drop each time, recommended interval of 4 to 6 hours.~Day6 was administered at 8:00 am ±1h, and ZKY001 eye drops were dropped into the test eye (the surgical eye was taken as the test eye). Day6 was given only once, 1 drop each time."
214285250|NCT07131345|DRUG|iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy|"Novel Bispecific Checkpoint Inhibition:~QL1706(iparomlimab and Tuvonralimab) was generated by using MabPair, a new technological platform that enables the production of two antibodies close to their natural forms from a single host cell line and is manufactured as one product. QL1706 contains a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 that were produced together in a fixed ratio. Each antibody was individually optimized to achieve desirable target coverage and antibody effector functions.~Chemotherapy for first-line treatment (pemetrexed plus cisplatin or carboplatin )~Chemotherapy for second-line treatment (pemetrexed, gemcitabine or vinorelbine)"
214285251|NCT07132307|DEVICE|Mandibular advancement device (MAD)|The intervention in this study involves fitting and using a mandibular advancement device (MAD), specifically the ProSomnus Sleep Device, to treat moderate to severe obstructive sleep apnea (OSA) in patients who are intolerant to CPAP and have failed hypoglossal nerve stimulation (HGNS) therapy.
214285252|NCT05846945|OTHER|Threshold inspiratory muscle trainer device|The threshold inspiratory muscle trainer (IMT) device offers resistance to respiration through the spring-loaded valve.
214285253|NCT05846945|OTHER|Adjusting mechanical ventilator trigger sensitivity|modifying the mechanical ventilator trigger sensitivity so that patients can only initiate inspiratory flow by producing more negative intrathoracic pressure
214844797|NCT04224194|COMBINATION_PRODUCT|Adalimumab|Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.
214844798|NCT06595004|DRUG|HCP1004|Test Drug
214844799|NCT06595004|DRUG|RLD2401|Reference drug
214285254|NCT05846945|OTHER|Chest physiotherapy|Conventional chest physiotherapy
214844800|NCT00876720|DEVICE|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
214844801|NCT00876720|DEVICE|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
214844802|NCT05390125|OTHER|A team, proficiency based progression, simulation training programme|The training programme will consist of two components (i) a short online training course including video examples of high performing teams and also poor practice (ii) a ward-based team huddle simulation training and assessment programme. The design and shape of the training and assessment will be based on the development of robust metrics. The design of the metrics and programme will centre around use in the acute hospital setting but will be readily adaptable to the obstetric, paediatric setting. The process of validating the metrics and building the online and simulation course involves the review of videotapes of safety huddle performance.
214844803|NCT00170703|DEVICE|Cortical Electrical Stimulation|
214844804|NCT02587806|BIOLOGICAL|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
214844805|NCT02587806|OTHER|Liberation therapy|
214844806|NCT04881513|DIAGNOSTIC_TEST|Narrow Band Imaging|Testing the taste buds structure (blood vessels morphology- classified to 5 types) and the number of taste buds per 20mm2, by Narrow Band Imaging technique before and after the operation (one and six months)
214285255|NCT06711484|OTHER|Speak up traning program|The intervention includes the training program to be applied to the experimental group. The aims and objectives of the training program, the training content and modules were prepared by the researcher in line with the needs analysis. The training program consists of four modules: Communication, Speaking UP, Patient Safety and Medical Error. Before the training program starts, the training booklet will be distributed to the experimental group participants. In the training, teaching techniques such as plain narration, question and answer, brainstorming, case study, case discussion, station technique, six thinking hats technique, video-based error scenario activity etc. will be used. The video activity to be used in the speak up session of the training program was created by recording the correct and incorrect scenarios of three patient safety errors by experienced actors.
214285256|NCT06704594|DRUG|sertraline 50 mg daily|The intervention will be in the form of an oral pill, taken daily, from the day of positive urine ovulation test result until the day of menses onset.
214285257|NCT06704594|DRUG|Placebo Oral Tablet|The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive urine ovulation test result until the day of menses onset.
214285258|NCT07040787|DRUG|HRS-5965 Capsules|Oral HRS-5965 capsules.
214285259|NCT07040787|DRUG|Clopidogrel|Oral clopidogrel.
214285260|NCT07040787|DRUG|Clarithromycin|Oral clarithromycin.
214285261|NCT06706414|DRUG|Denosumab (Prolia)|Subcutaneous injection with 60 mg Denosumab once
214285262|NCT06706414|DRUG|Letrozole (Aromatase Inhibitors)|Letrozole oral tablet 2.5 mg once daily
214285263|NCT07037758|DRUG|Tarlatamab|Administered as an IV infusion.
214285264|NCT07037758|DRUG|AB248|Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.
214285265|NCT07035665|DRUG|HRS-5965 Capsules|Oral doses of HRS-5965 capsules at fasted and fed conditions.
214285266|NCT06723821|OTHER|Neuromodulation group|During the 12 sessions of which the treatment consists in applying 60 minutes of microcurrent in low intensity.
214285267|NCT06723821|OTHER|Neuromodulation sham group|During the 12 sessions of which the treatment consists in applying 60 minutes of sham microcurrent in low intensity.
214285268|NCT06733285|DRUG|Sensodyne Rapid Relief|Toothpaste containing 0.454 % weight/weight (w/w) SnF2 (1100 parts per million \[ppm\] fluoride).
214844807|NCT04881513|DIAGNOSTIC_TEST|Tongue sensitivity testing|testing the tongue sensitivity change prior to surgery and after (1 and 6 months) the surgery with two point discrimination test in mm.
214844808|NCT04881513|OTHER|Qualitiy of life|Testing the patients quality of life before and after (one and six months) the stapes surgery by SF 36 questionnaire
214844809|NCT04881513|DIAGNOSTIC_TEST|Threshold change|Measuring the intraoperative chorda tympani stimulation threshold change at the beginning and at the end of the procedure- surgery
214844810|NCT04881513|DIAGNOSTIC_TEST|Taste|Taste is measured by applying taste strips (sweet, sour, salty, bitter) in 4 concentrations prior to, 1 and 6 months after surgery.
214844811|NCT00404625|BEHAVIORAL|Risk factors for infections due to ESBL+ Enterobacteriaceae|
214285269|NCT06733285|DRUG|Colgate Cavity Protection|A regular fluoride toothpaste containing 1000 ppm fluoride.
214285270|NCT06792136|DRUG|ONO-1110|ONO-1110 tablets once a day
214285271|NCT06792136|DRUG|Placebo|Placebo tablets once daily
214285272|NCT07061912|DEVICE|NSTI® HIV Self-Test|Each participant will be provided with the INSTI® HIV Self-Test(s) and asked to conduct self testing, unobserved. The participant will record their interpretation of the results. Subjects will perform the test without intervention or observation from the operator. The operator will then enter the room and also interpret the subject's self-test results then perform the comparator test. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing
214285273|NCT07070518|DRUG|GV20-0251|Part A: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks Part B: GV20-0251 preliminary RP2D administered by IV infusion once every 3 weeks
214285274|NCT05601453|PROCEDURE|Elective redo transcatheter aortic valve implantation (redo-TAVI)|Elective redo-TAVI procedure with the intention to treat the patient with a SAPIEN family valve implantation (currently the only registered medical devices for redo-TAVI use)
214285275|NCT06816459|OTHER|Cigarette smell test|Undergo cigarette smell test of 16 cigarettes in vials, then rate the overall smell on a 5 pt scale (not at all, a little noticeable, noticeable, clearly/very noticeable , do not know what this is).
214285276|NCT06816459|OTHER|Cigarette Taste Test|Participants will be present 3 vials , each containing a cigarette and sample in order specified on label, then complete a coolness measure on a 0-100 visual analog scale.
214285277|NCT06816459|OTHER|Study questionnaires|Sensory questionnaires will be administered using a web based application
214285278|NCT06807489|DEVICE|Digi-physical treatment tool|A digital treatment tool named Evira will be used to provide the treatment.
214285279|NCT06803823|DRUG|ONO-2020|ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily.
214285280|NCT06803823|DRUG|Placebo|Two ONO-2020 placebo tablets will be orally administered once daily
214285281|NCT07132996|DIAGNOSTIC_TEST|POCUS-based Splenic Volume Measurement|Splenic volume was measured at baseline and at 72 hours using the Butterfly iQ+ handheld ultrasound (Butterfly Network, Inc.) in abdominal preset mode. Certified POCUS operators obtained spleen length, width, and depth in standard orthogonal planes. Volumes were calculated using the prolate ellipsoid formula (length × width × depth × 0.523), a validated method in ultrasound volumetric studies. ΔSpleen was defined as the 72-hour value minus the baseline value.
214844812|NCT00404625|BEHAVIORAL|Risk factors for inadequate initial antimicrobial therapy|
214844813|NCT00404625|BEHAVIORAL|Overall and 30-day mortality in bad first antibiotic therapy|
214844814|NCT04326933|DRUG|Tyrosine kinase Inhibitors (Imatinib & Nilotinib)|Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day \& Nilotinib in adose of 600mg/day)
214844815|NCT04011098|DRUG|Epidural Fentanyl Bolus|Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
214844816|NCT04011098|DRUG|Standard Epidural Group|The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
214844817|NCT04621045|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
214844818|NCT04621045|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
214471887|NCT06805227|OTHER|Kinesiology Tape Application|"Application Area: Applied specifically to the dominant leg, targeting the rectus femoris, vastus medialis, and vastus lateralis muscles.~Tension Level: Applied with a standardized 50% tension. Duration: The tape was kept in place continuously for 30 days. Color: A blue-colored kinesiology tape was used to standardize the intervention and eliminate potential psychological effects of tape color.~Technique: Applied by a licensed physical therapist with expertise in kinesiology taping techniques, certified by the Saudi Commission for Health Specialties."
214844819|NCT04031560|BEHAVIORAL|Integrative treatment|The experimental group (62 patients) will take part on the integrative group program consisting of 12-sessions, 90 minutes each, once a week (4 focused on psychoeducation, 1 directed to the family relatives, 3 on mindfulness and 4 on functional remediation)
214844820|NCT02248116|DRUG|Talsaclidine|
214844821|NCT03437330|DRUG|Empagliflozin (Jardiance®)|Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)
214844822|NCT03437330|DRUG|Insulin Glargine (Lantus®)|"insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L~If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)"
214844823|NCT04608682|DRUG|Sugammadex|The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
214844824|NCT04608682|DRUG|Saline|The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
214844825|NCT01304979|PROCEDURE|Acupuncture therapies|Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
214844826|NCT01304979|PROCEDURE|Control|Indirect therapies that mimic direct therapy intervention
214844827|NCT02771028|BEHAVIORAL|Emotional Freedom Techniques|
214479466|NCT06861374|DRUG|Bivalirudin|"For rescued PCI, do not recommend to include patient who's ACT is more than 350s.~If fibrinolysis is successful, monitor ACT and wait till it's lower than 350s before randomization.~Monitor ACT before angiography, (1) if ACT\<180, bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI; (2) if 180s\<ACT\<225s, bivalirudin 0.5mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI; (3) if ACT\>225s, bivalirudin intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. (4) ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s, intravenous injection of 0.3 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds."
214844828|NCT00311220|DRUG|tuberculin for skin test|
214844829|NCT04736394|DRUG|APL-1202|APL-1202 single-agent oral treatment
214844830|NCT04736394|DRUG|Epirubicin Hydrochloride|Epirubicin hydrochloride
214844831|NCT03559725|OTHER|VLN menthol cigarettes (A)|0.4mg nicotine / g tobacco king size filter menthol cigarette
214844832|NCT03559725|OTHER|Usual Brand Menthol Cigarettes (B)|Usual brand king size menthol cigarettes
214844833|NCT03559725|DRUG|Nicotine gum (C)|4 mg nicotine gum
214844834|NCT04196348|PROCEDURE|Short BPL RYGB|Alimentary limb (AL) with 120 cm and BPL with 100 cm.
214844835|NCT04196348|PROCEDURE|Long BPL RYGB|AL with 120 cm and BPL with 200 cm.
214844836|NCT06235268|OTHER|Active systemic or non-systemic treatment (palliative or observation procedure)|The study includes medical visits and clinical-radiological re-evaluations according to clinical practice. The clinician will establish the number of visits necessary for each patient according to the needs encountered and depending on the treatment chosen.
214844837|NCT05434351|OTHER|vaginal dehydroepiandrosterone|the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated
214844838|NCT00005087|BIOLOGICAL|filgrastim|
214844839|NCT00005087|DRUG|cisplatin|
214844840|NCT00005087|DRUG|paclitaxel|
214844841|NCT00005087|PROCEDURE|conventional surgery|
214844842|NCT00005087|RADIATION|radiation therapy|
214844843|NCT00569777|DEVICE|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
214844844|NCT00569777|DEVICE|Placebo Lens|contact lens without drug
214844845|NCT04830241|DRUG|Antidepressant|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
214844846|NCT00384124|DRUG|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
214844847|NCT00480649|DRUG|Salmeterol/ fluticasone propionate|2 active arms (parellel group)
214285282|NCT07131436|OTHER|Horse therapy|Participating children received horseback riding and riding training twice a week for 30 minutes over an eight-week period. The training included developing body and object use skills, relationship building skills, language skills, social and self-care skills, and sensory skills. These included mounting and dismounting a horse; sitting correctly; holding and using the reins; bustling movements on the horse, forward and backward, sideways, and reaching with the hands; naming printed pictures; reading numbers; throwing objects at targets with the right and left hands; developing a dialogue with the trainer; standing up with and without stepping on the stirrups; sitting down and standing; reaching forward and backward and lying down on the horse; petting the horse with one's hands; trying to touch the horse's front legs with the right and left hands; and holding the horse's mane. At the end of the training, the parents of the participating children completed the Autism Behavior Checklist.
214285283|NCT07131722|DRUG|Trineumin|"Trineumin(Code name: PRG-N-01) is administered orally once daily. The study includes six dose levels.~Dose escalation decisions are based on observed DLTs."
214285284|NCT07131722|DRUG|Trineumin|Trineumin(Code name: PRG-N-01) is administered orally once daily at the lower dose selected from Phase 1 results.
214471888|NCT06802900|PROCEDURE|Clinical Outcomes and Surgical Insights from Nerve-Sparing Hysterectomy with Uterine Skeletonization for Deep Infiltrative Endometriosis|In this retrospective study, the patents whom underwent nerve sparing modified radical hysterectomy for deeply infiltrating endometriosis with uterine skeletonization technique will be reviewed. The uterine skeletonization technique was developed by the princible investigator (BK) for DIE modified radical hsyterectomy and performed systematically in Basaksehir Cam ve Sakura City Hospital. The detailed surgical steps, surgical data such as operation duration, surgical type (e.g., hysterectomy + salpingo-oophorectomy, excision of parametrial, rectovaginal, or vaginal nodules, and bowel resections), and intraoperative complications (organ injuries, blood transfusions, conversion to open surgery) will be recorded. Early and late postoperative complications (fever, deep vein thrombosis, sepsis, pelvic abscess, genitourinary fistulas, anastomotic leaks, reoperation, vaginal cuff bleeding or abscess, and bladder dysfunction) will also be evaluated.
214471889|NCT06806072|OTHER|Balneotherapy|The intervention consists in 3 weekly sessions of balneotherapy during 4 weeks.
214471890|NCT06572397|DRUG|H-1337 1.0%|ophthalmic solution
214471891|NCT06805292|OTHER|Acacia catechu|local delivery of acacia catechu gel in patient with chronic periodontitis stage 2
214471892|NCT06805292|OTHER|Low Level Laser Therapy|low-level laser as an adjunctive therapy in patient with chronic periodontitis stage 2
214471893|NCT06805292|OTHER|phase 1 therapy chronic periodontitis|patient with chronic periodontitis stage 2 will go for phase one therapy only
214471894|NCT06805292|OTHER|local drug delivary acacia +LLL|pateient with chronic periodontitis treated with LLL +acacia catehu gel
214471895|NCT06804330|PROCEDURE|root canal treatment and intracanal medicament|Root canal biomechanical preparation followed by intracanal placement of intracanal medicament according to the arm
214471896|NCT06804148|DEVICE|Myval Transcatheter Heart Valve|The Myval TAVR bioprothesis is a balloon-expandable THV developed by Meril Lifesciences, which has novel operator friendly design features to improve deliverability and aid precise deployment.
214471897|NCT02951091|OTHER|biomarker screening|immunohistochemistry and in situ hybridization
214471898|NCT06425536|OTHER|Home use|Home use twice a day
214471899|NCT04920149|DRUG|Mesalamine|The IMP will be supplied as sachets with slow-releasing granules.
214471900|NCT04920149|DRUG|Placebo|The IMP will be supplied as sachets with slow-releasing granules.
214471901|NCT06804798|DEVICE|Latex metal alloy coated catheter|Metal alloy works as an antiseptic whereby preventing the attachment of biofilm to the catheter lining.
214471902|NCT06804798|DEVICE|conventional latex urinary catheter|Latex catheters prove to be soft, flexible, inexpensive and thermo-sensitive towards body temperature. However, there is a risk of developing CAUTI as bacteria are more susceptible to adhere to latex.
214471903|NCT05317975|BEHAVIORAL|Add-on telerehabilitation and home-based rehabilitation|"1. 12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.~2. Add-on telerehabilitation for instruction and supervision of exercise training"
214471904|NCT05317975|BEHAVIORAL|Home-based rehabilitation alone|12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.
214471905|NCT05300035|DRUG|Recombinant human monoclonal antibody (bNAbs)|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
214471906|NCT05300035|DRUG|Placebo|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
214471907|NCT03866967|BIOLOGICAL|AK105|intravenous (IV) infusion
214471910|NCT06068283|BEHAVIORAL|LOTUS mHealth Intervention Group|A mobile, WebApp-based intervention comprised of tips for HIV prevention, a community wall for peer interaction and support, HIV prevention monitoring and reminders, guided discussions with a health care professional, a resource database, and a personalized profile. Intervention components are designed to promote HIV prevention service use, reduce stigma and improve social support, coping strategies, and positive affect.
214471911|NCT06068283|BEHAVIORAL|LOTUS Control Group|Access to an information-only website with content on HIV transmission, PrEP, harm reduction, and resources for women.
214844848|NCT00709306|DEVICE|UV-Detect Photos|UV-Detect Photos
214285285|NCT07131722|DRUG|Trineumin|Trineumin(Code name: PRG-N-01) is administered orally once daily at the higher dose selected from Phase 1 results.
214285286|NCT07131566|PROCEDURE|Sentinel Node detection and Biopsy|Fine Needle aspiration from sentinel Lymph Nodes
214285287|NCT07132086|DRUG|Daridorexant 50 mg orally, once daily at bedtime, administered as monotherapy or add-on therapy for chronic insomnia, in a real-world, observational, prospective clinical setting|Daridorexant 50 mg is administered once daily at bedtime, either as monotherapy or as add-on therapy in patients with chronic insomnia. The intervention is evaluated in a naturalistic, real-world setting over a 3-month observational period. Both subjective (questionnaires, sleep diary) and objective (actigraphy) sleep parameters are collected at baseline, 1 month, and 3 months. Actigraphy is used to assess total sleep time, sleep efficiency, wake after sleep onset, and circadian rhythm parameters. Sleep misperception is calculated as the discrepancy between subjective and objective sleep metrics. The study also explores potential predictors of treatment response such as age, sex, BMI, insomnia duration, and comorbid sleep disorders.
214844849|NCT00709306|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
214285288|NCT07131826|OTHER|Observational study, non-interventional|Observational study, non-interventional
214285289|NCT06927297|BIOLOGICAL|Engineered mitochondria vaccine|Participants were assigned to receive subcutaneous injections of the low dose, medium dose, or high-dose of the engineered mitochondrial vaccine. The regimen consisted of 3 doses of primary immunization, 1 dose of boost immunization and subsequent personalized treatment.
214844850|NCT00709306|BEHAVIORAL|Education|Education
214844851|NCT05116059|DRUG|Amphotericin B colloidal dispersion（ABCD）|The dosage and course of ABCD were determined by clinicians, and this study was registered according to clinical practice
214844852|NCT00866645|DRUG|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
214844853|NCT00866645|DRUG|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
214844854|NCT05162729|BEHAVIORAL|Game-like online working memory training|Participants in the WM group will be receiving two types of WM training tasks (two mini-games) in each session. Half of the training time will be spent on playing a game that requires visual-spatial WM, and the other half of the training time will be spent on playing a game that demands verbal WM. In both the games, the participant is asked to remember the pictures or audios (numbers) presented, and then recall them and select them on the screen.
214844855|NCT05162729|BEHAVIORAL|Game-like online social emotional training|"Participants in the SE group will be also receiving two types of SE training tasks in each session, to match with the ones in the WM training. There are two mini-games for training.~To match with the spatial-visual WM training, participants in the SE group will be asked to first look at a picture that depicts a daily social scenario (i.e., a child who fell down and hurt himself), and then to choose an emotion that the child in the picture may feel from four options of facial emotions displayed on the screen. The other mini-game, with the aim to match with the auditory WM training, will first tell a short story of a social scenario (i.e. David accidentally fell down and got hurt), and then will ask the child to choose the emotion that the character in the story may feel from the four options displayed on the screen. Each mini game lasts for about 7 minutes in each training session."
214844856|NCT02697539|OTHER|AmF/SnF2|AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
214844857|NCT02697539|OTHER|mHA|microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
214844858|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-A) for Adolescents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-A is designed for adolescents to self-evaluate and manage psychological wellbeing/mental health needs, as well as to gain resources and access and connect with adolescent peers.The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
214285290|NCT07132294|BEHAVIORAL|Exercise Intervention|"Supramaximal Interval Running (SIR) This protocol was individualized based on each player's Maximal Aerobic Speed (MAS). Training intensities were prescribed at 100% to 110% of each player's MAS. Each session consisted of eight sets. During the first three weeks, each set involved a 2-minute maximal effort run followed by 2 minutes of passive recovery. In the final three weeks, the duration of each set was extended to a 3-minute maximal run with 3 minutes of passive rest, increasing intensity and volume. SIR sessions were designed to enhance anaerobic capacity and lactate tolerance.~Small-Sided Games (SSG) SSG sessions were implemented to develop agility, acceleration, tactical decision-making, and match-relevant conditioning. Training took place on regulation-size grass pitches, adjusted to maintain a consistent length-to-width ratio across all formats. Over the six-week intervention, game formats progressed from 4v4 to 7v7, with gradual increases in duration and pitch dimensions."
214471912|NCT06280352|DEVICE|Custom made Total Knee Arthroplasty|Total knee replacement, patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)
214844859|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-P) for Parents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-P is designed for parents to self-evaluate their adolescent's development and mental health, gain awareness about their adolescent's mental health status, and learn strategies and resources to support adolescents' mental health. The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
214844860|NCT06403813|OTHER|Control Tooklit|The toolkit will have the same screening questions, with information, but without any decision support functions.
214844861|NCT04718129|BEHAVIORAL|Youth Mindful Awareness Program (YMAP)|The Mindfulness Intervention is an internet-based program that involves a coach. It is 9 weekly sessions and involves practicing the skills between sessions.
214844862|NCT03591731|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
214844863|NCT03591731|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
214844864|NCT00684801|OTHER|questionnaire administration|Patients complete questionnaires.
214285291|NCT06492330|DRUG|CS0159|The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive 4mg CS0159 (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
214285292|NCT06492330|DRUG|CS0159 placebo|The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive CS0159 placebo (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
214285293|NCT07101094|DRUG|xanomeline and trospium chloride (X/T) therapy|According to the product label
214285294|NCT04090619|OTHER|Questionnaire Administration|Complete questionnaires
214285295|NCT06829264|BEHAVIORAL|Individualized Placement and Support Model|The Individualized Placement and Support (IPS) model is an evidence-based approach to supported employment designed to help individuals with disabilities achieve and maintain competitive integrated employment (CIE). IPS emphasizes person-centered planning, rapid engagement, and focusing on individual strengths and preferences. Key features include prioritizing CIE, eligibility based on the desire to work, integration of employment services with mental health support, rapid job searches, tailored job development, and time-unlimited, individualized support. IPS also provides benefits counseling to help participants manage employment while maintaining government benefits. For this study, IPS is adapted to meet the needs of autistic individuals by enhancing provider training and family involvement to improve outcomes.
214285296|NCT06829264|BEHAVIORAL|Supportive Employment Intervention|This intervention consists of a weekly series of sessions designed for adult consumers, incorporating supportive elements inspired by the ACCESS (Acquiring Career, Coping, Executive, and Social Skills) program developed at the UC Davis MIND Institute. The sessions will provide time to discuss consumer experiences, give general guidance and some training in employment-related skills, including resume building, job interviewing, and strategies for giving and receiving feedback in the workplace.
214285297|NCT07121582|OTHER|Motor Brain Stimulation|For each grip trial (20 grip trials per block), participants will receive visual cues that signify the onset and offset of squeezing. Just prior to the start of the visual cue representing the onset of squeezing, participants will receive a burst of repetitive transcranial magnetic stimulation (rTMS) to their primary motor hotspot region. Motor brain stimulation will involve 3 bursts of 5 pulses/burst with a 20 Hz inter-pulse interval delivered at 90% of their resting or active motor threshold.
214285298|NCT07121582|OTHER|Visual Brain Stimulation|For each grip trial (20 grip trials per block), participants will receive visual cues that signify the onset and offset of squeezing. Just prior to the start of the visual cue representing the onset of squeezing, participants will receive a burst of repetitive transcranial magnetic stimulation (rTMS) to their ipsilesional occipital cortex region. Visual brain stimulation will involve 3 burst of 5 pulses/burst with a 20 Hz inter-pulse interval delivered at 90% of their resting or active motor threshold.
214285299|NCT06940271|PROCEDURE|Allografting|Undergo placement of MLG-Complete allograft
214285300|NCT06940271|OTHER|Survey Administration|Ancillary studies
214285301|NCT05205421|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Intravenous injection a single dose of RT-01
214285302|NCT04953468|DIAGNOSTIC_TEST|expression level of ANXA2 protein|The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry
214285303|NCT02499302|BEHAVIORAL|Mental training|
214285304|NCT02656121|DRUG|Vitamin D|6000 IU of vitamin D3
214285305|NCT02656121|DRUG|Ovulatory Agent|only Clomophine Citrate
214285306|NCT05984732|BEHAVIORAL|Reminiscence with digital storytelling|The older and young adult participants will be randomly assigned into the intervention (reminiscence) or control (social wellness) groups and then be randomly matched as dyads within each group. Older adults in the intervention group will receive 10 sessions of life-review with the trained young adult volunteers (1-1.5 hours each week for 10 weeks). During weeks 1-6, a life history interview will be carried out with different themes in each week: major turning points in life (W1), family history (W2), life/career accomplishments (W3), history of loves and hates (W4), stress experiences (W5), and meaning and purpose of life (W6). During weeks 7-10, the dyads will develop the DST together using tablets already owned by the UTA School of Social Work. The contents of sessions 7-10 will be structured as: outline/script, plan and storyboard (W7), film and record (W8), evaluate, integrate and finalize (W9), and publish/share (W10).
214844865|NCT00684801|PROCEDURE|quality-of-life assessment|Patients undergo quality-of-life assessments.
214844866|NCT01378962|DRUG|erlotinib|150 mg orally once a day for 12 months
214844867|NCT00942721|BEHAVIORAL|Web-based CBT for PPD|A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
214844868|NCT04087863|OTHER|Not applicable(observational study)|Not applicable(observational study)
214844869|NCT05793632|DRUG|Quetiapine|The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
214844870|NCT02196467|BIOLOGICAL|Myoblast transplantation|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
214844871|NCT02196467|PROCEDURE|Saline injection|A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
214844872|NCT05548335|PROCEDURE|Ocular Ultrasound|1\. Patients presenting to the emergency department and have a normal head and/or ocular computed tomography scan will be considered for inclusion in this study. Study staff will discuss the study with the patient and obtain consent. At that point, operator will perform ocular ultrasound. Procedure will start with either the linear or microconvex probe. A single-use sterile gel packet will be used to apply gel to one closed eyelid. The probe will be placed with minimal pressure on the eye. A transverse measurement of the ONSD will be taken. In this same view the maximal transverse diameter of the eyeball will also be measured. Images of the eye with ONSD and ETD measurements will be captured. Repeat until three measurements have been obtained resulting in an average ONSD and ETD for that eye. Repeat for other eye. Switch probe and repeat on both eyes.
214844873|NCT05762653|DIAGNOSTIC_TEST|Endoscopic ultrasound|Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
214844874|NCT02030535|DRUG|olodaterol|free combination with tiotropium
214844875|NCT02030535|DRUG|tiotropium|free combination with olodaterol
214844876|NCT02030535|DRUG|Placebo|
214844877|NCT02030535|DRUG|tiotropium|fixed dose combination with olodaterol
214844878|NCT02030535|DRUG|olodaterol|fixed dose combination with tiotropium
214285307|NCT05984732|BEHAVIORAL|Social wellness with scrapbook or journal|Older adults in the control group will have general social wellness discussion with the young adult volunteers, instead of structured reminiscence guidelines. The topics are: diet and health (week 1); exercise/activity and health (week 2); emotions and health (week 3); religious/spiritual practices and health (week 4); family/friend relationships and health (week 5); and social activities/engagement and health (week 6). For weeks 7-10, instead of DST, the young adult volunteer will work with the older adult to create an unstructured, non-digital record of the social visit related to wellness in later life (e.g. wellness scrapbook/journal).
214285308|NCT00876772|DRUG|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
214285309|NCT01945177|DEVICE|narrow band imaging|narrow band imaging
214285310|NCT01945177|DEVICE|white light endoscopy|white light endoscopy
214285311|NCT02597075|OTHER|standard therapy + physical activity program|
214844879|NCT01878864|DRUG|Bupivacaine lozenge|
214844880|NCT01878864|DRUG|Lidocaine-adrenalin injection|
214844881|NCT01166464|BEHAVIORAL|text messaging for smoking cessation|A 7-week program of daily text messages
214844882|NCT01166464|BEHAVIORAL|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
214844883|NCT01588548|DRUG|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
214844884|NCT00998595|OTHER|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
214285312|NCT02597075|OTHER|standard therapy|
214285313|NCT03605459|DEVICE|Comfort Plug™|
214285314|NCT02156596|DRUG|IV NSAI|100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
214285315|NCT02156596|DRUG|NM|3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
214285316|NCT02156596|DRUG|IV Serum Saline|50 ml of SS is given by IV root over 30 minutes
214285317|NCT02156596|DRUG|Nebulised Serum Saline|3 nebulisations of 5ml SS each are given over 30 minutes
214844885|NCT00292227|DRUG|Rotigotine|"Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
214844886|NCT00292227|OTHER|Placebo|"Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
214844887|NCT00292227|DRUG|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
214844888|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
214285318|NCT04638023|DEVICE|Arabin pessary|Arabin pessary was inserted intravaginally electively in women with cervical insufficiency (history based) or as emergency in those with short cervix on ultrasound.
214844889|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
214844890|NCT05148533|DRUG|TJ1133 Injection|TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
214285319|NCT04081168|DEVICE|Stereotactic Body Radiotherapy|Patients will undergo Stereotactic Body Radiotherapy (SBRT)
214285320|NCT04081168|DEVICE|Microwave Ablation|Patients will undergo Microwave Ablation (MWA)
214285321|NCT03024450|DRUG|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
214285322|NCT05436392|BEHAVIORAL|Peer Comparison Feedback|USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.
214285323|NCT05436392|BEHAVIORAL|Patient Informational Letter|Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.
214471913|NCT06280352|DEVICE|Functionally aligned robotically assisted total knee arthroplasty|Total knee replacement, Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker), using functional alignment strategy
214471914|NCT05168722|OTHER|No interventions|No interventions
214471915|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
214471916|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support (Wait-list)|Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
214471917|NCT04670874|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
214471918|NCT04670874|OTHER|Questionnaire Administration|Complete quality of life questionnaire
214471919|NCT06641557|DRUG|200mg of Ikt-148009|4 50mg capsules
214471920|NCT06642441|DRUG|Chemotherapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive a 10 mg dose of vitamin D2 injection until adjuvant chemotherapy is completed. They will receive a standard adjuvant chemotherapy regimen, which includes 10 mg of vitamin D2 injections per cycle during treatment. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
214471921|NCT06642441|DRUG|Chemotherapy|Participants will receive a standard adjuvant chemotherapy treatment regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
214471922|NCT05888376|DEVICE|Vascular access catheter to support dialysis or CRRT|A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
214471923|NCT05696197|BEHAVIORAL|Targeted touchscreen training|Participants will practice the Swipe Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants form different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 minutes per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14 seconds. Instruction and answers are also included. Feedback will be provided by means of knowledge of performance. On each training day, participants will receive a reminder on the training tablet.
214471924|NCT06642168|GENETIC|Whole exome sequencing to detect myocardial genetic mutations (SCA group only)|Whole exome sequencing to detect myocardial genetic mutations
214471925|NCT04933435|OTHER|Quality of life questionnaires|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
214471926|NCT04227483|DRUG|Deflazacort|Deflazacort for 4 months
214471927|NCT04227483|DRUG|Prednisolone|Prednisolone for 4 months
214471928|NCT05237284|DRUG|SAR443820|Tablet oral
214471929|NCT05237284|DRUG|Placebo|Tablet
214471930|NCT05443906|BEHAVIORAL|Home exercise|Exercise to address limitations impacting walking
214471931|NCT06241716|PROCEDURE|Ultrasound-assisted localization, US-AS|In the US-AS group, ultrasonic prescan to determine the best intervertebral space, best puncture Angle and best puncture depth. The optimal puncture section considered by the operator was selected to record the best gap, puncture Angle and depth.
214471932|NCT06241716|PROCEDURE|Real-time ultrasound guidance, US-RTG|In the US-RTG group, the optimal puncture section considered by the operator was selected and recorded directly in the plane of the paracentral transverse section, out of the plane of the paracentral sagittal section or in the plane of the paracentral sagittal section for real-time ultrasound guided lumbar epidural anesthesia.
214471933|NCT00313196|DRUG|bosentan|Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
214471934|NCT02950259|DRUG|Cyclophosphamide|One dose of cyclophosphamide 300 mg/m2 IV infusion
214471935|NCT02950259|DRUG|Indomethacin|Indomethacin 25 mg three times a day for 21 days
214471936|NCT02950259|DRUG|Omeprazole|One tablet of omeprazole daily for 21 days
214471937|NCT02950259|DIETARY_SUPPLEMENT|Multivitamin|Daily multivitamin containing 15-30 mg of zinc for 21 days.
214844891|NCT01275716|BEHAVIORAL|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications|Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
214285324|NCT01113983|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transapical and transfemoral approach
214844892|NCT03257254|DRUG|Varithena|Administration procedures and volume are per standard of care, full prescribing information, and instructions for use.
214844893|NCT05093686|BEHAVIORAL|RUBIES|RUBIES is an 8 module intervention that begins with foundational education on ASD (Session1), followed by introducing basic applied behavior analysis principles (Session 2). Instruction is then provided on strategies that can prevent problematic behaviors from occurring (Session 3 and 4). Reinforcement (Session 5) reviews the use of tangible and social reinforcers tools to promote new/desired behaviors while planned ignoring and functional communication training (Session 6) teaches that disruptive behavior can serve as a form of communication while ignoring disruptive communicative attempts. Sessions conclude with instruction on effective ways to deliver commands to promote compliance (Session 7) and targeting approaches to ensure positive behavior gains can maintain over time and strategies can be used across classrooms and staff (Session 8).
214844894|NCT05093686|BEHAVIORAL|Usual Care Training|Usual Care Training is an 8 module psychoeducation program that will provide foundational information on autism spectrum disorders, including the diagnostic criteria, appropriate educational services, common interventions, and how to promote social skills in the classroom.
214844895|NCT05440695|DEVICE|Continuous non-invasive arterial pressure (Infinity® CNAPTM, Dräger)|The basic working principle of CNAP is to keep the blood volume of the finger arteries constant by applying an exterior pressure to the vessel wall, that is done by an electronic system controlling the pressure inside a cuff around the finger. The pressure in the cuff, which is needed to keep the volume constant during arterial pulsation, corresponds to the AP.
214844896|NCT02966158|OTHER|AIT Group|"The AIT Group will begin with a one-month, run-in period where patients will perform current standard of care CR programming, which will involve traditional MICE. MICE at the Cardiac Rumsey Centre will consist of either track walking/jogging or treadmill walking/jogging for approximately 30-40 minutes, performed at an intensity of 60-80% of VO2peak, in addition to a warm-up and cool down period. In the second month of the study intervention, patients will begin to perform AIT three days per week, which involves performing 4-minute intervals at greater than 90% of peak heart rate, separated by 3-minutes of active recovery, with one of those AIT exercise sessions occurring at the Rumsey Centre under supervision, and 2 sessions per week of MICE, which will again consist of the 30-40 minutes of walking/jogging at an intensity of 60-80% of VO2peak, with an allotted warm up and cool down period."
214844897|NCT03530241|DIAGNOSTIC_TEST|Presence of bile duct stones|MRCP verified gall stones in the bile ducts
214844898|NCT03530241|DIAGNOSTIC_TEST|Non-presence of bile duct stones|MRCP without bile duct stones
214844899|NCT04038645|OTHER|Experimental group (laser)|"The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
214844900|NCT04038645|OTHER|Control group (Placebo)|Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.
214285325|NCT03194022|OTHER|Blood sample|measurement of electrolytes and blood count
214285326|NCT06287411|DIAGNOSTIC_TEST|FAPI PET/MR combined with gadoxetate disodium|Patients with clinical suspected hepatic malignancies will receive the FAPI PET/MR.
214285327|NCT04047940|DRUG|LY900020|Administered orally
214285328|NCT04047940|DRUG|Metformin XR|Administered orally
214285329|NCT04047940|DRUG|Atorvastatin|Administered orally
214479467|NCT06861374|DRUG|Unfractionated heparin|(1)If ACT\<180s, administer an intravenous bolus of unfractionated heparin at 70 U/kg before coronary angiography, with a maximum total dose of 6000U. (2)If 180\<ACT\<225s, administer an intravenous bolus of unfractionated heparin at 60 U/kg before coronary angiography, with a maximum total dose of 4000U. (3)If ACT\>225s, proceed directly with PCI and maintain 225s\<ACT\<350s.
214844901|NCT01396694|OTHER|Questionnaire|Questionnaire
214844902|NCT04015531|RADIATION|Conventional radiotherapy|50 Gy / 25 fractions / 5-6 weeks / Sequential boost of 10 Gy in 5 fractions, in case of conservative surgery.
214285330|NCT04047940|DRUG|Valsartan|Administered orally
214285331|NCT03867006|DIETARY_SUPPLEMENT|Protein|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.
214285332|NCT03867006|DIETARY_SUPPLEMENT|Protein and Carbohydrate|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.
214285333|NCT05825846|DEVICE|Virtual- reality active shooter drill|"The stress protocol used for this experiment utilized a previously studied virtual reality active shooter drill (VR-ASD). The VR-ASD scenario (\~2 min) involves the participant physically walking down a \~10-foot-long virtual hallway where they will encounter wounded victims. Once at the threshold of to the attack room, they will observe one victim on the ground with a traumatic head injury and the shooter firing his handgun at the last victim, the participant will fire a shot, and the shooter will fall after being shot."
214285334|NCT00410046|DRUG|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
214285335|NCT02035878|OTHER|Probiotics|probiotic intervention: 400mg of probiotic capsule
214285336|NCT02035878|DRUG|Placebo|placebo comparator
214285337|NCT03421028|DEVICE|Electromyography Biofeedback|EMG-Biofeedback- assisted training is a method in which electrodes situated on the surface of the skin detect small voltage changes which arise from the working muscles (in this case masseter and temporalis muscles). The voltage is transformed into a visual or sound time-variable signal which gives the patient feedback as he willingly tries to change the muscle tension (in this case to lower the excessive masseter tension)
214285338|NCT03421028|OTHER|Classic treatment for myogenous TMD|Combination of physiotherapy (manual therapy), stabilization occlusal splint usage and counseling
214285339|NCT02031666|DRUG|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
214285340|NCT02031666|DRUG|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
214285341|NCT02393508|OTHER|Fresh Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
214285342|NCT02393508|OTHER|Aged Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
214285343|NCT01384760|BEHAVIORAL|Lifestyle modification|During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
214285344|NCT01384760|BEHAVIORAL|Simple lifestyle advice|Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
214285345|NCT00000752|DRUG|Pseudoephedrine hydrochloride|
214285346|NCT00000752|DRUG|Guaifenesin|
214285347|NCT00000752|DRUG|Cefuroxime axetil|
214285348|NCT00000752|DRUG|Beclomethasone dipropionate|
214285349|NCT03487068|DEVICE|The FibroScan device|The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
214285350|NCT05237531|BEHAVIORAL|Standardized Preoperative Education|"The standardized preoperative education includes a brief video, an interactive quiz, and a written handout.~The video will provide information on the proper use and common side effects of opioid pain medications, the expected effects of a peripheral nerve block, and the concept of multimodal postoperative pain management with non-opioid medications and non-pharmaceutical pain management strategies. The interactive quiz will reinforce the critical components of the video in a question-and-answer format which requires active participation. The written handout will summarize the educational content in a form which can be easily referenced by patients at home."
214285351|NCT05237531|BEHAVIORAL|Standard of care|Education per provider preference (no standardization, current standard of care)
214285352|NCT05237531|BEHAVIORAL|Preoperative and postoperative questionnaires|Preoperative questionnaire: Demographic questions plus specific questions about chronic pain, prior opioid use, and mental health diagnoses Postoperative questionnaire: Questions about pain control after surgery, satisfaction with pain control, healthcare contact since surgery, opioid consumption since surgery, and satisfaction with education
214285353|NCT00666627|DRUG|Ibandronate|once monthly
214285354|NCT00666627|DRUG|Risedronate|Risedronate 35mg once weekly
214285355|NCT00666627|DRUG|Alendronate|Alendronate 70mg once weekly
214285356|NCT01942330|PROCEDURE|Laparoscopic-Assisted Natural Orifice Surgery|Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
214285357|NCT03602183|DEVICE|Macintosh laryngoscope|intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
214285358|NCT03602183|DEVICE|Miller laryngoscope|intubation will be performed using Miller laryngoscope
214844903|NCT04015531|RADIATION|Hypofractionated radiotherapy|40 Gy / 15 fractions / 3 weeks / Concomitant boost with total dose of 48 Gy in 15 fractions, in case of conservative surgery.
214844904|NCT03261024|DEVICE|Friction mechanics|Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.
214285359|NCT03602183|DEVICE|McGrath MAC EMS|intubation will be performed using McGrath MAC EMS video - laryngoscope
214285360|NCT03602183|DEVICE|GlideScope|intubation will be performed using GlideScope video - laryngoscope
214285361|NCT00963547|DRUG|MK-2206|\[Part 1\]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. \[Part 2\] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
214844905|NCT03261024|DEVICE|Frictionless mechanics|T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
214285362|NCT00963547|BIOLOGICAL|Trastuzumab|Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
214471938|NCT05522140|BEHAVIORAL|Nature-based social intervention (NBIS)|"Nature-based social prescribing is a multicomponent, multi-level, behaviorally based complex intervention applaied by facilitators after a specific training. It comprises: a psychosocial component and nature-based activities. The psychosocial component is adapted from the group dynamic of Circle of Friends methodolgy focused on loneliness(Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Prague and the target population (partitipants) of adults who lives in Prague. Participants start with an individual session and then meet once a week for two hours for 10 weeks.~At the first meeting together, participants select the nature-based activities they wish to conduct through a co-created menu."
214471939|NCT05522140|BEHAVIORAL|Usual care + menu with nature based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
214471940|NCT05990426|BEHAVIORAL|FAST Intervention|"Participants will alternate fasting days (FAST) with unrestricted eating (OFF, or Feast) days, for one week surrounding the start of each chemotherapy cycle. The participants will fast for two consecutive days in the middle of the ADF week - the day prior to chemotherapy start date, and chemotherapy day 1 for each cycle. Participants will consume regular diet (OFF/Feast) during other days 5-18 of each cycle."
214471941|NCT05987072|DRUG|Sisunatovir|Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
214471942|NCT06249555|DRUG|Vedolizumab (VDZ)|Participants will receive VDZ as part of routine care.
214471943|NCT06249555|DRUG|Ustekinumab (UST)|Participants will receive UST as part of routine care.
214471944|NCT06249555|DRUG|Risankizumab (RISA)|Participants will receive RISA as part of routine care.
214471945|NCT05036122|DEVICE|LabClasp|Non-invasive device that estimates blood \[lactate\] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood \[lactate\] and return a value to the subject via an accompanying tablet within 20 seconds.
214471946|NCT05842941|DRUG|DNL343|DNL343 is administered orally once daily per day for 24 weeks.
214471947|NCT05842941|DRUG|Matching Placebo|Matching placebo is administered orally once daily per day for 24 weeks.
214471948|NCT06806683|RADIATION|intensity modulated radiotherapy|intensity modulated radiotherapy
214471949|NCT05864196|RADIATION|Two-Fraction Stereotactic Body Radiation Therapy (SBRT)|Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer.
214471950|NCT05983445|DRUG|genakumab|200mg s.c.
214471951|NCT05983445|DRUG|placebo for Diprospan|i.m.
214471952|NCT05983445|DRUG|placebo for genakumab|s.c.
214471953|NCT05983445|DRUG|Diprospan|7mg i.m.
214471954|NCT05255120|OTHER|Intiensified structured perioperative information|The doctor takes a medical history and examines the patient according to regular routines, but uses the algorithm as support in deciding on the surgical method. After the doctor's visit, the patient must see a research nurse to receive the intensified preoperative information about hysterectomy. This information is designed according to a checklist. The patient can also download a mobile application. The study-specific mobile application (app) contains information about hysterectomy. The information is structured in three parts - Before the Operation, At the Hospital and After the Operation. A timeline describes the activities and events that occur before, around and after the operation. Within each section there are several information links, with eg checklists.
214471955|NCT06651060|BEHAVIORAL|Menu label|Participants will view a sample of items from a restaurant menu, displayed with labels
214471956|NCT06003985|OTHER|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
214471957|NCT03733925|DRUG|Golimumab|Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
214471958|NCT06232655|DRUG|Cladribine|A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.
214471959|NCT06232655|DRUG|Venetoclax|A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
214471960|NCT06232655|DRUG|Azacitidine|Medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA.. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
214471961|NCT03213873|BEHAVIORAL|HiBalance|Intervention of highly challenging balance training for 10 weeks.
214471962|NCT03213873|BEHAVIORAL|Speech and communication therapy|Intervention conducted by speech and language therapist for 10 weeks.
214471963|NCT06806319|DEVICE|single intervention by Sirolase ® lower power diode laser 970 ± 15 nm (0.5 watts) continuous emission, power =3 watts, fiber 320 μm|single intervention by Sirolase ® lower power diode laser 970 ± 15 nm (0.5 watts) continuous emission, power =3 watts, fiber 320 μm.single intervention the follow-up until 6 months
214471964|NCT06806319|DEVICE|single intervention by electrosurgical unit which was kept 38 watts rms ± 5%. The working frequency was adjusted to 1.5 MHz ± 5%.|single intervention by electrosurgical unit which was kept 38 watts rms ± 5%. The working frequency was adjusted to 1.5 MHz ± 5%.single intervention then follow-up until 6 months
214471965|NCT05804942|BEHAVIORAL|High glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:\>70), 20% fat and 20% protein.
214471966|NCT05804942|BEHAVIORAL|Medium glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:55-70), 20% fat and 20% protein.
214471967|NCT05804942|BEHAVIORAL|Low glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:\<55), 20% fat and 20% protein.
214844906|NCT04459130|BEHAVIORAL|Child Obesity Program|"The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.~The topics of the sessions are as follows:~Session 1: Healthy lifestyles~* Session 2: Self-esteem and positive thinking, Setting goals Session 3: Stress and Coping, Coping with Emotions in Healthy Ways Session 4: Personality and effective communication~* Session 5: Activity: Time for action Session 6: Nutrition basics Session 7: Reading tags Session 8: Portion size, nutrition and healthy food choices in schools Session 9: Snacks can also be healthy: Healthy choices~* Session 10: Together for a healthy life (Melnyk et al., 2006; 2007; 2009). Detailed information about the sessions is given in annex -3."
214844907|NCT00099957|DRUG|vildagliptin|
214844908|NCT04083443|OTHER|Additional blood sampling|Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
214844909|NCT06492408|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
214844910|NCT01543867|DRUG|somatropin|Prescribed at the discretion of the treating physician according to product labelling
214844911|NCT06409858|OTHER|Pilates|Twice-weekly mat Pilates class for 8 weeks, either in person or online (depending on participant availability)
214844912|NCT02725164|DRUG|oxygen concentration|oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
214844913|NCT02725164|DRUG|nitrous oxide concentration|nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
214844914|NCT02725164|DRUG|carbon dioxide concentration|carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
214844915|NCT02725164|DRUG|sevoflurane concentration|sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
214844916|NCT00655317|OTHER|Acupuncture|Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
214844917|NCT00655317|OTHER|Sham acupuncture|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
214844918|NCT00442546|DRUG|pregabalin|150 milligram (mg)/ day (double blind)
214844919|NCT00442546|DRUG|pregabalin|300 mg/day (double blind)
214844920|NCT00442546|DRUG|Placebo|Placebo
214844921|NCT02378441|DRUG|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
214844922|NCT02378441|DRUG|CJ-30056 20/750mg|fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
214844923|NCT03840382|BEHAVIORAL|Tele-PrEP Intervention|Telemedicine conferences with PrEP-specialists
214844924|NCT06899438|DRUG|Botulinum Toxin A Injection|
214844925|NCT06899438|DRUG|Prilocaine HCl % 2 injectable solution|
214844926|NCT06905496|DRUG|High-Dose|Caffeine
214844927|NCT06905496|DRUG|Low Dose|Caffeine citrate is a combination of caffeine and citric acid, commonly used as a central nervous system stimulant. It is primarily used to treat apnea of prematurity in neonates.
214844928|NCT06905028|OTHER|Fasting and Plant-Based Diet|The participants will undergo an initial 7-day fasting regime according to Buchinger (max. 350 kcal per day as liquids), followed by a dietary intervention that encompasses a plant-based diet (PBD) and time restricted eating (TRE) for 11 weeks.
214844929|NCT06513377|OTHER|Performance test|The participant will be asked to execute a protocol in the movement lab that induces progressive feelings of fatigue. This protocol includes a sequence of relevant functional activities, such as stair walking, slope walking, crouching, walking different path shapes. During this execution the Ratings of Perceived Exertion will be questioned, and simultaneously physiological and movement data will be collected.
214844930|NCT01322334|BEHAVIORAL|Singing exercises|A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
214844931|NCT06905015|DEVICE|High stroke volume variation group|Anesthesiologists will perform methods to achieve and maintain SVV at 13-20% during liver parenchymal transection (fluid restrictive phase). Central venous pressure monitoring will be concealed with drapes, and the room anesthesiologist will use SVV for guiding fluid management only during parenchymal transection phase. If SVV exceeds 20%, a balanced salt crystalloid will be administered in the minimal amount necessary to reduce the SVV to below 20%.
214844932|NCT06905678|OTHER|Questionnaires|The participants will fin in questionnaires about the financial and emotional burden they experience.
214844933|NCT06905678|OTHER|Semi-structured interviews|After the participants have filled in the questionnaires they will get the chance to participate in an interview to talk about their perceptions and experiences.
214844934|NCT06904911|DRUG|intra-arterial tenecteplase administration|Patients will receive a single dose of tenecteplase, administered intra-arterially after successful large vessel recanalization. The treatment will be administered via intra-arterial catheter in the distal M1 segment of the middle cerebral artery (distal to lenticulostriates).
214844935|NCT06904859|BIOLOGICAL|TCR-T Cells Injection|The TCR sequences of AML patients were analyzed by next generation sequencing to find the specific TCR clone against leukemia，then TCR gene-modified T cells were infused back into the patients
214844936|NCT06903689|DRUG|Pentoxifylline 400 MG Oral Tablet|Oral tablet, 400 mg, administered twice daily with food for 6 months. To be taken in addition to conventional medications for chronic kidney disease.
214906899|NCT01019343|OTHER|Behavioral tasks|To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non-exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.
214844937|NCT06903689|OTHER|Conventional Medications for Chronic Kidney Disease|This arm receives conventional medical management for chronic kidney disease (CKD). This includes medications and treatments as deemed necessary and appropriate by the participant's treating physician, according to established clinical guidelines for CKD. These may include, but are not limited to, medications for blood pressure control, management of diabetes, anemia treatment, mineral and bone disorder management, and fluid and electrolyte balance management. The specific medications and treatments are individualized and not dictated by the study protocol, but follow standard clinical practice for CKD.
214844938|NCT06904703|DRUG|General anesthesia|Patients will receive general anesthesia.
214844939|NCT06904703|DRUG|Bupivacaine 0.5%|Patients will receive general anesthesia and erector spinae plane block.
214844940|NCT06904703|DRUG|Bupivacaine 0.5%|Patients will receive general anesthesia and erector spinae plane block with pericapsular nerve block.
214844941|NCT06904690|OTHER|Educational training|"The educational training is divided into the following five modules:~Module 1: Raising Awareness of eHealth and Health Literacy (Introduction to the aims and context of JACARDI and diabetes);~Module 2: Acquiring New Knowledge (Health Literacy and Self-Management of Diabetes);~Module 3: Acquiring New Knowledge (Technological and Non-Technological Strategies to Support the Self-Management of Diabetes);~Module 4: Practicing New Skills (Usability with Practice Sessions);~Module 5: Self-Evaluation and Sustainability of Improvement (Final Questionnaire).~The training will be conducted over 10 weeks (one session every other week), with each session lasting an average of 90 minutes."
214844942|NCT06256549|DRUG|GZR18|Titrated to low dose or middle or high dose
214844943|NCT06256549|DRUG|Semaglutide|Titrated to 1.0 mg once a week
214844944|NCT06021470|BEHAVIORAL|Cognitive rehabilitation intervention|The intervention comprises a five-week group-based cognitive rehabilitation intervention delivered by a clinical neuropsychologist, with home activities tailored to each stroke survivor's identified goals. Sessions involve four patients and are delivered once per week lasting 2.5 hours with breaks.
214844945|NCT02562287|DRUG|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
214844946|NCT02562287|DRUG|Risperidone|Risperidone, in a flexible dosage
214844947|NCT02562287|DRUG|Olanzapine|Olanzapine, flexible dosage
214844948|NCT02562287|DRUG|Quetiapine|Quetiapine, flexible dosage
214844949|NCT00375791|DRUG|perifosine|100 - 150 mg daily
214844950|NCT00375791|DRUG|dexamethasone|20 mg twice weekly
214844951|NCT00735930|DRUG|Alvocidib Hydrochloride|Given IV
214844952|NCT00735930|DRUG|Lenalidomide|Given PO
214844953|NCT00735930|OTHER|Pharmacological Study|Correlative studies
214285363|NCT00963547|DRUG|Lapatinib|Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
214285364|NCT00002876|DRUG|cisplatin|
214285365|NCT00002876|DRUG|etoposide|
214285366|NCT05367648|DIETARY_SUPPLEMENT|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
214285367|NCT05367648|OTHER|Placebo|Placebo comparator
214844954|NCT00735930|OTHER|Laboratory Biomarker Analysis|Correlative studies
214844955|NCT01302509|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
214844956|NCT06051409|DRUG|Olverembatinib|Orally, once every other day (QOD).
214285368|NCT01216306|BEHAVIORAL|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
214285369|NCT03767504|DIETARY_SUPPLEMENT|Thymol|Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
214285370|NCT03962920|DRUG|Tigecycline 50 MG|Local instillation of drug directly to the tumour tissue
214285371|NCT03962920|OTHER|Placebo|Local instillation of sterile water directly to the tumour tissue
214285372|NCT00673569|DRUG|erlotinib hydrochloride|
214285373|NCT00673569|GENETIC|gene expression analysis|
214285374|NCT00673569|GENETIC|protein expression analysis|
214285375|NCT00673569|OTHER|immunoenzyme technique|
214285376|NCT00673569|OTHER|immunologic technique|
214285377|NCT00673569|OTHER|laboratory biomarker analysis|
214285378|NCT00673569|PROCEDURE|needle biopsy|
214844957|NCT06051409|DRUG|Imatinib|Orally, once daily (QD).
214844958|NCT02506205|BEHAVIORAL|Lee Silverman Voice Treatment (SVLT) LOUD|
214844959|NCT03209349|PROCEDURE|Water Exchange Sigmoidoscopy|See arm description.
214844960|NCT03209349|PROCEDURE|Air Insufflation Sigmoidoscopy|See arm description.
214844961|NCT06165263|BEHAVIORAL|Mobile earthquake education|The mobile earthquake education application was developed to increase high school students\&#39; knowledge about earthquakes through videos, activities or games. In the mobile earthquake education application, there are 4 modules that provide general information about the earthquake and what to do before, during and after the earthquake.
214844962|NCT01471925|DRUG|Nexium®|"The medication, esomeprazole magnesium trihydrate (40 mg), should be administered once a day (before breakfast) and the capsules should be taken on an empty stomach (orally) with liquid (water at room temperature - 200 to 250 ml.~The study treatment will last a total of 28 days."
214844963|NCT01471925|DRUG|Esomeprazol (40mg) + Sodium Bicarbonate (721mg)|"The medication, Esomeprazol (40 mg) + Sdium Bicarbonate (721 mg), should be administered once a day (before breakfast) and the capsules should be taken on an empty stomach (orally) with liquid (water at room temperature - 200 to 250 ml.~The study treatment will last a total of 28 days."
214844964|NCT05805813|COMBINATION_PRODUCT|peritoneal rest|Change continuous ambulatory peritoneal dialysis to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month. In this way, give a chance of peritoneum rest.
214844965|NCT02910024|DEVICE|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
214844966|NCT02910024|DEVICE|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
214844967|NCT03939949|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt."
214285379|NCT05077397|DEVICE|StO2|InSpectra Tissue Spectrometer Model 1615 probe (Hutchinson Technology Inc. Hutchinson, MN, USA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices and StO2 values in the devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
214844968|NCT03939949|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time."
214844969|NCT03939949|BEHAVIORAL|Active Control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in."
214844970|NCT05054322|DRUG|Fluticasone Propionate|Fluticasone propionate added to usual care, total dose 1000 mcg per day for 14 days
214844971|NCT01806610|DRUG|BPS804|Single dose BPS804 administration.
214844972|NCT01806610|DRUG|Placebo|Single dose placebo administration.
214844973|NCT04755621|OTHER|Core stability training|Core stability exercises
214844974|NCT04755621|OTHER|Rocabado Exercises|Exercises for Temporomandibular Disorders
214844975|NCT05756738|DIAGNOSTIC_TEST|Dried blood spot testing|To evaluate the efficacy defined as the rate of diagnostic tests against hepatitis C virus (HCV) performed with a dried blood spot test
214844976|NCT02121041|DRUG|Amlodipine|Amlodipine 5 mg or 10 mg
214844977|NCT02121041|DRUG|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
214844978|NCT02121041|DRUG|Losartan|Losartan 50 mg or 100 mg
214844979|NCT03868111|DRUG|Sufentanil|The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
214844980|NCT03868111|DRUG|Remifentanil|The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
214844981|NCT03477383|DIAGNOSTIC_TEST|donor-derived cell-free DNA (dd-cfDNA)|Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
214844982|NCT00865449|DRUG|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
214844983|NCT00865449|DRUG|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
214844984|NCT02939261|BEHAVIORAL|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
214844985|NCT02939261|BEHAVIORAL|Control|monthly emails with general health information
214844986|NCT00237419|DRUG|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
214285380|NCT05077397|DEVICE|O3|O3TM Regional Oximeter System (O3 System, Masimo Corporation, Irvine, CA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
214844987|NCT00403949|DRUG|Azelaic acid 15% gel|gel, applied once daily, for 6 weeks
214844988|NCT00403949|DRUG|Non-active base from azelaic acid 15% gel|gel, apply once daily for six weeks
214844989|NCT03040752|DRUG|Nifedipine 20 Mg|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
214844990|NCT03040752|DRUG|Ritodrine Oral Tablet|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor
214844991|NCT03201978|DRUG|GSK2894512 1% CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
214844992|NCT03201978|DRUG|GSK2894512 MATCHING VEHICLE CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
214844993|NCT03973788|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|A single section of rTMS (2,000 pulses)
214844994|NCT04266652|PROCEDURE|tooth block|tooth root blocks were used to increase the bone width
214844995|NCT04266652|PROCEDURE|autogenous bone block|autogenous bone block were used to increase the bone width
214844996|NCT03358095|DEVICE|Tannenbaum Fr 10 stent or WallFlex stent|A plastic or metallic endoprosthesis is placed to the biliary ducts.
214844997|NCT00978887|OTHER|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
214844998|NCT00978887|OTHER|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
214844999|NCT00088387|DRUG|Divalproex|
214845000|NCT00088387|DRUG|Lithium|
214845001|NCT03721302|OTHER|Main study clinical sepsis|No intervention-Observational study
214845002|NCT03721302|OTHER|Microbiology sub study|Analysis of Bacterial isolates
214845003|NCT06462365|BIOLOGICAL|TRX103|TRX103 infusion via central line.
214845004|NCT02394639|OTHER|video-EEG monitoring|
214845005|NCT00959322|DEVICE|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
214845006|NCT04529395|OTHER|Blending of essential oils|The mixture of essential oils will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
214845007|NCT04529395|OTHER|Apricot vegetable oil|The apricot vegetable oil will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
214845008|NCT03813225|OTHER|Bilateral serratus Intercostal plane Block|Will be performed by echo guided one puncture in the fifth costal arch with anterior axilary line, where the tip of the needle will be guided until it reaches a point above the external intercostal muscle, below the anterior serratus above the costal arch where they will be administered 21 ml of anesthesic mass, (20 ml of levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone.)
214471968|NCT06152094|OTHER|BP Activate Letter|"Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss."
214845009|NCT06291090|BEHAVIORAL|OUD treatment intervention|Participants received education on the diagnosis and management of OUD, have access to protocols to walk them through assessment of OUD using Diagnostic and Statistical Manual, fifth Edition (DSM)-5, COWS score to calculate severity of opioid withdrawal, buprenorphine or methadone initiation with pre-populated orders, and clickable links for OUD treatment referral post discharge.
214845010|NCT03730779|DRUG|Hyperoxia|Patients will receive nocturnal normobaric hyperoxia therapy
214845011|NCT05933473|PROCEDURE|Percutaneous coronary intervention|percutaneous intervention to oseal LAD with or without LM stenting
214845012|NCT00088049|DRUG|Olanzapine|
214845013|NCT00088049|DRUG|Aripiprazole|
214845014|NCT02617641|BEHAVIORAL|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
214471969|NCT06152094|OTHER|Control Letter|Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
214845015|NCT02617641|BEHAVIORAL|Publicly available websites|"* Le Programme de marche (Institut de Cardiologie de Montréal)~* L'activité physique (Institut de Cardiologie de Montréal)~* L'activité physique (Fondation des maladies du cœur et de l'AVC)~* Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~* Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)"
214845016|NCT06676293|DRUG|Anti-PD1|Pembrolizumab 100mg in normal saline 100ml infusion over 30 minutes for every two month
214845017|NCT06676293|DRUG|asparaginase|The patients will receive asparaginase 10000IU/vail IM QD for three or five days.
214471970|NCT06454175|BIOLOGICAL|Placebo|immunization schedule：Month 0，Month 2，Month 6
214471971|NCT06454175|BIOLOGICAL|15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)|immunization schedule：Month 0，Month 2，Month 6
214845018|NCT01938352|BIOLOGICAL|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
214845019|NCT01938352|BIOLOGICAL|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
214845020|NCT04904055|OTHER|Value-based Formulary|Prescription drug formulary tiers informed by estimated value
214845021|NCT02946606|DRUG|GX-H9|Human growth hormone
214845022|NCT02946606|DRUG|Genotropin|Human growth hormone
214845023|NCT02238132|DRUG|ATROVENT® inhalets|
214845024|NCT02824185|DEVICE|PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)|A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
214845025|NCT03245307|DRUG|Apatinib|Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A
214845026|NCT03245307|DRUG|Nifedipine GTIS|Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A
214845027|NCT03245307|DRUG|Warfarin Potassium|Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
214845028|NCT02464488|OTHER|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
214845029|NCT02192294|DRUG|Oral Bosutinib|a single dose of 500 mg oral bosutinib
214845030|NCT02192294|DRUG|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
214845031|NCT03561922|DEVICE|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
214845032|NCT02981316|BIOLOGICAL|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
214845033|NCT00640263|DRUG|lopinavir/ritonavir (LPV/r)|Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
214845034|NCT00640263|DRUG|Lamivudine (3TC)|"Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.~The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight."
214845035|NCT01087021|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
214471972|NCT05223088|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
214471973|NCT05223088|DRUG|Apatinib Mesylate|Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
214845036|NCT06317948|OTHER|treatment plan comparison|In order to assess inter-Institute variability of DVH prediction of the various models, for the different situations and the different OARs, DVH and dose statistics (min, mean, median, max and SD of the dose received by each OAR) predicted on the patients owning to the different centers by the different models will be compared
214845037|NCT01904422|PROCEDURE|conventional periodontal treatment|
214285381|NCT06352281|BIOLOGICAL|CAR-T cells|CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.
214845038|NCT03451604|OTHER|preoperative assessement|All data concerning study, involved in normal care of patient for his anesthesia (non interventional study), where included in anonymous computerized database by anesthesiologist during pre operative clinic.
214471974|NCT05223088|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
214471975|NCT05223088|DRUG|Tegafur|Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
214471976|NCT06329518|DRUG|Rezafungin|After receipt of Rezafungin, blood samples will be collected at various time points to determine the pharmacokinetics of Rezafungin.
214845039|NCT06678646|PROCEDURE|Elbow ultrasound-guided surgery|Percutaneous Ultrasound-Guided Release of the Lacertus Fibrosus for Median Nerve Entrapment at the Elbow
214845040|NCT03347357|DRUG|Tacrolimus|Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.
214471977|NCT05456581|BEHAVIORAL|'Scotoma awareness' Training|In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.
214845041|NCT00191464|DRUG|premeal insulin lispro mixtures|
214845042|NCT00191464|DRUG|insulin glargine|
214845043|NCT00191464|DRUG|metformin|
214845044|NCT04115709|DEVICE|Beacon Caresystem device with advice|Beacon Caresystem device provides ventilator settings advice to Doctors
214845045|NCT04115709|DEVICE|Beacon Caresystem device without advice activated|Beacon Caresystem device does not give ventilator settings advice
214845046|NCT00097786|DRUG|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
214845047|NCT00097786|DRUG|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
214845048|NCT00097786|DRUG|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
214906900|NCT01019343|PROCEDURE|TMS single/paired pulse|For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see sub-section EMG 7.1.3.1 for the details of the procedure).
214285382|NCT01479517|DRUG|Kovacaine Mist 0.1 mL x 4 sprays|Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
214285383|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 2 sprays|Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
214285384|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 1 spray|Dose = 1 intranasal spray of study drug
214285385|NCT03751488|DRUG|LY03010|Single Dose of LY03010 at 351 mg or 156 mg or 117mg
214471978|NCT05456581|BEHAVIORAL|Control Training|The task will be performed in the control group without the visible scotoma.
214471979|NCT03042754|DIAGNOSTIC_TEST|XpertMTB/RIF|
214471980|NCT05862129|PROCEDURE|surgical operation|Radical operation for the perianal abscess
214471981|NCT03535545|DRUG|[68Ga]CBP8|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
214471982|NCT03535545|DIAGNOSTIC_TEST|PET Imaging|All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.
214471983|NCT02939612|BEHAVIORAL|App for stress management|An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
214471984|NCT02897427|OTHER|Biomarker Analysis|Complete HPV testing
214471985|NCT02897427|PROCEDURE|Biospecimen Collection|Undergo collection of blood and oral gargle samples
214471986|NCT02897427|PROCEDURE|Ultrasonography|Undergo transcervical ultrasonography
214471987|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Scheduled|VSTs will be infused into stem cell transplant recipients on schedule.
214845049|NCT00097786|DRUG|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
214845050|NCT03214302|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
214845051|NCT03965637|DRUG|vitamin C|water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
214845052|NCT01378741|DRUG|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
214845053|NCT01378741|DRUG|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
214845054|NCT05616078|OTHER|laser treatment|a maximum of 4 sessions, with an interval of 3 to 4 weeks
214845055|NCT05616078|OTHER|cryotherapy|a maximum of 4 sessions, with an interval of 3 to 4 weeks
214471988|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Treatment|VSTs will be infused into stem cell transplant recipients only if viremia is detected.
214471989|NCT04170907|OTHER|standardized vaping protocol|The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.
214845056|NCT03001999|BEHAVIORAL|PP-MI health behavior intervention|"The positive psychology exercises include 3 modules:~Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 14 study sessions."
214845057|NCT02292511|BEHAVIORAL|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
214845058|NCT02039752|OTHER|Treatment|
214845059|NCT04270006|BIOLOGICAL|adipose derived stem cells exosomes|they are small extracellular vesicles
214285386|NCT03751488|DRUG|Invega Sustenna 156 MG in 1 ML Prefilled Syringe|Single Dose at 156mg
214285387|NCT04610268|DEVICE|transcranial direct current stimulation|Depending on the location of sEEG electrode implanted in the patient's head, the tDCS electrode (5 cm×7 cm each) was placed on occipital-frontal lobe or bilateral temporal lobe. Current intensity: 2 mA and 4 mA, Stimulus time: 3 min (each stimulus session).
214285388|NCT01288066|PROCEDURE|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
214285389|NCT01288066|PROCEDURE|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
214285390|NCT04813406|DRUG|Anlotinib + Sintilimab|"Anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Sintilimab: 200 mg/time, intravenous injection, every 3 weeks is one cycle."
214285391|NCT05006911|DRUG|Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound|To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
214285392|NCT00412659|PROCEDURE|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
214285393|NCT00412659|PROCEDURE|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
214285394|NCT03932227|DEVICE|Cardioskin|Subjects will have a 24h recording with Cardioskin, next will be unequipped.
214285395|NCT03932227|DEVICE|Holter|Subjects will have a 24h recording with Holter, next will be unequipped.
214285396|NCT01206608|DRUG|SKY0402 + bupivacaine HCl|Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
214285397|NCT01206608|DRUG|Mid-dose SKY0402 + bupivacaine HCl|Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
214285398|NCT00695487|DRUG|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
214845060|NCT00607295|DRUG|clino-san vaginal lubricant|Clino-san 2ml vaginal application 3 times per week for 12 weeks
214845061|NCT03576287|DRUG|Apremilast Oral Product|Apremilast
214845062|NCT00001662|DRUG|CX516 (Ampalex)|
214845063|NCT03115606|DEVICE|C-Mac D Blade|Videolaryngoscope
214845064|NCT03115606|DEVICE|Fastrach LMA|Laryngeal mask airway
214845065|NCT03803111|BEHAVIORAL|Initial exercise training|Initial exercise training program
214845066|NCT03803111|DRUG|Initial FCM|Initial intravenous iron supplementation (FCM)
214845067|NCT03803111|DRUG|Subsequent FCM|Subsequent intravenous iron Supplementation (FCM) after 2 months
214845068|NCT03803111|BEHAVIORAL|Subsequent exercise training|Subsequent exercise training program after 2 months
214845069|NCT04913207|PROCEDURE|method of device size selection|device size selection based on 3D-CTA
214845070|NCT02000531|DRUG|Erlotinib|150 mg oral dose of erlotinib given once daily
214845071|NCT02000531|DRUG|Chemotherapy|Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
214845072|NCT03631368|DRUG|Botox|Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
214845073|NCT03297372|DEVICE|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
214845074|NCT04265690|BEHAVIORAL|Cooking classes|Participants will receive 2 cooking classes (each 1-hour long) during their Centering group-care visit at the BMC teaching kitchen, taught by a Registered Dietitian. The recipes taught during the cooking classes will follow the Special Supplemental Nutrition Program for Women, Infants, and Children, the 2015-2020 Dietary Guidelines for Americans, and recommendations from The American College of Obstetricians and Gynecologists.
214845075|NCT04265690|BEHAVIORAL|Text messages|Participants will receive text messages, through a password secured phone, based on their content and frequency preferences.
214845076|NCT02130167|DRUG|Atropine|Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
214471990|NCT04617678|OTHER|Prehabilitation Program|We will assess whether prehabilitation intervention helps mitigate adverse symptoms (e.g., anxiety, depression, suicidality, distress, nutritional status, dysphagia, sarcopenia, and well-being) on a sample of head and neck cancer patients. Subjects will attend a Prepare for Surgery Heal Faster session and meet with a physical therapist, registered dietician, speech language pathologist, and masters of social work at pre-treatment, 6-8 weeks post-treatment, and 5-6 months post-treatment completion.
214845077|NCT01800435|DRUG|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
214845078|NCT01800435|DRUG|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
214471991|NCT05810987|OTHER|RESTORE|"Virtual educational curriculum organized into the following modules:~Module Specific Communication Strategies~1. Introduction~2. Preparing for and introducing a conversation \[Consider personal bias /Building rapport /Ask permission\]~3. Assessing understanding \[Avoid correcting /Open ended questions\]~4. Giving information \[Give a warning shot /Using silence /Wish/worry/wonder\]~5. Explore goals \[Reflective listening /Naming, validating emotion~6. Summarizing and recommending a plan \[Values-based recommendation /Aligning with goals /REMAP (Reframe, Expect emotion, Map goals, Align, Propose plan)\]"
214471992|NCT05810987|BEHAVIORAL|Medical Interaction and Coaching|Skills sessions with standardized patients (SPs) along with coaching feedback.
214471993|NCT05516758|DRUG|Peresolimab|Administered subcutaneously (SC)
214471994|NCT05516758|DRUG|Placebo|Administered SC
214471995|NCT05878080|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
214471996|NCT05996848|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide subcutaneously.
214845079|NCT00098228|DRUG|QAB149|
214845080|NCT00556491|DRUG|minocycline|given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
214845081|NCT00556491|DRUG|placebo|placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
214471997|NCT05996848|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide subcutaneously.
214471998|NCT05996848|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
214471999|NCT05996848|DRUG|Placebo Cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
214472000|NCT05511597|BEHAVIORAL|Split-belt treadmill training|Split-belt walking with various speed ratios between the two legs, applied with random-block practice
214472001|NCT05511597|BEHAVIORAL|Complex task practice|Overground gait flexibility training with added cognitive tasks
214472002|NCT05511597|BEHAVIORAL|Static balance exercise|Mindfulness and breathing combined with static balance exercises
214845082|NCT03269799|DRUG|Vitamin C 500 MG Oral Capsule|non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
214845083|NCT03269799|OTHER|placebo|non surgical periodontal treatment+placebo for 2 months
214845084|NCT06366945|DRUG|Carboplatin|Carboplatin AUC 5 on weeks 1, 3, and 6
214845085|NCT06366945|DRUG|Tislelizumab|Tislelizumab 200 mg on weeks 3, 6, and 9;if adjuvant immunotherapy is omitted, Tislelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery
214845086|NCT06366945|DRUG|Polymeric Micellar Paclitaxel|Polymeric Micellar Paclitaxel 300mg/mg/m2 on weeks 1, 3 and 6
214845087|NCT06366945|PROCEDURE|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
214845088|NCT06366945|RADIATION|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic assesment following induction systemic therapy and surgery is ypT(pCR 或 MPR) and ypN(pCR) or ypT（ pCR 或 MPR）and ypN（ MPR）without the presence of Serious Adverse Event, adjuvant radiation will not be administered. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
214845089|NCT00519974|OTHER|counseling intervention|
214845090|NCT00519974|OTHER|study of socioeconomic and demographic variables|
214845091|NCT00519974|PROCEDURE|management of therapy complications|
214845092|NCT00519974|PROCEDURE|psychosocial assessment and care|
214845093|NCT01239472|DRUG|Everolimus|Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
214845094|NCT02334241|DEVICE|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
214285399|NCT00039832|DRUG|Abciximab (ReoPro) and Reteplase (Retavase)|
214472003|NCT05850351|OTHER|Virtual reality|Virtual reality is a simulated experience that creates a virtual environment to give the user the feeling of an immersive virtual world, using glasses and a handheld device that can track hand movements. Activities that will improve the functional and respiratory capacity of children with cystic fibrosis will be developed and integrated into the virtual reality game.
214472004|NCT05850351|OTHER|Online|Online exercises are physical activities that are performed via a video-conferencing tool. Children will be at their home environment and exercises which will improve their functional and respiratory capacity will be instructed and supervised by a physiotherapist.
214472005|NCT03252938|DRUG|IMP321|LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
214472006|NCT03252938|DRUG|Avelumab|Avelumab i.v.
214472007|NCT06345989|PROCEDURE|Alginate impression|Alginate impressions are a traditional method for creating dental moulds which are used in orthodontic records. Plastic trays are sized to fit the upper and lower jaws, and the alginate is mixed into a putty before being placed in the trays. The putty is then used to take detailed impressions of the patient's teeth. To capture an accurate bite registration, the patient bites down on a piece of warmed wax.
214845095|NCT02334241|DEVICE|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
214472008|NCT06345989|PROCEDURE|Intraoral scan|Intraoral scanners capture multiple images of the mouth, which are combined to create a three-dimensional model of the patient's upper and lower teeth. The scanning wand is passed methodically over the surface of the teeth to gather all the necessary information, which is displayed in real-time on a computer screen.
214845096|NCT02201979|PROCEDURE|Vertical breast lift with implants|
214845097|NCT05752188|OTHER|Multimarker approach in acute coronary syndrome|The main objective of the study is to evaluate the prognostic role of the biochemical marker sST2 in patients attending the Emergency Department of our hospital with acute chest pain with suspected acute coronary syndrome.
214285400|NCT01563302|DRUG|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
214845098|NCT01470196|DRUG|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
214845099|NCT01470196|DRUG|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
214845100|NCT01470196|DRUG|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
214285401|NCT02771002|DEVICE|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
214285402|NCT03940404|DRUG|Anlotinib Hydrochloride|Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
214285403|NCT02601690|OTHER|Blood Sampling|
214285404|NCT01993147|BEHAVIORAL|Dual task paradigm pilot|
214285405|NCT05538221|DIAGNOSTIC_TEST|SILEMA|SILEMA consists of a webcam connected to a laptop, a LED reflector, and a software. To carry out gait analysis with SILEMA, an Evaluator must place six yellow auto-adhesive markers over certain anatomical landmarks in the lower limbs, namely, greater trochanter, external femoral condyle, head of the fibula, lateral malleolus and base and head of the fifth metatarsal. The patient is asked to walk barefoot through an eight meter walkway at a self-selected speed, while a webcam connected to a laptop records a video. Then, an Operator, making use of the software, processes the video, obtaining spatio-temporal and joint kinematic parameters.
214285406|NCT00719134|DRUG|Maxalt|anti-migraine drug
214285407|NCT00719134|DRUG|placebo pill|placebo pills
214285408|NCT00719134|DRUG|placebo pills|placebo pills
214472009|NCT00957047|DRUG|eslicarbazepine acetate|oral tablets
214472010|NCT00957047|DRUG|placebo|once daily placebo comparator
214472011|NCT00957047|DRUG|ESL - Part II|Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
214472012|NCT05475379|BIOLOGICAL|Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)|"Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited"
214472013|NCT02824731|RADIATION|Radiation with protons|
214472014|NCT02824731|RADIATION|Radiation with photons|
214472015|NCT05486481|DRUG|Venetoclax|Given orally (PO)
214472016|NCT05486481|DRUG|Dexamethasone|Given PO
214472017|NCT05486481|DRUG|Daratumumab|Given Subcutaneously (SC)
214472018|NCT05486481|DEVICE|Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay|Lab test
214472019|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
214472020|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
214285409|NCT01872988|DRUG|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
214285410|NCT01872988|DRUG|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
214472021|NCT06222671|DRUG|Placebo|Placebo subcutaneous (SC) injection.
214472022|NCT02852655|DRUG|MK-3475|
214845101|NCT04815252|BEHAVIORAL|CHIME|CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
214845102|NCT03018093|BIOLOGICAL|C-CAR-011|CD19-targeted chimeric antigen receptor T cells
214845103|NCT05840094|DRUG|18F-FDG|18F-FDG is injected intravenously with a dose of 0.1mCi/kg.
214845104|NCT05840094|DEVICE|MR STIR|The overall scanning time of MR is about 13min.
214845105|NCT05840094|PROCEDURE|EBUS-TBNA|Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively
214845106|NCT02839486|OTHER|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
214845107|NCT02839486|OTHER|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
214845108|NCT03974165|OTHER|Cereal-legume product 1|The intervention examines the effect of cereal based product fortified with legumes-1 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
214845109|NCT03974165|OTHER|Cereal-legume product 2|The intervention examines the effect of cereal based product fortified with legumes-2 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
214845110|NCT03974165|OTHER|Cereal product|The intervention examines the effect of cereal product in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
214845111|NCT03974165|OTHER|Reference food|The intervention examines the effect of reference food in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
214845112|NCT03433365|OTHER|MRD analysis|To collect 2 samples for MRD analysis in patients treated with Lenalidomide
214845113|NCT06616012|DEVICE|Neosense umbilical catheter|The Neosense umbilical catheter is used instead of a standard umbilical catheter
214845114|NCT06616948|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
214845115|NCT06616948|BEHAVIORAL|coaching calls|individuals will receive a phone call every 14 days to discuss ongoing exercise maintenance efforts.
214845116|NCT06616948|BEHAVIORAL|No coaching calls|Following completion of the 6-month cycling sessions, no maintenance calls will be placed.
214845117|NCT02667821|OTHER|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
214845118|NCT01996384|PROCEDURE|Classical Acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
214845119|NCT01996384|PROCEDURE|Non-classical acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
214845120|NCT01996384|DRUG|Lidocaine|Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
214285411|NCT03933345|OTHER|Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.|At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.
214285412|NCT01654341|BEHAVIORAL|Exercise, dietary and educational program|
214285413|NCT03547180|BEHAVIORAL|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
214845121|NCT03384706|BEHAVIORAL|Cognitive Processing Therapy (CPT)|"CPT looks at the impact the traumatic event has had on your life and helps you to examine and change unhelpful thoughts and feelings related to the event, yourself, others and the world.~CPT will be conducted in 5-15, 60 minute sessions held once or twice a week."
214845122|NCT03384706|BEHAVIORAL|Accelerated Resolution Therapy (ART)|"ART, like CPT also involves processing thoughts and feelings related to the event, but does this in a different way relying more on visualization or imagination rather than talking.~ART will be conducted in 5-15, 60 minute sessions held once or twice a week."
214845123|NCT06364878|DIAGNOSTIC_TEST|In vivo confocal microscopy|The patients cornea will be examined non-invasively by IVCM
214845124|NCT06364878|DIAGNOSTIC_TEST|Tear film sampling|Patients tear film will be collected and stored at -80 degrees for analysis
214845125|NCT03367325|DEVICE|CDS-NVAF|The CDS-NVAF is intended for patients diagnosed with NVAF and treated with VKA. This tool calculates the time in the therapeutic range (TTR) using the Rosendaal method considering the last International Normalized Ratio (INR) data. The INR data are found in the clinical history of NVAF patients. The CDS-NVAF will be activated when the physician introduces the last INR value. At this time the TTR will be calculated automatically. If the TTR value is \< 65%, a pop up screen with a warning text will open suggesting a change to DOAC therapy. The physician can decide whether to change or not the previous prescription. If the TTR value in \> 65% the pop up screen will not appear. The TTR value will remain registered on the screen of the follow up of oral anticoagulant use and can be consulted in future queries. The diffusion of the CDS-NVAF will be made by an announcement on the first day of the intervention when the health care professional opens the electronic clinical history.
214845126|NCT00362830|DRUG|vinflunine + ixabepilone|solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
214285414|NCT03547180|BEHAVIORAL|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
214285415|NCT03547180|BEHAVIORAL|In-vivo exposure|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
214285416|NCT03776383|OTHER|Antibiotic use feedback letter|Mailed letters indicating that the physician prescribes more antibiotics than 75% of their peers
214285417|NCT00557960|DRUG|Mixed salts of a single-entity amphetamine|
214285418|NCT00557960|DRUG|Atomoxetine hydrochloride|
214285419|NCT05213650|OTHER|non-abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Non-abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
214285420|NCT05213650|OTHER|abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
214285421|NCT05213650|OTHER|Efferdent|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water.The Efferdent tablet will be used once a week as an intervention to aligner cleaning during invisalign treatment.
214285422|NCT05213650|OTHER|Cleaning Crystals|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Invisalign Cleaning Crystals will be used once a week as an intervention to aligner cleaning during invisalign treatment.
214285423|NCT02603094|PROCEDURE|clear fluid ingestion|drinking of clear fluid in preoperative period
214285424|NCT06152978|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
214285425|NCT06152978|DRUG|Chemotherapy|Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
214285426|NCT00482612|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
214285427|NCT00482612|DRUG|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
214285428|NCT01366521|BIOLOGICAL|Mepolizumab|Monoclonal antibody
214285429|NCT04097002|BIOLOGICAL|ORCA-010|The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.
214285430|NCT00660023|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
214285431|NCT03804047|OTHER|kinesio tape|kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
214285432|NCT00684307|DRUG|AZD0837|ER tablet, PO, once daily for a period of 3-9 months.
214285433|NCT00684307|DRUG|Vitamin-K antagonist at INR 2-3|Tablet, PO for a period of 3-9 months.
214285434|NCT00684307|DRUG|AZD0837|ER tablet, PO, twice daily for a period of 3-9 months
214285435|NCT00928603|PROCEDURE|Focal Cryoablation|Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
214285436|NCT00275184|DRUG|Senna|
214845127|NCT01842126|BIOLOGICAL|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
214845128|NCT01842126|BIOLOGICAL|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
214845129|NCT01842126|DRUG|Placebo IV|Ascending Doses intravenous (IV) of Placebo
214285437|NCT00275184|DRUG|Citramag powder|
214285438|NCT00275184|DRUG|Metoclopramide|
214472023|NCT05100043|BIOLOGICAL|IL-4 and IFN-γ measurements|Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
214472024|NCT06436742|BIOLOGICAL|ARGX-119|Intravenous infusion of ARGX-119
214845130|NCT01842126|DRUG|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
214845131|NCT01655524|DRUG|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
214285439|NCT06040060|DRUG|Ketamine|The intervention was prepared by the research team (anesthesia resident) in the form of ketamine which had been diluted to a dosage of 10 mg/cc, taken according to the required dose based on actual body weight then diluted with 0.9% NaCl to 10 cc. Then the two solutions were given to researchers without knowing the contents of the drugs that had been prepared by the resident who assisted in this research.
214285440|NCT06040060|OTHER|Placebo|While the 0.9% NaCl solution was used as placebo was prepared in a 10 cc syringe
214845132|NCT02642796|DEVICE|transcutaneous electric nerve stimulation|"The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.~Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound."
214845133|NCT01638858|DRUG|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
214845134|NCT03585907|DIETARY_SUPPLEMENT|MAD|A high fat, low carbohydrate diet
214845135|NCT03585907|DIETARY_SUPPLEMENT|MIND|A combination of the Mediterranean and DASH diets
214845136|NCT00742599|DRUG|NPO-11|20 ml NPO-11
214845137|NCT00742599|DRUG|Placebo|20 ml NPO-11(Placebo)
214845138|NCT03574311|DRUG|Ferric carboxymaltose|A single dose of drug or placebo is administered preoperatively to participants
214845139|NCT03574311|OTHER|Physiological saline|Single infusion 100 ml physiological saline infusion preoperatively
214845140|NCT01280617|DRUG|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
214285441|NCT04883502|BIOLOGICAL|Blood sample collection|A blood sample will be collected at enrollment.
214285442|NCT04883502|BIOLOGICAL|Other biological sample collection|"The following biological samples will be collected during the first surgery:~* 1 blood sample~* 3 fragments of induced membrane~* 1 fragment of periosteum"
214285443|NCT04883502|DIAGNOSTIC_TEST|Surgical waste collection|The pieces of polymethylmethacrylate surgical cement will be collected during the second surgery.
214845141|NCT01280617|DRUG|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
214845142|NCT03452072|DRUG|0.25% Timolol gel with paraffin gauze dressings|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
214845143|NCT03452072|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
214845144|NCT05966090|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
214845145|NCT05966090|BIOLOGICAL|HZ/su vaccine|Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.
214845146|NCT00692224|DRUG|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
214845147|NCT00692224|DRUG|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
214845148|NCT04247984|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered on day 1 of a 2-week cycle.
214845149|NCT04247984|DRUG|Capecitabine|2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.
214845150|NCT04247984|DRUG|Irinotecan|180 mg/m2 intravenously administered on day 1 of a 2-week cycle.
214845151|NCT04247984|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 and 2400 mg/m2 continuous infusion over 44 hours of a 2-week cycle.
214845152|NCT04247984|DRUG|CF|300 mg/m2 intravenously administered on day 1 of a 2-week cycle.
214845153|NCT04247984|DRUG|Irinotecan|150 mg/m2 intravenously administered on day 1 of a 2-week cycle.
214845154|NCT03744078|DEVICE|Foley balloon catheter|18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
214845155|NCT00512837|BEHAVIORAL|Mobile phone technology|
214845156|NCT05640336|PROCEDURE|Single Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint. The polyethylene (plastic) insert, which acts as the articulating surface (modular component) of the prosthesis, will be removed and the exposed surfaces scrubbed, sterilized, and soaked. A new modular component will be placed with additional irrigation and antiseptic soak. Tissue cultures will be sent to the lab for further evaluation and antibiotic guidance. After the operation subjects will continue six weeks of IV antibiotics followed by oral antibiotic suppression for the life of the implant or at least two years after operation.
214845157|NCT05640336|PROCEDURE|Planned Double Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint with an additional irrigation and debridement scheduled for approximately 5 days after the initial DAIR. During the first washout, antibiotic cement beads will be placed in the joint and these will remain in the interim until they are removed during the second washout. During the second DAIR, the antibiotic beads are removed, and the modular components are once again removed and replaced with new components. Exposed surfaces are again irrigated and debrided following a standardized protocol. A six-week course of IV antibiotics will follow the DAIR with additional oral antibiotics for the life of the component (standard of care) or at least a minimum of two years.
214845158|NCT05135819|BEHAVIORAL|Cyber School for Grandparents|Educational program for secondary school students to become cyber tutors for their grandparents or for senior citizens, who are interested to learn new digital use and skills.
214285444|NCT04883502|DIAGNOSTIC_TEST|Radiological examination and functional exploration|A radiological examination and a functional exploration will be performed 6 weeks, 3 months and 6 months after the first surgery
214285445|NCT03506815|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg po daily x 90 (+/- 3 days)
214285446|NCT01502449|BEHAVIORAL|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
214285447|NCT01502449|OTHER|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
214845159|NCT03536182|RADIATION|Carbon Ion Radiation Therapy (CIRT)|Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
214845160|NCT03536182|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
214285448|NCT04497805|BIOLOGICAL|ALLO-ASC-SHEET|Hydrogel sheet containing Allogenic Mesenchymal Stem Cells
214845161|NCT06125756|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
214285449|NCT04160091|DRUG|FX006|Single intra-articular injection
214285450|NCT04160091|DRUG|Normal Saline|Single intra-articular injection
214285451|NCT01003730|OTHER|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
214285452|NCT05062798|PROCEDURE|Standart bottle|"1. After the surgery, standard bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
214285453|NCT05062798|PROCEDURE|Squeezable bottle|"1. After the surgery, squeezable bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
214285454|NCT02681562|DRUG|olaparib|
214285455|NCT04458974|DEVICE|Transcranial direct current stimulation|"The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour."
214285456|NCT04458974|PROCEDURE|Neuropsychological rehabilitation|"The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session)."
214285457|NCT05486676|BEHAVIORAL|VR-Moodboost; a Virtual Reality intervention for depression to enhance positive affect and reduce depressive symptoms.|All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
214285458|NCT06227845|OTHER|Fecal microbiota transplant|0.1-0.3 ml liquid containing 3.5 mg/ml of maternal fecal content, (0.35mg/kg)
214285459|NCT06278467|DIAGNOSTIC_TEST|visual pain scale (VASpain/fatigue), Beck depression index (BDI),|VAS (0-10)
214285460|NCT06278467|DIAGNOSTIC_TEST|Pain catastrophizing scale, sleep quality with a single Likert type question in the Pittsburgh questionnaire|PCS (Pain catastrophizing scale); sleep quality with a single Likert type question in the Pittsburgh questionnaire (0-3)
214285461|NCT06278467|DIAGNOSTIC_TEST|Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36),|functional disability level with Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36)
214285462|NCT06278467|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale (MOCA); Standard Mini mental test (SMMT)|cognitive status was measured by Montreal Cognitive Assessment Scale (MOCA) and Standard Mini mental test (SMMT)
214285463|NCT05647434|PROCEDURE|sustained inflations|Sustained inflation will be applied at a pressure of 30 cmH2O and will be held for a period of 30 secs. After each SI the standard ventilatory settings will be resumed with a PEEP setting of 8 cmH2O to prevent lung derecruitment. Lung recruitment will be stopped immediately if mean arterial pressure and/or heart rate change by at least 25% from baseline values.
214472025|NCT06436742|OTHER|Placebo|Intravenous infusion of placebo
214472026|NCT02123082|DEVICE|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
214285464|NCT04755127|PROCEDURE|Arthroscopic synovectomy of the wrist|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
214285465|NCT04755127|DRUG|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
214845162|NCT06125756|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
214845163|NCT06125756|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
214285466|NCT06408532|DRUG|IDegLira|The participants in this group will be switched to IDegLira once daily injection therapy.
214285467|NCT06408532|DRUG|Premixed insulin|The participants in this group will be have optimized premixed insulin regimen.
214285468|NCT04378218|BEHAVIORAL|High Intensity Interval Training (HIIT)|A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
214285469|NCT05532592|OTHER|Perceptions and attitudes towards COVID-19 and COVID-19 vaccine|Attitude towards COVID-19; Knowledge about COVID-19 vaccine
214285470|NCT01405599|DRUG|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
214285471|NCT01075724|DEVICE|Patient Warming with Forced Air|Forced Air warming via BairHugger
214285472|NCT01075724|DEVICE|Resistive Warming|Resistive Warming via HotDog device
214285473|NCT01529255|DRUG|telbivudine (ROADMAP)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
214285474|NCT01529255|DRUG|Telbivudine (Standard of Care)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
214285475|NCT02496273|BIOLOGICAL|CTL|Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
214285476|NCT04740788|DEVICE|Monofocal IOL|Patients are already implanted with a monofocal lens
214285477|NCT01443650|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
214285478|NCT02895906|DRUG|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
214285479|NCT02033694|DEVICE|NIRS-IVUS Imaging (TVC Imaging System)|Diagnostic Imaging Catheter
214845164|NCT04423159|BIOLOGICAL|OCV Vaccine|2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.
214285480|NCT04410224|DRUG|ASN004|ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
214285481|NCT02899988|DRUG|Mirikizumab|Administered SC
214285482|NCT02899988|DRUG|Placebo|Administered SC
214285483|NCT01819402|DRUG|Pioglitazone vs Glimepiride|
214285484|NCT03836937|DRUG|Obeticholic acid|Farnesoid X receptor ligand which is a semi synthetic bile acid analogue
214285485|NCT01618994|PROCEDURE|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
214285486|NCT01295502|DRUG|Carboplatin|Given IV
214285487|NCT01295502|DRUG|Cisplatin|Given IV
214285488|NCT01295502|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214285489|NCT01295502|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
214285490|NCT01295502|DRUG|Paclitaxel|Given IV
214285491|NCT01652560|DRUG|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
214472027|NCT02123082|DEVICE|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
214472028|NCT06295237|DEVICE|Intellisync+|mechanical ventilator software automatically detecting and adjusting ventilator parameters to control or reduce the number of events.
214845165|NCT04186559|DRUG|Topical Pentoxifylline Gel (Vehicle +PTX)|Patients will be given 1 tube containing 20 ml of topical PTX gel (containing 1,000mg of PTX) to be applied no fewer than four times per day with complete consumption of the entire tube each day.
214845166|NCT04186559|DRUG|Topical Placebo Gel (Vehicle)|Patients will be given 1 tube containing 20 ml of topical placebo gel to be applied no fewer than four times per day with complete consumption of the entire tube each day.
214845167|NCT06090682|DEVICE|Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)|We observed the changes in cognitive function of patients before and after different brain stimulation treatments, and further compared the effects of different brain stimulation treatments on cognitive function of PD patients and the related mechanisms according to whether DBS surgery was performed or TMS therapy was given only according to the surgical indications.
214845168|NCT04147962|DEVICE|intense pulsed light (usual practice)|collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
214845169|NCT01162278|RADIATION|SBRT|Single fraction SBRT
214845170|NCT02001051|PROCEDURE|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
214285492|NCT03935529|BEHAVIORAL|Behavioural Activation|"Participants will receive five sessions of Behavioural Activation. Behavioural Activation uses strategies such as activity scheduling, mastery and pleasure ratings, and graded task assignments to change a participant's perception of specific situations.~Behavioural Activation is based on the behavioural model of depression (Lewinsohn \& Shaffer, 1971). Specifically, that depression is a result of reduced positive reinforcement, particularly in social relationships. Behavioural Activation aims to reduce depressive symptoms by implementing a schedule of positive reinforcement by altering a participant's behaviour and/or their environment. As, in certain environmental contexts, behaviours that reduce depression will continue to occur through reinforcement and those that increase depression will decrease over time (Roane, Fisher, \& Carr, 2016).~Behavioural Activation has been shown to be an effective intervention for the reduction of depressed mood."
214285493|NCT02062034|DRUG|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
214285494|NCT02062034|DRUG|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
214285495|NCT02062034|DRUG|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
214285496|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
214285497|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
214285498|NCT02056782|DRUG|Dociparstat sodium|"The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days."
214285499|NCT02555189|DRUG|Enzalutamide|Given PO
214285500|NCT02555189|DRUG|Ribociclib|Given PO
214285501|NCT02555189|OTHER|Laboratory Biomarker Analysis|Correlative studies
214285502|NCT02555189|OTHER|Pharmacological Study|Correlative studies
214285503|NCT02555189|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214285504|NCT02555189|PROCEDURE|Biopsy|Undergo tumor biopsy
214285505|NCT02555189|PROCEDURE|Echocardiography|Undergo ECHO
214285506|NCT02555189|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214285507|NCT02555189|PROCEDURE|Bone Scan|Undergo bone scan
214285508|NCT02555189|PROCEDURE|Computed Tomography|Undergo CT
214285509|NCT02555189|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214285510|NCT02037698|DEVICE|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
214285511|NCT05183373|OTHER|Evaluation of inflammation and clotting|Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)
214285512|NCT02933125|BEHAVIORAL|Group psychotherapy|"Motivational enhancement psychotherapy (MEP) for Youths:~The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.~Parenting skill training (PST) for Caregivers:~The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist."
214285513|NCT02933125|BEHAVIORAL|Standard supervision|The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
214285514|NCT02554266|DEVICE|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
214472029|NCT05386563|PROCEDURE|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|"taVNS will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (cymba concha, earlobe, and ulnar side of the wrist). Stimulation is delivered by a 3000ms pulse train (100us pulse width and 25Hz stimulation frequency). The current applied will be between 0.01uA to 9uA. The intervention will be delivered over the course of four sessions approximately one week apart."
214285515|NCT06460857|OTHER|Manual Diaphragmatic Release Technique|Manual Diaphragmatic Breathing Technique, 2 sets with a 5 min rest interval between sets will be given, patient will lie supine in a relaxed position, Therapist will stand behind the patients head with the therapist forearm aligned towards patient shoulders, the hypothenar and the last three fingers of therapist hand will make contact bilaterally with underside of 7th, 8th, 9th, and 10th ribs costal cartilages, Patient is instructed to inhale deeply, therapist will pull the contact sites towards head and slightly in a lateral direction, during expiration therapist increases the contact depth beneath costal margins and maintain the resistance, therapist will continue to increase the depth of contact in the coming deep breath. Initially patient will be asked to take 5 deep breath/ set in the first week then it will progress to 10 deep breaths in the second,third and fourth week.
214472030|NCT05386563|PROCEDURE|Sham Stimulation|"Sham stimulation will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (either earlobe or forearm)."
214472031|NCT03149822|DRUG|Cabozantinib|Pharmaceutical form: tablets Route of administration: oral
214472032|NCT03149822|DRUG|Pembrolizumab|Pharmaceutical form: solution Route of administration: injection
214472033|NCT05965830|DEVICE|Diaphragm ultrasound|A single, simultaneous assessment of the diaphragm muscle functioning through dEMG and dUS at the time of spontaneous breathing.
214472034|NCT05232032|DRUG|Nociceptin Receptor Antagonist|Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.
214472035|NCT05232032|DEVICE|Aversive stimuli|As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
214472036|NCT03900221|OTHER|No intervention|No intervention
214285516|NCT06460857|OTHER|Chest Wall Expansion Exercises|Four different types of chest exercises will be given to second group for 2-3 days/week for 4 weeks along with generalized body stretching
214285517|NCT00709046|DRUG|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
214285518|NCT00709046|DRUG|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
214285519|NCT01091493|DRUG|Moxifloxacin|Moxifloxacin 400 mg administered once a day for 5 days
214845171|NCT02001051|OTHER|Observation|Observation for 6 months prior to surgery
214845172|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin level|Serum ferritin level will be collected with other clinical labs and measured in the research lab
214845173|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin iron content|Blood will be collected with other clinical labs and the iron content in the ferritin will be measured in the research lab
214845174|NCT03777904|DIAGNOSTIC_TEST|Urine Ferritin level|Urine will be collected non-invasively and analyzed for ferritin level
214845175|NCT03777904|DIAGNOSTIC_TEST|Urine ferritin iron content|Urine will be collected non-invasively and analyzed for iron content within the ferritin
214845176|NCT03841890|DEVICE|the Clarus Video System as a video stylet|video-guided intubation
214845177|NCT03841890|DEVICE|the Clarus Video System as a lightwand|The endotracheal tube will be initially guided into larynx in the dimly lit operating room by a bright glow moving in the anterior soft tissue of the neck and finally by the image of the trachea rings on the video screen.
214845178|NCT03841890|DEVICE|direct laryngoscope|Macintosh laryngoscope size 3
214845179|NCT03816449|OTHER|exercises|"Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks."
214845180|NCT06532968|DEVICE|Sham|Sham
214845181|NCT06532968|DEVICE|ORION spinal lamina cover|an artificial lamina coverage of the ORION spinal system
214845182|NCT03460158|DRUG|Restylane-L®|Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
214845183|NCT03460158|DRUG|Restylane-L® Lyft|Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
214845184|NCT03460158|DRUG|Restylane Silk®|Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
214472037|NCT03153683|OTHER|Registry|Collect standard of care clot, tissue and arterial blood during standard of care cerebrovascular procedure for lab analysis.
214845185|NCT01660477|DRUG|Isavuconazole|oral
214845186|NCT01660477|DRUG|Lopinavir/ritonavir|oral
214845187|NCT02136238|DEVICE|Hosmer 5XA voluntary opening hook|"Voluntary opening prosthetic terminal device (hand)"
214845188|NCT02136238|DEVICE|TRS Grip 3 voluntary closing hook|"Voluntary closing prosthetic terminal device (hand)"
214845189|NCT05878041|DIAGNOSTIC_TEST|Molecular and genetic screening|Molecular and genetic screening
214845190|NCT03952988|DIETARY_SUPPLEMENT|Probiotic ice cream|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (\>10(exp7)/g) every day for 4 weeks
214845191|NCT03952988|DIETARY_SUPPLEMENT|Placebo ice cream|One portion (50g) of an ice-cream without probiotic every day for 4 weeks
214845192|NCT04013698|OTHER|PEEP level 5 cmH2O|PEEP level set for 45 minutes
214845193|NCT04013698|OTHER|PEEP level 15 cmH2O|PEEP level set for 45 minutes
214845194|NCT03989011|DIAGNOSTIC_TEST|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celsius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
214285520|NCT01059825|DRUG|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
214285521|NCT01059825|DRUG|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
214285522|NCT01059825|DRUG|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
214285523|NCT01059825|DRUG|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
214285524|NCT01059825|DRUG|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
214285525|NCT01059825|DRUG|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
214285526|NCT01059825|DRUG|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
214472038|NCT03758625|BIOLOGICAL|a1DC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
214845195|NCT03989011|DIAGNOSTIC_TEST|Arterial stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~* Peripheral pressure parameters~* Central and abdominal aneurysm pressure parameters (derived using a transfer function)~* Cardiac output parameters (SEVR, ED)~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
214285527|NCT05639374|BEHAVIORAL|BASICS_HealthyClassroom|First, they will complete a 22-item online questionnaire, collecting all the variables of the research. After completing it, the students in the intervention group will receive personalized feedback by mail that visually summarizes the content of the questionnaire. Students will receive a motivational intervention with the aim of increasing the university's awareness of their alcohol consumption. In the intervention session of the program, the following aspects may be addressed, whenever the participant wishes: 1) Pattern of alcohol consumption of the student; 2) Social norm of alcohol consumption; 3) Negative consequences of alcohol; 4) Costs of alcohol consumption; 5) The change; 6) Specific education on alcohol; and 7) Advice and recommendations.
214285528|NCT04830020|DRUG|HMW-HA|Aerolized administration b.i.d.
214845196|NCT04888533|OTHER|EHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool|EHSSA will be used to evaluate every patient for suicide risk.
214285529|NCT03131050|DRUG|Scopolamine|Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
214285530|NCT03131050|DRUG|Escitalopram|Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
214285531|NCT03131050|DRUG|Saline|Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
214285532|NCT06124612|DIAGNOSTIC_TEST|Thrombotic assessment|"GTT~The Global Thrombosis Test (GTT) (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~TEG Thromboelastography (TEG, Haemonetics Corporation, USA) is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Citrated plasma will be stored for subsequent evaluation of thrombosis and fibrinolysis markers (including but not restricted to D-dimer, PAI-1, hs-CRP, NETs)"
214845197|NCT00529217|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
214285533|NCT02599272|OTHER|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
214285534|NCT02599272|OTHER|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
214285535|NCT02599272|OTHER|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
214285536|NCT02187484|DRUG|BIBR 277|
214285537|NCT04519151|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
214285538|NCT04519151|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
214285539|NCT05741567|PROCEDURE|correction of anterior prolapse|percentage of failed prolapse correction
214285540|NCT00168688|DIETARY_SUPPLEMENT|multi micronutrient supplement|
214285541|NCT00168688|DIETARY_SUPPLEMENT|MN1|Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
214285542|NCT00168688|DIETARY_SUPPLEMENT|MN2|Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
214285543|NCT02329249|BEHAVIORAL|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
214285544|NCT02329249|OTHER|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
214285545|NCT05964244|DEVICE|Vela Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
214285546|NCT05964244|DEVICE|Nivairo Standard Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
214285547|NCT05398211|BEHAVIORAL|Preferred Recorded Music (PRM)|Preferred Recorded Music (PRM) involves a credentialed music therapist in planning and administering, which qualifies it as music therapy, which is defined as a professional use of music and its elements to improve physical, social, communicative, emotional, intellectual, and spiritual health, optimize quality of life and wellbeing(Aigen, 2013; Bruscia, 2014). PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. During the PRM intervention the MT will start/stop the music and otherwise not engage with the participants during the listening session.
214285548|NCT05398211|BEHAVIORAL|Preferred Live Music (PLM)|Preferred Live Music (PLM) involves a credentialed music therapist in planning and administering which qualifies it as music therapy, which is defined as professional use of music and its elements to improve physical, social, communicative, emotional, intellectual and spiritual health, optimize quality of life and wellbeing (Aigen, 2013; Bruscia, 2014).PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. The MT will be more actively engaged in a musical interaction with the participants in the PLM interventions.
214285549|NCT02711540|PROCEDURE|Balloon Aortic Valvuloplasty|Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
214845198|NCT03776617|PROCEDURE|scalp block|Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
214472039|NCT03758625|BIOLOGICAL|a1DC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
214472040|NCT03758625|BIOLOGICAL|a1DC + no antigen|Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
214472041|NCT03758625|BIOLOGICAL|pgDC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
214472042|NCT03758625|BIOLOGICAL|pgDC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
214472043|NCT03758625|BIOLOGICAL|pgDC + no antigen|Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
214472044|NCT05903222|OTHER|Non-Interventional|This study is a non-interventional study of all patients previously enrolled in the PALACS trial
214472045|NCT02443961|BIOLOGICAL|Mesenchymal Stem Cell (MSC) therapy|3 doses of 5 million MSC will be administered
214472046|NCT02278887|PROCEDURE|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
214472047|NCT02278887|DRUG|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
214472048|NCT02278887|DRUG|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
214472049|NCT02278887|DRUG|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
214472050|NCT02278887|DRUG|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
214472051|NCT05674409|BEHAVIORAL|Brief Family-Involved Treatment (B-FIT)|Brief Family-Involved Treatment (B-FIT) is a manualized, 3-session intervention for Alcohol Use Disorder (AUD). Designed to be implemented in combination with any existing alcohol treatment program, the goals of B-FIT are to (1) increase reinforcement for AUD treatment engagement, (2) increase positive rewards from drinking reductions, and (3) decrease drinking cues by decreasing negative communication and increasing positive communication.
214472052|NCT05674409|BEHAVIORAL|Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)|Participants will receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).
214472053|NCT04715893|OTHER|Ostomy belt|Stealth ostomy belt continuous for eight weeks
214472054|NCT05920148|PROCEDURE|Knee arthroplasty|At multiple timepoints (i.e., ± 6 weeks before, and 1 day, 1 week, ± 2 weeks, and ± 6 weeks after surgery) before and after total knee replacement surgery blood will be collected to assess immune functioning
214472055|NCT05833867|DRUG|Sacituzumab govitecan|8 mg/kg Sacituzumab Govitecan is to be administered intravenously in 21-day cycles on Day 1 and Day 8; the next cycle should start a minimum of 14 days after the Day 8 dose (i.e., the Day 8 infusion will be counted as the first day of that 14-day period).
214472056|NCT05833867|RADIATION|Adaptive Radiotherapy|Concurrently, participants will receive an individualized tailored plan for radiation therapy.
214472057|NCT05843188|DRUG|Hydroxychloroquine|Anti-Inflammatory - antimalarial - aminoquinolines
214472058|NCT05843188|DRUG|Irinotecan|Antineoplastic agent
214472059|NCT05843188|DRUG|Leucovorin|Folic acid derivative
214472060|NCT05843188|DRUG|Fluorouracil|Antineoplastic agent
214472061|NCT05843188|DRUG|Bevacizumab|Antineoplastic agent
214472062|NCT05110989|DEVICE|AtriCure Cryo Nerve Block (cryoNB) Device Family|Use of Atricure Cryo Nerve Block Device Family to generate cryoanalgesia for the management of post operative pain.
214472063|NCT04900350|DRUG|AK117|Subjects receive AK117 intravenously.
214472064|NCT04900350|DRUG|Azacitidine|Subjects receive Azacitidine subcutaneously.
214472065|NCT05166850|BEHAVIORAL|PICHA7 mHealth program|The PICHA7 mHealth program is first delivered during a health facility visit by a health promoter bedside to a diarrhea patient (adults and child) and their accompanying household members during the time of illness followed by two home visits during the 7-day high risk period for diarrheal disease transmission. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A diarrhea prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After health facility delivery of the program, patient households receive weekly voice and text messages from the PICHA7 mHealth program over 12 months on the recommended WASH behaviors.
214472066|NCT05166850|OTHER|Standard Arm|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
214472067|NCT05159219|DRUG|Colchicine Pill|Anti-inflammatory
214472068|NCT05159219|OTHER|Placebo|Inert ingredients
214472069|NCT06336122|BEHAVIORAL|Peer Coach Training - Weekly|Peer participants will be contacted by peer coaches on a weekly basis.
214472070|NCT06336122|BEHAVIORAL|Peer Coach Training - Biweekly|Peer participants will be contacted by peer coaches on a bi-weekly basis
214472071|NCT03826901|DRUG|delgocitinib|Cream for topical application
214472072|NCT06828094|DIETARY_SUPPLEMENT|enteral nutrition|Nutritionally complete liquid diet used in the study to replace all (exclusive enteral nutrition) or half (partial enteral nutrition) of a participants daily energy intake
214472073|NCT05874362|OTHER|Diagnosis of depressive episode or post traumatic stress disorder|Clinical diagnosis of depressive episode or post traumatic stress disorder, confirmed
214472074|NCT05874362|OTHER|No diagnosis of depressive episode or post traumatic stress disorder|No elements in clinical assessment for the diagnosis of a depressive episode or post traumatic stress disorder
214472076|NCT05728138|BEHAVIORAL|CMAP Plus CBT|Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
214285550|NCT06023823|OTHER|Toe spread out|toe-spread-out exercise.
214285551|NCT06023823|OTHER|Dry needling+Toe spread out|The group will be given 3 sessions of dry needling with Seirin branded 0.6\*50 mm acupuncture needles for trigger pointe in the abductor hallucis muscle and additionally toe-spread-out exercise.
214285552|NCT04362787|DEVICE|High pressure non invasive ventilation in acute hypercapnic respiratory failure|Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
214285553|NCT01868750|DIETARY_SUPPLEMENT|Calcitriol|1.0ug twice daily for 7 days before surgery
214285554|NCT01868750|DIETARY_SUPPLEMENT|Control Pill|placebo pill taken twice daily for 7 days before surgery
214845199|NCT01845116|DRUG|Omegaven®|10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
214285555|NCT00549302|DRUG|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
214285556|NCT00549302|DRUG|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
214845200|NCT03112148|DRUG|10 mg dose MR formulations,10 mg dose of tofacitinib IR solution|"For the the relative bioavailability (BA) assessment , the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).~For the the food effect assessment, the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state."
214845201|NCT01098110|DRUG|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
214845202|NCT01098110|DRUG|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
214285557|NCT02326376|DRUG|anakinra (Kineret)|
214285558|NCT01442233|PROCEDURE|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
214285559|NCT01442233|PROCEDURE|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
214285560|NCT05608889|BEHAVIORAL|Total Worker Health Mindfulness Enhanced Program|"The intervention will be delivered during 12, 45-minute weekly meetings of Correctional Professionals while on shift. Those sessions will be a combination of a video, mindfulness activity, and a group learning activity. It will conclude with members stating personal goals that will be followed up at the next meeting.~Sessions will be scripted to make them easy to implement with high fidelity, and include tasks, learning activities, and wrap-up with practice instructions for each week. Coworkers will be responsible for running the sessions, which promotes shared norms and social support."
214285561|NCT03453944|DEVICE|VentFree prototype (VF03-K) active stimulation|Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)
214285562|NCT03453944|DEVICE|VentFree prototype (VF03-K) sham stimulation|Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
214285563|NCT03585504|DRUG|Etonogestrel contraceptive implant|Etonogestrel contraceptive implant
214285564|NCT03632525|DRUG|Ferric carboxymaltose|Single dose of 20 mg/kg ferric carboxymaltose (maximum 1000 mg for patients with haemoglobin \<14 g/dL or 500 mg for patients with haemoglobin ≥14 g/dL).
214285565|NCT01414114|DRUG|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
214285566|NCT05576714|OTHER|delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis|We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.
214285567|NCT03787953|DRUG|Anti-PD-1/PD-L1 antibodies|The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
214285568|NCT04298892|OTHER|clinical data and sample collection|Patients with hematologic malignancies and disorders will be asked to donate part of the samples collected as per clinical practice for the management of their disease for the aims of this study. In addition, patients will be asked to donate one oral swab sample, and urine samples. Collection of these additional samples is a non-invasive procedure with no associated risks for patients. Clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures) will be collected.
214285569|NCT00105482|DRUG|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
214845203|NCT01098110|DRUG|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
214845204|NCT02147587|DRUG|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
214845205|NCT02147587|DRUG|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
214285570|NCT00105482|DRUG|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
214285571|NCT00105482|BEHAVIORAL|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
214285572|NCT05479071|DIAGNOSTIC_TEST|Blood test|Screening of antibodies against LDL
214285573|NCT04661085|DIAGNOSTIC_TEST|Broader Medical history and clinical tests|Patients will be treated with standard care plus additional blood tests, urine culture and urine flow cytometry,
214285574|NCT04067895|PROCEDURE|epiphysiodesis|All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
214285575|NCT05620563|DRUG|LY3857210|Administered orally
214285576|NCT05620563|DRUG|Placebo|Administered orally
214285577|NCT00869206|DRUG|zoledronic acid|Given IV
214285578|NCT02823288|OTHER|Sonke CHANGE intervention|"The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~1. Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~2. Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~3. Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability."
214285579|NCT01649687|BIOLOGICAL|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10\^7 cells of allogeneic adipose-derived mesenchymal stem cells
214285580|NCT00411645|DRUG|maribavir|100 mg twice daily for up to 12 weeks
214285581|NCT00411645|OTHER|placebo|twice daily for up to 12 weeks
214285582|NCT00389363|DRUG|ALK HDM tablet|
214285583|NCT02326753|DEVICE|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
214285584|NCT02326753|DEVICE|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
214285585|NCT02326753|DEVICE|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
214285586|NCT05728307|DEVICE|neoGuard vital signs monitor|"The neoGuard device is a 4-in-1 wearable vital signs monitor developed by Neopenda, PBC (Chicago, Illinois). The system is designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2). It contains two non-invasive sensors: an optical reflectance pulse oximeter and a digital temperature sensor. These sensors measure signals from the surface of the patient's skin, and algorithms within the device calculate the pulse rate, respiratory rate, SpO2 and temperature.~The device is made of medical grade polyetherimide plastic and can be worn on the forehead through an adjustable band. The PR, RR, temperature and SpO2 data are collected, recorded and transmitted via Bluetooth Low Energy (BLE) to a tablet which can be placed within a range of 20-30 meter distance. The neoGuard technology has received CE mark certification and is also registered with the Kenya Pharmacy and Poisons Board (KPPB)."
214285587|NCT00002942|PROCEDURE|autologous bone marrow transplantation|
214285588|NCT00002942|PROCEDURE|peripheral blood stem cell transplantation|
214285589|NCT05314855|DEVICE|functional MRI|Subjects will undergo functional MRI at 4 time points in 24 hours.
214285590|NCT04528849|DRUG|Gonadotropin dose increment timing|Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
214285591|NCT02302781|OTHER|Questionnaires|Several validated questionnaires, depending on moment in fertility work up or treatment.
214285592|NCT04298554|OTHER|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration
214285593|NCT04298554|OTHER|Hemp Oil|CBD PURE HEMP OIL
214472077|NCT04000971|OTHER|Integrated Stroke Practice Unit|Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, and increase understanding and build positive behavior change for patients and caregivers. Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
214472078|NCT04000971|OTHER|Comprehensive or Primary Stroke Center|Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
214472079|NCT03069326|DRUG|Ruxolitinib|Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
214472080|NCT03069326|DRUG|Thalidomide|Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
214472081|NCT02834390|DRUG|Quizartinib|"\[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21.~\[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19.~\[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19."
214472082|NCT02834390|DRUG|Cytarabine|"\[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5.~\[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5."
214472083|NCT02834390|DRUG|Idarubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2."
214472084|NCT02834390|DRUG|Daunorubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2."
214285594|NCT06071091|DEVICE|Intracranial stenting|"In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible.~Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication."
214285595|NCT06071091|OTHER|Optimal medical care, without additional endovascular procedures|"The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts.~In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion.~The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list):~* Nursing~* Nursing care~* Symptomatic treatments: analgesics for example~* Systematic clinical monitoring and control imaging if necessary~* Rehabilitation if necessary)"
214285596|NCT03290898|BEHAVIORAL|High Intensity Interval Training|Training (HIIT)
214285597|NCT04977908|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid Lispro insulin
214285598|NCT04977908|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Dexcom G6 CGM
214285599|NCT06432920|DEVICE|ResWave|Prototype wearable in-phase chest wall vibration device
214285600|NCT02197845|BEHAVIORAL|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
214285601|NCT02197845|BEHAVIORAL|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
214285602|NCT03073044|DIAGNOSTIC_TEST|BELASTUNGSFRAGEBOGEN PARKINSON KURZVERSION (BELA-P-K)|"we proposed the translation and validation of Bela-p-K, a questionnaire that evaluates the Quality of Life in parkinsonian patients.~we applied the method of translation and back-translation at dutch version of questionnaire. after, we evaluated 103 PD patients with Bela-p-K and PDQ39.~The internal consistency of questionnaire was analyzed calculating alpha-Chronbach. We also evaluated the construct validity correlating Bela-p-K and PDQ39"
214285603|NCT01129479|DRUG|Galantamine|Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.
214285604|NCT01129479|DRUG|Placebo pill|Placebo pill each morning with food for 12 weeks.
214285605|NCT02664701|OTHER|Baseline evaluation with a psychiatrist|Baseline data and questionnaires are established.
214285606|NCT02664701|OTHER|Individual supportive therapy|6 sessions of individual supportive therapy with a psychologist, 1 session per week for 6 weeks
214285607|NCT02664701|OTHER|Cognitive behavioural group therapy|6 sessions of cognitive behavioural group therapy with a psychologist, 1 session per week for 6 weeks
214285608|NCT02664701|OTHER|Evaluations with a psychiatrist|Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.
214285609|NCT06221293|DIAGNOSTIC_TEST|immunoenzyme analysis|immunoenzyme analysis with EVOLIS system
214285610|NCT01943890|DEVICE|Hypertonic saline|1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily
214285611|NCT01943890|PROCEDURE|Physiotherapy|
214285612|NCT05231395|OTHER|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
214285613|NCT05231395|OTHER|Control Group|"Control group will be given breathing exercises 120 times/day, 7days/week, for 8 weeks as home program.~Control group will be followed-up by telephone once a week"
214285614|NCT03793777|DIETARY_SUPPLEMENT|Aronia|daily supplementation
214285615|NCT03793777|DIETARY_SUPPLEMENT|Placebo|daily supplementation
214472085|NCT05717530|PROCEDURE|wound site local anesthesic infiltration|: at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.
214285616|NCT00495339|DRUG|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
214285617|NCT00321802|DRUG|Simvastatin|Patients take 40 mg of simvastatin per day for 6 months.
214906901|NCT01019343|PROCEDURE|MEG|MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.
214906902|NCT01019343|PROCEDURE|EEG|EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.
214285618|NCT00321802|DRUG|Placebo|Placebo
214285619|NCT00320892|DRUG|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
214285620|NCT03143894|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
214285621|NCT03143894|OTHER|Sham tDCS|Sham Transcranial direct current stimulation (tDCS)..
214845206|NCT02759549|BEHAVIORAL|eSMART-MH|eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.
214845207|NCT02759549|OTHER|Mobile Mood Tracking (Mood 24/7)|Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.
214845208|NCT02759549|BEHAVIORAL|Theater Testing Workshop|The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
214285622|NCT04956497|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO under ongoing cardiopulmonary resuscitation (eCPR) in patients with refractory cardiac arrest
214285623|NCT04118166|DRUG|Ipilimumab|Ipilimumab 1 mg/kg, injection
214285624|NCT04118166|PROCEDURE|Cryoablation|Cryoablation of the tumors occur between investigational agent treatment Cycles 1 and 2, and will be performed according to standard procedures
214285625|NCT04118166|DRUG|Nivolumab|Nivolumab 3 mg/kg, injection
214285626|NCT00808366|DRUG|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
214285627|NCT00808366|DRUG|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
214285628|NCT05862233|DRUG|MIL62|An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at Week 1 and Week 3.If the treatment is effective, MIL62 will continue be administered at W25 and W27
214285629|NCT05862233|DRUG|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d in 2 divided doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks±3 days until the target blood concentration of 125\~175 ng/mL was reached.Optimized cyclosporine dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks.
214285630|NCT03521934|DRUG|Sotagliflozin|"Pharmaceutical form: tablet~Route of administration: oral"
214285631|NCT03521934|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214285632|NCT03434275|DRUG|N1539|Once Daily
214285633|NCT03434275|DRUG|Placebo|Once Daily
214285634|NCT04430543|BEHAVIORAL|Cognitive Bias Modification|"CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%)."
214285635|NCT04430543|BEHAVIORAL|Sham Training|"Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)"
214285636|NCT04997811|DRUG|Sodium Valproate, Bezafibrate, Medroxyprogesterone|Sodium valproate tablet 1 x 500mg bd, (starting 1 x 200mg bd) Bezafibrate standard release tablet 2 x 200mg tds, (starting 1 x 200mg tds) Medroxyprogesterone acetate tablet 1 x 400mg bd (starting 1 x 400mg od)
214285637|NCT04997811|DRUG|Danazol|Danazol 1 x 200mg capsules tds, (starting 1 x 200mg od)
214285638|NCT06166160|OTHER|Bulk fill flowable composite SDR Dentsply sirona|caries removal in class II cavities of primary molars and application of experminted restorations
214285639|NCT03020160|DRUG|Emicizumab|Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.
214845209|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular protein|Modular product supplementation is based on most recent breast analysis done for the participant.
214845210|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular carbohydrate|Modular product supplementation is based on most recent breast analysis done for the participant.
214845211|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular fat|Modular product supplementation is based on most recent breast analysis done for the participant.
214845212|NCT05402787|OTHER|Virtual visit|A virtual visit will be made to mothers whose babies are hospitalized in the neonatal intensive care unit
214845213|NCT01546519|DRUG|Vismodegib|oral repeating dose of 150 mg once daily
214285640|NCT03048968|PROCEDURE|Gait, sit-to-stand movement, stair climbing and treadmill gait|Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test. Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
214285641|NCT03048968|PROCEDURE|Sit-to-stand movement and treadmill gait|Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
214285642|NCT03048968|DEVICE|gait enhancing mechatronic system (GEMS)|"Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients."
214285643|NCT03048968|DEVICE|treadmill|Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
214285644|NCT01513473|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
214285645|NCT01513473|DRUG|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
214472086|NCT05717530|PROCEDURE|Erector spina plane block|Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.
214472087|NCT06453850|DEVICE|Use of FLEXIGO delivery catheter|Use of FLEXIGO delivery catheter for implantation of ventricular pacing lead
214472088|NCT05989022|DIAGNOSTIC_TEST|Injection of contrast enhancing agent Gadovist for MRI investigation|Image enhancing contrast agent will be injected to enhance MRI resolution in breast cancer diagnosis
214472089|NCT05989022|DIAGNOSTIC_TEST|Injection of contrast enhancing agent Imeron for B-CT investigation|Image enhancing contrast agent will be injected to enhance B-CT resolution in breast cancer diagnosis
214472090|NCT04165720|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
214472091|NCT06246084|BEHAVIORAL|Endocrine Therapy Education Program|Brief, video-based intervention program to improve endocrine therapy adherence and experiences and to provide detailed education to participants. The intervention is distributed and assessed via the MyEmma platform, a HIPAA-compliant, online communications platform.
214472092|NCT04544007|DRUG|Poly ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
214472093|NCT06553157|DRUG|Statin|Statins are drugs known to help lower total cholesterol and reduce the risk of a heart attack or stroke. Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.
214472094|NCT06553157|OTHER|placebo|placebo
214472095|NCT05402813|OTHER|Pure Tone Audiometry Assessment|Collection of Pure Tone Audiometry data performed in routine practice during study period
214472096|NCT05402813|OTHER|Quality of Life Questionnaires|Collection of Quality of Life questionnaire's answers during study period
214472097|NCT06578052|DRUG|Irinotecan liposome Capecitabine|"Irinotecan liposome: intravenous infusion, day 1, every 2 weeks Capecitabine: oral, twice daily (bid), days 1 to 7, take for one week and then have a one-week interval.~Each 2-week period is considered a treatment cycle, with an expected treatment of 6 cycles. Subsequent maintenance treatment will be determined by the investigator's protocol until disease progression or intolerable toxicity occurs."
214472098|NCT04538742|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
214472099|NCT04538742|DRUG|Durvalumab|Durvalumab: administered as an IV infusion
214472100|NCT04538742|DRUG|Paclitaxel|Paclitaxel: administered as an IV infusion
214472101|NCT04538742|DRUG|Pertuzumab|Pertuzumab: administered as an IV infusion
214472102|NCT04538742|DRUG|Tucatinib|Tucatinib administered orally (tablet) twice daily
214472103|NCT06793306|OTHER|Age|Breast cancer patients were divided into young breast cancer and non-young breast cancer by age 35
214472104|NCT06793306|OTHER|combination therapy|To observe and compare the difference in diagnosis, combined treatment and prognosis between young and non-young breast cancer
214472105|NCT06587906|OTHER|Pulmonary ultrasound examination|All ultrasound scans were performed by the same anaesthetists. Pulmonary ultrasound examination was performed at two time points for each patient: 20 min before starting mechanical ventilation of the lungs when patients were placed in the supine position(preoperative), 20 min after after surgery end at the time the patient was placed in the supine position (postoperative), before Intubation and after extubation Patientswere scanned in the supine position following the pulmonary ultrasound examination method The thorax was divided by the anterior axillary line, the posterior axillary line, and a horizontal line beneath nipple. Twelve intercostal spaces of each area were scanned and analysed. Aeration loss was assessedby calculating the modified LUS score that is calculated mainly using the amount of B-line The pulmonary ultrasound score of the hemithorax (0-18).
214472106|NCT03694145|OTHER|In-Person Eye Examination|Dilated in-person eye examination by a board-certified ophthalmologist or retinal fellow.
214479468|NCT06862245|DRUG|T received propofol at a dose of 2-2.5 mg/kg based on total body weight|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group T received propofol at a dose of 2-2.5 mg/kg based on total body weight. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison.
214285646|NCT01513473|DRUG|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
214285647|NCT02414984|BIOLOGICAL|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
214285648|NCT03890172|OTHER|20-100 ml venous blood will be drawn the from patient into sterilized centrifuge tube ,following centrifuge to separate PRP and at the bed side and tricked onto the ulcer twice weekly|topical application of platelets rich plasma after Centrifugation at diabetic foot ulcer to study group ,history taking . Ankle brachial index (ABI) measuring and laboratory testes including hemoglobin A1c ( HgA1)c,cbc and prothrombin time( pt) and prothrombin concentration ( pc)
214285649|NCT03890172|OTHER|standard treatment|Subjects in the control group will receive Standard Wound Care treatment for chronic ulcers according to accepted medical practices.
214285650|NCT02834507|DRUG|Placebo|Matching placebo capsules
214285651|NCT02834507|DRUG|BIA 3-202|Capsules containing nebicapone 75 mg or 150 mg
214285652|NCT02834507|DRUG|Comtan®|Capsules containing entacapone 200 mg
214285653|NCT02834507|DRUG|Sinemet®|levodopa/carbidopa (Sinemet®) dose patient used to take
214285654|NCT03817788|DRUG|polyethylene glycol|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.
214472107|NCT05806645|OTHER|Risk-guided transition of care intervention delivered through an integrated digital health strategy|Patients will receive transition of care plans that are tailored to their medical profile and risk and embedded within standardized discharge pathways within the EHR- Education and self-management guidance about AKI for patients, Medication guidance based on evidence-based indications for reducing risk of cardiac and kidney outcomes, Recommendations for subsequent laboratory testing of kidney function, proteinuria and electrolytes according to clinical characteristics and risks, Recommendations for timing and nature of PCP follow-up, Information about the patient's AKI and subsequent management provided to PCPs through discharge summary, Recommendations for outpatient Pharmacy follow-up for medication reconciliation and review according to patient risk and medication management gaps, Recommendations for Nephrology referral for high risk patients
214472108|NCT03604913|PROCEDURE|Aortic valve sparing operation|Aortic valve sparing instead of replacement during aortic root replacement
214472109|NCT03604913|PROCEDURE|Bentall operation|Aortic root replacement with replacement of aortic valve
214472110|NCT06827145|DRUG|Vebreltinib|Vebreltinib 100mg oral BID
214472111|NCT06827145|DRUG|Osimertinib|Osimertinib 80mg oral once daily.
214472112|NCT03647098|DRUG|Treatment|Treatment decisions guided by molecular profiling and clinical judgment of principal investigators
214472113|NCT06234345|DRUG|Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg|Participants randomized to this group will receive 1 capsule per inhalation twice a day
214472114|NCT06234345|DRUG|Comparator - Trimbow®|Participants randomized to this group will receive 2 triggering twice a day
214472115|NCT02998528|BIOLOGICAL|Nivolumab|Specified dose on specified days
214472116|NCT02998528|DRUG|Cisplatin|Specified dose on specified days
214472117|NCT02998528|DRUG|Vinorelbine|Specified dose on specified days
214472118|NCT02998528|DRUG|Gemcitabine|Specified dose on specified days
214472119|NCT02998528|DRUG|Docetaxel|Specified dose on specified days
214472120|NCT02998528|DRUG|Pemetrexed|Specified dose on specified days
214472121|NCT02998528|DRUG|Carboplatin|Specified dose on specified days
214472122|NCT02998528|DRUG|Paclitaxel|Specified dose on specified days
214472123|NCT02998528|BIOLOGICAL|Ipilimumab|This arm is closed and no longer enrolling patients.
214472124|NCT06478199|DIAGNOSTIC_TEST|semen analysis|lab invesigation
214472125|NCT05802160|BEHAVIORAL|Good Start Matters - Parenting intervention|The Good Start Matters - Parenting intervention is a 2-month mobile-Health (mHealth) parenting program that aims to improve parenting practices and child health behaviors among British Columbian families of preschoolers. This intervention uses a familial approach and blends the best practices and evidence to promote positive parenting regarding 3 main areas: nutrition, physical activity, and screen-time; which altogether aim to support the development of healthy habits among young children. The mHealth app releases new material on a weekly basis and participants' engagement with the app takes about 30 minutes per week.
214472126|NCT06299124|DRUG|RGT-419B|RGT-419B will be administered orally
214472127|NCT06439407|DEVICE|SAT-014(Software as Medical Device)|SAT-014(Software as Medical Device) + maintain previous treatment
214472128|NCT03674619|PROCEDURE|Anterior discectomy|Anterior discectomy will be performed and a microscope is used. After separation of the platysma muscle the pre-vertebral space is reached by an approach medial to the sternocleido-mastoid muscle and the carotid artery and lateral to the trachea and oesophagus. Then the disc is incided and the corpora are distracted to perform discectomy. Usually the posterior ligament is cut and the spinal root is decompressed and if necessary the arthritic rims are removed. An inter-vertebral fusion device is inserted, two levels are allowed in the spondylosis study.
214472129|NCT03674619|BEHAVIORAL|Conservative treatment|Patients will first attend an experienced specialist in physical medicine and rehabilitation who will answer concerns and questions and if necessary repeat the information given before inclusion. The aim of the brief intervention is to promote better understanding and coping of the condition. The intervention will include supervision by a physiotherapist (6 sessions altogether) and provide advice on how to handle secondary neck muscle pain and dysfunction, reduce eventual fear avoidance, and advice to stay active.
214472130|NCT05781711|DRUG|levodopa-carbidopa|levodopa-carbidopa is the standard therapy used in Parkinson's disease
214472131|NCT05781711|DRUG|Metformin|Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production
214472132|NCT00302887|DEVICE|combined ultrasound therapy|
214472133|NCT00302887|PROCEDURE|connective tissue manipulation|
214472134|NCT00279162|DRUG|Calcipotriene/betamethasone gel and ointment|
214845214|NCT00792584|DRUG|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
214285655|NCT03817788|DRUG|sodium phosphate|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
214285656|NCT01676389|OTHER|Sham OMM|Sham Osteopathic Manual Medicine (OMM).
214285657|NCT01676389|OTHER|Osteopathic Manual Medicine (Body Therapy)|OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
214285658|NCT03679936|DIAGNOSTIC_TEST|PET/CT dynamic scan|This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.
214285659|NCT04445389|DRUG|GX-19|DNA vaccine expressing SARS-CoV-2 S-protein antigen
214285660|NCT04445389|DRUG|Saline|Saline
214285661|NCT05122676|BEHAVIORAL|More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)|"This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains."
214285662|NCT01432860|BEHAVIORAL|In-person counseling|The design is a 3 \[in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care\] X 7 \[baseline, 4, 8, 12, 16, 20, and 24 month follow-up\] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
214285663|NCT01432860|BEHAVIORAL|Workbook|Participants will read a workbook and perform skills training exercises.
214285664|NCT01432860|BEHAVIORAL|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
214285665|NCT06637501|DRUG|Sonrotoclax|Administered orally
214285666|NCT06637501|DRUG|Zanubrutinib|Administered orally
214285667|NCT00134251|DRUG|SLV308|
214285668|NCT02552771|PROCEDURE|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
214285669|NCT02552771|PROCEDURE|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
214285670|NCT05999032|BEHAVIORAL|CASE in person version (High Intensity Package)|Controlling Asthma in Schools Effectively (CASE) is a multi-level school-based asthma management program delivered by a Community Health Worker (CHW) that includes 1) staff training involving education on asthma management in school, 2) child-based asthma management education with an emphasis on control of symptoms in the school setting provided in a group setting during the school day, 3) caregiver education after school involving supporting children's asthma control in the school setting, 4), and provision of an Asthma Action Plan (AAP) to the school for child enrollees.
214472135|NCT03657342|DRUG|Liposomal Cyclosporine A|This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
214472136|NCT03657342|DRUG|standard of care|Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.
214845215|NCT00792584|DRUG|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
214845216|NCT00350987|BEHAVIORAL|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
214845217|NCT02184741|DRUG|GB-0998|Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.
214845218|NCT02184741|DRUG|Placebo|Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
214845219|NCT05236842|DRUG|Sulthiame|oral
214845220|NCT06080659|DIAGNOSTIC_TEST|fMRI|functional MRI
214845221|NCT06080659|DIAGNOSTIC_TEST|CONFMEM|The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
214845222|NCT03862573|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
214845223|NCT03776734|OTHER|Cryotherapy application|Effects of 5-10- 20 minutes cold application on quadriceps muscle
214845224|NCT01140737|DRUG|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
214845225|NCT03904901|DIETARY_SUPPLEMENT|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.
214845226|NCT03904901|DIETARY_SUPPLEMENT|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
214845227|NCT03041207|BEHAVIORAL|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
214845228|NCT00277407|PROCEDURE|NAET with acupressure and/or chiropractic procedures|
214845229|NCT00003707|DRUG|gemcitabine hydrochloride|
214845230|NCT00003707|DRUG|tipifarnib|
214845231|NCT04088747|DIAGNOSTIC_TEST|Ultrasound Imaging|B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
214845232|NCT00055484|DRUG|zonisamide|
214845233|NCT00030641|BIOLOGICAL|oblimersen sodium|
214845234|NCT00030641|DRUG|docetaxel|
214845235|NCT01841541|BEHAVIORAL|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
214845236|NCT01625117|BEHAVIORAL|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
214845237|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously
214845238|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously
215033346|NCT06571682|DEVICE|Target Controlled Infusion|TCI (Target Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
214285671|NCT05999032|BEHAVIORAL|CASE-V remote version (Low Intensity Package)|CASE-V, the low intensity version of CASE, includes similar child and caregiver-based asthma management education that is provided in a remote format with adaptation to integrate technological feature of Zoom. All CASE-V components (for staff, children, and parents) have been adapted to promote engagement (e.g., use of chat and polling function).
214845239|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously
214845240|NCT03068949|BIOLOGICAL|FluBlok|FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
214845241|NCT03068949|BIOLOGICAL|Fluzone|Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
214845242|NCT03068949|BIOLOGICAL|FluCelVax|FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
214845243|NCT03068949|BIOLOGICAL|Fluzone HD|Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly
214845244|NCT03356106|DEVICE|Continuous positive airway pressure (CPAP)|A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
215033347|NCT06571682|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
215033348|NCT05861843|DIAGNOSTIC_TEST|Virtual Reality-based cue exposure paradigm|Virtual Reality (VR) cue exposure to alcohol-associated cues using head-mounted displays (HMD)
214845245|NCT01712815|OTHER|laboratory biomarker analysis|Correlative studies
214845246|NCT01712815|OTHER|pharmacological study|Correlative studies
214845247|NCT01712815|OTHER|questionnaire administration|Ancillary studies
214845248|NCT01712815|RADIATION|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
214845249|NCT01712815|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
214845250|NCT01519947|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants received 50-250 mcg SC according to local label
214845251|NCT00618033|PROCEDURE|Hemodialysis|varying concentration of glucose in dialysate
214845252|NCT01281787|DRUG|Metoprolol|Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
214845253|NCT01281787|DRUG|Losartan|Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
215033349|NCT03495414|OTHER|Brain Imaging|"* Structural MRI (T1 weighted)~* Diffusion Tensor Imaging (DTI)~* resting state functional MRI (rs-fMRI)~* functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation)."
215033350|NCT03495414|OTHER|Cognitive testing|"We will administer neuropsychological tests assessing objective measures for~* intelligence (Ravens Matrices)~* impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~* inhibitory control (Stop Signal Task)."
214845254|NCT02427087|BEHAVIORAL|Continuous Aerobic Training twice|Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
214845255|NCT02427087|BEHAVIORAL|Healthy Diet|Diet group (21) Recommendation for healthy diet.
214845256|NCT01736787|DIETARY_SUPPLEMENT|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
214845257|NCT01736787|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
214845258|NCT03633552|DRUG|Temozolomide|The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
214845259|NCT02741154|DRUG|induction with aromataze inhibitor|letrozole 2.5mg once daily start in the first day of menses for 5days
214845260|NCT02741154|DRUG|HMG|HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
214845261|NCT02741154|DRUG|GnRh a|antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
214845262|NCT02741154|DRUG|HCG|10.000 IU HCG injection when at least three follicles reach 17mm in diameter
214845263|NCT05871333|DRUG|Losartan 50mg Tab|Losartan 50 mg oral tablets
214845264|NCT01226537|DRUG|Taurine|500 mg taurine capsules twice per day for 6 months
214845265|NCT03795584|PROCEDURE|sterile repositionable hemostasis clipping device close the large duodenal papilla incision|After the bile duct stent was placed, the investigators can use sterile repositionable hemostasis clipping device to close large duodenal papilla incision at 11 o'clock on the duodenal papilla.
214845266|NCT01028911|DRUG|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
214845267|NCT01028911|DRUG|Placebo|"Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator."
214845268|NCT03704974|BEHAVIORAL|Video-Based Parent Training Program|An18-20 week evidence-based social cognitive theory-based parenting program where parents see brief video vignettes of effective and less effective parenting and develop concepts to modify their child's behavior.
214845269|NCT03086876|BEHAVIORAL|Level 4 Stepping Stones Triple P (SSTP)|Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
214845270|NCT04513860|DRUG|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
214845271|NCT02559076|BEHAVIORAL|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
214845272|NCT03811132|OTHER|Observation|There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.
215033351|NCT03495414|OTHER|Psychometric|Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).
215033352|NCT03495414|OTHER|Blood test|Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.
214845273|NCT02409186|DRUG|Nimotuzumab|400mg/w，d1, week 1-7
214845274|NCT02409186|RADIATION|radiotherapy|Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
215033353|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (intraoperative)|tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
214845275|NCT02409186|DRUG|chemoradiotherapy Paclitaxel|45 mg/m2, d1, week 1-7
214845276|NCT02409186|DRUG|chemoradiotherapy Cisplatin|20 mg/m2, d1, week 1-7
214845277|NCT02409186|OTHER|placebo|400mg/w，d1, week 1-7
214845278|NCT01992016|DRUG|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
214845279|NCT01303068|DEVICE|13C urea breath test Kit|20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
214845280|NCT04891692|DEVICE|StimaWell 120MTRS system|Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
214845281|NCT06227702|OTHER|Fluid management according to Venous Excess Ultrasound (VExUS) Score|Management of furosemide intravenous infusion according to VeXus results
214845282|NCT03920683|OTHER|Data collection|Retrospective : data from medical record Prospective : vital statuts from follow-up phone call
214845283|NCT05290779|PROCEDURE|selective lumbar nerve root injection|selective lumbar nerve root steroid injection for treatment of radicular pain.
214845284|NCT04886557|PROCEDURE|L4-L5 decompression and dynamic instrumentation|All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (\< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
214845285|NCT02274948|DRUG|Metformin|Metformin in the form of 500mg tablets were administer to the Metformin group
214845286|NCT02274948|DRUG|Placebo|A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
215033354|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (3 hours after operation)|tranexamic acid 1g administered intravenously 3 hours after operation
215033355|NCT02458729|DRUG|0.9% Normal Saline (intraoperative)|0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
215033356|NCT02458729|DRUG|0.9% Normal Saline (3 hours after operation)|0.9% Normal Saline 20ml administered intravenously 3 hours after operation
215033357|NCT02458729|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
215033358|NCT04555759|OTHER|2-minute walk test|The patients will do a 2-minute walk test, using their walking aids or braces
215033359|NCT03731429|DRUG|Lidocaine|prior to extubation
215033360|NCT03731429|DRUG|Saline Solution|Prior to extubation
215033361|NCT02278003|OTHER|memory test|
215033362|NCT02278003|DRUG|Propofol|
215033363|NCT06116123|DEVICE|Massage mattress with cube/block system|Patients with an odd number were assigned to group I, while those with an even number were allocated to group II. Patients in group I were provided with a pressure sore prevention bed featuring a support surface with vibration (massage) capabilities, a cube/block system creating a low-pressure area, and a ventilation system, routinely utilized in the unit. For group II patients, a viscoelastic pressure sore prevention mattress with an orthopedic support surface, routinely employed in the unit, was used.Within the first six hours after admission, patients in both groups underwent initial assessments using the Braden Scale to determine their pressure sore risk. Both groups were monitored for a maximum of four weeks, with daily pressure ulcer assessments conducted using the Pressure Ulcer Observation Form. Pressure sore area in both groups was calculated in square centimeters (cm2) using the Wound Measurement Ruler.
215033364|NCT06263803|OTHER|Music listening, classic physical therapy|Participants will listen to the music pieces Pachabel Canon in D major (20 minutes) and Mozart - Sonata for Two Pianos in D, K. 448 (25 minutes), free from external sounds (max 70 dB through headphones).
215033365|NCT04692506|OTHER|Probiotic|The study product is probiotic
215033366|NCT05425160|OTHER|Progressive lower limb activities (Chair rise and Step ups)|Progressive lower limb activities (Chair rise and Step ups) were be carried out weekly for upto 6 weeks. Before initiation, cardiopulmonary parameters i.e. Heart rate, oxygen saturation, cardiac output and stroke volume were measured at baseline and later at the termination of activity on each week. Initially, five repeated chair rise were conducted through SPPB and the time was noted to complete the task and step ups through 6MWD for a total period of 30 min. Lastly, fatigue component was assessed via FAS.
215033367|NCT05425160|OTHER|Standard aerobic exercise i.e. low intensity walking|Standard aerobic exercise i.e. low intensity walking were conducted in both the groups. Follow up phone calls and 1 OPD visit were scheduled accordingly
215033368|NCT00152126|PROCEDURE|Stem Cell Transplantation|Autologous stem cell transplantation
215033369|NCT00152126|DRUG|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
215033370|NCT04242680|DEVICE|Brainstim DLPFC|"The active tRNS will be delivered to bilateral DLPFC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right DLPFC, F3 and F4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75 milliampere (mA) (100-500 Hz), the duration of stimulation will be 20 min."
215033371|NCT04242680|DEVICE|Brainstim PPC|"The active tRNS will be delivered to bilateral PPC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right PPC, P3 and P4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75mA (100-500 Hz), the duration of stimulation will be 20 min."
215033372|NCT04242680|DEVICE|Brainstim Sham|The same electrode placement will be used as in the stimulation conditions (Brainstim DLPFC or Brainstim PPC), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held five consecutive days for two weeks for a total of ten days.
215033373|NCT04242680|BEHAVIORAL|Cognitive Training|"A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation)."
215033374|NCT00003486|DRUG|antineoplaston A10|
215033375|NCT00003486|DRUG|antineoplaston AS2-1|
215033376|NCT00003486|PROCEDURE|alternative product therapy|
215033377|NCT00003486|PROCEDURE|biological therapy|
215033378|NCT00003486|PROCEDURE|biologically based therapies|
215033379|NCT00003486|PROCEDURE|cancer prevention intervention|
215033380|NCT00003486|PROCEDURE|complementary and alternative therapy|
215033381|NCT00003486|PROCEDURE|differentiation therapy|
215033382|NCT04630483|OTHER|INHA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
215033383|NCT04630483|OTHER|TIVA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
215033384|NCT06062693|DEVICE|smart sensor egg training|The portable hand trainer has three principal functionalities: (I) Grasping, (II) Pronosupination, and (III) wrist and finger extension. Different exercises can be done.
215033385|NCT02947984|RADIATION|Standard Treatment|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
214845287|NCT04624152|BEHAVIORAL|Soccer heading|A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
214285672|NCT05999032|BEHAVIORAL|CASE and HARP in person (High Intensity package)|"Children with poorly controlled asthma will receive both the CASE and HARP programs. HARP is a home-visiting program that includes individualized asthma management education and strategies and supplies for environmental remediation. All 3 visits can be conducted by a CHW. The first includes a walk-through to identify triggers. Asthma education and self-management strategies are provided using a structured protocol and low-literacy flip-book (English or Spanish). Referrals and advocacy are offered to address asthma management barriers (e.g., communication with landlord/housing re: code violation). The 2nd and 3rd visits include delivery of supplies (e.g., HEPA vacuum, pest gels, mattress covers), instruction for use, review of AAP, and follow-up on environmental control recommendations provided during the 1st visit."
214285673|NCT05999032|BEHAVIORAL|CASE-V and HARP-V remote version (Low Intensity package)|"HARP-V replicates the content delivered in HARP in a remote format. The first session includes a virtual walk-through in which the educator uses a structured script and checklist to guide the caregiver through the home and show specific components of the environment (e.g., carpeting, area under the kitchen sink, exhaust fan in bathroom) to identify asthma triggers. Asthma education and self-management strategies are provided using a structured protocol and slide overview based on the HARP flip-book. Supplies for environmental remediation are delivered prior to the 2nd visit. The 2nd and 3rd visit include instruction for use of supplies, review of AAP, and follow-up on recommendations and referrals."
214285674|NCT06147362|DRUG|68Ga-NOTA-PEG2-RM26|Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before the PET/CT scans.
214285675|NCT02516345|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
214845288|NCT00707434|DEVICE|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
214845289|NCT04611984|PROCEDURE|Piezocision|Piezocisions were performed on the mesial and distal sides of the right maxillary canines. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
214845290|NCT04611984|PROCEDURE|Control|The mesial and distal sides of the left maxillary canines served as controls and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
214845291|NCT05440019|DEVICE|IMAGE CAPTURE SESSION|"The M3T FERTIGO® is an instrument to be used by a certified gynecologist and in particular by an IVF expert physician in order to observe and monitor the state of the endometrium lining of patients. The M3T device serves as a mini hysteroscope capable of magnification, capturing images and optional image processing thereof. The M3T enables to acquire in-vivo, magnified images of the endometrium surface, to identify key morphological parameters, calculate their attributes and statistics thereof and compare those for different acquisition images and to some standard tissue state tracks. One may then attempt to predict the Embryo transfer optimal timing, based on this analysis."
214845292|NCT05376618|OTHER|no intervention|no intervention
214845293|NCT01704937|DRUG|Fecal Microbiota Transplant (FMT)|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube"
214845294|NCT05669807|DRUG|Camrelizumab|200mg d1, the first day, every 14 days as a cycle
214845295|NCT05669807|DRUG|Albumin-Bound Paclitaxel|100 mg/m2, the 1st, 8th and 15th days, every 28 days as a cycle
214845296|NCT05669807|DRUG|Irinotecan|180 mg/m2, the first day, every 14 days as a cycle
214285676|NCT02516345|BEHAVIORAL|Incentives|Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
214285677|NCT04370938|BEHAVIORAL|Coping strategies video|No additional description
214285678|NCT02173327|DEVICE|Continuously helm CPAP|6 hours
214285679|NCT02173327|DEVICE|Intermittent Mask CPAP|10min every 2 hour for 18 hours
214285680|NCT05502757|OTHER|Fruit and vegetable provision|Fresh fruits and vegetables are provided to families at no cost
214285681|NCT00904644|DRUG|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
214285682|NCT06162221|DRUG|RMC-6291|Oral tablet
214285683|NCT06162221|DRUG|RMC-6236|Oral tablet
214285684|NCT06162221|DRUG|Pembrolizumab|IV Infusion
214285685|NCT06162221|DRUG|Cisplatin|IV Infusion
214845297|NCT01355848|BEHAVIORAL|Brief Intervention for Suicidality|Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
214845298|NCT04676880|DEVICE|Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)|Currently, there are two devices available on the Dutch market, Watchman and Amulet. After randomization to the intervention arm, additional randomization for type of device will follow. If the amount of procedures is too small to implant two devices, the centre will implant a device of choice.
214845299|NCT00583518|DRUG|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
214285686|NCT06162221|DRUG|Carboplatin|IV Infusion
214285687|NCT06162221|DRUG|Pemetrexed|IV infusion
214285688|NCT06162221|DRUG|RMC-9805|Oral Tablet
214285689|NCT02232165|OTHER|Hypotension avoidance|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP \>= 65 mmHg is not inferior to induced hypertension.
214285690|NCT02232165|OTHER|Induced hypertension|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
214285691|NCT05698797|OTHER|Hip strengthening exercises|Hip abductor and external rotator strengthening exercises were performed for 4 weeks.
214285692|NCT05698797|OTHER|Proprioceptive training|Proprioceptive training consisted of eight exercises was performed for 4 weeks.
214285693|NCT05698797|OTHER|Conventional physical therapy|Conventional physical therapy included interferential therapy and two types of knee-strengthening exercises.
214285694|NCT06311201|OTHER|Abdominal belt|This was used for all women in both groups (A and B) for 8 weeks starting from the 7th days after delivery. The women was asked to wear the abdominal belt throughout the day except when bathing, eating and sleeping. The binder was worn over the skin directly or on a thin layer of clothing. The side of the abdominal binder without the straps was pulled over by the woman's stomach with one hand. The side of the binder with straps was stretched across the stomach and pulled to the center of the abdomen. The straps then was fitted into the buckles. Women were instructed not to wear the binder too tight or too loose as it might irritate the skin and produce difficulty in breathing creating discomfort. They were asked to inspect their skin regularly for any signs of sensitivity.
214285695|NCT06311201|OTHER|Pilates exercises|"The Pilates exercise program for the study group (B) consisted of a 10-minute warm-up with low-intensity exercises, followed by a 40-minute central part with floor exercises like leg circles, kicks, and stretches. It included the classic hundred exercise, performed with proper form. Each exercise had two sets of 10 repetitions. The session ended with a 10-minute cool-down of stretching exercises, supervised by a physical therapist. The program was conducted three times per week, one hour per session, for eight weeks, starting from the 7th day after delivery."
214285696|NCT00000793|DRUG|Mexiletine hydrochloride|
214285697|NCT00000793|DRUG|Benztropine mesylate|
214285698|NCT00000793|DRUG|Amitriptyline hydrochloride|
214285699|NCT05407935|BEHAVIORAL|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
214285700|NCT05407935|BEHAVIORAL|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
214285701|NCT03911804|PROCEDURE|bolus group and infusion group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
214285702|NCT06076616|BEHAVIORAL|Prehabilitation and rehabilitation|A personalized lifestyle counseling programme.
214285703|NCT04943094|OTHER|Urodynamic examination|A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.
214285704|NCT06237660|PROCEDURE|Bronchoscopy, with bronchoalveolar lavage and endobronchial biopsy|These children who will be having a bronchoscopy (a long thin tube, with a camera at the end, which is put inside the lung to look at and collect samples) as part of their standard clinical management, determined by their own consultants or treating physicians. They will be having lung samples (washings from the lung and a tiny piece of tissue taken from the breathing tubes) taken as part of their usual medical management. The research team will ask for consent to use the leftover samples for the bronchoscopy, for the study
214285705|NCT06237660|DIAGNOSTIC_TEST|Skin prick test|To identify children with allergies. This test will not be done if the child has had allergy testing in the last 6 months
214285706|NCT06237660|DIAGNOSTIC_TEST|Finger prick blood test|Finger prick testing will be used for blood samples, and it is the same technique used by children with diabetes, to test their blood sugar levels, and therefore is regularly used in this age group successfully. The research team will be obtain the results within minutes, using a point-of-care device. A few more drops of blood, from the same finger prick sample, will be taken to look at how one of the blood cells work, in more detail, in the laboratory. There is no additional finger prick required for this lab test, and the drops of blood will be collected at the same time, from the same prick, as the point of care test.
214285707|NCT06237660|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|Breathing test will be performed using forced oscillation technique (FOT), to see how the child's lungs work and to detect airway inflammation. The test will be explained to the child and completed using our established protocols. This test will only require the child to breathe in and out normally, and therefore can be done in preschool aged children. The current test that is used to check lung function called spirometry cannot be used in preschool children, as it involves following complicated instructions. The aim is to assess how well this newer lung function test is tolerated, in children aged 1-5 years.
214285708|NCT06237660|PROCEDURE|Sputum induction|Sputum induction is a test of obtaining phlegm after inhalation of salt water mist (saline nebuliser) and this will allow the research team to look for any relationships between infection in the lungs and the accuracy of the less invasive, nose and throat swabs. The research team will obtain phlegm samples, with a quick suction after patients have inhaled the salty mist (saline nebuliser) which will help loosen up their phlegm. If the child can cough it up, they will be encouraged to do it.
214285709|NCT06237660|DIAGNOSTIC_TEST|Oropharyngeal swab|Swabs from children's nose and throats (similar to swab tests that are done for Covid tests), that will be used to test for bacterial infection
214845300|NCT05021913|DEVICE|DKL crosslinked sodium hyaluronate 23|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 23 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
214285710|NCT03446469|OTHER|Fascial Manipulation|Myofascial release of densified centers of coordination
215033386|NCT02947984|RADIATION|Higher Dose|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
215033387|NCT03369158|PROCEDURE|patient specific pedicle screw positioning guide|
215033388|NCT03369158|PROCEDURE|Free hand technique pedicle screw positioning|
214845301|NCT05021913|DEVICE|Juvéderm Volift™ with lidocaine (Allergan, Inc)|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Volift™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
214845302|NCT01077817|DRUG|Alendronate|
214845303|NCT01077817|DRUG|Etidronate|
214845304|NCT01077817|DRUG|Ibandronate|
214845305|NCT01077817|DRUG|Risedronate|
214285711|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
214845306|NCT01077817|DRUG|Raloxifene|
214845307|NCT03027921|OTHER|elastography|
214845308|NCT01765517|DIETARY_SUPPLEMENT|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
214845309|NCT01765517|DIETARY_SUPPLEMENT|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
214845310|NCT04158817|DRUG|68Ga-Labeled PSMA|All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.
215033389|NCT03369158|DEVICE|MUST pedicle screw|
215033390|NCT06268470|DRUG|Desloratadine plus cilostazol and dipyridamole|Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
215033391|NCT06268470|DRUG|Desloratadine|Desloratadine 20 mg/day
215033392|NCT04924348|PROCEDURE|Experimental: WALANT procedure|"The WALANT technique, performed under ultrasound, includes two punctures.~* The first is a puncture through a medial approach above the wrist and includes two injections. A first subcutaneous injection reproducing a bar above the wrist flexion line, and a second injection above the median nerve. The volumes injected vary from 8 to 10 milliliters (ml).~* The second puncture is performed at the base of the palmar surface of the hand and consists of a 10 ml subcutaneous injection of the local anesthetic in order to take advantage of the vasoconstrictive effects of adrenaline, thus allowing the surgical procedure to be performed without a pneumatic tourniquet."
215033393|NCT04924348|PROCEDURE|Active Comparator: Axial ALR|The anesthetic protocol in the axillary block consists of performing a puncture, using a needle (50 mm 22G with a short bevel), under the armpit at the level of the axillary hollow after skin disinfection. This puncture, performed under ultrasound, allows the injection of the local anesthetic around the median, radial, ulnar and musculocutaneous nerves. The volume injected per nerve can vary from 5 to 8 ml depending on the visual appreciation during the injection.
215033394|NCT04924348|PROCEDURE|Active Comparator: Truncal ALR|The anesthetic protocol in truncal block consists in injecting the local anesthetic around the median and ulnar nerves by a puncture performed at the elbow or forearm (depending on the practitioner's experience). The volumes injected remain the same and the puncture is also performed under ultrasound guidance. Additional local anesthesia is administered by injecting an additional 5 ml above the wrist flexion line to block the sensory territory of the musculocutaneous nerve.
215033395|NCT03738917|DRUG|Dextromethorphan 15 milligrams|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
215033396|NCT03738917|DRUG|Ipratropium Bromide 20Micrograms Inhaler|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
215033397|NCT03738917|DIETARY_SUPPLEMENT|Honey 30 g (full tablespoon)|This study product will be provided free to the participants by the sponsor.
215033398|NCT03738917|OTHER|Usual clinical practice|Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.
215033399|NCT04636632|DRUG|fosaprepitant|fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
215033400|NCT01689948|BEHAVIORAL|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
215033401|NCT00247546|BEHAVIORAL|Multifactorial prevention|
215033402|NCT01296308|OTHER|inpatient integrative treatment|two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
215033403|NCT03764969|BEHAVIORAL|standard smoking cessation program (SCP)|Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.
215033404|NCT03764969|BEHAVIORAL|Cognitive remediation treatment (CRT)|Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).
214845311|NCT04158817|DRUG|Non-labeled PSMA|Patient will be injected with microdose (\<100 ug) of THP-PSMA
214845312|NCT04344457|DRUG|Hydroxychloroquine|200 mg PO BID 7 days
214845313|NCT04344457|DRUG|Indomethacin|50 mg PO TID 14 Days
214845314|NCT04344457|DRUG|Zithromax Oral Product|500 mg PO QD 3 Days
214845315|NCT04817215|DRUG|ORMD-0801|Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
214845316|NCT05956964|BEHAVIORAL|Sleep Restriction|5 hours of sleep for 3 days
214845317|NCT05956964|BEHAVIORAL|Sleep Adequate|9 hours of sleep for 3 days
214845318|NCT03191110|OTHER|No intervention: observational study|
214285712|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
214285713|NCT04069494|OTHER|questionnaires|Two questionnaires in patients and another two questionnaires in carer.
214845319|NCT05930405|PROCEDURE|programmed intermittent epidural bolus|Bolus a certain amount of liquid at fixed intervals according to a predetermined procedure
214845320|NCT05930405|PROCEDURE|continuous epidural infusion|continuous epidural infusion
214845321|NCT06363526|OTHER|Digital respiratory intervention program|"A 4 times a week for a period of 5 weeks will be done, for a duration of 55-60 minutes (20 sessions), with an intensity adapted to the characteristics of each participant. Moreover, an intervention program will be used based on respiratory muscle training exercises, upper limb strength work, yoga, diaphragmatic awareness exercises, always trying to do them through the use of games, and even try to include exercises that use motor imagery.~The intervention program is carried out and stimulated through videos and therapeutic teaching to the caregivers in the first evaluation session, as well as as well as with a weekly follow-up using WhatsApp or Zoom as forms of communication, or a telephone call to ensure correct follow-up of the intervention program. Moreover, YouTube videos, own videos prepared by the physiotherapy will be used to help optimally resolve doubts that arise when carrying out the program by video call."
214845322|NCT06407076|OTHER|Interviews|Following the design of the questionnaire, using open-ended questions based on the availability, accessibility, acceptability and quality (AAAQ) framework, qualitative semi-structured personal interviews were used to collect the data. In this way it was possible to collect information in a more detailed way. The subjects included in the study had to answer the questions posed by the main researcher, responding with open or closed answers, through a questionnaire created for this purpose.
214845323|NCT00530348|BIOLOGICAL|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
214845324|NCT00530348|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
214845325|NCT04380038|DRUG|Dupilumab Injectable Product|Nasal inoculation, single dose 300 TCID50 in 1ml.
214845326|NCT03540758|DRUG|Diazoxide|"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
214845327|NCT03540758|DRUG|Nicotinic acid|T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
214845328|NCT03540758|DRUG|Placebo|"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study."
214845329|NCT04909112|OTHER|Evaluation of olfactory function|Evaluation of olfactory function using olfactory detection thresholds
214845330|NCT04909112|OTHER|Evaluation of taste function|Evaluation of taste function using taste detection thresholds
215033405|NCT03764969|BEHAVIORAL|Implicit computer-based habit-modifying training (ICHT)|Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
215033406|NCT02141321|DRUG|Misoprostol|
215033407|NCT02141321|DRUG|Placebo|
215033408|NCT01872884|DRUG|Sevorane Remifentanil|Sevorane Remifentanil
215033409|NCT01872884|DRUG|Remifentanil|Remifentanil
214845331|NCT04909112|OTHER|Evaluation of (intra-nasal and oral) trigeminal functions|Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.
214845332|NCT03292263|DRUG|Melphalan|iv infusion 70-100 mg/m2 on day -3, -2
214845333|NCT03292263|DRUG|Nivolumab|iv infusion 100 mg on day -3, +17
214845334|NCT03292263|PROCEDURE|Autologous Stem Cell Transplantation|peripheral blood stem cell transfusion at day 0
214845335|NCT04303624|OTHER|Health sciences survey|Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
214845336|NCT04364763|DRUG|RBT-9 (90 mg)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
214845337|NCT04364763|DRUG|0.9% sodium chloride (normal saline)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
214845338|NCT01165749|BEHAVIORAL|stop exercising|
215033410|NCT03174327|DIAGNOSTIC_TEST|Hepatic Transplantation|Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.
215033411|NCT04893863|DRUG|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
215033412|NCT04893863|DRUG|PluroGel|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
215033413|NCT03980639|DRUG|patient treated with DMARD|Case report of cancer overall
215033414|NCT00148356|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214845339|NCT02643927|BEHAVIORAL|standard 8-weeks MBSR|A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
214845340|NCT02643927|BEHAVIORAL|4-week shortened MBSR|This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
214845341|NCT02051660|BEHAVIORAL|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
214845342|NCT02051660|BEHAVIORAL|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
214285714|NCT01635192|BIOLOGICAL|VSL#3|"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."
214285715|NCT01635192|BIOLOGICAL|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
214845343|NCT05484791|OTHER|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization(LRSM) technique during two sessions per week. The LRSM technique is applied while patients are lying on their side. The uppermost hip and knee are placed in 90 degree flexion, this is to assist rotational stress, and the lower leg is placed in extension. The lower shoulder is strongly pulled; thus, the upper shoulder is positioned toward the posterior and the pelvis moves anteriorly. The clinician stands in front of the patient. They stabilize the upper shoulder with one hand, and place the palm of the other hand behind the hard part of the ilium wing, with forearm horizontal and fingers turned toward the clinician. A rotational force is applied with pressure in the horizontal direction by pulling the hand on the ilium toward the clinician. In this position, 30 slow repeated movements are performed. The same practice is performed on both sides
214845344|NCT00153257|DEVICE|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
214845345|NCT01386125|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
214285716|NCT04014842|DEVICE|RapidShock|Use of the Reconfirmation Analysis Mode algorithm
214285717|NCT02277301|BEHAVIORAL|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
214285718|NCT05616910|DRUG|inhaled nitric oxide|iNO will be provided by ventilator or nasal cannula for 4 hours each day.
214285719|NCT03691792|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT-SAD)|12 group sessions over 6 weeks
214285720|NCT03691792|OTHER|Light Therapy|10,000-lux initiated at 30 min upon waking and adjusted per treatment algorithm, continuing for 6 weeks
214845346|NCT01386125|DRUG|Placebo for MFNS|Two sprays in each nostril BID for up to 16 weeks
214845347|NCT04915222|OTHER|Natural apophyseal glides|Patients received conventional therapy and NAGS with 2-3 hertz (less than 6 repetitions) in 3 sets for 3 weeks. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
215033415|NCT00148356|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214285721|NCT06558565|PROCEDURE|stromal vascular fraction or platelet rich plasma|stromal vascular fraction will be injected in one half of the scalp \& PRP will be injected in the other half
214285722|NCT02590081|DRUG|Dextrose 5%|
214285723|NCT02590081|DRUG|normal saline|
214285724|NCT04488068|PROCEDURE|Sham Magnetic stimulation|Sham Magnetic stimulation for comparison.
214285725|NCT00717132|BEHAVIORAL|Individual Behavior Modification|Individual behavioral treatment for obesity. Children and parents meeting individually for 15 total behavioral modification intervention sessions.
214285726|NCT00717132|BEHAVIORAL|Family-based behavior modification|Family-base behavior treatment for obesity. Children and parents meeting together for 15 total behavioral modification intervention sessions.
214285727|NCT04165447|BEHAVIORAL|Front-of-pack labeling strategy|We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
214285728|NCT02063620|DRUG|Ketamine HCL|ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
214285729|NCT00112060|DRUG|PT-523 for Injection|
214285730|NCT00211809|BEHAVIORAL|Cognitive Behavioral Therapy|standard psychiatric evaluation
214285731|NCT00211809|DRUG|Venlafaxine|start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
214285732|NCT02984748|DEVICE|Cochlear implant|
214285733|NCT05559138|OTHER|no intervention|no intervention
214285734|NCT02513953|PROCEDURE|Laparoscopic|Four Port Laparoscopic cystectomy
214845348|NCT04915222|OTHER|Cervical manual traction|Patients received cervical manual traction (CMT) along with traditional therapy. Treatment frequency was 3 sessions per week for total three weeks duration. CMT applied was intermittent type traction.8 to 10 kg force was applied at an angle of 20 to 25 degree from horizontal. 5sets of cervical traction are performed. In every set traction is given for 1 minute with rest period of 20 seconds. The total time of traction session was 10 minute. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
214845349|NCT01866644|DRUG|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
214845350|NCT01866644|DRUG|Saline|Bath saline transplanted liver
214845351|NCT04085744|DRUG|Lidocaine 10% Spray|lidocaine will be apply on the cuff
214845352|NCT04085744|DRUG|Mometasone nasal spray|mometasone spray will be applied on the cuff
214845353|NCT05489796|DRUG|Fentanyl selector|Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
214845354|NCT05489796|DRUG|Fentanyl continuous|Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
214845355|NCT05489796|DRUG|Ketorolac continuous|Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
214845356|NCT04260035|DRUG|Vasoactive Intestinal Polypeptide (VIP)|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
214845357|NCT04260035|DRUG|Sterile saline|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
214845358|NCT05971524|DIETARY_SUPPLEMENT|6-BT|2,4 or 8mg of 6-BT once daily for 4 weeks
214845359|NCT05971524|DIETARY_SUPPLEMENT|Placebo|A placebo capsule once daily for 4 weeks
214845360|NCT01307943|OTHER|Mindfulness-based stress reduction program|Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
214845361|NCT01307943|OTHER|Usual care|The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
214845362|NCT02670785|DRUG|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
214845363|NCT02670785|DRUG|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
214845364|NCT00448227|DRUG|famciclovir|Administered orally as a single individualized dose between 25-200 mg based on body weight.
214845365|NCT00280930|DRUG|Letrozole|
214845366|NCT05960422|PROCEDURE|Popliteal Sciatic Nerve Block|Patients undergoing popliteal sciatic block, the side where the procedure would be performed in the prone position was sterilized after appropriate antisepsis. After visualizing the popliteal artery in the popliteal fossa with the probe it was advanced proximally in a horizontal and minimally lateral position to determine the point of separation of the tibial and peroneal nerves from the sciatic nerve. Subcutaneous local anesthesia was applied at this point after the skin, and the stimulator needle was advanced towards the sciatic nerve in an in-plane approach, passing through the skin and subcutaneous tissue, and then the nerve stimulator was opened up to 1 mA. After observing motor movement in the foot, the stimulator was reduced to 0.3-0.5 mA, and after observing motor movements for duration of 0.1 ms, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were administered to the target tissue
214845367|NCT05960422|PROCEDURE|Adductor canal block|Patients in the group undergoing popliteal sciatic block + adductor canal block, with the extremity to be blocked slightly externally rotated, the anterior part of the thigh was prepared with the necessary antiseptic procedures while the patient was in the supine position. Using an ultrasound probe, the femoral artery was visualized by advancing the ultrasound probe distally, and the saphenous nerve was identified just lateral to the femoral artery, beneath the sartorius muscle. At the junction of the sartorius muscle and vastus medialis, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were applied to the periphery of the saphenous nerve. Subsequently, the patient was turned prone, and a popliteal sciatic block was performed.
214845368|NCT00153439|BEHAVIORAL|Motivational enhancements, parent training|
214845369|NCT06039774|DRUG|α-Mangostin Hydrogel Film With Chitosan Alginate Base|Patients will apply α-Mangostin Hydrogel Film With Chitosan Alginate Base once a day for 7 days
214285735|NCT04294472|DRUG|MAU868|MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
214845370|NCT06039774|DRUG|Placebo|Placebo
214845371|NCT01353716|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
214285736|NCT04294472|OTHER|Placebo|250 mL D5W placebo IV to be labeled to match that of MAU868
214285737|NCT01191398|DRUG|Atropine (0.01mg/kg)|Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
214285738|NCT01191398|DRUG|Glycopyrrolate (0.01mg/kg)|Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
214285739|NCT01191398|DRUG|Normal saline 0.9%|Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
214285740|NCT03489824|PROCEDURE|modified- WIM colonoscopy|Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
214285741|NCT04922437|PROCEDURE|Native bladder implantation|Continent catheterizable channel implanted in the detrusor of the native bladder
214285742|NCT04922437|PROCEDURE|Enterocystoplasty implantation|Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
214285743|NCT05113472|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Patients who were administered any dose of the Pfizer-BioNTech COVID-19 vaccine.
214285744|NCT01619774|DRUG|GSK2118436|Starting dose 150 mg by mouth twice a day.
214285745|NCT01619774|DRUG|GSK1120212|2 mg by mouth daily.
214285746|NCT00589563|BIOLOGICAL|anti-thymocyte globulin|0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
214285747|NCT00589563|DRUG|cyclophosphamide|60mg/kg on days -5 and -4 from stem cell transplant
214285748|NCT00589563|DRUG|etoposide|60mg/kg on day -4 from stem cell transplant
214285749|NCT00589563|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
214285750|NCT00589563|DRUG|melphalan|Melphalan 140 mg/m2 on day -4 from stem cell transplant
214285751|NCT00589563|DRUG|methotrexate|For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
214285752|NCT00589563|DRUG|sirolimus|"Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.~Pediatric Patients \<40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose"
214285753|NCT00589563|DRUG|tacrolimus|0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
214285754|NCT00589563|PROCEDURE|allogeneic hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
214845372|NCT00564096|DEVICE|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
214285755|NCT00589563|PROCEDURE|hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
214285756|NCT00589563|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
214285757|NCT00589563|PROCEDURE|peripheral blood stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
214285758|NCT00589563|RADIATION|total-body irradiation|1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
214285759|NCT00426907|PROCEDURE|Unlimited postoperative weightbearing|Unlimited postoperative weightbearing
214285760|NCT04756492|DRUG|sandimmun|follow up for treatment response
214285761|NCT00740701|DEVICE|Cerebellar transcranial magnetic stimulation|single pulse TMS or repetitive TMS at 1 Hz frequency
214285762|NCT06049290|DRUG|LBL-034 for Injection|Initial dose - MTD; Q2W; intravenous infusion
214285763|NCT05989750|DEVICE|Ultrasonic scaler|Ultrasonic scaling for subgingival cleaning every 6 months for 2 years according to the manufacturer's procedures.
214285764|NCT05989750|DEVICE|Air-Flow Prophylaxis Master|AIR-FLOW PROPHYLAXIS MASTER with erythritol powder (AIR FLOW Powder Plus) will be used every month for 2 years for subgingival cleaning according to the manufacturer's procedures.
214285765|NCT03013478|BEHAVIORAL|Standard Treatment As Usual (TAU)|Treatment normally offered at this primary care clinic
214285766|NCT03013478|BEHAVIORAL|CBT4CBT program|
214285767|NCT01092104|DRUG|TBR-652|TBR-652 25 mg
214285768|NCT01092104|DRUG|TBR-652 Matching Placebo|Matching Placebo
214285769|NCT01092104|DRUG|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
214285770|NCT01092104|DRUG|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
214285771|NCT01092104|DRUG|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
214285772|NCT01092104|DRUG|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
214285773|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
214285774|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
214845373|NCT00564096|DEVICE|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
214285775|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
214285776|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
214285777|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
214285778|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
214285779|NCT00313391|DRUG|Risperdal Consta|
214285780|NCT00017446|DRUG|CP4071|
214285781|NCT02988843|DRUG|Brentuximab Vedotin|Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
214285782|NCT02988843|DRUG|Bevacizumab|15 mg/kg every 21 days
214845374|NCT04496037|DRUG|Rituximab|See NCT03994783
214845375|NCT04924751|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine needle biopsy|Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.
214845376|NCT00002727|RADIATION|radiation therapy|
214285783|NCT00524784|BIOLOGICAL|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
214285784|NCT03937011|DEVICE|Robotic Suturing of gastric sleeve oversew and vaginal cuff closure|"1. Robotic Bariatric Sleeve gastrectomy~2. Robotic Hysterectomy with or without oophorectomy;"
214285785|NCT01600469|DRUG|DAOI-B|250-1500 mg/day, oral, for 24 weeks
214285786|NCT01600469|OTHER|Placebo|placebo, oral, for 24 weeks
214285787|NCT02289417|DRUG|Apremilast|
214285788|NCT02289417|DRUG|Placebo|
214285789|NCT01837433|DRUG|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
214285790|NCT01837433|DRUG|Prednisone 6 weeks|Guidelines recommend
214285791|NCT02283385|BEHAVIORAL|PROTECT|8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
214285792|NCT04600128|OTHER|Dairy-based greek yogurt|Plain Greek yogurt (2% M.F; Danone, Boucherville, Quebec, Canada)
214285793|NCT04600128|OTHER|Dairy-based cheddar cheese|Mild cheddar cheese (31% M.F. ; Armstrong, Saputo Dairy Products, Saint-Laurent, Quebec, Canada)
214285794|NCT04600128|OTHER|Plant-based yogurt|Plain Greek yogurt alternative (Daiya, Rupert Street, Vancouver, Canada)
214472137|NCT04345874|BEHAVIORAL|Nutrition technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
214845377|NCT01710670|DRUG|Brivaracetam|"Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1."
215033416|NCT06264167|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound surveillance|Participants in the Interventional Treatment (serial ultrasounds) group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, follow-up appointments occur bi-monthly for 12 months, involving a clinical examination and groin ultrasound. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
214845378|NCT01710670|OTHER|Ethanol|"Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L."
215033417|NCT02649764|DRUG|Cytarabine|Given IV
214285795|NCT04600128|OTHER|Plant-based cheese|Medium cheddar style block (Daiya, Rupert Street, Vancouver, Canada)
214285796|NCT02704871|OTHER|SeptiCyte Lab molecular diagnostic test (non-interventional)|This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.
214285797|NCT04786990|DRUG|SPN-812|Viloxazine extended-release capsule
214285798|NCT06446167|OTHER|Exercises|All groups received a regimen of daily exercises, including stretches for the plantar fascia and Achilles tendon, and strengthening exercises for the calf muscles and foot intrinsic muscles. Each type of exercise was demonstrated to the participants by the same physiotherapist at the beginning of the treatment process, to be performed twice a day with 10 repetitions each time.
214285799|NCT06446167|OTHER|MLS Laser Treatment|The MLS Laser applied to the treatment group was administered using an ASA brand Mphi model device. Patients in the Laser group were positioned in a prone position. Treatment was applied continuously for 7 minutes along the plantar fascia, sole of the foot, heel area, and Achilles tendon in accordance with the plantar fasciitis treatment program on the device, at a dose of 1.73 J/cm2 and a frequency of 700 Hz. A treatment program was established with 3 sessions per week, totaling 10 sessions
214285800|NCT06446167|OTHER|ESWT treatment|The treatment group was administered with the Swiss DolorClast Master ESWT device, which produces radial shock waves. Patients in the ESWT group were positioned in a prone position. The most painful point in the heel area was identified through palpation. Gel was applied to this area, followed by the surrounding soft tissues, towards the plantar fascia and the attachment area of the Achilles tendon at the dorsal aspect of the heel. Radial ESWT treatment was applied at a frequency of 10 Hz, pressure of 2.5 bars, and 2000 impulses per session, once a week for a total of 4 sessions
214285801|NCT00714181|DRUG|hydroxychloroquine|
214285802|NCT00714181|DRUG|temozolomide|
214285803|NCT00714181|GENETIC|TdT-mediated dUTP nick end labeling assay|
214285804|NCT00714181|GENETIC|western blotting|
214285805|NCT00714181|OTHER|electron microscopy|
214285806|NCT00714181|OTHER|high performance liquid chromatography|
214285807|NCT00714181|OTHER|immunoenzyme technique|
214285808|NCT00714181|OTHER|immunohistochemistry staining method|
214285809|NCT00714181|OTHER|laboratory biomarker analysis|
214285810|NCT00714181|OTHER|mass spectrometry|
214285811|NCT00714181|OTHER|pharmacological study|
214285812|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
214285813|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
214285814|NCT02205632|DEVICE|MPS II|
214285815|NCT03657511|BEHAVIORAL|Educational Interventions to Promote Tobacco Cessation|"Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks."
214285816|NCT06347835|DIETARY_SUPPLEMENT|symbiotic|The intervention is made up of multiple probiotics and prebiotics (20g/d) and dietary pattern modification.
214285817|NCT06347835|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (20g/d) and dietary pattern modification.
214285818|NCT06347835|DIETARY_SUPPLEMENT|symbiotic placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
214285819|NCT06347835|DIETARY_SUPPLEMENT|whey protein placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
214285820|NCT03921671|COMBINATION_PRODUCT|Ramucirumab|Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.
214285821|NCT06094595|DIAGNOSTIC_TEST|MAS-p administration|Each patient will be assessed the first time at mealtime by two experienced speech therapists, and scores obtained on the MAS-p will be recorded independently and blinded to each other. The two scales selected for comparison will also be administered at the same time. The assessment with the MAS-p scale will be repeated 48 hours apart, a time considered optimal in order to avoid possible bias related to the clinical improvement of the patient undergoing rehabilitation treatment, by one of the two speech therapists.
214285822|NCT01918930|BIOLOGICAL|MGA271|MGA271 anti-B7-H3 monoclonal antibody
214285823|NCT05288244|OTHER|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
214285824|NCT05288244|OTHER|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
214285825|NCT05288244|OTHER|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
214285826|NCT01116583|DRUG|Gabapentin|"Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)~Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)~Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)~Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)"
214845379|NCT01710670|OTHER|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
214285827|NCT01116583|DRUG|Placebo|"Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4"
214285828|NCT06175910|PROCEDURE|percutaneous nephrolithotomy|"A 7 Fr ureteric catheter was placed into the ipsilateral ureteric orifice. The patients were then placed in the prone position. Opacification of the pelvicalyceal system was performed. The puncture was done by a 22-guage puncture needle was advanced into the posterior lower calyx under fluoroscopic guidance. After successful access is established, a 0.035-inch curved guide wire was advanced through the puncture needle into the kidney. The central Alkane Rod was passed over the guide wire. Under fluoroscopic guidance serial Amplatz dilators up to 30 Fr were advanced over central Alkane rod and guide wire. Then 30 Fr long Amplatz sheath was advanced over the last dilator.~26 Fr rigid long nephroscope used for stone fragmentation and retrieval. Stone fragmentation was done by pneumatic Swiss Lithoclast. Fragments removal was done using toothed peanut stone retrieval forceps."
214285829|NCT06175910|PROCEDURE|retrograde intrarenal surgery|"urethrocystoscopy was carried out then inserting of a 7F open ended ureteral catheter over the 0.035-inch straight floppy tip guide wire in the working channel of the 22Fr cystoscope under fluoroscopic guidance, access to the ureter was made.~Teflon ureteric dilators are used to dilate the distal ureter till 14 FR. ureteral access sheath placement 12 or 14 Fr. OTU, a disposable digital flexible ureteroscope, is then used then the tip of a 272 m holmium laser fiber is placed on the surface of the stone for fragmentation.~Intra renal lithotripsy was carried out using a 30 W Holmium: YAG laser (Sphinx Jr.) via a 272 m silica quartz laser fiber. 1.9 Fr tipless nitinol baskets were finally used to remove the large fragments. A Double-J (6 Fr) stent is generally applied at the end of the procedure, and a urethral catheter was applied."
214285830|NCT06332235|DRUG|Silodosin 8 mg|Dosing schedule: Oral, once daily
214285831|NCT03101683|RADIATION|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
214285832|NCT00923247|DRUG|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
214845380|NCT01710670|OTHER|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
214845381|NCT03733587|DRUG|GX-I7|GX-I7 25mg/ml/vial
215033418|NCT02649764|DRUG|Fludarabine Phosphate|Given IV
215033419|NCT02649764|OTHER|Laboratory Biomarker Analysis|Correlative studies
215033420|NCT02649764|DRUG|Prexasertib|Given IV
214845382|NCT03733587|DRUG|Cyclophosphamide|Cyclophosphamide 500mg/vial
214285833|NCT00923247|DRUG|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
214285834|NCT06504641|OTHER|Isla for Frailty|"Isla for Frailty - video-based patient records. Isla is a technology company providing a visual patient record platform. The platform allows anyone involved in a patient's care to capture and review visual data (photographs, videos) relating to a patient's health. The platform is web-based (a progressive web application) and supports secure capture of visual data with encrypted storage in the cloud.~Isla interfaces with Electronic Health Record (EHR) systems including Cerner, enabling health professionals to view data held on Isla's servers from within the electronic patient record, via the 'Cerner Red Button'. Health professionals can also view a patient's visual record through a secure weblink requiring an NHS email address and password."
214285835|NCT01782222|DRUG|Rotigotine|"Rotigotine, transdermal patches:~10 cm\^2 (2 mg / 24 hours); 20 cm\^2 (4 mg / 24 hours); 30 cm\^2 (6 mg / 24 hours); 40 cm\^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
214285836|NCT01782222|OTHER|Placebo|"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
214285837|NCT02071914|DRUG|CT-P27|Influenza A treatment drug.
214285838|NCT02071914|DRUG|Placebo|Placebo.
214285839|NCT05469828|DRUG|Crizanlizumab|patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).
214285840|NCT05469828|OTHER|control|Standard of care
214285841|NCT01756898|DRUG|5 mg ASB17061|Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
214285842|NCT01756898|DRUG|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
214285843|NCT01756898|DRUG|10 mg ASB17061|Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
214285844|NCT01756898|DRUG|20 mg ASB17061|Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
214285845|NCT00251485|DRUG|Cetuximab|Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
214285846|NCT02746744|DRUG|Rituximab|Infusion of Mabthera/Rituximab every 6 months
214285847|NCT02746744|DRUG|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
214285848|NCT02746744|DRUG|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
214285849|NCT06504823|OTHER|Light level|light application
214285850|NCT01500694|DRUG|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
214285851|NCT04971408|OTHER|passive heat stress|as above
214285852|NCT04971408|OTHER|control|participant engage in activity as usual
214285853|NCT01130012|BEHAVIORAL|Lifestyle: diet and exercise|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
214285854|NCT01130012|BEHAVIORAL|Close follow-up: reporting diaries of food and exercise|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
214285855|NCT00172133|DRUG|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
214285856|NCT02959931|OTHER|High Potassium Meal|Breakfast meal that provides \~2400 mg of dietary potassium. Meals are isocaloric.
214285857|NCT02959931|OTHER|Low Potassium Meal|Breakfast meal that provides \~540 mg of potassium. Meals are isocaloric.
214285858|NCT03918083|BEHAVIORAL|Wellness|Assess the feasibility of an integrated, prescriptive, and trackable wellness intervention amongst residents at Orange Park Medical Center (OPMC) by combining five wellness elements including: exercise, mindfulness, sleep, social connectedness, and nutrition.
214285859|NCT04260152|DEVICE|Geistlich Fibro-Gide|Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide
214285860|NCT04260152|PROCEDURE|Connective Tissue Graft (CTG|Surgical recession root coverage with coronally advanced flap in combination with CTG
214285861|NCT01961193|DEVICE|contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
214285862|NCT01961193|DEVICE|punctal plug|A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
214285863|NCT05298631|OTHER|Stabilization exercises|The activation of deep cervical muscle to reduce the activity of surface muscles is known as stabilization exercises
214285864|NCT05298631|OTHER|Dynamic exercises|The exercises in which muscle tension remains constant but muscle length changes is known as dynamic exercises
214285865|NCT00663169|BIOLOGICAL|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
214285866|NCT00663169|DRUG|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
214285867|NCT00663169|OTHER|placebo matching canakinumab|5% glucose in water intravenous infusion.
214285868|NCT00663169|OTHER|placebo matching dexamethasone|Placebo intravenous infusion.
214845383|NCT04973800|DRUG|Simvastatin 20mg|Simvastatin 20mg ON PO for 28-30 days
214845384|NCT04973800|DRUG|Placebo|Sucrose placebo ON PO for 28-30 days
214845385|NCT02907073|DRUG|BF4|Single IV dose of 9-11 millicurie (mCi) sodium \[Fluorine-18\] radiolabeled B4\^F
214845386|NCT00732160|DRUG|Aldosterone infusion (A)|Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
214845387|NCT00732160|DRUG|Vehicle Infusion (V)|Vehicle infusion for 12.5 hours
214845388|NCT00732160|OTHER|High Sodium Diet (HS)|160 mmol/d sodium diet for 7 days
214845389|NCT00732160|OTHER|Low Sodium Diet (LS)|20 mmol/d sodium diet for 9 days
214845390|NCT00676494|DEVICE|Pathway PV Atherectomy System|The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in lower limb peripheral vasculature during percutaneous interventional procedures.
214845391|NCT03826394|BEHAVIORAL|Exercise Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be exercise specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
214845392|NCT03826394|BEHAVIORAL|Dietary Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be diet specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
214845393|NCT01843257|OTHER|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
214845394|NCT01843257|OTHER|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
214285869|NCT04932278|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment (OMT) is hands-on care provided by an osteopathic physician (D.O.). During osteopathic manipulative treatment, an osteopathic physician may move participants' muscles and joints using osteopathic techniques including stretching, gentle pressure and resistance, as well as thrust techniques that apply a quick, therapeutic force of brief duration that travels a short distance.
214285870|NCT04932278|PROCEDURE|Usual care|Routine concussion management with healthcare professionals.
214285871|NCT00787852|DRUG|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily~Maintenance x 2 years\*"
214285872|NCT00787852|DRUG|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily Maintenance x 2 years\*"
214285873|NCT03758209|PROCEDURE|Prehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
214285874|NCT03758209|PROCEDURE|ERAS|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
214285875|NCT04271969|DEVICE|SmartVest Airway Clearance System|Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)
214845395|NCT04939558|DEVICE|N-Tidal C handset|Participants are to use the 'N-Tidal C' handset every day for 14 days. This will ideally be two times a day (once in the morning and once in the evening, before using any regular inhalers). Each breath record requires the participant to breathe through the mouthpiece for 75 seconds in a relaxed manner.
214845396|NCT04659486|BEHAVIORAL|Home-based exercise training|Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
214845397|NCT00218335|BEHAVIORAL|Intervention Condition|In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
214845398|NCT00218335|BEHAVIORAL|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
214845399|NCT00680524|OTHER|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
214845400|NCT00669435|DRUG|Losartan + Simvastatin|"tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months"
214845401|NCT00669435|DRUG|Amlodipine + Simvastatin|"tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months"
214845402|NCT03604549|DRUG|Lipiodol UF|Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
214845403|NCT03604549|DRUG|Saline|Up to 10cc of saline will be infused via intrauterine catheter
214845404|NCT02833636|PROCEDURE|ACEF score|
215033421|NCT03253081|BEHAVIORAL|PARENT focused intervention|The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent. Sessions will include a 20-minute welcome and supportive discussion where parents can provide updates on their week and seek advice and support from the group, followed by a 45-minute interactive education session focused on the principles of JASPER, and close with a 20-minute Mindfulness session. The Mindfulness session will be led by a certified expert.
214285876|NCT06504797|DEVICE|automatic massage|automatic massage
214285877|NCT01337232|BEHAVIORAL|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
214285878|NCT00496054|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 \& P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
214285879|NCT03193203|DRUG|Etanercept|50 mg/mL PFS and AI
214285880|NCT05373368|BEHAVIORAL|multi purpose activities|
214285881|NCT00023504|BIOLOGICAL|Pneumovax|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
214285882|NCT00023504|BIOLOGICAL|Rabavert|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
214285883|NCT00023504|BIOLOGICAL|Prevnar|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
214285884|NCT00023504|BIOLOGICAL|Tetanus diphtheria toxoid|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
214285885|NCT01105728|PROCEDURE|Endoscopic resection|Endoscopic resection of the gastric subepithelial mass
214285886|NCT02711592|GENETIC|Genetic Panel for Analgesics|All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
214285887|NCT05410691|DEVICE|Handheld US device|Handheld US-guided AVF/AVG cannulation
214285888|NCT01356108|DEVICE|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
214285889|NCT04766398|DRUG|KHK7791|oral administration
214285890|NCT04766398|DRUG|Placebo|oral administration
214285891|NCT02427022|OTHER|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
214285892|NCT05975944|DRUG|Selinexor，Olaparib|Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
214285893|NCT00596375|PROCEDURE|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
214285894|NCT00596375|DRUG|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
214285895|NCT03798405|BEHAVIORAL|Proactive Analgesic Inpatient Narcotic-Sparing|Medications suggested to the physician with enhanced ease of ordering.
214285896|NCT05095545|DRUG|AV5080|Hard gelatin capsules with a white body
214285897|NCT05095545|OTHER|Placebo|Hard gelatin capsules with a white body
214285898|NCT05251571|OTHER|Conventional Exercise Group with Telerehabilitation|Exercises such as conventional muscle strengthening and stretching given with telerehabilitation are applied.
214285899|NCT05251571|OTHER|Balance Coordination Group with Telerehabilitation|Functional muscle strengthening, stretching, balance and coordination exercises given with telerehabilitation are applied.
214285900|NCT05636683|PROCEDURE|Root surface debridement|subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
214285901|NCT05079529|DRUG|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
214285902|NCT05079529|DRUG|Placebo Group|Takes placebo capsule 3 times daily for 90 days
214285903|NCT01753505|OTHER|64-slice Multidetector coronary CT angiography|
214285904|NCT05923437|OTHER|Feeding model group with a chronobiological approach|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiologic approach simultaneously with the provision from the mother, and the newborn will be ensured to receive breast milk in accordance with the day cycle. Within the scope of the study, firstly, mothers and nurses in the NICU will be informed about the study. Mothers will be asked to put the milk mothers express between 06:00-17:59 in the daytime breast milk storage bag and the milk mothers express between 18:00-05:59 in the nighttime breast milk storage bag and bring them to the unit. The brought breast milk will be prepared by the nurses by matching day and night milk according to the dates, with the first milk brought in priority, and the newborns will be fed by using the time of day factor (cycle so that the milk collected during the day will be given during the day and the milk expressed at night will be given at night)."
214285905|NCT02367937|DRUG|PRC-4016 (icosabutate)|"Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description"
214285906|NCT04615481|OTHER|Elliptical Training Group|The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
214285907|NCT04615481|OTHER|Ergo-metric Training Group|The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
215033422|NCT03253081|BEHAVIORAL|CHILD focused intervention|The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist. One of these two sessions will involve the parent in hands-on training while the other will be interventionist-led while the parent observes. The remaining 30-minutes will include a snack for the child and time for the parent to discuss and ask questions of the interventionist regarding the session content.
214285908|NCT00508716|BEHAVIORAL|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
214285909|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
214285910|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
214285911|NCT03572062|BIOLOGICAL|Formulation A|RSV vaccine
214285912|NCT03572062|BIOLOGICAL|Formulation B|Adjuvanted RSV vaccine
214285913|NCT03572062|BIOLOGICAL|Formulation C|RSV vaccine
214285914|NCT03572062|BIOLOGICAL|Placebo|Placebo
214285915|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 1|Liquid formula produced by several food ingredients to provide a balance nutrient intake
214285916|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 2|Liquid formula produced by several food ingredients to provide a balance nutrient intake
214285917|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 3|Liquid formula produced by several food ingredients to provide a balance nutrient intake
214285918|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 4|Liquid formula produced by several food ingredients to provide a balance nutrient intake
214285919|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 5|Liquid formula produced by several food ingredients to provide a balance nutrient intake
214472138|NCT04345874|BEHAVIORAL|Children's environmental health technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
214472139|NCT00449085|PROCEDURE|Electrophysiology|
214472140|NCT00449085|DEVICE|CARTO™ XP EP Navigation System V9|
214472141|NCT03565029|DRUG|XELOX|Capecitabine and Oxaliplatin (4x cycles)
214472142|NCT03565029|RADIATION|Radiotherapy|Pelvic radiotherapy
214472143|NCT05829343|PROCEDURE|Laparoscopic Left colectomy|Patients are treated with a laparoscopic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
214472144|NCT05829343|PROCEDURE|Robotic left colectomy|Patients are treated with a robotic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
214472145|NCT06029452|OTHER|Machine learning algorithm|Software to calculate the predicted probability of ATTRwt-CM for these heart failure patients based on the presence and absence of certain features
214472146|NCT01784913|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
214472147|NCT05913817|BIOLOGICAL|AVT02 (Alvotech Biosimilar to Adalimumab)|Phase IV Study
214472148|NCT04175977|BEHAVIORAL|Aliviado Dementia Care-Hospice Edition QAPI program|Multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
214472149|NCT04175977|BEHAVIORAL|Usual Care|Usual care as provided by the hospice agency
214472150|NCT06150339|OTHER|OASIS Walking Intervention|Communication Care Plan, Sit to Stand Activity, Walking Program
214472151|NCT05334862|PROCEDURE|8 plate hemiepiphysiodesis|surgical procedure by lateral incision in proximal tibia and distal femur and fixation by using 8 plate and screws.
214472152|NCT06333639|OTHER|orthopaedic surgery|usual procedures for an orthopaedic surgery
214472153|NCT06333639|OTHER|orthopaedic surgery and fitted with a virtual reality headset|usual procedures for an orthopaedic surgery and fitted with a virtual reality headset
214472154|NCT06420167|DRUG|Dapagliflozin|10mg orally once daily
214472155|NCT05164055|DRUG|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
214472156|NCT05818553|DRUG|PRAX-562|Once daily oral or G-tube treatment.
214472157|NCT03976544|DRUG|Estradiol Valerate|Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
214472158|NCT03976544|DRUG|Micronized progesterone|If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
214472159|NCT00898235|GENETIC|clonality analysis|analyze clonality
214472160|NCT00898235|GENETIC|polymerase chain reaction|analyze polymerase chain reaction
214472161|NCT00898235|GENETIC|protein analysis|analyze protein
214285920|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 6|Liquid formula produced by several food ingredients to provide a balance nutrient intake
214285921|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 7|Liquid formula produced by several food ingredients to provide a balance nutrient intake
214285922|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 8|Liquid formula produced by several food ingredients to provide a balance nutrient intake
214285923|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 9|Liquid formula produced by several food ingredients to provide a balance nutrient intake
214285924|NCT06358716|DIETARY_SUPPLEMENT|Glucose|25 mg of glucose dissolved in 200 mL
214285925|NCT01408446|DRUG|Menthol|Capsule 48mg three times a day after meals 8 weeks
214285926|NCT01408446|DRUG|Placebo|Capsule 48mg three times a day after meals 8 weeks
214285927|NCT05127668|DEVICE|Airglove (TM)|A sterile polythene-balloon was inflated around the forearm using the AirGloveTM to 38.5oC at setting number-3 for 3 minutes, then removed and the degree of venodilation assessed by ultrasound.
214285928|NCT05127668|DEVICE|Warm-water Immersion|The upper limbs (to the level of mid-humerus) of participants were immersed in a container filled with a mix of cold-and warm tap-water to 38.5oC for 3 minutes in the WWI method. Arms were towel-dried, and the degree of venodilation was assessed by ultrasound
214285929|NCT00190697|DRUG|arzoxifene|
214285930|NCT00471328|DRUG|Nilotinib|Nilotinib 400 mg twice daily (bid)
214285931|NCT00471328|OTHER|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
214285932|NCT02983344|DRUG|Ropivacaine|Fascia iliaca compartment block using ropivacaine
214285933|NCT02983344|DRUG|Fentanyl|Intravenous fentanyl
214285934|NCT02983344|DEVICE|Ultrasound|Ultrasound-guided fascia iliaca compartment block
214285935|NCT04079608|BEHAVIORAL|FLASH curriculum|High School FLASH is a 15-session comprehensive sexual health curriculum designed for classroom settings in grades 9 to 12. The basis of High School FLASH is a public health approach to behavior change. The primary strategy used in the FLASH curriculum for preventing teen pregnancy, sexually transmitted diseases (STDs), and sexual violence is to address student behaviors and attitudes. To this end, FLASH uses a harm reduction and behavior change framework, implements best practices as outlined in the research on effective programs, addresses risk and protective factors for program goals, and rests on the theory of planned behavior. The instructional approach of High School FLASH employs key concepts in every lesson, which enables teachers to hone in on the risk and protective factors outlined in the curriculum logic model.
214285936|NCT04079608|BEHAVIORAL|Sexual Health Education for Adolescents|Sexual Health Education for Adolescents is a five-session knowledge-based sexual health curriculum designed for classroom settings. The lessons cover the reproductive system, pregnancy, birth control, abstinence, human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs), and healthy relationships. The goal of the curriculum is to increase student knowledge in all content areas. The primary strategy employed by Sexual Health Education for Adolescents is to address the cognitive learning domain. The curriculum aligns to national health education standards and is intended to be implemented by classroom teachers. The lessons can be delivered according to the schedule that works best for schools (e.g., twice a week, once a week, every days) within a school semester.
214285937|NCT04051008|BEHAVIORAL|Online - use of online grocery shopping platform|The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
214285938|NCT04051008|BEHAVIORAL|Default - use of online grocery shopping platform with default shopping carts|The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
214285939|NCT05608798|DEVICE|ODI-Tech medical device|"The device captures and stores frames of the movement of blood in capillaries and spectra containing information on oxygen saturation. Proprietary software is used to analyse the obtained frames and spectra to calculate microvascular parameters such as functional capillary density and microvascular oxygen saturation.~ODI-Tech can be brought to the patient's bedside and operates non-invasively. The device parts are in contact with the patient for less than 5 minutes."
214285940|NCT04765956|DEVICE|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
214285941|NCT03191994|BEHAVIORAL|Exercise|a structured, supervised eight week moderate intensity exercise intervention
214285942|NCT00958750|DRUG|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
214285943|NCT01082991|OTHER|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
214285944|NCT06318195|BEHAVIORAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
214285945|NCT03585998|DRUG|Durvalumab|Concurrent radiotherapy Maintenance therapy
214285946|NCT05422196|PROCEDURE|Platelet-rich fibrin|Addition of platelet-rich fibrin into the cleft site.
214285947|NCT05742100|DRUG|Darvadstrocel|expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas
214285948|NCT01605877|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
214285949|NCT00764647|BEHAVIORAL|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
214285950|NCT00458211|DRUG|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
214285951|NCT02818569|DRUG|Dexmedetomidine|Oral form
215033423|NCT06285799|DRUG|Low Dose IHAT|Once daily dose of 1 IHAT capsule (100mg IHAT per capsule) and once daily dose of 1 placebo capsule (carob flour)
214285952|NCT02818569|OTHER|Saline Placebo|Saline Placebo
214285953|NCT04403477|BIOLOGICAL|Convalescent plasma|Apheretic convalescent plasma from a COVID-19 survivor
214285954|NCT06505317|DIAGNOSTIC_TEST|AI-based PAD screening intervention|"Providers will receive alerts for a patient that is flagged by model as being high risk for PAD. This will allow the provider to review the alert, check the patient's previous history, develop additional questions to assess the risk of PAD, and initiate orders prior to seeing a patient. Depending on their assessment during the patient visit the provider may choose to order an ABI test (or perform one at bedside) and/or initiate other secondary prevention measures. All patients for which an alert is triggered will be included for secondary analysis."
214285955|NCT00052689|DRUG|bortezomib|Given IV
214285956|NCT00052689|DRUG|gemcitabine hydrochloride|Given IV
214285957|NCT05276193|OTHER|Observational health care register - no applicable intervention at present|Observational health care register - no applicable intervention at present
214285958|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with real coil|repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons
214285959|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with sham coil|repeated transcranial magnetic stimulation with sham coil is a placebo
214285960|NCT04984083|DIETARY_SUPPLEMENT|vitamin k|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
214285961|NCT05778916|PROCEDURE|5 year follow up on patients operated for hallux valgus deformity|Clinical and radiological control of patients operated for hallux valgus deformity between 2016-2018.
214285962|NCT03340532|OTHER|THE INFORMATION + APPEARANCE VIDEO|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
214285963|NCT03340532|OTHER|Information SunSmart video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
214285964|NCT03340532|OTHER|Sleep hygiene video|Contain information on better sleep hygiene
214285965|NCT00724360|DRUG|Herceptin (trastuzumab)|Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
214285966|NCT03158116|DRUG|Inhaled Aztreonam|Inhaled antibiotic with anti-pseudomonal properties
214285967|NCT04367636|BEHAVIORAL|Behavioral: OCAT-sham|Placebo version of the online contingent attention training preceded by psycho-education movieclip.
214285968|NCT04367636|BEHAVIORAL|Behavioral: OCAT|Online contingent attention training preceded by psycho-education movieclip.
214285969|NCT04367636|OTHER|psycho-education video|Both groups get to see a psycho-education video before the smartphone training starts.
214285970|NCT01897402|BIOLOGICAL|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
214285971|NCT01897402|BIOLOGICAL|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
214285972|NCT00451308|PROCEDURE|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
214285973|NCT00451308|PROCEDURE|Induction of labor with foley balloon with 30cc|30cc of saline in foley
214285974|NCT04655898|DRUG|[14C]CC-90001|Oral
214285975|NCT03920579|DRUG|CKD-386 formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
214285976|NCT03920579|DRUG|CKD-386 formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
214285977|NCT03920579|DRUG|D326, D337 and D013|A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
214285978|NCT03069547|OTHER|Quadriceps Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details can be requested rom the responsible party. In brief the QE-program consists of:~\- A short warm-up and 3 specific exercises for the quadriceps muscle~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, free weights, etc."
214285979|NCT03069547|OTHER|Hip Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details be requested rom the responsible party. In brief the HE-program consists of:~\- A short warm-up and 3 specific exercises for the hip abductor and extensor muscles~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, body weight etc."
214285980|NCT00510120|BEHAVIORAL|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
214472162|NCT00898235|OTHER|biologic sample preservation procedure|preserve biologic samples
214472163|NCT00898235|OTHER|laboratory biomarker analysis|analyze laboratory biomarkers
215033424|NCT06285799|DRUG|High Dose IHAT|Twice daily dose of 1 IHAT capsule (100mg IHAT per capsule)
215033425|NCT06285799|DRUG|Carob Flour|Twice daily dose of 1 placebo capsule (carob flour)
215033426|NCT03744637|DRUG|Frespaciguat|Single inhaled dose of frespaciguat 120, 165, 240, 300, 360, or 480 ug depending upon randomization
215033427|NCT03744637|DRUG|Placebo|Single inhaled dose of placebo to match frespaciguat
214285981|NCT00510120|BEHAVIORAL|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
214285982|NCT00510120|BEHAVIORAL|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
214285983|NCT05979701|OTHER|Simulation training|The intervention will consist of training participants through simulation in addition to theoretical training. The simulation will cover 3 themes, including diagnosis of haemorrhage, communication between healthcare providers, management of post-partum haemorrhage and transfusion monitoring.
214285984|NCT00757887|BIOLOGICAL|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
214285985|NCT02943278|BEHAVIORAL|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
214285986|NCT02943278|BEHAVIORAL|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
214285987|NCT01307007|DRUG|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
214285988|NCT01307007|DRUG|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
214285989|NCT05647655|DEVICE|Ultrasonography|Bedside thoracic ultrasound for patients complaining of acute dyspnea.
214285990|NCT02634320|DRUG|Aripiprazole Lauroxil|Monthly IM injection
214285991|NCT03210597|OTHER|Exercise|The subjects performed training in aquatic environment
214285992|NCT00121745|GENETIC|Rexin-G Dose 1|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
214285993|NCT00121745|GENETIC|Rexin-G Dose 2|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
214285994|NCT00121745|GENETIC|Rexin-G Dose 3|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml"
214285995|NCT00121745|GENETIC|Rexin-G Dose 4|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml"
214285996|NCT01096901|BEHAVIORAL|Behavioral Weight loss|Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
214285997|NCT00687323|DRUG|temozolomide|
214285998|NCT00387023|DRUG|Rituximab|250 mg/m\^2 IV over 4-6 hours for 2 weeks.
215033428|NCT05594875|DRUG|SHR-1921|Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
215033429|NCT03440385|DRUG|Ozanimod|Specified dose on specified days
215033430|NCT03440385|OTHER|Placebo|Specified dose on specified days
215033431|NCT04123704|DRUG|Sitravatinib|sitravatinib capsule
215033432|NCT04103242|OTHER|16s rRNA gene sequencing|High-throughput sequencing of the microbial 16s rRNA subunit to define the abundance of microbial phyla and genera
215033433|NCT05915377|OTHER|READI-SET GO UB-CAM delirium screening into EHR|UB-CAM Delirium screening tool integrated into EHR with education on best practices for delirium management
215033434|NCT01497730|DEVICE|Total Knee Replacement|"Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices."
215033435|NCT05260242|OTHER|Disparities Conversation|The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
214285999|NCT00387023|DRUG|Zevalin|5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
214286000|NCT04384211|OTHER|Computer Assisted Detection Software For Vertebral Fractures|A device named Smart Bone that is using CT image retrospectively acquired to entails a second review of CT images with Vertebral Compression Fractures through an interactive AI program developed by Quanta Computer Inc. was applied to the CT images. The device is a computer-aided detection (CADe) software application and is designed to assist radiologists to analyze Spine CT images. The device uses deep learning methods to perform vertebrae detection and classification of images.
214286001|NCT01209260|DEVICE|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
214286002|NCT01209260|DEVICE|Mechanical Needle|Mechanical needle for transseptal access
214472164|NCT00898235|PROCEDURE|fluorescence spectroscopy|perform fluorescence spectroscopy on specimens
215033436|NCT02985138|PROCEDURE|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
215033437|NCT02985138|PROCEDURE|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
215033438|NCT02985138|DEVICE|Pedicle screw and cage|Pedicle screw and cage
215033439|NCT04161482|DRUG|Furosemide 80 mg (8 mg/mL)|Furoscix will be administered as a subcutaneous infusion.
215033440|NCT05773040|DRUG|JV-213|Given by (IV) vein
215033441|NCT05773040|PROCEDURE|Leukapheresis|Given by IV (vein)
214286003|NCT02555072|BIOLOGICAL|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
214286004|NCT05281939|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Participants were divided into the intervention group and the control group using a random number table. The intervention group participants' cervical colposcopic image data and non-image data as follow：age, the infection of high-risk human papillomavirus (HR-HPV),the type of HR-HPV infection,the duration of HR-HPV infection, cervical cytology (TCT) results, HIV/sexually transmitted infection history, marriage and childbearing history,first sexual life history, sexual partner history, smoking history,oral contraceptives history,the use of immune drug and possible clinical symptoms of cervical lesions such as postcoital bleeding, abnormal vaginal secretions, vaginal bleeding symptoms, etc.
214286005|NCT04691505|DRUG|Methotrexate|Methotrexate is used as the reference group.
214286006|NCT04691505|DRUG|Hydroxychloroquine|Hydroxychloroquine is used as the exposure group.
214286007|NCT02616055|DRUG|tesevatinib|
214286008|NCT02132130|DRUG|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
214286009|NCT04984720|BEHAVIORAL|Smartphone based digital application|Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
214286010|NCT01580618|DRUG|normal saline|Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
214286011|NCT01580618|DRUG|TNK (Tenecteplase)|Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
214286012|NCT01179568|DRUG|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
214286013|NCT01179568|BEHAVIORAL|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
214286014|NCT01179568|OTHER|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
214286015|NCT03310775|BEHAVIORAL|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
214286016|NCT00838578|BIOLOGICAL|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
214286017|NCT00838578|DRUG|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
214286018|NCT05669495|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, we show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.
214286019|NCT04100265|DEVICE|Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.
214286020|NCT04100265|DEVICE|Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.
214286021|NCT00357968|DRUG|Prasugrel|Administered orally
214286022|NCT00357968|DRUG|Clopidogrel|Administered orally
215033442|NCT04682847|DRUG|Ferumoxytol injection|This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
214472165|NCT00898235|PROCEDURE|quality-of-life assessment|assess quality of life at each follow-up for life
214472166|NCT04475640|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214472167|NCT04475640|OTHER|Genetic Testing|Undergo genetic testing
215033443|NCT05569317|OTHER|primary nursing|The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
214286023|NCT00357968|DRUG|Placebo for Prasugrel|Administered orally
214286024|NCT00357968|DRUG|Placebo for Clopidogrel|Administered orally
214286025|NCT04736420|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure group
214286026|NCT04736420|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
214286027|NCT02812160|DEVICE|Spatz3 Adjustable Balloon|An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
214286028|NCT06755060|COMBINATION_PRODUCT|AI-associated strategy|The intervention in this study involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of ophthalmic diseases. Patients in the intervention group will undergo standard ophthalmic examinations, with clinical decisions guided by the recommendations generated by the AI system. In contrast, patients in the control group will receive only standard ophthalmic examinations and treatment, without the support of AI-assisted decision-making tools.
214286029|NCT06904469|OTHER|Access to a digital clinic|This intervention grants access to a digital clinic that provides chat-based primary care consultations via phone application and website.
214286030|NCT01730833|BIOLOGICAL|pertuzumab|Given IV
214472168|NCT05608252|DRUG|VS-6766|Taken Orally
214472169|NCT05608252|DRUG|Abemaciclib|Taken Orally
214472170|NCT05608252|DRUG|Fulvestrant|Administered by intramuscular injection
214472171|NCT02262117|OTHER|standard care|No specific medical care
214286031|NCT01730833|BIOLOGICAL|trastuzumab|Given IV
214845405|NCT04666753|DIETARY_SUPPLEMENT|ImmunoFormulation|The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at \<10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).
214845406|NCT03363698|OTHER|Cough variant asthma treatment|Evaluation of the treatment response to inhaled corticosteroids, long-acting beta-agonists, montelukast, prednisone.
214286032|NCT01730833|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214286033|NCT01730833|OTHER|laboratory biomarker analysis|Optional correlative studies
214845407|NCT04145245|DRUG|Levocarnitine|Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
214286034|NCT07090655|DRUG|Budoprutug|Subcutaneous or IV administration
214286035|NCT07090655|DRUG|Placebo|Placebo comparator
214286036|NCT07090616|DEVICE|Arm 1-Kronos brace|Subjects randomized to the treatment group will be measured and fitted with the KRONOS knee brace at their initial clinic visit after study enrollment
214286037|NCT07090616|DEVICE|Arm 2-Breg T-Scope brace|Subjects randomized to Breg T-Scope Postoperative Brace will be placed in this standard postoperative hinged knee brace in the operating room that will be locked in full extension.
214286038|NCT07093411|BIOLOGICAL|LUCAR-E9D or LUCAR-E9K cells product|Prior to infusion of the LUCAR-E9D or LUCAR-E9K cells product subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
214286039|NCT07096622|DEVICE|perceptual learning visual treatment,HVT|After receiving guidance from a trainer, treatment was conducted using the visual perception training therapy software (HVT, version number: V1.0.10000) on a network platform for 30 minutes per day, totaling 3 months.
214286040|NCT07132177|DRUG|Naltrexone (oral tablets)|All participants will receive 31 pills of 50 mg Naltrexone to take as needed over the month of January 2026.
214286041|NCT07132593|PROCEDURE|ventricular reconstruction|The Sandwich Procedure was developed at our institution to improve the strength and stability of heart wall reconstruction after tumor removal. It involves suturing two layers of treated biological tissue-both inside and outside the heart wall-to restore normal shape and function, while minimizing the risk of complications like aneurysm or bleeding.
214845408|NCT04423445|OTHER|Laser acupuncture combined with acupressure|Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
214845409|NCT01160445|DRUG|Zanolimumab|14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
214845410|NCT01160445|DRUG|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses.
214845411|NCT01467362|DRUG|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
214845412|NCT01467362|DRUG|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
214286042|NCT07131553|OTHER|Wheelchair school|Wheelchair skills training with pysiotherapist and peer mentor
214286043|NCT07131553|OTHER|Comparison group, conventional rehabilitation|Conventional rehabilitation at the same unit of similiar length and intensity
214286044|NCT07131748|OTHER|Physical Exercise Session in heated Swimming Pool - HEx|Warm Up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise (following the same control parameter of the experimental session); Resistance exercises - 20 minutes of resisted exercises, which will be divided into 6 exercises with 2 sets of 10 to 15 repetitions (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
214286045|NCT07131748|OTHER|Physical Exercise Session in Land- LEx|Warm up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise performed on treadmill and / or exercise bike (following the same control parameter of the experimental session); Endurance Exercises - 20 minutes of exercises resisted, also divided into 6 exercises with 2 sets of 10 to 15 repetitions. The large muscle groups of the upper limbs, lower limbs and trunk will be exercised in fitness machine and with free weights (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
214286046|NCT07131748|OTHER|Control Session Without Exercise- CON|Guidance to maintain the usual level of physical activity and not to enter physical exercise programs during the 12 weeks of follow-up.
214472172|NCT02262117|DRUG|specific treatment|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
214472173|NCT03006432|DRUG|Oxaliplatin|
214472174|NCT03006432|DRUG|5Fluorouracil bolus|
214472175|NCT03006432|DRUG|5Fluorouracil continu|
214472176|NCT03006432|DRUG|Docetaxel|
214845413|NCT01467362|DRUG|desonide 0.1% cream|cream, once a day (in the evening) during flares
214845414|NCT01467362|OTHER|Foaming gel|for the washing and cleaning
214845415|NCT01115062|DRUG|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
214845416|NCT01115062|DRUG|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
214845417|NCT01115062|DRUG|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
214845418|NCT01540344|PROCEDURE|CRS|complete macroscopic cytoreduction (CC-0/1)
214472177|NCT03006432|DRUG|Folinic Acid|
214845419|NCT01540344|DRUG|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
214286047|NCT06913660|BEHAVIORAL|MyGoals|"A smartphone game for ALHIV aged 15-21 yrs~MyGoals includes 3 components:~1. A role-playing narrative in which all players make decisions for male and female characters navigating scenarios from adolescence and early adulthood.~2. A series of mini-games to reinforce knowledge, skills and related self-efficacy, explored in the narrative.~3. A metanarrative component, My Story, where players will create an avatar and set personal goals."
214286048|NCT06913660|BEHAVIORAL|Standard of care|A minimum standard of care package will be identified prior to identification and recruitment of CCCs to ensure a comparable and adequate level of care is being offered to all control participants, since implementation of the range of support and care strategies recommended by the Kenya Ministry of Health differs by clinic.
214286049|NCT06425159|DRUG|BHV-7000|BHV-7000 75mg. Participants will take blinded investigational product (IP) once daily
214845420|NCT06678282|DRUG|JY231 Injection|The starting dose of this study was set at 1\~10×10\^6 transduction units (TU) / kg and escalated at 2\~5×107\^TU/kg and 6\~10×10\^7 TU/kg.
214845421|NCT01347320|OTHER|Preoperative MRI|Preoperative staging
214845422|NCT02126657|DRUG|70% glycolic acid|
214845423|NCT06024967|DRUG|PEG-somatropin|PEG-somatropin
214286050|NCT06425159|DRUG|Placebo|Matching placebo taken once daily
214286051|NCT06828042|BIOLOGICAL|anti-CD19 CAR T cell therapy|anti-CD19 CAR-γδ T cell therapy
214286052|NCT06734468|BEHAVIORAL|Lifestyle Management|"Each subject will receive a personalized intervention plan, comprised of:~1. An individualized exercise plan guided by a mobile phone app.~2. Healthy diet and nutrition recommendations.~3. Theriome metabolomics testing and individualized recommendations that include dietary supplements.~4. Guidance on healthy sleep patterns, stress management, and maximizing social engagement, as appropriate."
214286053|NCT06831526|DRUG|Azeliragon|Provided by Cantex Pharmaceuticals
214286054|NCT06831526|DRUG|Temozolomide|Standard of care.
214286055|NCT06831526|RADIATION|Radiation therapy|Standard of care.
214286056|NCT06831526|PROCEDURE|Surgery or LITT|Standard of care surgical resection or laser interstitial thermal therapy (LITT).
214286057|NCT06918041|DEVICE|FiberLocker® System (encompassing FiberLocker® Instrument SN & SpeedPatch® PET)|The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue.
214286058|NCT07114055|DRUG|ebastine|Tab. Ebastine 20mg once daily at night
214286059|NCT07114055|DRUG|Placebo|Tab. Placebo once daily at night
214286060|NCT07114536|DIETARY_SUPPLEMENT|Calcium-a-ketoglutarate|Description: Participants in the intervention group will receive oral calcium alpha-ketoglutarate (CaAKG) in granular tablet form. Each tablet contains 0.5 grams of CaAKG.Participants will take two tablets twice daily (morning and evening). The total daily dose is 2 grams. The intervention period will last for 12 weeks. CaAKG is a stabilized form of alpha-ketoglutarate that enhances bioavailability and provides supplemental calcium. The tablets are identical in appearance and texture to those in the placebo group to maintain blinding.
214286061|NCT07114536|OTHER|Placebo(starch)|Participants in the placebo group will receive oral tablets identical inappearance and texture to the CaAKG tablets, but containing starch with no active calciumalpha-ketoglutarate. Each tablet weighs 0.5 grams. Participants will take two tablets twicedaily (morning and evening), for a total daily intake of 2 grams. The placebo tablets arepackaged and administered in the same manner as the CaAKG tablets to ensure blindingthroughout the 12-weekintervention period.
214286062|NCT04847557|DRUG|Tirzepatide|Administered SC
214286063|NCT04847557|OTHER|Placebo|Administered SC
214286064|NCT06932952|DRUG|BYON4228 + Pembrolizumab|BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every three weeks until disease progression or unacceptable toxicity. Different doses. Pembrolizumab IV infusion (200 mg) every three weeks from the second treatment cycle onwards.
214286065|NCT07132801|DIETARY_SUPPLEMENT|Qualia NAD⁺ version 1|Qualia NAD+ version 1 manufactured by Qualia Life Sciences
214286066|NCT07132801|DIETARY_SUPPLEMENT|Qualia NAD⁺ version 2|Qualia NAD+ version 2 manufactured by Qualia Life Sciences
214286067|NCT07132801|DIETARY_SUPPLEMENT|Placebo|Rice Flour
214845424|NCT00959569|DRUG|Esmolol|esmolol (1-3 mg/kg) during cardiac surgery
214845425|NCT00959569|DRUG|Placebo|normosaline (same ml of the study drug)
214286068|NCT07131527|DRUG|Gabapentin|oral Gabapentin will be given 2 hours perioperative as postoperative analgesia patients undergoing laparoscopic cholecystectomy
214286069|NCT07131527|DRUG|Diclofenac Sodium|oral diclofenac sodium will be given 2 hours perioperative as postoperative analgesia patients undergoing laparoscopic cholecystectomy
214286070|NCT07132892|DEVICE|Galaflex Lite Scaffold|The GalaFLEX LITE is a surgical mesh scaffold composed of poly-4-hydroxybutyrate (P4HB) developed to prolong strength retention and reinforce soft tissue in patients undergoing plastic and reconstructive surgery.
214286071|NCT07132476|OTHER|No adjuvant therapy|Observe and record hypoglycemia
214286072|NCT07131462|PROCEDURE|Direct Composite Restoration|Application of direct composite resin to restore the fractured crown of permanent incisors.
214286073|NCT07131462|PROCEDURE|Cvek Pulpotomy|Partial pulpotomy (Cvek technique) will be performed for complicated crown fractures with vital pulp exposure. The goal is to maintain pulp vitality using biodentin.
214286074|NCT07131462|PROCEDURE|Endodontic Treatment|Root canal treatment will be applied to teeth with necrotic pulp or extensive pulp exposure not suitable for vital pulp therapy. Procedures will follow standard endodontic protocols.
214286075|NCT07131462|PROCEDURE|Pulp Capping|In cases of minimal pulp exposure, a direct pulp capping procedure will be performed using biocompatible materials such as calcium hydroxide to preserve pulp vitality.
214472178|NCT03245437|DRUG|Oxytocin nasal spray|nasal spray
214472179|NCT03245437|BEHAVIORAL|Social Cognition Skills Training|Group based training in social cognition skills
214472180|NCT03245437|BEHAVIORAL|Health Management|Group-based training in mental health management
214472181|NCT03245437|DRUG|Placebo nasal spray|placebo condition
214845426|NCT00671567|DRUG|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
214845427|NCT00671567|DRUG|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
214286076|NCT07131176|OTHER|Behavior Change through Education intervention|"The I-Change Model We used behavior alteration theory to identify areas of thinking or conduct that might potentially lead to issues in the process of collecting or consuming medicine. Subsequently, we proceeded to create and improve the substance of the message, and we aligned the messages with a standardized classification of evidence-based strategies for modifying behavior.~Unclear or confusing information in infographics and television videos was revised, while information that was deemed unhelpful or insignificant by both patients and clinicians was eliminated. Patients' feedback was used to create fresh material for television videos and infographics.~1. Encourage patients about routine clinic appointments~2. Provide relevant health-related information.~3. Help participants plan and organize various treatment adherence behaviors including medication collection and taking, diet, and exercise~4. Support positive adherence-related behaviors"
214286077|NCT07132580|DEVICE|Re-Timer® light therapy glasses|Participants wore Re-Timer® glasses that emitted bright white light at 506 lux for 30 minutes each morning, over a 4-week intervention period.
214286078|NCT07132580|OTHER|Usual Care|Participants received standard follow-up care with no light therapy intervention during the 4-week period.
214286079|NCT07132814|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol combustible cigarette
214286080|NCT07132814|OTHER|Product B|8 mg nicotine oral product
214286081|NCT07132814|OTHER|Product C|12 mg nicotine oral product
214286082|NCT07132814|OTHER|Product D|6 mg nicotine oral product
214286083|NCT07132814|OTHER|Product E|8 mg nicotine oral product
214286084|NCT07132814|OTHER|Product F|8 mg nicotine oral product
214286085|NCT07132814|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine polacrilex gum
214286086|NCT07132151|PROCEDURE|AI Controlled General Anesthesia|During painless abortion, anesthesia will be induced using ciprofol, and controlled by an AI model.
214286087|NCT07132151|PROCEDURE|General Anesthesia|Anesthesia will be induced using ciprofol, and controlled by experienced anesthesiologists.
214286088|NCT07132333|BIOLOGICAL|Biologic Agent|Intervention with biologic agents
214286089|NCT07131280|DRUG|Gcsf|G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30
214286090|NCT07131280|DRUG|Darbepoetin|Darbepoetin will be given s/c at dose of 40mcg once a week for 1 month
214286091|NCT07131280|OTHER|Standard Medical Treatment|Standard Medical Treatment
214472182|NCT05953038|DRUG|Lysergic Acid Diethylamide Tartrate|D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
214472183|NCT03374657|BIOLOGICAL|CPK850|In one of 4 dose levels administered via subretinal injection under anesthesia
214845428|NCT00671567|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
214845429|NCT04712916|BEHAVIORAL|Health education|Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
214845430|NCT02414763|BEHAVIORAL|Teachable Moment Brief Intervention|functional analysis, collaborative interpersonal style
214845431|NCT03904550|DRUG|Cisatracurium + Neostigmine|Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate
214845432|NCT03904550|DRUG|Rocuronium + Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
214845433|NCT00128817|RADIATION|Concurrent Chemoradiation|60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
214845434|NCT00128817|PROCEDURE|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy|Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
214845435|NCT04694703|DRUG|Covid-19 group|Routine COVID-19 treatment
214286092|NCT07131189|DRUG|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
214286093|NCT07131696|DEVICE|Transcutaneous Vagal Nerve Stimulation|Participants will receive up to 4 sessions per day of up to 20-minute stimulation, over the next 10 days of their inpatient hospital stay, following endovascular treatment. Stimulation will be provided by the tVNS device through a small electrode placed around the ear that will send low intensity, pulsed, electrical pulses the vagus nerve.
214472184|NCT03813862|OTHER|Non-interventional (observational only)|
214472185|NCT04410731|DRUG|Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy|Single bilateral intra-articular injection of manufactured cell cultured expanded allogeneic BM-MSCs for painful lumbar facet joint arthropathy
214472186|NCT06138197|PROCEDURE|Robotic-assisted hysterectomy|Robotic-assisted hysterectomy following usual surgical technique
214286094|NCT07132788|DIAGNOSTIC_TEST|blood draw|Research blood draw
214286095|NCT07132788|DIAGNOSTIC_TEST|Short Performance Physical Battery|test of physical performance, which involves measuring movement from sitting to standing, walking speed, and balance
214286096|NCT07132788|DIAGNOSTIC_TEST|Grip strength test|Measures grip strength
214286097|NCT07132788|DIAGNOSTIC_TEST|Six minute walk test|Measures distance walked in 6 minutes
214286098|NCT07132788|RADIATION|Chest CT scan|X-ray and computer technology takes detailed pictures of the organs and structures inside your chest
214286099|NCT07132788|RADIATION|Dual-Energy X-ray Absorptiometry Scan|Uses X-ray technology to measure the mineral density of your bones, and provides a ratio of fat tissue to lean mass (muscle) and bone
214286100|NCT07132788|BEHAVIORAL|Activity monitoring|A device worn on your non-dominant wrist which measures motion/ movement/ activity
214286101|NCT07132788|BEHAVIORAL|24 hour diet recall|A research dietitian will contact you and ask you to provide details of what you ate over the previous 24 hours
214286102|NCT07132788|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound technology to create moving images of your heart, valves, and chambers
214286103|NCT07132788|BEHAVIORAL|Quality of Life Questionnaire (emPHasis 10)|The emPHasis-10 is a pulmonary hypertension-specific questionnaire which is scored from 0-50 (with higher scores indicating worse quality of life.)
214286104|NCT07132788|BEHAVIORAL|International Physical Activity Questionnaire Short Form (IPAQ-SF)|The IPAQ-SF is a small set of questions to obtain comparable estimates of physical activity.
214286105|NCT07133048|PROCEDURE|Levobupivakain 0.25 %|"The high tuberosity approach blocks for blockage of II. branch of trigeminal nerve.~Standard intraoral approach for inferior alveolar nerve block."
214286106|NCT07133048|PROCEDURE|NaCl 0.9 %|"The high tuberosity approach blocks for blockage of II. branch of trigeminal nerve.~Standard intraoral approach for inferior alveolar nerve block."
214286107|NCT07133022|PROCEDURE|Early Prone Positioning Protocol|A structured protocol in which non-intubated patients with Acute Respiratory Distress Syndrome (ARDS) are positioned prone for 2-4 hours per session, multiple times per day, totaling approximately 8 hours daily for 5 consecutive days. Initiation begins within 24 hours of ARDS diagnosis. Administered by trained Intensive Care Unit (ICU) nurses under medical supervision.
214286108|NCT07133022|OTHER|Standard ICU Care|Participants receive routine Intensive Care Unit (ICU) care for Acute Respiratory Distress Syndrome (ARDS) without the implementation of a structured early prone positioning protocol. Care is provided at the discretion of the treating physicians, following standard ICU management practices.
214286109|NCT06508034|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
214286110|NCT06508034|DIETARY_SUPPLEMENT|Live Freeze-Dried Lactic Acid Bacteria Probiotic|Given PO
214286111|NCT06508034|OTHER|Questionnaire Administration|Ancillary studies
214286112|NCT06301295|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject suspected of early-stage, resectable lung cancer will undergo bronchooscopic procedure. Ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Subsequently, intratumoral washing is performed. After undergoing surgery for suspected early-stage lung cancer, the analysis of next generation sequencing is conducted on intratumoral washing, tissue from surgical specimen, and blood.
214286113|NCT06952257|PROCEDURE|Administration of general anaesthesia|The anaesthesia will be administered intravenously
214286114|NCT06952257|PROCEDURE|Neuraxial Analgesia|Will be administered as an epidural
214286115|NCT06947577|OTHER|pulsed electromagnetic field (PEMF) therapy and a tailored exercise program (TEP)|pulsed electromagnetic field (PEMF) therapy for addressing chemotherapy-induced peripheral neuritis in the lower limb, patients were first prepared by ensuring they were in a relaxed state, free from distractions, and instructed to remove any metallic items while wearing comfortable clothing. The treatment utilized the ASA Easy Terza series PEMF device from Italy, with each patient positioned comfortably in a supine posture. The device was connected to a 220 V electrical supply, and the solenoid was placed over the lower leg, operating at a frequency of 50 Hz and an intensity of 20 G for a duration of 20 minutes. Patients were situated in a position between sitting and lying, with their lower legs and feet positioned within the solenoid. The setup adhered to the manufacturer's guidelines to ensure effective delivery of the magnetic oscillations, with treatment parameters meticulously adjusted
214286116|NCT06947577|OTHER|Tailored Exercise Program|This TEP has been meticulously designed to address the rehabilitation needs of patients dealing with lower limb issues. The program encompasses a comprehensive approach, integrating various types of exercises aimed at enhancing strength, functional mobility, balance, coordination, flexibility, and pain management. The sequence of exercises begins with strengthening exercises targeting key muscle groups such as the gastrocnemius and tibialis anterior, followed by functional training activities that simulate daily movements. This is complemented by balance and coordination drills, coordination drills that challenge stability, and flexibility and stretching exercises to improve range of motion. Additionally, pain management techniques and therapeutic modalities like hot packs are incorporated to alleviate discomfort and enhance relaxation. Finally, the program concludes with low-impact aerobics, such as walking programs, to promote cardiovascular fitness. Prior to commencing the exercise
214472187|NCT05528939|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
214845436|NCT05152615|DIETARY_SUPPLEMENT|Short Chain Fatty Acids (SCFA) Dietary Supplement|Butryate 1000 mg three times daily will be used in this study.
214845437|NCT03079427|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
214845438|NCT03079427|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
214286117|NCT03249727|DIAGNOSTIC_TEST|IVDD for NK cell activity in whole blood|Once subject has been scheduled for a colonoscopy by the institution (up to 4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.
214286118|NCT02336711|RADIATION|dose escalation|molecular imaging based radiotherapy dose escalation
214286119|NCT03853265|BEHAVIORAL|Simulated dental office visit|An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
214286120|NCT03675607|OTHER|Complementary feeding behaviours|Any kind of complementary feeding practice
214286121|NCT02483728|OTHER|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
214286122|NCT02012998|BIOLOGICAL|HBVAXPRO 5µg|0.5mL intramuscular injection
214286123|NCT05924204|RADIATION|Photobiomodulation|Application of photobiomodulation
214286124|NCT05924204|OTHER|Simulation of Photobiomodulation|Simulation of photobiomodulation
214286125|NCT01103011|DRUG|ND0611|Continuous delivery of ND0611
214286126|NCT01103011|DRUG|ND0611|Solution of ND0611 delivered continuously
214286127|NCT00996216|DRUG|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
214286128|NCT00996216|DRUG|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
214286129|NCT04398498|DIAGNOSTIC_TEST|Diagnostic Test: TruGraf® Testing|5 mL collection PAXgene blood sample
214286130|NCT03553134|DIAGNOSTIC_TEST|transcranial doppler ultrasound scan|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 10 minutes)
214286131|NCT03553134|DIAGNOSTIC_TEST|ultrasound scan centered on the arterial canal|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 5 minutes)
214286132|NCT03758274|BEHAVIORAL|CBT by Phone to Promote Treatment|Structured phone intervention to identify concerns about getting alcohol use disorder treatment and to work through those concerns using cognitive behavioral principles.
214286133|NCT03758274|OTHER|Reading the Subject a Pamphlet on Obtaining Alcohol Use Disorder Treatment|The pamphlet was created by the National Institute on Alcohol Abuse and Alcoholism to describe evidence based treatments available for alcohol use disorder and how to obtain such treatment.
214286134|NCT00822991|DEVICE|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
214286135|NCT00822991|DEVICE|B-mode US|screening by conventional B-mode US every 3-5 months
214286136|NCT00793403|OTHER|As per routinary clinical care|As per routine clinical care
214286137|NCT05058248|PROCEDURE|pudendal block|general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco
214286138|NCT01737515|OTHER|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
214286139|NCT05725811|OTHER|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
214286140|NCT03276884|OTHER|Experimental Infant Formula|amino acid-based infant formula powder
214286141|NCT03276884|OTHER|Control Infant Formula|amino acid-based infant formula powder
214286142|NCT05601258|OTHER|Age, gender, hospitalization and mortality rates will be compared|Age, gender, hospitalization and mortality rates will be compared
214286143|NCT05066594|DEVICE|Transoral incisionless fundoplication|The intervention of transoral incisionless fundoplication using the EsophyX (EndoGastric Solutions) system allows, through the endoscopic route, the creation of a cardial neovalve of approximately 270 ° by placing 20-28 polyethylene sutures on the cardial circumference, resulting in an anti-reflux plastic functionally similar to that obtained with the surgical fundoplication.
214286144|NCT00254813|DRUG|Quetiapine|
214286145|NCT02518828|OTHER|High SpO2|SpO2 range ≥96%
214286146|NCT02518828|OTHER|Low SpO2|SpO2 range 90-92%
214286147|NCT04405986|PROCEDURE|Auditory Evoked Potentials (AEP)|Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).
214286148|NCT04405986|PROCEDURE|Blink and Masseter Inhibitory Reflex|Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
214286149|NCT00038207|DRUG|Liposomal Vincristine|Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
214286150|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
214286151|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
214286152|NCT01616524|BIOLOGICAL|Pegylated interferon alfa-2a (pegIFNα-2a)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
214286153|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 24 weeks
214286154|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 12 weeks
214286155|NCT01616524|DRUG|Daclatasvir|Tablets, Oral, 60 mg, Once daily, 12 weeks
214286156|NCT01616524|DRUG|Placebo matching Daclatasvir|Tablets, Oral, 0 mg, Once daily, 12 weeks
214286157|NCT03912766|DIAGNOSTIC_TEST|serum copeptin|routine surgical method using resectoscope inserted into the urinary bladder
214286158|NCT06089135|DEVICE|Intravascular Lithotripsy|Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
214286159|NCT06089135|DEVICE|Cutting Balloon|Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
214286160|NCT02597894|PROCEDURE|Biopsy of Prostate|Undergo biopsy
214286161|NCT02597894|OTHER|Laboratory Biomarker Analysis|Correlative studies
214286162|NCT03339960|OTHER|Ergonomic measurement|Ergonomic measurement of the surgeon and assistant
214286163|NCT00842712|DRUG|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
214286164|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
214286165|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.
214286166|NCT00842712|DRUG|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.
214286167|NCT00842712|DRUG|Cisplatin|Cis will be administered at a dose of 80 mg/m\^2 as intravenous infusion on Day 1.
214845439|NCT02324231|OTHER|39.0°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
214845440|NCT02324231|OTHER|38.5°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
214845441|NCT00925873|DRUG|Active comparator (no fludarabine)|"1. Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).~2. The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm~3. Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)"
214286168|NCT00842712|DRUG|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m\^2 as intravenous infusion on Days 1 and 8.
214286169|NCT00842712|DRUG|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.
214286170|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
214286171|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
214286172|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m\^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
214286173|NCT00842712|DRUG|Chemotherapy|Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
214286174|NCT03902067|BIOLOGICAL|UC-MSC|0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU， at the concentration of 2x10(7) cells/ml.
214286175|NCT03902067|BIOLOGICAL|Control Group|Routine treatment without catheter infusion
214286176|NCT02842918|PROCEDURE|Spinal Manual Therapy|
214286177|NCT02842918|PROCEDURE|Spinal Range of Motion|
214286178|NCT05439512|PROCEDURE|transantral orbital floor reconstruction by titanium mesh|reconstruction of orbital floor fracture by patient specific titanium mesh
214286179|NCT01617174|BEHAVIORAL|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
214286180|NCT03615976|PROCEDURE|high tibial osteotomy with or without arthroscopic circumpatellar denervation with or without arthroscopic circumpatellar denervation|"Arthroscopy will be done in all cases before osteotomy to assess lat. Comp and grade of patellofemoral O.A Arthroscopic patellar denervation with vaper or diathermy will be done plus open wedge high tibial osteotomy in one group and other group OWHTO only will be done comparing the rustles of two groups to assess the efficacy of this procedure~followed by an average follow up to 12 months. And follow up( 6th weeks ,3rd month ,6th month , 12th month)~By clinical examinationan and x-ray and knee scores~1. Scoring of patellofemoral disorders( Kujala) score~2. Knee Injury and Osteoarthritis Outcome Score (KOOS)"
214286181|NCT05252000|DEVICE|mechanical debridement|subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
214286182|NCT05252000|DEVICE|adjunctive aPDT|Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
214286183|NCT05252000|DEVICE|sham aPDT|subjects will receive saline and non-light emitting laser on the tooth
214286184|NCT04220450|DIAGNOSTIC_TEST|T1 mapping on Cardiovascular Magnetic Resonance Studies|On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined
214286185|NCT05323942|OTHER|Education and Exercise Therapy Group|"82 children were evaluated. Among those, 37 volunteered children were trained and demonstrated in practice about bruxism, parafunctional oral habits, sleep hygiene education, and 5x5 therapeutic exercises. Therapeutic exercises program 5x5 included breathing exercises, head-neck, and scapular posture exercises which included jaw muscle and neck muscle stretching and strengthening exercises. They were asked to repeat each exercise with 5 set and 5 times a day for 8 weeks.~Sleep hygiene education was given to parents and children with explanation of the parafunctional oral habits to raise awareness about being conscious about the oral habits. Sleep hygiene education includes routines about bedtime, sleeping room environment, and timing for exercise."
214286186|NCT02137733|DRUG|Bisoprolol|
214286187|NCT02137733|DRUG|Carvedilol|
215033444|NCT00939185|DRUG|Azithromycin|Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
215033445|NCT05870631|BIOLOGICAL|vaccinate with DTaP|vaccinate with DTaP
215033446|NCT05870631|BIOLOGICAL|vaccinate with DT|vaccinate with DT
214286188|NCT00574509|RADIATION|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
214286189|NCT00574509|DRUG|BEAM|Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran
214286190|NCT02371109|OTHER|selftaken versus clinically taken swabs|
214286191|NCT00999583|DRUG|EPOETINE ALPHA|5 injections of 40000 UI of EPO
214286192|NCT00999583|OTHER|Control arm|Usual take care of cardiac arrest
214286193|NCT00875212|DRUG|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
214286194|NCT00875212|DRUG|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
214286195|NCT00875212|DRUG|fluoride|use of a dentifrice containing fluoride (1500ppm) only
214286196|NCT00875212|DRUG|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
214286197|NCT03026452|PROCEDURE|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
214286198|NCT01989078|DRUG|Losartan|"Adults and Children \>50 kg:~* Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.~* Those with SBP \<100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.~Children \<50 kg weight:~* Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved."
214286199|NCT03379532|DEVICE|BCI-NMES|From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.
214286200|NCT03379532|DEVICE|Sham-NMES|Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.
214286201|NCT01020227|BEHAVIORAL|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
214286202|NCT02655939|DIETARY_SUPPLEMENT|Reflex Plus|Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
214286203|NCT02655939|DIETARY_SUPPLEMENT|Placebo|Fructose,Orange flavor and sucralose
214286204|NCT00002096|DRUG|Zidovudine|
214286205|NCT00002096|DRUG|Didanosine|
214286206|NCT00002096|DRUG|Ganciclovir|
214286207|NCT03063567|DEVICE|CPAP interfaces|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
214286208|NCT00822835|BIOLOGICAL|ILV-095|
214286209|NCT00822835|BIOLOGICAL|Placebo|
214286210|NCT00760578|DRUG|Placebo|Once daily, oral
214286211|NCT00760578|DRUG|Pioglitazone|Once daily, oral
214286212|NCT00760578|DRUG|MSDC-0160 90 mg|Once daily, oral
214286213|NCT00760578|DRUG|MSDC-0160 220 mg|Once daily, oral
214286214|NCT03432754|BEHAVIORAL|Mindfulness-Based Attention Training|The mindfulness-based attention training is closely modeled after the traditional mindfulness-based stress reduction (MBSR) protocol, it incorporates formal MBSR practices such as breath exercises, body scans and long sitting meditations. Specifically, MBAT is an abbreviated version of MBSR with a focus on the cognitive components.
214286215|NCT03432754|BEHAVIORAL|Lifestyle Education|"The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning and mind wandering in older adults, will comprise of scientific health and lifestyle information. Lectures will be focused on concepts presented in the book The Culprit and the Cure: Why lifestyle is the culprit behind America's poor health and how transforming that lifestyle can be the cure. Meetings will cover how to begin and maintain a more nutritious diet, classifying healthy choices across food groups, completing stretching/toning exercises, and reviewing homework."
214286216|NCT00686192|DIETARY_SUPPLEMENT|Calcium Carbonate|1500 mg per day
214286217|NCT01549860|DEVICE|MIST Therapy|Non-contact low frequency ultrasound therapy
214286218|NCT03898154|DRUG|Dexamethasone|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone
214286219|NCT03898154|DRUG|Methylprednisolone|Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
214286220|NCT00275769|DEVICE|Pacemaker|
214286221|NCT04432194|DIETARY_SUPPLEMENT|Nutritional supplementation and Pulmonary Rehabilitation|Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
214286222|NCT04946838|DEVICE|DS5 electrical stimulator|TENS
214286223|NCT03916198|DRUG|Polydeoxyribonucleotides|Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
214286224|NCT03916198|DRUG|Normal saline|Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
214286225|NCT00894569|DRUG|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
214286226|NCT00894569|DRUG|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
214286227|NCT03186222|DIAGNOSTIC_TEST|blood sample|"Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method."
214286228|NCT04677374|OTHER|Standard of care|Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.
215033447|NCT01160185|DRUG|paclitaxel|paclitacel
214286229|NCT04677374|BEHAVIORAL|Intensified Health Education|More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC
214286230|NCT04677374|BEHAVIORAL|SMS/telephonic Tracing|SMS tracing to remind participants of VMMC appointments
214286231|NCT04677374|BEHAVIORAL|Transportation Reimbursement|Transportation reimbursement to offset the cost of transportation for VMMC appointments
214286232|NCT06336850|PROCEDURE|Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement|The endoscopic ultrasound (EUS)-guided 25G fine needle aspirate (FNA) needle procedure is a straightforward minimally invasive technique for direct portal pressure measurements.
214286233|NCT02705495|OTHER|acupuncture|"Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The deqi sensation (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture."
214286234|NCT02705495|DRUG|Cranberry products|Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
214286235|NCT00827424|BEHAVIORAL|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
214286236|NCT06040112|DEVICE|Atelocollagen|Tendoregen (Atelocollagen) injection
214286237|NCT03965910|OTHER|Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data|"Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic."
214286238|NCT00680667|BIOLOGICAL|Coriolus versicolor extract|Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
214286239|NCT04271605|BEHAVIORAL|diet and exercise suggestion|diet and exercise suggestion according to blood biochemistry data and bone mineral density
214286240|NCT04462003|DRUG|Apixaban|10 mg/12 h for 1 week followed by 5 mg/12 h
214286241|NCT04462003|DRUG|Enoxaparin|1mg/Kg/sc/12h
214286242|NCT00002990|BIOLOGICAL|BCG vaccine|
214286243|NCT05012839|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
214286244|NCT03311815|DIAGNOSTIC_TEST|NGS techniques|Using NGS techniques we will detect the recurrently mutated genes in AML to establish the biological role of each mutation
214286245|NCT04496544|OTHER|Retrospective data collection|No intervention; retrospective data collection
214286246|NCT03349112|BEHAVIORAL|4% Lidocaine Spray|2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.
214286247|NCT03349112|BEHAVIORAL|2% Viscous Lidocaine|2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
214286248|NCT00053053|DIETARY_SUPPLEMENT|Juven|
214286249|NCT00053053|DIETARY_SUPPLEMENT|Non-Juven Supplement|
214472188|NCT05528939|OTHER|Control video game|The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
214472189|NCT06414408|DRUG|Doxycycline Pill|200mg Dose
214472190|NCT04361487|DEVICE|NOVOSTITCH PRO Meniscal Repair System|Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO
214286250|NCT06291025|PROCEDURE|PEX-FREE|The study/experimental procedure consists in replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).
214472191|NCT01726140|PROCEDURE|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be \>200, the patient will stop the treatment.
214472192|NCT01726140|PROCEDURE|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be \>200, the patient will stop the treatment.
215033448|NCT01160185|DRUG|cisplatin|cisplatin monotherapy
215033449|NCT01160185|DRUG|topotecan|topotecan
214286251|NCT02485301|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
214286252|NCT02485301|DRUG|Placebo|A single dose administrated intramuscular
214286253|NCT05951062|BEHAVIORAL|behavior management for anti-hypertensive medication|five sessions of educational interview and home visiting to improve medication-related self-management skills
214286254|NCT05951062|OTHER|placebo group|treatment as usual
214286255|NCT01770626|OTHER|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
214286256|NCT01282268|DRUG|arbaclofen|orally disintegrating tablet
214286257|NCT01282268|DRUG|placebo|orally disintegrating tablet
214286258|NCT01021540|DRUG|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
214286259|NCT04493281|DRUG|MT-1186|Oral suspension
214286260|NCT04493281|DRUG|MCI-186|Intravenous formulation
214286261|NCT04376372|DIAGNOSTIC_TEST|Functional testing, Magnetic resonance imaging, Electromyography|Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)
214286262|NCT03578289|BEHAVIORAL|Telemental Health - CBT|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
214286263|NCT04519710|BIOLOGICAL|o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B|to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
214286264|NCT02175888|DIETARY_SUPPLEMENT|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
214286265|NCT02175888|DIETARY_SUPPLEMENT|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
214286266|NCT03582202|PROCEDURE|Nutritional assessment and therapy|Nutritional screening, nutritional plan, follow-up and instructions on discharge
214286267|NCT03582202|PROCEDURE|Standard care|Nutritional handling by nurse
214286268|NCT01781403|DRUG|Temozolomide|Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
214286269|NCT00546845|DEVICE|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
214286270|NCT00546845|DEVICE|Use of self-expanding Expert stent|Nitinol stent
214286271|NCT00085631|DRUG|cisplatin|Given IV
214286272|NCT00085631|PROCEDURE|hyperthermia treatment|Patients undergo hyperthermia treatment over 60-90 minutes
214286273|NCT00085631|RADIATION|brachytherapy|Patients undergo brachytherapy for 2-3 days
214286274|NCT00085631|RADIATION|external beam radiation therapy|Patients undergo external beam radiation therapy once daily on days 1-5
214286275|NCT01662258|DEVICE|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
214286276|NCT03535103|DRUG|Gonal-F®|A single Subcutaneous injection, 225IU
214286277|NCT03535103|DRUG|LM001|A single Subcutaneous injection, 225IU
214286278|NCT05417945|DEVICE|JensClip transcatheter valve repair system|"Transcatheter mitral valve repair system is derived from the Edge-to-Edge technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation."
214286279|NCT06153511|PROCEDURE|Robot assisted spinal transpedicular fixation|Surgical technique which joins two or more vetebrae with screws and rods to prevent any relative movement between them. It is a major surgery that usually lasts several hours and in which the patient is subjected to general anesthesia. The screws to be placed go through a narrow area of the vertebra known as the pedicle. Each patient will undergo a singular intervention.
214286280|NCT01349790|DRUG|NewGam|NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
214286281|NCT00597545|PROCEDURE|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
214286282|NCT00597545|DEVICE|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
214286283|NCT01250405|DRUG|Cinacalcet|One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
214286284|NCT01250405|DRUG|Placebo|One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
214286285|NCT03358901|DRUG|YC-6|
214286286|NCT03358901|DRUG|Vehicle|
214286287|NCT06299033|DRUG|hNPC01|hNPC01, human forebrain neural progenitor cell product, intracerebral injection
214286288|NCT05587205|BIOLOGICAL|EO2002|Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
214286289|NCT05587205|OTHER|Sham injection|Sham injection
214286290|NCT02354079|GENETIC|hypobetalipoproteinemia genetic and genotypic screening|
214286291|NCT02085785|BEHAVIORAL|Coached group|Participants randomized to the coached arm will receive 1) education and self-monitoring materials \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur
214286292|NCT02085785|BEHAVIORAL|Self-directed control group|Participants randomized to the self-directed control arm will receive the same educational and self-monitoring materials as the coached group \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
214286293|NCT02085785|OTHER|Screened only|Screened only - No intervention -- individuals who are contacted and/or screened for eligibility
214286294|NCT04245332|DIETARY_SUPPLEMENT|Fish oil|Fish oil-derived omega-3 polyunsaturated fatty acids (4g fish oil concentrate: 2g EPA+ 1g DHA)
214286295|NCT04245332|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil (4g/d)
214286296|NCT00779467|DRUG|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
214286297|NCT00779467|DRUG|Bupivacaine|
214286298|NCT00779467|DRUG|fentanyl|fentanyl 2 mcg/ml
214286299|NCT00672867|DRUG|Clevudine|30mg
214286300|NCT00672867|DRUG|Adefovir dipivoxil|10mg
214286301|NCT02090569|DEVICE|Functional micro-Doppler Sonography (fmDS)|"1. Craniotomy according to MRI images~2. Dura opening~3. Sulcal Localization using neuronavigation~4. Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.~5. Exeresis of the dysplasic tissue~6. Control using fmDS before wound closure"
214286302|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
214286303|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
214286304|NCT00831168|BEHAVIORAL|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
214286305|NCT02692703|DRUG|glecaprevir/pibrentasvir|Tablet; glecaprevir coformulated with pibrentasvir
214286306|NCT04691453|PROCEDURE|QM-C Hysterectomy|This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.
214286307|NCT04691453|PROCEDURE|QM-B Hysterectomy|Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
214286308|NCT03247855|PROCEDURE|minimal invasive coronary artery bypass graft surgery|coronary artery bypass grafting surgery by using a minimal invasive technique
214286309|NCT01148784|PROCEDURE|ACL reconstruction|Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
214286310|NCT00025766|DEVICE|PCI with stenting|PCI with stenting of the occluded culprit infarct-related artery
214286311|NCT00025766|BEHAVIORAL|Optimal Medical Therapy|Participants will receive optimal medical therapy.
214286312|NCT04829708|OTHER|MRI Surveillance|Receive MRI surveillance
214286313|NCT04829708|RADIATION|Prophylactic Cranial Irradiation|Receive PCI
214286314|NCT04813445|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
214286315|NCT05076903|DRUG|OFA|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
214286316|NCT05076903|DRUG|Control|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
214286317|NCT02442869|BEHAVIORAL|Stage 1 Treatment as usual (TAU)|4-8 weeks of the treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.
214286318|NCT02442869|BEHAVIORAL|Stage 1 CAMS|4-8 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
214286319|NCT02442869|BEHAVIORAL|Stage 2 CAMS|4-16 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
214286320|NCT02442869|BEHAVIORAL|Stage 2 Dialectical Behavioral Therapy (DBT)|4-16 weeks of Dialectical Behavioral Therapy (DBT)
214286321|NCT05048784|DRUG|Sotorasib|Oral tablet
214472193|NCT03571789|DEVICE|Vine™|"The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.~The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters"
214286322|NCT00226707|DRUG|Pimecrolimus Cream 1%|
214286323|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
214286324|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
214286325|NCT02455232|PROCEDURE|upper limb muscle block|
214286326|NCT02455232|DRUG|4cc of lidocaïne®|
214472194|NCT06806735|OTHER|3D-Pictures|3D-Pictures will be taken of hypertrophic scars and keloids to document them.
214286327|NCT00068471|DRUG|anidulafungin|
214845442|NCT00925873|DRUG|Experimental (fludarabine)|"The same regimen with addition of fludarabine in every treatment sequence~1. Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~2. Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~3. Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2."
214286328|NCT00825591|DIETARY_SUPPLEMENT|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
214286329|NCT00825591|DIETARY_SUPPLEMENT|Placebo Comparator|Oral administration before bed. 6 week duration.
214286330|NCT05792891|OTHER|Collecting biological material from frail patients, with or without COVID-19|The study planned to collect demographic information, disease history, COVID-19 symptomatology, COVID-19 molecular test details, COVID-19 serological test results, and biobanking of biological specimens (PBMCs, sera, plasma). In addition, clinical analyses, anamnestic data, and pharmacological treatment pieces of information were collected.
214286331|NCT05526820|BIOLOGICAL|The live attenuated varicella vaccine and the inactivated hepatitis A vaccine|"The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd,the inactivated hepatitis A vaccine was manufactured by Sinovac Biotech Co., Ltd.~The live attenuated varicella vaccine:live varicella-zoster virus in 0.5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection.~The inactivated hepatitis A vaccine:250 U inactivated virus in 0.5mL of aluminium hydroxide solution per injection.~All subjects received hepatitis A vaccine in the upper left arm and varicella vaccine in the upper right arm."
214286332|NCT02315001|DRUG|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
214286333|NCT02315001|OTHER|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
214286334|NCT03378362|PROCEDURE|Partial denervation of the wrist joint|Partial denervation of the wrist (posterior and anterior interosseous neurectomy) through a single dorsal approach.
214286335|NCT06379477|PROCEDURE|Refractive surgeries|after primary phacoemulsification surgery any resulting refractive error surprises will be corrected with different refractive surgery options
214286336|NCT00161083|DRUG|ursodeoxycholic acid|
214286337|NCT03519932|DEVICE|comfilcon A toric lens|Contact lens
214286338|NCT03519932|DEVICE|samfilcon A toric lens|Contact lens
214286339|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
214286340|NCT01101646|DRUG|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
214845443|NCT04226586|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) group|Eligible children will be supplemented with Essential Amino Acids (EAA) for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
214286341|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
214845444|NCT04226586|DIETARY_SUPPLEMENT|Placebo|Eligible children will be supplemented with a placebo for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
214845445|NCT04946786|DIAGNOSTIC_TEST|Laboratory investigations, pelvi-abdominal US, fibroscan, and in body analysis|"1. Complete history taking.~2. Thorough clinical examination :Assessing for buffalo hump, double chin, acanthosis nigricans, skin tags or acrochordon and xanthelasma and anthropometric measurements as measuring height m, weight Kg, waist circumference (WC) Cm, hip circumference (HC) Cm.~3\. Pelvi-abdominal ultrasound. 4. Fibroscan examination will be done for all subjects to assess steatosis by measuring the CAP score.~5\. Body composition analysis: to detect water, muscle and fat percentage in the body.~6\. Laboratory investigations:All samples wil be analyzed for fasting blood glucose (FBG), and post-prandial (2hrs after meals) blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein (VLDL-C), alkaline phosphatase (ALK), aspartate transaminase (AST),alanine transaminase (ALT).~• Fasting insulin levels will be measured using ELISA kits"
214845446|NCT02816424|BEHAVIORAL|Teens Exploring and Managing Prevention Options (TEMPO)|
214845447|NCT00952224|OTHER|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
214845448|NCT02045524|OTHER|Deep muscle injection|
214286342|NCT05714813|BEHAVIORAL|High-Speed Circuit Resistance Training|Performance of 24 weeks of high-speed concentric and low-speed eccentric lift across three circuits on eleven pneumatic machines. Each training session will be in person and will last between 45 minutes and one hour.
214286343|NCT05714813|BEHAVIORAL|Lecture on Diet, Exercise and Cognition|Lectures on diet, exercise, and cognition. Lectures will be provided in person or online and will last approximately one hour.
214286344|NCT02918175|BEHAVIORAL|mHealth|Personalized step count feedback and medication teaching tool.
214286345|NCT01890356|DEVICE|Transcranial electrical stimulation|
214286346|NCT04435860|OTHER|Truncal flexion-extension muscle power|Patient performs a maximum truncal flexion laying supine on the bed with cap of muscle tester placed on sternum,
214286347|NCT04435860|OTHER|Truncal extension muscle power|Patient performs a maximum truncal extension laying prone on the bed while the cap of manual muscle tester placed on vertebrae at the level of midline between superior angles of scapulae.
214286348|NCT04435860|OTHER|Cervical flexion muscle power|Patient performs a maximum cervical flexion sitting while the cap of manual muscle tester placed on the middle of the forehead.
214286349|NCT04435860|OTHER|Cervical extension muscle power|Patient performs a maximum cervical extension sitting while the cap of manual muscle tester placed on protuberantia occipitalis.
214286350|NCT04435860|OTHER|Cervical lateral flexion muscle powers|Patient performs a maximum cervical lateral flexions on right and left sitting while the cap of manual muscle tester placed on relevant pterion.
214286351|NCT04435860|OTHER|Shoulder flexion muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior aspect of acromion and anterior elbow.
214286352|NCT04435860|OTHER|Shoulder extension muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior aspect of acromion and posterior elbow.
214286353|NCT04435860|OTHER|Shoulder internal rotation muscle power|Patient performs a maximum shoulder internal rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior elbow and wrist.
214286354|NCT04435860|OTHER|Shoulder external rotation muscle power|Patient performs a maximum shoulder external rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior elbow and wrist.
214286355|NCT04435860|OTHER|Shoulder abduction muscle power|Patient performs a maximum shoulder abduction of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line lateral aspect of acromion and lateral epicondyle.
214286356|NCT04435860|OTHER|Hip flexion muscle power|Patient performs a maximum hip flexion laying supine on the bed while the cap of manual muscle tester placed on middle of the anterior thigh.
214845449|NCT02045524|OTHER|Sub-Q Injection|
215033450|NCT02104193|DRUG|simvastatin in addition to radiation therapy|simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
214286357|NCT04435860|OTHER|Hip extension muscle power|Patient performs a maximum hip extension laying prone on the bed while the cap of manual muscle tester placed on middle of the posterior thigh.
214286358|NCT04435860|OTHER|Hip abduction muscle power|Patient performs a maximum hip abduction laying supine on the bed while the cap of manual muscle tester placed on middle of the lateral thigh.
214845450|NCT04983602|OTHER|Comprehensive Geriatric Assessment arm|The intervention will involve a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.,
214845451|NCT04983602|OTHER|EDPLUS|EDPLUS involves a 6 week physiotherapy led community based intervention involving 3 home visits and weekly telephone support.
214845452|NCT02626208|DEVICE|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
214286359|NCT04435860|OTHER|Hip internal rotation muscle power|Patient performs a maximum hip internal rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between lateral condyle of femur and lateral malleolus.
214286360|NCT04435860|OTHER|Hip external rotation muscle power|Patient performs a maximum hip external rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between medial condyle of femur and medial malleolus.
214286361|NCT04435860|OTHER|Bath Ankylosing Spondylitis Functional Index (BASFI)|"This questionnaire evaluates the functionality in patients with AS. The ten questions that comprise the BASFI were chosen with input from patients with AS. The first 8 questions evaluate activities related to functional anatomical limitations due to the course of this inflammatory disease. The final 2 questions evaluate the patients' ability to cope with everyday life. A visual analogue scale (with 0 being easy and 10 impossible) is used to answer the questions on the test. The final score varies between 0 and 10."
214286362|NCT04435860|OTHER|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|This questionnaire evaluates the disease activity level in patients with AS. The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS. The final score varies between 0 and 10.
214286363|NCT04435860|OTHER|The Health assessment questionnaire (HAQ)|The Health assessment questionnaire (HAQ) is a questionnaire for the assessment of disability in an individual. The patients report the amount of difficulty they have in performing eight daily living activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The final score varies between 0 and 3.
214286364|NCT04435860|OTHER|Bath Ankylosing Spondylitis Metrology Index (BASMI)|Bath Ankylosing Spondylitis Metrology Index, a combined index to assess the spinal mobility. It evaluates the patients regarding cervical rotation, tragus-to-wall distance, lumbar flexion, lumbar lateral flexion and intermalleolar distance. The total score varies between 5 to 15 in patients with ankylosing spondylitis
214286365|NCT03900078|OTHER|Incisional negative pressure wound therapy|A negative pressure dressing is applied to the skin incision.
214286366|NCT03900078|OTHER|Wound dressing with adhesive tapes|Regular adhesive wound tapes are applied over the closed skin.
214286367|NCT01374620|DRUG|Paclitaxel dose escalation|"Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~* 40~* 60~* 70~* 75~* 80~* 85~* 90"
214286368|NCT01374620|DRUG|Paclitaxel|Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
214286369|NCT01374620|DRUG|Cyclophosphamide|"D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days"
214286370|NCT01374620|BIOLOGICAL|Blood collection|At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
214286371|NCT01445561|DRUG|Interleukin-2 (100,00 IU/m(2) SQ)|100,000 International Units/m2 SQ daily for 5 days
214286372|NCT01247740|DRUG|NuTRIflex Lipid peri|parenteral nutrition
214286373|NCT01247740|DRUG|compounded monobag|parenteral nutrition
214845453|NCT01839838|RADIATION|Proton Therapy|
214286375|NCT00284050|DRUG|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
214286376|NCT00284050|DRUG|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
214286377|NCT00284050|DRUG|Sham injection|Non-treatment control for sham intravitreal injection.
214286378|NCT00038857|PROCEDURE|Megadose of CD34 Selected Progenitor Cells|Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.
214286379|NCT00038857|DRUG|Melphalan|140 mg/m\^2 on day -8
214286380|NCT00038857|DRUG|Thiotepa|10 mg/kg on day -7
214286381|NCT00038857|DRUG|Fludarabine|160 mg/m\^2 over 4 days on days -6, -5, -4, -3
214286382|NCT00038857|DRUG|Rabbit ATG|1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
214286383|NCT01602146|OTHER|ultramarathon running|"* blood samples before and after ultramarathon~* urinary samples before and after ultramarathon~* voluntary ant electrically muscular forces measuring before and after ultramarathon~* Broadband ultrasound Attenuation before and after ultramarathon"
214286384|NCT03662490|DEVICE|High resolution oesophageal manometry|High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
214286385|NCT02968251|BEHAVIORAL|Hand Washing Program (HWP)|HWP consists of integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
214845454|NCT02292550|DRUG|Ribociclib|CDK 4/6 inhibitor
214845455|NCT02292550|DRUG|Ceritinib|ALK inhibitor
214845456|NCT04854408|OTHER|healthcare workers with the coronavac vaccine|Health workers who are vaccinated will fill in the 20-question survey electronically.
214845457|NCT05857917|DEVICE|Virtual Reality|Virtual reality in PD catheter insertion surgery in the pre- and intraoperative setting.
215033451|NCT02104193|RADIATION|radiation therapy|radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
215033452|NCT00004419|DRUG|insulin-like growth factor I|
214286386|NCT02150798|OTHER|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
214286387|NCT02150798|OTHER|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
214286388|NCT04771442|DRUG|Stromal vascular fraction|Single dose
214286389|NCT00899262|OTHER|immunohistochemistry staining method|
214286390|NCT00899262|OTHER|laboratory biomarker analysis|
214286391|NCT00899262|OTHER|sputum cytology|
214286392|NCT00899262|PROCEDURE|Fourier transform infrared spectroscopy|
214286393|NCT00899262|PROCEDURE|diagnostic bronchoscopy|
214286394|NCT00727181|DEVICE|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
214286395|NCT06138301|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a psychotherapeutic intervention that focuses on challenging and changing cognitive distortions (such as thoughts, beliefs, and attitudes) and their associated behaviours to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, patients with SI will undergo 8 sessions of CBT (45 min, once a week), remotely. Techniques and strategies of the intervention will be based on a short telepsychotherapy protocol previously published by our group (Biagianti et. al., 2021). Instead, the content of each session will be adapted to the psychopathology associated with social isolation and the age of the subject. The psychotherapeutic sessions of the patients will be audio-recorded in order to conduct retrospective analyzes of the patient's speech.
214286396|NCT06138301|BEHAVIORAL|Cognitive Remediation (CR)|The cognitive training will consist of 10 hours (30 minutes/session) of computer-based exercises focusing on working memory, attention, executive functions and social cognition, which will be performed online using BrainHQ software. This software allows for the customization of the training based on the specific characteristics of each subject. For example, it allows automatic adjustment of the difficulty of the exercises, trial by trial and session by session, in order to guarantee an adequate level of attention and motivation for the entire duration of the training and therefore favor optimal learning rates.
214286397|NCT00742534|DRUG|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
214286398|NCT06076161|DIETARY_SUPPLEMENT|Spirulina supplementation and calorie restriction in obese men|The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction. The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.
214286399|NCT05360511|DRUG|particulate xenograft + erythropoietin gel.|"1. Surgical sites will be anaesthetized using local anaesthesia.~2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~   * In Group A (test group):~Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect."
214286400|NCT05360511|COMBINATION_PRODUCT|particulate xenograft|"* All surgeries will be performed by the same operator as follows:~  1. Surgical sites will be anaesthetized using local anaesthesia.~ 2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~ 3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~ 4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~ 5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~* In Group B (control group):~Particulate xenograft will be applied to fill the whole defect."
214286401|NCT03414619|BEHAVIORAL|Cognitive Control Tasks and Script Driven Imagery|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors and anxiety/mood symptoms. They then will complete a battery of neuropsychological executive functioning tasks on the computer, each of which measures a different facet of cognitive control (i.e., response inhibition, cognitive flexibility, and attentional control). Finally, they will be guided through a standardized script-driven imagery paradigm that involves generating and listening to an individualized imaginal script associated with a moderately distressing intrusive thought. Self-report and psychophysiological data will be collected during this exercise.
214286402|NCT03729960|OTHER|LENA recorder|The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
214286403|NCT00159536|DRUG|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
214286404|NCT00159536|DRUG|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
214286405|NCT02573350|DRUG|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
214286406|NCT02573350|DRUG|OBR|Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
214286407|NCT02786342|PROCEDURE|blood sample collection|
214286408|NCT03702946|OTHER|oxytocin in abdominal myomectomy|Women were divided into two groups randomly. In the study group 30 Units of oxytocin in 1000 ml normal saline were given during surgery, at the rate of 15units/hour. In control group, pure normal saline was given
214286409|NCT00064194|DIETARY_SUPPLEMENT|selenium|
214286410|NCT00064194|DIETARY_SUPPLEMENT|soy protein isolate|
214286411|NCT00064194|DIETARY_SUPPLEMENT|vitamin E|
214286412|NCT04473924|DRUG|Mycophenolate Mofetil|Body surface area-based dosing of mycophenolate
214286413|NCT04473924|DRUG|Mycophenolate Mofetil|Standard (fixed) dosing of mycophenolate
214286414|NCT01811160|DRUG|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
214286415|NCT01811160|DRUG|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
214286416|NCT04815161|BEHAVIORAL|Adherence|Adherence to medication using an electronic pillbox
214286417|NCT03090113|DRUG|Shuxuetong Injection|intravenous drip
214286418|NCT03090113|DRUG|Placebo Injection|intravenous drip
214286419|NCT03186560|DEVICE|gekoTM|The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
214286420|NCT05433714|OTHER|Assesment|The figure of walk test, Berg Balance scale, Timed 25-Foot Walk, Timed up and go test, Foursquare walk test
214286421|NCT00958152|DRUG|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
214286422|NCT00958152|DRUG|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
214286423|NCT00958152|DRUG|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
214286424|NCT00958152|DRUG|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
214286425|NCT01283360|OTHER|HEC Placebo Gel|The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
214286426|NCT01283360|DRUG|Tenofovir 1% Gel|Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
214286427|NCT05579821|DIAGNOSTIC_TEST|Typhoid DPP assay|The index test used in this study diagnose typhoid fever by detecting IgA antibodies against LPS and HlyE antigen in patient's serum.
214286428|NCT02164760|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
214286429|NCT00743340|DRUG|Emtricitabine|6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
214286430|NCT01929460|DRUG|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
214286431|NCT01929460|OTHER|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
214286432|NCT02708121|BEHAVIORAL|Motivational Intervention|Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.
214286433|NCT02708121|OTHER|Comparator Intervention|Participants informed that they have access to weight loss treatment.
214286434|NCT03508921|DRUG|Periprocedural Antibiotics|"One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection."
214286435|NCT03508921|DRUG|Extended Antibiotics|"Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only."
214286436|NCT03508921|PROCEDURE|Injection of OnabotulinumtoxinA (BTX-A)|Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
214286437|NCT01101932|DRUG|PF-04308515|PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
214286438|NCT01101932|DRUG|Placebo|Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
214286439|NCT01101932|DRUG|PF-04308515 Tablet|Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
214286440|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
214286441|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
214286442|NCT06197672|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
214286443|NCT04648072|PROCEDURE|Adductor Canal Block|As previously described.
214286444|NCT04648072|PROCEDURE|Periarticular Injection|As previously described.
214286445|NCT05184244|OTHER|Activity Limitation Assessment|The ACTIVLIM-CP scale evaluates the global activity performance and combined movements of the body.
214286446|NCT04446520|PROCEDURE|autogenic drainage|breathing control using expiratory airflow to mobilize secretions from smaller to larger airways. Secretions are cleared independently by adjusting the depth and speed of respiration in a sequence of controlled breathing techniques during exhalation in addition to traditional physiotherapy (deep breathing exercise, diaphragmatic breathing and splinted coughing)
214286447|NCT01425281|DEVICE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|XIENCE implantation in the treatment of coronary artery disease.
214286448|NCT01425281|DEVICE|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System|ABSORB BVS implantation in the treatment of coronary artery disease.
214286449|NCT04165785|DEVICE|OPT IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
214286450|NCT04165785|DEVICE|Sham OPT IPL|Sham Optimal pulsed technology intense pulsed light IPL will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
214286451|NCT04165785|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
214286452|NCT02383277|OTHER|Stretching|Stretching of the rib cage muscles
214286453|NCT02383277|OTHER|Control|Rest without stretching (sham)
214286454|NCT02383277|OTHER|Exercise|Constant load exercise on a bike
214286455|NCT04728074|OTHER|The Entering Employment and Sustaining Work Program|A structured, motivation and self-awareness based group intervention
214286456|NCT04728074|OTHER|vocational rehabilitation|An individual based, focused on desired job or occupation, face-to-face intervention
214286457|NCT01833520|DRUG|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
214286458|NCT03795987|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
214286459|NCT02333877|OTHER|Skinlink|suture using Skinlink
214286460|NCT02333877|OTHER|Nylon|conventional suture using nylon
214286461|NCT01328925|DRUG|Nitazoxanide|"Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days"
214845458|NCT05609695|DRUG|Immune checkpoint inhibitor|After signing the written informed consent form, patients begin to receive single or combined therapy with immune checkpoint inhibitor. The use of immune checkpoint inhibitors takes 3 weeks as a cycle, and the treatment dose for each cycle is carried out in accordance with the latest international authoritative guidelines.
214845459|NCT03417206|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%
214845460|NCT03417206|DEVICE|pupillary dilatation reflex|PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity \> 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5%
214286462|NCT03116893|DRUG|BI 685509 After Standardised Breakfast|High-fat high calorie breakfast
214286463|NCT03116893|DRUG|Itraconazole|Administration of itraconazole together with BI 685509
214286464|NCT03116893|DRUG|Rifampin|Administration of rifampicin together with BI 685509
214286465|NCT03116893|DRUG|BI 685509 Fasted Conditions|BI 685509, given alone
214286466|NCT03943134|OTHER|Minimally Processed Human Umbilical Cord Membrane|Implantation of minimally processed human umbilical cord membrane at the time of surgery
214286467|NCT03943134|OTHER|Standard Surgical Procedures|Standard surgical intervention for at least one targeted acute upper extremity trauma
214286468|NCT06171763|OTHER|Telemedicine|The telehomecare solution involves an early discharge with continued home monitoring through the use of telemedicine utilizing an user-friendly mobile. Additionally, there were a clinical reassessment in person 72 hours after discharge to evaluate the outcomes and results of the intervention.
214286469|NCT02743520|DEVICE|The Lifestar Act III|The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.
214286470|NCT02280785|DRUG|Brentuximab vedotin|Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
214286471|NCT04208789|DIAGNOSTIC_TEST|Rapid Molecular Drug-Resistant Tuberculosis Test|"GeneXpert MTB/RIF assay is a nucleic acid amplification (NAA) test which simultaneously detects DNA of Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) (i.e. mutation of the rpoB gene) in less than two hours. This system integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences. The primers in the XpertMTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair core region. The probes are able to differentiate between the conserved wild-type sequence and mutations in the core region that is associated with rifampicin resistance. The output of this procedure is detected, undetected, or indeterminate."
214286472|NCT04208789|OTHER|Artificial Intelligent Model|The artificial intelligent model is a model that developed from several associated factors with machine learning and deep learning method in order to classify the possibility of drug-resistant tuberculosis. The Artificial neural network will be built using deep learning software.
214845461|NCT01744964|DRUG|Apomorphine|1.5 mg Apomorphine
214845462|NCT04167384|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
214845463|NCT04167384|OTHER|Product B|Nicorette® Mint 4 mg nicotine lozenge
214845464|NCT04167384|OTHER|Product C|CSD1903-11, a hard nicotine lozenge, 2 mg nicotine
214845465|NCT04167384|OTHER|Product D|CSD1903-11, a hard nicotine lozenge, 4 mg nicotine
214845466|NCT04167384|OTHER|Product E|CSD1903-11, a hard nicotine lozenge, 8 mg nicotine
214845467|NCT04167384|OTHER|Product F|CSD1903-12, a soft nicotine lozenge, 2 mg nicotine
214845468|NCT04167384|OTHER|Product G|CSD1903-12, a soft nicotine lozenge, 4 mg nicotine
214286473|NCT04208789|DIAGNOSTIC_TEST|Drug Susceptibility Test|This procedure uses Löwenstein-Jensen (LJ) medium to determine whether the isolates of M. tuberculosis are susceptible to anti-TB agents. Media containing the critical concentration of the anti-TB agent is inoculated with a dilution of a culture suspension (usually a 10-2 dilution of a MacFarland 1 suspension) and control media without the anti-TB agent is inoculated with usually a 10-4 dilution of a MacFarland 1 suspension. Growth (i.e. a number of colonies) on the agent-containing media is compared to the growth on the agent-free control media. The ratio of the number of colonies on the medium containing the anti-TB agent to the number of colonies (corrected for the dilution factor) on the medium without the anti-TB agent is calculated, and the proportion is expressed as a percentage. Provisional results for susceptible isolates may be read after 3-4 weeks of incubation; definitive results may be read after 6 weeks of incubation. Resistance may be reported within 3-4 weeks.
214286474|NCT04555291|DRUG|Ropivacaine injection|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
214286475|NCT04555291|OTHER|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
214286476|NCT03489447|OTHER|ICU care|exposure to ICU treatment with or without diagnosed sepsis
214286477|NCT00913042|OTHER|sample blood|"* Early culture~* Bacterial DNA tests in blood"
214286478|NCT00000534|DRUG|calcium|
214286479|NCT00000534|BEHAVIORAL|dietary supplements|
214286480|NCT03928574|PROCEDURE|Ultrasound-Guided Plane Block|Ultrasound-Guided Plane Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
214286481|NCT03928574|PROCEDURE|Conventional Block|Conventional Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
214845469|NCT04167384|OTHER|Product H|CSD1903-12, a soft nicotine lozenge, 8 mg nicotine
214286482|NCT01264588|OTHER|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
214286483|NCT03729505|PROCEDURE|Pyloric injection of magnesium sulfate and lidocaine mixture|100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus
214286484|NCT03729505|PROCEDURE|Pyloric injection of saline|5 ml of normal saline is injected in the pylorus
214286485|NCT00489021|PROCEDURE|sub-acute hospitalization|
214286486|NCT00447460|PROCEDURE|Mesenchymal stem cell (MSC)|
214286487|NCT03066089|DRUG|Fenfuro|
214286488|NCT00004760|BEHAVIORAL|Exercise|
214286489|NCT01749514|DRUG|Luspatercept|Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).
214845470|NCT04747184|OTHER|DNA extraction and 16S rRNA sequencing|DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.
214845471|NCT04223284|OTHER|D-Limonene|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes
214845472|NCT04223284|OTHER|SLVO|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes
214845473|NCT02845011|DEVICE|Audiovisual compression feedback|The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.
214845474|NCT02845011|OTHER|Standard Manual Chest Compression|Cardiopulmonary resuscitation according to published international guidelines.
215033453|NCT00789711|DRUG|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
214286490|NCT04456660|DIAGNOSTIC_TEST|Markers of ultrasound|CRL, HR, and other ultrasound measurements.
214286491|NCT04456660|DIAGNOSTIC_TEST|Immunologic factors|Measurement of NK cells subpopulations types in the maternal serum
214286492|NCT04456660|DIAGNOSTIC_TEST|Serum factors|Measuring the maternal serum concentration of sFlt-1, PLGF, glycodelin-A, and other substances.
214286493|NCT03088982|OTHER|Questionnaire|"FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.~The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity."
214286494|NCT06564441|DRUG|Survodutide|Survodutide
214286495|NCT06564441|DRUG|Bupropion|Bupropion
214286496|NCT06564441|DRUG|Caffeine|Caffeine
214286497|NCT06564441|DRUG|Midazolam|Midazolam
214286498|NCT01979016|DRUG|Dupilumab|
214286499|NCT01979016|DRUG|Placebo|Matching placebo
214286500|NCT01979016|OTHER|Background treatment|Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
214845475|NCT03225352|DRUG|500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 500mg
215033454|NCT00789711|DRUG|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
215033455|NCT01596920|OTHER|Tissue|Allograft Tissue Cellular Repair Matrix
214286501|NCT04648631|DEVICE|antibiofilm surfactant wound gel (ABWG)|ABWG is a hydro-gel applied topically using a tongue depressor
214286502|NCT02851758|OTHER|autologous mitochondria transplantation|Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
214286503|NCT00494078|DEVICE|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
214286504|NCT00494078|DRUG|intensive insulin therapy|intensive insulin therapy according to an algorithm
214286505|NCT02657174|DEVICE|low level laser in auricular acupuncture points|40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
214286506|NCT02657174|DEVICE|low level laser device off in auricular acupuncture points|40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
214286507|NCT04022044|BEHAVIORAL|Observational group|
214286508|NCT04983264|DRUG|GBT021601|Tablets and capsules which contain GBT021601 drug substance
214286509|NCT04579185|DEVICE|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
214286510|NCT03571152|OTHER|Educational videos|The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
214286511|NCT05519410|DRUG|Sintilimab and Lenvatinib|Tislelizumab, 200mg, ivd,q3w; Lenvatinib,8mg/kg,po,qd.
214286512|NCT05519410|DRUG|HAIC-FOLFOX|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
214286513|NCT04661540|DRUG|CM4620-IE (Injectable Emulsion)|Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion
214286514|NCT04661540|DRUG|Placebo|Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
214286515|NCT03752632|DEVICE|Veinplicity with tourniquet|Veinplicity will be used with a tourniquet
214286516|NCT03752632|DEVICE|Tourniquet|A tourniquet alone will be used.
214286517|NCT01690208|OTHER|EMERALD|"Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule."
214286518|NCT01690208|OTHER|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment \& explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
214286519|NCT02344485|PROCEDURE|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
214286520|NCT00184691|DRUG|somatropin|
214286521|NCT06193720|DRUG|Arnica montana|Assess the effect of arnica montana on pain, swelling ans trismus after impacted third molar surgery
214286522|NCT06193720|OTHER|Placebo|Patients will take placebo drug after surgeries
214286523|NCT03287661|BEHAVIORAL|Acceptance-based Behavioural Therapy|The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
214286524|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
214286525|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
214286526|NCT03454776|DEVICE|Unloader One brace|A knee brace used to unload affected compartments in osteoarthritic knees
214286527|NCT03454776|DEVICE|Placebo brace|A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
214286528|NCT00468689|DRUG|SB-751689 oral tablets (100 and 400 ng)|
214286529|NCT00468689|DRUG|Ketoconazole (NIZORAL) oral tablets (200 mg)|
214286530|NCT02606604|DEVICE|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
214845476|NCT03225352|DRUG|1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 1000mg
214845477|NCT03225352|DRUG|400 mg ibuprofen(Nurofen)|Single intake of 1 tablet, 400mg
214845478|NCT03225352|DRUG|400 mg ibuprofen (Dolormin Extra)|Single intake of 1 tablet, 400mg
214286531|NCT03966703|BEHAVIORAL|mixing analysing test|The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
214286532|NCT04953546|OTHER|No Intervention|This is an observation study, with no intervention
214286533|NCT03520803|OTHER|Enhanced recovery after surgery protocol|Experimental enhanced recovery protocol for pre-surgery and post surgery
214845479|NCT06616649|DEVICE|Spinal cord stimulator implant|Participants will receive intervention in the operating room setting
215033456|NCT01596920|OTHER|Control|Non-adherent Dressing
214286534|NCT03867292|OTHER|Myofascial|"The aim of the application of the crossed hands technique is to produce a deep fascial release, placing the subject in prone position, while the standing physiotherapist will contact with one hand on the spine at the level of the thoracolumbar hinge and with the other hand on the sacrum, so that the hands are crisscrossed. The crossed hands technique will be performed between 90 seconds and 5 minutes.~The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally."
214286535|NCT03867292|OTHER|Electrotherapy|The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.
214286536|NCT02509156|BIOLOGICAL|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
214286537|NCT02509156|BIOLOGICAL|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
214286538|NCT00523354|DRUG|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
214286539|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with multimodal feedback (VRET-M)|The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.
214286540|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with bimodal feedback (VRET-B)|The VRET-B group will experience visual and auditive cues in the exposure sessions.
214845480|NCT02990078|DRUG|Sildenafil citrate|Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
214845481|NCT02990078|DEVICE|Functional Near Infared Spectroscopy|Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
214845482|NCT02990078|OTHER|Hypercapnia Challenge|The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
214845483|NCT03293771|OTHER|Focus group interviews|Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.
214845484|NCT03293771|DIAGNOSTIC_TEST|Questionnaire packet|Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
214845485|NCT03267654|DRUG|gefitinib combined with chemotherapy|"Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit."
214845486|NCT03267654|DRUG|gefitinib combined with apatinib|"gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death."
214845487|NCT03267654|DRUG|gefitinib single agent|Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
214845488|NCT01874977|BEHAVIORAL|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
214845489|NCT01874977|BEHAVIORAL|Educational materials|"Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment."
214845490|NCT01874977|BEHAVIORAL|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
214845491|NCT01618487|PROCEDURE|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
214845492|NCT01618487|PROCEDURE|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
214845493|NCT01618487|PROCEDURE|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
214845494|NCT05757037|DEVICE|laser acupuncture|a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\].
214845495|NCT01747577|DRUG|Solifenacin Succinate|Oral
214845496|NCT01747577|DRUG|Placebo|Oral
214845497|NCT00348153|DRUG|Adalimumab|
214286541|NCT05939986|BEHAVIORAL|Imagery exposure treatment (IET)|The IET group will experience its own subjective imagined environment without any external stimulation.
214286542|NCT00935597|BIOLOGICAL|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
214286543|NCT02547649|BIOLOGICAL|V114-A|Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
214286544|NCT02547649|BIOLOGICAL|V114-B|Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
214286545|NCT02547649|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
214286546|NCT04267367|BEHAVIORAL|Dietitian-led dietary approach to management of diabetes|In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process\[27\]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
214286547|NCT01126853|BIOLOGICAL|Twinrix|Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
214286548|NCT01790256|DEVICE|Cereve Sleep System at 30 degrees C|
214286549|NCT01790256|DEVICE|Cereve Sleep System at 14-16 degrees C|
214286550|NCT04326231|DEVICE|Usability assessment of Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
214286551|NCT01936688|DRUG|MK-3222 200 mg|MK-3222 200 mg administered SC.
214286552|NCT01936688|DRUG|MK-3222 100 mg|MK-3222 100 mg administered SC.
214286553|NCT01936688|DRUG|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
214286554|NCT01936688|DRUG|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
214286555|NCT01936688|DRUG|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
214286556|NCT04473014|BEHAVIORAL|Heat Pain Paradigm|A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.
214286557|NCT01148758|DRUG|RO5323441|cohorts receiving multiple doses iv
214286558|NCT01203150|OTHER|Exercise|CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
214286559|NCT00002144|DRUG|Foscarnet sodium|
214286560|NCT04075058|RADIATION|Hypofractionated Radiation therapy|
214286561|NCT00571987|DEVICE|AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)|Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
214286562|NCT00138476|DRUG|Placebo|120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
214286563|NCT00138476|BIOLOGICAL|Norwalk Virus|Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.
214286564|NCT00426855|DRUG|Bendamustine|starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w
214286565|NCT00426855|DRUG|Bortezomib|weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w
214286566|NCT00340080|DRUG|Abacavir|
214286567|NCT03748160|OTHER|Letter|Intervention consists of two different types of postal letters reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers
214286568|NCT05337007|OTHER|high protein diet|48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
214286569|NCT05337007|OTHER|moderate protein diet|48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
214286570|NCT06131983|DRUG|ARO-DUX4 for Injection|single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
214286571|NCT06131983|DRUG|Placebo|calculated volume to match active treatment by IV infusion
214286572|NCT06493721|PROCEDURE|Clear Aligner Treatment|Clear aligner therapy to treat incisors crowding
214286573|NCT06493721|PROCEDURE|Low level laser|Apply clear aligner therapy with low level laser application on incisors
214286574|NCT02551731|DRUG|Cannabidiol Oral Solution|20 or 40 mg/kg/day BID
214286575|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in
214286576|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT) + Air Stacking|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity
214845498|NCT05560451|BEHAVIORAL|Peer health coach intervention|Eligible participants will be randomly assigned to receive a telehealth delivered peer health coach intervention to promote health outcomes and behavior change among Veterans with multimorbidty.
214845499|NCT00981227|DRUG|Eslicarbazepine acetate|Scored tablets
214286577|NCT00971854|PROCEDURE|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
214286578|NCT00817024|DRUG|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
214286579|NCT00817024|DRUG|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
214286580|NCT00817024|DRUG|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
214286581|NCT06327867|DEVICE|Oro Tracheal Intubation by DL|DL
214286582|NCT06327867|DEVICE|Oro Tracheal Intubation by VL|VL
214286583|NCT05446467|COMBINATION_PRODUCT|pembrolizumab+cisplatin + 5-FU|ivgtt, pembrolizumab 200mg d1+cisplatin20 mg/m2 qd d1-d3 + 5-fluorouracil 3000mg/m2 last for 120hours, six circles. Subjects will undergo surgery after receiving neoadjuvant chemotherapy within 3 weeks, followed by adjuvant therapy and pembrolizumab alone maintenance treatment.
214286584|NCT00968656|RADIATION|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
214286585|NCT00968656|OTHER|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
214845500|NCT00981227|DRUG|Placebo|oral route
214845501|NCT04594720|OTHER|Identification group|papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)
214845502|NCT04594720|OTHER|Validation group|papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
214845503|NCT00985231|DEVICE|PureVision Multi-Focal contact lenses|Contact lenses to be worn on a daily wear basis for 2 weeks.
214286586|NCT00968656|OTHER|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
214286587|NCT00968656|OTHER|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
214286588|NCT00968656|DRUG|F-18-ISO|Patients receive F-18-ISO-1 i.v.
214286589|NCT05740761|OTHER|Gene editing in vitro|Testing of gene editing efficiency in vitro in human cellular models derived from patients
214286590|NCT00729989|PROCEDURE|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
214286591|NCT05259696|BIOLOGICAL|E-602|Subjects will receive E-602 (administered weekly, via IV infusion).
214286592|NCT05259696|BIOLOGICAL|Cemiplimab|Subjects will receive cemiplimab (administered once every 3 weeks, via IV infusion).
214286593|NCT06468397|DEVICE|iSeelr™|The iSeelr™ device will be used to deliver 1940nm laser output along with low airflow to seal a retinal tear
214286594|NCT06185374|BEHAVIORAL|Text Message Instructions/Motivation|For instructional messages, earlier messages will remind patients of the colonoscopy appointment and later messages will help patients complete the bowel preparation process in real-time. Motivational messages will be sent along with instructional messages.
214845504|NCT00985231|DEVICE|SofLens59 contact lens|Contact lenses to be worn on a daily wear basis for 2 weeks.
214845505|NCT04611594|BEHAVIORAL|Fluid restriction|Ingestion of approximately 20 ml / kg of ideal weight,
214845506|NCT02676960|OTHER|MRI without sedation|
214845507|NCT03869294|DRUG|GS|Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
214286595|NCT06412848|DRUG|Avelumab|This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT.
214286596|NCT04771520|DRUG|Avapritinib|Given PO
214286597|NCT01750242|DEVICE|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
214286598|NCT05149807|DRUG|SHR-1701 injection|SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin
214286599|NCT05149807|DRUG|Placebo|Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
214286600|NCT04696445|DRUG|Morphine & Oxycodone|Morphine and Oxycodone are used in daily practice as part of standard care. Morphine and Oxycodone will be acquired through the clinical pharmacy of St Antonius and administered according to the standard postoperative pain protocol.
214286601|NCT01287689|OTHER|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
214286602|NCT03012347|DRUG|BAY987517|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
214286603|NCT03012347|DRUG|BullFrog Gel Sunscreen Land Sport SPF-50|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
214845508|NCT03244982|DRUG|Fluorescein Na 10% Inj 500mg|Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
214845509|NCT03244982|DRUG|Fluorescein Na 10% Inj 250mg|Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
214845510|NCT01123291|PROCEDURE|follow-up coronary angiography|follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
214845511|NCT01123291|PROCEDURE|Clinical follow-up|no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
214845512|NCT04366180|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will received one capsule with Lactobacillus K8 per day (3x10\^9 cfu/day) during 2 months
214845513|NCT04366180|DIETARY_SUPPLEMENT|Control|The control group will received one placebo capsule per day during 2 months
214845514|NCT06503003|DEVICE|Leonardo® Diode laser|The intervention involves non-ablative dual-wavelength diode laser therapy for treating Genitourinary Syndrome of Menopause (GSM). This includes three monthly sessions of the Leonardo® Diode laser (Biolitec®), with wavelengths of 980 nm and 1470 nm, delivering 8 pulses per centimeter along the vaginal canal, using local lidocaine gel as an anesthetic. Evaluations are conducted at baseline, 3 months, and 6 months post-treatment.
214845515|NCT02735694|DRUG|Cycloserine|Capsule containing 250 mg of Cycloserine
214845516|NCT02735694|DRUG|Placebo|Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
214845517|NCT01463982|DRUG|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14"
214845518|NCT04190927|BIOLOGICAL|Compounded topical estradiol and compounded topical progesterone in a carrier cream|Apply topical compounded estradiol and progesterone in the amount prescribed twice daily for each day of the 28 day lunar or menstrual cycle. Repeat each cycle month. Make note of any AE's so that modifications in dosing can be made.
214845519|NCT02527330|OTHER|MR T2* imaging|Cardiac magnetic resonance imaging with T2\* imaging
214845520|NCT00650273|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fasting
214845521|NCT00650273|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fasting
214845522|NCT04810169|DEVICE|Smart inhaler|"* Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler~* Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given"
214845523|NCT05939804|DEVICE|TENS|TENS will be applied to the experimental group on the 0th and 1st days after the surgery, and the pain assessment at the time of movement/rest before and after the procedure will be made by the researcher.
214286604|NCT06030557|DRUG|Truvada|Participants will receive either Truvada or Descovy (based on prescription guidelines).
214286605|NCT03857243|DEVICE|dual transcranial direct current stimulation|Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
214286606|NCT03765918|BIOLOGICAL|Pembrolizumab 200 mg|200 mg administered IV infusion on Day 1 of each 21-day cycle
214286607|NCT03765918|RADIATION|Radiotherapy 60 Gray|Low risk participants administered 2 Gray in 30 fractions. Administered using intensity modulated radiation therapy.
214286608|NCT03765918|RADIATION|Radiotherapy 66 Gray|High risk participants administered 2 Gray in 33 fractions. Administered using intensity modulated radiation therapy.
214286609|NCT03765918|RADIATION|Radiotherapy 70 Gray|Participants with gross residual disease administered 2 Gray in 35 fractions. Administered using intensity modulated radiation therapy.
214286610|NCT03765918|DRUG|Cisplatin 100 mg/m^2|100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle
214286611|NCT06480747|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
214845524|NCT06677944|RADIATION|Preoperative PBI|Preoperative PBI: 21 Gy \* 1 fraction Preoperative PBI is administered within 6 weeks of the patient's initial registration, and surgery is scheduled within 8 to 12 weeks after PBI.
214845525|NCT00002244|DRUG|WF10|
214845526|NCT03038763|OTHER|Eligibility Screening|Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.
214845527|NCT03038763|DIAGNOSTIC_TEST|HCV test|Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.
214845528|NCT00165516|DRUG|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
214845529|NCT00165516|DRUG|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
214845530|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
215033457|NCT00363298|DRUG|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
214286612|NCT04202965|DRUG|PTG-300|Active treatment with PTG-300 injected subcutaneously.
214286613|NCT01589744|DEVICE|Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)|The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
214286614|NCT00006903|DRUG|Fulvestrant|Given intramuscularly
214286615|NCT01380275|DRUG|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
214845531|NCT04087317|DRUG|Ibuprofen 400Mg Tab|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
214845532|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
214845533|NCT04087317|DRUG|Ibuprofen 400 mg|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
214845534|NCT04087317|DRUG|MIR|At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
215033458|NCT00363298|DRUG|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
215033459|NCT05713487|OTHER|preventive treatment group|each athlete belonging to the preventive treatment group performed the protocol of preventive treatment 2 times a week, before or after the training session for five months
214286616|NCT01380275|DRUG|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
214286617|NCT03143413|OTHER|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
214286618|NCT03597776|DRUG|Lidocaine|Bolus of lidocaine will be given over 5 minutes before skin incision
214286619|NCT03597776|DRUG|Saline|Bolus of saline will be given over 5 minutes before skin incision
214286620|NCT01864811|BEHAVIORAL|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
214286621|NCT01864811|BEHAVIORAL|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
214286622|NCT04843293|BEHAVIORAL|Olfactory stimulation|Newborns in the experimental group will be given the smell of breast milk during 3 consecutive feedings and for 3 days in the morning. Smell stimulation will be started 1 minute before gavage feeding and the application of breast milk odor will continue until the feeding ends. A hand-cleaning researcher will drip 15 drops of breast milk on sterile gauze to apply the smell of breast milk. Sterile gauze dripped with breast milk will be placed as close to the newborn's nose as possible and not in contact with the newborn's skin. After the feeding of the newborn is completed, the application of the smell of breast milk will be terminated and the gauze will be removed from the incubator. A new sterile gauze will be used for each feeding, and these processes will be repeated with each smell stimulation for three days.
214286623|NCT00187369|PROCEDURE|Method of Delivery|CS or VB
214472195|NCT06807359|DEVICE|Photodynamic Therapy (PDT)|"The PDT treatment is provided with the SpectraCure P18 laser light delivery system.~PDT will be performed during general anesthesia. Optical fibers will be inserted into the prostate with a transperineal approach using transrectal ultrasound guidance. The intent is to deliver an adequate light dose throughout the prostate. Subjects will receive VFI intravenously, approximately 60-90 minutes prior to light delivery. The photosensitizer is activated with light of a specific wavelength that is delivered to the tumor via optical fibers. The activated photosensitizer reacts with oxygen to form highly toxic radicals which induce cell death in the tumour.~* Phase 1: Light dose escalation. Three subjects will be treated per dose level (20 - 40 J/cm2). If no dose-limiting toxicities occur, dose will be escalated (20 - 40 J/cm2) until the Recommended Phase 2 Dose (RPD2) is established.~* Phase 2: Cohort expansion with the RPD2."
214472196|NCT06807359|DRUG|Verteporfin Injection|Verteporfin for Injection (VFI), photosensitizing drug, will be administered intravenously at a dose of 15 mg/m2 body surface area.
214472197|NCT06807554|DRUG|Ketamine|In Group K, ketamine 0.25mg/kg diluted in normal saline to a total volume of 40 ml was instilled by the surgeon, 20 ml before starting gall bladder dissection over the surgical site and liver while remaining 20 ml at the end of procedure after securing haemostasis over gall bladder bed and liver.
214472198|NCT06807554|DRUG|Bupivacaine|In Group B, bupivacaine at a dose of 2 mg/kg was diluted in normal saline to a total volume of 40 ml. The administration was performed by the surgeon in two stages: the first 20 ml was instilled before starting the gall bladder dissection, applied over the surgical site and liver, while the remaining 20 ml was instilled at the end of the procedure after achieving hemostasis, applied over the gall bladder bed and liver.
214472199|NCT06805747|OTHER|Variable tidal volume ventilation (V-VCV)|Variable tidal volume ventilation (V-VCV) ：The initial tidal volume is set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW), and the maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) are set at 10-20% of the base tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiration to Expiration Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5 cm water column, and Inhaled Oxygen Concentration (FiO2) 41%.
214472200|NCT06805747|OTHER|Pressure-regulated volume-controlled ventilation (PRVC)|Pressure-regulated volume-controlled ventilation (PRVC) ：Initial tidal volume is set at 6-8 ml/kg IBW based on Ideal Body Weight (IBW), peak inspiratory pressure is capped at 30 cmH2O, maximum tidal volume (Vt\_max), and minimum tidal volume (Vt\_min) is set at 10-20% of basal tidal volume (Vt\_base). Respiratory Rate (RR) 12, Inspiratory Breathing Ratio (IBR) 1:2, Positive End-Expiratory Pressure (PEEP) 5 cm water column, and Inhaled Oxygen Concentration (FiO2) 98%.
214845535|NCT06106334|DRUG|S309309|Administered as oral capsules
214845536|NCT06106334|DRUG|Itraconazole|Administered as oral capsules
215033460|NCT02852915|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery for T4 cancer
214286624|NCT00075959|DRUG|NXY-059|
214286625|NCT01506128|OTHER|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
214286626|NCT02197000|DIETARY_SUPPLEMENT|DIM-Avail 100mg|DIM 100 mg\*1 daily for 2 years
214286627|NCT02254252|DRUG|Nicorandil|nicorandil (10mg tablets, two times a day)
214286628|NCT02254252|DRUG|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
214286629|NCT06293495|DEVICE|Gamma 3 Nail (Stryker)|Open reduction an internal fixation of proximal femoral fracture with a Gamma 3 nail (single cephalic screw system)
214286630|NCT06293495|DEVICE|Chimaera Nail (Orthofix)|Open reduction an internal fixation of proximal femoral fracture with a Chimaera nail (system with double cephalic screw)
214286631|NCT04245787|DRUG|Self assembling peptide with fluoride|peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
214286632|NCT03056885|OTHER|Conventional One-Lung Ventilation|Vt 10 ml/kg
214286633|NCT03056885|OTHER|Protective One-lung ventilation|Vt 5 ml/kg
214286634|NCT00622245|DRUG|Lu AA34893|per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
214286635|NCT00622245|DRUG|Quetiapine fumarate|per oral, once daily, during 12 weeks, followed by a one-week tapering period
214286636|NCT00622245|DRUG|Placebo|per oral doses, twice daily as capsules during 13 weeks
214286637|NCT02348606|DRUG|JZP-110|
214845537|NCT02462434|BEHAVIORAL|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
214845538|NCT05607563|DRUG|PM1009 injection|Participants receive PM1009 intravenously, every 2 weeks
214845539|NCT02123524|DRUG|Rivaroxaban|
214845540|NCT02123524|DRUG|Placebo|
214845541|NCT01283646|DRUG|Apevitin BC|3.5 to 5 ml 3 times a daily
214845542|NCT01283646|DRUG|Vitamin B Complex + Vitamin C|3.5 to 5 ml 3 times a daily
214845543|NCT05703841|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
214845544|NCT00916695|DEVICE|Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.|"Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique."
214845545|NCT03996616|DEVICE|Head UP Position|"CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a \<10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput."
214845546|NCT03996616|DEVICE|Impedance Threshold Device|An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
214286638|NCT02348606|DRUG|Placebo oral tablet|
214286639|NCT03849898|PROCEDURE|Surgery|Surgical fracture treatment
214286640|NCT03849898|OTHER|Non-Surgical fracture treatment|Non-Surgical fracture treatment
214286641|NCT01195558|OTHER|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
214286642|NCT02170597|DRUG|BIBR 1048 MS HPMC capsule|
214286643|NCT02170597|DRUG|BIBR 1048 MS gelatine capsule|
214845547|NCT03996616|DEVICE|New Automated CPR|Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
214845548|NCT04754555|OTHER|Arm Activity Measure (ArmA) in french|The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance
214845549|NCT02824887|OTHER|Electro-acupuncture|Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
214845550|NCT02824887|OTHER|Conventional treatment of Western Medicine|Routine non operative treatment of Western Medicine
214845551|NCT00144079|PROCEDURE|external beam radiotherapy|
215033461|NCT03134209|DEVICE|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
214286644|NCT01984177|DRUG|Corticotropin-Releasing Hormone|Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. \~15 minutes after Corticorelin/saline injection, \[11C\]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure (\[11C\]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
214286645|NCT01678911|DRUG|Gralise|"Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication)."
214286646|NCT03392701|BIOLOGICAL|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
214286647|NCT02706691|DRUG|BGJ398|Given by mouth (oral)
214286648|NCT01402492|DRUG|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
214286649|NCT01402492|DRUG|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
214845552|NCT04598633|DIETARY_SUPPLEMENT|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
214286650|NCT00965042|DRUG|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
214845553|NCT04598633|DIETARY_SUPPLEMENT|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia) 2 times per day for 12 weeks
214286651|NCT04254705|PROCEDURE|Rectal Biopsy|Suction biopsy or forceps biopsy
214286652|NCT03647982|DRUG|Meditoxin|injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
214286653|NCT03647982|DRUG|Botox|injection of Botox into the intradermal of each contralateral upper back in equal doses
214286654|NCT03498027|DEVICE|TaqMan Bacillus anthracis Detection Kit|The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
214286655|NCT04382339|DRUG|SOF/RBV/PegINFα-2|SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
214286656|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (one day)|Participants will engage in 40 minutes of cycling at 70-75% maximum heart rate (MHR).
214286657|NCT05972265|BEHAVIORAL|Placebo - Light Intensity Exercise (one day)|Control participants will engage in 40 minutes cycling at 40-50% maximum heart rate (MHR).
214286658|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (9 wks)|Participants will be asked to engage in moderate-intensity activity four days each week, 40 minutes each time, and will wear an activity monitoring device to assess their fidelity to the intervention.
214286659|NCT05972265|OTHER|Day 1 Assessments|Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), Life Events Checklist (LEC-5), and neuropsychological testing: approximately 1.50 hours
214286660|NCT05972265|OTHER|Symptom Measures and Neuropsychological Tests|Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), and neuropsychological testing: approximately 1.25 hours
214286661|NCT05972265|OTHER|Day 36 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
215033462|NCT03134209|OTHER|Monocryl + Dermabond|conventional sutures and skin adhesive glue
215033463|NCT03134209|OTHER|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
214286662|NCT05972265|OTHER|Day 57 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
214286663|NCT05972265|OTHER|Day 78 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
214286664|NCT01980992|DRUG|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
214286665|NCT03925974|DRUG|KN026 10 mg/kg QW|10 mg/kg QW as safety run-in dosage
214286666|NCT03925974|DRUG|KN026 20 mg/kg Q2W|20 mg/kg Q2W as target dosage
214286667|NCT03925974|DRUG|KN026 30 mg/kg Q3W|30 mg/kg Q3W as another target dosage
214472201|NCT06805747|OTHER|Conventional volume-controlled ventilation (C-VCV)|Conventional volume-controlled ventilation (C-VCV) ：The initial tidal volume is set at 6-8 ml/kg IBW based on Ideal Body Weight (IBW), and the maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) are set at 10-20% of the basal tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiration to Expiration Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5cm water column, FiO2 98%.
214472202|NCT06805747|OTHER|Pressure-controlled ventilation (PCV)|Pressure-controlled ventilation (PCV)：Set inspiratory pressure level, usually 20 cmH2O initial value, Respiratory Rate 12, Inspiratory to Expiratory Ratio 1:2, Positive End-Expiratory Pressure (PEEP) 5 cm water column, Inhaled Oxygen Concentration (FiO2) 98%.
214472203|NCT06805747|OTHER|Trendelenburg position|Trendelenburg position：Lower the head of the bed by 30 degrees with no more than 15 degrees of lateral tilt.
214845554|NCT05363579|OTHER|Physiotherapy|Physiotherapy can be defined as a treatment method that focuses on the science of movement and helps people to restore, maintain and maximize their physical strength, function, motion and overall well-being by addressing the underlying physical issues.
215033464|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
215033465|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
215033466|NCT01462331|OTHER|Sucrose|12g/dose, three times a day
214286668|NCT03018509|DRUG|JTE-451|Active drug tablets containing JTE-451
214286669|NCT03018509|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
214286670|NCT05306301|DRUG|Ponatinib|Ponatinib is a novel, synthetic, orally-active TKI discovered using a computational and structure based drug design approach. Ponatinib was specifically designed to inhibit all clinically relevant variants of BCR-ABL1, including the T315I mutant (15-17). In vitro assays have demonstrated that Ponatinib potently inhibits the kinase enzymatic activity of the T315I ABL kinase domain, as well as that of the native (unmutated) enzyme. In leukemia cell lines expressing these BCR-ABL1 variants, Ponatinib potently inhibited BCR-ABL1 signaling, leading to the reduction of cellular proliferation and induction of apoptosis. Ponatinib also inhibits the proliferation of cell lines expressing other major clinically-observed Imatinib-resistant mutants of BCR-ABL1.
214286671|NCT04742010|DRUG|Zoledronic Acid|"* A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted)~* Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)~* Administration: slow intravenous infusion with a duration of at least 15 minutes"
214286672|NCT04742010|DRUG|Placebo|as above
214286673|NCT01352858|DRUG|TolDC|Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
214286674|NCT01352858|DRUG|Arthroscopy & saline irrigation alone|
214286675|NCT00050934|DRUG|oxcarbazepine|
214286676|NCT03445104|OTHER|Huperzine A|During one of the two experimental sessions, participants will be given huperzine A.
214286677|NCT03445104|OTHER|Placebo|During one of the two experimental sessions, participants will be given a placebo.
214286678|NCT03196102|BEHAVIORAL|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
214286679|NCT03196102|BEHAVIORAL|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
214286680|NCT03196102|BEHAVIORAL|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
214286681|NCT02798575|DEVICE|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
214286682|NCT03042624|DIETARY_SUPPLEMENT|Fermented rice|7 g of powder obtained from Lactobacillus paracasei CBA L74
214286683|NCT03042624|DIETARY_SUPPLEMENT|Maltodextrins|7 g of maltodextrins powder
214286684|NCT03053284|DRUG|Pasireotide 0.6Mg Solution for Injection|Pasireotide 0.6Mg Solution for Injection will be given once per study visit
214286685|NCT03053284|DRUG|Saline Solution|Saline Solution injection will be given once per study visit
214286686|NCT03296358|DRUG|IV Dexamethasone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
214286687|NCT03296358|DRUG|Oral prednisolone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
214286688|NCT04380116|DEVICE|Soberlink|Soberlink is a comprehensive alcohol monitoring system designed to remotely monitor a person's Blood Alcohol Concentration (BAC). Combining a professional grade handheld breathalyzer with wireless connectivity, the technology includes real-time facial recognition, robust tamper detection and real-time alerting.
214286689|NCT05775874|DRUG|AZD4547|Initiation dose: 80mg BID,po.
214286690|NCT05775874|DRUG|Tislelizumab|Tislelizumab:200mg Q3W
214286691|NCT04826432|DRUG|Pasireotide 0.9 MG/ML|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
214845555|NCT05363579|OTHER|Tuina therapy|Tuina is mainly applied to the meridians or acupoints by manipulation techniques such as pushing, grasping, pressing and rubbing of the soft tissues or muscles of the body. It is reported to improve circulation and the qi in the body.
214845556|NCT05363579|OTHER|Physio and Tuina therapy|Physiotherapy mixed with Tuina
214845557|NCT03187587|DEVICE|imILT|The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.
214845558|NCT03187587|DRUG|Standard chemotherapy treatment|The standard chemotherapy treamtment arm recieves only chemotherapy.
215033467|NCT03537794|DIAGNOSTIC_TEST|PET scans|PET scans and PHNO scans
214286692|NCT04826432|OTHER|Saline water|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
214286693|NCT01599767|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
214286694|NCT05719766|OTHER|education ,psycological support and social support|we would give targeted-education according to our patients' need(reflected via questionnaire; we would provide psycological and social support to patients based on their need reflected by questionnaire
214845559|NCT04220775|DRUG|Bintrafusp Alfa|Given IV
214286695|NCT05984966|BEHAVIORAL|Supported Employment|PeerC2T is part of a supported employment program where PWID are trained and supported to provide PWID with job skills to be able to act as Peer Health Worker to facilitate distribution of rapid SARS-CoV-2 testing to other PWID. The effect of the training on the Peer Health Worker themself will be evaluated (Aim 1). In addition, in Aim 2 they will distribute the rapid test kits in places of residence such as tents, shelters, apartments, trailers, or houses or locations where other PWID frequently engage with services such as syringe exchange. The kit is the BinaxNOW COVID-19 Antigen Self Test, which is approved to be used as a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. PWID community members will be offered a free test kit, and the Peer Health Worker will record whether the community member elected to take the test (yes/no), and they will also collect administrative demographic data on the PWID.
214286696|NCT02817100|DRUG|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
214286697|NCT02817100|DRUG|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food \[Continental breakfast\])
214286698|NCT02817100|DRUG|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
214286699|NCT03500952|OTHER|Birth Control After Pregnancy|A 27-page patient decision aid in portable document format (and an accompanying 3-page supporting document in portable document format) hosted online.
214286700|NCT03500952|OTHER|Postpartum Birth Control|A 4-page patient information leaflet in portable document format and text format hosted online.
214286701|NCT03978338|DIETARY_SUPPLEMENT|brain polypeptide solution|The experimental group will take the brain polypeptide solution 60ml per day which contains nitrogen 90mg, soybean oil ,glycerin and soybean phospholipids in 84days.
214286702|NCT03978338|OTHER|same package of placebo|The control group was treated with the same package of placebo 60ml per day which contains soybean oil ,glycerin and soybean phospholipids in 84 days.
214286703|NCT00456560|DRUG|AV650|
214286704|NCT00456560|DRUG|Fluvoxamine|
214286705|NCT00456560|DRUG|Paroxetine|
214286706|NCT05299281|DEVICE|Micropulse transscleral cyclophotocoagulation (MP-TSCPC)|"patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively."
214286707|NCT04694417|OTHER|Compression stocking|Please see the description of the intervention in another section
214286708|NCT04694417|DIETARY_SUPPLEMENT|Magnesium tablet|Please see the description of the intervention in another section
214286709|NCT04694417|OTHER|Placebo tablet|Please see the description of the intervention in another section
214286710|NCT02116296|BEHAVIORAL|ToyBox-intervention|
214286711|NCT05549570|DRUG|Sitagliptin/Metformin HCl 50/850 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
214286712|NCT03639298|DEVICE|Intendu|intensive training with Motion Based Cognitive Video Games Software
214286713|NCT02408315|DRUG|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
214286714|NCT05268900|DEVICE|Volume control ventilation group|Volume control ventilation mode
214286715|NCT05268900|DEVICE|Pressure control ventilation-volume guaranteed group|Pressure control ventilation-volume guaranteed mode
214286716|NCT02810860|PROCEDURE|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
214286717|NCT00247091|BIOLOGICAL|standard-titer measles vaccine|
214286718|NCT01366209|DRUG|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
214286719|NCT01366209|DRUG|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
214286720|NCT01985867|DIETARY_SUPPLEMENT|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10\^8 CFU, twice daily, orally for 4 weeks)
214286721|NCT01985867|DIETARY_SUPPLEMENT|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
214845560|NCT04220775|OTHER|Quality-of-Life Assessment|Ancillary studies
214845561|NCT04220775|OTHER|Questionnaire Administration|Ancillary studies
214845562|NCT04220775|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215033468|NCT04367389|BEHAVIORAL|Physical activity promotion|Physical activity promotion activities consist of two phone or video calls with a therapists, two group video calls with a therapist, a complementary e-learning course and a fitness tracker that was provided.
214286722|NCT03406572|DEVICE|HFHO Group|"* Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~* Brand name: Airvo 2"
214286723|NCT03406572|DEVICE|Standard O2|Standard oxygen therapy
214286724|NCT02670837|DEVICE|Cellutome Epidermal Harvesting System|
214286725|NCT03546192|BIOLOGICAL|Fluzone Quadrivalent Influenza Vaccine|0.5-mL, Intramuscular, SH 2015 formulation
214286726|NCT01813591|DRUG|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
214286727|NCT02460614|PROCEDURE|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
214286728|NCT02460614|PROCEDURE|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
214286729|NCT02460614|OTHER|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
214286730|NCT04201860|DIAGNOSTIC_TEST|Arterial blood gas analyses and haemostasis measures|Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.
214286731|NCT00257478|DRUG|YM155|
214286732|NCT01612936|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|"On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent."
214286733|NCT01612936|PROCEDURE|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
214286734|NCT04419584|DRUG|Modified Qing-Ying Decoction|Herbal granules
214286735|NCT04419584|DRUG|Identical looking placebo|Placebo granules
214286736|NCT01856413|DRUG|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
214286737|NCT03658655|BIOLOGICAL|Stem Cells From Human Exfoliated Teeth|"Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline."
214286738|NCT05228262|OTHER|Cohort follow-up|"* Inclusion medical consultation,~* Inclusion clinical examination,~* Collection of biological samples (bone biomarkers, epigenetic biomarkers (microRNA)) and analysis of microbiota and genotyping,~* Calculation of the Kauppila score on profile spine radiographs by the rheumatologist,~* Cardiovascular investigations (FMD, Flow-Mediated Dilation); measurement of digital volume increase (RHI, Reactive hyperhemia index); measurement of microcirculatory perfusion of the skin at the hand (FLD, Flow Laser Doppler) ; measurement of the stiffness of the main arteries (aorta) by the Pulse Wave Velocity (PWV),~* Exploration of sarcopenia: questionnaires and tests: SARC-F, SPPB, muscle strength,~* Quality of life component questionnaires Pittsburgh Sleep (PSQI), Numerical Scale (NS), Brief Pain Inventory (BPI), Hospital Anxiety and Depression scale (HADs), and 36-Item Short Form Survey (SF-36) Quality of Life Questionnaire."
214286739|NCT00553514|DRUG|AS900672-Enriched 10 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 10 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
214286740|NCT00553514|DRUG|AS900672-Enriched 20 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 20 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
214286741|NCT00553514|DRUG|AS900672-Enriched 30 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 30 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
214286742|NCT00553514|DRUG|AS900672-Enriched 40 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 40 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
214286743|NCT00553514|DRUG|Follitropin alfa 75 international unit (IU)|Follitropin alfa (Gonal-f®) 75 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 14 (S14) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 10, 20, 30 and 40 mcg will also receive daily dose of follitropin alfa 75 IU subcutaneously from Stimulation Day 7 (S7) up to S14. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
214286744|NCT00553514|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to \[=\<\] 3 follicles with a mean diameter of greater than or equal to \[\>=\] 14 millimeter \[mm\], and one or two of these follicles with a diameter of \>= 17 mm).
214286745|NCT04464889|DRUG|MDG1021 dose 1|3 patients to receive dose1: target dose of 0.3x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
214472204|NCT06805747|OTHER|Reverse Trendelenburg position|Reverse Trendelenburg position：Elevate the head of the bed by 30 degrees with no more than 15 degrees of lateral tilt.
214472205|NCT06548880|OTHER|Structured exercise program|The intervention applied in this research has an online exercise training conducting with a structured exercise program including different types of exercise which are range of motion, stretching and low intensity aerobic exercises. The exercise program continued with sessions each lasting 60 minutes, once a week for 10 weeks.
214286746|NCT04464889|DRUG|MDG1021 dose 2|3 patients to receive dose 2: target dose of 1x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
214286747|NCT04464889|DRUG|MDG1021 dose 3|3 patients to receive dose 3: target dose of 3x10\^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
214286748|NCT04464889|DRUG|MDG1021 optimal dose|20 patients to receive the selected optimal dose
214286749|NCT04564729|OTHER|Shared Decision Making|The intervention group will receive a shared decision-making intervention including a decision aid and conversation with a study investigator. The intervention group will have the opportunity to choose the number of opioid pills they receive at discharge from hospital after total knee arthroplasty.
214286750|NCT05303636|DRUG|LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet|LF111 (drospirenone 4 mg tablet orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28) or drospirenone (DRSP) 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (USA only). Subjects in the USA who choose to use the hormonal contraceptive method may choose between LF111 and DRSP 3.5 mg chewable tablets. The DRSP 3.5 mg chewable tablets are not available to subjects in Europe. Subjects in Europe who choose to use the hormonal contraceptive method will only receive LF111.
214286751|NCT03767816|DRUG|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml around umbilicus
214286752|NCT03767816|DRUG|Ultrasound erector spinae plane block|Ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml at T7 level
214286753|NCT00382460|DRUG|PRAVASTATIN SODIUM|
214286754|NCT04021940|PROCEDURE|ULOD|ULOD
214286755|NCT03483051|DRUG|Potassium Nitrate|Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals \[610 mg, corresponding to 6.03 mmoles of NO3-\] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
214286756|NCT03483051|DRUG|Potassium Chloride|Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
214286757|NCT02365792|PROCEDURE|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
214286758|NCT06406283|BEHAVIORAL|High-Intensity Functional Training (HIFT)|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The training protocol will be designed based on Cross-Training workouts, emphasizing high-intensity interval training combined with functional resistance-training movements."
214286759|NCT06406283|BEHAVIORAL|Mindfulness-Based Stress Reduction Program (MBSR)|This intervention follows the official MBSR program designed by Jon Kabat-Zinn with some adaptations, as we did in Bermudo-Gallaguet, et al. (2022). The intervention will occur three days a week, including one 120-minute online synchronous session and two 20-40 min individual practices. The intensity of physical exercise will be adjusted to personal baseline characteristics.
214845563|NCT04983342|DEVICE|Apollo Armband|The Apollo armband is approximately the size of an Apple Watch and can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain. In addition to the wearable, Apollo is a software system that curates music for the body, rather than for the ears.
214286760|NCT06406283|BEHAVIORAL|Qigong|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The program includes the Baduanjin sequence, considered one of the most ancient and beneficial forms for physical and mental health within the Qigong tradition."
214286761|NCT00395369|DRUG|intraoperative aprotinin administration|
214286762|NCT06021145|DRUG|Empagliflozin|26-week use of automated insulin delivery system with empagliflozin (2.5 mg daily) in individuals with suboptimal time in range.
214286763|NCT06021145|DRUG|Placebo|26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.
214845564|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)|Marketed Drug
214845565|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)|Investigational Medicinal Product
214845566|NCT01325506|OTHER|Questionnaire|Questionnaire, telephone interviews, and clinical follow-up
214845567|NCT04362332|DRUG|Chloroquine Sulfate|cluster randomized
214286764|NCT06261203|DRUG|Aspirin|To investigate the efficacy of low dose aspirin for prevention of early pregnancy loss in women at high risk of preeclampsia.
214286765|NCT00492908|DEVICE|Helistent Titan2 (Titanium coated stent)|Titan2
214286766|NCT00492908|DEVICE|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
214286767|NCT01442675|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
214286768|NCT05130320|OTHER|Not Interventional their treatments are their routine NHS care|Not Interventional their treatments are their routine NHS care
214286769|NCT05238090|OTHER|Passive and active analytical stretching exercises|"For each stretching technique described, 3 repetitions of 15 seconds duration will be performed of 15 seconds duration each, within the patient's tolerance threshold. In any case, the impossibility of performing any technique due to exacerbation of pain shall be recorded in a patient record created for this study, noting the technique in question and the reason for its technique in question and the reason for its non-application. Passive stretches shall be applied in the same order for all subjects.~The physiotherapists in charge of applying the treatments will be trained in advance in the different techniques to be applied and will not in the different techniques to be applied and shall not intervene at any time in the two previous phases.~Both the control group and the study group will receive their respective treatments two days a week for four weeks. In no case will any other type of treatment be associated treatment during the whole process."
214845568|NCT04362332|DRUG|Hydroxychloroquine|cluster randomized
214286770|NCT05238090|OTHER|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
214286771|NCT04059978|DRUG|CBD|1600mg cannabidiol, single oral dose (8 ml oily solution)
214286772|NCT04059978|DRUG|Placebo|Placebo p.o, single oral dose (8 ml oily solution)
214286773|NCT04059978|DRUG|Remifentanil|Remifentanil 0.1 µg/kg/min i.v. for 30 min
214286774|NCT00006361|DRUG|semaxanib|
214286775|NCT01919723|DRUG|Ticagrelor|Ticagrelor loading dose
214286776|NCT01919723|DRUG|Eptifibatide|i.v. infusion
214286777|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
214286778|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
214286779|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
214286780|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
214286781|NCT00752232|OTHER|PBS|IM injection, Day 1, month 3, 6, 9, 12
214472206|NCT03099057|OTHER|follow-up of patients after interventional rhythm operation|The follow-up will take place at 3 months postoperatively, then at 1 year and then annually for 5 years.
214845569|NCT04362332|OTHER|Standard supportive care|cluster randomized
214845570|NCT04756778|PROCEDURE|Aortic surgery +/- aortic valve replacement|Replacement of aneurysmal proximal thoracic aorta +/- replacement of diseased bicuspid aortic valve
214286782|NCT01699282|BEHAVIORAL|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
214286783|NCT01699282|BEHAVIORAL|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
214286784|NCT01103648|DRUG|Simvastatin|Tablets of simvastatin 20 mg administered once a day for 12 weeks
214286785|NCT01103648|DRUG|Ezetimibe|Tablets of ezetimibe 10 mg administered once a day for 12 weeks
214286786|NCT01103648|DRUG|Combination Simvastatin plus Ezetimibe|"Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study."
214472207|NCT02675491|DRUG|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
214472208|NCT06746350|DEVICE|Thermotherapy|Radio frequency-induced heat treatment using the ThermoMed device at 50-degree centigrade for 30 seconds.
214845571|NCT01432028|DRUG|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
214845572|NCT01432028|DRUG|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
214286787|NCT00754260|BEHAVIORAL|Caffeine reduction|patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
214286788|NCT02324894|PROCEDURE|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
214286789|NCT02764515|DRUG|Kunxian Capsule|Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
214286790|NCT02764515|DRUG|Methotrexate|the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
214286791|NCT05776589|DEVICE|The mechanical ventilation mode|Changing the mechanical ventilation mode
214286792|NCT05787457|OTHER|Clinical examination|
214286793|NCT05787457|OTHER|Blood testing|
214286794|NCT05787457|OTHER|MRI|
214286795|NCT04502589|DRUG|Perampanel Tablet|Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
214286796|NCT04502589|DRUG|Disulfiram|Disulfiram will be kept at 250mg daily
214286797|NCT04938193|DIAGNOSTIC_TEST|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
214286798|NCT03234686|DRUG|Deferiprone 600mg delayed release tablets|The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
214286799|NCT03234686|DRUG|Placebo Oral Tablet|The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
214286800|NCT00555321|DRUG|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])
214286801|NCT00555321|DRUG|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
214286802|NCT00555321|DRUG|Belatacept More Intensive (MI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])"
214286803|NCT00555321|DRUG|Belatacept Less Intensive (LI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
214286804|NCT00555321|DRUG|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
214472209|NCT03853031|PROCEDURE|LVEDA cm2 guided intraoperative fluid in TEE /Study Group|Placement of Transoesophageal echocardiography probe in TEE group to measure Left ventricular end diastolic area cm2
214472210|NCT03853031|PROCEDURE|CVP guided intraoperative fluid in CVP / Control group|Ultrasound guided Internal Jugular Vein catheter placement in CVP group to measure CVP value cms H2O .
214472211|NCT05122416|DEVICE|FibroScan examination (S)|A FibroScan examination with the Exploratory S probe.
214472212|NCT05122416|DEVICE|FibroScan examination (M)|A FibroScan examination with the Optimized M probe.
214472213|NCT05122416|DEVICE|FibroScan examination (XL)|A FibroScan examination with the Exploratory XL probe.
214845573|NCT00153205|BEHAVIORAL|computerized physician order entry|
214845574|NCT03285464|OTHER|Triplanar Rotary Resistance|Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
214286805|NCT02235480|DRUG|Experimental Tazarotene Gel|
214286806|NCT02235480|DRUG|Placebo|
214286807|NCT00160251|DRUG|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
214286808|NCT00160251|BIOLOGICAL|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
214286809|NCT00160251|DRUG|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])
214286810|NCT03178981|OTHER|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
214286811|NCT03298594|DIAGNOSTIC_TEST|specific cervicograph|
214286812|NCT05571098|BEHAVIORAL|individualized colorectal cancer education|"Subjects taught within the scope of individualized colorectal cancer education:~* Common symptoms and management related to disease and treatment,~* Importance of nutrition in the treatment process."
214286813|NCT05571098|BEHAVIORAL|psycho-oncological counseling|"Topics discussed within the scope of psycho-oncological counseling:~* Psychological state (anxiety, depression, etc.),~* Coping strategies about the process,~* Presence of fear about the disease and/or treatment,~* Lifestyle changes/problems,~* Changes in body image,~* Family/friendship/work-related concerns,~* Additional issues, comments he wishes to convey"
214286814|NCT05571098|BEHAVIORAL|telephone support hotline service|Within the scope of the NNP, a telephone support hotline service was provided to the participants, where they could consult at any time about the subject they wanted.
214286815|NCT05451160|DEVICE|steep pulse therapy system|The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation
214286816|NCT05451160|DEVICE|RF Ablation System|RF Ablation System
214286817|NCT03782272|DIETARY_SUPPLEMENT|Enterade|enterade® (an amino acid-based oral rehydration solution \[AA-ORS\]) is a medical food product that consists of oral rehydration salts, natural flavor, steviol (sweetener), purified water, and a blend of amino acids that drive the uptake of water and electrolytes.
214286818|NCT03782272|DIETARY_SUPPLEMENT|Placebo|a placebo solution containing natural flavor, steviol (sweetener), and purified water.
214286819|NCT02055014|DRUG|Liraglutide|
214286820|NCT02055014|DEVICE|Duodenal-jejunal bypass liner - Endobarrier device|
214286821|NCT05083364|DRUG|ARO-C3|ARO-C3 for sc injection
214286822|NCT05083364|DRUG|Placebo|sterile normal saline (0.9% NaCl) for sc injection
214286823|NCT02840370|DEVICE|transcranial direct current stimulation|In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.
214286824|NCT02840370|DEVICE|Sham tDCS|S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
214286825|NCT04243681|COMBINATION_PRODUCT|CD 34 and MSC infusion|Combination of stem cells
214286826|NCT04243681|DRUG|Standard of care for Cirrhosis management|Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
214286827|NCT00582166|DRUG|Ibritumomab Tiuxetan (Zevalin) + Rituximab|Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
214286828|NCT02792972|OTHER|A. oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
214286829|NCT02792972|OTHER|70% alcohol|70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
214286830|NCT02279381|DRUG|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
214286831|NCT02279381|OTHER|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
214286832|NCT02279381|OTHER|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
214286833|NCT03128554|OTHER|Intervention with Training and Materials|Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
214286834|NCT00126568|DRUG|sorafenib tosylate|Given orally
214286835|NCT01717560|OTHER|Collaborative, multidisciplinary, integrated care|"Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management."
214286836|NCT05765240|DRUG|Hyaluronic Acid Topical Gels|Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.
214286837|NCT05765240|PROCEDURE|Diode Laser Biostimulation|Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
214286838|NCT04633694|DIETARY_SUPPLEMENT|insect, pea or whey protein|The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.
214286839|NCT03032315|DRUG|TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
214286840|NCT03032315|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
214286841|NCT03032315|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
214286842|NCT02345694|DEVICE|Effective CPAP|Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
214286843|NCT02345694|DEVICE|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
214286844|NCT02273024|BEHAVIORAL|Exercise|
214286845|NCT05139589|OTHER|None, observational|Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery
214286846|NCT02343627|DRUG|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
214286847|NCT02343627|DRUG|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
214286848|NCT05735132|PROCEDURE|Conventional Line-blocking|Participants will receive a 2 cm subcutaneous 1% lidocaine local infiltration injection parallel to the arm at the puncture site.
214286849|NCT05735132|PROCEDURE|Bar-blocking|Participants will receive a bar-shaped subcutaneous 1% lidocaine local infiltration injection in the vertical arm, 2 cm away from the puncture site.
214286850|NCT05735132|PROCEDURE|V-blocking|Participants will receive a V-shaped subcutaneous 1% lidocaine local infiltration injection at a 90-degree angle 2 cm away from the puncture site.
214286851|NCT00615758|DRUG|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression
214286852|NCT00705653|DRUG|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
214286853|NCT04966715|PROCEDURE|Epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of colorectal carcinomatosis by this way
214286854|NCT00580606|DRUG|Glycerinated peanut allergenic extract|Glycerinated peanut extract delivered sublingually.
214286855|NCT00580606|DRUG|Placebo for peanut extract (glycerin)|Placebo (glycerin) delivered sublingually.
214845575|NCT03327350|DEVICE|WATCHMAN transplantation|WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
214845576|NCT03327350|DRUG|Oral anticoagulant drugs|This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
214845577|NCT02802215|DRUG|metformin|Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
214845578|NCT02802215|DRUG|placebo (folic acid )|500 micro gram of folic acid every 8 hrs
214845579|NCT00931463|DRUG|raltegravir|400 mg raltegravir tablet taken every 12 hours
214845580|NCT00931463|DRUG|2N(t)RTI|2N(t)RTIs as prescribed
214845581|NCT00931463|DRUG|Ritonavir-boosted lopinavir|2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
214845582|NCT00436917|DRUG|zoledronic acid|zoledronic acid
214845583|NCT00436917|PROCEDURE|Letrozole as adjuvant therapy|standard care
214845584|NCT03822273|PROCEDURE|Traditional acupuncture (TA)|"Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min."
215033469|NCT04367389|BEHAVIORAL|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for persons with MS. However, they can be adjusted according to participants prior physical activity level and their time for exercise during the week.
214286856|NCT05376124|OTHER|original therapy|* Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
214286857|NCT05376124|OTHER|rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
214286858|NCT05730751|PROCEDURE|spinal anesthesia|spinal anesthesia
214286859|NCT05730751|PROCEDURE|caesarean section|LSCS
214286860|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
214286861|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
214286862|NCT05218460|DEVICE|MRI examination|All subjects (healthy and pathological subjects) will have an MRI examination with a component of the MRI system under development.
214286863|NCT00221585|BEHAVIORAL|Psychosocial treatment/Psychodynamic treatment|
214286864|NCT04525989|RADIATION|Radiation therapy|5 x 5 Gy external radiation therapy
214286865|NCT04553523|DEVICE|Hydrus Microstent|Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
214286866|NCT04553523|PROCEDURE|Cataract surgery|Cataract surgery performed using standard anesthesia and phacoemulsification techniques
214286867|NCT04553523|DEVICE|Monofocal IOL|Commercially available monofocal intraocular lens as determined by the investigator
214286868|NCT03918447|DRUG|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
214286869|NCT03918447|DRUG|Placebo oral capsule|Capsule containing an inert placebo
214286870|NCT03278613|DEVICE|ES-130|"The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device."
214286871|NCT05459038|DIAGNOSTIC_TEST|C-Arm Rotational View (CARV)|CARV includes predefined fluoroscopy landmarks of the uninjured side to correct for rotational malalignment of the injured side in which the rotation of the C-Arm Image Intensifier is used
214286872|NCT01405456|DRUG|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
214286873|NCT01405456|OTHER|placebo and lifestyle|placebo pill daily and lifestyle counseling
214286874|NCT06440408|DRUG|Ferumoxytol|Ferumoxytol will be used as a contrast agent for the cMRI
214286875|NCT07131449|OTHER|This is observational studies, participants are not assigned an intervention as part of the study.|This is observational studies, participants are not assigned an intervention as part of the study.
214286876|NCT07132983|DRUG|Ensifentrine 3 mg|Single dose, administered by oral inhalation using a standard jet nebulizer
214286877|NCT07132983|DRUG|Glycopyrrolate 42.5 mcg|Single dose, administered by oral inhalation using a standard jet nebulizer
214286878|NCT07132983|DRUG|Ensifentrine 1.5 mg|Single dose, administered by oral inhalation using a standard jet nebulizer
214286879|NCT07132983|DRUG|Ensifentrine 3 mg (marketed formulation)|Single dose, administered by oral inhalation using a standard jet nebulizer
214286880|NCT07132697|DRUG|L-Amino acid mixture|Continuous infusion of a L-amino acids mixture in a dose of 2 g/kg dry body weight/day (to a maximum 100 g/day) after induction of anesthesia and insertion of CVP line till 72 hours after treatment initiation
214286881|NCT07132697|OTHER|Standard of care|Standard peri tranplant care as per out institution including intra operative and post operative care. Its includes starting of immunosuppression after serial blood investigation monitoring.
214286882|NCT07131397|DEVICE|Inspiratory Muscle Traing|IMT will be performed by applying resistance at 40% of the maximum inspiratory pressure (1 set of 30 repetitions 30 breaths per session). Each week there will be a gradual increase in resistance by 10% of the initial maximum inspiratory pressure.
214286883|NCT07131397|DEVICE|Sham Inspiratory Muscle Training|Inspiratory muscle training will be applied with a constant resistance load of 7cmH20
214286884|NCT07132398|DRUG|Slow-tapering glucocorticoids + Inebilizumab|Slow-tapering glucocorticoids+Inebilizumab arm: A 300 mg intravenous infusion of inebilizumab will be administered on Day 1 and Day 15, followed by 300 mg infusions every 26 weeks thereafter. Prednisone will be initiated at a daily dose of 60 mg as concomitant therapy with inebilizumab. The prednisone dose will be tapered as follows: a reduction of 5 mg every 2 weeks until reaching 20 mg/day(Week 16); thereafter, a reduction of 5 mg every 4 weeks until discontinuation (a total duration of 32 weeks for combined inebilizumab and glucocorticoids therapy).
214286885|NCT07132398|DRUG|Rapid-tapering glucocorticoids + Inebilizumab|Rapid-tapering glucocorticoids+Inebilizumab arm: A 300 mg intravenous infusion of inebilizumab will be administered on Day 1 and Day 15, followed by 300 mg infusions every 26 weeks thereafter. Prednisone will be initiated at a daily dose of 60 mg as concomitant therapy with inebilizumab, with a tapering schedule of 5 mg reduction per week until discontinuation (a total duration of 12 weeks for combined inebilizumab and glucocorticoids therapy).
214286886|NCT07131098|OTHER|Early Enteral Feeding Protocol|Early enteral nutrition was initiated within 24-48 hours of ICU admission based on a structured protocol aligned with ASPEN and ESPEN guidelines. The protocol defined target caloric goals, methods of tube feeding initiation, rate advancement, and monitoring procedures. Nurses and ICU staff were trained in protocol implementation. The goal was to optimize nutrition early in critical illness to improve clinical outcomes such as ICU length of stay, ventilator dependence, and physiological stability.
214286887|NCT07131098|OTHER|Standard Nutritional Care|Patients in the control group received standard nutritional care per routine hospital practices. Initiation and progression of feeding were left to the discretion of the attending physician and nursing staff, without the use of a structured protocol or defined early feeding timeline.
214286888|NCT07125521|OTHER|GERCCare mobile app|Using the smartphone application GERDCare (with detailed instructions provided during recruitment)
214286889|NCT07133217|DEVICE|Root canal preparation with Hand Files (Dentsply Sirona)|Root canal treatments were performed with hand files
214286890|NCT07133217|DEVICE|Root canal preparation with the WaveOne Gold file system (Dentsply Sirona, Ballaigues, Switzerland)|Root canal treatments were performed with WaveOne Gold Files
214286891|NCT07133217|DEVICE|Root canal preparation with the ProTaper Ultimate file system (Dentsply Sirona)|Root canal treatments were performed with ProTaper Ultimate Files
214286892|NCT05570760|DEVICE|Adaptos®Ortho Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
214286893|NCT05570760|PROCEDURE|OWHTO without bone grafting|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation, without bone grafting. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
214286894|NCT05570760|DEVICE|chronOS® Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
214472214|NCT05122416|DEVICE|FibroScan examination (Standard M)|A FibroScan examination with the Standard M probe.
214472215|NCT05893940|PROCEDURE|Low Intensity Vibration Therapy|Undergo LIMS vibration therapy
214472216|NCT05893940|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
214472217|NCT05893940|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214472218|NCT05284409|DRUG|Pethidine|36 patients will receive 0.5 mg/kg Pethidine IVI
214286895|NCT06657235|OTHER|Transitional Care Program|Participants will receive personalized risk-factor management stroke care from a multidisciplinary team trained by our neurologists to understand the needs of stroke survivors and the nuances of stroke care. Risk factor data from in-home devices, health records, and self-reports will be collected along with functional status and behavioral data obtained through validated questionnaires and an occupational therapy evaluation. Syntrillo's neurology provider will review this data, assess the participant through a telemedicine encounter, and create a comprehensive secondary prevention plan to supplement the participant's care plan at discharge. Data generated through these clinical encounters will be de-identified and used for subsequent development of Syntrillo's stroke management technology.
214286896|NCT06591741|DIETARY_SUPPLEMENT|Oral PCA|PCA 1,000 mg BID until surgery, held until anticoagulation, and resumed at 1,000 mg daily for 4 years
214286897|NCT06590896|DRUG|Cenobamate|Cenobamate will be orally administered once daily.
214286898|NCT05353985|DRUG|TAK-062|TAK-062 tablets.
214286899|NCT05353985|DIETARY_SUPPLEMENT|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar|SIGE gluten bars.
214286900|NCT05353985|DRUG|TAK-062 Placebo|TAK-062 placebo-matching tablets.
214286901|NCT05353985|DIETARY_SUPPLEMENT|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar|SIGE gluten-free bars.
214286902|NCT07002476|DRUG|guideline-recommended SoC|Guideline-recommended SoC, including but not limited to oral lipid-lowering drugs, antiplatelet aggregation drugs, anticoagulant drugs, antihypertensive drugs, etc. It is to be determined by the investigator based on the subject's treatment needs.
214286903|NCT07002476|DRUG|Recaticimab (intensive)|Recaticimab is added to the guideline-recommended SoC. After randomization and before endovascular interventional treatment, patients will receive a subcutaneous injection of Recaticimab. The specific method is: Recaticimab 450 mg (3 vials) as a single subcutaneous injection, until the end of the follow-up for this study.
214286904|NCT07002684|DRUG|Esketamine|nasal
214286905|NCT07132216|DEVICE|Meta Quest 2 VR headset|The Meta Quest 2 VR headset with built-in headphones was used. Patients selected VR environments from a predefined list of five nature scenes (beach, forest, mountain, underwater, and meadow) with identical meditation audio tracks lasting 30 minutes each. Guided Meditation VR from Cubicle Ninjas (https://guidedmeditationvr.com/)featured 360-degree nature environments with standardized calming background music and guided meditation narration. VR was applied immediately after spinal anesthesia and before the surgical incision. Sessions lasted 30 minutes and were discontinued if the patient reported nausea, dizziness, or requested removal.
214286906|NCT07131085|DRUG|Allogeneic TCR-enhanced γδ T cell(QH101)|dose escalation (3+3) : dose 1 (5×10\^8 enTCR γδ cells) , dose 2 (1.5×10\^9 enTCR γδ cells), dose 3 (3×10\^9 enTCR γδ cells)
214286907|NCT07131085|DRUG|Fludarabine (FLU)|Intravenous fludarabine 20\~30 mg/m\^2/day on days -5, -4, and -3
214286908|NCT07131085|DRUG|Cyclophosphamide (CTX)|Intravenous cyclophosphamide 300\~500 mg/m\^2/day on days -5, -4, and -3.
214286909|NCT06869031|BEHAVIORAL|Standard Interactive Intervention for Hypertension Management|The standard interactive intervention is a doctor-patient interaction intervention conducted by follow-up physicians using an intelligent outbound call system as part of follow-up management. It is implemented once a month and is designed based on the Health Behavior Interaction Model, covering four key aspects: health information (e.g., potential risks of poor self-management behavior), professional skills(e.g., blood pressure measurement, medication guidance), emotional support , and decision-making participation.
214286910|NCT06869031|BEHAVIORAL|Intensified Interactive Intervention for Hypertension Management|The enhanced interactive intervention builds upon the standard interactive intervention by increasing the frequency of interactions. In addition to the monthly intervention, patients receive an additional brief interactive intervention every two weeks via the intelligent outbound call system, reminding them to adhere to self-management behaviors for hypertension control.
214286911|NCT06868719|DIETARY_SUPPLEMENT|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
214286912|NCT06868719|DIETARY_SUPPLEMENT|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
214286913|NCT06868719|DIETARY_SUPPLEMENT|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
214286914|NCT06678074|DRUG|Atibuclimab (IC14), 20 mg/kg intravenously, once|monoclonal antibody against CD14
214286915|NCT06678074|OTHER|Placebo, 150 mL intravenously, once|sterile normal saline for injection
214286916|NCT02584335|DRUG|"Lidocaine solution (A)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
214472219|NCT05284409|DRUG|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI
214472220|NCT05284409|DRUG|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI
214472221|NCT05701982|BEHAVIORAL|Every Step Counts-Tai Chi|The intervention is ESC-TC which is a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The intervention is delivered remotely.
214472222|NCT05701982|OTHER|Usual Care|Usual Care
214472223|NCT03742505|DRUG|Cholecalciferol|Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)
214286917|NCT02584335|DRUG|"Saline solution (B)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
214286918|NCT03770442|DEVICE|Cycling with FES|As described already
214286919|NCT03770442|OTHER|Routine physiotherapy|As described already
214286920|NCT04827550|OTHER|STUDY|Fibromyalgia Patient
214286921|NCT01539057|DRUG|Fibrinogen|"The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts"
214286922|NCT01539057|DRUG|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
214286923|NCT05816512|DRUG|Gold Nano particle from Pelargonium Graveolens Mouthwash|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
214286924|NCT05816512|DRUG|Chlorhexidine gluconate mouthwash .|Chlorhexidine gluconate mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
214286925|NCT02500888|RADIATION|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
214286926|NCT02298803|DEVICE|Holter and Glucose monitoring|"(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities."
214286927|NCT02786147|OTHER|Breast Cancer Genetics Referral Screening Tool 3.0|"The B-RST is a simple yet effective validated screening tool to quickly identify individuals who may be at risk for hereditary breast and ovarian cancer and should be referred for cancer genetic counseling to formally evaluate their family history and discuss the benefits and limitations of genetic testing for hereditary breast and ovarian cancer.~Clinic staff will give each patient arriving for a screening mammogram appointment a packet and briefly inform them about the opportunity to participate in a research study and that these materials can help them decide whether or not to participate.~Patients who indicate that they are interested in completing the B-RST screening while in the clinic will be provided with an electronic tablet that has a secure internet browser tab open to the web-based study version of the screening tool (the B-RST 3.0)."
214286928|NCT02786147|OTHER|Standard Handout|A document explaining the patient's positive test result indicating that they are at increased risk for HBOC (Hereditary Breast or Ovarian Cancer) which includes information on how to obtain cancer genetics services through Winship.
214286929|NCT02786147|OTHER|Physician Notification|Primary care physician or ordering physician will be notified vie EeMR that the patient screened positive on the B-RST. The note provides specific instructions on how to refer the patient for cancer genetic counseling services.
214286930|NCT02786147|OTHER|Automatic Follow-Up by Genetic Counseling Staff|Within 1-2 weeks after the mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment.
214472224|NCT03742505|OTHER|Placebo|Single enteral placebo dose equivalent in volume to the appropriate weight-based dose of cholecalciferol
214472225|NCT04785092|PROCEDURE|All Autologous Cartilage Regeneration|All patients will undergo firstly to a blood sampling and then to the arthroscopic debridement of the damage cartilage and subsequently will be harvested the surrounding healthy cartilage The harvested and healthy cartilage will shredded directly in situ with a shaver. This cartilage will then mixed with the patient's own Platelet Concentrate and may be injected directly into the cartilage defect. The Platelet Concentrate stimulates the healing of the cartilage most effectively. At the same time, the Platelet Concentrate will also used to produce autologous fibrin glue, which can be used to fix the applied cartilage chip / Platelet Concentrate product quickly and safely in the damaged cartilage.
214845585|NCT03822273|PROCEDURE|Laser acupuncture (LA)|"Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz\]; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2)."
214845586|NCT03822273|PROCEDURE|Sham laser acupuncture (SLA)|"Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group."
215033470|NCT04218981|DRUG|Antipsychotic drugs|Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group
215033471|NCT04218981|DRUG|Mood stabilizer|Choose lithium or valproate for bipolar disorder group
214286931|NCT05484518|BEHAVIORAL|Method of Levels Therapy|"Method of Levels (MOL) is a therapy that is the direct application of Perceptual Control Theory (PCT) (Powers, 2008) which proposes that psychological distress results from a person's reduced control over important life goals. A conflict between two or more goals can occur outside of a person's awareness (Carey, Mansell \& Tai, 2014) and the achievement of one goal leaves the other incompatible goal unachievable, leading to distress (Mansell, 2012). MOL therapy aims to help people develop awareness of important goals and conflicts between them, to increase their chances of developing potential solutions. Conflict can be resolved through reorganisation; a mechanism through which random change is continuously generated until control is restored (Tai, 2016).~Therapy uses a questioning style to help clients bring their attention to their problems long enough for them to restore control. In practice clients choose the number, frequency and duration of therapy sessions"
214286932|NCT06392503|DIAGNOSTIC_TEST|different diagnostic models|the patients were screened by different diagnostic models
214286933|NCT02085317|DRUG|acetylcholine Iontophoresis|Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
214286934|NCT02085317|DRUG|sodium nitroprusside Iontophoresis|After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
214286935|NCT01327105|DEVICE|TVU|Use of transvaginal ultrasound to determine location of micro-insert
214286936|NCT00001105|DRUG|F105 Monoclonal Antibody (Human)|
214286937|NCT00988611|OTHER|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
214286938|NCT00812578|DRUG|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
214286939|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo strength training classes
214286940|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo tai chi classes
214286941|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo stretching and relaxation classes
214286942|NCT01635413|OTHER|Questionnaire Administration|Ancillary studies
214286943|NCT04647578|DEVICE|GT3X Actigraph accelerometer.|GT3X Actigraph accelerometer during 7 days
214286944|NCT05699499|OTHER|KeryFlex|KeryFlex is a painless, in-office cosmetic application of artificial nails which improves the appearance of nails damaged by various nail disorders. The composite resin creates a flexible, nonporous nail that allows the remaining natural nail to grow. KeryFlex is a three-step procedure that takes 10 to 15 minutes for a typical nail. At least 15% of the existing nail must be present for the resin application. The material used in KeryFlex is approved as a cosmetic by the FDA.
214286945|NCT01920789|RADIATION|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (\<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
214286946|NCT01920789|RADIATION|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
214286947|NCT00173082|PROCEDURE|Glucose tolerance test|
214286948|NCT06382584|PROCEDURE|Femoral fracture surgery|Hip fracture surgery
214845587|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
215033472|NCT04218981|DRUG|Paroxetine|Patients with major depressive disorder are treated with paroxetine
214286949|NCT04550390|DIAGNOSTIC_TEST|Saliva collection|2 saliva samples are self-collected by participants
214286950|NCT02989194|DRUG|VIS410 low dose|Single intravenous fixed low dose of VIS410
214286951|NCT02989194|DRUG|VIS410 high dose|Single intravenous fixed high dose of VIS410
214286952|NCT02989194|DRUG|Placebo|Single intravenous infusion of placebo
214286953|NCT01033266|DIAGNOSTIC_TEST|CPET|CPET will be done on patients with overlap syndrome before and after clinical CPAP treatment.
214286954|NCT00765050|BIOLOGICAL|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
214286955|NCT04022902|OTHER|No intervention|This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
214286956|NCT04937491|DEVICE|New medical device (ReBalans)|Body worn, battery powered bioimpedance measuring patch device.
214286957|NCT01148823|OTHER|Incisions covered for 1 day|Dressing was removed on the first postoperative day.
214286958|NCT01148823|OTHER|Incisions covered for 6 days|Dressing was removed on the 6th postoperative day.
214286959|NCT02588807|DRUG|Spirit1|Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
214286960|NCT05067829|DEVICE|Train of four(TOF)|Train of four(TOF) monitoring after anesthesia induction
214286961|NCT00458198|BEHAVIORAL|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
214286962|NCT02775721|OTHER|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
214286963|NCT02775721|OTHER|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
214286964|NCT02775721|OTHER|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
214286965|NCT02775721|OTHER|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
214286966|NCT02775721|OTHER|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
214286967|NCT00031057|DRUG|Thiamine hydrochloride|
214286968|NCT00031057|DRUG|Riboflavin|
214286969|NCT04818281|BIOLOGICAL|SARS-CoV-2 VLP Vaccine|VLP adjuvanted vaccine
214286970|NCT04818281|BIOLOGICAL|Placebo|0.9% NaCl
214286971|NCT05187715|DRUG|Simvastatin 40mg|Simvastatin 40mg OD
214286972|NCT05187715|OTHER|Placebo|Placebo
215033473|NCT03148002|DRUG|Current Bowel Protocol (senna/lactulose)|Stimulant and Osmotic Laxatives.
214286973|NCT05187715|OTHER|Standard medical Treatment|Standard medical Treatment eccluding pentoxiphylline
214286974|NCT05084274|BEHAVIORAL|Lifestyle program|If the patient is allocated to the interventional group, the lifestyle modification program will be planned/started immediately after the intake at the fertility clinic. The lifestyle modification program has a duration of 12 weeks in which the subject will receive follow-up by the endocrinologist/diabetologist and dietitian to re-ceive an active dietary intervention plan, follow-up by the physiotherapist where sessions to start with physical exercise will be given. Monthly follow-up visits with the coordinating PCOS-midwife will be planned to enhance the subject's knowledge about PCOS and give emotional support. At the moment of randomization, the PCOS coordinating midwife will immediately plan all necessary appointments, with the endocrinologist and dietitian, physiotherapist and PCOS-coordinator, for the 12-week lifestyle program. This way, patients will have a clear overview of the following 12 weeks.
214286975|NCT05744154|BEHAVIORAL|Audit & feedback with educational outreach and facilitation|As in arm descriptions
214286976|NCT05744154|BEHAVIORAL|Simple audit & feedback (usual practice)|As in arm descriptions
214286977|NCT02257944|BEHAVIORAL|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
214286978|NCT02257944|OTHER|Treatment as Usual|treatment as usual
214286979|NCT02659306|DRUG|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
214286980|NCT01516931|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
214286981|NCT01516931|BEHAVIORAL|counseling|Placebo monthly by general counseling for 12 months.
214286982|NCT01327885|DRUG|Eribulin mesylate 1.4 mg/m^2 intravenous|Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
214286983|NCT01327885|DRUG|Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV|Administration of dacarbazine at a dose of 850 mg/m\^2, or 1,000 mg/m\^2, or 1,200 mg/m\^2 selected by the Principal Investigator \[PI\] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
214286984|NCT06276439|PROCEDURE|Surgical removal of breast cancer and lymph nodes|The patients will undergo a surgical procedure to remove tumor tissue in the breast and its associated lymph nodes. No clinical decision is based on the imaging device tested.
214286985|NCT06000514|DRUG|Sm29 Protein, Schistosoma Mansoni|Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
214286986|NCT06000514|DRUG|Pentavalent antimony (Sbv)|Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
214286987|NCT02003612|OTHER|Not applicable - observational study|No intervention exists as this is a retrospective observational study
215033474|NCT03148002|DRUG|PEG Bowel Protocol (PEG/lactulose)|Osmotic Laxatives.
215033475|NCT05482451|DRUG|Nivolumab|Nivolumab, an immune checkpoint inhibitors targeting PD-1, represents a popular treatment option for patients with cancers via immunological mechanism. However, previous studies using nivolumab alone in pancreatic cancer have failed.
214845588|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
214845589|NCT04855591|DRUG|SHR-1703|SHR-1703 will be administered subcutaneously
214845590|NCT04855591|DRUG|Placebo|Placebo of SHR-1703 will be administered subcutaneously
214845591|NCT00197080|DRUG|Ropinirole Extended Release (XR)|
214845592|NCT01410760|OTHER|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
214845593|NCT05308368|DEVICE|Ultrasound Imaging|We will collect ultrasound images during the grasping motion for both groups
214845594|NCT05308368|DEVICE|Electromyography|We will collect electromyography (EMG) signals of both the flexor and extensor muscles of the wrist during the grasping motion for both groups
214845595|NCT05308368|DEVICE|Inertial Measurement Units (IMU)|We will use data from the ultrasound images and EMG to develop a tremor model. The model will be validated in comparison to joint angle measurements from an Inertial Measurement Unit (IMU) collected during the grasping motion
214286988|NCT05346341|PROCEDURE|Minimally invasive techniques|"All patient will be treated under general anaesthesia An appropriate gland-preserving minimally-invasive surgical procedure will be performed for all patients according to the nature and extent of the disease for either submandibular or parotid ducts.~Minimally invasive techniques for ductal salivary gland pathologies include:~1. Sialolithotomy through a simple cutdown~2. Sialendoscopy~3. Transoral microscopic-assisted sialolithotomy."
214286989|NCT03824912|DRUG|Ketoconazole Cream 2%|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
214286990|NCT03824912|DRUG|Ketoconazole Cream 2% (G&W Laboratories Inc.)|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
214286991|NCT03824912|DRUG|Placebo|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
214286992|NCT03657706|PROCEDURE|group A (Tunnel procedure with subepithelial connective tissue graft (sCTG)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
214286993|NCT03657706|PROCEDURE|group B (Tunnel procedure with modified free gingival graft (mFGG))|modified free gingival graft (autogenous graft) will be harvested from the palate and will be used with the prepared tunnel to be used in treating gingival recession
214286994|NCT00075179|DRUG|Nesiritide (Natrecor)|Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
214286995|NCT00075179|PROCEDURE|Right Heart Catheterization|Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
214286996|NCT01577329|BEHAVIORAL|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
214286997|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|"Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L."
214286998|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG ®|"Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia"
214286999|NCT02642289|OTHER|Placebo|Innocuous substance
214287000|NCT01176669|DRUG|Apatinib|Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
214287001|NCT04337606|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
214287002|NCT04337606|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
214845596|NCT05308368|DEVICE|Functional Electrical Stimulation (FES)|We will use the develop closed-loop control methods for tremor suppression using information from the ultrasound-image based tremor models. FES will be used to provide stimulation that will help with tremor suppression
214845597|NCT00116480|DRUG|Misoprostol|600 mcg of sublingual misoprostol
214845598|NCT03601494|OTHER|perineural injection of platelet-rich plasma|Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
214845599|NCT03601494|DRUG|medical|vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
214845600|NCT02438540|DRUG|metformin|metformin tablet 500 mg
214845601|NCT02438540|OTHER|acupuncture|Electro body acupuncture and auricular acupuncture
214287003|NCT04337606|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
214287004|NCT05830851|OTHER|real tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters
214287005|NCT05830851|OTHER|sham tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with sham tDCS
214287006|NCT03589950|DRUG|anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
214287007|NCT03589950|DRUG|chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
214287008|NCT03933189|OTHER|Physical Therapy|Physical therapy modalities to treat chronic pain
214287009|NCT00260494|OTHER|acupuncture|standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
214287010|NCT00260494|OTHER|sham acupuncture|standardized sham acupuncture at same sites as acupuncture.
214287011|NCT03103633|PROCEDURE|mean artery pressure|mean artery pressure declined with less than 20% of baseline
214287012|NCT03103633|PROCEDURE|bispectral index|BIS 45-60 before and after CPB; and BIS 40-45 during CPB
214287013|NCT03103633|PROCEDURE|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
214287014|NCT03103633|OTHER|Controlled|receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
214287015|NCT00662610|DRUG|naproxcinod 375 mg -750 mg -1125 mg bid|naproxcinod 375 mg -750 mg -1125 mg bid
214287016|NCT00662610|DRUG|naproxen 250 mg - 500mg -750 mg bid|naproxen 250 mg - 500mg -750 mg bid
214287017|NCT02520050|BEHAVIORAL|Traditional MNT|Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
214287018|NCT02520050|BEHAVIORAL|Structured MNT|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
214287019|NCT02520050|BEHAVIORAL|Structured MNT plus Weekly Support|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
214287020|NCT02257788|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCR5
214287021|NCT02950025|DEVICE|Online, adaptive MR-guided SBRT|Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
214287022|NCT02950025|DEVICE|Online, non-adaptive MR-guided SBRT|Patients will not have online-adaptive treatment planning
214287023|NCT02950025|OTHER|European Organization for Research and Treatment of Cancer (EORTC) QLQ-30|"* 30 questions~* 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~* 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~* 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent"
214845602|NCT06165692|BIOLOGICAL|PRF|Post-operative PRF placement in the post-extraction socket after third molar surgery
214845603|NCT02913131|DRUG|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
214845604|NCT02913131|DEVICE|MRI|MRI scan following the pyruvate (13c) injection
214287024|NCT05076526|BIOLOGICAL|Hyaluronic acid (Synolis VA)|"Synolis VA harbours the following characteristics:~* NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~* Sorbitol: 40mg/mL~* Molecular weight of 2MDa, sterilized in moist heat"
214287025|NCT05076526|BIOLOGICAL|Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)|"The CM-PRP-HA tube is under vacuum containing the following:~* 2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~* 3g of inert cell-selector gel~* 0.6mL of anticoagulant (sodium citrate 4%)"
214287026|NCT01524510|RADIATION|CT scan|low dose radiation scan without contrast without and with MRA
214287027|NCT01524510|DEVICE|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
214287028|NCT05571241|BEHAVIORAL|Fast rehabilitation program|1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
214287029|NCT03836612|OTHER|No intervention|Observation of routine clinical practice
214287030|NCT02630550|DEVICE|Cheetah NICOM|The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
214287031|NCT02630550|DEVICE|Transesophageal echocardiography (TEE)|TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
214287032|NCT03171623|DRUG|globalagliatin hydrochloride|orally administration, single dose
214287033|NCT03171623|DRUG|placebo|orally administration, single dose
214287034|NCT03495076|OTHER|Saline injection|In the saline injection condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute pain. Saline will be injected into the right (or left) trapezius muscle at the level of C7 cervical level. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at the same depth. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster to ensure blinding.
214845605|NCT06677931|PROCEDURE|Placebo Comparator:1565 non-ablative fractional laser combined with normal Saline|Based on the patient's age, skin color, location of skin lesions, and Fitzpatrick skin type, adjust treatment parameters accordingly. The operator holds the treatment head, vertically applies parallel sweeps closely to the lesion area until the endpoint of slight skin redness is reached. After completion, apply normal Saline.
214287035|NCT03495076|OTHER|Sham injection|In the sham-injection condition (nocebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin without piercing the skin. A stimulus of 512 millinewtons (mN) will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided. The stimuli will be applied in exactly the same spot as the real injection in previous experimental condition.
214287036|NCT04841031|BEHAVIORAL|NET Treatment|Narrative Exposure Therapy (NET) aims to address PTSD symptoms among survivors of mass violence and torture (Onyut et al., 2004; Schauer, et al., 2005). Mainly, different from other psychosocial interventions which require the survivor to process a single traumatic event in his or her life at a given time, NET treatment recognizes that trauma survivors undergo multiple distressing events within their lifetime (Schauer et al., 2005). Focusing on the traumatic events, the patient constructs a chronological narrative of his or her life story and a coherent narrative is then structured with the assistance of the therapist. They received NET one to three months following their screening and randomization. The therapy involves 8 to 12 individual sessions of about 90 minutes each.
214287037|NCT04841031|OTHER|Alternative Intervention|Individuals in control group received non-NET psychosocial support in the interim that is provided to SGBV survivors as part of the Great Lakes SGBV project and will then receive NET after endline data has been collected.
214287038|NCT01779739|PROCEDURE|Perineorrhaphy|Procedure to build up the vaginal opening
214287039|NCT01693926|BEHAVIORAL|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
214287040|NCT01693926|BEHAVIORAL|placebo|
214287041|NCT03181087|OTHER|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
214287042|NCT01658891|DRUG|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
214287043|NCT01658891|DRUG|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
214287044|NCT04745429|OTHER|breathing exercises, cold exposure and meditation|It is a combination of exercises that include breathing exercises, cold exposure and meditation
214287045|NCT02254486|DRUG|NER1006|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
214287046|NCT02254486|DRUG|Trisulfate solution|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
214287047|NCT03687853|DEVICE|Intrahepatic Arterial Infusion|Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
214287048|NCT01427504|DRUG|boceprevir; etravirine|boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
214287049|NCT01911871|BIOLOGICAL|Blood sample|a blood sample was taken on the day of inclusion
214287050|NCT01350414|DEVICE|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
214287051|NCT04166435|DRUG|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
214287052|NCT01177592|DEVICE|VerifyNow, Verigene|Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19\*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
214287053|NCT06314542|OTHER|relaxing eligibility criteria|Quantitative evaluation of the impact of relaxing eligibility criteria on the risk-benefit profile of drugs for lung cancer based on real-world data
214287054|NCT01327521|DEVICE|CyberKnife|Standard of Care
214287055|NCT01327521|PROCEDURE|TACE|Standard of Care
214287056|NCT01327521|DRUG|CT Contrast|Standard of Care
214287057|NCT01327521|DRUG|doxorubicin|Standard of Care
214845606|NCT06677931|PROCEDURE|1565 non-ablative fractional laser combined with umbilical cord mesenchymal stem cell-derived exosomes.|Based on the patient's age, skin color, location of skin lesions, and Fitzpatrick skin type, adjust treatment parameters accordingly. The operator holds the treatment head, vertically applies parallel sweeps closely to the lesion area until the endpoint of slight skin redness is reached. After completion, apply exosomes.
214287058|NCT01327521|DRUG|Epirubicin|Standard of Care
214287059|NCT01327521|DRUG|5-fluorouracil|Standard of Care
214287060|NCT01327521|DRUG|Mitomycin C|Standard of Care
214287061|NCT01327521|DRUG|Gemcitabine|Standard of Care
214287062|NCT01327521|DRUG|Cisplatin|Standard of Care
214287063|NCT01327521|DEVICE|SMANCS|Standard of Care
214845607|NCT05193422|DIAGNOSTIC_TEST|Spirometry - baseline|"Standard spirometry using a Micro5000 spirometer to determine baseline FEV1, FVC, FEV1/FVC, FEF25-75 and PEF.~Baseline spirometry will be performed before CPET in both study arms"
214287064|NCT01572454|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
214287065|NCT01572454|DRUG|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
214287066|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in left side|
214287067|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in right side|
214287068|NCT05693779|BEHAVIORAL|Home exercise training|"Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study."
214287069|NCT05000476|OTHER|eye mask and earplugs|Materials similar to those offered on long commercial flights
214287070|NCT05000476|OTHER|Nurse Education and Environmental Regulation|providing orientation to the patient (frequent orientation of the patient to the place, time and person), cognitive stimulation (objects such as clocks and calendars in the patient's field of view), reducing noise and light (minimizing monitors and fluid infusion pump alarms at night), providing early mobilization ( passive-active joint movements, sitting and walking in bed), reducing social deprivation (receiving visitors, telephone calls)
214287071|NCT03649698|BEHAVIORAL|Home-based training program|Exercise intervention: During the intervention period, the participant will perform the optimized and personally adapted Otago Exercise Program (OEP). The participant is encouraged to perform the resistance exercises three times a week with a rest day in between. The participant is advised to perform the exercises in close temporal proximity to one of the moments of the intake of the protein supplement. The participant will also follow a walking plan in which he or she needs to walk 30 minutes twice a week. These 30 minutes can be broken down to three 10-minute walks throughout the day. During the follow-up period, participants may continue the OEP, but no personal encouragement will be given during this period.
214287072|NCT03649698|DIETARY_SUPPLEMENT|High-quality protein supplement|The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.
214287073|NCT03649698|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.
214287074|NCT03649698|DRUG|Placebo protein powder|Isocaloric maltodextrin powder. Amount based on food diary.
214287075|NCT03649698|DRUG|Placebo omega-3|Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
214287076|NCT02875483|OTHER|Expedited Scheduling|Patients are scheduled for tubal ligation surgery prior to discharge from the post-partum hospital service, with target date 4-8 weeks post-partum.
214287077|NCT02875483|OTHER|Standard Scheduling|Scheduling of tubal surgery occurs after completion of post-partum office visit
214287078|NCT04519684|DRUG|Mesenchymal stem cells|Allogeneic bone marrow derived mesenchymal stem cells
214287079|NCT04519684|OTHER|Placebo|Normal Saline
214287080|NCT01690247|DRUG|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
214287081|NCT01690247|DRUG|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
214287082|NCT00653250|DRUG|celecoxib|400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
214287083|NCT00653250|PROCEDURE|biopsy|in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
214287084|NCT00653250|PROCEDURE|therapeutic conventional surgery|surgery to remove the lung tumor
214287085|NCT03435744|DRUG|Simvastatin 20 mg|Simvastatin 20 mg added to TAU for 3 months.
214845608|NCT05193422|DIAGNOSTIC_TEST|Spirometry - post CPET|Standard spirometry using a Micro5000 spirometer to determine baseline % change in FEV1 after CPET and assess exercise-induced bronchoconstriction (defined as FEV1 decrease \>10% at 5 minutes after CPET) Post spirometry will be performed after CPET in both study arms
214845609|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - baseline|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured before CPET in both study arms"
214845610|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - post CPET|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured after CPET in both study arms"
214287086|NCT03435744|OTHER|Placebo Oral Tablet|Matched placebo added to TAU for 3 months
214287087|NCT03905187|BEHAVIORAL|Modified CR|Stress management involved modified cardiac rehabilitation
214287088|NCT03905187|BEHAVIORAL|Traditional CR|Traditional cardiac rehabilitation
214287089|NCT03905187|BEHAVIORAL|Education|Education
214845611|NCT05193422|DIAGNOSTIC_TEST|Oxygen saturation|Continuous monitoring of SpO2 using a Nonin 7500 pulse oximeter, in both study arms
214845612|NCT05193422|DIAGNOSTIC_TEST|Heart Rate|Continuous monitoring of HR using a Nonin 7500 pulse oximeter, in both study arms
214845613|NCT05193422|DIAGNOSTIC_TEST|End-tidal CO2|Continuous monitoring of EtCO2 using a Microstream capnograph, in both study arms
214845614|NCT05193422|DIAGNOSTIC_TEST|Respiratory rate|Continuous monitoring of RR using a Microstream capnograph, in both study arms
214845615|NCT05193422|DIAGNOSTIC_TEST|Temperature|Continuous monitoring of Temp in the face mask using a RHT03 sensor, only in the experimental study arm
214845616|NCT05193422|DIAGNOSTIC_TEST|Humidity|Continuous monitoring of Hum in the face mask using a RHT03 sensor, only in the experimental study arm
214287090|NCT01716351|BEHAVIORAL|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
214287091|NCT05550402|DRUG|Salbutamol|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
214287092|NCT05550402|DRUG|Ipratropium Bromide|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
214287093|NCT05550402|DRUG|Salbutamol plus Ipratropium Bromide|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
214287094|NCT05550402|OTHER|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
214287095|NCT01189214|DRUG|Memantine|Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
214845617|NCT05193422|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|"CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg.~CPET will be performed in both study arms"
214845618|NCT05193422|DIAGNOSTIC_TEST|Discomfort level|"Discomfort assessment using a special scale graded from 1 to 10 (Fikenzer, 2020).~Both study arms, after CPET."
214845619|NCT03884725|DRUG|Fibrinogen Concentrate|Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[mm\*kg/g\] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
214287096|NCT06200233|DRUG|Rivoceranib|700mg once daily
214287097|NCT01484197|DRUG|75 µg indacaterol maleate (LB)|75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
214287098|NCT01484197|DRUG|75 µg indacaterol maleate (PoS)|75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
214287099|NCT01484197|DRUG|37.5 µg indacaterol maleate (PoS)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
214287100|NCT01484197|DRUG|placebo to indacaterol (LB)|Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
214287101|NCT01484197|DRUG|placebo to indacaterol (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
214287102|NCT00586001|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Cognitive-behavioral treatment in development for emotional disorders
214287103|NCT05380804|DIAGNOSTIC_TEST|cutaneous silent period (CSP) measurement|CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
214287104|NCT05741632|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
214287105|NCT05741632|DRUG|Levofloxacin Ophthalmic|Levofloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
214287106|NCT04819074|PROCEDURE|Microsurgery|Microsurgery for unruptured intracranial aneurysm
214287107|NCT04785976|PROCEDURE|Surgical clipping and endovascular coiling|Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
214287108|NCT02875756|PROCEDURE|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
214287109|NCT02875756|PROCEDURE|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
214287110|NCT03033394|DRUG|Beta-lactam antibiotic|Routine clinical dosing
214287111|NCT02036294|OTHER|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
214287112|NCT02036294|OTHER|Usual Care|Standard Healthcare Services
214287113|NCT00356369|BIOLOGICAL|meningococcal ACWY (vaccine)|One intramuscular dose.
214287114|NCT00356369|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose.
214287115|NCT04674384|DIETARY_SUPPLEMENT|Optifast meal replacement shakes|Optifast® is provided as 53g sachet. Each sachet replaces one meal. It is available in 5 flavours: vanilla, strawberry, chocolate and coffee shakes and vegetable soup.
214845620|NCT03884725|OTHER|control|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF). 0.9% saline is to be infused over 1 to 2 minutes. After 0.9% saline infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
214845621|NCT04374422|BEHAVIORAL|fsfi survey|sexual behavior Questionaire
214845622|NCT04608201|DRUG|Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|"Treatment involves escalating doses to the target dose of 14 mg / day~1. / Dose escalation:~   * Level 1: 3.5 mg/day (1/2 patch) for 2 days (D1 and D2)~  * Level 2: 7 mg/day (1 patch) for 2 days (D3 and D4)~  * Level 3: 10.5 mg/day (1.5 patch) for 2 days (D5 and D6)~  * Level 4: target dose = 14 mg/day (from D7 to discharge from hospital + 1 week or maximum 5 weeks after the start of treatment)~2. / Decrease in dose (1 week after exit from hospital or maximum 5 weeks after the start of treatment): Decrease of 3.5 mg (1/2 patch) per week (over 3 weeks maximum)"
214845623|NCT04608201|DRUG|Placebo of NICOTINE Transdermal patch|Placebo of nicotine patch administered to the same administration schedule as in the experimental arm
214287116|NCT02749071|PROCEDURE|Laparoscopic implantation surgery|Laparoscopic surgery to implant the pulse generator and bipolar lead.
214287117|NCT02749071|DEVICE|EndoStim stimulation for first six months of study|Lower esophageal stimulation
214287118|NCT02749071|DEVICE|EndoStim stimulation from Month 6 thru end of study|Lower esophageal stimulation
214287119|NCT02749071|DEVICE|Sham EndoStim stimulation for first six months of study|"EndoStim device remains off (no stimulation delivered)"
214845624|NCT02166801|BEHAVIORAL|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand \& Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
214287120|NCT05104229|DRUG|Aspirin 81Mg Ec Tab|Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
215033476|NCT05482451|DRUG|all trans retinoic acid|Our previous basic studies revealed that all-trans retinoic acid repressed pancreatic adenocarcinoma cell growth and colony formation. All-trans retinoic acid represses ADAR1, a member of interferon-stimulated genes and a negative regulator of IFNs signaling. On the other hand, all-trans retinoic acid simultaneously increases PD-L1 expression for cancer cells to evade immune surveillance. Since combination of anti-PD1 antibody and all-trans retinoic acid may block self-regulating negative feedback loops of IFNs response, this therapeutic strategy may improve outcomes of pancreatic adenocarcinoma patients.
214287121|NCT05104229|DRUG|Standard of Care|Standard of Care VTE prophylaxis
214287122|NCT06354400|OTHER|Core stabilization training|Isometric exercises of the abdominal muscles in the supine, prone, and squatting positions; isotonic exercises in the supine, prone, squatting, and side-lying positions; isotonic exercises in coordination with the extremity movements in the supine, prone, and crawling positions; and trunk rotation exercises in the sitting position will be performed. The Swiss ball will be used for dynamic exercises. It will include isometric and isotonic exercises of the abdominal muscles. Exercises will start with 3 sets of 20 repetitions, gradually increase in intensity on static and dynamic surfaces, and progress towards difficulty. Each exercise will be performed in coordination with breathing control. Breathing control will be coordinated with every exercise.
214287123|NCT03545165|DRUG|177Lu-PSMA-617|\[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)\]
214287124|NCT03545165|DRUG|177Lu-J591|\[1.35 GBq/m2 or 36.5 mCi/m2\]
214287125|NCT03545165|DRUG|68Ga-PSMA-HBED-CC|\[185 ±74MBq or 5 ±2 mCi\]
214287126|NCT01666574|OTHER|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
215033477|NCT05234216|OTHER|Informed consent|the investigator will verify the inclusion criteria, the patient's understanding of the protocol and will obtain oral informed consent
215033478|NCT05234216|PROCEDURE|Surgery|The patient will undergo surgery in accordance with standard care
214287127|NCT01666574|OTHER|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
214287128|NCT05916014|DIAGNOSTIC_TEST|Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
214287129|NCT05623098|DIETARY_SUPPLEMENT|dietary fiber nutrients|Whether to add nutrients containing dietary fiber
214287130|NCT02117648|DRUG|Abemaciclib|Administered orally
214287131|NCT02117648|DRUG|Clarithromycin|Administered orally
214287132|NCT00438984|DRUG|cyclophosphamide|Given IV
214287133|NCT00438984|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
214287134|NCT00438984|BIOLOGICAL|aldesleukin|Given IV or SC
214287135|NCT00438984|OTHER|immunohistochemistry staining method|Correlative studies
214287136|NCT00438984|PROCEDURE|biopsy|Optional correlative studies
214287137|NCT00438984|OTHER|laboratory biomarker analysis|Correlative studies
214287138|NCT00438984|OTHER|immunologic technique|Correlative studies
214287139|NCT00438984|GENETIC|polymerase chain reaction|Correlative studies
214287140|NCT04173078|BEHAVIORAL|Computerized Distress Intolerance Intervention|
214287141|NCT04173078|BEHAVIORAL|Computerized Healthy Behaviors Intervention|
214287142|NCT04821921|OTHER|No intervention|Care as usual
214287143|NCT04219553|BEHAVIORAL|Antimicrobial stewardship|The multifaceted AMS intervention includes pharmacist education, a clinical decision support tool, a parent/guardian questionnaire, and individualized monthly audit and feedback with each pharmacist.
214287144|NCT04219553|OTHER|Comparator (no intervention)|No active intervention
214287145|NCT03957720|DRUG|DMPS|Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
214287146|NCT03957720|DRUG|Penicillamine|Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
214287147|NCT03957720|DRUG|DMSA|Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
214287148|NCT03957720|DRUG|Zinc gluconate|Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
214287149|NCT05040321|DRUG|MIB-626|Participants will be randomized to either receive MIB-626 or matching placebo. The proposed intervention - targets multiple contributors to the pathology of AD; MIB-626 improves mitochondrial function, bioenergetics, and insulin sensitivity, inhibits A beta accumulation by reducing its synthesis and increasing its clearance, reduces neuroinflammation, exerts neuronal protective effects, and promotes neuronal regeneration and connectivity in preclinical models.
214287150|NCT05040321|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 1000 mg MIB-626 twice daily orally.
215033479|NCT05234216|BEHAVIORAL|Comfort scale|The patient will be evaluated, in the post-operative care unit, with a comfort scale
215033480|NCT05234216|BEHAVIORAL|Pain|The patient will be evaluated, in the post-operative care unit, with a pain scale
214287151|NCT02755558|BEHAVIORAL|Low energy density|Low energy density milk served
214287152|NCT02755558|BEHAVIORAL|High energy density|High energy density milk served
214287153|NCT02755558|BEHAVIORAL|Small portion|Small portion of milk served
214287154|NCT02755558|BEHAVIORAL|Large portion|Large portion of milk served
214287155|NCT02669732|DRUG|DS-8500a|tablets
214287156|NCT02669732|DRUG|placebo|tablets
214287157|NCT01694589|DRUG|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
214472226|NCT05707481|OTHER|Clinical Pharmacist-Led Educational Intervention|Non Pharmacological management strategies include information related to life style modification, healthy dietary habits, physical activity and stress management techniques. In contrast, pharmacological educational intervention involves disease -related information ( diabetes/hypertension sign and symptoms, risk factor, complications, self-monitoring of blood pressure/glucose, symptoms and management of hypoglycemia/hypotension etc. ) and drug related information ( prescribed drug name, indication, contraindication, adverse effects etc.) as well as importance of adherence to prescribed medication and strategies to minimize DRPs issues. These teaching sessions will be carried out with the help of verbal communication, audio visual demonstration (including charts,pictorial etc) and information leaflets. Furthermore, a copy of educational package would be given to each participant for reference and guidance.
214472227|NCT06151184|PROCEDURE|Chiropractic adjustment|6 weeks of chiropractic care, with frequency and type of procedures determined by field clinician after initial examination.
214472228|NCT06822647|PROCEDURE|Cervical Length Measurement at the Beginning of the Anatomy Survey|This intervention involves performing a transvaginal ultrasound to measure cervical length at the beginning of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment.
214472229|NCT06822647|PROCEDURE|Cervical Length Measurement at the End of the Anatomy Survey|This intervention involves performing a transvaginal ultrasound to measure cervical length at the end of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment.
214472230|NCT02413489|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
214472231|NCT06808282|OTHER|White chocolate|To determine the effects of white chocolate consumption on risk factors of cardiovascular diseases
214472232|NCT06808282|OTHER|Dark chocolate|To determine the effects of dark chocolate consumption on risk factors of cardiovascular diseases
214472233|NCT06808425|DEVICE|Intervention A|Weighted blanket
214287158|NCT00967772|DRUG|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
214287159|NCT05145530|PROCEDURE|selective anterior cervical discectomy and fusion (ACDF)|selective anterior cervical discectomy and fusion (ACDF)
214287160|NCT05145530|PROCEDURE|SNRB+ selective anterior cervical discectomy and fusion (ACDF)|US-guided selective nerve root block (SNRB) + selective anterior cervical discectomy and fusion (ACDF)
214287161|NCT02461303|OTHER|Counseling|Subjects will be counseled on the impact of KS on the reduced fertility potential, and about providing a semen sample for semen analysis. Semen analysis is the gold standard for fertility preservation in adult patients, but is only rarely considered by post-pubertal adolescent and young adult patients and their families. Only the semen analysis parameters will be used by the study for the comparison with physical and endocrine measures to assess whether spermatogenesis in these patients coincides with pubertal development. All potential frozen samples will be stored for the patient's future use, and samples will not be used for research experiments.
214472234|NCT06808425|DRUG|Intervention B|Standard treatment (melatonin)
214472235|NCT05304819|DEVICE|AchilloCordPLUS™ System Implant|AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair
215033481|NCT05234216|OTHER|Questionnaires|Evaluation of the Experience of Local/General Anesthesia
215033482|NCT02534922|BIOLOGICAL|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
215033483|NCT02943161|DIETARY_SUPPLEMENT|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
214287162|NCT04090450|RADIATION|chemo-radiotherapy|The study will not have a direct intervention. It will recruit patients who have had chemo-radiation as part of their standard of care treatment for rectal cancer.
214287163|NCT01832987|DRUG|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
214287164|NCT01887873|DEVICE|Hyaluronan Thiomer i.o. implant|
214287165|NCT00279240|DRUG|Metformin|
214287166|NCT03530098|DEVICE|BoneAgeModel|BoneAgeModel is an Artificial Intelligence tool that takes in a hand radiograph and gender, and outputs the skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
214287167|NCT05825521|OTHER|MRI|During management, patients with hydrocephalus will be subjected to flow MRI and diffusion MRI. Flow parameters and diffusion parameters will be measured and compared to those found in control subjects receiving the same type of imaging
214287168|NCT04848545|OTHER|Observational|Prenatal maternal exposure to endocrine disrupting chemicals
214287169|NCT05577481|COMBINATION_PRODUCT|sham iTBS combined with antidepressants|Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
214287170|NCT05577481|COMBINATION_PRODUCT|iTBS combined with antidepressants|Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
214287171|NCT02727023|OTHER|Osteopathic Manipulative Medicine|The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each
214287172|NCT01453114|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
214287173|NCT05520944|DRUG|ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray|Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
214287174|NCT01230905|RADIATION|PET scan and ultrasound|Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
214287175|NCT02774525|BEHAVIORAL|Reinforcement for drug & alcohol abstinence|
214287176|NCT02774525|BEHAVIORAL|Parenting intervention|
214287177|NCT02774525|BEHAVIORAL|Treatment as usual (TAU)|Outpatient substance-abuse therapy plus drug \& alcohol screening plus support for personal goal setting
214287178|NCT02660502|DRUG|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
214287179|NCT02660502|DRUG|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
214287180|NCT02660502|DRUG|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
215033484|NCT00864279|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
214287181|NCT02660502|DRUG|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
214287182|NCT00226161|PROCEDURE|Inguinal herniorrhaphy|
214287183|NCT06164678|BEHAVIORAL|OMSC|The OMSC program uses a counselling approach to assist clients with tobacco cessation. If required, nicotine replacement therapy may be offered.
214287184|NCT02695498|OTHER|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class \[9 total classes.\] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
214287185|NCT02695498|OTHER|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
214287186|NCT03791840|DIAGNOSTIC_TEST|Ultrasound evaluation|High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
214287187|NCT06478355|DRUG|Immunotherapy|Immunotherapy: intravenously, every 3 weeks for at least 6 months, or until progression, intolerance, or spontaneous withdrawal of the patient.
214287188|NCT06478355|DRUG|Chemotherapy drug|TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W
215033485|NCT00864279|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
215033486|NCT02116023|OTHER|Orange flavored beverage|
214287189|NCT06478355|RADIATION|radiotherapy|Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
214287190|NCT06505369|DRUG|Daratumumab|Daratumumab will be administered by SC injection
214287191|NCT06505369|DRUG|Bortezomib|Bortezomib will be administered by SC injection
214287192|NCT06505369|DRUG|Lenalidomide|Lenalidomide will be administered by oral route
214287193|NCT06505369|DRUG|Dexamethasone|Dexamethasone will be administered by oral route
214287194|NCT06505369|DRUG|Talquetamab|Talquetamab will be administered by SC injection
214287195|NCT06505369|DRUG|Teclistamab|Teclistamab will be administered by SC injection
214287196|NCT04686071|OTHER|PNF method|Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
214287197|NCT04686071|OTHER|Standard rehabilitation|In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
215033487|NCT00091156|DRUG|gefitinib|
214287198|NCT05675397|DIETARY_SUPPLEMENT|donor human milk|Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding
214287199|NCT05063604|DRUG|Citalopram|20 mg tablet one or twice daily for 12 weeks
214287200|NCT05063604|BEHAVIORAL|Psychotherapy|One session weekly for 12 weeks
214287201|NCT00005571|DRUG|h5G1.1-mAb|
214287202|NCT02532972|DEVICE|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
214287203|NCT01308671|DRUG|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
214287204|NCT01308671|BEHAVIORAL|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
214287205|NCT00796198|DRUG|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
214287206|NCT00796198|DRUG|Xalatan|Xalatan ophthalmic solution one drop at 10pm
214287207|NCT01606436|DRUG|LY2140023|Administered orally.
214287208|NCT01606436|DRUG|Placebo|Administered orally.
214287209|NCT01606436|DRUG|Moxifloxacin|Administered orally.
214287210|NCT00502645|DEVICE|CS-1 DECISION SUPPORT SYSTEM|
214287211|NCT02859454|DRUG|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
214287212|NCT06139029|DRUG|3% normal saline|nebulization
214287213|NCT06139029|DRUG|steroid(beclomethasone dipropionate 400 μg/day) and salbutamol with 0.9% normal saline|nebulization
214287214|NCT05391516|DIAGNOSTIC_TEST|Evaluation of shoulder problems|The developed items and Shoulder Pain and Disability Index-SPADI will be directed to the participants.
214287215|NCT01841983|OTHER|Be Well Work Well|"The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.~Overall intervention objectives:~1. Motivate individual staff members to engage in targeted health and safety behavior changes;~2. build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;~3. facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and~4. promote co-worker and supervisor support for targeted health and safety behaviors."
214845625|NCT02166801|BEHAVIORAL|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
214845626|NCT00418067|DEVICE|Endeavor|Zotarolimus-eluting stent
214287216|NCT00813735|DRUG|Eszopiclone|Eszopiclone 2mg daily at bedtime
214287217|NCT00813735|DRUG|Placebo|Placebo daily at bedtime
214287218|NCT00813735|DRUG|Escitalopram|Escitalopram 10mg or 20mg
214287219|NCT02438098|DRUG|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
214287220|NCT00673803|PROCEDURE|cataract surgery|cataract surgery with implantation of an IOL
214287221|NCT06036212|DEVICE|Robotic System|Robotic assisted Unicompartmental Knee replacement (UKA)
214287222|NCT06036212|DEVICE|Conventional|Unicompartmental Knee Arthroplasty (UKA) with conventional approach and conventional manual instrumentation
214287223|NCT05495516|GENETIC|without Intervention|without Intervention
214287224|NCT01025752|BEHAVIORAL|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
214287225|NCT01025752|BEHAVIORAL|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
214287226|NCT03626883|PROCEDURE|single-bundle, single-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with single hamstring tendon
214845627|NCT00418067|DEVICE|Cypher|Sirolimus-eluting stent
214287227|NCT03626883|PROCEDURE|single-bundle, double-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with 2 hamstring tendons
214845628|NCT00418067|DEVICE|Taxus Liberte|Paclitaxel-eluting stent
214287228|NCT04026308|OTHER|Safety Net App|The Safety Net app is an electronic version of a safety plan and it is available for download in Apple's App Store. A preview of the app is available at: https://apps.apple.com/us/app/stanley-brown-safety-plan/id695122998. This app is owned by Two Penguins Studios, LLC. It was developed in partnership with the New York State Office of Mental Health. Unlike the paper version, the Safety Net app allows participants to email a copy of their safety plan to whomever they wish. It also allows patients to dial 911 or the National Suicide Prevention Lifeline from the app.
214287229|NCT01596400|DRUG|granisetron transdermal system|patch
214845629|NCT06427044|DRUG|Anterior serratus block group|Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a single anterior serranus plane block
214845630|NCT00091286|BIOLOGICAL|HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine|
215033488|NCT00091156|PROCEDURE|adjuvant therapy|
214287230|NCT01596400|DRUG|Granisetron IV|IV
214287231|NCT05938972|BIOLOGICAL|Mepolizumab|Monoclonal antibodies
214287232|NCT05177978|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine containing supplement (2 x chewable gummies/day; Total daily dose of 100 mg elemental phosphatidylserine)
214287233|NCT05177978|DIETARY_SUPPLEMENT|Placebo|Placebo comparator (2 x chewable gummies/day, matched to shape and color without active ingredient)
215033489|NCT01657188|DEVICE|Cheyne-Stokes respiration by adaptive servoventilation|
215033490|NCT00836706|DRUG|clarithromycin|500 mg Tablet
215033491|NCT00836706|DRUG|BIAXIN®|500 mg Tablet
214287234|NCT01625702|DEVICE|CellSearch® CTC kit|"Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
214287235|NCT02528071|OTHER|Diaphragmatic endurance test|This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
214287236|NCT00905073|DRUG|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
214287237|NCT01417234|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
214287238|NCT03550898|DIAGNOSTIC_TEST|Dynamic Ultrasonography|Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
214287239|NCT00023764|DRUG|bortezomib|Given IV
214287240|NCT04150393|DRUG|MaaT033 capsule|Oral capsule
214287241|NCT04757870|OTHER|frequency|Macro-scale risk factors for the frequency of and mortality of infection
214287242|NCT01656473|OTHER|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
214287243|NCT01656473|OTHER|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
214287244|NCT04216771|DRUG|Idarubicin|Idarubicin 10mg/m²/day, D1 (IV)
214287245|NCT04216771|DRUG|ID cytarabine|Cytarabine 1.5g/m² /12h, D1-D3 (IV)
214287246|NCT05833854|OTHER|Virtual reality glasses group|It is suggested that the use of virtual reality glasses during the injection will positively affect the pain and fear levels in children who received penicillin injection in the pediatric emergency department where the study was conducted.
214287247|NCT05833854|OTHER|Manual pressure group|In the pediatric emergency department where the study was conducted, pressure will be applied to the area to be injected for 10 seconds before the injection procedure in children who received penicillin injection. Pressing with the thumb of the hand, which will be passive in the pressing application, will be understood by the whitening of the nail, and thus pressure will be applied to the skin. It is suggested that it can positively affect pain and fear levels.
214287248|NCT03577691|OTHER|Training for use of web based Decision Aid|Subjects will be guided during a 30 minutes training session to use the website
214287249|NCT03577691|OTHER|No training for use of web based Decision Aid|Subjects will not be guided during a 30 minutes training session to use the website
214287250|NCT03577691|OTHER|Pretest surveys and posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
214287251|NCT03577691|OTHER|Only posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
214287252|NCT04368767|BEHAVIORAL|Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, usually in the afternoon. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. After pre-intervention measures of axillary temperature, heart rate, respiratory rate, and oxygen saturation by pulse oximetry (SPO2) are obtained; cotton balls placed in the diaper for urine collection will be removed and stored in an appropriate container. Salivary oxytocin and cortisol will be collected per protocol below. Mothers will be requested to sit in reclining chairs with a front opened blouse or hospital gown. Infants will be removed from the incubator and placed naked except for a diaper and hat directly onto the skin between the mother's breasts and covered with a blanket. All infants will be monitored. After the two hours of SSC is completed, the infant will be returned to the incubator.
214287253|NCT01528488|OTHER|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
214287254|NCT01528488|OTHER|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
214287255|NCT05459675|OTHER|Very low-calorie diet|Meal replacement (800 kcal/day, protein 90 g/day)
214472236|NCT06256939|OTHER|Therapy BRIDGE Program|A standardized education and coaching intervention will be developed to promote optimal neurodevelopmental outcomes through caregiver empowerment. This pilot study will enroll up to 15 infants with IVH and their caregivers during their NICU stay. These infant-caregiver dyads will receive up to 10 sessions utilizing the Therapy BRIDGE program over a four-month period that spans the hospital to home transition.
214472237|NCT06809413|DRUG|Sitafloxacin|Study medication: Sitafloxacin 100mg QD for 14 days.
214472238|NCT05589792|DRUG|Placebo oral capsule|Placebo before sleep for 3 nights before the study (inclusive)
214472239|NCT05589792|DRUG|Acetazolamide|Acetazolamide 250 mg 3 nights before the study at bedtime, Acetazolamide 500 mg for 2 nights before the study (inclusive) at bedtime.
214472240|NCT02257060|PROCEDURE|Endocardial Ablation|
214472241|NCT00223145|RADIATION|Radiotherapy 70 Gy|Radiotherapy to the prostate
214472242|NCT00223145|RADIATION|Radiotherapy 76 Gy|Radiotherapy to the prostate
214472243|NCT00223145|DRUG|Androgen blockade|Duration : 6 months
215033492|NCT03275987|BEHAVIORAL|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
215033493|NCT03275987|BEHAVIORAL|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
214287256|NCT05459675|PROCEDURE|Bariatric surgery|Bariatric surgery will be performed by single surgeon at Ramathibodi Hospital Mahidol University, Thailand. Postoperative diet progression according to the current guideline will be prescribed from early post-op period to 1 year after surgery
214287257|NCT02063360|DRUG|BMS-663068|BMS-663068
214287258|NCT02063360|DRUG|Darunavir (DRV)|Darunavir (DRV)
214287259|NCT02063360|DRUG|Ritonavir (RTV)|Ritonavir (RTV)
214287260|NCT02063360|DRUG|Etravirine (ETR)|Etravirine (ETR)
214287261|NCT00877253|DRUG|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
214287262|NCT00877253|DRUG|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
214287263|NCT00877253|DRUG|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
214287264|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using total-breath method
214287265|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using standard method
214287266|NCT05602181|BEHAVIORAL|ALL Phonics Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech.
214287267|NCT05602181|BEHAVIORAL|ALL Sight Word Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech. This group will only use the sight word lessons, as well as the library for sight word books. No phonics instruction will be provided through the app.
214287268|NCT06374641|DIETARY_SUPPLEMENT|Mitochondrial Substrate Supplement|Mitochondrial Substrate supplement, 2xdaily 65 mL drink
214845631|NCT04346940|OTHER|Telerehabilitation|15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.
214287269|NCT06374641|DIETARY_SUPPLEMENT|Placebo Supplement|Placebo supplement, 2xdaily 65 mL drink
214287270|NCT00254449|DRUG|NGX-4010|
214287271|NCT05524155|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
214287272|NCT05524155|DRUG|Sintilimab|200mg IV d1,Q3W
214287273|NCT05524155|DRUG|Regorafenib|80mg/day,PO,QD,d1～21,Q4W
214287274|NCT01596868|DRUG|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
214287275|NCT01596868|DRUG|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
214287276|NCT06254404|DRUG|Low dose protamine|Administration of 70% of the normal dose of protamine
214287277|NCT02245308|DRUG|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
214287278|NCT02245308|BEHAVIORAL|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
214287279|NCT02245308|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
214287280|NCT02245308|DRUG|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
214287281|NCT02245308|DRUG|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
214287282|NCT03661632|DRUG|BMS-986310|Specified dose on specified days
214287283|NCT03661632|BIOLOGICAL|Nivolumab|Specified dose on specified days
214287284|NCT02687945|PROCEDURE|Outpatient physiotherapy|
214287285|NCT02687945|PROCEDURE|Self-guided physiotherapy|
214287286|NCT05557799|RADIATION|Photobiomodulation|The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
214287287|NCT05557799|RADIATION|Placebo Photobiomodulation|The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
214287288|NCT02407704|DRUG|Venlafaxine XR|
214287289|NCT02407704|OTHER|Aerobic Exercise|
214287290|NCT02407704|DRUG|Lorazepam|Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
214287291|NCT03687489|DEVICE|Abdominal Aortic Aneurysm Stent Graft System|Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
214287292|NCT05318599|DEVICE|Lung auscultation|Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
214287293|NCT05318599|DEVICE|Lung ultrasound|Lung ultrasonography
214287294|NCT05318599|OTHER|Quality of Life's questionnaires|Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
214287295|NCT05318599|DIAGNOSTIC_TEST|Pulmonary functional tests|Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
214287296|NCT03747328|DRUG|ABI-009|nanoparticle albumin bound sirolimus
214287297|NCT06039826|DRUG|LY3437943|Administered SC.
214287298|NCT06039826|DRUG|Ethinyl Estradiol|Administered orally
214287299|NCT06039826|DRUG|Drospirenone|Administered orally
214287300|NCT05718128|PROCEDURE|Endocardiomyocardial biopsy|Endocardiomyocardial biopsy
214287301|NCT01806948|DRUG|Ramosetron|
214287302|NCT01336920|DRUG|carfilzomib|Given IV
214287303|NCT03703765|DEVICE|lower limb volume estimation|"The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort."
214287304|NCT03117101|DRUG|Lucitanib|
214287305|NCT02093845|DEVICE|Biomatrix NeoFlex coronary stent|Percutaneous coronary intervention involving use of stent
214287306|NCT02093845|DEVICE|SYNERGY stent|Percutaneous coronary intervention involving use of stent
214287307|NCT03557463|DIETARY_SUPPLEMENT|Dairy protein|A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
214287308|NCT03944954|DEVICE|Placebo TMS Sham|Individuals will receive placebo dose and sham TMS.
214287309|NCT03944954|DRUG|Marinol 10Mg Capsule TMS Sham|Individuals will receive 10mg dose and sham TMS.
214287310|NCT03944954|DRUG|Marinol 30Mg Capsule TMS Sham|Individuals will receive 30mg dose and sham TMS.
214287311|NCT03944954|DEVICE|Placebo TMS Real|Individuals will receive placebo and real TMS.
214287312|NCT03944954|OTHER|Marinol 10Mg Capsule TMS Real|Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
214287313|NCT03944954|OTHER|Marinol 30Mg Capsule TMS Real|Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
214287314|NCT04334408|DRUG|Fremanezumab|Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
214287315|NCT04334408|DRUG|Placebo|Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
214287316|NCT04426981|BEHAVIORAL|Behavioral Activation|Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities. In the first session, participants will begin to identify domains of their life which are important to them. In the second session, participants will be assisted in creating an action plan to engage in more activities in one or more domains of importance. In session 3-8, participants will be assisted in problem solving any challenges they encountered in implementing their previous action plan and will develop a new action plan. The intervention will continue until participants achieved three action plans or reach the eight-session limit, whichever comes first.
214287317|NCT04334551|DRUG|Doravirine|switches from etravirine to doravirine, in experienced HIV patients
214287318|NCT02356744|OTHER|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
214287319|NCT03209687|DRUG|human menopausal gonadotropin|Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
214287320|NCT04540029|OTHER|Maternal stress|Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.
214287321|NCT05350111|BEHAVIORAL|lifestyle education|education on healthy lifestyle through group sessions and telemedicine tools
214287322|NCT00424671|DRUG|Licarbazepine|
214287323|NCT05564429|DRUG|18F-SF12051|Injected intravenously followed by PET scanning
214287324|NCT00469183|DRUG|Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%|Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
214287325|NCT02480439|DRUG|TAK-648 Tablet|Tak-648 tablet
214287326|NCT02480439|DRUG|TAK-648 Oral Solution|TAK-648 oral solution
214287327|NCT02268084|DEVICE|Magnetic EEG/ECG-guided Resonance Therapy|A coil delivers a pulsed magnetic field to the cortex of the brain
214287328|NCT02268084|DEVICE|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
214287329|NCT05227027|BEHAVIORAL|Game Module|Receive access to the the game module through the free, 'Smoke Free' smartphone application
214287330|NCT05227027|BEHAVIORAL|Smoke Free smartphone application|Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
214287331|NCT03415217|OTHER|Neighbourhood Team Development Program|The Neighbourhood Team Development Program aims to both enhance team development and resident centredness in LTC. The Program has three components, designed to modify the physical environment, the organization and delivery of services, and the alignment of staff members, to function independently and collaboratively in providing resident-centred care.
214845632|NCT04346940|OTHER|Exercise brochure|The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
214287332|NCT00114946|DRUG|Avastin|
214287333|NCT01890551|OTHER|Dynamic kine-mri|Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
214287334|NCT03817307|DIAGNOSTIC_TEST|USPIO-enhanced MRI|The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.
214287335|NCT03342105|PROCEDURE|Cettum|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Moxibustion will be provided at 11 standard acupuncture points: EX-HN3, and both EX-HN8, LI20, LI4, GB2, ST36. A specifically designed device, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea), will be used to treat patients in this group. The expected total time of each treatment session will be 15 min.
214287336|NCT03342105|PROCEDURE|Acupuncture|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Acupuncture will be provided at same points in the Cettum group. Sterile stainless steel disposable acupuncture needles (0.25X30mm, DongBang Acupuncture Inc, Korea) will be used to treat patients in this group. The needles will be kept in place for 15 min.
214287337|NCT04702334|DRUG|Hyaluronic Acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
214287338|NCT04702334|DRUG|Lidocain|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
214287339|NCT03170401|DIETARY_SUPPLEMENT|Protein supplementation|enteral protein supplementation
214287340|NCT03170401|OTHER|Standard enteral nutrition|Standard enteral nutrition.
214287341|NCT01115634|BIOLOGICAL|Fibroblast|20 million cell in three injection
214287342|NCT01115634|BIOLOGICAL|fibroblast and gel|20 million cell in three injection plus filler
214287343|NCT02589184|OTHER|Hypergravity|the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
214287344|NCT02589184|OTHER|isometric load|at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
214845633|NCT01304186|BEHAVIORAL|Tailored Information|The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
214845634|NCT02421016|DEVICE|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
214845635|NCT02421016|DEVICE|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
214845636|NCT05678517|DRUG|Anti-VEGF|intravitreal ranibizumab or intravitreal aflibercept
214845637|NCT05371639|DRUG|Tian Ma Bian Chun Zhi Gan Tablets|Tian Ma Bian Chun Zhi Gan Tablets, 0.1g per pill which contains 14mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
214845638|NCT05371639|DRUG|Placebo|Placebo identified to Tian Ma Bian Chun Zhi Gan, 0.1g per pill which contains 0mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
214845639|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 day before ablation|24 hours Holter EKG - 1 day before ablation
214287345|NCT02589184|OTHER|normal gravity|the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
214287346|NCT01598012|DRUG|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
214287347|NCT01598012|DRUG|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
214472244|NCT04958486|DRUG|5-Azacytidine and trastuzumab infusion|Patients will receive once weekly 10 mg intraventricular 5-Azacytidine infusions for six consecutive weeks followed by observation in the infusion suite for a minimum of 30 minutes and once weekly 21 mg intraventricular trastuzumab infusions for six consecutive weeks followed by observation for a minimum of 2 hour after each infusion for the first 2 infusions. During this monitoring period, temperature, blood pressure, heart rate, and oxygen saturation will be measured. Patients will also have a neurological examination performed to observe for neurological changes. All patients will undergo an MRI of the brain and total spine with and without gadolinium within 7 days after the final 5-AZA and trastuzumab infusion to determine treatment response and to assess for any signal changes in the brain or spine caused by the infusions and they will have a 30 day and a 90 day follow-up assessment by telephone or in person for assessment of outcome measures and safety
214845640|NCT06276296|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation using radiofrequency ablation
214845641|NCT06276296|PROCEDURE|Pulsed field ablation|Pulmonary vein isolation using pulsed field ablation
215033494|NCT03275987|BEHAVIORAL|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
215033495|NCT02898688|BEHAVIORAL|Control Site|Control sites will continue with their standard practice regarding discussing vaccines with their patients.
214287348|NCT06066684|OTHER|n/a, observational|n/a, observational study
214845642|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 month after ablation|24 hours Holter EKG 1 month after ablation
214287349|NCT04954703|OTHER|Muscle energy technique of gluteus maximus and tensor fascia lata|it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.
214287350|NCT04954703|OTHER|Myofascial release of iliotibial band syndrome|Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
214287351|NCT03932721|DRUG|Evolocumab 140 MG/ML|Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
214287352|NCT00248989|DRUG|Dehydroepiandrosterone|3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
214287353|NCT00248989|DRUG|Placebos|3.0 ml of placebo cream applied on the skin twice daily.
214287354|NCT03537898|OTHER|Lactated Ringer's|Lactated Ringer's will be used whenever an isotonic crystalloid is ordered
214287355|NCT03537898|OTHER|Normosol|Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
214287356|NCT02231723|DRUG|BBI608|Administered continuously twice daily with doses separated by 12 hours
214287357|NCT02231723|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
214287358|NCT02231723|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
214287359|NCT02231723|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
214287360|NCT02231723|DRUG|Leucovorin|Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
214287361|NCT02231723|DRUG|Irinotecan|Arm B: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
214287362|NCT02231723|DRUG|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
214287363|NCT02231723|DRUG|MM-398|MM-398 70 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
214287364|NCT01233440|BIOLOGICAL|Recombinant Coagulation Factor IX Albumin Fusion Protein|Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
214287365|NCT01233440|BIOLOGICAL|Plasma derived FIX [pdFIX]|Single dose of 50 IU/kg of reference product, given as intravenous infusion
214287366|NCT01709890|DEVICE|YO2(R) catheter|
214287367|NCT03008681|DEVICE|Andresen functional removable orthodontic appliance|Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
214287368|NCT04542785|OTHER|Rate control|Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
214287369|NCT02214524|DEVICE|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
214287370|NCT03648268|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation"
214287371|NCT04334161|COMBINATION_PRODUCT|Administration of glucose and controlled induction of hypoglycaemia.|Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
214287372|NCT04405947|PROCEDURE|Reverse Shoulder Arthroplasty|implantation of a reversed shoulder prostheses through two different surgical approaches
214287373|NCT02911753|OTHER|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
214287374|NCT02911753|OTHER|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
214287375|NCT02911753|OTHER|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
214287376|NCT01503944|DRUG|18F-AV-133|185 MBq
214287377|NCT01503944|DRUG|18F-AV-45|185-370 MBq
214287378|NCT03504150|BEHAVIORAL|SPHERE|Comprehensive Internet-based CBT program with no human support
214287379|NCT03504150|BEHAVIORAL|PRISM|Brief Internet-based CBT program with no human support
214287380|NCT04464915|OTHER|Isopropyl alcohol swab|Treatment will be administered by taking one deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes or every 20 minutes for a total of one hour.
214287381|NCT03334448|DRUG|LY900014-U200|Administered SC
214287382|NCT03334448|DRUG|LY900014-U100|Administered SC
214287383|NCT05673512|COMBINATION_PRODUCT|Injection of IAH0968 + CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
214287384|NCT05673512|COMBINATION_PRODUCT|PLACEBO+CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
214287385|NCT02402439|DRUG|Islet cells|Transplantation of islets into the gastrointestinal submucosa
214287386|NCT02402439|PROCEDURE|Islet transplantation into the gastrointestinal submucosa|Transplantation of islets into the gastrointestinal submucosa
214287387|NCT03668912|BEHAVIORAL|Guided participation discharge programme|A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
214287388|NCT06189651|DEVICE|wrist splint|The same type of wrist splint to be used for at least 8 hours at night for 4 weeks, to be worn in a neutral position and in accordance with the wrist as described in previous studies to restrict movement in the wrist. Patients who did not sleep for 8 hours were asked to complete 8 hours of wrist splint use before going to sleep or after waking up.
214287389|NCT06189651|PROCEDURE|5% dextrose injection using USG-guided nerve hydrodissection method|2 ml each of 5% dextrose injection was administered once at the proximal wrist level above the median nerve separating the median nerve from the flexor retinaculum and below the median nerve separating the median nerve from the flexor tendons by nerve hydrodissection method in the transverse inplane plane under ultrasound guidance. After the application, the spread of the injectate was observed by looking longitudinally at the median nerve.
214287390|NCT02834208|OTHER|MRI (Magnetic resonance imaging)|
214287391|NCT02834208|GENETIC|Polymorphism (SNP in DNA)|
214287392|NCT02834208|GENETIC|quantitative measures of mRNA|
214287393|NCT02834208|OTHER|Neuropsychological assessment|
214287394|NCT01504945|OTHER|RBC transfusion|1 bag of packed red blood cells
214287395|NCT01504945|OTHER|Normal saline infusion|500 mL of normal saline infusion
214287396|NCT03648060|DEVICE|Digital kinematic biofeedback system|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
214287397|NCT04919850|DIETARY_SUPPLEMENT|Saccharomyces boulardii and SOD|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
214287398|NCT04919850|COMBINATION_PRODUCT|Placebo|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
214287399|NCT04746261|BEHAVIORAL|ASSIP + treatment as usual|"ASSIP:~First session: Videotaped narrative interview focusing on the background to the suicidal crisis.~Second session: Video playback. The patient and the therapist watch the recorded interview together, stopping the film regularly to add information. The patient is given a psychoeducational text to read and comment on as homework.~Third session: Compilation of a written case formulation of the individual's vulnerability and triggering events that preceded the suicidal crisis. Individual preventive measures are developed by the patient and the therapist together and written down in a document that the patient keeps and which is attached to the patient's medical record.~Fourth session (optional): Mini-exposure.~Standardized letters: The therapist contacts the patient by letter during two years, every three months the first year and every six months the second year.~Treatment as usual: As described bellow"
214287400|NCT04746261|OTHER|Treatment as usual and patient safety|"All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records."
214287401|NCT04940689|DRUG|Dexmédétomidine 0.5 g/kg + lidocaine 1.5 mg/kg|The patient will be anesthetized with Dexmedetomidine 0.5 g / kg + lidocaine 1.5 mg / kg for the induction instead of morphin.
214287402|NCT04940689|DRUG|Remifentanil|The patient will be anesthetized with morphin.
214287403|NCT02684266|DRUG|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
214287404|NCT03613012|DIAGNOSTIC_TEST|Pain index|Record the patients' EEG and extract pain index before and after pain treatments
214287405|NCT03775629|DRUG|Polmacoxib and Tramadol combination|Tramadol hydrochloride , Polmacoxib
214287406|NCT03775629|DRUG|Polmacoxib|Polmacoxib
214287407|NCT03775629|DRUG|Tramadol hydrochloride|Tramadol hydrochloride (HCl)
214287408|NCT01683383|DEVICE|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
214287409|NCT01683383|OTHER|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
214287410|NCT05846204|BEHAVIORAL|Progressive Muscle Relaxation|"The PMR exercise, which includes the systematic relaxation of the main muscle groups of the body aimed at physical and psychological relaxation, was applied twice a day, every weekday, for eight weeks.~DB exercises training was given to the patients in this group individually by face-to-face interview. During the application, the importance of deep and comfortable breathing was explained and correct breathing technique was taught."
214287411|NCT05846204|BEHAVIORAL|Deep Breathing Exercise Group-DBE|Breathing exercise is an exercise to improve breathing and functional performance. deep breathing exercise; It is a nursing intervention that helps to increase the function of respiratory muscles and improve ventilation and oxygenation.
214287412|NCT04081974|OTHER|Distal leg perfusion|On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
214845643|NCT04743817|DEVICE|OtoSet - Ear Cleaning System|Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
214287413|NCT05204238|DIAGNOSTIC_TEST|Transthoracic Echocardiography|LV dimensions, LV mass and indices of LV function LA area and volume Indices of diastolic function (E/A ratio, E/e' ratio) Heart valve assessment according to GL RV dimensions and indices of RV function PAPs (RV-RA gradient and vena cava dimensions and collapsibility) B-lines at lung ultrasounds (comet lung score) Speckle Tracking analysis of LV (GLS), LA (PALS) and RV (LS of free wall) Optional 3D analysis of left and right ventricle
214287414|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).
214287415|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)|Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).
214287416|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)|Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).
214287417|NCT06068478|DRUG|Qingzhu Granules|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
214287418|NCT06068478|DRUG|Qingzhu Granules Placebo|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
214287419|NCT02626546|PROCEDURE|Major surgical procedure|observation of postoperative outcomes
214287420|NCT05362097|OTHER|The reliability and validity of the Chinese version of CC-QoL|Cc-qol, LCQ, and VCD were repeated 1-2 times before and 1-13 weeks after treatment.
214287421|NCT00855920|DRUG|Rilonacept|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
214287422|NCT00855920|DRUG|Indomethacin|Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
214287423|NCT00855920|OTHER|Placebo (for Indomethacin)|Placebo (for Indomethacin) orally TID for 12 days.
214287424|NCT00855920|OTHER|Placebo (for Rilonacept)|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
214287425|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
214287426|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
214287427|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
214287428|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
214287429|NCT05886829|COMBINATION_PRODUCT|Chlorpheniramine Maleate 0.4% Nasal Spray|Chlorpheniramine Maleate 0.4% Nasal Spray
214287430|NCT05886829|COMBINATION_PRODUCT|Placebo|Placebo nasal spray
214287431|NCT03262909|DEVICE|GelrinC|Patients will undergo GelrinC implantation.
214287432|NCT03262909|OTHER|Microfracture historical control arm|Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
214287433|NCT05409456|OTHER|mild aerobic exercise|mild aerobic exercise given to group A on treadmill
214287434|NCT05409456|OTHER|moderate aerobic exercise|moderate aerobic exercise given to group B on treadmill
214287435|NCT04603690|DIETARY_SUPPLEMENT|Complementary therapy|A daily supplementation of 168 mg curcumin, 260 mg quercetin and 360 IU of vitamin D3 (cholecalciferol) for 14-days
214287436|NCT04603690|DRUG|Standard of care|This arm will receive standard of care as per the hospital guidelines
214287437|NCT04891874|RADIATION|Stereotactic radiotherapy|Radiation using stereotactic radiotherapy device.
214287438|NCT01845493|DIETARY_SUPPLEMENT|Alpha Sprout Homogenate|Alpha Sprout Homogenate
214287439|NCT01845493|DIETARY_SUPPLEMENT|Sulforaphane Homogenate|Active
214287440|NCT05639426|BEHAVIORAL|Culturally Responsive Practices (CRP)|The CRP component of the intervention targets pedagogy, curriculum, and potential teacher biases and discriminatory behavior. This component will consist of two intensive 4-hour workshops delivered by Morton and Billingsley in each school's first intervention year as well as one-hour annual boosters (Backpacks for Success and Culturally Relevant Pedagogy). All teachers and school administrators will participate in the workshops. The purpose of Backpacks for Success is to increase participants' awareness of structural racism, empathy for students, and motivation to change, while identifying equity targets and strategies to reach those targets. Culturally Relevant Pedagogy comprises classroom based strategies to promote equity, including use of culturally responsive curriculum, language, attitudes, and actions, with the goal of reducing interpersonal and cultural racism. Ongoing group coaching sessions will provide a space for peer support and learning around increasing CRP.
214845644|NCT01710124|OTHER|Financial incentives|
214845645|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
214845646|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
214845647|NCT03692091|PROCEDURE|Subacromial Injection|Injection in to subacromial space in the shoulder from anterior portal
214845648|NCT02993419|DRUG|Bacillus licheniformis Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
214845649|NCT02993419|OTHER|placebo Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
214845650|NCT01287455|DRUG|"Vitamin D3 as BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
214845651|NCT01287455|OTHER|placebo|drops, 70 placebo drops, once weekly for 6 weeks
214845652|NCT05108506|BEHAVIORAL|No Strict need to void following surgery|Certain patient will be randomized without a strict need to void prior to discharge following surgery.
214845653|NCT05108506|BEHAVIORAL|Strict need to void following surgery|Certain patient will be randomized with a strict need to void prior to discharge following surgery.
214287441|NCT05639426|BEHAVIORAL|Culturally-Responsive Schoolwide Positive Behavior Interventions and Supports (C-SWPBS)|We will implement SWPBS according to the equity-focused framework established by the Center on PBIS, with an increased emphasis on community integration. SWPBS involves creating a school team of 6-10 people, including at least one administrator, teachers, and staff members. We will include at least three community stakeholders on each C-SWPBS team to integrate the culture of the community, reducing institutional and cultural racism. Community stakeholders may be parents or other invested members of the local community not employed by the school district. The school climate specialists serve on the C-SWPBS team and provide consultation for the management of violence incidents and mental health concerns.
214287442|NCT02496611|DRUG|Weight loss with pharmacotherapy|Participants randomized to the drug intervention group will receive Exenatide extended-release.
214287443|NCT02496611|DRUG|Weight loss without pharmacotherapy|Participants randomized to the placebo group will receive a placebo.
214287444|NCT04226001|OTHER|Quality of life questionnaire|Quality of life questionnaire
214287445|NCT02551978|OTHER|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
214287446|NCT02850965|DRUG|BI 695501|
214287447|NCT02850965|DRUG|Humira|
214287448|NCT02152033|BEHAVIORAL|Home-based Continuing Care|All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
214287449|NCT02152033|BEHAVIORAL|Services as Usual|Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
214287450|NCT01767155|DRUG|AEZS-108 / zoptarelin doxorubicin|267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
214287451|NCT01767155|DRUG|doxorubicin|60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
214287452|NCT03682666|DEVICE|Kinesiotaping|Kinesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
214287453|NCT03682666|BEHAVIORAL|modified Constraint Induced Movement Training|A 2-hour time period would be arranged to constraint patient's unaffected hand by using a bandage by a therapist. During this two hours, patients would not be allowed to use this unaffected to do any activity, so that they will need to use the affected hand. The caregivers would also be educated to provide less help if it is not necessary. This intervention would be executed two hours a day for five days per week, for three weeks.
214845654|NCT03696043|OTHER|Axium Steatlh Image Guidance|The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
214287454|NCT03682666|DEVICE|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
214845655|NCT03696043|OTHER|EVD placement|A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
214845656|NCT01601938|DIETARY_SUPPLEMENT|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
214845657|NCT01601938|DIETARY_SUPPLEMENT|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
214845658|NCT05730452|BEHAVIORAL|Risk-stratified discharge and post-discharge care|"Interventional intensity is based on predicted risk. Predicted risk based on previously developed prediction algorithms.~Low risk: receive discharge education and counselling only; Moderate risk: Discharge education and counselling + 1 post-discharge follow-up referral at day 7; High risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14); Very high risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14, D28)"
214845659|NCT05375890|OTHER|no intervention|Narcolepsy patients in Russia gathered according to criteria.
214845660|NCT03993327|BIOLOGICAL|Iodine I 124 Monoclonal Antibody M5A|Given IV
214287455|NCT02788357|DRUG|Atomoxetine|Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
214287456|NCT02788357|DRUG|Placebo|Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
214287457|NCT02015871|DRUG|Degarelix|
214287458|NCT05954806|DRUG|Antivenom Snakes|No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
214287459|NCT00480298|DRUG|Administration of oral methylprednisolone|
214287460|NCT00691821|OTHER|Standard Dressings|Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
214287461|NCT00691821|DEVICE|Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])|Participants will receive negative pressure wound therapy.
214287462|NCT01780818|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
214287463|NCT01780818|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
214287464|NCT01780818|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
214287465|NCT05466877|DRUG|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
214287466|NCT05466877|DRUG|Placebo|MG-K10 Humanized Monoclonal Antibody Injection
214287467|NCT00371137|DRUG|Xyrem®|two doses
214287468|NCT00371137|DRUG|Placebo|Oral Solution
214845661|NCT03993327|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214845662|NCT01953094|PROCEDURE|Screening Anal Pap Smear - No High Resolution Anoscopy|
214845663|NCT01953094|PROCEDURE|Screening Anal Pap Smear - With High Resolution Anoscopy|
214845664|NCT02323802|BEHAVIORAL|educational group intervention|
214845665|NCT02323802|BEHAVIORAL|prescriptive diet|
214287469|NCT00536198|DRUG|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
214287470|NCT00536198|DRUG|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
214287471|NCT02013791|DRUG|Vehicle|Vehicle of cyclosporine administered as per protocol
214287472|NCT02013791|OTHER|Sham|Sham administered to non-study eye as per protocol on Day 1
214287473|NCT02013791|DRUG|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
214287474|NCT02923960|OTHER|Standard ONS|One serving (237 ml) standard oral nutritional beverage
214287475|NCT02923960|OTHER|Diabetes specific ONS 1|One serving (237 ml) diabetes oral nutritional beverage
214287476|NCT02923960|OTHER|Diabetes specific ONS 2|One serving (296 ml) diabetes oral nutritional beverage
214287477|NCT03798483|OTHER|Individualised exercise|The intervention will be comprised of up to 6, one-to-one physiotherapy sessions, over a maximum duration of 3 months. 1 or 2 extra sessions are allowed if deemed essential by the participant's physiotherapist. Less than 6 physiotherapy sessions can be agreed with the participant if they have achieved their goals. Throughout this time participants will be required to perform an exercise programme a minimum of 3 times per week. The exercise programme aims to increase leg muscle strength and facilitate a return to the participant's usual activities. It may include hopping and change of direction tasks if these are activities the participant would normally do. Behavioural change techniques to increase participant adherence to the exercise programme will also be used.
214845666|NCT00193973|DRUG|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
214845667|NCT00193973|RADIATION|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
214845668|NCT03705871|DEVICE|Differential Expansion|Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
214287478|NCT00450684|DEVICE|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
214287479|NCT00450684|DEVICE|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
214287480|NCT01678430|DRUG|Ofatumumab|
214287481|NCT01678430|DRUG|Chlorambucil|
214845669|NCT03705871|DEVICE|Fan-Fype Expander|Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
214845670|NCT05680792|DRUG|Nitazoxanide|1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
214287482|NCT01678430|DRUG|Bendamustine|
214287483|NCT03425747|DRUG|Calcium Carbonate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
214287484|NCT03425747|DRUG|Calcium Citrate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
214287485|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
214287486|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
214287487|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
214287488|NCT00632242|DRUG|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
214287489|NCT00632242|DRUG|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
214287490|NCT03900351|PROCEDURE|Wii fit protocol of virtual reality games|the Wii fit session by standing on the Wii fit board with bare feet, hands on hips and both eyes open. Pretest on Wii fit was done to make the subject familiar with the board and tasks of weight shift .
214287491|NCT03900351|PROCEDURE|Regular exercise rehabilitation protocol|It will be according to the criterion of Adams et al. (2012).
214287492|NCT02231333|DRUG|S-adenosylmethionine (SAMe)|
214287493|NCT02231333|DRUG|pentoxiphylline (PTX)|
214287494|NCT06451601|DEVICE|Intermittent hypoxia-hyperoxia therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, occupation, environment, body mass index, nutritional status, abdominal circumference, hip circumference, smoking, alcohol. Also, the patients performed a 6-minute walking test.~Other Names:~* Hydrokinetotherapy~* Hydrothermotherapy~* Electrotherapy~* Massage therapy~* Kinetotherapy"
214287495|NCT01377532|DRUG|131 I-Metaiodobenzylguanidine (131 I-MIBG)|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions. A radiation safety officer will instruct the patient, family, and caretakers about specific UCSF radiation safety guidelines for both hospitalization and discharge.
214287496|NCT03902288|OTHER|Fresh pomegranate juice|Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG \< 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
214287497|NCT00189150|DRUG|Mycophenolate mofetil|
214287498|NCT00189150|DRUG|Valganciclovir|
214287499|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
214472245|NCT04247802|OTHER|Backwards Walking (BW) programme|A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
214287500|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
214287501|NCT06208033|DRUG|SMET12|"1. chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
214845671|NCT05680792|DRUG|Atazanavir/ritonavir|300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
214287502|NCT02336971|BEHAVIORAL|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
214287503|NCT02336971|BEHAVIORAL|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
214287504|NCT00848471|DEVICE|Quark RMR|Quark RMR calorimeter (Cosmed)
214845672|NCT05220891|OTHER|Paracentesis|Paracentesis from ascitic patient
214845673|NCT00521482|DRUG|Temozolomide|
214287505|NCT00848471|DEVICE|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
214287506|NCT04581161|DEVICE|Life2000® Ventilator|"POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."
214287507|NCT04856189|BIOLOGICAL|Pembrolizumab|Given IV
214287508|NCT04856189|DRUG|Selinexor|Given PO
214287509|NCT06404502|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants;~PRISMA has four sessions."
214287510|NCT02742480|DRUG|Dabigatran|
214287511|NCT02742480|DRUG|Acenocoumarol|
214287512|NCT03899571|DRUG|Oseltamivir Oral Capsule for 5 days post-exposure|Patients will receive oseltamivir for 5 days after last influenza exposure.
214287513|NCT03899571|DRUG|Oseltamivir Oral Capsule for 10 days post-exposure|Patients will receive oseltamivir for 10 days after last influenza exposure.
214287514|NCT03312478|DRUG|Blood draw for insulin auto-anti body tests*|"Pharmaceutical form: N/A~Route of administration: N/A"
214287515|NCT01202292|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
214287516|NCT05881928|DRUG|Sodium Valproate 500 Mg Prolonged-Release Oral Tablet|sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :
214845674|NCT00521482|DRUG|Temozolomide plus Thalidomide|
214287517|NCT05881928|DRUG|Lamotrigine|lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .
214287518|NCT05881928|DEVICE|E.E.G|device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
214287519|NCT03502980|DEVICE|Bard PowerPICC|PICC Insertion
214287520|NCT03502980|DEVICE|Bard PowerMidline catheter|Midline Insertion
214845675|NCT00037531|DRUG|Sirolimus (RAPAMUNE)|
214287521|NCT02784275|DRUG|Cyclo-Z|
214287522|NCT02784275|DRUG|Placebo|
214287523|NCT00640601|DRUG|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
214287524|NCT04229563|DEVICE|AURYON™ System|"The AURYON™ System consists of two sub-units: 1) a single use catheter (AURYON™ catheter); and 2) a laser system."
214287525|NCT06255106|OTHER|cast treatment|Surgical intervention vs cast treatment
214287526|NCT06296966|DRUG|VSJ-110|ophthalmic solution
214287527|NCT06296966|DRUG|Placebo|ophthalmic solution
214472246|NCT04247802|OTHER|Usual Care|A 12 week physiotherapy exercise programme EXCLUDING backwards walking
214472247|NCT06432400|OTHER|Patient questionnaires|Patients questionnaires, on paper and data collection on patients medical file
214845676|NCT00003348|DRUG|O6-benzylguanine|
214845677|NCT00003348|DRUG|carmustine|
214845678|NCT03134430|OTHER|Normal saline|Injection of Normal saline around peripheral nerve
214845679|NCT03134430|OTHER|peripheral Nerve block|Injection of local anesthetics around peripheral nerve
214845680|NCT02434263|DEVICE|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
214845681|NCT02589886|OTHER|Education and self-help internet intervention|The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
214845682|NCT06275178|PROCEDURE|Medical thoracoscopy|The included particpants are the patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy.
214845683|NCT02285348|PROCEDURE|Lumbar puncture|Lumbar puncture is done according to general practice
214845684|NCT04889391|DRUG|[14C]-Danicopan|Liquid-filled capsules.
214845685|NCT02241135|BIOLOGICAL|CV7201 mRNA|CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
214845686|NCT06657872|PROCEDURE|water vapor therapy under general anesthesia|Water vapor procedure will be performe under conscious intravenous sedation with anesthesia team
214287528|NCT03695120|OTHER|Change of treatment plan|Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
214287529|NCT01848691|OTHER|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
214287530|NCT05157230|BEHAVIORAL|exercise|volunteers in the exercise arm instructed to do three basic deltoid muscle exercises 3 times daily at least 20 repetitions for each exercise for five days. exercises were side lateral shoulder raises, front shoulder raises with hyperextension and mid range arm circles.
214287531|NCT03228927|OTHER|comparison of twin A to twin B|Comparison of Twin A to Twin B
214287532|NCT03438344|BIOLOGICAL|Multi-antigen CMV-Modified Vaccinia Ankara Vaccine|Given IM
214287533|NCT03438344|OTHER|Laboratory Biomarker Analysis|Correlative studies
214287534|NCT03438344|OTHER|Placebo|Given IM
214287535|NCT00903799|DEVICE|Implantation of ENTERRA therapy|Gastric electrical stimulation using Enterra Therapy
214287536|NCT03039140|OTHER|Educational Intervention|Attend weekly educational sessions
214287537|NCT03039140|BEHAVIORAL|Exercise Intervention|Participate in CR program
214287538|NCT03039140|OTHER|Quality-of-Life Assessment|Ancillary studies
214287539|NCT03039140|OTHER|Questionnaire Administration|Ancillary studies
214287540|NCT03558178|PROCEDURE|Doin with acupuncture|Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated. Doin sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
214287541|NCT03558178|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
214287542|NCT03322878|DRUG|Magnesium SO4|The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
214287543|NCT00662805|DRUG|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
214287544|NCT03206528|DEVICE|Vital Signs Monitoring System|The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
214287545|NCT02088281|DRUG|Indigo naturalis extract in oil ointment|Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
214287546|NCT01918085|OTHER|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
214287547|NCT01918085|OTHER|Strata strip|An adhesive strip made of the Strata adhesive
214287548|NCT03761524|PROCEDURE|Customized V plate fixation|(CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .
214287549|NCT03761524|PROCEDURE|Conventional miniplates fixation|Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
214287550|NCT03637114|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
214287551|NCT03637114|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
214845687|NCT06657872|PROCEDURE|water vapor therapy under local anesthesia|Water vapor procedure will be performe under local anethesia administrated with Schelin® catheter via the trans-urethral route : injection of 20cc of lidocaine 2% intra-prostatically via the schelin catheter at 4 injection points (3cc at 1h, 3cc at 11h, 7cc at 4h, and 7cc at 8h).
214845688|NCT03024268|DEVICE|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
214287552|NCT05930977|PROCEDURE|total thyroidectomy followed by thyroid auto transplantation|"All studied cases received general endotracheal anaesthesia, and all underwent total thyroidectomy.~Frozen section will be done intraoperative to exclude malignancy and obtain piece of healthy tissue part .~Most healthy-looking part of gland was selected after complete excision. Thyroid tissue to be transplanted weighed between two and five grammes. This section was finely split into ten-fifteen fragments with scalpel. Small pocket was created in sternomastoid muscle, into which these minor fragments were implanted, and this pocket was closed with absorbable sutures to prevent displacement of implanted fragments and was marked with metallic stables, as well as good hemostasis of thyroid bed and skin was closed with subcuticular sutures using absorbable three-zero Vicryl sutures."
214287553|NCT00148018|DRUG|Bortezomib|
214287554|NCT00148018|DRUG|Dexamethasone|
214287555|NCT01207869|BIOLOGICAL|ucMSCs|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
214287556|NCT01207869|OTHER|Normal saline|the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
214287557|NCT04085809|OTHER|AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.
214287558|NCT04080414|BEHAVIORAL|Home-based high-intensity interval training|Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
214287559|NCT04080414|BEHAVIORAL|Home-based moderate-intensity continuous exercise|Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
214287560|NCT02535988|RADIATION|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
214287561|NCT02535988|DRUG|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
214287562|NCT03781596|DIAGNOSTIC_TEST|Retrospective evaluation of endoscopy prior to study drug|Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.
214287563|NCT03781596|OTHER|Symptom Survey|Patient will complete symptom survey prior to starting the study drugs.
214287564|NCT03781596|OTHER|Medication Compliance Phone Call|The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.
214287565|NCT03781596|DIAGNOSTIC_TEST|Endoscopy while on study drug|Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.
214287566|NCT03781596|OTHER|Symptom Survey|The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.
214287567|NCT03781596|DRUG|Fluticasone|Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.
214287568|NCT03781596|DRUG|Omeprazole|The participants in the experimental arm will be given oral omprazole capsules for an 8 week period (along with the swallowed fluticasone). Doses determined by age and weight.
214287569|NCT03781596|DRUG|Placebo oral capsule|The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
214287570|NCT05609006|DIETARY_SUPPLEMENT|High-Energy, Low-Volume ONS|2 bottles/day of a High-Energy, Low-Volume ONS
214287571|NCT05609006|DIETARY_SUPPLEMENT|High-Energy Standard ONS|2 bottles/day of a High-Energy Standard ONS
214287572|NCT01655472|DEVICE|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
214287573|NCT01655472|DEVICE|imaging follow up: Ultrasonographic examination|
214287574|NCT05881915|DRUG|Phenylephrine|phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
214287575|NCT05881915|DRUG|Epinephrine|epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
214287576|NCT06370650|PROCEDURE|platelet rich plasma, narrow band UVB|Role of PRP in treating stable vitiligo
214287577|NCT03640130|BEHAVIORAL|Gaze-contingent text enhancement|"In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight."
214287578|NCT00346112|PROCEDURE|psycho-educational|
214287579|NCT00313378|DRUG|Hypothetica|
214287580|NCT03585257|BIOLOGICAL|25% IV albumin|"Intravenous 25% albumin infusion 1.0 g/kg body weight (maximum 100gm) once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
214287581|NCT03585257|OTHER|Placebo|"Normal saline infusion 1.0g/kg body weight once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
214287582|NCT03721601|DEVICE|Heart rate monitor chest strap|Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
214287583|NCT03721601|DEVICE|Wrist band photoplethysmography|Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
214287584|NCT01914198|OTHER|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
214287585|NCT03778762|PROCEDURE|Blind tracheal intubation through AirQ|underwent blind intubation with correction manoeuvres
214287586|NCT03778762|PROCEDURE|Fiberscopic tracheal intubation through AirQ|: underwent fibreoptic guided intubation
214287587|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
214287588|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
214287589|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
214287590|NCT01382095|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
214287591|NCT01647620|DRUG|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
214287592|NCT01647620|DRUG|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
214287593|NCT00795314|DRUG|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
214287594|NCT00795314|DRUG|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
214287595|NCT01118221|BEHAVIORAL|pulmonary rehabilitation|structured exercise program
214287596|NCT01772108|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
214287597|NCT06436872|OTHER|informing patients with using a booklet|The intervention group was informed before discharge and was given an information booklet. A phone number was given so that the researcher could contact the nurse. In the 4th week, 8th week and 12th week, information was given according to the information needs of the patient and caregiver.
214287598|NCT06417294|OTHER|3D health education model|explanation combined with 3D printed health education model
214287599|NCT06417294|OTHER|traditional education|Regular education
214287600|NCT05782491|PROCEDURE|Interscalene Block|It is an ultrasound guided brachial plexus nerve block at roots/trunks used to anesthetize the shoulder and upper arm. Goal is to spread local anesthetic around superior and middle trunks of brachial plexus, between the anterior and middle scalene muscles.
214287601|NCT05782491|PROCEDURE|PECS II Block|PECS II block is comprised of two separate fascial plane blocks to anesthetize anterolateral chest wall using an ultrasound guided injection between the pectoralis major muscle and pectoralis minor muscle at third rib and a second ultrasound guided injection between pectoralis minor and serratus anterior. The goal is a high volume hydro dissection of the two fascial planes to anesthetize anterolateral chest wall and axilla.
214287602|NCT05782491|PROCEDURE|Superficial Cervical Plexus Block|This block is a superficial injection to the deep cervical fascia between the investing layer of the deep cervical fascia and the prevertebral fascia in the neck. This block provides anesthesia of the skin of the anterolateral neck and the ante-auricular and retro-auricular areas, as well as the skin overlying and immediately inferior to the clavicle on the chest wall. This is an ultrasound guided injection with the goal of placing the needle tip in the fascial layer underneath the SCM adjacent to the cervical plexus, which is contained within the tissue space between the Cervical fascia and posterior sheath of the SCM.
214287603|NCT04338698|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)
214845689|NCT05766787|DEVICE|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
214287604|NCT04338698|DRUG|Oseltamivir|Oseltamivir (75 mg orally twice a day for 5 days)
214287605|NCT04338698|DRUG|Azithromycin|Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
214287606|NCT01950507|DRUG|Budesonide|Entocort EC 3 mg given orally three times daily for at least 14 days
214287607|NCT01950507|DRUG|Fluconazole|400 mg orally once daily for CrCl greater than or equal to 50 ml/min
214287608|NCT01950507|DRUG|Voriconazole|Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours
214287609|NCT01950507|DRUG|Micafungin|Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
214287610|NCT00646776|DRUG|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
214287611|NCT00646776|DRUG|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)"
214287612|NCT05171595|DEVICE|Lifetouch single-lead ECG monitoring|The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
214287613|NCT05171595|DIAGNOSTIC_TEST|high-sensitive TnT measurements|Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
214287614|NCT00909051|DRUG|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
214287615|NCT01654029|BEHAVIORAL|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
214287616|NCT04464356|DEVICE|mechanical circulatory support|mechanical circulatory support: cardiopulmonary bypass, extracorporeal membrane oxygenation(ECMO), left ventricular assist device
214287617|NCT06381882|PROCEDURE|Pancreatic resection|Any kind of pancreatic resection will be included
214845690|NCT05766787|DEVICE|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
214287618|NCT04047394|DRUG|PEGylated recombinant candida urate oxidase|PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
214287619|NCT01658670|BEHAVIORAL|Enhanced Usual Care Group|The EUC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
214287620|NCT01658670|BEHAVIORAL|HEART Camp (HC) Intervention Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
214287621|NCT02304172|DEVICE|Thunderbeat (Group A)|hemostatic device utilized intraoperatively
214287622|NCT02304172|DEVICE|Harmonic (Group B)|hemostatic device utilized intraoperatively
214287623|NCT01831193|DRUG|Curcumin|
214287624|NCT02587715|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
214287625|NCT02587715|OTHER|Liberation therapy|
214287626|NCT02352350|OTHER|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
214287627|NCT02352350|OTHER|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
214845691|NCT05766787|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
214845692|NCT05578469|PROCEDURE|surgical treatment of Marfan Syndrome with subluxation lens|different surgical treatment of Marfan Syndrome with subluxation lens
214845693|NCT04759534|BIOLOGICAL|protein convertase subtilisin/kexin type 9 inhibitor|IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
214287628|NCT05229380|DRUG|Saccharin test|Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.
214287629|NCT04448574|OTHER|Chest Wall Deformities Questionaire|Questionaire about epidemiological data was sent to Patients and families
214287630|NCT04931745|DEVICE|Virtual reality|VR headset will be used 5-10 minutes prior to and during port access
214287631|NCT04931745|DEVICE|Tables distraction|Tablet distraction will be used 5-10 minutes prior to and during port access
214287632|NCT04931745|OTHER|No or non-technologic distraction|This approach will be used 5-10 minutes prior to and during port access
214287633|NCT01613729|DRUG|Rosuvastatin 5 mg|Rosuvastatin 5 mg
214287634|NCT01613729|DRUG|Rosuvastatin 10 mg|
214287635|NCT00205790|DEVICE|Vascular graft|
214287636|NCT00948129|OTHER|Laboratory Biomarker Analysis|Correlative studies
214287637|NCT00948129|BEHAVIORAL|Smoking Cessation Intervention|Undergo standard of care smoking cessation intervention
214287638|NCT00948129|BEHAVIORAL|Telephone-Based Intervention|Undergo telephone based smoking cessation intervention
214287639|NCT00948129|OTHER|Tobacco Cessation Counseling|Undergo smoking cessation counseling
214287640|NCT00439244|DRUG|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
214287641|NCT00439244|DRUG|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
214287642|NCT00439244|DRUG|Teriparatide|"Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days."
214287643|NCT00002136|DRUG|Tecogalan sodium|
214287644|NCT00386945|BEHAVIORAL|Brief counseling (Ask, Advise, Arrange)|Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
214845694|NCT04612530|DEVICE|Irreversible Electroporation (IRE)|Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
214845695|NCT04612530|DRUG|Nivolumab|Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
214845696|NCT04612530|DRUG|Toll-Like Receptor 9|Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.
214287645|NCT03655691|BIOLOGICAL|Vehicle|Vehicle Formulation
214287646|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
214287647|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
214287648|NCT03267108|COMBINATION_PRODUCT|INOpulse®|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
214287649|NCT03267108|COMBINATION_PRODUCT|Placebo|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
214287650|NCT03267108|COMBINATION_PRODUCT|Open Label Extension|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
214287651|NCT04674410|DRUG|Antibiotic|Empiric antibiotic therapy, subdivided according to Community Acquired Pneumonia coverage vs Hospital Acquired Pneumonia coverage
214287652|NCT03982628|DIAGNOSTIC_TEST|Abdominal CT imaging|Routine abdominal CT imaging
214287653|NCT06971055|DRUG|Sodium hypochlorite|sodium hypochlorite solution will be used as a root canal irrigant during pulpectomy in primary molars. A volume of 3 mL will be delivered into each canal using a syringe with a side-vented needle. Irrigation will be followed by microbial sampling for blood agar
214287654|NCT06971055|BIOLOGICAL|Moringa Oleifera Leaf Extract|extract of Moringa oleifera leaves will be used as an intracanal irrigant during pulpectomy. A volume of 3 mL will be used per canal, and post-irrigation microbial samples will be analyzed using the same methods as the control group.
214287655|NCT02061982|DIETARY_SUPPLEMENT|Coffee consumption|Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
214845697|NCT02885441|DRUG|Ketorolac|Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
214845698|NCT06682637|DRUG|Melflufen|Pepaxti 20 mg powder for concentrate for solution for infusion
214845699|NCT06682637|DRUG|Dexamethasone|SOLDESAM 8 mg/2 ml solution for injection SOLDESAM 0.2% oral drops, solution
214845700|NCT02176057|DRUG|Azithromycin|
214287656|NCT00225173|DRUG|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
214287657|NCT00225173|DRUG|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
214287658|NCT00225173|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
214287659|NCT00225173|DRUG|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
214287660|NCT00225173|DRUG|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
214287661|NCT00225173|DRUG|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
214287662|NCT00225173|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
214287663|NCT00225173|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
214287664|NCT00225173|DRUG|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
214287665|NCT04138654|DIETARY_SUPPLEMENT|Processed meat product|300 grams per day during 2 weeks
214287666|NCT04138654|DIETARY_SUPPLEMENT|White meat wash-out|300 grams per day during 2 weeks
214845701|NCT03296735|PROCEDURE|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
215033496|NCT02898688|BEHAVIORAL|Intervention Site|Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
214287667|NCT04138654|DIETARY_SUPPLEMENT|Processed meat products enriched with natural compounds|300 grams per day during 2 weeks
214287668|NCT04138654|DIETARY_SUPPLEMENT|Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds|3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
214287669|NCT01385553|BEHAVIORAL|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
214287670|NCT01385553|BEHAVIORAL|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
214287671|NCT01753856|DRUG|Teriparatide|Administered SC
214287672|NCT01753856|DRUG|Denosumab|Administered SC
214287673|NCT01753856|DRUG|Demeclocycline|Administered orally
214287674|NCT01753856|DRUG|Tetracycline|Administered orally
214287675|NCT01753856|DRUG|Calcium Supplement|Administered orally
214287676|NCT01753856|DRUG|Vitamin D|Administered orally
214287677|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
214287678|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
214287679|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
214287680|NCT00864214|DRUG|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
214287681|NCT05778097|DRUG|Apalutamide 60mg Tab|Apalutamide 60Mg Tab (4 x 60 mg) once daily on days 1-28 of a 28-day cycle
214287682|NCT05778097|DRUG|Androgen deprivation therapy(ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
214287683|NCT04386252|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
214287684|NCT05307068|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
214287685|NCT03942848|DRUG|zicotinide followed by placebo|The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
214287686|NCT03942848|DRUG|Placebo followed by zicotinide|The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
214845702|NCT03296735|PROCEDURE|Contralateral tilt|The operation table will be tilted 20 degrees left laterally.
214845703|NCT00924963|DEVICE|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
214287687|NCT03689478|OTHER|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
214845704|NCT00924963|DEVICE|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
214845705|NCT00924963|DRUG|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
214845706|NCT01547507|DEVICE|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
214845707|NCT01435928|DRUG|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
214845708|NCT01435928|DRUG|Matching Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
214845709|NCT03922139|DRUG|OnabotulinumtoxinA Injection|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
214287688|NCT06559033|BIOLOGICAL|Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS|Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.
214287689|NCT05109442|DRUG|AFM24|intravenous infusion
214287690|NCT05109442|DRUG|Atezolizumab 840 MG in 14 ML Injection|intravenous infusion
214287691|NCT04853225|OTHER|Prospective observational cohort study|Prospective observational cohort study
214287692|NCT05664737|BIOLOGICAL|Luspatercept|Specified dose on specified days
214287693|NCT05664737|DRUG|Placebo|Specified dose on specified days
214287694|NCT07001722|OTHER|TÜBSİS Web-based Psycho-education Programme|The theoretical infrastructure of the TÜBSİS Program, which consists of a total of 8 modules lasting 1 month, is supported by the integration of two different frameworks: Mindfulness Approach and HAPA Health Action Approach. While the progress process in the TÜBSİS Program was created with the HAPA Model, the module contents of it were created within the framework of the Mindfulness Approach. Each participant receives reminder emails during this asynchronous and distance learning process and can open each new module at least 3 days later. Participants in the intervention (as well as control group) were asked about sociodemographic and tobacco use characteristics at baseline. Health Action Process Approach (HAPA) Model Change Question Form, Warwick Edinburgh Mental Well-Being Scale, Fagerström Nicotine Dependence Test and Informed Consent Form were administered to the intervention group at the beginning, in the middle and at the end of the intervention study.
214287695|NCT07000890|DIAGNOSTIC_TEST|Synovial Biopsy|Synovial tissue and blood samples will be collected and processed for bulk and scRNAseq; serum, plasma, DNA, RNA and PBMCs as per below flow chart. Biomarker exploratory analysis will be performed.
214287696|NCT07001267|PROCEDURE|Anesthesia drugs during the surgery|During treatment for acute ischemic stroke, patients will be given either inhalation or intravenous anesthesia.
214287697|NCT07001501|DRUG|Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days."
214287698|NCT07001501|DRUG|Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
214845710|NCT05963841|DEVICE|treatment program|the study aims to set up an artificial intelligence diagnostic assistance program
214845711|NCT01932905|DEVICE|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
214845712|NCT06221124|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Sleep stage (bSTAGES) and respiratory event index (bAHI) are estimated.
214287699|NCT07001501|DRUG|Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days."
214287700|NCT07132411|BEHAVIORAL|Patients in Talk With Me Baby Clinics|Parent-child participants in TWMB clinics will attend their regular WCC visits (scheduled per routine clinic processes) following the AAP Periodicity Schedule.
214287701|NCT07132411|BEHAVIORAL|Patients in Care-As-Usual Clinics|Parent-child participants in Care-As-Usual clinics will attend their regular WCC visits (scheduled per routine clinic processes) following the AAP Periodicity Schedule. Measures will be completed at five time points.
214287702|NCT07132528|DRUG|SOX plus PD-1 inhibitor|SOX or XELOX plus PD-1 inhibitor
214845713|NCT04158427|PROCEDURE|Faecal transplantation|Faecal transplantation from a healthy donor via colonoscopy
214845714|NCT04158427|PROCEDURE|Placebo faecal transplantation|Placebo faecal transplantation containing patient's own feces via colonoscopy
214845715|NCT00163709|PROCEDURE|BNP test|
214845716|NCT04038606|OTHER|Determination of acceptance and / or rejection of mastectomy|Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
214845717|NCT04795869|DRUG|Brentuximab Vedotin|Given IV
214845718|NCT04795869|BIOLOGICAL|Pembrolizumab|Given IV
214287703|NCT07132528|DRUG|SOX Chemotherapy|SOX or XELOX
214287704|NCT07015138|RADIATION|TRT|"Comprehensive metastasis-directed radiotherapy:~* Targets: Primary prostate tumor + all metastatic lesions (≤10 sites confirmed by PSMA PET)~* Concurrent therapy: Standard systemic treatment (ADT + novel hormonal agents)"
214287705|NCT07015138|RADIATION|NTRT|"Standard primary radiotherapy:~* Targets: Prostate primary tumor only~* Concurrent therapy: Same systemic treatment as experimental arm"
214845719|NCT02682134|DRUG|xylocaine|First group were given xylocaine
214845720|NCT02682134|DRUG|Dexamethasone|Second group were given Dexamethasone
214845721|NCT02682134|DRUG|Xylocaine and Dexamethasone|Third group were given both Xylocaine and Dexamethasone
214845722|NCT04615494|PROCEDURE|Position|Pneumoperitoneum with Steep Trendelenburg position
214845723|NCT02452528|DRUG|ARC-520|
214845724|NCT02452528|DRUG|Placebo|
214845725|NCT02452528|DRUG|Entecavir|0.5 or 1.0 mg/day orally
214845726|NCT02452528|DRUG|Tenofovir|300 mg/day orally
214287706|NCT03773692|BEHAVIORAL|Passive feedback and JITAI|"Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA."
214287707|NCT07021976|DRUG|HRS-1893 Tablets|HRS-1893 tablets.
214287708|NCT07021976|DRUG|HRS-1893 Placebo Tablets|HRS-1893 placebo tablets.
214287709|NCT07018297|COMBINATION_PRODUCT|Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor|Each practice group randomized to early discharge with subcutaneous furosemide will provide the patient with prefilled units of Lasix® ONYU furosemide injection containing 80 mg per 2.67 mL in a single-dose prefilled cartridge co-packaged with a single-use Disposable Unit of the Infusor that will be used in conjunction with the reusable unit of the Lasix ONYU Infusor. Dosing based on pre-admission oral furosemide requirements: ≤80mg/day oral furosemide will be given 80mg subcutaneous once daily or \>80mg/day oral furosemide will be given 80mg subcutaneous twice daily. Dosing will be continued until clinical euvolemia is reached.
214287710|NCT04828304|DEVICE|PLASOMA|Treatment with cold plasma device
214287711|NCT07031219|OTHER|provider order set/order panel|Triple testing order panels will be built specifically for this study. An order for a screening blood test for any of the three bloodborne viruses (BBVs; i.e. HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV)) will be coupled with orders for the respective screening blood tests for the other two BBVs to be selected by default in a single order panel. These order panels will only be available to participating providers during their participation in the intervention arm.
214845727|NCT02452528|DRUG|diphenhydramine|50 mg orally as pretreatment antihistamine
214287712|NCT07030673|DRUG|antibiotic withdrawal|stop antibiotics on viral or negative results
214287713|NCT07030673|DRUG|Antibiotics|"standard of care~Antibiotics are :~Amoxicilline-acide clavulanique : 1g x3/j, 7j or Ceftriaxone : 1g/j, 7j or Pipéracilline-Tazobactam : 4g x3/j, 7j or Pristinamycine : 1g x 3/j, 7j"
214287714|NCT07131657|DRUG|Ropivacaine + Clonidine + Betamethasone|"Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)~Group I: A total of 20 mL will be injected: 10 mL Ropiclobet (1 ampoule) + 10 mL of 0.9% isotonic saline"
214287715|NCT07131657|DRUG|Ropivacaine + Clonidine + Betamethasone|"Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)~Group II: A total of 20 mL will be injected: 15 mL Ropiclobet (1.5 ampoules) + 5 mL of 0.9% isotonic saline"
214287716|NCT07131657|DRUG|Ropivacaine + Clonidine + Betamethasone|"Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)~Group III: A total of 20 mL will be injected: 20 mL Ropiclobet (2 ampoules)"
214287717|NCT07031895|COMBINATION_PRODUCT|a bovine-derived graft/xenograft enriched with hyaluronic acid|In study group a bovine-derived graft/xenograft enriched with hyaluronic acid will be placed in the extraction socket after tooth removal.
214287718|NCT07031895|COMBINATION_PRODUCT|a standart bovine-derived graft/xenograft|In comparison group a standard bovine-derived graft/xenograft will be placed in the extraction socket after tooth removal.
214287719|NCT06718348|OTHER|Use of the Exoskeleton JAPET.W|Phsysiotherapy sessions with the support of the Exoskeleton JAPET.W
214287720|NCT06741072|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214287721|NCT06741072|DRUG|Dulbecco''s Phosphate-Buffered Saline|Given SC
214287722|NCT06741072|BIOLOGICAL|Peptide Vaccine|Given OSU-2131 SC
214287723|NCT06741072|BIOLOGICAL|QS21|Given SC
214287724|NCT06890338|DRUG|Carboplatin|Intravenous (IV) infusion
214287725|NCT06890338|DRUG|Mirvetuximab Soravtansine|Intravenous (IV) infusion
214287726|NCT06890338|DRUG|Bevacizumab|Intravenous (IV) infusion (per investigator's discretion)
214287727|NCT06741657|DRUG|Litifilimab|Administered as specified in the treatment arm.
214287728|NCT06741657|DEVICE|AI|Administered as specified in the treatment arm.
214287729|NCT06741657|DEVICE|OBI|Administered as specified in the treatment arm.
214287730|NCT06741657|DEVICE|PFS|Administered as specified in the treatment arm.
214287731|NCT07064200|OTHER|TAP Block|the TAP block is a regional anesthesia technique that targets the somatic nerves supplying the anterior abdominal wall.
214287732|NCT07073417|DRUG|XW003 injection|Subcutaneous injection
214287733|NCT07073417|DRUG|semaglutide injection|Subcutaneous injection
214845728|NCT06768099|OTHER|Linear Cognitive Aid|"Key features of this tool include:~* Minimal input: Teams input the patient's age and clinical scenario (e.g. arrest, childbirth, or trauma).~* Linear logic: Based on initial simple input, the tool provides straightforward guidance without requiring multiple Y/N input or advanced decision-making.~* Guidance based on individual characteristics: The tool tailors AHA guidance for the specific emergency scenario to the individual patient's size (estimated by age), emphasizing key interventions for the individual scenario and giving appropriate size-based guidance regarding choice of equipment, medication dosage, and resuscitation technique (e.g., chest compression depth).~* Time-based and on-demand guidance: Based on the time elapsed from the start of the resuscitation, the app will provide audio guidance regarding the next key steps."
214845729|NCT01195116|DRUG|Dexmedetomidine|1 mcg/kg/hour
214845730|NCT01195116|DRUG|Normal Saline|1mcg/kg/hr
214845731|NCT02040961|DEVICE|ETView Double-Lumen Tube|Tracheal intubation is performed using a ETView Double-Lumen Tube
214845732|NCT01077505|BIOLOGICAL|albiglutide|albiglutide 50mg weekly subcutaneous injection
214845733|NCT01077505|DRUG|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
214845734|NCT00406016|DRUG|ATI355|
214845735|NCT03765190|COMBINATION_PRODUCT|Radiation: Proton Therapy+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
214845736|NCT00067132|PROCEDURE|Juven (nutritional), HMB (nutritional)|
214287734|NCT07131137|BEHAVIORAL|The Life Balance Training Intervention|The Life Balance Training intervention is administering as an individualized, therapist-guided program over a period of eight weeks, comprising two 45-minute sessions per week conducted via videoconferencing platforms. The program's objective was to enhance engagement in meaningful daily activities, promote a sense of life balance, and improve participation in instrumental activities of daily living (IADLs). Each session focused on fundamental components, including goal setting, skills training, activity planning, and problem solving. Caregiver involvement is encouraging when appropriate to support the generalization of skills to the home environment. The sessions commenced with a collaborative goal-setting process, centred on participants' desired modifications to their daily routines and occupational balance. The curriculum encompassed a range of pertinent subjects, including meal preparation, financial management, and time management.
214287735|NCT01804075|DRUG|Methadone|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
214287736|NCT01804075|DRUG|Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
214287737|NCT02175498|DRUG|Homoeopathic medicines|4 pills once a week of the indicated Similimum
214287738|NCT07132346|OTHER|AGING ANXIETY SCALE|This study was conducted as descriptive research to determine the mediating role of aging anxiety in the relationship between maternal ambivalence and pregnancy avoidance in women.
214287739|NCT05305105|DRUG|Psilocybin|Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.
214287740|NCT07124624|DEVICE|AI-Assisted CTA Interpretation|A locked, independently validated deep learning model was used to assist radiologists in interpreting head CTA scans. The model was trained on 16,546 CTA cases and externally validated on an independent set of 900 DSA-verified CTA cases, achieving a patient-level sensitivity of 0.943 and an average of 0.187 false positives per case.
214287741|NCT07124624|DIAGNOSTIC_TEST|Standard CTA Interpretation|Head CTA interpretation performed by radiologists using local routine diagnostic workflows without AI support.
214287742|NCT07124949|OTHER|No intervention|no intervention
214287743|NCT07131150|BIOLOGICAL|SC01009 injection|Menstrual Blood-Derived Mesenchymal Stem Cell (Product Code: SC01009) Injection is a cell therapy product developed by Zhejiang Sinocord Precision Medicine Technology Co., Ltd. The active component consists of mesenchymal stem cells (MSCs) derived from menstrual blood.
214287744|NCT07131150|BIOLOGICAL|Placebo Group(Vehicle)|The placebo consists of the SC01009 Injection formulation solution, containing all components identical to the active product except for the absence of mesenchymal stem cells.
214287745|NCT07132710|OTHER|Semi-structured interviews|Patients and caregivers will be interviewed about the barriers and facilitators to the use of VR masks in the management of pain and anxiety, in order to propose organizational changes that encourage their use.
214287746|NCT07131774|OTHER|Filling in a symptom diary|"Each patient will receive a diary form in which they are asked to record their symptoms, body temperature, and body weight on a daily basis. This approach is intended to provide a comprehensive overview of the disease course and the impact of treatment over time.~Depending on hospitalization status, disease severity, treatment progress, and national treatment guidelines, clinical, microbiological, and radiological follow-up assessments will be performed as part of routine care at intervals ranging from weekly to monthly. No additional study visits or microbiological or radiological diagnostics outside of standard clinical care will be conducted."
214287747|NCT00221273|PROCEDURE|ACL surgery|
214287748|NCT02367677|OTHER|Method comparison|
214287749|NCT00311610|DRUG|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
214287750|NCT02740777|BIOLOGICAL|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
214287751|NCT05891262|DRUG|BMS-986196|Specified dose on specified days
214287752|NCT05891262|DRUG|Loestrin|Specified dose on specified days
214287753|NCT00793598|DRUG|Placebo|
214845737|NCT06903962|BEHAVIORAL|Mind-Body Intervention|The mind-body intervention will include regular approximate 2 hour educational sessions and didactics learning mind body techniques. The sessions will be twice per week for the first 4 weeks and then subsequently once per week for a total of 13 weeks.
214287754|NCT00793598|DRUG|Brincidofovir|
214287755|NCT04085068|OTHER|cranioscaral treatment|dural release
214287756|NCT04386421|OTHER|Video on oral hygeine instructions|A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.
215033497|NCT02898688|BEHAVIORAL|Patient-level Control Group|"Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a yes or no response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions."
214287757|NCT04386421|DRUG|Plaque disclosing tablets|"Plaque disclosing tablets:~Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %"
214287758|NCT04508868|BEHAVIORAL|Brief Behavioral Activation with Mental Imagery|"Session 1:~Provide psychoeducation about depression; Provide treatment rationale for BA; Provide rationale and instructions for activity log; Plan activities for coming week.~Session 2:~Review activity log; Discuss life goals and values; Plan activities aligned with life goals and values for coming week; Provide rationale for Mental Imagery (MI); Go through MI-exercise for one of the planned activities.~Session 3:~Review activity log; Troubleshoot any problems carrying out activities; Plan activities aligned with life goals and values for coming week; Go through MI-exercise for one of the planned activities.~Session 4:~Review activity log; Troubleshoot any problems carrying out activities; Review treatment; Stress the importance of continuing to engage in activities aligned with life goals and values; Referral to additional services if necessary."
214287759|NCT04508868|BEHAVIORAL|Minimal Attention Control Intervention|Weekly call with follow-up of psychiatric symptoms and assessment of suicide risk.
214287760|NCT02384408|PROCEDURE|Endometrial Biopsy|Histological assessment
214287761|NCT02384408|DEVICE|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
214287762|NCT02384408|PROCEDURE|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
214287763|NCT04907721|DIAGNOSTIC_TEST|Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon|"The test consists of two experimental study days:~Day 1: intravenous bolus-injection of glucagon (0.2 mg at time 0 minutes) evaluating the effect of exogenous glucagon on amino acid disappearance. Blood samples will be obtained from time -10 to 120 minutes.~Day 2: 45-minute intravenous infusion of mixed amino acids (331 mg/min/kg body weight from time 0-45 minutes) to evaluate the effect of endogenous glucagon on amino acid metabolism. Blood samples will be obtained from time -10 to 180 minutes.~All participants will be subjected to a magnetic resonance imaging scan to assess whole-liver steatosis, and a bioelectrical impedance analysis to assess body composition.~Following study inclusion and the magnetic resonance imaging scan, participants will be stratified into groups based on hepatic steatosis. Individuals with \<5.6 % hepatic steatosis will be classified as controls and individuals with ≥5.6 % hepatic steatosis will be classified as MASLD."
214287764|NCT03048565|BEHAVIORAL|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
214287765|NCT02154490|DRUG|Docetaxel|Given IV
214287766|NCT02154490|BIOLOGICAL|Durvalumab|Given IV
214287767|NCT02154490|DRUG|Erlotinib Hydrochloride|Given PO
214287768|NCT02154490|DRUG|FGFR Inhibitor AZD4547|Given PO
214287769|NCT02154490|BIOLOGICAL|Ipilimumab|Given IV
214287770|NCT02154490|OTHER|Laboratory Biomarker Analysis|Correlative studies
214287771|NCT02154490|BIOLOGICAL|Nivolumab|Given IV
214287772|NCT02154490|DRUG|Palbociclib|Given PO
214845738|NCT06904131|DRUG|Cell therapy with bispecific antibodies|"The dose-escalation phase is designed with three predefined dose levels, following a 3+3 design and progressing from low to high doses. The 3+3 dose-escalation scheme is as follows: if no dose-limiting toxicity (DLT) occurs in the three subjects at a given dose level during the observation period, the dose will be escalated to the next higher level. If one subject out of the initial three experiences DLT at a dose level, an additional three subjects will be enrolled at that dose level for further DLT observation. The dose level at which no more than one subject out of the final six subjects experiences DLT will be defined as the maximum tolerated dose (MTD)."
214845739|NCT06293326|DRUG|bi-layer calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
214845740|NCT06293326|DRUG|Immediate release calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
214845741|NCT03182751|DRUG|Tranexamic Acid (TXA)|Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
214845742|NCT03182751|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
214287773|NCT02154490|OTHER|Pharmacological Study|Correlative studies
214287774|NCT02154490|BIOLOGICAL|Rilotumumab|Given IV
214287775|NCT02154490|DRUG|Talazoparib|Given PO
214287776|NCT02154490|DRUG|Taselisib|Given PO
214287777|NCT02154490|BIOLOGICAL|Tremelimumab|Given IV
214287778|NCT00955591|OTHER|Papanicolaou test|
214287779|NCT03746873|BEHAVIORAL|COPD Web|"The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52)."
214287780|NCT01157949|DRUG|Thymoglobulin|Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
214287781|NCT03757897|DRUG|Dexmedetomidine|The standard dosing of 1mcg/kg will be implemented over 10 minutes followed by a maintenance infusion of 0.2-1.0 titrated to a the target BIS (60-70) during the 20 minutes prior to MRI.
214287782|NCT05160220|DRUG|Psilocybin|0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.
214287783|NCT05160220|DRUG|Placebo|0.5 g dried edible non-psychoactive mushroom material.
214287784|NCT03896776|BEHAVIORAL|Keep It Up! 3.0|KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling \~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
214287785|NCT02633644|DEVICE|Harmony System|Percutaneous neuromodulation of the aortic wall
214287786|NCT02961751|DRUG|Ciprofloxacin|Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
214287787|NCT00939250|BEHAVIORAL|Diabetes and depression intervention|Disease self management for diabetes and depression
214287788|NCT00939250|BEHAVIORAL|Diabetes intervention|Disease self management for diabetes
214845743|NCT05724498|BEHAVIORAL|Brief CBT-I|4 session CBT-I
214845744|NCT05724498|BEHAVIORAL|Standard CBT-I|Standard VA 6 session CBT-I
214845745|NCT02374203|DIETARY_SUPPLEMENT|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
214845746|NCT01303237|DRUG|Cetuximab + RT|Cetuximab initial dose 400 mg/m² on week 1; Cetuximab maintenance dose 250 mg/m² continued for 7 weeks plus concomitant RT
214287789|NCT06087666|PROCEDURE|FICare|The Family Integrated Care (FICare) programme has been developed in a multicenter cluster randomised controlled trial, with 26 tertiary NICUs from Canada, Australia and New Zealand, comparing standard NICU care (which was mainly care by nurses) (891 infants) to FICare programme (895 infants). FICare model and showed that the involvement of parents in the direct care improved weight gain and increased breastfeeding rates in the preterm infants. In addition, their parents had lower rates of stress and anxiety. These results were confirmed in a cluster-randomised controlled trial. Subsequent studies carried out so far have shown promising positive effects on a variety of domains. Maturation profiles have been shown to accelerate with the FICare intervention as a shorter time to achieve exclusive enteral nutrition as well as oral nutrition has been shown in the preterm infants included in FICARE programmes compared to control babies
214287790|NCT00822250|OTHER|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
214287791|NCT03281681|DRUG|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
214287792|NCT02326961|DEVICE|Celution Device|ADRCs Prepared using the Celution Device
214287793|NCT02326961|OTHER|Placebo|Inactive Placebo
214287794|NCT06037291|DIETARY_SUPPLEMENT|Coriander Seed Oil|The study foresees the intake of 1 capsule per day during 56 days
214845747|NCT03762837|OTHER|Benigh gallbladder diseases|We aim to observe the relationship between the benigh gallbladder diseases and gallbladder cancer, and we will not take any actions to interrupt.
214845748|NCT01619579|DEVICE|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
214287795|NCT06037291|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
214287796|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.7～5.0 lgPFU|
214287797|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.7～5.0 lgPFU|
214287798|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.3～5.0 lgPFU|
214287799|NCT02526745|BIOLOGICAL|the vaccine with middle doses of virus content between 4.3～5.0 lgPFU|
214287800|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.3～5.0 lgPFU|
214287801|NCT02526745|BIOLOGICAL|placebo|
214287802|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
214287803|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
214287804|NCT00694213|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
214287805|NCT00694213|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
214287806|NCT01069107|OTHER|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
214287807|NCT00147888|PROCEDURE|Acoustic rhinometry (procedure)|Acoustic rhinometry is a procedure that uses sound waves to measure the cross-sectional area and volume of the nasal cavity.
214287808|NCT02373202|DRUG|Sarilumab|Pharmaceutical form:solution
214287809|NCT02373202|DRUG|Sulfasalazine|Pharmaceutical form: Tablet Route of administration: Oral
214287810|NCT02373202|DRUG|Leflunomide|Pharmaceutical form: Tablet Route of administration: Oral
214287811|NCT02373202|DRUG|Bucillamine|Pharmaceutical form: Tablet Route of administration: Oral
214287812|NCT02373202|DRUG|Tacrolimus|Pharmaceutical form: Capsule Route of administration: Oral
214287813|NCT02373202|DRUG|Mizoribine|Pharmaceutical form: Tablet Route of administration: Oral
214287814|NCT02324374|DEVICE|Endocystoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
214845749|NCT02124902|DRUG|Docetaxel|
214845750|NCT02124902|DRUG|Carboplatin|
214845751|NCT02124902|PROCEDURE|FDG-PET/MR|"* Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~* This is not optional for final 30 participants enrolled on the study"
214287815|NCT02324374|DEVICE|Endocytoscope|The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
214287816|NCT04992455|OTHER|Older Patients Receiving Chemotherapy|No Intervention
214287817|NCT02884674|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
214845752|NCT06318832|OTHER|ICBT|ICBT: Participants will receive the 10-week tailored ICBT Wellbeing program consists of 1) education about how taking on the role of care-partner can impact emotional and cognitive wellbeing through introduction to the CBT model; 2) structured problem solving; 3) cognitive therapy and thought challenging to manage one's wellbeing and impact of caregiving; 4) building communication and intimacy; 5) physical symptoms of depression (i.e., hypo-arousal), anxiety/anger (i.e., hyper-arousal); practicing behavioural activation and controlled relaxation; 6) overdoing-underdoing cycle of activity levels and issues around the fear avoidance of social, physical, and cognitive activities; practicing activity pacing and gradually tackling avoidance; 7) occurrence of setbacks in thought, physical, behavioural, and cognitive symptoms; signs of setbacks and creating setback plans.
214845753|NCT03636087|PROCEDURE|Access cavity preparation|High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
214845754|NCT03636087|PROCEDURE|Working Length Determination|The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
214287818|NCT02884674|DEVICE|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
214287819|NCT03936543|OTHER|Position change|Different position during central line catheterization
214287820|NCT03936543|OTHER|Conventional position|Conventional position during central line catheterization
214287821|NCT00055263|DRUG|DN-101|
214287822|NCT06024057|DRUG|LX101|LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye
214287823|NCT05611879|DRUG|Tislelizumab|Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles
214287824|NCT05611879|DRUG|Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
214287825|NCT05611879|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.
214287826|NCT04055142|PROCEDURE|electrocoagulation|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
214287827|NCT04055142|DRUG|cidofovir 1% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
214287828|NCT04055142|DRUG|sinecatechins 10% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
214287829|NCT02867189|OTHER|atlas of micro-instrument|Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
214845755|NCT03636087|PROCEDURE|Root canal instrumentation and chemo-mechanical preparation|Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
214287830|NCT00042770|OTHER|talc|Given intrapleurally
214287831|NCT00042770|PROCEDURE|dyspnea management|No talc
214287832|NCT03952000|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
214287833|NCT03316664|BEHAVIORAL|Integrated Neurocognitive Therapy (INT)|Information already included in arm/group description.
214287834|NCT03316664|BEHAVIORAL|Integrated Psychological Therapy (IPT)|Information already included in arm/group description.
214287835|NCT03316664|OTHER|COGPACK|Information already included in arm/group description.
214287836|NCT04834427|DRUG|Conventional therapy + S (+)-Ketamine|"In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~1. Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1\~0.25 mg/kg; Bolus intravenous injection (dose 0.1\~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h.~2. Intramuscular injection：The dose is 2\~4 mg/kg."
214287837|NCT04834427|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
214287838|NCT03019302|DEVICE|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
214287839|NCT06479798|DIAGNOSTIC_TEST|Endo bronchial ultrasound transbronchial needle aspiration(EBUS-TBNA)|Endo bronchial ultrasound enables visualization of parabronchial structures throughout a bronchoscopic procedure. EBUS-TBNA, which is considered a less invasive diagnostic tool for nodal staging compared to mediastinoscopy, allows real-time, direct sampling of hilar \& MLNs under sonograghic guidance with concurrent cytological and histopathological examination
214287840|NCT04040478|DEVICE|Transcutaneous monitoring|"Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery."
214287841|NCT03218033|BEHAVIORAL|Social Media|
214845756|NCT03636087|PROCEDURE|Root canal obturation|Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
214845757|NCT03636087|PROCEDURE|Coronal restoration build up|A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
214845758|NCT03636087|OTHER|Changing gloves before obturation|The treating dentist will change gloves before obturation
214287842|NCT00829946|BEHAVIORAL|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of \~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
214287843|NCT02036463|DRUG|Prednisone|
214287844|NCT02036463|DRUG|Placebo|
214287845|NCT04078477|OTHER|Body positioning|Comparison lateral tilt bed to standard patient´s body positioning in the bed.
214287846|NCT02299479|DEVICE|Dexcom G4 Platinum CGM|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
214287847|NCT02299479|DEVICE|Activity monitor|Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
214287848|NCT03494309|PROCEDURE|Open Reduction & Internal Fixation|Patients underwent surgery and the fractures were reduced under direct vision followed by internal fixation with titanium plates and screws
214287849|NCT03494309|PROCEDURE|Closed Reduction & External Fixation|Patients underwent closed reduction of the fracture and external fixation by arch bars \& guided elastics
214287850|NCT02855216|OTHER|Manual technique of sub-occipital inhibition|
214287851|NCT02855216|OTHER|Self-treatment by way of Occipivot®|
214287852|NCT02177045|DRUG|Sonovue, Bracco|Intravenous injection
214287853|NCT03600974|PROCEDURE|Stretta|Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
214287854|NCT03600974|PROCEDURE|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
214287855|NCT03600974|DRUG|Probiotic Agent|Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
214287856|NCT03600974|DRUG|PPI|PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
214287857|NCT03600974|DRUG|Prokinetic Motility Agents|Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
214287858|NCT03600974|DRUG|Neuromodulators|Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
214287859|NCT02938689|OTHER|Exercise|
214287860|NCT05455788|DRUG|Aminoglycoside|injection of sewing ring of prosthetic valve with aminoglycoside
214287861|NCT03780868|PROCEDURE|external dacryocystorhinostomy|external DCR under general anesthesia with standard sterilization procedures.
214287862|NCT03780868|PROCEDURE|canalicular silicone intubation with MMC|canalicular silicone intubation with MMC under general anesthesia with standard sterilization procedures.
214287863|NCT01907880|DRUG|Pamidronate|90mg IV once every 4 weeks for 3 cycles
214287864|NCT01907880|DRUG|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
214287865|NCT01907880|DRUG|placebo|
214287866|NCT01619345|DRUG|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
214287867|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
214287868|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
214287869|NCT04672447|DIETARY_SUPPLEMENT|Placebo|Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
214845759|NCT03636087|OTHER|Disinfecting rubber dam|2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
214845760|NCT03636087|OTHER|The use of new instruments at time of obturation|A new instrument's kit will be use at the time of obturation
214287870|NCT04672447|DIETARY_SUPPLEMENT|Glutathione|Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
214287871|NCT04812054|PROCEDURE|Hypothermic oxygenated machine perfusion|Hypothermic oxygenated perfusion using a Liver Assist device (Organ Assist, Groningen, the Netherlands). Temperature of the perfusate will be set to 12 degrees Celsius. Dedicated cannulas will be placed in the aorta for arterial perfusion and in the portal vein for portal perfusion. Pressure will be set at 25 mmHg for arterial line (pulsatile flow, 30 mmHg systolic pressure and 20 mmHg diastolic pressure, 60 beats per minute) and 3 mmHg for portal line (continuous flow). 100% oxygen will be supplied to the oxygenators with a flow of 500 ml / min or higher, in order to achieve pO2 of at least 450 mmHg.
214287872|NCT04812054|PROCEDURE|Simple cold storage|Following back-table preparation, the allograft will either be transferred to the operating room for implantation or stored in preservation solution at 4 degrees Celsius in a refrigerator
214287873|NCT02566083|DEVICE|non-toric intraocular lens|TECNIS One-piece Monofocal Model ZCB00
214287874|NCT02566083|DEVICE|toric intraocular lens|TECNIS One-piece Toric Models ZCT300 or ZCT400
214287875|NCT02310568|DRUG|PF-06372865.|Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
214287876|NCT03376022|OTHER|Attitudes, knowledge|To investigate attitudes and knowledge to oral Health and oral care
214287877|NCT02432014|BEHAVIORAL|PMTO-PTC Group clinic-based|
214287878|NCT02432014|BEHAVIORAL|PMTO Individual home-based|
214287879|NCT02432014|BEHAVIORAL|PMTO Individual clinic-based|
214287880|NCT02432014|BEHAVIORAL|Services as Usual|
214287881|NCT00441883|DRUG|PF-03187207 and Latanoprost Vehicle|
214287882|NCT00441883|DRUG|Latanoprost 0.005% and PF-03187207 Vehicle|
214287883|NCT04173468|OTHER|Moblization with Movement|patients with group 1 will receive two techniques pertaining to MWM intervention (straight leg raised with traction and tibial Gliding) Repeat it 10 times,3 sets and 1 mint interval. .For Tibial Gliding we will asks the patient to perform 10 repetitive active knee extensions. Practice will be performed by doing 10 reps for 3 sets with 1 min interval. After this home exercises will b guided stretching of hamstrings 8 to 10 reps 20 sec hold, strengthening of Quadriceps and VMO with 10 reps and 3 sets
214845761|NCT03636087|RADIATION|Cone Beam Computed Tomography scanning (CBCT)|CBCT will be taken before treatment and one year after completion
214845762|NCT03636087|RADIATION|Radiographic imaging using periapical radiographs|Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
214845763|NCT04490473|OTHER|survey work|Survey forms will be sent to individuals online. Information about the study will be given to individuals with the informative text at the beginning of the questionnaire form. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
214845764|NCT02938442|BIOLOGICAL|P10s-PADRE with MONTANIDE™ ISA 51 VG|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
214845765|NCT02938442|DRUG|Doxorubicin|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
214845766|NCT02938442|DRUG|Cyclophosphamide|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
214845767|NCT02938442|DRUG|Paclitaxel|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
214845768|NCT02928536|OTHER|no intervention|This is an observational study. No intervention is considered
214845769|NCT02096367|OTHER|Gait analysis|
214845770|NCT02096367|OTHER|Kinematic gait analysis in lower limb|
214845771|NCT02096367|OTHER|Analysis of static posture|
214845772|NCT02096367|OTHER|Gait on treadmill|Treadmill during 2 minutes
214845773|NCT02096367|DEVICE|Muscle vibration stimulation|Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
214845774|NCT02612181|DRUG|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
214287884|NCT04173468|OTHER|Mulligan knee taping|patient with group 2 will receive Mulligan taping technique. Tape will be applied for two days then we will change it. After this home based exercise will be guided which is stretching of hamstrings 8 to 10 reps 20 sec hold , strengthening of Quadriceps and VMO with 10 reps and 3 sets.
214287885|NCT04932551|OTHER|Questionnaire|physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.
214845775|NCT04100096|DRUG|Brexpiprazole|Tablet
214845776|NCT04100096|OTHER|Placebo|Tablet
214845777|NCT06331234|OTHER|Vena cava inferior diameter|he VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
214845778|NCT00137657|DRUG|Cotrimoxazole (trimethoprim sulfamethoxazole)|
214845779|NCT01118026|DRUG|ABVD|doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV
214845780|NCT01118026|DRUG|BEACOPP|bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4 mg/m\^2 IV on Day 8 procarbazine 100 mg/m\^2 orally on Days 1-7 prednisone 40 mg/m\^2 orally on Days 1-14
214845781|NCT01118026|RADIATION|radiation therapy|
214845782|NCT04047953|DRUG|Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1|Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg，bid, d1-14( BSA\<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA\>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.
214845783|NCT05195177|DRUG|Anti-histamine cream 1 hour|At the start of session 1, one area of the middle forearms of the participant will be located (4x4cm). On the area, anti-histamine cream will be applied for approximately 1 hour.
214845784|NCT05195177|DRUG|Local anesthetic cream 1 hour|At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will be applied for approximately 1 hour.
214845785|NCT02809820|DRUG|Carvedilol|Patients randomized to this group will receive carvedilol at the highest dose tolerated
214845786|NCT02809820|DRUG|Metoprolol|Patients randomized to this group will receive metoprolol at the highest dose tolerated
214845787|NCT04467099|OTHER|Foot Exam Follow-Up|All participants will have a clinical assessment of their surgery foot by the study doctor.
214845788|NCT04467099|RADIATION|X-ray|Standard x-ray of the foot.
214845789|NCT04467099|OTHER|Questionnaire|All participants will complete a questionnaire.
214845790|NCT02137382|DRUG|Creon®|active comparator
214845791|NCT02137382|DRUG|Creon N|experimental drug
214845792|NCT01566279|DRUG|Everolimus|All patients will receive everolimus 10mg q.d.
214845793|NCT00831233|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
214287886|NCT05711953|OTHER|Egyfil Pain Lotion|"Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1.~The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product."
214287887|NCT01439191|DRUG|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
214287888|NCT01439191|DRUG|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
214287889|NCT03742934|OTHER|Short peptide|Short peptide formula during bowel preparation
214287890|NCT03742934|OTHER|Liquid diet|Liquid diet during bowel preparation
214287891|NCT01129609|DEVICE|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
214287892|NCT03125343|PROCEDURE|endoscopy|"Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~* PET-CT is optional, but can be performed at inclusion~* Pelvic MRI including diffusion weighted imaging according to appendix C.~* Clinical examination~* Endoscopy (flexible sigmoidoskopy) with photodocumentation~* CEA~After two years the patients will be followed every six month with:~* Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~* Clinical examination~* Endoscopy with photodocumentation~* CEA"
214287893|NCT03125343|PROCEDURE|Surgery|Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
214287894|NCT03125343|DEVICE|MRI|
214287895|NCT00088985|BIOLOGICAL|therapeutic autologous dendritic cells|10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection
214845794|NCT00831233|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
214287896|NCT00088985|BIOLOGICAL|trastuzumab|4 mg/kg intravenously, every 14 days
214287897|NCT00088985|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
214287898|NCT01595698|OTHER|Physical Exercise|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
214287899|NCT01595698|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
214845795|NCT00831233|DRUG|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
214845796|NCT04729608|DRUG|Batiraxcept|Batiraxcept is an experimental drug
214845797|NCT04729608|DRUG|Paclitaxel|Paclitaxel is the standard of care, background therapy
214287900|NCT03208855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
214845798|NCT04729608|OTHER|Placebo|Matching placebo
214845799|NCT01960868|OTHER|standard physiotherapy|
214845800|NCT01960868|OTHER|experimental physical therapy|
214845801|NCT05276505|OTHER|Lavender Aromatherapy Tablet|Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff
214845802|NCT03068845|DEVICE|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
214845803|NCT03068845|DEVICE|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
214845804|NCT06068777|DRUG|Rosmary|inhale two drops of rosemary oil, from a gauze, for 3 minutes before the procedure of extraction of a primary molar
214845805|NCT06068777|DRUG|Lemongrass Oil|inhale two drops of lemongrass oil, from a gauze, for three minutes before the procedure of extraction.
214845806|NCT03397953|DRUG|Vinorelbine|Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
214845807|NCT05562453|DEVICE|FlowOx 2.0|Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.
214845808|NCT05562453|DEVICE|FlowOx2.0 (Sham)|Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.
214845809|NCT06677853|DRUG|Timolol Maleate Gel+Placebo|Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.
214845810|NCT06677853|DRUG|Timolol Maleate Gel|Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.
214845811|NCT06677853|DRUG|Placebo|Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.
214845812|NCT01956487|DRUG|Propafenone|Comparison of drug from 2 manufacturing sites
214845813|NCT04628845|DEVICE|Endo-perio therapy with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
214845814|NCT04628845|DEVICE|Endo-perio therapy without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals
214845815|NCT00256529|PROCEDURE|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
214845816|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
214845817|NCT00648245|DRUG|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
214845818|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
214845819|NCT00648245|DRUG|Placebo|Placebo given once daily for 21 days by nebulizer
214845820|NCT00648245|DRUG|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
214845821|NCT06613269|DRUG|68Ga-NY104 PET/CT|"68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist.~The scan begins 1 hour after intravenous injection of 68Ga-NY104."
214845822|NCT06613269|DRUG|18F-FDG PET/CT|18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG.
214845823|NCT06613269|RADIATION|Radiation Therapy|Radiation therapy will be delivered to cover as much metastasis as possible if not all. For new lesions after radiation plus systemic therapy, if the new lesions are considered suitable for RT, RT can be delivered again without changing systemic therapy.
214845824|NCT06613269|DRUG|Systemic therapy|Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist.
214845825|NCT01328912|OTHER|Remote ischemic preconditioning stimulus|The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
214845826|NCT01328912|OTHER|control|These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
214845827|NCT01338714|OTHER|Compound Herbal Formula (RHD-1)|100 ml/per day
214845828|NCT01338714|OTHER|dilute RHD-1|100 ml/per day
214845829|NCT02801435|DRUG|0.5% Icotinib hydrochloride cream|Topical administration for twice daily
214845830|NCT02801435|DRUG|1.0% Icotinib hydrochloride cream|Topical administration for twice daily
214845831|NCT02801435|DRUG|2.0% Icotinib hydrochloride cream|Topical administration for twice daily
214845832|NCT02801435|DRUG|4.0% Icotinib hydrochloride cream|Topical administration for twice daily
214845833|NCT02801435|DRUG|Placebo|Topical administration for twice daily
214845834|NCT06616116|DEVICE|Biosignal feedback|"1. Real-time neurofeedback guided mindfulness~   : Unlike standard mindfulness therapies, this intervention integrates real-time monitoring of brainwave activity (EEG). Participants in the experimental group receive immediate auditory feedback during their mindfulness sessions, which helps guide their practice and enhance engagement.~2. Tailored progress report In addition to real-time feedback, participants in the Mindfulness with biosignal feedback group receive detailed reports of their biosignal data (EEG and HRV) before, during, and after each session. These reports allow for deeper self-reflection and personalized adjustments to their mindfulness practice, which is not commonly provided in other mindfulness programs."
214845835|NCT06616116|DEVICE|Sham Comparator|Biosignal Monitoring (EEG and HRV) during Mindfulness without real-time feedback
214845836|NCT05149924|DRUG|QL1012|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
214845837|NCT05149924|DRUG|Gonal-f ®|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
214845838|NCT02541084|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
214845839|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-I)|0,05ml intravitreal injection
214845840|NCT02985619|DRUG|Triamcinolone Acetonide 10mg/mL (IVT-II)|0,03ml intravitreal injection
214845841|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-III)|0,05ml intravitreal injection
214845842|NCT01533649|BEHAVIORAL|Andrews/Reiter approach to epilepsy|"The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline."
214845843|NCT01533649|BEHAVIORAL|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
214845844|NCT04487899|DEVICE|Analysis of heart rate variability|The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
214845845|NCT00698087|BIOLOGICAL|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
214845846|NCT00698087|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 or 3 doses
214845847|NCT06334861|BIOLOGICAL|Herpes Zoster adjuvanted recombinant vaccine|patients will receive two doses of vaccine with an interval between the first and second dose of 2 months
214845848|NCT06393660|DEVICE|CliniMACS® CD34 TCR Alpha/Beta|CliniMACS System uses an automated antibody/magnetic beads column system that allows efficient depletion of TCRαβ and CD19+ cells without relevant loss of cell viability. Hematopoietic stem cells are retained in sufficient numbers to permit engraftment and hematopoietic reconstitution. Humanitarian Exemption IDE approval has been obtained for CD34+ cell selection as a method of T-cell depletion.
214845849|NCT04206722|DEVICE|Shock Wave Therapy|Shock Wave therapy - hip osteoarthritis program
214287901|NCT03132376|DIETARY_SUPPLEMENT|Water Preload Drink|Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.
214287902|NCT03132376|DIETARY_SUPPLEMENT|Whey Protein Isolate Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.
214287903|NCT03132376|DIETARY_SUPPLEMENT|Micellar Casein Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.
214287904|NCT03132376|DIETARY_SUPPLEMENT|Egg White Isolate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.
214287905|NCT03132376|DIETARY_SUPPLEMENT|Egg White Concentrate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
214287906|NCT01586676|BEHAVIORAL|SAU|Supervision-as-usual
214287907|NCT01586676|BEHAVIORAL|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
214287908|NCT03611764|BEHAVIORAL|Body Scan|-All efforts will be made to normalize their experience: for example, the desire to open their eyes, thinking about other things, wanting to move around - these are all normal and participants will be encouraged to become interested in and curious about, and to allow these natural tendencies
214287909|NCT03611764|OTHER|Rotterdam Symptom Checklist|"* 39 Likert-scale items, including physical and psychological symptoms (30 questions), daily function (8 questions), and overall valuation of life (one question)~* For the 30 questions pertaining to symptoms, the four-item Likert scale ranges from 'not at all=1' to 'very much=4'; the higher the total score, the greater the score, the higher the level of distress. The single question pertaining to overall valuation of life asks participants to circle one of the seven items, ranked from extremely poor to excellent"
214287910|NCT03611764|OTHER|Practice Logs|-Describe frequency of the Zen Den
214845850|NCT04206722|DEVICE|Ultrasound|Ultrasound 0.7W/cm2
214287911|NCT06036667|PROCEDURE|"28Fr coaxial smart drain chest tube"|"To evaluate the efficacy of one 28Fr chest tube (coaxial smart drain versus standard chest tube according to local practice, types of drainage availability in each centre, surgeon's choice etc) after Uniportal- or Biportal-VATS upper lobectomies."
214287912|NCT06369376|DIAGNOSTIC_TEST|New nerve conduction protocol|We opted for three different recording sites, each mimicking distinct parts of the pectoral muscle, allowing for a comprehensive assessment of nerve conduction across various regions.
214287913|NCT02940145|OTHER|Resistance Training|The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
214845851|NCT00622115|DRUG|Enoxaparin|
214845852|NCT04868864|DIAGNOSTIC_TEST|CT scan|Non-enhanced LDCT scans of the thorax will be taken using standard technology on helical CT system
214845853|NCT04868864|DIAGNOSTIC_TEST|Pulmonary Function Test|Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards
214845854|NCT02380313|DRUG|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
214845855|NCT02380313|DRUG|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
214845856|NCT02380313|DRUG|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
214845857|NCT02380313|DRUG|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
214845858|NCT05301686|PROCEDURE|Patients with Cyclop lesion|Arthroscopy with resection of Cyclop formation
214845859|NCT03221452|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
214845860|NCT03064087|DEVICE|Colli-Pee|First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.
214845861|NCT03064087|DEVICE|Multi-Collect Swab|At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH \& Co. KG, Wiesbaden, Germany).
214845862|NCT03064087|DEVICE|Evalyn Brush|Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)
214845863|NCT03064087|DEVICE|Qvintip|or with Qvintip (Aprovix AB, Uppsala, Sweden).
214845864|NCT03064087|DIAGNOSTIC_TEST|Abbott RealTime High Risk HPV|The hrHPV assay used, will be the Abbott PCR (Abbott GmbH \& Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the first urine sample and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.
214845865|NCT06615856|OTHER|Questionnaire|"Two questionnaires will be provided to participants to complete before their routine tests (which they would already be having regardless of the study and are not affected by their participation in the study).~The questionnaires include: A Gastro-Oesophageal Reflux Symptom Questionnaire; and the ROME-IV Diagnostic IBS Module Questionnaire"
214845866|NCT05507034|DIAGNOSTIC_TEST|Biomarkers|Each intervention is performed at 4 timepoints namely: before surgery, i.e. baseline (T0), 1-3 weeks post-surgery (T1), 3 months post-surgery (T2) and 1 year post-surgery (T4)
214845867|NCT02978352|OTHER|learning|
214845868|NCT06084169|DEVICE|Intra Ocular Lens (IOL) Implant|Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye
214845869|NCT02171767|DRUG|BIBW 2992 MA2 - single rising dose|
214845870|NCT04823507|DEVICE|BIOFLEX DUO+|"* Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment.~* Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine.~* Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test.~* Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared."
214845871|NCT02211014|DRUG|acalabrutinib|
214845872|NCT00003330|BIOLOGICAL|recombinant interleukin-12|
214845873|NCT01915940|DRUG|Bimatoprost|Bimatoprost ocular insert
214845874|NCT01915940|DRUG|Timolol 0.5%|Timolol 0.5% solution
214845875|NCT01915940|DRUG|Placebo Eye Drops|Placebo topical eye drops
214845876|NCT01915940|DEVICE|Placebo Ocular Insert|Ocular insert without any active drug
214287914|NCT05480085|BEHAVIORAL|School-based extracurricular intervention focusing on screen media use and time spent with friends|"The intervention includes the following components:~1. Within each class parents will engage in two meetings combining education and parent-to-parent communication about 1) the children's leisure time activities, and 2) family and class screen time culture. Parents will engage in a short exercise focusing on screen media dilemmas conducted by the teacher in the beginning of 4th grade.~2. Children will engage in school hour workshops focusing on the class culture related to screen media use and leisure time activities.~3. Afterschool club personal will engage in mini actions learning program consisting of three workshops aimed to increase participation rate in the afterschool club.~4. Local stakeholders, e.g., parents, school- and afterschool club personal and others relevant to children's leisure time (e.g., sports clubs) will engage in workshops to adjust the predetermined intervention components (1-3 above) to fit their local context and to develop a local action plan."
214287915|NCT00004224|DRUG|cyclophosphamide|
214287916|NCT00004224|DRUG|etoposide|
214287917|NCT00004224|DRUG|vincristine sulfate|
214287918|NCT00004224|PROCEDURE|adjuvant therapy|
214287919|NCT00004224|PROCEDURE|conventional surgery|
214287920|NCT00004224|RADIATION|radiation therapy|
214287921|NCT01224431|DRUG|Buffered Lidocaine J-tip|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
214845877|NCT04787952|OTHER|cold expossure|subjects were exposed for the cold, to activate and diagnose potential brown tissue activity
214845878|NCT00519922|OTHER|Kinesthesia, Balance, and Agility (KBA) Exercise|"Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion \& agility, dynamic proprioception,functional strength \& endurance.~Kinesthesia \& Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability \& confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia \& balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads."
214287922|NCT05385393|PROCEDURE|Arthroscopic posterior capsulotomy of the knee|"The arthroscopic posterior capsulotomy of the knee is performed according to the predefined surgical technique, which was described in detail in the following publication:~Malinowski K, Góralczyk A, Hermanowicz K, LaPrade RF, Więcek R, Domżalski ME. Arthroscopic Complete Posterior Capsulotomy for Knee Flexion Contracture. Arthrosc Tech. 2018 Oct 15;7(11):e1135-e1139. doi: 10.1016/j.eats.2018.07.008. PMID: 30533360; PMCID: PMC6262078."
214287923|NCT04811391|BIOLOGICAL|COVID-19 vaccine|Observation of individuals who receive the COVID-19 vaccine (2 doses of PfizerBioNtech COVID-19 vaccine).
214287924|NCT02240251|OTHER|Prospective Chart Review|The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
214287925|NCT04056689|DRUG|DNL151|Oral repeating dose
214287926|NCT04056689|DRUG|Placebo|Oral repeating dose
214287927|NCT04161989|DRUG|omega-3 fatty acids|. The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% \& Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
214287928|NCT04161989|DRUG|vaginal progesterone|Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
214287929|NCT02069301|BEHAVIORAL|Integrated Depression/Microfinance Group|LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
214287930|NCT02069301|OTHER|Treatment as Usual|National Guideline for antidepressant care
214287931|NCT02069301|OTHER|Livelihood Support|Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
214287932|NCT01635101|DRUG|IV Acetaminophen|IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
214287933|NCT01635101|DRUG|IV Control|IV Control q6h; 4 doses, in 24 hours
214287934|NCT02275650|RADIATION|nbUVB|2 SED nbUVB exposure will be given every other week
214287935|NCT02569723|DRUG|Carbon C 14 Oxaliplatin|Intravenous infusion
214287936|NCT02569723|DRUG|Oxaliplatin|Intravenous infusion
214287937|NCT02263794|PROCEDURE|Conventional Bronchial Thermoplasty|Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
214287938|NCT02263794|PROCEDURE|Image Guided Bronchial Thermoplasty|Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
214287939|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
214845879|NCT00519922|OTHER|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal \& external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
214287940|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
214287941|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
214287942|NCT02441777|DEVICE|Polarization-Sensitive OFDI|OCT Imaging of the eye
214287943|NCT03015012|GENETIC|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
214287944|NCT03015012|OTHER|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
214287945|NCT03232801|BEHAVIORAL|mindfulness-based multicomponent intervention|A group-based, multicomponent behavioral intervention rooted in mindfulness
214287946|NCT03232801|BEHAVIORAL|general health education group|A general health and aging education group
214287947|NCT05036551|DIAGNOSTIC_TEST|Kellgren Lawrence classification|The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
214287948|NCT02511184|DRUG|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
214287949|NCT02511184|DRUG|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
214287950|NCT05741320|OTHER|questionnaire|27 questions will be asked to public to find out what is the role of anesthetists after the covıd pandemic
214287951|NCT04202692|DEVICE|Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
214287952|NCT04202692|DEVICE|Placebo 1100 mg, identically-looking melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
214287953|NCT01499550|DEVICE|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
214287954|NCT01499550|OTHER|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
214287955|NCT05859789|PROCEDURE|kegel exercise|"* Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises."
214287956|NCT05859789|OTHER|Mediterranean diet regimen for 12 weeks.|kegel ex in addition to mediterrian diet . The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will be advised to consume at least 250-300 g of fruits, 125-150 g of vegetables and 25-50 g of nuts per day.
214287957|NCT00166673|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|
214287958|NCT02694874|DRUG|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
214287959|NCT02694874|DRUG|Placebo|This is the placebo control
214287960|NCT05877833|OTHER|Vibrancy Assessment|Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
214287961|NCT01522989|DRUG|PD-0332991|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
214287962|NCT01522989|DRUG|5-FU|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
214287963|NCT01522989|DRUG|Oxaliplatin|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
214287964|NCT03828357|OTHER|Study MRI scan|At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.
214287965|NCT02041286|DEVICE|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
214287966|NCT02670954|DRUG|Dexmedetomidine, tramadol and flurbiprofen|
214287967|NCT02670954|DRUG|tramadol and flurbiprofen|
214287968|NCT01720992|OTHER|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
214287969|NCT02985554|DRUG|Nivolumab|Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
214287970|NCT03372811|DRUG|TC cream|A well-characterized botanical drug for topical treatment of psoriasis vulgaris
214287971|NCT03372811|DRUG|Vehicle|Vehicle
214845880|NCT06400108|OTHER|Dementia Moves|"Dementia Moves: Dementia Moves is a multicomponent exercise program that can be individually tailored to the abilities of LTC residents with more advanced dementia and focuses on moderate- to high-intensity strength and balance activities with an aim to improve ADLs. Individualized strategies are implemented throughout the intervention to support and promote participation of individuals with more advanced dementia.~Each exercise will be individually prescribed for each participant by the physiotherapists (PT) at the beginning of the program. The intensity of the exercise will be adjusted throughout the program by the PT to ensure the target intensity of moderate to high intensity balance and strength exercises. The intervention will be provided face to face in groups of 4 residents with the PT, PTA, and three volunteers. Though the intervention is delivered in a group setting, the specific exercises that the participants complete are individualized based on their abilities."
214845881|NCT06071195|DIAGNOSTIC_TEST|Prostate Cancer Patients|see arm/group description
214287972|NCT06197854|PROCEDURE|Hernioplasty|Surgical hernioplasty
214287973|NCT05340608|OTHER|Smart, non-invasive shirt - Physiological parameters|Observation Group One and Control Group - Participants in these groups will be asked to wear a smart, non-invasive shirt while watching two different five-minute videos. One video will show relaxing images and will emit relaxing music (relaxing video). The second video will present impressive human body deformities accompanied by anxious music (disturbing video). Both videos will be presented with the participant in a sitting position. The duration of the entire session will be approximately 15 minutes. For the whole duration of the session, the smart shirt will collect data on participants' physiological parameters (electrocardiogram, heart rate, heart rate variability, respiration rate, minute ventilation, and body movement). Collected data will be used to develop an ad-hoc algorithm to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
214287974|NCT05340608|OTHER|Smart, non-invasive shirt - Relation with challenging behaviors|Observation Group Two - Each participant in this group will be asked to wear the smart, non-invasive shirt for seven consecutive days during waking hours, performing his usual daily activities. During the same seven days, the caregivers who care for the participant will be asked to accurately report the participant's status in a behavioral diary. Each evening, the data collected by the smart shirt will be uploaded to an online cloud along with the behavioral diary of the day. Collected data will be used to develop an ad-hoc algorithm able to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
214287975|NCT05340608|OTHER|Smart, non-invasive shirt - Proof of Concept|Proof of Concept - The participant with autism spectrum disorder enrolled in the proof-of-concept phase of this study will wear the smart, non-invasive shirt for seven days during all hours of attendance at the special school. At the end of the seven days, the healthcare professional and teacher who interacted with the developed system at the special school will participate in a focus group to analyze their experiences and opinions related to the system use.
214287976|NCT02533830|BIOLOGICAL|sugarless gum|"One Stick of Sugarless Gum (Samara for food \& Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
214287977|NCT02533830|OTHER|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
214287978|NCT04534023|DRUG|Idebenone|trial group
214287979|NCT04534023|DRUG|Placebo|control group
214287980|NCT03578991|DEVICE|Smart pillbox|The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
214287981|NCT03578991|OTHER|Interactive digital platform|The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
214287982|NCT01832376|PROCEDURE|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
214287983|NCT03445572|OTHER|Best Practice|Receive standard supportive care
214287984|NCT03445572|PROCEDURE|Meditation Therapy|Perform MSB
214287985|NCT03445572|PROCEDURE|Meditation Therapy|Perform IK meditation
214845882|NCT02577224|OTHER|Patient-initiated treatment|Please see Intervention Arm
214845883|NCT01741467|BEHAVIORAL|RT-CGM|Dexcom Seven+
214287986|NCT03445572|OTHER|Questionnaire Administration|Ancillary studies
214287987|NCT01824901|DRUG|docetaxel|Given IV
214287988|NCT01824901|DRUG|AZD4547|Given PO
214287989|NCT00844051|BIOLOGICAL|School-based influenza vaccination program|School-based influenza vaccination program
214287990|NCT02050074|DRUG|Colesevelam|
214845884|NCT02960438|DRUG|E6011|subcutaneous administration
214845885|NCT02960438|DRUG|Placebo|subcutaneous administration
214845886|NCT04987255|OTHER|Free visit|The persons with sedentary (healthy) in this group will have to visit the museum freely (without a guide) for a period of 75 minutes.
214845887|NCT04987255|OTHER|Guided visit|The persons with sedentary (healthy) in this group will have to visit the museum with a guide for a period of 75 minutes.
214845888|NCT04987255|OTHER|Guided visit (stroke)|The persons with motor disability after stroke in this group will have to visit the museum with a guide for a period of 75 minutes.
214845889|NCT00517543|DRUG|GW856553|
214845890|NCT03232255|OTHER|Mouthrinse (IQP-OLP-101)|Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
214845891|NCT05382156|DRUG|Osilodrostat|oral administration of Osilodrostat tablets at different doses according to patient's need
214845892|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) orally
214845893|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
214845894|NCT04815395|DRUG|Placebo|Administration of placebo orally
214845895|NCT03664050|DRUG|group A 2.5 mg letrozole oral tablets|2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
214845896|NCT03664050|PROCEDURE|laparoscopic ovarian drilling|Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
214845897|NCT05547334|BEHAVIORAL|Inference Based Approach (IBA)|The Inference Based Approach (IBA) (as described by Visser et al., 2015 and adapted for use in adolescents by L. Webers)is a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly and carried out as specified in a Dutch session-by-session IBA protocol, containing standardized forms for exercises and homework assignments. Each session has a standard format, starting with agenda setting and evaluating homework assignments, followed by determining and executing a new exercise and determining new homework. The IBA model is based on the assumption that adolescents with OCD and poor inside misjudge the actual state of affairs. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the childs attention from observable reality.
214845898|NCT02265341|OTHER|Laboratory Biomarker Analysis|Correlative studies
214845899|NCT02265341|DRUG|Ponatinib Hydrochloride|Given PO
214845900|NCT02265341|OTHER|Quality-of-Life Assessment|Ancillary studies
214845901|NCT02749760|OTHER|Strengthening program|Strengthening programs may be established to target the stabilizers of the elbows
214845902|NCT02749760|OTHER|Exercise program|Exercise program may be established to target the stabilizers of the elbows.
214845903|NCT02484313|OTHER|dietary treatments|commercially available food products
214845904|NCT04825041|DIAGNOSTIC_TEST|Patency test|Successive flow test, bubble flow test and peristalsis test
214845905|NCT06064734|DEVICE|LF-rTMS|H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).
214845906|NCT06615882|DEVICE|stent-angioplasty & nimodipine infusion (During the stent (Solitaire-X) -angioplasty, IA nimodipine was also infused)|"I. Procedure \& Intervention~1. Assess the presence and degree of cerebral vasospasm of the target vessel through cerebral angiography before the procedure.~2. Solitaire-X stent types are selected~3. During the stent-angioplasty, IA nimodipine was also infused.~4. Retrieve Solitaire-X after maintaining deployment for 3 minutes.~5. Additional procedures are determined through immediate post-procedure and 15-minute delayed cerebral angiography."
214287991|NCT02050074|DRUG|Metformin|
214287992|NCT02050074|OTHER|Placebo|
214287993|NCT01816633|DEVICE|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
214287994|NCT00462774|PROCEDURE|Intramyocardial injection of autologous CD133+ marrow cells|
214287995|NCT01685931|DRUG|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
214845907|NCT01647711|DRUG|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
214845908|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M2
214845909|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M3
214845910|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M2
214845911|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M3
214845912|NCT04822376|DRUG|ansuvimab|Human monoclonal antibody to Zaire strain GP (EBOV GP)
214845913|NCT04822376|BIOLOGICAL|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
214845914|NCT05664282|DEVICE|Damon self-ligating brackets|
214845915|NCT05664282|DEVICE|Victory self-ligating brackets|
214845916|NCT05403957|OTHER|TID video|"Main intervention: A video introducing the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 6 screenshots from the video and 6 true or false questions."
214845917|NCT05403957|OTHER|TID worksheet|"Main intervention: A worksheet using pictures and texts to introduce the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 8 pictures from the TID worksheet in the main intervention and 6 true or false questions."
214845918|NCT05403957|OTHER|SSB worksheet|"Main intervention: A worksheet using pictures and texts to introduce the beverage industry's marketing tactics to attract children and adolescents to drink SSBs and the health risks of SSBs.~Booster intervention: 8 pictures from the SSB worksheet in the main intervention and 6 true or false questions."
214845919|NCT01123096|PROCEDURE|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
214845920|NCT01123096|OTHER|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
214845921|NCT03898102|DRUG|Regorafenib|regorafenib plus zinc gluconate
214845922|NCT03898102|DIETARY_SUPPLEMENT|Zinc gluconate supplement|Zinc gluconate supplement
215033498|NCT02898688|BEHAVIORAL|Patient-level Intervention Group|"Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require yes or no responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants."
214287996|NCT03211689|OTHER|Exercise Program|Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week.
214287997|NCT03736317|DEVICE|sham TBS|Stimulate the dorsal lateral prefrontal cortex or medial prefrontal cortex for 2 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.
214287998|NCT03736317|DEVICE|real mPFC cTBS|Stimulate the medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
214287999|NCT03736317|DEVICE|real dlPFC iTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
214288000|NCT03736317|DEVICE|real dlPFC iTBS + real mPFC cTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
214288001|NCT03921086|DRUG|Antihypertensive medication according to the study's algorithm|"Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm."
214288002|NCT03258151|GENETIC|detection of genotype|detection of genotype by next generation sequencing
214288003|NCT03498690|BEHAVIORAL|Integrative|Stakeholder groups: a-b
214288004|NCT03498690|BEHAVIORAL|Role specific|Stakeholder groups: a or b
214288005|NCT03498690|BEHAVIORAL|Consecutive|Stakeholder groups: a=\> b
214288006|NCT05281445|BEHAVIORAL|Tic suppression task|Tic Suppression Task (TST, administered to Tourette syndrome participants only): At the beginning of the task, the child participant will be seated alone in front of a computer monitor with a countdown timer visible on the screen. For the first 10 minutes (baseline condition) they will be asked to tic freely and not to try to suppress their tics. For the second 10 minutes children will be asked to suppress their tics and will receive points for successful suppression. Participants will then be asked to sit alone in the room and tic freely for an additional 10-minutes.
214845923|NCT04694612|DRUG|Favipiravir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
215033499|NCT01329133|PROCEDURE|Deep Brain Stimulation (DBS)|In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
215033500|NCT00864357|DRUG|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
215033501|NCT00864357|DRUG|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
215033502|NCT01599286|DRUG|Carbaglu|"Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients \>15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste."
215033503|NCT01599286|DRUG|Placebo|Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
215033504|NCT02429960|DEVICE|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
215033505|NCT02429960|DEVICE|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
214288007|NCT00119002|DRUG|dexamethasone|1mg/kg dexamethasone
214288008|NCT00119002|DRUG|Placebo|1mg/kg placebo
214288009|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
214288010|NCT03989557|DEVICE|Light transmittance aggregometry|point-of-care method to assess platelet function by light transmittance aggregometry.
215033506|NCT02429960|DEVICE|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
214288011|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|maintenance dose of aspirin, clopidogrel and ticagrelor.
214288012|NCT04590261|OTHER|Blood sampling|Peripheral Blood sampling, 25 mL
214288013|NCT04590261|OTHER|Nasal Brushing|Nasal Brushing, facultative
214288014|NCT03542968|PROCEDURE|magnetic resonance imaging|Acquisition 4D Flow magnetic resonance Imaging-8 minutes
214288015|NCT00774150|BEHAVIORAL|Cognitive Behavioral Therapy|16 sessions of CBT
214288016|NCT00774150|BEHAVIORAL|Client Centered Therapy|16 sessions of CCT
214288017|NCT01963403|DRUG|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
214288018|NCT01963403|DRUG|Placebo|1 pill per day; daily during study participation (up to 84 days)
214288019|NCT04120831|DRUG|Abatacept Injection|Drug
214288020|NCT01580189|DIETARY_SUPPLEMENT|Whey protein|18g protein, immediately after training, 9 weeks
214288021|NCT01580189|DIETARY_SUPPLEMENT|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
214288022|NCT01580189|DIETARY_SUPPLEMENT|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
214288023|NCT04700982|OTHER|Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and \> 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
214288024|NCT06017440|BEHAVIORAL|EXERCISE|Participants will receive at 08:00 am a calibrated breakfast of 500kcal. They should not perform physical exercise during the day. They will be asked at 11 a.m. to cycle for 30 minutes at 65% of the maximal capacities and their energy expenditure will be measured by indirect calorimetry. At 11 a.m., teenagers will receive a calibrated meal of 800 kcal respecting the nutritional recommendations for this age. Questionnaires on feelings of hunger will be distributed to them at regular intervals. They will also be asked to complete a 10-minute computer exercise to assess their relationship to food before and after lunch (LFPQ. Leeds Food Preference Questionnaire, Liking/ wanting). Finally, from 60 minutes after the midday test meal, teenagers will have access to an ad libitum buffet for one hour.
214845924|NCT04694612|DRUG|Placebo|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
214845925|NCT04694612|DRUG|Remdesivir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
214845926|NCT01344616|BEHAVIORAL|lifestyle support|computer-based lifestyle improvement support and clinician support
214845927|NCT00388895|DRUG|chemotherapy|
214845928|NCT00388895|DRUG|Glivec|
214845929|NCT01706861|DEVICE|Celotres|Celotres following surgical removal of earlobe keloid.
214845930|NCT02760264|DRUG|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
214845931|NCT02760264|DRUG|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
214288025|NCT06017440|BEHAVIORAL|CONTROL|Teenagers should not perform any physical activity during the day and they will be asked to stay at 11 a.m., for 30 minutes, resting in a semi-supine position.
214288026|NCT03963362|DRUG|GLA5PR tablet 75 mg|GLARS-NF3 tablet
214288027|NCT03963362|DRUG|GLA5PR tablet 150 mg|GLARS-NF3 tablet
214288028|NCT01681732|OTHER|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
214288029|NCT01681732|OTHER|Control Standard Care|This is the standard care arm
214845932|NCT02760264|DRUG|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
214288030|NCT04894773|OTHER|Imaginary Resistance Exercises|In imaginary resistance exercises, resistive force is assumed to get applied by the patient after demonstrating some resistive objects and the kind of force exerted by them.
214288031|NCT04894773|OTHER|Physical Resisted Exercises|In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects.
214288032|NCT04945902|BEHAVIORAL|Synchronous Intervention|Weekly one-hour support groups. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connection and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
214288033|NCT04945902|BEHAVIORAL|Asynchronous Intervention|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include: (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
214288034|NCT03244345|BEHAVIORAL|Self-measurement scale of sensitivity to stress/emotion|Patient will answer self-questionner on Depression
214288035|NCT05743179|DRUG|Zoledronate|Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
214288036|NCT05513079|BEHAVIORAL|Positive Psychotherapy Based Counseling|The main purpose in Positive Psychotherapy is to develop the individual's main capacities. and to maintain balance in the four areas of life (body, success, relationships and future) in daily life. to help provide. The essence of Positive Psychotherapy is a five-step process: 1. Observation/distance phase, 2. Inventory phase, 3. Situational encouragement phase, 4. Verbalization phase, 5. Expanding the objectives phase. Shaping five-step model therapy It is a helpful guide.
214845933|NCT02760264|DRUG|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
214845934|NCT05918822|DRUG|Maribavir Commercial Tablet Formulation|Maribavir commercial tablet.
214845935|NCT05918822|DRUG|Maribavir Pediatric Powder-for-oral Suspension Formulation|Maribavir pediatric powder-for-oral suspension.
214845936|NCT05918822|DRUG|Rabeprazole|Rabeprazole tablet.
214845937|NCT00773942|BEHAVIORAL|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
214845938|NCT00773942|BEHAVIORAL|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
214845939|NCT03360175|OTHER|No intervention - observational study|No intervention - observational study
215033507|NCT02429960|DRUG|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
215033508|NCT01291589|BEHAVIORAL|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
214288037|NCT04106986|COMBINATION_PRODUCT|Pulsed electromagnetic field and Progressives resistance exercise|"The pulsed electromagnetic field treatment consist of 30 minutes pulsed electromagnetic field with 50 Hz pulses~The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
214288038|NCT04106986|OTHER|PRE|"The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
214288039|NCT02289690|DRUG|Veliparib|Capsules administered orally twice a day according to the dosing schedule.
214288040|NCT02289690|DRUG|Carboplatin|Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.
214288041|NCT02289690|DRUG|Etoposide|Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
214288042|NCT02289690|DRUG|Placebo|Placebo to veliparib administered orally twice a day according to the dosing schedule.
214288043|NCT04416464|OTHER|COVID-19 Pneumonia|Pneumonia due to proven or suspected SARS-Cov-2 infection
214288044|NCT01170754|DRUG|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
214288045|NCT01170754|DRUG|Golytely 4 liters|Golytely 4 liters
214288046|NCT00910312|DEVICE|Ice-Sense|Ice-Sense Cryoprobe
214288047|NCT04763798|OTHER|Straight-leg-raise (SLR)|The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the SLR, the knee was kept in full extension and then, hip flexion was performed until a marked resistance. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.The stretch lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes
214288048|NCT04763798|OTHER|Passive Knee extension test (PKE)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the PKE, the hip was kept in 90º flexion and then, knee extension was performed. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
214288049|NCT04763798|OTHER|Maximum hip flexion (MHF)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For MHF, a maximal hip flexion was performed and then, knee extension was applied. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
214288050|NCT03099421|PROCEDURE|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
214288051|NCT01612481|PROCEDURE|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
214288052|NCT01612481|PROCEDURE|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
214288053|NCT00468182|DRUG|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
214288054|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12
214288055|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 4D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12
214288056|NCT06062511|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix
214288057|NCT02263989|DRUG|Telmisartan film coated tablet|
214288058|NCT02263989|DRUG|Telmisartan conventional tablet|
214288059|NCT01444118|BIOLOGICAL|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
214288060|NCT04016285|DEVICE|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
214288061|NCT04016285|DEVICE|Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
214288062|NCT03256214|PROCEDURE|Closed suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
214288063|NCT03256214|PROCEDURE|Open suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
214288064|NCT02908555|OTHER|No intervention|This is a descriptive study with no intervention
214288065|NCT00642577|DRUG|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
214288066|NCT00642577|DRUG|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
214288067|NCT00642577|DRUG|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
214288068|NCT00642577|DRUG|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
214288069|NCT01391559|DRUG|arformoterol|15 mcg administered via nebulizer
214288070|NCT01391559|DRUG|salmeterol|50 mcg delivered vis Diskus
214288071|NCT05277740|DEVICE|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
214288072|NCT06315439|PROCEDURE|Endoscopic ultrasound fine needle biopsy|"EUS FNA/B for solid pancreatic lesions. After the FNA/FNB, the needle was removed from the EUS endoscope and the specimen obtained after the first needle pass was expelled and placed directly in a dedicated scaffold (Cytomatrix, UCS Diagnostics).~a drop of ethanol was put on it and the liquid was drained away thanks to the porous structure of the matrix. This step was followed by the deposition of a drop of acridine-orange for 20 and a rapid washing with buffered saline. After that, the Cytomatrix was put on a dedicated microscopic slide and covered with a second slide before the introduction in the slot of the machine.~The FCM VivaScope® 2500 (2500M-G4; VivaScope, Munich, Germany) was used for immediate imaging."
214288073|NCT00460408|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
214288074|NCT01380873|DRUG|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
214288075|NCT01380873|DRUG|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
214288076|NCT01380873|DRUG|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
214288077|NCT01654367|DRUG|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
214288078|NCT02829515|PROCEDURE|tonsil surgery with or without concomitant adenoidectomy|tonsillectomy, tonsillectomy with adenoidectomy, tonsillotomy, tonsillectomy with adenoidectomy
214288079|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
214288080|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Zagreb post-exposure immunization schedule at day 0,7,21.
214288081|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
214288082|NCT04207970|OTHER|Adapted Structured Clinical Management|Adapted form of a previous Evidence Based Treatment- adapted to local context, in light of input from service-users and commissioners.
214288083|NCT04478955|DIAGNOSTIC_TEST|Schirmer test|Tear tests Meibomian gland grading test
214288084|NCT00294268|BEHAVIORAL|cognitive behavioural therapy|20 weekly sessions of CBT integrated with motivational enhancement strategies
214288085|NCT04800705|OTHER|ultrasound assessment|Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)
214288086|NCT05953220|OTHER|Exclusive tobacco smoking|No intervention, participants own tobacco products
214288087|NCT05953220|OTHER|Exclusive e-cigarette use|No intervention, participants own e-cigarette products
214288088|NCT05953220|OTHER|Dual use of e-cigarettes and tobacco smoking|No intervention, participants own tobacco and e-cigarette products
214288089|NCT05953220|OTHER|No use of e-cigarettes or tobacco smoking|No intervention
214288090|NCT01413529|BEHAVIORAL|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
214288091|NCT01413529|BEHAVIORAL|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
214288092|NCT01442493|OTHER|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
214288093|NCT01442493|OTHER|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
214288094|NCT06049784|DEVICE|Visual Biofeedback using self operated home ultrasound device|participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home. Session records will be sent electronically to the sonographer for assessment and feedback.
214288095|NCT06049784|DEVICE|Visual Biofeedback using ultrasound at hospital|A single ultrasound biofeedback session using Transperineal Ultrasound will guide maternal pushing.
214288096|NCT00525460|BEHAVIORAL|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
214288097|NCT00774319|RADIATION|conventional radiotherapy with 'high' dose cisplatin|"radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43"
214288098|NCT00774319|RADIATION|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
214288099|NCT01626560|DRUG|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
214288100|NCT01626560|DRUG|Vancomycin|Vancomycin 1g q12h 10 - 14 days
214288101|NCT02461563|DRUG|200 mg MK-1075|Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
214288102|NCT02461563|DRUG|400 mg MK-1075|Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
214288103|NCT02461563|DRUG|800 mg MK-1075|Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
214288104|NCT01111149|OTHER|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
214845940|NCT06403072|DIAGNOSTIC_TEST|The Gynecologic Imaging-Reporting and Data System (GI-RADS)|The Gynecologic Imaging-Reporting and Data System (GI-RADS) using ultrasound
214845941|NCT06052020|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
214845942|NCT06052020|DRUG|Atorvastatin|Atorvastatin 20-40mg
214288105|NCT01111149|DRUG|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
214288106|NCT01111149|DRUG|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
214845943|NCT01796964|DRUG|ESBA1008 solution|For intravitreal (IVT) injection
214845944|NCT01796964|DRUG|Aflibercept|For intravitreal (IVT) injection
214845945|NCT04025684|OTHER|Oral B Indicator 123|Manual toothbrush (medium bristle stiffness; compact head, UK market).
214845946|NCT04025684|OTHER|Dr Best Original|Manual toothbrush (medium bristle stiffness; regular head, German market)
214845947|NCT04025684|OTHER|Dr Best Multi Expert|Manual toothbrush (medium bristle stiffness; compact head, German market)
214845948|NCT04025684|OTHER|parodontax Interdental|Manual toothbrush (soft bristle stiffness; compact head, German market)
214845949|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
214845950|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
214288107|NCT03535870|DRUG|Fluticasone propionate/salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device
214845951|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
214845952|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
214288108|NCT03535870|DRUG|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
214288109|NCT03535870|DRUG|Placebo|placebo dry powder administered via the LOMI inhaler device
214288110|NCT04539847|DEVICE|High-end hearing aid|hearing aid with premium level of technology
214288111|NCT04539847|DEVICE|Basic hearing aid|hearing aid with basic level of technology
214288112|NCT00759954|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
214288113|NCT00759954|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
214288114|NCT00126841|PROCEDURE|CT and MR fusion|
214288115|NCT01348945|OTHER|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
214288116|NCT00061880|DRUG|forodesine hydrochloride|
214288117|NCT01366560|DRUG|Active|GSK962040 125mg
214288118|NCT01366560|DRUG|Placebo|Matching Placebo
214288119|NCT00332033|DRUG|Pirfenidone|
214288120|NCT02368431|DRUG|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
214288121|NCT02368431|DRUG|Placebo|Placebo
214288122|NCT05975515|PROCEDURE|Connective tissue graft /Bone graft/ Customized HA|Soft tissue management and augmentation
214845953|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
214845954|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
214845955|NCT00627471|DRUG|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
214845956|NCT00627471|DRUG|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG\<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
214845957|NCT03301818|DEVICE|Vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
214845958|NCT01754818|DRUG|Bendavia 10mg|
214845959|NCT01754818|DRUG|Bendavia 50mg|
214845960|NCT01754818|DRUG|Bendavia 100mg|
214845961|NCT01754818|DRUG|Placebo|
214845962|NCT06177847|DEVICE|BIS|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
214845963|NCT05281978|BEHAVIORAL|Decrease Sedentary Time + Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise; personalized step count goals to increase daily volume of physical activity and displacement of sedentary time
214845964|NCT05281978|BEHAVIORAL|Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise
214845965|NCT02744755|BIOLOGICAL|Adalimumab - GP2017|Adalimumab - GP2017
214845966|NCT02744755|BIOLOGICAL|Adalimumab - US licensed Humira|Adalimumab - US licensed Humira
214845967|NCT06196944|BEHAVIORAL|Augmentative Alternative Communication|Traditional Method
214845968|NCT06196944|OTHER|Augmentative Alternative Communication Device|Augmentative Alternative Communication Device 3 session for 40 minutes
214845969|NCT04344626|DEVICE|Intra-operative brain tonometry|Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
214845970|NCT03033719|PROCEDURE|Laparotomy|Open surgery
214845971|NCT03033719|PROCEDURE|Laparoscopy|Minimally invasive surgery
214845972|NCT03988452|DRUG|Darunavir|Antiretroviral therapy
214845973|NCT03988452|DRUG|Ritonavir|Antiretroviral therapy
214845974|NCT03988452|DRUG|Dolutegravir|Antiretroviral therapy
214845975|NCT03988452|DRUG|Zidovudine|Antiretroviral therapy
214845976|NCT03988452|DRUG|Tenofovir|Antiretroviral therapy
214845977|NCT03988452|DRUG|Lamivudine|Antiretroviral therapy
214288123|NCT01890850|OTHER|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
214288124|NCT05460117|DEVICE|Radiofrecuency|he use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment looking for improve the quality of the tissue is still to be explored.
214288125|NCT00422175|DRUG|BAF 312|
214288126|NCT03124875|DEVICE|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia.
214288127|NCT04827329|OTHER|Questionnaire|Patients will complete a questionnaire regarding their anesthesia history, course and possible complications, and Questions about their treatment for their sleep disorder.
214288128|NCT03835611|OTHER|Game based treadmill Platform|"The protocol for the intervention group will be:~* Warm up exercised consisting of rhythmical large movements (10minutes)~* Dynamic standing balance training by playing commercial games with head rotations while standing on a compliant surface to increase balance demands. (10 Minutes)~* DT treadmill training, consisting of playing commercial computer games while walking on the treadmill at a self-selected comfortable speed. Participants will be allowed to take rest when required and total effective DT treadmill walking will be for 30minutes. Treadmill speed will be aimed to progress depending on participant performance and documented. An overhead safety harness will always be provided to participants while walking on the treadmill. (25minutes)"
214288129|NCT03835611|OTHER|Control Group|"* Warm-up exercise consisting of rhythmical large movements (10 minutes).~* Core standing balance exercises on a sponge surface (10 minutes).~* Treadmill walking for 20 minutes, which includes rests periods... An overhead safety harness will be provided to participants while walking on the treadmill~* Overground walking in an obstacle course. Participants will be instructed to walk along a curved path (marked by tape) and avoid obstacles placed randomly. The obstacle will be thin sponge pads with 10-12 inches in diameter (15minutes)."
214288130|NCT03852355|DRUG|Radiofrequency|), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
214288131|NCT03852355|DRUG|Steroids|received systemic steroids oral prednisolone tablet, 10 mg/day
214288132|NCT03220516|PROCEDURE|single use digital ureteroscope|All participants in this arm will undergo RIRS using a single use digital ureteroscope.
214288133|NCT03220516|PROCEDURE|reusable fiberoptic ureteroscope|All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope
214288134|NCT03220516|PROCEDURE|reusable digital flexible ureteroscope|All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
214288135|NCT03741179|DRUG|ASA-withdrawn group|Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
214288136|NCT01313936|DRUG|Metaiodobenzylguanidine (MIBG)|Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
214288137|NCT05039645|BEHAVIORAL|Patient specific, clinician determined Intervention|Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of \>2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment).
214288138|NCT00456131|BEHAVIORAL|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
214288139|NCT05808491|RADIATION|online resilience intervention|online resilience intervention were presented in four 60-minute sections, once a week for four weeks embracing four sections
214288140|NCT05560997|DIAGNOSTIC_TEST|10-year ASCVD risk estimation|High CVD risk was defined as a history of CVD or a 10-year ASCVD risk ≥10%. The 10-year ASCVD risk estimation was carried out according to 2016 Chinese guidelines for the management of dyslipidemia in adults.
214288141|NCT04035928|DEVICE|3D digital scanning for maxillofacial prosthetics|The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
214288142|NCT01277263|DEVICE|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
214288143|NCT04833881|OTHER||
214288144|NCT04697524|BEHAVIORAL|Support Group Therapy|Virtual group meetings
214288145|NCT04697524|BEHAVIORAL|Symptom Management Service (SMS) Consultation|Virtual individual meetings with symptom management service (SMS) over 5 minutes
214288146|NCT04697524|OTHER|Quality of Life (QOL) Questionnaires|Administered at each study visit
214288147|NCT04697524|OTHER|Interview|Virtual exit interview at end of study
214288148|NCT03628560|DEVICE|RespirAct Step-Wise Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
214288149|NCT03628560|DEVICE|RespirAct Slope Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
214845978|NCT01978899|BEHAVIORAL|Immediate Weight Loss Program Group|Participation in 15-week Healthy Living Program.
214845979|NCT01978899|BEHAVIORAL|Delayed Weight Loss Program Group|Participation in 15-week Healthy Living Program following 15-week wait period.
215033509|NCT04348474|DRUG|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
215033510|NCT04348474|DRUG|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
215033511|NCT02356237|OTHER|No episiotomy|Avoidance of episiotomy
214288150|NCT03628560|DEVICE|RespirAct Step-Wise Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
214288151|NCT03628560|DEVICE|RespirAct Slope Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
214288152|NCT03628560|DEVICE|ROBD Step-Wise desaturation sequence|Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
214288153|NCT05460845|BEHAVIORAL|Low-Carbohydrate Diet|Using a meal delivery service and a list of prepared meals and recipes, foods/meals will be delivered to participants weekly to maintain daily net carbohydrate intake to less than 40 grams.
214288154|NCT01073891|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions
214288155|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions
214288156|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions
214288157|NCT01910090|DRUG|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
214288158|NCT01910090|DRUG|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
214288159|NCT02521610|DRUG|Placebo|Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
214288160|NCT02521610|DRUG|RG7625|Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
214288161|NCT00260403|PROCEDURE|Photodynamic therapy versus Transpupillary thermotherapy|
214288162|NCT04412824|DRUG|Intravenous blood draw|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
214288163|NCT03325283|DEVICE|ProtEmbo Cerebral Protection System|A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
214288164|NCT01238471|DRUG|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
214288165|NCT01238471|DRUG|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
214288166|NCT05318170|PROCEDURE|Laparoscopic ultra-radical lymph node debulking|Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
214288167|NCT02922556|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
214288168|NCT02922556|OTHER|Commercially available computerized training|
214288169|NCT06093698|BIOLOGICAL|Recombinant Anti-EpCAM-CD3 Antibody Injection|Intravenous Infusion
214288170|NCT01931124|BEHAVIORAL|High Intensity Training|
214288171|NCT01931124|BEHAVIORAL|Moderate Intensity Training|
214288172|NCT00453882|DEVICE|flostat (TM) System|
214288173|NCT06124144|DRUG|Oleylphosphocholine|The trial is a dose escalation trial that follows a 3+3 approach. The sample size is determined by a decision-making algorithm and by the tolerability of the study drug in the study participants. This design follows predetermined rules that help identify notable toxicities in time with a reasonable degree of accuracy. The initial dose will be 50mg OlPC (1 capsule) and participants in subsequent cohorts will receive 100mg (2 capsules), 150mg (3 capsules), 200mg (4 capsules), 250mg (5 capsules), or 300mg (6 capsules) if the previous doses are tolerated. The study ends when the last cohort is completed or when it is determined that a dose (within a cohort) is not tolerable.
214288174|NCT01200602|DRUG|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
214845980|NCT06132152|PROCEDURE|Open hemorrhoidectomy with 'cold' scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.
214288175|NCT01200602|OTHER|clinical observation|No treatment is given.
214288176|NCT04887714|OTHER|Mask|Mask wearing
214288177|NCT00686660|BEHAVIORAL|cycling, walking|"In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years."
214288178|NCT00686660|BEHAVIORAL|cycling, non-walking|"In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training."
214288179|NCT00686660|BEHAVIORAL|walking, walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years."
214288180|NCT00686660|BEHAVIORAL|walking, non-walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community."
214288181|NCT01634815|PROCEDURE|The Edge|measuring blood lactate
214288182|NCT03764501|DEVICE|Image fusion system|Image fusion system for the 3D preoperative planning
214288183|NCT03789045|DIAGNOSTIC_TEST|Metabolic thresholds and fat oxidation points relationship|Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
214288184|NCT03041402|OTHER|PSP|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
214845981|NCT06132152|PROCEDURE|Open hemorrhoidectomy with electrosurgical scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
214845982|NCT03179449|DIAGNOSTIC_TEST|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
214845983|NCT03179449|PROCEDURE|Surgery|Undergo surgical resection
214845984|NCT03179449|DRUG|Ferumoxytol|Given IV
214845985|NCT03179449|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
214845986|NCT02975037|DRUG|Sildenafil|sildenafil 25 mg PO
214845987|NCT02975037|DRUG|Clarithromycin|clarithromycin 250 mg PO
214845988|NCT02975037|DRUG|Itraconazole|itraconazole 100 mg PO
214845989|NCT01343069|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
214845990|NCT05234320|DRUG|CG-SpikeDown, intranasal formulation|The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
214845991|NCT05234320|DRUG|Vehicle (Placebo)|patients will receive active drug or placebo in addition to standard of care
214845992|NCT05234320|DRUG|Standard of core (type of therapy is depend of decide of the site)|patients will receive active drug or placebo in addition to standard of care
214845993|NCT00894114|BIOLOGICAL|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
214845994|NCT00894114|BIOLOGICAL|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
214845995|NCT03669575|DIETARY_SUPPLEMENT|omega 7|Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
214845996|NCT03669575|DIETARY_SUPPLEMENT|Placebo|Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
214288185|NCT03041402|OTHER|NAVA|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
214288186|NCT03041402|OTHER|PSN|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
214288187|NCT00697762|DRUG|RWJ-333369|200 mg tablet twice daily for 12 weeks
214845997|NCT00377078|DRUG|recombinant human lactoferrin|
214845998|NCT03610828|OTHER|Vegetarian or Vegan Diets|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
214845999|NCT02396173|OTHER|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
214288188|NCT00697762|DRUG|RWJ-333369|100 mg tablet twice daily for 12 weeks
214288189|NCT00697762|DRUG|Placebo|Placebo tablet twice daily for 12 weeks
214846000|NCT03159286|BEHAVIORAL|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
214288190|NCT03455920|OTHER|Clinical nurse (supernurse) evaluation|The first evaluation of the patient refered to the sleep clinic will be performed by the clinical nurse then discussed with the pulmonologist in charge.
214288191|NCT03455920|OTHER|Pulmonologist evaluation|The first evaluation of the patient refered to the sleep clinic will be performed only by the pulmonologist.
214288192|NCT01929434|OTHER|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
214288193|NCT01929434|BIOLOGICAL|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
214846001|NCT03159286|BEHAVIORAL|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
214846002|NCT03159286|BEHAVIORAL|Control|Participants view social networking site profiles with no alcohol content.
214846003|NCT06363630|DRUG|Itraconazole|Specified dose on specified days.
214846004|NCT06363630|DRUG|Rifampin|Specified dose on specified days
214846005|NCT06363630|DRUG|Golcadomide|Specified dose on specified days
214846006|NCT03239236|PROCEDURE|Rapid sequence induction t-RSI|Preoxygenation via face mask, no ventilation with no PEEP until intubation
214846007|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-PEEP|Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
214846008|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-vent|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
214846009|NCT03239236|PROCEDURE|m-RSI-vent-cric|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
214846010|NCT03239236|PROCEDURE|Cricoid Pressure|Cricoid Pressure will be applied during RSI until laryngoscopy
214846011|NCT03239236|DRUG|Anesthetics|Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
214846012|NCT03239236|DIAGNOSTIC_TEST|Aspiration of gastric air via nasogastric tube|A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
214846013|NCT03239236|DIAGNOSTIC_TEST|Impression of gastric inflation at laparoscopy.|The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
214846014|NCT03239236|DIAGNOSTIC_TEST|Arterial blood gas|Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
214846015|NCT03138902|DIETARY_SUPPLEMENT|TRUTOL Glucose Tolerance Beverage|A caffeine-free, non-carbonated, glucose tolerance beverage
214288194|NCT01171339|OTHER|Optimization strategy (complex intervention)|"Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
214288195|NCT02408640|BEHAVIORAL|Cannabishjalpen.se|
214288196|NCT03856164|DRUG|Tranexamic Acid|Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
214288197|NCT03856164|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
214288198|NCT04181502|PROCEDURE|pneumatic tourniquet|a pneumatic tourniquet around 200 mmHg after venous chase of the lower limb, during 5 minutes then deflated. Repeated twice after general anaesthesia and prior to incision.
214288199|NCT04181502|OTHER|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
214846016|NCT05002686|DRUG|Sintilimab|200 mg Q3W on Day 1 by IV infusion
214846017|NCT05002686|DRUG|Albumin-Paclitaxel|200 mg/m\^2 Q3W on Day 1 by IV infusion
214288200|NCT05940207|DEVICE|e-Bandages|A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.
214288201|NCT05769439|OTHER|No intervention in an observational study|This study is an observational study only.
214288202|NCT00220870|BEHAVIORAL|Decision aid|
214288203|NCT03640845|OTHER|tele-expertise|"Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.~Tele-expertise is realized in three stages, that are~* the transmission, the collection and the organization of the data,~* the analysis of the data and their confrontation with the referential and recommendations~* the writing of a Personalized Pharmaceutical Plan"
214288204|NCT05252117|DRUG|Articaine Hydrochloride 40 MG/ML|Analysis of uterovaginal plexus block with articain for intrauterine device placement
214288205|NCT05252117|DRUG|Mepivacaine|Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement
214288206|NCT04541550|DRUG|AMP-001 Low Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
214288207|NCT04541550|DRUG|AMP-001 Medium Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
214288208|NCT04541550|DRUG|AMP-001 High Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
214288209|NCT06501482|DRUG|Postoperative reintroduction of FOLFIRI based chemotherapy|Postoperative reintroduction of FOLFIRI: irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion over 46 h biweekly. For a total of 12 cycles of perioperative chemotherapy including the preoperative chemotherapy
214288210|NCT04717115|GENETIC|Genetic diagnosis|No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
214288211|NCT00911053|DRUG|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
214288212|NCT00911053|BEHAVIORAL|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
214288213|NCT00911053|BEHAVIORAL|Light|Subjects will be exposed to light.
214288214|NCT02366520|DEVICE|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
214288215|NCT05070598|DRUG|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle
214288216|NCT03067168|DRUG|Bupivacaine|5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
214288217|NCT03067168|DRUG|normal saline 0.9%|5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
214288218|NCT06024356|DRUG|Thymalfasin|Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.
214288219|NCT03928600|COMBINATION_PRODUCT|Cervical Foley combined with Misoprostol|Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
214288220|NCT03928600|DRUG|Dinoprostone 10mg insert OR|Application for 24h of Dinoprostone 10mg insert
214288221|NCT03928600|DRUG|Misoprostol|Application of vaginal misoprostol 25ug 4/4h until 150ug
214288222|NCT02518750|DRUG|Dexamethasone|Given orally (PO).
214288223|NCT02518750|DRUG|Panobinostat|Given PO.
214288224|NCT02518750|DRUG|Liposomal vincristine|For intravenous (IV) use only.
214288225|NCT02518750|DRUG|Mitoxantrone|Given IV.
214846018|NCT05002686|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
214846019|NCT05002686|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
214846020|NCT05002686|RADIATION|Radiation|Radiotherapy for gastric lesions and high-risk areas of retroperitoneal lymph node before sugery, 45Gy\*25.
214846021|NCT05002686|PROCEDURE|Radical gastric cancer surgery|Radical gastric cancer surgery with D2 lymph node dissection
214846022|NCT01163084|DRUG|Goserelin Acetate|Given SC
214846023|NCT01163084|OTHER|Laboratory Biomarker Analysis|Correlative studies
214846024|NCT01163084|DRUG|Leuprolide Acetate|Given IM
214846025|NCT01163084|DRUG|Vismodegib|Given PO
215033512|NCT04329884|PROCEDURE|Cooled RFA treatment with COOLIEF* device|Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
214288226|NCT02518750|DRUG|Peg-asparaginase|"Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection."
214288227|NCT02518750|DRUG|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
214846026|NCT05025579|OTHER|Aerobic Exercise|"Since up in 2 min 10 repetitions active joint movement (while seated knee flexion and extension the ankle plantar and dorsal flexion , standing the hip flexion , extension the , abduction and adduction ) , treadmill for 3 minutes, 0.5 m / sec speed walk with and to adapt both warming bike 5 minutes, RPE ( Rating of Perceived exertion discoverable by exertion rate) will be 2/10 in a way was built.~As aerobic exercise, the first week will be RPE 4/10 for 10 minutes, the second week with RPE 4/10 12 minutes, the third week with RPE 4/10 14 minutes, the fourth week with RPE 4/10, 16 minutes, the fifth week with RPE 5/ 2 0 will be as 18 minutes sixth week RPA 10.6 will form was done 20 minutes of exercise .~Cooling period in the RPE 2.10 will be the 5 minute turning cycling, 5 min active range of motion exercises and stretching was done."
214846027|NCT03687879|OTHER|Questionnaires|Reporting of medical gestures or acts, speech, embarrassing or hurtful attitudes during pregnancy follow-up or during hospitalization outside childbirth, or during childbirth or immediate after birth among women giving birth in one of the 26 maternity hospitals in the period of observation period.
214846028|NCT00021489|DRUG|Abacavir sulfate|
214846029|NCT00021489|DRUG|Mycophenolate mofetil|
214846030|NCT00002787|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|Given SC
214846031|NCT00002787|BIOLOGICAL|sargramostim|Given SC
214846032|NCT00002787|BIOLOGICAL|aldesleukin|Given SC
214846033|NCT00002787|OTHER|laboratory biomarker analysis|Correlative studies
214846034|NCT04683757|OTHER|Establishment of a Survival Prediction Model|a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer
214846035|NCT06296524|OTHER|Footcore exercises and conventional therapy|30 minutes exercises protocol will be provided
214288228|NCT02518750|DRUG|Intrathecal Triples|Given IT as ITMHA.
214288229|NCT02518750|DRUG|High-dose methotrexate|Given intrathecally (IT) or IV.
214846036|NCT06296524|OTHER|conventional therapy|conventional therapy will be provided.
214846037|NCT03119493|BEHAVIORAL|Periodized aerobic interval training|The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
214846038|NCT02916693|DRUG|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
214846039|NCT03024931|OTHER|observational study|No intervention
214846040|NCT01120769|DRUG|Acetaminophen|single dose
214846041|NCT01120769|DRUG|Placebo|single dose
214288230|NCT02518750|DRUG|6-Mercaptopurine|Given PO at consistent time each day.
214288231|NCT02518750|DRUG|High-dose cytarabine|Given IT or IV.
214288232|NCT02518750|DRUG|Nelarabine|Given IV
214288233|NCT02518750|DRUG|Cyclophosphamide|Given IV.
214288234|NCT02518750|DRUG|Etoposide|"Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used."
214288235|NCT02518750|DRUG|Clofarabine|"Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II."
214288236|NCT01365910|DRUG|linifanib|Given PO
214288237|NCT01401270|BEHAVIORAL|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
214288238|NCT05950932|DIETARY_SUPPLEMENT|Melissa phytosome|Melissa phytosome® is composed of dry extract of Berberis aristata root (550mg/cpr), complexed with phospholipids (soy lecithin), Pisum sativa proteins, and proanthocyanidin oligomers from Vitis vinifera. 2 tablets of 200 mg Melissa phytosome will be provided to participants, to be taken 30 minutes before bedtime for 14 days.
214288239|NCT05950932|OTHER|Placebo|2 tablets with an equivalent form, color, flavor, and coating as the experimental product, to take 30 minutes before bedtime.
214288240|NCT01294267|DEVICE|Circulatory Support System|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
214288241|NCT03035370|BIOLOGICAL|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
214288242|NCT03035370|BIOLOGICAL|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
214288243|NCT03035370|BIOLOGICAL|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
214846042|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions|"The Experimental will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a multisensory experience merging visual and digital auditory stimuli. The audio recording also included some ambient natural sound effects, to make the practice more immersive."
214846043|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions without audio guided experience|"The Control will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a monosensorial experience with video guided stimulation of naturalistic scenarios."
214846044|NCT02264535|DRUG|0.1mg/ml Ginkgolides Meglumine Injection|
214846045|NCT02264535|DRUG|1mg/ml Ginkgolides Meglumine Injection|
214288244|NCT03035370|BIOLOGICAL|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
214288245|NCT03681405|OTHER|Informational Intervention|Given information about mindful movement and breathing
214288246|NCT03681405|OTHER|Questionnaire Administration|Ancillary studies
214288247|NCT03681405|BEHAVIORAL|Telephone-Based Intervention|Receive caring attention phone call
214288248|NCT06505655|DIAGNOSTIC_TEST|trehalase levels|We think that in surgical patients requiring hypotensive anesthesia, acute kidney injury, which may occur due to intraoperative renal hypoperfusion, can be diagnosed early by evaluating the urine trehalase value using the ELISA method
214288249|NCT00833794|DRUG|Tramadol Once a day|
214288250|NCT00833794|DRUG|Placebo|
214288251|NCT04238702|DRUG|Empagliflozin 10 MG|Empagliflozin 10 MG 7 days intervention period
214288252|NCT04238702|DRUG|Losartan 50Mg Tab|Losartan 50 MG 7 days intervention period
214288253|NCT04238702|OTHER|Placebo|Placebo 7 days intervention period
214288254|NCT05221515|BEHAVIORAL|Anger can go!|"The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation."
214288255|NCT05221515|BEHAVIORAL|Parent psycho-education|Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
214288256|NCT03791489|DEVICE|ClariFix|The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
214288257|NCT00188669|DRUG|pentoxifylline|
214288258|NCT00188669|DRUG|alpha-Tocopherol|
214288259|NCT00138996|DEVICE|automated direct feedback on CPR from defibrillator|
214288260|NCT04124276|DIETARY_SUPPLEMENT|Lycium barbarum polysaccharide|Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks
214288261|NCT04124276|DIETARY_SUPPLEMENT|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks.
214288262|NCT02090244|DRUG|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
214288263|NCT05745584|DRUG|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
214288264|NCT02589756|OTHER|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (\~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
214288265|NCT02589756|OTHER|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
214288266|NCT02589756|OTHER|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
214288267|NCT06372002|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|"The intervention will consist of the Spanish adapted version of Cognitive Stimulation Therapy (CST) followed by the Maintenance CST program.~CST is a cognitive intervention for treating mild to moderate dementia consisting of fourteen 45-minute group sessions that take place twice a week for 7 weeks. Each session follows a main topic (reminiscing about the person's life, current events, word games…) and is led by two group facilitators. The same structure is followed in every CST session: 1. Introduction (5 minutes). 2. Main Activity (25 minutes). 3. Closing (5 minutes).~The Maintenance CST program follows the principles and structure of the original CST program and consists of 24 sessions, one per week, that will be administered after the original program.~The topic, activities, and materials required for each session are specified in the CST-ES manuals, which also provide the key principles that should guide the intervention and other information necessary for its implementation."
214288268|NCT01525368|BEHAVIORAL|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
214846046|NCT02264535|DRUG|5mg/ml Ginkgolides Meglumine Injection|
214846047|NCT04236583|OTHER|Telehealth|Post-discharge virtual visit
214846048|NCT05517161|BEHAVIORAL|INSIGHT|See Keegan et al., 2020
214846049|NCT01283815|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
214846050|NCT01283815|PROCEDURE|Conservative management with percutaneous drainage|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
214846051|NCT01969474|DRUG|Cannabis|Cannabis capsules given once daily for a month
214846052|NCT01969474|DRUG|Placebo|Placebo
214288269|NCT03623802|OTHER|Local Movement Therapy|Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
214288270|NCT03623802|OTHER|Integral Movement Therapy|Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
214288271|NCT04451239|DRUG|topical steroids and cyclosporin-A|All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
214288272|NCT01755013|PROCEDURE|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
214288273|NCT00044278|DRUG|lamotrigine|
214288274|NCT01929915|PROCEDURE|Epidural patient controlled analgesia|Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
214288275|NCT01929915|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
214288276|NCT01927367|OTHER|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
214288277|NCT01997632|BIOLOGICAL|a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)|a single dose m-IPV2 HD (study vaccine), 0,5ml
214288278|NCT01997632|BIOLOGICAL|a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).|a single 0.5 ml dose Imovax Polio (control vaccine)
214288279|NCT01422317|DRUG|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
214288280|NCT01422317|DRUG|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
214288281|NCT03331003|DEVICE|low level light therapy|iRestore low-level light therapy on androgenetic alopecia
214288282|NCT03331003|DEVICE|non-LLLT wavelength group|A LED light device is non-curative for the patients.
214288283|NCT03251300|DRUG|daytime dosing of mirabegron|All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron
214288284|NCT03251300|DRUG|nighttime dosing of mirabegron|All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron
214288285|NCT01152242|DRUG|Isoglycemic Clamp|Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
214288286|NCT01152242|DRUG|Comparator: insulin glargine|Insulin glargine at 0.4 U/kg
214288287|NCT01161862|DEVICE|Bi-hormonal (insulin and glucagon) artificial pancreas|Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
214288288|NCT02310061|PROCEDURE|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
214288289|NCT02310061|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
214288290|NCT00598832|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
214288291|NCT00598832|DRUG|Adapalene Lotion Vehicle|Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
214288292|NCT05138497|OTHER|HILIT|A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
214288293|NCT05381116|DEVICE|Avation System|Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.
214288294|NCT05381116|DEVICE|Sham Avation System|Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.
214288295|NCT01429753|OTHER|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
214288296|NCT01429753|DEVICE|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
214288297|NCT02760069|DRUG|Inhaled isopropyl alcohol|Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
214288298|NCT02760069|DRUG|Oral ondansetron|Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
214288299|NCT02760069|DRUG|Inhaled normal saline|Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
214288300|NCT02760069|DRUG|Oral placebo|Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
214846053|NCT06044194|DRUG|L-arginine and liposomal vitamin C|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group) or an oral supplement of Placebo once a day for 3 months (control group)
214288301|NCT04995991|BEHAVIORAL|RRT rhythm only|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.
214846054|NCT04968860|OTHER|This study is observational|"* Clinical evaluation of the oral health condition~* Microbiota evaluation by analyzing the collected saliva~* Application of questionnaires of quality of life"
214846055|NCT00002262|DRUG|Tumor Necrosis Factor|
214846056|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
214846057|NCT01014962|DRUG|Placebo|Placebo oral once daily for 5 days
214846058|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
214846059|NCT01014962|DRUG|Placebo|Placebo oral every 12 hours for 5 days
214846060|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
214846061|NCT01014962|DRUG|Placebo|Placebo oral every 8 hours for 5 days
214288302|NCT04995991|BEHAVIORAL|RRT rhythm + visual cue|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
214288303|NCT02465216|OTHER|Placebo|Placebo
214288304|NCT02465216|BIOLOGICAL|ID93 + GLA-SE|ID93 + GLA-SE
214288305|NCT00439660|BIOLOGICAL|Oral Rotavirus Vaccine 116E Live Attenuated|
214288306|NCT04830774|DEVICE|ILR, PMK, ICD|"* Patients receive a newly implanted ILR, PMK, or ICD during COVID-19 hospitalization or within 30 days after hospital discharge and are followed by daily automated remote transmissions.~* Patients have a previously implanted ILR, PMK, or ICD and are followed by daily automated remote transmissions"
214846062|NCT02668848|DIETARY_SUPPLEMENT|water|If USG\>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
214846063|NCT03418857|DRUG|Yogurt smoothie with BB-12|During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.
214846064|NCT03418857|DRUG|Yogurt smoothie|During the one month control period, the participants will consume one yogurt smoothie daily.
214846065|NCT00206830|DEVICE|Triage Profiler S.O.B. Panel|
214846066|NCT02594371|DRUG|Oraxol|
214846067|NCT02594371|DRUG|IV paclitaxel|
214846068|NCT04914624|BEHAVIORAL|ACBT training|Performed 5 days before surgery and one month after surgery, twice a day.
214846069|NCT04914624|DEVICE|acpella®PEP|Continuously instruct patients to perform positive expiratory pressure training 5 days before surgery and one month after surgery, twice a day.
214846070|NCT04914624|DEVICE|EDP-type II external diaphragm pacemaker|Use external diaphragm pacemaker to stimulate patients' diaphragms.
214846071|NCT00845234|BEHAVIORAL|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
214288307|NCT05015465|DIAGNOSTIC_TEST|Anterior Segment OCT|AS-OCT for juvenile SLE patients and compare them with normal subjects
214846072|NCT03675334|PROCEDURE|Root coverage with collagen matrix graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
214846073|NCT03675334|PROCEDURE|Root coverage with subepithelial connective tissue graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
214846074|NCT03675334|OTHER|Basic periodontal treatment|profilaxis, coronary polishing and scaling and root planning
214846075|NCT03452124|DEVICE|I quit ordinary smoking (IQOS)|I quit ordinary smoking (IQOS) assisted cessation program
214846076|NCT03452124|OTHER|Conventional cigarette|Conventional cigarette smoking continuation
214846077|NCT05335213|DIAGNOSTIC_TEST|16S rRNA gene sequencing|"DNA extraction and 16S rRNA gene sequencing DNA extraction, 16S rRNA gene amplification, and deep sequencing of the 16S rRNA amplicon performe.~The V4-V5 region of the 16S rRNA gene amplify with barcodes for multiplexing."
214846078|NCT06308835|OTHER|questionnaires|BREF(Batterie d'efficience Frontale), SDMT (Symbol Digit Modalities Test), TMT (Trail making test), Empans verbaux et BNT (Boston naming Test)
214846079|NCT05266079|DRUG|Intervention Group|Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction
214288308|NCT04606082|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
214288309|NCT04606082|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
214288310|NCT02733939|DEVICE|Home monitoring kit|"The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~* leaves the home without notice, since this might occur in a moment of disorientation;~* leaves a water tap open;~* forgets something on the stove;~* gets out of bed during the night and doesn't come back within a certain time interval;~* never goes to the bathroom in 24 hours;~* never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~* automatically turn on a light to help avoid a fall during the night;~* alert the caregiver when the temperature in the house falls or rises excessively;~* act as burglar alarm in some areas of the home."
214288311|NCT01648205|DRUG|Placebo|Matching Placebo will be given for first month.
214288312|NCT01648205|DRUG|Ranolazine|Patients will receive ranolazine 1000mg bid for subsequent 5 months.
214288313|NCT00078637|DRUG|E7820|
214288314|NCT02292602|BEHAVIORAL|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
214846080|NCT05266079|DRUG|Control Group|Er-Xian decoction
214846081|NCT06676449|DRUG|Immunotherapy|PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.
214846082|NCT06676449|DRUG|chemotherapy: Paclitaxel/Cisplatin|Paclitaxel 135mg/m2 d1, cisplatin 25mg/m2 d1-3, once every 3 weeks for 4 cycles.
214846083|NCT06676449|RADIATION|TDLN-sparing RT|TDLN-sparing radiotherapy 50.4Gy/28Fx.
214846084|NCT05872334|DEVICE|Monofix|a new absorbable barbed suture device
214846085|NCT04473716|DRUG|Toripalimab|Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22
214846086|NCT04473716|DRUG|Paclitaxcel|Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22
214846087|NCT04473716|DRUG|Cisplatin|Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22
214288315|NCT01414010|DIETARY_SUPPLEMENT|Trametes versicolor extract|1,200 mg, 3 times daily on an empty stomach for 14 days
214288316|NCT01414010|DIETARY_SUPPLEMENT|Saccharomyces boulardii|250 mg, 3 times daily on an empty stomach for 14 days
214288317|NCT01414010|DRUG|Amoxicillin|250 mg 3 times daily at least 1 hour before meals for 7 days
214288318|NCT04748120|PROCEDURE|Operative management|Patients will undergo surgical removal of the affected organ. The initial approach will be in a minimally invasive, laparoscopic fashion. If necessary, conversion to an open operation may be performed. These patients will be treated preoperatively and postoperatively with similar antibiotic regimens, however the duration of antibiotic therapies will be dependent on factors such as intraoperative findings, resolution of laboratory abnormalities, and tolerance of oral medications.
214288319|NCT04748120|PROCEDURE|Non-operative management|"Patients will be treated with 3 days of intravenous antibiotics followed by 7 days of oral antibiotics, as described below:~Non-penicillin allergic patients~* piperacillin/tazobactam 3.375g IV every 6 hours for 3 days~* amoxicillin/clavulanate 875/125mg by mouth every 12 hours for 7 days~Penicillin allergic patients~* ertapenem 1g IV every 24 hours for 3 days~* ciprofloxacin 500mg every 12 hours AND metronidazole 500mg every 8 hours for 7 days~Patients may be considered to have failed non-operative management (e.g. treatment failure) if they experience absence of clinical improvement, worsening abdominal pain and/or localized/diffuse peritonitis in the judgment of the treating surgeon at any point within the study window. If this occurs, then surgeons may proceed with rescue appendectomy or percutaneous drainage in the setting of appendicitis, or with placement of a percutaneous cholecystostomy tube in the setting of acute cholecystitis."
214288320|NCT06074315|DEVICE|Nail Genesis DLSO Product|Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).
214288321|NCT06074315|DEVICE|Nail Genesis DLSO Product (vehicle only)|The Nail Genesis DLSO product poly-urethane vehicle
214288322|NCT05950009|OTHER|No intervention (observational studies)|No intervention (observational studies)
214288323|NCT01700777|OTHER|"HABIT-ILE"|"90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards)."
214846088|NCT04473716|PROCEDURE|Radical surgery|Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.
214846089|NCT04473716|RADIATION|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
214846090|NCT02079675|DRUG|SKI3246 Low Dose|SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
214846091|NCT02079675|DRUG|SKI3246 High Dose|SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
214846092|NCT02079675|DRUG|Placebo|SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
214846093|NCT06285240|DRUG|MK-1167|1 mg and 5 mg oral capsules
214846094|NCT06285240|DRUG|Donepezil|10 mg oral tablets
214846095|NCT06285240|DRUG|Placebo|MK-1167 matching placebo administered oral capsules
214846096|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
214846097|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
214288324|NCT00790855|DRUG|Bendamustine|Starting dose of 50 mg/m\^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
214288325|NCT05339737|DEVICE|Nociception Level (NOL) Index|The NOL integrates multiple physiologic parameters that are captured through a finger probe with disposable sensor. These parameters include heart rate, heart rate variability, photoplethysmography pulse wave amplitude, skin conductance and temperature, and their time derivatives. All these parameters are analyzed simultaneously to provide the NOL index which can range from 0 to 100. Values \>25 were found to be indicative of nociception and related-pain in the field of anesthesia. The investigators will use the Pain Monitoring Device-200 (PMD-200)TM, which offers the multi-parametric NOL index (0-100) (Medasense Biometrics Ltd., Ramat Gan, Israel), and was approved by Health Canada for clinical use in September 2017.
214288326|NCT03466008|BEHAVIORAL|Whole-Body Cryotherapy|10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
214288327|NCT02350790|PROCEDURE|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
214288328|NCT02350790|PROCEDURE|Robotic excision|Robotic excision of endometriosis
214288329|NCT00461162|BEHAVIORAL|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
214288330|NCT00461162|BEHAVIORAL|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
214288331|NCT00461162|BEHAVIORAL|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
214288332|NCT02142959|DRUG|Omaveloxolone Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
214288333|NCT02142959|DRUG|Omaveloxolone Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
214288334|NCT02142959|DRUG|Vehicle Lotion|Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
214288335|NCT02142959|RADIATION|3D conformal radiation therapy|45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
214288336|NCT01777100|DRUG|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
214288337|NCT04495348|DRUG|Doravirine|Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
214288338|NCT05925660|DIAGNOSTIC_TEST|Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)|Mucorales PCR screening twice weekly during hospitalisation
214288339|NCT06234657|BEHAVIORAL|Telerehabilitation for stroke patient|The subjects of the study were intervened by telerehabilitation through video instructions and online group training via Online meeting software. The content of the intervention program included upper limb exercises, transfer, and ambulation functions. This training program was designed based on the clinical practice guidelines for post-stroke physiotherapy management from the United States Department of Veterans Affairs and the guidelines for the diagnosis, and treatment of rehabilitation stroke patients of the Vietnam Ministry of Health. The training results of the subjects will be evaluated by the Barthel Index
214288340|NCT00954070|DEVICE|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
214288341|NCT03358121|DIAGNOSTIC_TEST|Clamp study|Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.
214288342|NCT05832398|DRUG|FOLFOX , FOLFIRI or FOLFOXIRI regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle
214846098|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
214846099|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
214846100|NCT02228109|DEVICE|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
214288343|NCT05832398|DRUG|FOLFOX or CapeOX regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
214288344|NCT04397224|DIAGNOSTIC_TEST|Device interrogation|Ventriculo-ventricular conduction time measurement using device analyzer
214288345|NCT04742296|DEVICE|low level laser therapy|We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
214288346|NCT00981734|OTHER|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
214288347|NCT00088478|DRUG|Intramuscular Olanzapine Depot|
214288348|NCT00088478|DRUG|Placebo|
214288349|NCT02568085|DEVICE|Arista|Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
214288350|NCT01161147|DRUG|Meloxicam|Meloxicam Tablets 15 mg
214288351|NCT03674996|OTHER|Same day discharge|Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
214288352|NCT03674996|OTHER|Next-day discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group
214288353|NCT03674996|OTHER|2-days discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
214288354|NCT03642405|DIAGNOSTIC_TEST|Electrocardiogram examination|12-lead ECG monitored by Holter
214288355|NCT03642405|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in accordance to Danish Society of Cardiology
214288356|NCT03642405|PROCEDURE|Blood Samples|Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
214288357|NCT03642405|BEHAVIORAL|Questionnaire|Questionnaire regarding patients quality of life
214288358|NCT01050426|OTHER|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
214288359|NCT01050426|OTHER|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
215033513|NCT04329884|DRUG|intra-articular corticosteroid injection|Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
214288360|NCT04753060|PROCEDURE|Waxing|Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.
214288361|NCT02876354|DRUG|Menaquinone|Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
214288362|NCT03547687|DEVICE|Electrical Stimulation Treatment|"An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each"
214288363|NCT03547687|DEVICE|Neuromuscular Electrical Stimulation Treatment|"If a muscle contraction is not produced with the Intelect NMES portable device, the Vectra Neo Clinical Therapy System (Chattanooga Group) device will be used instead. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 10 seconds on, 30 seconds off Ramp up and down time: 2 seconds each"
214288364|NCT01691001|DRUG|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
214288365|NCT01691001|DRUG|normal saline|
214288366|NCT02892071|DRUG|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
214288367|NCT02892071|DEVICE|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
214288368|NCT02892071|DEVICE|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
214288369|NCT02052674|DEVICE|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
214846101|NCT02228109|DEVICE|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
214846102|NCT02228109|DEVICE|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
214846103|NCT00468793|PROCEDURE|Intravenous fluid|The same intravenous fluids will be used in both arms but the volume will be different
215033514|NCT04991948|DRUG|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
215033515|NCT04991948|DRUG|FOLFOX|5-FU, leucovorin and oxaliplatin
214288370|NCT02052674|DEVICE|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
214288371|NCT00679302|DRUG|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
214288372|NCT00679302|DRUG|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
214846104|NCT03074864|DRUG|Erlotinib Hydrochloride|Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
214846105|NCT04744428|BEHAVIORAL|Autism Parent Navigators|The Autism Parent Navigator program consists of six sessions delivered to parents in the home, supporting adjustment to ASD, accessing services, and coparenting support.
214846106|NCT04744428|BEHAVIORAL|Peer mentoring|Six in-home or telephone sessions, depending on family uptake, providing non-manualized general support as usual from parent peer mentors regarding adjustment to ASD.
214846107|NCT04751045|PROCEDURE|EUS liver biopsy|Endoscopic ultrasound guided liver biopsy
214288373|NCT05028478|DRUG|CN202|Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
214288374|NCT01773785|DRUG|SPI-1620|SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
214846108|NCT04044560|BIOLOGICAL|blinatumomab|Continuous intravenous infusion
214288375|NCT01773785|DRUG|Docetaxel|Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
214846109|NCT04082806|DRUG|GHB|50 mg/kg GHB at one experimental night
214846110|NCT04082806|DRUG|Trazodone|1.5 mg/kg trazodone at one experimental night
214846111|NCT04082806|DRUG|Placebos|placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
214846112|NCT03856606|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
214288376|NCT03130361|DEVICE|Non-Invasive Ventilation|
214288377|NCT03440021|DRUG|ORM-12741|Novel selective alpha2c adrenoceptor antagonist
214288378|NCT03440021|DRUG|Placebo|Identical in appearance to experimental drug, not psycho-active
214288379|NCT02480023|RADIATION|calcaneal quantitative ultrasound assessment|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
214288380|NCT03949504|PROCEDURE|New Find-risk questionnaire software|FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
214288381|NCT03627624|OTHER|Pulmonary rehabilitation|Stable COPD inpatients undergoing 30-STST and 6-minute walk test (6MWT) before and after PR were included. Responsiveness to PR was determined by pre-to-post PR (Δ) evaluation of 30-STST.
214846113|NCT03856606|BEHAVIORAL|Prolonged sitting with interval exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
215033516|NCT04991948|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
214288382|NCT02590848|DIETARY_SUPPLEMENT|Walnut intake|Nutritional intervention: 30g walnut kernels per day
214288383|NCT01867268|DRUG|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
214288384|NCT01867268|OTHER|prone positioning|prone positioning the patient for 10 days following the surgery
214288385|NCT01867268|OTHER|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
214846114|NCT03124134|DEVICE|Gelesis200|Encapsulated hydrogel
215033517|NCT03314090|DRUG|Silicone Gels|silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
215033518|NCT03134040|BEHAVIORAL|Incentives (Rebate)|
215033519|NCT03134040|BEHAVIORAL|Incentives (Donation)|
214288386|NCT03752580|DEVICE|User Instructions of novel nasal mask|User Unstructions interpretation of novel nasal mask for the treatment of obstructive sleep apnea (OSA).
214846115|NCT03124134|OTHER|Water, only (placebo)|300 mL of water
214846116|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 24 or 48 weeks
214846117|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 48 weeks
214846118|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
214846119|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 48 weeks
214846120|NCT00869661|DRUG|RO5024048|1000mg bid for 24 weeks
214846121|NCT00869661|DRUG|RO5024048|500mg bid for 12 weeks
214846122|NCT00869661|DRUG|RO5024048|1000mg bid for 8 weeks
214846123|NCT00869661|DRUG|RO5024048|1000mg bid for 12 weeks
214846124|NCT01999894|DRUG|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
214846125|NCT00004424|DRUG|fentanyl|
214846126|NCT00004424|DRUG|Midazolam|
214846127|NCT00004424|DRUG|propofol|
214846128|NCT05509959|BEHAVIORAL|Women SHINE|Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.
214846129|NCT05509959|BEHAVIORAL|Control|Single group session and access to website
214846130|NCT06617000|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
214288387|NCT03673553|OTHER|Multimodal treatment of patients with FM|The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.
214288388|NCT03673553|OTHER|Association of people with fibromyalgia|The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
214288389|NCT01745172|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
214288390|NCT03305653|DEVICE|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
214288391|NCT02520076|DRUG|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~* Pre-transplant Day -1~* Post-transplant Day 3~* Post-transplant Day 7~* Post-transplant Day 14"
214288392|NCT05725109|OTHER|Hepatitis C Treatment Alerts in CHORUS™|Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based healthcare analytics and reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients with certain conditions who have a scheduled appointment in the coming week and may require close attention. CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. In the after period of this study, the alert will identify patients with active hepatitis C infection.
214288393|NCT05725109|OTHER|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients with active hepatitis C infection will be disseminated.
214288394|NCT02048787|DRUG|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
214288395|NCT04147208|DRUG|GLS4|Administered GLS4 120 mg orally three times daily in fed state
214288396|NCT04147208|DRUG|RTV|Administered RTV 100 mg orally three times daily in fed state
214846131|NCT05181800|OTHER|Degarelix Cohort|Non-interventional
214846132|NCT02246088|PROCEDURE|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
214846133|NCT02246088|PROCEDURE|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
214846134|NCT05785806|BEHAVIORAL|Skin to skin contact and co-parenting theory course|On the day before delivery, pregnant women and their husbands attend a course on the theory of skin contact and co-parenting to explain the role and importance of skin contact ; to understand the knowledge of co-parenting and parenting care ; to learn the communication method and future parenting plan based on the theory of co-parenting, and to learn the operation of skin contact with newborns after delivery.
214846135|NCT05785806|BEHAVIORAL|Skin to skin contact instruction manual and co-parenting theory brochure|According to reading and analyzing the literature on skin contact, summarize the content of skin contact operation guidance ; read and analyze the relevant literature of co-parenting theory, and summarize the theoretical knowledge and practical operation methods of co-parenting. Pregnant women and their spouses can check in time.
214846136|NCT05785806|BEHAVIORAL|Daily face-to-face skin to skin contact guidance during hospitalization|After delivery, face-to-face skin-to-skin contact guidance and co-parenting communication and practice were given to the parturient and her husband on a daily basis during hospitalization. Establish a daily fixed skin contact duration target, and the specific operation is freely allocated by both parents.
214846137|NCT05785806|BEHAVIORAL|Online punching skin to skin contact|Share common parenting related knowledge, daily skin contact reminders, emphasize mutual recognition and mutual support of parents, and conduct WeChat follow-up every two weeks to understand the physical and mental status of both parties and the growth of infants.
214846138|NCT05785806|BEHAVIORAL|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
214288397|NCT04147208|DRUG|ETV|Administered orally ETV 0.5 mg once daily in fasted state
214288398|NCT04659304|DRUG|Allocetra-OTS|Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
214846139|NCT00615849|PROCEDURE|thoracoscopic surgery|stapled wedge resection of the lung mechanical pleural abrasion
214846140|NCT05398835|BEHAVIORAL|Online interventions promoting HIV self-testing|1\) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO
214288399|NCT05403905|PROCEDURE|non surgical treatment|Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
214288400|NCT05403905|PROCEDURE|surgical treatment|The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
214288401|NCT05489198|PROCEDURE|cataract surgery with Centurion phacoemulsification system|Cataract surgery performed with the Centurion phacoemulsification system
214288402|NCT05489198|PROCEDURE|cataract surgery with Quatera 700 phacoemulsification system|Cataract surgery performed with the Quatera 700 phacoemulsification system
214288403|NCT03833115|OTHER|vaginal gel containing or not sodium lauryl sulfate|Prevention
214288404|NCT05951504|DRUG|Methylprednisolone|Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
214288405|NCT02063022|DRUG|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
214288406|NCT02063022|DRUG|Intensified chemotherapy|"* Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~* Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~* Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
214288407|NCT03879226|DEVICE|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for the applications during the training and/or detraining periods will be 30 Joules (J) per site (510 J per lower limb). PBMT will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
214288408|NCT03879226|DEVICE|Placebo|Placebo will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
214288409|NCT04703335|DRUG|Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.
214288410|NCT03031678|DEVICE|Electric-Acoustic Stimulation (EAS) Cochlear Implant System|Combination of a cochlear implant and a hearing aid
214846141|NCT03691688|DRUG|Aspirin 100 mg|Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
214846142|NCT03691688|DRUG|Clopidogrel 75mg|Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
214846143|NCT04468906|PROCEDURE|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat LHBT lesions.
214846144|NCT04468906|PROCEDURE|"Self-locking T Tenotomy"|"Self-locking T Tenotomy describes the surgical procedure that will be performed to treat LHBT lesions."
214846145|NCT00386815|DRUG|pemetrexed|
214846146|NCT00386815|DRUG|cisplatin|
214846147|NCT01740791|DRUG|Velpatasvir|Tablets administered orally
214846148|NCT01740791|DRUG|Placebo|Tablets administered orally
214846149|NCT05070962|OTHER|clinical population|or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.
214846150|NCT00277160|DRUG|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
214846151|NCT00877994|BEHAVIORAL|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
214472248|NCT05015218|DIAGNOSTIC_TEST|Vacular Ultrasound|To visualize the internal jugular veins ( IJVs) a linear transducer with a 5-10 MHz linear probe was placed over the neck, and the IJV was measured just below the bifurcation of the sternal and clavicular heads of the muscle. The IJV measurements were performed on the transverse axis over a single respiratory cycle. Patients with evidence of IJV thrombosis were excluded. IJV measurements included the antero-posterior maximum diameter at the end of expiration (IJVmax), the antero-posterior mimimum diameter/area at the end of inspiration (IJVmin), the IJV collapsibility index (IJV-CI) during spontaneous, quiet, breathing, \[(IJVmax - IJVmin area)/IJVmax\] and the ratio (R) of IJVmax-to-IJV-CI.
214472249|NCT05644717|DRUG|Ertugliflozin 5 mg, 15mg|Ertugliflozin 5/15mg once daily in addition to standard of care
214472250|NCT00282516|PROCEDURE|In-home telemonitoring of pediatric patients with persistent asthma|
214472251|NCT05383274|COMBINATION_PRODUCT|Optilume Urethral DCB|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
214472252|NCT02575950|DRUG|LEO43204|
214472253|NCT02575950|DRUG|Placebo|
214472254|NCT05373758|OTHER|Standard of Care treatment strategy|Management of virologic failure on TLD using the Standard of Care strategy
214472255|NCT05373758|OTHER|Individualized Care treatment strategy|Management of virologic failure on TLD using the Individualized Care strategy
214472256|NCT05373758|OTHER|Immediate Switch|Management of virologic failure on TLD using the Immediate Switch strategy
214472257|NCT06853379|BEHAVIORAL|dietary recommendations|. receive dietary recommendations or nonspecific dietary advices such as reducing fluid intake after 6 p.m. The list of dietary advices have been made reviewing literature and consisted in a list of recommended food, not recommended food at evening and not recommended food
214472258|NCT06853379|OTHER|aroma therapy|the case receive aroma therapy
214472259|NCT06853535|DRUG|The ticagrelor|Ticagrelor 90mg should be taken as soon as possible. From the 2nd to the 21st day, the patient should receive dual anti - platelet therapy with ticagrelor 90mg twice a day (bid) combined with aspirin 100mg once a day (qd). From the 22nd to the 90th day, the patient should be given ticagrelor 90mg bid for anti - platelet treatment.
214472260|NCT06853535|DRUG|The Clopidogrel|From the 2nd to the 21st day, the patient should receive dual anti - platelet therapy with clopidogrel 75mg once a day (qd) combined with aspirin 100mg once a day (qd). From the 22nd to the 90th day, the patient should be given clopidogrel 75mg qd for anti - platelet treatment.
214472261|NCT06854003|DRUG|Bendamustine|An Alkylating agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
214472262|NCT06854003|DRUG|Rituximab|An Anti-CD20 antibody, single-use vials, via intravenous infusion per institutional standard of care.
214472263|NCT06854003|DRUG|Cytarabine|An Antineoplastic, single dose vial via intravenous infusion per institutional standard of care.
214472264|NCT06854003|DRUG|Zanubrutinib|A BTK inhibitor, capsule taken orally per protocol.
214472265|NCT06854003|DRUG|Sonrotoclax|A BCL 2 Protein Inhibitor, immediate release tablet, taken orally per protocol.
214472266|NCT06854510|DRUG|Gargle with 2.5% sodium bicarbonate solution during radiotherapy|"In addition to routine oral care, patients received sodium bicarbonate solution gargle therapy from the initiation of radiotherapy until its completion. The treatment protocol is as follows:~For patients with oral mucositis of grade 0 - 1, gargle with a 2.5% sodium bicarbonate solution (for 1 - 2 minutes each time) three times a day and spit out the liquid after each gargle. For patients with oral mucositis of grade ≥ 2, gargle with a 2.5% sodium bicarbonate solution (for 1 - 2 minutes each time) four to five times a day and spit out the liquid after each gargle."
214472267|NCT06854510|DRUG|Gargle with 0.9% sodium chloride solution during radiotherapy|In addition to routine oral care, patients received 0.9% sodium chloride solution gargle therapy from the initiation of radiotherapy until its completion. The treatment protocol is as follows: For patients with oral mucositis of grade 0 - 1, gargle with a 0.9% sodium chloride solution (for 1 - 2 minutes each time) three times a day and spit out the liquid after each gargle. For patients with oral mucositis of grade ≥ 2, gargle with a 0.9% sodium chloride solution (for 1 - 2 minutes each time) four to five times a day and spit out the liquid after each gargle.
214472268|NCT06811428|DEVICE|A novel device for immobilization of babies undergoing upright LP, the present working name (non-proprietary) for the device is LP Comfort Seat (LPCS)|The participant will be placed in the LPCS for their lumbar puncture procedure
214472269|NCT06811428|OTHER|Standard of Care (SOC)|The patient will be held in the upright position by a human assistant
214472270|NCT06853691|OTHER|glasses-free 3D visual training|"Trail group Conduct 15 minutes of naked-eye 3D vision training. Twice a day, five days a week.~Control groups The subjects watched ordinary 2D videos for 15 minutes each time, all under the same lighting conditions. This was done twice a day, five days a week."
214472271|NCT06804915|BEHAVIORAL|simulation|"Each team of physician and nurses will participate in 4 scenarios: 2 adult, 2 pediatric. In each scenario, physician and nurses will have a clinical description of the scenario with the age and weight of each patient.~The simulations will be conducted at the clinical simulation laboratory at Jean-Marc Lepage Pavilion of the University of Sherbrooke using high-fidelity mannequins. SimMan 3GPus will be used for adult scenarios and SimJunior for pediatric scenarios, both from Laerdal company. Participants will receive a briefing containing key information about the scenario and the patient just before starting the simulation.~During the scenarios, the physician is expected to prescribe medications by mentioning the name, the dose and the route of administration of every medication. Moreover, if multiple dilution for a medication is possible, the physician is expected to mention the desired dilution."
214472272|NCT06598618|OTHER|Graston technique+ Conventional PT|IASTM technique (graston technique) on iliotibial band. Frequency 2 sessions of stroking with 20 seconds rest in between 3 times/week for 3 consecutive weeks Intensity as tolerated by patient. Conventional PT including 1- Therapeutic ultrasound at frequency of 3.5 MHZ for 10 minutes. 2- Stretching exercise of hamstrings. 3-Isometric exercises of Quadriceps
214472273|NCT06598618|OTHER|Muscle energy technique + Conventional PT|Muscle energy technique (post facilitation stretch) on iliotibial band. Frequency 10 repetitions 3 times/week for 3 consecutive weeks Intensity starting from 50 percent resistance across barrier provided by physiotherapist.. Conventional PT including 1- Therapeutic ultrasound at frequency of 3.5 MHZ for 10 minutes. 2- Stretching exercise of hamstrings. 3-Isometric exercises of Quadriceps.
214846152|NCT00877994|BEHAVIORAL|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
214288411|NCT02793934|OTHER|Scales|"For stroke patients there are used scales:~Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia~For patients after THR:~The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
214846153|NCT05377125|BEHAVIORAL|Computerized cognitive training|This intervention offers 45-minute computerized training sessions to each participant. This intervention aims to improve the individual's RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
214846154|NCT05377125|BEHAVIORAL|Computerized placebo training|This intervention offers 45-minute computerized placebo cognitive training sessions to each participant. This intervention aims to exert no focused training on RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
214846155|NCT02758548|PROCEDURE|Blood sample|Fingerprick and venous
214846156|NCT02758548|DEVICE|POCT device|Investigational device
214846157|NCT02577068|DRUG|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
214846158|NCT02577068|DRUG|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
214846159|NCT00560326|DRUG|Tacrolimus Ointment 0.03%|Once or twice daily topical application
214846160|NCT02505724|BEHAVIORAL|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
214846161|NCT02505724|BEHAVIORAL|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
214846162|NCT03245216|BEHAVIORAL|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
214846163|NCT03245216|BEHAVIORAL|rest|Seated rest before motor learning
214472274|NCT04527445|PROCEDURE|Reduced radiation fluoroscopy|See previous information about each arm
214846164|NCT03245216|BEHAVIORAL|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
214846165|NCT06300606|DEVICE|NOL monitoring|Prospective observational study to assess pain during regional anesthesia for upper limb orthopedic surgery using NOL monitoring and the Algoplus pain scale
214846166|NCT05854706|DEVICE|Theta Burst Stimulation|Theta Burst Stimulation
214288412|NCT02793934|OTHER|New model of rehabilitation|
214846167|NCT05183711|BEHAVIORAL|Questionnaires|The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
214846168|NCT03307811|OTHER|22 gauge needle liver biopsy|EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
214846169|NCT05303961|DRUG|SA001 240mg + Rebamipide 200mg or Placebo|Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
214846170|NCT05303961|DRUG|SA001 480mg or Placebo|Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)
214472275|NCT04527445|PROCEDURE|Conventional fluoroscopy|See previous information about each arm
214472276|NCT06808386|OTHER|Strengthening 2 times per week|This group will consist of participants with patellofemoral pain and will receive treatment twice a week.
214472277|NCT06808386|OTHER|Strengthening 3 times per week|This group will consist of participants with patellofemoral pain and will receive treatment thrice a week.
214846171|NCT05303961|DRUG|SA001 710mg + Rebamipide 600mg or Placebo|Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
214846172|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
214846173|NCT05303961|DRUG|SA001 360mg or Placebo|Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)
214288413|NCT02793934|OTHER|Old model of rehabilitation|
214288414|NCT02793934|OTHER|ICF reader|
214846174|NCT05303961|DRUG|SA001 720mg or Placebo|Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)
214846175|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
215033520|NCT03134040|BEHAVIORAL|Feedback|
214288415|NCT06502574|OTHER|mobile application|The mobile application prepared for rational drug use andchronic disease self-management, suitable for use by olderadults, will be required to be used for 6 months.
214288416|NCT03944460|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any excipients.
214288417|NCT05849389|DRUG|Vosoritide|Vosoritide administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
214288418|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
214288419|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
214288420|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
214288421|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
214288422|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
214472278|NCT06355154|OTHER|Nutritional intervention|The intervention will contain a diet with a reduced amount of carbohydrates compared to the standard treatment today but without caloric restriction.
214472279|NCT05753215|DRUG|Omadacycline Pill|Omadacycline will be administered 300 mg orally daily without the loading dose.
214472280|NCT05753215|DRUG|Standard of Care|Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
214472281|NCT06557512|RADIATION|Hypofractionated Stereotactic Radiosurgery (SRS)|Undergo Hypofractionated Stereotactic Radiosurgery
214472282|NCT06557512|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
214472283|NCT06557512|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
214472284|NCT05649410|OTHER|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
214472285|NCT05649410|OTHER|sleeper stretch along with conventional therapy|it will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
214472286|NCT00306215|DRUG|CCX282-B|CCX282-B or placebo capsules
214472287|NCT03209973|DRUG|Tislelizumab|Administered as specified in the treatment arm
214472288|NCT05754177|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days
214472289|NCT05754177|OTHER|Placebo|Participants in this arm will receive an equivalent placebo for 84 days.
214472290|NCT05673759|DEVICE|Electroencephalogram (EEG) system|An FDA 510(k) approved EEG/ERP device designed by G-Tec ™ intended for the acquisition, display, analysis, storage, reporting and management of EEG and auditory evoked potentials (AEP) information and uses Bluetooth technology to securely transmit EEG signals to a computer. The device is patient-friendly, and no serious adverse events have occurred to-date in any research or clinical study or in clinical use.
214472291|NCT05673759|BEHAVIORAL|Standard Neuropsychological Testing|Prior to the EEG session, neuropsychological testing will be done to establish a baseline measurement. We administer a full standard neuropsychological battery (45 mins) for all participants which includes the following tests: MOCA (only for older participants), MMSE, CERAD, Phonemic Test and the Category Fluency test, Trails Making Test A and B, BNT, BAI, BDI, PANAS, Ishihara Color Blindness test, and the Snellen Eye Chart.
214472292|NCT05673759|BEHAVIORAL|Additional neuropsychological tests|Younger participants will receive additional testing along with the standard neuropsychological battery including Pittsburgh Sleep Quality Index (PSQI) \[37\] for sleep quality measures, the Test of Memory Malingering (TOMM) for effort measure, Ohio State Traumatic Brain Injury Identification Method questionnaire (OSU-TBI) \[38\] to gather lifetime TBI history, and the Neurobehavioral Symptom Inventory (NBSI) \[39\] for post-concussive symptoms. These additional tests will add an extra fifteen minutes, making the total time for neuropsychological questionnaires 1 hour in younger participants.
214472293|NCT06106906|BIOLOGICAL|CD19 CAR-T cell infusion|CD19 CAR-T cell intravenous infusion
214472294|NCT04785300|DRUG|Dasatinib|100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles
214472295|NCT04785300|DRUG|Quercetin|Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles
214472296|NCT06150404|BEHAVIORAL|White Noises and Maternal and/or Paternal voices|"The intervention group will receive white noise and maternal and/or paternal voice for a maximum of 4 hours per day, alternated as follows: 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice, 1-hour break, 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice. The intervention is expected to start at 08:00 in the morning and conclude at 13:00 and will be delivered from the day after the enrollment - when the parents provide their voice recording - until the day of discharge.~The device for administering white noise and maternal and/or paternal voice will be placed approximately 30 cm from the head of the infant in the incubator and at the foot of the infant in the open crib.~The volume will be 45 dB for infants in incubators and infants in open cribs."
214472297|NCT06775613|GENETIC|Long-read sequencing|The technology performed belongs to third-generation sequencing strategies and is capable of analysing very long DNA and RNA fragments.
215033521|NCT02541591|OTHER|Neuroprotective goal directed hemodynamic optimization|
214288423|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
214288424|NCT00708006|DRUG|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
214288425|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
214288426|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
214288427|NCT00615095|OTHER|health questionnaire, blood draw and skin exam|Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
214846176|NCT03025776|BEHAVIORAL|Reaching|sitting reaching under various task conditions (size, speed, location)
215033522|NCT02541591|OTHER|MAP > 65mmHg|MAP \> 65mmHg
215033523|NCT05892900|DEVICE|Transcutaneous vagus nerve stimulation (tVNS)|The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve
215033524|NCT05892900|DEVICE|Sham transcutaneous vagus nerve stimulation (Sham tVNS)|The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
214288428|NCT00016016|DRUG|cytarabine|Given IV
214288429|NCT00016016|DRUG|mitoxantrone hydrochloride|Given IV
214288430|NCT00016016|DRUG|alvocidib|Given IV
214288431|NCT00016016|OTHER|pharmacological study|Correlative studies
214288432|NCT00016016|OTHER|laboratory procedure|Correlative studies
214288433|NCT00462267|BEHAVIORAL|Enriched lifestyle intervention|Multi-component lifestyle intervention
214288434|NCT06445192|OTHER|Best Practice|Receive usual care
214288435|NCT06445192|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214288436|NCT06445192|OTHER|Exercise Counseling|Attend group counseling
214288437|NCT06445192|OTHER|Exercise Intervention|Receive aerobic and resistance exercise intervention via telehealth
214288438|NCT06445192|OTHER|Medical Device Usage and Evaluation|Wear Fitbit
214288439|NCT06445192|OTHER|Physical Performance Testing|Ancillary studies
214288440|NCT06445192|OTHER|Questionnaire Administration|Ancillary studies
214288441|NCT06445192|OTHER|Telemedicine|Receive aerobic and resistance exercise intervention via telehealth
214288442|NCT05188950|DEVICE|depression screening test App|The participants' use of the depression screening test App of 6 modules for 12 weeks, at least once a week, 20 minutes per once.
214288443|NCT04542135|DRUG|Sulindac Pill|Randomized participants will receive either 150 mg oral sulindac twice daily.
214288444|NCT04542135|DRUG|Placebo|placebo pills twice daily
214288445|NCT04356274|OTHER|Participatory System Dynamics (PSD)|Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
214288446|NCT04356274|OTHER|Audit and Feedback (AF)|Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
214288447|NCT01731392|DIETARY_SUPPLEMENT|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
214288448|NCT01731392|DIETARY_SUPPLEMENT|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
214288449|NCT01731392|DIETARY_SUPPLEMENT|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
214288450|NCT05319145|BEHAVIORAL|Intervention group|1\) Multi-component exercise intervention program based on Vivifrail©. It consists of 1 daily-30 minutes session, twice a week, for 10 consecutive weeks supervised by an experienced exercise specialist. Exercises (resistance, gait retraining, balance training) are personalized depending on the person's functional capacity (evaluated by the SPPB and a walking speed test) and the risk of falling. Between sessions, individual, unsupervised training by the own patient, supported in the case by the caregiver, will be stimulated, through the recommendations of ViviFrail©. 2) Nutrition. Personalized recommendations according to nutritional and medical status (active oncologic treatment, remission, or palliative stage) will be offered according to the ESPEN recommendations for cancer patients, aimed at compensating for inadequate energy intake, improving patients' malnutrition risk stage (assessed by means of the MNA-SF).
214288451|NCT05319145|OTHER|Control group|General recommendations (written and videos) will be offered.
214288452|NCT02176876|DRUG|GS-5745|GS-5745 400 mg administered intravenously
214288453|NCT02176876|DRUG|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
214288454|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
214288455|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
214846177|NCT03025776|BEHAVIORAL|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many \& which hand to use, kinematic data collected
214846178|NCT06216171|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy
214846179|NCT06216171|RADIATION|image guided radiotherapy without online adaptation|image guided radiotherapy without online adaptation
214846180|NCT01416116|DRUG|QUTENZA|topical
214846181|NCT01416116|DRUG|Lidocaine|topical
214846182|NCT01416116|DRUG|Tramadol|oral
214846183|NCT04053673|DRUG|RBN-2397|an oral PARP7 Inhibitor
214846184|NCT05507320|BEHAVIORAL|Mechanisms of action perception and execution|Study the mechanisms of action perception and execution
214846185|NCT04381676|OTHER|Flipped Classroom Approach|In the Flipped Classroom, participants form groups of 2-3 and are instructed to work together through clinical cases of the in-class case based activity, committing to group answers to the clinical questions before advancing to the next case. At the end of class, the faculty instructor facilitated a short interactive group discussion.
214846186|NCT02625376|DIETARY_SUPPLEMENT|Resvega|Dietary supplementation with Resvega BD
214846187|NCT02625376|DIETARY_SUPPLEMENT|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
214846188|NCT02625376|DIETARY_SUPPLEMENT|placebo|Dietary supplementation with a placebo BD
214846189|NCT05529368|BEHAVIORAL|Conventional Exercise and Tai Chi Exercise interventions|Subjects diagnosed with IAD were randomly assigned to the exercise group, the tai chi group, or the control group. The exercise group and tai chi group received conventional exercise and tai chi for 8 weeks.
214288456|NCT01092754|DRUG|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
214846190|NCT03170869|DEVICE|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
214846191|NCT02828280|DEVICE|NuMask|The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
214846192|NCT02828280|DEVICE|Traditional mask|A traditional air inflated facemark used to ventilate patients
214288457|NCT03405506|DEVICE|Quantitative Flow Ratio (QFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
214288458|NCT05505903|DIAGNOSTIC_TEST|Temerature measurement|Temerature measurement on admission to WBN or NICU
214846193|NCT02495376|BEHAVIORAL|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
214846194|NCT02314494|BEHAVIORAL|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
214846195|NCT04936594|DEVICE|iTBS|1800 pulses of iTBS
214846196|NCT04936594|DEVICE|TMS|MagVenture MagPro x100 device. This will be used as the comparator.
214846197|NCT02064140|DRUG|Rocuronium|
214846198|NCT05337644|DRUG|Indocyanine green solution|"5 ml of ICG were then injected intravenously to identify the stomach, carefully assessing the angle of His (preoperative written informed consent was obtained from the patient).~Adequate perfusion was defined as the direct and clear visualization of the fluorescence around the gastric tube, after an estimated time of 150-180 s followingi.v. administration."
214288459|NCT02726646|DRUG|Doxycycline|Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
214288460|NCT02726646|PROCEDURE|Mechanical debridement|Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
214288461|NCT02726646|DRUG|Placebo|The application of 1 mg of microspheres placebo
214288462|NCT06265727|DRUG|CRB-701|Nectin-4 targeted Antibody Drug Conjugate (ADC)
214288463|NCT06265727|DRUG|Anti-PD-1|checkpoint inhibitor
214472298|NCT03336281|DRUG|Ustekinumab|All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
214846199|NCT01350596|DRUG|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
214846200|NCT01350596|DRUG|Ibuprofen|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
214846201|NCT01118234|DRUG|Rituximab|Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
214846202|NCT00347906|PROCEDURE|laser treatment|
214846203|NCT01406249|DRUG|SP|"Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle."
214846204|NCT01406249|DRUG|XP|"Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
215033525|NCT01966627|OTHER|ogtt|oral glucose tolerance test
215033526|NCT01966627|OTHER|genotyping|genotyping to look for risk alleles
214472299|NCT04824105|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|A repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System will be used to deliver intermittent theta burst to ventromedial prefrontal cortex, and continuous theta burst to pre-supplementary motor area.
214472300|NCT06144281|BEHAVIORAL|Nudge for PHPC NP Referral|The attending and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for home palliative care services upon hospital discharge will be asked to refer their patient for these services.
215033527|NCT01966627|OTHER|abdominal and liver magnetic resonance imaging|magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
214288464|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
214288465|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
214288466|NCT01317030|OTHER|Non-Contact Lens Wear|No intervention
214288467|NCT06198868|PROCEDURE|Operable|Enrolled patients capable of surgical treatment
214288468|NCT06130579|DRUG|IFN-Α|Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
214288469|NCT04204668|PROCEDURE|TMR|Surgical procedure to connect injured proximal nerve stumps to motor nerve branches directly innervating a muscle
214288470|NCT04204668|PROCEDURE|RPNI|Surgical procedure to wrap the ends of injured nerves in small muscle grafts
214288471|NCT04204668|PROCEDURE|VDMT|Surgical procedure that creates a small muscle graft that is both denervated and vascularized, which will then receive the damaged nerve ending
214288472|NCT06423911|DRUG|olverembatinib|olverembatinib QOD
214288473|NCT06423911|DRUG|Bosutinib|Bosutnib QD
214288474|NCT06227910|DRUG|Vedolizumab|Vedolizumab IV infusion.
214288475|NCT06227910|DRUG|Upadacitinib|Upadacitinib over-encapsulated tablets.
214288476|NCT06227910|DRUG|Placebo|Upadacitinib matched placebo capsules.
214288477|NCT06122207|DIETARY_SUPPLEMENT|Probiotic|"* Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:~  * Women: 1 capsule of probiotic per day for 12 weeks.~* Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months."
214288478|NCT06122207|DIETARY_SUPPLEMENT|Placebo|"* Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:~  * Women:1 capsule of placebo per day for 12 weeks.~* Men: 1 capsule of placebo per day for 6-months."
214288479|NCT06562894|DRUG|SYHX1901|Administered orally, once daily (QD)
214288480|NCT06562894|DRUG|Placebo|Administered orally, once daily (QD)
214288481|NCT04073225|DEVICE|MindPod Dolphin|"The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience."
214288482|NCT04073225|BEHAVIORAL|10 Keys to Healthy Aging|"The 10 Keys™ to Healthy Aging Program in an evidence-based program that originated from the University of Pittsburgh Center for Aging and Population Health. This educates and empowers older adults to reach personal goals and help others to so in the community as well. It is designed to teach older adults how to reduce the risk of disease over the aging process by promoting healthy lifestyle changes with the most recent established scientific guidelines. The 10 Keys program also aims to empower individuals to be health ambassadors in the individual's own families and communities, teaching individuals to 'Share the Wealth on Health'. Participants will work towards personal health goal(s) adapted to the participant's lifestyle and abilities."
214288483|NCT06119685|DRUG|IDP-023|NK cell therapy
214288484|NCT06119685|DRUG|Rituximab|Anti-CD20 antibody therapy
214288485|NCT06119685|DRUG|Daratumumab|Anti-CD38 antibody therapy
214288486|NCT06119685|DRUG|Interleukin-2|Immune cytokine
214288487|NCT06119685|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214288488|NCT06119685|DRUG|Fludarabine|Lymphodepleting chemotherapy
214288489|NCT06119685|DRUG|Mesna|Chemoprotectant
214288490|NCT06119685|DRUG|Isatuximab|Anti-CD38 antibody therapy
214288491|NCT05659641|DEVICE|PerMed Stent Graft System In Surgical Operation|PerMed Branch Stent Graft
214472301|NCT06769984|DRUG|SCTT11|SCTT11 dose 1, dose 2, dose 3, dose 4
214846205|NCT05623852|DIETARY_SUPPLEMENT|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
215033528|NCT01966627|OTHER|stool sample|stool sample taken to investigate metabolites
215033529|NCT01966627|OTHER|liver biopsy|liver biopsy to examine for cellular change and steatosis
215033530|NCT05170802|OTHER|NanoKnife procedure|clinical data regarding use of the NanoKnife system intraoperatively (via laparotomy) to ablate the pancreatic tumors per the treating physicians discretion will be collected.
215033531|NCT04570202|BEHAVIORAL|EMDR|The EMDR therapy is organized in eight different phases, requiring attending multiple sessions, usually 12 separate sessions.
214846206|NCT06465875|OTHER|Reading a book|Individuals in the intervention group will be read a storybook for three nights.
214846207|NCT05328700|OTHER|Kinesiotaping|Perform a neuromuscular bandage with kinesiotape in patients with plantar fasciitis
214846208|NCT05328700|OTHER|Tape|Perform a neuromuscular bandage with tape (Hipofix(R)) in patients with plantar fasciitis
214288492|NCT05659641|DEVICE|Endovastec CRONUS® Intraoperative stent system|CRONUS® Branch Stent Graft
214288493|NCT06092710|DIAGNOSTIC_TEST|neuro-sensorial subjective evaluation of the airways collapsibility|verbal and manual guidance of subjects from a therapist to experiment the subjective perception of the air flow through their airways and airways collapsibility
214288494|NCT00005794|DRUG|perifosine|
214288495|NCT05073120|OTHER|Piqray Prescriber's/HCP guide for hyperglycemia|oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA were provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aimed to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
214288496|NCT06071377|OTHER|Biologic Specimen Collection|Participants will have blood and urine collected annually at Baseline, Year 1 and Year 2.
214288497|NCT03567304|DRUG|Rilpivirine 25 mg|Rilpivirine 25 mg PO OD with meal (and continue 2 back bone of NRTIs)
214288498|NCT04777071|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214288499|NCT04777071|DRUG|Gallium Ga 68 Gozetotide|Given IV
214288500|NCT04777071|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214288501|NCT04777071|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR scan
214288502|NCT04777071|PROCEDURE|Bone Scan|Undergo bone scan
214288503|NCT04777071|OTHER|Electronic Health Record Review|Ancillary studies
214288504|NCT04180579|DEVICE|PAXMAN Scalp Cooler|Scalp cooling will occur with each dose of chemotherapy.
214288505|NCT06501833|OTHER|FIFA 11+ KIDS PROGRAM|The experimental group will perform eight weeks of FIFA 11+ kids program (3/week).
214288506|NCT06501833|OTHER|REGULAR TRAINING|The control group will be continuing their regular training
214288507|NCT02744014|BEHAVIORAL|Add-on Therapy for Axial Spondyloarthritis|
214288508|NCT01163045|PROCEDURE|thyroidectomy|total thyroidectomy and lobectomy
214288509|NCT04783480|OTHER|Birthly|Women will receive a code to sign up for 3 free interactive childbirth education classes through the Birthly platform. They will be enrolled in 3 courses: Prenatal Education, Childcare and Breastfeeding. They will be encouraged to complete all courses prior to 36 weeks gestational age.
214288510|NCT04783480|OTHER|Standard of care|Subjects will participate in childbirth education at their own discretion.
214288511|NCT00850564|DRUG|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
214288512|NCT01847794|DEVICE|Cell Search® CTC epithelial kit|"Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
214288513|NCT04322461|DIETARY_SUPPLEMENT|Betaquik MCT supplement|50g/day divided in 3. Breakfast, lunch and dinner
214288514|NCT06990009|BEHAVIORAL|exercise|In line with the Puerperium and Newborn Care Guide, an exercise implementation protocol will be prepared by obtaining the opinion of a group of 10 experts on the appropriateness of the exercises and when they should be started. In this direction, a brochure and a video will be created for the participants to practice the exercises. A pilot study will be conducted in a group of 10 people on the use of the brochure and video, and the brochure and video will be finalized. Participants will be asked to do these exercises for 30 minutes a day, five days a week for eight weeks. A reminder message will be sent to the exercise group by the researchers to remind them of the exercises and provide motivation for eight weeks.
214846209|NCT02354807|DRUG|Mirabegron|One-time dose of 100mg of Mirabegron
214846210|NCT02354807|OTHER|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
214846211|NCT05442437|BIOLOGICAL|hUCMSCs|Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells
214846212|NCT06030115|OTHER|Exercise Component Of Cardiac Rehabilitation (Hybrid Model) Intensity Recovery Progression Protocol (IRPP)|Data collected on participants who completed the intensity recovery progression protocol program
215033532|NCT02390076|DEVICE|Left Low Level Light Therapy|Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
214288515|NCT06357754|BIOLOGICAL|Idecabtagene vicleucel|As per product label
214288516|NCT06357754|BIOLOGICAL|Lisocabtagene maraleucel|As per product label
214288517|NCT06995014|BEHAVIORAL|Retrieval-based word learning: Standard retrieval practice schedule|Novel nouns and their meanings are practiced on 2 consecutive days. At the beginning of each learning session, a retrieval trial will immediately follow hearing the word and what it likes (a study trial). In the standard condition, the remaining retrieval trials for each word will be spaced - occurring only after 3 other words have intervened. This practice schedule is repeated the next day (Day 2).
214288518|NCT06995014|BEHAVIORAL|Retrieval-based word learning: Adaptive retrieval practice schedule|Novel nouns and their meanings are practiced on 2 consecutive days. At the beginning of each learning session, a retrieval trial will immediately follow hearing the word and what it likes (a study trial). For the remainder of the session, there will be spaced retrieval trials for each word - occurring after 3 words have intervened. In the Adaptive condition, children will have additional retrieval opportunities throughout. These will be provided whenever the child does not remember the word form, whether it is an immediate (initial) or space retrieval trial. This practice schedule is repeated the next day (Day 2).
214472302|NCT06769984|DRUG|Placebo|Placebo dose 1, dose 2, dose 3, dose 4
214846213|NCT01966809|DRUG|Photofrin photodynamic therapy.|"The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery."
214846214|NCT04234061|COMBINATION_PRODUCT|ibrutinib and Tisagenlecleucel|Single-arm study investigating combination of ibrutinib and Tisagenlecleucel treatment
214846215|NCT06222229|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
214846216|NCT06222229|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended"
214846217|NCT03046082|DRUG|Antibiotics|Observation of antibiotic types given to patients with pneumonia.
214846218|NCT01017094|DRUG|silversulfadiazine|apply once a day
214846219|NCT00220727|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
214288519|NCT05355805|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
214288520|NCT05355805|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
214288521|NCT07002580|PROCEDURE|IPACK and adductor canal block with Bupivacaine 0.25%|iPACK block is infiltration between the Popliteal Artery and the Capsule of the Knee. iPACK and adductor canal blocks are performed with ultrasound guidence under sterile conditions.
214288522|NCT07002580|PROCEDURE|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia is a basic anesthesia method used for years to grant anesthesia for surgeries for lower extremities and lower torso surgeries.
214288523|NCT07000760|DRUG|Ultrasonic atomization of lidocaine|After induction of general anesthesia and before the end of the surgery, 100mg of 2% lidocaine was nebulized and inhaled respectively, and the nebulization time was 15-20 minutes each time.
214288524|NCT07000760|DRUG|Ultrasonic atomization of normal saline|After anesthesia induction and before the end of the surgery, the same volume of normal saline (5ml of 0.9% NaCl) was ultrasonically atomized, and the atomization time was 15-20 minutes each time.
214288525|NCT07000773|BEHAVIORAL|Bilateral Scapular Retraction with Shoulder External Rotation (BSR-SER) Exercise|Participants perform the Bilateral Scapular Retraction with Shoulder External Rotation (BSR-SER) exercise using a resistance band. The exercise is conducted under various conditions including stable and unstable surfaces (using BOSU® balance trainer) and in three different lower limb positions: standing, lunge, and squat. Each condition is randomized, and participants complete all conditions in a crossover design. The intervention aims to evaluate trapezius muscle activation patterns during these exercises using surface electromyography (EMG).
214288526|NCT07001176|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
214288527|NCT07001176|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg)
214288528|NCT07002268|DRUG|Azvudine tablets(FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+TAF 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 7 consecutive days; TAF: 25 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days."
214288529|NCT07002268|DRUG|Azvudine tablets(FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3 mg (1 tablet)+TAF 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 7 consecutive days; TAF: 25 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days."
214288530|NCT07002268|DRUG|Azvudine tablets(FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~TAF: 25 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3 mg (1 tablet)+TAF 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 7 consecutive days."
214472303|NCT06765564|DRUG|iPSC-MNP|Using iPSC-MNP Cells for the Treatment of ALS Patients
214288531|NCT07000968|OTHER|Virtual Reality Training Group|Virtual Reality Training Procedure; In general, virtual reality training will be developed taking into account neurorehabilitation principles; Type of game and specificity (there will be exercises specific to the disease), Intensity (will be gradually increased), Progress (exercises will be gradually progressed, variability (the environment will be changed) and Feedback (visual and auditory feedback will be provided). The virtual reality training to be applied will also be fun, It will include attention and problem-solving ability. The difficulty and skill level will gradually increase in order to ensure continuity of motivation and motor learning in individuals. It will be aimed to perform the exercises at moderate to severe intensity. The intensity level of the exercises will be at moderate intensity, and the perceived effort according to the Borg Scale will be 12- It will be checked by asking for 15 points.
214288532|NCT07000968|OTHER|Task-Oriented Training Group|ask Oriented Training Procedure; Task-oriented training focusing on improving balance and walking will consist of 8 different exercise stations. Individuals will continue the exercise at each station for 4 minutes and rest for 1 minute before moving on to the next station. The training completed in this way will consist of a total of 40 minutes and the exercise stations will be applied following the determined order: The exercises will first be demonstrated by the physiotherapist. The aim is to perform exercises at moderate to vigorous intensity. It will be checked that the intensity level of the exercises is moderate and that the perceived effort is 12-15 points according to the Borg Scale. Perception of perceived exertion; It will be controlled by asking to increase the speed, changing the ground, giving double tasks and using obstacles made of wooden blocks. Individuals will be given visual and auditory positive feedback during the exercises.
214288533|NCT07000968|OTHER|Conventional Training Group|Individuals in this group will continue classical physiotherapy exercises. There will be no intervention by us in the traditional training group.
214288534|NCT07002138|DEVICE|Digital Dental Impression|Digital dental impressions were performed using the Medit i700 intraoral scanner (Medit, Seoul, South Korea). The scanner utilizes 3D-in-motion video technology with UV-C and LED light sources and adaptive anti-fogging. Scans were taken of both upper and lower arches following manufacturer-recommended protocols. Two tip sizes were used (normal and small), and scanning included occlusal, lingual, and buccal surfaces. Moisture control was maintained with cheek retractors and saliva ejectors. Impression time was recorded using a chronometer. This procedure was used to evaluate patient comfort, anxiety, and preference.
214288535|NCT07002138|PROCEDURE|Conventional Dental Impression|Conventional impressions were taken using extra-fast setting flavored alginate (Hydrogum 5, Zhermack SpA, Italy) for both upper and lower arches. The impression material was manually mixed according to the manufacturer's instructions and applied using standard perforated plastic trays suitable for pediatric arches. Children were seated upright, and the impression sequence followed lower arch first, then upper arch. Comfort was evaluated using VAS scores and anxiety using the Venham Clinical Anxiety Scale (VCAS). The procedure was timed with a chronometer.
214288536|NCT07000838|DEVICE|Medially wedged ortheses|3 month long wear of medially wedged ortheses. Ortheses have to be worn for 6 to 8 hours daily during work shifts.
214288537|NCT07002541|PROCEDURE|PECS II block|The PECS-II block is an ultrasound-guided interfascial plane block designed to provide analgesia for surgeries involving the anterolateral chest wall, particularly breast surgery. It is an extension of the PECS-I block, which targets the medial and lateral pectoral nerves. In the PECS-II technique, a high-frequency linear ultrasound probe is used to identify the fascial planes. A 22G, 50 mm regional block needle is advanced in-plane under sterile conditions. A total of 30 mL of 0.25% bupivacaine is administered: 10 mL is injected between the pectoralis major and minor muscles (targeting the pectoral nerves), and 20 mL between the pectoralis minor and serratus anterior muscles (to block the lateral branches of intercostal nerves and intercostobrachial nerve).
214288538|NCT07002541|PROCEDURE|ESP block|The erector spinae plane (ESP) block is a fascial plane block performed under ultrasound guidance to provide multimodal analgesia for thoracic and abdominal surgeries, including breast procedures. In this technique, a high-frequency linear ultrasound probe is used to visualize the transverse process of the thoracic vertebra, typically at the T4-T5 level. With the patient in a seated position and under standard sterile conditions, a 22G, 50 mm regional block needle is inserted in-plane until the tip reaches the fascial plane between the erector spinae muscle and the transverse process. After negative aspiration, 1-2 mL of test dose is injected to confirm correct needle placement by observing separation of fascial layers. Then, 20 mL of 0.25% bupivacaine is injected incrementally.
214288539|NCT07002606|OTHER|medication errors reporting guidelines|the intervention is designed to reduce the medication errors and develop the culture of reporting the Medication errors in clinical settings.
214288540|NCT07001813|DEVICE|socket preserved|(8 cases): was treated by immediate socket preservation with S1-XB xenograft augmentation after extraction.
214288541|NCT07001813|DEVICE|non preserved socket|(8 cases): was not exposed to any type of socket preservation after the extraction procedure.
214288542|NCT07000500|DIETARY_SUPPLEMENT|Nutritional Supplement|Participants in this arm will receive a daily dose of a nutritional supplement for 90 consecutive days. The supplement is administered orally and aims to improve cognitive performance in older adults with signs of cognitive decline. Participants will also complete cognitive assessments before and after the intervention.
214288543|NCT07000500|OTHER|Placebo|Participants in this arm will receive a daily dose of an inert placebo that matches the supplement in appearance, taken orally for 90 consecutive days. The placebo is used as a control to compare the effects of the nutritional supplement on cognitive performance. Participants will undergo the same cognitive assessments as the experimental group.
214288544|NCT07001878|DRUG|Metformin|Metformin will be prescribed, reaching 1000mg/day (a standard dose). This will be done under the principal investigator's care and the patient's clinical team, including assessment of metformin adherence. Metformin will be prescribed for 6 months. Antipsychotic treatment will continue as per standard of care (metformin as adjunct therapy), as well as routine follow up.
214846220|NCT04037982|PROCEDURE|laparoscopic pancreaticoduodenectomy|During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
214846221|NCT04037982|PROCEDURE|Open pancreaticoduodenectomy|During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
214288545|NCT07002411|OTHER|Innovative hospital reception service with social robot NAO|The robot NAO welcomes the user and asks how it can assist them. At this point, the user responds, and the robot, in turn, replies in two possible ways: If it has not understood the request, it prompts the user to rephrase it, and the process returns to the previous point. If it has understood the request, it explains the route the user needs to follow. Once the interaction has been successful or two consecutive attempts have failed, the robot asks the user if the necessary information has been provided. If yes, the robot dismisses the user. If no, the interaction resumes from the point where the robot asks for the department to reach or the exam to take.
214472304|NCT04276532|PROCEDURE|sentinel lymph node sampling (SLN)|"Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).~1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines；~2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted；~3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted."
214472305|NCT04276532|PROCEDURE|pelvic lymphonodectomy (PLN)|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
214472306|NCT06083662|DRUG|Neratinib Maleate|"* neratinib 240mg po daily~* herzuma 8mg/kg (loading) --\> 6mg/kg q3w"
214472307|NCT06249048|BIOLOGICAL|STX-001|STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.
214472308|NCT06249048|BIOLOGICAL|Keytruda®|Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
214472309|NCT05338268|BEHAVIORAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth.
214472310|NCT05338268|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
214472311|NCT03871712|BEHAVIORAL|Motivational interview|The participants will be called twice with 2-4 weeks interval after the randomisation. This will be after 8 weeks of sick leave.
214846222|NCT00531362|DRUG|Plain aspirin|Plain aspirin 75 mg or 150 mg
214472312|NCT03871712|BEHAVIORAL|Stratified vocational advice|The participants will be called after the randomisation. The amount of calls/meetings will be decided after each call, but with a maximum of 4 for the high risk group. This may include physical meetings.
214472313|NCT05218096|DRUG|ALXN2050|Oral tablet.
214846223|NCT00637091|DRUG|Cetuximab, irinotecan|cetuximab, irinotecan
214846224|NCT02675374|DRUG|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
214846225|NCT02675374|DRUG|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
214846226|NCT06026631|PROCEDURE|Lipidomic analysis for breast cancer patients|Lipidomic analysis for breast cancer patients
214846227|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|A multi-detector row CT scanner with minimum section collimation of ≤1 mm and minimum number of data acquisition channels ≥ 16will be employed.
214846228|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|Control subjects will also proceed to CT thorax, and outcome measures be compared to subjects
214846229|NCT00000425|DRUG|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
214472314|NCT05218096|DRUG|Placebo|Oral tablet.
214472315|NCT03244020|DRUG|Aspirin 325mg|Aspirin 325 mg by mouth once daily
214472316|NCT03244020|DRUG|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Enoxaparin 40 mg subcutaneous injection once daily
214846230|NCT00000425|DRUG|Acetaminophen|
214846231|NCT06151067|DIAGNOSTIC_TEST|High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testing|High-Resolution Manometry Upper-GI endoscopy pH-Impedance testing
214846232|NCT03097939|DRUG|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
214472317|NCT06143059|DRUG|Ethanol|Sterile, 95% ethanol will be administered through IV infusion
214472318|NCT06143059|DRUG|Saline|Saline is administered as the placebo
214479469|NCT06862245|DRUG|Group L received propofol at 2-2,5mg/kg dose based on le|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group L received propofol at 2-2,5mg/kg dose based on lean body weight, which was calculated from CT imaging by a radiologist. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison
214846233|NCT03097939|DRUG|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
214846234|NCT02020967|OTHER|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
214846235|NCT02868996|DRUG|Recombinant human tissue kallikrein|Intravenous DM199
214846236|NCT00049296|DRUG|docetaxel|"Patients receive docetaxel IV over 30 minutes once weekly. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
214846237|NCT00049296|DRUG|thalidomide|"Patients receive oral thalidomide twice daily. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
214846238|NCT05332886|BEHAVIORAL|MetaHealth Group|Three metaverse rooms will be created via metaverse technology that aims to develop healthy nutrition, physical activity, and psychological resilience skills to reduce the risk of of NCDs in youth.
214846239|NCT05332886|BEHAVIORAL|MobileHealth Group|The intervention aims to develop healthy nutrition, physical activity, and psychological resilience skills using mobile application materials to reduce the risk of NCDs in youth.
214846240|NCT03507686|DRUG|BIIB111|Administered as specified in the treatment arm.
214288546|NCT07002411|OTHER|Innovative hospital reception service with social robot PEPPER|"The robot PEPPER welcomes the user and asks how it can assist them, stating the following phrase: Good morning and welcome to INRCA. I am PEPPER and I am here to provide directions to help you reach your desired location within the hospital. Which department do you need to reach or which exam do you need to take?  At this point, the user responds, and the robot, in turn, replies in two possible ways: If it has not understood the request, it prompts the user to rephrase it, and the process returns to the previous point. If it has understood the request, it explains the route the user needs to follow. Once the interaction has been successful or two consecutive attempts have failed, the robot asks the user if the necessary information has been provided. If yes, the robot dismisses the user as follows: Thank you for your participation. Have a good day. If no, the interaction resumes from the point where the robot asks for the department to reach or the exam to take."
214288547|NCT07001761|RADIATION|Ultrasound/ x rays|"* The MSK Ultrasound (US) will be performed using a General Electric LOGIQ P9 unit / Toshiba Applio 500 unit using a 7-13 MHz linear array transducer.~* Conventional Radio-graphic examination bi-plane weight-bearing semi-flexed (15) radiograms will be taken of the target knee; one in the posteroanterior view, and one in the lateral medial view"
214288548|NCT07001098|DRUG|Amino Acids|The participants receive a continuous infusion of a balanced mixture of amino acids (Trophamine) in a dose of 2g/kg/day (max 100g/day) starting at the time of cardiac surgery up to 3 days
214288549|NCT07001098|DRUG|Placebo|The participants receive a continuous infusion of a lactated ringers (placebo), equivalent volume to amino acids, starting at the time of cardiac surgery up to 3 days
214288550|NCT07000617|DRUG|DAPT regimen plus radiotherapy|Patients receive 6 cycles of DAPT regimen plus concurrent radiotherapy. The DAPT regimen is administered as follows: dexamethasone 10mg intravenously on days1-3, azacitidine 100mg subcutaneously on days 1-5, pegaspargase 2500IU/m2 intramuscularly on day 1, and tislelizumab 200mg intravenously on day 6, repeated every 21 days. Concurrent radiotherapy given to the tumor sites is started after 2 cycles of DAPT regimen. The specific doses and methods of radiotherapy are in accordance with the clinical guidelines for NK/T-cell lymphoma.
214288551|NCT07000799|BEHAVIORAL|CBT|The EMOTION Intervention is based on cognitive-behavioral therapy, which has been shown to be effective in both the treatment and prevention of anxiety and depression in children. The EMOTION intervention has been developed as a school-based program and consists of an intensive course lasting eight weeks, using a hybrid model with eight face-to-face group meetings at school and eight hours of digital sessions completed by the child at home. Additionally, it is desirable for parents to support their children; hence, guardians will be offered the opportunity to attend an informational meeting. They will also receive a brochure detailing how they can support and assist their child. A group leader manual and a workbook for the children have been developed (Martinsen et al., 2017).
214288552|NCT07000487|BEHAVIORAL|Yoga|Hatha yoga will be applied in this study. Yoga practice will be carried out by the researcher for 6 weeks, 1 day face-to-face and 1 day online, and each practice will be 60 minutes, in total 12 sessions, considering the studies done. It will be applied by a researcher with a yoga certificate. Pre-test and post-test nausea and pain measurements will be made.
214288553|NCT07133035|DIAGNOSTIC_TEST|Pulmonary function test|Participants' respiratory functions will be assessed in different positions with the Cosmed Pony Fx Digital Spirometer (11). Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC), and peak expiratory flow rate (PEF) will be determined during the pulmonary function test.
214846241|NCT00075686|BIOLOGICAL|cetuximab|Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles
214846242|NCT00075686|DRUG|gemcitabine hydrochloride|1000mg/m2 IV over 30 minutes
214846243|NCT03935841|DIETARY_SUPPLEMENT|3-OHB salt (NaCl)|36 gram 3-OHB salt diluted in 500 ml sterile water
214846244|NCT02508116|GENETIC|CYP2C19 genotyping|The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 \*2, \*3, and \*17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
214846245|NCT02630316|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
214846246|NCT02630316|DRUG|Placebo|Placebo administered four times daily
214846247|NCT04944316|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet
214479470|NCT06861088|DRUG|Isoquercetin|Isoquercetin with vitamin C and vitamin B3 capsules
214479471|NCT06861088|DRUG|Placebo|Placebo
214479472|NCT06616142|DRUG|[18F]CETO tracer|PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.
214846248|NCT04944316|BEHAVIORAL|Dietary intervention|Portion-controlled diet (compliant with ADA guidelines)
214846249|NCT00983528|BIOLOGICAL|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
214846250|NCT00983528|DRUG|Clofarabine|"Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5"
214846251|NCT01942447|BIOLOGICAL|FMT|
214846252|NCT01942447|DRUG|Vancomycin|
214846253|NCT00004188|BIOLOGICAL|filgrastim|Given IV
214846254|NCT00004188|DRUG|carboplatin|Given IV
214846255|NCT00004188|DRUG|cisplatin|Given IV
214846256|NCT00004188|DRUG|cyclophosphamide|Given IV
214846257|NCT00004188|DRUG|doxorubicin hydrochloride|Given IV
214846258|NCT00004188|DRUG|etoposide|Given IV
214846259|NCT00004188|DRUG|isotretinoin|Given IV
214846260|NCT00004188|DRUG|melphalan|Given IV
214846261|NCT00004188|DRUG|topotecan hydrochloride|Given IV
214846262|NCT00004188|DRUG|vincristine sulfate|Given IV
214846263|NCT00004188|PROCEDURE|autologous bone marrow transplantation|
214846264|NCT00004188|PROCEDURE|bone marrow ablation with stem cell support|
214846265|NCT00004188|PROCEDURE|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
214846266|NCT00004188|PROCEDURE|peripheral blood stem cell transplantation|
214846267|NCT00004188|RADIATION|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
214846268|NCT05541640|DRUG|normal saline group|normal saline infusion at the start of surgery
214846269|NCT05541640|DRUG|lidocaine group|lidocaine infusion at the start of surgery
214846270|NCT00575380|DRUG|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
214846271|NCT00575380|DRUG|Vigamox Eye Drops|One drop three times a day for seven days
214846272|NCT03722862|DIETARY_SUPPLEMENT|Low fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 3 gram doses
214846273|NCT03722862|DIETARY_SUPPLEMENT|Placebo|Participants will receive the placebo/dextrose.
214846274|NCT03722862|DIETARY_SUPPLEMENT|High fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 6 gram doses
214846275|NCT00973089|OTHER|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
214846276|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 1|Dressing with LU3103209 - Dose 1
214846277|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 2|Dressing with LU3103209 - Dose 2
214288554|NCT07133035|DIAGNOSTIC_TEST|Fonseca Anamnestic Index|The questionnaire consists of 10 questions covering headaches, neck pain, temporomandibular joint pain, pain during chewing, parafunctional habits, malocclusion, and stress, and is scored as 10 (yes), 5 (sometimes), and 0 (no). The total score ranges from 0 to 100. A higher total score indicates an increased risk of temporomandibular joint problems.
214846278|NCT03110796|DEVICE|Dressing without LU3103209|Dressing without LU3103209
214846279|NCT02546024|DRUG|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
214846280|NCT03424655|PROCEDURE|Twisted File Adaptive|Twisted file adaptive SM1 (size 20, .04 taper) and SM2 (size 25, .06 taper) were used serially with a single controlled motion according to the manufacturer's instructions.
214846281|NCT03424655|PROCEDURE|Balance Force|Flex-R files sizes 15-45 taper .02 were used according to the technique
214846282|NCT03424655|PROCEDURE|WaveOne|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
214846283|NCT03424655|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
214288555|NCT07133035|OTHER|Jenkins Sleep Scale|The Jennkis Sleep Scale consists of four questions that assess sleep problems over a 4-week period. Each question is scored from 0 to 5. The total score ranges from 0 to 20 and indicates increasing sleep disturbance.
214288556|NCT07133035|OTHER|Berlin Questionnaire|Berlin Questionnaire: The Berlin Questionnaire is a three-part assessment tool that assesses individuals' predisposition to sleep apnea. The first part contains five questions investigating snoring, the second part contains four questions investigating daytime sleepiness, and the third part contains two questions investigating hypertension and obesity. Each section is evaluated independently. Individuals who score 2 or higher in the first and second sections, and those who score 1 in the third section, are considered predisposed to sleep apnea. If two or more categories are positive, the participant is considered high risk for obstructive sleep apnea. If the participant scores two or more in the first and second categories, they are considered high risk. If blood pressure is high or BMI is above 30 kg/m2, the participant is considered high risk.
214288557|NCT07133035|OTHER|Headache Impact Test-6|"Headache Impact Test-6: The Headache Impact Test-6 (HIT-6) is administered to identify activities individuals are unable to perform due to headaches and to determine the extent to which headaches impact daily life. This six-question questionnaire includes columns with increasing scores, from never to always. Participants are asked to mark the box closest to their response. A high total score indicates that headaches negatively impact daily life."
214479473|NCT06616142|DRUG|Dexamethasone oral|Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan
214846284|NCT00559364|DRUG|Viokase® 16|Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
214846285|NCT00559364|DRUG|Placebo|Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
214846286|NCT00559364|DRUG|Proton pump inhibitor (PPI)|Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
214846287|NCT00559364|DRUG|Omeprazole|Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
214479474|NCT06616142|PROCEDURE|Adrenal vein sampling|Adrenl vein sampling
214846288|NCT01632384|BEHAVIORAL|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
214846289|NCT04006938|BEHAVIORAL|Single Bout ('S')|Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
214846290|NCT04006938|BEHAVIORAL|Multiple Bout ('M')|Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
214846291|NCT04458558|DRUG|Mifepristone|Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
214846292|NCT00384306|DRUG|prednisolone|
214846293|NCT02578745|DEVICE|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (\~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
214846294|NCT02578745|OTHER|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
214846295|NCT02979691|RADIATION|SIB-IMRT|
214846296|NCT02979691|DRUG|S-1|
214288558|NCT07033364|OTHER|Functional liver imaging using hepatobiliary scintigraphy (HEBIS)|The Hepatobiliary scintigraphy (HEBIS) or HIDA scan is a nuclear imaging technique that uses \[99mTc\]Tc-mebrofenin, a iminodiacetic acid (IDA) agent, which is a lidocaine analogue that is taken up by hepatocytes and is eliminated in the biliary tract (Arntz, 2023). This functional liver scan quantitatively assesses liver function of which the potential will be tested to measure liver function before and after radiotherapy.
214288559|NCT06925984|RADIATION|SBRT|SBRT of all oligoprogressive metastases (or other local therapy if SBRT not advisable), followed by continuation of the same systemic therapy.
214288560|NCT02167893|DRUG|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
214288561|NCT06729294|OTHER|Binaural beat music recital|Binaural beats music is therapeutic music that provides auditory stimuli at different frequencies to each ear. However, the maximum sound levels are 60 dB, which helps to relax and reduce stress.
214288562|NCT06745388|DRUG|Magnesium sulfate|Receive intravenous magnesium intra-operatively
214288563|NCT06745388|DRUG|Ketamine|Receive IV push ketamine intra-operatively
214288564|NCT06745388|DRUG|Placebo|Receives no additional medication or infusion
214288565|NCT06555328|DRUG|CSU lower dose treatment|CSU lower dose treatment
214288566|NCT06555328|DRUG|CSU high dose treatment|CSU high dose treatment
214288567|NCT06555328|DRUG|CSU non responders IgE - high dose treatment|CSU non responders IgE - high dose treatment
214288568|NCT06555328|DRUG|HS low dose treatment|HS low dose treatment
214288569|NCT06555328|DRUG|HS medium dose treatment|HS medium dose treatment
214288570|NCT06555328|DRUG|HS high dose treatment|HS high dose treatment
214288571|NCT07062159|OTHER|the psychoeducation intervention program|The content of the psychoeducation intervention program based on the Watson Human Caring Model will consist of the postpartum process and care, maternal blues, postpartum psychosis, postpartum depression, frequency, causes, predisposing factors, symptoms, effects on mother, child and community health, diagnosis and treatment, preventive practices, social support, adaptation to the role of motherhood, mother and baby bonding, practices that will strengthen mother-baby bonding, breast milk and breastfeeding, nutrition and baby care, problems encountered in baby care and solution suggestions.
214288572|NCT07062159|OTHER|routine care|routine care
214288573|NCT07065331|DRUG|AZD8630|Single inhaled dose of AZD8630 via dry powder inhaler.
214288574|NCT07065331|DEVICE|Dry powder inhaler|Single inhaled dose of AZD8630 via dry powder inhaler.
214288575|NCT06777485|PROCEDURE|Procedure/Surgery treatment|Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC
214288576|NCT06777485|DRUG|Anti-Tumor Drugs|Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
214288577|NCT06442397|BEHAVIORAL|Anti-Inflammatory Lifestyle Intervention|Content includes training in empirically-supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with evidence-based behavior change content adapted to meet the needs of EACS. Participants will also receive digital tools to facilitate daily self-monitoring (Fitbit activity monitor, wireless scales, self-monitoring app) and generate information for tailored weekly e-coaching
214288578|NCT06840444|BEHAVIORAL|Firefly Mobile App: A Digital Health Solution for Healthy Sleep in Teens|A six week cognitive behavioral therapy for insomnia program delivered via a mobile app.
214288579|NCT07071363|DRUG|Depigmenting Cosmetic Serum (Applied Morning and Evening)|Participants in Group 1 receive a depigmenting cosmetic serum with non-drug actives applied morning and evening, plus a placebo cream without hydroquinone applied in the evening. Group 2 receives a placebo serum (no active depigmenting ingredients) applied morning and evening, and a hydroquinone 4% cream applied in the evening. All participants apply an SPF50+ sunscreen in the morning throughout the 84-day study. The cosmetic serum is the investigational product; hydroquinone serves as the active comparator. Placebo products are visually matched to their respective actives to ensure blinding. The study distinguishes each intervention by active ingredients, timing of application (morning/evening), and role (test vs. reference vs. supportive care). All products are applied topically, and the regimen remains fixed across the study duration.
214288580|NCT06820476|DRUG|NNC0487-0111|Participants will be randomized to receive NNC0487-0111 tablet orally at dose levels 1, 2, or 3.
214288581|NCT06820476|DRUG|Placebo (NNC0487-0111)|Participants will be randomized to receive a placebo tablet orally matched to NNC0487-0111.
214288582|NCT06858150|DIAGNOSTIC_TEST|Ultrasound-Guided Needle Depth and Angle Measurement|This study utilizes ultrasound imaging to measure the needle insertion depth at Jianzhongshu (SI15) and an electronic goniometer to assess insertion angles. The aim is to collect anatomical reference data for acupuncture needling precision, focusing on the relationship between SI15 and the insertion point of the levator scapulae muscle. This is an observational study designed to collect anatomical reference data for acupuncture needling, without evaluating therapeutic effects.
214288583|NCT04818840|DEVICE|Resurfaced Patella|JOURNEY II CR Total Knee System was used for Total Knee replacement
214288584|NCT04818840|PROCEDURE|Un-resurfaced Patella|JOURNEY II CR Total Knee System was used for Total Knee replacement
214288585|NCT07131592|DRUG|IV TXA|Patients randomized to the IV TXA group will receive intravenous Tranexamic acid during the procedure. The dose will be 1g IV infused over approx. 10 minutes prior to skin closure (dosing of approx. 15 mg/kg, capped at 1 g, which is within safe limits).
214472319|NCT04601064|BEHAVIORAL|Collaborative Care Model|Collaborative care (CC) is an evidence-based model of integrated mental health and substance use disorder care endorsed by the American Psychiatric Association for the integration of mental health and substance use disorder care into primary care settings. CC includes the following components: 1) A collaborative care team of multidisciplinary health care providers consisting of the primary physician, a care manager and a consulting psychiatrist, providing care in a coordinated fashion; 2) A population focus with the team working together to provide care and continuously measure and track health outcomes of a defined population of patients; 3) A measurement-guided approach with systematic use of disease specific patient reported outcome measures, such as symptom rating scales like the PHQ-9 to drive clinical decision making; and 4) Evidence-based practices with the team adapting scientifically proven treatments within an individual clinical context to achieve improved health outcomes.
214472320|NCT05193409|DRUG|225 mg BNC210|225 mg BNC210
214472321|NCT05193409|DRUG|675 mg BNC210|675 mg BNC210
214472322|NCT05193409|DRUG|Placebo|Placebo
214846297|NCT00136760|DRUG|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
214846298|NCT00136760|DRUG|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
214846299|NCT00136760|DRUG|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
214846300|NCT00136760|DRUG|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
214846301|NCT06591182|OTHER|Survey using a questionnaire.|Observational study, participants are not assigned an intervention as part of the study (Survey using a questionnaire).
214846302|NCT00330460|DRUG|Alendronate|ALN; 70 mg; oral; once weekly
214846303|NCT00330460|DRUG|Denosumab|60 mg; SC; every 6 months
214846304|NCT05683782|DRUG|Split thickness Apically positioned flap with Chitosan based Erythropoietin Gel application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva .1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used by the patient two times daily for 14 days.
214846305|NCT05683782|DRUG|Split thickness Apically positioned flap without Erythropoietin application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva.The patient will use a Chitosan gel without being loaded with erythropoietin two times daily for 14 days
214846307|NCT06360029|BEHAVIORAL|LvL UP|"The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant."
214846308|NCT06360029|BEHAVIORAL|LvL UP + MI|"After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle)."
214846309|NCT06360029|BEHAVIORAL|Comparison|Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
214846310|NCT02663882|BEHAVIORAL|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
214846311|NCT02663882|BEHAVIORAL|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
214846312|NCT04068987|DIAGNOSTIC_TEST|MRI parametric mapping|Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2\* mapping, ECV mapping) to determine the MR signal characteristics of the body
214846313|NCT02839993|DEVICE|tDCS|
214846314|NCT02839993|BEHAVIORAL|training|
214846315|NCT00249015|BEHAVIORAL|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
214846316|NCT00388037|DRUG|sunitinib malate|Given PO
214846317|NCT00388037|OTHER|laboratory biomarker analysis|Correlative studies
214846318|NCT03070015|BEHAVIORAL|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI \> 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables \& no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch \& 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (\~50% kcal from carbohydrate,\~25% from protein,\~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
214472323|NCT05374018|DIAGNOSTIC_TEST|urinary kit for pneumococcus antigen assay|urine test for detection of pneumococcus antigen
214479475|NCT06617338|DIAGNOSTIC_TEST|CT scan unilateral knee|Intervention given to the Active Comparator arm
214472324|NCT05916495|OTHER|Hybrid care arm|Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
214472325|NCT05916495|OTHER|Standard of care arm|Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
214472326|NCT06222502|OTHER|Planning, Reminders, and Micro-Incentives|Participants will schedule planned walks during weekly phone calls with study staff. Participants will receive reminders for planned walks and receive micro-incentives after completion.
214472327|NCT06222502|OTHER|Health Education|"Participants in this group will receive health education tips during weekly phone calls with study staff."
214472328|NCT00957684|DRUG|eslicarbazepine acetate|once-daily oral tablet
214472329|NCT00957684|DRUG|placebo|once daily placebo comparator
214472330|NCT04662619|OTHER|B. infantis|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU), will be provided to infants once daily for 12 weeks."
214472331|NCT04662619|OTHER|Lactose Placebo|Powdered infant formula grade lactose will be provided to infants once daily for 12 weeks.
214472332|NCT06812897|OTHER|Sallie (TM) Life U|Testing of Sallie (TM) Life U platform
214472333|NCT03340051|BEHAVIORAL|Episodic Future Thinking (EFT)|EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
214472334|NCT03340051|BEHAVIORAL|Episodic Recent Thinking (ERT)|ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
214472335|NCT06469177|DEVICE|Pain Coach App|Pain Coach App is a mobile application that offers patients undergoing shoulder, hip and knee arthroplasty surgery preoperative educational tools and questionnaires to provide patient specific details to their surgeons for prescribing purposes as well as post operative pain assessment and medication reminders/tracking, problem troubleshooting and a resource library for further pain management tools and education.
214472336|NCT05412082|RADIATION|Intensity-modulated radiation therapy|MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.
214472337|NCT05412082|DRUG|5-fluorouracil|"5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.~During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week."
214472338|NCT05412082|DRUG|Leucovorin|Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
214472339|NCT05412082|DRUG|Oxaliplatin|Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.
214472340|NCT05412082|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
214472341|NCT05412082|RADIATION|Accelerated Radiation Therapy|"MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :~* Dose level -1: 10 Gy delivered in 4 fractions~* Dose level 0: 12 Gy delivered in 4 fractions~* Dose level 1: 14 Gy delivered in 4 fractions~* Dose level 2: 16 Gy in delivered 4 fractions"
214472342|NCT05412082|DRUG|Irinotecan|Irinotecan dose of 180 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
214472343|NCT04882891|DEVICE|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
214472344|NCT04824885|DEVICE|Chlorhydric acid based acid concentrate for bicarbonate hemodialysis (medical device)|usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months
214472345|NCT04647630|DIAGNOSTIC_TEST|urine test|test for pneumococcal antigen in urine
214472346|NCT06390241|DRUG|Avidin-biotin-Dota-90Y|Within 7-8 days after the VABB procedure, 6-10 mg avidin in 1 ml saline will be administered at the site of the occult carcinoma. Subsequently, 90Y DOTA-biotin in the range of 28-57-126 MBq (3 activity levels investigated) will be injected locally immediately after avidin injection.
214472347|NCT06823570|BEHAVIORAL|Individualized exercise therapy|Patients in the intervention group will receive an individualized exercise training program 3x/week.
214472348|NCT06823570|BEHAVIORAL|Lifestyle recommendations|The lifestyle recommendation group will receive general recommendations such as salt reduction, higher physical activity levels and stress reduction.
214472349|NCT06646939|BEHAVIORAL|PT and OT with a simulated environment|Upon admission to the inpatient rehabilitation unit, participants will undergo a physical and occupational therapy evaluation. The evaluations will include the outcome measures chosen to track for this study (10-meter walk test and Quality Indicators). If a patient meets inclusion/exclusion criteria, informed written consent will be obtained. Throughout the patient's stay, therapists will have the opportunity to perform community integration treatments using the simulated environment. This could include activities such as negotiating a curb, crossing a street, or shopping at a marketplace. The therapist will document the amount of time (units billed) spent performing these interventions. The research investigators will not act as a patient's therapist throughout their admission.
214472350|NCT06646042|DRUG|ibuzatrelvir|2x 300 mg tablet
214472351|NCT06646042|DRUG|carbamazepine ER|100 mg BID (Day 1-3) 200 mg BID (Day 4-7) 300 mg BID (Day 8-15)
214472352|NCT05520788|GENETIC|precise medicine|During screening stage, all patients should accept next-generation sequencing (NGS) test.
214472353|NCT06646484|DIAGNOSTIC_TEST|Impedancemetry evaluation|Each patient eligible for the study will, additionally to the standard care, have repeated measure of impedancemetry along their hospital stay ; Theses measure will be compared to the usual measure of hydration and natremia and agreement between clinical status of interest will be discussed.
214472354|NCT06646250|DEVICE|NeoDoppler - CE certified|The NeoDoppler is small and light weighed constructed as a single element transducer, that can be gently fixed over the fontanelle. The system is fully compatible for cooccurring use with other intensive care equipment for neonates as well as caregiving from the parents. It is capable of measuring cerebral blood flow at different depths of the brain simultaneously. The Doppler velocity measurements arise from a cylindrical volume of tissue. It is therefore less sensitive to the exact position and angle of the probe over the fontanel to target the vessels of interest than standard hand-held Doppler. This means that the NeoDoppler system may be placed by healthcare professionals who do not have specialized training performing diagnostic ultrasound exams of the cerebral vasculature in neonates.
214472355|NCT04222478|OTHER|Specific auriculotherapy|"3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
214472356|NCT04222478|OTHER|Non-specific auriculotherapy|3 sessions of auriculotherapy with semi-permanent needles on non-specific points.
214472357|NCT04285814|DIAGNOSTIC_TEST|Whole Fetal Cell (WFC) Testing|Performing WFC testing on blood specimens.
214472358|NCT06730230|BEHAVIORAL|Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support|CHWs will implement RPM by being provided with training modules and implementing electronic health record (EHR) support tools for HTN management.
214472359|NCT06823739|OTHER|Exercise|This exercise program in PDE group was designed to be performed at home without re-quiring any specialized equipment. It aims to improve physical health, balance, and coor-dination while maintaining muscle strength and flexibility. Patients performed brist walking at least three times a week for a duration of 10 to 30 minutes per session. It also included balance practice and coordination exercises for 10 minutes. These include: Standing on tiptoes, balancing on one foot while holding onto a chair for support, walking in a straight line as if on a narrow beam. Finally, the exercise session ended with a 10-minute cool-down, focusing on relaxing muscles and performing gentle stretches to improve flexibility and reduce tension. All of the exercises were both explained and given in a figured chart, to the patients or the relatives
214472360|NCT06823791|DRUG|Furazolidone|esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + furazolidone 100 mg bid, for 14 days. After stopping the medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months and 12 months, the experiment stop. If H. pylori is positive, check again after 6 months. If H. pylori is still positive, high-dose dual therapy will be used to resist H. pylori again. After stopping the second medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months, and the experiment stops. If H. pylori is still positive, check again after 6 months, and the experiment stops.
214472361|NCT06823791|DRUG|Clarithromycin|esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + clarithromycin 500 mg bid, for 14 days. After stopping the medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months and 12 months, the experiment stop. If H. pylori is positive, check again after 6 months. If H. pylori is still positive, high-dose dual therapy will be used to resist H. pylori again. After stopping the second medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months, and the experiment stops. If H. pylori is still positive, check again after 6 months, and the experiment stops.
214472362|NCT06205602|DRUG|3BNC117-LS|30 mg/kg to be administered via IV at Step 1 (Day 1)
214472363|NCT06205602|DRUG|10-1074-LS|10 mg/kg to be administered intravenously at Step 1 (Day 1)
214472364|NCT06205602|DRUG|Placebo for 3BNC117-LS|0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
214472365|NCT06205602|DRUG|Placebo for 10-1074-LS|0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
214472366|NCT04797195|OTHER|CKD-PD app with home monitoring equipment|use home monitoring equipment to measure blood pressure, body weight, and dialysate fluid volume and record in CKD-PD app
214472367|NCT06823310|DEVICE|Control (Standard treatment)|Directly printed orthodontic clear aligner without any additions
214472368|NCT06823310|DEVICE|Chitosan|Adding chitosan nanoparticles to directly printed orthodontic clear aligners in vivo to enhance anti- microbial activity against streptococcus mutans.
214472369|NCT05275998|DRUG|TMB-365/TMB-380|Monoclonal antibodies to be given intravenously
214472370|NCT06818383|DEVICE|Rezum therapy|minimal invasive technique for treating BPH
214472371|NCT04529070|BEHAVIORAL|Nightmare Rescripting and Rehearsal|This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy ('Nightmare Rescripting and Rehearsal Therapy' (NRRT)) administered by non-mental health professionals in a Primary Care setting.
214472372|NCT04529070|BEHAVIORAL|standard of care|standard of care
214846319|NCT03070015|BEHAVIORAL|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts \& sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day \& men ate 1500 kcal/day. Subjects with BMI \>40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
214479476|NCT06617338|DIAGNOSTIC_TEST|CT scan bilateral knee|Intervention given to the Experimental Arm
214846320|NCT00329628|DRUG|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
214846321|NCT00329628|DRUG|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
214846322|NCT01310361|DRUG|Amoxicillin|
214846323|NCT01310361|DRUG|Intramuscular Benzathin Penicillin G|It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
214846324|NCT02537509|DRUG|Cholecalciferol|
214846325|NCT02537509|DRUG|Placebo of cholecalciferol|
214846326|NCT05181267|DIETARY_SUPPLEMENT|Intermittent fasting|Subjects fast from after dinner and throughout the next day, i.e., 36 hours of fasting, after which they are allowed to eat as usual until dinner the same day. Then they fast again for 36 hours, and this regimen will continue for three entire weeks.
214846327|NCT04272489|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.
214288586|NCT07131592|DRUG|Topical TXA|Before wound closure, one 15mm round Jackson-Pratt (JP) drain is placed in each breast pocket, exiting through a lateral chest wall stab incision. The randomized topical TXA intervention is then applied through the drain into the breast after skin closure. The drains will then be temporarily clamped for 20 minutes to allow the TXA to dwell in the tissue and exert local effect. After this the clamp is released, the excess fluid sucked off and the drain connected to a drainage bottle.
214288587|NCT07131592|DRUG|Topical saline|Before wound closure, one 15mm round Jackson-Pratt (JP) drain is placed in each breast pocket, exiting through a lateral chest wall stab incision. The randomized saline intervention is then applied through the drain into the breast after skin closure. The drains will then be temporarily clamped for 20 minutes to allow the saline to dwell in the tissue and exert local effect. After this the clamp is released, the excess fluid sucked off and the drain connected to a drainage bottle.
214288588|NCT07126834|BEHAVIORAL|VIH|During the experimental session, they additionally performed a 5-minute VIH session (20 breaths/minute) after 1 hour of hypoxic exposure. Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc., Kelowna, British Columbia, Canada) equipped with 6-liter breathing bags were employed to perform VIH. The accompanying Isocapnic mobile app was used to guide breathing rhythm and monitor session duration.
214288589|NCT07131501|PROCEDURE|Radical surgery|Radical surgery
214288590|NCT07131501|PROCEDURE|TACE treatment|TACE treatment (cTACE, Idarubicin): Preoperative: 1 session; Postoperative: 1 session.
214288591|NCT07131501|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706)|Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W. Neoadjuvant: 2 cycles; Adjuvant: up to 17 cycles.
214846328|NCT05070390|DRUG|Enlicitide Chloride|10 mg capsule administered orally
214288592|NCT07131501|DRUG|Lenvatinib|Lenvatinib: 8mg (body weight \<60kg) or 12mg (body weight ≥60kg), orally (PO), once daily (QD), Q3W. Consistent daily timing. Neoadjuvant: 2 cycles.
214288593|NCT07132229|OTHER|Cervical High-Intensity Resistive Exercises|The patient will wear a neck harness, and a weight equivalent to 90% of the patient's measured maximum voluntary isometric contraction (MVIC) will be attached to it.
214288594|NCT07132229|OTHER|Conventional physical therapy|Conventional physical therapy consisting of TENS for pain control, soft tissue release for the cervical and associated muscles, activation and strengthening exercises for the deep neck flexors, extensors, and scapular muscles, as well as diaphragmatic breathing exercises.
214288595|NCT07133243|OTHER|testicular ultrasound|each patient will receive an testicular ultrasound to confirm diagnostic of testicular torsion
214288596|NCT07132554|OTHER|Combined 1:1 MICT and HIIT aerobic cardiac rehabilitation|Combining 1:1 MICT and HIIT in short (4 weeks) high-volume (32 sessions) early-to-very-early phase program post heart transplantation
214288597|NCT02152696|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
214288598|NCT02152696|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
214288599|NCT02152696|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
214288600|NCT00797472|DRUG|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
214288601|NCT00797472|DRUG|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
214288602|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
214288603|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is turned off.
214288604|NCT03592199|DRUG|Sunitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
214288605|NCT05236569|DRUG|Tranexamic acid injection|The tranexamic acid injection was given intradermally to the facial skin
214288606|NCT05236569|DRUG|Injection Water|The 0.9% normal saline injection was given intradermally to the facial skin
214288607|NCT06125353|DIETARY_SUPPLEMENT|Melatonin|Patients of the Intervention group (melatonin group) received a personalized dietary plan based on the Mediterranean Diet, together with a booklet of lifestyle guidelines (nutritional and physical activity), all generated by a Clinical Decision Support System (CDSS). Moreover, participants in the Intervention group consumed one melatonin tablet per day, containing 1 mg of melatonin, together with water for a total of three months.
214288608|NCT01252108|DRUG|SQ109|300 mg SQ109 daily for 14 days
214472373|NCT06348329|OTHER|Birth Preparation Training|Birth Preparation Training is planned to include a 4-week program by an internationally certified instructor.
214472374|NCT05903820|DRUG|Estradiol patch|Transdermal patch of estradiol
214846329|NCT03124290|OTHER|paced auditory serial addition test (PASAT)|A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
214846330|NCT06393764|OTHER|Collection of biological samples|Collecte of blood and urine samples
214846331|NCT05247073|PROCEDURE|patients of controlled group with routine closure of episiotomy|"Perineal trauma is traditionally repaired in three stages: a continuous locking stitch is inserted to close the vaginal trauma, commencing at the apex of the wound and finishing at the level of the fourchette with a loop knot. The perineal muscles are then re-approximated with three or four interrupted sutures and finally, the perineal skin is closed by inserting continuous subcutaneous or interrupted transcutaneous stitches.~The skin is then closed with inverted interrupted stitches placed in the subcutaneous tissue a few millimeters under the perineal skin edges (not transcutaneously)."
214846332|NCT05247073|PROCEDURE|The Mostafa Maged four-stitch technique fore closure of the episiotomy|"Identification of the apex of the episiotomy, then a simple suture is taken (0.5 cm) behind the apex of the episiotomy. First, the needle is inserted at the vaginal mucosa of the right edge of the episiotomy then extract the needle.~The second stitch is inserted on the deep muscle layer of the same side (Right side) of the episiotomy cutting edge then extracting the needle.~Then, insert the needle again on the left side of the episiotomy incision in the deep muscle layer on the left side of the episiotomy incision directing the tip of the needle upwards parallel to the second stitch taken.~The fourth step is inserting the needle in the vaginal mucosa of the left side parallel to the first stitch. Continue suturing the episiotomy incision continuously in the same way till reaching the remnant of the hymen.~Then suture the superficial perineal muscle in a continuous manner and the skin in a subcuticular manner as well."
214846333|NCT04258280|BEHAVIORAL|Education and counseling|Education includes a workbook, counseling includes peer support.
214846334|NCT04258280|BEHAVIORAL|Education|Education includes a workbook.
214846335|NCT00703976|DRUG|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
214846336|NCT00703976|DRUG|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
214846337|NCT00703976|DRUG|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
214846338|NCT00703976|RADIATION|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
214846339|NCT04323462|DRUG|Insulin Glargine|Three times bolus insulin with regular or Shorter acting insulin
214846340|NCT04323462|DRUG|Diabetic DM|Previously receiving OADs and/or basal insulin
214846341|NCT05778240|BEHAVIORAL|Phone call|"Participants were given the vaccination appointment card and participants received a telephone call every month two days before their appointment. Participants were reminded that they have a set appointment and were asked to plan the day of their appointment as detailed below. The standard script used in the telephone call in every hospital was as follows:Hello, we are calling you because you are enrolled in the palivizumab prophylaxis research program. As you know, you have a vaccination appointment on \[enter date\] at \[enter time\]. To help you plan your day of appointment, we have a few short questions.~1. At your appointment day, will you be coming to the hospital from home, or will you need to get permission from your workplace?~2. What kind of transportation do you plan to take to come to the hospital at your appointment day?~3. At what time do you plan to leave home or work to come to the hospital?"
214846342|NCT05778240|BEHAVIORAL|Text message|Participants were given the vaccination appointment card and participants were included in a messaging group (on Whatsapp or SMS, depending on the participant's preference) where, twice a month they received a message informing them on RSV, on the additional risks caused by RSV infection in children with congenital heart diseases and on the benefits of adherence to the prophylaxis program. These messages also involved statements about the high number of patient families that kept their appointments in the previous month.
214846343|NCT05778240|BEHAVIORAL|Control|Participants were given the vaccination appointment card.
214846344|NCT02119962|BEHAVIORAL|Working memory training|
214846345|NCT02119962|BEHAVIORAL|Placebo training|
214288609|NCT02422511|GENETIC|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
214288610|NCT02422511|OTHER|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
214288611|NCT05565651|OTHER|Fecal microbiota analysis|Data analysis
214288612|NCT02315781|DEVICE|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
214288613|NCT02315781|DEVICE|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
214288614|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
214288615|NCT02345850|PROCEDURE|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
214472375|NCT05903820|DRUG|Progesterone|Oral progesterone capsules 100mg/day
214846346|NCT04067154|DIAGNOSTIC_TEST|ALPE|Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
214846347|NCT00932594|PROCEDURE|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
214846348|NCT00932594|OTHER|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
214472376|NCT05617040|BIOLOGICAL|ChAdOx1-PCAQ|Recombinant nonreplicating chimpanzee adenovirus Oxford 1 (ChAdOx1) vector encoding 4 prostate cancer antigens: prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4).
214846349|NCT05543694|DRUG|Bupivacaine Hydrochloride|Subjects will receive a dose of bupivacaine as described in the arm section of this trial
214846350|NCT00647894|DRUG|Alprazolam Extended-Release Tablets 1 mg|
214846351|NCT00647894|DRUG|Xanax XR Tablets 1 mg|
214846352|NCT00760526|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor
214846353|NCT00760526|DEVICE|Home blood glucose monitor|Home monitoring 3 or more times a day
214846354|NCT05587257|DEVICE|Fractional CO2 laser|"Each patient will receive 6 sessions 2 weeks apart, after the laser treatment, a topical 5% minoxidil tincture will immediately applied.~All patients will advised not to use any other treatment during the study"
214846355|NCT05587257|DEVICE|Derma pen|, will be treated by microneedling using dermapen ( automated Derma Pen, DR Pen Ultima A6, China) which under complete aseptic precaution with a cartridge containing 12 needles moved diagonally, vertically, and horizontally for 4-5 times in each direction with 1.5 mm depth and speed 4-5(new cartridge every session), the application has been extended 1-2 cm perilesionally. The pinpoint bleeding will be considered an endpoint. topical 5% minoxidil tincture will immediately applied. Each patient will receive 6 sessions 2 weeks apart.
214846356|NCT05587257|DRUG|Niosome minoxidil|The patient of alopecia areata will be treated by topical nanominoxidil preparation twice daily for 3 months with no other treatment.
214846357|NCT05587257|DRUG|Minoxidil Topical Spray|The patient of alopecia areata will be treated by topical minoxidil 5% preparation twice daily for 3 months with no other treatment.
214846358|NCT06384794|DEVICE|Sperm capacitation through the ZyMōt®Sperm Separation Device®|This chip based on microfluidic properties will help us to separate and recover the semen sample with improved sperm quality. It is composed of two microwells, one initial and one final, and a porous membrane through which the sample will be filtered and the capacitated spermatozoa with better motility will be selected. Syringe 850µL of the initial seminal sample into the first well and 750µL of seminal wash medium into the second well. The device is incubated at 37°C for up to 30 minutes. During this incubation, the sample will travel by microfluidic properties from the first well through the porous membrane to the second well. This membrane will filter those spermatozoa with a higher motility. Thus, at the end of the established incubation time, the medium with the selected spermatozoa from the second well (final well) will be collected with a syringe. After this, the sample will be processed and ready for the following procedures.
214846359|NCT06384794|PROCEDURE|Swim-up|The swim-up is a sperm capacitation technique in which the motile spermatozoa of the seminal sample, after centrifugation and incubation, move to the upper part of the medium. In this way, spermatozoa with good progressive motility will remain in the supernatant.
214846360|NCT01199120|DIETARY_SUPPLEMENT|Omega 3|measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
214846361|NCT01472926|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
214846362|NCT01472926|DRUG|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
214846363|NCT02191566|DRUG|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
214846364|NCT02191566|DRUG|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
214846365|NCT03098693|BEHAVIORAL|HIV Self-Testing|Access to home-based HIV self-testing kits for stable couples.
214846366|NCT03098693|BEHAVIORAL|Immediate Access to ART for HIV infected couple members|Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
214846367|NCT03098693|BEHAVIORAL|Access to PrEP for HIV uninfected couple members|Access to PrEP for HIV uninfected couple members.
214846368|NCT00027417|DRUG|Liothyronine sodium/triiodothyronine|
214846369|NCT00027417|PROCEDURE|Cardiopulmonary bypass and cardiac surgery|
214846370|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with devices|Devices
214846371|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with no devices|No Devices
214846372|NCT00898768|PROCEDURE|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
214846373|NCT02539368|DRUG|CT-P13|biosimilar infliximab
214472377|NCT05617040|BIOLOGICAL|MVA-PCAQ|Replication-deficient recombinant Modified Vaccinia virus Ankara (MVA) vector encoding the same prostate cancer antigens as ChAdOx1-PCAQ (prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4))
214472378|NCT01467180|DEVICE|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
214472379|NCT01467180|DEVICE|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
214846374|NCT02539368|DRUG|Remicade|infliximab
214846375|NCT03230123|DIETARY_SUPPLEMENT|Green banana biomass|Green banana biomass will be suplemented to diet as 4.5 g per day.
214846376|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 1|Laparoscopic Hypo gastric Neural Plexus Block
214846377|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 2|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block
214846378|NCT00869440|DRUG|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
214846379|NCT00869440|DRUG|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
214846380|NCT04952467|DRUG|14C-XEN1101|Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101
214846381|NCT05996692|OTHER|Evaluation of adherence to walking prescriptions|Adherence to walking prescriptions was evaluated according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.
214846382|NCT04643392|PROCEDURE|Complex decongestive physiotherapy|Each patient received a treatment protocol of Complex decongestive physiotherapy for 5 days a week until they were discharged from the clinic. All patients fully completed all components of the treatment routine daily. The treatment was performed by a physiotherapist who was certified with Manual Lymph Drainage Combined Decongestive Physiotherapy. After the daily treatment protocol was completed, patients wore standard or individually sized compression grade II or III medical compression stockings for the rest of the day.
214846383|NCT00843830|RADIATION|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
214846384|NCT00843830|BIOLOGICAL|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
214846385|NCT00931996|DRUG|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
214472380|NCT06274723|OTHER|Expert|Participants will view a brief description of an expert source.
214472381|NCT06274723|OTHER|Peer|Participants will view a brief description of a peer source.
214472382|NCT06274723|OTHER|1 Sided|Participants will view e-cigarette education messages in one-sided.
214472383|NCT06274723|OTHER|2 Sided|Participants will view e-cigarette education messages in two-sided.
214846386|NCT01655251|BEHAVIORAL|Intervention|
214846387|NCT04063670|OTHER|Video Intervention|Peri-operative video series focusing on expanded education and coping skills before and after scoliosis surgery for adolescent idiopathic scoliosis
214846388|NCT04063670|OTHER|Control|Routine, Standard-of-Care
214846389|NCT03558139|DRUG|Magrolimab|Administered intravenously
214846390|NCT03558139|DRUG|Avelumab|Administered intravenously
214846391|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
214846392|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
214846393|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
214846394|NCT00267163|DRUG|donepezil|
214846395|NCT00267163|DRUG|Placebo|
214846396|NCT02586363|DRUG|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
214846397|NCT02586363|DRUG|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
214846398|NCT02586363|DRUG|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
214846399|NCT02095886|DRUG|BMS-955176|BMS-955176
214846400|NCT05186779|DRUG|Progestagen|Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer
214846401|NCT02752802|DEVICE|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
214846402|NCT00426179|DRUG|Imatinib|
214846403|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
214472384|NCT04362085|DRUG|Therapeutic Anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
214479477|NCT05257603|BEHAVIORAL|RPCW|Psychosocial intervention that includes two in-person group sessions two weeks apart and two on-line units during the intervening two weeks. Behavioral training, educational materials, discussions and videos, as well as interactive online materials are included to increase awareness of sexual assault cues, dating and drinking protective behavioral strategies, barriers to defending oneself, and saying no to hazardous drinking and sexual advances.
214846404|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 8 weeks
214846405|NCT05363995|BEHAVIORAL|i-Sleep & BioClock Intervention|"The 'i-Sleep \& BioClock' intervention aims at improving sleep and the biological clock among university students. It is incorporates evidence-based techniques such as cognitive behavioural therapy for insomnia (CBTi). The intervention has a duration of 5 weeks and consists of five modules:~1. psychoeducation on insomnia, sleep hygiene and the biological clock,~2. stimulus control and sleep restriction therapy,~3. worrying and relaxation exercises,~4. cognitive therapy to change dysfunctional thoughts about sleep, and~5. summary module, relapse prevention, and plan for the future.~The intervention is supported by e-coaches who give personalized written feedback. Students will fill in a sleep \& light exposure diary daily."
214846406|NCT02963584|OTHER|decision aid|The related information about CTO and PCI procedures will be told to the patients thoroughly.
214846407|NCT02588196|DRUG|Dexamethasone acetate|
214846408|NCT03143517|DIAGNOSTIC_TEST|Stool collection|Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.
214846409|NCT00151216|BIOLOGICAL|AAV2CUhCLN2 (3x10^12 particle units)|gene transfer; one-time administration via neuro surgery procedure
214846410|NCT03573817|DRUG|Revefenacin|Revefenacin is administered via a nebulizer.
214846411|NCT03573817|DRUG|Placebo|Placebo version of Revefenacin is administered via a nebulizer.
214472385|NCT06475950|OTHER|"Kid'EM app experimental group"|"In the Kid'EM app experimental group arm, only the application used differs. Visits are organized in the same way as in the controle app arm.~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
214288616|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
214472386|NCT06475950|OTHER|Kid'EM app control group|"Use of control application without guidance for goal setting~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
214288617|NCT02345850|DRUG|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
214288618|NCT02345850|DRUG|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
214288619|NCT02345850|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
214288620|NCT03898141|OTHER|Placebo (PL)|"Participants will get deceptive and receive an inert cream (=placebo intervention) that reduces pain."
214288621|NCT03898141|OTHER|Dog only (DO)|In the dog intervention a dog will be present during the second measurements. However, participants will only learn the true aims of the presence of the dog after the study (delayed informed consent).
214288622|NCT03898141|OTHER|Animal-assisted placebo (AAPL)|Participants receive the placebo intervention in the presence of a dog.
214288623|NCT05296759|DRUG|botulinum toxin A|botulinum toxin A injection
214288624|NCT05296759|DRUG|Gabapentin|Gabapentin oral intake
214472387|NCT06113965|DEVICE|Peripheral Nerve Stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
214472388|NCT06232564|COMBINATION_PRODUCT|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
214472389|NCT05255393|OTHER|Questionnaires|"A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module."
214288625|NCT05296759|DRUG|Duloxetine|Duloxetine oral drug intake
214288626|NCT00720837|PROCEDURE|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
214288627|NCT02590653|DRUG|Atorvastatin|Lipid-lowering therapy
214288628|NCT01110954|DRUG|PD L 506|Two different doses will be compared
214288629|NCT04801160|PROCEDURE|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
214288630|NCT04801160|PROCEDURE|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
214288631|NCT01045889|OTHER|Rituximab and CHOP regimen + PBSCT|
214288632|NCT06084403|DRUG|20 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine (Buvasin %5 flakon) 20ml will be injected here.
214472390|NCT06423820|DRUG|Ondansetron lozenge|Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
214472391|NCT05092659|BEHAVIORAL|Patient interview|Each patient included will be interviewed 3 times : before surgery, 3 and 6 months after surgery
214472392|NCT04660539|DRUG|satralizumab|Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
214472393|NCT04660539|DRUG|azathioprine (AZA)|Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
214472394|NCT04660539|DRUG|mycophenolate mofetil (MMF)|Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
214472395|NCT04660539|DRUG|oral corticosteroids|Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
214472396|NCT06202105|PROCEDURE|Laparoscopic gastrectomy|Gastrectomy with laparoscopic approach
214472397|NCT05256654|DRUG|LY3561774|Administered SC
214472398|NCT05256654|DRUG|Placebo|Administered SC
214472399|NCT06387147|DRUG|Gentamicin|Gentamicin 80 mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
214472400|NCT06387147|DRUG|Placebo|Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets
214288633|NCT06084403|DRUG|30 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 30ml will be injected here.
214288634|NCT06084403|DRUG|40 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 40ml will be injected here.
214288635|NCT01089959|DRUG|Esomeprazole|40 mg daily for 7 days
214288636|NCT01089959|DRUG|esomeprazole|40 mg. daily, oral medication, once daily for 7 days.
214288637|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 DPI|Inhalation with dry powder by Mia Monodose Inhaler
214288638|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 6% Solution|Inhalation with aerosolised solution by nebuliser
214288639|NCT01347450|DIETARY_SUPPLEMENT|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
214472401|NCT06387147|DRUG|Metronidazole|Métronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
214472402|NCT01167309|DRUG|LEO 27847|First in patient
214472403|NCT06285214|DRUG|V117957|V117957 1 mg - 1 tablet taken orally at bedtime.
214472404|NCT06285214|DRUG|Placebo|Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
214472405|NCT06018064|DEVICE|Prone Positioner|An innovative device to allow for infants to be supported while in the prone position
214472406|NCT06002438|DIETARY_SUPPLEMENT|Whole egg powder|15g daily dose for 24 weeks
214288640|NCT01347450|DIETARY_SUPPLEMENT|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
214288641|NCT04099927|DRUG|SHR0410|SHR0410 monotherapy,given intravenously
214288642|NCT01430091|DRUG|Prasugrel (clinical formulation)|Administered orally
214288643|NCT01430091|DRUG|Prasugrel (Orally Disintegrating Tablet [ODT])|Administered orally
214288644|NCT02415881|DRUG|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
214288645|NCT02415881|DEVICE|da Vinci Firefly|Da Vinci surgical robot with build-in fluorescence imaging option (Firefly technology)
214288646|NCT02415881|DEVICE|IMAGE1 + ICG Hopkins telescope and/or VITOM|IMAGE1 + ICG Hopkins telescope and/or VITOM -- Fluorescence camera allowing for imaging of IRDye800. Camera is suitable for open and laparoscopic surgery.
214472407|NCT06002438|DIETARY_SUPPLEMENT|Corn powder|15g daily dose for 24 weeks
214472408|NCT06002438|DIETARY_SUPPLEMENT|Supercereal Plus|Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.
214472409|NCT06002438|DIETARY_SUPPLEMENT|Micronutrient sprinkles|To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.
214472410|NCT06002438|DRUG|Sulfadoxine pyrimethamine|"Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants \>= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18."
214472411|NCT05525702|DEVICE|VRFS|Participants wear VR headsets and experience immersive virtual environments, where their family members will be present and offer companionship and comfort.
214472412|NCT05167864|DRUG|Onabotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
214472413|NCT05167864|DRUG|Abobotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
214472414|NCT05167864|DRUG|IncobotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
214472415|NCT05167864|DRUG|PrabotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
214288647|NCT00131833|BIOLOGICAL|Typhoid Vi vaccine|
214288648|NCT00131833|BIOLOGICAL|Meningococcal A (control)|
214288649|NCT00888251|OTHER|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
214288650|NCT01382056|OTHER|control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
214288651|NCT01382056|OTHER|Mixed bean (higher amount)|0.6 cup of mixed beans consumed 5 days per week for 8 weeks
214472416|NCT06007781|BIOLOGICAL|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
214472417|NCT06007781|BIOLOGICAL|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
214472418|NCT04403204|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
214472419|NCT04403204|OTHER|DCE-MRI|Characterize the relationship between bone perfusion as quantified by ICG based DCE-FI and DCE-MRI in human patients to develop an accurate depth-sensitive fluorescence imaging model that will correct for the surface-weighted feature of fluorescence imaging
214472420|NCT05786417|OTHER|Clinician Discretion|Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
214472421|NCT05786417|DRUG|Beta blocker|Selection of the specific BB and initial starting dose will be determined by the treating clinician.
214472422|NCT05786417|DRUG|Calcium channel blocker|Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
214846412|NCT03573817|DRUG|Formoterol|Administered sequentially in both revefenacin and placebo arms using a nebulizer.
214846413|NCT04305990|DEVICE|Demand-driven delivery method|The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.
214846414|NCT04305990|DEVICE|Free-flow delivery method|The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
214846415|NCT05899920|DIAGNOSTIC_TEST|Blood samples will be taken for pharmacokinetics and pharmacogenetics|To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
214846416|NCT00400582|DRUG|Candesartan up to 32 mg daily|Candesartan 4 to 32 mg daily
214846417|NCT02244931|DEVICE|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
214846418|NCT02244931|DEVICE|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
214288652|NCT01382056|OTHER|Mixed beans (lower amount)|0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
214288653|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
214288654|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
214288655|NCT01991067|BIOLOGICAL|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
214288656|NCT02406976|OTHER|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3."
214288657|NCT02406976|BEHAVIORAL|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3."
214288658|NCT02406976|OTHER|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
214472423|NCT06580171|OTHER|Walking and Remembering Test|Only Walking and Remembering Test will be applied to the group.
214472424|NCT06570863|OTHER|Antibiotics(doxycycline)|doxycycline 100 mg 2 stat the first day followed by od for 14 days
214472425|NCT06570863|OTHER|Probiotics|Probiotic powder of Lactobacillus Reuteri. After mechanical debridement patient will be prescribed with Lactobacillus rhamnosus SP1 \[(2x107colony forming units (CFU)/ day)\] (Macrofood S.A., Santiago de Chile, Chile) for 1 month. The dose would be one sachet taken orally daily. The sachets presented to the patients would be identical. Individuals will be instructed to dissolve 1 sachet in water (150 mL) and ingest it once a day after brushing their teeth.
214472426|NCT06570863|OTHER|Metronidazole gel 25%|After mechanical debridement, 25% of metronidazole gel was administered into the periodontal pockets. The gel was applied with a parojet syringe provided with a blunt cannula
214479478|NCT05257603|BEHAVIORAL|HEC|Health Education time and attention control that includes two in-person sessions two weeks apart and two on-line units during the intervening two weeks. The in-person sessions cover stress management and sleep, while the online units cover nutrition and physical activity. The in-person and online sessions are designed to foster discussion and be interactive.
214846419|NCT02244931|DEVICE|Standard manual Wheelchair|Standard manual Wheelchair
214846420|NCT02013531|DRUG|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
214846421|NCT01275157|DRUG|LY2452473|Administered orally as a liquid suspension
214846422|NCT02502331|BIOLOGICAL|Test Oral Cholera Vaccine|Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
214846423|NCT02502331|BIOLOGICAL|Euvichol®|Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
214472427|NCT03852550|OTHER|e-health application|In the first part of this study, an e-health application (MyREADY Transition\[TM\] BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
214846424|NCT04307472|BEHAVIORAL|Clinician Nudge|Active choice intervention in the electronic health record and peer comparison messaging on performance
214846425|NCT04307472|BEHAVIORAL|Patient Nudge|Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
214846426|NCT05827640|OTHER|data recording using conventional ventilation strategies (PCV and VCV)|no intervention
214846427|NCT05454358|DRUG|Letrozole 2.5mg|Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
214846428|NCT04476186|DRUG|Acyclovir|oral syrp
214846429|NCT04476186|DRUG|KOH 10 %|solution for local application
214846430|NCT00932217|DRUG|filgrastim|subcutaneous filgrastim administration
214846431|NCT00932217|DRUG|lenograstim|subcutaneous lenograstim administration
214846432|NCT01567241|OTHER|clinical hypnosis or relaxation music|25 minute tape recording
214846433|NCT00005075|PROCEDURE|high-intensity focused ultrasound ablation|
214846434|NCT00351286|DRUG|L-citrulline tablets, 1000 mg|
214846435|NCT00351286|DRUG|Placebo tablets matching L-citrulline tablets|
214846436|NCT00351286|DRUG|Background simvastatin at a stable dose of 40 mg qHS|
214846437|NCT05118477|DEVICE|Ambulatory monitoring system|Patients will use AMS.
214846438|NCT05118477|DEVICE|Active alerting system|Clinical staff alerted if AMS detects deterioration
214846439|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Toric|Daily disposable soft toric contact lens
214846440|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Sphere|Daily disposable soft spherical contact lens
214846441|NCT04462744|OTHER|educational program|an oral health educational program regarding the emergency management of traumatic dental injuries.
214846442|NCT02400476|DRUG|Neratinib|
214288659|NCT03011398|PROCEDURE|Orthobiologic Procedures|To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.
214288660|NCT00378274|BEHAVIORAL|Observation|
214288661|NCT01075204|DRUG|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
214288662|NCT00969176|DRUG|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
214288663|NCT03108833|DRUG|Recombinant Human Prourokinase|The drug is used for intravenous thrombolysis therapy
214288664|NCT03108833|DRUG|Alteplase|The drug is used for intravenous thrombolysis therapy
214288665|NCT01012518|DEVICE|Standard PCT|The standard technique, performed without video guidance
214288666|NCT01012518|DEVICE|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
214472428|NCT04188912|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tears, saliva, buccal mucosa, feces, and tissue samples
214288667|NCT05745558|BEHAVIORAL|Prehabilitation|"The prehabilitation program consists of 4 components:~1. Fitness training led by a physiotherapist. The patients will receive personalized training schedules to perform at home. The training sessions focus on improving aerobic fitness (biking or walking) and muscle strength (specific exercises for the different patient groups) and respiratory exercises aimed to relax.~2. Nutritional counseling led by a dietician. All patients will be offered an intake with a dietician (60 min) to discuss current eating habits and give personalized advices. Based on indication, patients will receive follow-up consults.~3. Smoking cessation counseling led by a trained social worker. For patients that are currently smoking, a social worker will offer counseling sessions to coach the patient in the process of smoking cessation.~4. Psychosocial counseling led by a psychologist. All patients will be offered counselling by a psychologist."
214472429|NCT04188912|PROCEDURE|Optical Coherence Tomography|Undergo optical coherence tomography
214472430|NCT04188912|PROCEDURE|Spirometry|Undergo portable spirometry
214472431|NCT04188912|OTHER|Survey Administration|Complete survey
214472432|NCT04188912|OTHER|Digital Photography|Undergo digital photography
214846443|NCT02400476|DRUG|Loperamide|
214846444|NCT02400476|DRUG|Colestipol|2 g twice daily with or without food for one 28 day cycle
214846445|NCT02400476|DRUG|Budesonide|9 mg extended release tablets once daily with or without food for 28 days
214846446|NCT02604576|DRUG|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
214846447|NCT02604576|DRUG|Bromopride 10 mg|Bromopride 10 mg
214846448|NCT00003862|DRUG|cisplatin|
214846449|NCT00003862|DRUG|fluorouracil|
214846450|NCT00003862|DRUG|leucovorin calcium|
214846451|NCT00003862|DRUG|paclitaxel|
214846452|NCT00003862|PROCEDURE|conventional surgery|
214846453|NCT00003862|PROCEDURE|neoadjuvant therapy|
214846454|NCT00003862|RADIATION|radiation therapy|
214846455|NCT02803931|DEVICE|Cardiogoniometry|Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
214846456|NCT02803931|DEVICE|12-lead ECG|
214846457|NCT03396874|DRUG|68Ga-PSMA|"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
214846458|NCT06678165|DRUG|YOLT-204|The intervention group will receive YOLT-204 on day0
214846459|NCT04906330|DIAGNOSTIC_TEST|Oncoliq: test for early breast cancer detection.|Oncoliq is a novel early detection breast cancer test based on liquid biopsies and miRNAs. The main advantage of this test is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.
214846460|NCT00588731|DRUG|Cannabidiol|Active Cannabidiol daily over 6 weeks
214846461|NCT00588731|DRUG|Placebo|Placebo
214846462|NCT06406322|OTHER|PFMT|Pelvic floor muscle training will be given to patients with strengthening and endurance exercises for 8 weeks. PFMT will be applied at a patient-specific progression for 8 weeks.Exercises will be given in different positions (supine, sitting, etc.).
214846463|NCT06406322|OTHER|Aerobic Exercise|Aerobic exercise will be applied as a progressive program in the form of a walking program, at least 4 days a week for 8 weeks. There will be 5-minute warm-up and cool-down periods (walking at a light pace) before and after exercise.
214846464|NCT00094367|DRUG|Abacavir/Lamivudine|
214846465|NCT05361486|OTHER|Training on revised algorithm|relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly
214846466|NCT05361486|OTHER|Enhancing Pharmacovigilance|Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.
214846467|NCT05361486|OTHER|Supervision of malaria services in selected facilities.|Supervisors in target regions will be trained as for the HCPs.
214846468|NCT05361486|DIAGNOSTIC_TEST|G6PD testing|G6PD test after Malaria Vivax diagnosis
214846469|NCT05361486|DRUG|Tafenoquine|300 mg (2x150mg tablets) tafenoquine
214846470|NCT05361486|DRUG|Primaquine|0.5mg/kg/7 days
214846471|NCT05361486|OTHER|Follow Up Visit at Day 3 [+2 days] after treatment start|It will be checked if all patients have a Follow Up Visit at Day 3 \[+2 days\] after treatment start
214846472|NCT03463018|DIETARY_SUPPLEMENT|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
214846473|NCT03463018|DIETARY_SUPPLEMENT|Placebo|Placebo tablet containing matching excipients to the active intervention
214846474|NCT01010035|OTHER|Plasma kinetic study|this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
214846475|NCT00444821|DEVICE|AneuRx AAA stent graft / Talent AAA stent graft|Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
214846476|NCT02917252|OTHER|3-hydroxybuturate|Drink of ketone bodies
214846477|NCT02917252|OTHER|Placebo|Drink of saline
214846478|NCT00724620|BIOLOGICAL|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
214846479|NCT00724620|DRUG|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
214846480|NCT03337217|PROCEDURE|Position during colonoscopy|Position during colonoscopy
214846481|NCT00108576|DRUG|Divalproex|anticonvulsant; mood stabilizer
214846482|NCT00108576|OTHER|placebo|Look-a-like placebo
214846483|NCT03118219|OTHER|Positive adjustment coping intervention|see arm description
214846484|NCT03118219|OTHER|Brainteaser|see arm description
214846485|NCT00612677|DRUG|Oxaliplatin|Dose Regimen: 120 mg/m\^2 on Days 1 every 21 days
214288668|NCT01132404|DRUG|Leuprorelin|Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
214288669|NCT01132404|DRUG|TAK-448|"Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months"
214288670|NCT00543348|PROCEDURE|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
214288671|NCT00543348|PROCEDURE|Balloon angioplasty|HIGH PRESSURE BALLOON
214288672|NCT03909295|DRUG|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
214472433|NCT04188912|OTHER|Quality-of-Life Assessment|Ancillary studies
214472434|NCT04188912|OTHER|Medical Chart Review|Review of medical charts
214846486|NCT00612677|DRUG|Pemetrexed|Dose Regimen: 500 mg/m\^2 on Days 1 every 21 days
214846487|NCT04051216|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention
214846488|NCT04051216|OTHER|Activity monitor|Participants will receive at least 1 of 4 activity monitoring devices
214846489|NCT04051216|OTHER|Interview|Participants will be interviewed about their experience using the device(s)
214846490|NCT04051216|OTHER|Survey Administration|Participants will receive surveys
214846491|NCT04051216|OTHER|Laboratory Biomarker Analysis|Correlative studies
214846492|NCT01758237|DEVICE|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
214846493|NCT01758237|PROCEDURE|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
214846494|NCT01415050|DEVICE|Whole body vibration|15 times WBV
214846495|NCT03359837|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
214288673|NCT02189746|OTHER|Continuous Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
214288674|NCT02189746|OTHER|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
214472435|NCT05204654|OTHER|In-office fabricated appliance|A 0.022 Slot MBT™ second molar mini tube that has been modified to have a 2 mm length will be placed on the maxillary first molar and a 0.018 slot MBT™ maxillary canine bracket will be placed on the maxillary canine, with a 0.016x0.022 stainless-steel wire spanning from the maxillary first molar to the maxillary canine. A bayonet bend will be placed mesial to the molar tube. A curve will be bent into the wire, so that the wire is able to passively rest on the buccal surface of the maxillary canine. A stainless-steel closed coil will span the molar to canine and lay flush to the mesial portion of the molar tube and the distal portion of the canine bracket. The wire will be cinched mesial to the maxillary canine tie-wing and also 2-3 mm distal to the maxillary first molar to ensure that the molar can rotate during treatment, if needed. A stainless-steel tie will be used to secure the wire into the canine bracket. AP correction will be completed following CMA protocol
214472436|NCT05204654|DEVICE|Carriere Motion Appliance|A bar spanning from the maxillary first molar to canine with a ball and socket joint at the molar and a canine pad at the canine. A slight bend is present between the molar and canine bracket. The ball and socket is designed to allow the molar to rotate to -15 degrees along it's longitudinal axis. The appliance claims that it allows for Class II correction with minimal secondary tooth movements when used with mandibular anchorage.
214472437|NCT04779320|DRUG|Vedolizumab IV|Vedolizumab IV
214472438|NCT05897476|OTHER|ultrasound|brief external ultrasound will be proceed on each patient included searching signs of aortic dissection
214472439|NCT01976286|OTHER|Salicylic Acid Peels|
214472440|NCT01976286|OTHER|Glycolic Acid Peels|
214472441|NCT02807545|BEHAVIORAL|Scoliosis Specific Exercises|
214472442|NCT05207982|BEHAVIORAL|Family Based weight management program|"Weight management program that involve the patient AND a family member or a care taker. Families will receive a 12-week FBT adapted for first episode psychosis. This will be delivered in 12 weekly meetings with a trained case manager and two eating plan education sessions. Both the patient with psychosis and parents are targeted for eating and activity/exercise change to ensure a change in the shared family environment, which will also help weight control in both sets of participants, as well as medical issues that accompany obesity, including glycemic control, hypertension and hyperlipidemia. If parents are not overweight/obese, they will still target improved health behaviors. They will learn about GREEN, YELLOW, and RED foods (healthy vs. unhealthy foods), energy density, glycemic index of foods, reducing serving sizes, eating less, healthy lifestyle and programmed activity programs and recording their diets and activity."
214472443|NCT05608109|BEHAVIORAL|Alcohol personalized normative feedback (APNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.
214472444|NCT05608109|BEHAVIORAL|Social media personalized normative feedback (SMPNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
214472445|NCT03974893|OTHER|Vegetarian Diet|Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
214472446|NCT04868123|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Transcutaneous nerve stimulation (TENS) is a simple home base treatment to manage pain. It involves electrical current applied to the skin through self-adhering electrodes, using a TENS3000 device (TENSPros.com).
214472447|NCT04868123|BEHAVIORAL|Mindfulness Meditation|Mindfulness mediation is a guided mediation process to improve awareness of being present in the moment.
214472448|NCT04974151|DRUG|Amlodipine besylate|The amlodipine used in this study is a listed product.
214472449|NCT04974151|DRUG|Amlodipine besylate And Folic Acid|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020.
214472450|NCT04974151|DRUG|5-methyltetrahydrofolate (5-MTHF)|The 5-MTHF used in this study is a listed product.
214846496|NCT03359837|DRUG|Insulin Glulisine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
214846497|NCT03359837|DRUG|Biphasic insulin aspart 30|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
214846498|NCT03359837|DRUG|Repaglinide|"Pharmaceutical form: tablet~Route of administration: oral administration"
214846499|NCT03359837|DRUG|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
214846500|NCT03359837|DRUG|Metformin|"Pharmaceutical form: tablet or capsule~Route of administration: oral administration"
214472451|NCT04974151|DRUG|Amlodipine placebo|Amlodipine placebos are dummy pills of amlodipine with identical appearance.
214472452|NCT04974151|DRUG|Amlodipine folic acid placebo|Amlodipine folic acid placebos are dummy pills of amlodipine folic acid with identical appearance.
214472453|NCT04974151|DRUG|5-MTHF Placebos|5-MTHF placebos are the dummy pills of 5-MTHF with identical appearance.
214472454|NCT03608579|DRUG|Autologous Adipose Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
214472455|NCT04089059|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)"
214472456|NCT04149990|DRUG|Entresto Pill|NO other interventions
214846501|NCT05197829|DEVICE|Continuous Glucose Monitoring|Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.
214846502|NCT05197829|OTHER|Care Coordination|All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
214846503|NCT01908894|DRUG|BIOD-123|
214846504|NCT01908894|DRUG|BIOD-125|
214846505|NCT01908894|DRUG|Humalog|
214846506|NCT04615845|BIOLOGICAL|Cellgram-DC-PC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
214846507|NCT02146976|DRUG|propofol|introvenious infusion of propofol
214846508|NCT02146976|DRUG|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
214846509|NCT00613730|DRUG|Gemcitabine|Intravenous administration
214846510|NCT00613730|DRUG|panitumumab|Intravenous administration
214846511|NCT05367765|DRUG|Flumatinib|Flumatinib 600mg orally daily
214846512|NCT05367765|DRUG|Imatinib|Imatinib 400mg orally daily (Reference drug instructions)
214846513|NCT00133679|DRUG|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
214846514|NCT00133679|DRUG|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
214846515|NCT00679250|DRUG|levocetirizine|5 mg once nightly before visit
214846516|NCT00679250|DRUG|placebo to levocetirizine|1 tablet once nightly before visit
214846517|NCT00352196|DRUG|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
214846518|NCT00352196|OTHER|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
214846519|NCT02056652|DEVICE|Bioteque cup pessary|
214846520|NCT02401841|DRUG|Two different types of drug for resolution of neuro-muscular blockade|
214846521|NCT05783856|COMBINATION_PRODUCT|LiveSpo X-secret|In Vietnam, LiveSpo X-secret is manufactured as a Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
214846522|NCT05783856|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 15 mL-bottle that is used for LiveSpo X-secret.
214846523|NCT02093923|DRUG|DX-2930|Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
214846524|NCT02093923|DRUG|Placebo|Participants will receive matching placebo subcutaneously.
214846525|NCT06155773|PROCEDURE|Highly viscous glass ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
214846526|NCT06155773|PROCEDURE|Low shrinkage Flowable Composite (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
214288675|NCT02189746|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
214288676|NCT02189746|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
214288677|NCT01411228|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
214288678|NCT03120546|DEVICE|rigid video stylet intubation|intubation using rigid video stylet
214288679|NCT03120546|DEVICE|video laryngoscope intubation|intubation using video laryngoscope
214288680|NCT01951742|BIOLOGICAL|ANT-1401|Active
214846527|NCT06155773|PROCEDURE|Resin Modified Glass Ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
214846528|NCT06155773|PROCEDURE|Bioactive Ionic Resin (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
214846529|NCT02769741|OTHER|Cashews followed by Control|Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
214846530|NCT02769741|OTHER|Control followed by Cashews|Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
214288681|NCT01951742|BIOLOGICAL|Vehicle|Vehicle
214288682|NCT00937443|OTHER|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
214288683|NCT00937443|BIOLOGICAL|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
214288684|NCT02201706|PROCEDURE|Multi-electrocoagulation retinectomy|"a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.~All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.~Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process."
214288685|NCT00004984|DRUG|Parenteral Insulin|Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.
214288686|NCT00004984|OTHER|Close Observation|Study visits every 6 months including an oral glucose tolerance test
214288687|NCT00004984|DRUG|Oral Insulin|Capsules oral insulin, 7.5 mg of recombinant human insulin crystals
214288688|NCT00004984|DRUG|Placebo|Placebo for oral insulin
214288689|NCT02569216|DEVICE|Electrical Inhibition (EI)|constant direct current 1-20mA transvaginal 10 second bursts only when needed
214288690|NCT04565431|DRUG|Tysabri|Participants with RRMS who are planning to begin treatment with Tysabri will be compared to a group of healthy individuals who are matched for age, gender, and education.
214288691|NCT01974375|DRUG|micafungin|Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing \<40 kg)
214288692|NCT01974375|DRUG|Fluconazole|Fluconazole 100\~200mg/day, IV care until oral medication becomes possible
214288693|NCT03247075|BEHAVIORAL|Cognitive Behavior Therapy|Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms
214288694|NCT03247075|BEHAVIORAL|Support and Counseling|Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
214288695|NCT04329169|OTHER|Virtual Implant Planning|According to the virtual implant plan, a CAD/CAM tooth supported surgical guide will be fabricated to place the dental implant with a fully guided surgical protocol.The surgical guide will be manufactured from a photopolymer resin using a 3D printing machine. A hex- shaped metal sleeve will be inserted in the surgical guide with the flat surface located buccally so that it will help in orientation of the implant hex during the implant placement.
214288697|NCT01752907|OTHER|General Education DVD|A general chemotherapy side effects education DVD
214288698|NCT01752907|OTHER|Bone Pain Education DVD|
214288699|NCT06358365|DEVICE|The AquaPass System|The system is a non-invasive, renal-independent, single-patient, multiple-use device intended for use at the hospital, outpatient clinic, or home. The system administers warm, dry air around the patient's body to create an environmental condition that activates the eccrine glands to produce sweat, in return it removes fluids from the interstitial compartment, where fluids accumulate in fluid overload.
214288700|NCT05773508|DEVICE|Video regulation and emergency kit|Video regulation and emergency kit
214288701|NCT01950650|BEHAVIORAL|No treatment given|Survey conducted through computer-assisted telephone interviewing.
214288702|NCT01950650|BEHAVIORAL|survey|Survey conducted via the Internet.
214288703|NCT04371991|DIAGNOSTIC_TEST|blood test|blood test (serum samples) for biochemical examination
214288704|NCT02696473|DIETARY_SUPPLEMENT|Carrot|
214288705|NCT03912285|DRUG|Amlodipine10mg|Amlodipine 10mg will be administered orally twice a day for 9 days
214288706|NCT03912285|DRUG|Losartan potassium 100mg|Losartan 100mg will be administered orally once a day for 9 days
214288707|NCT03912285|DRUG|Amlodipine plus Losartan|"Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan"
214288708|NCT00333814|DRUG|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
214288709|NCT00333814|DRUG|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
214288710|NCT00333814|DRUG|Sham injection|Sham injection at Day 0
214288711|NCT00187876|PROCEDURE|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
214288712|NCT00187876|PROCEDURE|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
214288713|NCT02550249|DRUG|Nivolumab|Intravenous administration of nivolumab
214288714|NCT02670083|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
214288715|NCT02670083|DRUG|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
214288716|NCT00713050|BEHAVIORAL|Imitate Therapy|Imitation-based computer therapy
214288717|NCT02014597|DEVICE|HOCD|feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma
214288718|NCT03223597|DRUG|Radium-223 dichloride|Registry of patients who receive Radium-223.
214472457|NCT06551311|BEHAVIORAL|cycling training exercise|"Participants were randomly allocated to one of three groups: control (CTL), concentric cycling training (CON), or eccentric cycling training (ECC).~CTL: Received standard health education guidance.~CON and ECC: Participants in both the CON and ECC groups engaged in 24 exercise sessions, performed three times per week, lasting between 20 and 30 minutes. Both groups trained on a stationary bicycle, with the CON group performing concentric cycling and the ECC group performing eccentric cycling. The exercise intensity for both groups was set to a rating of perceived exertion (RPE) level of 13. Sessions began at 20 minutes and increased incrementally by 3-5 minutes each week until participants could sustain a 30-minute duration. The initial exercise intensity was set at 50% of the maximal output determined by a cardiopulmonary exercise test, and it was progressively increased by 5-10% of the estimated target power weekly, with adjustments made primarily to maintain an RPE of 13."
214846531|NCT02498249|DEVICE|low level laser therapy|Will be performed irradiation with low-intensity laser in upper trapezius muscle
214846532|NCT02498249|DEVICE|Placebo low level laser therapy|Will be not performed irradiation with low-intensity laser in upper trapezius muscle
214472458|NCT06067945|OTHER|microleakage|prevention of microleakage and secondary carries
214846533|NCT03253094|DRUG|Fluconazole|Oral Antifungal comparator
214846534|NCT03253094|DRUG|SCY-078|Investigational Antifungal
214846535|NCT00559026|BIOLOGICAL|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
214846536|NCT00559026|OTHER|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
214472459|NCT00186147|PROCEDURE|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
214472460|NCT04185246|DRUG|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
214472461|NCT04185246|DIAGNOSTIC_TEST|Echocardiogram|Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
214472462|NCT03728608|DEVICE|Feeding tube dwell time of 48 hours|Feeding tube dwell time of 48 hours for first 4 weeks of life.
214472463|NCT03728608|DEVICE|Feeding tube dwell time of 7 day|Feeding tube dwell time of 7 days for first 4 weeks of life.
214472464|NCT04032782|DRUG|HM15136|10 mg/mL as protein in prefilled syringes
214472465|NCT04032782|DRUG|Placebo of HM15136|Placebo in prefilled syringes
214472466|NCT04815239|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.
214472467|NCT04815239|BEHAVIORAL|The Healthy Lifestyle Behavior Intervention (HL)|HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
214846537|NCT04938986|DIAGNOSTIC_TEST|IMMUNOSCORE®|recommendation for patient care according to the result of the IMMUNOSCORE®
214846538|NCT02282202|DEVICE|Oscillating Positive Expiratory Pressure (Aerobika ®)|"The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.~There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks."
214846539|NCT00006399|DRUG|Donepezil|
214846540|NCT00006399|DRUG|Estrogen|
214846541|NCT00006399|DRUG|Progesterone|
214472468|NCT02329262|BEHAVIORAL|Mentoring to be Active with Accelerometers|Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
214472469|NCT02329262|BEHAVIORAL|Planning to be Active with Accelerometers|Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
214846542|NCT04509999|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily
214846543|NCT04509999|DRUG|Placebo|Placebo as formulated by mouth daily
214846544|NCT00248170|DRUG|Letrozole|2.5 mg tablets
214846545|NCT00248170|DRUG|Anastrozole|1 mg tablets
214846546|NCT02346682|DRUG|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
214846547|NCT01557582|DEVICE|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
214846548|NCT05507528|DEVICE|reborn treatment|Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure
214846549|NCT06020482|OTHER|Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity|The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.
214846550|NCT04351347|DRUG|Ivermectin|ivermectin
214846551|NCT06427369|OTHER|Radioconjugate|1241-hJAA-F11 IV administration
214846552|NCT06427369|PROCEDURE|Positron Emission Tomography|PET/CT Imaging
214472470|NCT04579692|DEVICE|ExAblate Transcranial treatment|Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.
214472471|NCT05715814|DRUG|Empagliflozin 25 MG|PO once daily
214472472|NCT03529396|DRUG|Chloroquine|Standard chloroquine (three days)
214472473|NCT03529396|DRUG|Primaquine|Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.
214472474|NCT03529396|DRUG|Primaquine|Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.
214472475|NCT03529396|DRUG|Chloroquine|Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)
214472476|NCT03529396|DRUG|Primaquine|Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.
214846553|NCT06427369|PROCEDURE|Computed Tomography|PET/CT Imaging
214846554|NCT06427369|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|FDG PET/CT Imaging
214846555|NCT06427369|PROCEDURE|Biospecimen Collection|Blood sample collection imaging
214846556|NCT02521181|DRUG|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
214472477|NCT04594005|DRUG|abemaciclib+paclitaxel|"Phase 1b: About 3-6 patients enrollment is expected at dose level 1, -1 and -2. Dose reduction will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.~level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 100mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks level-2: abemaciclib 50mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks~Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study."
214472478|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
214472479|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
214472480|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
214472481|NCT05207956|BEHAVIORAL|Behavioral economics strategies|Behavioral economics features designed to increase motivation to collect data and ease of data collection on the electronic platform.
214472482|NCT05207956|OTHER|Electronic platform|Electronic platform to collect data
214472483|NCT02473042|PROCEDURE|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
214472484|NCT02473042|DRUG|Zofran|4 mg by vein for 1 dose.
214472485|NCT02473042|DRUG|Dexamethasone|10 mg by vein for 1 dose.
214472486|NCT02473042|DRUG|Phenergan|6.25 mg by vein for 1 dose.
214472487|NCT02473042|DRUG|Pepcid|10 mg by vein for 1 dose.
214472488|NCT02473042|BEHAVIORAL|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
214472489|NCT06156670|DEVICE|PFO closure|"The operation of endovascular closure of PFO is performed on X-ray angiographic devices with digital processing of X-ray images. Endovascular closure of a PFO will be performed by femoral venous access using the following instruments: diagnostic catheter, diagnostic guidewire, high-stiffness guidewire for delivery system, interatrial septum occluders of PFO, UNI, ASD types.~Preoperative preparation and control of device implantation will be performed using modern echocardiographic equipment."
214472490|NCT05628584|COMBINATION_PRODUCT|High FODMAP diet with metformin|Controlled High FODMAP diet (15g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
214846557|NCT02521181|DRUG|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
214846558|NCT02521181|DRUG|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
214846559|NCT02843659|DRUG|BMS-931699|Specified dose on specified days
214846560|NCT02843659|DRUG|BMS-986142|Specified dose on specified days
214846561|NCT02843659|DRUG|Placebo|Specified dose on specified days
214472491|NCT05628584|COMBINATION_PRODUCT|Low FODMAP diet with metformin|Controlled low FODMAP diet (3g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
214472492|NCT03127189|DRUG|Rilpivirine|Rilpivirine 25 mg immediate release oral solution.
214472493|NCT03127189|DRUG|Rilpivirine Long-acting Parenteral Formulation|RPV LA 600 mg extended-release suspension for IM injection.
214472494|NCT06503250|DRUG|Atezolizumab|Observational Study
214472495|NCT06503250|DRUG|Bevacizumab|Observational Study
214846562|NCT00862017|DIETARY_SUPPLEMENT|MSg supplementation|
214846563|NCT00862017|DIETARY_SUPPLEMENT|NaCl supplementation|
214846564|NCT06357156|RADIATION|CBCT|The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.
214846565|NCT02413294|DEVICE|Re-Timer glasses|Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
214846566|NCT01304381|OTHER|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
214472496|NCT06503250|RADIATION|Transarterial Chemoembolization|Observational Study
214846567|NCT01304381|OTHER|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
214846568|NCT06722755|DEVICE|CPAP device|Eligible participants with OSA will be started on automatically-adjusting CPAP.
214846569|NCT06722755|BEHAVIORAL|CPAP technical support|Trained personnel will conduct mask selection and fitting, provide continual troubleshooting, and train participants on CPAP.
214846570|NCT06722755|BEHAVIORAL|Phone follow-up for adherence feedback and self-management skills|The research coordinator will call participants approximately monthly to provide any needed support.
214846571|NCT06722755|BEHAVIORAL|myAir|Study personnel will assist participants in registering for and using the myAir (ResMed) self-tracking app. This app also provides a library of how-to videos and provides email updates to participants.
214846572|NCT06722755|BEHAVIORAL|Tailored messages|Tailored text messages will be sent to participants. Two-way texting messaging will also be available between the study team and participants.
214846573|NCT06722755|BEHAVIORAL|Written Materials|A binder of written educational materials will be provided to participants.
214846574|NCT06722755|BEHAVIORAL|Motivational Enhancement Therapy (MET)|A trained sleep coach will conduct up to 5 MET sessions with participants and 2 sessions with a CPAP partner during the study time period.
214846575|NCT01631682|DRUG|Propranolol|40mg single pill
214846576|NCT01631682|BEHAVIORAL|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
214846577|NCT01631682|DRUG|Mifepristone|1800mg, 9 tablets
214846578|NCT01631682|DRUG|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
214846579|NCT05522218|DEVICE|Eluvia drug eluting stent|Eluvia drug eluting stent for peripheral arterial disease
214846580|NCT02408445|DRUG|testosterone cypionate 200mg/ml|Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
214846581|NCT04854213|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment
214846582|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) injection every 3 months
214846583|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) infusion every 3 months
214846584|NCT00503113|DRUG|Alendronate|70mg per oral (po) weekly
214846585|NCT01962649|BIOLOGICAL|ICG|
214846586|NCT01962649|DEVICE|Optical molecular imaging|
214846587|NCT01253317|DRUG|rhIGF-1|1\) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
214846588|NCT01083862|BEHAVIORAL|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
214846589|NCT01083862|BEHAVIORAL|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
214846590|NCT01039454|DRUG|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
214846591|NCT01039454|DRUG|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
214846592|NCT00700245|BEHAVIORAL|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)|The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.
214846593|NCT00700245|BEHAVIORAL|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet|Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.
214288719|NCT04687878|DRUG|Insulin|20 IU twice a day, intranasally, every day for 12 weeks
214288720|NCT04687878|DRUG|Normal saline|twice a day, intranasally, every day for 12 weeks
214288721|NCT01780636|DRUG|botulinum toxin|
214288722|NCT01279278|OTHER|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
214288723|NCT01279278|OTHER|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
214288724|NCT02028624|BEHAVIORAL|Nutrition counseling|Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
214288725|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
214288726|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
214288727|NCT05954026|DEVICE|ExVent|ExVent Accessory (inserted into the O2Vent Optima device) for treatment of sleep apnea
214288728|NCT00603993|BIOLOGICAL|Adalimumab|40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
214846594|NCT00700245|BEHAVIORAL|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).|The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session
214846595|NCT02495532|OTHER|Lymph node clearing technique with Carnoy solution|"Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
214846596|NCT02495532|OTHER|Lymph node clearing technique with GEWF solution|"Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
214846597|NCT01598545|DRUG|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
214846598|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
214846599|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
214472497|NCT06558994|PROCEDURE|Transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis.
214846600|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
214846601|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
214846602|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
214846603|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
214846604|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
214846605|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
214846606|NCT04836520|DRUG|SHR6390+anatrozole|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
214846607|NCT06893562|BEHAVIORAL|Safe Hands and Safe Bladder intervention|Evaluating changes in urinary tract infections and bladder distension nine-year after implementing preventive measures
214846608|NCT06749925|BIOLOGICAL|Dendritic Cell Vaccine|This intervention distinguishes itself from others by utilizing allogeneic dendritic cells derived from healthy donors fused with autologous tumor cells from patients, which is a novel approach compared to the commonly used autologous DC-based vaccines (DCVax).
214846609|NCT06749925|COMBINATION_PRODUCT|Pembrolizumab|Recent findings have shown that the anti-PD1 monoclonal antibody, a checkpoint inhibitor, can sustainably enhance the anti-tumor immune response. In this study, all patients in the intervention group (vaccine) who reach the fifth dose will be randomized to receive either pembrolizumab or a placebo as an addition to the experimental treatment regimen.
214846610|NCT06749925|OTHER|Placebo|In this study, all patients in the intervention group (vaccine) who reach the fifth dose will be randomized to receive either pembrolizumab or a placebo as an addition to the experimental treatment regimen.
214846611|NCT06895382|PROCEDURE|Caudal Epidural Block|A caudal epidural block was performed after the induction of general anesthesia. Using a 35-mm 22G or 30-mm 25G block needle, the sacral hiatus was identified, and the needle was inserted through the sacrococcygeal ligament into the epidural space under aseptic conditions. After confirming negative aspiration for cerebrospinal fluid or blood, 1 mL/kg of 0.25% bupivacaine was administered.
214846612|NCT06895382|PROCEDURE|Transversus Abdominis Plane (TAP) Block|A transversus abdominis plane (TAP) block was performed after the induction of general anesthesia. Using a 22G, 50-mm insulated block needle, the injection was administered under ultrasound guidance using a linear probe and in-plane technique. The needle was advanced into the fascial plane between the internal oblique and transversus abdominis muscles. After confirming placement with a 0.5-1 mL test dose of 0.9% NaCl and negative aspiration for blood, 0.3 mL/kg of 0.25% bupivacaine was administered.
214288729|NCT05531084|DEVICE|Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)|Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.
214472498|NCT06558994|PROCEDURE|Ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
214472499|NCT02296684|BIOLOGICAL|MK-3475 (neoadjuvant)|
214472500|NCT02296684|PROCEDURE|Surgery|Standard of care
214472501|NCT02296684|RADIATION|Intensity modulated radiation therapy|Recommended, standard of care
214472502|NCT02296684|RADIATION|Image-guided radiation therapy|Recommended, standard of care
214472503|NCT02296684|DRUG|Cisplatin|Standard of care
214288730|NCT05118503|BEHAVIORAL|Customized education|Half of subjects will receive access to a customized app that will include brief educational videos that have been selected for each patient based on their medical history. These videos will address stroke etiology, underlying risk factors, and stroke prevention medications.
214472504|NCT02296684|BIOLOGICAL|MK-3475 (adjuvant)|
214472505|NCT02296684|PROCEDURE|Peripheral blood|-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery
214472506|NCT06390137|DEVICE|Frequency Specific Microcurrent|The participant will receive an FSM treatment of 40 Hz on channel A and 97 Hz on channel B at 200 uamp with alternating current with a sharp square wave slope for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest. The TENS unit will be wrapped in an opaque bag so that the device is indistinguishable from that of the sham treatment.
214472507|NCT06390137|DEVICE|Sham microcurrent treatment|The participant will receive a sham FSM treatment with the machine off wrapped in an opaque bag for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest.
214472508|NCT05603052|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
214288731|NCT05118503|BEHAVIORAL|Standard of care discharge education|Half of subjects will be randomized to receive typical discharge education, per the institutional guidelines for standard of care education for stroke patients.
214288732|NCT03268720|OTHER|FODMAP low diet|2 week FODMAP low diet
214288733|NCT03268720|OTHER|gluten-free diet|2 week gluten-free diet
214472509|NCT05603052|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
214472510|NCT06494774|DRUG|BI 1815368|BI 1815368
214288734|NCT03858114|OTHER|Mild-to-moderate physical activity|"According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:~1. warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;~2. Active phase (45 minutes), from \>40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;~3. cool down (10 minutes), \< 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length."
214472511|NCT06494774|DRUG|Placebo matching BI 1815368|Placebo matching BI 1815368
214472512|NCT02275416|DRUG|Ipilimumab|
214472513|NCT02275416|BIOLOGICAL|UV1 vaccine|
214472514|NCT02275416|BIOLOGICAL|GM-CSF|
214472515|NCT04572243|DRUG|Placebo|Placebo matching to lorcaserin oral tablet, administered as oral suspension.
214472516|NCT04572243|DRUG|Lorcaserin|Lorcaserin oral tablet, administered as oral suspension.
214472517|NCT05303584|BIOLOGICAL|Ad5-nCoV-IH|The orally aerosolized Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. The Ad5-nCoV vaccine was supplied in 1.5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. 0.1 ml of Ad5-nCoV vaccine will be aerosolized by using Continuous Vapouring System. Then, the aerosolized droplets will be poured into a disposable suction cup and be inhaled by participants through mouth.
214472518|NCT05303584|BIOLOGICAL|Ad5-nCoV-IM|The Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. It was supplied in 1·5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. Participants will be administrated 0.5ml（5×1010VP）of Ad5-nCoV vaccine intramuscularly.
214472519|NCT05303584|BIOLOGICAL|CoronaVac|CoronaVac is an inactivated whole-virion vaccine with aluminium hydroxide as the adjuvant, prepared with a novel coronavirus (CZ02 strain) inoculated in African green monkey kidney cells (Vero cells). One dose of CoronaVac contains 3 μg of SARS-CoV-2 virion in a 0.5 mL aqueous suspension for injection with 0.45 mg/mL of aluminium.
214472520|NCT05604274|OTHER|App to monitor stool consistency and symptoms|App to monitor stool consistency and symptoms
214472521|NCT03902912|DRUG|Prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
214472522|NCT04860830|DRUG|BI 425809|BI 425809
214472523|NCT04860830|DRUG|Placebo|Placebo
214472524|NCT06562257|OTHER|Honey|Honey has a long-standing reputation for promoting wound healing and offers a more economical treatment modality. Nusantara Honey, a GMP-certified product available on the market, met our criteria for quality and safety.
214472525|NCT06562257|OTHER|PHMB Solution|PHMB is an antimicrobial polymer that is effective against intracellular and biofilm forms of S. aureus. PHMB is quite effective in the treatment of wounds in deep neck abscesses.
214472526|NCT06562933|DEVICE|Sham vacuum|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. The vacuum electrodes will apply continuous vacuum mode for only 10 minutes without delivering interferential current. Following the sham vacuum therapy, a hot pack will be applied to the painful neck area for 20 minutes.
214472527|NCT06562933|DEVICE|Interferential Current Therapy Vacuum Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the vacuum electrodes. After the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
214846613|NCT06895382|DRUG|Bupivacaine 0.25%|"0.25% bupivacaine was administered in both intervention arms as part of the regional anesthesia procedure In the Caudal Block group, 1 mL/kg of 0.25% bupivacaine was administered into the caudal epidural space.~In the TAP Block group, 0.3 mL/kg of 0.25% bupivacaine was administered into the transversus abdominis plane under ultrasound guidance"
214846614|NCT06897085|DEVICE|viscoelastic gel containing polynucleotides and hyaluronic acid|"Defects randomized to test treatment will receive a viscoelastic gel containing polynucleotides and hyaluronic acid (PN-HA gel) immediately at the completion of intra-surgical instrumentation. PN-HA gel will be also applied on the surgical wound at the completion of the suturing phase."
214846615|NCT06897085|OTHER|No intervention|"Defects randomized to control group will be accessed with the SFA and no PN-HA gel will be applied."
214846616|NCT01947686|DEVICE|Robotically guided patellofemoral UKA isolated patellofemoral implants|A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
214846617|NCT00475917|DRUG|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
214846618|NCT00475917|DRUG|Gemcitabine|once-weekly 30-minute IV infusion
214846619|NCT05924867|OTHER|plasma activated saline|The plasma activated normal saline used in the intervention was prepared by a self-made machine, and the safety of the plasma activated water produced by the machine has passed the national quality inspection.
214846620|NCT05924867|OTHER|Routine nursing|For postoperative incision infection group and infected ulcer group, conventional dressing change treatment was given, namely chlorhexidine disinfectant washing, drainage and bandaging; For the fat liquefaction group, conventional treatment was given, namely negative pressure suction.
214846621|NCT00383058|DRUG|the extract of green tea|
214846622|NCT06760273|OTHER|No Intervention: Observational Cohort|Observational study, no additional intervention
214846623|NCT06897969|DRUG|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|Monthly intralesional injection
214846624|NCT06897969|DRUG|Verapamil Injection|2.5 mg of intralesional Verapamil injection monthly
214846625|NCT06767943|DIAGNOSTIC_TEST|12-lead electrocardiography|All patients were admitted to the intermediate care unit for the 1st 24-h PO for follow-up for the possibility of developing acute myocardial infarction (AMI), which was diagnosed according to the 2017 ESC Guidelines; by 12- lead electrocardiography
214846626|NCT06891924|COMBINATION_PRODUCT|14-day daily pre-operative application of the formulations containing MLYAAT-1002® before Fotona4D treatment|All enrolled subjects will complete a 14-day washout period followed by a 14-day run-in phase prior to Fotona 4D® laser treatment. During the initial washout phase, participants will exclusively use basic skincare products: sunscreen, cleansing foam, and moisturizing emulsion. Then the subjects will apply the formulations containing MLYAAT-1002® of the active comparator to randomly assigned split-face (the treatment side) for the subsequent 14-day period. Following completion of the product application regimen, all participants will undergo a single session of Fotona 4D laser therapy.
214846627|NCT06891924|COMBINATION_PRODUCT|14-day daily pre-operative application of the formulations without MLYAAT-1002® before Fotona4D treatment|All enrolled subjects will complete a 14-day washout period followed by a 14-day run-in phase prior to Fotona 4D® laser treatment. During the initial washout phase, participants will exclusively use basic skincare products: sunscreen, cleansing foam, and moisturizing emulsion. Then the subjects will apply the formulations without MLYAAT-1002® of the placebo comparator to randomly assigned split-face (the control side) for the subsequent 14-day period. Following completion of the product application regimen, all participants will undergo a single session of Fotona 4D laser therapy.
214846628|NCT06895486|BIOLOGICAL|Novel Oral Polio Vaccine Type 1 (nOPV1)|nOPV1 containing \>10\^7.0 CCID50 per dose
214846629|NCT06895486|BIOLOGICAL|Novel Oral Polio Vaccine Type 2 (nOPV2)|nOPV2 containing ≥10\^5.0 CCID50 per dose
214846630|NCT06895486|BIOLOGICAL|Placebo (Sterile Water)|Sterile, nonpyrogenic preparation of water which contains no bacteriostat, antimicrobial agent, or added buffer
214846631|NCT06900335|DRUG|GH treatment (Somatropin)|Treatment with Somatropin (recombinant GH), with doses starting from 0.2 mg/day and adjusted as necessary.
214846632|NCT06900335|BEHAVIORAL|Eating|Allowing patients to break fasting.
214846633|NCT03888612|DRUG|ARV-110|"Part A: Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment~Part B: Daily oral dosage and schedule at a recommended Phase 2 dose based on data from Part A"
214846634|NCT05941611|DEVICE|Powered toothbrush|Oral-B powered toothbrush
214846635|NCT06442410|DEVICE|DTM™ spinal cord stimulation therapy delivered via Intellis™ neurostimulator system|Along with the appropriate Conventional Medical Management treatment made by the Investigator, the subject will be trialed and implanted with an Intellis™ neurostimulator system using DTM™ SCS programming parameters.
214288735|NCT03858114|OTHER|Cultural group program|A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.
214288736|NCT03500627|DRUG|OP-101|Intravenous Injection of OP-101 in healthy volunteers.
214288737|NCT00464087|DRUG|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
214288738|NCT02442362|DRUG|paclitaxel+oxaliplatin+fluorouracil|"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."
214288739|NCT02442362|DRUG|oxaliplatin+S1|"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area \< 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"
214288740|NCT04218305|DIAGNOSTIC_TEST|Serum Level Of Fetuin A|
214288741|NCT00275054|DRUG|Fludarabine|cycles 1-6: 25 mg/m² i.v., d2-4, q28d
214288742|NCT00275054|DRUG|Cyclophosphamide|cycles 1-6: 250 mg/m² i.v., d2-4, q28d
214288743|NCT00275054|BIOLOGICAL|Rituximab|"cycle1: 375 mg/m² i.v., d1, q28d~cycles 2-6: 500 mg/m² i.v., d1, q28d"
214288744|NCT02737189|PROCEDURE|Mechanical embolectomy|Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
214846636|NCT06442410|OTHER|Conventional Medical Management (CMM)|The CMM treatment can be modified at any moment by the investigators based on their clinical evaluation and local standard of care. They may also consists of one or more of the following treatments: medications, combined physical and psychological management, physical therapy, back rehabilitation program, spinal manipulation and spinal mobilization, traction, acupuncture, cognitive behavioral therapy, biofeedback, nerve blocks, radio frequency ablation, epidural steroid injections, transcutaneous electrical nerve stimulation, intradiscal electrothermal therapy, nucleoplasty, also called plasma disc decompression (PDD) or similar
214846637|NCT04163588|DRUG|Metolazone|Study participants receive loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
214846638|NCT04163588|DRUG|Loop Diuretics|Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
214846639|NCT02500615|OTHER|ECIG liquid vehicles|The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
214846640|NCT06903806|OTHER|Treadmill Exercise|Participants perform moderate to strenuous exercise for up to 20 minutes on a treadmill after swallowing a microbiome sampling capsule.
214472528|NCT06562933|DEVICE|Interferential Current Therapy Carbon-silicon Pad Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four carbon-silicon pad electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the carbon-silicon pad electrodes. Following the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
214472529|NCT06563388|PROCEDURE|Stereotactic Ablative Radiotherapy|Radiation therapy begins after 3 months of Standard of care
214472530|NCT06563388|OTHER|Best Practice|Receive standard of care therapy
214472531|NCT06556927|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
214472532|NCT04174105|GENETIC|zocaglusagene nuzaparvovec|AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
214472533|NCT05053854|DRUG|Talazoparib|During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks
214472534|NCT05858346|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
214472535|NCT05858346|BEHAVIORAL|Cognitive Behavioral Therapy for Social Anxiety Disorder|To provide an evidence-based comparison for the TBT condition, the research-supported psychological treatment of CBT for SAD will be used. CBT for SAD demonstrates efficacy in improving SAD symptoms and quality of life for patients with SAD, with durable improvements evidenced at follow-up assessments. CBT for SAD was used as a comparison to TBT in previous preliminary research. CBT for SAD involves several primary components, including: 1) psychoeducation, 2) training in cognitive restructuring, 3) exposures, 4) advanced cognitive restructuring, and 5) termination.
214472536|NCT05326477|BEHAVIORAL|Behavioral weight loss treatment|The weight loss intervention consists of the first 6 months of the Centers for Disease Control and Prevention's Prevent T2 program.
214472537|NCT06561711|DRUG|Vonoprazan|Potassium competitive acid blocker
214472538|NCT06561711|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214472539|NCT06561711|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
214472540|NCT06561711|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
214472541|NCT05835349|DEVICE|transcatheter pulmonary valve implantation (TPVI)|A stent-mounted valve is introduced over a guidewire and positioned in the RVOT, followed by balloon inflation to deploy the valve.
214472542|NCT02489604|DRUG|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
214472543|NCT02489604|DRUG|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
214472544|NCT06454630|DRUG|REGN7508|Administered by single intravenous (IV) dose
214472545|NCT06454630|DRUG|Enoxaparin|Administered by subcutaneous (SC) dose daily through the time of venography (or day 12, whichever is earlier)
214472546|NCT05873517|BEHAVIORAL|Immediate Narrative Exposure Therapy (NET)+|The basis of this intervention is adapted Narrative Exposure Therapy (NET)+. All participants receive 4-8 active NET+ sessions, including a psychoeducational session.
214472547|NCT05873517|BEHAVIORAL|Waitlist + NET+|Waitlist control group participants receive 1 psychoeducational sessions and will be added to a waitlist; waitlist control group participants randomly selected from the waitlist be offered the opportunity to receive the active intervention (NET+).
214472548|NCT01254864|DRUG|Abiraterone Acetate|1000 mg by mouth each day of a 28 day cycle.
214472549|NCT01254864|DRUG|Prednisone|5 mg by mouth twice daily of a 28 day cycle.
214472550|NCT01254864|DRUG|Sunitinib|37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
214472551|NCT01254864|DRUG|Dasatinib|100 mg by mouth each day of a 28 day cycle.
214472552|NCT03895996|DRUG|AVT001|autologous dendritic cell therapy
214472553|NCT03895996|OTHER|Placebo|matched placebo
214472554|NCT06278194|PROCEDURE|Gasserian Ganglion Radiofrequency Thermocoagulation|Gasserian ganglion radiofrequency thermocoagulation is performed in the operating room under fluoroscopy. In sterile condition, the foramen ovale is shown by the pain management specialist under fluoroscopy guidance. After this condition, the entry of the needle is marked and anaesthetised with local anaesthetic. After the entry of the gasserian ganglion with the radiofrequency needle, 10 cm long, the location is checked with sensory and motor stimulation. If the placement is correct, 70 degrees 70 seconds of radiofrequency thermocoagulation is applied.
214472555|NCT02693509|OTHER|GWTG Heart Failure program|Evidence based guideline recommended therapies and counseling prior to hospital discharge
214472556|NCT05260125|DRUG|Ultrasound-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. A linear probe with a frequency of 7-8 MHz on the SonoScape A8 ultrasound device will be used for suprascapular block under ultrasound guidance. the ultrasound probe was placed in the coronal plane over the suprascapular fossa. Suprascapular fossa was scanned from medial to lateral side to identify suprascapular nerve. After identification, solution of suprascapular nerve block will be injected into the area around the nerve under the scanning with in-plane technique with a 22 gauge 90 mm spinal needle."
214472557|NCT05260125|DRUG|Anatomical Landmark-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. The suprascapular notch projection will be determined using the anatomical landmark technique defined by Dangoisse et al., and then suprascapular nerve block will be applied with a 22 gauge 90 mm spinal needle to the patients"
214472558|NCT05312983|OTHER|Audiological and vestibular tests|"6h of audiological and vestibular tests divide in 3 sessions :~* Session A : objective audiological tests~* Session B ; subjective audiological tests~* Session C : balance tests."
214472559|NCT05312983|OTHER|Blood sampling|A 10 mL blood sample will be collected during the study.
214472560|NCT05312983|OTHER|neurocognitive self-questionnaire|Four self-questionnaires to fill out to measure sleep quality, memory and emotional state
214472561|NCT03849651|DRUG|Cyclophosphamide|"Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9"
214472562|NCT03849651|BIOLOGICAL|Fludarabine|"Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.~fludarabine phosphate IV QD on days -8 to -4"
214472563|NCT03849651|DRUG|Thiotepa|Thiotepa is a cell-cycle nonspecific polyfunctional alkylating agent.
214846641|NCT06903806|DEVICE|Cooling Gloves|Cooling gloves to prevent rise in core body temperature during exercise
214846642|NCT06903806|DEVICE|Microbiome Capsule|Capsule used for collecting intestinal tract contents
214472564|NCT03849651|DRUG|Melphalan|"Melphalan, a derivative of nitrogen mustard, is a bifunctional alkylating agent. Melphalan is active against tumor cells that are actively dividing or at rest.~melphalan IV QD on days -2 to -1"
214846643|NCT03907241|DRUG|Octanorm 16.5%|Human normal immunoglobulin
214846644|NCT03164837|DRUG|68Ga-NOTA-RM26|Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
214846645|NCT04769115|DEVICE|Alert for temperature delta|If alert for potential complications refer to appropriate specialist
214846646|NCT02717078|OTHER|Diet Therapy|The intervention for both study groups will be a change in diet.
214846647|NCT02872051|BEHAVIORAL|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
214846648|NCT02872051|OTHER|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
214846649|NCT02012452|BEHAVIORAL|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
214846650|NCT02012452|BEHAVIORAL|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
214846651|NCT04244006|DRUG|Dupilumab Prefilled Syringe|administration of dupilumab corresponding to dupilumab arm
214846652|NCT04244006|OTHER|Placebo Prefilled Syringe|administration of placebo corresponding to placebo arm
214288745|NCT02737189|DRUG|Medical Treatment|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
214288746|NCT04817371|DEVICE|Volatile Organic Compounds analysis (e-noses)|VOC analysis in exhaled air with e-noses.
214288747|NCT04817371|OTHER|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
214288748|NCT04817371|DEVICE|Volatile Organic Compounds analysis (mass spectrometry)|VOC analysis in exhaled air with mass spectrometry.
214288749|NCT04817371|DEVICE|Volatile Organic Compounds analysis in sweat (mass spectrometry)|VOC analysis in sweat with mass spectrometry.
214288750|NCT01564797|BEHAVIORAL|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
214846653|NCT02688387|DRUG|FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
214846654|NCT02688387|DRUG|Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)|Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
214846655|NCT02209116|OTHER|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
214288751|NCT04762433|DEVICE|Kegel Exercise Pregnancy Training - app|"KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT."
214288752|NCT00836290|BEHAVIORAL|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
214288753|NCT00836290|BEHAVIORAL|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
214288754|NCT00193154|DRUG|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
214288755|NCT00193154|DRUG|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
214288756|NCT02562794|BEHAVIORAL|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
214288757|NCT00099853|DRUG|Vildagliptin|Vildagliptin 50 mg tablets
214288758|NCT00099853|DRUG|pioglitazone|pioglitazone 45 mg qd
214288759|NCT00099853|DRUG|Placebo|Vildagliptin matching placebo
214288760|NCT02399501|PROCEDURE|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
214288761|NCT02399501|DEVICE|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
214288762|NCT02399501|DEVICE|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
214288763|NCT02399501|DEVICE|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
214288764|NCT02425046|BEHAVIORAL|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
214288765|NCT02425046|BEHAVIORAL|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
214288766|NCT04849455|DRUG|0.2% ropivacaine local anesthetic continuous erector spinae plane block|Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)
214288767|NCT04849455|DRUG|0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block|Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
214288768|NCT04849455|DRUG|Spinal Morphine|200-300 mcg of spinal morphine
214288769|NCT02272920|PROCEDURE|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
214288770|NCT00756860|DRUG|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
214288771|NCT00756860|DRUG|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
214288772|NCT01514929|DRUG|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
214288773|NCT01514929|DRUG|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
214288774|NCT01514929|DRUG|Moxifloxacin|400mg oral pill given once
214288775|NCT01514929|DRUG|Placebo|Placebo oral pill given once
214288776|NCT00507962|DRUG|Cisplatin|100 mg/m\^2 Intraarterial On Day 1 Every 4 Weeks
214288777|NCT00507962|DRUG|Liposomal Doxorubicin|Starting dose 20 mg/m\^2 IV On Day 1 Every 4 Weeks
214288778|NCT00891254|DEVICE|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
214288779|NCT03958721|DRUG|Capecitabine|1,000 mg/m2 twice daily taken by mouth every other week
214288780|NCT03958721|RADIATION|Radiotherapy|Once daily (Monday through Friday) for six weeks
214288781|NCT00017498|DRUG|gemcitabine hydrochloride|
214288782|NCT00931762|DRUG|Panobinostat|Panobinostat oral capsules
214288783|NCT04998474|BIOLOGICAL|FRAME-001 personalized vaccine|Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs.
214288784|NCT05552950|BIOLOGICAL|BioBlock® antiviral nasal spray|SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.
214288785|NCT03386682|DEVICE|ESTYME® MATRIX Breast Implants|Breast implant surgery in breast reconstruction or breast augmentation
214288786|NCT05634304|BEHAVIORAL|A mobile app self-management (mSM) program|The mSM program is developed on Bundura's self-efficacy theory, which provides four sources of information for SM. The strategies of the mSM consist of mobile app to management program including peer support, appraisal, goal setting and self-monitoring of exercise for OA and symptom management.
214288787|NCT03696511|DEVICE|Orthodontic miniscrew insertion|orthodontic treatment using miniscrews as anchorage reinforcement
214288788|NCT04049396|OTHER|Berberine|24 Patient consumed 6,25 g/day Berberine for 6 weeks
214288789|NCT01432886|DRUG|E7389|Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
214288790|NCT02692716|DRUG|semaglutide|For oral use once daily.
214288791|NCT02692716|DRUG|placebo|For oral use once daily.
214288792|NCT05855460|DIAGNOSTIC_TEST|Skin biopsy|biochemical assessment for measurement IL35 by ELISA (Enzyme linked immunosorbent assay) technique in tissue and serum samples of all thirty patients and healthy controls.
214288793|NCT04478474|DRUG|Ganciclovir|Type of allogeneic transplant, HLA match, graft manipulation, use of ATG and/or Campath, CMV status (donor and recipient), maximal acute GVHD stage and grade, CMV viremia/disease through day +100, days received ganciclovir prophylaxis, adverse events related directly or secondary to ganciclovir prophylaxis.
214288794|NCT02508402|DRUG|Dexamethasone|"The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using"
214288795|NCT02508402|DRUG|Placebo|two milliliters of normal saline given to placebo group .
214288796|NCT03709771|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Measurement|"Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure."
214288797|NCT03873233|DEVICE|Aisys Carestation ventilator and normal endotracheal tube|Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
214288798|NCT03873233|DEVICE|Evone ventilator and Tritube|Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
214288799|NCT05784064|BEHAVIORAL|Survey|This is a nationalwide survey developed in order to know the management of patients diagnosed of acute uncomplicated diverticulitis.
214288800|NCT03980106|OTHER|Reciprocal Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract antagonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
214288801|NCT03980106|OTHER|Post-Isometric Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract agonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
214288802|NCT03421821|DRUG|Ropivacaine|Subfascial injection OR extrafascial injection
214288803|NCT03902197|BIOLOGICAL|CD19 hsCAR-T|CD19 hsCAR-T will be administered by I.V. infusion
214288804|NCT05445986|PROCEDURE|flap elevation and guided bone regeneration|to rebuild the alveolar ridge convexity
214288805|NCT05445986|PROCEDURE|gap filling|to use biomaterials to fill the jumping gap
214288806|NCT05445986|PROCEDURE|connective tissue graft|to change the soft tissue phenotype by connective tissue graft
214288807|NCT01024803|DEVICE|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.~Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
214288808|NCT02284594|BEHAVIORAL|text message|series of text messages regarding influenza vaccination
214288809|NCT04252456|PROCEDURE|Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
214846656|NCT03388502|OTHER|Automated Text Messaging (SMS) Bot (intervention group)|Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.
214846657|NCT03388502|OTHER|Routine perioperative education & teaching (control group)|Patients will receive the 'Routine perioperative education \& teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
214846658|NCT04403399|DRUG|Varenicline|Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.
214846659|NCT04403399|DRUG|Placebo|Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
214846660|NCT03093935|DEVICE|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
214846661|NCT00172068|DRUG|Zoledronic acid + Calcium/Vitamin D|
214288810|NCT05983276|DRUG|Decitabine|Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
214288811|NCT05983276|DRUG|Carboplatin|Carboplatin is classified as an alkylating agent that is used to treat ovarian cancer.
214288812|NCT05983276|DRUG|Paclitaxel|"Paclitaxel is classified as a plant alkaloid, a taxane and an antimicrotubule agent."
214288813|NCT05983276|DRUG|Selinexor|Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.
214288814|NCT02187185|OTHER|Sonicare/Elite-Flexcare Toothbrush|Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
214288815|NCT02187185|OTHER|Manual Toothbrush|traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
214288816|NCT00672412|DRUG|GPO-Vir Z30 tablet|Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
214288817|NCT00672412|DRUG|Lamivudine|Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
214288818|NCT00672412|DRUG|Nevirapine|Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
214288819|NCT00672412|DRUG|Zidovudine|Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
214288820|NCT02364973|OTHER|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
214288821|NCT04859023|DIAGNOSTIC_TEST|saliva sample combined to an anterior nare self-swabbing (Self-samples)|Tested by antigenic test.
214288822|NCT04859023|DIAGNOSTIC_TEST|saliva sample (Self-sample)|Tested by RT-PCR.
214288823|NCT04859023|OTHER|Survey of SARS-COV-19 knowledge|collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.
214288824|NCT04859023|OTHER|Survey of acceptability of the different self-samples.|collection of : assessment and acceptability of the tolerance of self-samples.
214288825|NCT00217386|BIOLOGICAL|anti-thymocyte globulin|
214288826|NCT00217386|BIOLOGICAL|etanercept|
214288827|NCT00468416|DEVICE|Compression Anastomosis Ring (CAR)|
214288828|NCT02964351|BIOLOGICAL|High PSA levels|
214288829|NCT01012960|DRUG|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
214288830|NCT00972569|DRUG|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
214288831|NCT00972569|DRUG|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
214288832|NCT02782780|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
214288833|NCT05431452|OTHER|Pain management|Nonpharmacological pain management during blood collection in preterm infants
214288834|NCT03562481|DRUG|1% Buffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
214288835|NCT03562481|DRUG|2% Unbuffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
214288836|NCT02664441|DRUG|Exenatide|Weekly injections of active drug.
214288837|NCT02664441|DRUG|placebo|Weekly placebo injections
214288838|NCT00353561|DRUG|Boric|Gelatin capsules filled with 600 mg of boric acid
214288839|NCT00353561|DRUG|Fluconazole|150 mg oral fluconazole gives once in 14 days
214288840|NCT01994460|DRUG|Linezolid|
214288841|NCT01994460|DRUG|Ethambutol|
214288842|NCT01602874|DRUG|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
214288843|NCT01602874|DRUG|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
214846662|NCT01606228|DRUG|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
214846663|NCT00613860|DEVICE|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
214846664|NCT02915237|DIETARY_SUPPLEMENT|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
214846665|NCT02915237|DIETARY_SUPPLEMENT|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
214846666|NCT00546910|DRUG|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
214846667|NCT00546910|DRUG|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
214846668|NCT01115855|DRUG|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
214846669|NCT01115855|DRUG|Placebo|Placebo once daily or every once daily
214846670|NCT03658863|PROCEDURE|endoscopic ultrasound|Evaluation of bile ducts with endoscope with special ultrasonographic function
214846671|NCT03658863|PROCEDURE|intraoperative cholangiography|evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
214846672|NCT03658863|PROCEDURE|ERCP|evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
214846673|NCT03658863|DEVICE|Ultrasound endoscope|Endoscope with built-in ultrasound function
214846674|NCT03482219|OTHER|Occupational therapy|The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.
214846675|NCT03482219|OTHER|Home app intervention|The app consists of videos depicting each exercise and ability to track adherence to exercises.
214846676|NCT02294448|DRUG|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
214846677|NCT02765672|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
214846678|NCT02765672|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
214846679|NCT02765672|BEHAVIORAL|Propensity for Angry Driving Scale|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
214846680|NCT02765672|BEHAVIORAL|Community Integration Questionnaire|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
214846681|NCT02765672|BEHAVIORAL|Satisfaction with Life|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
214846682|NCT02765672|BEHAVIORAL|Fitness-to-Drive Screening Measure (FTDS)|Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
214846683|NCT02765672|PROCEDURE|Simulated Driving Evaluation|This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
214846684|NCT02765672|PROCEDURE|Driving Safety Education|This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
214846685|NCT02765672|PROCEDURE|Occupational Therapy Driving Intervention (OT-DI)|This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
214288844|NCT01602874|DRUG|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
214288845|NCT01602874|DRUG|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
214288846|NCT04857242|DIAGNOSTIC_TEST|Apnea test, alveolar recruitment|Alveolar recruitment following the phase of apnea testing
214288847|NCT01413191|BIOLOGICAL|Cixutumumab|10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
214288848|NCT01413191|OTHER|Laboratory biomarker analysis|Correlative studies
214288849|NCT04023786|PROCEDURE|PEEP-TEST|The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
214288850|NCT03942627|BEHAVIORAL|Mindfulness Program|The intervention consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of mindfulness practices delivered via audio recordings to assist mothers in managing stress during the NICU stay and another series for the transition home.
214472565|NCT03849651|BIOLOGICAL|G-csf|G-csf (granulocytic colony stimulating factor), is a biosynthetic hematopoietic agent that is made using recombinant DNA technology in cultures of Escherichia coli. G-CSF stimulates production, maturation and activation of neutrophils. In addition, endogenous G-CSF enhances certain functions of mature neutrophils, including phagocytosis, chemotaxis and antibody--dependent cellular cytotoxicity.
214472566|NCT03849651|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide. Following glomerular filtration, mesna disulfide is rapidly reduced in the renal tubules back to mesna, the active form of the drug.
214472567|NCT03849651|DEVICE|CliniMACS|Cells for infusion are prepared using the CliniMACS
214472568|NCT03849651|BIOLOGICAL|ATG (rabbit)|"Anti-thymocyte globulin is a purified, pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes.~rabbit anti-thymocyte globulin IV daily over 6 hours on days -5 to -3,"
214472569|NCT03849651|DRUG|Blinatumomab|"Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that mediates formation of a synapse between T cells and the CD19+ target cell, resulting in lysis of that CD19+ cell.Blinatumomab will be given to patients with a history of CD19+ malignancy as determined by St. Jude hematopathologist review of current and historical specimens and reports.~blinatumomab IV for 28 days beginning at least 1 week post-DLI"
214472570|NCT03849651|BIOLOGICAL|TCRα/β+|IV on day 0 and may receive an additional dose on day 1
214472571|NCT03849651|BIOLOGICAL|CD19+|IV on day 0 and may receive an additional dose on day 1
214472572|NCT03849651|BIOLOGICAL|CD45RA-depleted DLI|infusion IV
214472573|NCT02405364|DRUG|Carfilzomib/Lenalidomide/Dexamethasone|Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
214472574|NCT04846036|DRUG|Sonlicromanol|Oral administration of sonlicromanol twice daily
214472575|NCT04846036|DRUG|Placebo|Oral administration of matching placebo twice daily
214472576|NCT06180980|DRUG|Pirtobrutinib|Administered orally.
214472577|NCT06273072|DRUG|Metformin hydrochloride extended-release tablets|titrated to 2000 mg once daily
214472578|NCT06273072|DRUG|Visually identical placebo Metformin hydrochloride extended-release tablets|placebo
214472579|NCT05474027|OTHER|Avoidance of Deliberate Hypotensive Anesthesia|The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to the patient's baseline throughout the surgery.
214472580|NCT05474027|DRUG|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|1g of tranexamic acid will be given intravenously to patient undergoing orthognathic surgery as routinely performed about 5-15 minutes before first surgical incision.
214472581|NCT04907669|OTHER|Brief contact intervention|"The BCI in this study is a series of structured messages, and messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details are yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.~Noted, the same messages will also be sent to patients' LHSs."
214472582|NCT03730558|COMBINATION_PRODUCT|aflibercept + FOLFIRI|aflibercept + FOLFIRI
214472583|NCT04241276|DRUG|ATRA|45 mg/m2 orally (in two divided doses) from days 1 to 15 of each cycle
214472584|NCT04241276|DRUG|Gemcitabine|1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
214472585|NCT04241276|DRUG|nab-paclitaxel|125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
214472586|NCT05266001|DRUG|GM-CSF|same as arm/group description
214472587|NCT05266001|OTHER|Placebo|same as arm/group description
214472588|NCT05703360|DEVICE|Audiovisual Stimulation|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
214472589|NCT01828112|DRUG|Ceritinib|Ceritinib was the investigational treatment and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.
214472590|NCT01828112|DRUG|Pemetrexed|Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m\^2 every 21 days.
214472591|NCT01828112|DRUG|Docetaxel|Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m\^2 every 21 days.
214472592|NCT04779827|BEHAVIORAL|Online Social Network and Collective Intelligence Intervention|The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.
214472593|NCT04779827|BEHAVIORAL|Independent Control|Independent control aims to test the baseline of population understanding of health behaviors and choices. Participants will respond to health questions independently without getting any feedback from others.
214846686|NCT02765672|PROCEDURE|On-road driving test|This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
214846687|NCT02765672|PROCEDURE|Driving triggers evaluation|The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
214288851|NCT03942627|BEHAVIORAL|Infant Health Education Program|The active control condition consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of audio recordings providing information on infant health and development for mothers to use during the NICU stay and another series for the transition home.
214288852|NCT02319746|BEHAVIORAL|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
214288853|NCT02319746|BEHAVIORAL|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
214288854|NCT01280916|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
214288855|NCT03051035|DRUG|KO-947|Intravenous administration
214288856|NCT05162131|DRUG|Bentracimab (PB2452) 100 mg or Placebo|"Experiment 1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
214288857|NCT05162131|DRUG|Bentracimab (PB2452) 300 mg or Placebo|"Experiment 1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
214288858|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo|"Experiment 1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)~Drug: PB2452 Infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion"
214288859|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
214288860|NCT05162131|DRUG|Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
214288861|NCT05162131|DRUG|Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
214288862|NCT05162131|DRUG|Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
214288863|NCT01308346|DEVICE|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
214288864|NCT01308346|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
214288865|NCT05456464|OTHER|Reiki|Reiki is applied touching the energy centers of the body (chakras). There are seven main and many small chakras on a body. Chakras are located on the front and back sides of the body in a vertical line that runs along the middle of the body in humans. A complete Reiki therapy includes all the chakras and organs.
214288866|NCT05212649|DIAGNOSTIC_TEST|cardiopulmonary exercise test|CPET was performed in this HF cohort within one month after being discharged and interpreted as previously described. Patients underwent an upright graded cycle ergometer exercise using a personalized ramp protocol or a motorized treadmill using a modified Bruce or Cornell protocol. Peak VO2 data measured by cycle ergometer were increased by 10% to allow a comparison between the two different procedures. Peak VO2 was defined as the highest 30-second average value obtained during exercise. Submaximal CPET variables such as ventilatory efficiency were calculated by the slope of VE versus VCO2 below the ventilatory compensatory point (VCP). If the slope of VE/VCO2 can't be calculated, we used the nadir of VE/VCO2, or the ratio of VE/VCO2 at the anaerobic threshold (AT) as the variable of ventilatory efficiency. The AT was determined by the V-slope method.
214288867|NCT01640145|DIETARY_SUPPLEMENT|Protein|Whey protein intake
214288868|NCT01640145|OTHER|Exercise|Unilateral low intensity exercise
214288869|NCT04566211|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
214288870|NCT04566211|DRUG|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
214288871|NCT02938871|DIETARY_SUPPLEMENT|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
214288872|NCT02938871|DIETARY_SUPPLEMENT|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
214288873|NCT03654651|DRUG|Peanut|Roasted, unsalted peanuts will be purchased from a local grocery store and provided to subjects to consume.
214288874|NCT03654651|DRUG|High carbohydrate snack|Whole wheat crackers will be purchased from a local grocery store and provided to subjects to consume with a spread (e.g. cream cheese or margarine).
214288875|NCT00001008|DRUG|Methadone hydrochloride|
214288876|NCT00001008|DRUG|Zidovudine|
214288877|NCT01702454|BIOLOGICAL|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
214288878|NCT03989453|OTHER|Chi Kung|The duration of the intervention is 12 weeks, with 2 sessions per week of Chi Kung. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up (Based on breathing and concentration exercises), of 10 minutes duration, a 40-45 minute Chi Kung session and finally 10 minutes of guided relaxation.
214472594|NCT04745520|DEVICE|Rib fixation|"Rib fixation is performed by a senior surgeon. The patient is under general anesthesia. A thoracotomy focused on the fracture is performed to optimize access to the rib to be repaired. Video-assisted thoracic surgery (VATS) can be performed to better localize rib fractures. Significant muscle division is avoided. Removal of the periosteum is not required. The broken rib segments are approximated with forceps and the medical devices are used to fix the fracture. The medical devices are implemented according to the manufacturers' recommendations. The goal is to stabilize the chest wall. It is not useful to fix all fractures to stabilize the wall. A chest tube can be placed at the end of the operation.~Medical devices~The following medical devices can be used:~* MatrixRIB™, De Puy Synthes Companies, Zuchwill, Switzerland~* STRATOS™, MedXpert GmbH, Heitersheim, Germany~* NiTi Fixing PlatesTM, IAWAI, Yandzhou, China"
214472595|NCT04745520|DRUG|Analgesia|Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
214472596|NCT06767696|OTHER|Cuff pressure measurement|"Intubation tube cuff pressure in cmH2O at 3 different time periods with a cuff manometer (VBM Medizintechnik, GmbH, Germany)~Time periods:~Cuff pressure value measured in neutral position after intubation (cmH2O) - T0 Cuff pressure measurement value after hyperextension (cmH2O) - T1 Cuff pressure measurement value in neutral position after surgical procedure (cmH2O) - T2"
214472597|NCT01842477|PROCEDURE|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
214472598|NCT05342701|BEHAVIORAL|Motor Skills Intervention|"The behavioral motor skill intervention (CHAMP) is an intervention strategy that uniquely address differences in children's development. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to development improvement in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP consists of 35 minutes/day X 3-4 days/week for 19 weeks (dose of 1995 - 2240 minutes). Each session will consist of three parts: (a) 3-5 min of motor skill introductory activity, (b) 25 min of motor skill instruction and practice, and (c) 3-5 min motor skill closure activity."
214472599|NCT06618092|DEVICE|Relisten|Patients will be attended using Relisten
214472600|NCT01188928|DRUG|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
214472601|NCT01188928|DRUG|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
214472602|NCT01188928|DRUG|Calcipotriene|Topical suspension once daily for up to 8 weeks.
214472603|NCT01188928|DRUG|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
214472604|NCT04014166|OTHER|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10\^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10\^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10\^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
214472605|NCT05496088|PROCEDURE|Re-PVI only|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
214472606|NCT05496088|PROCEDURE|Re-PVI + substrate ablation|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
214472607|NCT05756686|BEHAVIORAL|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
214472608|NCT05756686|BEHAVIORAL|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
214846688|NCT00116493|DIETARY_SUPPLEMENT|Iron-folic acid and mebendazole|"100 mg iron for pregnant women, 25 mg iron for children~1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children"
214846689|NCT00116493|DRUG|Mebendazole|100 mg twice a day for 3 days; Iron-folic acid also given
214846690|NCT00116493|DIETARY_SUPPLEMENT|Multivitamins|Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
214846691|NCT00116493|DRUG|Mebendazole + Multivitamin|Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
214846692|NCT04893122|OTHER|COVID-19 pandemic|Study focuses on the impact of the COVID-19 pandemic on emergency attendances and admissions.
214846693|NCT01675076|DRUG|Dabigatran|NOAC
214288879|NCT03274401|DEVICE|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
214288880|NCT03274401|DEVICE|5 day ECG patch|Selection of device for monitoring clinicians' choice
214288881|NCT00221728|DEVICE|Radiofrequency|
214288882|NCT00221728|PROCEDURE|conservative surgery|
214288883|NCT04981743|DIETARY_SUPPLEMENT|Nigella Sativa capsule twice daily|investigate the safety and efficacy of Nigella Sativa versus Vitamin D3 versus Nigella Sativa / vitamin D3 combination as supplement for management of COVID-19 .
214288884|NCT02061267|DIETARY_SUPPLEMENT|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
214288885|NCT02061267|DIETARY_SUPPLEMENT|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
214288886|NCT02061267|DIETARY_SUPPLEMENT|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
214288887|NCT02061267|DIETARY_SUPPLEMENT|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
214288888|NCT04774107|DRUG|P1101 + Ribavirin|P1101 400 µg SC
214288889|NCT02000973|DRUG|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
214288890|NCT02000973|DRUG|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
214472609|NCT02945176|DEVICE|ARGOS-IO system|This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
214472610|NCT05244187|DEVICE|OrthoCor Active System|The OrthoCor Active System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy for General Use of temporary pain relief, utilizing wraps that position the therapy, such as on the ankle, back, knee, wrist, elbow, shoulder, foot, or neck.
214472611|NCT04410328|DRUG|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
214472612|NCT04410328|OTHER|Standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks. Standard of care treatment consist of an intravenous Remidesivir 200 mg loading dose and then 100 mg/daily for a total of 4 days for non-intubated patients and 10 days for intubated patients, intravenous/oral decadron 6 mg/daily for 10 days and prophylactic subcutaneous LMWH daily, started on the day of enrollment and for the duration of hospitalization. If the patients are discharged before 10 days, they are prescribed oral decadron 6 mg daily to complete the course of 10 days.
214472613|NCT02902055|DRUG|Neuromuscular Blocking Agents|Neuromuscular blockae
214472614|NCT02902055|DRUG|Isotonic saline|Placebo
214472615|NCT06038396|DRUG|RC118|Dose A or dose B, Q2W
214472616|NCT06038396|DRUG|Toripalimab|Fixed dose, Q3W
214472617|NCT06038396|DRUG|RC148|Fixed dose, Q3W Other Names: RC148 injection
214472618|NCT06214143|BIOLOGICAL|T3011 high dose|T3011 high dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
214472619|NCT06214143|BIOLOGICAL|T3011 middle dose|T3011 middle dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
214472620|NCT06214143|BIOLOGICAL|T3011 low dose|T3011 low dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
214472621|NCT06432699|OTHER|micro osteoperforation|one side used for mops while other side will be control in same patient
214472622|NCT04299581|DRUG|Camrelizumab|a PD-1 immune check inhibitor
214472623|NCT04299581|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
214472624|NCT02446236|DRUG|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
214472625|NCT02446236|DRUG|Ibrutinib|560 mg PO daily
214472626|NCT02446236|DRUG|Rituximab|375 mg/m2 IV Day 1
214472627|NCT05010668|DRUG|cryoablation|Cryoablation treatment starts at day 0.
214472628|NCT05010668|DRUG|Sintilimab|Sintilimab will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214846694|NCT01675076|DRUG|Rivaroxaban|NOAC
214288891|NCT02000973|DRUG|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
214288892|NCT02000973|DRUG|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
214288893|NCT05641051|DRUG|Metoclopramide|Cases will receive 10 mg intravenous metoclopramide every 6 hours.
214288894|NCT05641051|DRUG|Placebo|Cases will receive the same volume of IV placebo / 6 hours.
214288895|NCT06144489|DIETARY_SUPPLEMENT|Tart Cherry|Tart cherry supplementation in two doses
214288896|NCT06144489|DIETARY_SUPPLEMENT|Placebo|Control group
214288897|NCT03510884|DRUG|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous injection
214288898|NCT03510884|DRUG|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
214288899|NCT03510884|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
214288900|NCT03510884|DRUG|Simvastatin|Pharmaceutical form:Tablet Route of administration: Oral
214288901|NCT03510884|DRUG|Pravastatin|Pharmaceutical form:Tablet Route of administration: Oral
214288902|NCT03510884|DRUG|Lovastatin|Pharmaceutical form:Tablet Route of administration: Oral
214288903|NCT03510884|DRUG|Fluvastatin|Pharmaceutical form:Capsule Route of administration: Oral
214288904|NCT03510884|DRUG|Ezetimibe|Pharmaceutical form:Tablet Route of administration: Oral
214288905|NCT03510884|DRUG|Cholestyramine|Pharmaceutical form:oral suspension Route of administration: oral
214288906|NCT03510884|DRUG|Nicotinic acid|Pharmaceutical form:Tablet Route of administration: Oral
214288907|NCT03510884|DRUG|Fenofibrate|Pharmaceutical form:Tablet Route of administration: Oral
214472629|NCT05010668|DRUG|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214472630|NCT03891485|BIOLOGICAL|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, or other second line according to physician's choice)
214846695|NCT01675076|DRUG|Apixaban|NOAC
214846696|NCT01974076|DEVICE|Active tDCS + CBT|
214846697|NCT01974076|DEVICE|Sham tDCS + CBT|
214846698|NCT03815240|OTHER|No dressing|no dressing at sacrum
214846699|NCT03815240|OTHER|Mepilex® Border Sacrum|adhesive sacrum dressing
214846700|NCT03815240|OTHER|ALLEVYN Life Sacrum|adhesive sacrum dressing
214288908|NCT03510884|DRUG|Omega-3 fatty acids|Pharmaceutical form:capsule Route of administration: oral
214288909|NCT03510884|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous injection
214288910|NCT02198742|DEVICE|Miller blade|To participate in the study the subjects must have \>500 intubations with the miller blade.
214288911|NCT02198742|DEVICE|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
214472631|NCT06580600|DIAGNOSTIC_TEST|Point of care respiratory virus testing|"Patients to be randomised to receive OCS based on the the result of the RSV results within their respiratory virus test. This test will be performed as a point of care (POC) test in ED.~This intervention will stratify the randomisation in a 1:1 ratio, to receive OCS or not.~NB) Whilst the respiratory pathogen test is not routine care to determine the OCS prescription, it is frequently used within this setting. Additionally both the receipt (or not the receipt) of OCS is within standard care pathway. For the purpose of the trial OCS = Dexamethasone, which is delivered as oral suspension 300mcg/kg as per standard practice within the local Trust."
214288912|NCT02198742|DEVICE|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
214288913|NCT00856284|DRUG|Alogliptin|Alogliptin tablets
214288914|NCT00856284|DRUG|Metformin|Metformin tablets
214288915|NCT00856284|DRUG|Glipizide|Glipizide tablets
214288916|NCT02374554|DEVICE|Structured Light Plethysmography (Thora-3Di)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
214472632|NCT05750589|DRUG|IRX-101|IRX-101 is a novel ocular anti-septic
214472633|NCT05750589|DRUG|Providone-Iodine|5% Providone-Iodine
214472634|NCT04252989|OTHER|data collection|"* Demographic data: age, sex~* Ophthalmological history: refraction of parents, previous refractions~* Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics~* Potential undesirable events (halos, photophobia...)"
214472635|NCT06799689|BEHAVIORAL|esmadem education|"By providing information about Esma-i Husna, the journey of knowing oneself and character building with Esma-i Husna will be emphasized. It will be carried out with the aim of building on 99 names, namely Allah, Rahman and Rahim, and reducing depressive feelings by benefiting from the guidance of these names.In the second session, it will be explained through the names Esma-i Husna, Celal and Cemal in order to manage depressive feelings and contribute to positive coping. The togetherness of pain as well as happiness, ease along with difficulty, joy along with sadness in a balanced life will be discussed with the name Zü'l Celâl ve'l İkram and the study of Journey to perfection through the names Celal and Cemal. The meaning of existence and life in spirit will be discussed through the name Rab, the life cycle will be explained by establishing a relationship with the names Hafıd-Râfi, Kâbıd-Bâsıt, Muız-Müzil. In addition, it will be carried out within the framework of the name Hakim,"
214472636|NCT04301765|DRUG|testosterone 1.62% gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
214472637|NCT04301765|OTHER|placebo gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
214472638|NCT06526364|OTHER|All participants will be asked to provide data and samples for collection and analysis.|"During the first year, data related to demographics, lifestyle, clinical examinations will be collected at baseline, at 6 months (optional) and at 12 months. PROs, cognitive and motor assessments will be performed using the Healios+Me smartphone app. Additionally, participants will be asked to provide biological samples (i.e., blood, cerebrospinal fluid and stool, saliva and hair) and imaging data (if performed as per standard of care). One unscheduled visit may be performed in case the participant comes to the hospital with the occurrence of flare or for a treatment change.~A long-term follow-up (FU, starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term FU medical data are collected either every 6 month or on a yearly basis, and PROs are collected every 6 months. Whether study visits are conducted in 6- or 12-monthly intervals depends on the schedule of the study visits for the Swiss MS cohort (SMSC)."
214472639|NCT05580991|DRUG|CAN1012|CAN1012 IT injection (once every 4 weeks)
214472640|NCT06770283|DIETARY_SUPPLEMENT|Spirulina tablet|In the Spirulina tablet intervention group, patients will receive oral Spirulina tablet treatment (2g/day) for at least 3 weeks before liver transplantation.
214472641|NCT06770283|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|In the control group, patients will receive oral maltodextrin tablet treatment (2g/day) for at least 3 weeks before liver transplantation.
214472642|NCT05231070|OTHER|TeleSPC|Multidisciplinary video consultations with the SPC team. The team is multiprofessional and composed by physician, nurse, psychologist, social worker, physiotherapist and a chaplain, which is in line with the staffing of most SPC teams in Denmark and abroad. Video consultations will follow the same approach already used in physical consultations at the Section of Palliative Medicine, considering patients' changing needs and providing differentiated treatment and support, with the addition of a psychological intervention for dyadic coping between patient and closest informal caregiver
214472643|NCT05184452|DRUG|PGDM1400LS (5mg/kg, IV)|5 mg/kg to be administered via IV infusion
214472644|NCT05184452|DRUG|PGDM1400LS (20mg/kg, IV)|20 mg/kg to be administered via IV infusion
214472645|NCT05184452|DRUG|PGDM1400LS (20mg/kg, SC)|20 mg/kg to be administered via SC infusion
214472646|NCT05184452|DRUG|PGDM1400LS (40mg/kg, IV)|40 mg/kg to be administered via IV infusion
214472647|NCT05184452|DRUG|PGDM1400LS (40mg/kg, SC)|40 mg/kg to be administered via SC infusion
214472648|NCT05184452|DRUG|PGDM1400LS (1.4g, IV)|1.4gram to be administered via IV infusion
214846701|NCT03815240|OTHER|Optifoam® Gentle Sacrum|adhesive sacrum dressing
214288917|NCT02374554|DEVICE|BCI Capnograph 9004 (Smiths Medical)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
214472649|NCT05184452|DRUG|PGDM1400LS (1.4g, SC)|1.4gram to be administered via SC infusion
214472650|NCT05184452|DRUG|VRC07-523LS (20mg/kg, IV)|VRC07-523LS 20mg/kg administered via IV infusion
214472651|NCT05184452|DRUG|VRC07-523LS (20mg/kg, SC)|VRC07-523LS 20mg/kg administered via SC infusion
214472652|NCT05184452|DRUG|VRC07-523LS (1.4g, IV)|VRC07-523LS 1.4g administered via IV infusion
214472653|NCT05184452|DRUG|VRC07-523LS (1.4g, SC)|VRC07-523LS 1.4g administered via SC infusion
214472654|NCT05184452|DRUG|VRC07-523LS (40mg/kg, IV)|VRC07-523LS 40mg/kg administered via IV infusion
214472655|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, IV)|PGT121.414.LS 20mg/kg administered via IV infusion
214472656|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, SC)|PGT121.414.LS 20mg/kg administered via SC infusion
214472657|NCT05184452|DRUG|PGT121.414.LS (1.4g, IV)|PGT121.414.LS 1.4g administered via IV infusion
214472658|NCT05184452|DRUG|PGT121.414.LS (1.4g, SC)|PGT121.414.LS 1.4g administered via SC infusion
214472659|NCT05184452|DRUG|PGT121.414.LS (40mg/kg, IV)|PGT121.414.LS 40mg/kg administered via IV infusion
214472660|NCT05876533|DEVICE|Cordio HearO|"Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or app) that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients"
214472661|NCT02255799|DRUG|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
214846702|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
214472662|NCT02255799|DRUG|Placebo|Placebo capsule once daily for 70 days.
214472663|NCT04772196|DRUG|Vitamin D3|50,000 IU Vitamin D3 weekly for 8 weeks
214472664|NCT05766332|OTHER|Clinical Evaluation|Undergo clinical evaluation
214472665|NCT05766332|OTHER|Electronic Health Record Review|Medical records reviewed
214472666|NCT03923374|DRUG|Subutex / Buprenorphine|Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.
214472667|NCT03923374|DIAGNOSTIC_TEST|Fetal & Neonatal MRI|Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.
214472668|NCT03923374|DIAGNOSTIC_TEST|DNA/Genetic/Pharmacokenetic Blood Draws|Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
214472669|NCT03187535|DEVICE|TEAS via ES-130|Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.
214472670|NCT03187535|OTHER|No TEAS|No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
214472671|NCT05654675|DIAGNOSTIC_TEST|FDG PET/CT|Besides the standard care FDG PET/CT examination, subjects receive a dynamic whole body PET/CT examination.
214846703|NCT03009487|DRUG|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
214846704|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
214472672|NCT05586490|DEVICE|Multifunctional RehabilitationDevice (MRD)|Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP
214472673|NCT05586490|DEVICE|existing standard rehabilitation device|existing standard rehabilitation device to be used for in-home comparison testing for aim 3
214472674|NCT05845502|BIOLOGICAL|SZ003 CAR-NK|Drug: SZ003 CAR-NK In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8 ,2.0×10\^8 and5.0×10\^8 cells. The infusion is given every 2 weeks.
214472675|NCT02935478|DEVICE|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
214472676|NCT04452721|OTHER|dynamic compression system|It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it
214472677|NCT06773754|OTHER|Five-days-On and Two-days-Off|Take Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir alafenamide five days a week (Five-days-On and Two-days-Off)
214472678|NCT05247255|DRUG|Active Comparator|QL block with 0.25% ropivacaine
214472679|NCT05247255|DRUG|Placebo Comparator|QL block with saline
214472680|NCT06665113|DEVICE|taVNS real stimulation|For the real stimulation group, two modified point electrodes will deliver stimulation near the auricular branch of the vagus nerve in the left concha cymba. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs; continuous stimulation for 60 seconds, followed by a 10-second off period, repeated for 30 minutes.
214472681|NCT06665113|DEVICE|taVNS sham stimulation|For the sham stimulation group, two modified point electrodes will deliver stimulation to the earlobes.Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs; continuous stimulation for 60 seconds, followed by a 10-second off period, repeated for 30 minutes.
214472682|NCT06048419|BEHAVIORAL|Home Program|Home program for 6 weeks (1 hr and 15 minutes per week)
214472683|NCT04786119|DEVICE|CORI Robotics|Knee arthroplasty with robotics assisted surgery using the CORI Robotics System.
214472684|NCT03546361|BIOLOGICAL|Autologous Dendritic Cell-Adenovirus CCL21 Vaccine|Given via CT-guided or bronchoscopic IT injection
214472685|NCT03546361|BIOLOGICAL|Pembrolizumab|Given IV
214846705|NCT03442010|OTHER|Detection of adverse drug events|Detection of adverse drug events
214846706|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
214288918|NCT02338414|DRUG|Romiplostim|Subcutaneous Romiplostim (weekly injection) -\> if titrated with maintaining PLT count between 50-200 x 10\^9/L -\> Subcutaneous Romiplostim (biweekly injection)
214288919|NCT01036035|DRUG|Tolterodine|Comparison of different dosages of drug
214288920|NCT01036035|DRUG|Pilocarpine|Comparison of different dosages of drug
214288921|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
214288922|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
214288923|NCT01036035|DRUG|placebo capsule|Comparison of different dosages of drug
214288924|NCT04862364|OTHER|Endo Patients with Endometriosis Health Profile -30 (EHP-30) Test|The appointment of the patients consists of patients who were surgically diagnosed with Endometriosis in our clinic.
214288925|NCT02043249|OTHER|CORD MILKING|MILKING OF UMBILICAL CORD OF THE BABY
214288926|NCT05744544|PROCEDURE|External Oblique Block|Patients will be followed after EOIB which are routinely performed in our clinic.
214472686|NCT04118023|DIAGNOSTIC_TEST|7 Tesla Magnetic Resonance Imaging Test|MAGNETOM Terra - 7T MRI Scanner by Siemens Healthineers. Each patient enrolled will undergo the study imaging test prior to planned diagnostic knee arthroscopy.
214472687|NCT05506878|DEVICE|NSS-2 BRIDGE|"NBD® will be applied to either the right or left ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.~Once the device is placed, subjects will be asked to perform a pinch test throughout the duration of their time wearing the device. To perform the pinch test subjects must pinch down on the electrodes and ground to ensure the electrodes are still placed in their designated locations and have not come loose."
214472688|NCT05506878|DEVICE|Sham NSS-2 BRIDGE|Sham NBD® will be applied to either the left or right ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.
214472689|NCT05840354|DEVICE|Magstim Rapid2|"1-4 weeks after administration of the SJI, participants will attend their first rTMS session. rTMS will be delivered using a biphasic stimulator (DuoMag) and a figure-of-eight coil to the corticomotor representation of the first dorsal interosseous muscle contralateral to the side of worst pain. Recording electrodes will be positioned in a belly-tendon montage over the FDI for electromyography recording. The hotspot and resting motor threshold (rMT) of the FDI will be determined and saved using a Brainsight Neuronavigation system to ensure accurate coil repositioning within and between sessions.~The hotspot and rMT will be confirmed and adjusted if needed at each intervention session. Each rTMS session will consist of 40 trains of 5s delivered at 10Hz, at an intensity of 85% of the resting motor threshold for the FDI muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session)."
214472690|NCT05840354|DEVICE|Placebo D70mm Air Film Coil|Sham intervention will follow same protocol as active rTMS using a sham coil that does not deliver actual magnetic stimulation.
214472691|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
214472692|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
214472693|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
214472694|NCT05406284|PROCEDURE|double kissing nano culotte stenting|patients with true coronary bifurcation lesion treating with double kissing nano culotte stunting technique
214472695|NCT06558825|BEHAVIORAL|Integrated Intervention to Promote PrEP Uptake|Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting.
214472696|NCT06558825|OTHER|Standard Treatment Condition|Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
214472697|NCT05996406|DRUG|Venetoclax|Venetoclax 400mg po qd for 1 year
214472698|NCT05996406|DRUG|Dexamethasone Oral|Dexamethasone 40mg po qw for the first 6 months, then 10mg po qw for the next 6 months
214472699|NCT04593095|OTHER|NeuroN-QI|SSC session lasting 2-hr during the day 4 times/wk including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise followed by a 1-hr quiet period where infants will rest in their incubator/crib with olfactory stimulation and where the control of light and noise levels will be continued.
214846707|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
214846708|NCT03122587|DEVICE|Active sham transcranial alternating current stimulation|Active sham (placebo)
214846709|NCT03170388|DRUG|IDP-126 Gel|Gel
214846710|NCT03170388|DRUG|IDP-126 Component A|Component A
214846711|NCT03170388|DRUG|IDP-126 Component B|Component B
214846712|NCT03170388|DRUG|IDP-126 Component C|Component C
214846713|NCT03170388|DRUG|IDP-126 Vehicle Gel|Vehicle Gel
214846714|NCT02285634|DRUG|Oxymetazoline 0.05%|sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
214846715|NCT02285634|DRUG|Phenylephrine 0.25%|sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
214846716|NCT02285634|DRUG|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
214846717|NCT02285634|DRUG|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
214846718|NCT04567758|OTHER|Telerehabilitation|"The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises~A web-based telerehabilitation platform (Fizyoweb) will be used to deliver the exercise program. Using the Fizyoweb web application, exercises will be presented to the patients in the form of audio-video and detailed instructions with explanations. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. The exercise protocol will be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each."
214846719|NCT04567758|OTHER|Conventional Rehabilitation|"The home exercise program, which will be given with conventional rehabilitation, will be educated to the patient in the clinic on the first day. Exercise information form including explanation and picture of the exercises will be given to the patients. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.~The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises"
214846720|NCT03618329|OTHER|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
214846721|NCT05260723|BEHAVIORAL|Behavioral: Sit Less|The Sit Less arm uses habit formation, social cognitive theory, and motivational interviewing techniques to support behavior change and includes: 1) 7 health coaching sessions to set personalized goals and review progress; 2) wearing an activPAL (thigh worn accelerometer that measures sitting time); 3) intervention tools to support behavior change (e.g., standing desk, wrist worn monitor).
214846722|NCT00002702|BIOLOGICAL|aldesleukin|
214846723|NCT00002702|PROCEDURE|adjuvant therapy|
214846724|NCT00002702|PROCEDURE|conventional surgery|
214846725|NCT00002702|PROCEDURE|neoadjuvant therapy|
214846726|NCT00002702|RADIATION|radiation therapy|
214846727|NCT01705860|BIOLOGICAL|Santyl|
214846728|NCT04154826|DRUG|Recombinant human interleukin-7|weekly intra-muscular (IM) administration
214846729|NCT01854086|OTHER|Questionnaires about compliance and persistence with bisphosphonates treatment|
214846730|NCT02823314|DEVICE|Cure Tape™ covering T 7 and T 8 dermatomes|The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.
214846731|NCT02823314|DEVICE|Cure Tape™ away from dermatomes T 7 and T 8|The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
214288927|NCT05744544|PROCEDURE|m-TAPA block|m-TAPA block
214288928|NCT02560584|DRUG|Hexaminolevulinate hydrochloride|Instillation in bladder
214288929|NCT02560584|DEVICE|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
214288930|NCT01728701|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
214288931|NCT01728701|BIOLOGICAL|Normal Saline (NS)|Normal saline
214288932|NCT05277701|DRUG|Lazertinib|Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
214846732|NCT05424614|OTHER|Functional outcome follow-up of patients|Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
214288933|NCT03063554|PROCEDURE|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement;
214288934|NCT03063554|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
214288935|NCT02266745|DRUG|PT-112 Injection|
214846733|NCT02303886|DRUG|Methylene blue|In NaCL0.9% 100 ml
214846734|NCT02303886|DRUG|Methylene blue|in NaCl 0.9% 100 ml
214846735|NCT00752284|PROCEDURE|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
214846736|NCT00752284|PROCEDURE|Total Excision|Total excision of lower third molar
214846737|NCT02255188|PROCEDURE|blood sampling procedure|30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
214846738|NCT03173170|DRUG|TAK-954|TAK-954 Infusion
214846739|NCT03173170|DRUG|Itraconazole|Itraconazole Capsule
214472700|NCT04099472|BEHAVIORAL|Delirium Education, Prevention, and Management|"Patients and families will have a choice of either watching a 6-minute video or reading an educational booklet with a competent research assistant on the signs of delirium, risk factors, and prevention and management strategies.~Caregivers will practice identifying delirium with the Sour Seven questionnaire, using previously validated case vignettes of hypothetical ICU patients. Family members will also complete a daily checklist of non-pharmacological interventions (ie. orientation, mobility, and environmental cues).~Delirium detection by family caregivers will be assessed by the Sour Seven Questionnaire and communicated to the bedside nurse."
214472701|NCT04099472|BEHAVIORAL|Standard Care|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission.
214472702|NCT04151550|DEVICE|Bilateral Laser Scleral Microporation procedure|"Device: Laser Scleral Microporation~Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern."
214472703|NCT06141733|OTHER|NIRS group|Standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.
214472704|NCT06310668|BEHAVIORAL|group cognitive behavioral therapy sessions|12 group CBT sessions based on catching and challenging cognitive errors and behavioral techniques to deal with substance use problems
214846740|NCT01066117|OTHER|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
214846741|NCT00548379|DRUG|vitamin D|vitamin D 100,000 units once in 3 months
214846742|NCT00548379|DRUG|placebo|olive oil 1ml
214846743|NCT04880720|OTHER|Blood sampling|Blood sampling - 10mL
214846744|NCT02372591|DRUG|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
214846745|NCT02372591|DRUG|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
214846746|NCT02372591|DRUG|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
214472705|NCT05986552|BEHAVIORAL|Individual Schema Therapy (IST)|IST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in individual sessions by trained therapists.
214846747|NCT02358967|DIETARY_SUPPLEMENT|TRF (Tocotrienol-rich-fraction)|2 x 150 mg capsules
214846748|NCT02358967|DIETARY_SUPPLEMENT|Placebo|2 x 150 mg capsules
214472706|NCT05986552|BEHAVIORAL|Individual-Group Schema Therapy (IGST)|IGST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in the combination of individual sessions and group therapy sessions by trained therapists.
214846749|NCT02423317|DEVICE|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
214846750|NCT02423317|DEVICE|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
214846751|NCT03237299|OTHER|Collection of data|Collection of data on clinical, bacteriological and computed tomography data concerning the case, which will be needed by the adjudication committee and for defining the index date.
214846752|NCT03237299|OTHER|No collection of data|The interviewer will note sociodemographic characteristics (age, weight, sex), symptoms and their evolution, and all drug intakes of the patient during the month before the index date.
214846753|NCT00089076|BIOLOGICAL|ipilimumab|Given IV
214846754|NCT00089076|OTHER|laboratory biomarker analysis|Correlative studies
214846755|NCT01716676|OTHER|Telemedicine CPAP monitoring (webpage and televisit)|
214846756|NCT01716676|OTHER|Standard CPAP monitoring|
214846757|NCT05589259|PROCEDURE|Axillary Brachial Plexus Block plus Physiotherapy|"Participants will receive a single-shot axillary-approach brachial plexus block. For the procedure, a 22g or larger peripheral intravenous cannula will be placed, and skin will be sterilized with chlorhexidine. Using aseptic technique, the anesthesiologist will anesthetize the skin and tract with 5cc of 1% lidocaine using a 25g 1.5 needle. After this, a 50mm 21g Pajunk needle will be guided under ultrasound with an in-plane technique to anesthetize the median, ulnar, radial, and musculocutaneous nerves. Identification of the axillary artery, vein and surrounding vessels will be done to ensure an intravascular injection is avoided. Once proper location is confirmed, the anesthesiologist will aspirate to ensure the needle is not intravascular. Once aspiration is confirmed negative, bupivacaine 0.25% 1.5mg/kg (lean body weight) will be injected in divided doses.~30 minutes after placement of the block, the standardized physiotherapy protocol will begin."
214846758|NCT05589259|PROCEDURE|Physiotherapy alone|"Participants in the EXP arm and the CON arm will complete the same physiotherapy program.~PHYSIOTHERAPY PROTOCOL The physiotherapy program will include manipulation with or without a block. The goal of manipulation is to break up adhesions, possibly overcoming microvascular dysfunction. After the manipulation, participants will take part in a 6-week program which will include a weekly one-hour session with a physiotherapist at the KHSC-CPC and a home exercise program (HEP). During each session, the physiotherapist will work with the participants to increase ROM and limb function using manual therapy, stretching, and strengthening exercises specific to the affected joint(s) and most importantly using GMI. At the end of each session, the physiotherapist will prescribe exercises to complete at home."
214846759|NCT02289937|DRUG|Ropivacaine|
214846760|NCT02289937|DRUG|Placebo|
214472707|NCT04104633|PROCEDURE|Blood samples|30 ml of blood collection
214472708|NCT05662293|OTHER|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part). The assessment will be done via mail, letter or phone
214846761|NCT02289937|DEVICE|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
214846762|NCT01321437|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214846763|NCT01321437|OTHER|laboratory biomarker analysis|Correlative studies
214846764|NCT01321437|DRUG|Axitinib|Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
214846765|NCT01321437|OTHER|pharmacological study|Correlative studies
214472709|NCT05662293|OTHER|Data collection: Quality of Life (QoL) Questionnaire (prospective part)|"Data collection: Quality of Life (QoL) Questionnaire (prospective part). The questionnaire EQ-5D-5L questionnaire will be used to assess quality of life."
214472710|NCT05662293|OTHER|Data collection (retrospective study)|Anonymized search and review of patients electronic health records of the University Hospital of Basel for patients with a reduced LVEF and a concomitant (±1year or after any observation of a reduced LVEF in imaging) diagnosis of arrhythmia known to be causing AiCM.
214472711|NCT05662293|OTHER|Data collection (prospective study database)|Data collection on alcohol consumption, family history, rhythm disorder, hospitalizations, cardiac assessments, adverse events at baseline, 6 months, 1 year, 2 years and 5 years.
214472712|NCT05839262|OTHER|Conventional physical rehabilitation plus Active video games (CPR+AVG)|"In each session a routine of conventional physical rehabilitation and active video games is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR+AVG: Consists of conventional exercises (aerobic, muscle strengthening, postural balance and flexibility) added to a set of interactive video games available for the Nintendo Switch console."
214472713|NCT05839262|OTHER|Conventional physical rehabilitation alone (CPR)|"In each session a routine of conventional exercises is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility)."
214472714|NCT04743856|BEHAVIORAL|ActiveGOALSv2|13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
214472715|NCT04743856|BEHAVIORAL|PAT|Participants will receive a physical activity tracker and encouragement to increase activity.
214472716|NCT05076266|OTHER|Questionnaire|Complete the survey questions
214472717|NCT06805968|OTHER|High Intensity Exercise + Placebo|high intensity exercise
214472718|NCT06805968|OTHER|Low Intensity Exercise + Placebo|low intensity exercise
214472719|NCT06805864|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab is administered at 200 mg every 3 weeks for the first 2 cycles during Chemo-CIRT, after completion of radiotherapy, the dose is increased to 400 mg and given every 6 weeks for a total of 17 cycles over 2 years.
214472720|NCT05569772|DRUG|Semaglutide Pen Injector|maintenance dose of 1mg SC once weekly
214472721|NCT05569772|DRUG|Semaglutide placebo|maintenance dose of 1mg SC once weekly
214472722|NCT05967351|GENETIC|delandistrogene moxeparvovec|No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
214472723|NCT04706832|DEVICE|Thoracic Splanchnic Magnetic Neuromodulation Therapy|ThorS-MagNT is performed by low-frequency, low-intensity repetitive magnetic stimulation bilaterally around T7-8 intervertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
214472724|NCT06804759|OTHER|Investigational Facial Serum #1|Investigational Facial Serum #1 is made with Activated Silk™ 27P-α.
214472725|NCT06804759|OTHER|Investigational Facial Serum #2|Investigational Facial Serum #2 is made with an active comparator.
214472726|NCT06804759|OTHER|Investigational Facial Serum #3|Investigational Facial Serum #3 is a placebo comparator
214472727|NCT03453567|PROCEDURE|Valve Replacement|Aortic valve replacement
214846766|NCT01009515|DRUG|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
214846767|NCT03668951|DRUG|Dexmedetomidine buccal|DEX 2 mcg/kg buccal
214472728|NCT06804941|BEHAVIORAL|Online transdiagnostic CBT|This treatment is provided through a secure web platform in which psychoeducation, worksheets, and exercises are presented in online modules similar to chapters in a book. Participants will receive weekly written feedback on their work and progress by a therapist who gives gradual access to the treatment modules. The lion's share of the contact between the therapist and the patient thus takes place through messages (similar to email) in the online treatment platform. It is however allowed to also have one to three face-to-face sessions on-site or through video calls to provide technical assistance and therapeutic support in accordance with the treatment model. Core components are: (a) psychoeducation about emotions and CBT, (b) functional analysis, (c) mindfulness practice, (d) breaking dysfunctional emotion-driven behaviors, and (e) exposure exercises.
214472729|NCT06804941|OTHER|Primary care as usual|It is mandatory for primary care services in Stockholm, Sweden, to have staff with adequate competence in the assessment and treatment of common mental disorders. Typically, these patients are handled by general practitioners, psychologists, nurses, or social workers. As this comparator is intended to reflect real routine primary care, the interventions will not be controlled by the research project. We expect that participants allocated to this condition will receive an active treatment.
214846768|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 3 mcg/kg intranasal
214472730|NCT06804460|BEHAVIORAL|Dietary intervention|The vegan mediterranean diet is mainly composed of whole plant-based foods, similar a una dieta mediterránea, but the animal sources of protein and fat are substituted with plant foods rich in protein and fat. During the vegan diet, participants are supplemented with 1000 µg of cyanocobalamin (vitamin B12) twice a week (Harrison Sports Nutrition, Granada, Spain) to compensate for the deficiency in vitamin B12 intake induced by the vegan diet.
214472731|NCT06558188|DRUG|Romosozumab|romosozumab 210 milligrams monthly
214472732|NCT06558188|DRUG|Teriparatide|teriparatide 20 micrograms daily
214472733|NCT06805981|OTHER|telerehabilitation group|Asynchronous exercise videos were sent for follow-up for 8 weeks.
214472734|NCT06805981|OTHER|conventional rehabilitation group|An exercise brochure with exercises to be followed for 8 weeks was given.
214846769|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 4 mcg/kg intranasal
214846770|NCT00466843|DRUG|Antithymocyte globulin (ATG)|ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
214846771|NCT00466843|DRUG|Prednisone|All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
214846772|NCT00206596|DRUG|Sargramostim (Leukine)|Once daily via subcutaneous injection for up 22 weeks
214846773|NCT00206596|DRUG|Placebo|Once daily via subcutaneous injection for up 22 weeks
214846774|NCT03420768|DRUG|BMS-986263|Administered by intravenous (IV) infusion
214846775|NCT03420768|OTHER|Placebo|Administered by intravenous (IV) infusion
214846776|NCT00983476|BEHAVIORAL|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
214846777|NCT00983476|BEHAVIORAL|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
214472735|NCT05426395|DRUG|Vitamin B12 2.6 µg|There are four groups of women (n = 20 total) who will receive B12 dosing once daily, including group 1a (sufficient baseline B12, pregnant), group 1b (sufficient baseline B12, non-pregnant), group 1c (insufficient baseline B12, pregnant), and group 1d (insufficient baseline B12, non-pregnant).
214846778|NCT01405274|OTHER|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
214846779|NCT05044494|PROCEDURE|non-prompt surgery|
214846780|NCT00083694|DRUG|Thalidomide|
214846781|NCT02969876|DRUG|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
214846782|NCT01575262|BEHAVIORAL|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
214846783|NCT01575262|BEHAVIORAL|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
214846784|NCT02090231|DEVICE|rTMS, Magstim Rapid2|5 Hz rTMS
214288936|NCT00664976|PROCEDURE|Electroconvulsive therapy|Electroconvulsive therapy
214288937|NCT00664976|OTHER|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
214288938|NCT03848650|DEVICE|OpSens Medical OptoWire|"The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries."
214288939|NCT03848650|PROCEDURE|FFR|A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
214288940|NCT02904512|DEVICE|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
214288941|NCT02904512|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
214288942|NCT00227435|DRUG|val-mCyd|
214288943|NCT00568074|DRUG|repaglinide|
214288944|NCT00568074|DRUG|Glurenorm®|
214288945|NCT00568074|DRUG|Glucobay®|
214288946|NCT00269282|BEHAVIORAL|Self-Management Training|Asthma education and self-monitoring strategies
214288947|NCT00269282|BEHAVIORAL|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
214288948|NCT02942394|DEVICE|sinus-Obliquus Stent System|
214288949|NCT04140799|DEVICE|vocal cord ultrasonography|assess vocal cord motion and recurrent nerve function by Transcutaneous laryngeal Ultrasonography in patients scheduled for anterior cervical spine surgeries
214288950|NCT02144051|DRUG|AZD5312|AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
214288951|NCT01705184|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
214288952|NCT01705184|DRUG|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
214288953|NCT01705184|DRUG|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
214288954|NCT06167044|OTHER|thoracic mobilization|Thoracic mobilization will be performed for the thoracic spine mobilization group, thoracic mobilization therapy will be performed for five minutes.
214288955|NCT00607412|BEHAVIORAL|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
214288956|NCT00607412|BEHAVIORAL|12-step based supportive therapy|supportive psychotherapy based on 12-step model
214288957|NCT06122129|PROCEDURE|Flexible ureteroscope with ureteral access sheath|The flexible ureteroscope either directly or via an access sheath, depending on the size of the ureter, a 9.5/11.5 Fr or a 12 Fr access sheath will be used.
214288958|NCT06122129|PROCEDURE|Flexible ureteroscope without ureteral access sheath|Ureteroscopy will be carried out without a ureteral access sheath
214288959|NCT04980690|BIOLOGICAL|IBC0966|IBC0966 is an investigational product.
214288960|NCT06255314|PROCEDURE|ventral hernia repair|"Laparoscopic transabdominal retromuscular repair is a minimally invasive approach to the open Rives Stoppa retromuscular sublay repair for ventral hernia.~In ventral hernia repair, it relies on initiation of dissection in one retrorectus space and then crossover to the contralateral retrorectus space The sublay mesh technique is an open surgical procedure for ventral and incisional hernias"
214288961|NCT05851781|DRUG|Lacosamide tablet|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
214472736|NCT05426395|DRUG|Vitamin B12 10 µg|There are two groups of women (n = 10 total) who will receive B12 dosing once daily, including group 2a (sufficient baseline B12, pregnant) and group 2b (insufficient baseline B12, pregnant).
214472737|NCT05426395|DRUG|Vitamin B12 50 µg|The participants (n = 20 total) will be randomly assigned to receive either a once per day B12 dose or a twice per day B12 dose. The four groups at this dose level include: group 3a (sufficient baseline B12, pregnant, Q12), group 3b (sufficient baseline B12, Q24), group 3c (insufficient baseline B12, pregnant, Q12), group 3d (insufficient baseline B12, Q24).
214472738|NCT05959616|BIOLOGICAL|Shigella sonnei 53G|Lyophilized S. sonnei 53G strain (Lot 1794)
214472739|NCT05959616|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin (500 mg orally twice daily for three days),
214472740|NCT06805916|BEHAVIORAL|NAO-Assisted Therapy|The intervention sessions included tasks designed to engage the child in verbal and social interactions, such as naming objects, responding to questions, and performing gestures. The NAO robot provided consistent and predictable feedback, while therapists supported and reinforced appropriate communicative behaviors.
214472741|NCT06805916|BEHAVIORAL|Standard therapeutic|Standard therapeutic approaches included exercises aimed at improving verbal communication and social engagement, such as naming objects, sentence construction, and comprehension tasks. Therapists adapted the intervention to the child's individual communication goals.
214846785|NCT05062148|OTHER|Float-REST|Subjects receiving Float-REST will float for 60 minutes three times a week.
214846786|NCT05062148|OTHER|Photobiomodulation|Subjects receiving photobiomodulation will undergo a 20-minute therapy session three times a week.
214846787|NCT05964673|DEVICE|bioptron light therapy|patients will receive patient education program and bioptron light therapy for four weeks
214846788|NCT01175473|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
214846789|NCT01175473|DEVICE|Pen auto-injector|
214846790|NCT01175473|DRUG|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
214846791|NCT01175473|DEVICE|Pre-filled pen injector|
214846792|NCT01175473|DRUG|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
214472742|NCT06617611|PROCEDURE|Surgical intervention and anesthesia|Any surgical procedure
214472743|NCT06246734|BEHAVIORAL|Hasbro Joy for All robot pet companion|The robot pets are stuffed animals (dogs and cats) that have features that make them seem lifelike. For example, the animal toys turn their heads when petted, purr or make puppy sounds, feel warm, have a heartbeat, and go to sleep when they are ignored. They respond to attention and petting like a real pet. The robot pets do not collect information and do not require any maintenance, except a battery. Engagement with the device is at the discretion of participants.
214472744|NCT06804577|OTHER|peanut ball|The experimental group will use peanut balls;
214472745|NCT06806007|DEVICE|Group A|"Each child in the group A will receive the incentive spirometer training , attending three sessions per week for three consecutive months. The duration of the session will be half an hour Set up~1. Begin bothering child sit on the mat or chair.~2. Hold the incentive spirometer in an upright position.~3. The child Breathe out normally.~4. Place the spirometer mouthpiece in child's mouth and ask him to close his / her lips tightly around it.~5. Ask the child to Breathe in through mouth as slowly and deeply as he can,~6. Hold breath for as long as possible, or at least five seconds. Exhale slowly~7. Rest for a few seconds, and then repeat the first five steps at least 10 times every hour you're awake.~8. After each set of 10 deep breaths, ask child cough deeply to clear lungs"
214846793|NCT00760786|DRUG|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
214846794|NCT00760786|DRUG|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
214846795|NCT00760786|DRUG|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
214846796|NCT00760786|DRUG|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
214846797|NCT02887924|DEVICE|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
214846798|NCT01236417|BEHAVIORAL|Exercising block|Exercising for 8 weeks using an elastic band
214846799|NCT01705002|DRUG|Promitil|2 mg/kg dose IV
214846800|NCT01705002|DRUG|Capecitabine|1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
214846801|NCT01705002|DRUG|Bevacizumab|for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
214846802|NCT05099510|BIOLOGICAL|NatrunixTM|The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha). The entire XB2001 heavy and light chain sequences are identical to those found in naturally-occurring human IgG4-kappa, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual.
214846803|NCT05099510|BIOLOGICAL|Placebo|Placebo control for NatrunixTM subcutaneous injection.
214846804|NCT02091349|OTHER|polydextrose|polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
214846805|NCT02091349|OTHER|soluble corn fiber|nutirose- 7, 14, or 21 grams/day
214846806|NCT01083238|DRUG|AZD5069|120mg single oral dose
214846807|NCT01996423|DIETARY_SUPPLEMENT|Vitamin D3|
214846808|NCT01996423|DIETARY_SUPPLEMENT|Placebo|
214846809|NCT01997723|DEVICE|Portable monitoring|A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
214846810|NCT01997723|OTHER|Polysomnography|One attended diagnostic sleep study.
214846811|NCT01997723|DEVICE|Home portable monitoring|Portable monitoring with WP200 device - applied by participants once at home.
214846812|NCT01997723|DEVICE|Laboratory portable monitoring|Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
214846813|NCT04393623|BEHAVIORAL|Cognitive Reappraisal|This cognitive reappraisal microintervention lasts 45-60 minutes.
214846814|NCT04393623|BEHAVIORAL|Psychoeducation|This psychoeducational microintervention lasts 45-60 minutes.
214846815|NCT05518032|PROCEDURE|Biopsy|Undergo biopsy
214846816|NCT05518032|BIOLOGICAL|Pembrolizumab|Given IV
214472746|NCT06806007|OTHER|Group B|"Each child in the group B will receive the oropharyngeal motor training programme , attending three sessions per week for three consecutive months. The duration of the session will be an hour The training programme consisted of 10 individual mobilization exercises involving orofacial and pharyngeal area that required 45 minutes Each exercise had to be repeated for 10 times.~The 10 exercises are:~* Exercise 1: Pushing Up The Tongue~* Exercise 2: Touching Nose~* Exercise 3: Touching Chin~* Exercise 4: Pushing Tongue Right and Left~* Exercise 5: Folding Tongue~* Exercise 6: Clicking the Tongue~* Exercise 7: Pushing Tongue Against Spoon~* Exercise 8: Holding A Spoon~* Exercise 9: Holding Button with Lips~* Exercise 10: Gargling"
214472747|NCT06806007|COMBINATION_PRODUCT|Group C|Each child in the group C will receive a combination program of the incentive spirometer training and oropharyngeal motor training programme attending three sessions per week for three consecutive months. The duration of the session will be one hour and half that Will be designed into half an hour for the incentive spirometer training and an hour for the oropharyngeal motor training programme
214472748|NCT04818671|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
214472749|NCT04977869|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
214472750|NCT04977869|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
214472751|NCT05526196|DRUG|Cannabis|Dried flower cannabis cigarette with 22% THC
214472752|NCT05526196|DRUG|Tobacco|Dried flower cigarette with active nicotine
214472753|NCT05526196|DRUG|Cannabis tobacco|Dried flower cigarette with active nicotine and cannabis
214472754|NCT05526196|DRUG|Placebo|Dried flower cigarette with both placebo tobacco and cannabis
214472755|NCT05552443|DRUG|Hydromorphone 2.5 mcg/kg|2.5 mcg/kg intrathecal
214846817|NCT05518032|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given intratumorally
214846818|NCT02656654|OTHER|Whole-body compression|
214846819|NCT01082224|DRUG|iodinated contrast dye|iodinated Radiocontrast dye for imaging enhancement
214472756|NCT05552443|DRUG|Hydromorphone 2.75 mcg/kg|2.75 mcg/kg intrathecal
214472757|NCT05552443|DRUG|Hydromorphone 3 mcg/kg|3 mcg/kg intrathecal
214472758|NCT05552443|DRUG|Hydromorphone 3.25 mcg/kg|3.25 mcg/kg intrathecal
214472759|NCT05552443|DRUG|Hydromorphone 3.5 mcg/kg|3.5 mcg/kg intrathecal
214472760|NCT05552443|DRUG|Hydromorphone 4 mcg/kg|4 mcg/kg intrathecal
214472761|NCT05552443|DRUG|Hydromorphone 4.5 mcg/kg|4.5 mcg/kg intrathecal
214472762|NCT05552443|DRUG|Hydromorphone 5 mcg/kg|5 mcg/kg intrathecal
214472763|NCT05131815|BEHAVIORAL|Virtual group based physical activity (BurnAlong) and Social Media Discussion Board|Participants will engage in two to three virtual physical activity sessions a week through the BurnAlong app for three months with a chosen partner and participate at least twice a week in the research team-mediated social media message board. Additionally, participants will be asked to participate in one live physical activity session per month with an exercise physiologist.
214472764|NCT04972942|DRUG|Daratumumab|"Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)~2. Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~3. Maintenance: DARA every 4 weeks (Stop at Day +270)"
214472765|NCT06840418|DRUG|Indocyanine green (ICG) injection for intraoperative lymph node imaging|Injection is performed at the 3 o'clock and 9 o'clock positions of the cervix, with 1 ml on each side, for a total dose of 2 ml. Injection depth: The tracer is injected into the superficial (2 mm) and deep (1 cm) layers, with the superficial injection performed first, followed by the deep injection.
214472766|NCT06156813|DIAGNOSTIC_TEST|Diagnostic test|Measurements for validity and reliability
214472767|NCT06836102|DIETARY_SUPPLEMENT|Orange|usage of orange peel extract in gel layer in treatment of epistaxis
215033533|NCT02390076|OTHER|Attention bias modification|The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
214472768|NCT06833879|DEVICE|Activity Tracking Watch|Device includes a wristwatch that tracks physical activity and a data storage unit that transmits data to a central database.
214472769|NCT06836674|OTHER|Jigsaw|In this learning method, students will be divided into main and expert groups. Then, an expert from each group will come and the student will be provided with expertise in the subject given to him/her by the instructor. After the student has specialized, he/she will return to his/her own group and will provide training to his/her friends on the subject he/she has specialized in under the supervision of the instructor of the course. During the student\&#39;s specialization process on the subject given, the necessary literature support and controls will be provided by the instructor of the course.
214846820|NCT01082224|DRUG|motexafin gadolinium|motexafin gadolinium
214846821|NCT01082224|OTHER|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
214846822|NCT00090116|DRUG|Neramexane|
214846823|NCT04329299|DIAGNOSTIC_TEST|blood-based biomarkers analyses|Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
214846824|NCT04114942|BEHAVIORAL|Never Coach|20 weeks of didactic training and 10 weeks of internship, but no coaching.
214846825|NCT04114942|BEHAVIORAL|Internship Only Coach|20 weeks of didactic training with no coaching and 10 weeks of internship with coaching.
214846826|NCT04114942|BEHAVIORAL|Constant Coach|20 weeks of didactic training and 10 weeks of internship, with coaching throughout.
214846827|NCT04029454|BIOLOGICAL|birth dose vaccination against hepatitis B strategy|"Complex intervention targeting healthcare workers and involving:~* training on hepatitis B awareness and management~* training on EPI vaccination and cold chain~* training on the modalities for the birth dose administration~* the use of a monovalent unidose vaccine against Hepatitis B"
214846828|NCT01118845|DRUG|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
214846829|NCT01118845|DRUG|Rituximab|The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
214846830|NCT02588820|DRUG|Antiretroviral Therapy (Experimental)|"1. Initial ART until HLA-B5701 results became available (48 hours):~   1. Tenofovir 245 mg once a day~  2. Emtricitabine 200 mg once a day~  3. Dolutegravir 50 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day~2. Three months continuation treatment (after HLA-B5701 confirmed as negative):~   1. Dolutegravir 50 mg once a day.~  2. Abacavir 600 mg once a day~  3. Lamivudine 300 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~3. Nine months continuation treatment (till complete 12 months treatment):~   1. Abacavir, 600mg once a day~  2. Lamivudine, 300 mg once a day~  3. Dolutegravir, 50 mg once a day"
214846831|NCT04540692|DRUG|Docetaxel or Paclitaxel|Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks
214846832|NCT04540692|DRUG|Cyclophosphamide + Doxorrubicin|Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles
214846833|NCT01857973|DEVICE|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
214288962|NCT05851781|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
214288963|NCT02634684|DRUG|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
214288964|NCT02634684|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
214288965|NCT03704454|DIETARY_SUPPLEMENT|50 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
214288966|NCT03704454|DIETARY_SUPPLEMENT|100 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
214288967|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 50 mg PYC|4 weeks on placebo, then 4 weeks on PYC
214288968|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 100 mg PYC|4 weeks on placebo, then 4 weeks of PYC
214288969|NCT01514812|DRUG|YM150|oral - modified release formulation of YM150
214288970|NCT01514812|DRUG|placebo|oral
214288971|NCT01514812|DRUG|digoxin|oral
214288972|NCT00948623|BEHAVIORAL|physical activity counseling program|
214288973|NCT00948623|BEHAVIORAL|sham counseling program|
214288974|NCT02557698|OTHER|Balneum oil bath|
214288975|NCT02069990|DRUG|Cholecalciferol|
214288976|NCT05791266|DEVICE|Sticker pads containing lavender and ylang ylang oil|Sticker pads , size 160 mm2, were produced by a certified ISO 9001 manufacturer and contained 0.3% lavender oil and 0.7% ylang ylang oil. The sticker pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad.
214288977|NCT00358228|DRUG|Rimonabant|
214472770|NCT06836674|OTHER|Metaverse|In this learning method, the topics determined on pediatric drug applications will be prepared weekly by the relevant instructor of the course and will be transferred to the metaverse and presented to the student in the form of weekly modules.
214472771|NCT06836674|OTHER|Classical Education|In this learning method, the subjects determined by the instructor will be explained to the students in a laboratory environment by the instructor using a presentation (power point) method.
214472772|NCT06827184|DEVICE|Electrical Impedance Tomography|It utilizes electrical impedance tomography to analyze a series of physiological changes in the lungs following treatment
214472773|NCT05015192|DRUG|NH102|tablets, orally
214472774|NCT05015192|DRUG|Placebo|tablets, orally
214472775|NCT04961593|DRUG|Caspofungin|For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
214846834|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
214846835|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
214288978|NCT02480842|OTHER|Alloplastic free ROM|
214288979|NCT02480842|OTHER|Alloplastic limited ROM|
214472776|NCT06834620|BEHAVIORAL|Rhythmic and Gymnastic Activities-Based School Physical Education Program|A structured, year-long school-based physical education program integrating rhythmic movements, gymnastics, and small equipment exercises designed to enhance motor and physical fitness. The program included 80 sessions (two per week) focusing on rhythmic activities such as twisting, partner balance, animal walks, tumbling, and rope exercises. The intervention aimed to improve strength, flexibility, agility, and cardiovascular endurance compared to traditional physical education classes.
214288980|NCT02480842|OTHER|Oncoplastic free ROM|
214288981|NCT02480842|OTHER|Oncoplastic limited ROM|
214288982|NCT02742584|PROCEDURE|Cough Stress Test|Varying bladder volumes during cough stress test.
214288983|NCT06520852|OTHER|Group using artificial intelligence tools in addition to traditional tools in preparing educational materials|Students in the intervention group used AI tools in addition to tools such as books, journals, and websites.
214288984|NCT05181683|DRUG|Casirivimab+Imdevimab|Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
214288985|NCT01073709|DRUG|Acetaminophen|
214288986|NCT00449020|DRUG|Carboplatin|CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
214288987|NCT00449020|DRUG|Docetaxel|DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
214288988|NCT00449020|DRUG|irinotecan hydrochloride|IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
214288989|NCT00449020|RADIATION|radiation therapy|Radiotherapy will start on the first day of scheduled chemotherapy. The daily administered dose will be 1.8 Gy, 5 days a week for 4.4 weeks, 22 fractions, ( 39.6 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV). After 39.6 Gy, the same targets will be treated by oblique fields at 1.8 GY for 3 fxs to a toal dose of 45 GY. Thereafter, the primary tumor and involved nodal metastasis (secondary planning target volume SPTV) will be boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose will be 63 Gy in 35 fractions over seven weeks.
214288990|NCT03262818|DEVICE|Transvaginal ultrasound|-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
214288991|NCT03262818|DEVICE|Ultrasound/Photoacoustic imaging|-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
214288992|NCT00267046|DRUG|Palifermin|180 mcg/kg 3 days prior to chemotherapy
214288993|NCT00267046|DRUG|Placebo|Single dose 3 days prior to chemotherapy
214288994|NCT00267046|DRUG|Adriamycin (Doxorubicin)|30 mg/m\^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m\^2).
214288995|NCT00267046|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m\^2); for patients receiving the AI Regimen.
214288996|NCT00267046|DRUG|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
214288997|NCT00267046|DRUG|Cisplatin|120 mg/m\^2 on day 0, for patients receiving the AP Regimen.
214288998|NCT05485597|DEVICE|Myosuit-based gait training|In a period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit. The sessions will be started with a therapist, and if possible and as soon as possible, the patient will train with an assistant. During the therapy sessions, the patient will be asked to perform various task-specific exercises with the Myosuit, such as Sit-to-stand-, Balance- and walking exercises. Depending on the individual skill level of the participant, a higher level of difficulty in task-specific exercises can be performed. The training sessions are set to last 45 minutes. All training sessions will be accompanied by a certified (physio)therapist or trained assistant and a study investigator.
214288999|NCT03421392|OTHER|non interventional study|non interventional study
214289000|NCT00853801|BEHAVIORAL|Lifestyle intervention and provider feedback|"Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.~Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months."
214289001|NCT02212392|DRUG|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
214289002|NCT01674270|DRUG|Degarelix|
214289003|NCT01674270|DRUG|Casodex|
214289004|NCT01674270|DRUG|LHRH Agonist|
214289005|NCT06507982|DEVICE|EWL|the working length determination with EAL method
214472777|NCT06837558|DIAGNOSTIC_TEST|fibroblast growth factor 23|"Investigations: including the different following modalititis~A. Laboratory investigations include:~1. Complete blood picture, PT PC INR, RBS Kidney function tests, eGFR Urine analysis, 24 hours' protein in urine~2. Specific laboratory investigations for SLE and lupus nephritis: ANA,AntiDsDNA,C3,C4~3. Laboratory investigations of Bone mineral density predictors Ca, phosphorus, PTH, vitamin D (OH), Alkaline phosphatase, Fibroblast Growth Factor 23 (FGF 23)~B. Imaging studies:~1 - Abdominal ultrasound 2- chest x-ray 3- Echocardiography (in lupus nephritis with activity form) 4- DEXA bone scan~C. Invasive modality:~Renal biopsy of Patients with SLE with lupus nephritis"
214472778|NCT06835816|DIETARY_SUPPLEMENT|Amino acid supplementation (Glavamin, Fresenius Kabi)|Mixture of amino acids (67 g / 500 ml) given intravenously
214472779|NCT05963646|DIAGNOSTIC_TEST|Natural history study|Patients were monitored with a panel of visual function tests and imaging modalities. Functional tests included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), and contrast sensitivity function evaluation (qCSF method). Imaging assessments included fundus autofluorescence, optical coherence tomography and optical coherence tomography angiography.
214472780|NCT04975945|DRUG|Ceftriaxone Sodium|Intravenous vs local action
214289006|NCT06507982|DEVICE|SWL|In this method, an endodontic motor with a built-in EAL that provides continuous feedback during root canal instrumentation and allows clinicians to make real-time adjustments to the WL. Thus, it provides continuous feedback, allowing the clinician to make real-time adjustments. The motor of devices using this method has automatic apical reverse and automatic apical stop operation. In this way, when the tip of the file reaches the apical foramen, the file safely reverses and stops rotating.
214289007|NCT06507982|DEVICE|RWL|Radiographic method was used for determining the working length
214289008|NCT00001830|DRUG|Th2 cells in allo HSCTT|
214289009|NCT00001830|DRUG|Th2 Cells|
214846836|NCT01634412|DRUG|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
214846837|NCT01634412|DRUG|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
214289010|NCT03028714|BEHAVIORAL|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
214289011|NCT05657314|DIETARY_SUPPLEMENT|Active Comparator|Consists of 15 grams of pea protein
214289012|NCT00777478|DRUG|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
214289013|NCT04390945|DRUG|Camrelizumab|Camrelizumab combined with concurrent radiotherapy and chemotherapy
214289014|NCT00481000|BEHAVIORAL|Dialectical Cognitive Therapy|Dialectical Behavior Therapy in Combination with Traumafocused CBT
214289015|NCT01417273|DIETARY_SUPPLEMENT|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
214289016|NCT01417273|DRUG|Drug: placebo|1 cap placebo/day for 12 month
214289017|NCT05841394|DRUG|Esomeprazole 40mg|40 mg i.v. twice daily (q12h)
214289018|NCT05841394|DRUG|Ilaprazole Sodium|10 mg i.v. once daily, 20 mg i.v. in the first day.
214289019|NCT05841394|DRUG|Placebo 1|Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
214289020|NCT05841394|DRUG|Placebo 2|Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
214472781|NCT05435638|DIAGNOSTIC_TEST|Serum chemistry|"Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126).~Serum chemistries will include assessment of total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), alkaline phosphatase, glucose, sodium, potassium, blood urea nitrogen (BUN), and creatinine."
214472782|NCT05435638|DIAGNOSTIC_TEST|Hematology|Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126). The CBC assessment will include a red blood cells (RBC), hemoglobin, hematocrit, platelet count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MCV), white blood cells (WBC), neutrophils (% and abs.), lymphocytes (% and abs.), monocytes (% and abs.), eosinophils (% and abs.), basophils (% and abs.), large unstained cells (% and abs.).
214472783|NCT05435638|DIAGNOSTIC_TEST|Urinalysis|"General urinalysis will be performed, by dipstick, during Screening, on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Cohort 2: Day 112) and follow-up EoS visits (arm 1: Day 91; Arm 2: Day 126).~Approximately 7-10 mL urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin urobilinogen and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated."
214472784|NCT05435638|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed at Screening, at all in-clinic study visits, and at the End of Study visit.~The physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital, musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~• Symptom-directed physical examinations will be performed at all other study visits."
214472785|NCT05435638|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (body temperature, pulse and resting systolic and diastolic blood pressure) will be measured at Screening, at all in-clinic study visits, and at the End of Study visit. Vital signs will be measured in supine position after at least five minutes of rest.
214472786|NCT05435638|DIAGNOSTIC_TEST|ECG Test|A 12-lead, resting, digital ECG will be taken for each participant during Screening, on Days 42 and 84 (for both arms), and on day 112 (Arm 2 only), after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT and QRS intervals and QTC. The report will be signed by the Investigator, who will record in the CRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the participants will be reviewed.
214846838|NCT05806931|DRUG|TAS-102, oxaliplatin, irinotecan with bevacizumab|Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
214846839|NCT00908882|BEHAVIORAL|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
214289021|NCT05288075|DRUG|Indacaterol/glycopyrronium|"In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration."
214289022|NCT04094363|OTHER|Product A|Usual Brand, filtered combustible cigarette
214289023|NCT04094363|OTHER|Product B|CSD1902-11, an electronic nicotine delivery system
214289024|NCT04094363|OTHER|Product C|CSD1902-21, an electronic nicotine delivery system
214289025|NCT04094363|OTHER|Product D|4mg Nicotine gum
214289026|NCT04593563|DRUG|Psilocybin|Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
214289027|NCT01224067|DRUG|Quetiapine|Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
214289028|NCT05263323|OTHER|Patient education|Providing patient education to hemodialysis patients according to Neuman Systems Model by the researcher.
214289029|NCT05263323|OTHER|Data Collecting, No Education|Data were collected at the beginning and end of the study without training the control group.
214472787|NCT05435638|DIAGNOSTIC_TEST|PK|"Blood PK analyses will be performed on ≥5ml blood collected in 5-mL K-EDTA CRO coded pre-labeled tubes, refrigerated immediately after collection. Plasma will be separated by centrifugation within 2h, and then frozen at -20C.~Blood samples will be collected pre-dose on Days 0, 7, and 84, as well as pre-dose at EoT (Arm 2: Day 112), and at any point during the in-clinic visit at EoS (Arm 1: Day 91; Arm 2: Day 126)."
214472788|NCT05435638|DIAGNOSTIC_TEST|IGA scoring|"Lesions severity will be assessed using the Investigator's Global Assessment (IGA) scale,which is a 5-point scale (from 0 =no disease to 4=severe disease) based on Simpson et al. 2020, IGA for atopic dermatitis (see Table 4; Simpson et al. 2020).~The IGA score is selected using the descriptors below that best describe the overall appearance of the lesions at a given timepoint. It is not necessary that all characteristics under morphological description are present. Excoriations should not be considered when assessing disease severity."
214472789|NCT05435638|DRUG|KM-001 1% cream 12 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
214289030|NCT03182101|BEHAVIORAL|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
214472790|NCT05435638|DIAGNOSTIC_TEST|Clinician global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator at screening and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
214472791|NCT05435638|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"The VAS score will be collected on every in-clinic visit during the treatment period (Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.).~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
214846840|NCT04139031|DEVICE|Ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
214289031|NCT05627960|DRUG|AG-01 Compound|"Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D."
214289032|NCT00936585|OTHER|Immunologic Monitoring|blood draws and colonoscopy before and after receiving study drug
214289033|NCT00150449|DRUG|Pregabalin|
214289034|NCT01974349|DRUG|selumetinib (oral)|Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
214289035|NCT01124422|DRUG|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
214289036|NCT01124422|DRUG|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
214289037|NCT03762421|BEHAVIORAL|Psycho-social skills development workshops based on PM plus|5 weekly, psycho-social skills development workshops will be conducted for newly inducted civil servants in groups, based on the problem management plus intervention. These workshops will be integrated into routine induction sessions of trainee civil servants. Workshop 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, teaches the difference between technical and adaptive challenges, and trains participants in a basic stress management strategy. Workshop 2 addresses a participant-selected problem using problem-solving techniques and introduces behavioral activation. Workshops 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks whenever required. In Workshop 5, education about retaining intervention gains are provided and all learned strategies are reviewed.
214289038|NCT03762421|BEHAVIORAL|Routine training induction sessions|The control group will receive 5 routine training induction sessions. These orientation sessions include lectures introduction to governance, public sector management, basic information technology, economics and public finance and official rules of procedure of the government of Pakistan. These lectures are held in a friendly and supportive environment.
214289039|NCT05657834|DRUG|[14C]-TVB-2640|50 mg of TVB-2640 oral administration
214289040|NCT05060055|PROCEDURE|Immediate dental implant placement|Immediate dental implant placement
214289041|NCT00650624|DRUG|valdecoxib|valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
214289042|NCT00650624|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
214289043|NCT00650624|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
214289044|NCT00650624|DRUG|placebo|placebo tablet by mouth once daily in the morning for 6 weeks
214846841|NCT02277431|DIETARY_SUPPLEMENT|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am \& pm) offering a total daily serving of:~* Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units \[CFU\])~* Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~* Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
214846842|NCT02277431|DIETARY_SUPPLEMENT|placebo|
214846843|NCT05787067|BEHAVIORAL|Health Belief Model-Based Mobile Online Training|Health Belief Model-Based Mobile Online Training
214846844|NCT00574067|DRUG|Buprenorphine +OTP|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
214846845|NCT00574067|DRUG|Buprenorphine +CHC|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
214846846|NCT00574067|DRUG|Counseling +OTP|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
214846847|NCT00574067|DRUG|Counseling +CHC|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
214846848|NCT04458467|DEVICE|Continuous Infusion|A continuous infusion of ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
214846849|NCT04458467|DEVICE|Automated Intermittent Boluses|Administration of automated intermittent boluses of ropivacaine 0.2% (8 mL every 2 hr with 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room, but with a 5-hour delay for the first bolus (can be overridden by patients if they would like to initiate their perineural infusion earlier than 5 hours).
214846850|NCT02291367|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
214846851|NCT02291367|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
214846852|NCT02215772|DRUG|BI 44370 BS|
214846853|NCT03754504|DIETARY_SUPPLEMENT|Cranberry powder|3 capsules /day of whole cranberry powder (500mg/each)
214846854|NCT03754504|DIETARY_SUPPLEMENT|Placebo|3 capsules/day of a placebo comparator
214846855|NCT04766216|OTHER|Patient self-management|Patient makes independent decisions regarding warfarin therapy changes using warfarin dosing tools
214846856|NCT04766216|OTHER|Usual care provided by anticoagulation providers|Normal care provided by anticoagulation providers
214846857|NCT06157463|RADIATION|Ga-68 FAPI|FAPI PET scans will be performed in addition to other staging/restaging work-up
214289045|NCT03038334|DIETARY_SUPPLEMENT|Magnesium sulfate|Transdermal application of Magnesium sulfate 250mg every four hours per day for 90 days.
214289046|NCT01631578|PROCEDURE|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
214289047|NCT00053040|BIOLOGICAL|cintredekin besudotox|IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
214289048|NCT00053040|PROCEDURE|conventional surgery|Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
214289049|NCT02520843|DRUG|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
214289050|NCT02775162|DEVICE|Normothermic Machine Perfusion (NMP)|
214289051|NCT02775162|OTHER|Standard of Care (Ice)|
214289052|NCT03886350|OTHER|blood and sputum samples|Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation
214289053|NCT00137046|DRUG|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
214846858|NCT00117117|DRUG|Aranesp|
214846859|NCT01662934|DEVICE|I RUNE|
214846860|NCT01662934|DEVICE|sham|
214846861|NCT01731886|PROCEDURE|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.
214846862|NCT01731886|DRUG|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
214846863|NCT01731886|DRUG|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
214846864|NCT01731886|PROCEDURE|Stem cell collection|Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is \>2500 x 109 cells/liter; platelet count is \>20 x 103/mm3.
214846865|NCT01731886|DRUG|Melphalan|Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
214846866|NCT01731886|DRUG|G-CSF|Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
214846867|NCT01731886|DRUG|Cyclophosphamide|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
214846868|NCT01731886|DRUG|Mesna|Mesna will be provided with the cyclophosphamide.
214289054|NCT00137046|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
214289055|NCT04334629|DRUG|Ibuprofen|Lipid ibuprofen 200 mg
214289056|NCT06123104|DEVICE|Occlusion of blood flow diagnosed by Point of Care UltraSound (POCUS)|Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds
214846869|NCT05260034|OTHER|FAST Program|This program aims to teach how to effectively reduce impact forces during a sideways fall by 1) changing the trunk/knee angles during descent to decrease body acceleration, 2) using a rolling movement to allow for an optimal distribution of impact forces applied to any site along the contact path; and 3) tucking the chin to protect the head.
214846870|NCT05260034|OTHER|Otago Exercise Program|The Otago Exercise Program (OEP) was chosen, rather than no control intervention, to increase the level of evidence required to demonstrate efficacy, and because, similar to the safe fall training used here, it was designed to be performed individually or in small groups.
214846871|NCT00271024|DRUG|Naltrexone (drug)|50 mg q.d. for 13 weeks
214846872|NCT00271024|DRUG|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
214846873|NCT00129116|BIOLOGICAL|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
214846874|NCT00129116|BIOLOGICAL|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
214846875|NCT00129116|BIOLOGICAL|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
214846876|NCT00129116|BIOLOGICAL|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
214846877|NCT00129116|BIOLOGICAL|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
214846878|NCT03969316|PROCEDURE|Transversus abdominis plane block, Quadratus lumborum block|The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
214846879|NCT03739216|DEVICE|ClariFix|The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
214846880|NCT04152369|PROCEDURE|Anti-microbial prophylaxis for an endourological procedure or ESWL|anti-microbial prophylaxis according to urine culture results
214846881|NCT03493321|OTHER|PRF with Theracal|using the PRF which is a new technique with an bioactive material which is the Theracal to evaluate its effect upon the radicular pulp tissue
214846882|NCT06535555|DEVICE|Investigational Safety and Feasibility|"Technical feasibility will be assessed based on a five-point rating scale assessing the ease-of-use, ureteral visibility, and time required to identify the ureter using ActivSight™. All images and video of the ureter will be recorded, but surgeon feedback will be used to assess technical success based on a five point scale, rather than these (subsequently de-identified) recordings.~Safety will be confirmed through clinical assessments and evaluation of adverse events intraoperatively and through a 28-day follow-up period using the criteria listed below. All adverse events will be adjudicated by the site's Principal Investigator (PI) to judge the relatedness of the adverse event to either the administration of riboflavin or the use of the prototype ActivSight™ device (or whether the adverse event was unrelated to either)"
214289057|NCT02345382|DRUG|Atuveciclib, BAY1143572|The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
214289058|NCT03959566|DRUG|Sutezolid|Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.
214289059|NCT03959566|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
214289060|NCT03959566|DRUG|Midazolam oral solution|Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
214289061|NCT05279443|OTHER|yoga-based exercises therapy|Accompanied by a certified yoga instructor, and under the supervision of an PMR specialist and a Sports Medicine specialist, YBEs were administered to our patients included in the study for 8 weeks, 2 sessions a week, and with sessions of 60 minutes, using personal mats and equipment in a 2475 m3 (18mx25mx5.5m) gym area that belonged to our hospital, in the form of group therapy for 5 (five) people and in accordance with the social distancing rules. The exercises program was applied as a exercise program consisting of physical postures (asana) to improve the body's muscle strength and flexibility, breathing exercises (pranayama) to increase respiratory function, and relaxation and meditation (dhyana) techniques.
214289062|NCT00495183|DRUG|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
214289063|NCT00495183|DRUG|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
214289064|NCT00495183|DRUG|Placebo|Placebo
214289065|NCT03362008|DRUG|Zeropix|administration of Zeropix
214289066|NCT03362008|DRUG|Champix®|administration of Champix®
214289067|NCT02658929|BIOLOGICAL|bb2121|bb2121
214846883|NCT05279638|DIAGNOSTIC_TEST|serum ATG5|This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
214846884|NCT03743090|DIAGNOSTIC_TEST|Polysomnography.|A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
214846885|NCT04674709|DRUG|Oleander 4X - single|Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
214846886|NCT04674709|DRUG|Oleander 4X - double|Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
214289068|NCT02312661|DRUG|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
214289069|NCT02312661|DRUG|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
214289070|NCT02312661|DRUG|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
214289071|NCT00222794|DRUG|Atomoxetine (Strattera)|
214289072|NCT04913402|OTHER|Sufentanil administered by paramedics after the phone call consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
214472792|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI-C scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) answering the question Since the start of the trial, my overall status has."
214472793|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI-S scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) answering the question Please rate the severity of your disease right now."
214472794|NCT05435638|DIAGNOSTIC_TEST|Lesion photography|High-quality photographic documentation of the treated lesions will be performed on screening, and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, pre-dose, if applicable.
214472795|NCT05435638|DRUG|KM-001 1% cream 16 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
214472796|NCT05425420|DRUG|methadone hydrochloride 0.1mg/kg|Single dose of methadone hydrochloride administered via intravenous (IV)
214472797|NCT04771897|DRUG|BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 1, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
214472798|NCT04771897|DRUG|BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 2, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
214472799|NCT04508582|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance|Imaging of the heart with CMR, without use of contrast agents.
214472800|NCT04508582|DIAGNOSTIC_TEST|Echocardiography|Imaging of the heart with ultrasound.
214472801|NCT04508582|DIAGNOSTIC_TEST|Blood test|Time- matched blood samples will be taken from patients to assess immune cell phenotype and function, paying particular attention to neutrophil and T-cell phenotype. Plasma samples will be collected for the analyses of cardiac specific factors (BNP, troponin) as well as measurement of steroid hormones (progesterone and oestradiol), and soluble inflammatory and anti-inflammatory mediators
214472802|NCT06031012|DRUG|CGECC combined with thalidomide|Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
214472803|NCT06031012|DRUG|CGECC alone|Patients received CGECC alone from the beginning of radiotherapy to one week after radiotherapy.
214472804|NCT06374329|OTHER|Interceptive Slow Maxillary Expansion with removable plates|Interceptive Slow Maxillary Expansion with removable plates (see Willems et al 2023) https://doi.org/10.1093/ejo/cjad014
214472805|NCT06194110|DIAGNOSTIC_TEST|Ergometric test|Ramp test followed by a step test, both with ergospirometry
214472806|NCT04889521|OTHER|No intervention|No intervention. Study is cross-sectional observational.
214472807|NCT03184792|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
214472808|NCT03184792|OTHER|Physical therapy|Physical therapy to improve arm and hand functions
214472809|NCT05280574|DEVICE|Blinded GE Portrait Monitoring|Continuous vital signs will be monitored and recorded by GE Portrait but not available to clinicians.
214472810|NCT05280574|DEVICE|Unblinded GE Portrait Monitoring|Continuous vital signs will be monitored and evaluated by clinicians using GE Portrait.
214472811|NCT05203445|DRUG|Olaparib|Olaparib 300 mg orally BID
214472812|NCT05203445|DRUG|Pembrolizumab|Pembrolizumab 400 mg intravenously q6weeks
214472813|NCT05068414|DIAGNOSTIC_TEST|Blood panel|"* Thrombin generation test~* Residual plasma concentration of dabigatran, rivaroxaban and/or apixaban (direct oral anticoagulants)~* International Normalized Ratio (if anti-vitamin K therapy is prescribed)~* Platelet aggregation test"
214472814|NCT06434441|PROCEDURE|Autogenous bone augmentation|Maxillary alveolar bone reconstruction
214472815|NCT05305794|DRUG|Insulin + semaglutide treatment|Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
214472816|NCT05305794|DRUG|Usual insulin treatment|Usual insulin treatment
214472817|NCT05305794|BIOLOGICAL|Biological check-up|at D0, D90 and D180
214846887|NCT04674709|DRUG|Oleander 4X - quadruple|Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
214846888|NCT04674709|DRUG|Placebo|The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
214846889|NCT00602537|DRUG|Venlafaxine|75 to 375 mg
214846890|NCT00602537|DRUG|Lithium Carbonate|300 to 2400 mg
214846891|NCT01290237|DRUG|vancomycin hydrocloride|see description of study arms
214846892|NCT01456429|PROCEDURE|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
214846893|NCT06437184|DIAGNOSTIC_TEST|ODP|se previously
214846894|NCT03788135|BEHAVIORAL|cooling|the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
214846895|NCT01739413|PROCEDURE|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
214472818|NCT06256497|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Revita System is a hydrothermal ablation system, (CE) certified, intended to impart insulin-sensitizing properties to the body via ablation \& rejuvenation of the duodenal mucosa. As an adjunct to diet and exercise, Revita is intended to 1. improve glycemic control in patients with T2D who have preserved pancreatic beta cell function and whose diabetes is inadequately controlled despite oral and/or injectable glucose lowering medications and/or long-acting insulin therapy, 2. Reduce liver fat in patients with T2D and Non-Alcoholic Fatty Liver Disease (NAFLD). The single use Revita Catheter and Line Set are provided sterile and are not implantable or reusable. These disposables are used with the Revita Console an electromechanical device that controls the ablation cycle and submucosal expansion. The Revita System is used in a suitably equipped endoscopy suite. The Catheter contacts the patient's digestive tract for approximately 45-60 minutes.
214472819|NCT05877586|OTHER|CLARE app|"CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge."
214472820|NCT06521801|OTHER|Observation|Observation
214472821|NCT04902508|BEHAVIORAL|Implicit-only|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment.
214472822|NCT04902508|BEHAVIORAL|Explicit-added|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment. Interventionists will also present the rule/pattern guiding the target form.
214472823|NCT06851884|OTHER|Standard of Care (SOC)|Universal welcome leaflet on patient admission
214472824|NCT06851884|OTHER|Video capsules|3 video capsules of 3 minutes each
214472825|NCT06851884|OTHER|Cartoon|3 cartoons
214472826|NCT06851884|OTHER|Virtual reality|3 virtual reality programs
214472827|NCT06851884|OTHER|"Set of end-of-life and grief informational and educational tools"|Including a video capsule, a cartoon, and a kit of two leaflets
214289073|NCT04913402|OTHER|Sufentanil administered by paramedics based on their competency, without consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics with competency to administer sufentanil without medical doctor consultation.
214289074|NCT02268604|DRUG|BIIB 722 CL|
214289075|NCT02268604|DRUG|Placebo|
214289076|NCT02003820|BEHAVIORAL|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
214289077|NCT00642876|DEVICE|Allograft Fusion and ATLANTIS™ Cervical Plate System|The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.
214472828|NCT06851884|OTHER|Standard of Care (SOC)|Universal welcome leaflet on patient admission
214472829|NCT06852157|DIAGNOSTIC_TEST|Tissue, diagnostic and prognostic accuracy|"The clinical data and histological samples of patients with a diagnosis of CIN/SIL on cervical biopsies or conization (performed as required by the normal procedure) will be consecutively acquired from all those taken at the Operative Unit of Gynaecology and Physiopathology of Human Reproduction starting from January 2000 and stored at the Operative Unit of Pathological Anatomy and Histology.~Samples fixed in neutral buffered formalin and paraffin added at 50°C will be analysed by repeating histological examination and performing immunohistochemistry for BAG3. All analyses will be performed blinded to the clinical data of the patients and the results of the original examinations. No patients will be examined ex novo, as only paraffin-embedded tissue samples obtained at the time of the initial diagnosis will be analysed."
214472830|NCT05603884|DRUG|Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen|"venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC \> 20×109/L"
214472831|NCT05466942|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate|Measurement of physiological parameters
214472832|NCT06649383|DEVICE|Virtual reality|Participant will try virtual reality glasses with tailormade software films to see if it's possible to use them as distraction during awake surgery. We will measure doses of propofol given, level of anxiety, experience of the patient and surgeons satisfaction.
214289078|NCT00642876|DEVICE|PRESTIGE® Cervical Disc|The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
214289079|NCT03357159|DRUG|Cyclophosphamide|In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg , the second phase will use the MTD cyclophosphamide dose identified in the first phase.
214289080|NCT03357159|DRUG|anti-human T-lymphocyte immunoglobulin (ATLG)|15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation
214289081|NCT00594984|DRUG|Cetuximab|IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
214289082|NCT00594984|DRUG|Irinotecan|IV solution, IV, Q3W, 350 mg/m2, until progression
214472833|NCT06649539|DRUG|Collagenase Clostridium Histolyticum|"4 Series given to each participant, 6 weeks apart. Medication administered on back-to-back days. If failing to achieve an adequate response, men may receive up to 2 additional series 9-12 months after the 4th series.~Total of 0.9 mg administered with each series, diluted to 0.8 mL"
214289083|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
214289084|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
214289085|NCT00594984|DRUG|Brivanib Placebo|Oral, tablet, QD, until progression
214289086|NCT01849224|OTHER|Pelvic and lower extremity exercise|
214289087|NCT01906203|DEVICE|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
214289088|NCT03223246|OTHER|Additional teaching|A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
214289089|NCT02730455|DRUG|natalizumab|Administered as specified in the treatment arm
214289090|NCT02730455|DRUG|Placebo|Matched placebo
214289091|NCT03763591|BEHAVIORAL|Trauma Systems Therapy for Refugees Group Intervention|Psychological skills group for youth of refugee and immigrant backgrounds.
214289092|NCT05908695|DRUG|GV-971|Administered PO
214289093|NCT05908695|DRUG|Placebo|Administered PO
214289094|NCT01329731|DRUG|elmex® gelée|1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
214289095|NCT01329731|DRUG|negative control (placebo)|0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
214289096|NCT03235154|DRUG|sofosbuvir/velpatasvir|12 week treatment with once daily sofosbuvir/velpatasvir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
214289097|NCT05875090|DIAGNOSTIC_TEST|Glaucoma Screening|Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic
214289098|NCT01953055|RADIATION|Stereotactic ablative radiotherapy|
214289099|NCT05329701|OTHER|Individualized treatment duration strategy|As listed under arm description.
214289100|NCT05084521|DRUG|Famotidine 400 mg/50 mL|Administration of a suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
214289101|NCT02781493|DRUG|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
214472834|NCT06649539|DEVICE|RestoreX|Restorex initiated beginning on post-injection day 3 or as soon as tolerated - 30 min daily, continuing until 6 weeks after final injection of the final CCH series.
214472835|NCT06649539|DRUG|Sildenafil|Men will be prescribed sildenafil 25 mg nightly beginning treatment day 2 until 6 weeks after final injection of the final series.
214472836|NCT06649201|OTHER|Vulvovaginal Symptom Questionnaire|Participants will undergo assessment of vulvovaginal symptoms via the vulvovaginal questionnaire once pre-transplant, six months, and develop months post-transplant.
214472837|NCT06649201|DIAGNOSTIC_TEST|Vaginal Microbiome Evaluation|A vaginal microbiome evaluation will be performed via vaginal exam by a gynecologist with collection of vaginal samples once pre-transplant, six months, and twelve months post-transplant.
214289102|NCT02781493|DRUG|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
214289103|NCT03012802|PROCEDURE|Colorectal Surgery|Postoperative Audit
214289104|NCT03236740|DRUG|Ethinyl Estradiol-cyprosterone acetate|Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
214289105|NCT03236740|DRUG|Metformin Hydrochloride|Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
214289106|NCT06384040|PROCEDURE|platelet-rich plasma knee injection|platelet-rich plasma knee injection and observation for 12 months for definition of responder and non responder
214289107|NCT02747589|PROCEDURE|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
214289108|NCT00816985|PROCEDURE|Liposuction|Liposuction is a procedure that involves the removal of fat from deposits beneath the skin using a hollow stainless steel tube with the assistance of a powerful vacuum. Liposuction can be accomplished either with the use of local or general anesthesia.
214289109|NCT00816985|OTHER|Quality of Life Questionnaires|Ratings of 0 to 4, with 0 being Not at ll and 4 being Very Much, regarding how true each statement has been. Statements are in the following categories: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns.
214289110|NCT02303288|DEVICE|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
214472838|NCT06647862|DRUG|IMM01|IV infusion
214472839|NCT06647862|DRUG|Azacitidine|subcutaneous injection
214472840|NCT06647862|DRUG|Placebo|IV infusion
214472841|NCT06848712|OTHER|Observational Study - No intervention|This is an observational study evaluating brain structural abnormalities in post-COVID headache patients. No experimental intervention is applied.
214289111|NCT03851068|DEVICE|Foldax Tria Aortic Valve|Aortic Valve Replacement
214289112|NCT00620867|DRUG|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
214289113|NCT00620867|DRUG|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
214289114|NCT00620867|OTHER|placebo|matched placebo orally for 6 weeks
214289115|NCT05713747|OTHER|Life Skills Boot Camp|"The boot camp is designed to be taken by undergraduate students across all disciplines with no pre-requisite coursework and students who participated in the Life skills 101 course and have selected to participate in a boot camp training as part of their Individual Self Development Plan. The boot camp will consist of 3 training programs with 4 sessions (1.5 hour per session) each, including an introductory and a closing part.~Content The boot camp was designed by a team of academics having several years of experience in clinical psychology, educational psychology, and health psychology. The focus of the bootcamp is to teach students practical skills in three different domains of soft skills: a) Interpersonal Skills, b) Resilience and Flexibility and c) Emotion Regulation."
214289116|NCT06141395|DIAGNOSTIC_TEST|NGS-based assay for bacterial identification|A total volume of 26ml of whole blood will be sampled from each enrolled patient for three consecutive days. This will be used for Standard-of-Care (SoC) culture and Next Generation Sequencing (NGS), for identification of circulating microorganisms.
214289117|NCT04159844|DEVICE|URGOBD001|Application with 50% overlapping
214289118|NCT04159844|DEVICE|URGOBD001 associated with wading|Application with 50% overlapping in association with wading
214289119|NCT00237198|DRUG|Letrozole|
214289120|NCT03283592|OTHER|Rank-Heat Plot|provides a visual presentation of treatment hierarchy across multiple outcomes
214289121|NCT03283592|OTHER|SUCRA Plot|provides a visual presentation of treatment ranking for a single outcome.
214289122|NCT04602455|BEHAVIORAL|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
214289123|NCT06474052|DRUG|Gelofusine 4%|Gelofusine 4% 10 ml/kg is administered following anaesthesia induction in 30 minutes.
214289124|NCT00433121|DRUG|Risperidone|
214289125|NCT00433121|DRUG|Olanzapine|
214289126|NCT00433121|DRUG|Haloperidole|
214657251|NCT05436379|DEVICE|Theta Burst Stimulation|TBS, a next-gen form of transcranial magnetic stimulation (TMS), requires shorter duration and frequency of stimulation and provides comparable clinical efficacy to traditional repetitive TMS for depression. Thus it is an appropriate technique for use with young adults with depression. TBS can be delivered safely and effectively on an accelerated schedule with two sessions/day. Based on an earlier (ongoing) study of TBS to dorsomedial prefrontal cortex, investigators will administer TBS to dmPFC over 2 weeks in young adults with depression. Addressing the behavioral aspects of anhedonia and reward processing, a subset of participants will also receive positive affect training. Magnetic resonance imaging will guide the personalized location of TBS and will be used to examine change in frontostriatal circuitry with TBS. This study has the potential to influence development of new treatments for depression and anhedonia, with possible mechanisms in frontostriatal brain function.
214657252|NCT05979493|DRUG|Bupivacain|30cc IM injection in each quadratus lumborum muscle (60cc total).
214657253|NCT05979493|DRUG|Saline|30cc IM injection in each quadratus lumborum muscle (60cc total).
214657254|NCT01610921|OTHER|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
214657255|NCT06448988|OTHER|Park Bench position|To evaluate, during the procedure, the variation in regional distribution of intrapulmonary volume in the dependent and non-dependent lung regions in patients undergoing neurosurgical intervention between supine and Park-Bench position.
214657256|NCT05798923|DRUG|LAM-001|LAM-001 administered via dry powder inhalation
214289127|NCT00433121|DRUG|Quetiapin|
214289128|NCT00433121|DRUG|Escitalopram|
214289129|NCT00433121|DRUG|Citalopram|
214289130|NCT00433121|DRUG|Sertralin|
214289131|NCT02423876|DRUG|Epidural analgesia|"Receive epidural placement. Standard epidural medications and dosage are as follows:~* 0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate~* 3 mL/hr RN bolus, to be used as needed based on pain ratings~* 3 mL/30 minutes patient bolus, which is available on patient demand."
214289132|NCT02423876|OTHER|Intraoperative Complication Management and Prevention|Undergo ERP
214289133|NCT02423876|PROCEDURE|Pain Therapy|Undergo ERP
214289134|NCT02139631|OTHER|Noninvasive ventilation|Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
214289135|NCT01927172|DEVICE|AirSonea|
214289136|NCT00952575|DRUG|polyclonal anti-D immunoglobulin|single injection of 300 µg
214289137|NCT00952575|DRUG|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
214289138|NCT03985514|DRUG|Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).|Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
214289139|NCT03985514|OTHER|Active observation|In-hospital observation without antibiotics
214289140|NCT02725710|DRUG|Gabapentin|600mg Gabapentin administered orally 1-2 hours prior to procedure
214289141|NCT02725710|DRUG|Placebo|Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
214289142|NCT00946699|BIOLOGICAL|MEDI-551|0.1 mg/kg
214289143|NCT00946699|BIOLOGICAL|Placebo|0.3 mg/kg
214289144|NCT00946699|BIOLOGICAL|MEDI-551|1.0 mg/kg
214289145|NCT00946699|BIOLOGICAL|MEDI-551|3.0 mg/kg
214289146|NCT00946699|BIOLOGICAL|MEDI-551|10.0 mg/kg
214289147|NCT00946699|OTHER|Placebo|Placebo
214289148|NCT04946188|DEVICE|Opuz NICGM|A wearable and non-invasive prototype device that allows for measurement of bioimpedance data with the aim to help develop a mathematical model to predict blood glucose levels.
214289149|NCT00941785|DRUG|DHA-PQ|"Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days"
214289150|NCT00941785|DRUG|SP-AQ|"Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg"
214289151|NCT03194607|OTHER|Functional walk tests|
214289152|NCT03194607|OTHER|3D analysis of locomotion and posture|
214289153|NCT03194607|OTHER|questionnaires|
214289154|NCT04038684|BEHAVIORAL|Mindfulness-Based Weight Control (MBWC)|Mindfulness-Based Weight Control will be administered over 12 group-based sessions with weekly home practice (e.g., mindfulness exercises, dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Sessions will include BWC and mindfulness components. BWC components include: 1) a dietary plan based on a balanced, caloric deficit diet; 2) increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g., breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of emotions and their relation to emotional eating.
214289155|NCT04038684|BEHAVIORAL|Standard Behavioral Weight Control (SBWC)|Standard Behavioral Weight Control will be administered over 12 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Group sessions will include SBWC component, including: 1) a balanced, caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
214289156|NCT04138121|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
214289157|NCT00719420|DRUG|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
214289158|NCT00719420|DRUG|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
214289159|NCT01784159|DRUG|Aspirin|Aspirin administration for 7 days
214289160|NCT02817308|OTHER|samples of blood, saliva and urine|Spot samples of Blood, urine and saliva
214289161|NCT01721655|DRUG|Spironolactone|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
214289162|NCT01721655|DRUG|Placebo|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
214289163|NCT01462097|BEHAVIORAL|Aerobic exercise training|12 months of aerobic exercise
214289164|NCT01462097|BEHAVIORAL|Health Education|12 months of health education sessions
214289165|NCT02364752|PROCEDURE|Blood Draw|
214289166|NCT02364752|PROCEDURE|Loop Diuretic Withdrawal/Salt Load|
214289167|NCT03798496|PROCEDURE|Open reduction and internal fixation|Open reduction of the Galeazzi fracture dislocation with a plate.
214289168|NCT06387095|PROCEDURE|1. no block|After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
214289169|NCT06387095|PROCEDURE|2. superficial parasternal block|After induction, the patient will undergo an ultrasound-guided superficial parasternal plan block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
214472842|NCT06848504|BEHAVIORAL|MedSMA℞T Mobile|MedSMA℞T Mobile is an innovative mobile digital health intervention that integrates technology-based learning to facilitate family communication and creation of a personalized Family Medication Safety Plan. The Family Medication Safety Plan (FMSP) is a tool for families to record important information about their medications and create a plan for safe use, storage, and disposal. Participants will play MedSMA℞T Mobile for up to 30 minutes at the first study visit.
214472843|NCT06852456|DRUG|Iparomlimab and Tuvonralimab (QL1706)Injection|PD-1/CTLA-4
214472844|NCT06852456|DRUG|Paclitaxel|Chemotherapy
214472845|NCT06852456|DRUG|Cisplatin|Chemotherapy
214472846|NCT04197869|DRUG|Polyethylene Glycol Powder|Polyethylene Glycol 3350 17g should be mixed in 8 ounces of fluid for administration. Polyethylene glycol is a high molecular weight, water soluble polymer which can form hydrogen bonds with water molecules. It is an osmotic laxative solution which stimulates bowel movements by increasing the amount of water absorbed in the GI tract. It decreases feces consistency and increases their volume by promoting peristalsis and evacuation. The side effects of polyethylene glycol are bloating, gas or diarrhea. The half-life of polyethylene glycol is 4-6 hours and after 18 hours the concentration declines to non-quantifiable levels.
214472847|NCT05181462|DRUG|Carboplatin|Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks
214472848|NCT05181462|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks
214472849|NCT05181462|DRUG|Nadunolimab|Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.
214472850|NCT01946386|DRUG|LEO 90100 Aerosol, foam|The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
214472851|NCT01946386|DRUG|Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle|
214472852|NCT01946386|DRUG|LEO 90100 Aerosol, foam, vehicle|
214472853|NCT01946386|DRUG|Daivobet® ointment|
214472854|NCT01946386|DRUG|Dermovate® cream|
214472855|NCT01946386|DRUG|Synalar® ointment|
214472856|NCT02398747|DRUG|AZD2014|50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
214846896|NCT06533371|DIAGNOSTIC_TEST|Relationship between lung ultrasound and computed tomographic scan|"Ultrasonographic findings will be obtained with clinical machines. Additionally, US scans as acquired with the Ula-Op open research platform will also be gathered. For both scanners, 10seconds videos will be recorded and stored in each landmark.~To correlate LUS artefactual patterns with peripheral parenchymal changes evaluated by HRCT of the chest, all chest CT findings will be analysed by an image processing platform designed to provide visualization and quantification of areas with abnormal CT tissue density indicative of emphysema and air trapping. Post-processing image analysis will be performed on images by using automated detection of potential emphysema systems."
214846897|NCT03417830|DRUG|GSK2315698 (CPHPC)|GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
214846898|NCT03417830|DRUG|GSK2398852 (unlabeled anti-SAP mAb)|Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
214472857|NCT06264193|OTHER|hypoxia|The athletes were living in hypoxic rooms, and training was carried out on lowlands.
214472858|NCT06576479|DIETARY_SUPPLEMENT|Nutritious Shake|Powder 70 g/d diluted in 237 ml natural water
214472859|NCT06576479|BEHAVIORAL|Nutritional counseling|Specialized nutritional recommendations for CKD
214472860|NCT01878422|DRUG|Arm A: FOLFIRI or FOLFOX + Bevacizumab|Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
214472861|NCT01878422|DRUG|Arm B: FOLFIRI or FOLFOX|Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
214472862|NCT01878422|DRUG|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
214846899|NCT03417830|DRUG|89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)|89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
214846900|NCT06655974|OTHER|Health-related social needs decision support system|"The clinical decision support intervention will present emergency department clinicians at an Indianapolis, IN ED with a likelihood score for an adult patient screening positive for the following health-related social needs (HRSNs): housing instability, food insecurity, transportation barriers, financial strain, and history of legal involvement. For each HRSN, the likelihood of screening positive is reported as high, medium, or low. These categorizations are the product of logistic regression models. The clinical decision support intervention will be delivered through an existing FHIR (Fast Healthcare Interoperability Resources) standards-based clinical decision support platform."
214846901|NCT00823199|DRUG|Allopurinal|300mg once daily by mouth for four weeks
214846902|NCT01419899|BEHAVIORAL|Brief motivational intervention|A 20-30 minute motivational based discussion
214846903|NCT02800031|DEVICE|Transvaginal ultrasonography|
214846904|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
214846905|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
214472863|NCT01878422|DRUG|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
214472864|NCT06119646|OTHER|Warm Pads Applied to the Breast|Applying a warm pad to a breast during episiotomy repair
214472865|NCT02371135|GENETIC|colonic biopsies|
214472866|NCT02371135|GENETIC|questionnaires|
214472867|NCT06650319|BIOLOGICAL|intravenous LY-M003|The study was a single intravenous infusion of LY-M003 at a rate of 1 mL per minute.
214472868|NCT06650592|OTHER|All patients who were candidates for immediate lymphatic reconstruction (ILR)|All patients who were candidates for immediate lymphatic reconstruction (ILR)
214472869|NCT06467448|DEVICE|EMG Assessement of Recovery of Neuromuscular Function|EMG Train of Four Assessment of Recovery of Neuromuscular Function
214472870|NCT01385189|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
214472871|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
214472872|NCT01385189|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
214472873|NCT01385189|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
214472874|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
214472875|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
214472876|NCT01385189|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
214472877|NCT04984642|OTHER|diet|have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
214657257|NCT06376994|DEVICE|Air cleaner|The intervention is two active air cleaners with high efficiency particulate air (HEPA) filters which remove PM, as well as activated carbon filters to remove NO2 (and other trace gases). These will be run for a year in a participant's house.
214472878|NCT06651411|BEHAVIORAL|STARS (Scalable Technology for Adolescents and youth to Reduce Stress)|"The intervention is a chatbot-based stress management intervention developed by the World Health Organization (WHO). It consists of 10 sessions, which include: Introduction (1), Psychoeducation (2), Emotion Regulation (3, 4), Behavior Activation (5, 6), Managing Problems (7), Thought Challenging (8, 9), and Relapse Prevention (10). Each session consists of psychoeducation and exercise parts. Trained e-helpers contact participants to support them individually weekly.~The effect of the intervention will be compared against a control group that receives basic psychoeducation. The intervention is provided in Lithuanian."
214472879|NCT06651411|BEHAVIORAL|Basic psychoeducation|Basic psychoeducation includes basic information on stress management.
214472880|NCT03892824|DEVICE|Vine™ Embolic Protection System|"The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button."
214289170|NCT06387095|PROCEDURE|3. deep parasternal block|After induction, the patient will undergo an ultrasound-guided deep parasternal plane block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
214289171|NCT03231605|BIOLOGICAL|Hepatitis A Vaccine|Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
214289172|NCT00525330|DRUG|KRP-104 QD Drug: Placebo Drug: Metformin|KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
214289173|NCT00525330|DRUG|Placebo Drug: Metformin|Two tablets 15 to 30 minutes before each meal, morning and evening.
214289174|NCT00525330|DRUG|KRP-104 BID Drug: Placebo Drug: Metformin|KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
214289175|NCT03092921|DEVICE|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
214289176|NCT03092921|DEVICE|F&P Mask|Investigative Mask to be used for OSA therapy
214289177|NCT03002766|PROCEDURE|Breast conservative surgery|
214289178|NCT03932110|DIAGNOSTIC_TEST|omentin, visfatin|diagnostic blood test
214289179|NCT01666782|BIOLOGICAL|Standard Trivalent Influenza Vaccine|Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.
214289180|NCT01666782|BIOLOGICAL|High-Dose Influenza Vaccine|Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.
214289181|NCT06169696|DEVICE|Intervention/Treatment|Non-invasive EEG headband device
214289182|NCT04031391|OTHER|Physical activity|"The intervention group: engaged in a therapeutic physical activity program involving low-intensity exercise, strength and balance work for 2 days a week over a 12-week period, with each session lasting 90 minutes. Both the intervention group and the control group separately completed the various baseline surveys which were part of the study. Once the intervention was over, they answered them again, also separately.~The classes were led by an experienced physiotherapist who followed the physical exercise guidelines established by the American College of Sports Medicine (ACSM), although the intensity of the exercises was adapted to the participants' tolerance levels"
214289183|NCT03971214|DRUG|PD-1 inhibitor JS-001|The extensive-stage SCLC patients will receive PD-1 inhibitor treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
214289184|NCT00041483|DRUG|Anecortave Acetate 15 mg sterile suspension|
214289185|NCT00041483|OTHER|Photodynamic Therapy (PDT)|
214289186|NCT05533684|DRUG|Gabapentin|single preoperative dose of 600 mg gabapentin
214289187|NCT02393170|OTHER|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks."
214289188|NCT02393170|OTHER|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
214289189|NCT04764903|OTHER|No intervention|There is no intervention in this study
214289190|NCT03560232|DRUG|Ceftriaxone|See arm description
214289191|NCT03560232|DRUG|Ampicillin/sulbactam|See arm description
214289192|NCT03560232|DRUG|Piperacillin/tazobactam|See arm description
214289193|NCT03560232|DRUG|Cefazolin + Gentamicin|See arm description
214289194|NCT03560232|DRUG|Clindamycin + Gentamicin|See arm description
214289195|NCT03809052|DRUG|GB1211|Hard capsules for oral use
214289196|NCT03809052|DRUG|Placebo|Hard capsules for oral use
214472881|NCT06581081|BIOLOGICAL|Senl_B19 autologous CAR-T (S1904) treatment|Subjects enrolled in this study will first receive Senl\_B19 autologous CAR-T (S1904) treatment.
214472882|NCT05906069|BEHAVIORAL|ICBT|The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.
214472883|NCT05451303|DEVICE|OralViome Cancer Testing System|The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
214289197|NCT04397783|PROCEDURE|construction of an end colostomy|longitudinal incision in the construction of an end colostomy
214289198|NCT03328312|DRUG|Sugammadex|Time period from administration of the reversal agent to recovery of TOFR \>0.9
214846906|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
214846907|NCT01048463|DRUG|Nutriall|The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
214846908|NCT01048463|DRUG|LDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
214846909|NCT01048463|DRUG|Placebo|The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
214846910|NCT01048463|DRUG|HDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
214846911|NCT01048463|DRUG|Chemotherapy|Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
214846912|NCT05022563|DRUG|Parenteral anticoagulant|Parenteral anticoagulant only
214846913|NCT05022563|DRUG|Warfarin|Warfarin-based
214472884|NCT05611775|DEVICE|Triaxial accelerometer|Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
214472885|NCT05903274|DRUG|JSP191|Subjects will receive intravenous JSP191
214472886|NCT02361216|DRUG|Ingenol Mebutate|
214472887|NCT02361216|OTHER|Vehicle|Vehicle gel
214472888|NCT04225585|BEHAVIORAL|CST-PSP|skills training and experiential learning exercises
214472889|NCT04225585|BEHAVIORAL|General health education|general health education intervention that focuses on improving overall health
214472890|NCT03505008|DRUG|Methotrexate|Route of Administration: Oral
214289199|NCT03328312|DRUG|neostigmine+atropine|Number and time of bradycardic episodes (HR\<60 bpm) as well as that of tachycardic episodes (HR\>100 bpm) before tracheal extubation
214289200|NCT03328312|DRUG|neostigmine+atropine+sugammadex|4\. Time of extubation
214289201|NCT05540405|DIETARY_SUPPLEMENT|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
214289202|NCT05540405|DIETARY_SUPPLEMENT|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
214289203|NCT05540405|DIETARY_SUPPLEMENT|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
214289204|NCT04923191|OTHER|Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care|percutaneous coronary intervention
214289205|NCT03714867|DRUG|Pregabalin 150mg|150 mg concealed pregabalin capsule
214289206|NCT03714867|OTHER|Placebo|Concealed placebo capsule
214472891|NCT03505008|DRUG|Adalimumab|Route of Administration: Subcutaneous
214472892|NCT06068413|DEVICE|CT image-assisted detection software|CT image-assisted detection software can help doctor to diagnosis the focal liver lesion
214289207|NCT02447042|PROCEDURE|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
214289208|NCT02447042|DEVICE|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
214289209|NCT02165969|PROCEDURE|endoscopic endonasal surgery with UPSIT|
214289210|NCT01798511|PROCEDURE|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
214289211|NCT01798511|OTHER|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
214472893|NCT06496581|DRUG|177Lu-PMSA-617|Once every 6 weeks, 7400 MBq 177Lu-PMSA-617 will be administered for up to a total of 4 cycles.
214472894|NCT06496581|DRUG|Standard of Care|ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care
214472895|NCT03619980|OTHER|No intervention|Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
214472896|NCT05925101|BEHAVIORAL|Extinction-only condition|In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).
214289212|NCT01691781|DRUG|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
214289213|NCT03978520|DRUG|Elsubrutinib|Capsule; Oral
214472897|NCT05925101|BEHAVIORAL|Rate-drop condition|In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.
214472898|NCT05925101|BEHAVIORAL|Rate-hold condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline.
214472899|NCT05925101|BEHAVIORAL|Magnitude-drop condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR according to a VI 1.5-s schedule, but we will deliver the reinforcer for just 6 s each time. This change from delivering 60 s of access to the functional reinforcer following destructive behavior in baseline to delivering 6 s of reinforcer access for the FCR during FCT will produce a large reduction in the magnitude of reinforcement relative to baseline.
214846914|NCT05022563|DRUG|Apixaban|Apixaban
214846915|NCT05022563|DRUG|Rivaroxaban|Rivaroxaban
214846916|NCT05022563|DRUG|Dabigatran|Dabigatran
214846917|NCT05022563|DRUG|Edoxaban|Edoxaban
214846918|NCT01640184|PROCEDURE|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
214846919|NCT01640184|DRUG|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
214289214|NCT03978520|DRUG|Placebo for elsubrutinib|Capsule; Oral
214472900|NCT05925101|BEHAVIORAL|Magnitude-hold condition|This condition will be identical to the magnitude-drop condition except that we will deliver 60 s of access to the functional reinforcer contingent on the FCR, so that the magnitude of reinforcement will equal that delivered in baseline for destructive behavior. To ensure that the magnitude of reinforcement does not drop in the magnitude-hold condition, we will yoke the rate and timing of reinforcer deliveries for the FCR during FCT to the rate and timing of reinforcer deliveries for destructive behavior in baseline.
214472901|NCT05925101|BEHAVIORAL|Quality-drop condition|In this condition, we will place destructive behavior on extinction and deliver the reinforcer from the paired-choice assessment that the participant chooses approximately 1/12th as often as the highest preference stimulus from that assessment. This change from the most preferred stimulus from the paired-choice assessment to one chosen 1/12th as often will constitute a large drop in the quality of reinforcement during FCT relative to baseline.
214472902|NCT05925101|BEHAVIORAL|Quality-hold condition|We will place destructive behavior on extinction and deliver the most preferred reinforcer from the paired-choice assessment on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline in this condition.
214472903|NCT05925101|BEHAVIORAL|Rate-drop/quality-increase condition|In this condition, we will program the same large drop in reinforcement by delivering reinforcement on a VI 15-s schedule, but we also will increase reinforcement quality by simultaneously delivering the highest quality reinforcer identified during a competing stimulus assessment. We will use the competing stimulus assessment in Ex 4 because it directly assesses the quality of alternative reinforcement relative to the quality of the reinforcer for destructive behavior, whereas the paired-choice assessment could not guarantee that the selected stimulus would be of a higher quality than the reinforcer for destructive behavior.
214472904|NCT03493230|BIOLOGICAL|quantification of BRAF and NRAS mutation|Quantification of cell-free BRAF and NRAS mutations with digital PCR
214472905|NCT05499390|DRUG|AK112|Subjects receive AK112 intravenously.
214472906|NCT05499390|DRUG|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
214472907|NCT03498638|BEHAVIORAL|Couples Therapy|Couples in the intervention group will receive couples therapy for 8 weekly sessions. Each therapy session will last approximately an hour. All therapies will be conducted by the PI, Dr. Gunnur Karakurt. Dr. Karakurt is a Licenced Marriage and Family Therapist and AAMFT (American Association of Marriage and Family Therapy) approved clinical supervisor. All therapies will be conducted as a couple. Training on stress management and safety planning will be performed as individuals. There will not be any group sessions. The goal of couple therapy is to help and improve couples' capacity to regulate emotions, solve problems, and communicate through therapy with the couple together.
214472908|NCT03498638|OTHER|Control|Couples in the control group will be taught safety planning, given information on local resources to help victims of violence, and will be instructed in stress and anger management strategies. Following this 8 week period, they will receive 8 weeks of couple therapy unless they choose not to.
214289215|NCT03978520|DRUG|Upadacitinib|Film-coated tablet; Oral
214472909|NCT01730937|DRUG|Sorafenib|By mouth (PO)
214472910|NCT01730937|RADIATION|stereotactic body radiation therapy|Intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are allowed.
214472911|NCT06423040|OTHER|Social Media Chatbot on Physical Activity Education|a social media chatbot was used to provide a continuous and real-time multimedia health education program on physical activity for the older adults, as well as supportive messages and feedbacks.
214472912|NCT06487559|DRUG|Livmoniplimab|Intravenous infusion
214289216|NCT03978520|DRUG|Placebo for upadacitinib|Film-coated tablet; Oral
214289217|NCT04546945|DIAGNOSTIC_TEST|CD56|detection of CD56 by flow cytometry
214472913|NCT06487559|DRUG|Budigalimab|Intravenous infusion
214472914|NCT03980925|DRUG|Nivolumab|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin area under the curve (AUC5) Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
214472915|NCT03980925|DRUG|Carboplatin|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
214289218|NCT04355845|DRUG|Sumatriptan|25 milligrams (mg) single dose tablet
214289219|NCT04355845|DRUG|PF-06651600|PF-06651600 400 mg single dose
214289220|NCT04804969|DEVICE|MyoVista wavECG Test|The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.
214289221|NCT00655044|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
214657258|NCT06376994|DEVICE|Sham air cleaner|The sham intervention is two sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow, and overall appearance compared to active air cleaners, thus blinding participants to filter status. These will be run for a year in a participant's house.
214846920|NCT01640184|PROCEDURE|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
214846921|NCT06357923|DIAGNOSTIC_TEST|dosage|Presence of mutation on the gene panel and Frequency of allele variation
214846922|NCT00539708|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
214846923|NCT02252523|DRUG|Dexmedetomidine|
214289222|NCT00230607|DRUG|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
214289223|NCT05725967|PROCEDURE|Primary Obesity Endoscopic Procedures|Any primary endoscopic procedure for treatment of obesity including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), Aspiration therapy, pylorus sparing antral myotomy (PSAM), primary obesity surgery endoluminal (POSE), gastroplasty with endoscopic myotomy (GEM).
214289224|NCT05725967|PROCEDURE|Endoscopic Revision of Bariatric Surgical Procedures|Any endoscopic revision procedure in a post-bariatric surgical patient, including transoral outlet reduction (TORe), restorative obesity surgery endoluminal (ROSE), argon plasma coagulation of the outlet (APC), endoscopic suturing.
214289225|NCT05725967|PROCEDURE|Bariatric Surgery Procedures|Any bariatric surgical procedure including Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB)
214289226|NCT05725967|DEVICE|Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction|Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.
214289227|NCT05725967|DEVICE|Intragastric Balloon|An endoscopic bariatric procedure involving the placement of an intragastric balloon.
214289228|NCT05725967|DEVICE|Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal|Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.
214289229|NCT05725967|DEVICE|Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy|Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.
214289230|NCT05725967|DEVICE|Aspiration Therapy|Placement of an aspiration therapy device for the treatment of obesity.
214289231|NCT06394297|RADIATION|SBRT|SBRT to reproduce HDR BT dose distribution in non-operated patients LACC
214289232|NCT03758352|PROCEDURE|remote ischemic preconditioning (rIC)|Short intermittent peripheral occlusions and reperfusions of the blood flow in the right lower extremity with the help of a tourniquet.
214289233|NCT03758352|OTHER|non remote ischemic preconditioning (non-rIC)|Retrospective group who have not undergone intervention.
214289234|NCT04597788|OTHER|Protein supplemented very low calorie diet program|"Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss."
214289235|NCT04597788|OTHER|Conventional low calorie diet program|Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
214289236|NCT02481232|BIOLOGICAL|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
214289237|NCT01119417|DRUG|BQ123|Low dose day: 25 nmol/min, single IV infusion for 15 min.
214289238|NCT01119417|DRUG|BQ123|Low dose day: 50 nmol/min, single IV infusion for 15 min
214289239|NCT01119417|DRUG|Bq123|High dose day: 100 nmol/min, single IV infusion for 15 min.
214289240|NCT01119417|DRUG|BQ123|High dose day: 300 nmol/min, single IV infusion for 15 min.
214289241|NCT01119417|DRUG|Saline|2-3 IV saline infusions for 15 min each.
214289242|NCT03116971|DRUG|M3814|Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
214289243|NCT03116971|DRUG|Cisplatin|Cisplatin 75 milligram per square meter (mg/m\^2) was administered over a 60-minute intravenous infusion on Day 1.
214289244|NCT03116971|DRUG|Etoposide|Etoposide 100 mg/m\^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
214472916|NCT03980925|DRUG|Etoposide|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
214472917|NCT05233189|OTHER|MOOC|"Registrants will be offered a personalized e-education consisting of 3 to 11 modules adapted to the treatment received in childhood by each in the form of a MOOC entitled Cancer in childhood, living well after over a total duration of about 3 to 7 weeks of training."
214846924|NCT01521078|BEHAVIORAL|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
214846925|NCT00810888|DRUG|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
214846926|NCT00810888|DRUG|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
214846927|NCT01684878|DRUG|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
214846928|NCT01684878|DRUG|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
214846929|NCT01684878|DRUG|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
214846930|NCT01684878|DRUG|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
214846931|NCT01684878|DRUG|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
214846932|NCT05618145|OTHER|Clinical information|The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
214846933|NCT04060511|DRUG|HS-10342|HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
214846934|NCT05434130|BEHAVIORAL|High Dose Exercise|The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (\>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
214846935|NCT01305876|BEHAVIORAL|yoga intervention|yoga session 2 x week over 3-1/2 months
214846936|NCT02692482|DEVICE|hydrocellular polyurethane foam multilayer dressing|Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care
214846937|NCT02692482|PROCEDURE|standard care|Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
214846938|NCT04995120|DRUG|chemotherapy TP regimen combined with Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
214846939|NCT01435031|DEVICE|CTO Treatment Device|"Subjects receiving at least 1 of the following for the treatment of CTO:~* XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~* HT PROGRESS and/or HT PILOT guide wires in recanalization~* MINI-TREK Coronary Dilatation Catheter in predilatation"
214846940|NCT03376620|DRUG|1,4-Diaminobutane|Daily application to surgical breast scars of 1,4 diaminobutane on the active side
214846941|NCT03376620|DRUG|10% Urea cream|Daily application to surgical breast scars of 10% Urea cream on the sham side
214846942|NCT03639974|OTHER|PEP in a blow-bottle device|A 500-milliliter enteral nutrition vial will be used, which will contain a hole in the side, where two silicone tubes of 20 centimeters long will be inserted together with tape on the bottleneck of the vial. To perform the exercise, the vial will be filled with water leaving a water column of 10 cm high. Deep inspirations will be requested at a volume greater than the tidal volume and less than the total lung capacity that can be performed via nasal or oral, then with the mouth connected to the extensors, the patient will exhale slowly, avoiding to totally empty the lungs. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA.
214846943|NCT03639974|OTHER|EPAP|The Vital Signs ® EPAP kit will be used. Exercises will be performed in the bed, and as soon as the patient is released by the medical team to leave the bed, they can be performed in the sitting position or in orthostasis. For performing the exercise, the EPAP mask will be connected to the face of the patient. The expiratory pressure will be adjusted to 10cmH2O. Deep inspirations will be requested at a volume greater than the tidal volume and below the total lung capacity, then the patient will exhale slowly. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA, as described in the conventional physiotherapy group.
215033534|NCT02390076|DEVICE|Right Low Level Light Therapy|Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
214472918|NCT05233189|OTHER|No intervention|Patients will be followed up until 18 months only
214472919|NCT06511245|OTHER|Randomisation|Technique assigned through randomization
214472920|NCT06153602|DRUG|Nalbuphine Hydrochloride 10 MG/ML|Nalbuphine(10mg/ml) 0.8 mg intrathecal
214472921|NCT06153602|DRUG|Sodium Chloride 0.9 % in 5 ML Injection|0.9% Sodium Chloride 0.08 ml intrathecal
214472922|NCT06153602|DRUG|Bupivacaine Hydrochloride, Spinal|0.5% Hyperbaric or Isobaric Spinal Bupivacaine 1-4 ml intrathecal
214472923|NCT06153602|DRUG|Nalbuphine Hcl 10Mg/Ml Inj|4 mg IV prn for postoperative pain score\>=4 q 6 h
214472924|NCT06153602|DRUG|Acetaminophen 500Mg Tab|1 tab oral prn for postoperative pain score 1-3 q 6 h
214472925|NCT06153602|DRUG|Ondansetron 8mg|8 mg IV prn for nausea or vomiting q 8 h
214472926|NCT03367754|OTHER|Placebo|Single dose of Placebo given via intravenous (IV) infusion.
214846944|NCT03639974|OTHER|conventional physiotherapy|Conventional physical therapy consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resisted lower limb exercises; stretching, cough and walking guidelines. Initially the exercises will be performed in the bed, as soon as this is withdrawn and the patient is released by the medical team to leave the bed, the progression of the exercises to be performed in the sitting position, orthostasis, and ambulation is performed, this usually occurs on the 2nd postoperative day, after the removal of the mediastinal drain . Under supervision of the physiotherapist, the protocol will be performed twice daily, two sets of ten repetitions.
214846945|NCT00913796|DRUG|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
214846946|NCT00913796|DRUG|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
214846947|NCT02927834|DRUG|6 day Prednisone|6 day prednisone burst
214846948|NCT02927834|DRUG|Augmentin|Antibiotic augmentin for 3 weeks
214846949|NCT02927834|DRUG|21 day Prednisone|21 day prednisone burst
214846950|NCT04818996|BEHAVIORAL|Mediterranean Diet|"While calculating the energy of the Mediterranean diet applied to the individuals participating in the study, Mifflin-St. Jeor equation is used. The macronutrient composition of the Mediterranean diet was calculated as 36-40% fat, 40-45% carbohydrate and 15-20% protein. This diet is enriched with natural foods (fruits, vegetables, legumes, whole grain foods, fish, olive oil and oilseeds such as walnuts and almonds).~In addition, anthropometric measurements and body composition analysis of the participants were performed both at the beginning and at the end of the study, and some biochemical parameters (IL-6, TNF-α, CRP, MDA, TAS, TOS and routine blood parameters) were evaluated."
214846951|NCT04825717|OTHER|Nutrition and fluid plans prepared using calorimetry-based measurements.|Nutrition and fluid plans prepared using calorimetry-based measurements.
214846952|NCT02390648|DRUG|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
214846953|NCT02390648|DRUG|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
215033535|NCT02390076|DEVICE|Sham Low Level Light Therapy|Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
214289245|NCT05544604|DEVICE|Transcranial direct current stimulation|tDCS will be delivered with current strength of 2 mA for 20 min . Current will be applied through two concentric electrodes target electrode; return electrode. First we will fill the electrode cage with an electroconductive gel, and then position the electrodes, with the target electrode over the FDI hotspot, and finally we fasten the electrodes with a tubular net-shaped elastic bandage in mesh tissue, making sure that it will not push the electrode forward or backward. This procedure will aim at reducing contact impedance and at creating a uniform adherence between the whole surface of the electrodes and the scalp, avoiding uneven distribution of the current (Fertonani, 2015). We will position the central electrode (anode) according to the study group over C3 or C4 , the stimulating electrode will be placed on the scalp at T7 or T8 for the insular cortex per the 10-20 (EEG) system.
214289246|NCT01939743|DRUG|Diclofenac suppository plus lidocaine gel|
214289247|NCT01939743|DRUG|Lidocaine gel only|
214289248|NCT02032810|DRUG|Panobinostat|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
214289249|NCT02032810|DRUG|Ipilimumab|Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
214289250|NCT00000489|PROCEDURE|coronary artery bypass|
214289251|NCT05914805|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
214289252|NCT05914805|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
214289253|NCT03273595|DRUG|Lapatinib|
214289254|NCT03273595|BIOLOGICAL|Trastuzumab|
214289255|NCT03273595|DRUG|Paclitaxel|
214289256|NCT03273595|DRUG|Epirubicin|
214289257|NCT03273595|DRUG|Cyclophosphamide|
214289258|NCT02260700|DRUG|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
214289259|NCT02260700|DRUG|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
214472927|NCT03367754|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (immunoglobulin \[Ig\] G4 kappa isotype) that binds to PD-1, thus blocking the receptor from binding with its ligands. Single dose of Pembrolizumab 200 mg given via intravenous (IV) infusion.
214289260|NCT02260700|DRUG|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
214289261|NCT01157260|DRUG|Kremezin|AST-120 2g three times a day
214289262|NCT03405129|BEHAVIORAL|Phoenix|Phoenix cessation app
214289263|NCT03405129|BEHAVIORAL|NRT order button|Ability to order NRT through smartphone app
214289264|NCT03405129|BEHAVIORAL|Factoid|Factoid app
214289265|NCT01183156|BEHAVIORAL|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
214657259|NCT06161077|DIAGNOSTIC_TEST|Voice Biomarker Screening Too|The investigators will develop a screening tool using voice that can predict disease severity in idiopathic subglottic stenosis
214657260|NCT05764330|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214846954|NCT01161394|DRUG|Pioglitazone 15mg|
214846955|NCT01161394|DRUG|pioglitazone 30mg|
214846956|NCT01161394|DRUG|placebo|
214472928|NCT05389332|BEHAVIORAL|Hispanics Skin Cancer intervention|With the insights from the community, the investigators will then develop the mobile intervention targeting Hispanics at risk for skin cancer to promote sun protection and SSE and get feedback to optimize the intervention. After the random allocation participants will receive instructions on how to use WhatsApp and then the intervention. They will receive WhatsApp messages about skin cancer for three months with optimal frequencies determined by prior aims and complete a post-intervention survey which contains the same questions in the pre-survey. The pilot RCT will be conducted around the spring/summer of Year four of the R00 when UVR is generally the highest in the US. The participants will be contacted at six months after the baseline survey to complete another survey similar to the post-intervention survey.
214472929|NCT05389332|BEHAVIORAL|Control group: physical activity and nutrition for Hispanics|Content will be developed from established websites such as CDC's Division of Nutrition, Physical Activity and Obesity. We selected these topics because they are also of concern among Hispanics and provide an unrelated attention control.
214472930|NCT05734222|PROCEDURE|A new method of repair of the abdominal wall of mid-lateral postoperative ventral hernias|"1. It is planned to study potential sources of bleeding and hematoma formation during SRM plastic surgery. On this basis, recommendations on the technique of the operation will be formulated.~2. It is supposed to find a way to preserve intercostal neurovascular bundles when performing SRM repair. This should improve the quality of abdominal wall reconstruction by preserving neurovascular bundles of muscles and reducing neuroalgic pain syndrome.~3. It is proposed to develop a method for combining retromuscular and subaponeurotic spaces in the treatment of mid-lateral hernias~4. It is planned to substantiate the effectiveness and expediency of the application of the developed surgical techniques based on the analysis of the immediate and long-term results of treatment."
214472931|NCT05471037|PROCEDURE|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
214472932|NCT05471037|PROCEDURE|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
214472933|NCT05529316|DRUG|Botensilimab|An anti-CTLA-4 monoclonal antibody
214472934|NCT05529316|DRUG|Balstilimab|An anti-PD-1 monoclonal antibody
214472935|NCT03621254|OTHER|[LO-LONG]|Both interventions are different modalities of FES-evoked leg exercise, three-four times per week for 6-8 weeks (24 therapy sessions). The comparator intervention (\[LO-LONG\]) uses 20-40 min (patient state of fitness dependent) of continuous leg exercise of lower intensity.
214472936|NCT03621254|OTHER|[HI-SHORT|One intervention (\[HI-SHORT\]) uses a variety of leg exercise interval training of higher intensity for 10 x 2-min intervals.
214472937|NCT05636072|BEHAVIORAL|WISER|Participants will engage in one or more positive psychology well-being tool(s).
214472938|NCT01866163|DRUG|LEO 90100|
214472939|NCT01866163|DRUG|Vehicle|
214472940|NCT05130814|DEVICE|blue light photobiomodulation|1 minute irradiation of blue light performed with EmoLED device.
214472941|NCT05130814|PROCEDURE|cleansing|cleaning of the wound area with saline or ringer's lactate
214472942|NCT05130814|COMBINATION_PRODUCT|hyaluronic acid gauze plus polyurethane foam|every 48 hours or as needed
214472943|NCT05130814|DRUG|zinc cream or hyaluronic acid sodium salt + metallic silver|applied to prevent and/or treat the skin maceration of the surrounding area
214472944|NCT05130814|PROCEDURE|topical treatment|topical treatment indicated for that stage of the lesion
214472945|NCT05130814|PROCEDURE|bandage|"it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system"
214472946|NCT06543303|DRUG|BTV100 Low dose|1% Cevimeline Ophthalmic Solution
214472947|NCT06543303|DRUG|BTV100 Mid dose|2% Cevimeline Ophthalmic Solution
214472948|NCT06543303|DRUG|BTV100 High dose|4% Cevimeline Ophthalmic Solution
214472949|NCT06543303|DRUG|Placebo|Placebo
214472950|NCT06561061|DRUG|zinc sulfate|Dispersible (20 mg) tablet
214472951|NCT06561061|DRUG|Placebo|Dispersible tablet
214472952|NCT06804980|DRUG|Rosuvastatin (Crestor)|The patient will take 3 28-day packs of placebo and 2 28-day packs of rosuvastatin. The order in which they take the placebo or rosuvastatin will be assigned at random.
214472953|NCT06804980|DRUG|Placebo|The patient will take 3 28-day packs of placebo and 2 28-day packs of rosuvastatin. The order in which they take the placebo or rosuvastatin will be assigned at random.
214472954|NCT05848947|DRUG|99mTc-Macro Albumin Aggregate|Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
214472955|NCT04710732|DRUG|Standard Enoxaparin 40 mg once-daily before randomization|"Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2"
214472956|NCT04710732|DRUG|Standard Enoxaparin 40 mg once-daily after randomization|Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
214472957|NCT04710732|DRUG|Escalated Enoxaparin 30 mg twice-daily after randomization|Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
214472958|NCT04710732|DEVICE|Anti-embolic elastic compression stockings|Applied before or just after the surgery and used around the clock until discharge
214472959|NCT04710732|DIAGNOSTIC_TEST|Thrombodynamic test (TD)|"Blood sampling for TD:~* 12 hours after key injection 1 (TD-12) on the POD 1~* 24 hours after key injection 2 (TD-24) on the POD 2~* 24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)"
214472960|NCT06806410|DRUG|Liposomal bupivacaine (LB)|our study team wishes to determine effect of liposomal bupivacaine in regional nerve blocks for surgery of the upper extremity (finger, hand, wrist, elbow)
214472961|NCT06806410|DRUG|Dexamethasone|dexamethasone injected in perineural area can extend the regional nerve block
214657261|NCT05764330|OTHER|Dietary Intervention|Undergo CER intervention
214657262|NCT05764330|OTHER|Dietary Intervention|Undergo IF intervention
214657263|NCT05764330|BEHAVIORAL|Fasting|Undergo fasting
214472962|NCT04507841|DRUG|Niraparib|Neoadjuvant niraparib monotherapy with an individualized starting dose of 200mg/day or 300mg/day based on body weight or platelet count. The 28-day treatment cycle consists of 21 days of medication followed by a 7-day break. Two cycles of neoadjuvant niraparib monotherapy were used, and the investigator may choose to have an additional cycle based on the patient's condition.
214289266|NCT01183156|BEHAVIORAL|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
214289267|NCT02071121|DRUG|BIIB061|BIIB061 capsules for oral administration
214289268|NCT02071121|DRUG|Placebo|BIIB061 matching placebo capsules
214289269|NCT02071121|DRUG|14C-BIIB061|Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
214289270|NCT00088517|DRUG|[11C]NNC-112|
214289271|NCT01322178|DRUG|Cetuximab; mFOLFOX6|"Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1~Oxaliplatin: 85 mg/m2 iv gtt over 2 hours, D1; leucovorin: 400 mg/m2 iv gtt , D1; 5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h~repeated every two weeks for 4.5 months(9 cycles)"
214289272|NCT03240614|DEVICE|Non-rebreather oxygen mask|This intervention will be preoxygenation using a Non-rebreather that will be placed upon the participant for preoxygenation. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After 3 minutes, an ABG will be taken and labeled as Intervention A.
214289273|NCT03240614|DEVICE|Bag-valve-mask|This intervention will be preoxygenation using a BVM apparatus for preoxygenation for 3 minutes. At the end of 3 minutes an ABG will be obtained.
214289274|NCT03240614|DEVICE|High Flow Nasal Cannulae|This intervention will be preoxygenation using High Flow Nasal Cannulaes at an FiO2 of 100%. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After the 3 minutes, an ABG will be taken and labeled as Intervention C.
214289275|NCT03566316|DRUG|Telmisartan/Amlodipine|
214289276|NCT03566316|DRUG|Rosuvastatin|
214289277|NCT03566316|DRUG|Telmisartan|
214289278|NCT02868320|OTHER|SMS messages|"Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.~Weekly reminder messages of blood glucose testing."
214472963|NCT03663218|RADIATION|Dose escalation|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
214472964|NCT06807450|PROCEDURE|closure of oro-nasal fistula in cleft palate patients|group I : Oro-nasal fistula will be closed in two layers, nasal layer by closing the fistula margin and turning over of flap and oral layer will be closed using two flap palatoplasty group II; the same procedure with insertion of free graft of buccal pad of fat between oral and nasal layers
214472965|NCT05742932|DEVICE|Trauma surgery using Global D's implants.|Major or minor participants who will be treated by an trauma surgery with ORTRAUTEK® or MINITEK/MICROTEK® implant(s).
214472966|NCT06807255|DIAGNOSTIC_TEST|Lactate levels were assessed via a venous blood gas test utilising an IV cannula already placed in the woman's limb upon admission|Lactate levels were assessed via a venous blood gas test utilising an IV cannula already placed in the woman's limb upon admission; subsequent analysis was conducted using rapid processing (under 5 minutes from the pre-test) with the Rapidpoint 500 Systems-Siemens (Siemens, Milano) emogasanalyzer
214472967|NCT04098666|DRUG|Placebo oral tablet|Placebo tablet identical to metformin, up to 4 tablets a day
214472968|NCT04098666|DRUG|extended release metformin|Metformin extended release 500 mg tablets, up to 4 tablets a day
214472969|NCT06806384|OTHER|ExerGame-based Stroke Rehabilitation|The intervention involves training using the Dividat Senso platform (Dividat, Schindellegi, Switzerland), a pressure-sensitive platform (1.13 m × 1.13 m) equipped with 20 sensors. The training includes a series of ExerGames designed to challenge balance, coordination, and cognitive processing speed. These games focus on weight shifting, stepping accuracy, and reaction time, with difficulty levels progressively adjusted based on participant performance. To ensure safety, participants are allowed to use a waist-high parallel bar for support during the exercises. Additionally, participants receive conventional physical therapy methods that do not interfere with the study protocol. These include range-of-motion exercises, upper-limb training, and respiratory training, delivered in 30-minute sessions, five days per week, over a four-week period.
214657264|NCT05954910|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
214657265|NCT03317964|OTHER|Saliva sample|Extract sample of saliva only once
214657266|NCT02237235|DRUG|MMFS-202-302|"Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks"
214289279|NCT02868320|OTHER|Instruction booklet|General detailed instructions addressing the same SMS categories.
214289280|NCT04698460|PROCEDURE|Hybrid coronary revascularization|A staged procedure with a minimally invasive direct coronary artery bypass grafting of left anterior descending artery by left internal mammary artery (LIMA-LAD MIDCAB) at first stage, and percutaneous stenting of iFR-significant lesions in non-LAD arteries at the second stage
214289281|NCT04698460|PROCEDURE|Coronary artery bypass grafting|A conventional procedure of median thoracotomy with on-pump bypass grafting of left anterior descending artery by left internal mammary artery and saphenous vein grafting of circumflex and/or right coronary artery
214289282|NCT01164982|DEVICE|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
214846957|NCT05470829|DRUG|ZM-H1505R|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
215033536|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (meta-cognitive imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of meta-cognitive imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
214472970|NCT06806384|OTHER|General balance exercise for stroke rehabilitation|The intervention consists of a standardized program of balance exercises designed to improve postural control and stability. The program incorporates weight-shifting training performed once daily for 30 minutes, five days per week, over a four-week period. Weight-shifting activities include anterior-posterior and mediolateral movements, with a focus on loading the affected limb. Participants are instructed to adopt a lunge posture for forward-backward movements, maintain parallel foot positioning for lateral movements, and utilize a balance pad to enhance postural stability. A trained therapist adjusts the intensity and difficulty of the exercises to match the individual abilities of each participant, ensuring a personalized and progressive approach.
214472971|NCT06806384|OTHER|Conventional physical therapy for stroke rehabilitation|The intervention includes conventional physical therapy methods that are compatible with the study protocol. These methods consist of range-of-motion exercises, upper-limb training, and respiratory training. The sessions are delivered for 30 minutes per day, five days per week, over a four-week period.
214472972|NCT02988661|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The CDSMP consist of 6 weekly classes of two and a half hours each one, for six weeks. A group of 10-16 people with different chronic conditions attend the classes together. Classes are facilitated by two certified leaders, one or both of whom are non-health professionals with chronic diseases. The workshop covers topics such as: 1) how to deal with frustration, fatigue, pain and isolation, 2) exercise for maintaining and improving strength, flexibility, and endurance, 3) communicating effectively with family, friends, and health professionals, 4) nutrition, 5) decision making, 6) appropriate use of medications and how to evaluate new treatments. Participants receive a companion book, Living a Healthy Life with Chronic Conditions, and an audio relaxation CD, Relaxation for Mind and Body.
214472973|NCT06541067|DRUG|Posaconazole|"Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols).~On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose"
214472974|NCT05907252|BEHAVIORAL|Supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
214472975|NCT05907252|BEHAVIORAL|Non-supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
214472976|NCT05907252|BEHAVIORAL|Non-supervised Individual-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
214657267|NCT02237235|DRUG|Placebo|Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
214846958|NCT05470829|OTHER|ZM-H1505R Placebo|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
214846959|NCT00747292|PROCEDURE|epidural|Patients in this limb receive epidural analgesia
214846960|NCT00747292|PROCEDURE|PCA|Patients in this limb receive a PCA for their pain control
214846961|NCT00747292|PROCEDURE|Spinal|Patients in limb will receive spinal analgesia
214289283|NCT01441206|DRUG|rifampin|"Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth \< 32 weeks - PNA \< 14 days: 10 mg/kg QD GA at birth \< 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA \< 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD"
214289284|NCT05154006|BEHAVIORAL|Information about benefits of the behavior|The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply \[5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)\]
214472977|NCT05560165|PROCEDURE|F-18 sodium fluoride PET/CT guided robotic arm assisted injection of combination of local anesthetic and steroids|A surgical aseptic approach will be followed for the procedure. Local anesthesia of the skin and soft tissue at the entry site will be achieved by 1% lignocaine. A 23G lumbar puncture needle will be introduced and the real-time final placement of the needle will be confirmed with low dose CT (40 mA) fused with pre-procedure PET images. After confirming the real-time position, the local anesthetic and steroid injection (0.5ml of 0.5% Bupivacaine per joint and a total dose of 80mg of Methylprednisolone acetate divided equally based on the number of joints to be injected) will be injected intraarticularly and periarticularly around the target joint through the lumbar puncture needle. The skin entry site will be compressed manually to achieve hemostasis. The same procedure will be repeated if multiple joints are to be injected. After the procedure, patient vitals will be observed for thirty minutes in the recovery area and discharged in stable condition.
214472978|NCT06410508|OTHER|Just Do You|"As described in further detail previously, the experimental intervention is a brief psychotherapeutic intervention informed by principles of CBT and motivational interviewing that is co-delivered by a mental health clinician and peer support worker. This intervention will be a version of the initial intervention delivered in the Just Do You trial by Munson et al.(2022), adapted for increased suitability with our clinical population."
214472979|NCT05924074|BIOLOGICAL|Biological sampling|The procedure will consist of an additional bone marrow sample and blood sample
214472980|NCT06804993|DRUG|Transvaginal repair & botulinum toxin type A injection|100 units of lyophilized botulinum toxin type A were diluted in saline to 50 U/mL before the injections. A total of 30 units of type-A botulinum toxin was injected with a 22-G needle evenly divided in 3 sites, 2 on either side of the internal anal sphincter (3 and 9 O'clock) and the third anteriorly (at 12 O'clock)
214472981|NCT06804993|PROCEDURE|Transvaginal repair & distilled water injection|A total of 30 units of distilled water was injected with a 22-G needle evenly divided into 3 sites, 2 on either side of the internal anal sphincter (3 and 9 O'clock) and the third anteriorly (at 12 O'clock)
214289285|NCT05154006|BEHAVIORAL|Instruction on how to perform a behavior|"For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) \[4.1 Instruction on how to perform a behavior (Michie et al., 2013)\]"
214472982|NCT05533814|DRUG|Perampanel|Perampanel tablets.
214472983|NCT04204083|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
214472984|NCT06374667|PROCEDURE|Y-3 ICO injection|Patients included will be given skull outer plate drilling surgery and Y-3 ICO injection under local anesthesia and sedation. The injection will be given for 3 consecutive days.
214472985|NCT06374667|DRUG|Y-3 intravenous injection|Patients included will be given Y-3 intravenous injection for 7 consecutive days.
214472986|NCT06374667|OTHER|Conventional treatment|standard treatment and management according to related guidelines during the entire treatment period
214472987|NCT06145997|OTHER|Acupuncture therapy|Acupuncture therapy (AT) is delivered by Licensed Acupuncturists (LAcs). Treatment plans are determined according to each patient's presentation and resulting traditional East Asian medicine (TEAM) differential diagnosis. TEAM therapeutics include AT, Chinese herbal medicine (CHM), Kampo herbal medicine, gua sha, tui na, cupping and lifestyle advice. All TEAM therapeutics are allowed in this study because it is a pragmatic, effectiveness study.
214472988|NCT05656092|DRUG|HIP0612|Test drug
214472989|NCT05656092|DRUG|HPP2202|Placebo drug
214472990|NCT05656092|DRUG|RLD2204|Reference drug
214472991|NCT05656092|DRUG|HPP2201|Placebo drug
214472992|NCT06270134|OTHER|Bicarbonate|Bicarbonate is added to hemodialysis fluids to correct the metabolic acidosis that arises from kidney failure. Some dialysis units in Canada add bicarbonate to a level of 32 mmol/L, while other units add bicarbonate to a level of 38 mmol/L. It is unknown whether one level is better for people's health.
214472993|NCT06805240|DIAGNOSTIC_TEST|Air Charged Catheter ARM Procedure|Normative datasets for traditional measures of anorectal function with an air charged HRAM catheter will be collected in healthy subjects using the IAPWG standardized testing protocol and London classification for ARM measurement.
214472994|NCT06805240|DIAGNOSTIC_TEST|Solid State Catheter ARM Procedure|Normative datasets for traditional measures of anorectal function with a solid state HRAM catheter will be collected in some healthy subjects using the IAPWG standardized testing protocol and London classification for ARM measurement for comparison to the air charged catheter.
214472995|NCT06805474|OTHER|Observational|Observational
214479479|NCT06091163|BEHAVIORAL|Ketogenic Diet|"A Ketogenic Diet (KD) is a high-fat and very low-carbohydrate intake. Participants will follow a modified KD (estimated 20-50g carbohydrates/day based on a 2000 kcal diet) without energy restriction. Participants will test for ketosis in their morning urine at least twice a week to monitor adherence.~To support adherence in people with depression, delivered pre-prepared KD meals (3 meals per day) and additional ketogenic snacks will be sent to participants. A registered dietitian will provide weekly 30-minute nutritional counselling sessions. The dietitian will schedule appointments and assess the participants' experience with adhering to the KD diet, troubleshoot as required, give guidance on how to prevent or overcome side effects of KD diets, and keep record of participants' ketosis level and suicide risk."
214472996|NCT06805110|BEHAVIORAL|Monthly RDT validation during DHIS2 data review meetings|The Nigeria national malaria program will lead monthly RDT validation at selected legal government areas (LGAs). Health facilities will be asked to retain all RDT cassettes performed for the prior month and bring them to a monthly validation meeting. During these meetings, RDT cassettes will be scanned using the HealthPulse application, which will automatically tally the number of RDTs by brand and result. The application will also allow for the entry of aggregated testing data, including the total number of tests conducted and the RDT results recorded in the health facility register. Discrepancies between the HealthPulse data and facility records will be calculated, with a focus on identifying and addressing discrepancies exceeding a designated threshold (e.g., 10%) that takes into account the proportion of cassettes that may have changed results over the past month. Facilities with significant discrepancies may undergo a detailed audit to align RDT cassettes with patient records.
214472997|NCT06805942|DEVICE|Lipiodol (ethiodized oil) injection|Lipiodol will be used as an embolic agent for arterial embolization targeting neovascularity in the plantar fascia to reduce inflammation and pain.
214472998|NCT06185192|DIETARY_SUPPLEMENT|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
214472999|NCT06804356|PROCEDURE|Tendon interposition arthroplasty|Trapeziometacarpal arthroplasty using autologous tendon interposition to fill the space left by resecting affected joint surfaces.
214473000|NCT06804356|PROCEDURE|Poly-L-D-lactic acid implant (RegJoint) interposition arthroplasty|Trapeziometacarpal arthroplasty using poly-L-D-lactic acid implant (RegJoint) interposition to fill the space left by resecting affected joint surfaces.
214473001|NCT06512337|DRUG|Deucravacitinib|As per product label
214473002|NCT03223155|DRUG|Nivolumab|"Patients in Sequential Arm will begin treatment with nivolumab (given with ipilimumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with nivolumab (given with ipilimumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with nivolumab 3 mg/kg as a 30-minute infusion +/- 10 minutes every 2 weeks for a maximum of 24 months. Patients will receive treatment on days 1, 15, and 29 of each 6 week cycle."
214473003|NCT03223155|DRUG|Ipilimumab|"Patients in Sequential Arm will begin treatment with ipilimumab (given with nivolumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with ipilimumab (given with nivolumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with ipilimumab 1 mg/kg as a 30-minute +/- 10 minutes infusion every 6 weeks for a maximum of 24 months. Patients will receive treatment on day 1 of each 6 week cycle."
214473004|NCT03223155|RADIATION|Stereotactic body radiation therapy|All patients will receive 3 or 5 fractions of radiation as determined by the location of the lesions to be irradiated. There should be a minimum of 40 hours between treatments for an individual lesion. However, a patient may receive radiation for different lesions on consecutive days. Starting dose depends on metastasis locations.
214473005|NCT06807073|PROCEDURE|Prophylactic defect closure|Endoscopists will use at least one new generation closure device to approximate the healthy mucosal surrounding the submucosal defect to ensure complete defect closure. Adequate apposition of the mucosal defect margins will be achieved when no visible submucosal areas \>3 mm along the closure line are present.
214473006|NCT06807073|PROCEDURE|No prophylactic defect closure|After performing EMR with thermal ablation, prophylactic defect closure will not be performed.
214473007|NCT06314776|OTHER|Usual physiotherapy without Whole-Body Vibration|Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
214473008|NCT06314776|OTHER|Pre-Usual physiotherapy|(GMFM, Test 10M, Test Time Up and Go)
214473009|NCT06314776|OTHER|Post-Usual physiotherapy|(GMFM, Test 10M, Test Time Up and Go)
214473010|NCT06322212|DIETARY_SUPPLEMENT|Thiamine|Participants will be provided instruction to take one 500 mg capsule of Thiamine (Vitamin B1) each day in the morning for 3-months.
214473011|NCT06322212|OTHER|Placebo|Participants will be provided instruction to take one capsule (placebo) each day in the morning for 3-months.
214289286|NCT05154006|BEHAVIORAL|Self-efficacy|Self-efficacy will be promoted by the four sources of self-efficacy (Bandura, 1977): 1) Mastery Experiences (experience that one is able to successfully apply the behavior), vicarious experience (observing successful others performing the safe carrying behavior), verbal persuasion (receiving positive feedback when performing the behavior and encouraging messages to do so) and emotional state (e.g. being in a positive emotional state when performing the behavior). \[6.1 Demonstration of the behavior; 8.1 Behavioral practice/rehearsal; 15.1 Verbal persuasion about capability; 15.2 Mental rehearsal of successful performance; 15.3 Focus on past success;15.4 Self-talk; 5.4 Monitoring of emotional consequences (Michie et al., 2013)\]
214473012|NCT04732507|COMBINATION_PRODUCT|1% plain lidocaine and 0.25% plain bupivacaine|A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.
214473013|NCT05523869|DRUG|Intravitreal topotecan|Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.
214473014|NCT05523869|PROCEDURE|Pars plana vitrectomy with or without scleral buckle|Standard three-port pars plana vitrectomy with or without scleral buckle.
214473015|NCT04954885|PROCEDURE|Biospecimen Collection|Undergo stool sample
214473016|NCT04954885|OTHER|Physical Performance Testing|Undergo short physical performance battery
214473017|NCT04954885|OTHER|Physical Performance Testing|Perform 6-minute walk test
214473018|NCT04954885|OTHER|Questionnaire Administration|Complete questionnaires
214473019|NCT03473249|DRUG|Contrast-Enhanced Ultrasound using Lumason|Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
214906903|NCT01019343|PROCEDURE|MRI techniques|MRI sub-studies will be conducted on 3.0 T or 7T units in the NMR Research Center. All volunteers will comply with the yearly requirement of a standard clinical diagnostic MRI scan of the head performed at 3.0T, to be submitted to the Diagnostic Radiology Department of the Clinical Center for interpretation. If the subject does not have a clinical scan performed within 12 month of the exam, a standard clinical MRI will be performed and reviewed before the research MR. The standard examination takes approximately 15 minutes to complete; after that, the research MR scans will be performed. Standard clinical MRI of the head will be repeated on an annual basis and read by the Diagnostic Radiology Department of the Clinical Center.
214473020|NCT05660863|DRUG|MN-08 24 mg/day|Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
214473021|NCT05660863|DRUG|MN-08 60 mg/day|Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
214473022|NCT04473378|DEVICE|FreeStyle Libre Pro|The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
214473023|NCT06307886|PROCEDURE|Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With manipulator|patients who underwent laparoscopic hysterectomy with using uterine manipulator
214289287|NCT05154006|BEHAVIORAL|Social Support|A self-selected social partner from the same or neighboring household (e.g. husband, mother-in-law) will be involved in the learning process (observational learning, feedback). The partner will participate in the intervention activities and will be instructed to provide emotional social support and practical informational support. \[3.2 practical support, 3.3 emotional support; 6.3 Information about others' approval (Michie et al., 2013).\]
214289288|NCT04225611|DRUG|Dexamethasone|The investigators have developed a topically-applied corticosteroid-delivery system that has the potential to treat recurrent cystoid macular edema with fewer risks to patient, and more dose control. The system is comprised of a drug-polymer film that is completely encapsulated within the periphery of a hydrogel that is commonly used to make contact lenses.
214289289|NCT04134013|DIETARY_SUPPLEMENT|Combination: Nutrition AND Chiropractic Adjustment|LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
214289290|NCT04134013|OTHER|Chiropractic Adjustment: Spinal Manipulation Therapy|LBP chiropractic adjustment per protocol
214473024|NCT06307886|PROCEDURE|lPatients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy without uterine manipulator|patients who underwent laparoscopic hysterectomy without using uterine manipulator
214473025|NCT05819476|PROCEDURE|OLP-injection|Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.
214473026|NCT05819476|OTHER|Scripted Evidence-based treatment rationale|As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
214473027|NCT05819476|OTHER|Experimental model of acute pain|Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).
214473028|NCT05743426|OTHER|Survey|Patient Reported Outcome (PRO) questionnaire
214473029|NCT05743426|OTHER|Toxicity Assessments|Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).
214473030|NCT05762107|DRUG|Placebo|Subject receives Placebo by subcutaneous injection daily for 28 days
214473031|NCT05762107|DRUG|ZT-01, 7 mg|Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
214473032|NCT05762107|DRUG|ZT-01, 15 mg|Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
214473033|NCT05762107|DRUG|ZT-01, 22 mg|Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
214473034|NCT06324344|DEVICE|High-Dose TENS|high-dose TENS device delivers 1 hour of TENS therapy per session.
214473035|NCT06324344|DEVICE|Low-Dose TENS|low-dose TENS device delivers 6 minutes of TENS therapy per session.
214473036|NCT06371157|DRUG|AK104|intravenous
214473037|NCT06371157|DRUG|Lenvatinib|oral
214473038|NCT06371157|PROCEDURE|TACE|TACE (chemo and embolic agent injection into the hepatic artery)
214473039|NCT06371157|OTHER|Placebo for AK104|intravenous
214473040|NCT06371157|OTHER|Placebo for Lenvatinib|oral
214473041|NCT04750538|DEVICE|BreEStim 120|120 BreEStim stimuli will applied for about 10-15 minutes.
214473042|NCT04750538|DEVICE|BreEStim 240|240 BreEStim stimuli will applied for about 20-30 minutes.
214473043|NCT04152096|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
214473044|NCT04152096|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
214479480|NCT06091163|BEHAVIORAL|Phytonutrient Diet|Participants in the control group will receive the same degree of dietetic input and be told that their diet is a modified fat and phytonutrient diet. The photo diet aims to increase vegetable consumption, reduce saturated fat intake and increase poly- and mono-unsaturated fat intake. Participants in the control group will receive food vouchers (£20 every two weeks) to help purchase these items. This aims to be a plausible placebo dietary treatment for depression. There is no clear evidence that these manipulations will change depression severity. The dietitian will create written materials to explain the diet and suggest foods by colour with supporting recipe suggestions.
214289291|NCT05284214|BIOLOGICAL|Sargramostim|Sargramostim for injection
214473045|NCT05211596|BEHAVIORAL|Deaf Weight Wise intervention|The DWW intervention consists of groups of 5 subjects who meet together for 16 weeks, 2 hours each week. Group meetings will be held virtually on Zoom. A trained, deaf, ASL-fluent counselor will lead the sessions. Each session includes group sharing, problem solving, discussion of a weight management topic, and goal setting and action planning for the next week. A key principle of DWW is motivational interviewing, in which the counselor acts as a facilitator to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The maintenance phase starts immediately after the 16-week intervention, and consists of two meetings of the original group via Zoom; one at month 3 and one at month 6 of the maintenance period. Counselors also email participants bi-weekly to check in and provide additional support.
214473046|NCT05789316|OTHER|Ototoxicity Screening Protocol|The ototoxicity screening protocol contains a functional and objective component. The functional component is the Hearing Handicap Inventory for the Elderly - Screening Version (HHIE-S). The objective component will be pure tone audiometry. A 2 kHz tone at 40 dB will play through over-the-ear headphones and subjects will indicate whether they heard it.
214473047|NCT00780494|DRUG|bevacizumab|Intravenous 15 mg/kg
214473048|NCT00780494|DRUG|carboplatin|AUC 6, Intravenously Day 1 every 21 days
214473049|NCT00780494|DRUG|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
214473050|NCT06205160|DEVICE|SOFT ECoG subdural grid electrode|"Test Device (SOFT ECoG subdural grid electrode): used for recording. During epilepsy surgery, in addition to standard clinical protocol (recording with comparator device), subjects will undergo ≥ 2 additional intracranial recordings with the SOFT ECoG flexible high density electrode grid (TD). Recording will be registered pre- and post-resection.~All procedures will be conducted according to standard clinical practice. Any medical decision making will be done using the standard of care CE-marked device (CD). The investigational, non-CE marked device is not used for clinical decision making."
214473051|NCT05000515|OTHER|High-resistance inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
214657268|NCT05286879|BEHAVIORAL|Patient Navigator|Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period
214473052|NCT05000515|OTHER|Aerobic exercise|Participants will perform brisk walking.
214473053|NCT05389878|OTHER|rehabilitation|All patients addressing intemsive inpatient post stroke rehabilitation undergo a shared evidence based Integrated Care pathway that is routinely adopted in all the participating Centres
214846962|NCT04359563|BEHAVIORAL|Mindfulness-Based Intervention|"The MBI consists of four 2h online group sessions spread over eight weeks. In between sessions, online support will be offered to assist participants in their practice. Each session consists of guided mindfulness exercises (e.g., focus on the breath, body scan, breathing space, mindful yoga, insight meditation, walk meditation), sharing of experiences of these exercises, reflections in small groups, psycho-education (e.g., stress, depression, self-care), and review of home practices. An overview of core elements is given in Van der Gucht et al. (2017b).~The MBI is supported by homework assignments and audio material. Groups will include 5 participants, yielding 6 groups in total. The MBI will be delivered by highly qualified certified trainers with more than 10 years of experience in mindfulness meditation and extensive experience working with adolescents. Trainers will attend inter- and supervision moments on a regular basis to check treatment fidelity and trainer adherence."
214846963|NCT05896969|DRUG|SNK-396 - SAD cohort|A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.
214846964|NCT05896969|DRUG|SNK-396 - MAD Cohort|Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.
214846965|NCT06139055|DRUG|GSBR-1290 (Capsule/Tablet)|Participants will receive GSBR-1290 oral capsules or tablets.
214846966|NCT06139055|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral tablets.
214846967|NCT06139055|DRUG|Placebo|Participants will receive matching-placebo oral tablets.
214846968|NCT06139055|DRUG|Placebo (Capsule/Tablet)|Participants will receive matching-placebo oral capsules or tablets.
214479481|NCT05291507|DEVICE|Muse MRgFUS System|The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.
214657269|NCT05286879|BEHAVIORAL|Mobile Health Unit|Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
214657270|NCT05053659|DRUG|Loncastuximab tesirine|Loncastuximab tesirine 50 - 150 μg/kg will be administered as a 30 minutes IV infusion on Day 1 of each cycle for 6 cycles. On doses over 100 μg/kg, subsequent dosing (i.e. beyond 100 μg/kg) will be done at 50% of the dose that is administered on the first 2 cycles.
214657271|NCT05053659|DRUG|Venetoclax|"Participants will receive venetoclax at target doses of 400 - 800mg orally on days 1 - 5 of each (21 day) cycle.~On cycle 1, venetoclax dose will be escalated to reach the target dose over the course of 5 days for target dose 400mg, 6 days for target dose 600mg and 7 days for target dose 800mg~Venetoclax should preferably be given after a meal and on cycle 1 should be preceded by prophylaxis for tumor lysis syndrome (TLS)."
214657272|NCT00873275|BIOLOGICAL|bevacizumab|5mg/kg IV day 1 and 15 of each 28 day course of treatment
214657273|NCT00873275|DRUG|FOLFOX regimen|Leucovorin, 5-FU and Oxaliplatin
214657274|NCT00873275|DRUG|fluorouracil|400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
214657275|NCT00873275|DRUG|leucovorin calcium|400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
214846969|NCT01878721|RADIATION|PET/CT|positron emission tomography/computed tomography
214846970|NCT01211951|DRUG|KCT-0809|
214846971|NCT01211951|DRUG|KCT-0809|
214846972|NCT01211951|DRUG|KCT-0809|
214846973|NCT01211951|DRUG|Placebo|
214846974|NCT00479388|DRUG|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
214846975|NCT00479388|DRUG|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
214846976|NCT00479388|DRUG|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
214846977|NCT06595147|BEHAVIORAL|Structured Exercise Training|Participants will complete 12-weeks of supervised, structured moderate-to-high intensity aerobic and resistance training three times per week.
214846978|NCT06595147|BEHAVIORAL|Group-based Yoga and Stretching|Participants will complete 12-weeks of supervised group-based yoga and stretching once per week.
214473054|NCT02154412|OTHER|Respiratory Training|Assembled together using a T-shaped connector, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) \& an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. During inhalation, the subjects will initiate each breath from residual volume (RV) and to sustain the effort until their lungs feel full. During exhalation, the subjects will breathe from total lung capacity and sustain their effort until their lungs feel empty. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
214473055|NCT04781855|DRUG|Ibrutinib|Given PO
214473056|NCT04781855|BIOLOGICAL|Ipilimumab|Given IV
214473057|NCT04781855|BIOLOGICAL|Nivolumab|Given IV
214473058|NCT03624465|DEVICE|Levita Magnetic Surgical System|Device for use as a surgical tool.
214473059|NCT06471582|DIETARY_SUPPLEMENT|Artificially Sweetened Carbohydrate Beverage|Beverage containing 0.7 g carbohydrate/ kg body mass/ h as a 2:1 mixture of glucose and fructose and artificial sweetener
214473060|NCT06471582|DIETARY_SUPPLEMENT|Artificially Sweetened Beverage|Beverage containing no carbohydrates or kilocalories and an artificial sweetener
214846979|NCT03737916|OTHER|5 cc 5% Dextrose solution|Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
214846980|NCT03737916|OTHER|5 cc salin|Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
214846981|NCT05467826|DRUG|Sofosbuvir/Velpatasvir + Ribavirin|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
214473061|NCT06504407|BEHAVIORAL|Bingo Educational Game|The intervention involves Bingo games designed to educate African American/Black community members about cancer and clinical trials. During each game, educational facts are shared, and prizes promoting healthy lifestyles are awarded. Led by a Diversity Navigator, the sessions include pre- and post-test surveys to assess knowledge gain and engagement. The intervention also connects participants with needed medical services.
214289292|NCT05284214|BIOLOGICAL|Ipilimumab-containing therapy|Treatment for cancer containing ipilimumab at either 1 mg/kg or 3 mg/kg, intravenously..
214473062|NCT03213678|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
214473063|NCT03213678|PROCEDURE|Computed Tomography|Undergo CT
214473064|NCT03213678|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
214473065|NCT03213678|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214473066|NCT03213678|DRUG|Samotolisib|Given PO
214846982|NCT05467826|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
214846983|NCT01878513|DRUG|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
214846984|NCT03548662|BIOLOGICAL|Platelet-Rich Plasma|Platelet-Rich Plasma prepared by RegenKit® PRP, Regenlab SA
214846985|NCT03548662|DRUG|Hyaluronic Acid|Hyruan Plus Inj. produced by LG Life Sciences, Ltd.
214846986|NCT03548662|OTHER|Exercise|passive range of motion (PROM) exercise, active-assisted range of motion (AAROM) exercise, active range of motion (AROM) exercise, rotator cuff strengthening exercise, and peri-scapular muscle strengthening exercise
214846987|NCT00777855|DRUG|warfarin plus rifampin|warfarin 7.5mg po x 1; rifampin 600mg IV x 1
214846988|NCT00777855|DRUG|warfarin|warfarin 7.5mg po x 1
214846989|NCT01876368|DRUG|LCZ696|
214846990|NCT01876368|DRUG|Olmesartan|
214846991|NCT01876368|DRUG|Placebo of LCZ696|
214846992|NCT01876368|DRUG|Placebo of Olmesartan|
214289293|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
214289294|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
214289295|NCT01201382|BEHAVIORAL|IPT-AST|A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
214289296|NCT01201382|BEHAVIORAL|Group Counseling|Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
214473067|NCT03213678|PROCEDURE|X-Ray Imaging|Undergo x-ray
214473068|NCT04224064|DIAGNOSTIC_TEST|Blood sampling|Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
214473069|NCT04218851|DRUG|Posaconazole IV|Posaconazole (POS) 6 mg/kg body weight by IV infusion
214473070|NCT04218851|DRUG|Posaconazole PFS|Dosing based on weight-band taken orally
214473071|NCT04218851|DRUG|Posaconazole tablet|POS tablet 300 mg taken orally
214657276|NCT00873275|DRUG|oxaliplatin|85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
214846993|NCT01955044|DIETARY_SUPPLEMENT|LCPUFA supplement|
214846994|NCT01955044|DIETARY_SUPPLEMENT|placebo|
214846995|NCT06534931|PROCEDURE|High velocity low amplitude thoracic spine manipulation|Participants were supine on a treatment table. The chiropractor determined levels of apparent spinal dysfunction by means of static palpation. Participants were then asked to curl forward and bring their knees to their chest as the chiropractor placed a fist just inferior to the targeted level, anywhere between the T4 - T10 vertebrae. The participant was instructed to inhale and then exhale, at which point the chiropractor lowered the participant's torso back to the table and delivered a thrust using his body into his fist.
214846996|NCT06534931|PROCEDURE|Sham|A previously validated physiologically inert manual procedure to the thoracic spine
214473072|NCT05109468|OTHER|Quality of life questionnaire|to assess the quality of sexual life of patients treated for anal cancer treated with radiotherapy, during their treatment, then 3 months after treatment and, finally, 2 years after cancer diagnosis.
214473073|NCT06135545|COMBINATION_PRODUCT|Bupivacaine Liposome SAPB|Dilute 266mg of bupivacaine liposome with saline solution to 30ml.The patients are placed in the lateral position and the probe is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The investigators count the ribs inferiorly and laterally, until The investigators identify the fifth rib in the midaxillary line. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) are then easily identifiable by ultrasound overlying the fifth rib.
214473074|NCT06135545|COMBINATION_PRODUCT|Traditional TPVB|The TPVB was recommended by the American Society of Anesthesiologists.The transducer is placed sagitally over a transverse process(TP), placing it at the center of the ultrasound image. Alternatively, the space in-between two adjacent transverse processes may be positioned at the center. The needle is inserted using an out-of-plane technique and advanced until the central TP is contacted, or else the cranial of the two, with no or minimal angulation in the sagittal plane or the transversal plane. Subsequently, the needle is walked off the TP into the TPV space and advanced 1 to 1.5 cm beyond the TP without further visualizing the needle tip on ultrasound. Entering of the needle tip into the TPV space can result in a loss of resistance to normal saline and by visualizing anterior displacement of the pleura upon injection. Select the fifth TP as the insertion point, and inject 20ml of 0.5% ropivacaine (Hengrui, Jiangsu) into the TPV space.
214473075|NCT06478979|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to assess gait improvement in patients with Idiopathic Normal Pressure Hydrocephalus (iNPH). In this clinical trial, it is used for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH).
214473076|NCT03298945|DRUG|Miralax-Gatorade Prep|2-L split-dose Miralax-Gatorade bowel prep for colonoscopy
214473077|NCT03298945|DRUG|Golytely|4-L split dose Golytely is the current standard prep at the VA
214473078|NCT05797428|OTHER|logotherapy|The logotherapy is carried out in an individual way in this study. The full-time assistant will give the experimental group 3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy to guide the participant to find the meaning of his life and value.The location is mainly in the hospital when the participant has to return for consultation, or at the participant's home.
214473079|NCT05384860|DEVICE|Auricular Trauma Protocol (ATP) Acupuncture|Small filiform (needle) like needles use low frequency electrostimulation at eight ear points for 60 minutes while patient is sedated during surgery. All other aspects of the surgical procedure will go as planned according to the hospital's standard of care.
214473080|NCT05384860|OTHER|No Acupuncture Group|This involves not receiving the acupuncture treatment and surgery going entirely as normal according to the hospital's standard of care.
214473081|NCT06159842|COMBINATION_PRODUCT|Aminolevulinic Acid 20% Topical Solution with Blue Light|Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
214473082|NCT05851144|BEHAVIORAL|Bienestar/Neema Coordinated School Health Program (BN CSHP)|Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula, is a multi-prong intervention
214846997|NCT01451320|DRUG|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
214846998|NCT01451320|DRUG|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
214846999|NCT01451320|DRUG|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
214289297|NCT02135302|DRUG|eravacycline|Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
214289298|NCT03972553|PROCEDURE|Sugarbaker technique for repairing parastomal hernia|The bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
214289299|NCT03972553|PROCEDURE|Keyhole technique for repairing parastomal hernia|The bowel will be brought through defects in the posterior rectus sheath or contiguous peritoneum, mesh, and anterior fascia.
214473083|NCT04128995|PROCEDURE|Advanced Medical Therapy and Bariatric Surgery|Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
214473084|NCT04128995|DRUG|Advanced Medical Therapy|Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
214473085|NCT04128995|PROCEDURE|Bariatric Surgery|Vertical Sleeve Gastrectomy for youth without type 2 diabetes
214847000|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
214847001|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
214847002|NCT01264198|BEHAVIORAL|Resistance Training|Supervised Resistance Training
214847003|NCT04004845|DRUG|Cytotec|Misoprostol 25mcg vaginal
214847004|NCT04004845|DRUG|oxytocin|Oxytocin 10 IU/ml Solution for infusion
214847005|NCT04004845|DEVICE|Cervical Foley Balloon|Cervical Foley will be inflated to 80cc
214289300|NCT00709930|DEVICE|Magnetic field generator|dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
214473086|NCT04174495|DIAGNOSTIC_TEST|DXA and CT-scan|DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
214473087|NCT06485310|OTHER|Teleconsultation for psychological support|Teleconsultation with a nurse for psychological support, after the diagnosis has been announced, before hospitalization for the first treatment (chemotherapy, surgery, radiotherapy) in addition to the standard practice
214473088|NCT02313194|DEVICE|Epidural Stimulation|Determine if epidural stimulation can improve motor function
214473089|NCT02313194|DRUG|Buspirone|Determine if the pharmacological agent in combination with the stimulator can improve motor function.
214473090|NCT06249984|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214473091|NCT06249984|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
214473092|NCT06249984|BEHAVIORAL|Smokeless Tobacco Use|Use moist snuff
214473093|NCT06249984|OTHER|Survey Administration|Ancillary studies
214473094|NCT06822192|DEVICE|temporally interfering electrical stimulation|temporally interfering electrical stimulation
214473095|NCT06342466|DRUG|Bortezomib|Bortezomib 1.3mg/m2 sc weekly
214847006|NCT01755117|OTHER|Sciatic, femoral, obturator nerve blocks|
214847007|NCT01755117|OTHER|Sciatic nerve block, posterior lumbar plexus block|
214847008|NCT02962089|DIETARY_SUPPLEMENT|Branched chain amino acids (BCAA)|
214847009|NCT02962089|DIETARY_SUPPLEMENT|Placebo|
214847010|NCT02260258|DRUG|Rocuronium|Neuromuscular Blockade
214847011|NCT02260258|DRUG|Normal Saline|Normal Saline
214289301|NCT00709930|DEVICE|Placebo magnetic field generator|Placebo device with no magnetic fields
214289302|NCT01112241|DRUG|albuterol plus tiotropium|Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.
214289303|NCT00400751|BEHAVIORAL|FAMCON (Family Consultation)|
214289304|NCT01218230|DRUG|Intravitreal Pegaptanib|Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
214289305|NCT01550302|PROCEDURE|Superficial Cervical Plexus Block|"At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site."
214289306|NCT01550302|DRUG|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
214473096|NCT06342466|DRUG|Pomalidomide|4mg per day taken orally on 1-21 of repeated 28-day cycles
214473097|NCT06342466|DRUG|Dexamethasone|Dexamethasone 20mg-40mg weekly
214473098|NCT03702270|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
214473099|NCT05980533|DIAGNOSTIC_TEST|Ultrasound|Ultrasound at hospital discharge and at follow up at 7-10 days
214473100|NCT03040596|DRUG|Fluticasone propionate|fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
214473101|NCT03040596|BEHAVIORAL|Standard voice therapy|Standard voice therapy sessions
214473102|NCT06823206|OTHER|Sensorimotor training with movement representation techniques|Sensorimotor training will be implemented with movement representation techniques using a standardized retraining sequence of a shoulder control exercise during arm elevation with 3 phases: Phase 1: Action Observation Training; Phase 2: Mirror therapy; and Phase 3: Sensorimotor training of the involved arm. Each session will last 60 minutes, with one supervised intervention session over the 12 weeks.
214473103|NCT05062200|DRUG|JNJ-77242113|JNJ-77242113 will be administered as an oral tablet.
214473104|NCT05062200|DRUG|Placebo|Matching placebo will be administered as an oral tablet.
214473105|NCT06006247|DRUG|CVN424 150 mg|Participants will receive 1 CVN424 tablet (150 mg) per day.
214473106|NCT06006247|DRUG|Placebo|Participants will receive 1 matching placebo tablet per day.
214473107|NCT06674954|PROCEDURE|Regional Anesthesia|"After the patients are monitored and in the supine position, after appropriate field sterilization, interscalene brachial plexus block, superficial cervical block, and supraclavicular brachial plexus block will be applied to these patients under ultrasound guidance. Total of 40 ml of local anesthetic solution (20 ml %0.5 bupivacaine + 10 ml %2 lidocaine + 10 ml physiological saline) will be prepared; 15 ml will be used for interscalene brachial plexus block, 10 ml will be used for superficial cervical block, and 15 ml will be used for supraclavicular brachial plexus block.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
214847012|NCT03655119|BEHAVIORAL|Parent toolkit|The parent tookit is a resource that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth.
214847013|NCT03655119|BEHAVIORAL|Enhanced Care|PES clinical staff will receive training on the best practices in brief crisis-focused interventions in emergency settings with parents and youth.
214847014|NCT03655119|BEHAVIORAL|Caring Follow-Up Messages|Parents will receive caring contacts via phone, text, or email to provide support, additional education, and problem solving assistance in the days and weeks post-discharge.
214847015|NCT05312086|OTHER|MRI|"Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes.~Performing MRI does not require the injection of contrast products or radiopharmaceuticals."
214847016|NCT05925725|DRUG|• harpagozid • boswellin = LOXACON|Exercise therapy
214847017|NCT06043622|OTHER|Optical coherence tomography angiography|Optical coherence tomography angiography
214847018|NCT06043622|OTHER|ophthalmological exam|ophthalmological exam
214847019|NCT00556101|PROCEDURE|Whole body magnetic resonance angiography|
214847020|NCT01644149|DEVICE|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
214847021|NCT01644149|DEVICE|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
214473108|NCT06674954|PROCEDURE|General Anesthesia|"Anesthesia induction will be performed with 2.5 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl. Maintenance will be achieved with sevoflurane (MAC: 0.9-1.0) and remifentanil (0.05-0.2 mcg/kg/min). Remifentanil titration will be done according to basal heart rate and blood pressure.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
214473109|NCT00492817|PROCEDURE|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
214473110|NCT06809257|BEHAVIORAL|Exercise|12 week moderately aerobik exercise
214473111|NCT06569407|OTHER|Online Educational Intervention|An educational program for EBP based on the online learning model was planned to be developed based on the literature and expert opinions. In the program, in line with the literature, the introduction to the EBP, the importance of EBP, EBP steps, clinical research question design in line with PICO, and introduction of EBP databases. It is planned to include topics such as literature search strategies, types of research, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflection of EBP on patient care and clinical decision-making processes, and it is planned to determine the final version of the education content with expert opinions. The program will include recorded videos, slides and documents for each module. The content of the program will be integrated into the Koç University Online Programs Platform by the experts working at Koç University Educational Technologies Unit.
214479482|NCT04882904|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
214479483|NCT06862505|PROCEDURE|Biopsy|Biopsy of soft tissue were taken randomly at 8 or 16 weeks to compare soft tissue
214847022|NCT01644149|BIOLOGICAL|2011-2012 Fluzone trivalent inactivated influenza vaccine|
214847023|NCT06427187|DEVICE|an array of devices are used in thrombectomy. These include guide catheters, stent-retrievers, microcatheters, aspiration catheters, and aspiration pump systems|each patient with distal vessel occlusion subjected to mechanical thrombectomy using aspiration technique or stent retriever
214847024|NCT03357354|BEHAVIORAL|collective workshop|diet, sports games, food budget, feeling of satiety and hunger, self-image
214847025|NCT04470531|DRUG|oral co-trimoxazole|oral co-trimoxazole + standard therapy
214847026|NCT01411488|DEVICE|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
214847027|NCT03513536|OTHER|Citrus-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
214847028|NCT03513536|OTHER|Mint-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
214847029|NCT03513536|OTHER|Spice-Scented Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
214847030|NCT03513536|OTHER|Control|This control is a blend of plant derived oils which have been expressed from crude plant matter.
214847031|NCT05555927|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
214847032|NCT00265772|DRUG|MODULEN IBD (R) (specific Enteral Nutrition)|
214847033|NCT00265772|DRUG|prednisolon|
214289307|NCT03403660|OTHER|non White coat|Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
214289308|NCT02042378|DRUG|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
214289309|NCT01133483|DRUG|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
214289310|NCT03242057|OTHER|NAVA|Infant will be extubated to NAVA, settings based per protocol
214289311|NCT03242057|OTHER|NIPPV|Infant will be extubated to NIPPV, settings detailed in protocol
214289312|NCT00076284|DRUG|GW873140|
214289313|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy with proctoring|Implementation standardised laparoscopic right hemicolectomy with proctoring
214289314|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy without proctoring|Implementation standardised laparoscopic right hemicolectomy without proctoring
214289315|NCT02547454|DRUG|Methoxy polyethylene glycol-epoetin beta|
214289316|NCT04104945|RADIATION|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
214289317|NCT04203784|OTHER|Plasma concentration measurements|Plasma concentration measurements
214289318|NCT05196165|OTHER|No Intervention|No investigational product (IP) will be administered in this study
214847034|NCT06109701|PROCEDURE|Debridement with ultrasonic device and scaling with plastic curettes|Supragingival and subgingival debridement
214473112|NCT06569407|OTHER|Educational Booklet|An educational booklet for EBP was planned to be developed based on the literature and expert opinions. The learning objectives and content of the educational booklet to be developed will be created by considering Bloom\&#39;s taxonomy. In line with the literature, it is planned to include topics such as introduction to EBP, importance of EBP, evidence-based practice steps, clinical research question design in line with PICO, introduction of evidence-based databases, literature search strategies, research types, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflections of EBP on patient care and clinical decision-making processes, and finalization of the booklet topics with expert opinions.
214847035|NCT06109701|PROCEDURE|Debridement with erythritol based air-polishing powde|Supragingival and subgingival debridement
214473113|NCT06809465|DIETARY_SUPPLEMENT|Bactopral®|Oral Probiotic Bifidobacterium bifidum PRL2010 supplement
214473114|NCT06809465|OTHER|Plcebo|Oral placebo
214473115|NCT06374589|DEVICE|Closed-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
214473116|NCT06374589|DEVICE|Conventional|Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.
214473117|NCT04250051|DRUG|Cytarabine|Given IV
214473118|NCT04250051|BIOLOGICAL|Filgrastim|Given SC
214473119|NCT04250051|DRUG|Fludarabine|Given IV
214847036|NCT04565496|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
214847037|NCT04851275|BEHAVIORAL|Physicians trained in shared decision making|Physicians in this group were trained in shared decision making
214847038|NCT04851275|BEHAVIORAL|Physicians were not trained in shared decision making|Physicians did not receive training in shared decision making
214906904|NCT01019343|PROCEDURE|Peripheral Nerve Stimulation|Constant-current, 0.1 to 0.5 ms square-wave single pulses of electrical stimulation will be delivered through standard bar electrodes to nerves of the upper limb or of the lower limb. To study somatosensory evoked potentials, for example, the stimulus intensity will be set at just above the motor threshold for evoking a slight limb movement. Location of the electrical stimulation will depend on the specific objective of the sub-study. Peripheral nerve stimulation might be delivered during other types of experiments as well.
214473120|NCT04250051|DRUG|Fludarabine Phosphate|Given IV
214473121|NCT04250051|DRUG|Ivosidenib|Given PO
214473122|NCT06808295|DRUG|Dexmedetomidine Hydrochloride|drug will be given before induction and anesthetic doses and hemodynamics will be assessed pre- intra and postoperative
214473123|NCT06810492|DRUG|Ribociclib; abemaciclib; palbociclib; Dalpiciclib|"Neoadjuvant therapy: CDK4/6 inhibitor combined with endocrine, a total of 6 cycles, 1 cycle every 28 days.~CDK4/6 inhibitors (choose one of the following four types):~* Dalpiciclib 125 mg orally once a day d1-21 every 28 days for a cycle (3 weeks/1 week off)~* Palbociclib 125 mg orally once a day, d1-21, every 28 days in cycles (3 weeks/1 week off)~* Abemaciclib 150 mg orally twice daily in 28-day cycles (may be reduced to 100 mg orally twice daily if not tolerated)~* Ribociclib 400 mg orally once a day in a 28-day cycle Endocrine therapy drugs: take according to the label. Premenopausal patients need to be treated for ovarian function suppression."
214473124|NCT06808568|COMBINATION_PRODUCT|STIMULAN VG|
214473125|NCT04745390|RADIATION|Radiation therapy|Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.
214473126|NCT05847478|OTHER|Auricular acupressure of traditional Chinese Medicine|"The participants will be randomly assigned to receive the auricular point patch therapy.~The selected acupoints include Shenmen, hungry point, endocrine, stomach, mouth and subcortical. The opaque patch with vaccaria seed is used for acupoint pressing. Pressing the acupoints once a day before and after eating, each time for 1 minute, lasting for 2-3 days, follow up visit once a week. The intervention period is 3 months."
214473127|NCT05847478|BEHAVIORAL|Intermittent low carbohydrate diet|"The participants will be randomly assigned to the intermittent low carbohydrate diet group.~The intermittent carbohydrate diet includes 7 days of low carbohydrate diet within 2 weeks (consecutive or nonconsecutive, carbohydrate intake be controlled as ≤ 50g per day). The study duration is 3 months, including 1-month intervention period and 2-month self-maintenance period."
214473128|NCT05847478|BEHAVIORAL|Health education|Health education is conducted once a week during 3-month intervention for all participants. Health education including the understanding of childhood obesity and cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
214473129|NCT06853821|OTHER|Comfort Theory Based Care|In the research, this group includes care-based intervention
214473130|NCT06853821|OTHER|Virtual Reality Glasses|In the research, this group includes interventions with virtual reality glasses.
214473131|NCT06855446|BEHAVIORAL|Intervention with social robot NAO|12 session of 30 minutes, one sessione per week with social robot NAO and a therapist, working on social intransitive gestures
214473132|NCT06855446|BEHAVIORAL|Treatment as usual|Psychomotor/behavioral or speech therapy as usual
214473133|NCT06223139|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength will be measured by 3 efforts.
214473134|NCT06810856|DEVICE|Abilar® Resin Salve|Abilar® Resin Salve is a medical-grade Norway spruce (Picea abies) resin-based topical medical device, classified as a Class IIb medical device in the EU. It is designed for wound care and skin protection, forming a moist healing barrier while exhibiting antimicrobial properties. It contains 10% of medical-grade Picea abies resin.
214473135|NCT06814964|DRUG|Low dose group|The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma × 0.009 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
214473136|NCT06814964|DRUG|Medium dose group|The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma × 0.018 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
214473137|NCT06814964|DRUG|High dose group|The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma × 0.027 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
214473138|NCT06813859|OTHER|exercise testing|incremental cycling test on a bicycle ergometer
214473139|NCT06814652|DRUG|Trodon® Hemofarm|Consent was taken from each patient prior to the enrollment into the study during the first interview and 2 ml of blood was withdrawal for the CYP2D6 genotyping. After the cesarean section surgery, each patient received one dose of 100mg/2ml Trodon® Hemofarm for treating the postpartum pain and the patients were monitored for 24 hours. Follow-up was performed for each enrolled patient in which the VAS score, blood pressure, heart rate, oxygen saturation and any new effects after 1 hour, 6 hours of tramadol administration were recorded. In addition, after 24 hours evaluations for nocturnal pain, dietary state and bowel movement were performed.
214473140|NCT06807840|OTHER|influenza virus infection|Participants with active influenza virus infection will be enrolled in this study.
214473141|NCT06548958|PROCEDURE|Second Stem Cell Transplantation (SCT2)|"1. Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally; Day -6: Total Body Irradiation (TBI) 4Gy; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion;~2. Donor Stem Cell Infusion (Second Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."
214473142|NCT06651762|PROCEDURE|unilateral Radiofrequency|unilateral genicular nerve cooled radio frequency ablation pre-operative
214473143|NCT06651762|PROCEDURE|bilateral Radiofrequency|bilateral genicular nerve cooled radio frequency ablation pre-operative
214473144|NCT06651762|PROCEDURE|Epidural|Patients will receive epidural anesthesia intra operative and epidural analgesia post-operative
214473145|NCT06814366|OTHER|music and white noise intervention|The experimental groups were played a combination of music and white noise through headphones that blocked ambient noise during the surgical procedure. A playlist consisting of the popular songs of the era was prepared in advance. The patient could choose the music they wanted to listen to from the playlist using a hand-held tablet.
214473146|NCT06814366|OTHER|music intervention|The experimental groups were played music a through headphones that blocked ambient noise during the surgical procedure. A playlist consisting of the popular songs of the era was prepared in advance. The patient could choose the music they wanted to listen to from the playlist using a hand-held tablet.
214473147|NCT06814106|DRUG|Enlicitide Chloride|Oral Capsule
214847039|NCT05924334|OTHER|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
214847040|NCT05924334|OTHER|placebo|placebo
214847041|NCT04590768|OTHER|Fermotein based meals|various meal products: bread, soup and an occasional burgers
214847042|NCT04590768|OTHER|Matching control meals with whey protein and wheat bran|various meal products: bread, soup and an occasional burgers
214847043|NCT02483338|BEHAVIORAL|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
214847044|NCT05839145|OTHER|Strength force measurment|The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)
214847045|NCT05839145|OTHER|Time tests|Lower and upper limb capacities of the patients will be measured during timed tests
214847046|NCT05839145|OTHER|Motor scales|Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)
214847047|NCT05839145|OTHER|Questionnaires|Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)
214847048|NCT05839145|DEVICE|Accelerometry|Patients physical activity will be measured at home using accelerometer sensors
214847049|NCT05839145|OTHER|MNR|Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs
214847050|NCT05839145|OTHER|Bio-impedance analysis|The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)
214847051|NCT01651546|BEHAVIORAL|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
214847052|NCT01610063|OTHER|Pharmacogenomic algorithm|Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
214906905|NCT01019343|PROCEDURE|EMG|EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
214473148|NCT06814106|DRUG|Placebo|Placebo oral capsule matching enlicitide chloride
214473149|NCT03899428|DRUG|Durvalumab|Durvalumab 1500 mg IV (intravenous infusion)
214473150|NCT03899428|DRUG|Sorafenib|Prescribed by physician.
214473151|NCT03899428|DRUG|Lenvatinib|Prescribed by physician.
214473152|NCT03899428|DRUG|Regorafenib|Prescribed by physician.
214473153|NCT03899428|DRUG|Cabozantinib|Prescribed by physician.
214473154|NCT06220721|DRUG|Nifedipine ER|Initiation of nifedipine ER postpartum at randomly assigned threshold during the first 6 weeks postpartum.
214657277|NCT00873275|DRUG|ursodiol|Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.
214657278|NCT00873275|GENETIC|RNA analysis|Analysis on discard tissues
214847053|NCT05057026|OTHER|Training Program Adult Mental Health Practice Support Program|"The Adult Mental Health Practice Support Program (PSP) was designed in 2009 by the General Practice Services Committee (GPSC) to address needs expressed by the province's family physicians to improve patient care in British Colombia. Its content and delivery model has been designed using evidence-based key ingredients and implication factors understood to be important for effective stigma reduction. These include the following:~* the use of contact-based education,~* skills-building to increase confidence and provide another management option with or without drugs particularly if access to mental health support services is difficult or absent~* tools - using the principles of cognitive behavioural theory~The training will be delivered virtually over a total of 4 sessions two weeks apart, covering an 8-week period. A two hour virtually delivered booster session will be provided to students approximately one year after the delivery of the initial training."
214847054|NCT06070974|DIAGNOSTIC_TEST|CMR and blood collection|All patients enrolled will undergo 2 CMR examination (within 3-5 days post PCI and after six months), and blood collection at third day after PCI (T0). Patients recruited at Centro Cardiologico Monzino will be subjected to a blood withdrawal also at different time points: 1- 3- 6 months after STEMI (T1, T2, and T3 respectively).
214847055|NCT06608355|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen of brain.
214847056|NCT06425445|PROCEDURE|Measurement of maximal expiratory pressures during forced static expiratory maneuvers sustained over 5 seconds|Participants perform forced static expiratory maneuvers sustained over a five second period
214847057|NCT06609434|PROCEDURE|Radiofrequency ablation|This study is the first to apply radiofrequency ablation to multiple recurrent intrahepatic lesions of colorectal cancer liver metastases.
214289319|NCT01331798|DEVICE|Cohera TissuGlu Surgical Adhesive|TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
214289320|NCT01331798|PROCEDURE|Control- Standard of care|Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
214289321|NCT03945578|OTHER|Pelvic Floor muscle training - PFMT|Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).
214289322|NCT03945578|OTHER|Visceral Manual Therapy - VMT|Visceral manual therapy:is a manual treatment intended to the release of visceral fascias. The VMT protocol was based on the work proposed by Vanderheyden-Busquet (2014). To act on the abdominal and pelvic visceral fasciae, the VMT was performed through slow and deep mobilizations, respecting the participant's tissue resistance and painful response, in different regions of the abdômen.
214289323|NCT03945578|OTHER|Manual Sham Therapy - MST|The manual sham therapy protocol was perfomed by gentle techniques applied to the thoracic spine, scapular waist and cervical spine
214289324|NCT01756547|DRUG|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
214289325|NCT01756547|DRUG|Placebo|
214289326|NCT04107610|DEVICE|I-PAS|I-PAS is a portable, head-mounted display goggle system with integrated eye tracking technology. I-PAS records eye movements in response to visual and auditory stimuli.
214289327|NCT05378880|BEHAVIORAL|Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission|The study teams will work with communities and authorities to develop, implement and evaluate a multifaceted intervention bundle that will optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission, by targeting the general public (including farmers) and medicine stores.
214289328|NCT04073069|DRUG|The DR group|Miscible liquid of diprospan and ropivacaine in this study will be peri-incisional scalp infiltration with 0.5 ml diprospan, 15 ml 1% ropivacaine and 14.5 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
214289329|NCT04073069|DRUG|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
214473155|NCT06860568|OTHER|Retrospective Study|Retrospective Study This study will use a retrospective Test Dataset of eye scans collected by Optina under different study protocols. MHRC H5 Images collected as part of Optina studies CIP-22-003, CIP-22-004, DOC100463 or RWD-24-011 will be reviewed by an Optina Data Analyst and flagged for potential match to the Target Population. Of the flagged images, 40 will be selected and allocated to the Test Dataset. All selected images must have a matching OCT image for review as part of the Reference Data. The Test Dataset will be documented in the CIP-24-015 data spreadsheet and archived in the CIP-24-015 central files.
214289330|NCT02356224|DRUG|SHR3824|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
214289331|NCT02356224|DRUG|Placebo|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
214289332|NCT04557371|OTHER|Serum|Participants will topically apply the serum to the face as per normal home use application in place of their current facial serum product.
214289333|NCT04557371|OTHER|Lotion|Participants will topically apply lotion to the face as per normal home use application in place of their current facial lotion product.
214473156|NCT05868733|DRUG|Day 1 Lower Dose (2×106 pfu)|rVSV∆G-LASV-GPC
214473157|NCT05868733|DRUG|Day 1 Higher Dose (1×107 pfu)|rVSV∆G-LASV-GPC
214473158|NCT05868733|DRUG|Placebo|Placebo
214473159|NCT04173949|DRUG|Ramipril 2.5 MG|3 month of treatment with daily Ramipril 2.5 MG
214473160|NCT02065765|BIOLOGICAL|Ramucirumab|Administered intravenously (IV)
214473161|NCT05645757|DRUG|Ertapenem|A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics
214473162|NCT05645757|OTHER|Placebo|Placebo
214473163|NCT05645757|DRUG|WCK 6777|A combination of ertapenem (ERT) and zidebactam (ZID)
214473164|NCT05645757|DRUG|Zidebactam|A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class
214847058|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 1 (Reference)|Formulation 1 (FM1) powder for oral suspension.
214847059|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 2 (Test)|Formulation 2 (FM2) powder for oral suspension.
214847060|NCT04405739|DRUG|EIDD-2801|Oral capsule of EIDD-2801
214847061|NCT04405739|DRUG|Placebo|Oral placebo capsule
214847062|NCT02912767|BEHAVIORAL|questionnaire|A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
214847063|NCT04252716|DEVICE|OVD|Intraocular administration
214847064|NCT01436643|DRUG|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
214847065|NCT01436643|DRUG|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
214847066|NCT01436643|DRUG|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
214847067|NCT01436643|DRUG|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
214847068|NCT03171064|BEHAVIORAL|Resistance and Endurance Exercise|Machine-based, 2x/week endurance and resistance training for 12 weeks
214473165|NCT06342986|DRUG|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.
214473166|NCT06342986|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.
214847069|NCT04736758|DRUG|GP681 tablet|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
214847070|NCT04736758|DRUG|GP681 Simulant|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
214847071|NCT05002114|DRUG|Cannabidiol|Topical CBD cream - special formulation
214847072|NCT05002114|OTHER|Placebo|Not the drug
214847073|NCT01109758|DRUG|Fenofibrate|145 mg
214847074|NCT03069417|BEHAVIORAL|Integrating Nuanced Support for Perinatal adherence and Depression|A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
214847075|NCT01867606|BIOLOGICAL|serum-derived bovine immunoglobulin protein isolate|Given PO
214847076|NCT01867606|OTHER|placebo|Given PO
214847077|NCT01867606|OTHER|laboratory biomarker analysis|Correlative studies
214847078|NCT01867606|OTHER|quality-of-life assessment|Ancillary studies
214473167|NCT06342986|DRUG|CY|CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.
214473168|NCT03924635|COMBINATION_PRODUCT|SYMBICORT and salbutamol|SYMBICORT will be given in a TURBOHALER. Salbutamol will be given in a pressurised metered dose inhaler.
214473169|NCT05238103|COMBINATION_PRODUCT|Corrie Hybrid Cardiac Rehabilitation Program|The Corrie Hybrid Cardiac Rehabilitation Program is a multi-component intervention. It consists of the Corrie smartphone app for cardiovascular health optimization which is paired with wristband device (Apple Watch or Fitbit), Bluetooth-enabled Omron blood pressure monitor and exercise resistance bands. The program also includes individualized treatment plan development, setting health goals and communication with trained Corrie Health Coach. Furthermore, the intervention includes motivational text messages sent to participants throughout the study to aid with risk factor modification.
214473170|NCT00539591|DRUG|Peginterferon alfa-2b|Given either IV or SQ. Therapeutic drug class: interferon.
214473171|NCT00539591|DRUG|Temozolomide|Given PO. Therapeutic drug class: antineoplastic agent.
214473172|NCT00539591|DRUG|Recombinant interferon alfa-2b|Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
214473173|NCT04972201|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
214473174|NCT06839066|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214473175|NCT06839066|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214473176|NCT06839066|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214847079|NCT01867606|OTHER|questionnaire administration|Ancillary studies
214906906|NCT01019343|PROCEDURE|Trancutaneous spinal direct current stimulation (tsDCS)|Direct current (DC) stimulation is a non invasive tool used to promote plasticity of the central nervous system. Recently, DC stimulation has been applied to the human spinal cord, and known as transcutaneous spinal direct current stimulation (tsDCS).
214906907|NCT07036523|DRUG|BI 765423|BI 765423
214473177|NCT05359328|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line|Measurement of physiological parameters
214473178|NCT06834438|GENETIC|ST002|Single multi-point intra-tumoral injection of ST002, a lentiviral vector designed to drive expression of the NF2 protein product, Merlin.
214473179|NCT05919589|OTHER|Care Integration for Children With Special Health Care Needs|The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
214847080|NCT06309914|DIETARY_SUPPLEMENT|Placebo|Subjects will consume one capsule of the Placebo twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
214473180|NCT06278558|OTHER|Interviews with a psychologist/psychiatrist|All patients with a high score (≥11) on the HADS anxiety and/or depressive symptoms scale and who are not already receiving known psychological treatment or treatment mentioned in the file will be contacted by telephone by the investigator or a qualified person designated by him/her in order to conduct a telephone interview with the patient and refer him/her to a psychologist or psychiatrist if necessary. The number and percentage of consultations with a psychologist or psychiatrist following this telephone interview will be calculated in order to highlight the benefits of such a practice (HADS assessment + telephone interview with +/- referral) for earlier and easier referral. Depending on the number of patients contacted, consideration may be given to testing the effect of this approach on post-traumatic development.
214473181|NCT04118439|OTHER|Motor Imaginery and Action Observation|A set of tasks done with the shoulder, first with an Action Observation perspective and then asked to perform this tasks with motor imaginery
214847081|NCT06309914|DIETARY_SUPPLEMENT|Enovita Grape Seed Extract|Subjects will consume one capsule of Enovita twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
214847082|NCT06309914|DIETARY_SUPPLEMENT|Mirtoselect Bilberry Extract|Subjects will consume one capsule of Mirtoselect twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
214847083|NCT06309914|DIETARY_SUPPLEMENT|Virtiva Plus Ginko Biloba Extract|Subjects will consume one capsule of Virtiva Plus twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
214847084|NCT06175715|PROCEDURE|carotid endarterectomy|carotid endarterectomy under local or general anethesia
214473182|NCT03811886|DRUG|Natalizumab|"Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study."
214473183|NCT01960452|BEHAVIORAL|Serial awakenings|The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
214657279|NCT00873275|GENETIC|gene expression analysis|Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial
214657280|NCT00873275|GENETIC|polymerase chain reaction|Analysis on discard tissues
214657281|NCT00873275|GENETIC|western blotting|Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
214473184|NCT06162390|DRUG|Remifentanil|"Following a sequential allocation scheme, the predetermined Ce of remifentanil for each patient will be determined by the Dixon up-and-down method. The Ce of remifentanil for the first patient will be 4.0 ng/ml, and then the remifentanil Ce will be increased or decreased in 0.5 ng/ml increments for subsequent patients depending on the success or failure of intubation.~The Ce of remifentanil to provide acceptable intubation at low dose neuromuscular blockade, the primary outcome, will be determined by obtaining seven crossovers of patients with acceptable intubation/unacceptable intubation and then calculating the mean of the midpoint doses for each independent pair of patients. According to previous studies that estimated EC50 by Dixon's up-and-down method, 6-8 failure/success crossover pairs are required, so this study aims to collect independent data of 7 pairs of intubation acceptable/unacceptable patients."
214473185|NCT06555081|DRUG|Ruxolitinib IR|Tablet
214473186|NCT06555081|DRUG|Ruxolitinib XR|Tablet
214473187|NCT04414722|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
214473188|NCT04414722|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
214473189|NCT04414722|OTHER|Control Yogurt|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
214473190|NCT05764876|DRUG|Linezolid Oral Tablet|Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
214473191|NCT05764876|DRUG|Azithromycin Oral Tablet|Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
214473192|NCT03956888|DRUG|N-acetylcysteine|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
214473193|NCT06024564|DEVICE|Sonu Acoustic Resonance Therapy|Participants will receive Sonu treatment twice a day for 90 days
214473194|NCT04249362|DRUG|Durvalumab|All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
214847085|NCT01246713|DRUG|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
214847086|NCT01246713|DRUG|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
214847087|NCT04991012|DEVICE|PDT Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
214289334|NCT04557371|OTHER|Cream|Participants will topically apply cream to the face as per normal home use application in place of their current facial cream product.
214289335|NCT02164812|DRUG|Moxifloxacin|
214289336|NCT02164812|DRUG|Placebo|
214289337|NCT02164812|DRUG|Efavirenz|
214289338|NCT05633420|DRUG|Pyramax|"Participant body weight~* ≥65 kg (Pyramax 4 tablets)~* ≥45 kg and \<65 kg (Pyramax 3 tablets)"
214289339|NCT03329950|DRUG|CDX-1140|CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
214289340|NCT03329950|DRUG|CDX-301|CDX-301 will be injected once a day for five days before Cycles 1 and 2.
214289341|NCT03329950|DRUG|pembrolizumab|pembrolizumab will be administered every 3 weeks.
214289342|NCT03329950|DRUG|Chemotherapy|Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
214473195|NCT06052839|DRUG|Pembrolizumab|Immunotherapy that works by helping the immune system to kill cancer cells by targeting and blocking a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
214473196|NCT06052839|DRUG|Carboplatin|A chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
214473197|NCT06052839|DRUG|Paclitaxel|A chemotherapeutic agent used as a treatment for various cancers; paclitaxel is a mitotic inhibitor.
214473198|NCT05938543|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces an electrical current in neurons and allows for modulation of neural circuitry.~Other Name: iTBS"
214473199|NCT04819243|DRUG|Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab|"* Palbociclib 125mg~* AI~* GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist)~* Talazoparib~* Atezolizumab"
214473200|NCT04819243|DRUG|Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,|"* Palbociclib 125mg~* AI~* GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist)~* Talazoparib"
214473201|NCT03655028|BEHAVIORAL|rhythmically auditory stimulation enhanced music|Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program
214473202|NCT03655028|BEHAVIORAL|control|Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program
214473203|NCT03513302|DIETARY_SUPPLEMENT|placebo|2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
214473204|NCT03513302|DIETARY_SUPPLEMENT|nitrate|2 x 70 mL concentrated beet root juice per day for 14 days.
214473205|NCT06449781|DRUG|Lutetium (177Lu) vipivotide tetraxetan|The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan
214473206|NCT05732779|OTHER|DOT intervention|A mobile health application developed by eMocha Health Inc. facilitates asynchronous mobile video directly observed therapy (DOT) intervention, empowering users to track dose-by-dose medication adherence
214473207|NCT05618587|DRUG|Lithium|Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.
214473208|NCT05618587|DRUG|Placebo|Inactive pill
214473209|NCT06285448|DRUG|Lecanemab|Bi-weekly infusions of lecanemab \[exposure\].
214847088|NCT04991012|DRUG|Triamcinolone (Substance) therapy side|th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
214906908|NCT07036523|DRUG|Placebo|Placebo to BI 765423
214906909|NCT06708936|BIOLOGICAL|KSD-201|Patients will receive approximately 5x10\^6 cells/dose DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
214906910|NCT06882746|DRUG|BI 765049|BI 765049
214906911|NCT07038746|DRUG|Inhaled Epinephrine|"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."
214906912|NCT06724614|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
214906913|NCT06724614|DRUG|Placebo|Placebo
214906914|NCT06886009|DRUG|Spevigo®|Intravenous
214289343|NCT05174897|BEHAVIORAL|emotional liberation technique|experimental group; The child, to whom an intravenous catheter will be applied, is placed on a stretcher. pain ve score fear will be evaluated before the procedure. Then, the emotional liberation technique (EFT) will be applied for 10 minutes and an intravenous catheter will be applied to evaluate the pain and fear scores during and after the procedure.
214289344|NCT05333146|PROCEDURE|Cardiac Surgery|Cardiac surgery (e.g. coronary bypass surgery, cardiac valve surgery, ascending aortic surgery)
214289345|NCT00540826|DRUG|Atomoxetine|in-label use
214289346|NCT00540826|DRUG|stimulants (any approved ADHD medication)|in-label use
214289347|NCT03694821|DRUG|Ketorolac Tromethamine Injection|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
214289348|NCT03694821|DRUG|Methylprednisolone Acetate Injection|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
214289349|NCT03694821|DRUG|Hylan G-F 20|One knee injection of Hylan G-F 20 (Synvisc-One)
214289350|NCT02805101|DRUG|Biodentine|Biodentine is going to be used as the sealing agent for the perforation.
214289351|NCT02805101|DRUG|MTA|MTA is going to be used as the sealing agent for the perforation.
214289352|NCT03181568|DEVICE|MolecuLight i:X™ Imaging Device|Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
214289353|NCT03181568|PROCEDURE|Wound care|Standard wound care of chronic wounds e.g. sampling, debridement, infection control
214289354|NCT00018200|DRUG|Desipramine|Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
214289355|NCT00018200|DRUG|Fluoxetine|Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
214289356|NCT00018200|DRUG|Benztropine|Daily dose 0.125 to 0.5mg
214289357|NCT01747798|DRUG|auranofin|Given PO
214289358|NCT01747798|OTHER|laboratory biomarker analysis|Correlative studies
214289359|NCT04316923|DIAGNOSTIC_TEST|ECG|ECG will be performed during each visit in the study group.
214289360|NCT04316923|DIAGNOSTIC_TEST|24-hour ECG monitoring|24-hour ECG monitoring will be performed during each visit in the study group.
214289361|NCT04316923|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test (CPET)|CPET will be performed during the first and the last visit in the study group.
214289362|NCT04316923|DIAGNOSTIC_TEST|Cardiac biomarkers|Cardiac biomarkers will be assessed during each visit in the study group.
214289363|NCT02888444|DRUG|Varenicline|Two 0.5mg tablets taken twice daily
214289364|NCT02888444|BEHAVIORAL|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
214289365|NCT02888444|DRUG|Placebo|Two 0.5mg tablets taken twice daily
214289366|NCT06177587|OTHER|Assesment of biomarkers in acute coronary syndromes|Collection of 20ml of blood from peripheral vein.
214289367|NCT05013593|DIETARY_SUPPLEMENT|Red Clover Extract (RCE)|Red clover extract containing isoflavones Formononetin and biochanin A together with a heterogenous culture of probiotic lactic acid bacteria, and a natural sugar free raspberry/orange flavor. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening together with a meal)
214289368|NCT05013593|OTHER|Placebo (PL)|Placebo containing water, brown coloring, and natural sugar free raspberry/orange flavor.
214289369|NCT05045014|OTHER|Balance assessment|Romberg test and one-leg standing test will be used.
214289370|NCT05045014|OTHER|Unterberger test|During 50 steps, he will count in place with 45 degrees of hip flexion, and after 50 steps, the angle of rotation between the first position and the final position of the right foot will be measured with the help of a goniometer and the displacement distance.
214289371|NCT05045014|OTHER|Corsi Block Tapping (mobıl app)|Spatial memory will be evaluated.
214289372|NCT05045014|OTHER|Navigation performance|Two triangles (one equilateral, one oblique triangle, at 30°, 60° and 90° angles respectively) with route segment lengths between 150 and 300 cm will be marked on the floor and the participants will be asked to complete the task with their eyes closed. The final deviation amount will be recorded.
214289373|NCT05045014|OTHER|Cobb angle measurement|It will be evaluated with the help of X-ray.
214289374|NCT05045014|OTHER|Scolio Detector (mobıl app)|The degree of rotation will be measured with the mobile application called Scolio Detector.
214289375|NCT06046391|BIOLOGICAL|LP-003 dose 1|Liquid in vial
214289376|NCT06046391|BIOLOGICAL|LP-003 dose 2|Liquid in vial
214289377|NCT06046391|BIOLOGICAL|Placebo|Liquid in vial
214289378|NCT06112262|DRUG|Heparin|Comparison between heparin and hirudin
214473210|NCT04693533|DRUG|Fremanezumab Prefilled Syringe [Ajovy]|The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.
214847089|NCT05147974|BEHAVIORAL|DOZE app|"Complete DOZE app: Delivering Online ZZZ's with Empirical support (DOZE) app plus a Consensus Sleep Diary (CSD).~The DOZE app, is a web-based app optimized for desktop, smartphone, or tablet use. It is a self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected applications that will allow tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log onto the sleep dairy (via automated alerts) once a day over a 10-week period to complete sleep diary entries, develop and track their goals, and receive sleep health education/tailored sleep health interventions.~1-week pre- and post- intervention, participants will complete a battery of baseline study questionnaires and have the option of using a Geneactiv actigraphy device along with a CSD."
214847090|NCT02568007|DRUG|Cyproheptadine|
214847091|NCT00002869|BIOLOGICAL|recombinant interferon alfa|
214847092|NCT00002869|DRUG|cytarabine|
214847093|NCT00002869|DRUG|hydroxyurea|
214847094|NCT03459352|OTHER|ePRO|"Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms.~These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit.~Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction."
214847095|NCT00402025|BIOLOGICAL|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
214847096|NCT05846256|OTHER|Sperm DNA Fragmentation|Sperm DNA Fragmentation analysis.
214847097|NCT05663372|DRUG|Efez 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
214847098|NCT05663372|DRUG|INSPRA® 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
214847099|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation without the support of the RAYVOLVE app|"Phase 1 does not involve any intervention: residents, emergency physicians, and radiologists will interpret the x-rays without the support of the RAYVOLVE application.~The emergency physician interprets the x-ray and manage the case as per protocol, all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated."
214847100|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation with the support of the RAYVOLVE app|The residents interpret the X-ray with the RAYVOLVE application's support and indicate the presence or not of a fracture without sharing it with the senior emergency physician. A senior emergency physician manages the case as usual, and all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated
214289379|NCT02554487|DEVICE|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI \> 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI \< 5) following stroke serve as a control group
214289380|NCT05544916|DRUG|XC221|200 mg/day, for 5 days
214289381|NCT05544916|DRUG|Placebo|2 tablets/day, for 5 days
214289382|NCT00203996|DEVICE|continuous positive airway pressure (CPAP)|CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
214289383|NCT00203996|DRUG|depot leuprolide plus estrogen/progestin replacement|Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
214289384|NCT00203996|DRUG|pioglitazone|Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
214289385|NCT00203996|PROCEDURE|REM frag|Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
214847101|NCT03371329|BIOLOGICAL|MSC|bone marrow derived cultured MSC (mesenchymal stem cell)
214847102|NCT05500768|PROCEDURE|hypothermic compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants, a frozen prosthesis is added
214847103|NCT05500768|PROCEDURE|Conventional compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants
214847104|NCT02482558|OTHER|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
214847105|NCT02157363|PROCEDURE|Repositioning|
214847106|NCT02157363|PROCEDURE|Single positioning|
214289386|NCT00203996|PROCEDURE|SWS supp|SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
214289387|NCT02789202|OTHER|Silver diamine fluoride|Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
214473211|NCT03981263|DEVICE|MEAVANTI prothesis|"The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart."
214473212|NCT03981263|DEVICE|Standard prothesis|This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.
214847107|NCT03528096|DEVICE|Somnomat B|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
214473213|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at Day 4|Participants will undergo an abbreviated physical exam, assessment of concomitant medications, and reassessment for signs/symptoms of TB
214473214|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at Day 4|Peripheral blood samples, including serum, PBMC, and whole blood, are collected from participants. A tongue swab is also collected from each participant.
214473215|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at week 26|Participants will undergo another complete physical exam and have their medical (including TB) history, potential TB signs/symptoms, and concomitant medications reassessed. Chest radiography will be obtained for all participants. An assessment of TB outcomes will also be performed.
214473216|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at week 26|Peripheral blood samples, including serum, PBMC, and whole blood, will be collected. Participants not previously identified as living with HIV will undergo HIV diagnostic testing, while participants living with HIV will have their HIV viral load and CD4+ T-cell count measured.
214847108|NCT03528096|OTHER|Sound|Sound of the moving bed was recorded and played back during the baseline night.
214847109|NCT02751892|BEHAVIORAL|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
214473217|NCT04496154|DIETARY_SUPPLEMENT|Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)|Triple Strength Omega-3 from Webber Naturals
214473218|NCT05842135|PROCEDURE|Laparoscopic approach to small bowel obstrcuction|Bowel viability assessment by indocyanine green fluorescent angiography during laparoscopic approach to small bowel obstruction
214473219|NCT06057324|DEVICE|AI-based Apps|Families which will use the digital interactive tools to empower parents in their daily dietary choices.
214473220|NCT06057324|BEHAVIORAL|Mediterranean-based diet toolkit and activities|Families which will receive educational materials and adolescents will perform educational activities.
214473221|NCT06057324|OTHER|Healthy plant-based snacks|Families in which children will include the snacks in their diet.
214473222|NCT06057324|OTHER|AI-based Apps + Mediterranean-based diet toolkit and activities|Families which will use the digital interactive tools and receive educational material, and adolescents will perform educational activities.
214473223|NCT06057324|OTHER|AI-based Apps + Healthy plant-based snacks|Families which will use the digital interactive tools and children will include the snacks in their diet.
214473224|NCT06057324|OTHER|Mediterranean-based diet toolkit and activities + Healthy plant-based snacks|Families which will receive educational material, adolescents will perform educational activities, and children will include the snacks in their diet.
214473225|NCT06057324|OTHER|AI-based Apps + Mediterranean-based diet toolkit and activities + Healthy plant-based snacks|Families which will use the digital interactive tools and will receive educational material, children will include the snacks in their diet, and adolescents will perform educational activities.
214473226|NCT05815485|DRUG|Azeliragon|30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).
214473227|NCT05815485|DRUG|Placebo|Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).
214657282|NCT00873275|OTHER|immunohistochemistry staining method|Performed on tumor blocks from the primary and the metastases from the patients on study
214657283|NCT00873275|OTHER|laboratory biomarker analysis|Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
214657284|NCT00873275|OTHER|pharmacological study|Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.
214847110|NCT05747560|DIETARY_SUPPLEMENT|Buckwheat|Take buckwheat at a dose of 500 mg twice a day for 6 months.
214847111|NCT05747560|DIETARY_SUPPLEMENT|Astragalus extract|Take astragalus extract at a dose of 450 mg twice a day for 6 months.
214847112|NCT05747560|DIETARY_SUPPLEMENT|Wolfiporia extract|Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.
214847113|NCT02571933|OTHER|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
214847114|NCT02571933|OTHER|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
214847115|NCT02571933|OTHER|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
214847116|NCT06873035|DRUG|infigratinib 0.128 mg/kg/day|Oral infigratinib 0.128 mg/kg/day
214847117|NCT06873035|DRUG|infigratinib 0.25 mg/kg/day|Oral infigratinib 0.25 mg/kg/day
214847118|NCT06875791|COMBINATION_PRODUCT|Green Tea Extract with Morphine|TV5M01 is a novel oral rinse combining 5% green tea extract with 0.1% morphine in a gel formulation specifically designed for the treatment of radiation-induced oral mucositis. This unique combination leverages the antioxidant and anti-inflammatory properties of green tea polyphenols (particularly EGCG) with the analgesic effects of morphine delivered directly to the oral mucosa. Unlike other interventions, this formulation is administered as a 10 mL rinse three times daily with subsequent ingestion, targeting both local tissue healing and pain relief through a dual-action mechanism.
214473228|NCT04470934|DEVICE|SeQuent® SCB drug-coated balloon catheter|"treatment of coronary artery disease with SeQuent® SCB of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
214473229|NCT05946850|PROCEDURE|Caudal analgesia|Caudal analgesia for chronic lumbosacral pain
214473230|NCT03268382|DRUG|APR-246|Intravenous infusion
214473231|NCT03268382|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion
214473232|NCT04576130|DEVICE|Implantable cardioverter defibrillator|Implantation of an ICD for secondary prevention
214473233|NCT06585358|OTHER|MIPD|This is a non-inverventional study
214473234|NCT06584656|BEHAVIORAL|Aerobic exercise condition|Aerobic session will last 30 min. The average intensity of the aerobic sessions will be 60-70% of the Maximal Heart Rate. Therefore, participant will perform a continuous moderate intensity aerobic bout of exercise on a cycle ergometer.
214473235|NCT06584656|BEHAVIORAL|Resistance exercise condition|Resistance exercise will last 30 min at 4-6 RPE (OMNI-Resistance Exercise Scale of Perceived Exertion from 0-10). The bout of resistance exercise will include a combination of upper and lower body exercises using elastic bands and the participants' body weight as the primary resistance. Eight different exercises will be performed per set, with 40 seconds per exercise, for a total of 3 sets. The exercises are based on basic movement patterns and include: glute bridge, front plank, standing face pull, incline push-up, squat, pallof press, walking lunge and seated shoulder press.
214847119|NCT06875791|COMBINATION_PRODUCT|Active Comparator: Triple Mixture Oral Rinse for Radiation-Induced Mucositis|This arm will receive a Triple Mixture oral rinse (combination of 0.19% w/w Lidocaine, 0.29% w/w Nystatin, and 5.50% w/v Hydroxides). Participants will use 10 mL of the preparation three times daily at 8-hour intervals (±2 hours) from the diagnosis of grade 1 or higher mucositis until mucositis resolves. The medication should be administered at consistent times daily without fasting requirements. Doses vomited while in clinic may be replaced; however, participants should not take replacement doses for self-administered doses vomited at home. Missed doses should be skipped rather than doubled at the next scheduled time
214847120|NCT03846063|OTHER|Home-based rehabilitation program|The duration of the program is 12 weeks. Patients start the program within 7 days after of the surgery. Patients perform exercises independently at home using the tablet PC for instructions. The program includes strengthening and walking exercises based on increasing the muscle force, balance, and functionality. The exercises comprise movements that train abductors, flexors, and extensors of the affected hip. The content of the program is based on previous research and on guidelines from the American Association of Orthopaedic Surgeons. For the rest, the program is designed in line with the most recent guidelines from the Royal Dutch Society for Physical Therapy. Patients are asked to exercise at least 5 days a week, with rest days on Thursday and Sunday. Strengthening exercises will be performed 3 times a week. The instructions for the exercises will be provided by videos on the tablet PC, which patients have to imitate.
214847121|NCT03179748|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
214847122|NCT03814122|BEHAVIORAL|Action-based cognitive remediation|Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.
214473236|NCT06828523|BEHAVIORAL|Listener judgements of speech produced in different tasks|Listeners will hear recorded speech of PALS and age-matched speakers across interactive and non-interactive tasks and indicate what they heard by clicking one of four words displayed on the screen. Standard attention checks and minimum performance thresholds (Theodore, 2021) will be used to ensure that listeners are engaged and are able to provide meaningful perceptual judgments.
214473237|NCT06252623|DRUG|Exenatide|Exenatide will be purchased commercially as Bydureon® for subcutaneous injection and administered at 2 mg once a week for 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
214473238|NCT06252623|DRUG|Placebo|Sterile saline will be used as the placebo and administered subcutaneously once a week for 6 weeks.
214473239|NCT05786066|DRUG|Perampanel 6 MG|Perampanel will be administered 2.5 hours before Ketamine infusion
214473240|NCT05786066|DRUG|Ketamine|Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.
214473241|NCT05786066|DRUG|Placebo|Placebo will be administered 2.5 hours before Ketamine infusion
214847123|NCT03814122|OTHER|Waitlist Control Group|Receive treatment-as-usual through regular early psychosis programming.
214289388|NCT02789202|OTHER|Fluoride Varnish|Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
214289389|NCT04074460|DRUG|Propofol|General Anaesthesia
214289390|NCT04074460|DRUG|isoflurane, sevoflurane or desflurane|General Anaesthesia
214289391|NCT05950490|DRUG|Intravitreal injection of methotrexate|"Intravitreal injection of methotrexate:400ug/0.1mL，Once a week\*4 weeks → Once every two weeks\*4 weeks → once a month \*10 times(16 times a year)~Systemic therapy:~Induction period:（Zanubrutinib + Rituximab，ZR） (28 days/cycle) x 6 cycles:Rituximab iv375mg/m2 D1, Zanubrutinib 160mg bid D1-D21; Maintenance treatment:Zanubrutinib 160mg bid x 2 years"
214473242|NCT04260854|DRUG|Bupivacaine Hydrochloride|Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.
214473243|NCT04260854|DRUG|Saline|Normal saline injections.
214473244|NCT03442309|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
214473245|NCT03442309|DEVICE|Fluoride Varnishes|Fluoride varnish (FV)
214473246|NCT03442309|DEVICE|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
214473247|NCT04862416|BIOLOGICAL|R0.6C transmission blocking vaccine|Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.
214847124|NCT04086160|DEVICE|Transcranial direct current stimulation device (Soterix Medical, New York, NY)|Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
214847125|NCT00198536|DRUG|Ecabet 2.83%|
214847126|NCT00198536|DRUG|Ecabet 3.70%|
214289392|NCT02551276|DRUG|Salbutamol|
214289393|NCT02551276|DRUG|Placebo|
214289394|NCT02551276|OTHER|Resistance training|
214289395|NCT04358120|DEVICE|Hyaluronic Acid Combined With Chondroitin Sulfate|"Subjects' participation in the study will last 26 weeks. The study includes 7 visits that consist of a Screening visit, three treatment visits and three follow-up visits.~Eligible subjects will undergo a Baseline visit (V1 at week 0) during which, after the confirmation of eligibility, assessments and ultrasound evaluation, the study subjects will be treated with the 1st injection of 2%Hyaluronic Acid and 2% chondroitin sulfate Subsequent treatments will be administered at weekly intervals during Visit 2 (V2 at week 1) and Visit 3 (Visit 3 at week 2) after the effectiveness assessments.~Study subjects will return for Follow-up visits 1 month (Visit 4 at week 6), 3 months (Visit 5 at week 14) and 6 months (Visit 6 at week 26) after the last injection"
214289396|NCT00989378|BEHAVIORAL|baseline study|normal bedtimes
214289397|NCT03064451|PROCEDURE|cartofinder guided ablation followed by PVI|cartofinder guided ablation followed by PVI
214289398|NCT04140591|DRUG|Proton-pump inhibitor|PPI: Pariet EC 20mg/QDAC
214289399|NCT04140591|DRUG|Propranolol+Proton-pump inhibitor|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure \>90mmHg) PPI: Pariet EC 20mg/QDAC
214289400|NCT05944874|DEVICE|high definition transcranial direct current stimulation|Transcranial direct current stimulation, in recent decades, has been identified as a non-invasive tool for transiently modulating human brain activity. The technique consists of the application of a low-intensity continuous electric current, through electrodes applied to the scalp, acting in a regulatory way on the frequency of triggered action potentials, however, without interacting directly with the neurons.
214289401|NCT02706340|OTHER|No intervention - observational study only|
214289402|NCT02401438|OTHER|5D ultrasound|
214289403|NCT02401438|OTHER|2D ultrasound|
214289404|NCT04008615|OTHER|2 times : 6-minute stepper test with cardiorespiratory parameters and gaz exchange monitoring (with a rest of 20min between each test).|"For the 6-minute stepper test, please refer to NCT02842463 and NCT04004689. Gaz exchange analyzer will be calibrate before every test. Data will be recorded breath by breath.~Heart rate will be monitored using a 12-lead electrocardiogram. Transcutaneous oxygen saturation will be assessed using a pulse oxymetry system at the earlobe."
214289405|NCT00935753|DRUG|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
214289406|NCT03793933|PROCEDURE|Liver resection|Surgery for the liver
214289407|NCT03592108|OTHER|CSR remote monitoring|The intervention will consist to modify the method used to analyse the data collected by remote monitoring in OSA-patients treated by CPAP (device : AirSense™10 Autoset™, ResMed) in order to alert physicians when Cheynes-Stokes respiration (CSR) occurs during sleep and then to set up emergency pulmonology and cardiology consultations to screen the onset of a significant cardiac event (heart failure, rhythm disorder, diastolic dysfunction).
214289408|NCT00242489|DRUG|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
214289409|NCT00242489|DRUG|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
214289410|NCT04274842|OTHER|observation by D-OCT|observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
214289411|NCT03462264|DEVICE|Scoliogold App|The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
214289412|NCT03462264|OTHER|Pre-Formatted Diary|The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
214289413|NCT01154764|DRUG|CG100649|I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time
214289414|NCT01154764|DRUG|Ketoconazole|I period: ketoconazole + CG100649 II period: CG 100649
214289415|NCT01402791|OTHER|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
214289416|NCT05471778|BEHAVIORAL|Watching comedy movie|A 25-minute comedy film created by the researchers was watched.
214847127|NCT00198536|DRUG|Vehicle|
214847128|NCT04614857|OTHER|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
214289417|NCT05471778|BEHAVIORAL|listening to music|25 minutes of music created by the researchers was played.
214289418|NCT05600491|DRUG|Temozolomide|Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).
214289419|NCT04880525|OTHER|Dietary intervention|In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
214289420|NCT04718051|DRUG|Shen Pu Yang Gan Wan|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.
214289421|NCT04718051|DRUG|Placebo|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
214289422|NCT02305056|DRUG|C13 N15 Valine|C13 N15 Valine administration
214289423|NCT01447095|DRUG|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
214847129|NCT03695211|PROCEDURE|Conventional landmark technique|inject at the midpoint of the posterior border of the sternocleidomastoid muscle
214847130|NCT03695211|PROCEDURE|Precise block technique|inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
214847131|NCT01066130|BEHAVIORAL|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
214289424|NCT01447095|DRUG|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
214473248|NCT03495180|OTHER|Standard EEG or SSEP|The gamma frequency range (30 -100 Hz) of standard EEG or somatosensory evoked potential (SSEP) correlate with intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
214473249|NCT01836705|DRUG|SAR302503 (TG101348)|"Pharmaceutical form:capsule~Route of administration: oral"
214473250|NCT01836705|DRUG|Placebo SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
214473251|NCT01836705|DRUG|Panolosetron|"Pharmaceutical form:solution~Route of administration: intravenous"
214473252|NCT02745860|DRUG|Selexipag (adult formulation)|One selexipag film-coated tablet of 200 µg
214473253|NCT02745860|DRUG|Selexipag (pediatric formulation)|Four selexipag film-coated tablets of 50 µg
214473254|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 1: low intensity clinician training|"A booster of the established LSTDI implementation strategy. Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study. Online training options and when and how to complete goals of care conversations and documentation will be highlighted."
214473255|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 2: high intensity clinician training|"This includes two components:~1. Team facilitation to help the primary care team (advance practice provider, nurse, social worker) work together to create roles and responsibilities for accomplishing goals of care conversations with patients~2. A patient list trigger of patients potentially eligible for goals of care conversations (the patient study population) will be sent to the primary care clinicians."
214847132|NCT01066130|BEHAVIORAL|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
214847133|NCT01680367|PROCEDURE|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
214847134|NCT01680367|PROCEDURE|wound care management|Receive native collagen wound dressing
214289425|NCT01447095|DRUG|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
214289426|NCT00064844|BEHAVIORAL|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
214289427|NCT00064844|DRUG|Nicoderm CQ nicotine patch|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
214289428|NCT00064844|DRUG|Placebo gum|Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
214473256|NCT05001009|BEHAVIORAL|Low patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website.
214473257|NCT05001009|BEHAVIORAL|High patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website. Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
214473258|NCT06198517|OTHER|Moxibustion|The experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally.
214473259|NCT06198517|OTHER|Symptomatic treatment|The control group received conventional symptomatic treatment.
214473260|NCT06254534|DIAGNOSTIC_TEST|optic nerve ultrasonography|The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.
214473261|NCT06263959|DRUG|GST-HG131|GST-HG131 will be administered.
214473262|NCT06263959|DRUG|Placebo to match GST-HG131|Placebo to match GST-HG131 will be administered.
214473263|NCT06147401|PROCEDURE|PENG plus LFCN block|"The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine."
214473264|NCT06147401|PROCEDURE|FIC Block|"The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment."
214473265|NCT06636370|DIAGNOSTIC_TEST|Contrast-enhanced mammography (CEM)|This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program
214847135|NCT01680367|OTHER|questionnaire administration|Ancillary studies
214847136|NCT01114581|DRUG|Mucinex|Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
214847137|NCT01114581|DRUG|Placebo|Placebo given as 2 tablets
214847138|NCT01629537|PROCEDURE|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
214847139|NCT01629537|PROCEDURE|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
214473266|NCT06636370|DIAGNOSTIC_TEST|Abbreviated MRI (AB-MRI)|This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program
214473267|NCT06296199|OTHER|VR|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to watch and listen with VR headphones to a concert by a group of musicians playing music."
214473268|NCT06296199|OTHER|Music only|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to listen with conventional headphones to a concert by a group of musicians playing music."
214473269|NCT04862234|DRUG|Dulaglutide|A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.
214473270|NCT04862234|DRUG|Placebo|A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
214473271|NCT04862234|DEVICE|Continuous glucose monitor (CGM), blinded|Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
214473272|NCT02584647|DRUG|PLX3397|PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.
214473273|NCT02584647|DRUG|sirolimus|"Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day."
214473274|NCT03500081|DEVICE|MRI Scan|The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
214473275|NCT04160013|BEHAVIORAL|Discipline education|Discipline education using the Play Nicely program.
214473276|NCT04160013|BEHAVIORAL|Cavity Prevention|Cavity prevention using a 2 page handout.
214473277|NCT03956784|DEVICE|E-assessed clinical and biological follow up|"Clinical questionnaire: self-evaluation of pain (0 to 10), resumption of transit, bleeding, fever, pulse. In case of no filling, the patient is contacted.~An automatic alert system is defined and divide the patient according to three situations:~* Normal situation~* Situation requiring the nurse to call back the patient and contact the surgeon if the assessment requires medical advice~* Disturbing situation requiring contact of the first-line surgeon if a potentially serious event is suspected. Each speaker's place is described for each item in the detailed protocols~Biological questionnaire:~Biological monitoring (blood count, Ionogram, C-Reactive Protein, urea, creatinine) is performed on D1, D3 and D7.~All information is accessible in real time by the surgeon who receives notifications by email and on his smartphone in case of clinical or biological abnormality on patient monitoring."
214473278|NCT03956784|OTHER|Usual at home follow up|"An information sheet on the clinical parameters to be monitored will be given to patients and will include the following information:~1. Immediate complications and warning signs:~   * Tachycardia\> 120 bpm~  * Dyspnea~  * Rectorragies and / or melena~  * Vomiting with or without presence of blood~  * Major abdominal pain (visual analogue scale\> 6/10)~  * Fever\> 38~2. Management to deal with complications: call the service and / or the surgeon~3. Actions to be performed by the patient after the exit:passage of the nurse during 10 days for anticoagulant morning and evening (identical in both study groups)~Each patient will be given a prescription to perform a C-Reactive Protein assay on D1, D3 and D7, similarly."
214847140|NCT05355519|OTHER|Electronic curriculum and instructor-led course, then placebo|Electronic curriculum and instructor-led course
214473279|NCT03292484|BIOLOGICAL|AR101|AR101
214847141|NCT05355519|OTHER|Placebo, then electronic curriculum and instructor-led course|Electronic curriculum and instructor-led course
214847142|NCT05094570|DRUG|Dupilumab Prefilled Syringe|Dupilumab 300 mg
214847143|NCT00039910|DRUG|(PN-152,243)/ PN-196,444|
214473280|NCT06142773|DEVICE|Tidal Volume set on ventilator|Mechanically ventilated patients who are undergoing MRI examinations under general anesthesia in isocapnic and isoxic conditions will have brain activity investigated under two different tidal volumes, 6 ml/kg and 12 ml/kg applied for 3-5 minutes.
214473281|NCT06485089|DRUG|tirzepatide|Women taking tirzepatide as part of standard care in the Weight Managment Clinic
214473282|NCT05438407|DRUG|Leniolisib|The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
214473283|NCT06180317|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI and VAS just before the endometrial biopsy procedure, VAS during the procedure and again with STAI and VAS after the procedure.
214473284|NCT06476392|DRUG|Melatonin 10 MG|2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.
214847144|NCT05271227|OTHER|Transthoracic echocardiography and Carotid artery doppler (PHILIPS HD11 XE ultrasound device) before and after PLR test.|VTI-LVOT was measured by echo by placing the pulsed wave Doppler sample gate in the LVOT diameter in apical-5-chamber window. VTI-LVOT was obtained by manually tracing the Doppler velocity spectrum. LVOT velocity time integral was recorded before and after PLR test within 2 minutes. Carotid blood flow was measured by using two-dimensional image, the optimal image of the long-axis view was obtained at the common carotid artery. The sample volume was placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination,The angle correction cursor was placed parallel to the direction of blood flow. A PLR will be performed in 2 sequential steps, first step patient is seated in the semi recumbent position (45°) then using an automatic bed elevation technique, the lower limbs will be then raised to a 45° angle while the patient's trunk will be lowered in supine position. Thus, the angle between the trunk and the lower limbs will remain unchanged (135°).
214473285|NCT06476392|DRUG|Placebo|2 placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
214847145|NCT05397301|PROCEDURE|Controlled sedoanalgesia|Controlled sedoanalgesia was applied with Bispectral index and dexmedetomidine
214847146|NCT03485001|OTHER|Sham|This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.
214847147|NCT03485001|PROCEDURE|Argon Laser Treatment|This group will receive argon laser medical treatment to the body and head of pterygium
214847148|NCT02375945|DEVICE|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
214847149|NCT02375945|DEVICE|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
214847150|NCT04204096|BIOLOGICAL|Vi-DT (Multi-dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~* Storage Conditions: +2 to +8°C"
214847151|NCT04204096|BIOLOGICAL|Vi-DT (Single dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~* Storage Conditions: +2 to +8°C"
214847152|NCT04204096|BIOLOGICAL|Control Vaccine|"* For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~* For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject."
214847153|NCT04975724|DRUG|Liposom Forte|Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
214847154|NCT04975724|DRUG|Citalopram|The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC
214847155|NCT04975724|OTHER|Placebo|Liposom Forte Placebo (2 ampoules of 2 ml solution for injection)
214289429|NCT00064844|DRUG|Nicotine gum - Nicorette®|Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
214289430|NCT04928040|DIAGNOSTIC_TEST|Measurement of optic nerve sheath diameter|The fluid challenge effects of optic nerve sheath diameter
214289431|NCT04461730|DEVICE|deep brain stimulation|Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation
214289432|NCT00263133|DRUG|Sertraline|
214289433|NCT04567433|DRUG|Hydroxyethyl starch|Hydroxyethyl starch compared to 0.9% saline
214473286|NCT03308578|DRUG|Atorvastatin|Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
214473287|NCT03308578|DRUG|Placebo oral capsule|Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
214473288|NCT05290493|DRUG|NB-001|Non-stimulant modulator of metabotropic glutamate receptors (mGluRs)
214473289|NCT05290493|OTHER|Placebo|Matching, inactive placebo
214473290|NCT06071234|PROCEDURE|3D reconstruction technology|Preoperative application of 3D reconstruction technology to evaluate the breast blood supply of participants and observe whether the incidence of ischemic complications in the flap and nipple areola complex is reduced compared to surgery without preoperative evaluation.
214473291|NCT06211933|PROCEDURE|HIFU intervention|HIFU intervention on non resectable pancreatic lesions at day 0 for each patient included
214473292|NCT05419830|BEHAVIORAL|BBTI|Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
214473293|NCT05419830|OTHER|PM antihypertensive dosing or Chronotherapy|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
214473294|NCT05419830|OTHER|AM antihypertensive dosing|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
214473295|NCT04608318|BIOLOGICAL|Ibrutinib|Cycles 1 - X: 420 mg daily, d1-28 p.o.
214473296|NCT04608318|BIOLOGICAL|Venetoclax|"Arm VG~Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.~Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.~Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.~Arm VI~Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.~Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o."
214473297|NCT04608318|BIOLOGICAL|Obinutuzumab|Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.
214473298|NCT03428828|DEVICE|Amygdala Neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
214473299|NCT03428828|DEVICE|Parietal Neurofeedback|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
214473300|NCT05391737|DIAGNOSTIC_TEST|Echocardiography|Echocardiography after swimming (acute) and at rest (baseline)
214473301|NCT05391737|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Electrocardiogram (ECG) after swimming (acute) and at rest (baseline)
214473302|NCT05391737|DIAGNOSTIC_TEST|Cardiac biomarkers|high sensitive (hs)-Troponin I and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after swimming (acute) and at rest (baseline)
214473303|NCT05726292|DRUG|Relacorilant|Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is being used in this study as an experimental drug combined with other treatments for prostate cancer.
214473304|NCT05726292|DRUG|Enzalutamide|Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.
214473305|NCT05726292|OTHER|Placebo (Sugar Pill)|This would be a sugar pill consisting of 2 softgels. This is not an experimental drug or treatment.
214473306|NCT05726292|OTHER|Androgen Deprivation Therapy|"All participants in this study, who meet the requirements to participate, will get Androgen Deprivation Therapy (ADT; a form of hormone therapy) continuously before their radical prostatectomy surgery. As part of this study, ADT consists of one injection every 1-3 months. In this study, ADT is a gonadotropin releasing hormone (GnRH) agonists or antagonist; the choice of which brand of ADT to use is up to your treating physician. GnRH agonists and antagonists are drugs that lower the production of androgens (male hormones) in your body. Prostate cancer cells usually require androgens, such as testosterone, to grow.~Androgen Deprivation Therapy (ADT) has been approved by United Stated Food and Drug Administration (US FDA) to treat patients with prostate cancer but is not approved to treat patients prior to prostatectomy."
214847156|NCT03234608|BEHAVIORAL|AASPIRE Healthcare Toolkit|The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
214473307|NCT05726292|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is surgery to remove the entire prostate gland and surrounding lymph nodes to treat men with localized prostate cancer.
214473308|NCT05762211|DRUG|Pooled allogeneic fecal microbiotherapy|Capsule for oral use
214847157|NCT02105701|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
214847158|NCT02105701|DRUG|Ribavirin|200 mg capsule
214289434|NCT04567433|DRUG|Hydrocortisone|Hydrocortisone compared to Placebo
214473309|NCT05762211|DRUG|Placebo|Capsule for oral use
214473310|NCT04400331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
214473311|NCT06743152|BEHAVIORAL|Synchronous exercise program|The synchronous exercise group will be conducted online with synchronous supervision under the supervision of a physiotherapist. The exercise program will be performed for 8 weeks, 2 days a week. In the exercise program, 3 sets, 8 repetitions in 1 set will be progressed to 10-12-15-20-25 repetitions according to tolerance. There will be a 1-2 minute rest between sets.
214657285|NCT00873275|PROCEDURE|positron emission tomography (PET)|Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
214847159|NCT04802551|OTHER|Sensory integration therapy|Sensory integration disorder is defined as the inability of a person to use the information he / she receives through his / her senses properly in order to continue his daily life properly. Intervention group have some therapy sessions which include sensory integration therapy exercises.
214847160|NCT04593394|DIAGNOSTIC_TEST|Continous laryngoscopy exercise test|Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored
214289435|NCT04567433|PROCEDURE|Early Goal Directed Therapy|Early Goal Directed Therapy compared to Usual Care
214289436|NCT02733068|BIOLOGICAL|HPV-16/18 vaccine|0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
214289437|NCT02733068|BIOLOGICAL|HPV-16/18 placebo|0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
214473312|NCT06743152|BEHAVIORAL|Asynchronous exercise group|The Asynchronous Exercise Group will be conducted with a video-based structured exercise program. For the asynchronous video-based group, a closed channel will be created on Youtube that only patients can access, and the exercises will be uploaded to the system asynchronously. In the asynchronous exercise group, how each exercise is performed will be shown in detail by the physiotherapist in the video content.
214473313|NCT05331729|RADIATION|FMISO-PET Protocol|"* injection of 18F-FMISO~* Monitoring for 2 h~* PET scan (30 min) 2h post injection~* Monitoring for 2h~* PET (30min) 4h post injection~* Discharge of the subject with appropriate recommendations after a PET/CT"
214473314|NCT06165172|DEVICE|MyoRegulator®|Study participants will receive treatment using the MyoRegulator® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.
214473315|NCT06493188|OTHER|High-fidelity interprofessional simulation|Students will participate in realistic (high-fidelity) interprofessional simulation scenarios to practice and interpret ABG procedures.
214473316|NCT06493188|OTHER|Low-fidelity interprofessional simulation|Students will take part in low-fidelity interprofessional simulation scenarios. Cases will be discussed, and reflection on ABG execution and interpretation will be guided using paper descriptions and clinical files.
214473317|NCT03677141|DRUG|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab.
214473318|NCT03677141|DRUG|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV.
214473319|NCT03677141|DRUG|Rituxumab|Participants will receive rituxumab via IV.
214473320|NCT03677141|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide via IV.
214473321|NCT03677141|DRUG|Doxorubicin|Participants will receive doxorubicin via IV.
214473322|NCT03677141|DRUG|Vincristine|Participants will receive vincristine via IV.
214473323|NCT03677141|DRUG|Prednisone|Participants will receive oral prednisone.
214473324|NCT03677141|DRUG|Tocilizumab|Participants will receive tocilizumab via IV.
214473325|NCT05498675|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
214473326|NCT05498675|DRUG|ACEI/ARB|"There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."
214473327|NCT05457478|OTHER|Medical Device Qardio® smart scale Usage and Evaluation|Weight monitored using a Qardio® smart scale
214473328|NCT05457478|OTHER|Questionnaire Administration|Ancillary studies
214847161|NCT04593394|DIAGNOSTIC_TEST|Overnight respiratory polygraphy|Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea
214847162|NCT05741931|DEVICE|mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)|The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
214473329|NCT04280276|DIAGNOSTIC_TEST|TruGraf test|To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.
214473330|NCT03018366|DRUG|17beta Estradiol|Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
214473331|NCT03018366|DRUG|Transdermal placebo patch|Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.
214473332|NCT03018366|DRUG|Progesterone|After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.
214473333|NCT03018366|DRUG|Placebo Pill|After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
214473334|NCT06804382|BEHAVIORAL|Academic detailing|Academic detailing is an evidence-based, 1-on-1 outreach education technique intended to promote clinician behavior change. Information gained during earlier focus groups will be used to develop study-specific materials.
214473335|NCT06806124|DEVICE|Elevation Training Mask|The Elevation Training Mask (ETM) 2.0 was used in all 36 training sessions over the 12 weeks of the study with progressive increases in air restriction to simulate altitude training. This methodology of using ETM during exercise was chosen following the study by Porcari et al. The first week, the additional altitude simulation was 914 m and in the second, 1,829 m. These initial 2 weeks served to adjust the use of the ETM during training, as a process of acclimatization to the altitude simulation and airflow restriction. For the period between weeks 3 and 6 (both inclusive) the simulated altitude was 2,743 m, and for weeks 7-12 (both inclusive), the ETM was set to simulate 3658 m altitude.
214473336|NCT06806124|DEVICE|Sham Elevation Training Mask|For the Control Group, the Elevation Training Mask (ETM) 2.0 was used for 12 weeks with the largest openings available and without using the air restriction filters, so that there was little respiratory obstruction and the reduction in air flow was minimal, with the aim of having a simulated ETM treatment
214657286|NCT06094010|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as an oral suspension per body weight (≥80 kilograms (kg): 80 milligrams (mg); ≥20 kg to \< 80 kg: 40 mg; \<20 kg: 2 mg/kg).
214657287|NCT06360822|BEHAVIORAL|ED-LCS|This is a lung cancer educational intervention for patients in the emergency department.
214847163|NCT03652831|OTHER|Soft Tissue Mobilization with Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
214847164|NCT03652831|OTHER|Soft Tissue Mobilization without Neural Mobilization|"* Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
214847165|NCT02148445|OTHER|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
214847166|NCT02148445|OTHER|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
214847167|NCT02148445|DRUG|Nicotine replacement therapy|
214847168|NCT05659524|OTHER|Nasal saline irrigation|"The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations:~* Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily.~* Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative."
214847169|NCT04618419|DIAGNOSTIC_TEST|internal jugular vein distensibility index|It is a prospective observational clinical study to correlate hemodynamic monitoring between Electrical Cardiometry and internal jugular vein distensibility index by sonogram
214847170|NCT06350617|DEVICE|High-Frequency, ipsilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
214847171|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
214847172|NCT06350617|DEVICE|High-Frequency, Lt. DLPFC|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: Lt. DLPFC~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
214847173|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
214847174|NCT02170831|DRUG|BIBR 1048 MS low|
214847175|NCT02170831|DRUG|BIBR 1048 MS medium 1|
214847176|NCT02170831|DRUG|BIBR 1048 MS medium 2|
214847177|NCT02170831|DRUG|BIBR 1048 MS high|
214847178|NCT02170831|DRUG|BIBR 1048 MS placebo|
214847179|NCT01097551|DRUG|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
214847180|NCT01097551|DRUG|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
214847181|NCT01097551|DRUG|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
214847182|NCT01097551|DEVICE|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
214657288|NCT05372172|OTHER|none, observational study|none, observational study
214847183|NCT00325104|PROCEDURE|Parathyroid hormone testing|
214847184|NCT00325104|PROCEDURE|Serum calcium testing|
214847185|NCT04984187|OTHER|high intensity laser plus exercise|high intensity laser plus exercise
214847186|NCT04984187|DEVICE|high intensity laser only|high intensity laser only
214847187|NCT04984187|OTHER|exercise|exercise only
214847188|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Suspension|PDP-716
214847189|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Solution|Three Times Brimonidine Tartrate Ophthalmic Solution
214657289|NCT05604807|OTHER|Dementia course with virtual reality|dementia virtual reality activity, intergenerational learning, world café teaching method and community practice
214473337|NCT06805799|OTHER|Follow up to Mindfulness RCT using a Still Face Paradigm|Mothers who participated in an RCT of mindfulness to prevent hypertensive disorders of pregnancy and their infants at 6 months of age will attend one session in which they are consented and prepared for the Still Face Paradigm (SFP). The SFP consists of a sequence of three, 2-minute episodes in which the parent and the infant are seated about one meter away from each other. Across a pre-task baseline, task episodes (free play and still-face), and recovery periods, mothers and infants will wear wireless heart rate monitors to assess respiratory sinus arrhythmia and heart rate. At 12 months, mothers will complete lab work to assess cardiovascular risk and infants' growth velocity will be culled from pediatric medical records.
214473338|NCT06836921|OTHER|Standard of Care (Investigator Choice)|Participants in the control group will receive usual care, consisting of regular management by their neurologist, family physician, and other healthcare providers. This standard care may include referrals to community services, allied health professionals, and other support typically provided during the waitlist period for MDC visit.
214473339|NCT06836921|OTHER|MDC visit|"The multidisciplinary clinic visit will use a shared appointment model and will include a specialized team comprising movement disorder neurologist, a palliative and critical care neurologist, a cognitive neurologist, a specialist nurse, a physiotherapist (PT), an occupational therapist (OT), a speech-language pathologist, and a social worker. Care will be delivered in an outpatient setting at a University Hospital. Prior to the initial visit, patients with APS and their care partners will receive a pre-visit questionnaire to identify their top three care priorities.~During the visit, the multidisciplinary team will convene with the patient and their care partner in a single appointment room. The session will begin by addressing each of the priority issues identified by the patient and care partner. The team will collaboratively discuss management strategies, focusing on self-management, and will provide real-time guidance and recommendations. As indicated, hands-on PT and OT evaluatio"
214473340|NCT05165628|COMBINATION_PRODUCT|CYP-006TK|CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing
214473341|NCT05206565|PROCEDURE|Neurotization - Autologous Reconstruction with DIEP/TRAM|"* Transverse Rectus Abdominis Muscle/Deep Inferior Epigastric Artery Flap Harvest - Prior to elevation of flaps in the suprafascial plane from using loupe magnification to identify medial and lateral row of perforators bilaterally, sensory nerves T10-12 are identified and dissected into the muscle bilaterally to prepare for nerve coaptation, nerves are divided at the level of the fascia where they are pure sensory nerves.~* Chest Intercostal Nerve Harvest - During standard of care chest vessel dissection, intercostal nerves T3-4 are identified. After completion of vein coupling it will be determined whether neurotization can be performed or if autograft. Primary nerve coaptation will be performed if there is adequate length for direct end to end apposition.~* Coaptation of nerve or nerve graft endings will be performed using 9-0 nylon suture in an interrupted fashion."
214473342|NCT06466356|OTHER|Psychoeducational Course for Suicide Prevention|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
214473343|NCT06466356|OTHER|Individual therapy session|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
214473344|NCT06466356|OTHER|Treatment as usual|Treatment as usual (TAU) may include the use of psychotropic drugs, in and out-patient treatment, occupational therapy and other interventions the patients physician deem necessary.
214473345|NCT06573567|DEVICE|Bioimpedance|Experimental: use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month
214473346|NCT06573567|DEVICE|Control|Placebo Comparator: the measurements will also be obtained once per month, but not revealed to the participants and the care providers
214473347|NCT06575465|BEHAVIORAL|Healthy lifestyle nutrition, culture and physical activity workshops|The intervention will include monthly sessions in the community setting of physical activity. In addition, monthly nutrition and culture sessions will be held.
214473348|NCT06575465|OTHER|Usual care|Usual care patients receive in their primary health care
214473349|NCT06374147|DEVICE|SVS mattress|The intervention group will receive standard therapy plus continuous SVS stimulation using the Prapela SVS incubator pad. The control group will receive only standard therapy, using an inert pad (identical to the SVS pad, its controller, and green light, but without the transducer and therefore incapable of vibration), in order to mask caregivers. Treatment with the pad will continue until an infant is apnea-free for 3 days and \<2 weeks from anticipated discharge or at the clinician's discretion to discontinue treatment. After ending treatment, clinicians will observe patients 24 hours later and if apnea returns, should re-initiate treatment as needed. At 1 and 2 years of age, parents will be contacted for a brief telephone follow up survey to assess neurological development
214473350|NCT06416020|BEHAVIORAL|HC-MOUD Only|MOUD with buprenorphine provided in a hub buprenorphine clinic
214906915|NCT06707766|OTHER|Oculomotor Exercise along with conventional Therapy|"Oculomotor Exercises: Saccadic eye movement, Smooth pursuit, Adaptation X1, Adaptation X2.~Time duration will be 2 minutes for each exercise.~conventional therapy: hot pack 20 mins Kendall exercises: Strengthening the deep cervical flexor, Stretching the cervical extensors, Strengthening shoulder retraction, Stretching of the pectoralis major muscle strengthening exercise: 12 repetitions\* 3 sets, 2-8 sec hold stretching exercise was: 3 reps\* 30 seconds' hold~Total duration of treatment would be 4 weeks, 3 days a week with total 12 sessions."
214473351|NCT06416020|BEHAVIORAL|BT-MOUD with Buprenorphine|MOUD with buprenorphine provided by a hub buprenorphine provider either in the hub clinic or via telemedicine at a community hub; Recovery Guiding provided to participants
214473352|NCT01408225|PROCEDURE|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
214473353|NCT05032963|BEHAVIORAL|Overnight polysomnography examinations|sleep lab for overnight polysomnography examinations
214473354|NCT05838027|BEHAVIORAL|Cash Transfer|Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
214473355|NCT03550170|BEHAVIORAL|Teleconference|This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
214473356|NCT03550170|BEHAVIORAL|Internet|The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.
214473357|NCT03550170|BEHAVIORAL|1-to-1, in-person or videoconference|Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person or videoconference course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
214473358|NCT05083806|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive optoacoustic imaging of muscular structure
214473359|NCT02671448|BEHAVIORAL|Home monitoring teleconsult visits|A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
214473360|NCT02671448|BEHAVIORAL|Patient Reported Outcomes (PRO)|Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
214473361|NCT02671448|BEHAVIORAL|Caregiver Reported Outcomes instruments|Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
214473362|NCT05969483|DEVICE|pEEG monitoring|pEEG monitoring during PICU admission
214657290|NCT05604807|OTHER|Dementia course with no virtual reality|dementia course, intergenerational learning, world café teaching method and community practice
214473364|NCT04056611|DRUG|JNJ-53718678 250 mg|JNJ-53718678 250 mg will be administered orally.
214473365|NCT04056611|DRUG|Placebo|Matching placebo will be administered orally.
214473366|NCT04056611|DRUG|JNJ-53718678 125 mg|JNJ-53718678 125 mg will be administered orally.
214473367|NCT06425666|PROCEDURE|Intervention group /arm 1 (Cataract surgery alone)|Cataract surgery (arm 1) is performed using a small incision technique. The tunnel is used both for cataract surgery and for implantation of the DMEK graft (arm 2). The centres confirmed that the main incision will be localized between 11 and 12 o'clock and will have a width of 2.4 to 2.8 mm. A tunnel suture will only be placed if there is leakage from the incisions. If cataract surgery alone (arm 1) is performed, a thin dispersive viscoelastic is applied to the endothelium for protection before phacoemulsification. A hydrophobic acrylic monofocal IOL will be implanted into the bag. The centers confirmed that Barret Universal II formula is the standard IOL calculation formula for both groups and for all axial lengths.
214473368|NCT06425666|PROCEDURE|Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)|After cataract surgery DMEK is continued using the surgeon's standard technique for graft implantation and unfolding in triple-DMEK. In all cases the graft will be implanted using the same main incision as for IOL implantation. Once the DMEK graft is unrolled and attached to the posterior corneal stroma the complete anterior chamber will be filled with SF6 20%.
214473369|NCT02946736|BEHAVIORAL|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
214473370|NCT02946736|BEHAVIORAL|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
214847190|NCT05568173|OTHER|Boxing Training|"In addition to boxing training, stretching exercises and posture training will be given at BG. A physiotherapist with a boxing training certificate will perform modified boxing training that progresses according to the degree of difficulty. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~In the first level, patients will be asked to punch the fixed boxing mat hanging on the wall with various instructions. Then, in levels 2-4, target gloves and heavy punching bags will be used to increase the difficulty level. As the sessions progress, the resistance and frequencies between the levels will be increased by the physiotherapist. There will be 3 sessions of 30-minute boxing training per week for 8 weeks at BG."
214473371|NCT00005398|OTHER|There is no intervention|No applicable
214657291|NCT03896581|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
214657292|NCT03896581|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points.
214847191|NCT05568173|OTHER|Scapular Stabilization|"In addition to scapular stabilization training, stretching exercises and posture training will be given in SSG. Progressive strengthening training for the scapular muscles will be used in the SSG. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~At the first level, scapular clock exercise, obstacle crossing exercise, wall gliding exercise with teraband, push up exercise, trunk rotation and maximum hip flexion will be performed. Then at levels 2-4, as the levels increase, the exercises at the first level will be more difficult (ball weight, surface, number of hurdles and hurdle crossing exercise position, by changing the teraband elasticity, push-up position). In SSG, 3 sessions of 30-minute scapular stabilization training will be applied per week for 8 weeks."
214847192|NCT05958056|OTHER|Resistance exercise|The training session included leg curl and leg extension exercises with 4 sets each. Participants started with leg extension exercise for 4 sets with a 30-second rest periods between the sets. Then, participants took a rest for 60 seconds. Afterward, participants performed leg curl exercise for 4 sets with a 30-second rest periods between the sets. Exercises in each set were performed continuously (uninterrupted) with a speed of 2 seconds for each repetition and a medium exercise performance speed.
214847193|NCT05327439|OTHER|Nicotine (electronic cigarette)|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at in-person and phone assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose one of two e-liquid flavors (tobacco, menthol) at baseline.
214289438|NCT00844688|DRUG|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~1. Progression of disease.~2. The patient is unlikely to benefit from further treatment as~   Judged by the Investigator.~3. Intolerable toxicity of the drugs.~4. Withdrawal of consent for any reason."
214289439|NCT00844688|DRUG|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 \& 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
214289440|NCT06521294|OTHER|Mulligan SNAG mobilization tecnique|Mulligan SNAG mobilization tecnique
214289441|NCT06521294|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
214289442|NCT02700815|DRUG|Diclofenac|
214289443|NCT02700815|DRUG|Capsaicin|
214289444|NCT02700815|DRUG|Placebo|
214289445|NCT03542981|DEVICE|Interferential Current|
214289446|NCT03542981|DEVICE|Sham Interferential Current|
214289447|NCT04784949|PROCEDURE|portland cement|pulpotomy with PRF and white Portland cement
214473372|NCT03774641|DRUG|Lamictal|Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
214473373|NCT02631746|OTHER|Laboratory Biomarker Analysis|Correlative studies
214473374|NCT02631746|BIOLOGICAL|Nivolumab|Given IV
214473375|NCT02631746|OTHER|Pharmacogenomic Study|Correlative studies
214473376|NCT06532630|GENETIC|Anti-CD19-CAR-T cells|"Each subject will be infused with single dose of anti-CD19-CAR-T cells.~A classic 3+3 dose escalation will be employed."
214473377|NCT06532630|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
214473378|NCT06532630|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
214473379|NCT06380309|BIOLOGICAL|IDOV-SAFE|Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression
214289448|NCT04784949|PROCEDURE|Mineral trioxide aggregate|pulpotomy with PRF and white Mineral trioxide aggregate
214289449|NCT04784949|PROCEDURE|Biodentine|pulpotomy with PRF and Biodentine
214289450|NCT04016753|DRUG|BMS-986256|30 mg(6ml)
214289451|NCT04016753|DRUG|Loestrin|1.5 mg Norethindrone and 30ug ethinyl estradiol
214289452|NCT00524368|DRUG|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
214289453|NCT00524368|DRUG|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
214289454|NCT02201654|OTHER|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
214289455|NCT03683108|DRUG|Resveratrol and Carbossimetyl Beta Glucan|Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
214289456|NCT03683108|OTHER|Saline Solution|Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
214289457|NCT06293755|DEVICE|Microneedle patch|with 20 units botulinum toxin
214289458|NCT06293755|DEVICE|Intradermal injection|with 20 units botulinum toxin
214289459|NCT01876160|OTHER|Transcutaneous electrical nerve stimulation|
214473380|NCT05933499|DRUG|IV bimagrumab|IV bimagrumab (30mg/kg IV administered at 0, 4, 16, 28, and 40 weeks)
214473381|NCT05933499|DRUG|IV placebo|IV placebo (administered at 0, 4, 16, 28, and 40 weeks)
214473382|NCT05933499|DRUG|Semaglutide|Semaglutide 2.4mg SQ qweek
214473383|NCT05933499|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Elemental calcium 1200 mg + vitamin D3 800 IU PO daily
214473384|NCT05933499|BEHAVIORAL|Lifestyle and nutrition counseling|Lifestyle and nutrition counseling consistent with current guidelines for weight management
214473385|NCT06105580|PROCEDURE|Conduction system pacing|Conduction system pacing implant as a Resynchronization therapy.
214473386|NCT06105580|PROCEDURE|Biventricular pacing|Biventricular pacing implant
214473387|NCT05674851|OTHER|MRI|collection of MRI scans for mathematical model development
214657293|NCT06834880|DEVICE|No intervention; Observational study|Sample bank with Health Questionnaire
214473388|NCT04571619|BEHAVIORAL|Pain Coping Skills Training (PCST)|The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.
214473389|NCT04571619|DRUG|Buprenorphine|At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
214473390|NCT05776875|DRUG|Atezolizumab Injection|Atezolizumab is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma It is a fully humanized, engineered monoclonal antibody of Immunoglobulin G1 (IgG1) isotype against the protein programmed cell death-ligand 1 (PD-L1).
214473391|NCT05776875|DRUG|Bevacizumab|Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
214473392|NCT05776875|COMBINATION_PRODUCT|Transarterial chemoembolization|Transarterial chemoembolization (TACE) is a local therapy for HCC which induces tumor necrosis.
214473393|NCT05889247|OTHER|Circulating tumor DNA treatment monitoring|A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
214473394|NCT05669391|DIAGNOSTIC_TEST|Genomic analysis of antidepressants|Genomic analysis of all antidepressants. Tris EDTA anticoagulation and salting out were used to extract DNA. OD 260/280 was between 1.6-1.8 and the concentration was greater than 50 ng/ μ L。 Using the PCR gene chip detection method and the Asian Screening Array (ASA) chip detection technology of Illumina Company (this chip is the first whole genome SNP chip designed based on the whole genome sequencing data of 9000+East Asian populations, which contains 750000 markers, with 85% of the effective loci), we can obtain the genetic information of polymorphic loci related to the individual differences of drug effects of subjects.
214473395|NCT05354765|OTHER|blood sample|lymphapheresis before and during treatment, blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression
214473396|NCT05354765|OTHER|blood sample|lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment
214473397|NCT06138977|DEVICE|Powered prosthesis|A powered prosthesis will be used to restore normative leg biomechanics to above-knee amputee participants during different activities of daily life.
214473398|NCT06731621|DRUG|Psilocybin|"2 dosing sessions 1 week apart, each about 6-8 hours duration~Psilocybin-assisted therapy (PAT), is a psychotherapeutic intervention in which the psychological effects of psilocybin play a significant role. PAT procedures typically involve psychological preparation prior to therapist-supported psilocybin dosing sessions. These sessions are used to establish a therapeutic relationship, inform participants about what to expect, and set expectations for the dosing session. During the psilocybin dosing session, trained therapists support the individual through their experience and psychological integration therapy occurs after the dosing experience. PAT has shown impressive antidepressant effects in people with TRD or severe MDD in at least six modern-era clinical trials (Andersen et al., 2021)."
214473399|NCT05308238|BEHAVIORAL|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
214473400|NCT05308238|BEHAVIORAL|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
214473401|NCT04709419|DEVICE|Celliant Diabetic Medical Socks|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction."
214473402|NCT04709419|DEVICE|Control (placebo) Medical Socks|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
214473403|NCT05683340|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
214473404|NCT05683340|DRUG|Placebo|placebo, tablet, once daily, for 12 weeks
214473405|NCT05317234|GENETIC|Whole-exome sequencing|The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
214473406|NCT06359002|DRUG|BYON4413|BYON4413 will be administered by IV infusion.
214473407|NCT03204916|BEHAVIORAL|Discussion|Participate in focus group
214473408|NCT03204916|OTHER|Medical Chart Review|Data abstraction and central review
214473409|NCT03204916|OTHER|Questionnaire Administration|Complete questionnaire
214473410|NCT05200923|DEVICE|Sacral Neuromodulation|Sacral neuromodulation delivers electrical stimulation to a sacral nerve
214473411|NCT03536767|DRUG|AG10|AG10 800mg twice daily, oral administration
214473412|NCT05320718|DRUG|Ropivacaine|20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
214473413|NCT06088095|OTHER|Mobility group|Patients will be mobilized in accordance with the gradual mobilization procedure 12 hours after the angiography procedure.
214473414|NCT02224144|DRUG|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
214847194|NCT05327439|OTHER|Nicotine (nicotine pouch)|Participants will be provided with 4mg nicotine pouches for 8 weeks and encouraged at in-person and phone assessments to use the nicotine pouches any time they would normally smoke. Participants will be able to choose one of two nicotine pouch flavors (tobacco, mint) at baseline.
214473415|NCT02224144|DRUG|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
214473416|NCT02224144|DRUG|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
214473417|NCT06210594|COMBINATION_PRODUCT|Mupirocin + Nozin + chlorhexidine gluconate|Education/household supplies + antibiotic + antiseptic regimen
214473418|NCT06210594|BEHAVIORAL|Education + Household supplies|Education/household supplies
214847195|NCT06627894|BEHAVIORAL|Therapist-Assisted Internet Cognitive-Behavioral Therapy for Depression|Good Days Ahead (MindStreet, Inc.)
214847196|NCT06627894|BEHAVIORAL|Active Control|Depression education, symptom monitoring, and standard depression care
214847197|NCT05705791|DEVICE|QuiremSpheres|166Holmium selective internal intra-arterial radiation therapy at C1D15 of the Atezolizumab and Bevacizumab therapy
214847198|NCT04230876|BEHAVIORAL|Auditory Brian Training Games/Activities|Game-based activities that encourage listening to words and sentences in noisy situations. Participants will receive subscriptions to the clEAR online auditory training activities and recommended protocol for those who recently received new hearing aids.
214847199|NCT03485027|DRUG|the rechallenge regimen|XELOX regimen: Oxaliplatin 130mg/m2, intravenous, on day 1; Capecitabine 1000mg/m2, oral, twice daily, continuously for 14 days; ±bevacizumab 7.5mg/kg, intravenous, on day 1; repeating every 3 weeks. FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours; ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Irinotecan monotherapy regimen: Irinotecan 180mg/m2 on day 1, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1; ± Cetuximab 500mg/m2, repeating every 2 weeks.
214847200|NCT03066934|OTHER|noninvasive ventilation respiratory support|
214847201|NCT03255863|OTHER|Questionnaire|Patient Self reported questionnaire filled in.
214847202|NCT00739973|DRUG|Placebo|
214847203|NCT00739973|DRUG|Aliskiren 150 mg tablet|
214847204|NCT00739973|DRUG|Aliskiren 300 mg tablet|
214289460|NCT05194592|DRUG|Dapagliflozin|The patients assigned to the Dapagliflozin group will take Farxiga Pill 10mg for 6 months.
214847205|NCT00739973|DRUG|Amlodipine 5 mg capsule|
214847206|NCT00739973|DRUG|Amlodipine 10 mg capsule|
214847207|NCT00739973|DRUG|Aliskiren/amlodipine 150/5 mg tablet|
214847208|NCT00739973|DRUG|Aliskiren/amlodipine 150/10 mg tablet|
214847209|NCT00739973|DRUG|Aliskiren/amlodipine 300/5 mg tablet|
214847210|NCT00739973|DRUG|Aliskiren/amlodipine 300/10 mg tablet|
214847211|NCT01010789|DRUG|Armodafinil|flexible dose 150-250mg/day
214847212|NCT01010789|DRUG|Armodafinil|150-250mg/day; flexible dose
214289461|NCT05194592|DRUG|Gemigliptin|The patients assigned to the Gemigliptin group will take Zemiglo Pill 50mg for 6 months.
214473419|NCT06118502|BEHAVIORAL|Switching to a different medication|Participants will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again at week 4.
214473420|NCT06118502|BEHAVIORAL|Continued use of the same medication|Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.
214473421|NCT06118502|BEHAVIORAL|Switching to a harm reduction tobacco product|Participants will receive four weeks of e-cigarette products with instructions to switch completely at Week 8
214473422|NCT03995550|DRUG|LEO 142397|A compound in development by LEO Pharma A/S
214473423|NCT03995550|DRUG|Placebo|Placebo
214473424|NCT06371950|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis|5 billion colony forming units (CFU) per day for 9 weeks (3 weeks before surgery to six weeks after surgery)
214473425|NCT06371950|OTHER|Placebo|Placebo
214473426|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
214473427|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
214473428|NCT03671044|DRUG|Taxotere® (100 mg/m2)|Docetaxel Injection Concentrate; 20 mg/0.5 mL
214473429|NCT04871568|PROCEDURE|Temporary central dialysis catheterization|Placement of temporary central dialysis catheter
214473430|NCT04014907|PROCEDURE|Frozen Elephant Trunk Technique|Endovascular technique forTAA repair
214473431|NCT06015659|DRUG|Zentalis|Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
214473432|NCT06015659|DRUG|Gemzar|Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
214847213|NCT01010789|DRUG|Matching placebo|Placebo comparator
214847214|NCT05515107|DEVICE|Videolaryngoscope size 1 Miller blade|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
214847215|NCT01571817|BIOLOGICAL|Isolated Human Pancreatic Islets|
214847216|NCT05988424|OTHER|Left atrial mapping|Creation of a left atrial voltage map
214847217|NCT01965626|DRUG|Oseltamivir|Oseltamivir 75 mg twice per day, 10 consecutive days
214847218|NCT01965626|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
214473433|NCT05520593|DIETARY_SUPPLEMENT|Complex Carbohydrate Drink|Patients will drink a complex carbohydrate drink 3 hours before surgery. Drink to be given at the preoperative holding area.
214473434|NCT06350500|BEHAVIORAL|Patient Navigation|Receive patient navigation
214473435|NCT06350500|OTHER|Questionnaire|Ancillary studies
214473436|NCT06452914|DEVICE|Semiconductor Embedded Therapeutic Socks|Semiconductor Embedded Therapeutic Socks
214473437|NCT06452914|DEVICE|Placebo Socks|Socks not containing the Semiconductor Embedded Therapeutic fabric
214473438|NCT03989778|DRUG|Vitamin D|Vitamin D supplementation
214473439|NCT05046639|DRUG|10 mL 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine. Crossover treatment 5 days later using image guided sciatic nerve anesthetic block of the contralateral limb with 10 mL preservative-free saline.
214473440|NCT05046639|DRUG|10 mL preservative free saline|"Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.~Crossover treatment 5 days later using Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine."
214473441|NCT03911011|OTHER|Fresh air|Fresh air insufflation of 2 L/min toward mouth/nose.
214473442|NCT01401751|DEVICE|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
214847219|NCT02240004|DEVICE|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
214847220|NCT01662362|DEVICE|Testing Donor Specimens with ESA Chagas|Donors will be asked to return for a follow-up blood draw.
214847221|NCT00170144|DRUG|Branchamin 4%|
214289462|NCT01759030|DRUG|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
214473443|NCT06052514|DEVICE|Continuous positive airway pressure|Patients with moderate or severe OSA will be treated with CPAP
214473444|NCT06014749|PROCEDURE|undergo|regional anesthesia
214657294|NCT06833463|DRUG|LCP Tacro (tacrolimus)|Treatment with LCP Tacro will begin on the day of the kidney transplant. If a patient is switching from another form of tacrolimus to LCP Tacro, the transition will be completed no later than day 8, following the standard procedures of the medical institution.
214847222|NCT04118868|COMBINATION_PRODUCT|Pembrolizumab administered using the Sofusa® DoseConnect™|pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
214847223|NCT00932724|DRUG|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
214847224|NCT00932724|DRUG|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
214847225|NCT06397222|DRUG|Sin-Bev-SIRT|Sintilimab 200mg I.V. q3w and bevacizumab 7.5mg/kg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab and bevacizumab will last up to 24 months. Patients will be allowed to have sintilimab or bevacizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
214847226|NCT02197208|PROCEDURE|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
214289463|NCT02773355|DRUG|liraglutide 3.0 mg|Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
214289464|NCT00531232|DRUG|Clofarabine|"Pharmaceutical form: Tablet,~Route of administration: Oral"
214847227|NCT02197208|PROCEDURE|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is \>/= 17 mm and the endometrium measures \>/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
214289465|NCT00840346|DRUG|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
214473445|NCT06014749|DEVICE|ultrasound|ultrasound guided
214473446|NCT06014749|DRUG|Local anesthetic|local anesthetic
214473447|NCT02962076|DRUG|[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)|this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
214473448|NCT05175521|OTHER|Eucalyptus Oil Scent|Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
214473449|NCT05175521|OTHER|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
214473450|NCT03650712|DIAGNOSTIC_TEST|Oral glucose tolerance test|oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
214847228|NCT02197208|DEVICE|ultrasound|
214847229|NCT01181531|DRUG|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
214473451|NCT03650712|DIAGNOSTIC_TEST|Continuous glucose monitoring|a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days
214473452|NCT03650712|DIAGNOSTIC_TEST|Dexa scan|low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
214473453|NCT06024083|BEHAVIORAL|Dialectical Behavior Therapy skills video intervention|A series of 14 animated videos (9 acceptance-oriented and 5 change-oriented skills videos) available in both English and Mandarin Chinese.
214473454|NCT06482359|BIOLOGICAL|coformulated CIC Vaccine|SARS-CoV-2 rS (35 µg) + trivalent hemagglutinin nanoparticle influenza (tNIV) antigen (180 µg; 60 µg per strain) + Matrix-M adjuvant (75 µg)
214473455|NCT06482359|BIOLOGICAL|Fluzone HD trivalent|60 µg per strain of 3 strains (sodium phosphate buffered isotonic sodium chloride solution + formaldehyde and octyl phenol ethoxylate)
214473456|NCT06291350|OTHER|Plaque sampling and stool collection|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
214473457|NCT06291350|OTHER|periodontal examination|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
214473458|NCT05693701|BEHAVIORAL|Implementation Strategy Bundle|Bundle includes multimodal communications to notify donors about high cholesterol and its treatment, website with resources, and an optional care navigator. Resources for their primary care provider will also be disseminated.
214473459|NCT05693701|OTHER|Usual care notification|Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.
214473460|NCT04741776|BEHAVIORAL|Resilience Enhancement Skills Training|Family therapy
214473461|NCT04741776|BEHAVIORAL|Problem-Solving Individual Therapy|Individual therapy
214473462|NCT04089865|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.
214473463|NCT03520790|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
214473464|NCT03520790|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
214473465|NCT03520790|DRUG|Paricalcitol|Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
214473466|NCT03520790|OTHER|Placebo|Placebo
214473467|NCT05656105|DRUG|DPA-714 PET/MRI|DPA-714 PET/MRI
214473468|NCT04181970|OTHER|Quality assessment|There is no intervention on study subjects. A tumor review will be performed by expert centers.
214473469|NCT04666636|DRUG|Placebo|Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
214473470|NCT04666636|DRUG|Mirabegron|Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
214473471|NCT05975580|DRUG|Topiramate|Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
214473472|NCT05975580|DRUG|Phentermine|Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine
214473473|NCT05975580|DRUG|Placebo|Placebo is an inactive substance.
214473474|NCT05088694|BEHAVIORAL|Peaceful Coexistence|"The Peaceful Coexistence intervention seeks to target important risk and protective factors related to tolerance and acceptance.~The Anti-Extremism intervention seeks to take the same risk and protective factors covered in the Peaceful Coexistence intervention and have students' psychosocial factors shift their skills and behavior."
214473475|NCT01761305|PROCEDURE|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
214473476|NCT01761305|BEHAVIORAL|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
214473477|NCT01761305|OTHER|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
214657295|NCT04375761|PROCEDURE|Collection of Biological Samples|Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.
214473478|NCT06378554|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM). The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
214473479|NCT05142384|BEHAVIORAL|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later."
214473480|NCT05142384|COMBINATION_PRODUCT|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies
214473481|NCT05043051|DEVICE|Vagal stimulation|Vagal stimulation
214473482|NCT05043051|DEVICE|Sham stimulation|Sham vagal stimulation
214473483|NCT03835065|PROCEDURE|Closed Reduction|The primary goal of closed reduction is to maintain appropriate bony alignment and angulation to allow for appropriate healing.
214473484|NCT03835065|OTHER|Long Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
214473485|NCT03835065|OTHER|Short Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
214473486|NCT04874688|DIETARY_SUPPLEMENT|Small-quantity lipid-based nutrient supplement|Small Quantity Lipid-based Nutrient Supplement (SQ-LNS) is a food supplement rich in both macro and micronutrients (calories, proteins, fat and multivitamin mix). SQ-LNS is not considered a regulated drug product in Zimbabwe, or by the United States Food and Drug Administration (FDA). It is commercially available for prevention of chronic malnutrition, produced by Nutriset (https://www.nutriset.fr/products/en/enov-nutributter2). Each child will receive a daily sachet of 20g SQ-LNS between 6-12 months of age, consumed directly from the sachet or mixed with porridge.
214657296|NCT04375761|PROCEDURE|Symptom and Exposure Surveys|Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.
214847230|NCT01181531|DRUG|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
214847231|NCT06010745|DIETARY_SUPPLEMENT|Biotin and silicon|The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.
214847232|NCT06010745|DIETARY_SUPPLEMENT|Placebo|Inert ingredients only
214847233|NCT00987831|OTHER|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
214847234|NCT00987831|OTHER|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
214847235|NCT00987831|DRUG|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
214847236|NCT01000688|DRUG|vildagliptin + acarbose|4 week treatment
214847237|NCT01000688|DRUG|acarbose + vildagliptin|4 week treatment
214847238|NCT04593147|OTHER|BBN|BBN to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
214847239|NCT04593147|OTHER|Brand|Brand to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks
214473487|NCT04874688|DIETARY_SUPPLEMENT|Provitamin A biofortified maize|Provitamin A Maize Meal is orange maize-meal processed from provitamin A-rich orange maize. PVA maize meal will be sourced from International Maize and Wheat Improvement Centre (CIMMYT). Children in the intervention arm will consume 13g - 128g of pro-vitamin A (PVA) maize meal, with added powders. Each family will receive a monthly ration of 5kg PVA maize and this ration takes into consideration of household sharing. Families with children in the IYCF arm will receive white maize meal.
214473488|NCT04874688|DIETARY_SUPPLEMENT|NUA-45 biofortified sugar beans|NUA 45 bean powder is ground from roasted iron and zinc-rich biofortified sugar beans. NUA 45 bean powder will be sourced from Sky Brands Ltd Company. Children will consume a daily dose of 5g - 15g of NUA 45 bean powder added to complementary foods.
214473489|NCT04874688|DIETARY_SUPPLEMENT|Moringa oleifera|Moringa oleifera is an edible plant abundant in dry tropic regions including Zimbabwe. It is known to be rich in micronutrients and has been widely used in Zimbabwe and around the world both as a food and a herb. Moringa oleifera leaf powder, is a dried and ground powder produced from Moringa oleifera leaves using traditional methods. It has been widely used to fortify complementary foods in the African region with the aim of improving micronutrient status. Moringa oleifera leaf powder will be sourced from Lemex Products Company. Children will receive a daily dose of 5g - 15g of Moringa leaf powder added to complementary foods.
214473490|NCT04874688|DIETARY_SUPPLEMENT|Whole egg powder|Egg Powder is hydrolysed non-genetically modified organism (GMO), fine and unflavoured whole egg powder. It is processed with no additives, preservatives, lecithin, added sugar, soy or monosodium glutamate. Egg powder will be sourced from France (A \& D Food Ingredients - distributor in South Africa). Children in the IYCF-plus arm will receive a daily dose of 14g egg powder. A 15% extra amount of egg powder will be provided to families taking into consideration of household sharing. Egg powder will be provided in sealed plastic jars similar to that of peanut butter and households will receive promotion messages to store the powder in a cool, dry place and avoiding contact with water or moisture during use.
214473491|NCT04874688|DIETARY_SUPPLEMENT|White maize meal|Commercial white maize meal will be provided monthly. Infants age 6-8 months will receive 45g (3 tablespoons) daily; infants aged 9-12 months will receive 71g (4.5 tablespoons) daily.
214473492|NCT05230914|OTHER|Simplified imaging strategy|NCCT and CTA will be used to screen patients for endovascular treatment
214473493|NCT05230914|OTHER|Standard imaging strategy|NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
214473494|NCT05255237|DRUG|Jaktinib|75mg BID
214473495|NCT05660512|PROCEDURE|Intracept Procedure|Radiofrequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
214473496|NCT05482360|OTHER|PrEP Optimization Interventions|There were three bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders
214473497|NCT06040476|BIOLOGICAL|hUCB|hUCB
214473498|NCT06343610|DIETARY_SUPPLEMENT|Active product|Contains a complex of: Calaguala leaves extract (Polypodium leucotomos), vitamin C (L-ascorbic acid), blood orange fruit extract (Citrus sinensis; red orange extract), vitamin E (alpha-tocopheryl acetate), vitamin A (retinyl palmitate), vitamin D3 cholecalciferol.
214473499|NCT06343610|DIETARY_SUPPLEMENT|Placebo|No active ingredients.
214473500|NCT02700009|BEHAVIORAL|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
214473501|NCT02700009|OTHER|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
214473502|NCT06246409|BEHAVIORAL|Modernized patient instructions|Patients will be given modernized patient instructions prior to radiotherapy treatment.
214473503|NCT06246409|BEHAVIORAL|Existing patient instructions|Patients will be given the patient instructions currently in use prior to radiotherapy treatment.
214657297|NCT03797001|DRUG|Anakinra|100 mg subcutaneous injection, daily for 24 weeks
214847240|NCT02246686|DRUG|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
214847241|NCT02246686|DRUG|Placebo|Application over 12 weeks 20 drops three time daily
214847242|NCT02593344|DEVICE|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
214847243|NCT03220126|BIOLOGICAL|LY3074828|Administered IV
214847244|NCT03220126|BIOLOGICAL|LY900021|Administered SC
214847245|NCT02425501|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
214847246|NCT01784198|DIETARY_SUPPLEMENT|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
214847247|NCT02285205|DRUG|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
214847248|NCT04593303|PROCEDURE|Internal iliac artery ligation with cervicoisthmic compression suture|Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed
214847249|NCT04593303|PROCEDURE|Cervicoisthmic compression suture without Internal iliac artery ligation|Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
214847250|NCT02571803|BEHAVIORAL|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
214657298|NCT03797001|DRUG|Placebo|subcutaneous injection, daily for 24 weeks
214847251|NCT02571803|OTHER|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
214847252|NCT05057793|DEVICE|geko|The geko device will be self-administered and deliver 12 hours of therapy daily.
214847253|NCT00576303|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
214847254|NCT04452695|DEVICE|Doctor Spot|Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
214847255|NCT03955939|DRUG|LY3295668 Erbumine|Administered orally.
214847256|NCT03955939|DRUG|Endocrine therapy|Administered according to label instructions.
214289466|NCT02652520|PROCEDURE|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
214289467|NCT04716569|DRUG|intranasal ivermectin spray|usage of ivermectin as intranasal spray for treating early covid patiens
214473504|NCT04417998|DRUG|18F-FDG|A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.
214473505|NCT04417998|DRUG|18F-AV1451|A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.
214289468|NCT01850550|BEHAVIORAL|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
214473506|NCT04417998|DEVICE|Siemens E7 Reconstruction Tool|Software to correct for motion
214473507|NCT06200779|DIAGNOSTIC_TEST|Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test|"Described in Arms section"
214473508|NCT06200779|DRUG|Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)|"Described in Arms section"
214473509|NCT06200779|DRUG|PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-sensitive strain
214289469|NCT02233816|BIOLOGICAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
214289470|NCT02233816|BIOLOGICAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
214289471|NCT02233816|BIOLOGICAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
214289472|NCT02233816|BIOLOGICAL|Placebo|A single dose of placebo
214289473|NCT03021408|OTHER|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
214473510|NCT06200779|DRUG|PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-sensitive strain
214473511|NCT06200779|DRUG|Bismuth quadruple therapy (Pylera®) for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-resistant strain
214473512|NCT05538286|DEVICE|ClearFit implant|The ClearFit implant is an FDA cleared implant in regular use in the United States. The ClearFit implant and other PMMA cranioplasty implants manufactured by Longeviti have been reported to be safe and effective as cranial implants that permit transcranial ultrasound to be performed. The PMMA cranioplasty implant (Longeviti Neuro Solutions, Hunt Valley, MD) is clear, sonolucent, and was recently shown to be safe and effective in transcranial ultrasonography for bypass patency assessment. The ClearFit cranioplasty being used in this study is industry standard of care.
214473513|NCT05538286|PROCEDURE|transcranial ultrasonography through sonolucent cranioplasty|The implantation of the ClearFit PMMA sonolucent implant permits TUSC to be performed at the bedside for patients in both the in-patient and outpatient settings. While the patient is an inpatient, the clinical or research teams will attempt to perform TUSC within 1 hour of neuroimaging if that neuroimaging is performed at a time when a trained ultrasound operator is present.
214473514|NCT06565546|OTHER|Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin|CYP2D6 genotype testing for assessment of medication metabolism to guide prescription of postoperative pain medication
214473515|NCT06565546|OTHER|Acetaminophen and Gabapentin: standard postoperative pain medications|Participants will receive standard postoperative pain medications
214657299|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening with tension.|A Foley balloon will be placed for cervical ripening with tension.
214847257|NCT03955939|DRUG|Midazolam|Administered orally.
214847258|NCT05982249|DEVICE|Hypnosis|Patients will be given earphones to hear a hypnotic script that was recorded by Dr. Zahi Arnon, a psychologist specializing in hypnosis after observing about ten BM examinations at the hematology institute. The length of the recording is about 7 minutes.
214847259|NCT05982249|DEVICE|Virtual reality (VR)|Patients will be connected to a VR device that will transmit to the patient's choice a 3D screen and soothing noise for about 7 minutes.
214847260|NCT04552912|BEHAVIORAL|Build Stamina Program|Build StaMINA intervention is a self-management intervention that provides information, motivation, behavioral skills to engage in PA, and ultimately a tailored PA program for adults with AL who are receiving consolidation/maintenance chemotherapy.
214847261|NCT05792319|DIAGNOSTIC_TEST|24 hour copper in urine and liver function test|sampling 24 hour copper in urine and liver function test
214847262|NCT00810602|PROCEDURE|reduced intensity, related donor stem cell transplant|"Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant."
214847263|NCT00810602|DRUG|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
214847264|NCT00810602|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
214847265|NCT00810602|DRUG|vorinostat|"Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher \[probably or definitely related to the drug\] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study."
214473516|NCT04859608|DRUG|Spacing of Eculizumab infusions|Personalized spacing of eculizumab infusions using a pharmacokinetic population model to estimate eculizumab concentration ( a one-week spacing of eculizumab infusion will be decide if predicted eculizumab concentration in the event of spacing is \> 150 mg/L). Spacing of infusion can be decided every 3 months.
214473517|NCT05278780|OTHER|Screening for eligibility|Asynchronous screening
214473518|NCT02780700|DRUG|Nintedanib|
214473519|NCT02780700|DRUG|Capecitabine|
214473520|NCT04824079|DRUG|Keynatinib|The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
214473521|NCT06406088|DEVICE|EarGenie MVP test|The EarGenie MVP test consists of placing the EarGenie headgear containing light emitting diodes (LEDs) and light detectors on the infant and running the fNIRS tests of sound detection or sound discrimination via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation in temporal and prefrontal regions of the cortex. Automatic analyses are run to determine whether the infant heard the sounds (at levels 35, 50, and 65 dBSPL) or discriminated between two sounds (Ba/Tea, Ba/Bee, or Ba/Ga). The infant will be in a natural sleep or quiet awake state when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
214473522|NCT05210855|DIAGNOSTIC_TEST|CT scan|Scan with classic dose followed by ultra-low dose
214473523|NCT04795661|DRUG|Pembrolizumab|Administered intravenous (IV)
214473524|NCT05865743|DRUG|SDD|"The intervention group receives SDD treatment additional to standard care, comprising two distinct liquids for oral administration: first the 5 ml amphotericin B suspension (100 mg/ml) and subsequently the 5 ml SDD base for suspension, containing both colistin sulphate (20 mg/ml) and tobramycin sulphate (16 mg/ml).~Patients take the 5 ml amphotericin B, followed by the 5 ml SDD base for suspension, four times daily for one week, starting three days prior to the surgery. On the day of surgery, intake is limited to an early morning and a late evening dose."
214473525|NCT02818426|DRUG|UCPVax|
214473526|NCT04622774|DRUG|IMGC936|Antibody Drug Conjugate
214847266|NCT05338476|DRUG|Midazolam|Administered orally.
214847267|NCT05338476|DRUG|Selpercatinib|Administered orally.
214847268|NCT02792218|DRUG|Ofatumumab subcutaneous injection|Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
214847269|NCT02792218|DRUG|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
214473527|NCT06298851|OTHER|Neural Mobilization Group (NMG)|"Femoral nerve gliding: Mobilization of the femoral nerve will performed while the participant in the prone position and the hip hyperextended. Tension will applied by placing the knee in full flexion and the ankle in plantar flexion.~Sciatic nerve gliding: Participants will take turns while sitting with the trunk in thoracic flexion; perform knee extension/dorsiflexion with cervical extension and knee flexion/plantar flexion with cervical flexion. Tension will applied by flexing the hip and dorsiflexing the ankle to the point where stress will felt.~Peroneal nerve gliding: The participant will asked to maintain this position in a supine position by placing the ankle in inversion and plantar flexion. From a starting position consisting of ankle dorsiflexion, knee, and hip extension, the patient will return to the starting position by simultaneously performing ankle plantar flexion and inversion, full knee flexion, and 90 degrees of hip flexion."
214473528|NCT06298851|OTHER|Dynamic Stretching Group (DSG)|Exercises will include functional activities that provided dynamic stretching of the hamstrings, quadriceps, hip flexor, extensor, abductor and adductor muscles, and gastrosoleus muscle. All stretching exercises will be performed in two circuits in an area of 15 m2. 4 sets of 10 repetitions will be performed, each exercise cycle lasting 6 seconds, and a 1-minute rest period will be given between sets. This process will be repeated for both extremities.
214473529|NCT06298851|OTHER|Static Stretching Group (SSG)|"Static stretching exercises will be described to the participants as given below:~Standing quadriceps stretch: The participant will stand upright, fold one knee and bring the heel towards the buttock while holding the foot with one hand.~Modified hamstring stretching: The participant will be in a seated position with one leg straight and will place the other foot on the inside of the straight leg and reach forward.~Gastrocnemius stretching: The participant stands with feet 60-90 cm from the wall, leaning against the wall with both hands, keeping the back leg straight and the front leg slightly bent.~Adductor stretching: Participants will be in a sitting position with an erect spine, bending and releasing their knees with the soles of their feet touching.~Lumbar stretching: In a sitting position, participants keep one leg straight and place the other foot on the outside of the straight leg and rotate the body diagonally."
214847270|NCT02792218|DRUG|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
214847271|NCT02792218|DRUG|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
214847272|NCT00824369|DRUG|No drug will be administered|No drug will be administered.
214847273|NCT01745952|DEVICE|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
214847274|NCT01745952|DEVICE|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
214847275|NCT01745952|DEVICE|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
214473530|NCT04948476|OTHER|Standardized Dialysis and Structured Discontinuation (S2D2)|"Prescription to minimize dialysis-induced ischemia~* Cool dialysate (35.0◦C)~* Dialysate sodium of 145mmol/L~* Dialysate calcium of 1.5mmol/L~* Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)~  * Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.~Structured dialysis discontinuation (all criteria met)~* Most recent pre-dialysis potassium \<6mmo/L and bicarbonate \>12mmol/L~* Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis \<1L/session~* If available, timed urine collection with result for mean creatinine and/or urea clearance \>12mL/min"
214473531|NCT04948476|OTHER|Usual Care|Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.
214473532|NCT06397443|OTHER|5-day sailing activity|"* Sailing activity (4 h/die)~* Stretching exercises pre and post-sailing activity~* Post-activity debriefing"
214473533|NCT05127044|DEVICE|Diffuse Reflectance Spectroscopy|DRS will be used as a non-invasive optical spectroscopy method to collect key biological information from neonatal skin including skin maturity, blood oxygenation, and bilirubin content.
214473534|NCT05127044|DIAGNOSTIC_TEST|BiliChek|BiliChek will be used as a control for determining bilirubin content.
214473535|NCT05623306|DEVICE|PMT Stereoencephalography (SEEG)|For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.
214473536|NCT05623306|DEVICE|Vercise Genus™ Deep Brain Stimulation (DBS) System|For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
214473537|NCT03868579|PROCEDURE|Biopsy|Undergo biopsy
214473538|NCT03868579|OTHER|Medical Chart Review|Review medical chart
214847276|NCT03167502|OTHER|eccentric work|patient will follow 2 eccentric trainings per week during 6 weeks
214847277|NCT03167502|OTHER|concentric work|patient will follow 2 concentric trainings per week during 6 weeks
214847278|NCT04752488|OTHER|Telerehabilitation (TR)|The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
214847279|NCT04752488|OTHER|Conventional Rehabilitation (CR)|The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
214847280|NCT05520606|PROCEDURE|pancreatoduodenectomy|Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
214847281|NCT00392782|BIOLOGICAL|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
214847282|NCT00392782|DRUG|fludarabine phosphate|Fludarabine 40 mg/m\^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m\^2).
214847283|NCT00392782|DRUG|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
214847284|NCT00392782|PROCEDURE|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
214847285|NCT00392782|RADIATION|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
214847286|NCT06188052|DRUG|Tranexamic acid|Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
214847287|NCT01463150|DRUG|Clopidogrel|Clopidogrel 150mg per day for 15 days
214847288|NCT01463150|DRUG|Prasugrel|Prasugrel 5mg per day for 15 days
214473539|NCT03868579|PROCEDURE|Thoracoscopy|Undergo pleuroscopy
214473540|NCT06498687|DRUG|CYR-064|Theophylline Nasal Spray
214657300|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening without tension.|A Foley balloon will be placed for cervical ripening without tension.
214657301|NCT05630846|BIOLOGICAL|Investigational MMRV(H)NS vaccine|1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.
214657302|NCT05630846|BIOLOGICAL|Investigational MM(H)RVNS vaccine|1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.
214657303|NCT05630846|BIOLOGICAL|Investigational M(L)M(L)R(L)V(L)NS vaccine|1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.
214657304|NCT05630846|BIOLOGICAL|Marketed MMRV_Lot 1 and Lot 2 vaccine|1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.
214657305|NCT05690048|DRUG|Fecal microbiota transfer|FMT via capsule (50 g of fecal matter) on day 0 and day 21.
214657306|NCT05690048|DRUG|Vancomycin Oral Capsule|Vancomycin orally (250 mg 4xd, day -3 to 0).
214657307|NCT05690048|DRUG|Atezolizumab + Bevacizumab|Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).
214473541|NCT03687762|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
214473542|NCT03687762|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
214473543|NCT03687762|BEHAVIORAL|Behavioral Activation (BA)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
214473544|NCT06266299|DRUG|KK2269|KK2269 administered intravenously
214473545|NCT06266299|DRUG|Docetaxel|antineoplastic drug administered intravenously
214473546|NCT03928002|OTHER|4D Flow magnetic resonance imagery|acquisition of anatomical, volume, right ventricular remodeling and intracardiac flow information
214847289|NCT03201354|PROCEDURE|Filtration surgery with Ex-PRESS|Filtration surgery with Ex-PRESS
214847290|NCT03201354|PROCEDURE|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy
214847291|NCT03201354|PROCEDURE|Cataract extraction|Cataract surgery and IOL implantation
214847292|NCT02736630|OTHER|body temperature|intermittant tympanic temperature measurement during surgery
214847293|NCT00864617|DRUG|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
214847294|NCT00864617|DRUG|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
214847295|NCT00858013|DRUG|Nateglinide|Nateglinide 90\~120mg three times a day
214847296|NCT00858013|DRUG|Glimepiride|Glimepiride 1\~2mg once a day
214847297|NCT04762459|DRUG|Almonertinib|Almonertinib 110mg PO once daily
214847298|NCT04762459|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) Pemetrexed
214847299|NCT04762459|DRUG|Cisplatin|75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
214847300|NCT00297245|DRUG|cognitive function|
214473547|NCT03928002|PROCEDURE|Cardiac catheterization|pulmonary vascular resistance calculation ;
214473548|NCT05967390|DEVICE|Transcranial Magnetic Stimulation|One time for each day, lasting for three weeks.
214473549|NCT04980885|DRUG|AK117|Subjects receive AK117 intravenously.
214473550|NCT04980885|DRUG|Azacitidine|Subjects receive Azacitidine subcutaneously.
214473551|NCT05340621|DRUG|OKI-179 + binimetinib|"Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D."
214847301|NCT02418624|DRUG|carboplatin, olaparib|2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
214847302|NCT06887322|DRUG|Ciplukan|A minimum amount of 20 psoriasis vulgaris lesion treated with the topical formulation containing 20% ciplukan (Physalis angulata Linn.) extract, applied twice a day for 14 days.
214473552|NCT03257969|BEHAVIORAL|The DROP program of pharmaceutical interventions|Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.
214847303|NCT06887322|DRUG|Bethametasone valerate 0,1% cream|A minimum amount of 20 psoriasis vulgaris lesion treated with the bethametasone valerate 0,1% cream, applied twice daily for 14 days.
214847304|NCT06474481|DRUG|Zanubrutinib|Zanubrutinib, 160mg PO BID.on days 1-28 Induction treatment: 4-6cycles ; Maintenance: 1 year;
214473553|NCT03257969|BEHAVIORAL|Standard of care|In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
214657308|NCT05690048|DRUG|Placebo Vancomycin Oral Capsule|Placebo Vancomycin orally (4xd, day -3 to 0).
214847305|NCT06474481|DRUG|Obinutuzumab|Induction treatment: Obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-4/6); for 4-6 cycles, 1 cycle = 28 days Maintenance: Obinutuzumab (G), 1000mg, IV, every 2 months for 1 year;
214847306|NCT06474481|DRUG|Prednisone|Prednisone (P), 100 mg, PO, D2-6；for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
214847307|NCT06474481|DRUG|Cyclophosphamide|Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
214847308|NCT06474481|DRUG|Vincristine|Vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
214847309|NCT06474481|DRUG|Doxorubicin|Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ，1 cycle = 28 days
214847310|NCT01007279|DRUG|ROSUVASTATIN|40 mg before procedure
214847311|NCT06889935|OTHER|Exercise diary|The respiratory exercise diary was prepared by reviewing the literature in order to record the time, number and frequency of respiratory exercises performed by patients with the use of a spirometer. On the first page of the diary consisting of two pages; the patient's name and surname, date of surgery, date of birth, how and how often to use the spirometer, and a pictorial information note to remind the position to be taken were included, while on the second page; the chart in which the patients would write the number of exercises they performed with the spirometer during the first three postoperative days opposite the relevant hour was included.
214473554|NCT05988931|BEHAVIORAL|Web Program + App|Youth receive a brief interactive web program made available online to prevent alcohol misuse. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
214473555|NCT05988931|BEHAVIORAL|Web Program + App + Text Messages|Youth receive a brief interactive web program made available online to prevent alcohol misuse. This is followed by 8 weeks of supportive text messages. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
214473556|NCT05316571|BEHAVIORAL|One 5-Minute Walking Bout Each Hour|One 5-minute light intensity walking break per hour throughout the 4-hour SB condition
214473557|NCT05316571|BEHAVIORAL|One 15-Minute Standing Bout Each Hour|One 15-minute standing break per hour throughout the 4-hour SB condition
214473558|NCT05316571|BEHAVIORAL|One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour|Two breaks per hour throughout the 4-hour SB condition, alternating between a 5-minute light intensity walking break and a 15-minute standing break
214473559|NCT05316571|BEHAVIORAL|Uninterrupted Sitting|No breaks will be provided throughout the 4-hour SB condition. This will be used as the control condition
214473560|NCT06017895|DRUG|doxepin solution|2.0 mL doxepin solution (5mg/mL) sprayed to the posterior pharyngeal wall
214473561|NCT06017895|OTHER|Placebo|2.0 mL placebo sprayed to the posterior pharyngeal wall
214473562|NCT06560502|OTHER|Standard of Care-DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
214473563|NCT06560502|OTHER|AmnioCore - DFU|Participants will receive weekly applications of AmnioCore and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
214473564|NCT06560502|OTHER|Amnio Quad-Core - DFU|Participants will receive weekly applications of Amnio Quad-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
214847312|NCT00986024|BEHAVIORAL|aerobic exercise|carried out 3 times per week for 12 weeks
214847313|NCT00986024|BEHAVIORAL|strength training|carried out 3 times per week for 12 weeks
214847314|NCT05338372|BEHAVIORAL|Two days forest therapy|Participants attend two days (with a break day in between) of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
214847315|NCT05338372|BEHAVIORAL|Three days forest therapy|Participants attend three days of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
214847316|NCT03512002|DEVICE|HIRREM|Technology
214847317|NCT03512002|OTHER|Continued Current Care|Continue their current clinical care.
214847318|NCT00145613|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
214847319|NCT00145613|DEVICE|Miltenyi Biotec CliniMACS|stem cell selection device
214847320|NCT00145613|DRUG|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
214847321|NCT01363466|PROCEDURE|hysterectomy|
214473565|NCT06560502|OTHER|Standard of Care-VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
214473566|NCT06560502|OTHER|Amnio Tri-Core - VLU|Participants will receive weekly applications of Amnio Tri-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
214473567|NCT06560502|OTHER|AmnioCore Pro|Participants will receive weekly applications of AmnioCore Pro and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
214473568|NCT06560502|OTHER|Amniocore Pro +|Participants will receive weekly applications of Amniocore Pro + and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
214473569|NCT05526521|DRUG|Dupilumab|Injection solution Subcutaneous
214473570|NCT03824366|DEVICE|Volumetric MR imaging|This will most frequently be supine with arms positioned so not in the way of treatment beams.
214473571|NCT03824366|RADIATION|Radiation therapy|-Standard of care
214473572|NCT05561764|DRUG|Imipenem/Cilastatin/Relebactam|Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.
214473573|NCT05473793|DIETARY_SUPPLEMENT|Dried chicory root particles|The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (\~3mm).
214473574|NCT05473793|OTHER|Placebo|The control arm receives a placebo consisting of rice puff particles.
214847322|NCT02280226|DEVICE|magnetic resonance imaging (MRI)|
214847323|NCT04979845|OTHER|Telerehabilitation|Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises
214847324|NCT04979845|OTHER|Video exercise|Patients will receive video instructions for home based exercises
214847325|NCT03518216|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
214473575|NCT05817812|DRUG|Efanesoctocog alfa|Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
214473576|NCT05509309|BEHAVIORAL|APERS-based model|APERS-assessments followed by in-service training, APERS-feedback and on-site coaching to improve primary school classroom quality for students with ASD/SCC
214473577|NCT01449513|DRUG|Ingenol mebutate|0.05% Ingenol mebutate Gel once daily for 2 consecutive days
214473578|NCT01449513|DRUG|Placebo Gel|Gel vehicle of PEP005
214657309|NCT05690048|DRUG|Placebo Fecal microbiota transfer|Placebo Fecal microbiota transfer (FMT) via capsule on day 0 and day 21.
214473579|NCT06560879|BIOLOGICAL|Lactobacillus casei|Lacticaseibacillus casei is a species of Gram-positive anaerobic bacteria found in the intestine and mouth of humans. This lactic acid-producing bacterium is used in the dairy industry in the production of probiotic foods.
214473580|NCT06560879|BIOLOGICAL|Lactobacillus rhamnosus|A live form of a bacterium that makes lactic acid (a substance derived from milk sugars and also made by the body). Lactobacillus rhamnosus GG is given to help with digestion and normal bowel function. In addition, it may help maintain a healthy gastrointestinal tract. It is being studied for the prevention of infections in patients who received donor stem cell transplants and for other conditions.
214473581|NCT06560879|BIOLOGICAL|Bifidobacterium bifidum|B. bifidum is an essential bacteria found in the human intestine. When it is low or absent all together in the human intestine, it is an indication of being in an unhealthy state. Intestinal flora can be improved if someone takes oral B. bifidum. Also, oral B. bifidum is used for other things such as therapy for enteric and hepatic disorders, for activating the immune response, and for preventing some cancers
214473582|NCT06560879|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production.The most common form is used in vitamin supplements or tablets
214473583|NCT04587024|OTHER|mHealth intervention|Subjects will receive mHealth direct observation of therapy for 12 weeks
214473584|NCT04587024|OTHER|standard of care|Subjects will receive standard of care observation for 12 weeks
214473585|NCT06152614|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
214473586|NCT06152614|BEHAVIORAL|Food Delivery and Cooking PLUS Aerobic Training (FoRKS+)|Food Delivery and Cooking PLUS Aerobic Training (FoRKS+) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes, and an additional 12 weeks of aerobic exercise.
214473587|NCT04466098|BIOLOGICAL|Mesenchymal stromal cells|Thawed product containing MSC(300x10\^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin \[total volume 60 mL\]
214473588|NCT04466098|OTHER|Placebo|Dextran 40 + 5% human serum albumin \[total volume 60 mL\]
214473589|NCT05069896|DRUG|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
214847326|NCT06880796|BEHAVIORAL|Mindfulness-based therapy|Mindfulness-based therapy provided in a group format.
214289474|NCT03021408|OTHER|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
214289475|NCT03021408|OTHER|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
214289476|NCT04351321|PROCEDURE|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
214473590|NCT05069896|DRUG|Mirikizumab Autoinjector|Administered SC by autoinjector
214473591|NCT05372822|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
214473592|NCT05372822|PROCEDURE|Sham spinal cord stimulation|No spinal cord stimulation is provided
214473593|NCT05372822|DEVICE|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Abbott will be implanted: ProclaimTM XR implantable pulse generator and Octrode® 8-contact lead"
214473594|NCT06444698|DIETARY_SUPPLEMENT|cookies that contain 50 grams of quinoa|250 grams of ground quinoa will be mixed with 250 grams of ready-to-use cookie flour and 100 gram of butter, one egg, and 75 gram of chocolate chips will be added. After mixing, the ingredients will be divided into (10) cookies (each cookie will continue 25 grams of quinoa) and bake them in oven for 9-11 mint at 190 °C. The placebo control group will receive cookies that continue the same ingredient but without quinoa and the cookies will look like the experimental group cookies. Cookies delivery will be every 3 to 4 days for each participants.
214473595|NCT06444698|DIETARY_SUPPLEMENT|cookies without quinoa|The placebo control group will receive cookies that continue the same ingredient of experimental group but without quinoa and the cookies will look like the experimental group cookies.
214473596|NCT04068831|DRUG|Talazoparib|1 mg talazoparib daily
214473597|NCT04068831|DRUG|Avelumab|800 mg avelumab every 2 weeks
214473598|NCT06274944|DEVICE|nasogastric tube placement pH confirmation device|Each participation will get the contents tested by the novel device and the standard of care procedure.
214473599|NCT02770222|DRUG|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
214473600|NCT02770222|DRUG|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
214473601|NCT02770222|DRUG|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
214473602|NCT05789173|DRUG|Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)
214473603|NCT05789173|DRUG|Efavirenz, Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
214847327|NCT06880796|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usually provided.
214847328|NCT01449045|DRUG|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
214847329|NCT01449045|DRUG|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
214847330|NCT03672305|BIOLOGICAL|c-Met/PD-L1 CAR-T cell injection|injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes
214847331|NCT00749411|DRUG|Placebo|matching placebo
214473604|NCT05776524|DRUG|Nab paclitaxel|125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
214473605|NCT05776524|DRUG|Gemcitabine|1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
214473606|NCT05776524|DEVICE|TheraBionic|This treatment consists of delivering low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
214473607|NCT04288128|PROCEDURE|Lumbar puncture|Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)
214473608|NCT04288128|OTHER|Magnetic Resonance Imaging (MRI)|Each participant will undergo scanning at 3 visits (M0, M6 and M12)
214473609|NCT03804905|OTHER|No-cost Medications|Patients will be connected to Trillium Health Partners outpatient pharmacy, and they will be given an information sheet with further details. The patients will get free access to diabetes, blood pressure and cholesterol medications and for glucose test strips. They can attend the pharmacy in person or arrange for home delivery.
214473610|NCT06202235|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both CKD Patients and Healthy Volunteers will undergo Magnetic Resonance Elastography (MRE) to evaluate liver and renal viscoelasticity. For CKD patients, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, CKD patients will undergo a renal biopsy to assess the extent of fibrosis
214847332|NCT00749411|DRUG|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
214289477|NCT04351321|PROCEDURE|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-Assisted Total Gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
214473611|NCT05637762|OTHER|- EEG video recording or extension of an EEG video recording planned as part of the care - Wearing a connected heart rate and motion recording patch|The study consists of creating a database to develop an algorithm using machine learning methods.
214473612|NCT05791864|GENETIC|TTX-381|One time subretinal dose in study eye
214473613|NCT04820322|OTHER|Fibersym|RS4-type resistant modified wheat starch
214473614|NCT04820322|OTHER|Control cookie|control cookie
214473615|NCT05677802|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214473616|NCT05677802|OTHER|Medical Chart Review|Undergo medical cart review
214473617|NCT05677802|PROCEDURE|Stress Management Therapy|Receive biobehavioral stress reduction intervention
214473618|NCT05677802|OTHER|Survey Administration|Ancillary studies
214473619|NCT05071287|OTHER|mHealth + low-fat diet|A restricted total calorie and reduced total fat consumption.
214473620|NCT05071287|OTHER|mHealth + low-carb/ketogenic diet|A low-carb/ketogenic diet
214473621|NCT06437847|OTHER|Questionnaire|Questionnaire assessing the use of cognitive tests.
214473622|NCT04331509|OTHER|No Intervention|No Intervention
214473623|NCT04939649|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.
214473624|NCT04939649|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.
214473625|NCT06779032|DIAGNOSTIC_TEST|blood draw|PCR method to see leucocyte telomere length
214473626|NCT06779032|DIAGNOSTIC_TEST|blood draw|PCR method to see p16
214473627|NCT06019637|OTHER|Onasemnogene Abeparvovec|Retrospective and prospective observational study. There is no treatment allocation.
214473628|NCT05795556|OTHER|Assessing sarcopenia and potential biomarkers of sarcopenia in fall patients|Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles (ultrasound), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)
214473629|NCT06054971|OTHER|Remote Administration of NSAA|Remote Administration of NSAA
214657310|NCT06357221|DRUG|Cetaphil|Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.
214657311|NCT05868616|DEVICE|Cardiac Resynchronization Therapy (CRT)|Cardiac resynchronization therapy (CRT) is a modality of cardiac pacing used in patients with left ventricular (LV) systolic dysfunction and dyssynchronous ventricular activation that provides simultaneous or nearly simultaneous electrical activation of the LV and right ventricle (RV) via stimulation of the LV and RV (biventricular pacing) or LV alone.
214657312|NCT06258993|BEHAVIORAL|Core Exercise Promotion Program|Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
214657313|NCT06258993|BEHAVIORAL|Affect-based exercise prescription|"Participants assigned to Affect-Rx will receive instructions to select a pace of exercise that makes you feel as good as possible. The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to stay in the green zone on the Feeling Scale."
214657314|NCT06258993|BEHAVIORAL|Effort-based exercise prescription|"Participants assigned to RPE-Rx will receive instructions to select a pace that would make it challenging for you to carry on more than a short conversation. The exercise intensity prescription section of their exercise plan will include the Rating of Perceived Exertion (RPE) scale as an attachment and participants will be given the instruction to stay in the green zone on the RPE Scale."
214657315|NCT05394402|DRUG|SHR0410 Injection|SHR0410 Injection
214657316|NCT05394402|DRUG|Placebo for SHR0410 Injection|SHR0410 Injection blank preparation
214657317|NCT06521489|DEVICE|Asymmetrical High Flow Nasal Cannula Oxygenation|Asymmetrical High Flow Nasal Cannula Oxygenation will be implemented in this study group. (1st study group, 60l/min airflow, 60% fiO2)
214473630|NCT04758390|BEHAVIORAL|IMARA (intervention group)|The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
214473631|NCT04758390|BEHAVIORAL|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
214473632|NCT03759522|DRUG|DPA-714 PET/MRI|DPA-714 PET/MRI
214473633|NCT05472259|DRUG|Nanoliposomal irinotecan|In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
214473634|NCT05472259|DRUG|5 FU|In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
214473635|NCT05472259|DRUG|Leucovorin|In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
214473636|NCT05472259|DRUG|Oxaliplatin|Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
214473637|NCT05395871|BEHAVIORAL|Behavioural Message|Messaging involving increased salience, increasing positive emotions and information on health consequences
214473638|NCT05395871|BEHAVIORAL|Behavioural Message + Video|Messaging as above. The video also includes information on emotional consequences, problem solving, anticipated regret, reducing negative emotions and credible source techniques.
214473639|NCT05395871|OTHER|Usual Care Message|Standard usual care message involving link to non-behavioural science informed video
214289478|NCT04602832|OTHER|Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19|ENHANCE is a 12-session program designed to help improve subjective well-being, especially through the challenges of a pandemic. The ENHANCE program introduces and teaches people about the evidence-based principles and skills that have been shown across decades of research to improve overall health and well-being.
214473640|NCT06779097|DRUG|Vunakizumab (IL-17A inhibitor)|Vunakizumab (IL-17A inhibitor)
214473641|NCT06777693|BEHAVIORAL|Unified Protocol|"The Unified Protocol group format involves 12 sessions focusing on goal setting and motivation, understanding emotions, mindful emotion awareness, cognitive flexibility, countering emotionat behaviours, understanding and confronting physical sensations, emotion exposure and relapse prevention.~The UP model directly approaches the patient\&#39;s emotion regulation by focusing on cognitive flexibility, exposure exercises, mindful awareness, acceptance, and other evidence-based therapeutic approaches known from cognitive-behavioural therapy (CBT), emotion-focused therapy (EFT) and mindfulness-based interventions."
214473642|NCT00323856|DRUG|Alphanate SD/HT|Plasma-derived preparation of Factor VIII
214473643|NCT06071832|OTHER|Instructions for family Zoom session|Within both play and reading conditions, we will manipulate the method of enacting the structured activities with the goal of facilitating different types of grandparent-initiated joint attention.
214847333|NCT02214706|DRUG|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
214847334|NCT02214706|OTHER|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
214847335|NCT02214706|DEVICE|Pulsed Dye Laser|
214289479|NCT06539559|DRUG|Eribulin|Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer
214289480|NCT06539559|DRUG|Bevacizumab|Study E2100, AVADO and RIBBON-1 found that in the first-line chemotherapy for advanced breast cancer, the addition of bevacizumab can significantly improve the efficacy of traditional chemotherapy drugs. Study RIBBON-2 and TANIA have confirmed the effectiveness of bevacizumab in the second and third line treatment of advanced HER2 negative breast cancer. Compared with chemotherapy alone, the addition of bevacizumab can prolong the PFS by 0.6 to 2.1 months.
214289481|NCT03240796|PROCEDURE|minimal invasive surgery and secondary IOL implantation|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
214289482|NCT03240796|PROCEDURE|traditional cataract surgery and secondary IOL implantation|"traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus."
214289483|NCT03395912|DRUG|Intervention|After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
214289484|NCT03566927|COMBINATION_PRODUCT|FLEX Scoring Catheter with Lutonix DCB|Treatment by the FLEX Scoring Catheter, a plain balloon angioplasty, followed by a Lutonix DCB.
214289485|NCT00653146|BEHAVIORAL|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
214289486|NCT00653146|BEHAVIORAL|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
214473644|NCT06100731|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (FC6, 10-10 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/ out at the beginning and end of the 15-minutes of stimulation over the course of 15 seconds.
214473645|NCT04650568|DEVICE|Autologous Bone Marrow Derived Mesenchymal Stem Cells|Autologous Bone Marrow Derived Mesenchymal Stem Cells injected into the ACL allograft prior to graft implantation.
214473646|NCT04650568|OTHER|Sham incision|Small incision over the site where bone marrow aspirate would have been obtained
214473647|NCT05852457|DEVICE|DAT Clip|All patients scheduled to undergo endoscopic procedures as medically indicated will be considered for the study. Data will be prospectively recorded according to the data collection form. The use of the DAT clip will be performed as medically indicated and consistent with the indications for endoscopic clipping (e.g., management of bleeding, treatment of fistulas, perforations, tissue approximation). The investigators on this project will also oversee the medical care of all patients that will participate in the study. Therefore, follow-up will be carried out as medically indicated and no clinical visits will be needed specifically for the purpose of this study.
214473648|NCT04209595|DRUG|PLX038|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. PLX038 (PEGylated SN38) will be administered as a 1 hour (-10 minutes / +30 minutes) intravenous (IV) infusion on Day 1 of each cycle (21 days).
214473649|NCT04209595|DRUG|Rucaparib|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. Rucaparib will be given orally at designated dose twice a day on days 5 to 19 of every 21-day cycle.
214473650|NCT04209595|DRUG|Ondansetron|Participants will be recommended to have 8 mg of ondansetron taken with a small meal or snack to prevent nausea and vomiting approximately 30 minutes prior to each dose of rucaparib.
214473651|NCT06634355|DRUG|Sugammadex|In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured.
214473652|NCT06032455|BEHAVIORAL|Multisystemic therapy|Multisystemic Therapy (MST) is an intensive, evidence-based treatment aimed at preventing out-of-home placement of adolescents with severe behavioural problems. The intervention is home-based and focuses not only on the adolescent, but also on the various systems surrounding the adolescent, such as the family, neighbourhood, school, and friends. MST helps parents increase their parenting competencies such as parental monitoring and find (more) social support in their environment. MST also helps adolescents improve their relationship with their parents, school participation, and social activities, and promotes contact with pro-social peers. These goals are achieved by working together with key figures in the family's environment. MST treatment duration is three to five months. In MST, a family can contact a therapist 24/7.
214473653|NCT06032455|BEHAVIORAL|Multisystemic therapy - intellectual disabilities|Multisystemic therapy - intellectual disabilities (MST-ID) is a specialisation of standard MST (see above), tailored to the needs and skill deficits of families in which the adolescent and/or parent(s) has/have a known or suspected ID. In MST-ID, among others, simplified language and visual support are used, and extra attention is paid to the generalisation of what has been learned in the treatment sessions.
214473654|NCT04691804|DRUG|Fuzuloparib , Abiraterone acetate and Prednisone|"1. Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po~3. Prednisone tablets (strength: 5 mg) 5mg, Bid po"
214473655|NCT04691804|DRUG|Fuzuloparib Placebo， Abiraterone acetate and Prednisone|"1. Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po~3. Prednisone tablets (strength: 5 mg)5mg, Bid po"
214473656|NCT03156465|DEVICE|Hybrid L24|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
214473657|NCT05615675|OTHER|Virtual Reality Headset|Patient uses a virtual reality headset and support during prone pain procedure
214473658|NCT04116528|DRUG|Ketamine|0.5mg/kg
214473659|NCT04116528|DRUG|Buprenorphine|Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
214473660|NCT04116528|DRUG|Placebo oral tablet|Buprenorphine or Placebo orally dissolving tablet
214473661|NCT06587737|DRUG|Colchicine 0.5 MG|colchicine 0.5mg once-daily
214473662|NCT06587737|DRUG|Placebo|matching placebo, lacking active ingredient, once-daily
214473663|NCT04116203|DRUG|Metformin|Manufacturer's standard 500 mg. Submission Control No.:128147
214473664|NCT04116203|COMBINATION_PRODUCT|Fish Oil and Metformin|Combo of 2 other arms
214473665|NCT04116203|DIETARY_SUPPLEMENT|Fish Oil|NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral
214473666|NCT02420977|DRUG|Pelvic DCFPyL PET-MRI fusion or PET/MRI|"* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
214473667|NCT03420339|DRUG|Stimulant|The stimulants used must meet FDA dosage guidelines for age.
214473668|NCT05423522|DRUG|NanoLithium® NP03|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
214473669|NCT05423522|DRUG|Placebo|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
214847336|NCT01008137|BIOLOGICAL|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
214473670|NCT06480734|OTHER|symptom-based scoring system (symptom-questionnaire, paper version)|The patients are asked to complete a paper-based questionnaire (symptom-based scoring system, paper version) once a week during and up to 24 weeks following radiotherapy. The patients state and score symptoms potentially associated with pneumonitis, namely cough, shortness of breath and fever. Scoring points are assigned to severity of the symptoms, and sum scores are used to identify pneumonitis. During the radiotherapy course, patients complete the questionnaire prior to regular appointments with a physician. Following radiotherapy, they are contacted by phone (to minimize the number of hospital visits) once a week for completion of the questionnaire. In case of an increase of the total score when compared to baseline, patients receive a follow-up phone call after 3 days, are asked to come to the hospital as outpatients or are admitted to hospital.
214473671|NCT06543810|OTHER|Hula for Parkinson's|A feasibility study for a Hula program for Parkinson's Disease patients.
214473672|NCT05603650|OTHER|Lumineux Oral Essentials rinse|mouthrinse
214473673|NCT05603650|OTHER|Listerine rinse|mouthrinse
214473674|NCT04200313|COMBINATION_PRODUCT|Bionic Pancreas (BP) with Aspart or Lispro|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor using lispro or aspart insulin.
214473675|NCT04200313|COMBINATION_PRODUCT|Bionic Pancreas with Fiasp (BPFiasp)|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls Fiasp insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor.
214473676|NCT04200313|OTHER|Usual Care (UC)|Using pre-study insulin regimen with the Dexcom G6 CGM
214473677|NCT04200313|OTHER|BP Guidance Insulin Dosing|Pre-study insulin delivery method with SMBG and blinded CGM with dosing guidance by the BP
214473678|NCT06246188|DIAGNOSTIC_TEST|Cardiac MRI using Regadenoson and GE-267|Performing stress-cardiac MRI for clinical diagnostic in adult patients with suspected coronary artery disease
214473679|NCT05675865|DEVICE|cryoablation procedure|ablation procedure for VT using the investigational device
214473680|NCT05091112|PROCEDURE|Spinal surgery|In participants who undergo elective lumbar spinal surgery and consented for research, the medial branch and dorsal rami will be harvested for histological analysis.
214473681|NCT05091112|OTHER|Histology|The harvested nerves will be fixed, cut into smaller sections. Analysis of macroscopic and light microscopic sections will be carried out
214473682|NCT06605157|BEHAVIORAL|AMUSED|Delivered live by a board-certified music therapist (MT-BC) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. A Multimodal mUSic therapy intervention for Engaging persons with severe Dementia (AMUSED) uses live participant-preferred music and progressively layers singing, touch, and rhythmic instrument playing concurrent with participant behavioral responses. Follows the Clinical Practice Model for Persons with Dementia and implementation strategies that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. Each small group works with the same music therapist throughout the study.
214289487|NCT03715218|OTHER|Mothers Touch Program|Mothers Touch Program with bed rest, Relaxation program to reduce stress, massage for mother and infant, gently physical exercise and special dietary program each week.
214473683|NCT06605157|BEHAVIORAL|Reading Aloud|"Delivered live by a trained research assistant (interventionist) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. The interventionist will read aloud from age-appropriate books (Chicken Soup for the Golden Soul by Jack Canfield; World of Wonders by Aimee Nezhukumatathil) selected to have sufficient material for all sessions, contain short stories to accommodate for attention span and session length, and offer choice. Follows implementation strategies identical to the music therapy arm (i.e., within the Clinical Practice Model for Persons with Dementia) that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. However, no music (including musical references) is used. Each small group works with the same reading interventionist throughout the study."
214473684|NCT05820490|OTHER|Whole Room Calorimeter|The indirect calorimetry system allows your oxygen / carbon dioxide exchange to be measured, thereby showing the number of calories burned.
214473685|NCT05820490|OTHER|Mixed-Meal Tolerance Test (MMTT)|The MMTT is done to measure how much body handles a mixed meal.This test shake will raise blood sugar and cause the body to produce insulin.
214473686|NCT05820490|OTHER|Core Body Temperature|Participants will be asked to swallow a core body temperature monitor prior to entering the whole room calorimeter. This monitor is used to record participants core body temperature.
214289488|NCT03715218|OTHER|Usual Care Program|Usual care group had advice, support and educational program delivered by midwife, or physicians.
214289489|NCT03486132|PROCEDURE|repair of episiotomy|Different techniques for repair of episiotomy incsicion
214289490|NCT02066740|DEVICE|EverFlex™ stent with Entrust™ delivery system|
214473687|NCT05820490|OTHER|Morningness-Eveningness Questionnaire|Participants will fill out a questionnaire that asks about your preference for morning or evening.
214473688|NCT05820490|PROCEDURE|Muscle Biopsy|Participants will have two skeletal muscle biopsies (one in the evening and one in the morning). This procedure is used to sample muscle cells from the right and left leg Vastus Lateralis (thigh) muscle.
214473689|NCT05820490|OTHER|Serial Blood Sampling|Participants will have blood sampled every hour for 24 hours to assess changes in circulating hormones.
214473690|NCT04380337|DRUG|FOLFOXIRI|Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil
214847337|NCT01008137|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
214847338|NCT05187325|OTHER|no intervention|there is no intervention
214289491|NCT06468631|BEHAVIORAL|Complex Nursing Intervention|"Training prepared as an expert opinion on patient handover, starting to use the standard patient handover form for each patient, ensuring standardization in handover and supporting this improvement work by managers were expressed as interventions.~Training offered; It includes the importance of patient handover, how to ensure standardization and why we should use the standard patient handover form."
214289492|NCT03900767|OTHER|Electronic Health Record intervention|AAC
214473691|NCT04380337|DRUG|FOLFOX regimen|Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2
214473692|NCT04380337|DRUG|XELOX|Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2
214473693|NCT04380337|RADIATION|IMRT|Radiotherapy (5 Gy x 5 fractions) with an additional boost fraction (5 Gy x 1 fraction) delivered sequentially
214473694|NCT06368700|DEVICE|Hyalex Knee Cartilage System|Surgical implantation of the Hyalex Knee Cartilage System
214473695|NCT05759819|DEVICE|Standard stenting|The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
214473696|NCT04538378|DRUG|Olaparib|Olaparib tablet will be administered at a total daily dose of 600 mg orally in two divided doses, approximately 12 hours apart.
214473697|NCT04538378|DRUG|Durvalumab|Durvalumab will be administered intravenous (IV) into a peripheral or central vein on Day 1 of every cycle at a flat dose of 1,500 mg.
214847339|NCT00096122|DRUG|cytarabine|Given IV
214847340|NCT00096122|DRUG|idarubicin|Given IV
214473698|NCT04538378|DIAGNOSTIC_TEST|EKG|Screening and all cycles Day 1 and Day 15 (+/- 3) days. One cycle is 28 days.
214473699|NCT04538378|PROCEDURE|Tumor biopsy|Baseline and all cycles Day 15 (+/- 3) days. One cycle is 28 days.
214847341|NCT00096122|DRUG|tipifarnib|Given orally
214847342|NCT02608840|OTHER|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
214473700|NCT04538378|DIAGNOSTIC_TEST|CT chest, abdomen and pelvis|Screening and baseline and every 8 (+/-1) weeks after start of therapy.
214473701|NCT04538378|DIAGNOSTIC_TEST|MRI chest, abdomen and pelvis|Screening and baseline and every 8 (+/-1) weeks after start of therapy.
214473702|NCT06489665|DIAGNOSTIC_TEST|Experimental Intervention|Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
214473703|NCT04452851|DEVICE|BREATHE|The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.
214473704|NCT04452851|DEVICE|BiPAP|BiPAP stands for Bilevel Positive Airway Pressure, and is very similar in function and design to a CPAP machine (continuous positive airway pressure). A BiPAP machine is a non-invasive form of therapy for patients suffering from sleep apnea.
214473705|NCT04452851|DRUG|COPD Inhaler|Inhaler medication to support quick relief from COPD symptoms
214473706|NCT02676193|BEHAVIORAL|Effect of Packaging on Smoking Perceptions and Behavior|The intervention is the use of the assigned pack design.
214473707|NCT03068689|PROCEDURE|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is \> 185mm HG the cuffs are inflated to 15 mmHG above that level.
214847343|NCT02608840|OTHER|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
214847344|NCT00332267|PROCEDURE|Endotoxin infusion, Normobaric hypoxia|
214847345|NCT06840093|BEHAVIORAL|Limited Restrictions|Patients will receive a handout with the following instructions: After discharge from the hospital, resume your normal activities as soon as you feel comfortable. There is no weight limit on lifting. There are no specific activities you should avoid (other than pelvic rest as described below). We recommend pelvic rest, nothing in the vagina (no intercourse, hot tubs, tub bathing or swimming) for 2 weeks.
214847346|NCT06840093|BEHAVIORAL|Standard Restrictions|Patient will receive a handout with the following instructions: After discharge from the hospital, avoid doing any strenuous activity (any activity that requires so much exertion that you cannot have a conversation comfortably while doing it). Do not lift anything over 15 pounds for 6 weeks after surgery. For 6 weeks, we recommend complete pelvic rest, nothing in the vagina (no intercourse, hot tubs, tub bathing or swimming).
214289493|NCT03900767|BEHAVIORAL|Smoking Cessation Intervention|Receive standard Utah Quitline treatment
214289494|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
214289495|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
214289496|NCT03625791|BIOLOGICAL|blood sample|1 tube with 4 ml of blood per patient
214289497|NCT00469989|PROCEDURE|Infection with hookworm larvae|
214473708|NCT03068689|OTHER|Placebo|Placebo
214473709|NCT05534321|RADIATION|Prophylactic Radiotherapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) techniques may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
214473710|NCT05534321|DRUG|Standard of care systemic therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
214473711|NCT03193333|DRUG|PRO-122|Posology: 1 drop every 12 hours for 90 days
214473712|NCT03193333|DRUG|Timolol eye drops|1 drop every 12 hours for 90 days
214473713|NCT03193333|DRUG|Dorzolamide-Timolol Ophthalmic|1 drop every 12 hours for 90 days
214473714|NCT03193333|DRUG|Brimonidine Ophthalmic Solution|1 drop every 12 hours for 90 days
214473715|NCT03193333|OTHER|Placebo1|1 drop of each dropper bottle every 12 hours for 90 days
214473716|NCT03193333|OTHER|Placebo 2|1 drop of each dropper bottle every 12 hours for 90 days
214473717|NCT03193333|DRUG|Krytantek|Posology: 1 drop every 12 hours for 90 days
214657318|NCT06521489|DEVICE|Conventional High Flow Nasal Cannula Oxygenation|Conventional High Flow Nasal Cannula Oxygenation will be implemented in this study group. (2nd study group, 60l/min airflow, 60% fiO2)
214847347|NCT06646887|OTHER|Electroporation|Unlike traditional thermal ablation techniques such as radiofrequency (RF) and cryoablation, the electroporation systems used in this study rely on pulsed electric fields (PEF) to selectively target and ablate cardiac tissue. This non-thermal mechanism reduces the risk of collateral damage to nearby structures, such as the esophagus, phrenic nerve, and coronary arteries.
214473718|NCT05699915|PROCEDURE|Cardiology consultation|"* Electrocardiogram (ECG).~* Echocardiogram: A comprehensive evaluation of systolic and diastolic function, ventricular and atrial geometry will be performed. Special attention will be given to acquire a 3D measurement of left ventricular ejection fraction (LVEF) and to perform deformation imaging of left ventricle (global longitudinal strain (GLS)). The right ventricular function will be evaluated by tricuspid annular plane systolic excursion (TAPSE) and peak systolic velocity S' derived from color coded tissue Doppler imaging (TDI). Diastolic dysfunction will be based on average E/e' ratio \> 15 and left atrial (LA) area \> 30 cm2."
214473719|NCT05699915|DIAGNOSTIC_TEST|Chest Computed Tomography (CT) without contrast|Calcium score. This will be performed at baseline, 12 and 24 months. The scans at 12 and 24 months will be combined, if possible, with standard of care scans for cancer treatment.
214473720|NCT05699915|PROCEDURE|Non-invasive endothelial function tests|"* FMD~* PAT~This aspect of the study will only be performed in the patients included by the Antwerp University Hospital due to organizational/practical issues."
214473721|NCT05699915|PROCEDURE|Electrocardiogram|An ECG will be taken prior to each ICI cycle during the first three months of treatment.
214473722|NCT05699915|DIAGNOSTIC_TEST|Extra serum sample (7.5 mL)|An extra serum sample will be taken at baseline, 3, 6, 12, 24 months and in case of sudden cardiac problems. This will subsequently be analysed to determine high-sensitivity troponin I, high-sensitivity troponin T and NT-proBNP.
214473726|NCT03793023|DRUG|Teneligliptin 20mg|
214847348|NCT06874842|BIOLOGICAL|Low dose antigen and low dose adjuvant of LYB004|0.5 mL per dose, containing a total of 25 μg VZV-gEM adjuvanted with A01C.
214847349|NCT06874842|BIOLOGICAL|Low dose antigen and high dose adjuvant of LYB004|0.5 mL per dose, containing a total of 25 μg VZV-gEM adjuvanted with A01B.
214847350|NCT06874842|BIOLOGICAL|High dose antigen and low dose adjuvant of LYB004|0.5 mL per dose, containing a total of 50 μg VZV-gEM adjuvanted with A01C.
214847351|NCT06874842|BIOLOGICAL|High dose antigen and high dose adjuvant of LYB004|0.5 mL per dose, containing a total of 50 μg VZV-gEM adjuvanted with A01B.
214847352|NCT06874842|BIOLOGICAL|Placebo|0.5 mL per dose, without antigen and adjuvant.
214847353|NCT06874842|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
214847354|NCT06555289|DEVICE|Clareon PanOptix IOL|Spherical and toric T3
214847355|NCT06898528|BEHAVIORAL|The group-based mat exercise training on experimental group.|The training program is divided into two phases: the first phase focuses on fundamental movements, whereas the second phase introduces more advanced exercises. With progress, additional exercise equipment is incorporated, along with increased sets, duration, movement variations, and training intensity. Training sessions (10-week duration) can be conducted in a simple, progressive manner or a game-competitive format.The control group maintained their usual daily activities.
214847356|NCT06898528|BEHAVIORAL|The control group|The control group maintained their usual daily activities.
214473727|NCT05709288|DRUG|BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
214473728|NCT05359185|BEHAVIORAL|Family Wellness|https://familywellness.com/
214473729|NCT05359185|BEHAVIORAL|Career Coaching|Individualized career coaching and employment services.
214473730|NCT05359185|BEHAVIORAL|Financial Planning|Individualized financial planning services.
214473731|NCT05715528|DRUG|Obeldesivir|Tablet administered orally without regard to food.
214847357|NCT06823752|DRUG|Lemborexant 10 MG|An orally ingested tablet containing 10mg Lemborexant taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
214847358|NCT06823752|DRUG|Placebo|Placebo tablets will contain similar excipients without the active ingredient (Lemborexant) and manufactured under the same condition as the active. Placebo tablets, packs and instructions will be identical in every respect to enable the double-blind study design.
214847359|NCT06778265|BIOLOGICAL|UX-DA001|"UX-DA001 (Human Midbrain Dopaminergic Progenitor Cells) is used for treating patients with iPD via implanting into bilateral putamina under stereotactic neurosurgery.~Two dose levels will be planned. Each patient only receives one corresponding dose of UX-DA001."
214847360|NCT03183141|BIOLOGICAL|SER-109|SER-109, an oral, biologically derived, live microbiome therapeutic that comprises purified bacterial spores
214473732|NCT05715528|DRUG|Obeldesivir Placebo|Tablet administered orally without regard to food.
214473733|NCT04598932|DEVICE|Brillouin microscopy|The Brillouin clinical instrument is comprised of three parts: a human interface, a laser-scanning confocal microscope, and an etalon-based spectrometer. The human interface is a modified ophthalmic slit-lamp instrument with chin support and headrest. The light source is a single longitudinal mode CW laser at 780 nm. A polarizing beam splitter and quarter-wave plate assembly sends the laser beam to the human interface. To focus light into the eye, a long-working distance microscope objective is used. Brillouin scattered light from the eye is collected with a single-mode optical fiber. For spectral analysis, a two-stage VIPA-etalon spectrometer configured with the cross-axis cascade principle and the spectrum is measured on a EM-CCD camera.
214473734|NCT06257901|OTHER|Interviews/Focus groups/Participatory workshops|Qualitative study (no intervention delivered)
214473735|NCT06091657|DRUG|Ketamine Hydrochloride|intravenous injection
214473736|NCT04759456|OTHER|Remotely-supervised rehabilitation program|Include nutrition, health-related lifestyle and behavioral changes recommendations, and at least 5 times a week 30 minutes of moderate-intensity aerobic training, 10 minutes of inspiratory and expiratory muscle training with breathing device and 10 minutes of oropharyngeal exercise along with individually titrated CPAP therapy
214473737|NCT04116996|DEVICE|DEEP BRAIN STIMULATION|NEUROMODULATION
214473738|NCT06402383|BIOLOGICAL|Vaccination Provision|HPV vaccination #1 will be offered by provider at the first visit when the HPV self-sample is collected. HPV Vaccination #2 will be offered at 6 months for HPV negative women and at 12 months for HPV positive women.
214473739|NCT06402383|BIOLOGICAL|Vaccination Provision 2|"HPV vaccination #1 will be offered by the provider after an HPV negative result is received with vaccine #2 given at 3 months after negative test results obtained.~For HPV positive women - vaccination #1 will be offered at 12 months and vaccination #2 will be offered at the 15 month mark."
214473740|NCT06574438|BEHAVIORAL|AIFIGA program|receives the Artificial Intelligence Family Involvement Generative Agent (AIFIGA) program and uses it for 3 months
214473741|NCT06002750|OTHER|disease|Do you have dermatomyositis
214473742|NCT06676995|DEVICE|Transcranial Pulse Stimulation (TPS)|Transcranial Pulse Stimulation (TPS) is a non invasive brain stimulation technology that applies repetitive single high-pressure ultrashort shockwave pulses within the ultrasound frequency range to stimulate the brain. Subjects will receive 12 TPS sessions conducted three times weekly, for about 40 to 50 minutes/day, over four consecutive weeks.
214473743|NCT06103474|DIAGNOSTIC_TEST|Lumbar Magnetic Resonance Imaging (MRI)|Lumbar Magnetic Resonance Imaging (MRI)
214473744|NCT05781672|DIAGNOSTIC_TEST|cardiac ultrasound with speckle tracking analysis|"Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography."
214473745|NCT05205486|DRUG|Cefazolin 3gm for Injection USP and Dextrose Injection USP|Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing \>/= 120 kg
214473746|NCT02418832|PROCEDURE|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
214473747|NCT04250857|DEVICE|HeartStart FRX|Automated External Defibrillator
214473748|NCT06008353|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
214473750|NCT04838405|DRUG|CT-388|Synthetic Peptide
214473751|NCT04838405|DRUG|Placebo|Placebo
214289498|NCT05605392|OTHER|Deinstitutionalization process|"Phase 1: Comprehensive geriatric assessment to evaluate who might be a candidate for deinstitutionalization.~Phase 2: Intervention:~1. Support plan: design a plan agreed upon with the participant to provide resources to the person's needs and which guarantees support during the transition and beyond.~2. Transition process: progressive withdrawal of support in the institution and implementation of support and adaptation in the community, with different types of accommodation depending on the needs and preferences of each participant. Coordination with primary care teams, social services, and other community resources.~3. Case follow-up and gradual withdrawal of the project team. If the process does not go as the person expects, or difficulties are encountered that cannot be resolved, the participant will have the option and choice, if desired, to return to the residence at any time during the process."
214289499|NCT06142045|DEVICE|RespirACT RA-MR System|RespirAct RA-MR™ is a computer-controlled gas blender to implement precise control of blood gases for a consistent and repeatable stimulus.
214473752|NCT05834478|DEVICE|Transcutaneous Cervical Vagal Nerve Stimulation|Participants will receive stimulation of the vagus nerve with the non-invasive transcutaneous cervical Vagal Nerve Stimulation (tcVNS), which does not require surgery or implantation, and electrically stimulates the vagus nerve as it passes through the neck, dampening the sympathetic nervous system and modulating brain regions to a single side of the neck with the GammaCore device. Participants will be trained on self-stimulation and from days 1-7 patients undergo four times daily self-stimulation with tcVNS first for two minutes on one side, followed by a one-minute pause, then two minutes on the same side. The intensity of the stimulus (i.e. the current amplitude) will be adjusted by the user, to the maximum tolerable level without causing excessive pain \[typically 10-30 V and 60milliamperes (mA) (peak)\], with an alternating current (AC) signal consisting of five 5 kilohertz (kHz) pulses 200 microseconds in duration, repeating at a rate of 25 Hz (about once every 40 milliseconds).
214473753|NCT05834478|DEVICE|Sham Stimulation|Participants will have the same procedures as with the tcVNS but will instead receive a device that appears identical to the active tcVNS device in look, weight, visual and audible feedback, and also in user controls. The Sham device looks and sounds like an active device but does not deliver an electric current.
214473754|NCT05834478|DRUG|[F-18]Fallypride|\[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
214473755|NCT05583552|DRUG|Imetelstat sodium|Intravenous injection
214473756|NCT06263855|OTHER|CURE|A large language model (LLM) to help clinicians prepare discharge summaries for hospitalized patients.
214473757|NCT04214860|DRUG|APR-246|APR-246 4.5 g/day
214473758|NCT04214860|DRUG|Venetoclax|Venetoclax 400 mg once daily
214473759|NCT04214860|DRUG|Azacitidine|Subcutaneous injection, or intravenous infusion
214473760|NCT03485729|DRUG|Dordaviprone (ONC201)|625 mg dordaviprone (ONC201)
214473761|NCT06419660|DRUG|BI 300202|BI 300202
214473762|NCT06419660|DRUG|esomeprazole|esomeprazole
214473763|NCT04078568|DRUG|IVIG|IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
214473764|NCT04078568|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
214473765|NCT04078568|DRUG|Prednisolone|Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
214473766|NCT06462729|DEVICE|LDGraft|LDGraft 0.5mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
214473767|NCT06462729|DEVICE|LDGraft|LDGraft 1.0mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
214473768|NCT06462729|OTHER|Allograft Bone|Allograft bone (100% human tissue product) applied within intervertebral cage with placement of anterior fixation (plate and screws)
214473769|NCT05573243|OTHER|bonding strategies|The universal adhesive can be bonded using 3 different bonding strategies. Therefore, three bonding strategies will be assigned for 3 arms: etch-and-rinse, selective enamel etching, self-etch
214473770|NCT05444699|DRUG|Prednisolone Sodium Phosphate|Oral suspension administered 1 mg/kg once a day for three days
214473771|NCT05444699|DRUG|Sugar syrup|Oral suspension administered the same amount in milliliters as experimental product once a day for three days
214473772|NCT04358315|BEHAVIORAL|Behavioral Intervention|Smell or puff e-liquids
214473773|NCT04358315|OTHER|Questionnaire Administration|Ancillary studies
214473774|NCT04254107|DRUG|SEA-TGT|Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
214473775|NCT04254107|DRUG|sasanlimab|Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle
214473776|NCT04254107|DRUG|brentuximab vedotin|Given by IV on Day 1 of each 21-day cycle
214473777|NCT05912543|PROCEDURE|Titration of FiO2|The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
214473778|NCT05912166|BEHAVIORAL|Wakeful Spanish|"Wakeful Spanish is the Spanish-language version of Wakeful, a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs. Wakeful makes one new class available to users each week for 9 weeks. Users receive weekly email notifications from Wakeful informing them when a new class is available. Estimated class duration is 1-1.5 hours.~With Wakeful, users can -~1. Write what they observed during meditations.~2. Be guided by videos/audios through breathing exercises and gentle stretching.~3. See what others experienced and their tips for overcoming challenges.~4. Access videos/audios that explain how mindfulness benefits the body and mind.~5. Receive suggestions on meditations to do during the week~6. Set an intention for the week based on class content."
214473779|NCT03083405|DRUG|Opipramol|The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
214473780|NCT00544414|DRUG|cisplatin|
214473781|NCT00544414|DRUG|docetaxel|
214473782|NCT00544414|DRUG|fluorouracil|
214473783|NCT00544414|DRUG|gemcitabine hydrochloride|
214473784|NCT00544414|DRUG|leucovorin calcium|
214473785|NCT00544414|GENETIC|gene expression analysis|
214473786|NCT00544414|GENETIC|protein expression analysis|
214473787|NCT00544414|OTHER|laboratory biomarker analysis|
214473788|NCT00544414|PROCEDURE|adjuvant therapy|
214473789|NCT00544414|PROCEDURE|biopsy|
214473790|NCT00544414|PROCEDURE|conventional surgery|
214473791|NCT00544414|PROCEDURE|neoadjuvant therapy|
214473792|NCT00544414|PROCEDURE|quality-of-life assessment|
214473793|NCT00544414|RADIATION|radiation therapy|
214473794|NCT05716373|BEHAVIORAL|pain|reiki
214473795|NCT05035654|DRUG|LYR-220 Design 1 (Part 1 only)|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
214473796|NCT05035654|DRUG|LYR-220 Design 2 (Part 1 and Part 2)|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
214473797|NCT05035654|DRUG|Bilateral sham procedure control (Part 2)|Bilateral sham procedure control
214473798|NCT03854500|DRUG|Tenecteplase|0.4 mg/kg single bolus intravenously
214473799|NCT03854500|DRUG|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
214473800|NCT06149702|OTHER|Combined intervention: Keep-on-Keep-Up-LITE (KOKU-LITE) programme and dementia and falls prevention leaflet|KOKU-LITE programme will be used by the participants for 6 weeks and outcome assessments will be performed at baseline and 6 weeks of use. Participants will also use dementia and falls prevention leaflet for 6 weeks.
214473801|NCT05346692|OTHER|Survey Administration|Complete Survey
214473802|NCT05346692|OTHER|Interview|Complete Interview
214473803|NCT05346692|OTHER|Text Message-Based Navigation Intervention|Complete mindfulness intervention
214473804|NCT05346692|OTHER|Interview|Complete interview
214473805|NCT06804291|OTHER|Running|Participants were expected to run 6.44 kilometers.
214473806|NCT06804291|OTHER|Cycling|Participants were expected to cycle 39 kilometers
214473807|NCT06804291|OTHER|Rugby|Participants were expected to play in one rugby match.
214473808|NCT06804291|OTHER|control group|Participants were asked to refrain from exercise for 24 hours.
214473809|NCT06166901|DEVICE|AcrySof IQ PanOptix IOL|Trifocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism, with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence.
214473810|NCT06166901|DEVICE|AcrySof IQ PanOptix Toric IOL|Toric trifocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence.
214473811|NCT04880733|PROCEDURE|Acupuncture for pain management|A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.
214473812|NCT04880733|OTHER|Usual care for pain management|Patient will receive usual care for pain management.
214473813|NCT05921162|BIOLOGICAL|Gene Therapy product:vMCO-I|Safety evaluation to monitor long term effects of previously injected vMCO-I in RP patients
214473814|NCT03812289|OTHER|Quality-of-Life Assessment|Ancillary studies
214473815|NCT03812289|OTHER|Questionnaire Administration|Ancillary studies
214473816|NCT03812289|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214473817|NCT04934072|DRUG|FKS518|subcutaneously by single-use prefilled syringe (PFS)
214473818|NCT04934072|DRUG|US-licensed Prolia (Amgen)|subcutaneously by single-use PFS
214473819|NCT05023096|OTHER|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
214473820|NCT04523701|DRUG|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"
214473821|NCT06361251|DEVICE|CRYONOVE (EC14_4osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
214473822|NCT06361251|DEVICE|CRYONOVE (EC05osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
214473823|NCT05202951|OTHER|questionnaires|Electronic case report form integrating questionnaires on chronic pain related to haemophilia, associated-comorbidities, sociodemographic characteristics and analgesic treatments used.
214473824|NCT02484430|OTHER|Laboratory Biomarker Analysis|Correlative studies
214473825|NCT02484430|OTHER|Pharmacological Study|Correlative studies
214473826|NCT02484430|DRUG|Sapanisertib|Given PO
214847361|NCT03111667|BEHAVIORAL|Teen Marijuana Check Up|Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.
214847362|NCT03111667|OTHER|Treatment as Usual|Referral to community resources
214847363|NCT03111667|BEHAVIORAL|Gold Standard Coaching|Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.
214847364|NCT03111667|BEHAVIORAL|As Needed Coaching|As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
214847365|NCT05049668|DRUG|ATGAM plus CsA with or without Eltrombopag|Standard treatment with or without Eltrombopag
214847366|NCT01872845|DRUG|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
214847367|NCT01872845|DRUG|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
214847368|NCT04052698|DRUG|Wilate|"Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute."
214473827|NCT03932162|DRUG|Insulin-Like Growth Factor 1|Growth factor protein
214473828|NCT03932162|OTHER|No Insulin-Lie Growth Factor 1|No Insulin-Like Growth Factor 1 will be given.
214473829|NCT05058040|DRUG|Sodium Oligomannate Capsules|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
214473830|NCT06026306|BEHAVIORAL|Problem Management Plus (PM+)|PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session
214473831|NCT05081934|BEHAVIORAL|A-CRA|12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. The average time for a placement within SiS is for boys 5,9 months and for girls 4,5 months. To further adjust A-CRA to the closed institutional care, frequency of sessions may be increased to twice a week. This is to facilitate maintaining of focus in treatment and closely follow treatment progress. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Example of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to youth individual goals and needs.
214847369|NCT05306951|DIAGNOSTIC_TEST|Computed tomography|Head computed tomography
214847370|NCT01637831|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
214847371|NCT04846647|BEHAVIORAL|unexplained hypophoshatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
214847372|NCT02853864|DRUG|0.0 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0 ng/ml
214847373|NCT02853864|DRUG|0.4 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4 ng/ml
214847374|NCT02853864|DRUG|0.6 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6 ng/ml
214847375|NCT02853864|DRUG|0.8 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8 ng/ml
214847376|NCT02853864|DRUG|Propofol|The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
214473832|NCT05081934|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
214473833|NCT06162299|BIOLOGICAL|YS-HBV-002|YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant
214473834|NCT06167239|OTHER|Threshold inspiratory muscle trainer or ventilator pressure setting inspiratory muscle training techniques|New techniques to train inspiratory muscles in mechanically ventilated patients
214473835|NCT03964376|OTHER|Nasal High Flow|Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher \& Paykel Inc.) with airflow of 20 to 50 Litre/minute
214473836|NCT03964376|OTHER|Usual Care|Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask
214473837|NCT03394612|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
214473838|NCT03394612|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
214473839|NCT06492382|DIAGNOSTIC_TEST|Home Oxygen Monitors|Weaning of home oxygen using information gathered from home moniotr devise
214473840|NCT03174275|DRUG|Durvalumab|Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
214473841|NCT03174275|DRUG|Carboplatin|Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
214473842|NCT03174275|DRUG|Nab-paclitaxel|Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
214473843|NCT03174275|DRUG|Cisplatin|Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
214473844|NCT03174275|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
214473845|NCT03174275|RADIATION|IMRT|"involved field radiation will refer to areas demonstrated to harbor disease on pathology, and not elective areas"
214473846|NCT05296889|DEVICE|posterior stabilization for the cervical spine|The Ennovate® Cervical Spinal System is a posterior stabilization for the cervical and upper-thoracic spine. The implants are used for the posterior monosegmental and multisegmental stabilization of the occipitocervical junction and of the cervical and upper thoracic spine.
214473847|NCT06823323|DIETARY_SUPPLEMENT|Lactobacillus johnsonii|It is previously reported Lactobacillus johnsonii #CGMCC29884 in Cell. Animal studies showed it combined with Clostridium sporogenes to produce indolepropionic acid, modulating CD8+ T cell immune quiescence in the tumor microenvironment and sensitizing immunotherapy in CRC, breast cancer, and melanoma. Mager et al. found Lactobacillus johnsonii enhanced CTLA-4 mAb antitumor effects in CRC mouse models. Studies showed it's a typical probiotic widely distributed in various hosts' guts and has long been applied in food and feed industries. Preclinical studies indicated it improved memory through the gut-brain axis, had anti-inflammatory and antibacterial effects, and regulated metabolic diseases. Randomized trials found it effectively inhibited Helicobacter pylori colonization without obvious adverse reactions, suggesting it's a potentially safe and effective treatment.
214473848|NCT06823323|OTHER|Placebo|Placebo
214473849|NCT04421846|OTHER|Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)|Collection of biological samples and clinical/paraclinical data
214473850|NCT04421846|OTHER|Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)|Collection of biological samples and clinical/paraclinical data
214473851|NCT05631743|BEHAVIORAL|VR-CBT|The therapy is focused on emotion regulation through guided learning in virtual reality. The manual is a modified conventional cognitive behavioral therapy to include these aspects and the suggestions of an advisory committee of Inuit and non-Inuit health service providers (e.g., cultural adaptation).
214473852|NCT05631743|BEHAVIORAL|Self-management|The previously developed commercial VR program involves guided relaxation and meditation techniques.
214473853|NCT05970640|DRUG|BI 3006337|BI 3006337
214473854|NCT05970640|DRUG|Placebo matching BI 3006337|Placebo matching BI 3006337
214473855|NCT05470218|OTHER|Meal|Liquid mixed meal with different amounts of protein and leucine
214473856|NCT04790058|OTHER|Knowledge translation of the CSRS practice recommendations|The intervention is knowledge translation of the CSRS practice recommendations; the application of the practice recommendations will occur during the patient's ED visit and patients who are eligible for 15-day cardiac rhythm monitoring will have Holter monitor applied at the time of ED discharge. For the secondary objective to validate the accuracy of the ultra-low risk criteria of CSRS and assess for potential improvements in the practice recommendations and the prediction models we will request verbal consent during the index ED visit for addition of cardiac biomarker measurements \[troponin and NT-proBNP\] for patients who did not have such measurements performed as part of routine clinical care, and a 30-day telephone follow-up for serious outcome assessment. Patients who do not consent will be excluded from these portions of the study but included in the health resource utilization and generic patient safety outcome assessment objectives.
214473857|NCT04456296|DRUG|Aveed Injectable Product|Testosterone undecanoate administered by intramuscular injections.
214473858|NCT04456296|DRUG|Fortesta|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
214473859|NCT04456296|DRUG|Testim|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
214473860|NCT02229968|DRUG|Amicar (ε-aminocaproic acid)|
214473861|NCT02229968|DRUG|normal saline|
214473862|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fasting condition, 1 tablet at a time, once a day.
214289500|NCT06083272|DEVICE|Vitalthings Guardian M10 fixed and M10 mobile|VitalThings Guardian M10 / M10 mobile (VitalThings, Norway), are the investigational devices. These are the same technical devices made in two versions: one wall-mounted (VitalThings Guardian M10 fixed) and one mounted on a trolley (VitalThings Guardian M10 mobile). The Nox T3s and Nonin will be used as comparator devices.
214289501|NCT03608501|DRUG|Ixazomib|Ixazomib capsules.
214289502|NCT03608501|DRUG|Thalidomide|Thalidomide capsules.
214289503|NCT03608501|DRUG|Dexamethasone|Dexamethasone tablets.
214289504|NCT06334783|BIOLOGICAL|Autologous tumor-infiltrating lymphocyte cells|On day 0, all patients will receive autologous tumor-infiltrating lymphocyte cells administered.
214289505|NCT01876030|DEVICE|FES|
214473863|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
214473864|NCT06569394|DRUG|Broad Spectrum Cannabidiol (bsCBD) 400 mg|Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
214473865|NCT06569394|DRUG|Placebo|Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
214473866|NCT06808269|PROCEDURE|Vivalto Dom follow-up|"During the pre-operative consultation, the patient receives a prescription for medication (analgesics and anti-inflammatories) for immediate post-operative pain relief. They also receive a patient information booklet (see appendix 6). On discharge from surgery, the patient returns home with Vivalto Dom in charge of nursing care and follow-up medication.~Vivalto Dom is a homecare structure whose mission is to coordinate the discharge of patients back home, and to ensure continuity of overall care (care and social aspects) between the hospital and the city."
214473867|NCT06808269|PROCEDURE|Liberal follow-up|"The pre-operative and operative course (fasting rules, skin preparation, hospitalization, surgery) is the same as for all routine care patients. The patient is informed before surgery that he or she must make an appointment with a nurse for post-operative care at home; a prescription for medication (analgesics and anti-inflammatories) has been given by the anaesthetist for immediate analgesic treatment, and on discharge from hospital he or she receives another prescription from the surgeon for oral relay treatment.~Follow-up at home takes place over 3 days, with a private nurse visiting the patient's home every day.~During the follow-up, the nurse performs clinical monitoring of the following items: pulse, blood pressure, temperature, pain, bleeding, monitoring of the surgical wound, transit, nausea and vomiting. The patient is also guided through the medication protocol."
214473868|NCT06809959|DEVICE|In-phase-tACS|21 minutes and 30 seconds of bifocal stimulation at 3 mA peak-to-peak per field, targeting the aIPS and PMv of the lesioned hemisphere. The stimulation is delivered at 24 Hz with the waveforms of both fields aligned in phase. A 10-second ramp-up at the beginning and a 10-second ramp-down at the end are included to ensure participant comfort. The protocol is administered using the Starstim® device with gel-based electrodes, each with a π cm² surface area.
214289506|NCT02322918|GENETIC|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
214289507|NCT02024633|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
214289508|NCT02024633|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
214289509|NCT00113217|DRUG|Bevacizumab|10 mg/kg IV on day 1 of each 14-day cycle.
214473869|NCT06809959|DEVICE|Out-of-phase-tACS|21 minutes and 30 seconds of bifocal stimulation at 3 mA peak-to-peak per field over the aIPS and PMv of the lesioned hemisphere at 24 Hz. In this condition, the waveforms of the two fields are shifted by 180°, creating an out-of-phase stimulation pattern. A 10-second ramp-up and ramp-down are included, and the protocol is administered using the Starstim® device with gel-based electrodes, each with a π cm² surface area.
214473870|NCT06809959|DEVICE|Sham -tACS|21 minutes and 30 seconds of stimulation mimicking the setup of active tACS, with an initial 10-second ramp-up followed by a 10-second ramp-down. The remainder of the session is stimulation-free. This protocol is administered using the Starstim® device and gel-based electrodes with a π cm² surface area, maintaining the same setup as the active conditions to ensure comparability.
214473871|NCT06808659|OTHER|Neural Mobilization|A total of 20 patients were selected in Group A received neural mobilization of sciatic nerves treatment for 3 days a week for 2 weeks
214473872|NCT06808659|OTHER|Stretching|A total of 20 patients were selected in Group B received stretching of piriformis muscle treatment for 3 days a week for 2 weeks
214473873|NCT06810336|DRUG|Remifentanil|Intravenous Remifentanil
214473874|NCT06810336|DRUG|Methadone|Intravenous Methadone
214473875|NCT06808542|OTHER|No intervention|No intervention
214473876|NCT06808880|DEVICE|Single-gene Noninvasive Prenatal Testing (sgNIPT)|Natera sgNIPT is intended for use in pregnant people whose 'fetus/ fetuses are identified as at increased risk for a single gene disorder when there is no reproductive partner (paternal) screening available or when there is positive reproductive partner screening, but prenatal diagnostic testing is not an option or when there is concern for a single-gene disorder in the fetus/ fetuses irrespective of carrier status (e.g., based on fetal ultrasound findings).
214473877|NCT02997202|DRUG|gilteritinib|oral
214473878|NCT02997202|DRUG|Placebo|oral
214473879|NCT05790655|OTHER|oPRP|Prepared sample from patient's own blood collected and processed. Either PRP or serum is injected into the patient's ovary. All other care is standard for the IVF process
214473880|NCT05790655|OTHER|Placebo- Serum|Patient's serum is injected into ovary instead of PRP as placebo
214473881|NCT05347563|PROCEDURE|Electrical impedance tomography|All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment…)
214473882|NCT05887791|DIETARY_SUPPLEMENT|Collagen hydrolysate|Single dose
214473883|NCT05887791|OTHER|Placebo|Single dose
214847377|NCT03319095|DEVICE|Intravaginal Electrical Nerve Stimulation|The Intervention group will receive Intravaginal Electrical Nerve Stimulation using Quark® Dualpex equipment, once per week during 8 weeks. The selected current will be biphasic, and the stimulation parameters will be: 50 Hz frequency, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds, relaxation time (Toff) of 10 seconds, intensity of current defined according to the sensitivity (tolerance) of the patient, and total stimulation time of 20 minutes once a week delivered by an experienced Physiotherapist. In the last 10 minutes of each electrical nerve stimulation session women will be requested to perform voluntary PFM contractions along with the contractions induced by the electrical stimulation. Women will not be instructed to perform any aditional exercise or therapy at home.
214847378|NCT00519103|OTHER|exercise|
214847379|NCT03169621|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|"On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE."
214847380|NCT01523236|DRUG|Mometasone furoate|50 mcg/actuation Nasal Spray
214847381|NCT01523236|DRUG|Nasonex®|50 mcg/actuation Nasal Spray
214847382|NCT01523236|DRUG|Placebo|Nasal Spray
214847383|NCT04731584|BIOLOGICAL|Blood sample|Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke
214847384|NCT00711841|DRUG|dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
214847385|NCT00711841|DRUG|Placebo|Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
214847386|NCT00711841|DRUG|dexamethasone|dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
214847387|NCT03973099|DIETARY_SUPPLEMENT|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
214847388|NCT05194449|OTHER|Comfort Talk® App|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
214847389|NCT05194449|OTHER|Placebo App|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
214847390|NCT05497141|DEVICE|Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
214847391|NCT04292366|PROCEDURE|Invitation procedure|Optimised invitation procedures in an organised colorectal cancer screening programme
214847392|NCT01084018|BEHAVIORAL|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
214289510|NCT02165774|DEVICE|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
214289511|NCT02165774|DEVICE|Turning ON the neuromodulator|
214289512|NCT00107445|DRUG|EF5|Given IV
214473884|NCT05634902|BEHAVIORAL|CME Educational Intervention|The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.
214473885|NCT05634902|BEHAVIORAL|Study Developed Educational Materials for Patients|Patient-oriented materials are incorporated into a mobile responsive website with information/instruction about BPPV, and self-management resources; information/instruction on gaze stabilization exercises for vestibular neuritis
214289513|NCT06334471|OTHER|no intervention needed|no intervention needed
214473886|NCT06056258|DIETARY_SUPPLEMENT|VL-NL-02|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
214473887|NCT06056258|DIETARY_SUPPLEMENT|Placebo|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
214473888|NCT05684367|BEHAVIORAL|Center-Based Walking Exercise|Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.
214847393|NCT01507090|DEVICE|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
214847394|NCT02900482|OTHER|Sampling saliva|
214847395|NCT06152705|DEVICE|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
214847396|NCT02521753|DRUG|Metformin|Intervention also includes weight reduction diet and exercise therapy
214847397|NCT02521753|DIETARY_SUPPLEMENT|Magnesium|Intervention also includes weight reduction diet and exercise therapy
214847398|NCT02521753|DIETARY_SUPPLEMENT|PUFA|Intervention also includes weight reduction diet and exercise therapy
214847399|NCT06902168|OTHER|Intensive swimming program|The participants will be enrolled in an intensive swimming program for 8 weeks (45 minutes) in the swimming pool. The swimming program will be to improve safety and functional independence in the water. The hydrotherapy will be performed at a swimming pool temperature suitable for the weather temperature.
214847400|NCT05264831|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.
214847401|NCT05264831|PROCEDURE|PVI procedure associated with substrate modulation|PVI procedure associated with substrate modulation
214847402|NCT06904560|OTHER|phacoemulsification|one group with BSS at room temperature and the other group with cold BSS
214847403|NCT06904573|DRUG|Probiotics Compound (Biolosion)|15g, PO, qd
214847404|NCT06904573|DRUG|Nab-paclitaxel|230mg/m2, IV, days 1, 8, q3w
214847405|NCT06904573|DRUG|Cisplatin|70mg/m2, IV, days 1-3, q3w
214847406|NCT06904573|DRUG|Gemcitabine|1.2g/m2, IV, days 1, 8, q3w
214847407|NCT06904573|DRUG|Disitamab vedotin|2.5mg/kg, IV, q2w
214289514|NCT04982887|OTHER|Exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
214289515|NCT04590365|DEVICE|Carrageenan nasal and throat spray|Iota-carrageenan nasal and throat spray (verum Coldamaris plus i.e. Iota-Carrageenan 0.12% plus 0.04% Kappa-Carrageenan in 0.5% saline)
214289516|NCT04590365|DEVICE|Saline nasal and throat spray|Saline nasal and throat spray (placebo Coldamaris sine i.e. 0.5% saline)
214289517|NCT04525664|DRUG|Clarithromycin 500mg|500 mg per os twice daily for 14 consecutive days.
214847408|NCT06904573|DRUG|Enfortumab Vedotin|1.25mg/kg, IV, days 1, 8, q3w
214289518|NCT04525664|DRUG|Amoxicillin 1000 MG|1000 mg per os twice daily for 14 consecutive days.
214289519|NCT04525664|DRUG|Omeprazole 40 MG|40 mg per os twice daily for 14 consecutive days.
214289520|NCT04525664|DRUG|Omeprazole 20 MG Oral Tablet|20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
214289521|NCT01708681|DIETARY_SUPPLEMENT|Lean seafood|
214289522|NCT01708681|DIETARY_SUPPLEMENT|Meat, egg, milk|
214289523|NCT06410820|DEVICE|Procedure/Surgery: Ultrasound method group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
214473889|NCT05684367|BEHAVIORAL|Home-Based Walking Exercise|Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
214847409|NCT06904573|DRUG|Pembrolizumab|200mg, IV, q3w
214847410|NCT06904573|DRUG|Toripalimab|240mg, IV, q3w
214847411|NCT06904716|OTHER|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation
214847412|NCT06905301|DRUG|Ribociclib|CDK4/6 inhibitor
214847413|NCT06905301|DRUG|Letrozole|Aromatase inhibitor
214847414|NCT06905301|DRUG|Anastrozole|Aromatase inhibitor
214847415|NCT06904144|BEHAVIORAL|Health Coaching|12 virtual health coaching sessions will be provided over a 16 week period by a certified health coach.
214847416|NCT06905769|COMBINATION_PRODUCT|Aquatic Therapy|Group A was treated with Aquatic Therapy for 30-45 minutes for 3 sessions per week for 8 weeks . Patient should Seated .Therapist will standing or seated beside the patient Therapist Perform gentle stretching on wrist, hand, and finger joints. Exercises to improve range of motion and reduce stiffness. Then perform aquatic therapy for 10 minutes. Therapist instruct patients hands in bath tube. Water temperature 88°F - 94°F (31°C - 34°C).Water depth is Waist-deep or deeper depending on patient comfort
214847417|NCT06905769|DIAGNOSTIC_TEST|Neuro-Dynamic Technique|Group B (Neuro-Dynamic Technique) Group B was treated with Neuro-Dynamic Technique for 15 minutes 3 sessions per week for 8 weeks. Patient should Seated or supine with the affected hand relaxed. Therapist will standing or seated beside the patient. Techniques Time duration is 3 minutes for each technique. wrist distraction 3 sets for 3 minute rhythmic and gentle stretching of the transverse carpel ligament Release of palmar fascia gliding of finger flexor tendons release of upper forearm muscle and fascia.
214473890|NCT04874948|DRUG|500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043|Single oral administration of 14C-labeled radioactive 500mg BTZ-043
214473891|NCT06648915|DIAGNOSTIC_TEST|Lipoprotein(a)|Measurement of Lp(a) was performed at the time of entry to the registry. Lp(a) level was measured using immunenephelometric assay
214473892|NCT05967728|DEVICE|Remote ischemic conditioning (RIC) progammable device|RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.
214289524|NCT06410820|DEVICE|Landmark method group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
214289525|NCT01761331|OTHER|Acupuncture|"Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute."
214289526|NCT05534997|OTHER|intensive combined rehabilitation therapy|graded exercise therapy and cognitive behavioral therapy
214289527|NCT01779102|BIOLOGICAL|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
214289528|NCT01779102|BIOLOGICAL|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
214289529|NCT01779102|BIOLOGICAL|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
214289530|NCT00814190|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
214289531|NCT00609492|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
214289532|NCT00609492|BIOLOGICAL|Infanrix™-IPV/Hib|Single dose, intramuscular injection
214289533|NCT00720434|DRUG|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
214289534|NCT00720434|DRUG|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
214289535|NCT00720434|DRUG|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
214473893|NCT06652932|OTHER|Low temperature (15°C) group|The exposure group will be exposed to low temperature (15°C) in a chamber for about 2 hours, resting during the whole periods.
214473894|NCT06652932|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
214289536|NCT00720434|DRUG|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
214289537|NCT02057406|DRUG|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
214289538|NCT02057406|DRUG|High EPA|
214289539|NCT02057406|OTHER|Placebo|
214289540|NCT00139009|DRUG|Cyclosporine A|
214289541|NCT02175589|OTHER|Colchicine Cessation|Colchicine Cessation
214289542|NCT04189211|DRUG|BAT8001|IV infusions.
214289543|NCT03061838|DRUG|MabThera®|1000 mg intravenously
214289544|NCT03061838|DRUG|Ritumax®|1000 mg intravenously
214289545|NCT02669381|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
214289546|NCT02075229|DEVICE|Cochlear implant|A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
214289547|NCT03147365|BEHAVIORAL|Aerobic exercises|Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
214289548|NCT03147365|BEHAVIORAL|Modified strength training|Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
214289549|NCT03982927|OTHER|Laparoscopic skills workshop|One day laparoscopic skills workshop was offered to the surgical residents
214473895|NCT05818410|DEVICE|Prosthetic device (Lunaris)|Participants with an amputation will conduct experiments with the prosthetic device
214473896|NCT05818410|OTHER|No prosthetic device|Able-bodied individuals will conduct experiments to enable comparison with the participants with amputation
214473897|NCT05818410|DEVICE|Prosthetic device (Sach foot)|Participants with an amputation will conduct experiments with the prosthetic device
214473898|NCT05573204|DRUG|Obeticholic Acid Oral Tablet|Obeticholic acid used as 10 mg tablet once daily for 6 months
214473899|NCT05573204|DRUG|Vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
214473900|NCT06651697|RADIATION|Radiation therapy|Radiation therapy with full bladder or empty bladder protocols
214473901|NCT06652347|OTHER|Cancer care delivery|Early vs. delayed sharing of GA and OFS diagnostic results and how that sharing affects patient preferences, decision- making, and satisfaction in the context of participants' cancer care.
214473902|NCT03844061|DRUG|Belimumab|Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.
214473903|NCT03844061|DRUG|Rituximab|Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.
214473904|NCT03844061|OTHER|Placebo Subcutaneous Injection|Normal Saline
214473905|NCT03844061|OTHER|Placebo Infusion|Normal Saline
214473906|NCT03844061|DRUG|MMF|MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
214473907|NCT04567706|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214473908|NCT06252038|BEHAVIORAL|Zoom Group Video (GV)|Zoom delivery of the DPP. Participants have access to Prevent T2 Curriculum and connected technology to track weight and physical activity.
214473909|NCT06252038|BEHAVIORAL|Self Directed (SD)|Self directed delivery of the DPP. Participants have access to online curriculum, lifestyle coach and connected technology to track weight and physical activity.
214473910|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 Ag Ultra|The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.
214473911|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
214473912|NCT06820606|DEVICE|Rezum|In the REZUM arm, water vapour treatment will be preformed.
214657319|NCT06054737|PROCEDURE|SPA THERAPY|"Balneotherapy program Four balneotherapy sessions per day, 6 days a week during 3 weeks~The balneotherapy sessions included:~* 10- minute walking session in a specially designed pool with tracks in semideep (80 cm) cool (30°C) water (training of muscle pump function under water compression);~* 20-minute whirlpool bath session with automatic air or submarine bath if hypodermis (aimed at relaxation and mobilization of the superficial skin volume flow); followed by a 10-minute hydrojet bath (2 sessions) with customized underwater strong massaging jets (mobilization and softening of the sclerotic subcutaneous tissues);~* Fresh thermal water compresses at 24°C. The cool temperature of the compresses also has an analgesic and decongestant effect. This treatment is carried out last and is followed by a rest for a total duration of 60 minutes"
214847418|NCT06904768|DEVICE|Shoulder Sling|Use of a shoulder sling (Reh4mat AM-SOB) on the affected upper limb during mobility and balance testing.
214847419|NCT06904768|OTHER|No Sling|Functional mobility tests performed without the use of any assistive shoulder device.
214847420|NCT06904092|DEVICE|Transcranial ultrasound stimulation|The TUS was administered using Transcranial Ultrasound Stimulator UNS-III (model UNS-III), which has passed the safety test for medical electrical equipment (GB9706.1-2007). Transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
214847421|NCT06903767|DEVICE|Automated Impaction (HAMMR)|For cases that are randomized to the automated impaction HAMMR group, the surgeon will utilize an automated impactor device for impaction of the implant during total hip arthroplasty.
214289550|NCT05713721|DEVICE|Transcranial magnetic stimulation (TMS)|TMS over the left primary motor cortex will be performed. To investigate sensorimotor integration, an electrical stimulus on the right index finger will precede the TMS pulse.
214657320|NCT05622747|OTHER|Passive heating|1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C)
214657321|NCT04552145|PROCEDURE|surgery|standard decompression surgery
214847422|NCT06903767|DEVICE|Manual Malleting|For cases that are randomized to the manual malleting group, the surgeon will utilize a mallet for impaction of the implant during total hip arthroplasty.
214289551|NCT05713721|OTHER|Video-based clinical examination|A standardized neurological examination will be performed and video taped. The videos will be rated by movement disorder specialists, wo are blinded for the symptom and mutation status of the participants.
214289552|NCT05713721|OTHER|24 hours drug withdrawal of dopaminergic medication|Examinations will be done under chronic dopaminergic treatment and after a 24 hours dopaminergic drug withdrawal.
214289553|NCT05713721|OTHER|Evaluation of deep brain stimulation|Examinations will be done before and after implantation of deep brain stimulation (clinically optimal stimulation vs. switched off stimulation)
214657322|NCT04552145|BEHAVIORAL|Physiotherapy|3 month physical therapy treatment including home activity based on a well defined program and 4 to 6 visits at physical therapy intervention center.
214657323|NCT06222268|DRUG|Cannabidiol (CBD) only|Cannabis consisting of 2.5mg CBD and 0mg Delta-9-tetrahydrocannabinol (THC) is delivered through a vaporizer.
214289554|NCT00846131|DRUG|Sorafenib|Randomized to Y-90 ± Sorafenib
214473913|NCT06820606|DEVICE|UroLift|In the UroLift arm, prostatic urethral lift treatment will be performed.
214473914|NCT05297279|BEHAVIORAL|Home delivery Omega-3 rich Food|The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.
214473915|NCT05297279|BEHAVIORAL|Dietary Motivational Coaching|The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.
214473916|NCT05297279|BEHAVIORAL|Home delivery Food|The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
214473917|NCT06813313|DEVICE|repetitive transcranial magnetic stimulation|A burst of 3 pulses sent at a frequency of 50 Hz, repeated with a frequency of 5 Hz for 2 seconds, followed by an 8-second pause. This sequence is repeated for 59 cycles, totaling 9 minutes and 50 seconds, with a total of 1800 pulses.
214473918|NCT06807034|OTHER|buccal swabs|buccal swabs for microbiota analysis before and after radiotherapy
214473919|NCT04271046|BEHAVIORAL|STAR-C-VTF|"1. One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study and to acquaint the caregiver with the STAR-VTF components of good dementia care; distribute printed educational material (and links to same material online);~2. Six 30-minute follow-up phone calls with the caregiver following each of the 6 learning modules to review STAR-VTF concepts, and further brainstorm strategies to modify identified activators and consequences with the objective of reducing behavioral symptoms;~3. secure message support, as needed, with the coach to help with personalizing the STAR-VTF curriculum for up to 6 months."
214473920|NCT04271046|BEHAVIORAL|Control|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study. Controls will receive usual care from their primary care provider and/or psychiatrist. We will give participants an information package from the Alzheimer's Association including a list of resources. To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia. Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association. This attention control is proposed to assess the additional impact of STAR-VTF above treatment as usual. Investigators do not intend to track non-study training receipt in the control arm."
214473921|NCT06793618|OTHER|Z-track technique|In this method, the neonates are in supine position, the skin is moved and held from the injection site 2 to 3 cm to the side or downward using the non- dominant hand, to ensure that blood vessel wasn't penetrated aspiration on the syringe must perceive the injection and then the medication is to be injected slowly. Researcher assistant that is unaware of the injection method performs the recording of the pain intensity and leakage diameter on the observation form.
214473922|NCT05274282|OTHER|Animation Therapy|Stop-motion movie shooting process designed for improving attention skill and regulating hyperactive and impulsive behaviours.
214473923|NCT00303459|DRUG|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
214473924|NCT00303459|DRUG|placebo|Matching bosentan placebo/b.i.d.
214473925|NCT06807528|BEHAVIORAL|Intermittent fasting|Participants will follow a 16:8 protocol whereby they will be asked to fast for 16 hours per day and allowed to eat ad-libitum for the remaining 8 hours. While (for feasibility purposes) it will be a requirement that the fasting period include time spent asleep, participants will be allowed some degree of flexibility in the start and end time of their fasting period. This will be performed in order to accommodate participant preferences (sleeping/eating/medication schedules) as best as possible and provide a sense of autonomy. During the non-fasting hours, participants will be permitted to eat ad libitum.
214473926|NCT06807528|BEHAVIORAL|Behavioral Support Strategies|Evidence-based self regulatory health behaviour support techniques including education, ongoing tailored feedback and encouragement, self monitoring tools, and goal setting will be used to help participants adhere to the fasting protocol. These techniques will be implemented via weekly phone calls to allow for coaching (e.g. barrier identification, strategies/action planning to overcome barriers, goal setting) as well as a smartphone app. The smartphone application will provide information pertaining to intermittent fasting including lay summaries of clinical trials as well as infographics related to healthy eating for the ad-libitum eating periods. Tips for healthy eating on a budget and adhering to an intermittent fasting protocol will also be provided. The smartphone app will also feature intermittent fasting start and stop time reminders, hydration reminders, and the ability to set one's individualized fasting schedule and record actual daily fasting windows.
214473927|NCT06878898|BEHAVIORAL|Education and mobile phone text-messaging|The investigators piloted a knowledge and mobile text-messaging intervention using a prospective group design, allocating 14 (asthma=8; COPD=6) and 15 (asthma=9; COPD=6) participants to control and intervention groups respectively, after stratifying by type of disease.
214473928|NCT06878898|OTHER|Education only|Participants in the control group only received the educational intervention.
214473929|NCT06807905|DRUG|Heparin anticoagulation|Hemodiafiltration will be performed with heparine anticoagulation
214473930|NCT06807905|DRUG|Citrate anticoagulation|Patient will perform dialysis with citrate anticoagulation
214473931|NCT04452305|PROCEDURE|Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting|Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
214473932|NCT01570361|DEVICE|Catheter Ablation|Treat subjects with Paroxysmal Atrial Fibrillation (PAF)
214473933|NCT01570361|DRUG|Drug Treatment|Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
214473934|NCT04129554|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
214289555|NCT00846131|DRUG|Yttrium-90 (Y-90)|Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
214473935|NCT04129554|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
214473936|NCT04129554|DRUG|Placebo for JNJ-73763989|Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
214473937|NCT04129554|DRUG|Placebo for JNJ-56136379|Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
214473938|NCT04129554|DRUG|Entecavir (ETV) monohydrate|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
214473939|NCT04129554|DRUG|Tenofovir disoproxil fumarate (TDF)|TDF will be administered orally once daily up to 48 weeks as NA treatment.
214473940|NCT04129554|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
214473941|NCT06812468|DEVICE|Bellus 3D smart application|Bellus3D is a modern multi-digital digicam, 3-D face scanning that captures in an expert grade, complete 3-D face scans with the pressing of an unmarried button in seconds. It takes 10 s to create an excessive decision 3-D face scan. Bellus3D's excessive precision scanning detects the soft tissue parameters and over a hundred facial andmarks. It uses two Infrared structured light VCSEL (vertical-cavity surface-emitting laser) projectors for high-resolution face scanning. The technique of facial scanning by (Bellus3D) and measuring facial index by (Medit) software was performed following manufacture instructions , The patient's head Stabilized and aligned with the center of the face scan software (Bellus 3D) to avoid scan distortion, The head was tilted towards right and then towards left along with the face analog in the scan software combined with upward and downward movement to ensure complete detection and record of facial landmarks. Then the obj 3D file exported to Medit Software.
214473942|NCT06812468|DEVICE|Medit i-700 intraoral scanner|Medit i-700 intra oral scanner was used to measure the teeth dimensions , it has several advantages including that it can capture up to 70 FPS (FRAMES PER SECOND), which is significantly faster than the previous model. It delivers high image resolution for better quality. The Medit i700 offers a remote control mode and a built-in UV-C disinfection function. In this study a zigzage movement was used which more accurate rout for recording all anterior teeth dimensions and surrounding tissue while scanning. In agreement with a previous study, we started from the posterior left area by scanning the occlusal side, then it proceeded toward the posterior right area by following a zigzag movement when the anterior teeth were scanned. After the occlusal area, the palatal/lingual side was scanned from the right to the left area, and then the buccal side was scanned from the posterior left area to the posterior right one,Then the obj 3D file exported to Medit Software.
214473943|NCT01146704|DIETARY_SUPPLEMENT|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
214473944|NCT01146704|DIETARY_SUPPLEMENT|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
214473945|NCT03309644|OTHER|Peripheral nerve blockade|Participants who receive a peripheral nerve block identified through the medical chart.
214473946|NCT03309644|OTHER|No peripheral nerve blockade|Participants who did not receive a peripheral nerve block identified through the medical chart.
214473947|NCT06817759|DEVICE|Virtual Reality Hypnosis|An intervention program (VRH) that combines VR and hypnosis; Can use it whenever and how much they want. It contains 200 landscapes in VR and 4 different VRH sessions
214847423|NCT06904950|BEHAVIORAL|Nightmare Deconstruction and Reprocessing|Eight-sessions that include 1 session of psychoeducation and treatment orientation and 7 sessions of NDR. NDR consists of three stages: (1) nightmare image deconstruction, (2) meaning making and reprocessing of cognition and emotions related to images, (3) rescripting new dream images and rehearsal of new images.
214847424|NCT06905379|OTHER|Moringa Oleifera|Moring Oleifera Varnish application Using a disposable bond brush, the varnish will be painted on the diagnosed surfaces, then the patient will be instructed to avoid brushing or flossing and to avoid hard and sticky food or any products that may contain alcohol (oral rinses, beverages, etc.) for the next 4 hours after application.
214847425|NCT06905379|OTHER|Varnish|"MI Varnish application~The varnish will be applied on the clean surfaces according to manufacturer instructions as follows:~1. The foil cover of the MI Varnish unit dosage bottle will be peeled-off and MI Varnish will be stirred with the disposable brush before application.~2. The surfaces will be covered with a thin uniform layer using a disposable bond brush to avoid clumping.~3. The area will be allowed to become wet to ensure the setting of the varnish."
214847426|NCT06905470|PROCEDURE|Eccentric (KREHA) training|20 eccentric resistance training sessions will be performed on a symmetric arm-crank ergometer in a supine position.
214473948|NCT06817759|DEVICE|VRH : Beach|Hypnosis session with a VR immersion at the beach; one accompanied session
214473949|NCT06817759|DEVICE|VRH : Forest|Hypnosis session with a VR immersion in forests; one accompanied session
214473950|NCT06817759|DEVICE|VRH : MagicHand|Hypnosis session with a VR immersion with techniques to reduce pain; one accompanied session
214473951|NCT06817759|DEVICE|VRH : SecurityProtection|Hypnosis session with a VR immersion with techniques to reduce anxiety; one accompanied session
214473952|NCT06817837|BEHAVIORAL|hypnosis|Eight hypnosis sessions will be offered to address various issues: sleep disorders, behavioral issues, anxiety, and pain.
214473953|NCT06820164|DRUG|Cooled Sodium Chloride Injection|Injection of a solution containing sterile, cooled 0.9% sodium chloride and 1% lidocaine with epinephrine (1:100,000).
214847427|NCT06905470|PROCEDURE|Standard clinical routine strength (STAN) training|The regular strength training intervention consists of a total of 20 training sessions at the gym of the study center, performed following clinical routine procedures.
214847428|NCT06904209|DEVICE|AI|"Each photo will be uploaded and analyzed by AI to predict the adequacy of their bowel preparation with immediate results of pass or not pass, indicating if their bowel preparation is adequate or inadequate. If the result is pass, patients will stop consuming the remaining PEG solution. If the result is not pass, patients will be advised to gently rub their lower abdomen in a clockwise direction or walk around and continue consuming the remaining PEG until the AI evaluation gives a pass result or until the full dose of 3 L PEG have been consumed. If the patient's rectal effluent deems IBP after consumption of the full dose of 3 L of PEG, an additional 1 L or more of PEG will be administered as a remedial dose at the discretion of the physician-in-charge."
214847429|NCT06904014|PROCEDURE|HAIC|FOLFOX-hepatic artery infusion
214847430|NCT06904014|DRUG|Sintilimab|200mg, ivgtt, D1, Q3W
214847431|NCT06904014|DRUG|Lenvatinib|8 mg，qd，D1-D21,Q3W
214847432|NCT06904014|PROCEDURE|surgery|surgery
214847433|NCT06905808|DEVICE|eSense 7Fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted into the body to measure pressure for urodynamics.
214473954|NCT06820645|DRUG|calcium gluconate|3g IV or IO calcium gluconate.
214473955|NCT06820645|DRUG|Control: Placebo|3g of IV or IO saline placebo.
214473956|NCT04372797|DEVICE|Diagnostic test|A battery of oculomotor tests
214473957|NCT06817460|PROCEDURE|tran-sumbilical laparoendoscopic single-site surgery|Different types of surgery
214473958|NCT06817460|PROCEDURE|transvaginal natural orifice transluminal endoscopic surgery|Different types of surgery
214473959|NCT06817941|BEHAVIORAL|Speech only|Participants will be using a computer-based speech therapy games at home to train their speech clarity for 8 weeks. While playing these games, a webcam will be recording the participant's speech loudness and mouth opening.
214473960|NCT06817941|BEHAVIORAL|Hand/Arm only|Participants will be using a computer-based therapy games at home to train their hand and arm movement for 8 weeks. While playing these games, a motion detector will be used to measure how quickly and accurately the participants can move their fingers, wrist, and arm.
214473961|NCT06817941|BEHAVIORAL|Speech and arm combined|Participants will be using a computer-based therapy games at home to train their speech clarity and hand/arm movement together for 8 weeks. While playing these games, a webcam will be recording the participant's speech loudness and mouth opening. A motion detector will also be used to measure how quickly and accurately the participants can move their fingers, wrist, and arm.
214473962|NCT06820619|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), is a two-part program involving teacher training and delivery of SEED. The teacher training is consist of a 12-hour mindfulness course and a 1-day (6 hours) workshop to get familiarized with the understanding and practice of mindfulness, and the details of the SEED Curriculum. The SEED Curriculum involves 8 short sessions of basic techniques in mindfulness with 10 minutes each. In addition, it has 12 mindfulness-based lessons with specific themes for children in K1 and K2. Each lesson lasts for approximately 30-40 minutes.
214473963|NCT06855472|OTHER|The MAR method|"The study was conducted in three isolated stations. Two faculty researchers designed the scenarios, while three others supervised training. Medical student investigators recorded blood loss estimates and estimation times.~Before the study, investigators received 20-minute training. Participants and investigators were blinded to actual blood volumes. Group 1 and Group 2 attended a 10-minute briefing, including consent and study introduction.~The study had two phases. In Phase 1, Group 1 used the Visual Estimation (VE) method, while Group 2 received a 2-minute MAR method training before making estimations. In Phase 2, Group 1 was trained in the MAR method and repeated estimations.A data form recorded demographics, blood loss estimates, and estimation times.~Group 1's VE data and Group 2's MAR data were compared between groups, while Group 1's VE and MAR data were analyzed within the group. Combined MAR data from both groups were used to assess the impact of gender, height, and weight."
214473964|NCT06857760|OTHER|Ice cube|ıce cube
214473965|NCT06857760|OTHER|Mouth wash|Mouth wash
214473966|NCT06857760|OTHER|Menthol lozenge|menthol lozenge
214473967|NCT06857708|DEVICE|Cytal® Wound Matrix|This is the only study to use this intervention in necrotizing soft tissue wounds
214473968|NCT06857708|DEVICE|MicroMatrix®|This is the only study to use this intervention in necrotizing soft tissue wounds
214473969|NCT05571267|DRUG|Avacincaptad Pegol|Zimura 2 mg, administered by intravitreal injection
214289556|NCT05352334|DIAGNOSTIC_TEST|self-report Emotional Intelligence test (SSCEIT)|The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
214289557|NCT06066658|DEVICE|cranial electrotherapy stimulation (Alpha-Stim AID)|Alpha-Stim AID
214289558|NCT01571427|BEHAVIORAL|Active social engagement group|Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention
214473970|NCT05571267|DRUG|Avastin|Avastin 1.25 mg, administered by intravitreal injection
214473971|NCT05571267|DRUG|Lucentis|Lucentis 0.5 mg, administered by intravitreal injection
214473972|NCT05571267|DRUG|Eylea|Eylea 2 mg, administered by intravitreal injection
214473973|NCT04199689|BIOLOGICAL|9vHPV Vaccine|9vHPV is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
214473974|NCT04199689|OTHER|Placebo (Saline for Injection)|0.9% sodium chloride given as a 0.5-mL intramuscular injection
214473975|NCT03993392|DRUG|TM buprenorphine|4mg TM buprenorphine, investigator choice as to brand
214473976|NCT03993392|DRUG|SUBLOCADE|300mg subcutaneous injection
214473977|NCT06588920|BEHAVIORAL|Cognitive function, gait, and electroencephalogram|Measurement of cognitive function, gait performance, and electroencephalogram
214657324|NCT06222268|DRUG|Placebo only|Placebo is administered in the same way as active drugs through the vaporizer. Placebo cannabis material obtained through National Institute of Drug Abuse (NIDA) contains 0mg THC and 0mg CBD
214657325|NCT06222268|DRUG|Delta-9-tetrahydrocannabinol (THC) only|Cannabis containing 2.5mg THC and 0mg CBD is delivered through a vaporizer.
214657326|NCT06222268|DRUG|THC:CBD 1:1|Cannabis containing 2.5mg of THC and 2.5mg of CBD is delivered through a vaporizer.
214473978|NCT06604117|DRUG|Statin|Participants who opt for this group will receive guideline-recommended conventional lipid-lowering therapy. For those with a history of ischemic stroke (IS), myocardial infarction (MI), acute coronary syndrome within the past year, symptomatic peripheral artery disease, or two or more high-risk factors, the target LDL-C level will be set at 1.4 mmol/L. For other IS participants, the LDL-C target will be set at 1.8 mmol/L. All participants will receive moderate-intensity statin therapy as the primary treatment. If LDL-C levels are not adequately controlled, ezetimibe will be added. If lipid levels remain unsatisfactory, the addition of PCSK9 inhibitors will be considered. Moderate-intensity statins are defined as atorvastatin 10-20 mg or rosuvastatin 5-10 mg.
214473979|NCT06604117|DRUG|Probucol|Participants who choose this group will receive Probucol in combination with guideline-recommended lipid-lowering therapy. Specifically, participants in this group will take 0.5 grams of Probucol twice daily alongside the conventional lipid-lowering therapy mentioned in Group 1. The combination of Probucol and conventional therapy aims to further improve lipid profile and address atherosclerosis.
214473980|NCT06821295|OTHER|Smart-T Alcohol|The Smart-T Alcohol intervention offers on-demand content and automated contextually tailored messages to reduce alcohol consumption. The intervention period will span eight-weeks (i.e., weeks 2-9), with follow-up assessments occurring at weeks 9, 13, and 26. All participants will complete brief daily smartphone-based surveys for 13 weeks.
214473981|NCT06821295|OTHER|Usual Care|Participants will receive standard shelter-based treatment (Usual Care) along with completing surveys and assessments.
214473982|NCT06825130|BEHAVIORAL|Exercise|Participants will attend 30-min training sessions 3 times a week for 12 weeks. The intensity of HIIT will be at 80% HR@VT2 measured in the first week and will increase to 90% in the second week. By week 3, the intensity will reach HR@VT2.
214473983|NCT01116895|DRUG|LEO 22811|Oral solution
214473984|NCT01116895|DRUG|Placebo|Placebo
214657327|NCT06222268|DRUG|THC:CBD 1:10|Cannabis containing 2.5mg THC and 25mg CBD is delivered through a vaporizer.
214847434|NCT04947150|BEHAVIORAL|Location-triggered notification|"If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF."
214847435|NCT04947150|BEHAVIORAL|Reflections on benefits of change|Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.
214847436|NCT04947150|BEHAVIORAL|Coach monitoring|Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.
214847437|NCT04947150|BEHAVIORAL|Household support|If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
214847438|NCT06905431|DIAGNOSTIC_TEST|Plyometric Training|"Frequency: Three sessions per week on non-consecutive days to allow for adequate recovery.~Intensity: High-intensity exercises performed at 80-90% of maximum effort. Exercises include box jumps, depth jumps, lateral bounds, and tuck jumps targeting explosive power and agility.~Time: Each session lasts approximately 45-60 minutes, including: Warm-up (10 minutes), Core Plyometric Exercises (30-40 minutes), Cool-down (5-10 minutes) Type: Explosive lower-body movements utilizing the stretch-shortening cycle (SSC) to improve neuromuscular coordination, sprint speed, and power."
214289559|NCT01571427|BEHAVIORAL|Control group|No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device. Participants will be reassessed at the 3rd and 6th month after completion of the intervention.
214289560|NCT02093754|PROCEDURE|MRI and biopsy|
214289561|NCT02068833|PROCEDURE|Gastrectomy|
214289562|NCT02068833|PROCEDURE|BPD-DS|
214289563|NCT00845689|DRUG|placebo|NaCl 0,9 %
214289564|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0, 2 %
214289565|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0,2 %
214473985|NCT06825325|OTHER|Music Listening|Selection of Sufi music will be played to the patients before the wound debridement.
214473986|NCT04646395|DRUG|Tafasitamab|200 mg powder for reconstitution with 5 ml water for injection
214657328|NCT04913766|BEHAVIORAL|Problem Management Plus|Five session psychological intervention focusing on problem management skills.
214657329|NCT04913766|BEHAVIORAL|Services as Usual|Mental health services provided by a mental health specialists according to their standard practices of care
214657330|NCT05554939|BIOLOGICAL|Allogenic CD19 CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (6 × 10\^6 cells/kg) , dose 2 (1.2 × 10\^7 cells/kg), dose 3 (1.8 × 10\^7 cells/kg); Phase 2 : dose of RP2D.
214657331|NCT05554939|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
214473987|NCT04646395|DRUG|Acalabrutinib|100 mg hard gelatin capsules
214473988|NCT04024254|DRUG|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
214473989|NCT03794011|DEVICE|fetoscopy|The fetoscopic arm is described above. Patients who have an appropriate window (posterior placenta) and choose fetoscopic surgery will be offered the two fetoscopic options, (i) laparotomy assisted and, (ii) totally percutaneous expandable port assisted. Patients with an anterior placenta will only be offered the lapartotomy assisted approach. All patients will undergo a fetoscopic repair of the fetal open neural tube defect including a the use of a Durepair patch.
214473990|NCT06397534|OTHER|Education|"In the experimental group, students will be administered the Introduction Characteristics Form, Stoma Care Knowledge Assessment Form (pre-test), and the General Self-Efficacy Scale (pre-test). Subsequently, digital materials (such as stoma care presentation materials and stoma care demonstration videos) will be prepared by the researchers. The video content will be uploaded to the 'Edpuzzle' program, which is accessible via internet connection or downloadable to devices. The video content in the 'Edpuzzle' program will consist of stoma care procedural steps. Following this, students will apply the stoma care skill in the skills laboratory under the supervision of instructors. To reinforce the implementation in the experimental group, online activities such as word clouds and quizzes will be sent. After the implementation and 4 weeks later, the 'Stoma Care Knowledge Assessment Form (post-test)' and the 'General Self-Efficacy Scale (post-test)' will be administered online."
214473991|NCT06610994|DEVICE|local vibration apply|Local vibration (LV) application will be made with the Vibrasens© (Techno Concept, Mane, France) device. Vibrasens© is a mechanical vibrator that produces transcutaneous vibration stimulations used in sensory-motor rehabilitation. Vibrasens©; It is a non-invasive, therapeutic device. Vibrasens© includes 1 pilot unit, 1 manual vibrator VB200, 4 flat skin contactors for tendon application, 4 round skin contactors for skin application, 1 power supply, 1 user manual and 1 protocol guide. LV application will be applied to the most swollen part of the spastic medial gastrocnemius muscles in the treatment group for 10 minutes. LV will be applied to one of the treatment groups at a frequency of 80Hz with an amplitude of 1 mm.
214473992|NCT06671704|OTHER|Genetic counseling months 4-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 4 to month 15.
214473993|NCT06671704|OTHER|Genetic counseling months 6-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 6 to month 15.
214473994|NCT06671704|OTHER|Genetic counseling months 8-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 8 to month 15.
214473995|NCT06671704|OTHER|Genetic counseling at months 10-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 10 to month 15.
214473996|NCT06671704|OTHER|Genetic counseling at months 12-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 12 to month 15.
214473997|NCT06671704|OTHER|Genetic counseling at months 14-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 14 to month 15.
214473998|NCT05926258|DRUG|Chloroprocaine 3% eye gel|ocular surface anesthesia
214473999|NCT05926258|DRUG|Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops|ocular surface anesthesia
214474000|NCT06677918|DRUG|EP395|Capsule for oral use
214474001|NCT06677918|DRUG|Placebo|Capsule for oral use
214474002|NCT04554940|BIOLOGICAL|vosoritide|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
214474003|NCT06488495|BEHAVIORAL|Exercise Program|The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.
214474004|NCT06488495|BEHAVIORAL|Exercise Program|The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.
214474005|NCT05748613|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|Brief computerized treatment for anxiety sensitivity
214474006|NCT05748613|BEHAVIORAL|Health Education Control|Brief computerized presentation on healthy behaviors
214474007|NCT03668041|DRUG|Trazodone|Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.
214474008|NCT03668041|DRUG|Eszopiclone|Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.
214657332|NCT05554939|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
214289566|NCT00845689|PROCEDURE|Liver resection|Liver resection with Pringle maneuver
214289567|NCT00224315|DRUG|ziprasidone|
214289568|NCT00224315|DRUG|risperidone|
214474009|NCT03668041|OTHER|Placebo|The active study medications listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it.
214474010|NCT06839664|DRUG|HS-20094 injection|Administered SC
214474011|NCT06839664|DRUG|Placebo injection|Administered SC
214474012|NCT04221464|BIOLOGICAL|biological collection|Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
214474013|NCT04221464|OTHER|Tissues collections|Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
214474014|NCT05961358|PROCEDURE|snapshots or videos of monitor|The mobile device（a phone）was used to obtain the screen image of the monitor, and the arterial blood pressure waveform is extracted by image processing technology.
214474015|NCT05961358|PROCEDURE|Pressure transducer|Arterial catheter were connected to conventional pressure transducers and Flotrac-Vigileo transducers.
214657333|NCT05091346|DRUG|E7386|E7386 tablet.
214657334|NCT05091346|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
214657335|NCT05091346|DRUG|Lenvatinib|Lenvatinib capsule.
214474016|NCT05962814|DEVICE|EarGenie MVP test|The EarGenie test consists of placing the EarGenie headgear on the infant and running the fNIRS tests via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation. Automatic analyses are run to determine whether the infant heard the sounds or discriminated between them. The infant will be in a natural sleep when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
214474017|NCT04528407|OTHER|Observation without intervention|This study is a follow-up study without intervention.
214474018|NCT05039554|BEHAVIORAL|Acceptance and commitment therapy|Intervention will be provided over 12 weeks with weekly 1-hour sessions using a group format with the overall goal to foster psychological flexibility. ACT will assist participants to notice their internal triggers; abandon their attempts to manage these triggers via active avoidance (suppression or other control-based strategies including opioid or other substance use) and to make commitments to engage in behaviors consistent with their chosen values or goals (rather than allowing negative thoughts, feelings, or pain symptoms to dictate behavior).
214474019|NCT05039554|OTHER|Valera Smartphone Application|For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.
214474020|NCT05039554|OTHER|Treatment as Usual|TAU for BUP treatment typically consists of regularly scheduled visits every 1-2 months with primary care physicians and/or nurse care managers in Montefiore primary care settings. During these 15-min follow up visits, providers typically inquire about opioid and other substance use, opioid craving, symptoms of opioid withdrawal, and risk of relapse. In addition, at each visit, urine toxicology tests are conducted and providers review results of prior urine toxicology tests with patients. If opioid or other substance use is ongoing, typically providers will intensify treatment, including increasing the frequency of visits, referring to social workers or mental health providers, recommending self-help groups, and/or recommending outpatient drug treatment programs (e.g., individual and group counseling).
214474021|NCT04279834|BEHAVIORAL|PAP Treatment|Motivational enhancement plus remote-monitoring and participant self-monitoring of PAP use.
214474022|NCT04279834|BEHAVIORAL|Sleep Education I|Motivational enhancement plus participant self-monitoring of sleep.
214474023|NCT05612880|DRUG|androgen receptor signaling inhibitors|Prior to or within 8 weeks of ARSI initiation, men with advanced prostate cancer will perform baseline testing, with follow ups at 12 and 24 weeks
214474024|NCT06717126|DRUG|roginolisib|rognolisib
214474025|NCT06717126|DRUG|Investigator choice of standard therapy|Investigator will choose the most appropriate treatment standardly given to patients
214474026|NCT04826471|DEVICE|DermoRelizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
214474027|NCT03453528|DRUG|68Ga-PSMA|68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
214474028|NCT06101511|PROCEDURE|Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs|The intervention is intraoperative ventilation using the available ventilator with individualized high PEEP titrated to the lowest ΔP with RMs. After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial
214474029|NCT06789809|DIAGNOSTIC_TEST|Exercise MRI|Exercise stress MRI with ergometer
214474030|NCT05270876|DEVICE|Cochlear Implant and sound processor device fitting paradigm or diagnostic/measurement technique|The investigational device will be a new device fitting paradigm or diagnostic/measurement technique implemented for use with the commercially available sound processor and implant.
214657336|NCT06087835|DRUG|Zibotentan/Dapagliflozin|Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
214657337|NCT06087835|DRUG|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized to
214657338|NCT03496506|DRUG|Selexipag|Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
214657339|NCT03496506|DRUG|Clopidogrel|Each film-coated tablet containing 75 mg of clopidogrel (oral use)
214657340|NCT05121415|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
214657341|NCT05564767|DIETARY_SUPPLEMENT|B. adolescentis Bif-038|B. adolescentis Bif-038 (probiotic capsule) delivered orally once daily at a minimum of 5 billion CFU/day
214657342|NCT05564767|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12® (probiotic capsule) delivered orally once daily at a minimum of 1 billion CFU/day
214657343|NCT05564767|DIETARY_SUPPLEMENT|Placebo|Placebo capsule delivered orally once daily
214657344|NCT04850183|BEHAVIORAL|Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis|The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
214657345|NCT03751332|DRUG|Tacrolimus|Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
214657346|NCT05590572|DRUG|Sulfatinib|(1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
214847439|NCT06905431|COMBINATION_PRODUCT|(High-Intensity Interval Training (HIIT)|Frequency: Three sessions per week (e.g., Tuesday, Thursday, Saturday) with a rest day between sessions. Intensity: Alternating between 85-95% of maximum heart rate during high-intensity intervals and 50-60% of maximum heart rate during recovery periods. Work-to-rest ratio of 1:2 (e.g., 30 seconds of high-intensity sprints followed by 60 seconds of low-intensity walking). Time: Each session lasts approximately 45-50 minutes, including: Warm-up (10 minutes), HIIT Intervals (25-30 minutes with 8-12 work-rest cycles), Cool-down (5-10 minutes) Type: Cardiovascular exercises such as sprinting, cycling, or shuttle runs designed to enhance anaerobic capacity, agility, and sprint speed.
214474031|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - PIOS MC|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
214474032|NCT05437900|PROCEDURE|Pressure Wire guided strategy - PIOS - PW|Use of Pressure Wire during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
214474033|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - Standard of care|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive standard of care treatment.
214474034|NCT05437900|PROCEDURE|Pressure Wire guided strategy - Standard of care|Use of Pressure Wire during PCI. After the PCI, the patient will receive standard of care treatment.
214474035|NCT05269849|DRUG|Sirolimus|Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
214474036|NCT04304144|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
214474037|NCT04304144|DRUG|SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)|According to institutional standard of care.
214474038|NCT04304144|DRUG|Daratumumab|Treatment for AL amyloidosis
214474039|NCT05239000|OTHER|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy.
214474040|NCT05239000|OTHER|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits.
214474041|NCT04302051|DIAGNOSTIC_TEST|Thermo-acuostic image acquisition of liver|Estimation of hepatic fat content with thermo-acoustic device
214474042|NCT04302051|DIAGNOSTIC_TEST|MRI-PDFF estimation of hepatic fat|Estimation of hepatic fat content with MRI
214474043|NCT04681690|OTHER|No intervention, observation only.|Observation only
214474044|NCT06559475|PROCEDURE|Super-Bore Thrombosis Aspiration Catheter treatment group|For the subjects randomized to the Super-Bore Thrombosis Aspiration Catheter treatment group, Mechanical thrombectomy will be performed using a Super-Bore 8/7F Thrombosis Aspiration Catheter.
214474045|NCT06559475|PROCEDURE|Conventional thrombectomy device treatment group|For the subjects randomized to the conventional thrombectomy device treatment group, mechanical thrombectomy will be performed using a commonly used thrombectomy devices in clinic, except for Super-Bore 8/7F Thrombosis Aspiration Catheter.
214474046|NCT03850457|OTHER|No intervention|The treatments will be determined by their neonatologists and no additional investigational drugs will be applied to the infants included in this study.
214474047|NCT06469359|DEVICE|Nasal tissue-resident memory T and B cells|Nasal tissue-resident memory T and B cells are quantified using flow cytometry.
214474048|NCT06469359|DEVICE|Nasal fluid sampling|Nasal fluid is collected using strip (Hunt Development) in both nostrils
214474049|NCT06469359|DEVICE|Saliva sampling|Saliva is collected using Oracol (Malvern Medical Developments)
214474050|NCT06469359|OTHER|Blood sampling|Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood
214474051|NCT06469359|DIAGNOSTIC_TEST|ELISA|ELISA to measure antibody responses in mucosal fluids and blood
214474052|NCT06469359|DIAGNOSTIC_TEST|Neutralization test|Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood
214474053|NCT06469359|DIAGNOSTIC_TEST|ELISPot|ELISPot to measure cellular responses in blood
214474054|NCT06469359|DIAGNOSTIC_TEST|Transcriptomics|Transcriptomics to quantify the gene expression of immunological markers in blood
214474055|NCT05216653|DRUG|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
214474056|NCT05216653|DRUG|Oxaliplatin|130mg/m2，ivgtt，d1
214474057|NCT05216653|DRUG|Capecitabine|1000mg/m2，po，bid，d1-14
214474058|NCT05216653|RADIATION|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
214474059|NCT05216653|PROCEDURE|TME surgery, total mesorectal excision|The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient.
214474060|NCT06220851|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength will be measured by 3 efforts.
214474061|NCT01743950|DRUG|Bevacizumab|10mg/kg every 2weeks.
214474062|NCT01743950|RADIATION|PRDR|Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
214474063|NCT03804788|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
214474064|NCT03804788|BEHAVIORAL|Sleep Hygeine|All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
214474065|NCT04615273|DRUG|Lonapegsomatropin|Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
214474066|NCT04615273|OTHER|Placebo|The placebo for lonapegsomatropin drug product contained the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution was administered by subcutaneous (SC) injection via syringe and needle. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo received the same dose volume as if they were randomized to once-weekly lonapegsomatropin.
214474067|NCT04615273|DRUG|Somatropin|Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
214474068|NCT05769283|OTHER|Platelet Rich Plasma|Platelet rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. It is then injected into the anterior vaginal wall and periclitoral area
214474069|NCT05769283|OTHER|Saline|Normal Saline to be injected into the anterior vaginal wall and periclitoral area
214474070|NCT05834777|DRUG|Icatibant|Icatibant will be administered with an infusion rate of 100µg/kg/h for 15 minutes before their hemodialysis session (pre-infusion) and 50µg/kg/h during their routine hemodialysis session (maintenance infusion).
214474071|NCT05834777|DRUG|Placebo|0.9% sodium chloride will be administered as the same rate as icatibant
214474072|NCT05094271|OTHER|Supplemental Oxygen|Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats \>90% based on oximetry readings.
214474073|NCT05094271|DEVICE|Continuous Positive Airway Pressure Machine|Continuous positive airway pressure is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of a person.
214474074|NCT05094271|OTHER|Room Air|Subjects will be instrumented with a nasal cannula to receive 2L/min pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats \>90% based on oximetry readings.
214847440|NCT06905756|DIAGNOSTIC_TEST|Accelerated rehabilitation|15 subjects in group A will be receiving Accelerated Rehabilitation protocol alongwith baseline treatment. Accelerated rehabilitation consisting of three phases, following 12 week exercise regime. Pain reduction, mobility, strengthening, and functional recovery are part of the accelerated rehabilitation protocol for Achilles tendinopathy. Ice, TENS, range-of-motion exercises, isometric calf contractions, and a progressive transition to full weight-bearing based are the mainstays of Phase 1 (Weeks 1-4). Phase 2 (Weeks 5-8) focuses on balance training, resistance band exercises, and seated and standing calf raises as well as light functional workouts like cycling or walking. Phase 3 (Weeks 9-12) progresses to sport-specific and endurance exercises like swimming or running after including plyometric drills, eccentric heel drops, and advanced strengthening. Each exercise will be performed under supervision of skilled physiotherapist for 2 times daily, 2 sets of 5 repetitions.
214847441|NCT06905756|COMBINATION_PRODUCT|Eccentric strengthening exercises|Group B will be receiving eccentric strengthening exercises alongwith baseline treatment. Techniques of Curwin, Stanish et al will be used for eccentric training. For every exercise, participants do three sets of 15 repetitions, with a 30-second break in between. Weight is added gradually to enhance resistance (5-10 lbs or more, depending on tolerance). The eccentric strengthening regimen for Achilles tendinopathy advances every week. Participants use both feet without dorsiflexion to perform eccentric contractions in Week 1. By Week 3, the focus of the workouts is on the injured foot in maximum dorsiflexion. In Week 4, 10% body weight resistance is introduced, and in Week 5, an extra 5-10 pounds. From Week 6 to Week 8, resistance rises every two weeks. From Weeks 9 to 12, functional motions like hopping, single-leg heel drops, and sport-specific drills are incorporated, all of which are customized to meet individual goals.
214289569|NCT00617045|DRUG|duloxetine|"Total treatment period is 12 weeks~30mg po qd times 1 week~60mg po qd times 11 weeks"
214289570|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 1|Mango (pulp/flesh) (500 g)
214289571|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
214289572|NCT03365739|DIETARY_SUPPLEMENT|Control Comparator|Vitamin C (100 mg)
214289573|NCT05919381|DRUG|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
214289574|NCT05919381|DRUG|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
214289575|NCT06398535|DEVICE|magenetic resonance and ultrasound|examination of patient using magentic resonace coil for imaging of knee and comapring the results obtaines by ultrasound examination using the ulatrsound tarsnsducer .
214474075|NCT05465239|DEVICE|SurePace Powered Walker User|Participants will be asked to perform one baseline 5-minute trial with the lab's instrumented walker in passive mode (no powered locomotion) and two 5-minute trials with the walker in active mode (powered locomotion).
214474076|NCT05918120|DEVICE|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
214474077|NCT05918120|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
214474078|NCT03947697|DEVICE|Neuromuscular Electrical Stimulation (Sensory)|Group will receive Electrical Stimulation up to sensory level
214474079|NCT03947697|DEVICE|Neuromuscular Electrical Stimulation|Group will receive Electrical Stimulation up to maximum tolerable level
214474080|NCT03947697|OTHER|Resistance Training|Group will receive exercise training.
214474081|NCT03344965|DRUG|Olaparib|olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.
214657347|NCT05590572|DRUG|Etoposide|(1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
214474082|NCT01853631|GENETIC|Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells|"Three dose levels will be evaluated.~Group 1: CD19.CAR/28137ζ at 1×10\^6 cells/m\^2 and CD19.CAR/28ζ at 1×10\^6 cells/m\^2~Group 2: CD19.CAR/28137ζ at 5×10\^6 cells/m\^2 and CD19.CAR/28ζ at 5×10\^6 cells/m\^2~Group 3: CD19.CAR/28137ζ at 2×10\^7 cells/m\^2 and CD19.CAR/28ζ at 2×10\^7 cells/m\^2"
214474083|NCT01853631|GENETIC|Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells|The primary goal of the expanded cohort is to further study the safety profiles of CAR-T cells in each of the disease settings, both with or without lymphodepleting chemotherapy given before CAR-T cell infusion.
214474084|NCT04542616|DEVICE|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
214474085|NCT05739253|PROCEDURE|Transcatheter aortic valve replacement|All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
214474086|NCT05075577|DRUG|Enzalutamide|Daily oral dose of enzalutamide
214847442|NCT06905106|BIOLOGICAL|Collection of tube bottoms from blood samples taken in the clinic|Collection of tube bottoms from blood samples taken in the clinic
214847443|NCT06905145|OTHER|Biomarkers evaluation|Evaluate the prognostic role of the markers TP53, P16, Cyclin D1, EGFR, Akt, PDL-1, ERCC1 examined on biopsy samples.
214847444|NCT03757091|DEVICE|Laryngoscopy|Undergo video laryngoscopy
214847445|NCT03757091|PROCEDURE|Tracheal Intubation|Undergo flexible scope intubation
214847446|NCT06903871|DRUG|TORIPALIMAB INJECTION(JS001 )|Participants will receive toripalimab 240 mg IV once every 3 weeks. Treatment continued until disease progression, death, unacceptable toxicity, investigator decision, withdrawal, or completion of 1 years of treatment, whichever occurred first.
214847447|NCT06904989|DEVICE|Silicone orthosis|"in addition to standard treatment, shoe and insole treatment, a new type of treatment for CIPN is being evaluated, a silicone orthosis.The silicone orthosis consists of a half-sock designed for indoor use.~The participants feet are examined, and the foot shape is scanned barefoot using a three-dimensional foot scanner from Volumental. This is performed to use a basis for manufacturing individual silicone orthoses. Activity measurement with an activity sensor, attached to the thigh with tape, is planned for two weeks after receiving the assistive device.~Participants who receive a silicone orthosis are asked to keep a diary of how much they have used it. The follow-up takes place at the Oncology Department 3-6 weeks after the participant has received the assistive device."
214847448|NCT06904989|DEVICE|Standard Treatment|"The standard treatment is that patients are provided with customized insoles and shoes. Foot status is recorded during the orthopedic technical assessment at OTA, identifying signs of neuropathy, impaired blood circulation, foot deformities, and skin pathologies. A modified version of the validated D-Foot instrument is used to assess the risk of foot ulcers, especially in diabetic patients. The evaluation also includes lower extremity function, gait abnormalities, and existing footwear and insoles.~Differences in foot anthropometry are compared between scanned foot measurements of the study group and those of a control group representing a female Swedish normal population.~ActivePal is a reliable method for measuring and classifying activity levels. Activity measurement is conducted over two weeks."
214847449|NCT06905743|DIAGNOSTIC_TEST|Isometric Contraction-Based Pain Modulation Protocol for Achilles Tendinopathy|The standard recommendation for tendinopathy rehab became 30 to 45 second heavy isometric contractions repeated for 3 to 5 repetitions
214847450|NCT06905743|COMBINATION_PRODUCT|Eccentric Strengthening (Alfredson's Protocol for Achilles Tendinopathy )|The eccentric loading protocol, popularized by the research of Alfredson, consisted of 3 sets of 15 for both bent knee and straight knee heel raises with each heel lowering lasting 3-seconds
214847451|NCT06904742|DRUG|Tea tree oil|Our study's findings might have a important impact on the field of periodontology, providing valuable insights into the potential of herbal mouthwashes as an adjunct to NSPT in gingivitis treatment. A literature review reveals that regarding the mouthwash protocols, most studies mentioned use twice daily . Most studies used 10-15 ml as a dose, and rinsing time ranged from 30-90 s. In this study, similar to the literature, patients were prescribed to rinse twice daily, 15 ml for 30 s. The operator explained information about oral hygiene practices at baseline. With this approach, adequate mechanical cleaning action was obtained, and participants became more aware of importance of oral hygiene. Low scores of PI and GI in placebo group at 3rd month can be attributed to this interaction and can mask the maximum effects of herbal mouth rinses.
214847452|NCT06904742|DRUG|Thyme oil hydrosol|Our study's findings might have a important impact on the field of periodontology, providing valuable insights into the potential of herbal mouthwashes as an adjunct to NSPT in gingivitis treatment. A literature review reveals that regarding the mouthwash protocols, most studies mentioned use twice daily (Santi et al., 2019). Most studies used 10-15 ml as a dose, and rinsing time ranged from 30-90 s (Santi et al., 2019). In this study, similar to the literature, patients were prescribed to rinse twice daily, 15 ml for 30 s. The operator explained information about oral hygiene practices at baseline. With this approach, adequate mechanical cleaning action was obtained, and participants became more aware of importance of oral hygiene. Low scores of PI and GI in placebo group at 3rd month can be attributed to this interaction and can mask the maximum effects of herbal mouth rinses.
214289576|NCT04359433|BEHAVIORAL|Exercise programme|"Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~* 8 anerobic movements in 20 seconds is a set~* Rest for 10 seconds before another set~* Finish 4 sets every time, it shall take you 4 minutes~* Do 4 sets 2 to 3 times a week"
214474087|NCT05075577|DRUG|EPI-7386 with Enzalutamide|Daily oral dose of EPI-7386 in combination of enzalutamide
214474088|NCT06306638|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214474089|NCT06306638|PROCEDURE|Computed Tomography|Undergo CT
214474090|NCT06306638|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo EBUS
214474091|NCT06306638|PROCEDURE|Interstitial Photodynamic Therapy|Undergo I-PDT
214474092|NCT06306638|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
214474093|NCT06306638|OTHER|Physical Performance Testing|Ancillary studies
214474094|NCT06306638|OTHER|Questionnaire Administration|Ancillary studies
214474095|NCT06306638|DRUG|Verteporfin|Given IV
214474096|NCT06306638|DEVICE|Laser: ML7710-PDT|Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.
214474097|NCT05621187|DEVICE|Pamira ICD lead family|Implantation, measurements and follow-up schedule
214474098|NCT03911739|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
214474099|NCT03911739|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
214474100|NCT00875888|DEVICE|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
214474101|NCT06569043|OTHER|Breakfast Bar|Packaged breakfast bar product available in retail stores
214474102|NCT06575738|DRUG|Injectable semaglutide|Subcutaneous weekly injectable semaglutide
214474103|NCT06575738|BEHAVIORAL|Standard postoperative care|Standard postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.
214474104|NCT06571123|OTHER|İnteractive floor|Interactive floor The interactive floor system includes a computer, camera and projection. With the projection, videos that are ready on the computer are projected on the floor, image processing is done with the camera and it detects whether there is an object on the floor or not and creates effects on the video. For example, on the floor containing colored balloons, the balloons burst with the movement of the child. With this visual mobility, it is aimed to draw the child's attention to another direction.
214474105|NCT06575569|BEHAVIORAL|high-intensity interval training|Patients had no adverse events after 2 weeks of adaptive exercise training and voluntarily continued participants, intensive interval training under the care of specialists for 12 weeks, 30-40 minutes per week, including starting 5-minute warm-up and last 5-minute cooling-off period, during exercise including 4 intervals, 85-95% of maximum heart rate (HR) reserve for 4 minutes, followed by 50-70% of maximum HR reserve for 3 minutes, so cycling 4 times. Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and health education materials pushed by cardiovascular nurses.
214474106|NCT06575569|BEHAVIORAL|Moderate-intensity continuous training|Using routine postoperative care and follow-up, establish WeChat group as contact for postoperative follow-up, no adverse events after 2 weeks of adaptive exercise training and voluntary participants, patients exercise prescription for 12 weeks, 30-40 minutes, including 5 minutes of warm-up and cooling-off period of the last 5 minutes, during exercise intensity is 70-75% maximum heart rate reserve. The warm-up and cooling-off periods can be performed by stretching, flexibility exercises (i. e., neck, shoulders, upper back, hips, and ankles), and medium to low intensity (50-70% heart rate reserve). Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and pushed health education materials by cardiovascular nurses.
214474107|NCT06432309|DRUG|Opicapone 50 mg|Evaluate the addition of the COMT-I, Opicapone, to the Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
214474108|NCT06432309|DRUG|Duodopa|Evaluate Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
214847453|NCT06904742|DRUG|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Our study's findings might have a important impact on the field of periodontology, providing valuable insights into the potential of herbal mouthwashes as an adjunct to NSPT in gingivitis treatment. A literature review reveals that regarding the mouthwash protocols, most studies mentioned use twice daily. Most studies used 10-15 ml as a dose, and rinsing time ranged from 30-90 s . In this study, similar to the literature, patients were prescribed to rinse twice daily, 15 ml for 30 s. The operator explained information about oral hygiene practices at baseline. With this approach, adequate mechanical cleaning action was obtained, and participants became more aware of importance of oral hygiene. Low scores of PI and GI in placebo group at 3rd month can be attributed to this interaction and can mask the maximum effects of herbal mouth rinses.
214474109|NCT06574048|DRUG|saline placebo|IV saline bolus
214474110|NCT06574048|DRUG|Dexamethasone|10mg IV Dexamethasone
214474111|NCT06299319|DRUG|Psilocybin|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered twice during the trial, in conjunction with supportive therapy.
214474112|NCT06573554|DEVICE|Total Contact Cast|Knee High Fiber Glass Total contact Cast
214474113|NCT06573554|DEVICE|Posterior Slab|Posterior Slab Knee high non walking
214474114|NCT01627301|DEVICE|Device-Guided Breathing (DGB)|The RESPeRATE device will be used for 15 minutes of device-guided breathing daily for 8 weeks. The participant places the elastic belt with a respiration sensor around the upper abdomen, and wears earbuds for audio feedback. The device monitors the breathing rate, calculates inspiration and expiration times, and generates a personalized melody of two distinct ascending and descending tones for inhalation versus exhalation. Users effortlessly entrain their breathing pattern with the tones, and the device gradually guides the user to a prolonged expiration time and slower respiratory rate (to \< 10 breaths/minute). The device automatically stores usage data, allowing for quantification of adherence and performance.
214474115|NCT01627301|DEVICE|Sham DGB|The sham device is identical to the DGB device, except it does not guide respiratory rates to slow down and instead maintains a rate of 14 breaths per minute. The sham device is used for 15 minutes per day for 8 weeks.
214847454|NCT06904742|DRUG|Placebo|Placebo mouthwash had been used in 13 patients for 3 months
214474116|NCT01627301|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|tVNS is a noninvasive method that involves placing a device over the skin overlying the vagus nerve on the neck. The device delivers mild electrical stimulation, using transcutaneous electrical nerve stimulation (TENS) unit. The stimulation is increased until there is a vibration and slight muscle contraction in the lower face or neck. Then the stimulation is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes. The tVNS device is used twice daily for 8 weeks.
214474117|NCT01627301|DEVICE|Sham tVNS|Sham stimulation is delivered using a device that is identical to the gammaCore device but is programed to deliver a lower frequency that can be felt by the participant but does not actually stimulate the vagus nerve. The sham device is used twice daily for 8 weeks.
214474118|NCT03673501|DRUG|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
214847455|NCT05828303|DRUG|TPX-0005|Oral TPX-0005 capsules
214474119|NCT03673501|DRUG|Sunitinib|Oral receptor tyrosine kinase (RTK) inhibitor
214474120|NCT06115759|BEHAVIORAL|T-REX Twente precautions|The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).
214474121|NCT06115759|BEHAVIORAL|Usual (restrictive) sternal precautions|The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
214474122|NCT06642324|DIAGNOSTIC_TEST|Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing|Histopathology for carcinoma detection, Immunohistochemistry for carcinoma-related protein expression, Real-Time PCR for HPV association and HPV typing, Sequencing for genetic study or mutation analysis.
214474123|NCT06790953|PROCEDURE|Group- A Conventional Sensed Mouth Wash|"In Group- A Conventional Sensed Mouth Wash will be used for treatment of Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity."
214474124|NCT06790953|PROCEDURE|Group-B Novel Titania nanoparticles enriched Mouth Wash|"In Group-B Novel Titania nanoparticles enriched Mouth wash will be used to treat the Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity."
214474125|NCT03424850|RADIATION|HDR brachytherapy|"* Dose constraints for 21 Gy:~  * Bladder and rectum: V70 \< 1 cc~ * Urethra: V115 \< 1 cc~ * V135: 0%~* Dose constraints for 23 Gy:~  * Bladder and rectum: V65 \< 1 cc~ * Urethra: V105 \< 1 cc~ * V125: 0%~* Dose constraints for 25 Gy:~  * Prostate V100 \>90% (\>95% preferred)~ * Bladder and rectum: V70 \< 1 cc, Dmax \<115%~ * Urethra: V110 \< 1 cc, Dmax \<120%"
214474126|NCT04599634|DRUG|Obinutuzumab|Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.
214474127|NCT04599634|DRUG|Venetoclax|For follicular lymphoma (FL) patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL (Marginal Zone Lymphoma), MCL (Mantle Cell Lymphoma) or CLL (Chronic Lymphocytic Leukemia) patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.
214474128|NCT04599634|DRUG|Magrolimab|Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.
214474129|NCT04599634|DRUG|Acetaminophen|Premedication with 650mg acetaminophen 30-60 minutes prior to obinutuzumab doses.
214474130|NCT04599634|DRUG|Diphenhydramine|Premedication with 25-50mg diphenhydramine 30-60 minutes prior to obinutuzumab doses.
214847456|NCT05828303|DRUG|Metformin Hydrochloride|oral solution
214847457|NCT05828303|DRUG|Digoxin|oral tablet
214847458|NCT05828303|DRUG|Rosuvastatin Calcium|oral tablet
214847459|NCT06903858|DRUG|Toripalimab combined with celecoxib|Toripalimab is administered via intravenous infusion at 3 mg/kg over 30 minutes (initial infusion time is 60 minutes), once every two weeks, for a total of 12 doses before surgery. Celecoxib is taken orally at 200 mg per dose, twice daily, for a duration of 6 months.
214289577|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
214289578|NCT03138889|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
214474131|NCT04599634|DRUG|Prednisone/prednisolone|Premedication with 100mg intravenous prednisone/prednisolone 30-60 minutes before obinutuzumab infusion.
214474132|NCT04599634|DRUG|Methylprednisolone|Premedication with intravenous methylprednisolone 80mg 30-60 minutes before obinutuzumab infusion.
214474133|NCT04599634|DIAGNOSTIC_TEST|CT Scan chest/abdomen/pelvis|Screening, baseline, window Cycle -1/pre cycle 1, cycles 6-12; cycles 3-9, end of treatment and follow-up.
214474134|NCT04599634|DIAGNOSTIC_TEST|MRI|Screening, baseline, window Cycle -1/pre cycle 1, cycles 6-12; cycles 3-9, end of treatment and follow-up.
214474135|NCT04599634|DIAGNOSTIC_TEST|18-FDG-PET|Baseline, Cycle -1, Day 1, window Cycle -1/pre cycle 1, cycles 6-12, end of treatment and follow-up.
214474136|NCT04599634|PROCEDURE|Bone Marrow Biopsy|Screening, Cycle 7-12, Day 1 and end of treatment.
214847460|NCT06903858|PROCEDURE|Curative resection of colorectal cancer|Patients who do not achieve cCR based on radiographic imaging (CT/MRI of chest, abdomen, pelvis, and rectal MRI), endoscopy, and digital rectal examination (if applicable) are recommended to undergo curative resection of colorectal cancer.
214847461|NCT06903858|OTHER|Watch-and-wait strategy|Patients achieving clinical complete response (cCR) based on radiographic imaging (CT/MRI of chest, abdomen, pelvis, and rectal MRI), endoscopy, and digital rectal examination (if applicable) are recommended to adopt a watch-and-wait strategy.
214847462|NCT06904040|BIOLOGICAL|CM313 injection|600 mg (4 mL per vial), administer once at Week 0, 1, and 2, and then every 6 months thereafter or determined based on clinical assessment
214847463|NCT06904040|BIOLOGICAL|glucocorticoids|Administer medium- or long-acting glucocorticoids 1-3 hours before injection
214847464|NCT06905795|DIAGNOSTIC_TEST|Fibroscan test|Perform Fibroscan testing on the study subjects every six months.
214847465|NCT06905795|BEHAVIORAL|Nutrition guidance|Each family will be matched with a nutritionist, who will provide daily online dietary guidance for parents and students during the first 21 days, followed by weekly sessions thereafter.
214847466|NCT06905795|BEHAVIORAL|Increase physical activity|Increase physical activity time in and out of school by professional sports trainer.
214847467|NCT06905795|OTHER|Health education|Knowledge of healthy lifestyle will be delivered in various forms such as health lectures, brochures, posters, etc.
214847468|NCT06905522|DRUG|Bedaquiline (B)|The initial dose of bedaquiline is 400 mg daily for 2 weeks, followed by 200 mg three times a week.
214289579|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
214289580|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
214289581|NCT03138889|DRUG|Cisplatin|Cisplatin will be dosed per the pharmacy manual
214474137|NCT04599634|PROCEDURE|Bone Marrow Aspiration|Screening, Cycle 7-12, Day 1 and end of treatment.
214474138|NCT06529133|OTHER|Evaluation of postural control|Postural stability, limits of stability, and modified clinical test of sensory interaction in balance tests will be performed with Biodex Balance System (BBS). 1) Postural Stability: The test will be performed on a stable platform and mean, anterior/posterior and medial/lateral stability indices will be calculated. 2) Limits of Stability: The test will be performed on a static platform and directional control will be evaluated and expressed as a percentage value. 3) Modified Clinical Test of Sensory Interaction in Balance: The test will be performed with a static platform setting on a flat surface with eyes open and eyes closed, on a foam floor with eyes open and eyes closed. Half an hour later, the same tests will be repeated during the cognitive dual task. The cognitive tasks given were counting day-month-season, rhythmic forward and backward counting (counting by 2, 3, 5, 10, etc.), counting words related to a given letter (animal names starting with the letter A, city names, etc.).
214474139|NCT05684484|DRUG|Roflumilast 500 MCG Oral Tablet [DALIRESP]|Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
214474140|NCT05684484|DRUG|amino salicylic acid|conventional treatment
214474141|NCT06090279|DEVICE|OmniFlow Breathing Therapy BioFeeback System|FDA approved healthcare gaming system that is used for patients who have difficulty breathing and allows the patients to participate in breathing exercises for pulmonary rehab. Each game usage itself is expected to last 15-20 minutes.
214474142|NCT01775085|BEHAVIORAL|manualized group intervention|MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts \& Sources of Meaning; 2) Identity, Cancer Survivorship, \& Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present \& Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity \& Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, \& Humor; and 8) Transitions: Reflections \& Hopes for the Future.
214474143|NCT01775085|BEHAVIORAL|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
214474144|NCT03714815|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
214474145|NCT04999111|BIOLOGICAL|Ad26.COV2.S|Participants will receive IM injection of Ad26.COV2.S.
214474146|NCT04715685|BEHAVIORAL|40 minute session|The 40 minute session will include all of the content contained in the 20 minute session, but will include a greater explanation of each of the mind and body skills, followed by in vivo practice of each skill with the nurse. Sessions will also include review of home practice for each group.
214474147|NCT04715685|BEHAVIORAL|20 minute session|For participants randomized to the 20 minute session, content will include pain education, followed by brief explanations of each of the mind and body skills, in vivo diaphragmatic breathing practice and demonstration of use of biofeedback card. Sessions will also include review of home practice for each group.
214474148|NCT04715685|BEHAVIORAL|home practice e-health|Participants will be provided and instructed on access to a migraine-specific interactive web portal, Migraine e-Health. This web-based tool actively guides participants in practicing evidence-based mind and body skills. Use of the Migraine -e-Health application for the high dose capitalizes on teaching participants mind and body skills while increasing accessibility due to implementation on mobile devices.
214289582|NCT03138889|DRUG|Carboplatin|Carboplatin will be dosed per the pharmacy manual
214289583|NCT03138889|DRUG|Nab paclitaxel|Nab-paclitaxel will be dosed per local practice and label
214474149|NCT04715685|BEHAVIORAL|home practice handout|Participants will be given a handout of commercially available free apps relevant to the mind body skills introduced.
214474150|NCT04715685|BEHAVIORAL|phone call|The dose of phone call will occur about 4 weeks following the face-to-face mind and body introduction session and will last approximately 5-10 minutes. The phone call will be used to promote adherence to home-practice and answer questions related to skill use/home practice completion.
214474151|NCT06209684|PROCEDURE|Titanium|Spinal stabilization using titanium screws and rods
214474152|NCT06209684|PROCEDURE|Carbofix|Spinal stabilization using CarboFix screws and rods
214474153|NCT02691078|OTHER|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
214474154|NCT02361554|DEVICE|Medtronic Percept with SensSight Deep Brain Stimulation System|Placement of Deep brain stimulation System for treatment of chronic auditory hallucinations in treatment-resistant schizophrenia
214474155|NCT04806841|BEHAVIORAL|Motivational intervention|Three group meeting of 60 minutes to help create effective goals and methods on maintaining motivation to exercise regularly. These meetings will help participants create effective goals and methods on maintaining their motivation to exercise regularly. They will then receive a monthly phone call follow-up at months 4-6.
214474156|NCT04806841|OTHER|Control intervention|Participants in the control group will be simply encouraged to exercise at the EPIC center and complete the online surveys. Participants in the control group will receive the skills/tactics at the end of the study.
214847469|NCT06905522|DRUG|Sitafloxacin (S)|200mg once daily
214847470|NCT06905522|DRUG|Linezolid (L)|600mg once daily
214847471|NCT06905522|DRUG|Pyrazinamide (Z)|20-30 mg/kg/day; 1000 mg for patients weighing \<50 kg, 1500 mg for patients weighing ≥50 kg but \<75 kg, and 2000 mg for patients weighing ≥75 kg.
214847472|NCT06905522|DRUG|Isoniazid (H)|4-6 mg/kg once daily, 300 mg once daily
214289584|NCT03138889|DRUG|Paclitaxel|Paclitaxel will be dosed per local practice and label
214289585|NCT03138889|DRUG|Pemetrexed|Pemetrexed will be dosed per the pharmacy manual
214289586|NCT03138889|DRUG|Atezolizumab|Atezolizumab will be dosed per current label indication
214474157|NCT05587842|PROCEDURE|Early Weightbearing management post operation|Subjects will be instructed to be weightbearing, as tolerated, on their ankle starting at two weeks post operation.
214474158|NCT05587842|PROCEDURE|Delayed Weightbearing management post operation (Traditional)|Subjects will be instructed to be non-weightbearing on their ankle until at least 6 weeks. After 6 weeks, the subject will be instructed to be weightbearing as tolerated.
214474159|NCT05333068|PROCEDURE|PCI revascularization strategy based on combined FFR and OCT assessment|PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with \> 70 % AS or MLA \< 2.5 mm2.
214474160|NCT05333068|PROCEDURE|PCI revascularization strategy based FFR assessment|PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)
214474161|NCT06579677|OTHER|Without any intervention|No interventions will be performed.
214474162|NCT06651502|DEVICE|dental implant placement and immediate provisionalization|dental implant placement and immediate temporization
214474163|NCT03183895|DEVICE|Left ventricular restoration|The AccuCinch® Ventricular Repair System, implanted in the sub-valvular space of the left ventricle, is intended to reduce significant symptomatic mitral regurgitation and reverse left ventricular remodeling due to dilated cardiomyopathy of either ischemic or non-ischemic etiology via percutaneous interventional methods.
214474164|NCT04409457|OTHER|fasting state|16 hours of fasting
214474165|NCT04409457|OTHER|fed state|fed a standardized meal
214474166|NCT04409457|OTHER|magnetic resonance imaging|neuroimaging with computational modeling
214474167|NCT06101277|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
214474168|NCT04280458|BEHAVIORAL|Intentive rehabilitation|"Intervention included:~* psychomotor 5 hours/week ±30 minutes~* kinesitherapy 1.5 hour/week ±20 minutes~during 12 months."
214474169|NCT04280458|BEHAVIORAL|Routine care|"Intervention included:~* kinesitherapy 0.5 hour/week ±10 minutes~* psychomotor 30 min/week ±10 minutes during 12 months."
214474170|NCT04191057|OTHER|Free light chains|Blood samples will be collected and analyzed
214847473|NCT06905522|DRUG|Rifampicin (R)|8-12 mg/kg once daily, 450 mg for patients weighing \<50 kg, 600 mg for patients weighing ≥50 kg but \<75 kg, and 750 mg for patients weighing ≥75 kg.
214847474|NCT06905522|DRUG|Ethambutol (E)|15-25 mg/kg once daily, 750 mg once daily
214474171|NCT05320822|OTHER|Active Rehab (Group 2)|"The Active Rehab protocol builds off of initial chief complaints and duty profile and addresses symptom control followed by a progressive and prescribed integration of activities to full return to duty that should be integrated with the current PRA TBICoE protocols. The specific activity areas in the intervention include low-intensity aerobic exercise that does not exacerbate symptoms, cognition, balance, visual/vestibular, and comfort/ general well-being.~Participants can be progressed daily according to symptom limitations. At least 3-4 sessions each week are recommended based on a trial of sport-related mTBI and other interventions of this type concerning mTBI/concussion. During each phase, low level aerobic exercise that does not significantly exacerbate symptoms, such as nature walks, will be recommended. The additional activity types that may be chosen include cognitive, balance, visual/vestibular, and comfort/general well-being."
214474172|NCT05320822|OTHER|Progressive Return to Activity (Group 1)|Participant will be asked to use symptoms to guide activity from the time of the injury until participant is asymptomatic. Once asymptomatic, participant will begin the PRA TBICoE clinical recommendation. During this time clinicians will document activities in each stage in addition to initial symptom checklist, stage of PRA CoE progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
214474173|NCT04134754|OTHER|6% Carbon dioxide/50% oxygen/balance nitrogen mixture|In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
214474174|NCT05057052|DRUG|Sintilimab|Sintilimab plus regorafenib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
214847475|NCT06905522|DRUG|Moxifloxacin (M)|400mg once daily
214847476|NCT06905522|DRUG|Pretomanid (Pa)|200mg once daily
214847477|NCT06905639|BEHAVIORAL|Aerobic and Strength Exercise|A supervised physical exercise intervention was carried out, specifically designed to improve post-breast cancer lymphedema. The program will include a combination of strength exercises and aerobic exercises, with the aim of improving mobility, reducing inflammation, and increasing muscle strength in the arm affected by lymphedema
214847478|NCT00924586|DRUG|ONO-1101|Placebo for one minute IV
214474175|NCT05057052|DRUG|Regorafenib|Regorafenib will be initiated on day 14 after cryoablation. Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214474176|NCT05057052|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
214474177|NCT04540068|DRUG|Transforaminal Epidural Injection|Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
214847479|NCT00924586|DRUG|ONO-1101|0.125 mg/kg for one minute IV
214847480|NCT03769831|DRUG|SHR2285|Ascending dose oral adminstration
214847481|NCT03769831|DRUG|Placebo|Ascending dose oral adminstration
214847482|NCT06611150|DRUG|Nab-paclitaxel|All participants enrolled in the study will be treated with nab-paclitaxel during radical radiotherapy following induction chemotherapy. The doses are increased progressively (180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m²).
214847483|NCT02449473|BIOLOGICAL|Tralokinumab|Subcutaneous Injection
214847484|NCT02449473|OTHER|Placebo|Subcutaneous Injection
214847485|NCT04712734|DRUG|Iloperidone|oral tablet, long-acting injection
214847486|NCT05774652|BEHAVIORAL|Lifestyle intervention Dietary advise and/or advise on physical activity|Lifestyle intervention Dietary advise and/or advise on physical activity
214474178|NCT06470217|DRUG|tirilizumab with albumin-bound paclitaxel and cisplatin|tirilizumab administered by intravenous drip (no prophylaxis required) at a fixed dose of 200 mg. each infusion was given for 30 min (not less than 20 min and not more than 60 min) every 3 weeks, and 3 preoperative cycles of albumin-bound paclitaxel 260 mg/m2 and cisplatin 75 mg/m2 on d1, with 1 cycle every 21 days; 3 preoperative Cycles. After neoadjuvant therapy, patients underwent surgery and were stratified according to pathological conditions after surgery; if significant pathological remission (MPR) was achieved, 6 cycles of adjuvant therapy with tirilizumab monotherapy (concurrent radiochemotherapy was available for those with high-risk factors) were performed; if MPR was not achieved, concurrent radiochemotherapy was performed.
214474179|NCT06470217|PROCEDURE|surgery|patients underwent direct surgical treatment, with postoperative radiotherapy or radiochemotherapy depending on the presence or absence of histological or pathological high-risk factors.
214474180|NCT02661932|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."
214474181|NCT04104360|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
214474182|NCT04104360|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
214474183|NCT05653466|BEHAVIORAL|Adaptive Spacing Condition|"Each of the 200 target words for practice are presented on a schedule determined by an algorithm that relies on the pattern of correct vs. incorrect responses for each item. Items in the active learning state need to be answered correctly a certain number of times before being categorized as learned. Each item must be answered correctly 3 times in a row (immediately, then at one-minute and five-minute intervals) before it is categorized as learned. Then, it will be scheduled at ever-increasing intervals, until answered incorrectly, at which point the item would be returned to the active learning state, requiring three correct responses in a row to return again to the learned expanding interval state."
214474184|NCT05653466|BEHAVIORAL|High-Item Non-Adaptive Spacing Condition|Each of the 200 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
214474185|NCT05653466|BEHAVIORAL|Low-Item Non-Adaptive Spacing Condition|Each of the 40 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
214474186|NCT03931408|DRUG|Gentamicin Sulfate|Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
214657348|NCT05590572|DRUG|Isophosphamide|(1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
214847487|NCT05138926|OTHER|Cervical Manipulation|high speed, low amplitude cervical manipulation
214847488|NCT05138926|OTHER|Sham Cervical Manipulation|Cervical mobilization without performing spinal manipulation
214847489|NCT05247931|DIAGNOSTIC_TEST|TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine|Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
214847490|NCT04014582|BEHAVIORAL|Communal Coping Intervention|This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
214847491|NCT04014582|BEHAVIORAL|Diabetes Education|Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
214847492|NCT04819373|DRUG|BDB001|BDB001 is an immunotherapy agent.
214847493|NCT04750668|OTHER|Multisensory Balance Training|Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
214847494|NCT01831986|DIETARY_SUPPLEMENT|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
214847495|NCT01831986|OTHER|Placebo|Caps
214289587|NCT05948254|PROCEDURE|Triple function scan body|The scan bodies were used to scan the implant position, Jaw registration and facial scan alignment, First of all scan bodies were selected according to vertical dimension of occlusion, then the emergence profile together with the selected scan body were scanned,All scan bodies were then removed from the patient mouth except one or even two that were scanned in the jaw scan step, this scan body was utilized as a stopper, the patient was asked to bite until the scan body came in contact with the lower or upper teeth in case of edentulous upper or lower arch respectively, scan body in place (in the same orientation of the previous jaw scan ) provided that at least the tip of the scan body appeared when the patient is asked to smile which would be used as a common area so that the intra oral scanner can relate the jaw scan to the lips and face.
214289588|NCT00551733|DRUG|carboplatin|Given IV
214474187|NCT03931408|OTHER|Placebo instillation (saline alone)|Saline will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
214474188|NCT03931408|OTHER|No instillation|Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
214474189|NCT00319033|DRUG|bosentan|
214474190|NCT05422430|BEHAVIORAL|Rebreathing-induced hypoxia|Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.
214474191|NCT05422430|BEHAVIORAL|Spontaneous breathing|Participants will be spontaneously breathing during an oral glucose tolerance test.
214474192|NCT02829437|OTHER|Treatment for EST|Surgery and/or Chemotherapy and or/radiotherapy for EST treatment according to disease guidelines: no specific treatment is imposed by protocol (observational study)
214474193|NCT04340505|DRUG|Fluocinolone Acetonide|Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.
214474194|NCT05759663|PROCEDURE|MIRRAD|Repair of the diastasis with MIRRAD technique
214474195|NCT05759663|PROCEDURE|Plication of the entire diastasis arm|Plication of the entire diastasis
214474196|NCT04086589|OTHER|Observational study without intervention|Observational study without intervention
214474197|NCT01314105|DRUG|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
214474198|NCT01314105|DRUG|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
214474199|NCT01314105|DRUG|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
214474200|NCT05342415|OTHER|Internally Focused Exercise|While performing the exercises participants will be instructed to focus on the muscle itself.
214474201|NCT05342415|OTHER|Externally Focused Exercise|While performing the exercises participants will be instructed to focus on the external target (towel, target line, etc.)
214847496|NCT00689845|BIOLOGICAL|bleomycin sulfate|Given IV
214847497|NCT00689845|BIOLOGICAL|filgrastim|Given subcutaneously
214289589|NCT00551733|DRUG|paclitaxel|Given IV
214847498|NCT00689845|BIOLOGICAL|rituximab|given IV
214289590|NCT00551733|DRUG|paclitaxel poliglumex|Given IV
214289591|NCT03395886|DRUG|Remifentanil|The noninvasive ventilation intolerated patients was sedated by remifentanil.
214289592|NCT03395886|DRUG|Dexmedetomidine|The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
214289593|NCT01053728|DRUG|SAR161271|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
214289594|NCT01053728|DRUG|Insulin glargine HOE901|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
214289595|NCT00004443|DRUG|NTBC|
214847499|NCT00689845|DRUG|cyclophosphamide|Given IV
214847500|NCT00689845|DRUG|cytarabine|Given subcutaneously
214847501|NCT00689845|DRUG|doxorubicin hydrochloride|Given IV
214847502|NCT00689845|DRUG|etoposide phosphate|Given IV
214847503|NCT00689845|DRUG|ifosfamide|Given IV
214847504|NCT00689845|DRUG|methotrexate|Given IV
214847505|NCT00689845|DRUG|prednisolone|Given orally
214847506|NCT00689845|DRUG|prednisone|Given orally
214847507|NCT00689845|DRUG|vincristine sulfate|Given IV
214847508|NCT00689845|DRUG|vindesine|Given IV
214847509|NCT02107079|DRUG|Melatonin|swallowing 1 piece, collecting saliva afterwards
214474202|NCT06305078|OTHER|Personalized ADHD Medication Experiment|All parent/adolescent dyads will select and complete a medication experiment.
214474203|NCT03380962|DRUG|Clazakizumab|All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
214474204|NCT02871726|DEVICE|TRUS-Robot|A robotic device used to hold and manipulate the ultrasound probe during a transrectal prostate biopsy.
214474205|NCT02871726|OTHER|TRUS biopsy|Uronav for prostate biopsy.
214474206|NCT06272734|DEVICE|Reprieve System|"The study is broken into stages:~1. In Stage one, Subjects enrolled in the study received Reprieve System (RS) therapy, a hospital bedside fluid management system designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure. (complete, N=10)~2. In future Stages, Subjects enrolled in the study will receive RS therapy and will be given varying levels of water consumption to challenge the algorithm. Future Stages will also assess new RS hardware and software features."
214474207|NCT03841253|PROCEDURE|Trans-epithelial PTK|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
214847510|NCT04034355|DRUG|Calmangafodipir (5 µmol/kg)|PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.
214847511|NCT04034355|OTHER|Placebo|Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
214847512|NCT01751919|DRUG|Imatinib mesylate tablet 400 mg, 1 Tablet|
214847513|NCT01751919|DRUG|Glivec film-coated tablet 100 mg, 4 Tablets|
214847514|NCT05276687|DRUG|Betadine|Wound irrigation
214847515|NCT05276687|DRUG|Vancomycin|instillation in the wound
214847516|NCT00550888|PROCEDURE|suture techniques|
214474208|NCT03841253|PROCEDURE|Trans-epithelial PTK (retrospective data collection)|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
214474209|NCT03841253|PROCEDURE|EpiMaster Application Software|The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
214474210|NCT02056834|DEVICE|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
214474211|NCT06757946|COMBINATION_PRODUCT|Mulligan Medial/Lateral glide with compression/ decompression technique|"Warm up (10 minutes with hot pack) and cool down exercises for a period of 5 to 10 minutes was given before starting and after the completion of exercises in supervised exercise program in all the groups. The following ergonomical advice were given to all the subjects, Avoid extreme knee bent positions, avoid squatting, crossed-leg sitting, frequent stair climbing or lifting heavy objects, avoid fatiguing postures except for infrequent short durations tasks, change posture frequently and use support where possible and avoid giving excess strain to the knees.~Mulligan mobilisation consisted of Medial glide mobilisation with movement, Lateral glide mobilisation with movement, with active knee flexion (61) depending on the subjects condition. The gliding force was sustained while the patient performed 3 sets of 10 repetitions.~Total 12 treatment sessions was given to each subject with the frequency of 3 sessions per week for 4 consecutive weeks."
214474212|NCT06757946|COMBINATION_PRODUCT|Mulligan Medial/Lateral glide|"Warm up (10 minutes with hot pack) and cool down exercises for a period of 5 to 10 minutes was given before starting and after the completion of exercises in supervised exercise program in all the groups. The following ergonomical advice were given to all the subjects, Avoid extreme knee bent positions, avoid squatting, crossed-leg sitting, frequent stair climbing or lifting heavy objects, avoid fatiguing postures except for infrequent short durations tasks, change posture frequently and use support where possible and avoid giving excess strain to the knees.~Total 12 treatment sessions was given to each subject with the frequency of 3 sessions per week for 4 consecutive weeks. After completing the therapeutic session, post- intervention data of the outcome parameters were taken."
214474213|NCT05816655|DRUG|Fulvestrant plus AI plus ribociclib|Fulvestrant + AI + ribociclib +/- GnRH agonist
214474214|NCT05816655|DRUG|AI plus ribociclib|AI + ribociclib +/- GnRH agonist
214474215|NCT06429033|DRUG|PEP (Purified Exosome Product)|Injection of PEP into hypodermis of abdomen
214474216|NCT06046053|DRUG|Placebo Vaginal Film with Square Corners|"2 x 2 placebo vaginal film with square corners"
214474217|NCT06046053|DRUG|Placebo Vaginal Film with Rounded Corners|"2 x 2 placebo vaginal film with rounded corners"
214474218|NCT04378244|DRUG|DeltaRex-G|"This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced."
214474219|NCT05701163|OTHER|Abstinence followed by semen sample collection.|Abstinence is the intervention. Semen samples will be collected after abstinence periods.
214289596|NCT00403442|DEVICE|Verteporfin Therapy/ Drug: Bevacizumab|
214474220|NCT04432116|BEHAVIORAL|virtual reality 1|the subject is in a virtual waiting room, there is no other intervention. The principle of this intervention is to make the subject wait with as little interfering events as possible
214474221|NCT04432116|BEHAVIORAL|virtual reality 2|Subjects are in a virtual environment mimicking a space ship. On the screen there is a red light and subjects wait for this red light to become green. They press on a pad each time the red light becomes green
214474222|NCT05606900|BEHAVIORAL|addiction-focused eye movements desensitization and reprocessing (AF-EMDR)|AF-EMDR includes desensitization and functional reprocessing of the targeted memory or the moment with lateral eye movements. In each session of the psychotherapy, which will be applied as 3 sessions, a memory or a moment that causes alcohol craving will be practised. The processing will continue until the patient becomes desensitized to the memory or the moment that cause the craving. In the first session, a memory of craving will be discussed, in the second session a current trigger that causes craving, and in the third session, a moment that is thought to cause craving in the future will be focused.
214657349|NCT05105243|DRUG|CVN766|highly selective orexin-1 receptor (Ox1R) antagonist
214847517|NCT06508840|OTHER|Verbal Health Literacy training session|"Five respiratory physiotherapists and half (6/12) weight management programme advisors, will receive a two hour Verbal Health Literacy training session. The training session will focus on three techniques: simple language, 'Teachback' and 'Chunk and check'. They will also receive implementation support from a Health Literacy Officer.~All pulmonary rehab patients will attend programmes run by physiotherapists trained in Verbal Health Literacy techniques.~Weight management programme service users will attend programmes run by trained and untrained staff."
214847518|NCT03146273|DIETARY_SUPPLEMENT|Multivitamins|"After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins."
214289597|NCT04107194|DRUG|Pantoprazole 40mg|Proton pump inhibitor
214289598|NCT04107194|DRUG|Amoxicillin 1000 MG|Antibiotic
214289599|NCT04107194|DRUG|Clarithromycin 500mg|Antibiotic
214289600|NCT04107194|DRUG|Metronidazole|Antibiotic
214289601|NCT04107194|DRUG|Tetracycline 125 MG|Antibiotic
214289602|NCT04107194|DRUG|Bismuth Subcitrate|Antibiotic adjuvant
214289603|NCT04107194|DRUG|Rifabutin 150 MG|Antibiotic
214289604|NCT04107194|DRUG|Levofloxacin 500mg|Antibiotic
214289605|NCT02715414|BEHAVIORAL|Multiple Family Group + Clinic Implementation Team|Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
214474223|NCT03217110|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
214474224|NCT03217110|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
214474225|NCT06106022|DRUG|Vonoprazan|Administered orally
214474226|NCT05875519|DRUG|Local anaesthesia with vasocontrictor (Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg)|Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg
214474227|NCT06193070|OTHER|Educational Intervention|Play virtual misinformation escape room game
214289606|NCT02715414|BEHAVIORAL|MFG|MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
214289607|NCT00865124|DRUG|Spironolactone|25 mg capsule daily for 6 months
214289608|NCT00865124|DRUG|Hydrochlorothiazide + potassium|hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
214289609|NCT00865124|OTHER|Placebo|Placebo capsule daily
214289610|NCT03287440|BEHAVIORAL|COPD Wellness|This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
214289611|NCT03287440|BEHAVIORAL|Health Advocate|The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
214474228|NCT06193070|OTHER|Interview|Ancillary studies
214474229|NCT06193070|OTHER|Survey Administration|Ancillary studies
214474230|NCT06193070|OTHER|Telemedicine|Play virtual misinformation escape room game
214474231|NCT04426669|DRUG|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
214474232|NCT04426669|DRUG|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
214474233|NCT04426669|BIOLOGICAL|Tumor-Infiltrating Lymphocytes (TIL)|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
214474234|NCT04426669|DRUG|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
214474235|NCT04520139|DRUG|N-Acetyl-Cysteine|Given PO
214474236|NCT04520139|OTHER|Placebo|Given PO
214474237|NCT03697577|DIAGNOSTIC_TEST|CT scans|Patients will undergo CT or PETCT as part of standard of care
214474238|NCT03697577|DIAGNOSTIC_TEST|DEXA scan|Patients will undergo DEXA scan to measure body fat mass (DEXA will be performed only if available)
214474239|NCT03276676|DRUG|[18F]FLT|PET exams of \[18F\]FLT will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
214474240|NCT03276676|DRUG|[18F]Fluciclovine|PET exams of \[18F\]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
214474241|NCT04753788|DIAGNOSTIC_TEST|PCR|qPCR for T.pallidum
214847519|NCT05898763|DRUG|TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)|Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in an alternating limb. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).These patients will receive three rounds of combination treatment with TEIPP24 vaccination and pembrolizumab every three weeks. Pembrolizumab will be administered as per standard of care.
214847520|NCT03354455|DEVICE|Repetitive transcranial magnetic stimulation|"Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot."
214847521|NCT02190279|DRUG|18F DCFBC|Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
214847522|NCT02190279|DRUG|Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)|
214847523|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Parryscope technique"|A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present \[10\]. At least 30 seconds of observation per ostia is performed if patency is not observed.
214847524|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Tubal flow technique"|"a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
214847525|NCT01467479|DRUG|Telaprevir|Tablet
214847526|NCT01467479|DRUG|Ribavirin|Tablet
214847527|NCT01467479|BIOLOGICAL|Pegylated Interferon Alfa-2a|Subcutaneous Injection
214474242|NCT04753788|DIAGNOSTIC_TEST|LAMP|LAMP assay for T.pallidum
214474243|NCT06799832|DEVICE|urethal perfusion index monitoring|The urethral perfusion index will be monitored using the IKORUS System (Vygon, Écouen, France)
214474244|NCT05576038|DRUG|L-Tryptophan|L-tryptophan is an essential amino acid responsible for activating the aryl hydrocarbon receptor (AhR). Dietary tryptophan is metabolized by the gut microbiota producing several 'indoles' such as (indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3 propionic acid (IPA), indole-3-acetaldehyde (IAAld), indole-3-lactic acid (ILA) and indole-acrylic acid) and tryptamine, which are ligands for the AhR, a nuclear transcription factor involved in activating target genes responsible for maintaining gut integrity. Prior literature suggests that patients with active celiac disease have a lower functional capacity to produce these AhR ligands, which further impairs the AhR pathway. Hence, the aim of this study is to assess the effects of tryptophan supplementation in patients with celiac disease, non-responsive to a GFD for more than 1 year compared with the effects of an inactive, placebo comparator, L-leucine.
214474245|NCT05576038|DRUG|Freedom SimpleCap Powder|Freedom SimpleCap Powder is a high functionality capsule and tablet excipient composite comprised of filler, glidant, disintegrant and lubricant (ingredients include: Microcrystalline Cellulose, Silicon Dioxide Colloidal, Sodium Starch Glycolate, Sodium Stearyl Fumarate). This capsule is dye, lactose and gluten free and will not interfere with the AhR pathway. Freedom SimpleCap Powder makes oral capsule formulation convenient, quick and simple Thus, this SimpleCap Powder will be an appropriate placebo comparator for this study.
214474246|NCT05015751|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
214474247|NCT03362177|BIOLOGICAL|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.
214474248|NCT03362177|OTHER|Placebo|Placebo Comparator
214474249|NCT06772584|DRUG|Desmopressin Acetate 0.2 mg Tablets|3 groups of patients one received only desmopressin and group ginkobiloba ablnd group for both
214474250|NCT06772584|DRUG|Ginkgobiloba|Group s take it as treatment of deep sleep in nectornal enuresis
214474251|NCT05577234|OTHER|Animal-assisted intervention|The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation. Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.
214474252|NCT05577234|BEHAVIORAL|Venham scale modified by Veerkamp|The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
214474253|NCT06391255|OTHER|scintigraphy|oesophageal and gastric emptying
214474254|NCT03926130|DRUG|Mirikizumab|Administered IV
214474255|NCT03926130|DRUG|Mirikizumab|Administered SC
214474256|NCT03926130|DRUG|Ustekinumab|Administered IV
214474257|NCT03926130|DRUG|Ustekinumab|Administered SC
214474258|NCT03926130|DRUG|Placebo|Administered IV
214474259|NCT03926130|DRUG|Placebo|Administered SC
214474260|NCT03583333|DRUG|IMI/REL FDC|500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial
214474261|NCT03583333|DRUG|PIP/TAZ FDC|4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial
214474262|NCT03583333|DRUG|Linezolid|Open-label 600 mg Linezolid
214474263|NCT06461130|OTHER|Study Group|Group of people doing dual tasks during double-leg cycling training.
214474264|NCT06461130|OTHER|Control Group|The group that received only aerobic exercise.
214474265|NCT05174611|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
214474266|NCT05174611|OTHER|Placebo|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
214474267|NCT05687890|DRUG|Placebo of SC0062|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
214474268|NCT05687890|DRUG|SC0062 low dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
214474269|NCT05687890|DRUG|SC0062 medium dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
214474270|NCT05687890|DRUG|SC0062 high dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
214474271|NCT04469270|BIOLOGICAL|Engensis|Intramuscular injections
214474272|NCT04469270|OTHER|Placebo|Intramuscular injections
214474273|NCT06365697|DEVICE|Ton-bridge carotid stent|carotid artery stenting with Ton-bridge carotid stent
214474274|NCT06365697|DEVICE|WALLSTENT carotid stent|carotid artery stenting with WALLSTENT carotid stent
214474275|NCT05723575|DEVICE|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
214474276|NCT05723575|BEHAVIORAL|somatosensory acuity measurement|Somatosensory acuity will be measured through a tactile discrimination task using the corticalmetrics Brain Gauge. Participants lightly press their tongue onto two vibrating probes and report which one vibrated first or with greater amplitude.
214474277|NCT03807401|BEHAVIORAL|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to perform pointing movement toward visual target.
214474278|NCT03807401|BEHAVIORAL|Virtual reality device|The lateral displacement will be simulated thanks to a virtual reality environment. Participants will wear an Oculus Rift instead of the prismatic goggles and will perform pointing movement as well.
214847528|NCT01467479|DRUG|Highly Active Antiretroviral Therapy (HAART)|Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
214474279|NCT03807401|BEHAVIORAL|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to mentally perform pointing movement toward visual target. There will be no concurrent movement execution.
214474280|NCT05513261|DIAGNOSTIC_TEST|High definition colonoscopy (standard colonoscopy) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply the standard colonoscopy without computer-aided colonoscopy (polyDeep)
214474281|NCT05513261|DIAGNOSTIC_TEST|PolyDeep assisted high definition colonoscopy (CAD system) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply polyDeep assisted high definition colonoscopy (CAD system).
214474282|NCT04093583|PROCEDURE|Exodontia|Atraumatic exodontia followed by simple suture
214474283|NCT04093583|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
214474284|NCT04093583|DEVICE|Preparation of PRGF using Endoret technology|Preparation of PRGF using Endoret technology following manufacturer instructions
214474285|NCT05400122|DRUG|Vactosertib|Vactosertib is a highly selective, potent inhibitor of the protein serine/threonine kinase activity of transforming growth factor (TGF)-β receptor type 1 (TGFBR1; also known as activin receptor-like kinase 5 \[ALK5\]). Vactosertib inhibits the phosphorylation of the ALK5 substrates Smad2 and Smad3, as well as the intracellular signaling of TGF-β.
214289612|NCT03750604|DIAGNOSTIC_TEST|visceral fat obesity (surface area and function)|"WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein"
214474286|NCT05400122|DRUG|Fludarabine Phosphate|Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoroara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
214474287|NCT05400122|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity.
214474288|NCT05400122|DRUG|IL-2|"Proleukin® (aldesleukin) has been shown to possess the biological activities of human native interleukin-2. In vitro studies performed on human cell lines demonstrate the immunoregulatory properties of Proleukin, including: a) enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines; b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.~The in vivo administration of Proleukin in animals and humans produces multiple immunological effects in a dose dependent manner. These effects include activation of cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and the production of cytokines including tumor necrosis factor, IL-1 and gamma interferon. In vivo experiments in murine tumor models have shown inhibition of tumor growth"
214474289|NCT05400122|DRUG|Natural Killer Cells|Adoptive NK cell therapy has demonstrated the potential for cancer immunotherapy in various malignancies with particular potential in hematologic malignancies including acute myeloid leukemia (AML), and colon cancer \[14, 19-23\]. This therapeutic approach is extremely well tolerated in patients even when massive numbers of cells are utilized (\~109 NK cells/kg). In fact, studies suggest that high doses of NK cells are not only well tolerated but have potential to lead to higher levels of efficacy.
214474290|NCT04396145|DIAGNOSTIC_TEST|Subjective Visual Vertical|All subjects will have Virtual SVV before and after the operation
214474291|NCT01569659|DRUG|Lurasidone|80 mg/day for up to 30 weeks
214474292|NCT01569659|DRUG|Lurasidone|Up to 240 mg/day for up to 30 weeks
214474293|NCT04665648|DRUG|Nicorandil|6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention
214474294|NCT04665648|DRUG|Placebo|placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
214474295|NCT01167725|BIOLOGICAL|bevacizumab|Given IV
214474296|NCT01167725|BIOLOGICAL|cetuximab|Given IV
214474297|NCT01167725|DRUG|FOLFIRI regimen|Given IV
214474298|NCT01167725|DRUG|FOLFOX regimen|Given IV
214474299|NCT01167725|DRUG|capecitabine|Given IV
214474300|NCT01167725|DRUG|fluorouracil|Given IV
214289613|NCT03247530|DRUG|Placebo|Placebo was administered once daily
214474301|NCT01167725|DRUG|irinotecan hydrochloride|Given IV
214474302|NCT01167725|DRUG|leucovorin calcium|Given IV
214474303|NCT01167725|DRUG|mitomycin C|Given intraperitoneally
214474304|NCT01167725|DRUG|oxaliplatin|Given IV
214474305|NCT01167725|PROCEDURE|therapeutic conventional surgery|Patients undergo cytoreductive surgery
214474306|NCT04723147|DRUG|Carbidopa Levodopa|Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
214474307|NCT04723147|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
214474308|NCT05723250|OTHER|Table-based Educational Intervention|Tablet based educational tool with videos about care coordination, cancer knowledge and self-advocacy.
214474309|NCT04947735|DEVICE|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
214474310|NCT04947735|DEVICE|Spectacle lenses|Single vision, impact resistant spectacle lenses
214474311|NCT06340178|PROCEDURE|Fluid application during ct-guided lung biopsy|Injection of a small amount of fluid (max. 20 ml sodium chlorid) in the pleural cavity at the biopsy site
214474312|NCT04999423|DEVICE|LVIS EVO and HydroCoil Embolic System|Stent assisted Coiling
214474313|NCT02793999|DEVICE|Near-Infrared Spectroscopy (NIRS)|
214474314|NCT04667013|DRUG|Tetramethylpyrazine nitrone (TBN) tablet / Placebo|Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.
214474315|NCT03747419|DRUG|Avelumab|Avelumab is a form of immunotherapy, which means it is designed to help the patient's immune system kill cancer cells.
214474316|NCT03747419|RADIATION|Radiation|Cancer treatment that uses ionizing radiation to kill cancer cells.
214474317|NCT05055804|DEVICE|ELG|"The effectiveness of ELG to standardized blood test methods (fingerstick) and comparison to AlcNOW + (or equivalence) and of laboratory test results.~Human subject requirements during ELG study will not challenge diabetics or non-diabetics glycemic event. For example, diabetes type 1, the subject will not have to adjust their insulin or glucose. For type 2 diabetes, the subject will not have to adjust their oral hypoglycemic agent or glucose, as well."
214474318|NCT04925193|DRUG|Selinexor|Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).
214474319|NCT04925193|DRUG|Pomalidomide|Oral Table
214474320|NCT04925193|DRUG|Daratumumab|Injection
214474321|NCT04925193|DRUG|Carfilzomib|Injection
214474322|NCT04925193|DRUG|Dexamethasone|Oral tablet or injection
214474323|NCT06609148|DIETARY_SUPPLEMENT|De Simone formulation probiotic|Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days
214474324|NCT06609148|DIETARY_SUPPLEMENT|Placebo|Subjects will be given a placebo for 21-24 days
214474325|NCT05686525|PROCEDURE|Transurethral Microwave Thermotherapy|TUMT is performed by a urologist and/or a trained urological nurse. In TUMT a specially designed instrument that sends out microwave energy is inserted inside the prostate through the urethra. Cooling fluid circulates the instrument to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate a temperature sensor is inserted into the patient's rectum and at the penoscrotal angle. If the temperature reaches the safety limit the microwave generator's output will be shut off automatically. Microwave is then used to heat the prostate (preferably to 50-60 degrees Celsius) and destroy hyperplastic prostate tissue. As the prostate heals it will shrink and reduce the blockage of urine flow and the symptoms of BPH.
214474326|NCT05686525|PROCEDURE|Prostate Artery Embolisation|In PAE an interventional radiologist will insert a small catheter into the vessels that supply blood to the prostate. An arteriogram is done to map the blood vessels feeding the prostate. Tiny embolization particles are injected through the catheter and into the blood vessels to reduce the blood supply to the prostate. This procedure is intended bilaterally at both sides of the prostate. Following the procedure, the prostate will begin to shrink reducing the symptoms of BPH.
214474327|NCT05516602|OTHER|Peer Support|"Peer-led support groups over the weekend will include the following activities:~* Peer leader counselling on oral PrEP and HIV risk reduction~* Peer leader discussion to dispel myths and misconceptions around oral PrEP~* Peer leader sharing of experiences of daily pill taking~* Participants sharing experiences of influencers and barriers to oral PrEP uptake and adherence followed by a discussion by group members.~* 1-2 role plays per support group session."
214474328|NCT00254423|DRUG|Dasatinib|Given PO
214289614|NCT03247530|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
214289615|NCT03247530|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
214474329|NCT00254423|OTHER|Laboratory Biomarker Analysis|Correlative studies
214474330|NCT00254423|OTHER|Pharmacological Study|Correlative studies
214474331|NCT00254423|OTHER|Quality-of-Life Assessment|Ancillary studies
214474332|NCT00254423|OTHER|Questionnaire Administration|Ancillary studies
214474333|NCT03957902|DRUG|acetylsalicylic acid|Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
214474334|NCT05416424|OTHER|LIFE program|During the nutritionist visits, subjects will be asked to discuss and evaluate their current diet and will be given recommended dietary changes. The recommended dietary changes include focusing on eating nutrient dense foods, staying consistent with the timing of meals, limiting added sugars, aiming to have balanced meals and snacks, being a mindful eater, and aiming to drink approximately 2 liters of water a day. Additionally, they will review the nutrition survey with the registered dietician. During the office visits with a doctor, subjects will be given exercise counseling. They will be asked to do 150 minutes per week of moderate intensity aerobic activity
214474335|NCT04086121|DRUG|Spesolimab|Solution for SC injection
214474336|NCT02299999|DRUG|AZD2014|Target: m-TOR
214847529|NCT02376660|OTHER|Oats|
214474337|NCT02299999|DRUG|AZD4547|Target: EGFR
214474338|NCT02299999|DRUG|AZD5363|Target: AKT
214474339|NCT02299999|DRUG|AZD8931|Target: HER2, EGFR
214474340|NCT02299999|DRUG|Selumetinib|Target: MEK
214474341|NCT02299999|DRUG|Vandetanib|Target: VEGF, EGFR
214474342|NCT02299999|DRUG|Bicalutamide|target: Androgen receptor
214474343|NCT02299999|DRUG|Olaparib|Target: PARP
214474344|NCT02299999|DRUG|Anthracyclines|DNA intercalation
214474345|NCT02299999|DRUG|Taxanes|Target: mitotic tubulin and microtubules
214474346|NCT02299999|DRUG|cyclophosphamide|Alkylating agents
214474347|NCT02299999|DRUG|DNA intercalators|DNA intercalators
214474348|NCT02299999|DRUG|Methotrexate|DNA intercalators
214474349|NCT02299999|DRUG|vinca alkaloids|Target: mitotic tubulin and microtubules
214474350|NCT02299999|DRUG|Platinum based chemotherapies|Platinum based chemotherapies
214474351|NCT02299999|DRUG|Bevacizumab|Target: VEGF
214474352|NCT02299999|DRUG|Mitomycin C|Alkylating agents
214474353|NCT02299999|DRUG|Eribulin|Microtubule modulator
214474354|NCT02299999|DRUG|MEDI4736|Target: PD-L1
214474355|NCT06778967|DRUG|GZR18|Administered SC
214847530|NCT04828434|OTHER|Virtual Individual Cognitive Simulation Therapy|Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.
214847531|NCT03512912|DEVICE|transcutaneous electrical calf muscle stimulation + supervised walking therapy|transcutaneous electrical calf muscle stimulation + supervised walking therapy
214474356|NCT06778967|DRUG|semaglutide|Administered SC
214847532|NCT06504498|DEVICE|0.5 mm-thick Duran® clear aligner|0.5 mm-thick clear aligner was used for orthodontic treatment.
214289616|NCT00635960|DRUG|Growth Hormone (Somatropin)|The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.
214474357|NCT05180552|DEVICE|HEALiX is an alternative restraint patient safety device|The HEALiX is a rigid, spiral, exoskeleton-like device made of lightweight stainless steel (Austenitic SAE 316 or equivalent) that comes in various sizes to fit different arm lengths circumference of the patient's bicep. After appropriate measuring and following the fit guide, the HEALiX is placed on the patient's arm so that the hand rests on a soft, padded hand cradle. The trajectory of the end hand cradle is at a 30-degree upward angle to prevent peripheral dependent edema. This hand cradle is surrounded by foam to provide increased support for the patient and also to protect the medical team from any injury. A wrist bracelet (wrist assist) goes around the patient's wrist and prevents the patient from removing the device. The spiral exoskeleton holds the arm in a neutral position with contact points with the patient's skin at the upper deltoid region only.
214474358|NCT05180552|DEVICE|soft wrist restraints|Soft wrist restraints are padded cloth restraints that are worn by patients on wrist and secured to bed frame.
214474359|NCT06099093|DRUG|18F-DCFPyl|Fluorine-labeled small molecule, via intravenous infusion per protocol.
214474360|NCT06778837|DEVICE|Wearable devices to detect lymphedema|All participants will undergo measurement of the upper extremities to test the validity and safety of wearable sensors to measure lymphedema.
214474361|NCT05092984|DRUG|Spironolactone|"77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
214474362|NCT05092984|DRUG|Placebo|"77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
214474363|NCT04444518|BEHAVIORAL|VAX-MOM Intervention|The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
214474364|NCT04444518|BEHAVIORAL|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
214474365|NCT05345509|DRUG|Aricept Tablet|Donepezil Tablet once daily P.O
214474366|NCT05345509|DRUG|IVL3003|Donepezil Long-Acting Injection, once S.C Injection
214474367|NCT05345509|DRUG|IVL3003|Donepezil Long-Acting Injection, once IM Injection
214474368|NCT05974579|DRUG|89Zr-DFO-AP-101|"At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.~At 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated."
214474369|NCT04580914|DEVICE|Treatment with IntellaNav StablePoint Ablation Catheter|Patients will be treated with an ablation catheter
214474370|NCT04911816|DRUG|Hydroxychloroquine sulfate|Hydroxychloroquine, oral, dose escalated (400mg, 800mg, 1200mg) beginning concurrent with mFOLFIRINOX and extending 2 weeks post-operatively. Dose will be assigned to patients using 3+3 Algorithm to identify the Maximum Dose Tolerated.
214289617|NCT00635960|DRUG|Placebo|Same as for Growth hormone group
214289618|NCT02533427|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily
214289619|NCT02533427|DRUG|VOX|100 mg tablet administered orally once daily
214474371|NCT03580356|BIOLOGICAL|Ligelizumab|Liquid in vial
214289620|NCT02533427|DRUG|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
214289621|NCT02086994|DRUG|misoprostol|given after the delivery of the anterior shoulder of the baby.
214289622|NCT02086994|DRUG|carbetocin|given after delivery of anterior shoulder
214289623|NCT01261689|DRUG|Ropivacaine/ Sufentanil according to local hospital protocol|according to local hospital protocol
214289624|NCT01261689|OTHER|Care-as usual pain treatment|Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
214289625|NCT04671407|DRUG|Hypertonic Saline|Hypertonic Saline 3% and 0.9%
214289626|NCT00528385|DRUG|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
214289627|NCT05004753|DIETARY_SUPPLEMENT|Artemisinin|a herbal supplement
214289628|NCT05004753|DRUG|Dexamethasone|corticosteroids
214289629|NCT00203177|DRUG|rasagiline mesylate|0.5 rasagiline mesylate
214289630|NCT00203177|DRUG|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
214474372|NCT03580356|BIOLOGICAL|Omalizumab|Lyophilized powder for solution in vial
214474373|NCT03580356|OTHER|Placebo|Liquid in vial
214474374|NCT01540994|RADIATION|Radiation Therapy|Stereotactic Body Radiation Therapy
214474375|NCT06379607|DEVICE|"High Flow High Flow Nasal Cannula"|High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use higher flow rates.
214474376|NCT06379607|DEVICE|"Low Flow High Flow Nasal Cannula"|High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use lower flow rates.
214474377|NCT04689204|DRUG|CTA30X|CTA30X cell injection by intravenous infusion
214847533|NCT06504498|DEVICE|0.75 mm-thick Duran® clear aligner|0.75 mm-thick clear aligner was used for orthodontic treatment.
214847534|NCT03446365|BEHAVIORAL|ASMAS|A high school peer led group intervention for middles school students targeting asthma education and asthma management practices.
214847535|NCT03446365|BEHAVIORAL|Asthma education plus child health|Health educator led intervention focused on asthma education and other child health topics.
214474378|NCT05285202|OTHER|Active TB case finding with linkage to preventive therapy (ACF/TPT)|ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative and eligible for TPT (limited in April 2024 to those with close TB contact or known HIV infection).
214474379|NCT03953144|DEVICE|Synapse 3D Lung Modelling|The 3D virtual models provided by Synapse 3D will be made by experts in medical image analysis using the high-resolution CT scans. Patients will have 3D virtual reconstructions of their pulmonary anatomy with the target lesion created pre-operatively.
214474380|NCT03953144|DRUG|IC-Green (ICG)|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
214474381|NCT03944772|DRUG|Osimertinib|Osimertinib given orally at 80 mg once daily
214474382|NCT03944772|DRUG|Savolitinib|Savolitinib will be given orally at 300 mg or 600mg once daily
214474383|NCT03944772|DRUG|Gefitinib|Gefitinib given orally at 250 mg once daily
214474384|NCT03944772|DRUG|Necitumumab|Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
214474385|NCT03944772|DRUG|Durvalumab|Durvalumab given IV at 1500 mg on Day 1 of every cycle
214474386|NCT03944772|DRUG|Carboplatin|Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles
214474387|NCT03944772|DRUG|Pemetrexed|Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle
214474388|NCT03944772|DRUG|Alectinib|Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.
214474389|NCT03944772|DRUG|Selpercatinib|Selpercatinib given orally at 160mg twice daily
214474390|NCT03944772|DRUG|Selumetinib|Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment
214474391|NCT03944772|DRUG|Etoposide|Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.
214474392|NCT03944772|DRUG|Cisplatin|Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle
214474393|NCT03944772|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.
214474394|NCT03065231|DEVICE|Extraventricular Drain|As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.
214474395|NCT03065231|DEVICE|Lumbar Drain|
214289631|NCT04350840|BEHAVIORAL|feedback|feedback of optical diagnosis performance per 3 month
214474396|NCT04153539|BEHAVIORAL|Walking along a busy road|The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
214474397|NCT04153539|BEHAVIORAL|Walking in a traffic-free park|The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
214474398|NCT05023317|BEHAVIORAL|Strengths-based linkage to alcohol care|SLAC is a behavioral intervention designed to link persons with substance use/misuse to care
214474399|NCT05023317|BEHAVIORAL|Usual care|Usual care consists of brief screening and intervention and/or standard referral to alcohol care
214474400|NCT06461169|OTHER|stress ball|Patients squeeze the stress ball
214474401|NCT06225843|BIOLOGICAL|Sotevtamab|Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU)
214474402|NCT06225843|COMBINATION_PRODUCT|FOLFOX|FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.
214474403|NCT06018155|OTHER|Spine surgery|Cohort of patients suffering from low back pain and candidate to a spine surgery included in a database previously constituted
214474404|NCT03118518|DEVICE|Cryoablation|Pulmonary vein isolation via ablation with cryoballoon catheter
214474405|NCT03118518|DRUG|Antiarrhythmic drug|Antiarrhythmic drug initiation
214474406|NCT03983954|COMBINATION_PRODUCT|Obinutuzumab, naptumomab estafenatox and durvalumab|"Obinutuzumab is given intravenous (I.V.) 1,000 mg concentrate for solution for infusion, as pre-treatment.~Dose escalation and MTD Expansion: NAP is given as an intravenous (I.V.) bolus injection at multiple doses.~Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.~Esophageal cohort expansion: NAP is given as an intravenous (I.V.) bolus injection at multiple doses on cycles 1-6 and one dose per cycle starting cycle 7. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle during cycles 1-6, and at a dose of 1500 mg delivered once every 28 days starting cycle 7."
214474407|NCT03983954|COMBINATION_PRODUCT|Naptumomab estafenatox and durvalumab|NAP was given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab was given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.
214474408|NCT04393207|DRUG|Liposomal bupivacaine (LB)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with liposomal bupivacaine + bupivacaine or with bupivacaine alone.
214474409|NCT04393207|DRUG|Dexamethasone and methylprednisolone (CG)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with with bupivacaine alone.
214474410|NCT04393207|DRUG|Control group (Bupivacaine)- (BPG)|Transverse abdominis plane block will be performed with plain bupivacaine
214474411|NCT06111768|DRUG|Dapagliflozin|Receipt of 10mg oral dose of dapagliflozin once daily for three days
214847536|NCT03326986|DRUG|MK-7252|1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
214474412|NCT03827382|BEHAVIORAL|Lifestyle Intervention|Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
214474413|NCT04742608|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214474414|NCT04742608|OTHER|Electronic Health Record Review|Medical charts are reviewed
214474415|NCT05412069|DEVICE|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference.
214474416|NCT06593587|BIOLOGICAL|RSVpreF Vaccine|RSV Vaccine 120 mcg
214474417|NCT06593587|OTHER|Placebo|Placebo
214474418|NCT05839587|PROCEDURE|Robotic TAPP|Robotic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of docking of the robot and port placement and part 4 consists of de-docking and skin closure
214474419|NCT05839587|PROCEDURE|Laparoscopic TAPP|Laparoscopic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of port placement only and part 4 consists of skin closure only.
214474420|NCT03536884|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
214474421|NCT03536884|DRUG|Secukinumab|Subjects will receive secukinumab at pre-specified time-points.
214474422|NCT03536884|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
214474423|NCT06197360|BEHAVIORAL|Based on BCW Theory of Health Education|Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.
214474424|NCT06197360|BEHAVIORAL|General diabetes health education|Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.
214474425|NCT06826950|OTHER|comprehensive pharmaceutical care|The intervention group received comprehensive pharmaceutical care in addition to standard care. For first-cycle patients, oncology pharmacists conducted patient education, informing them about potential chemotherapy-induced adverse reactions and corresponding management strategies. Patients were instructed on the proper use of antiemetic medications, the recommended frequency of blood routine tests, and the appropriate timing, dosing, and administration of granulocyte colony-stimulating factor (G-CSF) and thrombopoietic agents. A QR code for oncology pharmacist consultation was provided to enable patients to seek advice on medication-related issues encountered outside the hospital.
214474426|NCT06826950|OTHER|Routine pharmaceutical services|The control group received standard care: After the doctor issues the chemotherapy order, the oncology pharmacist only reviews the order to ensure that the chemotherapy regimen and pretreatment regimen during the study are consistent with those of the experimental group. No other interventions are performed.
214474427|NCT03224936|DEVICE|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
214474428|NCT05937308|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
214474429|NCT05364788|OTHER|Retrospective tissue sample analysis|Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
214474430|NCT06630897|OTHER|Text Messages|small amounts of digital support will be in the form of text messages
214474431|NCT04204863|OTHER|collection of patient data|Extract data from the digital medical records, the electroencephalographic and microbiologic database.
214474432|NCT03489434|BEHAVIORAL|Intervention|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
214474433|NCT06827210|DEVICE|Optilume DCB|Optilume DCB is a drug-coated balloon catheter designed for the treatment of bulbar urethral strictures. It combines mechanical dilation with localized drug delivery to reduce stricture recurrence and promote urethral healing. The balloon is coated with paclitaxel, an antiproliferative agent, to minimize scar tissue formation and improve treatment outcomes.
214474434|NCT06827210|PROCEDURE|Standard Direct Visual Internal Urethrotomy (DVIU)|Standard Direct Visual Internal Urethrotomy (DVIU), also known as Sachse Internal Urethrotomy, is a minimally invasive endoscopic procedure for treating urethral strictures.
214474435|NCT03331835|BIOLOGICAL|Brodalumab|"Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).~Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis."
214289632|NCT03325361|OTHER|Tube drain insertion|A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
214474436|NCT03331835|DRUG|Fumaric acid esters|Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
214474437|NCT04931849|DRUG|Avatrombopag|Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
214474438|NCT04667468|BIOLOGICAL|Cold Stored Platelets (CSP)|early infusion of urgent release CSP
214474439|NCT04667468|BIOLOGICAL|Standard Care|standard care including blood and blood component therapy
214474440|NCT05316181|PROCEDURE|HIPEC|HIPEC perfusion, doxorubicin 35mg/m2 \& mitomycin 15 mg/m2, 41.5'C, 90 min.
214474441|NCT03643510|DRUG|Fulvestrant|Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles.
214474442|NCT03643510|DRUG|Abemaciclib|Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28.
214289633|NCT05841251|DRUG|Topical Phenylephrine Solution|phenylephrine-soaked pack using the whole 5 ml of the solution provided with.5% phenylephrine will be applied after induction of surgery and intubation, 15 minutes before surgery. 100 ml of normal saline will be given.
214289634|NCT05841251|DRUG|intravenous tranexamic acid|patients will receive intravenous Single dose of tranexamic acid 15 mg/kg in 100 mL normal saline over 10 minutes. Saline-soaked pack will be applied.
214474443|NCT05488548|DRUG|EP31670|EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
214474444|NCT06414356|DRUG|Ketamine|Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr. Participants will receive intravenous infusions of ketamine for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (ketamine 0.5 mg/kg IBW/hr)
214474445|NCT06414356|DRUG|Magnesium sulfate|Magnesium sulfate 3 grams will be diluted into 250 mL normal saline and infused at a rate of 62.5 mL/hr (over 4 hours until the entire contents are infused and then flushed with 20 mL of normal saline). The Mg only group will be randomly assigned to one of the treatment groups (moderate dose ketamine, or moderate dose ketamine +Mg) after 2 weeks and complete the full 24-week infusion treatment regime of the randomly selected treatment group in an outpatient setting.
214474446|NCT06414356|DRUG|Ketamine + Magnesium sulfate|Participants will receive intravenous infusions of ketamine and magnesium sulfate in combination. Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr Participants will receive intravenous infusions of ketamine and magnesium sulfate for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (Ketamine 0.5 mg/kg IBW/hr + magnesium sulfate 3 grams diluted into 250 mL normal saline)
214474447|NCT06465121|PROCEDURE|peripheral intravenous catheterization performed with ultrasound guidance by a trained nurse|Intravenous catheterization using ultrasound-guidance to allow real-time visualization of target veins in pediatric patients with difficult intravenous access
214474448|NCT05405387|DRUG|Budesonide EC|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
214474449|NCT05405387|DRUG|Placebo|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
214474450|NCT03634540|DRUG|Belzutifan|Belzutifan tablets administered orally.
214474451|NCT03634540|DRUG|Cabozantinib|Cabozantinib tablets administered orally.
214474452|NCT00179842|PROCEDURE|Stem Cell Transplant|
214474453|NCT05269706|DRUG|Cannabidiol 200mg|Cannabidiol 200mg (twice daily)
214474454|NCT05269706|DRUG|Epidiolex|Epidiolex 400mg (twice daily)
214474455|NCT05269706|DRUG|Cannabidiol 400mg|Cannabidiol 400mg (twice daily)
214474456|NCT05269706|DRUG|Placebo|Matching Placebo (Twice Daily)
214474457|NCT05791435|DEVICE|PneuRIP|Measuring respiratory indices through Respiratory Inductance Plethysmography
214289635|NCT03454893|DRUG|AVR-RD-01|Single IV infusion of between 3 - 20 x 10\^6 CD34+ cells/kg.
214289636|NCT02829450|OTHER|peritoneal ultrafiltration|Peritoneal fluids should be inserted intraperitoneally for several hours dwell
214289637|NCT03441776|OTHER|Generalized Vestibular Rehabilitation Treatment|These treatment visits are available twice a week and each visit lasts 45 minutes. Individuals receiving GVRT are allowed to choose the frequency at which they want to attend and the program is designed for each subject to complete 8 visits within a period between 4 and 8 weeks. The ideal number of patients receiving treatment at each class is from 3 to 6 but the system has capacity for a maximum of 8. GVRT is a standard of care treatment option and is not considered research.
214474458|NCT05791435|OTHER|biofeedback to assist with breathing|Measuring respiratory indices through Respiratory Inductance Plethysmography and providing visual biofeedback on a tablet screen
214289638|NCT03441776|OTHER|Individualized Vestibular Rehabilitation Treatment|Individuals receiving IVRT are scheduled depending on their individual needs and PT availability. These visits require one-on-one time with a PT. Individuals are commonly seen by the PT 3 times at two week intervals. These visits last 30 minutes and include PT evaluation designed to instruct patients on exercises for them to perform on their own. IVRT is a standard of care treatment option and is not considered research.
214474459|NCT05724745|DIAGNOSTIC_TEST|1. Standard spirometry|Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).
214474460|NCT05724745|DIAGNOSTIC_TEST|2. 3D dynamic lung MRI at UTE in prone and supine positions|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.
214474461|NCT05724745|DRUG|3. Reversibility test with salbutamol|Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
214474462|NCT05724745|DIAGNOSTIC_TEST|4. 3D dynamic lung MRI at UTE in supine and prone position|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.
214474463|NCT06477146|DRUG|Milk thistle (MT)|MT capsules will contain 300 mg of MT with 80% content of Silymarin, standardized to 240mg Silymarin content. Dosing will be based on body weight with maximum dose of 600 mg/day. Dosing will be either 1 or 2 capsules per day based on weight.
214474464|NCT06477146|DRUG|Placebo|The placebo is consistent of Psyllium husk fiber, in 500mg per capsule composition.
214657350|NCT06369779|DEVICE|TM Fill in combination with TM Flow|The newly developed resin composites (TM Flow in combination with TM Fill) will be used for the restoration of class I and II cavities (3 seconds light-curing mode, 3000 milliwatt per square centimeter).
214657351|NCT04892563|PROCEDURE|Erector Spinae Plane Block|Nerve block with local anesthetic in the erector spinae plane
214474465|NCT06477146|BEHAVIORAL|Lifestyle Modification|"The primary instructions for lifestyle modification are:~1. Physical activity goal- 20-30 minutes per day 5 to 7 days per week. The aim is 150 minutes a week and more than 300 calories burnt for each workout.~2. Adequate hydration- 4-5 bottles of water a day.~3. Limitation of sugar-free beverages- once daily and 1-2 (8 oz) cups of skim/1% milk (or dairy alternative) daily.~4. Avoidance of beverages with added sugar such as soda, Kool-Aid, juice, and Gatorade.~5. Ideal consumption- three meals daily(breakfast, lunch, dinner)and one snack.~6. Snack Goal \<200 calories. If a 2nd, 3rd, etc. snack is desired it will only be a vegetable.~7. Five servings of fruits/vegetables per day.~8. Each food we recommend eating should have dietary fiber \>3 grams/serving. Ideally \>5 grams/serving.~9. The given survival guide will have all information regarding serving size and portion allotment.~10. MyPlate.gov handout given which will guide participants in relation to portion control."
214474466|NCT06477146|DEVICE|Fibroscan|FibroScan will be completed to measure Elastography. Elastography works by emitting small pulse of energy which may be perceived as a vibration which quickly calculated the stiffness of the liver, which correlates to fat deposition and fibrosis.
214474467|NCT03886766|DRUG|Hot-melt extruded amorphous solid dispersion of Efavirenz|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
214474468|NCT03886766|DRUG|Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
214474469|NCT03886766|DRUG|Efavirenz solution|Efavirenz solution, 3 mg, oral administration (product 3)
214474470|NCT05210569|DEVICE|Vivity|Vivity intraocular lens (IOL)
214474471|NCT02959502|OTHER|Receive tDCS+CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
214474472|NCT02959502|OTHER|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
214474473|NCT06214936|OTHER|Benchtop Incubator|half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the benchtop incubator for the remainder of embryo culture
214474474|NCT06214936|OTHER|Box Incubator|half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the box incubator for the remainder of embryo culture
214474475|NCT04199871|OTHER|dichoptic 3D movies|dichoptic movies presented on a Nintendo 3DS
214474476|NCT04341064|BEHAVIORAL|SHINE Intervention|\[see arm/group descriptions\]
214474477|NCT05454852|OTHER|Survey|Interviewer-administered survey
214474478|NCT05454852|OTHER|Focus group|Focus group for selected participants
214474479|NCT01726257|DEVICE|Nellix System|Subjects in this study will receive a Nellix Endovascular Sealing System as part of their intervention.
214474480|NCT05626634|DRUG|LP352, bexicaserin|LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
214474481|NCT03972202|DIAGNOSTIC_TEST|MRI|Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
214474482|NCT03972202|DEVICE|TMS|Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
214474483|NCT03972202|BEHAVIORAL|Speech-motor behavioral testing|Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
214474484|NCT04991857|OTHER|T-FAME-HF|16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits
214657352|NCT04892563|DRUG|IV Analgesia|IV analgesia, typically Morphine/Opioid medications
214847537|NCT03326986|DRUG|Placebo|Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
214847538|NCT04877171|OTHER|telemedicine neurology consultation|consultations via phone-only at 12-14-day post-discharge. Consultations via phone both audio and video at 1, 3 and 6 months
214847539|NCT04877171|OTHER|in-person neurology consultation|consultation in-person at Hospital Internacional de Colombia
214847540|NCT02611011|DEVICE|Congo Red Test (GV-005)|The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
214847541|NCT00455962|DRUG|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
214847542|NCT00455962|DRUG|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
214847543|NCT00002829|BIOLOGICAL|Recombinant Interferon Alfa|Daily
214847544|NCT00002829|DRUG|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
214847545|NCT00002829|DRUG|Etoposide|Administered intravenously on Day -8
214847546|NCT00002829|DRUG|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
214847547|NCT00002829|PROCEDURE|Bone Marrow Transplantation|Infusion on Day 0.
214847548|NCT00002829|RADIATION|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
214474485|NCT04991857|OTHER|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by the team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
214474486|NCT06003608|DEVICE|Fluid biopsy capsule|Ingestion of two SIMBA capsules
214474487|NCT06003608|DRUG|Levodopa-Carbidopa Immediate Release|Single dose, Levodopa-Carbidopa Immediate Release
214474488|NCT05988853|OTHER|follow-up of patients|Follow-up of evidence of nosocomial infections of patients in music therapy
214474489|NCT05451108|DEVICE|PCL Pectus Scaffold implantation and autologous fat grafting|A small incision is made in the chest and pre-sternal pocked is defined. Following this, an empty scaffold is implanted at the site of the defect with skin closed directly over it. At the same stage, autologous fat transfer will be performed, harvesting fat from available donor sites such as the thighs and abdomen - depending on scaffold volume and patient morphology. The area will be infiltrated with local anaesthetic tumescent fluid, liposuction performed, and fat transferred to syringes for filtration prior to injection into the scaffold. Fat will not be processed beyond simple filtration to separate liquid from fat to be injected. The scaffold provides structural stability to the chest during the infiltration of the tissue inside the scaffold.
214474490|NCT05594368|DEVICE|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
214474491|NCT06804707|BIOLOGICAL|blood sampling|"This procedure will take place once during the patient's CARPUS first visit (Croix Rousse hospital (Hospice civils de Lyon).~A peripheral venous line of the cathlon 24 G type with tap without tubing will be inserted by a nurse. A blood sample will be taken at the same time to check creatinine levels before the MRI scan and to record the patient's cholesterol levels for the eCRF."
214474492|NCT06804707|DEVICE|ultrasound imaging exam|"This procedure takes place once immediately after the intervention 1. The patient will first have an ultrasound acquisition with the clinical ultrasound scanner (\~5 minutes) in order to locate the plaque. An acquisition with the research ultrasound scanner and matrix probe will then be performed for measurement for ultrasound spectroscopy (\~5 minutes).~An injection of 2.4 ml Sonovue followed by 10 ml saline will be performed during acquisition with the research ultrasound scanner for ultrasound localization imaging measurement (\~10 minutes).~The patient must remain under observation (in the waiting room) for 30 minutes after the examination."
214474493|NCT06804707|DEVICE|High resolution MRI plaque exam|"This procedure will take place once during the patient's CARPUS second visit (Pierre Wertheimer hospital (Hospice civils de Lyon)).~The patient is greeted in radiology, and his/her identity and absence of contraindications are verified.~A peripheral venous line of the cathlon 24 G type with tap without tubing will be inserted by a nurse.~Injection of gadolinium and MRI examination of the plaque used in clinical routine."
214474494|NCT04750941|DRUG|Copanlisib|Copanlisib will be infused intravenously on days 1, 8, 15 of each cycle, over 1 hour, of 28-day cycles.
214474495|NCT04750941|OTHER|Ketogenic Diet|"In cycle 1, patients will first start the ketogenic diet for 7 days (Day -6 to Day 0).~Only the patients who demonstrate compliance and tolerance with the ketogenic diet, as confirmed by pertinent blood and urine tests and a diary of diet, will be allowed to continue the study and start copanlisib on Day 1. The ketogenic diet will continue daily throughout the treatment days.~In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1.~The ketogenic diet will then continue daily throughout the treatment days."
214474496|NCT05835297|OTHER|Physical exercise interventions|Participants will undergo a 12-week multicomponent exercise regimen, twice per week on non-consecutive days for 45-60 min each. The session will be divided into 4 min of warm-up; range of motion exercises of upper and lower extremities, followed by light walking, then 8 min balance exercises, followed by 15 min strength exercises; two sets of 13-15 repetitions maximum of chair rises with progression, two sets of 13-15 repetitions of modified squats (holding a chair backrest if needed) with progression, 2 sets of 20-30 repetitions of seated or 2 sets of 13-15 repetitions of standing calf raises, then 15 min aerobic exercises; five 3-min bouts of walking between two strengthening exercises and/or 2 balance exercises, finally 3 min cool down exercises of light walking and stretching exercises.
214474497|NCT06353061|DRUG|Metformin|Patients randomized to the metformin group will start taking metformin within 1 day after group allocation. They will take one tablet of metformin (850 mg) once daily for three consecutive days. Subsequently, they will take metformin orally twice daily throughout the entire external and internal irradiation period, with each administration consisting of one tablet.
214474498|NCT06353061|RADIATION|Radiotherapy|The study requires all subjects to sequentially undergo external beam radiotherapy (EBRT) and intracavitary brachytherapy (BT). All radiotherapy must be completed within 7-8 weeks after treatment initiation. The total prescribed dose EQD2 for EBRT combined with BT should be ≥80 Gy; for subjects with squamous carcinoma with lesions ≤4 cm, the HR-CTV D90 should be ≥80 Gy; for subjects with adenocarcinoma or lesions \>4 cm, it is recommended that HR-CTV D90 should be ≥85 Gy. When the prescribed dose is limited by organs at risk (OAR), priority should be given to covering HR-CTV. The radiotherapy plan in this study is based on image guidance. Imaging scans can use MRI or CT, and the scanning area should extend at least 5 cm above and below the PTV.
214474499|NCT06353061|DRUG|Chemotherapy|The dosage of cisplatin is 40 mg/m2, administered once weekly during radiotherapy for a duration of 5 weeks. Prior to and following cisplatin administration, 1-2 liters of fluid should be given for adequate hydration. Treatment should continue until disease progression or intolerable toxicity occurs.
214474500|NCT06353061|DIAGNOSTIC_TEST|PET/CT|Using 68Ga-NY104 as a small molecule targeted imaging agent for CA-IX, two CA-IX PET/CT scans will be conducted in patients: one upon enrollment and another one week after randomization.
214474501|NCT04647448|DIAGNOSTIC_TEST|Application of sensor patch|Application of sensor patch to chest to record acoustic signals due to disturbed blood flow.
214474502|NCT04465487|DRUG|REGN6569|Administered by intravenous (IV) infusion
214474503|NCT04465487|DRUG|Cemiplimab|Administered by IV infusion
214657353|NCT05850741|DEVICE|Cardiokit|The CardioKit prototype used in the study can monitor cyclical heart-beat motion, cyclical respiratory motion and non-cyclical heart position changes while the patient is lying in supine position.
214474504|NCT06412679|BEHAVIORAL|Life Skills Education|The RESETTLE-IDPs study compares two innovative delivery approaches for a culturally-adapted life skills education (LSE) intervention aimed at improving the mental health and well-being of internally displaced persons in Nigeria. The interventions are distinguished by their mode of delivery (in-person vs. WhatsApp-based), their focus on peer support and skill-building, and their tailoring to the specific needs and challenges of IDP populations.
214474505|NCT04560595|BEHAVIORAL|Caffeine Reduction Manual|We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.
214474506|NCT04305444|DRUG|DTRM-555|Oral once-daily administration
214474507|NCT06443580|OTHER|interoceptive group based intervention|8 week online group intervention aiming to improve interoception.
214474508|NCT05331625|BEHAVIORAL|Offering Additional Resources to Promote Symptom Management|Participants will be offered additional resources to promote symptom management.
214474509|NCT03314740|DRUG|Paclitaxel|Comparator active compound
214474510|NCT03314740|DRUG|Cediranib|Experimental compound
214474511|NCT03314740|DRUG|Olaparib|Experimental compound
214474512|NCT02367040|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
214474513|NCT02367040|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
214474514|NCT02367040|DRUG|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
214474515|NCT03426904|DRUG|Neoadjuvant FOLFOX|4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy
214474516|NCT03426904|DRUG|Conventional adjuvant FOLFOX|12 cycles of postoperative FOLFOX chemotherapy
214474517|NCT05877430|DRUG|CJRB-101|In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
214474518|NCT05877430|DRUG|Pembrolizumab injection|200 mg given by intravenous (IV) infusion once every 3 weeks
214474519|NCT02772731|PROCEDURE|Partial mastectomy plus additional Shave Margin|"For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin."
214474520|NCT02772731|PROCEDURE|Partial mastectomy|Surgeons will be instructed to close after partial mastectomy with no further excision.
214474521|NCT03785834|PROCEDURE|Punch Biopsy|The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
214474522|NCT05814211|DEVICE|Investigational device - newly developed intermittent catheter|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
214474523|NCT05814211|DEVICE|Comparator device #1 - SpeediCath Eve|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
214474524|NCT05814211|DEVICE|Comparator device #2 - SpeediCath Compact Plus Female|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
214474525|NCT06033378|OTHER|Blood pressure elevation|Increasing systemic blood pressure for measurement of cerebral blood flow changes
214474526|NCT03707808|DRUG|intratumoral injection of autologous CD1c (BDCA-1)+ myDC|intratumoral injections plus intravenous administration
214847549|NCT05019482|BEHAVIORAL|University-based intervention to promote PA and reduce ST|"This intervention was realized with all college student and involved:~1. Design-based innovative workshops during the first week;~2. 8-weeks program of Physical Activity constructed by users~3. Information session focusing on the promotion of active behaviors~4. Feedback provided to the users with an individualized report"
214847550|NCT01014416|DRUG|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
214474527|NCT03707808|DRUG|Intratumoral injection of ipilimumab and AS01b|Intratumoral injection of ipilimumab and AS01b
214474528|NCT03707808|DRUG|IV nivolumab|Nivolumab administered intravenously
214474529|NCT04075318|BIOLOGICAL|UB-312|A synthetic peptide-based vaccine
214847551|NCT01882179|DRUG|Mineralocorticoid receptor antagonist potassium-canrenoate|
214474530|NCT04075318|BIOLOGICAL|Placebo|Matching placebo
214474531|NCT04477291|DRUG|CG-806|CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.
214474532|NCT06269861|DEVICE|patient transfer scale|patient transfer scale is a device to measure actual weight for critically ill patient who are unable to stand
214657354|NCT00960076|DRUG|Saxagliptin|5mg oral tablet once daily
214657355|NCT00960076|DRUG|Metformin XR|500mg oral tablet once daily
214847552|NCT01882179|DRUG|placebo|
214847553|NCT05118516|DRUG|ASC43F|One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
214474533|NCT06517719|OTHER|lutetium (177Lu) vipivotide tetraxetan|This is an observational study. There is no treatment allocation. The decision to initiate lutetium vipivotide tetraxetan will be based solely on clinical judgement.
214847554|NCT01347658|DIETARY_SUPPLEMENT|Echinacea purpurea|Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
214847555|NCT02049021|DEVICE|MECTA SPECTRUM 5000Q ECT|
214847556|NCT02049021|PROCEDURE|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
214847557|NCT05649735|DEVICE|Logusgyn ovules|"LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
214847558|NCT05649735|DEVICE|Logusgyn Lavander|"LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
214847559|NCT05649735|OTHER|Placebo|Sterile saline solution
214847560|NCT05406024|DEVICE|Digital platform|The digital platform consists of 84 exercise sessions of progressive intensity. Each day, the tool offers 8 exercise sessions of about 5 to 10 minutes each, spaced out over an hour. One session can represent several exercises. The patient is asked to perform them daily.
214847561|NCT02480218|OTHER|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
214847562|NCT03736187|DRUG|Cephalexin|Giving cephalexin and metronidazole in one group \&cephalexin alone in another group
214847563|NCT04617392|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.
214847564|NCT04617392|OTHER|Strength endurance training|Patients included in the active cohort arm with physical activity will undergo three months of strength endurance training under the supervision of a professional physiotherapist
214847565|NCT01739725|DEVICE|Stent insertion|The patient will receive the helical stent
214289639|NCT05061810|BEHAVIORAL|Smartphone application self-management programme|The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.
214289640|NCT00047814|DRUG|FK788|
214474534|NCT06550401|OTHER|BREAST-Q Physical Well-Being|This BREAST-Q domain measures pain or tightness and difficulty with mobility, such as lifting arms or running. The preoperative survey contains 10 items, whereas the postoperative survey contains 11 items. Values for BREAST-Q subscales are converted to summary scores, ranging from 0 to 100, via Q-Score software. Higher scores correlate with better patient quality of life. 37 This survey is administered as part of standard care for all patients.
214474535|NCT06550401|OTHER|QuickDASH|QuickDASH, also known as the Arm and Shoulder Range of Motion survey within MSK Engage is an 11-item survey that measures physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. It is currently standard of care for breast cancer surgery patients. It is a valid, reliable, and responsible survey that can be used for clinical and/or research purposes. Higher scores indicate greater disability.
214474536|NCT06550245|OTHER|Infants observing familiar and unfamiliar racial groups|All infants will see videos of people from familiar and unfamiliar racial backgrounds. Depending on the caregiver's race, infants will be assigned to see people who are from the same racial background as their caregiver (i.e., familiar) and people who are not.
214474537|NCT03979742|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|Active ingredients: Monocytes, CD34+, CD133+ cells Dose: 4 injections of 16-μliter (100,000 cells/μliter)
214847566|NCT02604472|OTHER|CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
214847567|NCT02604472|OTHER|IC+CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
214474538|NCT03979742|OTHER|Locomotor Training|Locomotor training for up to 6 hours a day, 6 days a week, and for 3-6 months
214474539|NCT05018377|PROCEDURE|Racz adhesolysis|adhesiolysis in failed back surgery
214847568|NCT02575508|DRUG|Fluorouracil|Given IV
214847569|NCT02575508|DRUG|Irinotecan Hydrochloride|Given IV
214847570|NCT02575508|OTHER|Laboratory Biomarker Analysis|Correlative studies
214847571|NCT02575508|DRUG|Oxaliplatin|Given IV
214847572|NCT02575508|DRUG|pan FGFR Kinase Inhibitor BGJ398|Given IV
214847573|NCT02575508|OTHER|Pharmacological Study|Correlative studies
214847574|NCT01197417|DRUG|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
214847575|NCT01197417|DRUG|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
214847576|NCT02265172|PROCEDURE|Physiotherapy screening|Physiotherapy screening.
214847577|NCT02265172|PROCEDURE|Standard practice|Orthopaedic surgeon assessment
214847578|NCT02804555|OTHER|Oxygen|Oxygen administration
214847579|NCT00013494|PROCEDURE|Stroke Rehabilitation|
214847580|NCT01572519|DRUG|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
214289641|NCT02071251|PROCEDURE|Prospective wound complication protocol|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
214474540|NCT05018377|DEVICE|NAVI adhesolysis|adhesiolysis in failed back surgery
214474541|NCT05856435|BEHAVIORAL|Chicago Parent Program for Foster Care|The Chicago Parent Program for Foster Care FC consists of a 12-session parent training program that focuses on building caregiver-child relationships, behavioral management strategies, managing caregiver stress, and skill maintenance.
214474542|NCT05403086|DRUG|Psilocybin|Psilocybin, \[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate.
214474543|NCT05403086|DRUG|Ketamine|ketamine hydrochloride injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.
214474544|NCT06752642|PROCEDURE|Implant overdenture|patients received implant overdenture
214474545|NCT06756178|DRUG|Propofol Group 1|"Postoperative Use:~Bolus: 10-20 mg intravenously as needed for sedation initiation. Continuous infusion: 0.3-0.5 mg/kg/hour to maintain light sedation adjusted based on clinical response."
214474546|NCT06756178|DRUG|Remimazolam Intervention|"Postoperative Use:~Initial bolus: 5 mg intravenously upon ICU arrival. Continuous infusion: 0.2-0.3 mg/kg/hour to maintain light sedation with a maximum dose of 0.8 mg/kg/hour.~Rescue sedation with propofol or midazolam will be allowed if patients become agitated or if Remimazolam is ineffective in maintaining target sedation."
214474547|NCT06756178|DRUG|Dexmedetomidine Intervention|"Postoperative Use:~Loading dose: 0.5-1 μg/kg over 10-20 minutes after ICU arrival. Continuous infusion: 0.2-0.7 μg/kg/hour for sedation maintenance, adjusted as needed to maintain light sedation.~Rescue sedation with propofol or midazolam will be administered if Dexmedetomidine fails to maintain adequate sedation or if patients become agitated."
214474548|NCT05939518|OTHER|Lactated Ringer's Fluid Bolus Response to Low Urinary Output|During the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains \<0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches \>0.3 ml/kg/h.
214474549|NCT05939518|OTHER|Post-Anesthesia Care Unit Lactated Ringer's Fluid Management Protocol|During their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.
214474550|NCT01821612|DRUG|oxaliplatin|IV
214474551|NCT01821612|DRUG|irinotecan|IV
214847581|NCT01572519|DRUG|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
214847582|NCT01572519|DRUG|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
214847583|NCT01572519|DRUG|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
214289642|NCT06224101|BEHAVIORAL|Simulation-based training|simulation training consists of practicing diagnostic coronary angiography with 3D printed simulator-SimulHeart.
214474552|NCT01821612|DRUG|leucovorin|IV
214474553|NCT01821612|DRUG|5-fluorouracil|IV
214474554|NCT01821612|DRUG|capecitabine|PO
214474555|NCT01821612|RADIATION|radiation|
214474556|NCT01821612|PROCEDURE|surgery|
214474557|NCT01821612|DRUG|gemcitabine|IV
214474558|NCT02323880|OTHER|Pharmacological Study|Correlative studies
214474559|NCT02323880|DRUG|Selinexor|Given PO
214474560|NCT03278379|DRUG|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
214474561|NCT00360087|DRUG|Bosentan|
214474562|NCT06015672|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will have two accelerated transcranial magnetic stimulation (TMS) visits. Each TMS visit will be separated by 5 months. During each TMS visit, they will receive four TMS sessions, each separated by 60 minutes of rest.
214474563|NCT06061159|DRUG|Remimazolam besylate|initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg
214847584|NCT01572519|DRUG|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
214847585|NCT00699530|OTHER|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
214847586|NCT03918941|DEVICE|Carey|mobile application
214289643|NCT05885204|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted laparoscopic radical cystectomy
214289644|NCT05885204|PROCEDURE|Conventional laparoscopic radical cystectomy|Conventional laparoscopic radical cystectomy
214474564|NCT06061159|DRUG|Remimazolam besylate|initial dose is based on the findings from the school-age group；adjust dosage is 0.05mg/kg
214474565|NCT05695430|BEHAVIORAL|Brief Cognitive Behavioral Therapy for People with Physical Disabilities|12 sessions of of Brief Cognitive Behavioral Therapy that has been adapted for people with physical disabilities will be administered through telehelath.
214474566|NCT03480776|DRUG|Acetylsalicylic acid|81 mg PO daily or 325 mg PO daily
214474567|NCT03480776|OTHER|Placebo|One tablet PO daily
214657356|NCT00960076|DRUG|Metformin XR|750mg, 2 tablets once daily
214657357|NCT00500266|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
214657358|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
214657359|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
214657360|NCT01431287|DRUG|tiotropium|low dose or high dose
214657361|NCT01431287|DRUG|tiotropium|low dose or high dose
214657362|NCT01431287|DRUG|olodaterol|one dose only
214657363|NCT01431287|DEVICE|Respimat|Respimat inhaler
214847587|NCT03918941|OTHER|conventional information|leaflet, internet link and oral information
214474568|NCT04981600|DEVICE|Radiofrequency ablation|Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.
214474569|NCT04981600|DEVICE|Laser|"The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day."
214474570|NCT04935619|BEHAVIORAL|Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
214289645|NCT00002079|DRUG|Butyldeoxynojirimycin|
214474571|NCT04935619|BEHAVIORAL|Non-Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
214474572|NCT04548713|DEVICE|4% EDTA|Sterile Catheter Lock Solution
214474573|NCT04548713|DEVICE|Saline|Saline Lock Solution
214474574|NCT05282459|DRUG|Enasidenib mesylat dose escalation|Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.
214474575|NCT03421340|DEVICE|DSC|Stone removal without fluoroscopy using the SpyGlass device.
214474576|NCT03421340|DEVICE|ERC|Standard of care stone removal with fluoroscopy.
214474577|NCT05660434|OTHER|Aroma Inhaler with Bergamot essential oil|The intervention group will receive an aroma inhaler and logbook to use three times a day for 7 days and complete pre and post surveys for comfort, ease, and stress.
214474578|NCT05860413|BEHAVIORAL|Intermittent energy restriction (IER)|During Phase 1 (Weight Loss), participants will follow a very-low energy diet (VLED; 550-800 kcal/d) 2-3 days per week. On other days, participants do not have a specific kcal goal (non-fasting days). After Phase 1, IER participants will be instructed to follow a VLED 1-2 days per week as needed for weight maintenance.
214474579|NCT05860413|BEHAVIORAL|Time Restricted Eating (TRE)|Participants will eat within an 8-hour period most days (at least 5 days per week). All foods and beverages containing calories will be restricted to this 8-hour period but calorie-free beverages (coffee, tea, diet soda, etc.) are allowed at any time. TRE participants will follow healthy eating guidelines for weight loss during Phase 1 but not follow a specific kcal prescription or restrict intake thereafter.
214474580|NCT04203524|DIAGNOSTIC_TEST|Procalcitonin Levels|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first. A PCT-guided algorithm will be available to guide the management of patients in the PCT group.
214474581|NCT04203524|OTHER|Control|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first.The results of the PCT levels obtained will be blinded and all clinical team members will not be able to access the results.
214657364|NCT02583984|PROCEDURE|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
214847588|NCT03432988|BEHAVIORAL|Nursing Solution-Focused|Two two-hour training modules were designed. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays. Solution-focused communication on IDWG. In the case of IDWG improvement, nurses were trained to congratulate the patient and then to explore in detail, from a stance of curiosity, how s/he had accomplished the weight reduction. Nurses were trained to invite patients to share specific behavioral details, to describe their own behavior from the perspective of significant family members and also to compliment patients on their accomplishments and to invite them to keep track of anything else they might find useful to control fluid intake over the next days.
214289646|NCT00002079|DRUG|Zidovudine|
214289647|NCT01830699|DRUG|Rilonacept|160 mg intra-bursal once
214289648|NCT01830699|DRUG|Corticosteroid|2 cc (40 mg/mL) triamcinolone intra-bursal once
214289649|NCT03683446|PROCEDURE|Laparoscopic rectal surgery|Minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon.
214289650|NCT03683446|PROCEDURE|Open rectal surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
214847589|NCT02139618|DRUG|Methyl Aminolevulinate (MAL)|
214847590|NCT02139618|DRUG|Placebo|
214289651|NCT04579731|DRUG|Lactitol Monohydrate|Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
214289652|NCT02309489|BEHAVIORAL|Partner involvement|Partner is involved in maternity care
214289653|NCT00125801|DRUG|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
214289654|NCT05211791|PROCEDURE|erector spinae block|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
214474582|NCT05565326|DEVICE|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system using CE marked low-field MR coils as provided by the company will be taken for volunteers in phase I. In phase II and III, after therapy beginning those images will be taken once per week per subject using CE marked low-field MR coils as provided by the company. This is done over the entire course of radiotherapy, which takes between 3 and 6 weeks.
214289655|NCT05211791|PROCEDURE|paravertebral block anesthesia|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
214289656|NCT05211791|PROCEDURE|Thoracic epidural anesthesia|insertion of Thoracic epidural catheter for anesthesia analgesia at level of T6
214289657|NCT01986985|DEVICE|PET/MRI system|Compared to PET CT
214474583|NCT04080622|DRUG|Selenium|Selenium 300 µg/day (IV infusion)
214474584|NCT04080622|DRUG|Placebos|NaCl 0,9% (IV infusion)
214474585|NCT06194188|DRUG|Subcutaneous injection of CU-20401|Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.
214474586|NCT05656027|DRUG|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
214474587|NCT05656027|DRUG|Aceclidine|LNZ100 Aceclidine ophthalmic solution
214474588|NCT05656027|DRUG|Brimonidine|Brimonidine ophthalmic solution
214474589|NCT06514612|DRUG|STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers|STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers
214474590|NCT06514612|OTHER|Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers|Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers
214847591|NCT05139277|DIAGNOSTIC_TEST|CONVIVO system|Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.
214847592|NCT05139277|OTHER|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
214847593|NCT02052791|DRUG|nusinersen|Administered by intrathecal (IT) injection
214847594|NCT00005026|DRUG|carboplatin|
214847595|NCT00005026|DRUG|paclitaxel|
214289658|NCT00182377|DRUG|Pentastarch (displace either 500 ml or 1000 ml of pump prime with pentastarch)|
214289659|NCT03042533|DEVICE|Conventional Compression|Method of Nail fitting
214289660|NCT03042533|DEVICE|Standard Backslapping|Method of Nail fitting
214289661|NCT03042533|DEVICE|Dynamic Locking with Backslapping|Method of Nail fitting
214289662|NCT06159712|OTHER|Blood samples|Extra blood samples
214474591|NCT04347200|DRUG|Antiplatelet Drug|single or dual antiplatelets, triple antithrombotic therapy
214474592|NCT03978663|RADIATION|Neoadjuvant radiotherapy|Neoadjuvant radiation therapy delivered to a portion of the index tumour for high-risk breast carcinoma for immune priming prior to neoadjuvant radiation
214474593|NCT05424380|DRUG|GSK3745417|GSK3745417 will be administered
214847596|NCT00005026|DRUG|topotecan hydrochloride|
214847597|NCT02317679|DRUG|Bosentan|Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
214474594|NCT05696119|BEHAVIORAL|I-PROTECT|I-PROTECT is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes end-user-targeted information and injury prevention physical and psychological training, specifically tailored for youth handball. The intervention is delivered through a mobile application (I-PROTECT GO) specifically developed for the I-PROTECT project, including coach, player, club administrator, and caregiver modules. Tailored support to implement I-PROTECT is specifically developed for Swedish community youth handball.
214474595|NCT05696119|BEHAVIORAL|Control|"Coaches of youth teams in the control group clubs will be offered currently available injury prevention training (i.e., Redo för Handboll, English: Ready for Handball), accessible online through the Swedish Handball Federation's coach education material."
214474596|NCT03533517|DEVICE|AccuCinch® Ventricular Restoration|AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
214474597|NCT02909686|DIETARY_SUPPLEMENT|Boswellia Serrata|
214474598|NCT02909686|DIETARY_SUPPLEMENT|Curcumin|
214474599|NCT02909686|DIETARY_SUPPLEMENT|Epimedium|
214474600|NCT02909686|DIETARY_SUPPLEMENT|Fisetin|
214474601|NCT02909686|DIETARY_SUPPLEMENT|Luteolin|
214474602|NCT02909686|DIETARY_SUPPLEMENT|Nettle|
214474603|NCT02909686|DIETARY_SUPPLEMENT|Pycnogenol|
214474604|NCT02909686|DIETARY_SUPPLEMENT|Reishi Mushroom|
214474605|NCT02909686|DIETARY_SUPPLEMENT|Resveratrol|
214474606|NCT02909686|DIETARY_SUPPLEMENT|Placebo|
214657365|NCT02583984|PROCEDURE|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
214657366|NCT00136864|PROCEDURE|PET Diagnostic Imaging|Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
214474607|NCT06391697|DEVICE|eOPRA Implant System for Transtibial Amputees and Magnetic Bead Tracking System|"The Magnetic Bead Tracking System is an investigational device that consists of pairs of magnetic beads, and a set of magnetic field sensors that measure and track the length of muscles and the speed at which they move in real-time. When the beads are implanted in muscle in the residual limb of an amputee, the muscle length signal is communicated to an investigational, robotic ankle-foot prosthesis.~The e-OPRA is an investigational implant system that lets a lower leg prosthesis attach securely to the remaining tibia bone. The e-OPRA device has been designed so that it can be implanted with an electrode set that consists of an electrical connector and electrodes to allow it to be used with both a neuro-mechanical (powered) prosthesis system, in addition to the standard prosthesis.~The operation to implant these devices will represent a modification of the surgical technique currently employed for standard below knee amputation."
214474608|NCT03113435|OTHER|Oxygen consumption optimization|hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
214474609|NCT05291273|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST). The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
214474610|NCT05291273|DIAGNOSTIC_TEST|Prone Bridge Test|"The prone bridge test also known as the plank or hover measures the muscular endurance of the abdominal muscles. Subjects will start in the down push up position with their feet together and their hands shoulder width apart. When the test starts the subject will push up to the prone bridge position so they are resting on their hands and toes making sure they maintain a straight line from the shoulders through the hips to the knees. The outcome measure will be the time where the subject stay in this position."
214474611|NCT05291273|DIAGNOSTIC_TEST|Measurement of the muscle strength of the shoulder complex|Maximum isometric force of the external and internal rotators and abductors/adductors measured by a dynamometer.
214474612|NCT05943756|BEHAVIORAL|Signature Strengths|The treatment group will complete 6 web-based sessions of Signature Strengths(1 sessions per week for 6 weeks), designed to teach lessons focused on the Aware-Explore-Apply interventional framework. Sessions are approximately 60 minutes long.
214474613|NCT05943756|BEHAVIORAL|TBI Education Course|The control group will complete 6 web-based sessions of a TBI Education Course(1 sessions per week for 6 weeks), designed to teach lessons based on the TBI Model Systems Knowledge Translation Center's fact sheets. Sessions are approximately 60 minutes long.
214474614|NCT03858517|DEVICE|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
214474615|NCT03265808|DRUG|allogeneic human mesenchymal stem cells (allo-hMSCs)|Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
214474616|NCT03265808|DRUG|Placebo|Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
214474617|NCT03636243|BIOLOGICAL|Vascularly biological assessment|22.5 ml of blood will be collected at day -15, month 3 and month 12.
214657367|NCT01365221|DRUG|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
214847598|NCT02317679|DEVICE|Pulsed dye laser (PDL)|A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
214847599|NCT02184559|DRUG|Ropivacaine|comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section
214847600|NCT02184559|DEVICE|The infiltration continues catheter|
214847601|NCT01529658|PROCEDURE|Renal hypothermia|"Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery."
214847602|NCT02533284|DRUG|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
214847603|NCT02533284|DRUG|bupevecaine|US guided TAP using Bupevecaine 0.25 %
214847604|NCT02533284|DRUG|saline|US guided TAP using placebo (saline)
214847605|NCT04997395|DRUG|MediCabilis Cannabis sativa 50|Already described
214289663|NCT03578029|DRUG|RGN-137|It will be applied topically to the appropriate wound once a day for up to 84 days.
214289664|NCT03578029|DRUG|Placebo|It will be applied topically to the appropriate wound once a day for up to 84 days.
214289665|NCT04421729|BEHAVIORAL|Group sessions over 3 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 6 sessions.
214847606|NCT03013881|BIOLOGICAL|UB-921|150 mg/vial
214289666|NCT04421729|BEHAVIORAL|Group sessions over 6 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 3 sessions.
214289667|NCT05442320|DEVICE|Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)|Toothpaste with 500 or 1000 ppm of fluoride
214289668|NCT04384328|OTHER|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
214474618|NCT03636243|BIOLOGICAL|Analysis of vasomotor endothelial function|Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.
214474619|NCT03636243|BIOLOGICAL|Analysis of arterial compliance|Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12
214474620|NCT03636243|BIOLOGICAL|Exploration of microcirculation|The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12
214474621|NCT03636243|BIOLOGICAL|Venous Doppler Ultrasound|aneurysm screening at day -15, month 3 and month 12
214474622|NCT03636243|BIOLOGICAL|Arterial pressure measurement|measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12
214474623|NCT03636243|BIOLOGICAL|Intima-Media Thickness measurement|Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12
214474624|NCT03636243|BIOLOGICAL|Exploration of neuropathy|non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12
214474625|NCT03636243|BEHAVIORAL|level of physical activity|pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12
214474626|NCT03636243|OTHER|thoracic scanner|non-injected thoracic scanner visit at month 3
214474627|NCT03647358|DEVICE|PET/CT Scan|Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
214474628|NCT03647358|DRUG|Iodine-124|Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose. (If a holiday is present in the work week, 124I can be administered orally on Day 2, if needed).
214474629|NCT04934462|PROCEDURE|physiotherapy|Six months physiotherapy aimed at hip stability.
214474630|NCT04934462|PROCEDURE|arthroscopy|Arthroscopic plication of hip joint capsule.
214474631|NCT05820516|DEVICE|TricValve implantation|TricValve implantation
214474632|NCT06799208|PROCEDURE|Laparoscopy|Minimal invasive approach. Have peritoneal tissue sparing character . Minimal blood loss . Reduction of postoperative adhesions.
214474633|NCT06783478|BIOLOGICAL|NK cell infusion|Six infusions of 1 x 10⁷/kg of haploidentical NK cells, in vitro expanded and activated.
214289669|NCT04130126|BEHAVIORAL|Taking cold showers|Showering behaviour
214289670|NCT01354951|OTHER|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
214474634|NCT06783478|OTHER|Placebo|Six infusions of placebo
214474635|NCT05664958|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block with liposomal bupivacaine and immediate release bupivacaine
214289671|NCT06135701|DIAGNOSTIC_TEST|One-legged knee-extensor exercise with Doppler measurements|Doppler ultrasound is used while participants exercise according to the one-legged knee-extensor exercise model
214289672|NCT01266954|DRUG|GSK2141795|GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
214474636|NCT05664958|DRUG|bupivacaine liposome injectable suspension|133 mg liposomal bupivacaine per side.
214474637|NCT05664958|DRUG|bupivacaine|20 ml bupivacaine 0.25% per side.
214474638|NCT05935605|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.
214474639|NCT05935605|DIAGNOSTIC_TEST|Lung ultrasound|A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.
214474640|NCT05674981|DIETARY_SUPPLEMENT|Probiotic group|Two-strain probiotic supplement includes Lactobacillus reuteri ADR-1 (alive) and Lactobacillus rhamnosus GM-020 ( alive).
214474641|NCT05674981|OTHER|Placebo group|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
214474642|NCT05707598|PROCEDURE|Laparoscopic surgery|The laparoscopic approach was used for the treatment of clinical T4b colorectal cancer
214474643|NCT05819268|BEHAVIORAL|ReACT|ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.
214474644|NCT05819268|BEHAVIORAL|CATCH-IT|CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.
214474645|NCT05099965|BIOLOGICAL|CMV-MVA Triplex|5 x 108 plaque-forming unit (pfu) ±0.5 x 108 pfu of MVA Vaccine
214474646|NCT05099965|BIOLOGICAL|Placebo|7.5% Lactose in phosphate-buffered saline \[PBS\]
214474647|NCT04808323|DRUG|Capecitabine|825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
214474648|NCT04808323|DEVICE|Initial Dose of Radiation before Dose Escalation|50 Gy over 25 frac.
214474649|NCT04808323|DEVICE|Cohort A: Dose Escalation Radiation|Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.
214474650|NCT04808323|DEVICE|Cohort B: Dose Escalation Radiation|Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.
214474651|NCT04808323|DEVICE|Cohort C: Dose Escalation Radiation|Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.
214289673|NCT01845350|OTHER|M2 macrophage introduction|"* Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~* Intrathecal introduction of autologous M2 macrophages"
214289674|NCT02734446|DRUG|Reuterin D3 drops|5 drops/day for 3 months
214474652|NCT04808323|DRUG|FOLFOX|After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
214474653|NCT05783414|BEHAVIORAL|f2f CST|An evidence-based group CST protocol adapted for Hong Kong Chinese culture. It consists of 14 sessions of group activities (group size: 6) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
214474654|NCT05783414|BEHAVIORAL|f2f carer support|Centre-based carer support programme for dementia carers provided in a community care service centre, which provide group education on caring skills, mutual support groups, and group-based self-care training over 6 months.
214474655|NCT05783414|BEHAVIORAL|vCST|A home-based version of f2f CST delivered via an information and communication technology platform (Zoom plus a web-based CST platform). It consists of 14 sessions of group activities (group size: 3) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
214474656|NCT05783414|BEHAVIORAL|online carer support|A home-based carer support service delivered via an information and communication technology platform (Zoom plus a web-based carer platform). It consists of 4 group sessions (group size: 6) and 3 individual sessions, and 3 optional self-learning sessions over 6 months, with an empowering care management approach to strengthen carer self-efficacy.
214474657|NCT05924113|BEHAVIORAL|Latin Dance|Latin dance sessions that include a warm-up routine with music, two choreographed dances, and a cooldown routine with music.
214474658|NCT04337255|OTHER|Behavioral Dietary intervention ( MIND Diet)|The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.
214474659|NCT04337255|OTHER|Behavioral Usual Care Diet Intervention|The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components
214474660|NCT04964310|GENETIC|genetic polymorphism|Observe the genetic polymorphism frequency difference between case and control groups
214474661|NCT04951076|DRUG|BNC210|BNC210 900 mg twice daily (b.i.d.) for 12 weeks
214474662|NCT04951076|DRUG|Placebo|Placebo twice daily (b.i.d.) for 12 weeks
214474663|NCT03517007|OTHER|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
214847607|NCT03013881|BIOLOGICAL|Herceptin|440 mg/vial
214847608|NCT02516384|BIOLOGICAL|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (\>18 year old) patients with active ulcerative colitis (UC).
214847609|NCT01652729|DRUG|Exenatide once weekly suspension|
214847610|NCT01652729|DRUG|Sitagliptin|
214847611|NCT01652729|DRUG|Placebo|Placebo oral capsule once daily
214289675|NCT02734446|OTHER|Placebo|5 drops/day for 3 months
214847612|NCT00288665|DEVICE|Export catheter (Medtronic)|
214847613|NCT06082297|DEVICE|Chattanooga Physio, DJO, neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) was applied with a device called Chattanooga Physio (DJO), testing 10 different combinations of parameter-settings. The parameter-settings that were varied and combined were frequency (1Hz and 36Hz) and plateau times (0.5s, 1.5s, 3s, 5s, 7s). The NMES was applied to the calf of the participants via transversally placed textile electrodes (3x3 cm) integrated in a sock starting with very low current amplitude followed by gradual small increases in current amplitude until induction of ankle plantar flexion, at which time-point the outcomes where measured.
214847614|NCT02588066|PROCEDURE|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
214847615|NCT01563926|DRUG|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
214289676|NCT05693246|DRUG|Glycopyrrolate|At 10 minutes after endotracheal intubation, the Glycopyrrolate group was injected intravenously with 0.004mg/kg glycopyrrolate.
214289677|NCT05693246|OTHER|normal saline|At 10 minutes after endotracheal intubation, the Control group was intravenously injected with equal dose of normal saline.
214289678|NCT01550640|DRUG|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
214289679|NCT01096524|OTHER|Standard Physiotherapy|The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
214474664|NCT05226871|DRUG|Palbociclib|oral
214474665|NCT05226871|DRUG|Cetuximab|Intravenous (IV) infusion
214474666|NCT05226871|DRUG|Fulvestrant|Intramuscular (IM)
214474667|NCT05226871|DRUG|Letrozole|oral
214474668|NCT02871167|PROCEDURE|Controlled ovarian hyperstimulation (COH)|"After information and consent, patients are addressed to a reproductive medicine center.~The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation."
214657368|NCT01365221|DRUG|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
214474669|NCT02871167|PROCEDURE|Oocyte/embryo freezing|Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes. Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min. 10 years).
214474670|NCT03995394|OTHER|Positive Reinforcement Text Message|"A text message comprising the words, Great job! We're so proud of you! Keep up the good work!"
214474671|NCT06822296|OTHER|Physical Therapy|Exercises to improve function of children with CP
214474672|NCT06822296|OTHER|Designed rehabilitation program|Program of exercises to enhance function
214474673|NCT04916626|BEHAVIORAL|OPUS YOUNG|OPUS YOUNG is a two year out-patient specialized early intervention service for children and adolescents with a first episode psychosis. The OPUS YOUNG treatment consists of the following elements: modified assertive community treatment, low patients to case manager ratio, cognitive-behavioural case management (CBCM), psycho-educational family treatment including multiple family groups(MFG) and psychoeducational siblings groups, Social Cognition and Interaction Training (SCIT), possible individual Cognitive Behavioural Therapy (CBT) in addition to CBCM, and manual based psychopharmacologic treatment. Additional, special transition support, individual school/employment support, and prevention and treatment of substance abuse.
214474674|NCT04916626|BEHAVIORAL|Treatment as Usual|The patients allocated to TAU will be offered non-manualized treatment following national Danish guidelines and local guidelines. Treatment is provided by a multidisciplinary team and consists of case-management (no defined upper case load), family support and psychoeducation, in addition to psychopharmacological treatment. In some cases, social skills training and CBT may be offered. In general, office visits take place in outpatient clinics.
214847616|NCT00685490|PROCEDURE|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
214847617|NCT03629613|DIETARY_SUPPLEMENT|Oral antioxidant cocktail|"Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
214847618|NCT03629613|OTHER|Baseline|No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
214847619|NCT02784678|PROCEDURE|closed reduction group|Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.
214847620|NCT02784678|DEVICE|open reduction group|Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
214474675|NCT05112302|OTHER|Virtual reality|Use of virtual reality goggles during procedure
214847621|NCT05122767|DRUG|Dolutegravir|"Groups 1a/1b: Participants will take the FDA-approved weight-based DTG once daily + either TDF/FTC, TDF/3TC, ABC/3TC or AZT/3TC x 4 weeks. During HP treatment and for two weeks afterward, DTG dose will be increased to twice daily.~Participants will continue with the NRTI regimen they have previously tolerated, except where their age and weight allow them to transition from either AZT or ABC to TDF, as per South African National ART Guidelines. HLA-B\*5701 screening will therefore not be performed, as children will be currently taking and tolerating an ABC-containing regimen at enrolment. If any clinically suspected hypersensitivity reaction to ABC is suspected by history, ABC will not be continued.~Groups 2a/2b: Participants will take weight-based DTG dosing twice or once daily, depending on the results of the modelled data for the Group 1a (for Group 2a) and/or Group 1b (for Group 2b) participants in the interim analysis."
214847622|NCT05122767|DRUG|3HP|3HP Dosing is by Age and Weight Children 2-15 years of age: 10-15kg (P 300mg, H 300mg); 16-23kg (P 450mg, H 500mg); 24-30kg (P 600mg, H 600mg); 31-34kg (P 750mg, H 700mg). Children 15-17 years, \>=30kg (P 900mg, H 900mg)
214847623|NCT04911465|DEVICE|Flashback CRI T1 Tablet|Collect continuous data on the compensatory reserve index, a measurement of a patient's central volume status.
214847624|NCT03039348|OTHER|semi-structured interview using a questionnaire|semi-structured interview using a questionnaire
214847625|NCT04153448|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
214847626|NCT04681196|OTHER|patients shifted to nasal mask after persistent OSA with oronasal mask|In this group were selected OSA patients exhibiting persistent obstructive events and paradoxical obstruction with oronasal masks during CPAP , that were fully recovered (no more OSA detected) with the shift to nasal one
214847627|NCT01364324|DRUG|standard first line anti-TB drugs|We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
214847628|NCT04569513|BIOLOGICAL|Thyroid and parathyroid disease|To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.
214847629|NCT00474435|DRUG|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):~* emtricitabine 200 mg~* tenofovir DF 300 mg~* efavirenz 600 mg"
214847630|NCT05983666|DIAGNOSTIC_TEST|Ultrasound Oesophageal Intubation|Ultrasound Oesophageal intubation detection
214847631|NCT04813016|DRUG|Tramal 1|Early intraperitoneal injection of tramal and bupivacaine
214847632|NCT04813016|DRUG|Tramal 2|Late intraperitoneal injection of tramal and bupivacaine
214847633|NCT04813016|DRUG|Dexmedetomidine 1|Early intraperitoneal injection of dexmedetomidine and bupivacaine
214847634|NCT04813016|DRUG|dexmedetomidine 2|Late intraperitoneal injection of dexmedetomedine and bupivacaine
214474676|NCT06274632|BEHAVIORAL|ADELANTE|A manualized problem-solving intervention that addresses barriers to viral suppression in Latinos with HIV. At the patient-level, CHWs use motivational interviewing to facilitate problem-solving skill development around attending HIV care and adherence and establish an individually tailored goal-setting plan. We target emotional well-being and self-management through a rapport with CHW and the integration of an HIV-centered telenovela to facilitate participant reflection on difficult topics for skill-building. The CHW will also link the participant to needed services.
214474677|NCT01820611|DEVICE|Arcos Revision Stem System|Revision Hip System
214474678|NCT02642471|PROCEDURE|no systematic pelvic lymphadenectomy|systematic pelvic lymphadenectomy is omitted in surgical treatment
214474679|NCT06000046|DEVICE|Automatic image analysis|After referral for suspected prostate cancer, the patient is scanned with magnetic resonance imaging (MRI) in accordance with guidelines of the standardized healthcare pathway. For consenting patients, the images are interpreted in two ways: first, in the conventional manner, i.e., manually by a radiologist, to determine whether clinically significant cancer is suspected. If so, the radiologist will delineate the suspicious lesions. In the second approach, the software will perform the same task as the radiologist, but automatically. If either or both interpretations point to significant cancer, the patient will be sent for targeted biopsy sampling. Histopathologic evaluation of the samples will then determine whether significant cancer is present in each of the targeted lesions (delineated by the radiologist, software, or both).
214474680|NCT04271956|BIOLOGICAL|Tislelizumab|Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg
214474681|NCT04271956|DRUG|Zanubrutinib|Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
214474682|NCT04271956|DRUG|Sonrotoclax|"Cycle 1: Sonrotoclax Start Ramp-up to 320 mg QD po Days 1-2 Sonrotoclax 2 mg (2 tabl. at 1mg) Days 3-4 Sonrotoclax 5 mg (1 tabl. at 5mg) Days 5-6 Sonrotoclax 10 mg (2 tabl. at 5mg) Days 7-8 Sonrotoclax 20 mg (1 tabl. at 20mg) Days 9-10 Sonrotoclax 40 mg (2 tabl. at 20mg) Days 11-12 Sonrotoclax 80 mg (1 tabl. at 80mg) Days 13-14 Sonrotoclax 160 mg (2 tabl. at 80mg) Days 15-16 Sonrotoclax 320 mg (4 tabl. at 80mg)~Cycle 2-6: Day 1-21 Sonrotoclax 320 mg QD po"
214474683|NCT03977233|DRUG|Oxaliplatin|85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
214474684|NCT03977233|DRUG|Leucovorin|400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
214474685|NCT03977233|DRUG|Irinotecan Hydrochloride|180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
214474686|NCT03977233|DRUG|5-FU|400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
214474687|NCT05541276|DRUG|Melatonin|Melatonin for injection 1 mg/mL
214474688|NCT05541276|DRUG|Isotonic sodium chloride solution|Sodium chloride 0.9 % for injection
214474689|NCT04833907|DRUG|rAAV-Olig001-ASPA|Intracerebroventricular administration of a single dose
214474690|NCT04833907|DRUG|Levetiracetam|Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
214474691|NCT04833907|DRUG|Prednisone|Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.
214474692|NCT05736458|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
214474693|NCT05736458|PROCEDURE|High controllability TMS target|Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
214474694|NCT06513520|BIOLOGICAL|Blood sampling|Additional blood tube collection during routine blood sampling.
214474695|NCT06620198|DEVICE|Armeo® Power 2 Exoskeleton - Active Rehabilitation with Feedback and Exercise Gaming|Patients will undergo 20 session of 45 minutes each with an exoskeleton for upper limb rehabilitation. The assistance provided by the device is adjusted based on the maximum force (as a percentage of the upper limb's weight) the robot needs to exert to assist the patient's movements. Each session will include exercises designed to improve the range of motion (ROM) of the shoulder, elbow, wrist, and enhance hand coordination. The training parameters, such as difficulty level, duration, and visual stimuli, will be adjusted based on the patient's residual abilities. The selected exercises may involve movements of a single joint along one axis, combined movements of a single joint around 2 or 3 axes, selective exercises for the opening and closing hand, or multi-joint exercises. All exercises will be realized with audiovisual feedback.
214474696|NCT06620198|DEVICE|Armeo® Power 2 Exoskeleton - Passive Mobilization without Feedback|Patients will undergo 20 session of 45 minute of a neurorehabilitation intervention with a SHAM treatment under the guidance of the experimental therapist. This will involve passive mobilization using the exoskeleton for the upper limb, without any audiovisual feedback. They will not realize any active movement during the training.
214474697|NCT02990338|DRUG|Isatuximab|Pharmaceutical form: solution for infusion Route of administration: intravenous
214847635|NCT01610609|BEHAVIORAL|Population Health Management Intervention|"This intervention includes:~* Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~* Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention"
214474698|NCT02990338|DRUG|Pomalidomide|Pharmaceutical form: capsule Route of administration: oral
214474699|NCT02990338|DRUG|Dexamethasone|Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
214474700|NCT06195553|BEHAVIORAL|STEPPS plus Family Connections|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients and dialectical and behavior treatment using Family Connections for the families. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Main components Family Connections: psychoeducation, skills training and peer support.
214847636|NCT00602134|DRUG|6-Mercaptopurine|
214847637|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
214474701|NCT06195553|BEHAVIORAL|STEPPS|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Waiting list group: Participant's relatives of this group will be able to receive the Family Connections intervention after the research end.
214474702|NCT00971087|DEVICE|Hologic Selenia Dimensions Digital Breast Tomosynthesis System|Subjects are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects undergoing a biopsy procedure will be imaged on the investigational device prior to their procedure.
214474703|NCT04479761|BEHAVIORAL|Visual and Auditory Cues|Within each scene there will be 2 levels of visual input (static or dynamic) combined with 3 levels of sounds (static, none or dynamic). Postural responses to each combination will be evaluated in order to assess the role of generated and natural sounds in postural control and whether static sounds can improve balance within dynamic virtual environments.
214474704|NCT06186817|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
214474705|NCT06186817|PROCEDURE|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
214474706|NCT06186817|BEHAVIORAL|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
214474707|NCT06186817|PROCEDURE|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
214474708|NCT03552471|OTHER|Laboratory Biomarker Analysis|Correlative studies
214474709|NCT03552471|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
214474710|NCT03552471|OTHER|Pharmacokinetic Study|Correlative studies
214474711|NCT03552471|DRUG|Rucaparib Camsylate|Given PO
214474712|NCT04186819|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
214474713|NCT04186819|DIAGNOSTIC_TEST|Positron Emission Tomography scan|imaging test with radioligand
214474714|NCT06476483|BEHAVIORAL|DIALOG+|A person-centred and solution-focused intervention linked to the DIALOG outcome measure (a measure of patient experience and quality of life).
214474715|NCT06476483|BEHAVIORAL|DIALOG|An outcome measure consisting of 11 questions, with 8 related to quality of life and 3 items on treatment satisfaction. Patients can rate their satisfaction on a 7-point scale for each of the 8 life domains and 3 treatment aspects, resulting in scores for both quality of life and treatment satisfaction. The DIALOG scale does not provide any guidance for patient and clinician interactions.
214474716|NCT04357093|OTHER|Grape seed extract mouthwash|Mouthwash 15% grape seed extract
214474717|NCT04357093|OTHER|Sodium fluoride mouthwash|Sodium fluoride mouthwash
214474718|NCT05728463|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
214474719|NCT02832505|OTHER|No intervention but only observational|This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
214474720|NCT04291560|BEHAVIORAL|Stretching Exercise Intervention|Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
214474721|NCT06105203|PROCEDURE|Robotic-assisted total mesorectal excision|TME will be performed with the assistance of robot in rectal cancer
214474722|NCT06105203|PROCEDURE|laparoscopic-assisted total mesorectal excision|TME will be performed with the assistance of laparoscopy in rectal cancer
214474723|NCT05825170|DEVICE|FASY L|Subjects will receive FASY L in lips at level of their scar.
214474724|NCT05249114|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
214474725|NCT05249114|DRUG|Lu-177|Currently, the only FDA-approved PRRT consists of dotatate, a somatostatin analogue, radiolabeled with Lutetium-177 (Lu177), a beta-minus emitter (brand name Lutathera). Lu177 induces cell death via DNA strand breaks, caspase-3 apoptosis, and interfering with DNA-PK expression (which is associated with DNA repair). PRRT with Lu-177 DOTATATE is a targeted, intravenous therapy inducing DNA damage by delivering ionizing radiation to somatostatin receptor positive tumors.
214474726|NCT04011644|BEHAVIORAL|A-CHESS self-monitored|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a research team member. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
214474727|NCT04011644|BEHAVIORAL|A-CHESS peer-supported|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a counselor. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
214474728|NCT04011644|BEHAVIORAL|A-CHESS clinically-integrated|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a health coach. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
214474729|NCT06197503|PROCEDURE|Conduction system pacing|Left bundle branch pacing or His bundle branch pacing
214474730|NCT06197503|PROCEDURE|Right ventricular pacing|Conventional pacing
214474731|NCT06809634|OTHER|Large Language Model|The intervention in the experimental group is distinguished by the integration of a Large Language Model (LLM)-based interactive platform (ChatGPT) into clinical reasoning training for physical therapy students. Unlike traditional educational approaches, this intervention provides real-time, AI-generated patient interactions, allowing students to actively engage in virtual clinical case simulations.
214474732|NCT06809634|OTHER|Conventional|The intervention in the control group follows a traditional case-based learning approach, which is commonly used in physical therapy education. Unlike the experimental group, this training method relies solely on human-led instruction and written case analysis, without the integration of artificial intelligence or interactive digital tools.
214474733|NCT06809855|DRUG|Dexamethasone|single 8mg post-operative intramuscular injection
214474734|NCT05757726|DEVICE|Velocity pAVF system|A second generation percutaneous AVF device that creates an AVF between the proximal radial artery and cubital perforating vein.
214474735|NCT06808698|OTHER|Determine the gut microbiome at baseline and 12 months.|There is no separate treatment, surgery, or other intervention.
214474736|NCT06804161|DRUG|SGLT2|10 mg
214474737|NCT06804161|DRUG|Placebo|1 tablet
214474738|NCT05215405|DRUG|Venetoclax|"Venetoclax will be administered orally once daily (QD), continuously. Each dose of venetoclax should be taken with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast.~* Day 1 (200 mg equivalent):~  * Patients 20 \< 30 kg will take 70 mg~ * Patients 30 \< 35 kg will take120 mg~ * Patients 35 to 45 kg will take 200 mg~* Day 2 onwards (400 mg equivalent):~  * Patients 20 \< 30 kg will take 170 mg~ * Patients 30 \< 35 kg will take 250 mg~ * Patients 35 to 45 kg will take 400 mg"
214474739|NCT05215405|DRUG|Navitoclax|"Navitoclax will be administered orally once daily, starting on day 3 of cycle 1 and then may start on day 1 for subsequent cycles. Navitoclax should be taken at the same time each day approximately 24 hours apart. Dosing will be based on the recommended phase II dosing as per the phase I data and subsequent dose recommendations.~* Patients 20 \< 45 kg will take 25 mg~* Patients 45 kg or more will take 50 mg"
214474740|NCT06809205|DRUG|Tamsulosin 0.4 mg|administered tamsulosin 0.4 mg
214474741|NCT06809205|DRUG|Tadalafil 5mg|administered tadalafil 5 mg
214474742|NCT06809205|DRUG|Tamsulosin and Tadalafil|administered tamsulosin 0.4 mg plus tadalafil 5 mg
214474743|NCT06804889|DEVICE|CANNEFF® VAG SUP vaginal suppositories|CANNEFF® VAG SUP vaginal suppositories containing 100 mg cannabidiol - CBD and 6.6 mg hyaluronic acid - HA.
214474744|NCT06804889|DEVICE|Placebo Suppositories|Received placebo vaginal suppositories with identical composition as for Active Comparator, but without both active ingredients (CBD - cannabidiol and HA - hyaluronic acid).
214289680|NCT01096524|DEVICE|Kneehab|"NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.~Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes."
214474745|NCT06805344|PROCEDURE|Extracorporeal cardiopulmonary resuscitation based approach|ECPR-based approach is defined as ACLS per current guidelines with aim to proceed to in-hospital or out-of-hospital V-A ECMO if ROSC is not achieved before the cannulation.
214474746|NCT06805344|PROCEDURE|Conventional cardiopulmonary resuscitation|CCPR is defined as conventional ACLS per current guidelines without MCS use until sustained ROSC is achieved or the patient pronounced dead.
214474747|NCT06806189|DRUG|Lipiodal|Injection of lipiodal for delineation of interface between the removed mouth/throat cancer and the healthy tissue reconstructing the defect for radiation planning.
214474748|NCT06805604|PROCEDURE|Each group was received monolithic ceramic crowns fabricated using different technique|-Different digital techniques used for fabrication of the monolithic ceramic crowns were chosen for the current study, Clinical performance of all crowns regarding; marginal adaptation, fracture of restoration during service, color stability and wear behavior will be evaluated according to Modified United States Public Health Service (USPHS) Criteria at base line (1 week), 3 and 6 months after cementation of crowns.
214474749|NCT06081829|DRUG|Ivosidenib|Subjects will take 2 tablets (500 mg total) orally once daily.
214474750|NCT06809816|DRUG|Sodium pentaborate pentahydrate|Sodium pentaborate pentahydrate will be administered orally in capsule form, following the standard protocol outlined in the study design.
214474751|NCT06810024|COMBINATION_PRODUCT|Home-based therapy|"The home-based intervention includes the following modules:~1. Management of Stroke Recurrence Risk Factors: Home-based monitoring and management of blood pressure, blood sugar, cholesterol, and medication adherence.~2. Functional Rehabilitation and Daily Living Skills: Home-based physical therapy, rehabilitation exercises, and recovery of daily living skills.~3. Psychological Health and Emotional Management: Home-based counseling and mental health support to address anxiety, depression, and stress.~4. Nutritional and Lifestyle Interventions: At-home guidance on healthy eating, lifestyle changes, and behavior modification to reduce stroke recurrence.~5. Risk and Complication Prevention: Home monitoring to prevent infections and other complications during recovery.~6. Caregiver Empowerment: Home-based caregiver training and support to improve caregiving skills and reduce caregiver stress."
214474752|NCT06810024|OTHER|Standard Care (in control arm)|"The standard care intervention involves:~Outpatient Visits: Routine follow-up visits to healthcare providers for stroke recovery monitoring, medication management, and adjustments.~Inpatient Rehabilitation: Physical, occupational, and speech therapy delivered in hospital or rehabilitation centers, if required.~Follow-up Appointments: Regular visits with stroke specialists and rehabilitation professionals for ongoing care."
214474753|NCT06809946|DRUG|injection with 15 mg bevacizumab-800CW before bronchoscopy|Patients will receive an intravenous administration of 15 mg bevacizumab-800CW before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.
214474754|NCT06809946|DRUG|injection with 25 mg bevacizumab-800CW before bronchoscopy|Patients will receive an intravenous administration of 15 mg bevacizumab-800CW before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.
214474755|NCT06809335|OTHER|Personalized circadian mHealth|SHIFT is a mobile application designed to improve sleep in night shift workers. The SHIFT mobile application is used to collect data from an Apple Watch to assess an individual shift worker's body-clock timing and make personalized recommendations of light exposure schedules that are designed to align the body-clock with the night shift work schedule.
214474756|NCT06809504|BEHAVIORAL|Exercise based intervention|"12 sessions over 4 weeks, 45-minute sessions divided into:~o 15 minutes for physical exercises"
214474757|NCT06810596|PROCEDURE|Insulin infusion protocol|comparing the efficacy of 2 different protocols for glycemic control in diabetic critically ill patients.
214474758|NCT05726721|OTHER|Treatment as usual, Psychotherapy|The three treament sites will offer psychotherapy as usual. All including elements of cognitive behavioral therapy and some sites also additional elements from either narrative therapy or interpersonal therapy
214474759|NCT01585623|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
214474760|NCT01585623|DRUG|omeprazol|"Pharmaceutical form:capsule~Route of administration: oral"
214474761|NCT01585623|DRUG|metoprolol|"Pharmaceutical form:tablet~Route of administration: oral"
214474762|NCT01585623|DRUG|midazolam|"Pharmaceutical form:solution~Route of administration: oral"
214474763|NCT03663361|OTHER|SMART Intervention|Ankle rehabilitation with the addition of sensorimotor components
214474764|NCT03663361|OTHER|Standard of Care Intervention|Ankle rehabilitation focused on restoring range of motion, strength and balance
214474765|NCT05265065|BIOLOGICAL|Tozinameran - Standard Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose."
214474766|NCT05265065|BIOLOGICAL|Tozinameran - Fractional Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose."
214474767|NCT05844150|DRUG|PM8002|IV infusion
214474768|NCT05844150|DRUG|Platinum|IV infusion
214474769|NCT05844150|DRUG|Etoposide|IV infusion
214474770|NCT06616467|BEHAVIORAL|Tummy Time for the prevention of childhood obesity|"A cognitive-behavioral intervention aimed at mothers of infants is presented that aims to increase the practice of TT and maintain a healthy weight in the infant, called \&#34;Tummy Time for the prevention of childhood obesity\&#34;, within the intervention modifiable variables are involved that directly impact the expected results such as: the knowledge and beliefs of the mothers, infant temperament, parental self-efficacy and self-efficacy for the practice of TT.~The intervention lasts 12 weeks from the first contact with the participants and consists of eight sessions broken down as follows: the first session is presented in a face-to-face format with expository, audiovisual and demonstrative means; sessions two, four, five and seven are provided through a text message with use WhatsApp® and the use of visual media. Sessions three, six and eight are delivered via telephone call with the aim of offering feedback on the doubts generated up to that point."
214474771|NCT06124014|DEVICE|At-Home Stimulation|The stimulation paradigm in this trial consists of six weeks of daily, 60-minute at-home stimulation sessions.
214474772|NCT03252288|BEHAVIORAL|Reminders|Text of phone-call based reminders to mobile phones
214474773|NCT03252288|BEHAVIORAL|Conditional financial transfers|Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs \>1 week but within 4 weeks of the scheduled visit
214474774|NCT06641336|DEVICE|RehAtt|Each patient received the RehAtt intervention.
214474775|NCT04860635|DRUG|F14 (sustained release celecoxib)|Celecoxib in BEPO® drug delivery system
214474776|NCT04574583|DRUG|SX-682|SX-682 will be given orally at designated dose twice a day every day
214474777|NCT04574583|DRUG|M7824|Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.
214474778|NCT04574583|BIOLOGICAL|MVA-BN-CV301|MVA-BN-CV301 will be given as four subcutaneous injections (4x10\^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)
214289681|NCT02288559|OTHER|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
214474779|NCT04574583|BIOLOGICAL|recombinant fowlpox viral (FPV)-CV301|FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).
214474780|NCT03309332|DEVICE|AMPLATZER™ PFO Occluder|Implantation of the AMPLATZER™ PFO Occluder in the PFO
214474781|NCT06841107|OTHER|Training was provided on spinal health.|Bus drivers were told about the practices they could do during and outside of work hours, and were asked to comply with these practices every day for 3 months.
214474782|NCT06841107|OTHER|Training on spinal health was provided and lumbar region support was applied for 3 months.|Bus drivers were told about the practices they could do during and outside of work hours, and were asked to comply with these practices every day for 3 months. In addition, lumbar region support was used every day during working hours for 3 months.
214474783|NCT05013411|OTHER|Qualitative study|Individual interviews and focus groups will be conducted to explore current strengthens and barriers in obtaining patient observations. Views on use of technology in assisting with patient observations will also be discussed and documented.
214474784|NCT02630121|DRUG|Oxymetazoline Hydrochloride|Proportion of the subjects with 50% reduction in AHI.
214289682|NCT02288559|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
214474785|NCT02630121|DRUG|Placebo|Proportion of the subjects with 50% reduction in AHI.
214474786|NCT05900154|BIOLOGICAL|RSVpreF 120 µg|RSVpreF standard dose level
214474787|NCT05900154|BIOLOGICAL|RSVpreF 60 µg|RSVpreF low dose level
214474788|NCT06257290|BIOLOGICAL|blood sample|at Day 1 - date of patient inclusion at time of VTE diagnosis
214474789|NCT06257290|BIOLOGICAL|blood sample|at 6 months (in the patient follow-up)
214474790|NCT06853574|DRUG|Fluid therapy|Infusion of 8 ml/Kg/30' or 16 ml/kg/60' of fluids.
214474791|NCT06853574|DRUG|Noradrenaline infusion|dosage will be titrated in order to obtain mean arterial pressure target
214474792|NCT06024993|DEVICE|Flow-controlled ventilation (FCV)|20 minutes of FCV, delivered with the CE-marked Evone ventilator (Ventinova medical, the Netherlands)
214474793|NCT06024993|DEVICE|Conventional volume-controlled ventilation (VCV)|20 minutes of conventional VCV, delivered with the CE-marked Aisys CS3 (GE Healthcare, USA) or Flow-i (Getinge, Sweden) ventilators.
214474794|NCT05904730|DRUG|Axitinib|The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)
214474795|NCT06855238|DEVICE|THAITI software|"THAITI is an AI-based software which predicts on the fly personalised TI for late gadolinium enhancement imaging during cardiovascular magnetic resonance scans.~The clinical investigators will be provided by the computer scientists investigators with a software, based on the developed AI model. During the CMR in the experimental group, investigators will input patients' data on the software (e.g. age, sex, dose of contrast…). The software will provide a TI value to be input in the MRI scanner. TI will be set accordingly to the AI prediction. A LGE series of 3 long axis (4-, 2- and 3-chambers view) and a short-axis stack will be acquired.~For all the patients, a doctor expert in CMR will be at the scanner and quality check the images in real time. Every image where the myocardium is not optimally nulled will be repeated with a TI set by the CMR doctor."
214474796|NCT06855095|DRUG|Somatostatin analog|Timing of LA-SSA injection prior to PRRT (either 4-6 weeks or 1-7 days).
214474797|NCT06813040|DEVICE|Active rTMS|Repetitive TMS will be applied at 10Hz on the motor cortex. The protocol consists of 2000 pulses per session and an intensity of 90% of the resting motor threshold. There will be 10 sessions with a minimum interval of 24 hours and a maximum of 72 hours. A figure-8 coil will be used.
214474798|NCT06813040|DEVICE|Sham rTMS|The sham TMS will have the same visual and sound characteristics, but without the passage of the magnetic field to the scalp.
214474799|NCT06811064|OTHER|Testimony video|A testimonial video on the experiences of parents of premature babies during the transfer of their newborn from the intensive care unit to the neonatal unit. This video will be performed with the collaboration of the carers and resource parents.
214474800|NCT06852586|DEVICE|conventional nanohybrid composites|Incremental layering technique is used for restoration
214474801|NCT06852586|DEVICE|Bulk fill composites|Single increment in bulk form is applied for restoration
214474802|NCT04142632|PROCEDURE|clinical and paraclinical examination|Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
214474803|NCT06660888|BEHAVIORAL|• Fatigue Severity Scale (FFS). • Hamilton Rating Scale for Depression (HRSD-17). • Hamilton Anxiety Rating Scale (HAM-A).|"1. Fatigue Severity Scale The FSS is one of the most commonly used fatigue questionnaires in chronic diseases. It measures how fatigue affects motivation, exercise, physical functioning, carrying out duties, work, family, or social life.~2. Hamilton Depression Rating Scale The 17-item Hamilton Depression Rating Scale (HRSD-17) is the most popular depression measure in antidepressant clinical trials.~3. Hamilton Anxiety Rating Scale The HAM-A was one of the first rating scales developed to measure the severity of anxiety symptoms."
214474804|NCT06815146|DIAGNOSTIC_TEST|Numeretic rating scale (NRS)|NRS is a pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
214474805|NCT06815146|DIAGNOSTIC_TEST|Quality of Results (QoR-40)|Several rating scales have been developed to measure quality of recovery after surgery and anaesthesia, but the most extensively used is the QoR-40, a 40-item questionnaire that provides a global score and subscores across five dimensions: patient support, comfort, emotions, physical independence, and pain.
214474806|NCT06815146|OTHER|Opioid consuption|Opioid consuption will be recorded from PCA
214474807|NCT06431867|OTHER|Guidelines for primary care management of osteoporosis|All usual care of osteoporosis in primary care
214474808|NCT05163041|DRUG|BT7480|Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
214474809|NCT05163041|DRUG|Nivolumab|Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
214474810|NCT03434769|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
214474811|NCT03434769|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
214474812|NCT03434769|BIOLOGICAL|CAR-T Cells|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
214474813|NCT05755087|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214474814|NCT05755087|PROCEDURE|Computed Tomography|Undergo CT
214847638|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
214474815|NCT05755087|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214474816|NCT05755087|DRUG|Tegavivint|Given IV
214474817|NCT06526221|DIAGNOSTIC_TEST|Urine isoniazid testing (IsoScreen test)|Developed by Arkansas' Public Health Service in the 1970s, this test detects metabolites of isoniazid, a drug present in drug-susceptible TB regimens. IsoScreen (GFC Diagnostics, UK) is a commercial version of the Arkansas method with reagents enclosed in a plastic vial, into which 2mL of urine can be injected with a syringe. If the urine contains isoniazid, reagents turn purple/blue (suggesting a dose was taken in the last 24 hours or appropriate adherence) or green (suggesting a dose was taken 24-48 hours before or one missed dose). A yellow result (no color change) suggests medication has not been taken for \>48 hours (two or more missed doses).
214474818|NCT06816641|PROCEDURE|Surgical Evacuation of Intracerebral Hemorrhage|Surgical Evacuation of Intracerebral Hemorrhage
214847639|NCT03642522|DEVICE|repetitive transcranial magnetic stimulation|rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
214474819|NCT04181736|DRUG|Guanfacine Tablets|Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth and will be compounded by a pharmacy to the required doses used in this study.
214474820|NCT06818773|DRUG|Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor|A 21-day cycle is used, with the initial dose of inetuximab at 8 mg/kg (IV), followed by 6 mg/kg (IV) on Day 1 of each subsequent cycle. Gemcitabine (1000 mg/m²) + cisplatin (25 mg/m²) are administered in combination on Day 1 and Day 8 of each cycle. The appropriate PD-1/PD-L1 inhibitor will be selected by the investigator based on the patient's specific condition, and its administration will strictly follow the dosing instructions provided in the relevant drug's package insert.
214474821|NCT06817070|DIAGNOSTIC_TEST|Food Consumption survey|A comprehensive survey was created using Google Forms® to collect sociodemographic, clinical, anthropometric, dietary data, and physical activity information from participants across most Mexican states. All self-administered surveys began with informed consent and were distributed via instant messaging (WhatsApp), social networks (Facebook, Twitter), and email using a snowball sampling method. Sociodemographic data included age, gender, and residence, while anthropometric data covered weight, height, and physical activity. Food intake was assessed using a 48-item semi-quantitative tool based on the National Health and Nutrition Survey 2021, with participants reporting the frequency and quantity of food consumed on a Likert scale. Responses were converted to daily consumption values and caloric intake using the Mexican System of Foods and Equivalents. Foods and beverages were categorized into twelve groups: six healthy (fruits, vegetables, legumes, natural dairy, white meat, nuts, and
214474822|NCT06675227|DIETARY_SUPPLEMENT|electrolyte beverages|Using Electrolyte Beverages as replacement for water to dissolve PEG(2L plan) in bowel preparation process.
214474823|NCT06817083|PROCEDURE|E-C Clamp Technique|"The E-C clamp technique involves forming a C with the thumb and index finger around the mask while the remaining fingers form an E to lift the mandible. This technique aims to provide a good seal while opening the airway."
214474824|NCT06817083|PROCEDURE|T-E Technique|"The T-E technique is a variation where the thumb and index finger form a T over the mask while the other fingers provide chin lift and jaw thrust.~This method is designed to optimize airway patency and mask seal. While these techniques are widely taught and practiced, they often fall short in obese patients due to the difficulty in maintaining an adequate seal and achieving sufficient ventilation pressures. Complications such as hypoxemia and gastric insufflation are more common in this population."
214474825|NCT06817083|PROCEDURE|The Hook Technique|e is a novel method for single-hand ventilation that has shown promise in preliminary studies. This technique involves a unique hand positioning that aims to improve mask seal and ventilation efficacy, particularly in patients with challenging airway anatomy. In Hook Technique using the thumb and index finger to form a hook around the mask, creating a more secure and adjustable seal and utilizing the remaining fingers to apply consistent mandibular lift, enhancing airway patency.
214474826|NCT06819761|DIETARY_SUPPLEMENT|Salivarius SALI-10|Lozenge with 10B CFU (Colony Forming Units)
214474827|NCT04861740|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
214474828|NCT04861740|OTHER|Screening Intervention|Autism screening intervention only.
214474829|NCT06657586|OTHER|neuromuscular exercises|The exercise was applied in 18 sessions of 6 weeks.The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
214474830|NCT06657586|OTHER|conservative treatment|The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
214474831|NCT05666193|DEVICE|CBCT Imaging|Subjects are scheduled for two imaging sessions on the Ethos system with the HyperSight CBCT. One session is on the same day as the CT simulation scan for treatment planning. The second session is on the same day as the delivery of ther 21st treatment fraction. If the subject is sent for a mid-treatment FBCT for re-planning, a third HyperSight CBCT imaging session will be scheduled on the same day as the mid-treatment FBCT.
214474832|NCT05759039|PROCEDURE|Medial patellofemoral ligament reconstruction|Medial patellofemoral ligament reconstruction
214474833|NCT05759039|PROCEDURE|Tibial tubercle osteotomy|Tibial tubercle osteotomy
214474834|NCT06855602|DRUG|Chinese herbal medicine formula (S-2196)|During the 2-week intervention, all participants are required to take 150ml of S-2196 decoction (a Chinese herbal medicine formula containing four herbs) twice per day
214474835|NCT06857799|PROCEDURE|Light Power Density and Light Duration 40 mW/cm²*1000s|Use light power density and light duration 40 mW/cm²\*1000s treatment
214474836|NCT06857799|PROCEDURE|Light Power Density and Light Duration 80 mW/cm²*1000s|Use light power density and light duration 80 mW/cm²\*1000s treatment
214474837|NCT06856083|BEHAVIORAL|Gamified Virtual Reality Sports Exercise Program|"Participants in the experimental group will participate in a variety of sports exercises designed in a virtual reality environment utilizing gamification elements to enhance engagement. The intervention will include:~* Structured virtual reality sports sessions guided by specially trained facilitators.~* Use of gamified features such as rewards, points, and friendly competition to stimulate motivation.~* Incorporation of social elements where participants can interact with each other during sessions to foster community and support."
214474838|NCT06856083|BEHAVIORAL|Traditional Sports Exercise Program for Elderly Individuals with Suicidal Thoughts|"participants will engage in a traditional sports exercise program aimed at elderly individuals experiencing suicidal thoughts. The intervention consists of structured physical activity sessions that include a variety of low-impact sports and exercises designed for older adults. These activities will be conducted in a supportive group setting to foster social interaction and community engagement.~The sessions will be led by experienced facilitators who specialize in elderly fitness and mental health. Each session will last approximately 60 minutes and will include a warm-up, the main exercise component, and a cooldown period to promote physical well-being and relaxation. Participants will be encouraged to engage at their own pace, ensuring that individual capabilities and comfort levels are respected."
214474839|NCT06857812|OTHER|there is no intervention|there is no intervention
214847640|NCT00757549|BIOLOGICAL|cetuximab|
214847641|NCT00757549|DRUG|cisplatin|
214474840|NCT06856200|DRUG|Sirolimus (albumin - bound)|Sirolimus (albumin - bound): Dose escalation, intravenous infusion
214474841|NCT06856200|DRUG|Palbociclib|Palbociclib: the dosage is 125 mg, orally once a day. taken continuously for three weeks followed by a one - week break, with a treatment cycle of four weeks
214474842|NCT06856200|DRUG|Fulvestrant|Fulvestrant: the dosage is 500 mg, intramuscular injection. It is given on the 1st and 15th days of the first cycle, with a treatment cycle of four weeks. After that, it is administered once every four weeks.
214474843|NCT06291896|DEVICE|MammoWave|"Women undergoing conventional breast screening examination will be asked by the clinical staff if they are interested in taking part in the study.~A short visit should be performed to check the inclusion/exclusion criteria, review demographic data, and the volunteer's medical history. After performing this visit, the volunteers will perform the MammoWave exam on both their breasts.~The exam will be composed of two phases: data acquisition and data processing. During the acquisition, which should take about 8 minutes, the volunteers would be lying down in a prone position, on the bed which is part of MammoWave.~When the acquisition is completed, the data will be processed through a dedicated microwave imaging algorithm. The output will be composed of microwave images, plus parameters describing the images. MammoWave output will also comprise a label obtained using an optimized classification algorithm."
214474844|NCT06856928|OTHER|Meal Challenge|The meal challenge scheduled for 4-6 days after the patient's last injection. The study team will insert an indwelling venous catheter into the participant's forearm for serial blood draws. Immediately prior to the meal, participants will consume 1500 mg of acetaminophen (off-label) to facilitate the analysis of gastric emptying. The participant will then begin the meal challenge by eating the test meal, a breakfast casserole, containing 33% of their current resting energy expenditure needs estimated by Mifflin-ST Jeor equation with a composition of 50% carbohydrate, 30% fat and 20% protein. Participants must completely consume the test meal within 25 minutes of initiating the meal. Participants will fill out behavioral questionnaires after consuming the test meal. After the 2-hour blood draw period, participants will be dismissed. Blood will be drawn prior to the meal and at 5, 10, 15, 30, 60, 90, and 120 minutes after initiating the meal.
214474845|NCT06856447|DRUG|Coenzyme Q10|"100 mg once daily starting after the first chemotherapy cycle. Patients will receive 12 cycles of the modified FOLFOX-6 regimen with Coenzyme Q10 (100 mg once daily in the morning), starting after the first chemotherapy cycle and continuing until the end of the 12th cycle. Based on McRae (2023), 200 mg/day for 12 weeks reduced TNF-α and IL-6; thus, 100 mg/day for 6 months was selected (one cycle every 2 weeks = 24 weeks).~Supportive care: Includes a 5-HT3 antagonist for nausea prevention and pantoprazole to prevent gastric irritation.~Intervention Details:~Oxaliplatin: Part of the FOLFOX-6 regimen. 5-Fluorouracil (5-FU): Part of the FOLFOX-6 regimen. Leucovorin: Part of the FOLFOX-6 regimen. 5-HT3 Antagonist: Used for nausea prevention. Pantoprazole: Used to prevent gastric irritation."
214474846|NCT06856447|DRUG|Oxaliplatin|Part of the modified FOLFOX-6 chemotherapy regimen
214474847|NCT06856447|DRUG|5-Fluorouracil (5-FU)|Part of the modified FOLFOX-6 chemotherapy regimen.
214474848|NCT06856447|DRUG|5-HT3 Antagonist|Used for nausea prevention during chemotherapy.
214474849|NCT06856447|DRUG|Pantoprazole|Used to prevent gastric irritation during chemotherapy
214474850|NCT06855797|OTHER|Observation|questionnaire
214474851|NCT06661304|OTHER|Benson Relaxation Exercise|Benson relaxation exercise is based on the patient relaxing their body muscles by focusing on deep breathing and a word that means something to them.
214474852|NCT06661304|OTHER|Ongoing treatment|In addition to their medical treatment and care in the clinics, patients participate in activities such as group activities, leisure time and walking.
214474853|NCT06660056|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progressive Gliomas of the Brain|Use of Ommaya capsules
214657369|NCT01622426|DIETARY_SUPPLEMENT|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
214657370|NCT01622426|DIETARY_SUPPLEMENT|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
214657371|NCT05809934|DRUG|AZD2693|AZD2693 solution SC once per month
214474857|NCT06657989|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
214474858|NCT06657989|BEHAVIORAL|Walking|Overground walking
214474859|NCT06218056|DRUG|Cannabidiol (CBD) 800 mg|CBD (400 mg) will be administered orally twice daily in the morning and again in the evening in 4 capsules each containing 100 mg of the active ingredient in the Ananda investigational new drug, ATL5. ATL5 is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
214474860|NCT06218056|DRUG|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. 4 softgel capsules of placebo will be administered to match the capsule number of the active compound, daily in the morning and evening for each of 56 days.
214474861|NCT04710355|DEVICE|Spinal cord stimulation|Adhesion of Intellis spinal cord stimulator to the skin of the abdomen for 4 weeks for baseline recording of activity level prior to trial with spinal cord stimulation.
214474862|NCT02245867|DRUG|Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4|The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
214474863|NCT06825052|BEHAVIORAL|Resistance Training with Deloading Periods|Participants performed an 8-week unilateral resistance training program in which training volume and intensity were reduced during weeks 4 and 8 to facilitate recovery and adaptation.
214474864|NCT06825052|BEHAVIORAL|Continuous Resistance Training|Participants followed an 8-week unilateral resistance training program without any deloading periods. Training volume and intensity remained consistent throughout the study.
214474865|NCT06824142|OTHER|Evaluate in real-life conditions the effectiveness of an adapted external aid as a tool to support temporal orientation rehabilitation for individuals with Alzheimer's disease or related dementias in|Unlike other interventions, the E3D tool combines an intuitive, user-friendly interface with real-time temporal cues, offering a personalized experience designed to improve cognitive engagement. This external aid is aimed at fostering independence and improving daily functioning by providing clear and consistent information on time-related aspects, such as season, month, day of the week, and current date.
214474866|NCT06550726|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Subjects will undergo MRI scanning in our 3T machine with dedicated high resolution sequences (including 2D T1-weighted inversion recovery sequences, 3D FLAIR MRI whole brain, 3D T1-weighted Sagittal MPRAGE; plus other sequences for the clinical purpose of pre-operative planning as per consensus with referring doctor)
214474867|NCT06825533|DIAGNOSTIC_TEST|Fasting blood sugar level|Assess the level of Blood sugar level in fasting conditions at inclusion
214474868|NCT06825533|DIAGNOSTIC_TEST|Glycated hemoglobin|Assess the level of glycated hemoglobin at inclusion
214847642|NCT00757549|GENETIC|TdT-mediated dUTP nick end labeling assay|
214474869|NCT06825793|DRUG|Semaglutide Subcutaneous Injection|All subjects received subcutaneous injections of semaglutide over a 28-week treatment period, which included an initial 16-week dose-escalation phase. The escalation protocol began with a starting dose of 0.25 mg administered once weekly. Every 4 weeks, the dose was gradually increased in a stepwise manner to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each administered once weekly.
214474871|NCT04170855|DRUG|Furosemide Injection|"We will measure kidney sodium content in patient with cardiorenal syndrome. we will inject within the week of this first measurement furosemide only in patient who will be resistant to diuretics (Based on these parameters, diuretic response will be defined as:~* A reduction in fractional spot urinary sodium~* An increase in urinary volume~* A \>1 kg reduction in body weight within 24 hours from diuretic administration (extrapolation of guidance on management of acute HF) and we will do another measurement of kidney sodium content after furosemide injection."
214474872|NCT05080283|DEVICE|CP1110 Sound Processor System with automated ForwardFocus On (SCAN 2 FF)|Sound Processor
214474873|NCT05080283|DEVICE|Nucleus 7 Sound Processor (model: CP1000) system|Sound Processor
214474874|NCT05080283|DEVICE|CP1110 Sound Processor System with ForwardFocus Off (SCAN 2)|Sound Processor
214474875|NCT04334343|OTHER|Additional Muscle Biopsy Collection|Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
214474876|NCT06822127|OTHER|CT scan|6 months postop CT scan
214474877|NCT06822127|OTHER|VLASTIC test|Measurement of the elasticity of the facial integument using the VLASTIC cutometer (Volume-based Light Aspiration device for in vivo Soft Tissue Characterization)
214474878|NCT04689360|DRUG|elamipretide|Elamipretide is an aromatic-cationic tetrapeptide that readily penetrates cell membranes and transiently localizes to the inner mitochondrial membrane.
214474879|NCT04094610|DRUG|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
214474880|NCT05385575|DRUG|KN056 (0.1mg)|The participants will receive assigned single dose of KN056 on Day 1
214474881|NCT05385575|DRUG|KN056 (0.3mg)|The participants will receive assigned single dose of KN056 on Day 1
214474882|NCT05385575|DRUG|KN056 (1.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
214474883|NCT05385575|DRUG|KN056 (3.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
214474884|NCT05385575|DRUG|KN056 (6.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
214289683|NCT03294057|BEHAVIORAL|Tele-coaching programs|Tele-coaching program conducted 12 times (one time for one week), and more than 20 minutes each by a trained nurse. Coaching content specifically, 1) evaluation, 2) facing and accepting the health crisis, 3) setting up new goals, 4) making decisions and plans, and 5) practice.
214289684|NCT03294057|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)
214289685|NCT03294057|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
214289686|NCT00054314|DRUG|ortataxel|
214289687|NCT03927664|OTHER|Radiological assessment|Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
214289688|NCT04597827|OTHER|Metacognition tests|Test on episodic or semantic memory
214289689|NCT05098925|OTHER|Biological testing|Blood sampling, microcapillary sampling, temperature monitoring, saliva testing, EHI questionnaire
214289690|NCT04728581|DRUG|Mirtazapine|Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.
214474885|NCT05385575|DRUG|KN056 (12.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
214474886|NCT05385575|DRUG|KN056 (18.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
214657372|NCT05809934|OTHER|Placebo|Sodium chloride 0.9% solution SC once per month
214847643|NCT00757549|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
214847644|NCT00757549|OTHER|immunohistochemistry staining method|
214847645|NCT00757549|OTHER|laboratory biomarker analysis|
214847646|NCT00757549|RADIATION|fludeoxyglucose F 18|
214847647|NCT00757549|RADIATION|radiation therapy|
214847648|NCT02872350|DEVICE|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
214847649|NCT00035321|DRUG|Olanzapine|
214847650|NCT00035321|DRUG|Fluoxetine|
214847651|NCT04397289|DRUG|Heparin and Rivaroxaban|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
214474887|NCT06589362|DEVICE|Transcutaneous auricular vagus active nerve stimulation|In the active stimulation, two electrodes are placed in the cymba conchae of one of the ears, an area thought to be exclusively innervated by the auricular branch of the vagus nerve.
214474888|NCT06589362|DEVICE|Transcutaneous auricular vagus sham nerve stimulation|In the sham stimulation, the electrodes are placed on the tail of helix, which is free of vagal innervation.
214474889|NCT06600360|OTHER|Teledentistry|Measuring the accuracy of the mobile photographic method of teledentistry for diagnosis and treatment need in dental caries detection
214474890|NCT05714579|PROCEDURE|Transcatheter Aortic Valve Implantation|"The TAVI procedure is performed transfemorally under local anesthesia most often, or more rarely under general anesthesia via the subclavian or transaortic route. Identification is carried out under fluoroscopy in the cardiac catheterization room. The crossing of the aortic valve allows the establishment of a guide at the bottom of the left ventricle. Aortic valve predilation can be performed. The tightness of the device is checked by an aortography. Sometimes, post-dilation of the implanted bioprosthesis proves necessary, particularly in the event of under-deployment or significant para-prosthetic leakage.~The duration of the intervention is approximately 1 hour."
214474891|NCT06139978|BEHAVIORAL|ultrasound observation|The relationship between the anteroposterior diameter of the CM and the gestational age and gender
214474892|NCT06825845|DRUG|Zevorcabtagene Autoleucel|Non-intervention
214474893|NCT05371132|PROCEDURE|Positron Emission Tomography|Undergo PET
214474894|NCT05371132|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214474895|NCT05371132|DRUG|Zirconium Zr 89-Df-Crefmirlimab|Given IV
214474896|NCT05371132|RADIATION|Intensity Modulated Radiation Therapy|IMRT for Lymphoma patients only
214474897|NCT04758533|BIOLOGICAL|AloCELYVIR|Mesenchymal allogenic cells + ICOVIR-5: 500.000 cells/kg
214474898|NCT05220631|BEHAVIORAL|Technology intervention|Older Adult Technology Services (OATS) 5-week technology intervention
214474899|NCT05220631|BEHAVIORAL|Digital Nutrition Intervention|15-week nutrition intervention delivered completely online
214474900|NCT05312645|DRUG|Diclofenac 1% Topical|2 grams topically four times daily for 2 weeks to posterior cervical spine
214474901|NCT05312645|OTHER|Petroleum Jelly|2 grams topically four times daily for 2 weeks to posterior cervical spine
214474902|NCT06681441|DRUG|QRL-101 Dose A|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
214474903|NCT06681441|DRUG|QRL-101 Dose B|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
214289691|NCT04728581|DRUG|Quetiapine|Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.
214289692|NCT04728581|DRUG|Placebo|a gelatinous capsule without an active ingredient
214289693|NCT03629067|DRUG|Treatment T|Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
214289694|NCT03629067|DRUG|Treatment R|Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
214289695|NCT01971411|DRUG|Calcium 500mg with 200 IU Vitamin D - 2 tablets daily|
214474904|NCT06681441|DRUG|Placebo|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
214474905|NCT04627922|DRUG|N-Acetyl cysteine|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers with current tobacco use disorder and cannabis use will be randomized to receive NAC 3600 mg per day over 8 weeks.
214474906|NCT04627922|OTHER|Placebo comparator|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers and cannabis users with current tobacco use disorder will be randomized to receive placebo per day over 8 weeks.
214474907|NCT04627922|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants in both groups will receive 8 weekly cognitive behavioral therapy sessions for substance use disorder targeting both tobacco and cannabis use.
214474908|NCT04046094|DRUG|Ascorbic Acid|Ascorbic Acid Intravenous
214474909|NCT06852300|DEVICE|Concussion Assessment Battery|"The conclusion test battery will comprise five assessment designed to evaluate sport-related concussion:~1. Health Questionnaire - Including as assessment of signs and symptoms.~2. Sport Concussion Assessment Tool (SCAT)~3. Vestibular Ocular Motor Screening (VOMS)~4. Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT)~5. Postural stability assessment (NeuroCom VSR Sport).~Functional Neuroimaging Functional Near-Infrared Spectroscopy (fNIRS) is a non-invasive neuroimaging technology that measures brain activity by detecting changes in blood oxygenation. The NIRSIT scanner will be employed at each testing session to assess cognitive function using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and postural stability using the NeuroCom VSR Sport system."
214474910|NCT02865538|DRUG|BAY3427080|
214474911|NCT02865538|DRUG|Placebo (for BAY3427080)|
214474912|NCT04440592|DRUG|MT-7117|MT-7117
214474913|NCT04440592|DRUG|Placebo|Placebo
214474914|NCT02622438|OTHER|Followed with an initial assessment, 12 months and followed annually corresponding to the usual follow-up of the patient.|
214474915|NCT06847750|DIAGNOSTIC_TEST|Elastography Ultrasound|The US imaging protocol will include three parts: (i) gray-scale; (ii) color Doppler, and (iii) Shear-wave elastography (SWE)
214474916|NCT06847750|OTHER|The Localized Scleroderma Quality of Life Instrument (LoSQI )|The questionnaire is a validated disease-specific patient-reported outcome measure that covers different domains (skin sensations, physical functioning, body image and social support, designed for children and adolescents with localized scleroderma
214474917|NCT05975268|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005/placebo
214474918|NCT02818829|OTHER|Collection of biological samples|Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas
214474919|NCT06804473|PROCEDURE|Exercise|The exercise intensity will range from 60-75% of their maximum heart rate (HRmax), with each session lasting 28 minutes, three times per week. The exercise protocol will involve interval aerobic training consisting of four intervals
214474920|NCT06851923|OTHER|3Tesla magnetic resonance imaging of the healthy human visual system|The present project presents a series of monocentric MRI studies carried out on healthy adult human volunteers. All neuroimaging will be performed at the Cliniques Universitaires Saint-Luc (CUSL, IRM de recherche). Participants will not directly benefit from their participation. All studies will manipulate the visual properties of the experimental stimuli in a within-subject way, and therefore do not rely on any participation group assignation/randomization method. The duration of studies will vary between 3h to 6h, i.e., from 2 to 4x1h30 3Tesla magnetic resonance imaging sessions depending on the experimental design.
214474921|NCT06348316|OTHER|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
214474922|NCT06348316|OTHER|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
214474923|NCT05979337|BEHAVIORAL|Empowered Relief|"This is a single-session (2-hour) behavioral intervention utilizing pain psychology principles (cognitive-behavioral therapy for pain, pain neuroscience education).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
214474924|NCT05979337|BEHAVIORAL|Health Education (HE)|"This is a single-session (2-hour) health education class reviewing principles of medically indicated self-management of migraine headaches (e.g., consistent dietary and hydration habits, exercise, understanding of and adherence to medical treatment regimens).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
214474925|NCT05979337|BEHAVIORAL|Treatment as Usual|"Participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life. In addition, participants will complete daily diaries for 28 days.~If participants are interested in attending classes that were not part of this group assignment, participants will be invited to do so after completing the 6-month follow-up questionnaire."
214474926|NCT05784714|BEHAVIORAL|NOLA GEM|This is a mobile application that has 6 psychoeducational sessions and related skills, local resources, and a way for participants to track their progress. Further information is in the arm descriptions.
214474927|NCT06804746|PROCEDURE|DHOPE-COR-NMP|Resuscitation and viability assessment through the previously published protocol of sequential hypo- and normothermic liver machine perfusion with controlled oxygenated rewarming (DHOPE-COR-NMP) based on a blood-based perfusate.
214474928|NCT06560216|DIETARY_SUPPLEMENT|Apigenin|0.2 mM in freezing medium
214474929|NCT03106740|DRUG|Minocycline Hydrochloride 100mg Capsule|Minocycline 100mg will be administered by mouth daily for 2 weeks
214474930|NCT03106740|DIAGNOSTIC_TEST|Magnetic Resonance-Positron Emission Tomography Imaging|Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
214474931|NCT03106740|OTHER|Placebo Capsule|1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
214474932|NCT04112381|DEVICE|Exablate Model 4000 Type 1.0/1.1|Exablate thalamotomy of non tremor dominant side of the brain
214474933|NCT05970809|DEVICE|SAGA-001 (A)|Use of a novel microneedle and laser device as a treatment for male patten hair loss with additional microwounding.
214474934|NCT05970809|DEVICE|SAGA-001 (B)|Use of a novel microneedle and laser device as a treatment for male patten hair loss without additional microwounding.
214474935|NCT05532566|OTHER|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
214474936|NCT02055833|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
214474937|NCT02055833|OTHER|Nutritional counseling|Nutritional counseling
214474938|NCT04565990|DRUG|Selexipag|Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily.
214657373|NCT03900195|OTHER|BottlePEP|Positive expiratory device with a bottle
214657374|NCT05726370|DRUG|Pembrolizumab|Immunoglobulin G4 monoclonal antibody, via IV infusion
214657375|NCT05726370|DRUG|CISPLATIN|Platinum agent, via IV infusion
214289696|NCT01971411|PROCEDURE|Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH|
214289697|NCT01971411|BEHAVIORAL|Usual sun exposure documentation|
214289698|NCT01971411|BEHAVIORAL|Dietary intake of calcium, vitamin D, magnesium|
214289699|NCT03231865|DIAGNOSTIC_TEST|Non-invasive measurement of ZincProtoporphyrin IX|Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
214474939|NCT05151302|DIAGNOSTIC_TEST|computer vision symptom scale (CVSS) questionnaire|Subjects working at VDT for \>20 hours a week and accessing to the Eye Clinic in order to complete an ocular examination and subjects working at the Foundation accessing to the Eye Clinic in order to complete an ocular status evaluation according to Italian Law 81/08 will be asked to self-complete the questionnaire in presence of the attending junior ophthalmologists prior to the visit with the Ophthalmologist, to avoid interference with visit results (communication of bad/good news)
214474940|NCT04797858|BEHAVIORAL|COVID-19 self-test|5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19. Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.
214474941|NCT04797858|BEHAVIORAL|COVID-19 test referral|5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19. These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites. Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.
214474942|NCT05334992|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Individual therapy 12 to 16 weeks
214474943|NCT05334992|BEHAVIORAL|Behavior Activation|Individual therapy 12 to 16 weeks
214474944|NCT02065726|DIETARY_SUPPLEMENT|Whey protein|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
214474945|NCT02065726|OTHER|Nutritional counseling|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
214474946|NCT05910268|BEHAVIORAL|NIATx + ECHO|Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
214474947|NCT06965049|OTHER|Probiotic|Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery
214474948|NCT06965049|OTHER|Placebo|Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery
214474949|NCT06965608|BEHAVIORAL|WhatsApp-Based Cancer Prevention Messaging|Participants in this group will receive a structured series of WhatsApp messages containing evidence-based cancer prevention recommendations from the Latin America and Caribbean Code Against Cancer (LAC Code). Messages will be delivered over four weeks, 3 times a week, covering key topics such as smoking cessation, healthy diet, physical activity, and regular screening. Engagement metrics will be tracked to assess feasibility and adherence.
214474950|NCT06965608|BEHAVIORAL|Online Cancer Prevention Workshop for Healthcare Professionals|Healthcare professionals assigned to this group will participate in an online workshop designed to improve their knowledge of the LAC Code and communication strategies for cancer prevention counseling. The workshop includes recorded lectures, interactive modules, and knowledge assessments. Completion rates and participant satisfaction will be measured.
214474951|NCT06965608|BEHAVIORAL|Combined WhatsApp Messaging and Online Workshop|Participants in this group will receive both interventions: WhatsApp messages with cancer prevention recommendations and access to the online workshop. The intervention aims to assess whether a combined approach enhances adherence and impact. Engagement with both interventions will be monitored.
214474952|NCT06965855|PROCEDURE|conventional surgery|This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with conventional surgery
214474953|NCT06965855|PROCEDURE|piezoelectric surgery|Description: This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with piezoelectric surgery
214474954|NCT05789225|BEHAVIORAL|Fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program is group-based with 8 participants in each group, led by a facilitator, and performed online. It comprises seven two-hour sessions held once a week, and a booster session held four weeks after the seventh session. In addition participants will receive a brochure about falls and fall risk factors.
214474955|NCT05789225|OTHER|Brochure|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
214474956|NCT05766670|DRUG|Vancomycin Hydrochloride|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
214474957|NCT05766670|DRUG|Gentamicin|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
214474958|NCT05766670|OTHER|Standard Intramedullary Nail|Standard Intramedullary Nail
214474959|NCT01961986|PROCEDURE|TSR - traditional subscapularis release|Total Shoulder Replacement surgery performed using the traditional subscapularis release approach.
214474960|NCT01961986|PROCEDURE|TSR - rotator cuff sparing|Total Shoulder Replacement surgery performed using the rotator cuff sparing approach.
214474961|NCT06514807|DRUG|Ropeginterferon alfa-2b (BESREMi®)|Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.
214657376|NCT05726370|DRUG|Carboplatin|Platinum agent, via IV infusion
214657377|NCT05726370|DRUG|Docetaxel|Antineoplastic agent, via IV infusion.
214847652|NCT02084368|PROCEDURE|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
214657378|NCT02271490|OTHER|Acrosome Reaction induction|
214657379|NCT02271490|OTHER|capacitation in incubation medium prior to ICSI|
214847653|NCT02084368|PROCEDURE|Combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8\~10mg at L2-3 or L3-4.
214847654|NCT02084368|DRUG|Ropivacaine|Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
214289700|NCT02187250|DRUG|metformin|
214289701|NCT02187250|DRUG|liraglutide|
214289702|NCT02187250|DRUG|roflumilast|
214847655|NCT02084368|DRUG|Bupivacaine|Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8\~10mg.
214474962|NCT03229057|DRUG|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
214474963|NCT03229057|DRUG|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
214474964|NCT03229057|DRUG|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
214474965|NCT05460780|DEVICE|MATTISSE TEC|Tissue engineering chamber MATTISSE
214474966|NCT04842682|BIOLOGICAL|Solo 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
214474967|NCT04842682|BIOLOGICAL|Solo 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
214474968|NCT04842682|BIOLOGICAL|Solo 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
214474969|NCT04842682|BIOLOGICAL|Combi 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
214847656|NCT04863157|BEHAVIORAL|Survivor-SHIP|Parent/guardian education about healthy sleep practices to improve their child's sleep health.
214847657|NCT02037282|DRUG|Anti-influenza IVIG|
214847658|NCT04239482|DIETARY_SUPPLEMENT|L-arginine + Nitrate / Nitrite|Longer-term supplementation (8 weeks)
214474970|NCT04842682|BIOLOGICAL|Combi 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
214474971|NCT04842682|BIOLOGICAL|Combi 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
214474972|NCT04842682|BIOLOGICAL|Late boost CD40 alone|CD40.HIVRI.Env at 0.3 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
214474973|NCT04842682|BIOLOGICAL|Late boost CD40 adjuvanted|CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
214474974|NCT05423730|OTHER|White Wine|One serving (5 ounces) of white wine daily for 3 weeks
214474975|NCT05423730|OTHER|Grape Juice|One serving (6 ounces) of white grape juice daily for 3 weeks
214474976|NCT05101837|DEVICE|Home program|Regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality
214657380|NCT04746521|DIAGNOSTIC_TEST|Multitest 6 color TBNK and BD Lyotubes|The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells
214847659|NCT04239482|DIETARY_SUPPLEMENT|Placebo|Longer-term supplementation (8 weeks)
214847660|NCT03478865|DRUG|Vitamin A palmitate|Provide vitamin A to participants with pre/post assessments of vision.
214847661|NCT01470417|DRUG|Chemotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
214847662|NCT01470417|DRUG|Chemotherapy + ChemoRadiotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
214847663|NCT02310516|DEVICE|preoperative adequate explanations about awake surgery|
214847664|NCT02310516|OTHER|no preoperative explanation|
214847665|NCT05453786|DRUG|SID1903|Single oral administration of SID1903 after an overnight fast
214847666|NCT05453786|DRUG|SID1903-R1/SID1903-R2|Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
214847667|NCT02418455|DRUG|UX003|solution for intravenous infusion
214847668|NCT05927779|DRUG|TFX06 tablet|TFX06 tablet taken orally
214847669|NCT02539784|DEVICE|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
214847670|NCT02721706|OTHER|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h \<50%, serum albumin \<3 g/dl, body mass index \<18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
214847671|NCT00270933|DEVICE|Registry|
214474977|NCT04170634|OTHER|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
214847672|NCT06037278|DEVICE|MyPAO|use of MyPAO surgical guide to support periacetabular osteotomy procedures for treatment of acetabular dysplasia
214847673|NCT03966391|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
214847674|NCT00975962|DRUG|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
214847675|NCT00975962|PROCEDURE|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
214474978|NCT06578455|DRUG|Cannabidiol (CBD) Powder|66.68 mg CBD per capsule for a total of 400 mg CBD per serving
214474979|NCT06578455|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|100 mg CBD/mL for a total of 400 mg CBD per serving
214474980|NCT06804343|BEHAVIORAL|first aid training|A pre-test will be applied to the participants in a single group before the training. After the training is applied, a post-test will be done and a follow-up will be done at the end of 6 months and a post-test will be applied.
214474981|NCT06805955|OTHER|NDT|"The neurodevelopmental therapy program aimed to reduce muscle tone, improve hand functions, enhance fine motor skills, and support daily living activities such as eating and personal care.~Specific exercises included:~Finger and wrist flexion/extension, Shoulder and elbow stretching and mobilization, PNF exercises, Functional tasks like screw and nut manipulation, Velcro tasks, door handle turning, button pressing, zipper pulling, and laundry peg placement/removal."
214474982|NCT06805955|OTHER|NDT+Hand Robot|"In this group, participants received 25 minutes of hand robot-assisted therapy following neurodevelopmental treatment. After the robot therapy, they performed fine motor skill exercises, including:~Picking up buttons from one container and placing them in another, Opening a loosely closed jar lid using the robot, Stacking checkers pieces on a table, Flipping over and placing cards back on the table, Transferring weighted cubes from one table to another at a different height. These activities aimed to improve fine motor coordination and hand functionality."
214474983|NCT06804434|DRUG|Lidocaine Intravenous Infusion|intravenous lidocaine 10 mg/ml continuous infusion
214474984|NCT06804434|DEVICE|NOL|Intraoperative Nociception Level index monitoring and guided analgesia
214474985|NCT06805513|COMBINATION_PRODUCT|Tadalafil 5 mg tablets with a digital tool.|The combination product will be a Drug (Tadalafil 5 mg) and Health Survey Assessment (as a mandatory digital tool). Tadalafil 5 mg will be taken orally, 1 tablet daily to use for treatment of erectile dysfunction. This study will be conducted remotely, via video interaction.
214474986|NCT06804733|BEHAVIORAL|12-week individualized aerobic exercise training|After enrollment, subjects directly participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level measured by International Physical Activity Questionnaire (IPAQ), with the exercise intensity being increased every four weeks.
214474987|NCT06804733|BEHAVIORAL|12-week control intervention followed by 12-week aerobic exercise training|After enrollment, subjects first undergo a 12-week control intervention (i.e., routine treatment) and then participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level IPAQ, with the exercise intensity being increased every four weeks.
214847676|NCT04415684|DEVICE|Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
214847677|NCT04415684|DEVICE|No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
214474988|NCT06533423|BEHAVIORAL|Newly diagnosed with Inflammatory arthritis - a Self-MAnagement intervention (NISMA)|The NISMA intervention is a flexible intervention and comprises three mandatory individual sessions with a nurse, supplemented by two optional group sessions over a period of 12 months, to provide comprehensive support tailored to each participant's needs. The intervention is grounded in the theoretical framework Social Cognitive Theory and inspired by the questioning techniques in Acceptance and Commitment Therapy (ACT). These methods play a crucial role in helping participants enhance their self-efficacy. The key components of our approach include: a person-centered approach by addressing challenges identified by each participant to foster self-efficacy through targeted problem-solving and goal-setting. This is utilized by interviewing techniques derived from ACT to assist participants in accepting and committing to self-management. The program is designed to last between 6-12 months, allowing for gradual skill development and adaptation.
214474989|NCT00085930|BIOLOGICAL|EBV specific CTLs|CTLs: 2x10e7 cells/m2
214847678|NCT02973321|DRUG|SAR425899|Self-administered by SC injection using a solution for injection in cartridge.
214847679|NCT02973321|DRUG|Placebo|Self-administered by SC injection using a solution for injection in cartridge.
214847680|NCT02973321|DRUG|Liraglutide|Self-administered by SC injection using a pre-filled pen.
214847681|NCT02973321|DRUG|Metformin|Orally administered at a stable dose , \>=1500 mg daily stable dose or maximal tolerated dose.
214847682|NCT01189526|DRUG|Ranibizumab|Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
214847683|NCT01189526|PROCEDURE|macular laser photocoagulation|Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
214474990|NCT03989141|PROCEDURE|Repeated cannulation Buttonhole.|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
214474991|NCT03989141|PROCEDURE|Single cannulation Buttonhole.|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
214474992|NCT00560651|PROCEDURE|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
214474993|NCT06804525|DIAGNOSTIC_TEST|CIDI-5|The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10) . Trained interviewers will administrate selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes.
214474994|NCT06804525|DIAGNOSTIC_TEST|LHC-CIDI-5|The interviewer will start by asking the respondent's age and significant personal experiences, which is expected to take 15 minutes. Remembering and recording the experiences provide cognitive engagement and information which can further serve as memory cues for respondents in the following screening of CIDI-5. Subsequently, the respondents will proceed to the screening section for CIDI-5 and will refer to the completed calendar from the LHC section when they are asked to report lifetime experience or age-of-onset for mental disorders. Trained interviewers will conduct all interviews in a computer-assisted personal interview. To validate the diagnoses in the LHC-CIDI-5 group, clinical re-interviews for MDD, GAD, and PTSD will be conducted by a trained mental health professional with previous experience using DSM-5.
214474995|NCT06805760|OTHER|variable tidal volume ventilation (V-VCV)|The initial tidal volume was set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW).The maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) were set at 10-20% of the basal tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiratory to Expiratory Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5cm water column, and Inhaled Oxygen Concentration (FiO2) 41%.
214474996|NCT06805760|OTHER|pressure-regulated volume-controlled ventilation (PRVC)|The initial tidal volume was set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW), the upper limit of peak inspiratory pressure was 30 cmH2O, the maximum tidal volume (Vt\_max) and the minimum tidal volume (Vt\_min) was set at 10-20% of the base tidal volume (Vt\_base). Respiratory Rate is 12, Inspiration to Expiration Ratio is 1:2, Positive End-Expiratory Pressure (PEEP) is 5cmH2O, and Inhaled Oxygen Concentration (FiO2) is 98%.
214474997|NCT06805760|OTHER|conventional volume-controlled ventilation (C-VCV)|The initial tidal volume was set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW).The maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) were set at 10-20% of the basal tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiratory to Expiratory Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5cm water column, and Inhaled Oxygen Concentration (FiO2) 98%.
214474998|NCT06805760|OTHER|pressure-controlled ventilation (PCV)|The inspiratory pressure level is set, usually with an initial value of 20 cmH2O, a respiratory rate of 12, an inspiratory/expiratory ratio of 1:2, a positive end-expiratory pressure (PEEP) of 5 cm water column, and an inspired oxygen concentration (FiO2) of 98%.
214657381|NCT04746521|BIOLOGICAL|genomicDNA extraction|Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood \& Tissue kit (QIAGEN), according to manufacturer protocols
214847684|NCT04000191|PROCEDURE|MAC|Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
214847685|NCT04000191|OTHER|Perianal ice application|Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
214847686|NCT04685694|DRUG|Misoprostol|sl 800 mcg misoprostol
214847687|NCT02057536|OTHER|Arm A Directed exercise program|
214847688|NCT02057536|OTHER|Observation|
214847689|NCT03785769|PROCEDURE|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by washing and drying the cavity with cotton balls; and fill with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
214847690|NCT03785769|PROCEDURE|HVGIC restoration with non pre-etching|Restoration with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
214847691|NCT01514825|DRUG|YM150|oral
214847692|NCT01514825|DRUG|Placebo|oral
214847693|NCT05871086|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 soft gelatin capsules daily for 3 months
214847694|NCT05871086|OTHER|Placebo|Placebo Capsules
214847695|NCT05871086|DRUG|Standard Regimen|"Patients may be receiving any of these commonly used JIA treatments including:~* Ibuprofen - 30 to 40 mg/kg/day in 3 to 4 divided doses~* Diclofenac - 2 to 3 mg/kg/day in divided doses 2 to 3 times daily~* Methotrexate - Initial: 10 to 15 mg/m2 once weekly; adjust gradually up to 20 to 30 mg/m2 once weekly~* Leflunomide - Weight based, 10-20 mg once daily~* Sulfasalazine - 30 to 50 mg/kg/day in 2 divided doses~* Etanercept - 0.8 mg/kg/dose once weekly~* Adalimumab - Weight based, 10-40 mg every other week"
214847696|NCT00149149|OTHER|Zinc Carnosine coadministered with Indomethacin|
214847697|NCT00149149|OTHER|Placebo coadministered with Indomethacin|
214847698|NCT02066337|PROCEDURE|scaling and root planing|
214847699|NCT02066337|DRUG|placebo gel|
214847700|NCT02066337|DRUG|Ozonated olive oil gel|
214847701|NCT02827890|DRUG|Januvia Tab. 100mg|Januvia Tab. 100mg\*1T/day for 5days, QD, PO
214847702|NCT02827890|DRUG|Januvia Tab. 100mg + Duvie Tab. 0.5mg|Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO
214847703|NCT02407171|DRUG|MK-3475|200 mg every 2 weeks by IV infusion
214474999|NCT06804954|BEHAVIORAL|Online transdiagnostic CBT|This treatment is provided through a secure web platform in which psychoeducation, worksheets, and exercises are presented in online modules similar to chapters in a book. Participants will receive weekly written feedback on their work and progress by a therapist who gives gradual access to the treatment modules. The lion's share of the contact between the therapist and the patient thus takes place through messages (similar to email) in the online treatment platform. It is however allowed to also have one to three face-to-face sessions on-site or through video calls to provide technical assistance and therapeutic support in accordance with the treatment model. Core components are: (a) psychoeducation about emotions and CBT, (b) functional analysis, (c) mindfulness practice, (d) breaking dysfunctional emotion-driven behaviors, and (e) exposure exercises.
214475000|NCT06804954|OTHER|Primary care as usual|It is mandatory for primary care services in Stockholm, Sweden, to have staff with adequate competence in the assessment and treatment of common mental disorders. Typically, these patients are handled by general practitioners, psychologists, nurses, or social workers. As this comparator is intended to reflect real routine primary care, the interventions will not be controlled by the research project. We expect that participants allocated to this condition will receive an active treatment.
214475001|NCT01989013|OTHER|biweekly intervention|10 step craniosacral therapy protocol through manual therapy at feet , thoracic diaphragm, neck and cranium
214475002|NCT05818358|DIETARY_SUPPLEMENT|black beans|¾ cup of cooked black beans
214475003|NCT05818358|DIETARY_SUPPLEMENT|wheat berries|¾ cup of cooked whole wheat grain
214475004|NCT05818358|DIETARY_SUPPLEMENT|white rice|¾ cup of cooked white rice
214475005|NCT06561893|DIETARY_SUPPLEMENT|Broccoli sprouts extract supplementation|Intake of broccoli sprouts extract supplement (Brand: Source Naturals, Scotts Valley, CA 95066 - USA) in an acute dose (84 umol of glucoraphanin) before and after 2 weeks of probiotic or placebo supplementation, to assess sulforaphane bioavailability measured in urine metabolites
214475006|NCT01130519|DRUG|Bevacizumab|Commercially available. Administered by intravenous infusion.
214475007|NCT01130519|DRUG|Erlotinib|Commercially available. Administered orally.
214847704|NCT02407171|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
214475008|NCT05624489|BEHAVIORAL|Engagement Strategies|The study's mobile app (Oralytics) will be used to deliver engagement prompts. The prompts contain messages that leverage three engagement strategies: reciprocity, reciprocity by proxy, and curiosity.
214847705|NCT01934738|DRUG|PF-06273340|Tablets, 100 mg TID, 14 days
214847706|NCT01934738|DRUG|Placebo|Tablets, TID, 14 days
214847707|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
214289703|NCT03303079|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
214289704|NCT03303079|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
214289705|NCT03303079|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
214289706|NCT02005445|DEVICE|CPAP|Continuous positive airway pressure
214289707|NCT02005445|BEHAVIORAL|HLSE|Healthy living and sleep education
214475009|NCT05363163|DEVICE|Gana X|Injection in the deep dermis and subcutaneous layer of the buttocks on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
214475010|NCT04484740|DRUG|Gepotidacin|Single oral dose of 1500 mg gepotidacin
214475011|NCT06852950|DEVICE|Libre 3 Plus Continuous Glucose Monitor|Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
214475012|NCT06852950|DEVICE|Dexcom G7 Continuous Glucose Monitor|Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
214475013|NCT06572423|PROCEDURE|Personalized ultrafractionated stereotactic adaptive radiotherapy|PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment.
214475014|NCT06572423|RADIATION|Volume Modulated Arc Therapy|Use HyperArc technology
214475015|NCT06572423|PROCEDURE|Computed Tomography|Undergo CT simulation for radiation planning
214475016|NCT06572423|PROCEDURE|Positron Emission Tomography|Undergo PET
214475017|NCT06572423|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214475018|NCT06572423|OTHER|Best Practice|Undergo standard of care
214475019|NCT06572423|BEHAVIORAL|University of Washington Quality of Life Scale, Version 4|Complete questionnaire
214475020|NCT06572423|BEHAVIORAL|Functional Assessment of Cancer Therapy-Head & Neck|Complete questionnaire
214847708|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
214847709|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
214847710|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
214847711|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
214847712|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
214847713|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
214847714|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
214847715|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
214847716|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
214847717|NCT05460221|DIETARY_SUPPLEMENT|Optimized oil group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
214475021|NCT05676905|DEVICE|Neocement|Bone graft substitutes
214475022|NCT03904979|OTHER|Writing exercises|Participants will be given journals with writing prompts to be completed throughout their pregnancy.
214475023|NCT06574802|PROCEDURE|ERL + air polishing|Er:YAG laser (ERL) plus sub-gingival air polishing treatment
214475024|NCT06574802|PROCEDURE|ERL|ERL treatment
214475025|NCT06572566|OTHER|Non-invasive examination and assessment.|1\) Test the blood and urine components of all subjects to evaluate the damage to kidney function caused by excessive cadmium. 2) Conduct MRI examinations on all subjects to evaluate changes in brain functional connectivity, metabolism, and structure after excessive cadmium exposure. 3) Conduct bone density examinations on all subjects to evaluate changes in bone density after excessive cadmium exposure. (3) Clinical psychiatric assessment: All subjects will be assessed on their mental and psychological conditions such as pain, cognitive function, depression, anxiety, mania, sleep quality, and suicide risk.
214475026|NCT06207513|PROCEDURE|Suction Circuit Flushing with Chlorhexidine|Patient intubated with an endotracheal tube and on a mechanical ventilator will receive endotracheal suctioning procedure using an open endotracheal suction catheter that is used multiple times during a 12-hour nursing shift. Flushing of the suctioning circuit will be performed with 40 ml of chlorhexidine gluconate 0.2% after every endotracheal suction procedure
214475027|NCT06573203|DEVICE|Non-contact heart rate and respiratory rate monitoring system|Each neonate enrolled underwent four sleep and vital signs monitoring procedures after admission.
214475028|NCT06573203|DEVICE|Mindray ECG monitor|Heart rate and respiratory rate of each enrolled child were monitored after admission.
214475029|NCT06573203|DEVICE|aEEG|Each enrolled child underwent a 6-hour sleep-wake cycle, quiet sleep, and active sleep monitoring after admission.
214475030|NCT06573203|OTHER|Neonatal Sleep-Wake Assessment Tool (NSWAT) included four dimensions: eye movement, respiratory rate, facial expression and muscle activity.|The study nurses observed and scored the children's sleep-wake status 10 minutes after two meals during the mattress test period, each time for 5 minutes.
214475031|NCT06008860|DRUG|Experimental: Primary Cohort|Astepro (azelastine) is a second generation antihistamine, as well as an anti-inflammatory and mast cell stabilizer8. It is available as a 0.1% and 0.15% nasal spray by prescription in the USA and over-the-counter in the European Union (EU). Dosing for adults and adolescents 12 years and older is 1 or 2 sprays per nostril twice daily (0.1%) or 2 sprays per nostril once daily (0.15%)9. It is approved by the FDA for treatment of seasonal allergic rhinitis symptoms (rhinorrhea, sneezing, and nasal pruritus) in adults and children 2 years and older, perennial allergic rhinitis in adults and children ages 6 months and older, and the symptoms of vasomotor rhinitis (rhinorrhea, nasal congestion and postnasal drip) in adults and adolescents 12 years and older9.
214847718|NCT05460221|DIETARY_SUPPLEMENT|Functional oil group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
214847719|NCT05460221|DIETARY_SUPPLEMENT|Control group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
214847720|NCT02714296|DRUG|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
214847721|NCT02714296|DIETARY_SUPPLEMENT|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
214847722|NCT00146796|DEVICE|Rapid diagnostic test for malaria|
214847723|NCT02833207|DRUG|Drug Trial 1 (EDD)|"Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description."
214847724|NCT02833207|DRUG|Drug Trial 2 (ROV)|"Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description."
214847725|NCT03318887|DRUG|Sofosbuvir/daclatasvir with or without ribavirin|Direct-acting antiviral treatment for hepatitis C virus infection
214847726|NCT05722028|PROCEDURE|hysteroscopy|Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.
214847727|NCT00003317|DRUG|carboplatin|
214847728|NCT00003317|DRUG|paclitaxel|
214847729|NCT00003317|RADIATION|radiation therapy|
214289708|NCT06476457|BEHAVIORAL|STAIR Coach|STAIR is a brief, low-intensity intervention targeting difficulties in affective and interpersonal regulation that tend to be a significant problem for those exposed to traumatic events.
214289709|NCT01010386|PROCEDURE|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
214475032|NCT06008860|OTHER|Placebo Comparator: Primary Cohort - Placebo|A Placebo will be provided by Bayer which features similar color and packaging as azelastine.
214657382|NCT01848314|PROCEDURE|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
214847730|NCT00003317|PROCEDURE|surgery|
214847731|NCT05380219|OTHER|dual task strength training|strength training and dual task
214847732|NCT00552149|DRUG|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
214847733|NCT01935648|DRUG|Ropivacaine|
214475034|NCT06385301|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
214475035|NCT06385301|OTHER|6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
214475036|NCT00670241|DRUG|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
214475037|NCT00670241|DRUG|LEO 80185 vehicle|Once daily application
214475038|NCT00670241|DRUG|Tacalcitol ointment|Once daily application
214475039|NCT00950638|DRUG|Avacincaptad Pegol|intravitreal injection
214475040|NCT03735745|OTHER|Blood collection|30cc of blood will be collected.
214475041|NCT03735745|OTHER|Saliva collection|5cc of saliva will be collected.
214475042|NCT03735745|OTHER|Tissue collection|Up to 10mg of tissue will be collected.
214475043|NCT03735745|OTHER|Surveys|The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.
214475044|NCT06235320|OTHER|routine clinical treatment of pain with paracetamol or ibuprofen|No intervention beside clinical routine management
214475045|NCT04414475|DRUG|Selinexor|Participants will receive Selinexor oral tablets.
214475046|NCT04414475|DRUG|Dexamethasone|Participants will receive Dexamethasone oral tablets.
214475047|NCT04414475|DRUG|Bortezomib|Participants will receive Bortezomib SC injection.
214475048|NCT06125210|BEHAVIORAL|early bedside rehabilitation|① electrical diaphragm stimulation, ② electrical muscle stimulation, ③ passive limb movement, ④ respiratory rehabilitation.
214475049|NCT06125210|DIETARY_SUPPLEMENT|nutrition program|(1) nutrition department consultation, (2) MDT to develop individualized nutritional pathways, nutrient formulations and use methods, and achieve the target nutritional level within 2 weeks
214475050|NCT06125210|PROCEDURE|tracheotomy|early tracheotomy for special diseases (e.g central nervous system diseases) receiving mechanical ventilation 14-21 days recommended tracheotomy
214475051|NCT05863052|BIOLOGICAL|Immunotherapy|immunotherapy
214847734|NCT03444441|PROCEDURE|Foot or ankle surgery|Surgery for foot or ankle
214289710|NCT01010386|PROCEDURE|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
214289711|NCT00240903|BIOLOGICAL|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
214475054|NCT06804642|DEVICE|Spinal cord transcutaneous stimulation (scTS)|"scTS mapping: Each intervention session will be approximately 2 hours each which includes time to place the scTS stimulating pads and other sensors as needed. Participants will be asked to train 3 days per week during the intervention periods so that they achieve at least 12 sessions. In instances in which availability is limited or they must cancel a session, the intervention period will need to be extended slightly (up to a maximum of four weeks) so that they can achieve at least 12 sessions (1-month intervention period) or 24 sessions (2-month intervention periods) of training. The main study interventions are described below.~Step-scTS:~Step-scTS is spinal cord transcutaneous stimulation (scTS) targeted for stepping function. The scTS mapping assessment(s) will assist the study team in determining optimized stimulation parameters for each body and f"
214475055|NCT02839265|DRUG|FLT3 Ligand Therapy (CDX-301)|See Arm 1 descriptions
214475056|NCT02839265|RADIATION|Stereotactic Body Radiotherapy (SBRT)|See Arm 1 descriptions
214475057|NCT05145426|DEVICE|Low Intensity Focused Ultrasound|Application of LIFU
214475058|NCT06807645|DEVICE|Clinical Trial Intervention Description General Study Setup Objective: To compare the efficacy of using a custom-made prefabricated acrylic splint versus no splint in maintaining premaxillary stabilit|"Clinical Trial Intervention Description General Study Setup Objective: To compare the efficacy of using a custom-made prefabricated acrylic splint versus no splint in maintaining premaxillary stability post-alveolar cleft repair.~Primary Outcome: Premaxillary stability. Secondary Outcomes: Wound healing and complications. Intervention Details~1\. Common Procedures for Both Arms:~Surgical Procedure: All surgical procedures will be conducted under general anesthesia with nasotracheal intubation.~Antibiotic Prophylaxis: A first-generation cephalosporin will be administered prior to incision as per .~Bone Graft Harvesting: Autogenous bone grafts will be harvested from the anterior iliac crest using a pediatric minimally invasive technique with a 2 cm skin incision 1 cm lateral to the iliac crest.~Alveolar Cleft Repair:~Incision and Flap Design: A sulcular incision will be made to develop full thickness mucoperiosteal advancement flaps extending into the cleft with caref"
214475059|NCT05410587|DEVICE|Fracture Monitor (implantable device class III)|Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
214475060|NCT06555731|GENETIC|Ultra rapid genome sequencing|DNA extraction from blood sample and whole genome sequencing
214475061|NCT05552508|COMBINATION_PRODUCT|Benralizumab|Participants will receive benralizumab subcutaneously.
214657383|NCT01150110|DEVICE|resilient occlusal splints|"A resilient occlusal splints (silicone 2mm) was fabricated on the maxillary arch, using a vacuum pressing machine. The occlusal splints were adjusted to eliminate the gross interferences and to obtain occlusal stability with maximum posterior bilateral contacts.~Patients were instructed to use the occlusal splints for 24 hours during 30 days. The use was interrupted only during meals."
214847735|NCT03278509|DRUG|Metoprolol Succinate|Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
214847736|NCT03278509|DRUG|Bisoprolol|Please see the section above.
214847737|NCT02270749|DRUG|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
214475062|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir|"Patients will be randomly divided into two groups. Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 0.9-mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth."
214475063|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.|Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9-mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
214475064|NCT05500690|DIETARY_SUPPLEMENT|Folic Acid Tablet|5 mg folic acid supplement
214475065|NCT06109805|OTHER|Gastric cancer|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
214475066|NCT06206486|OTHER|no intervention, observational|This study is observational. No intervention description available.
214475067|NCT04863261|OTHER|Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App|The CHORUS App has been developed as a tool for clinicians to easily visualize important patient information from their smart phones. Relevant information is electronically distributed and placed within the corresponding module in the CHORUS HCP mobile app for iOS and Android.
214475068|NCT05895929|DRUG|Mepolizumab|In vitro exposure of human nasal epithelial cells to mepolizumab
214475069|NCT06266728|DEVICE|Total30 for Astigmatism Contact Lenses|Participants must be refit into Total30 for Astigmatism Contact Lenses and wear them over the course of this one month study.
214475070|NCT05565989|BEHAVIORAL|MBM and II|An initiation to MBM practice (including 4 exercices) and 2 intention implementation exercices are proposed to participants
214475071|NCT05565989|BEHAVIORAL|MI|A motivational Interview will be conducted with participant.
214847738|NCT02270749|DRUG|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
214847739|NCT00697970|BIOLOGICAL|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
214847740|NCT00697970|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
214847741|NCT02129309|PROCEDURE|Forearm plethysmography|Dose response study
214847742|NCT02129309|PROCEDURE|Haemodynamic studies|Dose response study
214475072|NCT06080698|DRUG|Intravenous Antibiotics|Participants will continue to receive intravenous antibiotics until the completion of the treatment course
214475073|NCT06080698|DRUG|Oral Antibiotics|Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course
214475074|NCT06197997|BEHAVIORAL|Chicago Parent Program (CPP)|The Chicago Parent Program (CPP) is a 12-session group-based parenting intervention designed to strengthen parenting skills and parent engagement in children's learning and improve children's social-emotional and behavioral competence.
214475075|NCT04842513|DRUG|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
214475076|NCT05248802|DRUG|Placebo caplet of DLBS2411|1 caplet of placebo DLBS2411, twice daily
214475077|NCT05248802|DRUG|DLBS2411|1 caplet of DLBS2411 250 mg, twice daily
214657384|NCT03156530|DEVICE|Auricular acupunture|Evaluation of balance before, during and after applying of auricular acupuncture.
214657385|NCT03156530|OTHER|Control|Not receive stimulation.
214847743|NCT00194792|DRUG|exemestane|Given PO
214847744|NCT00194792|DRUG|triptorelin pamoate|Given IM
214847745|NCT00194792|DRUG|capecitabine|Given PO
214847746|NCT00194792|DRUG|methotrexate|Given IV
214847747|NCT00194792|DRUG|vinorelbine tartrate|Given IV
214847748|NCT00194792|DRUG|paclitaxel|Given IV
214847749|NCT00194792|PROCEDURE|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
214847750|NCT00194792|RADIATION|radiation therapy|Undergo radiation therapy
214847751|NCT00194792|OTHER|laboratory biomarker analysis|Correlative studies
214847752|NCT02582788|OTHER|Bathing Additive|
214847753|NCT01714739|DRUG|Lirilumab|Specified dose on specified days.
214847754|NCT01714739|DRUG|Nivolumab|Specified dose on specified days.
214847755|NCT01714739|DRUG|Ipilimumab|Specified dose on specified days.
214847756|NCT01853241|PROCEDURE|Single Balloon|All patients in this group will undergo single balloon enteroscopy
214847757|NCT01853241|PROCEDURE|Spirus|All patients in this group will undergo Spirus Enteroscopy
214847758|NCT00092950|BEHAVIORAL|Physical activity|
214847759|NCT01570816|DEVICE|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
214847760|NCT04783116|DIETARY_SUPPLEMENT|Plant stanols (3g/day)|Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
214847761|NCT04783116|DIETARY_SUPPLEMENT|Placebo|Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
214847762|NCT00139724|DRUG|tolterodine extended release capsule|
214475078|NCT06645678|DRUG|Elranatamab|"Elranatamab: Participants will receive SC administration of elranatamab QW or Q2W. The initial doses of elranatamab will be 12mg (C0D1), 32mg (C0D4), and 76mg (C0D8) and will serve as the 2 step-up priming regimen (Cycle 0). Then, 76mg weekly C1-C6 \> then 76mg bi-weekly from C7 for those achieving PR or better \> then 76mg q4weeks from C12 for those achieving CR or better response. If the participant subsequently begins to have an increase of disease burden not yet qualifying as PD according to IMWG criteria, dose intervals will return to weekly dosing.~premedication for Elranatamab: Acetaminophen 650mg (or paracetamol 500mg), Diphenhydramine 25mg (or equivalent), Dexamethasone 20mg (or equivalent).~In case of mezigdomide discontinuation due to reasons other than disease progression, elranatamab continuation +/- dexamethasone will be allowed until loss of response. The administration of elranatamab +/- dexamethasone will continue per study protocol schedule."
214475079|NCT06645678|DRUG|Mezigdomide|"The first day of study treatment dosing with mezigdomide is considered Day 1 of a cycle. (per recommended phase 2 dose, daily \[qd\], D1-21, q 4weeks). Capsules of mezigdomide will be taken by mouth with or without food.~In case of elranatamab discontinuation due to reasons other than disease progression, mezigdomide continuation +/- dexamethasone will be allowed until loss of response. The administration of mezigdomide will continue per study protocol."
214475080|NCT06645678|DRUG|Dexamethasone|"Administered at the dose of 20 mg/day from C1-3, then 10mg/day from C4-6 as a premedication for elranatamab.~(for those \>=75 yrs, with uncontrolled diabetes mellitus, history of intolerance: 10mg/day -\> 5mg/day)"
214475081|NCT06402864|RADIATION|contact X-ray brachytherapy (CXB)|3 fractions of contact X-ray brachytherapy (CXB) every two weeks before neoadjuvant chemo radiotherapy (nCRT).
214475082|NCT05910411|DEVICE|Inelastic compression|Inelastic compression used in the treatment of lymphedema
214475083|NCT02785029|DEVICE|OCT|
214475084|NCT06228248|OTHER|metagenomics|Feces used for metagenomic testing
214475085|NCT05948995|DEVICE|Abduction external rotation brace|Abduction external rotation brace Arm position : Abduction , External rotation
214475086|NCT02879136|DRUG|Methylphenidate|Patient will be randomized to Methylphenidate
214475087|NCT02879136|OTHER|Physical Therapy|All Patients will have standard of care PT used for PD patients
214475088|NCT02879136|DRUG|Atomoxetine|Patient will be randomized to Atomoxetine
214847763|NCT05435586|OTHER|Web Based Breastfeeding Education and Counseling with Digital Game Support|The educational content prepared by the researcher on the web page will be integrated into the game program designed with the gamification technique. In this designed program, users will be notified at appropriate times to enter the system and play games from the link sent via e-mail. After the users have finished the game, they will fill the scale in the relevant week and will only be able to exit the system in that way.
214847764|NCT01885416|OTHER|consumption of test meal based on dairy products|
214847765|NCT01885416|OTHER|consumption of high fat test meal without dairy products|
214847766|NCT01885416|OTHER|consumption of high fat test meal with dairy products|
214847767|NCT00006387|BIOLOGICAL|QS21|
214847768|NCT00006387|BIOLOGICAL|ras peptide cancer vaccine|
214847769|NCT00865514|DRUG|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
214847770|NCT00865514|GENETIC|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
214289712|NCT01443754|PROCEDURE|LIMA-LAD surgical revascularization|"Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:~* use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;~* minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another."
214289713|NCT01443754|PROCEDURE|PCI|"State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.~Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites."
214289714|NCT00109889|PROCEDURE|magnetic resonance imaging|magnetic resonance imaging (MRI)
214289715|NCT00109889|PROCEDURE|positron emission tomography|positron emission tomography (PET)
214475089|NCT03998059|PROCEDURE|splenectomy|These patients should fail to have sustained response to multiple first- and second-line treatments of ITP and agree to have splenectomy.Before splenectomy, these patients will be reassessed and still diagnosed with ITP.Their platelet level will be raised to a safe state before surgery, and the laparoscopic splenectomy will be performed in Tianjin People's Hospital.
214475090|NCT06438029|OTHER|Education group|the students in the experimental group will be trained on disaster and disaster response
214475091|NCT06438029|OTHER|control group|the students in the experimental group will be trained on disaster and disaster response
214475092|NCT06135220|DIAGNOSTIC_TEST|New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.|The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
214475093|NCT06342141|DRUG|Empagliflozin 25 milgrams (Mg)|Load dose
214475094|NCT06342141|DRUG|Empagliflozin 10 Mg|Maintenance dose
214475095|NCT06153212|PROCEDURE|Membrane placement with bone grafting|The diseased dental implant will be cleaned and the bone defect will be filled with bone graft and covered by a membrane.
214475096|NCT05101863|BEHAVIORAL|Motivational interviewing|MI is a goal-oriented style of communication, and focuses on resolving a patient's ambivalence, while eliciting his/her own reasons to change addictive behavior, also known as change talk.
214475097|NCT04259281|DRUG|GTX-102|antisense oligonucleotide
214475098|NCT04871048|DEVICE|Transcranial direct current stimulation (tDCS) active|Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.
214475099|NCT04871048|DEVICE|Transcranial direct current stimulation (tDCS) non active|The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures.
214475100|NCT06208605|BEHAVIORAL|Transdiagnostic Network Informed Personalized Treatment|Idiographic network analysis is used to determine individuals' top central eating disorder symptoms. Participants then receive modules to address these specific symptoms.
214475101|NCT06208605|BEHAVIORAL|Enhanced Cognitive Behavioral Therapy for Eating Disorders|Manualized CBT-E (Fairburn 2008) including regular eating, self-monitoring, and CBT modules implemented flexibly.
214475102|NCT02507141|DEVICE|Reflectance Confocal Microscopy|Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
214475103|NCT06099379|DRUG|∆9-tetrahydrocannabinol|Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled
214475104|NCT06037668|DEVICE|BVR-100|Experimental self-guided VR intervention for the treatment of SAD
214475105|NCT06037668|DEVICE|BES-100|Active at-home VR intervention comparator
214847771|NCT00865514|OTHER|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
214475106|NCT04819737|PROCEDURE|SC MRI|SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.
214475107|NCT04819737|OTHER|patient questionnaire|12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability
214475108|NCT06035354|DRUG|AK120|subcutaneous injection once a week
214475109|NCT06035354|DRUG|AK120|subcutaneous injection once a week
214475110|NCT06035354|DRUG|Placebo|subcutaneous injection once a week.
214475111|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
214475112|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
214475113|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
214475114|NCT06035354|DRUG|Placebo|subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.
214475115|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks
214847772|NCT00865514|OTHER|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
214847773|NCT03920280|DEVICE|LID015385 contact lenses|Investigational silicone hydrogel contact lenses
214475116|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
214475117|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
214475118|NCT06079255|DEVICE|IscAlert sensor(s) in patient with risk of acute compartment syndrome|of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)
214475119|NCT05825742|DEVICE|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
214475120|NCT05825742|OTHER|Standard oral health instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
214475121|NCT05180058|OTHER|Wrapping + Breastmilk Group|Interventions applied during orogastric tube insertion
214475122|NCT06614309|OTHER|Acute Placebo Visit|The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.
214847774|NCT03920280|DEVICE|Comfilcon A soft contact lenses|Commercially available silicone hydrogel contact lenses
214847775|NCT03920280|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting system
214847776|NCT01557920|DRUG|Propofol|Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.
214847777|NCT01557920|DRUG|Sevoflurane|Sevoflurane will be administered via mask inhalation to achieve anesthesia.
214847778|NCT00258778|DRUG|Human Glucocerebrosidase (prGCD)|
214847779|NCT00466804|PROCEDURE|Heart transplant|People in this study will have a heart transplant and be monitored for signs of rejection
214289716|NCT01980914|DEVICE|iPro2 glucose sensor attachment|At the same time the glucose sensor is started, a trained research nurse will connect the patient to an Icentia CardioSTAT, a continuous ambulatory ECG cardiac monitor.
214475123|NCT06614309|OTHER|Acute Progressive Carbon Dioxide|The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.
214475124|NCT06614309|OTHER|Acute Intermittent Hypoxia|The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.
214475125|NCT06614309|OTHER|Training: Progressive Carbon Dioxide Ramping|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the progressive CO2 ramp protocol of 60-minute sessions, which will include 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles, for every visit during the 14 days.
214475126|NCT06614309|OTHER|Training: Intermittent Hypoxic Exposure|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the intermittent hypoxia exposure protocol of 60-minute sessions, which will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air for every visit during the 14 days.
214475127|NCT06614309|OTHER|Training: Placebo Control|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days.
214475128|NCT05899673|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
214475129|NCT05241210|DEVICE|AI program for colonoscopy|Provides real-time feedback on the endoscopist moniter during colonoscopy.
214475130|NCT03919266|PROCEDURE|Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the realization of a nasopharyngeal swab in the two strategies, and the PCT assay at D1, D3 and D7 in the pathogen-directed strategy
214475131|NCT03919266|PROCEDURE|Control: usual antibiotic treatment|usual antibiotic treatment
214847780|NCT04157972|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
214847781|NCT04157972|DEVICE|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
214847782|NCT01309724|OTHER|USCOM-guided fluid administration|Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
214847783|NCT03532750|DEVICE|Particle|"1. 300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.~2. 300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.~3. Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.~4. Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578."
214847784|NCT03532750|DEVICE|Coil|Ruby or Interlock detachable coils
214289717|NCT01174927|DRUG|diacetylmorphine (DAM)|The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
214289718|NCT01174927|OTHER|Placebo|Saline
214475132|NCT05886933|DRUG|Fexuprazan Hydrochloride|Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet)
214475133|NCT01473784|PROCEDURE|transoral robotic surgery|Undergo TORS using the Da Vinci Robotic Surgical System
214475134|NCT01473784|PROCEDURE|quality of life assessment|After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
214475135|NCT05825508|DEVICE|ankle robot|home ankle robot and video game
214847785|NCT00635336|BIOLOGICAL|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
214847786|NCT05458037|PROCEDURE|Speed of tenaculum application|Fast or slow closure of the tenaculum for application to the uterine cervix
214847787|NCT03290313|DRUG|shu gan yi yang capsule|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
214847788|NCT03290313|DRUG|shu gan yi yang capsule simulation agent|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
214847789|NCT03290313|OTHER|Supportive psychotherapy|Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
214289719|NCT02946645|DEVICE|Neuromuscular Bite (orthotic/sub-lingual)|Bite is a device which simulates a set of properly positioned teeth
214289720|NCT02946645|PROCEDURE|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises~1. Place knuckle of index finger between top and bottom teeth.~2. Remove it, keeping the teeth separated one-knuckle apart.~3. Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
214289721|NCT02946645|OTHER|Placebo|No interventions.
214475136|NCT04796324|DRUG|Ixabepilone Injection|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
214475137|NCT06249295|OTHER|oral cryotherapy|The experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies, and then intervened in the post-surgical period using oral cold therapy (ice lolly in the mouth)
214475138|NCT06698549|DRUG|ALG-097558|Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)
214847790|NCT00004988|DRUG|VNP20009|
214475139|NCT05137067|DIETARY_SUPPLEMENT|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)|Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.
214475140|NCT05137067|DRUG|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo|Placebo
214475141|NCT05137067|DRUG|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
214475142|NCT06263257|BEHAVIORAL|Mandala Art Therapy|"In art therapy, visual arts (such as drawing, painting, and sculpting) can be used as a tool to facilitate the expression of emotions and enhance coping skills. Naisin and colleagues (2006) reported that a one-hour art therapy session significantly reduced anxiety levels in hospitalized adult oncology patients. The word mandala is now typically associated with circular, geometric designs and often appears in adult coloring books aimed at promoting mindfulness and stress reduction. However, the methodology and theory of Jung related to mandalas are based not only on coloring pre-drawn templates but also on the activity of creating mandalas. The act of creating a mandala is claimed to provide immediate benefits in improving mood. The mandala is expressed as an instantaneous outward expression of the inner world of the person drawing it."
214475143|NCT04012931|DRUG|Rilpivirine|Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
214475144|NCT04012931|DRUG|ARV Background Regimen|The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine \[AZT\], abacavir \[ABC\], tenofovir alafenamide \[TAF\], or tenofovir disoproxil fumarate \[TDF\] in combination with emtricitabine \[FTC\] or lamivudine \[3TC\]), whichever are approved and marketed or considered local standard of care for children aged between 2 and \< 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir \[DTG\] or raltegravir) can also be administered in combination with RPV, as appropriate.
214475145|NCT05285137|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
214475146|NCT05285137|DRUG|Saline placebo|Sterile normal saline for injection
214847791|NCT01109017|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
214475147|NCT06772103|PROCEDURE|self-locking biceps tenodesis|The LHB tendon is detached from its origin at the level of the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
214475148|NCT06772103|PROCEDURE|Biceps Tenodesis with 360 Suture anchor|The LHB tendon is detached from its origin and sutured. Next, the LHB tendon is fixed in the bicipital groove using a 360-loop tenodesis technique with the Knotless FiberTak® biceps implant system. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
214475149|NCT06660290|DRUG|0.003% AR-15512 ophthalmic solution|Investigational ophthalmic solution for topical instillation
214475150|NCT06660290|DRUG|REFRESH® Classic ophthalmic solution|Commercially available ophthalmic solution for topical instillation
214847792|NCT02194140|OTHER|oral iodinated contrast material|diluted in water
214847793|NCT02024594|DRUG|Nitrous Oxide-Oxygen conscious sedation|
214475151|NCT06823518|BEHAVIORAL|Thrive Initiative Parent-Education Programming|The Thrive Initiative Parent-Education programs are universal prevention programs designed to support parents as they raise their children. There are four programs that correspond to specific child developmental periods. The programs include: Take Root for parents/caregivers of 0-3-year-old children; Sprout for parents/caregivers of 3-5-year-old children; Grow for parents/caregivers of 5-10-year-old children; and Branch Out for parents/caregivers of 10-18-year-old children. Each program focuses, in developmentally appropriate ways, on three primary dimensions: positive parenting, stress management, and healthy lifestyles. Each program is available in either an online-only format or a hybrid format, which includes group meetings in addition to the online program components.
214847794|NCT02024594|BEHAVIORAL|cognitive-behavioral therapy|
214847795|NCT00779220|DRUG|placebo|Intravenous repeating dose
214847796|NCT00779220|DRUG|methotrexate|Oral repeating dose
214847797|NCT00779220|DRUG|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
214847798|NCT00779220|DRUG|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
214847799|NCT00779220|DRUG|ocrelizumab 500mg|Intravenous repeating dose (500mg)
214847800|NCT01030094|DRUG|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
214289722|NCT02680912|DEVICE|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
214289723|NCT02680912|DEVICE|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
214847801|NCT01030094|DRUG|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
214847802|NCT01030094|DRUG|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
214847803|NCT01030094|DRUG|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
214847804|NCT01265667|DRUG|CF101|orally q12h
214847805|NCT01265667|DRUG|Placebo|orally q12h
214847806|NCT05103917|DRUG|X4P-001|CXCR4 inhibitor
214847807|NCT01767610|DRUG|micronized fenofibrate 160mg|
214847808|NCT01767610|DRUG|pitavastatin Ca 2mg|
214847809|NCT01767610|DRUG|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
214847810|NCT00944684|DRUG|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
214475152|NCT01437787|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
214475153|NCT01437787|DRUG|Placebo|"Pharmaceutical form:capsule~Route of administration: oral"
214475154|NCT03717935|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) Supplement|Powder supplement
214847811|NCT00944684|DRUG|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight \<65kg) or 1,200mg (body weight equal or \>65kg)
214847812|NCT00307970|DRUG|HFA FP MDI|
214475155|NCT03717935|OTHER|Placebo|Powder that will be similar to the essential amino acid supplement
214475156|NCT04601480|BEHAVIORAL|Choice Architecture Nudge|During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.
214475157|NCT04601480|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
214475158|NCT04872166|DRUG|BTX-A51|One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.
214847813|NCT00307970|DEVICE|conventional chamber/mask; anti-static chamber/mask|
214847814|NCT01857206|BIOLOGICAL|Mammalian cell based flu vaccine|
214475159|NCT03560973|DRUG|Gemcitabine|ramucirumab/ placebo was added to gemcitabine
214475160|NCT03560973|DRUG|Ramucirumab|ramucirumab/ placebo was added to gemcitabine
214475161|NCT05882916|DEVICE|HIV self-testing|Oral fluid-based HIV self-test kits for secondary distribution
214847815|NCT01857206|BIOLOGICAL|Egg based flu vaccine|
214847816|NCT03776929|BEHAVIORAL|Dialectical Behavioral Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that focuses on the balance between change and acceptance. DBT skills include four modules: two that enforce acceptance-oriented skills, mindfulness and distress tolerance, and two that promote change-oriented skills, interpersonal effectiveness and emotional regulation.
214289724|NCT06300242|BEHAVIORAL|Reminders|Reminders
214289725|NCT06300242|BEHAVIORAL|Financial Incentive|$50 financial incentive for getting vaccinated within 1-week
214289726|NCT06300242|OTHER|Placebo|No special messages or incentives
214289727|NCT00449540|DEVICE|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
214289728|NCT00449540|DEVICE|Sham TMS Device|Simulated Sham treatment without TMS delivery
214289729|NCT06152757|BIOLOGICAL|First dose|1.0×10\^8cells,Intravenous infusion，1 subject is planned to be enrolled
214289730|NCT06152757|BIOLOGICAL|Second dose|3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
214475162|NCT05882916|BEHAVIORAL|Behavioral economic 'nudges'|Salient information for men included with the self-test kit on clinic location and hours within their cluster, and pilot-tested messaging on the importance of early ART initiation, and the availability and benefits of PrEP
214289731|NCT06152757|BIOLOGICAL|The third dose|1.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
214289732|NCT06152757|BIOLOGICAL|The fourth dose|3.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
214475163|NCT04666714|DRUG|Praga formulation|Praga formulation tablet
214475164|NCT04666714|OTHER|Placebo pregabalin 75mg|Placebo pregabalin 75mg tablet
214475165|NCT04666714|OTHER|Placebo Pregabalin 150mg|Placebo Pregabalin 150mg tablet
214475166|NCT04666714|DRUG|Pregabalin 75mg|Pregabalin 75mg tablet
214475167|NCT04666714|DRUG|Pregabalin 150mg|Pregabalin 150mg tablet
214475168|NCT04666714|OTHER|Placebo Praga formulation|Placebo Praga formulation tablet
214475169|NCT03316053|OTHER|Tissue sample for genetic testing|Tissue sample to be obtained during routine endoscopy
214475170|NCT04667455|DIAGNOSTIC_TEST|Biomarker analysis at enrolment|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
214475171|NCT04667455|DIAGNOSTIC_TEST|Biomarker analyses throughout the study|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
214475172|NCT03059264|OTHER|Natural history|Longitudinal disease progression
214475173|NCT03631173|PROCEDURE|Surgical og radiological intervention, antibiotics|Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
214847817|NCT06086496|DEVICE|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
214847818|NCT00273416|DRUG|PF-00592379|
214847819|NCT00273416|DRUG|Sildenafil 100mg|
214847820|NCT04561336|DRUG|Avelumab|avelumab in combination with cetuximab
214847821|NCT04561336|DRUG|Cetuximab|avelumab in combination with cetuximab
214847822|NCT04467320|BEHAVIORAL|Teaching Recovery Techniques|Teaching Recovery Techniques is a 7-session group programme, with 5-sessions for the young person and 2-sessions for the carer. All sessions will be held online. The carer sessions are focused on psychoeducation around trauma and PTSD, as well as skills for supporting a young person through the intervention and with PTSD symptoms more broadly. The young person sessions are primarily focused on skill building and include: psychoeducation and understanding intrusive memories; intrusive images, worries and dreams; arousal, emotions, relaxation and coping; avoidance and triggers; and, memories.
214847823|NCT04467320|BEHAVIORAL|Care as usual|In the care as usual arm, social workers will follow their standard care protocol for young people experiencing psychological distress. A typical response may include a referral to either the specialist local CAMHS or general CAMHS.
214847824|NCT05368558|DRUG|Cariprazine|Oral Capsule
214475174|NCT06142292|BEHAVIORAL|Individual counseling|Individual counseling sessions with a licensed mental health counselor
214475175|NCT06142292|BEHAVIORAL|Group counseling|Group counseling sessions with a licensed mental health counselor
214475176|NCT06481540|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). After this period, participants will perform an additional 16 weeks of maintenance EMST. EMST therapy sessions will be completed at home on two days (minimum) of the participant's choosing each week.
214475177|NCT06481540|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period).After this period, participants will perform an additional 16 weeks of maintenance EMST. EMST therapy sessions will be completed at home on two days (minimum) of the participant's choosing each week.
214475178|NCT04866836|COMBINATION_PRODUCT|Radiotherapy|Patients who meet the criteria for enrollment first receive radiotherapy, either IMRT or SBRT, and the relative biological effect dose is\> 40Gy. On the 7th day (±3 days) after radiotherapy, start to give tislelizumab 200 mg, IVD, q3w, and continue the treatment until disease progression, unacceptable toxic radiotherapy, death or meet the description in the protocol Any discontinuation criteria shall be subject to whichever occurs firs
214475179|NCT05196854|OTHER|Group 1. Standard Home Blood Pressure Measurement|Measurement of Blood Pressure using Home blood pressure monitor
214475180|NCT05196854|OTHER|Group 2. Hypnosis script prior to home blood pressure measurement|Pre-recorded clinical hypnosis script (approx 5 mins long) used prior to standard home blood pressure measurement. Clinical Hypnosis is used as a non-pharmacological technique for reducing procedural anxiety, distress and discomfort with patients.
214475181|NCT06178523|DRUG|Clomiphene Citrate.|Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).
214475182|NCT06178523|DRUG|Sildenafil Citrate|Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle (Group-A).
214475183|NCT06178523|PROCEDURE|Intrauterine Insemination|IUI (Group-B).
214475184|NCT01017055|OTHER|Voice and Swallowing evaluations|Fiberoptic exam to evaluate vocal cord and swallowing function
214475185|NCT03484819|DRUG|Copanlisib Hydrochloride|Given IV
214475186|NCT03484819|BIOLOGICAL|Nivolumab|Given IV
214475187|NCT04643041|BEHAVIORAL|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3w) therapy and start watch and wait.
214475188|NCT06264453|DRUG|KH001|topical applications of KH001
214475189|NCT06264453|DRUG|Placebo|topical applications of Water for Injection
214475190|NCT05549479|BEHAVIORAL|Peer Matching|Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.
214475191|NCT05549479|BEHAVIORAL|Qualified Exercise Professional Support Sessions|Dyads will participate in weekly virtual sessions with a QEP for 10 weeks. Each session will last up to 1 hour. The QEP (i.e., registered kinesiologist) will provide a tailored exercise program, focusing on aerobic activity for both individuals in the dyad based on personal circumstances, cancer-related characteristics, side effects, current fitness level (consistent with home-based exercise strategies), and personal preferences.
214475192|NCT04576715|BEHAVIORAL|TEaM Intervention|"Multi-setting mTBI (mild traumatic brain injury) Evaluation and Management Intervention incorporates provider education and information technology support systems, based on the best available evidence and tailored to a specific environment (acute care setting vs primary care clinic). Facilitates linkages between providers (ED/UC to primary care) and systems (healthcare to school).~* Provider Training Modules: Training includes decision-making support alerted by positive triage screening and concussion-specific eMR template~* Management based on current best practices (however, may have additional education from the provider training)~* Return to school letters~* Primary Care Follow Up"
214475193|NCT04576715|BEHAVIORAL|Standard of Care|"Continue with CHOA current best practices for mTBI:~* No TEaM Provider training (but will be offered to all providers at end of study)~* Will not be trained on utilization and implementation of the concussion screening alert and eMR template"
214479484|NCT06862297|DEVICE|Ultrasonic Jaw Tracking Device|"This study investigates the effectiveness of the Ultrasonic Jaw Tracking Device, a novel non-invasive diagnostic tool designed to monitor dynamic jaw movements during sleep. The device is equipped with advanced ultrasonic sensors and proprietary algorithms to track jaw position and motion in real time.~The intervention involves placing the device on the participant's mandible during polysomnography (PSG) sessions to simultaneously measure jaw movement data alongside standard PSG parameters. The primary goal is to evaluate the accuracy and efficacy of the device in detecting sleep-related conditions such as obstructive sleep apnea (OSA) compared to traditional PSG metrics."
214847825|NCT05368558|DRUG|Placebo|Oral Capsule
214847826|NCT04225286|OTHER|Human breast milk|Intranasal human breast milk
214847827|NCT00334763|BIOLOGICAL|bevacizumab|
214847828|NCT00334763|DRUG|carboplatin|
214289733|NCT03055351|BEHAVIORAL|Stop&Go Intervention|Stop\&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
214847829|NCT00334763|DRUG|chemoprotection|
214847830|NCT00334763|DRUG|paclitaxel|
214847831|NCT00334763|RADIATION|radiation therapy|
214475194|NCT05862922|DEVICE|Analgesia Nosiception İndex Monitoring|"ANI is a monitor that can be measured continuously and non-invasively. It measures parasympathetic tone - based on electrocardiography - by analyzing minimal changes in heart rate that occur under anesthesia, in the early stages of awakening, and in each respiratory cycle of awake patients. At the end of the measurement, a value between 0-100 is obtained.~Parasympathetic modulation (stress level, e.g., pain) is obtained with a minimum value of 0 and a maximum of 100. ANI values measured in the early period of recovery correlate with pain scores. When compared with hemodynamic parameters, it has been reported that the ANI response is more sensitive to nociceptive stimuli occurring in the intraoperative period."
214475195|NCT06208085|DIETARY_SUPPLEMENT|Avocado|Intervention arm
214475196|NCT06225427|PROCEDURE|Biopsy|Undergo tissue biopsy
214475197|NCT06225427|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214475198|NCT06225427|PROCEDURE|Computed Tomography|Undergo CT scan
214475199|NCT06225427|PROCEDURE|Echocardiography|Undergo echocardiography
214475200|NCT06225427|DRUG|Gilteritinib|Given PO
214475201|NCT06225427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214847832|NCT01677208|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
214847833|NCT01677208|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
214289734|NCT01121887|BEHAVIORAL|Standard treatment|"Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
214475202|NCT06225427|OTHER|Questionnaire Administration|Ancillary studies
214475203|NCT06244433|GENETIC|whole genome sequencing|Study of all coding and non-coding sequences in the genome to identify pathogenic allelic variants
214475204|NCT04998162|PROCEDURE|SVF injection|Patients with ankle osteoarthritis will be treated with a single injection of 5 cc of SVF (stromal vascular fraction), obtained from patient's abdominal adipose tissue and concentrated through OPTYFAT device. Infiltration of the ankle, occurs from the safest portal, that is, from the antero- medial, between the tibialis anterior and the saphenous vein and nerve at the level of the articular rima.
214475205|NCT06435624|DEVICE|intelligent robotic-assisted training|"Using an intelligent robotic-assisted training (IRAT) system to simulate a real work environment, providing functional oriented treatment for stroke patients and improving upper limb motor function.~The instrument used is the Burt upper limb robot training system produced by Estun Medical Co., Ltd."
214475206|NCT06435624|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
214475207|NCT06435624|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
214475208|NCT04224558|DRUG|Mesna|"Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol."
214475209|NCT04224558|DRUG|Cyclophosphamide|"Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)"
214475210|NCT04224558|DRUG|Filgrastim|"Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of \>1000/μL"
214475211|NCT04224558|PROCEDURE|Apheresis catheter placement|Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.
214475212|NCT04224558|PROCEDURE|Leukapheresis|Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10\^6 CD34+ cells/kg body weight.
214475213|NCT04224558|DRUG|Fludarabine|Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.
214475214|NCT04224558|DRUG|Methylprednisolone|Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines
214475215|NCT04224558|DRUG|Diphenhydramine|Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines
214475216|NCT04224558|DRUG|Acetaminophen|Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
214475217|NCT04224558|DRUG|anti-thymocyte globulin (rabbit)|Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.
214475218|NCT04224558|DRUG|lymphocyte immune globulin|Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia \& Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
214475219|NCT04224558|BIOLOGICAL|Peripheral Blood Stem Cell Infusion|PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.
214475220|NCT04224558|DRUG|Cytoxan|Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
214847834|NCT01677208|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
214847835|NCT04904484|DEVICE|iZephyr hood|Assessment of an aerosol containment device
214847836|NCT06025552|DRUG|TU7710|In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1\~4 PK, PD, safety, and exploratory efficacy data.
214475221|NCT06808165|DIAGNOSTIC_TEST|relaxin|The primary source of relaxin in pregnancy is the corpus luteum, but it is also produced in other tissues, such as the decidua and placenta. Importantly, relaxin's pleiotropic effects include endothelial-dependent vasodilation, extracellular matrix remodeling, and potential contributions to placental development. These properties make relaxin a molecule of interest in the context of PAS disorders, where abnormal placental invasion may reflect disruptions in vascular and extracellular matrix regulation. Additionally, recent findings have indicated altCirculating relaxin levels were assessed before routinely storing maternal venous blood and umbilical cord arterial blood samples are anelyzed. This study aimed to compare relaxin levels in umbilical cord and peripheral blood and estimated placental volumes (EPV) between PAS cases and controls. Additionally, subgroup analysis was conducted to evaluate relaxin levels and EPV among PAS subtypes (accreta, increta, and percreta).
214475222|NCT06809127|OTHER|Behavioral tasks with MEG recording|The patients will undergo two visits, during which MEG will be recorded in two types of behavioral tasks: motor task and emotion recognition task. One visit will take place before surgery. The second visit will take place after the surgical intervention and the face motor rehabilitation, 3 to 18 months after the 1st visit.
214475223|NCT06809426|DRUG|177Lu-LNC1011|75 mCi (2.78 GBq) of 177Lu-LNC1011 Injection intravenously each time, injections every 6 weeks, not to exceed a total of 6 injections.
214475224|NCT06810557|BEHAVIORAL|Optimize Sleep Primary Care (OSPC)|In addition to standard care within Temple University Primary Care (TUPC), two face-to-face zoom sessions and four brief phone follow-ups (two during active treatment and two during maintenance) that focus on using effective behavioral strategies (e.g., goal setting, self-monitoring, positive reinforcement, stimulus control, problem-solving) to enhance children's sleep by approximately one hour/night.
214475225|NCT06810557|OTHER|Enhanced Usual Care|In addition to standard care within Temple University Primary Care (TUPC), the provision of six education contacts regarding children's sleep needs and the benefits of getting a good night's sleep.
214475226|NCT06199505|DRUG|GZR101|Once daily
214475227|NCT06199505|DRUG|insulin degledec/insulin aspart|Once daily or twice daily
214475228|NCT06810648|PROCEDURE|GDFT|Hydration was goal-directed and guided by Stroke Volume Variation (SVV) using the FloTrac/Vigileo monitor, while analgesia was provided with intravenous analgesics.
214475229|NCT06810648|PROCEDURE|GDFT/ED|Hydration was goal-directed and guided by Stroke Volume Variation (SVV) using the FloTrac/Vigileo monitor, while analgesia was administered via epidural analgesics.
214475230|NCT06810648|PROCEDURE|CFT|Patients received conventional fluid therapy (based on heart rate, urine output and mean arterial pressure) and analgesia was provided with intravenous analgesics.
214847837|NCT06025552|DRUG|Normal saline|Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
214847838|NCT00807209|DRUG|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
214847839|NCT00807209|DRUG|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
214475231|NCT06810648|PROCEDURE|CFT/ED|Patients received conventional fluid therapy (based on heart rate, urine output and mean arterial pressure) and analgesia was administered via epidural analgesics.
214289735|NCT01121887|BEHAVIORAL|Motivational Interviewing|"Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
214475232|NCT06809660|OTHER|Collection of biological samples and clinical data|"* Collection of a hair sample~* Collection of urine~* Collection of stool samples~* Collection of clinical, paraclinical data, and exposure questionnaire"
214475233|NCT06808360|BEHAVIORAL|Supportive and Dignified Maternity Care|SDMC is a theory-driven, inclusive service-delivery package which will be developed using the principles of the human-centred design approach. The model will include capacity-building of maternity teams, and the improvement of governance and accountability mechanisms within public health facilities to ensure that all women are treated with compassion and dignity, while also catering for their diverse needs, including disabilities and common mental health conditions. The integration of psychosocial support in routine maternity care will be a unique feature of the intervention package, a principal aim of which is to address the psychological needs of birthing women and their companions.
214475234|NCT06570720|BEHAVIORAL|Alcohol-focused Support of Survivors in Sororities Training (ASSIST)|A web-based intervention that includes sorority and individual values, personalized normative feedback (adapted to address sexual assault, support, and acceptability of encouraging peer drinking), psychoeducation on sexual assault and alcohol, and skills training in behaviors to support sexual assault survivors without heavy drinking.
214475235|NCT06808529|DEVICE|Pilates exercises and TENS Acupuncture|All performed Pilates exercises for 24 session, 3 sessions per week for (2 consecutive menstrual cycle), each session lasted for 30 minutes in addition to application of TENS acupuncture therapy for 30 minutes, 3 sessions in the first 3 days for (2 consecutive menstrual cycle).
214847840|NCT00807209|DRUG|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
214847841|NCT00807209|DRUG|Fentanyl via PCA|Fentanyl via PCA
214847842|NCT00807209|DRUG|Bupivacaine via epidural|Bupivacaine via epidural
214847843|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment A|Single oral dose
214847844|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment B|Single oral dose
214847845|NCT04071054|DIAGNOSTIC_TEST|Carnation Ambulatory Monitor (CAM)|7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
214847846|NCT04750382|DRUG|HX008+Cisplatin+Gemcitabine|Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m\^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m\^2, Day 1, Day 8, Q3W for up to 6 cycles
214289736|NCT00427466|DRUG|Pemetrexed|
214289737|NCT00022009|DRUG|gemcitabine hydrochloride|
214475236|NCT06808529|DRUG|ibuprofen 400 mg|All took capsules of ibuprofen(400-milligram) and instructed to take them once every eight hours for three days, one day before the start of their menstrual cycle and on the first two days of menstruation for (2 consecutive menstrual cycle).
214475237|NCT05493852|DEVICE|FARAPULSE Pulsed Field Ablation System|Patients diagnosed as paroxysmal atrial fibrillation with indication of ablation will be treated by FARAPULSE Pulsed Field Ablation System.
214475238|NCT06810102|OTHER|VIRTUAL REALITY GLASSES|There will be a video screening
214475239|NCT06167746|OTHER|Digital Health Information (DHI)|Digital health information websites.
214475240|NCT06167746|BEHAVIORAL|Virtual Health Coach for You|Study participants in the intervention group will receive 10-session virtual health coaching intervention session delivered over 6 months with the goal of improving caregiver self-care and coping, decreasing stress, and improving the hospital-to-home experience The 10 sessions are on average 60 minutes and cover the following topics: care transitions, caregiving demand, self-care, and coping.
214475241|NCT06810232|PROCEDURE|Gastrointestinal endoscopy|Patients will be divided into groups according to general health risk factors detected during preoperative anesthesia evaluation (hypertension, diabetes, asthma, obesity, chronic disease, medication history, immobility, smoking, etc.) and will be evaluated in terms of age, gender, weight and height will be combined to report BMI in kg/m2, alcohol, allergy, ASA, endoscopy site, complications that may develop related to anesthesia and sedation (such as hemodynamic instability, hemoglobin desaturation, pulmonary aspiration and apnea), additional interventions, and hospital stay.
214475242|NCT06809088|BIOLOGICAL|Albumin|Albumin
214475243|NCT06809088|OTHER|Standard Medical Treatment|Standard Medical Treatment
214475244|NCT04842877|DRUG|Valemetostat tosylate|200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
214475245|NCT05130268|DRUG|Dronedarone|Dronedarone 400 mg twice daily in addition to usual care
214475246|NCT06805578|OTHER|Heritage art programme|The 6-week 'Refresh and Reconnect!' programme includes guided gallery tours led by the museum's Care Facilitator volunteers and artist-led hands-on activities based on various art forms (e.g. artist-led dance, art, or drama workshops).
214475247|NCT06806111|PROCEDURE|Suture|Hemostatic sutures at the palatal donor site; 5-0 non-resorbable suspensory mattress sutures will be anchored to the soft tissues apical to the palatal wound area (5-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA).
214475248|NCT06806111|PROCEDURE|Cyanoacrylate bioadhesive|Several drops of a high-viscosity cyanoacrylate bioadhesive will be applied (Cuantum Oral Adhesive, Cuantum Medical Cosmetics S.L., Spain) to create a uniform adhesive layer.
214475249|NCT06808776|OTHER|Cancer survivor narrative|"The narrative video intervention has three parts: (1) Cancer experience - the cancer survivor narrates his/her experience with an HPV-related cancer, including diagnosis, treatment, and how cancer affected their personal life or family; (2) Vaccine recommendation - the cancer survivor provides brief information about the safety and effectiveness of the HPV vaccine and recommend that parents get the HPV vaccine for their child to prevent cancers; and (3) Closing message - The sentence HPV vaccine is cancer prevention. Talk to your child's healthcare provider about getting the HPV vaccine during the next clinic visit will appear on the screen."
214475250|NCT06808776|OTHER|Healthy eating tips|A publicly available video about healthy eating tips for families with children.
214475251|NCT06564324|DRUG|Taletrectinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met."
214847847|NCT02918682|OTHER|Exercise - FIRST PHASE|the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
214289738|NCT02709785|DRUG|SmartMouth Clinical DDS mouthrinse|Subjects use SmartMouth Clinical DDS mouth rinse for six weeks.
214289739|NCT02709785|DRUG|0.12% chlorhexidine rinse|Subjects use chlorhexidine mouth rinse for six weeks.
214289740|NCT02709785|DRUG|Placebo rinse|Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
214289741|NCT01910610|BIOLOGICAL|FOLFIRI-cetuximab|
214289742|NCT01910610|BIOLOGICAL|mFOLFOX6-bevacizumab|
214289743|NCT01910610|BIOLOGICAL|OPTIMOX-bevacizumab|
214289744|NCT01910610|BIOLOGICAL|irinotecan-based chemo + bevacizumab|
214289745|NCT01910610|BIOLOGICAL|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
214289746|NCT01910610|BIOLOGICAL|XELOX + bevacizumab|
214475252|NCT06564324|DRUG|Crizotinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met. Crossover from control group (crizotinib) to taletrectinib is also permitted, at the Investigator's discretion with the Sponsor's approval, for qualifying participants who have experienced objective progression confirmed by the BIRC."
214475253|NCT06387342|DRUG|Namodenoson 25mg|oral capsule
214475254|NCT06809244|OTHER|Exercise|"Strength training as described under arm"
214475255|NCT06808087|PROCEDURE|Transversus abdominis plane blockage|"1. Patient monitoring~2. Preparation of the skin with 10% povidone-iodine and ensuring appropriate draping~3. Placement of a high-frequency linear transducer transversely between the right iliac crest and subcostal margin along the midaxillary line. Structures visualized on ultrasound from superficial to deep include: skin, subcutaneous fat, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum. The TAP block will be performed in the transversus abdominis plane (TAP) between the internal oblique and transversus abdominis muscles.~4. A 23-gauge, 60 mm blunt-tipped needle will be directed toward the TAP, and negative aspiration will be confirmed upon entry into the fascial layer.~5. An injection of 20 mL of 0.25% bupivacaine, prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline, will be performed.~6. Visualization of the oval spread of bupivacaine in the TAP."
214475256|NCT06808087|PROCEDURE|Erector spinae plane blockage|"1. Patient monitoring~2. Positioning the patient in the prone position~3. Preparation of the skin with 10% povidone-iodine and ensuring appropriate draping~4. Counting the transverse processes from the sacrum to find the L1 level~5. Placing a low-frequency curvilinear transducer (depth set to 3-5 cm) parasagittally, and identifying the tip of the right transverse process at this level~6. Visualizing the erector spinae muscle overlying the transverse process~7. Inserting a 22G, 80 mm needle between the transverse process and the fascia of the erector spinae muscle~8. Injecting 1 to 3 mL of saline to confirm the separation of the erector spinae muscle fascia from the transverse process after negative aspiration~9. Injecting 20 mL of 0.25% bupivacaine, prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline, after another negative aspiration~10. Visualizing the oval spread of bupivacaine over the erector spinae muscle."
214475257|NCT06808087|DRUG|Tramadol|50 mg of tramadol will be administered via IV infusion over 15 minutes in 100 cc of isotonic 0.9% NaCl (normal saline).
214847848|NCT02918682|OTHER|Exercise - SECOND PHASE|the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
214906916|NCT06707766|OTHER|sub-occipital muscle energy technique along with Conventional Therapy|"Sub-occipital muscle energy technique (PIR) 3 rep \* 1 set with 20 sec hold~conventional therapy: hot pack 20 mins Kendall exercises: Strengthening the deep cervical flexor, Stretching the cervical extensors, Strengthening shoulder retraction, Stretching of the pectoralis major muscle~strengthening exercise: 12 repetitions\* 3 sets, 2-8 sec hold stretching exercise was: 3 reps\* 30 seconds' hold~Total duration of treatment would be 4 weeks, 3 days a week with total 12 sessions."
214475258|NCT06808893|OTHER|Psychiatric interview and documentary|"Nursing students who interview psychiatric patients will be provided with an Interaction Form to systematically evaluate and record their interviews. This form consists of the following columns: date of interview, duration of interview, duration of interview, verbal/non-verbal statements of the nurse and patient, effective communication technique and evaluation. The duration of the interview is expected to be between 30 and 45 minutes. Another component of the combination is the documentary Us, You, Them prepared by the Federation of Schizophrenia Associations of Turkey, which deals with the life stories of schizophrenia patients and lasts approximately 56 minutes."
214475259|NCT06808893|OTHER|Psychiatric interview|"Nursing students who interview psychiatric patients will be provided with an Interaction Form to systematically evaluate and record their interviews. This form consists of the following columns: date of interview, duration of interview, duration of interview, verbal/non-verbal statements of the nurse and patient, effective communication technique and evaluation. The duration of the interview is expected to be between 30 and 45 minutes."
214475260|NCT05256381|DRUG|Nanrilkefusp Alfa|Subcutaneous (SC) injection.
214475261|NCT05256381|DRUG|Pembrolizumab|Intravenous (IV) infusion via peripheral or central venous line.
214475262|NCT06808347|DRUG|application of the vaginal estrogen cream|patients will apply the vaginal estrogen cream
214475263|NCT06173323|BEHAVIORAL|ImPart - Improving Chronic Kidney Disease Decisional Partnerships|ImPart is a decision support intervention developed and refined in partnership with a advisory group of patients with and caregivers of people living with Chronic Kidney Disease. The program is designed to support decision-making throughout the illness experience.
214475264|NCT06810271|BEHAVIORAL|Eccentric resistance exercise|150 maximal, unilateral eccentric contractions of the quadriceps muscles on a computerized dynamometer.
214475265|NCT06810245|DRUG|PIPE-791|PIPE-791 tablet, taken once daily for 4 weeks
214475266|NCT06810245|DRUG|Placebo|Placebo tablet, taken once daily for 4 weeks
214475267|NCT06350877|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will be a 6-week supervised program. Participation will involve engaging in a weekly 1-h session provided in-person at the campus athletics and recreation centre. Each 1-h session will include: (1) 30 min of behaviour change coaching; and (2) 30 min of supervised and structured physical activity training. The intervention materials will include a behaviour change workbook for facilitating the 30 min of behaviour change coaching. Each week participants will complete the behaviour change workbook in session with the program trainer, whereby the overarching goal is to introduce and reinforce engagement in behaviour change techniques and to facilitate the learning objectives and experiences for each weekly session.
214475268|NCT04890067|OTHER|Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
214289747|NCT03272074|OTHER|Egg and egg white|Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.
214289748|NCT00000507|DRUG|streptokinase|
214475269|NCT05697250|OTHER|Laser power settings (Thulium Fiber Laser)|Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).
214475270|NCT01199133|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year.
214475271|NCT01199133|DRUG|Placebo tablet|One sublingual tablet daily for one year.
214475272|NCT05637541|DRUG|GST-HG141|The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment
214475273|NCT04631445|OTHER|Ketogenic Diet|Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to \< 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).
214475274|NCT03427996|PROCEDURE|Rotational atherectomy|Percutaneous coronary intervention with rotational atherectomy
214475275|NCT06175754|PROCEDURE|Laser ablation|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser
214475276|NCT06175754|PROCEDURE|Laser with Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser plus sclerotherapy
214475277|NCT06175754|PROCEDURE|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy
214475278|NCT06645132|BEHAVIORAL|exercise intervention|Exercise intervention leveraging wearable devices and a custom smartphone application to cue exercise as a reminder during idle time during an inpatient hospital stay, post allogenic bone marrow transplant.
214475279|NCT05415709|DRUG|Carboplatin|Given IV
214475280|NCT05415709|DRUG|Cisplatin|Given IV
214475281|NCT05415709|PROCEDURE|Cytoreductive Surgery|Undergo CRS
214475282|NCT05415709|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
214475283|NCT05415709|DRUG|Paclitaxel|Given IV
214475284|NCT05415709|OTHER|Quality-of-Life Assessment|Ancillary studies
214475285|NCT05415709|OTHER|Questionnaire Administration|Ancillary studies
214847849|NCT02918682|OTHER|Exercise - FOURTH PHASE|at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
214906917|NCT06884202|DEVICE|Delefilcon A contact lenses with different base curves and diameters|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.
214475286|NCT05415709|PROCEDURE|Biospecimen Collection|Undergo stool sample collection
214475287|NCT05415709|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
214475288|NCT04200300|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
214475289|NCT05153252|BEHAVIORAL|Morning Exercise|Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
214475290|NCT05153252|BEHAVIORAL|Evening Exercise|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
214475291|NCT06827522|PROCEDURE|Birth Under General Anesthesia|Before anaesthesia, GSR electrodes will be connected and signal recording will be started. After caesarean section, the newborn will be evaluated and GSR signals will be recorded again after the mother wakes up by providing skin-to-skin contact.
214475292|NCT06827522|PROCEDURE|Birth Under Spinal Anesthesia|GSR electrodes will be connected before anaesthesia, and since the mother will be conscious during caesarean section, the newborn will have skin-to-skin contact with the mother immediately after birth. During this process, GSR signals of the mother and the baby will be recorded.
214475295|NCT05977907|DRUG|Pembrolizumab|Pembrolizumab is an investigational drug in this study
214475296|NCT05977907|DRUG|IO102-103|IO102-103 is an investigational drug in this study.
214475297|NCT03114072|DEVICE|Blue-blocking glasses|Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
214475298|NCT03114072|DEVICE|Light grey control glasses|Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
214475299|NCT03890614|OTHER|Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates|Bone marrow aspirates will be collected from participants with hematologic malignancy being evaluated for relapsed disease to create three-dimensional constructs using a three-dimensional bioprinting methodology for automated organoid biofabrication.
214475300|NCT05868421|BEHAVIORAL|Support Person Coaching Call|Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The session will be delivered by research staff by phone or video call. Support persons in the intervention group and the control/no intervention group will receive existing written material resources on support strategies to stop smoking, and resources on how to stop smoking by postal mail or email.
214475301|NCT05868421|BEHAVIORAL|SP written materials|Written materials covering tips on effective supportive strategies for smoking cessation
214475302|NCT05868421|BEHAVIORAL|Written Smoking Cessation Materials|Written materials on resource and referral information for VHA and non-VHA EBCT options
214847850|NCT02918682|OTHER|Exercise - THIRD PHASE|participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
214475303|NCT03988621|BEHAVIORAL|ViCCY|Virtual Caregiver Coach for You
214475304|NCT06649682|DRUG|68Ga-NYM096 PET/CT and 177Lu-NYM096|Patients recruited in this study will undergo 68Ga-NYM096 PET/CT to evaluate the expression of carbonic anhydrase 9. Those with high CA9 expression will undergo 177Lu-NYM096 treatment, starting from 50mCi and increasing to 100mCi, 150mCi, 200mCi at most using a 3+3 design.
214475305|NCT05013385|DRUG|Spesolimab|Spesolimab
214475306|NCT05013385|DRUG|Placebo|Placebo
214475307|NCT06650098|OTHER|artificial intelligence-supported mobile application|It is aimed that an artificial intelligence-based mobile application that includes information, nutrition, exercise programs, complications and medication tracking, personalized suggestions, alarms and reminders, which will enable diabetic individuals to follow their glucose targets, support patients in their diabetes education, awareness and disease management to continue more actively. In addition, it is aimed that patients can easily access information, prevent acute and chronic complications, present physical activity and nutrition suggestions in accordance with the person\&#39;s lifestyle, follow up on medications with alarms and reminders, prevent the negative results of complications in advance, and improve individuals\&#39; diabetes-specific knowledge levels, compliance with treatment, self-management and care with information and guidance about foot care to reduce the risk of diabetic feet, which is particularly risky for diabetic patients.
214475308|NCT06650098|OTHER|WEB based application|The content plan for the web-based mobile application group will be prepared with technical support as specified. Patients will be able to log in to the mobile application with a username and password that will be defined specifically for them. Patients will be informed about how the website is used during the first meeting. They will be able to access all the information they need about diabetes with the web-based mobile application. Statistical data such as the frequency of individuals visiting the site, which sections they use more often and how much time they spend will be calculated.
214475309|NCT06650514|DRUG|OMO-103|OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).
214475310|NCT03887780|DRUG|Rivaroxaban (Xarelto,Bay 59-7939)|15 mg and 20 mg (OD)
214475311|NCT05283265|BEHAVIORAL|Sentence Type|Subjects read different types of sentences (object-relative, subject -relative and control sentences) to observe how that sentence affects their intracranially recorded neural activity.
214475312|NCT05283265|OTHER|Direct brain stimulation|On some trials the investigators will apply intracranial electrical current through the electrodes implanted in the participants and observe the effect this has on their behavior (which picture they choose at the end of the trial) and the effect this has on their neural activity that the investigators record simultaneously through-out the experiment.
214475313|NCT06649994|DEVICE|Active iTBS of the DLPFC|Participants will receive a 3 minutes intermittent Theta Burst Stimulation of the DLPCF of the left hemisphere while not performing any other task
214475314|NCT06649994|DEVICE|Active iTBS of the vmPFC|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vmPFC while not performing any other task
214475315|NCT06649994|DEVICE|iTBS of the vertex (sham)|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vertex while not performing any other task
214475316|NCT06649994|BEHAVIORAL|Computerized inhibitory control training|"Participants will perform the task of the FoodT app for 10 minutes immediately after iTBS (taking advantage of time of maximum brain potentiation, Rossi et al., 2009).~This task pairs high-calorie meals with the no-go cue. Images appear on the left, right or center of the smartphone screen and they must touch it or not (depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses: If the image has a green border around it, you must tap the image and win 1 point. But if the image has a red border around it, you must inhibit the tapping response or you will lose 1 point. Participants must respond as quickly and accurately as possible and improve reaction time.~Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal"
214475317|NCT06650956|OTHER|Integrated HPV and SRH Service Package|"1. Integrated Service Package combines HPV vaccination with sexual and reproductive health (SRH) education. The vaccine in the intervention package is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18.;~2. The package will be delivered through multiple touch-points such as school-based programs, health facility services, and community outreach. i) In school, the intervention incorporates Comprehensive Sexuality Education, empowering boys and girls with knowledge about their bodies, health, and rights. This goes beyond simply providing information about HPV and vaccination. ii) At health facilities, the intervention package will also be delivered in adolescent-friendly ways, ensuring that boys and girls feel comfortable accessing SRH information. iii) Since not all boys and girls attend school, the intervention includes community outreach that ensures wider reach and accessibility for adolescents aged 10-13, including those not enrolled in school."
214475318|NCT06650956|BIOLOGICAL|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|The vaccine itself is not the intervention of interest as this is delivered in both intervention and comparison arms. The vaccine is a single dose of recombinant Human Papilloma Virus Quadrivalent (Types 6, 11, 16, and 18). The administration of the vaccine is an intramuscular injection of 0.5 mili liter of suspension form.
214475319|NCT06203834|DIETARY_SUPPLEMENT|I-Fiber Pearl|Eat 200g for once, and once a day.
214475320|NCT06203834|DIETARY_SUPPLEMENT|placebo|Eat 200g for once, and once a day.
214475321|NCT06652503|BEHAVIORAL|online mental health coaching|SWAG-R Program: A 6-week Coaching Program Designed for NSU Undergraduate Students to Decrease Anxiety, Depression, and Stress and Improve Mental Health, Quality of Life, and Resiliency
214475322|NCT06651866|DRUG|D-CMG|"Liposomal mitoxantrone hydrochloride injection (Doxorubicin®): Used after dilution with 250mL of 5% glucose injection (50mg/mL), with an intravenous drip time of at least 60 minutes.~* Level 1: 12mg/m2, IV drip, day 4;~* Level 2: 18mg/m2, IV drip, day 4; Decitabine: 25mg, IV drip, days 1-3; Cytarabine: 10mg/m2, every 12 hours, IV drip, days 4-10; G-CSF: 300 ug, IV drip, days 1-5; Each cycle is 4 weeks, with a total of 2 cycles, and DLT is observed in the first cycle.~Note: Patients who achieve CR (Complete Remission) and PR (Partial Remission) in the first cycle can continue with the original dose for one more cycle, and then the investigator decides whether to continue this regimen or choose another regimen for maintenance therapy; Patients with NR (No Remission) in the first cycle will be withdrawn from this study."
214475323|NCT06651957|OTHER|Biospecimen Collection|Specimen swabs will be obtained.
214475324|NCT06651957|OTHER|Questionnaires|Given to participants
214475325|NCT06653322|DRUG|HR-1703|HR-1703 will be administered by SC injection.
214475326|NCT06653322|DRUG|Placebo|Matching Placebo will be administered by the SC injection.
214475327|NCT04417166|DRUG|Pembrolizumab|50 mg powder for concentrate for solution for infusion
214475328|NCT04417166|RADIATION|Involved Field Radiation Therapy|"50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age \> 60 years, stage II, elevated serum LDH levels).~Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed."
214475329|NCT03165786|BEHAVIORAL|FREE|Cognitive behavioral therapy with real-time continuous glucose monitoring.
214475330|NCT06652971|DRUG|CKD-379|QD, PO
214475331|NCT03973827|DRUG|ProTrans|Single infusion of 25, 100 or 200 million cells per patient.
214475332|NCT03973827|OTHER|Control|No intervention. Control subjects.
214475333|NCT06652100|DIAGNOSTIC_TEST|ProNephro AKI (NGAL)|ProNephro AKI™ (NGAL) is an immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine.
214475334|NCT06653036|PROCEDURE|Dural puncture epidural|The Dural puncture epidural technique is done by assessing the epidural space using the Touhy needle and puncturing the dura matter with a finer needle.
214475335|NCT06653036|PROCEDURE|Standard Epidural Technique|The Standard Epidural Technique is usually performed by identifying the epidural space using the loss of resistance technique and threading the epidural catheter in the epidural space for administration of analgesic drugs.
214475336|NCT04629339|DRUG|INCB086550|INCB086550 will be administered orally twice a day.
214475337|NCT02488564|DRUG|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
214475338|NCT02488564|DRUG|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
214475339|NCT02488564|DRUG|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
214475340|NCT02488564|DRUG|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
214475341|NCT04705519|DRUG|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w.
214475342|NCT00302744|DRUG|Psilocybin (drug)|Capsule (.2 mg/kg).
214475343|NCT00302744|OTHER|Niacin|Active Placebo
214475344|NCT00302744|DIAGNOSTIC_TEST|MRI|MRI required for study inclusion for purpose of ruling out metasteses to brain
214475345|NCT05562557|BEHAVIORAL|Motivational Enhancement|To encourage intrinsic motivation to engage in fatherhood activities
214475346|NCT05562557|BEHAVIORAL|HERO Dads Fatherhood Program|Fatherhood engagement curriculum to increase awareness, knowledge, and skills for parenting and co-parenting
214475347|NCT05562557|BEHAVIORAL|Contingency Management|To reinforce healthy behaviors, including attendance at services
214475348|NCT05562557|BEHAVIORAL|Case Management|Referrals to treatment, social services, and employment services
214475349|NCT03998527|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)|TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.
214475350|NCT06059456|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
214475351|NCT06059456|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
214475352|NCT05238519|BEHAVIORAL|Motivational interview (MI)|"The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH."
214475353|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation Randomized)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.
214475354|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation-Open Label)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 8 weeks using a non-invasive brainstem modulation device.
214475355|NCT03270059|DRUG|Ferumoxytol|Given IV
214475356|NCT03270059|DRUG|Gadolinium|Given IV
214475357|NCT03270059|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214475358|NCT05303129|BIOLOGICAL|Blood sampling|Blood sampling for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts )
214475359|NCT04381299|OTHER|autologous platelet rich plasma|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
214475360|NCT04381299|OTHER|saline solution|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
214475361|NCT04938726|DIETARY_SUPPLEMENT|Ketone Monoester|Ketone supplement will be taken by mouth at a dose of 15 mL twice per day
214475362|NCT04864353|BEHAVIORAL|RestDep: Internet-delivered intervention targeting residual cognitive symptoms|The intervention is fully digital with weekly telephone guidance. Key intervention elements are 1) psychoeducation, 2) attention training, 3) strategy training. Cognitive domains as attention, memory and executive functions are covered and rumination.
214475363|NCT06288659|DEVICE|Intraventricular intracranial pressure monitoring|The postoperative management of ICP is guided by quantifiable Intraventricular ICP parameters. The remaining treatments are consistent with those in the control group.
214475364|NCT06026969|OTHER|Neurodevelopmental assessments and follow-up|All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
214475365|NCT05749900|DRUG|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
214475366|NCT04233255|DEVICE|Neuromuscular Ultrasound (US)|"Quantitative ultrasound measurements will be performed to studied muscles according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.The study will be performed using My lab 7 ultrasound system (Esaote company, Italy) that is equipped by 7-19 MHz linear array transducer and color and power Doppler.~Technique: evaluation of studied muscles for echo intensity (ECHO), quantitative assessments of echointensity, muscle perfusion, transverse and longitudinal sections of the muscle and its thickness at rest and during maximal voluntary contractions (MVC), overlying subcutaneous fat, cross-sectional area (CSA), and angled fibers of pennate muscles."
214475367|NCT04233255|DEVICE|Electrophysiological studies|"Includes: Motor and sensory nerve conduction study, F-wave and H-reflex study to assess the proximal roots, Electromyography (EMG) of the studied muscles.~using machine: recordings will be performed with a Nihon Kohden equipment (model 7102) with the following parameters: sweep time 8 ms/D, sensitivity 0.5 mV/D, low frequency filter 2 Hz, high frequency filter 10 kHz, stimulation duration 0.1 ms and stimulation frequency 1 Hz."
214475368|NCT04233255|DIAGNOSTIC_TEST|Seum CPK, CK-MM levels, Lactate dehydrogenase and alanine aminotransferase.|measured in U/L using ELISA.
214475369|NCT05610319|DRUG|Faricimab|Faricimab will be administered via intravitreal injection.
214475370|NCT04548778|DIAGNOSTIC_TEST|BÜHLMANN fPELA assay|BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
214475371|NCT06044493|DRUG|Myreptic-N Tablet|Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit
214847851|NCT06617676|DEVICE|Transcutaneous tibial nerve stimulation|Two electrodes will be place over the tibial nerve over the medial ankle. The electrical stimulation will be turned up to patient tolerance at a sensory level only.
214847852|NCT03668431|DRUG|Dabrafenib|"Dabrafenib will be taken twice a day for 28 consecutive days~."
214847853|NCT03668431|DRUG|Trametinib|Trametinib will be taken once a day for 28 consecutive days
214847854|NCT03668431|DRUG|PDR001|PDR001 will be administered IV every 28 days
214475372|NCT06044493|DRUG|Mycophenolate mofetil Tablet/Capsule|Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit
214475373|NCT06119503|BEHAVIORAL|Elongating Time HOrizons for Reentry (ETHoR)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in an incarceration free future.
214475374|NCT06119503|BEHAVIORAL|Standardized Episodic Thinking (SET)|In the standardized episodic thinking (SET) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
214847855|NCT00003531|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214847856|NCT02487082|DRUG|Melatonin and Donepezil|10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.
214475375|NCT04829526|OTHER|data collection|Retrospective extraction of demographic, clinical, laboratory, and electrophysiological data from the digital medical records
214475376|NCT01447719|DRUG|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
214475377|NCT06568458|DRUG|Nintedanib|Specified Dose on specified days
214475378|NCT06568458|DRUG|BMS 986278|Specified dose on specified days
214475379|NCT03717753|OTHER|Pathway|The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components. Both groups will receive identical postoperative follow-up.
214475380|NCT05102942|BEHAVIORAL|Attentional Control Training Program|The 268 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 134), or Group B: ACTP sham training delivered via a smartphone application + TAU (n = 134) Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks).
214475381|NCT03914469|BEHAVIORAL|Behavioral Intervention Group|The active intervention will include eight tele-delivered health coach sessions, three tele-based outcome assessments, and up to two semi-structured interviews at 6 months post-intervention. Each tele-based outcome assessment is roughly 45-60 minutes and will be conducted by a member of the research team. Each intervention session will be delivered by a trained health coach over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
214475382|NCT04791865|BEHAVIORAL|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
214475383|NCT04791865|BEHAVIORAL|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
214475384|NCT05637684|DEVICE|low intensity pulsed ultrasound|mechanical sound waves
214475385|NCT05683132|BEHAVIORAL|Trauma-Informed CBT-I|5 individual sessions incorporating behavioral and cognitive therapy components and trauma-informed adaptations with a trained instructor.
214475386|NCT05683132|BEHAVIORAL|PTSD Psychoeducation|5 individual sessions incorporating psychoeducation about PTSD symptoms with a trained instructor.
214475387|NCT06082050|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1， Subjects may voluntarily accept the second study drug treatment at the OBD (Optimal Biological Dose) level.
214475388|NCT05209984|DRUG|ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg|Participant will receive for two (2) weeks one (01) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsule once daily + one (01) sibutramine placebo capsule 10mg; after that 2 weeks, participants will receive one (01) placebo capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) 10mg sibutramine placebo capsule; after this period, they will receive two (02) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 10mg of sibutramine and 50mg of topiramate) + a placebo capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once a day + one (one) 10mg sibutramine placebo capsule, taken once daily, for two (02) additional weeks, on the titration scheme. On the treatment period, will receive one (01) ADF Sibutramine IR/Topiramate XR 15mg/75mg capsule + one (01) Sibutramine IR 15mg placebo capsule (Sibus®) + one (01) Topiramate XR 100mg placebo capsule, once daily, for 52 weeks.
214475389|NCT05209984|DRUG|ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg|Participant will receive for two (02) weeks one (01) capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once daily + one (01) capsule of placebo sibutramine 10mg; after this initial period of 2 weeks, participants will receive (02) ADF sibutramine IR/topiramate XR 5mg/25mg capsules (totaling 10mg of sibutramine and 50mg of topiramate) + one (01) 10mg sibutramine placebo capsule, taken once daily, for two (02) weeks; after this period, they will receive three (03) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 15mg of sibutramine and 75mg of topiramate) + one (01) capsule of 10mg sibutramine placebo, taken once daily, for two ( 02) additional weeks, on titration scheme. On the treatment period, will receive one (01) Sibutramine IR 15mg capsule (Sibus®) + one (01) Topiramate XR 100mg capsule + one (01) ADF placebo capsule sibutramine IR/topiramate XR 15mg/75mg, taken once daily, taken once daily, for 52 weeks.
214475390|NCT05209984|DRUG|SIB Group Sibus (Sibutramine) 15mg|Participant will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) 5mg/25mg sibutramine ADF placebo capsule IR/topiramate XR; after this initial period, they will receive for two (02) weeks one (01) 10mg sibutramine capsule + two (02) placebo capsules of ADF sibutramine IR/topiramate XR 5mg/25mg; after this 4-week period, participants will receive one (01) 10mg sibutramine capsule and three (03) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) additional weeks. This corresponds to the titration scheme.On the treatment period, patient will receive one (01) Sibutramine 15mg capsule + one (01) Sibutramine IR/topiramate XR 15mg/75mg placebo capsule + one (01) placebo capsule of Topiramate XR 100mg, taken once daily, for 52 weeks.
214479485|NCT06671171|DEVICE|Apple Watch Series 9|"Participants will wear Apple Watch Series 9 during cardiopulmonary exercise test (in Visit 1), 1-week study period and 6-Minute walk distance test (in Visit 2) to have assessment of maximal oxygen uptake and pre- and post-SaO2.~During 1-week study period, participants will measure their oxygen saturation once daily with a medical-grade pulse oximeter while wearing the smartwatch continuously."
214847857|NCT02487082|OTHER|Placebo|For both groups: 5 weeks of Placebo in the Run-In Phase. For Group B: an addition 5 weeks of Placebo in Phase 1.
214847858|NCT04733248|OTHER|Kinesiotaping group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHING EXERCISES(10 reps 3sets) hold for 2 sec~* Apply KINESO- TAPE on upper trapezius (from I-O for Inhibition purpose)~HOME PLAN OF EXPERIMENTAL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec (In neck flexion, In neck extension, In side bending) In experimental group kinesiotape was applied on upper trapezius from insertion to origin for inhibition purpose. As it had increased the functional status of the patient. Post -intervention assessment was taken on 1 st, 2nd and 3rd visit."
214847859|NCT04733248|OTHER|stretching group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHINGS EXERCISES (10 reps 3sets) hold for 2 sec 5.9HOME PLAN OF CONTROL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec In neck flexion In neck extension In side bending Post-intervention assessment was taken on 1 st, 2nd and 3 rd visit"
214847860|NCT02601768|DEVICE|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
214847861|NCT03588650|DRUG|HLX20|a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein
214847862|NCT05549050|OTHER|interdialytic weight gain|interdialytic weight gain during hemodialysis
214847863|NCT00251316|DRUG|Lithium Carbonate|30 mCi of 131I
214475391|NCT05209984|DRUG|Placebo Group|participants randomized to the Placebo Group will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) sibutramine IR/ topiramate XR 5mg/25mg placebo capsule; after this initial period, they will receive one (01) sibutramine 10mg placebo capsule + two (02) sibutramine IR/ topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) weeks; after this 4-week period, participants will receive one (01) 10mg sibutramine placebo capsule + three (03) ADF placebo capsules, taken once daily, for two (02) weeks.On the treatment period, patient will receive one (01) Sibutramine 15mg placebo capsule + one (01) ADF sibutramine IR/Topiramate XR 15mg/75mg placebo capsule + one (01) Topiramate XR 100mg placebo capsule, in once daily intake for 52 weeks.
214475392|NCT06541041|DEVICE|Brief intraoperative electrical stimulation|Intraoperative brief electrical stimulation (BES) will be performed using a handheld nerve stimulator (Checkpoint Guardian) to stimulate the donor nerves at 2 mA with a 200 µs pulse duration for 10 minutes per nerve.
214475393|NCT06541041|DEVICE|Temporary Postoperative Peripheral Nerve Stimulation|An implantable temporary peripheral nerve stimulator (SPRINT PNS System) will be placed during the surgery with one lead for each donor nerve. The implantable peripheral nerve stimulator will be programmed to optimize postoperative pain control on an individualized basis. The peripheral nerve stimulator will be explanted after 60 days, as is intended for this device.
214475394|NCT06828484|DRUG|Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP)|Cat-allergic and non-allergic participants will be exposed to AP Cat in the NAC.
214475395|NCT05308979|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
214475396|NCT04588415|OTHER|Bereavement Virtual Support Group|"Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased)."
214475397|NCT06818409|DIAGNOSTIC_TEST|The Diagnostic and Statistical Manual of Mental Disorders (DSM) - 5 criteria for delirium diagnosis|Delirium presence will be assessed using DSM-5 criteria twice daily (morning and evening) for three days, after surgery.
214475398|NCT06815809|BEHAVIORAL|Floor-HI (intervention combines floor exposure with floor rise strategies)|"Floor HI training consists of the following three systematic steps~1. Positioning on the floor: Participants are first taught the backward chaining method. This technique involves using nearby furniture as support to move from an upright position to a kneeling position, through prone and side lying positions, and finally to a supine position.~2. Ground hugging: In this phase, participants will assume a position on the floor. They are encouraged to simulate a fall scenario by observing their surroundings while using relaxation techniques. This includes deep breathing exercises.~3. Getting up from the floor: The final phase focuses on teaching participants techniques to recover from a fall, tailored to their individual balance abilities.~The intervention is carried out on printed surfaces that mimic high fall risk surfaces such as icy, cluttered, wet surfaces."
214475399|NCT06036147|BEHAVIORAL|Concussion-focused cognitive behavioral therapy|Youth randomized to receive this component will participate in six 30-minute sessions of cf-CBT. The intervention includes modular CBT targeting post-concussive, anxiety and depressive symptoms. In this CBT treatment, the adolescent can be taught coping skills, relaxation strategies, and cognitive strategies to manage their symptoms, while they are encouraged to increase appropriate activation, including pacing of activities. Six sessions from the CHIP Study Cognitive and Behavioral Skills for Concussion Recovery will be chosen by the interventionist based on the youth's goals in the Introduction Session.
214475400|NCT06036147|BEHAVIORAL|Parent skills training|The focus of the PST component is on the use of positive parenting skills as well as helping parents manage their own emotional distress. Parents are taught to set positive recovery expectations, and to use praise or attention to increase their teen's positive coping behaviors and decrease unhelpful coping behaviors. They are also taught positive communication skills to use with their teen, and guided to schedule pleasant events together in order to strengthen the relationship. In-vivo skills practice and feedback are provided to help parents generalize and use PST techniques. Parents randomized to receive this component will participate in six 30-minute sessions of PST, chosen from the CHIP Study Parent Support Skills Training for Concussion recovery based on the parent's goals in the Introduction Session.
214479486|NCT06671197|DEVICE|Pulmonary vein isolation|Pulsed field ablation
214479487|NCT06671197|DEVICE|Pulmonary vein isolation+posterior left atrial wall line+superior vena cava isolation|Pulsed field ablation
214479488|NCT02361658|OTHER|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
214847864|NCT00251316|DRUG|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
214847865|NCT00346164|DRUG|doxorubicin hydrochloride|Given IV
214847866|NCT00346164|OTHER|clinical observation|Patients undergo observation
214847867|NCT00346164|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
214847868|NCT00346164|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
214847869|NCT00346164|DRUG|ifosfamide|Given IV
214847870|NCT02266849|DRUG|Loperamide|12 mg Loperamide each day for three days
214847871|NCT02266849|DRUG|Placebo|6 tablets daily for three days
214847872|NCT00692952|DRUG|a novel Benzalkonium Chloride (BZK) contraceptive gel|insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.
214847873|NCT00692952|DRUG|LELEMI® contraceptive gel containing 50mg nonoxynol-9|insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
214847874|NCT06616493|OTHER|kinesio taping|measure the subjects' lower extremity biomechanical characteristics with 3 different conditions respectively (kinesio taping, placebo kinesio taping, no taping)
214475401|NCT06036147|BEHAVIORAL|Care management|In the CM component, parents are provided support regarding advocating for their child's needs across different contexts in the healthcare system, school and athletic departments (including guidance regarding medication referrals), using applied problem-solving together with the skills coach to address emergent needs. Adolescents can also be involved in CM, if developmentally appropriate based on their age, independence, and interest. Of note, while the CM component engages youth and parents, treatment effects are hypothesized to result from facilitating access to supportive services including medication referrals at the organizational level. Families randomized to receive this component will participate in six 30-minute sessions of CM, following the guidelines in the CHIP Care Management Manual.
214475402|NCT03263988|DEVICE|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
214475403|NCT06738888|OTHER|Observations on clinicopathological factors influencing the difficulty of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data, thyromental distance, neck circumference, sternomental distance, ratio of height-to-thyromental distance, RHTMD, ratio of height-to-sternomental distance, RHSMD
214475404|NCT05093933|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
214475405|NCT05093933|DRUG|Placebo|0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
214475406|NCT05304078|BEHAVIORAL|Telehealth Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.
214475407|NCT05304078|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
214475408|NCT06279533|DRUG|LV232/Placebo|"Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 40mg Group:~6 subjects will receive LV232 40mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 60mg Group:~6 subjects will receive LV232 60mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally."
214475409|NCT06279533|DRUG|LV232|"Drug: LV232 20mg Group:~12 subjects will receive LV232 20mg, orally~Drug: LV232 60mg Group:~12 subjects will receive LV232 60mg, orally"
214475410|NCT04050410|DRUG|Moxonidine|active drug given as 1 dose
214475411|NCT04050410|DRUG|Placebo|placebo pill given as 1 dose
214475412|NCT04372433|BIOLOGICAL|IO-202|IO-202 as monotherapy
214475413|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
214475414|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine + Venetoclax|IO-202 and azacitidine + venetoclax combination therapy
214475415|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
214475416|NCT06038513|DEVICE|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 24 hours
214475417|NCT06070987|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 100 units. The dose range of each target muscle is as below:100 units in rectus femoris.
214475418|NCT06070987|OTHER|BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot after BoNT-A injected in the affected rectus femoris, then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
214475419|NCT06070987|OTHER|None BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot (do not inject BoNT-A in the affected rectus femoris), then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
214475420|NCT05282030|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablets Route of administration: oral
214475421|NCT05082454|DEVICE|Open repair|Open repair of the aortic heart valve and ascending thoracic aorta
214847875|NCT02025088|PROCEDURE|Laser|Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
214475422|NCT06822153|DRUG|ET-26 0.8mg/kg(low-dose) group|In a 2:1 ratio, Placebo was administered with normal saline and ET-26 0.8mg/kg for a duration of 60 ±5 seconds.
214475423|NCT06822153|DRUG|ET-26 2.8mg/kg(high dose) group|In a 2:1 ratio, Placebo was administered with normal saline and ET-26 2.8mg/kg for a duration of 60 ±5 seconds.
214475424|NCT04993170|DIAGNOSTIC_TEST|Bleeding assessment tool|The standardized application of the questionnaire serves to identify patients at risk of bleeding at an early stage and to adapt and optimize perioperative coagulation management accordingly by initiating targeted diagnostics and therapy
214475425|NCT03944356|DRUG|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
214479489|NCT02361658|OTHER|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
214475426|NCT06828770|DEVICE|Minima Stent System|Minima Stent System is indicated for use in the treatment of native or acquired pulmonary artery stenoses or coarctation of the aorta in neonates, infants, and children at least 1.5kg in weight.
214475427|NCT04936178|DRUG|NB003 tablets|NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.
214475428|NCT04350177|DRUG|IkT-148009|Oral administration gelatin capsule
214475429|NCT04350177|DRUG|Placebo|Oral administration gelatin capsule
214475430|NCT04683081|DEVICE|mechanical cervical ripening|mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
214475431|NCT03235440|BEHAVIORAL|Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
214475432|NCT02815150|DIETARY_SUPPLEMENT|preoperative oral carbohydrate drink|5% glucose solution 250ml 2-3 hours before surgery
214475433|NCT05384561|OTHER|Smell training|For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
214475434|NCT05977556|BEHAVIORAL|Combined neuromuscular exercise training and 'sit less, move more' program|"Neuromuscular strength training: The experimental group will receive up to 24 sessions of neuromuscular strength training led by a physical therapist with expertise in geriatrics and movement behaviors. The program includes exercises such as pelvic lifts, lunges, step-ups, squats, and sit-stands. The difficulty level will progressively increase using techniques like manual resistance, dumbbells, and unstable surfaces.~Sedentary behavior intervention: The experimental group will also undergo a sedentary behavior intervention based on social cognitive theory. It involves weekly coaching sessions to enhance self-efficacy in reducing sedentary time and increasing light-intensity activity throughout the day. Participants will be provided with a wrist-worn Fitbit activity monitor for daily feedback and to track adherence to the intervention. The aim is to encourage participants to sit less and move more throughout their waking hours."
214475435|NCT04391595|DRUG|Abemaciclib|100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
214475436|NCT04391595|DRUG|LY3214996|400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
214475437|NCT03318159|DRUG|Posaconazole|"Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~\*if posaconazole tablet intolerance: posaconazole suspension 200mg tid"
214475438|NCT06768177|DRUG|PRP injection|3 ML OF PRP
214475439|NCT06768177|DRUG|Alprostadil 20 micrograms|1 ML
214475440|NCT06853964|OTHER|AlloMend® Acellular Dermal Matrix allograft|AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
214475441|NCT06854302|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance imaging|Observational diagnostic tests will include adenosine-stress perfusion cardiovascular magnetic resonance imaging before undergoing percutaneous coronary intervention.
214475442|NCT06854302|DIAGNOSTIC_TEST|Coronary physiology|Invasive coronary function tests using a diagnostic guidewire (PressureWire-X, Abbott), thermodilution, intravenous or intracoronary infusion of adenosine and intracoronary infusions of acetylcholine.
214475443|NCT06854523|DRUG|PCSK9 inhibitor|The patient used Trastuzumab 150mg within 24 hours before or after PCI, and then every two weeks for 12 months
214475444|NCT06854523|DRUG|Statin+ezetimibe|The patient used statins and ezetimibe within 24 hours before or after PCI, and then once a day for 12 months
214475445|NCT06854523|BEHAVIORAL|Blood lipid levels meet the recommended guidelines|Early use of intensified lipid-lowering therapy during hospitalization led to a rapid decrease in blood lipids and met the recommended guidelines.
214475446|NCT06854523|BEHAVIORAL|Blood lipid levels don't meet the recommended guidelines|The patient did not receive intensified lipid-lowering treatment during hospitalization or did not meet the recommended guidelines for blood lipids
214475447|NCT06853769|DRUG|Anlotinib hydrochloride,Penpulimab|Penpulimab 200mg IV D1 Anlotinib 12mg P.O. QD D1-14
214475448|NCT06853509|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
214475449|NCT06809556|OTHER|EEG (electroencephalogram) monitoring of Parkinson's patients undergoing deep brain stimulation|Parkinson's patients undergoing deep brain stimulation (DBS) will be monitored with EEG to detect burst suppression signals during surgery and will undergo postoperative cognitive testing for postoperative delirium.
214475450|NCT06853834|DEVICE|Cryobiopsy with liquid nitrogen|Forceps vs Cryo Endobronchial Biopsy
214475451|NCT06853834|DEVICE|Endobronchial Forceps Biopsy|Comparision of forceps and cryo endobronchial biopsy
214479490|NCT02361658|OTHER|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
214479491|NCT06678945|PROCEDURE|Bar-Clip attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using clip.
214479492|NCT06678945|PROCEDURE|Bar- OT Equator attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using the OT Equator.
214475452|NCT06804902|BEHAVIORAL|Monthly RDT Validation Meeting|Health facilities in intervention districts will bring all RDT cassettes performed in their facility and all outpatient registers to a monthly data validation meeting led by the surveillance, monitoring and evaluation officers (CSE). During these meetings, Audere's HealthPulse application will be used to take photos of each facility's RDT cassettes, tallying the total number of RDTs and total by result. The test positivity rates (TPRs) from the registers will be manually entered into the application and compared with the TPR from the RDT photos. Healthcare facilities with a discrepancy above a certain threshold between TPR derived from register data and the TPR derived from the RDT images may be asked to carry out a more detailed audit to better understand the source of discrepant results. If discrepancies are identified, the CSE will determine what corrections are required before entry into the DHIS2.
214475453|NCT06810479|DIAGNOSTIC_TEST|Polygraphy|Polygraphy will be caried out at the patients home to evaluate each MRA after 3 monhts
214475454|NCT06810479|OTHER|Questionaire|"Epworth Sleepiness Scale~o Johns, Murray W. A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale. Sleep, vol. 14, no. 6, 1991, pp. 540-545."
214475455|NCT06810479|OTHER|Questionaire|"Patient experience questionnaire~o Ng, E.T., Perez-Garcia, A., en Lagravère-Vich, M.O. Development and Initial Validation of a Questionnaire to Measure Patient Experience with Oral Appliance Therapy. Journal of Clinical Sleep Medicine, vol. 19, nr. 8, 1 aug. 2023, pp. 1437-1445. doi: 10.5664/jcsm.10562. PMID: 37082817; PMCID: PMC10394373"
214475456|NCT06810479|OTHER|Question|Patient final choice of preferred MRA
214475457|NCT06854770|BEHAVIORAL|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
214475458|NCT06855407|OTHER|Blood pressure elevation|Increasing systemic blood pressure for measurement of cerebral blood flow changes
214475459|NCT06813118|DRUG|Clomiphene Citrate and letrozole|clomiphene citrate 100mg once daily along with letrozole 5mg to one group and letrozole 5mg to second group
214475460|NCT06655727|DIAGNOSTIC_TEST|Ultrasound evaluation|No intervention
214475461|NCT06811623|PROCEDURE|Laparoscopic Sleeve Gastrectomy with omentopexy|Laparoscopic Sleeve Gastrectomy with omental fixation to the gastric tube
214475462|NCT06811623|PROCEDURE|Laparoscopic Sleeve Gastrectomy without omentopexy|Laparoscopic Sleeve Gastrectomy without omental fixation to the gastric tube
214847876|NCT02025088|PROCEDURE|Microneedling|"Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
214847877|NCT04464109|PROCEDURE|Evisceration with orbital implantation|Evisceration will be performed. Alloplastic orbital implant will be inserted either posterior to the sclera or partly within the scleral canal.
214475463|NCT01121588|DRUG|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
214475464|NCT06498128|DRUG|Daridorexant|Dosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
214475465|NCT06498128|DRUG|Non-orexin receptor antagonist medications for insomnia|Dosing and treatment duration of non-orexin receptor antagonist medications for insomnia as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
214475466|NCT06498128|OTHER|No insomnia medication|No insomnia medication was administered.
214475467|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Baseline|Measurement of rubella IgG antibody levels at baseline
214847878|NCT03370107|DEVICE|rTMS|Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
214847879|NCT02283593|BEHAVIORAL|eChange.se|7 modules: 1. Making a decisional balance 2. Setting a goal for alcohol consumption 3. Learning self control skills 4. Identifying risk situations 5. Dealing with urges 6. Dealing with emotions and with social pressure 7. Developing a crisis plan
214847880|NCT01402154|BIOLOGICAL|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
214847881|NCT01402154|BIOLOGICAL|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
214847882|NCT01049347|DRUG|amitriptyline|150 mg oral, daily, single evening dose, 35 days
214475468|NCT05923970|DIAGNOSTIC_TEST|Serology to assess cell mediated immune (CMI) response - Baseline|Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.
214475469|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Post third dose of MMR vaccine|Measurement of rubella IgG antibody levels post third dose of MMR vaccine
214475470|NCT05923970|DIAGNOSTIC_TEST|Serology to assess CMI - Post third dose of MMR vaccine|Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.
214475471|NCT04257461|DRUG|Fluoropyrimidine|Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
214475472|NCT04257461|DRUG|Oxaliplatin|Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
214475473|NCT04466683|RADIATION|Low dose radiation 35 cGy|A dose of 35 cGy of whole thorax irradiation will be delivered at a single timepoint
214475474|NCT04466683|RADIATION|High dose radiation 100 cGy|A dose of 100 cGy of whole thorax irradiation will be delivered at a single timepoint
214847883|NCT01049347|DRUG|paroxetine|40 mg oral, single dose, morning, 35 days
214847884|NCT05118360|DRUG|ASC41 2 mg|2mg of ASC41 orally once daily for 52 weeks
214847885|NCT05118360|DRUG|ASC41 4 mg|4mg of ASC41 orally once daily for 52 weeks
214847886|NCT05118360|DRUG|Placebo|Matching placebo orally once daily for 52 weeks.
214475475|NCT06841276|DEVICE|QoLibri Digital Therapy|A personalized program intended for chronic pain patients. It includes digitalized physical and psychological complementary approaches dedicated to symptoms management and quality of life improvement.
214475476|NCT06814704|OTHER|Hypopressive exercises , hot packs, acetaminophen, progressive strengthening exercises|20 subjects combined HE with traditional treatments for low back pain (heat therapy, medication, and progressive strength training).
214475477|NCT06814704|OTHER|heat therapy, pharmacological therapy, progressive strengthening exercises|"Hypopressive exercises :The women were instructed to hold breath with chest extension for approximately 10 seconds before they began to breathe again. Then, using a series of upper and lower limb positions, the subjects were shown how to apply a series of hypopressive postures"
214475478|NCT06814067|DRUG|Pembrolizumab|Two cycles of neoadjuvant pembrolizumab (200mg q3w) followed by radical surgery. Adjuvant radiotherapy/chemoradiotherapy is decided based on pathological risk factors. Fifteen cycles of pembrolizumab (200mg q3w)maintenance therapy was given.
214475479|NCT06814067|DRUG|Ivonescimab|Two cycles of neoadjuvant Ivonescimab (10mg/kg q3w) followed by radical surgery. Adjuvant radiotherapy/chemoradiotherapy is decided based on pathological risk factors. Fifteen cycles of Ivonescimab maintenance therapy (10mg/kg q3w) was given.
214475480|NCT06814067|PROCEDURE|Surgery|Radical surgery
214475481|NCT06814067|RADIATION|Adjuvant radiotherapy|Adjuvant radiotherapy with/without concurrent cisplatin-based chemotherapy, based on pathologic risk factors.
214475482|NCT06814418|PROCEDURE|Non-surgical periodontal treatment|Step I and II of periodontal treatment.
214847887|NCT05085769|PROCEDURE|Bariatric surgery|A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
214847888|NCT02412462|DRUG|AB-16B5|
214847889|NCT02506231|DRUG|Folinic acid|
214847890|NCT02506231|DRUG|Placebo|
214847891|NCT02039063|DRUG|E6011 2 mg/kg|
214847892|NCT02039063|DRUG|E6011 5 mg/kg|
214847893|NCT02039063|DRUG|E6011 10 mg/kg|
214847894|NCT02039063|DRUG|E6011 15 mg/kg|
214847895|NCT03241316|BEHAVIORAL|Observational study of behaviour|As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
214847896|NCT02621463|DEVICE|Noninvasive Ventilator (V60, Philips)|The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
214847897|NCT05487755|DRUG|Tadalafil 20Mg Oral Tablet|Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
214475483|NCT06814418|PROCEDURE|Injectable Platelet Rich Fibrin (I-PRF)|Infusion of I-PRF in sited with PPD≥5mm.
214475484|NCT06812338|DEVICE|mechanical traction|Participants will receive traction therapy as follows: force will start at 25% of Body weight, gradually increasing until the tolerance for pulling is reached with maximum of 50% of body weight. The session will be 15 minutes long (1min for acceleration, 13 min application, 1min deceleration); it will be intermittent with ratio of 30 s on and 10s off
214475485|NCT06841796|DEVICE|Real time continuous glucose monitor (Stelo)|Real time CGM will be worn continuously for 24 weeks. Participants will be able to see the glucose data from the CGM facilitating changes in nutritional habits and physical activity
214475486|NCT06841159|RADIATION|Ultra-fractionated radiation therapy|Radiation therapy will be delivered every 3 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of sintilimab.
214475487|NCT06841159|DRUG|Sintilimab|Sintilimab will be given at 200 mg q3w every 3 weeks and schedule to the next day of every pulses of radiation.
214475488|NCT06841159|DRUG|Standard systemic therapy|"First-line standard systemic therapies in cohort A include: FOLFOX/FOLIRI/XELOX+ bevacizumab, FOLFOX/FOLIRI/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only).~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events."
214475489|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~* At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~* Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~* For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch."
214475490|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age."
214475491|NCT06842745|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS, is a form of non-invasive brain stimulation, that uses magnetic pulses to stimulate specific areas of the brain. In this study we will utilize theta-burst stimulation which uses a higher frequency pulse of 50 Hz delivered for 40 seconds for a total of 600 pulses.
214847898|NCT05487755|DRUG|Pentoxifylline 400 MG Oral Tablet|Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
214847899|NCT00006143|DRUG|Somatropin|
214847900|NCT03186599|BEHAVIORAL|low adherence intervention group|Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
214847901|NCT05183087|DIAGNOSTIC_TEST|3T Connectome MRI|MRI scan of structural connectivity
214847902|NCT05183087|DIAGNOSTIC_TEST|7 Tesla MRI|MRI scan of functional connectivity
214847903|NCT05183087|DIAGNOSTIC_TEST|TSPO PET|PET scan of neuroinflammation
214847904|NCT05183087|DIAGNOSTIC_TEST|Tau PET|PET scan of tau deposition
214475492|NCT06842745|BEHAVIORAL|Speech-Language Therapy (SLT)|"Our SLT protocol draws from two theories and evidence-based cognitive-linguistic frameworks: (1) conversational alignment, which engages priming of lexical and syntactic structures through dialogue and conversation and (2) increased tolerance of memory load in the context of sentence repetition and dialogue tasks. Administration of these tasks will abide by principles of constraint-induced language therapy, i.e., intense treatment schedule and verbal responding only.~All participants will receive SLT."
214475493|NCT06752174|BIOLOGICAL|sIPV+bOPV|"2+1 sequential immunization program (sIPV-sIPV-bOPV)"
214475494|NCT06752174|BIOLOGICAL|wIPV+bOPV|"2+1 sequential immunization program (wIPV-wIPV-bOPV)"
214475495|NCT06599723|DRUG|Conventional lumbar steroid injections|Patients will receive conventional lumbar steroid injections.
214475496|NCT06599723|PROCEDURE|Racz catheter|Patients will receive lumbar epidural steroid using Racz catheter.
214475497|NCT05408663|DRUG|EXT608|EXT608 is an investigational drug administered via subcutaneous injection
214475498|NCT05408663|OTHER|Placebo|matching placebo administered via subcutaneous injection
214475499|NCT06591819|RADIATION|Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost|Brachytherapy boost will be delivered and then whole pelvis proton radiation therapy in 5 fractions.
214475500|NCT06603051|PROCEDURE|Cryoneurolysis|Those randomized to the intervention group (Group B) will receive a standard treatment of Cryoneurolysis to their surgical knee within 7-10 days of their scheduled surgery. Treatment nerves for the procedure will include the anterior femoral cutaneous nerve (AFCN), supra-patellar branch of the saphenous nerve (SPBSN) and infra-patellar branch of the saphenous nerve (IPBSN).
214475501|NCT06590610|DEVICE|Radial pressure wave (RPW) - Intelect RPW2 Chattanooga|RPW treatment on one leg at the Gastrocnemius and NMES electrostimulation on the opposite leg. RPW or NMES treatment on each leg will be randomized prior to application with each device having an equal chance of being placed on the either leg (dominant and non-dominant).
214475502|NCT06593327|BEHAVIORAL|Intensive Prevention Strategy|Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.
214475503|NCT02938923|DRUG|Testosterone|Topical testosterone gel 1%
214475504|NCT02938923|DRUG|Placebo gel|Inactive skin gel
214475505|NCT02938923|BEHAVIORAL|Supervised exercise training|Multicomponent exercise program focused primarily on progressive resistance exercise training
214475506|NCT02938923|BEHAVIORAL|Home exercise program|Flexibility exercises performed at home 3 times per week and reviewed by study staff once a month.
214475507|NCT02938923|BEHAVIORAL|Health Education Modules|30-40 minute presentations conducted by study staff for participants focused on health concerns unrelated to exercise.
214475508|NCT04750564|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
214475509|NCT04750564|DEVICE|EStim|EStim will applied for 10 to 20 minutes.
214475510|NCT05428007|DRUG|Sarilumab|Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.
214475511|NCT05428007|DRUG|Ipilimumab Injection|Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.
214475512|NCT05428007|DRUG|Nivolumab/Relatlimab|The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
214475515|NCT06806761|OTHER|Longitudinal prospective cohort study|Description: Patients after stroke who meet the in- and exclusion criteria will be examined up to 6 times during the first 6 months after their stroke.
214475516|NCT05519683|DEVICE|TEA|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
214475517|NCT05519683|DRUG|Lexapro|This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
214847905|NCT05183087|DIAGNOSTIC_TEST|Cognitive and Behavioral Assessments|Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
214847906|NCT05183087|DIAGNOSTIC_TEST|Blood Biomarkers|Blood-based assessments of proteomic and metabolic biomarkers of brain injury
214847907|NCT05049811|BEHAVIORAL|mini program|To design, construct, and test the mini program in patients managing cancer pain
214847908|NCT05049811|BEHAVIORAL|conventional pharmaceutical care|Regular education includes medication guidance from doctors, nurses and pharmacists.
214847909|NCT02883517|GENETIC|Cytogenetic and molecular studies|Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
214475518|NCT05238311|DRUG|Elranatamab|
214475519|NCT04332211|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.
214475520|NCT04332211|DRUG|Pseudoephedrine 60 MG|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
214475521|NCT04332211|DRUG|Placebo oral tablet|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
214475522|NCT06746792|OTHER|Low-load resistance exercise with blood flow restriction|BFR-RE group performed bilateral leg extension exercises to volitional exhaustion (90 seconds rest between sets, 30% 1RM) with BFR cuffs applied at 60% of limb occlusion pressure.
214475523|NCT06746792|OTHER|High-load resistance exercise|The HL-RE group performed the same exercise to volitional exhaustion (90 seconds rest between sets, 70% 1RM) without BFR cuffs.
214475524|NCT03229083|OTHER|Carevive software|In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
214475525|NCT06809699|DRUG|Busulfan (Busulfex)|For myeloablative conditioning: Busulfan (Bu，3.2 mg/kg/d IV -8d \~-6d) For reduced intensity conditioning: (Bu，3.2 mg/kg/d IV -7d\~-5d)
214475526|NCT06809699|DRUG|Cyclophosphamide (CTX)|Cyclophosphamide is only used in myeloablative conditioning (Cy，1.8g/m2, -5d, -4d)
214475527|NCT06809699|DRUG|Fludarabine (Fludara)|For myeloablative conditioning: Fludarabine (Flu，30 mg/m2/d IV -6d \~ -2d) For reduced intensity conditioning: Fludarabine（Flu，30mg/m2 /d IV -10d\~-5d）
214475528|NCT06809699|DRUG|Semustine (MeCCNU)|For both myeloablative and reduced intensity conditioning: Semustine (MECCNU，250 mg/m2 orally-3d).
214475529|NCT06808906|OTHER|Hand Massage Application|Hand massage was applied for a total of 12 sessions in two weeks. Care was taken to perform the hand massage application outside the treatment and care hours, and it was performed in a quiet environment. The application was started from the same hand in the same patient in each session, and the same clinic nurse massaged all patients. Since the patients were in the intensive care unit, their vital signs were monitored 24. It was carefully monitored whether there was any change in vital signs during the massage. The patient's hand to be applied was placed on the pillow or bed. Clothes covering the upper extremity starting from the elbow area were removed. The patient was placed in a supine or semi-fowler position. The nurse practitioner took a standing position. She started the massage with effleurage, first on the back of the hand, then on the palm, from the fingertips towards the heart direction, placing the thumbs on the area to be treated and applying effleurage 5 times in a half-mo
214475530|NCT04984590|DEVICE|IOPCL AMD MAG|The IOPCL MAG (intraocular pseudophakic capsular lens magnifier) consists of a 4.5 mm diameter optic. The central 1.8mm of the anterior surface has a power of 10.0 diopters. This IOPCL MAG will be implanted over an Alcon Model SN60WF or SA60AT intraocular lens to improve near vision.
214475531|NCT04320680|OTHER|description of a lupus patient cohort|description of a lupus patient cohort
214475532|NCT04583280|DRUG|Rilematovir|Participants of age group greater than or equal to (\>=) 28 days to less than (\<) 3 months (age group 1) or \>= 3 months to \< 6 months (age group 2) or \>= 6 months to less than or equal to (\<=) 5 years (age group 3) will receive rilematovir orally twice a day (BID) from Days 1 to Day 7 or Day 8.
214475533|NCT04583280|DRUG|Rilematovir X mg/kg|Participants of age group birth at term (after at least 37 weeks of gestation) to \< 28 days (age group 4) will receive rilematovir orally BID from Days 1 to Day 7 or Day 8. The dose is dependent on outcome of the substudy in neonates and following independent data monitoring (IDMC) review and recommendation.
214475534|NCT04583280|DRUG|Placebo|Participant of age group 1, 2, 3 and 4 will receive matching placebo of rilematovir BID from Days 1 to Day 7 or Day 8 as per assigned age group.
214475535|NCT04068792|OTHER|RSV Mobile Application|Participants will not receive any intervention in observational phase of this study. Participant's respiratory symptoms will be captured by RSV mobile application installed in participant's caregiver/parent mobile phone.
214657386|NCT00968266|BEHAVIORAL|Patient-centered group intervention|"Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent."
214657387|NCT00075881|DRUG|bortezomib|Given IV
214657388|NCT00075881|OTHER|laboratory biomarker analysis|Optional correlative studies
214657389|NCT04537611|DIAGNOSTIC_TEST|dHb contrast and gadolinium contrast imaging|see arm description
214657390|NCT04285528|DRUG|General anesthetia Fentanyl and Propofol|Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
214657391|NCT04285528|COMBINATION_PRODUCT|PFK|A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
214847910|NCT00003894|DRUG|thalidomide|
214847911|NCT00004294|GENETIC|human glucocerebrosidase gene into autologous peripheral blood stem cells|
214475536|NCT04068792|DRUG|Placebo|Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.
214475537|NCT04068792|DRUG|JNJ-53718678 2.5 mg/kg|JNJ-53718678 will be administered to Age Group 1 twice daily for 7 days.
214475538|NCT04068792|DRUG|JNJ-53718678 3 mg/kg|JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
214475539|NCT04068792|DRUG|JNJ-53718678 4.5 mg/kg|JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
214475540|NCT06248086|DRUG|ASP2802|Intravenous (IV) infusion
214475541|NCT06248086|DRUG|MA-20|IV infusion
214479493|NCT06678516|DIETARY_SUPPLEMENT|Intermittent fasting|Participants are asked to abstain from any form of fasting or calorie restriction in one month of the study (which is also a pre-fasting washout for those volunteers that might be performing forms of fasting before the study) and then start with one month of intermittent fasting, with daily fasting duration from 7:30 to 18:30. Food is abstained from during fasting, only water and zero-calorie drinks like black coffee and unsweetened tea are allowed.
214479494|NCT06323044|OTHER|Best Practice|Receive usual care
214479495|NCT06323044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214479496|NCT06323044|OTHER|Electronic Health Record Review|Ancillary studies
214479497|NCT06323044|OTHER|Interview|Ancillary studies
214479498|NCT06323044|OTHER|Medical Device Usage and Evaluation|Receive MedSupport intervention
214479499|NCT06323044|OTHER|Medical Device Usage and Evaluation|Use MEMS device
214479500|NCT06323044|OTHER|Survey Administration|Ancillary studies
214479501|NCT05844956|DRUG|DZD8586|Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
214479502|NCT04959695|BEHAVIORAL|PE Coach|PE Coach is a treatment companion mobile application designed with features to support the tasks of prolonged exposure psychotherapy and the homework between sessions.
214479503|NCT04959695|BEHAVIORAL|Prolonged exposure without PE Coach|Standard PE treatment protocol without PE Coach
214479504|NCT06866860|OTHER|Implant surgical guide with internal irrigation|"* Virtual surgical plan will be completed in the implant planning software (BlueSky plan, BlueSky Bio, USA), and the implant type, position, and sleeve height will be adjusted.~* The entry point of the surgical drill into the alveolar bone will be identified.~* An irrigation channel will be added, directed toward the entry point of the drill and adjusted to have the same diameter as the irrigation system tube."
214479505|NCT06866860|OTHER|Conventional implant surgical guide with external irrigation|Virtual surgical plan will be completed in the implant planning software (BlueSky plan, BlueSky Bio, USA), and the implant type, position, and sleeve height will be adjusted. Conventional guide will be printed
214479506|NCT06865352|BIOLOGICAL|HSCT donor leukemia-specific cytotoxic T-cells|donor T-cells stimulated with patient leukemia blasts
214479507|NCT05744895|DEVICE|Device: Robotic MAKO total knee|Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine
214479508|NCT05744895|DEVICE|FocusMotion knee brace|Focusmotion knee brace measures range of motion during exercises
214479509|NCT05744895|DEVICE|Fitbit tracking device|Fitbit will measure patients steps, HR, and sleep
214479510|NCT05744895|DEVICE|FocusMotion app|Will survey patients with PROMS
214479511|NCT06483308|RADIATION|Radiotherapy|Radiotherapy using 30Gy in 6 fractions (alternate days) over 12 days.
214479512|NCT06662305|BEHAVIORAL|Kick-Nic! mobile phone application|The Kick-Nic! app has seven modules that cover core CBT strategies using skills, graphic illustrations, and interactive components to help adolescents quit using e-cigarettes.
214479513|NCT06662305|BEHAVIORAL|NCI Quit Vaping website|The NCI webpage provides quitting tobacco resources for youth, including for e-cigarettes. The information provided is similar to the CBT skills modeled by the Kick-Nic! app.
214479514|NCT05412758|DIETARY_SUPPLEMENT|Oral Stimulant Drink|For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath
214479515|NCT03771612|DRUG|Naproxen|Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)
214479516|NCT03771612|DRUG|Placebos|Half of the participants will be randomly assigned to receive a placebo pill twice daily
214479517|NCT05727085|OTHER|All pregnant women with a twin pregnancy and the offspring|No intervention
214479518|NCT00001481|DRUG|Estradiol|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
214479519|NCT00001481|OTHER|Placebo|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
214479520|NCT00001481|DRUG|Progesterone|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
214479521|NCT06681077|PROCEDURE|Community Health Education|Receive I CAN intervention
214479522|NCT06681077|OTHER|Survey Administration|Ancillary studies
214479523|NCT06681766|DRUG|Nomlabofusp|Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.
214479524|NCT06681766|DRUG|Placebo|The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.
214479525|NCT05997082|OTHER|Mindfulness Self-Compassion Course|This course is designed to reduce burnout and compassion fatigue among specialist rehabilitation providers. Course materials are adapted from the Center for Mindful Self-Compassion (CMSC).
214479526|NCT06484400|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a well-established psychological treatment that focuses on identifying, understanding, and changing negative thinking and behavior patterns. The intervention involves structured sessions where participants are taught strategies to alter detrimental thoughts and behaviors to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, CBT will be delivered in 12 one-hour weekly sessions conducted in person and on a one-on-one basis. This intervention is designed to reduce symptoms of depression and anxiety through cognitive restructuring and behavioral adaptations.
214479527|NCT06484400|BEHAVIORAL|Ericksonian Hypnotehrapy|Ericksonian Hypnotherapy is a form of psychotherapy using clinical hypnosis and indirect suggestion to modify unconscious behaviors and thought patterns. Named after Dr. Milton H. Erickson, this therapeutic approach emphasizes adaptability and utilizes the patient's own experiences and internal resources for healing. The therapy is known for its effectiveness in addressing anxiety and depression by encouraging flexibility in perception and behavior. Like CBT, this intervention will be administered over 12 one-hour sessions, each conducted in person and tailored to the individual's unique psychological landscape.
214657392|NCT01149200|DRUG|TC-6499|5mg enteric-coated oral hard gelatin capsule, administered twice daily
214657393|NCT01149200|DRUG|Placebo|placebo as enteric-coated oral hard gelatin capsule, administered twice daily
214657394|NCT00000264|DRUG|30% Nitrous oxide|
214657395|NCT00000264|OTHER|0.35 g/Kg ethanol|
214657396|NCT00000264|OTHER|0.7 g/Kg ethanol|
214657397|NCT00000264|OTHER|0 g/Kg ethanol|
214657398|NCT04873687|DEVICE|External Counter Pulsation (ECP) therapy|ECP therapy consist of 36 session, each session @1 hour/day, five days a week with initial pressure of 300mmHg
214657399|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 5mg QD
214657400|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD
214657401|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
214847912|NCT02896543|OTHER|measurement|Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
214847913|NCT02345291|DRUG|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
214657402|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 25 mg QD
214657403|NCT00393562|DRUG|modafinil|
214657404|NCT00393562|DRUG|methylphenidate|
214657405|NCT03019549|DRUG|Lanabecestat|Administered orally
214657406|NCT03019549|DRUG|Rosuvastatin|Administered orally
214657407|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT with post procedure curettage
214657408|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT without post procedure curettage
214657409|NCT00659295|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
214657410|NCT04360304|DEVICE|Echocardiographic exam|"An echocardiographic exam is realised after inclusion, measuring especially :~* LVOT VTI~* Respiratory variation of inferior veina cava diameter For theses two measurements, the manual method is first recorded, and then the automated one is done.~For patients that need fluid resuscitation of at least 250mL in less than 10minutes (indication at the discretion of the physician in charge of the patient), a second echocardiography is done according to the same protocol described before."
214657411|NCT05973409|DEVICE|scleral lens|scleral lens with and without hydra-peg coating
214657412|NCT02714530|DRUG|Erlotinib|Tarceva daily during radiotherapy course
214657413|NCT02714530|RADIATION|Radiation|Radiotherapy
214657414|NCT02509325|DEVICE|Parkinson's Kinetigraph|
214847914|NCT02345291|DRUG|Placebo to match NRD135S.E1|Placebo capsule to match NRD135S.E1 capsules
214847915|NCT06596499|DEVICE|CH-VAD|The CH-VAD pump is a fully magnetically levitated (maglev), centrifugal continuous-flow blood pump.
214847916|NCT00467831|DRUG|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
214847917|NCT00467831|DRUG|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
214847918|NCT00467831|DRUG|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
214847919|NCT00467831|DRUG|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
214847920|NCT00467831|DRUG|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
214657415|NCT05811195|DEVICE|Diode Semiconductor, Duo|Intraoral photobiomodulation therapy (660nm, 3s/point, 10J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
214657416|NCT05811195|DEVICE|Gemini laser|Extraoral photobiomodulation therapy (810 + 980 nm, 20s/point, 4.07J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
214657417|NCT04942548|OTHER|Ketogenic Diet|Ketogenic diet intervention that is high in fat and low in carbohydrates, causing the body to induce a state of metabolic ketosis, whereby fat is broken down into ketones to provide an energy source for the body.
214657418|NCT01322828|PROCEDURE|Distal bicep tendon reconstruction|Randomized to either a single incision technique or a double incision technique.
214657419|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in capillary blood|After a finger prick, patients will be taken a drop of capillary drop. This drop will be used to perform the MagIA IBC test.
214657420|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in other matrices|Blood samples will be taken and used to perform the MagIA IBC in veinous blood, serum and plasma.
214657421|NCT02109029|DRUG|Insulin Peglispro|Administered IV
214657422|NCT02109029|DRUG|Human Insulin|Administered IV
214657423|NCT01902108|DRUG|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
214657424|NCT01902108|DRUG|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
214657425|NCT01858103|DRUG|BMN 110|
214657426|NCT04039139|BEHAVIORAL|Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
214657427|NCT04039139|BEHAVIORAL|Mind Body Intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
214657428|NCT02451956|DRUG|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
214657429|NCT02451956|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
214657430|NCT00110305|DRUG|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
214657431|NCT00110305|DRUG|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
214657432|NCT00110305|DRUG|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
214847921|NCT00200317|BEHAVIORAL|Internet and print-based interventions|
214847922|NCT06503549|OTHER|Assessments|Only the current assessments will be made
214657433|NCT00110305|DRUG|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
214657434|NCT00110305|DRUG|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
214657435|NCT00142506|DRUG|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
214657436|NCT00142506|DRUG|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
214657437|NCT05290467|BEHAVIORAL|Online antenatal care|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Messages, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
214657438|NCT00033735|DRUG|fluorouracil|5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
214657439|NCT00033735|DRUG|Irofulven|Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
214657440|NCT00581503|DEVICE|diagnostic|oct imaging
214657441|NCT06131645|DIAGNOSTIC_TEST|IASLC grading system|A cohort of 2160 patients with invasive nonmucinous EGFR-mutant LADCs were retrospectively collected and classified according to the IASLC grading system. The role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy was investigated.
214657442|NCT04128098|OTHER|Evaluation|"* Functional tests: 400-meter walking test, 200-meter brisk walking test, Sorensen test, Shirado test, measurement of maximum isometric force of extensors/back flexors.~* 3D analysis of locomotion and posture~* Test of the flexion-relaxation phenomenon of the lumbar erector muscles"
214657443|NCT04128098|OTHER|Questionnaires|Self-questionnaires: Oswestry, Québec, SF-12, VAS pain, HAD, pain dramatization questionnaire, physical activity questionnaires, VAS and GPE satisfaction, FABQ, GPE functional status and EPICES score.
214657444|NCT04128098|OTHER|Rehabilitation care program|"* Personalized global exercises (aerobics) on ergometers~* Muscle strengthening with resistance~* Balneotherapy~* Learning health skills related to their condition (therapeutic education)~* Personal and group motivational interviews~* Nutritional advice~* Relaxation session"
214657445|NCT05617885|DRUG|Darolutamide|Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
214657446|NCT05617885|DRUG|Abemaciclib|"Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing."
214657447|NCT05617885|DRUG|GNRH-A Leuprolide Acetate|Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
214657448|NCT05617885|DRUG|GNRH-A Goserelin|Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
214847923|NCT05563688|OTHER|Hypoxia exposure|"Each participant will be exposed to the hypoxic environment on 2 occasions (one after a normal sleep night and one after sleep deprivation).~Each exposure will be for 5 hours at a FiO2 of 13.2% (3500 m simulated altitude).~This exposure will be carried out in a normobaric hypoxic tent (Sporting Edge®)."
214657449|NCT05617885|DRUG|Degarelix|Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
214657450|NCT04776850|DRUG|Bortezomib|Given IV
214657451|NCT04776850|DRUG|Busulfan|Given IV
214657452|NCT04776850|DRUG|Cyclophosphamide|Given IV
214657453|NCT04776850|DRUG|Dexamethasone|Given IV
214657454|NCT04776850|DRUG|Fludarabine Phosphate|Given IV
214657455|NCT04776850|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
214657456|NCT04776850|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
214657457|NCT04776850|DRUG|Mycophenolate Mofetil|Given IV or PO
214657458|NCT04776850|PROCEDURE|Plasmapheresis|Undergo plasmapheresis
214657459|NCT04776850|BIOLOGICAL|Rituximab|Given IV
214657460|NCT04776850|DRUG|Tacrolimus|Given IV or PO
214657461|NCT01673048|PROCEDURE|3-Nail-ESIN in femoral shaft fractures|
214847924|NCT05563688|OTHER|Sleep deprivation|"Each participant will be exposed to sleep deprivation on 2 occasions (one before normoxia exposure and one before hypoxia exposure).~Each sleep deprivation involves a time spent in bed of 3 hours (03h00 - 06h00). Sleep deprivation will be carried out in a sleep apartment. Sleep duration and quality will be assessed using a sleep headband (Dreem®), actigraphs Actiwatch® and E4 Empatica®) and a sleep diary."
214847925|NCT05563688|BEHAVIORAL|Cognitive tasks|"Participants will perform several cognitive tasks in the following conditions:~* in normoxia (FiO2 = 21%) after a night of usual sleep (\> 6 hours) ;~* in normoxia (FiO2 = 21%) after a night of reduced sleep (3 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of normal sleep (\> 6 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of reduced sleep (3 hours)."
214847926|NCT05365152|DIETARY_SUPPLEMENT|Meal Replacement|Meal Replacement
214847927|NCT05612087|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy at jejunum, duodenum and stomach
214847928|NCT01198873|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
214479528|NCT05334355|OTHER|Family history of hypertension|Presence or absence of a family history of hypertension in a cross sectional study design.
214479529|NCT06609421|OTHER|Informative Appointment|The only intervention involving the participants is non-clinical, which is an extra 30-minute informative telephone appointment added to the standard care consultation schedule of interested IVF patients where they will be presented with a digital consent PDF form to sign by a study nurse or clinically trained research personnel. Participants will be in the study for 24-30 months. During this time their discarded, unfertilised oocytes and follicular fluid collected during routine oocyte retrieval along with information from their electronic medical records will be collected and analysed.
214479530|NCT06669338|OTHER|Music therapy|patients listen to music for 20 minutes with headphones before colonoscopy.
214479531|NCT06669338|OTHER|listen to white noise|patients listen to white noise with headphones for 20 minutes before colonoscopy.
214479532|NCT06669338|OTHER|listen to hospital ambient sound|patients listen to recorded ambient sound for 20 minutes with headphones before colonoscopy.
214479533|NCT06157086|OTHER|ofatumumab|There is no treatment allocation. Participants with MS that initiated treatment with ofatumumabas per neurologist practice and regardless of the study protocol
214479534|NCT06376474|DRUG|Hemay005|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
214479535|NCT05104983|DRUG|Sirolimus|The investigational drug product to be used in this study is sirolimus, provided in oral suspension.
214479536|NCT05104983|DRUG|Placebo|Matching placebo
214479537|NCT03384537|COMBINATION_PRODUCT|Listerine total care zero|reducing intra-oral cariogenic microorganism.
214479538|NCT03384537|COMBINATION_PRODUCT|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
214479539|NCT04024059|BEHAVIORAL|Contingency Management for adherence|Incentives contingent on buprenorphine adherence
214479540|NCT04024059|BEHAVIORAL|Contingency Management for abstinence|Incentives contingent on opiate abstinence
214479541|NCT05496140|BEHAVIORAL|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
214479542|NCT06622135|DEVICE|Tasso Lancet Device|blood samples will be obtained from all participants using Tasso device
214479543|NCT06622031|PROCEDURE|Transjugular intrahepatic portosystemic shunt|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the participants received a diuretic treatment and a salt-limited diet.
214479544|NCT06622031|DRUG|Lenvatinib|12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg
214479545|NCT06622031|DRUG|PD-1 inhibitor|Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
214479546|NCT06618859|BEHAVIORAL|Time-restricted eating|Participants will be advised to consume meals and calorie-containing drinks only during a window of 8 hours, to be self-selected by the participant and advised by the investigators based on their daily routine and eating habits during the run-in phase.
214479547|NCT06618859|BEHAVIORAL|Active control|Participants will be advised to keep the same eating rhythm and timing of meals per day during the intervention.
214479548|NCT05211869|BEHAVIORAL|T1D-CATCH|"As defined by the CDC, a CHW is a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities. CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities.~CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology."
214479549|NCT05698368|BEHAVIORAL|Mindset intervention|Participants receive a digital mindset intervention to improve mindsets about osteoarthritis and exercise.
214479550|NCT05698368|OTHER|Active comparator|Participants receive a series of osteoarthritis education videos and reflective questions that matches the digital mindset intervention in duration and attention.
214479551|NCT06870227|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform emergency eclampsia in labour
214657462|NCT03793478|DRUG|Quizartinib|"Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28"
214657463|NCT03793478|DRUG|Fludarabine|30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
214657464|NCT03793478|DRUG|Cytarabine|"2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18"
214657465|NCT03793478|DRUG|Intrathecal (IT) triple chemotherapy prophylaxis|IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
214657466|NCT03793478|DRUG|Etoposide|"Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5"
214657470|NCT04385498|BEHAVIORAL|BREATHE Intervention|5 session program focusing on breathing retraining, psychoeducation, and positive coping.
214657471|NCT04385498|BEHAVIORAL|Waitlist Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm. At the end of the trial Participants will be able to receive the BREATHE Ethiopia treatment.
214657472|NCT03417388|DRUG|High dose potent statin|The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.
214657473|NCT03417388|DRUG|ACE-I (lisinopril) or ARB (losartan)|Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.
214657474|NCT03417388|DRUG|Aspirin 81 enteric coated tablet daily|Will be recommended to IMT women without contraindications or bleeding risk.
214657475|NCT03417388|BEHAVIORAL|Lifestyle Counseling|The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.
214657476|NCT03417388|BEHAVIORAL|Quality of Life Questionnaires|Quality of Life Questionnaires will be obtained.
214657477|NCT02243878|RADIATION|Stereotactic radiotherapy (16 Gray or Sham)|Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
214657478|NCT02243878|DRUG|0.5 mg ranibizumab|Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
214657479|NCT04759898|DEVICE|transcranial direct current stimulation (noninvasive recording)|Subjects will enter the EEG lab and be seated in a chair. The 26-electrode EEG array will be placed using a conductive paste. The electrodes will be connected to a clinical grade EEG machine used in standard of care routine EEG monitoring. Next, a soft cloth cap will be placed over the subject's head with the tDCS electrodes pre-positioned in place. The cap will be positioned so that the tDCS electrodes cover the scalp without disturbing the underlying EEG electrodes. Conducting gel will be applied in direct contact with the scalp to facilitate stimulation. In addition, lidocaine jelly will be added topically to provide local anesthesia. The tDCS electrodes will be connected to a low-current generator. Participants receive 2.0 milliamps in electrical stimulation from the tDCS machine for 20 minutes. The device will be manually controlled by study personnel assisting with the experiment. A virtual reality environment will be utilized to collect kinematic data during the study.
214847929|NCT01198873|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
214847930|NCT03139240|DRUG|Oxycodone 10mg oral|Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
214847931|NCT03139240|OTHER|Placebo|Placebo given in addition to standard of care medications in women undergoing medical abortion
214847932|NCT02810249|OTHER|No intervention used|
214847933|NCT04581876|DRUG|raltitrexed for injection|Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
214847934|NCT04581876|DRUG|nab-paclitaxel|Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
214847935|NCT04751630|OTHER|Therapeutic Exercise|Online and structured exercise therapeutic program based on flexibility, strength, balance and aerobic exercises. The program have been supervised by an expert on the field and it participants will perform it under the supervision of an expert physiotherapist.
214847936|NCT05340192|DRUG|Octreotide 1 MG/ML|100 mcg (1 ml) of Octreotide
214847937|NCT06814470|OTHER|Virtual reality guided imagery acupuncture treatment (VRGAIT)|Subject watching Virtual reality video of acupuncture needle stimulation
214847938|NCT06814470|OTHER|Virtual reality guided imagery acupuncture treatment control|Subject watching VR video of swab touching
214847939|NCT01253395|BEHAVIORAL|Strength training|Daily supervised strength training.
214847940|NCT01253395|BEHAVIORAL|Aerobic exercise|Daily supervised aerobic exercise.
214657480|NCT04759898|DEVICE|sham transcranial direct current stimulation (noninvasive recording)|Subjects receiving sham undergo the same setup as the stimulation group with the exception that sham subjects experience stimulation for one minute only (30 second ramp-up to 2 milliamps immediately followed by 30 second ramp-down to 0 milliamps for the remaining 19 minutes). This provides similar sensory feedback to sham subjects that treatment subjects experience. The same electrode array, soft cloth cap, conducting gel application, and lidocaine are applied as in a stimulation subject. The tDCS electrodes will be connected to a low-current generator. A virtual reality environment will be utilized to collect kinematic data during the study.
214657481|NCT04759898|DEVICE|transcranial direct current stimulation (invasive recording)|Subjects are brought into the operating room. The scalp is prepped with a sterilizing solution. Following infiltration with local anesthetic and incision, a 6-contact electrocorticography strip is inserted into the burr hole covering primary motor cortex. Electrocorticography strip terminals are connected to an amplifier for signal recording. Gas-sterilized transcranial direct current stimulation electrodes are placed on the scalp directly overlying primary motor cortex. tDCS electrodes are connected to a low-current generator. During electrocorticographic recording, stimulation is turned on while subjects are asked to flex each arm. At the conclusion of the experiment, the electrocorticography strip and tDCS electrodes are removed and the surgery proceeds as planned.
214657482|NCT03667820|DRUG|Osimertinib|Osimertinib 80mg tablet to be taken once daily.
214657483|NCT03667820|RADIATION|SABR|Stereotactic Ablative Radiation (SABR)
214657484|NCT03890679|DIAGNOSTIC_TEST|rapid whole genomic sequencing (rWGS)|rWGS and NewbornDx are genomic sequencing platforms
214657485|NCT05011396|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
214657486|NCT05011396|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
214657487|NCT00215150|DRUG|Ziprasidone|Sertraline augmentation with ziprasidone
214657488|NCT00215150|DRUG|Sertraline|Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
214657489|NCT02251743|DEVICE|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~2. Average voltage of theta waves~3. Average voltage of beta~4. Average ratio of theta to beta power (TBR)"
214657490|NCT05983432|DRUG|BL-B01D1|BL-B01D1 will be administered either on a Day 1 or Day 1 Day 8 dosing regimen
214657491|NCT00077454|DRUG|erlotinib hydrochloride|Given orally (PO)
214657492|NCT00077454|DRUG|temozolomide|Given PO
214657493|NCT00077454|OTHER|pharmacological study|Correlative studies
214657494|NCT00077454|OTHER|laboratory biomarker analysis|Correlative studies
214657495|NCT04724590|RADIATION|IMRT(IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY )|Evaluation the optic neuropathy in nasopharynx cancer patients treated in our clinic.
214657496|NCT01810887|DRUG|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
214657497|NCT01810887|DRUG|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
214657498|NCT03052153|OTHER|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
214657499|NCT00716521|DRUG|placebo|single oral dose placebo
214657500|NCT00716521|DRUG|zolpidem|single oral dose, 5 mg zolpidem
214657501|NCT00716521|DRUG|zolpidem|single oral dose, 10 mg zolpidem
214847941|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
214847942|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
214657502|NCT00205192|PROCEDURE|Cardiac resynchronization pacing|various pacemaker modes used over 1 hour
214657503|NCT04154488|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
214657504|NCT03581942|DRUG|Ibrutinib|(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
214657505|NCT03581942|DRUG|Copanlisib|(MTD) Copanlisib 60 mg weekly (3w on/1w off)
214657506|NCT03215966|COMBINATION_PRODUCT|Macitentan / tadalafil FDC|Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
214657507|NCT03215966|DRUG|Macitentan (Opsumit®)|Film-coated tablets for oral administration formulated at a strength of 10 mg
214657508|NCT03215966|DRUG|Tadalafil (Adcirca®)|Film-coated tablets for oral administration formulated at a strength of 20 mg
214657509|NCT06144515|PROCEDURE|Blood test|"Blood is collected in order to perform in vitro research:~1. If a routine blood test is performed for clinical tests, the sponsor will receive the results of the Complete blood count (CBC) and an additional blood sample from the same puncture of 20ml to maximum 40ml will be collected for this study.~2. If no routine blood test is performed for clinical tests, a CBC will be performed for the study and an additional blood sample of 20ml to maximum 40ml will be collected.~Additional Bone marrow (BM) material will be obtained from the same puncture performed for routine clinical tests:"
214657510|NCT05464355|PROCEDURE|Intraoperative electroencephalography recording|Intraoperative electroencephalography measurements, a non-invasive routine monitoring device used during anaesthesia to measure the brain's electrical activity
214657511|NCT05464355|PROCEDURE|Neurofilament light chain measurement|Measurement of the level of neurofilament light chain in a blood sample
214657512|NCT05464355|PROCEDURE|Tau protein measurement|Measurement of the level of tau protein in a blood sample
214847943|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
214657513|NCT03021577|DEVICE|Orbital Atherectomy System (OAS)|The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.
214657514|NCT03021577|DEVICE|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
214657515|NCT03021577|PROCEDURE|Magnetic Resonance Imaging (MRI)|In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
214657516|NCT02231775|DRUG|Dabrafenib|Given PO
214657517|NCT02231775|OTHER|Laboratory Biomarker Analysis|Correlative studies
214657518|NCT02231775|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214657519|NCT02231775|DRUG|Trametinib|Given PO
214657520|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Therapeutic|"Photobiomodulation (PBM) is a non-invasive treatment option that uses nonionizing light sources such as laser diodes and light-emitting diodes in the visible and near-infrared spectrum.~Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'therapeutic setting' of 35mW/cm2 = 42J/cm2"
214657521|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Control|"Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'non-therapeutic setting' of 0mW/cm2 = 0J/cm2"
214657522|NCT02407535|DEVICE|Intraoperative ultrasound|Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
214657523|NCT04489654|BIOLOGICAL|deproteinized bovine bone mineral (DBBM) by OneXeno Graft. ( OneGraft, Germany)|deproteinized bovine bone mineral (DBBM) put in the gap between implant and labial shield
214657524|NCT02935972|DRUG|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
214657525|NCT02935972|DRUG|Lidocaine 1%|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
214657526|NCT02935972|DRUG|Diazepam and Lidocaine 1%|received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
214657527|NCT02947919|BEHAVIORAL|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
214657528|NCT00260208|DRUG|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
214657529|NCT00260208|DRUG|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
214847944|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
214847945|NCT04813562|BIOLOGICAL|a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
214847946|NCT04813562|BIOLOGICAL|a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
214657530|NCT02154646|DRUG|LY2157299|Administered orally
214657531|NCT02154646|DRUG|Gemcitabine|Administered IV
214657532|NCT05152186|DRUG|Topical Solution|Topical administration
214657533|NCT05152186|DRUG|Topical Foam|Topical administration
214657534|NCT05152186|OTHER|Topical|Topical administration
214847947|NCT04813562|BIOLOGICAL|a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
214847948|NCT04813562|BIOLOGICAL|a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
214847949|NCT02248506|OTHER|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
214847950|NCT02360306|PROCEDURE|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
214847951|NCT02123420|DEVICE|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J\&J International, St-Stevens-Woluwe, Belgium)."
214847952|NCT01529931|DEVICE|Hair2Go|Hair2Go treatment once a month for 6 months
214847953|NCT05583682|OTHER|Dental restoration|Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material
214847954|NCT00171340|DRUG|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
214847955|NCT00171340|DRUG|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
214847956|NCT00265044|BEHAVIORAL|Provider Education|
214657535|NCT03739619|DRUG|Bendamustine|Given IV
214657536|NCT03739619|DRUG|Gemcitabine|Given IV
214657537|NCT03739619|BIOLOGICAL|Nivolumab|Given IV
214657538|NCT04612075|DIAGNOSTIC_TEST|FDG-PET/MRI|Performed at baseline, interim and at 12-16 weeks post radiotherapy.
214657539|NCT03844087|DEVICE|Multiplanar neuromuscular training|See arm description
214657540|NCT04778839|DRUG|Paclitaxel Micelles for Injection|Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
214657541|NCT04778839|DRUG|Paclitaxel injection|Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
214657542|NCT04797286|DRUG|Sildenafil|Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
214657543|NCT04797286|OTHER|Placebo|Oral pill placebo.
214847957|NCT00265044|BEHAVIORAL|Hypertension Alert|
214847958|NCT00265044|BEHAVIORAL|Patient Education|
214847959|NCT02725424|DRUG|S-1|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
214847960|NCT02725424|DRUG|Trastuzumab|Her-2 positive patients with SOXT Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.
214847961|NCT02725424|DRUG|Oxaliplatin|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
214847962|NCT02725424|DRUG|Docetaxel|Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
214847963|NCT01584895|BEHAVIORAL|Cardiac Rehabilitation|A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
214847964|NCT03020784|DRUG|Placebo|Placebo
214847965|NCT03020784|DRUG|PF-06818883|Treatment
214847966|NCT00305916|PROCEDURE|Multislice spiral computed tomography coronary angiography|
214847967|NCT00305916|PROCEDURE|conventional coronary angiography|
214847968|NCT01576302|BEHAVIORAL|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
214847969|NCT01576302|BEHAVIORAL|Muscle relaxation|Progressive passive muscle relaxation
214847970|NCT03345264|BEHAVIORAL|Online, interactive self-help program|Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
214847971|NCT01998243|DEVICE|Intragastric Balloon (IGB), group A|the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
214847972|NCT01998243|OTHER|diet, control group B|the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
214657544|NCT06487780|BEHAVIORAL|Lifestyle-focused Occupational Therapy Intervention|The proposed intervention, led by trained occupational therapists, will focus on establishing sustainable self-care routines. It will consist of approximately 12 biweekly sessions, each lasting about an hour on average. Therapists will customize session timing and duration based on participant needs.
214657545|NCT06487780|OTHER|Education|Participants in the education group will receive standardized education materials on diabetic foot ulcers (DFUs), foot care, and offloading treatment to prevent foot ulcer recurrence.
214657546|NCT05166057|OTHER|Synchronized online telerehabilitation exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient by videoconference.
214657547|NCT05166057|OTHER|Videobased telerehabilitation exercise program|A video containing breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be given to the patient and will be asked to exercise regularly.
214847973|NCT02235584|DRUG|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
214847974|NCT05516459|BIOLOGICAL|Pfizer BNT162b2 Vaccine|The Pfizer-BioNTech COVID-19 vaccine (INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada
214847975|NCT00006245|DRUG|alvocidib|
214847976|NCT00006245|DRUG|paclitaxel|
214847977|NCT04187209|DEVICE|Use of the Atalante exoskeleton|A session includes a stand-up, walks over a distance of 10 meters, exercises with or without the assistance of the exoskeleton, U-turns and a sitting.
214847978|NCT05717244|DEVICE|2WIN-S|Determining pupil diameter by 2WIN-S
214847979|NCT05717244|DEVICE|OPD|Determining pupil diameter by OPD
214847980|NCT01056640|DEVICE|Intel Health Guide|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
214847981|NCT01056640|OTHER|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required.
214847982|NCT00316394|DEVICE|Preventive Care Checklist Form|
214847983|NCT05601960|OTHER|anti-acne dermocosmetic|Topical application once daily for 2 months
214847984|NCT02845726|OTHER|Stent examination, urinary analysis, USSQ questionnaire|
214847985|NCT02930629|DEVICE|Train-of-Four (TOF) Watch|"For patients, on arriving in PACU after having had muscle relaxants during general anaesthesia~* Two ECG electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist after cleaning the skin with alcohol swabs.~* The TOF force transducer will be placed on the volar aspect of the thumb.~* The TOF Watch leads will be attached to the ECG electrodes.~* A TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each twitch lasting 0.2ms, and at a current of 50 mA. As far as possible, this will be done when patients are still slightly drowsy from the effects of anaesthesia.~* Two TOF ratio will be elicited (two sets of four twitches 15 seconds apart), and an average of the two taken"
214847986|NCT03585426|DRUG|Vancomycin|Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
214847987|NCT05015374|DIETARY_SUPPLEMENT|Astaxanthin|350 mg/capsule (2mg Astaxanthin)
214847988|NCT05015374|DIETARY_SUPPLEMENT|Placebo|Placebo
214847989|NCT00455026|DRUG|remifentanil|target effect site concentration during induction
214847990|NCT03030326|BEHAVIORAL|heart rate variability biofeedback|Patients learn to increase heart rate variability by breathing at the resonance frequency of the cardiovascular system, at approximately 6 breaths/min, varying among people.
214847991|NCT01720420|DEVICE|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
214847992|NCT02850172|BEHAVIORAL|Walk, Eat, & Breathe|"1. Walking exercise: 3 times per week, 20\~30 mins per section~2. Eat: nutritional assessment and advice weekly~3. Inspiratory muscle training: twice every day, 7 days a week, 6\~8 weeks before surgery"
214847993|NCT02403739|OTHER|No Intervention|No Intervention
214847994|NCT04569786|BIOLOGICAL|V590|Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).
214847995|NCT04569786|OTHER|Placebo|Placebo administered via IM injection.
214847996|NCT00867841|PROCEDURE|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
214847997|NCT01301924|DRUG|Meglumine antimoniate|"Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine."
214847998|NCT02201459|DRUG|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
214847999|NCT02201459|DRUG|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|"* Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~* Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation."
214289749|NCT04417920|PROCEDURE|Express implant device|"Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock."
214289750|NCT05328882|OTHER|Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation|The implanted loop recorder will be interrogated to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then the late recurrence rate will be compared (3-12 months post-procedure) between groups with and without early recurrences.
214289751|NCT01095016|DRUG|Meptin swinghaler|"* Dose: 10ug/puff, 2 puffs daily~* Frequency: QD (total 20ug/day)~* Treatment duration: 2 days"
214289752|NCT01095016|DRUG|Berotec|"* Dose: 100ug/puff, 2 puffs daily~* Frequency: QD (total 200ug/day)~* Treatment duration: 2 days"
214289753|NCT05304156|OTHER|Biobanking blood and bone marrow specimens|"Interventions, procedures added for research purposes :~Blood Samples :~* Peripheral blood (20mL EDTA) (at Screening, pre-ICT Day 1, Day1 H8, Day 2, Day 3, Day 4 and Day of EOI evaluation~Bone Marrow samples :~* Biopsy at Screening and at EOI Evaluation~* Additional volume (2mL EDTA) on the Screening,2 and EOI Evaluation aspirations for single-cell analyses.~* Aspiration at D8 for Smears and 2 mL EDTA for single-cell analyses (instead of D15 standard care)."
214289754|NCT03992820|DEVICE|TENS machine|"The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
214289755|NCT03992820|COMBINATION_PRODUCT|EMLA cream|"The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
214289756|NCT06339723|BEHAVIORAL|Pecha Kucha|Pecha Kucha Method training was given
214289757|NCT02601131|BIOLOGICAL|Platelet transfusion|
214289758|NCT00837304|DEVICE|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
214289759|NCT00837304|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
214289760|NCT01327898|BEHAVIORAL|empowerment theory-based small group discussion|four small group discussion sessions followed by one individual counseling session
214289761|NCT01327898|BEHAVIORAL|individual resilience counseling|one individual resilience counseling session
214289762|NCT01961323|DRUG|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP\<140 and DBP \<90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
214289763|NCT01808287|DEVICE|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
214475542|NCT06879405|OTHER|The Labor Hopscotch|"Labor Hopscotch consists of 4 basic parameters including movement (mobilization), positioning (birth stool, sitting on the toilet, birth ball, birth mat), water therapy and non-pharmacological methods for reducing pain. There are sub-contents for each of these parameters and hopscotch consists of 7 steps in total. Labor Hopscotch Model Steps;~Step 1: Mobilization (squat, pelvic tilt, using stairs, movement) Step 2: Birth Stool (oral fluid support, massage, breathing techniques) Step 3: Sitting on the Toilet (urinating, dim lighting, music) Step 4: Water Therapy (Warm shower, breathing techniques, Squat, oral fluid support) Step 5: Birth Ball (drawing 8 with the birth ball, slow movement techniques) Step 6: Birth Mat (massage, exercise on the mat, quadruped position) Step 7: Alternative Methods (massage, aromatherapy)."
214475543|NCT06653634|DRUG|Methotrexate|Gradual withdrawal of the medication
214475544|NCT06653634|DRUG|TNF Inhibitor|Gradual withdrawal of the medication
214475545|NCT04225572|BEHAVIORAL|Physical Therapy: Dependent on Patient's Needs|"Therapeutic exercise:~* ROM: Begin with passive upper extremity ROM and progress to active ROM.~* Strengthening: Progressive upper extremity resistive exercises starting with light weights.~* Aerobic: Select a suitable, individual aerobic exercise program (walking, yoga, etc.) Manual therapy~* Soft tissue mobilization, myofascial release, and stretching of identified tight and stiff tissue.~Lymphedema treatment~* Manual lymph drainage: Gentle lymphatic massage to lymph nodes and vessels by PT for 1-2 weeks. Instruct patient in self MLD to perform 1-2×/day for 10 minutes during the remaining weeks.~* Compression therapy: Gradient compression bandaging for daily wear with activities and exercise for 1-2 weeks. Instruct in self compression bandaging or issue a compression garment to wear with exercise or activity, or with worsening symptoms of AWS (i.e. cording extends down arm) or lymphedema."
214475546|NCT00317486|DRUG|bosentan|
214289764|NCT02186912|DEVICE|Nobel Active, Nobel Procera IBO|
214289765|NCT03472469|DRUG|Acetaminophen IV/PO|Acetaminophen 1g IV/PO every 6 hours
214289766|NCT03472469|DRUG|Acetaminophen PO|Acetaminophen 1g PO every 6 hours
214289767|NCT03472469|DRUG|Ketorolac|Ketorolac 30mg IV once
214289768|NCT03472469|DRUG|Celebrex|Celebrex 200mg PO every 12 hours
214289769|NCT03472469|DRUG|Naproxen|Naproxen 500mg PO every 12 hours
214289770|NCT03472469|DRUG|Tramadol|Tramadol 100mg PO every 6 hours
214289771|NCT03472469|DRUG|Pregabalin|Pregabalin 100mg PO every 8 hours
214289772|NCT03472469|DRUG|Gabapentin|Gabapentin 300mg PO every 8 hours
214289773|NCT03472469|DRUG|Lidocaine|Lidocaine patch every 12 hours
214289774|NCT03472469|DRUG|Opioids|Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
214475547|NCT03606512|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as IM injection at a dose of 2.5\*10\^10 vp.
214475548|NCT03606512|BIOLOGICAL|Placebo|Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.
214475549|NCT03606512|BIOLOGICAL|Nimenrix|Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
214475551|NCT06554379|OTHER|Periodontal health and gingivitis|The presence or absence of periodontal disease in the gingiva was determined.
214289775|NCT03472469|DRUG|Regional anesthesia|Regional anesthesia
214289776|NCT02550548|DRUG|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
214289777|NCT02550548|DRUG|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
214289778|NCT02550548|DRUG|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
214289779|NCT03698747|DEVICE|McDESPOT|myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
214289780|NCT02746874|PROCEDURE|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
214289781|NCT02746874|PROCEDURE|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
214475552|NCT04646187|BIOLOGICAL|Infliximab|Dosing interval lengthening from 8 to 12 weeks
214475553|NCT04646187|BIOLOGICAL|Adalimumab|Dosing interval lengthening from 2 to 3 weeks
214657548|NCT05166057|OTHER|Hospital based outpatient exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient in the hospital..
214848000|NCT06126861|DRUG|[14C]LP-168|single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state
214848001|NCT04028154|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
214289782|NCT05421234|OTHER|diagnostic test and sperm analysis|"Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test."
214289783|NCT04139187|OTHER|Combined training with power and strength exercises|"The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks)."
214289784|NCT03140020|PROCEDURE|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
214289785|NCT03140020|PROCEDURE|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
214289786|NCT05049876|OTHER|urine sample taken during consultations|urine sample taken during consultations
214289787|NCT02402543|DRUG|Gabapentin|
214289788|NCT02402543|DRUG|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
214289789|NCT02402543|DRUG|Acetaminophen|
214289790|NCT02402543|DRUG|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
214289791|NCT02402543|DRUG|Placebo|
214289792|NCT01037647|OTHER|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
214289793|NCT03179995|DRUG|Octreotide|Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.
214289794|NCT03179995|OTHER|Placebo|Normal saline will be administered in the same fashion as Octreotide
214289795|NCT05715073|DIETARY_SUPPLEMENT|TeaCrine and Caffeine|Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
214289796|NCT05715073|DIETARY_SUPPLEMENT|Caffeine|Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
214289797|NCT05715073|OTHER|Placebo|Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.
214289798|NCT01541774|DEVICE|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
214289799|NCT02320149|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day,
214289800|NCT02320149|DRUG|Placebo|Placebo-matching sarecycline tablets taken orally at the same time each day.
214289801|NCT06420843|DIETARY_SUPPLEMENT|FOODMAP|Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) have been recently investigated in the management of functional gut symptoms in IBS.
214289802|NCT00005610|BIOLOGICAL|sargramostim|
214289803|NCT01342146|DRUG|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
214289804|NCT01342146|DRUG|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
214289805|NCT01342146|DRUG|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
214289806|NCT00190996|DRUG|Duloxetine Hydrochloride|
214289807|NCT00190996|DRUG|placebo|
214289808|NCT02089633|BIOLOGICAL|PACOX|Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
214289809|NCT01481233|DRUG|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
214289810|NCT01390311|DRUG|Azacitidine|
214289811|NCT01390311|DRUG|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
214289812|NCT01390311|BIOLOGICAL|Donor Leukocyte Infusion (DLI)|
214289813|NCT00473642|DRUG|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
214289814|NCT00473642|DRUG|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
214289815|NCT00473642|DRUG|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
214289816|NCT00539331|DRUG|AZD2171|oral tablet
214289817|NCT00539331|DRUG|Paclitaxel|intravenous infusion
214289818|NCT00539331|DRUG|Carboplatin|intravenous injection
214289819|NCT04071496|OTHER|Blood samples|1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml
214289820|NCT00055081|BEHAVIORAL|Critical Time Intervention|
214289821|NCT01156311|DRUG|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
214289822|NCT05505019|OTHER|Music listening|This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.
214289823|NCT05505019|OTHER|Podcast listening|This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.
214289824|NCT00740142|DRUG|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
214848002|NCT04028154|PROCEDURE|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
214475554|NCT04692012|OTHER|FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION|VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.
214475555|NCT05513937|DRUG|Nebivolol|Tablets administered orally once daily according instructions provided by Principal Investigator.
214475556|NCT05513937|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
214475557|NCT06351397|BEHAVIORAL|Mixed Reality (MR)|"Mixed Reality simulation of medical crisis scenarios.~MR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario"
214475558|NCT06760351|DRUG|TCM Herbal Therapy|Administration of customized herbal formulations for the TCM group, targeting qi and blood regulation. Pulse diagnosis parameters were evaluated monthly to guide treatment adjustments.
214475559|NCT06760351|DRUG|Standard Western Medicine Treatment|Administration of standard Western medical care, including blood transfusions and erythropoiesis-stimulating agents, focusing on hemoglobin restoration and anemia management.
214475562|NCT06496997|DRUG|Methylprednisolone|Methylprednisolone at a dose of 1 mg/kg/day (an average dose of 70 mg/day based on 70 kg body weight)
214475563|NCT06496997|DRUG|Dexamethasone|Dexamethasone at an equivalent dose of 13 mg/day
214475564|NCT06496997|DRUG|Hydrocortisone|Hydrocortisone at an equivalent dose of 350 mg/day
214475565|NCT02846545|BIOLOGICAL|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
214475566|NCT02846545|BIOLOGICAL|Placebo|Matching Placebo to golimumab.
214475567|NCT04757337|DRUG|Doxorubicin|6 x 3-week cycles corresponding to a maximal duration of 18 weeks
214475568|NCT04757337|DRUG|Cyclophosphamide|Until progression up to 24 months
214475569|NCT05899387|PROCEDURE|Swap collection|"Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site."
214475570|NCT05899387|PROCEDURE|Seroma punction|Puncturing of a seroma in case of occurence and clinical need
214475571|NCT05899387|PROCEDURE|Blood sampling|Blood sampling at defined time points according to protocol
214475572|NCT05899387|DIAGNOSTIC_TEST|Sonographic correlation Seroma|If a seroma occurs, a sonographic correlation is performed to determine the exact size of the seroma
214475573|NCT04113382|DRUG|CLENPIQ|"CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL."
214475574|NCT04113382|DRUG|MIRALAX|MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol \[PEG\] 3350).
214475575|NCT06468982|DEVICE|Intra-aortic Balloon Pump|It will be applied to patients with acute myocardial infarction who have elevated troponin levels and recurrent or persistent chest pain at rest, hemodynamic instability, multivascular disease, left main coronary artery disease, and patients with narrow and/or tortuous coronary artery anatomy in whom PCI has failed or is not applicable.
214475576|NCT03509662|DRUG|Vitamin C|Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).
214475577|NCT03509662|DRUG|Thiamine|All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.
214475578|NCT03509662|DRUG|Placebos|One group receives a placebo.
214475579|NCT03691298|DEVICE|SUTUREFIX ULTRA Suture Anchor and SUTUREFIX CURVED Suture Anchor|Fixation device intended to provide secure fixation of soft tissue to bone
214475580|NCT04072861|DRUG|RBT-9|intravenous administration
214475581|NCT02492711|BIOLOGICAL|Margetuximab|15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,
214475582|NCT02492711|BIOLOGICAL|Trastuzumab|8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle
214657549|NCT05265208|DRUG|Capecitabine|Capecitabine will given at 1250mg/m², 2 times a day with an interval of about 12 hours between two intakes, 2 weeks on, 1 week off, for 4 pre-surgery cycles.
214848003|NCT06000761|PROCEDURE|Standardized oral Care|One sponge-tipped swab, saturated with sterile water or human milk, will used clean the oral cavity with 15 seconds each area. Surfaces include all 4 quadrants of the gum surface and upper posterior part of the oropharynx. A second swab, with sterile water or milk will be used on the ventral and posterior surfaces of the tongue. A third swab, saturated with sterile water or human milk, will be used to clean the outer surface of any dwelling oral tubes (endotracheal tube, NAVA or feeding tube). Lips will be cleaned with a sterile gauze saturated with sterile water or human milk. Oral cavity will be suctioned as needed with an oral suction devise to remove secretions.
214848004|NCT02341521|DRUG|OC000459|Taken orally for 8 days
214848005|NCT02613078|BEHAVIORAL|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
214848006|NCT02613078|DIETARY_SUPPLEMENT|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10\^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
214848007|NCT02613078|BEHAVIORAL|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
214848008|NCT01413282|RADIATION|Cardiac CT|Calcium scan and CT coronary angiography
214848009|NCT05596292|DEVICE|Immersive Virtual Reality glasses|The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
214848010|NCT05596292|OTHER|early mobilization protocol|Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
214848011|NCT04958382|DRUG|ciprofol|intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance
214848012|NCT04958382|DRUG|medium/long chain fat emulsion injection (C8-24Ve)|at the infusion rate of 25-30 mL/h
214848013|NCT02624167|DRUG|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
214848014|NCT02624167|DRUG|Placebo|Patients will be given oral dose of matching Placebo
214848015|NCT05909917|OTHER|Half-Day First Responder Training|Participants in both study arms will undergo a half-day first responder training course designed for laypeople. The course will consist of five curricular categories: scene management, airway and breathing, hemorrhage control, fracture management, and victim transport. Course material will not differ between in-person and virtual arms, however the method of information dissemination will vary.
214848016|NCT00608595|DRUG|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
214848017|NCT00608595|GENETIC|gene expression analysis|not noted
214848018|NCT00608595|GENETIC|protein expression analysis|Not noted
214848019|NCT00608595|OTHER|immunohistochemistry staining method|not noted
214289825|NCT00740142|DRUG|placebo and lactulose|placebo 3 times a day for 7 days
214848020|NCT00608595|OTHER|laboratory biomarker analysis|not noted
214848021|NCT00608595|OTHER|mass spectrometry|
214848022|NCT00608595|PROCEDURE|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
214848023|NCT00608595|PROCEDURE|neoadjuvant therapy|not noted
214289826|NCT03128112|OTHER|Exam room with poster|This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
214848024|NCT00608595|PROCEDURE|therapeutic conventional surgery|not noted
214475583|NCT02492711|DRUG|Physician's choice of chemotherapy.|Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
214475584|NCT06409689|DRUG|Oliceridine fumarate low dose|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.1 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
214475585|NCT06409689|DRUG|Oliceridine fumarate high dose|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.5 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
214475586|NCT06409689|DRUG|Oliceridine fumarate moderate dose|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.35 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
214475587|NCT06409689|DRUG|morphine|The first loading dose of morphine was 4 mg in all patients after operation. The PCA dose of the patients was 1 mg, and the locking interval was 6 min. A supplemental dose of 2 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 60 mg.
214475588|NCT06606119|OTHER|Data and tissue collection|Collection of bone marrow, blood, feces, medical record data, and patient response surveys.
214475589|NCT06759740|RADIATION|68Ga-DOTA-SEMA|68Ga-DOTA-SEMA is GLP1R imaging agent
214475590|NCT05959889|OTHER|Placebo|Patients will receive placebo tablets for 4 cycles of AC.
214475591|NCT05959889|DRUG|Montelukast|Patients will receive motelukast 10 mg for 4 cycles of AC.
214475592|NCT05301348|DEVICE|Photoacoustic Flow Cytometry|Detection of circulating blood clots
214475593|NCT06759363|DRUG|Sodium-Butyrate|1000 mg/day of sodium-butyrate
214475594|NCT06759363|DRUG|Calcium Butyrate|1000 mg/day of calcium-butyrate
214475595|NCT06590623|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will receive an exogenous ketone supplement (KetoneAid KE4) in a fasted state in the morning, at a dosage of 0.75 g/kg of body weight.
214475596|NCT06600997|DEVICE|Flow Diversion for Endovascular Treatment of Intracranial Aneurysms|Flow Diversion for Endovascular Treatment of Intracranial Aneurysms
214475597|NCT06600997|DEVICE|Conventional endovascular therapy (stent-assisted coiling, balloon-assisted coiling, or coiling) for endovascular treatment of intracranial aneurysms|Conventional endovascular therapy (stent-assisted coiling, balloon-assisted coiling, or coiling) for endovascular treatment of intracranial aneurysms
214848025|NCT05048641|OTHER|Whatsapp reminder|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
214848026|NCT04351841|OTHER|arabinogalactan|A beverage will be prepared by thoroughly mixing the 15 g of arabinogalactan with water and Crystal Light flavoring
214848027|NCT04351841|OTHER|maltodextrin|A beverage will be prepared by thoroughly mixing the 15 g of maltodextrin with water and Crystal Light flavoring
214848028|NCT02868541|OTHER|Naso pharyngeal swab|Naso pharyngeal swab
214475598|NCT06815614|DEVICE|A Photoplethysmography-Based Continuous Automated Non-Invasive Sphygmomanometer|The investigation medical device under evaluation is oCareTM BP 100, a non-invasive continuous blood pressure monitoring system developed by Taiwan Biophotonic Co. (tBPC). The main function is to use a fingerclip sensor to receive PPG signals and collect continuous blood pressure values and uninterruptedly within the initialization time. In this study, according to the latest released ISO 81060-3:2022 standard requirements, non-invasive blood pressure measurement by cuff at the start and the end time points will be used as oCareTM BP 100 start-to-end blood pressure calibration. The A-line invasive arterial catheter blood pressure measurement will be used as a reference invasive BPM equipment. The purpose of the study is to confirm the stability of the investigational medical device under evaluation and its performance of blood pressure change tracking.
214475599|NCT05932407|DRUG|Vortioxetine Tablet|Vortioxetine Tablet
214657550|NCT05265208|DEVICE|Selective Internal Radiotherapy (SIRT)|During the first week of cycle 2 of capecitabine, patients will receive SIRT using Yttrium-90 glass microspheres. Treatment with Yttrium-90 glass microspheres requires two steps, one or two weeks apart. Both stages are performed under local anesthesia after a short hospitalization : the treatment simulation and therapeutic angiography.
214657551|NCT05265208|PROCEDURE|Surgery|Surgery will be performed according to local practice.
214657552|NCT06226597|DEVICE|Fitbit device|Daily use of a fitbit wearable activity tracker device.
214657553|NCT03352401|OTHER|Ultrasouund assessment of gastric contents|A qualitative and quantitative ultrasound evaluationof the stomach will be performed when the patient arrives in the pre-anesthesia room. The examination will be held in the right lateral decubitus with a low frequency convex ultrasound probe.
214475600|NCT05932407|DRUG|SSRI|SSRI: Selective Serotonin Reuptake Inhibitor
214475601|NCT06797830|DEVICE|AllCore|"AllCore360° is a novel core-strengthening machine intervention designed to target trunk muscles through gravity by means of high-intensity constant velocity rotating exercise (allcore360.com).~AllCore360° is systematic, consistent and designed for use over time. The core is strengthened because a patient's core muscles are used in anterior, lateral, and posterior contractions sequentially during a single rotation (Palevo). The patient must resist gravity with the rotation as well as contract and fire isometrically to keep proper posture. Using proper posture, the patient must keep their back straight and neck neutral throughout the length of the intervention without relying on their lower body muscles at all (this is assisted by straps rendering the legs useless and by securing the pelvis in the chair)."
214657554|NCT03543969|DRUG|Encorafenib|450 mg encorafenib daily by mouth
214657555|NCT03543969|DRUG|Binimetinib|45 mg binimetinib daily by mouth
214657556|NCT03543969|DRUG|Nivolumab|240 mg Nivolumab IV every 2 weeks
214657557|NCT06538155|DEVICE|Wearable device|Wearable devices that are preferentially Food and Drug Administration (FDA) and/or Conformité Européenne (CE) marked
214848029|NCT02492841|DRUG|Mineral trioxide aggregate|Mineral trioxide aggregate
214848030|NCT02492841|DRUG|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
214848031|NCT02492841|DRUG|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
214475602|NCT06818474|BIOLOGICAL|Lanadelumab 300 mg|no other intervention
214657558|NCT06538155|OTHER|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation
214657559|NCT06538155|OTHER|CT scan, TEE exam, or chest X ray|Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray
214657560|NCT02443402|DRUG|Sitagliptin|Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) \< 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
214475603|NCT06818565|DRUG|Meropenem Injection|Meropenem 2 gm iv TDS
214475604|NCT06818565|DRUG|Ceftazidime-avibactam|Ceftazidime-avibactam 2.5 gm iv TDS
214848032|NCT04431414|OTHER|Sample collection|"* blood, nasal swab, nasal wash, and saliva~* optional stool swab"
214475605|NCT06818565|DRUG|Teicoplanin|Teicoplanin 400 mg iv BD 3 doses followed by 400mg iv OD
214657561|NCT02443402|DRUG|Placebo|One pill daily until discharge
214848033|NCT03746002|DRUG|Metolazone 60 minutes prior to furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
214848034|NCT03746002|DRUG|Metolazone concurrently with furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
214848035|NCT04925713|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
214475606|NCT06816082|BEHAVIORAL|Internet delivered acceptance and commitment therapy|7 week long treatment with therapist asynchronous support in mainly text format. Treatment includes for example mindfulness, psychoeducation, values, and self-compassion
214475607|NCT06816966|RADIATION|split-course adaptive hypofractionated radiotherapy|Each treatment cycle comprises a solitary radiotherapy session, which allows for its integration with chemotherapy and immunotherapy. The radiotherapy sessions are scheduled at three-week intervals, thereby affording extended recovery periods for normal tissues. An adaptive radiotherapy plan is implemented for each cycle, enabling precise adjustments to the treatment target area in response to the reduction in tumor volume.
214848036|NCT03752554|PROCEDURE|segmental resection|All cases will undergo surgery under general anesthesia. The mandibular lesion will be segmentally resected. The cuts will be performed with the aid of the prefabricated digital template. The neurovascular bundle will be separated and protected. Then reconstruction will be performed
214848037|NCT03708159|DEVICE|active tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
214848038|NCT03708159|OTHER|sham tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
214848039|NCT02588547|DRUG|Granisetron|IV granisetron 1 mg before spinal anethesia
214848040|NCT02588547|DRUG|Granisetron|IV granisetron 0.7 mg before spinal anethesia
214289827|NCT03909256|OTHER|NUTRI-HAB|"The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian."
214289828|NCT00639054|PROCEDURE|Bone marrow examination|7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
214289829|NCT00639054|PROCEDURE|Blood samples|24 ml of cubital vein blood drawn in addition to diagnostic samples.
214289830|NCT03470818|OTHER|Preparatory instructional videos (flipped classroom model)|"The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
214289831|NCT03470818|OTHER|Sham video|"Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
214289832|NCT03012958|OTHER|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
214475608|NCT06818240|DEVICE|Active transcranial direct current stimulation|In the active tDCS session, real stimulation was delivered via a current stimulator (DC-STIMULATOR MC, NeuroConn, Germany) using saline-soaked 4×6 cm² electrodes. The anode was positioned over the left-DLPFC identified as F3 according to the 10-20 international EEG system, and the cathode over the right supraorbital ridge.
214848041|NCT02588547|DRUG|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
214289833|NCT00344747|BEHAVIORAL|dietary, behavioral, physical activity|
214289834|NCT01288248|DEVICE|Airway laryngeal mask classic|"This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.~The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned"
214289835|NCT01288248|DEVICE|endotracheal tube|"This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.~The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age."
214289836|NCT03259854|DEVICE|non invasive mechanical ventilation in pediatrics|use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation
214848042|NCT03544814|DRUG|icotinib combined with pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
214848043|NCT03544814|DRUG|first icotinib and then pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
214848044|NCT02489591|DEVICE|Oral appliance|Patients will bring their prescribed oral appliance.
214289837|NCT03259854|DEVICE|oxygen mask|use of oxygen mask after successful weaning from invasive mechanical ventilation
214289838|NCT03449082|BIOLOGICAL|High concentration of Allo-ASC|10 million cells of Allo-ASC 0.5cc
214289839|NCT03449082|BIOLOGICAL|Low concentration of Allo-ASC|1 million cells of Allo-ASC 0.5cc
214289840|NCT03449082|DRUG|Fibrin glue|Fibrin glue 0.5cc
214289841|NCT03449082|DRUG|Normal saline|Normal saline 0.5cc
214289842|NCT00226954|DRUG|zoledronic acid|
214289843|NCT04876443|DIAGNOSTIC_TEST|Study questionnaire|Study questionnaire related to drinking behaviour
214289844|NCT03695107|DRUG|Nifedipine controlled released tablets|lower blood pressure
214289845|NCT05955950|BEHAVIORAL|Gratitude list|Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.
214289846|NCT05955950|BEHAVIORAL|List of any event|Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
214289847|NCT02118844|DRUG|rocuronium|
214289848|NCT02812147|DRUG|L-DOPS|Added as described in the Arm/Group Descriptions.
214289849|NCT02812147|DRUG|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
214289850|NCT01741701|DRUG|Oxaloacetate (OAA)|
214289851|NCT01741701|DRUG|Placebo|
214289852|NCT05373329|DEVICE|Sanvello (app)|Sanvello is a commercially available mobile app designed to teach users strategies to manage their stress, anxiety, and depression. Users can choose which tools they want to use. The strategies are digital implementations of existing practices in psychology such as thought records, mindfulness meditation \& relaxation exercises, and behavioral activation.
214289853|NCT02404376|DRUG|Exenatide|Intravenous administration of Exenatide
214289854|NCT02404376|OTHER|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
214289855|NCT02404376|DRUG|Placebo|Intrevenous administration of Placebo
214289856|NCT00487747|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
214289857|NCT02296268|BEHAVIORAL|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
214289858|NCT04931355|OTHER|Acupuncture|The Acupuncture intervention（Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.） will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.
214289859|NCT04931355|OTHER|Western medicine|Western medicine
214289860|NCT01669915|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
214289861|NCT01669915|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
214289862|NCT01669915|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
214289863|NCT01669915|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
214289864|NCT00946959|PROCEDURE|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
214289865|NCT00006488|DRUG|recombinant-methionyl human glial cell line-derived neurotrophic factor|
214289866|NCT05025189|OTHER|Table Grape Powder|Freeze Dried Whole Table Grape Powder
214289867|NCT05025189|OTHER|Beige Diet|Low Fiber, low polyphenol Diet
214289868|NCT04500210|DIETARY_SUPPLEMENT|Placebo|Placebo in gelatin capsules
214289869|NCT04500210|DIETARY_SUPPLEMENT|Turmeric|Turmeric in gelatin capsules
214289870|NCT03134287|PROCEDURE|two-finger method, reverse sellick's method|Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method
214289871|NCT03251820|DRUG|corticosteroid|Each patient will be subjected to a one month course of steroids and then re-evaluated
214289872|NCT02093481|OTHER|Test meal|
214289873|NCT02093481|OTHER|Reference|
214289874|NCT02093481|OTHER|Priming|The reference or test meal was eaten 3 days prior to measurements of variables.
214289875|NCT02093481|OTHER|No priming|The reference or test meal was eaten 1 days prior to measurements of variables.
214289876|NCT03762109|DRUG|Dantrolene|muscle relaxant
214289877|NCT03762109|DRUG|Placebo Oral Tablet|inactive pill
214289878|NCT01291758|DIAGNOSTIC_TEST|Submaximal bicycle exercise stress tests performed 24 hr apart|Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.
214289879|NCT00914524|DRUG|olmesartan medoxomil|olmesartan medoxomil tablets, once daily
214475609|NCT06818240|DEVICE|Sham transcranial direct current stimulation|In the Sham tDCS session, Sham stimulation was delivered via a current stimulator (DC-STIMULATOR MC, NeuroConn, Germany) using saline-soaked 4×6 cm² electrodes. The anode was positioned over the left-DLPFC identified as F3 according to the 10-20 international EEG system, and the cathode over the right supraorbital ridge.
214475610|NCT06818617|PROCEDURE|Epidural steroid injection (ESI)|epidural nerve block procedures for patients with spinal conditions such as stenosis or disc herniation
214475611|NCT06816381|DEVICE|Shear wave elastography measurements|Shear wave elastography measurements in kilopascals via ultrasound
214848045|NCT02489591|DEVICE|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
214475612|NCT06819514|DRUG|EXG110 Injection|EXG110 Injection is gene therapy for Fabry Disease , uses a proprietary AAV capsid with improved liver and muscle specificity.
214475613|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI alone|patients use ventoline pMDI alone
214657562|NCT02443402|DRUG|Regular Human Insulin|Continuous intravenous insulin given to ICU patients with a BG \> 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
214657563|NCT02443402|DRUG|Insulin glargine|"When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate \>2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~* If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~* If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~* If fasting and pre-dinner BG is \> 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~* If fasting and pre-dinner BG is \< 100 mg/dL in the absence of hypoglycemia: stop glargine"
214848046|NCT02826291|DEVICE|RD-100i, OSNA|quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
214906918|NCT06884202|DEVICE|Delefilcon A contact lenses with standard base curves and diameters|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.
214906919|NCT06888323|RADIATION|Actinium Ac 225 Lintuzumab|Given IV
214906920|NCT06888323|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214906921|NCT06888323|PROCEDURE|Buccal Swab|Undergo buccal swab
214906922|NCT06888323|PROCEDURE|Computed Tomography|Undergo SPECT/CT
214906923|NCT06888323|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214906924|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 5 mg QW|IIb：Efsubaglutide Alfa 5 mg QW
214475614|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer
214475615|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer
214475616|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber
214289880|NCT02232633|DRUG|BBI503|
214289881|NCT00434655|PROCEDURE|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
214289882|NCT04431648|DRUG|DEFINITY|MRI-guided ultrasound-stimulated microbubble-treatment
214289883|NCT04431648|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
214289884|NCT03271112|OTHER|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
214289885|NCT04828447|DIETARY_SUPPLEMENT|Olive Oil|Subjects will be randomized to either high or low dose of olive oil and follow a whole food plant based diet.
214289886|NCT04464629|DRUG|Dextenza|Intracanalicular sustained release dexamethasone insert 0.4 mg
214289887|NCT04464629|DRUG|Prednisolone Acetate|Topical Prednisolone acetate 1% ophthalmic suspension
214289888|NCT03125317|OTHER|Music|a kind of music which the participant likes will be listened using speakers
214289889|NCT03125317|OTHER|Valsalva maneuver|Participant will be asked to take a deep breath and exhale the air out in 15 seconds
214289890|NCT03125317|OTHER|control|No intervention
214289891|NCT04388202|DRUG|Sertraline|FDA approved antidepressant
214289892|NCT04388202|DRUG|Escitalopram|FDA approved antidepressant
214289893|NCT02209389|DEVICE|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
214289894|NCT01296620|DRUG|Ulimorelin Intravenously (IV)|160 µg/kg daily (QD)
214289895|NCT01296620|DRUG|Ulimorelin Invtravenously (IV)|480 µg/kg daily (QD)
214289896|NCT01296620|DRUG|5% dextrose in water|Placebo
214289897|NCT03293589|PROCEDURE|open revascularization|surgical revascularization (i.e. Bypass surgery)
214289898|NCT03293589|PROCEDURE|endovascular revascularization|endovascular revascularization (stent, ballon angioplasty)
214289899|NCT03949374|DRUG|CRESTOR, reference formulation of rosuvastatin|Use of ROVASRO for hypercholesterolemia
214289900|NCT03949374|DRUG|ROVASRO, generic formulation of rosuvastatin|Use of CRESTOR for hypercholesterolemia
214289901|NCT00372112|DRUG|GW642444|GW642444H
214289902|NCT00372112|OTHER|Placebo|Placebo administered twice daily
214848047|NCT02396082|BEHAVIORAL|MIND-S Intervention|MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
214848048|NCT02396082|OTHER|Augmented Usual Care|Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
214848049|NCT03923231|DRUG|Atazanavir 300mg/ Ritonavir 100 mg once daily|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care
214848050|NCT03923231|DRUG|Atazanavir 250 mg / ritonavir 80 mg|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg
214848051|NCT04661826|DRUG|Oncofid-P-B|Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
214848052|NCT04978844|BEHAVIORAL|IWOTCH|Arm 1
214848053|NCT04978844|BEHAVIORAL|Dyadic therapy|Arm 2
214475617|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer
214475618|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer
214475619|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer|patient use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer
214475620|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer
214475621|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the MDI package|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the MDI package
214475622|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the hand-made paper sheet spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the hand-made paper sheet spacer
214475623|NCT05623462|DEVICE|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
214475624|NCT05623462|OTHER|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program includes the following:~\- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
214475625|NCT05158634|OTHER|Evaluations|"Within the scope of the study, the participants will be evaluated for 30 minutes in a single session. The participants' trunk stabilization and endurance, balance, functional mobility, upper extremity endurance, functional health and quality of life will be questioned by questionnaires, scales and tests. Evaluation will begin with a literature-supported demographic data form prepared for the participants.~Assessments to be made are listed below. Trunk Control Measurement Scale (TCMS) Pediatric Balance Scale (PBS) Time Up and Go test (TUG) Trunk Flexor Test (TFT) The Pediatric Outcomes Data Collection Instrument (PODCI)"
214475626|NCT06148012|OTHER|dental implant|"Digital panoramic radiographs taken during the patients' treatment periods (T0, T1) were used in the study. Measurements of marginal bone levels on radiographs were performed using the Image J software. The distance between the most coronal part of the implant neck and the most apical part of the defect caused by marginal bone loss was measured.~Fractal analysis (FA) was conducted on panoramic radiographs (OPG) with a size of 2952x1435 pixels and a depth of 32 bits. FA on these radiographs at T0 and T1 times was performed using the box counting method determined by White and Rudolp with the ImageJ program(23)."
214475627|NCT04315610|OTHER|Access to mobile phone application|Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application. After discharge, assessments using the application are performed if necessary.
214475628|NCT04315610|OTHER|Treatment as usual|Active comparator group, based on traditional information and follow-up.
214657564|NCT02443402|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
214848054|NCT01841216|DEVICE|Lower Body Exercises with and without resistance|lower body exercises with and without resistance designed to activate the gluteal/hip musculature
214848055|NCT01494441|PROCEDURE|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
214289903|NCT01025791|DRUG|MK-8266 0.1 mg|Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
214289904|NCT01025791|DRUG|MK-8266 1.0 mg|MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
214289905|NCT01025791|DRUG|Placebo|Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
214657565|NCT02443402|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG \> 400 mg/dL; 7-9 units of insulin aspart"
214657566|NCT03332888|DRUG|Rituximab|Rituximab will be studied in patients with HFrEF, and verify the patients safety.
214657567|NCT02241486|DRUG|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
214657568|NCT02770521|DRUG|Treprostinil|Administered SC.
214657569|NCT02770521|DRUG|Placebo|Administered SC.
214657570|NCT02770521|DRUG|LY900014|Administered SC.
214657571|NCT02770521|DRUG|Insulin Lispro|Administered SC.
214289906|NCT04470674|DRUG|Durvalumab|Durvalumab 1500 mg
214289907|NCT04470674|DRUG|Carboplatin|carboplatin AUC 5
214289908|NCT04470674|DRUG|Pemetrexed|pemetrexed 500 mg/m2
214289909|NCT04649060|DRUG|Melflufen|Powder for solution for i.v. infusion
214289910|NCT04649060|DRUG|Dexamethasone|Oral tablets
214289911|NCT04649060|DRUG|Daratumumab|Solution for s.c. injection
214289912|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
214289913|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
214289914|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
214289915|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
214289916|NCT05502601|PROCEDURE|Non-surgical periodontal treatment|"SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
214289917|NCT02866552|DRUG|Stromal Vascular fraction|
214289918|NCT02866552|DRUG|Ringer lactate|
214289919|NCT01427686|DRUG|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
214289920|NCT01427686|DRUG|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
214289921|NCT03759847|OTHER|Fluid intake app|Use of fluid app to monitor intake of fluids
214289922|NCT03759847|OTHER|Survey|A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
214289923|NCT05699395|DIAGNOSTIC_TEST|Non interventional|No intervention
214289924|NCT01965275|DRUG|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
214289925|NCT03001531|DEVICE|HydroSun|a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp
214289926|NCT03001531|DEVICE|Hilotherm|a skin area of the lower limb will be treated three times with heat applied by a sleeve
214289927|NCT05002855|OTHER|Enhanced Recovery After Surgery (ERAS)|Multidisciplinary approach to perioperative care.
214289928|NCT03362073|DRUG|Ketamine|"Application of ketamine using continuous intravenous infusion method during 5 days~* Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid~* Dose schedule: 0.05mg/kg/hr -\> 0.10mg/kg/hr -\> … -\> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)"
214289929|NCT04737083|GENETIC|CGH array|a CGH array is systematically offer to women when the fetus show bilateral clubfoot during prenatal ultrasound screening
214289930|NCT03459547|DEVICE|dental implant|Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
214289931|NCT00629681|DRUG|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
214289932|NCT02026739|PROCEDURE|low supplemental oxygen concentration|low supplemental oxygen concentration would be used during the surgery
214289933|NCT02026739|PROCEDURE|high supplemental oxygen concentration (conventional)|high supplemental oxygen concentration would be used during the surgery
214848056|NCT01494441|DEVICE|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
214848057|NCT01494441|DEVICE|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
214848058|NCT03275584|DRUG|N-13 ammonia intravenous injection|"Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging"
214848059|NCT03966859|DRUG|Atorvastatin 20mg|oral dose, once daily for 7 days
214848060|NCT03966859|OTHER|Lactose placebo|oral dose, once daily for 7 days
214848061|NCT02187107|DRUG|TMC114|300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
214848062|NCT02187107|DRUG|rtv|100 mg tablet of Norvir®
214848063|NCT03851588|OTHER|Placebo|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
214475629|NCT06816537|RADIATION|Low Level Laser Therapy|A low-level medical gallium-aluminum-arsenide (GaAlAs) diode laser device will be used on the 1st permanent molars in the test quadrants
214475630|NCT06816537|OTHER|No Interventions|The handpiece was also held on the placebo treatment side without laser irradiation (fake irradiation) following the same application protocol as the LLLT treatment side.
214475631|NCT06818864|DEVICE|Deep Brain Stimulation|Patients will arrive on the morning of surgery to the medical imaging department of the Sunnybrook Hospital. They will have a stereotactic frame attached directly to their skull, after infiltration with local anesthesia. The frame allows precise coordinates to be acquired so that deep brain structures can be targeted with implanted electrodes. The patient will then undergo a CT scan with the frame in place, followed by transport directly to the operating room. The anesthesia team will insert an intravenous line and may use gentle sedation to relax the patient prior to and during the operation, as they will remain awake during the first stage of the operation. In the operating room the patient's head, via the frame, will be attached to the operating room table, and their scalp infiltrated with additional local anesthetic. A skin incision will be made and two burr holeswith approximately 1.4cm in diameter drilled through the skull. A small electrode will identify the optimal spot for ele
214475632|NCT05340569|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
214475633|NCT06816654|OTHER|Data extraction from medical records|Data extraction from medical records
214475634|NCT06820775|COMBINATION_PRODUCT|A TRIPLE INTERVENTION NUTRITION AND PHYSICAL ACTIVITY|"Intervention group: Health advice and triple intervention: 15 ml apple cider vinegar diluted in a glass of water before meals, order in the sequence of meals (sequence of food intake: first vegetables, second proteins, third fats and finally carbohydrates) and physical activity immediately after meals.~Description of all interventions:~Patients in both groups: all patients will receive health advice on sports practice from the WHO, Osakidetza and the Basque Government."
214475635|NCT06657807|BEHAVIORAL|Online CBT|Online CBT targeting anxiety in pediatric asthma
214475636|NCT06652659|OTHER|Non-union|Observational study looking prospectively at many different factors that may affect non-union of midshaft clavicle fractures.
214475637|NCT05625204|BEHAVIORAL|Center based attention (stretching only) control|Center based attention (stretching only) control
214475638|NCT05625204|BEHAVIORAL|Center based HIIT|Center based HIIT
214475639|NCT05625204|BEHAVIORAL|Home based HIIT|Home based HIIT
214475640|NCT06820086|DRUG|Rosuvastatin 20mg|Preventive statin treatment with rosuvastatin 20mg, 1 tablet per day, for healthy individuals with top 20% CAD PRS.
214475641|NCT04669288|DRUG|Azithromycin|"oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging."
214848064|NCT03851588|DRUG|Dolutegravir 50 mg|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
214848065|NCT02355756|DRUG|Maxadilan|
214848066|NCT02355756|DRUG|Placebo|
214848067|NCT05117047|PROCEDURE|liver resection|After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
214848068|NCT02237547|BIOLOGICAL|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
214475642|NCT04669288|DRUG|Placebo|"oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging."
214475643|NCT06856564|PROCEDURE|Frenectomy|The study involves using a diode laser and scalpel to treat ankyloglossia in cases that are unresponsive to tongue exercises or exhibit severe restrictions. The techniques employed range from simple frenotomy to complex frenuloplasty, depending on the severity of the condition. Electrocautery is frequently used to minimize bleeding, although it may result in scar formation.
214475644|NCT06856785|OTHER|Resonance Tube Voice Therapy in Water|Resonance Tube of 28 cm in length and 9 mm diameter for adults will be submerged into a bowl of water .Both flexible soft walled tubes,glass tubes or straws can be used
214475645|NCT06855589|DRUG|6 months of Eligard|Total of two 3-month injections of a LHRH agonist for total duration of 6 months
214848069|NCT02543151|PROCEDURE|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
214848070|NCT01995331|DRUG|cyclophosphamide,cyclosporine A|"Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.~Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was \>1×109/L."
214906925|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 10 mg QW|Efsubaglutide Alfa 10 mg QW
214657572|NCT00321516|DRUG|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
214848071|NCT02479477|OTHER|kinesio therapy|during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
214848072|NCT05460962|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
214848073|NCT05460962|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
214848074|NCT01898234|DEVICE|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
214475646|NCT06855589|DRUG|12 months of Eligard|Total of four 3-month injections of a LHRH agonist for total duration of 12 months
214475647|NCT06855589|RADIATION|prostate SBRT or prostate brachytherapy with radiation therapy|Patients may receive prostate stereotactic body radiation therapy or a combination of high-dose rate brachytherapy with radiation therapy; as per the treating physician's preference
214475648|NCT06857838|PROCEDURE|MBBG|The patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG)，fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. No atherosclerotic plaque or merely mild atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
214475649|NCT06857838|PROCEDURE|MB CABG|The patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG)，fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The moderate-to-severe atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
214475650|NCT06857838|PROCEDURE|MB unroof|"The patients with superficial type(depth\<2mm) and short-segement(length\<25mm) of myocardial bridge will be allocated to receive myocardialbridge unroof surgery，when fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The MB was superficial and short confirmed by coronory artery CT angiography."
214475651|NCT03460769|OTHER|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
214475652|NCT06659458|OTHER|blood draw|A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.
214475653|NCT06659458|OTHER|Gene sequencing|Subjects will have their DNA sequenced within and around the EGFR gene.
214475654|NCT06354881|DEVICE|Transcranial Doppler Ultrasonography (TCD) during sit-stand manoeuvres|TCD will be used to measure the cerebral blood flow in the middle and posterior cerebral arteries. This will be done at rest and during two sit-stand manoeuvres, whereby the participant will be asked to stand (from a seated position) and stay standing for 1 minute. The participant will then be given time to recover before repeating the manoeuvre. This will occur at the first visit and the follow-up visit 4 weeks after.
214475655|NCT04472195|OTHER|Simulation Airway Coaching|Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
214475656|NCT04784299|DEVICE|YVOIRE volume plus|Hyaluronic acid dermal filler
214475657|NCT04784299|DEVICE|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
214475658|NCT06164444|OTHER|Intervention: Reusable drapes and gowns|Reusable drapes and gowns used during surgery.
214475659|NCT06164444|OTHER|Comparator: Disposable (single-use) drapes and gowns|Disposable drapes and gowns used during surgery.
214475660|NCT03615664|DRUG|Bendamustine|Bendamustine (B) 90 mg/m2 i.v. day 1, 2
214475661|NCT03615664|DRUG|Gemcitabine|Gemcitabine (G) 800 mg/m2 i.v. day 1, 4
214657573|NCT04927273|OTHER|Survey|Surveyed neurological and orthopedic surgeons
214657574|NCT03892421|DRUG|Rituximab|Rituximab 375 mg/m²
214657575|NCT03892421|DRUG|Carboplatin|Carboplatin AUC5
214657576|NCT03892421|DRUG|Cytarabine Injection|Cytarabine 2000 mg/m² qd 2 days
214657577|NCT03892421|DRUG|Dexamethasone|Dexamethasone 40 mg
214657578|NCT03892421|DRUG|Filgrastim 0.3 MG/ML|One subcutaneous injection daily for 5 days
214848075|NCT01898234|DEVICE|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
214848076|NCT01898234|DEVICE|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
214906926|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 20 mg QW|Efsubaglutide Alfa 20 mg QW
214475662|NCT03615664|DRUG|Dexamethasone|Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4
214475663|NCT03615664|DIAGNOSTIC_TEST|PET/CT|"PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:~* in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment~* in case of SMD - exclusion from the trial~* in case of PMD - exclusion from the trial"
214475664|NCT03615664|PROCEDURE|Autologous Stem Cell Transplant|"Must be performed within 3 months after the end of BGD treatment.~When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT."
214657579|NCT00003060|BIOLOGICAL|filgrastim|
214657580|NCT00003060|DRUG|busulfan|
214657581|NCT00003060|DRUG|cyclophosphamide|
214657582|NCT00003060|DRUG|cyclosporine|
214657583|NCT00003060|DRUG|methotrexate|
214657584|NCT00003060|PROCEDURE|allogeneic bone marrow transplantation|
214657585|NCT02363829|DRUG|Nelfinavir|
214657586|NCT02363829|BIOLOGICAL|Cisplatin|
214657587|NCT03819075|DEVICE|Lightwalker Laser (Fotona)|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.
214657588|NCT03819075|OTHER|standard|Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
214657589|NCT04453150|OTHER|Standard hypocaloric die|Standard hypocaloric diet
214657590|NCT04453150|OTHER|Intermittent fasting 16/8 (early fasting)|Intermittent fasting 16/8 (early fasting)
214657591|NCT04453150|OTHER|Intermittent fasting 16/8 (late fasting)|Intermittent fasting 16/8 (late fasting)
214848077|NCT01898234|DEVICE|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
214657592|NCT04453150|OTHER|Alternate-day fasting|Alternate-day fasting
214657593|NCT04453150|OTHER|Ketogenic diet|Ketogenic diet
214475665|NCT02636517|BIOLOGICAL|Fecal Microbiota Transplant|Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
214475666|NCT04805307|DRUG|CMG901|CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until confirmed Progressive Disease(PD), unacceptable toxicity, initiation of new anti-tumor therapy, withdrawal from the study, or death, whichever occurs first.
214475667|NCT05246319|DIAGNOSTIC_TEST|preoperative imaging|evaluation of preoperative imaging (versus nodes observed on pathology)
214848078|NCT00611325|DRUG|Avastin|Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
214475668|NCT06825039|DEVICE|Shockwave therapy|Focused ESWT will be applied to the scarred area in the 3 intervention groups. Each group will receive 10 ESWT treatments with a frequency of 1x/week. Energy levels (EFD mJ/mm2) or bar in radial can range between 0.01-0.33 mJ/mm2 (33). Based upon experimental papers, the described energy flux density, frequency and number of shots should activate or modulate the signaling pathways of interest and are used in the treatment of scars.
214475669|NCT06824090|OTHER|Smartphone Addiction Scale-Short Form|Smartphone Addiction Scale-Short Form: In our study, the Smartphone Addiction Scale-Short Form will be filled out in order to evaluate the intensity of smartphone use of students, and the daily duration of smartphone use will be recorded. The scale is a 6-point Likert-type scale consisting of 10 items used to measure the risk of smartphone addiction. Scores obtained from the scale vary between 10-60 and an increase in the score indicates an increased risk for smartphone addiction. The cut-off score of the scale was determined as 31 for men and 33 for women. In the Turkish validity and reliability study, Cronbach's alpha coefficient was found to be 0.86.
214657594|NCT01046812|DRUG|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
214657595|NCT06404489|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals."
214848079|NCT00611325|DRUG|Bortezomib|Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs \& 2.5 mg/m2 for patients taking EIAEDs.
214848080|NCT02563769|DRUG|Clavulanic acid|Clavulanic acid will be administered orally in 250mg capsules
214475670|NCT06824090|OTHER|Hand Grip Strength Assessment|Hand grip strength was measured with 'Saehan Hydraulic Hand Dynamometer'. Participants were informed about the correct holding position and use of the instrument. In the measured arm, the position of 90̊ flexion from the elbow joint and completely adjacent to the body was used. The participant's hand was placed in the second grip position of the dynamometer and asked to make the strongest grip he/she could make, right and left measurements were taken.
214475671|NCT06824090|OTHER|Finger Lateral Grip Strength Assessment|Finger lateral grip strength was measured with 'Saehan Hydraulic pinch gauge'. Participants were informed about the correct holding position and use of the instrument. While the participant was sitting on a chair with arms supported, the shoulder was adjacent to the trunk and neutral, the elbow joint was in 90 ̊ flexion, the forearm was neutral, the wrist was in 0-30 ̊ extension and 0-15 ̊ ulnar deviation. Right and left finger lateral grip measurements were taken.
214657596|NCT04504318|DRUG|Apixaban 2.5 MG Oral Tablet|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
214657597|NCT04504318|DRUG|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
214848081|NCT02563769|DRUG|Intravenous cocaine|20/40mg Cocaine will be administered by IV
214848082|NCT02563769|DRUG|Placebo|Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose
214848083|NCT05184179|DRUG|Olmesartan Medoxomil|Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
214848084|NCT04229290|DRUG|Dolutegravir|Switch of virally suppressed participants to Dolutegravir
214906927|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 20 mg Q2W|Efsubaglutide Alfa 20 mg Q2W
214906928|NCT06921486|DRUG|Phase IIb：Placebo|Placebo
214657598|NCT05292469|BEHAVIORAL|Comprehensive approach to hypertension management|Trained health workers will review blood pressure (BP) logs and provide treatment. The patients will receive a BP lowering informational package, BP monitoring device and log book and pill-box and medication table. The participants will receive monthly home visits (6 visits) to discuss hypertension and ways to manage it. They will be encouraged to identify problems and developing an action plan to solve them. The participants will be encouraged to set behavioral goals. The follow up visits will review the progress made in implementing action plan and goals set and updating them. Review BP logs and facilitate tailored discussion on topics based on problems faced by participants on barriers to medication adherence, physical activity, weight management or diet. The family members will be involved and be accountable in supporting the patients in achieving the action plans.
214848085|NCT04701424|DEVICE|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
214289934|NCT03535610|DEVICE|Uterine Embolization|Uterine Embolization with PVA Microspheres
214289935|NCT04981769|DIAGNOSTIC_TEST|Covid-19 test|PCR Covid-19 test
214657599|NCT06649357|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
214657600|NCT06649357|PROCEDURE|BiTURP|Patients with an indication for surgery for BPH viaEEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
214657601|NCT06657339|PROCEDURE|Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)|"The patient will undergo therapeutic endoscopy under general anesthesia, either as outpatient or inpatient care, based on the recommendations of the investigating physician, taking into account anesthetic risks and comorbidities. Two CE-marked gastric suturing devices may be used at the discretion of the investigating center based on their practices~OverStich™ allows for tissue fixation via a gastroscope, creating a durable suture through a transabdominal fixation technique. The procedure lasts about 45 minutes and includes measures to prevent vomiting.~Endomina™ is a single-use device that captures the gastric mucosa to create successive plications, allowing for effective suturing along the greater curvature of the stomach."
214657602|NCT06960395|DRUG|VIR-5525|Pharmaceutical Form: Solution for Infusion Route of Administration: Intravenous (IV) infusion
214657603|NCT06960395|DRUG|Pembrolizumab|Pharmaceutical Form: Solution for Infusion Route of Administration: Intravenous (IV) infusion
214657604|NCT02935738|DRUG|Prednisolone treatment|Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
214657605|NCT04072770|DIETARY_SUPPLEMENT|Pea|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
214657606|NCT04072770|DIETARY_SUPPLEMENT|Casein|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
214657607|NCT06960447|DEVICE|Nd:YAG Laser|Nd:YAG laser applied to one side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.
214657608|NCT06960447|DEVICE|Alexandrite Laser|Alexandrite laser applied to the contralateral side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.
214657609|NCT00469508|DRUG|Modafinil|400mg pills taken orally daily for 12 wks.
214657610|NCT00469508|DRUG|Placebo|400mg pills taken orally daily for 12 wks
214657611|NCT04721873|DRUG|Phentermine-Topiramate|Patients will be randomized to either once-daily, oral phentermine-topiramate 15-92mg or placebo, in a 1:1 fashion, for 22 weeks, with clinic visits with an obesity medicine specialist, for intensive counseling for diet and lifestyle intervention. All patients will be dose-titrated within the first 4 weeks, starting at phentermine-topiramate 3.75-23mg, or placebo. Dose titration will be performed as follows 3.75-23mg x 1 week --\> 7.5-46mg x 1 week --\> 11.25-69mg x 1 week --\> 15-92mg. Patients who experience side effects would undergo slower titration, and dose would be down-titrated and capped at highest tolerated dose.
214657612|NCT04721873|DRUG|Placebo|Matching placebo, titrated as active intervention
214657613|NCT06836830|PROCEDURE|PEEP 5 mbar|Positiv-End-Expiratory Pressure
214657614|NCT06836830|PROCEDURE|ZEEP 0 mbar|Zero-End-Expiratory Pressure
214657615|NCT01552057|DRUG|Duloxetine 60 mg|Duloxetine 60 mg taken orally once every day for 15 weeks
214657616|NCT01552057|DRUG|Placebo|Placebo taken orally once every day for 15 weeks
214657617|NCT03211182|BEHAVIORAL|lifestyle modification intervention|healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI\>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
214289936|NCT01850771|PROCEDURE|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
214289937|NCT01850771|PROCEDURE|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
214289938|NCT03090178|OTHER|electronic-Patient Report Outcome and wear of a wristband actigraph|Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
214657618|NCT05192603|DIETARY_SUPPLEMENT|low FODMAP or SSRD|The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
214657619|NCT04727515|DRUG|fentanyl 2µg/kg intravenously and maintained with isoflurane|Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact and fentanyl 2µg/kg intravenously and maintained with isoflurane (end tidal up to 1.5%), oxygen in air 50:50 via a laryngeal mask.
214657620|NCT04727515|PROCEDURE|Axillary nerve Block|Axillary block will be performed using ultrasound technique. Patients will receive an axillary block under ultrasound guidance using a linear 5-12 MHz probe.
214657621|NCT02811705|OTHER|Quality of life|Quality of life
214657622|NCT05899348|BEHAVIORAL|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities.
214657623|NCT00863616|DEVICE|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
214657624|NCT01389245|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
214475672|NCT06824090|OTHER|Myoton Assessment|Myoton PRO device was used to objectively evaluate the biomechanical properties of the hand and wrist muscles such as tone, stiffness and elasticity. Tenar region, flexor carpi radialis, flexor carpi ulnaris, extensor digitorum, extensor carpi radialis and extensor carpi ulnaris muscles were evaluated bilaterally. Three measurements were recorded at one second intervals and the mean value was used for analysis.
214657625|NCT02065778|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
214475673|NCT06346873|DEVICE|JOGO|AI driven mobile app and wearable sensors to provide virtual treatments
214475674|NCT06598514|DRUG|Chlorhexidine|Participants will use a 2% chlorhexidine perineal lavage following defecation
214475675|NCT06598514|DRUG|Sterile Water|Participants will use a sterile water perineal lavage following defecation
214475676|NCT06588647|BEHAVIORAL|Improving Participation after Stroke Self-Management Program (IPASS)|The IPASS-R program is a group-based self-management intervention that aims to improve problem-solving, action-planning, and resource utilization skills for improved community living and participation. The Activity-Barriers-Changes-Doing-Evaluation (ABCDE) framework is a user friendly problem-solving and goal setting framework that is used repetitively in each session throughout the program. Participants are guided to identify (1) an activity that they want to improve or re-engage in (A); (2) individual and environmental barriers that hinder their engagement (B); (3) changes that they can make to deal with the barriers and improve their engagement (C); and (4) an action plan to pursue (D). After the action plan, participants come back in the next session and evaluate their performance in following through on their plans (E).
214657626|NCT03317587|BEHAVIORAL|INSPIRE|Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
214657627|NCT02975128|DEVICE|BLES system and conventional lumpectomy|Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
214657628|NCT02411123|GENETIC|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
214657629|NCT05844917|DEVICE|ultrasound|Ultrasound detection of subclinical arthritis among Patients With SLE
214657630|NCT00003029|DRUG|cisplatin|
214657631|NCT00003029|DRUG|fluorouracil|
214657632|NCT05090241|DIAGNOSTIC_TEST|Instrumental measurement of balance and gait|The balance measurement was performed on a force platform. The walk test was carried out using sensors to analyze and retrieve data from the participant's walk (gait speed, step length, duration of the double support phase).
214475677|NCT06588647|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The program is facilitated by two trained leaders in small groups in a community setting with individuals who have chronic health problems and will follow the CDSMP protocol. Participants receive education on various health-related topics applicable to a range of chronic conditions, share experiences, and support one another.
214475678|NCT06608316|DEVICE|Intermittent Theta Burst Stimulation|A novel transcranial magnetic stimulation protocol called intermittent theta pulse stimulation (iTBS) effectively mimics the brain's naturally occurring theta rhythms and promotes significant synaptic changes. Compared to traditional stimulation methods, iTBS is more effective at initiating long-term potential (LTP) and produces significant excitatory effects in a shorter period of time.
214657633|NCT05127486|DRUG|Galcanezumab|Administered SC.
214657634|NCT05127486|DRUG|Rimegepant|Administered orally.
214657635|NCT05127486|DRUG|Placebo|Administered orally.
214657636|NCT05127486|DRUG|Placebo|Administered SC.
214657637|NCT03456479|DIAGNOSTIC_TEST|skin prick test - specific serum IgE|The study will assess the diagnosis of Cow's milk protein allergy (CMPA) among infant and children in Assiut University Children Hospital using skin prick test and specificserumIgE
214657638|NCT03175523|DEVICE|quantitative coronary angiography guided Bioresorbable scaffold implantation|In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
214657639|NCT03175523|DEVICE|imaging guided Bioresorbable scaffold implantation|In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
214657640|NCT03020511|OTHER|Ancient wheat flours|Ancient wheat flours will be administered in open label for 30 days
214848086|NCT04701424|OTHER|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
214848087|NCT03401554|PROCEDURE|titanium mesh|closing the lateral window for maxillary sinus floor elevation with titanium mesh
214848088|NCT03401554|PROCEDURE|collagen membrane|closing the lateral window for maxillary sinus floor elevaion with collagen membrane
214848089|NCT02078921|DRUG|Sodium Nitrate|
214848090|NCT02078921|DRUG|Placebo|
214848091|NCT05227677|OTHER|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals in both groups. The anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
214848092|NCT05227677|OTHER|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals. Investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
214848093|NCT04144426|BEHAVIORAL|Normal diet|Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
214848094|NCT04144426|BEHAVIORAL|Modified diet|Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
214848095|NCT00690482|DRUG|AZD1981|Oral tablet, twice daily
214848096|NCT00690482|DRUG|Placebo|Placebo Oral tablet, twice daily
214848097|NCT04178031|DEVICE|IUD insertion|"Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman."
214848098|NCT02777684|OTHER|Qualitative study|
214848099|NCT02820740|DEVICE|NeuroBlate System|Laser Interstitial Thermal Therapy
214848100|NCT04507594|PROCEDURE|Lung lobectomy OR esophagus cancer resection|Lunge lobectomy (total) Resection of esophagus cancer
214848101|NCT00484991|DRUG|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
214848102|NCT06278038|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
214289939|NCT03975608|BEHAVIORAL|"Adaptation of CALM"|"The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.~The sessions address the 4 dimensions of the original program designed for palliative cancer patients:~1. Symptom management and communication with healthcare providers~2. Changes in self and relations with each others~3. Spirituality, sense of meaning, and purpose~4. Thinking of the future, hope, and mortality~As an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control."
214289940|NCT01830972|DRUG|SA-ER 500 mg|oral tablets
214289941|NCT01830972|DRUG|SA-IR 500 mg|oral capsules
214475679|NCT04143295|DRUG|Diiodothyropropionic acid (DITPA)|Drug Administration
214475680|NCT06826001|DRUG|topical finasteride|Group A will receive topical finesteride spray 0.25% twice daily for 12 weeks
214475681|NCT06826001|DRUG|Topical minoxidil|Group B will receive topical 5% minoxidal twice daily for 12 weeks
214475682|NCT06825650|OTHER|Questionnaire study|Questionnaire application
214475683|NCT01345851|RADIATION|hypofractionated radiation therapy|Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks
214475684|NCT01345851|OTHER|laboratory biomarker analysis|Correlative studies
214475685|NCT01345851|RADIATION|image-guided radiation therapy|Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.
214475686|NCT01345851|DRUG|carboplatin|The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.
214475687|NCT01345851|DRUG|paclitaxel|The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.
214475688|NCT01345851|RADIATION|stereotactic body radiation therapy|Undergo hypofractionated RT
214475689|NCT06598683|OTHER|tDCS|Stimulation in each session will be applied for 20 min by two 5 × 4 cm (20 cm2) saline-soaked sponge electrodes at an intensity of 1.5 mA (0.075 mA/cm2). A gradual ramp up and down of stimulation for 10 s at the beginning and the end of stimulation
214657641|NCT06962332|DRUG|Zanzalintinib|Administered as specified in the treatment arm.
214848103|NCT06278038|DRUG|Venlafaxine hydrochloride sustained-release tablets|75 mg or 150 mg or 225 mg orally once daily dosing for 8 weeks
214848104|NCT04301245|OTHER|Educational program|"The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment."
214848105|NCT03409991|BEHAVIORAL|Opening Doors|This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
214848106|NCT02919826|BEHAVIORAL|Adapted Dialectical Behaviour Therapy|12 weekly sessions of DBT group therapy
214848107|NCT03770078|DEVICE|Test Product A|The test product is a newly developed ostomy product
214848108|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
214848109|NCT03658473|DRUG|550 mg naproxen + placebo + 20 mg rabeprazole|Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
214848110|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + placebo|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
214657642|NCT03566212|DEVICE|Conventional Syringe|local anesthesia was administered in first group using Conventional syringe
214657643|NCT03566212|DEVICE|Camouflage Syringe|local anesthesia was administered in second group using Camouflage syringe
214657644|NCT00870688|DRUG|sodium valproate|valproate sustained release minitablets, once daily.
214657645|NCT01287754|DRUG|erlotinib [Tarceva]|150 mg daily orally
214657646|NCT06962111|BEHAVIORAL|Psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss who live alone. In addition, during this intervention, participants will have access to general and personalized virtual resources with materials for use during and after the intervention.
214657647|NCT03392233|RADIATION|Stereotactic Body Radiation Therapy|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time
214657648|NCT06526026|BEHAVIORAL|Virtual crisis stabilization support with a multi-disciplinary team|Daily 1:1 sessions with multidisciplinary team via a range of virtual modalities (videoconferencing, phone, text, email), group programming, self-management resources, remote home monitoring app, referrals and linkages to community programs.
214657649|NCT02637687|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
214657650|NCT03220477|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
214657651|NCT03220477|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
214848111|NCT03658473|DRUG|550 mg naproxen + placebo + placebo|Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
214848112|NCT00925301|DRUG|migalastat hydrochloride|Oral capsule QOD
214848113|NCT00925301|DRUG|Placebo|Oral capsule QOD
214848114|NCT04890080|OTHER|Pulmonary Rehabilitation|Exercise training consisted of supervised breathing, aerobic, strengthening and stretching exercises for 8 weeks, 2 days a week. Breathing exercises included pursed lip, diaphragmatic, thoracic expansion and basal expansion exercises. Strength training included the lower and upper extremities, and it was performed 8-10 repetitions, either against gravity or using free weight, according to patient tolerance.
214848115|NCT05310617|OTHER|Survey|Survey on the parental project and its realisation
214848116|NCT03195452|DRUG|Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)|All virologically suppressed
214848117|NCT05482425|OTHER|Autologous facial fat graft injection|Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
214848118|NCT00294892|DRUG|carbamazepine and nevirapine|Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
214848119|NCT00294892|DRUG|Nevirapine|Nevirapine 200mg is taken prior to delivery during labor.
214848120|NCT01358396|OTHER|Respond to therapy for diabetic macular edema|Correlate HBA1c with visual acuity outcome to therapy.
214848121|NCT00494351|PROCEDURE|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
214848122|NCT05335083|DEVICE|CPAP|A positive CPAP intervention
214848123|NCT04771247|PROCEDURE|Cardia Band Ligation|Patients will undergo cardia band ligation at the level of the GEJ.
214848124|NCT03754387|DRUG|Ceftazidime|Patients choosing AT group were admitted to the hospital for observation and to receive intravenous antibiotics Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) was administered for 3 days.
214848125|NCT03754387|PROCEDURE|appendectomy|APPT group consisted of admission to the hospital with promptinitiation of intravenous antibiotics and appendectomy
214848126|NCT01117987|DRUG|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
214848127|NCT01117987|DRUG|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
214848128|NCT02571309|DEVICE|Asthmatuner|Asthmatuner is an app for self-management of asthma.
214848129|NCT00042549|DEVICE|Extracorporeal Shock Wave Lithotripsy|
214657652|NCT03220477|DRUG|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
214657653|NCT05218811|DEVICE|Cryoablation Assisted Partial Nephrectomy|Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
214657654|NCT03457961|DRUG|Perampanel|This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
214848130|NCT00042549|DRUG|ursodiol|
214848131|NCT02317250|PROCEDURE|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
214848132|NCT02317250|PROCEDURE|FDG-PET|\[F-18\] FDG-PET brain scans are administered once to all arms.
214848133|NCT00615524|DRUG|exemestane and pazopanib|
214848134|NCT01850719|PROCEDURE|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
214906929|NCT06921486|DRUG|Phase III：Recommended Phase 3 Dose High Dose|The Recommended Phase 3 Dose High Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
214848135|NCT01850719|OTHER|Physical Therapy|"Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.~In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study."
214848136|NCT04399265|DIETARY_SUPPLEMENT|Trehalose|A disaccharide sugar usually used as food preservative, but for this study it is given at a higher dose
214848137|NCT04399265|DIETARY_SUPPLEMENT|Maltose|Maltose power
214848138|NCT02838251|OTHER|No intervention|
214848139|NCT04117945|BIOLOGICAL|Cetuximab|Given IV
214289942|NCT02319993|DRUG|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
214289943|NCT02319993|DRUG|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
214289944|NCT02319993|DRUG|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
214289945|NCT05244330|OTHER||
214289946|NCT04119882|DIAGNOSTIC_TEST|Blood collection|New biomarker test
214289947|NCT01660698|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin powder
214289948|NCT01660698|DIETARY_SUPPLEMENT|Probiotic|probiotic blended in maltodextrin powder
214289949|NCT01053416|PROCEDURE|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
214289950|NCT01102504|DRUG|Placebo|Placebo
214475690|NCT06598683|OTHER|Conventional|ROM exercises for upper and lower extremities, Stretching of agonists, Strengthening of antagonists, Core stability exercises, Static and dynamic balance activities, Gait training, Functional training
214475691|NCT06841705|DRUG|Vedolizumab 300 MG Injection [Entyvio]|This is a biologic medication to treat colitis
214475692|NCT06841705|DRUG|Prednisone (and methylprednisolone)|This is a steroid
214475693|NCT06841705|DRUG|Prednisone Taper|This is a tapering dose of prednisone
214475694|NCT06841705|OTHER|Placebo Prednisone Capsules|Placebo for Prednisone
214475695|NCT06841705|OTHER|Placebo Vedolizumab|Placebo for Vedolizumab
214475696|NCT06841705|OTHER|Sulfamethoxazole-Trimethoprim|Antibiotic if on \>21 days of steroids
214475697|NCT06841705|DRUG|Placebo for Sulfamethoxazole-Trimethoprim|Placebo for antibiotic (Sulfamethoxazole-Trimethoprim) Antibiotic. Only if on \>21 days of prednisone/placebo
214475698|NCT03245840|DRUG|Budesonide oral suspension|BOS 10 mL twice daily.
214475699|NCT06826274|OTHER|tDCS|Transcranial direct current stimulation
214475700|NCT06825065|BEHAVIORAL|PAPE Protocol|In this intervention, participants perform a warm-up consisting of 3 repetitions at 90% of 1RM. After a 10-minute rest, they perform 3 sets of half-squats at 75% of their 1RM until volitional failure. This protocol is designed to enhance performance through the post-activation potentiation effect.
214475701|NCT06825065|BEHAVIORAL|Control Protocol|In this intervention, participants perform a warm-up consisting of 8 repetitions at 50% of 1RM. After a 4-minute rest, they perform 3 sets of half-squats at 75% of their 1RM until volitional failure. This protocol is used as a baseline for comparison with the PAPE protocol.
214475702|NCT06818838|BIOLOGICAL|LY-M001 injection|LY-M001 injection is administered intravenously as a single dose
214475703|NCT06820788|OTHER|music therapy|Local music will be played in the patient room 2 hours after the patient is transferred from the postoperative care unit to the clinic, which is the most appropriate time after surgery, when vital signs have stabilized and clinical adaptation has been achieved.
214475704|NCT06824272|OTHER|MOBIL AND ONLINE EDUCATION|The intervention group attended synchronous online sessions twice weekly (2 hours) for four weeks before IVF, with the mobile app available from the first session. During IVF cycles, the app provided scheduled educational content, reminders, creation of lifestyle maps, feedback,counseling scheduling, and daily motivational messages based on hypnofertility principles to enhance support.
214475705|NCT06751680|DEVICE|Rhomboid Intercostal and Subserratus Plane Block|Upon entry, electrocardiogram (ECG), blood pressure, and oxygen saturation were monitored. The patient is placed in the prone position with their arms abducted and internally rotated. Ultrasound equipment (SonoSite Edge II; Fujifilm SonoSite, Bothell, WA, USA) with a linear 13-6 MHz transducer (HFL50x; Fujifilm SonoSite, Bothell, WA, USA) was used. Each nerve block was performed by initially injecting a 5 mL test dose, observing for clinical signs of pain relief in the affected thoracic dermatome, and then injecting the remaining volume of medication after confirmation of the injection site. Patients received ultrasound-guided nerve blocks every 48 hours, for a total of three treatments.The RISS block is a composite nerve block technique that involves two injection sites, located in the inter-rhomboid plane and the sub-serratus plane, respectively. The choice of block plane depended on the patient's site of pain.
214475706|NCT06751680|DEVICE|PVB block|The patient is placed in the prone position with their arms abducted and internally rotated. Ultrasound equipment (SonoSite Edge II; Fujifilm SonoSite, Bothell, WA, USA) with a linear 13-6 MHz transducer (HFL50x; Fujifilm SonoSite, Bothell, WA, USA) was used. Each nerve block was performed by initially injecting a 5 mL test dose, observing for clinical signs of pain relief in the affected thoracic dermatome, and then injecting the remaining volume of medication after confirmation of the injection site. Patients received ultrasound-guided nerve blocks every 48 hours, for a total of three treatments.After confirming needle tip placement, 10 mL of 0.5% ropivacaine with 10 mg of triamcinolone acetonide was slowly injected in divided doses, observing for the spread of the local anesthetic to ensure adequate distribution within the PVS for effective block. If multiple nerves were involved, the injection sites were spaced one thoracic vertebral segment apart.
214657655|NCT04442607|DEVICE|artificial intelligence image processing|Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.
214657656|NCT06278519|BIOLOGICAL|Blood, urinary and feces collection|Blood, urinary and feces collection, at inclusion during acute phase of STEMI, and one year after inclusion visit.
214848140|NCT04117945|DRUG|Irinotecan|Given IV
214848141|NCT04117945|BIOLOGICAL|Panitumumab|Given IV
214848142|NCT04117945|DRUG|Regorafenib|Given PO
214657657|NCT06278519|DEVICE|Cardiac MRI|Cardiac MRI at the acute phase of STEMI (Day 5 +/- 3) and at 1-year follow-up
214289951|NCT01102504|DIETARY_SUPPLEMENT|Ateronon|Tomato extract containing 28 mg lycopene/ day
214289952|NCT02994212|DIETARY_SUPPLEMENT|Monthly distribution of RUTF|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.
214289953|NCT03907358|PROCEDURE|phacoemulsification|
214289954|NCT00380497|DRUG|PEG-Lyte®|
214289955|NCT00380497|DRUG|Pico-Salax®|
214289956|NCT05083962|BEHAVIORAL|Healthy Lifestyle Program|An intensive behavior change curriculum designed to help create and sustain healthy habits
214289957|NCT02649998|DRUG|Furosemide|Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
214289958|NCT02649998|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
214657658|NCT06278519|OTHER|Quality of life and cognitive status questionnaire|Quality of life and cognitive status questionnaire at the acute phase of STEMI and at 1-year follow-up
214657659|NCT06642480|DRUG|Post Operative Analgesia|administering 100 mg of intravenous tramadol 30 minutes before the operation is completed
214657660|NCT06642480|DRUG|Post Operative Analgesia|VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes.
214848143|NCT04686994|DRUG|ASC 41|Oral tablets
214848144|NCT04686994|DRUG|ASC 41 Placebo|Oral tablets
214848145|NCT06617403|OTHER|non|non
214848146|NCT06616038|OTHER|Data collection|Given the observational nature of the study, the intervention is a simple data collection
214848147|NCT01044134|BEHAVIORAL|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
214848148|NCT02767934|OTHER|Laboratory Biomarker Analysis|Correlative studies
214848149|NCT02767934|BIOLOGICAL|Pembrolizumab|Given IV
214848150|NCT02752386|BEHAVIORAL|Biofeedback Training|Participants will received biofeedback training to reduce arousal and pain
214848151|NCT02617082|RADIATION|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
214848152|NCT02631252|DRUG|Hydroxychloroquine|Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
214848153|NCT02631252|DRUG|Mitoxantrone|Dose: 10mg/m2 IVPB in 50ml NS
214848154|NCT02631252|DRUG|Etoposide|Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
214848155|NCT00190489|DRUG|AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|
214848156|NCT00190489|DRUG|Docetaxel 60mg/m2 every 21 days for 6 cycles|
214848157|NCT00190489|DRUG|AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles|
214848158|NCT01443689|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
214848159|NCT01443689|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
214848160|NCT01443689|DRUG|Conventional therapy|Participants will be given conventional therapy only.
214848161|NCT03529565|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214848162|NCT03529565|OTHER|Laboratory Biomarker Analysis|Correlative studies
214848163|NCT03529565|OTHER|Quality-of-Life Assessment|Ancillary studies
214848164|NCT03529565|OTHER|Questionnaire Administration|Ancillary studies
214848165|NCT01917968|DEVICE|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
214848166|NCT01917968|PROCEDURE|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
214848167|NCT05255302|DRUG|Pembrolizumab before randomization|Pembrolizumab 200 mg every 3 weeks before randomization
214848168|NCT05255302|DRUG|Chemotherapy|Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
214848169|NCT05255302|DRUG|Pemetrexed|Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
214848170|NCT05255302|DRUG|Pembrolizumab after randomization|Pembrolizumab 200 mg every 3 weeks after randomization
214848171|NCT03400215|DIAGNOSTIC_TEST|Diagnostic Breast Cancer Scan|clinically indicated diagnostic breast MRI scans
214848172|NCT03400215|DIAGNOSTIC_TEST|Research Scan for Gradient-echo Spectroscopic Imaging (GSI)|15-min research MRI scan
214848173|NCT05486845|OTHER|survey|We are planning a questionnaire survey. We combine our own questions with validated, official questionnaires. Validated forms ask for an assessment of the extent of low back pain and the quality of experienced stress.
214848174|NCT01222949|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
214848175|NCT05668026|DRUG|Venetoclax|In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
214848176|NCT02214563|DIETARY_SUPPLEMENT|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
214848177|NCT02214563|DIETARY_SUPPLEMENT|Olive oil|
214848178|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
214848179|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
214848180|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
214848181|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
214848182|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
214657661|NCT06642974|OTHER|Education module on learning disabilities|Data will be collected for a period of one -year. samples will be equally distributed among experimental and control group. Socio -demographic data and knowledge and attitude of primary school teachers on learning disability will be assessed by interview method using questionnaire. Control group will receive general information on children with learning disabilities while experimental group will receive education training program. After 15 days again education program will be repeated as a reinforcement. Pre and posttest will be conducted for both the groups at one-month interval. Required data will be collected for one-year period by interview method using questionnaire. Competency assessment will be done by using checklist on identification of learning disabilities Teachers' competency for experimental group then the competency will be verified by education counselor . As a follow up of the research study, after one-month interval no of referral by each teacher will be collected to m
214657662|NCT06642974|OTHER|pamphlet on learning disability|Education pamphlets will be provided to total of 67 samples
214657663|NCT04600570|OTHER|ultrasound|ultrasound measurement for optic nerve outer diameter
214657664|NCT06176521|PROCEDURE|Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh|Comparison of pre and postoperative POP-Q values of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy SurgeriesWithout Using Mesh Comparison of pre and postoperative PISQ-12 scores of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Without Using Mesh
214657665|NCT06642753|BIOLOGICAL|immediate implant with buccal plate augmentation using sticky bone|"* Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the pouch ."
214657666|NCT06642753|BIOLOGICAL|immediate implant with sticky bone as a filling material in the jumping gap|"Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the jumping gap."
214657667|NCT05426057|BEHAVIORAL|eHealth Familias Unidas Mental Health|eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
214657668|NCT06578078|DRUG|Sodium Zirconium Cyclosilicate|Use of sodium zirconium cyclosilicate to optimize RAASi therapy, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines
214657669|NCT06578078|DRUG|Standard of care treatment (RAASi therapy)|Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate
214657670|NCT06379698|OTHER|personalized 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a personalized 3D models will be presented to the patients according to the allocated study group
214657671|NCT06379698|OTHER|generic 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a generic 3D models will be presented to the patients according to the allocated study group
214657672|NCT06638099|BEHAVIORAL|CGM Toolkit Prescriber Training|A CGM prescription toolkit was created for prescribing clinicians and staff that includes written guidance on CGM eligibility criteria, instructions for screening patients for eligibility using EHR records and during healthcare visits, recommended provider documentation templates to address all required eligibility criteria for insurance coverage of CGM device and supplies (e.g., Medicare, Medicaid), sample scripts for communicating with patients about the purpose and use of CGM, and patient-level frequently asked questions (FAQs), including free resources available to learn more about CGM benefits, where/how to acquire CGM, and determining out-of-pocket costs. The toolkit will be introduced during a 20 minute initial training session and reinforced during a 10 minute booster training approximately one month after initial training
214657673|NCT04971226|DRUG|Imatinib|Comes in 100 mg and 400 mg tablets and taken orally
214848183|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
214848184|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
214848185|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
214657674|NCT04971226|DRUG|Nilotinib|Comes in 150 mg and 200 mg capsules and taken orally
214657675|NCT04971226|DRUG|Bosutinib|Comes in 100 mg and 400 mg tablets and taken orally
214657676|NCT04971226|DRUG|Dasatinib|Comes in 20 mg, 50 mg, 70 mg and 100 mg tablets and taken orally
214657677|NCT04971226|DRUG|Asciminib|Comes in 40 mg tablets and taken orally
214657678|NCT06036875|OTHER|Non-Interventional Study|Non-interventional study
214848186|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
214848187|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
214848188|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
214848189|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
214657679|NCT02516657|DRUG|Liraglutide|Liraglutide 0.6 mg
214657680|NCT06643455|BEHAVIORAL|Behavioral Dietary Intervention|Participate in the MIND program
214657681|NCT06643455|OTHER|Best Practice|Participate in SOC
214657682|NCT06643455|OTHER|Electronic Medical Record|Ancillary studies
214657683|NCT06643455|OTHER|Questionnaire Administration|Ancillary studies
214657684|NCT05000905|BEHAVIORAL|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
214475707|NCT05166213|OTHER|focus group discussions (FGD)|FGD to explore patients' attitudes/ concerns towards OLP implementation into clinical practice by means of assessment of qualitative information: 1) Patients' attitudes towards clinical usage of OLPs 2) Personal acceptance of OLP intervention 3) Perceived ideas, concerns regarding OLP implementation. Core questions: 1) Attitudes: After all that I told you about placebos, i.e. that there is a concept that patients are openly elucidated that they receive placebos: What does this elicit in you/What is your opinion on this? How do you like the idea? 2) Context of Acceptance: Under which conditions would you personally take placebos knowing that they are placebos? 3) Concerns: Why would you not take openly administered placebos? 4) Ideas for clinical implication: How could an open placebo intervention look like in the hospital? Where could it be possible to receive placebos and how could a placebo intervention in the best manner take place? What would be important from your point of view?
214475708|NCT06767540|DRUG|Placebo|placebo subcutaneous injection Q2W until week 46.
214475709|NCT06767540|DRUG|placebo|placebo subcutaneous injection Q3W until week 45.
214657685|NCT05000905|BEHAVIORAL|Questionnaires|Computer based assessments measuring attention, memory, daily habits, and mental health
214657686|NCT06261385|BEHAVIORAL|typology-based intervention|"The typology-based intervention includes:~1. typology-based counselling,~2. personalized E-message based on the counselling content discussed~3. a booklet introducing the typology of quit identity.~All interventions and materials are delivered by smoking counselling."
214848190|NCT04920058|DEVICE|Continuous Glucose Monitor|Continuous glucose monitor - a device that monitors blood glucose levels in a continuous closed-loop manner. This can also refer to the process of continuous glucose monitoring
214848191|NCT04920058|OTHER|<Active Comparator?>|\<describe, Comprehensive Wellness Program incorporating a low carbohydrate diet (\<50g/day) and associated education \>
214289959|NCT01050972|BEHAVIORAL|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
214289960|NCT01907815|DRUG|Akt Inhibitor GSK2141795|Given PO
214289961|NCT01907815|OTHER|Laboratory Biomarker Analysis|Correlative studies
214289962|NCT01907815|DRUG|Trametinib|Given PO
214657687|NCT06261385|BEHAVIORAL|Routine Treatment|"The routine smoking cessation intervention includes:~1. Routine counselling generic advice on preventing smoking relapse~2. Brief e-messages that consist of general quit advice for 4 weeks.~Counsellors implement both routine practices."
214657688|NCT05548634|DRUG|TAVO412|Biologic
214657689|NCT03464045|DRUG|empagliflozin|empagliflozin
214657690|NCT03464045|DRUG|DPP-4 inhibitors|DPP-4 inhibitors
214657691|NCT03398161|OTHER|Quality-of-Life Assessment|Ancillary studies
214657692|NCT03398161|OTHER|Questionnaire Administration|Ancillary studies
214657693|NCT03398161|RADIATION|Radiation Therapy|Undergo ultra low dose radiation therapy
214657694|NCT04203147|BEHAVIORAL|Supportive Therapy (Control)|Description: 8-weekly sessions of in-home, supportive therapy and monthly booster sessions from months 3-12 via telephone.
214657695|NCT04203147|BEHAVIORAL|Home DM-BAT|Description: 8-weekly sessions of in-home, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) and monthly booster sessions from months 3-12 via telephone.
214657696|NCT00001337|DRUG|Etoposide|"Etoposide 50mg/m\^2/day were delivered as continuous intravenous (CIV) infusions over 96 hours starting on day 1 every 21 days.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
214657697|NCT00001337|BIOLOGICAL|Rituximab|"Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
214657698|NCT00001337|DRUG|Prednisone|"Prednisone 100mg by mouth (PO) twice a day (bid) on days 1 through 5 every 21 days.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
214657699|NCT00001337|DRUG|Cyclophosphamide|"Cyclophosphamide 750mg/m\^2 on day 5 every 21 days.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
214848192|NCT02528058|PROCEDURE|Vitrectomy with internal limiting membrane peeling|
214848193|NCT02556853|DEVICE|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
214906930|NCT06921486|DRUG|Phase III：Recommended Phase 3 Dose Low Dose|The Recommended Phase 3 Dose Low Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
214906931|NCT06921486|DRUG|Phase III：Placebo|Placebo
214657700|NCT00001337|DRUG|Vincristine|"Vincristine 0.4mg/m\^2/day.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
214657701|NCT00001337|DRUG|Doxorubicin|"Doxorubicin 10mg/m\^2/day.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
214657702|NCT00001337|DIAGNOSTIC_TEST|MRI|Baseline and/or on completion of therapy.
214657703|NCT00001337|DIAGNOSTIC_TEST|CT|Baseline and/or on completion of therapy.
214475710|NCT05619432|DEVICE|HMD: Immersive VR|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~STIMULATION:~One or more of the spheres is temporarily cued (target). Then all spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using a laser pointer, the initially cued target(s) among the eight spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
214475711|NCT03995979|OTHER|4 Day Protein Restricted Diet|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided. They may also drink water. No food, other beverages, or alcohol may be consumed. The amount of diet to be consumed will be calculated for each patient based upon resting energy expenditures plus additional energy needs. These will be consumed by the study subjects at home in an unrestricted manner, in that they may be consumed at any point of time in the day.
214475712|NCT05362721|DIAGNOSTIC_TEST|Pressure-volume loop catheter|The cardiac catheterization procedure will be done according to standard protocol as part of the standard clinical care. This has become the standard of care in any patient in which it feasible and is performed with low risk.
214657704|NCT00001337|PROCEDURE|Biopsy|Baseline and/or on completion of therapy.
214657705|NCT00001337|DIAGNOSTIC_TEST|PET scan|As clinically indicated.
214848194|NCT02556853|OTHER|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
214848195|NCT00973310|OTHER|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
214848196|NCT00834236|OTHER|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
214848197|NCT00834236|OTHER|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
214848198|NCT03133728|DIAGNOSTIC_TEST|Alere Q Testing|Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.
214848199|NCT02921516|BEHAVIORAL|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
214657706|NCT00001337|PROCEDURE|Laparotomy|As clinically indicated.
214848200|NCT02921516|BEHAVIORAL|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
214848201|NCT02921516|BEHAVIORAL|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
214848202|NCT00000953|DRUG|Sorivudine|
214657707|NCT00001337|OTHER|Ondansetron|Nausea and/or vomiting.
214657708|NCT00001337|OTHER|Prochlorperazine|Nausea and/or vomiting.
214657709|NCT00001337|OTHER|Omeprazole|Gastroesophageal reflux disease (GERD).
214289963|NCT01169974|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 \& 3 minutes
214289964|NCT00808977|DRUG|Dersalazine sodium|Dersalazine sodium 2400 mg daily
214289965|NCT00808977|DRUG|Mesalazine|Mesalazine 2400 mg daily
214289966|NCT00808977|DRUG|Placebo|Placebo matching active and experimental treatments
214289967|NCT00869453|OTHER|test meal|Mixed meal containing bread, butter, beef
214289968|NCT00869453|OTHER|glucose|administration of a glucose meal
214657710|NCT00001337|OTHER|Docusate Sodium + Sennosides|Constipation.
214657711|NCT00001337|OTHER|Lactulose|Constipation
214475713|NCT06147232|DRUG|Sotagliflozin|Sodium-glucose-co-transporter 1 and 2 inhibitor
214848203|NCT00000953|DRUG|Acyclovir|
214906932|NCT07048288|OTHER|Multi-angle isometrics|Multi angle exercises include cervical flexion training, Cervical extension training, and Cervical lateral flexion training
214906933|NCT07048288|OTHER|Kinesio taping|Kinesio taping is a therapeutic technique used in rehabilitation to support muscles and joints without restricting movement.
214289969|NCT00869453|OTHER|fat|administration of a lipid meal
214289970|NCT00869453|OTHER|protein|administration of a protein meal
214289971|NCT00869453|OTHER|control|no meal
214657712|NCT05932732|DEVICE|HydraFacial Syndeo System|Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.
214475714|NCT06147232|DRUG|Placebo|Placebo tablet
214475715|NCT06862739|COMBINATION_PRODUCT|Empagliflozin+Linagliptin+Metformin|Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients
214657713|NCT05932732|DRUG|ReGen-GF|The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
214657714|NCT05932732|DEVICE|HydraFacial Elite MD System|Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.
214657715|NCT06179472|DEVICE|BALT GOLDBAL2 Balloon|Placement and retrieval of the GOLDBALLOON Detachable Balloon for severe CDH
214657716|NCT04506892|BEHAVIORAL|Meditation|meditation
214657717|NCT05347407|PROCEDURE|Colonoscopy|Patients will be provided with a kit and be asked to bring a stool sample to their colonoscopy appointment. Mucosal biopsies will be collected with standard forceps during colonoscopy. If the physician determines that the patient will need colonoscopy with biopsy as part of their routine clinical care, they will take 6-8 additional biopsies for use in the research study. If the physician determines that the patient will need colonoscopy without biopsy as part of their routine clinical care, they will take 6-8 biopsies for use in the research study only. The collection of additional biopsies will add an estimated two minutes to the whole procedure.
214657718|NCT04218370|PROCEDURE|Dialysis|Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)
214657719|NCT05753254|OTHER|Firefighting training exercises with no fire|The participants will be performing firefighting equivalent work in a clean environment, without fire (no ambient temperature, soot or smoke).
214657720|NCT05753254|OTHER|Firefighting training exercises under wood fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under wood fire conditions.
214657721|NCT05753254|OTHER|Firefighting training exercises under gas fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under gas fire conditions.
214657722|NCT03452839|DRUG|Meropenem|Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
214848204|NCT03391115|BEHAVIORAL|Storytelling Intervention for Patient Participants|The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.
214906934|NCT07048288|OTHER|Dynamic exercise|The dynamic exercise program included dynamic cervical flexion, dynamic cervical extension, and dynamic lateral flexion.
214475716|NCT06781554|DEVICE|MD-Small Joints Collagen Medical Device|The infiltrations will be performed using 2.5ml syringes and 26 gauge/13mm needles under complete aseptic conditions. The first 3 infiltrations will be carried out at both intra- and peri-articular levels by injecting MD-Small Joints Collagen Medical Device into the trapeziometacarpal joint until a counter-pressure is felt, preventing further penetration of the liquid; the remaining quantity (usually about 1ml) will be injected at the peri-articular level by retracting the needle tip. The fourth and fifth infiltrations will be performed only at the peri-articular level.
214475717|NCT06864052|DRUG|Administration of Apixaban|Apixaban 2.5mg BID or Apixaban 5mg BID
214657723|NCT06182293|OTHER|Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota|Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.
214657724|NCT06150599|DEVICE|Sacral neuromodulation|Interstim X, which includes an implantable pulse generator and lead, will be implanted surgically in a single-stage procedure.
214657725|NCT06617429|DRUG|GTX-102|antisense oligonucleotide
214475718|NCT06864052|DRUG|Administration of Edoxaban|Edoxaban 15mg QD or Edoxaban 30mg QD or Edoxaban 60mg QD
214475719|NCT05249543|BEHAVIORAL|Unified protocol|Transdiagnostic cognitive-behavioral therapy
214475720|NCT05249543|BEHAVIORAL|Diagnosis-specific cognitive-behavioral therapy|Diagnosis-specific cognitive-behavioral therapy
214475721|NCT05221619|DRUG|Nipocalimab|Depending on the dose received at their last administration in the MOM-M281-006 (NCT04119050) study, participants will continue to receive either nipocalimab dose-1 every 2 weeks (Q2W) or nipocalimab dose-2 every 4 weeks (Q4W) by intravenous (IV) infusion.
214475722|NCT01258036|RADIATION|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
214475723|NCT01258036|BIOLOGICAL|Sampling|Urine and blood samples
214657726|NCT06617429|PROCEDURE|Sham-LP|Small needle prick on the lower back at the location where the LP injection is normally made
214906935|NCT07048288|OTHER|Conventional Physiotherapy|Conventional physiotherapy included transcutaneous electrical nerve stimulation
214906936|NCT04636788|PROCEDURE|Venous sampling|venous sampling of 12ml
214475724|NCT01258036|RADIATION|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
214475725|NCT05027529|DEVICE|CytoSorb|An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit
214475726|NCT05027529|OTHER|VA-ECMO only|only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added
214657727|NCT06524830|DRUG|VLS-01-203 BU|VLS-01 buccal transmucosal administration
214657728|NCT06524830|DRUG|VLS-01-BU Placebo|Placebo buccal transmucosal administration
214657729|NCT06771492|DRUG|Amoxicillin|Antibiotic treatment (amoxicillin) with a dosage of 1000 mg (3 times a day) for a period of 100 days
214657730|NCT06771492|OTHER|Placebo|Placebo with a dose of 1000 mg (3 times a day) for a period of 100 days
214657731|NCT05085561|DRUG|REC-994|REC-994 200 mg tablets
214848205|NCT03391115|BEHAVIORAL|Storytelling Intervention for Nurse Participants|"Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material."
214657732|NCT05085561|DRUG|Placebo|Placebo Tablets
214657733|NCT05760898|BEHAVIORAL|Blood pressure intervention arm|The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.
214657734|NCT05590377|DRUG|Modakafusp Alfa|Modakafusp alfa intravenous infusion
214657735|NCT05590377|DRUG|Daratumumab|Daratumumab SC injection
214657736|NCT05207826|DIAGNOSTIC_TEST|Cystometrogram|Serial cystometrogram every 3 days for acute traumatic spinal cord injured patients
214657737|NCT06033586|DRUG|Open-label rusfertide|subcutaneous rusfertide
214657738|NCT01256541|DRUG|Kristalose|The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
214657739|NCT05397236|DRUG|Bupivacaine- Magnesium|Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
214657740|NCT05397236|DRUG|Bupivacaine dexamethasone|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
214848206|NCT03680261|RADIATION|chemoradiotherapy|CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
214848207|NCT03680261|DRUG|chemotherapy|CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
214848208|NCT00862537|DEVICE|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
214848209|NCT05907148|OTHER|Sensory integration training|"Sitting position:~1. Sit in a chair without a backrest while the feet on firm surface. without backrest while the feet on soft surface.~2. Sit on a ball while the feet on firm surface. while feet on soft surface.~3. Sit in a chair without a backrest with the feet on firm surface and perform sit-to-stand motion.~   without a backrest with the feet on soft surface and perform sit-to-stand motion.~4. Sit on a ball with the feet on the firm surface and perform sit-to-stand motion. with the feet on the soft surface and perform sit-to-stand motion.~5. Perform bipedal standing on a firm surface. on a soft surface.~6. Perform a semi-tandem stance on firm surface. on soft surface.~7. Walk forward on firm surface. on soft surface.~8. Walk forward on firm surface, cross obstacle, and continue to walk.~9. Walk forward on the soft surface, cross obstacle, and continue to walk."
214848210|NCT05907148|OTHER|Routine physical therapy|It consist of active joint mobilization, muscle stretching, motor coordination exercises and general balance training
214848211|NCT05907148|OTHER|General coordination exercise|"In supine lying:~1. Patients are told to place heel of one leg on shin or knee of the other leg,~2. Patient bends one leg and extends the other leg like bicycling motion.~3. Flexing one leg while extending other leg~4. Flexing and extending of one leg while abduction and adduction of other leg.~In sitting:~1. Patient performs marching without backrest or back support,~2. Patient reaches forward and sideways with arms~3. Rotation of trunk with physioball in hand without back support.~4. Patient reaches with legs to marked point in sitting.~In standing:~Patient performs 10 repetitions of~1. Clock Reach~2. Side Leg Raises~3. Leg Swings and~4. Ball catch and throw"
214848212|NCT05904262|OTHER|Foot Sole Sensation Evaluation|Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
214657741|NCT05397236|DRUG|Bupivacaine saline|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
214848213|NCT04232540|DEVICE|MedViewer report|Results from the analysis of hair samples performed using the MedViewer
214848214|NCT01174667|PROCEDURE|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
214848215|NCT01174667|OTHER|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
214657742|NCT00442598|DRUG|Glufosfamide|
214657743|NCT03985176|DEVICE|ROTEM|ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH
214657744|NCT03985176|PROCEDURE|EEG|Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH
214657745|NCT03985176|PROCEDURE|bilateral compression ultrasound of the lower extremity veins|to exclude asymptomatic deep venous thrombosis once over days 3 to 7
214657746|NCT04801407|PROCEDURE|percutaneous radiofrequency trigeminal rhizotomy|percutaneous radiofrequency trigeminal rhizotomy is a perctaneous procedure that ablate the sensory part of the nerve and
214657747|NCT04801407|PROCEDURE|Microvascular decompression of the trigeminal nerve|Microvascular decompression is a procedure that decompress the nerve from vascular conflict
214657748|NCT06056947|DRUG|EVEGYN A|EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
214657749|NCT06056947|DRUG|EVEGYN B|EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
214475727|NCT04505410|OTHER|"A plant based high fiber diet that mimics fasting (FMD) plus advanced therapy"|Patients will do two 5-day cycles of a fasting mimicking diet. They will start the first diet cycle 1 week after initiating a new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
214475728|NCT04505410|DRUG|Advanced therapy only without dietary intervention|Patients in this group will start an advanced therapy and follow a diet solely based on dietary tolerance: new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
214657750|NCT06056947|DRUG|Gynomax® XL Vaginal Ovule|200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)
214475729|NCT06862531|BIOLOGICAL|blood sample|A sample of blood (1mL) was taken
214657751|NCT05595538|BIOLOGICAL|Multiple doses of anti-SARS-CoV-2 Convalescent Plasma|SARS-CoV-2 Convalescent Plasma(1-2 units; \~300-600 mL with the presence of IgG anti-SARS-CoV-2.
214475730|NCT06592599|DRUG|Toripalimab|Toripalimab will be administered 240 mg intravenously every three weeks in combination with the induction chemotherapy regimen for 3 cycles, and for 9 cycles as adjuvant treatment following radiation as specified in the overall sequential treatment plan.
214475731|NCT06592599|RADIATION|Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation|"Radiation treatment will be initiated 3-6 weeks following day 1 of the last induction cycle using institutional standards of care and support as follows:~Intensity modulated radiotherapy, 70 Gy in 33 fractions M-F once daily plus cisplatin 40 mg/m2 IV weekly for up to 7 doses.~Following the completion of concurrent chemoradiation, capecitabine will be administered using institutional standards of care as follows:~Capecitabine 650 mg/m2 PO BID x 12 months beginning 12 to 16 weeks following the end of radiation treatment. Dose reductions and discontinuance of capecitabine will be according to the standard of care applied at the treating institution.~Adjuvant Toripalimab 240 mg IV q 21d x 9 maximum doses will be initiated concurrently with the initiation of adjuvant capecitabine, beginning 12-16 weeks following the end of radiation."
214475732|NCT01586910|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
214475733|NCT01586910|PROCEDURE|Surgical Aortic Valve Replacement (SAVR)|
214475734|NCT01586910|DEVICE|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
214475735|NCT06280495|DRUG|Oxaliplatin|5 mg/m2 IV on day 1
214657752|NCT00753389|OTHER|None (anesthesia)|anesthesia
214657753|NCT01262898|DRUG|GSK962040 (5 mg tablet)|5 mg tablet
214657754|NCT01262898|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
214657755|NCT01262898|DRUG|GSK962040 (125 mg tablet)|125 mg tablet
214657756|NCT01262898|DRUG|Placebo|matching placebo tablet
214657757|NCT05838326|DEVICE|Symmetrical high flow nasal cannula (HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%."
214475736|NCT06280495|DRUG|Fluorouracil|400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours
214657758|NCT05838326|DEVICE|Asymmetrical high flow nasal cannula (DUET HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.~A 5-10min 'washout' phase using VM, between different interfaces, will be allowed."
214657759|NCT04026568|DRUG|4-Aminopyridine|Single drug test for nerve continuity
214475737|NCT06280495|DRUG|Serplulimab|200 mg IV infusion on day 1
214657760|NCT04026568|DRUG|Placebo oral tablet|Placebo arm
214657761|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI structured group CBT|ReInventing Yourself after SCI intervention integrates positive psychotherapy concepts into structured group cognitive behavioral therapy (CBT) to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle. The intervention consists of six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion.
214657762|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI study-specific workbook|A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.
214475738|NCT06280495|DRUG|Bevacizumab|5 mg/kg IV infusion on day 1
214475739|NCT06952608|DRUG|Ciprofol group|General anesthesia induction and maintenance were performed using ciprofol.
214475740|NCT06952608|DRUG|Propofol group|General anesthesia induction and maintenance were performed using propofol.
214475741|NCT06488859|BEHAVIORAL|Positive Affect Treatment|Sessions 1-8: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects
214475742|NCT06488859|BEHAVIORAL|Positive Affect Treatment and Negative Affect Treatment|Sessions 1-4: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects Sessions 5-8: Exposure therapy to feared or avoided situations, sensations, or memories
214475743|NCT06154382|DRUG|Eltroxin administration|eltroxin administration
214848216|NCT00703131|DEVICE|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
214475744|NCT05502315|DRUG|Cabozantinib|40 mg taken orally
214475745|NCT05502315|DRUG|Nivolumab|480 mg by infusion
214848217|NCT06468722|BEHAVIORAL|Exercise-based rehabilitation|Patients performed regular physical exercise during inpatient rehabilitation
214848218|NCT00083434|DRUG|Epoetin alfa|
214475746|NCT06141252|DEVICE|Hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated with hypothermia
214848219|NCT01348204|OTHER|quercetin|health food supplement
214657763|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI YouTube videos|YouTube videos containing the content of the ReInventing Yourself after SCI structured group CBT sessions
214657764|NCT02197377|DEVICE|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
214848220|NCT03568604|DRUG|Prasterone|6.5 vaginal insert prasterone (dehydroepiandrosterone)
214848221|NCT04646694|DRUG|Ketamine|The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
214848222|NCT04646694|OTHER|Placebo|A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
214848223|NCT00411333|DRUG|triamcinolone acetonide (Kenalog)|
214848224|NCT04403945|DEVICE|Sidestream dark field(SDF) imagining|SDF imaging consists of a hand-held device that illuminates a region by surrounding a central light guide with concentrically placed light emitting diodes,which thus provide SDF illumination.
214848225|NCT04034654|OTHER|Questionaire|Child behavior checklist is a questionaire, designed to evaluate 1.5-5 years old child's behavior. The checklist is filled out by parents/caregivers.
214848226|NCT03248986|OTHER|Dry needling|Dry needling of the spastic muscles of the affected arm through DNHS®.
214848227|NCT01981317|BEHAVIORAL|Stepped Care Cognitive Behavioral Therapy|
214848228|NCT01981317|BEHAVIORAL|Cognitive Behavioral Therapy|
214848229|NCT01029509|DRUG|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
214906937|NCT00656552|DRUG|Escitalopram|Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
214906938|NCT02492867|RADIATION|Response-driven Adaptive Radiation Therapy|
214475747|NCT06201299|OTHER|Standard Exercise Program|The program content consists of breathing exercises, upper and lower extremity strengthening with theraband and self-walking. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Resistance exercises will be performed as strengthening exercises for the major muscle groups of the upper and lower extremities using medium-hard theraband. Patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
214475748|NCT06201299|OTHER|Chair-based Exercise Program|The program content consists of breathing exercises and chair-supported exercises. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Chair exercises are given in the exercise brochure. Exercises are performed with a chair support or sitting on a chair. In addition, patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
214475749|NCT06966089|DEVICE|Urinary ExoDx test|A urine sample for ExoDx Study Kit will be collected onsite and shipped to Exosome Diagnostic's laboratory.
214475750|NCT06966089|DIAGNOSTIC_TEST|Transrectal ultrasound-guided prostate biopsy|Participants will be scheduled for transrectal ultrasound-guided prostate biopsy as per the standard diagnostic practice after urinary test.
214475751|NCT06966089|DIAGNOSTIC_TEST|Transperineal 12-core prostate biopsy|Participants will be scheduled for transperineal 12-core prostate biopsy as per the standard diagnostic practice after urinary test.
214475752|NCT02539290|BEHAVIORAL|Detection of ovulation|Detecting the luteinizing hormone surge using test sticks in a urine sample
214475753|NCT02539290|PROCEDURE|Uterine flushing|Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
214475754|NCT02539290|PROCEDURE|Vaginal flushing|Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
214475755|NCT02539290|BEHAVIORAL|Sexual intercourse|Sexual intercourse on the day of the intervention and the following day
214475756|NCT03154190|OTHER|Best Practice|Receive usual care
214475757|NCT03154190|OTHER|Laboratory Biomarker Analysis|Correlative studies
214475758|NCT03154190|PROCEDURE|Supportive Care|Undergo health care coach support
214475759|NCT03154190|OTHER|Survey Administration|Ancillary studies
214475760|NCT04019535|DEVICE|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
214475761|NCT06462482|DRUG|Nandrolone Decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
214475762|NCT06462482|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
214475763|NCT06644300|DRUG|BM230|SC injection
214475764|NCT06644300|DRUG|BM230|SC injection
214657765|NCT02197377|DEVICE|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
214906939|NCT02492867|DRUG|Carboplatin|AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV
214906940|NCT02492867|DRUG|Paclitaxel|40 mg/m\^2 IV concurrent with RT; 200 mg/m\^2 during consolidation. Given IV
214475765|NCT06369142|DEVICE|Intravascular lithotripsy (IVL)|Intravascular lithotripsy (IVL) and ballons with a nominal rated burst pressure of ≤ 18 atm
214475766|NCT06369142|DEVICE|Standard non-IVL methods|Standard non-IVL methods treating severely calcified lesions such as special high, super high and cutting balloons and ablative procedures
214657766|NCT00502840|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
214657767|NCT02339948|RADIATION|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
214657768|NCT05631132|PROCEDURE|BAL + PAP|May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
214657769|NCT01700829|DRUG|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
214657770|NCT01700829|DRUG|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
214906941|NCT02492867|DEVICE|FDG-PET|
214906942|NCT02492867|DEVICE|V/Q SPECT|
214906943|NCT02492867|DRUG|Durvalumab|10 mg/kg during consolidation. Given IV
214657771|NCT04177303|DRUG|Metformin|Participants will be randomized to metformin 2000 mg
214657772|NCT04177303|DRUG|Placebo|Participants will be randomized to placebo
214657773|NCT05357794|DRUG|Brentuximab vedotin|Given by Vein (IV)
214657774|NCT00431392|DRUG|Phenylephrine|
214657775|NCT00431392|DRUG|NG-Monomethyl-L-Arginine|
214657776|NCT00431392|DRUG|Propanolol|
214657777|NCT00431392|DRUG|Atropine|
214657778|NCT05871203|OTHER|Gene sequencing|Participants were taken blood samples for gene sequencing at three time periods: before, after, and 24 hours after the end of the surgery
214657779|NCT04996719|DRUG|Rapamune|We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).
214657780|NCT01629303|PROCEDURE|sacral nerve modulation|"After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks"
214657781|NCT00645086|DRUG|clarithromycin extended-release tablets|5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
214657782|NCT00645086|DRUG|clarithromycin immediate-release tablets|7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
214848230|NCT05694117|BEHAVIORAL|self-determine sequence exercise program|The Taichi exercise utilized the simplified eight styles of Taichi. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
214289972|NCT06505616|DEVICE|Compared the trombogenicity of the Solacea dialyzer with synthetic dialyzers after progressively decreasing heparin until discontinuing it|The duration of the study was four weeks, carried out in two phases. After screening, patients were randomized to be dialyzed with the Solacea™ hemodialyzer versus the usual hemodialyzer, which in all cases had to be a synthetic membrane. In both arms, heparin was progressively decreased until it was discontinued. Afterwards the patients were crossed over to the other arm.
214657783|NCT04345419|DRUG|Remdesivir|Remdesivir as antiviral drug
214657784|NCT04345419|OTHER|Standard of care treatment|Standard of care treatment
214657785|NCT02331576|DRUG|rocaine|
214657786|NCT02331576|DRUG|Fentanyl|
214657787|NCT05146167|BEHAVIORAL|Bodhi AIM (intervention group)|"Bodhi AIM (Action In Mindfulness) is a smartphone-based app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations (e.g., attending a party)."
214657788|NCT05146167|BEHAVIORAL|HIB (control group)|"HIB (Health In Balance) is a smartphone-based app that is matched to Bodhi AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in Bodhi AIM. Like Bodhi AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts."
214657789|NCT02739087|PROCEDURE|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
214657790|NCT02739087|DEVICE|Magnetic resonance imaging|
214289973|NCT01414283|DRUG|PSMA ADC|PSMA ADC administered IV
214657791|NCT05244772|OTHER|Remote monitoring|Remote monitoring with a smartphone application of pain and nausea after day care surgery
214657792|NCT05628922|DRUG|Toripalimab|"Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months."
214657793|NCT05628922|OTHER|Induction chemotherapy and concurrent chemoradiation|"Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w \* 2 cycles."
214657794|NCT00058864|DEVICE|Energy absorbing and distributing trochanteric pad|
214657795|NCT01591980|DRUG|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
214657796|NCT01591980|DRUG|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
214657797|NCT01591980|DRUG|placebo|Identical placebo capsules will be administered in the same way.
214657798|NCT05503953|DRUG|AGSAVI|Uptitation
214657799|NCT05503953|DRUG|AGLS|Uptitration
214657800|NCT03469076|OTHER|YUN ACN Cream|YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
214657801|NCT04894799|OTHER|Vestibular stimulation|In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
214657802|NCT04894799|OTHER|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
214657803|NCT04714112|DRUG|dexamethasone|Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
214657804|NCT01948492|DIETARY_SUPPLEMENT|Protein intake|On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
214657805|NCT06124989|DIAGNOSTIC_TEST|MINERVA Machine Learning model|The MINERVA score for the prediction of the risk of relapse of acute pancreatitis in patients who did not undergo early cholecystectomy after the first episode of acute biliary pancreatitis will be grounded upon a Machine Learning model that takes into account patients' demographic, clinical, and laboratory variables that can be easily collected and recorded at index patient admission.
214657806|NCT03415165|DRUG|green tea buccal tablet|buccal tablet for 8 hrs 3 times aday
214657807|NCT03415165|DRUG|Corticosteroids Topical|kenacort in orabase 4 times aday
214657808|NCT00426348|DRUG|Valsartan|Valsartan (80-160mg/day)
214657809|NCT00426348|DRUG|Probucol|Probucol (750mg/day)
214657810|NCT00426348|DRUG|Placebo|Placebo
214657811|NCT02351102|DRUG|Valacyclovir|
214657812|NCT02351102|DRUG|Placebo|
214657813|NCT03128463|DRUG|Intravitreal injection of conbercept|We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
214657814|NCT02687269|DRUG|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
214657815|NCT02687269|DRUG|Placebo|Patients receive Placebo twice daily in the three days before surgery
214657816|NCT01901887|DRUG|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
214657817|NCT01901887|DRUG|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
214657818|NCT00495027|BEHAVIORAL|Internet-delivered Stress Innoculation Training|
214657819|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
214657820|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
214657821|NCT03406962|DRUG|MGTA-456|Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.
214657822|NCT03955367|RADIATION|Prophylactic extended-field Irradiation|CTV covers pelvis and para-aortic lymph nodes region.
214657823|NCT03955367|RADIATION|Pelvic irradiation|CTV covers pelvis.
214657824|NCT03955367|RADIATION|Intracavitary brachytherapy|The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.
214657825|NCT03955367|DRUG|Concurrent chemotherapy|Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
214657826|NCT03747952|PROCEDURE|Tibiotalocalcaneal arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
214657827|NCT03747952|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
214657828|NCT04960891|DRUG|Tebentafusp|Concentrate solution for intravenous infusion
214657829|NCT04381234|DEVICE|dialyzer|Asymmetric triacetate dialyzer
214657830|NCT04381234|COMBINATION_PRODUCT|hemodialysis with citrate-containing dialysate|acetate-free dialysate
214657831|NCT04381234|OTHER|predilution hemodiafiltration|predilution hemodiafiltration
214657832|NCT04782622|DRUG|Apatinib+Camrelizumab|Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
214657833|NCT05681728|DRUG|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
214657834|NCT05681728|DRUG|Paclitaxel|On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
214657835|NCT05681728|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
214657836|NCT05681728|DRUG|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
214657837|NCT03229577|BEHAVIORAL|Sudarshan Kriya Yoga|Yoga-based breathing program.
214657838|NCT03229577|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness program.
214657839|NCT03229577|BEHAVIORAL|Emotional Intelligence|Emotional Intelligence program.
214848231|NCT05694117|BEHAVIORAL|resistance training|The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions). Participants in the RTG completed four sets of each movement, with two to three minutes of rest between each set.
214848232|NCT05694117|BEHAVIORAL|Taichi exercise and resistance training|The training of the Taichi exercise and resistance training group consisted of two cycles, the first cycle was aimed at learning and consolidating Taichi exercise, and the second cycle was aimed at improving and consolidating. The Taichi exercise and resistance training group was scheduled for 30 min of Taichi exercise per training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
214848233|NCT05694117|BEHAVIORAL|Randomly selected exercise program|Participants in the randomly selected exercise program group who chose Yijinjing exercise were required to complete one hour of Yijinjing exercise training, and those who chose Yijinjing exercise hybrid strength training had to complete half an hour of Yijinjing training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
214848234|NCT04715906|BEHAVIORAL|UP-Caregiver|The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
214848235|NCT03438006|OTHER|Safety data collection (following routine vaccination)|"This study assessed the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine when administered routinely according to the Prescribing Information in female Chinese subjects aged between 9 and 45 years.~The intervention consisted in the active surveillance of adverse events following immunization and pregnancy outcomes if the vaccine was administered inadvertently during pregnancy. Information of potential adverse events and pregnancy outcomes were collected at immunisation visits, telephone contacts and through spontaneous reporting by the patient/LAR/physician."
214848236|NCT03895229|DRUG|Empagliflozin 10 MG Oral Tablet [Jardiance]|Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
214848237|NCT04646525|DIAGNOSTIC_TEST|Physical examination|Pediatric patients diagnosed with COVID-19 and who have had infection will be examined, adenoid and tonsillar tissues will be evaluated in terms of hypertrophy, chronic, or recurrent infection.
214657840|NCT06143410|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
214657841|NCT06143410|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
214657842|NCT06143410|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol using target controlled infusion (TCI)
214657843|NCT06143410|PROCEDURE|gastroscopy|esogastroduodenoscopy
214657844|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
214657845|NCT00327444|DRUG|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
214657846|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
214657847|NCT03978650|OTHER|Observational|Participants from the Canadian Longitudinal Study on Aging will be evaluated for cognitive status, occurrence of falls, and fall-related injuries.
214657848|NCT05861583|OTHER|fat tissue|fat tissue sample collected while cosmetical liposuction
214657849|NCT05861583|OTHER|lipoedema tissue (stage 1)|lipoedema tissue sample (stage 1) collected while medical liposuction
214848238|NCT03236363|BEHAVIORAL|MOVI-da10! active breaks|MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
214657850|NCT05861583|OTHER|lipoedema tissue (stage 2)|lipoedema tissue sample (stage 2) collected while medical liposuction
214289974|NCT00002602|RADIATION|3D-CRT|3 dimensional conformal radiation therapy
214657851|NCT05861583|OTHER|lipoedema tissue (stage 3)|lipoedema tissue sample (stage 3) collected while medical liposuction
214657852|NCT02678806|RADIATION|Postoperative radiotherapy|The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy
214657853|NCT02678806|DRUG|Postoperative TACE|In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 \~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
214657854|NCT00049387|DRUG|tipifarnib|Given PO
214657855|NCT00049387|DRUG|temozolomide|Given PO
214657856|NCT00049387|RADIATION|radiation therapy|Undergo partial brain radiation therapy
214657857|NCT03155646|DRUG|Dexmedetomidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
214657858|NCT03155646|DRUG|Clonidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
214657859|NCT03155646|DRUG|Levobupivacaine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
214657860|NCT03787589|BEHAVIORAL|Exercise Prescription|"Participants in the intervention group will be given an exercise prescription to increase their baseline steps by 1200 and 2000 steps per day at least 3 days a week over the first 3 months. If tolerated and accepted, the participants will increase their step counts by an additional 600 to 1000 steps per day at least 3 days a week for the next 3 months.This will be followed by a 6-month maintenance phase. The research coordinator will instruct the participants on the proper use of the Nordic walking poles which can be used to help participants achieve their prescribed number of steps.~All participants will be encouraged to wear the pedometer throughout the trial in order to follow the step-count prescription and monitor adherence."
214657861|NCT04439344|DRUG|Binimetinib|Given PO
214657862|NCT01425099|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
214657863|NCT01425099|DRUG|Prednisone|Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
214657864|NCT03607773|BEHAVIORAL|Mindfulness Behavioural Intervention (MBI) group|While every MBI session is different, in general they will help you develop skills in focused attention, and emotional and behavioural regulation in a group environment made up of other people with MS who may share common experiences with you. MBI sessions are group-based which means you will be attending the sessions with other people who are also in this study and facilitated by trained personnel .
214657865|NCT00552110|DRUG|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).
214657866|NCT00552110|DRUG|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
214657867|NCT00552110|DRUG|mometasone furoate nasal spray (MFNS) once daily|MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.
214657868|NCT00552110|DRUG|oxymetazoline nasal spray (OXY) twice daily|OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.
214848239|NCT03236363|BEHAVIORAL|MOVI-da10! integrated physical activity|MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate \<150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
214848240|NCT03683329|OTHER|Antibiotic de-escalation|"All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation."
214848241|NCT03683329|OTHER|Standard treatment|Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
214289975|NCT01840501|DRUG|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
214848242|NCT03200535|OTHER|EHR gaps|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
214848243|NCT03200535|OTHER|Bulk outreach|A bulk letter or email will be sent
214848244|NCT03200535|OTHER|Dietician call|Patients will receive a personalized call by a registered dietitian
214848245|NCT05542849|DRUG|Acarbose Tablets 50mg|"Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals."
214848246|NCT05697757|OTHER|Dynamic Lighting|This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.
214289976|NCT01840501|DRUG|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
214289977|NCT01840501|DRUG|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
214289978|NCT01840501|DRUG|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
214657869|NCT00552110|DRUG|Placebo|Matching placebo to MFNS given every morning and every evening x 2 weeks.
214657870|NCT02237690|DRUG|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
214657871|NCT06418620|DRUG|Venglustat|Pharmaceutical form:Tablet-Route of administration:Oral
214657872|NCT03624647|DEVICE|Power toothbrush|Experimental power toothbrush
214657873|NCT03624647|DEVICE|Manual toothbrush|Marketed manual toothbrush
214657874|NCT00454207|DRUG|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
214657875|NCT03103893|DRUG|Rapamycin|topical formulation
214657876|NCT05383924|PROCEDURE|postplacental IUD insertion|"patients will have immediate postplacental IUD insertion as follows: The IUD is inserted after removal of the placenta and after the uterus has become hemostatic. After initiating closure of the uterine incision, the IUD is placed at the top of uterine fundus manually. Before closing the uterine incision, the strings are placed gently in the lower uterine segment manually. After this is accomplished, the uterine incision closure can be completed. The strings will usually descend spontaneously through the cervix during the puerperal period. If the cervix is closed, it'll be dilated from above with ring forceps. Strings can be passed through the cervix with ring forceps. If this is done, the surgeon will recheck to make sure IUD remains at the fundus of the uterus prior to closing the uterine incision. Strings can be trimmed at a follow-up visit.~Ultrasound will be done after the CS to ensure proper placement of the IUD."
214657877|NCT05383924|PROCEDURE|delayed IUD insertion|cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit as follows: Prepare IUD prior to starting procedure Place vaginal speculum then prepare vaginal wall with betadine Apply tenaculum at anterior cervical position then insert and remove uterine sound Place IUD according to package insert then cut threads 2-3 cm from cervical os. Ultrasound will be done to ensure proper placement of the IUD.
214657878|NCT05320575|DRUG|Zanubrutinib|The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.
214657879|NCT05726214|OTHER|Exercise|"The face-to-face multicomponent program entailed:~* Strength training of upper and lower limbs. Familiarization phase included 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets lasted 1-3 minutes.~* Balance exercises included proprioception, agility and weight transfer exercises. Difficulty progressively increased by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~* Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~The Vivifrail exercise wheel corresponding to each participant was given according to their functional level type."
214657880|NCT05726214|OTHER|Recommendations for active lifestyle|After the baseline assessments, all participants received individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants were encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations were transmitted verbally and through written material.
214657881|NCT02345798|PROCEDURE|Standard Follow-Up Care|Undergo usual care
214657882|NCT02345798|OTHER|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
214657883|NCT02345798|OTHER|Educational Intervention|Undergo video-assisted intervention
214657884|NCT02345798|OTHER|Quality-of-Life Assessment|Undergo quality of life assessment
214657885|NCT02345798|OTHER|Questionnaire Administration|Undergo questionnaire administration
214657886|NCT04214652|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
214657887|NCT04214652|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
214657888|NCT02160457|OTHER|Intervention with IGA|"Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis~The instrumented gait analysis consists of four steps:~1. Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)~2. Impairment-Focused Interpretation~3. Recommendation for interdisciplinary interventions~4. Dissemination of recommendations~The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group."
214657889|NCT00716716|DRUG|rFIXFc|As specified in the treatment arm
214657890|NCT02272790|DRUG|Adavosertib|Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.
214657891|NCT02272790|DRUG|Paclitaxel|"Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards."
214657892|NCT02272790|DRUG|Carboplatin|Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.
214848247|NCT05697757|OTHER|Placebo Lighting|We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
214906944|NCT05928312|DRUG|Fruquintinib Combined With Chemotherapy|"1.Security introduction period:~\[1\] Safety introduction period (N=6), fruquintinib combined with three-week regimen:~1\. Fruquintinib: Three-week regimen of combined chemotherapy: 4mg/d, orally, once a day, taking the drug for 2 weeks and stopping the drug for 1 week, 3 weeks as a treatment cycle.~\[2\] Safety introduction period (N=6), fruquintinib combined 2-week regimen:~1. Fruquintinib: two-week combination chemotherapy regimen: 4mg/d, orally, once a day, taking the drug for 3 weeks and stopping the drug for 1 week, 4 weeks as a treatment cycle.~2. Dose expansion phase design(N=60) Cohort 1 (30 patients) : Fruquintinib combined with oxaliplatin. Cohort 2 (30 patients) : Fruquintinib combined with irinotecan ."
214657893|NCT02272790|DRUG|Gemcitabine|Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.
214657894|NCT02272790|DRUG|PLD|PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
214657895|NCT03036878|OTHER|ReNu|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
214657896|NCT01206907|DRUG|oxymorphone IR|oxymorphone IR liquid
214906945|NCT00003627|DRUG|cisplatin|
214289979|NCT02205814|DRUG|Fasitibant- low dose|Single intra-articular injection of low dose of fasitibant
214289980|NCT02205814|DRUG|Fasitibant- intermediate dose|Single intra-articular injection of intermediate dose of fasitibant
214657897|NCT01882361|DRUG|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
214657898|NCT01882361|DRUG|placebo comparator|this placebo has no specific pharmacological activity
214657899|NCT05975229|OTHER|Knitting and education (pamphlet)|Pamphlet and knitting program (-8-week duration). The knitting program has two components: bi-weekly 20-minute group knitting sessions and 20-minute home daily knitting on the 5 remaining weekdays.
214657900|NCT05975229|OTHER|Education (pamphlet)|Receive only the pamphlet, not the knitting program.
214657901|NCT00332202|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
214657902|NCT00332202|DRUG|placebo|oral, daily
214657903|NCT00836940|DRUG|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
214657904|NCT05006053|OTHER|Interviews/Focus groups|Qualitative study (no intervention delivered)
214657905|NCT04812561|DIETARY_SUPPLEMENT|Bronch™|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
214657906|NCT04812561|DIETARY_SUPPLEMENT|placebo|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
214657907|NCT01061489|OTHER|auditory discrimination training|10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
214657908|NCT01061489|OTHER|physical movement training|10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
214657909|NCT01656642|DRUG|Atezolizumab|Atezolizumab will be administered q3w or q2w.
214657910|NCT01656642|DRUG|Cobimetinib|Oral repeating dose
214657911|NCT01656642|DRUG|Vemurafenib|Oral repeating dose, depending on arm/cohort
214657912|NCT03006653|BEHAVIORAL|Assessment only|Mobile ecological assessment only.
214289981|NCT02205814|DRUG|Fasitibant- high dose|Single intra-articular injection of high dose of fasitibant
214657913|NCT01883037|OTHER|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
214657914|NCT04934293|PROCEDURE|Virtual reality|Before proton therapy, virtual reality sessions will be performed.
214657915|NCT02977715|BIOLOGICAL|JYNNEOS (Liquid Formulation)|Two doses of attenuated live virus smallpox vaccine (JYNNEOS liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
214657916|NCT02977715|BIOLOGICAL|JYNNEOS (Lyophilized Formulation)|Two doses of attenuated live virus smallpox vaccine (JYNNEOS lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
214657917|NCT03871491|DRUG|Azithromycin|The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
214657918|NCT03871491|DRUG|Placebo|Identical appearing placebo, administered as a single oral dose directly after randomization.
214657919|NCT05238584|PROCEDURE|Partial omentectomy|Partial omentectomy: with preservation of the greater omentum at \>2 cm from the gastroepiploic arcade.
214657920|NCT00142948|DRUG|Naltrexone|naltrexone
214848248|NCT00440609|DRUG|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
214848249|NCT05734209|BEHAVIORAL|Virtual food|Virtual food eaten using immersive virtual reality equipment
214906946|NCT00003627|DRUG|fluorouracil|
214289982|NCT02205814|DRUG|Placebo comparator|Single intra-articular injection of placebo
214289983|NCT01426373|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
214289984|NCT04952402|BIOLOGICAL|Study-provided Moderna mRNA-1273 COVID-19 vaccine|Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
214657921|NCT00142948|DRUG|Placebo|placebo
214657922|NCT04439331|DRUG|Defactinib Hydrochloride|Given PO
214657923|NCT02882256|OTHER|Video discharge instructions|Discharge instructions provided in video form
214657924|NCT06302257|DRUG|Chlorprocaine|we aim to examine whether selective nociceptive analgesia can be obtained in epidural analgesia for women in labor by using a combination of lidocaine (opens TPRV-1 and TPRA-1 channels) and chlorprocaine (polarized local anesthetic)
214657925|NCT06302257|DRUG|Lidocaine|Study participants will receive lidocaine alone
214657926|NCT06302257|DRUG|Lidocaine-chlorprocaine combination|study participants randomized to this study arm will receive a a 50:50 mixture of both drugs - where all drugs are administered in concentrations based on their ED50 doses, together with epidural opioids (fentanyl)
214657927|NCT01009528|DEVICE|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
214657928|NCT02901314|OTHER|on-demand audio messages of heart failure education themes|
214657929|NCT01931046|DRUG|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
214657930|NCT05116384|DEVICE|catheter ablation|cryo energy via cryoballoon
214657931|NCT05116384|DEVICE|renal artery denervation|RF energy delivery to multiple sites within each major renal artery
214657932|NCT05327062|DEVICE|CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment|"The following information and data will be obtained from the routine clinical work up of the patients: Patient demographics, cardiovascular medical history, and clinical examination; 12-lead ECG; Standard echocardiography; Computed tomography angiography for visualization of atria, ventricle, and coronary sinus.~Imaging data will be transferred to the cloud-based web-platform using a dedicated software provided by study sponsor. Data processing includes evaluating the quality of the data and calculation of various anatomical and electrical parameters, and identification of the target zone as a point in the target vein closest to the latest activation zone.~LV-lead location is based on the information provided by the dedicated software followed by visual X-ray based verification of anatomically suitable/most desirable position.~The patient will undergo CRT device implantation according to local protocols."
214657933|NCT02749305|OTHER|Collection of patient-reported outcome measures|Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
214657934|NCT05607628|COMBINATION_PRODUCT|Low Calorie Animal Protein Meals|Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
214657935|NCT05607628|COMBINATION_PRODUCT|Low Calorie Plant Protein Meals|Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
214657936|NCT00490542|DRUG|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
214657937|NCT00490542|DRUG|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
214657938|NCT03884465|DRUG|Inhaled dry powder treprostinil (LIQ861)|Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
214657939|NCT02598414|PROCEDURE|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
214657940|NCT02598414|PROCEDURE|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
214657941|NCT02598414|DEVICE|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
214657942|NCT02113293|DRUG|CyclASol®|Cyclosporine A Solution
214657943|NCT02113293|DRUG|Placebo (vehicle)|Vehicle Solution
214657944|NCT06194877|DRUG|BGB-3245|Oral capsule
214657945|NCT06194877|DRUG|Panitumumab|Intravenous (IV) infusion via an infusion pump
214657946|NCT06649058|OTHER|Systemic Therapy|Participants will receive systemic therapy as a standard of care therapeutic option
214657947|NCT06649058|RADIATION|Stereotactic Radiosurgery|Participants will receive systemic therapy as a standard of care therapeutic option
214657948|NCT02390518|RADIATION|Stereotactic Radiosurgery|"Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a and 1a Expansion (starting at Dose Level 3) Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a \*Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a~\*\*Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions."
214657949|NCT06573853|PROCEDURE|Focal Pulsed Field Ablation (PFA)|Patients in the PFA group underwent ablation procedures utilizing a force-sensing PFA catheter for the treatment of PSVT.
214657950|NCT06573853|PROCEDURE|Focal Radiofrequecy Ablation (RFA)|Patients in the PFA group underwent ablation procedures utilizing force-sensing RFA catheters for the treatment of PSVT.
214657951|NCT05178420|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
214657952|NCT03158766|OTHER|Microdiscectomy|It will be an observational study without interventions. Subjects with diagnose of lumbar disc herniation undergoing open decompression surgery (microdiscectomy) will be included and analyzed. There will be no direct intervention to the patient proposed by the study.
214657953|NCT03860922|DEVICE|Magnetic Resonance Imaging|all patient will undergo Magnetic resonance imaging and magnetic imaging arthrography of the ankle joint.
214657954|NCT01501591|DRUG|Hydroxizine|25 mg orally, one time on two different days, 72 hours apart
214657955|NCT01501591|OTHER|Placebo|Matching placebo once on two different days, 72 hours apart.
214848250|NCT05734209|BEHAVIORAL|Real food|Real food eaten using regular utensils
214848251|NCT02720133|BIOLOGICAL|biochemical parameters|"patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison."
214289985|NCT04952402|BIOLOGICAL|Community-provided Moderna mRNA-1273 COVID-19 Vaccine|Participants received a two-dose series.
214289986|NCT04952402|BIOLOGICAL|Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine|Participants received a two-dose series.
214657956|NCT01501591|DRUG|hydroxyzine/placebo|25 mg hydroxyzine or placebo once on two different days, 72 hours apart
214475767|NCT06806956|DRUG|Treatment of severe malaria with rectal artesunate + Artemisinin based Combination Therapy is not inferior to rectal artesunate + injectable artesunate + ACT in terms of effectiveness in remote areas|The Community Health Worker will give rectal artesunate (RAS) +artemisinin based combination Therapy (ACT) to children aged 6 months to less than or equal to 5 years who fail to make the referral trip. Those who make the referral trip will receive injectable artesunate and artemisinin based Combination Therapy for three days. Giving of RAS +ACT is unique to this study. Children with non malaria severe disease will also receive amoxicillin from the community health worker before they are referred to the next level of care
214657957|NCT01813994|DRUG|Arm1: Statin|"Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
214657958|NCT01813994|DRUG|Arm2: Placebo|"Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
214657959|NCT04992702|BEHAVIORAL|Animated Video|Animated video to improve learning and motivation
214657960|NCT01289496|DRUG|Peg-interferon alpha-2a, Ribavirin|"* 4 weeks RBV priming;~* 24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);~* 24 weeks Follow-Up~Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.~Ribavirin 200 mg tablets"
214657961|NCT06255873|DIETARY_SUPPLEMENT|L- Carnitine|L-carnitine was taken after feeds in the form of tablets or dissolved tablets in a dose of 50 mg/kg/day, with maximum dose of 2 g/day.
214657962|NCT06255873|OTHER|ketogenic diet|ketogenic diet (KD) initiated under supervision of expert physician who considered patient's age, type of feeding, needs and preferences of the child and his/her family to select the type and initial ratio of KD therapy, KD ratio ranged from 1:1 to 4:1 of lipids to carbohydrates plus proteins in grams.
214657963|NCT03843047|DRUG|3 mg/mL nicotine strength e-liquid|Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
214657964|NCT03843047|DRUG|6 mg/mL nicotine strength e-liquid|Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
214657965|NCT03843047|DRUG|12 mg/mL nicotine strength e-liquid|Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
214657966|NCT03843047|DRUG|24 mg/mL nicotine strength e-liquid|Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
214657967|NCT00004826|DRUG|clozapine|
214657968|NCT05338229|DEVICE|the engineer-built system, video-game based Kinect sensor|The engineer-built system, video-game based Kinect sensor was developed by the researcher team.
214289987|NCT01126450|DRUG|lenalidomide|Given orally
214289988|NCT01126450|BIOLOGICAL|cetuximab|Given IV
214657969|NCT03216629|BEHAVIORAL|"Saying sorry"|"The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?"
214657970|NCT03658954|BEHAVIORAL|Advice|Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.
214657971|NCT03658954|BEHAVIORAL|Self-monitoring|Participants will complete daily smartphone-based sleep and alcohol diaries for two weeks.
214289989|NCT01126450|OTHER|mutation analysis|Correlative studies
214289990|NCT01126450|OTHER|polymerase chain reaction|Correlative studies
214289991|NCT01126450|GENETIC|polymorphism analysis|Correlative studies
214475768|NCT06261749|OTHER|Voluntary Abdominal Contractions|Abdominal contraction will be taught before exercise. They will be instructed to tighten their abdomen as if they were wearing tight pants and not to hold their breath. The visual biofeedback unit will be placed between the therapy table and the participant's abdominal area and will be used to monitor the contraction of the abdominal muscles. The visual biofeedback inelastic bag will be inflated to 70 mmHg and the participant will be instructed to draw the abdomen in and maintain the position. The participant will be asked to maintain a pressure of 60 mmHg during scapular retraction with visual feedback from an analog pressure gauge. Pressure changes of ± 5 mmHg due to breathing will be allowed. During exercise, the patient will be asked to perform the exercises while maintaining the pressure on the visual biofeedback.
214657972|NCT03658954|BEHAVIORAL|Feedback|Participants will receive feedback once per week for two weeks on their sleep and alcohol consumption, using all possible data derived from Philips actiwatches and SCRAM ankle biosensors \& smartphone diaries \& tailored coaching with a health coach
214657973|NCT04549532|BEHAVIORAL|Targeted Multidomain|Participants in the T-MD intervention group will be prescribed targeted interventions to address each individual's symptoms, impairments, and functional limitations in the areas of anxiety/mood, cognitive, migraine/headache, ocular, vestibular, sleep, autonomic. The length of the intervention period will be 4 weeks or until RTA, whichever comes first.
214657974|NCT04549532|BEHAVIORAL|Behavioral Management|1.3. Usual Care (Controls) Group Participants randomized to the usual care (control) group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
214657975|NCT06386406|DEVICE|TAP insole|"The patients will have to wear the TAP insole when walking during the everyday life activities.~This plantar insole is not a custom-made insole but a pre-confectioned one because designed according to two parameters: shoe size and gender."
214657976|NCT05795699|DRUG|Ripasudil|K-321 ophthalmic solution
214657977|NCT05795699|DRUG|Placebo|Placebo ophthalmic solution
214657978|NCT06186375|OTHER|Patients with planned biotherapy|Single additional volume of blood (10 ml) to be collected using the PAXgene system at the same time as the routine blood test before starting biotherapy.
214657979|NCT02399033|DRUG|Xihuang Capsules|In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
214657980|NCT00818259|DRUG|Experimental: aprepitant|aprepitant powder for suspension, 125 mg/sachet, PO
214657981|NCT00818259|DRUG|Experimental: fosaprepitant|fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
214657982|NCT00818259|DRUG|Comparator: ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
214657983|NCT00818259|DRUG|Ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
214657984|NCT00818259|DRUG|Dexamethasone|dexamethasone solution for infusion, IV, administered per local standard of care
214657985|NCT00421330|PROCEDURE|Open Aneurysm Repair|
214657986|NCT00421330|PROCEDURE|Endovascular Aneurysm Repair|
214657987|NCT03223571|OTHER|Motor rehabilitation training|Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
214657988|NCT06190457|OTHER|intrathecal rituximab|All children were treated with a modified NHL-BFM95 regimen for children NHL with the addition of rituximab, both intravenous and intrathecal, and rituximab intrathecal infusion is scheduled to be used simultaneously with rituximab intravenous drip. rituximab intrathecal doses are 10 mg, 15 mg, and 20 mg in increments every 3 weeks. rituximab intrathecal injection does not use methotrexate or/and cytarabine intrathecaline chemotherapy.
214657989|NCT05391438|OTHER|Meal-timing|We propose a cross-over, proof-of-concept study to measure glycemic and metabolic responses to a test meal (controlled for macronutrient profile and caloric amount) administered at various times of the day (early vs. afternoon vs. late) in thirty Latino adolescents (ages 13-19 years), with obesity, without diabetes, to determine how timing of eating impacts glycemic response to the test meal after a 16-h fasting period. All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period. Baseline and post-meal samples will be assayed for glucose, insulin, c-peptide, GLP-1, GIP, PP at times -10, -5, 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minutes after glucose.
214657990|NCT05941104|OTHER|frailty|Frailty is a group of common clinical syndromes in the elderly, characterized by systematic, dynamic and reversible, the core of which is the decline of physiological reserves and the destruction of self-balance.
214475769|NCT06261749|OTHER|Exercise|"Exercises;~1. Scapular retraction with arms next to the trunk~2. Scapular retraction with arms abducted at 45 degrees,~3. Scapular retraction with arms 90 degrees abducted,~4. Scapular retraction exercises with arms 120 degrees abducted The exercises will be performed with the shoulder head off the bed. The exercises will be repeated 3 times with 5 seconds rest between repetitions. To reduce the effect of fatigue, 2 minutes rest will be given between exercises. Each exercise will be performed with 3 seconds of concentric, 3 seconds of isometric and 3 seconds of eccentric contraction and muscle activation of UT-LT and SA muscles will be measured during these phases."
214475770|NCT03169972|BIOLOGICAL|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
214657991|NCT05754775|BEHAVIORAL|Calorie restriction via total food replacement|Restricted foods designed by a clinical nutritionist that delivers to home for diabetic patients.
214657992|NCT03629548|PROCEDURE|early amniotomy|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
214657993|NCT03629548|DEVICE|foley catheter balloon placement|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg PGE2 vaginal ovul will be inserted to the posterior fornix
214657994|NCT02863198|DEVICE|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
214657995|NCT01526421|OTHER|monetary reinforcer|Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
214475771|NCT06346041|BIOLOGICAL|Oncolytic Virus injection(IDOV-SAFETM)|Administered by intravenous injection as single agent.
214475772|NCT05670236|DRUG|Lidocaine Hydrochloride|10 mL of 1% lidocaine hydrochloride for each intraarticular knee injection
214475773|NCT04030533|DRUG|Guselkumab (SC): Dose 1|Participants will receive a single dose of guselkumab (dose 1) subcutaneously.
214475774|NCT04030533|DRUG|Guselkumab (SC): Dose 2|Participants will receive a single dose of guselkumab (dose 2) subcutaneously.
214475775|NCT04030533|DRUG|Guselkumab (IV): Dose 1|Participants will receive a single IV infusion of guselkumab (dose 1).
214657996|NCT05466643|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
214657997|NCT05466643|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
214657998|NCT06115109|OTHER|Non intervention, Observational study|Non intervention, Observational study
214848252|NCT03026309|OTHER|no intervantion|no intervention is being performed, only observational evaluations.
214475776|NCT04030533|DRUG|Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2).
214475777|NCT04030533|DRUG|Ustekinumab 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
214475778|NCT04117100|PROCEDURE|Polypectomy or myotomy|Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).
214906947|NCT00003627|RADIATION|radiation therapy|
214475779|NCT02437136|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDACs)
214657999|NCT06206096|DRUG|oxaliplatin+capecitabine+bevacizumab+PD-1 antibody|oxaliplatin will be administered once every 3 weeks at a dose of 130 mg/m2; Capecitabine will be taken orally at a dose of 1g/m2 twice daily for continuous oral administration over 14 days; Bevacizumab will be administered intravenously every 3 weeks at a dose of 7.5 mg/kg; PD-1 antibody was given due to different types.
214658000|NCT06544239|BEHAVIORAL|Virtual reality basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
214475780|NCT02437136|DRUG|pembrolizumab|A selective humanized monoclonal antibody (mAb)
214475781|NCT04117178|DRUG|Donepezil|Adjustment of treatment with donepezil according to serum level.
214475782|NCT04117178|DRUG|Memantine|Adjustment of treatment with memantine according to serum level.
214475783|NCT04117178|DIAGNOSTIC_TEST|Measurement of serum level of anti-dementia drug|"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."
214475784|NCT01862315|DRUG|Floxuridine (FUDR)|
214658001|NCT06544239|BEHAVIORAL|Traditional basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
214658002|NCT01483677|OTHER|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
214658003|NCT01483677|OTHER|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
214658004|NCT05943080|DRUG|PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|The application is made into the anatomical space between the posterior capsule and the popliteal artery before implantation.
214658005|NCT05943080|DRUG|IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.
214658006|NCT05943080|DRUG|ACB ( 0.25% marcaine + %0.9 saline)|It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.
214658007|NCT04762030|DRUG|Durvalumab Anlotinib Carboplatin Nab-paclitaxel|"Neoadjuvant treatment (durvalumab+carboplatin+nab-paclitaxel + anlotinib) will start within 1-3 days from enrollment. 2 cycles will be administered at 21-day (+/- 3 days) intervals (QW3). Then, two cycles of combined durvalumab and anlotinib (QW3) will be administered prior to surgery. Before surgery, a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 5rd-7th week from day 1 cycle 4 of neoadjuvant treatment (day 35-49 after day 1 of cycle 4). Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Twelve cycles of durvalumab adjuvant treatment (Q4W) will be administered."
214658008|NCT01832740|DEVICE|brain stimulation|oscillating direct current brain stimulation
214658009|NCT01832740|DEVICE|SHAM|no stimulation
214658010|NCT02380755|DRUG|Clomiphene Citrate|50 mg orally daily during 12 weeks
214658011|NCT02380755|DRUG|Placebo|1 pill orally daily during 12 weeks
214658012|NCT00457574|DRUG|GMX1777|
214658013|NCT01237951|DRUG|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
214848253|NCT04169555|PROCEDURE|Ultrasound|"The emergency physician will perform a point of care ultrasound. If signs of expansions of the pelvicalyceal cavities are found, an early CT scan will follow"
214848254|NCT04169555|OTHER|Standard care|Standard clinical care of patients. In regards of the clinical evolution and of biological results, a CT scan could be performed by the physician.
214658014|NCT01237951|DRUG|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
214658015|NCT01237951|DRUG|Gemcitabine|1875 mg/m\^2 IV (75 mg/ m2 bolus followed by 1800 mg/m\^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
214658016|NCT01237951|DRUG|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
214848255|NCT06695117|BIOLOGICAL|IIV-HD|Inactivated, split-virion
214848256|NCT06695117|BIOLOGICAL|rC19 (dose 1)|Protein subunit
214848257|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 1)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
214848258|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 2)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
214848259|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 3)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
214848260|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 4)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
214848261|NCT06695117|OTHER|Placebo (0.9% NaCl)|Normal saline
214906948|NCT03296527|DRUG|Follitropin alfa|GONAL-F dose was fixed for the first 5 stimulation days.
214475785|NCT01862315|DRUG|dexamethasone|
214475786|NCT01862315|DRUG|Gemcitabine|
214475787|NCT01862315|DRUG|Oxaliplatin|
214475788|NCT01862315|OTHER|MRI|
214475789|NCT01862315|OTHER|Research blood draws|These are optional
214475790|NCT04008563|PROCEDURE|Bariatric Surgery|Patients who are randomized to the intervention group will receive a progestin intrauterine device and be referred for bariatric service to undergo bariatric surgery within 3 months of their study consent.
214475791|NCT03974022|DRUG|Sunvozertinib|Daily dose of Sunvozertinib
214475792|NCT04312841|DRUG|Letermovir|Given PO
214475793|NCT06029153|PROCEDURE|Middle meningeal artery embolization|Middle meningeal artery embolization with coil.
214475794|NCT04134559|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.
214658017|NCT01237951|DRUG|Melphalan|60 mg/m\^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
214658018|NCT01237951|PROCEDURE|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
214658019|NCT01237951|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
214658020|NCT01943656|DEVICE|Tobii™ Eyegaze System|Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
214658021|NCT00825370|DRUG|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
214658022|NCT00825370|DRUG|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
214658023|NCT01841892|BEHAVIORAL|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
214658024|NCT04708587|DRUG|dual anti-platelet therapy at least 6 months|Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
214658025|NCT04708587|DRUG|dual anti-platelet therapy 3months or less|Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
214658026|NCT03498820|DEVICE|Analgesia Nociception Index|: Non invasive monitor based on heart rate variability analysis, assessing the parasympathetic nervous activity
214658027|NCT03498820|DRUG|Remifentanil|intravenous short-acting opioid routinely administered during general anesthesia
214658028|NCT01560065|DIETARY_SUPPLEMENT|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
214658029|NCT01560065|DIETARY_SUPPLEMENT|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
214658030|NCT06296563|PROCEDURE|HAIC|FOLFOX-hepatic artery infusion for 2 times.
214658031|NCT06296563|DRUG|Adebrelimab|Adebrelimab 1200mg, ivgtt, d1, q3w,up to one year of use at most.
214658032|NCT06296563|DRUG|Apatinib|Apatinib 250mg, po, qd,q3w,up to one year of use at most.
214658033|NCT06100783|DEVICE|Depot-medroxy Progesterone Acetate Injectable Contraceptives|Depot-medroxy progesterone acetate injectable contraceptives
214658034|NCT05394259|DRUG|Piflufolastat F18|Given by vein (IV)
214658035|NCT02662790|OTHER|Doppler|
214658036|NCT00924703|DRUG|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
214848262|NCT06631274|BEHAVIORAL|counseling|The intervention (IVY; Intervention for Victimized Youth) is an 8 week group counseling intervention delivered in a virtual environment.
214848263|NCT04651595|PROCEDURE|Caudal block|caudal block with low dose bupivicaine 0.25% to preserve tone
214658037|NCT05239689|BIOLOGICAL|CD38 CAR T-cells|Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection
214658038|NCT00666562|DIETARY_SUPPLEMENT|Defined Green Tea Catechin Extract|Given orally
214848264|NCT04651595|DRUG|Morphine|morphine to control pain and avoid using muscle relaxant
214658039|NCT00666562|OTHER|Laboratory Biomarker Analysis|Correlative studies
214658040|NCT00666562|OTHER|Pharmacological Study|Correlative studies
214658041|NCT00666562|DRUG|Placebo|Given orally
214658042|NCT00666562|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214658043|NCT03280251|DRUG|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
214658044|NCT03280251|DRUG|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
214658045|NCT03280251|OTHER|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
214658046|NCT03280251|OTHER|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
214658047|NCT02139150|RADIATION|[18F] FLT|
214658048|NCT02139150|DEVICE|PET/CT scans|
214658049|NCT06299943|OTHER|Biofeedback gait training by biomechanical target parameter|The patient walks using a treadmill at a comfortable speed until he gets tired. The patient is instructed that when performing a virtual task (in a virtual environment on the screen), his walking will be harmonized (without informing him on what parameter). If it fails to cope, then the zones of permissible changes (on the information columns) will expand, and the virtual task will signal its incomplete completion.
214658050|NCT06290440|OTHER|Telepharmacy-led counselling|The counselling process will be delivered as follows: (1) researchers assist patients in signing up and using the telepharmacy application; (2) researchers send the counselling information from the telepharmacy application to the patient's account (the information will be provided as leaflets and 3-5-minute videos to improve the accessibility); (3) the integrated chatbot system forwards any additional questions or concerns of the patients to the counselling pharmacists; and (4) the pharmacists directly address the patient's questions or concerns through phone calls within the shortest possible timeframe.
214658051|NCT06290440|OTHER|Pharmacist-led counselling|Pharmacists will counsel the patients on how to use their OAC. Each counselling section will take approximately 7-15 minutes, depending on the patient's questions or concerns. The counselling contents have already been compiled and validated by NDGD Hospital to ensure rationale and simplicity for every patient. Counselling pharmacists have received specialised training in drug information and patient communication so intervention delivery will be consistent across different pharmacists.
214658052|NCT05491759|DRUG|Product 1 - AquaCelle Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.
214906949|NCT03296527|DRUG|Follitropin delta|REKOVELLE (FE 999049) was fixed throughout the stimulation period.
214658053|NCT05491759|DRUG|Product 2 - AquaCelle Fish Oil Ethyl Ester|1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle
214658054|NCT05491759|DRUG|Product 3 - Standard Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).
214658055|NCT02029742|BEHAVIORAL|Community Health Worker (CHW)|CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.
214658056|NCT02029742|BEHAVIORAL|Education|Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
214658057|NCT06055166|DRUG|Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))|Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles
214658058|NCT00000191|DRUG|Carbamazepine|
214658059|NCT01106040|DRUG|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
214658060|NCT01908348|DIETARY_SUPPLEMENT|Erythritol|
214658061|NCT03971721|DEVICE|Wave 4.3|The Wave 4.3 mattress support is an insert, placed underneath the user's existing mattress, that when inflated increases the longitudinal incline of the mattress support, increasing in inclination in the direction of the head of the bed. The resulting mattress contours are such that the mattress has a lateral inclination of approximately 15 degrees in the head section and 10 degrees in the torso section. In addition to the features allowing the user to activate and deactivate creation of this Graduated Lateral RotationTM orientation, this device has sensors and monitoring system allowing for remotely monitoring the status of the system, including confirming that the supports are achieving the prescribed support angles, and that the system is working as planned.
214658062|NCT02238535|DRUG|Ventavis|
214658063|NCT02238535|DRUG|Warfarin|
214658064|NCT03286673|DIETARY_SUPPLEMENT|calcium phosphate|
214658065|NCT03286673|DIETARY_SUPPLEMENT|Tricalcium Phosphate|
214658066|NCT03286673|DIETARY_SUPPLEMENT|Calcium carbonate|
214658067|NCT03286673|DIETARY_SUPPLEMENT|Placebo|
214848265|NCT01921231|DRUG|Hyperbaric Prilocaine 1%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
214475795|NCT04722913|DIAGNOSTIC_TEST|Photogrametry , flexion rotation (FRT) test, Diagnosis of CGH according diagnostic criteria of the Cervicogenic Headache International Study Group (CHISG)|"Photogrammetry is the science and technology of obtaining reliable information about physical objects and the environment through the process of recording, measuring and interpreting photographic images and patterns of electromagnetic radiant imagery and other phenomena.~Flexion rotation (FRT) test:~FRT is a manual examination technique with high sensitivity and specificity. It is performed with the patient in supine by passively taking the cervical spine into full flexion. End-range cervical flexion imparts ligamentous tension that impedes movement at vertebral segments below C2.7 Maintaining the flexion position, the patient's head is then rotated to each side until the patient reports pain or the operator determines that end of motion has been achieved. It is then determined if a restriction in ROM is present."
214658068|NCT06381830|OTHER|Apheresis|Participants will undergo two separate apheresis procedures, including: G-CSF primed hematopoietic stem cell collection and peripheral blood mononuclear cell apheresis for CAR-T cell manufacturing.
214658069|NCT06381830|OTHER|Autologous Stem Cell Transplantation|Participants are designed to receive myeloablative conditioning regimen prior to infusion of a minimum 2 x 10\^6 CD34+ stem cells/kilogram.
214658070|NCT06381830|DRUG|CAR-T Cell Therapy|CAR-T cells will be infused within 7 days after autologous hematopoietic stem cell infusion (2-10×10\^6 CAR-T/kg，ivgtt).
214658071|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 1-12
214658072|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 13-24
214658073|NCT01587989|DRUG|placebo|methotrexate placebo orally weekly, Weeks 13-24
214658074|NCT01587989|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 24 weeks
214658075|NCT04429022|DRUG|Gabapentin|600mg PO PO x 1 prior to surgery (in pre-op) 300mg PO BID for 7 days post op
214475796|NCT06772129|OTHER|Aromatherapy|Studies have been reviewed and no lavender aromatherapy has been found to be used for delirium.
214658076|NCT04429022|DRUG|Acetaminophen|Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op
214658077|NCT04429022|DRUG|Celecoxib|Celecoxib 200mg PO q 12h x 7d post op
214658078|NCT04429022|DRUG|Ketorolac|30mg IV once at end of hysterectomy procedure
214658079|NCT04429022|PROCEDURE|Paracervical block with ropivacaine|0.5% ropivacaine; 10 mL bilaterally (2 point) for total of 20mL
214658080|NCT04429022|PROCEDURE|Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites|0.5% ropivacaine; at all laparoscopic port sites; another 10mL ropivacaine in total
214658081|NCT04429022|DRUG|Hydromorphone|1mg IV PRN q3h, post op, while inpatient
214658082|NCT04429022|DRUG|Oxycodone|To be discharged home with: 12 tabs of 5mg PRN q4h
214658083|NCT02590393|COMBINATION_PRODUCT|E-cigarettes|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
214906950|NCT04071834|DIAGNOSTIC_TEST|ELISA|Detection of blood orphanin and norepinephrine in patients
214475797|NCT06179524|BIOLOGICAL|CAR-T-19 cell injection|The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
214475798|NCT02827838|BIOLOGICAL|Durvalumab|Given IV
214475799|NCT02827838|OTHER|Laboratory Biomarker Analysis|Correlative studies
214475800|NCT02827838|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214475801|NCT05627726|DEVICE|PelviSense-assisted pelvic floor muscle training group|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays electrical activity measured in PFMs on the user's mobile device. The reusable, wearable EMG sensor is non-invasive and can be attached to the user's perineal region. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts. The mobile app can store data for up to 7 days, allowing participants to monitor their progress over the last 7 days in a graphical format.
214475802|NCT05627726|OTHER|Active comparator|Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
214475803|NCT05885256|DIAGNOSTIC_TEST|Amending current standard trauma order set|Blood draw happens as part of routine clinical care for all trauma activations. As part of the study, we will use existing blood that is drawn as part of routine clinical care, or when necessary, draw additional blood to obtain samples at 0, 3, 6, 12, 18, and 24 hours assessing ionized calcium, serum calcium, and magnesium. We will strive to have draws occur within +/- 1 hour of the goal times. However, given that the blood draws will be performed by way of the clinical team and the unpredictable nature of trauma care, missed draws or draws out of the goal time frame will not be considered protocol violations
214475804|NCT04466059|DIAGNOSTIC_TEST|Automated AI-Guided Diagnosis of Hematological Malignancies|In BELUGA, we want to investigate whether the automated analysis of blood (from peripheral blood and bone marrow aspirates) smears and flow-cytometry-based analyses can provide a benefit for diagnostic quality and, ultimately, patient care.
214475805|NCT01545999|OTHER|Brain Stimulation via Transcranial Magnetic Stimulation|"PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task."
214475806|NCT05136755|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
214475807|NCT05136755|DRUG|Placebo Cap|Use of placebo as a comparator
214475808|NCT05850052|DEVICE|McGrath videolaryngoscope for rapid sequence endotracheal intubation|Visualize a patient's airway to aid placement of tracheal tube with ease.
214475809|NCT05850052|DEVICE|Conventional direct laryngoscopy using a Macintosh blade|Examine a patient's airway to aid placement of tracheal tube with ease.
214475810|NCT06678464|OTHER|Moiz MM|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
214475811|NCT06678464|OTHER|Moiz XL|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
214475812|NCT06678464|OTHER|Moiz LMF 48|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day or as often as needed Route of Administration: Topical"
214475813|NCT03822494|RADIATION|CyberKnife SBRT|Radiation Therapy
214475814|NCT05255094|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
214475815|NCT05255094|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
214475816|NCT05255094|DRUG|Placebo|Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
214475817|NCT05255094|DRUG|Placebo|Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
214475818|NCT05492422|DEVICE|Central Executive Training (CET)|Central Executive Training (CET)
214475819|NCT05492422|BEHAVIORAL|Behavioral Parent Training (BPT)|Behavioral Parent Training (BPT)
214475820|NCT04209543|DRUG|Estetrol|Estetrol oral tablet: administered orally once daily
214475821|NCT04209543|DRUG|Placebo|Placebo oral tablet: administered orally once daily
214475822|NCT04209543|DRUG|Progesterone|Progesterone oral tablet: administered orally once daily
214475823|NCT03640286|DEVICE|VeSTAL|The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.
214475824|NCT06179303|DRUG|Abemaciclib|Given PO
214475825|NCT06179303|DRUG|Anastrozole|Given PO
214475826|NCT06179303|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214475827|NCT06179303|PROCEDURE|Computed Tomography|Undergo PET/CT
214475828|NCT06179303|PROCEDURE|Diagnostic Imaging|Undergo clinical imaging for tumor assessment
214475829|NCT06179303|DRUG|Exemestane|Given PO
214475830|NCT06179303|OTHER|Fludeoxyglucose F-18|Given IV
214475831|NCT06179303|DRUG|Fluorine F 18 Fluoro Furanyl Norprogesterone|Given IV
214475832|NCT06179303|DRUG|Fulvestrant|Given IM injection
214475833|NCT06179303|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given GnRH analog
214475834|NCT06179303|DRUG|Letrozole|Given PO
214475835|NCT06179303|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214475836|NCT06179303|DRUG|Tamoxifen|Given PO
214475837|NCT06179303|DRUG|Therapeutic Estradiol|Given PO
214475838|NCT05823948|DRUG|Insulin Icodec|Participants will receive insulin icodec once-weekly subcutaneously into the thigh, upper arm or abdomen.
214848266|NCT01921231|DRUG|Hyperbaric bupivacaine 0.5%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
214475839|NCT05524116|BEHAVIORAL|Mindful Exercise program|In this 8-week intervention, components of Mindful Based Stress Reduction Program will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis. The goal of this program is to train participants how to be mindful during their exercises.
214475840|NCT05524116|BEHAVIORAL|Exercise|In this 8-week intervention, participants will be given recommended strengthening and neuromuscular exercises for knee osteoarthritis. Participants in both the intervention and control group will receive these exercises.
214848267|NCT00487331|OTHER|Acupuncture|Acupuncture sessions 1-3 times per week.
214848268|NCT00487331|BEHAVIORAL|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
214848269|NCT01177163|DRUG|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
214848270|NCT01177163|DRUG|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
214475841|NCT06779266|PROCEDURE|Suturing|Endoscopic Suturing is a technique of the wound closure after advanced endoscopic third-space resections in the upper and lower gastrointestinal tract. In this technique, the needle is held on the opposite side from the tip with the needle holder. The needle is pierced perpendicularly into the tissue at the side of the wound with an appropriate margin, then driven through the tissue with rotation and grasped at the bottom of the defect. The same steps are repeated from the middle of the wound to create a symmetrical structure.
214848271|NCT01177163|DRUG|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
214848272|NCT03569488|DIAGNOSTIC_TEST|FT-LARS questionnaire|FT-LARS questionnaire
214848273|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
214848274|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
214848275|NCT01447225|DRUG|MM-121|MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
214848276|NCT01447225|DRUG|Carboplatin|administered at AUC 6
214848277|NCT01447225|DRUG|Pemetrexed|administered IV at 500 mg/m2
214475842|NCT06779266|PROCEDURE|Clipping|Clipping is a technique of the wound closure after advanced endoscopic third-space resections I the upper and lower gastrointestinal tract. In this technique, the through-the-scope clips are delivered to the site through the working canal. The arms of the clip are properly put on the both sides of the defect and the clip is closed to seal the margins. The procedure may be repeated along the resection site for complete closure.
214475843|NCT06779266|PROCEDURE|No closure|The resection site after endoscopic submucosal dissection was left open, without additional closure.
214475844|NCT03695016|BEHAVIORAL|ActiveGOALs|13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
214475845|NCT06778356|OTHER|Built environment|Participants will complete the study session at a University student center.
214475846|NCT06778356|OTHER|Natural environment|Participants will complete the study session in a nature trail.
214475847|NCT03181516|BIOLOGICAL|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
214475848|NCT03181516|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
214475849|NCT03947112|BEHAVIORAL|Physical activity registration|At start, participants and parents fills out a Self-report questionnaire and the UngKan-3 Questionnaire, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
214475850|NCT05405985|DRUG|Nemolizumab|Nemolizumab with Auto-Injector (AI).
214475851|NCT05405985|DRUG|Nemolizumab|Nemolizumab with Dual-Chamber Syringe (DCS).
214848278|NCT01447225|DRUG|Cabazitaxel|administered IV at 20 mg/m2 or 25 mg/m2
214475852|NCT05927688|BEHAVIORAL|Therapeutic management following access by the physician to his patient's ePROs|Therapeutic management following access by the physician to his patient's ePROs
214475853|NCT06806423|PROCEDURE|Immediate Dental Implant Placement without Adjunctive Treatments|Atraumatic extractions using periotomes and anterior forceps. Osteotomy was prepared with a standardized drilling sequence under copious irrigation. ROOTT R-line implants were selected based on socket dimensions. No topical vitamin D3 was applied. Implants were placed into fresh extraction sockets.
214475854|NCT06806423|PROCEDURE|Immediate Dental Implant Placement with Topical Vitamin D Gel Application|The same procedure as the control group, with the addition of sterile topical vitamin D3 (calcitriol) gel applied to both the implant surface and osteotomy site immediately before implant placement.
214475855|NCT03635424|DEVICE|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
214848279|NCT01447225|DRUG|Gemcitabine|administered IV at 1000 mg/m2 or 1250 mg/m2
214848280|NCT00109486|DRUG|GW685698X|
214848281|NCT05966987|COMBINATION_PRODUCT|Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin|laser and platelet rich fibrin
214848282|NCT03476031|DIAGNOSTIC_TEST|renal biopsy|needle biopsy will be taken from the kidney tissue then, diagnosed
214848283|NCT05210712|DEVICE|RS001.2 Respiree Cardio-Respiratory Monitor|The RS001.2 Respiree Cardio-Respiratory Monitor is intended as a noninvasive multiparameter monitor on the adult population
214848284|NCT03666325|DRUG|Pembrolizumab|Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
214848285|NCT03666325|DRUG|Cetuximab|In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
214848286|NCT01314768|BEHAVIORAL|Brief intervention|Structured behavioural Brief intervention given by trained GPs
214848287|NCT01314768|OTHER|Business as usual|GPs to treat patient as they have until now based on best established practice
214658084|NCT06127329|PROCEDURE|BAI combine with DEB-BACE|"1. First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 \~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 \~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery."
214658085|NCT03637049|DRUG|PBI-4050 and midazolam|A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
214658086|NCT00407355|DRUG|Intravitreal injection of ranibizumab .3 dose|PRN every 30 days withing retreatment criteria
214658087|NCT00407355|DRUG|Intravitreal injection of Ranibizumab .5 dose|Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
214658088|NCT03128957|DEVICE|IVOS cerebral oximeter|Measuring percutaneous cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
214658089|NCT03128957|DEVICE|Licox cerebral oxygenation monitor|Measuring tissue cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
214658090|NCT03128957|OTHER|Cerebral oxygenation|Measuring cerebral oxygenation with varying ventilation strategy
214658091|NCT03121391|PROCEDURE|Ventilator withdrawal algorithm|"Steps and decision trees in the algorithm include in descending order:~Ascertain patient consciousness, perform cuff-leak test, evaluate for indications for pre-medication, select a withdrawal method, assess for respiratory distress with Respiratory Distress Observation Scale, medicate for respiratory distress with morphine, make an extubation decision, ascertain need for continuous morphine, ascertain need for supplemental oxygen, assess for post-extubation stridor, treat post-extubation stridor"
214658092|NCT04590001|DEVICE|MobiusHD|The MobiusHD device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
214658093|NCT01417754|DRUG|Toremifene|20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
214658094|NCT05198713|DEVICE|New hearing aid|Participants will complete testing while using a novel hearing aid which has been fit to compensate for their hearing loss.
214658095|NCT00844233|DEVICE|Irinotecan Bead|Irinotecan eluting bead
214658096|NCT06682299|DEVICE|Transmagnetic Stimulation|TMS will be given for the maintenance treatment of treatment resistant depression following successful course of ECT (8-12 treatments).
214658097|NCT06682299|DEVICE|Electroconvulsive Therapy|Patients will remain in standard of care treatment and receive maintenance ECT treatments for treatment resistant depression
214658098|NCT06420765|DRUG|VX-150|Suspension for oral administration.
214658099|NCT06420765|DRUG|VX-548|Solution or suspension for oral administration.
214658100|NCT06420765|DRUG|VX-993|Suspension for oral administration.
214658101|NCT06420765|DRUG|Placebo|Suspension for oral administration.
214658102|NCT06907732|PROCEDURE|Fetoscopic robotic open spina bifida closure|"Three 9 mm laparoscopic trocars will be inserted into the uterus after the uterus is exteriorized through a maternal laparotomy. Partial amniotic carbon dioxide insufflation will be done with heated humidified gas. Using a surgical robot, multilayer closure of the lesion will be performed, similar to our current protocol in open fetal spina bifida closure (durapatch, myofascial flap, skin closure).~Pre- and postoperative management will be similar to our current open fetal surgery protocol. Delivery will be by cesarean section, either when spontaneous labor occurs or at 39 weeks, whichever presents first."
214658103|NCT05968209|DIETARY_SUPPLEMENT|Lab4P|Multi-strain Probiotic Product: Lactobacillus acidophilus CUL-60, Lactobacillus acidophilus CUL-21, Lactobacillus plantarum CUL-66, Bifidobacterium bifidum CUL-20, Bifidobacterium animalis subsp lactis CUL-34 (total 50 billion bacteria), Vitamin D (400 IU), Vitamin C (80 mg) \& Zinc (10 mg)
214658104|NCT06918327|OTHER|Concentrated Growth Factor|Bilaterally impacted third molar of the patients are removed surgically and concentrated growth factor is placed in one of the extraction sockets.
214658105|NCT06918327|OTHER|non-CGF|The other extraction socket is left empty for control purposes.
214658106|NCT06932575|DEVICE|Andullation Therapy Bed|andullation therapy applied for 30 minutes after oocyte retrieval
214658107|NCT03311971|DEVICE|Virtual reality glasses|Patients will be treated with virtual glasses
214658108|NCT03311971|DEVICE|No VR glasses|Patients will not use VR glasses
214658109|NCT06936826|OTHER|Delphi Consensus Process|Round 1: Evaluation of current Medical Screening Tools and Scoping Review Results Round 2: Rating previous Statements from Round 1 Round 3: Consensus Round 4: Testing Content and Construct Validity of the new Medical Screening Tool with Clinical Vignettes
214658110|NCT06936800|DRUG|Pinaverium bromide|Preoperative, intraoperative, and postoperative oral administration of 100mg povidonium bromide in P-ESWL
214658111|NCT06936800|DRUG|Placebo for control group|Preoperative, intraoperative, and postoperative oral placebo 100mg for P-ESWL
214658112|NCT06935097|BEHAVIORAL|Mediterranean diet-based Intervention|"Through existing collaboration with the Harris Health system's innovative food pharmacy, participants will be provided fresh fruit, vegetables and other foods every other week during the study.~Participants will receive olive oil and walnuts during the 8 week intervention (consistent with the PREDIMED6 intervention) to supplement their (and their families') diet during the 8-week intervention (while personalized education about diet, food choices and preparation is still occurring)."
214658113|NCT06935942|BIOLOGICAL|Ustekinumab - Standard Dosage|Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous dose of 90 mg UST at week 8.Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.
214658114|NCT05372809|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
214658115|NCT05372809|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen-alginate primary wound dressing~* Local offloading with felt pad for wounds on weight bearing surfaces~* Foam~* Multi-layer compression dressing~* Off-loading device such as a full-length boot or total contact cast (if full-length boot cannot accommodate the patient) or surgical shoe for ulcers in non-weight bearing locations"
214658116|NCT06935240|DEVICE|Treatment|Nöromusculer and Transcutaneus Electrical Neuron stimulations
214658117|NCT06936995|DRUG|Preemptive Multimodal Intravenous Analgesia|Combination of opioids, NSAIDs, and adjunctive medications to manage postoperative pain before and during surgery.
214848288|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
214848289|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
214848290|NCT04306172|OTHER|An US Readmission Risk Prediction Model|Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
214848291|NCT04306172|OTHER|LACE+ score|The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
214848292|NCT04306172|OTHER|SQLAPE model|The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
214848293|NCT04691440|DRUG|Hyperbaric oxygen|The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
214848294|NCT04108962|DRUG|Fasenra, 30 Mg/mL Subcutaneous Solution|Anti-IL5 receptor alpha monoclonal antibody
214848295|NCT04718649|DRUG|Celebrex with Joins or not|The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
214848296|NCT01451996|DRUG|Claritin|Subject will be given 10mg Claritin tablet.
214848297|NCT00230191|DRUG|RK-0202|
214848298|NCT03078478|DRUG|Insulin degludec|For subcutaneous (s.c., under the skin) injection once daily
214848299|NCT03078478|DRUG|Insulin glargine|For subcutaneous (s.c., under the skin) injection once daily
214848300|NCT06396637|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride: 20mg/kg, qd
214848301|NCT04350008|DEVICE|Renamic Neo programmer device, including software; PK-222-L ECG cable|Patients were enrolled either for implantation including subsequent pre-hospital discharge or for a follow-up visit only. ICM patients were included for follow-ups only. Implants were programmed and interrogated by using the investigational devices.
214848302|NCT00905788|PROCEDURE|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
214848303|NCT03788356|DEVICE|Inspiratory muscle training|Inspiratory muscle training with a device
214848304|NCT03788356|OTHER|Diaphragmatic breathing|Diaphragmatic breathing exercise
214848305|NCT02087891|BEHAVIORAL|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
214848306|NCT02087891|BEHAVIORAL|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
214848307|NCT02087891|BEHAVIORAL|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
214906951|NCT05366166|BIOLOGICAL|Pembrolizumab|In the induction phase, participants will receive a single intravenous infusion of pembrolizumab 400 mg prior to chemoradiotherapy. In the Maintenance Phase, participants will receive pembrolizumab 400 mg every 42 days for 8 cycles.
214658118|NCT06936995|PROCEDURE|Femoral Triangle Block|Local anesthetic injection around the femoral nerve to manage postoperative pain via regional anesthesia.
214658119|NCT06950476|PROCEDURE|Oocyte Retrieval|Oocyte retrieval is performed at the end of ovarian stimulation (OS) to collect oocytes for use in IVF or ICSI cycles.
214658120|NCT06398301|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals."
214658121|NCT04857359|DRUG|Dipraglurant|Oral 50mg and 100mg tablet
214658122|NCT04857359|DRUG|Placebo|Oral matching placebo tablet
214475856|NCT04498026|DEVICE|Adherus Dural Sealant System|Adherus Dural Sealant, In situ polymerizing sealant
214475857|NCT04498026|DEVICE|DuraSeal Exact Dural Sealant System|DuraSeal Exact (P080013b)
214475858|NCT06804447|RADIATION|Proton Beam Therapy|Proton Beam Therapy
214475859|NCT05533190|DEVICE|Wysa AI chatbot mental health app|Wysa is a guided self-help and triaging tool delivered to patients via an app. It includes a chatbot and makes use of a wide range of clinically underpinned modules to provide mental health support.
214658123|NCT03949764|DRUG|Sofosbuvir/velpatasvir (Epclusa®)|The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
214658124|NCT06787651|PROCEDURE|RIMA-SVG|Saphenous vein grafts (SVGs) are connected to the right internal mammary artery (RIMA)
214658125|NCT06787651|PROCEDURE|Ao-SVG|The ascending aorta is clamped, and SVGs are anastomosed to the aorta.
214475860|NCT06077175|OTHER|hand massage group|Each individual will receive a 10-minute hand massage, 5 minutes for each hand. Since the speed and number of repetitions of the massage movements should be at normal frequency, the massage will be performed at a speed that does not disturb the individual, is not stimulating and has a calming effect, and will not tire the practitioner. In the massage, effleurage (stroking) and friction (circular rubbing) movements will be used, which have a circulation-supporting and tissue-relaxing effect. Evaluations will be made within 30 minutes after the hand massage.
214475861|NCT03261011|BIOLOGICAL|AK-104|Subjects will receive AK104 by intravenous administration.
214848308|NCT00328484|BEHAVIORAL|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
214848309|NCT00328484|BEHAVIORAL|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
214848310|NCT02339090|DRUG|Somavaratan|Somavaratan will be administered per dose and schedule specified in the arm description.
214848311|NCT02339090|DRUG|rhGH|rhGH will be administered per dose and schedule specified in the arm description.
214848312|NCT01168687|DRUG|Levetiracetam (Keppra)|"Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days."
214848313|NCT01168687|DRUG|Placebo|
214848314|NCT02123732|DIETARY_SUPPLEMENT|DbXell|
214848315|NCT02123732|DIETARY_SUPPLEMENT|Placebo|
214848316|NCT04243096|BEHAVIORAL|Exercise-based Physical Therapy|Exercises for pain modulation, strengthening, and neuromuscular control
214848317|NCT00433277|DRUG|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
214475862|NCT06466980|OTHER|Ventilator associated event|Measure of incidence of Ventilator associated event
214475863|NCT05947331|PROCEDURE|Graded Anderson procedure|In graded Anderson proceduren only recession of yoke muscles is done.
214848318|NCT02737592|DEVICE|"Trojan Simply Pleasure Personal Lubricant"|silicone base without sensate
214848319|NCT05675358|BEHAVIORAL|Virtual Reality|Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used in the study.
214475864|NCT05947331|PROCEDURE|Kestenbaum procedure|In Kestenbaum procedure, recession of yoke muscles and resection of their antagonists is done based on Parks table for Kestenbaum procedure according to the preoperative amount of head turn.
214658126|NCT06033404|PROCEDURE|Normal Clinical practice|Normal Clinical practice
214658127|NCT06123988|BEHAVIORAL|Prolonged Overnight Fasting|"Participants will undergo a 12-week program of prolonged overnight fasting (POF) during which they will abstain from consuming food or drink after 8pm, and wait 12 to 14 hours before resuming eating the next day. Participants will fast overnight for six nights each week, with one night off, and log their fasting start and stop times and timing of food intake daily via text messaging, or via study-provided app accessible by web browser or smart phone, or via paper journal returned by mail at the end of each month.~Participants will also complete one weekly session with a health coach to review their fasting log and any barriers to and/or facilitators of meeting the POF goals. Sessions may be delivered in-person, by telephone, or by video call based on participant preference. Sessions will last 15 to 30 minutes each, for a total of 12 sessions.~Participants will be provided with a notebook with information and support to encourage meeting the POF goals."
214848320|NCT00120276|DEVICE|Less invasive mitral valve repair|
214848321|NCT02722252|DEVICE|Embryoscope|
214848322|NCT02722252|DEVICE|Embryo culture system without incorporated camera|
214848323|NCT00101413|DRUG|Sorafenib (Nexavar, BAY43-9006)|BAY43-9006 400 mg bid X 28 day cycles \[Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
214848324|NCT03684681|BEHAVIORAL|Peer Navigator Intervention|A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
214848325|NCT03684681|BEHAVIORAL|Social Work Intervention|A hospital social workers uses their own previous training to help people meet their goals.
214848326|NCT00061217|DEVICE|Unrectified prosthetic socket|
214848327|NCT00061217|DEVICE|Rectified prosthetic socket|
214658128|NCT06123988|BEHAVIORAL|Moderate-Intensity Exercise|"Participants will undergo a 12-week program consisting of three weekly sessions of moderate-to-vigorous aerobic and resistance exercises, under the supervision of a health coach. Sessions may be delivered either in-person or virtually via telehealth. Sessions will be tailored to the individual participant based on fitness level and symptoms at study entry, and limited to daylight hours as much as possible. Each session will last 30 to 50 minutes, as tolerated by the participant, for a total of 36 sessions.~Participants will receive a Fitbit device to track their activity, and to provide heart rate monitoring during each session. Participants without access to wi-fi will be loaned cellular-enabled tablets to allow them to participate in telehealth sessions. Participants will also receive a notebook with information and support to encourage exercise."
214848328|NCT00955721|DRUG|Gemcitabine|Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
214848329|NCT00955721|DRUG|Oxaliplatin|Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
214848330|NCT00955721|DRUG|Sorafenib|Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
214848331|NCT02306837|DRUG|Bu-CY-E|mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
214848332|NCT05065437|OTHER|Active (Virtual reality and spinal stimulation)|Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.
214848333|NCT06905314|DRUG|HRS-4029|HRS-4029
214848334|NCT06905314|DRUG|Placebo|Placebo
214475865|NCT01917084|OTHER|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
214475866|NCT04227288|DRUG|Enstilar Foam|Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
214475867|NCT06058910|DIAGNOSTIC_TEST|Bilistick System 2.0 point-of-care testing device|The routine standard-of-care blood sample collection involves a 0.5 milliliter whole blood draw by the heel stick method for bilirubin assessments under current reference clinical methodology for total bilirubin. An additional 0.035 milliliter of whole blood will be collected for measurement in the point-of-care Bilistick System 2.0 (Bilistick point-of-care testing device). The resulting Bilistick System 2.0 data (i.e., total bilirubin) will be recorded, but will not be entered into the patients' electronic medical records or used for any diagnostic or medical decision purposes.
214475868|NCT03938246|DRUG|TVB-2640 25 mg (US)|Oral dose, tablet, daily dosing
214475869|NCT03938246|DRUG|TVB-2640 50 mg (US)|Oral dose, tablet, daily dosing
214475870|NCT03938246|DRUG|Placebo (US)|Oral dose, tablet, daily dosing
214475871|NCT03938246|DRUG|TVB-2640 50 mg (China)|Oral dose, tablet, daily dosing
214475872|NCT03938246|DRUG|Placebo (China)|Oral dose, tablet, daily dosing
214475873|NCT03938246|DRUG|TVB-2640 75 mg (US)|Oral dose, tablet, daily dosing
214475874|NCT05526443|DRUG|all approved chemotherapeutic agents from second line|all approved chemotherapeutic agents from second line
214475875|NCT05379348|OTHER|Cognitive Assessment|Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.
214475876|NCT04451772|DRUG|Elsubrutinib|Capsule; Oral
214475877|NCT04451772|DRUG|Placebo for Elsubrutinib|Capsule; Oral
214475878|NCT04451772|DRUG|Upadacitinib|Film-coated tablet; Oral
214475879|NCT04451772|DRUG|Placebo for Upadacitinib|Film-coated tablet; Oral
214475880|NCT00708448|RADIATION|PET Imaging|Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.
214475881|NCT00708448|DRUG|Erlotinib|150 mg/day
214475882|NCT00708448|DRUG|Bevacizumab|15mg/kg q 21 days
214475883|NCT02161783|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
214475884|NCT02161783|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
214475885|NCT02161783|RADIATION|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
214475886|NCT02161783|BIOLOGICAL|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
214475887|NCT06066567|DEVICE|Interferential current stimulation|IF Current parameters will be applied as follow: Amplitude modulated frequency (AMF) 30Hz, Autosweep-5 sec, Dose-15 minutes, type of current dynamic vector field (Mitra, 2006), three days per week over four weeks (Corrêa et al., 2016) and current intensity will be increased gradually, according to the subject's condition
214475888|NCT06066567|OTHER|Draw- In exercises,,|From prone position, participants will lay face down on the bed and flexed their hips and knees at 0°. A PBU will be positioned below the pubis symphysis with the decreasing edge consistent with the ASIS and will be overstated to 70 mmHg. The participants will be trained to gently draw in the lower part of the abdomen under the navel. In addition, while maintaining the neutral pelvic position, the movement of the upper part of the abdomen will be restricted so that the pressure will be decreased by approximately 10 mmHg. The participants will maintain this position for 10 s
214475889|NCT03037242|PROCEDURE|Transtibial pullout technique|Evaluating radographs
214475890|NCT06377917|OTHER|Laser Assisted Hatching|Routine assisted hatching procedure will be performed on both groups at the different embryo developmental phases.
214475891|NCT05351229|DRUG|Morphine Sulfate|5 mcg/kg intrathecal preservative free morphine sulfate
214475892|NCT05351229|OTHER|Placebo|Sterile saline, placebo
214475893|NCT01678872|DRUG|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
214475894|NCT06305013|OTHER|Pulseless electrical activity recognition|The ability of nurses to recognize the pulseless electrical activity in the questionnaire (electronic survey)
214658129|NCT06123988|BEHAVIORAL|General Health Education Sessions|Participants will receive a general health education resource manual at study entry, followed by six bi-weekly sessions with a health coach to review the information. Six topics, one topic for each session, will be selected based on topics of potential interest to a population living with advanced breast cancer, focusing on general nutrition, healthy lifestyle, and quality of life, with no discussion of prolonged overnight fasting or exercise. Each session, administered via telephone or video call, will last about 15 to 30 minutes, and have a specific topic and call script for the health coach to follow to minimize any intervention drift and/or contamination. Participants will receive a Fitbit activity monitoring device and additional study materials at the end of their participation in the study.
214658130|NCT06834035|BIOLOGICAL|Immunoglobulin G|Purified IgG from human serum, delivered via IV
214658131|NCT03274687|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214658132|NCT03274687|OTHER|Laboratory Biomarker Analysis|Correlative studies
214658133|NCT03274687|OTHER|Quality-of-Life Assessment|Ancillary studies
214658134|NCT03274687|RADIATION|Radiation Therapy|Undergo conventional radiation therapy
214658135|NCT06954220|OTHER|Baduanjin exercises|Baduanjin has 8 movement forms, which are relatively less demanding. Assistive equipment is also not necessary during Baduanjin. These advantages make Baduanjin a suitable form of exercise training for post thyroidectomy patients. The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully. In 8 movement forms of Baduanjin all include shoulder joint function exercises, thus making Baduanjin a potentially useful method for improving activity level and arm strength.
214658136|NCT06951906|DIAGNOSTIC_TEST|fMRI|Baseline imaging will utilize advanced diffusion MRI metrics to determine which brain areas are structurally connected to the stimulation target and their structural integrity. Post-operative assessments will include behavioral measures of FOG response and imaging measures of neural response to stimulation. Pre- and post-operative data will be used to evaluate the association between structural integrity, connectivity and behavioral response.
214658137|NCT05556616|DRUG|Modakafusp alfa|Modakafusp alfa intravenous infusion.
214658138|NCT05556616|DRUG|Lenalidomide|Lenalidomide capsules orally.
214658139|NCT05556616|DRUG|Bortezomib|Bortezomib injection subcutaneously.
214658140|NCT05556616|DRUG|Carfilzomib|Carfilzomib intravenous infusion.
214475895|NCT06280781|DIAGNOSTIC_TEST|MRI Scans|"The regular use of MRI in active surveillance will lead to greater confidence in active surveillance for patients with low and medium risk prostate cancer. This is because such a strategy is likely to detect cancer progression earlier with fewer invasive biopsies. Those patients randomised to the intervention arm will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI.~Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4."
214475896|NCT04724460|DRUG|Long DOAC|Administration of Rivaroxaban for 18 months
214658141|NCT05556616|DRUG|Daratumumab|Daratumumab injection subcutaneously.
214658142|NCT05556616|DRUG|Pomalidomide|Pomalidomide capsules orally.
214658143|NCT05507203|DRUG|ABX464|Administered once daily in the morning with food
214658144|NCT05507203|DRUG|Placebo|Administered once daily in the morning with food
214658145|NCT04155749|DRUG|anitocabtagene-autoleucel|Chimeric Antigen Receptor T cells
214848335|NCT06905236|BEHAVIORAL|walking intervention|Moderate intensity intermittent walking training for a period of 10 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is four times a week.
214848336|NCT06905665|DEVICE|Virtual reality group|For the VR group, the purpose of the study was explained before the procedure, and both verbal and written informed consent were obtained. Additionally, patients were provided with detailed information about how to use the headset, what to expect, and the content of the video before viewing. Data collection forms and the State-Trait Anxiety Inventory (STAI I-II) were completed using a face-to-face interview technique before the procedure.During the urodynamic procedure, an Efnan G04EA VR Shinecon 3D headset was used. The patient was positioned appropriately on the examination table, and the VR headset was fitted onto their head with a smartphone placed inside. A thin pillow was placed under the patient's head, and efforts were made to ensure their privacy and comfort. Throughout the urodynamic procedure (approximately 30 minutes),
214658146|NCT06959550|DRUG|Ivonescimab|Given by IV
214658147|NCT06369246|DEVICE|Stereotactic Body Radiation Therapy|Undergo Radiation Therapy
214658148|NCT04057105|DEVICE|Active High-definition Transcranial Direct Current Stimulation (HD-tDCS)|Stimulation sessions will be conducted once a day on 10 weekdays over a period of 2-3 weeks. Anodal HD-tDCS will be delivered either in Active or Sham mode (as per the randomized order) in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
214906952|NCT05366166|DRUG|Olaparib|In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.
214906953|NCT05366166|DRUG|Cisplatin|"In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly."
214475897|NCT04724460|DRUG|Short DOAC|Administration of Rivaroxaban for 6 months
214475898|NCT04167553|DRUG|HM15136|"In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total."
214658149|NCT04057105|DEVICE|MusicGlove|Both groups will undergo MusicGlove video-game based hand exercises.
214658150|NCT04194060|COMBINATION_PRODUCT|Enhanced Recovery after Surgery group|"* Tracheal intubation and with General anesthesia~* Short acting anesthetic agents,avoid opioid agents~* Omental patch repair with placement of sub hepatic drain~* Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~* Post operative nausea and vomiting prophylaxis.~* Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~* Initiation of feeding-Oral sips on day 1, step up day 2 onward~* Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~* Removal of urinary catheter-after weaning from the effect of general anesthesia.~* Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~* Avoid opiod analgesics."
214658151|NCT04194060|COMBINATION_PRODUCT|Conventional|"Tracheal intubation~* Short acting anesthetic agents, avoid opiod anesthesia agents.~* Omental patch repair along with sub hepatic drain placement.~* Post operative nausea and vomiting prophylaxis.~* Ambulation-as per patients' own request.~* Initiation of oral feed- after passage of 1st flatus.~* Nasogastric tube removal-output \<300ml/day with resolution of ileus.~* Removal of urinary catheter- when patient sits on bed side/ambulate.~* Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~* Patient will receive opiod analgesics."
214658152|NCT05332860|PROCEDURE|Congenital Cardiovascular Surgery|Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.
214658153|NCT02768376|DRUG|Bupivacaine with Fentanyl (Spinal Anesthesia)|Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.
214658154|NCT02768376|DRUG|General anesthesia|Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
214658155|NCT02850302|OTHER|PET with FDG|A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
214658156|NCT02850302|OTHER|Tumor exome analysis|A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
214658157|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|
214658158|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal|
214658159|NCT06144008|BEHAVIORAL|Answering questionnaire|A questionnaires for each group has been developped and will be distributed for voluntary and anonymous completion.
214658160|NCT02325674|DRUG|Metreleptin|
214658161|NCT06385886|BEHAVIORAL|Linkage Coordinator|The Linkage Coordinator (LC) will be the initial contact with unaffiliated SCD patients to establish a relationship, champion preventative services, and support them in engaging with an SCD specialist by helping patients address barriers to care. Study staff will provide initial and ongoing training to the LC to ensure they have adequate support to effectively engage with patients.
214658162|NCT06556108|BIOLOGICAL|ALPP CAR-T cells|T cells genetically engineered with a CAR targeting ALPP (ALPP CAR) that display specific reactivity against ALPP target cells
214658163|NCT06556108|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
214848337|NCT02315547|DRUG|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
214848338|NCT06904976|BEHAVIORAL|Nature-focused mindfulness|The intervention consisted of a daily 30-minute self-guided practice structured in three parts: (1) participants first walked mindfully for 10 minutes in a natural environment of their choosing (e.g., local park, forest, garden), (2) upon reaching a suitable location, they engaged in a 10-minute guided mindfulness practice, and (3) concluded with a 10-minute mindful walk back.
214848339|NCT06904976|BEHAVIORAL|Noticing-nature|Participants allocated to the noticing-nature active control group will be instructed to walk in nature for 30 minutes per day and pay attention to how the natural objects/scenes they encounter in their daily surroundings make them feel over the 14-day period.
214906954|NCT05366166|RADIATION|IMRT (intensity modulated radiation therapy)|In the chemoradiation phase, participants will receive 70 Gray external beam radiotherapy, at 2 Gray/fraction dose, 35 fractions, delivered once a day, on weekdays, using Intensity Modulated Radiotherapy Treatments or proton radiotherapy techniques, over 7 weeks.
214658164|NCT06556108|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
214658165|NCT06295146|OTHER|Intervention A: 1-on-1 wheelchair skills training by a peer coach|"Trainees will engage in 1:1 virtual zoom meetings facilitated by the study team scheduled weekly for 6 sessions with the opportunity for 2 makeup sessions. Sessions will last approximately 30 minutes and may include goal setting, review of progress, instruction, and homework of prescribed content for trainees to review. Participants may upload videos of themselves completing skills through Qualtrics to get feedback."
214658166|NCT06295146|OTHER|Intervention B: Training via educational videos|Intervention B will be a series of educational videos that participants review and then are encouraged to the practice the skills. Participants will have access to the materials for 8 weeks. Group 3 will have access to approximately 3 hours of wheelchair skills video training content. Actual viewing time will depend upon the individual's training goal. While they will receive a weekly reminder about practicing, there is no prescribed frequency for how often they should be practicing the skills in the videos.
214658167|NCT05787613|DRUG|HLX26|Anti-LAG-3 monoclonal Antibody Injection
214658168|NCT05787613|DRUG|Serplulimab|anti-PD-1 humanized monoclonal antibody injection
214475899|NCT04167553|DRUG|Placebo|"In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total."
214475900|NCT05668351|RADIATION|SUPR-SABR treatment|SUPR-SABR prescription dose to the PTV\_4000 will be 8 Gy per fraction for five fractions. The prescription dose to PTV\_3625 will be a minimum of 7.25 Gy per fraction for five fractions. SABR will be delivered 2-3 times a week, every other day. There will be a minimum of 40 hours between fractions and maximum of 128 hours between fractions.
214658169|NCT05787613|DRUG|Chemotherapy drug|non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.
214658170|NCT05787613|DRUG|Placebo|placebo
214658171|NCT06331884|DRUG|AK1967 (Procizumab)|DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
214658172|NCT06331884|DRUG|Placebo|Application of placebo
214658173|NCT02750358|DRUG|Enzalutamide|
214658174|NCT02750358|BEHAVIORAL|assessment|
214658175|NCT03539432|DRUG|Gemfibrozil 600 MG|Gemfibrozil capsules (600 mg) taken twice per day
214658176|NCT03539432|DRUG|Placebo oral capsule|Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
214658177|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 1|The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.
214658178|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 2|The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.
214658179|NCT03934645|OTHER|Early prediction model for delirium in ICU patients|The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.
214658180|NCT03427437|DRUG|Bupivacaine|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
214658181|NCT03427437|DRUG|Adrenalin|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
214658182|NCT03427437|DEVICE|Ultrasound|caudal block was performed by ultrasound method
214658183|NCT01977287|DEVICE|Functional Electrical Stimulation|
214658184|NCT01977287|DEVICE|Ankle Foot Orthosis|
214658185|NCT02986672|DIETARY_SUPPLEMENT|Calanus oil|Omega-3 oil in form of calanus oil
214658186|NCT02986672|OTHER|Medical Paraffin|2ml per day
214658187|NCT00318292|DRUG|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
214906955|NCT04987151|OTHER|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups
214475901|NCT03852758|BEHAVIORAL|Outdoor Exercise|2 outdoor exercise sessions per week
214475902|NCT03852758|BEHAVIORAL|Indoor Exercise|2 indoor exercise sessions per week
214658188|NCT00318292|DRUG|Placebo|20 ml normal saline injection.
214658189|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
214658190|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
214658191|NCT01062477|BIOLOGICAL|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
214658192|NCT03975192|DEVICE|Percutaneous Electrical Nerve Field Stimulation|Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
214658193|NCT05272514|OTHER|Hypoxia|Individuals will be exposed to varying levels of hypoxia according to the protocol detailed above.
214658194|NCT06261788|DEVICE|Temporary pacing|Transvenous temporary cardiac pacing - right internal jugular insertion
214658195|NCT00220363|DRUG|SPM 907|
214658196|NCT06318208|DIAGNOSTIC_TEST|lung function testing|lung function testing including LCI, FEV1, FVC, DLCO
214658197|NCT00824564|DRUG|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
214658198|NCT00824564|PROCEDURE|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
214658199|NCT04404335|DIAGNOSTIC_TEST|Crevicular fluid analysis by using ELISA testing.|Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)
214658200|NCT05250856|DRUG|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
214658201|NCT05250856|DRUG|Placebo|Placebo, (0.9% Sodium Chloride for IV infusion)
214658202|NCT05629702|DRUG|Nabiximols|Oromucosal spray
214658203|NCT05629702|DRUG|Temozolomide|Oral capsule
214658204|NCT05629702|DRUG|Nabiximols-matched placebo|Nabiximols-matched placebo oromucosal spray
214658205|NCT04545307|BIOLOGICAL|Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis|The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
214658206|NCT05842954|DRUG|KLU156|Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg will take a fraction of the dose according to weight group as defined in the protocol.
214658207|NCT05842954|DRUG|Coartem|Oral use. Dosing will be selected based on patient's body weight as per product's label.
214658208|NCT04726085|DRUG|Indomethacin 150mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
214658209|NCT04726085|DRUG|Ibuprofen 2400mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
214658210|NCT06656819|DEVICE|Magstim Rapid2|"AIM 1: Investigate the estradiol effect on spinal circuit excitability post afferent (sensory) mediated subthreshold motor priming in young healthy women and men.~AIM 2: Characterize the Input output property of spinal circuit excitability following descending drive (motor) mediate priming in young healthy participants~AIM 3: Examine the estradiol effect on spinal circuit excitability following descending drive (motor) mediated priming in young healthy females"
214658211|NCT03396549|DEVICE|new sham tDCS|1 ch TCT transcranial stimulator
214658212|NCT03396549|DEVICE|real tDCS|1 ch TCT transcranial stimulator
214658213|NCT02214979|DRUG|Telmisartan/Ramipril|fixed dose combination tablet
214658214|NCT02214979|DRUG|Telmisartan|
214906956|NCT04987151|OTHER|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
214906957|NCT04987151|OTHER|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
214475903|NCT06763224|OTHER|Questionnaire and Physical Exam|The neuropathic pain measured with the Neuropathic pain DN4 Questionnaire (Echelle de la Douleur Neuropathique en 4 questions - Neuropathic Pain Scale in 4 questions) The global pain measured with Visual Analogue Scale (VAS) The patient's permanent functional disability measured with the Oswestry disability index (ODI) The quality of life measured with the questionnaire EuroQol-5 Dimension (EQ-5D-5L)
214475904|NCT06350981|DRUG|Exparel|20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine
214475905|NCT06350981|DRUG|Bupivacain|Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL
214475906|NCT05730621|DRUG|Sarpogrelate Sustained Release/Aspirin|Aspirin 100mg qd and Sarpogrelate Sustained Release 300mg qd for 12 weeks
214658215|NCT02214979|DRUG|Ramipril capsule|
214658216|NCT02214979|DRUG|Ramipril tablet|
214658217|NCT06960135|PROCEDURE|open partial nephrectomy|open partial nephrectomy
214658218|NCT06960135|PROCEDURE|laparoscopic partial nephrectomy|laparoscopic partial nephrectomy
214658219|NCT03446677|OTHER|Postural Stability Testing|Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks. Data of center of pressure, antero-posterior sways and medial-lateral sways were collected in each of the conditions. Each task took 30 seconds to be performed. The first 4 tasks were performed with the mat on the hard surface of the floor. These 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving head upward and downward, and standing with eyes closed and the head actively moving upward and downward. The subjects were asked to perform four more tasks while standing on a thick piece of balance foam that was placed on top of the MatScan®. The remaining 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving the head upward and downward, and standing with eyes closed with head actively moving upward and downward.
214658220|NCT05303454|BEHAVIORAL|Cartoons|cartoons were found to be effective in reducing children's pain and fear levels.
214658221|NCT05303454|BEHAVIORAL|musical-moving toys|musical-moving toys were found to be effective in reducing children's pain and fear levels.
214658222|NCT05387356|OTHER|prone position|thirty-one patients who had a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. Medical datas of the patients will be obtained from patients' files which are strictly filled during pandemic. Prone position indication of intensive care unit (ICU) is in case of severe ARDS with PaO2/FiO2 \<150 despite a PEEP \>10 cmH2O.
214658223|NCT00864760|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
214475907|NCT05730621|DRUG|Aspirin|Aspirin 100mg qd for 12 weeks
214475908|NCT04832958|DRUG|99m-TC-PSMA-I&S|"* 99mTc-PSMA-I\&S intravenous injection the day before surgery~* 99mTc-PSMA-I\&S SPECT/CT imaging~* 99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations"
214475909|NCT04561492|DRUG|[68Ga]Ga-PentixaFor|Tomography by emission of positons (PET) with theradiopharmaceutic \[68Ga\]Ga-PentixaFor
214475910|NCT06106204|OTHER|ROAD Home Intervention|Hospitals randomized to receive the ROAD Home Intervention will undergo (1) a baseline needs assessment to create a customized suite of stewardship strategies, (2) supported decision-making in selecting ROAD Home strategies to implement, and (3) external facilitation following an implementation blueprint.
214475911|NCT04789551|OTHER|Blood Sample|a blood sample will be collected
214475912|NCT05463913|DRUG|18F-FDG|Patients will receive a single intravenous injection of 3 MBq/kg 18F-FDG
214475913|NCT05463913|RADIATION|PET/CT imaging|Patient will undergo 2 CT acquisitions and multiple PET emission scans.
214475914|NCT06305117|OTHER|Distraction strategy|Distraction strategy combining the use of virtual reality and music
214658224|NCT00864760|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
214658225|NCT00476086|DRUG|Gemcitabine|
214658226|NCT00476086|DRUG|Oxaliplatin|
214658227|NCT00476086|RADIATION|Radiation|
214658228|NCT02427061|BEHAVIORAL|Intervention Program (Manhood 2.0)|
214475915|NCT03477435|BEHAVIORAL|Staff training and academic detailing|Both arms will receive training at baseline to help their patients quit smoking. The training will be a mix of content and process education. We will provide brief updates to staff every 6 months throughout the intervention period, which will focus primarily on process education. We will monitor which staff attend and reach out separately to staff who did not. During the month after implementation of the clinical reminders, two study investigators will make a brief outreach visit to each staff member. We will follow a script, using the seven steps recommended by the National Resource Center for Academic Detailing: 1) Introduction; 2) Needs Assessment; 3) Key Messages/Features/Benefits; 4) Understanding Barriers and Enablers; 5) Identifying and Handling Objections; 6) Summary; and 7) Close. The key message (Step 3) will include demonstration of the clinical reminder, review of the evidence for telephone counseling and text messaging and how to refer patients.
214475916|NCT02787031|PROCEDURE|Neuraxial anesthesia|
214475917|NCT02787031|PROCEDURE|General anesthesia|
214475918|NCT06212791|BEHAVIORAL|Self- Report Evaluation-Duke Activity Status Index|Complete the Self- Report Evaluation-Duke Activity Status Index
214475919|NCT06212791|BEHAVIORAL|Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire|Complete the Self- Report Evaluation, Atrial Fibrillation Effect on Quality of Life Questionnaire
214475920|NCT06212791|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise test (CPET)
214475921|NCT06212791|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Transthoracic echocardiogram at rest and immediately following peak exercise during CPET
214475922|NCT06212791|DIAGNOSTIC_TEST|Ambulatory cardiac rhythm assessment|Ambulatory cardiac rhythm assessment
214475923|NCT06212791|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) study at rest and during two stages of submaximal exercise (ExeCMR)
214475924|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
214475925|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
214475926|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
214475927|NCT06646055|DRUG|AK112, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
214475928|NCT06646055|DRUG|nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
214475929|NCT06308575|DRUG|Rivoceranib|Given by PO
214475930|NCT04278339|OTHER|Evoked Related Potentials|Evoked Related Potentials are measured by means of electroencephalography. During this measure, 2 informatic task will be performed to evaluated evoked related potentials.
214475933|NCT06083766|BEHAVIORAL|hormone therapy|Determine how gender affirming hormone therapy affects muscle physiology
214475934|NCT06167213|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
214475935|NCT05717400|DRUG|Bevacizumab|Given by vein (IV)
214475936|NCT05717400|DRUG|Atezolizumab|Given by vein (IV)
214475937|NCT05717400|DRUG|Sofosbuvir|Given by PO
214475938|NCT05717400|DRUG|Velpatasvir|Given by PO
214475939|NCT05717400|DRUG|Voxilaprevir|Given by PO
214475940|NCT05717400|DRUG|Ribavirin|Given by PO
214658229|NCT02427061|BEHAVIORAL|Control Program (Job Skills Training)|
214658230|NCT04178590|DRUG|SRP + Injectable Platelet-Rich Fibrin|Injectable Platelet-Rich Fibrin application as adjunct to scaling and root planing
214475943|NCT05663801|DRUG|Use of Bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and patients will be given 30 mL of 0.25% bupivacaine hydrochloride and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
214475944|NCT05663801|DRUG|use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
214658231|NCT04178590|DRUG|SRP + placebo|Saline application during scaling and root planing
214658232|NCT06786767|DRUG|BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg|As this is a non-interventional study, it is accordance with routing clinical practice. The assignment of patients to Trimbow 172/5/9 mcg should be made independently from the study.
214658233|NCT05067088|OTHER|CPAP (all patients receive CPAP as part of routine clinical care)|Continuous positive airway pressure
214658234|NCT06139770|BEHAVIORAL|Family based therapy- Metacognitive therapy|Family based therapy and Metacognitive therapy
214658235|NCT06161116|BIOLOGICAL|MK-6194|SC Injection
214658236|NCT06161116|BIOLOGICAL|Placebo|SC Injection
214658237|NCT02601417|OTHER|Ignoring result of bile culture|the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group
214658238|NCT05388357|OTHER|Intervention Procedure: PCI|Percutaneous Coronary Intervention
214658239|NCT03445481|DEVICE|Medacta femoral prosthesis|patients' treatment with a new implant prosthesis
214906958|NCT05243160|OTHER|medication review|The intervention consist of a medication review by a clinical pharmacologist.
214906959|NCT00122382|DRUG|Abatacept|abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
214906960|NCT00122382|DRUG|placebo|placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
214658240|NCT06850298|OTHER|Pasteurized milk contaminated with killed A(H5) virus|Milk to be used in the study will be obtained from the CDC. Pasteurized commercial milk likely to contain detectable A(H5N1) particles will be obtained from a source such as a recently affected dairy farm. The CDC Influenza Division laboratory (Viral, Surveillance, and Diagnosis Branch) will test the milk to confirm the presence of viral A(H5) RNA using a protocol developed and validated by the US FDA Agricultural Research Service. The US Food and Drug Administration (FDA) has indicated that the consumption of commercial pasteurized dairy products in the US is safe.
214658241|NCT06432959|BEHAVIORAL|Psychotherapy, Positive Affect Promoting Activities|"The specific activities that constitute the positive affect interventions will be determined by the therapist and participant collaboratively. Some examples of positive affect promoting activities are:~* Watch videos of animals and babies~* Eat a piece of candy~* Recall and describe a past positive experience~* Describe the positive attributes of the participant~* Engage in gratitude practice~* Do something nice for someone~The in-session positive affect activities will last approximately five minutes. For the first four weeks, the positive affect activities will be completed at the beginning of the session. After that, therapists will look for opportunities to incorporate positive affect activities at stuck points or before learning a new skill in-session. Additionally, therapists will work with participants to identify ways in which the participants can incorporate positive affect activities into their lives between sessions."
214658242|NCT06432959|BEHAVIORAL|Psychotherapy|Meet with treatment providers individually or in group to learn skills to address symptoms associated with depression and emotion dysregulation
214658243|NCT04666207|DIAGNOSTIC_TEST|PCR|RT-PCR for SARS-CoV-2
214658244|NCT02292849|BEHAVIORAL|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
214658245|NCT02292849|OTHER|Standard Mental Health Referral|Standard mental health referral to a community agency
214658246|NCT02623179|OTHER|culture versus Molecular diagnostics|Treatment based on the results of the FH C \& S testing - Odd Numbers on randomization table
214658247|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
214658248|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
214658249|NCT04274296|DEVICE|Activation of Advisory|Advisory is activated which will show if driving pressure is greater or equal 15
214658250|NCT02479347|DRUG|Chlorhexidine|Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
214658251|NCT02479347|DRUG|Povidone-Iodine|Preoperative skin preparation with povidone-iodine 10% aqueous solution
214658252|NCT01849926|DRUG|Ibuprofen|
214658253|NCT01849926|DRUG|Mecillinam|
214658254|NCT02883699|BEHAVIORAL|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
214658255|NCT02883699|BEHAVIORAL|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
214658256|NCT02883699|BEHAVIORAL|Standard resistance training|Machine based hypertrophy training 2 x per week
214658257|NCT02883699|BEHAVIORAL|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
214658258|NCT04957888|OTHER|none intervention|none intervention.
214658259|NCT04561505|PROCEDURE|Holmium laser enucleation of prostate|surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation
214658260|NCT04561505|PROCEDURE|monopolar transurethral resection of prostate|surgical management of BPH by monopolar TURP using distilled water for irrigation
214658261|NCT05731960|DRUG|Dexamethasone|10 mg IV dexamethasone provided immediately after spinal anesthesia
214658262|NCT05731960|DRUG|Metoclopramide|10 mg IV metoclopramide provided immediately after spinal anesthesia
214658263|NCT05383820|DRUG|Ketorolac|The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
214658264|NCT04791384|DRUG|Abemaciclib|taken orally
214658265|NCT04791384|DRUG|Elacestrant|taken orally
214658266|NCT02016014|DEVICE|Smartphone with APP|Smartphone with APP (EVIDENT) for 3 months
214658267|NCT02016014|BEHAVIORAL|Counseling on lifestyles|Counseling on physical activity and mediterranean diet
214658268|NCT00251602|DRUG|Atropine|One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
214658269|NCT00251602|DRUG|Propranolol|One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
214658270|NCT00251602|DRUG|Normal Saline|One-time 0.25 ml/min infusion over 30 minutes
214658271|NCT00886938|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
214658272|NCT03492164|DRUG|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
214658273|NCT04407715|PROCEDURE|The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater|The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.
214658274|NCT01689558|DRUG|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
214658275|NCT00002025|DRUG|Ganciclovir|
214906961|NCT00122382|DRUG|methotrexate|Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
214848340|NCT06905080|DEVICE|Catheter Caps Case (C3)|The nursing team will then assess the participant's catheter, catheter site, and lumens. The C3 device will be placed on the distal lumens and hub caps of the participant's hemodialysis catheter using clean technique and left in place for approximately 15 minutes. During this time, the participant will be asked to lay, sit, and stand while wearing the C3 device. The RN will stay with the participant during the entire time and will write down any comments or requests regarding the C3 made by the participant. After 15 minutes, the nursing team will remove the C3 device and reassess the condition of the catheter site and lumens, noting any changes. Finally, the participant will complete a 10 item post- intervention survey, developed by the study team and evaluated for face validity by all members of the team to provide feedback on the design of the C3 device.
214848341|NCT01117844|RADIATION|Proton Radiation|Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
214848342|NCT02331238|BEHAVIORAL|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
214848343|NCT02435316|OTHER|Case vignette-based teaching of cell recognition|Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
214848344|NCT02435316|OTHER|Compare-contrast basic science teaching of cell recognition|The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
214848345|NCT04222114|DRUG|Catumaxomab|The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.
214848346|NCT04222114|DRUG|The treatment of investigator choice|the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
214848347|NCT02247050|BEHAVIORAL|Commitment invitation|Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
214848348|NCT02406638|OTHER|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
214848349|NCT06002217|DRUG|Levobupivacaine|Patients in the tap block arm will receive an injection of levobupivacaine 2.5mg/ml
214848350|NCT06002217|OTHER|Placebo Tap block|Patients in the placebo arm will receive an injection of salin solution 2.5mg/ml , in the same way as tap block
214848351|NCT06185972|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
214848352|NCT06185972|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
214289992|NCT05508191|DEVICE|Fractional CO₂ Laser|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMIⓇ fractional CO₂ laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
214475945|NCT05663801|DRUG|Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL 0.25% Bupivacaine hydrochloride plus Magnesium Sulfate ( 28 ml Bupivacaine 0.25% plus 2ml magnesium sulfate 50%) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
214475946|NCT05505825|DRUG|AK104 IV infusion；Chiauranib oral|AK104 IV infusion once every 3 weeks；Chiauranib once a day oral
214475947|NCT06163274|DEVICE|Placebo Intravaginal Ring A|Placebo Intravaginal Ring A consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 40A (Shore A hardness scale). The ring holds two blank grey cassettes.
214475948|NCT06163274|DEVICE|Placebo Intravaginal Ring B|Placebo Intravaginal Ring B consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 50A (Shore A hardness scale). The ring holds two blank grey cassettes.
214475949|NCT03401840|RADIATION|postoperative hypofractionated stereotactic radiotherapy|total dose of 36Gy in 6 fractions over 11-13 days
214475950|NCT01895842|DRUG|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."
214658276|NCT00364793|DRUG|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|"Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)"
214658277|NCT03423355|DRUG|Dapagliflozin (Forxiga®)|10mg p.o. daily
214658278|NCT03423355|DRUG|Hydrochlorothiazide 25 mg|25mg p.o. daily
214658279|NCT03423355|DRUG|Placebo matching Dapagliflozin|Placebo matching Dapagliflozin p.o. daily
214658280|NCT02397252|DEVICE|Eve Medical self-collection system©|The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
214658281|NCT02397252|DEVICE|cobas® PCR Female swab self-sampling|Regular polyester swab for collection of vaginal cells.
214658282|NCT02397252|PROCEDURE|Physician-collected sampling|Routine colposcopy sample collected by a physician.
214658283|NCT05393154|DEVICE|Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner|Microscopic viewing and imaging of Bronchoscopic Biopsy Specimens using Full Field Optical Coherence Tomography and Dynamic Cell Imaging
214658284|NCT03037294|DIETARY_SUPPLEMENT|Preoperative protein supplementation|Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
214658285|NCT00972608|OTHER|Anatomic Reconstruction and Surgical Planning|Standard of care patient-images will be acquired and used to construct a model of the patient anatomy. The model will then be used to simulate surgical options and allow the surgeon to visually evaluate the optimal approach.
214289993|NCT05508191|DEVICE|Microneedle|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPenⓇ dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
214658286|NCT05902585|BEHAVIORAL|Virtual reality|In the virtual reality group, patients will view a video with the virtual reality glasses from the beginning to the end of the venipuncture.
214658287|NCT00310310|BEHAVIORAL|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
214658288|NCT00310310|BEHAVIORAL|Usual care|Usual sleep apnea and cpap care
214658289|NCT06076044|DEVICE|toDCS 2mA 1Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 1Hz.
214289994|NCT05935852|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses
214475951|NCT03631290|BEHAVIORAL|Deprescribing Intervention|"The deprescribing program was implemented as a clinical quality improvement project for patients receiving dialysis. Patients taking specific potentially inappropriate medications (PIMs) were identified in the medical record. The PIMs of interest included gabapentinoids, clonidine, alpha blockers, muscle relaxants, and Z-drugs. If their nephrologist agreed to attempt deprescribing the PIM, either the nephrologist (Provider Only Communication) or a study team member (pharmacist or nurse, Provider/Patient Communication) would engage the patient in discussion about deprescribing. This discussion included patient education materials about the risk of the medication. If the patient agreed, they were provided taper instructions (if indicated) and were followed up at 1 month and 3 months.~The patient was also invited to enroll in a study to be interviewed about the deprescribing decision and experience, and undergo brief assessment of geriatric problems at baseline and at 3 months."
214475952|NCT03718637|BIOLOGICAL|Smith & Nephew Bioinductive Implant|A bioinductive implant that is supposed to foster healthy tendon regrowth after surgery.
214475953|NCT03718637|PROCEDURE|Lateral Epicondylectomy|This procedure is the standard of care for lateral epicondylitis patients who fail conservative treatment options.
214475954|NCT03718637|RADIATION|Ultrasound Imaging|An ultrasound will be performed on each patient both preoperatively and at 6 months.
214475955|NCT05575882|OTHER|Skin hydration|Skin hydration outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
214475956|NCT05575882|OTHER|Barrier function measurement|TEWL measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
214475957|NCT05575882|OTHER|Potential of hydrogen measurement (pH)|pH measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
214475958|NCT05575882|OTHER|Clinical evaluation of atopic dermatitis|EASI score on each visit. Non invasive technique.
214658290|NCT06076044|DEVICE|toDCS 2mA 10Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 10Hz.
214658291|NCT06076044|DEVICE|tDCS 1mA|The subgroup treated by transcranial direct current stimulation of 1mA.
214658292|NCT06076044|DEVICE|sham|The subgroup treated by sham stimulation.
214658293|NCT05041738|PROCEDURE|Intraoral Cryotherapy|small ice packs wrapped in sterile gauze placed in the mouth on the vestibular surface of the treated tooth
214658294|NCT05041738|PROCEDURE|Intracanal Cryotherapy|Intracanal cryotherapy technique using 2.5°C cold saline irrigation as final irrigant
214658295|NCT04740957|OTHER|Distal limb reintroduction of ileostomy effluent|"Patients will undergo water soluble contrast enema to confirm anastomotic healing 8 weeks post operatively as per standard practice at Imperial.~Patients will be educated in how to reintroduce ileostomy output to the distal (downstream) loop of their ileostomy. They will be asked to reintroduce 50ml of ileostomy output using a conventional long-tipped bladder syringe daily until surgery to close the stoma."
214658296|NCT03615092|PROCEDURE|Root coverage with extended flap technique and acelular dermal matrix|At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
214658297|NCT05527925|DEVICE|MRI|Brain testing of patients using MRI
214658298|NCT01065935|DRUG|ALN-RSV01|Administered by nebulization once daily for 5 days
214658299|NCT01065935|DRUG|Normal Saline|Administered by nebulization once daily for 5 days
214906962|NCT01099592|DRUG|Citalopram|All patients will take citalopram once daily. Medication will be commercial tablets of 20 mg or 40 mg. All patients will start on a half dose of 10 mg and, if there are no severe side effects, will be increased to 20 mg after 1 week, and if the HAMD-24 at 6 weeks is not \< 8, the dose will increase to 40 mg.
214848353|NCT06471595|BEHAVIORAL|Partnership for Improving Lifestyle Intervention (PILI) Lifestyle Program + Social Determinants of Health (SDOH) Component|The PILI Lifestyle Program (PLP) is an adapted 3-month behavioral lifestyle intervention focused on addressing and initiating weight loss in Native Hawaiians and Pacific Islanders (NHPIs). The PLP covers 8 lessons that offer empirically supported strategies (e.g., plate method, stimulus control) based on the social cognitive theory to improve healthy eating, physical activity, and time and stress management across the 3 months. In this study, the PLP will be enhanced with social determinants of health (SDOH) components that address challenges such as access to healthy foods, housing, and employment issues. There will be 4 SDOH activities relevant to participants' needs and lives. These activities will be delivered during the 3-month PLP.
214848354|NCT04974736|BEHAVIORAL|iEHR + Navigator|"The iEHR + Navigator intervention consists of an iEHR part of the intervention in the pediatric primary care setting which will include routine screening of families for tobacco use and treatment delivery to parents who smoke and will be linked to the child's electronic health record.~The enrolled parents will also be offered support from Community Health Navigators, who will work with offices to provide customized cessation support to tobacco users, ensuring access to medications and services."
214848355|NCT04757181|OTHER|The IBD-AID|Subjects will meet with study personnel for to fill out baseline questionnaires (approximately a 1-hour visit). Subjects will be instructed to make dietary changes based one the IBD-AID guidelines. Dietary instruction will be delivered via individual and group sessions led by trained study personnel. Participants will be expected to learn the skills of dietary change to the IBD-AID and will begin their 8 weeks compliance period followed by endpoint measures. Participants are encouraged to attend 3 cooking classes (1.5 hours duration) in our teaching kitchen.
214848356|NCT03581188|DEVICE|Patient-led surveillance|Usual care plus reminders, ASICA instructional videos, a mobile dermatoscope, an app that facilitates store-and-forward teledermatology, and fast-tracked unscheduled clinic visits.
214848357|NCT03581188|BEHAVIORAL|Clinician-led surveillance|Usual care (scheduled clinician visits)
214848358|NCT03938415|PROCEDURE|Acupuncture|Acupuncture involving the Koffman protocol (body acupuncture) for anxiety control (needles will be placed at bilateral LR-3, bilateral LI-4, GV 24.5 and GV 20) and Auricular ATP Plus (ear) for pain control (needles will be placed at points hippocampus, amygdala, hypothalamus, prefrontal cortex, Point Zero, Shen Men, vagus, insula, external genitalia). Subjects who tolerate the auricular needles will be offered replacement with ASP acupuncture needles for continued pain management post-procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
214289995|NCT05426577|DIAGNOSTIC_TEST|ELISA, LAMP, Cytokine Release Assay|"IgG1 ELISA: ELISA that employs soluble Leishmania lysate or protein antigen.Results are recorded as antibody titres, which are measured by the absorbance values of products generated using enzyme conjugated anti-human antibodies.~Cytokine release assay (CRA): In this assay whole blood is stimulated for 24 hours with leishmania antigen. Cytokine levels are then assessed in the plasma fraction using flow cytometry with the BD™ Cytometric Bead Array for Human Cytokines or standard ELISA kits for human cytokines commercialized by Sigma-Aldrich (RAB0268-IL-2, RAB0222-IFN-g, RAB0224-IL-10, RAB0476-TNF-a, RAB0119-IP-10).~LAMP test for VL: We will use the LoopampTM Leishmania Detection Kit, CE-marked and produced Eiken Chemical Co., Japan."
214475959|NCT05575882|OTHER|Quality of life assessment|Cardiff questionnaires to assess quality of life of subjects and their family members.
214475960|NCT05575882|OTHER|Assessment of the effect on itching and sleep disturbances|Visual analogue scale from 0 to 10
214475961|NCT05575882|OTHER|Assessment of the tolerance of the study product or placebo|By collection of Adverse Events (AEs) on daily log and electronic Case Report Form (eCRF).
214475962|NCT05920889|DRUG|Semaglutide|0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
214475963|NCT05268081|OTHER|Virtual specialist conferences|"The intervention consists of four virtual conferences (45 min each in month 2, 5, 8 and 11) and an introductory webinar (90 min in month 1) to learn GPs about how to use the electronic Diabetes Overview to identify and manage patients with T2D. Each general practice is assigned to one specific endocrinologist they meet with throughout. The four virtual conferences are thematic: T2D and cardiovascular disease and heart failure, T2D and lipids, T2D and kidney disease and blood pressure, and T2D and a free topic selected by the GP. At each conference, the GP must bring 2-3 patient cases related to the theme and 1-2 patients of their own choice. The GP chairs the meeting. Each conference follows the same format: Check in (5 min); Short presentation by the endocrinologist (10 min); Presentation by GP and joint dialogue about theme-related patients (20 min); Presentation by GP and joint dialogue about theme-unrelated patients (optional, 5 min); (5) Wrapping-up (5 min)."
214475964|NCT02828358|DRUG|Azacitidine|Given IV
214475965|NCT02828358|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214475966|NCT02828358|PROCEDURE|Computed Tomography|Undergo CT scan
214475967|NCT02828358|DRUG|Cyclophosphamide|Given IV
214475968|NCT02828358|DRUG|Cytarabine|Given IV, SC, IT
214475969|NCT02828358|DRUG|Daunorubicin|Given IV
214289996|NCT02756689|OTHER|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
214475970|NCT02828358|DRUG|Daunorubicin Hydrochloride|Given IV
214475971|NCT02828358|DRUG|Dexamethasone|Given PO, NG, IV
214475972|NCT02828358|PROCEDURE|Echocardiography|Undergo ECHO
214475973|NCT02828358|DRUG|Hydrocortisone Sodium Succinate|Given IT
214475974|NCT02828358|DRUG|Leucovorin|Given PO, IV
214475975|NCT02828358|DRUG|Leucovorin Calcium|Given PO, IV
214475976|NCT02828358|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214475977|NCT02828358|DRUG|Mercaptopurine|Given PO, NG
214475978|NCT02828358|DRUG|Methotrexate|Given IT, IV, PO
214475979|NCT02828358|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214475980|NCT02828358|DRUG|Pegaspargase|Given IV
214475981|NCT02828358|DRUG|Prednisolone|Given PO, NG
214475982|NCT02828358|DRUG|Thioguanine|Given PO, NG
214475983|NCT02828358|DRUG|Vincristine|Given IV
214475984|NCT02828358|DRUG|Vincristine Sulfate|Given IV
214848359|NCT03938415|OTHER|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone (which include diazepam 5 mg by mouth (PO) x1 30 minutes prior to the procedure, an additional 5 mg PO x1 15 minutes later if desired effect is not achieved; and oxycodone/acetaminophen 5/325 mg PO x 1 30 minutes prior to the procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
214289997|NCT02756689|OTHER|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
214289998|NCT06204744|OTHER|Home-based GRASP program|The home-based Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve the upper extremity function for people with stroke, including exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
214658300|NCT04234438|DEVICE|SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)|Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
214658301|NCT04732663|OTHER|No Intervention|Cross-sectional study, no intervention.
214658302|NCT01179295|DRUG|BAY86-9766|BAY86-9766 30 mg twice a day (bid).
214658303|NCT01179295|DRUG|BAY86-9766|BAY86-9766 50 mg twice a day (bid).
214658304|NCT01179295|DRUG|BAY86-9766|BAY86-9766 100 mg once a day (od)
214658305|NCT01179295|DRUG|BAY86-9766|BAY86-9766 60 mg once a day (od)
214658306|NCT00363415|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
214658307|NCT00363415|DRUG|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
214658308|NCT00363415|DRUG|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
214658309|NCT04802837|DRUG|Ridinilazole|Ridinilazole 200mg dosed BID for 10 days.
214658310|NCT04802837|DRUG|Vancomycin|Vancomycin 125mg dosed QID for 10 days.
214658311|NCT00117767|DRUG|Terbinafine hydrochloride (HCl)|Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
214658312|NCT00117767|DRUG|Griseofulvin|Griseofulvin pediatric suspension o.d. administration
214658313|NCT04945655|OTHER|Adolescents and parents' education and motivation at school (component 1)|"The component 1 includes first an information group session (duration: 1h30) on HPV infection and vaccination for parents. This session starts with a webconference delivered by two medical experts on HPV, using a standardized presentation. Then, a discussion is open for parents' questions and/or comments.~Second, adolescents participate during the school time to two educational group sessions on HPV infections and vaccination, using a pedagogy based on active learning. These sessions (duration: 2h each) are delivered by the school staff (e.g., nurse, teacher in life sciences) using an educational package comprising: a guide that describes activities that should be implemented during each session; one video and a fact sheet developed by health students; a serious video game that promotes HPV vaccination and accessible on an internet website. Before the sessions, the school staff is encouraged to attend an e-learning training course (duration: 1 hour)."
214658314|NCT04945655|OTHER|General practitioners' training (component 2)|The component 2 consists of an individual e-learning training session for general practitioners (GPs) that is accessible on computer and smartphone. Lasting 3 hours, GPs are able to access to the training whenever they want and then to progress at their own pace. The training includes three main parts: up-dated information on HPV infection and vaccination; an introduction to the use of motivational interviewing techniques in the field of vaccination; and a presentation of the decision aid tool developed as part of the intervention and explanation of how to use it during consultations. GPs may ask questions to the consortium team by using a dedicated chat.
214658315|NCT04945655|OTHER|Access to vaccination at school (component 3)|The component 3 aims at enhancing access to HPV vaccination for adolescents by offering them the first free-of-charge injection at school, without any medical prescription. For each concerned school, we organise a vaccination day inside the school premises where health professionals (one physician and one nurse) from the local vaccination centre initiate HPV vaccination with Gardasil-9® (in accordance with the French recommendations) for all eligible adolescents.
214289999|NCT06204744|OTHER|Conventional occupational therapy home program|The conventional OT home program will be prescribed by the occupational therapists, customizing stroke rehabilitation exercises to individual patient goals, with a primary focus on improving upper extremity function.
214290000|NCT05546645|OTHER|Questionnaire|Hypersecretion questionnaire
214290001|NCT02060149|DRUG|C/S plus minocycline.|Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
214290002|NCT02060149|DRUG|nebulization with pH 7.4 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
214658316|NCT01722006|BEHAVIORAL|Pairing condition|
214658317|NCT01722006|BEHAVIORAL|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
214658318|NCT00997074|DRUG|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
214658319|NCT05449392|DRUG|Neosporin|Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
214848360|NCT05692076|DEVICE|High Velocity Nasal Insufflation|High-flow humidified oxygen with flow rates from 30 to100 L/min with high fraction of inspired oxygen( FiO2) is able to be delivered.
214848361|NCT02503475|OTHER|Real-Time fMRI|"Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements."
214848362|NCT02503475|BEHAVIORAL|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
214848363|NCT02503475|DEVICE|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
214290003|NCT02060149|DRUG|nebulization with pH 7.8 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
214290004|NCT02060149|DRUG|No nebulization|No nebulization will be given to the patients.
214290005|NCT00433095|DRUG|Navelbine|
214290006|NCT00433095|DRUG|Herceptin|
214290007|NCT00433095|DRUG|Navelbine (oraly)|
214290008|NCT01743053|DEVICE|Standard Care plus ReCell|
214658320|NCT05449392|OTHER|Vaseline|The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
214658321|NCT01969656|DRUG|2MD|
214658322|NCT01969656|DRUG|Calcitriol|
214658323|NCT01969656|DRUG|Placebo|
214658324|NCT04475094|DRUG|Rubidium-82|Consented subjects will undergo a rest/regadenoson stress myocardial perfusion PET study.
214658325|NCT04475094|BEHAVIORAL|Seattle Angina Questionnaire-7|Consented subjects will complete a SAQ-7.
214658326|NCT04475094|BEHAVIORAL|Rose Dyspnea Scale|Consented subjects will complete a RDS.
214658327|NCT05022446|OTHER|Survey Administration|Complete survey
214658328|NCT01128985|DRUG|Canagliflozin 50 mg|50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
214658329|NCT01128985|DRUG|Canagliflozin 100 mg|100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
214658330|NCT01128985|DRUG|Canagliflozin 300 mg|300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
214658331|NCT01128985|DRUG|Placebo|matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
214658332|NCT00188188|DRUG|quinipril|
214658333|NCT05988814|DRUG|FOLFIRINOX treatment|"Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression"
214658334|NCT06962878|PROCEDURE|Xenograft|The jumping gap and surrounding space will be augmented and packed with Xenograft
214658335|NCT06962878|PROCEDURE|Allograft|The jumping gap and surrounding space will be augmented and packed with Allograft
214658336|NCT06960954|DIAGNOSTIC_TEST|Prothrombin induced by vitamin K absence II (PIVKA-II)|Serum PIVKA-II level will be measured in HCC patients with and without PVTT.
214658337|NCT03963583|BEHAVIORAL|HEROIC|"The HEROIC intervention will include individualized, nurse-led sessions focused on;~1. a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~2. discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~3. co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~4. 'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals."
214658338|NCT06483074|DRUG|Empagliflozin 10 MG|empagliflozin oral 10mg daily for 6 months
214658339|NCT06577675|BEHAVIORAL|Group programme for DBT training|This programme comprises 16 sessions over approximately 5 to 6 months, with one 2.5-hour session every week in a closed group of 8 patients. These sessions will be supervised by two or four carers trained in DBT.
214658340|NCT05027802|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day.
214658341|NCT06498895|RADIATION|lung ultrasound|"Lung ultrasound score will be done within one hour of admission,12 hours post admission then 24 hours in intensive care unit,follow up of patients will continue for 72 hours .~a complete lung ultrasound evaluation will be performed using low frequency curved probe (2MHz-5MHz) according to the lung ultrasound score . The external lung fields will be examined by longitudinal and transverse plane scans, dividing the surface of the thorax into 12 zones: 6 on the right (anterior: upper R1 and lower R2; lateral; upper R3 and lower R4; posterior: upper R5 and lower R6) and 6 on the left side (front: upper L1 and lower L2; lateral: upper L3 and lower L4; rear: upper L5 and lower L6). LUS assigns 0 points to A lines or \< 2 separate B lines plus regular sliding; 1 point with lines B ≥ 3 or spaced focal points plus regular sliding; 2 points with coalescing B lines, and 3 points to pulmonary consolidations for each zone with a score ranging from 0 (normal lungs) to 36 (worst case scenario)"
214658342|NCT04318366|OTHER|Observational Study|Not required
214848364|NCT03064438|DRUG|ACCU-D1|ACCU-D1
214848365|NCT03064438|DRUG|Vehicle|Placebo Comparator
214848366|NCT01937351|DEVICE|Pantheris System|Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
214848367|NCT01961687|DEVICE|Resorbable Mesh|Phasix Mesh
214848368|NCT02107222|DEVICE|CO2-Removal (PALP-Device/MaquetCP)|extracorporeal circuit to remove CO2 out of the blood
214848369|NCT02997137|DIETARY_SUPPLEMENT|BOT-01|"Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
214290009|NCT01743053|OTHER|Standard Care|
214290010|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
214290011|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
214290012|NCT05553002|OTHER|Deneroll cervical extension traction|"Participants will lie flat on their back on the ground with their legs extended and arms by their sides. The denneroll will placed on the ground and positioned in the posterior aspect of the neck depending on the area to be addressed . The apex of the Denneroll orthotic will be placed in one of three regions based on lateral cervical radiographic displacements:~1. In the upper cervical region (C2-C4) region.~2. The apex of the Denneroll orthotic is placed in the mid-cervical region (C4-C6) region.~3. The apex of the Denneroll orthotic is placed in the upper thoracic lower-cervical region (C6-T1) region."
214848370|NCT02997137|OTHER|Placebo|"Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
214848371|NCT02284347|DEVICE|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
214848372|NCT01505361|BIOLOGICAL|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
214848373|NCT01505361|BIOLOGICAL|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
214848374|NCT04649489|DRUG|Atezolizumab|atezolizumab 1200mg and bevacizumab 15mg/kg
214848375|NCT04649489|PROCEDURE|Surgery|hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg
214848376|NCT03185182|DRUG|Ioflupane I123|"185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution."
214848377|NCT01562626|DRUG|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
214848378|NCT01562626|DRUG|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
214848379|NCT01562626|DRUG|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
214848380|NCT06617091|DRUG|GRAdHIVNE1 Vaccine|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
214848381|NCT06617091|OTHER|Placebo|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
214848382|NCT06163872|BEHAVIORAL|survey study|survey study
214848383|NCT02972021|DEVICE|High-flow nasal cannula|
214848384|NCT05477719|DEVICE|Wearing of specific compression stockings|The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body
214848385|NCT04328870|OTHER|oxytocin and spinal anesthesia|start oxytocin 10 IU/200 ml saline at the insertion of the spinal anesthesia
214290013|NCT05553002|OTHER|Traditional treatment|The participants will receive hot packs (15 minutes) and TENS therapy .During TENS application. Patients will be asked to adopt a prone position. The TENS therapy will be delivered at the lumbosacral region for 20 min. The frequency will set to 80 Hz and pulse width to 50 µs due to its analgesic effect . These conventional treatments will be repeated three times per week over the course of 10 weeks for 30 total sessions
214290014|NCT00150722|DRUG|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
214848386|NCT04328870|OTHER|General anesthsia|General anesthesia alone.
214848387|NCT02971722|DRUG|JY09|2mg/1ml/bottle
214848388|NCT02971722|DRUG|Placebo|1ml/bottle
214848389|NCT01789957|DRUG|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
214848390|NCT00401167|DRUG|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
214290015|NCT03971890|OTHER|Dance therapy|The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.
214290016|NCT03971890|OTHER|Educational group|The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
214290017|NCT03232021|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
214290018|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
214290019|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
214290020|NCT02592174|OTHER|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
214290021|NCT02592174|OTHER|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
214290022|NCT02592174|RADIATION|cerebral images sub-study|Standard magnetic resonance imaging
214290023|NCT00876629|DEVICE|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.~The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
214290024|NCT03053414|DIETARY_SUPPLEMENT|Vitamin D (ergocalciferol and/ or cholecalciferol)|To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
214290025|NCT04360954|DIAGNOSTIC_TEST|Diagnostic test|There is no intervention. This study will test deidentified archived biosamples.
214848391|NCT01301482|DEVICE|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
214475985|NCT05268276|OTHER|1-perineal ice-gel pad application|For the study group Immediately after delivery (within 30 minutes to one hour after delivery), an ice gel pad will be applied to perineal trauma. each gel pad will have fixed standardized diameter (an approximately 5 cm width, 23 cm length, and 1.5 cm thickness) and approved by Egyptian ministry of health. It will be kept in the freezer for 45-60 minutes and will be removed when frozen. Then, it will be wrapped in a sterile pad and applied to cover the perineum and anal region.The investigator will provide a clear and concise information through oral and written instructions about the following; 1) The ice gel pad's purpose, benefits, anticipated effects and how to apply it, 2) Apply the ice gel pad on perineum after birth within 30 minutes to an hour, 3) Instruct the women to apply the ice gel pad for about 20 minutes every two hours during the first 24 hours postpartum only
214658343|NCT03797560|OTHER|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-health-care Qigong exercise that has been practiced by Chinese people for at least eight hundred years. It consists of eight sets of simple movements. By combining meditation with slow, graceful movements, deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear, previous clinical trials have demonstrated that Ba-Duan-Jin can improve sleep quality, physical health, and mental health in patients with various chronic diseases"
214848392|NCT01272089|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
214848393|NCT02269956|BEHAVIORAL|12 week feasibility study|: At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
214848394|NCT06404541|DRUG|Dexamethasone, tobramycin, netilimicin|Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose
214848395|NCT00480324|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
214848396|NCT00480324|BIOLOGICAL|Placebo|Two-dose oral administration.
214848397|NCT03105934|PROCEDURE|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
214475986|NCT05268276|OTHER|2-performance of pelvic floor exercises (Kegel exercises)|women will receive instructions to practice pelvic floor exercises (Kegel exercises) and will be asked to perform these exercises from 6 hours postpartum and continue at home till one week. Before applying the technique, the investigator will teach the women how to recognize the accurate muscle, whereby she imagines holding passing gases or trying to stop the flow of urine midstream at the same time. The women will be taught to insert a clean finger into the vagina before practicing the exercises and if the women feeling pressure around her finger, she is on the right track, . The investigator will perform vaginal examination while the woman is doing the pelvic floor exercises (Kegel exercises) to ensure correct use of muscles. The investigator will instruct the women to continue contracting the muscles for about 5 seconds and then to loosen them for 5 seconds and repeat it for five times each set, perform at least five sets per day
214475987|NCT05268276|OTHER|3- perineal warm compresses application|women will be instructed to apply warm compresses on perineal trauma 48 hours postpartum at home. This will be done by using a clean pad soaked in warm water and squeezed to remove excess water then placed gently on the perineum, the warm compresses will be applied for 15 minutes three times per day (every 8 hours), and water in the bowl will be replaced with every application. Women will be asked to apply warm compresses on perineal trauma from 48 hours postpartum till one week.
214475988|NCT06520423|PROCEDURE|Urethral stent tube irrigation|During urethroplasty, a Fr3 ureteral catheter will be placed in the reconstructed urethra, with the proximal end extending approximately 2 cm beyond the urethral wound. The distal end will connect to an F6 single-lumen ureter and a urinary bag. On the second postoperative day, the urethra will be irrigated with 5 ml of saline twice daily. This irrigation routine will continue until the catheter is removed.
214475989|NCT06520423|PROCEDURE|Urinary catheter drainage|During urethroplasty, intraurethral retention of urethral catheters is used to drain urine from the bladder.
214475990|NCT06407297|DRUG|UCMSCs|Peripheral intravenous infusion of umbilical cord mesenchymal stem cells
214475991|NCT06407297|DRUG|Placebo|Peripheral intravenous infusion of Placebo
214475992|NCT05958537|DEVICE|High flow nasal oxygen|Use of High-flow nasal oxygen at 60% 50 L/min.
214475993|NCT06359587|BEHAVIORAL|Laboratory test overuse (LTO) Bundle|"Key Components of the LTO Bundle:~Educational materials, including an online module, clinical decision support tool, provision of lab utilization (Audit and Feedback) reports for healthcare providers.~Patient engagement tools, such as videos and educational infographics. System level implementation tools adapted to the local context, including EMR-based tools and order set changes, etc."
214475994|NCT05395299|PROCEDURE|SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )
214475995|NCT05766943|DEVICE|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
214475996|NCT05766943|DEVICE|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
214475997|NCT04165772|DRUG|TSR-042 or Dostarlimab|Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
214475998|NCT04165772|DRUG|capecitabine or 5-FU|Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
214658344|NCT03797560|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
214658345|NCT05898074|DEVICE|Non-Absorbable Packing (Silastic Splint)|Participant will have silastic splint applied to nasoseptal flap harvest site
214658346|NCT05898074|DEVICE|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site
214658347|NCT06059586|BEHAVIORAL|Pelvic health therapy|Female Sexual Function Index (FSFI) and VAS Pain Scale Questionnaires, Physical Therapy Evaluation including Pelvic Floor Muscle Examination, Dilator Education
214658348|NCT06059586|DEVICE|Dilator feasability|Patient Adherence to Vaginal Dilation Questionnaire
214658349|NCT03826875|DRUG|Fluoxetine|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life
214658350|NCT03826875|DRUG|Placebo|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life
214658351|NCT04889274|BIOLOGICAL|COVID-19 vaccine|COVID-19 vaccine as offered by NHS England
214658352|NCT04889274|BIOLOGICAL|Concentrate beetroot Juice|Beetroot juice containing approximately 5mmol/l nitrate
214658353|NCT04889274|BIOLOGICAL|Nitrate-deplete beetroot juice|Beetroot juice with nitrate removed
214658354|NCT06093672|DRUG|Givinostat|Oral. The dosage must be modified, according to the manifestation of toxicities or lack of efficacy, with the aim to achieve an optimized dose.
214658355|NCT06093672|DRUG|Hydroxyurea|Oral. The dosage must be modified, according to the manifestation of toxicities or lack of efficacy, with the aim to achieve an optimized dose.
214658356|NCT05755386|DRUG|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
214658357|NCT05755386|DRUG|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
214658358|NCT05344833|DRUG|Isatuximab|Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.
214658359|NCT05344833|DRUG|Lenalidomide|Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression.
214658360|NCT06121232|DEVICE|Abbott® DRG / Abbott®/Medtronic® SCS|Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.
214658361|NCT06121232|OTHER|Control Group|Participants will not receive any intervention
214658362|NCT02884635|DRUG|ASP1707|Oral
214848398|NCT04359537|DRUG|Hydroxychloroquine Sulfate 200 MG|Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described
214848399|NCT04359537|OTHER|Placebo|Control group will receive a Placebo tablet. Placebo 200mg will be given on Day 1 followed by Placebo 200mg every three weeks.
214658363|NCT02884635|DRUG|Placebo|Oral
214848400|NCT04403516|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.
214848401|NCT04403516|DRUG|Prednisolone Acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
214290026|NCT01624454|OTHER|Laxabon|4 l PEG solution split dose cleansing
214290027|NCT01624454|OTHER|CitraFleet|Small volume osmotic bowelcleansing
214290028|NCT00913367|DRUG|glimepiride + insulin glargine (Amaryl + Lantus)|"* Amaryl® 4 mg at breakfast + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
214658364|NCT02884635|DRUG|Methotrexate|Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
214658365|NCT03872180|DRUG|Bendamustine|Given IV
214658366|NCT03872180|BIOLOGICAL|Obinutuzumab|Given IV
214658367|NCT03872180|DRUG|Venetoclax|Given PO
214658368|NCT03733041|DEVICE|rTMS|This group will receive rTMS treatment
214658369|NCT03733041|DEVICE|Sham|This group will receive sham treatment
214658370|NCT03733041|OTHER|No intervention|This group will receive no intervention
214658371|NCT01506141|DRUG|Idursulfase-IT|Idursulfase-IT once monthly via IDDD.
214658372|NCT01506141|DRUG|Elaprase|Weekly IV infusions of commercially available Elaprase.
214658373|NCT05561751|DRUG|GPC-100|GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min
214658374|NCT05561751|DRUG|Propranolol|propranolol
214658375|NCT05561751|DRUG|G-CSF|G-CSF
214658376|NCT06408363|BEHAVIORAL|Maneuver group|These maneuvers for Eustachian tube opening will be performed continuously during the compression phase of the hyperbaric chamber, every 30 minutes after reaching the desired pressurization level, and continuously during the decompression phase.
214658377|NCT04677647|OTHER|OurChild mHealth Digital Platform|The intervention being created and tested in this study is OurChild an integrated mHealth/EHR app, initially designed for the Chinese American community in Sunset Park, Brooklyn. All participants will be assigned to either beta versions undergoing development, or to version 1.0.
214658378|NCT04607408|BIOLOGICAL|CH505TF gp120|HIV-1 CH505 transmitted/founder virus Env gp120 immunogen
214658379|NCT04607408|BIOLOGICAL|GLA-SE adjuvant|An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)
214658380|NCT04607408|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9% USP
214658381|NCT05910892|DRUG|Aromatherapy packet|5 deep breaths from packet prior to treatment
214658382|NCT05910892|DRUG|Placebo packet|5 deep breaths from packet prior to treatment
214848402|NCT00388934|DEVICE|Drug eluting stent|percutaneous intervention with implantation of drug eluting coronary stent
214848403|NCT03550534|DRUG|Calcium Carbonate|Calcium carbonate was obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
214848404|NCT03550534|DRUG|Placebo oral capsule|Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
214848405|NCT02327793|DRUG|Nitroglycerin|
214658383|NCT04726748|PROCEDURE|Comparisons between the Prostatic urethral lift (PUL) and the TURP/Laser cohorts|"Comparison between the PUL and the TURP/Laser cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables."
214658384|NCT04726748|PROCEDURE|Comparison between the Prostatic urethral lift (PUL) and the SNDS cohorts|"Comparison between the PUL and the SNDS cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables."
214658385|NCT04986007|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia is an automated, internet-based delivery system for the core components of cognitive behavioral therapy for insomnia (CBT-I). For this trial, dCBT-I will be delivered using Sleep Healthy Using the Internet (SHUTi), which delivers the core content of CBT-I in 6 interactive lessons called Cores: Getting Ready; Sleep Scheduling; Sleep Practices; Thinking Differently; Sleep Hygiene; and Moving On. The primary therapeutic approaches deployed through these cores are stimulus control and sleep restriction. The minimum acceptable dose for this study is completion of 4 out of 6 cores; completion of fewer than 4 cores will be considered a dropout.
214658386|NCT06304233|DIAGNOSTIC_TEST|Echocardiography|ultrasound assessment of heart structure, volume and function
214658387|NCT06304233|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|MRI assessment of heart structure, volume, function and tissue characteristics
214658388|NCT06304233|DIAGNOSTIC_TEST|Electrocardiography|Assessment of cardiac rhythm and electrical activity
214658389|NCT06304233|OTHER|Blood sampling|To measure DISC1 mRNA expression and other potential biomarkers
214658390|NCT04497285|OTHER|blood sample collection and collection of tumor tissue block|blood sample collection and collection of tumor tissue block
214658391|NCT05491200|DRUG|Prasugrel based short DAPT|Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus
214658392|NCT05491200|DRUG|Prasugrel based standard DAPT|Prasugrel based DAPT for 1 year
214658393|NCT05491200|DEVICE|OCT guided revascularization|OCT guided revascularization of the non-culprit lesions
214658394|NCT05491200|DEVICE|Angio guided revascularization|Angio guided revascularization of the non-culprit lesions
214658395|NCT06334939|DEVICE|Bispectral Index Monitoring|"Study patients will undergo perioperative bispectral index and BIS suppression ratio (SR) monitoring under anesthesia. The lowest BIS and BIS SR values and the values taken at 10-minute intervals will be recorded throughout the case.~The Richmond agitation scale will be calculated in the recovery room after anesthesia."
214658396|NCT05848622|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
214658397|NCT05848622|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
214290029|NCT00913367|DRUG|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|"* Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
214658398|NCT06043817|DRUG|STX-721 (Escalated)|STX-721 dose will be escalated per cBLRM-design.
214658399|NCT06043817|DRUG|STX-721 (3 dose levels)|Participants will receive STX-721 at one of two dose levels.
214658400|NCT06043817|DRUG|STX-721 (RP2D)|Participants will receive the RP2D of STX-721.
214658401|NCT04845347|DEVICE|Bright Light Therapy|Participants will be provided with active, unaltered Re-Timer glasses that will be worn in the morning daily for 60 minutes for 5 weeks on study.
214848406|NCT02327793|DRUG|Labetalol|
214848407|NCT03297567|BEHAVIORAL|verbal guidance and a booklet|Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
214848408|NCT01552369|DRUG|Valganciclovir|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
214658402|NCT04845347|DEVICE|Dim Light Therapy|Participants on this arm will wear the placebo version of the Re-Timer fitted with neutral density filters. These will be worn in the morning daily for 60 minutes for 5 weeks on study.
214658403|NCT05698732|DEVICE|Coroflex® ISAR NEO coronary stent system|Patients in whom treatment with Coroflex® ISAR NEO coronary stent system has been attempted
214658404|NCT04586504|DRUG|Intranasal midazolam|5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.
214658405|NCT06035887|DIAGNOSTIC_TEST|Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated)|RETEval Complete hand-held electroretinogram
214658406|NCT06035887|DIAGNOSTIC_TEST|Trolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated)|UTAS multifocal electroretinogram
214848409|NCT04514055|PROCEDURE|De-epithelialized connective tissue graft wall|A de-epithelialized free gingival connective tissue graft will be used to treat Cairo's recession type 2 and type 3 associated with inta-bony defects
214848410|NCT00401284|DRUG|EVT 201|
214848411|NCT06417164|BEHAVIORAL|Functional Movement Training Group|The program control group will use traditional physical training methods, while the experimental group will use a training program based on FMS functional movement design. The experimental group will receive a 12-week FMS functional movement training intervention, with each session lasting 40 minutes. The experimental group will be divided into two phases, a corrective intervention phase and a capacity enhancement phase, and the main assessment criteria will include the seven movements of the FMS Functional Movement Test (squat, hurdle step, deep squat, shoulder mobility, active straight leg raise, trunk stabilizing push-ups, and trunk rotational stabilization), as well as the ability to control the body's dynamic and static postures during aerobic exercise.
214848412|NCT02619448|DRUG|Carboplatin|chemotherapy
214658407|NCT06035887|DIAGNOSTIC_TEST|Spectral-Domain Optical Coherence Tomography (Standard of Care test)|Heidelberg Engineering Spectralis Spectral-Domain Optical Coherence Tomography (macular structural scan)
214658408|NCT06035887|DIAGNOSTIC_TEST|Macular Autofluorescence (Standard of Care test)|Heidelberg Engineering Spectralis Autofluorescence imaging (macular structural image)
214658409|NCT03279094|BIOLOGICAL|Hematopoietic stem cell transplantation|Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
214658410|NCT05899322|BEHAVIORAL|Primary Care Intervention for PTSD Spanish Speaking Adolescents|This treatment ranges from 1-3 sessions which last 30-50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the adolescent with optional parent involvement. The first session will also teach the adolescent a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the adolescent's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that address the adolescent's symptoms. This treatment will be delivered via telehealth and all materials have been developed in both Spanish and English.
214658411|NCT05899322|BEHAVIORAL|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
214658412|NCT05444959|DIETARY_SUPPLEMENT|HMB supplementation|Group taking oral HMB free acid supplementation in a blinded liquid form.
214658413|NCT05444959|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (in a blinded liquid form).
214658414|NCT04443348|RADIATION|Radiation Therapy Boost|Participants randomized to the low-dose or high-dose RT boost group will be receiving treatment on Day 1-3 of Cycle 1 of pembrolizumab. Proton therapy may be used in the high dose RT group.
214658415|NCT04443348|DRUG|Pembrolizumab|"Neoadjuvant Phase: Day 1 (once every 6 weeks) of Cycles 1-4 (by intravenous infusion) over about 30 minutes.~Adjuvant Phase: Pembrolizumab may be given post-surgery for up to 4 cycles (once every 6 weeks) by intravenous infusion over about 30 minutes. Pembrolizumab after surgery is optional and should be discussed with the study doctor."
214658416|NCT04443348|DRUG|Paclitaxel|Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes.
214658417|NCT04443348|DRUG|Carboplatin|"Carboplatin is optional for TNBC patients and should be discussed with the study doctor.~Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes."
214658418|NCT04443348|DRUG|Cyclophosphamide|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion).
214658419|NCT04443348|DRUG|Doxorubicin|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion). Doxorubicin will be administered after pembrolizumab.
214658420|NCT04443348|DRUG|Capecitabine|"Capecitabine after surgery is optional for TNBC patients and should be discussed with the study doctor.~Starting 3-6 weeks after surgery, administered orally twice daily for 6 courses, each 3 weeks long (for a total of 18 weeks)."
214658421|NCT05414071|DEVICE|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
214658422|NCT03896763|OTHER|Either supine or prone positioning and either CMV or HFOV|"Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver."
214658423|NCT05085366|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline)
214658424|NCT05085366|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214658425|NCT06213883|OTHER|Biobehavioral Response to in-lab exposure to physical activity|ED severity, biological and affective markers of physical activity response, and both exercise-specific and general positive (reward) and negative (avoidance/escape) valence sensitivities associate with physical activity will be comprehensively examined.
214848413|NCT02619448|DRUG|Paclitaxel|chemotherapy
214848414|NCT02619448|RADIATION|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
214848415|NCT05686148|OTHER|Vibration|The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.
214848416|NCT04933786|BEHAVIORAL|Digital Health Nudging|Short daily text messages with information and motivation concerning physical activity.
214848417|NCT03380520|DRUG|Ferric Carboxymaltose|Ferric carboxymaltose will be administered according to product specification dosing
214848418|NCT03380520|DRUG|Placebo|IV nacl 0.9%
214658426|NCT05416060|BEHAVIORAL|Dulce Digital Text-Based Education|Participants will be enrolled in the digital texting platform, Dulce Digital in which they will receive on-going support via text messages for 6 months, derived from the Project Dulce curriculum. Topics include medication reminders, motivational prompts, nutrition and stress reduction tips and request to submit weekly blood glucose numbers.
214658427|NCT05416060|BEHAVIORAL|Project Dulce Telehealth|Project Dulce will consist of a group-based telehealth diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
214658428|NCT05416060|BEHAVIORAL|Project Dulce Live|Project Dulce will consist of a group-based diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
214658429|NCT05469984|DRUG|Ampicillin Only Product|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
214658430|NCT05469984|DRUG|ampicillin plus gentamicin|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
214658431|NCT06379347|DIAGNOSTIC_TEST|POCUS performed on clinical indication|POCUS performed on clinical indication
214658432|NCT05286047|DIETARY_SUPPLEMENT|Bifidobacterium longum CCFM1029|Subjects take one capsule containing Bifidobacterium longum CCFM1029 daily at bedtime.
214658433|NCT05286047|DIETARY_SUPPLEMENT|Placebo|Subjects take one capsule containing maltodextrin daily at bedtime.
214658434|NCT05949580|DEVICE|MS Care Platform (icobrain ms and icompanion ms)|"The MS care management platform consists of the following components:~1. icobrain ms which is a a cloud-based solution to quantify brain volume and brain abnormalities and changes thereof on MRI scans;~2. icompanion ms which consists of free participant mobile application (app) and a web portal for HCPs.~The information collected in the icompanion ms patient app and icobrain ms is then brought together in the icompanion ms HCP web portal which allows a comprehensive overview of disease data for every single participant."
214658435|NCT06508892|BEHAVIORAL|risk of fall|Gather information that will assist in determining risk of fall. The researchers will ask the subjects to perform several motor tests and study-related questionnaires.
214658436|NCT02725788|DEVICE|New PIV Dressing|A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
214658437|NCT02725788|DEVICE|Standard PIV Dressing|A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
214658438|NCT05275101|BEHAVIORAL|Crisis Response Planning|Individuals complete an experimental collaborative suicide intervention.
214658439|NCT05275101|BEHAVIORAL|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
214848419|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
214848420|NCT01578668|DRUG|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
214290030|NCT00331279|DRUG|Oral Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
214658440|NCT05543681|DRUG|IGC-AD1-Active|A non-sterile solution for oral administration.
214658441|NCT05543681|DRUG|IGC-AD1-Placebo|A non-sterile solution for oral administration similar in color and texture to the Active.
214658442|NCT06334367|DRUG|CD25 treatment|CD25 prophylaxis
214848421|NCT01578668|DRUG|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS\<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
214848422|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
214290031|NCT00331279|DRUG|Placebo|Placebo pills in likeness of the cinnamon extract
214290032|NCT04737343|DRUG|Leflunomide|Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months
214290033|NCT04737343|DRUG|Azathioprine Tablets|Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
214290034|NCT00013429|PROCEDURE|Visual|
214290035|NCT01500161|DRUG|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
214290036|NCT01500161|DRUG|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
214290037|NCT01500161|DRUG|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
214848423|NCT06614660|OTHER|Metabolism genomics and imaging genomics|Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\&#39;s blood specimen was collected to collect metabolism genomics and imaging genomics.
214848424|NCT01546324|PROCEDURE|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
214475999|NCT04165772|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
214476000|NCT05955846|PROCEDURE|cataract surgery|Subjects will undergo surgery to remove cataract (natural cloudy lens) via phacoemulsification implant the IOL Both eyes will be treated one month apart. Subjects will be followed up during 12 months
214476001|NCT05955846|DEVICE|implantation of device IOL FG-80030.1|implant the IOL in both eyes. Both eyes will be treated one month apart. Subjects will be followed up during 12 months
214476002|NCT03068390|BEHAVIORAL|RICHH Intervention|Whole health cardiovascular disease (CVD) self-care risk reduction intervention
214476003|NCT03068390|BEHAVIORAL|Usual care|Referral to primary care provider
214476004|NCT06401954|DEVICE|High-intensity focused electromagnetic therapy|"High-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is set to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
214476005|NCT06401954|BEHAVIORAL|Foot core training|"Foot core training will consist of 4 exercises with 10 repetitions per set and 3 sets per session for each exercise.~Twice a week for a total of six weeks."
214476006|NCT06401954|DEVICE|Sham high-intensity focused electromagnetic therapy|"Sham high-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is unable to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
214476007|NCT05099133|DRUG|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
214476008|NCT05099133|DRUG|LEO 138559 Placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
214476009|NCT05224544|DEVICE|Investigational device|The test product is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
214476010|NCT05224544|DEVICE|Comparator|The comparator is a urinary catheter for bladder drainage through the urethra.
214476011|NCT05837169|OTHER|Mindfulness-based stress reduction|The control group will be assessed with the study surveys at baseline, will not receive MBSR intervention for the following 8 weeks, and will subsequently be reassessed with the study surveys at the same time points as the intervention group. At the end of the recruitment and follow-up of all the participants, the study will end and the control group will be able to receive the MBSR intervention free of charge according to the preference of the participants.
214476012|NCT04784494|DEVICE|Magnetic Seizure Theapy (MagPro XP MST)|"MST treatment will be administered over the frontal/vertex cortex using 100 Hz stimulation using the MagPro XP MST with Cool TwinCoil. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~MST treatments will be administered twice a week, for up to 16 treatments. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
214476013|NCT04804540|DRUG|Vedolizumab IV|Vedolizumab IV infusion
214476014|NCT03340675|DRUG|Ifetroban|Weight based, once daily oral ifetroban
214658443|NCT06334367|DRUG|low-dose ATG|HSCT pre-treatment with 7.5mg/Kg ATG(2.5mg/Kg/d) at day -4, -3 and -2.
214658444|NCT02292823|DEVICE|MGuard™ Prime Embolic Protection Stent System|
214658445|NCT00828464|DRUG|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
214658446|NCT04285060|DEVICE|Samsung GEMS-H|Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
214658447|NCT03007264|DEVICE|Cold Atmospheric Plasma|CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
214658448|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
214658449|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
214658450|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
214658451|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
214658452|NCT00809133|DRUG|BIBW2992|MTD dose of part A
214658453|NCT00809133|DRUG|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
214658454|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
214658455|NCT00809133|DRUG|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
214658456|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
214658457|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
214658458|NCT03420534|DRUG|Iloperidone 1 MG|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
214658459|NCT03420534|DRUG|Placebo|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
214848425|NCT06446310|DRUG|QLG2198|Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
214848426|NCT06446310|DRUG|Placebo|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis
214848427|NCT05618535|DEVICE|Transcranial Doppler.|"Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler."
214476015|NCT03340675|DRUG|Placebo|Matching oral placebo
214848428|NCT01316419|DRUG|Telmisartan|Telmisartan 40mg or 80mg
214848429|NCT01316419|DRUG|amlodipine|amlodipine 5mg or 10mg
214848430|NCT02999984|GENETIC|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
214848431|NCT02999984|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
214476016|NCT05172232|DIAGNOSTIC_TEST|Dermalyzer|To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
214476017|NCT05332613|BEHAVIORAL|TRE plus SOC|Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
214476018|NCT05332613|BEHAVIORAL|SOC|Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
214476019|NCT05332613|BEHAVIORAL|TRE|Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
214476020|NCT06198725|DIETARY_SUPPLEMENT|Trimtab|High fiber group will take Trimtab (a kind of multi bran and high fiber grain compound powder) 60g per day to intake 28g dietary fiber for 12 weeks.
214476021|NCT03740282|DEVICE|Lapiplasty|Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.
214476022|NCT03632798|DIAGNOSTIC_TEST|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
214476023|NCT03632798|DRUG|Chemotherapy|"Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel."
214476024|NCT01828021|BIOLOGICAL|Margetuximab|Anti-HER2 monoclonal antibody
214476025|NCT03964363|BEHAVIORAL|Unsupervised home-based physical prehabilitation|Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
214476026|NCT00844415|DRUG|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
214476027|NCT04943445|DRUG|carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
214476028|NCT04943445|RADIATION|Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
214476029|NCT04943445|DRUG|Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.|Consolidation immunotherapy
214476030|NCT06822023|DEVICE|virtual reality mask|Patients will be prepared as per the standard routine clinical care; they will then be wearing the VR mask for 10 minutes. No other study have looked into VR mask prior to cataract surgery
214476031|NCT03555422|DRUG|Selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
214476032|NCT03555422|DRUG|Matching placebo for selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
214476033|NCT05966181|BEHAVIORAL|experimental group|"Experimental Group-Repetitive Simulation~* First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~* Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation."
214476034|NCT06166498|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
214476035|NCT06166498|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
214476036|NCT06821659|BIOLOGICAL|anti-CD19 CAR-T cells|UWD-CD19
214476037|NCT06756243|OTHER|Hydrogen Ion Water（Shan Shang Water）|Hydrogen Ion Water (also known as Hydrogen-Rich Water or Hydrogen Water) refers to water that contains dissolved hydrogen gas (H₂). Hydrogen gas is a powerful antioxidant that is believed to neutralize free radicals in the body, which may help reduce oxidative stress and improve overall health.
214476038|NCT06756243|DRUG|Budesonide Nasal Spray therapy|Budesonide Nasal Spray: Administered as 2 sprays twice daily (bid).
214848432|NCT02999984|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
214848433|NCT04645979|OTHER|Online survey|Participants will be invited to complete an online questionnaire about their experience of product use.
214848434|NCT05402306|OTHER|Treatment group|Group metacognitive therapy, mainly with attention training technique over two weeks.
214848435|NCT03363477|DRUG|Enoxaparin|
214848436|NCT03363477|DRUG|Clexane|
214848437|NCT01304420|DEVICE|Ultrasonography|Scanning 5 joints bilaterally with an ultrasound scanner
214848438|NCT00513552|DRUG|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
214848439|NCT01556282|DEVICE|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
214848440|NCT00347529|BIOLOGICAL|pPML7789 with and without pPJV2012 administered by PMED|
214848441|NCT03609281|RADIATION|Ultrasound assessement of uterine scar|3D ultrasound assessment of scar characteristics
214476039|NCT04844294|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT is divided into three phrases. In phase I (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills such as relaxation and mindfulness. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
214476040|NCT04844294|BEHAVIORAL|Present-Centered Therapy (PCT)|PCT includes (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions. PCT differs from BCBT in several key ways including less structure (i.e., patients are allowed to have more input into PCT session agendas) and no systematic training in behavioral or cognitive strategies for managing emotions and changing suicide-focused thoughts. PCT will be used as an active comparator because it is an empirically supported treatment for depression and PTSD that also reduces suicidal ideation (Bryan et al., 2016; Resick et al., 2017), but contains unique elements that distinguish the treatment from BCBT.
214476041|NCT06245135|BEHAVIORAL|TIME at Home|"Sessions involve a 15-minute pre-video safety check and social time; streaming a 1-hour pre-recorded exercise video; and a 15-minute post-video social time. Two trained facilitators run each class, with a maximum group size of 10 people.~The 1-hour exercise videos include a seated warm-up and cooldown, and 40 minutes of functional, self-paced exercises. In the video, 2 healthcare professionals demonstrate a lower and higher difficulty level of each exercise. The program starts with a level 1 video and switches to a level 2 video midway.~A registered healthcare professional, called the healthcare partner, visits select classes and serves as a resource to participants and facilitators."
214476042|NCT03406351|OTHER|Observational|Observational deep phenotyping physiological readouts
214476043|NCT06429956|BEHAVIORAL|Mindful emotion awareness|"The mindful emotion awareness module will follow the manual by Barlow et al. (2018). In session 1, the participant will receive psychoeducation about the purpose of mindful emotion awareness (i.e., to cultivate present-focused, non-judgmental attention to one's emotional experiences) and will complete an in-session guided meditation exercise which they will be asked to practice daily using an audio file. In session 2 and 3, two additional exercises are introduced. With mindful mood induction, the participant is instructed to induce emotions and then practice mindful emotion awareness in this context. With anchoring in the present, the participant is taught four steps to help them use mindful emotion awareness to pull themself back to the present whenever they feel an emotional response start to build in their everyday life. For homework, the participant will practice mindful emotion using these exercises and the audio file."
214476044|NCT06429956|BEHAVIORAL|Cognitive flexibility|The cognitive flexibility module will follow the manual by Barlow et al. (2018) which is based on the principles by Beck (1976). In session 1, the participant will be psychoeducated about the purpose of cognitive flexibility (i.e., to encourage flexible thinking through reappraisal of one's automatic thinking), and how their thoughts influence their emotional reactions. For homework, the participant will be asked to monitor their automatic thoughts. In session 2, the participant will be introduced to the technique of cognitive flexibility (i.e., generating other possible interpretations), and this technique will be practiced throughout session 2 and 3. For homework, the participant will continue to monitor their automatic thoughts and generate and record other possible interpretations.
214476045|NCT02473445|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
214476046|NCT04881461|DRUG|5-grass mix SLIT-drops|Sublingual allergy immunotherapy drops, for daily administration
214476047|NCT04881461|DRUG|Placebo|Placebo
214476048|NCT06250374|PROCEDURE|Bilateral trans-cranial Doppler ultrasound|Velocity measurements in the middle cerebral artery are made using an ultrasound probe applied to the patient's temple during surgery.
214476049|NCT03015532|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), via instillation
214476050|NCT03015532|DRUG|Saline Placebo|Saline placebo via injection
214476051|NCT03015532|DRUG|Bupivicaine HCl|Bupivacaine HCl without epinephrine
214476052|NCT03015532|DRUG|Ropivacaine|Ropivacaine, via injection
214476053|NCT02600208|DEVICE|CliniMACs|Depletion of Alpha Beta T cells in the PBSC graft
214476054|NCT05970861|DIETARY_SUPPLEMENT|Freeze-dried Mare Milk (Saumal)|Freeze-dried Mare Milk (Saumal) is frequently reported for having therapeutic and dietary properties associated with specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, and B12, amino acids, enzymes, and trace elements (low molecular weight peptides, lactalbumins, and globulins). Saumal will be administered to patients at a dose of 25 grams of dry powder per 200 ml of water, 2 times a day, 30 minutes before the meal, for 4 weeks.
214848442|NCT04039919|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
214848443|NCT04039919|DRUG|Placebo (PSL)|Placebo will be provided matching Padsevonil to maintain the blinding.
214848444|NCT00754013|DRUG|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally."
214848445|NCT00754013|DRUG|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally."
214848446|NCT02310789|DRUG|Ivacaftor|150mg administered orally twice daily.
214848447|NCT02310789|DRUG|β-Adrenergic cocktail|Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
214658460|NCT03420534|DIETARY_SUPPLEMENT|fasting|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
214658461|NCT03420534|DIETARY_SUPPLEMENT|postprandial|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
214658462|NCT01321047|DRUG|Propofol|propofol (0.5 mg/kg body weight; 10 mg if age \> 70 or ASA class III-IV)
214658463|NCT01321047|DRUG|BPS|midazolam (0.05 mg/kg body weight; 1 mg if age \> 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age \> 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
214658464|NCT06334679|OTHER|Cold Gel Packet Application|Cold gel packs will be placed on the burn areas of the patients in the maturation phase and applied for 20 minutes.
214658465|NCT03510793|DRUG|balanced anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
214658466|NCT03510793|DRUG|Total intravenous anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
214658467|NCT06165588|OTHER|Tour de France|Participating in the Tour de France as cyclist
214658468|NCT01103739|DRUG|PF-04531083|PF-04531083: 100mg to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
214658469|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
214658470|NCT01103739|DRUG|PF-04531083|PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
214658471|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
214658472|NCT03714126|DEVICE|Cordio Medical|Recording to an app, no interference to the regular care
214658473|NCT06438328|DIAGNOSTIC_TEST|Left/ Right affected arm|Therapeutic exercises: eccentric and concentric exercises and wrist isometrics 10 repetitions of 3 sets with 10 seconds interval
214658474|NCT06438328|OTHER|Grip strength|assessed by using modified sphygmomanometer in which it first inflated to 100 mmHg with closed valve. The pressure was reduced to 20mmHg and the resisted wrist extension performed at baseline and at the 4th week.
214658475|NCT05662592|DEVICE|Broadband Light|Broadband Light device will be used for treatment of pigmented skin lesions
214848448|NCT02310789|DRUG|Pilocarpine Nitrate 5%|Administered subcutaneously using Macroduct sweat stimulator device.
214848449|NCT02310789|DEVICE|Macroduct sweat stimulator|
214848450|NCT02704234|OTHER|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
214848451|NCT02704234|OTHER|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
214658476|NCT02588378|PROCEDURE|multi-modal cSLO imaging|
214658477|NCT02490657|DRUG|Inhaled iloprost|"Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb."
214658478|NCT02490657|DRUG|normal saline (Saline 0.9%)|
214658479|NCT05900141|DRUG|Pelacarsen|Pelacarsen 80mg s.c. monthly
214658480|NCT03681717|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
214848452|NCT00164034|DEVICE|Real time computer prompted trauma algorithms|
214848453|NCT05703035|PROCEDURE|standby while firing staple|VOLUNTEER PATIENTS WHO ACCEPT THE SURGERY WILL HAVE TISSUE CLOSURE AND CUTTING WITH STAPLER IN AVERAGE 30 MINUTES DURING THE SURGERY AND THE PATIENT WILL BE FOLLOWED FOR 30 DAYS.
214848454|NCT00983918|DRUG|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
214290038|NCT01500161|DRUG|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
214290039|NCT01500161|DRUG|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
214658481|NCT01178021|DRUG|Chloroquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2
214658482|NCT01178021|DRUG|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
214658483|NCT03431610|DRUG|SB414 2%|Twice daily
214658484|NCT03431610|DRUG|SB414 6%|Twice daily
214658485|NCT03431610|DRUG|Vehicle|Placebo comparator
214658486|NCT05766592|BEHAVIORAL|LGBTQ-affirmative CBT|16-session LGBTQ-affirmative psychotherapy using cognitive behavioral techniques
214658487|NCT05766592|BEHAVIORAL|ABFT-SGM|16-session attachment-based family therapy for sexual and gender minority young adults and their nonaccepting parents
214658488|NCT04523662|DRUG|Camrelizumab Apatinib Mesylas|This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis
214658489|NCT03018548|OTHER|blood draw|subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
214658490|NCT05595876|PROCEDURE|stent retriever thrombectomy|The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
214848455|NCT00983918|DRUG|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
214658491|NCT05595876|PROCEDURE|contact aspiration thrombectomy|A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
214658492|NCT00562419|DRUG|CT-322|IV solution, weekly
214658493|NCT00562419|DRUG|irinotecan hydrochloride|IV solution, biweekly
214658494|NCT02589977|DRUG|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
214658495|NCT02024776|BEHAVIORAL|Prehabilitation|Tailored exercise training program
214658496|NCT04621903|OTHER|Shanshamani Vati Plus|Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.
214658497|NCT01025635|DRUG|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
214658498|NCT01025635|DRUG|Vehicle foam|Applied topically twice daily for 12 weeks
214658499|NCT06322082|DEVICE|The DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL AG)|"The LiESWT was applied to Pilates and Shock Wave group and Shock Wave group with 0.25 mJ/mm2 of intensity, 3000 pulses of shock, and 3 pulses/s of frequency, applicator was placed on the suprapubic skin area one session in the week for twelve weeks, totaling 12 sessions.~Pilates exercises were performed to Pilates and Shock Wave group and Pilates group. The sessions of Pilates were applied twice a week for twelve weeks, totaling 24 sessions. The 50 min Pilates sessions were divided into three phases: warm-up, strengthening, and stretching. They also received written orientations to perform three exercises and two of the Pilates session at home every day - Conventional pelvic floor exercises performed for all groups include Kegel exercise, squats, bridging, and squeeze and release exercises. These exercises were performed 3 times per day, lasting for 12 consecutive weeks"
214658500|NCT04239209|BEHAVIORAL|Indirect - other patients|Video depicting an indirect response focusing on a comparison to other patients.
214658501|NCT04239209|BEHAVIORAL|Indirect - physiology|Video of an indirect response focusing on the physiology of the patient.
214658502|NCT04239209|BEHAVIORAL|Redirection|Video of a redirection towards discussing the patient's values and possible future decisions.
214658503|NCT04239209|BEHAVIORAL|Direct communication|Video of a direct response.
214658504|NCT05763602|DRUG|povidone-iodine topical ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
214658505|NCT01511731|DRUG|Famotidine|Famotidine Tablets 40 mg
214658506|NCT01511731|DRUG|Pepcid|40mg tablets
214658507|NCT03716479|OTHER|Low Fiber|20 g of acacia gum will be added to orange juice
214848456|NCT00983918|DRUG|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
214290040|NCT01500161|DRUG|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
214658508|NCT03716479|OTHER|High Fiber|40 g of acacia gum will be added to orange juice
214658509|NCT03716479|OTHER|Placebo/Control|No acacia gum will be added to orange juice.
214658510|NCT05887999|DRUG|LY3532226|Administered subcutaneously (SC).
214658511|NCT05887999|DRUG|Placebo|Administered SC.
214658512|NCT01270334|OTHER|PH meassurment|meassuring ph USING PROBE
214290041|NCT01500161|DRUG|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
214290042|NCT04403971|DRUG|0.12% Chlorhexidine Oral Liquid Product|The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.
214290043|NCT04403971|DRUG|Listerine Oral Liquid Product|The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
214290044|NCT04403971|OTHER|Normal Saline Product|The control group received 10ml normal saline for oral rinse twice a day.
214290045|NCT00192205|BIOLOGICAL|CAIV-T or TIV|
214290046|NCT05760833|PROCEDURE|Ablation|Ablation of either the pulmonary veins or the atrioventricular node
214290047|NCT04068090|OTHER|Patient Questionnaires|FACT-Ntx, EORTC-CIPN20
214290048|NCT04068090|OTHER|Blood Collection|biomarker analysis
214290049|NCT00002714|BIOLOGICAL|bleomycin sulfate|
214658513|NCT00002283|DRUG|Trimethoprim|
214658514|NCT00002283|DRUG|Sulfamethoxazole|
214658515|NCT00002283|DRUG|Dapsone|
214658516|NCT03500744|PROCEDURE|Erector spinae plane block|Ropivacaine 0.5% 20 mL at each site of ESPB
214658517|NCT03500744|PROCEDURE|Sham block|Skin infiltration only
214658518|NCT04210726|DRUG|25% Hypertonic Saline Bath|25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).
214658519|NCT04210726|OTHER|0.9% Isotonic Saline Bath|0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
214658520|NCT02617914|PROCEDURE|individualized PEEP treatment, Invasive mechanical ventilation, ECMO,|
214658521|NCT01892488|DRUG|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
214848457|NCT00983918|DRUG|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
214848458|NCT02477852|DRUG|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
214848459|NCT02477852|DRUG|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
214848460|NCT02477852|DRUG|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
214848461|NCT02477852|DRUG|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
214848462|NCT00282750|DEVICE|Bar coded sponge and scanner|
214848463|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules|As previously published
214290050|NCT00002714|DRUG|Stanford V regimen|
214848464|NCT01205841|PROCEDURE|Buffalo Rule|As previously published
214848465|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia|As previously published
214848466|NCT01205841|PROCEDURE|Thompson Test|As previously published
214290051|NCT00002714|DRUG|doxorubicin hydrochloride|
214290052|NCT00002714|DRUG|etoposide|
214290053|NCT00002714|DRUG|mechlorethamine hydrochloride|
214290054|NCT00002714|DRUG|prednisone|
214290055|NCT00002714|DRUG|vinblastine sulfate|
214290056|NCT00002714|DRUG|vincristine sulfate|
214290057|NCT00002714|RADIATION|radiation therapy|
214476055|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL and r/r CTCL
214476056|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r ATLL
214476057|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL
214476058|NCT04710030|DRUG|Valacyclovir hydrochloride 500mg caplet|Active Comparator
214476059|NCT04710030|DRUG|Placebo sugar pill caplet|Placebo Comparator
214476060|NCT06041334|BIOLOGICAL|Collection of a urine sample|Collection of a urine sample for analysis of urinary biomarkers and urinary metabolomics (Inclusion and 1 year)
214476061|NCT06041334|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the bladder|Magnetic Resonance Imaging of the bladder (10 adults patients only) (Inclusion and 1 year)
214476062|NCT06366724|DRUG|Pyridostigmine|"Pyridostigmine timeline:~Weeks 0-2: 20mg TID (1.67 mL TID)~Weeks 2-4: 40mg TID (3.33 mL TID)~Weeks 5-13: 60mg TID (5mL TID)"
214476063|NCT06366724|DRUG|Low-Dose Naltrexone|"LDN timeline:~Weeks 0-2: 1.5mg QD (1.5mL QD)~Weeks 2-4: 3.0mg QD (3.0mL QD)~Weeks 5-13: 4.5mg QD (4.5mL QD)"
214476064|NCT06366724|OTHER|Placebo|"Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)"
214476065|NCT04007848|DRUG|Cobimetinib|Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
214476066|NCT04007848|DRUG|Placebo oral tablet|Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
214476067|NCT04706507|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
214476068|NCT06809829|PROCEDURE|Immediate Implant Placement|Eight patients undergoing immediate implant placement with the buccal gap filled with doxycycline loaded gelatin nanoparticles along with gelatin sponge (group A) Eight patients undergoing immediate implant placement with the buccal gap filled with doxycycline along with gelatin sponge (group B)
214476069|NCT06810206|OTHER|Bilateral Ultrasound Guidance M-TAPA|transversus abdominis, internal oblique, and external oblique muscles will be identified on the costochondral angle in the sagittal plane at the 10th costal margin. deep angle will be given to the costochondral angle at the edge of the 10th costa with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. The needle will be inserted in the cranial direction using the in-plane technique, and the needle tip will be moved to the posterior aspect of the 10th costal cartilage, and saline (5 ml) will be injected to confirm the location by observing dissection between internal oblique muscle and transversus abdominis muscle under the 10th costal cartilage, and local anesthetic will be injected into the lower surface of the chondrium. The local anesthetic to be used is bupivacaine 0.25% with Ultrasound Siemens® ACUSON X300 portable scanner with a high frequency linear transducer (10 MHz) using A Quincke 22 G . x 3½ in. (0.7x88 mm) A spinal needle
214476070|NCT06810206|PROCEDURE|Bilateral Ultrasound Guidance EOIPB|"The patients will be positioned in the supine position with the ipsilateral arm in abduction. The transducer will be positioned in a cephalad to caudad parasagittal plane at the anterior axillary line at the level of the sixth and seventh ribs in line with the xiphoid process. Using the in-plane technique, the needle will be advanced from cephalad to caudad until the tip lies in the plane between the external oblique muscle and intercostal muscles between the sixth and seventh ribs. Following hydro-dissection with 2 ml of 0.9% saline to confirm the correct needle tip position, LA injection will be given. The same procedure will then be repeated on the contralateral~* Local anesthetics to be injected: iBupivacaine (0.25%)~* Dose : 25ml on each side~* Device to be used: Ultrasound Siemens® ACUSON X300 portable scanner with a high-frequency linear transducer (10 MHz) that is covered in sterile plastic.~* Needle to be used : A Quincke 22 G . x 3½ inch (0.7x88 mm) spinal needle"
214476071|NCT06810115|OTHER|Viral PCR test|Viral PCR test regardles of symptoms
214476072|NCT06122168|OTHER|Mandala|verbal interview, standard health care, sheet of paper showing a mandala to be colored at will
214476073|NCT06122168|OTHER|Standard care|verbal interview and standard health care
214476074|NCT06810037|BEHAVIORAL|Mindfulness Practice Based on the Solution-Focused Approach|the experimental group received 90 minutes of solution-oriented based mindfulness practices one day a week for eight weeks
214476075|NCT06805669|OTHER|Early referral to palliative care|Participant will be referred to palliative care at start of systemic treatment
214476076|NCT06805669|OTHER|Standard Treatment|Participants will be referred to palliative care upon appearance of uncontrollable symptoms.
214476077|NCT06368206|DEVICE|Investigational device Aktiia G2C|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia G2C.
214476078|NCT06368206|DEVICE|Marketed device used as reference for blood pressure monitoring: double auscultation cuff|Study subjects are asked to stay seated and relaxed while successive measurements are taken with cuff for double auscultation.
214476079|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia Bracelet G2.
214658522|NCT01892488|DRUG|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
214658523|NCT00001189|PROCEDURE|radiotherapy|
214658524|NCT05292755|DRUG|Carboxymethylcellulose (CMC) Artificial Tears|A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.
214658525|NCT05292755|DRUG|Preservative-free, CMC-free Artificial Tears (control)|A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
214658526|NCT00005912|DRUG|Voriconazole|
214658527|NCT02155400|DEVICE|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
214658528|NCT02155400|DEVICE|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
214658529|NCT05078489|OTHER|Action-observation therapy|Action observation therapy involves the observation and perception of human movement performed by others. The observation of actions performed by others activates in the perceiver the same neural structures responsible for the actual execution of those same actions.
214658530|NCT05078489|OTHER|Placebo|Participants will watch a natural landscape without any human.
214658531|NCT03171922|BEHAVIORAL|Internet Diet|ID group have online dietary coach every 2 weeks
214658532|NCT03171922|BEHAVIORAL|Clinic Diet|CD group have every 2 weeks visit at clinic
214658533|NCT02586480|DEVICE|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
214658534|NCT06292897|OTHER|observational study|observational study
214848467|NCT01205841|PROCEDURE|Palpation of the fibula|Palpation of the fibula over its entire length.
214848468|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation of the cuboid bone|As previously published
214848469|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation over the deltoid ligament|As previously published
214848470|NCT01205841|PROCEDURE|Malleolar Zone Algorithm|As previously published
214658535|NCT05437887|DIETARY_SUPPLEMENT|Fucoidan|All patients consumed fucoidan.
214658536|NCT02343692|PROCEDURE|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
214658537|NCT03804151|BEHAVIORAL|FitSpirit intervention|The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
214658538|NCT06353672|DEVICE|Robotic liver resection|Liver resection using Da Vinci robotic system
214658539|NCT05490992|OTHER|Behavioral Skills Training In-person|"Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person."
214658540|NCT05987215|COMBINATION_PRODUCT|Radiologic diagnosis|Each CT scan is interpreted by a radiologist and is assigned as positive or negative for the diagnosis of otosclerosis
214658541|NCT05987215|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Each CT scan is screened by the deep learning algorithm and is assigned as positive or negative for the diagnosis of otosclerosis
214658542|NCT01418755|BIOLOGICAL|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
214658543|NCT05199584|DRUG|ENV-101 (taladegib)|tablets dosed once-daily
214658544|NCT00432809|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass
214658545|NCT00432809|PROCEDURE|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
214658546|NCT04810273|BEHAVIORAL|Early progressive mobilization|The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).
214658547|NCT02886429|DRUG|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
214658548|NCT02886429|DRUG|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
214848471|NCT01205841|PROCEDURE|Low Risk Exam|As previously published
214848472|NCT01205841|PROCEDURE|Bernese Ankle Rules|As previously published
214848473|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + swelling of the distal fibula|As previously published
214848474|NCT03082235|DRUG|E6742|gelatin capsules
214290058|NCT01214811|DEVICE|Mepilex Border Ag|Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
214658549|NCT04980131|DEVICE|Pointed lotus root regulator and guide template aided PPSF|20 patients in group C received PPSF with pointed lotus-style regulator
214658550|NCT04980131|DEVICE|Flat ended lotus root regulator and guide template aided PPSF|20 patients in group B received PPSF with flat ended lotus-style regulator
214848475|NCT03082235|DRUG|Placebo|gelatin capsules
214848476|NCT02560974|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
214848477|NCT02560974|DRUG|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.
214848478|NCT01106521|RADIATION|Permanent breast seeds implant|Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
214848479|NCT00832221|DRUG|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
214848480|NCT00832221|DRUG|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
214658551|NCT03754153|DEVICE|Balanced Binocular Viewing (BBV)|The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).
214658552|NCT03754153|OTHER|Standard Therapy - Occlusion (patching) or blurring (atropine)|The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies
214658553|NCT04438421|DRUG|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
214658554|NCT04438421|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
214658555|NCT04438421|DRUG|Placebo|Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
214658556|NCT00312130|DRUG|Vildagliptin|
214658557|NCT01073150|DRUG|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
214658558|NCT04433117|BIOLOGICAL|Shefabone|Silica-calcium phosphate composite.
214658559|NCT04433117|BIOLOGICAL|Bio-Oss|Xenograft Bone substitute. Bone from animals.
214658560|NCT04833036|DRUG|Irinotecan|180 mg/m2, ivgtt d1，q2w
214658561|NCT04833036|DRUG|cetuximab|500 mg/m2, ivgtt d1，q2w
214658562|NCT03758586|OTHER|Computerized spatial skill training|The spatial skills training session consisted of six practice trials that were run in a sequence. The objective of each practice was to manipulate the simulated robotic arm to grab the cubes and move them to a desired location using keyboard keys. The participant was required to reach a decision based on the visual-spatial information, before initiating subsequent movements of the simulated robotic arm. Each practice trial presented an initial state of the cubes in front of the robotic arm, and a target position of the cubes.
214658563|NCT03758586|OTHER|Watching a presentation regarding robotic surgery|Watching a 20-35 minute long power-point presentation regarding the history of robotic surgery.
214658564|NCT05313438|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
214658565|NCT00535340|DRUG|SR58611A|
214658566|NCT04837612|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
214658567|NCT00839631|DRUG|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
214658568|NCT01051739|PROCEDURE|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
214848481|NCT00832221|DRUG|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
214848482|NCT05558449|DEVICE|Hypnosedation|"Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
214848483|NCT05558449|DRUG|Midazolam injection|Midazolam intravenous injection 1 mg until RASS -3
214658569|NCT04381000|OTHER|Exercise Group|The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
214658570|NCT00707577|BEHAVIORAL|Internet-based maintenance program|The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
214658571|NCT02293681|DRUG|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
214658572|NCT02293681|DRUG|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
214658573|NCT02293681|DRUG|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
214658574|NCT03853694|DRUG|50 mcg Duramorph+ EXPAREL + multi-modal pain regimen|Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
214658575|NCT03853694|DRUG|150 mcg Duramorph + multi-modal pain regimen|Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
214658576|NCT03853694|DRUG|Exparel TAP + multi-modal pain regimen|EXPAREL administered via TAP infiltration + multi-modal pain regimen.
214658577|NCT02499952|DRUG|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
214658578|NCT04938856|DRUG|Lamotrigine tablet|Lamotrigine 100 mg immediate release Tablet
214658579|NCT02934607|DRUG|Symbicort pMDI with spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
214658580|NCT02934607|DRUG|Symbicort pMDI without spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
214658581|NCT01819792|OTHER|Multiplex respiratory viral PCR|
214658582|NCT05089708|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
214658583|NCT05089708|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
214658584|NCT00227058|DRUG|Orotic acid and Glutathione-(Nutritional Supplements)|
214658585|NCT04265391|DIETARY_SUPPLEMENT|cookies|Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
214658586|NCT02038062|PROCEDURE|Sevoflurane preconditioning|Preconditioning by transient application of sevoflurane
214658587|NCT06137352|OTHER|Follow up|Each subject was recruited in 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and followed up at 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, with a total of two follow-up visits. At enrollment and both follow-up visits, subjects were required to collect 2 tubes of peripheral venous blood each.
214658588|NCT03333577|DEVICE|SoundArc|non-surgical attachment method for wearing a bone conduction hearing system
214658589|NCT01768299|DRUG|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
214658590|NCT01768299|DRUG|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
214658591|NCT01443013|OTHER|Renal Transplant|urinary sample at month 3, 6 and 12
214658592|NCT02209766|DRUG|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
214658593|NCT02209766|DRUG|Placebo|"1. st cohort: Dose 1(2g) D5884(n=3) in Japanese~2. nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
214658594|NCT00507247|DRUG|Daptomycin|6mg/kg/day IV for at least 10 days.
214658595|NCT02832050|BEHAVIORAL|Play therapy|See previous description of play therapy intervention arm.
214658596|NCT02832050|BEHAVIORAL|Standard of care|See previous description of comparator arm.
214658597|NCT02421861|BEHAVIORAL|Anxiety Management in the ICU|"The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference."
214658598|NCT02421861|OTHER|Usual Care (UC)|The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C\&L service; (2) referral to psychiatry C\&L service; or (3) pharmacologic management.
214658599|NCT03384043|BEHAVIORAL|Smartphone Personal Assistant|Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location.
214658600|NCT03384043|BEHAVIORAL|Implementation Intention|Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment.
214658601|NCT02541630|BEHAVIORAL|Big Mind|mindfulness based intervention
214658602|NCT05418712|DRUG|Placebo|Placebo matched to VX-150 for oral administration.
214658603|NCT05418712|DRUG|VX-150|Solution or Suspension for oral administration.
214658604|NCT03376828|DEVICE|Macintosh laryngoscopy|Endotracheal intubation time using the Macintosh laryngoscope
214658605|NCT03376828|DEVICE|C-Mac Videolaryngoscope|Endotracheal intubation time using the C-Mac Videolaryngoscope
214658606|NCT06001606|DRUG|Shingrix|Shingrix vaccination
214658607|NCT06001606|DRUG|Placebo|Placebo vaccination
214848484|NCT05558449|DEVICE|Virtual reality|"Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
214848485|NCT02771106|OTHER|neuro vision rehabilitation|Neuro vision rehabilitation used to treat vision dysfunction following TBI
214848486|NCT00374075|DRUG|Valproic Acid|
214848487|NCT00384475|DRUG|Ciclesonide Nasal Spray|
214848488|NCT04341259|DRUG|Ipatasertib|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.
214848489|NCT05523570|DRUG|HNC364|2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension. Then 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 20 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
214658608|NCT00064701|DRUG|Tacrolimus Modified Release (MR)|The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
214658609|NCT00064701|DRUG|Tacrolimus|The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
214658610|NCT00064701|DRUG|cyclosporine microemulsion|The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
214658611|NCT00064701|DRUG|mycophenolate mofetil|Oral
214658612|NCT01405079|DRUG|Gefitinib|Gefitinib 250 mg/day oral daily
214658613|NCT01405079|DRUG|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
214658614|NCT02249052|DRUG|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
214658615|NCT02249052|DRUG|placebo|Placebo
214848490|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 40 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
214476080|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric upper-arm cuff.
214476081|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric wrist cuff.
214476082|NCT06368206|DEVICE|Marketed device used as reference for pulse rate monitoring: pulse finger oximeter|Study subjects are asked to stay seated and relaxed while successive measurements are taken with pulse finger oximeter.
214476083|NCT06805201|DIETARY_SUPPLEMENT|Gyngerlean|Alpinia galangal (Red Ginger), Kaempferia parviflora (Black Ginger), and Zingiber officinale (Yellow Ginger).
214476084|NCT03245593|OTHER|Shared-decision making process|Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
214476085|NCT03245593|OTHER|standard care|Care of patients according to standard practice of managing patients with bipolar disorder
214476086|NCT05667480|BEHAVIORAL|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
214476087|NCT05667480|BEHAVIORAL|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and pre-recorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
214476088|NCT06805045|PROCEDURE|augmented reality|To provide augmented reality (AR) guidance during robotic-assisted and laparoscopic surgeries, by overlaying the preoperative 3D virtual anatomical models to intraoperative surgical images (3D AR guidance).
214476089|NCT06810674|BEHAVIORAL|Get out of your head campaign and website 2.0|"The Get out of your head campaign and website were launched in 2022 to improve men's mental health and reduce stigma (Stas et al., 2024). Developed with experts, a communication agency, and the target audience, the campaign included videos, testimonies, and a website with tailored information on mental health, suicide prevention, and help-seeking (www.komuitjekop.be).~The new campaign and updated website will focus specifically on facilitating help-seeking behaviour among men experiencing suicidal thoughts by increasing their perceived need for support. More specifically, the new campaign will aim to enhance the recognition of their suffering, the relevance of seeking and receiving help and changing the perception of suicidal thoughts, namely that these are not fixed or part of life, but instead are changeable and can improve with the correct help."
214476090|NCT06808620|OTHER|The group where the peanut ball is used|Before the application, the appropriate ball size for the physical characteristics and comfort of the pregnant women will be determined. Pregnant women will be given 4 different sizes of peanut balls with a diameter of 40, 55, 65 and 75 cm. In order for the pregnant woman to continue her in-bed balance exercises and position changes, she will be allowed to sit on the peanut ball with her knees and hips at an angle of approximately 90° and her spine upright. A 40-55 cm birthing ball will be used for women between 150-160 cm tall, a 65 cm birthing ball for women between 160-170 cm tall, and a 75 cm birthing ball for women between 170-185 cm tall. Position changes with the peanut ball will be carried out in accordance with a position/exercise guide prepared by researchers in line with literature information. The peanut ball will be applied in 6 different positions. These positions to be applied will consist of side-lying positions, semi-sitting pose, forward bending pose and squatting pos
214476091|NCT06808373|BEHAVIORAL|hypnosis|Hypnosis will be applied to periodontitis patients
214476092|NCT06196710|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto the vessels.
214476093|NCT06196710|DEVICE|Hemo-clipping|Contact thermocoagulation using a 3.3mm probe, hemo-clips, or both. The use of the bipolar device involves firm mechanical compression and coagulation for about 8 seconds.
214476094|NCT05031832|DIAGNOSTIC_TEST|HIV test|HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status
214476095|NCT05970016|DRUG|TCC1727 tablet（1）|TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
214476096|NCT05970016|DRUG|TCC1727 tablet（2）|Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning , and 21 days/cycle on an empty stomach.
214476097|NCT06808724|PROCEDURE|implant with ozonated oil|Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. Ozonated oil (Surgy O3) will be applied to the implant surface and then the implant will be inserted into the prepared osteotomy site. A 3 mm high transepithelial abutment will be then screwed using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.
214476098|NCT06808724|PROCEDURE|non-activated implant|Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. In the control group, the implant will be inserted without any treatment. A 3 mm high transepithelial abutment will be then attached using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.
214658616|NCT01432639|OTHER|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
214658617|NCT00000899|DRUG|Nelfinavir mesylate|
214658618|NCT00000899|DRUG|Lamivudine|
214658619|NCT00000899|DRUG|Filgrastim|
214658620|NCT00000899|DRUG|Stavudine|
214658621|NCT00000899|DRUG|Cyclophosphamide|
214658622|NCT00482846|BIOLOGICAL|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is \>40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
214658623|NCT00482846|DRUG|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. \<60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
214658624|NCT00482846|OTHER|questionnaire administration|Day -5 to Day +28
214658625|NCT00482846|PROCEDURE|autologous peripheral blood stem cell transplantation|Day 0
214658626|NCT00482846|OTHER|quality-of-life assessment|Day -5 to Day +28
214658627|NCT01491945|DEVICE|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
214658628|NCT05787704|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
214848491|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 60 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
214290059|NCT05329272|OTHER|Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display \[HMD\] in delivering the VR intervention), audio, and motor equipment.
214290060|NCT03240250|PROCEDURE|VATS uni-portal lobectomy and lymphoadenectomy|VATS uni-portal lobectomy and lymphoadenectomy
214290061|NCT03240250|PROCEDURE|VATS three-portal lobectomy and lymphoadenectomy|VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
214658629|NCT02603523|BEHAVIORAL|Senior Dance|The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
214658630|NCT02137668|DRUG|Oral Vancomycin|Oral Vancomycin is given to PSC or BA participants
214658631|NCT02575209|OTHER|GENDER|
214658632|NCT05071131|DIETARY_SUPPLEMENT|Inulin|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
214658633|NCT05071131|DIETARY_SUPPLEMENT|Placebo|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
214658634|NCT01148173|DRUG|Combined systemic and intrathecal chemotherapy followed by HD-ASCT|Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
214658635|NCT03770403|BIOLOGICAL|ARGX-113|Intravenous administration of ARGX-113
214658636|NCT03633084|DRUG|RBM-007 Injectable Solution|(No additional description)
214658637|NCT05678803|OTHER|xrays and CT|A dedicated sheet will be used to record patients' data including all demographic data, detailed analysis of the mechanism of injury, time of injury, time and details of surgery (if any), neurological status on admission and all radiological findings. All patients will undergo plain X-rays and CT imaging. Patients with suspected discoligamentous injuries and/or neurological deficits will also be assessed by MRI.
214658638|NCT03591900|DEVICE|insulin pump/CGMS|"A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009)."
214658639|NCT01894672|DRUG|LGX818|
214658640|NCT03416231|DRUG|Apatinib|apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
214658641|NCT03416231|DRUG|Docetaxel|Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles.
214658642|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 1|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.
214658643|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 2|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
214658644|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 3|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
214658645|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 4|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
214290062|NCT03634462|OTHER|CDT with graded negative pressure|Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise. The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
214290063|NCT02904330|DRUG|K1-70 intramuscular or K1-70 intravenous|Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
214658646|NCT05173584|DRUG|Levalbuterol|Levalbuterol nebulizer solution 1.25mg/3ml with a total dose of 5 mg (12ml) for each patient.
214658647|NCT05173584|DRUG|Albuterol|Albuterol nebulizer solution 2.5 mg/3ml with a total dose of 0 mg (12ml) for each patient.
214658648|NCT00427856|DRUG|Obatoclax mesylate|Obatoclax mesylate 40mg, and 60mg
214658649|NCT00427856|DRUG|Rituximab|Rituximab
214658650|NCT03341884|DRUG|Ipatasertib|A single oral dose of 100 mg ipatasertib will be administered.
214658651|NCT04284540|RADIATION|Adjuvant hypofractionation|15 fractions of 2.7 Gy per fraction daily over 3 weeks for a total of 40.5 Gy to the post-operative bed and/or necks.
214658652|NCT04284540|RADIATION|Definitive Hypofractionation|15 fractions of 3 Gy per fraction daily over 3 weeks for a total of 45 Gy to regions of gross disease. Elective areas can be treated to 37.5 Gy in 15 fractions.
214658653|NCT01743573|OTHER|yoga|
214658654|NCT03084133|BEHAVIORAL|Therapeutic Education Strategy|"In the experimental arm of the study (intervention group), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the intention of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a competence approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002)."
214658655|NCT02847884|BIOLOGICAL|Infliximab|Patients will be prescribed Infliximab as a standard of care regardless of study participation.
214658656|NCT02704598|DRUG|Rivaroxaban|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
214848492|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 80 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
214848493|NCT01010022|DRUG|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
214848494|NCT01010022|DRUG|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
214848495|NCT04821752|BEHAVIORAL|Avoidance Education|Reduction of environmental toxins exposure from the diet will be achieved by switching to organic foods. Reduction of residential and occupational exposure to toxins from household cleaning products, cosmetics, personal care products, and other sources will be achieved by switching to safer products or avoidance of the toxic exposure.
214848496|NCT00031811|DRUG|raloxifene|
214848497|NCT00031811|PROCEDURE|quality-of-life assessment|
214848498|NCT02608970|DRUG|BMS-986177|
214848499|NCT02608970|OTHER|Placebo|
214848500|NCT04935788|DIETARY_SUPPLEMENT|milk protein|milk protein supplement
214658657|NCT02704598|DRUG|Warfarin|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
214848501|NCT04935788|DIETARY_SUPPLEMENT|micellar casein|micellar casein supplement
214848502|NCT04935788|DIETARY_SUPPLEMENT|pea protein|pea protein supplement
214290064|NCT02523898|DRUG|metformine|1500 mg metformine 8week plus 100 mg clomiphene for 5 days
214290065|NCT02523898|DRUG|placebo|placebo 8 weeks plus 100 mg clomiphene for 5 days
214290066|NCT02523898|DRUG|clomiphene citrate|100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
214290067|NCT06335914|DIAGNOSTIC_TEST|Ga 68 PSMA-11 PET|Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer
214658658|NCT02707185|BEHAVIORAL|Simulation-Based Training|An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.
214848503|NCT04935788|DIETARY_SUPPLEMENT|milk/pea protein blend|milk/pea protein supplement
214848504|NCT00798382|OTHER|soy protein formula|ad lib for 0-35 days of age
214848505|NCT00798382|OTHER|Commercially available soy formula|ad lib for 0-35 days of age
214848506|NCT00798382|OTHER|Soy formula experimental #2|ad lib for 0-35 days of age
214848507|NCT02253069|DEVICE|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
214848508|NCT02253069|DEVICE|Applying Placebo to tie-over dressings|Placebo control
214848509|NCT02948257|DEVICE|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
214848510|NCT00977548|DRUG|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
214658659|NCT02700451|DRUG|Ketorolac|"Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed."
214658660|NCT02700451|DRUG|Acetaminophen|Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
214658661|NCT02700451|DRUG|Placebo|Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
214658662|NCT04373460|BIOLOGICAL|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
214658663|NCT04373460|BIOLOGICAL|Plasma from a volunteer donor|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
214658664|NCT06300801|DIAGNOSTIC_TEST|Is the preoperative c-reactive protein/albumin ratio successful in predicting postoperative pancreatic fistula in patients undergoing pancreatoduodenectomy?|In this study, predicting pancreatic fistula before surgery will reduce postoperative complications and mortality.
214658665|NCT00977392|BEHAVIORAL|compliance monitoring|
214658666|NCT00977392|OTHER|cervical Papanicolaou test|
214658667|NCT00977392|OTHER|educational intervention|
214658668|NCT00977392|OTHER|screening questionnaire administration|
214658669|NCT00977392|OTHER|survey administration|
214658670|NCT00977392|PROCEDURE|colposcopy|
214658671|NCT00938730|DRUG|YM150|oral
214658672|NCT00938730|DRUG|Warfarin|oral
214658673|NCT01672957|DRUG|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
214658674|NCT01672957|DRUG|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
214658675|NCT06044896|PROCEDURE|Supine Positioning|The participant will be guided to the Multicare bed and will be positioned supine with the headboard not tilted. At this point, the participant will already have the EIT electrode belt and head, trunk and lower limb cushions around it, providing stability. After the participant has been correctly positioned, ventilatory monitoring will begin using the EIT. The environment must be fully controlled, that is, with adequate lighting, all collection members in silence, as well as the devices in the place, air-conditioned environment, without exposing the participant to heat or cold. Before starting the collection, the volunteer will be asked to try not to sleep or talk, making it clear that any discomfort can be reported at any time. To keep the volunteer awake, visual and sound stimuli can be performed. Furthermore, if you cough or sigh, the collection will restart. The intervention will last 5 minutes and will be repeated twice, with intervals between body lateralization.
214658676|NCT06044896|PROCEDURE|Body Lateral Positioning|The participant will start from the bench press to the 30-degree lateral position. The cushions placed at the beginning of the collection will provide stability so that the inclination does not compromise the correct positioning of the participant, preventing them from sliding on the bed. Furthermore, it is also a safety measure for the participant. The environment will be controlled throughout the intervention and visual and sound effects will also be performed in lateral positioning. The volunteer will remain in this position for five minutes and shortly after will be placed in the supine position again. To start the protocol for the second and final time, the participant will have a washout time of thirty minutes.
214658677|NCT05345470|OTHER|140 calories per 30 gram test meal|Food
214658678|NCT04466033|DEVICE|Magneto Microcatheter|All patients will be treated with Magneto Microcatheter
214658679|NCT04909905|DIETARY_SUPPLEMENT|Standard enteral nutrition|Standard enteral nutrition according to ICU nutrition protocol for 7 days
214658680|NCT04909905|COMBINATION_PRODUCT|Glutamine|Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days
214658681|NCT01578902|RADIATION|Stereotactic ablative body radiotherapy|35Gy/5 fractions/29 days
214658682|NCT02210663|DRUG|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
214658683|NCT01658267|OTHER|nutritional supplement|2 servings per day
214658684|NCT05220267|DRUG|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).
214658685|NCT01557790|RADIATION|Proton Radiation Therapy|
214658686|NCT02115308|DRUG|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
214658687|NCT00714779|DRUG|Fluoxetine|20-40 mg / day orally
214658688|NCT00714779|BEHAVIORAL|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
214658689|NCT01800942|DRUG|Azithromycin and Placebo|A single oral dose of 2g of Azithromycin will be given to the women in labour
214658690|NCT00642642|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
214658691|NCT00642642|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
214658692|NCT04770519|GENETIC|whole genome sequencing or whole exome sequencing|Whole genome sequencing or whole exome sequencing will be performed for all enrolled participants.
214658693|NCT03670355|DRUG|Tenofovir (TFV) IVR|Contains 1.4 g TFV
214658694|NCT03670355|DRUG|Placebo IVR|Contains placebo
214848511|NCT04714281|DEVICE|Dialyser|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
214658695|NCT02375867|DRUG|prednisolone|Oral administration of 1 mg/Kg/day
214658696|NCT02375867|DRUG|methylprednisolone|Intravenous injection of 0.8 mg/kg/day
214658697|NCT03543813|DRUG|CX-2029|CX-2029 Monotherapy
214658698|NCT06129630|PROCEDURE|Conventional occupational therapy sessions.|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
214848512|NCT03936179|RADIATION|high dose radiation therapy with concurrent chemotherapy|standard dose of 50 Gy concurrent weekly with paclitaxel (45 mg/m2) and carboplatin (area under curve 1.5 ), immediately followed by hyperfractionated radiotherapy boost of 36 Gy in 30 fractions of 1.2 Gy to residual metabolic disease as defined by PET/CT
214848513|NCT03100890|OTHER|Preoperative training (hospital)|Preoperative hospital training
214848514|NCT03100890|OTHER|Preoperative training (home)|Preoperative in-home training
214476099|NCT06808724|PROCEDURE|implant with plasma activation|Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. Implant will undergo vacuum-plasma activation immediately before insertion (Plasma X Motion, Megagen, Gyeongbuk, South Korea) and then it will be inserted into the prepared osteotomy site. A transepithelial abutment will then be attached using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.
214476100|NCT06808191|DEVICE|pulsed electromagnetic currant machine|Pulsed electromagnetic therapy will be delivered at the frequency of 12Hz, with magnetic flux density of 12G. Each treatment session will last for 1 hour, which will be repeated for 14 sessions within 4weeks.
214476101|NCT06808191|OTHER|Placebo|control group will receive intervention by using the same PEMF unit, but the output will be shut off.
214476102|NCT04667572|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
214476103|NCT06808711|OTHER|Buccocéan mouthwash|Normal conditions of use
214476104|NCT06808711|OTHER|Marketed mouthwash|Normal conditions of use
214476105|NCT04354129|DRUG|Cutaquig®|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
214476106|NCT06565611|DRUG|bremelanotide|bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume
214476107|NCT06565611|DRUG|tirzepatide|tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
214476108|NCT04488354|COMBINATION_PRODUCT|CLBR001 and SWI019|No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
214476109|NCT02371460|DIETARY_SUPPLEMENT|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
214476110|NCT02371460|COMBINATION_PRODUCT|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
214476111|NCT06648629|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a trans-diagnostic treatment that targets experiential avoidance as an underlying factor common to mental and behavioral health problems. Mindfulness skills and values-guided behavioral action plans are used to decrease experiential avoidance and impact a broad array of psychological symptoms via improved psychological acceptance.
214476112|NCT06648629|BEHAVIORAL|Brief Alcohol Intervention|The Brief Alcohol Intervention (BI) is a standard intervention for reducing alcohol use in PWH. The BI includes the creation of a drinking agreement, self-monitoring via drinking diary cards, discussion of risky moods/situation, and strategies for managing these moods/situations.
214476113|NCT06585696|DRUG|CU-20101 treatment for Moderate to Severe Glabellar Striae|"Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36)."
214476114|NCT05606211|OTHER|No intervention|Observational, no intervention
214476115|NCT06567730|OTHER|Ni-ti Closed-coil Spring|Ni-Ti closed-coil spring is a passive compressed spring made up of super elastic Nickel-titanium. Two eyelets are attached to each side of the coil to facilitate its application. The eyelets will be engaged in the hooks of the second premolar and canine brackets and will apply a force of 150 gm.
214476116|NCT06567730|OTHER|Elastomeric Power chain|Elastomeric power chains are resilient and latex-free orthodontic materials. They are made up of elastic material and consist of many connected rings. Each ring is engaged in a bracket to apply a force of 175-300 gm.
214476117|NCT05100628|DRUG|NOX66|"NOX66 800 mg (400 mg suppository twice daily \[BID\]).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
214476118|NCT05100628|DRUG|NOX66|"NOX66 1200 mg daily (600 mg suppository BID).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
214658699|NCT06129630|PROCEDURE|Conventional occupational therapy sessions + Nintendo Switch|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
214848515|NCT02380079|DRUG|SCD-101|Administered as gelatin capsules
214658700|NCT02423096|DRUG|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
214658701|NCT05427474|DRUG|Propranolol , gabapentin|The combined therapy of propranolol and gabapentine can prevent the occurrence of paroxysmal sympathetic hyperactivity in traumatic brain injury patients and improve the clinical outcomes in emergency ICU.
214658702|NCT01992822|OTHER|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm.
214658703|NCT03452267|DRUG|Metformin|oral, 850 mg twice daily
214658704|NCT03452267|DRUG|Pioglitazone|oral, 45 mg daily
214658705|NCT03452267|DRUG|Placebo|oral, once daily
214658706|NCT05397314|DIETARY_SUPPLEMENT|Punalpin|
214658707|NCT05397314|OTHER|Placebo|
214658708|NCT06261879|DEVICE|Special sanitary pad|The special sanitary pad is similar to the normal sanitary pad with 0.01 agar gel only. The agar gel is an approved source of food.
214476119|NCT05100628|DRUG|NOX66|"NOX66 1800 mg daily (600 mg suppository thrice daily).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
214476120|NCT05100628|DRUG|NOX66|MTD of the combination of NOX66 and doxorubicin will be determined in the dose-escalation cohort of the study. The selected dose will be administered in combination with Doxorubicin.
214476121|NCT05100628|DRUG|Doxorubicin|Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
214476122|NCT05649787|BEHAVIORAL|Supervised aerobic training|Supervised moderate to high-intensity interval aerobic training
214476123|NCT05649787|BEHAVIORAL|Supervised aerobic plus low to moderate-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
214476124|NCT05649787|BEHAVIORAL|Supervised aerobic plus moderate to high-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
214476125|NCT05671666|DIAGNOSTIC_TEST|Urea cycle flux study|Quantification of ureagenesis
214476126|NCT03347786|DRUG|10 mg Intra-arterial Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
214476127|NCT03347786|DRUG|20 mg Intra-arterial Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
214476128|NCT05405556|DIAGNOSTIC_TEST|eGFR reporting|"To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~1. only study-related eGFR values \>25% below baseline will be reported to patients and providers~2. all study-related eGFR will be provided to patients and providers"
214476129|NCT02106949|DEVICE|SMS contact with patient after discharge in intervention group|
214476130|NCT04513054|GENETIC|Blood collection for genetic analysis|Blood collection for genetic analysis
214476131|NCT06828016|OTHER|foot reflexology|foot reflexology, each session lasting 45 minutes to 1 hour
214476132|NCT06828016|OTHER|usual foot care|usual foot care, with each session lasting 45 minutes to 1 hour
214476133|NCT04060108|DRUG|MDMA|80mg, 120mg, Placebo
214476134|NCT03866837|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.
214476135|NCT03866837|DIETARY_SUPPLEMENT|Bovine lactoferrin|Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.
214476136|NCT03866837|DIETARY_SUPPLEMENT|Multiple micronutrient powders with 5 mg iron|The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg \[(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg\].
214476137|NCT05695820|OTHER|Blood Flow Restriction training|It is a method that involves reducing blood flow to a muscle by the application of an external constricting device, such as a blood pressure cuff or tourniquet, to provide mechanical compression of the underlying blood vessels. BFR is applied aiming to enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet
214476138|NCT06741007|PROCEDURE|Retroperitoneal pelvic lymphatic and uterine vessel dissection|ICG injection to cervix uteri at 3 and 9 o'clock followed by laparoscopic dissection of retroperitoneal space to detect uterine vessels (uterine arteries, SUVs and DUVs) bilaterally in addition to detect the location and biopsy of SLN stained by ICG.
214476139|NCT06573619|OTHER|Validation of questionnaire|Validation of questionnaire
214476140|NCT06212193|DEVICE|Trillium™|Trillium™ Stent Graft for Cross-Caval Tricuspid Valve Replacement
214476141|NCT06638996|DIETARY_SUPPLEMENT|CBG Intervention|50 mg CBG Administered
214476142|NCT06638996|OTHER|Placebo Intervention|Participants will be administered a placebo
214476143|NCT05398770|DIETARY_SUPPLEMENT|Vitamin D supplementation (30 µg/d)|The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
214476144|NCT05217589|OTHER|Funny/Amusing Video Clips|Participants watch 5-7 minutes of video clips that are funny/amusing in nature
214476145|NCT05217589|OTHER|Horror/Scary Video Clips|Participants watch 5-7 minutes of video clips that are scary in nature
214658709|NCT03622281|OTHER|quality improvement intervention using artificial intelligence|Colonoscopists received performance measure monitoring and feedback
214658710|NCT02344576|BEHAVIORAL|DT LVAD Decision Support Intervention|Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
214658711|NCT03773952|DRUG|PBF-677|oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
214658712|NCT03773952|DRUG|Placebo oral capsule|Oral capsules
214658713|NCT00468897|DRUG|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
214658714|NCT04760184|OTHER|Autologous stem cell transplantation|The study will describe the implications of COVID-19 infection following autologous stem cell transplantation
214848516|NCT05619159|DEVICE|microscopic pathological evaluation|description of moesin expression between endometrial hyperplasia and endometrial carcinoma
214658715|NCT02179840|PROCEDURE|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
214658716|NCT00712101|DRUG|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
214658717|NCT00712101|DRUG|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
214658718|NCT02534649|PROCEDURE|Newly obtained biopsy and Blood samples collection|"For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.~Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.~All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report."
214658719|NCT01778244|DRUG|metformin|1000mg/day for 24 weeks
214658720|NCT00370344|PROCEDURE|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
214658721|NCT00370344|PROCEDURE|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
214658722|NCT01413893|DRUG|linifanib|QD daily
214658723|NCT00269009|BEHAVIORAL|CHERL|
214658724|NCT04523740|DRUG|Placebo|Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
214658725|NCT04523740|DRUG|Paracetamol|Patients who use regular paracetamol will now receive 6 to 8 tablets of 500 mg paracetamol per day for 2 weeks
214658726|NCT06095830|DIAGNOSTIC_TEST|Complete blood count|Complete blood count done on admission and on discharge for patients, from which the blood indices of systemic inflammation will be calculated and correlated with outcome
214658727|NCT02340650|DEVICE|Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope|
214658728|NCT04976452|OTHER|Multi-component teaching content|The students assigned to Group 1 will undergo interactive module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines. Following completion of the module, students will be presented with a powerpoint lecture by the Primary Investigator on Blood Pressure. Students will then undergo a competency examination that assesses their ability to measure blood pressure following the guidelines of the American Heart Association.
214658729|NCT04233125|PROCEDURE|Core Decompression|Core Decompression
214658730|NCT04233125|PROCEDURE|PMMA augmentation|Polymethylmethacrylate (PMMA) augmentation
214658731|NCT04574843|PROCEDURE|Embolization of MMA|embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)
214658732|NCT05674448|BIOLOGICAL|HH-003 20mg/kg|HH-003 20mg/kg Q2W intravenously for 24 weeks
214848517|NCT02370459|OTHER|AFIX in-person consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
214658733|NCT05674448|BIOLOGICAL|HH-003 3mg/kg|HH-003 3mg/kg Q2W intravenously for 24 weeks
214658734|NCT02413203|DRUG|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
214658735|NCT02413203|DRUG|Placebo|Blood and urine collections before and 3 hours after placebo administration.
214658736|NCT02337387|BIOLOGICAL|Blosozumab|Administered SC
214658737|NCT02337387|OTHER|Placebo|Administered SC
214658738|NCT03731663|BEHAVIORAL|Exposure to pictures of appetizing food (known as Foodporn)|\- Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.
214290068|NCT06335914|DIAGNOSTIC_TEST|18F-DCFPyL PET|Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.
214290069|NCT06335914|DIAGNOSTIC_TEST|FDG PET|Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.
214290070|NCT01610544|DRUG|3'-deoxy-3'-18F fluorothymidine (FLT)|
214658739|NCT03731663|BEHAVIORAL|Exposure to neutral pictures|Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
214658740|NCT03372525|DEVICE|HFOV|Infants were randomized to HFOV
214658741|NCT03372525|DEVICE|CMV|Infants were randomized to CMV
214658742|NCT04947293|OTHER|Physical activity|Both groups will practice a physical activity adapted to their motor skills. They will have two group sessions (maximum 5 people per group) in a face-to-face setting, and one independent session at home supported by a video, each week. These programs last 12 weeks, and will be supervised by the same person, a physiotherapist.
214658743|NCT00790517|BEHAVIORAL|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
214658744|NCT00707356|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
214848518|NCT02370459|OTHER|AFIX webinar consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
214848519|NCT06130787|BIOLOGICAL|Blood and bone marrow sample|"Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12.~An optional bone marrow sample will be taken during the myelogram performed at diagnosis.~Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36"
214848520|NCT01757899|DRUG|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
214848521|NCT01757899|DRUG|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc \[methylprednisolone + diluting fluid\], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
214848522|NCT02994628|OTHER|Water|Water only without carbohydrate
214476146|NCT05217589|OTHER|Thrilling/Suspenseful Video Clips|Participants watch 5-7 minutes of video clips that are thrilling/suspenseful in nature
214658745|NCT05021809|DRUG|Calcium hydroxide intracanal medication application|The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .
214658746|NCT06152887|DEVICE|Sooma Oy (tDCS), Helsinki, Finland|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1)
214658747|NCT06152887|DEVICE|Sooma Oy (Sham), Helsinki, Finland|For the sham treatment, an electrical current will also be increased from 0 mA to 2 mA over the first 30 seconds, however, the current will be ramped back down to 0 mA after the initial ramp-up phase and no stimulation is delivered for the rest of the treatment.
214848523|NCT02994628|OTHER|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
214848524|NCT02994628|OTHER|Cavendish banana|Ingest Cavendish banana (common banana)
214848525|NCT02994628|OTHER|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
214476147|NCT00677365|DRUG|MP-376|3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days
214848526|NCT00003293|DRUG|leflunomide|
214848527|NCT00003293|DRUG|procarbazine hydrochloride|
214476148|NCT00677365|DRUG|Placebo|same frequency as study drug using the same nebulizer
214476149|NCT03346343|DEVICE|Non-invasive forced airway oscillometry|This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.
214476150|NCT05422885|DRUG|Dasatinib|Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks
214290071|NCT01610544|OTHER|PET/CT scan|
214290072|NCT01822340|DRUG|HM10560A|Once weekly HM10560A
214290073|NCT01822340|DRUG|Genotropin|Once daily Genotropin
214290074|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids)|"MaPa Kids is an 8-session parenting program delivered weekly to groups of parents (N=15 per group).~The program includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behavior; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behavior, and consequences for noncompliance, rule-breaking, and aggressive behavior; 6) problem solving with children; and 7) mindfulness based stress reduction."
214290075|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens)|"MaPa Teens is a 9-session parenting program delivered to groups of parents and children aged 10-17 (N=15 dyads per group).~The program includes the following content: 1) one-on-one time with parents and teens, 2) positive reinforcement of positive behavior, 3) managing anger and stress, 4) establishing rules and routines, 5) family budgeting, 6) accepting responsibility for actions, 7) resolving family conflicts, 8) keeping safe in the community and resolving conflicts, and 9) reflection and moving on."
214290076|NCT04268810|PROCEDURE|Bladder instillations|bladder instillations with either solution (DMSO or Uracyst)
214290077|NCT01516554|DRUG|Testosterone undecanoate|40 mg twice daily
214290078|NCT01516554|DRUG|placebo|twice daily
214290079|NCT01965496|DRUG|PEX168|A injection administered subcutaneously
214658748|NCT05052489|OTHER|registy|Children with diarrhea were registered in the hospital. Baseline information of the children was recorded and followed up to observe the distribution of disease types, clinical manifestations, treatment plans and clinical outcomes
214848528|NCT05151393|DIAGNOSTIC_TEST|Measuring vitamin D3 level|Measuring vitamin D3 in both groups
214658749|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
214658750|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
214658751|NCT03394638|OTHER|Access to online eLearning module|Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.
214658752|NCT03394638|OTHER|Access to measurement devices|Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.
214658753|NCT03394638|PROCEDURE|Conventional group|All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
214658754|NCT00887952|PROCEDURE|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
214658755|NCT00887952|PROCEDURE|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
214658756|NCT01869335|DEVICE|radiography|
214658757|NCT01869335|DEVICE|MRI (magnetic resonance imaging)|
214658758|NCT03512236|DRUG|BC Pram Ins|Injection of BC Pram Ins
214658759|NCT03512236|DRUG|Symlin® and Humulin®|Injection of pramlintide and human insulin
214658760|NCT03512236|DRUG|Humalog®|Injection of lispro
214658761|NCT03512236|DRUG|Placebo|Injection of 0.9% NaCl
214658762|NCT00831376|DRUG|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
214848529|NCT03328728|DEVICE|Cellular Matrix / A-CP HA Kit|Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
214848530|NCT03328728|DEVICE|Synvisc-One|Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
214848531|NCT04458961|PROCEDURE|One-stage|A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
214848532|NCT04458961|PROCEDURE|Two-stage|A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
214848533|NCT04577885|DRUG|SHR2554 and Rifampin|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
214848534|NCT05896215|DRUG|KNP2002|Dairy topical administration for 12 weeks
214848535|NCT05896215|DRUG|Placebo of KNP2002|Dairy topical administration for 12 weeks
214848536|NCT04531787|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
214848537|NCT05815082|PROCEDURE|Colorectal cancer resection combined with liver metastasis resection.|The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
214848538|NCT05815082|DRUG|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
214290080|NCT02431234|OTHER|serum RANKL|
214848539|NCT02656082|DRUG|Etanercept|Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
214290081|NCT00954434|DIETARY_SUPPLEMENT|red wine|intake of red wine on a daily basis
214658763|NCT00831376|DRUG|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
214658764|NCT00831376|DRUG|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
214658765|NCT04074486|DEVICE|BrainScope Ahead 300iP-O|BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.
214848540|NCT02070757|DRUG|Ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
214848541|NCT02070757|DRUG|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
214848544|NCT04955366|DRUG|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly
214848545|NCT04955366|DRUG|Abatacept|Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly
214848546|NCT04333472|DRUG|Piclidenoson|Piclidenoson 2 mg orally every 12 hours for up to 28 days
214848547|NCT04333472|DRUG|Placebo|Placebo orally every 12 hours for up to 28 days
214848548|NCT01546922|DRUG|Hydrocortisone|Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
214848549|NCT04171557|BEHAVIORAL|Bicycling|Total bicycling is reported in categories of: (0 - reference), (\>0 to \<60), (≤60 to \>150), (≤150 to \< 300) and (≥300) minutes/week
214848550|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
214476151|NCT05422885|DRUG|Quercetin|Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks
214476152|NCT04619173|OTHER|Thoracic manipulation|hot pack ,transcutaneous electrical nerve stimulation and manipulation along with stretching'
214848551|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home + SMS reminder|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
214848552|NCT03856684|BEHAVIORAL|"Letter offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
214848553|NCT03856684|BEHAVIORAL|"SMS offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
214848554|NCT05281926|DRUG|Poly ICLC|IT Poly-ICLC injection (1.0 mg) at Day 1 of weeks 0, 1 and 2. IM Poly-ICLC (20 μg/Kg) at Day 1 and Day 3 of weeks 3, 4, 5 and 6.
214476153|NCT04619173|OTHER|Conventional physical therapy Program|hot pack ,transcutaneous electrical nerve stimulation and stretching
214476154|NCT06855381|PROCEDURE|the ISBC group, SonoPlex needle and E-catheter|in the ISBC group, a 22G 50 mm SonoPlex needle with an indwelling cannula will be used. The E-catheter will be inserted into the indwelling cannula.
214476155|NCT06855381|PROCEDURE|single bolus injection|An ultrasound-guided peripheral nerve block puncture will be performed from the lateral to the medial side of the neck. In this group a 22G 50 mm needle will be used
214476156|NCT06854276|DRUG|SSS06|SSS06 is a highly glycosylated, long-acting recombinant protein product produced through recombinant gene technology by introducing site-specific mutations into the rHuEPO gene.
214476157|NCT06854276|DRUG|rhEPO|a recombinant human erythropoietin injection.
214658766|NCT04074486|DIAGNOSTIC_TEST|SCAT5|Sports Concussion Assessment Tool 5
214658767|NCT04074486|DIAGNOSTIC_TEST|Near Point Convergence|Manual ocular function measurement conducted only if electronic version on device fails
214658768|NCT04126837|OTHER|Diagnosis and treatment|Monocentric, Prospective and Biomedical Research excluding Health Product
214658769|NCT01082484|DRUG|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
214658770|NCT01082484|DRUG|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
214658771|NCT01082484|DRUG|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
214658772|NCT05919797|DRUG|Naltrexone-Bupropion Combination|Participants receive 28 weeks of naltrexone-bupropion weight loss medication during phase two of this study.
214658773|NCT05838417|BEHAVIORAL|REDS survey|R - Reactance, E - self-Exemption, D - Disbelief, S - Source derogation
214658774|NCT06439862|OTHER|Children with PUV|Male children aged 6 to 17 years old treated for PUV in their first year of life between 2006 and 2018 in Lyon, and managed in the Femme-Mère-Enfant Hospital in Lyon
214658775|NCT04781140|DRUG|100mg SPN-812|100mg SPN-812 will be administered once daily and compared to Placebo
214658776|NCT04781140|DRUG|Placebo|Placebo will be administered once daily
214658777|NCT05879159|BEHAVIORAL|Questionnaires|Survey
214658778|NCT05519215|DEVICE|ECHELON 3000 Stapler|There is no intervention, beyond necessary clinical care, in this study. Echelon 3000 Stapler is used for transection and resection in LSG or lung surgical procedure per its IFU.
214658779|NCT06201936|BEHAVIORAL|Preliminary information on neuroaxial procedures|Pre-existing information of pregnant women on neuroaxial pain-relieving procedures for childbirth and their informative sources
214658780|NCT00283556|DRUG|Irinotecan (Camptosar, CPT-11)|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
214658781|NCT05615428|DIAGNOSTIC_TEST|LS-ratio|Included infants will have a gastric aspirate sampled via an NG tube at birth. This sample will be analyzed to determine the LS-ratio The LS-ratio will retrospectively be compared to RDS development and need for surfactant treatment to establish the cut-off ratio for LS-ratio with respect to surfactant treatment.
214658782|NCT01254903|PROCEDURE|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
214658783|NCT02747004|DRUG|Abemaciclib|Administered orally
214658784|NCT02747004|DRUG|Tamoxifen|Administered orally
214658785|NCT02747004|DRUG|Prophylactic Loperamide|Administered orally
214658786|NCT06218251|DRUG|BOTOX|Intramuscular Injections
214658787|NCT05087030|DRUG|RGB-14-P|Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
214658788|NCT05087030|DRUG|Prolia®|Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
214848555|NCT03325972|DRUG|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
214848556|NCT03325972|OTHER|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
214848557|NCT02373995|BIOLOGICAL|LAB4|Additional treatment with the specific LAB4 probiotic preparation
214848558|NCT02826941|OTHER|hypothermia|Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours
214848559|NCT02826941|OTHER|normothermia|Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.
214848560|NCT04086641|DEVICE|Crossover foot|A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
214848561|NCT04086641|DEVICE|Energy Storing Foot|A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
214848562|NCT06355479|DRUG|OsrHSA|Recombinant Human Serum Albumin from Oryza Sativa
214848563|NCT06355479|DRUG|Plasbumin®-20|Albumin (Human) 20%, USP
214848564|NCT02551679|BIOLOGICAL|ACP-01|Injection into lower extremity
214658789|NCT06486012|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device home-use with a marker substance
214658790|NCT06486012|OTHER|Standard oral hygiene|Standard oral hygiene performed at home
214658791|NCT03653520|DRUG|Diazepam|5 or 10mg
214658792|NCT03653520|DRUG|Tramadol|50mg or 100mg
214658793|NCT03653520|DRUG|Ondansetron|1 or two tabs
214658794|NCT03653520|DRUG|MKO melt|1 or 2 MKO melts
214658795|NCT02998385|DRUG|Cisplatin|intravenous, concomitant to irradiation
214658796|NCT02998385|RADIATION|radiotherapy|66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week
214658797|NCT06090994|DRUG|Huaier granule|Oral administration, 10g once, 3 times a day, starting within 14 days-2 months after surgery. Please refer to the medication manual for specific usage.
214658798|NCT06090994|DRUG|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks, for a total of 4-6 courses.
214658799|NCT01444300|DRUG|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
214658800|NCT01444300|DRUG|Placebo|placebo pill, bid for 12 weeks
214658801|NCT05662826|BEHAVIORAL|Avatar-based Social Physical Activity|Exercise, group discussions, role-playing skits, and group painting done in a virtual setting.
214658802|NCT02619851|BIOLOGICAL|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
214658803|NCT02619851|DEVICE|Conventional Therapy|Typical therapy conducted for burn injury patients
214658804|NCT01048346|BEHAVIORAL|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
214658805|NCT05254795|OTHER|Molecular tumor board assisted care|Participants in this group will obtain recommendations for care from the molecular tumor board.
214658806|NCT04284657|DRUG|Pravastatin|Pravastatin 40 mg QD
214658807|NCT04284657|DRUG|sodium citrate|sodium citrate up to 30 ml TID
214658808|NCT01517035|PROCEDURE|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
214658809|NCT06267560|DRUG|TQJ230|TQJ230 80mg QM s.c.
214658810|NCT06267560|DRUG|Placebo|matching placebo
214658811|NCT01879657|DRUG|68Ga-DOTATATE|68Ga-DOTATATE (3-5 mCi ±25%; 111-185 MBq) is administered as a single intravenous bolus injection in each participant. These injections were performed within 28 days after the Octreoscan.
214658812|NCT01879657|DIAGNOSTIC_TEST|PET/CT|68Ga-DOTATATE PET images will be acquired 60 ±30 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET images were performed within 28 days after the Octreoscan.
214848565|NCT02551679|BIOLOGICAL|Placebo|Injection into lower extremity
214848566|NCT02940678|OTHER|No intervention|
214658813|NCT01879657|DIAGNOSTIC_TEST|111In-pentetreotide OctreoScan|OctreoScan™ was performed after intravenous injection of 111In-pentetreotide, a radiopharmaceutical that binds to somatostatin receptors, if the patient had not undergone such imaging as a standard of care. Subsequent planar and/or SPECT imaging was used to detect somatostatin receptor-positive lesions.
214658814|NCT01879657|DIAGNOSTIC_TEST|MRI|MRI (Standard of Care)
214658815|NCT02129673|DRUG|VS101 Insert Dose A|Sustained release of latanoprost into the eye
214658816|NCT02129673|DRUG|VS101 Insert Dose B|Sustained release of latanoprost into the eye
214658817|NCT02129673|DRUG|VS101 Insert Dose C|Sustained release of latanoprost into the eye
214658818|NCT02129673|DRUG|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
214658819|NCT02680353|PROCEDURE|Bilateral superficial cervical plexus block|A kind of anesthetic nerve block type performed to block the nerve function temporarily by administrating local anesthetics through the trajectory of the nerve.
214658820|NCT00120003|DRUG|Candesartan Cilexetil|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
214658821|NCT00120003|DRUG|Placebo|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
214658822|NCT03679325|DIETARY_SUPPLEMENT|vitamine D|a dose once a week
214658823|NCT03679325|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
214658824|NCT06217679|OTHER|Control Oral Glucose Tolerance Test|control oral glucose tolerance test
214658825|NCT06217679|OTHER|Mixed Exercise|exercise performed in randomized order
214658826|NCT05042726|DEVICE|cTBS First|Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 33.2s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.
214658827|NCT05042726|DEVICE|Pseudo-stimulation First|The transcranial magnetic stimulator operating system has a built-in control group option, in which the stimulation parameters are set consistent with the research group, which can realize the operation of only sound without stimulation.
214658828|NCT01053429|DRUG|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
214658829|NCT05337618|DIAGNOSTIC_TEST|Full-band Electrocorticography|Diagnosis of spreading depolarizations in continuous electrocorticography
214658830|NCT05337618|COMBINATION_PRODUCT|Treatment Algorithm|Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations
214658831|NCT04093830|DEVICE|hearing aid|hearing aid can be used in their non- implanted ear with residual hearing
214658832|NCT06202248|DEVICE|Experimental: DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
214848567|NCT01613378|OTHER|No intervention|No intervention administered in this study
214848568|NCT03113526|PROCEDURE|remove drain|remove drain when output is less than 30ml or less than 100ml per 24-hour
214658833|NCT06089044|DRUG|Dalbavancin Injection|Dalbavancin as long-term suppressive therapy.
214658834|NCT00003721|DRUG|incyclinide|This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
214658835|NCT02503605|DRUG|Biosimilar recombinant FSH|Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
214658836|NCT02503605|DRUG|Urinary FSH|Controlled ovarian stimulation with 150 IU/day urinary FSH
214658837|NCT02300649|DRUG|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
214658838|NCT02300649|DRUG|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
214658839|NCT01495143|PROCEDURE|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
214658840|NCT01374061|DEVICE|Classical intubation|Classical intubation
214658841|NCT01374061|DEVICE|GLIDESCOPE|GLIDESCOPE intubation
214658842|NCT00963807|DRUG|Cisplatin|Given IV
214658843|NCT00963807|PROCEDURE|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
214658844|NCT00963807|DRUG|Docetaxel|Given IV
214658845|NCT00963807|DRUG|FDG|Undergo FDG PET/CT
214658846|NCT00963807|DRUG|FLT|Undergo FLT PET/CT
214658847|NCT00963807|PROCEDURE|PET/CT|Undergo FDG PET/CT and FLT PET/CT
214658848|NCT00963807|PROCEDURE|Surgery|Undergo surgery
214658849|NCT05166707|DEVICE|BIXINK OC Free|OC Free is a 6-week ERP-based intervention to deliver Exposure and Response Prevention (ERP) to reduce the anxiety from obsessive thoughts and compulsive rituals.
214658850|NCT06960525|OTHER|Cervical joint mobilization|Passive cervical joint mobilization following Maitland's approach for 3 sets of 1 minute on the most painful segment with one minute rest between sets.
214658851|NCT06960525|OTHER|cervical strengthening exercises|concentric and eccentric training of the craniocervical, cervical flexors, extensors, muscles involved in cervical spine rotation and axioscapular muscles.
214658852|NCT00684177|DRUG|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
214658853|NCT00684177|DRUG|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
214658854|NCT04087226|DEVICE|PTFE Retraction Cord|Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
214848569|NCT05709769|OTHER|There are no interventions.|There are no interventions.
214848570|NCT02150772|PROCEDURE|Shear Wave Elastography (SWE)|
214658855|NCT06078176|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility and facilitate bowel emptying. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
214658856|NCT06606028|PROCEDURE|Blood Specimen Collection|Approximately 20 mL of peripheral blood (10 mL per tube, x 3 Streck tubes) will be drawn at each time point
214658857|NCT06606028|PROCEDURE|Tumor Tissue Collection|Formalin-fixed paraffin embedded tumor tissue samples (tissue blocks of 12 x 10 millimeter (mm) unstained slides) derived from biopsy or surgical resection will be collected at screening
214658858|NCT06606028|OTHER|Medical Record Review|Medical records will be reviewed to collect standard of care p16 staining by immunohistochemistry and/or high-risk human papillomavirus (HPV) DNA or RNA testing that is performed as part of standard of care
214658859|NCT06856187|DRUG|TAS-102+bevacizumab+local treatment|patients achieve disease control after second-line induction therapy with standard therapy(FOLFOX/FOLFIRI/XELOX/ mXELIRI＋bevacizumab/cetuximab), then achieve TAS-102+bevacizumab+local treatment
214658860|NCT06856187|DRUG|Standard chemotherapy|Standard therapy：FOLFOX/FOLFIRI/XELOX/ mXELIRI±bevacizumab/cetuximab
214658861|NCT05852756|BEHAVIORAL|pecha kucha|pecha kucha training
214658862|NCT05791058|PROCEDURE|ultrasound guided pericapsular nerve group shoulder block|The patient's arm is placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 20 cc of 0.25% bupivacaine hydrochloride with 4mg dexamesathone will be injected
214658863|NCT05791058|PROCEDURE|ultrasound guided suprascapular and axillary nerve block|The patient will be positioned in a semi-recumbent position with the operating arm on the contralateral shoulder. The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected below the supraspinatous fascia then the posterior surface of the humerus will be visualised in the short axis view. So, the AN and posterior circumflex artery will be visualised longitudinally. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected into space
214658864|NCT05791058|OTHER|general anesthesia without nerve block|this group will receive general anesthesia without nerve block
214658865|NCT06507904|DRUG|Osivelotor|A medicine to treat sickle cell disease.
214658866|NCT06507904|OTHER|Famotidine|Famotidine is a marketed medicine which decreases the amount of acid made in the stomach and is used to prevent and treat heartburn.
214658867|NCT06873308|DEVICE|UCP-LF CAA assay|dry LF-CAA, or CAA
214658868|NCT06688942|BEHAVIORAL|Horizons App Intervention|Participants will receive access to the Horizons app intervention. The intervention pairs patient-centered information about chronic graft-versus-host disease with self-management strategies. Within each module, patients will engage in didactics and exercises that are relevant to the participant's chronic graft-versus-host disease concerns. The app contains 6 digital modules delivered via tablet over approximately 6 weeks. Each module should take up to approximately 20 minutes and are self-guided.
214658869|NCT05516914|DRUG|LBL-007 Injection|Initial dose - MTD; Q3W; intravenous infusion
214658870|NCT05516914|DRUG|Tislelizumab Injection|Initial dose; Q3W; intravenous infusion
214658871|NCT05516914|DRUG|Cisplatin Injection|Initial dose；Q3W; intravenous infusion
214848571|NCT06617117|OTHER|High-intensity combined exercise|The main part consisted of interval cycling exercise, comprising 5x2 min at the second ventilatory threshold interspersed with 4x2 min at the first ventilatory threshold, followed by 2-min unloading pedalling. Subsequently, participants completed resistance exercises (2 sets of 12 repetitions), targeting the same muscle groups of the moderate-intensity exercise, at an intensity of 80% of their 1 repetition maximum.
214658872|NCT05516914|DRUG|Gemcitabine Hydrochloride for Injection|Initial dose；Q3W; intravenous infusion
214658873|NCT05516914|DRUG|Docetaxel injection|Initial dose；Q3W; intravenous infusion
214848572|NCT06617117|OTHER|Moderate-intensity combined exercise|The main part of the exercise session consisted of an 18-min cycling continuous aerobic exercise at the first ventilatory threshold, followed by 2-min of unloading cycling. Subsequently, participants engaged in resistance exercises - 2 sets of 12 repetitions at 60% of their one repetition maximum. These resistance exercises were part of a machine-assisted circuit training program, encompassing Chest Press, Leg Curl, Low Row, Leg Press, Lat Pull-down, and Leg Extension.
214848573|NCT00794417|DRUG|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
214848574|NCT00794417|DRUG|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
214848575|NCT00794417|DRUG|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
214848576|NCT01167517|OTHER|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge
214658874|NCT06723171|DRUG|IRX4204|Active Treatment
214658875|NCT06723171|OTHER|Placebo|Placebo
214848577|NCT05187858|DRUG|LNP3794|LNP3794 capsules administered orally once daily
214906963|NCT02588963|OTHER|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
214658876|NCT03709992|DRUG|Trospium Chloride|30 mg of Trospium chloride tablet twice daily
214658877|NCT03709992|DRUG|Tamsulosin|0.4 mg of Tamsulosin tablet once daily
214658878|NCT06773780|DRUG|local infiltration|The block procedure will be performed before the surgical procedure, following the induction of sedoanalgesia. Under sterile conditions, 30 mL of 0.25% bupivacaine will be administered to the targeted infiltration area. The local anesthetic will be specifically applied around the arterial and venous puncture sites.
214658879|NCT06773780|DRUG|PENG|With the patient in the supine position, a convex ultrasound (US) probe (4-8 MHz, Vivid Q) will be covered with a sterile sheath. An 80-mm block needle (Braun 360°) will be used. The probe will be placed transversely over the anterior inferior iliac spine. Subsequently, the probe will be rotated 45 degrees to visualize the pubic ramus. Once the femoral artery, iliopubic eminence, and psoas muscle are identified under ultrasound guidance, the needle will be advanced using an in-plane technique and positioned between the pubic ramus and the psoas tendon. After confirming the block site with 5 mL of saline, 30 mL of 0.25% bupivacaine will be injected as the local anesthetic.
214658880|NCT06773780|DRUG|FİB|The patient's legs will be positioned slightly externally rotated. A high-frequency ultrasound probe will be placed transversely along the inguinal ligament. Under ultrasound guidance, the femoral artery, iliopsoas muscle, and fascia iliaca will be identified. The needle will be advanced parallel to the ultrasound probe using the in-plane technique and positioned beneath the fascia iliaca. After confirming negative aspiration, 30 mL of 0.25% bupivacaine will be injected, and the spread of the solution beneath the fascia iliaca will be verified using ultrasound.
214658881|NCT06930209|DEVICE|CelluJuve®|CelluJuve® injected into upper brachium
214658882|NCT07108088|DEVICE|NEUROSWING Orthosis (experimental) : carbon orthosis with an active ankle articulation|"The patients will use the experimental device during 14 days straight as well, then a washout period of 7 days with no interventons and then the comparator during 14 days straight. The order in which they will use each device will depend on the groupe they have been randomized in :~* Arm 1 : Control device during 14 days, followed by a 7 day washout period, then exerimental device during 14 days~* Arm 2 : Experimental device during 14 days, followed by a 7 day washout period, then control device during 14 days"
214658883|NCT07108088|DEVICE|Carbon orthosis (control)|"The patients will use the experimental device during 14 days straight as well, then a washout period of 7 days with no interventons and then the comparator during 14 days straight. The order in which they will use each device will depend on the groupe they have been randomized in :~* Arm 1 : Control device during 14 days, followed by a 7 day washout period, then exerimental device during 14 days~* Arm 2 : Experimental device during 14 days, followed by a 7 day washout period, then control device during 14 days"
214658884|NCT06930937|OTHER|Lixiana® Film Coated Tablet|Lixiana® 60 mg filmtabletten (Film Coated Tablet) (Edoxaban)
214658885|NCT06930937|OTHER|Edoxaban Film Coated Tablet|Edoxaban 60 mg Film Coated Tablet
214658886|NCT06935721|DRUG|Y-4 tablet|Subjects will be admitted to research center in the afternoon of Day-1 prior to the dosing day and fasting for the next 10 hours overnight. In the morning of the following day (Day 1), subjects will be administered with one tablet of Y-4 , then subjects will be monitored and blood samples will be collected for the following 72 hours. Subjects will be discharged on Day 4.
214658887|NCT06935721|DRUG|Pregabalin capsule|Subjects will be admitted to research center in the afternoon of Day 7 prior to the dosing day and fasting for the next 10 hours overnight. In the morning of the following day (Day 8), subjects will be administered with one pregabalin capsule , then subjects will be monitored and blood samples will be collected for the following 72 hours. Subjects will be discharged on Day 11.
214658888|NCT06935721|DRUG|Riluzole tablet|Subjects will be admitted to research center in the afternoon of Day 14 prior to the dosing day and fasting for the next 10 hours overnight. In the morning of the following day (Day 15), subjects will be administered with one riluzole tablet, then subjects will be monitored and blood samples will be collected for the following 72 hours. Subjects will be discharged on Day 18 after safety evaluation.
214658889|NCT06936345|BEHAVIORAL|Cawthorne-Cooksey Exercises|A set of vestibular rehabilitation exercises aimed at improving balance and reducing dizziness through repeated head and body movements, delivered via home-based digital instructions.
214658890|NCT06936345|BEHAVIORAL|Brandt-Daroff Exercises|A traditional home-based vestibular exercise program for treating positional dizziness, involving repetitive lateral head movements performed daily.
214658891|NCT06936345|OTHER|Theta Binaural Beats|A digital auditory stimulation using two tones of slightly different frequencies to create a theta-frequency beat, intended to modulate anxiety and enhance vestibular rehabilitation effects.
214658892|NCT06935175|DRUG|SHR-1826|SHR-1826 will be administrated per dose level in which the patients are assigned.
214658893|NCT06935175|DRUG|SHR-1826 and immunotherapy combination therapy|SHR-1826 and immunotherapy will be administrated per dose level in which the patients are assigned.
214658894|NCT06936761|DRUG|Propofol|This is an observational study about routines of anesthesia induction and extubation
214658895|NCT06936761|DRUG|Sevoflurane|This is a retrospective evolution of anesthesia drugs used routinely in an anesthesia clinic.
214658896|NCT06936293|BEHAVIORAL|Mindfulness Meditation|"The experimental group received 30 minutes of mindfulness meditation according to Smith's (2005) protocol, which is a standardized theory-based intervention. Smith's (2005) protocol comprises six components:~1. Being mindful of the breath (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of the thought (5 minutes)~4. Being mindful of the sound (5 minutes)~5. Being mindful during walking (5 minutes)~6. Full meditation (5 minutes). An additional two-hour educational workshop about the rationale and procedures of intervention was provided before the actual training sessions. To ensure the consistent delivery of the intervention, the researcher recorded the intervention instructions in Arabic based on the intervention protocol and sent the audio-recorded instructions to the participants via WhatsApp or email to be accessed by their cell phones and headsets. The audio-recorded intervention contents were validated by two psychologists and experts in meditation."
214906964|NCT02588963|OTHER|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
214906965|NCT02588963|OTHER|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
214658897|NCT06936072|PROCEDURE|Titanium Ring Inlay Eminence Augmentation|"* Preauricular approach with subperiosteal dissection~* Dual osteotomy (transverse mid-eminence + vertical parallel to skull base)~* Titanium ring inlay placement with anatomical contouring~* Intraoperative functional assessment"
214658898|NCT06277648|PROCEDURE|PENG block|PENG block was performed by the primary investigator (B.C) following proper skin disinfection with the patient in the supine position. Under the guidance of a low-frequency curvilinear ultrasound probe, the iliopubic eminence and the psoas tendon were identified, and local anaesthetic as 30 mL 0.375% bupivacaine was injected between the periosteum and psoas tendon following negative aspiration.
214658899|NCT06277648|PROCEDURE|SIFIB|The high-frequency linear probe was placed medial to the anterosuperior iliac spine in a parasagittal orientation to visualize the bow tie appearance formed by the sartorius's internal oblique and iliacus muscles. The needle tip was placed under fascia iliaca through an in-plane approach, and local anaesthetic as 30 mL 0.375% bupivacaine was injected from the caudad to the cephalic direction.
214658900|NCT06936956|OTHER|Acupressure|Acupressure is a noninvasive type of acupuncture. It is applied using fingers, joints or a suitable acupressure tool.
214658901|NCT00787293|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
214658902|NCT06946160|DRUG|Abobotulinumtoxin A (Espad Pharmed Darou Co.)|Vial of Abobotulinumtoxin A (produced by Espad Pharmed Darou Co.), administered via deep intramuscular injection
214658903|NCT06946160|DRUG|Abobotulinumtoxin A (Ipsen Co.)|Vial of AbobotulinumtoxinA (Dysport®, produced by Ipsen Co.), administered via deep intramuscular injection
214658904|NCT06951893|OTHER|Hospital Anxiety and Depression Scale|It is a self-assessment questionnaire to identify the existence of anxious and depressive symptoms and to assess their severity.
214658905|NCT06951893|OTHER|Dutch Eating Behaviour Questionnary|"It allows the assessment of 3 distinct factors of eating behavior: cognitive restriction, emotional eating and externality. This tool was developed to better characterize the eating habits of obese subjects.~10min"
214658906|NCT06951893|OTHER|Impact of Weight on Quality Of Life|The EQVOD is a validated French scale created from the Impact of Weight on Quality of Life (IWQOL) questionnaire. This self-administered questionnaire is specific to the sociocultural factors of obesity and its dietary treatment in France. The questionnaire is composed of five dimensions: physical impact (11 items), psychosocial impact (11 items), impact on sexual life (4 items), dietary well-being (5 items), and experience of diet/dietetics (5 items). The total number of items is 36.
214658907|NCT06951893|OTHER|body schema|Tactile assessment of the body schema using a motorized caliper applied to different parts of the individual's body. The caliper is connected to a touch pad on which the person can report the difference felt between the two pressure points on their skin, using their thumb and index finger.
214658908|NCT06951893|OTHER|body mass index|patient weighing at each visit
214658909|NCT06951893|OTHER|waist size|waist size measure
214658910|NCT04355988|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
214848578|NCT04491578|BEHAVIORAL|"ACP programme Have a Say"|Each dyad of participants will receive a 4-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 2 group-based sessions and 2 dyadic discussions. One hour for each session. The group-based sessions are nurse-led, in which dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are led by trained ACP facilitator. Dyads of participants will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
214848579|NCT00792623|BIOLOGICAL|VarilrixTM|Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
214658911|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.|At-home remotely supervised tDCS delivered over the dorsolateral prefrontal cortex with the anode on the left, cathode on the right, at an intensity of 2 mA, delivered for 30 minutes five times per week (Monday-Friday) for 26 weeks (6 months).
214658912|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.|Sham treatment will consist of the current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining time of the 30-minute application period five times per week (Monday-Friday) for 26 weeks (6 months).
214658913|NCT06799195|DRUG|Attenuated-dose Cyclophosphamide|Cyclophosphamide administered at an attenuated dose of 25 mg/kg on days +3 and +4 post-transplant for GVHD prophylaxis.
214658914|NCT06799195|DRUG|High-dose Cyclophosphamide|Cyclophosphamide administered at the standard high dose of 50 mg/kg on days +3 and +4 post-transplant for GVHD prophylaxis.
214658915|NCT06799195|DRUG|Sirolimus|Sirolimus is started on day +5 with a loading dose of 6 mg, followed by a maintenance dose of 2 mg daily, adjusted to target trough levels of 8-12 ng/mL. Sirolimus taper is recommended to start at day +90 and to be completed by day +180, provided there is no evidence of acute GVHD.
214658916|NCT06799195|DRUG|Mycophenolate Mofetil (MMF)|MMF is started on day +5 at a dose of 15 mg/kg per dose (maximum 1 g per dose) three times daily. MMF is generally discontinued by day +35 in the absence of GVHD.
214848580|NCT06092190|DEVICE|EMG|Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction
214658917|NCT06111755|OTHER|SmokefreeTXT|National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.
214658918|NCT06111755|DEVICE|Smartband|A smartband that will track smoking in real-time and ask the individual to confirm/deny smoking. Participants will be asked to wear the smartband during their waking hours and to charge it overnight.
214658919|NCT00520026|DRUG|lithium|
214658920|NCT00520026|DRUG|placebo|
214658921|NCT05139524|OTHER|Evidence of past or recent RVF exposure|Detection of RVF exposure.
214658922|NCT01228773|BEHAVIORAL|Tailored web-based care program (Health Navigation®)|When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
214658923|NCT00784407|DEVICE|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
214658924|NCT02058121|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is provided in 12 weekly two hour long sessions in a group setting
214658925|NCT02058121|BEHAVIORAL|Treatment as usual|Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a physician, dietician and/or physiotherapist.
214658926|NCT03025412|PROCEDURE|endoscopic surgery|Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
214658927|NCT03025412|BEHAVIORAL|physiotherapy and exercise|Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
214658928|NCT00608465|DRUG|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
214658929|NCT00608465|DRUG|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
214658930|NCT02395315|DEVICE|Well-controlled diabetic (WC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
214658931|NCT02395315|DEVICE|Poorly controlled diabetics (PC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
214658932|NCT05794165|DRUG|Thrombate infusion|Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
214658933|NCT05794165|DRUG|Placebo|Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
214658934|NCT02042066|DEVICE|Omnispec model Vascuspec|Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
214658935|NCT05144165|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
214848581|NCT00521989|DRUG|CRx-102 (2.7/90)|CRx-102 dose 1
214848582|NCT00521989|DRUG|Prednisolone|Prednisolone
214848583|NCT00521989|DRUG|Placebo|Placebo
214848584|NCT00521989|DRUG|CRx-102 (2.7/180)|CRx-102 dose 2
214848585|NCT00521989|DRUG|CRx-102 (2.7/360)|CRx-102 dose 3
214658936|NCT01284192|DRUG|ASP3026|Tablet
214658937|NCT01671904|DRUG|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter \[mg/m\^2\]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
214658938|NCT01671904|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams \[mg\]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
214658939|NCT01671904|DRUG|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m\^2) on Day 1 of Cycle 1 and 500 mg/m\^2 administered on Day 1 of Cycles 2-6.
214658940|NCT01671904|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
214658941|NCT02863263|DEVICE|Foam Dressing|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device on its own. Subjects are randomised to one of 2 arms.
214658942|NCT02863263|DEVICE|Foam Dressing with Povidone Iodine|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device own. Subjects are randomised to one of 2 arms.
214658943|NCT03026803|DRUG|Oxaliplatin|Given IV
214658944|NCT03026803|DRUG|Capecitabine|Given PO
214658945|NCT06187506|DRUG|Disitamab vedotin|2.0 mg/kg, administered intravenously every three weeks
214658946|NCT06187506|DRUG|Bacillus Calmette Guerin Vaccine|Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
214658947|NCT00998101|DRUG|cetuximab|400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
214658948|NCT00998101|DRUG|carboplatin|AUC=6 Day 1 of treatment over 30 minutes every 21 days
214658949|NCT00998101|DRUG|ixabepilone|30 mg/m2 , Day 1 over 3 hours every 21 days
214658950|NCT01586728|OTHER|Air - oxygen|"1. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)~2. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
214658951|NCT01586728|OTHER|Oxygen - Air|"1. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~2. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
214658952|NCT04079777|DRUG|Clinical treatment|Liquid Resuscitation, Anti-infection
214658953|NCT06265545|DRUG|Ivosidenib,Venetoclax,gilteritinib,Selinexor|if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)
214658954|NCT00345072|DEVICE|Web-based decision aid system|
214658955|NCT01817257|DRUG|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
214658956|NCT04349930|DRUG|Cannabidiol vaginal suppository|Cannabidiol vaginal suppository
214658957|NCT04349930|DRUG|Placebo vaginal suppository|Placebo vaginal suppository
214658958|NCT05394298|DRUG|Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity from a pre-stablished list of antibiotics included
214848586|NCT06334419|DRUG|Gaboxadol|Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)
214658959|NCT05394298|DRUG|Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity a pre-stablished list of antibiotics included
214658960|NCT06434168|BEHAVIORAL|Yoga intervention|Patients in the yoga group will receive a 60-minute session, twice per week over 12 weeks for a total of 24 sessions. Each yoga session consists of a warm-up, yoga postures standing or seated depending on the capability of the patient, and relaxation.
214658961|NCT06434168|BEHAVIORAL|Control condition|Patients in the control group will receive care-as-usual from their healthcare providers and will be asked to avoid engaging in yoga during their 3 months in the study.
214658962|NCT03095703|DRUG|Sirolimus|Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
214658963|NCT05476796|DRUG|Trifluridine/Tipiracil|Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
214658964|NCT05476796|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
214658965|NCT05476796|DRUG|FOLFOX regimen|Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
214658966|NCT05476796|DRUG|Nivolumab|Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
214658967|NCT06272643|DIAGNOSTIC_TEST|IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography)|OCT and IVUS in Patients with LMCA lesion (25-60%)
214658968|NCT04905797|DIAGNOSTIC_TEST|Emotional Stop Signal Task|Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.
214658969|NCT04905797|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry
214658970|NCT04905797|OTHER|World Health Organizations Disability Assessment Schedule (WHODAS 2.0)|Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.
214658971|NCT04905797|DIAGNOSTIC_TEST|Personality Inventory for DSM-5 (PID-5)|Self-rated personality traits through Personality Inventory for DSM-5 (PID-5). Self-reported scores on domains of personality traits. Higher scores in one domain indicate more pronounced traits in this domain.
214658972|NCT04905797|DIAGNOSTIC_TEST|Stop Signal Task (CANTAB)|The estimate of time where an individual can successfully inhibit their responses 50% of the time.
214848587|NCT06334419|DRUG|Placebo|Two placebo capsules
214906966|NCT02748746|DEVICE|Bio Impedance Analysis Measurement|Self-adhesive electrodes will be placed to related side's hand dorsum and foot dorsum regarding to calculate for left or right upper extremity's impedance. After completing the measurements for each side, results will be saved by device and documented on paper. A patient total measurement time lasts approximately 3 minutes.
214658973|NCT04905797|DIAGNOSTIC_TEST|Intra-Extra Dimensional Set Shift (CANTAB)|"1. The number of trials for which the outcome was an incorrect response (subject pressed the incorrect button within the response window), calculated across all assessed trials.~2. The total number of times that the subject chose a wrong stimulus - i.e. one incompatible with the current rule, adjustment for every stage that was not reached."
214658974|NCT04905797|DIAGNOSTIC_TEST|Spatial Working Memory Test (CANTAB)|"1. The number of times the subject incorrectly revisits a box in which a token has previously been found. Calculated across all assessed four, six and eight token trials.~2. The number of times a subject begins a new search pattem from the same box they started with previously. If they always begin a search from the same starting point, we infer that the subject is employing a planned strategy for finding the tokens. Therefore, a low score indicates high strategy use (1 = they always begin the search from the same box), a high score indicates that they are beginning their searches from many different boxes. Calculated across assessed trials with 6 tokens or more."
214658975|NCT04905797|DIAGNOSTIC_TEST|Multitasking Test (CANTAB)|"1. The number of trials for which the outcome was an incorrect response.~2. The median latency of response (from stimulus appearance to button press). Calculated across all correct, assessed trials.~3. The difference between the median latency of response on the trials that were congruent versus the trials that were incongruent. A positive score indicates that the subject is faster on congruent trials and a negative score indicates that the subject is faster on incongruent trials. A higher incongruency cost indicates that the subjects take longer to process conflicting information.~4. The difference between the median latency of response during assessed blocks in which both rules are used versus assessed blocks in which only a single rule is used. A positive score indicates that the subject responds more slowly during multitasking blocks and indicates a higher cost of managing multiple sources of information."
214658976|NCT04905797|DIAGNOSTIC_TEST|Cambridge Gambling Task Test|"1. The proportion (0 - 1) of all trials where the subject chose the majority box color. Calculated over all assessed trials from both the ascending and descending conditions in which the number of boxes of each color differed.~2. Risk adjustment is a measure of sensitivity to risk, based on the ability to modify choices in the light of information about the probability of different outcomes and to track the optimal outcome on eaeh trial. The measure is calculated from the average proportion of points that the subject ehose to bet with, taking into aeeount the number of colored boxes in the majority.~3. Allows for the dissociation between risk taking and impulsivity by determining whether subjects simply just place a bet at the first opportunity. Calculated as CGT Risk Taking for all trials from the descending condition minus CGT Risk Taking for all trials from the ascending condition."
214658977|NCT06583083|DRUG|Sintilimab with P-GEMOX Regimen|Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
214658978|NCT06583083|DRUG|P-GEMOX Regimen|Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
214658979|NCT06081387|OTHER|Resistance training|Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.
214658980|NCT05054985|DEVICE|Multi-Branched Thoracoabdominal Stent Graft System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
214658981|NCT06387615|OTHER|Active cTBS|Active stimulation
214658982|NCT06387615|OTHER|Sham|Control stimulation
214658983|NCT01381094|DRUG|AKB-6548|oral dose administered once daily for 42 days
214658984|NCT01381094|DRUG|Placebo|oral Placebo administered once daily for 42 days
214658985|NCT04440267|DRUG|vincristine|acute lymphoblastic leukemia (ALL) -based chemotherapy
214658986|NCT04440267|DRUG|daunorubicin|acute lymphoblastic leukemia (ALL) -based chemotherapy
214658987|NCT04440267|DRUG|cyclophosphamide|acute lymphoblastic leukemia (ALL) -based chemotherapy
214658988|NCT04440267|DRUG|L-Asparaginase|acute lymphoblastic leukemia (ALL) -based chemotherapy
214658989|NCT04440267|DRUG|prednisone|acute lymphoblastic leukemia (ALL) -based chemotherapy
214658990|NCT04440267|DRUG|mercaptopurine|acute lymphoblastic leukemia (ALL) -based chemotherapy
214848588|NCT04286919|BEHAVIORAL|A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students|A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
214848592|NCT00143299|DRUG|varenicline (CP-526,555)|
214658991|NCT04440267|DRUG|methotrexate|acute lymphoblastic leukemia (ALL) -based chemotherapy
214658992|NCT04440267|DRUG|dexamethasone|acute lymphoblastic leukemia (ALL) -based chemotherapy
214658993|NCT04440267|DRUG|Tyrosine kinase inhibitor|acute lymphoblastic leukemia (ALL) -based chemotherapy
214848593|NCT05557448|DRUG|TYNADOTE|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
214848594|NCT05557448|DRUG|Placebo Oral Tablet|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
214658994|NCT01501487|DRUG|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
214658995|NCT01501487|DRUG|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
214658996|NCT01501487|DRUG|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
214658997|NCT01501487|DRUG|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
214658998|NCT01501487|DRUG|T + trastuzumab followed by CEF + trastuzumab|"Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.~Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr"
214658999|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).~Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week."
214659000|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
214659001|NCT01501487|DRUG|PTH followed by dose dense AC of FEC|"Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel."
214659002|NCT03530449|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
214659003|NCT03530449|DEVICE|Color Fundus Photography|Non-contact white light photography
214659004|NCT03530449|DEVICE|Optical Coherence Tomography|Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.
214848595|NCT01580657|BEHAVIORAL|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
214848596|NCT01580657|BEHAVIORAL|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
214848597|NCT01580657|BEHAVIORAL|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
214848598|NCT01580657|BEHAVIORAL|Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
214848599|NCT01580657|BEHAVIORAL|General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
214848600|NCT01580657|BEHAVIORAL|No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
214848601|NCT03679273|DIETARY_SUPPLEMENT|Abound|Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
214848602|NCT02286973|DRUG|Tranexamic Acid|
214848603|NCT02385201|DEVICE|Senza|Spinal Cord Stimulation
214848604|NCT01797926|DRUG|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
214848605|NCT01797926|DRUG|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
214848606|NCT01797926|DRUG|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
214848607|NCT01797926|DRUG|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
214659005|NCT00686556|DRUG|cyclophosphamide|60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
214659006|NCT00686556|DRUG|cyclosporine|Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
214659007|NCT00686556|DRUG|Fludarabine|25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
214659008|NCT00686556|DRUG|mycophenolate mofetil|Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients \<40 kg, 3 gm/day for patients \>40 kg.
214659009|NCT00686556|RADIATION|total marrow irradiation|Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
214659010|NCT00686556|PROCEDURE|umbilical cord blood transplantation|product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
214659011|NCT00686556|BIOLOGICAL|Granulocyte colony-stimulating factor|5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10\^9/L for 3 consecutive days.
214659012|NCT00686556|BIOLOGICAL|HLA-matched related donor bone marrow|Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
214659013|NCT04092257|PROCEDURE|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
214659014|NCT05354960|OTHER|Questionnaire validation|Validation and cultural adaption of the German version of the LIMB-Q
214659015|NCT03744650|BEHAVIORAL|"Care4Heart programme"|"A 4-week mHealth programme in the form of a smartphone app, named Care4Heart, has been developed. The content and scope of the design are developed by a thorough literature review and an extensive analysis of existing education leaflets and brochures used to prevent CHD. The contents are specified and tailored to the working population.~The app is developed by a team of software engineers from Computing School of NUS. Several functions include: (1) app using instructional video; (2) easy-to-read information on healthy lifestyle toward heart health, including information about the disease, CHD risk factors (e.g. diet, smoking cessation), stress, physical exercises and relaxation techniques; and (3) scheduled reminders for doing exercise and relaxation"
214659016|NCT06276569|DRUG|Sivelestat|(1)Experimental group: Received intravenous sivelestat sodium admission to the ICU. Sivelestat sodium was dissolved in 0.9% sodium chloride injection and a one-day dose (4.8mg/kg) was diluted in 50ml of 0.9% sodium chloride injection, which was then sealed for continuous intravenous administration at a rate of 0.2 mg/kg/h for seven consecutive days.
214659017|NCT06276569|OTHER|placebo|2)Control group: Receiving the same dose of placebo, 50 ml of saline, were administered intravenously at a rate of 0.2 mg/kg throughout the treatment period without any discernible impact on patient's regular treatment regimen.
214659018|NCT05075642|OTHER|Initial management of the urinary disorder/s identified during the screening phase|Intervention can be defined as the initial management of the LUTS identified during the screening phase; management lasts at least three months. As observation of routine clinical practice, no specific intervention is included, but any counseling/drug/rehabilitation included as first line management.
214659019|NCT01490593|BEHAVIORAL|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
214659020|NCT01934504|PROCEDURE|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
214659021|NCT02665689|DRUG|ranibizumab|Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
214659022|NCT03396289|OTHER|Conventional physiotherapy including balance exercises|Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
214659023|NCT03396289|OTHER|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
214659024|NCT00277537|DRUG|Mannitol|320mg BD 12 weeks followed by 40 weeks open label
214659025|NCT00277537|DRUG|placebo|BD for 12 weeks
214659026|NCT06398730|DRUG|GEH200520 Injection and GEH200521 (18F) Injection|Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
214659027|NCT06398730|DIAGNOSTIC_TEST|Static - PET/CT scan|Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection
214659028|NCT00003417|DRUG|carmustine|
214659029|NCT00003417|RADIATION|radiation therapy|
214659030|NCT02521129|DEVICE|Biopsy Track Ablator (STARmed, Goyang, Korea)|After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
214659031|NCT06489288|OTHER|ERAS protocol|The ERAS process mainly includes removing the urethral catheter before the recovery of anesthesia, removing the abdominal drainage tube within 3 days after surgery, removing the nasogastric feeding tu
214659032|NCT05203939|DRUG|OCU400 Low Dose|subretinal injection of up to 1.66×10E10 vg/mL
214659033|NCT05203939|DRUG|OCU400 Med Dose|subretinal injection of up to 3.33×10E10 vg/mL
214659034|NCT05203939|DRUG|OCU400 High Dose|subretinal injection of up to 1.66×10E11 vg/mL
214659035|NCT05203939|DRUG|OCU400 Second Eye Dosing|subretinal injection of 1.0x10E11vg/mL in 250 μl
214659036|NCT05122806|GENETIC|RNAseq|"1. Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify the ALK fusion partner and its variant and associated co-mutations.~2. ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be performed on blood samples"
214659037|NCT04964869|PROCEDURE|epinephrine solution injection|epinephrine solution injection at least 1 ml to the post- sphincterotomy wound
214659038|NCT05947149|OTHER|questionnaires administration|"Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS.~Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS.~Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43."
214659039|NCT03771625|RADIATION|radiotherapy|whole brain with/without spinal cord
214659040|NCT01295333|DRUG|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
214659041|NCT01295333|DRUG|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
214659042|NCT05283733|PROCEDURE|reverse conversion technique|converting open appendectomy to laparoscopic technique for proper control of intraabdominal sepsis
214659043|NCT04696549|BEHAVIORAL|Virtual visual art experience guided by Visual Thinking Strategies|All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
214659044|NCT00541307|DEVICE|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
214659045|NCT03222661|DIAGNOSTIC_TEST|Refraction|Refractive error measurement
214659046|NCT04466124|RADIATION|Liver Cancer Patients Treated With Proton Beam Therapy|Proton Beam Therapy
214659047|NCT02455557|OTHER|Laboratory Biomarker Analysis|Correlative studies
214659048|NCT02455557|DRUG|Montanide ISA 51 VG|Given SC
214659049|NCT02455557|BIOLOGICAL|Sargramostim|Given SC
214659050|NCT02455557|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
214659051|NCT02455557|DRUG|Temozolomide|Given PO or IV
214659052|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #1|Ad26.ZEBOV - Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
214659053|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #2|Ad26.ZEBOV - Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
214659054|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #3|Ad26.ZEBOV - Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
214659055|NCT02543268|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57.
214659056|NCT02543268|BIOLOGICAL|Placebo|One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
214659057|NCT03750825|DEVICE|NIDA Standard Research E-cigarette (SREC)|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
214659058|NCT06474663|DRUG|Cladribine|Given by IV
214659059|NCT06474663|DRUG|Cytarabine|Given by SC
214659060|NCT06474663|DRUG|Sorafenib|Given by PO
214659061|NCT06474663|DRUG|Decitabine|Given by IV
214659062|NCT06334835|DIAGNOSTIC_TEST|lncRNA signature analyses|Evaluation of a signature of identified lncRNA in a cohort of childhood T-ALL patients in comparison with healthy subjects.
214659063|NCT04915508|DRUG|Hormone Therapy|Receive hormonal therapy
214659064|NCT04915508|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214659065|NCT06960239|DEVICE|IRE System|Irreversible Electroporation (IRE) System for the Treatment of Upper Airway Obstruction due to Adenotonsillar Hypertrophy in Children
214659066|NCT02481765|DEVICE|High definition transcranial direct current stimulation|
214659067|NCT04728633|DRUG|Carmustine|Given via infusion
214659068|NCT04728633|DRUG|Ethiodized Oil|Given via infusion
214659069|NCT04728633|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
214659070|NCT04728633|OTHER|Medical Device Usage and Evaluation|Given gelatin sponge via injection
214659071|NCT04253132|DRUG|Tolfenamic Acid|Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
214659072|NCT04253132|DRUG|Placebos|oral placebo
214659073|NCT03173469|OTHER|magnetic resonance imaging of breast|all patients will undergo preoperative MRI
214659074|NCT04704180|BEHAVIORAL|Facilitation Tuchking Position|The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
214659075|NCT04705454|BIOLOGICAL|Loncastuximab Tesirine|
214659076|NCT06260787|PROCEDURE|In Vitro Fertilisation|Assisted reproductive technology in the form of in vitro fertilisation
214659077|NCT02900092|DRUG|Ganaxolone|Participants received ganaxolone
214659078|NCT03895203|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
214659079|NCT03895203|DRUG|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
214659080|NCT03895203|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points.
214659081|NCT01001585|DRUG|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
214659082|NCT06258278|PROCEDURE|Arthroscopic-assisted lower trapezius tendon transfer surgery|The procedure, conducted under general anesthesia, starts with diagnostic arthroscopy followed by excision of the posterior bursa and preparation of the rotator cuff footprint. Attention then shifts to harvesting the low trapezius tendon, accessed through a 10cm incision over the spina scapula. The tendon is detached, dissected, and released from adhesions, ensuring not to damage its pedicle. A fascia lata graft is harvested from the ipsilateral thigh and sutured to the low trapezius tendon in a continuous, locking manner to aid fixation on the humeral head. A subdeltoid tunnel is formed, and the graft is shuttled into the subacromial space and fixed at the bicipital groove and tuberculum majus with knotless anchors. The stability of fixation and mobility of the low trapezius muscle are verified, and the graft and tendon are sutured together with tension, with the arm held in 90° abduction and maximum external rotation.
214659083|NCT00996840|DRUG|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
214659084|NCT00996840|DRUG|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
214659085|NCT00996840|DRUG|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
214659086|NCT00996840|DRUG|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
214659087|NCT00996840|OTHER|Placebo|Placebo to match intervention
214659088|NCT02381158|DRUG|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
214659089|NCT02281812|PROCEDURE|Radiofrequency ablation|After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H\&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
214659090|NCT03237676|OTHER|Structured cognitive rehabilitation therapy|A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
214659091|NCT03237676|OTHER|Patient-centred cognitive therapy|"Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.~Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review."
214659092|NCT02914626|DRUG|Intravitreal ranibizumab|Intravitreal ranibizumab injection
214659093|NCT03455387|DIAGNOSTIC_TEST|sampling of the serum marker sFlt1 and PlGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
214659094|NCT05526560|DEVICE|MITRIS RESILIA Mitral Valve, Model 11400M|Replacement of mitral valve with MITRIS RESLIA Mitral Valve
214659095|NCT02433509|OTHER|hUCB|"1. The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million \~ 500 million will used.~2. 20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
214659096|NCT03975998|PROCEDURE|Mitral valve repair|Minimally invasive repair of severe organic mitral regurgiation
214659097|NCT03424109|BEHAVIORAL|healthcare service utilization in the six months following the ED visit|The analysis of the effect of PRIM-ER on ED disposition using a generalized linear binomial model with random site level effects.
214659098|NCT06502990|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
214659099|NCT02848755|DEVICE|Cranial ultrasonography|
214659100|NCT03755622|DEVICE|Conventional Transpalatal Arch (TPA)|In Group C, upper molar bands selection will be carried out by direct intra oral procedure. The conventional TPA is made on the stone working models.
214659101|NCT03755622|DEVICE|Transpalatal Arch (TPA) fabricated from 3D reconstructed model|In Group 3D, upper molar bands selection will be carried out on the 3D printed model instead of direct intra oral procedure. The 3D TPA will be fabricated on the 3D reconstructed model while the conventional TPA is made on the stone models.
214659102|NCT03604731|DEVICE|cytokine adsorbtion during extracorporeal circulation|preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
214659103|NCT06054217|DRUG|Vehicle of TP-03|The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
214659104|NCT01290926|DRUG|chemotherapy|sorafenib 600mg/day capecitabine 1250 mg/m²/day
214659105|NCT01485614|DRUG|Sitagliptin|Sitagliptin 100 mg tablet administered orally once daily
214659106|NCT01485614|DRUG|Metformin|Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
214659107|NCT01485614|DRUG|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet administered orally once daily
214659108|NCT01485614|DRUG|Placebo to metformin|Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
214659109|NCT01485614|DRUG|Glycemic Rescue 1|Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.
214659110|NCT01485614|BIOLOGICAL|Glycemic Rescue 2|Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
214659111|NCT05206461|OTHER|Trunk Control Measurement Scale|Trunk Control Measurement Scale, easy and simple to use, was used to evaluate trunk control
214659112|NCT03180814|OTHER|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
214659113|NCT02891421|BEHAVIORAL|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
214659114|NCT02891421|OTHER|Standard Care|Standard Care: Participants received standard care
214659115|NCT02210780|DRUG|Dupilumab|Administered via subcutaneous injection.
214659116|NCT02210780|DRUG|Placebo|An inactive substance containing no medicine administered via subcutaneous injection.
214659117|NCT00889356|DRUG|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
214659118|NCT00889356|DRUG|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
214659119|NCT01209858|DRUG|Perampanel and Microgynon-30|Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
214659120|NCT01209858|DRUG|Perampanel and Microgynon-30|Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
214659121|NCT02582515|DRUG|D-cycloserine|
214659122|NCT02582515|DRUG|Placebo|
214659123|NCT01093495|DEVICE|CPAP|CPAP
214659124|NCT01093495|DEVICE|Nasal Cannula|Nasal Cannula
214659125|NCT00775021|DEVICE|etafilcon A|Contact Lens
214659126|NCT00775021|DEVICE|nelfilcon A|Contact Lens
214659127|NCT00427414|DRUG|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
214659128|NCT02488278|DEVICE|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
214659129|NCT06483646|OTHER|Gaseous sampling:|the subject is asked to aspirate the gaseous contents of his oral cavity using a 1ml plastic syringe.
214659130|NCT01851967|OTHER|MoodGYM|MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
214659131|NCT04814264|BIOLOGICAL|Red blood cells|All transfused red blood cells will be obtained from Canadian Blood Services and will be the standard red blood cell products currently provided in Canada.
214659132|NCT04912167|DRUG|Sacubitril-Valsartan|After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
214659133|NCT04912167|DRUG|Enalapril|After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
214659134|NCT04912167|DRUG|Valsartan|For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
214659135|NCT04274322|OTHER|Nutrition support|Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement
214659136|NCT03409549|RADIATION|Fluciclovine PET/CT|Fluorine-18 Fluciclovine PET/CT scan of the brain
214659137|NCT04975958|DRUG|AN2025|oral administration
214659138|NCT04975958|DRUG|AN0025|oral administration
214659139|NCT04975958|DRUG|Atezolizumab 1200 mg in 20 ML Injection|infusion
214659140|NCT03190343|PROCEDURE|cholangio-pancreatoscopy|
214659141|NCT06323824|DRUG|Methadone|"Drug: Methadone~Possible formulations:~10 and 50 mg tablets"
214659142|NCT06323824|DRUG|Buprenorphine (BUP)|"Drug: Buprenorphine (BUP)~Possible formulations:~A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day~B. Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade) 8 mg q 7 days (Brixadi) 16 mg q 7 days (Brixadi) 24 mg q 7 days (Brixadi) 32 mg q 7 days (Brixadi) 64 mg q 7 28 days (Brixadi) 96 mg q 7 28 days (Brixadi) 128 mg q 7 28 days (Brixadi)"
214659143|NCT03078062|DRUG|Dexamethasone|Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
214659144|NCT03078062|DRUG|Normal saline|Administration of a single-dose of Normal saline during spinal anesthesia
214659145|NCT00206973|PROCEDURE|mannitol test|
214659146|NCT03431012|OTHER|Agency Assignment framing|Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch…') or the pandemic flu virus itself (VA: 'It can infect you when you touch…')
214659147|NCT03431012|OTHER|Attribute framing|Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
214659148|NCT03030287|DRUG|OMP-305B83|intravenous (in the vein) infusion
214659149|NCT03030287|DRUG|Paclitaxel|administered intravenously
214659150|NCT04796402|BIOLOGICAL|Bamlanivimab|700 mg/20mL IV over at least one hour OD
214659151|NCT04796402|OTHER|Standard of Care|Standard of care includes primary care and specialist care as indicated by the patient's primary care provider
214659152|NCT04520477|DIAGNOSTIC_TEST|Bio Impedance assesement (BIA)|BIA every 5 minutes od the test protocol. Patients stood up for 5 minutes, laid down for 70 minutes, followed by 5 minutes in a seated position and ending with 30 minutes standing. BIA was done every 5 minutes.
214659153|NCT04520477|DIAGNOSTIC_TEST|Blood and salava sample|Blood Samples were done at the initation of the protocol, and every 10 minutes after ingestion of the deutarated water
214659154|NCT04520477|DIETARY_SUPPLEMENT|Ingestion of deuterated water|15 minutes after the intiation of the test protocol, participants drink an amount of deuterated water corresponding with 0.25% of their TBW calculated using the Watson Formula
214659155|NCT04520477|DIAGNOSTIC_TEST|Urine sample|A urine sample is taken at the initiation and after termination of the protocol.
214659156|NCT06310369|RADIATION|radiation therapy|"Radiation therapy will be given in 20 fractions of 2.75 Gy covering the whole bladder over 4 weeks.~The use of a radiosensitizing agent is mandatory. Each recruiting center will have to choose 2 options of radiosensitizing agents."
214659157|NCT02815215|PROCEDURE|Minimally Invasive Carroll's Technique|Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
214659158|NCT02815215|PROCEDURE|Ponseti method|As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
214659159|NCT00929240|DRUG|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
214848608|NCT03704857|OTHER|Foraminal Enlargement / Irrigating solutions / Filling materials|"Instrumentation with foraminal enlargement and various irrigation solutions and filling materials will be performed according to the allocated group.~The foraminal enlargement provides better results in the bacterial removal of the apical portion of the root canal. This instrumentation will be done with the Reciproc 40 or 50 system in the apical foramen, determined by the apical locator.~To contribute to disinfection of the root canal, sodium hypochlorite and chlorhexidine are the most widely used irrigators. Sodium hypochlorite has a broad antimicrobial spectrum and an effective ability to dissolve organic matter and necrotic tissue; while chlorhexidine shows substantivity and antimicrobial residual activity when used as an irrigating substance.~Besides that, MTA Fillapex or AH Plus will be used and the recommended filling technique will be lateral condensation."
214848609|NCT03704857|OTHER|Photobiomodulation|aPDT will be performed with 0.01% methylene blue solution and it will be inserted into the root canal for 5 minutes. The excess will be removed and irradiation will be performed inside the root canal with the red laser of Índio Gálio Alumínio Fósforo (660nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) for 90 seconds. Laser therapy with Gallium-Aluminum-Arsenic infrared laser (808nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) will be performed on the gingiva from the vestibular face and on the palatal / lingual face, both located in the periapical region for 40 seconds.
214848610|NCT03704857|OTHER|Passive ultrasonic irrigation|PUI will be performed with Newtron P5 ultrasound (Satelec / Acteon Group, Bordeaux, France), at intensity 9 and with a 25mm (# 0.25, taper 0.00). The protocol of use will be 3 sequences of 20 seconds of ultrasonic activation with 2 ml of sodium hypochlorite 2.5% in each root canal.
214848611|NCT03704857|OTHER|OHIP-14|Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
214848612|NCT03704857|OTHER|Assessment of pain and edema|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
214848613|NCT03704857|OTHER|Assessment of periapical lesion|The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.
214848614|NCT03704857|OTHER|Longevity of rehabilitations|The teeth will be rehabilitated with resin and glass fiber post. The longevity of rehabilitations will be performed clinically and radiographically for 24 months.
214848615|NCT03704857|OTHER|Cryotherapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
214848616|NCT03704857|OTHER|Ozone therapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
214848617|NCT01477502|OTHER|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
214848618|NCT01477502|OTHER|standard treatment without homeopathy|participants receive standard UTI prophylaxis
214848619|NCT04372849|OTHER|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
214848620|NCT04372849|OTHER|Placebo|Single dose of placebo solution as nasal spray
214848621|NCT01771315|BEHAVIORAL|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
214848622|NCT06503107|DRUG|Nanobody-based biepitope BCMA-targeting CAR-T cells|Each patient will receive nanobody-based biepitope BCMA-targeting CAR-T cell by intravenous infusion on day 0.
214848623|NCT00385788|DRUG|Gemcitabine|800 mg/m\^2 IV over 30 minutes on Day -7 (1 day)
214659160|NCT00929240|DRUG|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
214848624|NCT00385788|DRUG|Fludarabine|33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)
214848625|NCT00385788|DRUG|Melphalan|70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
214848626|NCT00385788|DRUG|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
214848627|NCT00385788|PROCEDURE|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
214659161|NCT02635230|DRUG|Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.|
214659162|NCT04210479|PROCEDURE|Filled-bladder|Urinary bladder filling with 300 ml diluted methylene blue
214659163|NCT04210479|PROCEDURE|non filled-bladder|Pull up the empty (non-filled) urinary bladder using Allis forceps
214848628|NCT00385788|DRUG|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
214659164|NCT01026584|DRUG|Aripiprazole|6 week prospective study
214659165|NCT00175305|DRUG|Sandostatin LAR|
214659166|NCT03142607|DRUG|Metronidazole gel|1% Metronidazole gel
214659167|NCT03142607|DRUG|Chlorhexidine Gluconate|0.2% Chlorhexidene gluconate gel
214659168|NCT00632580|DRUG|intraarticular injection with ropivacaine|
214848629|NCT00385788|DRUG|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
214848630|NCT00385788|DRUG|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
214848631|NCT02555293|DRUG|XIFAXAN® (Rifaximin)|
214848632|NCT00856505|DRUG|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
214848633|NCT00880087|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
214848634|NCT00880087|PROCEDURE|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
214848635|NCT01239446|OTHER|Not relevant (there is no intervention in the present study)|Not relevant (there is no intervention in the present study)
214848636|NCT05952089|DRUG|Danicamtiv|Specified dose on specified days
214848637|NCT05952089|DRUG|Midazolam|Specified dose on specified days
214848638|NCT01999426|OTHER|Airway clearance intervention|Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
214848639|NCT00845325|BEHAVIORAL|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
214848640|NCT00845325|BEHAVIORAL|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
214848641|NCT04681625|BEHAVIORAL|Pelvic floor muscle training (PFMT) with suppressive urgency technique|"Pelvic floor muscle training with suppressive urgency technique:~1. Education about proper urination training in the period without pathological urgency.~2. Education about conscious urgency suppression through PFMT - suppressive urgency technique.~3. Education on the principle and effect of PFMT.~4. Exercises of varying intensity of pelvic floor muscles in different positions.~5. Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day."
214848642|NCT02166034|BEHAVIORAL|garden intervention|The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
214848643|NCT03925935|BIOLOGICAL|AB-205|Engineered human umbilical vein endothelial cells
214848644|NCT06290219|COMBINATION_PRODUCT|platelet-rich plasma combined with hyaluronic acid|The project investigator injects plasma mixed with hyaluronic acid into the nasal septum and the medial side of the middle turbinate of the patient's nasal cavity under a nasal endoscope.
214848645|NCT06290219|DRUG|Zinc Gluconate 10 MG Oral Tablet|one tablet three times a day for a period of 12 weeks
214848646|NCT06290219|DEVICE|4 bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove oil|Sniffing each odorant for 10 seconds, twice a day for 12 weeks
214848647|NCT02065713|DRUG|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
214848648|NCT02065713|DRUG|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
214848649|NCT02065713|DRUG|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
214848650|NCT03614494|DRUG|Piroxicam 40 mg|Additional co-treatment
214848651|NCT03614494|DRUG|Levonorgestrel 1.5mg|Standard treatment
214848652|NCT04625322|OTHER|HCV care provided by hospitalist during acute psychiatric admission|HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
214848653|NCT03715322|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
214848654|NCT03715322|OTHER|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
214659169|NCT00632580|DRUG|extraarticular injection with ropivacaine|
214659170|NCT03735940|OTHER|Spot monitoring device, excl. Sham|o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
214659171|NCT02850796|BEHAVIORAL|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
214659172|NCT02850796|OTHER|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
214659173|NCT02371629|DRUG|NVA237|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
214659174|NCT02371629|DRUG|Placebo|Placebo to NVA237
214848655|NCT03715322|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
214659175|NCT02371629|DRUG|Salbutamol|All patients received salbutamol (100 μg) as only rescue medication
214659176|NCT01152853|DRUG|PF00299804|PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
214659177|NCT05878509|OTHER|conducting questionnaires|The patients were administered TSK, Pain Catastrophizing Scale (PCS), Beck Anxiety Inventory (BAI) by face to face interview technique.
214848656|NCT03887416|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|"The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
214659178|NCT05878509|OTHER|assesment of the severity and pain|The Modified Hand Injury Scoring System (MHISS) to determine the severity of the injury, and Visual Analog Scale (VAS) to evaluate perceived pain levels were used.
214848657|NCT03887416|DRUG|Placebo Oral Tablet|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
214848658|NCT00483548|DRUG|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
214848659|NCT00483548|DRUG|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
214848660|NCT01998386|OTHER|Placebo gel without hydrogen peroxide|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
214848661|NCT01998386|OTHER|6.0% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
214848662|NCT01998386|OTHER|7.5% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
214848663|NCT01998386|OTHER|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
214848664|NCT04904016|DEVICE|FlowOx™|The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.
214848665|NCT04523324|BIOLOGICAL|Flublok™ Quadrivalent by Sanofi, Inc.|0.5 mL intramuscular dose of Flublok
214848666|NCT04523324|BIOLOGICAL|VaxigripTetra™ by Sanofi, Inc.|0.5 mL intramuscular dose of Vaxigrip
214848667|NCT02418117|OTHER|Stereolitographic template|Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
214848668|NCT02980302|PROCEDURE|Cutaneous biopsy|Under local anesthesia
214848669|NCT06405542|BEHAVIORAL|EX-CIPN|"The 10-week intervention includes:~Individualized Exercise Program: Each participant will receive an individualized progressive exercise program that includes cardiovascular and strength training as well as balance and desensitization exercises and will be adjusted to the needs of the patient.~Remote Monitoring: Fitbit™ devices will be used to monitor patients' physical activity over the duration of the program. Fitness trackers can promote behaviour change and allows for self-monitoring and feedback to the participant.~Remote Person-to-Person Clinical Support: Participants will have scheduled remote check-ins and health coaching sessions with their assigned RKin over Microsoft Teams (MSTeams) on weeks 2, 3, 4, 6, and 8 of the intervention. During these calls, the RKin will review, adapt, and progress the exercise program as needed, discuss and develop goals for the following week, and identify potential barriers and solutions in achieving their goals."
214659179|NCT04613011|DEVICE|Ultrasound|Checking vein width snd copression using US
214659180|NCT01995890|DRUG|nepafenac|
214659181|NCT03360812|OTHER|Online training resource|Please see information included in the description of the intervention group.
214659182|NCT00558090|DRUG|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
214659183|NCT03662295|BEHAVIORAL|Language treatment|Individual speech-language therapy sessions totaling 1.5 to 2.5 hours five days per week. Intervention activities include performing oral and written confrontation and responsive naming, writing single words to dictation, reading single words and sentences aloud, and generating written and spoken picture descriptions.
214659184|NCT03754985|DEVICE|Hyperbaric oxygen therapy|"The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session."
214659185|NCT01420575|BEHAVIORAL|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
214659186|NCT01420575|BEHAVIORAL|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
214659187|NCT06007612|BEHAVIORAL|Context Sensitivity in Emotion Regulation|Context Sensitivity of affective intensities and its association to Emotion Regulation Flexibility Selection
214659188|NCT00599768|OTHER|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
214659189|NCT01645163|BEHAVIORAL|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
214659190|NCT02764879|DIETARY_SUPPLEMENT|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
214659191|NCT02764879|PROCEDURE|scaling and root planing|
214659192|NCT02764879|OTHER|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
214659193|NCT04582240|OTHER|no intervention|no intervention
214659194|NCT04685148|DRUG|Transdermal patch estradiol|Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
214659195|NCT04685148|DRUG|Transdermal patch placebo|Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
214659196|NCT00805207|DRUG|Progesterone|Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.
214659197|NCT00805207|DRUG|testosterone|Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
214659198|NCT00805207|DRUG|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
214659199|NCT00805207|DEVICE|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.
214659200|NCT00805207|DRUG|Estrogen|Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.
214659201|NCT00805207|OTHER|Control|No treatment with studies performed 31 to 72 days apart
214659202|NCT00002676|DRUG|carmustine|
214659203|NCT00002676|DRUG|cyclophosphamide|
214659204|NCT00002676|DRUG|cytarabine|
214659205|NCT00002676|DRUG|dexamethasone|
214659206|NCT00002676|DRUG|doxorubicin hydrochloride|
214659207|NCT00002676|DRUG|methotrexate|
214659208|NCT00002676|DRUG|vincristine sulfate|
214659209|NCT00002676|RADIATION|low-LET cobalt-60 gamma ray therapy|
214659210|NCT00002676|RADIATION|low-LET photon therapy|
214659211|NCT00677261|PROCEDURE|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
214659212|NCT00677261|PROCEDURE|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
214659213|NCT00677261|PROCEDURE|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
214659214|NCT02469246|DRUG|F/TAF|200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
214659215|NCT02469246|DRUG|ABC/3TC|600/300 mg FDC tablets administered orally once daily
214659216|NCT02469246|DRUG|ABC/3TC Placebo|Tablets administered orally once daily
214659217|NCT02469246|DRUG|F/TAF Placebo|Tablets administered orally once daily
214659218|NCT02469246|DRUG|3rd ARV agent|An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
214848670|NCT01435447|DRUG|FLu-Bu-Cy|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
214659219|NCT00588679|OTHER|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
214659220|NCT00046566|DIETARY_SUPPLEMENT|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
214659221|NCT00046566|DIETARY_SUPPLEMENT|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
214659222|NCT00046566|BEHAVIORAL|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
214659223|NCT05917743|OTHER|Mat Pilates|Duration: 50 minutes per session Repetitions: 8-12 repetitions per exercise Sets: 2-3 sets per exercise Rests: 30-60 seconds rest between sets Frequency: 3 times per week for 4 weeks Exercises: A series of Mat Pilates exercises targeting core strength, flexibility, and muscle control
214659224|NCT05917743|OTHER|General Exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
214659225|NCT03135093|OTHER|No intervention|No Intervention
214659226|NCT04536194|DRUG|norepinephrine|to treat hypotension under general anesthesia with norepinephrine
214659227|NCT04536194|DRUG|dopamine|to treat hypotension under general anesthesia with dopamine
214659228|NCT03758937|PROCEDURE|volume-controlled ventilation|
214659229|NCT03758937|PROCEDURE|pressure-controlled ventilation|
214659230|NCT03540095|DRUG|Erector Spinae Plane Block|See arm description
214659231|NCT03540095|DRUG|Paravertebral Nerve Block|See arm description
214659232|NCT05460208|DIETARY_SUPPLEMENT|Enriched spread|The experimental spread is made with a base made with 90% extra virgin olive oil to which plant sterols are added.
214659233|NCT05460208|DIETARY_SUPPLEMENT|Control spread|The control spread will be the same base spread made with extra virgin olive oil without the added plant sterols.
214659234|NCT06422273|DRUG|Tranexamic Acid|Endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients
214659235|NCT06422273|OTHER|Saline (placebo)|Topical Saline (placebo) administered as endobronchial topical application prior to performing transbronchial biopsies in lung transplant recipients.
214476158|NCT06854172|BEHAVIORAL|Mindfulness based self-compassion training|Self-compassion training is a program that aims to help individuals develop a kind, understanding and tolerant approach towards themselves. In this training, individuals learn to be more compassionate towards themselves and to share. This training can help manage negative emotional states such as stress, anxiety and stress and can lead to a healthier internal balance. When combined with mindfulness techniques, self-compassion training allows individuals to accept the moment and develop a more compassionate approach towards themselves. It is thought that this training will be applied to the experimental group to develop parents' feelings of self-compassion and positively affect the parameters of caregiver burden, self-efficacy and emotion regulation designed in the study.
214659236|NCT04670653|DRUG|MAGNÓLIA NASAL GEL|Magnólia nasal gel spray
214659237|NCT04670653|DRUG|MOMETASONE FUROATE|Mometasone furoate nasal spray
214659238|NCT02688075|OTHER|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
214659239|NCT01919892|DRUG|Lithium|
214659240|NCT01524380|DRUG|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
214659241|NCT01524380|DRUG|Placebo|twice a day, 10 weeks
214659242|NCT05681715|DRUG|Rozanolixizumab|Rozanolixizumab self-administration via Syringe Driver or Manual Push.
214659243|NCT00183742|DRUG|liposomal doxorubicin and docetaxel|
214659244|NCT05564052|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
214659245|NCT05564052|DRUG|Lenalidomide|Lenalidomide capsules will be administered orally.
214659246|NCT05564052|DRUG|Rituximab|Rituximab will be administered IV.
214659247|NCT05564052|DRUG|Bortezomib|Bortezomib will be administered either intravenously or subcutaneously.
214659248|NCT04409704|DEVICE|Repetitive Transcranial Magnetic Stimulation|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week, 20-30 sessions.
214659249|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)|Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.
214659250|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)|Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.
214659251|NCT03696472|PROCEDURE|robotic assisted surgery|robotic assisted surgery was benefit to operation
214659252|NCT03696472|PROCEDURE|laparoscopic|conventional laparoscopic surgery
214659253|NCT03758560|OTHER|Pre-operative Nepali version of pain catastrophizing scale (PCS) questionnaire|Patients will be asked to complete the scores based Nepali version of pain catastrophizing scale (PCS) questionnaire preoperatively
214659254|NCT02548702|BEHAVIORAL|Fit4Life|Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
214659255|NCT00582894|DRUG|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
214659256|NCT03185546|OTHER|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.
214659257|NCT03185546|OTHER|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
214659258|NCT03185546|OTHER|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 13 weeks
214659259|NCT03185546|OTHER|Low nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
214659260|NCT03185546|OTHER|Tobacco Flavors|Participants can choose e-liquid flavors from a selection of tobacco flavors
214659261|NCT03185546|OTHER|Tobacco and non-tobacco e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
214659262|NCT00184457|BEHAVIORAL|Strength training intervention|
214659263|NCT02682836|BEHAVIORAL|Walk with Ease|
214659264|NCT03692416|DRUG|Ibuprofen|"Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Ibuprofen for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique."
214659265|NCT03692416|DRUG|Prednisone|"Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Steroids for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique."
214659266|NCT03692416|DRUG|Methotrexate|"Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Methotrexate for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique."
214659267|NCT00006187|DRUG|Investigational drug|
214659268|NCT00815958|PROCEDURE|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
214659269|NCT00815958|PROCEDURE|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
214659270|NCT02840136|DRUG|Piperacillin-tazobactam combination product|
214659271|NCT02840136|DRUG|Meropenem|
214659272|NCT02840136|DRUG|Ceftazidime|
214659273|NCT00308724|BEHAVIORAL|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
214659274|NCT00308724|BEHAVIORAL|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
214659275|NCT05535179|DRUG|honeysuckle and semen oroxyli solution|The patients in the treatment group were instructed to gargle the solution containing honeysuckle and semen oroxyli (25 mL) four times a day for 2 weeks.
214659276|NCT05798520|DRUG|BIIB091|Administered as specified in the treatment arm.
214659277|NCT05798520|DRUG|DRF|Administered as specified in the treatment arm.
214659278|NCT05798520|DRUG|Placebo|Administered as specified in the treatment arm.
214659279|NCT01207466|DEVICE|Nelfilcon A investigational contact lens|Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
214659280|NCT01207466|DEVICE|Nelfilcon A commercial contact lens|Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
214476159|NCT05626894|COMBINATION_PRODUCT|StrokeWear Motor and Behavioral Intervention|The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.
214659281|NCT02463461|DEVICE|ActiSleep Activity Monitor|Subjects in this group will wear a ActiSleep Activity Monitor.
214659282|NCT02463461|DEVICE|Jawbone Activity Monitor|Subjects in this group will wear a Jawbone Activity Monitor.
214659283|NCT02463461|DEVICE|Actiwatch 2 Activity Monitor|Subjects in this group will wear a Actiwatch 2 Activity Monitor.
214659284|NCT02463461|DEVICE|FitBit Activity Monitor|Subjects in this group will wear a FitBit Activity Monitor.
214659285|NCT02463461|DEVICE|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
214659286|NCT00588367|DEVICE|Mayo Interactive Breath Hold Monitor|Biofeedback device
214659287|NCT03835091|OTHER|BRASS score|Brainstem response on neurologic examination
214659288|NCT04573101|OTHER|Music listening / EEG recording|Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf
214659289|NCT01422954|DRUG|Chloroquine prophylaxis|Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
214659290|NCT01422954|DRUG|Mefloquine prophylaxis|Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
214659291|NCT01422954|BIOLOGICAL|Immunization|Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
214659292|NCT01422954|BIOLOGICAL|Controlled Human Malaria Infection|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
214659293|NCT01422954|DRUG|Malarone|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
214659294|NCT01554657|OTHER|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
214659295|NCT01554657|OTHER|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
214659296|NCT01938287|DEVICE|SENSIMED Triggerfish|
214659297|NCT04613986|DEVICE|therapeutic plasmaexchnage|established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)
214659298|NCT01166048|DRUG|Duloxetine|"Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)~day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg~day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg"
214659299|NCT01166048|DRUG|Duloxetine|2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
214659300|NCT02964598|BEHAVIORAL|Gamified intervention|A new mobile application for assisting in sleep regulation, duration 4-6 weeks
214659301|NCT02964598|BEHAVIORAL|Sleep coaching|A new personalized program, duration 4-6 weeks
214659302|NCT02964598|DEVICE|Bright light|Morning bright light 10 000 lux maximum duration 4-6 weeks
214659303|NCT02964598|OTHER|Control|Minimal information on sleep timing and advancing the sleep rhythm
214659304|NCT02964598|OTHER|Psychoeducation|An extensive information platform in the internet created for this purpose
214659305|NCT05159414|DEVICE|Pulse Electrical Stimulation|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
214659306|NCT01852084|DEVICE|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
214659307|NCT01852084|DEVICE|enVista control lens|Spherical Control lens
214659308|NCT00842933|DRUG|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
214659309|NCT00842933|DRUG|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
214659310|NCT04371796|DRUG|Sintilimab injection|Sintilimab injection 200mg, 2cycles of treatment before surgery
214659311|NCT01339442|DRUG|BKM120|
214659312|NCT01339442|DRUG|Fulvestrant|
214659313|NCT01339442|PROCEDURE|biopsy|Correlative studies
214659314|NCT01205009|DRUG|Ovitrelle|One dose of Ovitrelle 250 mcg
214659315|NCT01364805|DRUG|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
214659316|NCT01364805|DRUG|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
214659317|NCT04178655|DRUG|Tranexamic acid injection|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
214659318|NCT04178655|DRUG|PLACEBO|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
214659319|NCT06154902|DRUG|Idecabtagene vicleucel|According to approved product label in France
214659320|NCT06154902|OTHER|Not treated|Eligible for idecabtagene vicleucel treatment but not treated
214659321|NCT03544580|PROCEDURE|immediate implant with dentine chips|Using dentin chips
214659322|NCT03544580|PROCEDURE|conventional immediate implant|using xenograft
214659323|NCT01575613|DRUG|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
214659324|NCT01575613|BIOLOGICAL|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
214659325|NCT01575613|BIOLOGICAL|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
214659326|NCT01575613|BIOLOGICAL|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
214659327|NCT03322358|OTHER|Naps|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
214476160|NCT05626894|OTHER|Usual Care|The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
214476161|NCT04924868|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid will be administered to patients in the UDCA group as a prophylactic measure of future complications associated to gallstones
214476162|NCT04924868|DRUG|Placebo|Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.
214476163|NCT06855121|DRUG|Teclistamab|Real-world use and dosing
214476164|NCT06855121|DRUG|Elranatamab|Real-world use and dosing
214476165|NCT06855121|BIOLOGICAL|Ciltacabtagene Autoleucel|Real-world use.
214476166|NCT06855121|DRUG|Talquetamab|Real-world use and dosing
214476167|NCT06855121|BIOLOGICAL|Idecabtagene vicleucel|Real-world use and dosing
214476168|NCT06854146|DIAGNOSTIC_TEST|gastric cancer|patients diagnosed with gastric cancer
214476169|NCT06854146|DIAGNOSTIC_TEST|healthy|healthy participants
214476170|NCT06854250|PROCEDURE|Prostate cryoablation|Enrolled patients will receive prostate cryoablation within 6 months of starting androgen deprivation therapy.
214476171|NCT06854250|DRUG|Cyclophosphamide (CTX)|Enrolled patients will receive cyclophosphamide (50mg daily) one day after prostate cryoablation and continue for a total of six months.
214476172|NCT06853743|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|Nicotinamide riboside, 2 capsules of 500mg taken twice daily for 2 years
214476173|NCT06853743|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 capsules twice daily for 2 years
214476174|NCT06855017|OTHER|create a pillbox day|create a pillbox day based on two separate fictitious prescriptions
214476175|NCT06812676|DEVICE|Virtual Reality Goggles|The VR group will be given a VR headset to wear during the nasal endoscopic procedure at the clinic.
214476176|NCT06854211|DRUG|Morphine p.o.|Morphine 50mg PO will be given on sleep study night.
214476177|NCT06854211|DRUG|Placebo|Placebo will be given on the sleep study night.
214476178|NCT06420687|DEVICE|Clinically prescribed prosthesis|Clinically prescribed prosthesis:
214476179|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + 1-DOF|1-DOF wrist rotation and1-DOF hand
214476180|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Wrist flexion +1-DOF|2-DOF wrist (rotation and flexion) and 1-DOF hand
214476181|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Multi DOF hand|1-DOF wrist rotation and multi-DOF hand
214476182|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + wrist flexion + Multi DOF hand|2-DOF wrist (rotation and flexion) and multi-DOF hand
214476183|NCT06812767|DIAGNOSTIC_TEST|electrocardiography|12 standard leads
214476184|NCT06812767|DIAGNOSTIC_TEST|analysis for glucose and cholesterol in the capillary blood|express test
214476185|NCT06812767|DIAGNOSTIC_TEST|detection of microalbumuria|express test
214476186|NCT06812767|DIAGNOSTIC_TEST|heart ultrasound examination|Ultrasound examination with Lumify Handheld S4-1 Phased Array Ultrasound (Philips)
214476187|NCT06812767|DIAGNOSTIC_TEST|carotid artery ultrasound examination|Ultrasound examination with Lumify Handheld L12-4 Linear Array Ultrasound (Philips)
214476188|NCT05236764|DEVICE|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta (alpha beta+) T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
214476189|NCT06854978|OTHER|RETHA|The study will enroll up to 10 participants with stroke who will be paired with trained therapists to receive R3THA telerehabilitation. The participants with stroke will participate in 7 training sessions. The training includes hand and arm exercises.
214476190|NCT06808503|BEHAVIORAL|NIMH Clinical Pathway|Complete the implemented workflow and tools for suicide risk screening, assessment, safety planning and follow-up.
214476191|NCT05974280|DRUG|Alofisel|Alofisel is made up of 'mesenchymal stem cells' from the fat tissue of a donor. Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease
214476192|NCT05974280|DRUG|Fat stem cell|mesenchymal stem cells from adipose (fat) tissue injection
214476193|NCT06811402|OTHER|virtual reality|the patient will wear a VR mask during the session
214476194|NCT06851169|DRUG|Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib)|Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; anlotinib, 12 mg, po, qd, was taken orally for 2 consecutive weeks and stopped for 1 week. Anlotinib was stopped 1 week before surgery. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Adjuvant therapy (benmelstobart combined with anlotinib, 12 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; anlotinib, 12 mg, po, qd, was taken orally for 2 weeks and stopped for 1 week.
214476195|NCT06851169|DRUG|Cohort 2: Neoadjuvant therapy (benmelstobart only)|Cohort 2: Neoadjuvant therapy (benmelstobart only, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Adjuvant therapy (benmelstobart, 12 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1.
214659328|NCT03322358|DEVICE|Home sleep aids|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
214659329|NCT03322358|OTHER|Sleep incentives|After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
214659330|NCT03666351|DRUG|Amlodipine 5mg|Amlodipine 5 mg
214659331|NCT03666351|DRUG|Losartan|Losartan Potassium 50 mg
214659332|NCT03666351|DRUG|Losartan and Amlodipine|Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
214659333|NCT03666351|DRUG|Amlodipine/Losartan/Chlorthalidone|Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
214659334|NCT03666351|DRUG|current treatment|treatment is done by maintaining the current treatment
214659335|NCT03189979|BEHAVIORAL|Physical activity and healthy eating intervention|Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
214659336|NCT01649336|DRUG|MEK162, MEK inhibitor; oral|multiple dose, escalating
214659337|NCT01649336|DRUG|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
214659338|NCT04376450|PROCEDURE|Experimental- Nonincised papillae surgical approach|"The basic principle of the technique is the placement of only one buccal horizontal or oblique incision in the mucosa, as apically as possible from the periodontal defect and the marginal tissues, and the raising of a mucoperiosteal flap coronally, which permits apical access to the defect but leaving the marginal tissues intact, acting as a dome for the protection of the clot."
214659339|NCT04376450|PROCEDURE|Active comparator- Entire papilla preservation technique|The entire Papilla Preservation Technique is to preserve the whole integrity of the defect- associated papilla providing a tunnel-like undermining incision. The completely preserved interdental papilla provides an intact gingival chamber to stabilize the blood clot and improve the wound healing process. To provide adequate access for debridement, EPP requires a short buccal vertical releasing incision on the buccal side of the neighboring tooth extending just beyond the mucogingival line.
214659340|NCT01219556|DRUG|Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)|Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
214659341|NCT00738816|OTHER|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
214659342|NCT01237860|DEVICE|NESS L300 Plus System|The patients will receive the device for daily use of six (6) weeks.
214476196|NCT06852716|OTHER|Health education based on BCW theory|The intervention stage lasted for 3 months. The intervention measures in the intervention stage were as follows: stimulate the motivation to change (M), guide and motivate MCI patients to establish the health belief of insisting on long-term home oxygen therapy, and strengthen the importance and necessity of self-management; Training in behavioural change (C) Dissemination and presentation of knowledge manuals; Guide patients to correctly understand the definition, causes, clinical manifestations and hazards of COPD and MCI related diseases to improve their cognition and prevention awareness of the disease; Create a behavior change environment (O), provide a platform for patient communication, share and demonstrate home oxygen therapy skills, and improve long-term home oxygen therapy compliance. Along with the Visit stage: Collect relevant data during the patient's outpatient visit or home visit to understand the patient's long-term home oxygen therapy situation.
214476197|NCT06852716|OTHER|Routine health education|(1) Give disease-related knowledge guidance according to nursing routine; (2) Guide patients and their families to standardize oxygen inhalation and ensure that patients correctly master oxygen inhalation operation methods; (3) Patiently answer patients' doubts about the disease, encourage patients to treat the disease with a positive attitude, and establish a good relationship of trust with patients and their families.
214659343|NCT00265655|DRUG|Satraplatin|Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
214659344|NCT02658461|DRUG|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed \>1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
214659345|NCT05159193|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m\^2, i.v., d1, q3w
214659346|NCT05159193|DRUG|cyclophosphamide (C)|cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q3w
214659347|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
214659348|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
214659349|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 90\~100 mg/m\^2, i.v., d1, q3w
214659350|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 75 mg/m\^2, i.v., d1, q3w
214659351|NCT05159193|DRUG|carboplatin (Cb)|carboplatin (Cb) AUC 6, i.v., d1, q3w
214659352|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
214659353|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
214659354|NCT05124626|PROCEDURE|MIRPE with two bars|Minimally invasive repair of pectus excavatum utilizing two metallic bars
214659355|NCT05124626|PROCEDURE|MIRPE with one bar|Minimally invasive repair of pectus excavatum utilizing one metallic bar
214848671|NCT06022367|DIAGNOSTIC_TEST|Head Turn Activation Technique|Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
214659356|NCT04351412|OTHER|Gluma|Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
214659357|NCT04351412|OTHER|fluoride varnish|fluoride varnish is usually applied to patients to prevent caries development but was claimed in some cases to also relief dentine hypersensitivity and was applied as a thin layer to the surface of the tooth using an applicator. The varnish set rapidly, and thereafter moisture contamination was not a concern. Patients were advised to not brush or floss their teeth for a couple of hours and to abstain from hot beverages. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
214290082|NCT02495441|OTHER|Use of Rapid Immunoassay Tests for the Detection of PROM|"After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.~The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.~Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®."
214659358|NCT04351412|OTHER|Tetric N-Bond self-etch adhesive|Tetric N-Bond self-etch adhesive is one step dental adhesive and is also claimed to relief dentine hypersensitivity due to blockage of dentinal tubules. It was applied according to the manufacturer's instructions, in a thick layer, for at least 30 seconds, using a light brushing motion. Then, it was dried with a steady stream of air for 3 seconds and light-cured for 10 seconds. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
214659359|NCT05059990|OTHER|Low Intensity Aerobic Exercises Group|Intervention Low Intensity Aerobic Exercises i.e. stationary cycle(supervised) Intensity 55-65% of HRmax Frequency 3 times a week Duration 30 min each session
214659360|NCT05059990|OTHER|Active Exercises Group|Intervention Upper and lower limb ROM \& stretching exercises Intensity As per tolerance Frequency 12 repetition/4sets per exercise 3 times/week Duration 30 minutes each session
214659361|NCT00854269|PROCEDURE|surgery|cervical biopsy or specimen of hysterectomy
214659362|NCT00216034|DRUG|Tegafur-gimeracil-oteracil potassium (TS-1)|From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
214659363|NCT00216034|DRUG|Krestin (PSK)|From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
214659364|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg
214659365|NCT02319369|DRUG|AZA|AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously
214848672|NCT06022367|DIAGNOSTIC_TEST|Head Raise Activation Technique|Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
214848673|NCT02694549|DEVICE|CaveoVasc|
214476198|NCT06813183|OTHER|The palmar grasping reflex|"In the experimental group, the baby is monitored under a radiant heater before the procedure. After the infant's initial physiologic parameters and NIPS are recorded, the palmar grasp reflex is stimulated just before the procedure begins. The palmar grasp reflex can be stimulated by moving an object distally across the palm of the hand. In newborns, the right hand is more dominant than the left hand in the palmar grasp reflex ( Fagard et al., 2017). The researcher will stimulate the palmar grasp reflex by moving the index finger distally along the palm of the infant's right hand. The reflex stimulation will be continued until the end of the 5th minute.~Physiologic parameters will be scored by the investigator and a second nurse with at least 5 years of experience in neonatal intensive care and recorded on the follow-up form by scoring the pain levels 1 minute before (0 min), during, 2 and 5 min after the heel pricking procedure in the neonates in the NIPS intervention groups via the be"
214659366|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.
214659367|NCT02323022|DRUG|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
214659368|NCT02323022|DRUG|IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
214659369|NCT00705237|PROCEDURE|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
214659370|NCT01503216|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
214659371|NCT01503216|DIETARY_SUPPLEMENT|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
214659372|NCT01503216|DIETARY_SUPPLEMENT|Placebo|Placebo
214848674|NCT01534078|DRUG|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
214848675|NCT01534078|DRUG|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
214848676|NCT02459665|BIOLOGICAL|Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
214659373|NCT03817918|PROCEDURE|Lung ultrasonography|Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
214659374|NCT04839861|BEHAVIORAL|Mightier Family Games|Mightier Family Games includes five offline card games that can be played by two or more people. During card game play, one player wears the Mightier heart rate monitor, and can see a representation of their heart rate on a separate screen within the Mightier app. Each game includes elements that are tied to heart rate.
214659375|NCT04839861|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own."
214659376|NCT03326934|DIETARY_SUPPLEMENT|Dark chocolate|Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
214659377|NCT03326934|DIETARY_SUPPLEMENT|Milk Chocolate|Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
214659378|NCT04325503|DRUG|carbidopa|carbidopa and carbidopa-levodopa standard treatment
214659379|NCT00340470|BEHAVIORAL|Driver Education|
214659380|NCT03832387|DEVICE|Non-invasive mechanical ventilation|
214290083|NCT04811989|BEHAVIORAL|Instructive video on diabetic foot care|In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
214290084|NCT04811989|BEHAVIORAL|Informative leaflet with real-time guided reading|The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.
214659381|NCT03832387|DEVICE|Continuous positive airway pressure|
214659382|NCT03832387|DEVICE|Venturi mask|
214659383|NCT03832387|DEVICE|Reservoir mask|
214848677|NCT02459665|DRUG|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
214848678|NCT02459665|BIOLOGICAL|Vaginal Lcr35-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
214848679|NCT03532230|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
214848680|NCT02948920|DRUG|Ephedrine|9 mg of ephedrine (3 ml)
214848681|NCT02948920|DRUG|NSS|3 ml of normal saline
214848682|NCT04217655|DIAGNOSTIC_TEST|Low-dose computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
214848683|NCT04217655|DIAGNOSTIC_TEST|Standard-dose computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
214848684|NCT01220609|DRUG|Ixabepilone|Given IV
214290085|NCT04811989|BEHAVIORAL|Informative leaflet to read at home|Patients receive a leaflet about diabetic foot care to read at home.
214290086|NCT04811989|BEHAVIORAL|Face-to-face teaching|Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
214290087|NCT01733602|DEVICE|transcranial direct current stimulation|
214290088|NCT01018186|DRUG|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
214290089|NCT01018186|DRUG|Fluticasone propionate|Inhaled corticosteroid
214659390|NCT04297943|DEVICE|Orthosis fabrication|see summary
214659391|NCT04297943|DEVICE|Thermal Sensor Monitoring of Orthosis Use|see summary
214659392|NCT04297943|DIAGNOSTIC_TEST|4D CT Scan|see summary
214659393|NCT01856114|DRUG|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
214659394|NCT01856114|OTHER|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
214659395|NCT01856114|BEHAVIORAL|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
214659396|NCT05607134|OTHER|selected physical and occupational therapy program|The children in this group will receive a selected physical and occupational therapy programs one hour three times weekly for eight successive weeks.
214659397|NCT05607134|DEVICE|Radial Extracorporeal Shock Wave|The children in this group will receive in addition to the selected physical therapy and occupational program as single session of shock wave intervention once per week for four eight successive weeks using (STORZ MEDICAL AG, Tagerwilen, Schweiz) device. rESWT will be applied on flexor carpi ulnaris, flexor carpi radialis, in the middle of the muscle belly and tendons of flexor digitorum on the palm. The treatment protocol of rESW will follow; 1500 shoots for each muscle; 0.030 mj/mm2; 4 HZ with pressure 1 bar will be used.
214848685|NCT01220609|OTHER|Laboratory Biomarker Analysis|Correlative studies
214659398|NCT05607134|DEVICE|Peripheral magnetic stimulation|"The children in this group will receive in addition to the selected physical therapy program peripheral magnetic stimulation (PMS) therapy for twenty minutes, three sessions per week, for eight successive weeks using Peripheral magnetic stimulation device A MAGNUM XL Pro, Globus, Italia. The PMS consisted of 2000 stimuli at a stimulation frequency of 20Hz, a train duration of 1 second, and an intertrain interval of 2 seconds. Intensity was individually set at 10% to 100% of the maximum stimulus intensity."
214659399|NCT04604925|BEHAVIORAL|Remote patient monitoring for hypertension|Intervention involves practices making available remote physiologic monitoring treatment management services allowable under Medicare for blood pressure (and weight if desired) to Medicare patients in the practice when ordered by the patient's clinician.
214659400|NCT01992029|OTHER|Clinical evaluation|Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12
214659401|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy at M0
214290090|NCT03608592|BIOLOGICAL|umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
214659402|NCT01992029|PROCEDURE|Lumbar puncture|Lumbar puncture at M0 and M12
214659403|NCT01992029|PROCEDURE|Blood sampling|Blood sampling at M0, M4, M4, M8 and M12
214659404|NCT01992029|OTHER|Neurological assessments|Neurological assessments (MRC score and cognitive scales: MMS and BREF)
214659405|NCT01992029|PROCEDURE|Neuro-muscular biopsy and lumbar puncture|Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy
214659406|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy for patient explored for myopathy
214659407|NCT01992029|PROCEDURE|Blood sample|Blood sample for qRT PCR, detection and quantification for miRNA
214659408|NCT01992029|DEVICE|Cervical spinal cord and brain MRI|ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
214659409|NCT01337401|DRUG|Cediranib|30mg once daily, oral until disease progression
214659410|NCT01337401|DRUG|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
214659411|NCT05991024|BEHAVIORAL|the incisional hernia recurrent|Recurrence after repair was the main outcome
214659412|NCT00144170|DRUG|Tipranavir (with low dose ritonavir)|
214659413|NCT00144170|DRUG|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
214659414|NCT00981526|DRUG|Telmisartan|"Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks."
214659415|NCT00981526|DRUG|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
214659416|NCT00981526|DRUG|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
214659417|NCT00981526|DRUG|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
214659418|NCT01564784|DRUG|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m\^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
214659419|NCT01564784|DRUG|FLAG (fludarabine, cytarabine and G-CSF)|Dose: cytarabine 2.0 g/m\^2/day IV days 1-6 fludarabine30 mg/m\^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
214659420|NCT01564784|DRUG|HIDAC (high dose cytarabine)|cytarabine 3 g/m\^2 IV every 12 hours for up to 12 times
214659421|NCT01564784|DRUG|cytarabine and mitoxantrone|mitoxantrone 12 mg/m\^2 IV days 1-3 cytarabine 200 mg/m\^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
214659422|NCT00324103|DRUG|Structured Treatment Interruptions|
214659423|NCT04753125|BEHAVIORAL|follow-up by telephone|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
214659424|NCT04753125|BEHAVIORAL|follow-up via a game in a smartphone app|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
214659425|NCT04753125|BEHAVIORAL|conventional follow-up by a health professional|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
214659426|NCT02066064|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy
214659427|NCT02066064|PROCEDURE|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
214659428|NCT00730093|DIETARY_SUPPLEMENT|B12 vitamin (Cyanocobalamin)|Arm A: B12 vitamin (Cyanocobalamin)
214659429|NCT02347293|OTHER|High levels of indigestible carbohydrates|
214659430|NCT02347293|OTHER|Low levels of indigestible carbohydrates|
214659431|NCT01929070|DRUG|HCP1007|
214659432|NCT01929070|DRUG|Omarco and Crestor|
214659433|NCT00679887|PROCEDURE|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
214659434|NCT05546489|BEHAVIORAL|Lymfit intervention|Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
214659435|NCT06551623|DRUG|Midazolam|Midazolam Oral Solution 2 mg
214659436|NCT06551623|DRUG|Clarithromycin|Clarithromycin tablets 0.5 g
214659437|NCT06551623|DRUG|TNP-2198|TNP-2198 Capsules 400 mg
214659438|NCT00291304|PROCEDURE|MRI|pre-surgery
214659439|NCT02682329|OTHER|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
214659440|NCT02682329|OTHER|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
214659441|NCT03594994|BEHAVIORAL|Sleep extension|Extend time-in-bed by one hour
214659442|NCT05292196|DRUG|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
214290091|NCT03608592|BIOLOGICAL|normal saline|A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
214290092|NCT02356068|OTHER|ROTEM analysis|3 blood samples for ROTEM analysis
214659443|NCT05292196|DRUG|TQC3721 suspension placebo for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
214659444|NCT05202808|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments
214659445|NCT05202808|DEVICE|Control IOL|Control treatment group will receive a Control IOL
214659446|NCT05618197|OTHER|Passive heating|\~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C) sessions over a period of 6 weeks.
214659447|NCT04612738|BEHAVIORAL|Hello (serious game)|Commercially available, 'Hello' 32 is a serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The creators developed the questions following interviews with palliative care clinicians, hospice nurses, and funeral directors, and then revised them through a series focus groups with \>100 patients/caregivers from diverse backgrounds.
214659448|NCT04612738|BEHAVIORAL|The Conversation Project (CP) Starter Kit|"The CP Starter Kit is one of the most widely promoted and disseminated ACP tools nationwide, is available for free online, and does not require a healthcare professional for use. Like 'Hello', it is intended to help individuals have end-of-life conversations with loved ones. The 11-page workbook has open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so. It also prompts participants to rank priorities on a 5-point scale (e.g., What are your concerns about treatment? 1= I'm worried I won't get enough care, 5= I'm worried I'll get overly aggressive care). The CP website provides resources for running a community event using the 'CP Starter Kit', including a 23-page manual, Coaching the Conversation- A Guide to Facilitating Conversation Groups, with details on hosting a community-based program."
214659449|NCT04612738|OTHER|Table Topics (general conversation game)|Table topics is a popular, commercially available conversation starter game that consists of question cards to prompt conversations (e.g., 'What do you love about your hometown?').
214659450|NCT04149314|OTHER|HPI based hemodynamic optimization algorithm|Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
214659451|NCT02495948|DEVICE|Lotrafilcon B contact lenses|
214659452|NCT02495948|DEVICE|Samfilcon A contact lenses|
214659453|NCT02495948|DEVICE|Hydrogen peroxide solution|Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
214659454|NCT02495948|DEVICE|Saline solution|Used for rinsing contact lenses, as needed
214290093|NCT01931852|PROCEDURE|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
214659455|NCT02920125|DRUG|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
214659456|NCT02920125|COMBINATION_PRODUCT|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
214659457|NCT02920125|OTHER|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
214659458|NCT04825054|DEVICE|Mechanical ventilation with NAVA mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
214659459|NCT04825054|DEVICE|Mechanical ventilation with PCV mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
214848686|NCT02777515|BEHAVIORAL|using electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~1. A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~2. measurement of blood pressure~3. An electrocardiogram~4. A Holter-ECG 10 minutes~5. A transthoracic echocardiogram"
214848687|NCT02106650|DRUG|Folotyn and Leucovorin|
214290094|NCT01931852|OTHER|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
214290095|NCT03649464|DRUG|OKN-007|"Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study."
214290096|NCT05984160|OTHER|Paragastric neural block|A block method used to control patients' symptoms of pain, nausea and vomiting after surgery.
214848688|NCT02106650|DRUG|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
214848689|NCT02106650|DRUG|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
214848690|NCT02986035|OTHER|ECA cream|
214848691|NCT03456024|OTHER|Questinnaire|
214290097|NCT03049280|DEVICE|Transoral robotic surgery|Transoral robotic surgery for T1 \& T2 oropharyngeal cancers
214290098|NCT01382823|PROCEDURE|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
214290099|NCT04216095|DEVICE|Electroconvulsive Therapy (n=30)|Right unilateral (RUL) ECT (n=15) or bitemporal (BT) ECT (n=15) using a Thymatron IV device (Somatics LLC, USA) twice weekly.
214659460|NCT04825054|DEVICE|Mechanical ventilation with PSV mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
214659461|NCT01701622|DRUG|febuxostat|"If baseline allopurinol dose \< 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose \> 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks."
214659462|NCT03911414|DRUG|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
214659463|NCT03911414|DRUG|Open-label Treatment with N-acetylcysteine|Open-label Treatment with N-acetylcysteine
214659464|NCT03114033|OTHER|Targeted therapeutic mild hypercapnia|Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg
214659465|NCT03114033|OTHER|Targeted normocapnia (Standard care)|Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg.
214659466|NCT01752283|PROCEDURE|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
214659467|NCT01752283|PROCEDURE|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
214659468|NCT04073667|BEHAVIORAL|Exercise|"Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~* To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~* Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~* Teaching the correct scapular position, D. Postural correction exercises;~* Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~  a. Joint position sense:~* Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~  b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~  a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty."
214659469|NCT01936038|OTHER|CPAP|CPAP
214659470|NCT01936038|PROCEDURE|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
214659471|NCT04766853|DRUG|Dexamethasone|Dexamethasone 5mg/ml
214659472|NCT04766853|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
214659473|NCT04899908|RADIATION|Stereotactic Radiation|Focused radiation beams to treat tumors
214659474|NCT04899908|DRUG|AGuIX gadolinium-based nanoparticles|Intravenous injection
214659475|NCT04899908|OTHER|Placebo|Intravenous infusion
214659476|NCT04930770|DRUG|MRNA-1273|Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified.
214659477|NCT06160466|DEVICE|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a follow-up pateints in the screening population.
214659478|NCT06160466|DEVICE|White light|White light endoscopy
214659479|NCT04109729|DRUG|Nivolumab|Nivolumab 480mg IV every 4 weeks for up to 2 years
214659480|NCT04109729|DRUG|Radium-223|Radium-223 55 kilobecquerel (kBq)/kg IV q4 weeks for 6 cycles total
214659481|NCT00898547|OTHER|immunoenzyme technique|
214659482|NCT00898547|OTHER|laboratory biomarker analysis|
214659483|NCT04811560|DRUG|Bleximenib|Bleximenib is administered orally.
214659484|NCT00741819|DRUG|Inhaled treprostinil|
214659485|NCT02550899|PROCEDURE|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
214659486|NCT02550899|PROCEDURE|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
214659487|NCT02550899|PROCEDURE|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
214659488|NCT06545227|DEVICE|continuous blood glucose monitoring in a subset of women (n=25) in the early monitoring group.|To continuously monitor blood glucose from baseline to 28 weeks to determine if if there is hyperglycaemia in a subset of women (n=25)
214659489|NCT06545227|OTHER|Collection of urine, maternal blood at baseline and 28 weeks in a subset of women (n=25)|To study maternal metabolome
214659490|NCT06545227|OTHER|Collection of umbilical cord blood, placental samples and cord tissue in a subset of women (n=25)|To study mesenchymal stem cell differentiation, change in fetal epigenetic and placental signalling pathways.
214659491|NCT06545227|OTHER|Maternal and neonatal outcome data collection for all women in the study|Data for maternal and neonatal outcomes will be collected
214659492|NCT00926926|DRUG|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
214659493|NCT00926926|DRUG|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
214848692|NCT00070616|DRUG|Palifermin 6 x 60 μg/kg/day|
214848693|NCT00070616|DRUG|Palifermin 2 x 180 μg/kg/day|
214848694|NCT00070616|RADIATION|radiotherapy|
214659494|NCT05718362|BEHAVIORAL|Ayres Sensory Integration Therapy|It is an intervention method whose effectiveness is questioned. It is a therapy program applied according to Ayres Sensory Integration Fidelity Measure.
214659495|NCT05718362|BEHAVIORAL|Home Program|These are the activities created for the participants (both intervention and control groups) and to be done in the home environment.
214659496|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 100 mg)|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214659497|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214659498|NCT00752986|DRUG|Fulvestrant|All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
214659499|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 300 mg)|300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
214290100|NCT04216095|DEVICE|Magnetic Seizure Therapy (n=30)|High-dose magnetic seizure therapy (HD-MST) over the vertex using Magstim Theta device (Magstim Company Limited, Whitfield, Wales, UK) at 100% maximal output of the device (constant), with pulse frequency 100Hz and train duration 10 seconds twice weekly.
214659500|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)|Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214659501|NCT02522637|OTHER|Exercise training|"The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each \< 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%."
214659502|NCT02226965|DRUG|PNT2258|
214659503|NCT04769557|DRUG|paracetamol|tablet paracetamol 500 mg
214659504|NCT04769557|DRUG|Placebo|placebo
214659505|NCT00792779|DRUG|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
214659506|NCT03481270|BEHAVIORAL|Concordant|We will be randomizing across providers - we are particularly interested in racial concordance.
214290101|NCT03235076|DRUG|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
214659507|NCT03880877|DRUG|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
214659508|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
214659509|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
214659510|NCT03880877|GENETIC|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
214659511|NCT03880877|DRUG|Leucovorin and 5-FU|Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
214659512|NCT03107195|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
214659513|NCT04356456|DIETARY_SUPPLEMENT|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
214659514|NCT03563300|OTHER|Wheat flour|Wheat flour will be administered once daily for 7 days
214659515|NCT03563300|OTHER|Placebo Comparator|Placebo will be administered blindly versus wheat flour for 7 days
214659516|NCT00794586|DRUG|FTI, AZLI|Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
214659517|NCT00794586|DRUG|Placebo, AZLI|Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
214659518|NCT00986531|DRUG|AZD8529|2 capsules by mouth for 3 days
214848695|NCT00070616|DRUG|Chemotherapy|
214848696|NCT01825135|DEVICE|Neuromuscular electrical stimulation|
214848697|NCT01825135|DEVICE|sham stimulation|sham stimulation will be applied to the quadriceps
214290102|NCT03590106|BEHAVIORAL|Peer Recovery Support Program|See above
214290103|NCT00633386|DRUG|Celecoxib|400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
214290104|NCT00633386|OTHER|Placebo|Matched placebo
214659519|NCT00986531|DRUG|Placebo to match AZD8529|2 capsules by mouth for 3 days
214659520|NCT02970929|DRUG|SEP-363856|One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
214659521|NCT01798303|DRUG|LY2940094|Administered orally
214659522|NCT01798303|DRUG|Placebo|Administered orally
214659523|NCT05195606|OTHER|Auditory stimulus|Auditory stimulus will be applied to the patients in intervention group A. For the auditory stimulus, the sound recording of the relatives of the patients will be taken and the patients will be listened to with headphones.
214659524|NCT05195606|OTHER|Tactile stimulus|Tactile stimulus will be applied to the patients in the intervention group B. The tactile stimulus will be performed by the researcher with a foot massage to be applied to the patient.
214659525|NCT00291343|BIOLOGICAL|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
214659526|NCT00291343|BIOLOGICAL|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
214659527|NCT00291343|BIOLOGICAL|Mencevax™ ACWY|One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
214659528|NCT00004987|DRUG|Dextrin 2-sulfate|
214659529|NCT04143633|OTHER|Low FODMAP diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
214659530|NCT04143633|OTHER|Standard diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
214659531|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/p|solution for intramuscular injection, 0.5 ml
214659532|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/o/p|solution for intramuscular injection, 0.5 ml
214659533|NCT05308212|BIOLOGICAL|Ultrix [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
214659534|NCT04684199|DIETARY_SUPPLEMENT|Melatonin|Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
214659535|NCT04684199|DIETARY_SUPPLEMENT|Placebo|
214659536|NCT04894955|DEVICE|MARIA|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to ascertain their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® participant bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts and array are brought into contact with the breast. A scan sequence comprising of two complete scan rotations will then be performed, which takes around 5 minutes. The participant will then be assisted to adjust their positioning, and the scan sequence performed on the other breast.
214659537|NCT00988390|BEHAVIORAL|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
214659538|NCT02168582|BEHAVIORAL|physiotherapy as usual in primary care|
214659539|NCT03784196|OTHER|Conservative rehabilitation|WAD participants underwent 2-weeks rehabilitation.
214659540|NCT06213636|BIOLOGICAL|CD19/CD22-CAR T cells|"The intervention in this clinical trial involves a novel approach using CD19/CD22-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/CD22-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/CD22-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/CD22-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
214659541|NCT01245647|DRUG|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
214659542|NCT01245647|OTHER|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
214659543|NCT02370121|DRUG|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
214659544|NCT02370121|DRUG|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
214659545|NCT04416022|DIAGNOSTIC_TEST|Ultrasound examination|Women that are planned for labour induction, will undergo a routine ultrasound examination prior to the initiation of the induction process.
214659546|NCT05792202|PROCEDURE|microfracture procedure|double raw repair combined with microfracture procedure which promotes tendon healing by releasing growth factors
214659547|NCT05792202|PROCEDURE|only double raw repair|the double raw repair was used to repair the tendon tear
214659548|NCT03072602|DIETARY_SUPPLEMENT|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
214659549|NCT03072602|OTHER|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
214659550|NCT01260558|DEVICE|Sirolimus-Permanent-Polymer Eluting Stent|due randomization sirolimus-permanent-polymer eluting stent was implanted
214659551|NCT01260558|DEVICE|Sirolimus-Polymer-free Eluting Stent|due randomization sirolimus-polymer-free eluting stent was implanted
214659552|NCT04695873|DEVICE|Corn Foam Cushion|An anatomically shaped foam pad with a central hole. The upper layer is made from a honeycomb of interconnecting cells, the external facing surface is smooth, the underside is coated with adhesive.
214659553|NCT00482716|BIOLOGICAL|epoetin alfa|
214659554|NCT00482716|BIOLOGICAL|epoetin beta|
214659555|NCT00482716|DIETARY_SUPPLEMENT|iron dextran complex|
214659556|NCT00482716|DIETARY_SUPPLEMENT|iron sucrose injection|
214659557|NCT01848275|DEVICE|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
214659558|NCT01848275|DEVICE|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
214659559|NCT03912584|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
214659560|NCT03912584|DEVICE|P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
214659561|NCT02570672|DRUG|Metformin|Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
214659562|NCT02570672|DRUG|Placebo|Subjects will randomized to placebo will receive placebo
214659563|NCT02053688|DEVICE|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
214659564|NCT02053688|DEVICE|Toric Soft Contact Lenses|astigmatism correction using toric optics
214659565|NCT03388814|DRUG|Local infiltration of bupivacaine|Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
214659566|NCT03388814|DRUG|Pectoralis Nerve block|Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
214659567|NCT05242887|DIAGNOSTIC_TEST|Delirium screening using 3D-CAM and UB-CAM|Patients will be evaluated with 3D-CAM and UB-CAM by a trained examiner (geriatrician, resident or neuropsychologist). On the same day, they will be given a reference diagnosis of delirium based on DSM-V criteria by another trained examiner, blind to the results of the UB-CAM and 3D-CAM.
214659568|NCT00275561|DRUG|Fluticasone|Aerosolized swallowed fluticasone 880 mg twice a day
214659569|NCT00275561|DRUG|Placebo|Placebo inhaler swallowed twice a day for 6 weeks
214659570|NCT04312087|PROCEDURE|Lateral neck sentinel lymph node biopsy|Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
214659571|NCT04312087|PROCEDURE|Modified lateral neck lymph node dissection|Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
214659572|NCT04312087|PROCEDURE|Super selective lateral neck lymph node dissection|Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
214659573|NCT01769105|DEVICE|Lipiflow|Patients receive a single Lipiflow-treatment
214659574|NCT01769105|BEHAVIORAL|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
214659575|NCT01540643|DEVICE|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
214659576|NCT01984021|DEVICE|Acupuncture|
214659577|NCT01984021|DEVICE|Sham acupuncture|
214659578|NCT01530243|DRUG|Placebo|same as tolterodine and terazosin dose
214659579|NCT01530243|DRUG|Terazosine|2 mg BID
214659580|NCT01530243|DRUG|Tolterodine|2 mg daily
214659581|NCT01530243|DRUG|Tolterodine + Terazosin|2mg daily and 2mg BID
214659582|NCT06158243|OTHER|Sono-anatomical Study|The arm is abducted (90°), externally rotated, with the forearm flexed over the arm (90°). A linear ultrasound probe (8-15 MHz) is placed in front of the humeral head, in a sagittal plane. Location begins at axillary level, vessels, nerves and humerus are identified, and the probe is moved medially to reach and identify the humeral head.
214659583|NCT02784093|DRUG|Gastrograﬁn|
214659584|NCT02784093|PROCEDURE|enemas|
214659585|NCT04321343|DRUG|PXL065|PXL065 oral tablet
214659586|NCT04321343|DRUG|Placebo oral tablet|Placebo oral tablet
214659587|NCT03770143|OTHER|Feeding with palm olein formula|
214659588|NCT06249529|DEVICE|Airway Bypass|Bypass stent(s) are implanted to allow air trapped in the parenchyma to escape
214659589|NCT03088514|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice (70ml daily) with or without inorganic nitrate
214659590|NCT00245232|BEHAVIORAL|Cognitive Therapy|
214659591|NCT00245232|BEHAVIORAL|Cognitive Processing Therapy|
214659592|NCT00245232|BEHAVIORAL|Written Exposure|
214659593|NCT03399461|OTHER|Patient Interview guide|The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.
214659594|NCT03399461|OTHER|Caregiver interview guide|The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.
214659595|NCT03399461|OTHER|Sociodemographic questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.
214659596|NCT03399461|OTHER|Pediatric quality of life (PedsQL) questionnaire|The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.
214659597|NCT03399461|OTHER|Clinical questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.
214659598|NCT04915196|DIETARY_SUPPLEMENT|Liposomally-bound Iron|Ferric pyrophosphate microencapsulated in liposomal form is an over the counter natural health product approved by Health Canada and commonly used for iron replacement. If this product is prescribed as part of usual management of iron deficiency and patients consent to participation they will be contacted by telephone survey of gastrointestinal tolerability.
214659599|NCT04915287|DRUG|Avatrombopag maleate|"1. Mean baseline platelet count 40 to less than 50 × 10\^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure~2. Mean baseline platelet count less than 40 × 10\^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure"
214659600|NCT04915287|BIOLOGICAL|Platelet transfusion|Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: platelet transfusion if needed
214659601|NCT04915287|DRUG|Medicine|Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.
214659602|NCT03977246|BEHAVIORAL|Open-placebo|Application of the open-placebo intervention
214659603|NCT03977246|BEHAVIORAL|Control|Application of the control session
214659604|NCT03776656|DRUG|Allopurinol|Daily oral administration
214659605|NCT03818698|OTHER|Eplets mismatching numbers|In this study, the HLA high-resolution typing data of kidney transplant recipients from 2014 to the end of 2017 were analyzed with HLA Matchmaker for eplets mismatching number. To analyze the incidence of dnDSA and AMR after kidney transplant recipients with different eplets mismatching number posttransplant, and to elucidate the important role of tissue configuration patterns based on HLA eplets matching in long-term graft survival.
214659606|NCT04194944|DRUG|Selpercatinib|Administered orally
214659607|NCT04194944|DRUG|Carboplatin|Administered IV
214659608|NCT04194944|DRUG|Cisplatin|Administered IV
214659609|NCT04194944|DRUG|Pemetrexed|Administered IV
214659610|NCT04194944|DRUG|Pembrolizumab|Administered IV
214659611|NCT06580327|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
214659612|NCT06580327|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
214659613|NCT04238819|DRUG|Abemaciclib|Administered orally
214659614|NCT04238819|DRUG|Irinotecan|Administered IV
214659615|NCT04238819|DRUG|Temozolomide|Administered orally
214659616|NCT04238819|DRUG|Dinutuximab|Administered IV
214659617|NCT04238819|DRUG|GM-CSF|Administered SC
214659618|NCT06988462|OTHER|Bottarga|Participants will consume prepackaged daily doses of Bottarga, each containing the required amount (20 grams/day) for 8 weeks.
214659619|NCT06988462|OTHER|Comparator|Participants will consume 28g of cream cheese/day for 8 weeks.
214659620|NCT03228121|PROCEDURE|Treatment Then Placebo|Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.
214659621|NCT03228121|PROCEDURE|Placebo Then Treatment|Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
214659622|NCT01360203|OTHER|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
214659627|NCT01726179|DEVICE|Resin infiltration|Proximal caries lesions that are selected for this intervention will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, local anesthesia of the gingival papila, application of rubber dam, etching of the lesion surface for 120 s using 15%HCl gel, washing the lesion with water spray for 30 s, drying the lesion with 100% ethanol for 30 s and subsequent air blowing, application of the infiltrant for 180 s using an applicator provided with the kit, removing excess material from the lesion surface by air blowing and flossing, light curing of the infiltrant for 40 s, repeated application for 60 s, light curing for 40 s, polishing, and removal of the rubber dam.
214659628|NCT01726179|DEVICE|Control|Proximal caries lesions do not recieve a placebo treatment, but simply left untreated.
214659629|NCT06858488|PROCEDURE|Extremity Surgery|Patients 18 years of age or older with high energy closed extremity fractures. Provision of informed consent.
214659630|NCT06382090|OTHER|Laughter yoga|This practice, which includes deep breathing exercises and laughter exercises, takes approximately 45 minutes. The sessions will be conducted by the principal investigator.
214659631|NCT01783665|OTHER|aerobic exercise|
214659632|NCT01783665|OTHER|home exercise program|
214659633|NCT03542994|OTHER|EDP1066|EDP1066 is an orally administered monoclonal microbial
214659634|NCT03542994|DRUG|Placebo oral capsule|placebo
214659635|NCT05821270|OTHER|Ashtanga Vinyasa Yoga Supta|Ashtanga (asta - eight, anga - parts); Vinyasa (freely sequenced practice); Yoga (practice for evolution); Supta (closed eyes)
214659636|NCT00000479|DRUG|Aspirin|Participants will receive 100 mg of aspirin every other day.
214659637|NCT00000479|DRUG|Vitamin E|Participants will receive 600 IU of vitamin E every other day.
214659638|NCT00000479|BEHAVIORAL|Placebo|Participants will receive placebo.
214659639|NCT05798988|BEHAVIORAL|Neurophysiology-based exercise program|Neurophysiology-based exercise program combines physiotherapy exercises and neuro-physiology principles with focus on foot and core functional stabilisation and balance training.
214659640|NCT04203173|BEHAVIORAL|FINANCE-DM|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
214659641|NCT04203173|BEHAVIORAL|Active Comparator|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
214659642|NCT06238999|DEVICE|Restoration of non-carious cervical lesions|Non-carious cervical lesions will be treated with the experimental TM Flow or the well-established Tetric EvoFlow. The treatment workflow is very similar to other flowable composites.
214659643|NCT05803564|DEVICE|Thoracoabdominal aortic stent system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.
214659644|NCT03507140|OTHER|Multiple sampling|"Bile, saliva, feces, urine et blood samples before and after liver transplantation in recipients.~Bile, saliva, feces, urine et blood samples during liver removal in donors."
214659645|NCT04984889|DRUG|TAK-662|Lyophilized, sterile concentrate of human protein C
214659646|NCT05211778|BEHAVIORAL|Digital Education Group|Multimedia education provided to the intervention group via a digital tablet
214659647|NCT06863246|OTHER|Evaluation of cognitive task on static balance|Static balance with and without cognitive task (i.e., 1-back task)
214659648|NCT06863246|OTHER|Evaluation of visual feedback on static balance|Static balance with and without visual feedback (i.e., eyes closed and open).
214659649|NCT06676514|DIETARY_SUPPLEMENT|Probiotic Clostridium butyricum CBM588®|This group received probiotic Clostridium butyricum CBM588® treatment for IBS-D as three tablets daily for 8 weeks.
214659650|NCT06676514|OTHER|Standard of care IBS-D treatment|Patients in this group received standard of care IBS-D treatment of Trimebutine maleate maleate and followed a lactose-free, no-slag diet.
214659651|NCT05905783|DRUG|Placebo|Solution for injection
214659652|NCT05905783|DRUG|Izokibep|Solution for injection
214659653|NCT04708041|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
214659654|NCT06607991|DRUG|Blinatumomab Treatment|Blinatumomab treatment for CNI-resistant/Intolerant pediatric steriod-resistant nephrotic syndrome Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
214659655|NCT06867627|BEHAVIORAL|Moderate-intensity combined aerobic and resistance exercise training|Training sessions begin with a 10-minute warm-up period that includes jogging and dynamic muscle stretching. This is followed by 20 minutes of running/jumping rope on the playground. Each intervention participant will wear a heart rate armband (Polar OH1, Finland) for real-time heart rate detection to maintain achievement of a predetermined target heart rate and training intensity. Then, after 10 minutes of rest adjustment and preparation, a 20-minute resistance training session will be performed, including all major muscle groups. Resistance training will start at 50% of 1RM and increases intensity by 10% after every three sessions, with two sets of repetitions and 60-90 seconds of rest between sets. By the third week, it will reach 70% of 1RM, and repeat 3 sets at 70% of 1RM starting at week 4. After the end of week 6, re-evaluate the RM every 3 weeks and repeat 3 sets at 70% of the new 1RM (i.e., starting from Week 7 and Week 10), maintaining a 60-90 second rest between each sets.
214659656|NCT03765593|PROCEDURE|Biopsy Salivary Gland|A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
214659657|NCT02760290|PROCEDURE|Extraperitoneal cesarean section|
214659658|NCT02760290|PROCEDURE|Intraperitoneal cesarean section|
214659659|NCT06683482|OTHER|No intervention|No study drug will be administered as a part of this study.
214659660|NCT03431233|DIETARY_SUPPLEMENT|Protein-enriched bar, commercial cereal bar, or water|Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
214659661|NCT00045032|DRUG|Herceptin|Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
214659662|NCT00045032|DRUG|Herceptin|Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
214659663|NCT05906914|DRUG|cladribine + homoharringtonine + cytarabine|CHA Protocol: cladribine (5mg/m2, d1-3) + homoharringtonine (2mg/m2, d1-5) + cytarabine (100mg/m2 d1-7).
214659664|NCT07013019|OTHER|Measures of overall (internal+external) knee rotational amplitudes|Measures of overall (internal+external) knee rotational amplitudes by Dyneelax
214659665|NCT07015697|DRUG|Trastuzumab Deruxtecan|"Dose Escalation Part: Trastuzumab Deruxtecan will be administered at escalating doses to determine the RDE.~Expansion Part: Trastuzumab Deruxtecan will be administered at RDE."
214848698|NCT05723718|OTHER|Observational Survey|Evaluation of the nutritional status and body composition on tumor regression grade in gastric cancer patients scheduled for multimodal treatment. Nutritional status assessment will include: selected clinical variables evaluation (weight, BMI, nutritional status scales), bioelectrical impedance analysis and selected laboratory parameter assessment. After inclusion in the study, each patient will have four consecutive nutritional status assessments: (1) one day prior staging laparoscopy or during qualification to neoadjuvant chemotherapy, (2) one day before the gastrectomy, (3) one month after the gastrectomy, (4) after the last cycle of adjuvant chemotherapy.
214659666|NCT05698589|BEHAVIORAL|Compassion Focused Therapy|CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, …) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, …). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.
214659667|NCT05698589|BEHAVIORAL|Ending Self Stigma|Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals
214659668|NCT02926807|OTHER|FDG-PET Scan|a 18FDG-PET to quantify vascular inflammation
214659669|NCT02926807|OTHER|MDCT|a MDCT to calculate the Agatston score
214659670|NCT02926807|OTHER|biopsy and blood collection|biopsy and blood collection to assess biomarkers
214659671|NCT04488458|DIAGNOSTIC_TEST|MIC or MBEC+MIC based treatment algorithm|"i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.~ii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks."
214659672|NCT02489214|DRUG|donafenib tosilate tablets|200mg bid
214659673|NCT06686108|DRUG|Azacitidine (AZA) Days 1 - 5|Azacitidine, ih, 32mg/m2/d, days 1-5 of each 28-day cycle
214659674|NCT06686108|DRUG|Decitabine (DAC)|decitabine, 5mg/m2/d, days 1-5 of each 28-day cycle.
214659675|NCT06686108|DRUG|Venetoclax|venetoclax, 400mg/d, days 1-7 of each 28-day cycle
214659676|NCT02747524|OTHER|Vita Mamba peanut butter paste|
214659677|NCT06699563|BEHAVIORAL|Mobilization Motivation Card|On the morning of the surgery, the Mobilization Motivation Card and Pedometer will be introduced and the patient will be informed. On the morning of the first postoperative day, before the patient's first mobilization, pain assessment will be made with the Visual Analog Scale (VAS), and the Mobilization Motivation Card will be hung at the bedside during the day and will help increase the patient's participation in mobilization. Later, after a pedometer is attached to the patient's waist, the patient will be mobilized.
214659678|NCT06438757|DRUG|JYB1904|Participants will receive JYB1904 every 8 weeks for 24 weeks.
214659679|NCT06438757|DRUG|Omalizumab|Participants will receive Omalizumab every 2/4 weeks for 24 weeks.
214659680|NCT06691958|OTHER|Tortilla corn chips 4-5 pieces, eat one piece at time|Snack
214659681|NCT06691958|OTHER|Tortilla corn chips 90 grams|Snack
214659682|NCT06691958|OTHER|Extruded corn chips 90 grams|Snack
214659683|NCT06691958|OTHER|Extruded corn chips 4-5 pieces, eat one piece at time|Snack
214659684|NCT06683612|DRUG|PIPE-791|Subjects will receive a single oral dose of PIPE-791.
214659685|NCT03079440|DRUG|TEMCAP|Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
214659686|NCT06697171|OTHER|Group 1 Not an ad disclosure|Same social media post viewed as all other groups. @brandname in the narrative body of the social media post; #NotAnAd in the narrative body of the social media post
214659687|NCT06697171|OTHER|Group 2 Basic Disclosure|Same social media post viewed as all other groups. @brandname in the narrative body of the social media post; #ad in the narrative body of the social media post
214659688|NCT06697171|OTHER|Group 3 Basic + Paid Partnership Disclosure|"Same social media post viewed as all other groups. COI disclosures include paid partnership in the header and a tag for the industry partner; @brandname and #ad immediately at the beginning of the narrative body of the social media post;~#ad and #sponsored at the bottom of the narrative body of the social media post."
214290105|NCT04217876|DIAGNOSTIC_TEST|post-processing analysis of cardiac imaging (strain echocardiography)|"A dedicated software package for two-dimensional speckle tracking strain analysis (XStrain™, Esaote, Florence, Italy) was used to quantify both ENDO and EPI strains. Our echocardiographic imaging acquisition protocol for 2DSTE consisted in the acquisition of three consecutive cardiac cycles from non-foreshortened apical views (4, 2, and 3 chambers) obtained during breath hold. Frame-by- frame displacement of ENDO and EPI points was automatically evaluated, generating strain curves for each segment.~The tracking quality was verified for each segment, and subsequent manual adjustments were performed, when required. All data were analyzed with the aid of Fourier techniques, which ensure greater accuracy using the periodicity of the heart motion."
214659689|NCT06697171|OTHER|Control|No COI disclosure elements (i.e. no hashtags ). Only the @brandname is included within the narrative body of the social media post.
214659690|NCT06697171|OTHER|Group 4 Basic + Paid Partnership + Image label|"Same social media post viewed as all other groups. COI disclosures include paid partnership in the header and a tag for the industry partner; @brandname and #ad immediately at the beginning of the narrative body of the social media post; #ad and #sponsored at the bottom of the narrative body of the social media post; #ad (black text, white background) appears on the photo associated with the social media post"
214659691|NCT05818124|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
214659692|NCT05818124|DRUG|Placebo molnupiravir|Four placebo capsules matched to molnupiravir taken twice daily by mouth.
214659693|NCT05818124|DRUG|Placebo oseltamivir|Placebo capsule matched to oseltamivir taken twice daily by mouth.
214659694|NCT05818124|DRUG|Oseltamivir|One capsule of oseltamivir 75 mg taken twice daily by mouth.
214290106|NCT00929318|PROCEDURE|blood sampling|
214659695|NCT05818124|BIOLOGICAL|Influenza A Virus|Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
214659696|NCT06687837|BIOLOGICAL|autologous dopaminergic cell implantation|Dopaminergic progenitor cells derived from autologous induced pluripotent stem cells will be injected into the brain in two cohorts of Parkinson's patients, one receiving low dose and the other high dose (4 and 8 million cells, respectively)
214659697|NCT06723691|DRUG|Acetaminophen|Acetaminophen
214659698|NCT06723691|DRUG|Metformin|Metformin
214659699|NCT06723691|DRUG|Warfarin|Warfarin
214659700|NCT06723691|DRUG|Atorvastatin|Atorvastatin
214659701|NCT06723691|DRUG|Digoxin|Digoxin
214659702|NCT06723691|DRUG|HRS9531|HRS9531
214659703|NCT06409208|BEHAVIORAL|mHealth intervention (video and reminder SMSs)|intervention includes educational video related to postnatal care and reminder SMSs related to postnatal visits, family planning adoption and exclusive breast feeding practice.
214659709|NCT06887829|RADIATION|Low dose radiotherapy|Participants will receive low dose radiotherapy (0.5 Gy) 3 times per week, for two weeks delivered via the X-Strahl Orthovoltage device.
214659710|NCT06887829|OTHER|Sham comparator|Participants will receive identical treatment 3 times per week, for two weeks delivered via the X-Strahl Orthovoltage device, without radiation.
214659711|NCT06735248|BIOLOGICAL|mRNA-1195|IM injection
214659712|NCT06735248|BIOLOGICAL|Placebo|IM injection
214659713|NCT06744413|BEHAVIORAL|Multimodal prehabilitation program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of these three domains will be utilized to maximize their synergistic anabolic effect.~The duration of the program will be set at 4 weeks."
214659714|NCT06733974|OTHER|Multi-faceted Intervention|The participant, i.e. relative, will receive the multifaceted intervention which include: a first meeting with the healthcare team including written information about palliative care for dying patients, information on possibility to participate in care, pro-active communication, and dedicated interview and brochure after the patient's death with possibility of psychological follow up.
214659715|NCT06895681|PROCEDURE|Blood Sample|Obtained at the time of non-study related routine blood draw.
214659716|NCT06895681|PROCEDURE|Tissue Sample|Obtained at the time of non-study related routine biopsy or surgical procedure.
214659717|NCT06895681|PROCEDURE|Excess fluid Sample|Obtained at the time of non-study related routine biopsy, surgical procedure, paracentesis, or thoracentesis procedure.
214659718|NCT06895681|OTHER|Medical Chart Review|Demographic, clinical, and pathologic information will be extracted from the medical record
214659719|NCT06702995|DRUG|XNW5004|Oral continuous
214659720|NCT06702995|DRUG|enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
214659721|NCT06781190|BEHAVIORAL|Green motherhood education|Pregnant women selected for the experimental group will receive 4 weeks of green motherhood training.
214659722|NCT06745050|BEHAVIORAL|Text message mHealth Evidence-based intervention|MM! includes three messages per week in month one, then two messages per week for the six-month intervention period. Earlier messages include more informational and motivational content, while later messages include more behavioral skills.
214659723|NCT07072624|DRUG|Phenytoin|The Phenytoin group will be given a loading dose of phenytoin 20 mg/kg intravenously (maximum, 2 gm) at 50 mg per minute and then started on a maintenance dose (5-6 mg/kg/d, rounded to the nearest 100 mg, intravenously administered every 8 hours). The intravenous will be switched to oral once the patient is fit to take it orally or via Ryles tube. The oral dose would be a single 300 mg ER (extended-release) tablet per day. Both IV and/or oral doses of phenytoin will be given only for 1 week after head trauma. Patient= Patients with Traumatic brain injury as per eligibility criteria. Intervention= Phenytoin loading dose IV (20 mg/kg) followed by 100 mg IV TDS till patient accepts orally. Oral dose will be administered as a single 300 mg ER tablet per day. Both IV and oral phenytoin will be given for 1 week after traumatic brain injury and then stopped. Comparator= Matching Placebo
214659724|NCT07072624|DRUG|Levetiracetam|The Levetiracetam group will receive 25-30 mg/kg/d in two divided doses (rounded to 750 mg, administered intravenously every 12 hourly). The intravenous dose will be switched to oral form once the patient is fit to take it orally or via Ryles tube. The oral dose would be two tablets of 750 mg ER (extended-release) levetiracetam daily. Both IV and/or oral doses of levetiracetam will be given only for 1 week after head trauma. Patient= Patients with Traumatic brain injury as per eligibility criteria. Intervention= Levetiracetam IV dosing will be 25-30 mg/Kg/d in 2 divided doses (rounded to 750 mg IV BD) followed by 2 tablets of 750 mg ER once patient fit to take orally or via Ryles tube. Comparator= Matching Placebo.
214659725|NCT07072624|DRUG|Placebo|The Placebo group will be administered normal saline intravenously of similar amount that of intervention group and matching placebo tablets orally (double dummy) once the patient is fit to take orally. Similar to the intervention group, both IV and oral placebo will be given till 1 week after traumatic brain injury.
214659726|NCT07070115|DEVICE|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
214659727|NCT06842589|BIOLOGICAL|anti-CD19 CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
214659728|NCT06758063|OTHER|exercises therapy|exercises to improve balance of the body
214659729|NCT07074379|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications primarily include quitting smoking and alcohol consumption, as well as engaging in physical exercise.
214659730|NCT07074379|DRUG|Pancreatic enzyme (Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose , Metformin, Glimepirde Tablets, Insulin)|"This intervention involves the use of medications to control the pancreatic exocrine and endocrine dysfunction caused by chronic pancreatitis.~1. Pancreatic enzyme therapy: Patients will use pancreatic enzymes (pancreatin enteric-coated capsules or oryz-aspergillus enzyme and pancreatin tablets) to control the symptoms of exocrine pancreatic insufficiency.~2. Diabetes treatment: Patients with diabetes will also use antidiabetic medications (such as oral hypoglycemic drugs or insulin, depending on glycemic control needs)."
214659731|NCT07074379|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or Extracorporeal Shockwave Lithotripsy (ESWL)|This intervention involves the application of endoscopic retrograde cholangiopancreatography (ERCP) and/or extracorporeal shockwave lithotripsy (ESWL), conducted in accordance with established clinical guidelines. The procedures are tailored to the individual patient's condition, which may include sphincterotomy, balloon dilation of pancreatic duct strictures, stone extraction, and stent placement as indicated. ESWL may be used prior to ERCP to fragment pancreatic duct stones, facilitating their removal.
214659732|NCT03781986|DRUG|APG-115|APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
214659733|NCT03781986|DRUG|Carboplatin|Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
214659734|NCT07084298|DIETARY_SUPPLEMENT|Oral iron supplement|Encapsulated ferrous sulphate (150mg elemental iron)
214659735|NCT07084298|OTHER|Placebo|Encapsulated polysaccharide (maltodextrin)
214659736|NCT04620382|DRUG|Midodrine|Midodrine 5-10 mg, single oral dose
214659737|NCT04620382|DRUG|Placebo pill|single oral dose
214659738|NCT04620382|DEVICE|Abdominal compression|abdominal compression up to 40 mmHg during head-up tilt
214659739|NCT04620382|DEVICE|sham compression|Sham abdominal compression during head-up tilt
214659740|NCT01075347|OTHER|autologous serum|with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
214659741|NCT01075347|OTHER|Non-autologous serum|without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
214659742|NCT03275909|BEHAVIORAL|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
214659743|NCT05266872|OTHER|Observational study with sample and data collection|Observational study with sample and data collection
214659744|NCT07082530|PROCEDURE|Labor Induction at 39 Weeks|Labor induction at 39 weeks 0 days to 39 weeks 4 days
214659745|NCT07082530|PROCEDURE|Expectant management|Expectant management until spontaneous labor or induction at 41 weeks.
214659746|NCT07088471|DRUG|Sacubtril/Valsartan|Angiotensin-receptor blocker and neprilysin inhibitor therapy
214659747|NCT07097376|BEHAVIORAL|Purposeful Pathways|Purposeful Pathways is a manualized intervention to assist Veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.
214659748|NCT07097376|OTHER|Transitional Work|Provides individuals with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TW is time-limited. TW is staffed by vocational rehabilitation specialists (VRS).
214659749|NCT04634539|DRUG|Gemcitabine|Gemcitabine will be administered at 600, 800, or 1000 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Gemcitabine will be administered immediately after the infusion of nab-paclitaxel. Pre-medication with may be administered per institutional standard practice at the investigator's discretion with gemcitabine.
214659750|NCT04634539|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 75, 100, or 125 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Nab-paclitaxel will be given first, before infusion of gemcitabine. Pre-medication for nab-paclitaxel may be administered per institutional standard practice at investigator's discretion.
214659751|NCT04634539|DRUG|L-glutamine|The dose levels of L-glutamine in this study will be 0.1, 0.2, and 0.3 g/kg oral twice daily (rounded to nearest 5 g with an upper limit of 15 g twice daily (30 g/day) for any dose level) taken at the same time each day during the treatment period. L-glutamine will be administered for 1 week (+/-1 day) prior to addition of gemcitabine/nab-paclitaxel. Each dose of L-glutamine should be mixed immediately before ingestion with 8 oz. (240 mL) of a cold or room temperature beverage, such as water, milk or apple juice, or 4 oz. (120 mL) to 6 oz. (177 mL) of food such as applesauce or yogurt. L-glutamine is formulated in 5 gram packets as a white crystalline powder in paper-foil-plastic laminate. Complete dissolution is not required prior to administration.
214659752|NCT07100691|DRUG|Metoclopramide|Oral metoclopramide 10 mg, administered as three doses the day before surgery and one dose on the morning of surgery (total four doses over 24 hours). Used to enhance gastric emptying in patients taking GLP-1 receptor agonists.
214659753|NCT07089823|DRUG|YP05002|Tablet, QD
214659754|NCT07089823|OTHER|Placebo|Tablet, QD
214659755|NCT07107048|DEVICE|Pacemaker and defibrillator|Patients will be randomly assigned at enrollment (1:1) to undergo either LBBAP or CRT with biventricular stimulation. The devices implanted maybe defibrillators or pacemekers.
214659756|NCT07105540|DRUG|5% Dextrose|Ultrasound-guided hydrodissection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. 2.5 ml of 5% dextrose will be injected via an in-plane ulnar approach to mechanically separate the median nerve from the transverse carpal ligament. Subsequently, an additional 2.5 ml of 5% dextrose will be administered to separate the nerve from adjacent flexor tendons. The total injection volume will be 5 ml.
214659757|NCT07105540|DRUG|Betamethasone and local anesthetic|Ultrasound-guided perineural injection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. A total of 2 ml solution (1 ml betamethasone and 1 ml 2% lidocaine) is injected perineurally around the median nerve under ultrasound guidance at the scaphoid-pisiform level.
214659758|NCT07107581|DEVICE|Prospective / Subjects Knee Arthroplasty|Knee Arthroplasty
214659759|NCT07107581|DEVICE|Retrospective to Prospective|Knee Arthroplasty
214659760|NCT07107581|DEVICE|Retrospective Only Subjects|Knee Arthroplasty
214659761|NCT07106840|OTHER|No intervention (observational study)|This is an observational study with no intervention applied.
214659762|NCT07108218|PROCEDURE|lateral postion|The children will be positioned on their sides with their heads elevated by 30°, a thin pillow behind their backs, the upper legs bent, and the lower legs straightened.
214659763|NCT07108218|PROCEDURE|supine position|The children will be changed to a supine flat-lying position for extubation.
214659765|NCT06911983|DRUG|Metformin|Metformin • Initial dose: 500 mg twice daily • Titration: increased to 1,000 mg twice daily by Week 2 if tolerated • Maximal dose: 2,000 mg/day
214659766|NCT06911983|DIETARY_SUPPLEMENT|Berberine|"Berberine~* Dose: 500 mg three times daily (1,500 mg/day total)~* Formulation: standardized berberine HCl tablets~* Duration: 12 weeks"
214659767|NCT07106541|BEHAVIORAL|Replicating Effective Programs (REP)|The study team will deploy this stakeholder informed REP package across the 68 sites in the MSQC-COHR collaborative. The REP program uses a blend of formats including didactics, flipped classroom design, and narrative storytelling, the REP will address key barriers to adherence previously identified by surgeons.
214659768|NCT07106541|BEHAVIORAL|REP with facilitation (REP-PLUS)|This intervention is a stepped-up REP plus virtual facilitation. The facilitator will: 1) Initiate implementation and benchmark goals: The facilitator will partner with the identified site champions but be masked to primary and secondary outcomes. Together, the facilitator and site champions will review processes to organizationally embed clinical practice guidelines into practice, assess potential barriers and facilitators to these processes, and set measurable goals for adherence to recommendations; 2) Track adherence and provide feedback: Facilitators will use abstracted MSQC-COHR and site-specific operative data to track adherence to clinical practice guidelines, identify barriers to adherence, provide solutions to identified barriers, re-engage stakeholder groups responsible for unsatisfactory measurements, and continuously promote awareness of the guidelines.
214659769|NCT06914856|BEHAVIORAL|Financial Capability Support with Peer Support Services|The participants in this arm will receive one-on-one financial coaching, which entails monthly or more frequent meetings with a financial coach. Participants will also receive access to safe and affordable financial services, which includes support with managing any existing bank accounts, or supporting a person to open a new overdraft-free account. Coaches can also help people to access other financial products such as free tax preparation (VITA), credit builder loans, online bank accounts, or other products recommended by our Justice Tech partner. The participants will also receive will receive the additional services of one-on-one peer support provided by a trained Recovery Support Specialist. Recovery Support Specialist, also referred to as Wellness coaches, will provide weekly meetings (30-60 minutes in duration) to the participants.
214659770|NCT06935123|DIETARY_SUPPLEMENT|Sleep Supplements|Sleep supplements
214659771|NCT06935123|OTHER|Placebo|Matching placebo
214659772|NCT06936215|DRUG|tab baricitinib 4 mg daily|Group A participants will be given tab. Baricitinib 4 mg daily
214659773|NCT06936215|DRUG|tab methotrexate 25 mg weekly with folic acid 5 mg weekly|group A participants will be given tab. baricitinib 4 mg daily and group B participants will be given tab. methotrexate 25 mg weekly with folic acid 5 mg weekly
214659774|NCT06941727|DIAGNOSTIC_TEST|ultrasonographic imaging|masseter muscle elasticity
214659775|NCT06935409|DRUG|HS-20093|Study participants in the experimental group shall continue to receive HS-20093 by intravenous infusion at a dose of 12.0 mg/kg, once every 3 weeks (Q3W) with a 21-day treatment cycle. Treatment shall continue until objective disease progression (excluding cases of treatment beyond PD or crossover treatment) or until other criteria for termination of study treatment specified in the protocol are met.
214659776|NCT06935409|DRUG|Gemcitabine combined with docetaxel|Study participants in the control arm will receive gemcitabine in combination with docetaxel. Gemcitabine (1000 mg/m2) will be administered intravenously over approximately 30 minutes on Days 1 and 8 of each 21-day treatment cycle, followed by docetaxel (75 mg/m2) on Day 8, intravenously over approximately 1 hour until objective disease progression or other criteria for treatment discontinuation are met.
214659777|NCT06935305|DEVICE|OSNA|The search for lymph node metastases in surgically removed sentinel lymph nodes will occur using the OSNA method
214659778|NCT06935305|DEVICE|Ultrastaging|The search for lymph node metastases in surgically removed sentinel lymph nodes will occur using the ultrastaging method
214659779|NCT06935383|DEVICE|Therapeutic sequence|the required dose of treatment is administered through the CoFI system
214659780|NCT06935383|DEVICE|Diagnostic sequence|Diagnostic sequence to detect MVO
214659781|NCT06935695|DEVICE|Bronchoscopy|Bronchoscopy is a procedure that uses a bronchoscope (a thin, tube-like instrument with a light and a lens for viewing) to examine the inside of the trachea, bronchi (air passages that lead to the lungs), and lungs. The bronchoscope is inserted through the nose or mouth.
214848699|NCT05265819|DEVICE|X-BOX kinetic360|1\) Exergaming The practice of exergaming was performed using the Xbox 360 Kinect console,The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed two to three times a week, for a total of 12 weeks.
214848700|NCT05265819|DIETARY_SUPPLEMENT|mediterranean diet|Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
214848701|NCT05265819|DRUG|thyroid hormone replacement therapy|thyroid hormone replacement therapy
214848702|NCT00289003|DRUG|Soluble beta-1,3/1,6-glucan|
214848703|NCT02621801|BEHAVIORAL|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
214848704|NCT03432234|OTHER|Biomarkers|This is an observational study, there is no intervention
214290107|NCT00929318|PROCEDURE|blood sampling|
214659782|NCT06935981|OTHER|school-based mental health program|Week 1 Session 1-Beginning-Getting Acquainted Week 2 Session 2-Emotion, Thought and Behavior Wheel Week 3 Session 3- Optimism Week 4 Session 4- Forgiveness Week 5 Session 5- Saying No Week 6 Session 6- Effective Communication Week 7 Session 7- Problem Solving Week 8 Session 8- Saying Goodbye
214659783|NCT06935487|DIAGNOSTIC_TEST|transrectal ultrasound of prostate (TRUS) with AI software algorithm|Transrectal ultrasound of prostate (TRUS) with AI software algorithm for detection of lesions suspected for prostate cancer
214659784|NCT06935487|DIAGNOSTIC_TEST|MRI prostate|MRI for detection of lesions suspected for prostate cancer
214659785|NCT06935448|OTHER|enhanced recovery after surgery|ERAS group follows the enhanced recovery after surgery program which involves 20 elements
214659786|NCT06935851|BEHAVIORAL|VOCAB +|"The purpose of the study is to investigate how word characteristics (e.g., phonotactic probability) and orthography effect vocabulary learning by children with low oral language levels. We will be using a 2 x 2 within-subjects factorial design where every participant serves as their own control. This 12-week study aims to improve the Efficiency of vocabulary learning for children with low oral language levels.~The four interventions that are all participants will be exposed to are the following: high pp words with orthography; high pp words without orthography; low pp words with orthography; low pp words without orthography."
214659787|NCT06935214|DIETARY_SUPPLEMENT|Caffeine|5 mg/kg of caffeine in pill form
214659788|NCT06935214|DIETARY_SUPPLEMENT|Placebo|5 mg/kg dose of maltodextrin in pill form
214659789|NCT06935214|DIETARY_SUPPLEMENT|Caffeine|5 mg/kg dose of caffeine in pill form
214659790|NCT04547582|DEVICE|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
214659791|NCT06936488|DRUG|Ivonescimab,TAS-102|Ivonescimab,20mg/kg,i.v.,D1,Q3w TAS-102,35mg/m2,bid,D1-5,Q2W
214659792|NCT02581995|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
214659793|NCT00452725|DRUG|MAXOMAT ®, biosynthetic growth hormone|2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
214659794|NCT06947356|DRUG|TAF group|Pregnant women will start TAF treatment (25 mg tablet taken orally once daily) from 28 weeks of gestation until delivery. After that, they will be randomly assigned to two subgroups among postpartum mothers without treatment indications: one subgroup will stop treatment, while the other subgroup will continue with an additional 12 weeks of TAF treatment. The mothers and their infants will be followed up at 28 weeks postpartum. Infants will receive the hepatitis B vaccine and HBIG within 12 hours after birth, as well as booster doses of the hepatitis B vaccine at 4 weeks and 24 weeks.
214659795|NCT06947356|DRUG|TDF group|The mother will start receiving TDF treatment (300 mg tablet taken orally once daily) at 28 weeks of pregnancy until delivery. After that, mothers without treatment indications will be randomly assigned to two subgroups: one subgroup will stop treatment, while the other subgroup will receive an additional 12 weeks of TDF treatment. Infants will be vaccinated with the hepatitis B vaccine and HBIG within 12 hours after birth, as well as receive booster doses of the hepatitis B vaccine at 4 weeks and 24 weeks.
214659796|NCT06948682|DEVICE|Occlusal Splint and Bite Correction Therapy|Participants receive individualized occlusal therapy involving occlusal splint use and bite correction (if needed). The treatment is applied continuously over a 6-month period. Monthly follow-up visits are conducted to monitor symptoms, adjust therapy, and evaluate radiographic changes in the TMJ.
214659797|NCT06948682|OTHER|Conventional TMJ Therapy|Participants undergo a 6-month conventional management program including pain medication (NSAIDs), physical therapy (jaw exercises, hot/cold therapy), and lifestyle guidance (diet modifications, stress reduction). Monthly clinical evaluations assess functional improvement and symptom reduction.
214659798|NCT06948682|OTHER|Routine TMJ Care (Medication Only)|Participants receive standard pharmacological management for TMJ disorders (e.g., NSAIDs or analgesics) with no occlusal or physical therapy interventions. Follow-up assessments occur monthly for 6 months to monitor symptom progression and response to minimal intervention.
214659799|NCT01374282|DRUG|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
214659800|NCT00047567|DRUG|zonisamide|
214659801|NCT02412280|OTHER|retrospecive observational|
214659802|NCT04855656|DRUG|RP-6306|Oral PKMYT1 Inhibitor
214659803|NCT04855656|DRUG|RP-3500|Oral ATR Inhibitor
214659804|NCT04855656|DRUG|Debio0123|Oral WEE1 Inhibitor
214659805|NCT04907045|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
214659806|NCT04907045|BEHAVIORAL|Practice Facilitation|In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
214659807|NCT04907045|BEHAVIORAL|Standard Implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
214659808|NCT03408132|DRUG|FE203799|FE203799 5 mg subcutaneous once weekly
214659809|NCT03704766|DIAGNOSTIC_TEST|Synovial Alpha-defensin assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
214659810|NCT03704766|DIAGNOSTIC_TEST|Synovial Neutrophil elastase assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
214659811|NCT03704766|DIAGNOSTIC_TEST|Synovial lactate assay|Synovial Fluid (joint fluid) will be sent out to CD Diagnostics for this test.
214659812|NCT03704766|DIAGNOSTIC_TEST|Synovial C-reactive Protein (CRP)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
214659813|NCT03704766|DIAGNOSTIC_TEST|Synovial Staphylococcus spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
214659814|NCT03704766|DIAGNOSTIC_TEST|Synovial Candida spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
214659815|NCT03704766|DIAGNOSTIC_TEST|Synovial Enterococcus faecalis assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
214659816|NCT03704766|DIAGNOSTIC_TEST|Synovial bacterial culture by BacT/Alert|The synovial fluid (joint fluid) sent to CD Diagnostics for testing will also be cultured to see if any organisms grow.
214659817|NCT03704766|DIAGNOSTIC_TEST|Synovial Cell count + differential (CBC)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
214659818|NCT03704766|DIAGNOSTIC_TEST|Synovial Gram Stain|This will be performed by CD Diagnostics if any organisms are present in the synovial fluid.
214659819|NCT03704766|DIAGNOSTIC_TEST|Synovial Leukocyte Esterase Test Strips|These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.
214659820|NCT03704766|DIAGNOSTIC_TEST|Synovial PCR for Kingella kingae|In participants \< 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.
214659821|NCT03704766|DIAGNOSTIC_TEST|Serum Cell count + differential (CBC)|A blood test performed at the hospital.
214659822|NCT03704766|DIAGNOSTIC_TEST|Serum erythrocyte sedimentation rate (ESR)|A blood test performed at the hospital.
214659823|NCT03704766|DIAGNOSTIC_TEST|Serum C-reactive Protein (CRP)|A blood test performed at the hospital.
214659824|NCT03704766|DIAGNOSTIC_TEST|Serum D-dimer|A blood test performed at the hospital.
214659825|NCT03704766|DIAGNOSTIC_TEST|Serum Procalcitonin|A blood test performed at the hospital.
214659826|NCT03704766|DIAGNOSTIC_TEST|Blood Cultures|Blood will be cultured at the hospital to see if any organisms grow.
214659827|NCT03704766|DIAGNOSTIC_TEST|Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )|In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.
214659828|NCT04840836|BEHAVIORAL|Telehealth-supported LARC provision|"Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as adolescents)."
214659829|NCT03697564|DRUG|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 Q4W
214659830|NCT03697564|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV on Day 1 Q4W
214659831|NCT03697564|DRUG|Cabiralizumab|4mg/kg IV on day 1 and 15 Q4W
214659832|NCT03055026|DRUG|Rivaroxaban|Tablets
214659833|NCT03055026|DRUG|Placebo|Tablets
214659834|NCT01377493|DIETARY_SUPPLEMENT|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
214659835|NCT06443086|PROCEDURE|Radical operation and perioperative therapy|Surgical intervention, particularly radical excision, was performed for each patient, including the extent of resection and lymph node dissection. Information on adjuvant therapies, such as chemotherapy and radiotherapy, was also recorded, specifying the regimens and durations.
214659836|NCT02031679|DRUG|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
214659837|NCT02031679|DRUG|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
214659838|NCT02189265|OTHER|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
214659839|NCT04030195|GENETIC|PBCAR20A|"Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied."
214848705|NCT02199015|DEVICE|Lateral spinal cord surgical implant of electrodes|"The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.~A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG)."
214659840|NCT04030195|DRUG|Fludarabine|Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).
214659841|NCT04030195|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
214659842|NCT03404362|PROCEDURE|Bone Metastases Pain treatment|Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
214659843|NCT01812525|DRUG|NaCl 3%|NaCl 3%: 4ml QID
214659844|NCT01812525|OTHER|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
214659845|NCT02593929|DRUG|ruxolitinib|
214659846|NCT01980446|PROCEDURE|Auditory-evoked potentials|cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
214848706|NCT04147988|OTHER|screening and diagnostic assessment DONALD T unit list|Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
214848707|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
214848708|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
214848709|NCT02225665|GENETIC|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
214848710|NCT02225665|GENETIC|SB-728mR-T|\- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
214848711|NCT02225665|DRUG|Cyclophosphamide|\- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
214659847|NCT03916068|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.
214659848|NCT03916068|DRUG|Trental Pill|Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
214659849|NCT03916068|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily
214659850|NCT04057170|OTHER|accelerated protocol and mulligan method|manual therapy technic
214659851|NCT05136391|DRUG|XTR003|Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.
214659852|NCT03018015|DRUG|Ibuprofen 400 mg oral powder|
214659853|NCT03018015|DRUG|Ibuprofen 400 mg film-coated tablet|
214290108|NCT03552198|BEHAVIORAL|Alternative health advice|These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.
214659854|NCT03018015|DRUG|Ibuprofen 400 mg soft capsule|
214659855|NCT02759822|PROCEDURE|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).
214659856|NCT01024244|DRUG|Placebo|Administered po BID, prior to morning and evening meals for 12 weeks.
214659857|NCT01024244|DRUG|LY2599506|Administered po for 12 weeks
214659858|NCT03232112|DRUG|Exenatide 2 MG Injection|Subcutaneous injection once-weekly
214659859|NCT03232112|DRUG|BD PosiFlush (saline)|Subcutaneous injection once-weekly
214659860|NCT02981212|DRUG|Mycophenolate Mofetil|less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally
214659861|NCT02981212|DRUG|ACE inhibitor|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
214659862|NCT02981212|DRUG|Corticosteroid|combination with Mycophenolate Mofetil
214659863|NCT02981212|DRUG|ARB|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
214659864|NCT00539344|DRUG|ANG1005|IV infusion once every 21 days
214659865|NCT03120910|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse Oximeter Sensor will measure hemoglobin (SpHb), pulse rate (PR), perfusion index (PI), pleth variability index (PVI), oxygen reserve index (ORI), etc.
214659866|NCT01753492|DEVICE|Ologen|
214659867|NCT01912885|DEVICE|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
214290109|NCT02845453|DRUG|Quetiapine|Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
214290110|NCT02845453|OTHER|Placebo|Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
214659868|NCT01912885|DEVICE|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
214659869|NCT01912885|DEVICE|TENS 2-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
214659870|NCT01912885|DEVICE|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
214659871|NCT01912885|DEVICE|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
214659872|NCT02393092|BEHAVIORAL|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
214659873|NCT02393092|BEHAVIORAL|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
214659874|NCT02393092|BEHAVIORAL|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
214659875|NCT05195359|BEHAVIORAL|Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore|The Dein Schlaf. Dein Tag. application powered by SleepScore is a validated sleep measurement application using sonar technology that also provides evidenced-based sleep advice and sleep education content based on a user's objectively measured nightly sleep data. As participants engage with the app, the Dein Schlaf. Dein Tag. application provides personalized and dynamic sleep content and sleep and circadian rhythm improvement advice based in the principles of sleep hygiene, sleep-circadian science, and cognitive behavioral psychology. Participants will also receive personalized sleep challenges tailored to improve their sleep and circadian rhythms. Each challenge lasts for 7 tracked nights, ranging from optimizing sleep habits to limiting caffeine intake, and more. Additional sleep improvement features embedded within the app include sleep sanctuary bedroom checks, sleep sounds, smart alarms, bedtime reminders, and sleep education blogs and science content.
214659876|NCT02477098|DRUG|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
214659877|NCT02477098|DRUG|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
214659878|NCT03328039|DEVICE|Garmin wearable device|Physiological data capture only
214659879|NCT01232946|DRUG|liraglutide|1.8mg subcutaneous qd for 3 months
214659880|NCT01232946|DRUG|insulin detemir|5units subcutaneous bid titrated to fasting glucose of \<130mg/dL for 3 months
214659881|NCT01232946|DRUG|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose \<130mg/dL for 3 months.
214659882|NCT00928980|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
214659883|NCT00928980|DRUG|Optimal Medical Care|Therapeutic dose of antidepressant medication
214659884|NCT02748369|DRUG|Somatostatin|Somatostatin infusion to create a low insulin state.
214659885|NCT02748369|DRUG|Glucagon|Glucagon infusion in the setting of ongoing somatostatin.
214659886|NCT04052828|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
214659887|NCT01987544|OTHER|Ergometer Training|
214659888|NCT01987544|OTHER|Motivation|
214659889|NCT05692349|DEVICE|MRI|MRI will be employed to assess muscle composition, evidence of degeneration or replacement by fat
214659890|NCT04215094|DIAGNOSTIC_TEST|postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun|All patients in Intracranial Infection group were cured with antibiotic treatment
214659893|NCT02511522|OTHER|Best Supportive Care|Including analgesics, palliative care and/or pain specialist assessment as needed
214659894|NCT02511522|RADIATION|Palliative Radiation Therapy|8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
214659895|NCT00267254|DRUG|torcetrapib/atorvastatin|
214659896|NCT00267254|DRUG|simvastatin|
214659897|NCT06111326|DRUG|BC3402 injection|Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
214659898|NCT06111326|DRUG|Durvalumab injection|Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
214659899|NCT01596205|BEHAVIORAL|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
214659900|NCT01596205|BEHAVIORAL|Conventional cognitive training group|"Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil."
214659901|NCT05992779|OTHER|Measuring the vocal audiometry of patients.|Measuring vocal audiometry at 6 months, 1 year and annually until the last date of follow-up
214659902|NCT05992779|OTHER|Measuring data loging|Measuring data loging at 6 months, 1 year and then annually until last date of follow-up
214659903|NCT00036218|DRUG|sumanirole|
214848712|NCT06525922|BEHAVIORAL|Center M|Center M consists of weekly, 1-hour, telehealth, mindfulness-based Cognitive Behavioral Therapy (CBT) group sessions for four consecutive weeks. Participants joined group sessions on their personal computer, tablet, or phone. Each visit involved the introduction of a core mental well-being theme, learning skills to develop non-judgmental self-awareness and/or cognitive reappraisal skills, skills practice, and discussion of home practice materials. Home practice materials included written mindful awareness instructions, audio-guided meditations, self-compassion exercises, and practices in recognizing the interrelationships between thoughts, feelings, and behaviors.
214848713|NCT00607152|DRUG|Rasburicase|0.20mg/kg per day IV
214848714|NCT00607152|DRUG|Allopurinol|100mg tablets
214659904|NCT00036218|DRUG|ropinirole|
214659905|NCT06098885|OTHER|extraction orthodontic treatment|bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
214659906|NCT02660580|DRUG|MSB11022|Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
214659907|NCT02660580|DRUG|Humira®|Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.
214659908|NCT05723185|OTHER|Outpatient visit|Patients will be seen and treated at the outpatient clinic like in the usual care
214659909|NCT05823558|DIAGNOSTIC_TEST|Lomber Muscle Thickness Measurement|Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.
214659910|NCT00377962|DRUG|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
214659911|NCT00377962|DRUG|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
214659912|NCT00377962|DRUG|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
214659913|NCT00377962|DRUG|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
214659914|NCT05324072|OTHER|no intervention|observational study
214659915|NCT04632199|DRUG|111In-IPN01087 Low dose|Administered once via slow intravenous injection.
214659916|NCT04632199|DRUG|111In-IPN01087 High dose|Administered once via slow intravenous injection.
214659917|NCT05034679|BIOLOGICAL|Vcinated|Patients who were vacinated.
214659918|NCT05751408|PROCEDURE|gait analysis using 3D (Vicon) and IMU (Movella)|Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
214659919|NCT00186602|BEHAVIORAL|Peer counseling|
214659920|NCT06118879|DEVICE|Transcutaneous electrical stimulation|sensory level stimulation, one-leg standing and Y-balance training
214659921|NCT04677842|DRUG|ART Therapy|
214659922|NCT05671900|DRUG|Gemcitabine 1000 mg, Docetaxel 37.5g|6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
214659923|NCT02856737|OTHER|eye masks and earplugs|Materials similar to those offered on long commercial flights
214659924|NCT04511299|OTHER|SMOFlipid 20%|Fish oil-enriched intravenous lipid emulsion
214659925|NCT04511299|OTHER|Lipofundin 20%|MCT/LCT standard intravenous lipid emulsion
214659926|NCT02202603|DRUG|Teriparatide|single oral tablet
214659927|NCT02202603|DRUG|Teriparatide|subcutaneous standard injection
214659928|NCT02202603|DRUG|placebo|Oral placebo
214659929|NCT02786641|DRUG|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
214659930|NCT02786641|DRUG|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
214659931|NCT02786641|DRUG|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
214659932|NCT02786641|RADIATION|IMRT|IMRT for all patients
214659933|NCT02786641|DRUG|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
214659934|NCT04972383|COMBINATION_PRODUCT|Platelet Rich Plasma|In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.
214659935|NCT04972383|COMBINATION_PRODUCT|Hyaluronic Acid|In the Hyaluronic group, 3mLHYAJOINT Plus was given.
214659936|NCT02997124|PROCEDURE|local infiltration and TAP block|Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
214659937|NCT02997124|PROCEDURE|local infiltration only|Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
214659938|NCT03206658|DRUG|Spironolactone 25 mg|A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
214659939|NCT03206658|DRUG|Placebo oral capsule|The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
214659940|NCT00367809|BEHAVIORAL|Mindfulness-Based Stress Reduction (MSBR)|Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.
214659941|NCT00367809|BEHAVIORAL|Health Education (HE)|The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.
214659942|NCT00367809|BEHAVIORAL|Delayed Intervention|A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
214659943|NCT02691273|BEHAVIORAL|cellular application treating diabetes using breathing technique|
214659944|NCT03951987|DRUG|4 ml CG5503|4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
214659945|NCT03951987|DRUG|5 g charcoal powder|Oral administration of 5 g charcoal powder suspended in 100 ml tap water.
214659946|NCT00919659|DIETARY_SUPPLEMENT|parenteral nutrition|25kcal/kg bw with parenteral nutrition
214659947|NCT05442385|OTHER|Evidence based management|clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment
214659948|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.
214659949|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.
214659950|NCT02357992|RADIATION|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
214659951|NCT02139189|DEVICE|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
214659952|NCT02424370|PROCEDURE|TAVR|Percutaneous aortic valve replacement
214659953|NCT05224258|DEVICE|MiniMed 780G System|780G System used with Insulin Fiasp® (Insulin Aspart Injection)
214659954|NCT00221676|BIOLOGICAL|Alfarix|
214659955|NCT05258461|OTHER|use of a smartphone app for adverse event management|At their enrollment, patients will receive detailed introduction and adequate assistance on the use of the smartphone app. The smartphone app will offer proper advice for adverse event management based on calculated results by artificial intelligence on the innovative app, which was developed by YL et al. It was specifically intended for risk prediction, early prevention, as well as management of symptoms and concerns during adjuvant chemotherapy in the treatment of breast cancer. The app consisted of 4 modules: (1) Module 1: clinical data collection. (2) Module 2: risk evaluation for 12 common adverse events during breast cancer chemotherapy. (3) Module 3: personalized prophylaxis based on predicted risks of adverse events. (4) Module 4: Q\&A platform.
214659956|NCT05258461|OTHER|conventional adverse event management|Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience. For example, colony-stimulating factors and antibiotics may be used for febrile neutropenia, loperamide (or diphenoxylate plus atropine) as prophylaxis for diarrhea, together with eating low-lactose and low-fat frequent small meals. 5-hydroxytryptamine 3 receptor antagonist, neurokinin 1 receptor antagonist, and/or dexamethasone would be prescribed for patients at high risks of vomiting.
214659957|NCT00486902|DRUG|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
214659958|NCT00486902|DRUG|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
214659959|NCT04825548|OTHER|No intervention|Examination of patients with previous DVT
214659960|NCT01035151|BEHAVIORAL|Experimental|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
214659961|NCT01035151|BEHAVIORAL|Control|Written Cessation Materials
214659962|NCT04406571|OTHER|Data record|Data record
214659963|NCT05159180|DEVICE|cardioz mapping|Patients will be submitted to mapping of both voltage and tissue impedance.
214659964|NCT00743886|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
214659965|NCT00743886|DRUG|saline|injection of 6 cc of saline into injured area
214659966|NCT00418288|DRUG|glucagon-like-peptide-1|intravenous infusion of 1.2pmol/kg/min for 7 hours
214659967|NCT00418288|DRUG|placebo|intravenous infusion of 1.2pmol/kg/min
214659968|NCT02019706|RADIATION|DOTATATE PET-CT|68Ga-DOTATATE PET/CT
214659969|NCT02019706|RADIATION|F-DOPA PET CT|68Ga-DOTATATE PET/CT
214659970|NCT02019706|RADIATION|CT scan|routine CT scan
214659971|NCT02019706|DIAGNOSTIC_TEST|Routine MRI scan|routine 1.5 or 3T MRI scan
214659972|NCT02019706|DIAGNOSTIC_TEST|Gated MRI scan|Cardiac gated MRI scan
214659973|NCT02019706|DRUG|68Ga-DOTATATE|68Ga-DOTATATE radioligand
214659974|NCT02019706|DRUG|18F-DOPA|18F-DOPA radioligand
214659975|NCT02146781|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intradermal injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe."
214659976|NCT02146781|OTHER|Saline Control|The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
214659977|NCT01774916|GENETIC|blood samples|
214659978|NCT01655407|DRUG|Autologous Engineered Skin Substitute|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place."
214659979|NCT01655407|DRUG|Split-Thickness Autograft (AG)|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin."
214659980|NCT04439669|DEVICE|Sham nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2."
214659981|NCT04439669|DEVICE|Active nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2."
214659982|NCT03038724|DIAGNOSTIC_TEST|Rapid HIV test|
214659983|NCT04436913|OTHER|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
214848715|NCT03642353|DRUG|Triclosan|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
214848716|NCT03642353|DRUG|Placebo|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
214659984|NCT04436913|OTHER|Signal toothpaste|fluoride based toothpaste as a part of a caries preventive regimen
214659985|NCT04436913|OTHER|Signal toothpaste and fluoride varnish|application of fluoride varnish and using fluoride based toothpaste
214659986|NCT04645797|DRUG|APR003|This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.
214659987|NCT06324149|DIAGNOSTIC_TEST|completion of scales and questionnaires; venous blood sampling; muscle ultrasound; cardiac ultrasound; electrocardiogram; bioelectrical impedance analysis|The sub-investigator performs a multidimentional geriatric evaluation
214659988|NCT05904392|OTHER|Music|Music played prior to injection
214659989|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
214659990|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
214659991|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
214659992|NCT00733902|BIOLOGICAL|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
214659993|NCT01477021|DRUG|cyclophosphamide|Given IV
214848717|NCT00365937|BIOLOGICAL|Immunological peptides and immunological adjuvants|
214659994|NCT01477021|BIOLOGICAL|NY-ESO-1-specific T cells|Given IV
214659995|NCT01477021|OTHER|laboratory biomarker analysis|Correlative studies
214659996|NCT06245356|DRUG|Lonsurf|Trifluridine/tipiracil orally 35 mg/m²/dose (D1-D5 twice daily, D1=D15)
214659997|NCT06245356|DRUG|Oxaliplatin|Oxaliplatin intravenous injection 85 mg/m² every 2 weeks (D1=D15)
214659998|NCT06245356|DRUG|Panitumumab|Panitumumab intravenous injection 6 mg/kg (D1=D15)
214659999|NCT06245356|DRUG|Bevacizumab|Bevacizumab intravenous injection 5 mg/kg (D1=D15)
214660000|NCT06245356|DRUG|Trastuzumab|Trastuzumab intravenous injection 4 mg/kg (D1=D15)
214660001|NCT06245356|DRUG|Nivolumab|Nivolumab intravenous injection 240 mg (D1=D15)
214660002|NCT00235157|DEVICE|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
214660003|NCT03840629|OTHER|No study intervention.|
214660004|NCT02406664|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
214660005|NCT03763786|DRUG|Cetrorelix Acetate|Used a standard
214660006|NCT01162850|DIETARY_SUPPLEMENT|Polypodium Leucotomos|Oral capsule at 240 mg taken twice a day for 12 weeks
214660007|NCT01162850|DIETARY_SUPPLEMENT|Placebo|240 mg Placebo taken orally twice daily created by company which manufactured active ingredient
214660008|NCT00475163|BEHAVIORAL|Behavior modification|
214660009|NCT02510807|OTHER|Pedometer|The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
214660010|NCT06488950|BIOLOGICAL|GC203 TIL(gene-edited TIL) or autologous TILs|the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample
214660011|NCT00049127|DRUG|Imatinib Mesylate|Given PO
214660012|NCT00049127|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214660013|NCT00049127|OTHER|Pharmacological Study|Optional correlative studies
214660014|NCT00006383|DRUG|liposomal vincristine sulfate|
214660015|NCT05026073|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia|age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
214660016|NCT05026073|PROCEDURE|Blood and endometrial tissue sampling|"* All women will undergo planned hysterectomy.~* Venous blood sample will be collected prior to surgery.~* Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~* Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation."
214660017|NCT05026073|PROCEDURE|Lymph node sampling|"Lymph nodes will be excised if recommended as part of the standard treatment for endometrial cancer.~Each node will be cut in half or in quarters, depending on size, to expose the core. Wet and dry spectral analysis will be performed, followed by staining for histopathological confirmation."
214660018|NCT04548310|OTHER|Muscles Fatigue|An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.
214660019|NCT01029561|DEVICE|CPAP|Treatment with Continuous Positive Airway Pressure
214660020|NCT01029561|BEHAVIORAL|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
214660021|NCT06059885|DRUG|Tislelizumab plus tyrosine kinase inhibitor|Lenvatinib, tyrosine kinase inhibitor (TKIs)
214660022|NCT03465956|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy using the gastro-intestinal anastomosis stapler.
214660023|NCT03394222|DRUG|preoperative budesonide inhalation|
214660024|NCT03394222|DRUG|preoperative normal saline inhalation|
214660025|NCT05124808|OTHER|Intensive glycemic targets|Fasting blood glucose \<90 mg/dL, 1 hour post-prandial blood glucose \<120 mg/dL
214660026|NCT05124808|OTHER|Standard glycemic targets|Fasting blood glucose \<95 mg/dL, 1 hour post-prandial blood glucose \<140 mg/dL
214660027|NCT00928915|DRUG|Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)|intravenous, repeated until INR ≤ 1.2
214660028|NCT05375201|OTHER|VR skateboarding training|The virtual reality skateboard training (VR-skate) is used treadmill-based training. Virtual reality system is integrated into the split-belt treadmill for VR-skate. Participants slide the swing leg (sliding leg) along with the moving treadmill belt at a comfortable speed (same as walking speed).
214660029|NCT06108050|DRUG|JZP898|Investigational drug monotherapy
214660030|NCT06108050|DRUG|Pembrolizumab|Anti-PD1 antibody
214660031|NCT06273527|BEHAVIORAL|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
214660032|NCT06273527|OTHER|Sham Program|The Sham Program will be a similar task which researchers think will be less effective in training thinking skills.
214660033|NCT06294587|PROCEDURE|FGG Before GBR|Free Gingival Graft before the guided bone regeneration,
214660034|NCT06294587|PROCEDURE|FGG after GBR|Free Gingival Graft after the guided bone regeneration,
214660035|NCT06197984|PROCEDURE|ERCP|ERCP will serve as the exclusive therapeutic modality, aided by a therapeutic duodenoscope to access the common bile duct using a guidewire.
214660036|NCT05917145|DRUG|WSD0628|A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
214660037|NCT05372159|OTHER|none, observational study|none, observational study
214660038|NCT04754529|OTHER|Quality-of-Life Assessment|Ancillary studies
214660039|NCT04754529|OTHER|Survey Administration|Ancillary studies
214660040|NCT04754529|OTHER|Yoga|Receive yoga intervention
214660041|NCT05116813|DRUG|Dipraglurant|Oral 50 mg and 100 mg tablet
214660042|NCT06500754|OTHER|Ultra-strict gluten-free diet|ultra-strict gluten-free diet (avoiding traces and contamination) under dietitian supervision
214660043|NCT03227263|DRUG|Bevacizumab|Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations
214660044|NCT03227263|DRUG|sodium chloride 0.9%|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
214660045|NCT00274391|DRUG|7% NaCl|
214660046|NCT00274391|DRUG|Amiloride HCl|
214660047|NCT06528600|DEVICE|Hymovis ONE|Single injection of Hymovis ONE®, a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
214660048|NCT06528600|DEVICE|Monovisc|Single injection of Monovisc™ a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
214660049|NCT06340919|DEVICE|Sudden Sound Reduction Setting|Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low, High, or Maximum. Recordings with the different settings will be randomized from trial to trial.
214660050|NCT02744976|DRUG|Metformin|In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
214660051|NCT02744976|BEHAVIORAL|Lifestyle recommendations|Standard lifestyle recommendations
214660052|NCT03821857|DRUG|18-F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
214660053|NCT02599402|DRUG|Nivolumab|
214660054|NCT02599402|DRUG|Ipilimumab|
214660055|NCT05443022|RADIATION|Photobiomodulation|Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
214660056|NCT05443022|RADIATION|Simulation of Photobiomodulation|The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
214660057|NCT05664620|DIAGNOSTIC_TEST|Risk Stratification Tool|Patients will be allocated to three groups (Low,medium and high risk) by using the Risk Stratification Tool, and High risk patients will receive multidisciplinary treatment assigned to them by a physician
214660058|NCT03375385|DRUG|dexmedetomidine/ propofol|The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
214660059|NCT03488199|DEVICE|Stent Acculink ™|Carotid Artery Revascularization using Stents
214660060|NCT03488199|DEVICE|CGuardTM™|Carotid Artery Revascularization using Stents
214660061|NCT06286501|DEVICE|Lumoral Treatment|Home-use photodynamic antibacterial dual-light oral health care device with a marker substance
214660062|NCT06286501|OTHER|Standard, personalized oral health care|Home-based oral health care instructed by a professional, with emphasis on personal needs according to oral condition and previous oral health care habits.
214660063|NCT00833092|DIETARY_SUPPLEMENT|Sugar Pill|Sugar pill supplementation for 9 weeks
214660064|NCT00833092|DIETARY_SUPPLEMENT|magnesium|300 milligrams daily for 8 weeks
214660065|NCT02357511|DEVICE|Study Monitor used|
214660066|NCT00005104|DRUG|clomiphene citrate|
214660067|NCT00005104|DRUG|metformin|
214660068|NCT05366829|DRUG|Tislelizumab|Tislelizumab (also known as BGB A317) is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against programmed cell death protein-1 (PD-1) under clinical development for the treatment of several human malignancies. Tislelizumab consolidation therapy after radiation therapy can capitalize on the immunomodulatory effect of radiotherapy and improve tumor responses and patient outcomes.
214660069|NCT00699192|DRUG|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
214660070|NCT00699192|DRUG|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
214660071|NCT00699192|DRUG|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
214660072|NCT00699192|DRUG|Placebo|1 capsule placebo to match valsartan orally once daily
214660073|NCT04866927|DIETARY_SUPPLEMENT|Use of stable isotopic dilution to assess protein digestibility from Faba bean and to evaluate amino acid bioavailability|Each participant will receive a test meal containing 13C labelled spirulina, 2H labelled Fava bean and 13C phenylalanine. The test meal will be divided on 11 subdoses: 3 sub-doses will be administrated at T0 and 1 subdose will be administrated at 1, 2, 3, 4, 5, 6 and 7h. The remaining sub-dose will be kept for measurement of IAA in the test meal. After eating the test meal, blood, urine and breath samples will be collected from each participant at the baseline (T0) and after 5-6, 7h and 8h.
214660074|NCT04548076|OTHER|Block group|Control group
214660075|NCT04663750|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy
214660076|NCT04663750|DRUG|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.
214660077|NCT04663750|DRUG|subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls|Subretinal injection of recombinant TPA (Alteplase, Actilyse, Boehringer Ingelheim) up to a maximum of 25 micrograms in 0.2 mls.
214660078|NCT04663750|DRUG|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade.
214660079|NCT06457126|BEHAVIORAL|Attention Training Technique|"Phase 1: Non-concurrent multiple baseline design A-B design where the ATT (B) is introduced sequentially across participants. ATT and baseline (A) will be alternated on a weekly basis.~Phase 2: Alternating treatment design where an active (B) and passive (C) version of the ATT are rapidly and frequently alternative within the same participant on a weekly basis (e.g., A-B-A-C-A or A-C-A-B-A)."
214660080|NCT02980614|DEVICE|4D flow imaging|To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
214660081|NCT00116454|DRUG|131 I-lipiodol|intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
214660082|NCT01773473|DRUG|Insulin Lispro Mix25|Administered SC
214660083|NCT01773473|DRUG|Insulin Lispro Mix50|Administered SC
214660084|NCT02506738|DEVICE|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
214660085|NCT05069779|DRUG|Diazepam|Oral administration of 10 mg of diazepam
214660086|NCT06131710|OTHER|Isolated Strengthening Exercises|Isolated strengthening exercises can be beneficial for individuals with Patellofemoral Pain Syndrome (PFPS) to help address muscle imbalances and alleviate pain.
214660087|NCT06131710|OTHER|Combined Strengthening Exercises|Combined strengthening exercises for Patellofemoral Pain Syndrome (PFPS) typically include a mix of quadriceps strengthening exercises, hip strengthening exercises, and core stability exercises. The goal is to address muscle imbalances and improve the overall stability of the knee joint.
214660088|NCT00422279|DEVICE|Nobel Replace Tapered Groovy|Bone inductive implant placed in supralveoral position or extraction site
214660089|NCT04927312|DRUG|PF-06947386|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
214660090|NCT04927312|DRUG|Metronidazole|Metronidazole 0.5 g solution for injection.
214660091|NCT01783834|DRUG|Gefitinib|compare progression free survivla rate and safety to both drugs
214660092|NCT01783834|DRUG|Pemetrexed|compare PFS rate, safety to both drugs
214660093|NCT04179903|OTHER|Physical activity|Physical Activity program is performed in a group in a gym and at home
214660094|NCT04017403|DRUG|Bifidobacterium triple live capsule|Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
214660095|NCT04017403|DRUG|Placebos|Placebos were administrated as same as the bifidobacterium live capsule
214660096|NCT00893711|OTHER|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
214660097|NCT00893711|OTHER|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
214660098|NCT00893711|DIETARY_SUPPLEMENT|L.reuteri + Vit D|
214660099|NCT00893711|DIETARY_SUPPLEMENT|Vit D placebo|
214660100|NCT00605826|DEVICE|NASHA/Dx (Solesta) Gel|Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
214660101|NCT00605826|DEVICE|Sham Injection|Sham injection at the start of the blinded phase.
214660102|NCT01706913|OTHER|Dermatology consult|
214660103|NCT00099671|DRUG|Recombinant human interleukin-7|
214660104|NCT04919564|DRUG|Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL)|Furosemide 2 mg/hour infusion for 12 hours since induction
214660105|NCT04919564|DRUG|NaCl 0.9%|NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
214660106|NCT01241786|DRUG|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and \< 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
214660107|NCT01241786|DRUG|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
214660108|NCT04853940|OTHER|Data collection and clinical testing of subjects|6-months follow-up with clinical testing at 3 and 6 months
214660109|NCT04435340|DIAGNOSTIC_TEST|Selective Sonography of the ventral abdominal hernia level|The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
214660110|NCT02667184|DIETARY_SUPPLEMENT|Low FODMAP Oral Nutrition Supplement|
214660111|NCT00224562|DRUG|TNF-alpha antagonists|
214660112|NCT06226402|DRUG|Hypertonic saline 3% nebulizer|Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
214660113|NCT06226402|DRUG|Intravenous hypertonic saline 3%|Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
214660114|NCT00389155|DRUG|Vinflunine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
214660115|NCT00389155|DRUG|Gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
214660116|NCT00389155|OTHER|Placebo|
214660117|NCT05957081|DRUG|PMC-309 monotherapy|PMC-309 will be administered intravenously.
214660118|NCT05957081|DRUG|PMC-309 Dose Escalation in Combination with Pembrolizumab|Both PMC-309 and pembrolizumab will be administered intravenously. At the time of the combination therapy (Week 1/Day 1 of each cycle), participants will be dosed with pembrolizumab first, administered over 0.5 hours (± 10 minutes). Following an interval of 1 hour (± 15 minutes), participants will be dosed with PMC-309 administered over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.
214660119|NCT05957081|DRUG|PMC-309 Dose Expansion|"Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts:~* Cohort A: PMC-309 monotherapy therapy~  \- PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~* Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab"
214660120|NCT00215930|DRUG|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
214660121|NCT00215930|DRUG|Docetaxel|"RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days."
214660122|NCT00215930|DRUG|Gemcitabine|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days."
214660123|NCT00215930|DRUG|Carboplatin|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days."
214660124|NCT05802329|DRUG|OCU200|Intravitreal Injection
214660125|NCT03563534|DRUG|Silver Diamine Fluoride|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
214660126|NCT03563534|DRUG|Glass Ionomer|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
214660127|NCT02060422|BEHAVIORAL|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
214660128|NCT02060422|BEHAVIORAL|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
214660129|NCT01727960|BEHAVIORAL|Education and posture correction|a lecture concerning the fine posture for health and exercises
214660130|NCT04947202|DEVICE|Hernioplasty|Hernioplasty is the repair of the defect using mesh patches.
214660131|NCT05983640|OTHER|Video|Just in time training video on hands only CPR
214660132|NCT05983640|OTHER|AHA course|AHA Heartsaver CPR course
214660133|NCT06449339|DRUG|Carvedilol|Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.
214660134|NCT06042374|OTHER|Progressive Core Stabilization Training|The Progressive Core Stabilization Training was applied to study group as a group exercise with 5-10 athletes which was planned in the form of 3 days/week for a total of 9 weeks and 27 sessions. A session consisted of warm-up, core stabilization (30-40 min.), and cool-down exercises. During the training period, exercise volume, degree of difficulty, additional weight, and level of instability (contralateral limb movements and reduction of the support surface, etc.) for each exercise were incrementally increased in four steps.
214660135|NCT06042374|OTHER|Standard Core Strengthening Exercises|The athletes included in the CG performed only Standard Core Strengthening Exercises which is the first phase of the Progressive Core Stabilization Training on fixed surfaces (i.e. without pads and balls, with a flat floor and a bench) for 3 days/week and totally 9-week.
214660136|NCT01012908|DIETARY_SUPPLEMENT|Norzyme - Bergamo|2 - 8 tablets per day.
214660137|NCT01012908|DIETARY_SUPPLEMENT|Creon|2 - 8 tablets pet day
214660138|NCT03273621|PROCEDURE|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
214660139|NCT05319964|BEHAVIORAL|Anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~Participants were provided 30 minutes anti-gravity treadmill sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
214660140|NCT05319964|BEHAVIORAL|Conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
214660141|NCT05319964|BEHAVIORAL|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.
214660142|NCT05657769|DEVICE|Medwell Preventive Care Application|Regular diabetes treatment with additional Medwell application and wearable device.
214660143|NCT05657769|DEVICE|Manual Records|Regular diabetes treatment only with a diary card to record daily activities manually.
214660144|NCT04716322|BEHAVIORAL|Adapted Physical Activity|A 16-week health-adapted physical activity program, individualized from baseline evaluation of participants including the specificities of their pathologies
214660145|NCT01814657|DRUG|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
214660146|NCT01814657|DRUG|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
214660147|NCT01612234|DIETARY_SUPPLEMENT|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
214660148|NCT01021566|DEVICE|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
214660149|NCT01021566|DRUG|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
214660150|NCT00336102|OTHER|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
214660151|NCT00336102|PROCEDURE|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
214660152|NCT00336102|PROCEDURE|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
214660153|NCT01122927|DRUG|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
214660154|NCT04836286|BEHAVIORAL|Emotive Intelligent Spaces (EIS)|The EIS leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study11, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
214660155|NCT04290637|OTHER|Cold-water sea swimming|Continue sea swimming for 4-6 weeks
214660156|NCT04290637|OTHER|No cold-water sea swimming|Discontinue sea swimming for 4-6 weeks
214660157|NCT01656525|DRUG|Gantenerumab|75 mg subcutaneous doses every 4 weeks for 24 weeks
214660158|NCT01656525|DRUG|Gantenerumab|105 mg subcutaneous doses every 4 weeks for 24 weeks
214660159|NCT01656525|DRUG|Gantenerumab|225 mg subcutaneous doses every 4 weeks for 24 weeks
214660160|NCT01656525|DRUG|Placebo|subcutaneous doses every 4 weeks for 24 weeks
214660161|NCT06326944|PROCEDURE|Ultrasound- guided Fascia Transversalis plane block|Ultrasound probe will be placed in a transverse orientation above the iliac crest; and the external oblique, internal oblique (IO), and transversus abdominis TA muscles will be identified and traced posteriorly until first the TA muscle and then the IO muscle tapered into their common aponeurosis, adjacent to the quadratus lumborum muscle. The tip of a 22-gauge 80-mm block needle will be positioned just deep to the TA muscle and its aponeurosis at the point where the TA is tapered off. 0.4 ml/kg bupivacaine 0.25% will be injected into the plane between the TA and underlying transversalis fascia
214660162|NCT06326944|PROCEDURE|Ultrasound-guided Transversus abdominus plane block|the probe will be placed transversely in the mid-axillary line between the iliac crest and the costal margin at the level of the umbilicus. The external oblique, internal oblique and transversus abdominis muscles and their fascias will be visualized. A 22 gauge, 80 mm needle will be introduced anteriorly and in the plane of the ultrasound probe, and on entering the plane between IO and TA, 2 ml of 0.9% saline will be injected to verify the correct position of the needle. Following negative aspiration, 0.4 ml/kg of bupivacaine 0.25% will be injected.
214660163|NCT06326944|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
214660164|NCT06326944|DRUG|Pethidine|Pethidine IV will be given as rescue analgesia (0.5 mg/kg) if the FLACC pain score was more than 4 , the maximum allowed dose is 1mg/kg every 4 hours.
214290111|NCT06051929|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
214290112|NCT02101476|DRUG|Percocet|10mg/650mg
214290113|NCT02101476|DRUG|Xartemis|15mg/650mg
214660165|NCT06326944|DRUG|Acetaminophen|patients will be given paracetamol (15 mg /kg/8 hrs ).
214290114|NCT05914714|DRUG|Ruxolitinib 5 MG BID Oral Tablet|ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
214290115|NCT01116154|DRUG|lenalidomide|Given orally
214290116|NCT01116154|DRUG|vorinostat|Given orally
214290117|NCT01116154|OTHER|laboratory biomarker analysis|Correlative studies
214660166|NCT01774448|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
214660167|NCT03592862|DRUG|HTL0018318|Oral capsule
214660168|NCT03592862|DRUG|Placebo|Oral capsule
214660169|NCT02612597|OTHER|Bedrest|
214660170|NCT02612597|OTHER|Exercise Training|
214660171|NCT02747082|PROCEDURE|Retreatment of root-filled teeth with infection|Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
214660172|NCT00278525|DRUG|standard of care|standard of care medication will be given
214660173|NCT00278525|PROCEDURE|stem cell transplantation|The following is intervention: stem cell transplantation after conditioning regimen
214660174|NCT02735213|DEVICE|577-MPL|9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250\~400 milliWatts of power(50% threshold power),150\~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.
214660175|NCT02735213|DEVICE|TLT|contimuous wave,100um spot size, 0.05 seconds duration, 55\~60 milliwatts of power, 18\~27 spots,the laser area is the corresponding leakage on mid-phase FA.
214660176|NCT02277171|DEVICE|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
214660177|NCT00201539|DRUG|single dose Morphine|
214660178|NCT00201539|DRUG|double dose Morphine|
214660179|NCT00201539|DRUG|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
214660180|NCT06172101|OTHER|Free fat flap|Free fat flap In Recurrent neurogenic thoracic outlet syndrome Surgical Treatment
214660181|NCT02498210|OTHER|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
214660182|NCT05035498|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
214660183|NCT05035498|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
214660184|NCT03582111|OTHER|Study of medical records|Study of medical records
214660185|NCT01239927|PROCEDURE|Primary sigmoid resection with end colostomy (Hartmann)|
214660186|NCT01239927|PROCEDURE|Primary sigmoid resection and immediate anastomosis with diverting stoma (PRA)|
214660187|NCT04003714|DEVICE|Repetitive Transcranial Magnetic Stimulation|Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
214660188|NCT04003714|DEVICE|Sham Repetitive transcranial Magnetic Stimulation|Control group received sham r-TMS.
214660189|NCT04012255|DRUG|Semaglutide (administered by DV3396 pen)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks
214660190|NCT04012255|DRUG|Semaglutide (administered by PDS290 pen)|Increasing doses of semaglutide given sc in the stomach for 21 weeks
214660191|NCT01215084|DRUG|BIIB041 (Fampridine-PR)|A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
214660192|NCT01796132|DRUG|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
214660193|NCT05653895|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
214660194|NCT05653895|DRUG|Metformin|Metformin
214660195|NCT05653895|COMBINATION_PRODUCT|Acetyl-L-Carnitin, L Arginine, Co-Q10|Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10
214660196|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
214660197|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
214660198|NCT03676309|DRUG|Nutriceutical Oral Capsule,|nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks
214660199|NCT03676309|DRUG|Placebo Oral Tablet|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
214660200|NCT05564338|DRUG|Sitravatinib|Administered orally
214660201|NCT05564338|DRUG|Tislelizumab|Administered intravenously
214660202|NCT05564338|DRUG|sitravatinib-matching placebo|administered orally
214660203|NCT05564338|DRUG|tislelizumab-matching placebo|administered intravenously
214660204|NCT03431220|DEVICE|RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device|NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
214660205|NCT02950506|DEVICE|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
214660206|NCT02950506|OTHER|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
214660207|NCT05162157|DEVICE|NuvoAir platform|Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
214660208|NCT02366962|BIOLOGICAL|ASP7374|subcutaneous
214660209|NCT01220219|DRUG|Pregabalin controlled release, 82.5 mg|Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
214660210|NCT01220219|DRUG|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for four days.
214290118|NCT01107041|BEHAVIORAL|Mobilyze!|Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
214660211|NCT01220219|DRUG|Pregabalin immediate release, 75mg|75 mg immediate release capsule administered every 12 hours for four days
214660212|NCT02803216|DRUG|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
214660213|NCT02803216|DRUG|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
214660214|NCT02803216|DRUG|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
214660215|NCT01118910|DRUG|Vusion|Vusion will be applied to areas of intertrigo
214660216|NCT05344547|DIAGNOSTIC_TEST|Cardiac risk ratio (CRR)|Cardiac risk ratio (CRR) was calculated according to Genest et al. (23) as serum total cholesterol (TC) level divided by serum high-density lipoprotein-cholesterol (HDL-c) level and woman with CRR at ≥3.5 was considered at risk of cardiac disease (24).
214660217|NCT05328947|OTHER|Modified Functional Reach and Functional Reach|Establishment of Modified Functional Reach Test (mFRT) and Function Reach Test (FRT) values for individuals with no functional impairments.
214660218|NCT00599651|DEVICE|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
214660219|NCT00599651|OTHER|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
214660220|NCT04697225|BEHAVIORAL|weight loss strategies|Participants will receive recommendations on how to increase physical activity, decrease caloric intake, monitor their weight, and track the related behaviors and progress.
214290119|NCT03587012|OTHER|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
214660221|NCT04697225|BEHAVIORAL|weight loss coaching sessions and email support|Participants will receive weekly coaching sessions and tailored support emails.
214660222|NCT05220150|DEVICE|FFC-MRI scan|Undergo one FFC-MRI scan.
214660223|NCT02286102|DEVICE|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
214660224|NCT02286102|DEVICE|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
214290120|NCT03587012|OTHER|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
214290121|NCT01800864|OTHER|obesity|
214290122|NCT05874856|DIAGNOSTIC_TEST|Heart rate variability, blood pressure and pulse wave velocity|Resting HRV in supine and standing position, blood pressure and pulse wave velocity in supine position at first and last week of inpatient treatment
214290123|NCT05874856|DIAGNOSTIC_TEST|Assessment of cognitive function, balance, strength and cardiorespiratory fitness|"THINC-it test for cognitive function; One-leg Standing test for balance assessment; 10-time chair rise test and hand grip test for strength assessment; Åstrand-Ryhming Test for cardiorespiratory fitness.~All assessments will be performed at first and last week of inpatient treatment."
214290124|NCT05874856|BEHAVIORAL|Monitoring of physical activity and sleep|GENEActiv accelerometer will be worn on the wrist daily during 8-week inpatient treatment.
214290125|NCT05874856|BEHAVIORAL|Monitoring of self-rated exhaustion, mood and tension|Using the customized PsyMate app.
214660225|NCT04541069|BEHAVIORAL|Social Communication and Emotional Skill Development (SCESD) module|The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
214660226|NCT03411343|PROCEDURE|Interscalene Block|Injection with ultrasound guidance of 20mL of levobupivacaine 0.5% with 5 micrograms of epinephrine per mL in the interscalene groove of the brachial plexus.
214660227|NCT03411343|PROCEDURE|Costoclavicular Infraclavicular Block|Ultrasound guided brachial plexus block injecting 20mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in between the cords of the brachial plexus at the costoclavicular infraclavicular space.
214660228|NCT01368068|DRUG|Tibolone|2.5mg/oral/daily
214660229|NCT01368068|DRUG|Escitalopram|10mg/oral/daily
214660230|NCT01368068|DRUG|Natvia|serving size: 0.09g per tablet
214660231|NCT06192121|OTHER|Web Based Education|In this research, a reminder message will be sent 3 times a week along with web-based training.
214660232|NCT04180605|OTHER|Additional support for preoperative planning of LAA closure procedures|"The results of the computational simulations provided by FEops HEARTguideTM will be used in the computational simulation arm as an additional preoperative planning tool and their potential added value will be assessed by comparison to the standard of care arm."
214660233|NCT04180605|PROCEDURE|Left atrial appendage closure|Transcatheter device insertion to exclude the LAA from the cardiac circulation
214660234|NCT04339504|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
214660235|NCT04339504|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
214660236|NCT04339504|BIOLOGICAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
214660237|NCT05416892|OTHER|Pharmaclass® software|Clinical decision support tool via artificial intelligence in order to improve the patient's medication management.
214660238|NCT01440101|DRUG|Natalizumab (BG00002)|
214660239|NCT01440101|DRUG|Placebo|
214660240|NCT00201851|DRUG|Tamoxifen|20 mg po daily x 5 years
214660241|NCT00201851|PROCEDURE|Surgery: Oophorectomy|Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
214660242|NCT03257046|DRUG|ITI-214|Oral
214660243|NCT03257046|OTHER|Placebo|Oral
214660244|NCT03289689|DEVICE|Whole-body vibration (WBV)|Whole-body vibration (WBV) is a novel neuromuscular therapeutic intervention that has recently been developed since in the mid-1960s. Hagbart and Eklund showed in human experiments that a reflex muscle contraction can result as a consequence of applying vibrations to the muscular-tendon system. The subjects stand on a platform that generates stochastic vibrations at a frequency between 1-12.5 Hz.
214660245|NCT03094247|DRUG|Amoxicillin|All patients with severe acute malnutrition will receive a course of amoxicillin.
214660246|NCT03094247|DIETARY_SUPPLEMENT|HO-RUTF|HO-RUTF: Milk, perilla oil, palm oil, white sugar, high oleic peanuts
214660247|NCT03094247|DIETARY_SUPPLEMENT|D-HO-RUTF|D-HO-RUTF: DHA, milk, perilla oil, palm oil, white sugar, high oleic peanuts
214660248|NCT03094247|DIETARY_SUPPLEMENT|S-RUTF|S-RUTF: Milk, canola oil, palm oil, white sugar, standard peanuts
214660249|NCT03035812|DRUG|Alkali|Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
214660250|NCT00636818|DRUG|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
214660251|NCT02557503|DRUG|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
214660252|NCT02756455|OTHER|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
214660253|NCT00074958|BIOLOGICAL|Fabrazyme (agalsidase beta)|1 mg/kg every 2 weeks
214660254|NCT06535997|OTHER|Questionnaire|For patients alive only at the time of inclusion, completion of a quality-of-life questionnaire and a medico-economic interview (prospective).
214660255|NCT06175624|OTHER|Clinically Helathy|"Our study will include 25 people with clinically healthy patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
214660256|NCT06175624|OTHER|Gingivitis|"Our study will include 25 people with gingivitis patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
214660257|NCT06175624|OTHER|Periodontitis|"Our study will include 25 people with periodontitis patients.~Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study."
214660258|NCT03227874|DIETARY_SUPPLEMENT|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
214660259|NCT03227874|DIETARY_SUPPLEMENT|Muffin|two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
214660260|NCT02835430|PROCEDURE|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
214660261|NCT02835430|PROCEDURE|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
214660262|NCT06080594|BEHAVIORAL|High-intensity exercise training|Eight sessions of high-intensity interval exercise using a single-leg cycle ergometer are conducted on separate days over a 2-week period.
214660263|NCT06278688|DIETARY_SUPPLEMENT|Precision probiotics|The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/) The individual gut microbiota will determine the supplement and composition of probiotics.
214660264|NCT02643095|DEVICE|scleral contact lens|Scleral contact lens
214660265|NCT05785884|BEHAVIORAL|Diet|A 6 week randomized diet
214660266|NCT02553135|BIOLOGICAL|Injection of AAV2-REP1 (10e11 vg)|Single Group: single arm study
214660267|NCT02790489|DIETARY_SUPPLEMENT|Valedia|
214660268|NCT06644989|PROCEDURE|Spencer Technique|Spencer technique on the hip
214660269|NCT06644989|OTHER|Sham (No Treatment)|Spencer technique position but no pressure
214660270|NCT03779438|DRUG|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
214660271|NCT03779438|DRUG|placebo to 17-OHPC|patients received weekly placebo to17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
214660272|NCT02107755|BIOLOGICAL|ipilimumab|Given IV
214660273|NCT02107755|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
214660274|NCT02107755|OTHER|laboratory biomarker analysis|Blood and tissue samples will be collected for research purposes.
214660275|NCT06443658|OTHER|Hypertonic saline|Patients from intervention group will inhale hypertonic saline solution 5 minutes before performing the morning ELTGOL technique
214660276|NCT06443658|DRUG|Isotonic saline|Patients from placebo group will inhale isotonic saline solution 5 minutes before performing the morning ELTGOL technique
214660277|NCT06443658|OTHER|ELTGOL|Patients from control group will perform the ELTGOL technique twice-daily
214660278|NCT06319300|DEVICE|AI-assisted insulin dose adjustment model|We use an artificial intelligence-assisted insulin dose adjustment system to adjust insulin doses in hospitalised patients
214660279|NCT06319300|OTHER|doctor's insulin dose adjustment|participants' insulin doses are adjusted by doctors
214660280|NCT01658514|DRUG|Met DR|metformin delayed-release tablets
214660281|NCT01658514|DRUG|Met XR|metformin extended-release tablets
214660282|NCT01658514|DRUG|Placebo|
214660283|NCT00797420|DRUG|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
214660284|NCT00797420|DRUG|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
214660285|NCT04828824|DRUG|Ethinyl Estradiol / Norgestimate Oral Tablet|Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
214660286|NCT01572155|PROCEDURE|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
214660287|NCT01572155|PROCEDURE|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
214660288|NCT01677845|RADIATION|Radiation|"Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions."
214660289|NCT02214849|BEHAVIORAL|LATCH Intervention|
214660290|NCT02509208|DEVICE|SurgiClot haemostatic dressing|haemostatic dressing
214660291|NCT00426673|DRUG|Brivaracetam (ucb34714)|
214660292|NCT00284830|DEVICE|Implantable Pulse Generators|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
214660293|NCT04994925|OTHER|Control ready meal|Supermarket brand lasagne ready meal
214660294|NCT04994925|OTHER|Test ready meal|The Slimming World lasagne ready meal
214660295|NCT01833871|OTHER|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
214660296|NCT01833871|OTHER|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
214660297|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
214660298|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
214660299|NCT04295590|BEHAVIORAL|Frequency comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).
214660300|NCT04295590|BEHAVIORAL|Intensity comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
214660301|NCT05422092|DRUG|Canagliflozin|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
214660302|NCT05422092|DRUG|Pioglitazone|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
214660303|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
214660304|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
214660305|NCT03170830|DIAGNOSTIC_TEST|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
214660306|NCT04658602|PROCEDURE|Preformed stainless steal crown cemented by glass ionomer lutting cement (Ketac cem,3M Espe)|Covering the affected molar with preformed metal crown cemented by glass ionomer lutting cement
214660307|NCT03333473|BEHAVIORAL|PPFP Clinical and Counseling Skills|Facilities will receive whole-site orientations on PPFP basics and skills Through training of trainers, followed by classroom and model-based and clinical-based practice, providers will receive training in PPDP counseling and service provision.
214660308|NCT03333473|BEHAVIORAL|Facility-Level Leadership Management and Governance Training|The intervention will strengthen leadership management and governance practices required to help managers establish PPFP services at the facility level.
214660309|NCT00743704|OTHER|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
214660310|NCT00156663|BEHAVIORAL|Caring for Women Veterans|
214660311|NCT00049348|BIOLOGICAL|epoetin alfa|
214660312|NCT00049348|BIOLOGICAL|filgrastim|
214660313|NCT00049348|DRUG|cisplatin|
214660314|NCT00049348|DRUG|fluorouracil|
214660315|NCT00049348|DRUG|gemcitabine hydrochloride|
214660316|NCT00049348|PROCEDURE|adjuvant therapy|
214660317|NCT00049348|PROCEDURE|conventional surgery|
214660318|NCT00049348|PROCEDURE|neoadjuvant therapy|
214660319|NCT00049348|RADIATION|radiation therapy|
214660320|NCT05619848|DRUG|Rocuronium Bromide|0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
214660321|NCT04449692|DRUG|Dasiglucagon|Abdominal s.c. administration
214660322|NCT04449692|OTHER|Carbohydrate (dextrose tablets)|Oral administration
214660323|NCT01243268|DRUG|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
214660324|NCT01931514|DRUG|Torrent's Montelukast Sodium chewable Tablets 5mg|
214660325|NCT01931514|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
214660326|NCT03315429|DIAGNOSTIC_TEST|stress echocardiography|stress testing of patients with functional mitral regurgitation
214660327|NCT01042262|OTHER|Oxygen|100% Oxygen at a flow of 2 L/min
214660328|NCT01042262|OTHER|Placebo|No oxygen flow
214660329|NCT01620125|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
214660330|NCT01501643|DEVICE|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
214660331|NCT01501643|DEVICE|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
214660332|NCT00279747|DRUG|meloxicam 0.25 mg/kg|
214848718|NCT00365937|BIOLOGICAL|HLA-A2 peptides|Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
214848719|NCT00365937|BIOLOGICAL|Montanide ISA51|Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
214660333|NCT00279747|DRUG|meloxicam 0.125 mg/kg|
214660334|NCT00279747|DRUG|naproxen 10 mg/kg|
214660335|NCT00957853|DRUG|Cetuximab|First dose of 400 mg/m\^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m\^2 on week 2 and 3 (if applicable) given over 1 hour.
214660336|NCT00957853|DRUG|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
214660337|NCT00957853|PROCEDURE|Surgical tumor resection|Surgical tumor resection on Day 10.
214660338|NCT05707130|OTHER|gaze stabilization exercises|patients will perform gaze stabilization exercise, Static neck exercise, and Habituation exercise. Neck isometric exercises like isometric flexion, extension, lateral bending will be performed.
214660339|NCT05707130|OTHER|neck isometrics|Patients in Conventional group will get neck isometric exercises like isometric flexion, extension, lateral bending.
214660340|NCT00702143|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
214660341|NCT02229773|DRUG|BIBB 1464 MS low dose|
214660342|NCT02229773|DRUG|Placebo|
214660343|NCT02229773|DRUG|Pravastatin|
214660344|NCT02229773|DRUG|BIBB 1464 MS medium dose|
214660345|NCT02229773|DRUG|BIBB 1464 MS high dose|
214660346|NCT02631304|PROCEDURE|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
214660347|NCT02896478|OTHER|No intervention. Only observational study|
214660348|NCT03381443|OTHER|different assessments|coded survey about NTS and assessment
214660349|NCT02800174|DEVICE|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
214660350|NCT02800174|DRUG|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
214660351|NCT02145130|BIOLOGICAL|denovoDerm|Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
214660352|NCT02145130|BIOLOGICAL|denovoSkin|Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
214660353|NCT00655720|OTHER|infant formula|"1. hydrolyzed infant formula without probiotics~2. hydrolyzed infant formula with probiotics~3. hydrolyzed infant formula with probiotics"
214660354|NCT04388384|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
214660355|NCT05936580|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
214660356|NCT04174599|DRUG|F-627|Day 3 of each cycle, i.e., 48 ± 4 h after starting chemotherapy
214660357|NCT04174599|DRUG|GRAN®|Since day 3 of each cycle, i.e., 48 ± 4 h after starting chemotherapy, continuous treatment for ≤ 2 weeks or until ANC recovers to 5.0 × 10\^9/L from nadir (investigators may refer to ANC test results from the Department of Laboratory Medicine of each study sites to decide when to discontinue GRAN®)
214660358|NCT06428045|PROCEDURE|Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)|Participants will be administered MR-guided Laser Interstitial Thermal Therapy (LITT) as a single procedure, following stereotactic needle biopsy.
214660359|NCT06428045|DRUG|Abacavir|Participants will take one 600mg tablet of Abacavir orally once daily, as part of combination antiretroviral therapy (ART).
214660360|NCT06428045|DRUG|Lamivudine|Participants will take one 300mg tablet of Lamivudine orally once daily, as part of combination antiretroviral therapy (ART)
214660361|NCT06428045|DRUG|Ritonavir|"Participants will take one tablet of Ritonavir (RTV) orally twice daily, as part of combination antiretroviral therapy (ART), at one of the following dose levels:~* Dose Level 1: 100mg~* Dose Level 2 (starting dose): 300mg~* Dose Level 3: 400mg~* Dose Level 4: 600mg"
214660362|NCT06428045|DRUG|Temozolomide|Participants will take Temozolomide (TMZ) via capsule orally, during and after focal radiotherapy, as part of standard of care adjuvant therapy. During focal radiotherapy, Temozolomide will be administered at a dose of 75 mg/m2 once daily for six weeks (42 days) on a continuous dosing regimen, including weekends and holidays. After completion of focal radiotherapy, Temozolomide will be administered at 150 mg/m\^2 on days 1 through 5 of Cycle 1, and at 200 mg/m\^2 on days 1 through 5 of Cycles 2 through 6, for a total of six 28-day cycles of maintenance therapy.
214660363|NCT06428045|RADIATION|Focal Radiotherapy|Participants will be administered focal radiotherapy for six weeks (42 days), as part of adjuvant therapy, at a total dose of 50-60 grays (Gy) in 1.8-2.0 Gy fractions, depending on prognosis and as determined by the treating radiation oncologist.
214660364|NCT05638568|DIAGNOSTIC_TEST|LS test|If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)
214660365|NCT05332769|GENETIC|FLIM parameters|Cumulus samples (CCs) will be collected following the protocol on the day of oocyte pick up (OPU). CCs are frozen by the cryo-tech method, then stored in liquid nitrogen at -196oC. Information of CC samples and processed date/time is recorded. After all, samples are collected, they will be transferred to The Needleman Lab, Northwest Lab Building 359,52 Oxford Street Cambridge MA 02138 to measure mitochondria metabolism using FLIM.
214660366|NCT00646659|BIOLOGICAL|cetuximab|
214660367|NCT00646659|DRUG|carboplatin|
214660368|NCT00646659|DRUG|cisplatin|
214660369|NCT00646659|DRUG|docetaxel|
214660370|NCT00646659|DRUG|fluorouracil|
214660371|NCT00646659|GENETIC|fluorescence in situ hybridization|
214660372|NCT00646659|GENETIC|molecular genetic technique|
214660373|NCT00646659|GENETIC|reverse transcriptase-polymerase chain reaction|
214660374|NCT00646659|OTHER|immunoenzyme technique|
214660375|NCT00646659|OTHER|immunohistochemistry staining method|
214660376|NCT00646659|OTHER|laboratory biomarker analysis|
214660377|NCT00646659|PROCEDURE|biopsy|
214660378|NCT00646659|RADIATION|3-dimensional conformal radiation therapy|
214660379|NCT00646659|RADIATION|intensity-modulated radiation therapy|
214660380|NCT01016626|DRUG|CKD-4101 tablet|"CKD-4101 tablet 1000 mg~* 500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
214660381|NCT01016626|DRUG|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg~* 250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
214660382|NCT05088148|OTHER|. Pesticide and Pharmaceutical analysis|Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
214660383|NCT06584591|DEVICE|Combined (Robotic balance training and high-definition transcranial direct current stimulation)|The robotic platform will train the participants to maintain dynamic balance in the sagittal and the transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.
214660384|NCT06584591|OTHER|Standard of Care Balance Training|Participants in this group will receive a standard-of-care balance training administered by the Physical therapist.
214660385|NCT00656890|BIOLOGICAL|sterile saline for injection|10mg/kg/dose sterile saline injected every other week for a total of 4 doses
214660386|NCT00656890|BIOLOGICAL|MDX-1100|10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
214660387|NCT03726775|DRUG|Durvalumab|Infusion of durvalumab during RT and after RT during 6 months
214660388|NCT04447053|DRUG|Belimumab Injection [Benlysta]|Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.
214660389|NCT05366309|OTHER|Tailored education|Tailored Education: A delegated investigator will review the SD memory card data and share the results with the participant and/or parent/guardian. The investigator will explain whether there are partial or critical errors to inhalation technique that have been recorded. The participant will be informed about their overall adherence; including how and when they used their asthma medications. If errors in medication use are identified, specific coaching will be provided to help eliminate errors.
214660390|NCT05366309|OTHER|Standard care education|Participants randomised to this group will receive usual care in terms of their education.
214660391|NCT01281176|DRUG|Carboplatin|Given IV
214660392|NCT01281176|OTHER|Laboratory Biomarker Analysis|Correlative studies
214660393|NCT01281176|DRUG|Paclitaxel|Given IV
214660394|NCT01281176|OTHER|Pharmacological Study|Correlative studies
214660395|NCT01281176|DRUG|Vorinostat|Given PO
214660396|NCT03947229|DRUG|Clopidogrel mono-therapy|Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.
214660397|NCT03947229|DRUG|Dual-antiplatelet therapy|Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.
214660398|NCT05131607|PROCEDURE|Supine MRI|After completion of the standard prone MRI sequences the patient will be positioned supine, coils will be placed and baseline images will be obtained. Then a second dose of contrast equal to the first dose will be given, and additional images will be obtained
214660399|NCT01921998|PROCEDURE|Biomarker and health economics|Biomarkers CK18 and FLT3 Ligand will be collected
214660400|NCT00609622|DRUG|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
214660401|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
214660402|NCT00609622|DRUG|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
214660403|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
214660404|NCT02221609|OTHER|Treatment based on Movement System Impairment model|The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
214660405|NCT02221609|OTHER|General exercise|The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
214290126|NCT03610022|DRUG|Treatment with vismodegib|Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
214660406|NCT01696461|DRUG|Plerixafor|
214660407|NCT06201143|OTHER|BREATHING EXERCISE AND MOBILIZATION TRAINING|After cesarean mobilization and breathing exercise training, the number of breathing exercises performed and the duration of mobilization will be recorded. Thus, the effectiveness of the training will be examined in detail.
214660408|NCT06201143|OTHER|KINESIOLOGICAL TAPING + BREATHING EXERCISE AND MOBILIZATION TRAINING|It will be the first study to use kinesiotaping, breathing exercise and mobilization training together.
214660409|NCT00977652|PROCEDURE|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
214660410|NCT00977652|PROCEDURE|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
214660411|NCT03376633|BEHAVIORAL|Working on Womanhood (WOW)|A trauma-informed group counseling and clinical mentoring intervention for young women
214660412|NCT02643550|BIOLOGICAL|Monalizumab|
214660413|NCT02643550|BIOLOGICAL|Cetuximab|
214660414|NCT02643550|BIOLOGICAL|Anti-PD(L)1|
214660415|NCT02054858|PROCEDURE|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
214660416|NCT01999673|BIOLOGICAL|bavituximab|
214660417|NCT01999673|DRUG|Docetaxel|
214660418|NCT01999673|OTHER|Placebo (for bavituximab)|
214290127|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System
214660419|NCT01262430|PROCEDURE|OtisMed|OtisMed Custom-fit Shapematching Guides
214660420|NCT01262430|PROCEDURE|Computer Assisted Surgery (CAS)|Stryker Navigation System
214660421|NCT06657755|DIAGNOSTIC_TEST|Immunohistochemistry|This intervention will specifically focus on evaluating the role of ENPP1 in bladder cancer patients, distinguishing it from other interventions by targeting immune evasion and chemoresistance pathways. The intervention will include a combination of targeted molecular therapies and immunotherapy, aimed at assessing the therapeutic potential of ENPP1 inhibition in improving treatment outcomes for bladder cancer patients. This differs from previous studies by integrating advanced biomarker analysis and personalized treatment approaches based on ENPP1 expression levels.
214660422|NCT06657495|DRUG|TD0015|TD0015 is black, dark brown inside pilulae and has special smell of herbal, slightly sour then bitter taste.
214290128|NCT04658095|DEVICE|iStent inject|Ab-interno implantation of iStent inject (2 microstents)
214290129|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System
214290130|NCT03671460|BIOLOGICAL|CD19 CAR-T cells|T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
214290131|NCT02475746|DRUG|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
214660423|NCT06657495|DRUG|TD0015 Placebo|Placebo was packed in pack 5g
214660424|NCT06657521|DIETARY_SUPPLEMENT|osteoimplant|Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
214660425|NCT06657521|DIETARY_SUPPLEMENT|Placebo Oral Tablet|2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
214660426|NCT03614247|PROCEDURE|Retrograde intrarenal surgery|The procedure was performed with the patient in the dorsal lithotomy position under general anesthesia. Firstly, diagnostic ureteroscopy was done with a 6/7.5 Fr semi-rigid ureteroscope (Richard Wolf, Knittlingen, Germany). A 0.035mm double-tipped sensor guidewire was placed to the renal pelvis. A 10/12 Fr ureteric access sheath (Cook Medical, Indiana, USA) was used. A 7.5 Fr flexible ureteroscope (Flex X2, Karl Storz, Tuttlingen, Germany) was used for the main procedure. The stones were fragmented using a Holmium:Yttrium Aluminum Garnet laser (272 microns). At the end of each procedure, a double-j ureteric catheter and urethral catheter were routinely placed.
214660427|NCT03614247|PROCEDURE|Micro-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 4.8 Fr for micro PNL (PolyDiagnost, Pfaffenhofen, Germany). Stone fragmentation was carried out using laser in micro PNL. No nephrostomy was placed in any patient whom underwent micro PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
214660428|NCT03614247|PROCEDURE|Ultra-mini PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 7.5 Fr for ultramini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using laser in ultramini PNL. No nephrostomy was placed in any patient whom underwent ultramini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
214660429|NCT03614247|PROCEDURE|Mini-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 12 Fr for mini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in mini PNL. No nephrostomy was placed in any patient whom underwent mini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
214660430|NCT03614247|PROCEDURE|Standard PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 24 Fr for standard PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in standard PNL. A nephrostomy was placed in all standard PNL patients at the end of the procedure
214660431|NCT06819696|PROCEDURE|ACL reconstruction with a dual-flow arthroscopy sheath|ACL reconstruction will be performed by the surgeon without a tourniquet but using a dual-flow arthroscopy sheath.
214660432|NCT06819696|PROCEDURE|ACL reconstruction with a thigh tourniquet|ACL reconstruction will be performed by the surgeon using a thight tourniquet
214660433|NCT06819007|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
214660434|NCT06819007|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15/mg/kg IV Q3W
214660435|NCT03972488|DRUG|Lutathera|Lutathera is a sterile radiopharmaceutical supplied as a ready-to-use solution for infusion containing 177Lu-DOTA0-Tyr3-octreotate as a drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time). Each Lutathera infusion continued for 30 min.
214660436|NCT03972488|DRUG|30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
214660437|NCT03972488|DRUG|2.5% Lys-Arg sterile amino acid solution|Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.
214660438|NCT03972488|DRUG|High dose 60 mg octreotide long-acting repeatable|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
214290132|NCT02475746|DRUG|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
214290133|NCT01962805|DRUG|Proellex Formulation A|
214290134|NCT01962805|DRUG|Proellex Formulation B|
214660439|NCT06592638|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
214660440|NCT03435900|DRUG|Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.
214660441|NCT03435900|DRUG|Standard antibiotics intravenously|4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
214660442|NCT06614855|DRUG|C134|Initial Treatment . C134 Dose #1
214660443|NCT06614855|DRUG|C134|2nd Treatment. C134 Dose #2
214660444|NCT06251011|BEHAVIORAL|Exercise training|"1. Physical therapy training via video call~2. An advise and a leaflet for cardiopulmonary rehabilitation"
214660445|NCT06127797|BEHAVIORAL|Questionnaire/Interview|Participation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.
214660446|NCT07015840|BEHAVIORAL|Visual perceptual learning|Evaluation of the effect of visual training on cortical activity during sleep
214660447|NCT07107464|DEVICE|Short Neck Implant - Crestal Placement|A one-piece endosseous dental implant with a 1.8 mm short convergent neck, placed at the bone crest. Implant used: PRAMA implant (Sweden \& Martina, Italy) with UTM surface treatment.
214660448|NCT07107464|DEVICE|Standard Neck Implant - 1 mm Subcrestal Placement|A one-piece endosseous dental implant with a standard-length neck (2.8 mm total; 0.8 mm cylindrical + 2 mm convergent), placed 1 mm subcrestally. Implant used: PRAMA implant (Sweden \& Martina, Italy) with UTM surface.
214660449|NCT07107464|DEVICE|Long Neck Implant - 2 mm Subcrestal Placement|A one-piece endosseous dental implant with a long transmucosal neck (3.8 mm total; 0.8 mm cylindrical + 3 mm convergent), placed 2 mm subcrestally. Implant used: PRAMA implant (Sweden \& Martina, Italy) with UTM surface.
214660450|NCT07021859|DRUG|Calcitonin-gene related peptide (CGRP)|The participants will receive a continuous intravenous infusion of 1.5 μg/min of CGRP over 60 minutes.
214660451|NCT07021859|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 60 mL of placebo (isotonic saline) over 60 minutes.
214660452|NCT05898126|PROCEDURE|Renin-guided hemodynamic management|If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.
214660453|NCT05898126|PROCEDURE|Usual care|Standard of care
214660454|NCT06698822|DRUG|tofacitinib 2% cream|Given topical
214660455|NCT03136029|DIETARY_SUPPLEMENT|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
214660456|NCT03136029|DIETARY_SUPPLEMENT|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
214660457|NCT03136029|OTHER|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
214660458|NCT07029152|DIAGNOSTIC_TEST|Anal smear|"The intervention in this study involves the anal smear collection using the FLOQSwab® (COPAN, pouch type 502CS01). The swab is inserted 3-5 cm into the anal canal, reaching the transitional zone, the pressed against the canal wall and withdrawn in a spiral motion over approximately 20 seconds. After collection, the swab is immediately placed into a ThinPrep vial containing 20 ml of PreservCyt® and rinsed vigorously.~The procedure is performed by a physician or trained study team member and is designed to be quick, minimally invasive, and comfortable for participants. The FLOQSwab®'s patient-friendly design reduces irritation and false-positive results in comparison to earlier methods.~Samples collected in the ThinPrep PreservCyt® solution should be stored at room temperature and transferred to AML within a maximum of six weeks"
214660459|NCT07029152|BEHAVIORAL|Self-administered questionnaire|"It includes questions related to:~Socio-demographic characteristics Health-related issues Past HPV vaccination (indication? age at vaccination?) History of condylomata and/or other STIs Drug use, tobacco use, alcohol use Anal symptoms: discomfort, itch, pain, nodules, blood loss/discharge, constipation Sexual behavior Insertive/receptive intercourse, chemsex, number of sex partners (stable, occasional, anonymous), condom use."
214290135|NCT03586180|BEHAVIORAL|Medical Clowning for children|Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
214290136|NCT03550456|OTHER|ECC|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
214290137|NCT03550456|OTHER|ECC with CLE|Continuous Laryngoscopy is endoscopy of the larynx used to obtain a view of laryngeal obstruction during exercise.
214660460|NCT07029152|BEHAVIORAL|EQ-5D-5L questionnaire|"This questionnaire will be used after a negative HRA or during the communication of the results (per telephone) and during the treatment if indicated. This questionnaire assesses the impact of health conditions and treatments on person's quality of life. We will use an adapted version of the EQ-5D-5L. This modified version includes additional questions tailored to assess specific domains highlighted in the A-HRSI.~The additional items cover:~* Physical Symptoms: Question on anal symptoms such as pain, discharge, and burning sensations.~* Impact on Physical Functioning: Question on how these symptoms affect daily activities, including work, sitting, and social interactions.~* Impact on Psychological Functioning: Question on psychological and sexual well-being, including enjoyment and desire for sex, as well as challenges with intimacy."
214660461|NCT07029152|DIAGNOSTIC_TEST|High Resolution Anoscopy (HRA)|"HRA will be conducted using advanced tools, such as the Zeiss Extaro at UZ Brussel.~HRA will be conducted at participating centers with expertise in the technique, including UZ Brussel, UZ Gent, UZ Leuven, UZ Antwerpen, CHU St Pierre, AZ Sint-Jan Brugge, and Citadelle Liège. However, all biopsy specimens will be sent to AML Lab for analysis and stored in the biobank (BB190002).~In certain centers, HRA is performed using high-resolution scopes."
214660462|NCT07023016|DRUG|Sacubitril / Valsartan|Patients will receive sacubitril/valsartan at an initial dose of 24/26 mg Bid.
214660463|NCT07023016|DRUG|Ramipril (ACE-inhibitor)|Patients will receive ramipril at an initial dose of 2.5 mg Bid.
214660464|NCT07030140|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT to the primary tumor and metastatic lymph node at a dose of either 5 Gy × 5-8 fractions or 4 Gy × 15 fractions, delivered prior to systemic therapy.
214660465|NCT07030140|DRUG|Tislelizumab|Tislelizumab 200 mg administered intravenously every 3 weeks (on Day 1 of each 21-day cycle), for three to six cycles depending on surgical eligibility.
214660466|NCT07030140|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² administered intravenously on Days 1 and 8 of each 21-day cycle, for three to six cycles.
214660467|NCT07030140|DRUG|Cisplatin or Oxaliplatin|Cisplatin 25 mg/m² on Days 1 and 8 or oxaliplatin 100 mg/m² on Day 1 of each 21-day cycle, selected based on patient condition, for three to six cycles.
214660468|NCT06688435|BIOLOGICAL|SYS6020 injection|The SYS6020 is an injection of autologous CAR-T cells that have been temporarily transfected with LNP-mRNA targeting BCMA. Before each dosing, the infusion eligibility of SYS6020 is assessed by the investigator, and the eligible participants will receive 3 dosing SYS6020 injection treatment. The dosing interval is 7 days according to the protocol design.
214660469|NCT06707142|DRUG|TBD11|TBD11 will be administered orally.
214660470|NCT06707142|DRUG|Placebo|Placebo will be administered orally.
214660471|NCT06710847|DRUG|GSK4418959|GSK4418959 will be administered.
214660472|NCT06710847|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor will be administered.
214660473|NCT07036796|DRUG|Melatonin|"Melatonin (N-acetyl-5-methoxytryptamine), also called the hormone of darkness, secreted primarily by the pineal gland. Possesses antioxidant, anti-inflammatory, anti-diabetic and neuroprotective effects. All of which could be explained by its activation of Nrf2 signaling pathway.~Melatonin administration has shown to improve motor nerve conduction velocity and nerve blood flow, reduce the levels of pro-inflammatory cytokines, reinforce antioxidant defense, and decrease DNA fragmentation through upregulating nrf2 pathway, when tested in mice with diabetic peripheral neuropathy. Moreover, early treatment with melatonin has shown to prevent developing diabetic neuropathy in streptozotocin induced diabetic mice."
214660474|NCT06718491|BEHAVIORAL|Managing Physical Reactions to Overwhelming Emotions (IMPROVE)|Participants may be randomized to IMPROVE. IMPROVE is a three session virtual intervention delivered by research clinicians and augmented by a mobile application. The treatment is designed to target and reduce distress contributing to heavy alcohol use during medication for opioid use disorder treatment.
214660475|NCT06718491|BEHAVIORAL|Health Education Training (HET)|Participants may be randomized to HET. HET is an active control intervention that is equally intensive as IMPROVE It includes three virtual sessions and a mobile application. HET is designed to target healthy lifestyle behaviors such as diet and sleep.
214660476|NCT07040930|DRUG|GenSci120|a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
214660477|NCT07040930|DRUG|Placebo|a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
214660478|NCT07037784|OTHER|Continuous monitoring of vital constants with OXYFLEX® biosensor.|The comparison of physiological data (heart rate, respiratory rate, temperature, pulse oxygen saturation, hemoglobin levels) collected by the OXYFLEX® biosensor with those obtained through standard monitoring over a maximum duration of 10 hours.
214660479|NCT06884072|DRUG|Pimicotinib capsule|Pimicotinib capsule
214660480|NCT07043803|OTHER|Reduction of anticholinergic medication|Shared decision making between the patient and prescriber will determine the timing and speed of reduction over a period of 12 to 16 weeks. Some patients will be discontinued from these anticholinergic medications (benztropine/trihexyphenidyl), others will be tapered from their original dosage but not completely discontinued, and some patients may not be able to taper the anticholinergic medications at all.
214660481|NCT06884449|DIETARY_SUPPLEMENT|Arrabina P Prebiotic 5.0 g|Active Powder
214660482|NCT06884449|DIETARY_SUPPLEMENT|Arrabina P Prebiotic 3.5 g|Active Powder
214660483|NCT06884449|OTHER|Placebo|Placebo Powder
214660484|NCT06926296|OTHER|Self-Questionnaires for Healthcare Workers|Health workers will be invited to complete an online self-questionnaire.
214660485|NCT06668805|DRUG|Vosoritide Injection|Modified recombinant human C-type natriuretic peptide Vosoritide
214660486|NCT06668805|DRUG|Human Growth Hormone|Commercial product containing somatotropin.
214660487|NCT06732466|DRUG|Chlorhexidine toothpaste|A toothpaste containing 0.3% chlorhexidine + 3% AmCl
214660488|NCT06732466|DEVICE|Toothbrush|Commercially available adult soft bristle toothbrush
214660489|NCT06732466|DRUG|Placebo toothpaste without chlorhexidine and AmCl|Negative Control Group assigned to use a placebo toothpaste without chlorhexidine and AmCl and brushing with a commercially available adult soft bristle toothbrush.
214660490|NCT06732518|DRUG|Fluoride Toothpaste|Fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base
214660491|NCT06732518|DRUG|Fluoride free toothpaste in a chalk base|Fluoride free toothpaste in a chalk base with herbal ingredients
214660492|NCT06732518|DRUG|Fluoride free toothpaste in a PCC/RNCC base|Fluoride free toothpaste in a PCC/RNCC base
214660493|NCT06732518|DEVICE|Toothbrush|A commercially available adult soft bristle toothbrush
214660494|NCT07049744|DEVICE|XII Medical HGNS System|XII Medical HGNS System
214660495|NCT07053852|DRUG|Ameluz|broad band light (BBL) with the use of Ameluz
214848720|NCT00365937|BIOLOGICAL|IMP321|"Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.~The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials."
214660496|NCT07053852|DEVICE|Sciton HEROic|Each subject will receive 2 treatments of photodynamic therapy using Ameluz and HEROic BBL to treat facial AK and signs of photodamage.
214660497|NCT06751030|BEHAVIORAL|The Mother Mentor program|The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care
214660498|NCT06751030|DIAGNOSTIC_TEST|GeneXpert HPV test|A cervical cancer screening tool.
214660499|NCT06162624|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in behavior change. Delivered over 8 weeks of self-guided study and homework assignments.
214660500|NCT06162624|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|As control condition, reflective journaling will be used.
214660501|NCT06753136|DEVICE|percutaneous, laparoscopic or laparotomy lesion electrochemotherapy|All patients will receive Bleomycin intravenously with a dosage of 15.000 IU/m2. After a drug distribution time of 8 minutes, the lesions will be electroporated using the Cliniporator (IGEA S.P.A., Carpi, Italy), applying special handpieces depending on the route used: laparoscopic electrode, flexible and expandable for the laparoscopic procedure, linear or hexagonal electrode for laparotomy surgical access, variable geometry electrode for percutaneous access. The ECT procedure must be completed within 40 minutes.
214660502|NCT06764992|OTHER|Questionnaire|Participants will be asked to complete a questionnaire on demographics, risk beliefs and perception and prostate cancer screening behaviors, intentions and awareness of informed decision making.
214660503|NCT06764992|OTHER|Saliva Sample|Participants will be asked to provide a saliva sample for genetic risk testing to generate a SNP risk profile using a saliva sample collection kit with collection, storage and mailing instructions. We will assess the proportion of consented men who will provide a saliva sample.
214660504|NCT05006794|DRUG|zamzetoclax|Tablet(s) administered orally
214660505|NCT05006794|DRUG|Docetaxel|Administered intravenously
214660506|NCT05006794|DRUG|sacituzumab govitecan-hziy|Administered intravenously
214660507|NCT06589414|OTHER|Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)|"A summary consultation with the patient's general practitioner (GP) will take place within 15 days of the consultation to announce the cancer diagnosis. This patient-general practitioner consultation will complement the initial consultation.~At the end of the summary consultation, the patient's satisfaction and that of the GP will be assessed using satisfaction questionnaires.~In addition, patients will be asked to complete a patient diary for the duration of their participation in the study (6 months), in order to record the dates of consultations with the GP and the dates of consultations and/or hospitalisations at the referral care centre."
214660508|NCT07064187|DRUG|Cationorm single-dose eye drop|Cationorm single-dose eye drop is a preservative-free, cationic oil-in-water nano-emulsion.
214660509|NCT07064187|DRUG|Artificial tear eye drop|Artificial tear eye drops are hyaluronic acid, polymers or cellulose derivatives eye drops
214660510|NCT07061145|DRUG|Tirosin Kinase Inhibitors|Tyrosine kinase inhibitor (TKI) administered as part of standard clinical care for CML. No experimental treatment is applied. Exposure to the drug will be analyzed in association with erectile dysfunction outcomes.
214660511|NCT07069595|DRUG|Datopotamab deruxtecan|Dato-DXd is administered adjuvantly at 6 mg/kg IV for eight cycles.
214660512|NCT07069595|DIAGNOSTIC_TEST|Circulating tumor DNA (ctDNA) testing|Circulating tumor DNA (ctDNA) testing is a type of biopsy that analyzes fragments of DNA shed by cancer cells into the bloodstream. These fragments, known as ctDNA, can provide valuable information about the genetic makeup of a tumor without needing a traditional tissue biopsy.
214660513|NCT06857396|PROCEDURE|PREPA-TRACH|Tracheal exposure without tracheostomy completion during trans-oral robotic oncologic surgery
214660514|NCT06761404|DEVICE|taVNS|Experimental. The current will be increased gradually for both sham and real stimulation at the beginning of the 90-minute stimulation to lessen the itchy/numb skin sensation and to create the same skin sensation for subject blinding.
214660515|NCT06900569|DIETARY_SUPPLEMENT|Ashwagandha|600 mg/d Ashwagandha
214660516|NCT06900569|DIETARY_SUPPLEMENT|Placebo|600 mg/d placebo
214660517|NCT06578520|DRUG|Dapagliflozin|10 mg once per day, oral tablets
214660518|NCT06591468|DRUG|Prednisone|Prednisone 30-40 mg/day, at 7am in the morning, gradually reduced after 1 month (5mg every 7-14 days) to 5-10 mg for maintenance treatment
214848721|NCT00572039|BEHAVIORAL|PST|PST will be delivered in subjects' homes over the course of 6 weeks.
214290138|NCT03550456|OTHER|Speech therapy|Patients with diagnosis of EILO will be sent to a speech therapist for at least 6 training sessions.
214848722|NCT00572039|BEHAVIORAL|ST|ST will be delivered in subjects' homes over the course of 6 weeks.
214290139|NCT06321315|BEHAVIORAL|Case-based instruction|"Case-based instruction will be applied to the students in the intervention group. Student Information Form, Critical Thinking Motivation Scale, Academic Motivation Scale and Knowledge Assessment Form will be . All students will receive classical in-class theoretical education about such as hemorrhages, hyperemesis gravidarum, oligohydramnios and urinary system diseases. In the intervention group, after the theoretical teaching of each subject within the scope of the Risky Pregnancy and Care course, cases prepared on the basis of the subject taught to the students will be applied. Student Information Form (13th and 14th questions), Critical Thinking Motivation Scale, Academic Motivation Scale, Knowledge Assessment Form and Visual Comparison Scale will be applied to all students as post-test data after case-based teaching of four topics."
214290140|NCT04975685|BEHAVIORAL|SMART|SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.
214660519|NCT06591468|DRUG|UDCA (Ursodeoxycholic acid)|13-15 mg/kg/day
214660520|NCT06843473|OTHER|No treatment given|No treatment given
214660521|NCT06115369|DIETARY_SUPPLEMENT|Medically Tailored Meals Delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
214848723|NCT04257383|OTHER|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
214848724|NCT03984123|DEVICE|Brachial cuff, in order to achieve ischemic stimuli|Standard treatment with no brachial cuff inflation
214660522|NCT06115369|DIETARY_SUPPLEMENT|Medically Tailored Meals Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement unconditionally for the entire study duration.
214660523|NCT06115369|DIETARY_SUPPLEMENT|Produce Boxes delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
214660524|NCT06115369|DIETARY_SUPPLEMENT|Produce Boxes Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement unconditionally throughout the entire study period.
214660525|NCT06842082|DEVICE|Intubation with standard laryngoscope|Anesthesia resident will intubate using a standard laryngoscope.
214660526|NCT06842082|DEVICE|Intubation with video laryngoscope|Anesthesia resident will intubate using a videolaryngoscope (Storz C-MAC, McGrath, Glidescope or other videolaryngoscope)
214660527|NCT06809010|BIOLOGICAL|Whole blood donation|This intervention involves the collection of a whole blood bag.
214660528|NCT06809010|BIOLOGICAL|Apheresis donation|This procedure involves the collection of a plasma/platelets bag by apheresis
214660529|NCT04468360|BEHAVIORAL|3-day differential fear conditioning, extinction, and extinction retention testing paradigm|Day 1: Fear acquisition involving the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a conditioned stimuli (CS) (Expts. 1 and 2). The CS will be different colored shapes appearing on a computer monitor. An auditory stimulus will serve as the startle probe. Day 2: Either extinction training (Expt. 1) or fear memory reactivation by a single CS+ with no US (Expt. 2) will occur followed by IV Allo vs. IV placebo administration. Day 3: The effects of IV Allo vs. IV placebo (administered on Day 2) on extinction retention (Expt. 1) or reconsolidation blockade (Expt. 2), as well as reinstatement of conditioned fear (Expts. 1 and 2) will be assessed.
214660530|NCT04468360|DRUG|Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of Allo will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of Allo will be infused over 30 minutes immediately following presentation of a single CS+.
214660531|NCT04468360|OTHER|Matching IV Placebo|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of the matching placebo formulation will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of the matching placebo formulation will be infused over 30 minutes immediately following presentation of a single CS+.
214660532|NCT06922825|DRUG|68Ga-FAPI-46|Participants will receive an IV injection of 68Ga-FAPI-46. Then, shortly after will undergo a PET/CT imaging using the 68Ga-FAPI-46. Additionally, MRI or contrast CT imaging will be conducted, either on the same day or within 14 days.
214660533|NCT06931015|OTHER|No interventions|No interventions
214660534|NCT06386978|PROCEDURE|Transverse Facia Plane Block (TAP Block)|Spinal Anesthesia + TAP block
214660535|NCT06386978|PROCEDURE|Transversalis Facia Plane Block (TFP Block)|Spinal Anesthesia + TFP block
214660536|NCT06386978|PROCEDURE|Control|Spinal anesthesia + No block
214660537|NCT03683186|DRUG|Ralinepag|Active
214660538|NCT06398431|DEVICE|Walking analysis sensor|Participant gait analysis with the inertial sensor
214660539|NCT06905327|DRUG|QCZ484|doses of 50, 150, 300 or 600 mg via subcutaneous injection
214660540|NCT06905327|DRUG|Placebo|via subcutaneous injection
214660541|NCT04869137|DRUG|Lenvatinib Oral Product|20mg of Lenvatinib will be taken orally once daily
214290141|NCT04975685|BEHAVIORAL|Sham brain training (Sudoku)|Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
214660542|NCT04869137|DRUG|Pembrolizumab|200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
214660543|NCT06755996|DRUG|Dexmedetomidine injection|Dexmedetomidine injection 3μg/kg
214660544|NCT06755996|DRUG|Remimazolam|remimazolam 0.5mg / kg
214660545|NCT07094776|OTHER|No intervention (observational study)|This is an observational study. No drugs, devices, or treatments are administered. Participants only provide a single blood sample for MG53 and routine metabolic measurements.
214660546|NCT07095296|BEHAVIORAL|Health Education|"The intervention-a culturally tailored and redesigned health education-will be guided by established behavioral theories, namely the Theory of Planned Behavior (TPB) and Social Cognitive Theory (SCT) and implemented in a culturally sensitive manner. The TPB focuses on attitudes toward utilizing PNC services, the influence of subjective norms such as cultural norm, and their perceived behavioral control including transportation (34), while SCT emphasizes self-efficacy, social modeling, and reinforcement(35). Both TPB and SCT have been extensively validated in various health behavior studies, supporting their relevance and applicability in this context(36, 37).~Our intervention will consist of a structured training and mentorship program for midwives, focusing on health education delivery. The intervention package, including the training curriculum and implementation manual, will be developed in accordance with guidelines from the World Health Organization (WHO) and the Federal Ministry"
214660547|NCT07099963|OTHER|one lung ventilation|Arterial blood gases during one lung ventilation
214660548|NCT07099677|DRUG|Beta Blocker|Participants in this group will receive standard antihypertensive treatment with a beta-adrenergic receptor blocker. The exact agent and dosage will be determined by the cardiology clinic according to clinical guidelines. Balance and fall risk assessments will be conducted at baseline (T0), week 2 (T1), and week 4 (T2).
214290142|NCT02326025|DRUG|Olaratumab|Administered IV
214290143|NCT02326025|DRUG|Doxorubicin|Administered IV
214660549|NCT07099677|DRUG|ACE inhibitor|Participants in this group will receive standard antihypertensive treatment with an angiotensin-converting enzyme inhibitor. The dose and specific agent will be prescribed based on routine clinical criteria. Assessments will take place at T0, T1, and T2.
214660550|NCT07099677|DRUG|Calcium channel blocker|This group will receive a calcium channel blocker as part of their standard hypertension management. Dosage and agent will follow standard cardiology practice. Postural balance and fall risk will be measured at all study time points.
214660551|NCT07094711|BIOLOGICAL|Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine|"Subjects will be randomized to a single intradermal injection of BCG or placebo vaccine.~Participants randomized to the BCG arm will receive TICE® BCG. Freeze-dried vaccine is produced in vials, each containing 1 to 8 x\^108 colony forming units (CFU). A vial will be reconstituted in 20 mL of preservative-free saline. Administration of 0.1 mL will contain \~2x\^106 CFU, which accounts for approximately 0.25 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally."
214660552|NCT07094711|DRUG|preservative-free saline|Patients randomized to the placebo arm will receive 0.1 mL preservative-free saline alone.
214660553|NCT00648401|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
214660554|NCT00648401|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
214660555|NCT06249139|BEHAVIORAL|Compass for Care (Well-being intervention)|Participants receive 12 weekly modules containing interactive activities and static content and tailored messages delivered via text message or email. The intervention focuses on five self-care behaviors critical to ADRD caregiver well-being: 1) taking time to recharge; 2) finding information about your loved one's diagnosis and needs; 3) discovering your strengths and limits; 4) exploring outside help; and 5) seeking emotional support.
214660556|NCT06249139|BEHAVIORAL|Compass for Care (Safety intervention)|Participants receive 12 weekly modules and tailored messages delivered via text message or email. The intervention focuses on safety behaviors (e.g., weather safety, first aid, home safety, etc.)
214660557|NCT07107724|OTHER|Noradrenalin|"After inclusion, patients will be tested for fluid responsiveness. Pulse pressure variation (PPV) will be evaluated.~In case of PPV\> 13% a fluid bolus of 500 mL of Lactated Ringer's will be administered in 10 minutes.~If PPV\< 8% Norepinephrine will be administered or increased. If PPV is in the gray zone, a PLRT will be performed and if CO increases more than 10% a fluid bolus will be prescribed, otherwise norepinephrine increased."
214660558|NCT07107724|OTHER|Fluid bolus|"After inclusion, patients will be tested for fluid responsiveness. Pulse pressure variation (PPV) will be evaluated.~In case of PPV\> 13% a fluid bolus of 500 mL of Lactated Ringer's will be administered in 10 minutes.~If PPV\< 8% Norepinephrine will be administered or increased. If PPV is in the gray zone, a PLRT will be performed and if CO increases more than 10% a fluid bolus will be prescribed, otherwise norepinephrine increased."
214660559|NCT07106567|BEHAVIORAL|Mediterranean diet education|The General Information Form, Physical Activity Questionnaire, Perceived Stress Scale, SF-36 Quality of Life Scale, and Mediterranean Diet Adherence Scale will be administered to hypertensive patients at each interview (at 0, 1, and 3 months). The intervention group will be trained on the Mediterranean Diet at the first meeting.
214660560|NCT07106567|OTHER|Control|The General Information Form, Physical Activity Questionnaire, Perceived Stress Scale, SF-36 Quality of Life Scale, and Mediterranean Diet Adherence Scale will be administered to hypertensive patients at each interview (at 0, 1, and 3 months).
214660561|NCT07106710|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection.
214660562|NCT07106710|BIOLOGICAL|BCMA CAR-T|Patients will receive BCMA CAR-T single dose (3.0 x 10\^6 cells /kg) infusion 3 days after ASCT.
214660563|NCT07106710|DRUG|GPRC5D/CD3 BiTEs|Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion and continuing for at least 2 years
214660564|NCT07106749|BIOLOGICAL|CD180 CART|Subjects screened to meet the requirements for CD180 CART use will enter clinical trials. Subjects were assessed at baseline. Fludarabine and cyclophosphamide based preconditioning should be performed within 1 week prior to CD180 CART infusion: fludarabine (Flu) 30mg/m2 ×3 days; cyclophosphamide (CTX) 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and VP-16. Infusion of CD180 CART must be performed 24 hours after completion of chemotherapy preconditioning. CD180 CART can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.
214660565|NCT07106918|BIOLOGICAL|SIBP-A16 injection|Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.
214660566|NCT07106918|BIOLOGICAL|Nirsevimab|Single administration via intramuscular.
214660567|NCT07106918|OTHER|SIBP-A16 buffer solution|Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.
214660568|NCT07105709|DRUG|GSK4527226|GSK4527226 will be administered.
214848725|NCT04127214|OTHER|ITA Integrated Treatment|The ITA Model combines outpatient intervention (mainly psychotherapy), day hospital care and hospitalization as a function of patients' characteristics. Case conceptualization of the psychological processes of patients is formulated and revised within a team including psychologists, psychotherapists, psychiatrists, nutritionists, physicians, nurses, and social workers. The major emphasis of the ITA model is on psychological interventions which include individual psychotherapy, family therapy and/or guidance, and group therapy of various formats and contents (e.g., drug abuse, mindfulness, emotion work) tailored to the needs of each patient. However, when required, drugs are prescribed adjusting type of medication and dosage to the need of the patient.
214848726|NCT03852524|DRUG|Methylnaltrexone|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
214290144|NCT01622790|DRUG|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
214660569|NCT07105436|DIAGNOSTIC_TEST|Persistent air leak quantification|"In this trial, patients with PALs will have their chest tubes connected to the Thopaz+ system. The Thopaz+ will continuously quantify the volume of air leaks, providing real-time data for analysis.~Data from both the Thopaz+ and standard serial occlusion test with Fogarty balloon will be combined and integrated to provide a comprehensive assessment of the air leak source. The bronchoscopic will perform standard visual assessment of changes in air leak during serial balloon occlusion in order to identify the best region for endobronchial treatments; use of measurements from the Thopaz and serial balloon occlusion test will be allowed as part of clinical reasoning but are not required to be used by the treating clinician."
214660570|NCT07106736|BIOLOGICAL|BCMA CAR-T|Patients will receive single-dose infusion of autologous BCMA-directed CAR-T cellsBCMA CAR-T single dose (3.0 x 10\^6 cells /kg).
214660571|NCT07106736|DRUG|GPRC5D/CD3 BiTEs|Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion.
214660572|NCT07107178|DRUG|BT02|monoclonal antibody injection with intravenous administration every 2 or 3 weeks
214660573|NCT07105488|BIOLOGICAL|BFB759|BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis
214848727|NCT03852524|OTHER|Placebo|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
214848728|NCT01936311|BEHAVIORAL|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
214848729|NCT06311019|DEVICE|Continuous glucose monitoring and use of connected insulinpen for bolus insulin|Continuous glucose monitoring (Abbott Freestyle Libre 2) and use of connected insulinpen (Novopen 6) for bolus insulin
214848730|NCT02622659|DRUG|Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
214848731|NCT02622659|DRUG|Xiaoer Jiebiao Oral Liquid|"1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day"
214848732|NCT06351696|DIETARY_SUPPLEMENT|Bromlein|1500 mg/day
214848733|NCT06351696|OTHER|Placebo|Placebo (1500 mg/day)
214848734|NCT05309720|PROCEDURE|Glyaderm|All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.
214848735|NCT02288494|OTHER|stewart approach|Prospective study, for ICU patient with severe hypoalbuminemia \< 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.
214848736|NCT03500367|DRUG|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
214848737|NCT01834209|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily for 28-day cycles
214660574|NCT07105488|DRUG|Placebo|Placebo for BFB759
214660575|NCT07106307|OTHER|Bioceramic Sealer|This intervention involves the use of Bioceramic Sealer during root canal obturation. The sealer will be combined with the cold lateral compaction or warm vertical compaction technique depending on the study arm.
214848738|NCT01834209|DRUG|Prednisone or prednisolone|5 mg tablet taken orally once daily
214848739|NCT01501968|DRUG|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
214848740|NCT01501968|DRUG|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
214848741|NCT01790113|DEVICE|Univers™|Control
214848742|NCT01790113|DEVICE|Eclipse™ Total Shoulder Replacement|Investigational
214848743|NCT04157478|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
214848744|NCT04157478|RADIATION|Radiation therapy|Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
214848745|NCT04157478|DRUG|Temozolomide|Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
214848746|NCT03585959|DEVICE|superDimension™ Navigation System Version 7.2|superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
214848747|NCT03059485|BIOLOGICAL|DC/AML Fusion Vaccine|The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells
214848748|NCT03059485|OTHER|Observation|Traditional care provided by the hospital.
214848749|NCT05844631|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
214848750|NCT04554095|OTHER|Clinical data collection|Respiratory parameters, analytic values, lung ultrasound and echocardiography
214848751|NCT00010413|DRUG|cyclophosphamide|
214848752|NCT00010413|DRUG|filgrastim|
214848753|NCT05965102|DRUG|Tirelizumab；Chemotherapy monotherapy|Tirelizumab combined with chemotherapy in first-line treatment of relapsed/metastatic non-small cell lung cancer with ECOG PS score of 2
214848754|NCT03093272|DRUG|Leuprolide Acetate|a GnRH agonist
214848755|NCT03093272|DRUG|Prednisone|Prednisone is a corticosteroid
214848756|NCT03093272|DRUG|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
214848757|NCT03093272|DRUG|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
214660576|NCT07106307|PROCEDURE|Warm Vertical Compaction|Warm vertical obturation is performed using a heat delivery device, which thermosoftens gutta-percha and allows vertical compaction into the root canal system. This technique will be used in combination with either resin-based or bioceramic sealers, depending on the study group.
214660577|NCT07106307|OTHER|Epoxy Resin-Based Sealer|This intervention involves the use of an epoxy resin-based root canal sealer during root canal obturation. The material will be applied in combination with either cold lateral compaction or warm vertical compaction techniques, depending on the study group.
214660578|NCT07106307|PROCEDURE|Cold Lateral Compaction|Cold lateral compaction is a root canal obturation technique in which a master gutta-percha cone is placed to working length and compacted laterally using a finger spreader. This method will be used in combination with either resin-based or bioceramic sealers, depending on the study group.
214660579|NCT06233331|DRUG|Dose Level 1 ACU-D1 ointment|"ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC.~Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks."
214660580|NCT06233331|DRUG|Dose Level 2 ACU-D1 ointment|Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.
214660581|NCT06233331|DRUG|Dose Level 3 ACU-D1 ointment|Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.
214660582|NCT06233331|PROCEDURE|Vulvar/ Perianal Biopsy|3 vulvar or perianal biopsies are to be performed at the screening as well as at the end of the study (week 4).
214660583|NCT07107165|BEHAVIORAL|Dyadic Problem Solving Training|DPST consists of teaching the patient and family caregiver problem-solving skills that they can apply to help them manage the medical regimen after stem cell transplant.
214660584|NCT07107165|BEHAVIORAL|Supportive Care|Supportive Care consists of providing support to the patient and family caregiver as they manage the medical regimen after stem cell transplant
214660585|NCT07107880|OTHER|Communication Assessment through AI and Human|Participants will remotely engage in an AI-generated simulation that presents an voice-based conversation with a simulated parent of a pediatric patient. The scenario involves discussing a clinical scenario concerning their child. Following the simulation, the participant's communication skills will be assessed using an artificial intelligence (AI) system trained to evaluate the key aspects of communication using standardized rating scales. In addition, two human evaluators will assess the participant's communication skills using the same rating scales.
214660586|NCT07108062|OTHER|Experimental|(lifestyle + dietary advice)
214660587|NCT07108062|OTHER|Placebo|No intervention
214660588|NCT07107373|DRUG|Mavacamten|According to the product label
214660589|NCT07106931|OTHER|This is an observational study with no intervention|This is an observational study with no intervention
214660590|NCT07106112|PROCEDURE|Ultrasound-guided carbon suspension (Black Eye) injection|"Under ultrasound guidance, 0.5 mL of sterile carbon particle suspension (Black Eye) is injected into the capsule of the metastatic axillary lymph node(s).~Technique: Performed using a high-frequency linear ultrasound probe (e.g., 12 MHz) and a 22G needle.~Target: Up to 3 pathologically confirmed metastatic lymph nodes. Timing: Performed before initiation of neoadjuvant systemic therapy (NST).~Rationale:~Carbon suspension provides long-term visual localization due to its black staining properties.~Inert and biocompatible, with minimal risk of allergic reactions. Patients proceed to standard NST based on tumor subtype (chemotherapy, targeted therapy, or endocrine therapy).~Post-NST imaging (ultrasound, CT, or PET-CT) to assess treatment response.~Surgical Intervention:~Targeted axillary dissection (TAD) with removal of marked nodes + sentinel lymph node biopsy (SLNB) using fluorescent dye.~Intraoperative frozen section analysis (hematoxylin \& eosin staining) of excised nodes."
214660591|NCT07106112|PROCEDURE|Ultrasound-guided metallic marker (TWIRL ULTRACOR) placement|"A 4-mm nitinol (nickel-titanium alloy) marker (TWIRL ULTRACOR) is deployed into the metastatic lymph node(s) under ultrasound guidance.~Technique: Uses a specialized introducer kit for precise placement. Target: Up to 3 pathologically confirmed metastatic lymph nodes. Timing: Performed before initiation of NST.~Rationale:~Nitinol markers are radiopaque, MRI-compatible, and resistant to migration. Standard method for tumor localization in breast cancer.~Post-Marking Protocol:~Identical NST and imaging follow-up as Group 1.~Surgical Intervention:~TAD with marker localization (palpation/imaging-guided excision) + SLNB. Intraoperative frozen section analysis."
214660592|NCT07107438|OTHER|The interventional group will be trained on ECG interpretation through thinqi digital interactive platform|The conventional group will be trained on ECG interpretation through handout exercises
214848758|NCT01368926|DRUG|RO4917523|single oral doses
214848759|NCT01368926|DRUG|RO4917523|multiple oral doses
214660593|NCT07106723|DRUG|ASCT+CD7-CART|Intravenous infusion of CD7-CART 3 days after ASCT
214660594|NCT07108179|DEVICE|Continuous Glucose Monitoring (CGM) System|Continuous Glucose Monitoring (CGM) System
214660595|NCT07106164|PROCEDURE|total body massage|Massage was done using the Field's Technique after starting phototherapy till discontinuation of phototherapy for 15 - 20 minutes, three times daily 1 hour after the morning, mid- day feeds and at night.
214660596|NCT07106164|DEVICE|photo therapy|neonates received phototherapy for the neonatal hyperbilirubinemia
214848760|NCT01368926|DRUG|placebo|oral doses
214848761|NCT00951951|PROCEDURE|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
214848762|NCT00951951|PROCEDURE|Posterior Approach|
214848763|NCT02054013|PROCEDURE|Prostatic artery embolization|
214848764|NCT02054013|PROCEDURE|monopolar transurethral prostatectomy|
214848765|NCT06586151|BEHAVIORAL|Transcendent Health|Gender-inclusive HIV prevention program: Text messaging-based program that lasts 5 months. Content includes information, motivation and behavioral skills about how to prevent HIV, as well as information about healthy and unhealthy romantic relationships, and navigating issues related to one\&#39;s gender.
214848766|NCT06586151|BEHAVIORAL|Text Messaging with Information|Text messaging-based program that lasts 5 months. Content includes information about HIV prevention and aspects of a healthy adolescent lifestyle (e.g., self-esteem).
214848767|NCT00272506|DRUG|inhaled corticosteroid|
214848768|NCT00272506|DRUG|long-acting beta2-agonist|
214660597|NCT07106827|DRUG|GV20-0251|Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks
214660598|NCT07107308|DEVICE|Microfocused Ultrasound|Before treatment, clean the treatment area, mark the treatment zone, and evenly apply a layer of ultrasound coupling agent about the thickness of a coin on the treatment area. The patient's face was treated with S1.5, S2, N3, N4.5, P1.5, P2.0, P3.0 and P4.5 treatment heads respectively. After the treatment, the face was cleaned and a medical mask was applied for 15 minutes. After the treatment, attention was paid to moisturizing and sun protection.
214660599|NCT07107308|DEVICE|Erbium-Doped Fiber Laser|Doctors and patients wear corresponding protective glasses. Apply cold gel to the treatment area on the patient's face and select certain treatment parameters based on the patient's skin lesion condition and skin type. After the treatment, clean your face. Decide whether to apply ice based on the severity of the skin lesion reaction. If ice application is necessary, the regular ice application time is 15 to 30 minutes, and apply a medical mask for 15 minutes. After the treatment, pay attention to moisturizing and sun protection.
214660600|NCT07107620|DIAGNOSTIC_TEST|one task|Single task tests consist of measuring walking times with normal walking (easy), walking with a 50% reduction in the base of support measured between the medial malleoli (medium difficulty) and tandem walking (difficult) tasks while applying the 10 meter walk test and time up go tests.
214660601|NCT07107620|DIAGNOSTIC_TEST|dual task|Dual task consists of single task plus tests of carrying glasses of water or counting backwards from a given number.
214660602|NCT07105943|OTHER|Control|"The intervention will be implemented in the 8 weeks phase 2 cardiac rehabilitation program.~Both groups will receive a pre-exercise evaluation and 16 individualized training sessions (two per week) based on FITT-VP principles and according to the European Association of Preventive Cardiology (EAPC) guidelines. A complementary physical activity program integrated into their daily life will be prescribed. It will receive regular briefing sessions regarding the health-related benefits of exercise. After these sessions, it will be recommended to maintain physical activity aiming to reach at least 150 min/week of moderate intensity PA."
214660603|NCT07105943|OTHER|Experimental|As for the experimental group, in the 16 individualized training sessions (two per week), attention will be given to exercise intensity assessment and manipulation, with the goal of optimizing the affective experience of exercise, while also respecting minimum and maximum intensity thresholds as proposed by the EAPC (self-selected intensity within individually defined limits). The pre-exercise evaluation, the number of sessions, and methodological approach will be the same to the control group. In this group it will be presented some awareness of the potential of choosing fun and pleasant activities.
214660604|NCT07107503|PROCEDURE|Radiofrequency ablation alone|RFA was performed by four US physicians with ≥ 10 years of experience in in-terventional US. Before ablation, the patients were placed in the supine position with the neck extended, and local anesthesia was administered with lidocaine (1%). RFAs were performed using the hydro-dissection, trans-isthmic and moving-shot techniques according to previously published guidelines. Ablation was terminated when the target tumor changed to a transient hyperechoic zone. Contrast-enhanced US (CEUS) was performed immediately after ablation to evaluate the ablation area. The presence of complications during or after thermal ablation and corresponding treatments was carefully evaluated. All patients were closely observed for 1-2 h after ablation in the hospital.
214660605|NCT07107503|PROCEDURE|surgical resection|SR was performed under general anesthesia by surgeons with\>15 years of expe-rience in thyroid surgery. The decision to perform total thyroidectomy or lobectomy was made by individual surgeons and patients, based on patient preferences in consu
214660606|NCT07108023|OTHER|No intervention (Observational Study)|This is a retrospective observational study with no assigned intervention. Data will be collected from patient medical records only
214660607|NCT07105800|BEHAVIORAL|Music-based dance|The dance routines emphasized perceptual-motor training through mutual physical guidance, spatial coordination, and social interaction among participants. The intervention aimed to enhance executive function, balance, and lower limb mobility by incorporating dual-task elements that challenge memory, attention, and physical control in a dynamic, enjoyable setting.
214660608|NCT07105800|BEHAVIORAL|Control|The training content is delivered through standardized, non-musical instructional videos. Participants in the control group follow fixed video demonstrations to perform functional lower limb exercises. The movement components include independent lower limb strength training and balance training.
214660609|NCT07106047|BEHAVIORAL|Nurse-Led Climate-Responsive Asthma Management Program|A structured behavioral intervention delivered by trained nurses, focusing on climate-adapted asthma self-management for older adults. The program includes personalized coaching on symptom monitoring, environmental risk response, inhaler technique, and safe physical activity planning during climate stress events. Intervention is delivered weekly over 12 weeks through a combination of phone and in-person sessions, supported by tools such as symptom diaries, air quality alerts, and peak flow meters.
214660610|NCT07107100|OTHER|a silicon jig/key is used to place/bond fixed retainer on teeth|a silicon jig/key is used to place/bond fixed retainer on teeth
214848769|NCT03527251|DRUG|Ipilimumab|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
214848770|NCT03527251|DRUG|SHR-1210|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
214848771|NCT05064748|DRUG|Benvitimod|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
214848772|NCT00028535|BIOLOGICAL|trastuzumab|Given IV
214848773|NCT00028535|DRUG|paclitaxel|Given IV
214848774|NCT00028535|BIOLOGICAL|recombinant interleukin-12|Given SC
214848775|NCT00614822|DRUG|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
214848776|NCT00755768|BEHAVIORAL|additional review by dietician|
214848777|NCT00604903|DEVICE|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
214848778|NCT02464826|DRUG|Nailprotex|Nailprotex apply to the abnormal nail twice daily
214660611|NCT07107451|DIETARY_SUPPLEMENT|OIT with low dose sesame protein|"After 8 months of continued low-dose sesame OIT, patients will undergo hospital-based assessments, including skin prick testing, laboratory evaluations, and an open Oral Food Challenge (OFC) to evaluate desensitization.~Patients who had a negative OFC after 3 months in the initial phase of the study-and thus confirmed desensitization-will skip the pre-break OFC and proceed directly to the next stage.~Following a 4-week interruption in OIT, patients will return for a final hospital visit, during which a concluding OFC will be conducted to assess sustained unresponsiveness. Additional laboratory tests and skin prick testing will also be performed at this visit."
214660612|NCT07105553|DEVICE|Surgical Glove Compression|Participants wore two tight-fitting surgical gloves (one size smaller than standard) on the non-dominant hand. The gloves were applied 30 minutes prior to each paclitaxel infusion, remained in place during the infusion, and were removed 30 minutes afterward. The dominant hand remained ungloved and served as an internal control. This intervention was entirely non-pharmacologic and was integrated into routine chemotherapy sessions.
214660613|NCT07101367|DRUG|Normal saline|After induction of anesthesia give 10 ml of normal saline then followed by infusion of normal saline till extubation of patient in ICU
214660614|NCT07101367|DRUG|Dexmedetomidine|After induction of anesthesia give loading dose of precedex 1 mcg/kg diluted in 10 ml normal saline then attach syringe pump of precedex infusion of 0.5mcg/kg/hr till extubation in ICU
214660615|NCT07101367|DRUG|Methylprednisolone|After induction of anesthesia give solumedrol of a dose 10mg/kg diluted in 10ml of normal saline followed by a normal saline infusion till the extubation of the patient in the ICU
214660616|NCT07105774|BEHAVIORAL|stress inoculation training program|The intervention group received the SIT program for 12 weeks. From 1st-2nd weeks, participants were admitted to an online training group set up via DingTalk, attending an offline stress reduction workshop were grouped into groups of 5-6, with games and small activities to promote group bonding. Psychiatric-psychological nurse specialist introduced the participants to the concept of SIT, the curriculum, and asked them to describe their initial knowledge and understanding of SIT. In addition, through cognitive restructuring training, the participants were made to review their work experience, understand the work stress and psychological pain they faced, and correctly recognize the role of cognition and emotion in causing and maintaining stress. From 3rd-6th weeks, participants were portrayed and discussed through videos and images, exploring personal, organizational and environmental stressors for new psychiatric nurses. Psychiatrists led relaxation exercises (e.g. positive thinking, med
214660617|NCT07105774|BEHAVIORAL|routine training|"The control group received training in accordance with the New Entry Nurse Training Syllabus (Trial), which included routine theoretical knowledge training and clinical practice training."
214660618|NCT07107022|DEVICE|Penumbra System ®|Neurovacular Mechanical Thrombectomy with the Penumbra System®
214660619|NCT07107139|OTHER|Copenhagen group|Participants use product for up to 30 minutes
214660620|NCT07107139|OTHER|Snus group|Participants use product for up to 30 minutes
214660621|NCT07107789|OTHER|Diabetes education with video animation|Providing diabetes education to the experimental group through a video animation Following the routine diabetes education provided by the hospital, the experimental group will receive diabetes education using a video animation prepared and staged by the researcher and approved by experts.
214660622|NCT07106684|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection.
214660623|NCT07106684|BIOLOGICAL|BCMA CAR-T|Patients will receive BCMA CAR-T single dose (3.0 x 10\^6 cells /kg) infusion 3 days after ASCT.
214660624|NCT07106684|DRUG|GPRC5D/CD3 BiTEs|Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion and continuing for at least 2 years
214660625|NCT07106190|OTHER|Patients will be informed during the rehabilitation process|Patients will be informed during the rehabilitation process about secondary complications of stroke
214660626|NCT07106996|DRUG|red yeast rice，RYR|Participants will take 6 grams of red yeast rice daily for 6 months.
214660627|NCT07105813|DEVICE|Navigational Positioning System for Puncture Surgery|Suitable for puncture surgery navigation and localization systems to assist in the procedure
214848779|NCT03601546|OTHER|Clinical examination|Blood test and patient interview as for standard patient care
214848780|NCT00097045|DRUG|omega interferon|
214290145|NCT01622790|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
214290146|NCT01622790|DRUG|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
214290147|NCT00001723|DRUG|Orlistat|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
214290148|NCT00001723|DRUG|Placebo|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
214290149|NCT04367220|DIAGNOSTIC_TEST|Diagnostic testing performed as per routine care|
214290150|NCT01265290|DEVICE|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
214660628|NCT06755437|DEVICE|Rehabilitation with a computerized device (in the morning)|Each group received face-to-face cognitive rehabilitation with the electronic device for 45 min. The exercises were selected by the therapist and divided into four sessions of 2 to 3 days each. Each session included 40 min of activity and 5 minute of break
214660629|NCT06755437|DEVICE|Self-treatment with a computerized device (in the afternoon)|In the afternoon, the experimental group performed 60 min. self-guided treatment with the electronic device.
214848781|NCT00097045|DRUG|Ribavirin|
214848782|NCT02772952|OTHER|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
214848783|NCT02772952|OTHER|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
214848784|NCT03634059|DRUG|Apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
214848785|NCT01072799|BIOLOGICAL|Placebo|Two doses (Day 1 and Day 22); 0.5mL
214660630|NCT06755437|BEHAVIORAL|self-treatment with pencil-and-paper exercises (in the afternoon)|In the afternoon, the control group performed 60 min of cognitive self-treatment with conventional paper-and-pencil instruments. The therapist created a variety of exercises every day
214660631|NCT07106671|DRUG|Siltuximab|Siltuximab 11mg/kg
214660632|NCT07106619|DEVICE|Isokinetic Exercises|Exercises will be performed at three different angular speeds (90 ̊/sec, 5 repetitions, 5 sets; 120 ̊/sec, 8 repetitions, 5 sets; 150 ̊/sec, 10 repetitions, 5 sets).
214660633|NCT07106619|OTHER|Conventional rehabilitation program|Ambulation and balance exercises
214660634|NCT07106346|PROCEDURE|The timing of endoscopic intervention for necrotizing pancreatitis is determined based on the degree of encapsulation|In the encapsulation-oriented group, participants undergo EUS-guided drainage of necrotizing pancreatitis when the degree of encapsulation reaches ≥80%, as confirmed by cross-sectional imaging (preferably contrast-enhanced CT). Imaging is repeated every 7-10 days after enrollment to assess encapsulation. Once sufficient encapsulation is observed and the patient presents with symptoms such as infection, abdominal pain, GOO or biliary obstruction, endoscopic drainage is performed. Drainage is typically performed using a lumen-apposing metal stent (LAMS) placed under EUS guidance, often accompanied by placement of an external drain. Step-up therapy, including endoscopic necrosectomy or additional drainage procedures, may be used if symptoms do not improve. If the patient improves with conservative therapy before encapsulation is achieved, drainage may be deferred. Endoscopic/percutaneous interventions should, in principle, be discussed with the expert panel beforehand.
214660635|NCT07106346|PROCEDURE|EUS-guided drainage based on the interval from the onset of acute pancreatitis|In the timing-oriented group, participants undergo EUS-guided drainage of necrotizing pancreatitis at 4 to 5 weeks after the onset of acute pancreatitis, regardless of the degree of encapsulation. Drainage is performed only in symptomatic patients who meet predefined clinical criteria, such as signs of infection, significant pain, GOO, or biliary obstruction. Imaging is performed before the procedure. The standard approach involves placing a LAMS under EUS guidance, optionally supplemented by external drains. If symptoms do not improve, step-up interventions such as endoscopic necrosectomy, percutaneous drainage may be considered. If inflammation and symptoms improve with conservative treatment (e.g., antibiotics), EUS-guided drainage may be omitted. Conversely, even before 4-5 weeks from onset, early drainage is allowed if conservative treatment is deemed insufficient by the attending physician. In principle, intervention decisions should be discussed with the expert panel.
214660636|NCT07106372|BIOLOGICAL|Stapokibatrt|Stapokibatrt Subcutaneous injection
214660637|NCT07108140|BIOLOGICAL|Anti ALPP CAR-T cells treatment|anti ALPP CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.
214660638|NCT03905434|GENETIC|miRNA sampling|Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)
214660639|NCT06916767|DRUG|BAFF CAR-T|Single infusion
214660640|NCT06916767|DRUG|Obinutuzumab|IV administered
214660641|NCT06916767|DRUG|Cyclophosphamide|500mg/m2 on days -5 to -3
214660642|NCT06916767|DRUG|Fludarabine|30mg/m2 daily on days -5 to -3
214660643|NCT06915298|BEHAVIORAL|Alcohol health warning label - cancer|A sticker with health information on alcohol causing cancer is applied to alcoholic beverage containers purchased by the participants.
214660644|NCT06915298|BEHAVIORAL|Responsibility message on alcohol label|A sticker with a message to drink responsibly will be applied to alcoholic beverage containers purchased by the participants.
214660645|NCT06915298|BEHAVIORAL|Front label|A sticker will be applied to the front of the alcoholic beverage containers purchased by the participants.
214290151|NCT01265290|DEVICE|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
214660646|NCT06915298|BEHAVIORAL|Back label|A sticker will be applied to the back of the alcoholic beverage containers purchased by the participants.
214660647|NCT06915298|OTHER|Outcome pre-testing|Primary outcome (knowledge of alcohol related harms) is tested at baseline.
214660648|NCT06915298|OTHER|No outcome pre-testing|Primary outcome (knowledge of alcohol related harms) is not tested at baseline.
214660649|NCT05639413|OTHER|Collection of blood samples|A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at each timepoint.
214660650|NCT06935916|PROCEDURE|pedicled or free tissue transfer|pedicled or free tissue transfer
214660651|NCT06943716|PROCEDURE|Modified Catheter Antegrade Cerebral Perfusion (Modified bACP)|A modified bilateral catheter antegrade cerebral perfusion technique used for acute Type A aortic dissection repair. This approach aims to reduce surgical trauma by avoiding additional right axillary access while maintaining stable cerebral perfusion.
214660652|NCT06943716|PROCEDURE|Conventional Brain Perfusion|Patients receiving the conventional perfusion strategy for aortic arch surgery, which may include standard bilateral ACP based on the surgeon's preference and the patient's condition.
214660653|NCT06936085|OTHER|Training|The Crime Scene Forensic Evidence Management training, which included theoretical knowledge and the presentation of sample cases, was completed for 144 volunteer participants. The content of the training includes topics such as forensic incidents, evidence, crime scene management, and evidence management, as well as the roles and responsibilities of paramedics in forensic cases such as injuries, violence, abuse, sexual assault, and suicide. Training was given to 4 groups of 35-37 students in each group in the classroom environment in two class hours (30+ 30 minutes + 1 break). Trainings were given by a single lecturer to avoid bias and ensure standardization.
214848786|NCT01072799|BIOLOGICAL|A/H1N1 2009 Influenza VLP Vaccine|Two doses (Day 1 \& Day 22); 0.5mL
214290152|NCT05377385|BEHAVIORAL|Questionnaire|Questionnaire about usability of the Omnipod DASH insulin administration system
214290153|NCT02643082|DRUG|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
214290154|NCT02643082|DRUG|Placebo MDI|Comparator: Placebo MDI which contains no active ingredients
214660654|NCT06936046|DRUG|Dual antibody A|Starting 2-6 weeks after surgery, synchronous TMZ radiotherapy and chemotherapy will be performed. After completing synchronous radiotherapy and chemotherapy for 28 days, TMZ combined with PD-1/VEGF dual antibody will be used as adjuvant therapy. PD-1/VEGF dual antibody 20mg/kg intravenous infusion once, with a cycle of 21 days.
214660655|NCT06936046|DRUG|Dual antibody B|Starting 2-6 weeks after surgery, synchronous TMZ radiotherapy and chemotherapy will be performed. After completing synchronous radiotherapy and chemotherapy for 28 days, TMZ combined with PD-1/CTLA-4 dual antibody will be used as adjuvant therapy. PD-1/CTLA-4 dual antibody 6mg/kg intravenous infusion once, with a cycle of 14 days.
214660656|NCT06936046|RADIATION|Modified Stupp|Starting 2-6 weeks after surgery, synchronous TMZ radiotherapy and chemotherapy will be performed. For partially resected lesions or short-term recurrence and progression lesions after surgery, high-dose PGTV 66Gy/30Gy will be given locally. PTV1 in high-risk areas around the tumor bed will be 60Gy/30F, and in low-risk areas will be 54Gy/30F. After completing synchronous radiotherapy and chemotherapy for 28 days, 6 cycles of adjuvant TMZ chemotherapy will be started.
214660657|NCT06936046|DRUG|Stupp protocol|Synchronized TMZ radiotherapy and chemotherapy will begin 2-6 weeks after surgery, and 6 cycles of adjuvant TMZ chemotherapy will begin 28 days after completing the synchronized radiotherapy and chemotherapy. Radiotherapy regimen: PTV1 60Gy/30F in high-risk areas around the tumor bed, 54Gy/30F in low-risk areas. TMZ synchronous chemotherapy regimen: 75mg/m2 po qd. TMZ adjuvant chemotherapy regimen: The first cycle is 150mg/m2 po qd on d1-5,28 days; Cycle 2-6: Cycle 1: 200mg/m2 po qd for d1-5,28 days.
214660658|NCT06946875|OTHER|Pain Threshold|The pain thresholds of the participants will be measured with an algometer device. With this device, the minimum pressure threshold that causes pain is recorded.
214660659|NCT06952686|BIOLOGICAL|SRP-9005|Solution for single IV infusion
214660660|NCT06952686|DRUG|Corticosteroid|Oral tablet (prophylactic)
214660661|NCT05457595|RADIATION|carbon ion radiation therapy|"CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks.~Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted."
214660662|NCT03277196|DRUG|IVA|Granules for oral administration.
214660663|NCT04183101|DRUG|Aliskiren|Patients will be randomized to start treatment with aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight. After 6 months switch to enalapril 2.5-20 mg daily and continue with that 2.5 years.
214660664|NCT04183101|DRUG|Enalapril|Patients will be randomized to start with enalapril 2.5-20 mg daily depending on weight. After 6 months switch to aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight and continue with this treatment for 2.5 years.
214660665|NCT02950623|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
214660666|NCT02950623|OTHER|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
214660667|NCT02912871|OTHER|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
214660668|NCT01166269|BIOLOGICAL|phleum pratense (grass-allergen)|6 injections of grass-allergen. Every dose will be 1000 SQ-U.
214660669|NCT01166269|BIOLOGICAL|phleum pratense (grass allergen)|3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
214660670|NCT01166269|OTHER|physiological saline|6 injections of placebo (physiological saline)in a lymph node.
214660671|NCT05659121|DEVICE|robotic exoskeleton training|robotic exoskeleton training using EksoGT will be incorporated into subject's conventional physiotherapy training.
214660672|NCT02094846|BEHAVIORAL|Voice messages|Voice messages reinforced with self-efficacy
214660673|NCT01213810|BIOLOGICAL|Zostavax|Biological/Vaccine
214660674|NCT01512524|OTHER|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
214660675|NCT06443073|OTHER|Patient-reported outcomes for speech disorders: positive|The Communicative Participation Item Bank (CPIB) aims to assess communication participation in all kinds of communication disorders. The Voice Self-Efficacy Questionnaire (VSEQ) monitors self-efficacy in individuals with self-declared voice problems before and after interventions. The Vocal Fatigue Handicap Questionnaire (VFHQ) and the Vocal Fatigue Index (VFI) aim at reflecting vocal fatigue. Both have been adapted to reflect purely positive wording.
214660676|NCT01225263|DRUG|Simvastatin|simvastatin, 20 mg, twice daily for 6 months
214290155|NCT04341454|DRUG|DWP14012 X mg|DWP14012 X mg, tablet, orally, once daily for 2 weeks
214290156|NCT04341454|DRUG|DWP14012 X mg placebo|DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks
214290157|NCT04341454|DRUG|DWP14012 Y mg|DWP14012 Y mg, tablet, orally, twice daily for 2 weeks
214290158|NCT04341454|DRUG|DWP14012 Y mg placebo|DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks
214290159|NCT01324999|DRUG|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
214660677|NCT01225263|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3, 1000 IU, twice daily for 6 months
214660678|NCT01225263|OTHER|Placebo|Two placebo pills, taken twice daily for 6 months
214660679|NCT06247150|BIOLOGICAL|Additional blood sample|The procedure will consist of an additional blood sample for 3 ETDA tubes collection (NGS analysis) and citrate tube collection (NETose analysis)
214660680|NCT06247150|BIOLOGICAL|cGVHD target tissue biopsy|For chronic GVH patients only, cGVHD target tissue biopsy
214660681|NCT03804541|DRUG|Ensartinib|A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
214848787|NCT06535464|DEVICE|Hypotension Prediction Index|Fluid management guided by Hypotension Prediction Index
214660682|NCT05349955|OTHER|Intensive guideline algorithm implementation|Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C\<7%, control blood pressure \<130/80mmHg， LDL-c\<1.8mmol/L at very high CV risk patients or \<2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
214660683|NCT05349955|OTHER|Conventional guideline algorithm implementation|The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.
214660684|NCT01380899|PROCEDURE|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
214660685|NCT01568216|DRUG|AMG 747|Three dose levels once-daily oral administration
214660686|NCT01568216|DRUG|Placebo|Once-daily oral administration
214660687|NCT03088501|BEHAVIORAL|Interactive voice response system|IVR allows the pregnant women, their family members to interact with a computer system using a telephone.Through IVR, women receive a 2-3 minute call that reminds them of lab test, their next follow-up visit and also provides information on child care attendance, breastfeeding, introduction of solid foods, motor development, and sleep.
214660688|NCT03088501|BEHAVIORAL|Mother and baby affairs workshop|Mother and baby affairs workshop will involve antenatal workshop and counseling for parents. The intervention will involve brief talk by health professionals, quiz activities, role-plays on personal hygiene, nutritional food, institutional delivery, precautions at the time of delivery, caring for the baby, feeding of colostrum, homemade baby food, immunization, and family planning measures.
214660689|NCT00648986|DRUG|Tazorac|All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
214660690|NCT06236217|OTHER|Carotid Ultrasound|The carotid artery corrected flow time (FTc) was used in patients to optimize the volume status before performing spinal anesthesia.
214660691|NCT06236217|OTHER|Electrical cardiometry|Stroke volume variation (SVV) measured by electrical cardiometry (EC) was used to optimize the volume status before performing spinal anesthesia.
214660692|NCT02502929|BEHAVIORAL|Social Services|
214660693|NCT02502929|BEHAVIORAL|Lifestyle|
214660694|NCT02502929|BEHAVIORAL|Lifestyle Plus Medication Therapy Management|
214660695|NCT06246682|PROCEDURE|Transcanal Endoscopic removal of atticoantral cholesteatoma|removal of the cholesteatoma presented in the atticoantral region by otoendoscope
214660696|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214660697|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
214660698|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 2|Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.
214660699|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
214848788|NCT06535464|DEVICE|No Hypotension Prediction Index|Fluid management not guided by Hypotension Prediction Index
214660700|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.2 Usage|Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.
214290160|NCT03131765|BIOLOGICAL|YS-0N-001|Cancer vaccine
214660701|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 3|Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.
214660702|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
214660703|NCT04410302|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue, blood, saliva, and urine samples
214660704|NCT00015548|DRUG|Olanzapine|
214660705|NCT00015548|DRUG|Quetiapine|
214660706|NCT00015548|DRUG|Risperidone|
214660707|NCT00015548|DRUG|Citalopram|
214660708|NCT04909567|BEHAVIORAL|Optimisation|Defined optimisation
214660709|NCT05178537|OTHER|AAS users|no intervention
214660710|NCT04662593|BEHAVIORAL|Whole Health Program|A mind-body-spirit intervention to improve health and well-being including weight loss.
214660711|NCT05819229|DRUG|Oral antibiotic therapy|"Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days."
214660712|NCT02351115|DRUG|A=Placebo|
214660713|NCT02351115|DRUG|B=Inhaled Alprazolam 0.5 mg|
214660714|NCT02351115|DRUG|C=Inhaled Alprazolam 1 m|
214660715|NCT02351115|DRUG|D= Inhaled Alprazolam 2 mg|
214660716|NCT02351115|DRUG|E=Placebo|
214660717|NCT06329388|DIETARY_SUPPLEMENT|TruHeight Growth Protein Shake|Participants will be administered two scoops of TruHeight Growth Protein Shake, mixed with 12-16 fluid ounces of water, once daily, five times per week for six months. The supplement is intended to support growth patterns in children by providing essential nutrients that contribute to bone development and overall growth.
214848789|NCT03063216|PROCEDURE|intraocular lens implantation|1）Pediatric cataract patients with intraocular lens implantation and those without intraocular lens implantation；2）Traumatic cataract patients with intraocular lens implantation and those without intraocular lens implantation
214660718|NCT00827489|DRUG|HTC-867|
214660719|NCT00827489|OTHER|Placebo|
214848790|NCT00263627|BIOLOGICAL|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
214660720|NCT03062501|DRUG|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
214660721|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
214660722|NCT02890719|DRUG|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
214660723|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
214660724|NCT02890719|DRUG|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
214660725|NCT02890719|DRUG|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
214660726|NCT03494647|DEVICE|Cheetah Heel Cup|The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.
214660727|NCT03494647|DEVICE|The X Brace|The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
214660728|NCT00651040|DRUG|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
214660729|NCT00651040|DRUG|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
214660730|NCT06393283|BEHAVIORAL|Diaphragm Training|Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
214660731|NCT00470496|DRUG|HPPH|Given IV
214660732|NCT00470496|DRUG|photodynamic therapy|Undergo laser light exposure
214660733|NCT00470496|PROCEDURE|conventional surgery|Undergo surgery
214660734|NCT02585557|OTHER|Primary Care Practice Support|The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
214660735|NCT04271163|DEVICE|MemorEM|The MemorEM device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range to the entire forebrain, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. Everyday for the 12M treatment period, the subject's caregiver will administer one or two 1-hour treatments (two daily treatments during the first 2M period).
214660736|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
214660737|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
214660738|NCT05616143|DEVICE|Isthmus Logic|Patient implanted with Isthmus Logic stent for the treatment of peripheral iliac artery disease
214660739|NCT03771872|DEVICE|Virtual Prism Adaptation Therapy|Hand trajectory will deviate to the right side in the virtual reality.
214660740|NCT03771872|DEVICE|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
214660741|NCT00503399|DRUG|Teriparatide|20 µg/day sc for 18 months
214660742|NCT00503399|DRUG|Risedronate|35 mg/week po for 18 months
214660743|NCT01676961|BIOLOGICAL|romiplostim|Given SC
214660744|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
214660745|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
214660746|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
214660747|NCT02224950|DEVICE|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
214660748|NCT02224950|OTHER|Non-medicated Emollient plus Cotton Sleeve|
214660749|NCT02224950|OTHER|Placebo Sleeve|
214660750|NCT01811914|OTHER|intraoperative TTE|
214660751|NCT04237493|DRUG|Metformin and Glimepiride (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 1.5 or 3 mg \[75% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
214660752|NCT04237493|DRUG|Metformin and Vildagliptin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; OD \[with Ifṭār\])"
214660753|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 9-33 units \[75% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
214660754|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 6-39 units (75% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 15-33 units before Ifṭār and 6-18 units before Suḥūr \[75% of the pre-Ramadan doses\])"
214660755|NCT04237493|DRUG|Metformin and Glimepiride (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 2 or 4 mg \[100% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
214660756|NCT04237493|DRUG|Metformin and Vildagliptin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; BID \[with Ifṭār and with Suḥūr\]\])"
214660757|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 11-44 units \[100% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
214660758|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 8-52 units (100% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 12-40 units before Ifṭār and 7-28 units before Suḥūr \[100% of the pre-Ramadan doses\])"
214660759|NCT02543242|DEVICE|InToneTM (InControl Medical, LLC) - Medical Device|
214660760|NCT01636557|DRUG|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
214660761|NCT01636557|DRUG|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
214660762|NCT01636557|DRUG|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
214660763|NCT01636557|DRUG|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
214660764|NCT01636557|DRUG|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
214660765|NCT01636557|DRUG|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
214660766|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
214660767|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
214660768|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
214660769|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
214660770|NCT00195650|BIOLOGICAL|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
214660771|NCT03375320|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214660772|NCT03375320|DRUG|Cabozantinib S-malate|Given PO
214660773|NCT03375320|PROCEDURE|Computed Tomography|Undergo CT
214660774|NCT03375320|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214660775|NCT03375320|OTHER|Placebo Administration|Given PO
214660776|NCT03375320|OTHER|Quality-of-Life Assessment|Ancillary studies
214660777|NCT03375320|PROCEDURE|X-Ray Imaging|Undergo x-ray
214660778|NCT01128387|DRUG|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
214660779|NCT06464211|BEHAVIORAL|Cognitive Behavioral Model-Based Family Counseling Program|A Cognitive Behavioral Model-Based Family Counseling Program is a therapeutic approach that focuses on identifying and changing negative thought patterns and behaviors within the family unit, using principles of cognitive-behavioral therapy to improve communication, resolve conflicts, and enhance overall family functioning.
214660780|NCT02898012|DRUG|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
214660781|NCT02898012|DRUG|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage \> grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
214660782|NCT04446208|PROCEDURE|Endoscopy|Endoscopic treatment will consist in placement of a metal stent in a patient with early fistula (\< 15 days) and/or a large fistula orifice, and no abscess, or double pigtail plastic stents if the fistula is older than 15 days and the orifice is small.
214660783|NCT03069911|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
214660784|NCT03069911|BIOLOGICAL|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
214660785|NCT04957173|OTHER|Lifestyle intervention|"The intervention includes a total of 17 virtual meetings and aims to achieve a weight loss of 0.8 to 1% of the initial weight per week.~This will include 3 successive phases:~1. A significant calorie restriction (A minimum deficit of 800 kcal / day of their daily energy expenditure) for a period of 4 weeks;~2. A moderate calorie restriction (minimum deficit of 500 kcal / day of their daily energy expenditure) for a period of 4 weeks;~3. A maintenance phase of weight loss for 16 weeks.~4. An optional phase of monthly follow-ups for a period of 3 months (no intervention)"
214660786|NCT02635204|DRUG|DFD06 Cream|Twice daily topical application for 14 days.
214660787|NCT02635204|DRUG|Vehicle Cream|Twice daily topical application for 14 days.
214660788|NCT00962715|BIOLOGICAL|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
214660789|NCT00962715|DRUG|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
214660790|NCT00962715|DRUG|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
214660791|NCT03534037|DRUG|Febuxostat 40 mg|Febuxostat 40 mg orally per day plus dietary control only
214660792|NCT03534037|DRUG|Benzbromarone 50mg|Benzbromarone 50mg orally per day plus dietary control only
214660793|NCT03534037|OTHER|Control|Dietary control only
214660794|NCT01021111|DEVICE|Activity Training with Feedback|The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
214660795|NCT03853421|DRUG|Sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
214660796|NCT00858832|DRUG|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
214660797|NCT01787071|OTHER|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
214660798|NCT01535235|DRUG|Lisinopril|Lisinopril 20mg QD x 24 weeks
214660799|NCT01535235|DRUG|Placebo|Placebo QD x24wks
214660800|NCT01343615|PROCEDURE|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
214660801|NCT01343615|PROCEDURE|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
214660802|NCT03717740|DRUG|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
214660803|NCT03717740|DRUG|Placebo|Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
214660804|NCT03475225|DRUG|Cholecalciferol|Cholecalciferol delivery
214660805|NCT03475225|DRUG|Placebo Oral|manufactured to mimic Cholecalciferol
214660806|NCT04800380|OTHER|Edpuzzle interactive videos|The effectiveness of the Edpuzzle application will be evaluated in developing the metric and drug dose calculation skills of first year nursing students.
214660807|NCT00416533|DRUG|docetaxel|
214660808|NCT00416533|DRUG|doxorubicin hydrochloride|
214660809|NCT00416533|DRUG|prednisone|
214660810|NCT03944837|OTHER|Oxygen gas|Transient maternal oxygen administration during echocardiographic and MRI imaging
214660811|NCT00389207|DRUG|nevirapine bid|nevirapine twice daily
214660812|NCT00389207|DRUG|nevirapine qd|nevirapine once daily
214660813|NCT00389207|DRUG|atazanavir|atazanavir once daily
214660814|NCT06349629|DEVICE|3D printed WE43 magnesium alloy|This 3D printed WE43 magnesium alloy has porous structure and suitable mechanical strength, can be stable in the bone support, and gradually degrade to promote bone healing.
214660815|NCT03140826|DRUG|meropenem|Antibiotics to treat infections.
214660816|NCT03973814|DEVICE|Thermax Blood Warmer|Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
214660817|NCT04265664|BEHAVIORAL|Telerehabilitation|Participants in the telerehabilitation program will receive a graded exercise and self-management intervention. This program will be delivered in a ≤2:1 participant:therapist ratio. Each participant grouping will receive two 60-90 minutes telerehabilitation sessions per week for 4 weeks focusing on lower extremity recovery (total 8-12 hours), with a therapist trained in the use of technology for the provision of rehabilitation. Participants will also be asked to complete at least one additional independent self-managed exercise session each week. This independent exercise session will include selected exercises from the telerehabilitation sessions that will be safe to perform without therapist oversight, and jointly agreed upon by the participant and therapist.
214660818|NCT05461443|DIETARY_SUPPLEMENT|Probiotic|
214660819|NCT02602067|COMBINATION_PRODUCT|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
214660820|NCT05316896|OTHER|Internal Perturbation|"* Raising and lowering arms 90 degrees forward and sideways with eyes open and closed.~* In tandem stance with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* While standing on one leg with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* Step forward and backward with right and left foot alternately~* Take a step back and step back alternately with right and left foot~* Put the right foot on the step and take it back, then do the same with the left foot and ask the patient to do it quickly.~* First step on the step with the right foot and put the left foot next to it, then step down with the right foot and take the left foot with it, repeat the same with the left foot and ask the patient to do this. rapidly.~* Normal gait, sideways gait, tandem gait, backward gait, raising and lowering the arms forward and sideways 90 degrees, respectively, during back-to-back tandem gait."
214660821|NCT05316896|OTHER|Eksternal Perturbation|"* Front, side, and rear loading and release, pushing and pulling while standing with eyes open and closed~* Front, side and rear loading and release, pushing and pulling while standing in tandem with eyes open and closed~* Loading and releasing from the front, sides and back, pushing and pulling while turning the head left and right while standing~* Front, side and rear loading and release, pushing and pulling while standing up and down with eyes open and closed~* Front, side, and rear loading and release, pushing and pulling while standing on one leg with eyes open and closed~* Holding the ball thrown by physiotherapist~* Kicking a ball thrown by physiotherapist~* Holding the ball thrown by the physiotherapist while standing in tandem, walking, walking sideways, walking in tandem, walking backwards."
214660822|NCT04626830|OTHER|Mobile Application Intervention|Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
214660823|NCT00515125|BEHAVIORAL|Dietary Advice|Dietary Advice sheet
214660824|NCT00515125|DIETARY_SUPPLEMENT|Oral Nutritional Supplements (Fortisip)|"These products are classified as non-medicinal, borderline substances, foods for special medical purposes.~A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period."
214660825|NCT05258227|OTHER|Conservational Physical Therapy and Proprioceptive Strength Training|The proprioceptive training cycle consist of squats, single leg stand, slide steps , forward and backward step, toe walking , heel walking , side sway etc.
214660826|NCT05258227|OTHER|Conservational Physical Therapy and Core Instability Strength Training|Core stability is essential part of lower limb rehabilitation; it is also known protocol which includes group of exercises in both standing and sitting improving biomechanics and functional performance of the body.
214660827|NCT03325764|OTHER|functional assessment|assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
214660828|NCT04824989|BEHAVIORAL|Sleep Health in Preschoolers (SHIP)|SHIP is an 8 session home visiting intervention to reduce child sleep problems using a framework that draws from motivational interviewing and social cognitive theory, and effectively improves sleep timing, duration, and quality. Following ecological assessment of child sleep and sleep routines, feedback is provided on family strengths and challenges in the child sleep domain, with motivational interviewing to increase parent knowledge of sleep, correct misperceptions, and raise outcomes expectations. The remaining sessions are targeted modules that give tailored feedback and education, and coach the parent in setting manageable goals, identifying action steps, anticipating barriers, and supporting positive behaviors. Targets: bedtime scheduling, consistency, and routines; media use, independent sleep onset, nightmares and fears, night wakings, and early waking; sleep location, nap issues, engaging other caregivers.
214660829|NCT04824989|BEHAVIORAL|Family Check-Up (FCU)|FCU is an 8 session home visiting intervention to reduce behavior problems for children through improved parenting. Over 30 years of research establishes its efficacy in reducing behavioral and emotional problems, including in low income toddlers. Following ecological assessment of behavior management and child behavior, family receives feedback on family strengths and challenges within the behavioral domain via a motivational interviewing approach. The remaining sessions are targeted modules drawn from the Everyday Parenting curriculum, individualized based on parent goals and identified challenge areas. Each session begins by establishing a collaborative skill set, involves teaching the rationale for a skill, teaching and modeling effective use of the skill, and then role play and experiential practice to coach the parent to success. Targets can include Positive Behavior Support, Limit Setting and Monitoring, Family Routines, Communication, and Problem Solving.
214660830|NCT04824989|BEHAVIORAL|Oral Health, Child Safety, and Environmental Health Intervention (Active Control)|This intervention serves as an active control condition to ensure that observed effects are due to the intervention content, rather than to study processes, staff attention, or general support and problem solving. The intervention is designed to be comparable to SHIP and FCU in intensity, personal contact, session structure and approach, but focused on Oral Health, Child Safety, and Environmental Health, domains which should not immediately affect study outcomes.
214660831|NCT01496664|PROCEDURE|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
214660832|NCT00104130|DRUG|KOS-862|
214660833|NCT01916577|DRUG|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
214660834|NCT04516304|DIETARY_SUPPLEMENT|Placebo|4 tablets/d (2 in the morning and 2 in the evening)
214660835|NCT04516304|DIETARY_SUPPLEMENT|S-equol|4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
214660836|NCT00326820|DRUG|ibandronate sodium|
214660837|NCT00326820|DRUG|zoledronic acid|
214660838|NCT00326820|DRUG|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
214660839|NCT04737044|OTHER|Study 1: MRBS|MRBS as added sugar based on their habitual diet
214660840|NCT04737044|OTHER|Study 2: White sugar & education module|White sugar for daily usage (\<10% daily energy intake)
214660841|NCT04737044|OTHER|Study 2: MRBS & education module|MRBS for daily usage (\<10% daily energy intake)
214660842|NCT00089557|DRUG|Capsaicin Dermal Patch|
214660843|NCT00420030|DRUG|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
214660844|NCT03456492|DIAGNOSTIC_TEST|serum sodium|Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.
214848791|NCT00263627|OTHER|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
214848792|NCT06077929|OTHER|No intervention done|No interventions done
214848793|NCT05633082|DEVICE|Lens 1 (omafilcon B)|Toric daily wear contact lens for 15 minutes
214848794|NCT05633082|DEVICE|Lens 2 (fanfilcon A)|Toric daily wear contact lens for 15 minutes
214848795|NCT02349074|PROCEDURE|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
214848796|NCT04479748|DRUG|Dexamethasone|Treatment of pain and inflammation following ophthalmic surgery
214848797|NCT04479748|DRUG|Prednisolone Acetate 1% Oph Susp|Topical steroid
214848798|NCT02674386|DRUG|Investigational Medical Product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
214660845|NCT03104582|PROCEDURE|ERCP Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
214660846|NCT03104582|PROCEDURE|PTBD Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
214660847|NCT05157425|DIETARY_SUPPLEMENT|Food Supplement|Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
214848799|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution|blood gas analysis of blood on different sample points and dialysis fluid
214848800|NCT03314363|DEVICE|filter replacement|Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.
214848801|NCT03314363|DEVICE|IC|monitor patients during the whole study period with indirect calorimetry
214848802|NCT03314363|DRUG|NaCl predilution|Replace citrate predilution with NaCl
214848803|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under NaCl predilution|repeat blood gas analysis of blood on different sample points and dialysis fluid
214848804|NCT03314363|DRUG|double ultrafiltration|double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
214848805|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution and double ultrafiltration rate|repeat blood gas analysis of blood on different sample points and dialysis fluid
214660848|NCT05157425|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
214660849|NCT00312520|DRUG|prednisolone|
214660850|NCT00312520|DRUG|methylprednisolone|
214660851|NCT01588821|DRUG|Cabozantinib|60 mg daily by mouth
214660852|NCT02413658|DRUG|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
214660853|NCT02413658|DRUG|Sugar solution|
214660854|NCT01989663|DRUG|1% vaginally applied tenofovir gel|
214660855|NCT01989663|DRUG|Tenofovir film- 10mg|
214660856|NCT01989663|DRUG|Tenofovir Film-40 mg|
214660857|NCT01989663|OTHER|HEC Placebo Gel|
214660858|NCT01989663|OTHER|Placebo Vaginal Film|
214660859|NCT01744561|BEHAVIORAL|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
214660860|NCT02093611|DIETARY_SUPPLEMENT|Placebo|
214848806|NCT03314363|DIETARY_SUPPLEMENT|pause and restart nutritional therapy|pause parenteral and enteral nutrition before indirect calorimetry is performed. and restart after first blood analysis for vitamine status
214848807|NCT03314363|DIAGNOSTIC_TEST|evolution of vitamin and trace elements|blood analysis for vitamin and trace elements. Perform this blood analysis after restart of CRRT but before restart of nutritional therapy, 30 minutes after restart of nutritional therapy and 24h after restart of nutritional therapy.
214848808|NCT00877617|BEHAVIORAL|QOL Questionnaire|Mailed survey.
214660861|NCT02093611|DIETARY_SUPPLEMENT|ATP|400 mg of ATP
214660862|NCT01159262|DRUG|Midazolam|Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
214660863|NCT01159262|DRUG|Fentanyl/Morphine|Per package insert, N-PASS scores and investigator discretion.
214660864|NCT01159262|DRUG|Dexmedetomidine|
214660865|NCT04722978|DRUG|Gemcitabine and carboplatin plus antibiotic (moxifloxacin)|Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)
214660866|NCT04722978|DRUG|Gemcitabine combined with carboplatin plus placebo|Standard chemotherapy (gemcitabine and carboplatin) plus placebo
214660867|NCT03124043|OTHER|Livongo for Diabetes program|See description in arm/group description.
214660868|NCT05696938|DIETARY_SUPPLEMENT|Wonderlab Nicotinamide Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
214660869|NCT05696938|DIETARY_SUPPLEMENT|Ordinary Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
214660870|NCT04154098|DEVICE|Scapula orthosis assistance|Participants are elevating their arm while their scapula is assisted by the scapula orthosis
214660871|NCT04154098|PROCEDURE|Manual scapula assistance|Participants are elevating their arm while their scapula is assisted by a trained personnel
214660872|NCT04154098|OTHER|No assistance|Participants are elevating their arm without being assisted
214660873|NCT04154098|OTHER|Functional Test|Participants perform a functional test once without (NO) and once with (OA) the orthosis
214660874|NCT05288465|DRUG|Cerebrolysin|Patients prescribed for Cerebrolysin treatment due neurological disease are invited to donate a scalp punch biopsy prior to and after completing the prescribed treatment.
214660875|NCT00666744|OTHER|Family Mediated Exercise Therapy|35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
214660876|NCT05282940|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Investigational Medicinal Product
214660877|NCT05282940|DRUG|Microgynon CD|Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
214660878|NCT02213718|DRUG|Desflurane|desflurane (7%-8% end-tidal concentration)
214660879|NCT02213718|DRUG|propofol|propofol (TCI:3.5-4.0μg/min)
214660880|NCT02213718|DRUG|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
214660881|NCT06228157|BEHAVIORAL|Routine therapy|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
214660882|NCT06228157|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214660883|NCT02696083|DEVICE|Provant Therapy System|
214660884|NCT00251069|DRUG|Glucosamine sulphate|
214660885|NCT04657848|PROCEDURE|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
214660886|NCT01664026|BEHAVIORAL|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
214660887|NCT01664026|BEHAVIORAL|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
214660888|NCT02522819|DEVICE|CPAP|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
214660889|NCT02970773|DRUG|Rivaroxaban Oral Tablet|oral application of Xarelto
214660890|NCT03820492|DIAGNOSTIC_TEST|OCT, FFR, CTA and FFRCT|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
214660891|NCT01497392|DRUG|dovitinib lactate|Given PO
214660892|NCT01497392|DRUG|gemcitabine hydrochloride|Given IV
214660893|NCT01497392|DRUG|capecitabine|Given PO
214660894|NCT01497392|OTHER|laboratory biomarker analysis|Correlative studies
214660895|NCT01497392|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214660896|NCT01497392|OTHER|pharmacological study|Correlative studies
214660897|NCT00294125|DRUG|Flavocoxid|Daily flavocoxid for 12 weeks
214660898|NCT00294125|DRUG|Placebo|Daily placebo for 12 weeks
214660899|NCT02226354|DIETARY_SUPPLEMENT|Ahiflower oil|9.73 ml per day for 28 days
214660900|NCT02226354|DIETARY_SUPPLEMENT|Flaxseed oil|9.73ml per day for 28 days
214660901|NCT05705726|DEVICE|ultrasound guided facia iliaca block|Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .
214660902|NCT05705726|DRUG|Intravenous drug|Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
214660903|NCT00635622|DRUG|LACTIN-V|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10\^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
214660904|NCT00635622|DRUG|Placebo control substance|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
214660905|NCT05026775|BEHAVIORAL|Initial Medication Adherence (IMA)|"The IMA intervention is a shared-decision making intervention that promotes health literacy and patient participation in the decision making process during the recommendation and prescription of a new drug for the management of a cardiovascular disease and diabetes.~The IMA intervention has four main components: training for healthcare professionals (general practitioners (GP), nurses and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; intervention decision aids (leaflets and website); implementation of the IMA intervention during the GP's consultation; and information support provided by the nurses and community pharmacists that will use the intervention decision aids to explore the patients's doubts and harmonise and standardise the discourse between primary healthcare professionals."
214660906|NCT05026775|OTHER|Usual care|Health professionals in the usual care group will prescribe medication and provide information as usual.
214660907|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by suprasternal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
214660908|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by transoesophageal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
214660909|NCT00222911|DEVICE|dorsiflexion night splint|
214660910|NCT00222911|DEVICE|medial arch support|
214660911|NCT02085811|OTHER|radiography standard|
214660912|NCT00584974|DRUG|SEP-225289|0.5 mg SEP-225289
214660913|NCT00584974|DRUG|SEP-225289|2.0 mg SEP-225289
214660914|NCT00584974|DRUG|Venlafaxine|150 mg Venlafaxine
214660915|NCT00584974|DRUG|placebo|Placebo
214660916|NCT03668132|OTHER|ischemic brain damage|Have or not have the ischemic brain damage and the location of the damage
214660917|NCT00371319|DRUG|tacrolimus|0.06-0.1 mg/kg/day
214660918|NCT00371319|DRUG|mycophenolate mofetil|2-3 gm/day
214660919|NCT05844384|DEVICE|Nanodropper|Nanodropper delivers 1/5 of eye drop volume compared to regular droppers
214660920|NCT05844384|DEVICE|Regular dropper|Delivers full eye drop volume
214660921|NCT02421874|BEHAVIORAL|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
214660922|NCT02421874|BEHAVIORAL|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
214660923|NCT06203431|DRUG|ET-26|freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
214660924|NCT06203431|DRUG|Etomidate Injectable Emulsion|lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
214660925|NCT05241587|OTHER|Gum Group:|"Gum Group:~Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010)."
214660926|NCT05241587|OTHER|Mouth Spray Group:|"Mouth Spray Group:~The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request."
214660927|NCT04067336|DRUG|Ziftomenib|Oral administration
214660928|NCT04067336|DRUG|Midazolam|Oral administration
214660929|NCT04067336|DRUG|Itraconazole|Oral administration
214660930|NCT03394495|OTHER|BCE Combination group|The combination intervention programme consists of a weekly exercise training sessions and 6 sessions of Behavioral Change Enhancement (BCE) programme.
214660931|NCT03202654|OTHER|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
214660932|NCT03202654|OTHER|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
214660933|NCT01794780|DRUG|LABA based treatment: indacaterol|LABA based treatment: indacaterol
214660934|NCT01794780|DRUG|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
214660935|NCT01794780|DRUG|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
214660936|NCT01794780|DRUG|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
214660937|NCT01794780|DRUG|theophylline based treatment|theophylline based treatment
214660938|NCT01794780|DRUG|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
214660939|NCT05077514|BEHAVIORAL|Experimental: Cognitive Behavior Therapy|Participants assigned to Group A were asked to participate in a talking session with a psychologist regarding thoughts about treatment. This session is designed to explore thoughts about behavioral health therapy for suicidality. The session was administered by phone, initially and again one month later. Participants discussed current functioning and their thoughts about seeking help with the goal of modifying thoughts about treatment. This phone session lasted approximately 45 to 60 minutes.
214660940|NCT05077514|BEHAVIORAL|Active comparator: National Crisis Line|Participants assigned to Group B received information about the VA's National Crisis Line.
214660941|NCT04814537|DRUG|Bupivacaine Hydrochloride|Local Anesthetic Agent
214660942|NCT03545243|DRUG|Pantoprazole 40mg|Peroral Pantoprazole 40mg once daily during 28 days
214660943|NCT03545243|OTHER|PPI withdrawal|PPI withdrawal for 8 weeks
214660944|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
214660945|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
214660946|NCT04740229|BEHAVIORAL|Yoga|Moderate-intensity flow-based yoga movements, breathing, and relaxation for 50 minutes, 3 times per week, for 8 weeks
214660947|NCT00668005|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
214660948|NCT00668005|DRUG|Placebo|Matching placebo
214660949|NCT03120143|OTHER|Small-sided ball game training with high protein intake|In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise
214660950|NCT03120143|OTHER|Small-sided ball game training with low protein intake|n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
214660951|NCT05400460|PROCEDURE|Anatomical single-bundle reconstruction（ASBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the ASBR group to receive anatomic single-bundle reconstruction.We used hamstring as an autograft in the operation, and we chose the anatomical footprint of the anterior cruciate ligament for the positioning of the bone tunnel.Arthroscopic ASB ACL reconstruction was conducted with AMP technique.
214660952|NCT05400460|PROCEDURE|Double-bundle reconstruction （DBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the DBR group to receive double bundle reconstruction.The hamstring autograft is still used for double-bundle reconstruction. The surgical approach is to treat the native ligaments as anteromedial bundles and posterolateral bundles and restore the structure of the two bundles of ligaments in the process of a
214660953|NCT05400460|PROCEDURE|Central axial single-bundle reconstruction（CASBR group）|"406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to CASBR group.Arthroscopic ASB ACL reconstruction was conducted with transtibial technique and using Hamstring as autograft.Single-bundle reconstruction is used in CASBR reconstruction surgery.~The footprint of the implant on the lateral femoral condyle was chosen to be the location of the AMB bone canal in DB reconstruction surgery while the footprint of the implant on the tibial plateau was chosen to be the location of the bone canal of the PLB in DB reconstruction surgery."
214660954|NCT05400460|OTHER|rehabilitation training protocol|The rehabilitation program for all patients followed a standardized Process. The first day after surgery, quadriceps sets, straight-leg raises, and prone hangs were initiated. All of the patients were allowed to walk with crutches and braces but with no weightbearing. The range of motion (ROM) progressed from 0 to 90 degrees 3 to 7 days postoperatively and reached 115 degrees within fourth week. Closed kinetic chain exercises and full weightbearing were started in the sixth week. Patients progressed to running without braces at 4 to 6 months.
214660955|NCT05400460|OTHER|Educate patients on return to sports and the importance of quadriceps strength|"Patients were interviewed by telephone preoperatively, 6 months postoperatively, and 1 year postoperatively to ask about Tegner scores and to encourage reasonable return to sports from 6 months postoperatively.~Inform patients of the possibility of osteoarthritis in patients undergoing ACL reconstruction preoperatively, 6 months postoperatively, and 1 year postoperatively in telephone interviews.Tell the patient that return to sports and quadriceps strength is a must if the knee cartilage damage is to improve."
214660956|NCT04673383|DRUG|SPL026|Intravenous solution
214660957|NCT04673383|DRUG|Placebo|SPL026-matched placebo
214660958|NCT05215522|DEVICE|The BCI-FES Intervention|To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
214660959|NCT01962142|OTHER|Assessment of activity capacities|
214848809|NCT01692886|BIOLOGICAL|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
214660960|NCT00615537|PROCEDURE|Laser Ablation of Thyroid Nodule|Laser ablation using a laser generator, disposable fiberoptic laser fiber, cooling catheter and pump, will be performed under conscious sedation. Ultrasound will be used to localize masses. Local anesthesia will be administered both intradermally and subcutaneously. The laser applicator will be placed into the mass and laser energy will be delivered at 15W for 30-120 seconds. Real-time ultrasound monitoring of the ablation front will be used to ensure complete treatment of the target lesion. In larger masses applicators may be placed of the applicator into multiple locations. The number of locations will be determined by the treatment team, and based on lesion morphology, size, location, and accessibility.
214660961|NCT05387655|BIOLOGICAL|BCG|BCG vaccination
214660962|NCT05387655|BIOLOGICAL|Placebo vaccine|Placebo vaccination
214660963|NCT04763525|BEHAVIORAL|Pythagorean Self-Awareness Intervention(PSAI)|The PSAI is a mental, stress-management technique that promotes self-awareness, cognitive reconstruction and self-improvement based on the Golden Verses moral framework of the ancient Greek philosopher Pythagoras. The individual must practice the technique twice daily( at bed-time and in the morning, every day, at home) and through a 3-stage internal dialogue (recall of daily events, inspection of related thoughts and emotions and self-appraisal)is encouraged to detect wrong choices and unhealthy behaviours and initiate self-correction towards a healthier lifestyle.
214660964|NCT02626377|BEHAVIORAL|Support provided by social worker|Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.
214660965|NCT02626377|OTHER|Information booklet receipt|Caregivers will only receive an information booklet (which informs about existing structures and actions)
214660966|NCT01953315|BIOLOGICAL|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
214660967|NCT03025581|OTHER|Nipple stimulation|For the intervention group participants will be instructed to gently massage alternate breasts, especially around the nipples for 15 minutes every 6 hours until the appearance of regular contractions but not more than 24 hours. Moist cloth or lubricating or moisturizing cream will be offered to facilitate the procedure according to individual preferences. In the control group all participants will be asked to avoid any breast stimulation during the study period.
214660968|NCT01261676|OTHER|Implementation aids|An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)
214660969|NCT03921112|DEVICE|lung ultrasound|bedside lung ultrasound will be done for patients
214660970|NCT03921112|OTHER|routine tools|chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
214660971|NCT05931770|PROCEDURE|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by the child. will be determined by children preference
214660972|NCT05931770|PROCEDURE|Parent (mother or father) selection according to parents' preference|Accompanying parentwho will accompany during the perioperative period will be determined by the parents. to be determined by
214660973|NCT06279923|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
214660974|NCT06197607|OTHER|theraputty hand exercises|Theraputty hand exercises will be done in following manners: Finger flexion, Metacarpophalangeal joint flexion, Interphalangeal joint flexion, Finger grip strengthening, Finger abduction and Rolling putty into ball and pinching it between, thumbs and finger with both the hands. There will be 20 repetitions with one set of each
214660975|NCT06197607|OTHER|sensory stimulation|Sensory Stimulations (30 min) will be given following forms; All and single joint shaking, Multivariate sensory stimulations, Skin stretch in the muscular region, Fast stretch of the upper limb joints in different directions of motor action, brushing on the large muscles of arm and forearm, brushing on the fingers, Circular massage of the thenar and hypothenar area and pressing the tip of fingers.
214660976|NCT06456710|BEHAVIORAL|Conventional IBS Health Education|Patients were provided with IBS related knowledge (e.g., the pathogenesis of IBS and the reasons affecting the treatment effect), exercise guidance, drug guidance and dietary management precautions; and timely answers to patients' clinical problems and psychological support.
214660977|NCT06456710|BEHAVIORAL|Based on ACT Theory of Psychological Intervention|"On the basis of the control group, the stigma intervention program of college students with IBS based on ACT theory was implemented. The duration of intervention was 40 to 50 minutes for 6 times, once a week for 6 weeks.~Week1: established relationships; introduced the core contents of ACT, the treatment process, and the effects of application.~Week2: encouraged to express negative emotions and behaviors; made patients accept the disease.~Week3: explained the importance of coping with negative emotions; instructed to separate negative thoughts from reality through cognitive dissociation exercises.~Week4: changed the concept of self and actively accepted IBS; guided to focus on the current life and true self.~Week5: introduced the values in ACT; helped clarify the values; guided to build confidence and focused on the core values.~Week6: introduced the importance of commitment to action; developed goals and plans together; encouraged to strengthen the use of ACT."
214660978|NCT01104831|DEVICE|Cryotherapy|cooled sleeve placed over fracture site.
214660979|NCT01104831|DEVICE|Room temperature cuff|sleeve with room temperature water placed over fracture site.
215033537|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (Imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
214660980|NCT03007277|OTHER|PANJO|PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
214660981|NCT04169477|DEVICE|CEFAR Primo Pro (TENS device)|"During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~\[Cross-over\] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer."
214660982|NCT04910750|DEVICE|Pulse oximetry|Pulse oximeters are a non-invasive, accurate and easy to use method of evaluating blood oxygen saturation
214660983|NCT04910750|DEVICE|Clinical Decision Support Algorithm|Tablet-based clinical decision support algorithms, based on guidelines for the assessment and management of sick children under 5 years of age at primary care
214660984|NCT02450253|DRUG|Tadalafil|single dose, 20 mg capsule p.o.
214848810|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
214660985|NCT02450253|DRUG|Placebo|single dose, matching capsule p.o.
214660986|NCT02450253|BEHAVIORAL|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
214660987|NCT02450253|BEHAVIORAL|Neuropsychological tests|"Neuropsychological tests will be performed prior to pre IMP dose MRI scan \& then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart"
214660988|NCT02450253|OTHER|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
214660989|NCT02362373|DRUG|levonorgestrel IUS|placement of levonorgestrel intrauterine system
214660990|NCT01985321|DRUG|ethanol/glycolic acid solution|ethanol/glycolic acid solution
214660991|NCT01985321|DRUG|Placebo/Ethanol|ethanol solution
214660992|NCT01462513|BIOLOGICAL|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
214660993|NCT01462513|BIOLOGICAL|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
214660994|NCT01588080|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
214660995|NCT01588080|DEVICE|SiPAP - placebo|The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
214660996|NCT06683521|OTHER|Supervised Low-Dose Oral Food Challenge (OFC)|All participants will undergo a supervised Low Dose OFC (300 mg food protein or amended) on Day 1.
214660997|NCT06683521|OTHER|At-Home Low-Dose Oral Food Challenge (OFC)|Participants who tolerate the Day 1 Low Dose OFC will undergo a daily Low-Dose OFC (300 mg food protein or amended) at home on Days 2-7.
214660998|NCT06683521|OTHER|Supervised High-Dose Oral Food Challenge (OFC)|Participants who tolerate the Days 1-7 Low Dose OFC will undergo a supervised High Dose OFC (maximum 3000 mg food protein) on Day 8.
214660999|NCT00942682|DRUG|Sorafenib|Taken orally twice daily
214661000|NCT00942682|DRUG|RAD001|Taken orally once daily in the morning
214661001|NCT06423417|BEHAVIORAL|LifeHack|See arm description
214661002|NCT03287492|OTHER|Informational Intervention|Receive QPS
214661003|NCT03287492|OTHER|Informational Intervention|Receive GIS
214661004|NCT03287492|OTHER|Questionnaire Administration|Ancillary studies
214661005|NCT01883505|DRUG|Levodopa and carbidopa|Subcutaneous continuous administration
214661006|NCT01883505|DRUG|Placebo|Subcutaneous continuous administration
214661007|NCT03709927|DRUG|ZTI-01|6g IV fosfomycin
214661008|NCT03709927|DRUG|Moxifloxacin 400mg|oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
214661009|NCT03709927|OTHER|Placebo IV|IV Placebo (0.9% Normal Saline)
214661010|NCT02404987|OTHER|Nutritional Supplement|
214661011|NCT04030000|DRUG|Paclitaxel/Carboplatin|IV paclitaxel in combination with IP carboplatin
214661012|NCT04030000|RADIATION|Pelvic radiation therapy|EBRT and vaginal brachytherapy
214661013|NCT04869241|DIAGNOSTIC_TEST|surface EMG|Carrying backpacks forward or backward
214848811|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
214848812|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
214848813|NCT01413763|DRUG|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
214661014|NCT03352245|BEHAVIORAL|Prescribed Activity|Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)
214661015|NCT03782337|BEHAVIORAL|multi-discipline disease management program|The multi-discipline disease management program consists of nursing lead education program, dietitian consultation, psychologist consultation and assessment, and cardiac rehabilitation program by physical therapist.The cardiovascular lead nurse will contact the patient by telephone within 3 days after discharge. An appointment at the outpatient clinic will be arranged within 1 to 2 weeks after discharge. The purposes of the telephone call are to reinforce self-management and recognition of HF symptoms and to screen post-discharge health status.
214661016|NCT03619629|OTHER|Kinesio-tape|"Kinesiotape will be applied both ankles as Correction technique."
214661017|NCT03619629|OTHER|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.
214848814|NCT01413763|DRUG|Placebo cream|placebo cream applied daily for 2 weeks
214848815|NCT05568316|DIETARY_SUPPLEMENT|Preoperative Immunonutrition|"Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
214848816|NCT05568316|DIETARY_SUPPLEMENT|Perioperative Immunonutrition|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
214661018|NCT03619629|OTHER|Sham Kinesio-taping|Sham Kinesio-taping technique will be applied both ankles.
214848817|NCT04560439|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo METFIT program
214848818|NCT05504824|OTHER|Case-based education|"The education phase This stage included the explanation of the CR process, the analysis of CR cases, the drafting of new cases suitable for the CR process by students, and the analysis process.~The education program was carried out on a web platform (Zoom) consistent with the changes in the COVID-19 pandemic process. The CR cases to be used in case-based education were sent to the students via e-mail before the group interview to make sure students came prepared for the group discussion. In case-based education, after the students read the case, they were asked some questions to determine their decisions and reasoning."
214661019|NCT03619629|OTHER|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement technique will be applied both ankles.
214661020|NCT00940277|BEHAVIORAL|Group Counseling|Group counseling
214661021|NCT03635931|PROCEDURE|Concentrated Growth Factor|surgical treatment with CGF for papilla regeneration
214661022|NCT02771834|OTHER|Biomechanical analysis|
214661023|NCT02771834|OTHER|Kiphosis analysis|
214661024|NCT02771834|OTHER|Vitamin D level|
214848819|NCT02746419|DEVICE|Vessix|Renal denervation using radio-ablation
214661025|NCT01130922|DRUG|moxifloxacin per IV|intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
214661026|NCT01130922|DRUG|moxifloxacin per os|oral administration of 400 mg moxifloxacin in a single dose
214661027|NCT05123560|OTHER|Anonymous online questionnaire|A QR code qill be provided to access the online questionnaire
214661028|NCT06031415|DRUG|GS-0272|Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
214661029|NCT06031415|DRUG|Placebo|Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
214661030|NCT02690701|DRUG|Secukinumab 300 mg|"Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
214661031|NCT02690701|BIOLOGICAL|Placebo|"Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
214661032|NCT05865184|OTHER|Data collection|Data collection of clinically relevant signals using home-based sensor system
214661033|NCT03091023|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|
214661034|NCT01442181|PROCEDURE|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
214661035|NCT01442181|OTHER|Medical therapy|Patients are treated with rhythm and rate control medications.
214661036|NCT06582342|PROCEDURE|Three dimensional imaging technology (3D-PANC MSP model)|The processing of the CT images obtained in each center for the creation of the 3D model will be performed centrally by the team of radiologists and computer scientists of the company Cella Medical Solutions. This team will be blinded to the reports of the CT scans.For each patient 4 NCCN check-lists will be filled in without knowing the result of the surgery or the AP study: 2 based on the conventional CT and two based on the 3D-MSP study.
214661037|NCT06582342|PROCEDURE|Computerized tomography group (conventional CT)|A multiphase CT (venous phase and pancreatographic phase) with 1mm thick slices and series of images in coronal, axial and sagittal reconstructions will be performed. This CT model will be performed at disease diagnosis and after completion of neoadjuvant chemotherapy treatment. Both CT scans will be independently reported by a radiologist from the hospital of origin. The preoperative CT scan will also be evaluated a posteriori by a radiologist from the sponsoring center with expertise in PAC. Both reports (the one from the radiologist of the center and the one from the radiologist of the sponsoring center) will be used to fill out the imaging study variables sheet based on the latest version of the NCCN 2022 guidelines. The radiologists will not know the outcome of the surgery or the anatomic pathology study at the time of the completion of the report.
214661038|NCT05426356|DEVICE|Surgical Intervention|Surgical sacral fracture fixation and SI joint fusion using iFuse-TORQ
214661039|NCT05426356|OTHER|Non-Surgical Management|Non-surgical management (NSM) is any treatment deemed appropriate for the subject that does not involve surgery.
214661040|NCT00158366|BEHAVIORAL|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
214661041|NCT00158366|BEHAVIORAL|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
214661042|NCT00158366|BEHAVIORAL|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
214661043|NCT00749203|DRUG|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
214661044|NCT00749203|DRUG|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
214661045|NCT00222079|DRUG|Esomeprazole (Nexium)|
214661046|NCT00384579|DRUG|Botulinum toxin B|Botulinum Toxin B
214661047|NCT00384579|DRUG|Placebo|Placebo
214661048|NCT05347615|PROCEDURE|IOL Implantation:EDOF lens|A EDOF lens is implanted in the dominant eye
214661049|NCT05347615|PROCEDURE|IOL Implantation: Monofocal lens|A monofocal lens is implanted in the non dominant eye.
214661050|NCT03821584|OTHER|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest
214661051|NCT00830921|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
214848820|NCT04636541|BEHAVIORAL|Goal Management Training|Goal Management Training® (GMT) has been developed to improve executive functions. It was validated in patients presenting executive dysfunction following many conditions: acquired traumatic brain injury, neurodevelopmental spina bifida, attention deficit and hyperactivity disorder (ADHD), subjective cognitive complaints and multiple sclerosis. GMT includes self-instruction strategies, self-monitoring exercises, cognitive training techniques, psychoeducation on cognitive processes, mindfulness exercises and assignments between sessions. It has been shown to increase patient awareness of deficits and improve cognitive control in goal-directed behaviors. The original GMT is a nine-week program administered to dysexecutive patients in 90-to-120-minute group sessions. Thus, it might be suitable for PD-MCI patients presenting with executive dysfunction.
214661052|NCT02184637|DRUG|Tafenoquine|A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
214661053|NCT02184637|DRUG|Dihydroartemisinin + Piperaquine tetraphosphate|"White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally"
214661054|NCT02184637|DRUG|Artemether + Lumefantrine|"Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally"
214661055|NCT02614209|DEVICE|In Vitro diagnostic tests|Prospective blood collection
214661056|NCT05240144|OTHER|IHG|Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.
214661057|NCT05240144|OTHER|Aerobic exercises|Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.
214661058|NCT05240144|OTHER|Sham IHG|Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period
214661059|NCT02295202|DEVICE|CPAP (REMstar System One Plus - Philips Medical Systems)|Standard device for treating obstructive sleep apnea.
214661060|NCT02295202|DEVICE|Nasal strips|
214661061|NCT04514614|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of arthritis by PET/CT.
214661062|NCT00511303|DRUG|STI571|
214661063|NCT00302393|DRUG|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
214661064|NCT00302393|DRUG|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
214661065|NCT02823457|BEHAVIORAL|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
214661066|NCT01993979|DRUG|Chemotherapy|
214661067|NCT01993979|OTHER|Surveillance|Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
214661068|NCT03271710|DEVICE|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
214661069|NCT04493047|BEHAVIORAL|Mobile health (mHealth) for pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers.
214661070|NCT02913989|OTHER|Smoking habits characterization|
214661071|NCT00441688|DRUG|GI265235|
214661072|NCT04476264|PROCEDURE|Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection|The present study serves to describe a novel approach to utilizing a single adjustable 8-0 polypropylene suture for scleral fixation without conjunctival dissection and to evaluate safety and efficacy outcomes associated with this technique.
214661073|NCT00372892|DRUG|Rituximab|375mg/m2 per week for 4 consecutive weeks
214661074|NCT00372892|DRUG|Placebo|Saline IV placebo once per week for 4 consecutive weeks
214661075|NCT00211003|DRUG|doripenem|
214661076|NCT03339895|OTHER|pvı-guided|pvı- guided total amount of crystalloid volume of fluid infused during colorectal surgery pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery If PVI value \<%13 and if MAP\>65mmHg continue with 2 ml/kg/h cristalloid infusion If PVI value \<%13 and if MAP\>65mmHg 5 mcg efedrin intravenous bolus till MAP\>65 mmHg If PVI value \>%13 and MAP\>65 mmHg infuse 250 ml Gelofusine bolus up to PVI value lowers to %13 every 5 minute If PVI value \>%13 and MAP \<65 mmHg infuse 250 ml Gelofusine bolus and 5 mcg efedrin intravenous up to PVI value lowers to %13
214661077|NCT03339895|OTHER|traditional-guided|traditional-guided total amount of crystalloid volume of fluid infused during colorectal surgery traditional-guided fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP \<65 mmHg or \<30%of basal value, infuse 250 ml Gelofusine bolus and 5 mcg efedrin If MAP\>65 mmHg no intervention
214661078|NCT00667706|PROCEDURE|laparoscopic operation Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
214661079|NCT00667706|PROCEDURE|laparoscopic operation Roux-en-Y Gastric bypass|Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of \<50, and \>50, respectively.
214661080|NCT02853760|BEHAVIORAL|walking|
214661081|NCT02853760|DEVICE|Treadmill|
214661082|NCT00277758|BIOLOGICAL|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
214661083|NCT00277758|DRUG|Ribavirin|Ribavirin @ 800 mg daily (\< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (\> 85 kg)
214661084|NCT00277758|BIOLOGICAL|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
214661085|NCT00277758|BIOLOGICAL|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
214661086|NCT00277758|DRUG|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight \<65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight \>85 kg.
214661087|NCT00240435|DEVICE|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
214661088|NCT00240435|DEVICE|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
214661089|NCT05872048|DEVICE|periodontal distractor|custom made device from hyrex screw
214661090|NCT02043886|DRUG|Acarbose|Acarbose 50 mg by mouth given during Meal Test
214661091|NCT02043886|DRUG|Placebo|Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
214661092|NCT00849589|BEHAVIORAL|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
214661093|NCT00849589|BEHAVIORAL|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
214661094|NCT01642212|DRUG|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
214661095|NCT01642212|DRUG|Placebo|
214661096|NCT06028620|BEHAVIORAL|Trauma Focused-Cognitive Behavior Therapy|TF-CBT consisted of 8 units in which different issues realted to trauma are reviewed. Units are: psychoeducation and parenting skills, relaxation techniques, affective expression and regulation, cognitive coping and processing, trauma narrative and processing, in vivo exposure, co-joint sessions and enhancing safety and future growth.
214661097|NCT03097887|PROCEDURE|Omega Loop Gastric Bypass|Bariatric/metabolic surgical procedure
214661098|NCT03097887|DEVICE|Bilitec 2000™|The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
214661099|NCT03097887|DEVICE|V-Loc|Sewing device to perform the anti-reflux sutures.
214661100|NCT02095301|OTHER|Herbal Beverage|
214661101|NCT01061281|DEVICE|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
214661102|NCT01061281|DEVICE|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
214661103|NCT05962008|DIETARY_SUPPLEMENT|DHAPS® product|Take 4 capsules per day after breakfast with warm water.
214661104|NCT05962008|DIETARY_SUPPLEMENT|BioPS® product|Take 4 capsules per day after breakfast with warm water.
214848821|NCT04636541|BEHAVIORAL|Psychoeducation|See the Arm section for full details. For a justification of how we designed this intervention: Many clinical guidelines include general recommendations about giving information to PD patients and family so they can take part into decision process. However, few standardized psychoeducation interventions are available, and they don't include information on PD cognitive decline. Some studies investigated Mindfulness Based Stress Reduction (MBSR) and other related mindfulness interventions in PD patients. In this approach, formal meditative exercises are included to develop non-judgmental attention to experiences in the present moment. In elderly patients with MCI unrelated to PD, mindfulness interventions show positive effects on cognitive functioning, including attention, executive functioning and memory (Gard et al., 2014). Therefore, non-pharmacological interventions for PD-MCI including both education on cognitive symptoms, as well as mindfulness exercises, are promising.
214848822|NCT01439724|DEVICE|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
214848823|NCT01439724|DEVICE|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
214848824|NCT01397955|DRUG|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
214848825|NCT02681406|BEHAVIORAL|ACHESS|Smartphone based additions focused application, encouraging social support
214848826|NCT02681406|BEHAVIORAL|TMC|Brief telephone monitoring and counseling
214848827|NCT04226339|PROCEDURE|total knee arthroplasty with a kinetic alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery"
214848828|NCT04226339|PROCEDURE|total knee arthroplasty with a mechanical alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment"
214848829|NCT03302572|OTHER|Brief information group|Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
214661105|NCT05962008|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules per day after breakfast with warm water.
214661106|NCT01574573|BEHAVIORAL|Self support, group sessions|Self support,group sessions
214661107|NCT01106001|DRUG|Levobupivacaine|The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
214661108|NCT01106001|DRUG|Saline|The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
214661109|NCT00346827|DRUG|Apomorphine Nasal Powder|
214661110|NCT00187590|BEHAVIORAL|Case manager phone call after an ER visit|
214661111|NCT02191748|PROCEDURE|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
214661112|NCT02191748|DRUG|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
214661113|NCT00123929|DRUG|docetaxel|100 mg/m2 every 3 weeks times 4
214661114|NCT00123929|DRUG|doxorubicin|75 mg/m2 every 3 weeks times 4
214661115|NCT04681261|OTHER|this study is not an intervention study|this study is not an intervention study
214661116|NCT01117376|DRUG|Erythromycin|Erythromycin 250 mg intravenous Q6h for 4 doses
214661117|NCT01117376|DRUG|Methylnaltrexone|Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
214661118|NCT06427109|DIETARY_SUPPLEMENT|Dietary intake of omega-3 fatty acid|Participants were stratified into omega-3 consumption quartiles to assess colorectal adenoma incidence trends
214661119|NCT03205787|DIETARY_SUPPLEMENT|Trifolium pratense|Red Clover extract standardized to isoflavone content.
214661120|NCT00663130|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
214661121|NCT00663130|DRUG|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
214661122|NCT03744689|PROCEDURE|Erector Spinae Plane block|Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
214661123|NCT03744689|PROCEDURE|Sham block|Sham block will be done with serum physiologic.
214661124|NCT03744689|DRUG|Bupivacaine Hydrochloride|20 ml 0,25% Bupivacaine will be used for block performances
214661125|NCT03744689|DEVICE|PCA|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
214661126|NCT00260130|OTHER|food in fluid form|dietary intake of fluid forms of vegetables
214661127|NCT00260130|OTHER|food in solid form|dietary intake of solid forms of vegetables
214661128|NCT03394950|DRUG|Butyphthalide combined with rtPA|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
214661129|NCT03394950|DRUG|rtPA|Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
214848830|NCT01749358|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
214848831|NCT01749358|BEHAVIORAL|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
214848832|NCT05140317|PROCEDURE|Transcatheter heart valve implantation with or withour predilatatation|long term up to 5 years echographic and clinical follow up
214848833|NCT04741152|PROCEDURE|Pancreatic resection|Different pancreatic resections
214848834|NCT06014879|BEHAVIORAL|Type 1 Doing Well (T1DW) Program|"Parent and youth will each have access to a version of the app. The study app activities include parents and youth:~* noticing what the youth does well for diabetes;~* setting and tracking a family diabetes goal in the app; and~* having a weekly meeting to review what the youth is doing well with diabetes and progress on the family diabetes goal.~Parents and youth will also have access to age-appropriate libraries of videos with diabetes-specific content.~Parents and youth will also have a conversation with the youth's diabetes care provider at a regularly scheduled diabetes appointment at participating hospital sites."
214848835|NCT06014879|OTHER|Diabetes-Related Information and Resources Program|Parent and youth will receive diabetes-related information and resources in the form of electronic handouts. They will receive one handout per month by email during the 6-month intervention period. These handouts include a variety of diabetes-related topics curated by the study team. Handouts will not include any specific information about the youth's health.
214848836|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
214848837|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
214848838|NCT01040793|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
214848839|NCT01040793|DRUG|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
214848840|NCT01040793|DRUG|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
214848841|NCT04689893|DRUG|68Ga-Dotatate|68Ga-Dotatate was injected into the patients before the PET/CT scans
214848842|NCT04689893|DRUG|68Ga-DOTA-JR11|68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
214848843|NCT04285827|BIOLOGICAL|CSL889|Administered as an IV infusion
214848844|NCT01922960|OTHER|micro-imaging|micro-imaging
214848845|NCT02740907|PROCEDURE|premolar autotransplantation|Autogenous tooth transplantation of premolars to the anterior maxilla to stimulate bone and soft tissue growth.
214848846|NCT05270486|PROCEDURE|Electromagnetic navigation system|The aim of this study is to assess the safety and efficacy of TELD assisted by electromagnetic navigation for treating lumbar disc herniation (LDH).
214848847|NCT01826916|DRUG|DX-88 (ecallantide)|solution for injection 10 mg/mL
214848848|NCT02309424|DIETARY_SUPPLEMENT|Vinegar|0,50mmol vinegar (6% acetic acid)
214848849|NCT02309424|OTHER|Placebo|50 ml water
214848850|NCT03946917|DRUG|JS001|JS001 3 mg/kg, iv drip, d1, d15, q4w
214848851|NCT03946917|DRUG|regorafenib tablet|80/120/160 mg, po, d1-d21, Q4w.
214848852|NCT01913795|OTHER|integrated pest management|integrated pest management and environmental strategy
214848853|NCT01913795|OTHER|air purifier|air purifiers
214848854|NCT01913795|OTHER|Sham air purifier|sham air purifiers
214848855|NCT01780376|PROCEDURE|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
214848856|NCT05554172|DEVICE|taVNS|Participants will receive vagal nerve stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
214848857|NCT05554172|DEVICE|Sham|Participants will receive sham stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
214848858|NCT06615934|OTHER|Aerobic and resistance exercise|"From the first day of transplantation in the ICU until 10 days after transfer to the ward or discharge from the hospital, if needed, the patients of the group will undergo respiratory physiotherapy once a day. The process of this program includes patient assessment, clinical decision-making, and implementation of therapeutic interventions.~The interventions of the therapeutic exercise group are divided into three phases:~1. From the time the patient enters the ICU until the time of extubation;~2. From the time of extubation to the time of transfer to the ward;~3. Duration of the patient's stay in the ward."
214848859|NCT06615934|OTHER|Respiratory physiotherapy|The participants of this group will receive respiratory physiotherapy daily after transplant until discharge.
214848860|NCT04721496|BEHAVIORAL|Power and Speed|"Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day."
214661130|NCT01999738|DRUG|EC1456 and EC20|"EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging."
214661131|NCT04519944|DRUG|Edoxaban|This is an observational, prospective study; no treatment will be administered.
214661132|NCT00004980|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
214661133|NCT00004980|DEVICE|sham stimulation|"132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site"
214661134|NCT01299025|OTHER|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
214661135|NCT01245244|DRUG|Morphine|Morphine oral mixture
214661136|NCT01245244|OTHER|orange juice|orange juice
214661137|NCT03671122|DIAGNOSTIC_TEST|Cardiac imaging in the PREFERS and CABG PREFERS cohorts|performed at baseline and after 1 year
214661138|NCT03671122|OTHER|Biomarker analysis in the PREFERS and CABG PREFERS chorts|blood samples will be taken for biomarker analysis at baseline and after 1 year
214661139|NCT03671122|PROCEDURE|Cardiac biopsies in the CABG PREFERS cohort|myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
214661140|NCT04351659|OTHER|Blood donation from convalescent donor|Donation of 1 unit of blood or leukapheresis
214848861|NCT00946491|DRUG|Haloperidol 10 mg Tablets (Cord Laboratories)|
214848862|NCT00946491|DRUG|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
214848863|NCT02893280|DRUG|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
214848864|NCT06076369|PROCEDURE|The tubular adenoma group|Biopsy or removal of polyps for pathological examination. Collect baseline data such as gender, age, BMI, etc. If the pathology confirms a pure tubular adenoma, the observed object will be included in the group for final comparative analysis.
214848865|NCT00939627|BIOLOGICAL|cetuximab|Given IV
214848866|NCT00939627|OTHER|placebo|Given orally
214848867|NCT00939627|DRUG|sorafenib tosylate|Given orally
214848868|NCT00939627|OTHER|laboratory biomarker analysis|Correlative studies
214848869|NCT00939627|PROCEDURE|quality-of-life assessment|Ancillary studies
214661141|NCT04472689|DRUG|Lidocaine|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
214661142|NCT04472689|DRUG|Normal saline|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
214661143|NCT03577990|BEHAVIORAL|Interactive Technology Enhanced Coaching (ITEC)|As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability.
214661144|NCT03577990|BEHAVIORAL|Interactive Technology-No Coaching (IT)|After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without coaching (IT). Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily.
214661145|NCT04178148|OTHER|Amikacin dose optimization|Therapeutic drug optimization of amikacin using the BestDose software algorithm
214661146|NCT00463437|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose.
214661147|NCT00463437|BIOLOGICAL|Prevenar|Intramuscular injection, 1 dose.
214661148|NCT00463437|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 1 dose. In Germany and Poland.
214661149|NCT00463437|BIOLOGICAL|Infanrix IPV Hib|Intramuscular injection, 1 dose. In Spain.
214661150|NCT00463437|BIOLOGICAL|Infanrix penta|Intramuscular injection, 1 dose. In Germany and Poland.
214661151|NCT00463437|BIOLOGICAL|Infanrix IPV|Intramuscular injection, 1 dose. In Spain.
214661152|NCT00463437|BIOLOGICAL|Meningitec|Intramuscular injection, 1 dose.
214661153|NCT00463437|BIOLOGICAL|NeisVac-C|Intramuscular injection, 1 dose.
214661154|NCT00463437|BIOLOGICAL|Menitorix|Intramuscular injection, 1 dose.
214661155|NCT05052203|OTHER|Exposure of interest: study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes|The primary objective is to study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes between sepsis survivors at ED admission and three months after hospital discharge
214661156|NCT03694158|DRUG|Dupilumab|anti-IL4 receptor antagonist
214661157|NCT03694158|OTHER|Placebo|Placebo for Dupilumab (packaged/administered the same as the active drug)
214661158|NCT00361530|DRUG|Statin|
214661159|NCT06561087|DRUG|Nivolumab|Given by injections
214848870|NCT02152462|OTHER|Exergaming|The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain \>150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
214661160|NCT04990167|DRUG|Tiotropium Bromide|Using Tiotropium as a single agent asthma controller medication
214661161|NCT05106387|DRUG|Noninterventional|No investigational treatment will be given in this noninterventional extension study
214661162|NCT05118204|DRUG|BUP microdose induction|"Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours"
214661163|NCT05118204|DRUG|TAU|2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
214661164|NCT05118204|BEHAVIORAL|Linkage to outpatient BUP treatment|Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
214661165|NCT02758769|BIOLOGICAL|ORENCIA Subcutaneous Injection|
214661166|NCT04451863|DRUG|Low THC|Vaporized THC (5 mg)
214661167|NCT04451863|DRUG|High THC|Vaporized THC (15 mg)
214661168|NCT04451863|DRUG|Low Myrcene|Vaporized Myrcene (0.5 mg)
214661169|NCT04451863|DRUG|High Myrcene|Vaporized Myrcene (12.0 mg)
214661170|NCT04451863|DRUG|Low Beta-Caryophyllene|Vaporized Beta-Caryophyllene (0.5 mg)
214661171|NCT04451863|DRUG|High Beta-Caryophyllene|Vaporized Beta-Caryophyllene (7.5 mg)
214661172|NCT04451863|DRUG|Placebo|Vaporized Placebo
214661173|NCT04432012|DRUG|Dexamethasone Sodium Phosphate 4 mg/ml intravenous|Perioperative intravenous injection of 3 ml of solution (9mg of dexamethasone)
214661174|NCT04432012|DRUG|Dexamethasone Sodium Phosphate 4 mg/ml intra-articular|Perioperative intra-articular injection of 3 ml of solution (9mg of dexamethasone)
214661175|NCT02793544|DRUG|Fludarabine|"* Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~* The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~* creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
214661176|NCT02793544|DRUG|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"* Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
214661177|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy on Day -1|"* 200 cGy TBI is administered in a single fraction on Day -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
214848871|NCT02369120|OTHER|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
214661178|NCT02793544|PROCEDURE|Infusion of non-T-cell depleted bone marrow on Day 0|"* On Day 0, the harvested bone marrow is infused.~* Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~* The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
214661179|NCT02793544|DRUG|Busulfan|"* Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM\*min (Perkins et al., 2012))~* Busulfan dosing is based on adjusted IBW (Appendix K)"
214661180|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
214848872|NCT02369120|OTHER|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
214848873|NCT03160586|DIAGNOSTIC_TEST|Stuttering severity instrument-3|To measure of degree of stuttering in child
214848874|NCT03160586|DIAGNOSTIC_TEST|Child Behavior Checklist for age 4-18|To measure of percent of anxiety in child by ask parents about his or her behaviour
214848875|NCT01906424|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
214848876|NCT00965016|PROCEDURE|hypothermia|Core temperature --\> 34.9℃ within 30 min --\> 33.5℃ within 120min --\> 33℃for 24 H Decrease temperature in 0.9℃/hour
214848877|NCT03600181|DEVICE|RAD - 97 pulse co-oximeter|"non-invasive sensor capable of measuring ORI (Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.~Values from the RAD 97 monitor will be blinded to clinicians who perform intubation (clinical research nurse will be in charge of watching RAD 97 monitor)"
214848878|NCT00798681|DIETARY_SUPPLEMENT|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
214848879|NCT00798681|OTHER|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
214848880|NCT00798681|OTHER|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
214661181|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
214661182|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"* 200cGy TBI is administered in twice daily on Days -3, -2, and -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
214661183|NCT02793544|DRUG|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"* Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~* Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~* Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
214661184|NCT02793544|DRUG|Sirolimus|"* Sirolimus dosing is based on adjusted IBW (Appendix K).~* Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~* A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects \< 18 years old:~* A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
214661185|NCT02793544|DRUG|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
214661186|NCT02793544|DRUG|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted."
214661187|NCT02793544|DRUG|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
214661188|NCT02793544|DRUG|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
214661189|NCT02793544|DRUG|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
214661190|NCT02793544|DRUG|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
214661191|NCT06348355|DRUG|[11C]savolitinib|Radiopharmaceutical; IMP; Sterile solution for IV injection, not more than 10 μg, single administration
214661192|NCT06348355|DRUG|Savolitinib|IMP; 300 mg tablet, oral single administration
214661193|NCT06567327|DRUG|Danuglipron|Danuglipron oral tablets
214661194|NCT06567327|DRUG|Atorvastatin|Atorvastatin oral tablets
214661195|NCT06567327|DRUG|Rosuvastatin|Rosuvastatin oral tablets
214848881|NCT03669016|BEHAVIORAL|Face-to-face group-based mindfulness|"An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. This training is based on Jon Kabat-Zinn's course Mindfulness Based Stress Reduction and book Williams \& Penman Mindfulness: a practical guide to finding peace in a frantic world and adapted for university students. In addition, a manual written in Cambridge University Mindfulness Skills for Students is utilized."
214848882|NCT03669016|BEHAVIORAL|Internet-based mindfulness|An eight-week course, including 60 minutes starting and ending meeting. Participants are practicing mindfulness, doing other tasks (writing, reading, reflecting) on their own. This course is created in University of Jyväskylä, Finland. It is based on mindfulness and Acceptance and Commmitment Therapy.
214848883|NCT06603181|OTHER|conventional treatment|exercise and splint
214661196|NCT05090345|OTHER|Biorepository Trial|participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
214848884|NCT06603181|OTHER|phonophoresis|exercise, splint and phonophoresis
214848885|NCT06603181|OTHER|extracorporeal shock wave therapy|exercise, splint and ESWT
214661197|NCT06090552|BEHAVIORAL|Letter|Letter about ACP
214661198|NCT06090552|BEHAVIORAL|AD|PREPARE advanced directive (AD)
214661199|NCT06090552|BEHAVIORAL|PREPARE website|PREPARE website
214661200|NCT06090552|BEHAVIORAL|reminders|reminders to complete the advance directive
214661201|NCT06090552|BEHAVIORAL|healthcare navigator|healthcare navigators provide assistance to complete the advance directive
214661202|NCT04714086|DRUG|Avapritinib|Avapritinib will be administered orally at 300 mg QD.
214661203|NCT00217633|PROCEDURE|Conventional Surgery|
214661204|NCT00363961|BEHAVIORAL|Resistance exercise|resistance exercise vs sham comparison
214661205|NCT04680650|DRUG|Anesthesia was maintained with sevoflurane|After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.
214661206|NCT04680650|DRUG|Anesthesia was maintained with propofol|After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
214661207|NCT03399383|OTHER|Patient education|Participation in the standardized education program (90min patient education). During sessions of 90-120 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings. Participants are provided with emergency cards and sets and are trained in self-injection of glucocorticoids.
214661208|NCT01639820|PROCEDURE|identification of sentinel nodes + full pelvic lymph-node dissection|identification of sentinel nodes + full pelvic lymph-node dissection
214661209|NCT01639820|PROCEDURE|only identification of sentinel nodes (without pelvic lymph-node dissection)|only identification of sentinel nodes (without pelvic lymph-node dissection)
214848886|NCT02629250|PROCEDURE|SV maximization|When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR \<100 bpm, Hb \>8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV \>10% or blood loss \>250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
214661210|NCT06159114|DRUG|Ningmitai capsule|Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
214848887|NCT02629250|PROCEDURE|supernormal DO2|Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
214848888|NCT06146855|PROCEDURE|Tunneling procedure with Amnion Membrane|Root Coverage by tunneling procedure with the addition of Amnion Membrane as a soft tissue substitute
214848889|NCT06146855|PROCEDURE|Tunneling procedure with De-epithelialized Free Gingival Graft|Root Coverage by tunneling procedure with the addition of De-epithelialized Free Gingival Graft
214906967|NCT02748746|DEVICE|Tissue Dielectric Constant Measurement|In this study, TDC device (Moisture Meter-D compact-MMDc will be implemented to upper extremity both affected and unaffected side. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. A gentle pressure must required to have accurate sub-tissue fluid percent. Triplicate measurements will be done and taken those average value for each point in order to reach sensitive screening. Computer software simultaneously save these measurements results automatically. A patient total measurement time approximately lasts 5 minutes.
214661211|NCT06159114|DRUG|Celecoxib capsule|Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.
214661212|NCT06159114|DRUG|Ningmitai placebo|Ningmitai placebo, a look-alike substance that contains no active drug, similar to Ningmitai capsule in color, smell, taste, shape, texture and other characteristics, 0.38g/ capsule.
214661213|NCT06159114|DRUG|Celecoxib placebo|Celecoxib placebo, a look-alike substance that contains no active drug, similar to Celecoxib capsule in color, smell, taste, shape, texture and other characteristics, 0.2g/ capsule.
214661214|NCT04222023|DRUG|Intravenous immunoglobulins (IVIG)|"Experimental group: administration of a single dose of IVIG at:~* Day 10+/- 4 days~* Day 41 +/- 7 days~* Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day."
214661215|NCT05922553|BEHAVIORAL|Active Ingredient Mukbang|Mukbang videos include the items which can truly improve the appetite of children with cancer, such as food images, eating sound and interactivity.
214661216|NCT05922553|BEHAVIORAL|General short videos|Short videos that don't contain any food cues.
214661217|NCT05425459|DEVICE|Corvia Atrial Shunt System / IASD System II|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
214661218|NCT05425459|OTHER|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
214661219|NCT06821464|DRUG|HRS-9813|Initial dose to planned dose（low dose）
214661220|NCT06821464|DRUG|HRS-9813|Initial dose to planned dose（high dose）
214661221|NCT04863885|DRUG|Ipilimumab|Participants will receive Ipilimumab 3 mg/kg
214661222|NCT04863885|DRUG|Nivolumab|Participants will receive Nivoumab 1mg/kg
214661223|NCT04863885|DRUG|Sacituzumab govitecan|Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
214661224|NCT06645509|DRUG|TTB gel (dose 1)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
214661225|NCT06645509|DRUG|TTB gel (dose 2)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
214661226|NCT06645509|DRUG|Placebo|A topical administration of a vehicle (Placebo) gel to both hands, once daily for 28 days
214661227|NCT06217783|DEVICE|Introcan Safety IV Catheter|Given by IV
214661228|NCT00100048|DRUG|Comparator: MK0518 monotherapy|MK0518 twice daily for 10 days
214661229|NCT00100048|DRUG|Comparator: MK0518 combination therapy|MK0518 twice daily for 48 weeks
214661230|NCT00100048|DRUG|Comparator: efavirenz|efavirenz 600 mg every night at bedtime for 48 weeks
214661231|NCT00100048|DRUG|Comparator: tenofovir|tenofovir 300 mg daily for 48 weeks
214661232|NCT00100048|DRUG|Comparator: lamivudine|lamivudine 300 mg daily for 48 weeks
214661233|NCT00100048|DRUG|Placebo monotherapy|Placebo to MK0518 twice daily
214661234|NCT00879450|OTHER|Booklet|booklet given to parents for home exercises
214661235|NCT01054066|BEHAVIORAL|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
214661236|NCT01624142|BIOLOGICAL|Evolocumab|Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
214661237|NCT01822561|DRUG|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
214661238|NCT00900003|GENETIC|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
214661239|NCT00900003|OTHER|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
214661240|NCT04116099|OTHER|Conservative care|May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
214661241|NCT04116099|DEVICE|Flexitouch Plus|Flexitouch Plus treatment.
214661242|NCT03991637|DEVICE|Non-Invasive Comprehensive Metabolic Panel|The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
214661243|NCT05350150|DEVICE|Auricular Vagal Nerve Stimulation|The Parasym device will be placed on the patient's left tragus to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
214661244|NCT06466733|PROCEDURE|Embolization of the middle meningeal artery|Embolization of the middle meningeal artery ipsilateral to the chronic subdural hematoma is performed infusing embolic polyvinyl alcohol (PVA) microparticles.
214661245|NCT06466733|PROCEDURE|Surgical Evacuation via burr hole or craniotomy|The standard of care for chronic subdural hematoma, burr hole or craniotomy are performed ipsilateral to the lesion.
214848890|NCT03225014|DEVICE|Accelerated Recovery Performance Wave Therapy|ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.
214661246|NCT06667843|BEHAVIORAL|Lifestyle Management|Behavioral intervention for lifestyle change
214661247|NCT06667843|DEVICE|Intervention|Full access to DTx function in the app, and digital follow up/communication with helthcare professionals at the Healthy Lives Center
214661248|NCT06667843|DEVICE|Control|Basic access to the app (daily logging functions). No digital follow up or communication with healthcare professionals at the Healthy Lives Center.
214661249|NCT06265558|PROCEDURE|Negative pressure therapy (NPT)|Negative pressure therapy (NPT) involves placing the surface of a wound under a pressure lower than the ambient atmospheric pressure. To achieve this, a specially designed dressing is connected to a vacuum source and an exudate collection system.
214661250|NCT06265558|PROCEDURE|Dressing|Fatty dressing or hydrocellular dressing
214661251|NCT04828226|DRUG|Clonidine|Clonidine 2mcg/kg Body Weight diluted in 100ml sodium chloride 0.9% compared to placebo (sodium chloride 0.9% alone) given over 10 minutes, 10 minutes prior to electroconvulsive therapy.
214661252|NCT04828226|DRUG|Placebo|Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
214661253|NCT02527213|DRUG|Sodium thiosulfate|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
214661254|NCT02527213|DRUG|Placebo|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
214661255|NCT06973837|OTHER|Real-life monitoring, experimental pain testing, brain imaging, blood and stool sampling.|See detailed study description and outcome measures.
214661256|NCT04524585|DRUG|Neuromuscular blockade|Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.
214661257|NCT02954380|DEVICE|Zio|long term continuous monitoring
214661258|NCT02740309|BEHAVIORAL|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
214661259|NCT02740309|BEHAVIORAL|Treatment as usual|Facilitated community referral for mental health treatment
214661260|NCT04826900|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 200 units to 500 units. The dose range of each target muscle is as below: 20 and 75 units for flexor carpi ulnaris and flexor carpi radials; 12.5-35 units per fascicle in the flexor digitorum sublimis and flexor digitorum profundus (maximum dose: 120 units for each of these muscles); 10-35 units in the flexor pollicis longus; 25-100 units in the brachioradial ; 50-200 units in the biceps brachii; and 25-75 units in the pronator teres
214661261|NCT04826900|OTHER|Robotic therapy (RT)|A wearable robotic hand system will be used in this study. The robotic hand system consisted with a wearable exoskeletal hand, sensor glove, and a control box. On the exoskeletal hand, there are five actuators on each of finger structure that can provide external power to bring individual finger moving. The sensor glove has five sensors that can detect the finger's posture during movement and then manipulates exoskeletal hand via the control box. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeleton hand, and the unaffected hand does the certain transitive and intransitive tasks as the mirror group, and then makes the affected hand do the same movements driven by the exoskeleton robotic hand.
214661262|NCT04826900|OTHER|Robotic mirror therapy (RMT)|Wearable robotic hand system and mirror system will be used in this group.. The patients in the group will wear the robotic hand to do the mirror therapy. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeletal hand, a mirror box with a mirror will be placed in the patient 's midsagittal plane beside the unaffected hand to block his or her view of the affected hand. The patient's unaffected hand does the certain transitive and intransitive tasks and the patient will be instructed to look at the reflection of the unaffected hand in the mirror as if it is the affected hand (the visual input). At the same time the affected hand will be passively moved by the exoskeleton robotic hand which is under the .control of the unaffected hand.
214661263|NCT04826900|OTHER|Functional task training|After either 45 minutes of RT or RMT, all participants receive 15 minutes of training in functional tasks. The functional tasks included taking up and holding bowl or using eating utensils , bringing a cup for drinking, drying sucks by clips, open ing or closing door , turning on or off the light, cleaning the table or window and so on . The functional tasks training will be bases on the needs and ability of patients.
214661264|NCT00202592|DRUG|Perindopril|
214661265|NCT04699630|DRUG|U3-1402|All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.
214661266|NCT02348073|DRUG|Vayarin®, supplementation of n-3 PUFA|"Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product."
214661267|NCT02348073|DRUG|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
214661268|NCT04671797|BEHAVIORAL|Early dinner|Dinner at DLMO-3, sleep at DLMO+2
214661269|NCT04671797|BEHAVIORAL|Late Dinner|Dinner at DLMO+1, sleep at DLMO+2
214661270|NCT04671797|BEHAVIORAL|Late Dinner + Late Sleep|Dinner at DLMO+1, sleep at DLMO+6
214661271|NCT06314126|DIETARY_SUPPLEMENT|D-Chiro-Inositol|Patients in the experimental group will receive 1200 mg of oral D-Chiro-Inositol per day.
214661272|NCT06314126|OTHER|Placebo|Patients in the control group will receive 1200 mg of placebo per day.
214661273|NCT05119556|BEHAVIORAL|Video Telehealth Pulmonary Rehabilitation|Participant will be asked to exercise 3 times a week at their home for 60 minutes each session, via live two-way videoconferencing using a data-enabled smart phone or similar device. A total of 36 sessions will be administered over 13 weeks post-discharge. Sessions will be administered by exercise physiologists located at the University of Alabama at Birmingham. Each session will be scheduled with up to three other participants at a time to mimic group sessions as delivered at center-based pulmonary rehabilitation programs. Exercise sessions will include aerobics, strength or resistance training, breathing exercises, and education sessions. The exercise plans will be tailored according to the participants' baseline exercise tolerance as determined by an initial six minute walk test and their answers to the questionnaires at the baseline visit.
214848891|NCT03225014|DIAGNOSTIC_TEST|Physical therapy|PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.
214848892|NCT06617377|OTHER|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan (estimated total scanning time = 45 min for all centers except for Toulouse = 60min) will be acquired at least after 72h from complete withdrawal of sedation in normothermia condition (between Day 1 and Day 7 after inclusion).
214848893|NCT02061176|PROCEDURE|Transanal Haemorrhoidal Dearterialization|
214848894|NCT02061176|PROCEDURE|Open Haemorrhoidectomy|
214848895|NCT03297294|DRUG|EMA401|capsules, oral
214848896|NCT03297294|DRUG|Placebo|Placebo to EMA401 capsules, oral
214848897|NCT03485482|DRUG|Bisoprolol|bisoprolo 5 mg tablets
214848898|NCT03485482|DRUG|Ivabradine|Ivabradine 10 mg tablet
214848899|NCT03485482|DRUG|combination of Ivabradine and bisoprolol|combination of 10 mg ivabradine and 5 mg bisoprolol
214848900|NCT04424966|DRUG|Infigratinib|The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.
214848901|NCT01221831|DRUG|estetrol, P 1 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P1 tablet per day~* Days 25-28: two placebo tablets per day"
214661274|NCT06581484|BEHAVIORAL|Digital patient empowerment intervention|The intervention has features such as a digital medical passport, updated health-related information, community support and patient/peer stories and advice
214661275|NCT06359340|BEHAVIORAL|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
214661276|NCT03746470|PROCEDURE|ACL reconstruction preserving insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis, preserving their insertion at the level of the hamstring.
214661277|NCT03746470|PROCEDURE|ACL reconstruction detaching insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis tendons completely detached from their insertion at the hamstring.
214661278|NCT05646836|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
214661279|NCT05646836|DRUG|XmAb24306|XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
214661280|NCT05646836|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
214661281|NCT06314243|DIETARY_SUPPLEMENT|"Pumpkin Seed Oil  Ronkin®, KMT PHARMA, Egypt. "|Ronkin soft gelatin capsules, each containing 1010 mg of pumpkin seed oil (Latin name: Curcurbita pepo), standardized to contain palmitic acid (8-15%), stearic acid (3-8%), oleic acid (15-35%), linoleic acid (40-65%), and other fatty acids (≤ 2.4%)
214661282|NCT01357811|DRUG|eliglustat; digoxin|repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
214661283|NCT01357811|DRUG|digoxin|oral 0.25mg dose of digoxin (single dose) on Day 1
214661284|NCT03550560|PROCEDURE|EUS-Guided drainage|Drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses.
214661285|NCT02597062|DRUG|Carfilzomib|
214661286|NCT02597062|DRUG|Cyclophosphamide|
214661287|NCT02597062|DRUG|Dexamethasone|
214661288|NCT03372941|DRUG|Dalbavancin|Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.
214661289|NCT04025645|DIAGNOSTIC_TEST|MEASUREMENT OF COMMON BILE DUCT PRESSURES|THE PRESSURES OF THE COMMON BILE DUCT WERE MEASURED
214661290|NCT02804360|DEVICE|dexamethasone injection|intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
214661291|NCT02034045|OTHER|Community Paramedicine|
214661292|NCT02034045|OTHER|Usual Care|
214661293|NCT00212407|BIOLOGICAL|Umbilical Cord Blood Transplantation|
214661294|NCT06273969|OTHER|Osteopathic Manipulative Treatment (OMT)|"The OMT protocol is designed to target the somatic dysfunction associated with TOS. The somatic dysfunction associated with TOS include muscular hypertonicity of the anterior and middle scalene muscles, hypertonicity of the pectoralis muscles, and tension in the fascia of the supraclavicular area between the clavicle and first rib. The OMT protocol will consist of the following four techniques:~Direct Thoracic Inlet Myofascial Release (TIMFR) - Reduce tension at the thoracic inlet fascia located between the thoracic outlet and the cervical spine.~Direct Muscle Energy for the Scalene Muscles -Reduce tension within the scalene muscle group~Direct Muscle Energy for the Pectoralis Muscles - Reduce tension within the pectoralis muscle group~Supraclavicular Fascial Release - Reduce fascial tension within the supraclavicular fossa"
214661295|NCT01126580|DRUG|Metformin|
214661296|NCT01126580|DRUG|LY2189265|
214661297|NCT01126580|DRUG|Placebo (oral)|
214661298|NCT01126580|DRUG|Placebo (subcutaneous)|
214661299|NCT00877344|PROCEDURE|Immediate insertion|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
214661300|NCT00877344|PROCEDURE|Interval insertion|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
214661301|NCT03461055|OTHER|Lavender|Lavender aromatherapy
214661302|NCT03461055|OTHER|Water|Water
214661303|NCT02948166|PROCEDURE|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
214848902|NCT01221831|DRUG|estetrol, P2 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P2 tablet per day~* Days 25-28: two placebo tablets per day"
214848903|NCT01221831|DRUG|Estradiol valerate, dienogest and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-26: one tablet of Estradiol valerate/dienogest per day~* Days 26-28: one placebo tablet per day"
214848904|NCT02127073|DRUG|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
214661304|NCT02948166|PROCEDURE|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
214661305|NCT01917786|DEVICE|ECG|
214661306|NCT00686543|DRUG|Posaconazole|Posaconazole will be used for prophylaxis
214661307|NCT06247969|DEVICE|endotracheal tube|Endotracheal Tube (ETT) is a flexible plastic tube that is inserted through the mouth or nose into the trachea to establish an artificial airway.
214661308|NCT00803114|DRUG|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
214661309|NCT00803114|DRUG|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
214848905|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
214848906|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
214848907|NCT04575714|OTHER|Data record|Data record
214848908|NCT03777345|DEVICE|cobalt-chromium framework partial dentures|It's a biocompatible metal alloy used in thin sections and are less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and is resistant to corrosion. Disadvantages include hypersensitivity, esthetic issues with metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production .
214848909|NCT03777345|DEVICE|PEEK framework partial dentures|It's a promising polymer-based framework material has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
214848910|NCT01884402|DRUG|Peginterferon alfa-2a|Treatment as usual clinical practice
214848911|NCT01884402|DRUG|Ribavirin|Treatment as usual clinical practice
214848912|NCT05321823|DEVICE|iBreast device|The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.
214661310|NCT02770157|DRUG|DA-3002|
214661311|NCT02770157|DRUG|Genotropin®|
214661312|NCT02631720|PROCEDURE|Blood Draw|
214661313|NCT02631720|PROCEDURE|Bronchoscopy|
214661314|NCT01708057|DRUG|AZD8683|AZD8683 administered via inhalation
214661315|NCT01708057|DRUG|Placebo|Placebo administered via inhalation
214661316|NCT01708057|DRUG|Tiotropium|Tiotropium administered via inhalation
214848913|NCT05321823|OTHER|Clinical Breast Examination|The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community
214848914|NCT05321823|DIAGNOSTIC_TEST|Breast ultrasound|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.
214848915|NCT05321823|DIAGNOSTIC_TEST|Mammography|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.
214848916|NCT05592249|OTHER|Dual Task MC|Dual Task MC group will receive 60 minutes motor - cognitive dual task intervention 5 day per week for 6 weeks in clinic.
214848917|NCT05592249|OTHER|Dual Task MM|Dual Task MM group will receive 60 minutes motor - motor dual task intervention 5 day per week for 6 weeks in clinic.
214848918|NCT04580849|OTHER|telerehabilitation with dance|Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
214848919|NCT05814133|DEVICE|Thulium Fiber Laser|Thulium Fiber Laser will be used to break renal stones \< 2 cm into fragments small enough to remove or pass spontaneously through the ureter.
214848920|NCT03902899|OTHER|Educational intervention (oral presentation)|A brief oral presentation (30-45 minutes) which focused on making endoscopists aware of the significance and characteristics of serrated polyps.
214661317|NCT02288637|OTHER|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
214661318|NCT02288637|OTHER|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
214661319|NCT02288637|OTHER|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
214661320|NCT02504255|BIOLOGICAL|Biological samplings|Blood, urine and faecal sampling every 3 months
214661321|NCT02504255|OTHER|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
214661322|NCT05646810|DIAGNOSTIC_TEST|Lidocaine (10 mg/ml)|Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
214661323|NCT05646810|DIAGNOSTIC_TEST|Isotonic saline|Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
214661324|NCT03184948|DEVICE|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
214661325|NCT04095520|PROCEDURE|Laser Etching|Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.
214661326|NCT04095520|PROCEDURE|Phosphoric acid etching|Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
214661327|NCT04740411|BEHAVIORAL|The Common Elements Toolbox (COMET)|COMET is an online unguided self-help intervention that lasts approximately 60-80 minutes.
214661328|NCT03240900|DEVICE|Electrical Stimulation|Electrical stimulation - a needle attached to an cathode polarity will be placed within the intercostal space near the 4th intercostal nerve. A second needle attached to the anode polarity will be inserted into the serratus anterior muscle. Both electrodes will then be attached to a Grass SD9 stimulator and the voltage and frequency of the stimulation will be titrated to the point where contraction of the intercostal muscles is palpable. It will be maintained at this level for one hour at which point the wires will be removed. This technique is part of the standard of care for peripheral nerve surgeries of the extremities and is proven to be safe in humans.
214661329|NCT03240900|PROCEDURE|Placebo|This breast will receive no electrical stimulation; the mastectomy and reconstruction will proceed with no intervention.
214661330|NCT00682630|DRUG|pyronaridine artesunate clinical trial reference tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
214848921|NCT06322459|BEHAVIORAL|Sport Education Curriculum|The six characteristics of The Sport Education Model include season, affiliation, formal competition, culminating event, Record-keeping, and Festivity. The intensity of the training is increasing in the first 30 minutes, and the intensity is gradually decreasing in the next 10 minutes.
214848922|NCT06322459|BEHAVIORAL|Normal teaching|The intervention content, frequency, and intensity were the same as those in the experimental group, but the type of intervention was different. The most significant difference between the two teaching methods lies in delivering basic content. The Sport Education Model includes Teacher-directed learning (10 minutes) and Team practice (10 minutes); Normal Teaching includes Teacher-directed learning (10 minutes) and Individual practice (10 minutes).
214848923|NCT06616233|DEVICE|Remote Ischaemic Conditioning with exercise|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm). During the cuff deflation phase, participants will undergo handgrip exercise at 20-30% of their maximal voluntary contraction for 3 minutes. There will be a total of 4 cycles of exercise.
214848924|NCT06616233|DEVICE|Other: Remote Ischaemic Conditioning|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm).. There will be a total of 4 cycles.
214848925|NCT02251977|DRUG|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
214848926|NCT02251977|DRUG|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
214848927|NCT02251977|DRUG|mFOLFOX6 or XELOX|"mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient."
214848928|NCT04973098|BIOLOGICAL|CT0181 Cells|5 dose levels each with or without lymphocyte clearance were tentatively determined.
214848929|NCT02199119|BEHAVIORAL|Exercise|30 min of moderate exercise on a treadmill
214848930|NCT02199119|BEHAVIORAL|TV viewing|watching TV (animated children's programming) for 30 min
214848931|NCT02199119|BEHAVIORAL|Sitting quietly|Sitting quietly for 30 min
214848932|NCT02004067|DRUG|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
214848933|NCT02004067|DRUG|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
214848934|NCT01491633|DRUG|Dasatinib|140 mg orally, daily in 28 day cycles
214661331|NCT00682630|DRUG|pyronaridine artesunate to-be-marketed tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
214661332|NCT04635176|DRUG|Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone)|real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
214661333|NCT04635176|DRUG|Sham iPACK block with 20ml normal saline|Sham iPACK block with 20 ml Normal saline
214661334|NCT00843570|DRUG|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
214661335|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
214848935|NCT05220969|GENETIC|Total Genotype Risk Score|A total genotype risk score has been generated based on the results of previously observed genetic association studies
214848936|NCT01772355|DEVICE|semi automated core needle biopsy of orbital tumors|
214848937|NCT02676791|DRUG|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
214661336|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
214661337|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
214661338|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
214661339|NCT00947349|DRUG|BI 201335 NA low placebo|Placebo
214661340|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
214661341|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
214661342|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
214661343|NCT00947349|DRUG|BI 201335 NA low|BI 201335 NA
214661344|NCT00947349|DRUG|BI 201335 NA high placebo|placebo
214661345|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
214661346|NCT00947349|DRUG|Placebo|
214661347|NCT03704337|DIETARY_SUPPLEMENT|Commercially Available Food Bar|Active
214661348|NCT03704337|DIETARY_SUPPLEMENT|Placebo|Placebo
214661349|NCT03941002|DIAGNOSTIC_TEST|Assesment of diaphragm function|Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation
214661350|NCT03354845|OTHER|Deprescribing intervention|Pharmacists assessed the appropriateness of target symptomatic medications and potential for discontinuation. After discussion with pharmacists and consideration of patients' and caregivers' preferences regarding discontinuation or dose reduction, doctors would deprescribe these symptomatic medications. Symptom recurrence, adverse drug withdrawal events (ADWEs), and the need for drug re-initiation or initiation of new symptomatic control medications after deprescribing were monitored and documented in the 1st, 2nd and 6th weeks.
214661351|NCT01697345|DRUG|Testosterone|
214661352|NCT00538681|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression
214661353|NCT00538681|DRUG|pemetrexed|500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
214661354|NCT00538681|DRUG|cisplatin|75 mg/m², IV, every 21 days, for each 21-day cycle
214661355|NCT00538681|DRUG|placebo|po, QD
214661356|NCT05718401|DEVICE|NMR|nuclear magnetic resonance in genomics
214661357|NCT04447547|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
214661358|NCT01209715|DRUG|Placebo|participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
214661359|NCT01209715|DRUG|Fluticasone /salmeterol|Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
214661360|NCT03895138|OTHER|Standard Glucommander Protocol (SGP)|Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.
214661361|NCT03895138|OTHER|Optimized Glucommander (OGM)|The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
214661362|NCT03321799|DEVICE|Negative Pressure Wound Therapy (NPWT)|A computer randomization system will be used on the day of surgery to allocate patients to either the conventional or NPWT dressing. Due to the nature of this study, blinding of patients and surgeons to their allocated cohort will not be possible.
214661363|NCT03321799|DEVICE|Sterile Antimicrobial Dressings|Control group, current hospital standard.
214661364|NCT00302640|DRUG|Alinia (nitazoxanide)|
214661365|NCT00859755|DRUG|ARRY-403, glucokinase activator; oral|single dose, escalating
214661366|NCT00859755|DRUG|Placebo; oral|matching placebo
214661367|NCT05369806|BEHAVIORAL|Interactive two-way SMS dialogue|This study uses Mobile WACh, a human-computer hybrid system that enables two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day. Women who experience pregnancy or infant loss will be enrolled into an infant loss track. The NLP model will be applied to incoming participant messages. Those flagged as urgent by the model will be flagged within the SMS system, allowing study nurses to triage and appropriately respond to those messages.
214661368|NCT05422976|DEVICE|EVI-01|High molecular weight Hyaluronic Acid
214848938|NCT00625755|BIOLOGICAL|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
214661369|NCT02812004|DEVICE|Ultra Q Reflex YAG laser (Ellex)|"Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.~For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses."
214661370|NCT04407169|OTHER|no intervention|There will be no intervention. It is only an observationnal study
214661371|NCT00140855|BIOLOGICAL|ipilimumab|
214661372|NCT03987945|DEVICE|left atrial appendage occlusion devices|All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
214661373|NCT01511757|DRUG|Fluconazole|Fluconazole Tablets, 200 mg
214661374|NCT01511757|DRUG|Fluconazole|fluconazole 200 mg
214661375|NCT00342355|DRUG|Zidovudine|600 mg once daily
214661376|NCT00342355|DRUG|Stavudine|40 mg once daily
214661377|NCT00342355|DRUG|Didanosine|\<60 kg/125 mg twice daily or \>60kg/200 mg twice daily
214661378|NCT00342355|DRUG|Lamivudine|300 mg once daily
214661379|NCT00342355|DRUG|Efavirenz|600 mg once daily
214661380|NCT00342355|DRUG|Lopinavir/Ritonavir|r/LPV 400mg/100mg twice daily
214848939|NCT02137694|OTHER|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
214848940|NCT00003430|DRUG|L-778,123|
214848941|NCT05861219|BEHAVIORAL|water immersion|mild physical activity then water immersion in tub
214848942|NCT05164913|OTHER|Achenbach Child Behavior Checklist （CBCL）scale|Use the Achenbach Child Behavior Checklist （CBCL）scale to assess children's behavior
214848943|NCT00467987|DRUG|androgel|androgel 1%
214661381|NCT03929250|DRUG|2g Centella asiatica water extract product|2g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
214661382|NCT03929250|DRUG|4g Centella asiatica water extract product|4g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
214661383|NCT00000984|DRUG|CD4 Antigens|
214848944|NCT00467987|DRUG|placebo|placebo
214848945|NCT02208752|OTHER|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
214848946|NCT02776553|OTHER|Nutritional consultation|Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids
214848947|NCT02776553|BEHAVIORAL|Physical training program|Physical activity prescription will target ≥10,000 steps/day, taking into account all activities performed throughout the day, although the increment in activity should be no less than 3000 steps/day above the baseline.
214848948|NCT02776553|BEHAVIORAL|Behavioral modification therapy|The behavior modification theory will be applied in the form of a structured set of cues and questions between investigator and participant at each visit in order to provide individually tailored counseling to enhance internal motivation and facilitate behavior change toward physical activity and dietary improvement that are adaptable to each participant's usual habits.
214848949|NCT03072654|PROCEDURE|Thyroidectomy|Remove the nodular goiter on the neck by thyroidectomy (standard procedure)
214848950|NCT00190580|DRUG|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
214848951|NCT00190580|DRUG|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
214848952|NCT02012231|DRUG|PLX8394|PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
214848953|NCT04203121|RADIATION|low dose whole brain radiation to treat Alzheimer disease|"subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions"
214848954|NCT01748955|DRUG|Paroxetine CR for Major Depressive Episode|Dosage will be 25mg every day for 2 weeks, then 37.5mg every day for 2 weeks, and then optional increase to 50mg every day for the remainder of treatment.
214848955|NCT01748955|DRUG|Bupropion XL for Major Depressive Episode|Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
214848956|NCT01946984|PROCEDURE|ERCP|endoscopy, retrograde cholangio-pancreaticography.
214848957|NCT01946984|DRUG|Diclofenac hydroxyethylpyrrolidine|
214661384|NCT01085188|BEHAVIORAL|ACC|Weekly community based behavioral counseling and case management
214661385|NCT01085188|BEHAVIORAL|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
214661386|NCT01085188|BEHAVIORAL|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
214661387|NCT05843214|OTHER|Non-invasive neuromonitoring evaluation (transcranial doppler, optic nerve envelope diameter and quantitative pupillometry)|4 days Post-operation follow-up. Data will be gathered before the surgery and at regular times after the surgery until day 4
214661388|NCT06653621|DRUG|Bupivacaine liposome|Subjects receive liposomal bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
214848958|NCT01946984|DRUG|Normal Saline|
214848959|NCT05592353|OTHER|Brace|Brace following hip arthroscopy
214848960|NCT01566526|DRUG|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
214848961|NCT06142669|DEVICE|EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert|Primary knee arthroplasty or a revision knee that requires a revision procedure.
214848962|NCT04845646|DRUG|ASC41|5mg/tablet
214848963|NCT04845646|DRUG|Itraconazole|200mg/capsule
214848964|NCT04845646|DRUG|Phenytoin|300mg/capsule
214848965|NCT06304714|OTHER|Patients suffering from envenomation by Bothrops|"For research purposes, the investigator will collect six additional tubes of blood during a venipuncture. This additional volume of blood will be used for research analysis.~The total volume drawn will be within the maximum volume of blood that can be drawn based on body weight.~Venous sampling is planned as part of routine care and the additional blood volumes collected are not significant. This is a low risk procedure due to the small amount of extra blood taken (25,5 ml)."
214848966|NCT05122221|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
214848967|NCT05122221|DRUG|Interleukin-2|Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.
214848968|NCT05122221|BIOLOGICAL|CRTE7A2-01 TCR-T Cell|On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
214848969|NCT02156921|OTHER|App-based training|
214848970|NCT04331964|PROCEDURE|partial pulpotomy|Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.
214848971|NCT02330744|BEHAVIORAL|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
214848972|NCT02330744|BEHAVIORAL|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
214661389|NCT06653621|PROCEDURE|Nerve block mode : adductor block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for adductor block under ultrasound guidance.
214661390|NCT06653621|DRUG|Bupivacaine|Subjects receive bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
214661391|NCT06653621|PROCEDURE|Nerve block mode: femoral triangle block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block under ultrasound guidance.
214661392|NCT06451874|BEHAVIORAL|Functional Power Training (FPT)|Participants will receive twice weekly FPT, a progressive functional-based exercises that target optimizing leg force production and leg velocity.
214661393|NCT06451874|BEHAVIORAL|Music-Based Digital Therapy (MBDT)|Participants will receive twice weekly MBDT, a technology-driven gait training that is grounded in evidence-based rehabilitation treatment, rhythmic auditory stimulation.
214661394|NCT06451874|BEHAVIORAL|FPT + MBDT|For non-responders who were randomized to augment treatment, they will receive combined FPT and MBDT treatment.
214848973|NCT02220595|PROCEDURE|Carotid endarterectomy vs. carotid stenting|
214848974|NCT00668447|DIETARY_SUPPLEMENT|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
214848975|NCT00668447|DIETARY_SUPPLEMENT|Control protein|20 grams of powder mixed in beverages or food daily for one year
214848976|NCT00668447|DIETARY_SUPPLEMENT|Novasoy isoflavones|3 tablets daily for one year
214848977|NCT00668447|DIETARY_SUPPLEMENT|Placebo tablets|3 tablets daily for one year
214848978|NCT04127292|BEHAVIORAL|Emotional Self Awareness (ESA) Individual Feedback|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
214848979|NCT05259904|DRUG|L-citrulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
214848980|NCT05259904|DRUG|Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
214848981|NCT00566280|PROCEDURE|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
214848982|NCT05822674|DRUG|Sitagliptin/metformin ( 50/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
214848983|NCT05822674|DRUG|Empagliflozin/metformin(10/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
214848984|NCT01043926|DRUG|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
214848985|NCT05210049|DIAGNOSTIC_TEST|Esocheck/Esoguard|All enrolled patients will complete the Esocheck screening test. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus. The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM. These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men. Diagnostic yield of this test among Veterans is unknown.
214661395|NCT01236391|DRUG|PCI-32765|560 mg daily
214661396|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology.
214661397|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta after determining the safe zones of clamping|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology. Before surgery, multispiral computed tomography data is evaluated using artificial intelligence and safe zones of aortic and arterial clampings are determined. Intraoperatively, clamping is performed in the settlement zones.
214661398|NCT04792294|DEVICE|Extracorporeal photopheresis|ECP can be used as second-line treatment in patients unresponsive to azithromycin. ECP has been firstly developed for treatment of cutaneous T cell lymphomas and later used in a variety of other indications including solid organ transplantation. The process starts with leukapheresis, followed by incubation of the isolated cells with 8-methoxypsoralen (8-MOP) and subsequent activation of 8-MOP with ultraviolet A radiation. At the end, the cells are reinfused into the patient. 8-MOP is a biologically inert substance, but in the presence of UVA light it cross-links DNA by forming covalent bonds with pyrimidine bases and causes apoptosis.
214661399|NCT05003362|BEHAVIORAL|ACT|mindfulness intervention for patients with pain/migraine
214661400|NCT02691000|DEVICE|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
214661401|NCT02691000|DEVICE|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
214661402|NCT05537025|DRUG|ARO-MMP7 Inhalation Solution|ARO-MMP7 by inhalation of nebulized solution
214661403|NCT05537025|DRUG|Placebo|Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution
214848986|NCT04709224|DRUG|Lumateperone Long-Acting Injectable|Lumateperone Long-Acting Injectable
214848987|NCT03710317|DRUG|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
214848988|NCT03710317|DRUG|Tranexamic Acid|1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
214848989|NCT03710317|DRUG|misoprostol|Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
214848990|NCT06412302|OTHER|Whey Protein+Resistance Training|WP group received 25g protein on one scoop of Whey Protein Isolate (Iso100 Dymatize) with 8 weeks of resistance training 3 days a week.
214848991|NCT06412302|OTHER|High protein yogurt+Resistance Training|PY group received 24.6g protein on two High Protein yogurts (Lonco Leche) with 8 weeks of resistance training 3 days a week.
214661404|NCT05462093|DEVICE|Liver Multiscan sequences|Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
214661405|NCT05462093|DEVICE|Liver Multiscan analysis|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
214661406|NCT05462093|DEVICE|MRCP+|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
214661407|NCT06654648|OTHER|Combined exercise nutrition intervention group|Combination Product: Combined exercise and nutrition intervention Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks). Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol. Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
214661408|NCT06654648|OTHER|Conventional medial care group|"Conventional medial care Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
214661409|NCT02278913|DRUG|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
214661410|NCT02278913|DRUG|Human Insulin|NPH twice a day + Regular insulin before meals
214661411|NCT04293016|BEHAVIORAL|Support as usual|This group receives current best practice which includes participation in ICU support groups and provision of community support resources
214661412|NCT04293016|BEHAVIORAL|Problem solving therapy|This group will receive one on one therapy based on identifying stressors and solutions to those stressors
214661413|NCT04293016|BEHAVIORAL|ICU diary|This group will be provided with a structured written diary that includes identification of stressors and development of solutions to those stressors
214661414|NCT05104944|RADIATION|Serial MRIs|Serial use of MRI at 3, 6, 9 and 12 months to identify disease resolution and thus discontinuation of immobilisation plus standard care.
214661415|NCT05232734|DRUG|Caffeine Citrate 20 MG/ML Oral Solution|Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
214661416|NCT02342834|DIETARY_SUPPLEMENT|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
214661417|NCT01865734|OTHER|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
214661418|NCT01865734|OTHER|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
214661419|NCT01097044|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
214661420|NCT01097044|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
214661421|NCT05983848|RADIATION|99mMaracticaltide imaging|7.3.1 99mTc-maraciclatide imaging This will be undertaken at baseline and optionally at 8-12 weeks. Not more than 75 µg of 99mTc-maraciclatide will be administered intravenously with an activity as close as possible to 740 MBq. Static whole-body imaging will be undertaken after a maximum of 2 hours with further dedicated views of the hands and feet. Total image acquisition time will be approximately 30 minutes. Images will be scored by quantitative and semi-quantitative methods by a blinded observer.
214661422|NCT00519870|DRUG|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
214661423|NCT00519870|DRUG|losartan|II: losartan
214661424|NCT00519870|DRUG|Nifedipine, losartan|I: nifedipine II: losartan
214661425|NCT05728814|DRUG|Dostarlimab|"The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles."
214661426|NCT01167296|DEVICE|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
214848992|NCT02596633|BEHAVIORAL|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
214848993|NCT00382629|DRUG|BHT-3009 0.5 mg|
214661427|NCT00013078|PROCEDURE|Physical restoration intervention|
214661428|NCT03435978|BEHAVIORAL|MetS+|
214661429|NCT03435978|OTHER|MetS-|Data processing from Patient Medical Files
214661430|NCT06550661|BEHAVIORAL|Ba duan jin|a kind of exercise
214848994|NCT00382629|DRUG|BHT-3009 1.5 mg|
214848995|NCT00382629|DRUG|Placebo|
214848996|NCT01722682|BIOLOGICAL|Human pancreatic islet transplantation|
214848997|NCT00738361|DRUG|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
214661431|NCT06817005|DEVICE|Intervention arm|Prior to general anesthesia induction, a finger is inserted into the probe which is connected to the PMD200® to provide the NOL index. This output, a single dimensionless number from 0 to 100, correlated proportionally to nociception.
214661432|NCT06657040|OTHER|MUSIC|The intervention group will receive a soundtrack through individual choice of anti-noise headphones. The music offer platform will be provided by an application developed by MusicCare (www.music.care/en/index.html) in two periods of the day (09:00 and 16:00), lasting 45 minutes each, for up to seven postoperative days or until discharge from the unit (whichever occurs first). MusicCare has been widely tested in several countries and there are a large number of publications in anesthesiology, ICU, cardiology and neurology, among other specialties, demonstrating its safety and efficacy69,70. Patients who were hospitalized for more than 48 hours, that is, who received a minimum of 4 intervention periods, will be considered as patients with effective intervention. Patients with less time will be evaluated in the form of intention to treat.
214661433|NCT06657118|PROCEDURE|Ultrasound guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* Transducer is placed over TMJ, parallel to the long axis of mandibular ramus. • Transducer is tilted until the optimal visualization is obtained.~* Disc is visualized as a thin homogenous, hypo-to-iso-echoic band lying adjacent to the inferior relation. The bony landmarks of the mandibular condyle and the articular eminence are visualized as hyperdense lines.~* Superior joint space located between the disc and articular eminence is the targeted point of the needle.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
214661434|NCT06657118|PROCEDURE|Conventional anatomically guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* A line will be drawn from tragus of the ear to the outer canthus of the eye with ink.~* Double needled canula is inserted into superior compartment of the joint space 2mm below and 10 mm ahead of mid-tragal end of Holmund Hellsing's line.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
214848998|NCT05105919|DRUG|Aspirin 80 mg EC Tab|Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
214848999|NCT00429624|PROCEDURE|Chiropractic manipulation|
214849000|NCT00429624|DRUG|acetaminophen|
214290161|NCT01310101|DRUG|ofatumumab plus dexamethasone|"Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18"
214849001|NCT06214416|BEHAVIORAL|Abstention|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote abstention.
214849002|NCT06214416|BEHAVIORAL|Mediterranean alcohol-drinking pattern|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote the Mediterranean alcohol-drinking pattern.
214849003|NCT05295654|OTHER|Kinect validation|Participants will perform several movements while both the vicon and kinect are measuring.
214849004|NCT02598895|DRUG|Carboplatin|Given IV
214849005|NCT02598895|DRUG|Docetaxel|Given IV
214849006|NCT02598895|OTHER|Laboratory Biomarker Analysis|Correlative studies
214849007|NCT05098457|DEVICE|GP0112|Injectable gel
214849008|NCT05098457|DEVICE|Restylane Lyft Lidocaine|Injectable gel
214849009|NCT02159287|DRUG|Enoxaparin|1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
214849010|NCT02159287|DRUG|Heparin|1000 unit per hour continuous intravenous infusion of heparin sodium
214849011|NCT03142659|OTHER|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
214849012|NCT00104247|DRUG|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
214849013|NCT01978652|BIOLOGICAL|Peginterferon Beta-1a|As specified in the treatment arm
214849014|NCT01886937|DRUG|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
214849015|NCT01886937|DRUG|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
214849016|NCT01051180|PROCEDURE|HALO|Ligation of haemorrhoidal arteries
214849017|NCT02405572|OTHER|infant formula|infant formulas
214849018|NCT06207292|RADIATION|Stereotactic Ablative Radiotherapy|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be chosen based on the target to be treated and its proximity to organs at risk(s):~Lung-peripheral 33-45 Gy/ 3 fractions~Lung-central/ultra-central 35-60 Gy/5 fractions~Mediastinal/supraclavicular node 35-45 Gy/5 fractions~Liver 45-54 Gy/3 fractions; 50-65 Gy/5 fractions~Bone non-spine 30-36 Gy/3 fractions; 35-50 Gy/5 fractions~Bone spine 30-33 Gy/3 fractions (SIB); 35-40 Gy/ 5 fractions (SIB)~Abdominal-pelvic node 33-39 Gy/ 3 fractions; 35-50 Gy/5 fractions~Adrenal gland 30-42 Gy/3 fractions; 35-50 Gy/5 fractions"
214849019|NCT02965664|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
214849020|NCT02965664|DRUG|Placebo|Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
214849021|NCT00063882|RADIATION|Brachytherapy (100/110)|100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
214849022|NCT00063882|RADIATION|Brachytherapy (125/145)|125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
214849023|NCT00063882|RADIATION|External Beam Radiation Therapy|Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
214849024|NCT04395248|PROCEDURE|Exploring potential risk factors of difficult intubation using ultrasound|Before surgery, ultrasound will be used to assess pretracheal soft tissue depth and height and width of tongue base. The distance from the skin to the anterior aspect of the trachea will be measured at three levels: vocal cords, thyroid isthmus, and suprasternal notch. With the patient in a seated position, the convex transducer of a portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be introduced to the skin of the neck in the submental region coronally, immediately cephalad to the body of the hyoid bone, and then in the area between the hyoid bone and the symphysis of the mandible. Maximal width of tongue base, tongue base height, and maximal height of mid-tongue will be measured. The laryngoscopy intubation will be performed using a size-3 or -4 Macintosh (Rüsch Inc., Duluth, GA, USA) blade and a styletted endotracheal tube. The laryngoscopic view will be graded according to Cormack and Lehane's classification with external laryngeal pressure applied.
214906968|NCT00708890|BEHAVIORAL|Brief motivation to participate in TSG|The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
214661435|NCT06092437|OTHER|Urine sodium guided diuretic algorithm|Loop diuretics are administered intravenously as soon as possible after diagnosis of ADHF and continued 3dd until recompensation. Spot urine sodium is measured 2 hours after administration of the first in-hospital IV diuretic dose and repeated until the target of 100mmol/L is reached in the first 72 hours of admission (after which, UrNa will be measured once daily). When target is not met, the next dosage of loop diuretic is doubled (max 3dd 250mg furosemide) and thereafter, other diuretics (thiazide, MRA) are added. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
214661436|NCT06092437|OTHER|Usual care|Treatment with IV loop diuretics left to the discretion of the treating physician. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
214661437|NCT05075161|DRUG|Pirfenidone|From days 1-7: 801mg/day; from days 8-14:1602mg/day, from day 15 to ICU discharge 2403 mg/day. All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
214661438|NCT05075161|DRUG|Placebo|All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
214661439|NCT06679790|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|All participants will receive 8 sessions of CBIT following a published treatment manual.
214661440|NCT06661239|BEHAVIORAL|benson relaxation|"The benson relaxation consisted of the following steps: (1) Sitting or lying down quietly in a comfortable position; (2) Closing eyes; (3) Deeply relaxing all muscles, beginning at the feet and progressing up to the face. Keeping them relaxed; (4) Breathing through the nose. (5) Maintaining a passive attitude and permitting relaxation to occur at its own pace; (6) Continuing for 15 minutes. When finished, sit quietly for several minutes, at first with eyes closed and later with eyes opened. Do not stand up for a few minutes.~According to the agreement, the patients in both groups were required to perform the Benson relaxation technique regularly twice daily (morning and evening) for seven days in a row. Each session lasted 15 minutes"
214661441|NCT06661239|BEHAVIORAL|Routine care in unit|The routine care include in the unit will be delivered to control group
214661442|NCT01077765|DEVICE|Eutrophill|Polyacrylamide Hydrogel
214661443|NCT03534648|DRUG|PF-06865571 administered Day 7-14|PF-06865571 administered Q12hr on Days 7-14
214661444|NCT03534648|DRUG|PF-06865571 administered Day 1-14|PF-06865571 administered Q12hr on Day 7-14
214906969|NCT02890602|DRUG|Darbepoetin alfa|Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
214661445|NCT03534648|DRUG|PF-05221304 administered Day 1-14|PF-05221304 administered Q12hr on Days 1-14
214661446|NCT03534648|DRUG|PF-05221304 administered Day 7-14|PF-05221304 administered Q12hr Days 7-14
214661447|NCT06478368|DIAGNOSTIC_TEST|Laparoscopic exploration|Laparoscopic exploration
214661448|NCT06661538|BEHAVIORAL|Food Security Screening & Referral Program|The I-FRESH (Implementing Food Referrals for Equity and Sustained Health) program is the food security nutrition support program that involves some combination and form of: 1) screening and identification of families experiencing food insecurity; 2) discussions with families to determine readiness to engage with nutrition support programs and other community resources; 3) referrals and support to engage with a program; and 4) conducting follow-up assessments to determine fit of program, track utilization, and assess need for additional referrals. The exact implementation and workflow for this program will be optimized for each clinic.
214661449|NCT00138762|DRUG|torcetrapib/atorvastatin|
214661450|NCT00138762|DRUG|atorvastatin|
214661451|NCT00138762|DRUG|placebo|
214661452|NCT02730546|DRUG|Carboplatin|Given IV
214661453|NCT02730546|PROCEDURE|Computed Tomography|Undergo CT scan
214290162|NCT01966900|BIOLOGICAL|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
214661454|NCT02730546|DRUG|Fluorouracil|Given IV
214661455|NCT02730546|OTHER|Laboratory Biomarker Analysis|Correlative studies
214661456|NCT02730546|DRUG|Leucovorin Calcium|Given IV
214661457|NCT02730546|DRUG|Oxaliplatin|Given IV
214661458|NCT02730546|DRUG|Paclitaxel|Given IV
214661459|NCT02730546|BIOLOGICAL|Pembrolizumab|Given IV
214661460|NCT02730546|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214661461|NCT02730546|RADIATION|Radiation Therapy|Undergo radiation therapy
214661462|NCT02730546|PROCEDURE|Therapeutic Conventional Surgery|Undergo curative-intent surgery
214661463|NCT04103918|DEVICE|Jalucomplex|Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
214661464|NCT06384872|OTHER|Shoe Cushioning Position and Properties|The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively, while remaining within the range of values of shoes available on the market (linear equivalent stiffness: about 40 to 60 and 50 to 80 N/mm, at the rear and forepart of the shoe, respectively). We expect a difference in shoe weight lower than 30 g between the three versions (for size 42). The difference in cushioning properties between shoe versions will be created by modifying the type of foam and the foaming process.
214661465|NCT01191593|PROCEDURE|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
214661466|NCT01191593|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
214661467|NCT05622500|PROCEDURE|Deep venous stenting|Endovascular reconstruction encompasses balloon venoplasty and venous stenting. A dedicated venous stent will be used, the brand of which the individual interventionist will decide.
214661468|NCT05622500|COMBINATION_PRODUCT|Best medical therapy|Compression stockings encompass a range of therapies used to provide an externally applied graduated-pressure up the length of the limb aiming to improve venous function and decrease lower limb swelling. Compression stockings can be classified by size and grade, i.e. the pressure the stockings applies to the limb. For the purpose of this trial Class II and Class III graduated compression stockings should be used, with the aim of providing Class III if tolerated. Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.
214661469|NCT02282787|DRUG|DEXMEDETOMIDINE|Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
214661470|NCT06861608|BEHAVIORAL|Screening Questionnaire|"Individuals will complete an online screening survey through an online study advertisement to determine initial eligibility. The screening survey will ask participants to report their gender and age and complete the Eating Attitudes Test - 26-item (EAT-26). EAT-26 scores equal to or greater than 20 indicate risk for an eating disorder. EAT-26, participants will meet the referral criteria which includes a score of 20 or more or meeting frequency criteria on bingeing, purging, laxative/diuretic use, and/or exercise. If an interested individual is not eligible, they will be notified that they are not currently eligible for the study and provided with resources."
214661471|NCT06861608|BEHAVIORAL|Pre-Intervention Questionnaires (~10 minutes)|Eligible participants will complete pre-intervention questionnaires including demographics and symptom measures.
214661472|NCT06861608|BEHAVIORAL|SSI (Single-session intervention (~30 minutes) Active arm|The SSI will consist of four components: 1)psychoeducation, 2) real-life examples, 3) common questions and misconceptions, and 4) providing advice to other young adults. Psychoeducation will focus on the brain bases of habit formation and EDs, as per REACH+ treatment manual. Participants will then be asked to think of a real-life example of an eating habit in which they have been engaged, such as limiting their intake of dessert foods. Participants will then be provided with REACH+ developed psychoeducation regarding changing habits, including information on competing responses, stimulus control, and exposure. Participants will have the opportunity to write out how they could use one of these strategies to tackle the habit that they previously wrote about. They will be provided with a worksheet to help them move through each aspect of changing their habit based on what they learned.
214661473|NCT06861608|BEHAVIORAL|SSI (Single-session intervention (~30 minutes) control arm|The control condition will be matched to the SSI by including both reading and writing exercises. The control intervention will consist of supportive therapy focusing on sharing emotions and include an introduction to emotions, writing about emotions, testimonials from other adolescents about the power of sharing emotions, and an exercise asking adolescents how different situations might make them feel.
214661474|NCT06861608|BEHAVIORAL|End-of-Intervention Questionnaires (~5 minutes)|Participants will complete additional questionnaires at the end of the intervention, including acceptability ratings and program feedback. Participants will provide an email address at the end of the questionnaires for receipt of four-week follow-up questionnaires.
214661475|NCT03740334|DRUG|Ribociclib|Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)
214661476|NCT03740334|DRUG|Dexamethasone|Corticosteroids are commonly used to treat ALL.
214661477|NCT03740334|DRUG|Everolimus|Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation
214661478|NCT06994507|DRUG|GM1|GM1 was administered intravenously one day before the administration of each cycle of chemotherapy. The experimental group was given 400 mg of GM1 injection. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.
214661479|NCT06994507|DRUG|Placebo|Placebo was administered intravenously one day before the administration of each cycle of chemotherapy. The control group was given placebo. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.
214661480|NCT05818670|DRUG|Tamsulosin|long term follow up
214661481|NCT05818670|DRUG|Tadalafil|long term follow up
214661482|NCT00562809|DRUG|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
214661483|NCT06322810|PROCEDURE|Erector spinae plane block (ESPB)|Bilateral ESP: 0.5% ropivacaine 0.3 ml per kg (ideal body weight) each side, 30 min before skin excision. After surgery, use pump to deliver an intermittent automatic bolus of 0.3 ml per kg 0.16% ropivacaine every 4 hours each side.
214849025|NCT04395248|PROCEDURE|Radial artery catheterization using ultrasound guidance or blind palpation|For all patients, the wrist will be extended and taped to a board to maintain wrist extension. All patients will receive local skin anesthesia at the anticipated puncture site. All radial artery catheterizations will be performed by anesthesiology residents with similar levels of experience in both blind-palpation and ultrasound-guided radial arterial catheterization. In the ultrasound group, a linear vascular probe of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image. In the palpation group, the radial artery will be identified by palpation, and the cannula will be directed by continuous or intermittent palpation of arterial pulsation. An attempt is defined as a new penetration of the skin with the needle, followed by an unlimited number of subcutaneous needle redirections.
214906970|NCT02890602|DRUG|R-CHOP|R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
214661484|NCT06322810|PROCEDURE|Pecto-intercostal fascial plane blok (PIFB)|Bilateral PIFB: 0.5% ropivacaine 0.3 ml per kg (ideal body weight) each side, 30 min before skin excision. After surgery, use pump to deliver an intermittent automatic bolus of 0.3 ml per kg 0.16% ropivacaine every 4 hours each side.
214661485|NCT04325594|BIOLOGICAL|Intracoronary administration of umbilical cord-derived MSCs|A suspension of 1×10⁷ umbilical cord-derived mesenchymal stromal cells in 20 ml of heparinized saline was administered by intracoronary infusion into the left coronary artery via a standard 6 Fr catheter over 10 minutes (2 ml/min). The infusion was performed without balloon occlusion or interruption of coronary blood flow.
214661486|NCT07004699|PROCEDURE|Laryngoscopy|Introduction of the laryngoscope to maintain spontaneous ventilation in order to observe, in real conditions, the evolution and movements of the otorhinolaryngology sphere.
214661487|NCT07004699|PROCEDURE|High-flow oxygen therapy|Introduction of High-flow oxygen therapy to maintain spontaneous ventilation in order to observe, in real conditions, the evolution and movements of the otorhinolaryngology sphere.
214661488|NCT06546839|DRUG|SPSIPB blcok|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
214661489|NCT06546839|DRUG|SAPB block|In the lateral decubitus position, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane concerning the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be injected for correction. Following confirmation of the correct position of the needle, 30 ml %0.25 bupivacaine will be administered for the block.
214661490|NCT06546839|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
214661491|NCT05929924|DIETARY_SUPPLEMENT|Extra virgin olive oil|EVOO will be included in the participant's daily diet for 6 months
214661492|NCT06867055|BIOLOGICAL|Injectable platelet-rich fibrin (I-PRF)|I-PRF were produced with 11-mL plastic tubes (16\*10 mm) using a Nuve NF 200 centrifugation device with a rotor angulation with a radius of 101 mm at the clot (Nuve NF 200, Nuve Industrial Materials Manufacturing and Trade Company, Ankara, Türkiye). The I-PRF at the top of the tube was collected with a syringe and transferred to the metal bowl. It was held for 20-25 min for polymerization.
214661493|NCT06867055|DRUG|0.8% hyaluronic acide (HA)|0.8% polyvinylpyrrolidone sodium hyaluronate (HA) (Gengigel Prof, Ricerfarma SRL.) gel was impregnated on a sterile gelatin sponge and sutured with 4/0 silk suture (4/0 Sterisilk, SSM Medical Equipment, Türkiye) on the palate area and bleeding control was provided with SX bioplast plate.
214661494|NCT06867055|OTHER|control group|Sterile gelatin sponge was sutured with 4/0 silk suture (4/0 Sterisilk, SSM Medical Equipment, Turkey) in the palatal region where FGG was taken and bleeding was controlled with SX bioplast plate.
214661495|NCT05885009|GENETIC|Liquid Biopsy|Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy
214849026|NCT04395248|DEVICE|Comparing the effectiveness of preoxygenation between high-flow nasal cannula and facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher \& Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs. After tracheal intubation, correct placement of the endotracheal tube will be confirmed by capnography and the nasal prongs of the HFNC group will be removed.
215033538|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (promoting positive imagery de novo)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of promoting positive imagery de novo.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
214661496|NCT05885009|GENETIC|Archival Tumor DNA sequencing|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
214661497|NCT06158100|DRUG|Venetoclax|Venetoclax will be given orally (PO) at the assigned doses of 50 or 100 mg once daily for 7, 14 or 21 days starting at day 1 of each 28-day cycle, for up to 12 cycles.
214661498|NCT06158100|DRUG|Azacitidine|Azacitidine will be administered at a dose of 20mg/m\^2 once daily subcutaneously (SC) or intravenously (IV) for five days (Days 1-5) of each 28-day cycle.
214661499|NCT06158100|BIOLOGICAL|Donor Lymphocyte Infusion|"Donor lymphocyte infusions (DLI) may be administered at the discretion of the treating physician, if certain criteria are met. Participants may receive up to three (3) infusions of donor lymphocytes (a type of white blood cell) at the following dose levels and study timepoints:~* DLI 1: 1x10\^6 cluster of differentiation 3+ (CD3+) cells/kg, after cycle 3~* DLI 2: 5x10\^6 CD3+ cells/kg, after cycle 5, if there is persistent MRD~* DLI 3: 1x10\^7 CD3+ cells/kg, after cycle 7, if there is persistent MRD."
214661500|NCT04865731|DRUG|Dermaprazole|Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
214661501|NCT04865731|DRUG|Aquaphor|Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
214661502|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order A-B|Research participants will be assigned to day shift condition and Diet A-B order condition.
214661503|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order B-A|Research participants will be assigned to day shift condition and Diet B-A order condition.
214661504|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order A-B|Research participants will be assigned to simulated night shift condition and Diet A-B order condition.
214661505|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order B-A|Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
214661506|NCT07016672|PROCEDURE|intra-articular injection of HA|3 injections at 7-day intervals
214661507|NCT07016672|PROCEDURE|intra-articular injection of PRP|3 injections at 15-day intervals
214661508|NCT07021066|DRUG|BL-M05D1|BL-M05D1 will be administered on D1 every 3 weeks.
214661509|NCT06127472|OTHER|Training in detection and diagnosis of ASD|To improve detection and diagnosis of ASD the participating mental health institutes will be trained by the research group on how to detect and diagnose autism in older adults. The basis of the ASD training involves two separate training sessions. Part one focuses on recognition and detection of ASD, specifically in older adults, and will be offered to the entire teams of the participating centres. The second part of the training focuses on the diagnosis of ASD and as such is offered primarily to diagnosticians. Follow up will consist of monthly recurring options for online consultation during the entire project to discuss clinical cases by experts in ASD in older adults from PersonaCura, clinical centre of excellence for personality and developmental disorders in older adults (dr. A. Videler and R. Wilting).
214661510|NCT06127472|OTHER|PE program|An adapted PE program for older adults with a (probability) diagnosis of ASD. The PE program consists of eight, two-hour group meetings on a weekly basis.
214661512|NCT06628713|DRUG|Sebetralstat|Oral Plasma Kallikrein Inhibator
214661513|NCT05405231|BEHAVIORAL|Crisis Line Facilitation (CLF)|Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase MVCL use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.
214661514|NCT05405231|BEHAVIORAL|Passive Implementation|The PI condition includes an educational resource brochure describing the MVCL, including the phone number for the crisis line, as well as other mental health services available to National Guard members.
214661515|NCT04008524|BIOLOGICAL|CAR-T cells|Chimeric Antigen Receptor-T cells
214661516|NCT06235229|BIOLOGICAL|GC012F|GC012F is a BCMA/CD19 dual CAR product
214661517|NCT07105618|DRUG|Dexmedetomidine|Dexmedetomidine as an adjunct to total intravenous anesthesia.
214661518|NCT07105618|DRUG|Fentanyl|Fentanyl as an adjunct to total intravenous anesthesia.
214661519|NCT07105618|DRUG|Magnesium|Magnesium sulphate as an adjunct to total intravenous anesthesia.
214661520|NCT07108127|DRUG|Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX|Trastuzumab biosimilars and pertuzumab biosimilars combined with oxaliplatin and capecitabine
214661521|NCT06935669|DRUG|Ketamine|Patients in this group will receive a transversalis fascia plane block using a combination of bupivacaine and ketamine.
214661522|NCT06935669|DRUG|Bupivacaine|Control group to evaluate the additional effect of ketamine in the experimental arm.
214661523|NCT06935669|DRUG|Bupivacain|Patients in this group will receive a transversalis fascia plane block using a combination of bupivacaine and ketamine.
214661524|NCT06935786|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Single appointment with a registered physiotherapist educating the patient for rehabilitating physical training and exercise to be performed independently and regularly by the patient at home, minimum of three times a week, during the study period.
214661525|NCT06936839|OTHER|Obversation|Observing the optimal flow rate to reduce left ventricular stress and enhance peripheral organ perfusion during ramp tests (conducted at QECMO levels of 100%, 75%, 50%, and 25%, provided that SVO₂ remains \>55% and NIRS rSO₂ remains \>50%)
214661526|NCT06935968|DEVICE|Levonorgestrel intrautrine system|Insertion of levonorgestrel intrautrine system and take a blood sample from the women to analyse it
214661527|NCT06936033|OTHER|Kinesiology taping|This study used Kinesio taping as an intervention to compare the biomechanical effects of stair descent in patients with acute ankle injuries before and after taping. Participants participated in two intervention conditions: the KT experimental group (Kinetoscopy taping) and the ST control group (no Kinesio taping), and each condition performed 20 separate stair descent tests.
214906971|NCT01702064|DRUG|Nilotinib|"Participants will remain on the same dose of nilotinib they have been receiving prior to enrollment on the trial. This will range from 300 mg PO BID to 400 mg PO BID.~Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose of ruxolitinib, based on the number of dose."
214661528|NCT06943898|OTHER|Core Egzercise|The core exercise group will perform core stabilization exercises for a total of 15 sessions, five days a week for three weeks. Exercises will include pelvic tilt, bridge, dead bug, bird dog, mini squats on a balance board, and wall planks. The number of repetitions will be increased from 10 to 20, and plank duration will be increased from 30 seconds to 45 seconds. A 5-minute warm-up and cool-down session will be included.
214661529|NCT06943898|OTHER|Core Exercises + Breathing Exercises|"This group will perform core stabilization exercises combined with the 360-degree breathing technique, for a total of 15 sessions over three weeks (five days a week).~360-degree breathing is a novel breathing method targeting deep and controlled inhalations into various regions of the body. Unlike traditional breathing exercises, 360-degree breathing ensures that all directions of the lungs are equally ventilated."
214661530|NCT02770807|DRUG|EryDex Low dose DSP|EDS-EP dose range of \~5-10 mg DSP/infusion
214661531|NCT02770807|DRUG|EryDex High dose DSP|EDS-EP dose range of \~14-22 mg DSP/infusion
214661532|NCT02770807|DRUG|Pooled Placebo|EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
214661533|NCT06946862|OTHER|no treatment, medication or intervention|will make an observational assessment of the participants' treatment expectations. Participants will not be subjected to any treatment or intervention, only their current situation will be observed.
214661534|NCT03396575|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
214661535|NCT03396575|BIOLOGICAL|TTRNA-xALT|During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
214661536|NCT03396575|DRUG|Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
214661537|NCT03396575|DRUG|Dose-Intensified TMZ|After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
214661538|NCT03396575|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
214661539|NCT03396575|BIOLOGICAL|Autologous Hematopoietic Stem Cells (HSC)|During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
214661540|NCT02017444|DRUG|AZD4017|
214661541|NCT02017444|OTHER|Placebo|Matched placebo (matched to AZD4017 arm)
214661542|NCT01186653|DRUG|budesonide / formoterol|budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
214661543|NCT01186653|DRUG|fluticasone/salmeterol|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
214661544|NCT05762705|BEHAVIORAL|Multilevel Gaming Adherence Intervention|Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages
214661545|NCT05762705|BEHAVIORAL|Treatment as Usual +|non-PrEP related mobile gaming application
214661546|NCT00229840|PROCEDURE|Functional MRI, Diffusion Tensor Imaging|
214661547|NCT05617092|OTHER|Physiotherapy treatment|physiotherapy individualized treatment according to the needs of the patient and clinical findings and symptoms
214661548|NCT05645094|DRUG|Envafolimab|Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.
214661549|NCT02293109|DRUG|carfilzomib|Given IV
214906972|NCT01702064|DRUG|Ruxolitinib|Dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose, based on the number of dose limiting toxicities seen at a specific dose.
214906973|NCT04042506|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV every 4 weeks
214661550|NCT02293109|DRUG|cyclophosphamide|Given IV
214661551|NCT02293109|DRUG|vincristine sulfate|Given IV
214661552|NCT02293109|DRUG|doxorubicin hydrochloride|Given IV
214661553|NCT02293109|DRUG|dexamethasone|Given PO
214661554|NCT02293109|DRUG|methotrexate|Given IV
214661555|NCT02293109|DRUG|cytarabine|Given IV
214661556|NCT02293109|DRUG|leucovorin calcium|Given IV or PO
214661557|NCT02293109|DRUG|methylprednisolone|Given IV
214661558|NCT02293109|BIOLOGICAL|rituximab|
214661559|NCT02293109|OTHER|laboratory biomarker analysis|Correlative studies
214661560|NCT03265691|OTHER|Early detection and treatment of hyponatremia|In the experimental group, hyponatremia will be diagnosed and treated early. Therefore, the researchers will review the patients' sodium levels at admission and throughout their stay.
214661561|NCT03265691|OTHER|No Intervention (SOC)|Usual pattern of work will be performed in all patients who enter in Hospital.
214661562|NCT02153840|DRUG|PSORI-CM01（YXBCM01） granule|
214661563|NCT02153840|DRUG|placebo|
214661564|NCT00509886|DRUG|Drysol|20% aluminum chloride hexahydrate
214661565|NCT00509886|DRUG|Drioff|1% aluminum acetate
214661566|NCT05170737|DRUG|AEF0217|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD."
214849027|NCT04395248|DRUG|Type of volatile anesthetics and M-Entropy guidance of anesthesia depth|"At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge."
214849028|NCT02592759|DEVICE|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
214849029|NCT01930175|DRUG|VAY736|
214849030|NCT01930175|DRUG|Placebo|
214849031|NCT03544359|DEVICE|Transcranial electrical stimulation (tES)|"In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS."
214849032|NCT06227520|OTHER|decellularized dermal matrix|Application of Wound bed
214661567|NCT05170737|DRUG|Placebo|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort."
214661568|NCT03001544|BIOLOGICAL|TS23|comparison of different doses
214661569|NCT00609921|DRUG|ARQ197|treatment
214661570|NCT03874234|DRUG|GSK3186899|GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
214661571|NCT03874234|DRUG|Placebo|Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
214661572|NCT02303587|DRUG|methylprednisolone|
214661573|NCT02803034|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number- SR15-60-Z15-030).
214661574|NCT05580289|OTHER|half-shower and hot pack|The patients in the experimental group will be given hot application and half shower applications and the pain levels of the patients and the development of bladder retention will be followed.
214661575|NCT00087295|DRUG|Depsipeptide|Depsipeptide wil be given 13 mg/m\^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
214661576|NCT01104389|DEVICE|Fluorescence imaging|Intraoperatively acquire fluorescence images of renal tumors
214661577|NCT00559338|DRUG|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
214661578|NCT00559338|DRUG|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
214661579|NCT04113629|DEVICE|HCV point of care machine|Xpert HCV Assay performed on the GeneXpert point of care machine
214661580|NCT02211339|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
214849033|NCT00834899|DRUG|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
214661581|NCT02211339|OTHER|Usual care|Staff-led social activity
214661582|NCT00825071|DRUG|Dexamethasone|8 mg, Intravenous
214849034|NCT00834899|DRUG|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
214849035|NCT00240617|DRUG|sumatriptan succinate/naproxen sodium|comparator
214849036|NCT00240617|DRUG|placebo|placebo to match
214849037|NCT01909128|DIETARY_SUPPLEMENT|fermented milk|fermented milk with Lactobacillus CBA-L74
214849038|NCT01909128|DIETARY_SUPPLEMENT|fermented rice|fermented rice wit Lactobacillus CBA-L74
214849039|NCT00078507|BEHAVIORAL|Sensory Re-training|
214849040|NCT00078507|BEHAVIORAL|Sensory Retraining|Facial Exercises
214849041|NCT00078507|BEHAVIORAL|Opening Exercises|
214849042|NCT05814991|DRUG|Nitroglycerin solution|Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.
214661583|NCT00825071|DRUG|Ondansetron|4 mg, intravenously
214661584|NCT00825071|DRUG|normal saline|2 ml, intravenously
214661585|NCT04438655|DRUG|Oral antibiotic drugs|"Oral antibiotic drugs:~\- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon."
214661586|NCT04438655|DRUG|Parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
214661587|NCT06001580|DRUG|BR101|BR101 injection was administered once for 28 days observation period and then weekly until the subject experienced unacceptable toxicity, disease progression, poor compliance, pregnancy, informed withdrawal, death, study interruption, and withdrawal from the study
214661588|NCT01358110|OTHER|Early palliative care consultation|Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
214661589|NCT01358110|OTHER|Care as usual|Standard care as usual which may or may not include palliative care consultation
214661590|NCT01046318|DRUG|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
214661591|NCT02085577|DRUG|(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml|Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
214661592|NCT02085577|DRUG|Isotonic sodium chloride 0.9 percent|Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
214661593|NCT02085577|DRUG|Paracetamol 1 g|Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
214661594|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
214661595|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
214661596|NCT02085577|DRUG|Ondansetron 2 mg/ml|Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
214661597|NCT02085577|DRUG|Usual daily opioids|The patients usual daily opioid consumption are administered during the study period
214661598|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
214661599|NCT02085577|DRUG|Sufentanil 5 microgram/ml|Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
214661600|NCT02514538|DRUG|Non- effervescent Paracetamol kern|1g
214849043|NCT05814991|DEVICE|monitoring of cerebral oxygen saturation|NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
214849044|NCT04079491|OTHER|questionnaire survey|A web-based questionnaire will be send by the trade union for dental hygienists
214849045|NCT03060759|DEVICE|Light Therapy box|"The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs."
214849046|NCT06331117|DIAGNOSTIC_TEST|Diagnostic test|Multiomics profiling
214849047|NCT01368627|DEVICE|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
214849048|NCT05799027|DIAGNOSTIC_TEST|Raman spectrum|The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.
214849049|NCT04417582|PROCEDURE|bariatric surgey|patients undergone bariatric surgery or prescribed antiobesity drugs
214849050|NCT03314662|BIOLOGICAL|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
214849051|NCT03314662|BIOLOGICAL|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
214849052|NCT03314662|BIOLOGICAL|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
214661601|NCT02514538|DRUG|Effervescent paracetamol termalgin|1 g
214661602|NCT01351662|BEHAVIORAL|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
214661603|NCT03103399|DRUG|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
214661604|NCT03103399|DRUG|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
214849053|NCT02692729|PROCEDURE|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
214661605|NCT03103399|DRUG|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
214661606|NCT03103399|DRUG|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
214661607|NCT02308280|DRUG|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
214661608|NCT00267241|OTHER|Mechanical Ventilation|Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
214661609|NCT03388970|DRUG|Vitamin K 1|Research group use Vitamin K1
214661610|NCT03388970|DRUG|normal saline|Placebo group use normal saline
214661611|NCT01623466|DRUG|levonorgestrel|transdermal contraceptive delivery system
214661612|NCT01701700|PROCEDURE|portable electronic magnifier|
214661613|NCT01701700|PROCEDURE|optical aids|
214661614|NCT02799381|DRUG|Optimized antiparkinsonian treatment|Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
214661615|NCT02799381|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|Dose levels were individually optimized.
214661616|NCT02799381|DEVICE|CADD-Legacy ambulatory infusion pump|(manufactured by Smiths Medical)
214661617|NCT02799381|DEVICE|Percutaneous endoscopic gastrostomy tube|(PEG tube)
214661618|NCT02799381|DEVICE|Jejunal extension tube|(J-tube)
214661619|NCT04063943|DEVICE|Sidus Stem-Free Shoulder|Device: Sidus Stem-Free Total Shoulder Arthroplasty System
214661620|NCT03648450|OTHER|Propeller EMD|Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
214661621|NCT00281450|BEHAVIORAL|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
214661622|NCT05918510|DIAGNOSTIC_TEST|Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx|The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.
214661623|NCT02214173|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
214661624|NCT02214173|DIETARY_SUPPLEMENT|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
214661625|NCT05619926|DRUG|STSP-0601 for Injection|Intravenous Injection
214661626|NCT00783289|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
214661627|NCT00783289|BIOLOGICAL|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
214661628|NCT00783289|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
214661629|NCT00783289|BIOLOGICAL|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
214661630|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
214661631|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
214849054|NCT02692729|PROCEDURE|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
214849055|NCT01631526|DIETARY_SUPPLEMENT|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
214849056|NCT00052026|DRUG|carvedilol|low-dose carvedilol administered twice daily for 8 months
214849057|NCT00052026|DRUG|placebo|administered twice daily for 8 months
214849058|NCT00052026|DRUG|carvedilol|high-dose carvedilol administered twice daily for 8 months
214849059|NCT01393457|DRUG|levodopa/carbidopa|800/200 mg/d
214661632|NCT00332657|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
214661633|NCT03952130|DRUG|LY900014|Administered SC
214661634|NCT03952130|DRUG|Insulin Lispro|Administered SC
214661635|NCT03952130|DRUG|Insulin Glargine|Administered SC
214661636|NCT03952130|DRUG|Insulin Degludec|Administered SC
214661637|NCT05598086|DRUG|Tranexamic acid|local infiltration of TXA or normal saline in the post-operation would
214661638|NCT00652821|DRUG|Tramadol/ APAP|Tablets 37.5mg /325mg
214661639|NCT00652821|DRUG|Ultracet|Tablets, 37.5mg/325mg
214661640|NCT04047030|OTHER|None- Observational Study|No Intervention
214661641|NCT00506389|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.
214661642|NCT00506389|DRUG|Placebo|The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
214661643|NCT04634669|DRUG|AXS-05 (dextromethorphan-bupropion)|\- AXS-05 tablet, taken daily (up to 15 months)
214849060|NCT01393457|DRUG|Ropinirole 2 mg/d|2 mg/d
214849061|NCT01393457|DRUG|Placebo|sugar pill
214849062|NCT01393457|DRUG|Ropinirole 4 mg/d|4 mg/d
214849063|NCT03858426|OTHER|no intervention|no intervention
214661644|NCT05375292|OTHER|PREHABILITATION|"Customized program made by the physical therapist based on the first visit.~It includes 3 parts :~1. Nutrition advices that ensures adequate caloric and protein intake to support muscle anabolism~2. Muscle building over a few sessions with a physiotherapist to learn exercises and then independently redo them~3. Cardio-respiratory endurance exercises."
214849064|NCT06180408|OTHER|manual therapy and exercise for the big toe|Maitland mobilization (Grade 3,4), Mulligan mobilization with movement techniques, muscle energy techniques, manual therapy for plantar fascia, strengthening exercises and self-stretching exercises was performed
214849065|NCT06180408|OTHER|lumbar stabilization exercise|core training and myofascial release therapy
214661645|NCT04243044|DEVICE|Transcutaneous spinal stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic stimulation with a single round electrode as the cathode placed directly over the spine at the T11/T12 (and the lumbar spine for dual-site stimulation) spinous interspace, and two interconnected dispersive (reference) electrodes placed on the abdomen, lateral to the umbilicus. Stimulation intensity will be set to the specified level determined through a pre-stimulation assessment (0.8x reflex threshold). Treatments will be a minimum of 48 hours apart.
214661646|NCT04600999|DRUG|Favipiravir|Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]
214661647|NCT03848520|PROCEDURE|TKA|TKA performed in the past
214661648|NCT00749099|DRUG|pancrelipase|"The test drug (PANCRECARB® \[pancrelipase\] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
214661649|NCT00749099|DRUG|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
214661650|NCT04150432|DEVICE|Edmon|New device for exhaled propofol concentration measurements
214661651|NCT05147246|BEHAVIORAL|ParentCorps-Professional Development (PD)|PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
214661652|NCT04668326|DEVICE|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
214661653|NCT04668326|DEVICE|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
214661654|NCT03747445|PROCEDURE|Roux-en-Y gastric bypass|laparoscopic surgical procedure
214661655|NCT05452382|PROCEDURE|Partial colecctomy|Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
214849066|NCT03418792|OTHER|Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography|Head \& neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
214849067|NCT02428179|PROCEDURE|StOP? - Control group|Control group - Surgical procedure without Study Intervention
214849068|NCT02428179|PROCEDURE|StOP? - Intervention group|Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
214661656|NCT05452382|PROCEDURE|Hemicolectomy|Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
214661657|NCT03057444|DIETARY_SUPPLEMENT|SymbioIntest|The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
214661658|NCT02384720|OTHER|Age: 20-40years|
214661659|NCT02384720|OTHER|Age: 41-64years|
214661660|NCT02384720|OTHER|Age: ≥65years|
214661661|NCT06098014|DRUG|Thalidomide Capsules|To see safety and efficacy of Thalidomide in Transfusion depended thalassemia
214661662|NCT06098014|DRUG|Placebo|compare with Thalidomide
214661663|NCT00002669|BIOLOGICAL|aldesleukin|
214661664|NCT00002669|BIOLOGICAL|recombinant interferon alfa|
214661665|NCT00002669|DRUG|cisplatin|
214661666|NCT00002669|DRUG|dacarbazine|
214661667|NCT01217749|DRUG|PCI-32765|420 mg PO daily
214661668|NCT01217749|DRUG|ofatumumab|per package insert as an IV infusion
214661669|NCT00437905|PROCEDURE|angioplasty|
214661670|NCT02956889|DRUG|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
214661671|NCT02956889|RADIATION|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
214661672|NCT02523586|OTHER|Oxygen administration|Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
214661673|NCT03033108|DRUG|Emixustat|Once daily, tablet for oral administration
214661674|NCT00680732|DIETARY_SUPPLEMENT|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
214661675|NCT00680732|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
214661676|NCT00680732|DRUG|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
214661677|NCT00680732|DRUG|Sulphadoxyne-pyrimethamine (SP)|Tablets
214661678|NCT00810797|DRUG|exemestane|Given orally
214476199|NCT06854666|OTHER|effectiveness of platelet-rich plasma (PRP) in treating lateral epicondylar tendinopathy (LET)|"The intervention involves the administration of PRP (platelet-rich plasma), L-PRP (leukocyte-rich platelet-rich plasma), and saline according to a protocol developed for patients with lateral epicondylitis (EPi lat). The intervention includes specific parameters such as centrifugation speed and dual injection to the painful site, which is repeated after one week.~Following the procedure, treatment continues with a rehabilitation program, including the use of an orthosis. The orthosis serves as support during the recovery process after the injection. The rehabilitation program and the use of the orthosis aim to improve joint function and reduce pain, supporting tissue healing and regeneration."
214661679|NCT00810797|OTHER|laboratory biomarker analysis|One year after completion of study treatment
214661680|NCT00810797|PROCEDURE|quality-of-life assessment|One year after completion of study treatment
214661681|NCT00810797|OTHER|immunohistochemistry staining method|Correlative studies
214661682|NCT02506777|DRUG|metformin|
214661683|NCT02506777|DRUG|Fluoruracil|
214661684|NCT02506777|DRUG|Doxorubicin|
214661685|NCT02506777|DRUG|Cyclophosphamide|
214661686|NCT02506777|DRUG|melatonin|
214661687|NCT00193843|PROCEDURE|Post-operative chemoradiotherapy / accelerated radiotherapy|
214661688|NCT01154413|BEHAVIORAL|Intensive education of the doctor/nursing team on the protocol|
214661689|NCT02795234|OTHER|Blood samples|
214661690|NCT03125642|DRUG|Etoposide|"BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
214661691|NCT03125642|DRUG|BCNU|BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6
214849069|NCT01207999|PROCEDURE|Collection of cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
214849070|NCT01207999|OTHER|Data collection|Questionnaire completion
214849071|NCT00920088|DRUG|darunavir/ritonavir|DRV/RTV 600/100mg
214849072|NCT00920088|DRUG|lopinavir/ritonavir|LPV/RTV 400/100mg
214849073|NCT00920088|DRUG|Midazolam|Midazolam 3mg
214849074|NCT00920088|DRUG|Dextromethorphan|Dextromethorphan 30mg
214849075|NCT00920088|DRUG|Flurbiprofen|Flurbiprofen 50mg
214661692|NCT03125642|DRUG|AraC|BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
214661693|NCT03125642|DRUG|Melphalan|BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1
214661694|NCT03125642|PROCEDURE|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
214661695|NCT03125642|BIOLOGICAL|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3
214661696|NCT03125642|DRUG|Cyclophosphamide|"CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
214661697|NCT03125642|RADIATION|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
214661698|NCT00704470|OTHER|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
214661699|NCT00704470|OTHER|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
214849076|NCT00920088|DRUG|GSK2248761|NNRTI under investigation
214661700|NCT04240743|DEVICE|cephalomedullary nail|For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.
214661701|NCT04240743|DEVICE|sliding hip screw|For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.
214661702|NCT00098631|DRUG|lapatinib ditosylate|Given orally
214661703|NCT00098631|OTHER|laboratory biomarker analysis|Correlative studies
214849077|NCT00056745|BIOLOGICAL|TBC-3B|
214849078|NCT02744131|DRUG|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
214849079|NCT02744131|DRUG|Metformin 1500mgs per day|
214849080|NCT02079337|DRUG|Rocuronium|
214849081|NCT02079337|DRUG|sugammadex|
214849082|NCT02079337|DRUG|placebo|
214849083|NCT04062994|BEHAVIORAL|Nudge to reduce intraoperative hypotension|Providers will be alerted if their patients are at high risk of hypotension or at increased risk of sequelae from hypotension. Intraoperatively, if patients have more than 10 minutes of hypotension an alert will be displayed on the screen.
214849084|NCT01117766|DRUG|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
214849085|NCT01117766|DRUG|Placebo|BID dosing for 28 days
214849086|NCT00438659|DRUG|mometasone furoate|Applied to treatment area
214849087|NCT00438659|OTHER|placebo|Applied to treatment area
214849088|NCT02312479|DEVICE|Nyxoah SAT system|The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
214661704|NCT04731064|PROCEDURE|HAL (Hemorrhoidal Artery Ligation) - RAR (Recto-Anal Repair)|The patient is operated on in the first perineal position, under general anesthesia or under locoregional or even local anesthesia, after rectal preparation by simple enema. The HAL equipment included a disposable transparent rectoscope fitted near its end with a centimeter window through which wire stitch ligatures will be made. A light source facilitating the exposure of the internal face of the rectum and a Doppler transducer secured to the base of the rectoscope containing the Doppler system. Everything is connected to a generator which transmits Doppler noises to the surgeon. A printer on the generator makes it possible to map ligatures and note the depth of linked arteries. Equipment includes needle holder, knot pusher, scissors and dissecting forceps. The material for HAL is identical, except for the disposable rectoscope which is more indented at its end and on one side.
214661705|NCT03888495|BEHAVIORAL|Gender Socialization Training workshop|Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.
214661706|NCT03888495|BEHAVIORAL|Financial Literacy Training Intervention|Hands-on training workshops including lectures, group activities, role play and group discussions focused on financial literacy.
214661707|NCT03888495|BEHAVIORAL|Family Planning Counseling and Services|Family planning counseling sessions and linkage to services.
214661708|NCT05887635|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
214661709|NCT02217735|BEHAVIORAL|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
214661710|NCT05051085|BEHAVIORAL|"Internet-delivered treatment: SpilleFri."|The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
214661711|NCT03367845|BEHAVIORAL|Control|Parents receive 8 phone contacts (1 per week) that do not focus on material in the sensitivity and couples communication intervention.
214661712|NCT03367845|BEHAVIORAL|Sensitivity Intervention|4 home visits take place. Mothers and fathers are video recorded with their infant (separately) for approximate 10-15 minutes at the beginning of each visit. The recorded situations are natural (e.g., playing together, bathing the baby, mealtime, etc.) and the family coach (interventionist) is not actively involved in the parent-child interaction. A different theme is covered across the four intervention sessions. For each parent-infant interaction recording, the family coach reviews the recordings between visits and provides feedback to parents in the following intervention session. The exception to this is that video of parent-child interactions during the lab pre-test is used for material at the first home visit. Each session takes approximately 90 minutes. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
214661713|NCT03367845|BEHAVIORAL|Couples' Intervention|The psycho-educational inter-parental conflict prevention curriculum is a 4-session program that takes place in the families' homes. Each session lasts approximately 90 minutes and involves discussion and practice of four themes pertinent to improving conflict process, communication, and emotional security in the family: Conflict Overview, Interparental Conflict and Children, Stresses of Parenting, and Emotional Security. The family coach scaffolds and supports the couples' development of constructive conflict behaviors. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
214661714|NCT03367845|BEHAVIORAL|Sensitivity and Couples' Intervention|This group receives both the Sensitivity and Couples' Intervention in their home. There are 8 home visits (4 for Sensitivity and 4 for Couples Intervention). Because of COVID-19, we now conduct remote visits using Zoom.
214661715|NCT05613270|DIAGNOSTIC_TEST|18F-FES PET/CT scan|Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.
214661716|NCT04548843|PROCEDURE|Bone Marrow mobilization|"During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis"
214661717|NCT04548843|PROCEDURE|Apheresis|Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
214661718|NCT04548843|BIOLOGICAL|MNV-BM-PLC infusion|"The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks."
214661719|NCT03118622|DEVICE|Pentax|Intubation using Pentax video laryngoscope in Pentax group
214661720|NCT02781974|OTHER|Exercise|Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
214661721|NCT01419509|GENETIC|DNA methylation analysis|
214661722|NCT01419509|GENETIC|microarray analysis|
214849089|NCT00987142|DRUG|CX501|Cultured chimeric skin
214661723|NCT01419509|GENETIC|polymerase chain reaction|
214661724|NCT01419509|OTHER|laboratory biomarker analysis|
214661725|NCT03677674|OTHER|Dehydration|Participants will be dehydrated (2% of their body weight) using sauna.
214661726|NCT01503021|DRUG|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
214661727|NCT01503021|OTHER|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
214661728|NCT00275080|DRUG|vorinostat|Given orally
214849090|NCT00987142|DEVICE|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
214906974|NCT04042506|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
214661729|NCT00275080|DRUG|decitabine|Given IV
214661730|NCT01449838|DRUG|Colistimethate sodium|active
214661731|NCT01449838|DRUG|Saline|placebo
214661732|NCT06486831|OTHER|Squeeze the stress ball.|The child and parents will be taken to the procedure room for the casting procedure. The plastering process in children takes an average of 10-15 minutes. In the experimental group, the stress ball selected by the child will be started 1-2 minutes before the casting process and will be watched for an average of 10 minutes. If the procedure is prolonged, the time for squeezing and playing with the stress ball will be extended.
214661733|NCT01331395|OTHER|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
214661734|NCT01079715|DRUG|Propranolol|"Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~* Atropine.~* Isoproterenol hydrochloride (isoprenaline.~* Terlipressin.~* Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular)."
214661735|NCT06002022|DEVICE|REBECCA system (smartwatch + mobile app use)|Patients will be trained in the use of the REBECCA system, which will provide in-depth information about their lifestyle (including physical activity levels, dietary habits, sleep quality and social mobility), as well as of their online behaviour (with outcome indicators of anxiety, PTSD and depression development) and self- or companion-reported measures of emotional state and quality of life. Based on the additional information, exploiting the enhanced monitoring capabilities of the REBECCA system, the supervising clinicians will be given the opportunity to continuously evaluate the progress of the patients, allowing them to schedule up to 3 phone-based consultation sessions in the first 12 months of treatment
214661736|NCT06487351|BEHAVIORAL|The adapted PHBI|The adapted intervention is expected to be an online 60-minute video with an educational part about implicit racial bias, its consequences in healthcare inequalities, how to mitigate it, and seven case scenarios (5 minutes each) to train pharmacy interns on aspects related to cultural competency and how and when to use IBMS to reduce the impact of bias on prescribing PrEP for people of color.
214661737|NCT06487351|BEHAVIORAL|The NIH Implicit Bias course|The NIH Implicit Bias course consists of three modules designed to teach users what bias is, how to recognize it, and how to minimize its impact
214661738|NCT01477905|DEVICE|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
214849091|NCT02244424|BEHAVIORAL|Tools for Teen Moms|"The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life."
214661739|NCT01477905|DEVICE|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
214661740|NCT01818349|OTHER|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
214661741|NCT01818349|OTHER|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
214661742|NCT06645340|OTHER|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length, and routine laboratory parameters.
214661743|NCT06544837|DIAGNOSTIC_TEST|Window of Implantation|Determine the subject's window of implantation through testing and adjust the embryo implantation time
214661744|NCT04259515|DRUG|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
214661745|NCT04259515|DRUG|Buckberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
214661746|NCT06022783|OTHER|Virtual reality intervention|Watching a relaxing video with using VR-G for 20 minutes
214661747|NCT02421198|BEHAVIORAL|YMCA Family Diabetes Prevention Program (YFDPP)|12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
214661748|NCT05592340|BEHAVIORAL|Exposure to calorie information|Calories for all foods and beverages
214661749|NCT05592340|BEHAVIORAL|Exposure to carbon footprint information|Carbon footprint labels for all foods and beverages
214661750|NCT01357213|DRUG|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
214661751|NCT01357213|OTHER|Placebo|Normal saline 100 ml
214661752|NCT01591005|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes
214661753|NCT01591005|PROCEDURE|endarterectomy|carotid endarterectomy
214849092|NCT01594034|PROCEDURE|expired air|collection of expired air from ventilator
214661754|NCT01591005|PROCEDURE|carotid stenting|percutaneous transluminal angioplasty and stenting
214661755|NCT01075087|DRUG|Placebo|Bilateral TAP block using sterile normal saline.
214661756|NCT01075087|DRUG|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
214661757|NCT01602731|DEVICE|Automated Medication Dispensing Device|All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
214661758|NCT05040191|OTHER|Traditional Education(control)|The application was made on the model that allows nasogastric tube application and the anatomical structure in the nasogastric region is seen. The student can experience the skill of applying a nasogastric tube to the nasogastric or orgastric region on this model. In the nursing skills laboratory, students were given a demonstration of nasogastric tube application on a model.
214661759|NCT05040191|OTHER|Haptic interactive virtual reality simulation training|Haptic interactive virtual reality simulation technology; It functions by using haptic gloves that are interactive, visually enhanced, containing three-dimensional video and animation, wearable by students. This program has been developed by a software developer who is an expert in the field of information technologies, using the unreal program with a nine-generation computer with a game engine. All the necessary steps in the NGT application have been in simulation.
214661760|NCT05040191|OTHER|Haptic interactive computer-based simulation training|"Clinical tvr (tactile simulator) produced by a foreign commercial company used in nursing education was used. Clinical tvr simulation applications can be accessed online or downloaded to a computer. This simulator; It functions by using an interactive, visually enhanced 2D, animated, haptic arm that can be held by students like a pen. It includes applications such as nasogastric tube placement, urinary bladder catheter placement, heart massage. These applications can be realized through both mouse and haptic arm computer input devices. clinical tvr; It is a simulator that incorporates the enhanced benefits of haptic feedback through the use of haptic technology. This simulator provides a near-realistic sensory experience where the learner can practice a skill as it actually is. Computer-based simulation with haptic interaction was used in this study with the haptic arm in NGT application skill."
214661761|NCT03766243|BEHAVIORAL|Brochure and DVD plus nursing training|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD.~The experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. For both groups an information brochure and an audio-visual DVD were developed specifically for the study. The audio-visual DVD is available on the IDI-IRCCS institutional website."
214661762|NCT03766243|BEHAVIORAL|Brochure and DVD only|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD."
214661763|NCT00184587|DRUG|candesartan cilexetil|
214661764|NCT00184587|DRUG|placebo|
214661765|NCT01779609|DRUG|Bosentan|
214661766|NCT01779609|DRUG|Placebo|
214661767|NCT01779609|BEHAVIORAL|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
214661768|NCT00606515|DRUG|Liposomal paclitaxel|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
214661769|NCT00606515|DRUG|Paclitaxel|Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
214661770|NCT03678974|BEHAVIORAL|Exercise Prescription|The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
214661771|NCT00283387|DRUG|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
214661772|NCT00283387|DRUG|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
214661773|NCT01931865|DRUG|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
214906975|NCT02463370|OTHER|suprazygomatic maxillary area infiltration|Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
214906976|NCT02463370|OTHER|non-suprazygomatic maxillary area placebo|The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)
214906977|NCT02463370|OTHER|non-suprazygomatic maxillary area infiltration|Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.
214906978|NCT02463370|OTHER|suprazygomatic maxillary area placebo|The remaining maxillary injection is placebo.
214906979|NCT05850611|DRUG|Methylene Blue|The first intervention group includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention for 4 weeks.
214661774|NCT01162525|PROCEDURE|Percutaneous tibial nerve stimulation (pTNS)|A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
214849093|NCT01784237|PROCEDURE|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
214849094|NCT01784237|PROCEDURE|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
214849095|NCT06616519|DEVICE|BenQ Materials MSENCI soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
214849096|NCT06616519|DEVICE|Visco Oxypure Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
214849097|NCT06615999|PROCEDURE|Simple fracture Tension band wiring|OPS 5-793.27
214849098|NCT06615999|PROCEDURE|Simple fracture locked plate fixation|OPS 5-793.k7
214849099|NCT06615999|PROCEDURE|Multi-fragmented tension band wiring|OPS 5-794.17
214849100|NCT06615999|PROCEDURE|Multi-fragmented locked plate fixation|OPS 5-794.k7
214849101|NCT02128009|OTHER|osteoporosis|
214849102|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive bilateral ultrasound guided QLB
214849103|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive ultrasound guided CB.
214849104|NCT01795235|DRUG|Saline|Saline s.c.
214849105|NCT01795235|DRUG|Glucagon|Glucagon s.c.
214849106|NCT01795235|DRUG|Placebo|Sugar Pill
214849107|NCT01795235|DRUG|Atenolol|Beta-1 receptor antagonist
214290163|NCT03823001|DIAGNOSTIC_TEST|virtual biopsy (VB) monitoring protocol|"1. PSA bi-annually or more often according to the discretion of the urologist.~2. Annual DRE.~3. Visit with the urologist bi-annually.~4. Multi-parametric MRI (mpMRI) every year for 3 years.~5. Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
214849108|NCT04325854|PROCEDURE|I and II level ART procedure|I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
214849109|NCT04807062|PROCEDURE|surgery|tunnel bone tamps method (TBTM) was used to reduce the depressed articular fragments and then structural bicortical autologous ICBG was used to fill the valley tunnel.
214849110|NCT03699254|DRUG|Valganciclovir|"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
214849111|NCT03699254|DRUG|Ganciclovir|"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
214849112|NCT00260273|BEHAVIORAL|Cognitive Behaviour Therapy|therapy
214849113|NCT03105973|BEHAVIORAL|Technology-Enabled CBT Treatment|CBT-based modules delivered via tablet over 4 weeks.
214849114|NCT03408431|DEVICE|Ambu® AuraGain™|Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
214849115|NCT03408431|PROCEDURE|neck extension|Patients' neck will be maximally extended (\~60°) during blind intubation.
214849116|NCT03799822|DRUG|Rivaroxaban 10 MG Oral Tablet|replacement of warfarin by rivaroxaban
214849117|NCT03799822|DIETARY_SUPPLEMENT|MK-7 2000µg thrice weekly|dietary supplement of vitamin K2 MK-7 2000µg thrice weekly
214849118|NCT03799822|DRUG|Vitamin K Antagonist - Drug|treatment with a vitamin K antagonist
214290164|NCT00824239|PROCEDURE|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
214290165|NCT00824239|PROCEDURE|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
214661775|NCT02748343|DEVICE|allograft bone|Use of the allograft bone to treat the bone defect in patients
214661776|NCT02748343|DEVICE|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
214661777|NCT00982605|PROCEDURE|EBUS_TBNA|EBUS during bronchoscopy
214849119|NCT03076749|OTHER|Creating models for the diagnosis of BL allergy|
214849120|NCT02636673|PROCEDURE|Sigmoid Resection|
214849121|NCT01047033|BEHAVIORAL|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
214906980|NCT05850611|OTHER|Milk (control)|Group B will receive 200 ml of milk for 4 weeks.
214661778|NCT05966818|DRUG|Dapagliflozin and Standard therapy (ACEI or ARB).|Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).
214661779|NCT05966818|DRUG|Standard Therapy (ACEI or ARB).|Standard Therapy which include either ACEI or ARB for 24 weeks.
214661780|NCT04779502|OTHER|oregawash|mouthwash containing oregano essential oil
214661781|NCT04779502|OTHER|corsodyl|0.2% chlorhexidine mouthwash
214661782|NCT04779502|OTHER|placebo|distilled water
214661783|NCT05280561|DIETARY_SUPPLEMENT|DHM|DHM is a positive modulator of GABA. We hypothesize the DHM could reduce stress/anxiety induced insomnia during the pandemic
214661784|NCT05280561|DIETARY_SUPPLEMENT|Placebo|Excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
214661785|NCT02176486|DRUG|Ixazomib|Ixazomib capsules.
214661786|NCT02176486|DRUG|Placebo|Ixazomib placebo-matching capsules.
214661787|NCT00872066|DEVICE|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
214661788|NCT00872066|DEVICE|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
214661789|NCT01069848|DEVICE|Vedera KXS|One treatment session with Vedera KXS
214661790|NCT01871792|DRUG|Pitavastatin|
214661791|NCT01871792|DRUG|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
214661792|NCT02335684|OTHER|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
214661793|NCT02335684|OTHER|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
214661794|NCT06185920|OTHER|Description of severe infection|Description of severe infections treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.
214661795|NCT01767233|PROCEDURE|ERCP and pancreatic stenting|
214661796|NCT03455946|BEHAVIORAL|DASH cloud with Alexa|"Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system."
214661797|NCT03613428|DRUG|Ruxolitinib|Dose escalation up to 80 mg administered orally
214661798|NCT03613428|DRUG|Vincristine|1.4 mg/m2 i.v. weekly for 4 weeks
214661799|NCT03613428|DRUG|Prednisone|1 mg/kg orally 5 consecutive days per week for 4 weeks.
214661800|NCT02793284|RADIATION|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
214661801|NCT03584009|DRUG|Venetoclax|Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.
214661802|NCT03584009|DRUG|Fulvestrant|Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
214661803|NCT03253640|OTHER|Exposure|Healthcare associated infection (HAI)
214661804|NCT03217760|PROCEDURE|Endodontic treatment|Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
214661805|NCT03217760|OTHER|VAS of stress|The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
214661806|NCT03217760|OTHER|CORAH scale|At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).
214661807|NCT03217760|OTHER|HAD Scale|At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.
214661808|NCT03217760|OTHER|Cardiovascular Parameters|For each subject, the physiological indicators of stress (ie, heart rate \[HR\], systolic blood pressure \[SBP\], and diastolic blood pressure \[DBP\]) are monitored during each of the 6 steps.
214661809|NCT03217760|OTHER|Cortisol Measurements|Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .
214661810|NCT03217760|OTHER|Discomfort and Pain Experienced During Treatment|Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.
214661811|NCT03217760|OTHER|Patient's preferences.|After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.
214661812|NCT03217760|OTHER|student preferences.|"When the treatment is complete the students are asked to report:~1. his/her level of satisfaction with the course of treatment,~2. whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session~3. whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment."
214661813|NCT00446030|DRUG|Docetaxel|"75 mg/m\^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg)."
214661814|NCT00446030|DRUG|Doxorubicin|50 mg/m\^2 administered IV on Day 1 for Cycles 1-6
214661815|NCT00446030|DRUG|Carboplatin|6 mg/mL/min (target area under the curve \[AUC\] dose) administered IV on Day 1 for Cycles 1-6
214661816|NCT00446030|DRUG|Cyclophosphamide|500 mg/m\^2 administered IV on Day 1 for Cycles 1-6
214661817|NCT00446030|DRUG|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
214661818|NCT00446030|DRUG|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
214661819|NCT02224430|DEVICE|schizophrenia/schizoaffective disorder.|Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
214661820|NCT01880450|BEHAVIORAL|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
214661821|NCT01880450|BEHAVIORAL|TEEN|Control condition the promote communication, decision-making skills etc.
214661822|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 50% MIP|Patients received IMT exercise program at a 50% MIP intensity for 12 weeks
214661823|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 10% MIP|Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
214661824|NCT02683369|DIETARY_SUPPLEMENT|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~* 15 mg of Vitamin C~* 400 mcg of Folate~* 30 mcg Vitamin of B-12~* 26 mg of Iron~* 125 mg of Beet Root"
214661825|NCT00608140|PROCEDURE|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
214661826|NCT00608140|DRUG|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
214661827|NCT01129947|DRUG|DHEA|DHEA 25 mg tid
214661828|NCT02420457|PROCEDURE|Epidural injection|After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
214661829|NCT02420457|DRUG|Epidural steroid injection as determined by routine care provider|Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
214290166|NCT05315128|DRUG|Methotrexate|A randomized comparative effectiveness clinical trial
214661830|NCT02886715|DRUG|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
214661831|NCT02886715|DRUG|Tazorac®|Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
214661832|NCT02886715|DRUG|Placebo|Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
214661833|NCT03473873|OTHER|Measures of muscle function|The participants will be assessed with various measures of muscle function at baseline and at follow up including: Isokinetic knee muscle strength, Isometric strength of trunk and lower extremity, single-leg hop for distance (SLHD), side hop, postural orientation errors (single leg-squat, stair descending, forward lunge, SLHD), hip and ankle range of motion, and muscular activation patterns.
214661834|NCT02625038|DEVICE|EUDAMED CIV-14-03-011940|
214661835|NCT03783910|DRUG|GRT9906|One prolonged-release tablet containing 40 mg of GRT9906
214661836|NCT03783910|DRUG|Placebo|Placebo matching GRT9906 tablets
214661837|NCT02406157|DEVICE|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
214661838|NCT02406157|DEVICE|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
214849122|NCT01047033|OTHER|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
214290167|NCT01987297|DRUG|ATRA+Arsenic|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients."
214661839|NCT03812510|DRUG|A-101|hydrogen peroxide topical solution 45%
214661840|NCT03003819|DEVICE|Control Collagen Wound Dressing|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
214661841|NCT03003819|DEVICE|Test Collagen Matrix|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
214849123|NCT04290494|DRUG|IV rtPA (intravenous recombinant plasminogen activator)|intravenous injection
214849124|NCT00176358|DEVICE|PTCA and Stent Implantation|
214849125|NCT00176358|BEHAVIORAL|Exercise Training|
214849126|NCT02272894|PROCEDURE|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
214849127|NCT03366194|DEVICE|SkinStylus Sterilock System|Microneedling device will be used to treat ventral hypertrophic scars.
214849128|NCT00268515|DRUG|cyclosporine|
214849129|NCT00268515|DRUG|tacrolimus|
214849130|NCT00268515|DRUG|prednisone|
214849131|NCT00268515|DRUG|azathioprine|
214849132|NCT02369354|BEHAVIORAL|TALKS Social Worker Intervention|TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
214849133|NCT02369354|OTHER|Financial Assistance Intervention|"The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating."
214849134|NCT05652309|PROCEDURE|spinal block and obturator nerve block|spinal block and obturator nerve block
214849135|NCT01090817|DRUG|Mesenchymal stromal cells (MSC) for infusion|MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
214849136|NCT02664987|OTHER|Patients receiving cancer pain treatment|
214476200|NCT06854926|BEHAVIORAL|Helping relationship from significant others|Helping relationship from significant others is the intervention of this study. We will use four strategies, including warning mechanisms, target setting, encouragement, and feedback.
214849137|NCT02563821|PROCEDURE|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
214849138|NCT02563821|DRUG|Levobupivacaine|
214849139|NCT02563821|DRUG|sufentanil|
214849140|NCT02563821|DRUG|clonidine|
214849141|NCT02563821|DEVICE|epidural catheter|
214849142|NCT06679764|PROCEDURE|Anterior quadratus lumborum block technique (AQLB)|"AQLB performed in the lateral position. A low-frequency convex probe for the abdomen (2-5) MHz convex probe, (Siemens ACUSON X300 Ultrasound System) was placed horizontally above the iliac crest. On ultrasound, The psoas major was located on the ventral side of the transverse process, the erector spinae was located on the dorsal side of the transverse process, and the quadratus lumborum was located on the lateral side of the transverse process.~A 38-mm 22-gauge regional block needle was advanced in-plane from posterior to anterior directing the needle tip in the fascial plane between the psoas major and the quadratus lumborum that was confirmed by injecting 1 ml saline and watchingt the fluil fting the muscle while not distending any of the two muscles (hydro-localization). Then 30mL of local anaesthetic (29ml of 0.25% bupivacaine + 1 ml of dexamethasone (4mgs) was injected with observation of local anaesthesia spread in the fascial plane."
214476201|NCT06854926|BEHAVIORAL|Usual team|Patients of this team accept usual care
214476202|NCT06855420|DEVICE|Vibration on|Sole vibration will be applied by a vibrating insole system for 10 days. Participants will wear the device for at least 4 hours per day.
214476203|NCT06855420|DEVICE|Vibration off|Participants will wear the device with vibration turned off for at least 4 hours per day during 10 days of intervention.
214476204|NCT06853717|BEHAVIORAL|Therapy Together|CIMT consists of retraining the preferred hand by covering the hand with a soft mitt to promote the use of the assisting hand. With consistent practice, a toddler or infant builds the fine and gross motor skills of their assisting hand and bilateral coordination skills.
214476205|NCT00758862|DRUG|2% TD1414 Cream|Application 3 times daily for 7 days
214476206|NCT06853899|DIETARY_SUPPLEMENT|Truology A2|Truology A2 (0.2% Retinaldehyde Serum) - Applied once daily at night after cleansing.
214906981|NCT05850611|DRUG|Methylene Blue and Platelet-Rich Plasma-Fibrin Glue|Group C will be undergone synergistic 4-week treatment with oral methylene blue and fibrin glue.
214906982|NCT05850611|OTHER|Milk and Platelet-Rich Plasma-Fibrin Glue (control)|Group D will be treated only with fibrin glue and 200 ml of milk for 4 weeks.
214906983|NCT02873793|GENETIC|Extraction of total RNA from healthy and tumour tissues|
214906984|NCT07061379|DRUG|Carboplatin/Cisplatin+Pemetrexed+Pembrolizumab/Cemiplimab for 4 cycles and then maintenance with Pemetrexed+Pembrolizumab/Cemiplimab up to 2 years or disease progression or unacceptable toxicity|Cohort A: Carboplatin/Cisplatin+Pemetrexed+Pembrolizumab/Cemiplimab (Keynote 189, EmpowerLung 3) for 4 cycles and then maintenance with Pemetrexed+Pembrolizumab/Cemiplimab up to 2 years or disease progression or unacceptable toxicity
214476207|NCT06853899|DIETARY_SUPPLEMENT|Truology C-Boost|Truology C-Boost - Applied twice daily (morning \& night).
214476208|NCT06853899|DIETARY_SUPPLEMENT|Truology Barrier Restore|Applied twice daily (morning \& night) as the final skincare step.
214476209|NCT06810284|DRUG|Sildenafil Citrate (IV)|Controlled hypothermia initiated before 6h after birth (servo-controlled 33.5°C during 72h followed by a 12-h rewarming period up to 36.5°C), open-label IV Sildenafil Citrate (Revatio®, 10 mg/12.5 mL, Pfizer) 0.4 mg/kg delivered over 3 hours, followed by a maintenance infusion at 1.6 mg/kg/day for 72h
214476210|NCT06854887|DEVICE|digital breast tomosynthesis and mammography|tomosynthesis is 3D image for the breast mammography is 2D image for the breast
214476211|NCT06654557|OTHER|Placebo beverage, kiwi-strawberry flavor (Part 1 and Part 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
214476212|NCT06654557|OTHER|0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214476213|NCT06654557|OTHER|0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214849143|NCT06679764|PROCEDURE|Pericapsular Nerve Group (PENG) block|With the patients in supine position, A low-frequency convex probe (2-5 MHz) in was placed in a transverse plane over the anterior inferior iliac spine and then it was rotated 45 degrees in counter-clockwise direction to be aligned with the pubic ramus. In this view, the ilio-pubic eminence, iliopsoas muscle tendon, femoral nerve and vessels was observed. With in-plane approach, a 38-mm 22-gauge (22-G, 50-mm) regional block needle inserted in-plane, from lateral to medial to place the needle tip underneath the iliopsoas tendon, exactly between the ilipsoas fascia anteriorly and the pubic ramus posteriorly. Following negative resistance and aspiration tests, correct location of the needle tip was confirmed by injecting 1 ml saline. Then, 30mL of local anaesthetic (29ml of 0.25% bupivacaine+ 1ml of dexamethasone (4mgs) was injected while observing for adequate fluid spread.
214849144|NCT06679764|DRUG|Control Group|Pataints received opioid analgesia with genaral anesthesia
214849145|NCT06739304|BEHAVIORAL|Mindfulness-based Relapse Prevention|250 adult USD females of Intervention group received the 8-week Group mindfulness intervention performed by psychiatrists.
214849146|NCT06904443|OTHER|PsySon is an innovative device that uses music in crisis management in hospitals|"during his hospitalization, the patient can benefit from listening sessions thanks to an original and innovative device, a sort of listening chair equipped with high-quality speakers, thus offering an immersive and enveloping experience (see photo). These sessions aim to anticipate or manage a moment of crisis, of less well, which patients often face in institutions."
214849147|NCT06903910|DRUG|Donepezil (Aricept)|Donepezil is a cholinesterase inhibitor tablet taken by mouth once nightly
214849148|NCT06905457|COMBINATION_PRODUCT|Vojta therapy|Vojta therapy, also known as Reflex Locomotion Therapy, is a specialized physiotherapy technique developed by Czech neurologist Václav Vojta, using sensory stimulation to activate innate movement patterns and improve motor skills, posture, and overall function
214849149|NCT06905457|COMBINATION_PRODUCT|Bobath therapy|Bobath therapy, also known as Neurodevelopmental Treatment (NDT), is a problem-solving approach to neurological rehabilitation, focusing on motor learning and efficient motor control to improve function and participation in daily activities
214849150|NCT06905782|PROCEDURE|AI chatbot study arm|Intervention arm will have to undergo bowel preparation using standard polyethylene glycol solution (Fortrans)
214849151|NCT06905782|PROCEDURE|Traditional counselling study arm|Intervention arm will have to undergo bowel preparation using standard polyethylene glycol solution (Fortrans)
214849152|NCT06905548|BEHAVIORAL|climate change awareness training|The climate change training planned for nurse managers consists of 4 sessions of 2 days, each lasting 40 minutes.
214476214|NCT06654557|OTHER|1% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214476215|NCT06654557|OTHER|6% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214476216|NCT06654557|OTHER|6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214476217|NCT06654557|OTHER|2% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
214476218|NCT06853405|BEHAVIORAL|Nutrition-related lifestyle group sessions|"In person lifestyle group sessions of 180-minutes per week, directed by a nutritionist, and comprising:~1. 120-minute nutrition education session for preparing healthy meals, followed by a period of social interaction while consuming the meals prepared. Participants will be encouraged to apply the healthy cooking techniques covered in each session in their home context.~2. 60-minute sessions of daily activities to reduce physical inactivity (e.g., walking to the supermarket to buy ingredients, playing traditional games, caring for community gardening, among others)."
214476219|NCT06853405|BEHAVIORAL|Nutrition-related cognitive training|Individualized nutrition-based cognitive training performed remotely, at home on their own. The participants will be invited to perform cognitive training exercises including novel nutrition-related exercises, and watch educational videos promoting nutrition literacy at least twice a week using COGWEB®, an online platform for cognitive training. For those unable to use computer devices, similar exercises will be available in paper-and-pencil format.
214476220|NCT06853405|BEHAVIORAL|Clinical nutrition consultations|A registered nutritionist will conduct individualized clinical nutrition consultations to each participant three times over the course of the study period.
214476221|NCT06853951|DRUG|ACE Inhibitors|0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.
214476222|NCT06853951|DRUG|β -Blockers|0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse.
214476223|NCT06654739|DEVICE|Laser therapy + physiotherapy/exercise protocol|laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol (program includes kinesitherapy, range of motion (ROM) exercises, stretching, strengthening, and flexibility exercises) for 6 consecutive weeks, for a minimum of 2 sessions per week
214476224|NCT06654739|DEVICE|Sham Laser therapy + physiotherapy/exercise protocol|sham laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol (program includes kinesitherapy, range of motion (ROM) exercises, stretching, strengthening, and flexibility exercises) for 6 consecutive weeks, for a minimum of 2 sessions per week
214476225|NCT06508567|RADIATION|High Dose Rate Brachytherapy|2 fractions of MRI-guided HDR Brachytherapy (13Gy each) delivered over 14 days (± 7 days).
214476226|NCT03655080|RADIATION|Radiation therapy|Using the View Ray System
214476227|NCT03655080|DRUG|nab-Paclitaxel|"* Dose 15 mg/m\^2~* Should be administered by IV over 30 minutes"
214849153|NCT06904898|DEVICE|Cougar LS/Syncage ALIF or CONDUIT LLIF/ALIF cage|Comparison between cages to determine the effectiveness and cost related to the study procedures.
214849154|NCT06458244|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
214849155|NCT06458244|DRUG|Chemotherapy|Chemotherapy for AML consolidation treatment
214849156|NCT06905418|DIAGNOSTIC_TEST|Clinic|group A will get treatment in clinic
214849157|NCT06905418|COMBINATION_PRODUCT|Mobile App|group B will use mobile application for treatment
214849158|NCT00972907|DRUG|Nifedipine coated suppositories|12 mg Nifedipine coated suppositories BID
214849159|NCT06616259|DRUG|mCapOX plus Cetuximab|"mCapOX plus Cetuximab Induction therapy：Capecitabine 1000mg/m2 po, bid, D1-7 + Oxaliplatin ivgtt 85mg/m2, D1 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
214849160|NCT06616259|DRUG|mFOLFOX6 plus Cetuximab|"mFOLFOX6 plus Cetuximab Induction therapy：Oxaliplatin ivgtt 85mg/m2, D1 + Leucovorin ivgtt 400mg/m2, D1 + Fluorouracil iv bolus 400mg/m2, D1 + Fluorouracil 2400mg/m2 continuous infusion for 46-48h + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
214906985|NCT07061379|DRUG|Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity|"Cohort B:~Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab (CheckMate9LA) for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity"
214290168|NCT01987297|DRUG|ATRA+Chemo|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients."
214290169|NCT02505867|DEVICE|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
214290170|NCT01862874|BIOLOGICAL|V501|Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
214476228|NCT05732272|DRUG|Bupropion|150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
214290171|NCT01862874|BIOLOGICAL|Placebo|Formulated with AAHS adjuvant
214476229|NCT05296746|DRUG|Ribociclib (neoadjuvant)|Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
214476230|NCT05296746|DRUG|Chemotherapy (adjuvant)|Adjuvant chemotherapy. 3 regimens are permitted.
214476231|NCT05296746|DRUG|Ribociclib (adjuvant)|Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
214476232|NCT00783510|BIOLOGICAL|adalimumab|As prescribed by treating physician
214476233|NCT00783510|DRUG|Methotrexate|As prescribed by treating physician
214476234|NCT06588946|DIETARY_SUPPLEMENT|Ketone monoester (KME) supplement|15g of a KME supplement orally consumed 3x daily for 14 days. This dosing protocol raises plasma β-OHB consistently during the waking hours. Oral KME will be provided in opaque bottles labelled A or B to maintain condition blinding. Each bottle will contain a drink providing 15g of a KME supplement: \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (ΔG®, TDeltaS, Oxford, UK).
214476235|NCT06588946|DIETARY_SUPPLEMENT|Placebo supplement|50mL taste-match inert calorie-free placebo drink orally consumed 3x daily for 14 days. Oral placebo will be provided in opaque bottles labelled A or B to maintain condition blinding.
214476236|NCT05651503|DIETARY_SUPPLEMENT|Probiotics|In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two Experimental groups
214476237|NCT05651503|DIETARY_SUPPLEMENT|Placebo tablet|In order to avoid possible bias, probiotics will be compared with placebo lozenges/no probiotic in two Control groups
214476238|NCT05265299|DRUG|Aspirin 81mg|Aspirin 81mg once daily
214476239|NCT05265299|DRUG|Aspirin 162 mg|Aspirin 162 mg once daily
214476240|NCT05265299|DRUG|Aspirin 325mg|Aspirin 325mg once daily
214476241|NCT05826600|DRUG|OMX-0407|Dose escalation, Dose expansion
214476242|NCT06100315|DRUG|Nalbuphine|bupivacaine 0.125% of 0.2 ml/kg and 0.1 mg/kg nalbuphine
214476243|NCT03307915|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5\*10\^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
214476244|NCT03307915|BIOLOGICAL|MVA-Mosaic|Participants will receive MVA-Mosaic 10\^8 pfu as IM injection at Weeks 24 and 36.
214476245|NCT03307915|BIOLOGICAL|Clade C gp140 + Mosaic gp140|Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.
214476246|NCT03307915|DRUG|Placebo|Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
214476247|NCT03904615|DIETARY_SUPPLEMENT|Whey Protein|30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
214476248|NCT03904615|DIETARY_SUPPLEMENT|Collagen Protein|30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
214476249|NCT03904615|DIETARY_SUPPLEMENT|Placebo|30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge
214661842|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid in clinical practice
214290172|NCT00306618|DRUG|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
214661843|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid on RUBY communication portals
214661844|NCT03629509|BEHAVIORAL|BEFORE decision aid|Review impact of BEFORE decision aid implementation in clinical practice
214661845|NCT03864965|OTHER|Advance Care Planning|The provider will guide advance care planning conversations with patients identified with mild or moderate dementia during their third office visit, approximately three months after the first visit.
214849161|NCT02806687|DRUG|Gene Therapy product CYL-02|"Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.~Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression)."
214849162|NCT02806687|DRUG|Gemcitabine|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
214849163|NCT03407612|DEVICE|Continuous Passive Motion|CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
214849164|NCT03489226|DIETARY_SUPPLEMENT|Capsimax|Capsimax
214849165|NCT03489226|DIETARY_SUPPLEMENT|Placebo|Placebo
214849166|NCT03489226|OTHER|Meal|Meal
214849167|NCT05172102|OTHER|breathing exercise, Aerobic exercises|6 min of quiet breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).
214849168|NCT06615700|DRUG|NA-931|NA-931 is a quadruple receptor agonist for weight loss
214849169|NCT06615700|DRUG|Placebo|Placebo of NA-931
214849170|NCT00245817|BEHAVIORAL|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
214849171|NCT00835939|DRUG|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
214849172|NCT00835939|DRUG|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
214849173|NCT00835939|PROCEDURE|sclerotherapy|
214849174|NCT01684215|DRUG|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
214849175|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
214849176|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
214849177|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
214290173|NCT02873000|BEHAVIORAL|Incentive Spirometry|Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
214290174|NCT03178903|OTHER|tDCS|Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
214849178|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
214849179|NCT00503230|BEHAVIORAL|Standard Care Intervention (SCI)|Standard Care Intervention (SCI)
214849180|NCT00503230|BEHAVIORAL|Culturally Tailored Intervention (CTI)|Culturally Tailored Intervention (CTI)
214849181|NCT05866718|BEHAVIORAL|Self-Compassionate Touch Intervention|Participants will be taught the micropractice (\<20-second/day personal practice) via video recording.
214849182|NCT05866718|BEHAVIORAL|Habit Formation Tools|Participants will receive evidence-based tools for promoting habit-formation.
214290175|NCT03178903|OTHER|Sham tDCS|Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
214849183|NCT01682642|DRUG|Zoladex|after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
214849184|NCT05951348|PROCEDURE|Delayed cord clamping for 30 seconds|waiting for 30 seconds after delivery of the fetus or milking of the cord in the direction of the fetus 10 times in time frame 10-15 seconds
214849185|NCT03102151|OTHER|Community Campaign La CLAVE|A community campaign to teach community residents and professional networks the signs and symptoms of psychosis using social media, community talks, and advertising.
214849186|NCT02009709|DRUG|Riboflavin 0.1% ophthalmic solution|Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
214849187|NCT02009709|DEVICE|CCL-VARIO UV lamp|Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
214849188|NCT02009709|DEVICE|CCL-VARIO at 18 mW/cm2|Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
214849189|NCT03400917|BIOLOGICAL|AV-GBM-1|Investigational treatment with AV-GBM-1
214849190|NCT03670134|DEVICE|The Nvision VLE Imaging System|Volumetric laser Endomicroscopy (VLE) will be performed by using the Nvision VLE Imaging System (Nine Point Medical, MA) consists of an imaging console, monitor and optical probe. The optical probe is centered by a balloon (diameter: 14 mm, 17 mm, 20 mm; length: 6 cm) that is deployed through a diagnostic gastroscope's instrument channel. Imaging is performed by automatic helical pullback of the probe from the distal to the proximal end of the balloon over 90 seconds.
214849191|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
214849192|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
214849193|NCT04079049|PROCEDURE|Surgical intervention|Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment
214849194|NCT04079049|DRUG|Control|Oncological treatment in control group
214849195|NCT06389916|DEVICE|Euclid orthokeratology MAX (current design)|The current lens design
214849196|NCT06389916|DEVICE|Euclid orthokeratology MAX Phoenix (new design)|The new lens design
214849197|NCT02329119|OTHER|electrophysiological recordings|
214849198|NCT02234752|DRUG|Galantamine ER|
214849199|NCT02234752|DRUG|Memantine XR|
214849200|NCT00000334|DRUG|Buprenorphine|
214849201|NCT01914523|DEVICE|Macintosh|Laryngeal exposure and tracheal intubation using that device
214849202|NCT01914523|DEVICE|King Vision|Laryngeal exposure and tracheal intubation using that device
214849203|NCT01914523|DEVICE|Glidescope|Laryngeal exposure and tracheal intubation using that device
214290176|NCT03178903|BEHAVIORAL|Aerobic Exercise (AE)|Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
214290177|NCT03630952|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
214849204|NCT01914523|DEVICE|AirTraq|Laryngeal exposure and tracheal intubation using that device
214849205|NCT01582919|OTHER|Neuroimaging|
214849206|NCT02406430|PROCEDURE|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
214476250|NCT06602934|OTHER|Blood samples|Four blood samples will be taken outside standard care for groups A, B, C and D: at inclusion, M6, M18 and M30 (only at inclusion for group C).
214849207|NCT02946684|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
214476251|NCT06602934|OTHER|Oropharyngeal swabs|An oropharyngeal swab will be taken to analyze patients\&#39; upper airway microbiome at inclusion, M6, M18 and M30.
214476252|NCT06602934|OTHER|Calcium score (CT scan)|A calcium score will be taken at 30 months, to assess individual cardiovascular risk.
214476253|NCT06602934|OTHER|ECG|Performed at inclusion, M6, M18 and M30
214476254|NCT06602934|OTHER|Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test|Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test: These tests will be performed consecutively for 2 hours at inclusion (6-minute walk test only), at M6 and at M30. These tests will be performed to assess respiratory and cardiac function.
214476255|NCT06814873|BEHAVIORAL|Neurofeedback|The participants received visual feedback of the processed result of neural signals acquired online.
214476256|NCT06814873|BEHAVIORAL|Sham-feedback|Previously recorded neural signals are processed and presented to participants as if the signals from them are processed online.
214476257|NCT06815120|DEVICE|Experimental ureteric stent with specially shaped side-holes that prevent stagnation points (i.e., areas of low flow that cause particles to settle and E&B)|Kidney stone patients and Oncology patients admitted to either the University Hospital Southampton (UHS) or University College London Hospital (UCLH) for management of kidney stones or for the management of urine drainage in ureter will have a novel ureteric stent instead of their planned conventional stent. The novel stent will be removed after 4 weeks (kidney stone patients) or 25 weeks (oncology patients). Recruitment to the cohort of oncology patients will only commence once the results for kidney stones patients have been reviewed.
214476258|NCT06815120|OTHER|Qualitative interview|Kidney stone patients, Oncology patients and doctors will be interviewed about their experience of having a stent, or their experience in managing patients with a stent.
214476259|NCT06815094|PROCEDURE|Regional analgesia either CEA or ESP|Ultrasound guided local anesthetic injection in the course of the conducting nerve to decrease pain transmission.
214476260|NCT06813560|DIAGNOSTIC_TEST|hair cortisol|To extract cortisol from the hair, the sample is carefully sectioned into segment lengths that will approximate the time period of interest (from the outermost part, if the hair is 3 cm long, the cortisol secreted proportionally by the individual in the last 3 months of life will be extracted). Then, an approximate average weight per sample of 150 mg will be selected. The samples will be individualised and placed in eppendorfs (one for each patient) and sprayed with scissors. After incubation in methanol for 36 hours, the supernatant portion is extracted, which already contains dissolved cortisol. This solution shall be evaporated to dryness, and then the pellet shall be reconstituted with phosphate (PBS). A commercial kit for the quantification of cortisol by immunoassay (ELISA Victor X5) shall be used. The ELISA kit for the detection of cortisol in saliva (ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen).
214661846|NCT05957874|OTHER|Combined package program|"Combined package program content:~* Training: A one-week sleep hygiene training will be given to the experimental group. The training will take an average of 30 minutes for three consecutive days and a training booklet will be provided. In addition, two posters will be prepared to hang in the classroom. In one of the posters, a sleep hygiene rule will be placed at each hour using the clock order. In the other poster, good and bad sleep habits will be placed in the form of do-do.~* Task Flower: Tasks that will facilitate the transition to weekly sleep will be given to the children of the experimental group. Tasks are applications to be done within 30-60 minutes before going to bed. After the tasks, the children will perform their daily sleep routine and go to sleep.~* Notifications: As part of using technology positively, reminders will be sent to families every day for two weeks via a social media tool. These warnings will include sleep hygiene principles."
214849208|NCT02946684|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
214849209|NCT03400280|OTHER|Best practice algorithm for postoperative care|See arm/group description
214849210|NCT02776813|BIOLOGICAL|ACTR087|
214849211|NCT02776813|BIOLOGICAL|rituximab|
214849212|NCT01559987|OTHER|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
214849213|NCT01559987|OTHER|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
214849214|NCT01559987|OTHER|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
214849215|NCT06176625|BEHAVIORAL|Communication Signage|Signage regarding effective communication strategies posted on door to patient's room.
214661847|NCT04629729|DRUG|FT819|Experimental Interventional Therapy
214661848|NCT04629729|DRUG|Cyclophosphamide|Lympho-conditioning agent
214849216|NCT06176625|BEHAVIORAL|Amplifier Use|Patient is provided amplification device and signage regarding effective communication strategies with reminder to utilize the amplification device posted on door to patient's room.
214661849|NCT04629729|DRUG|Fludarabine|Lympho-conditioning agent
214661850|NCT04629729|DRUG|IL-2|Biologic response modifier
214661851|NCT04629729|DRUG|Bendamustine|Lympho-conditioning agent
214661852|NCT04130815|DRUG|Inhaled furosemide|4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
214661853|NCT01120626|DRUG|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
214661854|NCT01120626|DRUG|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
214849217|NCT04711967|BIOLOGICAL|Fecal Microbiota Transplantation|fecal microbiota transplantation
214849218|NCT04711967|DRUG|drug|drug
214849219|NCT05085795|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
214661855|NCT00146042|DRUG|Docetaxel|
214661856|NCT00146042|DRUG|Trastuzumab|
214661857|NCT00146042|PROCEDURE|Erythromycin Breath Test (ERMBT)|
214661858|NCT03883893|DRUG|Intravenous acetaminophen|Intravenous acetaminophen will be given in the OR.
214661859|NCT03883893|OTHER|Normal saline|Normal saline will given if randomized to this group.
214661860|NCT02053974|DRUG|Spironolactone|Spironolactone
214661861|NCT02053974|OTHER|Placebo|Placebo
214661862|NCT00318955|DRUG|Dexmedetomidine|
214661863|NCT00318955|DRUG|Propofol|
214661864|NCT01883570|OTHER|training in visual search strategy|
214849220|NCT05577806|DRUG|Dydrogesterone|progestin primed ovarian stimulation
214849221|NCT00406588|DRUG|Levodopa (Pardoprunox)|12-42mg
214849222|NCT00406588|DRUG|Placebo Comparator|Placebo
214849223|NCT01679197|DRUG|Metreleptin|
214849224|NCT02855619|PROCEDURE|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
214661865|NCT01883570|OTHER|access to a library of chest x-rays without search strategy|
214661866|NCT03497299|DEVICE|Active rTMS (20Hz)|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
214661867|NCT03497299|DEVICE|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
214661868|NCT00551707|DRUG|CRx-102 (2.7/180)|prednisolone 2.7 mg plus dipyridamole 180 mg
214661869|NCT00551707|DRUG|prednisolone|prednisolone (2.7 mg)
214661870|NCT00551707|DRUG|dipyridamole|dipyridamole 360 mg
214661871|NCT00551707|DRUG|placebo|placebo
214661872|NCT00551707|DRUG|CRx-102 (2.7/360)|Prednisolone 2.7 mg plus Dipyridamole 360 mg
214661873|NCT02700529|DRUG|ubenimex|
214661874|NCT02700529|OTHER|placebo|
214849225|NCT02855619|PROCEDURE|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
214849226|NCT02855619|PROCEDURE|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
214849227|NCT01699919|DRUG|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
214849228|NCT03271606|COMBINATION_PRODUCT|ERAS|The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery
214849229|NCT03271606|COMBINATION_PRODUCT|Traditional measures|The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
214849230|NCT05287152|DEVICE|titanium tacks or pins|using tacks or pins made of titanium 2.5 mm diameter and 4mm length for free gingival graft fixation.
214849231|NCT05842304|DEVICE|active cTBS|Each patient will receive three 600-pulse cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
214849232|NCT05842304|DEVICE|sham cTBS|Each patient will receive three 600-pulse sham cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
214849233|NCT03919448|BIOLOGICAL|Bevacizumab|Single-dose infusion
214849234|NCT03438539|BEHAVIORAL|Normative Feedback|Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
214849235|NCT03438539|BEHAVIORAL|Inhibitory Control Training|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control.
214849236|NCT03438539|BEHAVIORAL|Working Memory Training|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task.
214849237|NCT05319613|OTHER|Virtual clinical visits with home lab kits and mailed HIV PrEP|Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
214849238|NCT05143203|OTHER|Self-hypnosis training|Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires
214849239|NCT00389779|DRUG|Darusentan|Darusentan capsules administered orally once daily
214849240|NCT00389779|DRUG|Guanfacine|Guanfacine capsules administered orally once daily
214849241|NCT00389779|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
214849242|NCT02429375|DRUG|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
214849243|NCT01139749|DRUG|oral isotretinoin|capsules of 20 mg a day, every other day, for six months
214849244|NCT01139749|DRUG|salicylic acid and ciclopirox olamine|Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
214849245|NCT03333499|DRUG|YanXinShi placebo pills|participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure
214849246|NCT03333499|DRUG|YanXinShi pills|participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure
214849247|NCT03333499|DRUG|Trimetazidine pills|participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
214849248|NCT03333499|DRUG|YanXinShi and Trimetazidine pills|participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
214849249|NCT03481413|DEVICE|Ablation|Ablation therapy for cardiac arrhythmias
214849250|NCT00384488|BEHAVIORAL|Interactive Voice Response System (IVR)|
214290178|NCT03630952|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
214849251|NCT05329285|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
214849252|NCT02667678|BIOLOGICAL|Cohort HIVOL, patients infected by HIV|Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
214849253|NCT04213209|DRUG|Brentuximab Vedotin (Genetical Recombination)|Brentuximab Vedotin Intravenous Infusion
214849254|NCT06471309|DEVICE|Theta burst transcranial magnetic stimulation|The stimulation intensity of TBS was 80%RMT, with a total of 600 pulses, five times a week for two weeks. In the bilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the unilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the sham stimulation group, sham iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. When giving sham stimulation, put the coil vertically so that the coil is perpendicular to the patient's skull surface , it will not produce real therapeutic effect.
214849255|NCT04733209|OTHER|TENS, US, exercise|Physiotherapy
214849256|NCT06598293|BEHAVIORAL|PRO-CTCAE, Pain NRS|The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a PROM developed to systematically and objectively reflect patients' experiences and perceptions of therapeutic drugs in toxicity evaluation and adverse event reporting. PRO-CTCAE can be used to monitor patients' symptoms and side effects, support therapeutic decision-making, facilitate communication among medical staff, implement patient-centred care, and screen for health conditions.
214849257|NCT04684693|DEVICE|Laser|Laser puncture and exercise
214849258|NCT04684693|PROCEDURE|Control|Exercise
214661875|NCT01073943|DRUG|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
214290179|NCT03630952|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
214290180|NCT04258397|DRUG|Pirfenidone|Pirfenidone vs. matching placebo
214661876|NCT01073943|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
214661877|NCT01073943|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
214661878|NCT05412706|DRUG|Niraparib|"Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles."
214661879|NCT04987593|DIETARY_SUPPLEMENT|Probiotics|Once a day daily intake of probiotics, at least for 28 consecutive days before giving birth and for at least 28 consecutive days after giving birth
214661880|NCT01296906|BEHAVIORAL|Recall conducted by private practices|All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.
214661881|NCT01296906|BEHAVIORAL|Recall conducted centrally by local health department|A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
214661882|NCT01644877|DRUG|DAS181 dry powder, formulation F02|
214661883|NCT01644877|DRUG|Lactose Placebo|
214661884|NCT05288088|DIAGNOSTIC_TEST|No intervention|This is an observational study
214849259|NCT01013428|OTHER|Ultrasound|Ultrasound will be used to evaluate tendons.
214849260|NCT01208428|BEHAVIORAL|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
214849261|NCT01208428|BEHAVIORAL|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
214849262|NCT06403683|DIAGNOSTIC_TEST|WaLIDD score / Insomnia Severity Index (ISI) / International Physical Activity Questionnaire (Short-form) / Six-Minute Walk Test|Case control trial study
214849263|NCT06329791|DRUG|AZR-MD-001|AZR-MD-001 sterile ophthalmic ointment 0.5%
214849264|NCT06329791|OTHER|Vehicle|AZR-MD-001 Vehicle
214849265|NCT02283190|DRUG|Erwinase|Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
214849266|NCT01002794|PROCEDURE|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital and Martina Hansens Hospital.
214849267|NCT01002794|OTHER|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training. Carried out at Nimi Ullevaal Oslo or Gnist trending- og fysioterapi, Baerum
214849268|NCT03479931|PROCEDURE|Without placement of a catheter|Elective cesarean section without preoperative placement of a urinary catheter.
214849269|NCT03479931|PROCEDURE|With placement of a catheter|Elective cesarean section with preoperative placement of a urinary catheter.
214849270|NCT03451240|BEHAVIORAL|Corporate Athlete® Resilience|"The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~1. Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~2. Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work."
214849271|NCT01820858|DRUG|Paclitaxel|175 mg/m(2), intravenously (IV)
214849272|NCT01820858|DRUG|Paraplatin (Carboplatin Injection)|AUC=5, IV
214849273|NCT01820858|RADIATION|Pelvic Radiation|45-50 Gy
214849274|NCT01820858|RADIATION|Vaginal Brachytherapy 1|5 Gy, 3 times
214849275|NCT01820858|RADIATION|Vaginal brachytherapy 2|5 Gy, 2-4 times
214849276|NCT04449224|DRUG|Adalimuab, Etanercept, Tocilizumab, or Abatacept|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
214661885|NCT05330520|PROCEDURE|"Butterfly Medical Prostatic Retraction Device (the Butterfly device) removal/replacement"|when necessary, the device may be removed or replaced easily through the urethra due to its minimal surface and easy release from the mucosa covering it.
214661886|NCT01126229|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo daily for 12 weeks
214661887|NCT01126229|DRUG|Low dose Resveratrol|2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
214661888|NCT01126229|DRUG|High dose Resveratrol|2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
214849277|NCT04449224|DRUG|Tofacitinib or Baricitinib|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
214849278|NCT01812135|BIOLOGICAL|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
214849279|NCT05693818|OTHER|Clinical Limping Evalution|"Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp).~If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided."
214661889|NCT06213571|OTHER|Exercise Counseling|Participate in exercise coaching sessions
214661890|NCT06213571|OTHER|Exercise Intervention|Participate in home-based exercise program
214661891|NCT06213571|OTHER|Health Promotion and Education|Receive resistance band and exercise booklets
214661892|NCT06213571|OTHER|Interview|Ancillary studies
214661893|NCT06213571|OTHER|Physical Performance Testing|Ancillary studies
214661894|NCT06213571|OTHER|Questionnaire Administration|Ancillary studies
214661895|NCT06213571|OTHER|Telemedicine|Participate in sessions remotely
214849280|NCT03104621|DRUG|Benzalkonium chloride (BAK)|Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
214849281|NCT03104621|DRUG|0.0015% tafluprost|Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
214849282|NCT05356936|DIETARY_SUPPLEMENT|Vitamin K2 (MK-7)|Participants will receive Vitamin K2 (MK-7) daily by mouth.
214849283|NCT05356936|DIETARY_SUPPLEMENT|Vitamin D3|Participants will receive Vitamin D3 daily by mouth.
214849284|NCT00609284|DRUG|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
214849285|NCT00609284|DRUG|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
214849286|NCT00609284|RADIATION|Radiotherapy|70 Gy in 7 weeks
214849287|NCT05540821|DIAGNOSTIC_TEST|Hysterosalpingo-contrast sonography and sonoPODography|"Before operation, phloroglucinol 40mg of antispasmolysis was injected intramuscular, and then cervical dilation was performed according to aseptic operation requirements. A 12G double-lumen catheter was inserted into the uterine cavity, and 1.5-1.8ml of normal saline was injected into the sacculus.~Transvaginal 2/3/4D hysterosalpingo-contrast sonography: One operator extracted 2ml of Sonovue and injected 18ml of normal saline through a dual-lumen catheter, and the other operator started the four-dimensional ultrasound mode to collect dynamic volume data.~sonoPODography: Sterile saline was injected into the intrauterine cavity, with an upper limit of 20ml. The normal saline flowed from the intrauterine cavity into the pelvic cavity through the bilateral fallopian tubes, forming a good acoustic window. Pelvic observation was then performed."
214849288|NCT02471079|RADIATION|Radiotherapy|
214849289|NCT00384384|DRUG|oral 18B Glycyrrhetinic acid versus placebo|
214849290|NCT03115528|BEHAVIORAL|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
214849291|NCT04351230|DRUG|Abemaciclib|Given IV
214849292|NCT04351230|BIOLOGICAL|Trastuzumab Emtansine|Given PO
214849293|NCT03399994|DEVICE|device implantation during coronary angioplasty|device implantation during coronary angioplasty
214849294|NCT05253222|DIAGNOSTIC_TEST|retrograde image by colonic TET|"Delivery of contrast fluid by colonic TET Each participant will receive one delivery of 200 ml contrast fluid by colonic TET to the distal portion of the lesion.~One group will be taken CT investigation, another group will be taken X-ray fluoroscopy.~Imaging parameters will be collected and evaluated."
214849295|NCT00933881|OTHER|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
214849296|NCT03441295|PROCEDURE|Dynamic Intraligamentary Stabilization|DIS, Ligamys
214849297|NCT03441295|PROCEDURE|Internal Brace Ligament Augmentation|IBLA
214849298|NCT03441295|PROCEDURE|ACL Reconstruction|Conventional
214849299|NCT03331614|DEVICE|Flowaid FA-100 SCCD|The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
214849300|NCT00992095|DRUG|buprenorphine hydrochloride|single dose 8 mg sublingual tablet
214661896|NCT05445193|BEHAVIORAL|PEaters Choice Module|There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
214661897|NCT00001923|PROCEDURE|Transcranial magnetic stimulation|
214661898|NCT00710190|DEVICE|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
214661899|NCT05495607|DEVICE|CARPEDIEN|Continuous renal replacement therapy
214661900|NCT02704104|DEVICE|AC5 Topical Hemostatic Device|Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
214661901|NCT06292481|OTHER|Brunnstorm movement therapy|this group received Brunnstorm Movement therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
214661902|NCT06292481|OTHER|Combined Brunnstorm Movement therapy and low level laser therapy|this group received Combined Brunnstorm Movement therapy and low level laser therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
214661903|NCT04462237|PROCEDURE|Root coverage procedures|Treatment of multiple adjacent gingival recession using a coronally advanced flap
214661904|NCT03792503|DRUG|Apatinib|Apatinib 500 mg Po qd
214661905|NCT03792503|DRUG|Pemetrexed|Pemetrexe 500 mg/m2 d1×q3w
214661906|NCT05059132|BEHAVIORAL|Tele-rehabilitation|The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.
214661907|NCT05059132|OTHER|Education only|The education only arm will receive information on the importance of general exercise following lung cancer treatment.
214661908|NCT05696340|OTHER|semi-structured interview|"Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis.~The number of participants cannot be determined in advance; it will be determined after data saturation."
214661909|NCT03527043|DRUG|Escitalopram|10mg by mouth daily for 6 weeks
214661910|NCT03527043|OTHER|Placebo|matched placebo control by mouth for 6 weeks
214661911|NCT03839602|RADIATION|Reducing CTV|CTVs were delineated in line with tumor stage, i.e. tumor invasion.
214661912|NCT06010810|DRUG|3 % Topical Tranexamic Acid|Patient will be given 3% Topical Tranexamic Acid, on half of the face, twice a day for 2 months
214661913|NCT06010810|DRUG|4% Topical Hidroquinone|Patient will be given 4% Topical Hidroquinone, on half of the face, twice a day for 2 months
214661914|NCT01906840|DRUG|Turmeric|
214661915|NCT01906840|DRUG|placebo|
214661916|NCT00125333|DRUG|NF-kappaB Decoy|
214661917|NCT00927485|DRUG|Calcumin (Curcumin)|Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
214661918|NCT00927485|OTHER|Risk Factor Questionnaire|Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
214661919|NCT00927485|OTHER|Blood samples|Three tubes of blood at visits 0, 4 and 12 months.
214661920|NCT00927485|OTHER|Biopsies (Sigmoidoscopy)|Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
214661921|NCT00927485|OTHER|Biopsies (Upper endoscopy)|Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
214661922|NCT03607227|DRUG|Levobupivacaine|Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
214661923|NCT03607227|DRUG|Saline Solution|Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
214661924|NCT04109040|DEVICE|slit lamp|diagnostice device to examine anterior segment of the eye and for fundus examination
214661925|NCT02822365|PROCEDURE|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
214661926|NCT02822365|DEVICE|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
214661927|NCT02822365|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
214661928|NCT05493514|DEVICE|Robotic Assisted Gait Training with G-EO system|Robotic-assisted gait training is a rehabilitation treatment that applies robotic technologies to improve mobility of patients with stroke or other neurological disorders. In this study, participants will use the G-EO system robotic device according to the daily clinical practice of the Don Gnocchi Foundation.
214661929|NCT03716791|DIETARY_SUPPLEMENT|methylsulfonylmethane|3g per day
214661930|NCT03716791|DIETARY_SUPPLEMENT|placebo|white rice flour
214661931|NCT02605577|PROCEDURE|new systemic nutrition management protocol|a new established systemic nutrition management protocol
214661932|NCT03830281|DRUG|Ultra-Rapid Lispro|Administered SC
214661933|NCT03830281|DRUG|Insulin Lispro|Administered SC
214661934|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
214661935|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with low levels of vitamin D3 and high K1|The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
214661936|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and low K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
214661937|NCT02615301|DIETARY_SUPPLEMENT|Supplement with vitamin D and Calcium|The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
214661938|NCT02226068|DRUG|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
214661939|NCT02226068|OTHER|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
214661940|NCT04194177|OTHER|mechanical ventilation during robotic surgery|protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg
214661941|NCT03293680|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
214661942|NCT02201940|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
214661943|NCT02201940|DRUG|Placebo|Tablet administered orally once daily
214661944|NCT02126488|BEHAVIORAL|treadmill slip perturbation|Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
214661945|NCT02126488|BEHAVIORAL|treadmill training placebo|An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
214661946|NCT02126488|BEHAVIORAL|observation training|An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
214661947|NCT05102474|OTHER|Polysomnography (PSG)|PSG is the gold standard for objectively measuring sleep in the laboratory setting. The procedure consists of electrodes measuring brain activity (electroencephalography, EEG), eye movements (electrooculography, EOG), muscle activity (electromyography, EMG), respiratory events, snoring activity, blood oxygen saturation, and body position. Video surveillance during the sleep study can also monitor for itching events that occur during the night.
214661948|NCT00013052|BEHAVIORAL|Peer led classes. Led by trained veterans with a chronic disease.|
214661949|NCT06448377|PROCEDURE|Videolaryngoscopy|Situations in which the practitioner performs endotracheal intubation using a videolaryngoscope during airway intervention will be included in this group.
214661950|NCT06448377|PROCEDURE|FOB|Situations in which the practitioner performs endotracheal intubation using a fiberoptic bronchoscope during airway intervention will be included in this group.
214661951|NCT06448377|PROCEDURE|FOB+Aintree|Situations in which the practitioner performs endotracheal intubation using a Fiberoptic intubation via LMA with aintree catheter during airway intervention will be included in this group.
214661952|NCT06448377|PROCEDURE|Classic intubation with laryngoscopy|Situations in which the practitioner performs endotracheal intubation using a macintosh laryngoscope during airway intervention will be included in this group.
214661953|NCT06448377|PROCEDURE|Others|Cases in which intubation cannot be performed, those who are awakened from anesthesia, or those in whom a surgical method is used for airway access will be included in this group.
214661954|NCT05928884|OTHER|There is no intervention. It is a phenotyping study only|See above, this is only a phenotyping study but NIH required us to register it as a trial.
214661955|NCT05112731|DIAGNOSTIC_TEST|BAFF and MGO|measurement of BAFF and MGO levels before reperfusion and after 3 months
214661956|NCT03437603|DRUG|Eltrombopag|Starting Eltrombopag daily on empty stomach (2 hour before breakfast) for 8 weeks.
214661957|NCT04045067|PROCEDURE|Isolation of pulmonary veins|Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
214661958|NCT04045067|PROCEDURE|Ablation by radiofrequency of low-voltage areas|The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
214661959|NCT03192904|DEVICE|Energy Instruments|Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.
214661960|NCT03192904|DEVICE|Stapling Device|Stapling Device, including linear stapler and curved stapler.
214661961|NCT05841940|DRUG|[14C]HLX208|Carbon-14 labeled HLX208
214661962|NCT01309737|DRUG|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
214661963|NCT01309737|DRUG|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
214661964|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
214661965|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
214661966|NCT02335502|DEVICE|Implantation with the commercially available Axium neurostimulator|
214661967|NCT00539019|OTHER|calories measured 5x following wound healing|measure REE at various time points postburn
214661968|NCT00908284|BEHAVIORAL|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
214661969|NCT00908284|BEHAVIORAL|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
214661970|NCT01907165|DRUG|Temozolomide|
214661971|NCT01907165|DRUG|Disulfiram|
214661972|NCT01907165|DIETARY_SUPPLEMENT|Copper gluconate|
214661973|NCT00056199|DRUG|EYE001|
214661974|NCT02150031|DRUG|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
214661975|NCT02150031|DRUG|1% Chlorhexidine|subgingival irrigation
214661976|NCT02150031|DRUG|1% Chlorhexidine|supragingival irrigation
214661977|NCT02150031|PROCEDURE|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
214661978|NCT02150031|DRUG|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
214849301|NCT03781024|COMBINATION_PRODUCT|Footwash|footbath/footwash can help cleanse the wound, remove dead tissue, increase circulation and puts the wound in direct contact with medication to promote faster healing.
214849302|NCT01694017|DRUG|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
214849303|NCT01694017|DRUG|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
214849304|NCT01005329|BIOLOGICAL|Bevacizumab|Given IV
214849305|NCT01005329|DRUG|Carboplatin|Given IV
214849306|NCT01005329|DRUG|Cisplatin|Given IV
214849307|NCT01005329|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214849308|NCT01005329|DRUG|Paclitaxel|Given IV
214849309|NCT02997657|BEHAVIORAL|Positive Psychotherapy|Exercises designed to boost moods, positive behaviors, and positive cognitions.
214849310|NCT02997657|BEHAVIORAL|Standard smoking cessation counseling|Counseling designed to provide support and problem solving for smoking cessation
214849311|NCT02974491|OTHER|Fuji apple juice|On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
214661979|NCT02150031|PROCEDURE|Tooth extraction|dental extraction
214661980|NCT00882414|DRUG|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
214661981|NCT00882414|DRUG|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
214849312|NCT04756596|DIAGNOSTIC_TEST|DDVIT testing|One randomly selected eye will be included for each study participant. Participants respond to the DDVIT test in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
214849313|NCT04756596|DIAGNOSTIC_TEST|ETDRS testing|The same eye is included for each study participant. Participants respond to the standard ETDRS chart of our Ophthalmology Department in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
214661982|NCT00709202|DRUG|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..
214849314|NCT00908557|OTHER|readability improvement and good practice redaction|improvement using Flesch readability index and good practice in redaction of informed consent documents.
214849315|NCT00908557|OTHER|Control|information based on the classic informed consent document
214849316|NCT01583257|BEHAVIORAL|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
214849317|NCT04049916|DRUG|Pyronaridine Tetraphosphate/Artesunate|Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
214849318|NCT04049916|DRUG|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
214849319|NCT04049916|DRUG|Primaquine Diphosphate|Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
215033539|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (visuospatial working memory tasks)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of visuospatial working memory tasks.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
215033540|NCT04816032|OTHER|Pennebaker's expressive writing intervention|It focuses on the emotional aspect of the written event
214290181|NCT04258397|DRUG|matching placebo|matching placebo
214290182|NCT05184218|DRUG|IGM-6268|Active Comparator
214849320|NCT00643214|DEVICE|Tetrix|Twice daily topical application
214849321|NCT00643214|DEVICE|Tetrix|Twice daily topical application
214849322|NCT02128555|PROCEDURE|Total Ankle Replacement|The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.
214849323|NCT02128555|PROCEDURE|Arthrodesis|The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
214290183|NCT05184218|DRUG|Placebo|Placebo Comparator
214661983|NCT00709202|DRUG|Placebo Oral Tablet|
214661984|NCT00465257|DRUG|artesunate + amodiaquine|
214661985|NCT02903004|DRUG|Trabectedin|
214661986|NCT02903004|DRUG|Pegylated Liposomal Doxorubicin|
214661987|NCT02903004|DRUG|Topotecan|
214661988|NCT02903004|DRUG|Gemcitabine|
214661989|NCT02903004|DRUG|Weekly Paclitaxel|
214661990|NCT02903004|DRUG|Carboplatin|
214661991|NCT00199004|DRUG|Cyclophosphamide|
214661992|NCT00199004|DRUG|Dexamethasone / Prednisolone|
214661993|NCT00199004|DRUG|Vincristine|
214661994|NCT00199004|DRUG|Daunorubicin|
214661995|NCT00199004|DRUG|Asparaginase|
214661996|NCT00199004|DRUG|Methotrexate|
214661997|NCT00199004|DRUG|Cytarabine|
214661998|NCT00199004|DRUG|Mercaptopurine|
214661999|NCT00199004|DRUG|G-CSF|
214662000|NCT00199004|DRUG|Vindesine|
214662001|NCT00199004|DRUG|VP16|
214662002|NCT00199004|DRUG|Adriamycin|
214662003|NCT00199004|DRUG|Thioguanine|
214662004|NCT00199004|DRUG|VM26|
214662005|NCT00199004|DRUG|Rituximab|
214662006|NCT00199004|PROCEDURE|CNS irradiation|
214662007|NCT00199004|PROCEDURE|Mediastinal irradiation (if residual TU)|
214662008|NCT00199004|PROCEDURE|Stem cell transplantation|
214662009|NCT01271686|DRUG|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
214662010|NCT01070420|OTHER|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via Rt central femoral vein.
214662011|NCT01070420|OTHER|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via continuous peripheral vein.
214662012|NCT00989599|OTHER|compress of Chamomilla recutita infusion|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
214662013|NCT00989599|OTHER|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
214662014|NCT04623957|DEVICE|ForgTin©|"The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises."
214662015|NCT06329050|DRUG|Losartan|Administration of Losartan tablets(50 mg)
214662016|NCT06329050|DRUG|Placebo|Administration of Placebo tablets
214662017|NCT00730340|PROCEDURE|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
214662018|NCT00730340|PROCEDURE|Tonsillectomy with open fossa|SOP for a tonsillectomy.
214662019|NCT04614818|OTHER|Non-intervention research|Non-intervention research
214662020|NCT03379519|BEHAVIORAL|Multi-domain Attention Training (MAT)|The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.
214662021|NCT03379519|BEHAVIORAL|Passive information activities (PIA)|The active control group (Passive information activities) training content included reading online e-books and playing online games.
215033541|NCT04816032|OTHER|Neutral writing|Description of neutral topics with less emotional involvement
215033542|NCT03981874|OTHER|telephonic interview|Telephonic interview
214662022|NCT00814931|DRUG|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
214662023|NCT00814931|DRUG|Placebo|matching oral liquid suspension placebo twice a day for 8 days
214662024|NCT01090557|OTHER|Collection of exhaled breath|balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
214662025|NCT00931164|DRUG|Sodium Oxybate|dosage is by weight
214662026|NCT01288768|PROCEDURE|Knee arthroscopy|Knee arthroscopy within 4 weeks.
214662027|NCT01002781|DRUG|Tocilizumab|Tocilizumab, IV, 8 mg/kg, every 2 weeks
214662028|NCT04538404|PROCEDURE|Colon Surgery|Right, left colon surgery, transverse colon surgery, multiple colon surgery in open and minimally invasive surgert
214662029|NCT05523180|DIETARY_SUPPLEMENT|Probiotic|"Active ingredients:~Lactobacillus plantarum RSB11, 5 Billion colony forming units (CFU) Lactobacillus acidophilus RSB12, 5 Billion CFU Lactobacillus rhamnosus RSB13, 5 Billion CFU Holy basil leaf extract, 42.0 mg Turmeric root extract, 30.0 mg Vasaka leaf extract, 48.0 mg~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
214849324|NCT05927181|PROCEDURE|TAOM|In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
214849325|NCT04692025|DRUG|ASC41 tablet|Oral tablet
214849326|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Placebo|Colored water
215033543|NCT06544460|PROCEDURE|Secondary cytoreduction|Repeated tumor cell reduction surgery for recurrent ovarian cancer patients
214662030|NCT05523180|OTHER|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
214662031|NCT04454411|DRUG|Brixadi|Extended release injectable Buprenorphine
214849327|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Caffein|Sugar free energy drink at 5mg/kg caffeine
214662032|NCT04454411|DRUG|Vivitrol|Extended release injectable Naltrexone
214662033|NCT06371339|DEVICE|"Additional acquisitions with the investigational gamma-camera  MoTI ."|"The gamma-camera MoTI will be used for the study to carry out 3 or 4 additional acquisitions (depending on the therapeutic indication) compared with those provided for in standard practice with a conventional gamma camera (Syngula).~Patients will receive their treatment as usual in two stages:~* 1/ Pre-therapy phase:~  1. Administration of a tracer dose of 131I (Day 0).~ 2. Assessment of 131I uptake/fixation rate at Day 0, Day 1, Day 5.~ 3. Determination of the therapeutic dose of 131I to be administered to the patient after collegial discussion.~* 2/ Therapy phase:~  1. Administration of the therapeutic dose (Day 0).~ 2. Thyroid scintigraphy within 4 hours of treatment before the patient returns home (Day 0).~For the study, scintigraphic acquisitions will be carried out respectively using both the standard gamma camera Syngula and the gamma camera MoTI."
214849328|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Decaf|Sugar free decaf energy drink (vitamins only)
214849329|NCT02244749|OTHER|skin specimen|skin specimen
214849330|NCT01304758|DEVICE|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
214849331|NCT02011919|DEVICE|Echopulse|HIFU Under ultrasound guidance
214849332|NCT01574664|DEVICE|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
214662034|NCT01283737|DEVICE|DBX Putty|OCD of the knee will be treated with DBX Putty
214662035|NCT01283737|PROCEDURE|Mosaicplasty|Mosaicplasty procedure performed to treat OCD of the knee
214662036|NCT05405829|OTHER|Health education|theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
214662037|NCT03746730|DEVICE|ultrasound|gray scale and doppler ultrasound
214662038|NCT05229965|DRUG|Paracetamol|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
214290184|NCT03935204|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
214662039|NCT05229965|DRUG|Paracetamol Codeine|14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
214662040|NCT05229965|DRUG|Paracetamol caféine|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
214662041|NCT01442298|PROCEDURE|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
214662042|NCT01442298|PROCEDURE|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
214662043|NCT01397851|DEVICE|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
214662044|NCT04976465|DRUG|Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH"
214662045|NCT04976465|DRUG|Without Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ"
214662046|NCT04661696|DRUG|Paclitaxel (albumin-bound)|The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
214662047|NCT00189826|DRUG|tacrolimus|immunosuppression
214662048|NCT06853171|DRUG|KarXT|Specified dose on specified days
214662049|NCT06853171|DRUG|KarX-EC|Specified dose on specified days
214662050|NCT00040157|DRUG|ACH126-443 (Beta-L-Fd4C)|
214662051|NCT06197126|RADIATION|Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .|The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
214662052|NCT05634603|DIETARY_SUPPLEMENT|Lactose-free milk formula (Frisolac LF ®)|Following the initial rehydration phase, children were alternately assigned to receive 100 ml/kg/day of either lactose-free or lactose-containing formula
214662053|NCT05641688|DRUG|[18F]PI-2620|The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
214662054|NCT02215681|DEVICE|acupuncture|
214290185|NCT03935204|BIOLOGICAL|Placebo|Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
214290186|NCT02322398|DRUG|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
214662055|NCT03991247|BEHAVIORAL|Computerized behavioral therapy program delivered by internet for insomnia management|"The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm)."
214662056|NCT03991247|OTHER|Spa treatment|"Spa treatment is harmonized in the different stations. It consists in:~* a medical thermal follow-up: weekly medical consultation of 15 minutes during the 3 weeks spa treatment.~* an institutional follow-up: support, help and monitoring of patients during spa treatment~* Crenotherapy: 18 baths of 10 minutes in running water, 18 spa showers of 3 minutes, 9 massages under water of 20 minutes, 18 baths of 10 minutes in pool. Water temperature of pool is between 31°C and 33°C. Water temperature for other care is 35°C and 38°C."
214290187|NCT02322398|DRUG|hMG|150-300 IU/d hMG
214290188|NCT00708968|BEHAVIORAL|FOCUS Program|Supportive, educative sessions with patients and spouses.
214290189|NCT04180228|OTHER|self-administred questionnaire|On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.
214290190|NCT02967835|BEHAVIORAL|Tele-psychiatry consult|tele-psychiatry consult for evaluation and treatment recommendations
214662057|NCT00779168|DRUG|white button mushroom extract|For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
214662058|NCT00779168|OTHER|flow cytometry|Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
214662059|NCT00779168|OTHER|immunologic technique|Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
214662060|NCT00779168|OTHER|laboratory biomarker analysis|Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
214662061|NCT00779168|OTHER|gas chromatography-mass spectrometry|Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
214662062|NCT00779168|OTHER|pharmacological study|Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
214662063|NCT03836144|DIETARY_SUPPLEMENT|Potassium citrate|
214662064|NCT00375245|DRUG|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
214662065|NCT00375245|OTHER|Grapefruit Juice|Daily oral doses starting during the second week on study.
214662066|NCT03934684|DRUG|Drug: Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~* Carfilzomib will be administered as a 30-minute infusion.~* Dexamethasone will be taken by mouth or intravenously."
214662067|NCT03934684|DRUG|Drug: Carfilzomib + Lenalidomide + Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~* Carfilzomib will be administered as a 10 minute infusion.~* Lenalidomide will be taken orally.~* Dexamethasone will be taken by mouth or intravenously."
214662068|NCT04266938|BEHAVIORAL|Rapid start of antiretrovirals|Utilize health navigators to link patients with newly diagnosed HIV into care and treatment within 7 days
214662069|NCT04266938|BEHAVIORAL|Retrospective analysis|Review historical standard of care relative to time to start antiretrovirals and impact on retention in care.
214662070|NCT04266938|BEHAVIORAL|Non- RAPID start|Review of patients who failed to establish care and start ART within 7 days of HIV diagnosis and analyze impact on retention in care.
214662071|NCT06577818|PROCEDURE|CC+SI (Chest compression during sustained inflation)|CC+SI (Chest compression during sustained inflation)
214662072|NCT06577818|PROCEDURE|3:1 C:V (3:1 Compression:Ventilation ratio)|"3:1 C:V Group (Control group - Standard of Care): Newborns randomized to 3:1 C:V will receive a CC rate of 90/min and 30 ventilations/min as per current resuscitation guidelines. The PIP used for the 30 inflations will also be 30cmH2O) as per current resuscitation guidelines. Every 60sec, a HR assessment as per neonatal guidelines will be performed to assess if HR is \<60/min - continue CC or \>60/min - stop CC (current standard of care). 3:1 C:V will be continued until ROSC."
214662073|NCT05816954|DIAGNOSTIC_TEST|Chest Computed Tomography Scan per normal clinical practice|Normal Clinical practice
214290191|NCT06141109|DRUG|Sintilimab 200mg+MB07133 600mg|"1. Adopting the classic 3+3 scheme design, 3 dose groups, with a cycle of 21 days. On the first day of each cycle, a single infusion of Sintilimab is given, and MB07133 is given for 7 consecutive days after a 2-hour interval between infusion initiation.~2. Sintilimab 200mg+MB07133 1800mg, recruiting 30 subjects，the administration method is as 1."
214290192|NCT04548570|PROCEDURE|approximation of both rectus muscles|closure of both rectus muscle before closure of rectus sheeth
214662074|NCT05979259|OTHER|Serious game nutrition education intervention|"Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will play the Foodbot Factory nutrition education serious game for 10-15 minutes. The Foodbot Factory serious game and lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide."
214662075|NCT05979259|OTHER|Conventional nutrition education intervention|Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will use conventional learning activities, such as worksheets, sourced from an online teaching resource repository. The lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide.
214662076|NCT06581393|DEVICE|Moda-flx Hemodialysis System|All participants will complete up to 4 dialysis treatments on the Moda-flx Hemodialysis System over a period of up to 2 weeks.
214662077|NCT06344130|RADIATION|Radiation Therapy|Radiation therapy will be administered via a linear accelerator using 6 megavoltage (MV) photons or greater.
214662078|NCT06303505|DRUG|TUB-040|A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
214662079|NCT04996797|DRUG|Tulisokibart|Administered by IV infusion
214662080|NCT04996797|DEVICE|Companion Diagnostic (CDx) Testing|PRA023 CDx Genotyping Assay
214290193|NCT00534391|DRUG|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
214662081|NCT04996797|OTHER|Placebo|Placebo administered by IV infusion
214662082|NCT05259566|BEHAVIORAL|menthol ban in cigarettes only|menthol ban in cigarettes only, menthol available in e-cigarette
214662083|NCT05259566|BEHAVIORAL|total menthol ban|menthol ban in both cigarettes and e-cigarettes
214662084|NCT06506136|DRUG|Fluoxetine|"Participants will receive fluoxetine tablets, 40 mg once daily, administered 30 minutes after breakfast for 12 weeks.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~polyethylene glycol：13.7 g enema Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
214662085|NCT06506136|DRUG|Placebo|"Participants in the Placebo Control Group will receive placebo tablets that are identical in appearance and taste to the fluoxetine tablets. They will take one placebo tablet orally twice a day for 12 weeks, following the same schedule as the treatment group to maintain blinding.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~polyethylene glycol：13.7 g enema Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
214662086|NCT02892305|PROCEDURE|Hepatic Resection or Ablation with Pancreaticoduodenectomy|"Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care."
214662087|NCT00458471|DEVICE|Insertion of a urinary catheter coated with benign E. coli|
214662088|NCT06146101|DRUG|IHL-42X Low Dose|Softgel capsule
214662089|NCT06146101|DRUG|IHL-42X High Dose|Softgel capsule
214662090|NCT06146101|DRUG|Placebo|Softgel capsule
214662091|NCT06146101|DRUG|IHL-42X (Optimal Dose)|Softgel capsule
214662092|NCT06146101|DRUG|Dronabinol|Softgel capsule
214290194|NCT00534391|DRUG|Artificial tear|4 times daily
214662093|NCT06146101|DRUG|Acetazolamide|Softgel capsule
214662094|NCT06146101|DRUG|Placebo|Softgel capsule
214662095|NCT06471205|DRUG|BL-B01D1|Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.
214662096|NCT06471205|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks (Q3W).
214662097|NCT04091217|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
214662098|NCT04091217|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.
214662099|NCT05885555|BIOLOGICAL|Ianalumab|Intravenous infusion, prepared from concentrate solution
214662100|NCT06521346|PROCEDURE|Active cycle breathing technique|The ACBT was included if it was described as containing three essential components: 1) breathing control, 2) forced expiration technique and 3) thoracic expansion exercises. The technique may also include postural drainage (PD) or percussion/shaking.
214662101|NCT06521346|PROCEDURE|Routine care|Routine care delivers after extubating such as percussion or chest physiotherapy
214662102|NCT01978002|BEHAVIORAL|Pain sensitivity testing|
214662103|NCT01978002|BEHAVIORAL|Urodynamic testing|
214662104|NCT03573024|DRUG|Azacitidine|On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.
214662105|NCT03573024|DRUG|Venetoclax|Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3 and 600 mg on day 4. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.
214662106|NCT03437187|PROCEDURE|Cholecystectomy|Laparoscopic technique
214290195|NCT04942691|OTHER|physical activity|training with trampoline. Each session lasted sixty minutes. Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
214290196|NCT06504602|DEVICE|Active Virtual Reality|Active virtual reality group will play a game through a virtual environment.
214290197|NCT06504602|DEVICE|Passive Virtual Reality|Passive virtual reality group will watch a movie through a virtual environment.
214662107|NCT04888611|BIOLOGICAL|Camrelizumab plus GSC-DCV|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and GSC-DCV IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
214662108|NCT04888611|BIOLOGICAL|Camrelizumab plus Placebo|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and Placebo IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
214662109|NCT05662332|DRUG|Insulin Efsitora Alfa|Administered SC
214662110|NCT05662332|DRUG|Insulin Glargine|Administered SC
214662111|NCT05558566|OTHER|Neurofeedback from the SMA|Feedback is provided regarding activity in the SMA and participant attempts to control SMA activity using the feedback as a training signal
214662112|NCT05558566|OTHER|Neurofeedback from control region|Feedback is provided regarding activity in a control region and participant attempts to control activity in that region using the feedback as a training signal.
214290198|NCT01979887|PROCEDURE|Meibum Expression|Meibum expression as per protocol. No investigational drug is administered in this study.
214662113|NCT06503016|DRUG|Phosphocreatine|Administration of Phosphocreatine
214662114|NCT06503016|DRUG|Placebo|Saline solution of NaCl 0.9%
214662115|NCT01042379|DRUG|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
214662116|NCT01042379|DRUG|AMG 386 with or without Trastuzumab|Arm is closed.
214662117|NCT01042379|DRUG|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
214662118|NCT01042379|DRUG|MK-2206 with or without Trastuzumab|Arm is closed.
214662119|NCT01042379|DRUG|AMG 386 and Trastuzumab|Arm is closed.
214662120|NCT01042379|DRUG|T-DM1 and Pertuzumab|Arm is closed.
214662121|NCT01042379|DRUG|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
214662122|NCT01042379|DRUG|Ganetespib|Arm is closed.
214849333|NCT06357949|DEVICE|High-intensity laser|"All patients will receive a rehabilitation program consisting of stretching, strengthening, balance, and walking exercises targeting the lower extremities for 45 minutes, 5 days a week, for 6 weeks. Walking training will initially begin on level ground and gradually progress to different levels and surfaces.~High-intensity laser will be applied continuously in biostimulation mode 3 days a week, once a day, for a total of 9 sessions over 3 weeks"
214849334|NCT06357949|DEVICE|Sham laser|The same procedure will be followed, but sham laser will be applied at 0 j/cm2 for 10 minutes.
214849335|NCT02349243|DRUG|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
214849336|NCT02349243|DRUG|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
214849337|NCT01491308|OTHER|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
214849338|NCT01272921|DRUG|Bupivacaine|Varying doses to determine the duration of analgesia
214849339|NCT01272921|DRUG|Ropivacaine|Varying doses to determine the duration of analgesia
214849340|NCT04119219|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
214849341|NCT01132664|DRUG|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
214849342|NCT01132664|DRUG|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
214849343|NCT01132664|DRUG|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
214849344|NCT00006108|BIOLOGICAL|trastuzumab|
214849345|NCT00006108|DRUG|capecitabine|
214849346|NCT00006108|DRUG|paclitaxel|
214849347|NCT02382549|DRUG|BRAF inhibitor|BRAF inhibitor
214849348|NCT02382549|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
214849349|NCT02382549|DRUG|MEK inhibitor|MEK Inhibitor
214849350|NCT01279252|DRUG|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
214849351|NCT05717270|PROCEDURE|Two-layered suture repair|The ruptured Achilles tendon will be sutured in two-layer.
214849352|NCT00982891|DRUG|Opioid (morphine sulphate) in low dose|individualized titration
214849353|NCT00126126|OTHER|EBAR Program|Evidence Based Amputee Rehabilitation Program
214849354|NCT00705120|OTHER|Bone Marrow Cell Transplantation|
214849355|NCT00705120|RADIATION|Irradiation, Total Body|
214849356|NCT00705120|DRUG|Cyclophosphamide|
214849357|NCT00705120|DRUG|Cyclosporin|
214849358|NCT00705120|PROCEDURE|Mesenchymal Stem Cell Transplantation|
214849359|NCT00705120|DRUG|Busulfan|
214849360|NCT00002351|DRUG|Indinavir sulfate|
214849361|NCT01394848|DEVICE|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
214662123|NCT01042379|DRUG|ABT-888|Arm is closed.
214849362|NCT01394848|DEVICE|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
214849363|NCT01394848|DRUG|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
214849364|NCT01394848|DRUG|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
214849365|NCT02343757|DEVICE|PET/MRI|
214849366|NCT02682186|DRUG|Ropivacaine after dilution with sodium chloride 0.9%|"After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.~Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.~In the other group, sterilization, sheating and US are performed but the needle is not inserted."
214662124|NCT01042379|DRUG|Neratinib|Arm is closed.
214662125|NCT01042379|DRUG|PLX3397|Arm is closed.
214849367|NCT02339610|DEVICE|ATTUNE Primary, Cemented Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
214849368|NCT04677855|DRUG|PCUR-101|50 mg capsules
214849369|NCT04677855|DRUG|Dutasteride 0.5 mg|0.5 mg capsules
214849370|NCT04677855|DRUG|Abiraterone and Prednisone|500 mg tablets Abiraterone with 5 mg Prednisone Tablets
214849371|NCT04745208|BEHAVIORAL|Simulation based education|high fidelity simulation with moulage
214849372|NCT06063096|DIETARY_SUPPLEMENT|D-allulose|Fruit-flavoured drink with d-allulose at 2 dosages
214849373|NCT06063096|DIETARY_SUPPLEMENT|Placebo|Fruit-flavoured drink with high fructose corn syrup
214849374|NCT01389934|DRUG|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
214849375|NCT01389934|DRUG|Placebo|Women of this group be infused saline 2 ml / h for 48h.
214849376|NCT03469817|DIAGNOSTIC_TEST|MRI|"Patients who are part of Arm 2 will undergo an MRI at their 1 year post-operative visit."
214849377|NCT00567736|DRUG|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
214662126|NCT01042379|DRUG|Pembrolizumab - 4 cycle|Arm is closed.
214662127|NCT01042379|DRUG|Talazoparib plus Irinotecan|Arm is closed.
214662128|NCT01042379|DRUG|Patritumab and Trastuzumab|Arm is closed.
214662129|NCT01042379|DRUG|Pembrolizumab - 8 cycle|Arm is closed.
214662130|NCT01042379|DRUG|SGN-LIV1A|Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
214662131|NCT01042379|DRUG|Durvalumab plus Olaparib|Arm is closed.
214662132|NCT01042379|DRUG|SD-101 + Pembrolizumab|Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for \>T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
214662133|NCT01042379|DRUG|Tucatinib plus trastuzumab and pertuzumab|Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
214662134|NCT01042379|DRUG|Cemiplimab|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
214662135|NCT01042379|DRUG|Cemiplimab plus REGN3767|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
214662136|NCT01042379|DRUG|Trilaciclib with or without trastuzumab + pertuzumab|"Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles~For HER2+:~Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization"
214662137|NCT01042379|DRUG|SYD985 ([vic-]trastuzumab duocarmazine)|SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
214662138|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
214849378|NCT00567736|DRUG|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
214849379|NCT01173913|DRUG|ModraDoc001 10mg capsules|Bi-daily administration. One cycle will last 7 days
214849380|NCT01173913|DRUG|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
214849381|NCT01173913|DRUG|ModraDoc006 10 mg tablet|Bi-daily administration. One cycle will last 7 days
214849382|NCT03274713|DEVICE|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
214849383|NCT03274713|DEVICE|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
214849384|NCT02217696|OTHER|Computerized reading training|
214849385|NCT03445299|BEHAVIORAL|Music|Listening to music for 30 minutes at bedtime
214849386|NCT01005706|DRUG|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
214849387|NCT01005706|DRUG|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
214662139|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
214662140|NCT01042379|DRUG|Amcenestrant|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks
214662141|NCT01042379|DRUG|Amcenestrant + Abemaciclib|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
214662142|NCT01042379|DRUG|Amcenestrant + Letrozole|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
214662143|NCT01042379|DRUG|ARX788|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
214662144|NCT01042379|DRUG|ARX788 + Cemiplimab|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
214662145|NCT01042379|DRUG|VV1 + Cemiplimab|VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
214662146|NCT01042379|DRUG|Datopotamab deruxtecan|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
214662147|NCT01042379|DRUG|Datopotamab deruxtecan + Durvalumab|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
214662148|NCT01042379|DRUG|Zanidatamab|Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
214662149|NCT01042379|DRUG|Lasofoxifene|Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
214662150|NCT01042379|DRUG|Z-endoxifen|Z-endoxifen: 10 mg QD, p.o., for 24 weeks
214662151|NCT01042379|DRUG|ARV-471|ARV-471: 200 mg QD, p.o, for 24 weeks
214662152|NCT01042379|DRUG|ARV-471 + Letrozole|ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
214662153|NCT01042379|DRUG|ARV-471 + Abemaciclib|ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks
214662154|NCT01042379|DRUG|Endoxifen + Abemaciclib|Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks
214662155|NCT01042379|DRUG|Rilvegostomig + TDXd|Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks
214662156|NCT01042379|DRUG|Dan222 + Niraparib|DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks
214662157|NCT01042379|DRUG|Sarilumab + Cemiplimab + Paclitaxel|Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
214662158|NCT01042379|DRUG|GSK 5733584|Route: Intravenous infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection. Will receive a max of 12 weeks.
214662159|NCT01042379|DRUG|GSK 5733584 + Dostarlimab|"GSK 5733584 Route: Intravenous Infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection x 12 weeks max.~Dostarlimab Route: Intravenous Infusion Dosage Form: 500 mg fixed dose intravenous Q3W for infusion x 12 weeks max."
214662160|NCT06645756|OTHER|Test meal|Test meal consisting of fries, chicken nuggets and eggs
214662161|NCT05692830|DRUG|Alcohol|Alcohol administered orally at multiple doses and consumption speeds to test transdermal device accuracy
214662162|NCT05623670|PROCEDURE|minimally invasive cardiac surgery using a VJI cannula.|Observation of postinterventional internal jugular vein thrombus after minimally invasive cardiac surgery using VJI cannulation to achieve complete CPB.
214662163|NCT04350333|BEHAVIORAL|CBT-I|Strategies and techniques of Cognitive behavioral therapy for insomnia adapted for pregnant women: stimulus control; sleep hygiene; sleep restriction; cognitive control etc.
214662164|NCT04350333|BEHAVIORAL|Assertive communication training|Intervention based on improving assertive communication and regulating emotions.
214662165|NCT04034017|OTHER|no intervention|descriptive study, no intervention
214662166|NCT02429999|DRUG|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
214662167|NCT02429999|DRUG|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
214662168|NCT03878485|DEVICE|MRIdian Linac System from ViewRay|"* 0.35T MRI combined with a linear accelerator~* This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy"
214662169|NCT03878485|RADIATION|Stereotactic MRI-guided Adaptive Radiotherapy|-The MR-linac will be delivering the radiation
214662170|NCT04992988|DRUG|Toripalimab|Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT
214662171|NCT05807308|BEHAVIORAL|Technology-based cognitive and artistic therapeutic activities|Therapeutic and artistic activities within the program (drawing, mandala, etc.). The program will be implemented in 6 sessions in two weeks. At the beginning and end of the program, children's anxiety and spiritual well-being levels will be evaluated.
214662172|NCT01006343|OTHER|Higher Protein (HP)|
214662173|NCT01006343|OTHER|Lower Protein (LP)|
214662174|NCT04230109|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan via iv, predetermined dosage per protocol, two days per 21-day cycle, for 4 cycles (monotherapy cohort)
214662175|NCT04230109|DRUG|Pembrolizumab|Pembrolizumab via iv, predetermined dosage per protocol, per 21-day cycle, for 4 cycles (combination cohort)
214662176|NCT06107192|OTHER|Dietary intervention - apple catechin diet|The intervention will provide a catechin-containing apple juice, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.
214290199|NCT01714635|DEVICE|Tecnis Multifocal Intraocular Lens|
214662177|NCT06107192|OTHER|Dietary intervention - low catechin diet|The intervention will provide a nutritionally-matched beverage without catechins, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.
214662178|NCT06665074|BIOLOGICAL|Endotoxin (E. coli O:113, Reference Endotoxin)|Dosage of endotoxin is 0.8 ng/Kg body Weight
214662179|NCT06665074|OTHER|Saline (Placebo)|Volume of saline to be the same as volume of endotoxin
214662180|NCT04870424|DRUG|Colchicine|Colchicine in a loading dosage of 1mg single dose per os the day before TAVI and 1mg single dose at the day of procedure. Thereafter, colchicine 0.5mg once daily per os up to post-procedural day 12.
214662181|NCT04870424|DRUG|Placebo|Placebo once daily per os the day before TAVI and once at the day of procedure. Thereafter, once daily per os up to post-procedural day 12.
214662182|NCT06974396|BIOLOGICAL|Prothrombin time|"Comparison of prothrombin time results obtained with the different thromboplastins reagent for subgroup (extrinsic pathway factor and for those with hepatocellular insufficiency) by a regression line and a Bland-Altman representation.~Comparison of extrinsic pathway factor assays obtained with the different thromboplastins reagent for each subgroup by a regression line and a Bland-Altman representation.~Evaluation and determination of the sensitivity of the prothrombin time according to the activity rate obtained for each factor (for each reagent)."
214662183|NCT05293249|COMBINATION_PRODUCT|dMAb AZD5396|Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
214662184|NCT05293249|COMBINATION_PRODUCT|dMAb AZD8076|Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
214662185|NCT05293249|COMBINATION_PRODUCT|CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device|The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.
214662186|NCT05293249|DRUG|Hylenex|Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.
214662187|NCT05293249|COMBINATION_PRODUCT|CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device|The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.
214662188|NCT05723484|DEVICE|GIFT Device|The GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
214662189|NCT06459674|DEVICE|PrO2 Fit (IMT Trainer)|The device is used four times a week over a period of 8 weeks.
214662190|NCT06975735|PROCEDURE|TAP Plane Block|The transversus abdominis plane block (TAPB) is a technically simple and safe form of regional anesthesia that can provide effective analgesia for 12 hours in patients with acute postoperative pain
214662191|NCT06975735|PROCEDURE|TFP Block|The transversalis fascia plane block (TAPB) is a technically simple and safe form of regional anesthesia that can provide effective analgesia for 12 hours in patients with acute postoperative pain
214662192|NCT03267524|BEHAVIORAL|Exercise Intervention|Receive Walking for Recovery from Surgery prehabilitation intervention
214662193|NCT03267524|OTHER|Quality-of-Life Assessment|Ancillary studies
214662194|NCT03267524|OTHER|Survey Administration|Ancillary studies
214662195|NCT05167227|OTHER|Extension for Community Healthcare Outcomes|ECHO is a technology enabled multi-disciplinary team-based care model centered on case-consultation and peer-to-peer sharing of emerging best practices (i.e., teleECHO) to support management of complex cases associated with Long COVID, ME/CFS, and other PIFI.
214662196|NCT06376422|PROCEDURE|Spongioflex®|partial meniscal replacment during surgery, follow-up visits at the end of hospital stay and after 6 weeks, MRI evaluation and questionnaires after 6, 12, 24 and 60 months.
214662197|NCT06376422|OTHER|non-operated|no surgery, MRI evaluation and questionnaires follow-up after 6, 12, 24 and 60 months
214662198|NCT00697996|DRUG|Rituximab for transplant rejection|
214662199|NCT03011645|DRUG|Ziprasidone|Given by mouth, single dose of 60 mg.
214662200|NCT03011645|DRUG|Lorcaserin|Given by mouth, single dose of 20 mg.
214662201|NCT03011645|DRUG|Placebo Oral Tablet|Given by mouth, single dose.
214662202|NCT02471690|DRUG|Oritavancin|IV - Single dose 1200 mg Oritavancin
214662203|NCT02471690|DRUG|Dextrose|D5W 5% in Water
214662204|NCT01696357|DEVICE|Automated Device for Asthma Monitoring (ADAM)|Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
214290200|NCT01714635|DEVICE|Monofocal Intraocular Lens|
214290201|NCT05086991|OTHER|Follow up|like group descriptions
214290202|NCT05322876|BEHAVIORAL|Healthy Hearts Family Program|Participants will participate in a baseline health and knowledge screening, followed by a 6-week once-weekly class series, and 3- and 6-month follow-up health and knowledge screenings.
214290203|NCT02771054|DRUG|TAF/FTC|Change of nucleoside backbone
214290204|NCT03103737|BEHAVIORAL|Virtual Reality (VR) and Reminiscence Intervention|First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
214290205|NCT01927224|DRUG|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
214662205|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every week|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214662206|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every two weeks|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214662207|NCT04320836|PROCEDURE|Cervical epidural steroid injection|Interlaminar cervical epidural steroid injection with steroid and normal saline at C6-7 and C7-T1 (standard of care).
214662208|NCT03772912|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
214662209|NCT04495660|DEVICE|Near InfraRed Spectroscopy (fNIRS)|Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
214662210|NCT04495660|BEHAVIORAL|Passive perceptual stimulation|Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
214849388|NCT03919487|PROCEDURE|Back to back colonoscopy|After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
214849389|NCT04026373|BEHAVIORAL|modified Prolonged Exposure|
214849390|NCT04026373|BEHAVIORAL|Treatment as usual|May include consult to health psychology and any follow-up deemed appropriate
214849391|NCT05528640|OTHER|Mental Health Literacy Program|Six educational sessions will be delivered on a private YouTube channel which consists of information about mental health literacy (knowledge about priority mental illnesses, attitude/ stigma related to mental illnesses, and help-seeking efficacy). There will be six-weeks unrestricted access period. Afterwards, the round-up session which consists of problem-based learning and group sharing will be delivered in person. Two vignettes based on the clinical scenarios will be given for discussion. Furthermore, participants are encouraged to share their opinion on mental health literacy, strategies for dealing with difficulties of caring for patients with mental illnesses in general hospitals, way to promote mental health literacy of healthcare professionals in general hospitals
214849392|NCT05500092|DRUG|Nivolumab|Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
214849393|NCT05500092|RADIATION|(8gy x 3)|sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
214662211|NCT04495660|BEHAVIORAL|Task A not B|Task A not B: the child will play with an adult who will hide an object under a cloth several times. The child will have to find the hidden object. Duration 10 minutes maximum
214662212|NCT04495660|BEHAVIORAL|VSWMT task|VSWMT task: the child will be on the parents' lap in front of a screen and will watch a monkey hiding bananas in the trees several times. Duration of 10 minutes maximum.
214662213|NCT04495660|BEHAVIORAL|Perceptual Go-No-Go|Perceptual Go-No-Go: This perceptual task consists in the discrimination of images (faces) and sounds (words) through 3 conditions (auditory, visual and visuo-auditory) presented independently of each other and lasts 15 to 20 minutes in total. It is presented by means of a computer
214290206|NCT01927224|DRUG|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
214290207|NCT01927224|DRUG|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
214290208|NCT00095901|DRUG|Capecitabine|
214290209|NCT02860169|BEHAVIORAL|Participants self-administered questionnaire and assessment|Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
214662214|NCT04495660|BEHAVIORAL|Verbal memory task|Verbal memory task :the child will be presented with 5 lists of 5 words which he will have to restore after a predefined delay of a few seconds. Its duration does not exceed 10 minutes.
214849394|NCT05500092|DRUG|Platinum Doublet|Standard of care doublet platinum therapy
214849395|NCT01749748|PROCEDURE|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
214849396|NCT03720574|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
214849397|NCT03720574|DRUG|Matching Placebo BID|Matching Placebo tablet each morning and evening for a duration of 48 weeks
214849398|NCT02900274|DEVICE|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
214849399|NCT01567826|DRUG|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor \[any dose\] and Crestor \[less than 40mg\]"
214849400|NCT01567826|DRUG|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
214849401|NCT03023657|OTHER|Detection of arousal|Detecting facial microexpression before visible facial expressions in patient with disorder of consciousness after severe brain injury
214662215|NCT04495660|BEHAVIORAL|The sensory room|The sensory room: the child will sit in the middle of a carpet and play with the adult. He will hear everyday noises and see light effects. Duration 8-10 minutes
214662216|NCT01667263|DRUG|All-trans retinoic acid|
214662217|NCT01667263|DRUG|Danazol|
214662218|NCT00423826|DRUG|Busulfan|3 mg/kg intravenously over 3 hours
214662219|NCT00423826|DRUG|Cytarabine|Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
214662220|NCT00423826|DRUG|Fludarabine phosphate|25 mg/M2/day IV
214662221|NCT00423826|DRUG|mycophenolate mofetil|Orally at the dose of 1 gm every 8 hours.
214662222|NCT00423826|DRUG|tacrolimus|0.015 mg/kg IV every 12 hours by continuous infusion.
214662223|NCT00423826|PROCEDURE|allogeneic hematopoietic stem cell transplantation|10 days post drug intervention
214662224|NCT00423826|PROCEDURE|umbilical cord blood transplantation|10 days post drug intervention
214662225|NCT00423826|RADIATION|total-body irradiation|10 days post drug intervention
214662226|NCT01106547|DRUG|Methylprednisolone 125mg|Single dose 60-90 minutes preoperatively
214662227|NCT01106547|DRUG|Sodium Chloride 2 ml|Single dose 60-90 min preoperatively
214662228|NCT01815957|DRUG|Rnalozine|. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
214662229|NCT04357171|PROCEDURE|Low anterior resection with protective loop ileostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning ileostomy is performed.
214662230|NCT04357171|PROCEDURE|Low anterior resection with protective loop transverse colostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning transverse colostomy is performed.
214662231|NCT03501927|DIAGNOSTIC_TEST|FOCUS (focused cardiac ultrasound)|"A ultrasound of the heart and pleura will be performed. This provide information on~* Left ventricular systolic function~* Left ventricular diastolic function~* Right ventricular systolic function~* Right ventricular pressure overload~* Biventricular sizes~* Pathology of the mitral- and aortic valves~* Pericardial fluid~* Gross fluid status~* Pleural effusion"
214662232|NCT04567563|DEVICE|Remote Ischemic conditioning (RIC)|Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
214662233|NCT02876978|GENETIC|CAR-GPC3 T Cells|Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
214662234|NCT02876978|DRUG|Fludarabine|30 mg/m\^2/day x 4 days
214662235|NCT02876978|DRUG|Cyclophosphamide|500 mg/m\^2/day x 2 days
214662236|NCT04532788|PROCEDURE|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
214662237|NCT04532788|PROCEDURE|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
214662238|NCT02071238|BEHAVIORAL|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
214662239|NCT02071238|BEHAVIORAL|Group Consultation|Informed consent discussion in group-format
214290210|NCT02601508|DRUG|Rocuronium|Continuous infusion of rocuronium for PTC 1 + Sugammadex
214290211|NCT02601508|DRUG|cis-atracurium|Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine \& Glycopyrrolate
214290212|NCT04743297|DRUG|Prostaglandin E2 (Propess)|Propess - The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour or at the occurrence of hyperstimulation.
214662240|NCT04101175|PROCEDURE|Evaluation of the procedure of abortion|Observational study using questionnaires
214662241|NCT00342368|PROCEDURE|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
214662242|NCT00108329|BEHAVIORAL|Weight Loss|
214662243|NCT05262764|DRUG|JARDIANCE®|Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS).
214662244|NCT05040529|PROCEDURE|pure laparoscopic donor hepatectomy|pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital
214662245|NCT05040529|PROCEDURE|conventional open donor hepatectomy|conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
214662246|NCT04747405|OTHER|therapy group|therapy group of maximum 8 people repeated twice
214662247|NCT00820430|OTHER|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
214290213|NCT04743297|DRUG|Prostaglandin E2 (Prostin)|Prostin - 3 mg vaginal tablet is placed in the posterior vaginal fornix. Dose can be repeated every 8 hours till onset of active labour or the occurrence of hyper-stimulation.
214662248|NCT00670787|DRUG|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
214662249|NCT03793543|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
214662250|NCT03957915|DRUG|INA03 administration|INA03 will be administered IV on Day 1, Day 14 of 28-day cycles. The administration of INA03 will begin at 0.02 mg/kg. Study Part I is a titration study to determine the dose for the first INA03 infusion. Patients will be enrolled in sequential cohorts of 2 patients to receive ascending starting doses of INA03, starting from the lowest starting dose (0.02 mg/kg), and followed by subsequent administrations of INA03 (D14 and beyond) at a fixed dose of 0.1 mg/kg. The starting dose will be increased every cohort of 2 patients until evidence of absence of marrow residual erythroblasts by D14 myelogram. This dose is referred to as the MEID and will be selected as the D1 dose for the study Part 2. Patient accumulation in Part I of the study will continue until no evidence of non-hematological DLT within 28 days post dosing
214662251|NCT00124306|DRUG|Amitriptyline|Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
214662252|NCT00124306|OTHER|Placebo|Placebo will be dosed exactly as active arm.
214662253|NCT00001303|DRUG|Reference Endotoxin|
214662254|NCT00001303|DRUG|Inhaled Nitric Oxide|
214662255|NCT01392183|DRUG|Pazopanib|800 mg by mouth daily in 4 week study cycle.
214662256|NCT01392183|DRUG|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
214662257|NCT01392183|BEHAVIORAL|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
214662258|NCT01392183|DRUG|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
214662259|NCT00011115|BEHAVIORAL|Weight loss motivations|
214662260|NCT03981601|DRUG|Lovastatin 40 MG|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
214662261|NCT03981601|PROCEDURE|without drug with Bone graft|after tooth extraction, put teh bone graft wifin tooth socket
214662262|NCT04419103|OTHER|no intervention|Natural exposure of iodine.
214662263|NCT01916772|OTHER|no interventions|no interventions
214662264|NCT01261403|BIOLOGICAL|PDA001|Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
214662265|NCT01261403|DRUG|Vehicle Controlled Placebo|"Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7"
214662266|NCT06593652|BEHAVIORAL|Teen Intervene - Adolescent Only|Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills.
214662267|NCT06593652|BEHAVIORAL|Teen Intervene with Caregiver Session|Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills. In this condition, the caregiver session will address caregiver expectations around youth substance use and strategies for promoting positive youth behavior change including reduced substance use.
214290214|NCT03172455|DRUG|Glassia|Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)
214662268|NCT06593652|BEHAVIORAL|Family Check Up|Family Check-Up Online (FCU-O) is a self-paced, parent-driven, fully HIPAA compliant online version of the Family Check-Up (FCU), a brief intervention that integrates assessment, motivation-enhancement, and skill building to help parents effectively manage behavior and build positive relationships with their children aged 2-17 in order to reduce emotional and behavioral problems among youth.
214662269|NCT05602428|DRUG|esketamine sub-anesthetic,|the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
214662270|NCT05602428|DRUG|esketamine sub-anesthetic|Esketamine subanesthetic dose combined with lumbar plexus block was used
214662271|NCT05602428|DRUG|esketamine sub-anesthetic|general anesthesia was performed with esketamine subanesthetic dose.
214662272|NCT05243771|PROCEDURE|Rectal resection with diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created
214662273|NCT05243771|PROCEDURE|Rectal resection without diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created
214849402|NCT02839668|DRUG|Lidocaine|Continuous infusion of lidocaine
214290215|NCT06386250|PROCEDURE|regional block|In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.
214290216|NCT06386250|PROCEDURE|Caudal block|In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.
214290217|NCT06386250|PROCEDURE|Epidural|In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.
214290218|NCT05945043|OTHER|Surface parasternal eletromyogram|The surface parasternal EMG of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
214662274|NCT05243771|PROCEDURE|Rectal resection with permanent colostomy|Patients in this group will receive a rectal resection and a permanent colostomy will be created
214662275|NCT03810989|DEVICE|infra-red sauna|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
214662276|NCT03810989|DEVICE|argometer and treadmill|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
214662277|NCT03810989|DEVICE|combination of sauna and hot bath|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
214662278|NCT04604327|DRUG|Bemiparin sodium|Prophilactic vs full-dose for 10 days
214662279|NCT03430310|OTHER|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
214662280|NCT03430310|OTHER|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
214662281|NCT01305915|BEHAVIORAL|Getting Back on Track|The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
214662282|NCT01960010|DRUG|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
214662283|NCT01960010|DRUG|Vehicle|Vehicle dosed BID
214662284|NCT02134886|DRUG|Erlotinib Hydrochloride|Given PO
214662285|NCT02134886|OTHER|Laboratory Biomarker Analysis|Correlative studies
214662286|NCT02134886|OTHER|Pharmacological Study|Correlative studies
214662287|NCT02134886|OTHER|Quality-of-Life Assessment|Ancillary studies
214662288|NCT00765765|DRUG|hydroxychloroquine|Dose escalation from 200 mg po qd to 200 mg po bid.
214662289|NCT00765765|DRUG|ixabepilone|Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
214662290|NCT05437796|DEVICE|Hypnotic virtual reality support using hypnosis software Hypno-VR®|Hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
214662291|NCT05437796|DEVICE|No Hypnotic virtual reality|Group without Hypnotic virtual reality
214662292|NCT03476239|DRUG|Blinatumomab|"Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator."
214662293|NCT03476239|DRUG|Dexamthasone|Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
214662294|NCT01835444|OTHER|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
214849403|NCT02839668|DRUG|Sevoflurane|maintenance of hypnosis during anaesthesia with sevoflurane
214849404|NCT02839668|DRUG|TIVA-TCI|maintenance of hypnosis during anaesthesia with sevoflurane
214849405|NCT02839668|DRUG|Acetaminophen|administration of 1 g acetaminophen for postoperative analgesia
214849406|NCT02839668|DRUG|Tramadol|administration of tramadol for postoperative analgesia
214290219|NCT05945043|OTHER|Surface diaphragm electromyogram|The ipsilateral and contralateral surface diaphragm EMG of participants will be measured pre and immediately post pleural fluid removal
214290220|NCT05945043|OTHER|Parasternal muscle ultrasound|The thickness of the parasternal intercostal muscle of participants will be measured using thoracic ultrasound pre and immediately post pleural fluid removal
214290221|NCT05945043|OTHER|Breathlessness assessment|The VAS breathlessness score and Dyspnoea-12 questionnaire of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
214849407|NCT02839668|DRUG|Neostigmine|A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
214849408|NCT02839668|DRUG|Atropine|A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
214849409|NCT02839668|DEVICE|BIS|For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
214290222|NCT03598556|DIETARY_SUPPLEMENT|Vitamin D3|180,000IU Vitamin D3 oral emulsion
214290223|NCT03598556|OTHER|Placebo|Placebo
214662295|NCT04905862|DIAGNOSTIC_TEST|Immune response|"1. Venous blood samples will be collected at seven-time points: before dose 1 of vaccine, 21 days after dose 1, within 14-21 days after dose 2 and 3,6,9,12 months after vaccination. From the volume of about 8 ml of the patient's peripheral blood, a fraction of PBMC (peripheral blood mononuclear cells) will be isolated.~2. The level of antibodies against the SARS-CoV-2 nucleocapsid (N) antigen will be detected in serum using the Abbot Architect™SARS-CoV-2 IgG test.~3. The level of neutralizing IgG and IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S) will be detected in serum using the DiaSorin LIAISON®SARS-CoV-2 S1/S2 IgG serology COVID-19 S-Protein (S1RBD) Human IgA ELISA Kit respectively.~4. The cellular component of the immune response will be tested using the ELISPOT method, which involves testing the amount of INF-γ and IL-2 released from leukocyte cells."
214662296|NCT04905862|OTHER|Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events|The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials. Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination. Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
214662297|NCT04836039|OTHER|A questionnaire and scales.|Participants will be evaluated by applying a questionnaire and scales created by the researcher physiotherapists based on the researches and examples in the literature.
214662298|NCT02519660|DRUG|Lidocaine/Tetracaine patch|
214662299|NCT02519660|DRUG|Lidocaine/Prilocaine cream|
214662300|NCT02871479|DRUG|SAN007 5% cream|5% EISO in a cream formulation applied twice a day for up to 28 days.
214662301|NCT02871479|DRUG|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
214662302|NCT02871479|DRUG|SAN007 10% cream|10% EISO in a cream formulation applied twice a day for up to 28 days.
214662303|NCT01446809|DRUG|Doxorubicin Hydrochloride|Given IV
214662304|NCT01446809|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
214662305|NCT01446809|DRUG|Ifosfamide|Given IV
214662306|NCT01446809|OTHER|Laboratory Biomarker Analysis|Correlative studies
214662307|NCT01446809|DRUG|Pazopanib Hydrochloride|Given PO
214662308|NCT01446809|OTHER|Pharmacological Study|Correlative studies
214662309|NCT01446809|OTHER|Placebo|Given PO
214662310|NCT01446809|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214662311|NCT02157454|OTHER|Website access|Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
214662312|NCT02600299|BEHAVIORAL|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
214662313|NCT02600299|BEHAVIORAL|Usual Care|Usual Care
214662314|NCT06316479|DEVICE|PTMC Dermal Filler|A total of 120 subjects will receive treatment with PTMC Dermal Filler. The volume of filler injected will vary depending on the severity of the nasolabial fold. Injections will be administered by the investigator at the beginning of the study, with the injection technique, plane, and volume recorded. Touch-up treatments are permitted at the 1-month follow-up visit, if necessary.
214662315|NCT06227403|BEHAVIORAL|Leadership, Engagement, and youth Action Program with Mindfulness|The Leadership, Engagement, and youth Action Program with Mindfulness intervention (LEAP) was designed and co-created with youth to improve youth well-being by enhancing leadership opportunities and by developing mindfulness in day-to-day life. LEAP seeks to foster these improvements in youth as a strategy to increase mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
214849410|NCT01349101|RADIATION|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
214849411|NCT01349101|DRUG|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
214849412|NCT01349101|DRUG|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
214849413|NCT01349101|DRUG|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
214849414|NCT01349101|DRUG|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
214849415|NCT01349101|DRUG|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
214849416|NCT01349101|GENETIC|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
214849417|NCT00040430|DRUG|111In-DAC|
214849418|NCT00040430|PROCEDURE|Diagnostic|
214849419|NCT02062801|DRUG|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (\<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
214849420|NCT02062801|DRUG|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
214849421|NCT06529939|DRUG|Psilocybin|"Individuals will be given 15 milligrams (mg) of psilocybin orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) brain scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
214662316|NCT06227403|BEHAVIORAL|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential skills including digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
215033544|NCT06544460|DRUG|Hyperthermic intraperitoneal chemotherapy|Using the BR-TQR-I intraperitoneal hyperthermic perfusion chemotherapy instrument, after the surgical operation is completed, four drainage tubes are placed in the left and right upper abdomen and lower abdomen respectively. Connect all pipelines and preheat the instrument before starting treatment. The treatment temperature is controlled at 43 ℃± 0.1 ℃, the treatment time is 90 minutes, and the circulation pump flow rate is 400-600ml/min. Within 48 hours after the surgery, cisplatin 75mg/㎡ was added to 3000ml of physiological saline for intraperitoneal hot infusion. Through the comprehensive effects of circulation flushing, hyperthermia, chemotherapy, and thermochemotherapy sensitization, it kills and removes residual cancer cells or small lesions in the abdominal cavity.
214662317|NCT00365755|DRUG|carboplatin|
215033545|NCT02873156|DRUG|E2027|Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.
215033546|NCT02873156|DRUG|E2027 matched placebo|Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
214662318|NCT00365755|DRUG|cisplatin|
214662319|NCT00365755|DRUG|cyclophosphamide|
214662320|NCT00365755|DRUG|etoposide|
214662321|NCT00365755|DRUG|melphalan|
214662322|NCT00365755|DRUG|vincristine sulfate|
214662323|NCT00365755|PROCEDURE|autologous bone marrow transplantation|
214662324|NCT00365755|PROCEDURE|conventional surgery|
214662325|NCT05792826|OTHER|BSZY Cream|The patients receive BSZY Cream twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
214662326|NCT05792826|OTHER|emulsion matrix|The patients receive emusion matrix twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
214662327|NCT01920906|PROCEDURE|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
214662328|NCT01331161|BIOLOGICAL|ZOSTAVAX|shingles vaccine, one dose
214662329|NCT00785577|DRUG|Placebo|"LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks"
214849422|NCT06529939|OTHER|Placebo|"Individuals will be given a placebo orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
214849423|NCT02358850|DRUG|Norco (Hydrocodone and Acetaminophen)|Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
214849424|NCT02358850|DRUG|Percocet (Oxycodone and Acetaminophen)|Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
214849425|NCT02358850|DRUG|Dilaudid (hydromorphone)|Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
214662330|NCT00785577|DRUG|Pregabalin|"Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
214662331|NCT00785577|DRUG|LY545694 21 mg|"LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
214662332|NCT00785577|DRUG|LY545694 49 mg|"LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks."
214662333|NCT00785577|DRUG|LY545694 105 mg|"LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks"
214662334|NCT00025038|DRUG|tipifarnib|Given orally
214662335|NCT00025038|DRUG|isotretinoin|Given orally
214662336|NCT00025038|DRUG|fludarabine phosphate|Given IV
214662337|NCT00025038|DRUG|cytarabine|Given IV
214662338|NCT00025038|RADIATION|radiation therapy|Undergo total body irradiation
214662339|NCT00025038|DRUG|cyclophosphamide|Given IV
214662340|NCT00025038|BIOLOGICAL|anti-thymocyte globulin|Given IV
214662341|NCT00025038|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
214662342|NCT00025038|PROCEDURE|double-unit umbilical cord blood transplantation|
214662343|NCT00025038|PROCEDURE|umbilical cord blood transplantation|Undergo allogeneic cord blood transplant
214662344|NCT00025038|OTHER|laboratory biomarker analysis|Correlative studies
214662345|NCT01212445|DRUG|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
214662346|NCT00991900|DEVICE|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
214662347|NCT01583036|DRUG|Digoxin Alone|Single administration of digoxin 0.25mg
214662348|NCT01583036|DRUG|Digoxin + Retigabine|Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
214662349|NCT02532049|BIOLOGICAL|ChAd63 Pfs25-IMX313|
214662350|NCT02532049|BIOLOGICAL|MVA Pfs25-IMX313|
214662351|NCT06842199|DRUG|ICP-488 Tablets|Eligible patients will receive ICP-488 orally as per the protocol
214662352|NCT06842199|DRUG|ICP-488 Placebo|Eligible patients will receive ICP-488 Placebo orally as per the protocol
214662353|NCT06792539|DEVICE|Polymotion Hip Resurfacing (PHR) System|Surgical
214662354|NCT06812715|DRUG|Pirtobrutinib|Pirtobrutinib is a first-in-class, oral noncovalent Bruton tyrosine kinase (BTK) inhibitor (BTKi) that was approved in January 2023 in the United States for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL) and later that same year CLL. It is currently being investigated across several global randomised phase III trials for frontline and R/R chronic lymphocytic leukaemia (CLL).
214662355|NCT06656403|DRUG|0.1% sodium hyaluronate|After baseline measurement, 0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
214662356|NCT06656585|OTHER|Individual food selectivity protocol|"Children in the experimental group wear Oculus headsets and interact with virtual foods for 20 minutes. In the Pairing in the Kitchen phase, Oculus is removed. Two identical plates with 6 foods are placed in front of the child. The operator, seated next to the child, interacts with the food without eating it, maintaining a positive expression, and discussing non-food topics. No prompts to eat are given, and the child can leave at any time. Progress to the next phase if the child sits calmly for 30 seconds across 3 sessions.~Shaping Phase: Two identical plates are prepared. The operator comments on the food and keeps a small container of the child's favorite food visible but out of reach. Any food-related behavior is reinforced with praise and the favorite food. Target behaviors are adjusted if no response occurs for 15 seconds or if negative emotions are observed. Differential reinforcement is used."
214662357|NCT06656585|OTHER|Traditional food selectivity protocol|"Step 1:Pairing in the Kitchen Propose enjoyable activities in the kitchen. Move to Step 2 when the child plays in the kitchen for 5 minutes over 3 consecutive sessions.~Step 2:Transition to Kitchen Two plates with 6 identical foods are placed in the kitchen. The operator engages the child in a welcome game, waiting 30 seconds for spontaneous interaction. If no response, the operator prompts the child to go to the kitchen. If the child doesn't follow within 30 seconds, the session is postponed. The operator sits next to the child and interacts with the food, without encouraging the child to eat. Progress when the child stays seated for 30 seconds without problem behavior for 3 sessions.~Step 3:Shaping Two plates are prepared, and the operator comments on the food. A visible container with the child's favorite food is used for reinforcement. Target behaviors are reinforced with praise and the favorite food. Adjust behaviors if there's no response for 15 seconds or negative emotions occur"
214662358|NCT06656767|OTHER|No intervention|This study utilises pre-collected samples only.
214662359|NCT06657404|DRUG|use Amiodarone, Bisoprolol and Digoxin|"Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.~The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.~Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.~Digoxin 0.125mg qd orally."
214662360|NCT06657573|BEHAVIORAL|An AI-enabled chatbot tailored for influenza vaccine consultation|The AI-enabled influenza vaccine chatbot can be accessed online through WeChat or any web browsers. The foundation of this chatbot is an expansive knowledge database, constructed with information sourced exclusively from healthcare authorities such as China CDCs and Health Departments, and thoroughly verified by public health experts. This database integrates data on the disease's burden, susceptibility, and severity, along with in-depth details about the vaccines, including their importance, efficacy, safety, and recommended demographics and timing for vaccination. It also covers types and costs of vaccines, societal norms such as vaccination guidelines, expert recommendations, and vaccination trends both in China and internationally. It also includes misinformation and fact-checking contents and provides information about vaccination services such as locations and appointment scheduling.
214662361|NCT06656832|OTHER|Heart Failure network care|Patients will receive three visits within the first three months after randomization for improving heart failure therapy at a cardiologist or the outpatient heart failure clinic
214662362|NCT01682044|BIOLOGICAL|pegfilgrastim|Given SC
214662363|NCT01682044|BIOLOGICAL|rituximab|Given IV
214662364|NCT01682044|OTHER|flow cytometry|Correlative studies
214662365|NCT01682044|PROCEDURE|biopsy|Correlative studies
214662366|NCT01682044|OTHER|immunohistochemistry staining method|Correlative studies
214662367|NCT01682044|GENETIC|western blotting|Correlative studies
214662368|NCT00083161|DRUG|cisplatin|60 mg/m2 IV day 1, every 21 days for 4 cycles.
214662369|NCT00083161|DRUG|cyclophosphamide|25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
214662370|NCT00083161|DRUG|etoposide|120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
214662371|NCT00757315|DEVICE|NdYag Laser(hair removal laser) plus topical corticosteroid|NdYag laser and topical corticosteroid are applied to one half of the scalp.
214662372|NCT00757315|DRUG|Topical corticosteroid alone|topical corticosteroid alone is applied to one half of the scalp
214662373|NCT06979557|DEVICE|Odyssey IOL|Bilateral implantation with the Odyssey IOL
214662374|NCT06985758|DRUG|Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg|Intravenous administration of a first dose of Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg to study the pharmacokinetic parameters of the drug.
214662375|NCT06598787|DRUG|BL-B01D1 for Injection|Administration by intravenous infusion for a cycle of 3 weeks.
214662376|NCT06817980|BEHAVIORAL|Physical activity|"\- Physical activity: We will compare the impact of 3 different environments (with no object in the environment, vs. with some objects but no hidden objects vs. with objects at the fore- and background) during (total of 9 sessions of 30 minutes + 3\*5 minutes of testing), on the measure of self (see below).~Visit 10: We will repeat a walking session. Participants will wear mixed-reality goggles, which allow them to visualize the environment and superimpose a continuous stream of light. This session is intended to test the idea that this flow would enable SZ patients to suffer less from the discontinuous appearance of information when moving around.~Measure of 'self' : the participants will decide whether the line presented on a computer screen is static or moving. They will be immobile, walking on the spot in front of the computer, or passively mobilized with a whole-body movement platform. The latter condition will be used only in the first phase of the protocol"
214662377|NCT06656871|DIETARY_SUPPLEMENT|iron supplementation|The iron tablet group received iron supplementation (30 mg, 1 tablet/day of iron) for 4 weeks
214662378|NCT06656871|DIETARY_SUPPLEMENT|Biostimulated lettuce supplementation|the intervention group SwE lettuce group received lettuce biostimulated with Ecklonia Maxima algae (SwE lettuce, 100 grams/day) daily for 4 weeks
214662379|NCT06657261|PROCEDURE|The patient group receiving deep and superficial serratus anterior plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
214662380|NCT06657261|PROCEDURE|The patient group receiving a combination of deep serratus anterior plane block and transverse thoracic muscle plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
214662381|NCT06656468|DEVICE|Pacemaker and defibrillator|Leadless pacemaker implantation procedure performed accordng to usual clinical practice. The indication for pacemaker implantation will be based on current guidelines.
214662382|NCT06656546|DIAGNOSTIC_TEST|Tracheal Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. A linear transducer will be placed perpendicular to the trachea at the level of the cricoid membrane. During ETI, visualization of the ETT moving within the trachea, specifically behind the cricothyroid membrane, indicates successful intubation. In contrast, if the ETT is mistakenly placed in the esophagus, a double-lumen appearance lateral to the trachea, created by the ETT within the esophagus, suggests esophageal intubation.
214662383|NCT06656546|DIAGNOSTIC_TEST|Lung Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. Following ETI, the presence of lung sliding will be evaluated using ultrasound with the aid of a linear probe.The transducer will be placed bilaterally along the mid-axillary line, between the second and fifth intercostal spaces, in a coronal orientation. After the ETT is placed and ventilation is initiated, the movement of the visceral and parietal pleura will be assessed. The presence of sliding motion between these pleural layers during ventilation indicates successful intubation, whereas the absence of this movement suggests a failed intubation.
214662384|NCT06656546|DIAGNOSTIC_TEST|Diaphragm Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Curvilinear Probe (2-8 MHz) or the eSaote MyLab Seven Curvilinear Probe (1-8 MHz), will be selected based on suitability for the procedure at the time. Using a curvilinear transducer, the probe will be placed along the mid-axillary line, approximately at the seventh to ninth intercostal spaces, in a coronal orientation. The movement of the diaphragm during ventilation will be assessed over the spleen and liver. Diaphragmatic motion during ventilation indicates successful ETI, while the absence of bilateral diaphragmatic movement suggests esophageal intubation. If diaphragmatic movement is only observed on one side, it is indicative of endobronchial intubation.
214662385|NCT06855836|BEHAVIORAL|MI-CHANCE (TS + FTIR + MI)|MI-CHANCE was built following key principles of MI (partnership, acceptance, compassion and evocation) to empower PWUD, help them identify potential benefits of DCS and strategies to integrate these into their daily lives. The manual follows three key stages: 1) introducing DCS, 2) generating change talk, and 3) verbalizing commitment, using open questions, affirmations, reflections and summaries. Pros and cons for regularly using CheckSD and changing drug use behaviors accordingly were identified in the literature and through discussions with PWUD and HRCSD staff. Peer support specialists are urged to mirror participants' own language (e.g., oxy or M30s=oxycontin; carga= heroin; malilla=withdrawal, fetty=fentanyl). Challenges were categorized into 8 key areas: legal, financial, scheduling, transportation, ability to change drug use behaviors, communication with SSP staff, managing mood and substance use.
214662386|NCT06855836|BEHAVIORAL|TS + FTIR + Flu and Hepatitis A Education|Naloxone and educational materials (i.e. pamphlets) on overdose prevention, videos (English or Spanish) on naloxone, flu and Hepatitis A education.
214662387|NCT05114772|DIAGNOSTIC_TEST|Measuring Serum bio-markers|ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha
214662388|NCT01659151|DRUG|High Dose Interleukin-2 (IL-2)|A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.
214662389|NCT01659151|PROCEDURE|ACT with TIL Infusion|Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).
214662390|NCT01659151|DRUG|Vemurafenib|Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.
214662391|NCT01659151|DRUG|Lymphodepletion|"The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion."
214662392|NCT04535063|BIOLOGICAL|COVID19 convalescent plasma infusion|intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)
214849426|NCT02358850|DRUG|Tylenol (Acetaminophen)|Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
214849427|NCT04273919|DEVICE|HTC Vive with Karuna Virtual Reality Program|HTC Vive head-mounted display and an HTC Vive body tracker adhered to a belt on the patient's low back, which will be placed 2 inches below the waist
214849428|NCT04273919|DEVICE|HTC Vive with Lumen Program|HTC Vive head-mounted display with Lumen program
214849429|NCT01223235|BIOLOGICAL|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
214662393|NCT06985914|PROCEDURE|CT scan|CT scan in the emergency department
214662394|NCT02205450|DRUG|Recombinant Somatropin|
214849430|NCT02573935|DRUG|Clarithromycin|p.o. clarithromycin 500 mg twice daily for 63 days
214849431|NCT02573935|DRUG|Placebo|Placebo tablet twice daily for 63 days
214849432|NCT02573935|DRUG|VCD induction therapy|Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
214849433|NCT04975321|DEVICE|Nu Smile Zirconia crown|Placement of an anterior primary crown restoration
214290224|NCT03341949|BIOLOGICAL|Recurring blood sample|An additional tube will be collected for the assay of CD146s as part of the research
214662395|NCT02837679|OTHER|Geriatric Follow up|
214662396|NCT06411444|DEVICE|Grape Design Nasal Stent|Grape Design Nasal Stent
214662397|NCT07107633|DRUG|Technetium [99mTc]-H7ND injection|Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
214662398|NCT06988761|BEHAVIORAL|Standard of care treatment for Fibromyalgia|Patients will receive standard of care as decided by treating physician which may include patient education, physical therapy, occupational therapy, cognitive behavioral therapy, biofeedback therapy, massage, acupuncture, graded activity therapy, sleep hygiene therapy, relaxation therapies, and meditative movement therapies.
214662399|NCT06988761|BEHAVIORAL|Longitudinal Behavioral Health Techniques|Patients will receive standard of care as decided by treating physician, along with the integration of longitudinal behavioral health techniques provided by Lin Health. Patients have 24/7 access to digital content and will be able to interact directly with care team members on average three times per week.
214662400|NCT03320629|COMBINATION_PRODUCT|apatinib S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
214662401|NCT03320629|COMBINATION_PRODUCT|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
214849434|NCT04975321|DEVICE|Nu Smile Pre Veneered crown|Placement of an anterior primary crown restoration
214662402|NCT06685120|COMBINATION_PRODUCT|PRP + HA injection|Following autologous PRP harvesting and production, 5 mL of PRP and 40 mg/2 mL of HA will be infiltrated into the knee joint affected by gonarthrosis. The combined procedure will be performed by first infiltrating the hyaluronic acid, and next, leaving the needle inserted into the joint to avoid a second needle insertion, the PRP will be infiltrated, respecting the conditions of sterility. In this way, the two products will not be mixed in the same syringe.
214662403|NCT06685120|BIOLOGICAL|PRP injection|Following autologous PRP harvesting and production, patients randomized into control group 1 will undergo single intra-articular PRP infiltration. Five mL of PRP will be infiltrated into the knee joint affected by gonarthrosis.
214849435|NCT04975321|DEVICE|Composite strip crown|Placement of an anterior primary crown restoration
214849436|NCT02207335|DRUG|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
214849437|NCT02207335|DRUG|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
214849438|NCT03286608|OTHER|observational study (no intervention)|Statistical association between adherence to a pattern of polyphenol intake and the risk to develop dementia and Alzheimer's disease over 12 years
214849439|NCT03399617|DIETARY_SUPPLEMENT|Micronutrient Powders|Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
214849440|NCT03399617|BEHAVIORAL|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.
214849441|NCT03399617|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
214662404|NCT06685120|DEVICE|HA injection|Patients randomized into control group 2, will undergo similar blood sampling as the PRP+ HA group and the PRP group to maintain blinding. They will then undergo intra-articular infiltration of 40 mg/ 2 ml HA into the knee with gonarthrosis.
214849442|NCT02044432|OTHER|ginger compress|Kidney ginger compress
214662405|NCT07015047|DIETARY_SUPPLEMENT|Magnesium L-Threonate|Participants in this arm will take 1 gram of magnesium L-threonate (Magtein), provided in capsule form, once daily in the evening for 4 weeks. This supplement is known for its ability to cross the blood-brain barrier and may enhance sleep architecture, autonomic recovery, and cognitive function.
214849443|NCT04364737|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
214849444|NCT04364737|OTHER|Saline solution|Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
214849445|NCT04671537|DRUG|Preloading with crystalloid fluid|crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
214849446|NCT00156715|DRUG|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
214662406|NCT07015047|OTHER|Placebo|Identical-looking inert capsule taken nightly for 4 weeks. Used as a comparator to magnesium L-threonate to assess changes in sleep, recovery, and performance metrics.
214662407|NCT02971592|DEVICE|MDcure|reception of real working MDcure - device that does apply the electromagnetic field
214662408|NCT02971592|OTHER|Mock Device|reception of device that does not apply the electromagnetic field
214662409|NCT07023536|BEHAVIORAL|TELEREHABILITATION-YES|This intervention consists of a structured 8-week cardiac rehabilitation program performed at the patient's home using a certified telemedicine platform. Sessions are delivered in synchronous mode with real-time supervision by a physiotherapist through secure video conferencing. Each session includes warm-up, endurance training, and cooldown exercises, with personalized intensity based on cardiopulmonary exercise testing. Patients are equipped with wearable medical devices for continuous monitoring of vital signs (ECG, heart rate, blood pressure, oxygen saturation) and motion sensors to assess exercise execution and adherence. All data are transmitted securely and stored automatically in the system's database. In addition to the exercise protocol, participants undergo baseline and follow-up assessments including blood biomarkers, echocardiography, cardiopulmonary exercise testing, and quality-of-life questionnaires.
214849447|NCT02540499|RADIATION|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
214849448|NCT05342311|DIAGNOSTIC_TEST|preoperative ultrasonographic evaluation of right common femoral vein diameter|preoperative ultrasonographic evaluation of right common femoral vein diameter to predict spinal anesthesia-induced hypotension in elderly patients
214849449|NCT05349578|DIAGNOSTIC_TEST|swab RUT|rapid urease test using swab instead of biopsied tissue
214849450|NCT01680783|DEVICE|Non invasive ventilation using a helmet hyperbaric device|"Patients randomized to the intervention group will receive noninvasive ventilation delivered via a latex-free helmet connected to the ventilator by conventional tubing.~If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay."
214849451|NCT01680783|OTHER|Noninvasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
214849452|NCT01030211|PROCEDURE|Platelet transfusion|4 units of platelets for patients with platelet count \<20x10\^3/uL
214849453|NCT01030211|OTHER|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
214849454|NCT01088282|PROCEDURE|Cataract surgery|Implantation of multifocal or monofocal IOL
214849455|NCT03144817|OTHER|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
214849456|NCT02262858|DRUG|Telmisartan and HCTZ|
214849457|NCT02262858|DRUG|Telmisartan|
214849458|NCT02262858|DRUG|HCTZ|
214849459|NCT00868296|DRUG|pantoprazole|
214849460|NCT06224621|PROCEDURE|Percutaneous Endocardial Septal Radiofrequency Ablation|Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
214849461|NCT01094249|DRUG|divalproex sodium ER/paliperidone ER|Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
214849462|NCT04529226|DRUG|Clozapine|Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
214849463|NCT04529226|DRUG|haloperidol, pimozide, olanzapine, risperidone, amisulpride|Treatment as usual using first-generation or second-generation antipsychotics
214849464|NCT05026931|OTHER|Foam rolling|Group A will be treated with foam rolling effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
214849465|NCT05026931|OTHER|Stretching exercises|Group B will be treated with stretching exercises effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
214849466|NCT01264640|DRUG|Aspirin and Clopidogrel|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
214849467|NCT05387148|DRUG|Cannabidiol (CBD)|Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.
214849468|NCT05387148|DRUG|Placebo|The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
214849469|NCT05790148|DEVICE|3Shape|original (Straumann), non-original (Medentika) and generic scan-bodies (3Shape) were utilized for direct digitalization using intraoral scanner with image stitching algorithm. Full contour temporary restorations were fabricated from each digital record, and were evaluated in terms of clinical and analytical.
214849470|NCT00750022|BEHAVIORAL|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
214849471|NCT00750022|BEHAVIORAL|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
214849472|NCT01843686|DEVICE|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
214849473|NCT01843686|OTHER|Placebo Saline Gel and Usual and Customary Standard of Care|
214849474|NCT05675241|DIAGNOSTIC_TEST|Clinical examination of a dental implant|Clinical examination includes bleeding on probing, pocket depth, gingival biotype, suppuration, gingival index
214849475|NCT05675241|DIAGNOSTIC_TEST|Radiological Examination|A standardized periapical radiograph in parallax technique will be taken.
214849476|NCT05675241|DIAGNOSTIC_TEST|Peri-implant crevicular fluid sample collection|A sample of the peri-implant crevicular fluid will be collected using paper strip for 60 seconds. The sample of the fluid will be a resultant of inserting six different strips at the same time in six sites of the implant including mesiobuccal, midbuccal, distobuccal, distopalatal/distolingual, midpalatal/midlingual, mesiopalatal/mesiolingual sites of the implant.
214849477|NCT03712241|DRUG|K-285|Topical
214849478|NCT03712241|DRUG|Indomethacin|Capsule
214662410|NCT07023536|BEHAVIORAL|TELEREHABILITATION-NO|This intervention involves a traditional 8-week cardiac rehabilitation program carried out at a hospital-based outpatient facility. Patients attend sessions in person under the direct supervision of a physiotherapist. Each session includes warm-up, endurance training using a stationary bike, and cooldown. Vital signs (e.g., heart rate, blood pressure, oxygen saturation) are monitored manually by the physiotherapist, and exercise tolerance is assessed using standardized clinical scales (e.g., Borg and RPE). In addition to the exercise protocol, participants undergo baseline and follow-up assessments including blood biomarkers, echocardiography, cardiopulmonary exercise testing, and validated quality-of-life questionnaires. This group serves as the control for evaluating the effectiveness of the home-based telerehabilitation model.
214662411|NCT07030920|DRUG|Fostemsavir|Addition of fostemsavir to the patient's current antiretroviral regimen: once daily oral administration (Rukobia 600 mg extended-release tablets) for 24 months
214662412|NCT07031791|OTHER|PETRA questionnaire|The questionnaire is given to the patient to complete in the waiting room. The completed questionnaire is given to the doctor at the end of the consultation.
214662413|NCT07032129|BIOLOGICAL|BCMA/GPRC5D CAR-T cells|"The intervention in this clinical trial involves a novel approach using BCMA/GPRC5D Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/GPRC5D Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, BCMA/GPRC5D CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial BCMA/GPRC5D CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
214662414|NCT07031908|PROCEDURE|Minimally invasive cytoreduction|Minimally invasive cytoreduction in patients with advanced ovarian cancer treated with 6 cycles of neoadjuvant chemotherpy
214662415|NCT06717321|PROCEDURE|(Arm 1): PEG|A 20-French pull type percutaneous endoscopic feeding tube placed into the stomach using endoscopic guidance
214662416|NCT06717321|PROCEDURE|(Arm 2): PEG-J|24-French pull type percutaneous endoscopic feeding tube placed into the stomach with a 12-French jejunal extension tube advanced through the PEG and positioned post-pyloric in the small bowel using endoscopic guidance
214662417|NCT06434077|BIOLOGICAL|GcMAF injections (100 ng)|The GcMAF 100 ng (Gc protein macrophage-activating factor) will be injected subcutaneously.
214662418|NCT06434077|OTHER|placebo|the placebo solution will be injected subcutaneously 100 ng.
214662419|NCT03812653|DEVICE|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
214662420|NCT06744816|DRUG|Qutenza Patch|Given topical
214662421|NCT06757348|DIAGNOSTIC_TEST|Fecal elastase|\*\*Stool Samples\*\* To investigate exocrine pancreatic insufficiency (EPI), a stool sample will be requested from all patients for fecal elastase (Fel-1) analysis. Participants will be instructed to collect their stool sample in a sterile, disposable plastic container and submit it to the Gastroenterology Chemistry Laboratory (Litwin Laboratory) for processing and analysis. Based on previously published reports, samples will be stored refrigerated at 4-8 °C for no more than 48 hours. The concentrations of Fel-1 in all samples will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (ScheBo-Pancreatic Elastase 1™, Giessen, Germany), and fecal elastase will be extracted and analyzed according to the manufacturer's instructions.
214849479|NCT06309316|BEHAVIORAL|Person-centred care (PCC)|In addition to usual care, patients will receive PCC through physical visits, telephone and through a web-based platform for 15-months. Primary outcome is after 3 month (we expect the need of support is largest in the beginning) but the intervention will continue for the period of care 12-18 months, increasing transferability to regular care.
214849480|NCT01974024|DRUG|methylprednisolone|Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).
214849481|NCT04906317|DRUG|midazolam and dezocine|Midazolam (0.05 mg/kg) and dezocine(5mg) sedation during colonoscopy, targeted to a painless level
214849482|NCT04906317|DRUG|Propofol|standard propofol (1.5mg/kg) induction during colonoscopy, targeted to a moderate sedation level
214849483|NCT03068650|BIOLOGICAL|rindopepimut|Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
214849484|NCT02536235|OTHER|heat|activated heating pad to lower abdomen
214849485|NCT01183117|DEVICE|SM-01|SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
214849486|NCT01183117|DEVICE|PTA|balloon angioplasty
214849487|NCT03829358|DRUG|Lactobacillus plantarum IS-10506|Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.
214849488|NCT03829358|DRUG|Placebo|Fermented milk containing placebo to be consumed once daily for three weeks.
214849489|NCT05319834|DRUG|Aspirin tablet|group1: oral aspirin at a dose of 100mg once daily at the same time with progesterone
214849490|NCT05319834|DRUG|Placebo|group 2: oral placebo once daily at the same time with progesterone
214849491|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group I: 10 patients will be treated with Lysis and lavage
214849492|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group II: 10 patients will be treated with operative arthroscopy
214849493|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group III: 10 patients will be treated with operative arthroscopy + discopexy
214290225|NCT04689633|PROCEDURE|nerve block|bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
214662422|NCT06757348|DIAGNOSTIC_TEST|Ecoendoscopy|\*\*Diagnosis of Pancreatic Steatosis\*\* The diagnosis of pancreatic steatosis will be performed using endoscopic ultrasound. A Pentax EG-3870UTK endoscope will be used in conjunction with Hitachi Avius ultrasound equipment. The procedure is performed under anesthesia using propofol.
214662423|NCT06757348|DIAGNOSTIC_TEST|Fibroscan|\*\*Fibroscan Procedure:\*\* This is a new technique based on the evaluation of liver elasticity or stiffness that allows for the measurement of liver hardness and quantification of liver fibrosis in a simple and completely painless manner using ultrasound. The results are obtained immediately and can be safely repeated periodically.
214662424|NCT06757348|DIAGNOSTIC_TEST|Serum cytokines|Peripheral blood will be drawn from all participants in the Gastroenterology Division of the Hospital de Clínicas. Samples will be collected in EDTA tubes, centrifuged, and the serum will be frozen at -80 °C until processing. Serum cytokine levels will be measured using a commercial kit (Bio-Plex Pro human cytokine, Bio-Rad Lab., Inc.), which includes a panel of 27 cytokines: FGF basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, MIP-1α, IL-12 (p70), MIP-1β, IL-13, PDGF-BB, IL-15, RANTES, IL-17, TNF-α, IP-10, VEGF, MCP-1 (MCAF).
214662425|NCT06765122|BEHAVIORAL|Program for Alleviating Relationship Trauma and Stress through New Behaviors (PARTS-NB)|"PARTS-NB (Program For Alleviating Relationship Trauma and Stress through New Behaviors) is a group-based program for people who use violence and aggression in intimate relationships. Phase I is 4-weeks of 120 minutes of weekly group-based sessions focused on clarifying the way parts work in the mind, increasing inner compassion and emotion regulation, and explaining the role of trauma and stress in substance use and the use of violence in relationships. Phase II lasts 8-weeks, maintaining the 120 minutes of weekly group-based sessions. This phase introduces the model and focuses on practicing unblending, helping individuals gain awareness and acceptance of internal and external experiences. The final phase, Phase III runs 8 weeks and consists of weekly 120-minute group sessions which addresses and releases trauma-based beliefs and experiences through a process called unburdening."
214662426|NCT07100145|OTHER|Coconut oil|The composition per 100 g of virgin coconut oil 50% in oral mucoadhesive gel will be coconut oil (50 ml), tween 20 (surfactant-2.5 g) or span 60 (surfactant-2.5 g), Carbopol 940 (gelling agent-1 g), triethanolamine (viscous organic compound-0.2 g) and vanillin (0.001 g)
214662427|NCT07100145|DRUG|Triamcinolone Acetonide|topical corticosteroid
214662428|NCT07108257|DEVICE|ExAblate Neuro 4000|ExAblate Neuro 4000 is an MR-guided focused ultrasound (MRgFUS) device used to perform noninvasive thermal ablation of targeted brain tissue. In this study, ExAblate Neuro 4000 will be used to ablate the anterior limb of the internal capsule (capsulotomy) in patients with treatment-resistant bipolar depression (TRBD). The procedure is conducted under real-time MRI guidance and thermometry to assess safety and initial effectiveness in improving clinical symptoms and quality of life.
214662429|NCT07105696|OTHER|Web-Based CORE|"The intervention planned for the study is a web-based digital CORE method. Students in the intervention group taking the Health Diagnosis course will be administered a web-based digital CORE to assess the cardiovascular, respiratory, musculoskeletal, and gastrointestinal systems.~Students in the experimental group will be administered the web-based digital CORE exam. Students in the control group will be asked the same multiple-choice questions in a digital environment. Two weeks later, students in the experimental and control groups will be administered another exam. Differences in achievement scores between the two groups will be evaluated."
214662430|NCT07107672|DRUG|[14C]X842|50 mg/100 µCi \[14C\] X842 suspension
214662431|NCT07106255|OTHER|Task-oriented training|"Participants included in the experimental group will underwent an 8-week TOT intervention, administered twice weekly, with each session lasting 45 minutes.~Within this framework, the intervention will comprise sessions involving meaningful and repetitive activities tailored to both the patient and their specific context. The occupations will be selected by each participant through the Canadian Occupational Performance Measure (COMP) tool in the initial assessment. The activities were randomly ordered and focused on the reconstruction of complete tasks. To support task segmentation, a range of custom-designed materials will be employed, alongside therapeutic tools and materials such as therapeutic putty, TheraBand, and others commonly used in physical rehabilitation interventions. Throughout the intervention, participants will receive positive reinforcement that will fade over the time to prevent unnecessary dependency."
214662432|NCT07106255|OTHER|Standar medical care and leaflet fatigue management|Participants included in the control group will continue with their usual treatment and will receive a pamphlet containing information on fatigue management.
214662433|NCT07106060|DEVICE|EEG-based rehabilitation training device (L-B300)|Participants will use an EEG-based rehabilitation training device (L-B300). After wearing an EEG cap and lying supine, their lower limbs will be positioned on a pedal with the hip, knee, and ankle joints of the unaffected (stronger) leg maintained at 90°. The leg support will be adjusted to the mid-calf and secured with straps. Participants will be instructed to focus on a screen and perform MI training. If they fail to activate the device within 30 seconds under guidance, the EEG difficulty level will be reduced until successful activation within 30 seconds. The EEG difficulty level will be adjusted throughout the trial based on the participant's MI ability.
214849494|NCT01057381|DRUG|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
214849495|NCT01057381|DRUG|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
214849496|NCT01057381|DRUG|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
214290226|NCT04023604|OTHER|Controlled diet with beef raised without antibiotics|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised without antibiotics.
214290227|NCT04023604|OTHER|Controlled diet with beef produced in conventional systems|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised with antibiotics.
214662434|NCT07106060|DEVICE|EEG-based rehabilitation training device (L-B300)（Not connected）|Participants will lie supine, with their lower limbs fixed to the L-B300 device using the same method as Group A. The computer screen will be turned off, and the machine will be set to drive passive or active cycling movements of the lower limbs.
214662435|NCT07107360|OTHER|Pain Neuroscience Education|The study included two groups, consisting of participants who met the inclusion criteria and adhered to the procedures. Participants in the intervention group received a 20-minute Pain Neuroscience Education (PNE) session delivered face-to-face one hour prior to their scheduled surgery. The PNE focused on the biopsychosocial aspects of pain and included both theoretical and practical strategies for postoperative pain management.
214662436|NCT07107360|OTHER|Conventional preoperative education|Participants in the experimental group received pain neuroscience education, while participants in the control group received a booklet summarizing this education in addition to routine preoperative care.
214662437|NCT07106476|OTHER|Single-Leg Squat with Internal Focus Intervention|"Administration: Participants were instructed to focus on specific muscular or joint movements during single-leg squats (3 sets of 8 repetitions on the affected side, 1-minute rest between sets). Verbal cues included contract your glutes or keep your knee aligned. Data Collected: Surface EMG (Gluteus Medius, Biceps Femoris, Lateral Gastrocnemius, Peroneus) and pedobarographic parameters."
214662438|NCT07106476|OTHER|External Focus Intervention|"Administration: Participants were instructed to focus on the environmental effects of single-leg squats (3 sets of 8 repetitions on the affected side, 1-minute rest between sets). Verbal cues included push against the floor or drive your foot downward. Data Collected: Surface EMG (Gluteus Medius, Biceps Femoris, Lateral Gastrocnemius, Peroneus) and pedobarographic parameters."
214662439|NCT07106476|OTHER|No Focus Intervention|"Administration: Participants performed single-leg squats naturally without specific attentional instructions (3 sets of 8 repetitions on the affected side, 1-minute rest between sets).~Data Collected: Surface EMG (Gluteus Medius, Biceps Femoris, Lateral Gastrocnemius, Peroneus) and pedobarographic parameters."
214662440|NCT07107594|BEHAVIORAL|Multimodal prehabilitation|Multimodal prehabilitation program during NACT (4-6 months) that will combine: 1) Physical exercise: cardiovascular and strength exercises designed by specialized physiotherapists, structured in 1-hour sessions twice a week. The characteristics of the activity will be adapted to the treatment phase and the physical condition of each woman. 2) Psychological therapies: standardized mindfullness practice by a specialized psychologist. As an alternative, patients who refuse mindfullness could receive psychological sessions on stress and anxiety management. 3) Nutritional counseling: periodic sessions with a specialized nutritionist providing dietary recommendations and nutritional advice adapted to the disease and condition of the patients.
214662441|NCT07105449|DRUG|Cannabis (30% THC Concentrate)|Participants will vape 30% THC concentration of liquid cannabis ad libitum.
214662442|NCT07105449|DRUG|Cannabis (60% THC Concentrate)|Participants will vape 60% THC concentration of liquid cannabis ad libitum.
214662443|NCT07105449|DRUG|Cannabis (90% THC Concentrate)|Participants will vape 90% THC concentration of liquid cannabis ad libitum.
214662444|NCT07106645|DEVICE|Active iTBS|Patients in this condition will undergo 20 sessions of iTBS, one per day for 20 consecutive working days (4 weeks). Each visit will last approximately 20 minutes, including preparation, 3 minutes of stimulation, and debriefing. The coil position will be identified using a neuronavigation system based on each participant's MRI. Intermittent theta burst stimulation will involve the delivery of triplets of pulses at 50 Hz, repeated at 5 Hz, at 100% of the individual motor threshold.
214662445|NCT07106645|DEVICE|Sham stimulation|Patients in this condition will undergo 20 sessions of sham stimulation, one per day for 20 consecutive working days (4 weeks). Each visit will last approximately 20 minutes, including preparation, 3 minutes of stimulation, and debriefing. The coil position will be identified using a neuronavigation system based on each participant's MRI. Sham stimulation will be identical to active stimulation, with the only difference being the use of a sham coil, which produces the same sound as the real coil without generating a magnetic field
214662446|NCT07108192|OTHER|Hand Holding|Hand holding intervention will be performed by the researcher. Before cataract surgery, the researcher will sit in a chair next to the patient and warm his/her hands to a level that does not disturb the patient. 1-2 minutes before cataract surgery, the researcher will hold the patient's hand without gloves, with one hand, with moderate pressure, without rubbing or squeezing it uncomfortably. The hand holding intervention will continue until the cataract surgery is completed
214662447|NCT07108192|OTHER|Stress Ball|According to the randomization, the patient in the stress ball group will first be taught the use of stress balls face to face by the researcher. The researcher will place a round, medium-hard, high-quality stress ball of the same brand in the patient's active hand 1-2 minutes before the cataract surgery is started. The patient will be asked to squeeze and relax the stress ball by counting to 5 during cataract surgery. After squeezing the stress ball, he/she should count to 5 and then loosen it. The patient will be asked to continue this process until the cataract surgery is completed.
214662448|NCT07108192|OTHER|Control Group|Patients who did not receive any intervention other than standard treatment and care during cataract surgery were defined as the control group.
214849497|NCT01057381|DRUG|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
214849498|NCT02947724|DRUG|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
214849499|NCT05156424|OTHER|Exercise|An individualised, progressive and autoregulated exercise programme, supervised by a trained professional.
214849500|NCT00541164|DRUG|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
214290228|NCT01126476|OTHER|Proton Radiotherapy|
214290229|NCT03667924|BEHAVIORAL|PorchLight Project|Senior Companions (or other LSS-MN volunteers providing senior companionship services) who deliver the PorchLight Project will complete online CARES® Dementia Care Specialist training modules, additional trainings delivered by the research team (1. overview of the PorchLight Project, 2. review of the National Consensus Guidelines on Palliative Care, 3. review of the list of guided questions, and 4. review of journaling approach and LTSS resources), and participate in unstructured monthly check-ins (discussions and case review as applicable) with the research team.
214849501|NCT00541164|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
214290230|NCT02128178|DRUG|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
214662449|NCT07105462|DEVICE|Arm 1 - Experimental Group Intervention Name: ADRRPs Vergence Training Intervention Description: Participants wore an Automatic Dual Rotational Risley Prism (ADRRPs) headset to perform vergence eye|"ADRRPs Vergence Training~Intervention Description:~Participants wore an ADRRPs headset that applied alternating base-in and base-out prism power to stimulate vergence eye movements. Prism levels were customized based on each participant's fusional vergence. Training was performed twice weekly for 15 minutes over four weeks while viewing a near video target.~Sham Visual Training with Plano Lenses~Intervention Description:~Participants wore an identical ADRRPs headset fitted with plano lenses that produced no prism effect. The procedure and schedule matched the experimental group but provided no vergence stimulation, serving as a sham control."
214290231|NCT02128178|DRUG|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
214662450|NCT07105462|DEVICE|1. Experimental Group Intervention Name: ADRRPs-Based Vergence Training; 2. Control Group Intervention Name: Sham Training with Plano Lenses.|"ADRRPs-Based Vergence Training This intervention used the Automatic Dual Rotational Risley Prisms (ADRRPs) system to deliver alternating base-in and base-out prism stimulation for vergence training. Prism levels were customized based on each participant's fusional vergence. Training was conducted twice per week for four weeks, 15 minutes per session, while participants viewed a near video target. This protocol provides automated and symmetric vergence demand, distinguishing it from conventional near-point or static prism exercises.~Sham Training with Plano Lenses Participants used the same ADRRPs headset as the experimental group but with plano lenses that produced no prism effect. The training schedule and visual tasks matched the experimental condition, but no vergence stimulus was applied. This design enabled participant masking while providing no active optical stimulation, serving as a sham comparator distinct from both active training and no-treatment controls."
214662451|NCT07107490|DRUG|ALPS12|ALPS12 as an IV infusion
214662452|NCT07107490|DRUG|obinutuzumab|Obinutuzumab as an IV infusion
214662453|NCT07108101|BEHAVIORAL|tDCS stimulation (sham)|"Participants will receive sham tDCS stimulation in a 20 minute long task.~Targets will be fitted with the tDCS stimulation electrode cap and instructed that they will receive 20 minutes of tDCS stimulation for the task. Sham tDCS will target the motor cortex at 2mA for 15 sec at the beginning of the session, and then the stimulator will turn off. The participant will then sit for the remaining time of the session with the electrode cap on their heads but turned off and not delivering stimulation.~All participants will receive sham tDCS stimulation (n=120)."
214662454|NCT07108101|BEHAVIORAL|tDCS stimulation (real)|"In their second session, participants will receive real tDCS stimulation in a 20 minute long task.~Targets will be fitted with the tDCS stimulation electrode cap and instructed that they will receive 20 minutes of tDCS stimulation for the task. Real tDCS stimulation will target the motor cortex at 2mA for 20 minutes (full duration of task).~All participants will receive real tDCS stimulation (n=120)."
214662455|NCT07108101|BEHAVIORAL|Mindful state induction|"Experimenters trained in high-competence and high-warmth will train Group 1 participants on mindful state induction (n=60). Participants will undergo two stages for this training: 1) pain education to increase beliefs in endogenous brain regulatory capacities; and 2) the Stanford Hypnotic Induction Profile (HIP) test of hypnotizability and hypnotic induction of a relaxed state receptive to suggestion.~In Stage 1, participants will receive education that pain and affect are processes designed to protect the body from danger, which are transmitted rapidly and automatically to the brain. In Stage 2, participants are (a) seated in an upright, alert posture; and (b) receive suggestions that the ability to attend to and discriminate affective perceptions is achievable and that suppressing attention to the body and focusing on the task will allow them to perform optimally under pressure. Mindful state induction will only be explicitly instructed during session 1 for Group 1 participants."
214662456|NCT07108101|BEHAVIORAL|No minfulness induction|Participants in the No-mindfulness group will go through comparable stages but with different instructions. In the first stage, they will receive education about pain and affect as protective processes of the body. In the second stage, they will be seated in an upright, alert posture and receive suggestions to focus on the task and suppress attention to the body.
214662457|NCT07107074|DRUG|AD04|Each patient will receive 6 single s.c. injections of IMP at monthly intervals over a 5-month treatment period.
214662458|NCT07107074|DRUG|Placebo|Each patient will receive 6 single s.c. injections of Placebo at monthly intervals over a 5-month treatment period.
214662459|NCT07107542|OTHER|Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities (EPAs) Assessment|Participants undergo standard fieldwork assessments using Mini-CEX and EPAs during their internship to evaluate fieldwork competence and readiness for independent practice. These are observational assessments without additional experimental interventions.
214662460|NCT07105852|DRUG|Sacituzumab tirumotecan (iv)+Putolizumab injection (iv)|"When administering sacituzumab tirumotecan and putolizumab on the same day, the drugs should be given sequentially. Putolizumab is administered first. For the first co-administration, a 4-hour interval is required. If no severe infusion reactions or allergic reactions occur, subsequent administrations may proceed with a minimum interval of 60 minutes before administering sacituzumab tirumotecan.~Putolizumab dosing:~Dosage: 200 mg, intravenous (IV) infusion Dosing cycle: Every 3 weeks (administered on Day 1 of each cycle) Dose interruptions due to adverse events (AEs): Refer to the prescribing information.~Sacituzumab tirumotecan dosing:~Dosage: 4 mg/kg, intravenous (IV) infusion Dosing cycle: Every 2 weeks (administered on Day 1 of each cycle, with a permissible dosing window of 14 ± 3 days between doses) Dose interruptions due to adverse events (AEs): Refer to the prescribing information."
215033547|NCT00030264|DRUG|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
215033548|NCT00030264|DRUG|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
215033549|NCT00950521|PROCEDURE|Intercerebral implantation of Autulogous Stem Cells|2-8 millions Stem cell per patients plus convention therapy
215033550|NCT00950521|DRUG|convention therapy|antiplatelet
214290232|NCT01033591|BEHAVIORAL|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
214290233|NCT01033591|BEHAVIORAL|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
214662461|NCT04362540|DIAGNOSTIC_TEST|MRI scan|On attendance to antenatal clinic with confirmed diagnosis of gestational diabetes based on OGTT and following informed consent: Ultrasound scan: Those with positive OGTT results (i.e. GDM positive) will attend an appointment for an ultrasound scan, as per routine practice. These women will,at that appointment, be assessed for presence/absence of NAFLD as well as undergoing their routine foetal assessment. This is a simple addendum to the existing scan, taking no more than 5 minutes. Participants will have been informed during the consent process that the results (regarding the presence / absence of NAFLD) will be compared to MRI after delivery.
214662462|NCT07106411|DIAGNOSTIC_TEST|Endoscopic Ultrasound|Conventional EUS will be performed to evaluate lesion size, echogenicity, border, and layer of origin for differentiation between GISTs and leiomyomas and risk stratification of GISTs.
214662463|NCT07106411|DIAGNOSTIC_TEST|Contrast-Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS)|CEH-EUS will be conducted using a contrast agent to assess vascularity and enhancement patterns of the lesion for differentiation between GISTs and leiomyomas and risk stratification of GISTs.
214662464|NCT07106697|BEHAVIORAL|First Aid Training Combined With Video-Assisted Guidance|Participants received a 45-minute structured first aid training session on unconscious victim management, followed by a 15-minute video-guidance instruction. During simulation, children received real-time video guidance from a dispatcher via smartphone.
214662465|NCT07106697|BEHAVIORAL|Video-Assisted Guidance Without Prior Training|Participants received a 15-minute instruction on video-assisted guidance use, without prior first aid training. During simulation, real-time video guidance was provided by a dispatcher via smartphone to assist with first aid tasks.
214662466|NCT07106203|BEHAVIORAL|Pursed-Lip Breathing (PLB)|Children in the intervention group will receive Pursed-Lip Breathing exercises twice daily for three days under nurse supervision. Exercises will be applied using playful techniques with a toy (e.g., saxophone ball). Physiological parameters will be measured before and after each session.
214662467|NCT07106606|BEHAVIORAL|Mandala coloring activity|This technique is a creative art-based relaxation method that aims to reduce children's anxiety and fear levels. The application was carried out to make children feel psychologically safer and calmer before the examination. The selected mandala forms were created in accordance with the attention span, motor skill capacity and visual perception development of children between the ages of 9 and 12 by choosing simple but symbolic structures with moderate level of detail.
214662468|NCT07107750|DRUG|CA-4948|Provided by Curis.
214662469|NCT07107750|DRUG|Gemcitabine|Standard of care.
214662470|NCT07107750|DRUG|Cisplatin|Standard of care.
214662471|NCT07107750|BIOLOGICAL|Durvalumab|Standard of care.
214662472|NCT06923111|DRUG|Xromi|Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age as part of standard clinical practice
214662473|NCT07105592|DRUG|Nimotuzumab+Adebrelimab+Chemotherapy|"Phase Ib Treatment Regimen:~Nimotuzumab: Three dose groups (200 mg, 400 mg, 600 mg), administered via intravenous infusion over at least 60 minutes, once every 3 weeks, until disease progression, intolerable toxicity, or subject withdrawal from the trial.~Adebrelimab: Fixed dose of 1200 mg, administered via intravenous infusion, once every 3 weeks, until disease progression, intolerable toxicity, or subject withdrawal from the trial.~Albumin-bound Paclitaxel: 100 mg/m², administered intravenously on Days 1 and 8, once every 3 weeks, for 6 cycles.~Carboplatin: AUC=2 (calculated using the Calvert formula), administered intravenously on Days 1 and 8, once every 3 weeks, for 6 cycles.~Phase II Treatment Regimen:~Nimotuzumab: Recommended Phase II dose (RP2D) as determined from Phase Ib, administered via intravenous infusion on Day 1, once every 3 weeks, until disease progression, intolerable toxicity, or subject withdrawal from the trial.~Adebrelimab: Fixed dose of 1200 mg, administered via"
214662474|NCT06930105|DRUG|Blinatumomab plus Reduced-dose Chemotherapy|"Newly diagnosed Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (Ph-negative B-ALL) patients aged 18-60 years were enrolled.~Treatment Protocol~1. Low-intensity chemotherapy (VIP regimen)~   * V (Vincristine): 1.4 mg/m² (max 2 mg) on days 1 and 8.~  * I (Idarubicin): 8 mg/m²/day on days 1 and 8.~  * P (Prednisone): 60 mg/m²/day (max 100 mg/day) or equivalent dexamethasone dose on days 1-14.~2. Sequential induction therapy:~   * Blinatumomab administered for 2 weeks following the VIP regimen.~3. Consolidation therapy for morphological complete remission (CR)~   * Patients achieving CR receive two cycles of consolidation chemotherapy:~  * Cycle 1: VDCP regimen (Vincristine, Daunorubicin, Cyclophosphamide, Prednisone).~  * Cycle 2: VP + HD-MTX regimen (Vincristine, Prednisone + High-Dose Methotrexate).~4. Allogeneic hematopoietic stem cell transplantation (allo-HSCT):~   * Patients with multiparameter flow cytometry-confirmed minimal res"
214662475|NCT06936852|PROCEDURE|Serratus posterior superior intercostal plane block|Under complete aseptic technique, a high frequency linear probe will be placed adjacent to upper medial part of scapula to visualize the second and third ribs. The needle will be introduced with in plane approach, from caudal to cranial and 30 ml of 0.25% bupivacaine will be injected in the fascial plane between serratus posterior superior and intercostal muscles at the level of second and third ribs.
214849502|NCT05532579|OTHER|Invasive Physiotherapy Group|The study participants corresponding to the intervention group will receive the treatment proposed by their medical doctor. In addition, and as the main part of the intervention, they will receive an invasive physiotherapy protocol consisting of 3 sessions of ultrasound-guided percutaneous neuromodulation, with a time margin of one week between the first and second session and two weeks between the second and third session. The session will last approximately 15 minutes. Each treatment session will consist of the application of a symmetric biphasic current of 3Hz frequency, 250µsec pulse width, 10 impacts of 10 seconds duration with 10 seconds of rest between them. This application will be performed with acupuncture needles placed in an echoguided manner in the proximity of the dorsal root of the last 3 lumbar levels and in the proximity of the sciatic nerve at its exit from the piriformis muscle.
215033551|NCT02012517|DRUG|Prolonged antibiotic treatment|
215033552|NCT02012517|DRUG|Short antibiotic course (standard of care)|
214290234|NCT01593215|DRUG|Yohimbine|Yohimbine capsule
214290235|NCT04160897|DRUG|Entecavir|entecavir naive for chronic hepatitis B patients
214290236|NCT04160897|DRUG|Tenofovir Disoproxil|tenofovir disopropyl naive for chronic hepatitis B patients
214849503|NCT05532579|OTHER|Sham Group|Study participants corresponding to the sham group will receive the treatment proposed by their medical doctor. In addition, they will receive the application of the simulated transcutaneous electrical stimulation technique, placing the patches on the same points where the needles are located, remaining in prone position for the necessary time after the technique is performed until 15 minutes have elapsed. This technique has been studied as a placebo technique for neuromodulation interventions.
214849504|NCT04746599|PROCEDURE|Autologous Fat Grafting|The trochanteric area or the periumbilical abdominal region represents the donor sites. Following Coleman's technique and after the administration of modified Klein solution, a skin incision is performed in the selected area. Adipose tissue is harvested and after suture the area is managed with an elastic-compressive dressing, to be kept in place for 5 days to prevent hematoma formation. The adipose tissue is the centrifuged at 920 × g for 3 min in sterile conditions. Only the intermediate layer containing adipocytes and stromal vascular component will be then injected using a blunt cannula. The terminal branches of the patient's leg arteries are mapped to facilitate graft placement. Under local anesthesia multiple injections of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries.
214849505|NCT03425487|BEHAVIORAL|Mindfulness based Intervention|MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
214662476|NCT06936852|PROCEDURE|PECS II block|. Under complete aseptic technique, a high frequency linear probe will be placed in the infraclavicular region, angulated and directed laterally towards the axilla to visualize the third and fourth ribs with pectoralis major, minor and serratus anterior muscles from superficial to deep. The needle will be introduced with in plane approach from medial to lateral, 10 ml of 0.25% bupivacaine will be injected in the fascial plane between pectoralis major and pectoralis minor then the needle will be further introduced to the fascial plane between pectoralis minor and serratus anterior muscles with injection of 20 ml of 0.25% bupivacaine.
214662477|NCT06936423|PROCEDURE|Open herniotomy|Open inguinal herniotomy through inguinal incision then dissection and separation/ligation of the hernial sac
214662478|NCT06936423|PROCEDURE|Needlescopic percutaneous Internal ring suturing|Laparoscopic extracorporeal percutaneous Internal ring suturing using epidural needle and prolene/ethibond suture
214662479|NCT06936150|OTHER|Electrocardiography|Electrocardiography (ECG) is a non-invasive test used to measure the electrical activity of the heart. It involves placing electrodes on all four extremities and the chest area of the person and measuring the derivation between these electrodes. This procedure is painless and does not contain any elements that will disrupt the integrity of the body.
214662480|NCT00341328|BIOLOGICAL|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
214662481|NCT06159335|RADIATION|F-Fluciclovine radiotracer|Participants will receive PET radiotracer and MRI
214662482|NCT06515587|DIAGNOSTIC_TEST|Lewis genotype detection reagent|By evaluating the results of the Lewis gene test combined with the CA19-9 test, different subtypes of pancreatic cancer patients were differentiated to evaluate the prognosis
214662483|NCT06111209|DRUG|Testosterone cypionate|weekly by intramuscular injection
214662484|NCT06111209|DRUG|Placebo|weekly by intramuscular injection
214849506|NCT03425487|BEHAVIORAL|Compassion based Intervention|ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
214849507|NCT03425487|OTHER|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
214849508|NCT03010982|DRUG|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
214849509|NCT00311350|DRUG|MOA-728|
214849510|NCT03914235|COMBINATION_PRODUCT|Tumescent Anesthesia|A tumescent solution is prepared with 2% lidocaine (10ml), 1:1000 epinephrine (0.4ml) and 7.5% sodium bicarbonate (4ml) dissolved in 0.9% saline solution (40ml) and applied from 3 to 20ml (depending on the pathology to be repaired) at the incision site.
214849511|NCT03914235|DRUG|Lidocaine|Apply 3 to 20 ml at the incision site, depending on the pathology to be repaired(carpal tunnel syndrome, trigger finger or Quervain syndrome).
214849512|NCT03914235|DEVICE|Pneumatic tourniquet|Level of the forearm at 250 mmHg, after exsanguination with Esmarch bandage.
214849513|NCT03914235|PROCEDURE|Open release of the tendon|Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.
214849514|NCT00288717|DRUG|Candesartan|
214849515|NCT00288717|DRUG|Telmisartan|
214849516|NCT02019082|DEVICE|Electrical Stimulation (BTL-5000 series, United Kingdom)|Direct current ES
214849517|NCT02019082|DEVICE|placebo|the intervention procedure was the same as that the ES group, but the current intensity was zero
214849518|NCT03346252|DRUG|Botulinum Toxin type A|"All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart."
214849519|NCT00004175|DRUG|cyclophosphamide|
214849520|NCT00004175|DRUG|docetaxel|
214849521|NCT00004175|DRUG|doxorubicin hydrochloride|
214849522|NCT00004175|PROCEDURE|conventional surgery|
214849523|NCT05315622|OTHER|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
214849524|NCT05315622|OTHER|Placebo|"Manual tension without reaching the manipulation thrust"
214849525|NCT00724490|PROCEDURE|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
214849526|NCT03780946|PROCEDURE|Magnetic anastomosis for pancreaticojejunostomy|Magnetic anastomosis for pancreaticojejunostomy
214849527|NCT03780946|PROCEDURE|Traditional hand-sewn anastomosis|Traditional manual anastomosis for pancreaticojejunostomy
215033553|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging plus peer support|Regular supportive/reminder text message will be delivered to patients who will also receive face to face and interactive text message support from peer support workers
214662485|NCT06524297|OTHER|Metaverse system (Patients)|The experimental group will undergo preoperative training using the metaverse surgical simulation system for 15 minutes before selecting the surgical incision site (this refers to residents receiving the assisted training). The trial process requires participants' consent to provide high-resolution CT images as the basis for reconstructing digital twin organs. Except for the intervention training, the surgery, postoperative care, follow-up, and other treatment processes the participants receive will be the same as those for typical patients.
214662486|NCT06524297|OTHER|Metaverse system (Resident Physician)|The participants (residents) will receive 15 minutes of preoperative training using the Metaverse surgical simulation system. They will superimpose the digital twin model onto the patient on the operating table and use the CT cross-sectional matching function within the Metaverse system to locate the lesion. The participants (residents) can use the system to repeatedly simulate incision sites and mark planned entry points on the patient by overlaying the virtual model onto the real patient. Except for the intervention training with the system, the subsequent surgery, postoperative care, follow-up, and other treatment processes the patients receive will be the same as usual.
214662487|NCT06305182|DRUG|Metreleptin|"Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake.~Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection."
214662488|NCT06305182|DRUG|Sodium chloride|The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
214662489|NCT02464150|DIETARY_SUPPLEMENT|Gluten challenge|Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
214662490|NCT02639676|OTHER|Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections|
214662491|NCT03665155|DRUG|89Zr-daratumumab|2 mCi of 89Zr-daratumumab will be administered on day 0.
214662492|NCT03665155|DEVICE|PET/CT scans|PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
214662493|NCT03665155|OTHER|Blood draws|Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
214662494|NCT05277012|DRUG|Etrumadenant|Etrumadenant capsule and tablet formulations
214662495|NCT01826214|DRUG|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
214662496|NCT06051630|DRUG|Lidocaine intravenous|Perioperative lidocaine intravenous administration
214662497|NCT06051630|DRUG|Serum saline intravenous|Perioperative serum saline intravenous administration
214662498|NCT00525291|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
214662499|NCT00525291|DEVICE|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
214662500|NCT00664170|DRUG|ANX-514|75 mg/m\^2
214662501|NCT00664170|DRUG|docetaxel|75 mg/m\^2
214662502|NCT03176290|DIAGNOSTIC_TEST|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml-1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 - platelet count (×109 l-1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
214662503|NCT04865848|PROCEDURE|Dental local anesthesia|Dental local anesthesia
214662504|NCT06543992|DRUG|Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir|Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
214662505|NCT04007484|DEVICE|Hemoperfusion|Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
214662506|NCT01959360|PROCEDURE|Direct lateral|Total hip replacement; direct lateral approach
214662507|NCT01959360|PROCEDURE|minimal invasive|Total hip replacement; minimal invasive approach
214662508|NCT01959360|PROCEDURE|modified minimal invasive|Total hip replacement; modified minimal invasive approach
214662509|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fed state
214662510|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fast state.
214662511|NCT05902728|DRUG|HLX208|450 mg
214662512|NCT05902728|DRUG|HLX208|900 mg
214662513|NCT05902728|DRUG|Itraconazole 200 mg|200 mg
214662514|NCT05902728|DRUG|Rifampicin|600mg
214662515|NCT03067220|OTHER|Virtual outpatient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
214662516|NCT03067220|OTHER|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
214662517|NCT04792229|OTHER|Whole Body Viberation|WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
214662518|NCT01309126|BIOLOGICAL|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
214662519|NCT01309126|DRUG|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
214662520|NCT04484909|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
214662521|NCT04484909|RADIATION|Radiation Therapy|Undergo radiation therapy
214662522|NCT03176849|DIETARY_SUPPLEMENT|Vitamin D3|The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
214662523|NCT03176849|DIETARY_SUPPLEMENT|Standard Vitamin D3 Supplementation|"Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally."
214662524|NCT03101072|OTHER|"Fixed long antibiotic course of 14 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
214662525|NCT03101072|OTHER|"Fixed short antibiotic course of 7 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
214662526|NCT03101072|OTHER|"Individualized duration of antibiotic therapy"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
214662527|NCT02455115|OTHER|Alternating mean arterial pressure|In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
214662528|NCT02455115|DRUG|Norepinephrine|Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
214662529|NCT02455115|DRUG|Chromium ethylenediaminetetraacetic acid|Extraction of 51Cr-EDTA measured for FF and GFR
214662530|NCT06091501|BEHAVIORAL|Lev Livet|"The program consists of a total of 9 sessions with a duration of two and a half to three hours for each session. In the first four sessions coping skills are taught across different chronic diseases. In this part of the program citizens suffering from different chronic diseases can participate. Citizens living with T2D then move on to four diabetes-specific sessions, followed by a ninth follow up session. The sessions are held consecutively over eight weeks. The ninth session is held three weeks after the eighth session.~The 8 weeks supervised HIIT-protocol will be comprised of blocks of 5 x 1 min high-intensity intervals interrupted by 1 min active recovery. The HIIT intervention will progress continuously, from two weekly training sessions with two training blocks (22 minutes of training) in the first two weeks, to two weekly training sessions with four training blocks in the last four weeks of the intervention."
214662531|NCT04622852|DEVICE|Open reduction internal fixation (ORIF) with an angular stable plate|Operative treatment of proximal humeral fracture
214662532|NCT01710761|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
214662533|NCT01710761|DIETARY_SUPPLEMENT|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
214662534|NCT05374343|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule orally (by mouth) on Day 1
214662535|NCT06116383|DEVICE|NIRS|Renal perfusion will be evaluated with NIRS
214662536|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
214662537|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
214662538|NCT04034615|BIOLOGICAL|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
214662539|NCT01861197|DRUG|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
214662540|NCT02350543|DRUG|Aspirin|
215033554|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging|Regular supportive/reminder text message will be delivered to patients who will NOT receive any face to face or interactive text message support from peer support workers
214662541|NCT01158183|DRUG|BAY86-5046_Interferon-beta-1b|Electronic questionnaires
214662542|NCT01317849|DRUG|Folic Acid|0.8mg
214662543|NCT01317849|DRUG|Vitamin B6|10mg
214662544|NCT01317849|DRUG|Vitamin B12|500ug
214662545|NCT01317849|DRUG|placebo|0.8 mg
214662546|NCT01317849|DRUG|placebo|10mg
214662547|NCT01317849|DRUG|placebo|500ug
214662548|NCT01403298|BEHAVIORAL|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
214662549|NCT01403298|OTHER|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
214662550|NCT06132568|DEVICE|VITALYST System|The VITALYST System is a temporary ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively in hemodynamically stable subjects with severe coronary artery disease.
214662551|NCT02801175|PROCEDURE|Pulmonary vein isolation|
214662552|NCT06070363|OTHER|Manual Acupuncture|Acupuncture Needle Insertion
214662553|NCT00849550|DRUG|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
214662554|NCT04314687|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
214662555|NCT04314687|BIOLOGICAL|Conditioned Medium|Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.
214662556|NCT04314687|OTHER|Standard Therapy|Standard therapy for cerebral palsy such as physiotherapy
214662557|NCT03409302|BEHAVIORAL|ALGEApp (Brief iACT intervention)|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.
214662558|NCT03409302|BEHAVIORAL|Active control group|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
214662559|NCT05060861|OTHER|ChAdOx1 nCoV-19 vaccine|covid-19 vaccine
214662560|NCT03184870|DRUG|BMS-813160|Specified dose on specified days
214662561|NCT03184870|BIOLOGICAL|Nivolumab|Specified dose on specified days
214662562|NCT03184870|DRUG|Nab-paclitaxel|Specified dose on specified days
214662563|NCT03184870|DRUG|Gemcitabine|Specified dose on specified days
214662564|NCT03184870|DRUG|5-fluorouracil (5-FU)|Specified dose on specified days
214662565|NCT03184870|DRUG|Leucovorin|Specified dose on specified days
214662566|NCT03184870|DRUG|Irinotecan|Specified dose on specified days
214662567|NCT03607370|PROCEDURE|Surgery after 12 weeks of delay after chemoradiotherapy.|Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
214662568|NCT06176703|DEVICE|mobile application|using mobile application along with standard treatment of diabetes mellitus
214662569|NCT01954290|DRUG|Conivaptan|Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
214662570|NCT01954290|DRUG|Hypertonic saline|Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
214662571|NCT01954290|DRUG|Mannitol|Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
214662572|NCT04181281|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|This is a regular ultrasound scanner used with an ultrasound contrast agent injected through veins to allow for kidney perfusion acquisition.
214662573|NCT04181281|DIAGNOSTIC_TEST|Arterial Spin Labelling -Magnetic Resonance Imaging|Arterial spin labelling is an MRI technique allow for measuring tissue perfusion. It uses magnetically labelled arterial blood water protons as a tracer.
214662574|NCT02101437|PROCEDURE|miRNA within 24hr|miRNA within 24hr
214662575|NCT02101437|PROCEDURE|miRNA after 1 week|miRNA after 1 week
214662576|NCT02101437|PROCEDURE|miRNA after 1 month|miRNA after 1 month
214662577|NCT06049316|OTHER|Scapular stabilization exercises|"In Scapular stabilization exercise, following treatment protocol will involve.~* In supine position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree. After this patient will raise his hand overhead with 90 degree flexion and elbow extension and also perform scapular retraction. (10 sec hold, 10 reps, 20 sec break).~* In quadrupled position with 120 degree flexion and shoulder abduction patient will lifted his hands. (10 sec hold, 10 reps, 20 sec break) TYI exercises will be administered~* T shape: Place both arms horizontal with thumbs up. (10 times, 5 sec hold, 3 sets)~* Y-shape: In prone lying place arms in 45 degree. (10 times, 5 sec hold, 3 sets)~* I-shape: In prone position patients will place his both arms overhead. (10 times, 5 sec hold, 3 sets).~These above exercises will perform 3 times a week for eight weeks."
214662578|NCT06049316|OTHER|Scapular functional exercises|"In Scapular functional exercises, following treatment protocol will involve~* Press-up (in a chair).~* Push-up plus, Grade 1, in oblique position exercise will be performed with the support of a table. After progression perform this in horizontal plane.~* Lateral pull down~* Horizontal pull apart~* Prone flexion: in prone position on plinth. Both arms placed overhead, and then raise arms towards ceiling.~* Prone rows: in prone position, with elbow straight, slowly raise arms towards ceiling while bending the elbows.~These all above exercises will perform by holding dumbbells in hands (20RM at first week, 10RM at last week) with 3 sets, 3 times a week for eight weeks."
214662579|NCT01106638|BEHAVIORAL|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
214662580|NCT01106638|BEHAVIORAL|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
214662581|NCT04553887|DRUG|Almonertinib|single agent, 110mg p.o once daily until disease progressed
214662582|NCT01979510|DRUG|MK-0663B|MK-0663B once daily for 8 days.
214662583|NCT01979510|DRUG|DOLOCAM PLUS®|DOLOCAM PLUS® once daily for 8 days.
214662584|NCT01979510|DRUG|Acetaminophen 500 mg|Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
214662585|NCT06958679|DRUG|SYS6005|SYS6005 administered via IV infusion on , Day 1 of each 21-day cycle
214662586|NCT01538771|DRUG|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
214662587|NCT01538771|DRUG|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
214662588|NCT02993237|DRUG|DRV/COBI FDC placebo tablet|Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
214662589|NCT02993237|DRUG|D/C/F/TAF FDC placebo tablets|Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
214662590|NCT02821286|OTHER|Observational study|Blood sampling
214662591|NCT04329936|BEHAVIORAL|Retention center Geispolsheim population|All recently held individuals in the retention center can be included in the study after signing the information and consent protocol.
214662592|NCT00459927|DEVICE|Floseal tonsillectomy|
214662593|NCT00459927|DEVICE|Coblation tonsillectomy|
214662594|NCT03984526|DRUG|normal saline|intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
214662595|NCT03984526|DRUG|atropine 0.5mg|intravenous atropine 0.5mg pretreatment at the onset of dexmedetomidine infusion
214849528|NCT05685901|DIETARY_SUPPLEMENT|High polyphenolic olive oil. (Early harvest olive oil).|High polyphenolic olive oil is normal olive oil obtained from early harvest olives, this early harvest olive oil has been widely used for culinary purposes for centuries. The investigators wanted to study if oromucosal immunoprophylaxis with small quantities of high polyphenolic olive oil (2 mL of olive oil equivalent to 5 mg of polyphenols) adiministered twice a day could have clinical mitigating effects on the disease caused by SARS-CoV-2 infection.The primary outcome was to determine the effect of high polyphenolic olive oil on Coronavirus disease incidence, duration and severity.
214849529|NCT05775822|DIAGNOSTIC_TEST|CT scan and blood sample collection|"Each enrolled patient performs:~* preventive clinical cardiology assessment visit, addressed to individualized risk profile assessment and addressed to chest CT scan.~* a blood sampling (1 citrate tube of 5 ml) will be done the same day just the chest CT scan and analyzed locally also for future research of biomarker discovery (single sample, for those patients who agree in ICF)~* CT scan"
214849530|NCT03072199|DRUG|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
214849531|NCT00804141|DRUG|N-methylnaltrexone bromide (MOA-728)|MOA-728 will be administered as per the dose and schedule specified in the arm.
214849532|NCT05417360|DIETARY_SUPPLEMENT|Akkermansia muciniphila|"During the weight management period (weeks 8 to 32), the pasteurized A. muciniphila product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks) capsules. It appears as a white homogenous powder.~."
214849533|NCT05417360|DIETARY_SUPPLEMENT|Placebo|During the weight management period (weeks 8 to 32), the placebo product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks). It appears as a white homogenous powder.
214849534|NCT03889834|PROCEDURE|Autologous Blood Transfusion|Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days
214849535|NCT03889834|OTHER|No transfusion|no transfusion
214849536|NCT00841152|DEVICE|Bioactive glass|Surgical implantation
214849537|NCT00841152|DEVICE|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
214849538|NCT00841152|PROCEDURE|Autograft|Surgical transplantation from iliac crest
214849539|NCT00841152|PROCEDURE|Allograft (frozen femoral head)|Surgical transplantation
214849540|NCT06227117|DRUG|Disitamab Vedotin Injection （18 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
214849541|NCT06227117|DRUG|Toripalimab （18weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
214849542|NCT06227117|DRUG|Carboplatin|AUC 3 Q2W or AUC1.5 QW intravenous infusion
214849543|NCT06227117|DRUG|Disitamab Vedotin Injection （12 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
214849544|NCT06227117|DRUG|Sequential Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
214849545|NCT06227117|DRUG|Sequential CTX|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
214849546|NCT06227117|DRUG|Toripalimab （12weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed.
214849547|NCT00335335|DRUG|iodixanol|
214849548|NCT02334111|BEHAVIORAL|RESPECT-Plus|A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
214849549|NCT06324786|BEHAVIORAL|IBMT|IBMT is an effortless mindfulness technique
214849550|NCT06324786|BEHAVIORAL|NF|NF is a mental training technique.
214849551|NCT05155527|DRUG|Ivermectin Tablets|6 mg/tablet
214849552|NCT05155527|OTHER|Placebo|The placebo has same form as Ivermectin.
214849553|NCT02842723|RADIATION|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
214849554|NCT03584217|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
214849555|NCT03584217|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
214849556|NCT03584217|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
214849557|NCT04339595|BIOLOGICAL|Tildrakizumab|Participants who have participated and completed the long-term extension phase of the reSURFACE 2 study (NCT01729754) and 12 weeks after the last Tildrakizumab dose will be included in the present study. Participants will not receive any study medication during the present study. Participants will remain in the study for 96 weeks or until they initiate any systemic therapy for psoriasis (including phototherapy), whichever occurs first.
214849558|NCT04948671|OTHER|there will be no intervention, this is an observational study|this is an observational study
215033555|NCT03404882|BEHAVIORAL|Peer support only|face to face support from peer support workers but no interactive or daily supportive/reminder text messages
215033556|NCT01822925|DRUG|DA-9801 300mg|300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
214662596|NCT03984526|DRUG|ephedrine 8mg|intravenous ephedrine 8mg pretreatment at the onset of dexmedetomidine infusion
214662597|NCT00934895|DRUG|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
214662598|NCT00934895|DRUG|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
214662599|NCT02108457|RADIATION|[18F]Fluorothymidine (FLT) PET/CT Imaging|
214662600|NCT06793644|DRUG|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
214662601|NCT02655198|DRUG|Fenfluramine|study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
214662602|NCT01695369|DEVICE|Senofilcon A; Comfilcon A|Senofilcon A; Comfilcon A
214662603|NCT01695369|DEVICE|Comfilcon A; Senofilcon A|Comfilcon A; Senofilcon A
214849559|NCT00001873|DEVICE|Isolex 300i plus MoAbs|
214849560|NCT03589196|PROCEDURE|Ejaculation Preserving Photoselective Vaporization|Ejaculation Preserving Photoselective Vaporization
214849561|NCT03589196|PROCEDURE|Ejaculation Preserving Plasma Kinetic Vaporization|Ejaculation Preserving Plasma Kinetic Vaporization
214849562|NCT03589196|PROCEDURE|Ejaculation Preserving Transurethral Resection Of The Prostate|Ejaculation Preserving Transurethral Resection Of The Prostate
214849563|NCT05021887|DRUG|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
214849564|NCT05021887|DRUG|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
214849565|NCT04645940|DRUG|fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole|"fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
214849566|NCT04645940|DRUG|fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole|"fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
214849567|NCT00024388|DRUG|DHA-paclitaxel|
214849568|NCT04973813|BEHAVIORAL|Guideline + Active Choice + action&coping planning (GA+)|Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning
214849569|NCT04973813|BEHAVIORAL|Guideline + Active Choice (GA)|Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
214849570|NCT04973813|BEHAVIORAL|Guideline + information (GI)|Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.
214849571|NCT04973813|BEHAVIORAL|Guideline (G)|Web-based information about the national physical activity guideline.
214849572|NCT02504814|DEVICE|Nasal Highflow (NHF)|changes in breathing physiology in NHF
214849573|NCT03589131|PROCEDURE|Total Operative time|Investigators compare the preparation time of the procedure in the operating room and the actual operative time
214849574|NCT03589131|PROCEDURE|Margin assessment|In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.
214849575|NCT03589131|PROCEDURE|Conversion rate to open surgery|In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
214849576|NCT03589131|PROCEDURE|Baseline demographics|These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
214849577|NCT03589131|PROCEDURE|Preoperative data|"These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared"
214849578|NCT03589131|PROCEDURE|Postoperative data|These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission \& 30-days mortality. All were analyzed and compared
214849579|NCT00596206|DRUG|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
214662604|NCT02592564|BEHAVIORAL|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
214662605|NCT03050684|PROCEDURE|vaginal lavage group|vaginal washing will be applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
214662606|NCT03050684|PROCEDURE|Control Group|vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
214662607|NCT03410147|DIAGNOSTIC_TEST|13C-octanoate breath test for gastric emptying|"The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations."
214662608|NCT00643539|DRUG|Zithromax|azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
214662609|NCT00643539|DRUG|Clamoxyl|Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
214849580|NCT03220113|COMBINATION_PRODUCT|Dexamethasone, Lidocaine, Thiamine cohort|Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
215033557|NCT01822925|DRUG|DA-9801 600mg|600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
214662610|NCT04782739|OTHER|None - Descriptive study|Descriptive study
214662611|NCT05600010|OTHER|Microplastics|Detection of microplastics as a yes/no value
214662612|NCT03545516|DRUG|Bupivacaine|Injection of bupivacaine into the surgical incision prior to its closure.
214662613|NCT03545516|DRUG|Dexmedetomidine|Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
214662614|NCT03545516|DRUG|Placebo|Injection of a placebo into the surgical wound
214662615|NCT04086043|DEVICE|Endovascular Denervation|multi-electrode catheter-based endovascular denervation
215033558|NCT01822925|DRUG|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
215033559|NCT01822925|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
214662616|NCT04558008|BEHAVIORAL|Online MBSR|Described previously
214662617|NCT01344122|OTHER|KPI training only|See comparison arm description.
214662618|NCT01344122|OTHER|KPI plus OLI|See experimental arm description.
214662619|NCT06394622|COMBINATION_PRODUCT|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
214662620|NCT00745030|DRUG|Rozerem|Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
214662621|NCT00745030|DRUG|Placebo|Placebo 8 mg tablets
214662622|NCT03361670|OTHER|Observational Study|
214662623|NCT01471327|BIOLOGICAL|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
214290237|NCT00881582|DRUG|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 \& 4: 48 weeks; genotypes 2 \& 3: 24 weeks)
214662624|NCT01471327|OTHER|Placebo|Saline IV, single dose at Day 1
214662625|NCT06382688|DIETARY_SUPPLEMENT|NAD+ (nicotinamide adenine dinucleotide) IV|NAD+ enables cells to generate cellular energy from the food that one eats
215033560|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(RESTORE DEB）|
215033561|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(SeQuent® Please）|
215033562|NCT02196532|DEVICE|Device: Optical coherence tomography|
214662626|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) IV|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an IV administration.
214662627|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) oral|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an oral administration.
214662628|NCT06382688|OTHER|Placebo|These individuals received a saline IV
214662629|NCT01056107|DRUG|ROSE-010|The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
214662630|NCT01056107|DRUG|Placebo|Placebo subcutaneous injection daily
214662631|NCT01839994|RADIATION|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
214662632|NCT01839994|RADIATION|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
214662633|NCT01839994|DRUG|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
214662634|NCT04219306|OTHER|Alert on dispatchers screen 'Suspect cardiac arrest'|Alert on dispatchers screen 'Suspect cardiac arrest'
214662635|NCT04275752|OTHER|Exercise Program|Perform endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training twice a week for a period of one hour per session, for a total of 16 sessions.
214662636|NCT01526226|DEVICE|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
214662637|NCT01526226|DEVICE|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
214662638|NCT01614457|DRUG|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
214662639|NCT01614457|DRUG|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
214662640|NCT06512402|DRUG|Norepinephrine|patients will receive norepinephrine infusion at rate of 0.05 mcg/Kg/min
214662641|NCT06512402|DRUG|Epinephrine|patients will receive epinephrine infusion dose of 0.03 mcg/Kg/min
214662642|NCT06128512|OTHER|Auricular acupuncture|Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch containing the needle will remain in place until the student completes the examination.
214662643|NCT06128512|OTHER|Sham Auricular acupuncture|Sham Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, without a needle. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch will remain in place until the student completes the examination.
214662644|NCT04577768|DEVICE|HD-tDCS 2 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA
214662645|NCT04577768|DEVICE|HD-tDCS 1.5 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
214662646|NCT04577768|DEVICE|HD-tDCS sham|sham stimulation of the right primary motor cortex
214662647|NCT05863429|BIOLOGICAL|Taking biological samples (blood) and keeping records with phone calls|Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.
214662648|NCT05604105|OTHER|Questionnaire|The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.
214662649|NCT04273243|GENETIC|AT-GTX-501|No study drug is administered in this study. Subjects who received AT-GTX-501 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
214662650|NCT02795910|BEHAVIORAL|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
215033563|NCT04585178|DEVICE|Biobeat patch|"The Biobeat device (BB-613WP) is a class IIa medical device and is a non-invasive patch used for monitoring vital signs in clinical and non-clinical settings. The sensor continuously records the photoplethysmographic waveform that allows the calculation of several physiological parameters: heart rate (HR), SPO2, systolic blood pressure (SBP) and change in SBP, diastolic blood pressure (DBP) and change in DBP, stroke volume (SV), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), and respiration rate (RR).~Translated with www.DeepL.com/Translator (free version)"
214662651|NCT02795910|BEHAVIORAL|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
214662652|NCT00381316|DRUG|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
214290238|NCT02822768|PROCEDURE|Packing|The patient will receive packing as part of their wound care
214290239|NCT02822768|OTHER|No packing|The patient will not receive packing as part of their wound care
214662653|NCT00381316|DRUG|Thallous Chloride T1-201|Myoview SPECT Imaging
214662654|NCT01341873|OTHER|educational intervention|Undergo APN FCI
214662655|NCT01341873|OTHER|psychosocial support for caregiver|Undergo APN FCI
214662656|NCT01341873|PROCEDURE|quality-of-life assessment|Ancillary studies
214662657|NCT01341873|OTHER|questionnaire administration|Ancillary studies
214662658|NCT06044870|PROCEDURE|Modified laterally stretched technique with a connective tissue graft.|Modified laterally stretched technique with a connective tissue graft.
214662659|NCT03397420|OTHER|FAM-CARE|Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers
214662660|NCT01854567|BIOLOGICAL|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
214662661|NCT01854567|BIOLOGICAL|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
214662662|NCT04296136|OTHER|Advance Care Planning Discussion|Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
214662663|NCT06069687|BIOLOGICAL|MELPIDA|A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg
214662664|NCT00886821|BIOLOGICAL|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
215033564|NCT02937571|DRUG|Carfilzomib|
215033565|NCT02937571|DRUG|Lenalidomide|
214849581|NCT04250831|DIETARY_SUPPLEMENT|agglomerated glucomannan, oligofructose and chromium mixture|Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.
214662665|NCT04985708|OTHER|data collection of clinically available procedures|when to place Impella related to PCI in patients with AMICS
214662666|NCT06097936|DIAGNOSTIC_TEST|HPV-ASSOCIATED OROPHARYNGEAL CANCER|The study involves the coexistence of a retrospective part, in which a group of patients with HPV-associated OPC for whom follow-up data of at least 2 years after diagnosis are available, designed in order to evaluate the expression of HPV16-specific E5 transcript as well as that of pEGFR and HLA, and a multicenter prospective part, involving the enrollment of a control group, enrolled at the ENT outpatient clinic of the IRE and the outpatient clinics of the relevant LILT provincial committees, to better elucidate the role of HPV16-E5 in identifying potentially transforming infections due to the presence of HPV.
214662667|NCT05872425|DRUG|DingKunDan(GuangYuYuan)|"The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment."
214662668|NCT05872425|DRUG|Drospirenone and Ethinylestradiol Tablets (Ⅱ)|The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
214662669|NCT00914628|GENETIC|HSV-Tk|Infusion of approximately 1±0.2 x 10\^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
214662670|NCT00914628|OTHER|T-cell depleted or T-cell replete strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10\^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
214662671|NCT04567251|OTHER|Noona® application|A digital symptom tracking application focused on Health-Related Quality of Life (HRQOL) and cognition in cancer survivors who received brain irradiation
214662672|NCT03624660|RADIATION|HR-A|"The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
214849582|NCT04073017|DIETARY_SUPPLEMENT|Enterade®|Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks
214849583|NCT04073017|OTHER|Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)|Ancillary studies
214849584|NCT02092337|OTHER|computer-assisted speech training|
214849585|NCT03752398|BIOLOGICAL|XmAb®23104|Monoclonal bispecific antibody
214849586|NCT03752398|BIOLOGICAL|Yervoy® (ipilimumab)|Monoclonal antibody
214849587|NCT01054352|DRUG|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
214849588|NCT01054352|DRUG|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
214849589|NCT01054352|DRUG|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
214849590|NCT01054352|DRUG|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
214849591|NCT01309217|BEHAVIORAL|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
214849592|NCT01309217|OTHER|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
214849593|NCT02075606|DRUG|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
214849594|NCT05108844|PROCEDURE|Videocapsule endoscopy|Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
214849595|NCT02462486|DRUG|Abicipar Pegol|Abicipar pegol intravitreal injection.
214849596|NCT02462486|DRUG|Ranibizumab|Ranibizumab intravitreal injection.
214849597|NCT02462486|OTHER|Sham Procedure|Sham injection.
215033566|NCT02937571|DRUG|Dexamethasone|
214290240|NCT00488176|DRUG|montelukast|montelukast sodium
214290241|NCT00488176|DRUG|cetirizine|cetirizine
214290242|NCT00488176|DRUG|montelukast and cetirizine|montelukast and cetirizine
214662673|NCT03624660|RADIATION|HR-B|"The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Electively treat the entire uninvolved seminal vesicle to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent when part of the seminal vesicle is involved with tumor.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
214662674|NCT04720729|BIOLOGICAL|Chemotherapy monitoring by circulating tumor DNA analysis|"During the screening step (2nd chemotherapy line, cycle 1) : at each time point (L2C1D1 \& L2C1D15), 30 ml of blood will be drawn on special tubes with conservative suited for ctDNA analyses (e.g. STRECK® tubes).Then cell-free circulating DNA (cfcDNA) will be extracted from plasma following the manufacturer recommendations. cfcDNA will be quantified, and minimum 500-1000 copies will be analyzed by droplet digital PCR (ddPCR). Analyses will define if ctDNA could be detected during L2.~For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (\> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be changed."
214662675|NCT03404960|DRUG|Niraparib + Nivolumab|Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
214662676|NCT03404960|DRUG|Niraparib + Ipilimumab|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
214662677|NCT05675709|BEHAVIORAL|Training and Education|Undergo group trainings
214662678|NCT02823522|OTHER|Patients recruitment|Between July and November 2016, the patients included in the previous retrospective study were contacted by phone, mail and e-mail and invited to come back to the respective clinics where they had been initially diagnosed as NCWS patients: the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (province of Agrigento).
214662679|NCT05117970|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
214662680|NCT06843902|OTHER|Health Education|Health Education
214662681|NCT06843902|OTHER|Subspecialty clinic referral|This intervention will entail referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement.
214662682|NCT04886414|OTHER|Phone-based monitoring|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.
214662683|NCT04886414|OTHER|Oxygen saturation monitoring|Oxygen saturation will be monitored and recorded at regular intervals.
214662684|NCT04886414|OTHER|Alcohol-based hand sanitizer|Alcohol-based hand sanitizer will be distributed to subjects.
214662685|NCT04987281|PROCEDURE|Computed Tomography|Undergo CT
214662686|NCT04987281|DRUG|Indocyanine Green Solution|Given via injection
215033567|NCT06236646|OTHER|Thai dance with twenty-five squares (TDT)|The participants received a Thai dance with twenty-five squares (TDT) program 3 days/week, 12 weeks. This training comprises 10 minutes of warm up, following by 40 minutes of exercise at 40-50% of heart rate reserve at week 1-4, 50-60% of heart rate reserve at week 5-8, and 60-70% of heart rate reserve at week 9-12, 5 minutes of cool down.
214662687|NCT04987281|DEVICE|Therapeutic Bronchoscopy|Undergo bronchoscopy using Ion robotic bronchoscope
214662688|NCT04585685|BEHAVIORAL|Cognitive Processing Therapy|A 12-session cognitive behavioral therapy for posttraumatic stress disorder
214662689|NCT04585685|BEHAVIORAL|Self-Compassion Therapy|A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion
214662690|NCT03311126|DRUG|Bendamustine|Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of chronic lymphocytic leukemia (CLL) and for indolent B cell non-Hodgkin lymphomas (NHLs) progressing during or within 6 months of rituximab or a rituximab - containing regimen.
214662691|NCT03311126|DRUG|Obinutuzumab|Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 monoclonal antibody (mAb).
214662692|NCT00885443|DRUG|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
215033568|NCT06236646|OTHER|Control (CON)|The CON group did not have any intervention but usual care.
214662693|NCT00885443|DRUG|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
214662694|NCT06394063|BIOLOGICAL|Telitacicept|Telitacicept 160 mg SC every other week
214662695|NCT06394063|DRUG|Placebo|Placebo to Telitacicept
214662696|NCT05955742|DEVICE|Control|The operator prepared the glide path using a #15K-type stainless-steel hand file.
214662697|NCT05955742|DEVICE|ProGlider|The operator prepared the glide path using the ProGlider file.
214662698|NCT05955742|DEVICE|WaveOne Gold Glider|The operator prepared the glide path using the WaveOne Gold Glider file.
214662699|NCT00014742|DRUG|collagenase|
215033569|NCT05384483|DRUG|Cariprazine|Cariprazine 1.5 to 3 mg per day
215033570|NCT05384483|DRUG|Placebo|Matching placebo
214662700|NCT03707093|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,10 mg/kg or 300mg flat dose depending on cohort at enrollment.
214662701|NCT01717846|DRUG|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
214662702|NCT01717846|OTHER|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
214662703|NCT02864875|DRUG|Fibrinogen concentrate|Receive fibrinogen concentrate 50mg/kg of body weight after randomization
214662704|NCT02641899|DRUG|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
214662705|NCT02641899|DRUG|Acetaminophen|Oral acetaminophen 1000 mg on Day 1 and Day 27
214662706|NCT02641899|DRUG|Atorvastatin|Oral atorvastatin 40 mg on Day 2 and Day 28
214662707|NCT02641899|DRUG|Lisinopril|Oral lisinopril 20 mg on Day 2 and Day 28
214662708|NCT02641899|DRUG|Warfarin|Oral warfarin 25 mg on Day 2 and Day 28
214662709|NCT02641899|DRUG|Digoxin|Oral digoxin 0.5 mg on Day 2 and Day 28
214662710|NCT03903055|DIAGNOSTIC_TEST|MDS group|patients diagnosed as MDS with high risk，aged 18-80，men/wemen
214662711|NCT02194881|DRUG|CF patients with a G551D mutation and treated with Ivacaftor|
214662712|NCT02857465|DRUG|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
214662713|NCT02857465|DRUG|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
214662714|NCT02857465|DRUG|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
214662715|NCT02857465|DRUG|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
214662716|NCT02553603|DRUG|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
214662717|NCT02553603|DRUG|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
214849598|NCT06502210|PROCEDURE|Personalized surgical therapy of neuroblastoma|If the size of the tumor tissue is too large, the doctor gives the patient chemotherapy and then performs surgery to remove the tumor. In this study, the genotypes of children with neuroblastoma are screened by using Deep Sequencing Technology and Third Generation Sequencing Technology, and the treatment will be performed according to different therapeutic modalities.
214849599|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, simple mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation"
214662718|NCT04599790|DRUG|TACE combined with lenvatinib and sintilimab|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
214662719|NCT05780840|OTHER|Dihydroxyacetone|Application of 10% dihydroxyacetone (2 mg per square cm skin)
214662720|NCT05780840|OTHER|Placebo|Application of lotion to the skin (2 mg per square cm skin)
214662721|NCT01183962|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 3000 IU daily
214662722|NCT01183962|OTHER|No medication|No intervention
214662723|NCT05424692|DRUG|5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
214662724|NCT04570579|DEVICE|Vivity Extended Depth of Focus Intraocular Lens|Patients selected to have bilateral sequential cataract surgery using the Vivity (spherical and/or toric where applicable) intraocular lens implant will subsequently be offered enrollment into this observational study. Visual outcomes will be recorded at postoperative day 1, week 1, month 1 and month 3.
214662725|NCT02203370|DEVICE|NIRS - Near-infrared spectroscopy|
214662726|NCT06152120|OTHER|Nurse-facilitated advance care planning intervention|"The intervention consists of two components:~Component 1. Palliative care needs assessment - The research nurse will conduct a palliative care needs assessment and also review related information from the medical chart, which will enable the nurse to provide tailored information on the patient's illness, prognosis, and palliative care needs during subsequent ACP consultations.~Component 2: Structured nurse-facilitated ACP consultations - The research nurse will conduct post-discharge ACP consultations with the family surrogate, with content that includes: assess readiness for discussions, introduce video decision aides to provide related ACP information and share examples of family surrogates with similar experiences."
214662727|NCT05804162|DRUG|Cagrilintide|Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.
215033571|NCT04617860|DRUG|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide. It is administered monthly via intrathecal injection.
215033572|NCT00009178|DRUG|Fluoxetine|
215033573|NCT00009178|BEHAVIORAL|Guided Self-Help|
214662728|NCT05804162|DRUG|Cagrilintide Placebo|Participants will receive cagrilintide placebo subcutaneously once weekly.
214662729|NCT05804162|DRUG|Moxifloxacin|Partcipants will receive a single dose of moxifloxacin orally.
214662730|NCT05804162|DRUG|Moxifloxacin Placebo|Partcipants will receive a single dose of moxifloxacin orally.
214662731|NCT00374556|DRUG|Placebo|3mg placebo capsule, once daily at bedtime
214662732|NCT00374556|DRUG|Eszopiclone|3mg capsule, once daily at bedtime
214662733|NCT01568723|GENETIC|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
214662734|NCT04345185|OTHER|Infant egg consumption (i.e., age of introduction and frequency of intake)|
214662735|NCT05679882|OTHER|Masking Sounds|Masking sounds will be played from outdoor speakers.
214662736|NCT05679882|OTHER|No Masking Sounds|No masking sounds will be played from outdoor speakers.
214662737|NCT04146688|OTHER|Music Balance Board|The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
214662738|NCT01355406|DEVICE|FlexStent® Femoropopliteal Self Expanding Stent System|Transcatheter over guidewire placement of an intravascular stent(s)
214662739|NCT05352191|DRUG|Beclomethasone|inhaled 800ug
214662740|NCT04831450|DRUG|Cemiplimab-Rwlc|350 mg Cemiplimab administered via intravenous infusion over 30 minutes on Day 1 of a 21-day cycle.
214662741|NCT04207398|PROCEDURE|Transjugular intrahepatic portosystemic shunts|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).
214662742|NCT04207398|OTHER|Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)|Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
214662743|NCT01938859|DRUG|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
214662744|NCT01938859|DRUG|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
214662745|NCT01938859|DRUG|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
214662746|NCT00473694|DRUG|sugammadex|Administered as an intravenous (IV) infusion
214662747|NCT00473694|DRUG|neostigmine|Administered as an IV infusion
214662748|NCT00473694|DRUG|vecuronium|Administered as an IV infusion
214662749|NCT00473694|DRUG|rocuronium|Administered as an IV infusion
214662750|NCT00473694|DRUG|glycopyrrolate|Administered as an IV infusion
214662751|NCT05268848|OTHER|Thermographic photo|Barefoot patient, thermographic photo of the sole of the feet is taken
214849600|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
214849601|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, simple mobility|"Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
214849602|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation."
214662752|NCT06387056|DRUG|Rezvilutamide|240mg by mouth once a day for 24 weeks.
214662753|NCT06387056|DRUG|Goserelin Microspheres for Injection|3.6mg by intramuscular injection once 4 weeks for 24 weeks.
214662754|NCT06387056|DRUG|Docetaxel|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
214662755|NCT06387056|DRUG|Pamiparib|60mg by mouth twice a day for 20 weeks.
214662756|NCT06387056|DRUG|Cisplatin|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
214662757|NCT06387056|DRUG|Tislelizumab|200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
214662758|NCT03062917|DIAGNOSTIC_TEST|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
214662759|NCT00673855|OTHER|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
214662760|NCT00673855|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
214662761|NCT04368754|OTHER|Questionnaire|Patients evaluated with different questionnaire.
214662762|NCT02197325|DEVICE|PICSO|Pressure controlled Intermittent Coronary Pressure Occlusion
214662763|NCT03285529|DEVICE|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
214662764|NCT03285529|DEVICE|VICRYL|Vicryl #1
214662765|NCT06282692|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg|Dose : 1 dose 0.5 ml containing 5 µg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
214662766|NCT02870673|DRUG|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
214662767|NCT02870673|DRUG|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
214662768|NCT02870673|DEVICE|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
214662769|NCT02870673|DEVICE|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
214662770|NCT03325309|OTHER|Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
214662771|NCT02372162|OTHER|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
214662772|NCT02372162|OTHER|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
214662773|NCT04689308|DRUG|MH048|Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
214662774|NCT02132221|BEHAVIORAL|Cognitive Behavioral Therapy|10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
214662775|NCT05738863|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.~rTMS application Magventure MagPro R30 device is planned to provide magnetic stimulation with its stimulator. The stimulation pattern was shaped according to the protocols used in previous studies.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
214662776|NCT05738863|DEVICE|Sham rTMS Protocol|"It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
214662777|NCT03893292|PROCEDURE|Total knee replacement|Patients will undergo total knee replacement surgery.
214662778|NCT03893292|DEVICE|COOLIEF|The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
214662779|NCT04775823|PROCEDURE|Hybrid composite nano-ceramic|Indirect bonding the hybrid composite nano-ceramic restoration to the tooth to be restored of worn dentition patients
214662780|NCT05928143|PROCEDURE|Traditional corticotomy|A flap covering the alveolar process will be elevated. Perforations will be done using surgical burs, and then the flap will be returned, and sutures will be performed.
214662781|NCT05928143|PROCEDURE|Flapless corticotomy|Some incisions will be made in the mucosa of the alveolar process. Then these incisions will allow the working head of the piezotome to cut the bone in grooves. The whole procedure will not require flap elevation and replacement.
214662782|NCT06380140|PROCEDURE|Open Tension-free Inguinal Hernia Repair|A blood sample is taken the day after surgery
214662783|NCT04036084|DIAGNOSTIC_TEST|Cerebral Magnetic resonance imaging (MRI)|Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
214662784|NCT03540823|BIOLOGICAL|Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)|Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
214662785|NCT01836315|OTHER|Observational Study|
215033574|NCT02800733|DIETARY_SUPPLEMENT|Saffron|20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.
215033575|NCT02800733|DIETARY_SUPPLEMENT|placebo|20 patients with mild to moderate GAD who receive sertraline will receive placebo too
214662786|NCT00469079|DRUG|Nicotine gum and lozenge|Nicotine replacement
214662787|NCT00469079|OTHER|Taboka|smokeless tobacco product
214662788|NCT00469079|OTHER|Camel Snus|smokeless tobacco product
214662789|NCT03028493|BEHAVIORAL|Original SAFE Intervention|A CDC recommended, evidence-based falls prevention intervention.
214662790|NCT03028493|BEHAVIORAL|Adapted SAFE Intervention|An adapted version of the SAFE intervention meant to target older adults with low vision.
214662791|NCT00942162|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
214662792|NCT03941444|DRUG|ANAVEX2-73|Liquid oral solution
214662793|NCT03941444|DRUG|Placebo|Liquid oral solution
214662794|NCT06214728|PROCEDURE|Hyaluronic acid gel application|HA gel was applied to the periodontal pockets where the intraosseous defect was located using a sterile injector with a plastic needle. The gel was applied until it overflowed from the gingival sulcus. Patients were instructed not to eat, drink or brush their teeth for at least one hour. Subgingival application of HA was repeated 4 weeks after the first session.
214662795|NCT06214728|PROCEDURE|Placebo gel application|The control group received placebo HA gel probe without rinsing. Placebo application was repeated 4 weeks after the first session.
214662796|NCT05581043|DIETARY_SUPPLEMENT|3-hydroxybutyrate (3-OHB)|The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
214849603|NCT03898531|PROCEDURE|Primary implanted hip prosthesis|"Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis."
215033576|NCT01182350|DRUG|Bevacizumab|
215033577|NCT01182350|DRUG|Erlotinib|
215033578|NCT01182350|DRUG|Temozolomide|
214662797|NCT03739970|DIETARY_SUPPLEMENT|Investigational Product (Silk Peptide)|"* Ingredient: Silk Peptide~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 9g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
214662798|NCT03739970|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Microcrystalline Cellulose~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 0g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
214662799|NCT00203567|DRUG|carbamazepine ER|Active study drug, no comparator
214662800|NCT04057443|OTHER|Nutritional support|Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.
214662801|NCT04057443|OTHER|Physical exercise|The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.
214662802|NCT04057443|DRUG|Hematologic Drug|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
214662803|NCT04087499|DEVICE|Acupuncture|acupuncture treatment on selected acupoint
214662804|NCT06453694|DRUG|Efgartigimod Alfa|"2,016 mg will be administered subcutaneously by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
214662805|NCT06453694|DRUG|Placebo|"Subcutaneous injection of placebo will be administered by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
214662806|NCT02833311|BEHAVIORAL|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
214662807|NCT02833311|BEHAVIORAL|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
214662808|NCT02833311|BEHAVIORAL|Contact Control Group|Participants are prescribed an exercise program and given information on healthy eating.
214662809|NCT01670201|DEVICE|Mepilex Transfer Ag|Silver dressing
214662810|NCT00775164|DRUG|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
214662811|NCT00775164|DRUG|Metformin|Metformin XR; 1000 mg once daily
214662812|NCT04619407|DIAGNOSTIC_TEST|Nasopharyngeal swab|SARS-CoV-2 PCR
214662813|NCT04619407|DIAGNOSTIC_TEST|Serum testing|Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
214662814|NCT04209738|OTHER|This is an observational study being conducted as a substudy of another trial.|This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.
214662815|NCT03560362|DRUG|Bupivacaine liposome|
214662816|NCT03560362|DRUG|Bupivacaine / Epinephrine|
214662817|NCT06476080|PROCEDURE|ultrasound guided erector spine block|Ultrasound guided thoracic erector spinae block
214662818|NCT06476080|PROCEDURE|Serratus anterior block|Ultrasound guided serratus anterior block
214662819|NCT02655861|OTHER|Observation|
214662820|NCT01319955|BIOLOGICAL|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
214662821|NCT02486068|DEVICE|ABSORB scaffold|
214662822|NCT02486068|DEVICE|Xience|
214662823|NCT03560440|OTHER|Plasma exposure vancomycin|Investigation of plasma exposure of vancomycin.
214662824|NCT00388089|DRUG|bortezomib|Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
214849604|NCT03898531|PROCEDURE|hip prosthesis removed metal/metal|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation"
215033579|NCT01182350|RADIATION|Radiation|
214662825|NCT00388089|DRUG|topotecan hydrochloride|Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
214662826|NCT00388089|OTHER|flow cytometry|No description
214662827|NCT00388089|OTHER|immunoenzyme technique|No description
214662828|NCT00388089|OTHER|immunohistochemistry staining method|No description
214662829|NCT00388089|OTHER|laboratory biomarker analysis|No description
214662830|NCT05794529|OTHER|There are no interventions in the present study|There are no interventions in the present study
214662831|NCT01587963|DRUG|Ascorbic Acid|66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
214662832|NCT01587963|OTHER|Ringers Lactate or Normal Saline|Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
214662833|NCT04101890|DRUG|Diaper care with Theraworx|Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
214662834|NCT00679107|DEVICE|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
214662835|NCT02189382|DEVICE|Potassium Oxalate|
214662836|NCT02189382|OTHER|Water|
214662837|NCT01175928|DEVICE|Sham device|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
214662838|NCT01175928|DEVICE|NormaTec PCD (Peristaltic Pulse PCD)|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
214662839|NCT00583401|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
214662840|NCT03868722|DRUG|Acalabrutinib|Acalabrutinib 100 mg BID from cycle 1 day 1 for 3 cycles of 28 days.
214662841|NCT03868722|DRUG|Venetoclax|Venetoclax, ramp up during the first five weeks starting cycle 1 day 1, 7 days treatment on each dose level (20-50-100-200-400 mg), thereafter 400 mg once daily for a total of 3 cycles of 28 days.
214662842|NCT04807491|OTHER|Kabat Technique's|"As with all cranial nerves, some specific techniques can also be applied on the facial nerve to enhance responses and improve recovery; the most important are: The rhythmic start: shows and guides the subject into the movements and the scheme; agonist investigation utilizes sequential concentric and eccentric contractions; The inversion of the antagonist: reinforces responses through the induction phenomenon; Repeated contractions: calls for a response with repeated stretching that briefly enables movement; Isometric contractions: for stabilizing and reinforcing the response.~Conventional therapy exercises"
214662843|NCT04807491|OTHER|Neuromuscular Re-Education|"After the baseline assessment, the participant in the control will receive Neuromuscular Re-Education. The duration of session will be 45 minutes.Neuromuscular Re-Education: For initiation (acute phase): Active-assisted exercise,Massage and stretch for affected side.For Facilitation ,Active-assisted exercise.For Movement control:Massage and stretching for facial retraction,Assisted and active exercises on involved side.~For Relaxation,Thermotherapy,Relaxation exercises,Alternating rhythmic movements.~Conventional therapy exercises"
214662844|NCT02140125|DRUG|ASP2408|subcutaneous administration
214662845|NCT02140125|DRUG|Placebo|subcutaneous administration
214662846|NCT02812680|OTHER|Blood Draw|Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
214662847|NCT00725738|GENETIC|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
214662848|NCT03016234|DRUG|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4\~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
214662849|NCT03016234|DRUG|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
214662850|NCT02638181|PROCEDURE|trabeculectomy|
214662851|NCT00181298|DRUG|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
214662852|NCT00181298|DRUG|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
214662853|NCT04712175|DIAGNOSTIC_TEST|Nasopharyngeal sampling|Swabs will be taken of nasopharyngeal samples for RT-PCR
214662854|NCT04712175|DIAGNOSTIC_TEST|Saliva sampling|A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
214662855|NCT04556604|BEHAVIORAL|Educational meetings and visual prompts|Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
214662856|NCT01821963|DRUG|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
214662857|NCT01821963|DRUG|Ribavirin|Starting dose: 1,000 mg by mouth daily.
214662858|NCT01821963|DRUG|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
214662859|NCT03195101|PROCEDURE|transconjunctival orbitotomy approach|approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
214662860|NCT03368859|DRUG|Leucovorin|Intravenous
214662861|NCT03368859|DRUG|Fluorouracil - bolus|Intravenous
214662862|NCT03368859|DRUG|Bevacizumab|Intravenous
214662863|NCT03368859|DRUG|Fluorouracil - infusion|Intravenous
214662864|NCT03368859|DRUG|ABT-165|Intravenous
214662865|NCT03368859|DRUG|Irinotecan|Intravenous
214662866|NCT05704530|OTHER|Blood sample|Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.
214662867|NCT02698410|DRUG|Lanreotide (Autogel formulation) and Temozolomide|
214662868|NCT01713348|DEVICE|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
214662869|NCT01713348|DEVICE|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
214290243|NCT00488176|DRUG|placebo|placebo
214662870|NCT03021837|OTHER|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
214662871|NCT01896232|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
214662872|NCT01896232|DRUG|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
214662873|NCT01896232|DRUG|Oral Placebo|Administered orally once a day.
214662874|NCT01896232|DRUG|Intravenous Placebo|Administered intravenously (IV) three times per week.
214662875|NCT00834548|PROCEDURE|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
214476261|NCT06813560|DIAGNOSTIC_TEST|salivary cortisol|Three saliva samples will be collected from each subject, at 8:00, 15:00 and 23:00 hours. Before collecting the saliva they will be instructed to rinse their mouth with cold water, without brushing their teeth. They should also not eat or drink in the hour before the sample is taken. Approximately 1 ml of saliva, collected by direct expectoration into an ependymal tube, shall be obtained and the samples shall be stored for 24 hours at 4°C . Subsequently, samples shall be centrifuged at 2 500 rpm/10 min and the supernatant shall be stored at -20 °C until processing by ELISA kit as per the above protocol.
214849605|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ceramic|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation"
214849606|NCT05777382|OTHER|inquiry to postnatal mothers|structured questionnaires was asked to postnatal mothers
214849607|NCT03767062|DRUG|Topamax|An antiepileptic agent used for migraine prophylaxis.
214849608|NCT03767062|PROCEDURE|Greater Occipital Nerve Block + Supratrochlear Nerve Block|An injection to paralyze the occipital and supratrochlear nerves.
214662876|NCT02562729|PROCEDURE|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
214662877|NCT04425850|COMBINATION_PRODUCT|Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)|Topical application in the nose and oral cavity
214476262|NCT06813560|DIAGNOSTIC_TEST|salivary Oxytocin|The treatment and collection of saliva as a biological sample shall be identical to the protocol described for the determination of cortisol. The determination of oxytocin shall be carried out by the use of ELISA kit for immunoassay (Oxytocin ELISA Kit (ab133050 ABCAM)
214476263|NCT06813560|DIAGNOSTIC_TEST|Bayley-III Child Development Assessment Scales|They are a set of three standardised assessment scales, which assess the cognitive, motor and language development of children aged 1 and 42 months. For our study, we will use only the motor scale, which is composed of two subscales, the gross motor scale and the fine motor scale. This motor scale is composed of 138 items (the gross motor scale is composed of 72 items and the fine motor scale of 66 items) which assess the degree of control of the body, the coordination of large muscle masses and the manipulative ability of hands and fingers. The total administration time of the motor area for 12-month-old children, as in the case of the sample, is between 15 and 20 minutes.
214476264|NCT06813560|DIAGNOSTIC_TEST|Strange Situation|The Strange Situation is a standardised observational procedure in which the child is exposed to two moments of separation from his/her attachment figure, two moments of reunion with the attachment figure and moments in which he/she interacts with an unknown person, specifically 8 episodes (lasting 3 minutes) in which the level of stress provoked in the child increases in intensity as the situation progresses. It is estimated to last around 20 minutes. It is assessed on a 7-point Likert-type scale, so that low scores indicate low frequency and intensity of the behaviour. These responses allow us to identify three types of attachment: secure attachment, insecure-avoidant attachment and insecure-ambivalent attachment. The strange situation only allows us to assess attachment in children between 1 and 2 years of age.
214476265|NCT06813560|DIAGNOSTIC_TEST|Parenting Stress Index (PSI)|It assesses the stress experienced in parenting through several subscales such as parental distress, dysfunctional parent-child interaction and whether the child is a difficult child based on how parents perceive their children's behaviour.
214476266|NCT06813560|DIAGNOSTIC_TEST|Perinatal Risk Inventory|"\- The Perinatal Risk Inventory is a measuring instrument that provides information on the neonatal situation prior to discharge and facilitates an estimate of the biological risk that the child may present from a very early age. The factors that are analysed in this inventory are evaluated with a score from 0 to 3 for each of the factors mentioned above, ranging from a minimum of 0 points to a maximum of 51. The levels of risk were determined as follows:~1. Low Neonatal Risk: 0 to 6 points.~2. Moderate Neonatal Risk: 7 to 9 points.~3. High Neonatal Risk: 10 or more points."
214476267|NCT06813560|DIAGNOSTIC_TEST|Neonatal Behavioural Assessment (NBAS)|is an assessment technique that provides a profile of scores that allows us to detect a possible alteration or pathology, but at the same time, within normal parameters, to detect both the potential or 'strong points' and the problems or 'weak points' of the newborn, as well as their peculiar ways of acting and reacting to environmental variables. Therefore, a profile of the child's behavioural characteristics is obtained, which can be considered as a first outline of the child's temperamental traits. It evaluates the behavioural repertoire of the newborn in 28 behavioural items that are assessed according to a 9-point scale. The scale also includes an assessment of neurological status in 18 reflex items, each with a 4-point rating. In the second edition of the NBAS a series of 7 supplementary items were added with the intention of better capturing the degree of fragility and the quality of behaviour of high-risk children.
214476268|NCT06813560|DIAGNOSTIC_TEST|Galvanic Response|Galvanic Response: has the function of measuring the galvanic response of the skin, also known as electrodermal activity (EDA). It is used to record the electrical behaviour of the skin, which varies according to the activity of the sweat glands. This measurement of electrodermal activity is essential for studying the activity of the autonomic nervous system, which controls involuntary body functions such as sweating and heart rate. It will be measured with the BIOPAC MP36R device.
214476269|NCT06813560|DIAGNOSTIC_TEST|electrocardiography (ECG)|"ECG is used as a monitoring target for various cardiovascular conditions. It will be measured with the BIOPAC MP36R device.~P, Q, R, S, T, U waves; QRS complex, PR interval and QT interval and PR segment and ST segment."
214476270|NCT06813560|DIAGNOSTIC_TEST|Breathing respiratory rate|The transducer is attached to a strap that is placed around the subject's chest, allowing chest movements to be detected during breathing. The strap ensures a secure and comfortable fit for the subject during the measurement process. This transducer is used in conjunction with other BIOPAC components to assess physiological responses. The data obtained from the transducer provides information on respiratory patterns and their relationship to other physiological measures. It will be measured with the BIOPAC MP36R device.
214476271|NCT06815380|OTHER|No Intervention|This is non-interventional study.
214476272|NCT06842394|OTHER|Adaptive E-learning|An adaptive e-learning program comprising 13 modules each unfolding and testing the learners knowledge and ability to assess own competence regarding specific acute and time critical medical patient conditions.
214662878|NCT01701791|OTHER|Computerized Decision Support System|
214662879|NCT03088241|OTHER|switch|switch to second-line ART
214662880|NCT00852644|PROCEDURE|computed tomography|Standard CT scans
214662881|NCT00852644|RADIATION|fludeoxyglucose F 18|standard doses with CT scans
214662882|NCT00852644|RADIATION|hypofractionated radiation therapy|4 doses over 2 weeks
214662883|NCT00852644|RADIATION|stereotactic radiosurgery|CyberKnife radiosurgery
214662884|NCT04293848|OTHER|Vibroacoustic therapy|listening to low-frequency sound of 40 Hz with biorhythmic sequential modulation combined to music
214662885|NCT04293848|OTHER|Only music (no vibrations)|listening to music, no vibrations
214662886|NCT04185467|OTHER|Intervention (rehabilitation exercise)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
214662887|NCT01086683|BEHAVIORAL|Psychosocial rehabilitation course|Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
214662888|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a high concentration liquid formulation
214662889|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a lyophilized formulation
214662890|NCT00006418|PROCEDURE|DNA collection|
214662891|NCT05976737|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
214662892|NCT05976737|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
214662893|NCT06223425|BEHAVIORAL|virtual reality Situation-Based Flipped Learning|Situation-Based Flipped Learning, and Gamification have gained attention as promising tools to engage nursing students and promote a deeper understanding of complex concepts. This study aims to investigate the effectiveness of combining these strategies in a virtual reality Situation-Based Flipped Learning environment with elements of Gamification on nursing students' learning attitudes, problem-solving abilities, and empathetic skills.
214662894|NCT01972477|DRUG|DLBS1449|Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
214662895|NCT01972477|OTHER|Placebo|Placebo will be given every day for 8 weeks.
214662896|NCT02721004|DRUG|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
214662897|NCT00686205|DEVICE|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
214662898|NCT00265941|DRUG|cetuximab|Cetuximab 400 mg/m\^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m\^2 IV weekly for 7 weeks
214662899|NCT00265941|DRUG|cisplatin|Cisplatin 100 mg/m\^2 IV on days 1 and 22
214662900|NCT00265941|RADIATION|Accelerated Fractionation by Concomitant Boost|3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks
214662901|NCT00265941|RADIATION|Intensity-modulated radiation therapy|70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
214662902|NCT03741439|DEVICE|Treatment|Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
214662903|NCT03741439|DEVICE|Sham|Sham treatment
214662904|NCT02413983|PROCEDURE|hepatectomy conventional incision|This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
214662905|NCT02413983|PROCEDURE|hepatectomy midline incision|
214662906|NCT02413983|PROCEDURE|hepatectomy transverse incision|
214662907|NCT02475460|PROCEDURE|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
214662908|NCT02475460|DEVICE|HeartMate 3™|HM 3 LIS
214662909|NCT04154553|DIAGNOSTIC_TEST|Buccal swab|Pharmacogenetic panel testing is conducted by Stratipharm with the DNA of the buccal swab. TaqMan® polymerase chain reaction is proceeded to express the genetic information. Stratipharm is a product offered by Humatrix Aktiengesellschaft (AG). It consists of a laboratory analysis of approximately 100 pharmacological relevant genetic variations (polymorphisms) in over 30 different genes, which code for transport proteins, metabolizing enzymes, or drug targets.
214662910|NCT04154553|DIAGNOSTIC_TEST|EDTA Blood sample (4.9mL)|Genetic testing of potentially relevant genetic variants using the DNA extracted from the EDTA blood sample.
214662911|NCT04154553|DIAGNOSTIC_TEST|Serum sample (7.5mL)|blood sample to determine the actual levels of the compound in patients on medication assumed to be associated to an observed ADR (phenotype).
214662912|NCT04154553|OTHER|communication of test results|Certified study pharmacist evaluates and communicates clinically relevant test results to the subject and to the responsible physician
214662913|NCT04154553|OTHER|unstructured interview|One and six months after the communication of test results, the study center will make a phone call to the patient for an unstructured interview in order to gather information about potential outcomes
214662914|NCT02373930|DRUG|DTG 50 mg|Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
214662915|NCT02373930|DRUG|RPV 25 mg|Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
214849609|NCT03321474|PROCEDURE|modified gull wing preparation|"preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
214662916|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AS|DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
214662917|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AM|DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
214662918|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AQ|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
214662919|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AK|DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
214662920|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AR|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
214662921|NCT00984789|DRUG|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
214662922|NCT00984789|DRUG|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
214662923|NCT00898053|OTHER|laboratory biomarker analysis|Correlative studies
214662924|NCT01583647|DRUG|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
214662925|NCT01583647|DRUG|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
214662926|NCT00173953|PROCEDURE|immune response|
214662927|NCT03816995|DEVICE|CleanCision Wound Retraction and Protection System|wound retraction and irrigation
214662928|NCT03816995|DEVICE|Alexis O Wound Protector|wound retraction
214662929|NCT01668082|PROCEDURE|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
214662930|NCT03691558|OTHER|Ketogenic diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). Macronutrients percentage is 68% fat, 26% protein and 6% carbohydrate Paoli et al. 2013). Very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), are used for a better compliance to the dietary intervention
214662931|NCT03691558|OTHER|Western Diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). The diet macronutrient percentage distribution is the following: protein is 25% of TDC (total daily calories), fat is 20% of TDC and carbohydrates represented the 55% of TDC
214662932|NCT01864577|OTHER|Negative Pleural Suction at -20 cm H2O|
214662933|NCT01864577|OTHER|Water seal|
214662934|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at T0|
214662935|NCT03123523|DIAGNOSTIC_TEST|Exercise test|
214662936|NCT03123523|BIOLOGICAL|Biological assays|Creatinin, hematocrit and BNP assays
214849610|NCT06260891|DRUG|25 mg/day zinc|25 mg of zinc as zinc gluconate taken orally once a day
214662937|NCT03123523|DEVICE|MRI with contrast agent injection|With injection of gadolinium
214662938|NCT03123523|DEVICE|MRI without contrast agent injection|Without injection of gadolinium
214662939|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at M24|
214662940|NCT06082778|BEHAVIORAL|Fermented food intake above habitual level|Participants increase their habitual intake of fermented foods by three portions per day, compared to their habitual intake level at baseline.
214662941|NCT03109951|DRUG|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
214662942|NCT05882890|OTHER|Craniosacral Therapy|Manual treatment, 5 grams, on the airway system, the throat, the neck, the meninges, the cranial nerve sleeves, the visceral cranium, and the soft tissue in the mouth.
214662943|NCT05882890|OTHER|Exercices Targeting Upper Posture and Respiration|Exercises targeting upper posture and breathing exercises. The exercises is given when the therapist has reached some anatomical milestones in the treatment protocol. For example, an exercise with diaphragmatic breathing is given after manual treatment of diaphragma.
214662944|NCT06488755|DRUG|SIM0718 injection|"Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks.~Duration of medication: 52 weeks"
214662945|NCT06488755|DRUG|SIM0718 injection of placebo|"Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks.~Duration of medication: 52 weeks"
214662946|NCT03187561|BEHAVIORAL|Infant sleep-adapted coparenting intervention|The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.
214662947|NCT06225050|DEVICE|CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)|PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
214662948|NCT06475807|DIETARY_SUPPLEMENT|High-fermented food|Step 1: patients will consume high-fermented food
214662949|NCT06475807|DIETARY_SUPPLEMENT|High fiber supplementation|Step 2: High fiber supplementation
214662950|NCT06373003|OTHER|Diagnostic accuracy|To assess the diagnostic accuracy of non-criteria aPL (anti-vimentin/cardiolipin and anti-phosphatidylserine/prothrombin) in identifying APS in patients with thrombosis/ recurrent adverse pregnancy outcomes
214662951|NCT02239172|BIOLOGICAL|PA83-FhCMB|
214662952|NCT03370757|OTHER|3-hour bundled care|Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.
214662953|NCT03370757|OTHER|6-hour bundled care|Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
214662954|NCT00932087|PROCEDURE|Blood sample|Blood sample for lipidomic study
214662955|NCT01770184|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|
214662956|NCT01407120|BEHAVIORAL|New Beginnings Program|A preventive intervention for divorced families.
214662957|NCT01617486|BEHAVIORAL|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
214662958|NCT05200988|DRUG|Ipilimumab + nivolumab|"Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~* Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~* Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy"
214662959|NCT01986335|BIOLOGICAL|DTP/HB/Hib Vaccine|DPT/HB/Hib vaccine (Bio Farma)
214662960|NCT04813744|PROCEDURE|Atraumatic restorative treatment|
214662961|NCT05726695|DIAGNOSTIC_TEST|microRNA test|Laboratory analysis for the detection of microRNA in blood samples.
214662962|NCT05726695|DIAGNOSTIC_TEST|Heart ultrasound examination|Heart ultrasound examination will be performed as a standard cardiology examination.
214662963|NCT00775567|DIETARY_SUPPLEMENT|Fructose powder|30g in 250ml water twice a day
214662964|NCT05015101|OTHER|Cohort observation|Cohort observation
214662965|NCT06312306|DEVICE|transcranial direct current stimulation|Anodal tDCS applied using a direct current stimulator and two saline-soaked electrodes. The anode electrodes will be positioned approximately 2 cm anterior to Cz according to the International 10/20 EEG System. The cathode will be positioned over the inion. Stimulation intensity will be at 2.0 milliampere (as suggested to achieve excitation in the lower limb motor cortex areas)
214662966|NCT06312306|OTHER|Pilates based core training|The Pilates training program will last 30 min per session, Each action in the training will be repeated eight times these actions are at beginner level, considering the characteristics of stroke patients. The selected exercises will be given to all patients and progressed week-wise.
214662967|NCT06312306|OTHER|conventional physiotherapy program|"Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs"
214662968|NCT05429814|OTHER|Menthol Application|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
214662969|NCT04008212|OTHER|Fusion imaging|Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
214662970|NCT04549987|DEVICE|Space closure without changing working archwire monthly|Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
214662971|NCT04549987|DEVICE|Space closure withchanging working archwire monthly|Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
214662972|NCT03037216|OTHER|Exercise Intervention|10 Week aerobic exercise training
214662973|NCT05321186|PROCEDURE|minimally invasive spinopelvic fixation|"Bilateral percutaneous L4 and L5 pedicle screws will be placed under fluoroscopic guidance with Jamshidi needles, and these were will also be used the iliac fixation via percutaneous S2 alar iliac screws.~Cases presenting with significant instability, minimally invasive Transforaminal lumbar interbody fusion (MIS-TLIF) will be performed. Additionally, in cases with neurological deficit, posterior decompression will be performed."
214662974|NCT02859701|DRUG|AK002|IV AK002
214662975|NCT02859701|OTHER|Placebo|
214662976|NCT00719810|DRUG|delafloxacin|300 mg intravenous every 12 hours
214849611|NCT06260891|DRUG|40 mg/day zinc|40 mg of zinc as zinc gluconate taken orally once a day
214662977|NCT00719810|DRUG|delafloxacin|450 mg intravenous every 12 hours
214662978|NCT00719810|DRUG|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
214662979|NCT01137630|DRUG|K40a|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
214662980|NCT01137630|DRUG|K40b|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
214662981|NCT01137630|DRUG|Placebo|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
214662982|NCT04581187|OTHER|Quality of life assessment|Quality of life questionnaires
214662983|NCT06132490|DEVICE|Valveless Insufflator with 12 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under low intra-abdominal pressure throughout the surgery.
214662984|NCT06132490|DEVICE|Valveless Insufflator with 8 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under ultra-low intra-abdominal pressure throughout the surgery.
214849612|NCT00504478|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 supplement will be given in addition to high complex carbohydrate diet.
214476273|NCT06842329|BEHAVIORAL|Halfer Skin Tape Technique|Helfer Skin Tap Technique (HSTT) is a non-pharmacological pain management method that involves a series of gentle taps on the skin prior to an intramuscular injection. This technique is intended to distract the patient from the pain of the injection and reduce perceived pain intensity by stimulating different sensory pathways.
214662985|NCT02599389|DEVICE|Drug-coated balloons|
214662986|NCT02599389|DEVICE|Excimer Laser|
214662987|NCT04066621|DRUG|Ceftriaxone Sodium and Sulbactam Sodium for Injection|daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days
214662988|NCT02061995|DRUG|PREOB® Intravenous Infusion|Each patient will undergo a single intravenous administration of PREOB®.
214662989|NCT05948878|DEVICE|Novel Taping Method|Subjects will be asked to have the novel taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
214662990|NCT05948878|DEVICE|BCH Emergency Department Taping Method|Subjects will be asked to have the BCH emergency department taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
214662991|NCT05948878|DEVICE|Chevron Taping Method|Subjects will be asked to have the Chevron taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
214662992|NCT00085969|DRUG|Placebo 0.04 mL twice daily|Subcutaneously injected, 0.04 mL, twice daily
214662993|NCT00085969|DRUG|Placebo 0.04 mL once daily|Subcutaneously injected, 0.04 mL, once daily
214662994|NCT00085969|DRUG|Placebo 0.08 mL once daily|Subcutaneously injected, 0.08 mL, once daily
214662995|NCT00085969|DRUG|B - Exenatide 10 mcg twice daily|Subcutaneously injected, 10 mcg (0.04 mL), twice daily
214662996|NCT00085969|DRUG|C - Exenatide 10 mcg once daily|Subcutaneously injected, 10 mcg (0.04 mL), once daily
214662997|NCT00085969|DRUG|Exenatide 20 mcg once daily|Subcutaneously injected, 20 mcg (0.08 mL), once daily
214662998|NCT02221076|DEVICE|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
214662999|NCT03090191|BIOLOGICAL|Clostridium difficile vaccine|Toxoid-based Clostridium difficile vaccine
214663000|NCT03090191|BIOLOGICAL|Placebo|Normal saline solution (0.9% sodium chloride)
214663001|NCT06340594|PROCEDURE|Laproscopic cholecystectomy (LC)|Removal of gallbladder via laparoscopy
214663002|NCT06340594|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Removal of bile duct stones via endoscopy
214663003|NCT03450772|DRUG|Creon® 25000|Experimental drug
214663004|NCT03450772|DRUG|Creon® 10000|Active comparator
214663005|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method A|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
214663006|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method B|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
214663007|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method C|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
214663008|NCT04930250|OTHER|Placebo Comparator: Minimally-processed oat bran (Positive Control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
214663009|NCT04930250|OTHER|Placebo Comparator: Readily-digestible carbohydrate (negative control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
214663010|NCT05128617|DRUG|Epirubicin-cyclophosphamide|1 cycle of Epirubicin-cyclophosphamide
214663011|NCT05128617|DRUG|Paclitaxel|1 cycle of Paclitaxel
214476274|NCT06842329|BEHAVIORAL|ShotBlocker Technique|ShotBlocker is a non-pharmacological device that applies pressure to the skin at the injection site to disrupt pain signals and reduce the pain perception during intramuscular injections. The pressure stimulates the sensory nerve fibers, which helps block the sharp pain from the needle insertion.
214663012|NCT04463394|DRUG|Vasopressin|Vasopressin administered intravenously
214663013|NCT04062955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary counseling
214663014|NCT04062955|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
214663015|NCT04062955|OTHER|Questionnaire Administration|Ancillary studies
214663016|NCT03068962|OTHER|beetroot Juice|Beetroot Juice
214663017|NCT03068962|OTHER|Buxton water|natural mineral water
214663018|NCT03068962|OTHER|antiseptic mouthwash then beetroot juice|Chlorhexidine glocunate
214663019|NCT02466256|PROCEDURE|Intraocular lens implantation|Intraocular lens implantation
214663020|NCT02466256|DEVICE|Autosert Injector|Motorised injection device for intraocular lens implantation
214663021|NCT02466256|DEVICE|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
214663022|NCT02466256|DEVICE|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
214663023|NCT04503980|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
214663024|NCT00502060|DRUG|AZD2171|
214663025|NCT00502060|DRUG|ZD1839|
214849613|NCT00504478|OTHER|high complex carbohydrate diet|
214849614|NCT06283121|BIOLOGICAL|BioTTT001 intraperitoneal infusion|Monotherapy lead-in phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3; Combination therapy phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3, 3 weeks per cycle
214849615|NCT06283121|DRUG|SOX regimen|Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle
214849616|NCT06283121|DRUG|toripalimab|Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
214663026|NCT01335646|PROCEDURE|Lumbar Microdiscectomy|lumbar discectomy within 1 month of randomization
214849617|NCT01337726|BEHAVIORAL|Combined Psychotherapy and Illness Management|Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
214663027|NCT01335646|OTHER|Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories|Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
214663028|NCT02195115|PROCEDURE|Laparoscopic Cholecystectomy|
214663029|NCT02195115|DRUG|amitriptyline|
214663030|NCT02195115|OTHER|low-fat and low cholesterol diet|
214663031|NCT05489068|BEHAVIORAL|Motivational Interviewing at Intake (MII)|The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.
214663032|NCT05489068|BEHAVIORAL|Intake as Usual (IAU)|In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.
214663033|NCT01146470|DIETARY_SUPPLEMENT|RGC|dosage of Red Grape Cells once a day, during 3 months
214663034|NCT01146470|DIETARY_SUPPLEMENT|Placebo|dosage of Placebo once a day, during 3 months
214663035|NCT03751202|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg|2 inhalations of Test and Reference product in each study period
214663036|NCT03751202|DRUG|ADVAIR DISKUS|2 inhalations of Test and Reference product in each study period
214663037|NCT04272307|BIOLOGICAL|Blood samples|"At inclusion, at day 5, day 42 and at 3 months, one 2 ml EDTA blood tube will be collected for metabolomics.~Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method.~At inclusion, one 2 ml EDTA tube will be stored as a DNA collection."
214663038|NCT04272307|PROCEDURE|Stool samples|"One stool sample will be taken at baseline, day 5, day 42 and at 3 months and frozen at -80°C and divided in 2 aliquots.~One stool aliquot will be used for metabolomics. Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method. The other one will be used for microbiota analysis. Samples will be sent to the McGill University (Prof. SALEH's lab) for extraction and then, Génome Québec Innovation Centre (McGill University, Montréal, Canada) for sequencing of the V4 region of the 16S rRNA gene on Illumina MiSeq in paired-end mode."
214663039|NCT04272307|PROCEDURE|Colorectal biopsies|During routine flexible sigmoidoscopy, 6 biopsies will be collected with a 5 mm biopsy forceps at baseline and at 3 months. Biopsies will be placed into a sterile vial containing RNAlater (Qiagen, Hilden, Germany) and stored at -80°C. Two biopsies will be used for mucosal microbiome analysis in the same way as the stool sample. Four biopsies will be used for RNAseq. Samples will be shipped to Prof. SALEH's lab in Montréal for nucleic acid extraction. The McGill University and Génome Québec Innovation Centre (McGill University, Montréal, Canada) will provide library preparation and next generation sequencing. The average number of uniquely mapped reads per sequencing run will be 30 million reads per sample.
214663040|NCT02432807|DRUG|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
214663041|NCT02432807|DRUG|Placebo|Placebo
214663042|NCT01045954|DRUG|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
214663043|NCT05381961|DEVICE|Bioimpedance spectroscopy (BIS) measurement, SOZO device|All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.
214663044|NCT00960271|PROCEDURE|EBUS|a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
214663045|NCT02353949|DRUG|Flutemetamol (Vizamyl)|PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
214663046|NCT06056973|DRUG|jinghua weikang capsule|Oral Jinghua Weikang Capsule, two capsules each time, three times a day
214663047|NCT02997930|BEHAVIORAL|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
214663048|NCT02997930|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
214663049|NCT02997930|BEHAVIORAL|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
214663050|NCT02997930|BEHAVIORAL|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
214663051|NCT02997930|BEHAVIORAL|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
214849618|NCT01337726|BEHAVIORAL|Illness Management Only|Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
214663052|NCT02997930|BEHAVIORAL|General Depression Scale (GDS)|A measure of the of presence of depression.
214663053|NCT01441544|BEHAVIORAL|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
214849619|NCT02240186|DEVICE|Microprocessor Knee (MPK)|MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
214663054|NCT04345549|OTHER|Individualised Ayurveda|Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing
214849620|NCT02240186|DEVICE|Non-Microprocessor Knee (NMPK)|A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
214849621|NCT05606952|DEVICE|Color Doppler|color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter
214849622|NCT00272649|BIOLOGICAL|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
214849623|NCT04533906|DEVICE|Coldamaris lozenges|sucking carageenan containing lozenge
214849624|NCT04414033|DEVICE|Bubble: A New VR-AI Way of Treatment for Hot Flashes|Bubble Bubble is a virtual reality (VR) mobile application. Bubble offers a psychological intervention based upon cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) protocols. The bubble mobile application offers the intervention in a virtual reality (VR) coaching environment and in a winter wonderland setting called Frosty. Frosty provides both a virtual reality winter wonderland experience as well as guided meditation. The cold, winter-like experience is designed to help patients calm down and feel cooler.
214476275|NCT06842329|OTHER|Standard Intramusculer injection|The control group will receive a standard intramuscular injection without the use of any pain management techniques (such as HSTT or ShotBlocker). This group serves as a baseline to compare the effect
214663055|NCT03530540|DEVICE|low-intensity extracorporeal shockwave therapy|Active shockwaves
214663056|NCT03530540|DEVICE|Placebo LI-ESWT|Placebo shockwaves
214663057|NCT03530540|DEVICE|Penile pump|both groups will be treated with a penile pump
214663058|NCT03042949|DEVICE|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
214663059|NCT03042949|DEVICE|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
214663060|NCT02864303|OTHER|Saliva samples|saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides
214663061|NCT06378710|PROCEDURE|Optimized PEEP|Optimized PEEP
214849625|NCT00001554|DEVICE|intraoperative infrared (IR) neuroimaging|
214849626|NCT03695809|BIOLOGICAL|G9a protein|To assess G9a protein expression on vulvar cancer
214849627|NCT05424731|COMBINATION_PRODUCT|DBV712 250 mcg|Daily epicutaneous delivery.
214849628|NCT06461377|DRUG|Glucagon-like peptide-1 receptor agonist：Semaglutide|The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention
214849629|NCT00672776|DRUG|paroxetine|
214849630|NCT00672776|DRUG|placebo|
214849631|NCT04897191|OTHER|Age|Determination of age-dependence
214849632|NCT05445531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Functional and morphologic imaging of the lungs
214849633|NCT05445531|DIAGNOSTIC_TEST|Nailfold capillaroscopy|Imaging of nailfold microvasculature
214849634|NCT05445531|DIAGNOSTIC_TEST|Spiroergometry|Cardiopulmonary exercise testing
214849635|NCT05445531|DIAGNOSTIC_TEST|Realtime deformability cytometry|High-throughput measurement of cell deformability and physical properties
214849636|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
214849637|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
214849638|NCT05857462|PROCEDURE|Post-admission FICB|Post-admission supra-inguinal FICB in hip fracture patient with 0.33% bupivacaine 30 ml
214849639|NCT01877460|OTHER|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
214476276|NCT06815549|DRUG|Fluorothiazinone, tablets 300 mg|patients will receive Fluorothiazinone, tablets 300 mg at a dose 1200 mg/day (2 tablets twice a day) for 14 days
214476277|NCT06815549|DRUG|Nitrofurantoin 100 MG|Comparison arm patients will receive Nitrofurantoin in accordance with the instructions for medical use.
214476278|NCT06841848|DIAGNOSTIC_TEST|Fundoscopic Exam|visualization of the retina using an ophthalmoscope
214476279|NCT06815679|DRUG|salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)|To evaluate the patient's respiratory effort, the pressure-time product (PTPes) and the delta of Pes oscillations during inspiration (∆ Pes) will be obtained from the analysis of the Pes curve. Global and regional pulmonary tidal volumes will be evaluated with Electrical Impedance Tomography
214476280|NCT06814379|BEHAVIORAL|Rehabilitation|"30-60 minutes. A total of 3 session/week at home. 4 weeks.~* Warm-up.~* Aerobic: walking (20-25 minutes).~* Strength: (25-30 minutes).~* Cooling.~* Education: WHO recommendations."
214476281|NCT06814379|BEHAVIORAL|Virtual reality based rehabilitation|"30-60 minutes. A total of 3 session/week (2 sessions at home and 1 session at the University of Granada). 4 weeks.~The 2 sessions at home will be the same as the sessions in the rehabilitation group (group 2).~The session at the University of Granada will be done with virtual reality (Nintendo Switch) and will follow the same outline as the rest of the sessions:~* Warm-up.~* Aerobic: walking (20-25 minutes).~* Strength: (25-30 minutes).~* Cooling.~* Education: WHO recommendations."
214476282|NCT06809998|DRUG|Corticosteroid Injection - 80mg methylprednisolone (total volume 2ml) with 6 mL of 1% Bupivacaine without epinephrine (Total Volume 8 mL).|Corticosteroid Injection - 80mg methylprednisolone (total volume 2ml) with 6 mL of 1% Bupivacaine without epinephrine (Total Volume 8 mL).
214476283|NCT06809998|OTHER|Band-Aid|Band-Aid
214476284|NCT06812962|OTHER|Online quiz competition|The intervention and control students participated in an online quiz game on tobacco and healthy eating topics, respectively. Each day, students could answer a maximum of 5 questions randomly selected from the respective pool of questions by the platform. The students logged onto the online platform and played the quiz competition on weekdays for 4 weeks (i.e. total of 20 days).
214476285|NCT06842290|PROCEDURE|Botulinum toxin-A injection|Botulinum toxin-A Injection Mentalis muscle in lower anterior teeth
214476286|NCT06842290|PROCEDURE|Coronally advanced flap|Coronally Advanced Flap andDe-epithelized Free Gingival Graft
214476287|NCT06812728|DRUG|mFOLFIRINOX|Neoadjuvant chemotherapy
214476288|NCT06812728|DRUG|mFolfox6|Neoadjuvant chemotherapy
214476289|NCT06811025|DRUG|Contezolid|Contezolid 800mg once daily (QD) for 7 days;
214476290|NCT06811025|DRUG|Linezolid (LZD)|Linezolid 600mg once daily (QD) for 7 days.
214663062|NCT03780517|DRUG|BOS172738|Oral capsules
214663063|NCT03976401|DRUG|EFX|Administered by subcutaneous injection
214663064|NCT03976401|DRUG|Placebo|Administered by subcutaneous injection
214663065|NCT01845025|DRUG|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
214663066|NCT01845025|DRUG|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
214663067|NCT01845025|DRUG|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
214663068|NCT01845025|DRUG|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
214663069|NCT01845025|DRUG|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
214663070|NCT00089128|DRUG|gemcitabine hydrochloride|
214663071|NCT00089128|DRUG|irinotecan hydrochloride|
214663072|NCT06170658|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, silicone hydrogel investigational lenses for one week
214663073|NCT06170658|DEVICE|Control Lenses (omafilcon A)|Daily disposable, hydrogel commercially available lenses for one week
214663074|NCT06240598|PROCEDURE|Second Look Laparoscopy|Second Look Laparoscopy (SLL)
214663075|NCT06408844|BEHAVIORAL|Physical activity behavior change program implemented with 5A model|"According to the 5A model, the personal action plan includes the following items:~1. List specific goals by behavioral period~2. List obstacles and strategies to address them~3. Determine follow-up plan~4. Sharing the plan with the child and family In accordance with this plan, it is aimed to increase physical activity behavior in the classroom and during online meetings for 8 weeks. Additionally, after the training, motivational reminders will be held at regular intervals until the 28th week."
214663076|NCT04518384|PROCEDURE|colon or rectum resection|surgical procedure to resect the colon or rectum
214663077|NCT01283256|DRUG|zonisamide|zonisamide 100mg tablets
214663078|NCT01324830|DRUG|day 1 to day 5|low to high dose
214663079|NCT01324830|DRUG|day 1 to day 14|low to high dose
214663080|NCT03467620|DRUG|Cannabidiol|Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
214663081|NCT03467620|DRUG|Placebo oral capsule|Administration of one oral placebo capsule daily for a duration of 12 weeks
214849640|NCT03322020|RADIATION|Cyberknife boost 18 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx
214849641|NCT03322020|RADIATION|Cyberknife boost 21 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
214849642|NCT00338130|DRUG|AZD6244|Oral liquid or Capsule
214476291|NCT06811701|PROCEDURE|Scalp nerve block|Patient in this group will receive a scalp nerve block using bupivacaine before skull pin fixation to manage to pain.
214476292|NCT06811701|DRUG|Opioid Anesthetics|Patient in this group will receive IV opioid for pain management before skull pin fixation
214476293|NCT06811701|PROCEDURE|Local Anesthetic Injection|"Patients in this group will receive a local anesthetic (such as lidocaine) injection at the pin site before skull pin fixation."
214476294|NCT06811688|OTHER|Two mobile applications: Brushout and Brush teeth reminder applications|These applications were adjusted to send notifications twice daily in the morning and night as reminders to practice oral hygiene.
214476295|NCT06813209|DEVICE|tDCS|For true tDCS, the technique will be performed with the anode over the right dorsolateral prefrontal cortex and the cathode over the left dorsolateral prefrontal cortex, positioned at F4 and F3, respectively, according to the International 10/20 Electrode Placement System. The current intensity will be set to 2 milliamperes (mA) for 20 minutes over five consecutive days.
214476296|NCT06813209|DEVICE|tVNS|For true tVNS stimulation, the technique will be performed with the electrodes positioned on the upper concha of the left ear, using gel for better current distribution.
214476297|NCT06813768|DEVICE|Microfractured adipose tissue injection and plug placement|surgery + infiltration of micro-fractured autologous adipose tissue at the level of the internal orifice and placement of a biological prosthesis
214476298|NCT06813625|BEHAVIORAL|Shared book reading intervention|The intervention involved us pairing each teen DS with a college student to form a duo. Each group consists of one person with DS and at least one college student who will work together throughout the shared reading intervention. A weekly event hosted by a graduate student. It begins with ice-breaking activities such as color and music games to promote social interaction between participants. After the game, participants chose from a selection of 20 books suitable for different age groups. They can choose their own reading method, such as reading aloud or assigning roles, and are encouraged to share experiences in their own duos or in a large group of multiple duos. The session ends with a sharing and reflection activity where participants can discuss what they have read and plan for the next session.
214476299|NCT06814223|DRUG|• Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA|"Patients with an elevated risk of infection will be randomly assigned to two groups using stratification for new catheter placement versus catheter replacement. Fifty percent of the high-risk patients will receive prophylactic antibiotics targeting gram-positive and gram-negative bacteria. The antibiotic regimen will include:~* Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously.~* Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA colonization will receive vancomycin (2 grams)."
214476300|NCT06814808|OTHER|Conventional Therapy|All three groups will receive a conventional physiotherapy program (TENS, therapeutic ultrasound, hot pack) 5 times a week for 4 weeks and the same exercise program 3 days a week for 4 weeks.
214476301|NCT06814808|OTHER|Ischemic Compression Group|The ischemic compression group will receive ischemic compression therapy for the upper trapezius, levator scapulae, splenius capitis, and lower trapezius muscles.
214476302|NCT06814808|OTHER|Strain-Counter Strain|The strain counterstrain technique will be applied to the upper trapezius, levator scapulae, splenius capitis, and lower trapezius muscles.
214476303|NCT06814808|OTHER|Integrated Neuromuscular Inhibition Technique (INIT)|This group will be subjected to INIT for the upper trapezius, levator scapulae, splenius capitis, and lower trapezius muscles, 3 sessions per week for 4 weeks (12 sessions in total).
214849643|NCT00338130|DRUG|Temozolomide|oral
214663082|NCT00942409|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
214663083|NCT01240070|OTHER|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
214663084|NCT03617926|DEVICE|X92001666|the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
214663085|NCT03617926|OTHER|RID shampoo|Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
214663086|NCT03550248|BEHAVIORAL|Healthy Together|The Healthy Together (HT) program is designed to reduce overweight and obesity among children and youth in priority populations such as Indigenous, immigrant and refugee, and low income families.The HT program consists of 30 sessions, each of which includes cooking and eating together, physical activity and a learning activity covering topics that promote healthy weights. The HT program is delivered by trained facilitators who are provided with a program manual and resources. Trained facilitators in participating community organizations offer the HT program by integrating it within core programming.
214663087|NCT03339141|PROCEDURE|Intubation position|The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
214663088|NCT00817414|DRUG|LCI699-matching placebo|LCI699-matching placebo oral capsules
214663089|NCT00817414|DRUG|LCI699|LCI699 oral capsules
214663090|NCT06075056|OTHER|No Intervention|No intervention is planned as part of this study, this is a feasibility/pilot study
214663091|NCT04940923|DIAGNOSTIC_TEST|MRI|"T2 weighted and DTI MRI images of brachial plexus and wrist. Quantitative sensory tests include warm and cold detection and pain thresholds, paradoxical heat sensation, mechanical detection thresholds, mechanical pain sensation and thresholds, wind up ratios, vibration thresholds and pressure pain thresholds.~Clinical tests include standard neurological tests and test for heightened nerve mechanosensitivity.~Blood serum to analyse inflammatory proteins. Questionnaires include neck disability index, painDETECT, PTSD8, pain catastrophising scale, eq-5D-5L, DASS 42 and global perceived recovery"
214663092|NCT06022770|DIETARY_SUPPLEMENT|Nutritional counseling，Enteral Nutrition|patients with esophageal cancer and gastric cancer undergoing chemotherapy were selected as the study objects for nutritional risk screening, malnutrition assessment and quality of life assessment. Randomly enter the nutrition consultation group (NC) and nutrition support treatment group (NST)
214663093|NCT02966314|DRUG|Omalizumab|Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
214663094|NCT02966314|DRUG|Placebos|Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
214663095|NCT00054470|BIOLOGICAL|trastuzumab|
214663096|NCT00054470|DRUG|tipifarnib|
214663097|NCT05078814|OTHER|Observational research|Observational research
214663098|NCT00838487|OTHER|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
214663099|NCT00838487|OTHER|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
214663100|NCT00222105|DRUG|Doxil|Doxil 40 mg/m2 IV day 1
214663101|NCT00222105|DRUG|Thalidomide|50-100 mg day 1-28
214663102|NCT00222105|DRUG|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
214663103|NCT04724889|DIAGNOSTIC_TEST|blood test|Blood test to check high sensitivity troponin. Additional blood biomarkers maybe added in light of new research
214663104|NCT00204087|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
214663105|NCT00204087|BEHAVIORAL|Supportive Counselling (SC)|
214663106|NCT01172067|DEVICE|Cardiac Resynchronization Therapy|Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.
214663107|NCT01172067|DEVICE|Optimization using echocardiography|Optimization of the AV/PV and VV delays using echocardiography
214663108|NCT01152099|OTHER|Compression Bandaging|"Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
214663109|NCT01152099|OTHER|Manual Lymph Drainage (MLD) and Compression Bandaging|"Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
214663110|NCT00597649|DRUG|Bicifadine|SR dosage form of 400 mg bid or tid for one year
214663111|NCT04698928|DEVICE|Theta burst stimulation|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
214663112|NCT02473406|DRUG|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
214663113|NCT02473406|DRUG|normal saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
214663114|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
214663115|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
214663116|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
214663117|NCT04273724|OTHER|Targeted Interventions for Impairments Identified During Geriatric Assessment|Participants will be referred for specific evidence-based interventions based on impairments identified during a baseline comprehensive geriatric assessment.
214663118|NCT02469129|DRUG|[18F]FluorThanatrace|"For the Dosimetry Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection."
214663119|NCT05638321|DEVICE|MIMS|sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.
214663120|NCT03591887|BIOLOGICAL|ABY-035|ABY-035 solution for injection
214663121|NCT03591887|BIOLOGICAL|Placebo|Placebo to ABY-035 solution for injection
214663122|NCT03348514|DRUG|CPX-POM - 30 mg/m^2|CPX-POM
214663123|NCT03348514|DRUG|CPX-POM - 60 mg/m^2|CPX-POM
214663124|NCT03348514|DRUG|CPX-POM - 120 mg/m^2|CPX-POM
214663125|NCT03348514|DRUG|CPX-POM - 240 mg/m^2|CPX-POM
214663126|NCT03348514|DRUG|CPX-POM - 360 mg/m^2|CPX-POM
214663127|NCT03348514|DRUG|CPX-POM - 600 mg/m^2|CPX-POM
214663128|NCT03348514|DRUG|CPX-POM - 900 mg/m^2|CPX-POM
214663129|NCT03348514|DRUG|CPX-POM - 1200 mg/m^2|CPX-POM
214663130|NCT03502746|DRUG|Nivolumab|Nivolumab 240mg, IV over 30 minutes.
214663131|NCT03502746|DRUG|Ramucirumab|8mg/kg, IV over 60 minutes.
214663132|NCT01400646|DRUG|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
214663133|NCT01400646|DRUG|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
214663134|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
214663135|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
214663136|NCT01400646|DRUG|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
214663137|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
214663138|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
214849644|NCT06443255|DRUG|Cociane hydrochloride 4%|2 mL of 4% cocaine
214849645|NCT06443255|DRUG|Lidocaine 4%|1.5 mL of 4% lidocaine
214849646|NCT06443255|DRUG|Xylometazoline 0.1%|0.5 mL of xylometazoline 0.1%
214849647|NCT06443255|DRUG|Saline 0.9%|2 mL of saline 0.9%
214663139|NCT03147027|PROCEDURE|VT ablation|Substrate mapping for VT will be performed with the CARTO electroanatomical system.
214663140|NCT03147027|OTHER|medication|medication to prevent sustained VT and ICD therapies
214663141|NCT03232307|DRUG|Dexamethasone|Given PO
214663142|NCT03232307|DRUG|Ibrutinib|Given PO
214663143|NCT03232307|DRUG|Lenalidomide|Given PO
214663144|NCT03232307|BIOLOGICAL|Rituximab|Given IV
214663145|NCT03823664|DIAGNOSTIC_TEST|Cardiorespiratory Fitness|Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
214663146|NCT01571492|PROCEDURE|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
214663147|NCT01571492|PROCEDURE|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
214663148|NCT01088425|OTHER|Observation|"Alberta infant motor scale~Griffiths test~Kauffmann ABC"
214663149|NCT03016611|DRUG|Chewing Ticagrelor LD|180 mg Chewing Ticagrelor
214663150|NCT03016611|DRUG|Chewing Prasugrel LD|60 mg Chewing Prasugrel
214663151|NCT03116880|PROCEDURE|Endovascular aortic repair|Endovascular aortic repair
214663152|NCT00824421|DRUG|UK-453, 061|UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
214663153|NCT00824421|DRUG|UK-453, 061|UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
214663154|NCT00824421|DRUG|EFV +TVA|Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
214663155|NCT04820270|OTHER|Autologous T regulatory cells|Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation
214663156|NCT03578406|DRUG|HPV E6-specific TCR-T cells|Patients were infused with HPV E6-specific TCR-T cells
214663157|NCT01027689|DRUG|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
214663158|NCT01027689|DRUG|alprazolam test sublingual tablet|1 mg tablet, single dose
214663159|NCT03489213|OTHER|Dietary Intervention|Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
214663160|NCT03489213|BEHAVIORAL|Exercise Intervention|Participants will wear a FitBit every day and monitor daily physical activity.
214663161|NCT03489213|OTHER|Laboratory Biomarker Analysis|Correlative studies
214663162|NCT03489213|DIETARY_SUPPLEMENT|Nutritional Intervention|Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
214663163|NCT03489213|OTHER|Questionnaire Administration|Ancillary studies
214663164|NCT04407377|DRUG|Tolperisone Hydrochloride|Study Drug
214663165|NCT04407377|DRUG|Cyclobenzaprine Hydrochloride 10 MG|Active Comparator
214663166|NCT04407377|OTHER|Placebo|Placebo Comparator
214663167|NCT04046302|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
214663168|NCT04046302|DRUG|placebo|one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
214663169|NCT04871815|DRUG|sodium pyruvate nasal spray|Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
214663170|NCT03205969|DEVICE|Functional mobile game|Functional mobile game for chemotherapy side effect education
214663171|NCT02120417|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
214663172|NCT02120417|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
214663173|NCT02120417|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
214663174|NCT02448550|DRUG|Bivalirudin|
214663175|NCT02448550|DRUG|Unfractionated heparin|
214663176|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin and flaxseed|2 capsules hesperidin and 30 g flaxseed
214663177|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin|2 capsules hesperidin
214663178|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: flaxseed|30 g flaxseed
214663179|NCT03734510|OTHER|control|no supplementation
214849648|NCT04922450|DRUG|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/3weeks)
214849649|NCT04922450|DRUG|Albumin Paclitaxel|Albumin Paclitaxel(260mg/m²),every 3 weeks
214849650|NCT04922450|DRUG|Cisplatin|Cisplatin（80mg/m²）, every 3 weeks
214849651|NCT02748655|OTHER|Alkaline ionized water|
214849652|NCT02748655|OTHER|Tap water|
214663180|NCT01948752|OTHER|Nutrition information on menus|
214663181|NCT05531240|PROCEDURE|Prostate Artery Embolization|Prostate Artery Embolization (PAE) is performed by experienced interventional radiologists. The method involves catheterization of the prostate vessels superselectively with two to three French microcatheters. PAE is performed with microspheres of 250 to 400 µm in size.
214663182|NCT05531240|PROCEDURE|Transurethral Prostate Resection (TURP)|Under general/regional anesthesia, a resectoscope is inserted into the urethra that carries an electric metal loop (monopolar or bipolar diathermy) that is used to cut and extract the prostate tissue.
214663183|NCT03885297|DRUG|Saxenda|Obesity pharmacotherapy
214663184|NCT03885297|OTHER|Lifestyle modification|Tier 3 NHS weight management
214663185|NCT03885297|DIAGNOSTIC_TEST|Metabolomics|Small molecule intermediates and products of metabolism
214663186|NCT03885297|DIAGNOSTIC_TEST|miRNA|Small non-coding RNA molecules
214663187|NCT05223101|DRUG|Telminone 80 mg|Single administration of telmisartan 80 mg
214663188|NCT05223101|DRUG|Drug: Micardis 80 mg|Single administration of telmisartan 80 mg
214663189|NCT05259475|OTHER|Lifestyle Advice|Maintain a weekly healthy diet and regular exercise.
214663190|NCT05259475|OTHER|Diet Intervention|Calorie-restricted meals (lunch and dinner)
214663191|NCT05259475|OTHER|OCFA Meal-Based Diet-Intervention|OCFA-containing food product
214663192|NCT05990530|BIOLOGICAL|YD02-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
214663193|NCT01965925|DRUG|Modafinil|Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
214663194|NCT01965925|DRUG|Placebo|For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
214663195|NCT06231043|DRUG|Diclofenac/Tramadol|"Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse."
214663196|NCT05863936|DRUG|Methylprednisolone Injectable Suspension|Methylprednisolone pulse therapy, total dose from 1500mg to 3000mg.
214663197|NCT05863936|DRUG|Belimumab Injection|Belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks for 24 weeks.
214663198|NCT05863936|DRUG|Immunosuppressive Agents|"1. Mycophenolate Mofetil, oral, 1.0-1.5g per day;~2. Tacrolimus, oral, 2-4mg per day."
214663199|NCT03578705|DEVICE|"Electrical Impedance Myography unit or EIM"|
214663200|NCT01413386|DEVICE|biliary stent|palliative treatment for malignant patients
214663201|NCT05897541|DRUG|S-217622|Administered as a tablet.
214849653|NCT02241109|OTHER|no intervention|progression monitoring by echocardiography
214849654|NCT02276768|DRUG|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
214849655|NCT02276768|DRUG|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
214849656|NCT02276768|DRUG|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
214849657|NCT02276768|DRUG|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
214849658|NCT02276768|OTHER|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
214849659|NCT03367689|DRUG|Olaparib|Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
214849660|NCT00921284|DRUG|NaCl 9/00|Same volume as in the dexmedetomidine group
214849661|NCT00921284|DRUG|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
214849662|NCT02026544|DEVICE|Low Frequency Therapeutic Ultrasound|29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
214849663|NCT03259191|PROCEDURE|anti-reflux mucosectomy|Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
214849664|NCT00368563|DRUG|Helioblock SX|
214849665|NCT03321994|DEVICE|stereotaxic unit, navigation|CT-guided needle guidance using stereotaxic unit, navigation
214849666|NCT03321994|DEVICE|conventional biopsy technique|CT-guided needle guidance using conventional biopsy technique
214663202|NCT05897541|DRUG|Placebo|Administered as a tablet.
214663203|NCT00937222|DIETARY_SUPPLEMENT|Peanuts and peanut butter|Peanuts and peanut butter
214663204|NCT02604264|DEVICE|ClearGuard HD end cap|The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
214663205|NCT04765137|DRUG|Atorvastatin Oral Tablet|Atorvastatin pill 40 mg to be taken every night
214663206|NCT03648164|OTHER|CHAT-CS Survey|Students will complete a computer-based survey
214663207|NCT03097380|DRUG|AZD2115|AZD2115
214663208|NCT03097380|DRUG|SPIRIVA|Tiotropium
214663209|NCT03097380|RADIATION|[11C]AZ13754366|Radioligand
214663210|NCT02747914|DEVICE|Transcranial magnetic stimulation|TMS 1Hz under the motor zone of cortex.
214663211|NCT02747914|OTHER|Conventional exercise|Exercise will be administrated in a conventional way.
214663212|NCT02533089|OTHER|KT intervention|Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
214663213|NCT01284803|BEHAVIORAL|an educational intervention|To elaborate an educational program for the management of depression in primary care
214663214|NCT04268719|DIAGNOSTIC_TEST|wireless pH capsule recording|wireless pH capsule recording for up to 96 hours
214663215|NCT05974306|DEVICE|implantable loop recorder|Implantation of an implantable loop recorder
214663216|NCT04846114|PROCEDURE|Dental implant surgery|
214663217|NCT03589001|OTHER|Activity modification|Activity modification, exercises and gradual return to sport
214663218|NCT00109811|BIOLOGICAL|PSA:154-163(155L) peptide vaccine|Given subcutaneously
214663219|NCT00109811|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
214663220|NCT00109811|OTHER|laboratory biomarker analysis|Correlative studies
214663221|NCT02186392|DEVICE|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
214663222|NCT01402219|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
214663223|NCT01402219|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
214663224|NCT05246410|DEVICE|Spot stent system|Spot stent system designed and produced by Acotec
214849667|NCT03605524|OTHER|Sensory training|12 weeks sensory training
214849668|NCT01353248|DRUG|GS-5885|tablet, 30 mg QD
214849669|NCT01353248|DRUG|Tegobuvir|capsule, 30 mg BID
214849670|NCT01353248|DRUG|GS-9451|tablet, 200 mg QD
214849671|NCT01353248|DRUG|ribavirin tablet|(weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
214849672|NCT01353248|DRUG|GS-5885|tablet, 90 mg QD
214849673|NCT00941720|DRUG|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
214849674|NCT00941720|DRUG|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
214849675|NCT00941720|PROCEDURE|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
214849676|NCT03762746|DEVICE|Transcranial Magnetic Stimulation|A custom TMS stimulator (MagStim) is used to generate repetitive biphasic magnetic pulses. Magnetic pulses are delivered with a figure-8-coil (Magnetic Coil Transducer). During the experiment, rTMS pulse intensity is adjusted to 90% of the motor threshold. Patients will be randomly assigned to receive a 1 Hz. The target area is stimulated for 10 consecutive days. Stimulation at 1 Hz was applied once a day for 10-days
214849677|NCT03762746|DRUG|Control|The control group is receiving treatment as usual. EEG recording and psychopathological ratings are performed one day before the start and on the last day of the study
214849678|NCT01682148|BIOLOGICAL|Botulinum toxin type A|
214849679|NCT05299567|DRUG|Azithromycin|Placebo with the same color and size than azithromycin tree days a wek for 6 months
214849680|NCT05123781|DRUG|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the test product was administered orally with 240 ml of water
214849681|NCT05123781|DRUG|Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orally with 240 ml of water
214849682|NCT03466541|BEHAVIORAL|Riskbruk|The Riskbruk model incorporates alcohol screening through a widely employed alcohol screening questionnaire, the Alcohol Use Disorders Identification Test (AUDIT) and a standard alcohol biomarker, carbohydrate-deficient transferring in serum (CDT), with brief consultations using the motivational interviewing (MI) technique. MI is a collaborative conversation style used to increase awareness and reflection around one's own drinking habits, as well as strengthening the person's motivation for a lifestyle change. The conversation style includes expressing empathy through reflective listening, communicating respect and acceptance of the participants and their feelings, and open up for self-reflection and exploration around the drinking behaviour.
214849683|NCT03466541|BEHAVIORAL|Balance|Balance is a new Norwegian eHealth programme, and incorporates two approaches to behaviour modification interventions: a brief interventions and an intensive self-help programme. The intervention is based on cognitive-behavioural and self-help principles, and is given to the participants through multiple interactive sessions.
214663225|NCT05246410|DEVICE|Self-expanding peripheral stent system|Self-expanding peripheral stent system designed and produced by Ev3, Inc
214663226|NCT05716919|DRUG|Ivaltinostat|Ivaltinostat capsule
214663227|NCT05716919|OTHER|Placebo|Placebo capsule
214663228|NCT05776160|DRUG|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
214663229|NCT06555068|DRUG|HRS-6209 in Combination with Fulvestrant|HRS-6209 in Combination with Fulvestrant
214663230|NCT06555068|DRUG|HRS-6209 in Combination with HRS-1358|HRS-6209 in Combination with HRS-1358
214663231|NCT06555068|DRUG|HRS-6209 in Combination with Letrozole|HRS-6209 in Combination with Letrozole
214663232|NCT06555068|DRUG|HRS-6209 in Combination with HRS-8080|HRS-6209 in Combination with HRS-8080
214663233|NCT06555068|DRUG|HRS-6209 in Combination with HRS-1358|HRS-6209 in Combination with HRS-1358
214663234|NCT06976112|BEHAVIORAL|Pork Diet|The diet will follow the Dietary Guidelines for Americans with 80% of the meat consumption per week being pork. Other animal protein (e.g., turkey, chicken, beef) will be minimized in the dietary plans (≤ 20%) so lean and processed pork are the primary protein source consumed. Within each day, \~80% of the daily pork intake will be fresh, unprocessed lean cuts (e.g., tenderloin, loin chops, sirloin roast, flank, and rump roast) and \~20% will be cured sources (e.g., Canadian bacon, pork sausage).
214663235|NCT06976112|BEHAVIORAL|Plant Diet|The diet will be a Lacto-Ovo Vegetarian Diet following the Dietary Guidelines for Americans with no more than 21 oz per week of animal protein (e.g., eggs, cheese).
214663236|NCT04039230|DRUG|Talazoparib|Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged DNA (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in the cancer cells so that the cancer cannot fix its damaged DNA.
214663237|NCT04039230|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading.
214849684|NCT05248984|DRUG|Ketorolac|"Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg"
214849685|NCT00004079|DRUG|SarCNU|Given PO
214849686|NCT00004079|OTHER|pharmacological study|Correlative studies
214849687|NCT00004079|OTHER|laboratory biomarker analysis|Correlative studies
214849688|NCT02729779|OTHER|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
214849689|NCT02729779|OTHER|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
214849690|NCT04814784|RADIATION|Neoadjuvent radiotherapy either short or long course chemoradiation in treatment of locally advanced cancer rectum|Study the effect of neoadjuvent radiotherapy in treatment of locally advanced cancer rectum e higher possiblity of preservation of anal sphincter and decreased rate of locoregional recurrence compared to surgery alone
214849691|NCT00855075|DEVICE|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
214849692|NCT00727077|BIOLOGICAL|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
214849693|NCT00727077|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
214849694|NCT03968497|OTHER|Postoperative pain assessment with female investigator|Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
214849695|NCT03968497|OTHER|Postoperative pain assessment with male investigator|Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
214849696|NCT00746291|OTHER|6 min walk test, Step climbing|walking for 6 minute and climbing steps
214849697|NCT00980889|DEVICE|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
214849698|NCT00980889|DEVICE|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
214849699|NCT01017939|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
214849700|NCT01017939|DRUG|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
214849701|NCT01017939|DRUG|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
214849702|NCT01017939|DRUG|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
214849703|NCT00975741|DEVICE|OXIMAX|
214849704|NCT00975741|DEVICE|ASMANEX TWISTHALER|
214849705|NCT02165514|PROCEDURE|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
214849706|NCT01709812|OTHER|individualized patient support program|individualized patient support with compliance supporting tools
214849707|NCT01709812|OTHER|Standard care|
214849708|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity and stigma content|Participants viewed an interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
214849709|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with stigma content only|Participants viewed a non-interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
214849710|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity only|Participants viewed an interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
214849711|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with no interactivity and no stigma content|Participants viewed a non-interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
214849712|NCT00489164|DEVICE|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
214849713|NCT01698593|DRUG|Bupivacaine 0.5%|
214849714|NCT01698593|DRUG|Bupivacaine 0.5% + Epinephrine (1:200,000)|
214849715|NCT00775528|DRUG|Pancrelipase Delayed Release|3,000, 6,000 and 12,000 unit Lipase Capsules
214849716|NCT02377180|PROCEDURE|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
214849717|NCT02377180|PROCEDURE|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
214849718|NCT02377180|PROCEDURE|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
214849719|NCT06050876|PROCEDURE|Laparoscopic cholecystectomy for gallbladder volvulus|Laparoscopic cholecystectomy for volvulus of gallbladder
214849720|NCT05553782|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Percutaneous CT image-guided placement of the microdevice(s). At least one, and up to 3, devices will be placed in each tumor.~* Drugs will be released from the microdevice into local tumor tissues. The duration of drug release will be for a period of 3-5 days while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice harbors up to 20 drugs and/or drug combinations relevant to the treatment of salivary cancer. The drugs used will include some standard agents approved by the Food and Drug Administration (FDA) for treatment of different types of cancers, or drugs classes under investigational.~  * Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations: Lenvatinib, Axitinib, All trans retinoic acid (ATRA), Venetoclax, Pembrolizumab, Cisplatin, Carboplatin, Vinorelbine"
214849721|NCT03329976|OTHER|measurement of visual acuity|complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
214849722|NCT02087176|DRUG|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
214849723|NCT02087176|DRUG|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
214849724|NCT02087176|DRUG|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
214849725|NCT02087176|DRUG|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
214849726|NCT04373382|BEHAVIORAL|Peer Resilience Champion|PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.
214849727|NCT04373382|BEHAVIORAL|Enriched Survey Feedback|This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.
214849728|NCT02266394|DRUG|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
214849729|NCT02266394|PROCEDURE|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
214849730|NCT04010916|OTHER|Group Preoperatively Adductor Canal Block|The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
214290244|NCT04997434|BEHAVIORAL|Art-therapy in the emergency department|"The intervention will begin with a 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. Since the art-therapeutic intervention that will be proposed seeks to generate pleasant feelings, it will be important to rely on the patient's tastes. At the end of the interview, modern art therapy will be presented to the patient and several artistic activities will be proposed (origami, drawing, creative writing).~Once the activity has been chosen, the patient will have 15 to 20 minutes to carry it out, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the 15 to 20 minutes of the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session."
214290245|NCT06350825|PROCEDURE|Cytoreductive prostatectomy or brachytherapy|local treatment+SOC for metastatic prostate cancer
214849731|NCT04010916|OTHER|Group Preoperatively Tourniquet Adductor Canal Block|The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
214663238|NCT06561438|DRUG|Vortioxetine 20Mg Tab|20 mg oral vortioxetine tablet 2 hours before the procedure
214663239|NCT04543331|DRUG|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
214663240|NCT02912273|OTHER|Baseline Participant Assessment|"* Section 1 contains demographic questions~* Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months~* Section 3 has the participant list all medication~* Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)~* Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very~* Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
214663241|NCT02912273|OTHER|Baseline Healthcare Provider Assessment|"* Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
214663242|NCT02912273|OTHER|Follow-up Participant Assessment|"* Section 1 contains multiple choice questions about daily actives and several physical function questions~* Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~* Section 3 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
214663243|NCT02912273|OTHER|Follow-up Healthcare Provider Assessment|"* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
214663244|NCT02912273|OTHER|End-of-study Participant Assessment|"* Section 1 contains multiple choice questions about daily actives and several physical function questions~* Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~* Section 3 contains multiple questions about the participant's concern about falling with answers ranging from 1=Not at all to 4=Very~* Section 4 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
214663245|NCT02912273|OTHER|End-of-study Healthcare Provider Assessment|"* Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
214663246|NCT05163704|DRUG|Dexmedetomidine|Dexmedetomidine is a beneficial sedative for children. It provides a sedation equivalent to a natural deep sleep with negligible respiratory effects. Administration via the nose provides better absorption and faster impact effect. The drug does not taste and does not sting when administered.
214663247|NCT00195130|BEHAVIORAL|There are no interventions in this study|
214663248|NCT03192579|DRUG|EPA and high dose rosuvastatin|After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
214663249|NCT03192579|DRUG|Standard dose rosuvastatin|After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
214663250|NCT04576442|BEHAVIORAL|Asthma-PASS|The investigator will collaborate with the student's primary care provider (PCP) by sending a letter via facsimile, and/or email to ensure appropriate medications are prescribed or adjusted and rescue medications are available at school. Community Health Workers (CHWs) will follow up with PCPs as needed to provide reminders about prescriptions for controlled medications and to ensure a MAF is provided to schools to allow rescue medication administration by nurses. CHWs will work with local pharmacies when possible to have prescribed medications delivered to schools and homes. For students without a PCP, we will refer families to one of Montefiore Medical Center's 20 practices throughout the Bronx. For students without medical insurance or who are unable to go to a Montefiore clinic, the NYC DOE physicians who routinely attend NYC schools will provide medical care and prescribe appropriate medications.
214663251|NCT04576442|BEHAVIORAL|Basic Asthma Management (AM)|PCPs and caregivers will be notified that children in the AM group have persistent/uncontrolled asthma that warrants use of guideline-based preventative medications.
214663252|NCT04576442|BEHAVIORAL|Child/Caregiver Education session|The investigator will provide in-school child asthma education sessions delivered by trained, bilingual (English-Spanish) Community Health Workers (CHWs) using an established manualized protocol from past and current studies designed to improve knowledge and self-efficacy. Each child will receive two 1-on 1, 20-minute developmentally appropriate educational sessions at school 3-4 weeks apart. Sessions will cover: 1) asthma basics, symptoms and triggers; and 2) medications and correct administration technique. Caregivers will be called after each child session to highlight key points reviewed with the child and answer questions.
214663253|NCT00256295|DRUG|Gemcitabine|1000 mg/m2 IV over 100 minutes Every 21 days
214663254|NCT00256295|DRUG|Oxaliplatin|65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
214849732|NCT04010916|OTHER|Group Postoperatively Adductor Canal Block|The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
214849733|NCT04081441|DEVICE|Inyenyeri clean cookstove and fuel system|The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp
214849734|NCT04081441|BEHAVIORAL|I-ACT (Individual, Agency-Centered Training) workshop|The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)
214849735|NCT02257619|DRUG|Itacitinib|Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.
214849736|NCT02257619|DRUG|docetaxel|Administered as an intravenous infusion in the clinic at 75 mg/m\^2 Q3W for Part 1 of the study.
214849737|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (Low dose)|Pumpkin seed extract standardized with specific peptides (300 mg/day)
214849738|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (High dose)|Pumpkin seed extract standardized with specific peptides (600 mg/day)
214849739|NCT05738655|DIETARY_SUPPLEMENT|Placebo|Placeo (300 mg/day)
214849740|NCT03648879|DEVICE|Endoscope+Cellvizio(R) 100 microscope|Patients will undergo white-light, upper endoscopy. In addition, during this endoscopy patients will undergo Confocal Endoscopic Microscopy (CEM) using the Cellvizio probe (Mauna Kea Technologies) to scan the same anatomic zones.
214849741|NCT04855448|DEVICE|Micro Hand S robot and da Vinci robot|The surgeries are performed with the Micro Hand S robot and da Vinci robot
214849742|NCT04855448|DEVICE|da Vinci robot|The surgeries are performed with the da Vinci robot
214849743|NCT02230618|DRUG|insulin degludec/insulin aspart|Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
214849744|NCT04776954|DEVICE|Forced Air Warming System|"The forced air warming system has a heater unit that blows air through a conduit to an air blanket that inflates with forced air that circulates throughout the blanket, and exits through tiny perforations on the patient-side of that blanket. The heat primarily warms the subject through convective means. As the warmed air escapes through the perforations in the blanket, it creates an environment of continuously circulating warm air that is in contact with the skin."
214849745|NCT04776954|DEVICE|Resistive Blanket Warming System|This blanket is equivalent to an operating-room-safe electric blanket. Through a power cord, a separate power source powers a semiconductor layer within the resistive blanket to generate heat. The heat primarily warms the subject by conductive warming through direct skin contact, and, secondarily, by warming the air around the participant in areas where there is no direct skin contact.
214849746|NCT06616480|DEVICE|BenQ Materials DSFNC1 soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
214849747|NCT06616480|DEVICE|Visco SiHy Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
214849748|NCT05612282|DIAGNOSTIC_TEST|body composition analysis|A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer
214849749|NCT05612282|OTHER|anthropometric measurements|An assessment of the status of nutrition based on anthropometric measurements was carried out.
214849750|NCT05612282|OTHER|Interview questionnaire|An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.
214290246|NCT06350825|DRUG|ADT+second-generation antiandrogens ± chemotherapy|SOC(Triplet or doublet therapy) for mHSPC
214290247|NCT06472063|OTHER|pre- or perioperative treatment and D2 gastrectomy|pre- or perioperative treatment and D2 gastrectomy
214290248|NCT03423095|BEHAVIORAL|Active Jaw Exercise with Relaxation|This is the control group that will complete exercises unrelated to the primary outcome measures.
214290249|NCT03423095|BEHAVIORAL|Active Tongue Exercise|This is the active comparator group that will complete exercises already shown to increase tongue strength measures.
214290250|NCT03423095|BEHAVIORAL|Active Tongue Exercise + Mental Practice|This is an experimental group that will complete active tongue and mental tongue exercises to assess effect on tongue strength measures.
214290251|NCT03423095|BEHAVIORAL|Mental Practice Tongue Exercise|This is an experimental group that will complete mental tongue exercises only to assess effect on tongue strength measures.
214663255|NCT05982340|DIAGNOSTIC_TEST|Lithium clearance|Blood and urine samples
214663256|NCT01868360|DRUG|Subconjunctival aflibercept|subconjunctival aflibercept injection
214663257|NCT01868360|OTHER|Placebo: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
214663258|NCT03980314|DRUG|Nivolumab|Specified dose on specified days
214663259|NCT05606172|BEHAVIORAL|Primary Care Intervention for PTSD (PCIP) Youth aged 6 -11|This treatment ranges from 1-4 sessions which last 50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the parent or both the parent and child. The first session will also teach the parent and child a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the child's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that the parent and child can learn together. There is also material for parents to address behavior problems in youth. This treatment will be delivered via telehealth.
214663260|NCT05606172|BEHAVIORAL|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
214663261|NCT01586845|DRUG|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
214663262|NCT01586845|DRUG|tacrolimus|tacrolimus as per labeled dose
214663263|NCT06485128|DIAGNOSTIC_TEST|Optical coherence tomography(-angiography) OCT(A)|OCTA is a non-invasive diagnostic tool capable of generating cross-sectional coupes of the retina and choroid. Novel algorithms allow to render a 3-dimensional model of the ocular microcirculation based merely on the motion contrast of the circulating blood.
214663264|NCT06485128|DIAGNOSTIC_TEST|Fundus pictures|Visucam (Zeiss), Topcon NW8 fundus camera, NFC 600 (Crystalvue)
214663265|NCT06485128|DIAGNOSTIC_TEST|DVA 3.0|IMEDOS GmbH
214663266|NCT06485128|DIAGNOSTIC_TEST|Hyperspectral retinal images|Ximea SNm4x4 hyperspectral snapshot camera
214663267|NCT06485128|DIAGNOSTIC_TEST|SphygmoCor|Sphygmocor Excell
214849751|NCT05612282|DIAGNOSTIC_TEST|biochemical parameters|The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.
214849752|NCT05612282|DIAGNOSTIC_TEST|cardiopulmonary fitness test|Cardiopulmonary fitness was assessed using the Modified Bruce protocol
214849753|NCT05612282|OTHER|nutritional interview|A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
214849754|NCT03812991|DRUG|Miacalcin Calcitonin Salmon Nasal Spray|Miacalcin nasal spray is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily
214849755|NCT04740931|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
214849756|NCT04740931|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
214849757|NCT04740931|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
214849758|NCT00419887|DRUG|Vildagliptin (LAF237)|
214849759|NCT00345215|BEHAVIORAL|High Sodium Diet|250-350 mmol
214849760|NCT00345215|BEHAVIORAL|Low Sodium Diet|25-35 mmol
214849761|NCT06236568|DEVICE|D-HOPE machine perfusion|use of the device
214849762|NCT06236568|PROCEDURE|Liver transplantation|Liver transplantation for HCC within Milan criteria
214849763|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
214849764|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft|Transforaminal lumbar interbody fusion with local bone graft
214849765|NCT03153826|OTHER|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
214849766|NCT02812654|DRUG|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
214849767|NCT02812654|DRUG|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
214849768|NCT02812654|RADIATION|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
214849769|NCT06677658|DIETARY_SUPPLEMENT|Olive Oil|Group 1 included patients who consumed at least 20 ml of oral olive oil daily. Group 2 included patients who did not consume olive oil.
214849770|NCT06677658|DRUG|Methylprednisolone|Both groups were diagnosed with Covid-19 pneumonia and were given pulse steroid ( methylprednisolone ) treatment at 250 mg/day for 3 days.
214849771|NCT03916562|BEHAVIORAL|Manipulation of spatiotemporal coordination during walking|A description of the intervention is included in the description of the study arms.
214849772|NCT03460145|OTHER|Lavender Oil on Nasal Strip (Lx)|Usage of Aromatherapy for Preoperative Anxiety
214663268|NCT06485128|DIAGNOSTIC_TEST|Sphygmomanometer|For the measurement of the blood pressure.
214663269|NCT06485128|DIAGNOSTIC_TEST|Blood sample|For both routine cardiovascular health biomarkers as well as genetic markers (DNA, mRNA, miRNA).
214663270|NCT06485128|DIAGNOSTIC_TEST|Skin biopsy|Spatial proteomics and transcriptomics for endothelial function.
214663271|NCT06485128|DIAGNOSTIC_TEST|Neuropsychological examination|Moca, Stroop color word test, concept shifting test, COWAT, (R)AVLT, Beck depression inventory, GDS
214663272|NCT03521947|DIAGNOSTIC_TEST|Complete blood picture|Iaboratory investigation
214663273|NCT05522426|DEVICE|SyntrFuge System|Microsized Adipose Tissue
214663274|NCT04109599|BEHAVIORAL|PlaySmart|Participants played the developed PlaySmart game over the course of a week.
214663275|NCT04109599|BEHAVIORAL|PlaySmart Storyline|Participants played through one PlaySmart Storyline during one 1-1.5 hour session.
214663276|NCT04109599|BEHAVIORAL|Play Smart Mini-Game|Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
214849773|NCT03460145|OTHER|Strip without Lavender Oil (Px)|Strip without Lavender Oil (Px)
214849774|NCT03460145|DRUG|Propofol 1 % Injectable Suspension|Propofol 1% (10mg/mL)
214290252|NCT06463327|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
214663277|NCT05564559|OTHER|multifamily group psychoeducation|The intervention involves 8 weeks of multifamily psychoeducation for families. Duration of sessions: 75 minutes on average Context: First session: psychoeducation on substance-abuse disorders; second session; effects of addiction on the family; third session; illness management; fourth session; supporting recovery; fifth session; improving stress coping skills/stress management; sixth session; developing problem-solving skills; seventh session; strengthening the family; eighth session; working with stigma Preferred approach: face-to-face, multi-family Approach: Psychoeducation
214663278|NCT04807959|OTHER|20Lighter anti-obesity program|A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.
214663279|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the evening (PM) for 28 days
214663280|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD in the PM for 28 days
214663281|NCT01731002|DRUG|Latanoprost ophthalmic solution 0.005%|Administered to study eye, QD in the PM for 28 days
214663282|NCT04820751|DRUG|Cyproheptadine Hydrochloride 4 MG|Cyproheptadine associated to standard care
214663283|NCT03590860|DRUG|LY3322207|Administered by SC injection
214663284|NCT03590860|DRUG|Placebo|Administered by SC injection
214663285|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
214663286|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
214663287|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
214663288|NCT04423848|OTHER|Home Hospital for Lymphoma|Remote monitoring and home-based care designed for hospitalized patients with lymphoma
214663289|NCT04474730|DEVICE|BMT Physical Activity app|This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
214663290|NCT04474730|OTHER|Watch Only|A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
214663291|NCT04223466|PROCEDURE|Subxiphoid surgery procedure|Subxiphoid procedure for thymectomy
214663292|NCT04223466|PROCEDURE|VATS surgery procedure|VATS procedure for thymectomy
214663293|NCT06239194|DRUG|MDX2001|MDX2001 intravenous infusion
214663294|NCT04444570|DEVICE|Continuous glycemia measuring device (Dexcom) implantation into the subcutaneous tissue|14 days before the date of the surgery and after the surgery patient will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
214663295|NCT03040154|OTHER|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
214663296|NCT03040154|OTHER|Usual Care Video that is publicly available|
214663297|NCT05141682|DRUG|Oral Azacitidine|Given PO
214663298|NCT01390168|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
214663299|NCT01390168|BEHAVIORAL|Waitlist|active waitlist
214849775|NCT00895037|DRUG|ReFacto AF (Moroctocog alfa)|Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
214290253|NCT07000929|DIAGNOSTIC_TEST|Videonystagmography|In the regular examination of patients with vertigo, videonystagmography with thermal testing (caloric) is already an established and necessary examination procedure that is used to diagnose many different vertigo disorders.
214663300|NCT01140087|PROCEDURE|Face Transplant|Transplantation of donor facial skin, tissue, muscle, and bone as needed
214663301|NCT00628355|DRUG|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
214663302|NCT00628355|PROCEDURE|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
214663303|NCT05519631|OTHER|electroencephalogram|The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.
214663304|NCT04032340|OTHER|dog presence|This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
214849776|NCT01391845|DRUG|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
214849777|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
214849778|NCT01391845|DRUG|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
214849779|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
214849780|NCT02063087|OTHER|Head CT Decision Aid|The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
214849781|NCT00142987|DRUG|Tegaserod|
214663305|NCT01571479|PROCEDURE|2- mini-instrument|"The patient was positioned in the supine position with the head and right side up.~Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.~A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups."
214663306|NCT00797121|PROCEDURE|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
214663307|NCT04975802|OTHER|Placebo|10 oz (296 ml) cherry flavored still beverage
214663308|NCT04975802|DIETARY_SUPPLEMENT|Coffeeberry|10 oz (296 ml) cherry flavored still beverage
214663309|NCT04975802|DIETARY_SUPPLEMENT|Caffeine|10 oz (296 ml) cherry flavored still beverage
214663310|NCT00433888|DRUG|R744|100μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
214663311|NCT00433888|DRUG|R744|150μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
214663312|NCT01466244|BIOLOGICAL|cetuximab|
214663313|NCT01466244|DRUG|cisplatin|
214663314|NCT01466244|GENETIC|gene expression analysis|
214663315|NCT01466244|GENETIC|microarray analysis|
214663316|NCT01466244|OTHER|immunohistochemistry staining method|
214663317|NCT01466244|OTHER|laboratory biomarker analysis|
214663318|NCT03935516|OTHER|Cast|The use of plaster and/or fiberglass for casting of subject arm.
214663319|NCT03392766|DEVICE|single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.
214663320|NCT03392766|DEVICE|double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube.
214663321|NCT00319514|DRUG|Docetaxel|
214663322|NCT03202693|DRUG|PA-824|
214663323|NCT05295628|DEVICE|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
214663324|NCT05295628|DEVICE|SENTINEL™ Cerebral Protection System|The SENTINEL CPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
214663325|NCT03542682|DEVICE|Quick Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp."
214849782|NCT04093154|DEVICE|wearing the virtual headset|watching the application by wearing virtual glasses to the child/adolescent
214849783|NCT06677840|OTHER|probiotic (GKB7/placebo)|The objectives of this double-blind randomized placebo-controlled trial are to evaluate the tolerability, safety, and efficacy of the probiotic intervention with Clostridium butyricum GKB7 among 90 4-15-year-old children and adolescents with a clinical diagnosis of ASD according to the DSM-5
214849784|NCT02346149|OTHER|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
214849785|NCT00496028|DRUG|AZD0530|oral tablet
214849786|NCT00496028|DRUG|Carboplatin|intravenous infusion
214849787|NCT00496028|DRUG|Paclitaxel|intravenous infusion
214849788|NCT05095649|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of cluster of differentiation 25hi regulatory T cells from cluster of differentiation antigen 8 and/or cluster of differentiation antigen19 pre-depleted leukapheresis products.
214849789|NCT02851732|BEHAVIORAL|Quality Improvement Intervention|The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
214849790|NCT05040126|DRUG|Linezolid|"Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment"
214663326|NCT03542682|DEVICE|Standard Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp."
214663327|NCT05428176|OTHER|Best Practice|Receive usual care
214663328|NCT05428176|OTHER|Internet-Based Intervention|Undergo eHealth intervention
214663329|NCT05428176|OTHER|Quality-of-Life Assessment|Ancillary studies
214849791|NCT05040126|DRUG|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms
214849792|NCT05040126|DRUG|Pretomanid|Pretomanid is administered as one tablet once a day for 26 weeks in all three arms
214663330|NCT05428176|OTHER|Questionnaire Administration|Ancillary studies
214663331|NCT05987527|DIAGNOSTIC_TEST|Blood sample|Routine procedures
214663332|NCT00248729|DRUG|Etomidate (20mg) or Midazolam (7mg)|
214663333|NCT06459687|DRUG|Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of Socazolimab (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with Socazolimab (5 mg/kg), Q3w."
214663334|NCT06459687|DRUG|Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of placebo (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with placebo (5 mg/kg), Q3w."
214663335|NCT04259359|DRUG|Insect Venom|Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
214849793|NCT04221126|DEVICE|TMFI|Tixel rapidly transfer thermal energy by a metallic pyramid tip that enable skin contact through integrated pulsed movements. The rapid heating dehydrates he epidermis and superficial dermis and creates micropores with no coagulative damage of surronding tissue.
214849794|NCT04221126|DRUG|ALA cream|ALA compounded in a cream
214849795|NCT04221126|DRUG|ALA gel|ALA compounded in a gel
214849796|NCT04558333|OTHER|blood and exhaled breath specimens|identification of possible biomarkers
214849797|NCT03944109|DRUG|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
214849798|NCT03944109|DRUG|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
214849799|NCT03496987|DEVICE|Vacuum Bottle Drainage|Patients undergo drainage via vacuum bottles
214849800|NCT00925756|DRUG|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
214849801|NCT01509482|OTHER|blood samples|blood samples to test for primary and secondary outcome measures
214849802|NCT01509482|OTHER|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
214849803|NCT06378788|OTHER|Demographic information form|aims to collect basic demographic data( Age reported by years , weight and height will be combined to report Body Mass index (BMİ) in kg/m2, Smoking habit reported as smoker or non-smoker , Level of Education reported as illiterate, literate, Primary school, Middle school, High school, University or Post-graduate, Profession type, Significant medical records and Medications.
214849804|NCT06378788|DIAGNOSTIC_TEST|widespread pain index (WPI)|"The Widespread Pain Index is a 19-point checklist that assesses the presence of pain or tenderness (within the prior seven days) in 19 specific areas of the body; each affected area receives one point. The 19 regions on the WPI include the following:~Right and left jaw, Right and left shoulder girdle, Right and left upper arm, Right and left lower arm, Right and left hip/buttock Right and left upper leg Right and left lower leg Upper and lower back Neck Chest Abdomen A fibromyalgia diagnosis is confirmed if a WPI is ≥7 with an SS scale ≥5 OR a WPI range between 4-6 with an SS scale ≥ 9."
214849805|NCT06378788|DIAGNOSTIC_TEST|symptom severity scale (SSS)|SS scale score: Fatigue, waking unrefreshed, and cognitive symptoms. For each of the three symptoms above, indicate the severity level over the past week utilizing the following scale: 0 no problem; 1 slight or mild problems, generally mild or intermittent; 2 moderate, considerable problems, often present and/or at a moderate level; 3 severe: pervasive, continuous, life-disturbing problems. Considering somatic symptoms in general, indicate whether the patient has: 0 for no symptoms, 1 for a few symptoms, 2 for a moderate number of symptoms, and 3 for many symptoms. The SS scale score sums the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the severity) of general somatic symptoms. The final score is between 0 and 12.
214849806|NCT06378788|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
214849807|NCT06378788|DIAGNOSTIC_TEST|Tender Point examination|Tender points are specific sites on the body that cause pain when pressed.. There are 9 pairs of tender points. Each pair has one point on each side of the body, for a total of 18 points.Prior to 2010, the diagnosis of fibromyalgia required at least 11 painful point of 18 but now tender points are no longer used as a diagnostic tool. The score will be reported as the number of tender points found with palpation.
214849808|NCT06378788|OTHER|Muscle Architecture visualized with ultrasound|The three head of Quadratus femoris ( Vastus lateralis, Vastus Medialis and Rectus Femoris), Tibialis Anterior, the two heads of Gastrocnemius ( vastus Lateralis and vastus Medialis) ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.
214849809|NCT06378788|OTHER|Sarcopenia assessed by measuring isometric strengths of different parts of the body|Cervical Flexion (CF), Cervical Extension (CE), Right and Left Cervical Lateral Flexion (CLF R/L), Truncal flexion (TF), Truncal extension (TE), Shoulder flexion (SF), Shoulder extension (SE), Shoulder abduction (SAB), Shoulder internal rotation (SIR) and Shoulder external rotation (SER), Hip flexion (HF), Hip extension (HE), hip abduction (HAB), hip internal rotation (HIR), hip external rotation (HER), knee extension (KE), Knee Flexion (KF), Ankle Dorsiflexion (ADF) and Ankle Plantar flexion (APF) muscle strengths will be evaluated with hand held dynamometer
214849810|NCT06378788|OTHER|Timed Up & Go (TUG)|The test will be used by investigators as a simple evaluative test used to measure participants functional mobility.
214849811|NCT04108832|DRUG|TCM OA2|Usage: 3g twice daily
214849812|NCT04108832|DRUG|PLACEBO|Usage: 3g twice daily
214849813|NCT02060045|OTHER|Bundle implementation|
214849814|NCT06128187|OTHER|Control Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of virtual reality training will be given.
214849815|NCT06128187|OTHER|Study Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of dual-task training will be given
214849816|NCT01021267|DRUG|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
214849817|NCT02731963|DRUG|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
214849818|NCT06616792|COMBINATION_PRODUCT|Dexamethasone phonophoresis|Ultrasound therapeutic device with the use of 0.4% Dexamethasone sodium phosphate gel for phonophoresis.
214849819|NCT06616792|DEVICE|Laser Acupuncture|low level laser therapy placed in contact with the skin perpendicular over the body acupoints (LI 4) - (LI 20) - (EX- HN5) - (GV 20) - (GV 24) - (ST3) - (ST 7) in both sides and on (EX-HN3) acupoint,
214849820|NCT06616792|OTHER|Traditional medication|Each participant in this group receive the traditional medication.
214849821|NCT02822196|DRUG|Lidocaine|Local Anesthesia using 1% Lidocaine
214849822|NCT02822196|DRUG|Bupivacaine|Local Anesthesia using 0.25% Bupivacaine
214849823|NCT05416463|PROCEDURE|Intra-Operative Device for THA|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
214849824|NCT01029392|DRUG|Vitamin D|2000iu once a day
214849825|NCT05494216|OTHER|PICSI|Sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
214849826|NCT05494216|OTHER|MACS|Sperm selection using MACS for selecting sperm with lower DNA fragmentation index
214849827|NCT01588535|DRUG|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
214849828|NCT01588535|DRUG|placebo|placebo solution, five drops in affected ear canal each hour as needed
214849829|NCT00334256|DRUG|Tenofovir (TDF)|
214849830|NCT00334256|DRUG|Emtricitabine (FTC)|
214290254|NCT07002164|PROCEDURE|Immediate coronary angiography|Immediate coronary angiography ≤2 hours after randomization
214290255|NCT07002164|PROCEDURE|Delayed coronary angiography|Delayed coronary angiography after stabilization
214663336|NCT03116529|COMBINATION_PRODUCT|Combination Radiation, Immunotherapy, Surgery|"Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as \>10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease."
214663337|NCT05911763|DRUG|Efanesoctocog Alfa BIVV001|Given per investigator's discretion
214663338|NCT06963229|PROCEDURE|Spinal Anesthesia (bupivacaine)|L3-L4 or L4-L5 3cc of 2% bupivacaine
214663339|NCT06963229|PROCEDURE|Peripheral Nerve Block|"Sciatic Nerve Block 20ml of Anesthetic Mixture, Paravertebral Nerve Block (L3-L4 and L4-L5) 20ml of Anesthetic Mixture~Mixture Details:~* 5ml Lidocaine 2%~* 5ml Lidocaine 1% with Adrenaline (1-200000)~* 10ml Bupivacaine 0.5%"
214663340|NCT05218213|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
214663341|NCT03226197|DIETARY_SUPPLEMENT|Ketone ester drink|Ketone ester drink
214663342|NCT05200351|BEHAVIORAL|Equine assisted Therapy (EAT)|15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.
214663343|NCT00853632|DEVICE|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
214663344|NCT06244082|DRUG|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
214663345|NCT04098601|BEHAVIORAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
214663346|NCT04164667|BEHAVIORAL|Mental and physical (MAP) training intervention|"In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).~Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise."
214849831|NCT00775788|PROCEDURE|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
214849832|NCT04131231|DRUG|microparticles packaging methotrexate (MPs-MTX)|50ml, intrapleural infusion, day5,6,7,8
214849833|NCT04131231|DRUG|recombinant human interleukin-2(rhIL-2)|50ml, intrapleural infusion, day5,8,11
214849834|NCT05249972|DRUG|AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)|Topical cutaneous spray
214849835|NCT05249972|DRUG|Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)|Topical foam
214849836|NCT05249972|OTHER|Placebo|Placebo cutaneous spray
214290256|NCT04675645|OTHER|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
214290257|NCT01086722|DRUG|"karolinska cocktail"|"The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol"
214849837|NCT04375995|DIAGNOSTIC_TEST|Impulse oscillometry|Impulse oscillometry test will be applied to all groups.
214849838|NCT04375995|DIAGNOSTIC_TEST|Spirometric pulmonary function test|Spirometric pulmonary function test will be applied to all groups.
214849839|NCT04375995|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide (FENO) test|FeNO test will be applied to asthma group.
214849840|NCT04375995|DIAGNOSTIC_TEST|Thorax Computed Tomography|Thorax Computed Tomography will be taken to the asthma group.
214290258|NCT03482440|DRUG|Salsalate Oral Tablet|1500mg twice daily for 4 days prior to experimental testing
214290259|NCT03482440|DRUG|Placebo Oral Tablet|Placebo oral table twice daily for 4 days prior to experimental testing
214290260|NCT01954602|PROCEDURE|Guide-wire cannulation|Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
214290261|NCT01954602|PROCEDURE|Sphincterotome assisted guide-wire cannulation|Sphincterotome is inserted initially a few millimeters through the papillary orifice
214849841|NCT04375995|DIAGNOSTIC_TEST|Blood eosinophil level|The blood eosinophil level will be evaluated to determine the phenotype in the asthma group.
214849842|NCT04375995|OTHER|Asthma control test|Asthma control test questions will be applied to the asthma group.
214849843|NCT04375995|OTHER|Asthma quality of life scale|Asthma quality of life scale (AQLQ) will be applied to the asthma group.
214849844|NCT04375995|DIAGNOSTIC_TEST|Chest X Ray|Chest X Ray will be applied to the healthy control group.
214849845|NCT06480604|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules once daily, for 6 months.
214849846|NCT06480604|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for the duration of the study (6 months).
214849847|NCT01100450|BEHAVIORAL|Progressive Resistance Training|12-week progressive resistance training (PRT) exercise program
214663347|NCT06082401|DEVICE|hemodiafiltration (HDF)|Hemodiafiltration (HDF) is a variation of conventional HD. By the addition of a substitution solution, convection forces are significantly increased. This substitution solution is added to the blood and is completely removed again in the dialyzer. This increases the negative pressure on the dialysate side and the removal of toxins through convection. The substitution solution can be added in a pre-dilution (before the dialyzer) or post-dilution (after the dialyzer) manner. Pre-dilution is associated with longer run times, less filter clotting, but is also less effective in removing toxins. Post-dilution offers a better toxin clearance capacity, but is associated with an increased risk of filter clotting. Several studies have shown that HDF provides higher clearance rates for both small and middle molecule solutes. Moreover, effective cytokine removal has been shown in HDF both in acute and chronic renal disease patients.
214663348|NCT06082401|DEVICE|Ex vivo lung perfusion (EVLP)|"Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. One of the major obstacles in the modern transplant era is the fact that the need for organs by far exceeds availability. This leads to growing waiting lists with mortality rates ranging between 10-30%. On the other hand, up to 80% of offered lungs from brain dead donors are rejected because they do not meet predefined donor selection criteria.~Recently, ex vivo lung perfusion (EVLP) has become available as a tool to expand the donor pool. Based on experimental work by Stig Steen, the Toronto lung transplant group developed an EVLP system with the purpose to evaluate lungs with uncertain quality. Consequently, Aigner et al. have expanded the indications for EVLP by showing that primarily unacceptable donor lungs can be reconditioned and then become suitable for transplantation. This concept of organ repair by EVLP has recently been highlighted by a number of publications."
214663349|NCT04633343|OTHER|Small volume breath and fast breathing rate for 5 minutes|Small volume breath and fast breathing rate delivered via mechanical ventilator.
214663350|NCT04633343|OTHER|Large volume breath and slow breathing rate for 5 minutes|Large volume breath and slow breathing rate delivered via mechanical ventilator.
214663351|NCT06084806|DRUG|[18F]F-ARAG PET|Two imaging sessions
214663352|NCT01163422|DEVICE|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
214663353|NCT06782906|BEHAVIORAL|≥10,000 daily steps (≥5 days/week) and stopping evening snacking|Participants in the intervention arm will be asked to perform ≥10,000 daily steps (≥5 days/week) and omit evening snacking after 8:00 p.m.
214663354|NCT04568330|OTHER|best support care|Best support care
214663355|NCT04568330|OTHER|moisture cream|BSC plus moisture cream
214663356|NCT04568330|OTHER|10% urea-based cream|BSC plus 10% urea-based cream.
214663357|NCT03609164|PROCEDURE|Suture-bridge augmentation of single-row repair|
214663358|NCT02172118|DRUG|BI 1774 CL|
214663359|NCT00001446|DRUG|thalidomide|
214663360|NCT05415280|BEHAVIORAL|Mindfulness Based stress reduction|The aim of the psychological intervention to reduce the mental health problems of the participants.
214663361|NCT00452621|PROCEDURE|blood draw|
214663362|NCT02851654|DEVICE|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
214663363|NCT00022932|DRUG|Iodine-131 Anti-B1 Antibody|
214663364|NCT02463942|DRUG|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
214849848|NCT04530279|PROCEDURE|Clinical assessment|Clinical assessment of burn depth and the percentage of total body surface area (TBSA) burnt with any method
214849849|NCT06231459|DRUG|Evolocumab|Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response. Clinical-demographic and anthropometry data were collected during a direct interview. Blood sample was processed to obtain glycated hemoglobin complete blood count and serum lipids. Likewise, flow cytometry was used to characterize baseline circulating M1-, M2-macrophages and monocytes. Multiplexing of plasma samples was used to compare plasma fraktaline, IL-1, IL-4, IL-6, IL-8, IL-10, MCP-1 and TNF-alpha. Endpoints consisted of: 1) lower serum lipids; 2) modification of pro-inflammatory mediators (neutrophils, lymphocytes, NtLR, soluble pro-inflammatory cytokines).
214849850|NCT01293552|BIOLOGICAL|ANT-1207|single dose application
214849851|NCT01293552|BIOLOGICAL|Vehicle|
214849852|NCT01103479|BEHAVIORAL|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
214849853|NCT01103479|BEHAVIORAL|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
214849854|NCT01534637|DRUG|aprepitant|Given PO
214663365|NCT02463942|DRUG|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
214849855|NCT01534637|DRUG|gemcitabine hydrochloride|Given IV
214849856|NCT01534637|DRUG|capecitabine|Given PO
214849857|NCT01534637|DRUG|fluorouracil|Given IV
214849858|NCT01534637|PROCEDURE|radiation therapy|Undergo radiation therapy
214849859|NCT01534637|OTHER|questionnaire administration|Ancillary studies
214849860|NCT01534637|PROCEDURE|quality-of-life assessment|Ancillary studies
214849861|NCT01534637|PROCEDURE|nausea and vomiting therapy|Receive aprepitant
214849862|NCT01534637|PROCEDURE|management of therapy complications|Receive aprepitant
214849863|NCT06412042|DIETARY_SUPPLEMENT|Probiotic BLa80|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
214476304|NCT06814990|DIAGNOSTIC_TEST|Cardiac MRI|Additional to standard clinical practice Patients will receive a cardiac magnetic resonance imaging without contrast. Measured parameters are enddoastolic and endsystolic volume (in ml oder ml/body surface area (BSA)), stroke volume (in ml) of right and left ventricle absolute and relatvie to body surface area (BSA), ejection fraction in % of right and left ventricle, myocardial Strain in % of right and left ventricle if applicable. T1 and T2 relaxation times are obtained and aortic and pulmonary artery flow parameters are measured.
214476305|NCT06814990|DIAGNOSTIC_TEST|Blood samples|We will take additional blood samples for the analysis of markers of bacterial translocation (e.g. LBP, EndoCAb, 16S rRNA), detection of bacterial markers (bacterial extracellular vesicles), inflammatory markers (e.g. IL-1ß, TNF-α, TGF-ß, IL-6, CXCL8, IL1-RA, IL-10, IL-18) and monocyte/macrophage activation markers (sCD14, sCD163, sCD87, sCD206), bile acids (including TCA, GCA, GCDCA, TCDCA, TLCA, GLCA, TDCA, GDCA, CA, CDCA, UDCA, DCA, TUDCA, LCA), lipids and lipoproteins (triglyerides, cholesterol, LDL/HDL cholesterol), coagulation factors (e.g. VWF, ADAMTS13, fibrinogen), markers of cardiac remodeling (e.g. NT-proBNP; troponin, VEGF-D, cleaved Gasdermin D, HMGB1) and Immunophenotyping of monocytes/macrophages, T and B cells (e.g. CD14, CD16, MERTK, CD4, CD127, CD25, TREM1/2).
214476306|NCT06814990|DIAGNOSTIC_TEST|Echocardiography|Patients will receive an extended echocardiographic protocol. In addition to standard clinical parameters, we will collect study specific parameters such as LV EF in %, global longitudinal strain in %, septal e' velocity (cm/s), E/e' ratio, left atrial volume index (LAVI) (in ml/m2), tricuspid regurgitation velocities (m/s).
214476307|NCT06841601|OTHER|topical anesthetic gel|gels applied directly to the mucous membranes to provide localized relief of pain by numbing the area. They typically contain active ingredients such as lidocaine, benzocaine, or prilocaine, which work by blocking nerve signals to reduce sensation and discomfort
214476308|NCT06841601|OTHER|Vibration|The vibration generated by the Buzzy device functions as a non-pharmacological agent that can reduce pain perception in children based on the principles of the Gate Control Theory of Pain.
214476309|NCT06841601|OTHER|Cold pack|cold packs are also provided by the Buzzy device. they act as non-pharmacological agents that can reduce pain perception in children based on the Gate Control Theory of Pain.
214476310|NCT06841367|OTHER|Mindfulness-based stress reduction training|It is expected that improvements in physiological parameters and anxiety levels will be observed in the preeclampsia group with awareness-based stress reduction training.
214476311|NCT06842810|DIAGNOSTIC_TEST|Serum FGF21 measurement by Enzyme- linked immunosorbent assay (ELISA)|Venous 5 ml blood will be collected, then centrifugation at the speed of 2000-3000 rpm for 20-min., supernatant will be collected and stored at -20°C for later analysis then tha sample will be tested for fibroblast growth factor 21
214476312|NCT06841263|OTHER|Not applicable- observational study|Not applicable - observational study
214476313|NCT05550376|OTHER|Registry|Non-interventional registry
214476314|NCT06106529|DRUG|Oxybutynin|Oxybutynin 5 mg twice per day for 6 weeks
214476315|NCT06106529|DRUG|Venlafaxine|Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks
214476316|NCT05677594|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|Magnetic resonance imaging of the entire body from skull base through distal thighs/knees without contrast material
214476317|NCT06790589|DRUG|Levothyroxine Oral Tablet [Synthroid]|"Round, colour coded, scored tablet debossed with SYNTHROID on one side and potency on the other side."
214476318|NCT06598865|OTHER|adapted physical activity|After the initial training in adapted physical activity (APA), patients will receive regular support from an APA instructor, and they will be asked to participate in 3 sessions per week of APA, if possible in a Sport-Health center close to their home, for the entire duration of the study. The content of the additional APA sessions (up to 2 additional sessions per week) can be discussed with the APA instructor. They will also be asked to return to the study center for a visit at 3 months (Visit 3) to assess the effect of the APA conducted during this period
214476319|NCT04977271|DRUG|Venlafaxine|The Immediate Release generic formulation of this drug will be used due to its ability to be crushed for those patients who rely on parenteral administration of medications.
214476320|NCT02542631|DEVICE|Bolus Insulin Patch (Calibra Finesse)|
214476321|NCT02542631|DEVICE|Insulin Pen (Novo-Nordisk FlexPen®)|
214476322|NCT02641730|DRUG|Guselkumab|Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
214476323|NCT02641730|DRUG|Placebo|Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
214476324|NCT06806891|BEHAVIORAL|Buddhist walking meditation|the participants will be on hemodialyis. they complain restless leg syndrome. the participants will receive Buddhist walking meditation. this program of meditation will be 30 minutes thrice weekly. before and after Buddhist walking meditation .. The number of patients in the group will be 20. the total duration of Buddhist walking meditation will be 12 weeks.
214476325|NCT06595212|OTHER|multiomic profile to assess genetic and environmental risk factiors|Genomic, epigenetic, proteomic, microbiome, immunology, biomarker, metabolite, pesticide, metal, and metalloid investigations will be conducted. The twins will be followed longitudinally from a clinical perspective, with biological sample collections to assess discordance and identify early disease signatures in unaffected individuals.
214476326|NCT00319046|DRUG|Miglustat|Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)
214476327|NCT06597253|DEVICE|Lactate sensor|Continuous interstitial fluid lactate monitoring using the non-invasive Nemaura Investigational Lactate Device.
214476328|NCT06807684|DEVICE|transcranial magnetic stimulation|The investigators will deliver a type of high frequency rTMS known as intermittent theta burst stimulation (iTBS), 2400 stimulations per session, equally divided between the bilateral IPL and IFG.
214849864|NCT06412042|OTHER|Placebo Maltodextrin|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
214849865|NCT02505152|PROCEDURE|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
214849866|NCT00605917|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration."
214849867|NCT01476228|DEVICE|EEG recording|EEG recording
214849868|NCT00757614|GENETIC|DNA analysis|
214849869|NCT00757614|GENETIC|polymorphism analysis|
214849870|NCT00757614|OTHER|laboratory biomarker analysis|
214849871|NCT00757614|OTHER|questionnaire administration|
214849872|NCT00881413|DRUG|Esomeprazole|Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
214849873|NCT00881413|DRUG|Pantoprazole|After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
214849874|NCT00890552|DRUG|Lenalidomide|"Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle."
214849875|NCT00890552|DRUG|Melphalan|"Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle"
214849876|NCT00890552|DRUG|Dexamethasone|"Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle"
214849877|NCT05235659|BEHAVIORAL|Basic modules|Caregivers will only have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child.
214849878|NCT05235659|BEHAVIORAL|"Basic modules and experimental condition My coach"|Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Professional support of the caregiver will be provided. Caregivers will receive one phone call (50 minutes) to support processing of information from module 1 and 2. Finally, they will receive text messages or emails with the core message of the modules.
214849879|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
214849880|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Who am I and where do I belong? and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 5. Finally, they will receive text messages or emails with the core message of the modules."
214849881|NCT05235659|BEHAVIORAL|"Basic modules and experimental module You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
214849882|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 4. Finally, they will receive text messages or emails with the core message of the modules."
214476329|NCT00721149|DEVICE|Radiofrequency Ablation|The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
214849883|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
214849884|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 4, and 5. Finally, they will receive text messages or emails with the core message of the modules."
214849885|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Watch out!"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior."
214849886|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 3. Finally, they will receive text messages or emails with the core message of the modules."
214476330|NCT06803732|OTHER|Observations on postoperative pain intensity|pain intensity was assessed using a standard visual analogue score, with a score of 0 to 10 corresponding to no pain to the most severe pain on operation day, postoperative day 1, postoperative month 1, postoperative month 3
214476331|NCT04820036|DIAGNOSTIC_TEST|Insulin Resistance|Insulin resistance: Fasting glucose and insulin will also be measured to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), as a surrogate of IR
214476332|NCT04820036|BEHAVIORAL|Quality of Life Assessment|Quality of life will be assessed using the Chronic Liver Disease Questionnaire.
214663366|NCT02463942|OTHER|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
214663367|NCT03783156|PROCEDURE|hot snare|polypectomy with hot snare
214476333|NCT04820036|DIAGNOSTIC_TEST|Liver Function Test|EUS-guided liver biopsy and portal pressure gradient measurement
214476334|NCT04820036|DIAGNOSTIC_TEST|Radiologic features of NASH|Controlled attenuation parameter (CAP) and liver stiffness scores assessed by transient elastography (TE)
214476335|NCT04820036|DIAGNOSTIC_TEST|Serologic features of NASH|Laboratory value assessment of alanine aminotransferase (ALT), liver chemistries, platelet counts, albumin and calculated NAFLD Fibrosis Score (NFS).
214476336|NCT01850888|DRUG|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
214476337|NCT01850888|DRUG|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
214476338|NCT01850888|DRUG|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000).
214476339|NCT01850888|PROCEDURE|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum \> 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum \>2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
214476340|NCT05591677|DRUG|D-Cycloserine|D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.
214476341|NCT05591677|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.
214290262|NCT01461941|DRUG|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
214663368|NCT03783156|PROCEDURE|cold snare|polypectomy with cold snare
214663369|NCT01672892|RADIATION|Standard radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. Whole pelvis treated with a four-field technique (AP/PA/R lateral/L lateral) to 45 or 50.4 Gy at 1.8 Gy/fraction. The dose is prescribed to the isocenter which is defined as the intersection of the four beams and can be normalized to an isodose line between 97-100%. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
214663370|NCT01672892|RADIATION|intensity-modulated radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. All targets treated simultaneously. The vaginal planning target volume (PTV) (ITV with 7.0 mm margin) and nodal PTV receives 45 Gy in 25 fractions or 50.4 Gy in 28 fractions. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
214663371|NCT02976506|BEHAVIORAL|Unsupervised exercise program|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
214663372|NCT02976506|BEHAVIORAL|Physical fitness and quality of life|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
214663373|NCT05714371|DRUG|Nivolumab|Patients receiving nivolumab
214663374|NCT05714371|DRUG|Ipilimumab + nivolumab|Patients receiving ipilimumab + nivolumab
214663375|NCT05714371|DRUG|Pembrolizumab|Patients receiving pembrolizumab
214663376|NCT05714371|DRUG|Dabrafenib + trametinib|Dabrafenib + trametinib
214663377|NCT03401606|DRUG|remifentanil|remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
214663378|NCT03401606|DRUG|Dexmedetomidine|dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
214663379|NCT01385696|DEVICE|Genuair® (Almirall S.A.)|Inhaler with only placebo, once daily, 14 days
214663380|NCT01385696|DEVICE|HandiHaler® (Boehringer Ingelheim's)|Inhaler with only placebo, once daily, 14 days
214663381|NCT02652429|DRUG|Inhaled Nitric Oxide|
214663382|NCT04264104|OTHER|neural mobilization|This is a type of mobilization that uses a specific combination of joint movements
214663383|NCT05926206|DRUG|Devimistat|Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3
214663384|NCT05926206|DRUG|Modified FOLFIRINOX|Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1
214663385|NCT03160144|PROCEDURE|open lung approach|
214663386|NCT04676243|DRUG|Quizartinib|20 mg coated tablets, orally administered
214663387|NCT04676243|DRUG|Treatment according to Physician's Choice|Usually daunorubicin/ cytarabine or idarubicin/Cytarabine plus FLT3 inhibitor (usually midostaurin)
214663388|NCT04676243|DRUG|Standard of Care Chemotherapy|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine
214663389|NCT05978869|OTHER|physical fitness training|Through a three-step process, gamified physical fitness training was developed by a multidisciplinary team.
214663390|NCT00597558|DRUG|Egg white protein|Egg white protein powder
214663391|NCT02687308|PROCEDURE|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
214290263|NCT01461941|DRUG|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
214663392|NCT02687308|PROCEDURE|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
214663393|NCT04072042|DRUG|Apatinib monotherapy|patients will receive Apatinib 250mg tablet by mouth, bid.
214290264|NCT06880263|DEVICE|use 360 degree VR training|Participants will use Virtual Reality (VR) training
214663394|NCT03513380|BEHAVIORAL|Exergaming|free access to the exergame PedalTanks during 6 months
214663395|NCT04177654|DRUG|Benzimidazoles|A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.
214663396|NCT03932955|BIOLOGICAL|MC-19PD1 CAR-T cells|T cells purified from the PBMC of subjects, transduced with anti-CD19 CAR and PD1/CD28 chimera lentiviral vector, expanded in vitro for future administration.
214849887|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
214849888|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 5. Finally, they will receive text messages or emails with the core message of the modules."
214476342|NCT05602545|OTHER|food consumption in periodontal health and disease|To determine individuals' daily energy and nutrient intakes and the consumption amounts of food groups, food consumption records were kept by the nutritionist for three consecutive days, with one of them was weekend, using the 24-hour recall method. Data on individuals' frequency and amount of consumption of some fermented products were recorded, considering the foods available in our culture and the market.
214476343|NCT05862298|DIAGNOSTIC_TEST|venous excess ultrasound score|Venous congestion is classified into 4 grades. If the Inferior vena cava is not plethoric, there is deemed to be no congestion (grade 0), and further Doppler examination is not performed. When the IVC is plethoric but there are no severely abnormal waveforms (defined as S-wave reversal on hepatic, \>50% pulsatility on portal, and a monophasic pattern on intrarenal Doppler), congestion is considered to be mild (grade 1). Plethoric IVC with at least 1 severely abnormal pattern is considered to be moderate congestion (grade 2), while 2 or more abnormal Doppler patterns constitute severe congestion (grade 3)
214663397|NCT05080829|DIAGNOSTIC_TEST|Myeloid mutations measurement|Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done
214663398|NCT05325164|DRUG|Methadone|Methadone
214663399|NCT05325164|DRUG|Morphine|Morphine
214663400|NCT01733563|PROCEDURE|Soft drink consumption|
214663401|NCT04611477|OTHER|Rice Hulk|Placebo
214663402|NCT04611477|OTHER|Synbiotic365 Ver 5|Active Comparator
214663403|NCT04611477|OTHER|Synbiotic365 Ver 7|Active Comparator
214476344|NCT01240122|DEVICE|Biotrue MPS|Multi-purpose contact lens care solution
214476345|NCT01240122|DEVICE|Investigational MPS|Multi-purpose contact lens care solution
214476346|NCT06813612|BEHAVIORAL|cognitive behavioral play intervention|In the CBPI condition, children use dolls and miniature props to engage in play aimed at fostering positive thinking, a key element of quality of life. Each session includes stories on health, emotional well-being, social interactions, and school activities. The researcher demonstrates problem-solving steps, such as identifying and evaluating solutions, repeating this process three times. In each session, the researcher models problem-solving four times and provides at least five positive affirmations. Both the CBPI intervention and the free play control condition are similar, with the researcher using standardized prompts and providing equal time and positive attention. The key difference is that in the CBPI condition, the researcher models positive thinking and problem-solving, while in the free play condition, the researcher follows the child's lead without guiding play.
214476347|NCT06810258|OTHER|Blood sample during native kidney biopsy|blood sample during standard of care visit for a native kidney biopsy (17.5mL)
214476348|NCT06810258|OTHER|Blood sample during renal graft biopsy|blood sample during standard of care visit for a renal graft biopsy (17.5mL)
214476349|NCT06810258|OTHER|Urine sample during renal graft biopsy|Urine sample during standard of care visit for a renal graft biopsy (50mL)
214476350|NCT06810258|OTHER|Urine sample during native kidney biopsy|Urine sample during standard of care visit for a native kidney biopsy (50mL)
214476351|NCT06813521|OTHER|NaP1%+VitCG3% leave-on lotion (formula 1256103)|leave-on lotion
214476352|NCT06813521|OTHER|vehicle (formula 1256145)|vehicle lotion
214476353|NCT06813521|OTHER|reference Octopirox 0.25% (formula 1256149).|lotion reference Octopirox 0.25%
214476354|NCT06812585|DRUG|Metformin (Cidophage®)|Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.
214476355|NCT06812585|OTHER|Usual Care|Active Comparator: Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®) Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)
214476356|NCT06085820|BEHAVIORAL|Experimental (birth ball)|"It is a large and firm ball made of soft, thick plastic, inflated with air. It can be easily inflated and deflated, washable, available in different sizes (55-65-75 cm in diameter) and strong enough to carry weight up to 136 kg.~When the literature was examined, it was seen that birth balls between 55-75cm were generally used in accordance with the intended use. Appropriate ball size will be determined by the participant's height. In order for the pregnant woman to continue balance exercises, she should be allowed to sit on the round birthing ball with her knees and hips at an angle of approximately 90°, with an upright spine.~birth ball; It is performed in sitting (pelvic rocking movement, forward-backward and right-left rocking, forward-supported sitting, springing movement), kneeling and squatting (hugging the ball and pelvic rocking movement) positions."
214663404|NCT03864354|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a cost-effective, noninvasive treatment that is used to optimize the body's structure and function. By improving the biomechanical, autonomic, and circulatory mechanisms involved in the disease process of asthma, OMT can help maximize respiratory function. The specific OMT protocol used in this study included the following: supine OA joint myofascial release (MFR), supine cervical spine Still technique, supine thoracic inlet MFR, supine rib raising soft tissue, supine rib MFR, supine abdominal diaphragm MFR, seated thoracic spine Still technique, and seated posterior rib Still technique. Treatments were performed by Predoctoral Osteopathic Manipulative Medicine (OMM) Fellows at Des Moines University (DMU) and supervised and checked by one of two board-certified OMM/NMM physicians from the OMM Department at DMU. The treatment lasted an average of 21 minutes and repeated three times, spaced one week apart.
214663405|NCT01418872|OTHER|Didactic Concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
214663406|NCT00003323|DRUG|finasteride|5 mg/d PO
214663407|NCT00003323|DRUG|flutamide|250 mg PO tid
214663408|NCT00003323|OTHER|quality-of-life assessment|Assessment survey administered at baseline, and 3 \& 6 months post initiation of treatment
214663409|NCT06513468|OTHER|Group education session by DESMOND Program|is a validated structured education program for people with type 2 diabetes and their family members or carers (as appropriate)' This management approach was advised by the National Institute for Health and Care Excellence (NICE) in the UK since 2008. The program consists of a 6-hour face-to-face education session delivered by two trained educators over one day or two half-days to a group of 8-12 people with newly-diagnosed or ongoing type 2 diabetes. Annual reinforcement and review are part of the program , it is delivered as a business and usual in the secondary healthcare system of Qatar. The program is culturally adapted for Qatar considering beliefs and other health festivities.
214663410|NCT02347358|DEVICE|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
214663411|NCT02347358|DRUG|IV r-tPA|intravenous recombinant human tissue plasminogen activator
214663412|NCT02559505|BIOLOGICAL|Seasonal IIV 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
214663413|NCT02559505|OTHER|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
214663414|NCT02559505|BIOLOGICAL|Seasonal IIV 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
214663415|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 100mg
214663416|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 200mg
214663417|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 300mg
214663418|NCT01557010|DRUG|Control|Tablets, oral administration, Placebo
214663419|NCT00189761|DRUG|Tacrolimus|
214663420|NCT04079023|PROCEDURE|Sleeve Gastrectomy|Subtotal vertical gastrectomy
214663421|NCT01584024|DEVICE|Resin infiltration|"Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062"
214663422|NCT01584024|DEVICE|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
214663423|NCT01217606|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
214663424|NCT01217606|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
214663425|NCT02677779|PROCEDURE|CO2 laser|Single session of CO2 laser debridement
214663426|NCT02677779|PROCEDURE|traditional surgery|Single session of traditional debridement
214663427|NCT06566209|DEVICE|Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)|Receive 18F-FDG PET/CT
214663428|NCT00753636|DRUG|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
214663429|NCT03095105|DRUG|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
214663430|NCT01773824|BEHAVIORAL|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
214663431|NCT01773824|BEHAVIORAL|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
214663432|NCT00702624|DRUG|Corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
214663433|NCT00702624|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH administered under protocol P05690
214663434|NCT00702624|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
214663435|NCT00702624|BIOLOGICAL|human chorion gonadotropin (hCG)|hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
214663436|NCT00702624|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
214663437|NCT00702624|DRUG|placebo-recFSH (follitropin beta)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
214849889|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
214849890|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 4. Finally, they will receive text messages or emails with the core message of the modules."
214849891|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
214849892|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation. They will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Further access will be provided to module 4 You are safe here on improving children´s relationship-related safety and facilitating solid relationships. Access to module 5 Who am I and where do I belong? will support caregivers in helping their child develop an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support will be provided. They will receive four phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, 4, and 5. Text messages or emails with the core message of the modules will be provided."
214849893|NCT05262192|OTHER|nutrition education|Nutrition education will be given to the patients in the experimental group.
214849894|NCT03417791|OTHER|no intervention|no intervention
214849895|NCT02562417|DRUG|Normal saline|
214849896|NCT02562417|DRUG|IV dexamethasone|
214849897|NCT01872702|DRUG|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
214849898|NCT00724373|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
214849899|NCT00724373|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
214849900|NCT03821363|BIOLOGICAL|SCT-I10A|Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
214849901|NCT05616403|OTHER|No intervention|This is an observational study without any intervention
214849902|NCT01653795|DEVICE|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
214849903|NCT01653795|DEVICE|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
214849904|NCT05670145|OTHER|PRECISE|"The target group is working pregnant women. Further, a smaller group of non-pregnant women from the same workplaces and with the same work tasks (colleagues) will be included. Around 95% of pregnant women in Denmark have a 1st trimester ultrasound scan.(17) To ensure a representative population, the recruitment to the project takes place at four obstetric departments. After giving informed written consent for participation, the pregnant women receive a baseline questionnaire followed by short weekly questionnaires by SMS until maternity leave.~Exposure to occupational standing/walking and bending are measured by use of triaxial accelerometers (Axivity sensors) worn on the back and thigh for 24 hours/day. Exposure to lifting is quantified through continuous observations during a workday with registration of number of lifts, weight of burdens, and number of person-liftings."
214849905|NCT03749954|DIAGNOSTIC_TEST|Detachable string magnetically controlled capsule endoscopy|Esophagogastroduodenoscopy is performed 2 hours after the magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
214849906|NCT02155374|DRUG|Sliding scale insulin|
214849907|NCT02155374|DRUG|Intermediate acting insulin|
214663438|NCT00702624|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
214663439|NCT00702624|BIOLOGICAL|open-label recFSH (follitropin beta)|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
214663440|NCT01962454|DRUG|Deuterated Water|D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
214663441|NCT01962454|DRUG|Testosterone enanthate|Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
214849908|NCT02155374|BEHAVIORAL|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
214849909|NCT02155374|DRUG|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
214849910|NCT02155374|DRUG|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
214849911|NCT01490320|BEHAVIORAL|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
214849912|NCT01490320|BEHAVIORAL|Play Nicely Program|Multimedia program available at www.playnicely.org.
214849913|NCT01490320|OTHER|Control Group|Standard care in primary care clinic.
214849914|NCT04062682|BEHAVIORAL|Healthy Diet|Receive counseling to meet guidelines for healthy dietary patterns
214849915|NCT05676060|COMBINATION_PRODUCT|quasi|block facet joint in back pain due to afacet cause
214849916|NCT05785689|DRUG|Dexmedetomidine|To reduce postoperative agitation
214849917|NCT05785689|DRUG|Placebo|Placebo bolus saline
214849918|NCT01229644|DRUG|Crenolanib (CP-868,596)|Highly potent inhibitor of both PDGFR receptors alpha and beta
214849919|NCT03099629|BEHAVIORAL|inspiratory muscle training|inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
214849920|NCT05382520|DIAGNOSTIC_TEST|Questionares and practice|Questionares and practice
214849921|NCT03433131|DRUG|Pitolisant|Tablets
214849922|NCT02549573|DRUG|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
214849923|NCT02549573|BEHAVIORAL|Physical Therapy|All subjects will participate in a standardized PT intervention
214849924|NCT00161382|BEHAVIORAL|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
214849925|NCT00161382|BEHAVIORAL|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
214849926|NCT01211782|DRUG|caprylic triglyceride|oral, 20 gm, daily x 6 months
214849927|NCT01211782|DRUG|long-chain triglyceride|oral, 14 gm, daily x 6 months
214849928|NCT05237440|BIOLOGICAL|Biological dosage|Metabolic, hormonal and psychometric evaluations will be carried out during inclusion inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out at inclusion
214849929|NCT03383419|DRUG|Epclusa|If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
214849930|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
214849931|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
214849932|NCT00847106|DRUG|Daclizumab|
214849933|NCT00847106|BIOLOGICAL|Dendritic cells|
214849934|NCT03794518|DRUG|Pioglitazone Plus dapaglifliozin|Pioglitazone Plus dapaglifliozin
214849935|NCT03794518|DRUG|Placebo|(Beta blockers, ACEI, ARB, and aldosterone )
214849936|NCT04239118|COMBINATION_PRODUCT|Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets|Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
214849937|NCT04239118|PROCEDURE|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
214849938|NCT01473121|OTHER|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
214849939|NCT06604195|PROCEDURE|Modified sciatic nerve mobility exercises|Each participant was made to lie down in a supine position on the treatment couch. The participant's leg was moved to about 30-45 degrees hip flexion with knee extension. The ankle was then moved to maximum dorsiflexion with inversion and hip internal rotation within the participant's tolerance, and this position was maintained for 30 seconds. While the therapist performed dorsiflexion with inversion and hip internal rotation in the supported straight leg raise position, the participant was instructed to actively flex the cervical spine slowly until they perceived a tolerable stretch sensation in the hamstring muscle and lower leg. The synchronous alternating movements were performed rhythmically for 10-15 repetitions. This maneuver was repeated 3 times in a single session, 3 days per week, and continued for 3 consecutive weeks.
214849940|NCT06604195|PROCEDURE|Dynamic hamstring muscle stretching|"The participant was instructed to stand straight with the unaffected foot supported on the floor and the toes pointing forward. The heel of the testing leg was placed on an 18 high step with the toes directed upwards with knee extension. Once cued, the participant was asked to flex forward at the hip while maintaining the spine in a neutral position and reaching the arms forward. The knee joint remained fully extended as the participant continued to flex the hip until a gentle stretch was felt in the posterior thigh. Once the position was achieved, the participants were asked to hold it for 20-30 seconds. The same procedure was repeated 3 times daily, 3 days a week for three consecutive weeks."
214849941|NCT06824012|BEHAVIORAL|Growth Mindset Intervention|"A structured, daily-activity-based intervention program designed to foster a growth mindset among adolescents in youth custody frameworks and their staff. The intervention involves:~Guided engagement in practical, meaningful daily activities tailored to individual and group needs.~Reflective feedback sessions to reinforce principles of a growth mindset. Pre- and post-intervention assessments using standardized tools, including the Canadian Occupational Performance Measure (COPM) and structured questionnaires."
214849942|NCT02194569|DRUG|Citrate|
214663442|NCT01962454|DRUG|Placebo to match testosterone enanthate|Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
214663443|NCT01320228|DIETARY_SUPPLEMENT|Control|Alli treatment plus placebo (rice flour)
214663444|NCT01320228|DIETARY_SUPPLEMENT|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
214663445|NCT01320228|DIETARY_SUPPLEMENT|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
214663446|NCT01320228|DIETARY_SUPPLEMENT|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
214849943|NCT00759434|PROCEDURE|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
214849944|NCT00759434|PROCEDURE|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
214849945|NCT05542979|DRUG|HH-003 injection|HH-003 injection is administrated via I.V. infusion
214849946|NCT05542979|DRUG|Placebo|Placebo is administrated via I.V. infusion
214849947|NCT03353454|DRUG|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
214849948|NCT03353454|DRUG|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
214849949|NCT03544398|OTHER|robot assisted gait training|we use two types of robot assisted gait training and we will compare two groups.
214849950|NCT06857058|DEVICE|NOVA DES|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
214849951|NCT00772720|DRUG|raltegravir|raltegravir 400 mg BID for 7 days
214849952|NCT00772720|DRUG|Placebo|Placebo BID for 7 days
214849953|NCT00211991|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
214849954|NCT03043560|DRUG|Ezogabine|daily for 5 weeks
214849955|NCT03043560|DRUG|Placebos|placebo pill daily for 5 weeks
214849956|NCT05356143|DRUG|Rupatadine|Oral single dose 10 mg tablet
214849957|NCT02662166|DEVICE|MR imaging|3 T MRI of the urinary bladder
214849958|NCT06766721|DEVICE|Ultrasound (USG)|The intervention involves the use of a portable ultrasound (USG) device to assess costochondral joint separation in patients with blunt thoracic trauma. The ultrasound examination will focus on detecting disruptions in the connection between the ribs and cartilage, providing a non-invasive, radiation-free diagnostic method. A 12-MHz linear transducer will be used to scan the rib area for fractures or separations. The findings will be compared to those of computed tomography (CT), considered the gold standard. This intervention is designed to evaluate the accuracy, sensitivity, and specificity of ultrasound as a diagnostic tool in this context.
214849959|NCT00003822|DRUG|apomine|
214849960|NCT03844230|OTHER|Control - Inhibition|Taste and spit up water 10 minutes before drinking a glucose load
214849961|NCT03844230|OTHER|Experimental I- Inhibition|Taste and spit up water 10 minutes before drinking a glucose load mixed with lactisole
214849962|NCT03844230|OTHER|Experimental II- Inhibition|Taste and spit up sucralose 10 minutes before drinking a glucose load mixed with lactisole
214849963|NCT03844230|OTHER|Control- Stimulation|Taste and spit up water 10 minutes before drinking a glucose load
214849964|NCT03844230|OTHER|Experimental I- Stimulation|Taste and spit up sucralose 10 minutes before drinking a glucose load
214849965|NCT03844230|OTHER|Experimental II- Stimulation|Drink sucralose 10 minutes before drinking a glucose load
214849966|NCT03844230|OTHER|Sensory Evaluation|Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold
214849967|NCT02293616|DIETARY_SUPPLEMENT|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
214849968|NCT02293616|DIETARY_SUPPLEMENT|Placebo|
214849969|NCT03825744|DRUG|Hetrombopag Olamine+Standard Therapy|once daily
214849970|NCT03825744|DRUG|Placebo+Standard Therapy|once daily
214849971|NCT04761471|DEVICE|TI transcranial electrical stimulation|"Participants will undergo transcranial electrical stimulation, which will be delivered with low current amplitudes (\<= 2 mA) established with international safety guidelines for electrical stimulation. Threshold for the current amplitude will be established by participants themselves, such that they cannot distinguish when stimulation is applied and not applied.~Duration of stimulation will not last longer than 30 minutes."
214849972|NCT00238563|DRUG|Triamcinolone injection, sub-tenon|
214849973|NCT00465231|DRUG|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
214849974|NCT00465231|DRUG|preservative free saline|10mL saline solution
214849975|NCT00440115|BEHAVIORAL|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
214849976|NCT00440115|BEHAVIORAL|Low intensity disease management|Health education mailings, one motivation interview/counseling
214849977|NCT00440115|BEHAVIORAL|Comparison group|Health education mailings
214849978|NCT00440115|DRUG|Bupropion|Buproprion or Nicotine Replacement Therapy
214849979|NCT01839695|DEVICE|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
214849980|NCT00206102|DRUG|quetiapine fumarate|flexible dose oral
214849981|NCT00206102|DRUG|risperidone|flexible dose oral
214849982|NCT01332786|DRUG|Tigecycline|"Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~* Level 1: 50 mg daily x 10 doses; 1 week rest~* Level 2: 100 mg daily x 10 doses; 1 week rest~* Level 3: 150 mg daily x 10 doses; 1 week rest~* Level 4: 200 mg daily x 10 doses 1 week rest~* Level 5: 250 mg daily x 10 doses; 1 week rest~* Level 6: 300 mg daily x 10 doses; 1 week rest~* Level 7: 350 mg daily x 10 doses; 1 week rest"
214849983|NCT02693431|OTHER|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.~The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.~At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
214849984|NCT01398202|DIETARY_SUPPLEMENT|vitamin D3|20 micrograms per day for 10 weeks
214849985|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
214849986|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
214849987|NCT01398202|DIETARY_SUPPLEMENT|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
214849988|NCT03204474|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
214849989|NCT03204474|DRUG|Lacosamide (LCM) solution for infusion|Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
214849990|NCT01388452|DEVICE|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
214849991|NCT03123783|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody
214849992|NCT03123783|DRUG|Nivolumab|Nivolumab is an immune checkpoint (PD-1) blocking antibody
214849993|NCT00000239|DRUG|Buprenorphine|
214849994|NCT00958802|OTHER|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
214663447|NCT01568944|DRUG|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
214663448|NCT01568944|PROCEDURE|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
214663449|NCT04298411|DEVICE|Falcon|The Falcon contains a selection of 25+ games that require wrist extension and challenges children to grasp the controller with their affected hand. As children progress, they may advance to more difficult games that challenge the child to work against a resistance and/or apply greater grip forces. Therapists will be trained on the system, games, and given a guide summarizing the available games and the motor function areas targeted in the game. Using this guide, therapists can choose the games that are most suited to the child's abilities and goals. As multiple games will target many of the same motor function areas, children will have the option of choosing the games they like best to maximize motivational value. While this introduces some variability in the intervention, this flexibility is required to ensure that the therapy is targeting the specific interests, needs and goals of each individual child and is reflective of how ICP is used in a clinic setting.
214663450|NCT02314806|DRUG|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
214663451|NCT02314806|DRUG|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
214663452|NCT02314806|DRUG|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
214849995|NCT00958802|OTHER|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
214849996|NCT02188082|DRUG|IvabRadine hemisulfate Sustained-release Tablets|
214849997|NCT02188082|DRUG|placebo|
214849998|NCT03643926|PROCEDURE|Arthroscopic Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view
214849999|NCT03643926|PROCEDURE|Open Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
214850000|NCT04850248|OTHER|no intervention, this is an observational study|no intervention, this is an observational study
214850001|NCT04678063|OTHER|Exposure to Placebo|Patients are exposed to placebo in the EEC
214663453|NCT02650310|DEVICE|Thermostable device|Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
214663454|NCT00023348|DRUG|Isoniazid|
214850002|NCT04678063|OTHER|Exposure to dose A and dose B of cat allergen|Patients are exposed to dose A and B for successive exposures in the EEC
214850003|NCT04678063|OTHER|Exposure to a single dose of cat allergen|Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)
214850004|NCT01182662|OTHER|Human umbilical cord-derived MSCs and cyclosporin A|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
214850005|NCT01182662|OTHER|cyclosporin A|cyclosporin A 5mg/kg po for 12 months
214850006|NCT06390566|OTHER|calpaïnopathies|Identify and quantify the loss of strength of upper and lower limb muscle groups in patients with LGMD2A
214850007|NCT04299217|DIETARY_SUPPLEMENT|Zynamite®|Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.
214850008|NCT04299217|OTHER|Placebo|Placebo comparator (carrier)
214850009|NCT02681484|BEHAVIORAL|Anthroposophic speech therapy|"Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking."
214850010|NCT06734728|DEVICE|Profilm Cold Sores|The treatment will consist of daily applications of the product as soon as the first symptoms of an outbreak appear, and until the outbreak subsides, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
214850011|NCT02642237|BIOLOGICAL|Fluenz|intranasal inoculation with Fluenz
214850012|NCT02642237|OTHER|placebo|
214663455|NCT00023348|DRUG|Rifabutin|
214663456|NCT03139370|DRUG|KITE-718|A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
214850013|NCT02642237|OTHER|LPS|
214850014|NCT01370239|BIOLOGICAL|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
214850015|NCT05488886|DIETARY_SUPPLEMENT|Whole Aronia Berry Powder Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce A will additionally contain whole aronia berry powder (Milne MicroDried, Nampa, ID).
214663457|NCT03139370|DRUG|Cyclophosphamide|Administered intravenously
214663458|NCT03139370|DRUG|Fludarabine|Administered intravenously
214663459|NCT03139370|DEVICE|MAGE - A3/A6 Screening Test|A screening test for MAGE-A3/A6+ tumors
214663460|NCT06392490|OTHER|Technology Based Asthma Program|Evaluate the impact of peer-led and adult-based technology-based education on the quality of life, asthma control, asthma knowledge and self-efficacy in adolescents diagnosed with asthma.
214663461|NCT03154138|DEVICE|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
214850016|NCT05488886|DIETARY_SUPPLEMENT|Aronia Berry Extract Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce B will additionally contain aronia berry extract (Artemis International, Fort Wayne, IN).
214850017|NCT05488886|DIETARY_SUPPLEMENT|Phospholipid-Polyphenol Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce C will additionally contain PLP which will be prepared with commercially-available aronia juice concentrate (Greenwood Associates, Niles, IL) and soy lecithin (Whole Foods, Austin, TX).
214850018|NCT05488886|OTHER|Low-Polyphenol Control Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce D will not contain additional polyphenol-rich ingredients and is thus considered a low-polyphenol control.
214850019|NCT06904755|DEVICE|It is loaded with a mesenchymal stem cells reaction device for blood purification|Artificial liver blood purification therapy is performed using a mesenchymal stem cells reactor.
214850020|NCT06904170|DRUG|Durvalumab Plus Tremelimumab|"Systemic infusion of :~Tremelimumab 300 mg, single dose at Cycle 1 Durvalumab 1500 mg at Cycle 1 then every 4 weeks until disease progression or unacceptable toxicity.~Durvalumab and Tremelimumab will be delivered during a single angiography. Implantable catheter is also allowed.~Durvalumab infusion will start 1 hour after the end of the tremelimumab infusion."
214850021|NCT06904170|DRUG|HAIC (GEMOX)|"Hepatic Arterial Infusion of Chemotherapy (HAIC) :~Gemcitabine 1000 mg/m² over 30 minutes, followed by Oxaliplatin 100 mg/m² over 2 hours. Administered every 2 weeks for 4 cycles. When a Durvalumab cycle match with an HAIC infusion, HAIC will be delivered on the same day."
214850022|NCT06905184|BEHAVIORAL|Activity PRN|"An Activity PRN plan will be delivered to consenting patients, as described above. The intervention will be communicated to them as a new approach that 'supports the individual to engage in personalised meaningful activities, which they can engage in as and when required'.~Activity Resources are organised within a suitable, accessible location according with the patient's risk management and support plan. Dependent on the plan, resources may be kept on their person, in their bedroom, in a communal area, or in a locked or unlocked accessible cupboard.~Ward staff will facilitate prn activities on an 'as and when required' basis. This can occur when: 1) a patient requests an activity from their card, 2) the patient appears disengaged, or 3) staff deem that the patient may benefit from participation in an activity for the purpose of engagement or distraction."
214850023|NCT06904430|OTHER|Bucket Group|This Bucket Intervention is behavioral and studies the effect of players limiting their throw count during practice to reduce pain occurrence
214850024|NCT06904430|DEVICE|Brace Group|The Brace intervention studies the use of players using an elbow throwing brace during practice to reduce the occurrence of pain
214850025|NCT06905587|DRUG|Methylphenidate (MPH)|"10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.~For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol."
214850026|NCT06905587|DRUG|Placebo|"10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.~Dosage will follow the exact same principles as for the study drug (methylphenidate)."
214850027|NCT06472180|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
214850028|NCT06472180|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
214850029|NCT02953678|DRUG|Ruxolitinib|
214850030|NCT02953678|DRUG|Prednisone or methylprednisolone|Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
214850031|NCT03259685|OTHER|710 ml of regular soft drinks, taken daily for 10 weeks|Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).
214850032|NCT03259685|OTHER|710 ml of diet soft drinks, taken daily for 10 weeks|Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
214850033|NCT03259685|OTHER|710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks|Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
214850034|NCT05859243|BEHAVIORAL|Traditional concurrent training|The subjects will perform two sessions per week of traditional concurrent training, consisting of strength training followed by aerobic exercise over 12 weeks, with progressive intensities and training volumes. Each traditional concurrent training session will consist of specific warm-up performed on equipment for upper and lower limbs with a load of less than 30% of the training load. Then the bench press, low row, leg press, extension and knee flexion exercises will be performed. Participants will be instructed to perform the concentric phase of the movement in one second and the eccentric phase in two seconds. After strength training, aerobic training (walking outdoors or on a treadmill) will be performed with intensity based on the adapted BORG effort perception scale (ranged to 0 = minimum effort, to 10 = maximal effort).
214850035|NCT05859243|BEHAVIORAL|Concurrent training consisting of strength training combined with dance classes|Each concurrent training session associated with dance classes will consist of the same strength training as the traditional concurrent training group, but the traditional aerobic training will be replaced by a dance class. Each dance class will consist of a 5-minute general warm-up with joint mobility exercises and dynamic stretching. Then the main part will be performed with the elaboration of choreography, lasting approximately 20 minutes. Finally, there will be a 5-minute cool-down with stretching exercises. Classes will be held in four different dance modalities, divided into four modules.
214850036|NCT01343875|PROCEDURE|tear of the distal tendon in the biceps muscle|
214850037|NCT05183412|DEVICE|The Sedakit Oncomfort VR glasses (30-minutes Aqua program)|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone. The patients watch a VR underwater view of the ocean while listening to speeches to induce relaxation and meditation.
214850038|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery without VR glasses|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are NOT subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone.
214850039|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Ultrasound-guided regional nerve block and hand surgery with VR glasses
214850040|NCT06380374|OTHER|Gamification in Disaster Nursing Education|The contact information of the students who meet the inclusion criteria will be collected by the researchers. The topic of disaster nursing will be explained to all students enrolled in the course by the researcher in the classroom environment. Pre-tests will be taken from students attending the course on disaster nursing. Randomization will be carried out by the researcher, who does not have an active role in the research process. Students in the experimental and control groups will be hidden from the researchers, who will conduct the application until it begins. The Program will be carried out face-to-face. Students in the experimental group will be on the playground. Students will attend the sessions in groups of 6. Each student will compete independently within the group, and each group will have a winner. Students will encounter a total of 30 questions in each game round. The entire game process consists of 7 sessions. After the game process is completed, post-tests will be taken.
214850041|NCT04864808|BEHAVIORAL|Behavioral Parent Training|Parents will receive sessions of behavioral parent training with components specifically targeted toward parents with ADHD. The number of sessions will be informed based on stakeholder feedback. Treatment will be delivered via telehealth.
214850042|NCT06322966|OTHER|Air Action Curriculum|"The goal of integrating a new curriculum into classrooms is to improve student knowledge on the health effects of air pollution, specifically of wildfire smoke.~The goal is to implement a student-designed and student-driven air quality study in each school that will lead to improved air quality and health impacts in schools, promote health equity, and train young people to be more informed about their health and proactive citizens in their school community and beyond."
214850043|NCT05358704|DRUG|combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)|To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
214850044|NCT05565105|RADIATION|Total Body Irradiation (TBI)|Hyper-fractioned TBI is administered by a linear accelerator at a dose rate of \< 15 cGy/minute.
214850045|NCT05565105|DRUG|Thiotepa|Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).
214850046|NCT05565105|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m\^2 x 5 if cyclophosphamide is contraindicated
214850047|NCT05565105|DRUG|Busulfan|Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
214850048|NCT05565105|DRUG|Melphalan|Melphalan: 70 mg/m\^2/day x 2
214850049|NCT05565105|DRUG|Fludarabine|Fludarabine: 25 mg/m\^2/day x 5
214850050|NCT03520491|DRUG|Nivolumab|Nivolumab 3 mg/kg or Nivolumab 1 mg/kg
214850051|NCT03520491|DRUG|Ipilimumab|Ipilimumab 3 mg/kg
214850052|NCT03520491|PROCEDURE|Radical cystectomy|RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)
214850053|NCT03377387|DRUG|Capecitabine|Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
214850054|NCT03377387|DRUG|Neratinib|Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Phase II The MD has been determined as 240mg of neratinib
214850055|NCT03377387|BEHAVIORAL|EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30|Questionnaires Every Cycle (+/- 3 days) (For phase II)
214850056|NCT01901172|DRUG|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
214850057|NCT01901172|DRUG|RO5503781|Daily for 5 days followed by 23 days rest per cycle
214850058|NCT01901172|DRUG|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
214850059|NCT01901172|DRUG|RO5503781|Single doses Days 1 and 11
214663462|NCT03154138|DEVICE|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
214663463|NCT03926403|OTHER|"State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)"|"Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least lightly anxious about their management (score ≥ 36)."
214663464|NCT03926403|PROCEDURE|hypnosis techniques|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
214663465|NCT03926403|PROCEDURE|local anaesthesia|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
214663466|NCT05013060|DIETARY_SUPPLEMENT|Probiotics and microcapsulated sodium butyrate|The patients who give their consent to take part in this study, will receive an oral microencapsulated sodium butyrate and a mixture of probiotics formulation 2 times a day for a period of 12 weeks.
214663467|NCT05013060|DIETARY_SUPPLEMENT|Maltodextrin|The patients who give their consent to take part in this study will receive an oral maltodextrin as placebo 2 times a day for a period of 12 weeks.
214663468|NCT00841724|DRUG|Fludarabine, Busulfan, Thymoglobuline|
214663469|NCT00893789|DRUG|Armodafinil|Armodafinil 50 mg/day
214663470|NCT00893789|DRUG|Armodafinil|Armodafinil 150 mg/day
214663471|NCT00893789|DRUG|Armodafinil|Armodafinil 250 mg/day
214663472|NCT00893789|OTHER|Placebo|Placebo
214663473|NCT01174914|OTHER|ARV's + Placebo|Patients continued ARV's plus a placebo nightly for 9 months
214663474|NCT01174914|DRUG|Naltrexone|Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
214663475|NCT01174914|DRUG|Naltrexone + ARV's|Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
214663476|NCT04127136|BEHAVIORAL|Multi-disciplinary obesity management therapy|In twenty weeks, trainings by the physician, dietitian, psychologist and physiotherapist are conducted about medical information about obesity, using the technology to aid weight loss, what, when, how and why to eat, nutrition groups, ration management, water consumption, self-awareness, stress management, obesity and the association between the psychological processes, warming up and mobilization, correct stance and posture, and adequate physical activity. In addition to group meetings, in monthly individual meetings, the progress of the patients are evaluated.
214663477|NCT02316444|BIOLOGICAL|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
214663478|NCT04427085|OTHER|Ultrasound assessment of optic nerve sheath diameter|Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.
214663479|NCT04887298|DRUG|Liposomal Annamycin (L-Annamycin)|2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
214663480|NCT05089630|BIOLOGICAL|Pentamer (low)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
214663481|NCT05089630|BIOLOGICAL|Pentamer (med)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
214663482|NCT05089630|BIOLOGICAL|Pentamer (med)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
214663483|NCT05089630|BIOLOGICAL|Pentamer (high)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
214663484|NCT05089630|COMBINATION_PRODUCT|Placebo (saline)|Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
214663485|NCT00691548|DRUG|Cetuximab-Zr. 89|"Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.~On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.~Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg)."
214850060|NCT01901172|DRUG|posaconazole|Multiple doses Days 8-14
214663486|NCT05439031|RADIATION|Stereotactic Arrhythmia Radiotherapy|Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
214663487|NCT06145230|OTHER||
214663488|NCT00499707|DRUG|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
214663489|NCT05267028|OTHER|AD-TAR|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
214663490|NCT05267028|OTHER|AD-Cognitive Stimulation|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
214663491|NCT06085066|PROCEDURE|Conventional Ultrafiltration alone on Cardiopulmonary bypass|Conventional Ultrafiltration was used on Cardiopulmonary bypass for patients who underwent open heart surgery
214663492|NCT06085066|PROCEDURE|Conventional Ultrafiltration followed by Modified Ultrafitration on Cardiopulmonary bypass|Modified Ultrafiltration was used following the Conventional Ultrafiltration on Cardiopulmonary bypass for patients who underwent open heart surgery
214663493|NCT01099345|PROCEDURE|cystometry (CMG)|recording device measuring pressures though catheters placed in bladder and rectum
214663494|NCT01099345|PROCEDURE|polysomnography (PSG)|Recording device measuring sleep activity through electrodes attached to the subject
214663495|NCT05265351|DIAGNOSTIC_TEST|Transdiaphragmatic pressure measurement|Ultrafast ultrasound imaging of the diaphragm during artificially evoked responses
214850061|NCT06063174|BEHAVIORAL|Education Program|12-week online psychoeducation program on environmental pollution exposures, the health impacts and sources of these exposures, and practical ways to reduce these exposures. Participants in the active control group will receive this form of intervention.
214663496|NCT05265351|DIAGNOSTIC_TEST|EMG|Surface electromyography of the diaphragm for phrenic nerve conduction study
214663497|NCT03554512|OTHER|Telehealth virtual appointment|Appointment with NICU clinician via telehealth equipment.
214663498|NCT04723537|DRUG|Part A: Upamostat 200 mg|1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
214663499|NCT04723537|DRUG|Part A: Upamostat 400 mg|2 capsules, each capsule comprising 200 mg of upamostat
214663500|NCT04723537|DRUG|Part A and B: Placebo|1 or 2 capsules, each capsule a matching placebo
214663501|NCT04723537|DRUG|Part B: Upamostat 200 or 400 mg|"Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days."
214850062|NCT06063174|BEHAVIORAL|Think Well Program|12-week online program in which participants learn to identify negative emotion and thinking patterns and participate in live online group coaching. Participants whose thinking style domain is dysregulated will be assigned to this intervention program.
214850063|NCT06063174|BEHAVIORAL|Be Well Program|12-week online program in which participants learn about the importance of social relationships, connectedness, and interpersonal conflicts, and participate in live online group coaching. Participants whose social relationship/conflict domain is dysregulated will be assigned to this intervention program.
214850064|NCT06063174|BEHAVIORAL|Eat Well Program|12-week online program in which participants learn about mindful eating and participate in live online group coaching. Participants whose diet domain is dysregulated will be assigned to this intervention program.
214850065|NCT06063174|BEHAVIORAL|Sleep Well Program|12-week online program in which participants learn about the importance of good sleep and participate in live online group coaching. Participants whose sleep domain is dysregulated will be assigned to this intervention program.
214850066|NCT06063174|BEHAVIORAL|Move Well Program|12-week online program in which participants learn about the importance of adequate physical activity for health and participate in live online group coaching. Participants whose physical activity domain is dysregulated will be assigned to this intervention program.
214850067|NCT01086345|RADIATION|radiosurgery|Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
214850068|NCT01086345|BIOLOGICAL|bevacizumab|Given IV
214850069|NCT01086345|DRUG|irinotecan hydrochloride|Given IV
214850070|NCT05601076|PROCEDURE|fixed with the triple-buffer system|The steps were as follows: i) elastic cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) was used at the proximal 15 cm from the incision, with 5 × 2.5 cm pieces glued to the skin and fixed with the drainage tube using surgical knots; ii) the distal end of the ligation was fixed using the same method, while the ligation position was higher than the first; iii) the ligature point was fixed next to the elastic soft cotton tape (5 × 5 cm), using the high-platform method to fix the drainage tube, with the drainage tube curved; and iv) the drainage tube between the two fixed points was inserted with a specific radian.
214850071|NCT05601076|PROCEDURE|fixed using the conventional lifting platform method|In terms of the control group, two lines of flexible cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) measuring 10 × 2.5 cm were used, and the drainage tube was fixed parallel to the long axis and glued to the middle-position 360° winding tube once the drainage tube was 0.5 cm higher than the surrounding skin. Next, the drainage tube was fixed at both ends to the patient's skin using adhesive tape. Then, the tube and the adhesive plaster were overlapped vertically and horizontally, the tube was inserted, the adhesive plaster was added, and then the chest tube was fixed on the adhesive plaster by knotting the interspersed cotton rope, which was equal to indirectly fixing the tube on the patient's skin
214850072|NCT03162068|OTHER|Osteodensitometry and pQCT|The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
214850073|NCT05752708|DIAGNOSTIC_TEST|Diagnostic Test|Evaluation of perioperative anxiety in parents of children undergoing thoracic surgery using standardized tests: The Amsterdam Preoperative Anxiety and Information Scale (APAIS), the State-Trait Anxiety Inventory (STAI).
214850074|NCT05886309|DIAGNOSTIC_TEST|Collection of Blood samples|"The following samples will be drawn from each study participant immediately after the venipuncture performed for the whole blood donation:~* 1 sample with no anticoagulant (5 ml) for SF measurement with the CDMS method~* 1 EDTA (Ethylendiamintetraazetat) sample (7,5 ml) for a complete blood count with red blood cell indices and reticulocytes~* 1 EDTA sample (2,7 ml) for the measurement of hepcidin~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of SF with the ECLIA (Electrochemiluminescence-enzymeimmunoassay) and of the complete set of iron biomarkers (Transferrin Saturation, serum iron, Soluble Transferrin Receptor)~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of CRP (C-reactive Protein)~* 1 sample with no anticoagulant (5 ml) for the measurement of SF with the CMIA (Chemiluminescence Immunoassay)~* 1 sample with no anticoagulant (5 ml) for storage"
214850075|NCT06392789|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Receive sleep education
214850076|NCT06392789|OTHER|Internet-Based Intervention|Receive access to website content modules
214850077|NCT06392789|OTHER|Medical Device Usage and Evaluation|Wear activity tracker
214850078|NCT06392789|OTHER|Questionnaire Administration|Ancillary studies
214850079|NCT06392789|OTHER|Text Message-Based Navigation Intervention|Receive sleep compression SMS conversations
214663502|NCT04984135|PROCEDURE|Percutaneous coronary intervention|All patients were treated with a loading dose of clopidogrel 300 or 600 mg before the procedure followed by maintenance clopidogrel 75 mg daily for 6 months. 100 U/ kg of unfractionated heparin was injected intravenously to maintain an activated clotting time ≥ 250 s during the procedure. For DCB treatment, the patient underwent predilation with an optimal-sized balloon (non-compliant balloon or cutting balloon) based on angiography (balloon-to-vessel ratio of 1.0), with the standard balloon shorter than the intended DCB size. The DCB was sized at 1:1 balloon-to-vessel ratio, delivered rapidly (median of 15 s) and inflated at nominal pressure for 60 s.
214663503|NCT00746772|DRUG|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
214663504|NCT00746772|DRUG|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
214663505|NCT02406755|OTHER|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
214663506|NCT02406755|OTHER|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
214663507|NCT02406755|OTHER|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
214663508|NCT05408858|BEHAVIORAL|LGBTQ-affirmative cognitive behavioral group therapy|10 sessions of supportive, LGBTQ-affirmative psychotherapy
214663509|NCT00432198|DRUG|Zolpidem (Myslee®)|Oral
214663510|NCT00432198|DRUG|placebo|Oral
214663511|NCT03115385|DIETARY_SUPPLEMENT|VSL#3|VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
214663512|NCT03115385|DIETARY_SUPPLEMENT|Placebo|A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
214663513|NCT06510478|BEHAVIORAL|Group Life Skill Intervention|This 13-session life skills program covers essential topics in one-hour sessions. It starts with introductions and team building, then progresses through leadership, self-esteem, communication, stress management, positive thinking, confidence building, volunteering, decision-making, problem-solving, conflict resolution, and negotiation. Each session includes ice-breakers, discussions, and targeted exercises. Each session incorporates ice-breakers, open discussions, and targeted exercises to ensure active learning and skill internalization. Duration of each session was 1 hour.
214663514|NCT06510478|BEHAVIORAL|Treatment as Usual for Control Group|Standard psychological interventions i.e. Debreathing, Meditation, supportive counseling, or psychoeducation.
214663515|NCT02755636|BEHAVIORAL|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
214663516|NCT02755636|OTHER|Usual care|Primary care as usual
214850080|NCT05028062|DRUG|XR-NTX 380 mg, intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
214850081|NCT05028062|BEHAVIORAL|Medical Management|All subjects will receive 8 weeks of medical management (Pettinati et al. 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
214850082|NCT05028062|DRUG|Placebo intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
214850083|NCT03535857|DEVICE|PTNS|Use of PTNS on the ankle for 30 minutes
214850084|NCT06316804|BEHAVIORAL|Video Intervention 1|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
214850085|NCT06316804|BEHAVIORAL|Video Intervention 2|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
214850086|NCT06316804|BEHAVIORAL|Video Intervention 3|An experimental self-administered video-based mobile app with narratives on mental illness after the waitlist period has been completed. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
214850087|NCT05909059|DRUG|Fludarabine|Received IV on Days -5 to -3 before CAR T cell therapy
214850088|NCT05909059|DRUG|Cyclophosphamide|Received IV on Days -5 to -3 before CAR T cell therapy
214850089|NCT00380757|PROCEDURE|bystander CPR using 30:2 ratio vs 15:2 ratio|Participants will use 2 CPR techniques with different chest compression to ventilation ratios
214850090|NCT03854344|DRUG|Lidocaine Hydrochloride|Injected subcutaneously for skin graft harvesting
214850091|NCT03854344|DRUG|Liposomal bupivacaine|Injected subcutaneously for skin graft harvesting
214663517|NCT03393351|OTHER|Shared decision-making program|"The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~1. shared decision-making trainings for health care professionals,~2. individual coaching for physicians,~3. patient activation strategy,~4. provision of patient information material and decision aids,~5. revision of the clinics quality management documents, and~6. critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3."
214663518|NCT03393351|OTHER|Usual Care|No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
214663519|NCT00058799|BIOLOGICAL|Dose Level 1|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
214663520|NCT00058799|BIOLOGICAL|Dose Level 2|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
214663521|NCT00058799|BIOLOGICAL|Dose Level 3|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 4.2 x 10\^7
214663522|NCT04419506|DRUG|BI 1015550|18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
214663523|NCT04419506|DRUG|Placebo|placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
214663524|NCT05839132|PROCEDURE|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
214663525|NCT02396862|DRUG|Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
214663526|NCT00715715|DRUG|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
214663527|NCT05352217|DEVICE|Mobile app ovarian cancer followup (ePRO)|The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.
214663528|NCT01268397|PROCEDURE|open reduction and internal fixation with a volar plate|flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion
214663529|NCT01268397|PROCEDURE|closed reduction and plaster treatment|closed reduction, below elbow plaster cast, semicircular for 5 week
214663530|NCT04933097|DEVICE|Microfet2®|"Conducting a day hospitalization including analyses:~1. Quantitative muscular analysis by measuring the DEXA of the whole body, the reference method for measuring body compartments and allowing the diagnosis of sarcopenia (IMMA\<7 in men and 5.5 in women)~2. Qualitative muscular analysis:~   * isokinetic measurement of muscular strength carried out on 3 muscle groups using a manual measurement sensor such as Microfet2 ® : quadriceps, triceps brachii, biceps~  * measurement of grip strength using Jamar® equipment validated as recommended by the EWGSOP~  * a walking test to assess the functional impact of sarcopenia and its severity"
214663531|NCT05983302|DRUG|Platelet-Rich Plasma-Fibrin Glue|The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
214663532|NCT05983302|DRUG|Repairing Gel|The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
214663533|NCT05983302|DRUG|Repairing Gel and Platelet-Rich Plasma-Fibrin Glue|The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
214663534|NCT05983302|OTHER|Classical wound irrigation (control)|For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
214663535|NCT05374941|DEVICE|Injectable and wearable neurostimulator for the hypoglossal nerve|Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve
214663536|NCT02513940|DRUG|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
214663537|NCT02513940|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
214663538|NCT02513940|DRUG|Placebo|Subjects will receive placebo transdermal gel and placebo (lactose) capsules
214663539|NCT02513940|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
214663540|NCT06281873|PROCEDURE|closure by PRF membrane|Oral fistulectomy was done with proper curettage. EMMA was performed. closure of the OAF by application of PRF membrane and covering it with an acrylic splint
214663541|NCT00354068|DRUG|imatinib mesylate|
214663542|NCT00354068|DRUG|temozolomide|
214663543|NCT00354068|OTHER|pharmacological study|
214663544|NCT01599351|RADIATION|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
214663545|NCT05823493|BEHAVIORAL|Schroth exercise therapy|The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.
214850092|NCT03854344|DRUG|Bupivacaine Hydrochloride|Used for regional nerve block for skin graft harvesting
214850093|NCT06324409|BEHAVIORAL|Reminder telephone call|A reminder telephone call with information on colorectal cancer screening in the language of origin (Urdu or Somali) in addition to the reminder letter in Norwegian (usual care)
214850094|NCT04407299|BEHAVIORAL|self-administered structured questionnaire|It was designed as a self-administered questionnaire with closed questions (yes/no questions, rating scale and multiple choice questions) and some open ended questions.
214850095|NCT00101842|DRUG|Pemetrexed|
214850096|NCT00101842|DRUG|Gemcitabine|
214850097|NCT00101842|DRUG|Platinol|
214850098|NCT02486913|OTHER|Enhanced Health Check|National Health Service Health Check enhanced by risk report
214850099|NCT04892121|OTHER|Prevention exercises|Participants will have to follow a warm-up prevention program (15 minutes) twice a week
214850100|NCT05574894|DRUG|Growth hormone|Growth hormone is supplemented during the ovarian stimulation till the day of trigger
214850101|NCT05574894|DRUG|GnRH antagonist|GnRH antagonist protocol for ovarian stimulation
214850102|NCT06286644|DIETARY_SUPPLEMENT|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo, 0,125 mg, 0,375 mg or 0,75 mg soluble Xanthohumol)
214850103|NCT06286644|DIETARY_SUPPLEMENT|Iso-alpha-Acids|Participants receive a study drink supplemented with Iso-alpha-Acids (0 mg = Placebo, 15 mg, 45 mg or 90 mg Iso-alpha-Acids)
214850104|NCT06286644|DIETARY_SUPPLEMENT|Xanthohumol + Iso-alpha-Acids|Participants receive a study drink supplemented with Xanthohumol + Iso-alpha-Acids (0 mg = Placebo, 0,125 mg + 15 mg , 0,375 mg + 45 mg or 0,75 mg + 90 mg soluble Xanthohumol + Iso-alpha-Acids)
214850105|NCT05529511|OTHER|Phase 1 - semi-structured interviews|Semi-structured face-to-face or virtual interviews.
214850106|NCT05529511|OTHER|Phase 2 - consensus meeting|Face-to-face or virtual meeting(s)
214850107|NCT06142929|PROCEDURE|Microfasciectomy|Using the microscope in Dupuytren's surgery
214850108|NCT06323551|OTHER|Mother's Smell|The mother of each baby whose heel blood will be taken will be given a specially made cover made of 100% cotton yarn, sterilized the day before, and the mother will be asked to put the cover on her bare skin (on her bare skin) after the shower and to keep the cover on the mother's chest for one night (8 hours). one).
214850109|NCT06323551|OTHER|Mother's Breast Milk Smell|In the study group that will be made to smell the scent of breast milk, the procedures for the scent of the mother will be carried out in the same way, and 20 drops of each baby's own mother's milk will be dropped onto the diaper.
214850110|NCT03363464|DRUG|Empagliflozin|Empagliflozin
214850111|NCT03363464|DRUG|DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor
214850112|NCT03363464|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist
214850113|NCT01730040|DRUG|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
214850114|NCT01730040|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
214850115|NCT01730040|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
214850116|NCT01730040|DRUG|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
214663546|NCT05823493|DEVICE|laser therapy|Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
214663547|NCT00875771|DRUG|Capecitabine+Irinotecan+Bevacizumab|"* Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~* Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~* Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity."
214850117|NCT01730040|DRUG|Placebo|Placebo for alirocumab and ezetimibe.
214850118|NCT06026852|DEVICE|Prediction of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, a prediction will be made by developed machine learning models about the expected plasma concentration of piperacillin-tazobactam or meropenem by using routinely collected health care data.
214850119|NCT06026852|DIAGNOSTIC_TEST|Determination of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, the total plasma concentration of piperacillin-tazobactam or meropenem will be determined. Were possible, this will be done using a blood sample that was collected during routine daily bloodwork which is performed in the morning. If no routine sample is available, a study specific sample will be drawn at approximately the same time as a routine sample would be drawn.
214850120|NCT06026852|OTHER|Daily short questionnaire|Physicians who care for patients included in the study will be asked to fill in a short daily questionnaire that evaluates the perceived necessity and added value of daily therapeutic drug monitoring.
214850121|NCT06093087|PROCEDURE|SAIF|The patient was placed in a prone position under general anesthesia. Using a C-arm X-ray machine and a positioning plate for navigation, the target position on the vertebral body was located one the surface of the body. The puncture needle core was withdrawn after puncturing, and a guide needle was inserted. After removing the puncture needle sleeve, a hollow bone cement screw was screwed into the anterior column of the vertebral body through the guide needle. Subsequently, bone cement was injected into the appropriate position through the bone cement screw to restore the vertebral height
214850122|NCT06093087|PROCEDURE|BKP|The patient was placed in a prone position after general anesthesia. Using a C-arm X-ray machine and a positioning plate for guidance, the target position on the vertebral body was located from the surface of the body. A puncture needle sleeve was inserted into the vertebral body. A PKP balloon was then inserted to perform vertebral restoration. After removing the balloon, an appropriate amount of bone cement was injected to ensure even distribution within the vertebral body. Vertebral height augmentation and restoration will then be achieved.
214850123|NCT06182904|DEVICE|Dynamic compression plate|Fixation of fibula in some cases with dynamic compression plate
214850124|NCT04808830|OTHER|Evaluation of musculoskeletal pain prevalence|Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.
214850125|NCT04808830|OTHER|Evaluation of quality of life|Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.
214850126|NCT04808830|OTHER|Evaluation of functional exercise capacity|Functional exercise capacity will be evaluated using 6-min walk test.
214850127|NCT04808830|OTHER|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form
214850128|NCT05082324|OTHER|Adapted physical activity|Patient participates in an adapted physical activity program for 3 months, with 2 one-hour sports sessions per week
214850129|NCT04027374|PROCEDURE|Fetal surgery for MMC repair|Fetal surgery for MMC repair
214850130|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunocytochemistry (ICC)|PD-L1 expression in the cytological specimens will be assessed using different antibodies.
214850131|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunohistochemistry (IHC)|PD-L1 expression in the histological specimens will be assessed using different antibodies.
214850132|NCT03529643|DRUG|Dexmedetomidine|Anesthesia with sevoflurane-remifentanil-dexmedetomidine
214850133|NCT03529643|OTHER|Without dexmedetomidine|Anesthesia with sevoflurane-remifentanil
214850134|NCT01317784|DEVICE|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
214850135|NCT01317784|DEVICE|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
214663548|NCT00862381|DRUG|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
214850136|NCT01317784|DEVICE|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
214850137|NCT01317784|DEVICE|HIV only|Choice of 4 different tests for HIV only.
214850138|NCT06214611|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy in the head and neck region
214850139|NCT00067171|BEHAVIORAL|Behavior Therapy|
214850140|NCT06449872|DEVICE|Obstetrics and Gynecology clinical applications for ultrasound diagnostic systems|Up to 5 healthcare professionals trained and experienced in Obstetrics and Gynaecology ultrasound qualitatively assessed the diagnostic image quality of the Kosmos Diagnostic Ultrasound System against the benchmark Mindray M9 Ultrasound System.
214850141|NCT05394766|OTHER|Omada Hypertension Program|The Omada Program: an online program that offers comprehensive lifestyle self-management support for hypertension.
214850142|NCT01042535|BIOLOGICAL|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
214663549|NCT00862381|DRUG|Placebo|NaCl 0.9%
214663550|NCT02783560|BEHAVIORAL|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
214663551|NCT02783560|BEHAVIORAL|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
214663552|NCT00112476|DRUG|bryostatin 1|Given IV
214663553|NCT00112476|DRUG|temsirolimus|Given IV
214663554|NCT02912663|DRUG|Verapamil and Magnesium Sulfate|Single dose strategy will be used
214663555|NCT02912663|OTHER|Placebo|Single matching dosing strategy will be used
214663556|NCT01973283|DRUG|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
214663557|NCT03023748|DRUG|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
214850143|NCT01042535|DRUG|1-methyl-d-tryptophan|Given orally (PO)
214850144|NCT01042535|OTHER|Laboratory biomarker analysis|Correlative studies
214850145|NCT04801719|DEVICE|Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK|Randomised patients in selected arm received endoluminal RFA by 8F catheter (Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK) before stenting procedure. Repeated ablations were processed through stenotic areas of bile ducts (10W, 90-120s, Rita 1500, Angiodynamics Ltd), all drained biliary tracts were used for introducing catheter and performance of ablation. Ablation procedure was followed with uncovered self-expandable metal stent insertion.
214850146|NCT00117741|BEHAVIORAL|Dialectical Behavior Therapy|Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
214850147|NCT00117741|BEHAVIORAL|Drug Counseling|Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
214850148|NCT01546142|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
214850149|NCT01546142|DRUG|Placebo|Phosphate buffered saline placebo for injection
214850150|NCT00682617|BEHAVIORAL|Structured exercise program|Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
214850151|NCT00682617|BEHAVIORAL|Waitlist, delayed intervention|Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
214850152|NCT05698706|DEVICE|TOOsonix System ONE-M|Selected BCC sites will be treated using high intensity focused ultrasound
214850153|NCT06468306|PROCEDURE|non-invasive ventilation teraphy, NIV|Routine management regimes of NIV
214663558|NCT04700267|DRUG|GLPG3970 film-coated tablet|GLPG3970 for oral administration
214663559|NCT04700267|DRUG|Placebo film-coated tablet|Placebo for oral administration
214850154|NCT01213836|DRUG|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
214663560|NCT05549388|OTHER|Front-of-pack labeling|The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.
214850155|NCT01213836|DRUG|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
214850156|NCT01213836|DRUG|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
214850157|NCT01213836|DRUG|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
214850158|NCT04531670|BEHAVIORAL|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
214850159|NCT04531670|OTHER|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
214850160|NCT05150756|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]|At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery
214850161|NCT05150756|DRUG|morphine sulphate (10mg/ ml ampoule)|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
214850162|NCT02450877|DRUG|Azacitidine|
214850163|NCT02450877|OTHER|Control Arm|
214850164|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
214850165|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
214850166|NCT00255151|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
214850167|NCT05332834|BIOLOGICAL|SM17|Peripheral intravenous injection
214850168|NCT05332834|OTHER|Placebo|Peripheral intravenous injection
214850169|NCT00107042|BIOLOGICAL|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
214850170|NCT00107042|BIOLOGICAL|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
214850171|NCT01431352|DRUG|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
214850172|NCT01431352|DRUG|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
214850173|NCT01764867|DRUG|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
214850174|NCT01764867|DRUG|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
214850175|NCT01764867|OTHER|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
214850176|NCT01764867|OTHER|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
214850177|NCT01764867|DRUG|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850178|NCT01764867|DRUG|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850179|NCT01764867|DRUG|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850180|NCT01764867|DRUG|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850181|NCT01764867|DRUG|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850182|NCT01764867|DRUG|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850183|NCT01764867|DRUG|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850184|NCT01764867|DRUG|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850185|NCT01764867|DRUG|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850186|NCT01764867|DRUG|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850187|NCT01764867|DRUG|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
214850188|NCT05828355|OTHER|Knee Care@Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
214850189|NCT01758419|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
214850190|NCT01613664|DRUG|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
214850191|NCT01613664|OTHER|no tisseel|the surgeon does not applied tissucol during the surgery
214850192|NCT04625075|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with gadolinium and manganese contrast
214850193|NCT04625075|DIAGNOSTIC_TEST|Cardiac CT|Cardiac CT to assess coronaries
214850194|NCT04625075|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|ECG to assess rhythm
214850195|NCT04625075|DIAGNOSTIC_TEST|Blood samples|renal function liver function full blood count, hematocrit glucose
214850196|NCT00873106|DEVICE|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
214850197|NCT03934749|DEVICE|Non Invasive Ventilation|NIV using standard mode or Lowenstein mode
214850198|NCT02825329|DEVICE|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
214850199|NCT00444093|DRUG|Opii normata treatment|"After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day."
214850200|NCT00444093|DRUG|Loperamid Treatment|"All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day."
214850201|NCT00423683|DRUG|Arixtra alone|Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
214850202|NCT00423683|DEVICE|Arixtra + filter|Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
214850203|NCT05466344|DEVICE|Herbst Group|"1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~4. Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~5. When reactivation of the telescopic piston is needed, extension rings are used."
214850204|NCT05466344|DEVICE|TFBC Group|"1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~5. Finally follow finishing steps for each patient."
214850205|NCT03740620|PROCEDURE|Bevel facing the cephalad direction of the patient|The bevel of the nasotracheal tube facing cephalad direction of the patient
214850206|NCT03740620|PROCEDURE|Bevel facing leftward of the patient|The bevel of the nasotracheal tube facing the left side of the patient
214850207|NCT02601274|DRUG|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
214850208|NCT01286558|DRUG|40 mg telmisartan|once daily
214850209|NCT01286558|DRUG|5 mg amlodipine|once daily
214850210|NCT01286558|DRUG|5 mg amlodipine|once daily
214850211|NCT01286558|DRUG|80 mg telmisartan|once daily
214850212|NCT03778723|DRUG|Total intravenous anesthesia (TIVA)|Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
214850213|NCT03778723|DRUG|Inhalation Anesthesia|Sevoflurane at a concentration of 2-2.5%
214850214|NCT03778723|DRUG|Rescue fentanyl|Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
214850215|NCT01674439|PROCEDURE|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
214850216|NCT01674439|PROCEDURE|Without supplementation of ADRC|Standard fat graft preparation
214850217|NCT00872924|DRUG|sumatriptan 100mg|
214850218|NCT06616935|OTHER|Intervention group one, community activities.|"Intervention group one: participants will have a list of free activities in the community provided by third sector organisations to choose from. Participants will be referred to their chosen activities and expected to attend for six months.~Intervention group two: Participants will attend weekly online exercises and activities led by the researcher."
214850219|NCT06616935|OTHER|Intervention group two|Online exercises and activities
214850220|NCT01407224|BEHAVIORAL|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
214850221|NCT03037034|DEVICE|Forcep|"Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current."
214850222|NCT00362817|DRUG|carboplatin|IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
214850223|NCT00362817|DRUG|temozolomide|150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
214850224|NCT05205018|BEHAVIORAL|Motivational interviewing performed remotely through videocalls|Remote motivational interviewing will be performed seven time over 12 months, through videocalls. The first four interventions will be performed within two months and the following three will be performed at five, eight and eleven months from enrollment.
214850225|NCT04104984|DEVICE|transvaginal ultrasound|a transvaginal ultrasound is done to patient to determine cervical length
214850226|NCT04104984|DRUG|Progesterone Vaginal Suppository|a progesterone vaginal suppository to prevent preterm labour
214850227|NCT04104984|PROCEDURE|cervical cercalage|Mcdonald's cervical cercalage . a stitch taken around the cervix to prevent preterm labour
214850228|NCT04104984|OTHER|digital vaginal exam|vaginal examination to detect short cervix
214850229|NCT04104984|DEVICE|abdominal ultrasound|use abdominal ultrasound to measure cervical length
214850230|NCT04104984|DRUG|Tocolytic Agents|a medication is given to prevent uterine contraction
214850231|NCT03662308|DEVICE|Heated Vest|Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
214850232|NCT03662308|DEVICE|Non-Heated Vest|A similarly insulated (compared to the experimental vest), but non-heated vest
214850233|NCT01672359|DIETARY_SUPPLEMENT|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
214850234|NCT01672359|DIETARY_SUPPLEMENT|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
214850235|NCT01672359|DIETARY_SUPPLEMENT|Placebo|
214850236|NCT03897478|DIAGNOSTIC_TEST|ISCDX blood test|"The ISCDX test is based on gene expression changes that occur as a result of the ischemic stroke. When the stroke occurs, the immune system in the body reacts and causes changes in gene expression in several types of cells, including white blood cells, related to activation of innate and adaptive immune systems.~The ISCDX test distinguishes between cardioembolic and large artery atherosclerotic origin of stroke using a gene signature. The pattern or signature of up or down regulation for all genes for a patient determines whether the patient's pattern of gene expression is more like the pattern seen in other cardioembolic patients or more like the pattern seen in patients with large artery atherosclerotic cause of stroke."
214850237|NCT00782028|OTHER|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
214850238|NCT00782028|OTHER|Standard Care|
214850239|NCT01387425|DRUG|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
214850240|NCT01387425|DRUG|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
214850241|NCT00949455|DRUG|lapatinib ditosylate|Given orally
214850242|NCT00949455|OTHER|Placebo|Given orally
214850243|NCT06193824|DEVICE|Experimental: downhill treadmill walking at -10% and -20% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% or -20% incline)
214850244|NCT03171441|DIAGNOSTIC_TEST|nailfold videocapillaroscopy|non-invasive nailfold videocapillaroscopy
214850245|NCT03171441|DIAGNOSTIC_TEST|inflammatory biomarkers|blood sample collection to asses leptin and C-reactive protein
214850246|NCT03717519|DIAGNOSTIC_TEST|Measurement of platelet count at diagnosis|Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
214850247|NCT05012202|DEVICE|Hemi device|A sample of vaginal blood will be collected following delivery and analyzed by the device to provide a hematocrit level, which will be masked to the clinical team.
214850248|NCT01991288|PROCEDURE|SNB Saphenous Nerve Block|Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
214850249|NCT01991288|PROCEDURE|NSNB Non Saphenous Nerve Block|All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
214850250|NCT02857829|DIETARY_SUPPLEMENT|CAF+|CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).
214850251|NCT02857829|DIETARY_SUPPLEMENT|Caffeine-alone|Caffeine (100 mg)
214850252|NCT02857829|OTHER|Placebo|Rice flour
214850253|NCT04009889|DIETARY_SUPPLEMENT|capsule containing a probiotic blend of 5 different Lactobacilli|n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
214850254|NCT04009889|OTHER|capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.|n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
214850255|NCT01587131|BIOLOGICAL|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
214850256|NCT01956448|DEVICE|Drug eluting stent|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
214850257|NCT02190448|DIETARY_SUPPLEMENT|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
214850258|NCT02190448|DIETARY_SUPPLEMENT|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
214850259|NCT03432065|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
214850260|NCT05443269|DIETARY_SUPPLEMENT|Jump Start Nutritional Program|Nutri-meal Active meal replacement shake and Metabolism pill at breakfast, lunch, and dinner, morning and evening Health Pak (multivitamin), 1 probiotic stick, and 300 calories fruits and vegetables daily
214850261|NCT05115526|OTHER|PEEP setting|PEEP setting according to various methods
214850262|NCT06108258|DRUG|IV iron administration|IV iron administration during pregnancy
214850263|NCT04109313|DRUG|LOU064|Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
214850264|NCT04062149|OTHER|single leg stance treatment|SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
214850265|NCT04062149|OTHER|Usual physiotherapy|Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
214850266|NCT04594915|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics \[SmPC\]).
214476357|NCT06085820|BEHAVIORAL|Experimental (birth dance)|"Thanks to the birth dance, the expectant mother perceives less pain. In fact, it is known that a change in position is effective in the perception of pain. On the other hand, if the woman focuses on a point other than the pain during the act, it makes it easier for her to perceive the pain less. The low cost of this application increases its usability.~The most appropriate time for the birth dance is from the active phase of the first phase of labor until the end of this phase . The expectant mother dances with rhythmic movements accompanied by soothing and soothing music with the help of a birth supporter (midwife, relative, spouse or partner). Optionally, sacral massage can be added to the birth dance. In fact, in addition to reducing the pain experienced through freedom of movement, upright position and massage, it is also aimed to provide emotional support to the woman."
214663561|NCT06196411|BEHAVIORAL|Task-oriented Training|Task-oriented training will be applied to study group 5 days a week, for a total of 6 weeks, in addition to Bobath training. Task-oriented training will consist of performing the lying, sitting, standing and walking exercises by performing tasks for specific goals. Exercises will be perform by accomplishing tasks such as touching the ball with the upper or lower extremities, reaching for the ball, crossing various tracks to move blocks from one place to another, walking through obstacles or climbing stairs.
214850267|NCT02936687|DRUG|NOS Inhibition|NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure \~8-15 mmHg that is within the range observed during exercise.
214850268|NCT02936687|DRUG|ET-1 Inhibition|ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
214663562|NCT06196411|BEHAVIORAL|Bobath Training|Bobath Concept includes sensory, perceptual and adaptive exercises aimed at improving function through mobilisation, weight-bearing, practicing more normal movement patterns and performing more efficient, less effortful tasks.
214850269|NCT02936687|DRUG|NOS Inhibition Placebo|Saline will be infused at the same rate and quantity as the corresponding drug visit.
214663563|NCT03538028|BIOLOGICAL|INCAGN02385|INCAGN02385 administered as an intravenous infusion over 30 minutes.
214850270|NCT02936687|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
214850271|NCT02936687|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
214663564|NCT01938183|PROCEDURE|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
214663565|NCT01938183|DRUG|Metronidazole tablet|750 mg metronidazole tablets
214663566|NCT01938183|DRUG|placebo gel|semi-solid suspension containing carbopol
214663567|NCT01938183|DRUG|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
214663568|NCT03537664|PROCEDURE|Root canal preparation|First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
214663569|NCT03537664|PROCEDURE|Intracanal medication|The second endodontic treatment includes the intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation
214663570|NCT03529656|BEHAVIORAL|Early rehabilitation program for liver transplantation|Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
214663571|NCT03864276|DRUG|inhalation (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
214663572|NCT03864276|DRUG|total intravenous (propofol) anesthesia|Anesthesia is induced and maintained with propofol and sufentanil
214663573|NCT06491043|OTHER|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells
214663574|NCT01867489|OTHER|No intervention|
214663575|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 1|"The intervention is food product, made from locally available food ingredients in Bangladesh.~Sharnali 1 made from rice, lentil, dried skimmed milk, sugar, vegetable oils and micronutrient premix."
214663576|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 2|Sharnali 2 made from chick peas, dried skimmed milk, sugar, vegetable oils and micronutrient premix.
214663577|NCT01802944|DRUG|Intranasal Insulin|
214663578|NCT01802944|DRUG|Placebos|
214663579|NCT05015387|PROCEDURE|Minimally invasive non-surgical therapy|Under local anesthesia subgingival instrumentation with ultrasonic and hand instruments and magnification (4.5x) was performed.
214663580|NCT05015387|COMBINATION_PRODUCT|Subgingival application of collagen hydrogels with proanthocyanidins|Patients received collagen hydrogel chips with proanthocyanidins from Pelargonium sidoides root extract, placed subgingivally in periodontal pockets with PPD≥4mm after minimally invasive non-surgical therapy.
214850272|NCT02936687|OTHER|Oral Glucose Tolerance Test|The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
214850273|NCT02936687|DRUG|ET-1 Inhibition Placebo|Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
214850274|NCT01164306|BEHAVIORAL|LifeSkills Training|"LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.~Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions."
214850275|NCT01164306|BEHAVIORAL|Healthy Lifestyle Behavior Choices|"The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.~Parents will also be given health related information by mail to parallel the information students receive in school health classes."
214850276|NCT01164306|BEHAVIORAL|NRT and Motivational Interviewing (MI)|For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
214850277|NCT01322971|DRUG|Metronidazole|Metronidazole 500mg orally twice daily for seven days
214850278|NCT01322971|DRUG|Placebo|Placebo will be administered orally twice daily for seven days
214850279|NCT02280720|PROCEDURE|Stenting using Optimax™|
214850280|NCT02280720|PROCEDURE|Stenting using PROMUS Element™ Plus|
214850281|NCT02215148|DRUG|Tolvaptan|
214850282|NCT01552967|DRUG|Capecitabine|"Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles."
214850283|NCT03676166|DRUG|Cannabis|Inhaled cannabis
214850284|NCT01152866|DRUG|Choriogonadotropin alpha (r-hCG)|Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).
214850285|NCT00655850|DRUG|Paclitaxel|"* Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~* Dexamethasone 20mg, intravenously (IV)~* Diphenhydramine 50 mg IV~* Ranitidine 50 mg IV~* Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~* The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~* Dose Level 1 \_\_\_\_\_\_\_\_80 mg/m2/weekly~* Dose Level -1 \_\_\_\_\_\_\_\_70 mg/m2/weekly"
214850286|NCT00655850|DRUG|Gemcitabine|"Premedication~* Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~* Prior to receiving paclitaxel chemotherapy~* Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~* The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~* Dose Level 2 \_\_\_\_\_\_\_\_300 mg/m2/weekly~* Dose Level 1 \_\_\_\_\_\_\_\_200 mg/m2/weekly~* Dose Level -1 \_\_\_\_\_\_\_\_150 mg/m2/weekly"
214850287|NCT00655850|BIOLOGICAL|Avastin|"* The dose of Avastin is 10 mg/kg IV every 2 weeks~* It will be administered following the administration of chemotherapy~* The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~* It should not be administered or mixed with dextrose solutions."
214850288|NCT04429334|DRUG|nangibotide|nangibotide 1.0 mg/kg/h
214850289|NCT04429334|DRUG|placebo|matching placebo
214850290|NCT06013917|DEVICE|Cardiac Monitoring|FDA cleared ECG monitoring device that will be used to obtain ECG recordings and capture cardiac arrhythmias/events from participants
214850291|NCT02231424|DRUG|Drug: Berodual®|
214850292|NCT05628558|DRUG|Desmopressin|"The interventions with desmopressin recorded in this study were all realized following the internationally recommended standard care of patients with mild/moderate hemophilia A. They were all retrospectively collected. These interventions comprised:~* An intravenous administration of desmopressin infused during 30 minutes at a dosage of 0,3-0,4 µg/Kg~* Measurements of Factor and von Willebrand factors levels just before the desmopressin infusion and after at 30 minutes, 1 hour, 2 hours, 4 hours and for some patients 6 hours and 24 hours.~The F8 gene variants were also diagnosed in the standard care."
214850293|NCT04702724|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
214850294|NCT02110017|OTHER|fMRI social cognition task|fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
214850295|NCT06094907|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in an ascending fixed-order of 15mg and 60mg.
214850296|NCT06023849|DEVICE|IUD insertion|Trans Caesarean Intra Uterine Contraceptive Device Insertion and Conventional Postpartum 6 Weeks Insertion
214850297|NCT03702049|BEHAVIORAL|Nurse-led Community Health Worker TBI (RN/CHW TBI) program|Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
214850298|NCT04707586|OTHER|Cold Application|Created by the researcher; A bandage with 3 pieces of 13x10 cm cold gel and a cold gel container in which they are placed will be used, which can be adjusted according to the head circumference of the patient between 60-80 cm in length. The ability of the cold gel cups of the bandage to be moved on the bandage will allow comfortable cold application to the patient's bilateral frontotemporal and occipital areas at the same time. After waiting for 20 minutes in the freezer part of the refrigerator, the temperature and temperature of the gels applied and the cold application area before and after each application will be measured and recorded. An Infrared Non-Contact Food Thermometer will be used for temperature measurement of cold gel packs, and an Infrared Non-Contact Thermometer device will be used for temperature measurement of the cold application area.
214850299|NCT02434224|PROCEDURE|Music Therapy|2 to 3 sessions per week of individualized creative music therapy
214850300|NCT05889234|DEVICE|Modified Electroconvulsive Therapy|MECT is performed using the Thymatron System IV (Somatics LLC, LakeBluff, IL, USA) electroconvulsive therapy (ECT) machine. Prior to ECT, all patients undergo laboratory tests such as routine blood, liver, kidney and thyroid function and an ECG and remain fasted for 12 hours. Initial treatment power is considered by age: percentage of power = age x 0.7. Stimulation power is adjusted according to seizure duration. If the seizure duration is less than 25 seconds, the energy is increased by 5% in the subsequent treatments. Anaesthesia and muscle relaxation were administered with propofol (1.5-2 mg/kg) and succinylcholine (0.5-1 mg/kg), respectively, and subjects were awakened after ECT treatment and adverse effects, such as subjective memory impairment, headache or nausea/vomiting, were recorded. Frequency of ECT treatment: 3-4 times per week for a total of 6-8 sessions
214850301|NCT05889234|DRUG|Conventional pharmacotherapy|Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
214850302|NCT03362996|DIETARY_SUPPLEMENT|Freshly-Pressed Extra Virgin Olive Oil|Dietary Supplement: Freshly-pressed extra virgin olive oil Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
214850303|NCT03362996|COMBINATION_PRODUCT|extra virgin olive oil|Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
214850304|NCT03362996|OTHER|mediterranean diet|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
214850305|NCT02598258|OTHER|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
214850306|NCT05613725|OTHER|Blood sample collection|Blood sample collection
214850307|NCT01819324|BEHAVIORAL|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
214850308|NCT01819324|BEHAVIORAL|Standardized Lifestyle Management|SLM material (every other week for 4 months)
214850309|NCT00057486|DRUG|IL-12|
214850310|NCT01129934|DRUG|Morphine-Promethazine|administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
214850311|NCT01129934|DRUG|morphine|Administration of intravenous morphine 0.1 mg/kg
214850312|NCT03896282|OTHER|Mobilization at a dedicated daycare facility|"All THA's are performed using a standard posterolateral approach with simple posterior soft-tissue repair. No infiltration anesthesia (LIA) is used in THA's. All TKA's are performed with a standard medial parapatellar approach without the use of tourniquet. Physiotherapy is started as soon as possible after surgery in the dedicated day care facility. Time till first mobilization is recorded as is total time mobilized supervised by a physiotherapist before discharge.~Patients are discharged if fulfilling the discharge criteria before 8 pm. Number of hours spent in hospital in total is recorded."
214850313|NCT00573170|DRUG|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)
214850314|NCT00573170|DRUG|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]
214850315|NCT00573170|DRUG|placebo|placebo
214850316|NCT00167128|DEVICE|hearing aid, Phonak EduLink-FM System|
214850317|NCT03032861|OTHER|Orange juice|Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
214850318|NCT04132401|DIAGNOSTIC_TEST|algorithm|The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
214850319|NCT02446834|BEHAVIORAL|intensive lifestyle intervention|3 months low GI diet and exercise
214850320|NCT02446834|DRUG|GLP-1 Receptor Agonists|Use GLP-1 Receptor Agonists 3 months to treat PCOS
214850321|NCT02446834|DRUG|Metformin|Use metformin 3 months to treat PCOS
214850322|NCT02446834|DRUG|Acarbose|Use acarbose 3 months to treat PCOS
214850323|NCT05990582|DIAGNOSTIC_TEST|CBCL|A questionnaire on behaviour
214850324|NCT05990582|DIAGNOSTIC_TEST|SDQ|A questionnaire on behaviour
214850325|NCT05990582|DIAGNOSTIC_TEST|CCC-2-NL|A questionnaire on communcational skills
214850326|NCT05990582|DIAGNOSTIC_TEST|MCH Feeding scale|A questionnaire on feeding problems
214850327|NCT05990582|DIAGNOSTIC_TEST|TRF|A questionnaire on behaviour
214850328|NCT05990582|DIAGNOSTIC_TEST|WISC-5-NL|An IQ test for children
214850329|NCT05990582|DIAGNOSTIC_TEST|Movement ABC|A test to assess motor function
214850330|NCT05990582|DIAGNOSTIC_TEST|CELF-5-NL|A test to assess language development
214850331|NCT05990582|DIAGNOSTIC_TEST|Emma Toolbox|Test of executive functions
214850332|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
214850333|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
214850334|NCT01060475|DRUG|Placebo LIM-0705 and tacrolimus|Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
214850335|NCT01060475|DRUG|Drug LIM-0705 and placebo tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
214850336|NCT00986570|BIOLOGICAL|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
214850337|NCT00280072|DEVICE|Renal Assist Device|
214850338|NCT01565772|RADIATION|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
214850339|NCT01565772|DRUG|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
214850340|NCT01565772|DRUG|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
214850341|NCT01884922|DRUG|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
214850342|NCT01884922|DRUG|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
214850343|NCT03525730|DRUG|Valproic Acid|Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
214850344|NCT03525730|DRUG|Pyrimethamine|Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
214850345|NCT01747122|DEVICE|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
214850346|NCT01747122|DEVICE|Epidural|
214850347|NCT04583748|BEHAVIORAL|Sahaj Samadhi Meditation|Sahaj Samadhi Meditation (SSM) is a form of automatic self-transcending meditation that involves relaxed attention to a precise sound (mantra), to allow stress reduction and deep relaxation. This technique is easy to learn and offers the support of a group and facilitator.
214850348|NCT04583748|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program (HEP) is a standardized program used to teach participants about health promotion, including the benefits of a lifestyle of healthy diet, music, recreation, and exercise. In HEP, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes.
214850349|NCT06427525|OTHER|Mobile application-based adolecent obesity education|Mobile application-based adolecent obesity education
214850350|NCT00953108|DRUG|quetiapine|300 mg per day
214850351|NCT00953108|DRUG|escitalopram|escitalopram 10 mg per day
214850352|NCT04060342|DRUG|GB1275|Oral
214850353|NCT04060342|DRUG|nab-paclitaxel and gemcitabine|IV infusion
214850354|NCT04060342|DRUG|pembrolizumab|IV infusion
214850355|NCT00269542|DRUG|Zinc and iron folic acid - Intervention|The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
214850356|NCT00269542|DRUG|Iron Folic Acid alone - Placebo|The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
214850357|NCT01276717|DRUG|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
214850358|NCT01276717|DRUG|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
214850359|NCT03696355|DRUG|GDC-0084|Given PO
214850360|NCT03696355|RADIATION|radiation therapy|Both photon and proton therapy modalities will be allowed.
214850361|NCT05515016|PROCEDURE|chin enhancement with a fatty flap sculpted from the double chin|Under general anesthesia, an incision was made behind the submental crease followed by the excision of the skin excess. The preplatysmal fatty compartment was individualized through a subcutaneous dissection. Then, the lower part of the preplatysmal fat was cut to start its separation from the platysma muscle, thus obtaining a real vascularized fatty flap. This flap could be folded on itself, then easily turned over to be fixed on the muscular layer of the chin.
214850362|NCT04107155|DIETARY_SUPPLEMENT|Weight Management Formulation|Saffron extract and Gynostemma extract with hesperidin
214476358|NCT06675344|DEVICE|Apollo Neuro Device|The Apollo Neuro wearable device is an Apple Watch-sized wearable device that delivers vibration at set frequencies , termed transcutaneous vibratory stimulation, or TVS. These low volume sound waves feel like a soothing touch to the skin (TVS) and activate touch receptors. Apollo is controlled via smartphone and worn on the wrist or ankle. The Apollo is fitted with an adjustable band, made of a durable neoprene material with polyester overlays. Participants are asked to wear it daily for a minimum time period for 6 weeks. Users can choose from different modes of vibration, with some being energizing, others relaxing.
214850363|NCT04107155|DIETARY_SUPPLEMENT|Placebo|Placebo
214850364|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
214850365|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
214850366|NCT00209846|DRUG|Gaboxadol|
214850367|NCT05089929|DEVICE|Endoflip 2.0|FLIP topography (Endoflip 2.0) analysis will be performed on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
214850368|NCT05089929|PROCEDURE|High Resolution Manometry|All patients undergoing routine evaluation for gastroesophageal reflux disease will undergo high resolution manometry (HRM) testing.
214850369|NCT04628104|RADIATION|cardiac magnetic resonance|"o CMR protocol:~* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.~* T2-weighted imaging to detect extent \& distribution of myocardial edema.~* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.~* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.~* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~* Post-processing analysis will be done on a dedicated workstation"
214850370|NCT04719104|DEVICE|Transcutaneous Bilirubin Meter - 'Bilimeter'|Taking a transcutaneous (TcB) measurement will involve using a 'biliflash'. This is a non-invasive measurement that involves flashing a light against the helix of the infant's ear and can be done at the cotside. This process takes approximately 1-2 minutes and does not cause the baby discomfort. The meter gives an immediate bilirubin level.
214850371|NCT05182619|PROCEDURE|ultrasound-guided stellate ganglion block|under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
214850372|NCT01027741|BEHAVIORAL|Phone Referral|Participants receive phone referral to cancer control and prevention services.
214850373|NCT01027741|BEHAVIORAL|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
214850374|NCT01027741|BEHAVIORAL|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
214850375|NCT03119506|BEHAVIORAL|Recess|Recess timing and duration effects on lunch intake
214850376|NCT02196519|DEVICE|Sylys Surgical Sealant|
214850377|NCT02993770|PROCEDURE|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
214850378|NCT02993770|PROCEDURE|External DCR|External DCR
214850379|NCT00276549|DRUG|docetaxel|docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
214850380|NCT00276549|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
214850381|NCT00000674|DRUG|Pyrimethamine|
214850382|NCT00000674|DRUG|Leucovorin calcium|
214850383|NCT00000674|DRUG|Clindamycin|
214850384|NCT02148679|OTHER|DASH/SRD|Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
214850385|NCT02148679|OTHER|Usual care|Standardized advice to restrict dietary sodium intake to \< 2000 mg/day
214850386|NCT00608517|BIOLOGICAL|anti-thymocyte globulin|Given IV
214850387|NCT00608517|DRUG|cyclophosphamide|Given IV
214850388|NCT00608517|DRUG|fludarabine phosphate|Given IV
214850389|NCT00608517|DRUG|methylprednisolone|Given IV
214850390|NCT00608517|RADIATION|total-body irradiation|Given daily for 1-4 days
214850391|NCT05778955|GENETIC|detection and monitoring of cirulating tumor DNA|detection and monitoring of cirulating tumor DNA in pediatric soft tissue sarcoma
214850392|NCT04862156|DEVICE|Normothermic Machine Perfusion (NMP)|Storage and transportation of the donated liver using the OrganOx metra device.
214850393|NCT03805308|PROCEDURE|Intra-arterial Therapy|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
214850394|NCT04091958|PROCEDURE|Pectoralis myo-glandular flap reconstruction.|Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
214850395|NCT04056871|DIAGNOSTIC_TEST|Frailty Screening Tools|This is an observational and prospective study of patients who are going for elective surgery, thus no intervention will be given.
214850396|NCT05568693|BIOLOGICAL|0.3ml of mRNA vaccine|Subjects received 0.3ml of mRNA vaccine intramuscularly
214850397|NCT04686838|BEHAVIORAL|READyR II: A|Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.
214850398|NCT04686838|BEHAVIORAL|READyR II: B|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.
214476359|NCT06675344|DEVICE|Sham device|The Apollo Neuro is an Apple Watch-sized wearable device that delivers vibration, termed transcutaneous vibratory stimulation, or TVS. The sham device is identical in appearance to the active intervention, but provides a lower frequency vibration that has no known therapeutic benefit.
214850399|NCT01833533|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
214850400|NCT01833533|DRUG|Ribavirin|Capsule
214850401|NCT01833533|DRUG|Placebo for Ribavirin|Capsule
214850402|NCT04628520|PROCEDURE|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
214850403|NCT04628520|PROCEDURE|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
214850404|NCT04628520|PROCEDURE|Maintenance|Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
214850405|NCT05633238|BEHAVIORAL|Visual Search Information Type (target or distractor information)|Participants will have information about targets, distractors, or neither in different blocks of the intervention.
214850406|NCT00666887|DRUG|Minocycline|100 mg twice daily to be taken for up to 2 years
214850407|NCT00666887|DRUG|Placebo|placebo twice daily for 2 years
214850408|NCT03029117|PROCEDURE|correction of rheumatic valve lesions|
214850409|NCT00002616|BIOLOGICAL|aldesleukin|
214850410|NCT00002616|BIOLOGICAL|filgrastim|
214850411|NCT00002616|DRUG|carboplatin|
214850412|NCT00002616|DRUG|cyclophosphamide|
214850413|NCT00002616|DRUG|thiotepa|
214850414|NCT00002616|PROCEDURE|peripheral blood stem cell transplantation|
214850415|NCT05797584|DRUG|Dobutamine|Dobutamine 5.0 - 10.0 mcg/Kg/min ev
214850416|NCT05797584|OTHER|Passive leg raising|Passive leg raising for acute volume load
214850417|NCT03177382|RADIATION|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
214850418|NCT03177382|RADIATION|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
214850419|NCT03177382|PROCEDURE|TME|The TME operation will be given after the end of the neoadjuvant treatment.
214850420|NCT03177382|DRUG|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
214850421|NCT01469507|DEVICE|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
214850422|NCT01469507|DRUG|Hyaluronan|3 weekly injections
214850423|NCT01122316|DRUG|Metformin|3\. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
214850424|NCT06267794|DRUG|Pirfenidone 1200 mg|1200 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
214850425|NCT06267794|DRUG|Pirfenidone 1800 mg|1800 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
214850426|NCT06267794|DRUG|Placebo|0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
214850427|NCT02457611|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214850428|NCT00384293|DRUG|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
214850429|NCT00384293|DRUG|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
214850430|NCT04702763|OTHER|Eye-Tracker®T2 + e-VOG|"* 1st step: eyes movements assessed with standard video-oculography device~* 2° step: eyes movements assessed with e-VOG digital application~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
214850431|NCT04702763|OTHER|e-VOG + Eye-Tracker®T2|"* 1st step: eyes movements assessed with e-VOG digital application~* 2° step: eyes movements assessed with standard video-oculography device~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
214850432|NCT02988869|DRUG|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
214850433|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
214850434|NCT02988869|DRUG|Formoterol|Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
214850435|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
214850436|NCT03541239|DEVICE|Single Cuff Tourniquet 8000|If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
214850437|NCT01367938|DEVICE|OMNI Apex Ultracongruent Knee Device|
214850438|NCT05701618|OTHER|Psychologically Informed Education Video Series|A short three video series (5-8.5 minutes each) provides psychologically-informed education at an age-appropriate level to address kinesiophobia, pain catastrophizing, and fear-avoidance beliefs.30 Participants will view the three-part education video series on an iPad at their first visit (video 1), one week (video 2), and three weeks (video 3).
214850439|NCT05701618|OTHER|Anatomy and biomedical education videos|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
214850440|NCT06015113|DRUG|Disitamab Vedotin plus pyrotinib or naratinib|"Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days."
214850441|NCT06557278|BIOLOGICAL|AlloStim|experimental immunotherapy to prime for checkpoint inhibitor
214850442|NCT06557278|DRUG|Bavencio|anti-PDL1 checkpoint inhibitor
214850443|NCT02668042|BIOLOGICAL|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
214850444|NCT02875041|DEVICE|Transcranial Magnetic Stimulation (TMS)|
214850445|NCT02875041|DEVICE|MAGSTIM Rapid2|
214663581|NCT05015387|DIAGNOSTIC_TEST|Collection of saliva samples|For MMP-3/TIMP-1 detection, the collection of saliva samples was performed using Salivette (SARSTEDT AG and Co, Germany) saliva sample collection kit. Saliva samples were collected at the baseline for all patients and 8 weeks after treatment. Samples were centrifuged at 3500 rpm (2 min), aliquoted and protease inhibitors cocktail (1 mg/ml) was added to each sample. All samples were stored at -80oC. MMP-3, TIMP-1 concentration in saliva samples was examined using commercial ELISA kits (Elabscience, USA) and Multiskan Microplate Photometer (Thermo Fisher Scientific) at 450 nm wavelength. Saliva MMP-3/TIMP-1 samples were collected before treatment and 8 weeks after treatment.
214476360|NCT05727280|BEHAVIORAL|Progressive Relaxation Exercise Practices|The intervention planned within the scope of the research are the Progressive Relaxation Exercise application. Patients in the intervention group undergoing open heart surgery will be given training on progressive relaxation exercise in the patient's room the day before the surgery. Correct breathing techniques will be taught and the relaxation exercises will be performed by using audio recordings. Afterwards, the relaxation exercise will be provided to the patient to practice the progressive relaxation exercise with mp3 accompaniment. After open heart surgery, progressive relaxation exercise will be applied to the patient on the 1st, 2nd and 3rd days of his admission to the service. The patient will be asked to perform the progressive relaxation exercise twice a day, once during the day and once in the evening.
214663582|NCT02809248|DEVICE|ZES|stent implantation (zotarolimus eluting stent)
214663583|NCT02809248|DEVICE|BMS|stent implantation (bare metal stent)
214663584|NCT00097539|BIOLOGICAL|Somatrem|
214663585|NCT00097539|BIOLOGICAL|Somatropin|
214663586|NCT01478555|DRUG|ISV 101|Bromfenac in DuraSite
214663587|NCT01552876|DEVICE|etafilcon A|A daily wear contact lens
214850448|NCT02862249|BIOLOGICAL|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
214850449|NCT02862249|BIOLOGICAL|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
214850450|NCT03662256|OTHER|Current Primary Care Referral Process|Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
214850451|NCT03662256|OTHER|Telemedicine Referral Process|In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
214850452|NCT04017559|BEHAVIORAL|Motivational Interviewing|A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
214850453|NCT00493454|DRUG|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
214850454|NCT00493454|DRUG|Rituximab|250 mg/m\^2 IV Over 6 to 8 Hours
214850455|NCT00493454|DRUG|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
214850456|NCT06615765|OTHER|Acupuncture|"Acupuncture sessions will use sterile, disposable stainless-steel needles (0.3 mm × 40 mm and 0.3 mm × 75 mm). Each session has two phases:~Supine Position:~* Needles (0.35 mm × 75 mm) are inserted into ST25, ST15, and SP14, reaching the abdominal muscle layer.~* Needles (0.30 mm × 40 mm) are inserted into CV12, CV4, ST36, ST37, and SP6.~* Electroacupuncture (EA) at ST25, SP15, and ST36 uses a continuous 5 Hz wave, 0.1 to 2.0 mA.~Prone Position:~* Needles are inserted into BL32, BL33, and BL35 with precise angles and depths.~* EA at BL32, BL33, and BL35 uses a continuous 5 Hz wave, 2.0 to 6.5 mA. Sessions occur three times a week for the first 4 weeks, then twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions."
214850457|NCT06615765|OTHER|Sham acupuncture|Sterile, disposable stainless-steel needles (0.30 mm × 25 mm) will be used. After skin sterilization, needles will be inserted into the same points as the acupuncture group but to a shallow depth of 2 to 3 mm and lightly manipulated for blinding. Paired alligator clips will be attached to the same points, but the sham EA apparatus will have no current output, though it mimics the active EA apparatus in appearance and sound. Sham sessions will follow the same schedule as the acupuncture group: three times a week for the first 4 weeks and twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions.
214850458|NCT02538835|BEHAVIORAL|Metacognitive therapy|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
214850459|NCT02538835|BEHAVIORAL|Mindfulness based cognitive therapy, group|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel \& Segal.
214850460|NCT02538835|BEHAVIORAL|Support groups|Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
214850461|NCT01253928|DRUG|Pioglitazone|45mg qd for 4 months
214663588|NCT01552876|DEVICE|nelfilcon A|A daily wear contact lens
214663589|NCT01552876|DEVICE|Filcon II 3|a daily disposable
214663590|NCT02339714|OTHER|acupuncture combined moxibustion|"Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).~Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether."
214663591|NCT02339714|DRUG|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
214663592|NCT03369847|DRUG|budesonide, beclomethasone|The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
214663593|NCT01455350|PROCEDURE|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
214663594|NCT01455350|DRUG|lidocaine|10 weeks of daily topical 5% lidocaine application
214663595|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
214850462|NCT04627831|DRUG|CE-Iohexol|Captisol-Enabled™ Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
214850463|NCT04627831|DRUG|Iohexol|Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
214850464|NCT03146637|BIOLOGICAL|Activated CIK|Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days
214850465|NCT03146637|BIOLOGICAL|CIK|Traditional CIK were infused for 3 days
214850466|NCT05343221|DEVICE|High Fidelity Simulator|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the High Fidelity CPR Simulator. This simulator is adult human sized and specialized for CPR practice. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
214850467|NCT05343221|DEVICE|Haptic|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the 3D technology Haptic Device Simulator. This tool has a computer screen and a swing haptic pen. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
214850468|NCT00504803|PROCEDURE|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
214850469|NCT06142188|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
214850470|NCT02244294|DRUG|FLOMAX® capsules|
214850471|NCT02244294|DRUG|Placebo capsules|
214850472|NCT03893734|DRUG|methadone|Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia
214850473|NCT03893734|DRUG|Hydromorphone|Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
214850474|NCT00103038|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
214850475|NCT00103038|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DCE-MRI
214850476|NCT00103038|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DSC-MRI
214850477|NCT00103038|DRUG|Ferumoxytol|Given IV
214850478|NCT00103038|DRUG|Gadolinium|Given IV
214290265|NCT06876103|OTHER|Religiously-integrated Cognitive Behavioral Therapy|"This study aims to assess the efficacy and feasibility of a newly developed online intervention for death anxiety based on Religiously Integrated Cognitive Behavioral Therapy (RCBT). Building upon the framework of Furer and Walker's 2008 intervention protocol, this adaptation incorporates beliefs in an afterlife, aligning with Turkish society's cultural and religious values.~The RCBT intervention consists of seven structured group therapy sessions, each lasting 90 minutes. The program is designed to help participants identify and challenge unhelpful thoughts related to death anxiety while integrating religious resources to promote cognitive restructuring. Key components of the intervention include psychoeducation, cognitive restructuring, exposure exercises, the concept of repentance in the context of trust and belief in the afterlife, gratitude, and value-oriented behaviors."
214850479|NCT00103038|PROCEDURE|MRI-Based Angiogram|Undergo MRA
214850480|NCT06177002|DIAGNOSTIC_TEST|Collection of biological data|Biological sample will be collected from the COVID19 patients and from healthy donors
214850481|NCT03301103|BIOLOGICAL|E. coli strain E1392-75-2A|After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
214850482|NCT03301103|DEVICE|PTM202|PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
214850483|NCT01218984|DRUG|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
214850484|NCT01218984|DRUG|Medisorb naltrexone 150 mg|Single administration via IM injection.
214850485|NCT01218984|DRUG|Medisorb naltrexone 300 mg|Single administration via IM injection.
214850486|NCT01218984|DRUG|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
214850487|NCT01218984|DRUG|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
214850488|NCT03476317|DRUG|Vancomycin|Oral suspension 4 times daily (Day 1-14)
214850489|NCT03476317|DRUG|Neomycin|Oral three times daily (Days 1-3)
214850490|NCT03476317|DRUG|Ciprofloxacin|Oral twice daily (Days 4-14)
214850491|NCT03476317|DRUG|Polyethylene Glycol 3350|Dissolved in Gatorade on day 2
214850492|NCT03476317|DRUG|Fluconazole|Orally once daily (Day 1-14)
214663596|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
214663597|NCT03941548|DRUG|CTP-543|Administered as 12 mg tablets.
214663598|NCT03941548|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
214663599|NCT05611138|DIETARY_SUPPLEMENT|Protein supplementation|Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.
214663600|NCT01023529|RADIATION|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
214663601|NCT02081963|DRUG|Amikacin|Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
214663602|NCT02081963|DRUG|Normal saline|Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
214663603|NCT03795350|DRUG|Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide|single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
214663604|NCT01898663|BIOLOGICAL|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DC vaccine plus CIK cells
214663605|NCT01128712|DRUG|Pregabalin|150 mg /day
214663606|NCT01128712|DRUG|Pregabalin|450 mg/day
214663607|NCT00358163|DRUG|PTK787/ZK 222584|Taken in tablet form daily
214663608|NCT00358163|DRUG|paclitaxel|Given as a 3-hour infusion once every 21 days
214663609|NCT06478836|OTHER|planter pressure|no intervention
214663610|NCT00861185|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
214663611|NCT00861185|DRUG|Placebo|Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
214663612|NCT01998607|OTHER|Physician Survey|Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
214663613|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Amygdala|Low intensity focused ultrasound pulsation will be administered to the amygdala in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 10Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the amygdala and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
214663614|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Entorhinal Cortex|Low intensity focused ultrasound pulsation will be administered to the entorhinal cortex in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the entorhinal cortex and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
214663615|NCT01563601|DRUG|Obatoclax Mesylate, Carboplatine and Etoposide|"Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles"
214663616|NCT01563601|DRUG|Carboplatin and Etoposide|"Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles"
214663617|NCT04223089|DIAGNOSTIC_TEST|Near Infrared Spectroscopy|"The Kent Camera is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of the following in superficial tissue:~* oxygen saturation (StO2),~* relative oxyhemoglobin level (HbO2), and~* relative deoxyhemoglobin (Hb) level~The Kent Camera displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. The Kent Camera is indicated for use to determine oxygenation levels in superficial tissues."
214663618|NCT00378846|PROCEDURE|infrared thermography|
214663619|NCT01242111|DRUG|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
214663620|NCT01232725|DIETARY_SUPPLEMENT|Donor Human Milk|Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
214663621|NCT04586712|DRUG|Active CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 2000mg/30mL (high).
214663622|NCT04586712|DRUG|Vehicle Control (Placebo)|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
214663623|NCT04006769|DRUG|Entacapone|Entacapone tablet
214663624|NCT04006769|DRUG|Imatinib Mesylate|Imatinib Mesylate tablet
214850493|NCT03091413|DIAGNOSTIC_TEST|diaphragm ultrasound|"For each patient intubated and ventilated in our ICU we will performed diaphragm ultrasound during the weaning process.~We will performed the measurement of diaphragmatic maximum excursion during a maximal inspiration using an abdominal standard preset with M-mode, with the so called anatomical M-mode.~We will put the probe in the right subcostal window to use the hepatic window to assess the movement of the diaphragm. We will performed the measure of the diaphragm excursion with patient in semi-recumbent position and through a transhepatic transverse oblique scan while the patient is on mechanical ventilation and undergo a Pimax maneuver, that consists in a temporary occlusion of the airway with an expiratory pause.~We will performed the measure three times, and we will take into account the best one made by the patient."
214850494|NCT03184259|DEVICE|Robotic ankle system|Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
214476361|NCT05992246|DIAGNOSTIC_TEST|Ratio of Femoral Vein Diameter to Femoral Artery Diameter|An ultrasound probe will be used to first scan the area of the upper thigh just below the inguinal ligament directing caudally seeking for the femoral vessels. The femoral artery and vein could be observed simultaneously. Under normal conditions, pulsation is an indication of the femoral artery, and its companion is the femoral vein. The mean femoral vein diameter and femoral vein diameter (3-5 diametral lines in different directions) will be measured during cough, crying, or performing the Valsalva maneuvers.
214476362|NCT06631079|BIOLOGICAL|NECVAX-NEO1|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
214476363|NCT03441100|DRUG|IMA202 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
214476364|NCT03441100|DEVICE|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.
214476365|NCT00631475|DRUG|Bosentan|"For patients who were administered Bosentan during BUILD 3 (NCT00391443):~continue on same dose~For patients who were administered placebo during BUILD 3 (NCT00391443):~Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.)"
214476366|NCT06128252|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in tablets of 1.0 gram of taurine powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.
214476367|NCT06128252|BIOLOGICAL|Serplulimab|Serplulimab
214476368|NCT06128252|DRUG|XELOX regimen|Oxaliplatin + capecitabine
214476369|NCT06128252|DIETARY_SUPPLEMENT|Placebo|Taurine placebo in tablets of 1.0 gram of starch powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.
214476370|NCT04062565|DRUG|Treprostinil Injectable Product|Injection
214476371|NCT04062565|DRUG|Riociguat Pill|Tablet
214476372|NCT06814249|OTHER|ligation of pancreatic stump with a quantified force|After severing the pancreas, the pancreas was ligated at 5 mm from the pancreatic stump with a quantified force.
214476373|NCT06814249|OTHER|Manual suturing or stapling closure.|Handle the pancreatic stump according to conventional methods (manual suturing or stapling closure).
214476374|NCT06810362|BEHAVIORAL|Cognitive Remediation (CR)|The CR consists of three 1-hour sessions per week of domain-specific computerized exercises, for a period of 12 weeks, totaling 36 hours
214476375|NCT06810362|BEHAVIORAL|Aerobic Exercise|Aerobic exercise consists in two session per week of cycling. Each session lasts for 45 min, with 15 min of warm up pre and post session
214476376|NCT06810362|OTHER|Cognitve Remediation + Aerobic Exercise|Patients performed both CR exercises and cycling
214476377|NCT06814548|OTHER|ICIs(Immune checkpoint inhibitors)|N
214476378|NCT06812572|DEVICE|Visibly Vision Test|The Visibly Vision Test is used as a digital self-administered device to measure visual acuity and to subjectively measure refractive value for a patient's eye to determine the optical prescription for the conditions of myopia and astigmatism
214476379|NCT06811987|BEHAVIORAL|Instructor-led AI-Triage educational serious game|Participants will use the AI-triage serious game guided by the instructors.
214476380|NCT06811987|BEHAVIORAL|Self play AI-Triage educational serious game|Participants will self-play the AI-Triage serious game during the class.
214476381|NCT01196715|DRUG|Darbepoetin alpha|Aranesp 500 mcg vials once every 2 weeks.
214476382|NCT01196715|DRUG|Filgrastim|300 mcg vials twice a week, 3-4 days apart
214476383|NCT01196715|PROCEDURE|Blood Red Cell Transfusion|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
214476384|NCT06565247|DRUG|[18F]PSMA-PET|Pre-surgical imaging using \[18F\]PSMA-PET at Umea University Hospital, 3.5 MBq/kg, i.v. injection.
214476385|NCT06565247|DEVICE|MRI sequences optimized for prostate cancer examinations|T2-WI, T1-WI, DCE and DWI at Umea University Hospital and at Skåne University Hospital
214476386|NCT06815159|BIOLOGICAL|Identification any tissue markers predictive or favoring early stenosis in AVF for haemodialysis.|"Primary objective~1. Identify any predictive or favoring tissue markers of early stenosis in AVF for hemodialysis.~   Secondary objectives~2. Compare the results on the possible different expression of tissue markers before and during dialysis.~3. Compare the results on the possible different expression of tissue markers between AVFs made with portions of cephalic vein and AVFs made with portions of basilic vein, in order to evaluate whether the different topographic origin of the AVF can influence its duration."
214476387|NCT06810635|DIETARY_SUPPLEMENT|Oral Polyphenol Challenge Test / PPPIL|Patients will receive a so-called oral polyphenol challenge test. It is a pill containing a multitude of polyphenol classes (doi: 10.1093/cdn/nzac072.020)
214476388|NCT06810635|DIAGNOSTIC_TEST|fasting blood sample|Fasting blood sample will be obtained for determination of markers of metabolic health.
214476389|NCT06810635|DIAGNOSTIC_TEST|Fasting urine collection|Subjects collect morning urine (or the urine thereafter ) in a separate urine container and write down the time of urine collection for determination of polyphenol metabolites
214476390|NCT06810635|DIAGNOSTIC_TEST|24 hours urine collection|Subjects collect urine over the entire 24h. for determination of polyphenol metabolites
214476391|NCT06810635|OTHER|Questionnaires|Questionnaires will be performed to collect information on lifestyle and baseline characteristics: physical activity (IPAQ), sleep (PSQI), drinking and smoking behaviour, drug intake and medical record.
214850495|NCT03184259|DEVICE|Robotic knee system|Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
214850496|NCT02795637|DRUG|dasotraline|dasotraline 8mg capsule/day
214850497|NCT01356784|OTHER|Tailored Physical Activity|Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
214850498|NCT01356784|BEHAVIORAL|"Chronic Pain Self-management Programme"|Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
214850499|NCT01356784|BEHAVIORAL|Health counselling|Health guidance (1,5h)
214290266|NCT06876103|OTHER|Classical Cognitive Behavioral Therapy|"The standard CBT intervention follows the structured protocol developed by Furer and Walker (2008), which targets cognitive distortions, avoidance behaviors, and excessive safety-seeking behaviors contributing to death anxiety. The researcher has adapted the session content to fit the protocol's core components while maintaining fidelity to the original intervention model. Sessions last 90 minutes and are conducted in an online group format.~Session Structure: Session 1: Treatment Rationale, Session 2: Reducing Excessive Checking, Reassurance Seeking, and Safety Behaviors, Session 3: Exposure, Session 4: Cognitive Reappraisal, Session 5: Enhancing Enjoyment of Life, Session 6: Healthy Lifestyle, and Session 7: Relapse Prevention."
214663625|NCT06380998|DIETARY_SUPPLEMENT|whey protien|Whey, the supernatant of yogurt and a byproduct of cheese, is rich in protein and consists of β-lactalbumin, α-lactoglobulin, immunogloblin, bovine serum albumin, and other minor proteins. Whey protein is a globally consumed food material and is well known for its health benefits
214663626|NCT02132338|BEHAVIORAL|The Education Health Program|The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
214663627|NCT00848991|DRUG|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
214663628|NCT00848991|DRUG|Propofol|evaulation of propofol for emergence from anesthesia
214663629|NCT04250805|DRUG|Lidocaine|Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
214663630|NCT04250805|DRUG|Ropivacaine|Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
214663631|NCT06468202|DRUG|Aspirin 81 mg|Participants will be assigned to 81mg Aspirin
214663632|NCT06468202|DRUG|Aspirin 162 mg|Participants will be assigned to 162mg Aspirin
214663633|NCT01971879|PROCEDURE|Remote ischemic preconditioning|"A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
214663634|NCT01971879|PROCEDURE|Control|"A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
214663635|NCT01021007|DRUG|Iodine|Rinse 2 times per day for 6 weeks
214663636|NCT01021007|OTHER|water|Use 2 times per day for 6 weeks
214663637|NCT02015819|BIOLOGICAL|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
214663638|NCT02015819|DRUG|flucytosine|Given orally
214663639|NCT02015819|DRUG|leucovorin calcium|Given orally
214663640|NCT02015819|OTHER|pharmacological study|Correlative studies
214663641|NCT02015819|OTHER|laboratory biomarker analysis|Correlative studies
214663642|NCT04287153|DEVICE|Cryotherapy on abdomen and saddlebags|Application of variable temperature (-10°c to -7°c) on the treated areas using the cryotherapy device FG660L-006 (Beijing ADSS Development CO., Ltd)
214663643|NCT05862363|DIETARY_SUPPLEMENT|Microbiota-directed balanced energy protein (MD-BEP)|Prototypes for nutritional interventions that are composed of locally available, affordable, culturally acceptable complementary foods commonly consumed in Bangladesh have recently been developed.
214850500|NCT03071328|DRUG|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
214850501|NCT02865395|DRUG|Belladonna and Opium Suppository|
214850502|NCT02865395|PROCEDURE|Rectal Exam|
214850503|NCT04597398|DEVICE|Evaluation of blood flow with indocyanine green|
214850504|NCT04570397|DRUG|Ravulizumab|Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
214663644|NCT05862363|DIETARY_SUPPLEMENT|Ready-to-use supplementary food-balanced energy protein (RUSF-BEP)|RUSF-BEP is composed of rice, lentil, sugar, soybean oil, and skimmed milk powder mixed with vitamin-mineral premix. MD-BEP is composed of chickpea flour, peanut flour, soy flour, green banana pulp, sugar, soybean oil, and vitamin-mineral premix. The results from previous studies support the notion that repair of impaired gut microbial community development could represent a new therapeutic concept for restoring healthy growth. RUSF-BEP will be given to one arm of low-BMI women of reproductive age and low-BMI pregnant women.
214663645|NCT05862363|PROCEDURE|Esophagogastroduodenoscopy (EGD)|Aim 1A consists of performing EGD to women with low-BMI and normal BMI women with function dyspepsia. In order to enroll 30 participants with normal duodenal mucosal histology, we are planning to perform EGD on 100 healthy women (BMI 20-24.9 kg/m2) of childbearing age who have been referred for evaluation of functional dyspepsia. Undernourished low-BMI (\<18.5kg/m2; 18-35 years) women of childbearing age will be enrolled from Bauniabadh and adjacent slum area of Mirpur, Dhaka and EGD will be performed among 60 women. A total of 6-8 biopsy samples from SI and a dry duodenal aspirate will be collected for biopsy, histochemical and immunocytochemical analysis.
214663646|NCT05862363|BEHAVIORAL|Counselling and follow-up|Normal BMI pregnant women will be counseled and followed up as per standard guidelines and will be provided routine antenatal care.
214850505|NCT01714349|PROCEDURE|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
214850506|NCT05820867|PROCEDURE|Single-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
214850507|NCT05820867|PROCEDURE|Two-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
214850508|NCT06531915|DRUG|Ciprofol|Participants in the ciprofol group will be intravenously injected with 0.4 mg/kg of ciprofol (batch number H20200013, Haisike Pharmaceutical Co., Ltd., Liaoning, China) and sufentanil (0.2 μg/kg).
214850509|NCT06531915|DRUG|Remimazolam|Participants in the remimazolam group will be intravenously injected with 0.1 mg/kg of remimazolam besylate (batch number HR7056, Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) and sufentanil (0.2 μg/kg).
214850510|NCT06679465|DRUG|Tiotropium (Spiriva®)|2 puffs tiotropium prior to allergen challenge
214850511|NCT06679465|DRUG|Placebo|2 puffs placebo
214850512|NCT00292331|PROCEDURE|cyanoacrylate injection to treat gastric variceal hemorrhage|
214850513|NCT00673192|PROCEDURE|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
214850514|NCT01501110|DRUG|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
214850515|NCT05893446|DIETARY_SUPPLEMENT|Nutrition care by RDN, medical nutrition therapy -stepped wedge cluster-randomized trial design. Everyone gets the intervention so no arms.|RDNs in the community will provide MNT and meals for three months post discharge from the hospital
214850516|NCT02438982|DRUG|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
214850517|NCT02438982|DRUG|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If \>5 B cells per mm3, it will be measured again after 1 week. If count is still \>5 B cells per mm3, third \& fourth doses of rituximab will be given.
214850518|NCT04394338|OTHER|self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia|to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
214850519|NCT06326177|PROCEDURE|Spine Posture Assessment|Spine posture will be assessed with double inclinometer method. After determining landmarks for each assessment, inclinometers will be placed and degree will be noted. Both degree which are obtained with different inclinometers will be used to summed up for determining postural alteration degree. Cervical, thoracal, thoracolumbar and lumbar spinal postures will be used. Spine postures are going to be expressed as, cervical lordosis degree, thoracal kyphosis degree, thoracolumbar posture degree and lumbar lordosis degree. Landmarks for cervical lordosis are C2 and C7, for thoracal kyphosis are T1 and T12, for lumbar lordosis are T12 and S1, for thoracolumbar posture C7 and S1.
214850520|NCT06326177|PROCEDURE|Spine Movement Assessment|Spine movement will be assessed via using bubble inclinometer in terms of degree. Bony landmarks will be spotted like done in spine posture assessment after that full spinal flexion and extension wanted in order to record degrees in inclinometers at the end range. As a result the difference between two inclinometer will give the motion of that segment. Lumbar and thoracolumbar spinal movement will be assessed with this method. For thoracal and cervical range of motion values will be recorded separately without substruction from both inclinometer. Thoracal rotation range of motion will be assessed with two landmarks and will be recorded separately according to landmark. Thoracolumbar range of motion will be assessed with two substruction of degrees. Landmarks for cervical range of motion are vertex and C7, for thoracal range of motion are T1 and T12, for lumbar range of motion are T12 and S1, for thoracolumbar range of motion C7 and S1.
214850521|NCT06326177|PROCEDURE|Core Muscle Endurance Assessment|Core muscle endurance is divided into three components. Trunk anterior flexion test will be used to assess anterior core region endurance. Lateral plank test will be used to determine lateral core muscle endurance. Trunk posterior extensor test will be used to determine endurance of the posterior core musculature. All of these test are calculated in predetermined positions according to literature with static contractions. Maximum duration of maintaining that position is needed. In trunk anterior flexion test participant will sit with 60 degree inclination from the ground while making contact with their feet when hips and knees are flexed. In lateral plank test participants should place their elbow to ground and lift their hip while feet are in contact with ground in side lying position. In trunk extensor endurance test participants will lie prone to the bed while maintaining contact with their ASIS and lower extremity. The upper body should stay outside of the bed.
214850522|NCT06326177|PROCEDURE|Scapular Dyskinesia|Scapular dyskinesia will be assessed with scapular dyskinesia test. Dumbbells which are 1,5kg will be used in the testing setting. Participant will perform full shoulder abduction for 5 times while examiner assesses the movement quality by ranking it as subtle dyskinesis, obvious dyskinesis and no dyskinesis according to the movement of the scapula. After that participant will perform 5 repetitions of shoulder flexion.
214850523|NCT06326177|PROCEDURE|Shoulder Strength|Shoulder strength will be assessed via usage of microfet hand held dynamometer. Isometric shoulder strength will be calculated in supine lying position while participant holding their arm at side with 90 degree elbow flexion. After that participant will apply maximal contraction towards external rotation while examiner resists that motion in order to prevent any motion with dynamometer. Eccentric shoulder strength will be assessed in sitting position. Participant will hold their shoulder at 90 degrees of abduction with 90 degree external rotation. Also elbow should be in 90 degree flexed position. After that examiner will give force towards neutral rotation while holding the arm. Participant will resist this motion eccentrically until neutral rotation is reached. Velocity of the shoulder should be same throughout all motion due to creation of isokinetic environment.
214850524|NCT02581878|DRUG|BAY1862864|Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
214850525|NCT04155827|OTHER|SIT|Sprint interval training of 4\*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
214850526|NCT04783194|DRUG|Dexamethasone+ Bupivacaine|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
214850527|NCT04783194|DRUG|Bupivacaine|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
214850528|NCT04982367|DEVICE|Sirolimus-eluting balloon catheter|Sirolimus-eluting balloon catheter designed and produced by Acotec
214850529|NCT04982367|DEVICE|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter (trade name:DHALIA)
214850530|NCT04217148|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
214850531|NCT04217148|DRUG|ATRA|ATRA, po,10mg bid, for 12 weeks
214850532|NCT03324217|OTHER|Mental Practise|They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
214850533|NCT01544517|DRUG|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
214850534|NCT05628441|OTHER|Computer Aided Detection system for Barrett's neoplasia|CADe system running in the back, not directly interfering with patient care
214850535|NCT03319069|RADIATION|Hypofractionated radiotherapy|"Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.~."
214850536|NCT03319069|RADIATION|Conventional fractionated radiotherapy|50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
214850537|NCT00964106|DRUG|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
214850538|NCT00964106|DRUG|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
214850539|NCT00964106|DRUG|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
214850540|NCT00964106|DRUG|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
214850541|NCT00964106|DRUG|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
214850542|NCT00964106|DRUG|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
214850543|NCT00964106|DRUG|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
214850544|NCT00964106|DRUG|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
214850545|NCT00964106|DRUG|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
214850546|NCT00964106|DRUG|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
214850547|NCT00964106|DRUG|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
214850548|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
214850549|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
214850550|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
214850551|NCT01483625|DRUG|tiotropium|18mcg
214850552|NCT01483625|DRUG|Placebo|placebo
214850553|NCT00337974|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
214850554|NCT00337974|OTHER|Educational DVDs|
214850555|NCT00275639|DRUG|Cozaar|
214850556|NCT01402973|OTHER|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
214850557|NCT04625673|DEVICE|OsciPulse|OsciPulse device and standard IPC device
214850558|NCT02010294|GENETIC|DNA samples, GAS strains|DNA samples,GAS strains
214850559|NCT05864924|BIOLOGICAL|Cohort A: 3.0x10^6 CAR-T cells/kg|Intravenous infusion
214850560|NCT05864924|BIOLOGICAL|Cohort B: 9.0x10^6CAR-T cells/kg|Intravenous infusion
214850561|NCT05864924|BIOLOGICAL|Cohort C:1.5x10^7 CAR-T cells /kg|Intravenous infusion
214850562|NCT02310763|BIOLOGICAL|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
214850563|NCT02310763|DRUG|Placebo|
214850564|NCT00489749|PROCEDURE|Protected early weightbearing/Achilles tendon surgery|
214850565|NCT02245698|BIOLOGICAL|Stem cell|Intrathecal autologous bone marrow mononuclear cell transplantation
214850566|NCT02598245|DEVICE|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
214850567|NCT02598245|DEVICE|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
214850568|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)|iTBS delivered to vmPFC for active treatment of spider phobia.
214850569|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), vertex|iTBS delivered to vertex for placebo treatment of spider phobia.
214663647|NCT05075564|DRUG|Part 1 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
214663648|NCT05075564|DRUG|Part 2 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
214663649|NCT06118528|DEVICE|Blur Obfuscation|Blurring is applied to the RGB images.
214850570|NCT05715476|PROCEDURE|cesarian surgery|The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.
214290267|NCT07132047|OTHER|Mulligan Mobilization SNAG with Home Exercise|This intervention combines manual mobilization and self-exercise. The therapist applies sustained postero-anterior glides to the second cervical vertebra for 10-30 seconds, up to six repetitions if pain decreases. The home program involves C1-C2 self-SNAG with a towel, maintaining end-range rotation for 10 seconds before returning to neutral. Exercises are completed twice daily for 10 repetitions each session. Participants receive illustrated instructions to promote correct execution and compliance.
214290268|NCT07132047|OTHER|Active Release Technique with Home Exercise|This approach integrates manual soft tissue release with targeted exercise. ART is applied to the neck and shoulder region, focusing on pectoralis major, upper trapezius, and levator scapulae. Exercises include wall angles, doorway stretches, Brugger's stretch, and head/neck retractions. Strengthening activities target rhomboids, deep neck flexors, and serratus anterior. The home routine consists of neck stretches, chin tucks, and postural drills, performed regularly to enhance muscle balance, posture, and headache relief.
214663650|NCT06118528|DEVICE|Cartoon Obfuscation|Cartoonization is applied to the RGB images.
214850571|NCT04837027|BEHAVIORAL|Aerobic training|Aerobic training on stationary bike 5x a week for 30 minutes a day
214850572|NCT04837027|BEHAVIORAL|Balance training|Training 5x a week for 30 minutes. Standard of care
214850573|NCT03738527|DRUG|Tranexamic Acid 100mg/mL, 20mL topical|"Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure"
214850574|NCT03738527|DRUG|Normal Saline Flush, 0.9%, 20mL topical|"Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure"
214850575|NCT02574338|DEVICE|Foley's Catheter|intracervical extraamniotic Foley's catheter
214850576|NCT02574338|DRUG|prostaglandin E1 analogue|intravaginal misoprostol
214850577|NCT02595827|OTHER|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
214850578|NCT01540292|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
214850579|NCT03080376|OTHER|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
214850580|NCT03080376|OTHER|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
214850581|NCT03080376|OTHER|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
214850582|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
214850583|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
214290269|NCT01937559|BIOLOGICAL|Tranexamic acid (TXA)|1.5g of TXA in 100ml normal saline solution
214290270|NCT01937559|DRUG|Normal saline|
214663651|NCT06118528|DEVICE|Edge Obfuscation|A black background and simple outlines of objects/people are applied to the RGB images.
214663652|NCT06118528|DEVICE|No Obfuscation (raw)|No editing is performed on the RGB images.
214663653|NCT00525252|DRUG|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
214850584|NCT01657526|BIOLOGICAL|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
214850585|NCT01613794|DRUG|Rosuvastatin|20 mg od
214850586|NCT02402491|DRUG|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
214850587|NCT02402491|DRUG|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
214850588|NCT02402491|DRUG|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
214850589|NCT02497131|DRUG|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
214850590|NCT01669031|OTHER|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
214663654|NCT00525252|DRUG|placebo|Placebo will be orally administered for 12 consecutive weeks
214663655|NCT06328010|BIOLOGICAL|Advanced Treatment Modalities for wound and injuries|Synthetic, Amniotic, Bovine, Porcine, or other non-human biological grafts or scaffolded grafts
214663656|NCT06328010|BIOLOGICAL|Standard of care|Standard of care without use of grafts or scaffolded grafts
214663657|NCT06328010|OTHER|Retrospective wound treatment data collection|Completed wound care treatment regardless of modality.
214663658|NCT05071664|DRUG|Guselkumab|Guselkumab will be administered as a SC injection.
214850591|NCT05708482|OTHER|Sling-Swing Position|The device is hammock which look likes a rope
214850592|NCT02142231|DEVICE|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
214850593|NCT02142231|DEVICE|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
214850594|NCT05990231|DRUG|Cadonilimab combined Anlotinib|Cadonilimab: intravenous administration at a dose of 10mg/kg on day 1 of each cycle, every 3 weeks (Q3W) Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle
214850595|NCT01110044|BIOLOGICAL|251154 vaccine|Intramuscular, single dose
214850596|NCT01110044|BIOLOGICAL|Infanrix hexa™|Intramuscular, four doses
214850597|NCT01110044|BIOLOGICAL|Synflorix™|Intramuscular, four doses
214850598|NCT01110044|BIOLOGICAL|Rotarix™|Oral, two doses
214850599|NCT05444543|DRUG|Fluticasone Propionate|Participants will cycle topical steroid in a three-months on three-months off fashion
214850600|NCT05444543|DRUG|Budesonide|Participants will cycle topical steroid in a three-months on three-months off fashion
214850601|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 350mg|
214850602|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 500mg|
214850603|NCT02930668|DIETARY_SUPPLEMENT|Placebo|
214850604|NCT05231369|BIOLOGICAL|ChulaCov19 BNA159 mRNA vaccine|ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine
214850605|NCT02301858|GENETIC|Genome analysis of tissue samples.|Genome analysis of tissue samples.
214850606|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing placebo|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
214850607|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing 250mg of Urolithin A (Mitopure)|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
214850608|NCT05659134|OTHER|Alfredson protocol|Alfredson eccentric therapeutical protocol.
214850609|NCT05659134|OTHER|Silbernagel protocol|Silbernagel concentric-eccentric protocol.
214850610|NCT01872624|PROCEDURE|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
214850611|NCT01261624|DRUG|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
214850612|NCT02904538|DRUG|Dexamethasone|
214850613|NCT02904538|DRUG|isotonic saline|
214850614|NCT04744155|BEHAVIORAL|Multi-Level Intervention|Behavioral intervention that assesses uptake of contraception and seeks follow-up care.
214850615|NCT04744155|BEHAVIORAL|Enhanced Standard of Care|Behavioral intervention that assesses uptake of contraception from follow-up care.
214476392|NCT06810635|DIAGNOSTIC_TEST|Stool collection|Optional: some subjects collect stool samples to test the capacity of the microbiome to degrade polyphenols with a batch experiment.
214850616|NCT01829815|BEHAVIORAL|Parents Make the Difference|"The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children."
214850617|NCT02094261|DRUG|AZD9291|Once daily tablet 80 mg
214850618|NCT03092882|BEHAVIORAL|Diabetes Self-Management Program|The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
214850619|NCT06295094|DRUG|Cisplatin|10.5 mg/m2 body surface in 150ml saline
214850620|NCT06295094|DRUG|Doxorubicin|2.1 mg/m2 body surface in 50ml saline
214850621|NCT04159194|OTHER|Control Diet|Players during the control trial will be instructed to maintain their normal food intake (\~55% CHO) and the type and amount of ingested food will be recorded.
214850622|NCT04159194|OTHER|Experimental Diet|The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
214850623|NCT00242229|DRUG|DVS-233 SR|
214850624|NCT05644886|BEHAVIORAL|FP Training and Technical Support|Same as in Intervention arm description
214850625|NCT05352724|DIETARY_SUPPLEMENT|Hydration drink|Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice
214850626|NCT02221063|OTHER|Thiamin fortified fish sauce (low concentration)|Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
214850627|NCT02221063|OTHER|Thiamin fortified fish sauce (higher concentration)|Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
214850628|NCT02221063|OTHER|Placebo fish sauce|Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
214850629|NCT02863549|DEVICE|MitraClip in tricuspid valve|MitraClip in tricuspid valve
214850630|NCT00855764|DRUG|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
214850631|NCT02154802|BEHAVIORAL|video: community member|
214850632|NCT02154802|BEHAVIORAL|video: physician|
214850633|NCT02154802|BEHAVIORAL|video: choice of video|
214850634|NCT01794754|OTHER|Care as usual|
214290271|NCT06877169|OTHER|Planned delayed implantation of kidney allograft with ex vivo machine perfusion kidney preservation.|During combined heart and kidney transplantation, heart and kidney allografts may be implanted during a single operative event, or with delayed kidney implantation in a second operative event. Timing of the delay is often determined by recipient stability and kidney availability; however, clinicians must balance recipient factors with accumulating cold ischemic time of the kidney allograft. This study uses hypothermic oxygenated machine perfusion to reduce ischemic injury to the kidney allograft and allow for improved recipient stability with planned delayed implantation of the kidney graft. Delays will allow for at least 6 hours of hypothermic oxygenated machine perfusion prior to implantation.
214476393|NCT06810635|DIAGNOSTIC_TEST|Transit time determination|Subjects take a pill containing 90mg of royal blue dye (E133) together with the polyphenol pill to determine their transit time. When their stool discolours, the subjects notify the researcher.
214663659|NCT05071664|DRUG|Golimumab|Golimumab will be administered as a SC injection.
214663660|NCT05071664|DRUG|Placebo|Placebo will be administered as a SC injection.
214476394|NCT05459701|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once daily for 24 weeks.
214476395|NCT05459701|OTHER|Placebo|Placebo
214476396|NCT06440304|DRUG|Fosfomycin|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
214476397|NCT06440304|DRUG|Eravacycline|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
214476398|NCT06440304|DRUG|ampicillin/sulbactam|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
214476399|NCT05158504|OTHER|Motivation|Motivational notifications were sent via SMS message to the nurses in the motivation group (n=30) at 07.00, 12.00 and 16.00 for 21 days.
214476400|NCT04986046|OTHER|Home Plate Lite|Home Plate Lite comprises electronic educational content (e.g. recipes, instructional videos) disbursed at least weekly over six weeks.
214476401|NCT04986046|OTHER|Home Plate|Home Plate comprises six 1.5-hour weekly sessions where parents work together with a study staff member to discuss the learning objectives and prepare the components of a meal, including entrees, side dishes, and desserts.
214476402|NCT04986046|OTHER|Fruit and Vegetable prescription|All families will receive FVRx over two months; FVRx can be redeemed for fresh, frozen, or canned produce at participating retailers in Philadelphia
214476403|NCT03434548|RADIATION|PET imaging|"PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain.~PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain."
214476404|NCT03434548|OTHER|Multi-modal MRI imaging|Multi-modal MRI imaging
214476405|NCT05026346|DIAGNOSTIC_TEST|Pathologic Exercise|"1. In the first phase of the project, a series of 5 active shoulder mobilization exercises characterized by an adequate range of motion will be tested to verify the set up for the video recording.~2. In the second phase shoulder movements will be recorder by a smartphone.~3. A questionnaire will be used and adapted on the basis of which to evaluate the correctness of the exercises performed by each healthy subject / patient. This questionnaire will provide a Clinical Score (CS) which assigns a numerical value to the patient's overall performance for each repetition.~4. The videos of each repetition of exercises performed by the healthy subjects / patients will then be evaluated by two different clinicians, blinded, using the questionnaire.~5. The Artificial Intelligence learning algorithm will be able to output an evaluation score that will be compared with that produced by clinicians."
214476406|NCT02893358|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
214476407|NCT02893358|DRUG|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
214476408|NCT06592248|DEVICE|Coc Knee|Implementation of a ceramic on ceramic knee prosthesis
214476409|NCT05127109|COMBINATION_PRODUCT|Nutrition Ecosystem pathway|"1. parenteral nutrition initiated within 72 hours of operative intervention~   * Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~2. metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~   * Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~  * BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~  * Philips Lumify L12-4 broadband linear array transducer ultrasound~3. expedited delivery of oral nutrition supplements and~4. a team-based approach on proper documentation of nutrition delivery and intake"
214476410|NCT05127109|OTHER|Comparator|retrospective cohort of 300 historical matched control subjects
214476411|NCT06817785|DEVICE|Lens 1 (ocufilcon D)|15 minutes of daily wear
214476412|NCT06817785|DEVICE|Lens 2 (somofilcon A)|15 minutes of daily wear
214476413|NCT06816745|PROCEDURE|Modified high flow tracheal oxygen|Modified high-flow tracheal oxygen with flow rates of 40L/min and 60L/min will be performed.
214476414|NCT06816745|PROCEDURE|Standard high flow tracheal oxygen|Standard high-flow tracheal oxygen with flow rates of 40 L/min and 60 L/min will be performed.
214290272|NCT06770257|DRUG|daunorubicin, cytarabine liposomes|First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
214663661|NCT05511961|BEHAVIORAL|Healthier Wealthier Families|Budget and debt counselling will involve at least one meeting with a counsellor. Examples of assistance the counsellors can offer include: suggestions on ways to improve a participant's financial situation; checking eligibility and helping to apply for social welfare support; helping to organise finances and develop a budget; and assistance with debt management, threatening letters or harassment by debt collectors, or imminent house eviction. The municipal budget and debt counselling services involved in the trial will receive guidance on how to work preventatively with families, which will align with the content of the 'Your child, your money'. The book covers topics such as planning finances, consumer rights, private insurance, family law, parental leave, pensions, saving, and budgeting.
214663662|NCT01571271|PROCEDURE|Laser Lithotripsy|Laser Lithotripsy
214663663|NCT01571271|PROCEDURE|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
214663664|NCT02372968|OTHER|Full body composition and of plasma and urine metabolites|"Full body composition in lean, fat and bone mass will be assessed from DXA scans.~Plasma and urine metabolites will be measured using metabolomics"
214663665|NCT05850234|BIOLOGICAL|GC012F (AZD0120)|GC012F (AZD0120) is a BCMA/CD19 dual CAR product under investigation for the treatment of patients with RRMM.
214850635|NCT01794754|OTHER|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
214850636|NCT01275560|DRUG|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
214850637|NCT01275560|DRUG|CArbosylane|
214850638|NCT06615830|DRUG|Standard chemotherapy|Each patient will receive the standard first-line chemotherapy (chosen among Gemcitabine-Abraxane, or Abraxane-Gemcitabine-FOLFOX or FOLFIRINOX, based on the clinical judgement of the treating oncologist) until disease progression.
214850639|NCT06615830|DRUG|Organoid-guided treatment|Upon disease progression confirmed radiologically, the patients will receive second-line chemotherapy. Second-line chemotherapy will be selected among the most promising effective drug (or drug regimens) as predicted in vitro by their benchmarking on patient-derived organoids.
214850640|NCT04155073|BEHAVIORAL|smoking cessation, early COPD detection, electronic visit|electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)
214850641|NCT04155073|OTHER|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
214850642|NCT03877926|BIOLOGICAL|AV7909|AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
214850643|NCT03877926|BIOLOGICAL|BioThrax|BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
214850644|NCT05804435|DEVICE|iNod™ System|The iNod™ Ultrasound Imaging System enables visualization of endobronchial lesions, peripheral lung nodules, or lung masses (referred to as lesions) using R-EBUS and performance of lung biopsy under direct R-EBUS visualization.
214850645|NCT06425367|DIAGNOSTIC_TEST|Antibiotic susceptibility testing|antibiotic susceptibility testing is performed on MHR-SIR or MH medium depending on randomization
214850646|NCT02618226|DEVICE|Optic nerve ultrasound|Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
214850647|NCT03795389|DRUG|DM199|Single SC dose
214850648|NCT02036801|OTHER|Lung specific elastance|Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
214850649|NCT03554317|DRUG|Testosterone cypionate|Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
214290273|NCT06770257|DRUG|Azacitidine|Given SC on days 1-7
214290274|NCT06770257|DRUG|Venetoclax|Given PO on days 1-14 or 1-21 or 1-28
214663666|NCT06154291|DRUG|XON7|The trial intervention (XON7) is a glyco-humanized polyclonal antibody drug which is formulated for intravenous (IV) administration
214290275|NCT05700045|DRUG|Dexmedetomidine|each side dexmedetomidine 0.5ug/kg TAP block
214290276|NCT06912919|OTHER|BFR-Aerobic Training|Low-intensity cycling exercise with BFR (pressure of 160-180 mmHg) for 20 minutes, 3 days a week for 6 weeks.
214290277|NCT06912919|OTHER|Aerobic Training Without BFR|Low-intensity cycling exercise (without BFR) for 20 minutes, 3 days a week for 6 weeks.
214290278|NCT04777994|DRUG|ABBV-CLS-484|Oral Capsule
214663667|NCT05256537|OTHER|Omission of the drug mycophenolate mofetil|Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
214663668|NCT06280625|OTHER|Replacement of wheat flour by soyflour|The intervention consist in replacing a fraction of wheat flour by soyflour
214663669|NCT05199870|DEVICE|RingLoc Bipolar Acetabular Cup|Patients that have been implanted with a RingLoc Bipolar acetabular cup.
214850650|NCT03554317|DRUG|Nivolumab|Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
214850651|NCT03345758|OTHER|outcome|telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
214850652|NCT03427476|DRUG|CTT1057|"Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging."
214850653|NCT01352182|DRUG|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
214850654|NCT00124462|DEVICE|Realigning knee brace and custom orthodic|A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
214850655|NCT00124462|DEVICE|Non realigning knee brace and flat orthodic|A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
214850656|NCT01816568|PROCEDURE|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
214850657|NCT01816568|PROCEDURE|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
214850658|NCT03956589|DRUG|Orkambi|Open label of Orkambi treatment during 3 months
214850659|NCT01790230|DEVICE|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
214850660|NCT04823819|DEVICE|Magnetic Stimulator DuoMag|Stimulation of the left dorsolateral prefrontal cortex
214850661|NCT04823819|DEVICE|neuroConn DC-STIMULATOR|One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
214850662|NCT01954914|DRUG|Plerixafor|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
214850663|NCT04845516|OTHER|Efficacy of apheresis|Efficacy of apheresis
214850664|NCT05178108|OTHER|Real-time MRI of swallowing|"The examination recording a total of 9 sequences of less than 30 seconds will be performed, in transverse section (passing through the epiglottis), frontal section, in the plane of the posterior pharyngeal wall, and in median sagittal section.~Each bolus of 20 ml will be administered in full, in one go, using a syringe. It is kept in the mouth for a few seconds and swallowed on demand.~The semi-liquid bolus of 20 ml comes from the mixture of 198 ml of pineapple juice to 10 gr of Nutilis Powder (NUTRICIA), food thickener containing neither gluten, nor lactose.~Ingredients: Dextrin-maltose, thickeners (modified starch (corn), tara gum, xanthan gum, guar gum).~* 3 sequences with no food~* 3 sequences with ingestion of a liquid bolus of 20 ml (pineapple juice) mouth closed~* 3 sequences with ingestion of a semi-liquid bolus of 20 ml (pineapple juice + Nutilis Powder) mouth closed"
214850665|NCT06208423|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
214850666|NCT02112279|BIOLOGICAL|Donor microbiota applied via colonoscopy.|"B. Preparation of donor sample 1. Instillation via Colonoscopy~1\. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.~Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe."
214850667|NCT02610270|DIETARY_SUPPLEMENT|2 Gums|760 mg DHA
214850668|NCT02610270|DIETARY_SUPPLEMENT|3 Gums|1140 mg DHA
214850669|NCT00537199|OTHER|Visual Examination|Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
214850670|NCT00537199|DRUG|OraTest|Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
214850671|NCT00663715|OTHER|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
214850672|NCT00510315|OTHER|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
214850673|NCT02388698|PROCEDURE|Cervical swab|"Cervical Swab at baseline.~HPV testing at recurrence, if applicable."
214850674|NCT02388698|RADIATION|PET-CT|PET-CT will be completed 3 month post chemoradiation.
214850675|NCT02388698|BIOLOGICAL|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
214850676|NCT04532398|OTHER|Gugging swallowing screen - ICU (GUSS-ICU) index test|"Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food)."
214290279|NCT04777994|DRUG|Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)|Oral Tablet
214290280|NCT04777994|DRUG|Programmed Cell Death-1 (PD-1) Inhibitor|Intravenous (IV) infusion
214663670|NCT05199870|DEVICE|Endo II Femoral Head|Subjects that have been implanted with an Endo II Femoral Head
214663671|NCT05780099|OTHER|Inpatient or Outpatient visit|Patients will be seen and treated at the clinics like in the usual care
214663672|NCT06118983|OTHER|I-TRANSFER-HF|"I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies (hospital-HHC agency dyads) across the US."
214663673|NCT02662478|PROCEDURE|Laparoscopic Surgery|Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
214663674|NCT05722002|DRUG|NSAID|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~* Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)"
214663675|NCT05722002|DRUG|Opioid|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~* Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses"
214663676|NCT05722002|DRUG|Acetaminophen|Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
214663677|NCT06526312|BEHAVIORAL|SMS/Text (CAMPI)|Configurable Assessment Messaging Platform for Interventions (CAMPI) is a SMS text messaging platform to promote motivation and home practice.
214663678|NCT06526312|BEHAVIORAL|Fidelity Monitoring (Lyssn and COACH)|"Lyssn's HIPAA-compliant, cloud-based platform uses embedded speech-to-text transcription from audio recorded sessions for rapid assessment and easy session review for supervisors and interventionists.~The COACH fidelity rating system assesses clinical skills in five domains considered essential for the effective provision of the FCU and the EDP intervention sessions. The COACH rating form is used to assess the extent to which the provider is:~Conceptually accurate and adherent to the intervention model Observant and responsive to the family's needs Active in structuring the session Careful when teaching and providing feedback Helpful in building hope and motivation"
214663679|NCT06526312|BEHAVIORAL|Family Check-Up 4 Health (FCU4Health)|An evidence-based, data-driven, individually tailored parenting intervention with evidence of effectiveness on child and family health behaviors and psychosocial well-being. The program includes three components: 1) a comprehensive family assessment, 2) feedback and motivation session, and 3) individually tailored follow-up support (including parent training modules from the Everyday Parenting curriculum and connection with community resources). Dosage and content of these follow-up sessions are driven by the results of the assessment and family interest. The assessment, feedback and motivation session, and follow-up support are repeated annually.
214663680|NCT06550076|DRUG|TAK-279|TAK-279 oral tablet
214663681|NCT05320367|DRUG|Cannabis, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.
214663682|NCT02406846|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
214850677|NCT04532398|OTHER|Flexible Endoscopic Evaluation of Swallowing (FEES) reference test|"Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test."
214850678|NCT01035476|BEHAVIORAL|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
214850679|NCT03680976|DRUG|CXA-10|Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
214850680|NCT03680976|DRUG|Placebo|Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
214850681|NCT04030663|DRUG|papaverine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
214850682|NCT04030663|DRUG|nitroglycerine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
214850683|NCT04030663|DRUG|xlyocaine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
214850684|NCT00005086|DRUG|cisplatin|
214850685|NCT00005086|DRUG|docetaxel|
214850686|NCT00005086|DRUG|gemcitabine hydrochloride|
214850687|NCT00005086|DRUG|methotrexate|
214850688|NCT03309917|OTHER|MAP set at 80-85 mmHg for 5 min|MAP is set at 80-85 mmHg for 5 min by infusion of noradrenaline.
214850689|NCT03309917|OTHER|MAP set at 70-75 mmHg for 5 min|MAP is set at 70-75 mmHg for 5 min by infusion of noradrenaline.
214850690|NCT03309917|OTHER|MAP set at 60-65 mmHg for 5 min|MAP is set at 60-65 mmHg for 5 min by infusion of noradrenaline.
214290281|NCT06504901|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
214290282|NCT06504901|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
214290283|NCT06504901|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
214290284|NCT06504901|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
214290285|NCT06504901|DRUG|Neupogen|rhG-CSF 5mcg/kg HD, QD d1-d14
214850691|NCT03340987|PROCEDURE|vestibular incision subperiosteal tunnel access|vertical vestibular incision will be made down to the periosteum followed by creating a tunnel without reflecting the interdental papilla. Then a free gingival graft will be optained from the palate and de-epithelialized extraorally. The connective tissue graft will then be applied through the tunnel and the gingival margin will be sutured and the sutures will be fixed to the tooth surface by flowable composite. Then the vestibular incision will be sutured.
214850692|NCT03340987|PROCEDURE|Coronally advanced flap|Two horizontal incisions will be made mesial and distal to the recession area followed by two oblique incisions extended to the alveolar mucosa and a full-split thickness flap will be elevated. De-epithelialization will be done to receive the connective tissue graft obtained from the palate by de-epithelializing a free gingival graft. Then the flap will be advanced coronally aand sutured without tension
214850693|NCT05449782|DIETARY_SUPPLEMENT|Cocoa flavanol|Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)
214850694|NCT05449782|OTHER|Placebo|Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
214850695|NCT05369091|DRUG|Simvastatin 10mg|Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
214850696|NCT04625062|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, participants view a dynamic display of the speech signal in the form of a real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants were cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency.
214850697|NCT04625062|BEHAVIORAL|Motor-based treatment|Motor-based articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract were used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
214850698|NCT00860743|DRUG|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
214850699|NCT03439579|BEHAVIORAL|Home weight loss program|Patient remote self-monitoring of diet, activity, and weight with clinician feedback provided remotely based on self-monitored data.
214850700|NCT01396382|RADIATION|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.
214850701|NCT05304026|DEVICE|Technique 1|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F pigtail catheter placed at the level of renal arteries to identify the lowest renal artery.
214850702|NCT05304026|DEVICE|Technique 2|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F introducer placed at the end of the proximal sealing zone to identify the lowest renal artery.
214850703|NCT05304026|DEVICE|Technique 3|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F pigtail catheter through the pigtail catheter placed at the level of renal arteries.
214850704|NCT05304026|DEVICE|Technique 4|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F introducer placed at the level of the contralateral iliac limb.
214850705|NCT06401967|BEHAVIORAL|Pivot Clear|A mobile app and program for alcohol reduction.
214850706|NCT06401967|DEVICE|BACtrack breathalyzer|Personal breathalyzer device that measures blood alcohol content.
214663683|NCT02406846|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
214663684|NCT05268380|DIAGNOSTIC_TEST|Covid-19, TB and HIV diagnosis|GeneXpert (sputum) will be used to diagnose active TB disease, IGRA will be used to diagnose latent TB infection, PCR will be used to diagnose Covid-19 active infection, HIV rapid test will be used to diagnose HIV seropositivity.
214663685|NCT03822949|DEVICE|Day Light|Patients are exposed to daylight for up to 10 days prior to surgery
214663686|NCT03822949|DEVICE|Placebo light|Patients are exposed to placebo light for up to 10 days prior to surgery
214663687|NCT03822949|DEVICE|ICU Intense Light|ICU Patients are exposed to daylight for up to 10 days after surgery
214663688|NCT03822949|DEVICE|ICU Placebo light|ICU Patients are exposed to placebo light for up to 10 days after surgery
214663689|NCT03710109|OTHER|EEG|non-invasive, non-interventional sensor
214850707|NCT03711916|DEVICE|PlasmaBlade 3.0S|PlasmaBlade (Medtronic) is approved by United States Food and Drug Administration (FDA) as a low thermal dissection device that has shown to be associated with effective cutting, and significantly lower temperature than traditional electrosurgical dissection devices.
214850708|NCT01685658|DRUG|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
214850709|NCT01685658|DRUG|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
214850710|NCT05380921|DEVICE|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
214850711|NCT05380921|DEVICE|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
214850712|NCT06327217|RADIATION|Bilateral hip x-ray|Patients will be asked to visit the clinic for a bilateral hip x-ray, in order to evaluate the degree os osteoarthritis.
214850713|NCT06327217|OTHER|Questionnaires|Patients will be asked to complete questionnaires on function, quality of life and pain (the modified Harris Hip Score (mHHS), Hip Outcome Score (HOS), the World Health Organisation Quality of Life Questionnaire (WHOWOL) and Visual Analogue Scale (VAS) for pain). One question will be asked: 'How satisfied are you with the results of the surgery?' on a 10-point scale.
214850714|NCT05801302|DEVICE|Foam rolling (shorter volume)|A single intervention will be performed (3 sets of 30 seconds, with between-sets intervals of 30 seconds).
214850715|NCT05801302|DEVICE|Foam rolling (longer volume)|A single intervention will be performed (3 sets of 60 seconds, with between-sets intervals of 30 seconds).
214850716|NCT03827018|COMBINATION_PRODUCT|mavrilimumab|1 mL of 150 mg in a pre-filled syringe
214663690|NCT03106233|PROCEDURE|LTP flap|A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
214663691|NCT00340431|DRUG|MSP1(42)-FVO & MSP1(42)-3D7|
214663692|NCT04908995|DRUG|EC5026 oral tablet|"12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~* Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~* Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2."
214663693|NCT04908995|OTHER|Placebo oral tablet|"6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period."
214663694|NCT00036335|DRUG|Duloxetine Hydrochloride|
214850717|NCT03827018|COMBINATION_PRODUCT|placebo|1 mL of placebo in a pre-filled syringe
214850718|NCT03827018|DRUG|prednisone|Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
214850719|NCT03808584|OTHER|Physiotherapy|4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
214850720|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 5 minutes in the recovery room
214850721|NCT02898103|DEVICE|Sham stimulation|Sham (placebo) stimulation for 5 minutes in the recovery room
214850722|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 2-4 weeks at home
214850723|NCT03359915|BEHAVIORAL|COPD Self-Management Plan|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
214850724|NCT01726127|OTHER|Broccoli and Brussels Sprouts|
214850725|NCT01726127|DIETARY_SUPPLEMENT|Cruciferous Complete|
214850726|NCT01726127|OTHER|Placebo|
214850727|NCT00627081|DRUG|remifentanil|dosage
214850728|NCT01625481|DEVICE|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
214850729|NCT00128037|DRUG|mitomycin C, vindesine, cisplatin and radiotherapy|
214850730|NCT02523937|OTHER|Soluble Fibrin|Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
214850731|NCT01362426|DRUG|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
214850732|NCT06616922|DRUG|RD03/2016 eye drops|1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.
214850733|NCT06616922|DRUG|Levofloxacin 0.5% eye drops solution (Oftaquix®)|1 drop, 8 times a day (approximately every 2 hours while awake) on Days 1 and 2, and 1 drop, 4 times a day (approximately every 4 hours while awake) on Days 3 through 5.
214850734|NCT06415214|DRUG|Placebo|Placebo
214850735|NCT06415214|DRUG|HRS-7535|HRS-7535
214850736|NCT05631821|PROCEDURE|differential rod bending with rod contours (MESA Spinal System)|differential rod bending with rod contours and Mesa Spinal system evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool
214850737|NCT02080507|DEVICE|Active Neuronetics rTMS stimulator|In the active group, magnetic power output will be delivered to the subject through the coils.
214850738|NCT02080507|DEVICE|Inactive Neuronetics rTMS stimulator|In the inactive group, no magnetic power output will be delivered to the subject through the coils.
214850739|NCT06193447|OTHER|None intervention|None intervention
214850740|NCT01058551|DEVICE|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
214663695|NCT02547727|BIOLOGICAL|rabies vaccine|Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
214663696|NCT02386774|DEVICE|Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml|used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
214850741|NCT01584531|DRUG|rigosertib|"Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.~Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.~The patient will fill a diary indicating the day and time of drug intake."
214850742|NCT00266240|DRUG|GK Activator (2)|Escalating doses po bid
214850743|NCT00266240|DRUG|Placebo|po bid
214850744|NCT04621916|DRUG|FVIII|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
214850745|NCT04621916|DRUG|Emicizumab|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
214850746|NCT00164541|BEHAVIORAL|Arts Based Program|
214850747|NCT00164541|BEHAVIORAL|Curriculum|
214850748|NCT00350402|BEHAVIORAL|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
214850749|NCT01918579|PROCEDURE|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
214663697|NCT02386774|DEVICE|Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)|"used for Multifluorescence IVCM~* anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~* Fluorescein 0,5%, Rose Bengal , Infracyanine"
214663698|NCT02386774|PROCEDURE|microangiography|realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
214663699|NCT00803556|DRUG|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
214663700|NCT00803556|DRUG|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
214663701|NCT00803556|DRUG|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
214663702|NCT05916352|DIETARY_SUPPLEMENT|Caffeine Supplement|Caffeine tablet
214663703|NCT02945657|DRUG|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
214663704|NCT03424226|DRUG|Acetazolamide|a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
214663705|NCT04390685|DRUG|Tacrolimus ointment|Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection
214663706|NCT00250393|DRUG|Istradefylline (KW-6002)|
214663707|NCT02038322|DEVICE|The Stork - Conception Aid|
214663708|NCT05283993|OTHER|No intervention|No intervention
214663709|NCT01276886|DRUG|antibiotic|
214663710|NCT01276886|PROCEDURE|Colonic resection with or without stoma|
214663711|NCT02595034|DRUG|Clindamycin and Benzoyl Peroxide Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
214663712|NCT02595034|DRUG|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
214663713|NCT02595034|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
214663714|NCT02436109|DEVICE|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
214663715|NCT03698734|DRUG|Evening primrose oil(EPO)|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol
214663716|NCT03698734|DRUG|Placebo - Cap|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
214663717|NCT01049776|DRUG|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
214663718|NCT01305499|DRUG|Entinostat days 3, 10|Given orally on days 3, 10
214663719|NCT01305499|DRUG|5AC|
214663720|NCT01305499|DRUG|Entinostat days 10,17|Given orally on days 10, 17
214663721|NCT00087438|RADIATION|stereotactic body radiation therapy|
214663722|NCT00994617|DRUG|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
214663723|NCT00994617|DRUG|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
214663724|NCT04460703|OTHER|Control message|2/15 of the sample will be assigned to the pure control group, which is a passage on the costs and benefits of bird feeding.
214663725|NCT04460703|OTHER|Baseline message|3/15 of the sample will be assigned to a control group with a message about the effectiveness and safety of vaccines.
214663726|NCT04460703|OTHER|Personal freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting people's personal freedom and by working together to get enough people vaccinated society can preserve its personal freedom.
214663727|NCT04460703|OTHER|Economic freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting peoples's economic freedom and by working together to get enough people vaccinated society can preserve its economic freedom.
214663728|NCT04460703|OTHER|Self-interest message|1/15 of the sample will be assigned to this intervention, which is a message that COVID-19 presents a real danger to one's health, even if one is young and healthy. Getting vaccinated against COVID-19 is the best way to prevent oneself from getting sick.
214663729|NCT04460703|OTHER|Community interest message|1/15 of the sample will be assigned to this intervention, which is a message about the dangers of COVID-19 to the health of loved ones. The more people who get vaccinated against COVID-19, the lower the risk that one's loved ones will get sick. Society must work together and all get vaccinated.
214663730|NCT04460703|OTHER|Economic benefit message|1/15 of the sample will be assigned to this group, which is a message about how COVID-19 is wreaking havoc on the economy and the only way to strengthen the economy is to work together to get enough people vaccinated.
214663731|NCT04460703|OTHER|Guilt message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and society must work together to get enough people vaccinated. Then it asks the participant to imagine the guilt they will feel if they don't get vaccinated and spread the disease.
214663732|NCT04460703|OTHER|Embarrassment message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the embarrassment they will feel if they don't get vaccinated and spread the disease.
214663733|NCT04460703|OTHER|Anger message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the anger they will feel if they don't get vaccinated and spread the disease.
214663734|NCT04460703|OTHER|Trust in science message|1/15 of the sample will be assigned to this message about how getting vaccinated against COVID-19 is the most effective way of protecting one's community. Vaccination is backed by science. If one doesn't get vaccinated that means that one doesn't understand how infections are spread or who ignores science.
214663735|NCT04460703|OTHER|Not bravery message|1/15 of the sample will be assigned to this message which describes how firefighters, doctors, and front line medical workers are brave. Those who choose not to get vaccinated against COVID-19 are not brave.
214663736|NCT04681326|DEVICE|biological prosthesis|retro-muscular positioning of a swine dermal collagen prosthesis
214663737|NCT00466505|BIOLOGICAL|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
214663738|NCT00466505|DRUG|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
214663739|NCT00466505|GENETIC|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
214663740|NCT00466505|OTHER|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
214663741|NCT00466505|OTHER|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
214663742|NCT00466505|OTHER|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
214663743|NCT03425903|DEVICE|Whole body cryotherapy sessions|Whole body cryotherapy (WBC) 10 sessions of 3 minutes at a temperature of -196ºC (point of evaporation of liquid nitrogen), on the basis of three sessions a week.Fills in questionnaires.
214663744|NCT06041750|PROCEDURE|Elective surgical procedure under general anesthesia|The incidence of postoperative pulmonary complications in OSAS patients undergoing elective surgery under general anesthesia will be determined.
214663745|NCT00811252|DRUG|Placebo|capsules; daily; orally
214663746|NCT00811252|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
214663747|NCT00811252|DRUG|Duloxetine|encapsulated tablets; daily; orally
214663748|NCT05732129|DRUG|Fluzoparib|150mg,orally, bid (days 1-7) every 2 weeks
214663749|NCT05732129|DRUG|Irinotecan|30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
214663750|NCT03420638|DRUG|Adjunct Exparel (bupivacaine liposome suspension 1.3%)|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.
214663751|NCT03420638|OTHER|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
214663752|NCT05293418|OTHER|data collection|data collection from medical records and the microbiological surveillance system of the enrolled patients
214663753|NCT00932997|BEHAVIORAL|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
214663754|NCT00932997|OTHER|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
214663755|NCT00932997|OTHER|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
214663756|NCT00932997|OTHER|questionnaire administration|Baseline and 9 months after enrollment and intervention
214663757|NCT00932997|PROCEDURE|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
214663758|NCT00932997|PROCEDURE|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
214663759|NCT01543750|DRUG|4-Aminopyridine|
214663760|NCT01543750|DRUG|Placebo|Placebo
214663761|NCT03456011|OTHER|Battlefield Acupuncture|Battlefield Acupuncture gold semi permanent needles
214663762|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, high-dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
214663763|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, standard dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
214663764|NCT03903757|OTHER|DNA methylome and total RNA sequencing|Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features
214663765|NCT03848819|DEVICE|VitaBreath device|The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
214663766|NCT03553173|OTHER|So-Lo-Mo|So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).
214663767|NCT03553173|BEHAVIORAL|Psychological advice|Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
214663768|NCT03553173|DRUG|Bupropion Pill|Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
214663769|NCT03553173|DRUG|Varenicline Pill|Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
214663770|NCT05448079|OTHER|Sexual counseling according to the PLISSIT model, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
214850750|NCT00304707|DRUG|Bupropion|300 mg QD
214850751|NCT00304707|DRUG|placebo|placebo
214663771|NCT02363205|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
214663772|NCT00000851|DRUG|Stavudine|
214663773|NCT00000851|DRUG|Didanosine|
214663774|NCT03728049|DIAGNOSTIC_TEST|CT-ADP performed during TAVI procedure|The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.
214663775|NCT03728049|OTHER|No CT-ADP performed during TAVI procedure|PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
214663776|NCT04295902|DEVICE|C-MAC indirect videolaryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Tuttlingen, Germany) with blades Miller nr 0 and Miller nr 1.
214663777|NCT04295902|DEVICE|Direct laryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
214663778|NCT01486264|BIOLOGICAL|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
214663779|NCT00813748|DRUG|Xolair|
214663780|NCT02978014|DEVICE|ProSpare|A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
214663781|NCT04872725|BEHAVIORAL|Time management & participation & the leisure time activity|evaluated in terms of leisure time activities, time management and participation
214663782|NCT04247048|OTHER|infusion of tracer [5,5,5-2H3] -L-leucine|A bolus of 6ml of \[5,5,5-2H3\] -L-leucine tracers will be performed followed by an infusion of 90 ml of \[5,5,5-2H3\] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.
214663783|NCT05459597|DRUG|antiepileptic drugs|phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
214663784|NCT03250741|DRUG|Rotigotine transdermal patch|Rotigotine transdermal patches 4mg/24hr
214663785|NCT03250741|OTHER|Placebo|Placebo transdermal patches of the same size as for Rotigotine transdermal patches
214663786|NCT04328480|DRUG|Colchicine|"The colchicine dosage schedule will vary according to the following scenarios:~1. In patients not receiving Lopinavir/Ritonavir~   * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~  * The next day 0.5 mg bid for 14 days or until discharge.~2. In patients receiving Lopinavir/Ritonavir~   * Loading dose of 0.5 mg (day 1)~  * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~   * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~  * Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube."
214663787|NCT04328480|OTHER|Local standard of care|Local standard of care for COVID-19 SARS moderate /high-risk patients
214663788|NCT01050621|DIETARY_SUPPLEMENT|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
214663789|NCT00047411|OTHER|Cardiopulmonary Resuscitation|Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
214663790|NCT00047411|DEVICE|Automatic External Defibrillation|Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
214663791|NCT03425708|DRUG|20mg Febuxostat|Participants take 20mg febuxostat pill once a day for at least six months.
214663792|NCT03425708|DRUG|40mg Febuxostat|Participants take 40mg febuxostat pill once a day for at least six months.
214663793|NCT00904254|RADIATION|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
214663794|NCT00002103|DRUG|Trimetrexate glucuronate|
214663795|NCT00002103|DRUG|Leucovorin calcium|
214663796|NCT02774590|DRUG|Timolol|Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
214663797|NCT01495871|DIETARY_SUPPLEMENT|Amino Acids|15 grams amino acids two times per day for 6 weeks
214663798|NCT01495871|DIETARY_SUPPLEMENT|Placebo of inert compounds|Placebo two times per day for 6 weeks
214663799|NCT01495871|DIETARY_SUPPLEMENT|Valine|2.5 grams valine supplementation two times a day for 6 weeks
214663800|NCT03979729|OTHER|Routine Screening Mammogram (3D + 2D)|Subjects that have undergone a routine screening mammogram (3D + 2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
214663801|NCT03979729|OTHER|Routine Screening Mammogram (2D)|Subjects that have undergone a routine screening mammogram (2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
214663802|NCT03979729|OTHER|No Screening Mammogram|Subjects will participate in a one-time facilitated focus group.
214663803|NCT03752905|DRUG|PTR-01|Recombinant human collagen 7 (rC7)
214850752|NCT02331693|BIOLOGICAL|anti-EGFR CAR T|
214850753|NCT05129254|DEVICE|Fractionated Thulium laser|For this study, the investigators will use non-ablative fractional Thulium laser (1927 nm), provided by LaseMD, (Lutronic, Inc, USA). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by LaseMD. More than one affected area of the scalp may be treated per session. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment preparation will consist of cleaning the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide.
214850754|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Injection|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be injected with a syringe and needle subcutaneously into the participant's scalp.
214850755|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Topical Application|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be applied topically with a syringe to one or more affected areas on the participant's scalp that were previously treated with thulium laser.
214850756|NCT01884688|DRUG|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
214850757|NCT03379155|OTHER|Internet-based self-help program|The intervention provided is based on the principles of cognitive behavioral therapy (CBT) (Bachem \& Maercker, 2013). The manual integrates a variety of approaches validated as treatments for PTSD, anxiety disorders, or depression; the selection focuses on exercises which are intended to target the main symptoms of AjD, namely preoccupations (e.g. constant rumination, excessive worry about the stressor) and failure to adapt (e.g. sleep disturbance, difficulties concentrating, loss of interest in previously enjoyable activities).
214850758|NCT02938013|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|antiviral therapy for HCV
214850759|NCT02938013|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|antiviral therapy for HCV
214850760|NCT05450484|DRUG|Fluorescence endoscopy using durvalumab-680LT|"Tracer administration: The PD-L1-targeted fluorescent tracer durvalumab-680LT will be administered intravenously 2-4 days prior to the endoscopy at the UMCG. Afterwards, patients will be monitored for half an hour by measurements of vital parameters for potential side-effects, such as infusion-related reactions.~Endoscopy procedure: Patients will undergo two endoscopies, before and after neoadjuvant therapy. First, routine high-definition white-light (HD-WL) inspection is used. Quantification of fluorescence using multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed both in vivo and ex vivo. Subsequently, fluorescence molecular endoscopy (FME) and endoscopic ultrasound (EUS) will be performed. EUS enables single fiber reflectance/single fiber fluorescence (SFR/SFF) spectroscopy measurements via fine needle aspiration (FNA) to gain insight in the drug distribution throughout the tumor. Additionally, biopsies will be obtained."
214850761|NCT04099641|DRUG|Bavituximab|Bavituximab IV infusion
214850762|NCT04099641|DRUG|Pembrolizumab Injection|Pembrolizumab IV Infusion
214850763|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.|"Fire dragon pot moxibustion treatment The main acupuncture points are as follows: Fengchi, Jianjin, Dazhui, Feiyu, Xinyu, Ganyu, Piyu, Shenyu, etc (all acupuncture points are positioned according to the national standard: GB/T12346-2006).~Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
214850764|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy|"Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
214850765|NCT02268539|PROCEDURE|ablation|Ablation ranging from 20-25 watts / 30-45 seconds
214850766|NCT00712244|DEVICE|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
214850767|NCT00712244|DEVICE|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
214850768|NCT00712244|DEVICE|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
214850769|NCT00712244|DEVICE|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
214850770|NCT03467282|DIETARY_SUPPLEMENT|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
214850771|NCT03467282|DIETARY_SUPPLEMENT|Placebo|1g polydextrose/maltodextrin - twice day
214850772|NCT01856439|DRUG|ProSavin|Long term follow up of patients who received ProSavin in a previous study
214850773|NCT04376359|PROCEDURE|hyperbaric oxygen therapy|Hyperbaric oxygen therapy is the patient put in airtight oxygen tank, by increasing the air pressure in the environment (1.5 to 3.0) under atmospheric pressure, to give 100% oxygen, the patient treatment time is approximately 60 minutes to 120 minutes in this way, can achieve the purpose of greatly increase the oxygen partial pressure in the organization, so as to achieve reverse brain edema, reduce lipid peroxidation, inhibiting leukocyte hyperactivity, rebuild the blood brain barrier.
214850774|NCT00298987|DRUG|Dasatinib|Tablets, Oral, 70 mg, Twice daily, 2 months.
214850775|NCT04263233|OTHER|Analysis using descriptive statistics of patient clinical outcomes.|"Evaluation of the following:~* Laboratory values at admission, week 4, and day 90.~* Pre and post blood pressure at week one and week 4.~* Intradialytic hypotension at week one and week 4.~* Ultrafiltration rates at week one, week 4, day 90, day 180, and day 360.~* Target weight defined and achievement in week one and week 4 and changes between week one and week 4.~* Dialysis access type at week one and day 90.~* Hospitalization and mortality rates."
214850776|NCT04263233|OTHER|Surveys with participants using validated survey tools.|Surveys will assess participants' Symptom index, Quality of Life, Patient Activation as well as satisfaction with the program.
214850777|NCT04263233|OTHER|Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.|Data will be collected using tracking tools throughout the program.
214850778|NCT00604227|OTHER|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
214850779|NCT01931527|DRUG|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
214850780|NCT05370261|DIETARY_SUPPLEMENT|Berberine LipoMicel|Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine
214850781|NCT05370261|DIETARY_SUPPLEMENT|Regular Berberine hard-gels|Total dose of 500 mg of berberine
214850782|NCT02018094|DRUG|Co-amoxiclav|Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
214850783|NCT02018094|DRUG|Iodine|Intra-operative skin preparation prior to incision to skin.
214850784|NCT02018094|DRUG|Metronidazole|500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
214850785|NCT02018094|DRUG|Chlorhexidine|Alcoholic Chlorhexidine skin pre-op preparation
214850786|NCT02018094|DRUG|Teicoplanin|Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
214850787|NCT02018094|DRUG|Clindamycin|Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
214850788|NCT04072315|DRUG|PLN-74809|PLN-74809
214850789|NCT04072315|RADIATION|Knottin tracer|Radiotracer
214850790|NCT05178576|DRUG|Gevokizumab|120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)
214850791|NCT05178576|DIAGNOSTIC_TEST|Signatera test|ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.
214850792|NCT05683210|BEHAVIORAL|Cup feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The feeding process was completed at the end of 30 minutes even if the infant did not take all of the food. The infant was followed up for 30 minutes after the end of feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
214850793|NCT05683210|BEHAVIORAL|Bottle feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. During the feeding period, heart rate and oxygen saturation were continuously recorded. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The infant was followed up for 30 minutes after the end of the feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
214850794|NCT05487768|OTHER|EEG measurement|"EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~* Knee extension while sitting (10x left - right)~* Bipodal squatting (10x)~* Unipodal stance (5x30 seconds left-right)"
214850795|NCT02210052|DEVICE|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
214850796|NCT04691700|DRUG|Goreisan|Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
214850797|NCT04691700|DRUG|Standard Treatment|Standard therapy without Goreisan
214850798|NCT04798482|DRUG|Dexmedetomidine|Patients will undergo the usual anal manometry study, with no adjuvant medications, per routine practice currently in the gastrointestinal unit. Following completion of manometry, 0.5 mcg/kg DEX will be administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Manometry measurements will be followed for 15 minutes in response to DEX.
214850799|NCT04456933|PROCEDURE|Extracorporeal left hemicolectomy anastomosis|"Standard surgical technique protocolized in the unit for laparoscopic surgery of the left colon, sigma and high rectum for the last 10 years.~After sectioning the distal colon using a mechanical stapler (60mm blue load), a pfannestiel-type suprapubic accessory incision is made, with externalization of the tumor under wound protection with a ringed retraction device. Both the resection of the left mesocolon or mesosigma, and the placement of the head of the circular stapler are performed extracorporeally by proximal section of the colon with a pursetring® self-suturing device, removal of the piece, placement of the head, and reconnection of the pneumoperitoneum for colorectal anastomosis with Circular Stapler Curved B. Braun®"
214850800|NCT04456933|PROCEDURE|Intracorporeal left hemicolectomy anastomosis|"o Intracorporeal resection of the left mesocolon~The mesocolon resection will be performed totally intracorporeally to its proximal end. The distal colon section will be performed using a mechanical stapler (blue charge 60mm)~o Preparation of Intracorporeal Anastomosis~The anastomosis will be performed in a mechanical end-to-end manner using a Circular Stapler Curved B. Braun®.~The Insertion of the stapler head into the proximal colon will be placed intracorporeally with an incision distal to the staple section. Once the head has been exteriorized at the terminal end of the proximal colon, a circular purse-type suture with prolene 2.0 will be made.~Once the mechanical colorectal anastomosis is performed, 4-6 stitches of anastomotic reinforcement with silk 2.0 will be placed.~The extraction of the piece will be carried out with endobag protection and with an accessory incision (pfannestiel or other location depending on the patient)"
214850801|NCT04146831|DRUG|Sintilimab|Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
214850802|NCT06552104|BEHAVIORAL|ACUPRESSURE APPLI ACUPRESSURE APPLICATION|Pre-test data were collected from participants who met the inclusion criteria and volunteered to participate in the study by researcher BI in the LDP rooms during the latency period of labor. Post-test data were obtained by the same researcher 16 hours after the cesarean section. Data were obtained using the Personal Information Form, Episiotomy Evaluation Form (EEF), Visual Analog Scale (VAS), and Spielberger Manual for State-Trait Anxiety Inventory (STAI).
214850803|NCT01859026|DRUG|MEK162|Treatment as outlined in study arms.
214850804|NCT01859026|DRUG|Erlotinib|Treatment as outlined in study arms.
214850805|NCT01192399|BIOLOGICAL|Eculizumab|
214850806|NCT01779388|PROCEDURE|Bronchoscopy|During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
214850807|NCT02438696|DRUG|BI 1060469, iFF, Test|
214850808|NCT02438696|DRUG|BI 1060469, iFF, Test|
214850809|NCT02438696|DRUG|BI 1060469, TF1, Reference|
214850810|NCT02438696|DRUG|BI 1060469, TF2, Test|
214850811|NCT02438696|DRUG|BI 1060469, TF2, Test|
214850812|NCT02438696|DRUG|BI 1060469, iFF, Test|
214850813|NCT02438696|DRUG|BI 1060469, TF1, Reference|
214850814|NCT02438696|DRUG|BI 1060469, iFF, Test|
214850815|NCT02438696|DRUG|BI 1060469, iFF, Test|
214850816|NCT02438696|DRUG|BI 1060469, TF1, Reference|
214850817|NCT02438696|DRUG|BI 1060469, TF2, Test|
214850818|NCT02438696|DRUG|BI 1060469, TF1, Reference|
214850819|NCT02438696|DRUG|BI 1060469, TF1, Reference|
214850820|NCT02438696|DRUG|BI 1060469, TF2, Test|
214850821|NCT02438696|DRUG|BI 1060469, TF2, Test|
214850822|NCT02438696|DRUG|BI 1060469, iFF, Test|
214850823|NCT02438696|DRUG|BI 1060469, TF2, Test|
214850824|NCT02438696|DRUG|BI 1060469, TF1, Reference|
214850825|NCT06490575|OTHER|Educational Intervention Based on Protection Motivation Theory to Improve Knowledge and Promote Nonpharmacological Approaches to Prevent and Manage Hypertension among Adults|Participants in the intervention group attended four face-to-face workshops (one session per week). Each session took about 30 minutes and consisted of lectures with PowerPoint presentations, discussion, questions and answers, and the distribution of educational pamphlets and booklets.
214850826|NCT04101695|DEVICE|tDCS|Ybrain tDCS System (Ybrain, Korea) is used for anodal stimulation of cerebellar hemisphere. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on right buccinator muscle.
214850827|NCT04596124|DEVICE|fitostimoline plus|randomized controlled multicentric study
214850828|NCT00789113|DRUG|Extended Release Lamotrigine|
214663804|NCT03752905|DRUG|Normal saline|Saline control
214663805|NCT00013884|DRUG|T-20|
214850829|NCT06247501|GENETIC|SNUH-CD19-CAR-T|CD19 CAR-T is a gene therapy that uses genetically modified autologous peripheral blood T-cells to target CD19 on the surface of B-cells. In this approach using CARs, lymphocytes are genetically manipulated, introducing the chimeric antigen receptor gene into the lymphocytes to combine the function of effector T-cells with antibody-like abilities. The chimeric antigen receptor can recognize cell surface antigens without the need for antigen processing. By using a single-chain variable fragment (scFv) antibody, which combines the variable regions of the heavy chain (VH) and light chain (VL) through a peptide linker of approximately 15 amino acids in length, the CAR gains the ability to bind to tumor antigens.
214850830|NCT04714151|DRUG|K-877 ER 0.2 mg/day (once daily)|K-877 ER 0.2 mg tablet
214850831|NCT04714151|DRUG|K-877 ER 0.4 mg/day (once daily)|K-877 ER 0.4 mg tablet
214850832|NCT04714151|DRUG|K-877 IR 0.2 mg/day (twice daily)|K-877 IR 0.1 mg tablet
214850833|NCT02560428|BEHAVIORAL|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
214850834|NCT03903159|BEHAVIORAL|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
214850835|NCT02443545|DRUG|Deferiprone|
214850836|NCT02401477|DRUG|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
214850837|NCT03589248|DIAGNOSTIC_TEST|GIF score|assessment by GIF score
214850838|NCT03589248|DIAGNOSTIC_TEST|US score|assessment by ultrasonography score
214850839|NCT00553592|DRUG|Bicifadine|600mg/day
214850840|NCT00553592|DRUG|Bicifadine|placebo tablet
214850841|NCT00553592|DRUG|Bicifadine|1200 mg
214850842|NCT03041168|DEVICE|Carotid Stenotic Scan|Each subject will have been scheduled for a carotid ultrasound, or other imaging test of the neck (carotids) as ordered by his/her physician for clinical or screening purposes. These studies will be read by a Jefferson radiologist and a report generated for standard clinical purposes. These reports and the images will be collected and de-identified to be used as comparator measurements to the CSS results. The CSS device is shaped like a stethoscope with 3 small gel pads. It is positioned with a gel pad on either side of the neck and one on the front of the chest. The scan takes about 1-2 minutes to provide an image on the screen of the device cart. The scan device pads just lie on the skin and do not use any invasive techniques to provide the image.
214850843|NCT03399240|DEVICE|Vitasitiq device|Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
214850844|NCT05037786|BEHAVIORAL|Infographic|Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic
214850845|NCT05037786|BEHAVIORAL|Powerpoint|Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
214850846|NCT01923584|DRUG|EPI-743 400mg|
214850847|NCT01923584|DRUG|EPI-743 200mg|
214850848|NCT00536484|DRUG|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
214850849|NCT00536484|DRUG|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
214850850|NCT02303314|DRUG|Trigonella Foenum-graecum Seed Extract|
214850851|NCT02303314|DRUG|Drug: Placebo|
214850852|NCT01506908|DRUG|oral nicotine|oral nicotine replacement product
214850853|NCT01506908|DRUG|Placebo|no active
214850854|NCT02860182|OTHER|measure the elastic properties of aortic wall|
214850855|NCT00591331|DRUG|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
214850856|NCT00591331|DRUG|placebo|
214850857|NCT02197026|DRUG|Hylan G-F 20|
214850858|NCT02197026|DRUG|Standard treatment|Standard drug treatment at the discretion of the investigator
214850859|NCT02197026|PROCEDURE|Physiotherapy|
214850860|NCT02197026|PROCEDURE|Hydrotherapy|
214850861|NCT02732691|DEVICE|JenaValve Pericardial TAVR System|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.
214850862|NCT02162355|DRUG|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
214850863|NCT02162355|DRUG|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
214850864|NCT02162355|DRUG|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
214850865|NCT02162355|DRUG|Placebo|1 or 2 matching placebo tablets once daily for 10 days
214850866|NCT01158352|DIETARY_SUPPLEMENT|Nutritional supplementation formula|Nutritional supplementation formula
214850867|NCT01158352|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
214850868|NCT06590376|OTHER|midwifery care based on swanson care theory|All stages in the Midwifery Care and Counselling Practitioner Guide for Couples Experiencing Pregnancy Loss, which was developed by the researcher and included care, education and midwife counselling consisting of eight interviews, four of which were face-to-face and four by telephone, were applied.
214850869|NCT02506608|PROCEDURE|Operation of sensorized hand prosthesis|"Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
214850870|NCT04211142|PROCEDURE|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)|Laparoscopic inguinal hernia repair
214850871|NCT04211142|PROCEDURE|Open Inguinal Hernia Repair (Lichtenstein repair)|Open Inguinal Hernia Repair
214850872|NCT00000963|DRUG|Didanosine|
214850873|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
214850874|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
214850875|NCT01644422|OTHER|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
214850876|NCT00074750|DRUG|DTGM|Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
214850877|NCT05426616|DEVICE|collagen membrane (Creos Xenoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved.
214663806|NCT02762058|DEVICE|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy system using occulus rift as virtual headset and kinect as motion tracking sensor.
214850878|NCT05426616|DEVICE|titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied.A titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Care is taken to leave a distance of at least 1 mm between the membrane and neighboring teeth. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved. The membrane is removed after 9 months, prior to implant placement.
214850879|NCT01776567|DEVICE|Everolimus eluting stents|
214850880|NCT00638833|DRUG|Memantine|Memantine 30 mg/day (20-10-0)
214850881|NCT00638833|DRUG|Placebo|Placebo pills
214850882|NCT03490474|OTHER|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
214850883|NCT03490474|OTHER|Pain Free Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
214850884|NCT03490474|OTHER|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
214850885|NCT02926781|DEVICE|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
214850886|NCT03669068|PROCEDURE|Gastrointestinal endoscopy|"Two separated groups will be included in the registry:~1. Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~2. Patients undergoing elective gastrointestinal endoscopy."
214850887|NCT03630094|DRUG|FEP-ZID|A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
214850888|NCT05861635|DRUG|Disitamab Vedotin combined with Tislelizumab|"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"
214850889|NCT03748355|GENETIC|Pharmacogentic Analysis|Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
214850890|NCT00562120|DRUG|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
214850891|NCT00562120|DRUG|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
214663807|NCT02762058|PROCEDURE|Traditional Mirror Therapy|Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
214850892|NCT00562120|DRUG|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
214850893|NCT00562120|DRUG|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
214850894|NCT05598164|OTHER|Botulinum toxin type A|"Patients of main group are treated with injection in internal sphincter botulinum toxin type A.~In the control group, the fissure is excised in combination with a injection in internal sphincter botulinum toxin type A."
214850895|NCT00545688|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
214850896|NCT00545688|DRUG|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
214850897|NCT00545688|DRUG|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
214850898|NCT00707421|DRUG|ketorolac acetate|
214850899|NCT00707421|DRUG|fluorometholone|
214850900|NCT00707421|DRUG|artificial lacrimal tears|
214850901|NCT00813826|DRUG|SLC022|SLC022 150 mg capsule, 900mg daily dose
214850902|NCT00813826|DRUG|Placebo|Placebo capsule, TID
214850903|NCT05655247|PROCEDURE|Split-thickness non-advanced tunnel (Zabalegui et al. 1999)|A split-thickness non-advanced tunnel will be performed according to Zabalegui et al. (1999).
214850904|NCT05655247|PROCEDURE|Full-thickness coronally-advanced tunnel (Aroca et al. 2010)|A full-thickness coronally-advanced tunnel (Modified Coronally Advanced Tunnel - MCAT) will be performed according to Aroca et al. (2010).
214850905|NCT05872464|OTHER|Artificial saliva containing cumin and ginger extract|Artificial saliva containing cumin and ginger extract in spray bottle
214850906|NCT05872464|OTHER|Placebo|Placebo containing composition close to the test group without cumin and ginger extract in spray bottle
214850907|NCT05992948|DEVICE|Transanal stapling device|Transanal stapling device used in low anterior- or anterior rectum resection, sigma resection, left hemicolectomy and intestinal reconstruction operations
214850908|NCT00932282|DRUG|Peanut Oral Immunotherapy|Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
214663808|NCT00716443|DRUG|tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)|Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections
214663809|NCT00716443|DRUG|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections
214850909|NCT00932282|DRUG|Omalizumab|Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
214850910|NCT06190886|DRUG|PTX-912|Investigation Product Monotherapy
214850911|NCT04678817|DEVICE|Etonogestrel contraceptive implant with oral levonorgestrel|Participants who present for emergency contraception and select the Etonogestrel contraceptive implant with oral levonorgestrel
214850912|NCT04678817|DEVICE|Levonorgestrel intrauterine device|Participants who present for emergency contraception and select the Levonorgestrel intrauterine device
214663810|NCT00002523|DRUG|fluorouracil|
214663811|NCT00002523|DRUG|leucovorin calcium|
214850913|NCT04678817|DEVICE|Copper T380A intrauterine device|Participants who present for emergency contraception and select the Copper T380A intrauterine device
214850914|NCT06286657|DIETARY_SUPPLEMENT|Xanthohumol|Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
214850915|NCT06286657|DIETARY_SUPPLEMENT|Placebo|Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
214850916|NCT01983514|DRUG|8IU intranasal oxytocin|
214850917|NCT01983514|DRUG|24 IU intranasal oxytocin|
214850918|NCT01983514|DRUG|1 IU intravenous oxytocin|
214850919|NCT01983514|DRUG|Placebo|
214663812|NCT00002523|PROCEDURE|conventional surgery|
214663813|NCT00002523|RADIATION|radiation therapy|
214663814|NCT05385562|DRUG|Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate|formulated with sodium hyaluronate and chondroitin sulfate
214663815|NCT05385562|DRUG|Triamcinolone Acetonide alone|Triamcinolone Acetonide alone
214663816|NCT00035893|DRUG|poly I-poly C12U|200-400 mg IV infusions 2x/week for 64 weeks
214663817|NCT00009672|DRUG|Nortriptyline|
214663818|NCT00009672|DRUG|Morphine|
214663819|NCT03876587|DRUG|Pyrotinib Maleate combine with Docetaxel|Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
214663820|NCT04894383|DEVICE|Aetrex L420 Compete Orthotic|An orthotic insole to be inserted into shoes. Orthotic for low arches to flat feet with no forefoot pain, featuring a posted heel to control over-pronation and provide balance. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia.
214663821|NCT04894383|DEVICE|Aetrex indoor comfort sandal with built-in arch support|An indoor comfort sandal with built-in arch support to be used at home. Provides extreme cushioning, shock absorption and durability. Arch support helps to stabilize and align feet and also helps to relieve common foot pain \& plantar fasciitis.
214663822|NCT01590329|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
214663823|NCT01517438|BEHAVIORAL|agitation|agitation score after desflurane anesthesia
214663824|NCT00744289|OTHER|Incentive condition|Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
214663825|NCT03777514|DRUG|Ferumoxytol|treatment of iron deficiency anemia with IV iron.
214663826|NCT03777514|DRUG|Ferrous sulfate|treatment of iron deficiency anemia with oral iron
214663827|NCT03777514|OTHER|Oral vitamin C|Oral vitamin C to be used as a placebo for participants receiving IV iron
214663828|NCT03777514|OTHER|Intravenous normal saline|Intravenous normal saline will be used as placebo for participants receiving oral iron
214663829|NCT04776343|OTHER|telemedecine follow-up|weekly home-based follow-up of visual acuity on electronic tablet
214663830|NCT00759577|DRUG|Solifenacin|5mg and 10 mg, oral once daily
214663831|NCT00327392|DRUG|AQUAVAN® (fospropofol disodium) Injection|
214663832|NCT03614936|OTHER|Geriatric Screening Test G8|Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).
214663833|NCT03614936|OTHER|Geriatric fragility test GERICO|"GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~* the socio-cultural evaluation scale,~* the ADL autonomy questionnaire,~* assessment of locomotor disorders,~* nutritional assessment,~* the MMSE Cognitive Function Evaluation Questionnaire,~* the GDS-4 mood rating scale,~* the comorbidity assessment test (Charlson Index)"
214663834|NCT03268798|DEVICE|Unilateral wrist extension training|Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
214663835|NCT00143325|DRUG|varenicline (CP-526,555)|
214663836|NCT02595242|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
214663837|NCT02595242|DRUG|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
214663838|NCT02595242|DRUG|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
214663839|NCT01175512|DRUG|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
214663840|NCT01175512|DRUG|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
214663841|NCT03971981|DIETARY_SUPPLEMENT|100% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
214663842|NCT03971981|DIETARY_SUPPLEMENT|22% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
214663843|NCT00719199|DRUG|IMO-2055|SC weekly injections
214663844|NCT00719199|DRUG|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
214663845|NCT00719199|DRUG|FOLFIRI|Given day 1 of each cycle
214663846|NCT02560454|BEHAVIORAL|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance's"
214850920|NCT04824144|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
214906986|NCT02040805|BEHAVIORAL|Group Cognitive Behavioral Therapy|"Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF."
214850921|NCT05824819|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|Biological materials (stool, peritoneal/ovarian cyst fluid, endometrial aspirate) will be secured and then subjected to molecular analysis using the Next Generation Sequencing (NGS) method. The stages will include: i) isolation of bacterial DNA from biological materials, ii) preparation of libraries for sequencing, including the performance of the PCR and nested-PCR methods on bacterial DNA isolates from the tested samples of biological materials, iii) purification of amplification products, indexing, validation of the concentration of amplicons, pooling and denaturation of libraries, iv) standardization and optimization of the procedure for the isolation of bacterial metagenomic DNA from biological materials from intestines, peritoneal cavity, uterine cavity and endometrial tissues, v) standardization of the nested-PCR method on bacterial DNA isolates from the tested biological materials, vi) submission of samples for sequencing.
214850922|NCT02682147|DRUG|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
214850923|NCT03081728|DEVICE|Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml|bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
214850924|NCT03081728|DRUG|IV diclofenac and IV paracetamol|iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
214850925|NCT02966184|DRUG|preservative free albuterol|Preservative free albuterol for nebulization
214850926|NCT03860207|BIOLOGICAL|Humanized 3F8 Bispecific Antibody|Phase I Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.
214850927|NCT03860207|OTHER|Blood draw|In cycle 1, blood is drawn for PK studies.
214850928|NCT05477459|DRUG|LSD tartrate|LSD tartrate equivalent to 25 microgram LSD base
214850929|NCT05477459|DRUG|Placebo|Placebo with equal appearance
214850930|NCT05535855|DRUG|CD19 Directed CAR T Cell|The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
214850931|NCT03879096|OTHER|Therapeutic Exercise and Education|Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
214850932|NCT04567576|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"Within a non-experimental setting, the routine disease-modifying antirheumatic drugs (DMARDs) prescription will be evaluated as the exposure."
214850933|NCT00095433|DRUG|rhuFab V2 (ranibizumab)|
214850934|NCT01792414|DEVICE|Sham TES|Neuroconn Eldith device
214850935|NCT01792414|DEVICE|Active TES|Neuroconn Eldith device
214850936|NCT04685551|BEHAVIORAL|Change in knowledge, motivation, skills, and resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to improve survivorship outcomes.
214850937|NCT01010126|BIOLOGICAL|Bevacizumab|Given IV
214850938|NCT01010126|DRUG|Temsirolimus|Given IV
214850939|NCT00635830|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
214850940|NCT04698772|DRUG|Ketamine|Blinded study group will receive ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)
214850941|NCT04698772|DRUG|Morphine|Blinded study group will receive morphine 4 mg IV push over 3-5 minutes for pain control
214850942|NCT00214331|DRUG|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
214850943|NCT00214331|DRUG|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
214850944|NCT00214331|DRUG|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
214850945|NCT02919241|BEHAVIORAL|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
214850946|NCT02919241|BEHAVIORAL|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
214850947|NCT04587102|OTHER|whole body viberation|vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform
214850948|NCT04587102|OTHER|Traditional program(balance exercises and resisted exercises)|balance exercises and resisted exercises
214850949|NCT01150162|DRUG|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
214850950|NCT01150162|DRUG|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
214850951|NCT05218109|DEVICE|tVNS|transcutaneous vagus nerve stimulation
214850952|NCT05218109|BEHAVIORAL|Mindfulness|Brightmind mobile mindfulness application
214850953|NCT05218109|DEVICE|sham tVNS|sham transcutaneous vagus nerve stimulation
214850954|NCT05218109|OTHER|Number Puzzle|Control number puzzle task delivered via mobile device
214850955|NCT01959490|BIOLOGICAL|trastuzumab|Given IV
214850956|NCT01959490|BIOLOGICAL|Pertuzumab|Given IV
214850957|NCT01959490|DRUG|docetaxel|Given IV
214850958|NCT01959490|DRUG|carboplatin|Given IV
214850959|NCT01959490|DRUG|doxorubicin|Given IV
214850960|NCT01959490|DRUG|cyclophosphamide|Given IV
214850961|NCT01959490|DRUG|paclitaxel|Given IV
214850962|NCT01959490|DRUG|Bevacizumab|
214906987|NCT02040805|BEHAVIORAL|Peer Facilitated Support Group|Fifteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
214906988|NCT01008605|OTHER|delivery system|syringe
214906989|NCT02884362|OTHER|clinical biological data collection on melanoma|collection and centralization of clinical and biological data of patients with melanoma
214850963|NCT04553835|BEHAVIORAL|Rhythmic auditory stimulation (RAS) for schizophrenia patients|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday."
214850964|NCT04553835|BEHAVIORAL|No RAS for schizophrenia patients|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
214850965|NCT04553835|BEHAVIORAL|RAS for at-risk individuals|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day."
214850966|NCT04553835|BEHAVIORAL|No RAS for at-risk individuals|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
214850967|NCT02753517|DEVICE|Hepatobiliary scintigraphy|hepatobiliary scintigraphy with functional assessment of the future remnant liver before an extended hepatectomy of 4 or more segments
214850968|NCT05213169|DRUG|Apomorphine Hydrochloride 5mg/ml|Product administered using an external continuous subcutaneous infusion pump.
214850969|NCT05213169|OTHER|Sodium chloride 9mg/ml|Product administered using an external continuous subcutaneous infusion pump.
214850970|NCT06051968|BEHAVIORAL|Online hearing support for first-time hearing aid users|Participants get hearing rehabilitation according to common practice and the online hearing support consists of five chapters that aim to give information, support, and advice to the new hearing aid users. The participants are assigned a new chapter between each visit at the clinic.
214850971|NCT06051968|BEHAVIORAL|Hearing rehabilitation according to common practice.|Participants get hearing rehabilitation according to common practice.
214850972|NCT04474431|OTHER|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
214850973|NCT06473402|DIAGNOSTIC_TEST|Muscle Strength Test|Hamstring muscle strength of the participants was measured with a dynamometer (Microfet 2, Hoggan Health Industries, HHD) with the knee flexed at 90 degrees. After the physiotherapist fixes and positions the dynamometer 5 cm proximal to the calcaneus with a belt, the participant will be asked to accelerate to maximum isometric strength by trying to bring his heel closer to his hip against this resistance. The isometric strength of the hamstring muscle will be measured in Newtons (N) by being asked to wait at maximum force level for three seconds. Measurements were made in 2 repetitions and the highest value was noted. There will be a 30-second rest period between attempts.
214850974|NCT06473402|DIAGNOSTIC_TEST|Hamstring Flexibility|The Sit and Reach Test will be administered to evaluate flexibility. Measurements will be made with a test stand with a length of 35 cm, a width of 45 cm and a height of 32 cm. The measurement of the participant who cannot reach the zero point of the sole of the foot on this tripod will be recorded as minus (-), while the measurement of the participant who can pass the zero point will be recorded as plus (+). Participants will be seated in a long sitting position with the soles of their feet resting on the testing apparatus, and the measurement will begin with their knee joints fully extended. While leaning his body forward, he will be asked to lie forward as far as he can, with his hands in front of his body, without bending his knees. The test will be repeated 2 times and the best value will be recorded in cm.
214850975|NCT06473402|DIAGNOSTIC_TEST|Knee Range of Motion|Joint range of motion measurement of the participants was made with a universal goniometer. Degree was used as the measurement unit. The measurement was made in the prone position. The pivot point of the goniometer is placed on the lateral epicondyle of the femur, and the fixed arm is kept parallel to the lateral midline of the femur, while the movable arm will follow the fibula. The joint range of motion of the participants was measured before and after manual therapy. AAOS (American of Orthopedic Surgeons) was taken as the reference value.
214850976|NCT06473402|DEVICE|Percussion Therapy|A percussion massage device was used in the study. Massage application was applied to the Hamstring muscle, adhering to optimal standards. During the application, a wide round head, which is the most preferred by clinical professionals, was used and 30 Hz, which is considered as the average application speed, was used. The application was applied for a total of 6 minutes, 2 minutes for each part of the muscle. Applications have been made many times on every part of the muscle, from the starting point to the ending point.
214850977|NCT06473402|OTHER|Manual Therapy Technique|Anterior and posterior innominate muscle energy techniques were performed on patients. In the anterior technique, the patient lay on their back with their leg on the diagonal shoulder. The clinician flexed the hip and knee, placed their hand on the back thigh, and instructed the patient to push, resulting in hip extension. After eight seconds, the patient inhaled and exhaled. The clinician then increased hip flexion and applied pressure against a new barrier. In the posterior technique, the patient lay on their side in the modified sims position. The clinician held the leg with their caudal hand and placed the hypothenar edge of their cranial hand on the right SIPS. The patient then pulled the leg towards themselves, applying equal counterforce for eight seconds before inhaling and exhaling. Finally, the clinician extended the leg and pushed it against a new barrier.
214850985|NCT03800225|PROCEDURE|Repair|Anterior ligament repair with internal brace.
214850986|NCT02440035|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 in Group 3.
214850987|NCT02440035|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 4.
214850988|NCT02440035|DRUG|Placebo|Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
214850989|NCT00005090|BIOLOGICAL|bleomycin sulfate|10 U/m\^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
214850990|NCT00005090|DRUG|carmustine|150/m\^2 on days -6 to -4 (4-6 days before transplant).
214850991|NCT00005090|DRUG|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
214850992|NCT00005090|DRUG|dacarbazine|375 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
214850993|NCT00005090|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
214850994|NCT00005090|DRUG|etoposide|60 mg/kg on day -4 (4 days before transplant).
214850995|NCT00005090|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
214850996|NCT00005090|PROCEDURE|peripheral blood stem cell transplantation|2 x 10\^6 CD34+ blood mononuclear cells/kg of actual body weight
214850997|NCT03572842|OTHER|quantiferon monitor test|different blood test with quantiferon monitor
214850998|NCT00784134|DRUG|Alteplase|1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
214290286|NCT05786885|PROCEDURE|Microneedling will be done with application of topical vitamin C paste for depigmentation|"A Dermapen device will be used to microneedle the gingival tissue (model M8) with 24 microneedles arranged in rows, which is adjusted with 1.5 mm depth at the 6th mode speed of 700 cycles/min.~It will be used in intermittent motion on the affected area for 30-40 seconds / tooth.~Once bleeding points are observed on all areas of the pigmented gingiva, it will be irrigated using saline solution and dried using sterile gauze.~Topical vitamin C powder (1000 mg/ml) will be mixed with saline, and the resultant slurry mix will then be applied to the gingiva for 10 minutes."
214850999|NCT00784134|OTHER|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
214851000|NCT05765799|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).
214851001|NCT03785145|DRUG|MT10109L|MT10109L will be injected into the LCL.
214851002|NCT03785145|DRUG|Placebo|Placebo will be injected into the LCL.
214851003|NCT03012659|BEHAVIORAL|Contraceptive Counseling Training|"Intervention sites will receive:~1. In person training: All staff at an intervention health center will participate in a one-day counseling training.~2. On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.~3. Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance."
214851004|NCT03554252|OTHER|Frequencies|Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)
214851005|NCT03554252|OTHER|Percentages|Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
214851006|NCT03694808|DRUG|Fluad Vaccine|single adjuvanted dose (AD) intramuscular injection
214851007|NCT03694808|DRUG|Fluzone HD Vaccine|single high dose (HD) intramuscular injection
214851008|NCT02113371|BEHAVIORAL|Intervention|
214851009|NCT00621920|DRUG|FM-601|Dose-escalation, split dosage, liquid
214851010|NCT04520776|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
214851011|NCT04520776|DEVICE|Mobi-C® Cervical Disc|surgery
214851012|NCT00320567|DRUG|norgestimate/ethinyl estradiol|
214851013|NCT03716531|RADIATION|IORT|IORT works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy
214851014|NCT00110188|DRUG|ridaforolimus|
214851015|NCT02631837|PROCEDURE|vNOTES hysterectomy|Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
214851016|NCT02631837|PROCEDURE|LSC hysterectomy|Surgical removal of the uterus by transabdominal laparoscopy
214851017|NCT05569330|OTHER|Air purification|Aerosol particles are removed from room air by several methods
214851018|NCT00500552|DRUG|Perhexiline/Placebo|
214851019|NCT03970265|DIAGNOSTIC_TEST|extraction of ELF and ILF from explanted lung tissue; meropenem concentration in ELF and ILF; ELF on postoperative day 1-5 when bronchoscopy is performed within clinical routine.|Interventions will only be performed on explanted lung tissue ex vivo and on supernatant of bronchoscopy and are therefore non-invasive
214851020|NCT03008239|DEVICE|FiberSense sensor|The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
214851021|NCT03008239|DEVICE|Dexcom Sensor|Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
214851022|NCT00953472|DRUG|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
214851023|NCT00953472|OTHER|no-added salt diet|instruction to reduce salt for one week prior to study
214851024|NCT00207948|DRUG|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
214851025|NCT04070339|OTHER|transfontanelle ultrasound|cerebral blood flow investigation using transfontanelle ultrasound
214851026|NCT00692146|DRUG|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
214851027|NCT00692146|DRUG|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
214851028|NCT04194684|DRUG|nab-paclitaxel|nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
214851029|NCT03250299|DRUG|Microtubule-Targeted Agent BAL101553|Given PO
214851030|NCT03250299|RADIATION|Radiation Therapy|Undergo radiation therapy
214851031|NCT02087124|OTHER|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
214851032|NCT03346070|DRUG|Sugammadex 2 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by ABW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of a second twitch (T2) in response to TOF stimulations."
214851033|NCT03346070|DRUG|Sugammadex 2 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by IBW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
214851034|NCT03346070|DRUG|Sugammadex 4 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex (4 mg/kg by ABW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
214851035|NCT03346070|DRUG|Sugammadex 4 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants will receive a single i.v. bolus of Sugammadex (4 mg/kg by IBW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
214851036|NCT03346070|DRUG|Neostigmine + Glycopyrrolate|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 µg/kg; 5 mg maximum) and Glycopyrrolate (10 µg/kg; 1 mg maximum), dosed according to participant ABW for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
214851037|NCT03346070|DRUG|Rocuronium or Vecuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide or Vecuronium Bromide administered via i.v. infusion and dosed according to participant ABW. NMBAs were concomitant medications used per label as adjunct to general anesthesia.
214851038|NCT01202071|DRUG|Rabeprazole sodium, 5 mg Tablets|"Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
214851039|NCT01202071|DRUG|Rabeprazole sodium, 10 mg Tablets|"Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
214851040|NCT01202071|DRUG|Rabeprazole sodium, 20 mg Tablets|"Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
214851041|NCT01202071|DRUG|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|"Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, \>=2 hours after the completion of breakfast."
214851042|NCT06456619|OTHER|Tooth restoration|Comparison of composite resin and CAD-CAM supported restorations for hypomineralized molar teeth in children
214851043|NCT01530594|DRUG|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
214851044|NCT01530594|DRUG|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
214851045|NCT01530594|DRUG|Lenalidomide|Lenalidomide/Low dose Dex (LLD
214290287|NCT05786885|PROCEDURE|Vitamin C injection|"1-1.5 ml Vitamin C will be injected into the gingiva, using an insulin syringe, once weekly, for 3 weeks.~All the injection procedures will be performed by the same operator. The treated area will be left without dressing in both groups."
214851046|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)|A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.
214851047|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid)|A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.
214851048|NCT00633516|DEVICE|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
214851049|NCT04796636|DRUG|Sodium Ascorbate|As previously described
214851050|NCT03660241|DRUG|PF-04965842|PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
214851051|NCT00934596|PROCEDURE|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV \& Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
214851052|NCT00934596|DRUG|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
214851053|NCT01007747|OTHER|Geranium oil|Daily topical application over neuropathic pain
214851054|NCT01355718|DRUG|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
214851055|NCT05210452|BIOLOGICAL|Follicular stem cells|Cultured autologous follicular stem cells
214851056|NCT05210452|OTHER|Standard treatment according to the clinical protocols|Standard treatment of alopecia according to the clinical protocols
214851057|NCT02848911|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
214851058|NCT04294342|BEHAVIORAL|Active Comparator: Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program. Each session consisting of warm-up, balance, strength, power and break fall exercises. There is clear a progression within the 10 week program in three main blocks. Block 1: learning the exercises and principle movements, Block 2 more resistance and advance falling techniques, Block 3 Power training and falling strategies from stand up positions.
214851059|NCT04047537|OTHER|Medical Food Formulation 1|WBF-0011
214851060|NCT04047537|OTHER|Medical Food Formulation 2|WBF-0011 (0.2X concentration)
214851061|NCT04047537|OTHER|Placebo|Placebo Capsules identical to those containing Formulation 1 and 2
214851062|NCT00523328|DRUG|BG9924|dosage administered as per Biogen-idec protocol
214851063|NCT05865808|OTHER|cervical spine mobilization|headache SNAGs, 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Eight weeks of treatment session will be provided and assessment of the improvement in cervicogenic headache will done at baseline, after 04, 06 and at the end of 8 week.
214851064|NCT05865808|OTHER|Rocabado 6x6|The Rocabado 6x6 program includes 6 types of exercises which are- rest position of the tongue, TMJ rotation control, upper cervical distraction, axial extension of cervical spine, shoulder girdle retraction, and rhythmic stabilization technique, which are to be performed 6 times in a day with 6 repetitions of each exercise in each session,
214851065|NCT00152191|DRUG|UFT (uracil, tegafur)|uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
214851066|NCT00152191|DRUG|cyclophosphamide, methotrexate, and fluorouracil|cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
214851067|NCT00000374|DRUG|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
214851068|NCT00000374|DRUG|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
214851069|NCT02712801|DRUG|Zidovudine|Dose will be adjusted according to the child's weight.
214851070|NCT02712801|DRUG|Nevirapine|Dose will be adjusted according to the child's weight.
214851071|NCT02712801|DRUG|Lamivudine|Dose will be adjusted according to the child's weight.
214851072|NCT02712801|DRUG|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
214851073|NCT03341546|OTHER|A single measurement of the patient's abdominal depth|A single measurement of the patient's anterior-posterior abdominal depth
214851074|NCT04156412|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
214290288|NCT06590987|DEVICE|Strolll AR|Strolll AR is an augmented-reality (AR) neurorehabilitation platform for delivering gait and balance exercises (assisted with cues when deemed beneficial) for Parkinson's disease onto state-of-the-art AR glasses.
214851075|NCT01622608|BEHAVIORAL|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
214851076|NCT00883623|DRUG|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
214851077|NCT00031850|DRUG|goserelin acetate|
214851078|NCT00031850|DRUG|raloxifene|
214851084|NCT04004117|DRUG|Fentanyl citrate solution sublingual|Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
214851085|NCT04004117|DRUG|Placebo oral liquid|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
214851086|NCT06077734|OTHER|In vitro analyse|In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies
214851087|NCT01221090|BEHAVIORAL|PDA|Technological assistance
214851088|NCT01221090|BEHAVIORAL|CDSMP|6-week classes
214851089|NCT01221090|BEHAVIORAL|PDA/CDSMP|Combined technology and education
214851090|NCT04663438|DRUG|Chemotherapy Drugs, Cancer|Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
214851091|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
214851092|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
214851093|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
214851094|NCT05246696|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
214851095|NCT04260321|DEVICE|AI|Artificial intelligence colonoscopy
214851096|NCT00708708|DRUG|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
214851097|NCT04417049|DRUG|Pentoxifylline 400 MG|All patients will be provided with pentoxifylline 400 mg to be orally ingested twice daily for 8 weeks.
214851098|NCT04424849|DIAGNOSTIC_TEST|CT-Scan|Chest CT scan on admission to the intensive care unit
214851099|NCT03050697|DEVICE|HARMONI® Modular Toric Intraocular Lens|Two-component system consisting of a base and a separate toric optic
214851100|NCT03050697|PROCEDURE|Cataract extraction with intraocular lens (IOL) implantation|Cataract removal via manual phacoemulsification, followed by HMTIOL implantation
214851101|NCT01747382|PROCEDURE|Renal denervation|
214851102|NCT01443377|BIOLOGICAL|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
214851103|NCT04281394|DEVICE|Robot assisted gait training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.
214851104|NCT04281394|OTHER|conventional gait training|even level gait training and range of motion exercises
214851105|NCT03416491|DRUG|KW-136|KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.
214851106|NCT03416491|DRUG|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
214851107|NCT02597582|PROCEDURE|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
214851108|NCT03224247|PROCEDURE|Transverse cutting|Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.
214851109|NCT03224247|PROCEDURE|vertical splitting|vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
214851110|NCT01886482|OTHER|nutrition intervention|high protein diet
214851111|NCT06147531|BIOLOGICAL|Delayed Cold-Stored Buffy Coat Platelets|To prepare cold-stored platelets, blood banks will transition conventional room temperature platelets up to 4 days after collection (with agitation) to cold-storage (at 1-6 C without agitation) for a minimum of 1 day (24 hours) and a maximum of 10 days after collection (for a total shelf life of ≤ 14 days after collection). Thus, cold-stored platelets will be produced and stored the same way as room temperature platelets up until their transition to cold-storage, ensuring similar products differing only in storage conditions and expiration date (as cold-stored platelets will have an expiration date beyond the current 5 days for pathogen inactivated platelets or 7 days for bacterially cultured platelets). Pathogen reduced platelets will be used for the pilot study (Canada is transitioning in 2022-23 to pathogen-reduced platelets and one site has already transitioned).
214851112|NCT06147531|BIOLOGICAL|Room Temperature Buffy Coat Platelets|Room temperature stored platelets are prepared from donor whole blood, which is centrifuged to collect the buffy coat layer containing platelets. Seven ABO matched buffy coats from male and/or female donors are pooled in 280 ml of platelet additive solution and split into a single dose after pathogen inactivation, resulting in a product with a final platelet count of approximately 1300 x 109. Pathogen inactivated platelets (shelf-life of 5 days, with recent Health Canada approval for an extension of the shelf-life to 7 days), will be used as Canada is transitioning in 2022-23 to pathogen-inactivated platelets and one site has already transitioned.
214851113|NCT03136874|OTHER|Interview and questionaires|"* Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.~* Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories."
214851114|NCT04815382|OTHER|Dynamic Upper Limb Orthosis|"The dynamic upper limb orthosis extends from subdeltoid level to 10 mm distal to the metacarpal-phalangeal joints. The orthosis will be tailored to include 20 degrees of wrist extension and to abduct the thumb. They made from nylon and lycra.~The orthosis will be used throughout the day, being removed when the patient lies down.~The orthosis will be used during 3 months"
214851115|NCT02130531|DRUG|Emixustat HCl Tablet|Tablet for oral administration
214851116|NCT02130531|OTHER|Placebo Tablet|Tablet for oral administration
214851117|NCT00389220|DEVICE|Coronary stent placement|Coronary stent placement
214851118|NCT00707564|DEVICE|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
214851119|NCT00707564|DEVICE|Gauze with pressure|Gauze with pressure
214851120|NCT04776746|DRUG|trofinetide|Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
214851121|NCT03392740|DRUG|Lisinopril|Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.
214851122|NCT03392740|DRUG|Placebo Oral Tablet|Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
214851123|NCT02507440|DRUG|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
214851124|NCT02507440|DRUG|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
214851125|NCT02507440|DRUG|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
214851126|NCT00025740|DRUG|clonazepam and paroxetine|
214851127|NCT00860366|DRUG|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
214851128|NCT00860366|OTHER|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
214851129|NCT06525272|DRUG|Recombinant Human Chymotrypsin(OsrhCT)|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.
214851130|NCT06525272|DRUG|Placebo for Recombinant Human Chymotrypsin(OsrhCT)|Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.
214851131|NCT03393416|BIOLOGICAL|MASCT-I|The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
214851132|NCT03393416|DRUG|PD1 antibody|"Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study."
214851133|NCT00440466|DRUG|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
214851134|NCT00440466|DRUG|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
214851135|NCT00440466|DRUG|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
214851136|NCT06468696|PROCEDURE|Suturing the cervical linea alba during endoscopic thyroid surgery.|Suturing the cervical linea alba during endoscopic thyroid surgery.
214851137|NCT06468696|GENETIC|Performing transcriptome sequencing|Performing transcriptome sequencing
214851138|NCT00563017|DRUG|Long-acting Risperidone microspheres injection|
214851139|NCT06446466|DEVICE|PEMF ON-OFF|"In the experimental condition PEMF ON-OFF, the participants will start the exercise session with PEMF in ON modality. The PEMF device will be kept ON for 17 minutes. Then, it will be turned OFF while the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect on PEMF at the onset of the exercise. Data acquired in the first 17 minutes (PEMF ON) will be compared with those recorded in the last 17 minutes (PEMF OFF) of the exercise session."
214851140|NCT06446466|DEVICE|PEMF OFF-ON|"In the experimental condition PEMF OFF-ON, the participants will start the exercise session with PEMF in OFF modality. The PEMF device will be kept OFF for 17 minutes. Then, it will be turned ON and the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect of PEMF during the exercise, when the muscle will have worked for 17 minutes. Data acquired in the first 17 minutes (PEMF OFF) will be compared with those recorded in the last 17 minutes (PEMF ON) of the exercise session."
214851141|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
214851142|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
214851143|NCT05742919|DRUG|NC0194-0499|Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
214851144|NCT00918918|DIETARY_SUPPLEMENT|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
214851145|NCT00918918|DIETARY_SUPPLEMENT|Orange juice|200 mL orange juice
214851146|NCT02759341|OTHER|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
214851147|NCT02759341|OTHER|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
214851148|NCT02759341|OTHER|State-Trait Anxiety Inventory form Y (STAI-Y)|
214851149|NCT02759341|OTHER|SF-36 Health-Related Quality of Life|
214851150|NCT02759341|OTHER|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
214851151|NCT04085536|PROCEDURE|Dental and medical treatment|If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
214851152|NCT05887219|DRUG|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months
214851153|NCT05887219|DRUG|Group B Azelaic Acid 20 % Cream for 6 months|Group B was managed with topical 20% azelaic acid (daily at night) for six months.
214851154|NCT06427902|OTHER|Periodontal clinical measurements, Saliva sampling|Clinical periodontal indices; Probing depth, Clinical attachment level, bleeding on probing, gingival index, and plaque
214851155|NCT04727684|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
214851156|NCT04727684|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
214851157|NCT04727684|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
214851158|NCT04727684|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
214851159|NCT00956787|DRUG|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
214851160|NCT01206049|DRUG|Gemcitabine|1,000 mg/m2 on day 1 of a 2 weeks cycle
214851161|NCT01206049|DRUG|Oxaliplatin|60 mg/m2 on day 1 of a 2 weeks cycle
214851162|NCT01206049|DRUG|Capecitabine|1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
214851163|NCT01206049|DRUG|Panitumumab|6 mg/kg on day 1 of a 2 weeks cycle
214851164|NCT01206049|DRUG|Bevacizumab|10 mg/kg on day 1 of a 2 weeks cycle
214851165|NCT04811365|OTHER|Screening|After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms
214851166|NCT03472742|DRUG|Mesenchymal Stem Cell|As this is a follow-up and an observation study, ADR-001 was administered in the previous study, not in this study.
214851167|NCT02681744|BEHAVIORAL|Resistance Training|24-weeks of progressive strength training
214851168|NCT04375709|OTHER|Physical exercise|The intervention consists out of combined aerobic and strength exercise supervised and guided by specialized physical therapists; additional methods like functional electrical stimulation or oxygen supplementation are added during the main training if indicated.
214851169|NCT04375709|BEHAVIORAL|Education sessions|Sessions include information on physical activity (behaviour), coping with stress and anxiety, dyspnoe, or fatigue; Professional support is given in case of risk for nutritional deficits or post-traumatic stress; sessions are conducted by medical specialists or specialized physiotherapists. All sessions are individually-tailored. In case of nutrition or psychological issues individual sessions are guided by specific health-professionals.
214851170|NCT03416556|PROCEDURE|Mobilization to the glenohumeral joint|The treatment condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder. In particular, a Grade III AP glide to the humeral head with the arm positioned in 90º of glenohumeral abduction and full internal rotation was used. The posterior gliding force to the humeral head was applied maintaining the glide at right angles to the plane of movement and at a frequency of 2 Hz which was controlled by means of a metronome. The arm was returned to its original position between each set.
214851171|NCT03416556|PROCEDURE|The manual contact condition|During the manual contact condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition. However, a simulated posterior glide was performed but with minimal pressure actually applied. The number of repetitions and sets were as per the treatment condition.
214851172|NCT03416556|OTHER|No-contact condition|During the no-contact condition, the subject remained in the initial starting position thorough the entire session but there was no manual contact between the therapist and the participant. The total treatment time was the same as per the other conditions.
214851173|NCT02563587|OTHER|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
214851174|NCT02563587|OTHER|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
214851175|NCT02563587|DRUG|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
214851176|NCT01957345|OTHER|Blood punction|"T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested."
214851177|NCT03382431|DRUG|PC786|Repeat doses
214851178|NCT03382431|DRUG|Placebo/vehicle|Repeat doses
214851179|NCT01766791|OTHER|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM
214851180|NCT01766791|OTHER|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - \< 75 1RM
214851181|NCT01766791|OTHER|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM and Protein Supplementation
214851182|NCT01766791|OTHER|Control|control group, no intervention, maintenance of physical activity
214851183|NCT05557903|BIOLOGICAL|Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection|Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
214851184|NCT01471899|DRUG|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
214851185|NCT01471899|DRUG|Naproxen|2 tablets every 8 hours for 4 days
214851186|NCT04782128|BIOLOGICAL|RC28-E injection|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
214851187|NCT03447340|BEHAVIORAL|Canteen and Behavior intervention|"canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes"
214290289|NCT05084638|DRUG|Ofatumumab|20mg subcutaneous injection
214851188|NCT03447340|OTHER|Canteen Only|canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
214851189|NCT00418522|DRUG|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
214851190|NCT00418522|DRUG|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
214851191|NCT01739634|DRUG|CASAD|CASAD is provided in 500mg capsules.
214851192|NCT04357613|DRUG|Experimental drug|Imatinib 800mg/d during 14days
214851193|NCT01430793|DRUG|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
214851194|NCT01430793|DRUG|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
214851195|NCT01430793|DRUG|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
214851196|NCT01430793|DRUG|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
214851197|NCT00825552|DRUG|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
214851198|NCT04446988|DEVICE|Sacroiliac joint injection|Injection of sacroiliac joint with local anesthetic and steroid
214851199|NCT00025129|DRUG|laromustine|
214851200|NCT04652544|DRUG|Cholecalciferol (Vitamin D3)|Vi-De 3® Monthly Dose from Dr. Wild \& Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.
214851201|NCT04652544|OTHER|Placebo|A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
214851202|NCT04425889|DIAGNOSTIC_TEST|COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)|a blood sample is drained for detection of IgG and IgM antibody
214851203|NCT03651726|DRUG|THX-110 (dronabinol plus PEA)|2.5 mg dronabinol capsules and 400 mg PEA tablets
214851204|NCT03651726|DRUG|Placebo|Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
214851205|NCT01800526|DRUG|N-Acetylcysteine|Oral and Intravenous administration of NAC
214851206|NCT05918757|OTHER|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day via enteral/parenteral nutrition
214851207|NCT05918757|OTHER|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day via enteral/parenteral nutrition
214851208|NCT03051139|BEHAVIORAL|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
214851209|NCT00455416|DRUG|Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))|1000mgx5 daily
214851210|NCT00455416|DRUG|Selenium (L-Selenomethionine),|100mcgx2 daily
214851211|NCT00455416|DRUG|Garlic extract (Allicin)|6 garlic pearls daily
214851212|NCT00455416|DRUG|Pomegranate juice (ellagic acid)|Pomegranate juice 100%, 660ml /495 ml every second day.
214851213|NCT00455416|DRUG|Grape juice (resveratrol, quercetin)|Merlot grape juice 100%, 660ml /495 ml every second day
214851214|NCT00455416|DRUG|Green Tea (Epigallocathechin gallate)|Green Tea. 2 cups daily
214851215|NCT01706016|PROCEDURE|Thermic destruction of tissue by Laser using the Novilase device|
214851216|NCT02440516|OTHER|Early treatment group|Physical- and occupational Therapy
214851217|NCT02440516|OTHER|Late treatment group|Waiting list - then Physical- and occupational Therapy
214851218|NCT02504723|DRUG|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure \>90 mm Hg.
214851219|NCT02504723|DRUG|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
214851220|NCT01111214|OTHER|no intervention|There is no intervention. This is a non interventional study.
214851221|NCT03505814|DEVICE|High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)|High flow and humidified oxygen support for new borns and young infants for post-extubation care
214851222|NCT03505814|DEVICE|Conventional oxygen therapy|conventional oxygen support for new born and young infants in post-extubation care
214851223|NCT04385524|BIOLOGICAL|Adjuvanted Hepatitis B Vaccine|Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
214851224|NCT00799916|DRUG|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
214851225|NCT00799916|DRUG|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
214851226|NCT06468423|DRUG|Deferasirox (DFX)|Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.
214851227|NCT06468423|DRUG|Deferoxamine (DFO)|DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.
214851228|NCT00882206|DRUG|cytarabine|"At baseline when peripheral blood draw and bone marrow aspirate performed.~\*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg."
214851229|NCT00882206|DRUG|decitabine|Days 1-4, 15 mg/m\^2 intravenously (IV) over 1 hour
214851230|NCT00882206|DRUG|doxorubicin hydrochloride|Day 5, 60 mg/m\^2 intravenously (IV) over 15 minutes
214851231|NCT00882206|DRUG|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age \<18 years and 400 mg orally every day for \>18 years on Days 5-33.
214851232|NCT00882206|DRUG|methotrexate|\*\*Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
214851233|NCT00882206|DRUG|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
214851234|NCT00882206|DRUG|prednisone|40mg/m2/day divided BID (days 5 - 33)
214851235|NCT00882206|DRUG|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
214851236|NCT00882206|DRUG|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
214851237|NCT04818437|OTHER|BALANCE TRAINING|Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
214851238|NCT04818437|OTHER|CORE STABILITY EXERCISES|"1. Abdominal bracing while lying in supine position.~2. Abdominal bracing with heel slide while lying in supine position.~3. Abdominal bracing with Leg lifts while lying in supine position.~4. Abdominal bracing with bridging while lying in supine position.~5. Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying"
214851239|NCT06364332|BEHAVIORAL|Social Media campaign|Participants receive content three times a week; in total 24 pieces of content in 8 weeks. The content can consist of one or more photos or images with a caption (explanation in text).
214851240|NCT00027742|BIOLOGICAL|pegylated interferon alfa|
214851241|NCT00027742|DRUG|temozolomide|
214851242|NCT04986852|DRUG|Olinvacimab|Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
214851243|NCT04691375|DRUG|PY314|Dose of PY314 as a single agent given in a standard 3+3 design.
214851244|NCT04691375|DRUG|Combination Therapy: PY314 + Pembrolizumab|Dose of PY314 alone and given in combination with pembrolizumab
214851245|NCT04977609|BEHAVIORAL|VR+MUSIC|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
214851246|NCT04977609|BEHAVIORAL|VR|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
214851247|NCT04977609|BEHAVIORAL|TAU|Traditional post-stroke upper limb motor rehabilitation under the supervision of a physical therapist, for 0 daily sessions of 30 minutes, over 2 weeks.
214851248|NCT03717493|BEHAVIORAL|Affect Regulation Training|Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking \& Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
214851249|NCT00932945|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
214851250|NCT02668094|DRUG|Lidocaine|
214851251|NCT02668094|DRUG|Pregabalin|
214851252|NCT02668094|DRUG|propofol|
214851253|NCT04539626|DRUG|Estrogen Therapy|EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)
214851254|NCT01633294|DRUG|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
214851255|NCT02379780|PROCEDURE|USG guided Subcostal TAP block|"Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71\*50 mm 22G\*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
214851256|NCT02379780|PROCEDURE|USG guided Paravertebral Block|"Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71\*50 mm 22 G\* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
214851257|NCT00024648|DRUG|LErafAON|
214851258|NCT03537157|DRUG|Rifaximin delayed release tablets|Active intervention
214851259|NCT03537157|OTHER|Placebo|Comparator placebo
214851260|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
214851261|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
214851262|NCT04507035|DRUG|Anlotinib hydrochloride capsules|Using anlotinib of 2 cycles as the first-line therapy.
214851263|NCT05863624|PROCEDURE|Open hernioplasty|Inguinal hernia is operated using open surgery
214851264|NCT05863624|PROCEDURE|TEP hernioplasty|Inguinal hernia is operated using laparoendoscopic technique
214851265|NCT02165618|OTHER|Medication review, based on but not limited to the RASP list|"Systematic approach:~1. Medication reconciliation~2. Applying the RASP list~3. Expert review (not based on the RASP list)~4. Multidisciplinary discussion"
214851266|NCT04289454|OTHER|Flavor additive|Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant
214851267|NCT03044236|PROCEDURE|Stretching|The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
214851268|NCT04751539|DRUG|AND017 single dose|AND017 administrated as oral single-dose on Day 1 in Part A
214851269|NCT04751539|DRUG|AND017 multiple dose|AND017 administrated once daily from Day 1 to Day 10 in Part B
214851270|NCT04751539|DRUG|Placebo|Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
214851271|NCT04832048|OTHER|Therapeutic physical exercise|"The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.~Intensity was be determined by Maximum Heart Rate (HRF)."
214851272|NCT04832048|OTHER|No physical exercise|No programmed physical exercise
214851273|NCT01466322|DRUG|GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state|Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
214851274|NCT01612884|DRUG|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
214851275|NCT01612884|DRUG|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
214851276|NCT01271179|PROCEDURE|sequential perfusion with ipv Ross solution and UW solution|Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
214851277|NCT01271179|PROCEDURE|sole perfusion with UW solution|Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
214851278|NCT01258088|DRUG|AN2728 Ointment|5mg/cm2, BID
214851279|NCT01258088|DRUG|AN2728 Vehicle|5mg/cm2 BID
214851280|NCT00865098|DRUG|Cetuximab|Patients receive Cetuximab at an initial dose of 400 mg/m\^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m\^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
214851281|NCT05685277|DRUG|Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg|Ramipril/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
214851282|NCT05685277|DRUG|Tritace® Plus tablet 10 mg/25 mg|Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
214851283|NCT03653624|OTHER|No intervention|No intervention is involved int his study. Fully anonymised blood pressure data will be collected from the vital signs monitors in the operating room.
214851284|NCT02790034|DRUG|Sarizotan low dose|2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 5 mg bid (≥13 years of age and weighing ≥25 kg). Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
214851285|NCT02790034|DRUG|Sarizotan high dose|5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 10 mg bid (≥13 years of age and weighing ≥25 kg) Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients
214851286|NCT02790034|DRUG|Placebo|Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
214851287|NCT02658916|DRUG|BIIB092|Same dose as corresponding CN002003 study panel.
214851288|NCT04747704|BEHAVIORAL|Three Principles Counseling|A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
214851289|NCT04102241|DRUG|15mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
214290290|NCT06152133|OTHER|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
214290291|NCT06791356|BEHAVIORAL|Cognitive-behavioral therapy for insomnia|8 sessions of therapy that focus on psychoeducation about sleep hygiene, cognitive restructuring of dysfunctional beliefs that reinforce insomnia, stimulus control to eliminate the association between the bed and wakefulness, sleep restriction in order to establish a consistent sleep schedule, and relaxation training to reduce anxiety that interferes with sleep
214290292|NCT06791356|BEHAVIORAL|Sleep hygiene education|One session of education about behavioral strategies to optimize sleep quality
214851290|NCT04102241|DRUG|Placebos|Placebos are the same as drugs, but contain no Hemay005.
214851291|NCT03440424|DRUG|Lemborexant|oral tablet
214851292|NCT02993692|DEVICE|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
214851293|NCT03795714|DIAGNOSTIC_TEST|IVUS or OCT and Invasive physiologic indices|IVUS or OCT measurement in order to evaluate the lesion morphology and stent optimization, and invasive physiologic measurement in order to functional significance of epicardial stenosis
214851294|NCT04031638|OTHER|Radioactive Iodine treatment|Patients with a thyroid tumor who received radioactive Iodine treatment.
214851295|NCT00099710|DIETARY_SUPPLEMENT|Curcumin C3 Complex|
214851296|NCT04783974|DEVICE|Dental implants|Treatment of total or partial edentulism through the placement of osseointegrated dental implants
214851297|NCT03844958|OTHER|Red Furu|"50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day"
214851298|NCT03844958|OTHER|Tofu|"50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day"
214851299|NCT05850988|OTHER|%80 Oxygen concentration|Patients will be administered %80 Oxygen for 3 minutes during preoxygenation.
214851300|NCT05850988|OTHER|%100 Oxygen concentration|Patients will be administered %100 Oxygen for 3 minutes during preoxygenation.
214851301|NCT05452135|OTHER|Observation of visual, audotory and motor reaction time|Visual, auditory and motor reaction time will be measured as a result of the measurements made during the dual task evaluation.
214851302|NCT01247246|DRUG|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
214290293|NCT05094622|OTHER|Physical exercise program|A specially designed exercise training program based on a previous study. The intervention of physical exercise will consist of different exercises to enhance muscle strength and endurance and will be individually adjusted and start in a different position with a progression in dose, intensity, and position. It will be performed 3 times /week during a period of 12-20 weeks.
214663847|NCT02560454|BEHAVIORAL|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
214663848|NCT04036825|DIETARY_SUPPLEMENT|Liquid Nutritional Supplement from Hospital Product|Liquid Nutritional Supplement from Hospital Product is given 2 times daily for 14 days
214663849|NCT04036825|DIETARY_SUPPLEMENT|Placebo|Standard nutritional supplement is given 2 times daily as placebo for 14 days
214663850|NCT03932240|DRUG|Fibrinogen Concentrate (FC)|The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
214663851|NCT03932240|DRUG|Cryoprecipitate|The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
214663852|NCT02195843|OTHER|Electrical optimization by RVLV Conduction Time with VectSelect|"VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.~The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode ."
214663853|NCT02195843|OTHER|Anatomical optimization of device and leads|Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.
214663854|NCT02195843|DEVICE|Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)|All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
214663855|NCT03114761|RADIATION|CT angiography|Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
214663856|NCT05695547|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
214663857|NCT01874483|DRUG|Placebo|placebo
214663858|NCT01874483|DRUG|BI 187004|BI 187004, dose 2
214663859|NCT01874483|DRUG|BI 187004|BI 187004, dose 4
214663860|NCT01874483|DRUG|BI 187004|BI 187004, dose 5
214851303|NCT01247246|DRUG|Placebo|Placebo
214851304|NCT04802408|COMBINATION_PRODUCT|Shampoo and saline|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
214851305|NCT04802408|COMBINATION_PRODUCT|Saline and Listerine|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
214663861|NCT01874483|DRUG|BI 187004|BI 187004, dose 6
214663862|NCT01874483|DRUG|BI 187004|BI 187004, dose 7
214663863|NCT01874483|DRUG|BI 187004|BI 187004, dose 1
214663864|NCT01874483|DRUG|BI 187004|BI 187004, dose 3
214851306|NCT04802408|COMBINATION_PRODUCT|Shampoo and Listerine|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
214851307|NCT04802408|COMBINATION_PRODUCT|Saline and Saline|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
214851308|NCT02588079|BEHAVIORAL|Internet-based cognitive behavioral therapy|
214851309|NCT02193607|PROCEDURE|TVT-O|Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
214851310|NCT02193607|PROCEDURE|Improved reconstruction pelvic surgery|Repair of severe pelvic organ prolapse with mesh.
214851311|NCT04067388|OTHER|Rapid Evaporative Ionisation Mass Spectrometry (REIMS)|Use of iKnife instrument during standard operative practice
214851312|NCT03083977|OTHER|Safe and Sound Protocol|The intervention features music processed based on the resonating frequencies of the middle ear
214851313|NCT01048502|DRUG|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
214851314|NCT01048502|DRUG|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
214851315|NCT01048502|DRUG|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
214851316|NCT01485484|DEVICE|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
214851317|NCT00104091|DRUG|TP-38|TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
214851318|NCT01828944|DIETARY_SUPPLEMENT|olive oil|
214851319|NCT01138826|DRUG|Amlodipine - reference|10 mg tablet, single dose, with water
214851320|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
214851321|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
214851322|NCT06337825|BEHAVIORAL|Activity Tracker (Fitbit)|Wearable, activity tracker
214663865|NCT02534337|DRUG|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
214851323|NCT06337825|DIAGNOSTIC_TEST|HbA1C|Average blood glucose (sugar) levels reported as a percentage
214851324|NCT06337825|BEHAVIORAL|The PROMPT Questionnaire|The PROMPT Questionnaire which is a 30-question previously validated assessment for non-specific symptoms in PHPT, will be administered to patients preoperatively and at 2-weeks and 6-months postoperatively
214663866|NCT02534337|DRUG|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
214663867|NCT05152355|DRUG|Budesonide 200 microgram/Puff, HFA MDI|Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
214663868|NCT05152355|DRUG|Budesonide 100 microgram/Actuation Powder for Inhalation|Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
214663869|NCT04227444|DIAGNOSTIC_TEST|Hologram|"Patient undergoing elective anatomical resection for lung cancer will receive standard preoperative CT scan of the chest (as usual); CT images will be subsequently elaborated by a Holographic computer to generate 3D images (holograms).Two radiologists and two thoracic surgeons will analyze CT images in a standard modality and report number of artery and vein branches for the lobe to be resected, moreover they will report every anatomical variation, according to the normal anatomy.~After that, the same two radiologists and thoracic surgeons will analyze 3D images by the use of Microsoft Hololens and perform the same analysis as quoted above.~For each review of the exam performed will be written a digitally signed clinical report to certify the timing of the evaluation and to be able to trace the analysis and any subsequent modifications of the interpretation of the CT images results."
214663870|NCT03844438|DRUG|LPM3480226|The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
214663871|NCT03906877|PROCEDURE|Acid hyaluronic injection laryngoplasty|Hyaluronic acid is injected into the paralyzed vocal fold
214663872|NCT03906877|BEHAVIORAL|Voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises"
214663873|NCT03906877|OTHER|Sham of injection|Injection of physiological saline under the skin of the neck (sham of injection).
214663874|NCT03906877|OTHER|Sham of voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture."
214663875|NCT02112110|DRUG|BMS-791325|
214663876|NCT02112110|DRUG|[13C]-BMS-791325|
214663877|NCT00761111|BEHAVIORAL|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
214663878|NCT06065722|DRUG|Akynzeo|OLANZAPINE
214663879|NCT03124069|DEVICE|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
214663880|NCT05607550|DRUG|furmonertinib 240 mg oral, daily|furmonertinib tablet
214663881|NCT05607550|DRUG|furmonertinib 160 mg oral, daily|furmonertinib tablet
214663882|NCT05607550|DRUG|platinum-based chemotherapy|(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
214663883|NCT00424398|DRUG|Bepreve|sterile ophthalmic solution
214663884|NCT00424398|DRUG|Placebo|sterile ophthalmic solution
214663885|NCT00424398|DRUG|Bepotastine Besilate|sterile ophthalmic solution
214663886|NCT05328050|OTHER|Registry|observational, data collection
214851325|NCT05462730|DRUG|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
214851326|NCT05462730|DRUG|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
214851327|NCT05036395|OTHER|The routine assessment protocol and AI-assisted cEEG Diagnostic tool|The AI-assisted cEEG diagnostic tool is an automated seizure reporting system, including a quantitively EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction. The tool can report electrographic seizures in real time during cEEG monitoring. The neonatologists will evaluate the neonates by AI-assisted cEEG diagnostic tool, clinical conditions, real-time cEEG and amplitude-integrated EEG traces. The investigators will make a decision after review the neonates clinical conditions, AI-assisted cEEG diagnostic report, the cEEG and amplitude-integrated EEG.
214851328|NCT05036395|OTHER|The routine assessment protocol|The routine assessment protocol is that the neonatologists will evaluate the neonates by clinical conditions, real-time cEEG and amplitude-integrated EEG traces.
214851329|NCT02302521|DEVICE|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
214851330|NCT06387680|OTHER|The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial|The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial
214851331|NCT05206448|DRUG|Letrozole|Letrozole tablet
214851332|NCT05206448|DRUG|Clomiphene Citrate|Clomiphene Citrate tablet
214851333|NCT06123182|BEHAVIORAL|Episodic Future Thinking|During the audio recorded guided imagery exercise participants will be asked to think in detail of a future (6 months to a year) where they have made healthy choices regarding physical activity and are physically active.
214851334|NCT06123182|BEHAVIORAL|Episodic Recent Thinking|During the audio recorded guided imagery exercise participants will be asked to think about a routine weekly activity.
214851335|NCT06123182|BEHAVIORAL|Positive Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the positive outcomes and sensations associated with an exercise bout.
214851336|NCT06123182|BEHAVIORAL|Neutral Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the physical sensations associated with an exercise bout.
214851337|NCT06123182|BEHAVIORAL|HIIT Exercise Intervention|"The high intensity interval training (HIIT) will be conducted 2 times per week for 6 weeks. The duration of each individual exercise session will last about 45 minutes. After the 5-minute warm-up at 30% peak workload, HIIT will consist of repeated 1-minute high intensity bursts (on interval) alternated with 1-minute interval recovery (off interval) for 25 minutes. The on interval will begin at 80% of peak watts (range: 75%-85%) followed by the off interval at 10% of peak watts. The session will end with up to 10 minute cool-down at 20% peak workload."
214851338|NCT03921060|DRUG|Denosumab|treatment with denosumab every 6 months for up to 5 years
214851339|NCT06700122|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) with systemic vitamin D|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) with systemic vitamin D
214851340|NCT06489626|DRUG|Methylprednisolone 4 milligram Tab|6-day 4 milligram methylprednisolone oral taper
214851341|NCT06489626|DRUG|Dexamethasone injection|4 milligram intravenous dexamethasone will be administered intraoperatively
214851342|NCT03360916|DRUG|Lipitor 20Mg Tablet|One tablet by mouth every day for 12 weeks.
214851343|NCT03360916|DRUG|Lipitor 80Mg Tablet|One tablet by mouth every day for 12 weeks.
214851344|NCT03360916|DRUG|Placebo|One matching placebo tablet by mouth every day for 12 weeks.
214851345|NCT03360916|BEHAVIORAL|Exercise Program|Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
214851346|NCT01402180|BIOLOGICAL|Nimotuzumab|
214851347|NCT01402180|RADIATION|Radiation therapy|
214851348|NCT01402180|RADIATION|radiation therapy|
214851349|NCT01402180|DRUG|chemotherapy|
214851350|NCT01402180|DRUG|chemotherapy|
214851351|NCT04441099|DRUG|NBE-002|NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
214851352|NCT01333072|DRUG|Aripiprazole|The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
214851353|NCT01333072|DRUG|Risperidone|Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
214851354|NCT03914768|BIOLOGICAL|Immunomodulatory DC vaccine to target DIPG and GBM|This study will inject DC vaccine cells near lymphoid tissue close to the tumor. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day. The cells will be repeatedly infused every month for six consecutive months depending on the response and the condition of the patient. The amount of DC vaccine cells per injection is based on prior report at 5-10x106. An initial dose escalation scheme will be imposed.
214851355|NCT04862884|DRUG|HRS4800 tablets|"1. Drug: HRS4800 tablets Low-dose group, single oral administration~2. Drug: HRS4800 tablets Low-medium dose group, single oral administration~3. Drug: HRS4800 tablets medium -dose group, single oral administration~4. Drug: HRS4800 tablets Medium and high dose group, single oral administration~5. Drug: HRS4800 tablets High-dose group, single oral administration"
214851356|NCT04862884|DRUG|placebo|"1. Drug: placebo Low-dose group, single oral administration~2. Drug: placebo Low-medium dose group, single oral administration~3. Drug: placebo medium -dose group, single oral administration~4. Drug: placebo Medium and high dose group, single oral administration~5. Drug: placebo High-dose group, single oral administration"
214851357|NCT03121014|DRUG|Fludarabine|40 mg/m\^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
214851358|NCT03121014|DRUG|Busulfan|targeting a 4800μM/min/ day from day -5 through day -2
214851359|NCT03121014|DRUG|ATG|0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
214851360|NCT03121014|RADIATION|Total Marrow Irradiation|dose of 3Gy on days -3, -2 and -1
214851361|NCT03121014|PROCEDURE|Stem Cell Product Infusion|Day 0 according to BMT unit policy
214851362|NCT03121014|DRUG|Tacrolimus|The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
214851363|NCT03121014|DRUG|Methotrexate|5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11
214851364|NCT06364254|DIETARY_SUPPLEMENT|Cannabidiol Capsules|300 mg of cannabidiol administered 2 hours before 2 mile run
214851365|NCT04290234|OTHER|fMRI assessment of cognitive and reactive fear|An fMRI paradigm will be used to probe how childhood maltreatment may modulate the defensive survival circuitry that facilitates escape decisions when subjects encounter fast- or slow-attacking threats.
214851366|NCT01911806|DEVICE|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
214851367|NCT01911806|PROCEDURE|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
214851368|NCT00688428|DRUG|Esomeprazole 40mg/ASA 325mg|combination capsule, administered as a single oral dose
214851369|NCT00688428|DRUG|Esomeprazole|40mg capsule, administered as a single dose
214851370|NCT00688428|DRUG|ASA|325mg tablet, administered as a single oral dose
214851371|NCT04553224|OTHER|Clinical evaluations|SCORAD and target SCORAD
214851372|NCT04553224|OTHER|Non-invasive instrumental measurements|TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index
214851373|NCT04553224|OTHER|Subject's evaluations|PO-SCORAD, target PO-SCORAD and subject's questionnaire
214851374|NCT00457210|PROCEDURE|Brain Radiotherapy/Stereotactic Radiosurgery|
214851375|NCT00619359|DRUG|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
214851376|NCT00619359|DRUG|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
214851377|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
214851378|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
214851379|NCT00619359|DRUG|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
214851380|NCT01626651|DRUG|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
214851381|NCT01626651|DRUG|Ketoconazole|Ketoconazole (400 mg \[2 x 200 mg\] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
214851382|NCT01197768|BEHAVIORAL|Nutrition Intervention|Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
214851383|NCT00992563|DRUG|AL-39324 ophthalmic suspension|
214851384|NCT00992563|DRUG|Ranibizumab 10 mg/mL|
214851385|NCT06475625|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
214851386|NCT06475625|DEVICE|Orsiro™ or Orsiro_Mission™ stent|Percutaneous coronary intervention with Orsiro™ or Orsiro\_Mission™ stents
214851387|NCT05650086|DEVICE|Thermalytix|One-time Thermal imaging is performed for this cohort.
214851388|NCT00201916|PROCEDURE|5250 cGy/20 fractions over 28 days|see above
214851389|NCT00201916|PROCEDURE|6600 cGy/33 fractions over 45 days|see above
214851390|NCT00478049|DRUG|Gefitinib|250 mg oral tablet
214851391|NCT00478049|DRUG|Docetaxel|intravenous infusion
214851392|NCT03678779|BEHAVIORAL|Incentive|$5 grocery gift card
214851393|NCT03678779|BEHAVIORAL|Education|Video-based brief nutrition education
214851394|NCT03678779|BEHAVIORAL|Combined|Both Incentive and Education interventions received
214851395|NCT00363402|PROCEDURE|PET-CT|
214851396|NCT04792879|DIAGNOSTIC_TEST|Peripheral veins Doppler ultrasound|Patients undergoing a right heart catheterization for PH diagnosis or annual follow-up in the cardiological unit of the university hospital of Poitiers will be included. A venous Doppler ultrasound will be performed by a vascular physician, with experience in vascular ultrasound imaging, within 4 hours before the right heart catheterization. Morphological parameters of vena cava, and velocimetric parameters of femoral, jugular and supra-hepatic veins will be assessed in order to study their correlation with right auricular pressure value.
214851397|NCT01363141|OTHER|Regular AGE Diet|Regular AGE Diet
214851398|NCT01363141|OTHER|Low AGE Diet|One year reduction in dietary AGE intake.
214851399|NCT06012721|DRUG|ORIC-114|Food effect healthy subjects
214851400|NCT04036149|DEVICE|Intraocular lens|Implantation as part of cataract surgery
214851401|NCT04121117|OTHER|Chronic obstructive pulmonary disease screening|"To verify the tobacco withdrawal, the patients will make a cooximetry.~For the detection of a possible obstructive pattern a measurement of the ventilatory capacity will be make using the COPD-6 device and for the confirmation of COPD diagnosis and the assesment of the airflow obstruction severity a spirometry will be make.~The patients will also complete the COPD-PS questionnaire."
214851402|NCT02502734|DRUG|Fluticasone furoate|FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
214851403|NCT02502734|DRUG|Placebo|Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
214851404|NCT02502734|DRUG|Salbutamol|Salbutamol will be provided as a inhaler.
214851405|NCT04390802|DRUG|5-aminolevulinic acid|Study participants who are deemed surgical candidates for management of their pituitary lesion will drink 20mg/kg 5-ALA 2-4 hours preoperatively. They will then be taken to the operation room and undergo general anesthesia. Intraoperative blood draw may occur from lines places for anesthesia purposes at any time during the operation. In alignment with the neurosurgeon's practice and discretion, the sella will be accessed and opened. During the surgical exploration of the sella, the surgeon will attempt to identify the pituitary mass. The location of the tumor will be assessed using the blue-light filtered microscope or endoscope. These steps will be documented photographically during the operation. A biopsy of the fluorescent region will be taken to confirm pituitary adenoma histopathology. The tumor will then be maximally resected. The tumor sample will be used for further clinical testing as part of the patient's routine care.
214851406|NCT02253602|DRUG|Ferumoxytol|maximum rate of administration 1 ml/sec
214851407|NCT03720769|BEHAVIORAL|Step-by-Step|Guided self-help programme delivered through an app/website for the treatment of depression
214851408|NCT03720769|BEHAVIORAL|Enhanced care as usual|Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
214851409|NCT02712437|BEHAVIORAL|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
214851410|NCT03338348|DRUG|Vosaroxin|Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
214851411|NCT03338348|DRUG|Azacitidine|"Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;~Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
214851412|NCT00682214|DRUG|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
214851413|NCT00682214|DRUG|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
214851414|NCT04128202|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
214851415|NCT04128202|BEHAVIORAL|Sunnyside Plus|Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
214851416|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
214851417|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
214851418|NCT04745715|PROCEDURE|craniectomy|craniectomy outcomes and survival
214851419|NCT04854252|DRUG|Fentanyl|TIVA opioid-containing anesthesia: fentanyl in a bolus dose of l3 mcg/kg (corrected weight) TIVA opioid-free anesthesia: dexmedetomidine 1-1.5 mcg/kg (corrected weight) for 40 minutes
214851420|NCT04487743|DRUG|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
214851421|NCT04487743|DRUG|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
214851422|NCT04531995|DEVICE|CANKADO PRO-React Onco|CANKADO PRO-React Onco is approved as class I medical device within the European Union (registration number DE /CA59 /371/2020-R/Hd) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B. The purpose of CANKADO PRO-React Onco is to be an automated digital support for patients to help them decide how urgent it is to contact the attending physician based on the symptoms they independently record in the system. It supports patients with cancer under systemic, anti-tumor or anti-hormonal therapy in adjuvant, neoadjuvant, post-neoadjuvant or palliative situations. It is unsuitable for patients undergoing radiotherapy, cell and gene therapy, surgical procedures or alternative healing methods.
214851423|NCT05558995|OTHER|ketogenic diet|All the subjects will be instructed by a nutrition professional to have at least 3 meals per day consisting of 20 g to 30 g of carbohydrate in the form of green vegetables and salad, and 80 g to 100 g of protein in the form of meat, fish, fowl, eggs, shellfish and cheese for 12 weeks. Polyunsaturated and monounsaturated fats will also be included in the diet. Micronutrients (vitamins and minerals) will be given to each subject in the form of one capsule per day. The adherence to diet will be confirmed weekly through a food log and urinary ketones assessment using dipstick to ensure that all individuals remain in a ketotic state.
214851424|NCT02794259|DEVICE|tDCS|
214851425|NCT02794259|DEVICE|sham-tDCS|
214851426|NCT05015335|DRUG|Adalimumab|ADA 40mg q2w
214851427|NCT05015335|DRUG|Methotrexate|MTX 10mg qw
214851428|NCT03649412|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
214851429|NCT03649412|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
214851430|NCT06240689|DRUG|Sintilimab|Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.
214851431|NCT06240689|DRUG|Placebo|Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
214851432|NCT02280187|PROCEDURE|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
214851433|NCT05661461|DRUG|nab-sirolimus|This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
214851434|NCT04668274|DRUG|200 mg resveratrol as JOTROL|Low (first) dose of single ascending dose study
214851435|NCT04668274|DRUG|500 mg resveratrol as JOTROL|Second (intermediate) dose of single ascending dose study
214851436|NCT04668274|DRUG|700 mg resveratrol as JOTROL|Third (highest) dose of single ascending dose study
214851437|NCT04668274|DRUG|500 mg resveratrol as JOTROL administered to assess influence of food|500 mg resveratrol as JOTROL administered to assess influence of food
214851438|NCT06365294|PROCEDURE|Rescue extracranial stenting|Rescue extracranial stenting in tandem occlusions
214851439|NCT03400436|OTHER|No intervention in observational studies|No intervention in observational studies
214851440|NCT05110131|DEVICE|Device for performing biopsy via electromagnetic navigation bronchoscopy|Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
214851441|NCT01047891|DRUG|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
214851442|NCT03328429|OTHER|Excision|Bartholin gland will be excised
214851443|NCT03328429|OTHER|Marsupialization|Bartholin gland will be marsupialised
214851444|NCT02363439|DRUG|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly|IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
214851445|NCT00464139|PROCEDURE|Laparoscopy|Laparoscopy
214851446|NCT00056381|DRUG|Anidulafungin|
214851447|NCT04712084|PROCEDURE|Positive pressure|Inspiratory support of 8 cmH2O was applied associated with PEEP at 6 cmH2O. After extubation, same support was applied by facemask for 3 minutes
214851448|NCT04429841|PROCEDURE|Radical gastrectomy with D1 lymphadenectomy|
214851449|NCT04429841|PROCEDURE|Radical gastrectomy with D2 lymphadenectomy|
214851450|NCT02023008|PROCEDURE|yoga therapy|Undergo integral yoga intervention with videoconferencing
214851451|NCT02023008|OTHER|internet-based intervention|Undergo integral yoga intervention with videoconferencing
214851452|NCT02023008|OTHER|questionnaire administration|Ancillary studies
214851453|NCT05190523|DRUG|ASC42 5 mg|5 mg of ASC42 tablets orally once daily for 12 weeks.
214851454|NCT05190523|DRUG|ASC42 10 mg|2 x 5 mg of ASC42 tablets orally once daily for 12 weeks.
214851455|NCT05190523|DRUG|ASC42 15 mg|15 mg of ASC42 tablets orally once daily for 12 weeks.
214851456|NCT05190523|DRUG|Placebo|Placebo tablets orally once daily for 12 weeks.
214851457|NCT01854255|DRUG|doxorubicin and cisplatin|doxorubicin and cisplatin as intraperitoneal chemotherapy
214851458|NCT06204575|OTHER|Data collection|Data collection
214851459|NCT01143649|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will be stimulated at 1 mA for 40 minutes.
214851460|NCT01143649|PROCEDURE|constraint induced movement therapy (CIMT)|
214851461|NCT01143649|DEVICE|transcranial alternating current stimulation (tACS)|Subjects will be stimulated at 15Hz for 20 minutes.
214851462|NCT00707447|BEHAVIORAL|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
214851463|NCT00707447|BEHAVIORAL|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
214851464|NCT05791747|OTHER|semi-structured interviews|This is an observational study Patients included in the study will conduct semi-structured interviews to discuss their knowledge and/or experience with supportive care, particularly hypnosis
214851465|NCT00508027|DRUG|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
214851466|NCT01719562|PROCEDURE|Magnetic resonance imaging|Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
214851467|NCT01719562|OTHER|Physical Activity|Tailored aerobic exercise program onsite and at home.
214851468|NCT01719562|OTHER|Healthy Living|Healthy living presentations at a centralized meeting place and over the phone.
214851469|NCT01719562|DEVICE|Cardiopulmonary Exercise Testing (CPET)|Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
214851470|NCT01719562|OTHER|Questionnaire Administration|A self-administered 13-item scale to assess fatigue in participants
214851471|NCT03485846|DRUG|Narlaprevir|100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
214851472|NCT03485846|DRUG|Ritonavir|100 mg, tablets, taken as 100 mg per os daily
214851473|NCT03485846|DRUG|Daclatasvir|60 mg, tablets, taken as 60 mg per os daily
214851474|NCT00175097|OTHER|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
214851475|NCT00175097|OTHER|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
214851476|NCT00175097|OTHER|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
214851477|NCT00175097|OTHER|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
214851478|NCT04061577|DEVICE|Transcranial Direct Current Stimulation (tDCS)|20 minutes of Cathodal tDCS after +/- before endovascular thrombectomy (EVT)
214851479|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg|Administration: Inject intravenously single dose
214851480|NCT05276076|BIOLOGICAL|VM-001 3X10^6 cells/kg|Administration: Inject intravenously single dose
214851481|NCT05276076|BIOLOGICAL|VM-001 5X10^6 cells/kg|Administration: Inject intravenously single dose
214851482|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg two dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, two dose in total, weekly"
214851483|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg four dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, four dose in total, weekly"
214851484|NCT00043576|DRUG|calcitriol|
214851485|NCT00043576|DRUG|docetaxel|
214851486|NCT01684527|OTHER|Respiratory secretions obtained|
214851487|NCT03208673|DEVICE|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
214851488|NCT05799716|DRUG|IVIG|0.5g/Kg
214851489|NCT06463717|DRUG|Transplant, Autologous|High-dose melphalan followed by autologous stem cell transplantation
214851490|NCT06463717|DRUG|Chemotherapy drug|Regimen such as Bortezomib plus Lenalidomide plus Dexamethasone
214851491|NCT01920984|DRUG|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
214851492|NCT01008514|PROCEDURE|adjuvant therapy|
214851493|NCT01008514|RADIATION|accelerated partial breast irradiation|
214851494|NCT01008514|RADIATION|intracavitary balloon brachytherapy|
214851495|NCT00768118|DIETARY_SUPPLEMENT|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
214851496|NCT00768118|GENETIC|electrophoretic mobility shift assay|
214851497|NCT00768118|OTHER|laboratory biomarker analysis|
214851498|NCT05420116|BEHAVIORAL|Cerdanya on Fitness|The intervention lasts 9 months. The participants will carry out group activities and will be followed individually by the different interdisciplinary professionals. Goals will be set for each visit. Before and after the training there will be an assessment of physical exercise, nutritional and positive mental health habits.
214851499|NCT04082936|DRUG|imvotamab|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
214851500|NCT01376206|DRUG|Fluticasone|Collection of safety data
214663887|NCT00855439|DRUG|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
214663888|NCT00855439|DRUG|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
214663889|NCT02485392|DEVICE|Da Vinci Single Site Robot-Assisted Cholecystectomy|
214851501|NCT03945799|DRUG|Anlotinib Hydrochloride|Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.
214851502|NCT03187028|BEHAVIORAL|Diet Only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
214851503|NCT03187028|BEHAVIORAL|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
214851504|NCT06842602|OTHER|gum|chewed gum within 2 hours before the procedure
214851505|NCT06842602|OTHER|candy|consumed candy within 2 hours before the procedure
214851506|NCT06842602|OTHER|strict fasting rules|followed strict fasting rules
214851507|NCT01868282|PROCEDURE|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
214851508|NCT01868282|PROCEDURE|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
214663890|NCT02485392|DEVICE|Single Incision Laparoscopic Cholecystectomy|
214663891|NCT03728244|DRUG|MEBO ointment|The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).
214851509|NCT01868282|PROCEDURE|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
214851510|NCT03891329|DEVICE|Acticor/Rivacor ICDs/CRT-Ds|pre-defined device programming, measurements and follow-up schedule
214851511|NCT03891329|DEVICE|Plexa S DX|Implantation, measurements and follow-up schedule
214851512|NCT00487929|DEVICE|nasal CPAP|Nocturnal
214851513|NCT00487929|DEVICE|Sham CPAP|Nocturnal
214290294|NCT02148692|PROCEDURE|Higher PEEP|
214851514|NCT04382430|PROCEDURE|Ultrasound guided venous access|Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.
214851515|NCT04382430|PROCEDURE|Conventional technique|Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
214851516|NCT05305768|DRUG|IncobotulinumtoxinA|Injection of glabellar rhytids
214851517|NCT06602492|DRUG|Lower nicotine e-liquid|A 3% nicotine concentration eliquid.
214851518|NCT06602492|DRUG|Higher nicotine eliquid|A 5% nicotine concentration eliquid.
214851519|NCT01293266|DRUG|Propofol|Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
214851520|NCT02740179|DRUG|Eplerenone|Eplerenone 50mg by mouth twice daily
214851521|NCT02740179|DRUG|Placebo|Placebo by mouth twice daily
214851522|NCT02740179|BEHAVIORAL|Lifestyle Modification|Counseling regarding diet and healthy activity
214851523|NCT02414373|DRUG|Ropivacaine 2mg/ml|local anesthetics, which will epidurally administered
214851524|NCT02414373|DRUG|Bupivacaine|local anesthetics, which will epidurally administered
214851525|NCT02414373|DEVICE|6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)|
214851526|NCT02414373|DEVICE|14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)|
214851527|NCT02326363|BEHAVIORAL|Mindfulness Based Relapse Prevention (MBRP)|Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
214851528|NCT02326363|BEHAVIORAL|Twelve-Step Facilitation Intervention (TSF)|"The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
214851529|NCT06678204|OTHER|Optimized illustrated pamphlets|Participants in the control group received traditional text-based pamphlets covering similar self-care information for RT. Pretests were administered before the start of treatment, and posttests were conducted two weeks after the completion of RT.
214851530|NCT01832402|DRUG|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
214851531|NCT01832402|DRUG|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
214851532|NCT01832402|OTHER|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
214851533|NCT01832402|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
214851534|NCT01832402|BEHAVIORAL|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
214851535|NCT03907917|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
214851536|NCT01445418|DRUG|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
214851537|NCT01483014|DRUG|imatinib mesylate|
214851538|NCT06368752|BIOLOGICAL|GIP[3-30]NH2|GIP\[3-30\]NH2 is the naturally occurring shorter (truncated) variant of GIP\[1-42\]. GIP\[3-30\]NH2 also stimulates the GIP receptor and therefore acts like a GIP receptorantagonist
214851539|NCT06368752|OTHER|Saline|Sodium chlorid with 0,5% human serum albumin.
214851540|NCT00823381|DIETARY_SUPPLEMENT|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
214851541|NCT00823381|OTHER|placebo|one placebo pill taken once a day with breakfast
214851542|NCT00823381|BEHAVIORAL|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
214851543|NCT05487560|DRUG|Esomezol Cap|Esomezol Cap, Once daily administered per the locally approved product information
214851544|NCT04031092|DEVICE|Wearable tech with feedback|An armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone.
214851545|NCT04031092|DEVICE|Wearable tech without feedback|An armwrist device measuring physical activity level, no reporting back to the user.
214851546|NCT04031092|BEHAVIORAL|Rehabilitation program|traditional inpatient rehabilitation program.
214851547|NCT04726189|OTHER|Standard exercises|Consists of a a standard exercise program with range of motion exercises from the third week and elastic band exercise from the sixth week.
214851548|NCT04726189|OTHER|Standard exercises plus Early progressive exercises|This exercise program consists of standard exercises plus the early progressive program that initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration. Exercises are isometric exercises from the second week and then gradually progression of load in seated heel-rise and resistance band exercises.
214851549|NCT05890092|OTHER|Observation|Observing for disease prevalence - actual and self-reported
214851550|NCT06193031|DRUG|C16TR|Administered as inhalation using a Philips Micro device inhaler.
214851551|NCT06193031|DRUG|Placebo|Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.
214851552|NCT06193031|DRUG|Tyvaso®|Administered as inhalation.
214851553|NCT05593731|BIOLOGICAL|dental implants with melatonin gel|platelet rich fibrin membrane around dental implants
214851554|NCT03439631|OTHER|Patient satisfaction questionnaire|Patient satisfaction questionnaire
214851555|NCT06287437|DRUG|HRS9531|HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.
214851556|NCT06287437|DRUG|HRS9531 placebo|HRS9531 placebo low frequency injection for 12 weeks.
214851557|NCT05039476|DIETARY_SUPPLEMENT|Retinol face cream|Retinol face cream
214851558|NCT05039476|DIETARY_SUPPLEMENT|Placebo face cream|Placebo face cream
214851559|NCT00006473|DRUG|oxaliplatin|Given IV
214851560|NCT05839327|DIAGNOSTIC_TEST|Montreal cognitive assessment scale (MOCA)|Tests to evaluate cognitive disorders (MOCA), anxiety and depression (HADS) Pos-traumatic stress disorder (PCL-C) and quality of life (SF-36)
214851561|NCT05699291|OTHER|Sentinel node detection technique|Patients cared for by a surgeon for histologically proven breast cancer and for whom an indication for detection of the sentinel lymph node is posed.
214290295|NCT02148692|PROCEDURE|Lower PEEP|
214290296|NCT04738344|DEVICE|Percutaneous Coronary Intervention and Stent Implantation|Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
214851562|NCT05032326|DRUG|Follow-up study of the treated cohort|follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
214851563|NCT05032326|OTHER|Follow-up study of the untreated cohort|follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study
214851564|NCT00992212|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
214851565|NCT02910414|DRUG|Dehydrated alcohol|Dehydrated Alcohol Injection, USP is used in the study.
214851566|NCT02910414|DEVICE|Peregrine System Kit (Sham Procedure)|Pre-procedural diagnostic renal angiography only, performed for confirmation of anatomical eligibility prior to randomization
214663892|NCT03728244|DRUG|Hyaluronic Acid gel|Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
214663893|NCT04658069|OTHER|no specific interventions|no specific interventions
214663894|NCT03419793|DEVICE|segmental vibration device|segmental vibration device
214663895|NCT03419793|OTHER|physical therapy exercises|
214663896|NCT05072405|DRUG|Simvastatin 20 mg (Zocor®, MSD)|Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
214663897|NCT05072405|DRUG|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
214663898|NCT03639740|DRUG|Secukinumab 150 milligram [Cosentyx]|For intervention description: see arm/group description
214663899|NCT05523934|DRUG|Capsaïcine patch|Patients with complex regional pain syndrome under maximal conventional treatment having a supplementary treatment by a capsaïcin patch.
214663900|NCT01179529|DRUG|Omalizumab (Xolair®)|
214663901|NCT04203901|BIOLOGICAL|CMN-001|Autologous Dendritic Cell Therapy
214663902|NCT04203901|BIOLOGICAL|Nivolumab+Ipilimumab|anti-PD-1 and anti-CTLA4 antibodies
214663903|NCT04203901|DRUG|Lenvatinib+Everolimus|TKI+mTOR inhibitors
214663904|NCT00257751|PROCEDURE|Aprotinine|
214663905|NCT05904587|DEVICE|SureSmile® VPro™|the pain is recorded when the patient is biting on the mouthpiece of the device during the debonding procedure
214663906|NCT05904587|OTHER|ortho technology, sports advantage, thermal forming soft EVA 3mm|the pain is recorded when the patient is biting on the EVA sheet during the debonding procedure
214663907|NCT05904587|OTHER|cotton roll|the pain is recorded when the patient is biting on the cotton roll during the debonding procedure
214663908|NCT02531815|BIOLOGICAL|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
214663909|NCT02531815|DRUG|Placebo|Placebo for PF-06741086, single dose
214663910|NCT00477087|DRUG|Mitoxantrone|Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.
214663911|NCT00477087|DRUG|GM-CSF|GM-CSF is a biologic response modifier, classified as a colony stimulating factor.
214663912|NCT00613626|DRUG|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
214851567|NCT02501551|DRUG|regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
214851568|NCT01202877|DRUG|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
214851569|NCT01202877|DRUG|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
214663913|NCT00613626|DRUG|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
214663914|NCT00613626|DRUG|Placebo|Matched placebo oral daily
214663915|NCT00613626|DRUG|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
214663916|NCT03234114|DRUG|Triple antithrombotic therapy|Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)
214663917|NCT03234114|DRUG|Dual antithrombotc therapy-1|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)
214663918|NCT03234114|DRUG|Dual antithrombotc therapy-2|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)
214663919|NCT03212261|BEHAVIORAL|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
214663920|NCT05301244|OTHER|laughter yoga for nurses|The experimental group was divided into three groups as 17-17-16 people. For four weeks, laughter yoga sessions were held between 20.00 and 21.00, 2 days a week for each group. Laughter yoga sessions were held for the 1st group between 20.00-21.00 on Mondays and Thursdays, for the 2nd group between 20.00-21.00 on Tuesdays and Fridays, and for the 3rd group between 20.00-21.00 on Wednesdays and Sundays. The first sessions lasted 45 minutes, every other session 40 minutes.
214663921|NCT05301244|OTHER|laughter yoga for nurses-Deep breathing exercises|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
214663922|NCT05301244|OTHER|laughter yoga for nurses-Warm-up exercises|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
214906990|NCT02582229|DEVICE|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
214906991|NCT01213966|DRUG|OZ439|po, single dose
214851570|NCT00396331|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
214851571|NCT06617130|DIETARY_SUPPLEMENT|Corn soy bean blended flour porridge plus indispensable amino acid|"Protocol treatment will start within two weeks of enrollment to the study. Following the baseline study assessments, each participant will receive corn-soy bean blended flour porridge supplemented with IAAs (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) dosed at 12g/d and providing 1.5 times the estimated average requirement (EAR) for a healthy child (Intervention group). The porridge will provide 30% daily energy requirement. The study foods will be taken once daily by the child with at least three observed feeding sessions per week over the 4 weeks of the study to assess compliance.~Children in the control arm will receive corn-soy blended flour porridge without added amino acids."
214851572|NCT01884584|DRUG|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
214851573|NCT06605625|BIOLOGICAL|Influenza vaccination|one annual dose of inactivated influenza vaccine
214851574|NCT06605625|BIOLOGICAL|SARS-CoV-2 vaccine|dose of SARS CoV2 vaccine
214851575|NCT06605625|BIOLOGICAL|Zoster Vaccine Recombinant|first and/or second vaccination for shingles (Herpes zoster)
214851576|NCT01351350|DRUG|MLN0128|MLN0128 capsules
214851577|NCT01351350|DRUG|paclitaxel|paclitaxel intravenous infusion
214851578|NCT01351350|DRUG|trastuzumab|trastuzumab intravenous infusion
214851579|NCT05589350|OTHER|saturated fat intake|Intake of saturated fat from yogurt and animal butter daily for 4-week period
214851580|NCT00606138|DRUG|ranibizumab|One 0.5 mg intravitreal injection
214851581|NCT00606138|PROCEDURE|Laser photocoagulation|panretinal photocoagulation (up to 500 300-500 um laser spots)
214851582|NCT02288208|DRUG|Antiviral Therapy (tenofovir or entecavir)|
214851583|NCT02288208|DRUG|Birinapant|
214851584|NCT02288208|DRUG|Placebo (for birinapant)|
214851585|NCT06011382|DEVICE|Advanced Molar Distalization Appliance (amda®)|AMDA is a prefabricated device anchored to the palate by miniscrews and it is a noncompliance appliance for maxillary molar distalization
214851586|NCT06011382|DEVICE|Buccal mini-implants|Buccal mini-implants for maxillary molar distalization
214851587|NCT04825015|DEVICE|VEnaRt Cardiac Output|Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter
214851588|NCT06061783|DRUG|Hypotonic Solution|"Intravenous administration of 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day.~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily."
214851589|NCT06061783|DRUG|Water Purified|administration of bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
214290297|NCT04203238|OTHER|Reduced Meat High Potato Diet|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes.
214290298|NCT04203238|OTHER|Reduced Meat High Pulses Diet|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses.
214290299|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 50mg|
214290300|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 25mg|
214290301|NCT04782024|DIETARY_SUPPLEMENT|Placebo|
214290302|NCT00733408|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214851590|NCT04812574|PROCEDURE|Periurethral injection|Patients were in the lithotomy position for the procedure. After preparation, topical Lidocaine gel was instilled around the meatus and a 16 F probe was attached. The catheter balloon was inflated to localize the bladder neck and to ensure that injections were performed in the correct anatomical plane. Hypertonic saline (10% NaCl) was injected to the alignment of the urethral meatus in the order of 3-6-9-12 hours of the clock (5 cc to each site, totaling 20 cc). Syringes with 27 Gauge (0.40 mm) outer diameter were used to ensure controlled injection. Since the female urethra is about 4 cm in length, the needle was advanced about 3 cm. Due to the possibility of significant pain with hypertonic saline, 2 cc of Lidocaine hydrochloride was added into the solution.
214851591|NCT04812574|DRUG|Hypertonic (10%) saline|Periurethral hypertonic saline (10%)
214851592|NCT02339740|DRUG|Arsenic Trioxide|Given IV
214851593|NCT02339740|DRUG|Cytarabine|Given IV
214851594|NCT02339740|DRUG|Dexamethasone|Given PO or IV
214851595|NCT02339740|DRUG|Idarubicin|Given IV
214851596|NCT02339740|OTHER|Laboratory Biomarker Analysis|Correlative studies
214851597|NCT02339740|DRUG|Mitoxantrone Hydrochloride|Given IV
214851598|NCT02339740|OTHER|Quality-of-Life Assessment|Ancillary studies
214851599|NCT02339740|OTHER|Questionnaire Administration|Ancillary studies
214851600|NCT02339740|DRUG|Tretinoin|Given PO
214851601|NCT03699033|RADIATION|2.5 Gy/fraction|Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
214851602|NCT03699033|DRUG|Carboplatin|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
214851603|NCT03699033|DRUG|Paclitaxel|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
214851604|NCT05550220|DIAGNOSTIC_TEST|Cuff Leak Test|Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
214851605|NCT00755378|DRUG|AZD8529|Oral
214851606|NCT00755378|DRUG|Placebo|Oral
214851607|NCT00374582|DEVICE|Bodystat Quadscan 4000|device determining body composition and nutritional status
214851608|NCT00374582|DEVICE|bodystat quadscan 400|device determining body composition and nutritional status
214851609|NCT02096588|DRUG|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
214851610|NCT02096588|DRUG|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
214851611|NCT01694082|BEHAVIORAL|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
214851612|NCT01694082|BEHAVIORAL|Brief brochure and assessment control|
214851613|NCT00017394|BIOLOGICAL|bevacizumab|Given IV
214851614|NCT00017394|DRUG|vinorelbine tartrate|Given IV
214851615|NCT00017394|OTHER|laboratory biomarker analysis|Correlative studies
214851616|NCT01795248|DRUG|Liraglutide|1.8 mg liraglutide
214851617|NCT01795248|DRUG|Placebo|Liraglutide without the GLP-1 analogue
214851618|NCT00653016|DRUG|norelgestromin; ethinyl estradiol|
214290303|NCT00733408|BIOLOGICAL|bevacizumab|Given IV
214851619|NCT00303667|BIOLOGICAL|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
214851620|NCT00303667|BIOLOGICAL|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10\^7 cells/kg.
214851621|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
214851622|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 40 mg/m\^2 on Days -18 through -14
214851623|NCT00303667|PROCEDURE|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
214851624|NCT00303667|RADIATION|total body irradiation|Administered on Day -13, 200 cGy two times.
214851625|NCT00303667|BIOLOGICAL|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
214851626|NCT00303667|DRUG|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
214851627|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
214851628|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 35 mg/m\^2 on Days -18 through -14
214290304|NCT00733408|DRUG|erlotinib hydrochloride|Given PO
214290305|NCT02965547|DEVICE|Remote ischemic conditioning equipment|The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.
214851629|NCT00958867|BEHAVIORAL|Exercise program (AT)|Six-month, twice-weekly aerobic training (AT) program
214290306|NCT02965547|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
214663923|NCT05301244|OTHER|laughter yoga for nurses-Childish games|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
214663924|NCT05301244|OTHER|laughter yoga for nurses-Laughter exercises|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
214851630|NCT00958867|BEHAVIORAL|Exercise training (RT)|Six-month, twice-weekly resistance training (RT) program
214851631|NCT00958867|BEHAVIORAL|Exercise training (S & R; control)|Six-month, twice-weekly stretch \& relax (S \& R; control) program
214851632|NCT05724446|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).
214851633|NCT05724446|DRUG|Prednisolone acetate ophthalmic suspension, 1%|Microfine sterile ophthalmic suspension of dense and whitish appearance.
214851634|NCT03418168|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
214851635|NCT04959383|OTHER|Low complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.
214851636|NCT04959383|OTHER|Moderate complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.
214851637|NCT04959383|OTHER|High complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.
214906992|NCT06817304|BEHAVIORAL|Tiny Heroes|This is a four modules online intervention based on cognitive behavioral therapy directed at parets of anxious children 3-6 years
214851638|NCT04959383|OTHER|Control Group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
214851639|NCT01577693|DRUG|dutasteride|novel dutasteride
214851640|NCT01577693|DRUG|dutasteride|dutasteride soft gel capsule
214851641|NCT03938129|OTHER|Blood sample|1st trimester blood sample for bio-bank
214851642|NCT03938129|OTHER|Urine sample|1st trimester urine sample for bio-bank
214851643|NCT03938129|OTHER|Pregnancy, maternal health, and fetal health data|Pregnancy, maternal health, and fetal health data
214851644|NCT04322578|DRUG|Crizotinib|Crizotinib 250mg po bid. Savolitinib 300mg po, qd.
214851645|NCT04322578|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt erery 21day.
214851646|NCT01057927|DRUG|OC000459|OC000459 capsules 2x100mg BID for 28 days
214851647|NCT01057927|DRUG|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
214851648|NCT06233019|OTHER|Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart|Prior to the procedure, patients will be instructed to avoid sun exposure during the treatment and to use broad spectrum sunscreen The treatment was started once daily over the entire face and maintained for two months. A fine layer of Glycolic Acid Plus Salicylic Acid face gel was applied on the whole surface where the warts were present, avoiding the eyelids and lips. In children 7 to 10 years of age, face gel was applied by their parents. Clinical controls were performed at Weeks 2, 4, 6, and 8.
214851649|NCT05878379|BEHAVIORAL|Dietary Iron Program|"Teachers Lesson 1: Discuss about causes, prevention and effects of anemia and ID, dietary iron, dietary enhancers and inhibitors of iron absorption, and school lunch menu Lesson 2: Participate in and observe how to teach children in an iron curriculum~Caregivers Lesson 1: Presentation and group talk about causes, prevention, and effects of anemia and ID, dietary iron, and dietary enhancers and inhibitors of iron absorption Lesson 2: Discuss benefits and barriers of changing to an iron-rich meal at home Lesson 3: Cooking class for preparing an iron-rich meal at home (2 times) Lesson 4: Home visit~Children Lesson 1: Group talk about causes and effects of anemia and ID Games: Where are you from? Lesson 2: Presentation and group talk about dietary iron, and dietary enhancers and inhibitors of iron absorption, and iron-rich food Games: What is the winner? Assignment: Market assignment Lesson 3: Cooking class (2 times)"
214851650|NCT03658187|DIETARY_SUPPLEMENT|Placebo|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
214851651|NCT03658187|DIETARY_SUPPLEMENT|IP|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
214851652|NCT01615887|DRUG|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
214851653|NCT01615887|DRUG|placebo|sugar pill
214851654|NCT02377921|DRUG|aceneuramic acid extended-release (Ace-ER)|tablets for oral use
214851655|NCT02377921|DRUG|Placebo|tablets for oral use
214851656|NCT00017459|DRUG|cisplatin|
214851657|NCT00017459|DRUG|tirapazamine|
214851658|NCT00017459|DRUG|vinorelbine tartrate|
214851659|NCT05760352|DEVICE|Eccentric bike|Received eccentric cycling exercise
214851660|NCT05760352|DEVICE|Helmet ventilation|Using helmet ventilation during eccentric cycling exercise
214851661|NCT01481870|DRUG|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
214851662|NCT01481870|DRUG|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
214851663|NCT00737737|DRUG|MS Contin|
214851664|NCT00737737|DRUG|Placebo|
214851665|NCT03517254|DIETARY_SUPPLEMENT|Glutamine|At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
214663925|NCT00708396|DRUG|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
214851666|NCT03517254|OTHER|Strength training program|One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
214851667|NCT03517254|OTHER|Placebo|Maltodextrin powder to mimic glutamine,
214851668|NCT03517254|OTHER|Dietary recommendations|All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
214851669|NCT02794935|OTHER|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
214851670|NCT02794935|OTHER|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
214851671|NCT05336305|DIETARY_SUPPLEMENT|Polydextrose|Administration of 3g polydextrose per day, for 2 months
214851672|NCT02540447|PROCEDURE|Purge|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
214851673|NCT04776057|OTHER|catarct surgery with toric intra ocular lenses|rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation
214851674|NCT05286840|DIAGNOSTIC_TEST|64Cu-SAR-bisPSMA|Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)
214851675|NCT00604201|BIOLOGICAL|Umbilical Cord Blood|unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
214851676|NCT04719741|OTHER|Parallel Assignment|Prospective, Triple blinded, randomized, controlled trial
214851677|NCT04951414|DIAGNOSTIC_TEST|ICF core set|KOA rehabilitation regimen based on the complete core combination of ICF was accepted
214851678|NCT00706355|DRUG|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
214851679|NCT04799613|OTHER|walking speed|walking speed (normal speed vs. fast speed). fast speed was 25% faster than normal speed
214851680|NCT04799613|OTHER|visual loading|visual loading (walking through narrow pathway using VR)
214851681|NCT04799613|OTHER|dual task|dual task (serial subtraction using VR)
214851682|NCT04799613|OTHER|best side reduction|best side reduction (split belt mode, the speed of best side was reduced by 25% compared to the other side)
214851683|NCT06445218|OTHER|Data collection|Collection of various data from patients' medical file, such as demographic data, diagnostic results, discharge, treatment....
214851684|NCT00530543|PROCEDURE|Robot-assisted gait training|
214851685|NCT01020799|DRUG|AZD7268|15 mg, oral, twice daily (BID)
214851686|NCT01020799|DRUG|Escitalopram|20 mg, oral, once daily (QD)
214851687|NCT01020799|DRUG|Placebo capsules|Placebo capsules to match AZD7268
214851688|NCT01020799|DRUG|Placebo tablets|Placebo tablets to match encapsulated escitalopram
214851689|NCT05349747|BIOLOGICAL|Biologic drugs|Assess the results of treatment with biologic drugs
214663926|NCT05194319|OTHER|All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)|The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .
214663927|NCT05480514|DEVICE|TEST LENS|etafilcon A with cosmetic pattern
214663928|NCT05480514|DEVICE|CONTROL LENS|Acuvue 1-Day Define Fresh Honey
214663929|NCT03384056|DEVICE|Self Pressurized Airway Device with Blocker|used in adult low risk females undergoing elective gynecological operations
214663930|NCT03384056|DEVICE|Proseal Laryngeal Mask Airway|used in adult low risk females undergoing elective gynecological operations.
214663931|NCT02149992|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
214851690|NCT04176588|DRUG|Etrasimod|Drug:Etrasimod Tablet other name:APD334
214851691|NCT04176588|DRUG|Placebo|Drug:placebo Tablet
214851692|NCT02180698|OTHER|Laboratory Biomarker Analysis|Correlative studies
214851693|NCT02180698|RADIATION|Radiation Therapy|Undergo radiation therapy
214851694|NCT02180698|DRUG|TLR4 Agonist GLA-SE|Given intratumorally
214851695|NCT02035020|DRUG|gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
214851696|NCT01425528|DRUG|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
214851697|NCT06026774|BIOLOGICAL|iNeo-Vac-R01 in combination with standard adjuvant therapy|Personalized mRNA vaccine encoding neoantigen, IH injection
214851698|NCT05265221|PROCEDURE|Endoscopic submucosal dissection|ESD was performed under conscious sedation. For sedation, midazolam and/or propofol were administered intravenously, with cardiorespiratory monitoring. Initially, indigo carmine dye was sprayed onto the tumor to clarify the margin. Then, markings were made 10 mm outside the tumor margin using argon plasma coagulation. After marking, a mixture of sodium hyaluronate with indigo carmine and epinephrine was injected into the submucosa outside the marking dots. Circumferential mucosal incision and submucosal dissection were performed using a Dual and/or IT knife. During the procedure, immediate bleeding was treated by Coagrasper. After ESD, chest and abdominal plain radiography were performed routinely for detection of gastric perforation.
214851699|NCT03130114|DRUG|Azithromycin|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
214851700|NCT03130114|OTHER|Placebo|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
214851701|NCT00379509|DRUG|lapatinib ditosylate|Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
214851702|NCT00379509|GENETIC|TdT-mediated dUTP nick end labeling assay|Genetic analysis of tumor tissue
214851703|NCT00379509|GENETIC|gene expression analysis|Genetic analysis of tumor tissue.
214851704|NCT00379509|GENETIC|microarray analysis|Genetic analysis of tumor tissue.
214851705|NCT00379509|OTHER|immunohistochemistry staining method|Laboratory analysis of tumor tissue.
214851706|NCT00379509|PROCEDURE|biopsy|Serial biopsies by skin punch or core biopsy or fine needle aspiration.
214851707|NCT00379509|RADIATION|radiation therapy|Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
214851708|NCT04689347|DRUG|Bevacizumab|Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
214851709|NCT04689347|DRUG|Irinotecan|irinotecan 165 mg/sqm intravenous infusion every 2 weeks
214851710|NCT04689347|DRUG|Leucovorin|leucovorin 200 mg/sqm intravenous infusion every 2 weeks
214851711|NCT04689347|DRUG|5Fluorouracil|48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
214851712|NCT04689347|DRUG|Temozolomide|Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
214851713|NCT06616376|OTHER|Anti-Embolism Stocking|To prevent patients undergoing TKA surgery from being affected by one another, the patients were hospitalized in separate rooms, and the orthopedic clinic team was made aware of the situation. The patients in the control group were told not to remove their socks until the sutures were removed after the operation, whereas the patients in the experimental group were told to remove their socks on the 10th day after the operation, so the patients had no idea which group they were in.
214851714|NCT03913260|DRUG|LY3375880|Administered SC
214851715|NCT03913260|DRUG|Buffer Matrix (No LY3375880)|Administered SC
214851716|NCT03913260|DEVICE|Autoinjector (AI)|AI used to administer LY3375880 or Buffer Matrix
214851717|NCT03913260|DEVICE|Manual Syringe|Manual syringe used to inject LY3375880
214851718|NCT01764243|DRUG|MT-4666|low dose, high dose
214851719|NCT01764243|DRUG|Placebo|
214851720|NCT00831636|DRUG|CP-4055|D1-5 and D8(+2)-12(+2) q4w
214851721|NCT00831636|DRUG|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
214851722|NCT06263062|BEHAVIORAL|Awareness-Based Coping with Fear of Cancer Programme|The content of the Training Program was created by researchers based on MBSR, in line with high-level research results and international guides.Then, the necessary arrangements were made bytaking the opinions of 10 experts ( faculty members of the department of obstetrics and gynaecology nursing, psychiatry specialist, faculty members of the gynaecology oncology department, oncology clinic psychologist, obstetrics and gynaecology clinic charge nurse). Content concluded in accordance with the comments received.
214851723|NCT03900117|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.
214851724|NCT03900117|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
214851725|NCT02624726|DRUG|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in \<5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
214851726|NCT02624726|DRUG|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
214851727|NCT02624726|DRUG|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
214851728|NCT02624726|DRUG|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
214851729|NCT02776527|DRUG|Apatinib Mesylate Tablets|taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
214851730|NCT03001752|DEVICE|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
214851731|NCT03001752|DEVICE|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
214851732|NCT03001752|DEVICE|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
214851733|NCT04184999|DRUG|dexamethasone intraocular suspension, 9%|single dose intracameral corticosteroid
214851734|NCT04184999|DRUG|Prednisolone Acetate 1% Oph Susp|topical ophthalmic steroid drop
214851735|NCT03829007|DIAGNOSTIC_TEST|PD-L1 imaging|89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection
214851736|NCT03829007|DRUG|Durvalumab|Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w
214851737|NCT04329416|OTHER|Predicted depth of insertion|A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.
214851738|NCT04329416|OTHER|Optimized depth of insertion|The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.
214851739|NCT04329416|OTHER|Adjustment of depth of insertion|If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
214851740|NCT00131755|DRUG|diazoxide|
214851741|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of Gpi|
214851742|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of STN|
214851743|NCT00302302|DRUG|L-arabinose|
214851744|NCT02709629|BEHAVIORAL|Individualized and adaptive computerized cognitive training|
214851745|NCT02709629|BEHAVIORAL|Active control|
214851746|NCT03016338|DRUG|Niraparib|200 or 300 mg daily PO, for 21 day cycle
214851747|NCT03016338|DRUG|TSR-042|500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
214851748|NCT00635518|BEHAVIORAL|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
214851749|NCT00656968|DRUG|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
214851750|NCT00656968|DRUG|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
214851751|NCT02262195|OTHER|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
214851752|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
214851753|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
214851754|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
214851755|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
214851756|NCT00952276|BIOLOGICAL|Normal saline solution|0.5 mL, Intramuscular on Day 0
214851757|NCT05424250|BEHAVIORAL|occasional aversive imagination|During six of the 27 exposure trials, participants in the experimental group are asked to imagine their most feared outcome towards spiders as vividly as possible while completing the specific trial.
214851758|NCT05424250|BEHAVIORAL|Exposure|• All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.
214851759|NCT05589038|OTHER|Baby Wash/Shampoo|Parent participant will bathe the baby participant with the baby wash/shampoo at least 3 times per week, but no more than once daily.
214851760|NCT05589038|OTHER|Baby Lotion|Parent participant will use the baby lotion on baby participants at least once daily.
214851761|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
214851762|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
214851763|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
214851764|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
214851765|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
214851766|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
214663932|NCT02149992|DEVICE|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
214663933|NCT02149992|DEVICE|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
214663934|NCT05596981|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
214851767|NCT05329818|DEVICE|high definition transcranial direct current stimulation|"Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down."
214851768|NCT02883478|DEVICE|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
214851769|NCT02883478|PROCEDURE|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
214851770|NCT02883478|DRUG|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
214851771|NCT02985879|DRUG|Placebo|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
214851772|NCT02985879|DRUG|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr. For participants in Cohort 2, ABBV-8E12 doses may have been decreased after the evaluation by the Data Monitoring Committee of available safety, tolerability and pharmacokinetic data.
214851773|NCT03431064|OTHER|Lung Recruitment Maneuver|Lung Recruitment Maneuver by Anesthesiologist
214851774|NCT03431064|OTHER|Fluid Administration|Administration of IV Fluid by Anesthesiologist
214851775|NCT05468372|DRUG|Posaconazole 600 mg followed by posaconazole 300 mg once daily|Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.
214851776|NCT05468372|DRUG|Liposomal Amphotericin B|"All study subjects will be administered intravenous liposomal amphotericin B \[5 mg/kg/day infusion in 5% dextrose solution\] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment."
214851777|NCT03883555|DEVICE|High flow nasal therapy (HFNT) : Optiflow™|"HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance"
214851778|NCT03883555|DEVICE|Non invasive ventilation (niv)|"NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort."
214851779|NCT04060914|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg plus aspirin for 12 months
214851780|NCT04060914|DRUG|Ticagrelor 90mg/60mg|1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
214290307|NCT02965547|PROCEDURE|dCA measurement|Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
214851781|NCT04060914|DRUG|Clopidogrel 75mg|Clopidogrel 75mg plus aspirin for 12 months
214851782|NCT04238637|DRUG|Durvalumab|Durvalumab IV (intravenous Infusion)
214851783|NCT04238637|DRUG|Tremelimumab|Tremelimumab IV (intravenous Infusion)
214851784|NCT04335188|OTHER|Prospective oberservational registry|Non interventional study.
214851785|NCT05721651|DRUG|Fruquintinib+PD-1|"This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;"
214851786|NCT04193319|DRUG|Fluzoparib|PARP inhibitor
214851787|NCT04193319|DRUG|Fluconazole|inhibitor
214851788|NCT00595335|DRUG|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
214851789|NCT00595335|DRUG|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
214851790|NCT00595335|DRUG|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
214851791|NCT05637853|DRUG|GDMT|Predifined fast uptitration of GDMT for HFrEF with support of home monitoring.
214851792|NCT05665673|OTHER|Physical functions test|Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
214851793|NCT00146380|DRUG|Zidovudine/Lamivudine and either Nevirapine or Nelfinavir|"Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum~ARVs continued for those that meet WHO treatment criteria"
214851794|NCT00146380|BEHAVIORAL|Breastfeeding for 6 months postpartum|Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued
214851795|NCT05984602|DRUG|Canakinumab|250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle
214851796|NCT05984602|DRUG|Tislelizumab|300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle
214851797|NCT05984602|DRUG|Nab-Paclitaxel|125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
214851798|NCT05984602|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
214851799|NCT06234878|DEVICE|REEV SENSE|Gait analysis with an Inertial Measurement Unit (IMU) sensor
214851800|NCT06234878|DEVICE|Motion capture system|Gait analysis with reflective markers and pressure sensors
214851801|NCT05745441|BEHAVIORAL|Early Dinner|Dinner before DLMO
214851802|NCT05745441|BEHAVIORAL|Late Dinner|Dinner after DLMO
214851803|NCT05745441|DRUG|Early Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner before DLMO
214851804|NCT05745441|DRUG|Late Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner after DLMO
214851805|NCT05466032|OTHER|Osteopathic Manual Manipulation (OMM) Curriculum|Osteopathic medical students are enrolled in the OMM curriculum while masters students are not enrolled.
214851806|NCT04930666|OTHER|BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease|BREATHE-ALD utilizes the patient's nurse practitioner (NP) to deliver a brief intervention using motivational interviewing and shared decision making, in a one-time 9-minute intervention. The NP will follow a 4-step script tailored to specific ALD self-management discussed during the most recent visit with the patient's pulmonologist. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
214851807|NCT06689592|DEVICE|Transcranial Magnetic Stimulation|Intermittent theta burst stimulation
214851808|NCT05857631|RADIATION|Hypofractionated Image guided External Beam Radiation Therapy (EBRT)|"External beam radiotherapy to pelvis:~Post operative hypofractionated external beam radiotherapy with intensity modulated/arc technique, to a dose of 39 Gy in 13 fractions, at 3 Gy per fraction, delivered once daily, 5 days a week, over 2.5-3 weeks."
214851809|NCT05857631|DRUG|Cisplatin|Patients who require adjuvant chemotherapy along with radiation, based on predefined risk features, will receive 5 cycles of cisplatin on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT.
214851810|NCT05857631|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy, two fractions of 6 Gy each, delivered 1 week apart.
214851811|NCT05251324|OTHER|Hot Flush Induction|A temperature-controlled, water-circulating heating pad at a constant temperature of 107˚F will be placed on the participant's torso, a microwaved heating neck pad will be placed on the participant's neck, and two warm balloons will be placed in the participant's hands for 30 min. Subjective (verbal start and end point to be marked on LabChart software) and objective (skin conductance and skin temperature) measures of hot flushes will be recorded.
214851812|NCT05671822|DRUG|SHR-A1811 and SHR-1701|(Arm 1A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion;
214851813|NCT05671822|DRUG|SHR-A1811 and capecitabine|(Arm 1B) Drug: SHR-A1811, administered as an IV infusion Drug：capecitabine, administered orally；
214290308|NCT04346537|DEVICE|INGEVITY+™ Pace/Sense Lead|The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.
214290309|NCT01035515|DRUG|Placebo|Single dose oral capsule placebo comparator
214290310|NCT01035515|DRUG|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
214663935|NCT03059290|DEVICE|neolix file|first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
214663936|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
214663937|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
214663938|NCT02299934|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
214663939|NCT02299934|DIAGNOSTIC_TEST|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
214663940|NCT05367661|DRUG|CHK336|Tablet
214663941|NCT05367661|DRUG|Placebo|Tablet
214663942|NCT04879940|DEVICE|Merit Medical Embospheres|Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.
214663943|NCT04879940|RADIATION|Radiation Therapy|Patients will undergo standard of care definitive radiation therapy.
214663944|NCT05324215|PROCEDURE|Transversalis fascia plane block and rectus sheath block|Transversalis fascia plane block and rectus sheath block will be administered after the surgery.
214663945|NCT05324215|DEVICE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
214663946|NCT04686890|PROCEDURE|erector spinea plane block administered preoperative open nephrectomy|erector spinae plane block applied in this group before open nephrectomy
214663947|NCT04686890|PROCEDURE|intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg|intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
214663948|NCT04798339|DRUG|Canakinumab Injection|Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose
214663949|NCT04798339|DRUG|Darbepoetin Alfa|Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle
214663950|NCT04557527|PROCEDURE|Pars plana vitrectomy, laser or cryo retinopexy and intraocular gas tamponade|Conventional pars plana vitrectomy procedure is used to treat rhegmatogenous retinal detachment- laser or cryo retinopexy intraocular gas tamponade (SF6, C2F6 or C3F8) are chosen according to the number and size of the causative retinal break(s) and surgeons clinical judgement
214663951|NCT04557527|DEVICE|Suprachoroidal viscobuckle with 2.3% Sodium hyaluronate (Healon 5 Ophthalmic viscoelastic device)|After drainage of subretinal fluid, approximately 0.5 ml of Healon 5 is injected in to the suprachoroidal space underlying the retinal break. Laser retinopexy is applied around the break .
214290311|NCT01035515|DRUG|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
214851814|NCT05671822|DRUG|SHR-A181, SHR-1701, and capecitabine|(Arm 1C) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally；
214851815|NCT05671822|DRUG|SHR-A1811, SHR-1316, and capecitabine|(Arm 1D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally；
214851816|NCT05671822|DRUG|SHR-A1811, SHR-1316, capecitabine,and oxaliplatin|(Arm 1F) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
214851817|NCT05671822|DRUG|SHR-A1811, SHR-1316, and 5-FU|(Arm 1G) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：5-FU，administered as an IV infusion
214851818|NCT05671822|DRUG|SHR-A1811, SHR-1316, and capecitabine|(Arm 2A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316 administered as an IV infusion; Drug：capecitabine, administered orally；
214851819|NCT05671822|DRUG|SHR-1316 and SHR-A1811|(Arm 2B) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion
214851820|NCT05671822|DRUG|SHR-A1811 and capecitabine|(Arm 2C) Drug: SHR-A1811, administered as an IV infusion Drug：capecitabine, administered orally；
214851821|NCT05671822|DRUG|SHR-A1811, SHR-1316, and 5-FU|(Arm 2D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：5-FU，administered as an IV infusion
214851822|NCT05671822|DRUG|SHR-A1811and 5-FU|(Arm 2E) Drug: SHR-A1811, administered as an IV infusion Drug：5-FU，administered as an IV infusion
214851823|NCT05671822|DRUG|SHR-A1811, SHR-1316, capecitabine,and oxaliplatin|(Arm 2F) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
214851824|NCT04279964|BEHAVIORAL|Boot Camp Translation|Practices in the intervention arm will participate in the Boot Camp Translation process, where BCT Community Advisory group members will come together to develop and implement practice relevant materials to promote adolescent vaccination.
214663952|NCT05660161|PROCEDURE|Nanofracture|"The planned study intervention consists of nanofracture surgical procedure for the treatment of cartilage lesions of the knee.~Nanofractures will be standardized 9 mm deep perforations in the subchondral bone.~Under arthroscopic view, the cartilage lesion is shaved to expose the margins of the lesion and remove damaged tissue. After a satisfactory lesion debridement is performed, a nanofracture device (Plasmaconcept NanoFx®) is placed through the arthroscopic portal. The awl is repeatedly penetrated through the bone until marrow elements are seen in the joint. The flow of arthroscopic fluid is interrupted to better observe the marrow elements emanating from the nanofracture holes. The distance between two consecutive perforations will be approximately 2-3 mm, and the number of perforations will depend on the cartilage lesion extension. All post-operative procedures, including the rehabilitation protocol, will be carried out according to the usual standard of care."
214851825|NCT04279964|OTHER|Control|No intervention. Practices will continue to behave as usual.
214851826|NCT05617625|DRUG|Busulfan|0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant
214851827|NCT05617625|DRUG|Melphalan|70 mg/m\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant
214851828|NCT05617625|DRUG|Fludarabine|25 mg/m\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant
214851829|NCT05617625|DEVICE|CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)|CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.
214851830|NCT02520687|DIETARY_SUPPLEMENT|Beetroot juice|70mls daily for seven days
214663953|NCT05071937|DRUG|ZEN003694|ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
214851831|NCT02520687|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|70mls daily for seven days
214851832|NCT04718545|PROCEDURE|Mucogingival surgery|The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
214851833|NCT04317872|DRUG|High dose of peri-operative intravenous dexamethasone|25mg aacidexam is administered during induction followed by 10mg on the ward after 12 hours
214851834|NCT04317872|DRUG|Low dose of peri-operative intravenous dexamethasone|10mg aacidexam is administered during induction followed by placebo on the ward after 12 hours
214851835|NCT03632135|DIAGNOSTIC_TEST|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses a patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
214851836|NCT03632135|DRUG|Chemotherapy|Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent high-grade glioma
214663954|NCT05071937|DRUG|Talazoparib|Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.
214851837|NCT06467292|DEVICE|continuous theta-burst stimulation (cTBS)|cTBS stimulation will be applied to different areas of the brain following learning. Stimulation will take place following learning in order to block motor memory retention.
214851838|NCT06467292|BEHAVIORAL|Adaptation|Auditory adaptation in speech
214851839|NCT06467292|DEVICE|Single pulse Transcranial magnetic stimulation (TMS)|TMS will be delivered 10 times in each motor evoked potentials (MEP) recording block.
214851840|NCT06467292|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
214851841|NCT04379635|DRUG|Tislelizumab|administered via Intravenous (IV) injection
214851842|NCT04379635|DRUG|Cisplatin injection|administered via IV infusion
214851843|NCT04379635|DRUG|Paclitaxel injection|administered via IV infusion
214851844|NCT04379635|DRUG|Pemetrexed Disodium|administered via IV infusion
214851845|NCT04379635|DRUG|Placebos|Placebo to match tislelizumab IV infusion
214851846|NCT04379635|DRUG|Carboplatin|administered via IV infusion
214851847|NCT06231563|DRUG|Ketamine|intravenous ketamine infusion 0.5 mg/kg
214851848|NCT06231563|DRUG|Remimazolam|intravenous remimazolam infusion 0.25 mg/kg
214851849|NCT05645471|BEHAVIORAL|Together After Cancer|This is an online couples intervention for Latina breast cancer survivors and their intimate partners.
214851850|NCT00688298|DEVICE|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
214851851|NCT00688298|DEVICE|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
214851852|NCT02075034|DRUG|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
214290312|NCT01134783|BEHAVIORAL|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
214663955|NCT06546319|BEHAVIORAL|Music Therapy|Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, not to occur on the same day, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
214663956|NCT06806137|BIOLOGICAL|Investigational varicella vaccine|Investigational varicella vaccine administered subcutaneously.
214663957|NCT06806137|BIOLOGICAL|Marketed varicella vaccine|Marketed varicella vaccine administered subcutaneously.
214663958|NCT06806137|BIOLOGICAL|MMR vaccine|MMR vaccine co-administered subcutaneously or intramuscularly.
214663959|NCT06806137|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
214663960|NCT06806137|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214663961|NCT06806137|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214663962|NCT06806137|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214663963|NCT06802159|BEHAVIORAL|Conventional therapy|"The methods of traditional neuropsychological rehabilitation used in the classes included:~* attention tasks: proofreading tests, Schulte's Table;~* spatial thinking tasks: copying, drawing, tasks using Nikitin cubes;~* text reading tasks: texts from the Luria album. Each session began with oculomotor exercises. The correction programs differed by the type of feedback given to the patient in the course of correction.~Feedback in this type of intervention is in the form of prompts from a specialist."
214663964|NCT06802159|BEHAVIORAL|Eye tracking based therapy|"Rehabilitation in this group was carried out using an alternative communication device - oculograph C-Eye Pro (Assistech). The use of the device is characterized by a number of features: the presence of the eye movement biofeedback function (the patient and the specialist can see where the patient's gaze is directed by the movement of the red dot on the screen), the device needs to be pre-calibrated before the beginning of the session. To implement rehabilitation activities such tasks were used as:~* Visual field training;~* Word composing;~* Vowel insertion;~* Reading;~* etc. The peculiarity of correction on the apparatus of alternative communication - oculograph - was the use of visual biological communication, visual biological communication, also in case of wrong answer a sound signal followed."
214663965|NCT06802159|BEHAVIORAL|Cognitive therapy|"Rehabilitation of patients in the second experimental group was carried out on the RehaCom modular therapeutic system. The modular system includes a dedicated keyboard that has: numbers 1-9, 4 ok buttons, 4 arrow buttons, 2 pause/tip buttons and 2 exit/cancel buttons. Most of the tasks are performed using the keyboard, some of the tasks involved touch screen control. Tasks with stimulus images in the left screen space were used for rehabilitation activities:~* Saccades;~* Attention and Concentration;~* Planar Imagination;~* General Presentation and Reading;~* Shopping;~* Daily routine. A feature of the correction on the modular therapy system was the involvement of a motor component, playing a sound cue or visual cue when an error occurred."
214663966|NCT06074887|BEHAVIORAL|transtheoretical model-based intervention|"Pretest data are collected for patients in the intervention group in a face-to-face interview in the hospital setting.~The training prepared according to the behavior change phase will be conducted one week later in the patients' home environment and the required data will be collected.~In the fourth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the eighth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the twelfth week of the study, post-tests will be collected in the hospital."
214663967|NCT05534724|OTHER|Partial weight-bearing (10 - 15kg)|Immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO shoe for 6 weeks
214663968|NCT05534724|OTHER|Complete weight-bearing|Complete post-operative weight-bearing with a VACOPASO shoe for 6 weeks
214851853|NCT03594825|DRUG|Valsartan|Different time of taking medicine
214851854|NCT05336435|DIAGNOSTIC_TEST|Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin|The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
214290313|NCT04221009|BEHAVIORAL|MI and CBT 4-session manualized intervention|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
214290314|NCT00133614|PROCEDURE|Prone Positioning|
214663969|NCT04111588|OTHER|Diagnostic Amino acid PET/MRI examination|Diagnostic Amino acid PET/MRI examination
214663970|NCT02078349|DRUG|KPT-330|Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
214851855|NCT06239714|DRUG|SGB-3403|SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
214851856|NCT06239714|OTHER|Atorvastatin|The dosage of atorvastatin was determined by the investigator
214851857|NCT06239714|OTHER|Placebo|Normal saline 0.9%
214851858|NCT00804206|DRUG|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
214851859|NCT00804206|DRUG|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
214851860|NCT02136303|DIETARY_SUPPLEMENT|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
214851861|NCT02136303|OTHER|S2: Kale extract versus kale purée|
214851862|NCT02136303|OTHER|S3: Kale extract: AMD-patients|
214851863|NCT04204031|BEHAVIORAL|Presentation of the adherence record|Adherence record will be presented to participants with an actual time of use less than prescribed. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.
214851864|NCT01647958|DEVICE|EsophyX System with SerosaFuse fasteners|Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication using the EsophyX System with SerosaFuse fasteners
214851865|NCT01647958|DRUG|PPI|Control Arm participants will take maximum standard dose of PPI during Initial Study period
214851866|NCT03190772|OTHER|Placebo nasal spray|The placebo nasal spray consists of sesame oil and does not contain any active drug.
214851867|NCT03190772|OTHER|Film sequence|All groups watch the film sequence that is supposed to induce sadness.
214851868|NCT00544817|RADIATION|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
214851869|NCT00544817|DRUG|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
214851870|NCT00544817|DRUG|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
214851871|NCT01131299|OTHER|Placebo|2 tablets PO 3 times a day for 12-14 weeks
214851872|NCT01131299|DRUG|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
214290315|NCT03038191|DEVICE|Neuroelectrics Enobio 8(R)|Monitoring
214851873|NCT00949728|PROCEDURE|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
214851874|NCT04877587|DRUG|Ascorbate|"A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~* 2 60 g/m2 IV Days (1,2,8,9,15,16)~* 1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~  * 1 30 g/m2 IV Days (1,2,8,9,15,16)"
214851875|NCT04877587|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
214851876|NCT01682629|OTHER|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
214851877|NCT01682629|OTHER|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
214851878|NCT00002194|DRUG|Erythromycin|
214290316|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol for emotional disorders whose aims are to learn and practice adaptive ways to regulate emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention. These components are organized in twelve modules.
214290317|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol for emotional disorders + PA regulation components has the purpose of learning and practicing adaptive ways to regulate emotions from a transdiagnostic perspective. This protocol includes the same components but it also includes 4 additional modules focused specifically on the regulation of positive affectivity.
214851879|NCT00002194|DRUG|Nevirapine|
214851880|NCT00002194|DRUG|Clarithromycin|
214851881|NCT05925244|OTHER|Control Condition|Control (no alteration to body mass).
214851882|NCT05925244|OTHER|+12% Body Mass|Loaded walking exercise (12% increase in body mass using a weighted vest).
214851883|NCT05925244|OTHER|-12% Body Mass|Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
214851884|NCT02105311|DEVICE|Selective laser trabeculoplasty|Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
214851885|NCT02105311|DRUG|Travoprost|Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
214851886|NCT00686244|OTHER|Combined 3-monthly endurance and strength training|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
214851887|NCT03050034|DEVICE|WIN @ Hospital system|WIN @ Hospital system is a wearable and wireless system (Medical Class IIA) that allows continuous and real-time vital signs monitoring, automatically calculating the NEWS score with a personalized alert system for the patient. It does not require the continuous presence of the nurse in front of the control room, but is working with alert on portable devices (ipad).
214851888|NCT03050034|OTHER|Traditional monitoring|Vital signs control performed by nurse staff each 6 hours or more, according to medical advice.
214663971|NCT03706586|PROCEDURE|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
214663972|NCT03706586|PROCEDURE|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
214663973|NCT05368675|DRUG|medication for opioid use disorder|This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
214663974|NCT00457639|DRUG|Cholic Acid|Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
214663975|NCT06504667|DEVICE|Point Mini|The Point Mini finger prosthetic system consists of 1-4 ratcheting mechanical digits and mounting brackets
214663976|NCT03638830|DRUG|Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)+placebo"
214663977|NCT03638830|DRUG|Ftortiazinon (tablets 300 mg) full dose + Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)"
214663978|NCT03638830|OTHER|placebo+Maxipim|placebo
214663979|NCT06127602|BEHAVIORAL|Reactive balance training with Neuromuscular Electrical Stimulation|REACT-NMES group: The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level. NMES will be delivered to the vastus lateralis synchronously with the perturbation, which will always occur 50 ms after slip-onset and last for 450 ms including the period between liftoff to touchdown of the first compensatory step.
214663980|NCT06127602|BEHAVIORAL|Reactive balance training without Neuromuscular Electrical Stimulation|REACT group: The REACT group will undergo the same reactive balance training (in terms of type, dosage: intensity, frequency) as the REACT-NMES group. The only difference will be that the REACT group will receive ShamNMES for same time after the compensatory step touchdown. The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level.
214663981|NCT06547489|DRUG|Zelquistinel|Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
214663982|NCT06418308|DRUG|Dexmedetomidine|5 mcg of dexmedetomidine
214663983|NCT06418308|DRUG|Epinephrine|200 mcg of epinephrine
214663984|NCT06418308|DRUG|Standardized Spinal Mixture|Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.
214663985|NCT06807164|DRUG|Capsaicin 8% Patch|One or two capsaicin patch (8%) are applied for 60 minutes to the site of neuropathic pain, in day-hospital. An oral, antalgic pre-medication may be done with one of the following medications (alone or association): paracetamol 1g, nefopam 30 mg, tramadol 100 mg, morphine 10mg, oxycodone 5mg. Capsaicin will be administered in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain persists, the capsaicin patch application may be repeated at 12 weeks.
214851889|NCT01398059|OTHER|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
214851890|NCT01398059|OTHER|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
214851891|NCT01398059|OTHER|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
214290318|NCT02346630|DRUG|Placebo|Placebo capsules daily for 3 weeks.
214851892|NCT02309853|OTHER|Visual and tactile scanning training|"20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~1. Visual or tactile scanning in the personal space~2. Visual or tactile scanning and trunk rotation in the peripersonal space~3. Visual scanning and trunk rotation in the extrapersonal space"
214851893|NCT02309853|OTHER|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
214851894|NCT00951184|BEHAVIORAL|telephone-based intervention|
214851895|NCT00951184|OTHER|screening questionnaire administration|
214851896|NCT00951184|OTHER|study of socioeconomic and demographic variables|
214851897|NCT00951184|PROCEDURE|assessment of therapy complications|
214851898|NCT00951184|PROCEDURE|psychosocial assessment and care|
214851899|NCT06332313|PROCEDURE|erector spina plane block|ESP block is a method used to provide postoperative analgesia by injecting local anesthetic between the erector spinae muscle and the transverse process of the vertebra under ultrasound guidance, targeting the dorsal and ventral rami of thoracic and abdominal spinal nerves. The aim of this randomized controlled study is to observe whether there is a difference in tramadol consumption within 24 hours after surgery between patients who undergo RIRS operations at T11 level with different volumes of ESP blocks performed under ultrasound guidance before general anesthesia induction.
214851900|NCT05016934|BIOLOGICAL|A vaccine composed of a recombinant S1 antigen|Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
214851901|NCT00810862|DRUG|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
214851902|NCT00810862|OTHER|placebo base cream|apply to affected study area twice daily for 21 days
214851903|NCT05981287|OTHER|Task-oriented activities based on NDT (TOA-NDT) principle and Conventional Physical Therapy|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
214851904|NCT05981287|OTHER|Gross motor task training and Conventional physical therapy (CPT)|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
214851905|NCT02536469|DRUG|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
214851906|NCT00642421|DRUG|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
214851907|NCT00642421|DRUG|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
214851908|NCT00274885|DRUG|oxaliplatin|
214851909|NCT00274885|PROCEDURE|management of therapy complications|
214851910|NCT00561171|DRUG|SPP635|oral once daily
214851911|NCT01215071|PROCEDURE|limited lymphadenectomy|Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
214851912|NCT01215071|PROCEDURE|extended lymphadenectomy|Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
214851913|NCT02647528|DEVICE|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
214851914|NCT02647528|DEVICE|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
214851915|NCT02365948|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous injection"
214851916|NCT02365948|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
214851917|NCT01508819|OTHER|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
214290319|NCT02346630|DRUG|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
214290320|NCT02346630|DEVICE|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
214290321|NCT04232124|BEHAVIORAL|Hypertension Management Model|"1. Blood Pressure readings by barbers~2. Clinical Pharmacist evaluation and counseling~3. Blood pressure measurement~4. Point of care basic metabolic panel measurement"
214290322|NCT03475537|DEVICE|transcranial direct current stimulation|the treatment of transcranial direct current stimulation
214290323|NCT02423577|DRUG|FF-3 dry powder|FF-3 dry powder administered by nasal inhalation
214851918|NCT01885182|DRUG|Oxycodone/Naloxone|
214851919|NCT01885182|DRUG|Oxycodone|
214851920|NCT00982501|DRUG|WS® 1442 900 mg/d|
214851921|NCT00982501|DRUG|WS® 1442 1800 mg/d|
214851922|NCT00982501|BEHAVIORAL|Nordic walking training 2 x 30 min/week|
214851923|NCT00982501|BEHAVIORAL|Nordic walking training 4x45 min/week|
214851924|NCT00522990|DRUG|AT9283|Three weekly intravenous administration of AT9283
214851925|NCT00444236|DRUG|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
214851926|NCT00444236|DRUG|Placebo|matching placebo for active drug
214851927|NCT00543452|OTHER|Oxygen|4 liters of oxygen a minute
214851928|NCT00543452|OTHER|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
214851929|NCT05887349|OTHER|Neck Stabilization Exercise|"1\. Control Group exercise program (Cervical Stabilization exercises group)~The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects."
214851930|NCT05887349|OTHER|Neck Stabilization Exercise + Rocabado Exercises|"2\. Intervention group exercise program (the group to which Robacado exercises will be added in addition to cervical stabilization exercises) The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. In addition, individuals in this group will be given Robacado exercises.~Robacado exercises:~1. Resting position for the tongue: The tip of the tongue is placed on the upper palate, just behind the front teeth (resting position for the tongue).~2. When the body is in an upright position, scapular retraction and depression movements are performed without disturbing the position of the cervical region.~3. When the body is in an upright position, at C2-C7 levels, hands are clamped on the neck and cranio-cervical flexion is studied."
214851931|NCT05665959|OTHER|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing.
214851932|NCT00053235|GENETIC|Comparative Genomic Hybridization|Correlative studies
214851933|NCT00053235|OTHER|Laboratory Biomarker Analysis|Correlative studies
214851934|NCT00053235|GENETIC|Polymerase Chain Reaction|Correlative studies
214851935|NCT03150355|PROCEDURE|Arthroplasty or open reduction and internal fixation|fixation of proximal femoral fractures or replacement with prosthesis
214851936|NCT01543555|DRUG|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
214851937|NCT01543555|DRUG|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
214851938|NCT03686150|DIETARY_SUPPLEMENT|Vitamin D3 oral regimen|Vitamin D3 oral regimens supplementation
214851939|NCT03827941|OTHER|1 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
214290324|NCT02423577|DRUG|Placebo|Placebo dry powder administered by nasal inhalation
214851940|NCT03827941|OTHER|20 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
214851941|NCT04174716|DRUG|IDX-1197|Until progression or unacceptable toxicity develops
214851942|NCT03421366|DRUG|Posaconazole|A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
214851943|NCT05409521|OTHER|Kinesio taping|Kinesio taping with the mechanical correction technique will be applied on the thoracic region
214851944|NCT05409521|OTHER|Placebo taping|Placebo taping with no tension and technique will be applied on the arm
214851945|NCT06198530|BEHAVIORAL|cognitive training in NLCs|In the nurse-led clinics(NLCs) training group, CCT was given twice a week during 1-6 months and once a week during 7-12 month in nursing clinic. There is 60 minutes at a time.
214851946|NCT06198530|BEHAVIORAL|cognitive training in home|In the home-based training group, CCT was given four times a week during 1-6 months and twice a week during 7-12 month in nursing clinic. There is 30 minutes at a time. Nurses teach patients to acquire and carry out CCT at home during hospitalization. Nurses set the daily reminder function at 9:00am through training system.
214851947|NCT06198530|BEHAVIORAL|cognitive training in tradition|In the traditional training group, the Home Cognitive Training Manual for Alzheimer's Disease compiled by our research team was distributed.
214851948|NCT06132633|DEVICE|Neospot vitals measurement|Vitals of participants in the intervention group will be measured using neospot alongside standard of care measurement.
214851949|NCT05430945|BIOLOGICAL|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
214851950|NCT01207440|DRUG|Ponatinib|Ponatinib tablets.
214290325|NCT02492347|PROCEDURE|Electrocardiogram|The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
214290326|NCT00428896|DRUG|ZD1839|ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
214851951|NCT03447886|OTHER|Phone interview|Collecting clinical and socio-demographic information.
214851952|NCT02544542|DEVICE|Rectum cooling system|
214851953|NCT02544542|DEVICE|Hyper-hypothermia blanket|
214851954|NCT03341000|DEVICE|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system within the first 3-5 days of the current study.
214851955|NCT00601757|BEHAVIORAL|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
214851956|NCT00601757|BEHAVIORAL|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
214851957|NCT03442881|PROCEDURE|Excision of adnexal mass through laprotomy|Through laparotomy incision, the adnexal mass will be excised
214851958|NCT02662231|PROCEDURE|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
214851959|NCT06465732|DRUG|Dupilumab|the active comparator arm receive dupilumab only
214851960|NCT06465732|DRUG|Tofacitinib|the experimental arm receive dupilumab plus tofacitinib.
214851961|NCT02053129|OTHER|TB screening Questionnaire|All subjects will be screened with the questionnaire which assesses TB symptoms.
214851962|NCT02053129|OTHER|Sputum smear and culture (only in HIV negative women who are symptomatic)|specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
214851963|NCT03677791|OTHER|Virtual tour in coronary computed tomography - 360° counselling environment|Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients
214851964|NCT03677791|OTHER|Current practice|counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
214851965|NCT01252719|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin was administered as a single IV dose.
214851966|NCT01252719|DRUG|IV Vancomycin|Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
214851967|NCT01252719|DRUG|Placebo|Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
214851968|NCT03766490|DRUG|Anlotinib Hydrochloride|Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle
214851969|NCT03766490|DRUG|Gefitinib|Tablet, P.O. 250mg qd
214851970|NCT03766490|DRUG|Icotinib|Tablet, P.O. 125mg tid
214851971|NCT04815421|OTHER|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.
214851972|NCT04815421|OTHER|the meridian group|Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
214851973|NCT05877079|DRUG|Menthol|Patients will wear hand and foot wraps with 8% w/w menthol lotion (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
214851974|NCT05877079|DRUG|Placebo|Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
214851975|NCT02632734|DEVICE|CoreBone Cone device|coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
214851976|NCT02632734|DEVICE|CoreBone 500 device|coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
214851977|NCT04542850|DIETARY_SUPPLEMENT|5-ALA-Phosphate + SFC (5-ALA + SFC)|"Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days"
214851978|NCT04082728|DRUG|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
214851979|NCT04082728|DRUG|Placebo oral tablet|Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
214851980|NCT05439811|PROCEDURE|Swan-Ganz Catheter|Swan-Ganz Catheter
214851981|NCT01997294|DRUG|Sequential therapy of atorvastatin|80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
214851982|NCT02813421|DEVICE|CGM Informed|
214290327|NCT05967806|PROCEDURE|assessment|2 ml volume of blood withdrawal
214851983|NCT05224284|OTHER|BPA levels|BPA (Bisfenol A) in blood and ejaculate samples
214851984|NCT02769884|DEVICE|MMPPC algorithm artificial pancreas|An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
214851985|NCT03734887|BEHAVIORAL|Social Network Feedback|Social networks are cost-free and highly influential social relationships and interactions that influence behavior and conversely are influenced by a patient's behavior. In addition to receiving a private text message regarding their medication adherence rate, participant's feedback will also be shared to a loved-one or friend that the participant is willing to share medical information with.
214851986|NCT03734887|BEHAVIORAL|Private Feedback|Participant will receive medication adherence feedback from a pharmacist at the start of the study.
214851987|NCT01328236|DRUG|Bortezomib|"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
214851988|NCT01328236|DRUG|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
214851989|NCT01328236|DRUG|Dexamethasone|"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
214851990|NCT01915719|PROCEDURE|Early non invasive ventilation|
214851991|NCT01915719|PROCEDURE|Oxygen therapy only|
214851992|NCT00005918|DRUG|Efavirenz|
214851993|NCT00005918|DRUG|Lamivudine|
214851994|NCT00005918|DRUG|Stavudine|
214851995|NCT05763706|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
214851996|NCT02759770|OTHER|no intervention|This is a clinical observational study, no intervention was included.
214851997|NCT03053336|BEHAVIORAL|App-technology to increase physical activity|Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.
214851998|NCT04731402|OTHER|Acupressure, laughter yoga and mindfulness stress reduction program|Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group
214851999|NCT03418506|BEHAVIORAL|SMOKELESS TOBACCO AWARENESS PROGRAM|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
214852000|NCT03135899|DRUG|BI 443651|Three doses, each 12 hours apart
214852001|NCT03135899|DRUG|Placebo|Three doses, each 12 hours apart
214852002|NCT05457517|DRUG|YL-13027，Sintilimab|"YL-13027 combined with Sintilimab will be used as a cycle for 21 days. YLl-13027 is administered orally twice a day. Starting dose of YL-13027 is 240mg/d，with escalation to 360mg/d in phase Ib, and RP2D was administered orally twice a day in phase II.~Sindilizumab is administered intravenously 200mg every three weeks"
214852003|NCT00003517|DRUG|antineoplaston A10|
214852004|NCT00003517|DRUG|antineoplaston AS2-1|
214852005|NCT00003517|DRUG|bicalutamide|
214852006|NCT00003517|DRUG|flutamide|
214852007|NCT00003517|DRUG|leuprolide acetate|
214852008|NCT00003517|PROCEDURE|alternative product therapy|
214852009|NCT00003517|PROCEDURE|antiandrogen therapy|
214852010|NCT00003517|PROCEDURE|biological therapy|
214852011|NCT00003517|PROCEDURE|biologically based therapies|
214852012|NCT00003517|PROCEDURE|cancer prevention intervention|
214852013|NCT00003517|PROCEDURE|complementary and alternative therapy|
214852014|NCT00003517|PROCEDURE|differentiation therapy|
214290328|NCT01108705|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
214290329|NCT01108705|DRUG|Placebo|Tablets, Oral, 0mg, once daily, until disease progression or toxicity
214852015|NCT00003517|PROCEDURE|endocrine therapy|
214852016|NCT00003517|PROCEDURE|hormone therapy|
214852017|NCT01452594|DRUG|Diphenylcyclopropenone|Topical administration
214852018|NCT01452594|DRUG|Placebo|Placebo
214852019|NCT00212576|BEHAVIORAL|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
214852020|NCT00212576|BEHAVIORAL|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
214852021|NCT04146363|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
214852022|NCT04146363|OTHER|Placebo|Subcutaneous Injection
214852023|NCT02548312|OTHER|Variations of financial competing interest statements|Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.
214290330|NCT04774874|DRUG|Topical formulation|Topical administration on the scalp once daily for 16 weeks
214852024|NCT01479257|BEHAVIORAL|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
214852025|NCT01479257|DEVICE|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
214852026|NCT01479257|DEVICE|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
214852027|NCT00003034|DRUG|doxorubicin hydrochloride|Given IV
214663986|NCT06807164|PROCEDURE|Serratus Plane Block|The Serratus Plane Block (SPB) is a nerve block performed by a trained anesthesiologist to provide localized pain relief. It involves the injection of a local anesthetic: Maximum 150 mg naropeine combined with 150 μg clonidine hydrochloride into the serratus anterior plane under ultrasound guidance. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation.The SBP will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks. The SPB may be repeated every two weeks up to four times in the initial 8-week period, with an additional repeat at 12 weeks if pain control remains insufficient.
214663987|NCT06807164|PROCEDURE|Botulinum Toxin A|Botulinum Toxin A (Botox-A) is injected into the affected area, with a total of 300 units administered across up to 60 injection sites. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation. This intervention will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks, and is aimed at providing prolonged pain relief for post-mastectomy neuropathic pain. Light sedation is provided, and injections may be repeated at 12 weeks if necessary.
214663988|NCT04885257|DRUG|Methylphenidate|Methylphenidate oral pill. Dosing instructions given to
214663989|NCT04885257|DRUG|Placebo|Placebo arm
214663990|NCT01746433|OTHER|Sitting up|"The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient."
214663991|NCT05066984|OTHER|structured, multidisciplinary and personalized post-ICU care|Structured, personalized and multidisciplinary post-ICU care tailored to patients' health problems initiated by ICU clinicians and coordinated by GPs.
214663992|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
214663993|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
214663994|NCT01579695|DRUG|Tesamorelin for injection|Daily 2 mg subcutaneous injections of Tesamorelin
214663995|NCT02867007|DRUG|KHK2455|oral dosing
214663996|NCT02867007|DRUG|Mogamulizumab|i.v. administration
214663997|NCT00927641|DRUG|Ketoprofen Patch|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
214852028|NCT00003034|DRUG|ranpirnase|Given IV
214852029|NCT06125496|OTHER|Pain management|Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP
214852030|NCT00165386|PROCEDURE|Magnetic Resonance Imaging|
214852031|NCT00165386|PROCEDURE|Bone Marrow Biopsy|
214852032|NCT01856036|PROCEDURE|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
214852033|NCT06411340|OTHER|Observation|Observation
214852034|NCT02914236|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
214852035|NCT04766541|OTHER|no intervention|There is no intervention.
214852036|NCT02109536|DEVICE|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
214852037|NCT01006941|BIOLOGICAL|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
214852038|NCT00555035|DRUG|GSK1349572|
214852039|NCT03698266|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP
214663998|NCT00927641|OTHER|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
214852040|NCT00441350|DRUG|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
214852041|NCT00441350|DRUG|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
214663999|NCT04760145|OTHER|Multicomponent Exercise with Blood Flow Restriction|"* 10 minutes of initial warm-up.~* 20 minutes of strength exercises.~* 10 minutes of resistance exercises.~* 10 minutes of coordination and balance exercises.~* 5 minutes of flexibility.~* 5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed with blood flow restriction."
214852042|NCT02216799|DRUG|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
214852043|NCT02216799|DRUG|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
214852044|NCT00021060|DRUG|paclitaxel|Given IV
214852045|NCT00021060|DRUG|carboplatin|Given IV
214852046|NCT00021060|BIOLOGICAL|bevacizumab|Given IV
214852047|NCT00021060|OTHER|laboratory biomarker analysis|Correlative studies
214852048|NCT03574922|OTHER|Balance exercises|Balance Exercises
214852049|NCT03574922|OTHER|Core Stabilization exercises|Core Stabilization exercises
214852050|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m\^2 for normal hepatic function.
214852051|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m\^2 for mild hepatic impairment (Child-Pugh A)
214852052|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m\^2 for moderate hepatic impairment (Child-Pugh B)
214852053|NCT00891748|GENETIC|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
214852054|NCT02676284|DEVICE|Durolane SJ|DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
214852055|NCT00909584|DRUG|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
214852056|NCT05177159|OTHER|The regional cerebral oxygen saturation (rSO2)|Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate
214852057|NCT05177159|OTHER|The glial fibrillary acidic protein (GFAP)|Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
214852058|NCT05177159|OTHER|The brain-derived-neurotrophic factor (BDNF)|Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
214852059|NCT01685073|DRUG|Zolpidem extended-release|nightly administration of zolpidem extended-release
214852060|NCT01685073|BEHAVIORAL|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
214852061|NCT02976259|DRUG|Dolutegravir|All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
214852062|NCT01332578|DRUG|Paracetamol|Present in both test and active comparator
214852063|NCT01332578|DRUG|Phenylephrine|Test product
214852064|NCT01332578|DRUG|Ascorbic Acid|Test product
214664000|NCT04760145|OTHER|Multicomponent Exercise without Blood Flow Restriction|"* 10 minutes of initial warm-up.~* 20 minutes of strength exercises.~* 10 minutes of resistance exercises.~* 10 minutes of coordination and balance exercises.~* 5 minutes of flexibility.~* 5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed without blood flow restriction."
214664001|NCT00000584|DRUG|immunoglobulins|
214664002|NCT01730248|DRUG|INC424|5 mg tablets administered orally twice daily
214664003|NCT01730248|DRUG|BKM120|10 mg and 50 mg hard gelatin capsules administered orally once daily
214664004|NCT02117687|DRUG|carboxymethylcellulose 0.5%/glycerin 0.9%|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
214664005|NCT02117687|DRUG|sodium hyaluronate 0.18%|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
214664006|NCT03419858|BEHAVIORAL|Mindfulness Meditation|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice mindfulness meditation.
214664007|NCT03419858|BEHAVIORAL|Placebo Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
214664008|NCT03419858|BEHAVIORAL|Slow-Breathing|Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.
214664009|NCT03419858|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.
214664010|NCT03419858|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
214664011|NCT01328457|DRUG|Paromomycin sulfate|Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
214664012|NCT03058744|DRUG|IDP-118 Lotion|Lotion
214664013|NCT03058744|DRUG|HP Monad Lotion|Lotion
214664014|NCT03058744|DRUG|Ultravate Cream|Cream
214664015|NCT03058744|DRUG|Tazorac Cream|Cream
214664016|NCT06657287|OTHER|Mixed meal test|The biochemical parameters, blood pressure, and heart rates of participants undergoing the mixed meal test will be recorded over a 5-hour period.
214664017|NCT04812860|DRUG|HR18042|Tablet, Dosing frequency: once daily, Route of administration: oral
214664018|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
214664019|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
214664020|NCT04812860|DRUG|Tramadol hydrochloride ER|Tablet,Dosing frequency: once daily, Route of administration: oral
214664021|NCT04812860|DRUG|Placebo|Tablet,Dosing frequency: once daily, Route of administration: oral
214664022|NCT01200433|DRUG|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
214664023|NCT01200433|DRUG|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
214664024|NCT06745947|BEHAVIORAL|EFT|Participants who meet the eligibility criteria will receive the EFT intervention, a cognitive training exercise designed to help them generate and visualize future events or goals. The intervention will be administered individually, in person, by a trained counselor
214664025|NCT06989788|BIOLOGICAL|AVX70371|AstriVax Therapeutics' HBV immunotherapeutic
214664026|NCT06989788|OTHER|Placebo|Placebo
214852065|NCT00717496|OTHER|Telephone Support Intervention to Improve Breastfeeding|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
214852066|NCT03393455|OTHER|not accurate|not accurate
214852067|NCT04703621|DRUG|Daratumumab Injection|subcutaneious daratumumab administration
214852068|NCT00002352|DRUG|Lobucavir|
214664027|NCT03086850|BEHAVIORAL|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~* \<6000 steps/day: increase by 3000 steps/day~* 6000 - 10000 steps/day: reach 10000 steps/day~* \> 10000 steps/day: maintain or increase steps"
214664028|NCT03086850|OTHER|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
214664029|NCT06558344|DRUG|BI 1569912|BI 1569912
214664030|NCT06558344|DRUG|Placebo matching BI 1569912|Placebo matching BI 1569912
214664031|NCT07107477|PROCEDURE|Tailored antibiotic and steroid therapy based on the IL-6 value in amniotic fluid obtained by amniocentesis in patients with premature rupture of membranes|"In Arm A, Amniocentesis will be performed once a week until delivery, with a maximum of seven procedures per patient. If the pregnancy continues beyond this period, follow-up will proceed without further amniocentesis.~* If IL-6 ≥ 2600:~* steroids and initial broad spectrum ABX will be administered,~* rotation of ABX according to cultures and PCR.~* If steroids already administered, a second course can be administered prior to 34+0 if at least 7 days have passed after the previous course."
214664032|NCT07107477|DRUG|Antenatal steroids administration|"1. Clinical and/or laboratory signs of chorioamnionitis will result in an intervention consisting of the course of antenatal steroids (if not already administered, or as a single course prior 34+0 if at least 7 days have passed after the previous course), initial broad spectrum antibiotics, or delivery, depending on the week of pregnancy and clinical status.~2. Uterine activity with progression of vaginal finding will result in course of antenatal steroids (if not already administered, or as a single course prior 34+0 if at least 7 days have passed after the previous course) and tocolysis"
214664033|NCT07107477|DRUG|Neuroprotection|In patients with imminent preterm birth prior 32+0 week of pregnancy, foetal neuroprotection will be administered consisting of MgSO4 in an intravenous loading dose of 4 g (administered slowly over 20-30 min), followed by a 1 g per hour maintenance dose. This regimen should continue until birth but should be stopped after 24 h if undelivered.
214664034|NCT07107477|DRUG|antibiotic prophylaxis|Antibiotics - Group B Streptococcus (GBS) prophylaxis + macrolides, always at admission.
214664035|NCT07107477|DRUG|Antibiotics administration|"1. GBS prophylaxis + macrolides: Penicillin G (benzylpenicillin) 5mil IU IV initially and then 2-3 IU (dose adjusted to body weight) IV every 4h twice, then every 6h + Clarithromycin 500mg po every 12h for 7-10 days or till delivery.~2. Initial broad spectrum ABX: Ampicillin/sulbactam 3g IV every 6 hours + Gentamicin 5 mg/kg IV (\<60 kg 240 mg, 61-80 kg 320 mg, \>80 kg 400 mg) every 24h for 5-7 days according to the clinical state.~Comments:~Alternative ABX in patients with allergy to PCN/AMP: Vancomycin 1g IV every 12 h or Clindamycin 600-900g IV every 8h taking antibiotic sensitivity into account.~Before administering the third dose of gentamicin, its serum level should be determined (at a level \>4 umol/l, the dose must be reduced)."
214664036|NCT07106333|OTHER|Topical Ozone Therapy|"The intervention involves local application of ozone in two forms:~Ozonated Water - used for irrigation of the extraction socket.~Ozonated Gel - applied topically inside the socket to promote healing and reduce pain.~Both are used after socket debridement and bleeding provocation, followed by standard analgesic administration (Diclofenac potassium)."
214664037|NCT07106333|OTHER|Irrigation with saline|The intervention involves irrigation with saline
214664038|NCT06860750|DRUG|SHR-1314 Injection|SHR-1314 injection.
214664039|NCT06860750|DRUG|SHR-1314 Placebo Injection|SHR-1314 placebo injection.
214664040|NCT06994260|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|"MSOT is an advanced imaging technology that combines laser-induced ultrasound and light absorption to visualize biological tissues. By detecting ultrasound waves generated from tissue absorption of multispectral light, MSOT provides high-resolution, real-time images with functional and molecular information. One of its use is in biomedical research and clinical applications to study blood oxygenation and tissue composition, making it valuable for areas such as vascular research.~In this study, we aim to utilize MSOT to differentiate between venous, arteriovenous and lymphatic malformations."
214664041|NCT06994260|DIAGNOSTIC_TEST|Ultrasound Localization Microscopy|"ULM is a cutting-edge imaging technique that significantly enhances the resolution of traditional ultrasound by tracking the movement of microbubble contrast agents within blood vessels. This approach enables the visualization of microvascular structures and blood flow dynamics at a super-resolution scale, beyond the diffraction limit of conventional ultrasound.~In this study, we aim to utilize ULM to differentiate between venous, arteriovenous and lymphatic malformations."
214852069|NCT01421199|PROCEDURE|Myringotomy|tube placement for children with multiple ear infections
214852070|NCT02950142|OTHER|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
214852071|NCT02950142|OTHER|CPOE without order sets for lab testing|CPOE only
214852072|NCT01839370|DEVICE|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
214852073|NCT00743509|DRUG|Cyclophosphamide and Sirolimus|"The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously"
214852074|NCT01891305|DRUG|VT-1161|
214852075|NCT01891305|DRUG|placebo|
214852076|NCT05449093|OTHER|Periodontal clinical measurements and gingival crevicular fluid sampling|"Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe.~Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device."
214852077|NCT03768726|DRUG|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
214852078|NCT03768726|DRUG|Placebo|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
214852079|NCT03518892|DIAGNOSTIC_TEST|Resting Metabolic Rate|30 minute test to determine daily caloric needs
214852080|NCT03518892|DIAGNOSTIC_TEST|Body Composition|Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat
214852081|NCT03518892|BEHAVIORAL|Dietary Assessment|Self administered dietary logs
214852082|NCT03769883|BEHAVIORAL|Exercise and diet|The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes
214852083|NCT03769883|BEHAVIORAL|Diet|Dietary intervention
214852084|NCT06495515|DRUG|Dalpiciclib，Toremifen|"1. Dalpiciclib : 150mg orally, once a day, taken for 3 weeks, stopped for 1 week, with a cycle of 4 weeks. It is recommended to take medication at the same time every day, with warm water for delivery. It is recommended to do so on an empty stomach and fast for at least 1 hour before and after taking the medication.~2. Toremifen: 60mg orally, once a day If it is a premenopausal or perimenopausal patient, it is necessary to combine with OFS (OFS includes bilateral ovariectomy or GnRHa drugs)."
214664042|NCT05591911|DIAGNOSTIC_TEST|Urine PCR testing|The urine PCR panel will be performed to evaluate the bacterial growth in the patient's urine who is admitted with acute urinary tract symptoms.
214664043|NCT06303349|OTHER|Samples collection|"from D1 to D10, 1 SSTII (Serum separator tubes II) dry tube of 6 mL blood and 1 EDTA (Ethylenediamine tetraacetic acid) tube of 6 mL blood are collected.~1 SSTII dry tube of 6 mL cerebral spinal fluid will be collected distally in external ventricular drain, after eliminating the dead volume of the collection burette, for patients with it."
214664044|NCT06871670|OTHER|Submaximal isometric contractions of knee extensors|Brief isometric contractions performed at 10, 20, 30, 40, 50 and 60% of maximal voluntary force in a random order.
214664045|NCT03463070|DRUG|rectal misoprostol 600mg|70 women who received 600 mg misoprostol postoperatively at operating theatre
214664046|NCT07015216|OTHER|VR-Assisted Dual Task Training|Virtual reality-based training will be conducted at ISÜFİZYOTEM in a custom-designed augmented VR environment. A 3D avatar and interactive scene (a 1 km crowded street) will be developed using Blender and Adobe Mixamo, with audio components from the Unity Asset Store. Participants will follow the avatar and perform exercises via a VR headset. After 1 minute of self-paced walking, a three-stage Stroop test will be introduced as a dual-task challenge. Sessions will be 20 minutes, supervised by a physiotherapist, with optional breaks. The intervention will be performed 3 times per week for 6 weeks.
214664047|NCT07015216|OTHER|Conventional Therapy Program|A pulmonary rehabilitation program will be administered to individuals with COPD once daily, three days per week for six weeks. The program will include diaphragmatic, chest, and bilateral segmental breathing exercises, breathing control training, relaxation positioning, peripheral muscle strengthening, and airway clearance techniques. Exercises will be explained and prescribed as a home-based program, to be performed twice daily with 10 repetitions. Patients will be given a daily log sheet to record adherence, which will be regularly monitored.
214664048|NCT01381081|BIOLOGICAL|platelet-rich plasma|a single intra-articular injection
214664049|NCT01381081|DRUG|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
214664050|NCT07018518|BIOLOGICAL|PIN +anti-PD1|"1. Initial treatment phase:~   PIN injection frequency:~   day 0 and day 3, per 3 weeks for 8 cycles; PIN injection dosage: Cycle1: 4e9 or 8e9 viral particles of PIN based on the number of injectable lesions, their longest diameter, and the tumor volume capacity .~   Cycle 2\~8: 4e9 or 8e9 viral particles of PIN based on the tumor volume's capacity.~   Anti-PD1: day -3, per 3 weeks for 8 cycles;~2. Maintenance treatment phase:~   No injection lesion: Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~   Have injection lesion: PIN: 4e9 or 8e9 viral particles based on the tumor volume's capacity, per 6 weeks (within first 24 weeks), then per 8 weeks till 2 years unless unavailability of injection lesion, PD or serious intolerable AEs.~   Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~3. Salvage treatment phase: Dosage and frequency of administration refer to the initial treatment phase and maintenance treatment phase."
214852085|NCT05650424|OTHER|Abdominal massage training|please refer to group description
214852086|NCT01538836|BEHAVIORAL|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
214664051|NCT07022184|DEVICE|Personalized Lifestyle Intervention|"The personalized lifestyle intervention (PLI) consists of the combined use of the Patient Journey App (PJA) alongside care provided by the general practitioner or mental health nurse.~The Patient Journey App integrates four digital health tools within a single smartphone application:~1. A brief lifestyle questionnaire covering six key areas: mental wellbeing, minimizing harmful substance use, social relationships, healthy eating, sleep, and physical activity.~2. A personalized summary of the questionnaire results, which supports the formulation of two personal lifestyle goals.~3. Tailored information and advice about lifestyle, including suggested interventions, based on the patient's personal goals.~4. Monitoring of depression symptoms over time to support measurement-based care.~General practitioners and mental health nurses will have access to the app to monitor patient progress and outcomes."
214664052|NCT02656472|DRUG|Tranexamic acid|TXA Loading dose: 31 mg/kg diluted to 2 ml/kg Normal saline (NS) -in syringe
214664053|NCT02656472|DRUG|Epsilon Aminocaproic Acid|Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS
214664054|NCT07024056|PROCEDURE|coracoclavicular ligaments reconstruction associated with acromioclavicular ligament reconstruction|The Gracilis or SemiT graft will be harvested from the ipsilateral knee. An oblique skin incision will be made starting from the ACJ and extended distally towards the tip of coracoid process. 2 drill holes will be prepared on the superior cortex of the clavicle at the footprint of the original 2 ligaments, using a 4.5-mm drill bit. The 2 holes will be around 1 cm apart and the lateral hole was around 2 to 2.5 cm proximal to the distal end of the clavicle. Another 4.5 mm drill bit hole was created in the acromion. The graft exiting laterally around the coracoid will be then passed through the conoid tunnel from inferior to superior and then passed through the acromial tunnel from superior to inferior. The graft exiting the acromion tunnel will be passed through the trapezoid tunnel from superior to inferior. The two free ends of the hamstring graft will be tied to one another with Ethibond No.2 sutures
214664055|NCT07024056|PROCEDURE|coracoclavicular ligaments reconstruction with acromioclavicular temporary k wire fixation|Two 2.4-mm tunnels corresponding to the origins of the conoid and trapezoid ligaments will be created through the distal clavicle, approximately 1.5cm apart from each other. The distal tunnel will be 2.5cm away from the AC joint. After harvesting the Gracilis or Semitendinosus from the ipsilateral leg, the graft was prepared with no. 2 Ethibond sutures and passed beneath the coracoid. Both ends of the graft will be passed inside out through the tunnels after enlarging the tunnels by 4.5 drill bit making a figure of 8 sling. The AC joint will be provisionally reduced with two 1.5/1.8-mm smooth K-wires while keeping the graft ends under adequate manual tension. The ends of the graft will be sutured onto themselves and the surrounding soft tissues. The wound will be closed in layers.
214664056|NCT07031856|OTHER|3D printer partial crown|Comprasion of partial restorations made with 3D printer
214664057|NCT07031856|OTHER|Treatment as usual|Cad-cam printer partial crown
214664058|NCT07031648|OTHER|Laughter Yoga Group|iving information about the yoga of meeting and laughter, Obtaining written consent through the informed consent form, Pre-test will be applied in the first week Providing routine pregnancy school trainings by midwife trainers in the pregnancy school, P
214664059|NCT07031648|OTHER|Pilates Group|Providing information about meetings and Pilates, Obtaining written consent through an informed consent form, Pre-test will be applied in the first week Providing routine pregnancy school trainings by midwife trainers in the pregnancy school, Doing a total of 8 sessions of pregnant pilates exercises for 4 weeks, 2 times a week, Sessions should consist of a maximum of 10 people, A total of 45 minutes of pilates exercise for pregnant women, At the end of the fourth week, the final test will be administered
214664060|NCT07031648|OTHER|Education Group|Providing information about the research, Obtaining written consent through the informed consent form, Pre-test will be applied in the first week Providing routine pregnancy school trainings by midwife trainers in the pregnancy school (pregnancy, postpartum care, baby care, breastfeeding, etc.) At the end of the fourth week, the final test will be administered
214664061|NCT07030192|BEHAVIORAL|Peer support service|"Peers approach identified patients who could potentially benefit from peer support services. Peers offer a range of supports tailored to individual patients' needs, which include referrals to clinical and social support services (e.g., social work, addictions specialist, Indigenous patient navigator, community-based addictions resources), resources (e.g., blankets, food, naloxone kit, sterile drug use supplies, information brochures), providing emotional support, and liaising between patients and healthcare providers to communicate information about patients' condition and ED trajectory.~Peer support workers share their personal experiences to guide patients through their ED visit and to facilitate awareness and understanding of available resources."
214664062|NCT07032064|PROCEDURE|Sequential ventricular pacing at five sites|"This intervention involves sequential temporary pacing at five distinct ventricular sites within the same patient during a single electrophysiological study. The pacing sites include:His bundle pacing (HBP),Deep septal pacing (DSP),Left ventricular septal pacing (LVSP),Non-selective left bundle branch pacing (NS-LBBP),Selective left bundle branch pacing (SLBBP).~Each pacing modality is tested under identical hemodynamic and electrophysiological conditions using a fixed output and AV delay. Electrical parameters and acute hemodynamic responses are recorded for each site. The study uses a within-subject crossover design, allowing direct intra-individual comparison of different pacing strategies in patients meeting standard CRT indications. No long-term device implantation is involved during this phase of the study."
214852087|NCT01538836|BEHAVIORAL|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
214852088|NCT01787279|DRUG|Peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
214852089|NCT02695719|DRUG|Placebo|Lubiprostone placebo-matching capsules
214852090|NCT02695719|DRUG|Lubiprostone|Lubiprostone capsules
214852091|NCT02572349|DRUG|IW-1701|
214852092|NCT02572349|DRUG|Matching Placebo|
214290331|NCT02862613|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
214852093|NCT01922752|DRUG|CEP-37440|"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."
214852094|NCT01941888|DRUG|Propofol|
214852095|NCT01941888|DRUG|Midazolam|
214852096|NCT01941888|DEVICE|Target Controlled Infusion|
214852097|NCT04526392|OTHER|Questionnaire|Pubertal course questionnaire
214852098|NCT00780260|BEHAVIORAL|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
214852099|NCT04377048|DRUG|Nivolumab|"as described in NGS Arm"
214852100|NCT04377048|DRUG|Gemcitabine|"as described in NGS Arm"
214852101|NCT04377048|DRUG|Tegafur-Gimeracil-Oteracil|"as described in NGS Arm"
214852102|NCT01294566|DRUG|GSK1322888|1 mg, 5 mg or 25 mg capsule
214852103|NCT01294566|DRUG|Placebo|matching placebo capsules
214852104|NCT05175924|OTHER|Nanpharmacological method|Virtual Reality
214852105|NCT03580564|DRUG|KL-A167|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
214852106|NCT02623452|DRUG|Insulin Lispro|Administered subcutaneously (SC)
214852107|NCT04119999|DEVICE|Mandibular Advancement Device|Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA
214852108|NCT04119999|DEVICE|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA
214852109|NCT00478452|BIOLOGICAL|DC-Ova|
214852110|NCT00478452|BIOLOGICAL|DC Ova with Cyclophosphamide|
214852111|NCT04869709|DRUG|Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
214852112|NCT03095898|DEVICE|Electroacupuncture|Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
214852113|NCT03046498|BEHAVIORAL|Evidence-Based Program|DSMP and DPP
214664063|NCT07031960|DEVICE|3D Eyeball Movement Simulator Group|"A physical, interactive 3D-printed educational model that replicates human eyeball movements and demonstrates the biomechanical action of extraocular muscles. The simulator allows hands-on manipulation to demonstrate all cardinal eye movements (adduction, abduction, elevation, depression, intorsion, and extorsion) through mechanical actuation of synthetic muscle analogues."
214852114|NCT01976455|OTHER|20% fewer calories|
214852115|NCT01976455|OTHER|40% fewer calories|
214852116|NCT01307839|DRUG|5% lidocaine patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
214852117|NCT01307839|DRUG|placebo patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
214852118|NCT00140413|DRUG|Nutropin AQ|Daily injection. Dosage dependent on weight.
214852119|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.
214852120|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.
214852121|NCT01046630|DRUG|AZD6765|single infusion
214852122|NCT01046630|DRUG|Ketamine|single infusion
214852123|NCT01046630|DRUG|Placebo|single infusion
214852124|NCT06389006|DRUG|Disitamab Vedotin for Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed
214852125|NCT06389006|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
214852126|NCT06389006|DRUG|Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.
214852127|NCT06389006|DRUG|Cyclophosphamide|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed
214852128|NCT04457453|OTHER|Macintosh in sniffing position|Macintosh direct intubation in sniffing position
214852129|NCT04457453|OTHER|Macintosh in Trendelenburg position and Sellick position|Macintosh direct laryngoscopic intubation in Trendelenburg position and Sellick position
214852130|NCT04457453|OTHER|AceScope in Trendelenburg position and Sellick position|AceScope videolaryngoscopic intubation in Trendelenburg position and Sellick position
214852131|NCT06070805|OTHER|depression|The score of Hamilton Rating Scale for Depression (HAMD) is ≥8
214852132|NCT03634345|DRUG|Period 1 - Day 1: PF-04965842 administered|Period 1: Single administration of 100 mg PF 04965842.
214852133|NCT03634345|DRUG|Period 2: Cohort 1: Fluvoxamine & PF-04965842|Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
214852134|NCT03634345|DRUG|Period 2: Cohort 2: Fluconazole & PF-04965842|Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
214852135|NCT05513287|OTHER|On the period of covid 19|In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
214852136|NCT01007474|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
214852137|NCT01007474|DEVICE|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
214664064|NCT07031960|OTHER|Conventional Teaching Methods Group|Standard medical education methods for teaching eye anatomy and movements, including: (1) didactic classroom lectures with 2D illustrations, (2) static anatomical models of the orbit and eyeball, and (3) textbook-based learning materials. This represents the current conventional approach to teaching this content in medical curricula
214664065|NCT07031115|DRUG|Linperlisib|Linperlisib 40 mg, orally, once daily. Following 2 weeks of treatment, efficacy was assessed. If the reticulocyte count remained \<20×10⁹/L, the dose was escalated to 60 mg, once daily. After an additional 2 weeks of therapy, a second efficacy assessment was performed. Patients failing to achieve partial response (PR) underwent further dose escalation to 80 mg, once daily. Treatment was discontinued if PR was not attained after 8 weeks at the maximum dose. Responding patients maintained therapy at their effective dose level. The core study period comprised 12 weeks, with responders continuing treatment at the investigator's discretion.
214664066|NCT07030621|DRUG|Semaglutide 0.5 mg|Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) analog, which has been found to have neuroprotective effects.
214664067|NCT07030621|DRUG|Normal Saline|Normal saline is the placebo drug.
214664068|NCT07030374|OTHER|conscious connected breathing exercises|conscious connected mouth breathing session where the diaphragm is activated
214664069|NCT07030205|OTHER|Blood sample|A blood sample (fasting), for biobanking purposes to measure certain bone biological markers known to be indicators of bone remodeling (osteocalcin, sclerostin, periostin, irisin, procollagen type 1 N-terminal propeptide (P1NP), Dickkopf-related protein 1 (DKK1), and collagen type 1 C-terminal telopeptides (CTX)).
214664070|NCT07030205|OTHER|Bone density exam|A bone density exam will be performed in order to verify the non-osteoporotic status of the healthy volunteers group.
214664071|NCT07030205|OTHER|Tests and questionnaires of study|An assessment of cognitive functions will be realized using Montreal Cognitive Assessment (MoCA), Cantab® tests (MOT, MTS, RTI, DGS), the Trail Making Test (TMT), verbal fluency, the Stroop test, the Dubois 5-word test, and the oral picture naming test. Other questionnaires will be used, assessing: sleep quality (Pittsburgh Physical Activity Questionnaire (PSQI)), anxiety and depression (the anxiety/depression scale (HAD)), quality of life (Short Form-36 quality of life questionnaire (SF-36)), physical activity (International Physical Activity Questionnaire (IPAQ)), and pain with the Brief Pain Inventory questionnaire (BPI) and the numerical scale (EN).
214664072|NCT07030205|OTHER|Functional connectivity value of brain networks at rest|A Resting-State Functional Magnetic Resonance Imaging will be conducted in order to evaluate and compared functional connectivity value of brain networks at rest between three groups.
214664073|NCT07030634|OTHER|conventional physical therapy|"consist of Strengthening exercise: will begin with isometric exercises performed against an immovable object in four directions of ankle movement (dorsiflexion, planter flexion, inversion, and eversion) and will be progressed to dynamic resistive exercises (isotonic exercises) using ankle weights.~and Bracing: The participants will receive instructions from the therapist about using and applying the soft brace. The soft brace will be based on the principles of the functional tape bandage"
214664074|NCT07030634|OTHER|Low load blood flow restriction|Patients in blood flow restriction training groups will receive low load resistance exercise (20-40 % 1RM) using tourniquet around thigh proximally to knee joint to occlude arterial blood flow by 50-80 %.
214664075|NCT07030634|OTHER|proprioception training|Patients will receive proprioception exercises in duration of 30 minutes per session, frequencies will be 3 times per week, and lengths for 4 weeks (Matthew et al., 2017). Progression of the proprioceptive training should be static to dynamic (such as lateral movements, backward movements, jumping, cutting, twisting, pivoting), slow speeds to faster speeds with balance and control, two legs to one leg, and with visual control to no visual control.
214664076|NCT07030387|BEHAVIORAL|Smoking cessation counselling group|3A-OR very brief intervention for smoking cessation
214852138|NCT01007474|DEVICE|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
214852139|NCT01007474|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
214664077|NCT07030387|BEHAVIORAL|Control group patients were those who had not received the 3A-OR intervention|Control Group (Patients of the other family physicians in the same family health centers)
214664078|NCT07031154|DRUG|Adebrelimab|Adebrelimab 1200mg, iv, D1，Q3W
214664079|NCT07031154|DRUG|Apatinib|Apatinib 250mg，P.O，qd，Q3W
214852140|NCT01007474|DEVICE|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
214852141|NCT03623620|BEHAVIORAL|Digital Delivery of Mindfulness-Based Cognitive Therapy|12-week program that emphasizes mindfulness and cognitive behavioral skills
214852142|NCT04092920|DEVICE|laser and SLA|"ligible patients will be randomized to 2 groups control group will receive SLA surface treated implant to replace badly broken tooth immediately after extraction and a study group will receive laser surface treated implant to replace badly broken tooth immediately after extraction.~atraumatic extraction will be performed and socket will be examined for presence of bone dehesince or fenestration if no, implant will be placed immediately and a implant primary stability will be measured using an ISQ unit and recorded as base Line reading .~gingival former will be attached to the implant and removed at 2 ,4,8,12 week intervals to record ISQ readings."
214852143|NCT00197522|BIOLOGICAL|CD34+ derived DCs|
214852144|NCT00811434|DRUG|Lactulose|1.5cc/kg/day po for three months
214852145|NCT00811434|DRUG|placebo|1.5 ml sugar water/kg day for three months
214852146|NCT01084434|DIETARY_SUPPLEMENT|probiotic|Bifidobacterium lactis HN019 10\^9 CFU/day 1 sachet once a day for 7 weeks
214852147|NCT01084434|DIETARY_SUPPLEMENT|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
214852148|NCT01084434|DIETARY_SUPPLEMENT|Synbiotic|(Bifidobacterium lactis 10\^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
214852149|NCT01084434|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
214852150|NCT02135120|DRUG|Combined spinal epidural anesthesia technique with intrathecal morphine|
214852151|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
214852152|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
214852153|NCT00793026|DRUG|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
214852154|NCT01360866|DRUG|OPC-34712|Tablet
214852155|NCT01360866|DRUG|Escitalopram|Tablet
214852156|NCT01360866|DRUG|Fluoxetine|Capsule
214852157|NCT01360866|DRUG|Paroxetine CR|Controlled-release tablets
214852158|NCT01360866|DRUG|Sertraline|Tablets
214852159|NCT01360866|DRUG|Duloxetine|Delayed-release capsules
214852160|NCT01360866|DRUG|Venlafaxine XR|Extended-release capsules
214852161|NCT02126930|OTHER|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
214852162|NCT02126930|OTHER|Routine care|Patients randomized to this arm will receive care in the habitual manner.
214852163|NCT02499224|DRUG|YYB101|"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"
214852164|NCT06094049|OTHER|Preference test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using flour fortified with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food.
214852165|NCT06094049|OTHER|Triangle test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using unfortified flour and fortified-flour with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food and who will be blinded to the flour type.
214852166|NCT02439203|DRUG|JM-010|
214852167|NCT02439203|DRUG|Placebo|
214852168|NCT00049699|DRUG|laromustine|
214852169|NCT03392675|BEHAVIORAL|Self-monitoring of BF and intervention|"Self-Monitoring: At discharge, mothers will complete daily diaries for self-monitoring to stimulate cognitive reframing on the occurrence, duration, and characteristics of nipple and breast pain, infants' latch and sucking pattern, positioning, length of each BF session, and the MAIBB.~Self-Regulation: To support self-regulation skills, mothers will be provided with several 5-minute video modules on pain and BF pain SM with additional resources links. After discharge mother will receive text message from a nurse 2X/week for BF support. Mothers may text the nurse for emergent BF support."
214852170|NCT04528199|DRUG|[18F]FLOR (FC303) Injection|Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.
214852171|NCT01272115|BEHAVIORAL|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
214852172|NCT01304693|BIOLOGICAL|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
214852173|NCT01304693|BIOLOGICAL|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
214852174|NCT03738176|DRUG|Sesame Oil|Sesame oil(80 gm NaCMC-20 gmSesame oil)
214852175|NCT03738176|DRUG|triamcinolone in orabase|triamcinolone 140 gm-Na CMC 50 gm
214852176|NCT05408182|PROCEDURE|Robotic colorectal resection with ERAS (or eRCS) perioperative care|All patients will undergo robotic colorectal resections using the Da Vinci xi system. All common colorectal procedures will be included: right/left colectomy, sigmoid colectomy, anterior resection with PME/TME/TaTME. Patient will undergo an enhanced recovery pathway perioperatively ensuring prompt recovery and early discharge. Most ERAS guidelines will be followed including preoperative nutrition, behavioral training, avoidance of drains, NG tubes, catheters, opioids, patient based volume repletion, wound local anesthetic infiltration, early mobilization, early postoperative feeding, spirometry and physiotherapy.
214852177|NCT00006182|PROCEDURE|Blood Transfusion|
214852178|NCT02129647|DRUG|Axitinib|
214852179|NCT03444272|DRUG|Sofosbuvir and Daklatasuvir|HCV Treatment (Sofosbuvir and Daklatasuvir)
214852180|NCT03647046|DEVICE|Customized Scleral Lens|A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
214852181|NCT03282968|DEVICE|REWIRE|First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
214852182|NCT03282968|OTHER|Balance exercises|The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
214852183|NCT00918463|DRUG|dasatinib|100 mg daily dosing
214852184|NCT00300326|PROCEDURE|Computer assist|same implant using a computer-assisted surgical technique.
214852185|NCT04995757|DEVICE|Stent Retriever|Stent Retriever for acute ischemic stroke
214852186|NCT05714566|DIAGNOSTIC_TEST|Clostridioides difficile toxin detection|Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.
214852187|NCT01784666|DRUG|Isradipine|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
214852188|NCT01784666|DRUG|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
214852189|NCT02979457|BEHAVIORAL|Awareness of degree of worry|degree of worry is a definition made for this project. It is roothed in coping psychology but has been influenced by the construct of self-rated health. Will blinding of DOW have an effect on triage outcome.
214852190|NCT01906086|OTHER|nutritional intervention|
214852191|NCT01906086|OTHER|life style intervention|
214852192|NCT01824134|OTHER|Klean & Klear The Dandy Day Corp|
214852193|NCT01824134|OTHER|The Skin Gel Herbal Answers, Inc|
214852194|NCT01321281|DIETARY_SUPPLEMENT|AquaCal|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg)."
214852195|NCT01321281|DIETARY_SUPPLEMENT|AquaPT|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract."
214852196|NCT01014624|DRUG|Prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
214852197|NCT01014624|DRUG|Clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
214852198|NCT00836017|OTHER|No Intervention|No intervention was administered as part of the study.
214852199|NCT02164734|DEVICE|Endotracheal intubation|
214852200|NCT02164734|DEVICE|Laryngeal mask airway|
214852201|NCT02164734|DRUG|remifentanil|additional premedication in the endotracheal intubation/INSURE arm
214852202|NCT01715896|BIOLOGICAL|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
214852203|NCT01715896|BIOLOGICAL|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
214852204|NCT04773717|DRUG|Ascorbic acid|200mg/kg/24h in four equal parts
214852205|NCT04773717|DRUG|Placebo|The same regimen as ascorbic acid.
214852206|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Sharp Dissection|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery
214852207|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Electrocautery|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
214852208|NCT04226235|BEHAVIORAL|Yoga session|a 1-hour yoga session was completed by all participants following a DVD.
214852209|NCT04031612|DRUG|Neoadjuvant therapy|Neoadjuvant therapy
214852210|NCT03923699|DEVICE|Anesthesia Control Tower monitoring|Real time data will be monitored through the AlertWatch® system as well as the patient's EHR.
214852211|NCT03863483|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
214852212|NCT03863483|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
214852213|NCT03863483|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
214852214|NCT03863483|DRUG|Placebo|0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
214852215|NCT04761705|DRUG|JV-GL1|Experimental Treatment
214852216|NCT04761705|DRUG|Latanoprost 0.005% Ophthalmic Solution|Active Control
214852217|NCT05748119|DRUG|MEB-1170|Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
214664080|NCT07031986|DEVICE|One-Lung ventilation with Double-Lumen Tube|To achieve the required one-lung ventilation during lung resection, patients will be managed with a double-lumen tube.
214852218|NCT05748119|DRUG|Placebo|Equivalent number and size of capsules containing placebo
214852219|NCT00472121|DEVICE|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
214852220|NCT04393090|OTHER|eHealth platform CANKADO|The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.
214852221|NCT00772135|DRUG|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
214852222|NCT00302549|DRUG|FK506|FK506,0.1mg/kg/d
214852223|NCT01946776|DEVICE|implantable heart rate monitor|Implantation of Reveal XT
214852224|NCT05223491|PROCEDURE|En Bloc resection|Tumour is resected and removed from the bladder in one piece, if possible.
214852225|NCT05223491|PROCEDURE|Conventional TURB|Tumour is resected piecemeal.
214852226|NCT01478737|DRUG|Intravitreal dexamethasone implant|Intravitreal Ozurdex after vitrectomy
214852227|NCT01478737|PROCEDURE|Vitrectomy|Vitrectomy only
214852228|NCT01764295|DRUG|DWJ1276|
214852229|NCT01764295|DRUG|Olmesartan|
214852230|NCT01764295|DRUG|Rosuvastatin|
214852231|NCT01764295|DRUG|Placebo|
214852232|NCT01820351|OTHER|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
214852233|NCT02630836|DRUG|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
214852234|NCT02630836|PROCEDURE|Surgical treatment|Isolated endomedullary nailing
214852235|NCT02283164|BEHAVIORAL|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
214852236|NCT01746264|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
214852237|NCT03566264|OTHER|Non-Interventional|Non-Interventional
214852238|NCT04841018|DRUG|High dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.5mg/kg of intravenous dexamethasone
214852239|NCT04841018|DRUG|Low dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.15mg/kg of intravenous dexamethasone
214852240|NCT02710097|DRUG|Active inhaled cannabis|"\~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
214852241|NCT02710097|DRUG|Placebo|Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
214852242|NCT02710097|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
214852243|NCT02710097|DRUG|Placebo|No active cannabinoids. Administered over 20 minutes via a vaporizer.
214852244|NCT04124666|BIOLOGICAL|Granulocytes|Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
214852245|NCT03192241|OTHER|Pump|Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
214852246|NCT03192241|OTHER|Book|Active control intervention is providing mother's with a children's book and information about reading to baby.
214852247|NCT05792124|PROCEDURE|Erector spina area block|After anesthesia and surgical intervention, bilateral ESP passage will be performed with ultrasonography from the T10 level 3 cm lateral to the midline. After cleaning the area with povidone iodine before the block, T10 transverse output will be determined using a linear ultrasound probe. Local anesthetic will be applied to the erector spina with the use of the needle used for peripheral block procedures and transverse access. With the serum treatment from the local anesthesia application, the location of the needle will be correct with the hydrodissection method. After the location of the needle is confirmed, a mixture containing 20 ml of LA and serum will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA is bupivacaine 0.5%, after 20 ml serum content.
214852248|NCT05792124|PROCEDURE|Retrolaminar block|The patient is in the prone position and the high-frequency linear ultrasound transducer is in parasagittal orientation, but the entry point is determined more medial than the ESP block. The needle entry point is 1-1.5 cm lateral to the targeted spinos process. The echogenic needle is advanced until it contacts the lamina in the craniocaudal plane and 0.5-1 for control. By giving cc 0.9 nacl solution, it is observed that the fluid is distributed between the erector spina muscle and the lamina. After the location of the needle is confirmed, a mixture of 20 ml of LA and saline will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA will consist of bupivacaine 0.5% and 20 ml physiological saline.
214852249|NCT03203135|BEHAVIORAL|Nutritional prevention programme|The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
214852250|NCT02377635|DIETARY_SUPPLEMENT|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
214852251|NCT02377635|DIETARY_SUPPLEMENT|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
214852252|NCT05558475|BEHAVIORAL|Virtual Coaching|The core coaching components are motivational support, clinical health education, and technical support. The specific objectives are: support PTBS engagement, foster subsequent treatment adherence, ensure appropriate implementation of guidelines for Sleep Restriction Therapy and Stimulus Control, identify and triage PTBS candidates who are not appropriate or need more intensive treatments, and provide PTBS course technical support.
214852253|NCT01046799|DRUG|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
214852254|NCT01173471|DRUG|AZD4017|tablet, oral, one tablet once daily, 28 days
214852255|NCT01173471|DRUG|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
214852256|NCT01173471|DRUG|AZD4017|tablet, oral 2 tablets twice daily, 28 days
214852257|NCT01173471|DRUG|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
214852258|NCT04952077|DEVICE|MRI|Magnetic Resonance Imaging (MRI)
214852259|NCT03564301|DRUG|Placebo oral capsule|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
214852260|NCT03564301|DRUG|Metronidazole 250 MG|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the antibiotic to be taken during the following days will be given to the patient.
214852261|NCT06288022|OTHER|total tubeless mini-PCNL|When finish the mini-PCNL operation, patient not receive placement both ureteral drainage tube (DJ-stent) and nephrostomy tube.
214852262|NCT06288022|OTHER|tubeless mini-PCNL|When finish the mini-PCNL operation, patient receive placement ureteral drainage tube (DJ-stent) but not receive nephrostomy tube.
214852263|NCT04636359|BEHAVIORAL|Acupuncture stimulation|The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
214852264|NCT06062849|DEVICE|nephrostomy tube|we will investigate if a nephrostomy tube really necessary after PNL operations
214852265|NCT06062849|DEVICE|double J stent|we will investigate if a JJ stent really necessary after PNL operations
214852266|NCT06062849|PROCEDURE|totally tubless|we will not insert any device after the procedure and investigate if a nephrostomy tube or JJ stent really necessary after PNL operations
214852267|NCT05089474|DEVICE|Streamline Surgical System|The Streamline System is a device that delivers viscoelastic into Schlemm's Canal.
214852268|NCT03487783|DRUG|Aripiprazole Oral Solution|Aripiprazole 2-20 mg/day (2-20 mL/day)
214852269|NCT03487783|DRUG|Placebo Oral Solution|Placebo 2-20 mg/day (2-20 mL/day)
214852270|NCT03433144|DRUG|Tranexamic Acid Injectable Solution|the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia
214852271|NCT03433144|OTHER|Placebo (normal saline 0.9%)|An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
214852272|NCT02908282|DEVICE|REMOGEN OMEGA|Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
214852273|NCT02908282|DEVICE|Povidone|Artificial tears: preservative-free eye drops containing 2% povidone.
214852274|NCT03028740|DRUG|Placebo|Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
214852275|NCT03028740|DRUG|Cenicriviroc|Cenicriviroc, 150 mg, tablet, orally, once daily for up to approximately 40 months.
214852276|NCT02583386|BEHAVIORAL|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
214852277|NCT02583386|OTHER|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
214852278|NCT05015881|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|Drink a single dose of ketone ester 1.9 kcal/kg
214852279|NCT05015881|DRUG|FDG|Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.
214852280|NCT03903926|BIOLOGICAL|5000 volunteers (6-35 months)-EV71 vaccine|two doses EV71 vaccines will be administrated on day 0, 30 respectively
214852281|NCT00259168|DRUG|Nateglinide|
214852282|NCT00413686|DRUG|AZD7762|intravenous infusion
214852283|NCT00413686|DRUG|Gemcitabine|weekly intravenous infusion
214852284|NCT03853018|DEVICE|CWAT intervention|Participant in the intervention group will wear an activity tracker for 12 weeks.
214852285|NCT03853018|DEVICE|CWAT + motivation intervention group|Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
214852286|NCT04060719|DRUG|BI 894416|tablet
214852287|NCT04060719|DRUG|Rifampicin|tablet
214852288|NCT04706962|DRUG|TH1902|Intravenous infusion
214852289|NCT00207454|BEHAVIORAL|Social Cognitive Counseling|
214852290|NCT02472535|OTHER|Run-In Period: Placebo|2 capsules, once a day for two weeks
214852291|NCT02472535|DRUG|MBX-8025 50 mg (Dose Escalation Period 1)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg capsule)"
214852292|NCT02472535|DRUG|MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg or 100 mg capsule)"
214852293|NCT02472535|DRUG|MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)|"1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)"
214852294|NCT04578886|DRUG|Guanfacine|Guanfacine 2 mg administered at 21:00 for up to 14 days or otherwise indicated by study protocol.
214852295|NCT04578886|DRUG|Placebo|Placebo, administered at 2100 for up to 14 days or otherwise indicated by study protocol.
214852296|NCT00894517|BIOLOGICAL|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
214852297|NCT00894517|DRUG|Placebo (saline)|Saline injected into the prostate on Day 1.
214852298|NCT05274672|DRUG|Nitrofurantoin|Prophylactic postoperative antibiotic use
214852299|NCT05274672|DRUG|Cephalexin|Prophylactic postoperative antibiotic use
214852300|NCT05274672|DRUG|Sulfamethoxazole Trimethoprim Combination|Prophylactic postoperative antibiotic use
214852301|NCT05274672|DRUG|Ciprofloxacin|Prophylactic postoperative antibiotic use
214852302|NCT05274672|PROCEDURE|Holmium Laser Enucleation of prostate|Endoscopic transurethral Holmium Laser enucleation of enlarged prostate followed by morcellation of prostatic tissue
214852303|NCT06617637|OTHER|Aerobic Based Virtual Reality Exercise Training|"With Aerobic Based Virtual Reality Exercise Training, participants will perform aerobic exercise training with the Xbox Kinect 360 game Your Shape Fitness Evolved 2012. Your Shape Fitness Evolved 2012 is a game that requires basic coordination and is designed to improve the fitness levels of individuals. The game is used as an entertaining aerobic training tool that includes many aerobic activities such as boxing, yoga, dancing, etc. with adjustable difficulty levels."
214852304|NCT06617637|OTHER|Traditional Aerobic Exercise Training|Using a treadmill, participants will be put through an exercise training consisting of a 10-minute warm-up at 0 degree incline, a 20-30-minute (by increasing the walking time by 5 minutes at the end of the first four weeks and the beginning of the last four weeks) walking at 40-80% of the heart rate reserve (moderate-vigorous intensity) and a 10-minute cool-down period. Treadmill walking levels will be changed if necessary to ensure the targeted exercise intensity.
214852305|NCT04490226|DIETARY_SUPPLEMENT|Beta-Hydroxybutyrate as Ca-Mg-salt, active|24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
214852306|NCT04490226|DIETARY_SUPPLEMENT|ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active|24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
214852307|NCT04490226|DIETARY_SUPPLEMENT|fasting, active|36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
214852308|NCT04490226|DIETARY_SUPPLEMENT|fasting, inactive|"36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later."
214852309|NCT06494800|DIAGNOSTIC_TEST|True cut needle biobsy|The biobsy procedure done at the radiology department and the cores are examined by the pathology department, the patient lie prone, supine or in lateral decubitus according to the location of the lesion. A thoracic CT scan was performed first to evaluate the needle pathway and distance from the puncture site to the lesion. The needle pathway was selected to avoid bone, visible vessels, bullae, and fissures. The puncture site was chosen by the CT gantry laser lights and landmarks using a homemade radiopaque grid on the patient's skin. Local anaesthesia was induced with 5 mL of 2% lidocaine. An 18-G coaxial needle was used to puncture the lung, and a repeat CT scan was performed to evaluate the site of the needle. When the needle tip reached the lesion, the specimen was obtained by pressing the trigger of the needle. The specimen was reviewed by the pathologist.The specimen was placed in 10% formaldehyde for pathological examination.
214852310|NCT06033157|BEHAVIORAL|Physiotherapist supervised training|"A 12 week physiotherapist supervised training program. The patient will receive supervision by a physiotherapist 6 times during the intervention period.~The patient is strongly encouraged to do the assigned training protocol at home 3 times a week. The supervised physiotherapy consists of introduction, review and progression of the assigned exercises. In addition, the patient will receive education and guidance in daily use of the arm and appropriate load on the shoulder."
214852311|NCT01826461|DRUG|PDI-192|
214852312|NCT01826461|DRUG|Vehicle|
214852313|NCT02327507|BEHAVIORAL|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
214852314|NCT03594409|DIAGNOSTIC_TEST|Biochemistry of gall stones|Analysis of gallstones is done to determine the biochemical types of gallstone like cholesterol stone, pigmented stones or mix stones
214852315|NCT01651611|BEHAVIORAL|Motivational interviewing|The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
214852316|NCT01651611|BEHAVIORAL|Smoking cessation counseling|The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
214852317|NCT01651611|BEHAVIORAL|Navigation to smoking cessation resources|The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
214852318|NCT01651611|BEHAVIORAL|Social support|Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
214852319|NCT02173652|DRUG|BI 1356, high dose|
214852320|NCT02173652|DRUG|BI 1356, low dose|
214852321|NCT00431782|DRUG|ATI-5923|
214852322|NCT01039194|DRUG|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
214852323|NCT01039194|DRUG|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
214852324|NCT01039194|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
214852325|NCT00911755|PROCEDURE|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
214852326|NCT00911755|PROCEDURE|Endotracheal Intubation|
214852327|NCT03382249|COMBINATION_PRODUCT|Sonodynamic therapy (SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
214852328|NCT03382249|COMBINATION_PRODUCT|pseudo-SDT|Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
214852329|NCT04259255|DRUG|Edaravone (Radicava®/Radicava ORS®)|"Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.~Biomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles."
214664081|NCT07031986|DEVICE|One-Lung Ventilation with Bronchial Blocker|To achieve the required one-lung ventilation during lung resection, patients will be managed with a bronchial blocker.
214664082|NCT06710184|DRUG|Aspirin|Aspirin bolus of 300 mg followed by 75 mg daily until CAG
214664083|NCT06710184|DRUG|Fondaparinux Sodium|Fondaprinux 2.5 mg subcutaneus daily until CAG (1.5 mg for patients with eGFR 20-50 ml/min/1.73m2)
214664084|NCT00002884|DRUG|chemotherapy|
214664085|NCT00002884|DRUG|cisplatin|
214664086|NCT00002884|DRUG|fluorouracil|
214664087|NCT00002884|RADIATION|brachytherapy|
214664088|NCT00002884|RADIATION|radiation therapy|
214664089|NCT06900634|BEHAVIORAL|Kisoboka Amaka|"KISOBOKA AMAKA intervention adapts and combines a behavioral intervention with a structural component. The behavioral intervention component includes, alcohol screening, financial literacy training, and counseling and goal setting related to savings, alcohol use, and HIV care engagement. The structural intervention component focuses on depositing earnings into mobile savings programs. Kisoboka Amaka content will be finalized in aims 1 and 2. However, we expect core intervention components to remain unchanged including: 4 counseling sessions (2 individual, 2 group), 2x weekly text message reminders of goals and mobile money set up. Potential additional components include: 1 family focused couples session, self monitoring of alcohol use (via mobile breathalyzer) and PEth (an objective biomarker measure of alcohol use) boosted alcohol counseling."
214664090|NCT06900634|BEHAVIORAL|Screening and Referral|Alcohol screening and referral and emphasizing the importance of HIV care engagement and ART adherence
214664091|NCT06899191|DIAGNOSTIC_TEST|Hemoglobin A1c|Prompt to order A1c
214664092|NCT06899191|BEHAVIORAL|Observation Unit|Electronic prompt nudging ED provider to consider admitting patient to the Observation Unit for care coordination and more aggressive glycemic control
214664093|NCT06853418|DEVICE|Oocyte Cryopreservation|"The DaVitri System is intended to semi-automate vitrification preparation of human oocytes.~The Overture Semi-Automated Vitrification System (DaVitri) is a medical device that uses semi-automated oocyte vitrification.~The system comprises the DaVitri Station, and the DaVitri Dish. The DaVitri Station is a piece of capital equipment with touch screen control that manages the vitrification preparation. The DaVitri Dish is a cartridge-like device onto which oocytes and vitrification reagents are loaded. When the DaVitri Dish is loaded into the DaVitri Station, and the cryo process is initiated, a microfluidic pump controls the flow of reagents to and from the DaVitri Dish containing the oocytes."
214664094|NCT07108244|DIAGNOSTIC_TEST|[18F]FET PET-MRI|All participants will undergo both \[18F\]fluoroethyltyrosine positron emission tomography-magnetic resonance imaging (\[18F\]FET-PET-MRI) and inferior petrosal sinus sampling (IPSS) as part of the diagnostic work-up for ACTH-dependent hypercortisolism. The purpose is to compare the diagnostic accuracy of these two modalities in distinguishing Cushing's disease from ectopic ACTH secretion. The results from both diagnostic tests will be communicated to the treating medical team and the participant to guide further clinical management.
214664095|NCT07106281|DIETARY_SUPPLEMENT|Grape Seed Extract|600mg of Grape Seed Extract
214664096|NCT07106281|DIETARY_SUPPLEMENT|Placebo|Placebo
214664097|NCT07108036|DRUG|N-803 (IL-15 Superagonist)|N-803 administered subcutaneously.
214664098|NCT07108075|DRUG|Carvedilol|Carvedilol 12. 5mg
214664099|NCT07108075|DRUG|Metformin|Metformin 1000 mg
214852330|NCT01555827|OTHER|Ophthalmological examination & Questionnaire|"The following examinations will be performed, after pupil dilation:~* Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)~* Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)~* Wide-field colour and autofluorescence imaging (Optomap)~* Measure of intra-ocular pressure (pneumotonometer)~The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:~* Age, gender~* educational level~* smoking~* cardiovascular diseases, current medications~* scores at neuropsychological tests"
214664100|NCT07105579|DRUG|BITE and DLI|"Blinatumomab dosage:~Cycle 1 (starting at day 60 post-transplant):Days 1-3: 9 μg/day，Days 4-14: 28 μg/day Cycles 2-4:Days 1-14: 28 μg/day Administration method: Continuous 24-hour intravenous infusion, one cycle every 3 months.~DLI eligibility criteria:No history of grade III-IV acute GVHD (aGVHD).No active aGVHD or chronic GVHD (cGVHD) at the time of infusion~DLI dosage:Administered at day 120 post-HSCT, CD3+ cell dose: 1 × 10⁷/kg"
214664101|NCT07106983|OTHER|No intervention (observational study)|Observational survey only
214664102|NCT07106905|OTHER|Measurements|These measurements are used in other clinical applications. However, the effectiveness of these measurements in discriminating the presence of low back pain in mothers of children with disabilities over the past year has been identified.
214664103|NCT07107893|DEVICE|double lumen tube with video|Methods used to confirm tube placement in one-lung ventilation: auscultation, fiberoptic bronchoscopy, and video to evaluate double-lumen tube use
214664104|NCT07106489|OTHER|beetroot juice - Placebo|Participants receive the beetroot and placebo in the form of waffles to ensure the study is blinded, as the 6 mmol of nitrates used require a high concentration of beetroot, which is masked by the waffle ingredients and food coloring.
214664105|NCT07106489|OTHER|40 meters sprint|The participant performs a race at maximum speed with two attempts, times are taken at 10, 30 and 40 meters, to evaluate acceleration and speed, the attempt with the shortest times is the one taken for the research.
214664106|NCT07106489|OTHER|Fitness test by bronco test|The participant runs a distance of 20, 40, and 60 meters, back and forth, 5 times at maximum speed. The variable to be measured is the total time taken to complete the test.
214664107|NCT07106489|OTHER|Maximal strength|Each participant performs squats and bench press to evaluate lower-body and upper-body maximal strength, thus identifying their maximum strength taken per kilogram lifted.
214664108|NCT07106489|OTHER|Borg scale|At the end of the tests, each participant is asked to evaluate their perception of fatigue by giving a number between 1 and 10, with 1 being the lowest level of fatigue and 10 being the highest.
214664109|NCT07107282|DEVICE|MyHip Verifier|Numerical information on the position of the implant is provided to the surgeon.
214852331|NCT04924374|DIETARY_SUPPLEMENT|Microbiota Transplant plus anti PD1 therapy|"Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (\>30g/day).~anti PD1 therapy every 2-3 weeks"
214852332|NCT04924374|DRUG|anti PD1 therapy|anti PD1 therapy every 2-3 weeks
214852333|NCT03878888|DRUG|Exparel 266 MG Per 20 ML Injection|patients receive Exparel in bilateral TAP blocks for open abdomen surgery
214852334|NCT00964288|DRUG|GSK1014802 low dose|oral tablet
214852335|NCT00964288|DRUG|Lidocaine|positive control
214852336|NCT00964288|DRUG|GSK1014802 high dose|oral tablet
214852337|NCT00964288|DRUG|Placebo|To match GSK drug and positive control
214852338|NCT03650959|OTHER|Method of learning simple interrupted sutures with instrument tie|Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
214852339|NCT03336242|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
214852340|NCT02447159|BEHAVIORAL|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
214852341|NCT00514969|DRUG|Imatinib (STI571)|
214852342|NCT03014193|DEVICE|Semiquantitative Multi-Level Pregnancy Test|
214852343|NCT02964819|OTHER|exercise|
214852344|NCT02964819|DEVICE|Interferential current therapy|
214852345|NCT02964819|DEVICE|Therapeutic Ultrasound|
214852346|NCT05421793|OTHER|Fermented product of carrot derived rhamnogalacturonan I|Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I
214852347|NCT04774341|DRUG|anticoagulation treatment|Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
214852348|NCT03494114|DRUG|Ga-EC2115|Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
214852349|NCT02904668|OTHER|self-managmeent program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (…), which were complemented by a problem-based session.
214852350|NCT03421782|BEHAVIORAL|Cognitive Behavior Therapy|Undergo PROSPECT internet-based CBT
214852351|NCT03421782|BEHAVIORAL|Exercise Intervention|Undergo POWER exercise intervention
214852352|NCT00251225|DRUG|Gleevec|Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV
214664110|NCT07106944|OTHER|Community pregnant women: rectal and throat swab|Community pregnant women: rectal and throat swab
214664111|NCT07107854|OTHER|cosmetic: EFFACLAR ULTRA CONCENTRATED SERUM|Transparent solution (gel)
214852353|NCT00251225|DRUG|Docetaxel|60 mg/m\^2 administered IV on day 0
214852354|NCT05749679|OTHER|training and audit|"An evaluation of the practices with clinical audit before and after the management will be carried out.Every 3 months for 2 years, the investigating physicians of the intervention group will report for these patients the modifications or cessation of treatment, modification or implementation of interventions such as physical activity or implementation of nutritional modifications. Physician investigators will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers.10 possible actions to be deployed :~1. Hygienic and dietary measures~2. Physical activity~3. Smoking cessation~4. Avoidance of nephrotoxic substances~5. Treatment of hypertension~6. Proteinuria reduction~7. Oral antidiabetics; choice~8. Optimal HBA1c~9. Statin~10. Compliance"
214852355|NCT05749679|OTHER|Routine care|"Physicians in the control group will receive training on the study procedures. An evaluation of practices with a clinical audit before and after the treatments will be carried out. Every 3 months for 2 years, the investigating physicians in the control group will report for these patients the modifications or cessation of treatment, the modification or implementation of interventions such as physical activity or the implementation of modifications in terms of nutrition. The investigating physicians will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers. Physician investigators in the control group will continue their care as usual."
214852356|NCT00003020|BIOLOGICAL|LMB-7 immunotoxin|
214852357|NCT02224573|DRUG|GWP42003-P|
214852358|NCT01456091|BEHAVIORAL|AIM 4 Teen Moms|The AIM (Adult Identity Mentoring) 4 Teen Moms program is a combination of individual and small group sessions intervention that encourages parenting young women ages 15-19 years old to delay rapid repeat pregnancies for 24 months or later.
214852359|NCT05179694|DIAGNOSTIC_TEST|Prostate biopsy|Prostate biopsy via either the Transrectal route (comparator) or Transperineal route (experimental), each under local anaesthetic.
214852360|NCT03132194|DRUG|DPSG 7.5%|topical gel
214852361|NCT03132194|DRUG|Aczone|topical gel
214852362|NCT03132194|DRUG|Placebo|topical gel
214852363|NCT02546362|DEVICE|Cefaly|
214852364|NCT03122340|DRUG|Ropren|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
214852365|NCT03122340|OTHER|Oil|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
214852366|NCT03861663|DEVICE|Ultrasound|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
214852367|NCT03365544|OTHER|Time-restricted eating|Groups will be required to only ingest calories in their designated 8 hour eating window.
214852368|NCT01557842|DRUG|Drug Treatment|Class I and III antiarrhythmic drug treatment.
214852369|NCT01557842|DEVICE|Catheter Ablation|Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
214852370|NCT06301087|DEVICE|Web Application|web application for monitoring children's development and postnatal depression of mothers
214852371|NCT03053583|DEVICE|Laryngoscope blade|The POGO score assesses the percent of the glottic opening that can be seen with each blade
214852372|NCT06513585|PROCEDURE|Superselective adrenal artery embolization or adrenalectomy|Arm A underwent SAAE treatment, and arm B underwent laparoscopic adrenalectomy.
214852373|NCT06526507|OTHER|Implementation strategy package|Package includes a Community of Practice, a quality improvement (QI) practice, and a training \& delivery toolkit.
214852374|NCT05655156|DEVICE|OrthoPure XT|"Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~* Size 5~  \- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 6~  \- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 8~  * Primary ACL reconstruction where autograft tissue is not suitable~ * Revision ACL reconstruction~ * Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 10~  * Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)"
214852375|NCT05391711|BEHAVIORAL|Culturally Smart Relationships|"Mentors assigned to the intervention will receive the following trainings and support:~1. Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~2. Culturally Smart Relationships Training (live, virtual)~3. JEDI enhanced monthly supervision from case managers~4. Monthly emails with activity suggestions for mentors and youth"
214852376|NCT04977661|DRUG|Vitamin E|Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.
214852377|NCT04977661|DRUG|Ursodeoxycholic acid|is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)
214852378|NCT04977661|DRUG|Pentoxifylline|"it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription"
214852379|NCT03005067|DRUG|Carbomer 980 (1146A)|Test product containing carbomer 980 gel
214852380|NCT03005067|OTHER|Placebo|Reference product containing vehicle without carbomer 980 gel
214852381|NCT06115304|OTHER|Large liquid meal, spinal catheter and venous line|"Large liquid meal (e.g. Nutricia® Energy 500 ml (750 kcal) admixed paracetamol 1000 mg (for estimation of gastric emptying).~Spinal catheter for 4 hours, with samples taken at one hour interval.~2 venous lines, one for saline and one for venous sampling every half hour"
214852382|NCT02269644|DRUG|Dalbavancin|dalbavancin 1500 mg IV over 30 minutes on Day 1
214852383|NCT02269644|DRUG|Linezolid|linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
214852384|NCT02269644|DRUG|Linezolid Placebo|Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
214852385|NCT02269644|DRUG|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
214852386|NCT02560779|DRUG|Carotuximab (TRC105)|Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.
214852387|NCT02560779|DRUG|Sorafenib|400 mg of sorafenib will be given twice daily.
214852388|NCT02782091|BEHAVIORAL|Multiple Errands Test (MET)|1 hour assessment in an unknown district with 2 independent raters.
214852389|NCT02296853|DRUG|TAF|25 mg tablet administered orally
214852390|NCT03128684|OTHER|Small Green Lentil Muffin|Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
214852391|NCT03128684|OTHER|Split Red Lentil Muffin|Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
214852392|NCT03128684|OTHER|Wheat Muffin|Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes
214852393|NCT03128684|OTHER|Small Green Lentil Chili|Consumption of small green lentil chili; consumption of ad libitum pizza test meal after 180 minutes
214852394|NCT03128684|OTHER|Split Red Lentil Chili|Consumption of split red lentil chili; consumption of ad libitum pizza test meal after 180 minutes
214852395|NCT03128684|OTHER|Rice Chili|Consumption of rice chili; consumption of ad libitum pizza test meal after 180 minutes
214852396|NCT05992831|DEVICE|Accelerated iTBS|The investigators will treat participants with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro TMS System with a Cool-B65 coil, targeting to direct the stimulation to the left dorsolateral prefrontal cortex (l-dlPFC). The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. Total treatment time will be controlled; all participants will perceive receiving active treatment for 10 3-min sessions with 10-15 min inter-session intervals, resulting in a 3-hour treatment day. At pre-treatment, a focal electrical sham will be individually titrated to participant tolerability. Participants then receive an individualized level of sham stimulation throughout treatment, to bolster the blind. Participants will be told that they will be receiving different doses throughout the treatment day, again to maintain the integrity of the blind.
214852397|NCT05992831|DEVICE|Sham Comparator|To achieve adequate blinding, participants will go through the same number of sessions per day irrespective of the active and/or sham dose-step combination to which they are assigned. Sham sessions will be assigned in random order over the 10 sessions. The sequence of active and/or sham sessions for each treatment day is assigned a random code that is entered into the TMS system by the coordinator to maintain the integrity of the blind.
214852398|NCT03233958|BEHAVIORAL|Systemic / family constellation|Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation \[Hunger, Weinhold, Bornhäuser, Link, \& Schweitzer, 2015\].
214852399|NCT06424106|OTHER|Glucagon|a variable rate glucagon infusion
214852400|NCT06424106|OTHER|Glucose|a variable rate glucose infusion
214852401|NCT06469281|OTHER|27T51|Intravenous (IV) infusion
214852402|NCT06469281|DRUG|Cemiplimab|IV infusion
214852403|NCT06469281|DRUG|Bevacizumab|IV Infusion
214852404|NCT01661881|DRUG|Rituximab|
214852405|NCT01661881|DRUG|Bendamustine|
214852406|NCT01661881|DRUG|Cytarabine|
214290332|NCT02862613|BIOLOGICAL|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
214664112|NCT07106892|DRUG|HLX43 Dose 1;|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 2.0mg/kg
214664113|NCT07106892|DRUG|HLX43 Dose 2;|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 2 is 2.5mg/kg
214664114|NCT07106892|DRUG|HLX43 Dose 3;|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 2 is 3.0mg/kg
214664115|NCT07106359|BEHAVIORAL|booklet|a clinical letter with a booklet for at-risk families highlighting implications of family history, testing motivators, steps for genetic testing, and potential costs.
214664116|NCT07106359|BEHAVIORAL|control clinical letter|a clinical letter with basic information about LS and implications of counseling and testing of LS, and a few websites for more information and locating genetic counselors.
214664117|NCT07107399|OTHER|microfragmented adipose tissue|"Receive micro fragmented adipose tissue obtained from the buccal pad of fat after arthrocentessis.~* Direct access to the buccal fat pad, is found at distobuccal depth of the maxillary tuberosity.~* It may be dissected during the resection an upper mucosal incision posterior to the second molar~* After a single scissor stab through the periosteum the (BFP)extrude into the operative site.~* Closure of the flap by suitable suture.~* Collection of lipids then manually manipulated with two syringes connecting together and pushing the lipids against each other to receive the injectable amount of micro fragmented adipose tissue .~* Ready for TMJ injection."
214664118|NCT07107399|OTHER|platelet-rich plasma|I - double-puncture arthrocentesis technique was followed, and 300 mL of Ringer's lactate solution was used to irrigate the joint space through the marked points . After arthrocentesis PRP was prepared from 5 mL of autologous venous blood sample taken from the antecubital vein. The collected blood was then transferred to a test tube containing 0.5 mL of sodium citrate (anticoagulant) (0.5 mL) and was centrifuged at a rate of 2100 rpm for 15 min. The plasma from the first harvest was fractionated by centrifugation at 3500 rpm for 10 min to prepare PRP.
214664119|NCT07107126|DRUG|RPT1G|RPT1G is a selective hyperbolic NAMPT inhibitor. RPT1G is administered orally.
214664120|NCT07105839|DRUG|Intraoperative rescue analgesia|If signs of inadequate analgesia occur (e.g., \>20% increase in heart rate or blood pressure), IV remifentanil infusion rate will be titrated upward within the safety margin.
214664121|NCT07105839|DRUG|Intraoperative rescue analgesia:|If signs of inadequate analgesia occur (e.g., \>20% increase in heart rate or blood pressure), IV dexmedetomidine infusion rate will be titrated upward (up to maximum safe dose).
214664122|NCT07107035|OTHER|No Intervention: Observational Cohort|No intervention
214664123|NCT07106866|PROCEDURE|sacrospinous ligament fixation|A longitudinal incision was made at the midline of the posterior vaginal wall, extending approximately 2-3 cm from the perineal body to the vaginal apex to form a tunnel. The incised vaginal epithelium was dissected from the underlying muscularis layer. Dissection was continued to the level of the ischial spine. The rectum was medialized to access the perirectal space. Upon palpating the ischial spine, the sacrospinous ligament was identified medial to it. Long retractors were placed over the ischial spine to protect the pudendal neurovascular structures. The bladder was retracted superiorly, and the rectum medially, for optimal visualization. Two separate or a loop 1-0 polypropylene suture(s) were placed approximately 1.5 fingerbreadths medial to the ischial spine on the ligament using a needle holder. These sutures were passed through the posterior vaginal tunnel to the apex and tied to secure the vaginal apex to the ligament
214664124|NCT07107958|PROCEDURE|Electroacupuncture|Electroacupuncture is applied using standardized stroke rehabilitation protocols. Needles are inserted at acupoints including LI15 (Jianyu), LI11 (Quchi), TE5 (Waiguan), LI4 (Hegu), GB30 (Huantiao), ST36 (Zusanli), and GB34 (Yanglingquan), and connected to an electroacupuncture device delivering alternating current stimulation at 10-20 Hz. Each session lasts 15-20 minutes, performed once daily, 5 days per week, for 4 weeks. The intervention follows Vietnam's national traditional medicine guidelines for post-stroke recovery.
214664125|NCT07107191|OTHER|Assessment|Data will be collected from all participants in assessmnet group.
214852407|NCT06834568|DEVICE|t:slim X2 insulin pump with Tandem Freedom Algorithm|t:slim X2 insulin pump with Tandem Freedom System consists of the Tandem t:slim X2 insulin pump and the Freedom algorithm embedded in the pump. Participants will also use the Dexcom G6 continuous glucose monitoring system.
214852408|NCT01560884|DRUG|Renazorb 1500 mg/day|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
214852409|NCT01560884|DRUG|Renazorb 3000 mg/day|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
214852410|NCT01560884|DRUG|Renazorb 4500 mg/day|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
214852411|NCT01560884|DRUG|Renazorb 6000 mg/day|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
214852412|NCT06117943|OTHER|data collection|Pregnant women who smoke personally or are passively exposed to cigarette smoke
214290333|NCT02392247|DEVICE|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
214852413|NCT05061914|PROCEDURE|pericardial effusion drainage|tamponading pericardial effusion is a life threatenning condition , pericardiocentesis is performed for patients who are vitally unstable and with a massive amount of effusion to prevent cardiac tamponade, Surgical drainage of pericardial effusion was classically conducted by either open thoracotomy or subxiphoid pericardiectomy. Thoracoscopy has established itself as an alternative to open thoracotomy for the management of many pericardial, pleural and pulmonary disorders
214852414|NCT01359748|DEVICE|Reference sphygmomanometer|\* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
214852415|NCT01359748|DEVICE|Sphygmomanometer under test|Electronic Oscillometric method.
214664126|NCT07106021|BIOLOGICAL|RNDP-001|Stem cells
214852416|NCT00730951|DIETARY_SUPPLEMENT|Korean Red Ginseng|500mg Capsulated Ground Dried Korean Red Ginseng Root
214852417|NCT00730951|DIETARY_SUPPLEMENT|Corn Starch|500mg Capsulated Corn Starch
214852418|NCT01450241|OTHER|Early antibiotic discontinuation|Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
214852419|NCT01450241|OTHER|Usual practice|Continued antibiotic treatment as accepted by guidelines for febrile neutropenia
214852420|NCT00604084|DRUG|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
214852421|NCT00604084|DRUG|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
214852422|NCT02651142|PROCEDURE|Patients receive SLNB|Patients receive sentinel lymph node biopsy
214852423|NCT03783988|COMBINATION_PRODUCT|DHEA and TRIAC|The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)
214852424|NCT06369649|DEVICE|Coolsense and Buzzy|Before the procedure, the independent observer, parent and child will be informed by the researcher about the method that will be used in the selected group and the scales that they will score. For children and parents in each group, a standard approach will be applied. Single blinding (participants) will be used in the research and the researchers will not have information about the other group. Cold application will be applied to children in group number one (Coolsense group). Coolsense, which does not contain any chemicals, provides cold application with the metal piece on its tip. In group number two (Buzzy group), vibration and cold application will be applied to the children. Buzzy is a handheld device with a bee-shaped motor that creates a small cold pad and vibration in the area in contact with the skin surface. Group number three (control group) will continue the standard procedure of the clinic and no different application or approach will be applied.
214852425|NCT02506218|DIETARY_SUPPLEMENT|10 + 20 g protein consumption|whey isolate
214852426|NCT02506218|OTHER|30 g protein breakfast|30 g mixed meal breakfast
214852427|NCT02506218|OTHER|10 g protein breakfast|10 g mixed meal breakfast
214852428|NCT01956708|PROCEDURE|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
214852429|NCT01191528|DEVICE|capnostream 20, Oridian Medical 1987 ltd, Needham MA|"Oxygen blood saturation measured by a s sensor that reflects infrared light on oxygenated and deoxygenated arterial blood via a noninvasive, clip on digit sensor connected to a combination capnometer and pulse oximeter monitor.~End-tidal Carbon dioxide (EtCO2) is measured with a noninvasive nasal cannula sampling line which calculates the EtCO2 from exhaled air. Measurements recorded at 5 second intervals."
214852430|NCT00719979|BEHAVIORAL|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
214852431|NCT00719979|BEHAVIORAL|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
214852432|NCT00719979|BEHAVIORAL|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
214852433|NCT01905059|DRUG|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
214852434|NCT01905059|DRUG|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
214852435|NCT05307406|BIOLOGICAL|Experimental|Participants will receive a single IV infusion in a double blind manner
214852436|NCT03207958|DRUG|Belimumab|-Given over 1 hour
214852437|NCT03988517|OTHER|timing of receiving the drug|each group took levothyroxine in different timing
214852438|NCT04154358|DIAGNOSTIC_TEST|HPV testing|will perform HPV testing with self-collected specimen
214852439|NCT00908219|DRUG|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
214852440|NCT00314431|PROCEDURE|Care coordination by telephone contacts with a nurse|
214852441|NCT01668121|DRUG|Symbicort Turbohaler|
214852442|NCT01668121|DRUG|Budesonide/formoterol Easyhaler|
214290334|NCT05558163|PROCEDURE|transverse scrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
214290335|NCT05558163|PROCEDURE|penoscrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
214664127|NCT07106021|DEVICE|Syringe Front-Loading Device|Delivers the stem cells
214664128|NCT07105787|OTHER|SDTT + VR triggered adaptations|The SDTT+ VR triggered adaptations program will trigger reactive gait adaptations by presenting obstacles in VR.
214852443|NCT02593396|DRUG|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
214852444|NCT02593396|DRUG|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
214852445|NCT01868763|DEVICE|telemedical devices (weighing machine and step counter)|
214852446|NCT01868763|BEHAVIORAL|care calls once per week for 12 weeks|
214852447|NCT03399578|BIOLOGICAL|ChAdOx1 MERS|The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
214852448|NCT02229565|DEVICE|Biopsy or prostatectomy|
214852449|NCT02989298|OTHER|No intervention|Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
214664129|NCT07105787|OTHER|Speed-dependent treadmill training (SDTT)|This training methodology focuses on adjusting the treadmill's speed according to the individual's walking pace, creating a more dynamic and adaptive exercise environment. SDTT is designed to mimic real-world walking conditions and challenges, promoting neuromuscular coordination, balance, and overall mobility. By tailoring the treadmill speed to match the user's gait, SDTT encourages the development of natural and efficient walking patterns. This training technique has shown promise in various clinical settings, aiding individuals with gait impairments caused by neurological conditions, musculoskeletal disorders, or post-injury rehabilitation. Its adaptability allows for progressive adjustments as a person's walking abilities improve, making it a versatile tool for optimizing gait mechanics and functional mobility. To ensure continued progress and integration into daily life, home-based walking training, supported by a phone application, will be included between T1 and T2.
214664130|NCT07106957|OTHER|CICAPLAST BAUME B5+|Twice a day (morning and evening) on face
214664131|NCT07106957|OTHER|Standard cream|Twice a day (morning and evening) on face
214664132|NCT07107932|DRUG|Siltartoxatug Injection (Brand name: Sintetol®)|The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
214664133|NCT07105475|DEVICE|Paired Associative Transcranial Magnetic Stimulation (TMS)|"Transcranial Magnetic Stimulation (TMS) is a non-invasive technique that uses magnetic fields to stimulate nerve cells in the brain. By placing a coil on the scalp, TMS generates magnetic pulses that induce electrical currents in specific brain regions. This can alter brain activity and potentially influence behavior and symptoms of various neurological and psychiatric conditions.~PAS involves the use of transcranial magnetic stimulation (TMS) at a low and high frequency to stimulate the prefrontal cortex at different areas of the brain. The goal is to assess its effects on cortical arousal and ADHD symptoms. Participants will receive daily sessions of this stimulation for three weeks, with the stimulation designed to influence brain activity and potentially alleviate symptoms of ADHD."
214664134|NCT07107919|OTHER|18F PET/MR|"Tracer: \^18F FAPI 04 is used in this study. A single intravenous bolus dose of 3.70-4.44 MBq/kg is administered.~• Simultaneous PET/MR Acquisition: During PET imaging, cardiac MR (CMR) is performed in the supine position. All images are acquired with ECG gating and respiratory gating, during end expiratory breath holds.~1. Cardiac Morphology and Function (Localization \& Cine):Assess cardiac structure and global/regional function~2. T2 Weighted Fat Suppressed Imaging:Evaluate myocardial edema~3. First Pass Perfusion Imaging:Quantitatively assess the extent and severity of myocardial perfusion defects~4. Late Gadolinium Enhancement (LGE): Detect and quantify myocardial necrosis and fibrosis~5. T1 Mapping (Pre and Post Contrast): Quantify myocardial interstitial fibrosis~6. T2 Mapping (Pre Contrast):Quantify myocardial edema~7. Cardiac PET Imaging:Evaluate myocardial fibrosis characteristics using \^18F FAPI PET data"
214664135|NCT07107269|OTHER|Low plant diversity beverage|Blended drink made from 3 organic vegetables (Power Greens mix)
214664136|NCT07107269|OTHER|Functional Food intervention|This is a 4oz shot made from 30 different organic vegetables and packaged in mylar pouches.
214664137|NCT06924060|BEHAVIORAL|Flywheel Resistance Training with two sets|For each training session, 4 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps french press). They will perform 2 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
214664138|NCT06924060|BEHAVIORAL|Flywheel Resistance Training with four sets|For each training session, 4 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps french press). They will perform 4 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
214852450|NCT04829760|DIETARY_SUPPLEMENT|Psyllium|Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks
214852451|NCT04829760|DIETARY_SUPPLEMENT|Coarse wheat bran|Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks
214852452|NCT04829760|DIETARY_SUPPLEMENT|Maltodextrin|Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (\~2 tablespoons) in two doses each day for 8 weeks
214852453|NCT00203541|DEVICE|TELFA™ A.M.D. Island dressing|
214852454|NCT04686513|OTHER|Observation|observational study
214852455|NCT02433119|DRUG|OROSARTAN® 5/160mg|
214852456|NCT02433119|DRUG|CODIOVAN® 160/12.5mg|
214852457|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and L-PRF + GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR +/- LPRF
214852458|NCT05681754|PROCEDURE|Experimental: RCT using conventional sealer and L-PRF + GTR|Endodontic treatment with conventional sealer followed by periodontal treatment with PRF + GTR
214852459|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR only
214852460|NCT05681754|PROCEDURE|Active Comparator: RCT using conventional sealer and GTR (bone substitute + collagen membrane)|Endodontic treatment with conventional sealer followed by periodontal treatment with GTR only
214852461|NCT04722328|DIAGNOSTIC_TEST|CSF metagenomic next generation sequencing (mNGS)|TestCSF routine, biochemical, smear staining (Gram staining, acid fast staining, ink staining), culture and mNGS。
214852462|NCT00132054|DRUG|amrubicin hydrochloride|
214852463|NCT00132054|DRUG|irinotecan hydrochloride|
214852464|NCT05790954|OTHER|Guided imagery|Three days before the cesarean section, the participants will be given a guided imagery audio recording and will be asked to listen to it before going to bed every evening until the day of the cesarean section. On the morning of the cesarean section, after the patient is prepared, the guided imagery audio recording will be played again.
214852465|NCT04623021|DRUG|Nafamostat Mesilate|Administered intravenously as a continuous infusion
214852466|NCT03998579|OTHER|The CanMoRe programme|An exercise intervention in Primary Health Care
214852467|NCT03998579|OTHER|Home exercise|An active control group
214852468|NCT03186703|BEHAVIORAL|Tailored knowledge translation|Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
214852469|NCT01321021|DRUG|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg
214852470|NCT06616168|DIAGNOSTIC_TEST|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest)|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features
214852471|NCT06616168|DRUG|Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)|Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
214852472|NCT06616168|COMBINATION_PRODUCT|Suppositoria for vaginal microflora recovery (Giynoflor)|Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.
214852473|NCT06616168|DRUG|Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)|Prescription of antifungal drugs. Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most
214852474|NCT04221607|OTHER|Sensate Focus exercise|Structured exercise to enhance intimacy
214852475|NCT03500042|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
214852476|NCT00355472|DRUG|KW-0761|IV administration at 4 escalating dose levels.
214852477|NCT02733952|DRUG|Tranexamic Acid|
214852478|NCT02733952|PROCEDURE|Pericervical Tourniquet|
214852479|NCT04551820|PROCEDURE|Regular Hours|The regular hours cohort includes cholecystectomies performed during the day shift at the Institution during Monday through Friday, not inclusive of national holidays.
214852480|NCT04551820|PROCEDURE|After Hours|The after hours cohort includes cholecystectomies performed outside of the day shift at the Institution during Monday through Friday, on the weekend, or during a national holiday.
214852481|NCT04551820|DEVICE|Robotic-assisted Cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
214852482|NCT00093184|DRUG|Angiomax (bivalirudin) anticoagulant|
214852483|NCT02640365|DRUG|MM-398|unresectable Advanced non-colorectal cancer
214852484|NCT02640365|DRUG|Irinotecan|unresectable metastatic colorectal cancer
214852485|NCT02640365|DRUG|Leucovorin (LV)|unresectable metastatic colorectal cancer
214852486|NCT02640365|DRUG|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
214852487|NCT02640365|DRUG|bevacizumab|unresectable metastatic colorectal cancer
214852488|NCT02640365|DRUG|MM-398|unresectable metastatic colorectal cancer
214852489|NCT02605252|DRUG|Peginterferon alfa-2b|peginterferon alfa-2b 80 micrograms/week for 48 weeks
214852490|NCT02959476|DRUG|Ropivacaine|Anesthetic
214852491|NCT02959476|DRUG|Placebos|Inactive comparator
214852492|NCT02269631|BEHAVIORAL|Legume diet group|about 1 1/2 cups of legumes included in lunch and dinner meals
214852493|NCT02269631|BEHAVIORAL|Control diet group|no legumes in lunch or dinner meals
214852494|NCT02269631|DEVICE|Smartpill|to assess how long food takes to pass through the digestive system
214852495|NCT02269631|OTHER|legumes|about 1 1/2 cups of legumes included in lunch and dinner meals
214852496|NCT01974882|OTHER|Ice pack|Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
214852497|NCT04944082|DRUG|Ivermectin|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
214852498|NCT00688402|DRUG|AZD3355|Single dose
214852499|NCT01803269|DRUG|topotecan hydrochloride|Given IV
214852500|NCT01803269|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
214852501|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops|
214852502|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops placebo|
214852503|NCT04952831|OTHER|diffusion MRI (dMRI)|All participants underwent dMRI scan at baseline
214852504|NCT05931120|DEVICE|Dry needling|"dry needling using 50mm or 60mm sized needles based on individual muscle bulk. Targeted dry needling will be performed on the muscles presenting with tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
214852505|NCT05931120|DEVICE|IASTM|"Instrument assisted soft tissue mobilization tools targeting tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
214852506|NCT03793920|OTHER|Facial Emotion Test|All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
214852507|NCT04647383|DRUG|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
214852508|NCT04647383|DRUG|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
214852509|NCT04647383|DRUG|Placebo|COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
214852510|NCT04647383|DRUG|Lemborexant 10 mg|COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
214852511|NCT01974128|PROCEDURE|ASC isolation and implantation|This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy
214852512|NCT01176019|DEVICE|Information about Prenatal Screening and Diagnosis|15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
214852513|NCT00254020|DRUG|Citalopram|Patients who are found to have major depression will be referred to a psychologist
214852514|NCT04483531|DRUG|Odevixibat|A4250 is a small molecule and selective inhibitor of IBAT
214852515|NCT02602834|OTHER|interval training|4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
214852516|NCT02602834|OTHER|moderate exercise|30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
214852517|NCT00873119|DRUG|belinostat, carboplatin, paclitaxel|
214852518|NCT00873119|DRUG|carboplatin, paclitaxel|
214852519|NCT00127517|DRUG|peptide-nucleic acid solution AVR118|
214290336|NCT04597996|OTHER|web based education for students|"Web-based education will include modules on the following subjects;~* Mental health literacy knowledge level~* Improving help-seeking behavior~* Avoiding self-stigmatization in seeking psychological help"
214664139|NCT06924060|BEHAVIORAL|Flywheel Resistance Training with six sets|For each training session, 4 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps french press). They will perform 6 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
214852520|NCT03803033|OTHER|Clinical pharmacy-based home medication management review service|A baseline interview by the clinical pharmacist was conducted with patients at their homes to assess their use of treatment and to collect all relevant information needed to identify TRPs. Upon TRP identification at baseline, the clinical pharmacist generated a written report of findings and recommendations, which was delivered directly to the patient's physician in a sealed envelope. Patients were asked to refer back to their physicians if they required confirmation of any changes in treatment. Physicians maintained the blinding of patients with regard to whether changes were based on recommendations by the pharmacist. In both the intervention and the control groups, the clinical pharmacist performed a follow-up interview with patients 3 months after the initial interview, during a regular follow-up visit to their physician at the hospital. Assessments in the follow-up interview, regardless of the study group, involved changes in treatment and number of TRPs.
214852521|NCT01367717|DIETARY_SUPPLEMENT|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
214664140|NCT06936605|DRUG|RGD Peptide|RGD peptide is an integrin binding site
214664141|NCT04067661|BEHAVIORAL|CHIP|The couples-based HIV prevention intervention consists of four couples counseling sessions focused on relationship skills to decrease HIV risk behaviors.
214664142|NCT04067661|BEHAVIORAL|Control|Enhanced standard of care, which includes information and referrals on HIV risk and prevention.
214664143|NCT03809624|DRUG|INBRX-105 - PDL1x41BB antibody|The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
214664144|NCT03809624|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
214664145|NCT00798512|DEVICE|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
214664146|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in intervention group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
214290337|NCT04085133|DIAGNOSTIC_TEST|Gene Xpert Chest x ray and MSCT chest|Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis
214290338|NCT02715076|OTHER|Ambient Temperature 19°C|Ambient Temperature 19°C
214852522|NCT01367717|DIETARY_SUPPLEMENT|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
214852523|NCT01418677|DRUG|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
214852524|NCT01418677|DRUG|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
214852525|NCT01418677|DRUG|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
214852526|NCT02378051|BEHAVIORAL|Staying Strong with Schools Intervention|"1. On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.~2. Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her."
214852527|NCT02378051|OTHER|Waitlist Control|Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
214852528|NCT00373191|DRUG|chemotherapy|N/A- not dictated by study
214852529|NCT00373191|DRUG|endocrine therapy|N/A- not dictated by study
214852530|NCT00373191|GENETIC|DNA methylation analysis|laboratory analysis
214852531|NCT00373191|GENETIC|protein analysis|laboratory analysis
214852532|NCT00373191|OTHER|laboratory biomarker analysis|laboratory analysis
214852533|NCT00373191|OTHER|questionnaire administration|questionnaire
214852534|NCT00373191|PROCEDURE|adjuvant therapy|N/A- not dictated by study
214852535|NCT00373191|PROCEDURE|conventional surgery|N/A- not dictated by study
214852536|NCT00373191|RADIATION|radiation therapy|N/A- not dictated by study
214852537|NCT00004481|PROCEDURE|genetic testing|
214852538|NCT05603455|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis|Supplement with Bifidobacterium adolescentis twice/day in morning and tonight for 6 months
214852539|NCT05603455|DIETARY_SUPPLEMENT|Placebo|Placebo
214852540|NCT04844021|BEHAVIORAL|Nudge|"EHR-based nudge"
214852541|NCT04844021|BEHAVIORAL|Nudge+|"EHR-based nudge plus facilitation"
214852542|NCT02610764|PROCEDURE|Blood Test for CTC evaluation|
214852543|NCT06502652|OTHER|hippotherapy|A hippotherapy simulator is a horse riding simulator exercise machine, mimicking a horse's gait and recreating the horseback riding experience within the safety of a therapy clinic. Child with down syndrome will be seated on the stimulator for 10-15 minutes every session. The patient's pelvis moves softly, rhythmically, and repetitively when riding this action is comparable to what the human pelvis does when walking normally
214852544|NCT06502652|OTHER|balance training|The therapist modified the railing height to suit each child, ensuring the children were standing erect on the treadmill. Treadmill training completed under three conditions in 1-min training cycles. For 15 s of each minute the child could hold on to the railings with both hands, for the next 15 s with one hand, and finally with no hands on the handrails for 30 s. Each child repeated this procedure 20 Times and cool down for 5 minutes
214852545|NCT06467552|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols.
214852546|NCT06467552|DIETARY_SUPPLEMENT|Nucare Curact group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery. In addition, the patients of control group will be instructed to take up to 4 doses of the nutritional supplement (Nucare Curact provided by DAESANG Wellife Inc.) per day for approximately 2 weeks before surgery and for about 4 weeks after surgery.
214852547|NCT03184532|DIAGNOSTIC_TEST|ultrasound|ultrasound examination of pyloric antrum
214852548|NCT00809315|OTHER|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
214852549|NCT00809315|BEHAVIORAL|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
214852550|NCT03984045|DRUG|Lidocaine topical|Intranasal 2% lidocaine delivered directly to SPG
214852551|NCT03984045|DRUG|Prochlorperazine Injection|intravenous prochlorperazine at 0.15mg/kg max 10 mg
214852552|NCT00914979|DEVICE|AngioSculpt|The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
214852553|NCT01353846|OTHER|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
214852554|NCT01353846|DRUG|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
214852555|NCT00147160|DRUG|Temozolomide, Cisplatinum|
214852556|NCT00990847|DRUG|Procaterol, Salbultamol|
214852557|NCT01216657|DRUG|Sunitinib|50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
214852558|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
214852559|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
214852560|NCT01258101|DRUG|ribavirin|800 mg orally daily
214852561|NCT01258101|DRUG|ribavirin|400 mg orally daily
214852562|NCT00603863|BIOLOGICAL|IMMU-107 (hPAM4)|90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
214852563|NCT06234319|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary glioma will receive a CXCR4 PET imaging.
214852564|NCT05393063|DRUG|AK127|Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
214852565|NCT01807117|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
214852566|NCT01807117|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
214852567|NCT01807117|PROCEDURE|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
214852568|NCT01807117|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
214852569|NCT05396664|BEHAVIORAL|ATWA|The Adolescent Transition in West Africa (ATWA) program is an in-school (Niger, Mali, Burkina Faso) and out-of-school (Niger and Mali) educational intervention implemented by local staff members at Save the Children, local community members, and teachers. ATWA provides internationally-recognized life skills education (LSE) to adolescents ages 10-19 years, and seeks to improve adolescents' knowledge and behaviors regarding sexual and reproductive health and rights. Outcome indicators to assess knowledge, behavior and attitudes of adolescents will vary by adolescent demographics as well as by country context, as based on the final set of curriculum deemed appropriate by the respective Ministries of Education (MOE).
214852570|NCT00577148|DRUG|Rimonabant|Tablet, oral administration
214852571|NCT00577148|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
214852572|NCT00992368|PROCEDURE|reduction mammaplasty|patients submitted to reduction mammaplasty
214852573|NCT02036450|DEVICE|Implantable loop recorder (Medtronic Reveal LINQ(TM))|The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, OAC is initiated. Decision about specific type of OAC, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.
214852574|NCT04126616|DIAGNOSTIC_TEST|chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent|chest MRI will be performed at rest and after moderate exercise
214852575|NCT04136418|DEVICE|COPDPredict mobile App|An App on a mobile device is used by the patient to track the status of their COPD and inform the patient's care team
214852576|NCT04136418|OTHER|Usual care|Patients self-manage their COPD using prescribed medication in accordance with basic guidance information
214852577|NCT00933959|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
214852578|NCT00933959|BEHAVIORAL|Sleep Hygiene|Treatment as usual
214852579|NCT03560687|DRUG|Sucrosomial Iron|CardioSideral 2 caps per day
214852580|NCT03349359|DRUG|HIV antiretroviral therapy|HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
214852581|NCT06617442|PROCEDURE|Pulmonary vein isolation|First pulmonary vein isolation performed for atrial fibrillation.
214852582|NCT04859036|DIAGNOSTIC_TEST|24 hours ambulatory Holter monitoring|
214852583|NCT00649727|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
214852584|NCT00649727|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
214852585|NCT01659164|BEHAVIORAL|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
214852586|NCT02463799|DRUG|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
214852587|NCT02463799|BIOLOGICAL|Sipuleucel-T|3 infusions of sipuleucel-T alone
214852588|NCT00379990|DRUG|GW274150|60 mg /day
214852589|NCT00379990|DRUG|Prednisolone|7.5 mg/day
214852590|NCT00379990|OTHER|Placebo|Placebo
214852591|NCT02215668|PROCEDURE|Physical exercise|Exercise muscle stretching and body warming.
214852592|NCT02243293|DRUG|ABT-493|Tablet
214852593|NCT02243293|DRUG|ABT-530|Tablet
214852594|NCT02243293|DRUG|ribavirin (RBV)|Tablet
214852595|NCT02243293|DRUG|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
214290339|NCT02715076|OTHER|Ambient Temperature 21°C|Ambient Temperature 21°C
214290340|NCT02715076|OTHER|Ambient Temperature 23°C|Ambient Temperature 23°C
214852596|NCT05585931|DRUG|TPN171H 10mg|Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
214852597|NCT05585931|DRUG|TPN171H Placebo|Subjects were given Placebo with 240 mL warm water under fasting condition.
214852598|NCT03026855|BIOLOGICAL|Autologous PRP Gel and PRP Injection|"Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.~Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.~Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment."
214852599|NCT02181296|DRUG|ropivacaine|
214852600|NCT02507817|OTHER|blood sample and tissue sample|"Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein"
214852601|NCT04955015|PROCEDURE|carotid endarterectomy|patients with carotid atherosclerosis refering to CEA
214852602|NCT06416917|DEVICE|bubble inclinometer|to measure range of motion
214852603|NCT03492658|DRUG|Abatacept|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
214852604|NCT03492658|DRUG|Methotrexate|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
214852605|NCT03839277|DEVICE|Endocuff Vision|Endocuff Vision is attached to the tip of colonoscope before intubation.
214852606|NCT02278419|DRUG|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
214852607|NCT02278419|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
214852608|NCT05472402|BEHAVIORAL|LADIES online intervention (R33 phase)|Participants will participate weekly online group sessions over 6 months. Participants will also receive access to written intervention materials, access to an online walking program, and access to weekly podcasts that are aligned with the intervention sessions and that support physical activity lessons with biblical scriptures.
214852609|NCT05472402|BEHAVIORAL|LADIES online control (R33 phase)|Participants will receive online access to a written self-guided curriculum that is self-paced and teaches participants how to increase physical activity. Participants will be encouraged to complete the self-guided curriculum within 6 months.
214852610|NCT04978116|DIAGNOSTIC_TEST|Chest X-Ray (CXR)|"The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm."
214852611|NCT04978116|DIAGNOSTIC_TEST|Low-dose CT scan (LDCT)|See above in CXR paragraph
214852612|NCT04978116|DIAGNOSTIC_TEST|Lung ultrasonography (LUS)|See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient
214852613|NCT06928740|OTHER|Music Care® device|Installation of the Music Care® device, selection of the sequence based on the patient's musical taste, listening to at least 20-minute sequence in the preparation room. Once placed on the scanner table, the patient listens to the same sequence as in the preparation room.
214852614|NCT06928740|OTHER|EMONO|Equimolar mixture of oxygen and nitrous oxide given as usual care
214852615|NCT02406794|DRUG|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
214852616|NCT06453525|OTHER|intubation|Tracheal intubation using one of the three existing videolaryngoscopes
214852617|NCT06456372|BEHAVIORAL|Digital Health Intervention Group|Our digital health intervention (DHI) uses Patient-Centered Digital Healthcare Technologies (PC-DHT) to promote co-regulation (child/parent), capture patient data, support efficient healthcare delivery, enhance patient engagement, and facilitate shared decision-making, thereby improving access to timely and targeted mental health intervention for children at great risk for poor outcomes. This system will integrate treatment across multiple points of care and will enable health care providers and caregivers to share reliable and targeted information that will facilitate collaborative decision-making (e.g., making decisions about changing or titrating medications/dosages or shifting behavioral therapy and educational intervention targets) and improve patient experiences and outcomes.
214852618|NCT06483282|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
214852619|NCT06483282|DRUG|Apatinib Mesylate|This product is an orally administered targeted therapy drug, with a recommended dosage of one tablet per day.
214852620|NCT06483282|DRUG|Etoposide|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 100mg/m2, administered every 3 Weeks (Q3W).
214852621|NCT06483282|DRUG|Carboplatin|This product is administered by intravenously guttae. AUC=5, administered every 3 Weeks (Q3W).
214852622|NCT02658487|DRUG|Cytarabine|Given IV
214852623|NCT02658487|DRUG|Vosaroxin|Given IV
214852624|NCT06147440|OTHER|Dietary intervention|Participants receive diets following different dietary patterns for 1 week.
214852625|NCT04237623|DRUG|Sargramostim|250mcg/m2/day IV starting Day +5
214852626|NCT04237623|OTHER|Control Arm|Standard G-CSF given to those who decline to receive GM-CSF
214852627|NCT03055741|DRUG|Donepezil|5mg or 10mg, once a day, 24 weeks
214852628|NCT03055741|DRUG|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
214852629|NCT03055741|DRUG|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
214852630|NCT03216109|BEHAVIORAL|Weekly telephone symptom assessment|Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
214852631|NCT04734834|DIETARY_SUPPLEMENT|"Prodovite® VMP35"|"Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo"
214852632|NCT06308133|OTHER|apheresis procedure|collection of hematopoietic stem cells carried out using the single-chamber and continuous mononuclear cell (cMNC) collection system with Spectra Optia (Terumo BCT)
214852633|NCT01300624|BEHAVIORAL|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
214852634|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part A)|20 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
214852635|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part B)|250 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
214852636|NCT05576623|OTHER|Placebo (Part B)|50 participants will receive placebo via intramuscular injection in the deltoid muscle
214852637|NCT03707041|DRUG|P218 (1000 mg) Oral Capsules|1000 mg P218 (4 x 250 mg capsules)
214852638|NCT03707041|DRUG|Placebo Oral Capsules|Placebo capsules matched to the P218 capsules with regard to appearance and taste
214852639|NCT03707041|DRUG|P218 (100 mg) Oral Capsules|100 mg P218 (2 x 50 mg capsules)
214852640|NCT03707041|BIOLOGICAL|PfSPZ Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
214852641|NCT03245034|BEHAVIORAL|Auricular Acupuncture Therapy|"Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG)."
214852642|NCT02696941|DRUG|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
214852643|NCT02696941|DRUG|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
214852644|NCT00614926|DRUG|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
214664147|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.
214664148|NCT01756976|DEVICE|OrthoPat Advance|The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
214664149|NCT01809236|BIOLOGICAL|Conbercept|intravitreal injection of 0.5 mg Conbercept
214664150|NCT00252850|GENETIC|CERE-120: AAV2-NTN|
214664151|NCT00918723|DRUG|Fludarabine Phosphate|Given IV
214664152|NCT00918723|DRUG|Cyclophosphamide|Given IV
214664153|NCT00918723|BIOLOGICAL|Rituximab|Given IV
214664154|NCT00918723|DRUG|Vorinostat|Given PO
214664155|NCT00051844|DRUG|Capravirine|
214664156|NCT03359291|DRUG|Rosuvastatin|Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
214664157|NCT03359291|DRUG|Macitentan|Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16
214664158|NCT05581576|DRUG|Pitolisant|Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
214664159|NCT02579603|DRUG|Nintedanib|Nintedanib 150mg bid
214664160|NCT02579603|DRUG|Pirfenidone|
214664161|NCT05281315|OTHER|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.
214664162|NCT00577187|DEVICE|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
214664163|NCT01006356|DRUG|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
214664164|NCT00003554|BIOLOGICAL|rituximab|
214664165|NCT00003554|DRUG|melphalan|
214664166|NCT00003554|DRUG|prednisone|
214664167|NCT01046149|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
214664168|NCT01046149|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
214664169|NCT02265328|DIETARY_SUPPLEMENT|Bovine colostrum|Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
214664170|NCT02265328|DIETARY_SUPPLEMENT|Enteral Nutrition|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
214664171|NCT02265328|OTHER|prednisolone|Oral prednisolone 40mg/day × 4 weeks and tapered to \<40mg/day for next 4 weeks. (If Lilli score \> 0.45 after 7 days, then prednisolone would be stopped)
214664172|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 75 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
214664173|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 100 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
214664174|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 150 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
214664175|NCT05813821|BEHAVIORAL|Antimicrobial stewardship in surgery|"Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment \>7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team."
214664176|NCT00430040|DRUG|Carvedilol Controlled Release (CR)|"lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study.~Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at least 2 weeks to achieve target blood pressure sSBP \<130 and sDBP \< 80"
214664177|NCT00430040|DRUG|lisinopril|lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study
214852645|NCT00614926|DRUG|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
214664178|NCT02981472|DRUG|Apixaban|Specified dose on specified days
214664179|NCT02981472|DRUG|Vitamin K Antagonist (VKA)|Specified dose on specified days
214852646|NCT02932020|DRUG|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
214852647|NCT02932020|DRUG|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
214852648|NCT02932020|DEVICE|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
214852649|NCT02932020|DRUG|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
214852650|NCT00809237|DRUG|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
214852651|NCT02354911|BIOLOGICAL|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (\~10 million cells/injection).
214852652|NCT02354911|OTHER|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
214852653|NCT02242318|DRUG|Telmisartan|
214852654|NCT02242318|DRUG|Valsartan|
214852655|NCT02242318|DRUG|Placebo|
214852656|NCT04625192|PROCEDURE|Trephine osteotomy|"* Using a trephine on a straight implant handpiece (at approximately 1800 rpm) with copious irrigation to avoid overheating the bone, a round bone cut will be made 4 -5 mm above the crest of the alveolar ridge.~* The trephine is positioned perpendicular to the lateral wall, removing the outer cortex with a very gentle touch to avoid tearing the schneiderian membrane."
214852657|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
214852658|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
214852659|NCT04669717|DRUG|1/d 500 mg Azithromycine Pfizer for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
214852660|NCT00312819|DRUG|chemotherapy +/- disulfiram|
214852661|NCT00118378|DRUG|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
214852662|NCT00118378|DRUG|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
214852663|NCT04969042|DEVICE|Pins Medical G122 RS|G122RS model implanted spinal cord stimulation device, which could give closed-loop functional stimulation in the epidural space
214852664|NCT00345020|PROCEDURE|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
214852665|NCT04461132|OTHER|Manual Lymphatic drainage (MLD)|MLD vith vodder technique was applied to leg
214852666|NCT04461132|OTHER|Skin Care|Wound was cleaned with salin and covered by dressing without including active products
214852667|NCT04461132|OTHER|Exercise|breathing and foot pump exercise was prescribed
214664180|NCT02981472|DRUG|Low Molecular Weight Heparin (LMWH)|Specified dose on specified days
214852668|NCT04461132|OTHER|Shame Manual Lymphatic drainage|manual lymphatic drainage was applied with light touch instead of real mld techniques
214852669|NCT05017779|BEHAVIORAL|Unstuck & On Target: High School|Unstuck \& On Target: High School (UOT:HS) is a group-based curriculum for high school students that targets executive function skills using Cognitive Behavior Therapy (CBT) techniques. UOT:HS focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Lessons are delivered by school personnel within the school setting. Home extension activities are provided to parents.
214852670|NCT05017779|OTHER|Treatment as Usual|Participants in schools assigned to the Treatment as Usual (TAU) condition will continue to receive the standard school-based IEP accommodations and school supports that would typically be provided. Data will be collected on the types of supports TAU schools offer, and what supports TAU students receive.
214664181|NCT06146114|DIAGNOSTIC_TEST|Collect HER2 expression in prostate cancer patients|HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
214664182|NCT00335712|DRUG|ONO-5129|
214852671|NCT00209287|BEHAVIORAL|Observe patients with inactive ulcerative colitis|Observe patients with inactive ulcerative colitis
214852672|NCT01032772|BEHAVIORAL|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
214664183|NCT01756157|BIOLOGICAL|CINRYZE with rHuPH20|
214664184|NCT02860793|OTHER|Bone marrow aspiration|
214664185|NCT02860793|OTHER|Blood sampling|
214852673|NCT01032772|BEHAVIORAL|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
214852674|NCT05707143|OTHER|home based stabilization exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
214852675|NCT05707143|OTHER|kegel exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
214852676|NCT01582984|OTHER|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
214852677|NCT05964790|DRUG|HS-10380|Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days
214852678|NCT05964790|DRUG|Placebo|Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days
214852679|NCT00826579|PROCEDURE|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
214852680|NCT00826579|PROCEDURE|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
214852681|NCT01790035|DRUG|LGG|
214852682|NCT01790035|DRUG|Placebo|
214906993|NCT05354167|OTHER|muscle energy technique|the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session; this technique was applied in 2 sessions for a week for 4 weeks.
214852683|NCT00856830|DRUG|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~* All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~* At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks."
214852684|NCT04642859|BEHAVIORAL|Computerized Cognitive abilities training battery for reading (CATB-R)|Specially designed Arabic computerized training program for dyslexia
214852685|NCT02978820|OTHER|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
214852686|NCT02978820|OTHER|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
214852687|NCT03580174|OTHER|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed therapy protocol one hour in a session, 2 times in a week during 8 weeks. GDPT will be a structural protocol and consists of daily life activities as sit to stand and reach, treadmill exercises, balance exercises with bosu-ball, orthotics, home program, following with exercise-diary.
214852688|NCT03580174|OTHER|Routine physiotherapy group|Ten children with CP will RPT applications will consist of unstructured stretching exercises, massage, passive range of motions, muscle strengthening, orthotics etc.) one hour in a session, 2 times in a week during 8 weeks.
214852689|NCT04927026|BEHAVIORAL|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|The WIPT include weekly face-to-face group sessions including mindfulness-based training and solution focused brief therapy (SFBT) involving psychoeducation and structured life review therapy catered to the personal needs of the participants.
214852690|NCT00336765|DRUG|XL647|Tablets supplied in 50-mg strength administered orally daily
214852691|NCT01025674|BEHAVIORAL|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
214852692|NCT02904499|DRUG|Dabigatran|
214852693|NCT04344197|OTHER|global survey|surgery questionnaire
214852694|NCT00207194|BEHAVIORAL|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
214852695|NCT00207194|BEHAVIORAL|Health Behavior Education|Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
214664186|NCT03351673|DIAGNOSTIC_TEST|endometrial volume 2D TVS|calculation the endometrial volume using 2D ultrasound and correlation the results with the pathological findings of endometrial biopsy
214664187|NCT00001515|DEVICE|virtual bronchoscopy|
214664188|NCT04191668|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
214664189|NCT03397186|PROCEDURE|Biopsy|Undergo biopsy
214664190|NCT03397186|OTHER|Laboratory Biomarker Analysis|Correlative studies
214664191|NCT03397186|DRUG|Trabectedin|Given as standard of care
214664192|NCT04154540|OTHER|Motion analysis|Gait and posture recording
214664193|NCT05285852|OTHER|Dry Needling|Dry needling technique is maneuvered by different skilled health practitioners aiming to reduce central sensitization, i.e., the hypersensitivity to pain of the central nervous system. It is also apprehended to reduce the local and referred pain, and improve the muscle activation patterns leading to improved range of motion.
214664194|NCT05285852|OTHER|Placebo Dry Needling|Placebo Dry Needling only causes a pricking sensation
214664195|NCT03636828|DIAGNOSTIC_TEST|ultrasonographic measurement of gastric antral cross-sectional area|Each participant fasted for 10 hours and subjected to a baseline gastric ultrasound and serial sonographic gastric evaluations was performed every hour after 2 hours of the ingestion of a 420 g, 536 Kcal rice-based meal (bibimbap) until the stomach was completely empty.
214664196|NCT02693977|PROCEDURE|Sleep Endoscopy|Sleep endoscopy will be performed prior to the adenotonsillectomy, under the same general anesthetic. The endoscopy will be performed using a flexible fiber optic endoscope which will be advanced trans nasally into the pharynx down to the level of the hypopharynx. We will take note of any obvious septal deviation or nasal obstruction as well as adenoid hypertrophy, and dynamic collapse at the level of the velum, oropharynx/lateral walls, tongue base, epiglottis, and supraglottis. Relatively fixed structures such as the nasal airway and adenoids should require 1 minute to fully assess. The endoscope will then be held for 2 minutes of observation above each subsequent site of potential dynamic airway collapse (the velum, oropharynx/lateral walls, tongue base, epiglottis/supraglottis).
214664197|NCT01498991|DEVICE|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
214664198|NCT01759303|DRUG|pazopanib|"For subjects \> 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA \< 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
214664199|NCT05906446|OTHER|Multicomponent (Exercise + Protein Supplementation)|"* Exercises selected from a pre-specified list, reassessed weekly~* Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week)~* Participants will also be offered a protein supplement within 30 min of exercise.~* Sessions will be supervised"
214664200|NCT01728259|DRUG|pomalidomide|Given PO
214664201|NCT01728259|DRUG|bortezomib|Given IV
214664202|NCT01728259|DRUG|dexamethasone|Given PO
214664203|NCT01728259|OTHER|Laboratory Biomarker Analysis|Correlative studies
214664204|NCT02907944|BEHAVIORAL|Implementation Facilitation|"Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.~* External Facilitator: Outside content expert who assists site~* Local Champion: Site stakeholder who promotes change~* Provider Education and Academic Detailing: Provision of unbiased peer education~* Stakeholder Engagement: Aligning goals of implementation and those impacted~* Tailor Program to Site: Addressing site specific needs based on Aim 1~* Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results~* Formative Evaluation: Quant. and qual. determination of impact~* Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders~* Program Marketing: Increase attention to availability of on-site addiction treatment services"
214664205|NCT03255278|BIOLOGICAL|Single GamTBvac vaccination (0.25 dose)|Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
214664206|NCT03255278|BIOLOGICAL|Placebo administration|Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
214664207|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.25 dose)|Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
214664208|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.5 dose)|Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
214664209|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (1.0 dose)|Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
214664210|NCT00275379|DRUG|ERB-041|
214664211|NCT04430348|DRUG|PTX-35|Monoclonal antibody PTX-35
214664212|NCT05395169|OTHER|dietary supplement ,electronic treadmill ,DASH diet.|Control group Will be receive medical treatment for 12 weeks. Study group Will be receive the same medication as in control group in addition to DASH diet and aerobic exercise for 12 weeks.
214664213|NCT04086303|OTHER|LSST test|LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
214664214|NCT05414968|DEVICE|Non-pharmacological Heat, Pressure, and Vibration|The innovation central to this approach is in the multifactorial combination of pressure, heat, and vibration stimuli to improve foot sensation. The heat stimuli will be provided with commercially available heating elements. The pressure stimuli will be provided via pneumatic garment. Lastly, the vibrotactile stimuli will be provided with commercially available vibrotactile motors. The non-pharmacological DPN device will be able to safely and consistently control temperature to 100-105°F within 1°F, control pressure to 50 mmHg within 5 mmHg at 0.25 Hz, and provide 5 distinguishable vibrational stimuli to 5 zones on the leg and foot.
214664215|NCT00368368|DRUG|GK Activator (2)|100mg po
214664216|NCT04038775|BEHAVIORAL|Volunteering|Subjects recommended volunteer by their provider.
214664217|NCT06512701|OTHER||This study is an observational study without any intervention measures.
214664218|NCT01144546|PROCEDURE|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
214664219|NCT03341403|DIETARY_SUPPLEMENT|Probiotical®/Bactecal®|"Probiotical/Bactecal® is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill."
214664220|NCT03341403|OTHER|Placebo|pills containing placebo
214664221|NCT03623269|PROCEDURE|posterior approach to total shoulder arthroplasty|The posterior approach to total shoulder arthroplasty approaches the patient from the back of the shoulder and spares the rotator cuff.
214664222|NCT02933515|OTHER|yoga and occupational therapy|group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
214664223|NCT03133897|DRUG|Dexamethasone|experimental group will receive 2 day treatment
214664224|NCT03133897|DRUG|Prednisone|control group will receive 4 day treatment
214664225|NCT05182333|OTHER|Examination|History taking, examination of upper limb
214664226|NCT06394219|PROCEDURE|traditional transperitoneal laparoscopic pyelolithotomy|Performing anterior Pyelotomy.
214664227|NCT06394219|PROCEDURE|modified transperitoneal laparoscopic pyelolithotomy|Performing posterior pyelotomy
214664228|NCT06379295|OTHER|Questionnaire|Self-administered questionnaire to assess the participants risk factors, history of heart disease and medications.
214664229|NCT04187820|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
214664230|NCT05577754|DRUG|Alpelisib (BYL719)|Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months
214852696|NCT03935022|OTHER|Rice|"Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~1. 80g of black rice Venere (Group A)~2. 80g of black rice Artemide (Group B)~3. 80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration."
214852697|NCT03274622|BEHAVIORAL|Impact Parent Training|
214852698|NCT03274622|BEHAVIORAL|No Impact|
214852699|NCT03131622|BEHAVIORAL|Digital Therapeutics|
214852700|NCT03142035|DRUG|Dienogest 2 MG|Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
214852701|NCT03142035|DRUG|gonapeptyl|gonadotropic releasing hormone agonist
214852702|NCT03142035|PROCEDURE|IVF/IVF+ART|In-vitro fertilization +/- assisted reproductive technology
214852703|NCT04832126|GENETIC|Genetic analysis|Genomic DNA will be purified from peripheral blood or mouth swabs. Whole blood will be collected by peripheral phlebotomy in tubes containing K2EDTA as an anticoagulant. Blood samples will be stored at 4-8 oC for up to a week before DNA purification. Mouth swabs will be collected using the ORAcollect • DNA kit (OCR-100) (DNA Genotek Inc., Canada). Genomic DNA from whole blood or mouth swab samples will be purified using DNeasy Blood \& Tissue Kit (QIAGEN).
214852704|NCT01914068|OTHER|Supervised exercise in hospital|
214852705|NCT00027794|PROCEDURE|conventional surgery|
214852706|NCT01494935|BEHAVIORAL|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
214852707|NCT01494935|BEHAVIORAL|Control diet|Normal fat, normal fat diet
214852708|NCT05386524|DRUG|sintilimab|sintilimab 200mg, ivgtt，d1
214852709|NCT05386524|DRUG|bevacizumab biosimilar|bevacizumab biosimilar 15mg/kg，ivgtt d1
214852710|NCT05386524|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 30mg/m2 d1，q3w
214852711|NCT02834806|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent System|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
214852712|NCT02954159|DRUG|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
214852713|NCT02954159|DRUG|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
214852714|NCT02954159|OTHER|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
214852715|NCT01311752|PROCEDURE|surgical management of high grade lesions|"Clinical, pathological and biological, data at diagnosis and during follow-up will be collected.~Surgical sample will be collected to study human papillomavirus related genital pathology."
214852716|NCT05695092|BEHAVIORAL|Progressive muscle relaxation|Progressive Muscle Relaxation (PMR): This method involved efficiently relaxing global muscles of body with the objective of mental and physical relaxation.
214852717|NCT05695092|OTHER|control|control group will not receive any intervention
214852718|NCT04815330|OTHER|increment sweep gas flow|If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
214852719|NCT04815330|OTHER|non-invasive ventilation|In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
214852720|NCT03465748|DEVICE|OrthoK|orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
214852721|NCT04094948|DRUG|Clenbuterol|20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
214852722|NCT04094948|DRUG|Placebos|dextrose-filled capsules
214852723|NCT00004748|DRUG|colchicine|
214852724|NCT00004748|DRUG|methotrexate|
214852725|NCT00004748|DRUG|ursodiol|
214852726|NCT05404412|PROCEDURE|Epidural Steroid Injection|This intervention is applied mostly for cervical or lumbar radiculopathy. The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then a combined local anesthetic and glucocorticoids are delivered to the epidural space.
214852727|NCT05518448|DIETARY_SUPPLEMENT|Ketone - beta-hydroxybutyrate (β-OHB)|Ketone - beta-hydroxybutyrate (β-OHB)
214852728|NCT01699386|OTHER|Control Study Formula|feed as lib
214852729|NCT01699386|OTHER|Experimental Study Formula|feed as lib
214852730|NCT02596321|DRUG|Mitizax|Allergen extract
214852731|NCT02596321|DRUG|Placebo|Placebo tablet
214852732|NCT02221908|DEVICE|Mespere Venus 1000 CVP System|
214852733|NCT01780779|OTHER|MRI|"MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment."
214852734|NCT06414239|DEVICE|Use of a VR mask|Virtual reality mask
214852735|NCT06414239|OTHER|Standard of care|Without any premedication or anesthesia
214852736|NCT04244201|DEVICE|Vaporous Hyperoxia Therapy|1 hour of treatment, 4 times per week
214852737|NCT03946020|PROCEDURE|Guided bone regeneration with or without autologous bone|Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
214852738|NCT02314572|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
214852739|NCT01231750|DRUG|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
214852740|NCT01231750|OTHER|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
214852741|NCT06304935|OTHER|Use of injectable platelet rich fibrin after tonsillectomy by injection of IPRF in one tonsillar bed and use of other side as control|Compare both sides of tonsillar beds in post operative healing, pain and hemostasis
214852742|NCT05378919|RADIATION|Radiotherapy 50 Gy|Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks
214852743|NCT05378919|DRUG|Fluorouracil/folic acid|Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
214852744|NCT05378919|DRUG|Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)|oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
214852745|NCT05378919|RADIATION|Radiotherapy 50 Gy|"Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil."
214852746|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 20º|With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
214852747|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 60º|With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
214852748|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 20º|With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
214852749|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 60º|With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
214852750|NCT00004402|DRUG|calcitriol|
214852751|NCT00004402|DRUG|interferon gamma|
214852752|NCT01117337|PROCEDURE|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
214852753|NCT03232099|DIETARY_SUPPLEMENT|Red Wine consumption|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
214852754|NCT03232099|OTHER|Period without alcohol consumption|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
214852755|NCT03575871|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
214852756|NCT03575871|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
214852757|NCT03575871|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
214852758|NCT03236142|PROCEDURE|SIPS Operation|The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
214852759|NCT03236142|PROCEDURE|Standard Duodenal Switch Operation|
214852760|NCT06341049|PROCEDURE|Intraperitoneal local anasthetic application + local anesthetic wound infiltration|For Group Intraperitoneal local anasthetic+ loal anesthetic wound infiltration, after the birth of the newborn and placenta, the uterus is taken out and closed, the blood accumulated in the pelvis is carefully wiped with surgical towels, and after complete hemostasis is achieved, sterilely prepared 20 ml 0.5% bupivacaine + 20 ml 2% lidocaine +1 A total of 40 ml of solution containing 200,000 epinephrine will be given to the surgeon. 10 ml of this solution will be instilled into all four quadrants of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer will be sutured or left open, depending on the surgeon's preference. 10 ml will be infiltrated around the edges of the rectus aponeurosis, and the remaining 20 ml will be infiltrated subcutaneously into the wound area.
214852761|NCT06341049|PROCEDURE|Intrathecal morphine application|Group Morphine will be given 11.2 mg hyperbaric bupivacaine + 15 µg fentanyl + 150 µg morphine into the spinal space.
214852762|NCT06341049|PROCEDURE|Quadratus lumborum block tip 1 application|In Group Quadratus lumborum block, Quadratus lumborum block type I, a total of 40 ml of a solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200,000 epinephrine will be applied bilaterally under ultrasound guidance.
214852763|NCT00474851|DRUG|Norethindrone acetate + estrogens|Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
214852764|NCT00474851|DRUG|norethindrone acetate + placebo|norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
214852765|NCT02537847|DRUG|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
214852766|NCT02537847|DRUG|Ertapenem|Control group will be given ertapenem only for 10 days.
214852767|NCT01370135|DRUG|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
214852768|NCT06227624|DRUG|Oral zinc sulfate and standard phototherapy|study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy
214852769|NCT01563419|DEVICE|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens"
214852770|NCT00325208|DEVICE|partial-vacuum milk bottle|
214852771|NCT00325208|DEVICE|anti-vacuum milk bottle|
214852772|NCT04238832|OTHER|Salt Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home salt base nicotine
214852773|NCT04238832|OTHER|Free Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home free base nicotine
214852774|NCT03174106|DEVICE|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
214852775|NCT02791893|DEVICE|VNS device|Hand held device to use for self administration of vagus nerve stimulation.
214852776|NCT02791893|DEVICE|Inactive device|Hand held device to use for self administration of simulated vagus nerve stimulation.
214852777|NCT05964192|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|The theta burst stimulation (TBS) technique consists in administering bursts of transcranial magnetic stimulation (TMS) at very high frequency (50Hz) for 5 minutes (3 pulses of stimulation given at 50 hz; 10 bursts/1 s train; inter-train interval : 8 s; number of trains : 30; 100% resting motor threshold; number pulses/session : 900). Total number of sessions : 20 sessions (single daily session).
214852778|NCT01610739|DRUG|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
214852779|NCT03858166|DRUG|PEG-rhG-CSF|6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
214852780|NCT02467608|DRUG|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
214852781|NCT02467608|DRUG|HRZE|the same as experimental group,without the excipient of HUEXC030 only
214852782|NCT01612039|DRUG|ASP3291|Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
214852783|NCT01612039|DRUG|Placebo|Matching placebo tablets
214852784|NCT03394755|BIOLOGICAL|Thrombosomes|Freeze-dried platelets
214852785|NCT06073535|PROCEDURE|Extraction of mandibular third molar|"After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle.~An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary."
214852786|NCT06073535|DEVICE|i-PRF|20 ml of venous blood will be drawn from the ante-cubital vein of all patients and collected in 2 plastic tubes (Vacutainer, Becton\& Dickinson, Rutherford, NJ) containing no anticoagulant or gelling agent. The tubes will be placed in a centrifuge (DUO Centrifuge, Nice, France) at 700 round per minute for 3 min, at the end of which time the blood will be separated into 2 fractions: the layer of injectable liquid i-PRF, which is more superficial, and the layer of red blood cells, in the deep part. From each tube, i-PRF will be withdrawn using a sterile syringe and it will be infiltrated into the lesion.
214852787|NCT03880799|BEHAVIORAL|Mindfulness Session|one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
214852788|NCT03286478|BEHAVIORAL|Mindfulness|Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
214852789|NCT03286478|BEHAVIORAL|Dissonance|Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
214852790|NCT03286478|BEHAVIORAL|Dove Confident Me|Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
214852791|NCT05589961|DRUG|TMZ|After enrollment, temozolomide 50mg/m2 was given orally for QD until progression, and radiotherapy and PF 0.2g/ time for TID were started one week later until progression. Pembrolizumab 200mg once every 3 weeks until progression; The radiotherapy regimen depends on the patient's recurrence and initial treatment.
214852792|NCT03604107|GENETIC|Preimplantation Genetic Testing-Aneuploidy|trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined
214852793|NCT03483207|DRUG|Warfarin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
214852794|NCT03483207|PROCEDURE|MVT with failure of anticoagulation therapy|"patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded."
214852795|NCT03483207|DRUG|Heparin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
214852796|NCT01744093|DRUG|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
214852797|NCT01744093|DRUG|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
214852798|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 1|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10\^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL."
214852799|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 2|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
214852800|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 3|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
214852801|NCT04936828|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
214852802|NCT04051463|DRUG|Netarsudil Ophthalmic Solution|Netarsudil eye drops instilled once daily
214852803|NCT04051463|DRUG|Placebo|Placebo eye drops instilled once daily
214852804|NCT03982563|BEHAVIORAL|Growth Mindset|Reading and writing activities designed to instill the belief that people can change.
214852805|NCT03982563|BEHAVIORAL|Gratitude|Reading and writing activities designed to practice noticing and appreciating good things in life.
214852806|NCT03982563|BEHAVIORAL|Behavioral Activation|Reading and writing activities designed to identify and schedule positive activities.
214852807|NCT03982563|BEHAVIORAL|Study Skills|Reading and writing activities designed to learn evidence-based study strategies.
214852808|NCT04883970|OTHER|124I-18B10(10L) PET/CT|Study participants will undergo 124I-18B10(10L) PET/CT scans
214852809|NCT02527499|BEHAVIORAL|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
214852810|NCT02527499|BEHAVIORAL|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
214852811|NCT02527499|BEHAVIORAL|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
214852812|NCT02756247|DRUG|Buparlisib|
214852813|NCT02756247|DRUG|Ibrutinib|
214852814|NCT03893474|DIAGNOSTIC_TEST|OCT|Optical Coherence Tomography of study eye.
214852815|NCT03893474|DIAGNOSTIC_TEST|Visual Acuity|Visual acuity measured by ETDRS
214852816|NCT06406660|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
214852817|NCT06224166|DIAGNOSTIC_TEST|Collection and use of tissue samples, blood and saliva|"For tissue collection, tumor and surrounding tissues will be used healthy specimens taken during surgical removal, according to clinical practice. Blood and saliva sampling will be carried out at different times:~i) the day before surgery; ii) the day after surgery (only for blood); iii) at the time of patient discharge (approximately 15 days after surgery); iii) during the check-up visit scheduled to monitor the follow-up (FU)"
214852818|NCT06322394|DRUG|high-dose BXOS110|3.0 mg/kg, maximum dose not exceeding 300 mg，Participants received one administration by intravenous infusion.
214852819|NCT06322394|DRUG|low-dose BXOS110|2.0 mg/kg, maximum dose not exceeding 200 mg，Participants received one administration by intravenous infusion.
214852820|NCT06322394|DRUG|Placebo|Does not contain any test drug active ingredients，Participants received one administration by intravenous infusion.
214852821|NCT00002922|DRUG|paclitaxel|
214852822|NCT06290518|DIETARY_SUPPLEMENT|Ligilactobacillus salivarius CECT5713|Oral administration of a capsule containing 9.5 log10 cfu of the strain.
214852823|NCT06290518|DIETARY_SUPPLEMENT|Placebo|Oral administration of a capsule containing maltodextrin.
214852824|NCT02524587|DEVICE|standard polyethylene acetabular irradiated at 3 Mrad|
214852825|NCT02524587|OTHER|radio stereometric analysis (RSA) of the acetabular|
214852826|NCT02524587|DEVICE|acetabular polyethylene vitamys®|
214852827|NCT05434377|OTHER|ergocalciferol supplementation|Participants in both groups will recieve ergocalciferol with different supplementation regimens for 6 months.
214852828|NCT05434377|OTHER|dialysis techniques|Both groups will have participants treated with maintenance hemodialysis and peritoneal dialysis.
214852829|NCT05434377|OTHER|sunlight exposure time|Both groups will be advised to receive similar hours of daily sunlight exposure time.
214852830|NCT00476632|BEHAVIORAL|Questionnaire|50 Minute Interview
214852831|NCT05690087|DRUG|Lidocaine|intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation
214852832|NCT05690087|DRUG|sodium chloride 0.9% solution|intravenous sodium chloride 0.9% solution volume matched bolus and infusion.
214852833|NCT06332287|DRUG|combination of Trilaciclib and Pemetrexed|This was a single-arm, exploratory study of the combination of Trilaciclib and Pemetrexed in patients with non-small cell lung cancer with leptomeningeal metastasis. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every six cycles to assess tumor response.
214852834|NCT00558909|DRUG|BI 44847|
214852835|NCT00558909|DRUG|placebo for BI 44847|
214852836|NCT00704093|DEVICE|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
214852837|NCT04583020|DRUG|Camrelizumab|Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
214852838|NCT04583020|RADIATION|radiation|60Gy/30
214852839|NCT04583020|DRUG|Temozolomide|Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
214852840|NCT05857826|OTHER|soft tissue release|Patient will be asked to lie in hook lying position using a clean glove will apply some water based lubricant gently sweep vaginal muscle from superficial to deep until find a trigger point press it and release it using circle motion for 1 to 2 minute until the trigger point is completely released.
214852841|NCT05857826|OTHER|vaginal dilators|Vaginal dilators will be used according to the patient's condition starting from small sizes to the wider ones.
214852842|NCT02251873|DRUG|TPV + RTV (low dose)|
214852843|NCT02251873|DRUG|TPV + RTV (high dose)|
214852844|NCT02251873|DRUG|ddl|
214852845|NCT05243186|DEVICE|Treadmill workstation|walking on a treadmill workstation next to desk with computer and screen
214852846|NCT05243186|DRUG|Methylphenidate|Using prescription drug
214852847|NCT02844517|DEVICE|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
214852848|NCT04680234|PROCEDURE|DMEP kit|Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C
214852849|NCT04680234|DEVICE|Dermapen|Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
214852850|NCT01415219|OTHER|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
214852851|NCT05495035|DRUG|Olverembatinib, APG-2575, Dexamethasone|"* Period 1: Subjects will orally take olverembatinib 40mg adult equivalent dose alone QOD from Day 1 to Day 14 (D1 - D14) =. The investigator may start the combination therapy in advance based on medical conditions of the subjects, but not earlier than Day 5/the third dose (D5).~* Period 2: 1) Subjects will orally take olverembatinib 40mg adult equivalent dose QOD from Day 15 to Day 42 (D15 - D42)).~  2\) Subjects will orally take APG-2575 at a ramp up 200mg/400mg/600mg adult equivalent dos QD from D13 to D42 at a dose . In addition, a 3-day dose escalation from D13 to D15 will be needed, and the designated reference dose will be reached on D15.~  3\) Subjects will orally take dexamethasone 6 mg/m2/day, QD from D15 to D42 at 6 mg/m2/day."
214852852|NCT00733031|DRUG|AZD6918|liquid suspension, daily, oral dose
214852853|NCT00733031|DRUG|gemcitabine|intravenous, doses are on an intermittent schedule
214852854|NCT00733031|DRUG|pemetrexed|intravenous, dose administered every 21-days
214852855|NCT00256776|DRUG|Velcade (Bortezomib)|
214852856|NCT00256776|DRUG|Thalidomide|
214852857|NCT00256776|DRUG|Dexamethasone|
214852858|NCT03815968|OTHER|low sodium diet|included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
214852859|NCT00751738|DRUG|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
214852860|NCT00685802|DRUG|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
214852861|NCT00685802|DRUG|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
214852862|NCT03204071|DRUG|placebo gel|Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
214852863|NCT03204071|DRUG|Aloevera|Oral prophylaxis followed by placement of aloevera gel
214852864|NCT03204071|DRUG|Metformin|Oral prophylaxis followed by placement of metformin gel
214852865|NCT06390202|OTHER|no intervention|there is no intervention in this study
214852866|NCT04966364|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
214852867|NCT04966364|DEVICE|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
214852868|NCT02708888|OTHER|Trunk training|The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.
214852869|NCT02708888|OTHER|Cognitive exercises|The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
214852870|NCT03998436|DRUG|Esmolol Hydrochloride|Galnobax-14% gel application along with Standard of Care
214852871|NCT03998436|OTHER|Only Standard of Care|Only Standard of Care treatment
214852872|NCT03998436|OTHER|Vehicle Gel|Vehicle gel application along with Standard of Care
214852873|NCT01017419|BEHAVIORAL|Counseling|Informational Counseling provided after hearing aid fitting
214852874|NCT00386126|DRUG|Iron Sucrose IV 200mg, once a week, for 5 weeks|
214852875|NCT00386126|DRUG|Ferrous sulfate 200mg PO TID, for 8 weeks|
214852876|NCT03507478|DEVICE|BPI1000013|Foam insole
214852877|NCT02914249|OTHER|Orange juice (500 mL/d)|Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
214852878|NCT01481857|OTHER|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
214852879|NCT01481857|OTHER|Segmental trunk exercise|Segmental trunk exercise
214852880|NCT05748197|BIOLOGICAL|ADCLEC.syn1 CAR T cells|There are 4 planned flat-dose levels: 25 × 10\^6, 75 × 10\^6 , 225 × 10\^6 , and 450 × 10\^6 CAR T cells and 1 de-escalation dose: 10 × 10\^6 CAR T cells.
214852881|NCT05748197|DRUG|Conditioning chemotherapy|Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
214852882|NCT02025010|DRUG|abiraterone acetate|Abiraterone acetate is a selective and irreversible inhibitor of CYP17 which has demonstrated clinical efficacy in patients with CRPC. Currently, AA is administered with concomitant prednisone.
214852883|NCT06260813|DIAGNOSTIC_TEST|Radiography|X-rays of the ankle; anterior-posterior, lateral, Mortise view and hindfoot alignment view. Standard weight bearing x-rays of the foot; anterior-posterior, lateral and oblique view.
214852884|NCT06260813|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the posterior tibial tendon to see if there is an irritation, elongation or rupture.
214852885|NCT06260813|DIAGNOSTIC_TEST|MRI|MRI when ultrasound is not conclusive to identify an irritation, elongation or rupture of the posterior tibial tendon.
214852886|NCT06260813|DIAGNOSTIC_TEST|CT-scan|CT-scan to identify arthritis of the tibial-talar, subtalar and/or Chopart joints.
214852887|NCT06260813|DIAGNOSTIC_TEST|Gait analysis|This lab is equipped with a 10-meter walkway surrounded by a passive optoelectronic motion analysis system consisting of 10 cameras to track the motion of markers. In the middle of the walkway, a force plate is integrated, with a pressure plate placed on top.
214852888|NCT05346354|DRUG|Ravulizumab|"Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight.~During the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight."
214852889|NCT04685655|OTHER|Therapeutic plasma exchange|Treatment with therapeutic plasma exchange. Plasma from healthy donors is used.
214852890|NCT00957619|DRUG|pentoxyfilline|The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
214852891|NCT00957619|DRUG|Placebo|This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
214852892|NCT02835963|OTHER|Data collection|Usual data collection
214852893|NCT01176643|OTHER|Standard care plus Yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
214852894|NCT01958515|OTHER|research blood draw and tissue biopsy|research blood draw and tissue biopsy
214852895|NCT01644487|DEVICE|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
214852896|NCT01644487|DEVICE|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
214852897|NCT00949988|DRUG|Dasatinib and Rituximab|"In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional"
214852898|NCT02249221|BIOLOGICAL|Quadrivalent cell-culture based influenza vaccin|GC3106, 0.5ml, intramuscular, a single dosing at Day 1
214852899|NCT02249221|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
214852900|NCT04353024|DRUG|Dimethyltryptamine (DMT)|Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min
214852901|NCT04353024|DRUG|Saline|Intravenous saline bolus and/or saline maintenance perfusion over 90 min
214852902|NCT00004150|DRUG|fluorouracil|
214852903|NCT00004150|DRUG|leucovorin calcium|
214852904|NCT00004150|PROCEDURE|adjuvant therapy|
214852905|NCT03123757|OTHER|6 Minute Walk Test|The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.
214852906|NCT03123757|OTHER|EQ-5D Survey|The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.
214852907|NCT03123757|OTHER|Short Physical Performance Battery|The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
214852908|NCT01345526|DEVICE|Reconval K1 Cream|
214852909|NCT01345526|DEVICE|Reconval Cream|
214852910|NCT02584088|OTHER|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
214852911|NCT00913198|DRUG|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214852912|NCT01980342|DRUG|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
214852913|NCT04317313|OTHER|FDG PET radiomic feature evaluation|"A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features.~In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature."
214664231|NCT05577754|DRUG|Matching placebo|During double-blind period of group A: matching placebo will be taken once a day each day over 6 months
214664232|NCT05577754|PROCEDURE|Optional lumbar puncture + blood sample|Between 6 and 24 months of treatment with Alpelisib
214664233|NCT03791970|DEVICE|Orchid 035 DCB Catheter|Stents placement for femoropopliteal arterial occlusions following with Orchid 035 DCB Catheter for post-dilation
214664234|NCT03791970|DEVICE|POBA Catheter|Stents placement for femoropopliteal arterial occlusions following with POBA for post-dilation
214852914|NCT01157715|BIOLOGICAL|intravitreal injection of KH902|
214852915|NCT04917081|BEHAVIORAL|Mindful Self-Compassion|Mindful Self-Compassion has been developed by Neff and Germer as a specific kind of Mindfulness-Based Interventions to promote self-compassion. It combines the skills of mindfulness and self-compassion, providing a powerful tool for emotional resilience and enhancing the capacity for emotional wellbeing. In this study, a shortened version of the MSC program is used which is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
214852916|NCT04917081|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a deep relaxation technique that helps relieve muscle tension and is based on the premise that mental calmness is a natural result of physical relaxation. In this study, Progressive Muscle Relaxation is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
214852917|NCT03964519|OTHER|Acute changes|In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.
214852918|NCT03964519|OTHER|Chronic changes|In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.
214852919|NCT03964519|OTHER|Familiarization|Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
214852920|NCT02152202|OTHER|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
214852921|NCT02152202|OTHER|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
214852922|NCT00365287|DRUG|anti-thymocyte globulin|
214852923|NCT00365287|DRUG|cyclophosphamide|
214852924|NCT00365287|DRUG|cyclosporine|
214852925|NCT00365287|DRUG|fludarabine phosphate|
214852926|NCT00365287|DRUG|mycophenolate mofetil|
214852927|NCT00365287|PROCEDURE|radiation therapy|
214852928|NCT00365287|PROCEDURE|umbilical cord blood transplantation|
214852929|NCT00553449|DRUG|rabeprazole|
214852930|NCT00617370|DRUG|epirubicin, cyclophosphamide, Paclitaxel,|EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
214852931|NCT02941510|DRUG|Budesonide|Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
214852932|NCT02941510|OTHER|Placebo|Subject(s) will participate in all study activities but will receive placebo.
214664235|NCT03478241|DEVICE|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
214664236|NCT03478241|DEVICE|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
214664237|NCT03478241|DEVICE|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
214664238|NCT02537860|OTHER|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
214852933|NCT03360357|PROCEDURE|Guided drills|"These residents will perform 5 set of exercises:~1. Needle Dance (Learning to manipulate the suture)~2. Loopy Loop (Learning to place needle through a loop)~3. Slalom Course (Passing the needle and suture through 5 rings right handed and left handed)~4. Dense Matter (Passing the needle through dense material without losing control of the needle)~5. Respect for tissue (Passing the needle through flimsy material without tearing)"
214852934|NCT04784884|DEVICE|HSI|diagnostic hyperspectral imaging
214852935|NCT05212883|BEHAVIORAL|Behavioral questionaires|Behavioral surveys and questionnaires
214852936|NCT05646628|BEHAVIORAL|Qualitative Interviews|Semi-structured Qualitative Interviews
214852937|NCT03349528|BIOLOGICAL|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily
214852938|NCT03349528|BIOLOGICAL|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
214852939|NCT00283322|OTHER|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
214852940|NCT00898534|DEVICE|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
214852941|NCT02623049|OTHER|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
214852942|NCT04075019|BEHAVIORAL|The Raising Healthy Children intervention, including teacher training, child skill development, and parent training|
214852943|NCT01453413|OTHER|Blood Glucose meter|Staff tested subject Blood Glucose using a Blood Glucose meter.
214852944|NCT00845975|DEVICE|Erchonia Hearing Lasers #1 & #2|"Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.~Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site."
214852945|NCT00845975|DEVICE|Placebo Lasers|The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
214664239|NCT02537860|OTHER|Placebo at T11 and L3|Two injections that contain saline are performed
214664240|NCT02537860|OTHER|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
214664241|NCT02537860|PROCEDURE|Herniorrhaphy|Unilateral inguinal hernia repair
214664242|NCT02537860|DRUG|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
214664243|NCT02537860|DRUG|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
214664244|NCT03158584|DRUG|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
214664245|NCT01011257|DRUG|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
214664246|NCT01011257|DRUG|Clopidogrel|clopidogrel 75 mg bid
214664247|NCT03715465|DRUG|Melatonin 0.5 MG|Melatonin tablet
214664248|NCT03715465|OTHER|Dim Light Melatonin Onset (salivary)|Test to determine the time of melatonin onset in saliva under dim light conditions
214664249|NCT05013840|BEHAVIORAL|Filling in an online survey|Physicians are asked to fill in an online survey regarding 1) goals to treat patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
214664250|NCT05952414|BEHAVIORAL|self-efficacy-based interventions|The intervention aims at increasing self-efficacy and consists of Cognitive Behavioural Therapy (CBT)-based exercises related to sources of self-efficacy beliefs: 1) mastery experiences, 2) vicarious experiences, 3) verbal persuasions, and 4) emotional and physiological states.
214664251|NCT01495988|DRUG|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
214664252|NCT01495988|DRUG|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
214664253|NCT01495988|DRUG|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
214664254|NCT04880174|DIAGNOSTIC_TEST|serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
214664255|NCT00738738|DRUG|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
214664256|NCT01218022|DRUG|Losartan Potassium Tablets|
214664257|NCT01737814|DRUG|Saline|
214664258|NCT01737814|DRUG|MST-188|
214664259|NCT00904124|DIETARY_SUPPLEMENT|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
214664260|NCT05812508|DEVICE|corneal topography|corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft
214664261|NCT03943381|DEVICE|Duplex US|Duplex US (Caliper, wave forms...)in evaluation of Pelvic Veins (namely left ovarian vein). in pelvic congestion syndrome
214664262|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia|FDA022-BB05, intravenously infusion, q3w
214664263|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib|FDA022-BB05, intravenously infusion, q3w
214664264|NCT01671670|OTHER|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
214664265|NCT01671670|OTHER|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
214664266|NCT01057264|DRUG|HAI Abraxane|Starting dose: 120 mg/m\^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
214664267|NCT01057264|DRUG|Gemcitabine|Starting dose: 600 mg/m\^2 by IV on Days 1 and 8 of 21 day cycle
214664268|NCT01057264|DRUG|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
214664269|NCT01057264|DRUG|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
214664270|NCT06265896|OTHER|Kinesio taping|Tape will be applied on rectus abdominis muscles using muscles facilitation technique from origin to insertion of muscle with a tension between 15-35%. Band will start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xiphoid process. Tape will be applied on the right and left external oblique muscles; the procedure will start without tension from bottom and of 6-12 ribs, then the hip will be placed in flexion and rotation to opposite direction and the tape will be attached to pubic bone with tension between 15-35%. Finally, the tape will be performed on the right and left internal oblique muscles; the procedure will start without tension from anterior superior iliac spine and then the hip will be placed in extension position and the tape will be attached to lower 4 ribs and linea alba with tension between 15-35%.
214664271|NCT06265896|OTHER|Pelvic floor exercise training|The intervention will be applied by a trained physical therapist. First of all, each participant will be instructed to relax thighs, bottom and abdomen musculature, then squeeze pelvic floor muscles 'focus on tightening without flexing abdomen, thighs or buttocks- avoid holding breath' 10 repetitions, 3 to 5 times a day (morning, afternoon, and night). Rest for 4 seconds and then repeat each contraction. Build up pelvic floor musculatures strength until each participant be able to do 10 slow contractions each time, holding them for 10 seconds each with rests of 4 seconds in between. Then do not hold your breath or tighten your stomach, bottom or thigh muscles at the same time. Will instruct participants to try holding each squeeze for a few seconds.
214664272|NCT06203808|OTHER|COMPLETION OF QUESTIONNAIRES|Both groups of patients will complete quality of life questionnaires at the time of treatment information, at 3 months, 6 months and at 12 months.
214664273|NCT00284115|DEVICE|Gait trainer|Mechanical gait repetitive training
214664274|NCT00284115|DEVICE|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
214664275|NCT02262637|DRUG|Micardis®|
214664276|NCT02262637|DRUG|MicardisPlus®|
214664277|NCT04902885|DRUG|Trilaciclib, carboplatin, etoposide，or Topotecan|Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients
214664278|NCT04902885|DRUG|placebo, carboplatin, etoposide，or Topotecan|placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients
214664279|NCT02652819|DRUG|FG-4592|
214664280|NCT02652819|DRUG|Placebo|
214664281|NCT04331899|DRUG|Peginterferon Lambda-1a|Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care
214852946|NCT02191475|DRUG|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
214852947|NCT02191475|DRUG|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
214852948|NCT02884323|DEVICE|geko™ device|The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
214852949|NCT02477241|PROCEDURE|Uroflowmetry|A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
214852950|NCT02477241|DEVICE|fMRI|Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
214852951|NCT02122718|DRUG|Allopurinol|
214852952|NCT02122718|DRUG|Placebo|
214852953|NCT05690126|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
214852954|NCT05690126|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are taken during 6 weeks by healthy volunteers
214852955|NCT01713426|DRUG|Qutenza|Cutaneous patch
214852956|NCT01713426|DRUG|Pregabalin|Oral capsule
214852957|NCT03421704|DEVICE|DreamStation BiPAP autoSV|Philips Respironics DreamStation BiPAP autoSV (PR DS-autoSV) is designed to deliver pressure support for patient ventilatory assistance
214852958|NCT00903552|BIOLOGICAL|Influenza VLP Vaccine|
214852959|NCT00903552|BIOLOGICAL|Placebo|phosphate-buffered saline (PBS)
214852960|NCT04799652|OTHER|Survey|Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.
214852961|NCT00878696|PROCEDURE|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
214852962|NCT03357081|DRUG|CEUS or Contrast enhanced Ultrasound|Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
214852963|NCT03095118|DRUG|Daratumumab|Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
214852964|NCT04730089|DEVICE|Electrical impedance tomography|A bolus of 10ml 10% NaCl was injected during a respiratory pause (≥10s) through the central venous catheter.The results of arterial blood gas analysis and the data of EIT were collected before the first prone session (time baseline), the end of prone positioning (time P).
214852965|NCT05705817|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|The ASSET program is a 15-session training program that combines specific skill training, structured learning, social performance training and a social hour to practice skills through a manualized group intervention. Specific skills taught within the program include communication, enthusiasm and attitude, teamwork, networking, problem-solving and critical thinking, and professionalism.
214852966|NCT03015714|OTHER|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
214852967|NCT03015714|OTHER|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
214852968|NCT02513836|OTHER|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
214852969|NCT02513836|OTHER|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
214852970|NCT01862393|DEVICE|400 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
214852971|NCT01862393|DEVICE|700 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
214852972|NCT01862393|DEVICE|1000 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
214852973|NCT05215093|OTHER|Direct access physiotherapy for acute low back pain|Interventions include physiotherapeutic treatment, without prescription of the general practitioner, for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
214852974|NCT05215093|OTHER|Usual care for acute low back pain|Interventions include standard of care by the general practitioner for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
214852975|NCT05917691|PROCEDURE|Bariatric surgery|Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.
214852976|NCT05917691|DRUG|General anesthetic|"Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database)."
214852977|NCT05917691|DEVICE|Indeterminate|Devices were indeterminate under the current study design (observational study of a deidentified database).
214852978|NCT03066791|DIETARY_SUPPLEMENT|Turmeric tablets|
214852979|NCT03066791|DIETARY_SUPPLEMENT|Curcumin and Bioperine tablets|
214852980|NCT03066791|DIETARY_SUPPLEMENT|Placebo tablets|
214852981|NCT01604369|PROCEDURE|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
214852982|NCT04421976|PROCEDURE|PEEP|"Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
214852983|NCT01561794|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|"(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.~2\) Hospital-acquired pneumonia (HAP): For the patient with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days."
214852984|NCT03847194|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
214852985|NCT04766229|COMBINATION_PRODUCT|Citalopram +/- Gabapentin + Sleepio + support person|All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
214852986|NCT04219787|PROCEDURE|Long BPL LRYGB|LRYGB with an 180 cm BPL and an AL of 80 cm.
214852987|NCT04219787|PROCEDURE|Short BPL LRYGB|The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.
214852988|NCT02408120|DRUG|Insulin glargine|"Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
214852989|NCT02408120|DRUG|Insulin aspart|"Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
214852990|NCT02408120|DRUG|Supplemental insulin aspart|"Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~* BG \>141-180 mg/dL; 2-4 units of insulin aspart~* BG between 181-220 mg/dL; 3-6 units of insulin aspart~* BG between 221-260 mg/dL; 4-8 units of insulin aspart~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart"
214852991|NCT02419625|BEHAVIORAL|questionnaires|questionnaires , serum samples will be used
214852992|NCT05227131|DRUG|Margetuximab|Margetuximab (15 mg/kg) will be administrated by intravenous infusion on Day 1 of each cycle.
214852993|NCT05227131|DRUG|Tucatinib|Tucatinib (300 mg) will be administrated orally twice daily (every 12 hours) continuously in 21-day cycles.
214852994|NCT05227131|DRUG|Capecitabine|Capecitabine (1000 mg per square meter of body-surface area) will be administrated orally twice daily on days 1 to 14 of each 21-day cycle
214852995|NCT03810573|DEVICE|NB1|rhNELL-1/DBX
214852996|NCT02023840|DRUG|metronidazole gel|
214852997|NCT02023840|PROCEDURE|ultrasonics|
214852998|NCT02023840|PROCEDURE|erythritol|
214852999|NCT02023840|DRUG|placebo|
214853000|NCT04657250|BEHAVIORAL|Smoking cessation + quitline linkage text messages|Smoking cessation text messages will provide behavioral skills and support for quitting smoking. Quitline linkage text messages will include contact information for the quitline, option to be contacted by the quitline and active referral to the quitline upon setting a Quit Date.
214853001|NCT04657250|BEHAVIORAL|Passive quitline referral|Single text message with contact information for the Quitline
214853002|NCT03818386|DRUG|AGuIX®|"3 intravenous injection at 100mg/kg~* D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~* Fr1: AGuIX® injection before the first radiation session~* Fr6: AGuIX® injection before the sixth radiation session"
214853003|NCT03818386|RADIATION|Whole Brain Radiation Therapy|30 Gy in 10 fractions of 3 Gy over 2-3 weeks
214853004|NCT01913717|RADIATION|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
214853005|NCT00744172|PROCEDURE|laparoscopy|laparoscopic hysterectomy
214853006|NCT00744172|PROCEDURE|vaginal|vaginal hysterectomy
214853007|NCT00744172|PROCEDURE|abdominal|abdominal hysterectomy
214853008|NCT02116894|BIOLOGICAL|PF-03446962|PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
214853009|NCT02116894|DRUG|Regorafenib|We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
214853010|NCT02293473|DEVICE|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
214853011|NCT02293473|DEVICE|BIS-Bispectral Index Monitor|Depth of anaesthesia
214853012|NCT02293473|DEVICE|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
214853013|NCT02293473|OTHER|Standard of care|Using standard of care
214853014|NCT00006331|PROCEDURE|renal transplant|
214853015|NCT03553563|DRUG|D961H capsule 10mg|All Groups can select either capsule or sachet during the study.
214853016|NCT03553563|DRUG|D961H sachet 10mg|All Groups can select either capsule or sachet during the study.
214853017|NCT05559463|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
214853018|NCT02540837|DRUG|Bupivacaine|Obturator nerve block
214853019|NCT02540837|DRUG|Saline|Obturator nerve block with saline(placebo)
214853020|NCT04715776|DIETARY_SUPPLEMENT|Brown seaweed|Uptake of 1650 mg brown seaweed product twice daily
214853021|NCT04715776|DIETARY_SUPPLEMENT|placebo|Uptake of 1650 mg placebo twice daily
214853022|NCT01838382|DEVICE|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
214853023|NCT04015960|OTHER|no intervention|qualitative research and patient reported outcome measure (PROm) development
214853024|NCT03989531|BIOLOGICAL|Adrecizumab|Drip infusion over 60 minutes
214853025|NCT03989531|DRUG|Placebo|Drip infusion over 60 minutes
214853026|NCT04553991|PROCEDURE|Ultrasound guided QL block|20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia
214853027|NCT04553991|PROCEDURE|Ultrasound guided TAP block|20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
214853028|NCT01975194|DRUG|Rosuvastatin|Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
214853029|NCT03551873|DRUG|Plecanatide|Subjects will have been breastfeeding or pumping for at least 4 weeks and must have been prescribed and taking TRULANCE® for at least 14 continuous days prior to Baseline. Breast milk for measurement of TRULANCE® (plecanatide) concentrations will be collected at Day 1.
214853030|NCT02278458|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
214853031|NCT02278458|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
214853032|NCT01144403|DRUG|Cyclophosphamide|as prescribed, 6 cycles
214853033|NCT01144403|DRUG|Fludarabine|as prescribed, 6 cycles
214853034|NCT01144403|DRUG|Mitoxantrone|as prescribed, 6 cycles
214853035|NCT01144403|DRUG|Rituximab|375 mg/m\^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
214853036|NCT02555982|DRUG|BOTOX ® 200 Unités|"Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
214853037|NCT02555982|DRUG|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
214853038|NCT02931292|PROCEDURE|Laparoscopic sleeve gastrectomy|"Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained."
214853039|NCT03176784|DRUG|Varenicline|0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
214853040|NCT03176784|DRUG|Nicotine patch|14 mg and 7 mg nicotine patches used. See arms for specific durations.
214853041|NCT03176784|OTHER|Placebo Patch|Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
214853042|NCT03176784|OTHER|Placebo Pill|Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
214853043|NCT00610324|DRUG|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
214853044|NCT00610324|DRUG|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
214853045|NCT03588052|PROCEDURE|VISTA using PRF|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
214853046|NCT03588052|PROCEDURE|VISTA using SCTG|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
214853047|NCT01526460|DRUG|Atorvastatin|80 mg
214853048|NCT01526460|DRUG|Rosuvastatin|40 mg
214853049|NCT01526460|DRUG|Placebo|no statin loading dose
214853050|NCT03901391|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole Exome Sequencing
214853051|NCT00003130|DRUG|paclitaxel|
214853052|NCT04412486|BIOLOGICAL|COVID Convalescent Plasma|One unit of COVID Convalescent Plasma transfused on Day 0
214853053|NCT03768284|OTHER|Saliva or buccal sample|Saliva or buccal sample
214853054|NCT02605213|DRUG|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
214853055|NCT02605213|DRUG|Placebo|Placebo for control Group of primary sclerosing vhlangitis
214853056|NCT00381823|BEHAVIORAL|Cognitive Behavioral Therapy|
214853057|NCT05540379|DEVICE|Virtual Reality Training|Training the obstetrics and Gynecologist Residents on Virtual endoscopic simulation and skills acquisition
214853058|NCT00783887|OTHER|Blood sample|Blood sample of 5 ml
214853059|NCT01825837|DRUG|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
214853060|NCT01825837|DRUG|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
214853061|NCT01825837|DRUG|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
214853062|NCT01825837|DRUG|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
214853063|NCT04007471|OTHER|Anonymous survey|Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
214853064|NCT00141661|DRUG|PF-04494700 - Low Dose Arm|30 mg loading dose for 6 days, followed by 10 mg daily
214290341|NCT02715076|DEVICE|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
214853065|NCT00141661|DRUG|PF-04494700 - High Dose Arm|60 mg loading dose for 6 days, followed by 20 mg daily
214853066|NCT00141661|DRUG|Placebo Comparator|Matching placebo.
214853067|NCT04309526|DRUG|NCO-48 Fumarate|NCO-48 Fumarate
214853068|NCT04309526|DRUG|Placebo|Placebo
214290342|NCT02715076|OTHER|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
214290343|NCT05219656|DRUG|Cyclosporine A|Rescue therapy in acute severe ulcerative colitis
214290344|NCT05762003|DRUG|interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab|Administered as part of routine clinical practice.
214853069|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
214853070|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
214853071|NCT00904748|DRUG|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
214853072|NCT01513031|OTHER|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
214853073|NCT03579134|DEVICE|partial overlay denture|removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
214853074|NCT03579134|OTHER|fixed temporary crowns|fixed crowns made from temporary material placed to the newly altered vertical dimension
214853075|NCT02221596|DIETARY_SUPPLEMENT|vitamin D|50,000IU/wk of vitamin D3
214853076|NCT02221596|OTHER|aerobic training|7 days of treadmill training during the 13th week of study
214853077|NCT01856387|BIOLOGICAL|high neutrophil to lymphocyte ratio|
214853078|NCT01856387|OTHER|normal neutrophil-to Lymphocyte ratio|
214853079|NCT05688397|DIETARY_SUPPLEMENT|Experimental 1|L. gasseri oral capsule once a day (1 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
214853080|NCT05688397|DIETARY_SUPPLEMENT|Experimental 2|L. gasseri and L. crispatus oral capsule once a day (1.5 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
214853081|NCT05688397|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
214853082|NCT04702347|DIAGNOSTIC_TEST|Urine biomarker|Bladder urine samples (\> 10 ml) will be collected for cytology and for the methylation test before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the upper urinary tract will be obtained via a ureteral catheter.
214853083|NCT06306092|BEHAVIORAL|Sleep on Schedule|Sleep education at school
214853084|NCT06306092|BEHAVIORAL|Technology restriction|Reduction of electronic media use before bedtime
214853085|NCT03990480|DRUG|valsartan (160 mg/d)|Group I treated with valsartan (160 mg/d, n = 100)
214853086|NCT03990480|DRUG|amlodipine (10 mg/d).|Group II amlodipine (10 mg/d, n = 100).
214853087|NCT05088031|DEVICE|shock waves therapy|"Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)"
214853088|NCT01067716|DEVICE|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
214853089|NCT02646917|PROCEDURE|Aesthetic Microneedling Treatment|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
214853090|NCT04751474|OTHER|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
214853091|NCT00680186|DRUG|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
214853092|NCT00680186|DRUG|Dabigatran etexilate|150mg bid
214853093|NCT00919984|DRUG|IP chemotherapy|IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
214853094|NCT00028379|PROCEDURE|Transcranial magnetic stimulation (TMS)|
214853095|NCT05766020|BEHAVIORAL|Listen training|Auditory skills with the inclusion of cognitive control.
214853096|NCT01099631|BIOLOGICAL|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.
214853097|NCT05472116|DEVICE|Mobile Health application (CapApp)|Mobile Health application (CapApp) will be used to measure capillary refill time in a healthy pediatric population and compared to two additional manual methods to include both human and computer annotation and mobile health application (Cap App).
214853098|NCT00285584|DRUG|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
214853099|NCT00285584|DRUG|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
214853100|NCT00427674|DRUG|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
214853101|NCT01373060|DRUG|ASP1941|oral
214853102|NCT01373060|DRUG|Placebo|oral
214853103|NCT04909541|OTHER|CEGSSS-Canadian Endourology Group Stent Symptom Score|Patient with ureteral stent complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
214853104|NCT03060850|DRUG|AC0010MA|Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
214853105|NCT01267006|DRUG|GSK1325756|GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
214853106|NCT01267006|DRUG|Placebo tablet|Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
214290345|NCT05763550|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
214853107|NCT00452608|DRUG|amido pill|one pill of amido/d by mouth for 10 days
214853108|NCT00452608|DRUG|atorvastatina|atorvastatina 80 mg/day by mouth for 10 days
214853109|NCT00645944|DRUG|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
214853110|NCT00645944|DRUG|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
214853111|NCT03617627|BEHAVIORAL|Self-management intervention|Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
214853112|NCT02389101|OTHER|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
214853113|NCT00414349|DRUG|Topical analgesic|max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
214853114|NCT00414349|DRUG|oral intake|300 to 600 mg per day taken orally
214853115|NCT00414349|DRUG|Topical analgesic|3 plasters for PHN patients per day 4 plasters for DPN patients per day
214853116|NCT01684059|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
214853117|NCT05854459|OTHER|HIIT and Nordic Curl exercise program|The training program in the HIIT+NC group was divided into the following parts: i) warm-up (10 minutes); ii) HIIT (25 minutes) consisting of a circuit of eight exercises; iii) Nordic curl exercise (10 mintues); and iv) stretching.
214853118|NCT05854459|OTHER|HIIT-only program|The HIIT group performed the same exercises in the warm-up, HIIT and stretching sections as the HIIT+NC group, however, they did not perform the NC eccentric exercises.
214853119|NCT01215799|DRUG|Bafetinib|Bafetinib 240 mg bid
214853120|NCT03474029|DRUG|Rifapentine daily for 6 weeks|600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
214664282|NCT04331899|OTHER|Placebo|Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection
214664283|NCT06251388|DRUG|AK104|AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W）maintained with no more than 1 year.
214664284|NCT01817010|BEHAVIORAL|Multi-Component Rehabilitation (CMC)|
214664285|NCT01817010|BEHAVIORAL|Control (CON)|
214664286|NCT02424669|OTHER|ALS Functional rating Scale-revised (ALS FRS-R)|
214664287|NCT02424669|OTHER|slow vital capacity|
214664288|NCT02424669|OTHER|Blood sample|
214664289|NCT02424669|OTHER|Cerebrospinal Fluid (CSF) sample|
214664290|NCT06346912|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
214664291|NCT00101361|DRUG|Oxandrolone|Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
214664292|NCT00101361|DRUG|Placebo|Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
214664293|NCT02669563|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
214664294|NCT02669563|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
214664295|NCT02669563|DRUG|[13N]ammonia|IV injection of \[13N\]ammonia
214664296|NCT02669563|DRUG|[11C]HED|IV injection of \[11C\]HED
214664297|NCT02446639|OTHER|Blood collection|
214664298|NCT02424539|DRUG|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
214664299|NCT02424539|OTHER|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
214664300|NCT02303080|OTHER|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
214664301|NCT02303080|OTHER|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
214664302|NCT02303080|OTHER|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
214664303|NCT02303080|OTHER|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
214664304|NCT02536482|DIETARY_SUPPLEMENT|Amix|Treat the children with cow's milk allergy for 5 months.
214664305|NCT01718314|DRUG|Sublingual Misoprostol|
214664306|NCT01718314|DRUG|Lidocaine pump spray|
214664307|NCT01718314|DRUG|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
214664308|NCT01718314|DRUG|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
214664309|NCT02985346|BIOLOGICAL|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
214664310|NCT03787433|DEVICE|ARC - Assisted Rehabilitation Care|"ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings."
214664311|NCT00072722|DRUG|CC-4047|
214853121|NCT03474029|DRUG|Rifapentine and Isoniazid weekly for 12 weeks|"Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing \> 50 kg. For persons weighing \< 50 kg, the following doses will be given: weight \> 25-32 kg - RPT 600 mg; weight \> 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max)."
214664312|NCT03500107|DEVICE|Blue Light Emitting Diode (LED) 401 +/- 5nm|The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
214664313|NCT02900677|BEHAVIORAL|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks
214664314|NCT01827501|DEVICE|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
214664315|NCT03393962|BIOLOGICAL|OC-EIEs|2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
214664316|NCT03340740|DRUG|Cetirizine Hydrochloride 1 MG/ML|Cetirizine oral suspension
214664317|NCT03340740|DRUG|Placebo - Concentrate|Similar-appearing liquid to cetirizine oral suspension
214664318|NCT00723658|BIOLOGICAL|rituximab|
214664319|NCT00723658|DRUG|bortezomib|
214664320|NCT00723658|DRUG|carmustine|
214664321|NCT00723658|DRUG|cisplatin|
214664322|NCT00723658|DRUG|cyclophosphamide|
214664323|NCT00723658|DRUG|cytarabine|
214664324|NCT00723658|DRUG|dexamethasone|
214664325|NCT00723658|DRUG|doxorubicin hydrochloride|
214664326|NCT00723658|DRUG|etoposide|
214664327|NCT00723658|DRUG|melphalan|
214664328|NCT00723658|DRUG|thalidomide|
214664329|NCT00723658|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|
214664330|NCT00723658|PROCEDURE|peripheral blood stem cell transplantation|
214664331|NCT01479725|PROCEDURE|HBOT|HBOT
214664332|NCT01223248|RADIATION|IGIMRT using a single dose of 24 Gy|Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
214853122|NCT03474029|DRUG|Rifampin and Isoniazid daily for 12 weeks|"Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*.~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max)."
214664333|NCT01223248|RADIATION|IGIMRT 27 Gy in 3 fractions|Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& within 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
214664334|NCT04382261|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
214664335|NCT00242879|DRUG|Physician determined comparator PI + ritonavir|
214664336|NCT00242879|DRUG|GW640385 + ritonavir|
214664337|NCT03514147|OTHER|Experimental|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
214664338|NCT03514147|OTHER|Control|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
214664339|NCT06807996|DIETARY_SUPPLEMENT|Zinc-enriched yeast capsule|Daily zinc supplementation: zinc-enriched yeast capsules (15 mg) for a total of 6 months.
214664340|NCT06807996|DIETARY_SUPPLEMENT|Edible yeast placebo capsule|Daily edible yeast placebo capsules (not zinc-enriched) (15 mg) for a total of 6 months.
214664341|NCT02458976|DEVICE|PDL|
214664342|NCT04169568|PROCEDURE|Manual cuff blood pressure|Blood pressure will be obtained using a sphygmomanometer. Only Registered Nurses will apply BP cuff after careful inspection of the upper extremity for bruising, swelling or tenderness.
214664343|NCT02719054|BEHAVIORAL|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
214664344|NCT01613092|DRUG|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
214664345|NCT01613092|DRUG|Cefazolin|Preoperative antibiotic
214664346|NCT03950323|RADIATION|MRI with Facial nerve tractography|MRI with Facial nerve tractography in addition to T1 imaging, T1 gadolinium imaging and T2 imaging.
214664347|NCT01657123|OTHER|ergometry|ergometry measurements
214664348|NCT01657123|OTHER|ergometry|Ergometry measurements
214664349|NCT00847340|PROCEDURE|Biopsy Excisional|Biopsied from genital warts will be taken through an excisional procedure. Homeostasis will be obtained by using apply of Monsel solution. Biopsied sample will be splinted in order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the pathology laboratory for haematoxiline - eosine paint and lecture.
214664350|NCT05632172|PROCEDURE|implant insertion|bone level dental implant insertion
214664351|NCT04074993|DRUG|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
214664352|NCT03014869|DEVICE|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
214664353|NCT00989326|OTHER|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
214290346|NCT05763550|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
214290347|NCT05763550|DRUG|Pregabalin 150mg|pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week
214664354|NCT00334750|OTHER|There is no intervention in this study.|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
214664355|NCT05965570|DRUG|Brensocatib|Oral tablets.
214664356|NCT05965570|DRUG|Clarithromycin|Oral tablets.
214664357|NCT03168061|DRUG|NC 6300|Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
214664358|NCT00602628|OTHER|questionnaire administration|
214664359|NCT00602628|PROCEDURE|adjuvant therapy|
214664360|NCT00602628|PROCEDURE|biopsy|
214853123|NCT03474029|DRUG|Rifampin daily for 16 weeks|"Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg."
214853124|NCT02224066|DRUG|Ticagrelor 90 mg twice per day during three months following TAVI|
214853125|NCT02224066|DRUG|Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI|
214853126|NCT01523587|DRUG|afatinib|Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
214853127|NCT01523587|DRUG|erlotinib|erlotinib taken once daily
214853128|NCT02375217|DRUG|Sugammadex|half dose
214853129|NCT02375217|DRUG|Sugammadex|full dose
214853130|NCT02375217|DRUG|Neostigmine|IV = 50mcg/kg
214853131|NCT02375217|DRUG|glycopyrrolate|
214853132|NCT04647617|BEHAVIORAL|Quantitative weight -bearing and report exercise sign data every weekly|keep their normal live style
214853133|NCT05150418|DRUG|Oxygen gas|Oxygen 15 l/min
214853134|NCT05150418|DRUG|Air|Room air 15 l/min
214853135|NCT00399737|DRUG|repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|
214853136|NCT01931228|PROCEDURE|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
214853137|NCT01931228|PROCEDURE|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
214853138|NCT05656079|DRUG|Pegylated liposomal doxorubicin|Drug: Pegylated liposomal doxorubicin (35 mg/m2) will be administered by an intravenous infusion on day 1 of each21-day cycle.
214853139|NCT05656079|DRUG|Epirubicin|Drug: Epirubicin (90 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
214853140|NCT05656079|DRUG|Cyclophosphamid|Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
214853141|NCT05656079|DRUG|Trastuzumab|Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
214853142|NCT05656079|DRUG|Pertuzumab|Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
214853143|NCT05656079|DRUG|Docetaxel|Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
214853144|NCT01298778|DRUG|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
214853145|NCT01298778|DRUG|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
214853146|NCT01298778|DRUG|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
214853147|NCT03155737|OTHER|Self-acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
214664361|NCT00602628|PROCEDURE|computed tomography|
214853148|NCT03155737|OTHER|Knee health education|A course regarding knee health will be offered to the subjects in this group.
214853149|NCT03135652|RADIATION|adjuvant SBRT|adjuvant SBRT of liver lesions
214853150|NCT03135652|DRUG|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
214853151|NCT03883282|OTHER|Not Provided|Not Provided
214853152|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
214853153|NCT01037582|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
214853154|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
214853155|NCT01037582|DRUG|placebo|Subjects will be randomized to receive a single dose of placebo.
214853156|NCT01037582|DRUG|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
214853157|NCT01037582|DRUG|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
214853158|NCT02804282|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
214853159|NCT03910660|DRUG|BXCL701 plus Pembrolizumab|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle."
214853160|NCT03910660|DRUG|BXCL701 monotherapy|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day."
214853161|NCT01123317|DRUG|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
214853162|NCT06616129|DIAGNOSTIC_TEST|Geriatric assessment|At the clinic further information on the somatic, social, psychological and functional domain will be gathered by the nurse and two validated tests to map the vulnerability and resilience of the patient will be used; the Cognitive Impairment Test and the timed Up and Go Test.
214853163|NCT06616129|OTHER|Shared decision-making conversation|"The nurse and nurse practitioner together will talk with the patient and their partner about possible treatment options as well as patients' expectations, preferences and their life in general.~During the conversation the OPT (Outcome Prioritization Tool) will be used to clarify the most important goals of treatment for the patient. The OPT exists of four universal treatment goals rated on a visual analogue scale from 0 to 100. The goals represented are: life extension, maintaining independence, reducing pain and reducing other symptoms. The goals will be explained and the patient will be asked to rate each outcome according to the trade-off principle meaning that two outcomes cannot be rated equally."
214853164|NCT00261131|DRUG|Botulinum Toxin A|
214853165|NCT04965389|DRUG|BMS-986177 Oral Solution|Specified dose on specified days
214853166|NCT04965389|DRUG|[14C]BMS-986177 Solution for Infusion|Specified dose on specified days
214853167|NCT04965389|DRUG|BMS-986177 Spray-dried Dispersion Capsules|Specified dose on specified days
214853168|NCT02138292|DRUG|Trametinib (2mg)/Digoxin (.25mg)|"1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."
214853169|NCT02356991|DRUG|Famitinib|
214853170|NCT02356991|DRUG|Placebo|
214853171|NCT03243929|BEHAVIORAL|Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
214853172|NCT03243929|BEHAVIORAL|Attention Control|Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
214853173|NCT01509521|DRUG|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
214853174|NCT01509521|DRUG|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
214853175|NCT05600205|BEHAVIORAL|GOAL!|GOAL! is a integrated support focused on a combination of lifestyle factors for achieving a healthier lifestyle for people with severe mental illness. The intervention consists of two year of guidance from a lifestyle coach and qualified professionals.
214853176|NCT03968198|DRUG|Autologous ASC (for Adipose-derived Stem/Stroma Cell)|After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.
214853177|NCT00027859|DRUG|docetaxel|
214853178|NCT00027859|DRUG|estramustine phosphate sodium|
214853179|NCT00027859|DRUG|ketoconazole|
214853180|NCT00027859|DRUG|therapeutic hydrocortisone|
214853181|NCT06308172|PROCEDURE|Hysterotomy closure|Hysterotomy closure is done in either one of two ways. Single layer closure consists in a single layer, unlocked suture. Double layer closure consists in a double layer, unlocked suture.
214853182|NCT00572117|DRUG|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
214853183|NCT03226119|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
214853184|NCT04916496|BEHAVIORAL|Acceptance and Commitment Therapy-based lifestyle counselling programme|"The ACT-LCP Group will receive an ACT-based lifestyle counselling programme, which composes of 5-weekly group sessions (2 hours per each, 15 hours in total). Acceptance, mindfulness, values clarification skills/exercises will be used to help patients to increase self-perspective taking and willingness to experience distressing sensations, discomfort and urges while engaging in healthy lifestyle behaviours.~One month after the programme, the participant will receive one 'booster' session (2 hours), followed by 2-weekly telephone follow-up calls (20-30 minutes per call) to evaluate the effort of behavioural change."
214853185|NCT04916496|BEHAVIORAL|Healthy lifestyle talk|"The Control Group will receive one 2-hour, healthy lifestyle education talk (at least 10 patients in the talk) based on the HEARTS technical package as recommended by the WHO as routine care. This package includes a collection of evidence-based protocols which standardizes a clinical approach to promote a healthy lifestyle among adults. The Control Group will receive routine psychiatric outpatient/rehabilitation services as provided by the clinic in NDH/community centre.~One month after the talk, three weekly follow-up telephone calls (20-30 minutes) will be arranged for each patient in the Control Group to evaluate the effort of behavioural change."
214853186|NCT04332016|OTHER|biological samples collection|collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
214853187|NCT04267263|BEHAVIORAL|Self-guided lifestyle intervention|The intervention will consist of one 60-minute group based online session, adapted specifically for young men based previous work with young adults, followed by a self-guided program for 12-weeks. Participants will receive a tool kit that includes evidence-based resources (scale for self-weighing, handouts that will include free self-monitoring apps and strategies for no-cost exercise, sample meal plans and meal planning tips, and tips for healthy living that emphasize risk areas) to assist them during the self-guided phase, as well as weekly health risk text messages.
214853188|NCT02709486|DRUG|Tanezumab|2.5 mg
214853189|NCT02709486|DRUG|Tanezumab|5 mg
214853190|NCT02709486|DRUG|Placebo|Placebo
214853191|NCT05082363|COMBINATION_PRODUCT|C4d evaluation in lupus nephritis in serum and renal tissue|C4d plasma levels were analyzed by a unique assay specifically detecting C4d arising from complement activation and C4 plasma levels were quantified with competitive ELISA. SLE patients in activitity with and without lupus nephritis In patient with lupus nephritis we will evaluate the C4d after developing remission in the form of reduction of proteinurea less than .5g/g measured as PCR as complete response and less than50% reduction in proteinurea in partial response according to KIDGO guide line Percutaneous renal biopsies were performed in SLE and non-SLE patients under ultrasonographic guidance. 10% formalin-fixed tissue was embedded in paraffin. Four μm-thick sections were stained with hematoxylin and eosin (H\&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAM), masson-trichrome and polyclonal rabbit anti-human C4d antibody, Renal biopsy specimens of SLE patients were assessed using the most recent modification of the World Health Organization (WHO)
214853192|NCT00209586|DRUG|fospropofol disodium|
214853193|NCT00888784|PROCEDURE|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
214664362|NCT00602628|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214664363|NCT00602628|PROCEDURE|magnetic resonance imaging|
214664364|NCT00602628|PROCEDURE|therapeutic conventional surgery|
214664365|NCT00602628|PROCEDURE|ultrasound imaging|
214664366|NCT00602628|RADIATION|radiation therapy|
214664367|NCT02207387|DRUG|Azilect|Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
214664368|NCT02207387|BEHAVIORAL|Exercise|Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
214664369|NCT02207387|OTHER|Music|
214664370|NCT04086940|DRUG|Esmolol|preventive
214664371|NCT01519115|OTHER|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
214664372|NCT01519115|OTHER|usual care|one physical therapy visit in hospital following ACF surgery
214664373|NCT04372589|DRUG|Heparin|"Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement."
214664374|NCT03102736|DRUG|Placebos|Placebo saline
214664375|NCT03102736|DRUG|Ketamine|0.5 mg/kg ketamine
214664376|NCT03102736|DRUG|Nitroprusside|0.5 mcg/kg nitroprusside
214664377|NCT00242177|DRUG|ACTOS (Pioglitazone)|
214664378|NCT04110249|PROCEDURE|Photoacoustic Imaging|Undergo PAI
214664379|NCT04110249|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
214664380|NCT00247481|DRUG|Gefitinib|
214664381|NCT00247481|DRUG|Docetaxel|
214664382|NCT03444337|DEVICE|Catheter Ablation|
214664383|NCT00290472|DRUG|temsirolimus|
214664384|NCT01599559|OTHER|observation|observation
214664385|NCT01599559|RADIATION|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
214664386|NCT00987415|DRUG|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
214664387|NCT00987415|DRUG|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
214664388|NCT05050240|OTHER|Cooling Vest Procedure|"A cold vest will be placed on the participant (consisting of a water-perfused CFA wearable vest, size S-M or M-L with adjustable straps Polar Products, Stow, OH; attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler; Product link: https://www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm This product is safe and recommended by experimental guidelines and BARCIST criteria for human BAT studies. Note, the cooling vest will be cleaned between participants according to the manufacturer's guidelines found here: https://www.polarproducts.com/polarshop/pc/catalog/pdf/Polar\_CoolFlow\_Manual.pdf.~Briefly, the vest will be hand washed with a mild detergent and warm soapy water and air-dried. The vest will then be stored in a clean, dry environment with ventilation."
214664389|NCT05050240|OTHER|Fasting overnight|Participants will be requested to refrain from food and caloric drinks overnight (starting at 10pm) prior to the hospital visit. Blood will then be drawn the following morning (between 8 and 9am) and 3hrs later (between 11am and noon). Participants will be sat in a room with ambient temperature (room temperature w/o cooling) between the two blood draws.
214664390|NCT01697215|OTHER|AirWave|
214664391|NCT05748379|PROCEDURE|Kompozite closure|Immediate implant placement and temporary closure of tapered implants with a custom-made composite shaper.
214664392|NCT05748379|PROCEDURE|Individual abutment|Immediate implant placement and temporary closure of tapered implant with a custom-made zirconium oxide abutment.
214664393|NCT05225155|DRUG|Enoxaparin|Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
214664394|NCT04082221|OTHER|no intervention|no intervention
214664395|NCT04258618|BEHAVIORAL|CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS|Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI. This includes weekly, one hour sessions addressing sleep for 6 weeks.
214853194|NCT00888784|DRUG|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
214853195|NCT04588441|DRUG|Adenosine|Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
214853196|NCT02214719|BEHAVIORAL|EASI-IDM use|EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
214853197|NCT00052416|DRUG|thalidomide|
214853198|NCT05322902|DRUG|remimazolam group|Remimazolam 6 mg/kg/hr is administered as an intravenous infusion until the patient loses consciousness. Anesthesia is maintained at 1 mg/kg/hr of remimazolam. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
214853199|NCT05322902|DRUG|propofol group|Propofol intravenous infusion is initiated by the application of a target concentration infusion (TCI) pump to cause the patient to lose consciousness. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
214853200|NCT01369602|DRUG|PF-04991532|single dose 300-mg
214853201|NCT01369602|DRUG|PF-04991532|single dose 300-mg
214853202|NCT01369602|DRUG|PF-04991532|single dose 300-mg
214853203|NCT01369602|DRUG|PF-04991532|single dose 300-mg
214853204|NCT00589849|PROCEDURE|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
214853205|NCT05407506|DIAGNOSTIC_TEST|THYROID AI|thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
214853206|NCT05813938|DEVICE|LabTest Checker|A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
214853207|NCT03024047|DEVICE|Pacemaker|
214853208|NCT06504147|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
214853209|NCT00110344|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
214853210|NCT00110344|DRUG|Placebo|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
214853211|NCT05202041|OTHER|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.
214853212|NCT05202041|OTHER|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
214853213|NCT01626963|PROCEDURE|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
214853214|NCT01626963|PROCEDURE|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
214853215|NCT00789763|DRUG|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
214853216|NCT00789763|RADIATION|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
214853217|NCT00789763|DRUG|Sorafenib|200-800 mg/day p.o. during 5 weeks
214853218|NCT00549952|OTHER|no intervention study|
214853219|NCT01932099|DEVICE|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
214853220|NCT03504761|DEVICE|ClariCore Optical Biopsy System|Demonstrate the efficacy and safety of the ClariCore System in obtaining prostate biopsies utilizing real-time tissue classification.
214853221|NCT01784354|OTHER|Acupressure|
214853222|NCT01784354|OTHER|Acupressure dilatation|
214853223|NCT01784354|BEHAVIORAL|education|
214853224|NCT02382926|OTHER|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
214853225|NCT04531657|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
214853226|NCT05684146|DEVICE|Emboliner Embolic Protection|Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
214853227|NCT05684146|DEVICE|Sentinel Cerebral Protection|The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
214853228|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
214853229|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
214853230|NCT04516408|BIOLOGICAL|Recombinant zoster vaccine|Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old. RZV contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system.
214853231|NCT04516408|BIOLOGICAL|Placebo|Sterilized water
214853232|NCT02919813|BEHAVIORAL|Mindfulness Based Group Cognitive BehaviorTherapy|Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.
214853233|NCT02919813|BEHAVIORAL|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
214853234|NCT03975413|OTHER|Fecal Microbiota Transplantation (FMT)|Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
214853235|NCT02335515|DEVICE|Soctec|Gastroretentive Drug Delivery System
214853236|NCT04765527|DIETARY_SUPPLEMENT|Turmeric Strength for Joint|Turmeric-based tablets
214853237|NCT04765527|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
214853238|NCT03665948|OTHER|Dietary Intervention - Ketogenic Diet (KD)|The experimental procedure for each randomly assigned participant included a 4-week of KD diet.
214853239|NCT03665948|OTHER|Dietary Intervention - Low-Glycemic Index Diet (CHO-LGI)|The experimental procedure for each randomly assigned participant included a 4-week of CHO-LGI diet.
214853240|NCT03236948|BEHAVIORAL|Women for Women International Intervention|
214853241|NCT02164630|BEHAVIORAL|Hope Therapy|Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
214853242|NCT02164630|OTHER|Pain Education|Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
214853243|NCT01855048|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
214853244|NCT01855048|OTHER|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
214853245|NCT04012372|OTHER|ROSA Water|Ad libitum hydration with ROSA oligomineral water
214853246|NCT04012372|OTHER|Control water|Ad libitum hydration with other waters
214853247|NCT02394691|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
214853248|NCT01704430|DIETARY_SUPPLEMENT|Glutamine|Enteric L-Glutamine
214853249|NCT01704430|DIETARY_SUPPLEMENT|Maltodextrin|Enteric Maltodextrin
214853250|NCT02596386|PROCEDURE|sialometry|potassium evaluation
214853251|NCT02596386|PROCEDURE|blood test|potassium evaluation
214853252|NCT02139124|DRUG|Placebo|Oral placebo capsule
214853253|NCT02139124|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
214853254|NCT02139124|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
214853255|NCT02139124|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
214853256|NCT02139124|DRUG|PRC-063 100 mg|Oral 100 mg capsule - active
214853257|NCT02691741|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
214853258|NCT02691741|DEVICE|AT LISA® tri IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
214853259|NCT03927924|PROCEDURE|High-intensity focused ultrasound|Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue
214853260|NCT01371084|BEHAVIORAL|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
214853261|NCT01371084|BEHAVIORAL|Pedal@Work|Worksite wellness program.
214853262|NCT00255255|DRUG|Budesonide/Formoterol|
214853263|NCT04867421|OTHER|No intervention|No intervention
214853264|NCT03465436|DRUG|Lasmiditan|100 mg administered orally (PO)
214853265|NCT03465436|DRUG|Lasmiditan|400 mg administered PO
214853266|NCT03465436|DRUG|Placebo|Placebo administered for lasmiditan or moxifloxacin
214853267|NCT03465436|DRUG|Moxifloxacin|400 mg moxifloxacin administered PO
214853268|NCT05613751|BEHAVIORAL|Nudge|Three text messages that are sent four weeks apart reminding to obtain the vaccines
214853269|NCT04636593|DRUG|Almonertinib|All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20\<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
214853270|NCT02399098|BEHAVIORAL|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
214853271|NCT04989777|DEVICE|IABP (Intra-aortic balloon pump ) implantation|Eligible AMI patients in SCAI-B stage will receive IABP implantation from the femoral artery
214853272|NCT02923882|OTHER|'$100Kitchen and improved cookstove'|
214853273|NCT04793074|COMBINATION_PRODUCT|Transforming nanoparticle dressing|Transforming nanoparticle dressing
214853274|NCT04793074|COMBINATION_PRODUCT|Conventional compression dressing|Conventional compression dressing
214853275|NCT05717582|DRUG|apalutamide|Patients receive apalutamide 240mg,qd,po.
214853276|NCT05717582|DRUG|androgen deprivation therapy|Patients receive systemic ADT.
214853277|NCT05717582|PROCEDURE|cytoreductive radical prostatectomy with/without pelvic lymph node dissection|Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.
214853278|NCT05717582|RADIATION|metastasis-directed therapy with radiation|Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.
214853279|NCT01478282|DRUG|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
214853280|NCT01478282|DRUG|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
214853281|NCT02697773|OTHER|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
214853282|NCT02697773|BIOLOGICAL|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
214853283|NCT02697773|BIOLOGICAL|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
214853284|NCT01995968|OTHER|Antenatal identification of fetal growth restriction|"FGR is considered as identified if:~* FGR was mentioned in medical charts~* OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~* OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~* OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~* OR utero-placental Doppler ultrasound indicated for suspicion of growth failure"
214853285|NCT05893316|DIAGNOSTIC_TEST|urine sample collection|The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.
214853286|NCT02404077|DRUG|Clonidine|
214853287|NCT06354855|OTHER|Group is doing breathing exercises while watching videos|Group is doing breathing exercises while watching videos: A video consisting of 30-minute exercises will be shot for these patients. And each patient will be asked to do the breathing exercise for 30 minutes by watching this video.
214853288|NCT06354855|OTHER|Medium pace walking group|Medium pace walking group: 30 minutes daily. Walking at a moderate pace is required. Physical activity levels will be monitored with the ActiGraph GT3X+ Accelerometer.
214853289|NCT06128694|DIETARY_SUPPLEMENT|NUTRICAN|Per serving/sachet NUTRICAN (±81g) contains 350 kcal energy, 9 g fat, 20 g protein, 48 g carbohydrate, 400 mg DHA, 300 mg EPA, 0.92 g Omega-3, 1 g L-Valine, 1.1 g L-Isoleucine, 2.1 g L-Leucine, 75 mg sodium, 12 vitamins and 9 minerals.
214853290|NCT06862713|BEHAVIORAL|pulmonary rehabilitation exercise|pulmonary rehabilitation exercise + standard protocol
214853291|NCT00333723|DRUG|Rosiglitazone|
214853292|NCT01118117|DEVICE|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
214853293|NCT00961454|DEVICE|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
214853294|NCT01448356|PROCEDURE|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~1. 25°C and 45% humidity;~2. 25°C and 65% humidity;~3. 30°C and 45% humidity;~4. 30°C and 65% humidity~After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition."
214853295|NCT04785508|DEVICE|neuromuscolar tape|neuromuscalar tape application in decompression technique (hand and arm)
214853296|NCT04785508|BEHAVIORAL|antigravity arm position|antigravity arm position
214853297|NCT04805619|DEVICE|Biomime Morph, a tapered drug eluting stent (DES) with hybrid design|Biomime Morph DES is a cobalt-chromium stent, with strut thickness of 65 µm, a hybrid cell design (closed cells in the extremity and open cells in the middle) and a conic shape, where the proximal part of the stent is 0.5 mm larger than the distal part (Table 1). In addition, the Biomime Morph elutes Sirolimus from a biodegradable polymer matrix.
214853298|NCT04741529|BEHAVIORAL|Healthy Minds Program app|"The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has \>100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP."
214853299|NCT00872326|PROCEDURE|Autologous Bone Marrow Mononuclear Cells|Infusion \> 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
214853300|NCT05412524|BEHAVIORAL|reading|Mothers and, if desired, mother's partner will read to preterm infant as frequently and as much as they are able to. Reading is the intervention. The variable of interest is parents' and infants' change in salivary oxytocin receptor gene methylation (OXTRm) over time.
214853301|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg on alternate weeks
214853302|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg every other week
214853303|NCT04758663|BEHAVIORAL|Nap/wake conditions on memory|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities.
214853304|NCT04758663|BEHAVIORAL|Nap/wake conditions on overnight physiology|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities. On the nights of the nap and wake conditions, physiology will be recorded in habitual and non-habitual nappers.
214853305|NCT04865913|OTHER|Observational|A brief 15 min phone call 1 week, 30 and 90 days post discharge.
214853306|NCT06367036|OTHER|Topical hypericum perforatum oil intervention|The research nurse working in the CICU applied 5-6 drops of hypericum perforatum oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied.
214853307|NCT00141141|DRUG|Atorvastatin|
214853308|NCT00141141|DRUG|Simvastatin|
214853309|NCT02149121|BIOLOGICAL|CT-P10|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
214853310|NCT02149121|DRUG|Rituxan|US-licensed reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
214853311|NCT02149121|DRUG|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
214853312|NCT02545855|DEVICE|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
214853313|NCT02545855|DEVICE|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
214664396|NCT04258618|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment. This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression. Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
214664397|NCT01829048|DRUG|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
214664398|NCT01829048|DRUG|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
214664399|NCT01829048|DRUG|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
214664400|NCT01829048|DRUG|Placebo|Placebo Q12h
214664401|NCT03038022|DRUG|MGL-3196|Oral
214664402|NCT03038022|DRUG|Placebo|Oral
214664403|NCT00504257|DRUG|Avastin|Day 1, every 21 day cycle
214664404|NCT00504257|DRUG|Docetaxel|Day 1, 8, every 21 day cycle
214853314|NCT06338735|OTHER|Ultra-High Frequency Ultrasound scan of minor salivary glands|Patients will undergo ultra-high frequency ultrasonography (70 MHz) of minor salivary glands, and the scans will be assessed using the OMERACT scoring system. Score 0 will be assigned in the presence of normal glandular tissue, Score 1 will correspond to mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 will be assigned to moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, while in Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis will be observed.
214664405|NCT02515240|BIOLOGICAL|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
214664406|NCT01033994|BIOLOGICAL|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
214664407|NCT03689218|DIETARY_SUPPLEMENT|Maamta (Nutritious Food Supplement)|Pregnant women will receive 30 sachets of Maamta during pregnancy and first six months of lactation.
214664408|NCT03689218|DIETARY_SUPPLEMENT|Wawamum (Lipid-Based Nutrient Supplement)|Children 6-24 months will receive 30 sachets of Wawamum every month during the study.
214664409|NCT05157633|OTHER|Controls|questionnaire food scale: HME data collection of food survey
214664410|NCT02453399|DEVICE|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
214664411|NCT04295187|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
214664412|NCT04295187|OTHER|Physical development and General Health|Physical development and General health examination
214664413|NCT04295187|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
214664414|NCT04219371|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214664415|NCT01945892|DRUG|Ozurdex|"\- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior."
214664416|NCT05326919|OTHER|Biobanking|For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.
214853315|NCT04043936|BEHAVIORAL|Cognitive Bias Modification Intervention for Help-Seeking Stigma|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
214853316|NCT04043936|BEHAVIORAL|Placebo Cognitive Bias Modification (CBM-Placebo)|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
214853317|NCT04043936|BEHAVIORAL|Self-Directed Psychoeducation|Material presented with information on mental health literacy, mental health stigma, \& treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
214853318|NCT00472875|DRUG|Glibenclamide|
214853319|NCT04316325|DRUG|Medical abortion|Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
214853320|NCT03195673|DRUG|Terazosin|TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
214853321|NCT03195673|PROCEDURE|Carotid artery stenting|Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
214853322|NCT00622687|DRUG|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
214853323|NCT00622687|DRUG|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
214853324|NCT00622687|DRUG|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
214853325|NCT00050882|DRUG|GM-611|
214853326|NCT03166124|DRUG|LY900014|Administered SC
214853327|NCT03166124|DRUG|Insulin Lispro|Administered SC
214853328|NCT03291041|DRUG|Tasimelteon|capsule
214853329|NCT03291041|DRUG|Placebo|capsule
214853330|NCT05064267|DIAGNOSTIC_TEST|phlebotomy|phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.
214853331|NCT06085339|BEHAVIORAL|Social Media|The social media arm participants will receive a diabetes curriculum designed to address diabetes self-efficacy and independence with diabetes management over the course of 6 months. Participants will have the option to engage with the study team and other participants through Instagram posts and direct messaging.
214853332|NCT02666391|BIOLOGICAL|umbilical cord mesenchymal stem cells|
214853333|NCT06297655|DRUG|Recombinant human activated coagulation factor VIII for injection|Recombinant human coagulation factor VIII for injection is a recombinant DNA product with functional characteristics comparable to endogenous factor VIII.
214853334|NCT04735731|DIAGNOSTIC_TEST|Echography|Echography of diaphragma and other respiratory muscles
214853335|NCT00774943|DRUG|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
214853336|NCT01398839|DEVICE|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
214853337|NCT01398839|DRUG|Riboflavin|Both treatment and sham groups will receive riboflavin
214853338|NCT03695055|DRUG|Maintenance therapy post-HSCT|Rituximab vs DPP/DCEP-G vs observation
214853339|NCT06269354|DEVICE|3D printed prostheses|3D printed prostheses
214853340|NCT01950676|DEVICE|Smart phone application|The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
214853341|NCT00922324|DRUG|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
214853342|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Biopsy would be taken from oesophageal cancer tissue and adjacent non-cancerous mucosa
214853343|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Random biopsy would be taken from normal non-cancer esophageal mucosa.
214853344|NCT01810094|DEVICE|Fracture Fixation|Thoracolumbar Fracture Fixation
214853345|NCT05719337|DEVICE|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
214853346|NCT02671682|PROCEDURE|Immunoadsorption|
214853347|NCT02671682|PROCEDURE|Plasmapheresis|
214853348|NCT03206567|DIETARY_SUPPLEMENT|Nutrafol Supplement capsules|NUTRAFOL's Synergen Complex® is a patent-pending formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some patented ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin), all of which are standardized and clinically tested. the Nutrafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
214853349|NCT03206567|OTHER|Placebo capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
214853350|NCT02105155|DRUG|Conversion at day 7 ± 3 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
214853351|NCT02105155|DRUG|Conversion at day 90±5 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
214853352|NCT00745719|PROCEDURE|parathyroidectomy|total parathyroidectomy with forearm autografting
214853353|NCT04226131|OTHER|Blood Draw|A study nurse will draw up to 150 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.
214853354|NCT04226131|OTHER|Disease Activity (DAS-28) Assessment|Participants in the RA cohort will receive a 28-joint examination by the study physician to assess RA disease activity and report their overall health assessment.
214853355|NCT04226131|OTHER|Skeletal Muscle Mitochondrial Respiratory Capacity|Near-Infrared Spectroscopy (NIRS) will be used to measure oxidative capacity of forearm flexor digitorum profundus and medial gastrocnemius muscles using the PortaMon device (Artinis Medical Systems, The Netherlands). NIRS is a low-cost, non-invasive method that estimates muscle oxidative capacity by measuring oxygen consumption (mVO2) recovery kinetics via assessment of intramuscular oxy- and deoxy-hemoglobin concentration following a sequence of brief, rapid arterial cuff occlusions. NIRS measures mitochondrial oxidative function as the mVO2 recovery rate constant k. In the absence of blood flow, changes in muscle oxygenation occur via oxygen consumption alone. In persons without RA, this non-invasive approach is highly correlated with muscle respiratory capacity assessed via muscle biopsies using in situ permiabilized fiber bundles and the Oroboros O2k system.
214853356|NCT04226131|OTHER|Muscle Biopsy|After local anesthesia (xylocaine, 2%) is injected, a small incision will be made in the thigh. Four to six small pieces of muscle about the size of a pea will be surgically removed. The incision site will be closed using steri-strips and/or derma-bond, and a light dressing applied.
214853357|NCT04226131|OTHER|Body Composition|Body composition assessments include circumference measurements and the BOD POD®. Minimal waist circumference measurements will be taken using a tape measure.
214853358|NCT04226131|OTHER|Cardiopulmonary Exercise Test (CPET)|Cardiorespiratory aerobic capacity (VO2 peak), will be assessed using a maximal treadmill test protocol with cardiopulmonary gas exchange. Subjects will be asked to exercise on a treadmill to their perceived maximum ability and effort during which time they will have a mouthpiece in their mouth to determine maximal oxygen use/consumption through breathing. For safety purposes the subject will be monitored by electrocardiogram (ECG) and their blood pressure will be measured at rest and throughout the exercise phase of this test.
214853359|NCT04226131|OTHER|Strength Testing|Strength assessments will include dynamometry-assessed grip and quadriceps strength (Cybex HUMAC NORM, Comp Sports Med, Inc., Stoughton, MA) tests
214853360|NCT04226131|OTHER|Questionnaires|Measures include global health, pain, fatigue, physical function, self-efficacy for disease management and sleep.
214853361|NCT04226131|OTHER|Skeletal Muscle Biomechanical Property Assessment|Passive skeletal muscle stiffness and elasticity measurements of bilateral biceps brachii, flexor carpi radialis, vastus lateralis, and tibialis anterior using mechanical deformation with myotonometry using the MyotonPro device.
214853362|NCT05045313|DRUG|Warfarin sodium tablets|Drug: Warfarin sodium, tablet, oral
214853363|NCT05045313|DRUG|Digoxin tablet|Drug: Digoxin, tablet, oral
214853364|NCT05045313|DRUG|Probenecid tablets|Drug: Probenecid, tablet, oral
214853365|NCT05045313|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
214853366|NCT01100879|DRUG|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
214853367|NCT05488717|OTHER|art-based mandala application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
214906994|NCT05354167|OTHER|oscillating manual energy therapy|It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow.
214906995|NCT00405561|DRUG|AMT2003|
214853368|NCT02801084|BEHAVIORAL|Reduced environmental stimulation|"Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 \& 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart."
214853369|NCT03103074|DRUG|Botulinum B Toxin|Intradermal injections
214853370|NCT03103074|OTHER|Placebo Saline|Intradermal injections
214853371|NCT02689999|DRUG|Dexrabeprazole 10 mg Enteric-Coated Tablets|
214853372|NCT03036774|PROCEDURE|Ultrasonic measurement of antral area|"Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures."
214853373|NCT04216420|DEVICE|MERM-observed self-administered therapy|The MERM device has an electronic module and a medication container that records adherence, stores medication, emits audible and visual on-board alarms to remind patients to take their medications on time and refill, and enables providers to download the data and monitor adherence. It is manufactured by Wisepill Technologies, South Africa.
214853374|NCT02774486|DEVICE|IQP-AK-102|IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
214853375|NCT02479373|OTHER|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
214853376|NCT02479373|OTHER|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
214853377|NCT02479373|OTHER|Biodex dynamometer|To study muscle strength
214853378|NCT02479373|OTHER|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
214664417|NCT00497224|DRUG|Erlotinib|Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
214664418|NCT04168086|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
214664419|NCT04168086|OTHER|Sham|The investigators will simulate focused ultrasound stimulation similar to the experimental groups but without stimulation.
214664420|NCT06103110|DEVICE|Photobiomodulation|Laser therapy using low level laser
214664421|NCT04249882|DRUG|Placebo|Matched to active medication
214664422|NCT04249882|DRUG|Naltrexone|50 mg once a day
214664423|NCT04249882|DRUG|Varenicline|1 mg twice a day
214664424|NCT00608088|BEHAVIORAL|Usual Care|"The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls."
214664425|NCT00608088|BEHAVIORAL|Community Health Nurse/Peer Councelor Team|"Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months."
214664426|NCT02440750|PROCEDURE|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
214664427|NCT02440750|DRUG|Dienogest|21 days administration of dienogest 2 mg/die
214664428|NCT02440750|DRUG|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
214664429|NCT00986960|DRUG|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
214664430|NCT00986960|DRUG|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
214853379|NCT02479373|OTHER|Quality of life questionnaires|
214906996|NCT06301074|DRUG|HS-10509|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
214664431|NCT00365781|DRUG|ISIS 113715|
214664432|NCT02252367|DRUG|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
214853380|NCT05745792|OTHER|Description of clinical, immunological and tumor features of patients harboring Hu Abs|This observationnal study involves clinical data and bio. samples (DNA and tumors block). Demographic and clinical data already in French Reference Center on PNS database will be reviewed. Additional data will be obtained from the referral physicians. The results of diagnostic tests performed to detect Hu-Abs in the patients are already in this database and will be retrospectively analyzed. In addition, the 4 available techniques (immunofluorescence, commercial immunodot, Western blot, and CBA) will be performed from Jan. 2022 to Dec. 2022.Tumor samples from 2 cohorts will be analyzed: (i) tumors of patients with Hu-Abs and PNS, and (ii) tumors of patients without PNS (mostly SCLC). After selecting patients, the study will involve 3 steps: (i) pathological confirmation; (ii) DNA sequencing and CNV analysis (panel of genes involved in anti-Hu autoimmunity; mainly ELAVL1 to 4, encoding for HuA to HuD, the 4 main proteins of the Hu family); and (iii) whole-genome RNA sequencing.
214853381|NCT01699763|DEVICE|Contour® NEXT LINK BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214853382|NCT01699763|DEVICE|OneTouch® UltraLink® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214853383|NCT01699763|DEVICE|Nova Max Link® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214853384|NCT00231218|DRUG|dietary supplement--echinacea, propolis, and vitamin c|
214853385|NCT03373136|DEVICE|Polypectomy|Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
214853386|NCT00210899|DRUG|ceftobiprole medocaril|
214853387|NCT00210899|DRUG|Vancomycin plus Ceftazidime|
214853388|NCT06444321|BEHAVIORAL|INTERCARE-HF|Develpent of an individualized treatment and follow-up plan tailored to co-morbidities, risk areas, cognitive function and functional level as well as the patients' symptoms and needs.
214853389|NCT01522079|PROCEDURE|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
214853390|NCT00094094|DRUG|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
214853391|NCT06412211|DEVICE|Photoacoustic finder|Sentinel lymph node detector using photoacoustic signal
214853392|NCT06920407|DEVICE|Breathing training device (Inspiratory Muscle Training)|Daily inspiratory muscle training (IMT) using the PowerBreathe IMT K3 device at varying resistance levels (15% for Sham and 65% for Experimental group) for 12 weeks. Participants will perform breathing exercises designed to assess the effects of different resistance levels on overall physical and emotional well-being, with a focus on how varying resistance impacts both respiratory strength and well-being.
214853393|NCT06920407|DEVICE|Oura Ring|The Oura ring measures daily biometrics such as heart rate, sleep, and blood oxygen levels, providing personalized health data and insights. Participants have access to this data through a mobile app, allowing researchers to assess whether increased access to health data and awareness has an impact on overall physical and emotional well-being.
214853394|NCT00683982|DRUG|Nitazoxanide|Nitazoxanide 15mg/Kg/day twice day for 3 days
214853395|NCT00683982|DRUG|Probiotic mix preparation|Probiotic preparation 1 gram twice a day for 5 days
214853396|NCT00683982|OTHER|Oral hydration solutions|Oral hydration solutions as needed
214853397|NCT02350582|DEVICE|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
214853398|NCT03536494|BEHAVIORAL|Review the use of mirabegron and its discontinuation|"A structured intervention was designed consisting of four major sections:~* General practitioners: information and training with written material and patient-centred prescribing.~* Specialized hospital care: information regarding the intervention for urologists and gynaecologists.~* Management support with the definition of a structured strategy.~* Monthly monitoring of the intervention."
214853399|NCT03779568|OTHER|Dose adjustment of bupivacaine|Spinal bupivacaine dose will be adjusted according to previous patient experience.
214853400|NCT06415279|DRUG|Winlevi (clascoterone) 1% cream|Twice daily (BID) dosing
214853401|NCT06029491|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the occluded cerebral vasculature using precisely pulsed aspiration. The system is comprised of the multi-use, non-sterile RapidPulseTM Aspiration Pump, the single use, sterile RapidPulseTM Tube set, the single use, non-sterile RapidPulseTM Collection Canister and the single use, sterile RapidPulseTM 071 Catheter.
214853402|NCT02960087|RADIATION|Low dose rate brachytherapy|I-125 to a total dose of 144 Gy
214853403|NCT02960087|RADIATION|High dose rate brachytherapy|27 Gy in 2 fractions
214853404|NCT05848778|DEVICE|Acute Intermittent Hypoxia|The acute intermittent hypoxia protocol will consist of 15 cycles of 1.5 min of inspiring ambient air (21% O2) alternating with 1.5 min of hypoxic air (9% O2)
214853405|NCT05848778|DEVICE|Normoxia|The normoxia protocol will consist of 15 cycles of 3 min of inspiring ambient air (21% O2)
214853406|NCT05555706|DRUG|B013+Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
214853407|NCT05368012|DRUG|MIDCAB|Ultrasound-guided administration of the nerve block MIDCAB into mid-calf as analgesic intervention for patients.
214664433|NCT02252367|OTHER|Placebo|Placebo tablet once daily for 12 weeks.
214853408|NCT06511167|DEVICE|TIGR® Matrix|bioresorbable, synthetic, surgical mesh
214853409|NCT03943537|DRUG|Intranasal Insulin|40 units Novolin R administered intranasally using ViaNase device.
214853410|NCT02403661|PROCEDURE|Post surgical electrical stimulation|Post surgical electrical stimulation immediately after surgical nerve repair
214853411|NCT06783140|DRUG|Nab paclitaxel|Paclitaxel Powder For Injectable Suspension Nanoparticle, Albumin-bound Paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity.
214853412|NCT06783140|DRUG|Gemcitabine|Gemcitabine is a hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity.
214853413|NCT06783140|DRUG|Cisplatin|Cisplatin is an alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.
214853414|NCT04974619|BEHAVIORAL|Online survey|Aim 1 Participants will be asked to complete a Qualtrics survey to identify knowledge gaps, health beliefs, attitudes, and educational learning preferences.
214853415|NCT04974619|BEHAVIORAL|Focus groups or Individual Interviews|Focus groups and/or individual interviews will be conducted in-person and/or remotely to receive feedback on the HPV vaccine education materials. Focus groups and/or individual interviews will be conducted with 24 young adult Latino men who have sex with men (YLMSM) in either English or Spanish (approximately 12 in Puerto Rico and approximately 12 in Florida). The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference, and aesthetics of the theoretically informed HPV education materials culturally targeted for Spanish- and/or English-speaking YLMSM.
214853416|NCT04974619|BEHAVIORAL|Interviews|In-depth interviews (n=20) will be conducted with key stakeholders (10 in PR and 10 in FL) eliciting feedback to inform intervention content and delivery methods and identify potential facilitators and barriers to intervention implementation.
214853417|NCT03929809|DEVICE|Cochlear Implant|adults with unilateral hearing loss who wish to regain bilateral hearing will be implanted with a cochlear implant on their deafened ear.
214853418|NCT06272292|DIAGNOSTIC_TEST|EOS|Every subject in this study will undergo a radiographic analysis of the hip and spine using a low-dose, full-body biplanar X-ray acquisition (in standing, sitting and squatting position, EOS imaging).
214853419|NCT06272292|DIAGNOSTIC_TEST|3D motion lab analysis|"A hip-specific 3D motion analysis will be performed. The 3D motion protocol will be divided into 2 main sections.~First section: Consist of movements categorized within the activities of daily living (walking at self-selected speed, uphill walking, standardized deep squat and non-standardized deep squat)~Second section: Consists of movements that are categorized within athletic training and have been specifically chosen to induce large hip ranges of motion (Sumo squats, dead lifts, forward lunges, running uphill and downhill)~Each movements will be repeated 6 times. Three times with the dominant foot/opposite leg on the force plate to collect kinetic data. All data will be captured using two 10-15 camera 3D motion capture systems and one capturing an instrumented treadmill (M-gait)"
214853420|NCT05473624|DRUG|HRS-1167|Participants will receive HRS-1167.
214853421|NCT06164951|DRUG|Infigratinib 0.25 mg/kg/day|Daily doses of oral Infigratinib (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
214853422|NCT06164951|DRUG|Placebo Comparator 0.25 mg/kg/day|Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
214853423|NCT05712382|BEHAVIORAL|Parent handbook|Handbook motivating parents to discuss alcohol use with their college student.
214853424|NCT05712382|BEHAVIORAL|Coping with negative emotions|Mindfulness-based techniques are taught to improve ability to cope with negative emotions.
214853425|NCT05712382|BEHAVIORAL|Problem-solving risky situations|Identifying and planning for barriers to change are encouraged.
214853426|NCT05712382|BEHAVIORAL|Recovering from slips|Peer and personalized techniques are discussed to facilitate resumption of moderate drinking after a heavy drinking episode.
214853427|NCT03702634|BEHAVIORAL|Spiritual Care Assessment and Intervention (SCAI) framework|The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
214853428|NCT06580704|DRUG|Lumbosacral Erector Spinae Plane Block|Patients will receive ultrasound-guided lumbosacral erector spinae plane block.
214853429|NCT06580704|DRUG|Psoas Muscle Compartment With Sciatic Nerve Block|Patients will receive ultrasound-guided psoas muscle compartment with sciatic nerve block.
214853430|NCT01741779|OTHER|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
214290348|NCT00951990|BEHAVIORAL|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
214853431|NCT01741779|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
214853432|NCT01741779|OTHER|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
214853433|NCT00368095|BEHAVIORAL|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
214853434|NCT06270628|BEHAVIORAL|Exercise group|Live-remote exercise sessions, personalized to the patients main side-effect
214853435|NCT03349827|PROCEDURE|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical gastrectomy and cytoreductive surgery
214853436|NCT03349827|PROCEDURE|HIPEC|Normal saline 3000ml-4000ml, Docetaxel 50mg/m2, Lobaplatin 50mg/m2, 43°C, 60min.
214853437|NCT03349827|DRUG|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week
214853438|NCT03349827|DRUG|Apatinib|500mg, once daily, day 1 to day 21.
214853439|NCT00493779|PROCEDURE|Blood Collection|4 weeks
214853440|NCT01951287|OTHER|Acute beverage (water) consumption|Acute beverage consumption includes water.
214853441|NCT01951287|OTHER|Acute beverage (Black Coffee) consumption|Acute beverage consumption includes black coffee.
214853442|NCT01951287|OTHER|Acute beverage (Orange Juice) consumption|Acute beverage consumption includes Orange Juice..
214853443|NCT01951287|OTHER|Acute beverage (Whole Milk) consumption|Acute beverage consumption includes whole milk
214853444|NCT01951287|OTHER|Acute beverage (2% Milk) consumption|Acute beverage consumption includes 2% milk
214853445|NCT01951287|OTHER|Acute beverage (Skim Milk) consumption|Acute beverage consumption includes skim milk
214853446|NCT03804164|OTHER|Educational Intervention|Attend Emerging from the Haze psychoeducational sessions
214853447|NCT03804164|OTHER|Quality-of-Life Assessment|Ancillary studies
214853448|NCT03804164|OTHER|Survey Administration|Ancillary studies
214853449|NCT03659084|DRUG|EXJADE|The patient having given his consent, will begin the Exjade at 10 mg / kg per day if the ferritin level reached 1000 ng / ml at 6 months after allograft, for a minimum duration of three months and up to 6 months. The iron parameters will be evaluated at 3, 6, 9, 12, 18 and 24 months after the beginning of the exjade treatment. The evaluation of the disease will be carried out according to the practices of the center. It is recommended to have a washout period of one week between stopping the ciclosporin and the beginning of treatment by exjade.
214853450|NCT01675024|DRUG|Rotigotine, Period 1|"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
214853451|NCT01675024|DRUG|Rotigotine, Period 2|"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
214853452|NCT02619136|PROCEDURE|Transfusion|Red Blood Cell Transfusion
214853453|NCT02969772|OTHER|Assessment of upper limb variables|International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).
214853454|NCT02969772|OTHER|Training protocol|The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
214853455|NCT01834781|DEVICE|Pulsed electromagnetic fields|
214853456|NCT01834781|DEVICE|w/o pulsed electromagnetic fields|
214853457|NCT03145402|BIOLOGICAL|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
214853458|NCT03145402|BIOLOGICAL|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
214853459|NCT02988479|OTHER|Out of pocket payments in patients|
214853460|NCT05626699|DEVICE|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
214853461|NCT01120652|BEHAVIORAL|Mind-Body Skills Training (MBST)|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
214853462|NCT01120652|BEHAVIORAL|Supportive Counseling (SC)|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
214853463|NCT01857648|OTHER|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
214853464|NCT01224028|DRUG|Tacrolimus|oral
214853465|NCT01224028|DRUG|Placebo|oral
214853466|NCT00618202|DRUG|Balsalazide|
214853467|NCT01475253|DRUG|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
214853468|NCT01475253|OTHER|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
214853469|NCT01475253|PROCEDURE|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
214853470|NCT05010824|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem. The second and third session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. Follow-up phone calls provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
214853471|NCT03521063|DRUG|Budesonide|Drug: Budesonide inhalation suspension
214853472|NCT03521063|DRUG|Poractant Alfa|Drug: Poractant alfa intratracheal suspension
214853473|NCT03521063|DRUG|Saline|Sodium chloride injection 0.9%
214853474|NCT04016792|DRUG|Placebo|Placebo will be administered once daily
214853475|NCT04016792|DRUG|200 mg SPN-812|200 mg SPN-812 will be administered once daily and compared to Placebo
214853476|NCT03995017|DRUG|Rucaparib|Rucaparib tablet
214853477|NCT03995017|DRUG|Ramucirumab|Ramucirumab intravenous solution
214853478|NCT03995017|DRUG|Nivolumab|Nivolumab intravenous solution
214853479|NCT05364996|DIAGNOSTIC_TEST|bronchial endoscopy with bronchoalveolar lavage (LBA)|Bronchial endoscopy under laryngeal mask and general anesthesia. BAL of saline at room temperature of 3 milliliters per kilogram limited to 20 milliliters x 3 according to recommendations
214853480|NCT05364996|DIAGNOSTIC_TEST|Blood sampling|collection of 5 milliliters of blood for total white cells count, C-Reactive Protein, specific immunoglobulin E assays, serum sRAGE assay
214664434|NCT01608334|DRUG|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
214664435|NCT01608334|DRUG|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
214664436|NCT05239104|OTHER|No intervention|This is an observational study with no intervention
214664437|NCT02317510|PROCEDURE|combined anesthesia|Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
214664438|NCT02317510|PROCEDURE|general anesthesia|General anesthesia for laparoscopic cholecystectomy
214664439|NCT04937699|DRUG|Standard-DAPT of Ticagrelor plus aspirin|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months
214664440|NCT04937699|DRUG|Sequential monotherapy of Ticagrelor and clopidogrel|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
214664441|NCT00552266|DRUG|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
214664442|NCT00787007|DRUG|S-equol|capsule, oral, single dose
214664443|NCT00787007|DRUG|Placebo|capsule, oral, single dose
214664444|NCT05516329|DRUG|A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide|The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60\~120 min after the injection.
214664445|NCT01519726|DRUG|Midazolam|
214664446|NCT05782088|PROCEDURE|Single Piezocision|Piezocision will be performed only once before the onset of canine retraction (T0) on one side of the maxillary arch that will be randomly chosen.
214664447|NCT05782088|PROCEDURE|Repeated Piezocision|Piezocision will be repeated three times, on a monthly basis (T0, T1, and T2), over the 12-week study period.
214664448|NCT02904226|DRUG|JTX-2011|Specified dose on specified days
214664449|NCT02904226|DRUG|Nivolumab|Specified dose on specified days
214664450|NCT02904226|DRUG|Ipilimumab|Specified dose on specified days
214664451|NCT02904226|DRUG|Pembrolizumab|Specified dose on specified days
214664452|NCT01906437|DEVICE|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
214664453|NCT05983393|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed
214664454|NCT05983393|PROCEDURE|Control|Erector spinae plane block was not applied.
214664455|NCT00728416|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
214664456|NCT00728416|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
214664457|NCT06021743|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
214664458|NCT06021743|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
214664459|NCT06021743|DIAGNOSTIC_TEST|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
214664460|NCT06021743|DIAGNOSTIC_TEST|Measurement of inflammatory cytokines|A panel of pro- and anti-inflammatory markers will be determined by flow cytometer microsphere-based assay.
214664461|NCT04937257|OTHER|Virtual Reality|The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.
214664462|NCT04937257|OTHER|E-module|The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
214664463|NCT02389881|DRUG|TAK-058|TAK-058 Solution
214664464|NCT02389881|DRUG|TAK-058 Placebo|TAK-058 placebo-matching solution
214664465|NCT02456220|DEVICE|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
214664466|NCT06075823|DEVICE|TEER|transcatheter edge-to-edge mitral valve repair for significant mitral regurgitation
214664467|NCT06075823|OTHER|Optimal Medical Therapy|optimal heart failure management of ATTR-CM
214664468|NCT02013219|DRUG|Alectinib|Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
214853481|NCT00594113|OTHER|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
214853482|NCT00594113|OTHER|Touch screen intervention|Touch screen intervention
214853483|NCT06091228|OTHER|tongue scraper|tongue cleaning with gentle strokes twice a day covering the whole surface of the tongue
214853484|NCT04340999|DIAGNOSTIC_TEST|Nerve conduction studies and Quantitative EMG ( MUNE and IPA)|"Nerve Conduction Studies: Electrophysiological method that tests the presence/absence of peripheral neuropathy.~MUNE: Electrophysiological technique that assess number of motor units. IPA: Electrophysiological method that assess interference pattern and hence, borderline cases of neuropathy/ myopathy"
214853485|NCT03113578|DEVICE|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
214853486|NCT03507348|DRUG|visits of tocilizumab injection (every 4 weeks, up to 5 visits)|every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).
214853487|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-30|Rituximab 375 mg/m2 at Day-30
214853488|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-15 (only for donors living)|Rituximab 375 mg/m2 at Day-15
214853489|NCT03507348|OTHER|Transplant Day-0|TRANSPLANTATION
214853490|NCT06037226|BEHAVIORAL|Postpartum pelvic floor rehabilitation|biofeedback with Pelvic floor muscle training (PFMT)
214853491|NCT00180076|DRUG|Budesonide|
214853492|NCT01677923|DRUG|Metformin|Metformin 500 mg BID for 12 months
214853493|NCT05311917|OTHER|home vision therapy|a group of vision therapy procedures in home to improve convergence insufficiency
214853494|NCT05311917|OTHER|base in prism prescription|base in prism prescription according to sheards criterion
214853495|NCT05311917|OTHER|conventional placebo|using near glasses with aimless eye training
214853496|NCT02961166|DRUG|IgM enriched Immunoglobulins|Treatment for 3 days
214853497|NCT05805735|OTHER|Face care product (Eye cream)|The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
214853498|NCT04206514|BEHAVIORAL|Person Centered Care - Post Abortion Support|Post abortion phone based support
214853499|NCT01476735|OTHER|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
214853500|NCT00500279|DRUG|Celecoxib|
214853501|NCT01139684|BEHAVIORAL|Repeated sprint test|
214853502|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity Only|The primary focus of the home activity program was based on collaborative parent-child cooking activities which the families undertook themselves at home. There were two key tasks: the first was to add one extra vegetable to the evening meal each day, the second was to select, prepare and cook one recipe from the cook book each week.
214853503|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity + cooking Workshop|The main purpose of these workshops was to provide hands-on successful food preparation and cooking experiences for the families and several opportunities to taste new vegetable-based recipes as well as promoting knowledge of cost and healthy eating. Children and their parents were then encouraged to take whatever was learned and apply it at home.
214853504|NCT03036241|DEVICE|Conventional angioplasty|Angioplasty with conventional balloon
214853505|NCT03036241|DEVICE|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
214853506|NCT01731899|DRUG|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
214853507|NCT05468788|BEHAVIORAL|Intervention: Integrative Community Therapy-based Psychodrama|Participants produce theatre scenes depicting issues that they have experienced. Group leaders then use a guide to facilitate a discussion of participants' feelings, coping strategies, and sharing of local knowledge.
214853508|NCT05468788|BEHAVIORAL|Control: Improvisational Theatre|Participants play improvisational theatre games.
214853509|NCT02273687|DEVICE|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
214853510|NCT00301847|DRUG|sorafenib tosylate|
214853511|NCT00761449|DRUG|lenalidomide|Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
214853512|NCT05154812|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
214853513|NCT05154812|DRUG|Routine medical care|Routine medical care
214853514|NCT03441724|DIAGNOSTIC_TEST|Mechanocardiography|Mechanocardiographic recording
214853515|NCT00690976|BEHAVIORAL|Proyecto SOL|Group intervention
214853516|NCT00690976|BEHAVIORAL|HCT|Offer of HIV counseling and testing
214853517|NCT04030182|DIAGNOSTIC_TEST|Level of Vitamin D|3 ml of venous blood will be taken to determine the level of vitamin D
214853518|NCT01599130|DRUG|Entecavir|entecavir 0.5mg per day
214853519|NCT01599130|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
214853520|NCT04790123|PROCEDURE|Injection of autologous freshly collected adipose tissue|injection of fresh autologous fat, previously lipoaspirates from the patient's abdomen and centrifugated, into the fistulous tract, after curettage and closure of the internal opening.
214853521|NCT04790123|PROCEDURE|sham|curettage and closure of the internal orifice of the anal fistula and simulated intervention in the abdomen.
214853522|NCT04311151|PROCEDURE|own seizures visualization|At the hospital discharge, patients
214853523|NCT03394911|BIOLOGICAL|250mg healthy adult male facial skin surface lipid liquid pheromone|Human Pheromone provided p.o. to tox-screen verified opioid drug addict
214853524|NCT04341857|DRUG|PD-1 Monoclonal Antibody(Sintilimab)|Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
214853525|NCT01305148|DEVICE|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
214853526|NCT05587114|DIAGNOSTIC_TEST|frozen blood plasma samples|Analysis of various biomarkers using frozen blood samples
214853527|NCT01087632|DIETARY_SUPPLEMENT|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
214853528|NCT03952611|PROCEDURE|Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
214853529|NCT03952611|DEVICE|distal Cap|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
214853530|NCT03952611|DEVICE|Endocuff|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
214853531|NCT01342536|BEHAVIORAL|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|"The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)"
214853532|NCT03840499|DRUG|Optimal medical therapy|Optimal medical therapy
214853533|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
214853534|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
214853535|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
214853536|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
214853537|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
214853538|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
214853539|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
214853540|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
214853541|NCT02589158|DRUG|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
214853542|NCT02589158|DRUG|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
214853543|NCT00836719|DRUG|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
214853544|NCT02148913|DRUG|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
214853545|NCT02148913|DRUG|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
214853546|NCT02148913|DRUG|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
214853547|NCT02148913|DRUG|Cohort 3b: Carfilzomib 27 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
214290349|NCT00951990|BEHAVIORAL|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
214853548|NCT03192852|OTHER|dental bleaching|dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel
214853549|NCT03192852|PROCEDURE|Gingivoplasty|gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
214853550|NCT05904249|OTHER|Internet Based Synchronized Telerehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
214853551|NCT05904249|OTHER|Face-to-Face Rehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
214853552|NCT02340494|BEHAVIORAL|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
214853553|NCT00431158|OTHER|Different Mechanical Ventilation Protocols|"OLA Group: Open lung approach protocol and recruitment maneuvers~ARDSnet Group: ARDSnet protocol"
214853554|NCT05602402|OTHER|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
214853555|NCT05602402|OTHER|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
214853556|NCT02678442|DEVICE|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
214853557|NCT02678442|DEVICE|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
214853558|NCT02490306|DEVICE|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
214853559|NCT06302972|OTHER|Traditional treatment|Hot Pack will be applied at the beginning of the session for 10 minutes. Wall corner stretching exercises, neck isometric exercises and neck stretching exercises will be performed Cold pack will be applied at the end of the session for a few minutes.
214853560|NCT06302972|OTHER|IASTM and CCEP|"Instrument Assisted Soft Mobilization Technique (IASTM); For pectoralis major:~Subjects will be asked to lay supine with their thorax front side exposed. In abduction, restriction or adhesions will be located using scanning and gel will be applied. IASTM also address soft tissue restrictions and pain in levator scapulae, suboccipital muscles and sternocleidomastoid muscle.~The Comprehensive Corrective Exercise Program (CCEP) will be designed in three phases, including initial, improvement, and maintenance.. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board"
214853561|NCT04336839|PROCEDURE|Portal vein resection / reconstruction|Portal vein resection and reconstruction, with or without concommitant arterial resection
214853562|NCT01805726|DRUG|xylocain|Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
214853563|NCT01805726|DRUG|Alfentanil|(A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
214853564|NCT01805726|DRUG|Dexmedetomidine|(D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
214853565|NCT04420338|BIOLOGICAL|Blood sample|rapid serological tests carried out
214853566|NCT04420338|BIOLOGICAL|Serum tube collection|SARS-COV2 seroconversion assay
214853567|NCT04289506|DIAGNOSTIC_TEST|mRNA expression|The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
214664469|NCT02013219|DRUG|Atezolizumab|Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
214853568|NCT00303875|BEHAVIORAL|behavioral dietary and exercise intervention|
214853569|NCT03176368|OTHER|Coconut Oil|Coconut Oil
214853570|NCT04891965|BIOLOGICAL|ART24|Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10\^9 CFU/capsule. Subjects will receive 1 capsule daily.
214853571|NCT04891965|DRUG|Placebo|Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
214853572|NCT03074539|DRUG|Riociguat|Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
214853573|NCT03074539|PROCEDURE|Pulmonary Endarteriectomy|Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.
214853574|NCT03074539|PROCEDURE|Ballon Pulmonary Angioplasty|Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
214853575|NCT00859001|DRUG|FM+R|Fludarabine-Mitoxantrone-Rituximab
214853576|NCT00859001|DRUG|Zevalin (Ibritumomab Tiuxetan)|
214664470|NCT02013219|DRUG|Erlotinib|Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
214853577|NCT04595916|DRUG|Polyene phosphatidylcholine injection 930 mg QD|Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
214664471|NCT03984409|DIETARY_SUPPLEMENT|Kroger low calorie orange juice beverage|Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
214853578|NCT04595916|DRUG|Magnesium Isoglycyrrhizinate injection 200 mg QD|Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
214853579|NCT03612739|BIOLOGICAL|NKR-2 CAR-T Cells|"The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5."
214853580|NCT01261741|DRUG|Memantine|Each subject will receive memantine 10mg tablets once daily
214853581|NCT01261741|DRUG|Placebo|Each subject will receive matching placebo tablets once daily
214853582|NCT05632341|DIETARY_SUPPLEMENT|Lactococcus lactis|1 capsule once a day
214853583|NCT05632341|OTHER|maltodextrin|1 capsule once a day
214853584|NCT03064321|BEHAVIORAL|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
214853585|NCT03064321|OTHER|Information Control|Information on websites that are general health promoting
214853586|NCT00725478|DRUG|Piribedil|
214853587|NCT02818387|DRUG|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
214853588|NCT02818387|DRUG|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
214664472|NCT03879291|OTHER|pinpointIQ|The study will utilize physIQ's multivariate analytical methods that detect vital sign relationship changes compared to a patient's individual baseline. Changes in vital signs relationships may be indicative of current or future important clinical events. These changes are indicated through the Multivariate Change Index (MCI), which is a scalar index between 0 and 1, where values close to 0 indicate no significant change from baseline and values close to 1 indicated greater changes from baseline
214664473|NCT06379334|DIAGNOSTIC_TEST|Urine test|Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.
214664474|NCT05363917|DRUG|Natrunix with MTX placebo (+folate)|True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
214664475|NCT05363917|DRUG|Natrunix placebo with MTX (+folate)|Natrunix placebo with MTX (+folate)
214664476|NCT02566512|OTHER|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
214664477|NCT02566512|OTHER|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
214853589|NCT02818387|DRUG|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
214853590|NCT01045993|DEVICE|Heat Device|8-Hour Heatwrap
214853591|NCT01045993|DEVICE|Sham Device|Inactive wrap worn for 8 hours
214853592|NCT01045993|DRUG|marketed analgesic|2 x 200 mg ibuprofen tablets
214853593|NCT01045993|DRUG|Placebo|2 x placebo tablets
214853594|NCT01827124|DRUG|Carbetocin|
214853595|NCT01827124|DRUG|oxytocin|
214853596|NCT00795808|DRUG|Metformin|500mg tds for 6 months
214853597|NCT00795808|DRUG|Placebo|One tablet tds for 6 months
214853598|NCT00795808|DRUG|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
214853599|NCT00795808|DRUG|Metformin|500mg tds for 6 months
214853600|NCT00795808|DRUG|Clomiphene|Ovulatory dose for 6 months
214853601|NCT04414839|DEVICE|Digital Intubation (Two-finger)|In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.
214853602|NCT04414839|DEVICE|Video Laryngoscopy|In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
214853603|NCT05506358|DIAGNOSTIC_TEST|High performance liquid chromatography|High performance liquid chromatography (HPLC) using the D10 System by Bio-Rad Laboratories will be used as the gold standard test.
214853604|NCT05506358|DEVICE|Automated sickling test|The standard sickling test using 2% sodium metabisulphite will be augmented using an automated microscope (such as Octopi) and machine learning, and will be used as one of the low-cost tests.
214853605|NCT05506358|DIAGNOSTIC_TEST|HbS solubility test|Standard HbS solubility test currently used in Nepal (e.g. Sicklevue) will be used as one of the low-cost tests
214853606|NCT05506358|DEVICE|HemoTypeSC|A point-of-care lateral flow assay, HemoTypeSC (https://www.hemotype.com/), will be used as one of the low-cost tests
214853607|NCT05506358|DEVICE|Sickle SCAN|A point-of-care lateral flow assay, Sickle SCAN (https://www.biomedomics.com/products/hematology/sicklescan/), will be used as one of the low-cost tests
214664478|NCT05600127|DRUG|Avelumab|3 cycles of avelumab (800mg, every 2 weeks)
214853608|NCT05506358|DEVICE|Gazelle Hb Variant Test|A portable electrophoresis machine, Gazelle diagnostic device (https://hemexhealth.com/), will be used as one of the low-cost tests
214853609|NCT01659736|DEVICE|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
214853610|NCT00391079|DRUG|Sativex|"Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg."
214853611|NCT00391079|DRUG|Placebo|Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
214853612|NCT02809170|DIETARY_SUPPLEMENT|Arginine|Arginine is an amino acids
214853613|NCT02809170|DIETARY_SUPPLEMENT|Citrulline|Citrulline is an amino acid
214290350|NCT00106392|DRUG|Tacrolimus|oral
214664479|NCT01696812|PROCEDURE|electrode position|
214664480|NCT01244737|DRUG|[18F] FLT|\[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
214664481|NCT05830383|BEHAVIORAL|PDCA circular management|"PDCA circular management means PlanDoCheckAction four steps"
214853614|NCT01004042|DRUG|Botulinum Toxin Type A|Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
214853615|NCT00338052|DRUG|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
214853616|NCT00397306|DEVICE|Bioimpedance Analysis|
214853617|NCT04529447|OTHER|Survey|The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
214853618|NCT03301532|DRUG|Triheptanoin|Dietary supplementation with triheptanoin
214853619|NCT01144728|DRUG|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
214853620|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques
214664482|NCT02304003|OTHER|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
214664483|NCT02304003|OTHER|Standard Care|Standard follow up in primary care.
214664484|NCT01667848|DEVICE|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
214664485|NCT01667848|DEVICE|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
214664486|NCT03398772|BEHAVIORAL|Comprehensive Health Coaching Program|Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
214664487|NCT02844738|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Days 7 and 14 \[PRP\]
214664488|NCT04299529|DIAGNOSTIC_TEST|In-vitro urinary diagnostic test|Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
214664489|NCT05942690|PROCEDURE|manual osteopathic intervention|The subject sits on the examination table for the manual osteopathic intervention. The expert osteopath, having no report from the sonographers, will manually test breathing diaphragmatic and will bring osteopathic manual treatment to the area of mobility restriction
214664490|NCT01187225|DRUG|Fibrinogen concentrate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
214664491|NCT01187225|DRUG|Cryoprecipitate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
214664492|NCT04554368|PROCEDURE|intra-arterial contrast enhanced Flat Detector CT|After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
214664493|NCT00071773|PROCEDURE|modified-ETDRS photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
214664494|NCT00071773|PROCEDURE|Mild Macular Grid photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
214664495|NCT03642561|DEVICE|radiotherapy ablation|We using Cool Tip system or RITA system to perform RFA
214664496|NCT03642561|DEVICE|transarterial chemoembolization(TACE)|TACE treatment is a first line treatment for BCLC stage B HCC
214664497|NCT01567436|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.
214664498|NCT05453799|DRUG|Vudalimab|Given IV
214664499|NCT01723306|GENETIC|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
214664500|NCT04184648|OTHER|no interventions|no intervention
214664501|NCT05614011|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test. A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's Instructions For Use (IFU) in one nostril.
214664502|NCT05614011|DIAGNOSTIC_TEST|Real-time PCR Test|Mid-turbinate nasal swab samples will be taken from the opposite nostril that was not swabbed for the comparator sample using Copan FLOQ swabs and placed into MSwab buffer. In instances where opposite nostrils cannot be swabbed for both the comparator and the candidate tests, a 15-minute waiting period to allow for viral reloading will occur before collecting the candidate test sample.
214664503|NCT01144754|DRUG|Rituximab|Calculated per patient
214664504|NCT00730236|DRUG|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
214290351|NCT00106392|DRUG|Placebo|oral
214290352|NCT01725620|DRUG|LBEC0101 (Etanercept 25mg)|
214290353|NCT01725620|DRUG|Enbrel (Etanercept 25mg)|
214664505|NCT06075303|BEHAVIORAL|Modified Cycles|
214664506|NCT02160418|BEHAVIORAL|Financial Incentives|
214664507|NCT02160418|BEHAVIORAL|Cognitive Incentives|
214664508|NCT02160418|BEHAVIORAL|Financial and Cognitive Incentives|
214664509|NCT02317731|OTHER|Straw|Bowel preparation ingestion with a straw
214853621|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia and additive bb-glasses|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques, bb-glasses worn from 3 hrs before bedtime.
214290354|NCT01365234|DEVICE|Pacing Lead|Implant and follow up of Model 20066 lead
214664510|NCT05434546|DRUG|Sepranolone|Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
214664511|NCT04619576|BEHAVIORAL|Occupational health workers|Questionnaire online
214853622|NCT04463498|OTHER|8-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
214853623|NCT00006091|DRUG|arsenic trioxide|
214853624|NCT00002199|DRUG|Indinavir sulfate|
214853625|NCT00002199|DRUG|Lamivudine/Zidovudine|
214853626|NCT00002199|DRUG|Abacavir sulfate|
214853627|NCT05051059|OTHER|Functional outcome|3D-motion analysis and strength assessment
214853628|NCT05051059|OTHER|Health related quality of life (HRQoL) assessment|Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
214853629|NCT02751970|PROCEDURE|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
214664513|NCT02039947|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
214664514|NCT02039947|DRUG|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
214853630|NCT02751970|PROCEDURE|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
214290355|NCT03652844|PROCEDURE|AAM|Subcutaneous injection procedure
214664515|NCT04057183|DIAGNOSTIC_TEST|Carotid Stenotic Scan|Noninvasive determination of presence or absence of carotid artery stenosis
214664516|NCT05251545|OTHER|Pulmonary vein isolation|Comparison of power levels in catheter ablation in regard of single procedure success rate (freedom of any atrial arrhythmia with a duration of more than 30 sec. 45 Watts versus standard power levels (30 Watts).
214664517|NCT06024252|DRUG|TACE|TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.
214664518|NCT04391764|DRUG|Naltrexone|Naltrexone at a dose of 50 mg per day
214664519|NCT04391764|DRUG|Placebo oral tablet|Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
214664520|NCT02183389|DRUG|Warfarin|
214664521|NCT02183389|DRUG|BI 1356|
214664522|NCT00644267|BEHAVIORAL|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
214664523|NCT04224623|BEHAVIORAL|Raising Well at Home|The Raising Well at Home intervention was delivered via 3 core home visits designed to be delivered every 4-6 weeks, with additional support via text or phone over 6 months. The home visits were designed to engage the whole family, build skills, and promote changes in the home environment to support lifestyle behavior change. These essential behaviors focused on reducing sugary beverage intake, promoting appropriate portion sizes, improving fruit and vegetable intake, increasing walking and reducing screen time/sedentary activity.
214664524|NCT03364218|DRUG|N-Acetyl Cysteine|Nebulized N-Acetyl Cysteine administered every 12 hours
214664525|NCT04543500|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
214664526|NCT04304677|DEVICE|Percutaneous coronary intervention|"1. Pre-PCI FFR pullback recording was done with conventional system~2. Automated algorithm to calculate delta FFR per unit time was developed~3. PCI was performed using 2nd generation DES"
214664527|NCT05939284|DRUG|Injection of Cetrorelix|Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.
214664528|NCT05939284|DRUG|Oral insertion of dydrogeserone|Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day
214664529|NCT03982225|DRUG|Polyene phosphatidylcholine injection|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
214664530|NCT03982225|DRUG|Placebo|Phosphate buffered saline placebo for injection
214664531|NCT01772134|DRUG|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
214664532|NCT01772134|DRUG|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
214664533|NCT01772134|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
214664534|NCT01772134|DRUG|Placebo|Inhalation Powder, Placebo
214664535|NCT06404190|COMBINATION_PRODUCT|Diode laser and 3% hydrogen peroxide|"Hydrogen peroxide due to its super radicals has a local antimicrobial effect. Since hydrogen peroxide can be easily available in a clinical setting and is cost-effective. It could be used for photo disinfection along with lasers.~The diode lasers that belong to the 655-980 nm spectrum could represent a safer alternative. Because of the transmission or scattering effect on hydroxyapatite, diode lasers have no effect on hard tissues and deposits. The photoactivation procedure uses photolysis of hydrogen peroxide with 810nm laser.~Hydrogen peroxide acts as an endogenous dye, which can increase the laser effect at this level and also generate ROS. Thus the combination of 3% H2O2 and laser light generate hydroxyl radicals as a result of photoactivation.~Therefore, the diode laser stimulation of 3%hydrogen peroxide has been utilized adjunctive to SRP to optimize clinical outcomes."
214853631|NCT02751970|PROCEDURE|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
214853632|NCT02751970|PROCEDURE|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
214853633|NCT02751970|PROCEDURE|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
214853634|NCT05160753|PROCEDURE|Laparoscopic gastric function preserving surgery combined with resection of the anterior lymphatic drainage area|A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method., and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed.
214853635|NCT02341950|BEHAVIORAL|SCI Hard|The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
214853636|NCT01953822|OTHER|Data collection|Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
214853637|NCT01509742|DRUG|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
214853638|NCT01509742|DRUG|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
214853639|NCT05181332|OTHER|Prediction model|Clinical models were developed and validated to predict liver-related complications and survival outcomes in pediatric patients with biopsy-proven with cirrhosis.
214853640|NCT01618136|DRUG|E7449 alone|Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.
214853641|NCT01618136|DRUG|E7449 plus TMZ|Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.
214853642|NCT01618136|DRUG|E7449 plus carboplatin and paclitaxel|Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
214853643|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
214853644|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
214853645|NCT00262041|BIOLOGICAL|MenACWY polysaccharide vaccine|
214853646|NCT05484843|BEHAVIORAL|telenursing training based on self-care theory|"* A training guide based on the self-care theory specific to individuals diagnosed with stroke was prepared.~* Identification of the study/control group (randomization)~* Patients were informed and consents were obtained.~* Sample suitability was evaluated in line with the cognitive levels and inclusion criteria of patients diagnosed with stroke.~* All patients included in the sample group were pre-tested before discharge.~* Training was offered for the study group patients in line with the guide prepared based on self-care theory.~* Tele-nursing training was applied to the study group patients.~* Control group patients were followed up~* Post-tests were administered at the end of the 12-week period~* The training of the control group patients was completed~* Your data has been evaluated"
214853647|NCT05484843|BEHAVIORAL|just observation|For 3 months, patients were observed without intervention. The standard discharge training of the clinic was given.
214853648|NCT06457399|DRUG|Heliox|Treatment for 30 minutes with Heliox from a commercial tank (Oxhelⓒ, Air Liquideⓒ) with a fixed mixture of 70% helium and 30% oxygen with non-rebreather mask or reservoir bag at a flow of 12-15 lpm.
214853649|NCT06457399|DRUG|Oxygen|Treatment for 30 minutes with oxygen at FiO2 of 31% with Venturi mask.
214853650|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
214853651|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
214853652|NCT00273481|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
214853653|NCT00273481|DRUG|latanoprost 0.005%/timolol maleate 0.5% fixed combination|
214853654|NCT00273481|DRUG|timolol maleate 0.5%|
214853655|NCT00273481|DRUG|placebo|
214853656|NCT03702361|DRUG|VPRIV|VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
214853657|NCT06205017|DIETARY_SUPPLEMENT|Foods for Special Medical Purposes|"In order to facilitate patient weaning and to improve the enjoyment of foods used in this semi-liquid phase, our Center intends to test Foods for Special Medical Purposes (AFMS) to ensure better nutritional intake, including vitamin D3 and calcium, good palatability, and thus better adherence to the recommended nutritional indications in the immediate postoperative period than the homogenized foods used in the standard diet."
214853658|NCT02384941|DRUG|Placebo|Placebo once daily, before first meal of the day.
214853659|NCT02384941|DRUG|Sotagliflozin|Sotagliflozin once daily, before first meal of the day.
214853660|NCT00124995|DRUG|terbutaline|
214853661|NCT02107820|BEHAVIORAL|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
214853662|NCT02107820|DEVICE|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
214290356|NCT05122520|OTHER|Questionnaire|The HMBT-Q is a 26-item questionnaire, split into four main sections: food related symptoms; general digestive symptoms; extra-intestinal symptoms and co-morbidities and Medication and onset.
214853663|NCT03716635|PROCEDURE|cryotherapy|2.5c cold saline is used as a final flush after chemomechanical preparation
214853664|NCT03716635|PROCEDURE|normal saline|a room temperature saline is used as a final flush after mechanical preparation
214853665|NCT05040308|OTHER|Integrating PrEP delivery|Integration of PrEP delivery services in NSP and MAT programs
214906997|NCT06301074|DRUG|Placebo|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
214906998|NCT03591874|DRUG|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.
214853666|NCT06027138|OTHER|blood flow resistance training|Muscle size and explosive power was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press ,vertical jump test and timed push ups and pull up tests .secondly treat the arm and thigh muscles to to blood flow resistance training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles.
214853667|NCT06027138|OTHER|slow motion strength training|We will use slow motion strength training method. Each exercise is performed by lifting weights for approximately 10 seconds, lowering the weight for another 10 seconds, and not resting between repetitions.before receiving treatment sample muscle size and explosive strength was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press (pre test).secondly treat the arm and thigh muscles to to slow motion weight training.weight training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles. (Post test).
214853668|NCT00971737|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
214853669|NCT00971737|BIOLOGICAL|trastuzumab|Given IV
214853670|NCT00971737|DRUG|cyclophosphamide|Given IV
214853671|NCT00252174|DRUG|Stage 1 Active Methylenedioxymethamphetamine|"Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
214853672|NCT00252174|DRUG|Stage 1 Low dose Methylenedioxymethamphetamine|"Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg."
214853673|NCT00252174|BEHAVIORAL|Psychotherapy|Psychotherapy conducted with low or active dose MDMA
214853674|NCT00252174|DRUG|Stage 2 Active Methylenedioxymethamphetamine|"Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
214853675|NCT05511220|BEHAVIORAL|PRIMeR|Virtual PRIMeR intervention consists of coaching parents to use strategies derived from Social Routines (to boost positive affect) and Reciprocal Imitation Training (to boost toy play)
214853676|NCT05511220|BEHAVIORAL|PRT|Virtual PRT intervention consists of coaching parents to use key PRT strategies to enhance children's communication skills
214853677|NCT00488930|OTHER|Observational|data collection ONLY
214853678|NCT06132620|DRUG|Femoston|"Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment."
214853679|NCT06132620|DRUG|Qingxin Zishen Decoction|Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
214853680|NCT05925504|DRUG|Luspatercept|The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.
214853681|NCT04529330|PROCEDURE|fasciotomy|if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
214853682|NCT02784782|DEVICE|Orthesis|
214853683|NCT02784782|BEHAVIORAL|No orthesis|
214853684|NCT02443584|OTHER|pharmacogenetic testing|pharmacogenetic testing for anti-depressant/anti-psychotic medications
214853685|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
214853686|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
214853687|NCT05179239|DRUG|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|Placebo + paclitaxel + cisplatin/carboplatin ± BP102
214853688|NCT03547973|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously.
214853689|NCT03547973|DRUG|Pembrolizumab|Administered per package insert
214853690|NCT03547973|DRUG|Cisplatin|Administered per package insert
214853691|NCT03547973|DRUG|Avelumab|Administered per package insert
214853692|NCT03547973|DRUG|Zimberelimab|Administered intravenously
214853693|NCT03547973|DRUG|Carboplatin|Administered per package insert
214853694|NCT03547973|DRUG|Gemcitabine|Administered per package insert
214853695|NCT03547973|DRUG|Domvanalimab|Administered intravenously
214853696|NCT03547973|DRUG|Enfortumab Vedotin|Administered intravenously
214853697|NCT06534320|DRUG|DA-302168S|SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 6 subjects receive DA-302168S tablets.
214853698|NCT06534320|DRUG|Placebo of DA-302168S|SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 2 subjects receive placebo of DA-302168S tablets.
214853699|NCT06534320|DRUG|DA-302168S|MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 8 subjects receive study DA-302168S tablets.
214853700|NCT06534320|DRUG|Placebo of DA-302168S|MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive study placebo of DA-302168S tablets.
214853701|NCT04769752|OTHER|collection of the allocated treatment|collection of the allocated treatment
214853702|NCT04769752|OTHER|collection of medical complications|collection of medical complications
214853703|NCT03714555|DIAGNOSTIC_TEST|Safety Laboratories|Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
214853704|NCT03714555|OTHER|AE Assessment|Assessment of Adverse Events (AE)
214853705|NCT03714555|OTHER|Physical Exam|Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
214853706|NCT03714555|OTHER|Concomitant Medication Review|Prior and Concomitant Medication Review
214853707|NCT03714555|DIAGNOSTIC_TEST|Tumor Imaging|Tumor CT or MRI
214853708|NCT03714555|DRUG|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
214853709|NCT03714555|DRUG|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
214853710|NCT03714555|DRUG|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
214853711|NCT03885219|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 , \< 1.5 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.
214853712|NCT00484419|DRUG|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
214853713|NCT00484419|DRUG|rosiglitazone maleate|rosiglitazone tablets 4mg
214853714|NCT00484419|DRUG|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
214853715|NCT06111079|DRUG|aspirin discontinuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
214853716|NCT06111079|DRUG|aspirin continuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
214853717|NCT00273741|DRUG|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
214853718|NCT00273741|DRUG|placebo comparator|placebo capsules
214853719|NCT03969199|BEHAVIORAL|Intervention|Dietary intervention in coordination with MANNA, who will deliver low sodium meals to patients for 90 days
214853720|NCT00359242|BEHAVIORAL|Infant Sleeping and Soothing|Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
214853721|NCT00359242|BEHAVIORAL|Repeated Food Exposure|Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
214853722|NCT00949611|BEHAVIORAL|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
214853723|NCT00949611|BEHAVIORAL|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
214853724|NCT00102687|DRUG|azacitidine|"Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation."
214853725|NCT00003621|DRUG|carmustine|
214853726|NCT00003621|DRUG|cisplatin|
214853727|NCT00003621|DRUG|etoposide|
214853728|NCT00003621|RADIATION|radiation therapy|
214853729|NCT06177314|OTHER|correlate the molecular signatures of active lesions of contact dermatitis with allergological results|Data will be collected retrospectively and prospectively from patients' medical records, and will include: clinical information (history, treatments, lifestyle, exposures, lesion location and appearance), patch-test results, histological analysis results, molecular analysis results.
214853730|NCT04626752|DRUG|BCMA CAR-T|Volunteers will be treated with BCMA CAR-T cells
214853731|NCT04626752|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
214853732|NCT04626752|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
214853733|NCT05051878|DEVICE|T-scan|occlusal analysis T-scan
214853734|NCT05051878|OTHER|articulating paper|articulating paper occlusal analysis
214853735|NCT04917627|DRUG|Vancomycin|one vial of vancomycin (1000 mg ) powder form.
214853736|NCT01341587|DEVICE|Telcare Blood Glucose Meter (BGM)|Cellular enabled glucometer
214853737|NCT01104428|DRUG|Placebo|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
214853738|NCT01104428|DRUG|"ziying granules"|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
214853739|NCT00542360|BEHAVIORAL|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
214853740|NCT01434576|BIOLOGICAL|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
214853741|NCT01434576|BIOLOGICAL|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
214853742|NCT01434576|DRUG|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
214853743|NCT02281682|DRUG|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
214853744|NCT02281682|DRUG|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
214853745|NCT02281682|DRUG|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
214853746|NCT02281682|PROCEDURE|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
214853747|NCT05127694|OTHER|Vestibular Rehabilitation|Vestibular Rehabilitation which is consist of repetitive exercises and canalit repositioning maneuvers
214853748|NCT02488668|DEVICE|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
214853749|NCT01117467|OTHER|Simulation scenario|Students performing their scenario will be paired, not solo
214853750|NCT01117467|OTHER|Simulation scenario|Students will perform their simulation scenario solo and receive feedback within the group
214853751|NCT04598360|PROCEDURE|Heart-Lung-Machine|blood sample before and during a single Heart-Lung-Machine procedure
214853752|NCT06600750|PROCEDURE|Arteriovenous fistula|Patients who underwent Radiocephalic arteriovenous fistula surgery
214853753|NCT06472544|BEHAVIORAL|Culturally Grounded Intervention|Education to increase awareness of Blackfeet culture and connectedness to Blackfeet community
214853754|NCT01459263|DEVICE|ClariVein|Using the ClariVein device, the GSV will be occluded.
214853755|NCT01935479|DRUG|AK159|transdermal administration of teriparatide acetate
214853756|NCT01935479|DRUG|MN-10-T|subcutaneous administration of teriparatide acetate
214853757|NCT01935479|DRUG|Placebo|Placebo AK159
214853758|NCT02788799|OTHER|Standard 12-Lead ECG|Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.
214853759|NCT02788799|OTHER|Posterior ECG Leads|Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
214853760|NCT06655194|DRUG|Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)|Chewable tablet, 81mg, oral
214853761|NCT06655194|DRUG|Acetylsalicylic Acid (BAYE004465, UI1615160)|Chewable tablet, 81 mg, oral
214853762|NCT03959995|OTHER|High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)|Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.
214476415|NCT06813586|OTHER|hospital-based registry|"The clinical data collected for each patient will reflect comprehensive multiprofessional clinical insights necessary for diagnostic definition and typically obtained during diagnostic evaluation and/or monitoring visits. In addition to these, instrumental data commonly acquired in clinical practice, such as neuroradiological and electrophysiological information, will also be collected.~For each enrolled subject, a checklist (CRF) will be completed to gather study-related data. These data will be entered into a specific database constructed on the REDCap platform and managed in an anonymized form. Subject enrollment will be conducted progressively.~This data collection will enable monitoring of study progress, including the number of enrolled subjects, completed assessments, and study adherence. Every three months, monitoring will be performed to assess study progress and the achievement of enrollment targets."
214853763|NCT03959995|OTHER|Wellness|control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 13 months.
214853764|NCT06467565|DRUG|Liposomal irinotecan|NALIRIFOX（Oxaliplatin 60 mg/m2 IV over 2 hours ; Liposomal Irinotecan 50 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion） on days 1 of a 14-day cycle.
214853765|NCT01847365|DEVICE|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
214853766|NCT04214665|DRUG|Alpha Lipoic acid 600 mg HR film coated tablets|
214853767|NCT06031220|OTHER|deep breathing exercise inform of diaphragmatic and costal breathing|deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks,
214853768|NCT06616220|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
214853769|NCT06616220|DRUG|0.9%NaCl|0.9% NaCl
214853770|NCT01142531|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
214853771|NCT00138957|PROCEDURE|Laparoscopic parastomal hernia repair with mesh|
214476416|NCT06808581|DIAGNOSTIC_TEST|blood test for pro-inflammatory cytokines and ultrasound of the median nerves|Blood test and ultrasound
214853772|NCT01652976|DRUG|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
214853773|NCT01652976|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
214853774|NCT00113724|DRUG|TPI 287 Injection|
214853775|NCT03739138|BIOLOGICAL|MK-4621|"MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data."
214853776|NCT03739138|BIOLOGICAL|Pembrolizumab|200 mg administered intravenously (IV) on Day 1 of each 21-day cycle beginning with Cycle 1 (Arm 2) or Cycle 2 (Arm 3).
214853777|NCT01419587|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
214853778|NCT05171894|DRUG|Hemopfin+Green Light|All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
214853779|NCT05171894|DEVICE|Vehicle+Green Light|All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
214853780|NCT03302377|BEHAVIORAL|physical activity counseling & Fitbit|Participants will receive individual counseling \& guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
214906999|NCT03591874|DRUG|Placebos|Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
214907000|NCT05157412|DRUG|Doxycycline 100 mg Oral Tablet|Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis
214907001|NCT05157412|DRUG|Prednisolone 20 mg|Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
214853781|NCT02497794|OTHER|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
214853782|NCT00038831|DRUG|Mylotarg|Starting dose 2 mg/m\^2 over 2-hour intravenous infusion on day -12.
214853783|NCT00038831|DRUG|Fludarabine|30 mg/m\^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.
214853784|NCT00038831|DRUG|Melphalan|140 mg/m\^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.
214853785|NCT00038831|DRUG|Anti-thymocyte globulin|Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.
214853786|NCT00038831|PROCEDURE|Stem cell transplant|Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
214853787|NCT04540055|PROCEDURE|Paravertebral block|The subjects in this group received general anesthesia and USG-guided paravertebral block
214853788|NCT04540055|PROCEDURE|General Anesthesia|The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
214853789|NCT03630419|DIETARY_SUPPLEMENT|Mito-Food Plan|Specialized anti-inflammatory diet plan based on subject's physiological results
214853790|NCT03630419|OTHER|Cellular Repair Therapy|the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
214853791|NCT00699478|DRUG|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
214853792|NCT03978312|OTHER|Nominal consensus group|NLit-UK linguistic and cultural adaptation (NLit-UK) 2 x nominal consensus groups evidence review and topic expert engagement
214290357|NCT02552563|BEHAVIORAL|Dementia Care Management|The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
214853793|NCT03978312|OTHER|Observational cohort (validity and reliability testing)|Nutrition Literacy Measurement Tool validation (NLit-UK). Target sample 366 on treatment cancer patients confirmatory binary analysis for validity and reliability.
214853794|NCT01128582|DRUG|Rozerem (ramelteon)|dosage= take 1 tablet(8 MG) 20 min. before bedtime
214853795|NCT01128582|DRUG|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
214853796|NCT01761669|DRUG|Vitamin D|
214853797|NCT02493920|OTHER|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm).
214853798|NCT02493920|DEVICE|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
214853799|NCT00466726|BIOLOGICAL|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
214290358|NCT03409406|BEHAVIORAL|Caregiver Intervention|This intervention is a 3-month (or 12 weeks) sequenced mobile health intervention provided to the parent/caregiver to use at home with the child. It supplements the 30 minute speech and language therapy session provided to the child at the hospital once a month
214853800|NCT00466726|BIOLOGICAL|sargramostim|
214853801|NCT00860691|PROCEDURE|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
214853802|NCT00860691|PROCEDURE|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
214853803|NCT00860691|OTHER|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
214853804|NCT04517929|OTHER|Group Psychotherapy|9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
214853805|NCT01174524|DRUG|gestoden 60 mcg|gestoden 60 mcg, once a day, administered in 24/4 regimen.
214853806|NCT01174524|DRUG|ethinylestradiol 15 mcg|ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
214853807|NCT04403763|DRUG|AGN-241622|Topical eye drop
214853808|NCT04403763|DRUG|Vehicle|Topical eye drop
214853809|NCT06127017|PROCEDURE|splinting dental implants with titanium bar|splinting of dental implants will be done in the placebo comparator group by welding a titanium bar intraorally to the temporary sleeves attached to the implants.
214853810|NCT06127017|PROCEDURE|splinting dental implants with PEEK bar|in the active comparator group ,the PEEK bar will be attached to the temporary sleeves using flowable composite resin material.
214853811|NCT02842463|OTHER|2 times : 6-minute stepper test with a rest of 20min between each test.|
214853812|NCT00749502|DRUG|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
214853813|NCT01376310|DRUG|GSK1120212|up to 2 mg/day
214853814|NCT01376310|DRUG|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
214853815|NCT01376310|DRUG|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
214853816|NCT01376310|DRUG|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
214853817|NCT01376310|DRUG|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
214853818|NCT01376310|DRUG|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
214853819|NCT01376310|DRUG|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
214853820|NCT01376310|DRUG|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
214853821|NCT02453633|OTHER|Emotional SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS."
214853822|NCT02453633|OTHER|Standard SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS."
214853823|NCT05836415|PROCEDURE|Tricuspid valve annuloplasty with 3D ring|A 3D ring is implanted to treat functional tricuspid valve regurgitation
214853824|NCT02857647|BEHAVIORAL|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
214853825|NCT01098994|DIETARY_SUPPLEMENT|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
214853826|NCT01098994|OTHER|Dummy pills|Daily placebo administration for 8 weeks
214853827|NCT01823276|OTHER|Tyrosine-Containing Bar|
214853828|NCT01823276|OTHER|Placebo Bar|
214853829|NCT02470091|BIOLOGICAL|Denosumab|Given SC
214853830|NCT02470091|OTHER|Laboratory Biomarker Analysis|Correlative studies
214290359|NCT03409406|BEHAVIORAL|ST Intervention|This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
214290360|NCT01500629|DEVICE|C-1266-7|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.
214290361|NCT01500629|DEVICE|C-1266-6 (placebo)|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
214853831|NCT02470091|OTHER|Pharmacological Study|Correlative studies
214853832|NCT01320020|DRUG|catumaxomab|Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
214853833|NCT00817947|DEVICE|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
214853834|NCT02947620|DRUG|Metformin/Atorvastatin 1500mg/40mg, QD|
214853835|NCT02947620|DRUG|Metformin 1500mg, QD|
214853836|NCT02947620|DRUG|Atorvastatin 40mg, QD|
214853837|NCT00176631|DIETARY_SUPPLEMENT|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
214853838|NCT00176631|DRUG|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
214853839|NCT04480801|OTHER|Thermal Evaluation and Foot Care|Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.
214853840|NCT04480801|OTHER|Foot Care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
214853841|NCT02610920|PROCEDURE|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
214853842|NCT02610920|DRUG|Iron tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
214853843|NCT05795348|DIAGNOSTIC_TEST|Personalised Musculoskeletal Modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop and inform personalised musculoskeletal models
214853844|NCT02521077|DRUG|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
214853845|NCT02521077|OTHER|Normal Saline|Saline 0.9%
214853846|NCT02240563|PROCEDURE|Low-level laser therapy|
214853847|NCT02240563|PROCEDURE|Non laser ordinary red light|
214853848|NCT00896194|BEHAVIORAL|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
214907002|NCT05278312|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
214853849|NCT00896194|BEHAVIORAL|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
214853850|NCT04290286|OTHER|i2TransHealth|i2TransHealth: online intervention for TGD people
214853851|NCT06616558|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
214853852|NCT06616558|OTHER|Sunscreen SPF 70|On the randomized side of the half-face, the product will be applied by a qualified technician
214853853|NCT02087917|DRUG|HS-25|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
214853854|NCT02087917|DRUG|Placebo|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
214853855|NCT03744221|DIETARY_SUPPLEMENT|Corn protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
214853856|NCT03744221|DIETARY_SUPPLEMENT|Bovine plasma protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
214853857|NCT03744221|DIETARY_SUPPLEMENT|Whey protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
214853858|NCT01453621|OTHER|Computerized clinical decision support|Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
214853859|NCT02083419|DEVICE|LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
214853860|NCT00168116|PROCEDURE|radiation treatment and surgery|
214853861|NCT00168116|PROCEDURE|radiation alone|
214853862|NCT01829919|DRUG|Brisdelle (paroxetine mesylate)|All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
214853863|NCT02135965|DRUG|2mg of Albuterol|2mg of Albuterol on metabolic rate
214290362|NCT03773679|PROCEDURE|Daily Exercise|Daily Exercise Programme
214290363|NCT00588848|DEVICE|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
214853864|NCT02135965|DRUG|4mg of Albuterol|4mg of Albuterol on metabolic rate
214853865|NCT02135965|DRUG|100mg of Caffeine|100mg of caffeine on metabolic rate
214853866|NCT02135965|DRUG|200mg of Caffeine|200mg of Caffeine on metabolic rate
214853867|NCT02135965|DRUG|Albuterol 2mg & Caffeine 100mg|Albuterol 2mg and 100mg of Caffeine
214853868|NCT02135965|DRUG|Albuterol 2mg and Caffeine 200mg|Albuterol 2mg and Caffeine 200mg on metabolic rate
214853869|NCT02135965|DRUG|Albuterol 4mg and Caffeine 100mg|Albuterol 4mg and Caffeine 100mg on metabolic rate
214853870|NCT02135965|DRUG|Albuterol 4mg and Caffeine 200mg|Albuterol 4mg and Caffeine 200mg on metabolic rate
214853871|NCT02457884|OTHER|Temporal Group|Visual Processing Training
214290364|NCT00588848|DEVICE|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
214853872|NCT02457884|OTHER|Spatial Group|Spatial visual span training
214853873|NCT02457884|OTHER|Combined Group|Visual processing speed and spatial visual span training
214853874|NCT02457884|OTHER|Control Group|Leisure reading activities
214853875|NCT01090375|OTHER|Exercise|
214853876|NCT01090375|OTHER|Non Exercise|
214853877|NCT01690975|DRUG|Placebo|Placebo - single dose at start of each treatment period
214853878|NCT01690975|DRUG|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
214853879|NCT01690975|DRUG|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
214853880|NCT02549846|DRUG|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
214853881|NCT01661634|DRUG|Ularitide|
214853882|NCT01661634|DRUG|Placebo|
214853883|NCT02153892|DEVICE|GDS Accucinch System|Percutaneous Coronary Intervention
214853884|NCT03508869|DRUG|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
214853885|NCT03508869|DRUG|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
214853886|NCT03508869|DRUG|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
214853887|NCT05876728|GENETIC|Genotyping|Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.
214853888|NCT04916483|OTHER|group cognitive stimulation therapy|The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
214853889|NCT04916483|OTHER|usual care|The control group maintains the unit routine treatment.
214853890|NCT05209906|DRUG|Fentanyl Buccal Soluble Film|Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.
214853891|NCT05327855|DRUG|OPL-0301 Dose 1|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
214853892|NCT05327855|DRUG|OPL-0301 Dose 2|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
214853893|NCT05327855|DRUG|Placebo|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
214853894|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
214853895|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
214853896|NCT04787770|OTHER|non-intervention|non-intervention
214853897|NCT01353807|DIETARY_SUPPLEMENT|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
214853898|NCT01353807|DIETARY_SUPPLEMENT|Olive oil|4 1-g gelatine capsules with virgin olive oil
214853899|NCT01426737|DRUG|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
214853900|NCT03571659|PROCEDURE|Laser|
214853901|NCT01553201|DRUG|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
214853902|NCT01553201|DRUG|Placebo|Saline, 4cc, one time intramuscular administration
214853903|NCT00020267|DRUG|interleukin-2|
214853904|NCT00020267|DRUG|MAGE-12 peptide vaccine|
214853905|NCT00020267|DRUG|Montanide ISA-51|
214853906|NCT02291471|DRUG|T0001，10mg|
214853907|NCT02291471|DRUG|T0001，20mg|
214853908|NCT02291471|DRUG|T0001，35mg|
214853909|NCT02291471|DRUG|T0001，50mg|
214853910|NCT02291471|DRUG|T0001，65mg|
214853911|NCT02291471|DRUG|T0001，75mg|
214853912|NCT00396461|DRUG|MCT/LCT (1:1)|Emulsion based on 20% MCT/LCT (50:50 ratio)
214853913|NCT00396461|DRUG|MCT/LCT/omega-3 (5:4:1)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
214853914|NCT04149028|PROCEDURE|PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml|intraovarian injection of 2 mml of PRP by laparoscopic guide
214853915|NCT02743728|DEVICE|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
214853916|NCT02743728|DEVICE|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
214853917|NCT02743728|BEHAVIORAL|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
214853918|NCT00003242|DRUG|bryostatin 1|
214853919|NCT00003242|DRUG|cisplatin|
214853920|NCT00003242|DRUG|paclitaxel|
214853921|NCT02166320|DEVICE|Partially covered SEMS|
214853922|NCT02166320|DEVICE|Fully covered SEMS|
214853923|NCT05904275|DRUG|caudal epidural injection|Preoperative Ultrasound guided caudal epidural injection in lumbosacral spine surgeries for postoperative analgesia.
214290365|NCT03171792|OTHER|semi-structured interviews|Semi-structured face to face or telephone interviews with an open-ended approach. Duration: about 45 minutes. Audio-recorded. Exploration of the experience of taking care of the suffering adolescents.
214853924|NCT01245036|DRUG|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. \>50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
214853925|NCT02306057|PROCEDURE|Pre BCPC|Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
214853926|NCT02306057|PROCEDURE|Pre TCPC|Routine catheterization before surgical procedure Total CavoPulmonary Connection
214853927|NCT02306057|PROCEDURE|BCPC surgery|Surgical procedure Bidirectional CavoPulmonary Connection
214853928|NCT02306057|PROCEDURE|TCPC|Surgical procedure Total CavoPulmonary Connection
214853929|NCT05414864|DRUG|Ramelteon (RozeremR)|8mg daily
214853930|NCT05414864|BEHAVIORAL|sleep hygiene|sleep behavioral guidelines
214853931|NCT03680079|OTHER|Group education sessions|Peer support and interaction both in-person during group education sessions and online via social media platforms
214853932|NCT04920526|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|No intervention will be administered
214853933|NCT03384433|BIOLOGICAL|exosome|allogenic mesenchymal stem cells derived exosome enriched by miR-124
214853934|NCT04477551|PROCEDURE|Diode laser (device) with scaling and root planing|Combined use of diode laser device and scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
214853935|NCT04477551|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
214853936|NCT03845413|BEHAVIORAL|Control|Schedule an appointment to attend tobacco cessation at Basic Health Unit
214853937|NCT03845413|BEHAVIORAL|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
214853938|NCT00483587|DRUG|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
214853939|NCT00155233|DRUG|Nalbuphine and morphine|
214853940|NCT04625452|BEHAVIORAL|BBCC+5A's+GS|"It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information."
214853941|NCT00325832|DEVICE|BpTRU|
214853942|NCT00325832|DEVICE|Conventional mercury sphygmomanometry|
214853943|NCT05298787|DRUG|RLS-0071|RLS-0071 is administered as an IV infusion
214853944|NCT05298787|DRUG|Saline Placebo|Placebo is administered as an IV infusion
214853945|NCT06304909|DRUG|Dexmedetomidine injection|Dexmedetomidine group will receive 0.5 mcg/kg
214853946|NCT04291807|BEHAVIORAL|Video education|Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
214907003|NCT05106179|DRUG|Atenolol Pill|Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
214907004|NCT05106179|DRUG|Propranolol Pill|Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
214907005|NCT00980252|BEHAVIORAL|Cognitive Behavioral Therapy|Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
214664536|NCT05742620|DRUG|anlotinib+CAPEOX/SOX|"Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1."
214664537|NCT00408278|DRUG|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
214664538|NCT00408278|DRUG|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
214664539|NCT00408278|DRUG|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
214664540|NCT00408278|DRUG|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
214664541|NCT01668277|DRUG|7.2% NaCl|
214664542|NCT01668277|DRUG|0.9% NaCl|
214853947|NCT04070287|COMBINATION_PRODUCT|SMART Pack|The SMART pack is a re-branded and repackaged box for HIV self-testing kits. The intervention aims to promote distribution of HIVST kits through in institutions, vocational centers, and social media platforms. The intervention would also include a referral systems, where participants provided with the HIV self-testing kits are provided with information with youth-friendly health facilities for uptake of testing for sexually transmitted infections. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the SMART pack and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Yaba local government area in Lagos state.
214853948|NCT04070287|COMBINATION_PRODUCT|Luv Box|"The Luv box is packaged in two colors: blue and pink. The LUVBox would be made available in supermarkets, on-line stores, mini-marts, pharmacies, neighborhood stores and markets, for easy accessibility in hard to reach areas. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the Luv Box and the location where the pack can be obtained for individuals who are interested.For this pilot study, the intervention will be implemented in Yaba in Lagos state."
214853949|NCT04070287|COMBINATION_PRODUCT|Bili Vibes|The HIV self-testing kits will be available for interested individuals at the community youth events. These events and information the HIV self-testing kits will be on flyers that would be promoted at community centers and schools. For this pilot study, the intervention will be implemented in Ngenevu/Bunker communities in Enugu state.
214853950|NCT04070287|COMBINATION_PRODUCT|BeterDoc|"The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the BeterDoc Safety Kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Ibadan, Dugbe and Agbowo in Oyo state."
214853951|NCT04070287|COMBINATION_PRODUCT|IUNGO|The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the HIV self-testing kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Akure South, Orita-Obele, Ipinsa, Ilara Mokin and Ijare in Ondo state.
214853952|NCT05914545|DRUG|FZ-AD004|"Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles."
214853953|NCT04686227|DIAGNOSTIC_TEST|3D Ultrasound|Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology
214853954|NCT03500497|DIAGNOSTIC_TEST|RetHe measurement (Sysmex)|RetHe measurement is done from blood samples gained during standard patient care perioperatively
214853955|NCT00594620|DIETARY_SUPPLEMENT|Flav-ein capsules|Soy/isoflavone supplementation
214853956|NCT00594620|DRUG|Placebo|Placebo
214853957|NCT04274582|DIETARY_SUPPLEMENT|chokeberry extract|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
214853958|NCT00722631|DRUG|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
214853959|NCT00722631|DRUG|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
214853960|NCT00767520|DRUG|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
214853961|NCT00767520|DRUG|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
214907006|NCT04390607|DIAGNOSTIC_TEST|leukocyte esterase electrochemical assay|A sample of blood drawn for routine standard of care laboratory assessments will be used to also test the new electrochemical assay. This is a validation study and the results of the electrochemical assay will not be used to treat patients
214664543|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
214664544|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
214664545|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
214664546|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
214664547|NCT05749588|DRUG|A1: SHR-A1811|A1: an anti-HER2 antibody-drug conjugate (ADC)
214664548|NCT05749588|DRUG|A2: SHR-A1811 with Camrelizumab|"A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
214664549|NCT05749588|DRUG|B1: TROP2 ADC|B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
214664550|NCT05749588|DRUG|B2: TROP2 ADC with Camrelizumab|"B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
214664551|NCT05749588|DRUG|C1: SHR-A1811|C1: an anti-HER2 antibody-drug conjugate (ADC)
214664552|NCT05749588|DRUG|C2: SHR-A1811 with BP102|"C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
214664553|NCT05749588|DRUG|D1: TROP2 ADC|D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
214664554|NCT05749588|DRUG|D2: TROP2 ADC with BP102|"D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
214853962|NCT05973682|OTHER|Post-isometric relaxation and Conventional treatment|"The term refers to the effect of subsequent relaxation experienced by a muscle or group of muscles, after brief periods during which an isometric contraction has been performed. Post isometric relaxation technique was applied to levator scapulae for 5 repetition using 20% of maximal isometric contraction for 7-10 sec. with complete relaxation of all element, the stretch is maintained for 30 sec.~\+ hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30 second hold. static stretching exercises two sessions per week for 3 weeks were given to each patient"
214853963|NCT05973682|OTHER|Conventional Physical Therapy|Conventional Physical Therapy; hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient
214853964|NCT04729647|PROCEDURE|Mastectomy|Mastectomy for breast cancer Blood sample for Complete Blood Cell Count and other blood parameters (Delta Neutrophil Index, Immature Granulocyte Count)
214853965|NCT00792519|BEHAVIORAL|HIV support group|group support
214853966|NCT00792519|BEHAVIORAL|CBT|group cognitive behavioral treatment
214853967|NCT06166784|DEVICE|Mectascrew B|reconstruction of ACL or PCL rupture
214853968|NCT00641784|DRUG|Magnesium|Intravenous Magnesium 6 gram load, 3 grams/hr
214853969|NCT00641784|DRUG|Nifedlipine|Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
214853970|NCT01096979|DRUG|LIPO-102|subcutaneous injection
214853971|NCT01096979|DRUG|Placebo|Placebo
214853972|NCT05329506|OTHER|patient population|questionnaires, standard of care
214853973|NCT03897647|DEVICE|General Electric (GE) VScan|This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
214853974|NCT02057445|DRUG|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
214853975|NCT02057445|OTHER|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
214853976|NCT03313882|OTHER|no intervention is involved|
214853977|NCT00485927|BEHAVIORAL|stress|
214853978|NCT05440331|OTHER|Training with AnesList©|Training with AnesList© as tool
214853979|NCT01487382|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
214853980|NCT04339426|DRUG|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
214853981|NCT01497626|DRUG|Lapatinib and bortezomib|"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."
214853982|NCT00720226|DRUG|Losartan|Losartan 100 mg daily
214853983|NCT00720226|DRUG|Placebo|Placebo pill daily
214853984|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
214853985|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
214664555|NCT05749588|DRUG|E1: SHR-A1811|E1: an anti-HER2 antibody-drug conjugate (ADC)
214853986|NCT00958126|BIOLOGICAL|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
214853987|NCT06208826|DRUG|Toripalimab|Toripamab, IV, 240mg, every 3 weeks for 15 cycles
214853988|NCT06208826|RADIATION|Radiation Therapy|Radiation Therapy
214853989|NCT06208826|DRUG|Cisplatin|Chemotherapy agent
214853990|NCT05223257|OTHER|AOT|Observation of video sequences showing unimanual and bimanual goal-directed actions followed by the execution of the observed actions with upper limbs for unimanual and bimanual actions.
214853991|NCT00733369|DEVICE|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
214853992|NCT00733369|DEVICE|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
214853993|NCT03401073|DRUG|Intravenous immunoglobulin|Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
214853994|NCT03401073|DRUG|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
214853995|NCT00522340|BEHAVIORAL|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
214664556|NCT05749588|DRUG|F1: TROP2 ADC|F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
214664557|NCT05749588|DRUG|G1: SHR-A1811|G1: an anti-HER2 antibody-drug conjugate (ADC)
214853996|NCT01481740|DRUG|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
214853997|NCT01481740|DRUG|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
214853998|NCT01334684|DRUG|Metformin|Metformin, pills, 850 mg three times a day for three months
214853999|NCT00286819|DRUG|the FEC75 and 95 regimen|"Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B"
214854000|NCT01949714|PROCEDURE|Removal of adrenal tumor|
214854001|NCT00279955|DEVICE|Cardiac Resynchronization Therapy Device|Patients with an ICD indication, a CRT indication and symptomatic heart failure who are implanted with a Cardiac Resynchronization Therapy Device.
214854002|NCT02112721|DIETARY_SUPPLEMENT|Vitamin D|
214854003|NCT02112721|DIETARY_SUPPLEMENT|Placebo|
214907007|NCT06196437|OTHER|Acupuncture|Participants will receive acupuncture.
214854004|NCT02510014|DRUG|SUBOXONE sublingual film|SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period.
214854005|NCT02510014|DRUG|RBP-6000|Injections administered subcutaneously every 28 days on alternate sides of participant's abdomen starting at 300 mg. Subsequent doses of RBP-6000 could be adjusted down to 100 mg with the possibility of adjusting back up to 300 mg based on the medical judgment of the investigator. De novo subjects receive up to 12 injections and roll-over subjects receive up to 6 injections.
214854006|NCT01343095|DEVICE|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
214854007|NCT01343095|DEVICE|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
214854008|NCT01913236|OTHER|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
214854009|NCT03116321|DRUG|Eslicarbazepine acetate (ESL)|Oral Tablet of 800 mg and 200 mg of ESL
214854010|NCT03260075|OTHER|cat|Cat living at the ward
214854011|NCT02332408|RADIATION|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
214854012|NCT02332408|RADIATION|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
214854013|NCT02801552|DEVICE|PRF|Regenerative Endodontic Procedure with PRF: autologous PRF will be used instead of blood clot in the second vist.
214854014|NCT05206487|DIETARY_SUPPLEMENT|Polydextrose|PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
214854015|NCT04714970|DEVICE|iTBS|Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.
214854016|NCT04714970|DEVICE|Shame stimulation|TMS coil vertical to the brain surface, with same protocol as iTBS
214854017|NCT00921037|PROCEDURE|Erbium-YAG laser vaporization|spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz
214854018|NCT01875471|DEVICE|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
214854019|NCT01875471|DEVICE|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
214854020|NCT02896777|OTHER|Transfer embryo from pH 7.20±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.20±0.02.
214854021|NCT02896777|OTHER|Transfer embryo from pH 7.3±0.02 either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.3±0.02.
214854022|NCT02896777|OTHER|Transfer embryo from pH of 7.4±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.4±0.02 from day 0 to 5/6
214854023|NCT04816747|BIOLOGICAL|Autologous PRP|Participants enrolled in this study will be managed with intradiscal and/or intra-articular injections of autologous PRP according to features of underlying pathology. Participants featuring FJS will be prior to PRP diagnostically and therapeutically injected with local anesthetic in order to verify FJS as the etiology of experienced pain. Injected PRP solution volume is designed to be 0.5-1 ml and 0.5 ml in cases of intradiscal and intra-articular injection, respectively. All participants are planned to receive a single dose of PRP, whilst a maximum of two compromised discs and four facet joints will be treated in each patient.
214854024|NCT06110247|DEVICE|NIRS|After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.
214854025|NCT06110247|OTHER|Taking a blood sample|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.
214854026|NCT00654654|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm biopsies~2. Two injection treatments of facial wrinkles and creases~3. Conduct of study assessments"
214664558|NCT05749588|DRUG|H1: TROP2 ADC|H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
214664559|NCT04702230|DIAGNOSTIC_TEST|MRI|Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE
214664560|NCT00138840|DRUG|STA-5326 mesylate|
214854027|NCT04179019|DRUG|Amlodipine|Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
214854028|NCT05369078|DRUG|THR-1442 20mg Single dose|THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
214854029|NCT05369078|DRUG|THR-1442 20mg Multiple dose group|THR-1442 20mg is administrated QD for 7days, then follow till day 14.
214854030|NCT05354089|BIOLOGICAL|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
214854031|NCT05354089|BIOLOGICAL|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
214854032|NCT05354089|DRUG|Placebo|Placebo IM on day 0 and day 21.
214854033|NCT00788229|DRUG|AT01|eye drop for 12 weeks
214854034|NCT00788229|DRUG|AT02|eye drop for 12 weeks
214854035|NCT00788229|DRUG|AT03|eye drop for 12 weeks
214854036|NCT00788229|DRUG|AT04|eye drop for 12 weeks
214854037|NCT02083926|DRUG|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
214854038|NCT02083926|OTHER|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
214907008|NCT06196437|OTHER|Sham Acupuncture|Participants will receive sham acupuncture.
214907009|NCT03046732|OTHER|"Implementing Explore Transplant Education"|"The Explore Transplant Ontario (ETO) education program"
214907010|NCT01729273|OTHER|Diet and Exercise Intervention|Remote Dietary and Exercise Intervention Program
214854039|NCT06583850|OTHER|The Neck Disability Index|The Neck Disability Index (NDI) is the most widely used self-report tool to assess neck pain status, and provides information not only about pain experiences but also about a person\&#39;s functional status. The NDI consists of 10 questions related to pain, functional activities, self-care, and quality of life that are measured on a 6-point scale (0, no disability; 5, full disability). The numeric score for each item is summed for a score ranging from 0 to 50; 0-4 points are defined as no disability, 5-14 points as mild disability, 15-24 points as moderate disability, 25-34 points as severe disability and above 35 points as complete disability.
214854040|NCT06583850|OTHER|Visual analog scale (VAS)|A 10 cm VAS numbered from 0 to 10 was used for the assessment. 0 indicates no pain and 10 indicates unbearable pain. Participants were asked to mark a point between 0-10 according to their pain status
214854041|NCT06583850|OTHER|Pittsburgh Sleep Quality Index|Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-report questionnaire
214854042|NCT06583850|OTHER|Cervical Range of Motion Assessment|Active Cervical Range Of Motion was measured with a universal goniometer in all three planes of motion in the cervical region: lateral flexion (frontal plane), axial rotation to both right and left sides (horizontal plane), and flexion-extension (sagittal plane).
214854043|NCT00705692|DRUG|Levamisole|
214854044|NCT00705692|DRUG|Placebo|
214854045|NCT04948957|DRUG|Esmolol|
214854046|NCT04948957|DRUG|Nitroglycerin|
214854047|NCT02350374|OTHER|carbohydrate counting|"patients must fill their logbook with the following data:~* cho amount at breakfast, lunch, snack and dinner~* insulin amount at breakfast, lunch, snack and dinner"
214854048|NCT02610816|OTHER|1 Food Elimination Diet|Participants eliminate milk from the diet for 12 weeks
214854049|NCT02610816|OTHER|4 Food Elimination Diet|Participants eliminate milk, egg, wheat, soy from the diet for 12 weeks
214854050|NCT02610816|OTHER|4 Food Elimination Diet (post 1FED failure)|Participants that fail to respond to 1FED in phase 1 eliminate milk, egg, wheat, soy from the diet for 12 weeks in Phase 2
214854051|NCT02610816|DRUG|Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)|Participants that fail to respond to 4FED in phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily for 12 weeks in Phase 2
214854052|NCT01949116|DRUG|LDMTX|"LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly"
214854053|NCT01949116|DRUG|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly"
214854054|NCT01949116|DIETARY_SUPPLEMENT|Folic acid|1-mg tablet of folic acid by mouth once a day
214854055|NCT00988936|DRUG|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with \[F-18\]RGD-K5
214854056|NCT04419623|DRUG|TL-895|TL-895, administered by mouth
214854057|NCT00780923|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
214854058|NCT05678855|BEHAVIORAL|A randomızed Controlled Study with pre-test and post-test|The intervention in this study is to apply multimedia-based instruction in distance education to the experimental group. control group students received distance education through traditional teaching. Experimental group students received distance education through interactive teaching prepared with multimedia tools. Experimental group, interactions were made using applications such as Icebreaker, Puzzle, QR code, Mentimeter, and Padlet. In addition, animation, infographics, animated slides (Multimedia tools) were used for the experimental group.In the control group, plain narration was given. Tests were administered to both groups before and after the intervention.
214854059|NCT04998578|DEVICE|Comparison of aesthetic techniques|Comparison of aesthetic techniques for rejuvenation and glazing of the genital region
214854060|NCT03438227|DRUG|Iron dextran|Single intravenous infusion of iron dextran 1000mg.
214854061|NCT03438227|DRUG|Ferrous sulfate 325mg|Oral iron supplementation with ferrous sulfate 325mg one to three times daily
214854062|NCT04079127|DEVICE|Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.|Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.
214854063|NCT05518630|BEHAVIORAL|Nomothetic Versus Idiographic Assessment in Chronic Pain|Participants with either endometriosis, vulvodynia, and/or fibromyalgia will answer a twice-daily diary for 42 days and a short weekly diary six times in total. In addition, they will answer two longer surveys at the start and at the end of the 42 days. These questionnaires ask about psychological flexibility, depression, catastrophizing, and pain interference. The data collected is only observational and does not include any intervention.
214854064|NCT04432675|DRUG|hydroxyethl starch|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
214854065|NCT04432675|DRUG|Lactated Ringer's solution|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
214854066|NCT04438590|DIETARY_SUPPLEMENT|Kelulut Honey|The Substance being tested to be used as an alternative
214854067|NCT04438590|DIETARY_SUPPLEMENT|Carborie|The commercially available substance
214854068|NCT04656730|DRUG|Iberogast® and Iberogast® N|Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
214854069|NCT02582372|DRUG|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
214854070|NCT02582372|DRUG|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
214854071|NCT00542763|DRUG|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
214854072|NCT02212340|DRUG|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
214854073|NCT02212340|DRUG|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
214854074|NCT01612416|DEVICE|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
214854075|NCT04523402|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy with GEMOX regimen before liver resection
214854076|NCT04127955|OTHER|Theory of Planned Behavior based Physical Activity Intervention|"Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial."
214854077|NCT03994549|DRUG|Dual GLP-1/GLP-2 Receptor agonists|Eight ascending doses of ZP7570
214854078|NCT04912336|DIAGNOSTIC_TEST|Standard coagulation profile|prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount
214854079|NCT04912336|DIAGNOSTIC_TEST|Specific coagulation tests|AT III, anti Xa, ACT, ROTEM
214854080|NCT04912336|OTHER|Bleeding Scores|Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
214854081|NCT01069952|DEVICE|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
214854082|NCT00049842|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg Weekly QW SC for 36 months
214854083|NCT01813071|BIOLOGICAL|WRSS1|
214854084|NCT03167593|DIETARY_SUPPLEMENT|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
214854085|NCT03167593|OTHER|Control placebo|Maltodextrin
214854086|NCT04476628|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
214854087|NCT04476628|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
214854088|NCT04476628|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
214854089|NCT04731311|DEVICE|Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease|4 participants with undergo 4 usability evaluations each, inter-spaced by days when researchers will address design changes. 2 participants will be elderly healthy and 2 will have the early Alzheimer's disease. Each session will last up to 1 hour, during which participants will interact with tasks in the form of games. Games will be gradated in level of difficulty, increasing from session to session. They will be played with one game controller or with two controllers while participants wear an all-in-one head mounted display. The degree of cognitive engagement during tasks will be measured with custom biosensors and used in adjusting level of difficulty. Each participant will fill subjective evaluation form and a USE form assessing ease of use, usefulness, and perceived technology issues. Scores will be analyzed and data published, in conjunction with game performance data.
214854090|NCT05144347|DRUG|XL114|Tablets of XL114
214854091|NCT00105573|BEHAVIORAL|Maternal interpersonal psychotherapy (IP)|Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
214854092|NCT00105573|BEHAVIORAL|Infant-parent psychotherapy|Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
214854093|NCT00105573|BEHAVIORAL|Informational meetings plus treatment as usual|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
214854094|NCT00613834|DRUG|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
214854095|NCT00613834|DRUG|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
214854096|NCT02405663|PROCEDURE|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
214854097|NCT02405663|PROCEDURE|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
214854098|NCT06000735|DEVICE|7-Day Continuous Glucose Monitoring with Abbott Freestyle Libre 2|All participants will go through the same intervention described above
214854099|NCT01843309|DRUG|Spironolactone 100mg|
214854100|NCT01843309|DRUG|Spironolactone 200mg|
214854101|NCT01843309|DRUG|Placebo|
214854102|NCT00842530|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
214854103|NCT00842530|BIOLOGICAL|Inactivated rabies virus vaccine|0.5 mL, Subcutaneous
214854104|NCT00842530|BIOLOGICAL|Placebo|Sodium chloride 0.9%
214854105|NCT01251978|DRUG|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
214854106|NCT01251978|DRUG|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
214854107|NCT06011616|OTHER|Sensory training|sensory training includes superficial sensory and deep sensory activities i.e. play with dough, painting with finger, recognizing objects with blocked vision, recognizing the drawn figure on palm, oint compression, bearing the weight on the paretic hand, leaning on the paretic side, walking with hand, rolling the heavy objects, dough squeezing etc.
214854108|NCT06011616|OTHER|Motor training|Motor training would involve activitoes such as throwing and catching a ball, targeted ball throwing, hand in hand ball transferring, ball rolling, hitting a ball to ground and wall, hand roller etc.
214854109|NCT06011616|OTHER|Conventional exercises|stretching exercises, muscle strengthening exercises, static weight bearing exercises, positioning
214854110|NCT01692314|OTHER|Resistance training|
214854111|NCT00944112|BIOLOGICAL|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
214854112|NCT00944112|BIOLOGICAL|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
214854113|NCT02939950|DEVICE|Bausch + Lomb Samfilcon A Soft Contact Lens|soft contact lenses
214854114|NCT02939950|DEVICE|Bausch + Lomb Pure Vision Soft Contact Lens|soft contact lenses
214854115|NCT00486018|DRUG|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
214854116|NCT00486018|DRUG|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
214854117|NCT00486018|DRUG|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
214854118|NCT00893451|DRUG|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
214854119|NCT00893451|DRUG|Placebo|Placebo orally twice daily
214854120|NCT00785681|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
214854121|NCT06461117|OTHER|Beetroot Juice|Beetroot juice (8 mmol NO3-) consumption before training at 6 days
214854122|NCT06461117|OTHER|Plesabo Drink|Plesabo drink (0,6 mmol NO3-) consumption before training at 6 days
214854123|NCT01660022|DRUG|100mg OZ439 single oral dose|100mg OZ439 oral suspension single dose
214854124|NCT01660022|DRUG|Placebo|Placebo
214854125|NCT01660022|DRUG|300 mg OZ439 single oral dose|300mg OZ439 oral suspension single dose
214854126|NCT01660022|DRUG|160mg Piperaquine single oral dose|160 mg Piperaquine tablet
214854127|NCT01660022|DRUG|480mg Piperaquine single oral dose|480 mg Piperaquine tablet
214854128|NCT01660022|DRUG|1440mg Piperaquine single oral dose|1440 mg Piperaquine tablet
214854129|NCT01660022|DRUG|800 mg OZ439 single oral dose|800mg OZ439 oral suspension single dose
214854130|NCT04881734|OTHER|Overtime pancreaticoduodenectomy|Compared with daytime surgery, the intervention in this study is to work overtime after 17:00 to perform pancreaticoduodenectomy.
214854131|NCT03327090|OTHER|Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).|Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
214854132|NCT02485821|DRUG|Estradiol|
214854133|NCT02485821|DRUG|Placebo|
214854134|NCT02485821|DRUG|Misoprostol|
214854135|NCT04969159|OTHER|no intervention|standard treatment in the clinical routine
214854136|NCT02409329|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.
214854137|NCT02409329|BEHAVIORAL|Helpline and A1c results|Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
214854138|NCT02409329|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
214854139|NCT01870245|DRUG|ACHN-975|Intravenous multiple dose
214854140|NCT01870245|DRUG|placebo|Intravenous multiple dose
214854141|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (low dose)|
214854142|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (high dose)|
214854143|NCT00794976|DRUG|Dexamethasone Passive Patch|
214290366|NCT05053789|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
214854144|NCT00794976|DRUG|Placebo Patch|
214854145|NCT03352895|DIETARY_SUPPLEMENT|resveratrol|Grape seed extract 100mg Microcrystalline Cellulose 90mg Magnesium Stearate 2mg Gelatin 100mg
214854146|NCT03352895|DIETARY_SUPPLEMENT|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
214854147|NCT04400760|DRUG|DAPA Tx|The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
214854148|NCT06489938|BEHAVIORAL|Mirror therapy|In mirror therapy, a wooden mirror (41×50×33 cm3) will be positioned in the participant's sagittal midplane, blocking the participant's view of the affected arm performance. We will also provide a foldable bed tray table to ensure that the participants focus on the mirror reflection of the less affected arm. The mirror therapy will consist of movement and functional practices.
214854149|NCT06489938|BEHAVIORAL|Task-oriented approach|The task-oriented approach will provide both bimanual common-goal and dual-goal tasks for the participants.
214854150|NCT06489938|BEHAVIORAL|Impairment-oriented approach|The impairment-oriented approach will focus on the movement components. Arm BASIS or Arm Ability training will be provided based on the severity of the participant's impairment.
214854151|NCT00378716|DRUG|5-fluorouracil|
214854152|NCT00378716|DRUG|leucovorin calcium|
214854153|NCT00378716|DRUG|tegafur|
214854154|NCT00378716|DRUG|uracil|
214854155|NCT01019863|DRUG|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
214854156|NCT01762124|DEVICE|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
214854157|NCT01736436|DRUG|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
214854158|NCT01736436|PROCEDURE|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
214854159|NCT01736436|PROCEDURE|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
214854160|NCT05993715|DIETARY_SUPPLEMENT|Nitrate supplementation|Participants ingested 2 × 70 mL/day shots of concentrate nitrate-rich (\~12.8 mmol/day nitrate) or nitrate-depleted (\~0.08 mmol/day nitrite) beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK). Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
214854161|NCT05993715|DIETARY_SUPPLEMENT|Placebo supplementtaion|2 × 70 mL/day shots of concentrate nitrate-depleted (\~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
214854162|NCT03443817|BEHAVIORAL|Tele rehab|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
214854163|NCT05486832|DEVICE|Cardiovalve TR valve replacement System|The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
214854164|NCT02761603|BEHAVIORAL|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
214854165|NCT02761603|BEHAVIORAL|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
214854166|NCT04178382|DIAGNOSTIC_TEST|PCR-CRISPR／Cas12a detection|Evaluate whether the combination of PCR and CRISPR/Cas12a detection of alveolar lavage fluid changes the choice of early antibiotics in patients with pneumonia in artificial airways, and whether it changes the prognosis compared with traditional pathogenic microbial detection techniques.
214854167|NCT06690138|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective period.
214854168|NCT06690138|DRUG|Itraconazole|Itraconazole will be administered BID on Day 1 and QD from Day 2 to 13 and as specified for the respective period.
214854169|NCT06688695|BEHAVIORAL|Neurodevelopmental support|The Intervention for Neurodevelopmental Support in Preterm Infants using Responsive parenting and E-health (INSPIRE) aims to support the infant's neurodevelopment by supporting the parents to develop a responsive approach. The intervention will enhance the infant's social and environmental interactions, focusing on developing both the infant's and parent's strengths, seeking opportunities instead of problems in behaviour, enhancing mutually satisfying interaction and parental empowerment.
214854170|NCT05998551|DRUG|Dexmedetomidine|intrathecal injection of dexmedetomidine added to hyperbaric bupivacaine
214854171|NCT05998551|DRUG|Fentanyl|intrathecal injection of fentanyl added to hyperbaric bupivacaine
214854172|NCT05998551|DRUG|Bupivacaine Hcl 0.5% Inj|intrathecal injection of hyperbaric bupivacaine only
214854173|NCT00766831|DRUG|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram \[mg\] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
214854174|NCT01980160|DEVICE|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
214854175|NCT01980160|DEVICE|Unactivated Nometex Device|
214854176|NCT06060184|GENETIC|Next-Generation Sequencing (NGS)|Sequencing of genomes (Long read NGS)
214854177|NCT03755089|DRUG|Phenazopyridine|200mg PO Phenazopyridine taken 1-2 hours prior to the Botox® injection procedure
214854178|NCT03755089|DRUG|Lidocaine 2% Injectable Solution|30mL 2% lidocaine instilled into the bladder lumen 20 via a urinary catheter 20 minutes prior to the Botox® injection procedure
214854179|NCT00508040|DRUG|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
214854180|NCT00508040|DRUG|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
214854181|NCT02823847|BEHAVIORAL|Screening Interview|Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
214854182|NCT02823847|DEVICE|Carbon Monoxide Test|Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
214854183|NCT02823847|BEHAVIORAL|Self-Help Materials|"Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.~Participants with premalignant and malignant oral lesions \[PMOL\]) given printed materials and web-based programs for tobacco and alcohol cessation."
214854184|NCT02823847|PROCEDURE|Visual Oral Screening Examination|Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
214854185|NCT02823847|PROCEDURE|Direct Fluorescent Oral Visualization Examination|Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
214854186|NCT02823847|PROCEDURE|Oral Biopsy|Premalignant and malignant oral lesions \[PMOL\]) still present 2 weeks after oral exam are biopsied.
214854187|NCT01782287|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
214854188|NCT01782287|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
214854189|NCT01783652|BEHAVIORAL|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
214854190|NCT02946216|GENETIC|ctDNA analysis|
214854191|NCT04430127|OTHER|No supplementary intervention is performed|No supplementary intervention will be applied
214664561|NCT00930410|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
214854192|NCT01038037|DRUG|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
214854193|NCT01038037|DRUG|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
214854194|NCT01038037|DRUG|panitumumab|i.v. day 1: 9 mg/kg q3w
214854195|NCT05361291|DRUG|Lidocaine Hydrochloride|Inferior alveolar nerve block
214854196|NCT00788593|DRUG|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
214854197|NCT00788593|DRUG|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
214854198|NCT00788593|DRUG|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
214854199|NCT06236256|DEVICE|MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system|The MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system consists of the following devices: MiniMed 780G insulin pump, Guardian Link (4) transmitter and the Guardian Sensor (4). It is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. Study participants will be connected to the system and glucose data will be collected throughout the 12 month study period.
214854200|NCT06236256|OTHER|MDI/CSII|Participants in the control group with continue their routine procedures that include eighter Multiple daily insulin injections (MDI) treatment or different kinds of Continuous subcutaneous insulin infusion (CSII) pumps depending on their treatment before the study. The participants will be connected to a standalone sensor at the start, middle and end of the study and glucose data will be collected.
214854201|NCT03020719|DRUG|Oral Glutathione|Oral Glutathione oral powder
214854202|NCT03020719|DRUG|Placebo|Placebo oral powder
214854203|NCT02198924|DRUG|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
214854204|NCT02198924|DRUG|placebo|control patients are supplied with the corresponding placebo with the same instructions.
214854205|NCT05154552|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.
214854206|NCT05154552|OTHER|Routine physical therapy|"Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises"
214854207|NCT00764231|BEHAVIORAL|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
214854208|NCT00764231|BEHAVIORAL|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
214854209|NCT02304068|OTHER|Home monitoring|
214854210|NCT02304068|OTHER|Hospital assessment|
214854211|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
214854212|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
214854213|NCT03856905|OTHER|Physical therapy program|It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.
214854214|NCT03856905|DEVICE|Extracorporeal shock wave therapy|It is an electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG). The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode.
214854215|NCT03856905|DEVICE|Functional electrical stimulation|It is a highly advanced medical device that consists of a battery-operated, single-channel electrical stimulator, two electrodes, and electrode leads with a cuff holds the system in place. The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait.
214854216|NCT01594359|OTHER|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
214854217|NCT01594359|OTHER|BEAN|Placebo
214854218|NCT02056067|BEHAVIORAL|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
214854219|NCT02056067|BEHAVIORAL|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
214854220|NCT00027508|DRUG|trabectedin|
214854221|NCT04553913|DEVICE|cooling device|device placed on patient in recovery on non surgical side to determine resolution of spinal anesthetics.
214854222|NCT01920542|DRUG|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
214854223|NCT01920542|DRUG|no dexmedetomidine|no administration of dexmedetomidine on control group
214854224|NCT03003260|OTHER|CBD chewing gum|
214854225|NCT03003260|OTHER|Placebo|
214854226|NCT04841330|DEVICE|Securis™ Stabilization Device|A trained clinician will apply and remove, and participants will wear the Securis™ Stabilization Device for up to one week (7 days) on their forearm. A shortened catheter will be placed (not inserted) over the Securis™ device in accordance with the product Information for Use (IFU), and an extension set attached to the catheter and secured in place, to simulate clinical use.
214854227|NCT00128934|DRUG|levonorgestrel/ethinyl estradiol|
214854228|NCT03257904|PROCEDURE|intracranial pressure monitoring|measurement of intracranial pressure
214854229|NCT04205396|BEHAVIORAL|Written emotional disclosure|Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
214854230|NCT04205396|BEHAVIORAL|Resilience training|Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
214854231|NCT04205396|OTHER|No treatment|Participants will complete baseline and outcome assessments and no intervention will be conducted.
214854232|NCT03245645|OTHER|Dietary Intervention|Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
214854233|NCT00462059|BEHAVIORAL|Treatment|
214854234|NCT02731014|OTHER|Dry Needling|Dry Needling targeting the posterior musculature of the cervical and thoracic spine.
214854235|NCT02731014|OTHER|Sham Dry Needling|Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.
214854236|NCT02731014|OTHER|Manual Therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
214854237|NCT02731014|OTHER|Exercise|Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
214290367|NCT05053789|DEVICE|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
214854238|NCT03512184|BEHAVIORAL|YMCA class|The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
214854239|NCT00710749|DEVICE|Disposable device|Disposable urine flow meter
214854240|NCT00710749|DEVICE|Digital device|Digital urine flowmeter
214854241|NCT00710749|DEVICE|Clinic flow measurement|Clinic gold standard flow measurement
214854242|NCT01088919|DRUG|ASP1941|oral tablet
214854243|NCT01088919|DRUG|pioglitazone hydrochloride|oral tablet
214854244|NCT00965055|DRUG|Ezetimibe|10 mg
214854245|NCT00965055|DRUG|Atorvastatin|"Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period"
214854246|NCT02358733|PROCEDURE|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
214854247|NCT02358733|PROCEDURE|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
214854248|NCT04583163|DIAGNOSTIC_TEST|Transcranial Doppler|Transcranial Doppler is a non-invasive, painless, ultrasound technique that uses high frequency sound waves to measure the rate and direction of blood flow vessels in the brain.
214854249|NCT06427915|OTHER|OLIPOP prebiotic soda|12oz serving containing Carbonated Water, OLISMART(TM) (Cassava Root Fiber, Acacia Fiber, Guar Fiber, Nopal Cactus\*, Marshmallow Root\*, Calendula Flower\*, Kudzu Root\*), Cassava Root Syrup, Apple Juice Concentrate, Lime Juice, Natural Cola Flavor, Alpinia Galanga Root\*, Stevia Leaf\*, Himalayan Pink Salt, Green Tea Caffeine\*, Natural Caramel Flavor, Natural Vanilla Flavor, Cinnamon\* (\*Extract)
214854250|NCT06427915|OTHER|Traditional sugar-sweetened cola|12oz serving containing carbonated water, high fructose corn syrup, caramel color, phosphoric acid, natural flavors, caffeine
214854251|NCT05017649|BIOLOGICAL|Blood sample|Blood sampling.
214854252|NCT06837246|DIETARY_SUPPLEMENT|Cognitive Nutritional Supplement|Pills of cognitive nutritional supplement
214854253|NCT06837246|OTHER|Placebo|Matching placebo to active
214854254|NCT06281509|PROCEDURE|Non-invasive tests to determine the presence or absence of the palmaris longus tendon in both hands.|Schaeffer's test (flexion of the wrist while the pinky and thumb are pressed against each other) Thompson's test (wrist flexion with a clenched fist) Mishra test I (wrist flexion while the examiner pushes the hand back) Mashra test II (thumb opposition while flexing the wrist)
214854255|NCT06281509|PROCEDURE|Ultrasound|A small mobile ultrasound device will be used to further asses the presence of the tendon.
214854256|NCT05866380|OTHER|heart failure risk factors|observational study with diabetes patient with heart failure risk factors
214854257|NCT05564117|DRUG|Semaglutide|Semaglutide tablets orally once daily for 64 weeks.
214854258|NCT05564117|DRUG|Placebo semaglutide|Semaglutide placebo-matching tablets orally once daily for 64 weeks.
214854259|NCT05064280|DRUG|Pembrolizumab|Given by IV (200 mg IV D1 Q3W)
214854260|NCT05064280|DRUG|Lenvatinib|Given by PO (20 mg PO QD)
214854261|NCT06357286|BEHAVIORAL|Work opportunities|Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
214854262|NCT05618353|DRUG|Colchicine|0.6 mg tablets
214854263|NCT05618353|DRUG|Placebo|Matching placebo
214854264|NCT02027870|DEVICE|EXCEL-II biodegradable polymer sirolimus-eluting stent|EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
214854265|NCT06406569|DEVICE|H-Man Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
214854266|NCT06406569|DEVICE|ReHandyBot|ReHandyBot is the portable version of ReHapticKnob a robot developed at ETH Zurich that provides neurocognitive therapy, focusing on hand opening and closing movements as well as prono-supination of the forearm.
214854267|NCT06406569|DEVICE|MyoPanda|MyoPanda is a passive wrist/hand device which patients use to train the hand and wrist function by controlling a virtual avatar with EMG activity measures.
214854268|NCT04300413|OTHER|High-Intensity Rehabilitation plus Mobility (HeRo)|Progressive, high-intensity strengthening and functional intervention coupled with structured mobility based in principals of behavioral economics.
214854269|NCT05113459|DRUG|Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy|disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
214854270|NCT06226701|DEVICE|Cryolipolysis device|"-Cryolipolysis device~1max cool shaping device ( inform china korean technology).Is used for fat lipolysis ,with no harm to the skin.The device consist of Cool sculptor applicator head , cool gel pad its alarge gel pad it should be adherent to the area to be treated before applying the cool sculptor applicator to protect the skin from bruising or ecchymosis. The device uses vacuum suction which can be adjusted according to the patient tolerance. Duration of session 45min at each of treatment session ,1session every 2weeks for 3months."
214854271|NCT01000610|DRUG|rituximab [MabThera/Rituxan]|1000 mg iv infusion on days 1 and 15
214854272|NCT01000610|DRUG|methotrexate|10-25 mg weekly (oral or parenteral)
214854273|NCT01000610|DRUG|methylprednisolone|100 mg iv prior to each rituximab infusion
214854274|NCT00576641|BIOLOGICAL|autologous dendritic cells|
214854275|NCT02917226|OTHER|Clinical decision support and monitoring system|
214854276|NCT04808882|DRUG|Tinzaparin, Low dose prophylactic anticoagulation|"Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
214854277|NCT04808882|DRUG|Tinzaparin, High dose prophylactic anticoagulation|"Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
214854278|NCT04808882|DRUG|Tinzaparin,Therapeutic anticoagulation|"Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
214854279|NCT00667082|DRUG|NPI-0052 (marizomib) + vorinostat|"NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle"
214854280|NCT02645344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
214854281|NCT02645344|BEHAVIORAL|Sensory Cueing (SC)|
214854282|NCT02645344|BEHAVIORAL|Conventional Rehabilitation|
214854283|NCT03898674|DRUG|Intra venous fluid|Volume of intra venous fluid administered during GDT protocol
214854284|NCT05476419|OTHER|Direct intra-oral scanning technique for the post space.|scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
214854285|NCT04299659|DIAGNOSTIC_TEST|Landolt C entry method|Four different methods for entering the Landolt C gap position are compared
214854286|NCT05979077|OTHER|MyChart Questionnaire|Prior to clinic visits, families completing the MyChart Questionnaire will enter details about their current management and visit goals, automatically populating their electronic health record for subsequent review/revision by the health care team before and during the visit, reallocating clinic time previously used for data acquisition to individual patient priorities
214854287|NCT03740113|BEHAVIORAL|Kids SipSmartER|Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
214854288|NCT04673448|BIOLOGICAL|Dostarlimab|Given IV
214854289|NCT04673448|DRUG|Niraparib|Given PO
214854290|NCT04673448|PROCEDURE|Biopsy|Undergo biopsy
214854291|NCT04673448|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214854292|NCT04673448|PROCEDURE|Computed Tomography|Undergo CT
214854293|NCT04673448|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214854294|NCT04843566|PROCEDURE|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
214854295|NCT04843566|PROCEDURE|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
214854296|NCT04843566|DRUG|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
214854297|NCT06857227|DRUG|GNC-038|Administration by intravenous infusion. Once a week (IV, QW), twice in total.
214854298|NCT06857227|DRUG|Placebo|The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.
214854299|NCT02631876|DRUG|Mirvetuximab soravtansine|Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
214854300|NCT02631876|DRUG|Paclitaxel|Paclitaxel will be administered per dose and schedule specified in the arm.
214854301|NCT02631876|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
214854302|NCT02631876|DRUG|Topotecan|Topotecan will be administered per dose and schedule specified in the arm.
214854303|NCT04212377|BIOLOGICAL|Dendritic Cells for endometrial cancer|Our study population consists of 8 mEC patients who receive carboplatin / paclitaxel chemotherapy in a weekly schedule on weeks 1, 2, 3 and weeks 5,6 and 7. In week 8, myeloid and plasmacytoid DC (nDC) are loaded with tumor lysate and MUC1 and survivin PepTivators, injected intranodally. An extensive immuno-motoring will be performed on all patients. Patients who show stable disease, partial response, or full response continue with extended three-week chemotherapy regimens with intranodal injections of nDC at weeks 17, 20, and 23.
214854304|NCT02915926|BEHAVIORAL|occupational performance coaching|
214854305|NCT02915926|BEHAVIORAL|standard OT|
214290368|NCT05642754|OTHER|Overall uncertainty language|Researchers are testing different forms of information about overall study uncertainty and margin of error around main result
214854306|NCT00785096|OTHER|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
214854307|NCT03877341|PROCEDURE|posterolateral fusion|Instrumented posterolateral fusion is a spinal surgery that combines bone graft fusion with the use of hardware like screws and rods to stabilize the spine, correct alignment, and promote successful fusion. It's used for various spinal conditions.
214854308|NCT03877341|PROCEDURE|posterior lumbar interbody fusion|Posterior lumbar interbody fusion (PLIF) is a spinal surgery that involves removing problematic discs, inserting bone graft material, and sometimes a spacer, to promote fusion and stabilize the spine.
214854309|NCT05704972|OTHER|the operating room environment risk|in determining the risks they face in the operating room environment.
214854310|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
214854311|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
214854312|NCT04661592|DEVICE|NeuroCatch Platform|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
214854313|NCT00726102|OTHER|Meat|2 0z of locally available meat per day
214854314|NCT00726102|OTHER|Cereal|Daily provision of cereal to infants from 6-18 mos
214854315|NCT00726102|OTHER|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
214854316|NCT06451718|DEVICE|Intracorneal implantation|Intracorneal implantation of the nitinol investigational device
214854317|NCT00567437|OTHER|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
214854318|NCT01592721|BIOLOGICAL|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
214854319|NCT00010166|DRUG|gemcitabine hydrochloride|
214854320|NCT00010166|PROCEDURE|adjuvant therapy|
214854321|NCT00010166|RADIATION|radiation therapy|
214854322|NCT00176540|DRUG|dextromethorphan hydrobromide|
214854323|NCT06154694|RADIATION|Stereo Radiographic EOS Measurements|"Healthy control will undergo a stereo radiographic EOS exam with their arm in various positions.~1. Relaxed standing (0 degree of abduction)~2. 45 degree of abduction in the coronal plane~3. 90 degree of abduction in the coronal plane~4. 120 degree of abduction in the coronal plane~5. 45 degree anterior flexion in the sagittal plane~6. 90 degree anterior flexion in the sagittal plane~7. 120 degree of anterior flexion in the sagittal plane~8. 45 degree extension in the sagittal plane"
214854324|NCT00784524|BIOLOGICAL|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10\^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
214854325|NCT00784524|BIOLOGICAL|aldesleukin|Subcutaneous aldesleukin (10 x 10\^6 International Units) will be given on day 7 and day 8 after each LMI injection.
214854326|NCT03570450|DRUG|Adipose derived Stem Cell|4 doses
214854327|NCT03570450|OTHER|placebo|placebo
214854328|NCT00494624|DRUG|prednisolone|
214854329|NCT01852734|PROCEDURE|embolizations ,uterine fibroid|"26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop"
214854330|NCT01852734|PROCEDURE|embolizations|comparison between the two microspheres
214854331|NCT00107718|DRUG|SB-485232|
214854332|NCT02277704|DRUG|TNX-102 SL|
214854333|NCT02277704|DRUG|Placebo|
214854334|NCT01408563|DRUG|Fludarabine|30 mg/m2/day IV x 6 days
214854335|NCT01408563|DRUG|Melphalan|100 mg/m2/day IV x 1 day
214854336|NCT01408563|RADIATION|Total Body Radiation|200 cGy on Day 0
214290369|NCT02350725|DRUG|Furosemide injection solution for subcutaneous administration (80 mg)|
214290370|NCT02350725|DRUG|Oral Furosemide tablets (80 mg)|
214290371|NCT05898815|DIAGNOSTIC_TEST|Medical record collection|Medical record collection
214290372|NCT03725696|DIAGNOSTIC_TEST|Semen Analysis|Sperm counts will be determined by semen analysis.
214290373|NCT03725696|DIAGNOSTIC_TEST|Hormonal panel|Blood test for LH, FSH, testosterone, and estradiol
214854337|NCT01408563|BIOLOGICAL|Cord Blood|2 cord blood units IV
214854338|NCT03142516|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
214854339|NCT03142516|DRUG|Irinotecan|Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
214854340|NCT03142516|DRUG|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
214854341|NCT03142516|DRUG|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
214854342|NCT02516410|DRUG|VX-661 plus ivacaftor combination|
214854343|NCT02516410|DRUG|Ivacaftor|
214854344|NCT02516410|DRUG|Placebo (matched to VX-661 plus ivacaftor combination)|
214854345|NCT02516410|DRUG|Placebo (matched to ivacaftor)|
214854346|NCT02894866|DEVICE|hyperbaric oxygen|The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
214854347|NCT06429839|COMBINATION_PRODUCT|Nimotuzumab with chemoradiotherapy|Radiotherapy,40-50.4Gy/20-28f. Nimotuzumab 400mg,ivgtt,W2d. Chemotherapy, S-1,40-60mg/m2, on BSA, orally twice daily on radiotherapy days.
214854348|NCT01432574|BIOLOGICAL|Gardasil|The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
214854349|NCT00996931|DRUG|lenalidomide|2.5 mgs per day orally for 12 weeks
214854350|NCT03824990|BEHAVIORAL|Quality improvement of management of neonatal jaundice|During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
214854351|NCT05492370|DIETARY_SUPPLEMENT|EpiCor|2 gummies daily
214854352|NCT05492370|DIETARY_SUPPLEMENT|Placebo|2 gummies daily
214854353|NCT03629600|DRUG|Lactated Ringer|High-volume Lactated Ringer Solution
214854354|NCT03629600|DRUG|Rectal Form Indometacin|Post-ERCP rectal administration of 100 MG Indomethacin
214854355|NCT04051684|PROCEDURE|Transverse abdominal plane block|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
214854356|NCT04051684|DRUG|Ropivacaine|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
214854357|NCT06141824|DEVICE|Lucira COVID-19 & Flu Test|The Lucira COVID-19 \& Flu Test is a rapid, single-use, molecular test for the qualitative detection and discrimination of SARS-CoV-2, Influenza A, and Influenza B viral RNA in nasal swab samples.
214854358|NCT04440319|BEHAVIORAL|Intervention group|Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
214854359|NCT02785536|BEHAVIORAL|RITCh Treatment|"The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together."
214854360|NCT02785536|BEHAVIORAL|Standard Treatment|The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
214854361|NCT00393536|BEHAVIORAL|Educational outreach visiting|
214854362|NCT00727519|DIETARY_SUPPLEMENT|Pomegranate juice|
214854363|NCT00727519|DIETARY_SUPPLEMENT|Placebo|
214854364|NCT01962181|DRUG|Ritalin|Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
214854365|NCT01962181|DRUG|Placebo|
214854366|NCT04902625|DRUG|Naltrexone-Bupropion Combination|Naltrexone-bupropion will be added to the BOT module in the interventional arm.
214854367|NCT00666848|DRUG|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
214854368|NCT00666848|DRUG|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
214854369|NCT00666848|DRUG|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
214854370|NCT00666848|DRUG|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
214854371|NCT02483143|DRUG|NAC|3 gr NAC was made up to 1000 ml with NS; a 1 ml/3 mgr NAC solution was obtained and 3 ml/kg NAC+NS solution was administered for 1 h before CTPA and a 1 ml/kg per hour NAC+NS solution was administered for a minimum 6 h after CTPA.
214854372|NCT02483143|DRUG|NaHCO3|132 mEq NaHCO3 was made up to 1000 ml with NS; and 3 ml/kg NaHCO3+NS solution was administered for 1 h before CTPA and 1 ml/kg per hour NaHCO3+NS solution was administered for a minimum of 6 h after CTPA.
214854373|NCT02483143|DRUG|Normal Saline|3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
214854374|NCT03832881|DIAGNOSTIC_TEST|ADAMTS13, VWF assay|
214854375|NCT05709041|OTHER|Individualized lung-protective ventilation|"Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.~The ventilator will be set to volume-controlled ventilation with a tidal volume of 6 mL/kg of ideal body weight, inspired oxygen fraction of 30%, inspiratory pause of 30%, inspiration-to-expiration ratio of 1:2, PEEP of 5 cm H2O, and flow of 3 L/min). The respiratory rate will be set to 12 breaths/min in the beginning then adjusted (within 10-20 breaths/ min) to maintain EtCO2 between 35 to 45 mm Hg.~The set PEEP will be then increased by 2 cm H2O every 2 minutes (up to a max of 30 cm H2O) to identify and maintain the lowest driving pressure, maximum compliance, and positive TPP. These steps will be performed every 30 minutes after intubation, and after instillation of the pneumoperitoneum, and after steep Trendelenburg positioning. These individualized PEEP settings will be maintained until the pneumoperitoneum is released."
214854376|NCT05709041|OTHER|Standard lung-protective ventilation|Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
214290374|NCT03725696|PROCEDURE|RYGB Gastric Bypass|Roux-en-Y Gastric Bypass
214854377|NCT04244669|DEVICE|IPG with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% in that area. It can be reprogrammed as many times as necessary during the 14-21 days of margin.
214854378|NCT04244669|DEVICE|IPG with SCS DTM|In this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms
214854379|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
214854380|NCT01029158|DRUG|RN1006 (Avotermin)|250 ng, intradermal injection, twice
214854381|NCT01029158|DRUG|RN1006 (Avotermin)|205 ng, Intradermal injection, once
214854382|NCT01029158|DRUG|RN1006 (Avotermin)|500ng, intradermal injection, once
214854383|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, intradermal injection, twice
214854384|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
214854385|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
214854386|NCT01029158|DRUG|RN1006 (Avotermin)|500 ng, intradermal injection, twice
214854387|NCT01029158|DRUG|Placebo|Placebo
214854388|NCT00735917|DRUG|saracatinib|Given PO
214854389|NCT00735917|OTHER|pharmacogenomic studies|Optional correlative studies
214854390|NCT00735917|OTHER|pharmacological study|Optional correlative studies
214854391|NCT00735917|PROCEDURE|positron emission tomography|Optional correlative studies
214854392|NCT00735917|RADIATION|fludeoxyglucose F 18|Optional correlative studies
214854393|NCT00735917|OTHER|laboratory biomarker analysis|Optional correlative studies
214854394|NCT05436704|PROCEDURE|EUS-FNB|EUS-FNB
214854395|NCT03321162|DIAGNOSTIC_TEST|scan protocol|Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
214854396|NCT02839148|DIETARY_SUPPLEMENT|Food supplementation|"Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS."
214854397|NCT02043613|OTHER|Contextually enhanced physical surroundings of exercise|"Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.~The differences with the physical surroundings of exercise is the primary intervention for this study."
214854398|NCT02043613|OTHER|Neuromuscular exercise|The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
214854399|NCT04725448|DRUG|Toripalimab|240mg, ivgtt, d1, every 3 weeks until disease progress or intolerable toxicity, up to 2 years of administration
214854400|NCT04725448|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, every 3 weeks, up to 2 years of administration
214854401|NCT04725448|DRUG|Nab-paclitaxel|260mg/m2,d1 or 130mg/m2,d1,8, ivgtt, every 3 weeks, up to 6 cycles
214854402|NCT04725448|DRUG|Carboplatin|AUC=4～5, d1, ivgtt, every 3 weeks, up to 6 cycles
214854403|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
214854404|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
214854405|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
214854406|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
214854407|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)\]
214854408|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
214854409|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
214854410|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
214854411|NCT02698865|DEVICE|MONOVISC|Two (2) intra-articular injections of 4 ml MONOVISC, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
214854412|NCT02698865|DEVICE|Saline|Two (2) intra-articular injections of 4 ml saline, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
214854413|NCT01323465|DRUG|Sativex and rifampicin|Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
214854414|NCT01323465|DRUG|Sativex and rifampicin|Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
214854415|NCT01323465|DRUG|Sativex and ketoconazole|Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
214854416|NCT01323465|DRUG|Sativex and ketoconazole|Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
214854417|NCT01323465|DRUG|Sativex and omeprazole|Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
214854418|NCT01323465|DRUG|Sativex and omeprazole|Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
214854419|NCT03861481|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
214854420|NCT03861481|OTHER|Placebo|Subjects will receive placebo in a specified sequence during the treatment period.
214854421|NCT00773734|DRUG|Apremilast 10mg|
214854422|NCT00773734|DRUG|Apremilast 20mg|
214854423|NCT00773734|DRUG|Apremilast 30 mg|
214854424|NCT00773734|DRUG|Placebo|
214854425|NCT00773734|DRUG|Apremilast 30mg|
214854426|NCT00773734|DRUG|Apremilast 20mg|
214854427|NCT03118388|BEHAVIORAL|Social Enterprise Intervention|The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).
214854428|NCT03118388|BEHAVIORAL|IPS|To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
214854429|NCT03605511|DIAGNOSTIC_TEST|ADAMTS 13, complement and angiogenic biomarkers|ADAMTS 13, complement and angiogenic biomarkers
214854430|NCT02473783|DRUG|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
214854431|NCT02473783|OTHER|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
214854432|NCT04158661|PROCEDURE|thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)|preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
214854433|NCT04158661|PROCEDURE|thymectomy by means of median sternotomy (transsternal)|with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
214854434|NCT04158661|PROCEDURE|no thymectomy (control)|routine medical care
214854435|NCT04722159|DEVICE|Renal denervation|Catheter-based inhibition of renal sympathetic nerve traffic.
214290375|NCT03725696|DIAGNOSTIC_TEST|IIEF Survey|International Index of Erectile Function is a validated 5-question survey examining sexual health in men
214854436|NCT00005809|PROCEDURE|computed tomography|
214854437|NCT00005809|PROCEDURE|diagnostic colonoscopy|
214854438|NCT00236067|DRUG|Gabitril|
214854439|NCT00002360|DRUG|Didanosine|
214854440|NCT01220297|DRUG|Sirolimus|"Immunosuppressant administered orally to:~* Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~* Children \< 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
214854441|NCT01220297|DRUG|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
214854442|NCT01220297|DRUG|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
214854443|NCT01220297|DRUG|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
214854444|NCT01220297|DRUG|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
214854445|NCT01220297|DRUG|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
214854446|NCT00085306|BIOLOGICAL|recombinant interferon beta|recombinant interferon beta
214854447|NCT01989988|PROCEDURE|LMGB|
214854448|NCT01989988|PROCEDURE|LRYGB|
214290376|NCT02859779|BEHAVIORAL|education programs|Four audio-recorded discussion groups will be organized in each of the 10 clinical settings
214290377|NCT02311010|DRUG|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
214290378|NCT02968745|OTHER|Observational study|Canadian Occupational Performance Measure (COPM) was applied to identify the main occupational performance problems
214854449|NCT01989988|PROCEDURE|SADJB|
214854450|NCT01287039|DRUG|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
214854451|NCT01287039|DRUG|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
214854452|NCT04437888|DRUG|Ketamine|Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
214854453|NCT04528888|DRUG|Enoxaparin|Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
214854454|NCT04528888|DRUG|Methylprednisolone|Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
214907011|NCT03958929|OTHER|Educational Video|The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q\&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
214907012|NCT01228682|DRUG|Tolvaptan|Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
214854455|NCT04528888|DRUG|unfractionated heparin|Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
214854456|NCT00417404|DRUG|Aquasol A|IM Aquasol A 10,000IU three times weekly
214854457|NCT00417404|DRUG|aquasol A|10,000 IU three times weeks, by intramuscular injection
214854458|NCT00417404|OTHER|sham injection|sham injection
214854459|NCT02843594|PROCEDURE|LEEP intervention|Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
214854460|NCT02843594|PROCEDURE|Standard Phaco Control|
214854461|NCT00099268|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
214854462|NCT00099268|DRUG|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
214854463|NCT00217269|DEVICE|Coronary Artery Stenting|Endeavor Drug eluting stent
214854464|NCT00217269|DEVICE|Coronary Artery Stenting|Taxus Drug Eluting Stent
214854465|NCT05016622|BIOLOGICAL|BNT162b2 vaccine|Administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
214854466|NCT03894241|BEHAVIORAL|physical activity|"Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)"
214854467|NCT05002413|DIAGNOSTIC_TEST|Resistell AST|The Resistell AST is intended for rapid antibiotic susceptibility testing of most common clinically relevant Gram-negative bacteria causing bloodstream infections (BSI) (bacteremia). In the scope of this study, the Resistell Phenotech device will be used to test the susceptibility of Gram-negative bacteria, in particular Escherichia coli and Klebsiella pneumoniae to ceftriaxone and ciprofloxacin.
214854468|NCT03892213|DRUG|Benznidazole|Benznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9\*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12\* until Day 15.
214854469|NCT03892213|DRUG|E1224|"E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).~On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly."
214854470|NCT05723419|PROCEDURE|axillary block using 5 ml local anesthetics|ultrasoud guided axillary block
214854471|NCT04822571|OTHER|Reliability of 3D motion analysis protocol|The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.
214854472|NCT04284514|DRUG|AKB-9778 Ophthalmic Solution|AKB-9778 Ophthalmic Solution
214854473|NCT04284514|DRUG|Placebo Ophthalmic Solution|Matched vehicle-control
214854474|NCT00033904|DRUG|autologous human tumor-derived HSPPC-96|
214854475|NCT06226922|OTHER|No intervention|No intervention
214854476|NCT01758822|OTHER|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
214854477|NCT03477019|DRUG|SonoVue|"consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol."
214854478|NCT03477019|PROCEDURE|Focused Ultrasound|ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
214854479|NCT04303650|DEVICE|Ultrasound measurement of quadriceps muscle layer thickness|With patient in supine position ultrasound will be performed using a 12MHZ Transducer connected to Sonosite M Turbo machine. The probe will be placed perpendicular to the long axis of the thigh on its anterior surface at the two thirds of the length between the anterior superior iliac spine and the upper border of the patella. After identifying the muscle tissue, the thickness of the quadriceps muscle will be obtained by measuring the distance between the cortex of femur and the most superficial muscular fascia. Measurements will be performed by applying maximal compression on the probe without inflicting pain to prevent underestimation of muscle wasting linked to subcutaneous edema. measurements will be made on both sides repeatedly on ICU days 1, 3, 7, and 10. Every time three ultrasound measurements will be taken per site and the average of three measurements for each site will be used and combined to provide total muscle depth
214664562|NCT02721862|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
214854480|NCT05208658|OTHER|Experimental: Classical Vision Therapy Treatment|Do classical vision therapy treatment for improve vergence
214854481|NCT05208658|OTHER|Control: Eye Movement Therapy Treatment|Do eye movement therapy treatment in order not to improve vergence
214854482|NCT06172413|DEVICE|transcranial alternating current stimulation (tACS)|"Three conductive electrodes will be applied to the scalp: one 4.45 × 9.53 cm electrode placed over the forehead (Fpz, Fp1, and Fp2 in the 10/20 international placement system) and two 3.18 × 3.81 cm electrodes over the mastoid areas.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~Each subject will receive 40 sessions of tACS intervention during 4 consecutive weeks at a fixed day time twice per day (once in morning and afternoon, respectively) from Monday through Friday. Each session lasts 40 min."
214664563|NCT02721862|DRUG|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
214854483|NCT06172413|DEVICE|Sham tACS|Sham tACS
214854484|NCT04818749|DRUG|Saline|Saline (placebo) will be administered intravenously before block performance and after the induction of general anaesthesia.
214854485|NCT04818749|DRUG|Dexamethasone 12 mg|Dexamethasone 12 mg will be administered intravenously before block performance and saline (placebo) will be administered intravenously after the induction of general anaesthesia.
214854486|NCT04818749|DRUG|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Dexamethasone 12 mg will be administered intravenously before block performance and dexmedetomidine 1 mcg/kg will be administered intravenously after the induction of general anaesthesia.
214854487|NCT06394726|BEHAVIORAL|Exercise İntervention|Aerobic and Core Stabilization Exercise Intervention
214854488|NCT00110006|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
214854489|NCT00110006|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
214854490|NCT00110006|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
214854491|NCT00110006|DRUG|prednisone|Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
214854492|NCT00110006|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
214854493|NCT00110006|PROCEDURE|positron emission tomography|Beginning 1 hour after receiving fludeoxyglucose F 18, patients undergo whole-body positron emission tomography (PET) scanning. Patients undergo repeat \^18FDG-PET scanning between days 7-10 of course 1, between courses 3 and 4, and then at the completion of R-CHOP.
214854494|NCT00110006|RADIATION|fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (\^18FDG) IV.
214854495|NCT03165877|OTHER|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (\<55%),consisting of salad, main course and dessert, respectively.
214854496|NCT03165877|OTHER|Control|Subjects ate standard lunches and dinners (\>60%),consisting of salad, main course and dessert, respectively.
214854497|NCT03056261|PROCEDURE|Combined general and epidural|Combined general and epidural anaesthesia
214854498|NCT03056261|PROCEDURE|General anaesthesia|General anaesthesia
214854499|NCT04686656|OTHER|nasal oxygen|Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.
214854500|NCT04686656|OTHER|buccal oxygen|Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
214854501|NCT00351598|RADIATION|Definitive Radiotherapy|60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
214854502|NCT01237353|DIETARY_SUPPLEMENT|betaine hydrochloride|betaine hydrochloride 1500mg po x 1 on day 5
214854503|NCT01237353|DRUG|Rabeprazole|rabeprazole po daily x 5 days
214854504|NCT03861793|BIOLOGICAL|ALKS 4230|SC injection administered in the back of the arm or the abdomen
214854505|NCT03861793|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion over 30 minutes
214854506|NCT01922167|DIETARY_SUPPLEMENT|Leucine|
214854507|NCT01922167|DIETARY_SUPPLEMENT|Alanine|
214854508|NCT05703243|DIAGNOSTIC_TEST|Comprehensive liquid molecular panel test|Lab test
214854509|NCT05703243|OTHER|EORTC QLQ-30|Quality of life questionnaire
214854510|NCT04689763|BEHAVIORAL|Training|The programs contain sequential cognitive and exercise training, health lectures, and groups of daily living participation. We plan to assess the participants before and after the intervention programs. We expect that elders receiving training will improve on outcome measures. The results of the study will provide evidence of interventions for elderly with cognitive decline.
214854511|NCT02581163|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
214854512|NCT02581163|DRUG|Dasabuvir|Tablet
214854513|NCT02581163|DRUG|Ribavirin|Tablet
214854514|NCT02629913|DEVICE|mementor somnium|
214854515|NCT02629913|OTHER|wait list|delayed access to mementor somnium
214854516|NCT02328222|DRUG|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
214854517|NCT00358748|DRUG|Hydrocortisone|See detailed description above.
214854518|NCT01880125|DRUG|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
214854519|NCT03744871|OTHER|N95 Respirator|SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
214476417|NCT06816576|OTHER|Emotional Freedom Technique|"Emotional Freedom Technique application; It is an application that works on cognitive and energetic levels. Emotional Freedom Technique Application Instructions~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with Subjective Units of Disturbance again"
214854520|NCT04553861|DEVICE|Ambulatory blood pressure monitoring|Every 30 minutes from 7 AM to 10 PM and every 1 hour from 10 PM to 7 AM
214854521|NCT04553861|DEVICE|Galaxy Watch Active2|Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
214854522|NCT03161548|DRUG|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
214854523|NCT03161548|PROCEDURE|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
214907013|NCT00318773|DRUG|sertraline|50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
214854524|NCT03161548|RADIATION|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
214854525|NCT02880748|OTHER|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
214854526|NCT02880748|OTHER|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
214854527|NCT05033366|DIAGNOSTIC_TEST|Proov Test|Rapid response urine PdG, FSH, E1G and LH test strips, Proov
214854528|NCT03438396|DRUG|tisotumab vedotin|All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
214854529|NCT02806258|RADIATION|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
214854530|NCT02806258|DRUG|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
214664564|NCT02721862|RADIATION|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
214854531|NCT02239107|DRUG|N-Acetyl cysteine|
214854532|NCT02239107|PROCEDURE|laparoscopic ovarian drilling|
214854533|NCT02006628|DRUG|Placebo|Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
214854534|NCT02006628|DRUG|GWP42003|GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
214854535|NCT00343239|DRUG|Docetaxel|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
214854536|NCT00343239|DRUG|Cisplatin|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
214854537|NCT00343239|DRUG|Fluorouracil|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days"
214854538|NCT05810558|PROCEDURE|glycine powder air-powered debridement|The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
214854539|NCT05810558|PROCEDURE|Ultrasonic instrumentation|The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
214854540|NCT01098864|DEVICE|transcranial magnetic stimulation|low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.
214664565|NCT02680288|DRUG|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
214664566|NCT02680288|DRUG|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
214664567|NCT02680288|OTHER|Oral Placebo|Oral inert treatment
214664568|NCT03928873|DEVICE|Low energy ESWT|1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks
214854541|NCT05633108|OTHER|No Intervention|No intervention will be administered.
214854542|NCT01421342|DRUG|Switching: Bupropion-SR|Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
214854543|NCT01421342|DRUG|Augmenting: Antidepressant + Bupropion-SR|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.~And~Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
214854544|NCT01421342|DRUG|Augmenting: Antidepressant + Aripiprazole|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.~And~Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
214854545|NCT06044532|OTHER|Experimental|At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
214664569|NCT03928873|DEVICE|High energy ESWT|1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks
214664570|NCT03928873|DEVICE|Sham ESWT|sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks
214664571|NCT02354950|DRUG|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
214664572|NCT01966510|OTHER|Cord Blood Transplantation|
214664573|NCT01872351|DRUG|Nutraceuticals|
214854546|NCT03578237|DEVICE|Cryoneurolysis (active)|Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
214854547|NCT03578237|DEVICE|Sham cryoneurolysis procedure|"Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe.~Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature"
214854548|NCT05484453|DIAGNOSTIC_TEST|Complete Eye Examination by Ophthalmologist|complete eye examination (gold standard) including cover test, biomicroscopy and cycloplegic refraction with retinoscopy, performed by an ophthalmologist.
214854549|NCT00044668|DRUG|AC2993|Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
214854550|NCT04214925|OTHER|Tai Chi|Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.
214854551|NCT02831218|PROCEDURE|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
214854552|NCT02831218|PROCEDURE|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
214854553|NCT02831218|PROCEDURE|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
214664574|NCT03304808|DEVICE|Exercise Programme +device+ lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
214854554|NCT02831218|PROCEDURE|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
214854555|NCT04899193|DRUG|Pergoveris FD|Participants will be administered with 900 IU of recombinant human follicle-stimulating hormone (r-hFSH) and 450 IU of recombinant human luteinizing hormone (r-hLH) freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
214854556|NCT04899193|DRUG|Pergoveris Liquid|Participants will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Pergoveris Liquid) as subcutaneous injection using disposable pen-injector on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
214854557|NCT04899193|DRUG|Gonal-f|Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
214854558|NCT04899193|DRUG|Luveris|Participants will be administered with 450 IU of lutropin alfa (Luveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
214854559|NCT02488330|DRUG|Onartuzumab|Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
214854560|NCT02488330|DRUG|Bevacizumab|All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
214854561|NCT02488330|DRUG|Erlotinib|All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
214854562|NCT03738020|DEVICE|HA IDF (YVOIRE classic)|Treatment with HA IDF
214854563|NCT03738020|DEVICE|Restylane|Treatment with Restylane
214854564|NCT04712721|DRUG|68Ga-FF58|Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
214854565|NCT04671030|DRUG|Neostigmine and Glycopyrrolate|Intravenous followed by transdermal administration of the two drug combination.
214854566|NCT04671030|DEVICE|Iontophoresis|Application of direct current to skin using an FDA-approved device
214854567|NCT01678001|DRUG|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
214854568|NCT01242930|DRUG|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
214854569|NCT01242930|DRUG|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
214854570|NCT01242930|DRUG|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
214854571|NCT01206816|DRUG|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
214854572|NCT03525743|DEVICE|NICOM (Non invasive cardiac output monitor)|Non invasive hemodynamic device utilizing bioreactance
214854573|NCT04963595|DRUG|Pyrotinib|400 mg once daily
214854574|NCT04963595|DRUG|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsules on day 1 to be taken at the hospital, and on day 8 at home.
214854575|NCT04963595|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
214854576|NCT02310243|DRUG|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
214854577|NCT03050203|OTHER|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
214854578|NCT03050203|OTHER|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
214854579|NCT01836406|DRUG|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
214854580|NCT00014625|DRUG|indisulam|
214854581|NCT03217396|PROCEDURE|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
214854582|NCT05515393|DRUG|XY03-EA|The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.
214854583|NCT05515393|DRUG|XY03-EA Placebo|XY03-EA Placebo
214854584|NCT00485628|DRUG|Atomoxetine Hydrochloride|
214854585|NCT02493777|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
214854586|NCT02493777|DRUG|Placebo|
214854587|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.
214854588|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced computed tomography|The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
214854589|NCT00267943|DRUG|telmisartan 80 mg + hydrochlorothiazide 25 mg|
214854590|NCT02264288|BIOLOGICAL|3 x 10^6 cells|3 x 10\^6 cells administered on Study Days 1 and 8
214854591|NCT02264288|BIOLOGICAL|10 x 10^6 cells|10 x 10\^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
214854592|NCT02264288|BIOLOGICAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
214854593|NCT02264288|OTHER|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
214854594|NCT03130218|OTHER|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
214854595|NCT01642914|DRUG|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
214854596|NCT01642914|DRUG|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
214854597|NCT01642914|DRUG|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
214854598|NCT01832935|DRUG|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
214854599|NCT01832935|DRUG|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
214854600|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 13 mCi radiation dose|13 mCi 18F-FDG dose
214854601|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 5 mCi radiation dose|5 mCi 18F-FDG dose
214854602|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 2.5 mCi radiation dose|2.5 mCi 18F-FDG dose
214854603|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with 6.5 mCi radiation dose|6.5 mCi 18F-FDG dose
214854604|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with not yet determined radiation dose|We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
214854605|NCT01705236|DRUG|Fingolimod|All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
214854606|NCT05348980|DRUG|Phenylephrine Hydrochloride 4 mg|Intramuscular Phenylephrine HCL 04 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
214854607|NCT05348980|DRUG|Phenylephrine Hydrochloride 8 mg|Intramuscular Phenylephrine HCL 08 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
214854608|NCT01344174|DRUG|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
214854609|NCT04363840|DRUG|Aspirin 81 mg|Aspirin 81 mg to be taken orally once daily for 14 days.
214854610|NCT04363840|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 50,000 IU to be taken orally once weekly for 2 weeks
214854611|NCT06319937|DIAGNOSTIC_TEST|Ultrasound|Ultrasound
214854612|NCT02442674|DRUG|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days"
214854613|NCT02442674|OTHER|Placebo|Placebo tablet matching active drug
214854614|NCT00171301|DRUG|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
214854615|NCT04319159|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|Combination Product: Photodynamic therapy (PDT) using BF-RhodoLED® (ALA-PDT, Ameluz®-PDT).
214854616|NCT02987023|PROCEDURE|uterus transplantation|Uterus transplantation from live donor
214664575|NCT03304808|BEHAVIORAL|Exercise Programme + lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
214664576|NCT00594399|BEHAVIORAL|Physical Activity Counseling|Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
214664577|NCT04107220|DRUG|Sacubitril/Valsartan|Effect of Sacubitril/Valsartan on BNP and NT-proBNP
214664578|NCT01018407|BEHAVIORAL|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen \& Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
214664579|NCT01018407|BEHAVIORAL|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
214664580|NCT04265612|PROCEDURE|"Pico® negative pressure dressing"|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy.The dressing will remain on for 7 days without waking up, unless it is saturated, in which case only the dressing will be changed"
214854617|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.1 mL, Intradermal. 2 vaccinations 12 months apart
214854618|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.5 mL, Intramuscular. 2 vaccinations, 12 months apart
214854619|NCT02100319|DRUG|Azilsartan|Azilsartan tablets
214854620|NCT02370914|DEVICE|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
214854621|NCT02370914|BEHAVIORAL|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
214854622|NCT01913379|DRUG|MDV3100|Oral
214854623|NCT01913379|DRUG|Gemfibrozil|Oral
214854624|NCT01913379|DRUG|Itraconazole|Oral
214854625|NCT03875014|DEVICE|surgery with implant for hip fracture|hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
214854626|NCT02485002|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
214854627|NCT02485002|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
214854628|NCT02664857|DRUG|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
214854629|NCT02664857|DRUG|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
214854630|NCT05742698|DRUG|Nabilone|Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
214854631|NCT05742698|DRUG|Placebo|The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
214854632|NCT00675636|OTHER|study of socioeconomic and demographic variables|database, no intervention
214854633|NCT00675636|PROCEDURE|evaluation of cancer risk factors|database, no intervention
214854634|NCT00675636|PROCEDURE|study of high risk factors|database, no intervention
214854635|NCT02721836|BEHAVIORAL|Yoga|Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation
214854636|NCT02721836|BEHAVIORAL|Nutrition Counselling|Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
214854637|NCT06051084|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
214854638|NCT06051084|BEHAVIORAL|App-Delivered Coloring|An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
214854639|NCT03898830|DEVICE|eon™ FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
214854640|NCT05907330|DRUG|CU104|CU104 will administer the study drug once a day after a meal
214854641|NCT05907330|DRUG|Placebo|Placebo will administer the study drug once a day after a meal
214854642|NCT03113448|DRUG|0.075% Capsaicin Lotion|To apply 3-4 times per day, every day until 8 weeks then stop
214854643|NCT03113448|DRUG|placebo|To apply 3-4 times per day, every day until 8 weeks then stop
214854644|NCT01009671|DRUG|ART 44|
214854645|NCT01009671|DRUG|ART 50|
214854646|NCT02349971|DEVICE|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
214854647|NCT04109586|BEHAVIORAL|Personalized nutritional therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
214854648|NCT05599022|DEVICE|Magnetic Stimulation|Transcutaneous Magnetic Stimulation
214854649|NCT00754442|DRUG|Teriparatide|"Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls"
214854650|NCT05230732|DEVICE|neuromodulation device|Active LLTS will be performed by use of a neuromodulation device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks
214854651|NCT05230732|DEVICE|SHAM|Sham LLTS will be performed by use of a neuromodulation device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks
214854652|NCT05169073|PROCEDURE|Virtual Reality training|In the Virtual Reality (VR) study arm, a VR software (Specto VRTM, version 4.0, Diffuse Ltd, Heimberg, Switzerland) will be used to display volumetric MRCP data using a tethered head-mounted display (HMD) prior to the operation. Specto uses volume rendering at 180 frames/sec to visualize the medical data in an immersive fashion in the VR environment and allows for viewing of the 3D reconstructed 3D imaging with 360° free movement. Each participant will perform a procedure with VR training and one with conventional preparation (MRCP).
214854653|NCT05169073|PROCEDURE|Conventional training|In the conventional study arm, the participants will view the preoperative MRCP.
214854654|NCT05279313|DRUG|Centanafadine Hydrochloride|Capsule
214854655|NCT05197777|DEVICE|tDCS associated to functional activities|The intervention will start by a pretest on the first day (day 0, baseline record). Tdcs will be applied associated functional task from an experimental workstation, consisting in a hairdressing dummy head fixed to a telescopic table, adjustable to each individual's height. Elbow angles will be adjusted in a static position with a manual goniometer (60 degrees). The task will be performed in a standing position inside a 1m2 perimeter during 30 minutes, undergoing repetitive movements. Performing a repetitive manual gesture. The cycle will be executed at a cadence of 30s/cycle with a metronome beat. The TCT - tDCS Stimulator Kit Research version, with 35 cm2 on M1 of the contralateral hemisphere for the rigth dominant hand. During the first 30 s of active tDCS, an initial period of ''ramping up'' is administered, in which the stimulator reaches the maximum programmed current (2 mA) to mimic cutaneous perceptions. A 2 mA intensity will be maintained during activity.
214854656|NCT05197777|OTHER|Conservative physiotherapy|Education and exercices for pain relief by usual tradicional physiotherapy in Hospital: walking, mobility, and transfert.
214854657|NCT00296491|DRUG|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
214854658|NCT00296491|DRUG|montelukast (MON)|montelukast capsule
214854659|NCT00296491|DRUG|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
214854660|NCT00296491|DRUG|placebo nasal|vehicle placebo nasal spray
214854661|NCT00296491|DRUG|ADVAIR DISKUS|ADVAIR DISKUS
214854662|NCT00296491|DRUG|placebo capsule|placebo capsule
214854663|NCT00296491|DRUG|placebo DISKUS|placebo DISKUS
214854664|NCT01300052|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
214854665|NCT01300052|DRUG|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
214854666|NCT04695756|OTHER|COVID-19 pandemic|The exposure of this observational study is the COVID-19 pandemic
214854667|NCT01183325|DEVICE|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
214854668|NCT01231373|DRUG|polidocanol injectable foam, 0.125%|active placebo for blinding
214854669|NCT01231373|DRUG|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
214854670|NCT01231373|DRUG|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
214854671|NCT01231373|DRUG|Vehicle|injection of vehicle comparator
214854672|NCT05642169|BEHAVIORAL|HIIT|"The training sessions will have a frequency of 3 times per week (Monday, Wednesday and Friday) and the duration will be between 39 to 54 minutes, depending on the training week.~The training program will be developed with the own body weight of each participant. Therefore, a progression according to the needs of this population will be fulfilled. The session model could be multi-joint exercises with self-loads, where the difficulty of the exercises will be worked progressively. Throughout the main part of each workout, 30 seconds of work will be performed at the corresponding intensity and 30 seconds of rest. Halfway through the total repetitions, there will be 2 minutes of recovery."
214854673|NCT05642169|BEHAVIORAL|HIIT+PA|In relation to the 2 groups that will perform HIIT, the HIIT+AF will have to complete 10.000 steps per day. In this way, they will be focusing on increasing their daily physical activity. In addition, this group will perform the same HIIT training programme as the other experimental group.
214854674|NCT05642169|BEHAVIORAL|CON|This group will not suffer any changes in their lifestyle
214854675|NCT03446599|DRUG|Hydroxocobalamin|One intravenous dose of 5mg hydroxocobalamin, which is the current FDA-approved adult dose for carbon monoxide poisoning, reconstituted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
214854676|NCT03446599|DRUG|Methylene Blue|One intravenous dose of methylene blue 2mg/kg, which has been the accepted dose for vasoplegia, diluted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
214854677|NCT03446599|DRUG|Normal saline|200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
214854678|NCT03451006|DRUG|Metformin|Oral metformin (up to 2gm) will be given in divided doses
214854679|NCT03451006|DRUG|Placebo|Oral Placebo will be given in divided doses
214854680|NCT03660215|OTHER|mediation|support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
214854681|NCT02650141|DRUG|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
214854682|NCT02650141|DRUG|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
214854683|NCT00437190|DEVICE|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
214854684|NCT00437190|DEVICE|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
214854685|NCT02547766|DRUG|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
214854686|NCT01929395|DEVICE|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
214854687|NCT03104348|DIAGNOSTIC_TEST|COPD screening|Self-questionnaire with 5 questions Fagerström's test Spirometry
214854688|NCT03693534|DIAGNOSTIC_TEST|Clinical Pregnancy Rate|The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
214854689|NCT05802108|DRUG|Evolocumab combined with statins|The experimental group was treated with evolocumab combined with statin for lipid-lowering
214854690|NCT05802108|DRUG|Statin|the control group was treated with statin only for lipid-lowering
214854691|NCT02752841|DIETARY_SUPPLEMENT|Nutritional vitamin D repletion and maintenance|Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D
214476418|NCT04555278|DEVICE|Active rTMS|"A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). The intensity of rTMS will be set at 95 % of the first dorsal interosseous (FDI) resting motor threshold (RMT).~Active rTMS will consist of 40 trains of 5 seconds each at 10 Hz (25-s intertrain interval) applied over M1 (on FDI cortical representation), for a total of 2000 stimulations lasting 20 minutes."
214854692|NCT06311669|PROCEDURE|iliac vein stenting|patients will undergo left common iliac vein stenting according to diameter measurements using balloon-mounted stents.
214854693|NCT06311669|PROCEDURE|pelvic vein embolization|embolization of pelvic veins by injection of left ovarian vein or parauterine veins pelvic escape points using sandwich technique of detachable or pushable coils and polidocanol 3 %.
214854694|NCT04372290|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
214854695|NCT04372290|OTHER|Product B|Nicorette® White Ice Mint 2 mg nicotine gum
214476419|NCT04555278|DEVICE|Sham rTMS|A sham coil will be use (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS (30 min).
214854696|NCT04372290|OTHER|Product C|CSD1904-01, a nicotine pouch, 2 mg nicotine
214854697|NCT04372290|OTHER|Product D|CSD1904-02, a nicotine pouch, 4 mg nicotine
214854698|NCT04372290|OTHER|Product E|CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
214854699|NCT03452618|DIAGNOSTIC_TEST|diagnosis variables|"The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~* Age of the patient~* Sex~* Presence of bulbar involvement or not~* Time from onset of first symptoms to diagnosis of ALS~* Score ALSFRS-R~* Presence of another underlying respiratory pathology (COPD, asthma ...)~* FVC measurement (Forced vital capacity)~* PaCO2 measurement~* Measure SNIP (Sniff nasal inspiratory pressure)~* Measure of Pimax (Pressure inspiratory maximal)~* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)"
214907014|NCT02245516|DRUG|KPI-121 0.25% Ophthalmic Suspension|KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
214907015|NCT02245516|DRUG|KPI-121 1.0% Ophthalmic Suspension|KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
214854700|NCT05385848|PROCEDURE|Autologous Platelet-rich Plasma (PRP) Injection|PRP contains a high concentration of platelets which contains multiple vaso-active peptides and cytokines such as Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) and Sphingosine-1-phosphate. Many of these cytokines have been implicated in important roles in ovarian function, follicular genesis and oocyte maturation. Intraovarian autologous PRP infusion was recently introduced in the context of addressing ovarian insufficiency, with several studies showing an increase in ovarian function and promising ART outcomes. Possible mechanisms include anti-inflammatory and mitogenic potentials in this growth factor rich fraction contributing towards tissues regeneration. Through being involved in the cell regeneration cycle, autologous PRP potentially gives women with premature ovarian insufficiency (POI) or diminished ovarian insufficiency (DOR) hope in achieving a healthy genetically related offspring.
214854701|NCT04583696|DIETARY_SUPPLEMENT|The Investigation of effect on Blood Lipid parameters with walnut addition of Diet|Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
214854702|NCT00850226|BEHAVIORAL|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
214854703|NCT00850226|BEHAVIORAL|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
214854704|NCT02521818|OTHER|Modified Atkins Diet|
214854705|NCT02521818|OTHER|NIA Diet for Seniors|
214854706|NCT03604341|DRUG|Dronabinol 5mg Cap|Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain
214854707|NCT03604341|OTHER|Placebo|Subjects randomized to placebo and ibuprofen 800mg for pain
214854708|NCT04963387|OTHER|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
214854709|NCT04963387|OTHER|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
214854710|NCT03786419|DRUG|Atezolizumab|Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
214854711|NCT05824117|OTHER|Individual Placement and Support (IPS)|"IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults.~Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning."
214854712|NCT04375839|DEVICE|Zirconia implant|Following standard surgical protocol, Zirconia implant will be placed in horizontally deficient ridge.
214854713|NCT04375839|DEVICE|Titanium implant|Following standard surgical protocol, Titanium implant will be placed in horizontally deficient ridge.
214854714|NCT03563846|DRUG|RP-G28|RP-G28 is a purified galacto-oligosaccharide (GOS) product
214854715|NCT00343434|BEHAVIORAL|behavioral dietary intervention|
214854716|NCT00343434|BEHAVIORAL|exercise intervention|
214854717|NCT00343434|DIETARY_SUPPLEMENT|soy isoflavones|
214854718|NCT00343434|DIETARY_SUPPLEMENT|soy protein isolate|
214854719|NCT00343434|OTHER|counseling intervention|
214854720|NCT00343434|OTHER|educational intervention|
214854721|NCT00343434|PROCEDURE|psychosocial assessment and care|
214854722|NCT00343434|PROCEDURE|quality-of-life assessment|
214290379|NCT05856201|PROCEDURE|Laparoscopic cervicosacropexy|The first step consists of a supracervical hysterectomy with morcellation. Anterior and posterior dissection of the vesicovaginal and rectovaginal space. Placing a flexible blade or a Breisky blade in the vagina which is manipulated by the assistant in order to improve exposure of the tissue planes. The retroperitoneum will then be opened from sacral promontory to cervix with the incision just medial to the uterosacral ligament. A low-weight preshaped Y-shaped polypropylene mesh will be secured to the anterior and posterior vagina with four to six separated absorbable 2.0 polyglactin sutures and two nonabsorbable 2.0 prolene sutures can be placed at the level of the remaining cervix. The mesh will be attached to the sacral promontory using two or three nonabsorbable monofilament 2.0 prolene suture. The retroperitoneal space will be closed with continuous 2.0 polyglactin suture or barbed 2.0 absorbable suture material.
214854723|NCT05916521|DRUG|0.454% stannous fluoride|Brush two times daily
214854724|NCT05916521|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
214854725|NCT05916521|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
214854726|NCT01653613|GENETIC|DNA analysis|
214854727|NCT01653613|GENETIC|fluorescence in situ hybridization|
214854728|NCT01653613|GENETIC|gene expression analysis|
214854729|NCT01653613|GENETIC|microarray analysis|
214854730|NCT01653613|GENETIC|mutation analysis|
214854731|NCT01653613|GENETIC|polymorphism analysis|
214854732|NCT01653613|GENETIC|reverse transcriptase-polymerase chain reaction|
214854733|NCT01653613|OTHER|laboratory biomarker analysis|
214854734|NCT02676713|DRUG|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
214854735|NCT02676713|DRUG|post-ovulation Decoction|"BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.~All are made into granules."
214476420|NCT04555278|OTHER|Motor Control Exercises|The rehabilitation program will consist of a 30-minute session of motor control exercises following the rTMS (Active or Sham) intervention. This approach aims to improve spine health through the optimization of spine loading. The first session will be preceded by an individualized evaluation of the participant's abilities and deficiencies to tailor the training program to each participant.
214664581|NCT04265612|PROCEDURE|"Aquacel Surgical® hydrogel dressing"|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
214664582|NCT06028815|BEHAVIORAL|Group music therapy|Music therapy intervention using active and receptive techniques, focusing on the technique of songwriting.
214664583|NCT03203629|DEVICE|Wearable Cardioverter Defibrillator (WCD)|Observe and compare the heart sound measurements recorded by the WCD
214664584|NCT00016315|DRUG|carboplatin|
214664585|NCT00016315|DRUG|gemcitabine hydrochloride|
214664586|NCT00016315|DRUG|paclitaxel|
214664587|NCT00016315|RADIATION|radiation therapy|
214664588|NCT01595217|DEVICE|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
214664589|NCT00167622|PROCEDURE|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
214664590|NCT00167622|PROCEDURE|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
214664591|NCT00579904|DIETARY_SUPPLEMENT|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
214664592|NCT00579904|DIETARY_SUPPLEMENT|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
214664593|NCT00749086|DEVICE|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
214664594|NCT00749086|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
214664595|NCT05712668|BEHAVIORAL|Preoperative counseling|Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
214664596|NCT05712668|BEHAVIORAL|Asynchronous telemedicine|An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
214664597|NCT03162718|BEHAVIORAL|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
214664598|NCT03953118|DRUG|Azithromycin Oral Product|Oral azithromycin dosed at 1 gram per week for 3 weeks
214664599|NCT03953118|DRUG|Placebo Oral|Oral placebo tablet
214664600|NCT00929630|PROCEDURE|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
214664601|NCT00929630|PROCEDURE|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
214664602|NCT00929630|PROCEDURE|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
214664603|NCT00929630|PROCEDURE|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
214664604|NCT04438135|OTHER|Repeated open application test|parallel application of two different types of lotion with and without aluminium.
214664605|NCT05597748|DEVICE|Modified Herbst Approach|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
214664606|NCT05597748|DEVICE|Conventional Herbst Approach|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
214854736|NCT02676713|DRUG|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
214854737|NCT02676713|DRUG|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
214854738|NCT02312713|BEHAVIORAL|Internet Based Exercise Training|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
214854739|NCT02312713|BEHAVIORAL|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
214854740|NCT05880121|DIAGNOSTIC_TEST|MRI|brain MRI
214854741|NCT03606421|RADIATION|SRS and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
214854742|NCT03606421|RADIATION|WBRT and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
214854743|NCT03153618|OTHER|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
214854744|NCT03627234|BEHAVIORAL|Same Day Discharge|Patients will be randomized to same day discharge
214854745|NCT03627234|BEHAVIORAL|Overnight Stay|Patients will be randomized to stay overnight
214854746|NCT05628779|DEVICE|TriClip TTVr system (Abbott Vascular)|Edge-to-edge leaflet approximation for the tricuspid valve
214854747|NCT05628779|DEVICE|PASCAL TTVr system (Edwards Lifesciences)|Edge-to-edge leaflet approximation for the tricuspid valve
214854748|NCT05510024|PROCEDURE|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous immunotherapy|The regulation and monitoring of the entire soft-coagulation process are conducted via the radiofrequency generator under endoscopic guidance. Lateral out-fracture of the inferior turbinate is performed if necessary. One month after surgery, allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
214854749|NCT05510024|PROCEDURE|SCIT|Allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
214854750|NCT04754334|DRUG|ORMD-0801|Oral Insulin
214854751|NCT04754334|OTHER|Placebo|Fish Oil
214854752|NCT03936049|DRUG|Liraglutide|Liraglutide dispensing claim is used as the exposure group
214854753|NCT03936049|DRUG|DPP-4 inhibitor|DPP-4 inhibitor dispensing claim is used as the reference group
214854754|NCT04579315|OTHER|Intervention group; NNRD group|The intervention is a whole food approach, meaning that the participants in the intervention group receives all daily food elements that they should consume
214854755|NCT00287300|DRUG|Sulfadoxine-Pyrimethamine|
214854756|NCT00287300|DRUG|Azithromycin|
214854757|NCT00287300|DRUG|Artesunate|
214854758|NCT01264549|DEVICE|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
214854759|NCT00897949|DRUG|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
214854760|NCT00897949|DRUG|Comparator: placebo|Placebo to rizatriptan
214854761|NCT02430805|OTHER|dna extraction and genotyping|blood and urine sample
214854762|NCT01553747|DRUG|Eluxadoline|Oral tablets twice daily
214854763|NCT01553747|DRUG|Placebo|Oral tablets twice daily
214854764|NCT01712919|RADIATION|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
214854765|NCT01712919|DRUG|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
214854766|NCT01712919|BIOLOGICAL|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
214854767|NCT00114621|DRUG|Anthrax Vaccine|
214854768|NCT00114621|PROCEDURE|Blood Chemistry|
214854769|NCT00114621|PROCEDURE|Hematology|
214854770|NCT00114621|PROCEDURE|Urinalysis|
214854771|NCT06242561|BEHAVIORAL|Data collection from sepsis management|observational study
214854772|NCT02011750|DRUG|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
214854773|NCT02011750|DRUG|Placebo|Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
214854774|NCT05166681|PROCEDURE|surgical wound suturing|single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
214854775|NCT03607552|DEVICE|Non-contrast DWI|Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.
214854776|NCT03607552|DEVICE|Non-contrast MRI|Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
214854777|NCT02371421|DRUG|Allopurinol|
214854778|NCT01089621|DRUG|Duloxetine|30 mg to 120 mg administered orally, daily for 12 weeks
214854779|NCT06234774|PROCEDURE|Robot-assisted laparoscopic surgery|
214476421|NCT06820749|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 12-week treatment period in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
214476422|NCT06820749|DRUG|Placebo|the placebo comparator of study
214664607|NCT01119040|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
214664608|NCT05653908|OTHER|StudentMood|StudentMood is an app that uses ecological momentary assessment method to asses mood and other mental health corelates. Participants will have to complete the application (the mood wheel, heart rate and other behavioral data as well as standardized scales) daily throughout the entire semester
214664609|NCT05596266|BIOLOGICAL|CD5 CAR-T|CD5 CAR-T will be administered by I.V. infusion.
214664610|NCT00623571|OTHER|Treatment of elderly patients in a GMW|
214664611|NCT00623571|OTHER|Treatment of elderly patients in GHHS|
214664612|NCT00889096|DRUG|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
214664613|NCT00889096|DRUG|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
214664614|NCT01023789|DEVICE|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
214664615|NCT00206167|DRUG|Budesonide/formoterol pMDI|
214664616|NCT00206167|DRUG|Formoterol Turbuhaler|
214664617|NCT00095563|DRUG|lapatinib ditosylate|Given orally
214664618|NCT00095563|OTHER|laboratory biomarker analysis|Correlative studies
214664619|NCT01349309|BEHAVIORAL|Swallowing Exercise Group|"Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
214664620|NCT04410874|BIOLOGICAL|Imvamune|Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10\^7, 1x10\^8, or 4x10\^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
214664621|NCT00898092|GENETIC|microarray analysis|
214664622|NCT00898092|GENETIC|molecular genetic technique|
214664623|NCT00898092|GENETIC|mutation analysis|
214664624|NCT00898092|GENETIC|polymerase chain reaction|
214664625|NCT00898092|GENETIC|reverse transcriptase-polymerase chain reaction|
214664626|NCT00898092|OTHER|diagnostic laboratory biomarker analysis|
214664627|NCT00166348|BEHAVIORAL|Cognitive Group Therapy|
214664628|NCT05303740|DRUG|Anlotinib|This is an observational study.
214854780|NCT06234774|PROCEDURE|Conventional (non-robotic) laparoscopic surgery|
214476423|NCT02266719|DEVICE|Fenestrated CMD|"The CMD that will be used in this IDE is structurally the same as the commercially available Zenith Fenestrated AAA Endovascular Graft.~In general, the Zenith® Fenestrated AAA Endovascular Graft is a modular system constructed of full- thickness woven polyster fabric sewn to self-expanding stainless steel z-stents with braided polyster and monofilament polypropylene sutures. In this study, fenestrated grafts with usually up to 4 fenestrations may be used.~Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms."
214476424|NCT02266719|DEVICE|Type I - III TAAA|"Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms. Devices will be implanted in patients with type I-III thoracic abdominal aneurysms.~The branches in this study will be constructed as internal/external cuffs, axially oriented and caudally or cranially directed, as necessary . Branch position will be determined by the anatomic location of the target vessels using a consistent craniocaudal and circumferential cuff position."
214476425|NCT02266719|DEVICE|Arch cohort|Arch branched devices may be designed using one of two configurations: (1) Zone 0 device with two inner antegrade branches for the innominate artery and the left common carotid artery with or without a retrograde left subclavian artery branch and (2) Zone 1-2 device with a single retrograde subclavian artery branch with double or triple wide scallop for the left common carotid artery. These devices are designed for a of proximal landing/fixation zone of at least 20 mm of healthy aortic segment or a previous graft.
214664629|NCT02034123|DRUG|GSK2879552|Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
214664630|NCT05230147|PROCEDURE|Spinal cord stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.
214664631|NCT05230147|PROCEDURE|Sham stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
214664632|NCT04193683|OTHER|Myofascial Release Technique|Myofascial release technique will bi applied bottom of the feet, back of the legs and hamstrings in both extremities. The practitioner will decide how long she should stay in a region according to the feeling of releasing in the tissue. The technique will be applied to a region at least 3 times.
214854781|NCT01404052|DEVICE|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
214854782|NCT04703543|DEVICE|Pilot evaluation study on use PSMA and Cu-PET/CT|This study aims at assessing the detection rate of both PSMA and Cu-PET/CT on tissue relapse, study whether this method is equivalent to mpMR
214854783|NCT03226171|DRUG|Dose-adjusted SK-1403|SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
214854784|NCT01134627|DRUG|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
214854785|NCT01134627|DRUG|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
214854786|NCT00351351|DEVICE|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
214854787|NCT00351351|DEVICE|single probe ultrasonic|FDA-approved - single probe ultrasonic
214854788|NCT05524428|BEHAVIORAL|Implementation Science Strategy|The investigators will be conducting focus groups and identifying barriers and facilitators, and the investigators will be matching identified barriers and facilitators to implementation strategies at the patient, provider, and system level which the investigators will be testing using rapid-cycle methods.
214854789|NCT00754494|DRUG|erlotinib hydrochloride|Given PO
214854790|NCT00754494|OTHER|placebo|Given PO
214854791|NCT00754494|OTHER|laboratory biomarker analysis|Correlative studies
214854792|NCT00314782|DRUG|ZD4054 (Zibotentan)|oral tablet
214854793|NCT00314782|DRUG|Docetaxel|intravenous infusion
214854794|NCT00314782|DRUG|Placebo|
214854795|NCT05815368|DEVICE|REMO|REMO training will consist of sEMG-biofeedback exercises provided by REMO device. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
214854796|NCT05815368|OTHER|Task-Oriented Training|Task-Oriented training will consist of task-specific functional exercises. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
214854797|NCT04883424|BEHAVIORAL|Diabetes Education Program Based on Health Belief Model|After the application, increase in family support and decrease in blood sugar levels are expected in diabetic patients. Family members' diabetic attitudes are expected to increase.
214854798|NCT03304340|DEVICE|functional electrical stimulation (FES)|Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
214854799|NCT03304340|DEVICE|transcutaneous nerve stimulation (TENS)|Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device \& Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
214854800|NCT03304340|OTHER|standard rehabilitation (SR)|The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
214854801|NCT05665517|DEVICE|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q\&A) corpora were formed."
214854802|NCT02568709|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
214854803|NCT02568709|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
214854804|NCT05818982|DRUG|Afatinib|Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.
214854805|NCT05818982|DRUG|Irinotecan|Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
214854806|NCT06616974|DRUG|TX000045- Dose A|The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.
214854807|NCT06616974|DRUG|TX000045- Dose B|The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.
214854808|NCT06616974|DRUG|Placebo|The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
214854809|NCT02592772|OTHER|Reduced Nicotine Non-Menthol (RNC)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
214854810|NCT02592772|OTHER|Reduced Nicotine Menthol (RNC-Men)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
214854811|NCT02592772|OTHER|Conventional Nicotine Non-Menthol (CN)|Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
214854812|NCT03662763|DRUG|Extended-release Guanfacine Hydrochloride (SPD503)|dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
214854813|NCT03662763|DRUG|Placebo oral capsule|
214854814|NCT00062101|DRUG|erlotinib hydrochloride|Given orally (PO)
214854815|NCT00062101|DRUG|celecoxib|Given PO
214854816|NCT00062101|OTHER|laboratory biomarker analysis|Correlative studies
214476426|NCT06820281|DRUG|Tirzepatide 2.5mg weekly|"Tirzepatide 2.5 mg/0.5 mL solution for injection vial or pre-filled pen. Each vial/ pre-filled pen contains tirzepatide 2.5 mg in 0.5 mL solution (2.5mg in 0.6mL if Kwikpen)~Tirzepatide will be administered by drawing up into a syringe, then administering by subcutaneous injection weekly by study nurses."
214854817|NCT02466802|DRUG|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
214854818|NCT02466802|DRUG|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
214854819|NCT00139438|BEHAVIORAL|Disease Management Assessment|
214854820|NCT02990806|DRUG|NI-071|IV infusion.
214854821|NCT02990806|DRUG|Remicade|IV infusion.
214854822|NCT03389087|DRUG|Apatinib and Etoposide Capsule|Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
214854823|NCT02593487|DRUG|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
214854824|NCT02593487|DRUG|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
214664633|NCT04193683|OTHER|Sham-Ultrasound|Sham-ultrasound will be applied to back of legs and thighs in both extremities without pressure and all parameters of the ultrasound device except the timer will be closed.
214664634|NCT04275427|DEVICE|LA-400 laser acupuncture|low level laser
214664635|NCT01411787|BEHAVIORAL|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
214664636|NCT05668221|BEHAVIORAL|Prehabilitation|Prehabilitation includes exercise prescription, cognitive function assessment and training, nutritional optimisation at least 4 weeks prior to surgery
214664637|NCT04558502|DRUG|Minocycline hydrochloride capsule|Antibiotic for H. pylori eradication
214664638|NCT04558502|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
214664639|NCT04558502|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
214664640|NCT04558502|DRUG|colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
214854825|NCT04387071|BIOLOGICAL|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Given IT
214664641|NCT04558502|DRUG|esomeprazole|Proton pump inhibitor
214664642|NCT00717730|DIETARY_SUPPLEMENT|Folic Acid|150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
214664643|NCT00717730|DIETARY_SUPPLEMENT|Vitamin B12|1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
214664644|NCT00717730|DIETARY_SUPPLEMENT|Placebo|Placebo with no active ingredients
214664645|NCT00717730|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
214664646|NCT05413330|DRUG|Triamcinolone Acetonide|Intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of phacoemulsification surgery will be injected at 3.5 mm inferolateral and posterior to the limbus.
214664647|NCT02698189|DRUG|Birabresib Dose 20 mg|Administered as an oral capsule twice a day for 21 consecutive days per cycle.
214854826|NCT04387071|DRUG|VLP-encapsulated TLR9 Agonist CMP-001|Given SC and IT
214854827|NCT05637476|OTHER|Functional strength training of hip abductors|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Pelvic drop.~2. Single leg -bridge.~3. Side-lying hip abduction with hip internal rotation.~4. Lateral step-up.~5. Standing hip abduction on stance or swing leg with extra resistance ."
214854828|NCT05637476|OTHER|A selected physical therapy exercise program|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Strength dorsiflexors of the ankle-using rubber band.~2. Eccentric calf exercise (calf raise) .~3. Balance and proprioceptive exercise using wobble boards.~4. Stretch planter flexors (three sets of thirty repetitions, thirty seconds rest in between, three times per week)"
214854829|NCT05981495|DEVICE|NanoDetect-TB|This study of the NanoDetect-TB investigational device will test plasma and serum samples from TB suspects. There is no intervention for the subjects and there will be a single visit blood draw.
214664648|NCT01175369|BEHAVIORAL|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
214664649|NCT02240706|PROCEDURE|Best Supportive Care|At Discretion of the Investigator (Transfusions)
214664650|NCT02240706|DRUG|BI 836858|Monotherapy with BI 836858
214664651|NCT03301857|DRUG|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
214664652|NCT03270748|DRUG|GvHD prophylaxis|Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
214664653|NCT00553995|DRUG|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
214664654|NCT00553995|DRUG|Placebo|
214664655|NCT02655484|DEVICE|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
214664656|NCT00298714|DRUG|Losartan|
214664657|NCT00206141|DRUG|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
214664658|NCT01726361|BEHAVIORAL|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
214664659|NCT01726361|BEHAVIORAL|Treatment as usual|Other kinds of out of home placement
214664660|NCT03140319|BIOLOGICAL|Fibroblast|Transplantation of 20 million cell by three injection
214664661|NCT03140319|BIOLOGICAL|Placebo|Injection of Placebo
214664662|NCT03295305|BEHAVIORAL|Action-Based Cognitive Remediation|
214854830|NCT02067767|DRUG|Abacavir/Lamivudine/Dolutegravir|"At Day 1 (D1):~* group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~* group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1."
214854831|NCT03288402|OTHER|ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast|effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
214854832|NCT04593212|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Evaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA)
214854833|NCT06768580|DRUG|Melatonin|Patients will receive one capsule of melatonin (5mg) orally the night before surgery at 9 pm, the night of the operation, and two nights after the surgical operation at 9 pm, also the patients will receive 10 ml bolus of saline intravenous (IV) over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) until the end of surgery.
214854834|NCT06768580|DRUG|Lidocaine|Patients will receive a bolus (10 ml) of intravenous lidocaine (1mg/kg) diluted with saline over 10 min before induction of anesthesia. Continuous infusion of 1.5 mg/kg/hr of intravenous lidocaine diluted with saline (20 ml/hr) will be administered until the end of the surgery, also will receive placebo capsule the night before surgery at 9 pm, the night of operation and two nights after the surgical operation at 9 pm.
214854835|NCT06768580|DRUG|Placebo|Patients will receive a bolus (10 ml) of saline over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) and placebo capsule the night before surgery at 9 pm, the night of the operation and two nights after the surgical operation at 9 pm.
214854836|NCT02948725|OTHER|Cross-education + standard rehabilitation|
214854837|NCT05827484|BIOLOGICAL|Autologous platelets rich plasma|30 ml of venous blood were drawn from the participant by means of venipuncture. The collected blood was mixed with 3 ml anti-coagulant acid citrate dextrose in the centrifugation sterile tube. The blood sample was then centrifuged using the centrifugation machine. 3 ml of PRP from the buffy coat layer were loaded in a 5 ml syringe. After local sterilization and draping of the site of injection and under US guidance the hematoma was aspirated from the injury site and the freshly prepared PRP was injected.
214854838|NCT05827484|COMBINATION_PRODUCT|Autologous platelets rich plasma + oral LOSARTAN administration|in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till day 30 after injury.
214854839|NCT05039437|DIETARY_SUPPLEMENT|MGF-4|Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
214854840|NCT05039437|DIETARY_SUPPLEMENT|MGF-7|Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
214854841|NCT00670033|DRUG|Travoprost ophthalmic solution (new formulation)|
214854842|NCT00670033|DRUG|Travoprost ophthalmic solution, 0.004%|
214854843|NCT00670033|DRUG|Vehicle|Inactive ingredients used as a placebo
214854844|NCT00933283|DRUG|Telaprevir|Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
214854845|NCT00933283|DRUG|Methadone|Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
214854846|NCT02903238|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
214854847|NCT02903238|DRUG|Placebo Oral Tablet|Lactose capsule
214664663|NCT03295305|BEHAVIORAL|Unstructured support group|
214854848|NCT02641002|DRUG|CC-90002|Monoclonal Ab to CD47
214854849|NCT04826068|BEHAVIORAL|Emotional Processing|Processing Emotions of others based on photographs of faces
214854850|NCT06616428|OTHER|Bike group fitness class|Comprised a rhythmic indoor cycling session, characterized by fluctuations in intensity corresponding to changes in position, music rhythm, cadence, and revolutions per minute. Participants were instructed to strictly follow verbal cues from the instructor, adjusting cycling cadence and resistance as directed, for 45 minutes.
214854851|NCT06616428|OTHER|Pump Power|Entails a comprehensive total-body weight-training program with a focus on improving strength, muscular endurance, and overall fitness of large muscle groups. The class, choreographed to music, involved participants performing a combination of barbell, body-weight exercises, and free-weight plates, during 45 minutes. Participants selected weights based on the target muscle group for the specific song or track and their individual fitness goals.
214854852|NCT06616428|OTHER|Global Training|Incorporated both aerobic and resistance components, combining athletic movements like running, lunging, and jumping with strength exercises such as barbells, body-weight exercises, and free-weight plates for the large muscle groups, during 45 minutes.
214854853|NCT02182167|DRUG|IV N-acetylcysteine (NAC)|
214854854|NCT02182167|DRUG|Water|
214854855|NCT02346851|PROCEDURE|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
214854856|NCT01967693|PROCEDURE|Retrospective analysis of data|Retrospective data analysis
214854857|NCT00700817|DRUG|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
214854858|NCT00700817|DRUG|sitagliptin|Tablets, 100 mg daily
214854859|NCT00700817|DRUG|metformin|Tablets, minimum 1500 mg daily
214664664|NCT02210338|DEVICE|Karl Storz C-MAC|
214664665|NCT02210338|DEVICE|Bonfils Intubation Fibrescope|
214854860|NCT00700817|DRUG|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
214854861|NCT06074302|DEVICE|RHA Redensity|RHA Redensity will be injected in a microdroplet technique to bilateral cheeks.
214854862|NCT06502587|OTHER|blood flow restriction training|"we will apply blood flow restriction training with low intensity exercises like knee flexion ,knee extension and straight leg raise 10 repetitions 2 sets a day and 3 times/week a rest interval of 2 minutes between exercises, for 30 minutes of this whole procedure.~total 12 sessions given in 4 weeks each session of maximum 30 minutes"
214664666|NCT03328819|OTHER|Acupuncture|The following depression-specific acupoints: Baihui (Du-20), Yintang (EX-HN3), Sishencong (EX-HN1), bilateral Cuanzhu (BL2), bilateral Toulinqi (GB15), bilateral Neiguan (PC6), bilateral Shenmen (HT7), bilateral Sanyinjiao (SP6), and bilateral Taichong (LR3). These depression-specific acupoints could raise up the qi, calm the mind, smooth liver qi stagnation, promote blood circulation, remove blood stasis, and nourish yin. The following pain-specific acupoints: bilateral Fengchi (GB20), bilateral Jianjing (GB21), bilateral Quchi (LI11), bilateral Shousanli (LI10), bilateral Hegu (LI4), bilateral Wangu (SI4), bilateral Shenshu (BL23), bilateral Huantiao (GB30), bilateral Weizhong (BL40), bilateral Feiyang (BL58), bilateral Yanglingquan (GB34), bilateral Yinlingquan (SP9), and bilateral Taixi (KI3). These pain-specific acupoints could eliminate wind, relax muscles, promote blood circulation, and supplement the kidney.
214664667|NCT00264407|DRUG|Hormone Replacement Therapy - HRT|
214664668|NCT03471026|DIAGNOSTIC_TEST|Advanced MRI sequences|Structural, diffusion and perfusion MRI sequences
214664669|NCT02998502|DEVICE|Freespira Breathing System|Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
214664670|NCT03679403|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
214664671|NCT02380131|DRUG|Oxaliplatin plus Capecitabine|A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
214664672|NCT02380131|DRUG|Herceptin|Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
214664673|NCT02792868|OTHER|24 h urines analyses|patient collects urines during 24h
214664674|NCT06002464|PROCEDURE|Acupuncture|Patient will have session of 30 minutes of acupuncture every day during 3 days
214664675|NCT06002464|PROCEDURE|Bilateral ESP catheter|Analgesia by Bilateral Continuous erector spine plane block catheter at T9 level for 2 days
214664676|NCT04756934|DRUG|HX008|HX008: 200mg, Q3W
214664677|NCT04756934|DRUG|LP002|LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W
214664678|NCT06062719|DRUG|PPI group|80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
214664679|NCT06062719|DRUG|PPI plus octreotide|octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
214664680|NCT00123084|BEHAVIORAL|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
214664681|NCT00123084|BEHAVIORAL|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
214664682|NCT03369795|DRUG|Methotrexate|Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
214664683|NCT03369795|OTHER|Placebo Arm|Pills equivalent to the study drug arm (10mg) will be given once a week for the first two weeks of the trial, followed by an increase in dose to 15mg of equivalent placebo once a week until week 16.
214664684|NCT02956655|OTHER|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
214664685|NCT02956655|DRUG|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
214664686|NCT02956655|OTHER|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
214664687|NCT02956655|BEHAVIORAL|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
214664688|NCT02956655|DEVICE|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
214664689|NCT05531357|DIAGNOSTIC_TEST|Transvaginal ultrasound scans|"Transvaginal ultrasound scans to map ovarian follicle growth and ovulation, finger-prick blood sampling for dried blood spot (DBS) hormonal assays and urine sampling for hormone metabolites, every consecutive day for an interovulatory interval.~Weekly venipuncture samples will be taken for standard ELISA hormonal assays. The hormones of interest are FSH, LH, estradiol, progesterone, AMH, inhibins A and B, GDF-9 and BMP-15."
214664690|NCT04078750|BEHAVIORAL|Tailored medication adherence plan|Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
214664691|NCT06037876|DRUG|IVM (200 µg/kg) + ALB (400 mg)|World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
214664692|NCT06037876|DRUG|ALB (400mg)|Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
214664693|NCT01246492|DIETARY_SUPPLEMENT|Artificial Sweeteners|A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
214664694|NCT04259502|PROCEDURE|Rhomboid intercostal block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
214664695|NCT04259502|PROCEDURE|Erector spinae plane block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
214664696|NCT00133926|PROCEDURE|Treatment of periodontal disease|
214664697|NCT05752448|BEHAVIORAL|POSTCare Survivorship transition process|Survivorship coaching intervention
214854863|NCT06502587|OTHER|ultrasound therapy|All subjects will be given Ultrasound therapy as per patient requirement with 1.5 Watts/cm\^2 in continuous mode around knee joint. Conservative exercises(quads isometric exercise, pillow squeeze, heel raise, straight leg raise and side leg raise) will be applied for 3 times per week (daily one set of 10 repetitions) They will be given this treatment for 3 times per week
214854864|NCT00775541|DIETARY_SUPPLEMENT|Vitamin C|One IV infusion of 2 gm vitamin C
214854865|NCT06053762|BEHAVIORAL|Peer-facilitated tobacco cessation|Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes
214854866|NCT06053762|BEHAVIORAL|Self-navigated tobacco cessation|Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves. Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
214854867|NCT01882920|DRUG|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) \<2.5 l/min/m2, stroke volume index (SVI) \< 35 SVI ml/m2 and stroke volume variation (SVV)\> 15%. In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV \< 15%, an infusion with dopamine was initiated.
214854868|NCT01882920|DRUG|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
214664698|NCT05994170|RADIATION|Reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as 5mm margin from GTVp,including pre-induction chemotherapy tumor extension( CTVp1=GTVp+5mm)
214664699|NCT05994170|RADIATION|Non-reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as whole nasopharynx as well as 5mm margin from GTVp( CTVp1=GTVp+5mm+whole nasopharynx)
214664700|NCT04654507|DRUG|Dexamethasone Oral|Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
214664701|NCT04654507|DRUG|Placebo|Placebo
214664702|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
214664703|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
214664704|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
214664705|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
214664706|NCT01089192|DRUG|Metformin|
214664707|NCT04032366|DRUG|inhaled nitric oxide|using of inhaled nitric oxide
214664708|NCT04032366|DEVICE|PEEP|increasing PEEP or decreasing PEEP
214664709|NCT01137214|DEVICE|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
214664710|NCT02497703|DEVICE|Knee robot|
214664711|NCT04728945|PROCEDURE|lung recruitment|Automatic lung recruitment using the anesthetic machines (with PEEP 15 cmH2O for 30 seconds) will be performed every 30 minutes during laparoscopy.
214664712|NCT04728945|PROCEDURE|Standard ventilatory management|"After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~\[initial setting\] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)"
214664713|NCT04626622|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
214664714|NCT04626622|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
214664715|NCT01640847|DRUG|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
214664716|NCT02031094|OTHER|Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure|Observational methods of measuring resting energy expenditure
214664717|NCT04108507|PROCEDURE|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
214664718|NCT01211691|DRUG|KB004, Monoclonal Antibody|
214664719|NCT05346302|DRUG|Pneumovax 23|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
214854869|NCT00216645|DRUG|doxorubicin hydrochloride|
214854870|NCT04175743|DRUG|CT-044 HCl|CT-044 HCl is a reactive species decomposition accelerant
214854871|NCT03166553|DRUG|Elemene|
214854872|NCT01338987|PROCEDURE|First Allogeneic Bone Marrow Transplant (BMT)|First Allogeneic Bone Marrow Transplant
214664720|NCT05346302|DRUG|Typhim VI|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
214664721|NCT05346302|OTHER|Saline|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
214664722|NCT04863716|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered before the surgery.
214664723|NCT04863716|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
214854873|NCT01338987|DRUG|Leuprolide|Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients \> 18 years and as a 3 month injection (adult preparation) for patients \< 18 years
214854874|NCT01338987|DRUG|18F FLT|For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
214854875|NCT01338987|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)
214854876|NCT01338987|DRUG|Methotrexate|Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
214854877|NCT01338987|DRUG|Tacrolimus|Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
214854878|NCT01338987|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
214854879|NCT01338987|DRUG|Busulfan|Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
214854880|NCT01338987|DRUG|Fludarabine|Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
214854881|NCT01338987|PROCEDURE|Second Allogeneic Bone Marrow Transplantation|Second Allogeneic Bone Marrow Transplantation
214854882|NCT03985787|BEHAVIORAL|Resistance Training|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
214854883|NCT01700478|DRUG|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
214854884|NCT01700478|DRUG|Vasopressin|Vasopressin was used in all patients during surgery.
214854885|NCT06205433|OTHER|IHSS Basic Training|The intervention is the Center for Caregiver Advancements 30-hour IHSS Basic training course.
214854886|NCT00489281|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
214854887|NCT00489281|DRUG|Fludarabine|Fludarabine 30 mg/m\^2/day IV on Days -6, -5, -4, -3, and -2.
214854888|NCT00489281|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.
214854889|NCT00489281|DRUG|Sirolimus|The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.
214854890|NCT00489281|PROCEDURE|Allogeneic bone marrow transplant|An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
214854891|NCT00489281|RADIATION|Total body irradiation - 200|200 centigray (cGy) in one fraction on Day -1.
214854892|NCT00489281|DRUG|Levetiracetam|Given at 500 mg PO twice daily from Day -6 to Day +365.
214854893|NCT00489281|BIOLOGICAL|Anti-thymocyte globulin|Test dose of 0.5 mg/kg IV given on Day -9, then 2 mg/kg/day IV on Day -8 and -7.
214854894|NCT00489281|RADIATION|Total body irradiation - 400|400 centigray (cGy) in one fraction on Day -1.
214854895|NCT04471402|DRUG|Precedex|Intranasal Precedex 3mcg/kg
214854896|NCT06616350|DEVICE|esTOCma: an app to fight stigma associated with OCD|The intervention consists of playing a serious game, called esTOCma, on a mobile phone. In the game, players must use their knowledge to battle the stigma monster of OCD, complete 10 missions, and release 10 individuals who have been afflicted by the esTOCma monster, a creature that feeds on false beliefs and misinformation in society.
214854897|NCT00606502|DRUG|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
214854898|NCT00606502|DRUG|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
214854899|NCT00606502|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
214854900|NCT00606502|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
214854901|NCT04133649|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
214854902|NCT04462484|BEHAVIORAL|videoconference|The intervention is a person-directed, individual, primary occupational intervention. It will be carried out via videoconference in six sessions of 45 minutes (on a weekly basis). Through guided dialogue, individual difficulties and opportunities of each subject will be examined in order to gain self-awareness of personal characteristics (strengths, limitations, maximum workload capacity) in their particular set of job demands and resources. Participants are encouraged to adopt the set of self-care strategies in each dimension, adapting them to their specific context. Activities will be carried out in Spanish by the researcher.
214664724|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|"Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patients success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2)."
214664725|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
214664726|NCT00816036|BEHAVIORAL|Smoking Cessation Guideline Implementation|"1\. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit."
214664727|NCT03433625|BEHAVIORAL|Behavioural experiments for intolerance of uncertainty (BE-IU)|CBT
214664728|NCT00853983|DRUG|[14C] AZD0530|Solution, Oral, once
214664729|NCT05432570|PROCEDURE|Group A - Muscle Relaxants Used|Induction will be achieved with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium stored at 4 degrees. After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
214664730|NCT05432570|PROCEDURE|Group B - No Muscle Relaxants|Induction will be provided with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol. After ventilation, vocal cords will be seen with a Macintosh laryngoscope, and 2cc of 2% lidocaine will be applied to the vocal cords as a spray with the help of a 5 ml injector. After ventilation, laryngoscopy will be performed with a Macintosh laryngoscope by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
214664731|NCT00499551|DEVICE|Iontophoresis second generation Eyegate II device|
214664732|NCT02270567|DEVICE|NETest|Non-invasive blood test
214664733|NCT00388466|DEVICE|GALILEO|
214664734|NCT02033226|DEVICE|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
214664735|NCT02033226|DEVICE|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
214664736|NCT02765841|DRUG|Lomitapide|
214664737|NCT04847986|BEHAVIORAL|acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
214664738|NCT04847986|BEHAVIORAL|Control group|The control group will receive care as usual with psychoeducation materials provided.
214664739|NCT02739412|BIOLOGICAL|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
214664740|NCT04636918|DRUG|Cyclosporine Ophthalmic|Prospective interventional study (single arm)
214664741|NCT02659449|DEVICE|made to measure compression gloves|Patients achieve tests with compression glove
214664742|NCT02659449|DEVICE|Compression bandaging|Patients achieve tests with compression bandaging
214664743|NCT02659449|OTHER|Free Hands|Patients achieve tests without device
214664744|NCT00986349|DEVICE|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
214664745|NCT01585649|DRUG|Lipegfilgrastim|Lipegfilgrastim 100ug/kg
214664746|NCT05893134|OTHER|Risk Assessment|A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest risk for dengue transmission in the study area
214664747|NCT05015712|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (\<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
214664748|NCT06380244|OTHER|anesthesia without opioids|Opioid free general anesthesia
214664749|NCT05295277|OTHER|Standard of care genetic testing group|N/A - no intervention as this is an observational study.
214664750|NCT02634515|DRUG|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
214664751|NCT02634515|DRUG|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
214664752|NCT00002700|DRUG|asparaginase|
214664753|NCT00002700|DRUG|cyclophosphamide|
214664754|NCT00002700|DRUG|cytarabine|
214664755|NCT00002700|DRUG|daunorubicin hydrochloride|
214664756|NCT00002700|DRUG|dexamethasone|
214664757|NCT00002700|DRUG|doxorubicin hydrochloride|
214664758|NCT00002700|DRUG|leucovorin calcium|
214664759|NCT00002700|DRUG|mercaptopurine|
214664760|NCT00002700|DRUG|methotrexate|
214664761|NCT00002700|DRUG|mitoxantrone hydrochloride|
214664762|NCT00002700|DRUG|prednisolone|
214664763|NCT00002700|DRUG|prednisone|
214664764|NCT00002700|DRUG|therapeutic hydrocortisone|
214854903|NCT01906359|OTHER|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
214854904|NCT01906359|OTHER|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
214854905|NCT01906359|OTHER|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
214854906|NCT03513042|RADIATION|Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy|"Standard of care:~* IMPT (conventional fractionation \[35x1,55/2Gy, 5 fractions/week\] or accelerated fractionation \[35x1,55/2Gy, 6 fractions/week\])~* with or without concurrent cisplatin (100 mg/m2 \[d1, d22 and d43\] or 40 mg/m2 weekly) or cetuximab (weekly 400 mg/m2 in 2h followed by 250 mg/m2 in 1h)"
214854907|NCT02854059|BIOLOGICAL|IdeS (0.25 mg/kg)|Single i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of efficacy and safety in the first 3 patients the dose may be increased in the following 3 patients to 0.5 mg/kg.
214854908|NCT02854059|BIOLOGICAL|IdeS (0.50 mg/kg)|Single i.v. infusion of IdeS (0.50 mg/kg).
214854909|NCT05767736|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
214854910|NCT05767736|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
214854911|NCT05767736|DRUG|Disease-Modifying Therapies (DMTs)|Administered as specified in the treatment arm.
214854912|NCT00121147|DRUG|Travatan|
214854913|NCT00121147|DRUG|Azopt|
214854914|NCT00121147|DRUG|Alphagan P|
214854915|NCT03543345|DIAGNOSTIC_TEST|echocardiography study|"Patients with right coronary artery occlusion lesion will be subjected to:~* Written consent.~* Complete history.~* Complete physical examination.~* Trans-thoracic echocardiography assessment of the right ventricular function before PCI to the RCA~* Follow up Trans-thoracic echocardiography assessment of the right ventricular function four weeks after the PCI."
214854916|NCT04882982|BEHAVIORAL|Caria app|App to improve symptoms of menopause
214854917|NCT04882982|BEHAVIORAL|Menopause Education|Educational materials about symptoms of menopause
214854918|NCT02480582|OTHER|Almonds|Whole raw almonds provided as a mid-morning snack - 0.9g\\kg
214854919|NCT02480582|OTHER|Cheese Savouries|Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
214854920|NCT02780427|DRUG|intranasal dexmedetomidine|"Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD)."
214854921|NCT02971982|DRUG|rituximab /Dexamethasone/cyclophosphamide|rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
214854922|NCT02971982|DRUG|Velcade/Dexamethasone/cyclophosphamide|Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
214854923|NCT06615791|BEHAVIORAL|FIT FIRST Teen|High intensity sports drills and games.
214854924|NCT03757780|OTHER|Questionaire|A questionaire will be made to pregnant ladies who take caffeine during pregnancy
214854925|NCT02529202|DRUG|Dexmedetomidine|Dexmedetomidine infusion
214854926|NCT01470612|DRUG|CP-690,550|5 mg tablets, BID, for at least 12 months
214854927|NCT01470612|DRUG|CP-690,550|10 mg tablets, BID, for at least 12 months
214854928|NCT01166555|DRUG|PF-04236921|single subcutaneous dose
214854929|NCT01397708|BIOLOGICAL|INXN-2001|"* approximately 1.0 x 1012 viral particles (vp) per injection~* one intratumoral injection of INXN-2001 per study cycle~* maximum of 6 study cycles"
214854930|NCT01397708|DRUG|INXN-1001|"* 4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~* 7 oral daily doses of INXN-1001 per study cycle~* maximum of 6 study cycles~* 1 Expansion cohort at a single dose level at or below MTD (160mg/day)"
214854931|NCT00065455|DRUG|Vitamin A|
214854932|NCT03314818|DEVICE|Ultrasound 3D Imaging|"Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism."
214854933|NCT05151575|BEHAVIORAL|supervised group-based walking and non-supervised individual-based walking interventions|Group exercise interventions tended to be systematic and supervised by professionals. The current intervention is proposing to conduct a randomized control trial that is not only examining the nature of walking on older adults' well-being but also involving the elements of group-based and professional supervision intervention, aiming at comparing with the individual-based intervention without professional supervision. Qualified professional fitness trainers (1 male and 1 female separately for male and female groups, respectively) will be involved in the group-based intervention programs in order to provide appropriate guidance and supervision to the participants. Whereas, the non-supervised individual-based intervention will be conducted by a research assistant (males and females) to ensure the attendance and general safety, but without providing professional advice or supervision.
214854934|NCT03686020|DIAGNOSTIC_TEST|Enzyme Linked Immunosorbent assay (ELISA)|measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)
214854935|NCT05012865|DRUG|avelumab|as provided in real world practice
214854936|NCT05012865|DRUG|axitinib|as provided in real world practice
214854937|NCT01770431|DRUG|Huaier Granule|Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
214854938|NCT03083626|OTHER|Cold pressor test|"The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached."
214664765|NCT00002700|DRUG|vincristine sulfate|
214664766|NCT00002700|PROCEDURE|allogeneic bone marrow transplantation|
214664767|NCT00002700|PROCEDURE|autologous bone marrow transplantation|
214664768|NCT00002700|RADIATION|radiation therapy|
214664769|NCT03304457|DRUG|Olanzapine|Olanzapine 10mg once daily orally for 6 weeks
214664770|NCT03304457|DRUG|Lurasidone|Lurasidone 80mg once daily orally for 6 weeks
214664771|NCT05232825|DRUG|Ocrelizumab IV|IV Injection
214664772|NCT05232825|DRUG|Ocrelizumab SC|SC Injection
214664773|NCT05232825|DRUG|Methylprednisolone IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
214664774|NCT05232825|DRUG|Diphenhydramine IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
214664775|NCT05232825|DRUG|Dexamethasone given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
214664776|NCT05232825|DRUG|Desloratadine given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
214664777|NCT03945279|DRUG|BIIB100|Administered as specified in the treatment arm.
214664778|NCT03945279|DRUG|Placebo|Administered as specified in the treatment arm.
214664779|NCT02722044|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
214664780|NCT02722044|DEVICE|Autoinjector|Subcutaneous administration
214664781|NCT05195632|DRUG|Encorafenib|Hard capsule
214664782|NCT05195632|DRUG|Binimetinib|Film-coated tablet
214664783|NCT04057378|DEVICE|Electroconvulsive therapy|Electrically induced convulsion under anesthesia
214664784|NCT04756544|DIETARY_SUPPLEMENT|Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175|probiotic
214664785|NCT04756544|OTHER|placebo|placebo
214664786|NCT04817540|DRUG|Herzuma|8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
214664787|NCT03531099|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
214664788|NCT03531099|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
214664789|NCT03531099|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
214664790|NCT03531099|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
214664791|NCT03531099|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
214664792|NCT04052737|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
214664793|NCT04052737|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
214664794|NCT06479603|DRUG|Nintedanib|The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily. In case of severe adverse effects, the drug will be stopped and reintroduced after a period of up to 1-4 weeks. A dose of 100 mg twice daily will be started and continued. One attempt to titrate the dose up to 150 mg twice daily will be permitted.
214664795|NCT06479603|DRUG|Standard of care|The subjects will receive the standard-of-care immunosuppressive treatment alone that may include glucocorticoids and other steroid-sparing agents that the subject would already be receiving.
214664796|NCT00843986|DRUG|conivaptan|Premix bag
214664797|NCT00843986|DRUG|placebo|Premix bag
214664798|NCT01909492|PROCEDURE|Blood Draw|Patients will provide a serum sample for research.
214664799|NCT01909492|PROCEDURE|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
214664800|NCT05988385|DEVICE|Positive airway pressure|Positive airway pressure (PAP) therapy is a sleep apnea treatment that uses a stream of compressed air to support the airway during sleep. With PAP therapy, a mask is worn during sleep and a portable machine gently blows pressurized room air from into your upper airway through a tube connected to the mask. This positive airflow helps keep the airway open, preventing the collapse that occurs during apnea, thus allowing normal breathing.
214664801|NCT05988385|DEVICE|Oral appliance therapy|Oral appliance therapy involves the use of a dental appliance or oral mandibular advancement device that prevents the tongue from blocking the throat and/or advances the lower jaw forward. These devices help keep the airway open during sleep.
214664802|NCT05988385|DEVICE|Positional therapy|A NightShift Sleep Positioner (Advanced Brain Monitoring) is a neck vibration device, FDA approved to treat positional sleep apnea. The device detects patient supine position and delivers a small vibratory signal to the back of the neck to prompt position change.
214854939|NCT02328950|DRUG|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
214854940|NCT04768894|PROCEDURE|Second transurehral resection of bladder tumour|Remove of the bladder tumour as endoscopically
214854941|NCT02906865|OTHER|Proximal hamstring tendons repair|Proximal hamstring tendons repair
214854942|NCT00674401|PROCEDURE|Radiofrequency catheter ablation|"* In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~  1. Empirical pulmonary vein antrum circumferential isolation, or~ 2. High frequency sites ablation in the LA~* In case of Persistent AF, patients will be randomized into one of 2 in the study:~  1. Empirical circumferential PV antrum isolation w/out roof line, or~ 2. A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
214854943|NCT01095419|OTHER|Massage Therapy|After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)
214854944|NCT01095419|OTHER|Control|no intervention
214854945|NCT04462016|OTHER|Calamansi|250 ml of a commercially sourced calamansi drink
214854946|NCT04462016|OTHER|Glucose|75 g of glucose dissolved in 250 ml of drinking water
214854947|NCT00208117|DRUG|Sertraline (Zoloft)|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
214854948|NCT00208117|DRUG|Simvastatin (Zocor)|The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
214854949|NCT01221246|DRUG|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
214854950|NCT01221246|DRUG|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
214854951|NCT05667636|RADIATION|salvage SBRT|steretactic body radiation therapy in the setting of salvage radiotherapy for prostate cancer
214854952|NCT01974908|PROCEDURE|Fibrillatory Factor calculation (FF)|During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
214854953|NCT02516423|DRUG|ixazomib|oral
214854954|NCT02516423|DRUG|lenalidomide|oral
214854955|NCT02516423|DRUG|dexamethasone|oral
214854956|NCT02516423|DRUG|zoledronic acid|IV
214854957|NCT03407118|DRUG|LY900014|Administered SC.
214854958|NCT03407118|DRUG|Insulin Lispro|Administered SC.
214854959|NCT00065013|BEHAVIORAL|strength training|
214854960|NCT04971213|DEVICE|Non invasive ventilation|Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)
214854961|NCT04971213|DEVICE|High-flow nasal cannula heated and humidified oxygen|AirVO2 device (Fisher and Paykel, New Zealand)
214854962|NCT06437418|DIAGNOSTIC_TEST|abdominal ultrasonography.|Evaluate the gallbladder ejection fraction (EF)
214854963|NCT02761213|DRUG|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
214854964|NCT02761213|DRUG|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
214854965|NCT01997021|OTHER|US|US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
214854966|NCT01997021|OTHER|IW|IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
214854967|NCT01997021|OTHER|CW|CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
214854968|NCT00911599|DIAGNOSTIC_TEST|Blood metal ion levels|Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
214854969|NCT02691832|DEVICE|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
214854970|NCT02556307|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
214854971|NCT02556307|DRUG|Ribavirin|Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
214854972|NCT01510652|PROCEDURE|BiP Group|Implantation of standard Left Ventricular (LV) lead
214854973|NCT01510652|DEVICE|Quad Group|Implantation of quadripolar Left ventricular (LV) lead Quartet
214854974|NCT03329807|DEVICE|Transcranial Magnetic Stimulation|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.
214476427|NCT06820281|DRUG|Placebo injection (normal saline)|Placebo will be given as 0.5mL normal saline (if comparator against vial or pre-filled pen), or 0.6mL (if comparator against Mounjaro Kwikpen), drawn up into a syringe and administered by subcutaneous injection weekly by study nurses.
214854975|NCT03329807|BEHAVIORAL|conventional sensory therapy|Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week.
214854976|NCT04574115|DEVICE|Omega Refractive Capsule with an FDA approved Intraocular Lens|Omega refractive capsule in conjunction with an FDA approved Intraocular Lens
214854977|NCT04574115|DEVICE|FDA approved Intraocular Lens|FDA approved Intraocular Lens
214854978|NCT04008537|DEVICE|Ring gantry kV-CBCT combined with linear accelerator|Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
214854979|NCT03913897|OTHER|distraction methods|The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over
214854980|NCT06603987|RADIATION|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
214854981|NCT06603987|DIAGNOSTIC_TEST|［18F］FBPA|Intravenous injection of ［18F］FBPA and radiation exposure from PET-CT scan.
214854982|NCT04191798|BEHAVIORAL|Telerehabilitation using the KinexConnect system for rehabilitation after TKA.|KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.
214854983|NCT04191798|BEHAVIORAL|Traditional outpatient PT for rehabilitation after TKA.|Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
214854984|NCT01344382|BEHAVIORAL|Community Reinforcement and Family Training|The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
214854985|NCT01344382|BEHAVIORAL|Al-Anon Facilitation|Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
214854986|NCT00384176|DRUG|Cediranib|oral tablet once daily
214854987|NCT00384176|DRUG|Bevacizumab|intravenous infusion
214854988|NCT00384176|DRUG|5-fluorouracil ( in FOLFOX)|intravenous infusion
214854989|NCT00384176|DRUG|Leucovorin (in FOLFOX)|intravenous infusion
214854990|NCT00384176|DRUG|Oxaliplatin (in FOLFOX)|intravenous infusion
214854991|NCT04810520|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
214854992|NCT04810520|OTHER|Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
214854993|NCT02409394|DRUG|Hetrombopag Olamine|
214854994|NCT00729131|DRUG|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
214854995|NCT05754229|DEVICE|AI-assisted colonoscopy|The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
214854996|NCT02999594|DRUG|Tramadol Hydrochloride|50mg intramuscularly
214854997|NCT02999594|DRUG|Distilled Water|2ml intramuscularly
214854998|NCT04387682|DIETARY_SUPPLEMENT|β-glucan|β-glucan, a biological response regulator, derived from yeast has been known for more than 45 years, and has anti-infective and anti-tumor activities. β-glucan is a molecule with a β-1,3-linked D-glucose backbone and β-1,6-linked side chains. Thus far, at least 4 receptors for β-glucan have been discovered in humans, which are surface antigens associated with macrophages or myeloid precursor cells as complement receptor 3 (CR3; CD11b/CD18, Mac-1, αMβ2 integrin) (Vetvicka et al. 1996; Xia et al. 1999), lactosylceramide (Zimmerman et al. 1998), scavenger receptor (Rice et al. 2002) and dectin-1 (Brown et al. 2003; Taylor et al. 2007; Saijo et al. 2007).
214854999|NCT05941273|DEVICE|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
214855000|NCT06048289|OTHER|Blood samples, tumor biopsy specimens will be collected|Blood samples, tumor biopsy specimens at baseline will be collected
214855001|NCT04854564|BEHAVIORAL|Prehabilitation intervention|The investigators will identify participants' perceived important information to develop a prehabilitation intervention in this study. Prehabilitation intervention consisting of physical activities, nutrition, and stress management.
214855002|NCT04854564|BEHAVIORAL|Caregiver intervention|The investigators will provide caregivers with variety of educational resources for patients experiencing ESLD.
214855003|NCT01785121|BEHAVIORAL|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
214855004|NCT01785121|BEHAVIORAL|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
214855005|NCT00102830|DRUG|AMG 386|
214855006|NCT00946049|DEVICE|Vicryl Plus|
214855007|NCT00946049|DEVICE|Vicryl|
214855008|NCT03407521|DRUG|Misoprostol|induction of abortion using misoprostol
214855009|NCT03407521|DRUG|isosorbide mononitrate|isosorbide mononitrate
214855010|NCT03407521|DRUG|Placebo|Placebo
214855011|NCT04108559|PROCEDURE|Kinesiologic Tape Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.
214855012|NCT04108559|PROCEDURE|Drain Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.
214855013|NCT04108559|OTHER|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
214855014|NCT05418075|OTHER|Psychotherapy|If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
214855015|NCT05307159|DIETARY_SUPPLEMENT|bean protein supplement|They will have a snack with bean protein for 21 days Participants will follow their usual diet, which will be quantified and evaluated.
214855016|NCT01330667|DIETARY_SUPPLEMENT|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
214855017|NCT03293173|COMBINATION_PRODUCT|R-CHOEP|rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
214855018|NCT03293173|COMBINATION_PRODUCT|DA-EPOCH-R|dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
214855019|NCT06420414|OTHER|Virtual Reality|"Participants engaged in a 15-minute HIIT session using the Facebook Oculus Quest 2 VR headset with the FitXR fitness game. The advanced level workout (High Speed) was chosen, where participants performed functional movements like squats, lunges, and trunk rotations while punching virtual targets. The VR environment provided a 10-second rest period between intervals and featured a virtual trainer's guidance."
214855020|NCT06420414|OTHER|Traditional HIIT|"Participants followed a non-VR 15-minute HIIT programme designed to replicate the exercises and patterns seen in the FitXR game. The traditional exercises included squats, lunges, and punches, matching the VR programme's intensity and interval structure. Participants watched a pre-recorded video on a laptop, which guided them through the workout. The 10-second rest periods were also maintained for consistency."
214855021|NCT04798235|BIOLOGICAL|TSHA-101|AAV9 viral vector containing HEXA and HEXB genes to be administered via Intrathecal injection
214855022|NCT03643679|OTHER|Kwit smartphone app|The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
214855023|NCT03603938|DRUG|potassium losartan|treated with bedtime or awakening doses of potassium losartan
214855024|NCT00854373|DRUG|Bravelle(follicle stimulating hormone)|One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
214855025|NCT00854373|OTHER|Saline ( placebo)|1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
214855026|NCT00307931|BIOLOGICAL|Certolizumab pegol|"certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks."
214855027|NCT03249740|DRUG|GB-102|Intravitreal injection of GB-102
214855028|NCT03249740|DRUG|Aflibercept|Intravitreal injection of Aflibercept.
214855029|NCT01414751|BEHAVIORAL|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
214855030|NCT01414751|BEHAVIORAL|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
214855031|NCT00403182|DRUG|chemotherapy|
214855032|NCT00403182|DRUG|letrozole|
214855033|NCT01380249|DRUG|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
214855034|NCT04948229|OTHER|Blood serum samples|Blood serum samples will be taken.
214855035|NCT04474782|DIAGNOSTIC_TEST|There is not an intervention|There is not an intervention
214855036|NCT05729919|PROCEDURE|Free gingival graft technique|"A horizontal partial thickness incision will be trace at the MGJ to dissect the alveolar mucosa from the keratinized tissue. The alveolar mucosa will be dissected from the underlying periosteum to create an envelope of 4-5 mm apical to the bone dehiscence associated with the gingival recessions. The keratinized tissue coronal to the first incision and neighboring the recession will be de-epithelialized to expose the connective tissue and create a trapezoidal recipient bed having a large apical base at the MGJ and a narrower coronal base just coronal to the CEJ of the experimental units. The grafts will be taken from the palate.The grafts will be positionned with the coronal edge of the CEJ.~Interrupted sutures (6-0 polypropylene, prolene) will be positionned to stabilize the graft. Sling crossed sutures anchored to the periosteum apical to the graft and placed to ensure a tight adaptation of the graft to the root surface"
214855037|NCT03917511|BEHAVIORAL|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
214855038|NCT03917511|BEHAVIORAL|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
214855039|NCT02728011|OTHER|Scientific Brain Training (SBT)|Cognitive training
214855040|NCT02728011|OTHER|Tetris|
214855041|NCT00312676|PROCEDURE|Rapid versus slow conversion|
214855042|NCT04871516|OTHER|Quality-of-Life Assessment|Ancillary studies
214855043|NCT04871516|OTHER|Questionnaire Administration|Ancillary studies
214855044|NCT04871516|RADIATION|Radiation Boost|Undergo radiation therapy boost
214855045|NCT04871516|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard surgery
214855046|NCT04871516|RADIATION|Whole Breast Irradiation|Undergo standard WBI
214855047|NCT04871516|OTHER|Breast MRI|A baseline breast MRI
214855048|NCT03187496|DRUG|Midazolam|Each subject will receive midazolam on Days 1 and 12.
214855049|NCT03187496|DRUG|Caffeine|Each subject will receive caffeine on Days 1 and 12.
214855050|NCT03187496|DRUG|Rosuvastatin|Each subject will receive rosuvastatin on Days 2 and 13.
214476428|NCT06648928|BEHAVIORAL|Clinician Supported PTSD Coach|Combines self-managed PTSD Coach application with four 20-30 minute sessions delivered by a clinician. The app includes modules on learning about PTSD, self-assessment, symptom management, and finding support.
214855051|NCT03187496|DRUG|EDP-305|Each subject will receive EDP-305 on Days 5 through 15.
214855052|NCT03297671|DRUG|RhIg prophylaxis|Two RhIg prophylaxis injections for Rh negative women
214855053|NCT03297671|DEVICE|ELDONCARD|ELDONCARD point-of-care test.
214855054|NCT03297671|DIAGNOSTIC_TEST|ELDONCARD Test|LHVs will perform ELDONCARD test.
214855055|NCT00014391|BIOLOGICAL|palivizumab|
214855056|NCT00014391|DRUG|ribavirin|
214855057|NCT05496673|DIAGNOSTIC_TEST|Pastorex Latex Agglutination Test|Rapid diagnosis of bacterial meningitis
214855058|NCT05496673|DIAGNOSTIC_TEST|Biofire PCR for meningitis|Rapid diagnosis of multiple forms of meningitis
214855059|NCT05496673|DIAGNOSTIC_TEST|Immy CrAg Lateral Flow Assay|Rapid diagnosis of cryptococcal meningitis
214855060|NCT03126422|DRUG|Dexmedetomidine|Pretreatment of different doses of dexmedetomidine
214855061|NCT05654194|DRUG|Azacitidine Combined With Venetoclax and ATRA group|AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
214855062|NCT01680874|DIETARY_SUPPLEMENT|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
214855063|NCT01680874|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
214855064|NCT02305173|DRUG|Intravenous Dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
214855065|NCT02305173|DRUG|intravenous salin water|Patients of the control group received homologated placebo 60 minutes before surgery.
214855066|NCT03653494|PROCEDURE|phrenic block|phrenic block by 1% ropivacaine 5ml
214855067|NCT03653494|PROCEDURE|no phrenic block|no phrenic block
214855068|NCT04497272|OTHER|COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
214855069|NCT01711749|DRUG|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
214855070|NCT01711749|DRUG|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
214855071|NCT00339872|DRUG|IMA-638|
214855072|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
214855073|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
214855074|NCT00515034|DRUG|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
214855075|NCT00515034|DRUG|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
214855076|NCT00000202|DRUG|Buprenorphine|
214855077|NCT02130778|DRUG|Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
214855078|NCT02130778|OTHER|500 ml 0.9% saline|infusion of saline
214855079|NCT05482204|OTHER|Low Climate Impact label|Menu labels indicating low climate impact on chicken, fish, and vegetarian food items on a simulated online fast food menu.
214855080|NCT05482204|OTHER|High Climate Impact label|Menu labels indicating high climate impact on beef food items on a simulated online fast food menu.
214907016|NCT04163003|BEHAVIORAL|Targeted Approaches for Promoting Adolescent Sleep (TAPAS)|The targeted intervention is a three part sleep program, involving a 2- minute psychoeducation video, an in-person session with a clinician focusing on sleep, and web-based goal setting related to sleep behaviors. Intervention approaches to promoting adolescent sleep and reducing insufficient sleep use a motivational interviewing style, rooted in cognitive-behavioral strategies for improving sleep.
214855081|NCT05976724|OTHER|TENS, exercise|"TENS: The patients were sat in a chair positioned next to a treatment table. The hand to be treated was placed on the treatment table with the forearm in the supine position. Electrodes were then placed on the transverse carpal ligament and palmar surface of the hand. Conventional TENS was applied, with the current transition time set to 50-100 µs, and performed at a frequency of 100 Hz for a period of 20 minutes at an amplitude that did not cause muscle contraction or any feeling of numbness or tingling.~The supervised exercises were performed by the patients in a seated position. Strengthening exercises were performed with both hands by means of Digi-Flex hand exerciser (IMC Products Corp, Hicksville, New York), modeling mass and elastics. The patients were tasked with performing these exercises 10 times in each session and three times daily."
214855082|NCT05976724|OTHER|Mulligan mobilisation|Each participant was tested with sustained manual glides in each of the possible directions during active wrist flexion and extension from the seated position. For the lateral glide, the therapist stabilises the lateral aspect of the distal radius using the first web-space. And glides the proximal row of carpal bones laterally (towards the thumb) using the first web-space of the other hand, following the joint line. For the medial glide, the therapist stabilises the medial aspect of the distal ulna using the first web-space. And glides the proximal row of carpal bones medially (away from the thumb) using the first web-space of the other hand, following the joint line.
214855083|NCT03527004|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.
214855084|NCT03527004|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in IQOS users residing in Italy.
214855085|NCT01392326|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
214855086|NCT01392326|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
214855087|NCT01392326|DRUG|Placebo Comparator|Placebo Comparator
214855088|NCT05429697|DRUG|SMT-NK inj.+Pembrolizumab|"SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle."
214855089|NCT05429697|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
214855090|NCT03358043|DEVICE|mechanical ventilation|Consecutive intubated pateints receiving mechanical ventilation with a PaO2/FiO2≤300 mmHg on positive end-expiratory pressure (PEEP) of 5 cmH2O or more and FiO2 of 0.3 or more.
214855091|NCT02194023|DRUG|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
214855092|NCT02194023|DRUG|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
214855093|NCT02194023|DRUG|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
214664803|NCT06994819|DEVICE|niostem headset (Active)|The niostem headset is a non-invasive electronic stimulation device designed to reduce hair loss and improve hair growth. It delivers low-level electrical stimulation through brush electrodes that contact the scalp. Used once daily for 30 minutes for 6 months. Sessions are guided via a smartphone app.
214664804|NCT06994819|DEVICE|Sham niostem headset (Placebo)|he sham niostem headset is visually identical to the active device but does not deliver electrical stimulation. Used once daily for 30 minutes for 6 months. Allows for blinding and placebo-controlled comparison.
214664805|NCT00777543|OTHER|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
214664806|NCT00777543|DIETARY_SUPPLEMENT|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
214664807|NCT00777543|DIETARY_SUPPLEMENT|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
214664808|NCT06991855|DIETARY_SUPPLEMENT|Animal-Based Oil Group|Participants in animal-based oil group will follow a diet in which the primary fat source is animal-based oil. The diet will supplement for 12 weeks.
214855094|NCT02194023|DRUG|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
214855095|NCT02508259|DRUG|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
214855096|NCT02508259|DRUG|Saline|50 ml IV over 30 minutes
214855097|NCT03743610|OTHER|Simulated altitude|Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
214855098|NCT03743610|OTHER|Placebo simulated altitude|Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
214855099|NCT01358149|OTHER|cocoa-based food|single intake of cocoa-based food
214855100|NCT01358149|OTHER|cocoa-based food|Single intake of cocoa-based food
214855101|NCT06368557|BEHAVIORAL|CoolMinds: Internet-based cognitive behavioral therapy (iCBT)|The intervention consists of 14 weeks of iCBT, where the main treatment components are psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The program comprises eleven sessions for adolescents and ten sessions for parents to be completed simultaneously. The participants will have the opportunity to get therapist feedback during the treatment period, the therapist may spend a maximum of 15 minutes giving feedback per week per participant.
214855102|NCT04880382|DRUG|ICI treatment discontinuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
214855103|NCT04880382|DRUG|ICI treatment continuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity
214855104|NCT00279539|GENETIC|Vascular Endothelial Growth Factor (VEGF1)|
214855105|NCT05213260|OTHER|Flipped Teaching method|Before the clinical skill laboratory session, the students will receive the learning materials that they have to read and assimilate before the in-class part which will include interactive, discussion-oriented, and practice-oriented activities.
214855106|NCT06045520|BEHAVIORAL|Information-Motivation-Behavioral Skills Model|1.-2.Meeting:Regarding the information component of the IMB model; Answers given by the adolescents to the epilepsy knowledge test, the topics on which the adolescent wants to get information will be agreed with the adolescent and an education training will be created.3.,4.,5.-6. Meeting:Personal motivation, which is the first step of the motivation component; A meeting will be held regarding the obstacles to the disease, attitudes and behaviors towards the disease. In order to strengthen social support systems, a one-session seizure management training will be planned with a person chosen by the adolescent from his parent or friend group.7-8. Meeting:Seizure self-efficacy and treatment compliance will be evaluated in the behavioral skills component. During training, achievable goals will be set to ask the adolescent to provide personal feedback, ask open-ended questions, engage in reflective listening, and increase personal and social motivation to comply with medical recommendations
214855107|NCT04873180|DIAGNOSTIC_TEST|sectioning and staining of renal neoplasms after nephrectomy operation|nephrectomy operations will be done to patients diagnosed as having renel tumors
214855108|NCT02870036|DRUG|Simmitecan|
214855109|NCT02870036|DRUG|5-fluorouracil and Leucovorin Calcium|
214855110|NCT02870036|DRUG|Thalidomide|
214855111|NCT02029781|PROCEDURE|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
214855112|NCT02726919|DRUG|Clobazam|Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
214855113|NCT04141696|DRUG|Ketamine|Given intravenously over 40 minutes
214855114|NCT04141696|DRUG|Midazolam|Used as placebo comparator; given intravenously over 40 minutes
214855115|NCT00669981|BEHAVIORAL|Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)|CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
214855116|NCT06489535|OTHER|RETAIN|"There are 6 different modules that a participant in the RETAIN intervention group can be placed in: Reinforce Antibiotic Completion, Linkage to Antibiotic Treatment/Alternate Plan, Reinforce Recovery, Linkage to MOUD/Alternate Plan, Reinforce Treatment Attendance, and Harm Reduction Support. Participants may be assigned to no more than three modules at a time until they finish their antibiotics. After the completion of antibiotics, participants may only be in two modules. Participants' intervention can range from 15 minutes- 60 minutes depending on what modules they are placed in and how much support they feel they need. Interventions will begin at the two-week follow up after a participant has been discharged from Boston Medical Center (BMC)."
214855117|NCT06489535|OTHER|Unrelated videos|These videos unrelated to the study topics will last approximately 30-45 minutes. Depending on the method of communication, participants will watch a video (in person) or listen to a podcast (remote)
214855118|NCT06084052|DEVICE|Path Active|Participant use of Path Active insoles, mobile phone app and clinician's dashboard (where pressure and temperature changes can be reviewed by a clinician). All participants will complete a patient questionnaire relating to use of the device and EuroQol - EQ5D at the beginning and end of the study.
214855119|NCT06084052|OTHER|Control Group|Control Group will receive care as usual.
214855120|NCT05640414|OTHER|Weekly Family Food Packages|Families receive weekly family food packages for 6 months
214855121|NCT05640414|BEHAVIORAL|Family Health Group Sessions|Families with children aged 6-17 years attend 6 monthly group sessions with cooking demonstrations
214855122|NCT05626803|DRUG|Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|The first 10 sentinel subjects will receive open label high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
214855123|NCT05626803|DRUG|Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|50 subjects will receive high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
214855124|NCT05626803|DRUG|Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose|50 subjects will receive Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets; total dose is 1×10 to the power 11 IU/dose
214855125|NCT05626803|DRUG|Placebo|25 subjects will receive matching placebo
214855126|NCT02553525|PROCEDURE|Therapeutic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
214855127|NCT02553525|PROCEDURE|Symptogenic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
214855128|NCT05854238|DEVICE|TIRA-VoM|"treat persistent atrial fibrillation~* The ablation temperature range is 50-60℃~* About 2 minutes per ablation"
214907017|NCT04163003|BEHAVIORAL|Sleep Monitoring Only|Participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.
214907018|NCT04147364|OTHER|no intervention|only retrospective reviews for medical records
214855129|NCT05867329|DRUG|Cyclosporine Injection (IV)|"Drug be administered as weight-based continuous infusion (2mg/kg/day) during the second stage of treatment (if applicable).~Cyclosporine monitoring will take place approximately 18-24 hours stage of treatment (Day 4 at the earliest). The goal is to achieve whole blood levels of 300 (range 200-400) ng/ml with adjustments according to the table in the protocol. The intravenous cyclosporine dosage is rarely raised above 4 mg/kg/day, in rare patients that are fast metabolizers."
214855130|NCT05867329|DRUG|Cyclosporine Oral Product|"Once participants meet discharge criteria, participant's that received IV Cyclosporine (stage 2) will be transitioned to oral Cyclosporine.~The oral dose is calculated to be approximately twice the daily intravenous dose or approximately 5 mg/kg, rounded to nearest 25 mg, and is administered every 12 hours (h). Oral cyclosporine solution will be administered as Sandimmune capsules available in 25mg 100mg capsules size.~After the intervention period (during hospitalization after IV cyclosporine is complete) and during the follow-up period any cyclosporine adjustments are permissible under the current study protocol according to the discretion of the treating physician."
214855131|NCT05867329|DRUG|Upadacitinib Extended Release Oral Tablet|"This will be administered orally once daily as 45mg (stage one) or twice daily as a 30mg oral tablet (first stage and second stage) of treatment (if applicable).~Upon discharge a patient will be switched from Upadacitinib 30mg twice daily to 45mg daily for 8 weeks followed by 30mg or 15mg subsequently if Upadacitinib is to be continued after discharge. The choice of induction/maintenance agent initiated after discharge will be determined by inpatient treatment team and in consultation with the outpatient gastroenterologist. No patient will continue Upadacitinib 30mg twice daily after discharge from the hospital."
214855132|NCT05867329|DRUG|Intravenous Methylprednisolone|Drug will be administered as 30mg twice daily during the first stage of treatment (if applicable) and through the second stage of treatment (if applicable). Prior to discharge a patient will be switched from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
214855133|NCT05867329|DRUG|Prednisone Oral Product|Patients that received IV Methylprednisolone will be switched prior to discharge from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
214855134|NCT05674526|BIOLOGICAL|WU-NK-101 - Dose Escalation|WU-NK-101 administered on Days 1, 15, 30 and 44
214855135|NCT05674526|DRUG|Cetuximab - Dose Escalation|Cetuximab 500mg/m2 administered on Days 29 and 43
214855136|NCT05674526|BIOLOGICAL|WU-NK-101 - Cohort Expansion|WU-NK-101 administered on Days 2 and 16
214855137|NCT05674526|BIOLOGICAL|Cetuximab - Cohort Expansion|Cetuximab 500mg/m2 administered on Days 1 and 15
214855138|NCT06679374|DRUG|Placebo|Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
214855139|NCT06679374|DRUG|Varenicline|Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
214855140|NCT01790802|DEVICE|2RT nanosecond laser|active laser therapy
214855141|NCT06679439|PROCEDURE|Surgical correction of lower eyelid retraction using autologous cartilage|Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous auricular cartilage graft spacer.
214855142|NCT06679439|PROCEDURE|Surgical correction of lower eyelid retraction using autogenous dermis graft spacer.|Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous dermis graft spacer.
214855143|NCT06216574|OTHER|Internet-based Intervention|Receive access to SHINE modules
214855144|NCT06308640|DEVICE|Insertion of the device intraorally|"* The distalizer appliance will be checked for adaptation intraorally, the two bands of the maxillary first molars will be fitted in their accurate position on the teeth.~* The screw insertion will be carried out with the patient under local anesthesia.~* They will be placed inside the two eyelets of the anterior arms of the screw in the appliance"
214855145|NCT00002473|PROCEDURE|conventional surgery|
214855146|NCT00678626|DRUG|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
214855147|NCT00678626|DRUG|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
214855148|NCT03216694|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
214855149|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
214855150|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
214664809|NCT06991855|DIETARY_SUPPLEMENT|Plant-Based Oil Group|Participants in plant-based oil group will follow a diet in which the primary fat source is plant-based oil. The diet will supplement for 12 weeks.
214664810|NCT01725880|OTHER|Observation|
214855151|NCT05392374|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2
214907019|NCT03644342|DRUG|Nirapaib|(see treatment regimen and method of treatment assignment)
214907020|NCT03718988|BEHAVIORAL|Meat products|Traditional meat products (beef burger patties, pork sausage, etc.)
214855152|NCT03812705|BIOLOGICAL|fecal microbiome transplantation|"1. Stop antibiotics treatment 1 day before fecal microbiome transplantation;~2. Fasting food 6 hours before fecal microbiome transplantation;~3. Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;~4. Perform fecal microbiome transplantation under colonoscopy or gastroscopy;~5. Perform up to 4 times if patient response;~6. Stop if no response after twice fecal microbiome transplantation."
214855153|NCT01758133|BEHAVIORAL|Exposure to medical clown activities|
214855154|NCT05259501|OTHER|RMIST|"RMIST will involve:~1. A study automated visual recognition web-based platform accessible on the participant's smartphone web browser.~2. A supply of methadone in single use bottles and previously described packaging to be kept securely at the methadone clinic/lab setting."
214855155|NCT04637035|OTHER|Supportive Oncology Care at Home|Intervention entailing remote monitoring of patients' symptoms, vital signs, and body weight with home-based care.
214855156|NCT05506930|DRUG|Intrathecal Morphine|One group of subjects will receive intrathecal morphine: spinal (neuraxial) dose of preservative free morphine (Duramorph), usually about 4-5mcg/kg. This is injected into the cerebrospinal fluid under sterile technique by a pediatric anesthesiologist while the subject is already under general anesthesia. This procedure is well-described in the pediatric population and used regularly for postoperative pain relief for a variety of procedures including ureteral reimplantation.
214855157|NCT05506930|DRUG|Quadratus lumborum block|The second group of subjects will have bilateral quadratus lumborum blocks: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per/ kg per side (total dose approximately 1mL/kg). This is injected in the subject's flank in the fascial plane between the quadratus lumborum muscle and the psoas muscle. Ultrasound guidance is used for needle and structure localization and this procedure is done by a pediatric anesthesiologist while the subject is already under general anesthesia. Quadratus lumborum blocks are regularly used in clinical practice for postoperative pain relief for a variety of abdominal procedures.
214855158|NCT04107402|OTHER|Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay|Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy
214855159|NCT02785653|DRUG|Sevoflurane|Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
214855160|NCT02785653|DRUG|Rocuronium|rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
214855161|NCT01805635|OTHER|No intervention|No intervention
214855162|NCT06651333|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
214855163|NCT05580952|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
214855164|NCT04227938|DRUG|ALPN-101|A single dose of ALPN-101 will be administered via intravenous infusion.
214855165|NCT04172519|OTHER|Pre- and post prostatectomy supervised PMFT|intervention before and after surgery, supervised exercises
214855166|NCT04172519|OTHER|Unsupervised PMFT|intervention after surgery, unsupervised exercises
214855167|NCT04172519|OTHER|Supervised PMFT|intervention after surgery and supervised exercise
214855168|NCT03695848|DEVICE|MRI scan|Before decompresssion surgery, DTI and fMRI will be recorded by a FDA approved 3T MRI scanner (Philips Achieva)
214855169|NCT03181698|DIAGNOSTIC_TEST|Magnetic resonance imaging|"A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls"
214855170|NCT04525638|DRUG|177Lu-Dotatate|7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
214855171|NCT04525638|DRUG|Nivolumab|240 mg flat dose of nivolumab intravenously as a 30-minutes infusion
214855172|NCT03659461|DRUG|Sitagliptin|oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.
214855173|NCT05017974|BEHAVIORAL|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement|MBSR+PS
214855174|NCT05017974|OTHER|Treatment as Usual|TAU
214476429|NCT06648928|BEHAVIORAL|Self Managed PTSD Coach|A widely available mobile application designed to help individuals manage PTSD symptoms available in English and Spanish.
214855175|NCT00396799|DRUG|bazedoxifene/conjugated estrogens|
214855176|NCT00120536|DRUG|vildagliptin|
214855177|NCT02054130|DRUG|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
214855178|NCT02054130|DRUG|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
214855179|NCT02054130|DRUG|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
214855180|NCT02054130|DRUG|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
214476430|NCT06857331|PROCEDURE|Erector Spinae Plane Block using 0.2% ropivacaine|Bilateral thoracic ESP block on the day of the transplantation with a subsequent catheterization will be suggested for the patients. In case of their written consent for the participation in the study this procedure will be performed on the day of the operation. 0.2% ropivacaine is going to be used throughout all the perioperative period.
214664811|NCT04256928|PROCEDURE|Preoperative electrical clipping|Body hair in the operative field will be clipped with an electrical clipper by hospital personnel during preparation to planned surgery.
214855181|NCT02060474|DRUG|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
214855182|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and sunflower oil|High saturated fat meal with a blueberry flavored shake and sunflower oil
214855183|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, blueberry powder and sunflower oil|High saturated fat meal with blueberry powder shake and sunflower oil
214855184|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and DHA|High saturated fat meal with a blueberry flavored shake and DHA
214855185|NCT00015769|DRUG|levetiracetam|
214855186|NCT00094458|BIOLOGICAL|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
214855187|NCT00094458|OTHER|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
214855188|NCT00094458|DRUG|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
214855189|NCT02322619|DRUG|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
214855190|NCT05881902|BEHAVIORAL|HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|"A total of 4 home visits and 2 phone calls will be made by giving awareness training based on the Health Belief Model to the participants in the Intervention 1 group in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made"
214855191|NCT05881902|BEHAVIORAL|STANDART CANCER EDUCATİON|The participants in the intervention 2 group will be given the standard training applied by the Ministry of Health in KETEM for women's cancers during home visits, and a total of 4 home visits and 2 SMS reminders will be made.
214855192|NCT01046552|PROCEDURE|preoperative ERCP and LC|preoperative ERCP followed by LC
214855193|NCT01046552|PROCEDURE|Intraoperative ERCP and LC|LC and intraoperative ERCP
214855194|NCT05695872|PROCEDURE|subtarsal approach|surgical approach
214855195|NCT05695872|PROCEDURE|conventional transconjunctival approach|surgical approach
214855196|NCT05695872|PROCEDURE|transconjunctival approach with Y- modification|surgical approach
214855197|NCT03421756|DRUG|Alemtuzumab|Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
214855198|NCT03421756|RADIATION|Total Body Irradiation|300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
214855199|NCT03421756|DRUG|Sirolimus|Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
214855200|NCT03443193|OTHER|Exercise training|Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
214855201|NCT02276898|DRUG|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
214855202|NCT02276898|DRUG|Isotonic Saline 0.9% (Placebo)|
214855203|NCT00999180|PROCEDURE|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
214855204|NCT00999180|PROCEDURE|Saline and Kinesiotherapy|Saline and Kinesiotherapy
214855205|NCT00046449|DRUG|Investigational Seasonal Affective Disorder (SAD) Drug|
214855206|NCT02765217|DRUG|Lactobacillus reuteri DSM 17938|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
214855207|NCT02765217|DRUG|Placebo|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
214855208|NCT02765217|DRUG|Amoxicillin-Clavulanic Acid|All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
214855209|NCT03822507|DRUG|KHK7580|oral administration
214855210|NCT03822507|DRUG|Cinacalcet Hydrochloride|oral administration
214855211|NCT04569448|DRUG|Brexpiprazole|Adjunctive variable dose (1-3 mg/day) Brexpiprazole
214855212|NCT05841290|PROCEDURE|Primary local anesthesia|Tooth will be anaesthetized using Local anesthesia containing Articaine with epinephrine 1:100,000.
214855213|NCT05841290|PROCEDURE|Supplemental local anesthesia|if needed
214855214|NCT05841290|PROCEDURE|Removal Of Caries and Access Cavity|• Access cavity will be performed using a carbide round steel bur and tapered diamond stone until complete deroofing.
214855215|NCT05841290|PROCEDURE|Rubber dam isolation of tooth|Rubber dam isolation of tooth using certain clamps .
214855216|NCT05841290|PROCEDURE|Bleeding control|bleeding is controlled by using excavator for the removing the pulp tissue . using a piece of cotton soaked with Sodium hypochlorite. using local anesthesia with vasoconstrictor if needed and if suitable for the patient.
214855217|NCT05841290|PROCEDURE|Canal negotiation|Coronal patency of the coronal and the Middle part of the canal using file #10 Apical patency of the apical part of the canal using #10
214855218|NCT05841290|PROCEDURE|Coronal flaring|Coronal flaring using Orifice opener of a certain Rotary system in and out motion first then brushing motion touching all the canal walls
214855219|NCT05841290|PROCEDURE|Working Length Determination (W.L)|Working length determination (W.L) using #10 K File , working length is recorded using apex locator and confirmatory radiograph.
214855220|NCT05841290|PROCEDURE|Glide path|Glide path of the canal Using #10 ,15 ,20 ,25 K files till becoming Super-Loose Inside the Canal at the recorded w.l to create a path for the rotary file .
214855221|NCT05841290|PROCEDURE|Irrigation|Irrigation using 5.25% sodium hypochlorite introduced using side vented needle
214855222|NCT05841290|PROCEDURE|Cleaning and shaping using rotary system|Cleaning and shaping using rotary system plus irrigation and apical patency between every rotary file .
214855223|NCT05841290|PROCEDURE|Second w.l determination|Second w.l determination using electronic apex locator before using final finishing rotary file .
214907021|NCT03718988|BEHAVIORAL|Plant Alternative products|Plant-based alternatives (The Beyond Burger, Beyond Sausage, etc.)
214907022|NCT00548678|DRUG|intravenous diclofenac sodium (DIC075V)|intravenous diclofenac sodium
214907023|NCT00548678|DRUG|ketorolac|intravenous ketorolac
214907024|NCT00548678|DRUG|oral diclofenac (Cataflam)|oral diclofenac (Cataflam)
214855224|NCT05841290|PROCEDURE|Apical gauging|"Establish the depth of apical constriction - this is the zero reading on your apex locator. your working length will be 0.5mm - 1mm short of this.~After cleaning and preparing the canal system to your working length, passively insert 02 taper hand files, starting from #15. If the file goes past the apical constriction (your working length + 0.5-1mm), then choose the next largest file and repeat.~When a file passively binds short of the apical constriction, that will be the upper limit of the apical constriction diameter. The smaller file before that would be the lower limit.~Apical gauging helps with:~Choosing the best master cone that closely matches canal length and taper Achieving true tug back - as opposed to false tug back! Minimising gutta percha extrusions during obturation"
214855225|NCT05841290|PROCEDURE|Activation of the irrigant|Activation of the irrigant using Manual Dynamic Agitation and Ultra x or eddy tips for activation
214855226|NCT05841290|PROCEDURE|Master cone check|Master cone check Clinically and confirmatory radiograph
214855227|NCT05841290|DRUG|application of resin based sealer inside the canal in the resin based sealer group|application done by inserting inside the canal by spreader or master cone
214855228|NCT05841290|DIAGNOSTIC_TEST|application of the sillicon based sealer inside the canal in the sillicon based group|application done by injection inside the canal
214855229|NCT05841290|PROCEDURE|Obturation|done by lateral condensation technique
214855230|NCT05841290|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"Pain is evaluated using visual analogue scale (VAS) which is a pain rating scale. Scores are based on measures that are self-reported of symptoms that are recorded through a single handwritten mark placed at one point along the length of a 10-cm line representing a continuum between the two ends of the scale; on the left end of the scale (0 cm) means no pain and the on the right end of the scale (10 cm) worst pain"
214855231|NCT05483803|BEHAVIORAL|Adhera® Caring digital intervention for Type 1 Diabetes|The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
214855232|NCT03055442|OTHER|Dosage of myo-inositol|Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
214855233|NCT03055442|OTHER|Dosage of D-chiro-inositol|Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
214855234|NCT00834652|DRUG|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
214855235|NCT00834652|DRUG|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
214855236|NCT03762551|OTHER|skin biopsy|Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
214855237|NCT00006472|DRUG|carboplatin|Carboplatin AUC 6 days 1 and 22
214855238|NCT00006472|DRUG|fluorouracil|5FU 225mg/m2 continuous infusion on days 1-42 during radiation
214855239|NCT00006472|DRUG|paclitaxel|taxol
214855240|NCT00006472|PROCEDURE|conventional surgery|
214855241|NCT00006472|RADIATION|radiation therapy|The initial fields should be treated AP:PA when possible to a dose of 4500 cGy in 180 cGy fractions
214855242|NCT06434922|DEVICE|Prevention Strategies|Data collection sessions lasted approximately 1 to 1.50 hours, with education and foot care provided once a month. Subsequently, patients underwent monthly follow-ups for three months, during which they received guidance on foot examination, foot care, dietary habits, physical exercise, and stress management.
214855243|NCT06434922|DEVICE|Standard Strategiies|Group were educated about DM management, medication adherence, dietary practices, physical exercise routines, and foot care through pamphlets
214855244|NCT00349726|DRUG|Inositol lower volume|60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
214855245|NCT00349726|DRUG|Inositol higher volume|120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
214855246|NCT00349726|DRUG|Placebo lower volume|60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
214855247|NCT00349726|DRUG|Placebo higher volume|120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
214855248|NCT01956617|OTHER|lumbar plexus block|
214476431|NCT06660446|OTHER|Exercise|The lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new PE project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic.
214855249|NCT04095949|DIETARY_SUPPLEMENT|Artichokes|Approximately 200 g of cooked artichokes
214855250|NCT03053219|DRUG|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
214855251|NCT00788502|BEHAVIORAL|Healing Touch|
214855252|NCT00788502|BEHAVIORAL|Desensitization Therapy|
214855253|NCT04131543|DRUG|Cabozantinib 20 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
214855254|NCT04131543|DRUG|Cabozantinib 40 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
214855255|NCT04131543|DRUG|Cabozantinib 60 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
214855256|NCT04943159|DRUG|Afamelanotide|Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
214664812|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition|Partial ablation of tumor using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel) and blood and CSF draws for liquid biopsy
214664813|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Thalamotomy|Ablation of VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel) and blood draws.
214664814|NCT07008404|DEVICE|online cognitive behavioral therapy|unguided online cognitive behavioral therapy app
214664815|NCT05563493|OTHER|Treatment group, Chair-Based Exercise Training|"The weights of the elastic bands to be used in the exercises will be determined by the physiotherapist according to the abilities and development of the participants.~The intensity of the exercise will be adjusted according to the dyspnea or fatigue patients feel according to the Modified Borg Scale.~During the exercises, heart rate and oxygen saturation will be measured with a pulse oximeter, and blood pressure will be measured with a sphygmomanometer.~Chair-based exercise training will be applied to the patients every day they are hospitalized."
214664816|NCT05563493|OTHER|Control group, Breathing exercise|Breathing exercise will be applied to the patients every day they are hospitalized.
214664817|NCT03132077|PROCEDURE|total knee arthroplasty|surgical intervention for end stage of knee osteoarthritis
214664818|NCT04790591|PROCEDURE|Same-day surgery|To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.
214664819|NCT05940597|DEVICE|Pulse field ablation|ablation of paroxysmal atrial fibrillation by Pulse field ablation
214664820|NCT05940597|DEVICE|Cryoballoon pulmonary vein isolation|ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation
214664821|NCT07010133|BEHAVIORAL|A workplace-based depression intervention for low-wage hospital workers|This intervention is a remotely delivered workplace-based depression intervention that is tailored to the specific social and behavioral needs of low-wage hospital service workers. The intervention involves assessment of depression-related work impairment, work-focused cognitive behavioral therapy, work coaching, social needs screening and referral, and text message support for mood and physical activity.
214664822|NCT06869187|DRUG|ABX-002|ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
214664823|NCT01901328|DRUG|CB-5945|
214664824|NCT01901328|DRUG|Placebo|
214664825|NCT06620107|DEVICE|noninvasive high frequency oscillation ventilation|"cases of group A extubated on NHFOV, and it will be provided by CNO, Medin device, Germany) via binasal prongs with the following parameters:~* MAP of 6 cmH2O and will be titrated targeting a FiO2 ≤ 25-30%, maximum FiO2 will be 40% and target oxygen saturation will be 90-95%.~* Frequency of 8 Hz and can be changed within the range of 8-12 Hz.~* Amplitude of 7 cmH2O and can be titrated within the range of 7-10 cmH2O according to PaCO2."
214664826|NCT06620107|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be provided by any type of neonatal ventilator available in the unit via binasal prongs starting with the following parameters:~* Positive end expiratory pressure (PEEP) of 5 cmH2O and can be titrated to 8 cmH2O according to the oxygenation .~* Peak inspiratory pressure (PIP) of 15 cmH2O and can be titrated to 25 cmH2O ,according to oxygenation , PaCO2 level and the chest expansion .~* FiO2 ≤ 25-30% and can be increased to 40 % maximally targeting oxygen saturation of 90-95% .~* Inspiratory time of 0.40-0.50 s .~* Rate of 30 bpm and can be increased to maximum 50 bpm .~* Synchronization will not be applied."
214855257|NCT01011075|DRUG|Imatinib mesylate|Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
214855258|NCT01011075|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
214855259|NCT03625518|DRUG|prostaglandins E2|insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction
214855260|NCT03625518|DEVICE|intracervical balloon catheter combined with pitocin|insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
214855261|NCT05991128|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
214855262|NCT05991128|DRUG|Placebo|n the placebo group, patients will receive the equivalent number of normal saline injections.
214664827|NCT07022015|PROCEDURE|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
214664828|NCT07023042|OTHER|Abdominal Kinesio taping|Application of medical-grade Kinesio tape (NKH-50R) to the abdomen using a standardized circular technique, in addition to standard care for malignant bowel obstruction and ascites. Tape is applied by trained professionals after a skin sensitivity test and changed every three days or as needed. The procedure avoids open wounds and tumor sites. Participants and caregivers are educated on tape care and removal.
214855263|NCT04124198|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Accelerated or hyper-fractionated radiotherapy
214855264|NCT04124198|DRUG|Cisplatin|Concurrent weekly cisplatin 40 mg/sqm to fit patients
214855265|NCT04124198|DRUG|Nimorazole.|Concurrent nimorazole
214855266|NCT04124198|PROCEDURE|Transoral Robotic Surgery (TORS) with neck dissection|Robotic-assisted resection of the primary oropharyngeal tumour and ipsilateral selected neck dissection of lymph node levels II-IV. Patients with a primary base of tongue cancer or with significant involvement of tongue base or the soft palate defined as above 1 cm, will be offered a bilateral neck dissection of levels II-IV.
214855267|NCT06217861|BIOLOGICAL|VGM-R02b|Administered as specified in the treatment arm.
214855268|NCT01131793|DEVICE|PowerAssert RF wire in crossing coronary in-stent chronic total occlusions|Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
214476432|NCT06825299|DIAGNOSTIC_TEST|Chest-Tube Insertion|The technique was performed according to a combination of the Chest-Tube Insertion (BTS) guidelines for chest tube insertion and ultrasound (US)-guided technique for chest tube insertion and US-guided pigtail insertion.
214855269|NCT02017860|DRUG|Everolimus|Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
214907025|NCT00548678|DRUG|aspirin|oral aspirin
214855270|NCT06213467|DEVICE|diode laser 940nm|Exposure for the two implants was done at the same visit, with one implant being exposed using diode laser and the other implant using traditional method
214855271|NCT00794391|BEHAVIORAL|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller \& Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
214855272|NCT00794391|BEHAVIORAL|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
214855273|NCT03242460|DRUG|Pomalidomide 4 MG|Pomalidomide 4mg Days 1-21
214855274|NCT03242460|DRUG|Dexamethasone 20mg|Dexamethasone 20mg Days 1, 8, 15, 22
214855275|NCT03242460|DRUG|Cyclophosphamide 400mg|Cyclophosphamide 400mg Days 1, 8, 15
214855276|NCT05579574|DRUG|BMS-986322|Specified dose on specified days
214855277|NCT05579574|DRUG|Loestrin|Specified dose on specified days
214855278|NCT00946348|DRUG|Dronabinol|Dronabinol 10 mg or 15 mg
214855279|NCT00946348|DRUG|Cannabis|Cannabis cigarette
214855280|NCT03743792|DIETARY_SUPPLEMENT|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
214855281|NCT03743792|DIETARY_SUPPLEMENT|Control breakfast|Control drink + buttermilk biscuit sandwich
214855282|NCT03000218|DRUG|Ursodeoxycholic acid|Ursodeoxycholic acid 300mg bid for 8 weeks
214855283|NCT03000218|DRUG|Metformin|Day 29 to 56: Metformin 500mg bid
214855284|NCT03000218|DRUG|Placebo|Day 1 to 56: Placebo bid
214855285|NCT02914093|OTHER|IMT|Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
214855286|NCT01087671|DRUG|tafluprost|prostaglandin analogue
214855287|NCT00378183|DRUG|risperidone|
214855288|NCT00004810|DRUG|-aminosalicylic acid|
214855289|NCT06651294|DIETARY_SUPPLEMENT|Neorenal Forte|This specialized formulation of phytotherapeutic extracts consists of proprietary Betula pendula leaves dry extract, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens. The product contains supplementary ingredients: microcrystalline cellulose, povidone, magnesium stearate, colorant film (brilliant blue FCF, iron dioxide).
214855290|NCT06651294|DIETARY_SUPPLEMENT|Placebo|The placebo product will be identical to the active form and will have the same composition but without the proprietary extract from Betula pendula, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens.
214855291|NCT06052787|DRUG|Cerebrolysin|Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.
214855292|NCT06052787|DRUG|amantadine sulfate|The dopaminergic agonist amantadine enhances presynaptic dopamine release and inhibits dopamine reuptake, resulting in an increased amount of dopamine in the synaptic cleft. Amantadine may also increase the density of postsynaptic dopamine receptors and alter the conformation of these receptors. Amantadine acts as an NMDA receptor antagonist, blocking glutamate, an NMDA channel activator. This effect may be responsible for amantadine's possible beneficial effect soon after TBI
214855293|NCT03865537|PROCEDURE|Cold snare EMR|Participants will have their large polyp removed without electrocautery
214855294|NCT03865537|PROCEDURE|Hot snare EMR|Participants will have their large polyp removed with electrocautery
214855295|NCT03865537|PROCEDURE|Eleview injection|Participants will have their polyp submucosally injected with Eleview
214855296|NCT03865537|PROCEDURE|Placebo injection|Participants will have their polyp submucosally injected with placebo
214855297|NCT00974948|PROCEDURE|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
214855298|NCT01863056|OTHER|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
214855299|NCT01643226|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
214855300|NCT01643226|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
214855301|NCT01643226|DEVICE|KXL System|30 mW/cm2
214476433|NCT05338164|PROCEDURE|cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
214476434|NCT06664918|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of 4-step milk ladder (muffin, pancake,baked hard cheese, yoghurt/pasteurised cow milk or modified cow milk)
214855302|NCT04491357|DRUG|Calcium Gluconate|Intravenous calcium gluconate within 4 hours of skin closure after total thyroidectomy
214855303|NCT04491357|DRUG|Normal saline|Normal saline within 4 hours of skin closure after total thyroidectomy
214855304|NCT00638794|DEVICE|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
214855305|NCT01829113|DRUG|OGX-427|Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
214855306|NCT01829113|DRUG|Placebo|Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
214664829|NCT07023042|OTHER|Standard Care Arm|Standard palliative care for malignant bowel obstruction and ascites, including symptom management, nutritional support, and medical treatment according to institutional protocols.
214664830|NCT07024693|DRUG|DT-168|Active
214664831|NCT00805415|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
214664832|NCT00805415|DRUG|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
214664833|NCT07030881|DRUG|pMDI Triple Inhaler and Spacer|Participants in this group will use a valved mouthpiece spacer in combination with standard triple inhaled therapy delivered by a pressurized metered-dose inhaler (ICS/LABA/LAMA). The spacer device helps reduce the need for hand-breath coordination, prolongs aerosol suspension time, and improves drug delivery to the lungs. Participants will be trained in proper spacer use, including device attachment, timing of actuation and inhalation, mouth seal technique, cleaning, and daily maintenance. This intervention aims to optimize inhalation technique, improve treatment adherence, and potentially reduce the incidence of moderate-to-severe exacerbations.
214664834|NCT07030881|DRUG|pMDI Triple Inhaler Only|Participants in the control group will receive a standard fixed-dose combination of inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA) administered via pressurized metered-dose inhaler (pMDI). No spacer will be used. All participants will receive standardized inhalation technique training at baseline, including hand-held device usage, actuation-inhalation timing, breath-hold, and mouth rinsing. This group represents the current standard-of-care for stable, high-risk COPD or asthma patients as per GOLD and GINA guidelines.
214664835|NCT07030946|BEHAVIORAL|Multimedia Health Education|A 10-minute multimedia video is provided to the intervention group during their final preoperative clinic visit. All participants receive standard verbal and printed education from the ophthalmologist. The video includes visual and auditory content on cataract surgery, preoperative instructions, postoperative care, and common concerns. Baseline data (T0) are collected before the intervention, including demographics, visual acuity, physiological indicators, BAI, and self-care knowledge. Follow-ups occur at T1 (surgery day), T2 (1 week postop), and T3 (1 month postop), assessing anxiety, physiology, vision, and self-care.
214664836|NCT07031206|DRUG|Paracervical block- Lidocaine without epinephrine|1-2 cc of Lidocaine at the tenaculum site on the cervix at 12 o-clock will be injected after pain scale #1 is completed. Pain scale #2 will be done then 3 cc of 1% lidocaine at 4 and 8 o'clock position of the cervix will be administered. The IUD insertion or EMB will be performed nd pain scale #3 will be done.
214664837|NCT07031206|DRUG|Benzocaine Gel applied to the cervix|After pain scale #1 is performed , topical benzocaine will be applied to the cervix with Procto swabs and this will be allowed to remain on cervix for 203 minutes. Then Betadine will be applied to the cervix and surrounding vaginal tissue followed by pain scale #2. IUD insertion or EMB will be done followed by pain scale #3.
214664838|NCT07031206|DRUG|Hydroxyzine Hydrochloride|Preprocedure, a GAD 7 scoring will be performed to determine level of anxiety. If \> 10 indicating Moderate anxiety, participants will be offered pretreatment with Anxiolytic (Hydroxyzine 25mg) approximately 15-20 mins before procedure. If this is done at the preceding visit, participants will be sent home with a prescription for hydroxyzine to be taken 10-15 mins before the procedure when participants are brought back for procedure visit.
214664839|NCT07030556|OTHER|Healthy Sleep Intervention|This intervention has a duration of nine weeks and starts with a kick-off event where the students of the action group provide explanations to fellow students. Furthermore, the intervention is structured in five themes of approximately two weeks each: 1) importance of healthy sleep, 2) sleep and wake cycle, 3) screen time, 4) exercise and nutrition and 5) screen use and mental well-being. Three posters are provided for each theme, five to seven Instagram posts and a class discussion. In addition, healthy sleep is explained during the biology lesson. Furthermore, a competition between classes is organized to sleep as well as possible with the help of an app, classes are given a planner to visualize the workload of school tasks, exercise snacks will be introduced during the lessons and students are given a notebook to write things down in case of worrying. Finally, a closing moment is provided. Flyers with information about healthy sleep in young people are distributed to parents.
214664840|NCT07030556|OTHER|Co-creation process|co-creation process with students and teachers: to adapt the existing intervention to the needs of the school. For this, schools can recruit 6 to 8 students via purposeful sampling to form an action group. They will be asked to participate in two sessions during the lunch break in which 1) the needs of the students at school in relation to healthy sleep are mapped out and the goals of the already developed intervention are supplemented or not based on the needs 2) a choice is made from the already developed intervention components 3) necessary adjustments are made to intervention components.
214664841|NCT07030556|OTHER|Training for teachers|implementation of the implementation intervention for teachers. The implementation intervention consists of a one-off training for all teachers of the 1st and 2nd year of secondary school in which the importance of sleep and the intervention and its materials are explained. A manual per theme is then provided to the teachers who will implement components (see also appendix 'Manual Sleep Project'). Consultation moments will be planned in consultation to discuss the progress of the implementation.
214855307|NCT06097793|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
214855308|NCT02770105|OTHER|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
214855309|NCT02770105|OTHER|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
214855310|NCT02770105|OTHER|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
214855311|NCT02770105|OTHER|Placebo|Oral administration of 200ml of distilled water
214855312|NCT06301061|DEVICE|Equistasi®|Four devices will be attached to the skin according the indication of the investigators for 6 hours/day every day except Thursday and Sunday
214664842|NCT07031076|DIETARY_SUPPLEMENT|Ready-to-eat lean pork in frozen, 5-oz packages|The dietary intervention lasts 16 weeks for each individual. Participants in the experimental group will receive this intervention. Each participant will acquire 4 portions of ready-to eat lean pork in frozen packages per week; each portion of ready-to-eat lean pork in this intervention will weigh 5 ounces.
214855313|NCT06301061|DEVICE|Sham|Four devices similar to the active one but not able to deliver the microvibration will be applied to the patients
214855314|NCT06301061|DRUG|Gabapentin; Pregabalin; Duloxetine; Amitriptyline|Patients will be treated with drugs (gabapentinoids, Serotonin-norepinephrine reuptake inhibitor, tricyclic antidepressants, opioids) according to guidelines.
214855315|NCT01570348|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
214855316|NCT01570348|DRUG|Cyclophosphamide|Given IV
214855317|NCT01570348|DRUG|Fludarabine Phosphate|Given IV
214855318|NCT01570348|OTHER|Laboratory Biomarker Analysis|Correlative studies
214855319|NCT01570348|DRUG|Mycophenolate Mofetil|Given PO
214855320|NCT01570348|DRUG|Mycophenolic Acid|Given PO
214855321|NCT01570348|OTHER|Quality-of-Life Assessment|Ancillary studies
214855322|NCT01570348|DRUG|Tacrolimus|Given IV or PO
214855323|NCT01570348|RADIATION|Total-Body Irradiation|Undergo TBI
214855324|NCT02563717|DEVICE|T-piece used for respiratory support (several manufacturers)|Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
214855325|NCT02563717|DEVICE|New system used for respiratory support|Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
214855326|NCT02909738|OTHER|Volunteer to pedal a bicycle|
214855327|NCT01490931|DRUG|Ketorolac Nasal Spray|15.75 mg nasal spray delivery to each nostril no more than every six hours
214855328|NCT04293094|DRUG|AMG 650|AMG 650 administered orally as a tablet.
214855329|NCT06531369|DRUG|Flumazenil Injection（F1 group）|Flumazenil Injection（F1 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
214855330|NCT06531369|DRUG|Flumazenil Injection（F2 group）|Flumazenil Injection（F2 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later.
214855331|NCT06531369|DRUG|Saline（C group）|Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
214855332|NCT06612918|DEVICE|high-intensity laser acupuncture and the exercise program|The experimental group will receive high-intensity lasers, and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40, and GB30. Exercises program: The patients will perform this exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises; and stretching exercises.
214855333|NCT06612918|OTHER|sham laser acupuncture and the exercises program|The patients will receive a sham laser acupuncture and the exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises and stretching exercises.
214855334|NCT03581214|OTHER|No oxygen|No facemask, room air only
214855335|NCT03581214|OTHER|Oxygen|10Liters/minute oxygen by facemask
214855336|NCT06806878|OTHER|Progressive muscle relaxation|We will apply progressive muscle relaxation exercises to reduce nursing students' anxiety about intramuscular injection administration
214855337|NCT05536830|OTHER|Nutrition Status|Participants will be examined by a registered dietitian to assess nutrition status.
214855338|NCT05004350|DRUG|Encorafenib|oral hard capsule
214855339|NCT05004350|DRUG|Cetuximab|intravenous infusion
214855340|NCT05004350|DRUG|FOLFIRI|"Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion"
214855341|NCT03729154|BEHAVIORAL|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
214476435|NCT06664918|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of 6-step milk ladder (cookie, muffin, pancake,baked hard cheese, yoghurt, pasteurised cow milk or modified cow milk)
214855342|NCT04736108|DRUG|Abiraterone acetate|1000 mg orally daily for 24 weeks before radical prostatectomy
214855343|NCT04736108|DRUG|Prednisolone|5 mg oral low dose prednisone, once daily
214855344|NCT04736108|DRUG|Goserelin|10.8 mg goserelin hypodermic once per 12 weeks
214855345|NCT06577051|DIAGNOSTIC_TEST|Eustachian tube function test with 226 and 1000 Hz probes|In children undergoing tonsillectomy ± adenoidectomy without eustachian dysfunction, tympanometry with 226 Hz and 1000 Hz probes, ipsi and contralateral acoustic reflexes with 226 Hz probe, eustachian function test with 226 Hz probe (automatic Williams test) and play audiometry in young children and pure tone audiometry in older children are aimed to control tubal functions in preoperative period, postoperative day 1 and week 2.
214855346|NCT00650988|PROCEDURE|Cryospray Ablation|Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
214855347|NCT02603978|BEHAVIORAL|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
214855348|NCT02603978|BEHAVIORAL|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
214855349|NCT02603978|BEHAVIORAL|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
214855350|NCT05730907|DRUG|Levosimendan|examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR
214855351|NCT03736759|BEHAVIORAL|Exercise|10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
214855352|NCT00232271|DRUG|Clexane|
214855353|NCT04273282|DRUG|Dexycu intracameral dexamethasone|To evaluate the safety and ocular efficacy of Dexycu.
214855354|NCT04273282|DRUG|Prednisolone Acetate|To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
214855355|NCT03808740|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day.
214855356|NCT03808740|DRUG|Placebo|sugar pill
214855357|NCT06123260|DIAGNOSTIC_TEST|renal function tests|BUN, eGFR , CBC , Electrolytes , Liver function tests
214855358|NCT02010255|DRUG|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
214855359|NCT02010255|DRUG|RBV|RBV tablets administered orally in a divided daily dose
214290380|NCT05856201|PROCEDURE|Shull technique via V-NOTES|Using a cold-bladed scalpel, pericervical colpotomy and subsequent opening of the Douglas and vesico-uterine space is performed. The following step is forcipressure and section of uterosacral ligaments bilaterally with cold blade scissors and ligation in Polysorb 0. A v-PATH® wall retractor is placed, after insertion of three trocars. Total hysterectomy is then performed by standard V-NOTES technique. After transperitoneal visualization of the ureters bilaterally, the peritoneum is incised between the ureters and the uterosacral ligaments, which are thus bilaterally isolated, and three points in polydioxanone 2/0 are placed per side. The v-PATH wall retractor is then removed. Finally the suspension of the vaginal vault at the uterosacral ligaments is made according to Shull technique. Eventual fascial corrections of concomitant anterior or posterior defects will be associated if needed.
214476436|NCT06597604|DEVICE|Intraoperative use of TenaTac in lung surgery|Use of innovative medical device : TenaTac
214476437|NCT06597604|DEVICE|Intraoperative use of usual sealant in lung surgery|Use of the usual scealant as a control
214664843|NCT07031999|COMBINATION_PRODUCT|PLA spacer|This is a phase 1/2 prospective, interventional, non-randomized, single-arm clinical study designed to evaluate the safety of using temporary articular spacers printed in PLA (polylactic acid) impregnated with vancomycin in patients with periprosthetic infections of the hip, knee, or shoulder.
214664844|NCT07032103|DRUG|Immunochemotherapy|Systemic chemotherapy with curative intent
214664845|NCT07030803|OTHER|Oxybutynin|oxybutynin
214664846|NCT07030803|DEVICE|medical device Urostim|medical device used to deliver posterior tibial nerve stimulation (PTNS)
214664847|NCT07032155|DEVICE|Resynk VR session|The study will use hardware and software to achieve this immersive virtual reality. The Resynk Virtual Reality programme (software) and the Meta Quest Virtual Reality Headset (hardware) will be used. Immersive virtual reality (VR) is when technology makes you feel like you're inside a different world. You wear a virtual reality headset that covers your eyes and ears, showing you a 3D world and playing matching sounds. The headset's head tracking, changing the view in the VR world as you look around. You can then interact with this virtual reality world depending on the application or game you use. The Resynk VR software launches automatically, guiding them through therapist-designed games that make rehabilitation engaging. The system uses advanced hand-tracking technology, eliminating the need for physical controllers. It detects joint movements in the hands and fingers, allowing users to perform key rehabilitation exercises such as supination, pronation, grasping, and pinching.
214664848|NCT07032155|OTHER|Using Resynk VR on stroke survivors|The Resynk Virtual Reality programme (software) and the Meta Quest Virtual Reality Headset (hardware) will be used by Occupational therapy participants to treat the stroke survivor participants
214855360|NCT04688047|BEHAVIORAL|Nursing care based on the transtheoretical model|Nursing care consists of urinary incontinence training, motivational interview and telephone/mail counseling processes.
214855361|NCT00867048|DRUG|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
214855362|NCT02382367|OTHER|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
214855363|NCT03261362|DIETARY_SUPPLEMENT|Branched-chain amino acids reduced intake|
214855364|NCT06297525|DRUG|STP938|Small molecule
214855365|NCT04528576|DEVICE|Dragonfly mitral valve repair system|With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
214855366|NCT04789967|BEHAVIORAL|Guided Imagery|Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
214855367|NCT04789967|BEHAVIORAL|Progressive Muscle Relaxation|Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.
214855368|NCT04789967|OTHER|Educational Audiobook|Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
214855369|NCT00977431|DRUG|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
214855370|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
214855371|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
214855372|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
214855373|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
214855374|NCT01010750|DRUG|Lisdexamfetamine Dimesylate (LDX)|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
214855375|NCT01010750|DRUG|Immediate Release Mixed Amphetamine Salts (MAS-IR)|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
214855376|NCT01010750|DRUG|LDX Placebo + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
214855377|NCT03381937|OTHER|speech trial|speech trial during different ventilation conditions
214855378|NCT03223454|BIOLOGICAL|hAECs|hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
214855379|NCT03223454|BIOLOGICAL|biological amnion|Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
214855380|NCT05519657|OTHER||
214855381|NCT06305520|DEVICE|Investigational medical device (SkinPlus-HYAL Implant Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
214855382|NCT06305520|DEVICE|Active Comparator: Active Comparator Medical Device (RESTYLANE Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
214855383|NCT05308680|BIOLOGICAL|BNT162b2|Administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19
214855384|NCT02399631|OTHER|Enhanced recovery program|Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
214855385|NCT01758341|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
214855386|NCT01758341|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
214855387|NCT01758341|DEVICE|HabibTM EndoHPB catheter|"Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)"
214855388|NCT04701034|DRUG|Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)|infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
214855389|NCT04701034|DRUG|Prednisolone Tablets|5 mg before ET and 10 mg after ET until gestational week 8+0
214855390|NCT04701034|DRUG|Human Albumin Solution|Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
214855391|NCT04701034|DRUG|Placebo tablet|1 tablet before ET and 2 tablets after ET until gestational week 8+0
214855392|NCT00161681|DRUG|Levonorgestrel/Ethinyl Estradiol|
214855393|NCT02983032|BEHAVIORAL|BBTI|3 group sessions over 4 weeks
214855394|NCT03143387|OTHER|Caries removal using only manual instruments|Caries removal using only manual instruments according to Atraumatic Restorative Treatment
214855395|NCT03143387|OTHER|Caries removal using Papacarie gel|Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
214855396|NCT03979833|GENETIC|Whole exome sequencing|DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
214855397|NCT04676815|PROCEDURE|NBI and interventional bronchoscopy|NBI used to enhance the contrast between the mucosal surface and underlying blood vessels
214855398|NCT00036647|DRUG|Tarceva (erlotinib HCl, OSI-774 )|
214855399|NCT03069677|OTHER|music|patients in this group will receive research-selected music after the golden moment has been completed between the patient, provider, and nursing staff
214855400|NCT03069677|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
214855401|NCT05470933|DRUG|WJ01075|"Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials."
214855402|NCT00469053|DRUG|Buprenorphine|
214855403|NCT04659551|DRUG|Epirubicin|Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
214855404|NCT04659551|DRUG|Cyclophosphamide|Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
214855405|NCT04659551|DRUG|Triptorelin|Triptorelin 3.75 mg i.m. every 4 weeks until surgery
214855406|NCT04659551|DRUG|Exemestane|Exemestane 25 mg oral continuous daily dose until surgery
214855407|NCT04659551|DRUG|Nivolumab|Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
214855408|NCT05331183|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
214855409|NCT05331183|DRUG|IVA|Tablets for oral administration.
214855410|NCT00518882|DRUG|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
214855411|NCT00518882|DRUG|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
214855412|NCT01295086|DRUG|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
214855413|NCT01295086|DRUG|Oxaliplatin|100 mg/m² day 1 every 3. week
214855414|NCT01295086|DRUG|Capecitabine|1250 mg/² continuously
214290381|NCT05931159|OTHER|Abdominal Hypopressive Training|"Week 1 and 2 - Patient education , Hypopressive Maneuvers in Standing, Sitting and Supine 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week.~Week 3 and 4, Hypopressive breathing in with varying arm movements along with Week 1 and 2 protocols.~Week 5 to 8 - Hypopressive breathing in kneeling, Four-point kneeling and sitting, and supine positions with varying arm movements 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week."
214855415|NCT01295086|DRUG|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
214664849|NCT07032142|DRUG|I-01/23|The I-01/23 will be administered over a 5-day period, with dosing adjusted according to the patient's body surface area (BSA).
214664850|NCT07031011|BIOLOGICAL|PD-1-M1-NK Cells|At dose escalation stage, four dose groups were initially determined: 5×106CAR NK cells/kg, 1×107CARNK cells/kg, 2×107CARNK cells/kg, and 5×107 CARNK cells/kg. Administration cycle: In Cycle 1 (C1), the drug was administered once on days 1, 4, 7, 10 and 13 respectively. A complete cycle was formed by five consecutive administrations. For subjects with stable, partial response or complete response in the tumor assessment at the first time in week 4, the treatment in Cycle 2 will continue subsequently. In Cycle 2, the drug was administered once every two weeks (Q2W: D14±7 days and D28±7 days).
214664851|NCT07030296|BEHAVIORAL|Sprint Training With Weighted Vest|Participants performed a sprint training program wearing a weighted vest equal to approximately 10% of their body weight. The program lasted 6 weeks and included 16 sessions of linear and change-of-direction sprint drills. The goal was to examine whether the added external load improved running speed over 30 and 60 yards.
214664852|NCT07030296|BEHAVIORAL|Sprint Training Without Weighted Vest|Participants completed the same sprint training program as the experimental group but without the use of a weighted vest. The intervention lasted 6 weeks and consisted of 16 sessions including sprint and agility exercises. This group served as the control condition to assess the effect of external resistance.
214664853|NCT07030816|DEVICE|Guardner Belt|The Guardner Belt is a commercially available elastic lumbar support belt designed to reduce low-back pain and improve posture. Participants wore the belt sized according to waist circumference for at least 8 hours per day during working hours for 4 weeks.
214664854|NCT07030114|DIAGNOSTIC_TEST|complete blood tests|"Complete Blood Count (CBC): Using automated hematology analyzers to measure various blood cell parameters.~* C-Reactive Protein (CRP): Quantitative analysis using immunoturbidimetric assay.~* Erythrocyte Sedimentation Rate (ESR): Measured using the Westergren method.~* Coagulation profile:~* Prothrombin Time (PT): Using thromboplastin reagents and automated coagulation analyzers.~* Activated Partial Thromboplastin Time (aPTT): Using phospholipid-based reagents and automated analyzers.~* International Normalized Ratio (INR): Calculated from PT results.~* Bleeding Time: Ivy method or template bleeding time.~* Liver function tests: Including ALT, AST, ALP, bilirubin using spectrophotometric methods.~* Kidney function tests: Creatinine and BUN using enzymatic methods."
214855416|NCT04669548|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
214855417|NCT05373381|DIETARY_SUPPLEMENT|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Following a screening period, subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles. Patients will receive dietary advice from a Registered Dietitian (RD) to allow for the design of personalized meal plans maintaining carbohydrates up to 33% of total caloric intake, and be asked to maintain a daily dietary log. To assist patients in understanding, monitoring and controlling their dietary choices to maintain a low carbohydrate diet, they will be trained and receive assistance on the use of an online tool for tracking nutrition \[Healthtrac\].
214855418|NCT05271136|OTHER|Anti-aging Serum|Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers
214855419|NCT05271136|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after serum
214855420|NCT05271136|OTHER|Cleansing Lotion|Facial cleansing lotion to be used by study participants
214855421|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of serum in the morning. Participants were asked to reapply every 2 hours
214855422|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of facial moisturizer in the morning. Participants were asked to reapply every 2 hours
214855423|NCT02138981|PROCEDURE|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
214855424|NCT02138981|PROCEDURE|Immediate Resection|patients received immediate surgical resection.
214855425|NCT05044728|DRUG|Anti-PD-1 antibody combined with Paclitaxel and carboplatin.|"Anti-PD-1 antibody, 240 mg, IV infusion for 30min (not less than 20min and not more than 60min), d1, every 3 weeks for total 2 cycles. Stratified regimen: group A, 24 hours after the end of chemotherapy; Group B will be given immunotherapy on the first day of each cycle.~Paclitaxel, 135 mg/m2, IV, d1, q3w, for total 2 cycles. Carboplatin, AUC=5 (according to Calvert formula), IV, d1, every 3 weeks for a total of 2 cycles. Stratified regimen: group A, chemotherapy will be given on day 1 of each cycle; Group B will be given chemotherapy drugs 24 hours after the end of immunotherapy."
214855426|NCT05044728|PROCEDURE|Surgical treatment stage|After the completion of neoadjuvant immunochemotherapy, patients will be tested again for the functional subsets of peripheral CD8 positive T cells. Alternative treatments will be sought for inoperable patients. For patients who are operable will receive minimally invasive or open surgery was performed 1 month after completion of neoadjuvant chemotherapy immunotherapy, and the functional subsets of peripheral CD8 positive T cells were detected again after surgery.
214855427|NCT05540873|DRUG|YYB-103|Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
214855428|NCT01849016|DRUG|N-Acetylcysteine|
214855429|NCT01849016|DRUG|Placebo|
214855430|NCT01397617|DEVICE|NobelActive Internal implant|Dental implant
214855431|NCT01397617|DEVICE|NobelActive External implant|Dental implant
214855432|NCT01397617|DEVICE|NobelReplace Tapered Groovy implant|Dental implant
214855433|NCT00006263|BIOLOGICAL|filgrastim|
214855434|NCT00006263|DRUG|carboplatin|
214855435|NCT00006263|DRUG|temozolomide|
214855436|NCT01130779|DRUG|Erlotinib (TARCEVA®)|Erlotinib 150mg/day, everyday
214855437|NCT01702077|PROCEDURE|Neurofeedback|
214855438|NCT01702077|PROCEDURE|Sham feedback|
214855439|NCT00168090|DRUG|Blood coagulation Factor VIII and vWF, human|
214855440|NCT06817538|BEHAVIORAL|Physiotherapy/Exercise Program|"Arm 1: Scoliosis-Specific Exercises Combined with Dual-Task Cognitive Training Participants with idiopathic scoliosis in this group received scoliosis-specific physiotherapeutic exercises combined with dual-task cognitive training. The intervention included motor exercises performed on balance boards and stability trainers to enhance postural control. While engaging in these motor exercises, participants simultaneously performed cognitive tasks such as word recall, identifying cities or countries starting with a given letter, and other memory-based games. This dual-task approach aimed to improve both motor and cognitive functions.~Arm 2: Scoliosis-Specific and Motor Exercises Only~Participants with idiopathic scoliosis in this group performed scoliosis-specific physiotherapeutic exercises along with motor exercises aimed at improving postural stability. The motor exercises were conducted using balance boards and stability trainers, focusing solely on physical performance without the"
214855441|NCT02758860|PROCEDURE|Colonoscopy|Patients will be submitted to diagnostic colonoscopy
214855442|NCT00567476|DRUG|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
214855443|NCT00567476|DRUG|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent
214855444|NCT00567476|DRUG|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
214855445|NCT00567476|DRUG|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
214855446|NCT00004876|DRUG|carboplatin|
214855447|NCT00004876|DRUG|thalidomide|
214855448|NCT04845620|DRUG|ARQ-151 Active|ARQ-151 Cream 0.05% - Active
214855449|NCT04845620|DRUG|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
214855450|NCT02696031|DRUG|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
214855451|NCT02696031|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
214855452|NCT04658316|BEHAVIORAL|Iowa Oral Performance Instrument|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
214855453|NCT04047563|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
214855454|NCT04047563|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
214855455|NCT04432519|PROCEDURE|Immediate dental implant placement|Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
214855456|NCT05339646|DRUG|SSD8432 dose 1~7 and Ritonavir|"Cohort 1 Period 1 single dose of SSD8432 dose 1 or placebo, on day 1. Period 2: single dose of SSD8432 dose 2 or placebo , on day 7. Period 3: single dose of SSD8432 dose 3 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 2:~Period 1 single dose of SSD8432 dose 4 or placebo, on day 1 Period 2: single doses of SSD8432 dose 5 or placebo , on day 7 Period 3: single dose of SSD8432 dose 6 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 3:~single dose of SSD8432 dose 7 or placebo on day1. ritonavir or placebo, before SSD8432 dose 7 and BID on SSD8432 dosing date."
214855457|NCT05339646|DRUG|SSD8432 dose 8~9|Cohort 4: SSD8432 dose 8 or placebo, on day 1 \~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 \~day6.
214855458|NCT05339646|DRUG|SSD8432 dose 10~12 and ritonavir|Cohort 6: SSD8432 dose 10 or placebo, on day 1 \~day6. Cohort 7: SSD8432 dose 11 or placebo, on day 1 \~day6. Cohort 8: SSD8432 dose 12 or placebo, on day 1 \~day6 Cohort 9: to be decided
214855459|NCT05339646|DRUG|SSD8432 dose 13 and Ritonavir|"Cohort 10:~Group A: SSD8432 dose 13, on day1 under fasting condition, on day 6 under fatty food condition, ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date.~Group B: SSD8432 dose 13, on day1 fatty food condition, on day 6 under fasting condition ,Ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date"
214855460|NCT05339646|DRUG|SSD8432 dose 14 and Ritonavir|Cohort 11: to be decided
214855461|NCT05420779|DRUG|TSL-1502 capsules(low dose)|350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
214855462|NCT05420779|DRUG|TSL-1502 capsules(high dose)|500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
214855463|NCT05420779|DRUG|Investigator's choice of chemotherapy|Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip (15 \~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 \~ 5 min)
214855464|NCT00802282|DRUG|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
214855465|NCT00802282|BEHAVIORAL|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
214855466|NCT00802282|BEHAVIORAL|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
214855467|NCT01473576|DIETARY_SUPPLEMENT|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
214855468|NCT01473576|DIETARY_SUPPLEMENT|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
214855469|NCT03758482|OTHER|Probe meal|The probe meal (total caloric content 750 Kcal) will be ingested at a standard rate in 10 min.
214855470|NCT04948294|DEVICE|Channeled blade|In the present group, a tracheal tube was launched in the channel of the blade before tracheal intubation
214855471|NCT04948294|DEVICE|Non-channeled blade|In the present group, a tracheal tube was not launched in the videolaryngoscope blade before tracheal intubation
214855472|NCT05125731|BEHAVIORAL|Parental absence|Parent does not accompany the child during dental treatment
214907026|NCT04667637|DRUG|edaravone dexborneol|Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
214855473|NCT05125731|BEHAVIORAL|Parental visual support|The parent does not accompany the child during the dental treatment but watches behind the glass and is seen by the child.
214855474|NCT05125731|BEHAVIORAL|Parental presence|Parent accompanies the child during dental treatment
214855475|NCT02480231|DEVICE|Retropubic Midurethral Sling|
214855476|NCT04303702|DRUG|Continue Oxytocin|The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
214855477|NCT04303702|OTHER|Discontinue Oxytocin|Patients will have their oxytocin discontinued in the second stage of labor. The patient will receive routine maintenance IV fluids per the discretion of the provider.
214855478|NCT02074267|DRUG|Carbatin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
214855479|NCT02074267|DRUG|Neurontin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
214855480|NCT06388837|OTHER|Injectable Platelet Rich Fibrin|Patients underwent mandibular symphysis Onlay bone graft mixed with injectable platelet rich fibrin (I-PRF) placement.
214855481|NCT06388837|OTHER|Xenograft|Patients underwent mandibular symphysis Onlay bone graft mixed with Xenograft (InterOss® Anorganic Cancellous Granules).
214855482|NCT01677013|OTHER|BMMCT|Bone marrow mononuclear cell transplantation via selective catheterization
214855483|NCT02135406|BIOLOGICAL|CART-19 T cells|
214855484|NCT03352752|DEVICE|HTC Vive|Wearing VR helmet before operation
214855485|NCT03352752|OTHER|Without HTC Vive|Wearing a blindfold before operation
214855486|NCT01094028|DRUG|Oxytocin|20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
214855487|NCT02787317|DRUG|bivalirudin|Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
214855488|NCT02787317|DRUG|Heparin|Heparin is used in patients undergoing percutaneous coronary intervention.
214855489|NCT00308126|DRUG|Hydroxyethyl Starch 130/0.4 (Voluven)|
214855490|NCT06616207|DRUG|Placebo|Placebo (Double distilled water matched in color and taste) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
214855491|NCT06616207|DRUG|Povidone-iodine solution|Povidone-iodine solution will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
214855492|NCT05009732|DRUG|GT0918|300mg once daily orally
214855493|NCT05009732|DRUG|Standard of care|Local standard of care per written policies or guidelines
214855494|NCT05009732|DRUG|Matching placebo|Matching placebo
214855495|NCT02593227|BIOLOGICAL|Low dose FRα vaccine|165ug per peptide ID injection
214855496|NCT02593227|DRUG|Cyclophosphamide|IV infusion over 1 hour
214855497|NCT02593227|BIOLOGICAL|High dose FRα vaccine|500ug per peptide ID injection
214855498|NCT02172482|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
214855499|NCT02777918|BEHAVIORAL|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
214855500|NCT04711720|DEVICE|"VTS surgical navigation system"|"TheVTS surgical navigation system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track the surgical instruments during the operation, and update the position of the surgical instruments on the patient's image in real time, so that the doctor can clearly understand the position of the surgical instruments relative to the patient's anatomical structure, and make the operation procedure more accurate and safer."
214855501|NCT00416026|BEHAVIORAL|Educational/Counseling/Training|
214855502|NCT00616174|PROCEDURE|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
214855503|NCT00976794|DRUG|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
214855504|NCT00976794|DRUG|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
214855505|NCT00632086|DRUG|PA32540|
214855506|NCT00632086|DRUG|aspirin component of PA32540|The 325 mg aspirin component of PA32540
214855507|NCT00632086|DRUG|Ecotrin|325 mg Ecotrin
214907027|NCT00839488|DRUG|pantoprazole 40 mg iv|pnatoprazole 40 mg iv qd
214907028|NCT00839488|DRUG|famotidine 20 mg iv|famotidine 20 mg q12h
214855508|NCT06601621|COMBINATION_PRODUCT|electroacupuncture+ self-acupressure|"Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi; is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2/10Hz for 30 minutes. self-acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi; for three minutes."
214855509|NCT06601621|COMBINATION_PRODUCT|sham electroacupuncture + sham self-acupressure|"Sham electroacupuncture: The sham electroacupuncture shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi; sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
214855510|NCT00488813|DRUG|Third generation cephalosporins|
214855511|NCT02116517|DIETARY_SUPPLEMENT|green tea extract|500 mg three times per day
214855512|NCT02116517|DIETARY_SUPPLEMENT|Placebo|cellulose 500mg three times a day for 6 weeks
214855513|NCT02815202|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-034)
214855514|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
214855515|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
214855516|NCT04352608|BIOLOGICAL|Two doses of placebo at the emergency vaccination schedule|Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.
214855517|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.
214855518|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ
214855519|NCT04352608|BIOLOGICAL|Two doses of placebo at the routine vaccination schedule|Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.
214855520|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
214855521|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
214855522|NCT04352608|BIOLOGICAL|Three doses of placebo at the emergency vaccination schedule|Three doses of placebo at the schedule of day 0,14,42
214855523|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
214855524|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
214855525|NCT04352608|BIOLOGICAL|Three doses of placebo at the routine vaccination schedule|Three doses of placebo at the schedule of day 0,28,56
214855526|NCT00058214|DRUG|perifosine|Given orally
214855527|NCT00058214|OTHER|laboratory biomarker analysis|Correlative studies
214855528|NCT05279508|BEHAVIORAL|Make My Day - stroke prevention program|A stroke prevention program within primary healthcare
214855529|NCT05283603|DIAGNOSTIC_TEST|ECG, Echocardiogram, Magnetic resonance|Clinical and instrumental follow-up
214855530|NCT04608799|DRUG|Perampanel|Efficacy of epilepsy drugs
214855531|NCT00442754|BIOLOGICAL|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
214855532|NCT00411398|DRUG|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
214855533|NCT04478461|DRUG|PD-1 monoclonal antibody|"The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W"
214855534|NCT05698927|PROCEDURE|Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)|Comparison of the postoperative opioid consumptions between Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
214855535|NCT00135382|DRUG|Videx EC|
214855536|NCT00135382|DRUG|Epivir|
214855537|NCT00135382|DRUG|Sustiva|
214855538|NCT04038086|DIAGNOSTIC_TEST|oral glucose tolerance test|Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
214855539|NCT04038086|OTHER|circadian rhythm|Blood and CSF will be collected five times throughout the day.
214855540|NCT04038086|DRUG|effect of insulin on peptide transport|Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
214907029|NCT05782933|DRUG|Rituximab|Rituximab combined with or without cyclosporine
214907030|NCT05782933|DRUG|Modified Ponticelli regimen|Corticosteroid and cyclophosphamide
214855541|NCT04649450|OTHER|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed just before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days at the neurosurgical ward they will receive music twice a day for 30 minutes.
214855542|NCT04053413|OTHER|Decision Aid|The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
214855543|NCT05470764|DRUG|PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
214855544|NCT05470764|DRUG|TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
214855545|NCT03808870|DRUG|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
214855546|NCT05106543|DEVICE|Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients|Kinesiological Taping
214855547|NCT00247299|DEVICE|IPL Quantum Product manufactured by Luminis Ltd.|
214855548|NCT04223999|PROCEDURE|Skullremodeling surgery|"Strategically placed cranial burrholes in order to improve the TTField dose focally in the tumor."
214855549|NCT04223999|OTHER|Control|Tumor treating fields combined with best medical treatment.
214855550|NCT05423470|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
214855551|NCT05423470|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
214855552|NCT00455442|DRUG|Mifepristone|
214855553|NCT01606852|DRUG|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
214855554|NCT05451732|PROCEDURE|Nanofat grafting|Naofat grafting in the urethral stricture. The autologous adipose tissue is transferred by injection and in this way, the access to the urethral stricture is carried out with a minimal incision of the male urethra while in the female urethra is transferred exclusively with injections, without incision of urethral tissue.
214855555|NCT02159937|OTHER|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
214855556|NCT03856593|BEHAVIORAL|Standard letter|The standard letter will be signed by the Chief Medical Examiner-Coroner and County Health Officer of Los Angeles County to notify prescribers of the death in their practice. The letter includes the decedent's name, date of birth and date of death, and outlines the annual number and types of prescription drug deaths seen by the medical examiner, discusses the value of and way to access the State's prescription drug monitoring program and includes five Centers for Disease Control and Prevention (CDC) guideline-recommended safe prescribing strategies: 1) Avoid co-prescribing of opioids with benzodiazepines, 2) prescribe minimal dose necessary for acute pain, 3) consider slow tapers with pauses to below 50 morphine milligram equivalents (MME) per day, 4) avoid prescriptions lasting greater than 3-months for pain, and 5) prescribe naloxone in conjunction with opioids for patients taking \> 50 MME per day. The letter also states that CURES review is required by law as of October 2, 2018.
214855557|NCT03856593|BEHAVIORAL|Comparator letter|"The comparator letter includes all the details in the standard letter plus additional text involving an if/when/then statement along with an injunction to providers to share safety information with patients so that they identify as a safe prescriber. Specifically, the additional text reads as follows: When your next patient presents with pain, keep the above 5 recommendations close at hand to assist with their safe care. Also, be comfortable voicing your concern about prescribing safety with them so that they are also aware of the dangers scheduled drugs may carry. If/when/then is a form of pre-suasion that provides simple rules that tie goals to specific actions and has been used successfully to encourage behavior in many areas including medication adherence and drug abuse rehabilitation."
214855558|NCT00962988|DRUG|Cost-Free Pharmacotherapy Group|"Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months."
214855559|NCT00962988|OTHER|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
214855560|NCT04954378|DIAGNOSTIC_TEST|radiomics|
214855561|NCT01155778|BIOLOGICAL|Recombinant human heparan N-sulfatase (rhHNS)|
214664855|NCT07030114|DEVICE|mechanical ventilation (MV)|"Mechanical Ventilation Parameters~* \- Ventilation Mode: Ventilator settings will record modes such as volume-controlled ventilation or synchronized intermittent mandatory ventilation (SIMV), which deliver breaths based on patient needs.~* Tidal Volume: Measured in milliliters per kilogram of predicted body weight. Tidal volume settings aim to optimize oxygenation while minimizing lung injury risks by adhering to evidence-based limits (\<6 mL/kg).~* Positive End-Expiratory Pressure (PEEP): PEEP levels will be recorded in cmH₂O to prevent alveolar collapse and improve oxygenation. Adjustments will balance oxygenation benefits with potential risks like reduced venous return or lung overdistension.~* Fraction of Inspired Oxygen (FiO₂): FiO₂ values will be documented as decimals, starting at 1.0 (100% oxygen) and adjusted downward based on patient oxygenation needs."
214290382|NCT05931159|OTHER|Conventional Physical therapy for DrA|"Week 1 to 4, Draw-in maneuver in supine, Quadruped and Prone lying, Bent knee Fallouts and Curl ups. (8 to 12 repetitions x 3 sets, 2 days/week)~Week 5 to 8, Front and side planks added to week 1 to 4 exercises. (12 to 20 repetitions x e sets, 2 days/week)"
214290383|NCT05528679|DRUG|610 100mg|100mg administered subcutaneously Q4W
214664856|NCT07030829|DEVICE|Laser Lithotripsy|Laser Lithotripsy
214664857|NCT07030829|DEVICE|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
214664858|NCT07031817|DIAGNOSTIC_TEST|Venous blood sample for measuring blood biomarkers related to bipolar disorder|Participants will undergo a venous blood draw for analysis by an investigational composite medical device designed to aid in the diagnosis of bipolar disorder. The device analyzes specific circulating biomarkers hypothesized to differ between patients with bipolar disorder and those with unipolar depression.
214664859|NCT07031817|OTHER|Standardized psychiatric assessment tools|Participants will complete validated psychiatric screening tools used as reference standards to evaluate bipolar disorder, including the Mood Disorder Questionnaire (MDQ). These tools will be used to compare their diagnostic output with that of the investigational blood test.
214664860|NCT07031492|DEVICE|FLEX-AP system will be implemented to T1D patients|A FLEX-AP system will be implemented to T1D patients after they have been given a Minimed 780G hybrid closed-loop system
214664861|NCT07030335|OTHER|Mobile-Atrial Fibrillation Training Program|Patient Information Form, Atrial Fibrillation Information Scale, Atrial Fibrillation Severity Scale and Atrial Fibrillation Impact on Quality of Life Questionnaire will be administered face-to-face by the researcher using Mobile Atrial Fibrillation Education Program (M-AFEP). The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants and the application will be added to the main screens by entering the relevant address from their phones. Participants will be asked to use M-AFEP for twelve weeks / at least ten minutes a week and the frequency and duration of use will be recorded on the mobile application. Participants in the intervention group will be followed up by phone once a week in the first, fourth and eighth weeks and a reminder message (sms) will be sent for the use of M-AFEP. At the end of the twelfth week, the scales will be filled in again through the application.
214664862|NCT07030335|OTHER|Routine Outpatient Clinic Care|"* Participants in the control group will be given M-AFEP application usage training by the researchers.~* The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants in the control group.~* Participants in the control group will enter the relevant address of the mobile application from their phones and the application will be added to their home screens.~* In the M-AFEP application of the participants in the control group, there will be a short general information section containing information specific to AF, different from the intervention group content.~Participants in the control group will continue only routine outpatient follow-up throughout the process and no intervention will be applied."
214664863|NCT07031167|BEHAVIORAL|Cognitive and functional stimulation using digital platforms|Participants in the intervention group receive personalized cognitive and functional stimulation over one year through digital platforms developed by the COMFORTage project. These include Eligence, a brain-training tool featuring interactive games targeting memory, attention, and language; Language Games, which assess and train linguistic and cognitive skills in realistic scenarios; and Healthentia, a platform that monitors daily health metrics and provides virtual coaching. Sessions are conducted both in person and remotely, and are adapted to each participant's abilities and level of digital literacy. The intervention aims to support cognitive health and daily functioning in individuals with MCI or mild AD.
214664864|NCT07031583|PROCEDURE|Delayed Umbilical Cord Clamping (DCC)|The umbilical cord was clamped between 60 and 180 seconds after birth or after the cessation of cord pulsation, in accordance with WHO recommendations. This procedure allows for additional placental transfusion and potential enhancement of neonatal antioxidant capacity.
214664865|NCT07031583|PROCEDURE|Early Umbilical Cord Clamping (ECC)|The umbilical cord was clamped within the first 60 seconds after birth. This represents the standard or traditional approach used for comparison with delayed clamping in terms of oxidative stress outcomes.
214855562|NCT04299451|OTHER|Open dialogue about CAM|1-hour dialogue about CAM with a nurse specialist as an integrated part of conventional oncology care
214907031|NCT04083547|DIAGNOSTIC_TEST|iCellate|New method of circulating tumour cell detection and capture.
214290384|NCT05528679|DRUG|610 300mg|300mg administered subcutaneously Q4W
214290385|NCT05528679|DRUG|placebo|administered subcutaneously Q4W
214290386|NCT03071627|OTHER|New items with spin|Interpretation of news items with spin
214907032|NCT02282540|PROCEDURE|Iodixanol to the Eustachian tube|Application of iodixanol to the middle ear for imaging of the ET.
214907033|NCT04290364|OTHER|Palliative care|The patients in the prospective part of the study are seen on home-visits and offered standard palliative care within three weeks of diagnosis.
214290387|NCT03071627|OTHER|New items without spin|Interpretation of news items without spin
214290388|NCT02510859|OTHER|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
214290389|NCT04087694|PROCEDURE|Microdecompression|comparative surgical treatment
214290390|NCT04413409|PROCEDURE|Metastasectomy for the metastatic sites|patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy
214855563|NCT02121561|BEHAVIORAL|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
214855564|NCT01838928|DRUG|Bupivacaine|
214664866|NCT07031505|DEVICE|Active Photobiomodulation|Local photobiomodulation using a high-power superpulsed diode laser (GeminiEvo, Ultradent, USA) with dual infrared wavelengths (810 nm and 980 nm). Eight sessions will be conducted (twice a week for 4 weeks). Application will be at one point each on the masseter, temporal, trapezius, and temporomandibular joint regions. Each point will be irradiated for 13 seconds with 4 J of energy (10.52 J/cm²), in contact mode. The procedure includes safety measures such as protective eyewear and disinfection of the laser tip.
214664867|NCT07031505|DEVICE|Sham Photobiomodulation|The same application protocol as the experimental group will be followed, using the same laser device (GeminiEvo, Ultradent, USA), but with the laser emission deactivated. The guide light and sound will remain active to preserve participant blinding. Application points, duration, frequency, and session environment will be identical to the active group.
214664868|NCT07031778|DRUG|Simvastatin|Simvastatin gel with 1.2% simvastatin
214664869|NCT07031778|DRUG|Simvastatin 10 mg|sponge of collagen impregned in saline solution with 10 mg of simvastatin
214664870|NCT07031778|DRUG|Simvastatin Placebo|Collagen sponge impregned in simvastatin placebo gel without simvastatin
214664871|NCT07030400|DRUG|Bruton's tyrosine kinase inhibitor|BTKi
214664872|NCT07030400|DRUG|B-Cell Lymphoma 2 Protein Inhibitor|BCL2i
214664873|NCT07031362|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|All patients who participated in the pulmonary rehabilitation and physiotherapy program underwent sessions lasting approximately two hours, conducted twice weekly over a period of eight weeks. The exercise program included breathing exercises, relaxation and stretching exercises, peripheral muscle strengthening exercises, and aerobic training.
214664874|NCT07031440|BEHAVIORAL|digital LWWCOPD|LWWCOPD (Living well with COPD) contains six modules conventionally delivered by trained LWWCOPD Coaches. For the digital delivery the six modules are as closely adapted to the conventional LWWCOPD program as possible to make the two approaches comparable. Participants can access the digital LWWCOPD application by a weblink using a smartphone, tablet or desktop computer. Since the program duration of the conventional LWWCOPD is 6 weeks (one module per week), patients will be instructed to complete the digital LWWCOPD also within 6 weeks at their own pace, although completion within 12 weeks (3 months) is still possible. Modules can be repeated as chosen by the user. In contrast to the conventional delivery, the online delivery of LWWCOPD does not preview face-to-face contact between participants and healthcare providers, however if needed additional phone calls or meetings are still possible.
214855565|NCT06148545|DRUG|Elemental iron|Group A who received standard therapy (Fe preparations) 3 mg/kg BW/day
214855566|NCT06148545|DRUG|Elemental iron and Vit D|Group B received standard therapy (Fe preparations) 3 mg/kgBW/day combination with vitamin D, 400IU).
214855567|NCT03996551|BEHAVIORAL|ExeRTiOn online resource|This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
214855568|NCT01464554|BEHAVIORAL|Usual care|alcohol and drug education
214855569|NCT01464554|BEHAVIORAL|Project Free Talk|motivational interviewing alcohol and drug program
214855570|NCT01129453|BIOLOGICAL|CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine|CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10\^6, 10\^7, 10\^8, or 10\^9 CFU per mL. Route: oral.
214855571|NCT01129453|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
214855572|NCT00792727|DRUG|ketoprofen Patch|2 topical patches applied once daily for 28 days
214855573|NCT00792727|OTHER|Placebo Patch|2 topical placebo patches applied once daily for 28 days
214855574|NCT03252327|OTHER|Multiple Sensory Integrations|breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
214855575|NCT00773682|OTHER|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
214855576|NCT03182894|DRUG|Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
214855577|NCT04399876|COMBINATION_PRODUCT|Microdevice|"Surgery Cohort: Placement of 1-6 microdevices: Drugs chosen have all been FDA approved for the treatment of cancer (so therefore safe) and there are phase 2 or 3 data that the drug has efficacy in prostate cancer. Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations~Ex vivo Cohort: Placement of multiple microdevices with miniature drug reservoirs but no drug is loaded into the removed prostate"
214855578|NCT03978091|DRUG|AZACTAM|A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
214855579|NCT03978091|DRUG|Ceftazidime-Avibactam|An antibacterial combination product containing ceftazidime and avibactam
214855580|NCT01197157|DRUG|Placebo|Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
214855581|NCT01197157|DRUG|Nitazoxanide|• Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
214855582|NCT02324673|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
214855583|NCT05820386|PROCEDURE|Skin-to-skin Contact (SSC)|For the Skin-to-skin Contact (SSC) transfer, the bare-chested father will seat in a wheelchair. Newborns who will wear only a diaper and a cotton cap or noninvasive ventilation headgear will be placed in the kangaroo position against the father's chest to ensure direct contact with the father's skin. Preterm infants with gestational age less than 33 weeks will be wrapped with their father using plastic bags plus warmed cotton towels. More gestationally mature infants will be wrapped with only warmed cotton wraps. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
214664875|NCT07031258|DRUG|Dose of docetaxel|According to the relative dose intensity of docetaxel (RDI; Defined as the ratio of the dose received to the full planned dose of 75mg/m2 per 6 cycles specified in the protocol) were divided into cohort 1 (patients receiving docetaxel dose intensity ≤80%) and cohort 2 (patients receiving docetaxel dose intensity ≤80%). A total of 50 patients who received docetaxel dose intensity \> 80% were planned to be enrolled, including 25 patients in the docetaxel dose intensity ≤80% group and 25 patients in the docetaxel dose intensity \> 80% group
214664876|NCT07030582|BEHAVIORAL|Internet-delivered cognitive behavioral therapy|The intervention group received a comprehensive core muscle training protocol delivered through a digital rehabilitation platform from hospital admission to 6 months post-surgery. The protocol began with initial screening, including online assessments of cognitive misconceptions, kinesiophobia, and posture analysis. Pain-related cognitive restructuring was addressed through virtual reality sessions, educational videos, and mindfulness breathing guidance. Behavioral activation incorporated graded exposure therapy with EMG biofeedback, interactive knowledge quizzes, and peer modeling. Exercise skills were developed through personalized progressive training with real-time video guidance, and protocols were adjusted based on mid-term assessments. Behavioral reinforcement strategies included recovery support groups, compliance tracking, and integration of exercises into daily activities. A three-tier warning system (Red/Yellow/Green) was implemented to monitor safety and compliance, trigger
214664877|NCT07030582|BEHAVIORAL|Basic Postoperative Care|All participants were instructed to maintain their usual daily activities and abstain from additional treatments throughout the 6-month study period.
214664878|NCT07030582|BEHAVIORAL|Conventional Postoperative Care|The control group received conventional postoperative care, which included the establishment of a WeChat support group and provision of a rehabilitation manual focusing on core muscle training on the first postoperative day. Physical therapists provided individualized bedside instruction to ensure proper exercise techniques. Structured follow-up was conducted via telephone or social media (weekly during the first month, then monthly from months 2-6, with each session lasting at least 15 minutes) to provide psychological support and exercise guidance through relaxation techniques and individualized core muscle training progression.
214664879|NCT07032025|PROCEDURE|Innovative Device Group|Catheter-based thrombectomy is performed within 4 hours after baseline CTPA acquisition. Pre-procedural anticoagulation with either low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) is administered prior to thrombectomy. Post-procedural oral anticoagulation is transitioned to rivaroxaban 20 mg once daily (QD).
214664880|NCT07032025|DRUG|Standard Pharmacological Therapy Group|Following thrombolytic agent administration, anticoagulation with rivaroxaban is initiated and maintained at 15 mg twice daily (BID) for the initial 3 weeks, then switched to 20 mg once daily (QD) thereafter.
214664881|NCT06843499|OTHER|The VeriSee AI-assisted diagnostic system|VeriSee AMD, VeriSee DR, and VeriSee GLC are AI-based medical software devices designed for screening age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, respectively. These systems utilize advanced AI algorithms to analyze color fundus photography images for disease assessment. By installing the software on a computer, the system can evaluate image quality, predict disease conditions, and instantly provide results to clinical physicians, serving as a diagnostic aid.
214664882|NCT06843499|OTHER|Data collection from the patient's clinical history|Data collection from the patient's clinical history was conducted because the VeriSee AI-assisted diagnostic system was not used.
214664883|NCT03232073|DRUG|Ponesimod|Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
214664884|NCT03900598|DRUG|JNJ-67856633|JNJ-67856633 capsule will be administered orally.
214664885|NCT07075341|OTHER|None - Observational study|None - Observational study
214664886|NCT06903182|PROCEDURE|Preoperative TAP Block|Patients will receive preoperative TAP block
214664887|NCT06903182|PROCEDURE|Postoperative TAP block|Patients will receive postoperative TAP block
214664888|NCT05225324|DRUG|Equfina 50 mg|Equfina 50 mg tablets.
214855584|NCT05820386|PROCEDURE|Incubator|In the incubator group, infants will be transferred after resuscitation in an incubator with air temperature set to 36°C. The newborn will be laid on his/her back in a polyethylene bag with a cap. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
214855585|NCT01602016|DRUG|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
214855586|NCT01602016|DRUG|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
214855587|NCT03463486|BEHAVIORAL|Physical activity|50min of endurance training combined with 50min of calisthenics; 1-3x/wekk; 6weeks up to 1year
214290391|NCT05514691|DIAGNOSTIC_TEST|iStatis COVID-19 Ag Rapid Test|SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
214907034|NCT05359744|DIAGNOSTIC_TEST|Performance testing|Performance testing on a bicycle ergometer.
214907035|NCT02028663|DRUG|CJ-12420|Once daily, Oral administration
214907036|NCT02028663|DRUG|Esomeprazole|Once daily, Oral administration
214855588|NCT05796063|DIAGNOSTIC_TEST|gastric point of care ultrasound|Patients will receive a gastric point of care ultrasound to evaluate for delayed gastric emptying. Gastric POCUS studies will be obtained using Kosmos, a handheld portable ultrasound that is FDA approved for clinical use. This product has already been validated for use, and this is not a novel application of the technology.
214855589|NCT02595008|DRUG|DSXS|Active treatment
214855590|NCT02667002|PROCEDURE|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
214855591|NCT02667002|PROCEDURE|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
214855592|NCT02667002|OTHER|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
214855593|NCT00190242|DRUG|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
214855594|NCT00190242|DRUG|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
214855595|NCT05772806|DEVICE|Electrocardiogram|"The electrocardiogram will help to diagnose atrial fibrillation and the electronic devices (App Fibricheck and Smart bracelet/watch) will help to detect an arrhythmic rhythm.~The echocardiography will be used for detecting criteria of atrial cardiomyopathy.~MRI may help to detect silent strokes."
214855596|NCT02032251|DRUG|oral administration of ginger|Oral administration of ginger in patients with infertility.
214855597|NCT02032251|DRUG|Placebo|
214855598|NCT04660305|DRUG|AT278|Concentrated rapid acting insulin aspart
214855599|NCT04660305|DRUG|NovoRapid|Rapid acting insulin aspart
214855600|NCT03695705|DRUG|Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day|Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
214855601|NCT01739920|OTHER|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
214855602|NCT01739920|OTHER|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
214855603|NCT02214420|DRUG|Simeprevir|
214855604|NCT02214420|DRUG|Sofosbuvir|
214855605|NCT02214420|DRUG|Ribavirin|
214855606|NCT03078582|DRUG|Zilucoplan (RA101495)|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
214855607|NCT05253274|DEVICE|Virtual Reality Glasses|In addition to the routine practice of the emergency service, the virtual reality (VR) group will watch a video with VR glasses during the emergency surgical intervention under local anesthesia. Before the emergency surgery, the patients will be asked to wear a VR glasses compatible with mobile phones with android operating system and a headset that minimizes sound loss. Patients will be shown their preferred 3D licensed video software with relaxing music in the background. VR glasses will be put on the patients before starting the emergency surgical procedure under local anesthesia and applied until the procedure was completed. Patients will be asked to refill the The State Anxiety Inventory at the end of the emergency surgical intervention. At the same time, blood pressure, heart rate, respiratory rate, SpO2 values will be monitored on a portable monitor.
214855608|NCT03112980|DEVICE|Transcatheter aortic valve implantation|(TAVI)
214855609|NCT03112980|PROCEDURE|Surgical aortic valve replacement|(SAVR)
214855610|NCT02046525|BIOLOGICAL|Autologous fecal microbiota therapy|
214855611|NCT02046525|OTHER|Placebo|Saline enema
214855612|NCT01633502|DEVICE|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
214855613|NCT01633502|DEVICE|Impella CP|Control group treated with Impella CP for a minimum of 48 hrs.
214855614|NCT04719234|DEVICE|lung ultrasonography|Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
214855615|NCT05895734|DEVICE|NDS-Powerball®,|Rehabilitation using the Powerball system
214669991|NCT06105957|BEHAVIORAL|Individual Coaching Calls|Participants will receive 3 online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss. The first call will emphasize amplifying motivation and promoting early treatment engagement by establishing rapport, exploring personal reasons for weight loss and lifestyle change, and reinforcing and expanding change talk, and it will occur prior to starting the core program. Subsequent calls will use a motivational interviewing-informed approach to problem solve barriers to self-monitoring, particularly dietary self-monitoring because of the strong role it plays in promoting better weight loss and will occur during the first half of the program, reflecting the critical role of early engagement in the treatment program on long term weight loss success. Coaching calls will be of approximately 30 min duration and will follow a semi-structured interview format.
214855616|NCT05895734|OTHER|Conventional treatment|Rehabilitation by conventional treatment
214855617|NCT02689063|DRUG|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
214855618|NCT02689063|DRUG|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
214855619|NCT02689063|DRUG|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
214855620|NCT02689063|DRUG|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
214855621|NCT02994355|OTHER|Systems Analysis and Improvement Approach|"1. Understanding the cascade from FP clinic enrollment to HIV testing~2. Use process mapping to identify modifiable bottlenecks~3. Define and implement workflow adaptations to eliminate modifiable bottlenecks~4. Monitor change in performance~5. Repeat the analysis and improvement cycle (steps 1-4)"
214855622|NCT00350155|DRUG|Lumiracoxib|
214855623|NCT04997655|DIAGNOSTIC_TEST|Ultrasound measurement|In the patient group who will undergo elective laparoscopic cholecystectomy, the diaphragmatic thickness values measured and recorded routinely at the pre-operative, post-extubation and post-operative 30th minute, at the end of inspiration and expiration, and the inspiratory amplitude in m-mode in the ultrasound measured from the right anterior axillary line subcostal area were observed as observational data. will be saved in our file.
214855624|NCT00480623|DRUG|Satraplatin plus radiation therapy|
214290392|NCT05514691|DIAGNOSTIC_TEST|"COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (Labcorp)"|The Labcorp COVID-19 RT-PCR or EURORealTime SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
214290393|NCT00255450|DRUG|ferumoxytol or placebo|
214855625|NCT04704349|RADIATION|Scintigraphy|The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.
214855626|NCT01362465|PROCEDURE|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
214855627|NCT05575635|DRUG|fruquintinib + concurrent radiotherapy + chemotherapy|"mFOLFOX6: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days, continuous infusion.~fruquintinib: 3mg/d, qd po, for 7 weeks continuously.~Radiation Therapy: radiation 45.0\~50.0 Gy (1.8-2.0 Gy/day or 25 fractions weeks 3-7)"
214855628|NCT01592136|DRUG|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
214855629|NCT03050918|BEHAVIORAL|Follow-up Phone Call|Patients will receive a first call attempt within 72 hours discharge.
214855630|NCT01995721|BIOLOGICAL|4-valent HPV vaccine|Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
214855631|NCT02972502|DRUG|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
214855632|NCT02972502|DRUG|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
214855633|NCT02972502|OTHER|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
214855634|NCT02972502|DRUG|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
214855635|NCT05895721|OTHER|Virtual Reality|Virtual Reality as adjunct treatment
214855636|NCT00592202|DEVICE|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
214855637|NCT03353402|PROCEDURE|Fecal Microbiota Transplant (FMT)|Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
214855638|NCT04439084|OTHER|Prospective Chart Review|Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.
214855639|NCT05767203|OTHER|Biological samplings|Blood and/or skin samples
214855640|NCT01774279|OTHER|Tissue, blood and clinical data collection|
214290394|NCT03280914|DEVICE|Auto-CPAP|Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
214855641|NCT04269733|DEVICE|Right ventricular pacing|Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
214855642|NCT01933464|DRUG|Cromolyn Sodium|
214855643|NCT01933464|DRUG|Normal Saline|
214855644|NCT01047579|DRUG|Rivastigmine transdermal|
214855645|NCT03351387|COMBINATION_PRODUCT|SPY Intra-operative Angiography|The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.
214855646|NCT04076670|OTHER|Psychological intervention for family caregivers of patients at the end of life|The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
214855647|NCT04794387|BIOLOGICAL|Amended LLS COVID-19 Registry|Do people with blood cancer who did not develop antibodies after a complete COVID-19 vaccination, develop antoibodies after a COVID-19 booster?
214855648|NCT00442000|PROCEDURE|Prostatectomy|Patients undergoing prostatectomy.
214855649|NCT01888575|DRUG|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
214855650|NCT00468078|PROCEDURE|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
214855651|NCT00468078|DRUG|F-18 FPCIT|5mCi, intravenous injection
214855652|NCT04912882|DIAGNOSTIC_TEST|Circulating tumor cell|detecting circulating tumor cell pre- and post operatively
214855653|NCT05734131|OTHER|Bio-psychosocial assessment|Kinematic parameters were analyzed by two functional tests, the 10-Meter Walking Test (10MWT) and the Time Up\&Go test (TUG).
214855654|NCT00227331|DRUG|Oral amoxicillin|
214855655|NCT02046668|DRUG|spironolactone|spironolactone 25mg daily for 12 weeks
214855656|NCT01569776|OTHER|Amino Acid formula|Amino Acid baby formula
214855657|NCT01569776|OTHER|Commercially available Amino Acid Formula|Hypoallergenic Baby formula
214855658|NCT03983694|OTHER|Erythrocyte transfusion|The cerebro-vascular effects of a clinically prescribed erytrocyte (red blood cell) transfusion is examined. Before the transfusion, BabyLux sensor is placed on the neonatal fronto-parietal region and held in place by a self-adhesive bandage. A baseline prior to transfusion is established through a series of five repeated measurements of 1 minute taken during a stable period just before the transfusion is started. Once transfusion has ended, another series of five repeated measurements of 1 minute taken during a stable period are performed to determine the responses. Cerebral oxygenation as determined by a commercial spatially resolved NIRS device with neonatal sensor will be continuously recorded during transfusion.
214669992|NCT06105957|BEHAVIORAL|Pre-Scripted Feedback|Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring within each of the following domains: dietary monitoring, physical activity monitoring, and self-weighing, as well as on weekly module completion. Feedback is automatically generated based on decision algorithms and will be sent from program staff.
214855659|NCT00773695|DRUG|Aromatase Inhibitor|Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
214855660|NCT00773695|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
214855661|NCT00773695|DRUG|Epirubicine|Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
214855662|NCT00773695|DRUG|5-Fluorouracil (5FU)|Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
214855663|NCT00773695|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
214855664|NCT00773695|DRUG|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.
214855665|NCT00773695|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
214855666|NCT02778503|OTHER|High Cost|Surfaces allocated to this group will be treated with a high-cost glass ionomer cement restoration (Fuji IX, GC America, USA), according to the manufacturer's instructions.
214855667|NCT02778503|OTHER|Low Cost|Surfaces allocated to this group will be treated with a low-cost glass ionomer cement restoration (Maxxion R, FGM, BRA), according to the manufacturer's instructions.
214855668|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 110 mg.
214855669|NCT01347866|DRUG|PD-0325901|PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
214855670|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 95 mg.
214855671|NCT01347866|DRUG|irinotecan|Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
214855672|NCT01072266|DRUG|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
214290395|NCT00589914|DRUG|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
214855673|NCT04133766|BEHAVIORAL|Community Based Nutrition Package (CNBP)|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
214855674|NCT03326674|DRUG|Tesetaxel and Capecitabine|Tesetaxel plus reduced dose of Capecitabine
214855675|NCT03326674|DRUG|Capecitabine|Capecitabine alone at approved dose
214855676|NCT00231257|DEVICE|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
214855677|NCT00231257|PROCEDURE|Brachytherapy|Brachytherapy
214855678|NCT01791231|DRUG|Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)|A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
214855679|NCT02161120|OTHER|Traditional Finnish rye bread|
214855680|NCT02161120|OTHER|Low FODMAP rye bread|
214290396|NCT00589914|DRUG|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
214290397|NCT06186011|PROCEDURE|Wire-guided surgery|If assigned to the WGS, the marking will be performed by the radiologist on the day prior to the intervention.
214290398|NCT06186011|PROCEDURE|Radioactive seed localization|If assigned to the RSL, the marking will be performed by the radiologist on the day prior to the intervention. The handling and traceability will be done by the nuclear medicine physician.
214855681|NCT00869024|BIOLOGICAL|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
214855682|NCT01079884|DRUG|esomeprazole 40 mg|40 mg daily for 4 weeks
214855683|NCT00717184|DRUG|Interleukin, NK cells|
214855684|NCT04652284|DRUG|Rifabutin|150 mg
214855685|NCT04652284|DRUG|Amoxicillin|1000 mg
214855686|NCT04652284|DRUG|Esomeprazole|40 mg
214855687|NCT04652284|DRUG|Clarithromycin|500 mg
214855688|NCT04652284|DRUG|Tinidazole|500 mg
214855689|NCT00293202|DRUG|Etanercept|Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week
214855690|NCT00293202|DRUG|Placebo|Hemodialysis patients will receive Saline by subcutaneous injection twice a week
214855691|NCT02059330|DRUG|Palbociclib 75mg|In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
214855692|NCT02059330|DRUG|Palbociclib 125mg|In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
214855693|NCT02059330|DRUG|Palbociclib 100mg|In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
214855694|NCT02059330|DRUG|Palbociclib|In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
214855695|NCT02059330|DRUG|Palbociclib 125mg|In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
214855696|NCT01508754|PROCEDURE|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
214855697|NCT01778153|BEHAVIORAL|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
214855698|NCT03531801|OTHER|Pressure algometry and mapping referred pain areas|The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
214855699|NCT00331071|DRUG|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
214855700|NCT00331071|DRUG|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
214855701|NCT02442271|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
214855702|NCT02442271|DRUG|ribavirin|Tablet
214855703|NCT06206083|GENETIC|Descriptive and analytical|Patients with EC endometroid
214855704|NCT02227654|PROCEDURE|Abnormal Ovarian Ultrasound|Ultrasound
214855705|NCT00765011|DRUG|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
214855706|NCT00765011|PROCEDURE|H&N surgery|Rescue surgery
214669993|NCT06479005|DEVICE|Oura Ring|The Oura ring will remotely monitor the patients vitals at home continuously
214855707|NCT05715554|OTHER|Homeopathy|Individualized homoeopathic medicines on impregnated lactose pellets was prescribed based on totality of physical, emotional, and mental symptoms.
214855708|NCT05123677|DIAGNOSTIC_TEST|Non-invasive haemodynamic assessment|Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded
214855709|NCT05123677|DIAGNOSTIC_TEST|Maternal ophthalmic artery doppler|Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
214855710|NCT04764955|DIETARY_SUPPLEMENT|Placebo|This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.
214855711|NCT04764955|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.
214855712|NCT05955495|OTHER|Food|Post-operative feeding includes water, liquid diet, soft diet.
214855713|NCT00234455|DEVICE|drug eluting-stent|PCI
214855714|NCT00234455|DEVICE|drug-eluting stent|PCI
214855715|NCT00408564|BIOLOGICAL|cetuximab|
214855716|NCT00408564|DRUG|capecitabine|
214855717|NCT00408564|DRUG|oxaliplatin|
214855718|NCT00408564|PROCEDURE|conventional surgery|
214855719|NCT00408564|RADIATION|radiation therapy|
214855720|NCT00408564|DRUG|Gemcitabine|
214855721|NCT04878614|DRUG|Levothyroxine Tablet|Standard clinical management
214855722|NCT04878614|DRUG|Levothyroxine Sodium|Liquid levothyroxine through enteral feeding tube
214855723|NCT00025636|BIOLOGICAL|filgrastim|
214855724|NCT00025636|DRUG|carmustine|
214855725|NCT00025636|DRUG|cisplatin|
214855726|NCT00025636|DRUG|cyclophosphamide|
214855727|NCT00025636|DRUG|cytarabine|
214855728|NCT00025636|DRUG|dexamethasone|
214855729|NCT00025636|DRUG|etoposide|
214855730|NCT00025636|DRUG|melphalan|
214855731|NCT00025636|DRUG|methotrexate|
214855732|NCT00025636|DRUG|vincristine sulfate|
214855733|NCT00025636|PROCEDURE|bone marrow ablation with stem cell support|
214855734|NCT00025636|PROCEDURE|peripheral blood stem cell transplantation|
214855735|NCT04254835|DRUG|Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein|Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
214855736|NCT04254835|DRUG|Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein|Conventional Fluoride varnish
214855737|NCT03261479|DIAGNOSTIC_TEST|Thermal image|We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
214855738|NCT04392284|BEHAVIORAL|Diet Counseling|"Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
214855739|NCT04392284|BEHAVIORAL|Exercise Counseling|"Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
214855740|NCT01560507|DRUG|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
214855741|NCT01560507|DRUG|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
214855742|NCT01560507|DRUG|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
214855743|NCT05318209|OTHER|Exercise|Closed-chain Shoulder Girdle Scapular Depression Exercise
214855744|NCT02080832|DRUG|Citalopram|20 mg or 40 mg daily for 8 weeks
214855745|NCT02080832|DRUG|Placebo|Placebo daily for 8 weeks
214855746|NCT03173053|DRUG|Doxycycline|tablet
214855747|NCT03173053|DRUG|Trimethoprim|tablet
214855748|NCT03173053|DRUG|Sulfamethoxazole/trimethoprim|tablet
214855749|NCT03173053|DRUG|Clindamycin|tablet
214855750|NCT03173053|DRUG|Clarithromycin|tablet
214855751|NCT03173053|DRUG|Ciprofloxacin|tablet
214855752|NCT03173053|DRUG|Fusidic Acid|tablet or ointment
214855753|NCT03173053|DRUG|Rifampin|tablet
214855754|NCT03173053|DRUG|Chlorhexidine|Mouthwash or bodywash
214855755|NCT03173053|DRUG|Mupirocin|Nasal ointment
214855756|NCT03173053|DRUG|Betadine|Shampoo
214855757|NCT05040178|DRUG|Carglumic Acid|Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.
214855758|NCT03446352|OTHER|Psychomotor exercise program|"Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (40 min), cool-down (10 min), and finishing ritual (5 min).~At the initial stage, the activation of different muscle groups will be performed, providing an elevation of the neurophysiological parameters. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation- physical performance (cardiovascular, strength, balance, flexibility, agility and movement accuracy)- alternating with exercises mainly focused on cognitive stimulation- executive functions (planning ability, information processing speed, attention and dual-task performance).~At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants share their sensations experienced."
214855759|NCT03446352|OTHER|Combined exercise program|"The EG2 intervention combines the psychomotor exercise program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.~The WBV will integrate 3 sessions / week of 6 minutes each, with programed increased exercise time, series, and frequencies throughout the intervention."
214855760|NCT03347552|BEHAVIORAL|HOME|"Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care."
214855761|NCT03199313|DRUG|Sutezolid|Sutezolid supplied as tablets and matching placebo for oral administration.
214855762|NCT03199313|DRUG|Placebo|Matching Sutezolid placebo
214855763|NCT06402682|PROCEDURE|Right approach|Right approach of the management of esophageal atresia with a right aortic arch
214855764|NCT06402682|PROCEDURE|Left approach|Left approach of the management of esophageal atresia with a right aortic arch
214855765|NCT02427984|OTHER|Metal ions dosage and evaluation of local/systemic reaction|"Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
214855766|NCT02427984|OTHER|Noise registration and metal ions determination|"Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of range of noise"
214855767|NCT02427984|OTHER|Metal ions dosage, evaluation of local/systemic reaction, noise registration|"Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
214855768|NCT05530473|DEVICE|capsular tension ring|To insert a capsular tension ring during the cataract surgery
214855769|NCT00549016|DEVICE|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
214855770|NCT03443518|PROCEDURE|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)
214855771|NCT03443518|PROCEDURE|Local Anesthesia infiltration|Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.
214855772|NCT03443518|DRUG|Normal saline 0.9% IV infusion|Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
214855773|NCT03443518|DRUG|Remifentanil infusion|Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
214855774|NCT03547726|OTHER|Physical Therapy|These patients will receive a formal physical therapy protocol by seeing a physical therapist in clinic.
214855775|NCT03547726|OTHER|Self-Rehab|These patients will be provided with a list of actions NOT to perform and allowed to self rehabilitate. They will not see a physical therapist.
214855778|NCT05982821|OTHER|Artificial Intelligent|Artificial intelligence assisted radiologists to extract ultrasound features of thyroid nodules.
214855779|NCT04900909|DEVICE|Aortic Valve Replacement|Surgical replacement of aortic valves
214855780|NCT05970419|OTHER|high power laser acupuncture (HPLA)|High power laser therapy A Zimmer Opton pro, integrated High-power class IV laser device (serial N: 15200013306 \& REF: 4682, made in Germany, manufactured by Zimmer Medizin System). It emits radiation in the infrared range to deliver topical heating and raise tissue temperature. The simultaneous application of two wavelengths of laser light (810 and 980nm) provides the user with a huge variety of therapy options. The laser probe - with the small spacer (3.1cm2) , with parameters of 3 watts, 5Hz, 50% duty cycle, 20 joule/ point for 13 seconds with 6.4 j/cm2 . Although a maximum power of 8000 W was reported in two studies, the average power of the lasers used in t
214855781|NCT05970419|OTHER|conventional treatment|"Superficial heat (hot packs). Will be applied 10 - 15 minutes. Guideline-endorsed treatment is to stay active, return to normal activity, and to exercise. Different exercise types are used in the treatment of CLBP such as strength and aerobic training on land as well as specific exercises such as motor control exercises (MCE).~General exercises activating the extensor (paraspinals) and flexor (abdominals) muscle groups will be used."
214855782|NCT05970419|OTHER|Sham laser|sham laser (Not active)
214855783|NCT00398931|DRUG|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
214855784|NCT00398931|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
214855785|NCT01293760|OTHER|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
214855786|NCT01293760|OTHER|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
214855787|NCT05061576|BEHAVIORAL|Standard of Care advice on physical activity|Oral advice on exercise from a physician.
214855788|NCT05061576|BEHAVIORAL|Structured advice on physical activity|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
214855789|NCT03913182|DRUG|apatinib|500mg po Qd
214855790|NCT05402462|DIAGNOSTIC_TEST|upper endoscopy|detect esphageal motility disorder by upper endoscopy and esophageal manometry
214855791|NCT02059720|PROCEDURE|HSCT|Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
214855792|NCT00960830|DRUG|mirtazapine|mirtazapine 15 mg daily tablets
214855793|NCT00960830|DRUG|mirtazapine|15 mg daily
214855794|NCT05818748|DEVICE|virtual reality|virtual reality distraction
214855795|NCT02527239|OTHER|Prospective observational study|Prospective observational study collecting data during a clinic vist including measurement of respiratory muscle strength, respiratory failure, lung function, physical performance and blood testing for enzymes related to Pompe's disease and muscle function.
214855796|NCT01491035|DRUG|Vortioxetine|5 mg tablets for 14 days; orally; once daily
214855797|NCT01491035|DRUG|Vortioxetine|10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
214855798|NCT01491035|DRUG|Vortioxetine|15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
214855799|NCT01491035|DRUG|Vortioxetine|20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
214855800|NCT02900963|OTHER|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
214855801|NCT01418716|OTHER|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
214855802|NCT01418716|OTHER|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
214855803|NCT03179163|DRUG|Captopril Pill|ACEi+SH
214855804|NCT03179163|DRUG|Enalapril Pill|ACEi
214855805|NCT03179163|DRUG|Hydrochlorothiazide|diuretic
214855806|NCT05978739|DRUG|Orelabrutinib High dose|Orelabrutinib will be administered as 3 tablets once per day
214855807|NCT05978739|DRUG|Orelabrutinib Low dose|Orelabrutinib will be administered as 1 tablet once per day
214855808|NCT00775684|DRUG|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
214855809|NCT00775684|DRUG|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
214855810|NCT00775684|DRUG|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose \< 110mg/dl
214855811|NCT01709279|BIOLOGICAL|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
214855812|NCT01277718|DRUG|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
214855813|NCT01277718|DRUG|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
214855814|NCT02139917|BEHAVIORAL|Transitional community based palliative care|"transitional palliative care include:-~* telephone follow up for early identification of signs and symptoms~* relief of signs and symptoms encountered~* home visit with spiritual support"
214907037|NCT01845441|DRUG|Dexmedetomidine|Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
214907038|NCT01845441|DRUG|Fentanyl|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
214907039|NCT01845441|DRUG|Midazolam|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
214290399|NCT06186011|PROCEDURE|Intraoperative ultrasound localization|If the patient is assigned to the Intraoperative ultrasound localization (IOUS), no further procedures will be necessary until surgery. Subsenquently, the primary surgery will be performed.
214855815|NCT01598519|BEHAVIORAL|suicide intervention|"universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net."
214855816|NCT01524913|DRUG|Hyaluronic acid|1 cc hyalgan to be injected into superior joint space
214855817|NCT01524913|DRUG|Corticosteroid|1cc celestone (6 mg/cc) will be injected into the joint space
214855818|NCT01524913|DRUG|Lactated Ringers|1 cc lactated ringers solution will be injected into the joint space
214855819|NCT02560441|OTHER|chemotherapy followed by radiotherapy|
214855820|NCT02560441|OTHER|radiotherapy followed by chemotherapy|
214855821|NCT02560441|DRUG|IPGDP regimen chemotherapy|
214855822|NCT00005823|DRUG|cytarabine|
214855823|NCT00005823|DRUG|daunorubicin hydrochloride|
214855824|NCT00005823|DRUG|etoposide|
214855825|NCT00005823|DRUG|hydroxyurea|
214855826|NCT00005823|DRUG|idarubicin|
214855827|NCT00005823|DRUG|mitoxantrone hydrochloride|
214855828|NCT00005823|DRUG|thioguanine|
214855829|NCT00005823|DRUG|tretinoin|
214855830|NCT00005823|DRUG|valspodar|
214855831|NCT04706923|DRUG|BCV|Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.
214855832|NCT04334655|OTHER|Physical Therapy|Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
214855833|NCT01783002|RADIATION|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
214855834|NCT01783002|RADIATION|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
214855835|NCT01783002|RADIATION|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
214855836|NCT05859321|OTHER|Virtual reality Exercises|Virtual reality exercises along with transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
214855837|NCT05859321|OTHER|Routine Physiotherapy|transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
214855838|NCT03257150|PROCEDURE|Irreversible Electroporation|Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die. Eligible patients will undergo in situ IRE performed via laparotomy surgery.
214855839|NCT03257150|DEVICE|NanoKnife System|A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the tumor.
214855840|NCT04363749|OTHER|hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint|the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure
214855841|NCT03596736|PROCEDURE|Elbow Hemiarthroplasty|
214855842|NCT03596736|PROCEDURE|Total Elbow Arthroplasty|
214855843|NCT00644384|DRUG|acitretin|
214855844|NCT00644384|GENETIC|gene expression analysis|
214855845|NCT00644384|GENETIC|northern blotting|
214855846|NCT00644384|GENETIC|polymerase chain reaction|
214855847|NCT00644384|GENETIC|protein expression analysis|
214855848|NCT00644384|OTHER|laboratory biomarker analysis|
214855849|NCT04667702|BEHAVIORAL|Interviews|We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.
214855850|NCT03339505|DIETARY_SUPPLEMENT|Salovum|Dietary supplement with high concentration of anti-secretory factor
214855851|NCT03339505|DIETARY_SUPPLEMENT|Placebo|Placebo for Salovum
214855852|NCT04054128|DRUG|Sodium Bicarbonate 7.5% Injection|Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
214855853|NCT04054128|DRUG|Heparin Sodium, 1000 Units/mL Injectable Solution 1|Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
214290400|NCT01488539|BEHAVIORAL|STAIR/NT treatment|STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.
214855854|NCT04566705|OTHER|Risks factors, maternal and neonatal outcomes/complications|Risks factors, maternal and neonatal outcomes/complications
214855855|NCT01940328|DEVICE|Transchoracic ultrasound Doppler|
214855856|NCT02397005|DRUG|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
214855857|NCT02397005|DRUG|Placebo matching ZL-2102|
214855858|NCT02459145|BEHAVIORAL|Graduated exercise protocol|Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)\_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
214855859|NCT03196674|OTHER|Biofeedback via motion capture|The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
214855860|NCT00869986|DRUG|dirucotide|500mg, intravenous, every 6 months for 15 months
214855861|NCT00869986|DRUG|placebo|intravenous, once every six months for 15 months
214855862|NCT04944134|BIOLOGICAL|COVID-19 Vaccination|Receipt of full COVID-19 vaccination
214855863|NCT00695435|DRUG|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
214855864|NCT00695435|DRUG|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
214855865|NCT00695435|DRUG|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
214855866|NCT05649449|BEHAVIORAL|Self-Directed Care|Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
214855867|NCT05649449|BEHAVIORAL|Services as usual|Participants receive usual outpatient psychiatric care delivered at community programs from which the person can choose from an array of services negotiated with the state mental health authority.
214855868|NCT04464993|BEHAVIORAL|Device-based feedback, self-monitoring, and education: CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
214855869|NCT04464993|BEHAVIORAL|Sedentary Screen Time lockout: LOCKOUT|Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
214855870|NCT04464993|BEHAVIORAL|Context-based prompts: TEXT|The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
214855871|NCT04464993|BEHAVIORAL|Earn sedentary screen time through moderate-vigorous physical activity: EARN|Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a \>5 min continuous bout of exercise (as defined by Fitbit minutes \>4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
214855872|NCT00038337|PROCEDURE|Health Literacy|
214855873|NCT04263428|BEHAVIORAL|Irregular sleep|Experimental-induced sleep variability
214855874|NCT04527328|DEVICE|AKST1210|AKST1210
214855875|NCT04527328|OTHER|Sham Control (No Intervention)|A covered surrogate object of similar size and shape as the investigational device
214855876|NCT04527328|PROCEDURE|Hemodialysis|Hemodialysis
214855877|NCT01627925|DEVICE|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
214855878|NCT03964610|DIAGNOSTIC_TEST|color fundus photography (CFP) and OCT-A|Included patients will have an ophthalmologic assessment (OCT-A and CPF) after stabilization and at 3 months follow-up.
214855879|NCT00336115|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)|
214855880|NCT02680418|DRUG|FDL169|
214855881|NCT05606588|BEHAVIORAL|Playful sensorimotor training|"For the max. duration of the first in-hospital phase (3weeks), all children will receive supervised training. When children go home they will be supplied with a manual, specific exercises and the necessary training devices. Regular supervision will allow to ensure that the training is performed at maximum benefit. Each session will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises chosen from a standardized pool of exercises according to the child's age, with increasing difficulty in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue."
214855882|NCT01469741|BEHAVIORAL|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
214855883|NCT00026052|DRUG|riluzole|
214855884|NCT05049031|OTHER|Questionnaire|A questionnaire will be given to patients who will ask them about their possible fractures, their bone and oncological follow-ups and their possible cardiovascular events since the end of treatment with hormone therapy.
214855885|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .23s|Aortic CTA performed with short (0.23 sec) gantry rotation time.
214855886|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .28s|Aortic CTA performed with standard (.28 sec) gantry rotation time.
214855887|NCT04878237|OTHER|Nasal Secretion Sampling|Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)
214855888|NCT04544137|BEHAVIORAL|BOKS|BOKS is an evidence-based physical activity program developed by Reebok to get kids active and establish a lifelong commitment to health and fitness. It was originally developed and tested as a 12-week program offered before or after school. In the present study, BOKS will be offered four days per week for eight weeks over the summer at a public park in one low-income community. The program will run one-hour prior to lunch service by the USDA's Summer Food Service Program. The BOKS curriculum includes lesson plans for 40-45 minute classes that follow the same daily format and focus on a functional fitness skill of the week (squat, plank, push up, etc) and engage participants in team-oriented games.
214855889|NCT01010815|PROCEDURE|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
214855890|NCT01010815|OTHER|stool collection|Stool will be collected from participants at study entry
214855891|NCT01010815|PROCEDURE|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
214855892|NCT01010815|OTHER|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
214855893|NCT05208879|BIOLOGICAL|Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only)|"Carotenoid status will be determined by measuring plasma and erythrocyte concentrations of lutein and zeaxanthin obtained during an annual blood draw. These molecules will be analyzed by high performance liquid chromatography.~The oxidative stress markers will be measured, in the blood sample already collected, thanks to specific assay kits: Erythrocyte reduced glutathione, Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Plasma and erythrocyte malondialdehyde, Plasma vitamin C, Plasma oxidized cholesterol, F2-isoprostanes.~This study does not result in any change in patient management, but requires the collection of an additional volume of blood (14 ml of study-specific blood) during the annual blood draw performed as part of routine patient follow-up."
214855894|NCT05208879|OTHER|Characterization, evaluation and comparison of macular pigment density|The macular pigment optical density (OD) will be determined by an additional photograph during the fundus usually performed for annual follow-up through two-wavelength autofluorescence imaging. Indeed, the measurement of the optical density consists of an additional post-examination analysis of additional retinal images obtained during the fundus performed for the patients' ophthalmologic follow-up.
214855895|NCT06257316|DRUG|EPHEDrine Hydrochloride 5 mg/ml|"In the present study, the expected rate of recovery of the internal carotid artery according to the dose of the inotropic agent was similar to that in a previous study in which the fraction maintaining mean arterial pressure within 80% of baseline by dose of inotropic agent was 0.9% for the ephedrine 0.1, 0.6, 0.8, 1. 0, 1.2, and 1.4 doses (mg/kg) were 9.9%, 21%, 41%, 47%, 65.5%, and 40%, respectively (Br J Anaesth. 2023 May;130(5):603-610), and it was assumed that the rate of internal carotid artery recovery by inotrope dose would be 90% of that result.~The study will randomize to dose in six cohorts and will include dose group and cohort variables in a logistic regression model to assess the trend between inotropic dose and rate of carotid revascularization after correcting for cohort effects on the outcome variable."
214855896|NCT00682552|PROCEDURE|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
214855897|NCT00280176|DRUG|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
214855898|NCT00280176|DRUG|fluorouracil|225mg/m2 given weekly, up to 6 weeks
214855899|NCT00280176|RADIATION|radiation therapy|180 cGy, every 5 days, up to six weeks
214855900|NCT01370486|DRUG|melatonin|melatonin cp 2 mg 1x/d for 1 month
214855901|NCT01370486|DRUG|placebo|placebo cp 1x/d for 1 month
214855902|NCT03351231|DRUG|BMS-986242|Specified dose on specified days
214855903|NCT03351231|BIOLOGICAL|Nivolumab|Specified dose on specified days
214855904|NCT01745354|DRUG|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
214855905|NCT01745354|RADIATION|Local Radiation|
214855906|NCT02858726|DRUG|CR845 0.5 mcg/kg|IV medication delivered three times/week
214855907|NCT02858726|DRUG|CR845 1 mcg/kg|IV medication delivered three times/week
214855908|NCT02858726|DRUG|CR845 1.5mcg/kg|IV medication delivered three times/week
214855909|NCT02858726|DRUG|Placebo|IV medication delivered three times/week
214855910|NCT01965184|BEHAVIORAL|Cognitive-Behavioral Therapy for Anger and Aggression|
214855911|NCT01965184|BEHAVIORAL|Supportive Psychotherapy (SPT)|
214855912|NCT03912402|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
214855913|NCT03912402|BIOLOGICAL|Bevacizumab|IV infusion
214855914|NCT03912402|DRUG|Paclitaxel|IV infusion
214855915|NCT03912402|DRUG|Cisplatin (or carboplatin)|IV infusion
214855916|NCT01972035|DRUG|Valacyclovir|Experimental Arm
214855917|NCT01972035|DRUG|Valganciclovir|Standard of care
214855918|NCT00233987|DRUG|carmustine|150 mg/m\^2 IV over 2 hours 4, 5, and 6 days before transplant.
214855919|NCT00233987|DRUG|cyclophosphamide|100 mg/kg IV 2 days before transplant.
214855920|NCT00233987|DRUG|etoposide|60 mg/kg IV over 4 hours 4 days before transplant.
214855921|NCT00233987|DRUG|melphalan|150 mg/m\^2 IV 1 day before transplant.
214855922|NCT00233987|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|2.0 x 10\^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
214855923|NCT00233987|RADIATION|radiation therapy|150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
214855924|NCT00190879|DRUG|Atomoxetine hydrochloride|
214855925|NCT00190879|DRUG|placebo|
214855926|NCT04094740|DEVICE|Jet Injector without A Needle|Patients in the experimental group will use a needle - free jet injector to inject insulin, which delivers insulin at a high velocity into subcutaneous tissue and dispenses insulin over a larger area than a syringe.
214855927|NCT01862419|OTHER|Alert|
214855928|NCT04778293|OTHER|Diacutaneous fibrolysis|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized, in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
214855929|NCT00518622|DRUG|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
214855930|NCT00518622|DRUG|Comparator: Placebo|MK7009 Placebo
214855931|NCT03256422|DRUG|Treatment discontinuation|"• Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir"
214855932|NCT01058928|OTHER|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
214855933|NCT01941108|BEHAVIORAL|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
214855934|NCT01996059|PROCEDURE|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
214855935|NCT01996059|PROCEDURE|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
214855936|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib
214855937|NCT03284502|DRUG|HM95573, cetuximab|Regimen: twice daily (BID), continuous dosing for HM95573
214855938|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1
214855939|NCT03284502|DRUG|HM95573, cetuximab|Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b
214855940|NCT01688726|OTHER|SYSTANE® BALANCE eyedrops|
214855941|NCT01688726|OTHER|Minims® Saline 0.9% eyedrops|
214855942|NCT04235972|OTHER|Follow-up consultation|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
214855943|NCT02456649|DEVICE|MarginProbe|Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to \< 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as \< 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
214855944|NCT06490887|OTHER|Use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing surgery or from pregnant women giving birth. Peripheral blood will be also collected from patients to conduct virological screening and isolate peripheral blood mononuclear cells.
214855945|NCT00258375|DRUG|custirsen sodium|
214855946|NCT00258375|DRUG|docetaxel|
214855947|NCT03567525|PROCEDURE|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels|After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection
214855948|NCT03567525|PROCEDURE|Standard surgical approach|After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
214855949|NCT00648024|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fasting
214855950|NCT00648024|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fasting
214855951|NCT05296876|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to perform CEA for patients. All patients will be assessed by SSPC evaluation system before CEA. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA and the type of CEA can be selected as conventional, eversion or a shunt or patch based on the discretion of the surgeon.
214855952|NCT00003972|BIOLOGICAL|filgrastim|
214855953|NCT00003972|BIOLOGICAL|sargramostim|
214855954|NCT00003972|DRUG|busulfan|
214855955|NCT00003972|DRUG|carboplatin|
214855956|NCT00003972|DRUG|cyclophosphamide|
214855957|NCT00003972|DRUG|melphalan|
214855958|NCT00003972|DRUG|paclitaxel|
214855959|NCT00003972|DRUG|tamoxifen citrate|
214855960|NCT00003972|DRUG|thiotepa|
214855961|NCT00003972|PROCEDURE|peripheral blood stem cell transplantation|
214855962|NCT00003972|RADIATION|radiation therapy|
214855963|NCT03163433|BEHAVIORAL|Feedback in the consultation|Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
214855964|NCT05160714|RADIATION|Real-time ADC-guided response adaptive Boost in HNC|"40 Gy in 20 fractions over 5 weeks (Monday to Thursday) to the adjuvant neck, simultaneous integrated boost with 56 Gy in 20 fractions in 5 weeks to the low-risk macroscopic tumor.~Once weekly Dose-escalated SBRT adaptive boost to an ADC-based high risk subvolume with graduated dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy"
214855965|NCT03163849|DRUG|Sofosbuvir , daclatasvir|Tablets
214855966|NCT03163849|DRUG|Placebos|oral tablets
214855967|NCT02614963|DRUG|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
214855968|NCT02614963|DRUG|placebo|Irritable bowel syndrome patients treated with placebo
214855969|NCT01198834|DRUG|MRX-7EAT|Application of up to two patches at the discretion of the investigator for up to 7 days.
214855970|NCT01198834|DRUG|Placebo|Application of up to two patches at the discretion of the investigator for up to 7 days.
214855971|NCT01198834|DRUG|Lidocaine|Application of up to two patches at the discretion of the investigator for up to 7 days.
214855972|NCT01198834|DRUG|Etodolac|Application of up to two patches at the discretion of the investigator for up to 7 days.
214855973|NCT01872052|DEVICE|Acutus Medical System Mapping|Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
214855974|NCT02882672|OTHER|Experimental|Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
214855975|NCT02882672|OTHER|Control|They did not do ant exercise training during 8 weeks.
214855976|NCT03046134|BIOLOGICAL|PCV13|Conjugated pneumococcal vaccine
214855977|NCT01036490|OTHER|Exercise|Exercise training for 12 weeks followed by home exercise for 40 weeks
214855978|NCT06142123|OTHER|3-D Ankle Mobility Exercises(A)|"The techniques will be first performed in prone lying against the resistance of the therapist and then in crook lying.~1. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the prone position according to the resistance of therapist.~2. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the prone position according to the resistance of therapist.~3. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the crook-lying position according to the resistance of therapist.~4. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the crook-lying position according to the resistance of therapist."
214855979|NCT06142123|OTHER|Eccentric Heel Drop Training(B)|": Group B will be treated with Eccentric Heel Drop Training. It will comprise of following exercises (14).~1. Eccentric loading exercises of calf muscles.~2. Conventional physiotherapy treatment including Ultrasound Plantar fascia stretching Calf muscle stretching Intrinsic muscles strengthening"
214855980|NCT02707133|OTHER|No intervention|
214855981|NCT01930318|DRUG|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
214855982|NCT02427295|DRUG|Sandostatin (Octreotide Acetate)|"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~* Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -\> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~* Frequency: every 4 weeks.~* Route of administration: IM injection."
214855983|NCT04208269|OTHER|postcard campaign|Post card sent to parent only
214855984|NCT04208269|OTHER|Health Information Technology system|Accessed by adolescent and provider only
214855985|NCT01709994|DRUG|Aspirin|100 mg/day of aspirin
214855986|NCT00791141|DRUG|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
214855987|NCT06927427|PROCEDURE|fiberoptic endoscopic evaluation of swallowing (FEES)|Using flexible endoscopy, the patient will be given a colored thin fluid to keep in their mouth and then swallow following the instructions of the examiner, then the examination will be repeated using semisolids (1 teaspoon of yogurt) and using solids (piece of bread). The evaluation of swallowing will involve four items: early spill of food (delayed triggering), aspiration, penetration, and retention (residue). And the results will be recorded.
214855988|NCT05865977|DEVICE|diaphragmatic tissue Doppler imaging，dTDI|dTDI was performed at the end of the SBT to assess excursion, velocity, and acceleration.
214855989|NCT05355038|BEHAVIORAL|lifestyle modification (dietary modification)|low glycemic index diet the researcher gave detail information about (importance of LGI diet, component of food, number of meals and snake, example of food taken in breakfast, lunch, dinner and snake in between, food allowed and not allowed). After that, the researcher required from the woman to make an example of food for one day according to her income level, if correction of the content of food needed, the researcher will explain this point again.
214855990|NCT05355038|BEHAVIORAL|lifestyle modification (physical activity)|health teaching about choose between two types of exercise to be selected according to the ability of GDM women to perform : brisk walking or seated arm exercise or selected both. Brisk walking should be performed for at least half an hour three time /week, while, seated arm exercise done three time after each meal for10 minute in each time. The researcher given a detail information about both types and its importance in decreasing blood glucose level, also how to perform and what should be done in case of appearance of fatigue manifestation during exercise, and the women have choice for perform both or selected one to perform according to your health condition.
214855991|NCT05355038|BEHAVIORAL|lifestyle modification( self glucose monitoring)|self-glucose monitoring the researcher explain the important of monitoring blood glucose level and instruct the women about how to perform self- glucose measuring, recording way of the result in schedule and to bring this result in the next antenatal visit. The women who have digital blood glucose monitoring instructed to measure it at least 5 time/day. while, the women who didn't have digital blood glucose monitoring measure went to nearest pharmacy to measure blood glucose at least one time per day especially when the woman felt the signs and symptoms of hypo or hyperglycemia and recorded the result in paper or sent the result in whatsapp for the researcher if you have whatsapp application. In addition to give the woman instruction about sings symptoms of hypoglycemia and hyperglycemia and the proper ways for management
214855992|NCT03697330|DRUG|Ringer lactate|"Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood."
214855993|NCT00603291|DRUG|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
214855994|NCT00603291|DRUG|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
214855995|NCT00603291|DRUG|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
214855996|NCT05783661|OTHER|Conventional antibiotic strategies|Treatment according to the local guidelines of the Hospital Clinic de Barcelona.
214855997|NCT05783661|OTHER|Regimens guided by epidemiological surveillance|Treatment according to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
214855998|NCT03602443|BEHAVIORAL|LSVT®BIG Intervention|Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
214855999|NCT03602443|BEHAVIORAL|Waitlist Control|Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
214856000|NCT00793494|OTHER|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
214856001|NCT00793494|OTHER|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
214856002|NCT03785392|PROCEDURE|Group 1 In-plane|"Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block."
214856003|NCT03785392|PROCEDURE|Group 2 out of plane|Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
214856004|NCT04732481|PROCEDURE|passive leg lift test|passive leg lift test
214856005|NCT03805100|BIOLOGICAL|Ranibizumab|Intravitreal injection
214856006|NCT00289757|BIOLOGICAL|Havrix™|2 doses at 6 months interval
214856007|NCT04104555|OTHER|Birthday card|Birthday card sent to participants in the post
214856008|NCT04104555|DEVICE|Prefabricated orthoses|Prefabricated insole
214856009|NCT04104555|OTHER|Signposting to multimedia|Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
214856010|NCT04104555|OTHER|Usual supportive care - exercises and footwear advice (the comparator)|Active comparator
214856011|NCT04766736|PROCEDURE|Quantification of netrin-1 signals by antibody-based approaches|Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
214856012|NCT03474432|DEVICE|Optical Coherence Tomography|OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
214856013|NCT02177136|DRUG|Obeticholic Acid (OCA)|
214856014|NCT02177136|DRUG|Placebo|
214856015|NCT03641391|PROCEDURE|Intraoperative direct cortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate cortex, was performed using a 5-mm wide bipolar electrode with a pulse frequency of 60 Hz and an amplitude of 1.5 to 6 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
214290401|NCT01488539|BEHAVIORAL|Treatment as Usual (TAU)|The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
214856016|NCT03641391|PROCEDURE|Intraoperative direct subcortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate subcortical pathways, was performed using a biphasic square-wave pulse delivered at 60 Hz with a current amplitude ranging from 1.5 to 10 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
214856017|NCT00870649|BIOLOGICAL|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
214856018|NCT00870649|BIOLOGICAL|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
214856019|NCT02512536|DRUG|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
214856020|NCT04171713|BEHAVIORAL|Mindfulness-Based Health Promotion + Treatment as usual|Structured and developed over eight weeks (8 sessions), participants meet weekly for an average of 2 hours to experience the techniques and conceptual learning about mindfulness and can be adapted to one or 1.5 hour sessions. to be applicable within the contexts of health, education, and organizations. Plus participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
214856021|NCT04171713|BEHAVIORAL|Attachment-based compassion therapy + Treatment as usual|It is a program based on one of the fundamental psychological constructs that explain individuals' interpersonal relationships, attachment styles. It lasts 8 weeks in which participants meet for 2 or 2.5 hours at each meeting.
214856022|NCT04171713|BEHAVIORAL|Treatment as usual|participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
214856023|NCT01793818|BIOLOGICAL|Tat Oyi|Three injections in the arm
214856024|NCT00854802|DRUG|Debio 025|Debio 025 supplied in soft gel capsules
214856025|NCT00854802|DRUG|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
214856026|NCT00854802|DRUG|Ribavirin|Ribavirin supplied in tablets
214856027|NCT00854802|DRUG|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
214856028|NCT00003521|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214856029|NCT00131378|DRUG|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
214856030|NCT00131378|DRUG|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
214856031|NCT03557359|DRUG|Nivolumab|Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
214856032|NCT02970435|BEHAVIORAL|Video Discharge Instructions|The video discharge instructions, will be provided to the patient at the time of surgical procedure.
214856033|NCT02970435|BEHAVIORAL|Telecommunication Reminders|Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up
214856034|NCT02970435|BEHAVIORAL|Standard of Care|Standard of Care: verbal and written discharge instructions for patients after surgery
214856035|NCT03197558|COMBINATION_PRODUCT|Tymbion Iontophoresis and Tube Delivery System (TDS)|Subjects will receive active Tymbion iontophoresis and tube insertion using the Tube Delivery System in all ears indicated for tube placement.
214856036|NCT03596619|DEVICE|PBN|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation \[SD\] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
214856037|NCT00353652|DRUG|Study#1: chlorthalidone (CTD), titrated dose|Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg
214856038|NCT00353652|DRUG|Study #1: spironolactone (SP), titrated dose|Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.
214856039|NCT00353652|DRUG|Study# 2 chlorthalidone (CTD), fixed dose|Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
214856040|NCT00353652|DRUG|Study# 2 spironolactone (SP), fixed dose|Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
214856041|NCT00353652|DRUG|Study# 2 irbsesartan (IR), fixed dose|Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
214856042|NCT00822393|DRUG|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
214856043|NCT00822393|DRUG|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
214856044|NCT02088190|PROCEDURE|Sleeve gastrectomy|Type of bariatric surgery
214856045|NCT02041936|DEVICE|NanoKnife IRE System|
214856046|NCT04910659|OTHER|acupuncture|P6, LI4 and LI 11 stimulation
214856047|NCT04306237|DRUG|IMB-1018972|IMB-1018972 200 mg tablet for oral administration
214856048|NCT04306237|DRUG|Placebo oral tablet|Matched placebo tablet for oral administration
214856049|NCT00466908|DEVICE|Pentacam and IOL Master|Pentacam and IOL Master
214856050|NCT00350649|BEHAVIORAL|Standard CBT|Manualized delivery of CBT by trained clinicians
214856051|NCT00350649|BEHAVIORAL|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
214856052|NCT00350649|BEHAVIORAL|CM/abstinence|Contingency Management
214856053|NCT00350649|BEHAVIORAL|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
214290402|NCT01732250|DRUG|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
214856054|NCT03263039|DRUG|Pembrolizumab|Pembrolizumab 200 mg Q3W
214856055|NCT03499418|OTHER|modified Silverman scale|Clinical assessment of severity of respiratory failure
214856056|NCT03499418|DIAGNOSTIC_TEST|echocardiography|echocardiographic evaluation of haemodynamic problems
214856057|NCT04999033|OTHER|no intervention|This is a cross-sectional study, and no intervention will be included
214856058|NCT03533374|DIAGNOSTIC_TEST|Electroencephalogram (EEG) and visual evaluation|Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).
214856059|NCT02072148|PROCEDURE|PET/CT|PET scan or CT scan q 4 months for 5 years
214856060|NCT02072148|RADIATION|Radiotherapy|Postoperative XRT 5000 cGy
214856061|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy"
214856062|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy"
214856063|NCT02466230|DEVICE|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
214856064|NCT03456895|OTHER|Light perception|We will be using Wi-Fi/IP programmable LED lighting systems that will replace conventional lighting systems and may be in canned lights, spot lights, light chains or table lights. These lighting systems can be fully controlled by web based applications on smart phones tablets and computer systems and can be combined with input systems such as switches, motion detection or voice activated. Differences in lighting perception will be explored by varying lighting color and brightness.
214856065|NCT03456895|OTHER|Sound perception|We will be using Wi-Fi/Bluetooth addressable sound systems that will be linked with sound sources such as media players on smart devices or computer systems. Differences in sound perception will be explored by varying sound types (i.e. different music types, ambient noise, etc.).
214856066|NCT03456895|OTHER|Smell perception|We will explore the use of consumer grade ventilation systems that can be equipped to distribute packaged scents. Differences in smell perception will be explored by varying the types of scents.
214856067|NCT03456895|OTHER|Vibration perception|We will explore the use of chairs or blankets that enable subjects to perceive vibrations. An initial implementation will be the use of on relaxing/massage chair that enables the experience of vibration sensation in the back or leg area. We may use also potentially vibration blankets in the arm or neck area. Differences in vibration perception will be explored by varying the location, frequency, etc. of vibrations with the subject being placed in a chair on an imaging table/bed.
214856068|NCT03456895|OTHER|Voice activation|We will explore the use and linkage of voice activation system such as Amazon Echo, Google home or similar devices. Some participants may be asked to use voice activations to verbally select and/or change the environmental settings according to their preferences. We are evaluating the feasibility of voice activation with the imaging environment.
214856069|NCT03858595|DEVICE|Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. We will also measure weight gain of the mothers at monthly basis."
214856070|NCT04132895|OTHER|observational only, no interventions are prescribed in protocol.|"* Treatment will be given as per usual standard of care.~* No treatments are specified by this protocol."
214856071|NCT03858738|DEVICE|Thermographic breast examination performed by Braster device|Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
214856072|NCT01376817|DRUG|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
214856073|NCT01376817|DRUG|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
214856074|NCT00782821|DRUG|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
214856075|NCT00782821|DRUG|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
214856076|NCT00782821|DRUG|Rituxan|Given via IV per group assignment.
214856077|NCT01799863|DRUG|Ketorolac trometamol 0.45% with carboxymethylcellulose|
214856078|NCT01799863|DRUG|Preservative free artificial tear|
214856079|NCT05355714|DEVICE|Sofwave|High-Frequency Non-Focused Ultrasound Device
214856080|NCT05355714|DEVICE|Ultherapy|Microfocused Ultrasound with Visualization
214856081|NCT00177502|BEHAVIORAL|behavioral exercise intervention|
214856082|NCT02915965|DRUG|DCX|docetaxel, cisplatin and capecitabine
214856083|NCT02915965|PROCEDURE|surgery|Ivor Lewis Esophagectomy
214856084|NCT03932123|DRUG|Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin，cefotaxime|Efficacy and safety of antibiotics
214856085|NCT02528123|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
214856086|NCT02528123|DRUG|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
214856087|NCT02528123|DRUG|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
214856088|NCT02528123|DRUG|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
214856089|NCT02528123|DRUG|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
214856090|NCT00687310|BEHAVIORAL|Educational intervention|Tailored asthma education based on needs assessment
214856091|NCT01598350|DEVICE|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
214856092|NCT03735134|DRUG|Colchicine Loading Dose|Two milligrams of colchicine will be administrated in addition to the standard of care treatment
214856093|NCT03735134|DRUG|Standard of care treatment prior to elective PCI|All medications normally given to patients prior to elective PCI
214856094|NCT05847439|DRUG|[14C]BMS-986419|Specified dose on specified days
214856095|NCT04856124|DRUG|Intranasal esketamine|Subjects with a clinically meaningful response to IV racemic ketamine were switched to IN esketamine
214856096|NCT04744350|PROCEDURE|Treatment of FFP type IIb and IIc|Patients will either be randomized in the surgical or conservative group.
214856097|NCT06000917|DRUG|pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel|"Pyrotinib tablets: 320mg qd, oral administration after breakfast, 21 days for 1 cycle, continuous administration of 6 cycles.~Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles.~Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given.~Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration"
214856098|NCT05225974|DRUG|Liraglutide injection|At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection
214856099|NCT05225974|DRUG|Liraglutide injection(Victoza®)|At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
214856100|NCT02922101|BEHAVIORAL|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
214856101|NCT02922101|BEHAVIORAL|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
214856102|NCT05927272|PROCEDURE|SKIN SAMPLES|"At baseline: one 4 mm Ø skin biopsies: on forearms (excluding skin folds): fresh At month 3 and month 6: Two 4 mm Ø skin biopsies will be performed on the same lesion selected at baseline (one on a repigmented area, one on a non-responded area): fresh~Fresh Skin biopsies will be analyzed the same day using Single-cell RNA sequencing (scRNAseq)."
214856103|NCT05927272|PROCEDURE|BLOOD SAMPLES|Blood samples will be taken (30 mL) at week 0, week 12, week 24 for the measurement of pro-inflammatory cytokines and chemokines ligands in blood sera.
214856104|NCT05927272|DEVICE|narrowband UVB|narrowband UVB (Nb-UVB) 2 times a week
214856105|NCT05927272|DRUG|Systemic Steroids|Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks
214856106|NCT00045669|DRUG|imatinib mesylate|
214856107|NCT01400386|OTHER|Coffee bioavailability trial|Coffee bioavailability trial
214856108|NCT03832309|BEHAVIORAL|Do we speak to them in a way that convinces them to have the dream|During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
214856109|NCT03832309|BEHAVIORAL|Speaking to them as a regualar person|During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
214856110|NCT05754307|PROCEDURE|Access Flap|Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.
214856111|NCT05754307|PROCEDURE|Closed Surgical Technique|"Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentionally excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required."
214856112|NCT02262793|DRUG|telmisartan|
214856113|NCT02262793|DRUG|ASA/ER-DP|
214856114|NCT02583893|DRUG|Sirolimus|Given PO
214856115|NCT02583893|DRUG|Mitoxantrone|Given IV
214856116|NCT02583893|DRUG|Etoposide|Given IV
214856117|NCT02583893|DRUG|Cytarabine|Given IV
214856118|NCT00003093|BIOLOGICAL|filgrastim|
214290403|NCT01732250|DRUG|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
214290404|NCT00531050|DRUG|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
214290405|NCT00531050|DRUG|Placebo|Single dose indacaterol matching placebo via Concept 1 device
214856119|NCT00003093|BIOLOGICAL|sargramostim|
214856120|NCT00003093|DRUG|carboplatin|
214856121|NCT00003093|DRUG|cyclophosphamide|
214856122|NCT00003093|DRUG|doxorubicin hydrochloride|
214856123|NCT00003093|DRUG|etoposide|
214856124|NCT00003093|PROCEDURE|conventional surgery|
214856125|NCT00003093|PROCEDURE|neoadjuvant therapy|
214856126|NCT00815256|PROCEDURE|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
214856127|NCT06204211|DIAGNOSTIC_TEST|ophthalmologic examinations|All the included personnel underwent routine ophthalmologic examinations on binoculus, including slit lamp microscope observation, intraocular pressure, diopters of refractive error, best corrected visual acuity, AL measurement, fundus photography and optical coherence tomography, adhering to the established and normalized principles.
214856128|NCT01703884|DRUG|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (\> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
214856129|NCT03361384|DRUG|Alcohol|
214856130|NCT03361384|OTHER|Placebo (non-alcoholic beverage)|
214856131|NCT01574482|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
214856132|NCT01574482|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
214856133|NCT02816866|OTHER|empowered primary care model|mode of survivorship care
214856134|NCT02816866|OTHER|specialty survivor clinic|mode of survivorship care
214856135|NCT01251029|DRUG|N-acetylcysteine|1200 mg orally; 600mg i.v.
214856136|NCT01251029|DRUG|Siran (N-acetylcysteine)|
214856137|NCT02274844|BEHAVIORAL|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
214856138|NCT06420544|BEHAVIORAL|JAPI: Cognitive, Emotional and Social Stimulation for Preschool Children|"Those children in the intervention group will play with the gaming platform Japi using a tablet device in a designated time given from schools' authorities. Early Year Educators will be present to help with the discipline and motivation of the students and Research Assistants will be there as well to provide technical support for the use of the equipment.~The intervention has 24 sessions, and the dosage will be two sessions of 15 minutes each per week for 12 weeks. Sessions number 1 to number 8 are focused on emotional regulation and inhibitory control. Sessions number 9 to 16 work on working memory and problem-solving. Sessions number 17 to 24 promote empathy and planification skills. Each session will have eight activities with increasing levels of difficulty."
214856139|NCT04360044|DRUG|THC ~5%|4 puffs of vaporized flower containing THC \~5%
214856140|NCT04360044|DRUG|CBD ~12%|4 puffs of vaporized flower containing CBD \~12%
214856141|NCT04360044|DRUG|THC ~5% and CBD ~12%|4 puffs of vaporized flower containing THC \~5% and CBD \~12%
214856142|NCT04360044|DRUG|Sham Cannabis|4 puffs of vaporized flower from which the THC and CBD have been extracted
214856143|NCT04008966|DRUG|combined oral contaraceptive pills|1 tablet daily between days 5 and 25 of the cycle before stimulation
214856144|NCT04008966|DRUG|recombinant FSH|300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
214856145|NCT04008966|DRUG|Urinaru gonadotropin|150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
214856146|NCT04008966|DRUG|GnRH antagonist|0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
214856147|NCT04008966|DRUG|Human chorionic gonadotropin|10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
214856148|NCT04008966|DRUG|GnRH agonist|0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
214856149|NCT04008966|PROCEDURE|Ovum pick up|34 hours after triggering under the guidance of transvaginal ultrasound
214856150|NCT04008966|PROCEDURE|Embryo transfer|Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
214856151|NCT04008966|DRUG|natural Progesterone|400 mg twice daily per vagina
214290406|NCT00531050|DRUG|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
214290407|NCT00132145|BEHAVIORAL|Vascular Management Program|
214290408|NCT00132145|BEHAVIORAL|Clinical Care Coordinators|
214290409|NCT00132145|BEHAVIORAL|Web-based Vascular Tracker for Patient and Physician|
214290410|NCT00132145|BEHAVIORAL|Automated Telephone Reminder System|
214856152|NCT03317665|DEVICE|Mesh for hernia repair|Permacol, Parietex, Progrip, Strattice Perforated, and Surgimend.
214856153|NCT01892657|DRUG|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
214856154|NCT01829841|DRUG|Famitinib|Famitinib 25 mg p.o. qd
214856155|NCT01829841|DRUG|Sunitinib|Sunitinib 50 mg p.o. qd
214856156|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
214856157|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
214856158|NCT01507155|DEVICE|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
214856159|NCT00017719|DRUG|Lamivudine|
214856160|NCT00017719|DRUG|Lamivudine/Zidovudine|
214856161|NCT00017719|DRUG|Nelfinavir mesylate|
214856162|NCT00017719|DRUG|Nevirapine|
214856163|NCT00017719|DRUG|Zidovudine|
214856164|NCT04779541|OTHER|observation|observation of the mechanisms of acceptance or rejection of the vaccine
214856165|NCT05657236|OTHER|medical treatment|traditional medical treatment and regular follow-up
214856166|NCT05657236|OTHER|plyometric exercise|Each session starts with a 5-minute warm-up of flexibility exercises (active range motion and stretching exercises).The main plyometric exercise set will be applied for 20-30 minutes and consisted of 10 exercises directed at the lower body that gradually progress by increasing the set/repetition number in two exercise blocks, each continue for 1 month .The cool down period is 5 minutes and includes walking at self-preferred speed and static stretches of the major muscle groups.
214856167|NCT00299936|DRUG|Ribavirin, PEG-Intron|
214856168|NCT03840616|DRUG|Oteseconazole (VT-1161) 150mg capsule|600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.
214856169|NCT03840616|DRUG|Fluconazole 150mg capsule|150mg administered every 72 hours in 3 sequential doses starting on Day 1.
214856170|NCT03840616|DRUG|Placebo|Administered once weekly starting on Day 14.
214856171|NCT05284396|RADIATION|IFRT vs NFRT|involved field irradiation versus nodal field irradiation
214856172|NCT00169819|DRUG|Abciximab|
214856173|NCT03166683|OTHER|Hemopatch|Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement
214856174|NCT03166683|OTHER|Standard of care|Standard of care include other sealant / hemostatic devices as patches or liquid/gels
214856175|NCT06062797|DEVICE|Mixed Reality Viewer|The Mixed Reality Viewer from Brainlab (Germany) enables the visualization of the fracture via a 3D hologram. In contrast to virtual reality, where the user is in a completely virtual world, the user of the mixed reality viewer sees the 3D hologram implemented in his real environment.
214856176|NCT06062797|DEVICE|X-ray or CT scan|X-ray or CT scan enables the visualization of the fracture in 2D.
214856177|NCT00302120|PROCEDURE|Contrast-enhanced MR mammography|
214856178|NCT05444686|DIAGNOSTIC_TEST|99mTc-FAPI|inject the tracer to subjects and perform SPECT/CT scans
214856179|NCT01168206|DIETARY_SUPPLEMENT|TK3|Tritofano 160mg / Timina140mg and starch 150 mg
214856180|NCT01168206|DIETARY_SUPPLEMENT|1 capsule, 3 times per day|Placebo
214856181|NCT03867799|DRUG|Nivolumab|Immunotherapy
214856182|NCT02158611|OTHER|Lifestyle counseling|
214856183|NCT00140621|DRUG|Agalsidase beta|
214856184|NCT05738759|DRUG|Epidural Anesthetic Cocktail|The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.
214856185|NCT05738759|DRUG|Placebo|The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
214856186|NCT00474474|PROCEDURE|Virtual patient is NOT introduced|
214856187|NCT00048204|DRUG|GW597599B|
214856188|NCT00048204|DRUG|paroxetine|
214856189|NCT03373734|DEVICE|Enjoy Your Bump|Online life skills course based on Cognitive Behavioural Therapy Principles.
214856190|NCT03463993|DRUG|Tranexamic Acid|TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.
214856191|NCT03463993|DRUG|Oxytocin|5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
214856192|NCT00932230|OTHER|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
214856193|NCT00930254|PROCEDURE|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
214856194|NCT03325465|DRUG|Pembrolizumab|Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
214856195|NCT03325465|DRUG|Epacadostat|Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
214856196|NCT06285630|OTHER|Observational, no intervation will be made|No intervention will be made, only longitudinal sample collection.
214856197|NCT05913466|DRUG|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
214856198|NCT05913466|DRUG|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
214856199|NCT00683267|DRUG|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
214856200|NCT00683267|DRUG|Placebo|One dose administered by direct instillation into the surgical site
214856201|NCT02709954|DRUG|Active inhaled delta-9-THC|"Low dose THC (\~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
214856202|NCT02709954|DRUG|Placebo|Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
214856203|NCT02709954|DRUG|Placebo|Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
214856204|NCT02709954|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
214856205|NCT05308264|DRUG|R906289 Monosodium (R289 Na)|Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)
214856206|NCT06079697|OTHER|Electronic Health Record Review|Ancillary studies
214856207|NCT06079697|OTHER|Exercise Intervention|Receive prehabilitation exercise intervention
214856208|NCT06079697|OTHER|Medical Device Usage and Evaluation|Wear Fitbits
214856209|NCT06079697|OTHER|Survey Administration|Ancillary studies
214856210|NCT01478828|DRUG|Lovastatin|oral qd varying dose escalations/de-escalations
214856211|NCT00328679|DEVICE|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
214856212|NCT03026907|DRUG|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
214856213|NCT03026907|DRUG|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
214856214|NCT04867187|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|20 minutes of high frequency (20Hz) rTMS.
214856215|NCT04867187|OTHER|Mirror therapy using virtual reality|active mirror-based therapy
214856216|NCT04867187|OTHER|Mirror therapy using sham mirror|20 minutes of sham mirror-based therapy
214856217|NCT06324799|OTHER|phototherapy treatment|The newborns in the study group will be subjected to position changes (supine, prone, lateral) every 2 hours
214856218|NCT06465485|DRUG|Benralizumab|Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be enrolled into this single arm treatment.
214856219|NCT06294236|BIOLOGICAL|SC291|SC291 is an allogeneic CAR T cell therapy
214856220|NCT05118087|PROCEDURE|Webril Padded Plaster Splint|Patients in the coaptation splint group will have a webril padded plaster splint that is placed around the humerus. The forearm and wrist are then suspended in a cuff and collar.
214856221|NCT05118087|PROCEDURE|Pre-Fabricated Fracture Brace|Patients in the sarmiento group will be given a fitted pre-fabricated fracture brace with a cuff and collar for the forearm. The patients will be educated on brace maintained, tightening, and care during at the time of the ER encounter.
214856222|NCT05496387|OTHER|Sciatic nerve neuromobilization techniques|Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
214856223|NCT06346340|DRUG|Miebo|Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.
214856224|NCT04967872|OTHER|Implementing risk management and control plan for the elderly during perioperative period|Visualization technology is used for preoperative evaluation, anesthesia management, bedside real-time monitoring and intervention, etc., to achieve accurate perioperative management of elderly patients and whole-process whole-person management
214856225|NCT00505648|DRUG|Tegeline®|2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
214856226|NCT01091272|DRUG|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
214856227|NCT01091272|DRUG|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
214856228|NCT01091272|DRUG|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
214856229|NCT01091272|DRUG|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
214856230|NCT00136318|DRUG|Escitalopram|
214856231|NCT00136318|DRUG|Placebo|
214290411|NCT04688762|OTHER|e-consult application (tool)|A numeric application used as a support in consultation to explain the surgical management of the patient.
214856232|NCT00136318|DRUG|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
214856233|NCT00136318|DRUG|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
214856234|NCT02686203|DEVICE|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment"
214856235|NCT01835379|DEVICE|Oasis|Oasis Ultra will be applied once per week for up to 12 weeks.
214290412|NCT01067456|RADIATION|Comprehensive Cardiothoracic CT arm|Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
214290413|NCT02781051|BEHAVIORAL|Print-based education|All subjects will be given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors. Topics covered within the book include benefits of exercise in breast cancer survivors; recommendations on type, duration, frequency and intensity of exercise; goal-setting; and advice on overcoming barriers.
214290414|NCT02781051|DEVICE|Fitbit|Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.
214856236|NCT01835379|OTHER|Standard|
214856237|NCT04845906|DEVICE|StatLock™ Catheter Stabilization Device and the StatLock™ stabilization device accessory (Foam Strip)|Each participant will have 2 separate devices applied, one to each arm, with or without a Foam Strip.The participant will also wear a dressing over top of a StatLock™ compatible catheter, which will be connected to an extension set. For this study, the catheter will not be inserted into the study participant but instead will be shortened or modified and placed on the skin and secured with the StatLock™ Stabilization Device. The use of the catheters, extension set, and the dressing represents how the device would be used in a clinical setting.
214856238|NCT00313456|DRUG|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
214856239|NCT06254144|BEHAVIORAL|functional magnetic resonance imaging (fMRI)|The investigators will utilize standard BOLD fMRI in blocked-design tasks and resting state (participant is given no overt task) in the study. Anatomical scans with T1-weighted contrast, quantitative measurement of spin relaxation times, and diffusion tensor imaging (DTI) are also used as an anatomical reference for functional activation as well as to investigate a brain structural relationship with the participants' task performance, including successful emotion regulation.
214856240|NCT05878184|DRUG|SC291|SC291 is an allogeneic CAR-T cell therapy
214290415|NCT02781051|BEHAVIORAL|Active Living counseling|The Active Living counseling program consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, and time management.
214856241|NCT05272982|DIAGNOSTIC_TEST|Thoracic fluid content by electrical cardiometry group|Thoracic fluid content will be measured using electrical cardiometry device (ICON ® Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). The ICON device will be connected to four electrocardiogram electrodes which will be placed over patients' skin after cleaning with alcohol at the neck below the left ear, just above the left clavicular midpoint, and two electrodes at left mid-axillary line one at the level of the xiphoid process, and the other electrode 5 cm below this point. The thoracic fluid content will be observed for 30 s and the average of the highest and lowest values will be recorded.
214856242|NCT05272982|DIAGNOSTIC_TEST|Ultrasound examination group|The 12-region technique for lung assessment will be performed using Philips ® (CX50 - Extreme edition) equipped with phased array transducer. B-line will be defined as laser like vertical hyperechoic artefact which extends between the pleural line and the bottom of the screen and moves with respiratory movements. Two types of B-lines will be evaluated.
214856243|NCT06046248|DRUG|Belumosudil|200mg PO QD x 24 cycles (28-day cycle)
214856244|NCT06046248|DRUG|Rituximab|375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
214856245|NCT06091280|DEVICE|Respiratory Muscle Strength Trainers|Devices provided to each participant. Resistance loading set at less than 50% of the peak inspiratory and peak expiratory flow rate.
214856246|NCT05020314|BEHAVIORAL|Healthy Weight Clinic|Patients meet with a multi-disciplinary team over a 12 month period. In addition to the clinical visits, group visits, and phone calls, patients will also receive education materials, community resources, and an optional text messaging/social media library of messages.
214856247|NCT06583018|BEHAVIORAL|In-Person Mindfulness-based Group Sessions|The 3-hour group-based session in week 1 focuses on experiential mindfulness practices, and a booster session in week 5 further consolidates these mindfulness techniques, reinforces mindful, healthy lifestyle, and provides peer support. Participants will enhance their self-awareness of positive, neutral, and negative body sensations, feelings, and thoughts while engaging in healthy behaviors, particularly physical activity.
214856248|NCT06583018|BEHAVIORAL|Ecological Momentary Interventions (EMI)|Participants will receive personalized instant messages with chat-based support throughout the 8-week intervention period. The message content is guided by existing international lifestyle modification guidelines and the Integrated Body-Mind-Spirit Model. The pre-set frequency of regular message delivery is five times per week. The schedule of message delivery will be personalized according to the participants' on-going needs/preferences over the intervention period. Chat-based support will be provided by trained research assistants, who will utilize motivational interviewing techniques to enhance participant compliance and effectiveness.
214856249|NCT06583018|BEHAVIORAL|In-person Lifestyle Education Session|A 3-hour group-based session in week 1 focused on general education on lifestyle modification based on the HEARTS technical package as recommended by the WHO, and will only receive reminder messages for the two assessment follow-ups. No chat-based support will be provided.
214856250|NCT06583018|DEVICE|Activity Monitoring|All participants will wear an accelerometer-based wristband activity tracker to monitor their physical activity in daily life.
214856251|NCT06439602|DRUG|AR882 50 mg|Solid Oral Capsule
214856252|NCT06439602|DRUG|AR882 75 mg|Solid Oral Capsule
214856253|NCT06439602|DRUG|Placebo|Matching Solid Oral Capsule Placebo
214856254|NCT04725058|OTHER|Medical Group Visit|A group of 20 or more participants will receive obesity management through endocrinologist and registered dietitian in a group seetting.
214856255|NCT04725058|OTHER|Dietitian Individual Visit|Participant receives obesity management individually from a registered dietitian.
214856256|NCT03284866|OTHER|Laboratory Biomarker Analysis|Correlative studies
214856257|NCT03284866|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
214856258|NCT03284866|OTHER|Saline|Given IM
214856259|NCT06849648|DEVICE|The Buzzy Device|In essence, the Buzzy device offers a multi-sensory approach (vibration + cold) in conjunction with a hygienic protocol, which is a key differentiator from other non-pharmacological interventions such as distraction through toys, videos, or verbal techniques. Currently, there is no studies evaluating the use of the Buzzy device and finger puppets, which are nonpharmacologic methods, in relation to the levels of pain, fear, and anxiety in children aged 4-7 years undergoing venipuncture procedures in emergency department settings.
214290416|NCT02781051|OTHER|Facility Access|Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.).
214290417|NCT02233309|OTHER|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
214290418|NCT01601249|PROCEDURE|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
214290419|NCT03590145|DIAGNOSTIC_TEST|Clinical examination|Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
214290420|NCT00255827|BIOLOGICAL|HyperAcute-Pancreatic Cancer Vaccine|
214290421|NCT04630418|OTHER|NanoSilk Cosmo|Participant will receive 30 mL of NanoSilk Cosmo jar.
214290422|NCT01737944|DRUG|Methotrexate (MTX)|Vibex MTX Device
214290423|NCT01052051|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU/daily
214856260|NCT06849648|DEVICE|Finger Puppet|Finger puppets were used to distract the participants during venepuncture procedure. Children are allowed to pick their favourite animals. These soft in various shaped finger puppets can be placed on adult's fingers. One minute before the venipuncture procedure, the researcher (K.O.) engaged the participants in finger puppet play and initiated conversation by asking; 'Hello, how are you? What is this figure? Do you know where this animal/figure live in? Have you previously seen this animal/figure alive? Have you been in a zoo? Additionally, techniques such as having the animals 'sing' or 'interact' with each other were employed to capture the child's attention on the finger puppets. Children in this group were not given any distraction techniques prior to the procedure. All groups' parents accompanied over their children during the process, but they were not permitted to comfort them.
214856261|NCT04890093|DRUG|PEN-866|PEN-866 will be given as an IV infusion once every week for the first two consecutive weeks out of every three-week (21 day) cycle.
214856262|NCT04890093|DRUG|Vincristine|Vincristine will be given at a dose of 1.5 mg/m2 by IV on days 1 and 8 of each 21-day cycle
214856263|NCT04890093|DRUG|Temozolomide|temozolomide will be given at a dose of 100 mg/m2, orally on days 1-5, of each 21-day cycle
214856264|NCT02172196|DRUG|BI 10773|
214856265|NCT02172196|DRUG|Sitagliptin|
214856266|NCT01884064|DEVICE|rTMS|rTMS
214856267|NCT01884064|DEVICE|Sham rTMS|Sham rTMS
214856268|NCT01164215|DRUG|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
214856269|NCT01164215|DRUG|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
214856270|NCT01164215|DRUG|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
214856271|NCT06617572|GENETIC|Non-conforming afamitresgene autoleucel|Non-conforming afamitresgene autoleucel, suspension for intravenous infusion (NC afami-cel), single dose administration
214856272|NCT02117388|BEHAVIORAL|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
214856273|NCT02117388|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
214856274|NCT02117388|BEHAVIORAL|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
214856278|NCT03910764|OTHER|no intervention|Investigators review patients' medical records and collect personal data, underlying diseases, indwelling catheter duration, laboratory data, diagnosis, treatment and prognosis.
214856279|NCT05342649|PROCEDURE|P-CTG|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
214856280|NCT05342649|PROCEDURE|CTG|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
214856281|NCT04593342|DEVICE|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
214856282|NCT04593342|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
214856283|NCT02551393|BEHAVIORAL|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
214856284|NCT06324058|PROCEDURE|Transurethral cryoablation|Using an intracavitary cryoablation balloon, cryoablation is performed on the wound surface after tumor resection. The wound surface is frozen for 2 rounds, with each round lasting 3 minutes, to fully cover the wound surface.
214856285|NCT06324058|PROCEDURE|Transurethral resection of bladder tumor|Resection of bladder tumor using resectoscopy, which is a standard procedure to treat non-muscle invasive bladder cancer
214856286|NCT06324058|DRUG|Bcg Intravesical|Bacillus Calmette-Guerin instillation of bladder after surgery according to the NCCN bladder cancer guidelines. At least 6 weeks induction instillation is required for high-risk NMIBC patients. At least 1 year maintenance instillation is recommended.
214856287|NCT04574128|PROCEDURE|No retransfusion of cardiotomy blood|No retransfusion of cardiotomy blood via heart- and lung mashine
214856288|NCT03304028|DEVICE|Connected Devices for 3 months|Inclusion will be proposed at a follow-up visit by the child's or adult's referring doctor. A written informed consent form will be obtained. Quality of Life and Anxiety-Depression will be collected. Then, each included patient will be equipped with CDs-spirometer, oxymeter, scale and watch during 3 months for base-line.
214856289|NCT03304028|BEHAVIORAL|Educationnal Intervention|After a first statistical analysis and interpretation (5 months), alert parameters for each patient are then fixed. An educational visit will be scheduled with patients and a personnalized action plan will be defined..
214856290|NCT03304028|DEVICE|Connected Devices for 12 months|Each included patient will be re-equipped with CDs-spirometer, oxymeter, scale and watch during 12 months. If alerts occur, patients will be informed by email or SMS, with data transmission to the medical team who will not interfere. Patients should apply the shared action plan they learned. Quality of Life and Anxiety-Depression will be collected.
214290424|NCT01052051|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 1500mg / daily
214856291|NCT03304028|OTHER|Interviews|At the end, semi-structured interviews will be completed to explore confidence on the CDs, impact on the doctor-patient relationship, change in the workload of medical team…etc.
214856292|NCT03304028|BEHAVIORAL|Refusal Questionnaires|Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal
214856293|NCT03185403|OTHER|paravertebral block|in the paravertebral block , the catheter was placed under ultrasound echography , at the right thoracic T4/T5 level
214856294|NCT03185403|OTHER|thoracic epidural block|in the epidural block the catheter was inserted without echography , at T4/T5 level
214856295|NCT03185403|DRUG|ropivacaine|
214856296|NCT03185403|DRUG|Sufentanil|
214856297|NCT00767338|BEHAVIORAL|Timed intercourse|Timed intercourse
214856298|NCT00767338|PROCEDURE|Microsurgical varicocelectomy|Microsurgical varicocelectomy
214856299|NCT00767338|PROCEDURE|Intrauterine insemination|Intrauterine insemination
214856300|NCT03295695|DIAGNOSTIC_TEST|Fluoro-D-glucose-positron Emission Tomography|2-deoxy-2-\[18F\]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.
214856301|NCT03295695|BIOLOGICAL|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|"2-deoxy-2-\[18F\]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.~Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer."
214856302|NCT03295695|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
214856303|NCT03100734|BIOLOGICAL|Benepali|As specified in the treatment arm
214856304|NCT03100734|BIOLOGICAL|Enbrel|As specified in the treatment arm
214856305|NCT03674502|DRUG|ADU-1604|anti-CTLA-4 monoclonal antibody
214856306|NCT00833352|DEVICE|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
214856307|NCT01408095|DRUG|LY2608204|Administered orally
214856308|NCT01408095|DRUG|Glimepiride|Administered orally
214856309|NCT04414436|BEHAVIORAL|GYNEA- digital coping program for women after gynaecological cancer|6 modules with relevant information and tools for coping after cancer
214856310|NCT06367595|DRUG|Magnesium sulfate|IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine
215033580|NCT04002375|OTHER|pectouteropexy|The surgical procedure was initiated after adhesiolysis had been performed by opening the peritoneal layer along the round ligament toward the pelvic side wall. Preparation started at the right external iliac vein and was performed in the medial and caudal direction. A segment of area approximately 3- 4 cm2 of the right lateral part of the iliopectineal ligament (Cooper ligament) adjacent to the insertion of the iliopsoas muscle was exposed.The peritoneum of the bladder was dissected, and the anterior parts of the distal uterus were prepared for mesh fixation. The uterus was elevated to the intended tension-free position using the transvaginal probe (POP-Q level 0-1). The mesh was fixed anteriorly to the cervix using four polyester permanent sutures (Ethibond Excel®; Ethicon). Finally, the mesh was covered with peritoneum using a continuous monofilament absorbable suture (Maxon™; Medtronic).
214856311|NCT00004997|DRUG|Leucovorin|
214856312|NCT00732433|PROCEDURE|digital mammography|Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
214856313|NCT04666519|DIAGNOSTIC_TEST|Zonulin Biomarker|During revision hip and knee surgery, discarded fluid/blood will be tested for the presence of zonulin biomarkers
214856314|NCT04560348|OTHER|adventure-based cognitive behavioral intervention|The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
214856315|NCT01969292|OTHER|Colometer|Real time software based image analysis tool.
214856316|NCT01969292|OTHER|Sham Software|Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
214290425|NCT03569540|DRUG|Glibenclamide|Placebo-controlled; Double blind test
214290426|NCT03569540|OTHER|Placebo|Amylum
214856317|NCT02255682|DRUG|Simvastatin|
214856318|NCT02255682|DIETARY_SUPPLEMENT|Q10|
214290427|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
214290428|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
214290429|NCT00384995|DRUG|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
214856319|NCT01524250|DRUG|corticosteroids|1250mg of oral prednisone daily for 3 days
214856320|NCT01524250|DRUG|corticosteroids|1000mg IV methylprednisolone daily for 3 days
214856321|NCT04710511|OTHER|Child and Youth Resilience Measure - Revised (CYRM-R)|(CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent
215033581|NCT03898180|BIOLOGICAL|Pembrolizumab|IV infusion
215033582|NCT03898180|DRUG|Lenvatinib|oral capsule
215033583|NCT03898180|DRUG|Placebo for lenvatinib|oral capsule
215033584|NCT02472249|RADIATION|CT perfusion|Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
215033585|NCT02472249|DRUG|Norepinephrine intra-arteriel/hepatic|A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds..
215033586|NCT02423486|DEVICE|Electromagnetic stimulation therapy (BIOCON-2000)|
215033587|NCT02423486|DEVICE|Electromagnetic stimulation therapy with biofeedback|
215033588|NCT05147220|DRUG|Remibrutinib|tablet taken orally
214856322|NCT02494817|BEHAVIORAL|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
214856323|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|0.5 mL, Subcutaneous
214856324|NCT01064141|BIOLOGICAL|OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|0.5 mL, Subcutaneous and 0.5 mL, Intravascular
214856325|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
214856326|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)|0.5 mL Subcutaneous and 0.5 mL Subcutaneous
214856327|NCT03552094|OTHER|Blood donations of hemochromatosis or polycythemia patients|Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
214856328|NCT03552094|OTHER|Blood donations of healthy donors|Blood samples are from blood donations of healthy donors.
214856329|NCT06482892|DRUG|TP03HN106|"During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia."
214856330|NCT05822245|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
214856331|NCT05822245|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
214856332|NCT05822245|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
214856333|NCT03453840|DRUG|Artemether-lumefantrine|Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.
214856334|NCT06330181|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart"
214856335|NCT06330181|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
214856336|NCT06387173|OTHER|Non-Interventional Study|Non-interventional study
214856337|NCT05322837|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires related to upper limb function and quality of life will be used
214856338|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
214856339|NCT00865631|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
214856340|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
214856341|NCT00378950|BEHAVIORAL|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
214856342|NCT00378950|BEHAVIORAL|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
214856343|NCT03250390|DEVICE|Collection of volatile organic compounds during exhalation|"The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)"
214856344|NCT01914172|OTHER|online questionairres|see group descriptions
214856345|NCT03527654|OTHER|Observational|Surveys, blood and urine collected prospectively over 24 months.
215033589|NCT05147220|DRUG|Teriflunomide|capsule taken orally
214290430|NCT00384995|DRUG|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
214290431|NCT04726423|OTHER|transcranial direct current stimulation|5 daily sessions of tDCS (2mA, 20 min) were recommended to all patients. Physical exercises were also done at the physiotherapy clinic. Physical exercises program was recommended to be continued at home after the week of physiotherapy visits.
214290432|NCT00002925|DRUG|ara-C|
214664889|NCT07087574|DEVICE|adapted cutlery handle printed with 3D printer|"The patient's autonomy will be assessed by the same ergotherapist, and the quantity of food ingested will be measured by a dietician at 3 similar lunch times:~* before using the adapted cutlery handles (Day0);~* when the adapted cutlery handles are used for the first time (Day1);~* after 3 days' use of the adapted cutlery handles (Day3) On Day0 and Day3, the ergotherapist will carry out an ecological assessment of the meals. Ecological assessment is used in occupational therapy to observe and analyze the patient's interactions with his environment and their repercussions on his ability to perform a task. The aim here is to assess whether the patient exhibits compensation of the upper limb (such as shoulder elevation or trunk inclination) during the meal performed without technical aids (Day0) and that performed after the learning phase of using the adapted handle (Day3).~The patient's participation will end at the end of the Day3 assessments."
214664890|NCT03856216|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given IV
214664891|NCT03856216|DRUG|Bendamustine|Given IV
214664892|NCT03856216|BIOLOGICAL|Filgrastim-sndz|Given IV
214664893|NCT03856216|DRUG|Fludarabine|Given IV
214664894|NCT03856216|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214664895|NCT03856216|DRUG|Melphalan|Given IV
214664896|NCT03856216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
214664897|NCT03856216|BIOLOGICAL|Rituximab|Given IV
214664898|NCT03856216|DRUG|Tacrolimus|Given IV and PO
214664899|NCT06904105|DRUG|HRS-7535 Tablets|HRS-7535 tablets.
214664900|NCT06904105|DRUG|HRS-7535 Placebo Tablets|HRS-7535 placebo tablets.
214664901|NCT07106073|OTHER|Collection of demographic, anthropometric and clinical data.|"Data collected is:~* demographic data: age, sex;~* anthropometric data: weight, height, body mass index;~* clinical data:~  * Palliative Performance Scale;~ * Palliative Prognostic Index;~ * comorbidities;~ * therapy;~ * presence of medical devices;~ * presence of pressure injuries;~ * time on waiting list;~ * place of care;~ * primary diagnosis;~ * length of stay;~ * symptom burden at admission (Edmonton Symptom Assessment System);~ * onset of fever and its characteristics (duration, intensity, treatment, etiology);~ * need for sedation (duration, refractory symptom(s));~ * outcome."
214856346|NCT06815601|OTHER|rTMS|Intermittent theta burst stimulation (iTBS) will be utilized since they have been reported to have a cortical neuromodulatory effect. The iTBS protocol will be applied over primary motor cortex to investigate its effect on corticospinal excitability and functional outcome. Theta burst stimulation (TBS) consists of bursts of pulses containing 3 pulses at 50 Hz (3 pulses per second) repeated at 200 ms intervals (5 Hz). During iTBS, a 2 second train of TBS is repeated every 10 seconds (600 pulses in 190 seconds).
214664902|NCT07107828|OTHER|Ambient air|Standard ambient air will be breathed during endurance training.
214664903|NCT07107828|OTHER|Oxygen|SSOT will be applied during endurance training
214664904|NCT07107828|OTHER|Altitude|Training will be performed at moderate altitude
214664905|NCT07107334|DRUG|Glucagon-like peptide 1 receptor agonist|Subjects will receive a glucagon-like peptide 1 receptor agonist by self-injection for as long as clinically indicated by the treating physician or until the subject receives clearance for staging hysterectomy or for pregnancy pursuit. The choice of glucagon-like peptide 1 receptor agonist for each subject will be at the treating physician's discretion. Subjects will discontinue the glucagon-like peptide 1 receptor agonist 2 weeks before any elective surgical procedure.
214664906|NCT05936359|DRUG|INCA033989|INCA033989 will be administered at protocol defined dose.
214664907|NCT05936359|DRUG|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
214664908|NCT07106502|PROCEDURE|testicular palpation training on a mannequin|Study of testicular palpation training on a mannequin on the ability to perform a testicular examination and diagnose testicular positioning abnormalities
214664909|NCT07107087|OTHER|Multi-Modal Integrated Intervention Combining Exercise, Anti-inflammatory & Dietary Advice (MMIEAD)|In addition to their standard care, the intervention group will receive MMIEAD - an individualised exercise programme, oral omega-3 supplementation and dietary advice.
214664910|NCT07108153|DRUG|SION-719|All participants receive SION-719, as specified by their treatment sequence assignment
214664911|NCT07108153|DRUG|Placebo-to-match SION-719|All participants receive placebo to match SION-719, as specified by their treatment sequence assignment
214856347|NCT06815601|OTHER|Sham rTMS|Sham iTBS protocols will be applied with the same parameters as in iTBS protocol. However, sham coil will be used.
214664912|NCT07106151|BEHAVIORAL|Transmission of additional AKI-D recovery information|Measuring residual kidney function at the time of hospital discharge by timed urine collection (6-24 hours in duration), transmitting the results (urine volume, urea clearance, and creatinine clearance) to the accepting nephrologist and to the patient, along with information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule.
214664913|NCT07106151|OTHER|No additional AKI-D recovery information|The same timed urine collection will be collected at the time of hospital discharge as in the intervention arm, but in the control arm the results will not be transmitted to the accepting nephrologist or to the patient and no information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule will be transmitted. Instead, the research team will call the accepting nephrologist to alert them that this is an AKI-D patient that is being followed by the research team for recovery for up to 60 days.
214664914|NCT07105566|DIAGNOSTIC_TEST|serum TPI|serum TPI level
214664915|NCT07106099|BEHAVIORAL|Training given with the tell-what-you-learned method|Students in the intervention group will be given training on diagnosing the symptoms and risks of child abuse and neglect, given by the tell-what-you-learned method, and will be given a practice in which its effectiveness will be evaluated.
214664916|NCT07105735|BIOLOGICAL|allogeneic CAR-T|Fludarabine injection (30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before RN1201 infusion.
214664917|NCT07105683|OTHER|hot pack therapy|Application of a commercial hot pack to the lumbar region for 20-30 minutes per session, twice daily, for 6 weeks.
214856348|NCT06815601|BEHAVIORAL|Motor training|The motor training will be focused on participant's hand motor function such as grasping function.
214290433|NCT00002925|DRUG|Daunorubicin|
214290434|NCT00002925|DRUG|Etoposide|
214856349|NCT06843356|PROCEDURE|Endovascular Treatment|Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
214856350|NCT06318039|OTHER|Novel program|Applying new training method; the Nordic hamstring exercise
214856351|NCT06318039|OTHER|Traditional program|Conventional rehabilitation training administered
214856352|NCT01897623|OTHER|ultrasound of aorta|
214856353|NCT04830917|OTHER|Immobilization type for mallet injury|Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury
214856354|NCT05054218|BIOLOGICAL|mRNA-1273|Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.
214856355|NCT00759278|PROCEDURE|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
214856356|NCT01076556|DRUG|Alvocidib Hydrochloride|Given IV
214856357|NCT01076556|DRUG|Cyclophosphamide|Given IV
214856358|NCT01076556|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214856359|NCT01076556|OTHER|Pharmacological Study|Correlative studies
214856360|NCT01076556|BIOLOGICAL|Rituximab|Given IV
214856361|NCT03700645|DRUG|Allopurinol|Allopurinol
214856362|NCT02669160|DEVICE|PC Innowalk|
214856363|NCT02669160|DEVICE|Conventional passive stander|
214856364|NCT05528861|DRUG|Lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
214856365|NCT05528861|OTHER|Placebo|Placebo
214856366|NCT01602172|BEHAVIORAL|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
214856367|NCT01602172|OTHER|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
214856368|NCT04448496|DRUG|Dexamethasone implant|Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
214856369|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv low dose.|Attenuated chimp adenovirus. 5x10\^9 virus particles.
214856370|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv high dose.|Attenuated chimp adenovirus at 5x10\^10 virus particles.
214856371|NCT01151319|BIOLOGICAL|pSG2.HIVconsv|DNA at 4mg per dose.
214856372|NCT01151319|BIOLOGICAL|MVA.HIVconsv|Attenuated poxvirus at 4x10\^8 plaque forming units per dose.
214856373|NCT01151319|OTHER|Placebo|Phosphate buffered saline
214856374|NCT01194102|BEHAVIORAL|Community Based Exercise Program|Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.
214856375|NCT01194102|OTHER|Living with Stroke Education program|Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.
214856376|NCT01194102|OTHER|YMCA membership|Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
214856377|NCT02654587|BIOLOGICAL|OSE2101|
214856378|NCT02654587|DRUG|Docetaxel|
214856379|NCT02654587|DRUG|Pemetrexed|
214856380|NCT04526652|DRUG|Dexmedetomidine|Evaluating anxiety score in both arms
214856381|NCT04526652|DRUG|Placebo|Evaluating anxiety score in both arms
214856382|NCT05883033|DEVICE|VAC|Vacuum Assisted Closure device
214856383|NCT00005119|PROCEDURE|Measures of calcium and bone turnover|
214856384|NCT04858659|DRUG|PK101|1 tablet at each time, 2 times a day
214290435|NCT00002925|DRUG|PSC-833|
214856385|NCT04858659|DRUG|PK101-002|1 tablet at each time, 2 times a day
214856386|NCT04858659|DRUG|PK101 placebo|1 tablet at each time, 2 times a day
214856387|NCT04858659|DRUG|PK101-002 placebo|1 tablet at each time, 2 times a day
214856388|NCT04224727|BEHAVIORAL|Group Commitment Contract|A group contract where the primary individual, who will be tracked by the study, can invite peers to join the contract and form their group. To initiate a contract, a user must choose: the stakes, start date, and (for weight loss contracts) target weight, and and, optionally, to allow other members to have the power to invite other people to join the group.
214856389|NCT04224727|BEHAVIORAL|Individual Monetary Rewards|Individuals eligible for a $100 monetary reward (incentive) following verified smoking cessation or weight loss.
214856390|NCT04224727|BEHAVIORAL|Individual Commitment Contract|Individuals will have the opportunity to create an individual commitment contract to quit smoking. They will have the option to set the stakes, start date, and (for weight loss contracts) target weight.
214856391|NCT04224727|OTHER|Information|"In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates."
214856392|NCT04606836|DRUG|Bupivacaine Hydrochloride|See group descriptions
214856393|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Calcipotriol ointment|
214856394|NCT02191007|DRUG|Calcipotriol Betamethasone ointment|
214856395|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Urea Cream|
214664918|NCT07105683|GENETIC|Kinetic control training|is an evidence-based rehabilitation approach, focused on retraining movement patterns by addressing and improving motor control of the lumbar spine and pelvis, correcting faulty movement strategies, enhancing stability in functional tasks. The principles of KCT entail the identification of direction-specific motor control deficit, uncontrolled extension, followed by focused retraining of movement control through specific exercises designed to improve the coordination and activation of deep stabilizing muscle systems, including the transversus abdominis, multifidus, and pelvic floor muscles. This approach is especially relevant in postpartum women, where motor control deficits and poor load transfer capabilities are commonly observed . Based on the clinical presentation of patients with postnatal low back pain, demonstrated symptoms that were aggravated during lumbar extension movements or when maintaining prolonged upright postures. The
214664919|NCT07106320|DEVICE|VDW Ultra Ultrasonic Irrigation Activation|Irrigation will be activated using an ultrasonic tip (IRRI S 21/25) connected to the VDW Ultra device (VDW GmbH, Munich, Germany), 2 mm short of working length. NaOCl and EDTA will each be activated for 20 seconds, repeated three times.
214664920|NCT07106320|DEVICE|EDDY Sonic Irrigation Activation|Irrigation solution will be activated using the EDDY sonic tip (VDW GmbH, Munich, Germany), positioned 2 mm short of the working length. NaOCl and EDTA will each be activated for 20 seconds, repeated three times.
214664921|NCT07106320|PROCEDURE|Conventional Needle Irrigation|Irrigation will be performed using a syringe and needle without activation. A total of 6 ml NaOCl, 2 ml EDTA and 5 mL of sterile saline will be used during final irrigation.
214664922|NCT07106177|OTHER|Scanning with verification jig|Comparing Relative Implant Positions of the 4 implants in each case obtained through desktop scanning of intraoral provisional verification jig. All-on-4 treatment for mandibular and maxillary edentulous cases were scanned using the Medit i700 intraoral scanner. Scan data were imported into Exocad software, where scan-body matching was performed using the Neodent library to determine the positions of multiunit abutment analogues.
214664923|NCT07106177|OTHER|Direct intraoral scanning|Comparing Relative Implant Positions of the 4 implants in each case obtained through direct intraoral scanning without jig. All-on-4 treatment for mandibular and maxillary edentulous cases were scanned using the Medit i700 intraoral scanner. Scan data were imported into Exocad software, where scan-body matching was performed using the Neodent library to determine the positions of multiunit abutment analogues.
214664924|NCT07105995|OTHER|Examination and questionnaire|Participants will be enrolled in the study and will complete the Temporomandibular Disorders/Diagnostic Criteria (TMD/DC) questionnaire. Subsequently, the investigator will conduct a clinical examination to assess each participant's eligibility based on the predefined inclusion criteria.
214664925|NCT07105995|OTHER|Intraoral scanning|The investigator will perform intraoral scanning of the participants' maxillary and mandibular dentitions, as well as record the bite registration.
214664926|NCT07105995|OTHER|Facebow registrations|The investigator will perform facebow registrations on the participants utilizing an optoelectronic tracking device.
214664927|NCT07105995|OTHER|Mandibular border movement registrations|The investigator will perform mandibular border movement registrations utilizing an optoelectronic mandibular movement tracking device.
214664928|NCT07105995|OTHER|Chewing registrations|The investigator will perform 5 chewing registrations with different test foods utilizing an optoelectronic mandibular movement tracking device.
214664929|NCT07105930|DEVICE|Debulging approach using the orbital atherectomy system|A uniform approach using only the orbital atherectomy system (Diamondback 360®), which sands away the calcium with a rotating crown
214664930|NCT07105930|PROCEDURE|Debulging using rotational atherectomy, scoring or cutting balloons, or shockwave therapy|A tailored approach, where the operator chooses from various available methods based on the patient's specific type of calcium
214664931|NCT07106242|DEVICE|Adaptive DBS|Subjects will receive Dual or Single Threshold aDBS which are acceptable
214664932|NCT07106242|DEVICE|cDBS|cDBS
214856396|NCT05732896|DEVICE|Nociception Leve Indeks|During TIVA-TCI, propofol (Schnider) effect site concentration (Ce) was titrated to BIS score between 40-60 and remifentanil (Minto) Ce to standard hemodynamic parameters in the control group and NOL index value between 10-25 in the study group.
214856397|NCT01900496|BIOLOGICAL|Brentuximab vedotin|Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.
214856398|NCT01900496|BIOLOGICAL|Rituximab|Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m\^2 IV. Additional doses are given at three and six months post week 27.
214856399|NCT01685541|OTHER|Maximum After Visit Summary Content|
214856400|NCT01685541|OTHER|Intermediate After Visit Summary Content|
214856401|NCT01685541|OTHER|Minimum After Visit Summary Content|
214856402|NCT01685541|OTHER|Usual AVS|
214856403|NCT04328519|OTHER|observation|observation
214856404|NCT01815112|OTHER|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
214856405|NCT01815112|OTHER|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
214856406|NCT02591212|BEHAVIORAL|Green Dot|Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
214856407|NCT02591212|BEHAVIORAL|Wellness Initiatives for Student Empowerment|Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
214290436|NCT00002925|BIOLOGICAL|Aldesleukin|
214856408|NCT05077956|DIAGNOSTIC_TEST|Cerebrospinal and Blood Serum Semaphorin 4A Levels|Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.
214856409|NCT02341833|DRUG|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
214856410|NCT03522571|BEHAVIORAL|Experimental gingivitis|Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
214856411|NCT00136578|DRUG|SB-715992|SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
214856412|NCT00136578|DRUG|carboplatin|Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
214856413|NCT00750126|DRUG|Fludarabine, Busulfan, Thymoglobulin|"study :~* acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~* the effectiveness of the protocol on tumor response~* overall survival"
214856414|NCT01843348|DRUG|Everolimus|
214856415|NCT01843348|DRUG|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
214290437|NCT06131307|PROCEDURE|Education|Paternalistic leadership training will be given to clinical manager nurses.
214856416|NCT01843348|DRUG|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
214856417|NCT01843348|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
214856418|NCT01843348|DRUG|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
214856419|NCT01843348|DRUG|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
214856420|NCT01843348|DRUG|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
214856421|NCT02823730|OTHER|PCI with Synergy Stent|500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
214856422|NCT06188130|OTHER|active rTMS|Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed dominant side abductor pollicis brevis (APB).The patient received robotic therapy for lower extremity just after each active TMS sessions.
214856423|NCT06188130|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for lower extremity just after each sham TMS sessions.
214856424|NCT06188130|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the Cz central (International 10/20 Electroencephalogram System) area, corresponding to the location of the dominant hemisphere lower extremity motor cortex and cathodal to the contralateral supraorbital region. The patient received robotic therapy for lower extremity just after each active tDCS sessions.
214290438|NCT06088550|DIETARY_SUPPLEMENT|BCAA|a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine \& 1.25 gm valine).
214856425|NCT06188130|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for lower extremity just after each sham tDCS sessions
214856426|NCT03313648|PROCEDURE|Laparoscopic Hepatectomy|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
214856427|NCT03313648|PROCEDURE|Radiofrequency Ablation|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
214290439|NCT06088550|OTHER|home-based graded exercise program|home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
214290440|NCT04959344|BIOLOGICAL|Kleb4V target dose|Two doses of the non-adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
214290441|NCT04959344|BIOLOGICAL|Kleb4V target dose + AS03|Two doses of the adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
214290442|NCT04959344|BIOLOGICAL|Kleb4V low dose|Two doses of the non-adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
214290443|NCT04959344|BIOLOGICAL|Kleb4V low dose + AS03|Two doses of the adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
214290444|NCT04959344|BIOLOGICAL|Placebo|Two doses of the Placebo will be administered intramuscularly 2 months apart
214290445|NCT03252301|DEVICE|PMD 200|finger sensor which estimate objectively the pain level
214856428|NCT01048216|RADIATION|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
214856429|NCT06166316|DEVICE|overdenture retained by locator attachments.|"• Implant-retained overdenture construction procedures:~1. Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~2. Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~3. Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~4. The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing."
214856430|NCT04158349|DRUG|Oxaliplatin|Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
214856431|NCT04158349|DRUG|mFOLFIRI|mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
214856432|NCT02254018|DRUG|bivatuzumab mertansine|
214856433|NCT02546349|DRUG|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
214856434|NCT02788149|DEVICE|Ultrasound Exam|Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
214856435|NCT02788149|DEVICE|Polysomnography|"Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as \>50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : \< 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr."
214856436|NCT01352728|DRUG|Axitinib|5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
214856437|NCT01801683|OTHER|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
214856438|NCT03520868|DIAGNOSTIC_TEST|Monitoring Anti Factor Xa level|Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
214856439|NCT02249676|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
214856440|NCT01817465|DRUG|Motilitone ®|
214856441|NCT01817465|DRUG|Pantoline®|
214856442|NCT01817465|DRUG|Motilitone® and Pantoline®|
214856443|NCT01762826|DIETARY_SUPPLEMENT|Myo-inositol|Dietary control plus Myo-inositol
214856444|NCT01762826|DIETARY_SUPPLEMENT|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
214856445|NCT01762826|DIETARY_SUPPLEMENT|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
214856446|NCT01762826|DIETARY_SUPPLEMENT|Placebo|Dietary control plus folic acid 400 mcg daily
214856447|NCT01389466|BIOLOGICAL|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
214856448|NCT01389466|BIOLOGICAL|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
214856449|NCT04946565|DIAGNOSTIC_TEST|Semen analysis|Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition
214856450|NCT06496074|DIAGNOSTIC_TEST|Head-up Tilt Test|Two protocols for the head-up tilt test (HUTT) are used in our center and in the collaborating centers: (1) passive or prolonged inclination protocol \[40 minutes\], (2) mixed protocol: passive phase \[first 20 minutes\] plus nitrate-provoked phase \[last 20 minutes\], with the use of 1.25 mg sublingual isosorbide dinitrate. All patients are submitted to 10 minutes of rest in the supine position at zero degree before the tilt phase of the HUTT. During this period, HR and systolic (SBP) and diastolic (DBP) measurements are obtained every 2 minutes. After this phase, the table is tilted at an angle of 70° with measurement of SBP / DBP and HR every minute. Patients older than 60 years are routinely investigated for carotid sinus hypersensitivity by carotid sinus massage during the passive phase of the HUTT. The exam is considered positive according to the criteria defined in guidelines.
214856451|NCT00266526|BIOLOGICAL|Recombinant birch pollen|
214856452|NCT00430950|DRUG|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
214856453|NCT00430950|DRUG|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
214856454|NCT02199340|OTHER|iStep exercise test|newly developed submaximal exercise test
214856455|NCT02199340|OTHER|CPET exercise test|maximal gold standard exercise test
214856456|NCT02537873|DRUG|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
214856457|NCT02537873|DRUG|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
214856458|NCT02537873|DRUG|Placebo comparator|Dextrose in gelatin capsule
214856459|NCT05160467|DIAGNOSTIC_TEST|Segmental multi-frequency bio electrical impedance analysis|"A segmental (eight-polar) multi-frequency bio electrical impedance analysis (Inbody S10, Seoul, Korea) is carried out at the initiation of the deresuscitation strategy, at day 1, 3 and 5, in lying posture with touch type electrodes. Raw and derived parameters are recorded. The measurement is performed 5 times for the first measurement and then one time at day 1, 3 and 5.~Measurement error is defined by the manufacturer as: reversed Impedance in different segment all between 5-500kHz; impedance over 50Ω in trunk, or over 700Ω in limb; sudden drop of impedance in trunk (more than 10Ω), or in limb (more than 50Ω). If it occurs, measurement is carried out three times maximum after solving potential technical issues to obtain a valid analysis."
214856460|NCT05874440|DRUG|Tenofovir Disoproxil Fumarate and Entcavir|Regular registration of side effects of the drugs, cause of non-compliance to treatment
214856461|NCT03265067|DEVICE|autoRIC|Application of the autoRIC device
214856462|NCT00005586|DRUG|L-leucovorin|
214856463|NCT00005586|DRUG|fluorouracil|
214856464|NCT00005586|PROCEDURE|adjuvant therapy|
214856465|NCT05905263|OTHER|Application group with virtual reality|Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously.
214856466|NCT01583517|PROCEDURE|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
214856467|NCT01583517|PROCEDURE|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
214856468|NCT01583517|PROCEDURE|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
214856469|NCT02429934|BIOLOGICAL|abatacept also known as Orencia also known as CTLA4-Ig|125mg injected subcutaneously weekly for 16 weeks
214856470|NCT02429934|DRUG|Placebo|
214856471|NCT02554734|DRUG|levodopa, carbidopa, ODM-104|
214664933|NCT04292717|BEHAVIORAL|Gait training|All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.
214856472|NCT02554734|DRUG|levodopa, carbidopa, entacapone|
214856473|NCT00337441|DRUG|Epoetin Alfa (drug)|
214856474|NCT04744324|BEHAVIORAL|Self-supporting Care|Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)
214856475|NCT04744324|BEHAVIORAL|Home health education|Individualized home health education
214856476|NCT04648124|DEVICE|IRMf-r (séquence resting state)|Functional MRI of functional brain networks
214856477|NCT02577341|DRUG|Nimotuzumab|Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.
214856478|NCT02577341|DRUG|docetaxel and cisplatin|Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
214856479|NCT02577341|RADIATION|daily RT to the chest|Patients received daily RT to the chest
214856480|NCT04054284|DIETARY_SUPPLEMENT|Antidiabetic Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
214856481|NCT04054284|DIETARY_SUPPLEMENT|Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
214664934|NCT06152328|OTHER|Virtual reality applications based on mirror therapy|Mirror therapy-based games will be played for 30 minutes every day for eight weeks, three days a week, for the VR group.
214856482|NCT06231719|OTHER|Cold Spray|Using cold spray for injection site before the Anti-D immunglobulin injection. 2 sprays of cold spray are applied from a distance of 25 cm.
214856483|NCT06231719|OTHER|Manuel Pressure|Using manuel pressure ( about 10 second ) before the Anti-D immunglobulin injection.
214856484|NCT06231719|OTHER|Standard Injection Procedure|Using any special method for injection
214856485|NCT00971984|OTHER|Medical records summary|Summary of Medical files and laboratory results.
214856486|NCT06138119|BEHAVIORAL|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/ she belongs. Stereotype threat manipulation will be performed on the male and female participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare fiberoptic intubation performance between male and female anesthesiologists. Additionally, we are investigating whether the high inclination of males towards computer games has any impact on their fiberoptic intubation success. The other participants (Control Group) will not be given any prior information."
214856487|NCT04248348|DRUG|Low Molecular Weight Heparin|Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
214856488|NCT02213952|DRUG|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
214856489|NCT02213952|OTHER|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
214856490|NCT00377936|DRUG|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
214856491|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
214856492|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
214856493|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
214856494|NCT04729465|DRUG|Propofol|Propofol
214856495|NCT04729465|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor
214856496|NCT00734201|DRUG|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
214856497|NCT04293549|DRUG|Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops|"rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment"
214856498|NCT01176110|DEVICE|LMA Perfect Temp|The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
214856499|NCT01023295|DRUG|fosbretabulin|single dose, intravenous infusion
214856500|NCT01023295|DRUG|Saline|single dose, intravenous infusion
214856501|NCT03023514|DIETARY_SUPPLEMENT|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
214664935|NCT06152328|OTHER|Conventional treatment|Bobath therapy, walking exercises, upper extremity active exercises, and proprioceptive neuromuscular facilitation techniques will be applied three days a week for eight weeks.
214856502|NCT03023514|DRUG|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
214856503|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol normospermic|4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.
214856504|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol OAT|B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months
214856505|NCT01828710|DIETARY_SUPPLEMENT|Folic Acid normospermic|Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
214664936|NCT06152328|OTHER|Mirror therapy|In conventional mirror therapy, the unaffected extremities of the individuals will be positioned outside the mirror, while the affected extremities will be placed inside the mirror so that the patient cannot see them. In this way, the image of the intact hand will be transferred to the affected side and activities will be performed three days a week for eight weeks.
214856506|NCT02216019|OTHER|Whole blood|preoparatoire whole blood and postoperative whole blood
214856507|NCT00703508|DRUG|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
214856508|NCT05070702|DRUG|CT-1500|Hard Capsule
214856509|NCT05070702|DRUG|Placebo|Hard Capsule
214856510|NCT03657108|RADIATION|Civasheet 60 Gy|implantable proposed doses of Civasheet are 60 Gy
214856511|NCT03657108|RADIATION|Civasheet 75 Gy|implantable proposed doses of Civasheet are 75 Gy
214856512|NCT03657108|RADIATION|Adjuvant external beam radiation therapy|45 Gy in 25 fractions
214856513|NCT00922558|OTHER|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
214856514|NCT00831623|RADIATION|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
214856515|NCT00831623|RADIATION|Proton|As above
214856516|NCT01064323|DEVICE|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
214856517|NCT05793814|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri 3613|Daily for 6 month
214856518|NCT05793814|DIETARY_SUPPLEMENT|Placebo|Daily for 6 month
214856519|NCT00283413|DEVICE|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
214856520|NCT00283413|DEVICE|Bare metal stent|Any commercially available bare metal stent for coronary indication
214856521|NCT03626506|DRUG|Spironolactone|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
214856522|NCT03626506|DRUG|Indapamide|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
214856523|NCT03626506|DRUG|Amlodipine|After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
214856524|NCT01763749|DRUG|Closone|Closone 75mg/100mg, 4weeks, PO
214856525|NCT01763749|DRUG|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
214856526|NCT01252849|DEVICE|iStent|Implantation of One iStent through a small temporal clear corneal incision.
214856527|NCT01252849|DEVICE|iStent|Implantation of Two iStents through a small temporal clear corneal incision
214856528|NCT01252849|DEVICE|iStent|Implantation of Three iStents through a small temperal clear corneal incision
214856529|NCT01758146|DRUG|Tamoxifen|20 mg once daily for 5 years
214856530|NCT01758146|DRUG|Letrozole|Letroz, Femara, Letronat
214856531|NCT05342207|PROCEDURE|Endoscopic plantar fascia release in cases of chronic resistant plantar fasciopathy|A medial portal will be developed 1cm away from the plantar skin along a vertical line passing through the posterior border of the medial malleolus with the foot in neutral position. A 5 mm cannula will be then introduced through the lateral portal over the trocar. Irrigation fluid will be then connected. A 30-degree 4.0 mm endoscope will be inserted inside the cannula. A 4.5 motorized incisor blade will be then used to debride the subcutaneous tissue until full visualization of the shiny fibers of the plantar fascia will be possible. A needle was inserted vertically through the heel skin to act as a land mark for the middle of the plantar fascia. A scalpel blade will then introduced through the medial portal to divide the full thickness of the medial half of the plantar fascia into two leaflets under direct visualization . The posterior leaflet will be then totally debrided using a motorized incisor blade . The tunnel will then be irrigated and stitches will be done.
214856532|NCT03621319|DEVICE|Hybrid argon plasma ablation (HAPC)|-The assigned HAPC ablation will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
214856533|NCT03621319|DEVICE|Radiofrequency ablation (RFA)|-The assigned RFA procedure will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
214856534|NCT03357887|OTHER|Analysis of cerebrospinal fluid and serum|Analysis of biomarkers in patient biological samples
214856535|NCT00998972|DRUG|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
214856536|NCT01988168|PROCEDURE|Suture closure|A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
214856537|NCT01988168|PROCEDURE|Staples closure|Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
214856538|NCT03525418|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|Allogeneic bone marrow-derived mesenchymal stem cell
214856539|NCT05307887|DEVICE|Sync VR Medical PICO G2 4K Virtual Reality Technology|Virtual reality headset and software
214856540|NCT01564459|DRUG|MK-6096|MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
214856541|NCT01564459|DRUG|Placebo|Matching compressed tablets, taken once daily at bedtime for 14 days.
214856542|NCT01443559|GENETIC|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
214856543|NCT01443559|GENETIC|homogenic cornea|homogenic corneas were sterilised by radiation
214856544|NCT04135521|DRUG|Intraperitoneal chemotherapy|Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy
214856545|NCT03951584|OTHER|ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset as primary outcome, to evaluate the damage and prognosis of vestibular function.
214856546|NCT02957266|RADIATION|Volumetric Arc Radiotherapy|Volumetric Arc Radiotherapy
214856547|NCT02957266|RADIATION|Interstitial brachytherapy|Interstitial High Dose Rate Brachytherapy
214856548|NCT02957266|DRUG|Cisplatin|Weekly Cisplatin
214290446|NCT05417061|OTHER|Saliva and serum sampling|"Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes.~Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis."
214664937|NCT06152328|OTHER|Placebo virtual reality|For 8 weeks, watching the uninteractive virtual environment for 10 minutes
214856549|NCT02957266|DRUG|Gemcitabine|Weekly Gemcitabine
214856550|NCT02957266|GENETIC|PIK3CA|PIK3CA mutations rate
214856551|NCT02957266|GENETIC|KRAS|KRAS mutations rate
214856552|NCT02957266|GENETIC|BRAF|BRAF mutations rate
214856553|NCT02957266|GENETIC|RRM1|RRM1 mutations rate
214856554|NCT00106938|DEVICE|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
214856555|NCT00106938|PROCEDURE|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
214856556|NCT00070538|DRUG|cytarabine|
214290447|NCT00298220|BEHAVIORAL|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
214290448|NCT00298220|BEHAVIORAL|Dissemination guideline and patient information letters|
214290449|NCT00298220|BEHAVIORAL|Tailored educational training|for GP(T)s
214856557|NCT00070538|DRUG|laromustine|
214856558|NCT04109859|DRUG|Saline|When using saline, if found mean arterial pressure \<65mmHg, Cardic Output\>4L/min, Sequential Vascular Response\<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
214856559|NCT04109859|DRUG|Methylene Blue|Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping
214856560|NCT02416011|BEHAVIORAL|GENERIC|The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
214856561|NCT02416011|BEHAVIORAL|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
214856562|NCT03277209|DRUG|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
214856563|NCT00366041|DRUG|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
214856564|NCT00366041|DEVICE|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
214856565|NCT03794791|BEHAVIORAL|education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
214856566|NCT03794791|BEHAVIORAL|no education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
214856567|NCT02030483|DRUG|Palbociclib|Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
214856568|NCT02030483|DRUG|Dexamethasone|20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
214856569|NCT02030483|DRUG|Lenalidomide|Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
214856570|NCT02494050|BEHAVIORAL|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
214856571|NCT02494050|BEHAVIORAL|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
214856572|NCT02494050|BEHAVIORAL|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
214856573|NCT05278572|BEHAVIORAL|Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST)|Cognitive-behavioral stress management/expressive supportive therapy (CBSM+) group targeting depression
214856574|NCT00706992|BIOLOGICAL|ALVAC-MART-1 vaccine|Given subcutaneously
214856575|NCT00706992|BIOLOGICAL|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
214856576|NCT00706992|BIOLOGICAL|Aldesleukin|Given subcutaneously
214856577|NCT00706992|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
214856578|NCT00706992|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
214856579|NCT00068081|DRUG|Capsaicin Dermal Patch|
214856580|NCT06347991|BEHAVIORAL|SelfBack|The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
214856581|NCT06918015|DRUG|ZGCVP|"Patients receive the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles at the following dose:~1. Zanubrutinib: 160mg orally twice daily;~2. Obinutuzumab: 1000mg intravenously on days 1, 8, and 15 of cycle 1 and on day 1 of subsequent 5 cycles;~3. Cyclophosphamide: 750m/m2 intravenously on days 1 of every cycle;~4. Vindesine: 3 mg/m2 (maximum dose 4 mg) intravenously on days 1 of every cycle;~5. Prednisolone: 30mg orally three times daily on day 1-5 of every cycle. Patients achieving CR at stage II underwent observation directly; those at stage III/IV receive obinutuzumab maintenance every 8 weeks for 2 years (1000mg intravenously) until disease progression or withdrawal. Patients with disease progression during treatment switch to second-line therapy."
214856582|NCT01077882|BEHAVIORAL|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
214856583|NCT01077882|BEHAVIORAL|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
214856584|NCT01077882|BEHAVIORAL|Lifestyle factors and psycho-education|by dietician and psychiatrist
214290450|NCT00298220|BEHAVIORAL|Tailored outreach based facilitator support|in the practices of the GPTs
214290451|NCT00298220|BEHAVIORAL|Facilitation of co-operation with local addiction services|
214856585|NCT01077882|OTHER|no educational program|standard care without educational program
214290452|NCT00298220|BEHAVIORAL|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
214290453|NCT00298220|BEHAVIORAL|Reminder-card for GP's desk|
214290454|NCT00298220|BEHAVIORAL|Personal feedback to patients|Patients receive advise based on their premeasurement answers
214856586|NCT05402982|DEVICE|Electrical Cardiometry (EC) ICON|Electrical Cardiometry (EC) ICON (Osypka Medical, Berlin, Germany) is an FDA approved device used for non-invasive measurement of some hemodynamic parameters as cardiac output,cardiac index, stroke volume,stroke volume variation, systemic vascular resistance, thoracic fluid content, ICON (index of contractility), variation of ICON,corrected flow time and systolic time ratio.The set data of EC are the height, weight,hemoglobin, Oxygen saturation(SPO2),age, gender ,blood pressure and heart rate(HR) of the patient
214856587|NCT05402982|OTHER|Rohrich formula|Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2
214856588|NCT01125020|DRUG|gemcitabine and oxaliplatin|Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
214856589|NCT01125020|DRUG|doxorubicin, 5-Fu and cisplatin|Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
214856590|NCT04579276|PROCEDURE|Thoracic paravertebral block|Intrathoracic method undergone through video assisted surgery (VATS
214856591|NCT04579276|PROCEDURE|thoracic epidural analgesia|locoregional analgesia under ultrasound control
214856592|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique + PRF|
214856593|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique|
214856594|NCT01400620|DRUG|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
214856595|NCT03545191|DRUG|Daridorexant 25 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
214856596|NCT03545191|DRUG|Daridorexant 50 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
214856597|NCT03545191|OTHER|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
214290455|NCT05908513|DRUG|N-acetylcysteine|Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
214290456|NCT05908513|DRUG|Placebo|Similar chemical structure of NAC but without function
214856598|NCT01769274|DRUG|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
214856599|NCT01769274|DRUG|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
214856600|NCT04694326|DIAGNOSTIC_TEST|HbA1c|The participants' age, sex, education level, known diseases, unit of hospitalization and inpatient diagnosis were questioned and recorded. Height, weight and waist circumference measurements were taken. Fasting blood sugar and HbA1c measurements were made
214856601|NCT00196131|DRUG|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
214856602|NCT04765774|OTHER|Ekspressive touch|Patients will be divided into three groups. The expressive touch group will touch the patient's hand.
214856603|NCT04765774|OTHER|Music|The music chosen by the patient will be played in the music group.
214856604|NCT03795831|DEVICE|ClearSight feasibility testing|A cuff is placed on a finger of the patient. The ClearSight system uses a volume clamp technology allowing measuring of continuous blood pressure waveform. Note: There will only be observational recordings, no interventions
214856605|NCT00949689|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
214856606|NCT02504346|DRUG|AZD9291|
214856607|NCT05981248|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
214856608|NCT01507974|DRUG|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
214856609|NCT01507974|DRUG|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
214856610|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
214856611|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
214290457|NCT00488436|DRUG|Antithymocyte globulin|
214856612|NCT01507974|DRUG|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
214856613|NCT01507974|DRUG|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
214856614|NCT06392204|PROCEDURE|CAD/CAM patient specfifc fracture reduction/plate guide and customized 3D grid plate|Mandibular angle fracture reduction and fixation using digitally designed and fabricated patient specific fracture reduction/plate positioning guide and customized 3D grid plate
214856615|NCT06392204|PROCEDURE|Champy's techqniue|Mandibular angle fracture reduction and fixation using a single superior border 2.0 miniplate
214856616|NCT03602040|BEHAVIORAL|PISICC|"PISICC consists of:~1. Standard disease-specific information leaflet~2. Personalised lifestyle consideration form~3. 1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c)."
214290458|NCT00488436|DRUG|Cyclosporine|
214290459|NCT00022139|DRUG|carboplatin|
214290460|NCT00022139|DRUG|fluorouracil|
214290461|NCT00022139|DRUG|paclitaxel|
214290462|NCT00022139|PROCEDURE|conventional surgery|
214290463|NCT00022139|RADIATION|radiation therapy|
214290464|NCT01643655|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
214290465|NCT02030392|BEHAVIORAL|Intervention group|Cognitive-behavioral intervention
214290466|NCT02030392|BEHAVIORAL|Active control group|Education and information
214290467|NCT04158440|DRUG|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab|Biological: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
214290468|NCT04158440|DRUG|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
214856617|NCT05991596|BEHAVIORAL|Psychodramatic psychotherapy|"The psychodramatic psychotherapy will include a total of 14 meetings during a 6 months period and they will be held in presence (or remotely in case of COVID-19 government restrictions) as follows:~* 1 individual motivational interview;~* 1 weekly group session lasting 2 hours for 1 month (total 4 meetings);~* 1 group session every 15 days lasting 2 hours, for 5 months (total 10 meetings).~Patients will also receive the pharmacological treatment usually recommended for vitiligo."
214856618|NCT05991596|BEHAVIORAL|Self-help activities|"The self-help activities will include:~* 1 individual motivational interview;~* 1 weekly, 2 hours group meeting, for 1 month (total 4 meetings);~* 1 group meeting lasting 2 hours every 15 days, for 5 months (total 10 meetings).~Patients will also receive pharmacological treatment usually recommended for vitiligo."
214856619|NCT05759117|PROCEDURE|thoracentesis|A type of pleural procedure that will yield pleural fluid for subsequent analysis
214856620|NCT01731717|BEHAVIORAL|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
214856621|NCT01731717|BEHAVIORAL|Bibliotherapy|"Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision."
214856622|NCT01731717|BEHAVIORAL|Online self-help|"Patient works with online self-help program Deprexis under general physician's supervision."
214856623|NCT01731717|BEHAVIORAL|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
214856624|NCT01731717|PROCEDURE|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
214856625|NCT01731717|BEHAVIORAL|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
214856626|NCT01731717|OTHER|Control group: treatment as usual|treatment as usual
214856627|NCT05368441|DRUG|Midazolam|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.
214856628|NCT05368441|DRUG|Saline|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
214856629|NCT02377063|DIETARY_SUPPLEMENT|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
214856630|NCT00306163|DRUG|Ciclesonide|inhaled Ciclesonide 160 µg, once daily in the morning
214856631|NCT00306163|DRUG|Fluticasone|inhaled Fluticasone 100 µg, twice daily
214856632|NCT03282734|OTHER|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
214856633|NCT03282734|OTHER|Conventional home rehabilitation exercise|Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
214856634|NCT04918641|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
214856635|NCT02902718|DEVICE|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
214856636|NCT06030349|DEVICE|Non-invasive ventilation|Non-invasive ventilation
214856637|NCT00195013|DRUG|glutamine|10 grams three times a day (orally) for four days and then stop
214290469|NCT01402544|DRUG|ranibizumab|0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
214290470|NCT00186381|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
214664938|NCT00316875|DRUG|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
214290471|NCT01324765|BEHAVIORAL|TARGET|12-session group therapy twice weekly 6 weeks
214290472|NCT01324765|BEHAVIORAL|SGT|12 sessions supportive group therapy twice weekly 6 weeks
214290473|NCT05133453|DRUG|Pirfenidone|drug intake three times daily for one year
214856638|NCT00195013|DRUG|Placebo|10 grams three times a day (orally) for four days and then stop
214856639|NCT02925806|OTHER|Non-interventional study - retrospective database review|
214856640|NCT04061642|DEVICE|Clinical Decision Aid|The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
214290474|NCT01828281|DEVICE|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
214664939|NCT00316875|DRUG|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
214664940|NCT06935734|DIAGNOSTIC_TEST|Diagnostic Colonoscopy|Phase A will serve to evaluate the safety of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies, and Phase B will evaluate the safety and efficacy of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies.
214856641|NCT05094752|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
214856642|NCT05094752|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
214856643|NCT03237533|DRUG|Dexamethasone|Dexamethasone will be applied locally on the lesion
214856644|NCT00280878|DRUG|gemcitabine|
214856645|NCT00280878|DRUG|vinorelbine|
214856646|NCT00280878|DRUG|ifosfamide|
214856647|NCT00280878|DRUG|rituximab|
214856648|NCT01754506|DIETARY_SUPPLEMENT|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
214856649|NCT03848169|OTHER|Radiofrequency|See previous page
214664941|NCT06955975|DIETARY_SUPPLEMENT|Pectin|10g of pectin with 10g of whey protein and 10g of cocoa powder added as flavour were randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
214856650|NCT01911663|DIETARY_SUPPLEMENT|KRG|500 mg Korea red ginseng (KRG)
214856651|NCT01911663|DIETARY_SUPPLEMENT|Placebo|500 mg placebo
214856652|NCT04722601|DRUG|Venetoclax|A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
214856653|NCT04722601|DRUG|Obinutuzumab|Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.
214856654|NCT04722601|DRUG|CC-486|An oral form of azacitidine (a standard chemotherapy drug).
214856655|NCT02746627|BEHAVIORAL|Positive Affect|Positive psychology intervention to improve motivation for diabetes management.
214856656|NCT02746627|BEHAVIORAL|Education|Educational materials on diabetes management
214856657|NCT04336124|DRUG|CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)|"Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur."
214856658|NCT02776514|DRUG|Triamcort|Fluoroscopic guided injection in the knee joint
214290475|NCT05241106|DRUG|HYML-122|each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
214664942|NCT06955975|OTHER|Whey protein|10g of whey protein with 10g of cocoa powder added as flavour served as the control/ placebo to compare the effects observed with pectin.
214664943|NCT06953687|BEHAVIORAL|Prolonged Exposure Therapy|PE is a cognitive-behavioral treatment for PTSD that is typically delivered in ten 90-minute sessions . For the current study using a variable length approach, participants may complete up to 24 sessions. Based on emotional processing theory PE addresses trauma-related avoidance of thoughts, behaviors, and situations, as well as unhelpful beliefs about oneself, others, and the world that were learned as a result of trauma.
214856659|NCT02776514|DRUG|Platelet-rich-plasma|
214856660|NCT02776514|DRUG|Suplasyn1|
214856661|NCT02776514|DRUG|Placebo|
214856662|NCT04117737|OTHER|Virtual reality combined with anti-gravity treadmill|"The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system.~The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life."
214856663|NCT01122589|BEHAVIORAL|Motivational Interviewing/CBT|6 sessions of in jail MI/CBT counseling will be administered.
214856664|NCT01122589|OTHER|CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)|a series of six weekly 30-45 minutes general wellness videos
214856665|NCT00697840|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 doses
214856666|NCT00697840|BIOLOGICAL|HBV-MPL 208129|Intramuscular injection, 2 doses
214856667|NCT00697840|BIOLOGICAL|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
214856668|NCT04596397|OTHER|Inpatient setting|These women stay at the hospital.
214856669|NCT04596397|OTHER|Outpatient setting|These women can leave the hospital.
214856670|NCT00810628|BEHAVIORAL|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
214856671|NCT04690569|DIAGNOSTIC_TEST|MeMed BV|The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
214856672|NCT05294835|DRUG|Ketamine|ketamine infusion
214856673|NCT02498535|DRUG|Nitric Oxide 160 ppm|Nitric Oxide 160 ppm
214856674|NCT03052972|DRUG|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose
214856675|NCT03052972|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
214856676|NCT05029934|PROCEDURE|use of EndoClot|deployment of EndoClot adhesive spray
214856677|NCT02004184|DRUG|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
214856678|NCT02004184|DRUG|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
214856679|NCT05296382|DRUG|Tebipenem tablet form|Tebipenem tablets will be administered intact or crushed
214856680|NCT05296382|OTHER|Tube feeds|Tebipenem tablets will be administered with or without tube feeds
214856681|NCT04126954|OTHER|Serum PTH concentrations results|To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
214856682|NCT02340221|DRUG|Taselisib|Taselisib 4 mg was administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
214856683|NCT02340221|DRUG|Placebo|Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
214856684|NCT02340221|DRUG|Fulvestrant|Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
214856685|NCT00919178|BIOLOGICAL|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
214856686|NCT00919178|BIOLOGICAL|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
214856687|NCT02008708|BEHAVIORAL|Livestock Microfinance|Participants randomized to the microfinance group receive the pig loan.
214856688|NCT02008708|OTHER|Delayed Control Group|Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
214856689|NCT01742559|PROCEDURE|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman \& Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
214664944|NCT06953687|BEHAVIORAL|Cognitive Processing Therapy|CPT is a 12-session, cognitive behavioral PTSD treatment typically delivered in 60-minute sessions that can be personalized to include fewer or additional sessions. For the current study using a variable length approach, participants may complete up to 24 sessions. CPT is based in cognitive theory and posits that impeded recovery following trauma occurs due to unhelpful and unrealistic beliefs that may develop after trauma, leading to chronic anger, guilt, shame, and avoidance of trauma reminders. During CPT, patients learn about PTSD symptoms, impeded recovery and cognitive theory, and the connection between trauma-based thoughts and feelings.
214856690|NCT01742559|PROCEDURE|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
214856691|NCT03705949|DRUG|Sodium Hyaluronate 0.1% drops|Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
214856692|NCT03705949|DRUG|Sodium Hyaluronate 0.2% drops|Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
214856693|NCT05946902|DRUG|tolterodine|tolterodine 4 mg per day
214856694|NCT05946902|DRUG|mirabegron|mirabegron 25 mg per day
214856695|NCT05946902|DRUG|tolterodine , mirabegron|tolterodine 4 mg and mirabegron 25 mg per day
214856696|NCT03499119|DRUG|AMG 334 Dose 1|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2"
214856697|NCT03499119|DRUG|AMG 334 Dose 2|Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
214856698|NCT03499119|DRUG|AMG 334 Dose 3|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
214856699|NCT05466175|DRUG|Olverembatinib|Given PO
214856700|NCT05466175|DRUG|Prednisone|Given Intravenous
214856701|NCT05466175|DRUG|Vincristine|Given Intravenous
214856702|NCT03010618|OTHER|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
214856703|NCT02336620|DRUG|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
214856704|NCT02336620|DRUG|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
214856705|NCT04940702|OTHER|Focal Vibration|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~The exercise is the same than traditional training group."
214856706|NCT04940702|OTHER|Blood Flow Restriction|Training with Blood Flow Restriction, the restriction is in the proximal part of the lower limb. The exercise is the same than traditional training group.
214856707|NCT04940702|OTHER|Traditional Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
214856708|NCT02858648|BEHAVIORAL|Behavior intervention with smart phone based self-monitoring|Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies
214856709|NCT02858648|BEHAVIORAL|Behavior intervention with paper diary based self-monitoring|Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
214856710|NCT01845402|BIOLOGICAL|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
214856711|NCT00588640|DRUG|d-Methadone|8 subjects to receive 40 mg d-Methadone twice a day
214856712|NCT00588640|DRUG|D-methadone|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
214856713|NCT00588640|DRUG|placebo|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
214856714|NCT01876849|DRUG|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
214856715|NCT03365999|DRUG|Oral Tranexamic Acid|Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
214856716|NCT03365999|DRUG|Oral Aminocaproic Acid|Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
214856717|NCT02744599|DEVICE|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
214856718|NCT00103402|DRUG|Alfuzosin|
214856719|NCT00103402|DRUG|Placebo|
214856720|NCT01393730|DRUG|Abiraterone acetate|
214856721|NCT01393730|DRUG|Dutasteride|
214856722|NCT01393730|DRUG|Prednisone|
214856723|NCT00003598|DRUG|tretinoin|
214856724|NCT03898895|COMBINATION_PRODUCT|Radiotherapy+anti-PD-1 antibody|The total radiation dose is over 45Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
214856725|NCT03606720|OTHER|low level laser therapy|low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
214856726|NCT03606720|OTHER|pelvic stabilization exercises|special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
214856727|NCT05730504|OTHER|Mobile app-based self-guided interventions|self-guided, app-based mobile psychological interventions based on CBT, meditation, mindfulness, journaling, and audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation
214856728|NCT02021253|DIETARY_SUPPLEMENT|Probiotic|Lactibiane TOLERANCE vs Placebo
214856729|NCT02021253|DIETARY_SUPPLEMENT|Placebo|
214856730|NCT02429141|PROCEDURE|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
214856731|NCT02429141|PROCEDURE|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
214856732|NCT01436565|DRUG|MM-121 (SAR256212)|"Pharmaceutical form:solution~Route of administration: Intravenous"
214856733|NCT01436565|DRUG|SAR245408|"Pharmaceutical form:tablet~Route of administration: oral"
214856734|NCT04463290|OTHER|No intervention, Patients selection based on clinical symptoms and radiological imaging|No intervention
214856735|NCT03182582|DEVICE|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
214856736|NCT03182582|PROCEDURE|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
214856737|NCT06177106|OTHER|Solar Simulated Light|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
214856738|NCT03056079|DRUG|Intravitreal aflibercept|Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
214856739|NCT00093951|DRUG|SGS742|
214856740|NCT01025219|GENETIC|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
214856741|NCT03235869|DRUG|Durvalumab|Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
214856742|NCT03235869|RADIATION|Radiation Therapy|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
214856743|NCT00449826|PROCEDURE|Computed Tomographic Angiography|CT scan
214856744|NCT03631082|OTHER|Slump stretching|Slump stretching will be provided to this group along with standardized exercises.
214856745|NCT03631082|OTHER|Lumbar mobilization|Lumbar mobilizations will be provided to this group along with standardized exercises.
214856746|NCT03814330|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
214856747|NCT03814330|DIAGNOSTIC_TEST|Quality of Recovery Score|Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
214856748|NCT03814330|OTHER|Sedation/Analgesia|Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.
214856749|NCT03814330|DEVICE|Laryngeal Mask Airway|Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
214856750|NCT02428686|DRUG|Epoetin beta (NeoRecormon)|Epoetin beta 60 000 IU/week
214856751|NCT03218163|DRUG|MEDI-551 Maintenance|Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
214856752|NCT04177563|OTHER|whole body cryostimulation|Whole-body cryotherapy
214856753|NCT02420418|DIETARY_SUPPLEMENT|N-acetyl-cysteine (NAC)|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
214856754|NCT02420418|OTHER|Placebo|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
214856755|NCT00933517|DRUG|vectibix|9mg/kg at D1 of each 21-days cycle
214856756|NCT00933517|DRUG|fluorouracile|500 mg/m2 at D1 of each 21-days cycle
214856757|NCT00933517|DRUG|Epirubicine|100 mg/m2 at D1 of each 21-days cycle
214856758|NCT00933517|DRUG|cyclophosphamide|500 mg/m2 at D1 of each 21 dyas cycle
214856759|NCT00933517|DRUG|docetaxel|100 mg/m2 at D1 of each 21 days cycle
214856760|NCT04378517|OTHER|psychosocial education in parents groups|psychosocial education
214856761|NCT04378517|OTHER|psychosocial parents support, interviews with APN|Family strength-oriented therapy conversation
214856762|NCT04309214|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
214856763|NCT05789719|BIOLOGICAL|STEM-OA|Combination of autologous or allogeneic MSC(AT)s and fat
214856764|NCT01804218|DRUG|Nadolol|
214856765|NCT01804218|DRUG|Placebo|
214856766|NCT01172821|DRUG|placebo|Placebo that represents BI drug
214856767|NCT01172821|DRUG|placebo|Placebo that represents comparator
214856768|NCT01172821|DRUG|placebo|Placebo that represents comparator
214856769|NCT01172821|DRUG|tiotropium Respimat® low dose|IMP
214856770|NCT01172821|DRUG|placebo|Placebo that represents BI drug
214856771|NCT01172821|DRUG|tiotropium Respimat® high dose|IMP
214856772|NCT01172821|DRUG|50 mcg salmeterol HFA MDI|Active comparator
214856773|NCT01172821|DRUG|placebo|Placebo that represents comparator
214856774|NCT04860050|DIETARY_SUPPLEMENT|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
214856775|NCT04860050|DIETARY_SUPPLEMENT|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
214856776|NCT04739150|DRUG|nintedanib|nintedanib
214856777|NCT00123955|DRUG|Spironolactone|25mg tablet daily for 9 months
214856778|NCT00123955|DRUG|Placebo|Placebo tablet daily for 9 months
214856779|NCT05983913|BEHAVIORAL|cognitive-motor training|The cognitive-motor training program consists of five cognitive tasks related to concentration, reaction time, and executive function, combined with physical exercises using an interactive system. The five tasks include: (1) number sequence, (2) number-word sequence, (3) card matching games, (4) memorizing numbers, and (5) route-finding games.
214856780|NCT05983913|BEHAVIORAL|cognition training|The intervention consists of five cognitive tasks (memory, attention, spatial and temporal perception) with difficulty levels adapted to the individual's cognitive abilities.
214856781|NCT00270049|DRUG|epoetin alfa|
214856782|NCT01066949|BEHAVIORAL|Behavioral self mangement|Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
214856783|NCT01066949|BEHAVIORAL|Support and discussion|Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
214856784|NCT05262036|DIETARY_SUPPLEMENT|Anti-aging Supplement|Mixture of different vitamins and nutrients
214856785|NCT05262036|DIETARY_SUPPLEMENT|Placebo|Excipient powder
214856786|NCT00304720|DRUG|Tacrolimus and MMF|
214856787|NCT03997214|DEVICE|inspiratory muscle strength training|The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
214856788|NCT01418482|DEVICE|Mepilex Border Ag|a silver dressing
214856789|NCT00979381|BIOLOGICAL|influenza vaccine|influenza vaccination
214856790|NCT00016276|DRUG|dexrazoxane hydrochloride|Given IV
214856791|NCT00016276|DRUG|doxorubicin hydrochloride|Given IV
214856792|NCT00016276|DRUG|cyclophosphamide|Given IV
214856793|NCT00016276|DRUG|paclitaxel|Given IV
214856794|NCT00016276|BIOLOGICAL|trastuzumab|Given IV
214856795|NCT00016276|PROCEDURE|therapeutic conventional surgery|Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
214856796|NCT00016276|RADIATION|radiation therapy|Undergo radiation therapy
214856797|NCT00016276|DRUG|tamoxifen citrate|Given orally
214856798|NCT00016276|OTHER|laboratory biomarker analysis|Correlative studies
214856799|NCT02475382|DRUG|Nivolumab|Specified dose on specified days
214856800|NCT06743373|BEHAVIORAL|Cannabis Discontinuation|Cannabis-using participants will participate in an orientation session with a clinician and asked to abstain from cannabis use for four weeks, using established procedures for abstinence monitoring and reinforcement.
214856801|NCT06895161|OTHER|Remotely supervised exercise at home or outdoors|Aerobic exercise at home/outdoors 30 minutes each session,five days a week for three weeks using a Polar H9 heart rate monitor.
214856802|NCT06895161|OTHER|Hospital-based exercise program|The aerobic exercise ,30 minutes each session,five days a week for three weeks at cardiopulmonary rehabilitation unit under supervision.
214856803|NCT06895161|OTHER|Phone calls with reinforcement feedback|Calls twice a week that include symptom inquiries and encouraging feedback on exercise
214856804|NCT06802224|DRUG|Norepinephrine|Intravenous Norepinephrine for both infusion and bolus dosing
214856805|NCT06802224|DRUG|Phenylephrine|Intravenous Phenylephrine for both infusion and bolus dosing
214856806|NCT04150198|DEVICE|TEP/IRM|All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
214856807|NCT01663727|DRUG|Bevacizumab [Avastin]|Intravenous repeating dose
214856808|NCT01663727|DRUG|Paclitaxel|Intravenous repeating dose
214856809|NCT01663727|DRUG|Placebo|Intravenous repeating dose
214856810|NCT06821191|DRUG|clopidogrel 75 mg|Clopidogrel 75 mg od for 30 ± 5 days
214856811|NCT06821191|DRUG|Prasugrel 5 mg|Prasugrel 5 mg od for 30 ± 5 days
214856812|NCT06798571|DRUG|Elagolix Oral Tablet|2 x 200 mg tablet
214856813|NCT06798571|DRUG|Estradiol patch|0.05 mg/day patch
214856814|NCT06798571|OTHER|cellulose placebo|placebo tablet
214856815|NCT06798571|OTHER|placebo patch|placebo patch
214856816|NCT06882655|PROCEDURE|PIFB group|A pecto-intercostal-fascial plane block (PIFB) will be performed bilaterally in a supine position after induction of anaesthesia. The in-plane needle approach will be applied under the guidance of a high-frequency Hockey Stick Linear-Array US transducer probe (SONOSITE M-TURBO). Under strict aseptic precautions, the transducer will be placed 1-2 cm lateral to and parallel to the sternum to count the ribs from the second to the sixth rib. A 22-gauge, 50-mm short bevel echogenic needle will be advanced in a caudal-to-cranial direction until the tip of the needle will be in the targeted fascial plane, a test bolus of normal saline (1-2 mL) will be injected (in real-time) to confirm that the tip was correctly placed, as shown by separation of the fascial layers. After excluding intravascular, the dose of local anaesthetic (0.4 mL/kg 0.25% bupivacaine) will be deposited into the fascial plane visualised in real-time.
214856817|NCT06882655|PROCEDURE|Intrathecal fentanyl(IT fentanyl)|IT fentanyl group (Group IT; n = 30) will be placed in lateral decubitus position immediately after intubation and catheterisation and receive an IT injection of 2 µg/kg of fentanyl in 0.2 mL/kg of normal saline through a 2-in., 25-gauge Quincke spinal needle inserted at L3-4 or L4-5. The dose of IT fentanyl will be based on a previous study. (15) with this route of fentanyl administration to provide intraoperative analgesia and blunt the stress response in pediatric cardiac anaesthesia. Successful dural puncture will be confirmed by observation of a free flow of cerebrospinal fluid, and the injection will be performed with the bevel of the needle oriented in the cephalic direction.
214856818|NCT06882655|PROCEDURE|IT + PIFB|Patients assigned to the combined IT fentanyl and PIFB (Group IT + PIFB; n = 30) will receive both a PIFB and IT fentanyl, with the use of the methods described for the other two groups.
214856819|NCT06846853|DRUG|Gadopiclenol|The enhanced images by Gadopiclenol and Gadobutrol will be compared.
214856820|NCT06846853|DRUG|Gadobutrol (Gadavist, BAY86-4875)|Gadobutrol will be used as a comparator
214856821|NCT06927791|OTHER|Machine learning based development of a diagnostic tool for acute cardiovascular disease|MALBEC will be delivered through five integrated work packages (WP) encompassing: (0) platform development and implementation, (1) data pooling, (2) model development, (3) performance comparison, (4) performance validation, and (5) platform plugin
214856822|NCT06927882|OTHER|WBV Therapy Group|"* Frequency: 3 sessions per week for 12 weeks.~* Duration: 25 minutes per session.~* Vibration Parameters: Participants will undergo whole body vibration therapy at a frequency of 30 Hz, for 25 minutes per session, 3 times a week, with an amplitude of 1-2 mm, over a duration of 12 weeks."
214856823|NCT06927882|OTHER|Placebo Group:|• Participants will stand on a non-vibrating platform and perform similar static and dynamic exercises for the same duration. The platform will mimic the active intervention's noise and display settings to maintain blinding.
214856824|NCT06927882|OTHER|Control|Only assessment at baseline, after 12 weeks and 6 months.
214856825|NCT06927401|DEVICE|Flower|"Flower is a single-use capsule endoscope designed for timely visualization of the human stomach. The patient drinks water to fill the stomach before swallowing the Flower capsule, which transmits wireless video, through an external dongle placed near the patient's abdomen, to a physician's computer or smartphone. Flower is weighted to orientationally bias the capsule upward, meaning that with a few simple position adjustments a complete viewing of the stomach can be achieved approximately 10 minutes.~The procedure requires no sedation or equipment other than the Flower System (capsule and dongle). As a simple means of screening, Flower functions equivalent to comparable technologies, but offers advantages of being less invasive and burdensome. Flower has fewer potentially adverse consequences than traditional endoscopy (EGD), and it does not require capital equipment as magnetic endoscopy does. Flower offers the identification and location of bleeding sources in the stomach."
214856826|NCT06928870|OTHER|MAP 55-65 mmHg|MAP will be maintained between 55-65 mmHg during anesthesia.
214856827|NCT06928870|OTHER|MAP 66-75 mmHg|MAP will be maintained between 66-75 mmHg during anesthesia.
214856828|NCT06927388|DEVICE|freeform myopia control spectacles|The open ring freeform myopia control spectacle lens designs incorporate positively powered cylindrical annular refractive elements (CARE) on the back surface with a superiorly positioned opening in each CARE. The CARE provides an effective optical myopic defocus signal for myopia control and the ring opening facilitates a defocus free zone to aid a smoother visual free transition from downgaze through to upgaze (far) vision for the wearer. The OR designs provide a difference in area and strength of myopia defocus by altering design parameters i.e. zone widths and zone powers. The OR2 and OR3 designs have wider zones and/or higher zone powers than OR1.
214856829|NCT06927388|DEVICE|Commercial myopia control spectacle lens (CML)|Myoless freeform peripheral plus myopia control spectacle lens by IOT
214856830|NCT06928987|OTHER|Touch Massage|"The practitioner performs the touch-massage for 15 minutes on clothed personnel in a seated position on an ergonomic massage chair. The massage focuses on the back, neck and arm areas. It's a precise, technical sequence of pressure, stretching and sweeping movements that follows the following pattern:~* Basic anti-stress maneuvers to relieve tension,~* Relaxation of the upper torso with weightless movements to loosen shoulders and arms,~* Stretching,~* Redynamization through rapid friction on the back.~Burnout, anxiety, affect, and musculoskeletal disorders (MSDs) will be assessed in participants using the following questionnaires at different times of the study."
214856831|NCT06926907|BEHAVIORAL|The Teacher Education and Classroom Habits (T.E.A.C.H.) Program|The T.E.A.C.H. Program utilized essential constructs of the Social Cognitive Theory to deliver virtual nutrition education to Montessori teachers over a 6-week period. The intervention consisted of four program components: 1. An interactive online nutrition education platform with 6 modules was developed using a WordPress website. Each module contained 5 topics including adult nutrition, child nutrition, classroom food practices, cultural practices, and teacher-parent communication. Teachers were provided login information via email containing a unique identifier to be used as their username and were prompted to complete one module per week for 6 weeks; 2. Live weekly virtual education sessions were held via Zoom to supplement and reinforce the online learning experience; 3. A Montessori-based nutrition curriculum with 6 weekly lessons to utilize in the classroom was provided to each participant; 4. Educational handouts to be disseminated to parents.
214856832|NCT06927050|BEHAVIORAL|Visual Communication Tool|MyCareGorithm will be used during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. MyCareGorithm is an online educational tool that will be displayed to the patient via iPad or Microsoft tablet.
214856833|NCT03496857|DEVICE|Light emitting diode|Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.
214856834|NCT03496857|OTHER|Bath Therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
214856835|NCT05711342|BEHAVIORAL|Aggression|"The intervention consists of 10 lessons:~1. Motivation - where are you now?~2. Where do you want to go?~3. Circle of aggression.~4. Thoughts.~5. Emotions.~6. Bodily sensations.~7. Techniques for self-control.~8. Asking for help.~9. Assertiveness.~10. Relapse-prevention. Each lesson consists of multiple components, i.e. written text, assignments and videos with therapists and/or experts by experience. After each lesson, the therapist sends written feedback on the assignments to the patient. Because 'Aggression' is a blended intervention, each lesson is briefly discussed in an in-person treatment session. Generally, participants work on one lesson per week."
214856836|NCT05711342|BEHAVIORAL|Treatment as usual|In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.
214856837|NCT06175247|OTHER|Low Glycemic Index Diet|A low glycemic diet will be initiated with dietician support and guidance.
214856838|NCT00951626|BEHAVIORAL|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
214856839|NCT00951626|BEHAVIORAL|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.~For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
214856840|NCT00951626|DIETARY_SUPPLEMENT|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
214664945|NCT06953687|BEHAVIORAL|Written Exposure Therapy|WET is a cognitive behavioral therapy for PTSD that typically consists of 5 weekly 50-minute sessions. For the current study using a variable length approach, participants may complete up to 7 sessions. WET is based on an extinction and emotional processing treatment model. First, patients learn about PTSD and the role of avoidance in maintaining PTSD symptoms. Next, patients are guided to write about their trauma for 30 minutes and afterwards, the therapist briefly checks in with the patient. This procedure is followed for the next 4 sessions, with guidance to first write about the trauma, and in later sessions to write about consequences of the trauma and the patient's current meaning of their lives. The goals of WET are to assist the patient in emotionally processing the event and reduce avoidance of trauma-related thoughts and memories, which facilities recovery.
214664946|NCT06953687|OTHER|Shared Decision Making (SHARE)|"The study will use the SHARE Approach to facilitate treatment planning and decision-making. SHARE stands for:~1. Seek the patient's participation~2. Help the patient explore and compare treatment options~3. Assess the patient's values and preferences~4. Reach a decision with the patient~5. Evaluate the patient's decision The Shared Decision Making Patient Preference Checklist will be used to determine the participant's preference for type of treatment, frequency of treatment sessions, and treatment delivery modality. Step 5 also includes following up with the patient and making changes if something it not working well for the patient."
214664947|NCT01689038|DRUG|F17464|Single dose
214664948|NCT02446964|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
214664949|NCT02446964|DRUG|Cyclophosphamide|Given IV
214664950|NCT02446964|DRUG|Fludarabine Phosphate|Given IV
214664951|NCT02446964|OTHER|Laboratory Biomarker Analysis|Correlative studies
214664952|NCT02446964|DRUG|Mycophenolate Mofetil|Given PO or IV
214664953|NCT02446964|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
214664954|NCT02446964|DRUG|Tacrolimus|Given IV and PO
214664955|NCT02446964|RADIATION|Total Marrow Irradiation|Undergo TMLI
214856841|NCT00951626|OTHER|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
214856842|NCT00951626|OTHER|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
214856843|NCT00951626|PROCEDURE|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
214856844|NCT00951626|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
214856845|NCT00951626|PROCEDURE|assessment of therapy complications|Collected throughout the 12 month study period
214856846|NCT00951626|PROCEDURE|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
214856847|NCT00951626|PROCEDURE|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
214856848|NCT00951626|PROCEDURE|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
214856849|NCT00951626|PROCEDURE|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
214856850|NCT06928896|PROCEDURE|This interventional trial enrolled a total of 42 patients, dividing them into two age groups: group 1. Using the friction and group 2. Using the frictionless|Cone beam computed tomography (CBCT) was conducted before and after retraction to evaluate alveolar changes and speed.
214856851|NCT06928935|BEHAVIORAL|d-DBT|d-DBT is an 8-week self-led online intervention that teaches mindfulness, emotional regulation, distress tolerance, and interpersonal effectiveness skills. Participants receive weekly digital navigator check-ins.
214856852|NCT06928649|DIAGNOSTIC_TEST|Blood sampling|Blood sampling: 3 first days of admision, 2 ml of plasma daily Urine, BALF, CSF sampling: 1 day during 3 first days of admission
214856853|NCT02218307|DRUG|Mupirocin|
214856854|NCT02218307|DRUG|Placebo|
214856855|NCT02332980|DRUG|Ibrutinib|Given PO
214856856|NCT02332980|DRUG|Idelalisib|Given PO
214856857|NCT02332980|OTHER|Laboratory Biomarker Analysis|Correlative studies
214856858|NCT02332980|BIOLOGICAL|Pembrolizumab|Given IV
214856859|NCT06826365|DIAGNOSTIC_TEST|Percentage distribution of immune system cells in peripheral blood|Assessment of the percentage distribution of the immune system cell population in peripheral blood by flow cytometry
214856860|NCT06826365|DIAGNOSTIC_TEST|Percentage distribution of immune system cells in endometrium|Assessment of the percentage distribution of the immune system cell population in endometrium by flow cytometry
214856861|NCT06616662|PROCEDURE|MAF|use mucosal advancement flap to treat PAF
214664956|NCT04163809|DEVICE|Virtual Reality with Oculus Go headset|The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
214664957|NCT03974919|OTHER|NO intervention required|NO intervention required
214664958|NCT03552783|BEHAVIORAL|FFL + Cognitive Behavioral Therapy|Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.
214664959|NCT03552783|BEHAVIORAL|Fathers for a Lifetime (FFL) only|"The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~1. Personal responsibility~2. Personal responsibility to your child~3. Responsibility to your family and community"
214664960|NCT00188448|DEVICE|MRI|
214664961|NCT00292773|PROCEDURE|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
214664962|NCT01936246|DIETARY_SUPPLEMENT|Increased protein|
214664963|NCT01491958|DRUG|atorvastatin|"donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first."
214664964|NCT01491958|DRUG|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
214664965|NCT01491958|DRUG|methotrexate|Day +1, +3, and +6 and +11
214856862|NCT06616662|PROCEDURE|LIFT|use LIFT surgery for treating PAF
214856863|NCT00554320|PROCEDURE|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
214856864|NCT00554320|PROCEDURE|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
214856865|NCT06924528|OTHER|using toy during inhaler treatment|The mask application on the toy will be performed only during the first inhaler treatment that the children receive in the emergency department.
214856866|NCT06928974|PROCEDURE|Bilateral Pedicled Vastus Lateralis Muscle Flaps Transposition|Bilateral Pedicled Vastus Lateralis Muscle Flaps Transposition to restore the function of underdeveloped or absent rectus abdomini muscles
214856867|NCT06927999|DRUG|Placebo|Placebo solution nasal spray containing no active drug
214856868|NCT06927999|DRUG|0.5 mg epinephrine|0.5 mg epinephrine per spray
214856869|NCT06927999|DRUG|1 mg epinephrine|1 mg epinephrine per spray
214856870|NCT05087862|PROCEDURE|Ultrasound-guided pericapsular nerves group of the hip block|After the ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% bupivacaine.
214856871|NCT05087862|PROCEDURE|Pericapsular local anesthetic infiltration of the hip|Intraoperatively, 60 mL of adrenalized 0.25% bupivacaine plus ketorolac 30 mg will be infiltrated by the surgeon.
214856872|NCT04075552|BEHAVIORAL|Pre Meal Presentation|Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
214856873|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Modeling|"Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model."
214856874|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Token Economy|Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
214856875|NCT01795742|DEVICE|Human-Powered Nebulizer|
214856876|NCT00261963|DEVICE|ultraviolet light|
214856877|NCT05051644|BEHAVIORAL|Steps 2 Change (S2C)|Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
214856878|NCT05051644|BEHAVIORAL|Control|The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
214856879|NCT00003138|BIOLOGICAL|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
214856880|NCT00003138|BIOLOGICAL|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
214856881|NCT00003138|PROCEDURE|Transfusion|Red cell and platelet transfusions
214856882|NCT00102518|DRUG|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
214856883|NCT03967951|OTHER|CT radiomic feature evaluation|"Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated.~In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be.~Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated."
214856884|NCT00107705|BIOLOGICAL|Tree MATA MPL|
214856885|NCT01752647|PROCEDURE|Low dose computed tomography|Low dose computed tomography scan
214664966|NCT06959199|PROCEDURE|Endovascular Treatment|EVT procedures may include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, or stenting, or other intra-arterial procedures as deemed appropriate by the treating physician.
214664967|NCT06959199|DRUG|Best Medical Treatment|Patients in this group will receive standard medical therapy in accordance with the guideline-directed management for acute ischemic stroke.
214664968|NCT03312855|DRUG|Revacept 80 mg|single dose, intravenous application of 80 mg Revacept
214664969|NCT03312855|DRUG|Revacept 160 mg|single dose, intravenous application of 180 mg Revacept
214664970|NCT03312855|DRUG|Placebo|single dose, intravenous application of Placebo solution
214664971|NCT01719575|DRUG|Motilitone|
214664972|NCT01719575|DRUG|Placebo|
214664973|NCT00775307|DRUG|PAZOPANIB|400 mg/day (24 weeks)
214664974|NCT00775307|DRUG|Placebo|Placebo 400 mg/day (24 weeks)
214664975|NCT04359966|DRUG|Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,|First line therapy
214664976|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|First line therapy second arm
214664977|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|Second line therapy for Helicobacter pylori infection
214664978|NCT04359966|DRUG|Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg|Second line therapy for Helicobacter pylori infection second arm
214856886|NCT04495283|DRUG|Pregabalin|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
214856887|NCT04495283|DRUG|Acetaminophen|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
214856888|NCT04495283|OTHER|Placebo 1|Placebo for APAP
214856889|NCT04495283|OTHER|Placebo 2|Placebo for combination
214856890|NCT03383237|DRUG|Apatinib|500mg/d,q.d.,p.o.
214856891|NCT06645444|OTHER|immediate implant placement with customized PEEK healing abutment|"* an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery."
214856892|NCT01792934|DRUG|XELOX regimen according to standard procedures|
214856893|NCT01792934|DRUG|FOLFOX regimen according to standard procedures|
214856894|NCT01792934|PROCEDURE|Surgery|
214856895|NCT01792934|OTHER|radiofrequency ablation (RFA)|
214856896|NCT01792934|OTHER|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
214856897|NCT01792934|RADIATION|stereotactic body radiation therapy (SBRT)|
214856898|NCT01792934|DRUG|Bevacizumab|may be added to both regimens according to standard procedures
214856899|NCT01792934|PROCEDURE|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
214856900|NCT05864287|BEHAVIORAL|Bodies in motion intervention program|Intervention groups will be offered separately to male- and female-identifying athletes; each group will consist of six to eight athletes and multiple groups may be run each academic term. Facilitators will use the gender-specific programs in their delivery. Intervention athletes will receive a participant workbook as well as be invited to join a BIM-specific, private social media platform that will allow them to share, connect, and support each other through out their involvement in the program. As part of our mixed-methods design, we will also conduct qualitative interviews to explore the student athletes' experiences of the BIM program. Following intervention, we will invite 12-16 male and 12-16 female identifying athletes who completed the BIM program to participate in the structured interviews. Interviews will be semi-structured and are expected to last 60-90 minutes
214856901|NCT02058082|PROCEDURE|Intracytoplasmic sperm injection|
214856902|NCT03028948|OTHER|Internet-Based Intervention|Access ITW
214856903|NCT03028948|OTHER|Questionnaire Administration|Ancillary studies
214856904|NCT03028948|OTHER|Survey Administration|Ancillary studies
214856905|NCT05200624|DEVICE|2RT subthreshold nanosecond laser|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
214856906|NCT01751542|BEHAVIORAL|Mindfulness + Residential Treatment|
214856907|NCT01751542|BEHAVIORAL|Residential treatment alone|
214856908|NCT00419549|DRUG|Glyceryl - trinitrate|Transdermal Patch once only
214856909|NCT00419549|DRUG|Valdecoxib|Single parenteral administration
214856910|NCT03993249|BIOLOGICAL|Nivolumab|standard of care chemoradiotherapy + Nivolumab
214856911|NCT03993249|OTHER|chemoradiotherapy|standard of care chemoradiotherapy
214856912|NCT05421104|OTHER|Ruxolitinib|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
214856913|NCT00474604|PROCEDURE|diffusion-weighted magnetic resonance imaging|A scan will be performed.
214856914|NCT00474604|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
214856915|NCT00474604|PROCEDURE|magnetic resonance spectroscopic imaging|A scan will be performed.
214856916|NCT05410158|DRUG|Ketamine in PECS block versus topical wound instillation|On arrival to the operating room, an intravenous line will be inserted in the contralateral upper limb to the side of surgery. Anesthesia will be induced for all participating patients with 2 μg/kg fentanyl, 2 - 3 mg/kg propofol and 1.5 mg/kg lidocaine. Endotracheal intubation will be facilitated by 0.15 mg/kg cis-atracurium.The patients will be randomly assigned into 2 groups ( pecs block group , topical instillation group) using a randomization-computer program . Anesthesia will be maintained by 1 - 1.5 MAC isoflurane in 50% oxygen/ air mixture and 0.03 mg/kg cisatrcurium, respectively, in ventilation parameters that maintain normocapnia. At the end of surgery, a reversal of the muscle relaxant will be done using neostigmine (0.04 mg/kg) and atropine (0.01 mg/kg). After extubation, all patients will be transmitted to the post anesthesia care unit (PACU) for follow up .
214856917|NCT03030716|DIETARY_SUPPLEMENT|95% condensed proanthocyanidins from grape seed extract|0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
214856918|NCT04612517|DRUG|ZP7570|Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
214856919|NCT04612517|DRUG|Placebo|Placebo; corresponding volume
214856920|NCT05753670|DRUG|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
214856921|NCT05753670|DRUG|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
214856922|NCT02104336|DRUG|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
214856923|NCT03093818|OTHER|Pharmacogenomic testing|"The pharmacogenomic panel to be used incorporates 48 genetic variants for the following 13 pharamacogenes: CYP2B6 (cytochrome P450), CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), NUDT15 (Nudix hydrolase), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex)."
214856924|NCT05142566|DEVICE|MANTA Vascular Closure Device|Evaluate the safety of ultrasound guided deployment of MANTA VCD.
214856925|NCT00969319|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
214856926|NCT02710513|DIETARY_SUPPLEMENT|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
214856927|NCT05124561|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
214856928|NCT05124561|BIOLOGICAL|Placebo|Nebulized inhalation through the mouth
214856929|NCT00400621|DRUG|acetaminophen|
214856930|NCT04180553|DIAGNOSTIC_TEST|Point of Care Ultrasound (POCUS)|The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP \<90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
214856931|NCT04180553|OTHER|Usual Care|"The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated."
214856932|NCT05417503|OTHER|Non-invasive ventilation bi-level|For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).
214856933|NCT05417503|OTHER|Non-invasive ventilation placebo|The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
214856934|NCT05228496|DRUG|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
214856935|NCT05228496|DRUG|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 1 cycle of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
214856936|NCT01939041|DEVICE|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
214856937|NCT01939041|DEVICE|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
214664979|NCT03551028|DEVICE|HPV self collection|The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
214664980|NCT02125994|PROCEDURE|Interscalene nerve block|
214664981|NCT04237883|BEHAVIORAL|Standard communication email|This is the base communication that all physicians will receive.
214664982|NCT04237883|BEHAVIORAL|Social comparison Intervention|The social comparison is added onto the standard communication email to provide some peer comparison between the physicians.
214664983|NCT04237883|BEHAVIORAL|Leadership Training|Clinic and Physician leads will be provided with a clinic leadership training seminars in leadership, quality improvement, and support from the Quality Improvement team at UCLA Health.
214664984|NCT04188158|COMBINATION_PRODUCT|CAPECITABINE AND OXALIPLATIN|Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
214664985|NCT02045199|DEVICE|Tested product : V0111 cream|Application twice a day during 28 days
214664986|NCT02045199|DEVICE|Placebo|Application twice a day during 28 days
214856938|NCT01939041|BEHAVIORAL|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
214856939|NCT02246439|DRUG|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
214856940|NCT02246439|DRUG|Placebo Oral Tablet|Placebo
214856941|NCT01598441|DRUG|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
214856942|NCT01598441|DRUG|distilled water|1-2 ml aerosolized distilled water inhalation per session
214856943|NCT03178721|DIAGNOSTIC_TEST|blood sample|study B regulatory in blood and its correlation with atherosclerosis
214856944|NCT00618930|DRUG|Moviprep®|use of Moviprep®
214856945|NCT00618930|DRUG|Fleet|Use of Fleet
214856946|NCT01553279|BIOLOGICAL|V419|Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate \[meningococcal outer membrane protein complex\], and Hepatitis B \[recombinant\] vaccine administered via 0.5 mL intramuscular injection.
214856947|NCT01553279|BIOLOGICAL|PREVNAR 13®|Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).
214856948|NCT01553279|BIOLOGICAL|MCC-TT|Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
214856949|NCT01553279|BIOLOGICAL|MCC-CRM|Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
214856950|NCT01553279|BIOLOGICAL|Hib-MCC|Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
214856951|NCT01553279|BIOLOGICAL|MMR Vaccine|Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
214856952|NCT03819621|DEVICE|IRISS Medical Technologies mediGrid app|IRISS mediGrid is standalone software, loaded on a mobile electronic platform, which is intended to record and document ophthalmic and other bodily characteristics and to aid in the diagnosis of abnormalities.
214856953|NCT02754908|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.
214856954|NCT02754908|BEHAVIORAL|tutoring classes|They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
214856955|NCT05055895|DRUG|Anticholinergic burden|"The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1."
214856956|NCT00380692|DRUG|Atomoxetine|
214856957|NCT00380692|DRUG|Placebo|
214856958|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
214856959|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula B|"Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age."
214856960|NCT05410366|OTHER|Safe harbor clinical practice guideline|A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
214856961|NCT00219583|DRUG|UK-390,957|
214856962|NCT00400361|DRUG|RG1507|Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
214856963|NCT00055133|DRUG|Micellar Paclitaxel for Injection|
214856964|NCT05925673|OTHER|Mirror Therapy|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
214856965|NCT05925673|OTHER|Neuromuscular Stimulation (NMES)|Participants will use a portable NMES machine to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
214856966|NCT05925673|OTHER|Mirror Therapy + NMES|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. During the exercises they will have a portable NMES machine set up to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
214856967|NCT05727072|DRUG|LY3848575|Administered IV.
214856968|NCT05727072|DRUG|LY3848575|Administered SC.
214856969|NCT05727072|DRUG|Placebo|Administered IV.
214856970|NCT05727072|DRUG|Placebo|Administered SC.
214856971|NCT00506649|OTHER|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
214856972|NCT03744663|DRUG|Suboxone® SL|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.
214856973|NCT03744663|DRUG|Sublocade®|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (\> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of \> 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
214856974|NCT02237742|DRUG|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
214856975|NCT04340349|DRUG|Hydroxychloroquine Sulfate|A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
214856976|NCT04340349|DRUG|Bromhexine 8 MG|TMPRSS2 blocker
214856977|NCT01947478|DEVICE|MDT-2113 Drug-Eluting Balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
214856978|NCT01947478|DEVICE|Standard angioplasty balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
214856979|NCT00001007|DRUG|Zidovudine|
214664987|NCT02012816|OTHER|Peer-referral incentive program to increase VMMC uptake|The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
214664988|NCT00656214|DRUG|Lycopene|08 mg/day in two divided dosage
214856980|NCT00886041|PROCEDURE|laparoscopy|subjected to laparoscopy
214856981|NCT00886041|OTHER|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
214856982|NCT05253924|DIAGNOSTIC_TEST|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1, Piezo1, Piezo2, TRPV1 andTRPM8) will be investigated. Saliva sample will be collected for PT and FT. Genomic DNA will be extracted from aliquots of 0. 4 ml of each saliva sample with the Oragene OG575 (DNA Genotek) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
214856983|NCT05253924|DIAGNOSTIC_TEST|EEG acquisition|Both PT and FT infants will have their EEG signal recorded during mother-baby interaction according to a modified version of the Still Face paradigm; the EEG signal will be recorded by means of the medical system eego mylab (AntNeuro), using special headphones equipped with 32 electrodes and suitable to acquire the EEG signal since early childhood. After spectral analysis of the EEG signal, the difference in signal strength in the alpha band recorded by two homologous electrodes (or electrode clusters) (i.e. right alpha - left alpha) will be calculated to obtain the FAA index. Because the alpha frequency band is associated with cortical inhibitory activity, a lower asymmetry reflects less left hemisphere activation than right hemisphere activation. The analysis of EEG data will be performed in MatLab environment using the eeglab software and algorithms developed ad hoc.
214856984|NCT05185258|DRUG|Enstilar|Topical foam
214856985|NCT05185258|DRUG|Placebo-vehicle|Topical foam
214856986|NCT03141879|OTHER|HUR equipment resistance training intervention|Resistance training intervention
214664989|NCT00656214|DRUG|Placebo|Two divided dosage
214856987|NCT04235699|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
214856988|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated with inorganic bovine bone associated.|Dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) associated with inorganic bovine bone associated with collagen matrix (Bio-Oss® Collagen).
214664990|NCT05089565|DIAGNOSTIC_TEST|Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation|Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination
214664991|NCT05307471|OTHER|Thoracotomy/scopy|
214664992|NCT04377529|BEHAVIORAL|Local Champion|Local champions (physiotherapists) will co-develop the champion training support based on a comprehensive behavioural analysis, previous implementation work and evidence-based theory. The study team will provide this training and support to the champions, who will then provide additional support to their peers participating in the study.
214664993|NCT04163783|DRUG|[14C]-BGB-3111|20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,
214664994|NCT04163783|DRUG|BGB-3111|Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
214856989|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated or not with inorganic bovine bone associated with collagen matrix.|dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) alone.
214856990|NCT03648242|BEHAVIORAL|Interruptive Clinical Decision Support|"An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~* One-click addition of elevated BMI to problem list~* Reminder to utilize Suggested PowerPlan~* One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~* Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~* Links to existing, evidence-based childhood obesity screening and management guidelines"
214856991|NCT00726154|BEHAVIORAL|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
214856992|NCT00726154|BEHAVIORAL|Collaborative Care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
214856993|NCT01031966|BIOLOGICAL|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
214856994|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
214856995|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
214856996|NCT06305130|OTHER|No intervention|No intervention
214856997|NCT01991665|OTHER|Digital examination|
214856998|NCT01991665|OTHER|Sonography evaluation|
214664995|NCT01826669|PROCEDURE|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
214664996|NCT03149835|OTHER|Non-invasive ventilation|NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
214664997|NCT00676039|DRUG|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
214664998|NCT00676039|DRUG|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
214664999|NCT00676039|DRUG|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
214665000|NCT00676039|DRUG|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
214665001|NCT02813538|DRUG|Indocyanine green clearance|To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
214665002|NCT02813538|OTHER|Thromboelastometry|To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
214665003|NCT02589587|PROCEDURE|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
214665004|NCT02589587|OTHER|no intervention|lean control group
214665005|NCT01519843|DEVICE|transcranial direct current stimulation tDCS|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
214665006|NCT01519843|DEVICE|transcranial magnetic stimulation TMS|TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
214665007|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 5g|Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
214665008|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 10g|Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
214665009|NCT03528681|DRUG|Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
214665010|NCT00955110|DRUG|Oxymorphone ER|15mg or 30mg
214665011|NCT00955110|DRUG|Oxycodone CR|30mg or 60mg
214665012|NCT00955110|DRUG|Placebo|The placebo was a sugar pill.
214665013|NCT00955110|DRUG|Hydromorphone|8 mg
214856999|NCT04190030|BEHAVIORAL|mindfulness training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
214857000|NCT04190030|BEHAVIORAL|cognitive reappraisal training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
214857001|NCT04111848|DRUG|Ketamine|"Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour."
214857002|NCT04111848|DRUG|ketamine and magnesium|Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
214857003|NCT01388166|PROCEDURE|Education|Education
214857004|NCT02899832|DEVICE|NIRS|Near Infra Red Spectroscopy
214857005|NCT01272362|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
214665014|NCT04072640|DRUG|Voriconazole 200mg|Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
214665015|NCT04072640|DRUG|amphotericin B deoxycholate (0.4-0.5mg/kg/d)|Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
214665016|NCT04072640|DRUG|Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)|Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
214665017|NCT03390231|COMBINATION_PRODUCT|Stem Cell Educator therapy|It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
214665018|NCT01195025|DRUG|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
214665019|NCT01195025|DRUG|colloid|Infusion of starch 10 ml/kg over 30 min
214665020|NCT01195025|DRUG|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
214665021|NCT01195025|DEVICE|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
214665022|NCT03927976|BEHAVIORAL|Path2Quit - culturally specific text message intervention|SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
214665023|NCT06103552|BEHAVIORAL|Building Lifestyle Options for Orthopedic Mobility (BLOOM)|This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.
214665024|NCT03335124|DRUG|Vitamin C|Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.
214857006|NCT06223217|OTHER|Surveys and Questionnaires|The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale
214857007|NCT05726461|DEVICE|AndroidAPS-rt-CGM;|Insulin therapy (aspart, lispro or glulisine) with AndroidAPS-rt-CGM.AndroidAPS-rt-CGM consists of three components:1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone.
214857008|NCT05726461|DEVICE|sensor augmented pump(SAP);|Insulin therapy (aspart, lispro or glulisine) with sensor augmented pump(SAP).SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
214857009|NCT00158756|BIOLOGICAL|Tritanrix™-HepB|GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
214857010|NCT00158756|BIOLOGICAL|Rotarix™|GSK Biologicals' live attenuated human rotavirus vaccine
214857011|NCT00158756|BIOLOGICAL|Zilbrix™|GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine
214857012|NCT00158756|BIOLOGICAL|Triple Antigen™|Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
214857013|NCT00158756|BIOLOGICAL|Engerix™-B|GSK Biologicals' hepatitis B vaccine
214857014|NCT00158756|DRUG|Placebo|Placebo for the Rotarix™ vaccine
214665025|NCT03335124|DRUG|Hydrocortisone|Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
214665026|NCT03335124|DRUG|Thiamine|Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
214665027|NCT03335124|DRUG|0.9% Sodium Chloride Injection|0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
214665028|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
214665029|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
214857015|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Individualized|Subject and parent begin by working with a therapist to create an individualized fear hierarchy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
214857016|NCT05777161|BEHAVIORAL|Cognitive Behavior Therapy|Subjects will work with a therapist using anxiety management strategies to address thoughts, feelings, and behaviors.
214857017|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Group (removed from study)|Subjects and parents will work in a group setting to receive exposure therapy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
214857018|NCT03234894|DEVICE|SiteSeal Endovascular|to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.
214857019|NCT02370225|OTHER|aerobic exercise|"Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).~The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end."
214857020|NCT03207841|OTHER|LC/HP|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include \~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio \<1.5 and fat intake set at \~30% of the total energy intake.
214857021|NCT02935166|OTHER|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
214857022|NCT02501434|DRUG|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
214857023|NCT02152735|PROCEDURE|Cleaning the uterine cavity|These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
214857024|NCT02590835|PROCEDURE|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
214857025|NCT02590835|PROCEDURE|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
214857026|NCT01409590|BEHAVIORAL|Exercise program|Homogenous exercise program in local fitness centers
214857027|NCT01409590|BEHAVIORAL|Diet|Weigh loss diet program prescribed by a professional nutritionist
214857028|NCT02138942|DEVICE|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
214857029|NCT01429051|DRUG|Intranasal Fentanyl Spray (INFS)|Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
214857030|NCT01429051|DRUG|Placebo|Matching intranasal placebo spray
214857031|NCT00852566|DRUG|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
214857032|NCT00852566|DRUG|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
214857033|NCT02091323|PROCEDURE|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 \~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
214665030|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
214857034|NCT05739214|DEVICE|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
214857035|NCT04132336|DRUG|Naproxen sodium/Caffeine (BAY2880376)|Tablet, oral, single dose
214857036|NCT04132336|DRUG|Naproxen sodium (Aleve)|Tablet, oral, single dose
214857037|NCT04132336|DRUG|Caffeine|Tablet, oral, single dose
214665031|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
214665032|NCT00839163|DRUG|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
214665033|NCT05631925|DRUG|propofol bolus|Propofol will be added in bolus doses of 0.5mg/kg.
214665034|NCT05631925|DRUG|propofol infusion|Propofol will be administered as 10mg/kg/hour infusion.
214665035|NCT02267928|OTHER|Check Symptoms|"Symptoms are Checked"
214665036|NCT02267928|OTHER|Uncheck Symptoms|"Symptoms are Un-checked"
214665037|NCT02267928|OTHER|Experienced|Focus of instructions is on symptoms the participant has experienced
214665038|NCT02267928|OTHER|Not Experienced|Focus of instructions is on symptoms the participant has NOT experienced
214665039|NCT05133596|OTHER|Clinical examination|The investigator will conduct a clinical examination to rule out other causes of olfactory impairment independent of COVID-19. The investigator will also collect the following information: socio-demographic data (age, sex, blood type, weight, height, etc.), history of olfaction disorder symptoms, past or current treatments received and tobacco/alcohol consumption.
214665040|NCT05133596|OTHER|Blood collection|12ml-blood sample
214665041|NCT05133596|OTHER|Olfactory evoked potentials|Olfactory evoked potentials will be recorded during olfactory tests.
214665042|NCT05133596|OTHER|Brushing of olfactory slits|collection of olfactory slits cells.
214665043|NCT05133596|OTHER|Neurological examination and neuropsychological assessment|"* MOCA, BREF~* CVLT~* WAIS IV, MEM III~* Right-side and left-side empan, Trail Making Test A and B (TMT), verbal fluency tests, PASAT, Attention Assessment Test~* Benton's Line Judgement, VOSP~* Assessment of psychological status, fatigue and screening for psychiatric comorbidities: depression \& anxiety scales (HAD scale, mADRS depression scale, STAI anxiety scale), Fatigue Severity Scale."
214665044|NCT05133596|OTHER|Nasal endoscopy|Nasal endoscopy
214665045|NCT05133596|OTHER|Assessment of olfactory and taste functions|"* scales: VAS and TSS~* Sniffin Stick test"
214665046|NCT00621023|DRUG|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
214665047|NCT01712360|DRUG|NAFT500 (pediatric)|Applied to both feet and groin area
214665048|NCT01712360|DRUG|NAFT600 (pediatric)|Applied to both feet only
214665049|NCT01712360|DRUG|NAFT500 (adult)|Applied to both feet and groin area
214665050|NCT01712360|DRUG|NAFT600 (adult)|Applied to both feet
214665051|NCT02123329|BEHAVIORAL|Pharmacist delivered smoking cessation program|"The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.~To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.~• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems"
214665052|NCT02123329|OTHER|Control arm (i.e: regular care)|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
214665053|NCT03083912|DIETARY_SUPPLEMENT|Fortimel Complete|The residents included receive 2 bottle por day.
214665054|NCT00450463|DRUG|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
214665055|NCT00450463|DRUG|Flutamide (Eulexin)|Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
214665056|NCT00450463|BIOLOGICAL|PROSTVAC-F/ TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.
214665057|NCT00450463|BIOLOGICAL|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
214665058|NCT01101074|OTHER|This is non-intervention observational study|This is non-intervention observational study
214857038|NCT04132336|DRUG|Placebo|Tablet, oral, single dose
214857039|NCT03532113|BEHAVIORAL|Updating|Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.
214857040|NCT03532113|BEHAVIORAL|Inhibition|Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.
214857041|NCT03532113|BEHAVIORAL|General knowledge|General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
214857042|NCT00940836|DRUG|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
214857043|NCT00940836|DRUG|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
214857044|NCT00940836|DRUG|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
214857045|NCT00204958|DRUG|nutritional supplement|
214857046|NCT00204958|DRUG|glutamine popsicle|
214857047|NCT06195696|BEHAVIORAL|employs questionnaires|The first phase is a quantitative study that employs a questionnaire to investigate the current state of illness perception and the distribution of coping styles in kidney transplant recipients, and to explore the differences in illness perception between positive coping and negative coping patients after kidney transplantation; The second phase involves a descriptive qualitative study that utilizes face-to-face, semi-structured, in-depth interviews to investigate the causes of differences in illness perceptions of different coping styles in kidney transplant recipients who experience idiosyncrasies.
214857048|NCT03256084|PROCEDURE|Blood and tumor samples|Blood and tumor samples
214857049|NCT00061243|BIOLOGICAL|HIV-1 DNA vaccine with protein vaccine boost|Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
214857050|NCT04426279|OTHER|questionnaire assesment|15-minute face-to-face questionnaire
214857051|NCT02908737|DEVICE|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
214857052|NCT02129296|DEVICE|Air filled balloon|Balloon filled with air according to the manufacturing company orders
214857053|NCT02129296|DEVICE|Bioenteric BIB® balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
214857054|NCT04561687|DRUG|Montelukast|Montelukast and nasal budesonide
214857055|NCT04561687|DRUG|Azelastine|Azelastine and nasal budesonide
214857056|NCT04561687|DRUG|Budesonide|To all groups
214857057|NCT04561687|DRUG|Placebo|Placebo and nasal budesonide
214857058|NCT05001711|DEVICE|Aria CV Acute PH System|The Aria CV Acute PH System is indicated for evaluation of hemodynamic responses (e.g. pulmonary arterial compliance, cardiac output, and effective arterial elastance) to an intravascular Balloon catheter temporarily placed in the pulmonary artery in symptomatic adult patients with WHO Group 2 or WHO Group 3 pulmonary hypertension and right ventricular dysfunction.
214857059|NCT05218382|DEVICE|Virtual reality|immersive virtual reality technology
214857060|NCT05218382|DEVICE|No virtual reality|Virtual reality with blank screen
214857061|NCT01310673|DRUG|Allopurinol|"Allopurinol 300mg po QD for 30 days.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
214857062|NCT01310673|DRUG|Placebo|"Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
214665059|NCT03873207|DEVICE|PopSole™ offloading device|Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.
214665060|NCT03873207|DEVICE|padded insole|the control arm will be provided with standard padded insole to wear inside footwear
214665061|NCT04893265|BEHAVIORAL|Text Messaging Only|Active Comparator
214857063|NCT04729192|OTHER|ObsQoR-10T Questionnaire|The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
214857064|NCT01350843|DIETARY_SUPPLEMENT|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
214857065|NCT03393871|DIAGNOSTIC_TEST|absolute blood flow measurement|Absolute maximum flow will be measured, using the RayFlow® multifunctional monorail infusion catheter. (This measurement takes a few minutes per artery, does not require any additional drug, but only 50-100 ml of saline per artery, and is not associated with any additional risk for the patient compared to the regular invasive procedure.
214857066|NCT02793570|OTHER|observational|
214857067|NCT04614493|DEVICE|SonoCloud-9 (SC9) device|"daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months) with 6 concomitant Blood Brain Barrier opening sessions by ultrasound~\+ 9 Blood Brain Barrier opening sessions by ultrasound without any associated drug"
214857068|NCT04614493|DRUG|Temozolomide according Stupp protocol|daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months)
214857069|NCT00008151|DRUG|cyclosporine|
214857070|NCT00008151|DRUG|fludarabine phosphate|
214857071|NCT00008151|DRUG|gemtuzumab ozogamicin|
214857072|NCT00008151|DRUG|methotrexate|
214857073|NCT00008151|DRUG|mycophenolate mofetil|
214857074|NCT00008151|PROCEDURE|allogeneic bone marrow transplantation|
214857075|NCT00008151|PROCEDURE|peripheral blood stem cell transplantation|
214857076|NCT00008151|RADIATION|radiation therapy|
214857077|NCT05578365|OTHER|Pilates method|Individuals in the Pilates group will perform specific exercises online. There will be 16 sessions, lasting 60 minutes, with 10 minutes of warm-up, 30 to 40 minutes of exercises focusing on the trunk stabilizers muscles, and 10 minutes of cool-down with relaxation, stretching, or meditation. In addition, the individuals will have access to the same information of the control group.
214857078|NCT05578365|OTHER|Pain education|Individuals in the control group will receive information on self-management of low back pain, pain education, and changes in lifestyle habits once a week during 8 weeks.
214857079|NCT02932514|DEVICE|Eversense (Senseonics) Continuous Glucose Monitoring System|"* Evaluate accuracy of Eversense CGM System to SMBG Meter.~* Compare performance between abdomen and arm insertion sites.~* Determine the usability of the Eversense System in a home-use setting for 180 days."
214857080|NCT04567914|DIAGNOSTIC_TEST|Bilaterally abdominal muscle thickness with ultrasonography|AIS group was evaluated for localization of curvature and degree of curvature. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness in the supine and standing positions in both groups. Spirometry evaluation was performed in both groups
214857081|NCT03820934|DIAGNOSTIC_TEST|Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
214857082|NCT04390321|OTHER|LLMcare|Participants will undergo 20 sessions of computerized cognitive and physical training, during a 2 month period. Both components have a duration of 30 minutes and are consecutive, but their sequence is pseudo-randomized. All sessions are conducted under supervision. Cognitive training uses the greek adaptation of the BrainHQ software (Posit Science Corporation), utilizing audiovisual stimuli, and targets memory, attention, cognitive-processing speed, orientation and social skills. Physical training is based on the WebFitForAll protocol and uses the motion sensor device Kinect. It consists of warm-up, aerobic, flexibility, strength, balance and cool down exercises.
214857083|NCT00405613|DRUG|Aspirin|
214857084|NCT04361903|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours
214857085|NCT01939496|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
214857086|NCT01939496|DRUG|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
214857087|NCT05223296|DEVICE|Compare between two procedure for II-IV degree pile excision|LigaSure or diathermy excision of III-IV degree pile?
214857088|NCT02756936|DRUG|Daclatasvir Zeta|1 tablet contains 60 mg Daclatasvir
214857089|NCT02756936|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
214857090|NCT03560349|DRUG|Lidocaine HCl Gel 2%|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
214857091|NCT03560349|DRUG|placebo gel|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
214857092|NCT00948727|BEHAVIORAL|Dose adaptation according to CN activity monitoring|The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
214857093|NCT00948727|DRUG|Cyclosporine (CsA)|Cyclosporine (CsA)
214857094|NCT05396131|DEVICE|Lung Sealant|The Aeriseal System uses a polymer foam to block or seal fissures, peripheral airways, alveoli, and collateral channels to achieve lung volume reduction.
214857095|NCT05396131|DEVICE|Endobronchial Valve (EBV)|The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.
214857096|NCT05075720|DIETARY_SUPPLEMENT|Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
214857097|NCT05075720|DIETARY_SUPPLEMENT|Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
214857098|NCT05075720|DIETARY_SUPPLEMENT|Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
214857099|NCT03703648|RADIATION|Radiotherapy (curative) for head and neck cancer|Curative intent radiotherapy for head and neck cancer. Doses will be prescribed by an independent Clinical Oncology team. There will be no alteration or experimentation of radiotherapy dosage
214665062|NCT04893265|BEHAVIORAL|INFORMED|Experimental
214857100|NCT01612026|PROCEDURE|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
214857101|NCT04547530|DIETARY_SUPPLEMENT|Vitamin D|as above
214857102|NCT04547530|DIETARY_SUPPLEMENT|Placebo|as above
214857103|NCT01007565|PROCEDURE|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
214857104|NCT03052322|DRUG|MSB11022|Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
214857105|NCT03052322|DRUG|EU-Humira|Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
214857106|NCT05783648|DRUG|Use of tranexamic acid|Percentage of correct use according to POISE-3 criteria of tranexamic acid
214857107|NCT03712839|OTHER|Cognitive-functional evaluation|The participants will be evaluated with a set of tools within the context of meaningful ADL.
214857108|NCT03660358|DEVICE|kinesiotape application|kinesiotape application to diaphragm, chest wall and abdomen in preterm infants.
214857109|NCT06168565|DEVICE|Intermittent pneumatic compression (AirRelax)|Moderate pressure (around 80mmHg); high pressure (around 200mmHg), both applied on the lower-limbs
214857110|NCT05727917|DRUG|Hetrombopag|After hematopoietic stem cell reinfusion, the patients begin to take hetrombopag orally 7.5mg/d, until the patients reach complete platelet response.The treatment will stop when patients accept 21 consecutive days of treatment or reach the discontinuation criteria.
214857111|NCT05727917|OTHER|placebo|After hematopoietic stem cell transfusion, the patients will be only observed, and the observation during the treatment period will be ended after 30 days
214857112|NCT04920916|BIOLOGICAL|Dupilumab|Participants will receive a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
214857113|NCT04920916|DRUG|Placebo|Normal Saline.
214857114|NCT00973765|DRUG|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
214857115|NCT00973765|DRUG|placebo|placebo 2 pills po BID x 7 days
214857116|NCT00000396|BEHAVIORAL|Patient self-care education|
214857117|NCT05818618|DRUG|Clobetasol Topical Gel|Topic Clobetasol gel applied locally on OLP lesions.
214857118|NCT05818618|DRUG|Placebo|Placebo oral gel applied locally on OLP lesions.
214857119|NCT02011113|DRUG|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
214857120|NCT02011113|DRUG|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
214857121|NCT02964949|DRUG|Edoxaban|Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
214857122|NCT03018808|OTHER|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
214857123|NCT03018808|OTHER|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
214857124|NCT03018808|OTHER|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
214857125|NCT03018808|PROCEDURE|Blood test|Blood samples will be collected at indicated time points
214857126|NCT03018808|OTHER|anthropometric measures|Anthropologic measures will be performed.
214857127|NCT03018808|OTHER|Oximetry|Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
214857128|NCT01093664|BIOLOGICAL|AFFITOPE AD02|s.c. injection
214857129|NCT05992818|DIAGNOSTIC_TEST|comparing DRS-R-98 (The Delirium Rating Scale--Revised-98) and 3D-CAM (3-minute diagnostic assessment for CAM-Confusion Assessment Method-defined delirium) tests to assess postoperative delirium|determine the test that is more effective and practical in the assessment of POD
214857130|NCT04327856|PROCEDURE|Cataract Surgery|The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
214857131|NCT03660293|DRUG|Atorvastatin|cardio-protective agents
214857132|NCT03660293|DRUG|Captopril|cardio-protective agents
214857133|NCT03660293|DRUG|L-carnitine|cardio-protective agents
214857134|NCT03949803|BEHAVIORAL|Chocolate 100gr|"Evening/Night Chocolate:~Eating 100gr of milk chocolate within 1 hours of habitual bedtime~Control Chocolate:~Eating no milk chocolate or other chocolate~Chocolate Morning:~Eating chocolate within one hour of habitual waketime."
214857135|NCT00468728|DRUG|PAR-101/OPT-80|capsules
214857136|NCT00468728|DRUG|Vancomycin|Capsules
214857137|NCT05949671|OTHER|mediterranean, gluten-free and mediterranean gluten-free diet intervention|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients in the control group (n=10) did not receive any special dietary intervention. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
214857138|NCT04057469|DRUG|Tulobuterol Hydrochloride|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
214857139|NCT04057469|DRUG|Placebo transdermal patch|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
214857140|NCT03163004|BEHAVIORAL|Implementation of standing desks|Three standing desks will be introduced to the classroom
214857141|NCT03251963|DRUG|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
214857142|NCT03251963|DRUG|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
214857143|NCT03308539|RADIATION|echocardiography and cardiac magnetic resonance|transthoracic echocardiography and magnetic resonance imaging of the heart
214857144|NCT00792870|BEHAVIORAL|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
214857145|NCT00653952|DRUG|CAELYX|Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
214857146|NCT00653952|DRUG|Paclitaxel HCl|Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
214857147|NCT04648332|DRUG|Bupivacaine Hydrochloride|compartment psoas block
214857148|NCT00290836|DRUG|Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)|
214857149|NCT00198653|BEHAVIORAL|Newborn Thermal Care Practice|
214857150|NCT04505293|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
214857151|NCT05172466|DEVICE|BeCare application|Participants will complete activities on the application 3 times a week for 2 weeks when they first join the study. They will then attend 4 in-person visits where they complete clinical and application based assessments. Activities are clearly marked in the application and participants are assigned specific assessments by the study team. The application analyzes user input during each evaluation to provide an outcome measure for that assessment.
214857152|NCT03055663|OTHER|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
214857153|NCT03055663|PROCEDURE|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
214857154|NCT03055663|DRUG|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
214857155|NCT02327416|DRUG|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
214857156|NCT02327416|DRUG|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
214857157|NCT02327416|DRUG|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
214857158|NCT01517659|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214665063|NCT02498223|OTHER|experiment protocol|"the subjects will undergo the following experiment protocol:~1. recruitment and medical examination day.~2. physiological evaluation day- the subjects will perform twice\* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.~3. biomechanical valuation day- the subjects will perform twice\* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.~   * once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances."
214857159|NCT05177874|DEVICE|Traumacel FAM Trium|Absorbable Hemostat (oxidized non-regenerated cellulose)
214857160|NCT05177874|DEVICE|Surgicel Fibrillar|Absorbable Hemostat (oxidized regenerated cellulose)
214857161|NCT02712333|BEHAVIORAL|Air Purifiers|The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
214857162|NCT02712333|BEHAVIORAL|Sham Air Purifiers|The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
214857163|NCT02199678|DRUG|Placebo|placebo
214857164|NCT02199678|DRUG|ketamine 25 mg|ketamine
214857165|NCT02199678|DRUG|ketamine 35 mg|ketamine
214857166|NCT02199678|DRUG|ketamine 50 mg|ketamine
214857167|NCT03725865|BIOLOGICAL|Induction of neural stem cells|Brain injection iNSC
214857168|NCT04975074|DRUG|Iron|One of each type of iron was taken orally according to the instructions and followed every two weeks
214857169|NCT03659474|OTHER|compression|compression by Game Ready
214857170|NCT03659474|OTHER|ice pack|cryotherapy for ice pack
214857171|NCT03659474|OTHER|immersion|immersion therapy
214857172|NCT00149188|DRUG|Lanreotide (Autogel formulation)|
214857173|NCT03577483|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).
214857174|NCT06464497|BEHAVIORAL|Whole Foods MyPlate Group|Families will receive 4-weeks of rotating menus that have been designed as a part of our preliminary work and will be adapted to support adherence with the adolescent in mind (e.g., school lunch options, on-the-go snacks). Menus and diet recommendations will align with the current macronutrient nutritional goals outlined by the 2020-2025 DGA for age-sex groups. Participants will be encouraged to eat ad libitum (i.e., as desired until full) without calorie restrictions. MyPlate will be used by participants to implement the diet. During the study, adolescents and adults in the intervention group will receive a MyPlate Plan to support daily food group and macronutrient goals that align with the whole foods diet per caloric needs.
214857175|NCT00004230|DRUG|captopril|
214857176|NCT00004230|DRUG|cyclophosphamide|
214857177|NCT00004230|PROCEDURE|autologous bone marrow transplantation|
214857178|NCT00004230|PROCEDURE|peripheral blood stem cell transplantation|
214857179|NCT00004230|RADIATION|radiation therapy|
214665064|NCT00573131|DRUG|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
214665065|NCT00573131|DRUG|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
214665066|NCT00573131|DRUG|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
214665067|NCT00573131|RADIATION|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
214665068|NCT00573131|PROCEDURE|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
214665069|NCT00400387|DRUG|Fragmin P Forte (dalteparin sodium)|subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
214665070|NCT00400387|DIETARY_SUPPLEMENT|Multivitamin supplement|general pregnancy support by multivitamin supplementation and close monitoring
214665071|NCT02990884|DRUG|ketamine|
214665072|NCT02482220|BEHAVIORAL|Physical activity intervention|
214665073|NCT01251575|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
214665074|NCT01251575|DRUG|Cyclosporine|Given PO or IV
214857180|NCT02707926|DRUG|Anti-HIV Agents|Therapy to treat HIV infection
214857181|NCT03654664|BIOLOGICAL|Inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 250 U (Name of viral strain: TZ84)
214857182|NCT03654664|BIOLOGICAL|Havrix Inj|720 ELISA/0.5 mL Junior (Inactivated hepatitis A virus antigen 160 U (Name of viral strain: HM175 Inj)
214857183|NCT00466895|DRUG|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
214857184|NCT03758573|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT)
214857185|NCT03758573|OTHER|Intensive Physiotherapy (IPT)|Intensive Physiotherapy (IPT)
214857186|NCT05201638|DRUG|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
214857187|NCT05201638|DRUG|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
214857188|NCT04000243|DIAGNOSTIC_TEST|Endoscopic diagnosis of Hp|Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature
214857189|NCT00172419|DRUG|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
214857190|NCT06035484|OTHER|Seat height|Seat height of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
214857191|NCT06035484|OTHER|Seat inclination|Seat inclination of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
214857192|NCT04063982|OTHER|none, only assessment at different time points|assessment at different time points
214857193|NCT00775606|DRUG|Lopinavir 400 mg/ritonavir 100 mg|Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
214665075|NCT01251575|DRUG|Fludarabine Phosphate|Given IV
214665076|NCT01251575|OTHER|Laboratory Biomarker Analysis|Correlative studies
214665077|NCT01251575|DRUG|Mycophenolate Mofetil|Given PO
214665078|NCT01251575|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
214665079|NCT01251575|DRUG|Sirolimus|Given PO
214665080|NCT01251575|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
214665081|NCT00687050|DIETARY_SUPPLEMENT|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
214665082|NCT00687050|DIETARY_SUPPLEMENT|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
214665083|NCT02545374|OTHER|Telemedicine|
214665084|NCT02545374|OTHER|Control|
214857194|NCT00775606|DRUG|Efavirenz|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
214857195|NCT01012141|DIETARY_SUPPLEMENT|phytochemical|
214857196|NCT01012141|DRUG|Docetaxel|
214857197|NCT02488031|BEHAVIORAL|Error-reduction|"During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.~The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed."
214857198|NCT02488031|BEHAVIORAL|International Cooperative Ataxia Rating Scale|The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
214857199|NCT02488031|BEHAVIORAL|Scale for the Assessment and Rating of Ataxia|The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
214857200|NCT02488031|BEHAVIORAL|Beck Depression Inventory, 2nd Ed|This is a 21 question self-report inventory for measuring severity of depression.
214857201|NCT02488031|BEHAVIORAL|Stroop|This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
214857202|NCT02488031|BEHAVIORAL|Purdue Pegboard|This test consists of a series of timed hand coordination and dexterity tasks.
214857203|NCT02488031|BEHAVIORAL|Brief Test of Attention|A cognitive test assessing focus and attention.
214857204|NCT02488031|BEHAVIORAL|6-minute Walk|This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
214857205|NCT02488031|BEHAVIORAL|Hand Grip Dynamometer|This tests measures hand grip strength.
214857206|NCT02488031|BEHAVIORAL|Montreal Cognitive Assessment|This test is used to assess cognitive abilities.
214857207|NCT02488031|BEHAVIORAL|Physical Performance Function|This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
214857208|NCT02488031|BEHAVIORAL|Biomechanical Assessments of Dysmetria|Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
214857209|NCT02488031|BEHAVIORAL|Neurophysiological assessment of brain activity|Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
214857210|NCT02488031|BEHAVIORAL|Biomechanical gait analysis|Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
214857211|NCT00284804|DRUG|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
214857212|NCT00111358|BEHAVIORAL|Lifestyle Modification|
214857213|NCT00111358|OTHER|No lifestyle modification|
214857214|NCT02278718|DRUG|NexoBrid|NexoBrid is an enzymatic debriding agent for Eschar Removal.
214857215|NCT02278718|PROCEDURE|Standard of Care|Surgical or Non-Surgical methods for Eschar Removal
214857216|NCT00380549|DIAGNOSTIC_TEST|Blood ion levels|Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
214857217|NCT01546649|DRUG|TAP-144-SR(6M)|
214857218|NCT01546649|DRUG|TAP-144-SR(3M)|
214857219|NCT04664868|PROCEDURE|Sphinkeeper™|Sphinkeeper™ prostheses are self-expandable solid prostheses, made of inert Hyexpan (polyacrylonitrile) and are inserted into the intersphincteric anal groove.
214857220|NCT04440449|BEHAVIORAL|Lifestyle App|A mobile app used to assist with lifestyle changes
214857221|NCT04440449|BEHAVIORAL|Look AHEAD behavior lifestyle intervention|A modified Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
214857222|NCT04440449|BEHAVIORAL|Abbreviated Look AHEAD behavior lifestyle intervention|An abbreviated Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
214857223|NCT05732259|OTHER|Percussion therapy|Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.
214857224|NCT05732259|OTHER|Manual Myofascial Release technique|Manual myofascial release technique for 90 sec continuous.
214857225|NCT03645499|DRUG|Topical TA-102 A|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
214857226|NCT03645499|DRUG|Topical TA-102 B|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
214857227|NCT03645499|DRUG|Topical TA-102 C|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
214857228|NCT03645499|DRUG|Topical TA-102 D|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
214857229|NCT03645499|DRUG|Topical TA-102 E|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
214857230|NCT04546932|PROCEDURE|Lung-protective mechanical ventilation|Patients were provided with a tidal volume of 7 ml/kg IBW and an intraoperative 10 cmH2O in PEEP. Simultaneously, the alveoli were recruited applying a stepwise increase in PEEP (from 4 to 10 cmH2O for 3 breaths, 10 to 15 cmH2O for 3 breaths, and 15 to 20 cmH2O for 10 breaths) with maximum PIP = 50 cmH2O \[24\]. The recruitment maneuvers were performed right after intubation, 30 minutes after CO2 insufflation, then every hour, and finally before extubation.
214857231|NCT01033578|OTHER|PVIC, TACE|"PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles."
214857232|NCT04884061|OTHER|NBI images and/or videos|A library of NBI images and/or videos will be established from previously recorded bronchoscopies in 30 patients (10 with a SARS-CoV2 infection, 10 with a lower respiratory tract infection not related to SARS-CoV2, and 10 in patients with pulmonary nodule). NBI images and/or videos of the bronchial tree will then be analysed by three experimented interventional pulmonologists blinded to the patient ID. Each investigator will describe the vasculature pattern according to a prespecified grid: Normal mucosal vascularity / increased capillary density / presence of capillary loops / presence of dotted vessels / complex vascular networks of tortuous vessels or abrupt ending vessels / dilated longitudinal vessels. In case of discordance between the investigators, images will be reviewed to obtain a consensus.
214857233|NCT02439632|DRUG|prulifloxacin|
214857234|NCT02439632|DRUG|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
214857235|NCT02439632|DRUG|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
214857236|NCT02439632|DRUG|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
214857237|NCT03212794|BEHAVIORAL|Recovery coach|The recovery coach will support the subjects in the following areas: 1) monitor and manage symptoms, 2) patient education and self-management, and 3) enlisting community and social supports. Encouragement to continue treatment will be a primary focus of the recovery coach. In addition, the coach will conduct weekly sessions on various topics and offer personal insights and facilitate a discussion.
214857238|NCT02316158|OTHER|Web-based support|Comparison between the efficacy between webb-based support and informational support
214857239|NCT05442242|PROCEDURE|Unicompartmental knee arthroplasty|Medial Unicompartmental knee arthroplasty
214857240|NCT05442242|PROCEDURE|High tibial osteotomy|Medial open wedge high tibial osteotomy
214857241|NCT04428099|BEHAVIORAL|Lifestyle change promotion program|The intervention consists of 8 group sessions centered on healthy physical activity, healthy diet, social life, Good Sleep Hygiene, healthy sun exposure, nature contact, how to stop ruminating, review and maintenance tips.
214857242|NCT04428099|BEHAVIORAL|Mindfullness based cognitive program|The intervention consists of 8 group sessions with a mindfulness-based cognitive program
214857243|NCT04428099|BEHAVIORAL|Written Information|Written information about lifestyle change suggestions
214857244|NCT00371306|DRUG|Insulin versus glucovance (glyburide/metformin)|
214857245|NCT00498342|DRUG|N-acetylcysteine|
214857246|NCT01763918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214857247|NCT01763918|DRUG|Placebo|Administered by subcutaneous injection
214857248|NCT04090970|DEVICE|Briagen|Natural complex carbohydrate wound dressing for skin wounds
214857249|NCT01973023|OTHER|Motion analysis|Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
214857250|NCT00426010|DRUG|caffeine/placebo|caffeine or placebo, either overt or covert
214857251|NCT02725775|DIETARY_SUPPLEMENT|100% Florida OJ|
214857252|NCT02725775|DIETARY_SUPPLEMENT|Placebo Equicaloric Orange Drink|
214857253|NCT04904159|PROCEDURE|Thyroidectomy|total thyroidectomy
214857254|NCT04904159|PROCEDURE|Lobectomy|Lobectomy
214857255|NCT00454519|PROCEDURE|cytoreductive surgery|the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
214857256|NCT00454519|PROCEDURE|intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin|Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
214857257|NCT01566019|PROCEDURE|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
214476438|NCT04823689|PROCEDURE|reductions|"Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula."
214857258|NCT04934150|DEVICE|navigated repetitive Transcranial Stimulation|High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.
214857259|NCT05611450|OTHER|disease self-management application|The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.
214857260|NCT05331157|DEVICE|ultrasound|the efficacy of prepuncture ultrasonography to facilitate epidural block in pediatric patients undergoing elective urological operations compared with the conventional anatomical landmark technique
214857261|NCT05212441|DEVICE|Light emitting diode therapy (LED therapy)|The patient's forearm is positioned on table with palm facuing upward during the therapy. For LEDT, the center of the light spot located at approximately 50% of landmark line from the medial epicondyle to the styloid process of the ulna, which is the center belly of ﬂexor digitorum superﬁcialis. The subject's forearm maintained in the rest state without moving during the therapy. LED is performed before exercise.
214857262|NCT05212441|BEHAVIORAL|Patient/family education program (Home program)|Patients and their families will instructed to learn the anti contracture positioning/splinting, scar massage and exercises program, application of the custom garments and inserts, and functional training to perform them on their own at home. Written and illustrative instructions and reciprocal demonstration sessions will be provided to the children and their families to ensure successful acquisition and delivery of rehabilitation skills at home program. The therapist will be reported about compliance with the home program every couple of days
214857263|NCT05212441|PROCEDURE|Positioning & Splinting|"The wrist joint is splinted at 30 hyperextension, the MCP joint in 90 of flexion, the IP joints in extension, and the thumb in abduction. The webs of fingers kept in abduction. The hands are elevated above the level of the heart to minimize post-burn edema.~Splinting: Splints are tailored to help to maintain the functional or anti-contracture position of the injured body parts.The intervals for monitoring vary from once every hour to once every 4-6 hours, depending on types of splints and skin conditions. It is described as 10 hours on and two hours off. When the splint is taken off, active and/or passive ROM should be carried out."
215033590|NCT05368883|OTHER|Exercise- One-Legged|The exercise program consisted of a 5-minute warm-up, followed by 10 minutes of cycling for each leg during the first 2 weeks, increasing to 15 minutes for each leg in the subsequent weeks (with a 5-10 minute rest period between switching legs), and concluded with a 5-minute cool-down period. During the exercise, the inactive leg was kept stationary and in contact with the ground . In the one-legged cycling exercise training, whether patients started with the dominant or non-dominant leg was determined randomly
214857264|NCT05212441|OTHER|Therapeutic Exercises|"1. Passive ROM (PROM).~2. Active ROM (AROM) \& Active-assistive ROM (AAROM): The exercise will focus on extending the wrist to 45 degrees, flexing the MCP joints to 90 degrees and keeping the IP joints in full extension, while maintaining a thumb web space. The exercises will performed in the following sequences; (1) MCP joints flexion and extension with the wrist in neutral or slight extension and the IP joints in neutral position. (2) IP joints flexion to only 30-40 degrees with the wrist stabilized in the neutral or slight extension, while the MCP joints held in full extension, (3) thumb and fingers abduction and adduction, and (4) thumb opposition (tip of the thumb to tip of the small finger). Each exercise was performed for 8-10 repetition, daily, for 6 days/week.~3. Stretching exercises: A low-load (low-intensity), long-duration stretch~4. Strengthening exercises: done in static mode initially and progress to dynamic strengthening using elastic bands."
214857265|NCT01620723|OTHER|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
214857266|NCT01620723|OTHER|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
214857267|NCT03405376|DRUG|Intravitreal aflibercept injection|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
214857268|NCT03645382|DIETARY_SUPPLEMENT|baked barley powder|The baked barley was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The baked barley powder capsule had approximately 900 mg/day, 336 mg of baked barley and 564 mg of nondigestible maltodextrin.
214857269|NCT03645382|DIETARY_SUPPLEMENT|jeju steam onion|The jeju steam onion was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The jeju steam onion capsule had approximately 900 mg/day, 336 mg of jeju steam onion powder and 564 mg of nondigestible maltodextrin.
214857270|NCT05886231|OTHER|music sound therapy|investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
214857271|NCT00215449|DRUG|Formoterol Fumarate|
214857272|NCT03395639|DRUG|Edoxaban|Edoxaban 15 mg or 30 mg tablets for participants 12 to \<18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
214857273|NCT03395639|DRUG|Standard of Care (SOC)|Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
214857274|NCT00186823|DEVICE|Miltenyi Biotec CliniMACS|A stem cell selection device.
214857275|NCT00186823|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
214857276|NCT00186823|DRUG|TBI, systemic chemotherapy and antibodies as follows:|Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
214857277|NCT03221231|DRUG|N-acetylcysteine|1200 mg/day, twice daily, N-acetylcysteine
214857278|NCT03221231|DRUG|Placebo Oral Tablet|twice daily, placebo
214857279|NCT03221231|OTHER|Magnetic Resonance Imaging|
214857280|NCT03221231|OTHER|Neurocognitive measures|
214857281|NCT03221231|OTHER|Neuro-inflammatory measures|
214857282|NCT00942331|BIOLOGICAL|Bevacizumab|Given IV
214857283|NCT00942331|DRUG|Cisplatin|Given IV
214857284|NCT00942331|DRUG|Gemcitabine Hydrochloride|Given IV
214857285|NCT00942331|OTHER|Laboratory Biomarker Analysis|Correlative studies
214857286|NCT00942331|OTHER|Placebo Administration|Given IV
214857287|NCT04142619|BIOLOGICAL|UCARTCS1A|Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
214857288|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 30ug, Intramuscular administration
214857289|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 100ug, Intramuscular administration
214857290|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 300ug, Intramuscular administration
214857291|NCT03699241|BIOLOGICAL|Placebo|Tris-NaCl Diluent
214857292|NCT00962884|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
214857293|NCT00962884|DEVICE|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
214857294|NCT02994251|DRUG|gemcitabine|1000 mg/m\^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
214857295|NCT02994251|DRUG|Cisplatin|25 mg/m\^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
214476439|NCT03655015|PROCEDURE|Lung Tumor Resection|Lung Tumor Resection
214857296|NCT02994251|DRUG|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
214857297|NCT01216098|BEHAVIORAL|Doula support|A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
214857298|NCT05125562|DRUG|ExoFlo|Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
214857299|NCT00443482|DRUG|formoterol|
215033591|NCT05368883|OTHER|Exercise-Two-Legged|The exercise program consisted of a 5-minute warm-up, followed by 20 minutes of cycling during the first 2 weeks, increasing to 30 minutes in the subsequent weeks, and concluded with a 5-minute cool-down period.
214857300|NCT05025280|OTHER|Adolescent/Adult Sensory Profile Questionnaire|"The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking."
214857301|NCT04475250|DEVICE|Tetragraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
214857302|NCT05273931|OTHER|Lifestyle intervention|Documents explaining the strategies to achieve and maintain recommended behaviours as part of a healthier lifestyle
214857303|NCT00597116|DRUG|Vinorelbine|
214857304|NCT00597116|DRUG|Vandetanib|once daily oral dose
214857305|NCT04272203|DRUG|ABBV-184|Intravenous (IV) infusion
214857306|NCT04030494|DIAGNOSTIC_TEST|BP measurement|sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation
214857307|NCT04030494|DIAGNOSTIC_TEST|AF detection|single lead ECG with Withings WPM04 and 12 lead ECG
214857308|NCT04030494|DIAGNOSTIC_TEST|VHD detection|phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
214857309|NCT04762940|DEVICE|Robotic|"The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user."
214857310|NCT04762940|DEVICE|Vibration|Vibration duration of approximately 20 minutes with a high vibration frequency will be conducted prior to robotic treatment. The intensity and timing of this treatment has been based on previous protocols, as previously justified in this project. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible (high frequency vibration of 300 Hz).
214857311|NCT04392557|DRUG|Metformin / alogliptin Oral Product|850 or 1000 mg/ 12.5 mg every 12 hours for 12 months
214857312|NCT04392557|DRUG|Metformin / Pioglitazone Pill|(850 mg/15 mg every 12 hours) for 12 months
214857313|NCT04392557|DRUG|triple therapy|Metformin / Alogliptin/ Pioglitazone
214857314|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30)
214857315|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30-200,201)
214857316|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30)
214857317|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30-200,201)
214857318|NCT01072786|BIOLOGICAL|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
214857319|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
214857320|NCT00183586|BEHAVIORAL|Family therapy (FT)|FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
214857321|NCT00183586|BEHAVIORAL|Individual therapy (IT)|IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
214857322|NCT06273020|DRUG|Cerebrolysin|Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days
214857323|NCT06273020|PROCEDURE|Brain-MRI with contrast after 10-14 days of cerebrolysin|Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
214857324|NCT04699526|OTHER|Universal Prevention Curriculum Training for Schools|School administrators and teachers participated in UPC training and formed prevention leadership action teams
214476440|NCT05512039|DRUG|Botox 50 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
214857325|NCT01163448|RADIATION|High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy|A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
214857326|NCT00253981|DEVICE|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
214857327|NCT04588688|DRUG|Mifepristone|Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
214857328|NCT04597489|PROCEDURE|Fractional flow reserve|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
214857329|NCT04597489|PROCEDURE|Angiography-only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
214857330|NCT05198388|DIAGNOSTIC_TEST|βeta endorphins, interleukin 6 and interleukin 38|"* \- Collection of peripheral blood samples in gel tube.~* \- Creparation of samples in centrifuge to obtain serum.~* \- Measurement of interleukin 6 and interleukin 38 and βeta endorphins using ELISA method."
214857331|NCT01671982|OTHER|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to \<50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
214857332|NCT01744119|DEVICE|Vascutek Anaconda™ Stent Graft System|
214857333|NCT00841360|OTHER|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
214857334|NCT00841360|OTHER|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
214857335|NCT03542084|OTHER|Unsolicited endocrine e-consult|The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
214857336|NCT00757848|DRUG|AZD9668|60 mg, oral tablet, twice daily for 28 days
214857337|NCT00757848|DRUG|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
214857338|NCT02071953|DEVICE|Experimental adhesive w/out phosphoric acid in post. rest.|Experimental adhesive without phosphoric acid in posterior restorations
214857339|NCT02071953|DEVICE|Experimental adhesive with phosphoric acid in post. rest.|Experimental adhesive with phosphoric acid in posterior restorations
214857340|NCT05610592|PROCEDURE|total mesorectal exicision|
214857341|NCT04953416|DEVICE|1565nm non ablative fractional laser|The ResurFX module contains Erbium:Glass Fiber Laser Technology with wavelength of 1565 nm, which is transferred to the ResurFX handpiece via a fiber.
214857342|NCT05920564|OTHER|Upper fibers of trapezius stretching|The Upper fibers of trapezius stretching intervention involves specific stretching exercises designed to target the upper fibers of the trapezius muscle. The stretching exercises will be performed under the guidance of a licensed physical therapist and will involve extending the neck while gently pulling the head downward to stretch the upper fibers of the trapezius muscle. The intervention is designed to improve neck range of motion, reduce pain intensity, and reduce disability in patients with cervical spondylosis. The duration and frequency of the stretching exercises will be standardized across participants, and adherence will be monitored throughout the study period.
214857343|NCT05920564|OTHER|Standard care|The Control Group in this study will receive standard care, including heat treatment and strengthening exercises, but will not receive the specific Upper fibers of trapezius stretching intervention that is being tested in the Treatment Group.
214857344|NCT05841147|DRUG|Tirofiban|Intravenous administration of tirofiban
214857345|NCT05841147|DRUG|normal saline|Intravenous administration of normal saline
214857346|NCT04828798|DEVICE|Deep brain stimulation of the VIM Thalamic nuclei|Deep brain stimulation of the thalamus, in a directional and nondirectional manner
214857347|NCT02025231|RADIATION|External beam radiotherapy|Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
214857348|NCT02422914|BEHAVIORAL|Smoking cessation program TFC and activity tracker|Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)
214857349|NCT02422914|BEHAVIORAL|Smoking cessation program TFC-free and activity tracker|"Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.~The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)."
214857350|NCT02422914|BEHAVIORAL|Smoking cessation program and activity tracker|Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
214857351|NCT05173870|DEVICE|Wearable device|The wearable devices has a biosensor able to daily collect,in a remote way, many biometric measurements such as: blood pressure, blood oxygenation, heart and respiratory rate
214857352|NCT01615042|DRUG|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
214857353|NCT00164749|DRUG|Placebo and ginkgo extract|Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
214857354|NCT00164749|DRUG|Curcumin and ginkgo extract|1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
214857355|NCT00164749|DRUG|Curcumin and ginkgo extract|4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
214857356|NCT00965770|DEVICE|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
214857357|NCT00465049|OTHER|PRIMARY CLOSRE|SUTURE
214857358|NCT00465049|OTHER|SECONDARY CLOSURE|ALLOW TO HEAL SPONTANEOUSLY
214857359|NCT00465049|OTHER|SPONTANEOUS HALING|SECONDARY HEALING AFTER I\&D
214857360|NCT04894071|DRUG|QA102|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
214857361|NCT04894071|DRUG|Placebo|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
214857362|NCT06052488|BEHAVIORAL|Strength After Breast Cancer|Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist
214857363|NCT00560027|OTHER|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
214857364|NCT04508920|OTHER|Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)|Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization
214665085|NCT05065021|DRUG|Niraparib|Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working. PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells. It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.
214665086|NCT05065021|DRUG|Dostarlimab|Dostarlimab is a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth. Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.
214665087|NCT05065021|DRUG|Bevacizumab|Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
214665088|NCT05065021|DRUG|Paclitaxel|Paclitaxel is a chemotherapy drug commonly used for the treatment of various cancers.
214665089|NCT02024464|DEVICE|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
214665090|NCT02024464|DEVICE|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
214665091|NCT02024464|PROCEDURE|Cataract removal and intraocular lens (IOL) implantation|Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects
214857365|NCT01901874|DEVICE|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
214857366|NCT01056094|DRUG|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
214857367|NCT03218891|BEHAVIORAL|Cardiac Rehabilitation|"The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~* 5 minutes warm up~* 30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~* 10 minutes of localized exercises;~* 5 minutes of relaxation."
214857368|NCT04352465|DRUG|Methotrexate|Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
214665092|NCT02551172|DRUG|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
214665093|NCT02551172|DRUG|HGP0816|Rosuvastatin
214665094|NCT02551172|DRUG|Placebo of HCP1105|Soybean Oil
214665095|NCT02551172|DRUG|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
214665096|NCT03818815|COMBINATION_PRODUCT|OP0201|OP0201 20mg per day in two divided doses for 10 days
214665097|NCT03818815|COMBINATION_PRODUCT|Placebo|Placebo 0mg per day in two divided doses for 10 days
214665098|NCT03818815|DRUG|Amoxicillin-clavulanate|Oral Amoxicillin-clavulanate in two divided doses for 10 days
214665099|NCT05288842|BIOLOGICAL|Lumbar puncture|5 mL of CSF
214665100|NCT05288842|BIOLOGICAL|blood sample|6x5 mL of blood sample collected :1 dry tube, 2 EDTA tubes, 1 fluoride tube, and 2 polypropylene tubes
214665101|NCT03618641|DRUG|CMP-001|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
214665102|NCT03618641|BIOLOGICAL|Nivolumab|A fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
214665103|NCT02158533|DRUG|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
214665104|NCT02158533|DRUG|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
214665105|NCT02158533|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
214665106|NCT00920543|DRUG|Placebo|Twice daily dosing
214665107|NCT00920543|DRUG|FP 100mcg|Twice daily dosing
214665108|NCT00920543|DRUG|FP 500mcg|Twice daily dosing
214665109|NCT00920543|DRUG|FP 250mcg|Twice daily dosing
214665110|NCT00920543|DRUG|FSC 100/50mcg|Twice daily dosing
214665111|NCT00920543|DRUG|FSC 250/50mcg|Twice daily dosing
214665112|NCT00920543|DRUG|FSC 500/50mcg|Twice daily dosing
214665113|NCT02801357|DRUG|lofexidine administration in subjects seeking buprenorphine dose reduction|
214665114|NCT03980093|BEHAVIORAL|Education|Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
214665115|NCT03980093|BEHAVIORAL|Values|An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
214665116|NCT00548314|OTHER|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
214665117|NCT00548314|PROCEDURE|Split skin graft|
214665118|NCT00548314|DEVICE|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
214665119|NCT01381523|DRUG|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
214857369|NCT04352465|DRUG|Methotrexate|Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
214857370|NCT04352465|DRUG|Methotrexate|Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
214857371|NCT00177463|DRUG|L-carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
214857372|NCT03718741|RADIATION|Radiotherapy +/- CT|Adiuvant Radiotherapy +/- weekly cisplatin
214857373|NCT01269281|DRUG|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
214857374|NCT04209335|OTHER|isometric core muscle endurance testing|holding previously described isometric positions until fatigue
214857375|NCT03507413|DRUG|Metformin Glucophage 500mg (IR) tablets M90|oral metformin Glucophage treatment 500 mg daily (2-0-2) for 1 year
214857376|NCT03507413|DRUG|Placebo Oral Tablet|Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
214857377|NCT01484184|DRUG|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
214857378|NCT05727475|PROCEDURE|Minimal invasive restorative treatment|Composite veneer facing without drilling or removal of enamel
214665120|NCT01381523|DRUG|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
214665121|NCT03928470|DRUG|EsoDuo Tab. 20/800mg|Nexium Tab. 20mg
214665122|NCT02526849|DRUG|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
214665123|NCT02526849|BEHAVIORAL|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
214665124|NCT00410371|DRUG|Lamotrigine|Lamotrigine
214665125|NCT00410371|DRUG|GI267119|25 mg ODT
214665126|NCT05186532|RADIATION|Dry Heat Application|50 postnatal women they were encouraged to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for ten minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researchers were demonstrated for each woman how to use infrared lamp, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study.
214665127|NCT05186532|OTHER|Moist Heat Application|included 50 postnatal women they were encouraged to sit in a basin (tub) of warm water (45 o C -59 o C) without pressure on the perineum and with the feet flat on the floor for 10 minutes. The researchers were demonstrated for each woman how to do warm sitz bath, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days.
214665128|NCT04369339|OTHER|Colposcopy|
214665129|NCT05325112|DIAGNOSTIC_TEST|FFRCT|FFRCT is a diagnostic test following a CCTA to help diagnose and treat coronary artery disease.
214665130|NCT05951127|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer and regional lymph nodes dissection.
214857379|NCT05727475|PROCEDURE|Fluoride gel application|Fluoride gel application 1.23%
214857380|NCT05526859|OTHER|Kinsiotaping for wrist flexor muscles|The flexor muscles of the wrist area will be targeted.
214857381|NCT05526859|OTHER|Kinesiotaping for wrist extensor muscles|The extensor muscles of the wrist area will be targeted.
214857382|NCT03511170|DRUG|XELIRI|Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle
214857383|NCT03511170|DRUG|XELOX|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
214857384|NCT01430975|DRUG|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
214857385|NCT01430975|DRUG|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
214857386|NCT03338179|BEHAVIORAL|Judgement of learning evaluation|The hardware consists of two lists of 30 pairs of French words, each pair of words being composed of a word index and a target word (names of concrete objects). Among the 60 word pairs, 30 are strongly associated items (or easy items, the other 30 being weakly associated or difficult items.
214857387|NCT04632706|DRUG|Ivermectin|Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study
214857388|NCT04632706|DRUG|Placebo|Matching Placebo to the Active IMP.
214857389|NCT04710537|OTHER|AlloDerm|Enrolled patients will have one of their breasts reconstructed with AlloDerm at the time of their breast reconstruction surgery.
214857390|NCT04710537|OTHER|DermACELL|Enrolled patients will have one of their breasts reconstructed with DermACELL at the time of their breast reconstruction surgery.
214857391|NCT03866915|DIAGNOSTIC_TEST|Aortic pulse wave velocity measurement|Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography
214857392|NCT03866915|DIAGNOSTIC_TEST|6 minutes walking test|This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
214857393|NCT05607251|OTHER|No intervention|There is no intervention as this is an observational study
214857394|NCT03987594|PROCEDURE|Transurethral fulguration of the Hunner lesion|Hunner lesion of the bladder is fulgurated with electronic surgical device under cystoscopic inspection. For the intervention, general or spinal anesthesia is required.
214857395|NCT03987594|PROCEDURE|Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion|Prior to Hunner lesion fulguration, bladder hydrodistension is performed for 8 minutes at pressure of 80cmH2O. And then transurethral fulguration is performed on the Hunner lesion.
214857396|NCT04316130|DEVICE|Uincare Homeplus|Interactive digital healthcare system
214857397|NCT04316130|OTHER|Brochure|Brochure
214857398|NCT00003014|DRUG|carboplatin|
214857399|NCT00003014|RADIATION|radiation therapy|
214857400|NCT00506818|OTHER|Multifactorial vascular-risk-factor-intervention|
214857401|NCT02234206|DRUG|Chandrakanthi Choornam (CKC)|"12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs \& cosmetic act 1940"
214857402|NCT03661606|OTHER|Simulated Altitude Chamber|"Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.~Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study."
214857403|NCT03347513|DRUG|triple attack therapy|eradication of H-pylori using triple attack therapy.
214857404|NCT03347513|DRUG|Ferrous(II)-glycine-sulphate complex 567.7 mg capsules|Iron therapy will be given to both groups twice daily for one month.
214857405|NCT01976013|DEVICE|Coaguchek|The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
214857406|NCT02247219|BEHAVIORAL|Counselling and education individually and in groups|The counselling method is based om Motivational Interviewing
214857407|NCT00117403|DRUG|Vitamin E, Vitamin C, and Alpha-lipoic Acid|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
214857408|NCT00117403|DRUG|Coenzyme Q|400 mg, compounded as a wafer, two wafers three times per day with meals
214857409|NCT00117403|DRUG|Placebo capsules|one placebo capsule three times per day with meals
214857410|NCT00117403|DRUG|Placebo wafers|two placebo wafers three times per day with meals
214857411|NCT01405287|DEVICE|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
214857412|NCT03290287|DRUG|Aclidinium bromide|Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
214857413|NCT03290287|DRUG|Other COPD medication|"Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol"
214857414|NCT03832738|DRUG|JTE-451 Tablets|Active drug tablets containing JTE-451
214857415|NCT03832738|DRUG|Placebo Tablets|Placebo tablets matching in appearance to the active drug tablets
214857416|NCT03580291|OTHER|Mesenchymal stem cells|The group receive pulse infusion of MSCs once of 2 x 10\^6/kg body weight
214857417|NCT03580291|DRUG|Mycophenolate Mofetil|This group receive oral MMF of 2.0 g / d.
214857418|NCT03580291|OTHER|Placebo of Mesenchymal stem cells|The group receive placebo of Mesenchymal stem cells.
214857419|NCT03580291|DRUG|Placebo of Mycophenolate Mofetil|The group receive placebo of oral mycophenolate mofetil.
214857420|NCT03763760|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
214857421|NCT03977701|BEHAVIORAL|Phonological treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.
214857422|NCT03977701|BEHAVIORAL|Morpheme treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of targeted morphemes following the methodology of Plante and colleagues. A minimum of 50 productions will be targeted per 1-hour session.
214857423|NCT05240131|DRUG|GB1211|GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
214857424|NCT05240131|DRUG|Placebo|Placebo is administered orally twice a day.
214857425|NCT05240131|DRUG|Atezolizumab|Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
214857426|NCT06374966|DRUG|Zonisamide|This is a real-world study，so we prospectively enrolled patients with focal epilepsy suitable for taking zonisamide as an add-on medication
214857427|NCT00278187|BIOLOGICAL|volociximab|
214857428|NCT00278187|DRUG|erlotinib hydrochloride|
214857429|NCT03096275|DRUG|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
214857430|NCT03096275|DRUG|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
214857431|NCT03096275|DRUG|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
214857432|NCT03096275|DRUG|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
214857433|NCT03096275|DRUG|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
214857434|NCT01431443|OTHER|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
214857435|NCT01431443|OTHER|Placebo Chocolate|Placebo intervention
214857436|NCT00702208|DEVICE|Delphi Screener|Self-sampling device for cervical vaginal lavage
214857437|NCT03823235|OTHER|Human embryo culture|humidifed or dry incubator
214857438|NCT04010019|BEHAVIORAL|Enhanced Facebook Condition|The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
214857439|NCT04010019|BEHAVIORAL|Control Facebook Condition|The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
214857440|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
214857441|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
214857442|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
214857443|NCT05692284|OTHER|routine care group|Firstly, informed consent was obtained from the patients in the control group, a pre-test was applied with the existing data collection methods, and routine nursing care continued. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
214857444|NCT05692284|OTHER|Care in accordance with Orem's theory group|Firstly, informed consent was obtained from the Intervention group, for which the pre-test was applied, and then care was given during their stay in the hospital in accordance with Orem's theory. This care was performed when the patient came to each chemotherapy cycle. After discharge, patient follow-up and care continued with the mobile application designed with Orem's theory, which will ensure the continuity of this care given in the clinic. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
214857445|NCT01566864|BEHAVIORAL|Improve clinic based measurement of blood pressure|This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.
214857446|NCT01566864|BEHAVIORAL|Provider education system to promote patient-centered care|The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.
214857447|NCT01566864|BEHAVIORAL|Introduce care management system in clinics|The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
214857448|NCT01993602|PROCEDURE|Breathing exercises|"The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.~The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.~The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.~Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise."
214857449|NCT02677649|OTHER|cranberry|the effect of cranberry on the gut microbiota
214857450|NCT02677649|OTHER|placebo|the effect of placebo on the gut microbiota
214857451|NCT00839059|DRUG|lenalidomide|"Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days"
214857452|NCT02025751|DRUG|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
214857453|NCT02025751|DRUG|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
214857454|NCT01709734|DRUG|galeterone|
214857455|NCT02546843|DRUG|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
214857456|NCT02546843|DRUG|Cisatracurium|cisatracurium 0.15mg/kg intravenously
214857457|NCT02546843|DRUG|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
214857458|NCT02546843|DRUG|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
214857459|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
214857460|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
214857461|NCT02996045|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.~This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored \>4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication."
214857462|NCT00817076|DRUG|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
214857463|NCT01978210|DEVICE|Wireless Moisture Pager (WMP)|The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
214857464|NCT06868420|BEHAVIORAL|Play therapy with transport cart|he intervention consisted of allowing pediatric patients to engage in five minutes of play with a toy transport cart, after which they were transported to the operating room in the same cart.
214857465|NCT06371144|DRUG|Paracetamol|Analgestic
214857466|NCT03021694|DIETARY_SUPPLEMENT|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
214857467|NCT04918160|OTHER|Exposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)|The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).
214857468|NCT00165230|DRUG|Thalidomide|
214857469|NCT00165230|DRUG|Temodar|
214857470|NCT00555802|OTHER|exercise|exercise
214857471|NCT06316713|BEHAVIORAL|One MORE (Spanish Adaptation)|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into two, 1-hour segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Participants will also be guided through a mindful pain management practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The second segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, as well as learning to focus on increasing the positive emotions that can attenuate pain with mindful savoring.
214857472|NCT03864042|DRUG|losartan|taken orally
214857473|NCT03864042|DRUG|dextromethorphan|taken orally
214857474|NCT03864042|DRUG|caffeine|taken orally
214857475|NCT03864042|DRUG|omeprazole|taken orally
214857476|NCT03864042|DRUG|midazolam|taken orally
214857477|NCT03864042|DRUG|rosuvastatin|taken orally
214857478|NCT03864042|DRUG|bupropion immediate release (IR)|taken orally
214857479|NCT03864042|DRUG|encorafenib|taken orally
214857480|NCT03864042|DRUG|binimetinib|taken orally
214857481|NCT03864042|DRUG|modafinil|taken orally
214857482|NCT02139371|OTHER|Injection of 64Cu-DOTA-AE105|One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
214857483|NCT00810173|BEHAVIORAL|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
214857484|NCT02220725|BIOLOGICAL|Andexanet|
214857485|NCT02220725|OTHER|Placebo|
214857486|NCT03370822|DEVICE|MONICA AN24 device|Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)
214857487|NCT00132834|DEVICE|R-Tube or EcoScreen|Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
214857488|NCT04812639|OTHER|Buccal infiltration technique|a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth
214857489|NCT04812639|OTHER|Inferior alveolar nerve block technique|a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
214857490|NCT04847596|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
214857491|NCT04847596|OTHER|Covid-19 vaccine|Prospective observational cohort study. There is no treatment allocation. Participants will obtain the COVID-19 FDA approved Emergency Use mRNA vaccine through their HCP (private insurance) or appropriate federal, state or local program.
214857492|NCT03801941|DEVICE|wearing ATLAS device during evaluation at 4th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
214857493|NCT03801941|OTHER|wearing ATLAS device during evaluation at 5th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
214857494|NCT00655278|DRUG|T2000|T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
214857495|NCT01987726|OTHER|cytology specimen collection procedure|Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H\&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
214857496|NCT01987726|OTHER|laboratory biomarker analysis|2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
214857497|NCT03466359|BEHAVIORAL|DEF-EI : Energy restriction induced energy deficit|DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.
214476441|NCT05512039|DRUG|Botox 100 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
214857498|NCT03466359|BEHAVIORAL|DEF-EX : Exercise induced energy deficit|DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
214857499|NCT04834739|OTHER|6 minute walk test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. 30 m long corridor is used for this test .
214857500|NCT04834739|OTHER|1 minute Sit to Stand Test|The 1-minute STS test is performed with a chair of standard height of 46 cm without arm rests. The patient should be ensured to be seated upright on the chair positioned against a wall. The patient sat with the knees and hips flexed to 90°, feet placed flat on the floor hip-width apart, and the hands placed on the hips.The number of repetitions is measured.
214857501|NCT04834739|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders
214857502|NCT04834739|OTHER|Medical Research Council (MRC) dyspnea scale|"The MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness: grade 1, I only get breathless with strenuous exercise; grade 2, I get short of breath when hurrying on the level or up a slight hill; grade 3, I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level; grade 4, I stop for breath after walking 100 yards or after a few minutes on the level; grade 5,  I am too breathless to leave the house."
214665131|NCT04059809|DEVICE|Photobiomodulation|Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 \~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
214476442|NCT06207708|OTHER|questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement|the patient is administered with questionnaires focused on diet, fatigue, nutrition screening and on body mass index at the beginning and at the end pf particle therapy radiation treatment
214857503|NCT04834739|OTHER|SF-12|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
214857504|NCT04834739|OTHER|Beck Depression Inventory|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
214857505|NCT04834739|OTHER|Beck Anxiety Inventory|Beck Anxiety Scale is a 21-item, internationally valid, self-report rating inventory that measures the anxiety level.
214857506|NCT04834739|OTHER|5 times sit to stand test|The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back (43-45 cm, 17-18 inches high). Then the instruction is given by asking the test taker to sit on the chair by resting their back. Also, the test taker is instructed to fold their arms across their chest. Then the test taker should be instructed to do sit-to-stand five times, as quickly as possible, at the count of go and without their back or leg resting on the chair between the interval of repetition.
214857507|NCT04834739|OTHER|6 point Likert Scale|"Job performance was assessed by asking How do you evaluate your job performance? on 6-point Likert scale.A 6 point likert scale forces choice and gives better data.The 6 point Likert scale offers options for ''Excellent, very good, good, fair, poor and very poor''. 6 point scale anges from 1(very poor) to 5 (excellent)."
214857508|NCT06698445|OTHER|Short film video|The short film training video will be prepared by researchers based on literature and appropriate for the level of children aged 7-12. The content will include topics such as preparation for KİAB, KİAB environment and the process after KİAB. Since the short film will be shot in a realistic manner, the scenario will include a doctor, a nurse, a child patient and a parent. The short film will be shot in the clinic where the data will be collected, at the appropriate time for the clinic. After the short film is shot, the editing process will be done and the final version will be given.
214857509|NCT06293443|OTHER|Lower extremity unilateral amputee|To evaluate the functionality of lower extremity unilateral amputees, to ensure that the results of the Medicare Functional K Classification System, which provides subjective data for the evaluator, become an objective evaluation method and to determine the functional levels of unilateral amputees; To create an objective data set by applying one-leg standing test, Ten meter walking test, L test, figure-8 walking test, joint range of motion, amputee mobility estimator scale, Houghton scale and joint position sense evaluation tests.
214857510|NCT00236249|DRUG|Lidocaine|
214857511|NCT03487848|DRUG|Daclatasvir|Specified dose on specified days for specified duration
214857512|NCT03487848|DRUG|Sofosbuvir|Specified dose on specified days for specified duration
214857513|NCT00731549|DRUG|Aripiprazole IM Depot|300mg or 400mg
214857514|NCT06232239|DRUG|Empagliflozin-Test product|Empagliflozin 10 mg tablets Test product Manufactured by: Thai Meiji Pharmaceuticals Co., Ltd., Thailand
214857515|NCT06232239|DRUG|Empagliflozin-Reference product|Empagliflozin 10 mg tablets Reference product Manufactured by: Boehringer Ingelheim Pharma Gmbh \& Co. Kg, Germany
214857516|NCT05098002|BEHAVIORAL|Mindfulness program|6 week class designed to improve psychological well-being
214857517|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
214857518|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
214857519|NCT06020001|OTHER|Placebo|Twice a day
214857520|NCT01233843|DRUG|carboplatin|70 mg per m2 and per day for four days. day 1; day 22; day 43
214857521|NCT01233843|DRUG|5 fluorouracil|600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
214857522|NCT01233843|RADIATION|radiation therapy|total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
214857523|NCT04072549|BEHAVIORAL|Free Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
214857524|NCT05114759|DRUG|SHR-A2009|"In dose Escalation:~SHR-A2009 will be administered intravenously. Six dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy."
214857525|NCT05563818|OTHER|WinterLight Mobile Phone Speech Analysis|N/A- observational study
214857526|NCT01946074|DRUG|paclitaxel|Paclitaxel will be administered by intravenous infusion.
214857527|NCT01946074|DRUG|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
214857528|NCT01946074|DRUG|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels.
214857529|NCT01946074|DRUG|ABBV-181|ABBV-181 will be administered by intravenous infusion.
214857530|NCT01404117|DRUG|Laquinimod 0.6|Laquinimod 0.6 capsule
214857531|NCT01404117|DRUG|Laquinimod 1.2|Placebo
214857532|NCT01404117|OTHER|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
214857533|NCT01001260|DRUG|No ASA|Alternative antiplatelet therapy instead of aspirin
214857534|NCT01001260|DRUG|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
214857535|NCT01001260|DRUG|325 mg ASA|high dose of aspirin prior to PTCA
214857536|NCT00522444|DRUG|Nebulized Magnesium Sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
214857537|NCT00522444|OTHER|Nebulized normal saline|standard of care
214857538|NCT02987803|OTHER|Data|The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
214857539|NCT06071819|DIAGNOSTIC_TEST|Structured Clinical Interview for DSM-5|A structured interview will be administered to confirm the diagnosis reported in clinical charts
214857540|NCT02333487|DRUG|Lu AF35700|5 mg tablets for oral administration
214476443|NCT06207708|DIAGNOSTIC_TEST|blood biomarkers|as per clinical routine, hemoglobin, lymphocytes, albumin and NLR will be collected
214857541|NCT03544151|DEVICE|Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)|Swan-Ganz CCOmbo V insertion
214857542|NCT02879110|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
214857543|NCT02879110|OTHER|Placebo|Placebo tablet is composed of starch.
214857544|NCT04013113|DRUG|Haemoperfusion|"Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required."
214857545|NCT04013113|DRUG|Standard Medical Treatment|Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
214857546|NCT04013113|OTHER|Plasma Exchange|"Fresh frozen plasma will be used as replacement fluid.TPE treatment shall be given on first day and continued on an a dailybasis/alternate day till the desired clinical or biochemical response is achieved.~The procedures of TPE and hemoperfusion will be stopped if any major side effects occur (described below), the patient expires or the patient is transplanted within 30 days (whichever is earlier)."
214476444|NCT00165256|OTHER|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
214476445|NCT05652010|DEVICE|New 2-piece Coupling|Flat or concave baseplate. SenSura Mio Click maxi bag (open, wide outlet) with new 50mm Ø coupling.
214857547|NCT00794482|DRUG|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
214857548|NCT00906113|DRUG|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
214857549|NCT00906113|DRUG|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
214857550|NCT04212533|DIETARY_SUPPLEMENT|Vitamin D|comparison between pre- and postoperative calcium and vitamin d level after vit d and calcium supplementation
214857551|NCT04212533|DIETARY_SUPPLEMENT|rice starch tablets|rice starch tablets as placebo
214857552|NCT02677259|DRUG|17-beta estradiol|
214857553|NCT02677259|DRUG|Micronized progesterone|
214857554|NCT03405558|OTHER|No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine
214857555|NCT06331520|DRUG|Netupitant / Palonosetron Oral Capsule [Akynzeo]|Akynzeo is the fixed-combination antiemetic comprising netupitant (neurokinin-1 receptor antagonist \[NK1 RA\]) and palonosetron (5-hydroxytryptamine-3 receptor antagonist \[5-HT3 RA\]).
214857556|NCT06331520|DRUG|Olanzapine|Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders. It belongs to the 2nd generation antipsychotics, its mechanism of action ranks among multireceptor antagonists (MARTA); it affects the dopamine, serotonin, adrenaline, histamine, and muscarinic systems.
214857557|NCT06331520|DRUG|Dexamethasone Oral|synthetic glucocorticoids
214857558|NCT05064774|OTHER|myofascial release technique|myofascial release group took myofascial release (MFR) therapy sessions twice a week for 4 weeks between 4 and 7 weeks. MFR was applied to upper trapezius, SCM, pectoralis major-minor and sternocostal fascia. muscle was replaced elongated position and pressure was applied for 60-120 second.
214857559|NCT05064774|OTHER|physiotherapy|patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.
214857560|NCT03997071|OTHER|functional outcome measurement|functional outcome measured in terms of joint position sense analysis, isokinetic muscle strength measurements, gait analysis, drop jump and single leg hop tests, and balance tests
214857561|NCT02758249|DRUG|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
214857562|NCT02758249|DRUG|propofol|patients are anesthetized by using propofol infusion
214857563|NCT01297322|OTHER|Manual compression|Standard of Care
214857564|NCT01297322|DEVICE|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
214857565|NCT03898921|RADIATION|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
214857566|NCT03898921|PROCEDURE|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 3 times.
214857567|NCT04219735|DRUG|Minocycline|Minocycline 100mg BID
214857568|NCT04219735|DRUG|Placebos|Placebo
214857569|NCT04736563|DEVICE|Joint and muscle gel Puressentiel|To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.
214857570|NCT03964636|DIAGNOSTIC_TEST|OCT-A (optical coherence tomography)|Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
214857571|NCT03516084|DRUG|ZL-2306(nirapairb)|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
214857572|NCT03516084|DRUG|Placebo|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
214857573|NCT05333484|OTHER|Programed Pilates|The 60 min Pilates sessions were held twice a week for 12 weeks. Each session included three stages: 10 min of warm-up exercises, 40 min of floor-based Pilates training, and 10 min of cool-down exercises. Each stage was adjusted according to the participants' physical capacity. Only participants with an attendance rate of \> 80% were included in the final sample. The content of the exercise program was determined according to their muscular strength, flexibility, and fitness levels. The training course was divided into three levels: elementary, intermediate, and advanced. Each motion was performed in conjunction with a specific breathing pattern for effective muscle activations of each exercise.
214857574|NCT01111019|DRUG|Recombinant human growth hormone (r-hGH)|Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
214857575|NCT01524302|DRUG|Ceftaroline|600 mg Q12h
214857576|NCT01524302|DRUG|Levofloxacin|750 mg QD
214857577|NCT01583218|DRUG|Betrixaban|"Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days"
214857578|NCT01583218|DRUG|Enoxaparin|"Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days"
214857579|NCT00986453|DEVICE|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
214857580|NCT00986453|PROCEDURE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
214857581|NCT05514236|OTHER|Virtual Reality Therapy|"Participants will be given the virtual reality device (a headset) with immersive video content for use during the hysteroscopy. Designated moving objects with sound will be broadcasted on the screen to the participant in this group.~Participant can adjust the volume of the sound according to her comfort."
214857582|NCT05514236|OTHER|Music Therapy|"Participants will be given a headphone playing either classical light music or 'POP' songs according to their option during the hysteroscopy.~Participant can adjust the volume of the music according to her comfort."
214857583|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for D-Dimer|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.
214857584|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for Fibrinogen|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.
214857585|NCT04508036|DIAGNOSTIC_TEST|Echocardiographic Examination|At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
214857586|NCT03168321|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
214857587|NCT03168321|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
214857588|NCT03521648|PROCEDURE|PAE|Prostatic artery embolization
214857589|NCT03521648|PROCEDURE|TURP|Transurethral resection of the prostate
214857590|NCT03521648|PROCEDURE|Other|Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
214857591|NCT04690036|DRUG|toripalimab injection|when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.
214857592|NCT05045352|DEVICE|echogenic needles for intravenous access|echogenic needles for intravenous access (subclavian vein) ultrasound guided procedure
214857593|NCT03983252|DRUG|[F-18]PBR06|PET radiopharmaceutical
214857594|NCT00375570|DRUG|ME-609|Topical treatment 5 times daily for 5 days
214857595|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
214857596|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
214857597|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
214857598|NCT05377593|DEVICE|eminoplasty with patient specific Zirconium dioxide onlay implant|Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants
214857599|NCT00712985|DRUG|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
214476446|NCT05652010|DEVICE|SenSura Mio Click|Flat or concave baseplate. SenSura Mio Click maxi bag (open, wide outlet) with 50mm Ø coupling.
214476447|NCT04513951|DRUG|5Fluorouracil|phase II
214476448|NCT04513951|DRUG|L-leucovorin|phase II
214857600|NCT03829137|DEVICE|Verum laser acupuncture|The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.
214857601|NCT03829137|DEVICE|Sham laser acupuncture|The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
214857602|NCT01856361|DRUG|Ramipril|Angiotensin Converting Enzyme Inhibitor
214857603|NCT01856361|DRUG|Placebo|Placebo pill that will match the treatment pill
214857604|NCT05080647|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
214857605|NCT01299805|DRUG|Vortioxetine|Encapsulated tablet
214857606|NCT01299805|DRUG|Placebo|Vortioxetine placebo-matching capsules.
214857607|NCT01753947|OTHER|Deliberate Practice|
214857608|NCT03811626|PROCEDURE|cognitive-behavioral rehabilitation|Combination of clinical examination and neuropsychological and psychological tests
214857609|NCT00266357|DRUG|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
214857610|NCT00266357|DRUG|Placebo / Duration of Treatment: 2 days for screening period|
214857611|NCT04461119|DRUG|Evenamide|oral capsules for 4 weeks of treatment
214857612|NCT04461119|DRUG|Placebo|oral capsules for 4 weeks of treatment
214857613|NCT00692718|DRUG|Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization
214290476|NCT05331274|OTHER|exercise group|"1 stage~* In a sitting position, pull the leg up and extend the knee forward~* Standing, bending forward and bending the knee~* Supine, tucked legs~* Maintaining spinal smoothness in crawling~* Prone heel pull to buttock~Stage 2~* Prone on forearms-hands~* Extending the supine hands to the knees~* Rounding and hollowing the waist in crawling~* Progressive sit-stand~* Standing up from sitting and putting on and taking off socks~* Reaching up while standing and maintaining the straightness of the spine~* Squatting~* Climbing and descending stairs~Stage 3~* Maintaining standing, arms forward~* Slipping hands on the bed while standing~* Initiating the standing throw and maintaining the position until the final interval~* Putting on and taking off socks while standing~* Taking weight towards the ground from a certain height~* Picking up different weights from the ground~* Push-pull items~* Crossing obstacles of certain height~* Walking a certain distance"
214857614|NCT02405949|GENETIC|Genetic test|Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
214857615|NCT04341649|OTHER|Manual Head Massage|Duration 10 minutes.
214476449|NCT04513951|DRUG|Irinotecan|phase II
214476450|NCT04513951|DRUG|Oxaliplatin|phase II
214476451|NCT04513951|DRUG|Cetuximab|phase II
214857616|NCT04341649|DEVICE|BREO Helmet Massager|Duration 10 minutes.
214857617|NCT04341649|DEVICE|Low Laser Therapy (LLT)|Duration 7 minutes.
214857618|NCT04341649|DEVICE|Sham LLT|Duration 7 minutes.
214857619|NCT04341649|DEVICE|TENS ear stimulation|Duration 7 minutes.
214857620|NCT04341649|BEHAVIORAL|Deep and Slow breathing|A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.
214857621|NCT04341649|BEHAVIORAL|Relaxed Reading time|Duration 10 minutes.
214857622|NCT00679536|DRUG|Busulfan|Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
214857623|NCT00679536|DRUG|Fludarabine|Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m\^2/day.
214857624|NCT00679536|DRUG|Thymoglobulin|The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
214857625|NCT00679536|RADIATION|Total Body Irradiation|On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
214857626|NCT00569790|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
214857627|NCT03334721|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
214857628|NCT03334721|DRUG|Placebo Oral Capsule|5 day trial of matched placebo
214857629|NCT03771937|OTHER|Education and telephone follow-up intervention|A telephone follow up and a pre-discharge education
214857630|NCT06015477|DRUG|Ticagrelor monotherapy|starting dose of ticagrelor was a single loading dose of 180mg (90mg x 2 tablets) and thereafter 1 tablet (90mg) each time, twice daily.
214476452|NCT04513951|DRUG|Avelumab|phase II
214857631|NCT06015477|DRUG|Dual Antiplatelet Therapy|Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.
214857632|NCT03716245|PROCEDURE|supraclavicular lymph node dissection|people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
214857633|NCT03716245|RADIATION|supraclavicular area radiotherapy|people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
214857634|NCT00463320|DRUG|Pazopanib eye drops and Allergen Refresh Plus eye drops|
214857635|NCT01624441|DRUG|Dinaciclib|Given IV
214857636|NCT01624441|DRUG|Epirubicin Hydrochloride|Given IV
214857637|NCT01624441|OTHER|Laboratory Biomarker Analysis|Correlative studies
214857638|NCT00878514|DRUG|Alprazolam|Alprazolam 1 mg tablet
214857639|NCT00878514|DRUG|Xanax|Xanax 1 mg tablet
214857640|NCT03898713|DIAGNOSTIC_TEST|Intelligence quotient|intelligence quotient (IQ) is a total score derived from several standardized tests designed to assess human intelligence
214857641|NCT00063414|DRUG|Alicaforsen|
214857642|NCT05935566|OTHER|health questionnaire|Telephone interview with patient to verify medical history, including tonsillectomy and adenoidectomy.
214857643|NCT01378455|OTHER|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
214857644|NCT01378455|OTHER|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
214857645|NCT03145831|DRUG|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
214857646|NCT04232813|DRUG|Estradiol 10 MCG Vaginal Tablet [VAGIFEM]|To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.
214857647|NCT04232813|DRUG|Promestriene Vaginal|To insert the cream the patient must use the applicator provided in the way explained in the prospectus.
214857648|NCT02702713|DIETARY_SUPPLEMENT|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
214857649|NCT02702713|DIETARY_SUPPLEMENT|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
214857650|NCT02702713|DIETARY_SUPPLEMENT|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
214665132|NCT04777955|OTHER|core stabilization exercises|"Core is at the center of almost all kinetic chains in the body. Core force, balance, and motion control maximize all kinetic chains of upper and lower limb function. A stable and strong core can contribute to more efficient use of the lower extremities. Core stability is defined as the ability of the lumbo-pelvic hip complex to prevent bending of the vertebral column and return to balance after perturbation.~Neuromuscular electrical stimulation (NMES) is a technique in which muscle contraction is electrically stimulated in the area where the surface electrodes are connected. It improves secondary muscle atrophy and weakness in immobilization by preventing a decrease in muscle protein synthesis.~Kinesiological banding (CT) is a treatment method used in the treatment of various musculoskeletal and neuromuscular deficits. The mechanism of action of CT is to facilitate muscle activation, increase blood and lymph circulation and reduce pain due to neurological suppression."
214665133|NCT06485544|DRUG|Adebrelimab + Etoposide + Platinum-based Therapy|"Intervention Description for Treatment Group:~This intervention includes Adebrelimab in combination with Etoposide and Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Adebrelimab is administered intravenously at a fixed dose of 1200 mg over 30 minutes on Day 1 of each 3-week cycle, followed by Etoposide at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
214665134|NCT06485544|DRUG|Etoposide + Platinum-based Therapy|"Intervention Description for Control Group:~This intervention includes Etoposide in combination with Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Etoposide is administered at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each 3-week cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
214665135|NCT02037919|OTHER|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
214665136|NCT02037919|OTHER|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
214665137|NCT00430807|DRUG|hydroxychloroquine/placebo|
214665138|NCT02079727|DRUG|chondroitin sulfate|
214665139|NCT02079727|DRUG|celecoxib|
214665140|NCT02079727|DRUG|placebo|
214665141|NCT06332443|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected.
214665142|NCT06332443|PROCEDURE|Sedation epidural anesthesia|Sedation-EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.
214857651|NCT02702713|DIETARY_SUPPLEMENT|Bakery placebo|Bakery placebo: Biscuits without enrichment
214857652|NCT02702713|DIETARY_SUPPLEMENT|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
214857653|NCT02702713|DIETARY_SUPPLEMENT|Egg placebo|Egg placebo: Frozen pancakes without enrichment
214857654|NCT03074747|DIAGNOSTIC_TEST|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
214857655|NCT01696136|DEVICE|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
214857656|NCT06181747|DEVICE|a serious mobile device-based game prototype (Save the Muse Home)|The cognitive impairment corresponding to the symptoms, which we are interested in, focuses on executive inhibition, motor inhibition, sustained attention, selective attention, working memory, and planning ability. The training content will be presented in different scenarios as effective training components. The story line of the warrior breakthrough runs through the whole game, each level is adapted according to the functional damage areas of different patients, and each level involves reward and punishment mechanisms to keep the interest of the players, the difficulty gradient of each level is kept moderate, and the game includes design elements such as space, time, object attributes, actions, rules, skills, and probabilities, etc., which ultimately completes Save the Muse Home, a serious game for the treatment of ADHD.
214857657|NCT06898437|DRUG|177Lu-LNC1004 Injection|Intravenous administration: a single dose of 80 mCi per Cycle
214857658|NCT01513564|DRUG|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
214857659|NCT01513564|DRUG|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
214857660|NCT06616298|OTHER|Assessing and Listening to Individual Goals and Needs (ALIGN)|Assessing and Listening to Individual Goals and Needs (ALIGN). ALIGN utilizes the skills of palliative care social workers (PCSWs) trained in family and systems-level theory to address changing preferences for care, family distress, and to facilitate communication across care transitions to improve care aligned with preferences. A patient navigator supports the patient/caregiver and social worker dynamic by helping patients access care and resources. The intervention is implemented virtually in community SNFs and follows patients for 45 days after SNF discharge to reflect real-world patient flow.
214857661|NCT06927726|DRUG|4% Articaine HCL With 1:100,000 Epinephrine|"Preoperative clinically and radiographic examination will be performed for each patient. Local maxillary infiltration anesthesia adjacent to the tooth with extraction will be the anesthetic method used throughout by a vestibular (1.5 ml) and a palatal injection (0.3 ml). The following agents will be applied for anesthetization: Septanest 4% Articaine HCL With 1:100,000 Epinephrine. The injections and the extractions will be performed by certified dentists of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Tanta University.~Dental extraction will be performed after full anesthesia, tested with a probe on the buccal mucosa, palatal mucosa, and the tooth itself each minute after injection, and after subjective symptoms of numbness by the patient."
214857662|NCT06927726|DRUG|3% plain mepivacaine HCL|"Preoperative clinically and radiographic examination will be performed for each patient. Local maxillary infiltration anesthesia adjacent to the tooth with extraction will be the anesthetic method used throughout by a vestibular (1.5 ml) and a palatal injection (0.3 ml). The following agents will be applied for anesthetization: Scandonest 3% plain mepivacaine HCL (Septodont, Manufactured By Novocol Pharmaceuticals of Canada). The injections and the extractions will be performed by certified dentists of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Tanta University.~Dental extraction will be performed after full anesthesia, tested with a probe on the buccal mucosa, palatal mucosa, and the tooth itself each minute after injection, and after subjective symptoms of numbness by the patient."
214857663|NCT06927687|BIOLOGICAL|ZG005 for Injection|Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.
214857664|NCT06928207|COMBINATION_PRODUCT|Provide the diagnostic (RDT) for free to clients suspected of having malaria and provide a subsidized ACT to only those testing positive|To promote the use of the recommended first line drug, we implement a conditional subsidy. The retail provider is given the malaria diagnostic for free and is instructed to test clients suspected of having malaria. Only if the test is positive, the provider is instructed to provide the ACT at a low cost.
214857665|NCT06928909|OTHER|Intensity-adapted pediatric acute myeloid treatment guidelines|This is an observational study evaluating the current standard of care AML therapy in Malawi. The therapy guideline used is an adaptation of the International Society of Paediatric Oncology (SIOP) guidelines for pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care in Malawi for all patients with AML. Receipt of this therapy guideline is independent of participation in research.
214857666|NCT06928779|DRUG|Dazucorilant|Dazucorilant 300 mg (4 X 75 mg) soft gelatin capsules for oral administration
214857667|NCT06926933|DRUG|Eligard® 45 mg|45 mg of leuprolide acetate
214857668|NCT01427166|OTHER|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
214857669|NCT01081314|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
214857670|NCT01081314|BEHAVIORAL|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
214857671|NCT06710457|OTHER|ESP|Patients will receive an erector spinae plane (ESP) block in addition to standard medical treatment to prevent PONV and postoperative pain.
214857672|NCT06710457|OTHER|No ESP|Patients will receive standard medical treatment to prevent PONV and postoperative pain.
214857673|NCT03077529|DIETARY_SUPPLEMENT|Galacto-oligosacchride|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
214857674|NCT03077529|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
214857675|NCT06927518|OTHER|Receptive language intervention by using the total communication|Receptive language intervention using Total Communication (TC) for children with autism can be highly effective. Total Communication involves using a combination of communication methods to support language comprehension and expression. It recognizes that individuals with autism often benefit from multi-modal communication rather than relying solely on spoken language.
214857676|NCT06927596|PROCEDURE|Interventional therapy|The fistula was occluded by coil and NBCA glue.
214665143|NCT01475955|DRUG|Broad Area ALA 1-hour incubation|20% ALA, broad area, 1 hour incubation
214665144|NCT01475955|DRUG|Broad Area ALA 2 hour incubation|20% ALA broad area 2-hour incubation
214857677|NCT06731374|BIOLOGICAL|PCV15|VAXNEUVANCE (Merck, Sharp \& Dohme LLC, a subsidiary of Merck \& Co, Inc., Rahway, NJ, USA \[MSD\]) is a 15-valent PCV containing capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F, and 33F adjuvanted with aluminium phosphate.
214857678|NCT06731374|BIOLOGICAL|Streptococcus pneumoniae serotype 3|Streptococcus pneumoniae SPN3 (Clade Ia, strain LIV014-S3) - Single inoculation at 80,000 colony-forming unit (CFU)/naris, 28 days after vaccination.
214857679|NCT06731374|BIOLOGICAL|Placebo|The placebo consists of 0.9% sodium chloride for injection
214857680|NCT03974412|DIAGNOSTIC_TEST|Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]"
214857681|NCT03974412|DEVICE|Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
214857682|NCT06702033|RADIATION|Radiation therapy|IMRT or IMPT
214857683|NCT06702033|DRUG|Cisplatin|Dose of 100 mg/m\^2 IVPB over 60 minutes
214857684|NCT06702033|PROCEDURE|Surgery|Standard of care
214857685|NCT02716350|DIETARY_SUPPLEMENT|B-GOS|comparison versus placebo
214857686|NCT02716350|DIETARY_SUPPLEMENT|Maltodextrin|placebo
214857687|NCT02605798|DRUG|Elbanovir|1 tablet contains 400 mg sofosbuvir
214857688|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
214857689|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
214665145|NCT01475955|DRUG|broad area ALA 3-hour incubation|20% ALA broad area 3 hour incubation
214665146|NCT01475955|DRUG|Spot ALA 2 hour incubation|20% ALA spot 2 hour incubation
214857690|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 8g protein/100kcal|Enteral feed containing 8g protein/100kcal
214857691|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 5g protein/100kcal|Enteral feed containing 5g protein/100kcal
214857692|NCT06461481|DEVICE|Withings Scanwatch|Data captured by the used smartwatches (Withings Scanwatch) includes activity-related data (step count, minutes in certain intensity levels), basic cardiovascular measurements such as heart rate, and sleep-related data (total time asleep, sleep efficiency and quality etc.).
214857693|NCT03801421|PROCEDURE|Mass continous suture with PDS|The surgical incision will be treated by mass continous suture with PDS.
214857694|NCT03801421|PROCEDURE|Interrupted suture with thread|The surgical incision will be treated by interrupted suture with thread.
214857695|NCT04064814|DRUG|Flunarizine 5mg|Flunarizine 5mg once daily,orally for 12 weeks
214857696|NCT04064814|DRUG|Alpha lipoic acid 300mg|Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
214857697|NCT03083821|DRUG|Baraclude|Specified dose on specified day
214857698|NCT04969861|DRUG|Bempegaldesleukin|Specified dose on specified days
214290477|NCT05331274|OTHER|pain training group|"The training provides participants with the opportunity to explain the central sensitization mechanism and also integrates the behavioral, psychological and environmental aspects that contribute to the persistence of pain. It is intended to teach that education reduces pain and improves endogenous pain inhibition, mental health, physical function, vitality and self-rated disability in patients with chronic pain, and reduces passive coping, kinesiophobia, and catastrophizing.~The same exercises will be applied as the exercise group."
214290478|NCT02133287|DEVICE|AVI® Arsenic trioxide drug eluting stent delivery system|
214857699|NCT04969861|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
214857700|NCT06920615|BEHAVIORAL|Fading and chaining combined with differential reinforcement|Intervention Treatment will involve backward chaining, fading and differential reinforcement.
214857701|NCT06920615|BEHAVIORAL|Differential reinforcement of high rate|This will be identical to baseline, except a DRH will be introduced: The participant will be instructed to complete his whole meal within set time criteria to receive an identified reinforcer.
214857702|NCT06920615|BEHAVIORAL|Response interruption with redirection|RIRD involves physically blocking a movement from occurring using the least amount of physical contact for max 3 s, and then redirecting behavior to an ongoing activity or movement. Stereotypi that is verbal or not possible to block physically will involve a demand to answer a verbal question or a motor task that sufficiently interrupts the behavior and then redirecting.
214857703|NCT06920615|BEHAVIORAL|Chained schedules|"The following procedures are based on Slaton et al. (2016): At the start of each session, the candidate or therapist will hold up the red card, prompt the participant to touch the card, while saying we are in red now, time to work. The participant will have to perform age- or function appropriate tasks without stereotypi to gain access to the green phase. Demand will be designated with a token economy, where each token represents completion of a certain amount of task-related responses. The participant will not be prompted to perform the tasks. If the participant makes an error in a task (e.g. answer a math question incorrectly), this will lead to an error correction and no token will be presented. If stereotypi occurs, it will be blocked for up to 3 s, and then all demands will be reset by removing all earned tokens."
214290479|NCT02133287|DEVICE|Firebird2® sirolimus eluting stent system|
214857704|NCT01021241|BIOLOGICAL|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
214665147|NCT01475955|DRUG|Vehicle PDT|Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
214857705|NCT02804230|DEVICE|Neuro Ablation - Functional|MR-Guided Focused Ultrasound
214857706|NCT06929065|PROCEDURE|HIFU vs Cryoablation|HIFU vs cryoablation
214857707|NCT06928532|BEHAVIORAL|Seated TC|3-month seated Tai Chi training (24 sessions in total) given to Parkinson's disease patients
214857708|NCT06928441|DEVICE|Transcutaneous Pulsed Electrical Stimulation (Device: WL-2103A)|The Transcutaneous Electrical Nerve Stimulator (TENS) creates electrical impulses from a 9VDC-battery whose continuous intensity rate can be controlled by the user. The alligator clip with 2 electrodes is placed on the tragus part of the ear (shown to be 45% innervated via auricular vagus nerve) to stimulate the vagus nerve with an adjustable peak intensity (0-80mA), a frequency of 2 - 250Hz and a pulse width of 30-260 µsec. The vagus nerve contains a mixture of different types of nerve fibres, which are organized into bundles (fascicles). The fibres vary in diameter and conduction velocity, with A-type fibres the largest and fastest and C-type fibres the smallest and slowest, with B-type fibres intermediate. During nerve stimulation, fibres are activated in order of size from the largest (A-type) to the smallest (C-type). It has been suggested that A-type fibres are mainly activated during the stimulation via auricular vagus nerve.
214857709|NCT02646449|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
214857710|NCT02646449|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
214857711|NCT00608192|BEHAVIORAL|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
214857712|NCT00608192|BEHAVIORAL|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
214857713|NCT03016221|OTHER|Axanova hot gel|Axanova hot gel is a topical product with a warming effect. It contains menthol, pine needle oil, wintergreen oil, rosemary oil, eucalyptus oil, incense oil.
214857714|NCT03016221|OTHER|Axanova activ gel|Axanova activ gel is a topical product with a revulsive effect. It contains menthol, pine needle oil, orange oil, lemon oil, wintergreen oil, glycosaminoglycans.
214857715|NCT03016221|OTHER|Perskindol Dolo Gel|Perskindol Dolo Gel is a topical product with a warming effect. It contains wintergreen oil, pine needle oil, aromatics, excipients.
214857716|NCT03016221|OTHER|Perskindol Classic Gel|Perskindol Classic Gel is a topical product with a revulsive effect. It contains menthol, wintergreen oil, pine needle oil, lemon oil, orange peel oil, lemon bergamot oil, rosemary oil, lavender oil, excipients.
214857717|NCT03016221|OTHER|Perskindol Cool Kühl-Gel|Perskindol Cool Kühl-Gel is a topical product with a cooling effect. It contains levomenthol, color E131, aromatics, excipients.
214857718|NCT03016221|OTHER|Dolor-X Hot Gel|Dolor-X Hot Gel is a topical product with a warming effect. It contains isopropyl alcohol, water, menthol, hyprolose, camphor, trometamol, paprika, wintergreen oil, excipients.
214857719|NCT03016221|OTHER|Dolor-X Classic Gel|Dolor-X Classic Gel is a revulsive product. It contains water, isopropyl alcohol, menthol, spruce, hyprolose, trometamol, wintergreen oil, excipients.
214857720|NCT03016221|OTHER|Dolor-X Cool Gel|Dolor-X Cool Gel is a cooling product. It contains water, isopropyl alcohol, menthol, trometamol, color E131, excipients.
214907040|NCT06250296|OTHER|New model of psychiatric inpatient care|"The intervention envisages major structural changes in wards, in particular the reorganization of clinical discussion and decision-making spaces, as well as the medical and nursing referral system, and the inclusion of relatives in care:~* Treatment planning involving the patient, with a focus on his or her needs and resources.~* Care by referral teams, present every day of the week, to ensure continuity and consistency of care.~* As few decisions as possible made without the patient, and transparency in decision-making.~* Emphasis on the subjective meaning of illness, beyond symptoms.~* Greater visibility of care planning for patients, who will benefit from weekly agendas~* Closer collaboration with relatives, through open invitations to all clinical discussions, telephone hotlines and meeting times.~* Openness to the network and community care, by promoting communication and exchanges between all stakeholders, and the development of early warning tools such as the joint crisis plan."
214290480|NCT06155409|DEVICE|Anterior cervical interbody fusion|Anterior cervical interbody fusion indicates a surgical approach in the cervical spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height.
214290481|NCT02448420|DRUG|Palbociclib|"Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles."
214290482|NCT02448420|DRUG|Trastuzumab|Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
214290483|NCT02448420|DRUG|Endocrine therapy|Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
214290484|NCT02448420|DRUG|Chemotherapy|Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
214290485|NCT02448420|DRUG|Antibody-Drug Conjugates|3.6 mg/kg iv every 3 weeks
214290486|NCT02959944|DRUG|ibrutinib|Ibrutinib capsules administered orally daily
214290487|NCT02959944|DRUG|Placebo|Placebo capsules administered orally daily
214290488|NCT02959944|DRUG|Prednisone|Prednisone administered daily
214290489|NCT06182189|OTHER|Observation of patients with a benign prostatic hyperplasia condition|Observation of patients with a benign prostatic hyperplasia condition who have undergone surgery
214290490|NCT00740844|DEVICE|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
214665148|NCT01475955|DEVICE|Blue Light Treatment|10 J/cm2 blue light delivered at 10 mW/cm2
214290491|NCT01521208|DEVICE|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
214857721|NCT05480891|PROCEDURE|Transnasal Esophagoscopy (TNE)|"While seated in an upright position a topical numbing medicine will be sprayed in your nose and the back of your throat.~A thin, flexible tube less than ¼ inch in diameter, will be placed in one of your nostrils and advanced to the back of your throat. When the tube reaches the back of the throat you will be asked to drink sips of water to help move the tube into and down the esophagus as it is advanced. The tip of the tube has a small light and camera built in that allows the doctor to see the structures of the mouth and esophagus as the tube is advanced. Once the tube is in the esophagus, the physician will examine your esophagus for any abnormal changes.~Once the visual inspection is complete the tube will be gently removed through your nose. The procedure will take approximately 10-15 minutes of time."
214857722|NCT06436404|OTHER|Hammock intervention|It is a hammock made of 100% cotton fabric that prevents heat loss and has an internal apparatus to support the position, which can be adapted to the incubator by the researchers.
214857723|NCT06436404|OTHER|Kangaroo care intervention|In the clinic, the baby will receive kangaroo care with his mother in a quiet room with reduced lighting.
214857724|NCT06520579|BEHAVIORAL|Proactive pharyngeal-laryngeal Exercise Program|This program consists of daily proactive pharyngeal-laryngeal exercises and weekly sessions with a speech-language pathologist post surgery. One week prior to surgery participants will begin daily proactive pharyngeal-laryngeal exercises and continue these daily exercises for 6 weeks post surgery. Beginning approximately one week after surgery, participants will meet with the speech-language pathologist. Sessions will occur weekly, for approximately 6 weeks, and will last approximately 45 minutes.
214857725|NCT06520579|DIETARY_SUPPLEMENT|Premier Protein Clear ® High Protein|Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink) 1 drink daily for 7 weeks.
214857726|NCT06520579|BEHAVIORAL|Hydration Counseling|Daily hydration goals are based on recommended guidelines for adults, by gender, from The United States National Academy of Medicine (US NAM) and the European Food Safety Authority (ESFA) (\~2.0 L/day for women; \~2.5 L/day for men of fluid intake, accounting for 20% daily fluid intake from food sources). Patients will be required to track via paper log whether they met their hydration goals daily.
214857727|NCT04816630|DEVICE|CBC-Diff Monocyte Volume Width Distribution|MDW is part of the CBC-Diff and will be collected but not reported to the physician. MDW will not impact standard of care.
214857728|NCT03074396|DEVICE|Use of DialysisNet for doctor|DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.
214857729|NCT03074396|DEVICE|Use of Avatar Beans for patient|Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
214857730|NCT02522403|PROCEDURE|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
214857731|NCT02522403|DEVICE|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
214857732|NCT06224322|OTHER|Assesment Scale|Caregiving burden will be assessed with Turkish validated scoring tools such as the Zarit scale and the Pediatric Quality of Life Inventory (PEDSQL) Family Impacts module before and after surgery.
214857733|NCT02006368|OTHER|Blood Collection and autologous re-infusion|"Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.~After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated."
214857734|NCT01121341|PROCEDURE|Vein harvesting|Endoscopic versus conventional vein harvesting
214857735|NCT02287909|DRUG|Clopidogrel|Swiching from ticagrelor to clopidogrel
214857736|NCT02287909|DRUG|Ticagrelor|Continue treatment with ticagrelor
214857737|NCT04718194|BEHAVIORAL|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
214857738|NCT04718194|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
214857739|NCT00297726|BEHAVIORAL|Self-Management Program|
214857740|NCT04749836|PROCEDURE|His bundle pacing implantation, Left bundle branch area pacing implantation, Bachmann bundle pacing|"Different active fixation leads and the dedicated delivery sheaths are introduced via standard transvenous approach under fluoroscopic guidance. His bundle potential mapping is performed in a unipolar setting with the use of the electrophysiological system for His bundle pacing. After localizing the His bundle potential, the pacing is attempted before the lead fixation to confirm HB capture. The lead is then screwed into position. Acute HBP threshold ≤ 2.5V at 1ms is considered acceptable. On the other hand, the initial site for LBBP is approximately 1-1.5 cm distal to the HBP lead position in the RV septum along the line between the HBP site and RV apex in the right anterior oblique (30°) fluoroscopic view. Bachmann bundle pacing (upper atrial septum) will be performed with the J-stylet modification technique or with specialized catheter method using the SelectSecure active fixation lead.~Stepwise approach for conduction pacing will also be tested."
214290492|NCT01521208|OTHER|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
214857741|NCT03732261|OTHER|Exercise and dietary|The 12-week study invention will take place between 6 to 8-weeks postpartum and 18 to 20-weeks postpartum, with a follow-up at one year postpartum. The six-week postpartum time point is to allow for exercise clearance from the participant's obstetrician. The exercise clearance is needed prior to the baseline laboratory measurement. Women will be randomized to an intervention group or minimal care group after all baseline measurements (anthropometrics, cardiovascular fitness test, human milk and blood samples and DXA) at six-weeks postpartum. A random numbers table will be used to stratify by parity and determine groups.
214857742|NCT00564226|DRUG|SSR240600C|oral administration
214857743|NCT00564226|DRUG|tolterodine|oral administration
214857744|NCT00564226|DRUG|placebo|oral administration
214857745|NCT01108666|DRUG|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
214857746|NCT05461118|PROCEDURE|Experimental:Treatment group|Osteotomy surgical planning to be done using intraoperative mixed reality augmentation of a commercially available navigation platform.
214857747|NCT04064619|DRUG|Solifenacin Succinate 5 MG|gradual weaning of drug vs. stopping
214857748|NCT06168318|DRUG|VH4004280 Formulation A|Oral administration of VH4004280 Formulation A in fasted or fed conditions.
214857749|NCT06168318|DRUG|VH4004280 Formulation B|Oral administration of VH4004280 Formulation B in fasted or fed conditions.
214857750|NCT06168318|DRUG|VH4004280 Formulation C|Oral administration of VH4004280 Formulation C in fasted or fed conditions.
214857751|NCT06168318|DRUG|VH4004280 Formulation D|Oral administration of VH4004280 Formulation D in fasted or fed conditions.
214857752|NCT06168318|DRUG|VH4004280 Formulation E|Oral administration of VH4004280 Formulation E in fasted or fed conditions.
214857753|NCT03755479|DEVICE|Hybrid Closed Loop Insulin Pump Minimed 670G|Five Day Group Education on Minimed 670G
214857754|NCT02091141|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
214857755|NCT02091141|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
214857756|NCT02091141|DRUG|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
214857757|NCT02091141|DRUG|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
214857758|NCT02091141|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
214857759|NCT02091141|DRUG|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
214857760|NCT02091141|DRUG|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
214857761|NCT02091141|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
214857762|NCT01908413|DRUG|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
214857763|NCT03914118|DRUG|Preoperative modafinil + postoperative placebo|200 mg modafinil pre-operatively and placebo immediately post-operatively.
214857764|NCT03914118|DRUG|Preoperative modafinil + postoperative modafinil|200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
214857765|NCT03914118|DRUG|Preoperative placebo + postoperative placebo|Placebo pre-operatively and placebo immediately post-operatively.
214857766|NCT02613741|OTHER|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
214857767|NCT04102813|BEHAVIORAL|Functional Therapy|It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
214857768|NCT04009538|OTHER|Rehabilitation program|exercise program twice a week
214857769|NCT05016687|DRUG|CUR-N399|CUR-N399 will be administered as oral capsules.
214857770|NCT05016687|DRUG|Placebo|Placebo capsules matching CUR-N399 will administered.
214857771|NCT00616044|PROCEDURE|continuous spinal anesthesia|bupivacaina isobaric 0.5%, 5 mg
214857772|NCT00616044|PROCEDURE|Spinocath a catheter for continuous spinal anesthesia|Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
214290493|NCT03507894|BEHAVIORAL|Multimodal Exercise Rehabilitation Program|Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
214290494|NCT00003081|BIOLOGICAL|filgrastim|
214290495|NCT00003081|DRUG|busulfan|
214857773|NCT00616044|PROCEDURE|combined spinal epidural anesthesia|CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
214290496|NCT00003081|DRUG|melphalan|
214857774|NCT00605865|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
214857775|NCT05352165|DRUG|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
214857776|NCT05352165|DRUG|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
214857777|NCT05352165|DRUG|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
214857778|NCT05352165|DRUG|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
214857779|NCT05352165|DRUG|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
214857780|NCT05352165|DRUG|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
214857781|NCT05000086|DRUG|99Tc methylene diphosphonate|22mg qd，Once a day for 7 consecutive days
214857782|NCT03676517|RADIATION|preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
214857783|NCT03955471|DRUG|Niraparib|Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
214857784|NCT03955471|DRUG|Dostarlimab|TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
214857785|NCT05320601|DEVICE|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at trigger point of upper trapezius muscle
214857786|NCT05320601|PROCEDURE|Dry needling|Dry needling at trigger point of upper trapezius muscle
214857787|NCT03012672|DRUG|Cladribine|Given IV
214857788|NCT03012672|DRUG|Cytarabine|Given IV
214857789|NCT03012672|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Given SC
214857790|NCT03012672|DRUG|Mitoxantrone Hydrochloride|Given IV
214857791|NCT03012672|OTHER|Quality-of-Life Assessment|Ancillary studies
214857792|NCT03012672|OTHER|Questionnaire Administration|Ancillary studies
214857793|NCT02115217|DEVICE|Leukotape K|All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
214857794|NCT02115217|DEVICE|Sham kinesiotape|KT put with no effects
214857795|NCT04566341|DEVICE|OCT - TCE|Participants will be asked to swallow the TCE. They may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE is past the pharynx. We will advance the TCE until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
214857796|NCT06423638|BEHAVIORAL|Virtual Tai Chi Easy|"The TCE intervention will be delivered asynchronously online. Participants can complete the classes at a time and in a location that is convenient for them. The classes will be offered for one hour twice weekly and were developed and recorded by a certified Tai Chi Easy practice leader.~TCE is a simple form of mind-body self-care that focuses on four components:~* Mindful movements that help to stretch, and relax the body while improving balance and coordination~* Breathing practices that reduce stress by inducing a relaxation response while improving energy and circulation and enhancing innate healing responses~* Self-applied massage to stimulate blood flow, relax the body, and improve circulation and energy~* Meditation practices to relax the body, center the mind, and calm the emotions"
214857797|NCT00522171|DEVICE|The Harmonic™ ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
214857798|NCT03898518|OTHER|12-week jump rope exercise program|Each jump rope exercise session of the program was performed for 50 minute, with a 5 minute warm-up and cool-down. Sessions were performed once a day, 5 days a week, for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool-down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased form 40-50% heart rate reserve (HRR) in weeks 1-4 and 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Ever subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
214857799|NCT03254030|OTHER|Colonic inspection|Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
214857800|NCT02018926|DRUG|Mocetinostat|Mocetinostat (a histone deacetylase \[HDAC\] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
214857801|NCT02018926|DRUG|Azacitidine|Azacitidine (a hypomethylating agent \[HMA\]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
214857802|NCT06306235|OTHER|Questionnaire|Part A: 30 patients will be interviewed. Part B: 300 patients will complete written questionnaire on tablet.
214857803|NCT04749472|OTHER|Sling|Participants wore six different shoulder slings in a randomized order.
214857804|NCT03081234|DRUG|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
214290497|NCT00003081|DRUG|thiotepa|
214857805|NCT03081234|DRUG|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
214857806|NCT03081234|DRUG|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
214857807|NCT03011736|OTHER|Laboratory Biomarker Analysis|Correlative studies
214857808|NCT03011736|PROCEDURE|Parathyroidectomy|Undergo parathyroidectomy
214857809|NCT00446836|DRUG|Paclitaxel polyglumex (Xyotax)|biologically enhanced chemotherapeutic
214857810|NCT02483832|BEHAVIORAL|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
214857811|NCT03715998|DRUG|Ramipril|1 or 2 capsules administered orally, twice daily
214857812|NCT03715998|DRUG|Firibastat|1 or 2 capsules administered orally, twice daily
214857813|NCT03291353|DRUG|pembrolizumab|200 mg IV given every three weeks
214857814|NCT01233648|OTHER|rate control via CRT-D and AVN ablation|rate control
214857815|NCT01233648|OTHER|rhythm control via pharmacologic, electrical or ablative therapies|rhythm control
214857816|NCT01660191|DRUG|Pitavastin 4mg|
214857817|NCT01660191|DRUG|Atorvastatin 20mg|
214857818|NCT01660191|DRUG|Rosuvastatin 5mg|
214857819|NCT02350244|BEHAVIORAL|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
214857820|NCT06125574|OTHER|Osteopathic Manipulative Medicine|Individuals in the experimental cohort will undergo a systematic osteopathic manipulative treatment protocol encompassing paraspinal inhibition, rib raising, and condylar decompression techniques.
214290498|NCT00003081|PROCEDURE|peripheral blood stem cell transplantation|
214290499|NCT00003081|RADIATION|radiation therapy|
214290500|NCT01810354|DRUG|Cefazolin|
214857821|NCT04146311|DRUG|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) into the left infrapatellar fat pad.
214857822|NCT04146311|DRUG|isotonic saline|A bolus injection (0.25 ml) of isotonic saline (5%) into the left infrapatellar fat pad.
214857823|NCT04146311|OTHER|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
214857824|NCT01032018|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
214857825|NCT01032018|DRUG|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
214857826|NCT01032018|OTHER|Standard care|Participants will receive standard of care from the current physicians
214857827|NCT02402114|DRUG|Hydrocortisone|120 mg Hydrocortisone given orally one time.
214857828|NCT05506410|DRUG|Rituximab|Young patients (\< 65 years of age) were treated with R-BAP for 6 cycles (efficacy was assessed every 2 cycles, and adverse events were recorded), together with oral ibrutinib, followed by oral ibrutinib for 1 year after chemotherapy (efficacy was assessed every 3 months). Elderly patients (≥65 years of age) received 4 cycles of R-BAP (efficacy assessed every 2 cycles, and adverse reactions recorded), followed by 4 cycles of rituximab consolidation (efficacy assessed every 2 cycles) and 1 year of oral zanubrutinib (efficacy assessed every 3 months).
214857829|NCT04882631|DRUG|PBI-100 Topical Cream|A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.
214857830|NCT04882631|DRUG|Positive Control - Sodium laurel sulfate (SLS)|Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.
214857831|NCT04882631|OTHER|PBI-100 Topical Cream, Vehicle|Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.
214857832|NCT04882631|OTHER|Negative Control|A blank patch was applied daily (excluding weekends) as a negative control test site.
214857833|NCT04047524|OTHER|Monitoring using a FitBit|Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
214857834|NCT02783430|DRUG|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
214857835|NCT02783430|DRUG|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
214857836|NCT02783430|DRUG|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
214857837|NCT02130583|BEHAVIORAL|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
214857838|NCT02130583|BEHAVIORAL|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
214290501|NCT06254586|PROCEDURE|Aerobic exercises|This group received a single session of low-intensity cycling for 20 minutes. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
214857839|NCT05916261|BIOLOGICAL|Personalized neoantigen tumor vaccine|neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
214857840|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + Regenfast + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland) mixed with polynucleotide and hyaluronic acid-based gel (Regenfast®). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
214857841|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
214857842|NCT04113824|PROCEDURE|trapezuis motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
214857843|NCT04113824|PROCEDURE|other Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
214857844|NCT02045992|DIETARY_SUPPLEMENT|caffeine|Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
214857845|NCT05325073|DRUG|Erythropoietin|Erythropoietin
214857846|NCT06616909|BEHAVIORAL|ACP GAME|,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents
214857847|NCT06616909|BEHAVIORAL|acp manual|acp manual
214857848|NCT06004778|BEHAVIORAL|Motivational Support Program|In studies conducted on adolescents with poor sleep quality, no study using motivational interviewing technique was found.
214857849|NCT06004778|BEHAVIORAL|Educational support|educational support
214857850|NCT05631834|PROCEDURE|Thoracic epidurale|Epidurale Perioperative infusion of Ropivacaine
214857851|NCT05631834|PROCEDURE|Erector spinae block|erector spinae interfascia Perioperative infusion of Ropivacaine
214857852|NCT04333238|OTHER|New progress note template|Residents assigned to document with new progress note template
214857853|NCT04333238|OTHER|Standard progress note template|Residents assigned to document with standard progress note template
214857854|NCT02709252|DEVICE|PVI and deltaPP after trendelenburg position change|Comparison of hemodynamic parameters during surgery after position change
214857855|NCT04896411|OTHER|Alternative phrasing for no code|This intervention will use the alternative phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
214857856|NCT04896411|OTHER|Standard of care for no code|This intervention will use the standard of care phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
214857857|NCT02291770|BIOLOGICAL|Mesenchymal Stromal Cells|Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
214857858|NCT03250949|PROCEDURE|implant site over drilling protocol|"Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.~osteotomy site of the implant is wider by 0.2mm than the implant diameter"
214857859|NCT03122067|DRUG|oxytocin treatment|intranasal administration of oxytocin
214857860|NCT03122067|DRUG|placebo treatment|intranasal administration of placebo
214857861|NCT05311748|DIAGNOSTIC_TEST|Ultrasound and doppler|Penile echocolour doppler ultrasound
214857862|NCT02119286|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
214476453|NCT04729751|DRUG|Maralixibat|"Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~* 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~* 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base"
214857863|NCT02119286|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
214857864|NCT02119286|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
214857865|NCT02119286|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
214857866|NCT03247517|DRUG|Placebo|Placebo was administered once daily
214857867|NCT03247517|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
214857868|NCT03247517|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
214857869|NCT00998478|OTHER|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
214857870|NCT06180265|DIAGNOSTIC_TEST|presepsin, procalciton, endotoxin|measurement of presepsin, procalciton, endotoxin plasmatic levels
214857871|NCT00170794|DRUG|Everolimus (RAD001)|
214857872|NCT02399930|OTHER|Respiratory & Heart Rate Data Collection|"This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.~Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.~If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns."
214857873|NCT04161846|BEHAVIORAL|Virtual Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered remotely over 10 weeks using an internet based approach.
214857874|NCT04161846|BEHAVIORAL|In Person Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered in person over 10 weeks.
214857875|NCT00619112|DRUG|temozolomide|single arm study
214857876|NCT03149939|DRUG|Febuxostat 40 milligramsTablet|Febuxostat 40 milligramsTablet every other day for 3 months
214857877|NCT02936011|DEVICE|CTO PCI using Absorb Bioresorbable Vascular Scaffolds|CTO PCI
214857878|NCT01529398|OTHER|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
214857879|NCT01529398|OTHER|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
214857880|NCT01529398|OTHER|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
214857881|NCT03778398|OTHER|Neurologic music therapy|Customized piano training
214290502|NCT06254586|PROCEDURE|Resisted exercises|This group received four sets of 15 repetitions of knee extension, hamstring curls, and standing calf raises (20-40% 1RM) with 30 sec to 1 minute rest period between sets. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
214290503|NCT02430584|OTHER|Observational - no intervention|
214290504|NCT04934384|DIAGNOSTIC_TEST|prehospital extended focused assessment sonography for trauma|Sonographic procedure performed in the prehospital environment aiming at evaluating peritoneal free fluid in trauma patients
214857882|NCT06273826|DIAGNOSTIC_TEST|"Colorectal Leakage App"|"The Colorectal Leakage App is a mobile application designed to aid in the early detection of anastomotic insufficiency after colorectal surgeries. The app is based on the Dutch Leakage Score (DLS) algorithm, which is a standardized protocol for postoperative monitoring."
214857883|NCT01749917|OTHER|Exercise program|Exercise program An brief exercise session including proprioceptive and dexterity activities
214857884|NCT01749917|OTHER|Control intervention|Active upper limb range of movement exercises for 15 minutes.
214857885|NCT03768518|DIAGNOSTIC_TEST|68Ga-exendin-4 PET/CT|68Ga-exendin-4 PET/CT
214857886|NCT00105300|DRUG|Adalimumab|
214857887|NCT01996332|DRUG|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
214857888|NCT06211608|DIAGNOSTIC_TEST|Two-dimensional and three-dimensional ultrasound of the female reproductive organ|Two-dimensional and three-dimensional ultrasound of the female reproductive organ using a Samsung WS80A or Samsung HERA W10 ultrasound device with a transvaginal or transabdominal transducer
214857889|NCT04044911|BEHAVIORAL|Task model (CogWatch)|
214857890|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
214857891|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
214857892|NCT00548951|OTHER|Control|Receive no sessions in a Snoezelen Room.
214857893|NCT03690661|BEHAVIORAL|Intervention Video Game|"The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues."
214857894|NCT03690661|BEHAVIORAL|Placebo Control Game|The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
214857895|NCT03049605|DEVICE|Magnetic therapy|low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.
214857896|NCT03049605|DEVICE|laser therapy|laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
214857897|NCT03049605|DRUG|Only medical treatment|Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
214857898|NCT02113189|OTHER|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
214857899|NCT02113189|OTHER|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
214857900|NCT02113189|OTHER|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
214857901|NCT04053361|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
214665149|NCT06487052|COMBINATION_PRODUCT|Standard Catheter-Directed Low Dose Thrombolysis|Using femoral or jugular vein access the mechanical blood clots fragmentation by PigTail 6F catheter circular rotational movements. For unilateral thromboembolism, the PigTail catheter is positioned in the obstructed branch of the pulmonary artery, 1 mg of alteplase is injected as a bolus, followed by a micro-jet injection of 1 mg/hour. For bilateral thromboembolism, the PigTail catheter is positioned in the pulmonary trunk with a bolus of 2 mg alteplase followed by an infusion of 2 mg/hour. The total duration of infusion will be 9 hours, the total dose of alteplase will be 10 mg for unilateral lesions and 20 mg for bilateral lesions. During the alteplase infusion, unfractionated heparin is continued with a target activated partial thromboplastin time (aPTT) of 50 to 60 seconds. After completion of the procedure, UFH therapy is continued for 24 hours, followed by a change to oral anticoagulants.
214665150|NCT06487052|DRUG|Standard Anticoagulation|Therapy with UFH with targeted аPTT lasts for 24 hours (no more than 48 hours in total). Then the change to oral anticoagulants is performed
214665151|NCT02872103|DRUG|F-627|F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
214665152|NCT02872103|DRUG|Placebo|Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
214665153|NCT04075643|DRUG|Reference drug|D935 Cap. 1 Cap., single oral administration under fasting condition
214665154|NCT04075643|DRUG|Test drug|CKD-385 Tab. 1 Tab., single oral administration under fasting condition
214665155|NCT00294151|PROCEDURE|Vertebroplasty|
214665156|NCT00082823|BIOLOGICAL|ziv-aflibercept|
214665157|NCT01855230|DRUG|ASM-024|ASM-024 b.i.d for 14 days
214665158|NCT01855230|DRUG|Placebo|Placebo b.i.d. for 14 days
214665159|NCT01160731|DRUG|cisplatin|
214665160|NCT01160731|DRUG|etoposide phosphate|
214665161|NCT01160731|DRUG|panobinostat|
214665162|NCT01160731|OTHER|laboratory biomarker analysis|
214665163|NCT01160731|OTHER|pharmacological study|
214665164|NCT04642144|OTHER|Yerba mate infusion|"Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate."
214665165|NCT04642144|OTHER|Carbohydrate meal|Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
214665166|NCT00756002|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
214665167|NCT00756002|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
214665168|NCT00666185|DRUG|Micafungin|IV
214665169|NCT00666185|DRUG|Fluconazole|IV
214665170|NCT01671410|DRUG|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
214665171|NCT01671410|DRUG|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
214665172|NCT03040050|OTHER|rPCR results|Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.
214665173|NCT03040050|OTHER|Control group|Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
214665174|NCT02454114|OTHER|HOMEFIRST|HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
214665175|NCT02454114|OTHER|Standard Hospital Care|"No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.~SF-12 (physical and mental function) \[performed twice in total\] - at recruitment (day 0) and 6 weeks~CAP-SYM \[performed 3 times in total\] - at recruitment day 0 (twice including day minus 30) and 6 weeks~Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor."
214665176|NCT01674426|BEHAVIORAL|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
214665177|NCT04112758|OTHER|High-intensity interval training|2 times weekly for 5 weeks Circuit training with 4 stations
214857902|NCT06160505|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
214857903|NCT00207675|DRUG|infliximab|
214665178|NCT04194931|BIOLOGICAL|Autologous BCMA CAR-T cells and CD19 CAR-T cells|Autologous BCMA CAR-T cells and CD19 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
214665179|NCT01718717|OTHER|Thoracic Epidural Analgesia (TEA)|
214665180|NCT01718717|OTHER|TEA followed by Intravenous morphine|
214665181|NCT03767738|DRUG|Intravitreal Aflibercept Injection (IAI)|IAI prepared and administered with a pre-filled syringe (PFS)
214665182|NCT01837082|DRUG|ferric carboxymaltose|
214665183|NCT01837082|DRUG|Placebo|
214665184|NCT05153408|DRUG|BLU-701|BLU-701 for oral administration
214665185|NCT05153408|DRUG|osimertinib|Osimertinib tablets for oral administration
214665186|NCT05153408|DRUG|carboplatin|IV infusion of carboplatin
214665187|NCT05153408|DRUG|pemetrexed|IV infusion of pemetrexed
214857904|NCT05070000|DIAGNOSTIC_TEST|Radiologic examination|Patients underwent US, CT or CT after US
214665188|NCT03648645|DEVICE|Self measurement of blood pressure|"Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient."
214665189|NCT03624998|OTHER|Cognitive and physiatric testing|Neuropsychological test battery and physiatric tests
214665190|NCT02417415|OTHER|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at \~44ºC continuously for 2 hr.
214665191|NCT02417415|OTHER|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
214665192|NCT06553781|DRUG|Temozolomide、Fruquintinib、Cadonilimab|"Combination treatment period:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; Temozolomide: 150\~200mg/m2, poqd, d1-5, q4W; The combined treatment lasted 6 cycles.~Maintenance treatment:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; The maximum duration of maintenance treatment is not more than 2 years."
214665193|NCT06962475|OTHER|Podiatric advice|A podiatrist with 11 years of clinical experience will take the negative foot impressions using a semi-weightbearing method with a foam box for both groups to ensure adequate blinding of participants. Then, the foam boxes of the experimental group will be scanned so that the FOs can be 3D printed. Both groups will receive identical clinical guideline-based information and support at the beginning of the trial. The instructions will be as follows: (1) undertake a familiarization protocol of 14 consecutive full days (2) wear the FOs (customized or sham) at all time when they are standing (targeted minimum of 5 hours per day), (3) avoid positions that cause the metatarsophalangeal joints to dorsiflex (e.g., squatting or tiptoeing), (4) mechanical stress load management according to the tissue stress model, (5) do not walk barefoot and (6) wear shoes with good cushioning in which the FOs will be properly placed.
214665194|NCT06962475|OTHER|Customized foot orthoses|The customized foot orthoses will be manufactured with a Nylon-11 shell with 6° medially wedged forefoot-rearfoot posts (2.6 mm if the participants' weight (PW) is inferior or equal to 45 kg; 3.2 mm if 45\<PW\<100 kg; 4.0 mm if PW\>100 kg), a full-length 3 mm Poron top cover and a metatarsal pad (15 shore A) located 5 mm proximal to the metatarsal heads.
214665195|NCT06962475|OTHER|Sham foot orthoses|The molded sham FOs will be manufactured from 3 mm ethylene vinyl acetate. They will have an identical top cover material, color and a similar shape than the customized FOs, however, they will provide negligible mechanical support, considering the very low stiffness of their medial arch. The only impact of these FOs on plantar pressure is under the heel. These devices have been used as a sham condition in previous trials and a study has validated them as being credible.
214665196|NCT03047005|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
214665197|NCT03047005|OTHER|Placebo|Placebo
214665198|NCT00450606|PROCEDURE|Balneotherapy and hydrotherapy|
214665199|NCT06392919|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS intervention timing: rTMS is applied after the tracheal tube is removed in the PACU. Stimulation site: DLPFC (left dorsolateral prefrontal cortex); Stimulation intensity: 100% RMT; Stimulation frequency: 10Hz; Total number of stimulation pulses: 2000. Pulse characteristics: Each duration lasts 5 seconds, with a 25-second interval.
214665200|NCT05809687|DRUG|DKP21102_C|Placebo
214665201|NCT05809687|DRUG|DKP21102_B|Treatment
214665202|NCT05809687|DRUG|DKP21102_A|Active Control
214665203|NCT02607527|DEVICE|Mitral Valve IRIS Ring|Transcatheter implantation of the IRIS
214665204|NCT05796661|OTHER|Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration|"Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow."
214665205|NCT06407375|DIAGNOSTIC_TEST|mpMRI|mpMRI
214857905|NCT02044406|DRUG|BI 1181181|single dose (low to high dose)
214665206|NCT06419439|DRUG|Ketamine hydrochloride|Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.
214665207|NCT06419439|BEHAVIORAL|Minimally Enhanced Usual Care|Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).
214665208|NCT06419439|BEHAVIORAL|Brief narrative intervention|"Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions.~Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention."
214665209|NCT05922904|DRUG|Brentuximab vedotin|Given by IV (vein)
214665210|NCT05922904|DRUG|Doxorubicin Hydrochloride|Given by IV (vein)
214665211|NCT05922904|DRUG|Pembrolizumab|Given by IV (vein)
214665212|NCT05922904|DRUG|Dacarbazine|Given by IV (vein)
214665213|NCT04164212|DRUG|Flumist Quadrivalent Nasal Product|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
214665214|NCT05036278|BIOLOGICAL|Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).|"Dosage Levels:~* 40 IU/kg/dose two times per week~* 50 IU/kg/dose every 5 days~* 60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU."
214665215|NCT04899271|DRUG|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
214665216|NCT04899271|OTHER|Placebo|Placebo was administered orally with the same scheme of administration of LDX to preserve blinding
214665217|NCT02416869|PROCEDURE|Intramuscular application|Patient receive 4mg of Dexamethasone by intramuscular application
214665218|NCT02416869|PROCEDURE|Submucosal application|Patients receive 4mg of Dexamethasone by submucosal application
214665219|NCT02416869|DRUG|4mg Dexamethasone submucosal|Patients receive 4mg of submucosal Dexamethasone
214665220|NCT02416869|DRUG|8mg Dexamethasone submucosal|Patients receive 8mg of submucosal Dexamethasone
214857906|NCT02044406|DRUG|BI 1181181, R|powder for oral solution
214857907|NCT02044406|DRUG|BI 1181181, T2|tablet, fasted
214857908|NCT02044406|DRUG|Placebo to BI 1181181|Placebo to BI 1181181
214857909|NCT02044406|DRUG|BI 1181181, T1|tablet, fed
214857910|NCT00166907|BEHAVIORAL|Balance and Exercise|
214857911|NCT03265288|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
214857912|NCT03265288|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
214857913|NCT03065595|DIETARY_SUPPLEMENT|Ophiochepalus striatus extract|each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day
214857914|NCT03065595|OTHER|Placebo|each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
214857915|NCT04693338|OTHER|Quality-of-Life Assessment|Ancillary studies
214857916|NCT04693338|OTHER|Questionnaire Administration|Ancillary studies
214857917|NCT04693338|OTHER|Supportive Care|Receive ICP tasks
214857918|NCT03648034|PROCEDURE|ropivacaine|To perform scalp nerve blocks with ropivacaine
214857919|NCT03648034|PROCEDURE|saline|To perform scalp nerve blocks with saline
214857920|NCT05828121|BEHAVIORAL|POINT1|Receiving treatment
214857921|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Analerg|
214857922|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Bronchi|
214857923|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
215033592|NCT06637930|OTHER|Edentulous Alveolar Ridge In Mandible|"implant retained mandibular overdenture using telescopic attachment system. all the patients received 2 implants at the canine region bilaterally using sterelithographic guide , then healing period for 3 months for proper osseointegration , then digital intraoral scanning was performed to detect implant position using scannable bodies , abutments which act as primary crowns were designed on cad software then milled using premilled titanium abutments.the study grouping was performed then virtual model was done for the designing of the frameworks then milled according to the grouping of the study. Try in of the frameworks was done and overdentures were inserted.~* Retention force test was done using digital force gauge.~* Probing depth using Teflon coated periodontal probe.~* Marginal bone level and bone density were measured using digital periapical x-ray"
214290505|NCT03428789|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve of the abdomen was reattached to a donor nerve in the chest area. The sensory branch of usually the 11th intercostal nerve was used as recipient nerve for nerve coaptation and the anterior cutaneous branch of the third intercostal nerve was used as donor nerve. Direct, end-to-end nerve coaptation was performed with two stitches.
214290506|NCT04876274|BEHAVIORAL|TMU-LOVE|Patients in intervention group could attend diabetes-related health educational video through the TMU-LOVE platform. Researcher would also send 2-3 videos per week with care massage every 2 weeks to the patients.
214857924|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
214857925|NCT01618188|DRUG|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
214857926|NCT01618188|DRUG|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
214857927|NCT02264093|DRUG|Propranolol|
214857928|NCT02264093|DRUG|Talsaclidine|
214857929|NCT04803188|DIAGNOSTIC_TEST|Magnetic Resonance|"Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.~All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy."
214857930|NCT04660890|DRUG|ALXN2050|ALXN2050 will be administered orally twice daily as powder-in-capsule.
214857931|NCT04660890|DRUG|ALXN2050-matching Placebo|ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.
214857932|NCT04660890|DRUG|Moxifloxacin|Moxifloxacin will be administered as a single oral dose.
214857933|NCT04660890|DRUG|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo will be administered as a single oral dose.
214857934|NCT00537108|BEHAVIORAL|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support \& skills-building for school continuation, higher education, and job readiness.
214857935|NCT06402201|BIOLOGICAL|CDR404|IV infusions
214857936|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
214857937|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
214857938|NCT00812422|DRUG|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
214857939|NCT03181321|BEHAVIORAL|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
214857940|NCT01426035|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
215033593|NCT06640140|BEHAVIORAL|Supervised aerobic plus strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training.
214857941|NCT02316249|DRUG|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
214857942|NCT02316249|OTHER|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
214857943|NCT06341387|OTHER|Breath, urine and blood analysis|"breath sampling: all subjects exhale into two sterile Tedlar bags, connected to a mouthpiece, in a condition similar to traditional spirometry.~Urine will be collected usual urine container.~The blood sample (\~ 5 ml) will be taken with a serum separator tube."
214857944|NCT00054041|BIOLOGICAL|HspE7|Given subcutaneously
214857945|NCT00054041|PROCEDURE|therapeutic conventional surgery|Undergo large loop excision
214857946|NCT00054041|OTHER|laboratory biomarker analysis|Correlative studies
214665221|NCT02416869|PROCEDURE|4mg Dexamethasone preoperative|Patients receive 4mg of Dexamethasone preoperatively
214665222|NCT02416869|PROCEDURE|4mg Dexamethasone postoperative|Patients receive 4mg of Dexamethasone postoperatively
214665223|NCT02555163|DEVICE|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
214665224|NCT02555163|DEVICE|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
214665225|NCT03511365|BIOLOGICAL|Probiotic Formulation VSL#3|Probiotic VSL#3 administration.
214665226|NCT01929083|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
214665227|NCT01929083|DRUG|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
214665228|NCT01929083|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
214665229|NCT01315574|DRUG|Travoprost|One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
214665230|NCT01315574|DRUG|Latanoprost|One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
214665231|NCT00332904|DRUG|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
214857947|NCT01297374|BEHAVIORAL|physical activities, dietician counseling and behavioral changes|One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
214857948|NCT00652028|DRUG|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
214857949|NCT05689593|OTHER|Low-intensity ESWT Group|ESWT; With the MODUS ESWT system, the patient's shoulder will be in 80° passive abduction, the elbow will be in 90° flexion, and the forearm will be applied to 2 separate parts of the shoulder. The first application will be applied from front to back in the anterior shoulder joint and the upper limit of the treatment will be approximately 1 finger lateral to the coracoid process, the second application will be applied from the lateral scapula to the posterior shoulder joint (0.06 mJ/mm2, 1500 impulses, 1.5 bar).( Modus ESWT® RadialShockwaveTherapy)
214857950|NCT05689593|OTHER|Low-intensity laser Group|The laser will be made parallel to the joint line with the patient's arm, the arm will be in internal rotation at the posterior of the shoulder and the arm will be in external rotation at the anterior of the shoulder. The wavelength of 850 nm will be applied for 5 minutes in total 30 Joules.
214290507|NCT02051608|DRUG|Placebo|Participants received Placebo SC injection Q4W.
214665232|NCT00332904|DRUG|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
214665233|NCT02207114|OTHER|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
214665234|NCT02233842|BEHAVIORAL|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
214665235|NCT01057277|DRUG|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
214665236|NCT04117750|DIETARY_SUPPLEMENT|cholecalciferol (vit D3)|42,000 IU oral vitamin D per week and 500 mg calcium carbonate
214665237|NCT06030934|DRUG|envafolimab and lenvatinib combined with paclitaxel-albumin|envafolimab: 200mg d1,15 s.c. Q4W; lenvatinib: 8mg (\<60kg) or 12mg (≥60kg) p.o. Q.d.; paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
214665238|NCT03981029|OTHER|4.0mg Folic Acid received through participation in FACT (NCT01355159)|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid intervention are provided below:~Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid"
214665239|NCT03981029|OTHER|Placebo received through participation in FACT|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid placebo are provided below:~Placebo x 4 tablets will be taken daily by oral administration."
214665240|NCT05102565|BEHAVIORAL|sleep education program|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
214665241|NCT03160729|DRUG|Dexamethasone|pre-operative, single-shot injection
214665242|NCT00235521|DRUG|aerosolized iloprost|
214665243|NCT02945982|DRUG|Entecavir+Carvedilol|The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
214665244|NCT02945982|DRUG|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
214665245|NCT04376619|OTHER|remote ischemic preconditioning|inflation and deflation of cuff 5min each cycle repeated 3 times
214857951|NCT05689593|OTHER|Conventional Control Group|Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
214857952|NCT03924011|DEVICE|Photobiomodulation therapy (PBMT)|PBMT sessions will be planned 2x/week after RT.
214857953|NCT03924011|DEVICE|Sham laser|Sham laser sessions will be applied 2x/week after RT.
214857954|NCT06441461|OTHER|Primary informal caregiver at work.|Employees becoming a primary informal caregiver for a child or an adolescent with mental health problems in the period from 2000 to 2018.
214857955|NCT03716076|DRUG|Carbetocin|50 mcg or 100 mcg bolus of carbetocin
214857956|NCT01385306|DEVICE|AlphaCore System|Non-invasive neurostimulation of the vagus nerve
214857957|NCT05645770|COMBINATION_PRODUCT|ECG, computerized task|ECG for cardiac waves computerized task for prospective memory
214857958|NCT03082170|DEVICE|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
214857959|NCT03082170|DIAGNOSTIC_TEST|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
214857960|NCT03082170|BEHAVIORAL|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
214857961|NCT03106558|DEVICE|Total Knee Arthroplasty using Manual Instrumentation|
214857962|NCT03106558|DEVICE|Total Knee Arthroplasty using Robotic Arm|
214857963|NCT03854786|DIETARY_SUPPLEMENT|Oxyjun|Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
214857964|NCT03854786|DIETARY_SUPPLEMENT|Pacebo|Methyl Crystalline Cellulose
214857965|NCT02192008|BIOLOGICAL|Salmonella Typhi|
214857966|NCT02192008|BIOLOGICAL|Salmonella Paratyphi|
214857967|NCT02944370|BEHAVIORAL|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
214857968|NCT03331237|PROCEDURE|scalene block|scalene block using 5ml of ropivacaine
215033594|NCT06644053|BEHAVIORAL|Quantified analysis of walking during a crossing task through different horizontal openings|Functional test that reproduce a task of daily living
215033595|NCT05406401|BIOLOGICAL|Zilovertamab Vedotin|IV infusion
214290508|NCT02051608|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
214857969|NCT03331237|PROCEDURE|ISO block|ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture
214857970|NCT02893137|DEVICE|Optune|For further information see www.optune.com
214857971|NCT02893137|PROCEDURE|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
214857972|NCT04436978|DRUG|30-day DAPT|DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.
214857973|NCT04436978|DRUG|Guideline-directed therapy|Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
214857974|NCT00031083|GENETIC|Interferon-beta|
214857975|NCT00872885|DRUG|GRT6005|liquid formulation, 200 to 600 µg, single dose, one day
214857976|NCT00872885|DRUG|Morphine|60 mg
214857977|NCT00872885|DRUG|Placebo|single dosage
214857978|NCT00003748|DRUG|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
214857979|NCT01047930|BEHAVIORAL|Exercise|"Each 3-day experimental period will include one of the following conditions:~1. Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~2. Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~3. No exercise - subject will watch television or read and they will be required to remain sedentary."
214857980|NCT01722565|PROCEDURE|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
214857981|NCT00931268|DEVICE|Macrolane VRF 30|One administration
214857982|NCT00750646|DEVICE|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
214857983|NCT04375930|OTHER|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION: It is consist of skills, discharge, compilation and algorithm education.
214857984|NCT04375930|OTHER|Control|It consists of only skills and discharge education
215033596|NCT05406401|DRUG|Cyclophosphamide|IV infusion
214290509|NCT00516438|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
215033597|NCT05406401|DRUG|Doxorubicin|IV infusion
215033598|NCT05406401|BIOLOGICAL|Rituximab|IV infusion
215033599|NCT05406401|BIOLOGICAL|Rituximab Biosimilar|IV infusion
215033600|NCT05406401|DRUG|Prednisone|IV or oral administration (per local guidelines)
215033601|NCT05406401|DRUG|Prednisolone|IV or oral administration (per local guidelines)
215033602|NCT01646827|DRUG|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
215033603|NCT00928668|DRUG|Placebo|Placebo device for comparison
215033604|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
215033605|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
215033606|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
215033607|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
215033608|NCT05000710|DRUG|Durvalumab|Durvalumab administered IV over 60 minutes at a dose of 1500 mg every 4 weeks
214290510|NCT00516438|DRUG|Topotecan|intravenous infusion
214290511|NCT00142584|DRUG|Nebivolol (NEB)|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
214290512|NCT00142584|DRUG|Metoprolol (MET)|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
214665246|NCT04376619|OTHER|KDIGO guidelines|KDIGO stands for Kidney disease Improving global outcomes guidelines, and have guidelines for prevention and treatment of AKI which is considered standard of care.
214665247|NCT02586805|DRUG|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
214665248|NCT02586805|DRUG|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
214665249|NCT02586805|DRUG|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
214665250|NCT02586805|DRUG|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
214665251|NCT04982133|DIETARY_SUPPLEMENT|Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment|"At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk."
214665252|NCT00367757|PROCEDURE|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
214665253|NCT00367757|PROCEDURE|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
214665254|NCT00367757|PROCEDURE|Combined approach for AF ablation|Combined trigger and substrate based approach
214665255|NCT03270722|DEVICE|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
214665256|NCT03270722|PROCEDURE|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
214665257|NCT00940706|DEVICE|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
214665258|NCT00940706|OTHER|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
214665259|NCT00940706|BEHAVIORAL|Monitoring physical activity|Activity monitoring with accelerometers
214665260|NCT02504541|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
214665261|NCT03645291|DIAGNOSTIC_TEST|Local insect allergen extracts skin test|Every patient received both local and commercial insect allergen extracts but in blinded methods
214665262|NCT04893668|OTHER|Depression|Any participants who develop depression symptoms according to DSM 5 criteria
214665263|NCT04893668|OTHER|Anxiety|Any participants who develop anxiety symptoms according to DSM 5 criteria
214665264|NCT02952716|BIOLOGICAL|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
214665265|NCT02952716|OTHER|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
214665266|NCT00634673|OTHER|sandwich|standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
214665267|NCT05727774|OTHER|Water Biking in hot water condition|Training protocol includes 10 water biking sessions in hot water temperature (35°C) for this group
214665268|NCT05727774|OTHER|Water Biking in neutral water condition|Training protocol includes 10 water biking sessions in neutral water temperature (25°C) for this group
214665269|NCT02375022|DRUG|Endostar and icotinib|Endostar and icotinib are used as combination therapy.
214665270|NCT05777928|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy involves vertical resection of a major part of the stomach, and a tubular remnant is retained along the lesser curvature.
214665271|NCT05777928|PROCEDURE|OverStitch™ Endoscopic Suturing System|Overstitch endoscopic procedure makes a review of gastro-jejunal anastomosis reducing surgical complications
214665272|NCT01412437|DIETARY_SUPPLEMENT|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
214665273|NCT01412437|DRUG|sapropterin dihydrochloride|20 mg/kg for 4 months
214665274|NCT01412437|DRUG|sapropterin dihydrochloride|
214665275|NCT01476930|PROCEDURE|cupping and serkangabin syrup|wet cupping serkangabin syrup
214665276|NCT01476930|DRUG|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
214665277|NCT00500071|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
215033609|NCT05000710|DRUG|Tremelimumab|Tremelimumab administered IV over 60 minutes at a dose of 300 mg , twice: at C1D1 and C4D1
214857985|NCT04310839|PROCEDURE|Colectomy|colectomy due to neoplastic (stage 1) or diverticulosis
214857986|NCT04929938|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This is a combination of cognitive-behavioural techniques oriented to improve the emotional regulation. The Unified Protocol is comprised of 8 modules and it is applied following The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders Manual (Barlow, 2017).
214857987|NCT01112813|DRUG|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
214857988|NCT05236920|DEVICE|Resuscitative Endovascular balloon occlusion of the aorta using a REBOA catheter device|In-hospital use of a REBOA catheter device during advanced cardiac life support
214857989|NCT01587586|BIOLOGICAL|PEGASYS 180 µg Q1W|48 doses, solution, 48 weeks
214857990|NCT01587586|BIOLOGICAL|P1101 180 µg Q1W, 48 doses|48 doses, solution, 48 weeks
214857991|NCT01587586|BIOLOGICAL|P1101 270µg Q1W, 48 doses|48 doses, solution, 48 weeks
214857992|NCT01587586|BIOLOGICAL|P1101 450µg Q2W, 24 doses|24 doses, solution, 48 weeks
214857993|NCT05046665|DRUG|89Zr-Girentuximab|Administration of 89Zr-girentuximab as per protocol.
214857994|NCT02138019|PROCEDURE|Fibrin Glue assisted external eye surgery|
214857995|NCT02138019|DEVICE|Fibrin glue|
214857996|NCT00376974|BEHAVIORAL|American Academy of Ophthalmology Glaucoma Educational Tape|
214857997|NCT05404074|DRUG|Cobitolimod 500mg|Rectal administration
214857998|NCT03336320|DEVICE|ICT Multidomain Intervention Training|Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.
214857999|NCT02541162|BEHAVIORAL|Oral information and interviews|interviews about sexuality and self experience during the disease
214858000|NCT02273791|DRUG|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
214858001|NCT02273791|DRUG|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
214858002|NCT00115557|OTHER|Practice intervention|Performance feedback, academic detailing, practice facilitation, IT support
214858003|NCT00115557|OTHER|Practice intervention 2|Performance feedback only.
214858004|NCT05384717|OTHER|Fidget Device|Fidget spinner, stress ball, pop-it, or fidget cube
214858005|NCT05384717|OTHER|Control group|No intervention
214858006|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
214858007|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
214858008|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
215033610|NCT05000710|RADIATION|Low dose irradiation|21 days after the first immunotherapy treatment 11 fractions of 3 Gy will be administrated to metastatic or primary lesion/s over 2 weeks and one day
214290513|NCT03886233|DRUG|Corticosteroid Series|immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
214476454|NCT06613243|DRUG|Esketamine 0.2 mg/kg|Esketamine 0.2 mg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
214858009|NCT00430495|DRUG|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
214858010|NCT02857738|DRUG|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
214858011|NCT02857738|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
214858012|NCT01739621|DRUG|Proellex 12 mg|
214858013|NCT01739621|DRUG|Proellex 24 mg|
214858014|NCT06067321|OTHER|abdominal ultrasound, insertion of naso-gastric tube|measurement antral cross sectional area, volume and pH of residual stomach contents
214858015|NCT03514654|PROCEDURE|Mastectomy|Removal of the whole breast.
214858016|NCT03514654|PROCEDURE|Therapeutic Mammoplasty|Excision via lumpectomy of multifocal or multicentric cancers with breast volume displacement techniques to maximise cosmetic outcomes.
214858017|NCT02751359|DRUG|Cannabidiol|200, 400, or 800 mg Cannabidiol
214858018|NCT02751359|DRUG|Placebo|0 mg Cannabidiol
214858019|NCT03257475|RADIATION|Brachytherapy|Intracavitary irradiation starts at the end of the external beam radiation using image-guided CT/SIM.CT/SIM (transverse axis) is done to complete 3/2D treatment planning. Measurement VRL, PIBS and PIBS ± 2cm, R-V were recorded; Brachytherapy plan: Point A: 24-30Gy/4-5f, or 21-28Gy/3-4f HR-CTV: ≥85Gy, IR-CTV 65Gy dose records
215033611|NCT00186459|BEHAVIORAL|Hypocaloric diet of varying macronutrient composition|
214858020|NCT04993300|DEVICE|transcranial magnetic stimulation (TMS)|The methamphetamine user will undergo a one-month TMS intervention. In Week 1, subjects will attend continuously 5 daily TMS sessions. From Week 2 to Week 4, subjects are treated once a week. Each session will have 40 repeats of 4-second train and 15-sec train interval.
214858021|NCT06091852|DIETARY_SUPPLEMENT|Intrinsically labelled milk protein|20 grams of protein dissolved in 500 mL of water
214858022|NCT01558336|DRUG|praziquantel|praziquantel 40 mg/kg oral tablets
214858023|NCT02400671|BEHAVIORAL|SMS messaging|
214858024|NCT01748331|OTHER|Fluid restriction|Patients will be randomized to strict fluid restriction \< 1 L/day versus moderate fluid restriction \< 2.5 L/day
214858025|NCT03124862|DEVICE|ARM sensor|Acoustic Monitoring sensor that monitors respiratory rate
214858026|NCT02796131|DRUG|RDX5791|
214858027|NCT02796131|DRUG|Placebo|Placebo
214858028|NCT04957420|DRUG|Neupro|Rotigotine Patches
214858029|NCT01485666|OTHER|Percutaneous Lead Management Kit|A kit of commercially available components to be used for HeartMate II driveline exit site cleaning, dressing and stabilization
214858030|NCT05555368|OTHER|Quality of Recovery Score|Descriptive
214858031|NCT06323486|DEVICE|active accelerated bilateral sequential theta burst stimulation and sham treatment|"We shall use the Magpro device (Magventure) employing the specialized Active/Sham B70 coil.~absTBS shall be administered consisting of 6 sessions daily (with a 50-minute interval between treatment sessions) on Mondays to Fridays or for a maximum of 5 working days of daily treatment. The target stimulation intensity will be set at 90 to 120% of the subject's resting motor threshold (RMT). Each session shall be composed of administration of continuous theta burst stimulation (triplet burst pulses at 50 Hz, repeated at 5 Hz, for a total of 600 pulses per session over 40 seconds administered on the right dorsolateral prefrontal cortex) and then intermittent theta burst stimulation (triplet burst pulses at 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, for a total of 600 pulses per session over about 3 min, administered on the left dorsolateral prefrontal cortex).~The sham treatment will be conducted for the same number of sessions and duration as the absTBS treatment sessions."
214858032|NCT04646486|BEHAVIORAL|Video debriefing|Obstetric teams will review their own performance on video in a debriefing session to improve future performance.
214858033|NCT02145026|DRUG|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
214858034|NCT01799317|DRUG|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
214858035|NCT01915693|RADIATION|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
214858036|NCT03008486|DEVICE|Real soft splint (6 cm)|
214858037|NCT03008486|DEVICE|Placebo soft splint (1 cm)|
214858038|NCT05288036|OTHER|Proprioceptive Neuromuscular Rehabilitation group|The PNF technique was performed in the supine position with the hip joints of the patients in 30° flexion and the lower extremities in semi-flexion. The application was performed in 2 different diagonal and 4 different patterns (flexion-abduction-external rotation/extension-abduction-internal rotation, and flexion-adduction-external rotation/extension-abduction-internal rotation) of the upper extremity. When starting the exercise, the muscles were first brought to their longest position and the patient was asked to move in the direction of the pattern with resistance (concentric contraction) and to maintain this position for 6 seconds at the end of the pattern (isometric contraction). Then, while the therapist was taking the patient's arm to the starting position, the patient was asked to prevent movement (eccentric contraction). All of these moves counted as one repetition. 3 sets of 8-12 repetitions were performed for each pattern.
214858039|NCT05288036|OTHER|Progressive Resistance Exercise Group|"Strengthening exercises targeting the upper extremity main muscles were applied to the PRE group with progressive resistance. Dumbbells and sandbags were used as resistance equipment. resistance intensity; 50-80% of a repetition maximum (RM) was determined according to the patient's tolerance. The exercises were applied as 8-12 repetitions and 3 sets. A rest period of 60-90 seconds was allowed between each set. After the 4th week of the training, 1 RM was measured again and the resistance density was updated. The 8 strengthening exercises to be applied were created by taking examples from the literature and in accordance with the Guidelines for implementing exercise programs exercise programs for cancer patients. These exercises are: dumbbell fly, triceps extension, biceps curl up, one-arm bent over row, dumbbell sides rise, lifting the arm forward, wrist curl and side lying shoulder internal -external rotation."
214858040|NCT05288036|OTHER|Control Group|The patients in the control group were instructed to continue their usual daily lives (not changing their physical activity levels, diet, drug use, etc.) until the date of re-evaluation after the initial evaluation. Information was given about the upper extremity normal range of motion exercises that they could apply at home, and a brochure was given.
214858041|NCT02023736|OTHER|Systemic Therapy Inventory of Change (STIC)|The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
214858042|NCT02023736|OTHER|Treatment as Usual|Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
214858043|NCT02719106|DEVICE|Ultimaster stent|
214858044|NCT00857792|DRUG|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
214858045|NCT01566357|OTHER|Toothpaste|
214665278|NCT00472303|DRUG|Tapentadol Extended Release|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
214858046|NCT01566357|DIETARY_SUPPLEMENT|Milk|
214858047|NCT01566357|DIETARY_SUPPLEMENT|Fluoridated Milk|
214858048|NCT01566357|DRUG|Tooth Mousse|
214858049|NCT01566357|DRUG|MI Paste Plus|
214858050|NCT01566357|DRUG|Elmex Erosion Protection|
214858051|NCT01797835|BEHAVIORAL|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
214858052|NCT01797835|BEHAVIORAL|usual care|Youth receive a brochure with information on AOD use.
214858053|NCT03564041|BEHAVIORAL|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
214858054|NCT03564041|BEHAVIORAL|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
214858055|NCT03728634|DRUG|ION-682884|ION-682884 administered SC
214858056|NCT03728634|DRUG|Placebo|Placebo comparator calculated volume to match ION-682884 administered SC
214858057|NCT03728634|DIETARY_SUPPLEMENT|Vitamin A|Oral supplement
214858058|NCT03185234|DEVICE|anodal tDCS|2 mA, 10 min, 5 sessions
214858059|NCT03185234|DEVICE|sham tDCS|sham stimulation, 10 min, 5 sessions
214858060|NCT02148341|OTHER|Community of Practice Facilitation|
214858061|NCT02148341|OTHER|Usual Care|
214858062|NCT01345435|PROCEDURE|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
214858063|NCT01345435|PROCEDURE|Telemonitoring & Telemedicine|The Telemonitoring \& Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
214858064|NCT01345435|OTHER|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
214858065|NCT03951896|BIOLOGICAL|PRP|A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects.All of the injections were done every two weeks, for a total of 3 times using 21 G injection needles with injection technique of posterior approach.
214858066|NCT03951896|OTHER|Saline injection|2 ml's of NaCl solution with 0,9% concentration was applied to the shoulders of the participants.
214858067|NCT04990596|BIOLOGICAL|additional blood sample|One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
214858068|NCT03538119|OTHER|High Intensity Interval Training Program|"The HIIT group performed 4 × 4-minute high-intensity intervals at 85%-95% HRpeak followed by a 1-minute recovery interval at 40% HRpeak, predicted with a supervised graded exercise test on a treadmill with the Bruce protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
214858069|NCT03538119|OTHER|Moderate Intensity Continuous Training Program|"The MICT protocol (usual care) consisted of a continuous bout of moderate-intensity exercise to elicit 70-75% HRpeak, rating of perceived exertion 3 to 5 (fairly light to somewhat hard), for 27.5 minutes to equate the energy expenditure with the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
214858070|NCT03880760|OTHER|L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
214858071|NCT03880760|OTHER|Placebo|Taking 1 placebo capsule twice a day before meals for six months.
214858072|NCT00937820|DRUG|YM150|oral
214858073|NCT01554826|BIOLOGICAL|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
214858074|NCT01554826|BIOLOGICAL|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
214858075|NCT04421586|BEHAVIORAL|VISTA|VISTA will be an educational intervention.
214858076|NCT05451186|OTHER|Eye patch and headphones|Patients in the experimental group will be asked to use an eye mask and earplugs from 22:30 to 6:30 in the morning on the 1st, 2nd and 3rd nights.
214665279|NCT00472303|DRUG|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
214858077|NCT02398357|DRUG|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
214858078|NCT02694471|BEHAVIORAL|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
214858079|NCT00967044|DRUG|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
214858080|NCT00967044|DRUG|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
214858081|NCT02715544|OTHER|Healthy lifestyle|The families will receive a designed for these purposes intervention
214858082|NCT02715544|OTHER|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
214858083|NCT00469157|DRUG|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
214858084|NCT03823014|DEVICE|Elator|Measurement for device, use of device
214858085|NCT03382314|COMBINATION_PRODUCT|HDDO-1614|"* Combination drug (Bazedoxifene + Cholecalciferol)~* Incrementally modified drug~* Not market authorized product"
214858086|NCT03382314|DRUG|Bazedoxifene / Cholecalciferol|Co- Administration of Bazedoxifene and Cholecalciferol
214858087|NCT04310813|DIAGNOSTIC_TEST|Multimodal spectroscopic analysis|During time of bladder or prostate resection, freshly excised cold cup biopsies of both bladder cancer or healthy bladder mucosa were taken and sent for inspection through label-free multimodal fiber optic spectroscopy (MFOS) within 30 minutes
214858088|NCT00753818|OTHER|DHA and ARA|various levels of DHA and ARA
214858089|NCT00753818|OTHER|Control|
214858090|NCT02453906|OTHER|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
214858091|NCT02453906|OTHER|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
214858092|NCT02453906|OTHER|Control 2|stimulation at 5 control points
214858093|NCT02453906|OTHER|Control 3|no stimulation at 5 control points
214858094|NCT00004218|DRUG|chlorambucil|
214858095|NCT00004218|DRUG|cyclophosphamide|
214858096|NCT00004218|DRUG|doxorubicin hydrochloride|
214858097|NCT00004218|DRUG|fludarabine phosphate|
214858098|NCT00004218|DRUG|prednisolone|
214290514|NCT01482754|DRUG|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
214290515|NCT05843981|DEVICE|Implant placement TS III|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with TSIII Implant. . After osseointegration, dental implants will receive definitive prosthesis.
214858099|NCT00004218|DRUG|vincristine sulfate|
214858100|NCT04642937|DRUG|Treatment with hP1A8|Treatment with hP1A8
214858101|NCT02619877|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
214858102|NCT02619877|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
214858103|NCT01268605|PROCEDURE|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
214858104|NCT01268605|PROCEDURE|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
214858105|NCT00500747|BIOLOGICAL|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
214858106|NCT00500747|DRUG|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
214858107|NCT02870387|OTHER|Comprehensive Care with Inpatient consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
214858108|NCT02870387|OTHER|Usual Inpatient Care|High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
214858109|NCT00132093|DRUG|Eplerenone|
214858110|NCT04370951|PROCEDURE|Erector Spinae Plane Block - Ultrasound guided|20mls 0.25% Levobupivicaine ultrasound guided bilaterally
214858111|NCT02218970|BEHAVIORAL|strength training|
214858112|NCT02218970|BEHAVIORAL|no training (control)|
214858113|NCT01011244|BIOLOGICAL|ADIPOPLUS|"autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula"
214858114|NCT05842096|DIAGNOSTIC_TEST|Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in both arms of the study
214858115|NCT05842096|DIAGNOSTIC_TEST|Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha depending on the blood concentrations of TSH, a-TPO and a-TG in women in both study arms
214858116|NCT05842096|DIAGNOSTIC_TEST|Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha and AMH, FSH in women in both study arms
214858117|NCT00076804|BEHAVIORAL|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
214858118|NCT04492865|DEVICE|MSCT|"-Laboratory tests: All routine indicators of CBC are evaluated~* Nasopharyngeal and oropharyngeal swabs are obtained from each patient to confirm the positivity to Covid-19 by performing RT-PCR to detect the viral RNA.~* MSCT Chest images of all patients are evaluated by three radiologists with variable experiences in CT chest interpretation. The readers are blinded of the RT-PCR results and the CBC indices of the patients and they have access only to the epidemiological history, clinical symptoms, and signs. By consensus, the radiologists score the chest CT as positive or negative for COVID-19 viral pneumonia. When the chest CT is classified as positive, the main CT features are recorded as present or absent (ground-glass opacity, crazy paving, consolidation, nodules, air bronchogram, air trapping, halo sign, reversed halo sign, bronchial wall abnormalities, vascular enlargement, pleural effusion, and lymphadenopathy."
214858119|NCT04677881|OTHER|Intervention group|intervention group: bread with sourdough control group: bread with yeast
214858120|NCT03979781|DRUG|tailored antiplatelet selection|antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
214858121|NCT03979781|DRUG|standard of care|antiplatelet selection using standard of care
214858122|NCT04657926|DRUG|APPA|APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) \& 2-hydroxy-4-methoxyacetophenone (2H4MA).
214858123|NCT04657926|DRUG|Placebo|Placebo capsules
214858124|NCT01284296|DRUG|Lidocaine digital block|One dose of lidocaine 2% injected locally into one finger (2 mls total)
214858125|NCT01284296|DEVICE|Masimo SpHb continuous hemoglobin monitor|Masimo SpHb continuous hemoglobin monitor
214858126|NCT04295135|BEHAVIORAL|Chronic Pain OneSheet|The Chronic Pain OneSheet (OneSheet) is an EHR decision support tool that uses behavioral economics to increase adoption of chronic pain guideline recommendations. OneSheet works by aggregating and structuring information that is already collected, that PCPs often need while caring for patients with chronic pain conditions. By aggregating and structuring this information in a more convenient manner, the goal of OneSheet is to make the information that is important in clinical decision making more readily available, and to reduce the amount of time that PCPs need to spend locating this information.
214858127|NCT00376025|DIETARY_SUPPLEMENT|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
214858128|NCT00698893|BIOLOGICAL|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
214858129|NCT03525925|DRUG|Ibrutinib|Given PO
214858130|NCT03525925|OTHER|Laboratory Biomarker Analysis|Correlative studies
214858131|NCT03525925|BIOLOGICAL|Nivolumab|Given IV
214858132|NCT03484117|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
214858133|NCT00002752|RADIATION|iodine I 131 monoclonal antibody 81C6|
214858134|NCT00054600|DRUG|Methoxsalen|
214858135|NCT00054600|PROCEDURE|Extracorporeal Photopheresis|
214858136|NCT04578652|DRUG|Metformin 850 mg oral tablet bid|MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).
214858137|NCT04578652|DIETARY_SUPPLEMENT|Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.|The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.
214858138|NCT03403166|BEHAVIORAL|DASH diet|Diet intervention
214858139|NCT03403166|BEHAVIORAL|Fruits and vegetables diet|Diet intervention
214858140|NCT03403166|BEHAVIORAL|Control diet|Diet intervention
214858141|NCT01138865|DEVICE|AutoSet Spirit--Wash--Modified-AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
214858142|NCT01138865|DEVICE|Modified-AutoSet Spirit--Wash-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
214858143|NCT00281606|DRUG|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
214858144|NCT00289874|DRUG|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
214858145|NCT00289874|DRUG|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
214858146|NCT05594303|BIOLOGICAL|Autologuos transplantation of bronchial basal cells|Autologuos transplantation of bronchial basal cells
214858147|NCT06258603|OTHER|oral care bundle|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, an oral care bundle containing an oral care combination was applied to the experimental group. According to this bundle application, patients were received tooth brushing (with chlorhexidine solution) and ice water application twice a day and moisturizing attempts 4 times a day.~In the 3rd stage, saliva pH, dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
214858148|NCT06258603|OTHER|clinical oral care|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, routine oral care protocol used in intensive care unit was applied to patients by the patients' primary nurse. According to this application, patients were received oral care using tongue depressor with wrapped in gauze and chlorhexidine solution 4 times a day.~In the 3rd stage, saliva pH (power of hydrogen), dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
214858149|NCT06058286|OTHER|Continuous quality improvement|Continuous quality improvement (CQI) is an approach to develop healthcare providers' capacity to improve quality of care processes and improve adherence to clinical guidelines. Key features of CQI include systematic, data-guided activities, designing interventions (or changes to facility processes) with local conditions in mind, and iterative development and testing of interventions. The approach is based on the premise that valuable improvement in organisational processes can be achieved through bottom-up initiatives of stakeholders and providers. It requires a 'team-based' culture of staff working together to collect and use available data to evaluate the effect of local solutions. Facility staff drive the development of solutions to quality of care shortcomings that they feel are best suited to the local context, and CQI works within existing resource constraints so it does not require large long-term investments to sustain improvements.
214858150|NCT05500196|DEVICE|Per Oral Endoscopy Myotomy (POEM)|POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to reach the inner circular muscle bundles of the LES to perform myotomy, while preserving the outer longitudinal muscle bundles. The result is decreased resting pressure of the LES, facilitating the passage of ingested material.
214858151|NCT05597735|DRUG|Tecovirimat|"The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~* 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~* 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days."
214858152|NCT05597735|DRUG|Placebo|The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
214858153|NCT02924636|BEHAVIORAL|ePPOP-ID program|This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
214858154|NCT00210613|DRUG|Dapoxetine|
214858155|NCT06166238|PROCEDURE|Millard and Tension Randal Technique|Millard recognized that the majority of Cupid's bow, one philtral column, and the philtral dimple were intact on the medial aspect of a unilateral cleft lip but required rotation to shift the tissue into a normal anatomic position (Millard, 1964b) The Tennison-Randall technique involves a back-cut that extends from the cleft Cupid's bow peak toward the center of the philtrum that is filled by a laterally based triangular flap whose width is the measured deficiency in lip height.
214858156|NCT04247152|OTHER|Intraoperative Aberrometry vs preoperative biometry|Hypothesis: Intraoperative aberrometry measures lower levels of astigmatism more accurately than preoperative biometry in patients undergoing cataract surgery.
214858157|NCT03939325|RADIATION|ESWL|The impact of different frequencies on pattern of disintegration of renal stones
214858158|NCT04414306|OTHER|In-person cancer screening education|Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
214665280|NCT00472303|DRUG|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
214665281|NCT02365428|BEHAVIORAL|Physical activity text messages|
214858159|NCT04414306|OTHER|Online educational video and website module|Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
214858160|NCT04414306|OTHER|Online educational video|Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
214858161|NCT04414306|OTHER|Message from healthcare system and online educational video and website module|Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
214858162|NCT04218500|OTHER|Niacinamide 4%|cream moisturizer
214858163|NCT04218500|OTHER|Virgin Coconut oil 30%|cream moisturizer
214858164|NCT05559775|DRUG|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
214858165|NCT01131572|DRUG|N-acetylcysteine NAC|N-acetylcysteine in the treatment of Bulimia Nervosa
214858166|NCT05854082|DRUG|Lidocaine 2% Polyampoule|Three intervention conditions in a repeated measures design - lidocaine; no perturbation, candy (lollipop)
214858167|NCT02404688|DRUG|Active delta-9-THC|"Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes."
214858168|NCT02404688|DRUG|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
214858169|NCT02404688|DRUG|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
214858170|NCT02404688|DRUG|Placebo|Control: no alcohol, administered for a total of 80 minutes.
214858171|NCT00576654|DRUG|Irinotecan Hydrochloride|Given IV
214858172|NCT00576654|OTHER|Laboratory Biomarker Analysis|Correlative studies
214858173|NCT00576654|OTHER|Pharmacological Study|Correlative studies
214858174|NCT00576654|DRUG|Veliparib|Given PO
214858175|NCT03835325|DIETARY_SUPPLEMENT|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
214858176|NCT06321991|DRUG|Vitamin E-creme (Remederm®) vs Vaseline (Placebo)|Louis Widmer Remederm® Face Cream Without Perfume 50 ml is a skin care product that contains vitamin E as an active ingredient. Before applying Remederm®, the following are advised: On dry clean skin thoroughly before applying Remederm®, apply a layer of cream cutaneous to the hand palm, twice a day: morning and evening, massage cream into skin until absorbed. This procedure is applied by the patient treated with Vaseline or Remederm®.
214858177|NCT06321991|PROCEDURE|Ultrasound measurement|Nodule evolution will be measured with ultrasound.
214858178|NCT06003751|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
214858179|NCT06003751|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
214858180|NCT06003751|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
214290516|NCT05843981|DEVICE|Implant placement ks|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with KS Implant. After osseointegration, dental implants will receive definitive prosthesis.
214858181|NCT03573960|DRUG|Lenvatinib|Lenvatinib capsules.
214858182|NCT02828592|DRUG|Fludarabine|30 mg/m2 IV QD x 5 days (Days -6 to -2)
214858183|NCT02828592|DRUG|Cyclophosphamide|14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)
214858184|NCT02828592|RADIATION|Total Body Irradiation|300 cGy x1 dose (Day -1)
214858185|NCT02828592|DRUG|Rabbit ATG|1.5 mg/kg/day x 3 days (Days -3 to -1)
214858186|NCT02828592|DRUG|Cyclophosphamide|Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
214858187|NCT06414954|DRUG|NMD670|Tablets taken twice a day for 21 days
214858188|NCT06414954|DRUG|Placebo|Tablets taken twice a day for 21 days
214858189|NCT06524856|DEVICE|Lung Master (Pulmonary Exerciser)|During the one-month using the Lung Master at their house, the participant will be using it at least one time every day, either in the morning or in the evening before going to sleep. During the session, the participants will sit upright and try to prolong the inhalation and exhalation breaths through the Lung Master device for at least three seconds. For each session, the participants will try to concentrate on 35-50 breaths in and breaths out which is about 2-5 minutes. Every session can involve using the Pulmonary Exerciser for a minimum of 5 minutes and a maximum of 20 minutes. After each session, participants will be asked to note how long they have used the device and when they have used it. Information from each session will be recorded on the Participant Device Log that will be provided.
214858190|NCT05741645|OTHER|Kinesiotaping|During the kinesio taping of the erector spina vs multifidus muscles, the patient is in a standing position. Kinesiotape is applied with 50% tension and stays in the patient for 30 minutes.
214858191|NCT05741645|OTHER|Sham Kinesiotaping|The elastic taping will be randomly applied to a place outside the area to be measured, without stretching, and without causing any effect.
214858192|NCT04654897|DRUG|[14C]-NT-814|120 mg radioactive labeled elinzanetant (\[14C\]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) \[14C\].
214858193|NCT04272476|OTHER|acupuncture and moxibustion|
214858194|NCT04272476|DRUG|Fluoxetine|
214858195|NCT03519984|DRUG|Cytarabine|Given IV
214858196|NCT03519984|OTHER|Laboratory Biomarker Analysis|Correlative studies
214858197|NCT03519984|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
214858198|NCT03519984|DRUG|Vincristine Liposomal|Given IV
214858199|NCT02856009|OTHER|completion of a quality of life questionnaire|
214858200|NCT03528785|DRUG|Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid|"* Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~* Irinotecan Liposomal Injection \[Onivyde\] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~* Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~* 5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle"
214858201|NCT01274806|OTHER|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
214858202|NCT01084382|DIETARY_SUPPLEMENT|Arthrospira platensis|"Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks."
214858203|NCT02159170|BIOLOGICAL|NGF injection|single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
214858204|NCT05990842|DRUG|Antibiotic|the individual will receive 1 dose of antibiotic during anesthetic induction
214858205|NCT05990842|OTHER|placebo|the individual will receive 10 ml of saline during anesthetic induction
214858206|NCT04016337|DIETARY_SUPPLEMENT|Beverages|The beverages were all made with lemon and maqui extracts, and different sweeteners
214858207|NCT05466279|DRUG|remazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.
214858208|NCT05466279|DRUG|Propofol|Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus
214858209|NCT05466279|DRUG|Midazolam|Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
214858210|NCT03852459|DRUG|S-Ibuprofen|Topical Gel 5%
214858211|NCT03852459|DRUG|Vehicle|Vehicle Gel
214858212|NCT02760706|DEVICE|Computed Tomography scan|
214858213|NCT01981499|DRUG|PF-05180999|Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
214858214|NCT01981499|DRUG|Placebo|Placebo tablets
214858215|NCT01981499|DRUG|120 mg MR PF-05180999|Single 120 mg dose administered as modified release formulation
214858216|NCT01981499|DRUG|360 mg MR PF-05180999|Single 360 mg dose administered as modified release formulation
214858217|NCT01981499|DRUG|10 mg cetirizine|Single 10 mg dose of cetirizine
214858218|NCT01981499|DRUG|Placebo|Placebo tablets
214858219|NCT05310799|OTHER|Shared Decision Making (SDM)|The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smart phone.
214858220|NCT00697606|DEVICE|Seprafilm®|Seprafilm® placed at time of primary cesarean
214858221|NCT00697606|OTHER|Control|no Seprafilm® used at primary cesarean
214858222|NCT05333237|DIETARY_SUPPLEMENT|Intervention #1: ProvideXtra Drink|Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
214858223|NCT05333237|DIETARY_SUPPLEMENT|Intervention #2: Fresubin Energy Drink|Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
214858224|NCT05333237|DIETARY_SUPPLEMENT|Intervention #3: Generic Glucose Solution|Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
214858225|NCT00578071|DRUG|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
214858226|NCT00578071|DRUG|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
214858227|NCT00578071|DRUG|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
214858228|NCT00578071|RADIATION|Radiation Therapy (RT)|Daily for 6 weeks
214858229|NCT03605251|DRUG|TAS5315 low dose|Oral administration for 12 or 36 weeks
214858230|NCT03605251|DRUG|TAS5315 high dose|Oral administration for 12 or 36 weeks
214858231|NCT03605251|DRUG|Placebos|Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)
214858232|NCT00336128|BEHAVIORAL|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
214858233|NCT00336128|BEHAVIORAL|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
214858234|NCT02514161|OTHER|Inspiratory Muscle training|This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
214858235|NCT02514161|OTHER|IMT + Manual Therapy and Motor Control Exercise|The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
214858236|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator flaps|closure of myelomeningocele defect by perforator island flap after complete incision of the flap all around based on perforator vessel .
214858237|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator-plus flaps|closure of myelomeningocele defect by perforator-plus island flap harvesting leaving skin bridge connecting to the flap and dissection of the perforator vessel
215033612|NCT01838226|BEHAVIORAL|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
214858238|NCT01609621|DEVICE|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
214858239|NCT00701974|BIOLOGICAL|collagenase (IRUXOL)|patients will be treated with collagenase one time per day.
214858240|NCT00701974|BIOLOGICAL|collagenase (Kollagenase)|patients will be treated with collagenase one time per day.
214858241|NCT06611085|OTHER|cold application group|The index finger of the child will be used in the cold application group. In this group, cold application will be performed by placing the index finger of the designated hand on a 10 x 10 cm ice pack for 30 seconds and then removing the ice pack immediately.
214858242|NCT06611085|OTHER|vibration group|The middle finger of the child will be used in the vibration group. In this group, vibration was applied by targeting the tip of the middle finger area using a vibrator device measuring 2x1x3 cm. The insertion of the needle will coincide with the application of the vibration stimulation.
214858243|NCT06611085|OTHER|vibration and ice group|In the vibration and ice group, cold and vibration stimulation will be applied to the child simultaneously. The ring finger of the designated hand was placed on a 10x10 cm ice pack for 30 seconds and subjected to cold application. Simultaneously, vibration stimulation will be applied to the tip of the middle finger area using a vibrator device with dimensions of 3x1 cm and 2x1 cm. After 30 seconds, the ice bag will be removed and the lancet pen will be adjusted for drilling from the fingertip while vibration stimulation continues.
214858244|NCT04544020|DIETARY_SUPPLEMENT|NG feeding|NG feeding
214858246|NCT01757574|DRUG|Alemtuzumab infusion|
214858247|NCT01727687|BEHAVIORAL|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
214858248|NCT00521274|BIOLOGICAL|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
214858249|NCT00521274|DRUG|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
214858250|NCT00563680|DRUG|AMG 479|AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
214858251|NCT05177562|OTHER|No intervention|There is no intervention in this study
214858252|NCT03749629|OTHER|GeneSight Psychotropic test|GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
214858253|NCT03749629|OTHER|Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines|Guidelines for treatment
214858254|NCT05196360|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
214858255|NCT04167176|PROCEDURE|Erector spinae plane block|Patients will be placed on their right side. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10-cm needle will be inserted using an in-plane approach in a cranial to caudal direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
214858256|NCT04167176|PROCEDURE|Port site infiltration|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of the LA mixture. The volume will be divided equally between port sites. A total of four ports-supraumbilical, subxiphoid and two ports in the right subcostal area at mid-clavicular and anterior axillary line will be made.
214858257|NCT04167176|DEVICE|Ultrasound machine (Mindray DP 9900 plus; Mindray Bio-Medical Electronics, Shenzhen, China)|Ultrasound will be used to identify the erector spinae muscles and to guide the LA mixture injection.
214858258|NCT04167176|DRUG|Bupivacaine 0.5%|Bupivacaine 0.5% will be included in the injected LA mixture.
214858259|NCT04167176|DRUG|Lidocaine 2%|Lidocaine 2% will be included in the injected LA mixture.
214858260|NCT00770692|DRUG|Eszopiclone 1 mg- Elderly|"Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
214858261|NCT00770692|DRUG|Eszopiclone 2 mg- Elderly|"Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
214858262|NCT00770692|DRUG|Eszopiclone 3 mg- Non-elderly|"Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
214858263|NCT00770692|DRUG|Eszopiclone 2 mg- Non-elderly|"Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
214858264|NCT05559112|OTHER|Vitamin D-enriched mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.
214858265|NCT05559112|OTHER|Study Powder|Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks. Study powder is a commercially available carbohydrate.
214858266|NCT02447926|PROCEDURE|Leukapheresis|"Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.~On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.~During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.~Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours."
214858267|NCT05587335|BEHAVIORAL|PREP|Relationship intervention to improve communication and conflict resolution for couples
214858268|NCT05587335|BEHAVIORAL|OurRelationship|Relationship intervention to improve communication and conflict resolution for couples
214858269|NCT03668821|OTHER|Questionnaire|Quality of life and frailty questionnaires
214858270|NCT03166813|PROCEDURE|Remote Ischaemic Preconditioning|The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
214858271|NCT03166813|OTHER|Control|Placement of blood pressure cuff without inflation for 30 minutes.
214858272|NCT06326502|DRUG|ETN101|Oral administration
214858273|NCT03288974|DRUG|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
214858274|NCT03201679|PROCEDURE|Repair of hip fracture|Patients undergoing hip fracture surgery
214858275|NCT02469779|BEHAVIORAL|Surveys|At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
214858276|NCT02469779|BEHAVIORAL|ASPIRE Website|Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
214858277|NCT02469779|BEHAVIORAL|ASPIRE Text-Based Website|Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
214858278|NCT02469779|BEHAVIORAL|Follow Up Survey|Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
214858279|NCT06194006|OTHER|Follow-up|Follow-up grafted patients as long as their condition allows
214858280|NCT00562770|DRUG|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
214858281|NCT00562770|DRUG|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
214858282|NCT06358287|PROCEDURE|cryogenic auriculotherapy|Compressed nitrogen is used to create a 'cryonic needle', using a cryopunctor device. An orifice is placed in appropriate acupoint and nitrogen flow is used to cool and activate the point.
214858283|NCT03957187|DIAGNOSTIC_TEST|Ferritin, iron and iron binding capacity, high sensitive C-reactive protein (CRP) measurement|"Ferritin, iron and iron binding capacity will be measured for evaluation of ID using Cobas c-e and Elecsys.~The relation of inflammation to iron deficiency will be evaluated by high sensitive C-reactive protein measurement."
214858284|NCT03840252|DIAGNOSTIC_TEST|3D gait analysis|Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics
214290517|NCT01573572|DRUG|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
214858285|NCT03840252|DIAGNOSTIC_TEST|rsfMRI|MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).
214858286|NCT03840252|DIAGNOSTIC_TEST|Montreal Cognitive assesment (MoCA)|Standard clinical questionnaire
214858287|NCT01147978|BEHAVIORAL|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
214858288|NCT05110807|DRUG|TQB3617|TQB3617 is a BET inhibitor.
214858289|NCT02713815|RADIATION|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
214858290|NCT02713815|RADIATION|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
214858291|NCT01138111|DRUG|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
214290518|NCT03146715|OTHER|Feeding trial|Children were asked to eat the designated portion of the assigned food once a day for six weeks.
214290519|NCT00741637|BIOLOGICAL|CholeraGarde®|"Live attenuated oral Cholera vaccine~Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials"
214290520|NCT00741637|BIOLOGICAL|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
214290521|NCT03070782|DRUG|ISIS 681257|ISIS 681257 solution for SC injection.
214290522|NCT03070782|DRUG|Placebo|Sterile normal saline (0.9% NaCl)
214858292|NCT03676751|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
214858293|NCT03676751|DRUG|Placebo|Oral suspension of placebo for azithromycin
214858294|NCT00560937|DRUG|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
214858295|NCT00560937|DRUG|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
214858296|NCT01698437|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
214858297|NCT01868711|BEHAVIORAL|Cognitive Behavior Therapy|
214858298|NCT03486054|DEVICE|INTERCEPT|The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD
214858299|NCT03486054|DEVICE|Standard of Care|The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
214858300|NCT05023577|DRUG|Rabeprazole|20mg bid
214858301|NCT05023577|DRUG|Bismuth potassium citrate|0.6g bid
214858302|NCT05023577|DRUG|Metronidazole|0.4g qid
214858303|NCT05023577|DRUG|Clarithromycin|0.5g bid
214858304|NCT05023577|DRUG|Levofloxacin|0.5g qd
214858305|NCT01026259|OTHER|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
214858306|NCT01026259|OTHER|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
214858307|NCT03629028|DIAGNOSTIC_TEST|Residual myometrium thickness|The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
214858308|NCT03629028|DIAGNOSTIC_TEST|Niche Presence|The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.
214858309|NCT03629028|DIAGNOSTIC_TEST|Adjacent myometrium thickness|The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
214858310|NCT03629028|DIAGNOSTIC_TEST|Niche Measurements (depth of niche, width of niche, length of niche)|The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.
214858311|NCT03046719|DRUG|Bupivacaine 0,5%|Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
214858312|NCT03046719|DRUG|NaCl 0,9%|NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
214858313|NCT04785157|BIOLOGICAL|serology testing profiles description|SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)
214858314|NCT04785157|BIOLOGICAL|immune response characterization|systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)
214858315|NCT04785157|OTHER|in vivo brain PET-TSPO acquisitions|in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)
214290523|NCT02338531|DRUG|PF-03084014|
214858316|NCT04785157|OTHER|brain MRI assessment|structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)
214858317|NCT04785157|BEHAVIORAL|neurocognitive assessment|multi-domains neurocognitive assessment
214858318|NCT00256711|DRUG|Gefitinib|
214858319|NCT00256711|DRUG|Vinorelbine|
214858320|NCT04637633|DRUG|topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,|topical preservative free artificial tears Q.I. D.
214858321|NCT00793741|DRUG|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
214858322|NCT00384007|PROCEDURE|Hydrodiscectomy with Spinejet|
214858323|NCT03694366|OTHER|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers"
214858324|NCT04116905|BEHAVIORAL|Intensive Lifestyle Intervention|"The intensive lifestyle intervention program employs a structured, multi-component approach under professional supervision to achieve and sustain 15% weight reduction from baseline. This 12-month intervention features:~1. A weight loss phase (months 1-5) incorporating:~   Individualized calorie restriction using partial meal replacement (carbohydrate energy supply ratio is 20\~25%, and the daily calorie intake is 22.5\*70% kcal/kg/d); exercise recommends at least 150 min of moderate intensity and 2 to 3 resistance training per week; with monthly follow-ups；~2. A maintenance phase (months 6-12) focusing on:~   Healthy balanced diet, total daily calorie intake is 20-25 kcal/kg/d; exercise recommends at least 150 minutes of moderate intensity and 2-3 resistance training per week; with follow-ups every 2 months；~3. Digital health integration:~Mobile application-based monitoring of metabolic parameters; real-time feedback and adherence tracking."
214858325|NCT04116905|BEHAVIORAL|Conventional Treatment|"The conventional treatment arm receive standardized metabolic syndrome management through monthly group education sessions and peer support, with a target of 7% weight reduction from baseline. The program incorporates:~1. A weight loss phase (months 1-5) incorporating:~   Structured lifestyle education; limit the total energy diet (total daily calorie intake is 22.5\*85% kcal/kg/d), with carbohydrates, fat, proteins accounting for 45-55%, 20-30%, and 20-30%, respectively, for the daily energy intake.; physical activity(150 min medium intensity exercise and 2 to 3 resistance training); with monthly follow-ups;~2. A maintenance phase (months 6-12) focusing on:~   Healthy balanced diet, total daily calorie intake is 20\~25 kcal/kg/d; physical activity(150 min medium intensity exercise and 2 to 3 resistance training);with follow-ups every 2 months;~3. Digital health integration:~Mobile application-based monitoring of metabolic parameters; real-time feedback and adherence tracking."
214858326|NCT06172855|DEVICE|Electroacupuncture at ST36|Electroacupuncture at ST36, which located at the anterior aspect of the lower leg, 3 cun below ST 35, one finger-breadth (middle finger) from the anterior crest of the tibia. Twice or 3 times per week, for 6 weeks.
214858327|NCT03380559|DRUG|Injection, botulinum toxin + corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
214858328|NCT03380559|DRUG|Injection, placebo of toxin + corticoid|"* Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
214858329|NCT03380559|DRUG|Injection, botulinum toxin + placebo corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)"
214858330|NCT04683237|DRUG|Liraglutide Injection|Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.
214858331|NCT04683237|DRUG|Megestrol Acetate 160 MG|160mg po qd
214858332|NCT02836834|BIOLOGICAL|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
214858333|NCT03922074|PROCEDURE|Sedation directed by an endoscopist|"The nurse begins with fentanyl infusion in bolus: 75 μg (1.5 ml) and initial propofol dose (10mg/ml) in bolus of 0.5 - 2.5 mg/Kg followed by a maintenance dose of 20 - 60ml/h through Target-controlled infusion (TCI) pump. In this way, we get a target level sedation between 1 - 3, according to Observer's Assessment of Alertness/Sedation Scale (OAAS).~The role of the nurse, directed by an endoscopist, it is exclusively the administration of intravenous drugs and the patient monitorship throughout the procedure."
214858334|NCT03922074|PROCEDURE|Sedation directed by an anesthesiologist|The choice of the drugs and the target level sedation are directed by an anesthesiologist
214858335|NCT01401257|DRUG|PXT3003 Low dose|Liquid,5 ml, twice a day, 12-month treatment
214858336|NCT01401257|DRUG|PXT3003 Intermediate Dose|Liquid,5 ml, twice a day, 12-month treatment
214858337|NCT01401257|DRUG|PXT3003 High Dose|Liquid,5 ml, twice a day, 12-month treatment
214858338|NCT01401257|OTHER|Placebo|Liquid,5 ml, twice a day, 12-month treatment
214858339|NCT06105320|OTHER|LCHF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%"
214858340|NCT06105320|OTHER|HCLF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%"
214858341|NCT02217631|DRUG|BI 653048 BS H3PO4|
214858342|NCT02217631|DRUG|Prednisolone low dose|
214858343|NCT02217631|DRUG|Prednisolone high dose|
214858344|NCT02217631|DRUG|Placebo|
214858345|NCT01918631|DRUG|tenofovir disoproxil fumarate|
214858346|NCT01918631|DRUG|Entecavir|
214858347|NCT02413931|OTHER|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
214858348|NCT01591889|DRUG|Tinidazole|500 mg tablet
214858349|NCT01591889|DRUG|Tinidazole|500 mg tablet
214858350|NCT03776292|OTHER|monitoring|Primary outcome; composite 1ry outcome \[1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring\] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)\] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.
214858351|NCT05667350|OTHER|Blood drawing|Blood drawing before anti-cancer therapy
214290524|NCT02338531|PROCEDURE|Breast cancer surgery|
214858352|NCT05667350|OTHER|Blood drawing|Blood drawing before radical treatment
214290525|NCT01083576|DRUG|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
214858353|NCT02168725|DRUG|briciclib|
214858354|NCT00492765|DRUG|Interferon-beta-1a|dosage and frequency as per label
214858355|NCT00492765|DRUG|Simvastatin|dosage and frequency as per Biogen Idec protocol
214858356|NCT00492765|DRUG|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
214858357|NCT02359201|DRUG|V0018|Oromucosal - Single dose
214858358|NCT02359201|DRUG|Placebo|Oromucosal - Single dose
214858359|NCT03858218|OTHER|questionnaires set|questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)
214858360|NCT03043118|OTHER|Variety Intervention|Vegetable flavor variety created with multiple herb and spice blends
214858361|NCT04107142|BIOLOGICAL|Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell|Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
214858362|NCT02687360|DEVICE|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
214858363|NCT02687360|DEVICE|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
214858364|NCT03184220|PROCEDURE|Physiotherapy treatment|"The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~* Suboccipital induction~* Posterior elongation of the cervical fascia in Supine position~* Assisted cervical fascia~* Myofascial induction of sternocleidomastoid"
214858365|NCT03184220|PROCEDURE|Physiotherapy treatment|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
214858366|NCT03885882|DRUG|E0302 SR1|E0302 SR1, oral tablet.
214858367|NCT03885882|DRUG|E0302 SR3|E0302 SR3, oral tablet.
214858368|NCT03885882|DRUG|E0302 SR2|E0302 SR2, oral tablet.
214858369|NCT03885882|DRUG|E0302 IR|E0302 IR, oral tablet.
214858370|NCT04668976|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
214858371|NCT04668976|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
214858372|NCT04668976|DRUG|Gemcitabine|Please see Detailed Description.
214858373|NCT04668976|DRUG|Oxaliplatin|Please see Detailed Description.
214858374|NCT04668976|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
214858375|NCT04668976|DRUG|Fluorouracil|Please see Detailed Description.
214858376|NCT04668976|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
214858377|NCT05483582|DEVICE|4-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
214858378|NCT05483582|DEVICE|2-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
214858379|NCT05198882|PROCEDURE|Laser technology for intracerebral thermocoagulation|One intervention : LITT (Laser Interstitial Thermal Treatment), technology that uses laser energy to thermally destroy (photo-thermal treatment) a brain injury under continuous MRI control (Validated by FDA - CE marking). The operator console + surgical laser generator + software that manages the power delivered by the laser is connected to an MRI - Provided by MEDTRONIC - FDA approved and CE certified.
214858380|NCT02989168|DRUG|GBT440|GBT440: Capsules which contain GBT440 drug substance in Swedish orange
214858381|NCT05739968|OTHER|Usual care + oncology case manager (OCM) care|Usual care + oncology case manager (OCM) care
214858382|NCT05739968|OTHER|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
214858383|NCT00356980|BIOLOGICAL|colloidal gold-bound tumor necrosis factor|
214858384|NCT00356980|OTHER|pharmacological study|
214858385|NCT04788160|OTHER|Cervical SNAGs along with conventional therapy|"cervical SNAG half rotation technique will be performed with the patient sitting on a chair in the erect posture. The therapist placed his thumb over thumb over the transverse process of C1. Then, he glided ventrally with active rotation of the restricted site 10 times holding for 10 seconds with overpressure at end of the rotation with 30 second rest in between each repetition and 3 session/week for 4 weeks.~* Conventional therapy will include:~* Hot pack over the cervical region for 10 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions with 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be done 10 times in sitting position."
214858386|NCT04788160|OTHER|Conventional Therapy|"* Patients in this group will undergo only conventional therapy which will include:~* Hot pack for 15 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions each 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be given to the patient by the therapist, 10 times in sitting position."
214858387|NCT01846273|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab
214858388|NCT01846273|DRUG|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
214858389|NCT01846273|DRUG|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
214858390|NCT00005765|DRUG|nicotine|
214858391|NCT00005765|DRUG|alcohol|
214858392|NCT03431974|DRUG|LD-Aminopterin oral capsule|anti-folate treatment
214858393|NCT03431974|DRUG|Placebo oral capsule|Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
214858394|NCT01520974|OTHER|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
214858395|NCT01520974|OTHER|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
214858396|NCT02379286|OTHER|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
214858397|NCT03440541|COMBINATION_PRODUCT|REGE pro|REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
214858398|NCT00456495|DRUG|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
214858399|NCT02939014|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
214858400|NCT05183295|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food
214858401|NCT03738514|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks
214858402|NCT03738514|OTHER|5% potassium nitrate dentifrice|5% potassium nitrate dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
214858403|NCT03738514|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks
214858404|NCT03436914|DRUG|PPI|After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
214858405|NCT05147038|DEVICE|Tele-coaching|"The participants are instructed to use a Fitbit fitness tracker to record the number of steps. This device is compatible with the m-PAC App, which was developed for this specific group of participants (individuals suffering from a chronic lung disease). The participants receive a feedback via the m-PAC App every day and they also receive a week report to be albe to adjust their step goal. They are asked to increase or keep their week goal every Sunday after reviewing a weekly report. The participants also receive tips for their PA improvement and they are asked for medication change specification (every Wednesday)."
214858406|NCT03244423|DRUG|Normal saline at induction|0.5 ml/kg
214858407|NCT03244423|DRUG|Normal saline infusion|1ml/kg/hr. during surgery for six hours
214858408|NCT03244423|DRUG|Intravenous tranexamic acid|50 mg/kg
214858409|NCT03244423|DRUG|infusion tranexamic acid|1mg/kg/hr infusionfor 6 hours
214858410|NCT03244423|DRUG|topical tranexamic acid|50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure
214858411|NCT03244423|DRUG|topical normal saline|2 ml/kg into the pericardial cavity before sternal closure
214858412|NCT03515902|DEVICE|mouthguard|mouthguard
214858413|NCT03515902|DEVICE|mouthguard with desensitizing toothpaste|mouthguard with desensitizing toothpaste containing 8% arginine with calcium carbonate
214858414|NCT03014336|DEVICE|memsorb|memsorb is a CO2 filter replacing current chemical CO2 absorbers
214858415|NCT02599259|DEVICE|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
214858416|NCT01806038|OTHER|RPh Counseling + Outpatient Med Dispensing at Discharge|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
214858417|NCT01806038|OTHER|Discharge Med Dispensing Plus Counseling - Current Practice|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
214858418|NCT01252875|PROCEDURE|Target : 100 mg/dL (+/-10 mg/dL)|Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
214858419|NCT01252875|PROCEDURE|70 mg/dL|Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
214858420|NCT05128370|OTHER|Visual observation of arm swing during walking|The gait pattern of the stroke patients will be scored based on a visual observation scale. Additional components concerning the arm swing have been added to an existing scale.
214858421|NCT00377507|DIETARY_SUPPLEMENT|catechin extracts|catechin extracts solution
214858422|NCT04407078|DRUG|Sugammadex Injectable Product|Sugammadex of 2 mg/kg is injected.
214858423|NCT04407078|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
214858424|NCT05344651|DEVICE|Surgery/implantation|The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
214858425|NCT05099523|PROCEDURE|taking arterial blood sample through the injector|taking blood samples from patients applied with different oxygen concentrations
214858426|NCT01858987|PROCEDURE|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
214858427|NCT01858987|PROCEDURE|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
214858428|NCT01858987|DEVICE|Ligasure|
214858429|NCT01858987|OTHER|vascular staple|
214858430|NCT00004135|BIOLOGICAL|filgrastim|
214858431|NCT00004135|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214858432|NCT00004135|DRUG|cyclophosphamide|
214858433|NCT00004135|DRUG|fludarabine phosphate|
214858434|NCT00004135|PROCEDURE|peripheral blood stem cell transplantation|
214907041|NCT05341219|PROCEDURE|Light needle therapy|The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
214907042|NCT05341219|PROCEDURE|Sham light needle therapy|The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
214858435|NCT05069155|BEHAVIORAL|Gamification|Each participant signs a pre-commitment contract agreeing to try their best to achieve their daily step goal. Each week over the 12 week intervention period, participants are endowed 70 points (10/day). Participants are informed they will lose 10 points for each day the step goal is not met. Points are replenished at the start of the week. At the end of the week, if the participant has 40 points or more, he/she will advance one level, or drop one level if they have less than 40 points. The levels include: blue (lowest), bronze, silver, gold, platinum (highest). Each participant begins in the middle (silver). Each participant will also select a spouse, family member, or friend that they see often to serve as a supportive sponsor that receives a weekly email participants progress including points, game level, and average step countThis supportive sponsor will help to enhance social incentives to motivate the individual towards his or her goal.
214290526|NCT01083576|DRUG|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
214290527|NCT01970449|BIOLOGICAL|DNA Nat-B env vaccine|The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
214290528|NCT01970449|BIOLOGICAL|NYVAC Nat-B env vaccine|NVYAC Nat-B env vaccine will be administered as a 3 × 10\^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
214290529|NCT01970449|BIOLOGICAL|DNA CON-S env vaccine|The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
214858436|NCT03940482|BEHAVIORAL|Time Restricted Eating As Treatment (TREAT) for Diabetes.|Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
214858437|NCT05181826|DIAGNOSTIC_TEST|Multi-analyte Blood Test|Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer
214858438|NCT00290394|DRUG|rosiglitazone(drug), blood pressure lowering effect|
214858439|NCT06142149|PROCEDURE|ultrasonographic evaluation|Screen the front of neck using ultrasound
214858440|NCT04209010|PROCEDURE|one-stage technique|breast reconstruction in one stage using silicone implant and acellular dermal matrix.
214858441|NCT04487002|PROCEDURE|surgical resection|
214858442|NCT02925585|OTHER|Pre/post imaging|
214858443|NCT02674061|BIOLOGICAL|Pembrolizumab|Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle
214858444|NCT02700711|DRUG|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
214858445|NCT02700711|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
214858446|NCT02700711|DRUG|Duloxetine|The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
214858447|NCT04356118|DRUG|Recombinant Human Endostatin|endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.
214858448|NCT04356118|DRUG|intrathcal methotrexate|Intrathecal chemotherapy specified dose on specified days.
214858449|NCT04356118|DRUG|Targeted drugs for non-small cell lung cancer|EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .
214858450|NCT01649466|DRUG|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
214858451|NCT01649466|DRUG|Protaphane|Protaphane will be used as commercially available injection pens
214858452|NCT05709977|OTHER|Acupuncture|Fixed set of acupuncture points
214858453|NCT05709977|DRUG|Antihistamine nasal spray|Carelastin® (1 mg/ml) azelastine nasal spray
214858454|NCT04183647|DEVICE|whole body vibration / local vibration|Both the whole-body vibration application and the local vibration application will be applied to the patients in our cross-over study. Between the two applications will be given a washout period of one week. Patients will be evaluated both local and whole body vibration applications, 1 minute and 60 minutes after the end of the applications. After the evaluation, the patient will be rested in the sitting position until the evaluation at the 60th minute.
214858455|NCT02706782|DRUG|TAI-meso-CART|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
214858456|NCT04407494|BIOLOGICAL|Reporting of anosmia, ageusia and other clinical symptoms|Reporting of anosmia, ageusia and other clinical symptoms related to COVID-19 - CODA test - SARS-CoV2 RT-PCR and ELISA
214858457|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
214858458|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
214858459|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
214290530|NCT01970449|BIOLOGICAL|NYVAC CON-S env vaccine|NVYAC CON-S env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
214858460|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
214858461|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
214858462|NCT04014855|DRUG|Iron Supplement|in iron deficiency anemia
214290531|NCT01970449|BIOLOGICAL|DNA Mosaic env vaccine|The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
214290532|NCT01970449|BIOLOGICAL|NYVAC Mosaic env vaccine|NVYAC Mosaic env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
214858463|NCT05834166|OTHER|Upper back strengthening and Postural correction|The treatment protocol will involve upper back strengthening exercises and postural correction exercises 3 times a week for 10 to 15 minutes. Upper back strengthening will involve exercises with light-to-moderate load of free weights (body weight or resistance bands) or with a stability ball. Postural correction will involve maintaining the correct posture.
214858464|NCT05662735|DEVICE|Mesh repair|Augmentation of hiatal hernia repair with TiMESH® reinforcement
214858465|NCT05662735|PROCEDURE|Suture repair|Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures
214290533|NCT01970449|BIOLOGICAL|Placebo|Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
214858466|NCT02945605|OTHER|Early Vestibular Rehabilitation|"Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~1. Eye-Head coordination, gaze stability and convergence exercises~2. Sitting balance~3. Standing static balance (i.e. feet-in-place)~4. Dynamic balance (feet moving, but not walking)~5. Ambulation (gait exercises)~6. Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others"
214858467|NCT02945605|OTHER|Standard of Care|Standard care as directed by a physician.
214858468|NCT00057213|DRUG|Radafaxine|
214858469|NCT02527018|DEVICE|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
214858470|NCT01250483|OTHER|PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography|
214858471|NCT03606876|DRUG|BAT1806 injection|Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
214858472|NCT03676699|DIAGNOSTIC_TEST|Ultrasound chest|Ultrasound detection of extravascular lung water
214858473|NCT00050232|DRUG|AVP-923|
214858474|NCT02757976|DEVICE|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave \> 7 mV, pacing threshold \< 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
214290534|NCT01970449|DEVICE|Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)|All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
214858475|NCT02757976|DEVICE|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
214858476|NCT06357663|OTHER|Mindfulness practice with Calligraphy|The unique style of Art Meditation where mindfulness (heightened awareness) is achieved by combination of movement and focus on Chinese Tao Calligraphy while chanting a mantra. The practitioners repeatedly trace the lines of Tao calligraphy with fingers and chant the mantra. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age.
214858477|NCT05336110|OTHER|Postponing surgery|Postponing surgery for patients with Sars-cov-2 infection
214858478|NCT01558297|BEHAVIORAL|Motivational Interviewing|5 sessions of motivational interviewing over a period of 3 months.
214858479|NCT01558297|BEHAVIORAL|Nutritional Counseling|5 sessions of nutritional counseling over a period of 3 months.
214858480|NCT01558297|BEHAVIORAL|Treatment as usual with primary care physician|Participants will be encouraged to continue their care with their primary care physician.
214858481|NCT02553278|DEVICE|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
214858482|NCT02553278|DEVICE|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
214858483|NCT00001253|BEHAVIORAL|cognitive tests and scales|
214858484|NCT03231319|PROCEDURE|Fascia iliaca compartment block with IV-PCA|1\. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.
214858485|NCT03231319|PROCEDURE|Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA|"1. Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.~2. Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL"
214858486|NCT03231319|PROCEDURE|IV-PCA|IV-PCA was programmed and provided to the patient for optimize pain control
214858487|NCT01334710|DRUG|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
214858488|NCT06881498|PROCEDURE|acute normovolemic hemodilution|The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
214858489|NCT05301530|DRUG|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
214858490|NCT05301530|DRUG|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
214858491|NCT05301530|DRUG|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
214858492|NCT06716879|DRUG|Donzakimig|Drug: Donzakimig Pharmaceutical form: Subcutaneous solution
214858493|NCT06716879|DRUG|Placebo|Drug: Placebo Pharmaceutical form: Subcutaneous solution
214858494|NCT00375492|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
214858495|NCT00375492|DRUG|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
214858496|NCT01937247|PROCEDURE|Patients will be inducted in the induction room|The patients will be inducted in the induction room
214858497|NCT01937247|PROCEDURE|Redesigned process|The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room
214858498|NCT01937247|DRUG|patient will be reversed with sugammadex 4mg/kg IV|The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR
214858499|NCT01937247|PROCEDURE|STANDARD PROCESS|standard process
214858500|NCT04339751|DRUG|Vorinostat|Administration of Vorinostat
214858501|NCT01232491|DRUG|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
214858502|NCT01232491|DIETARY_SUPPLEMENT|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
214858503|NCT06928857|DEVICE|EMG-based FES rehabilitation|Each subject will receive 15 individual rehabilitation sessions, each lasting 60 minutes, conducted 3 to 5 times per week over a period of 5 to 3 weeks, depending on the weekly frequency. Each participant will perform task-oriented exercises while using the FitFES device.
214858504|NCT06928857|OTHER|Traditional rehabilitation|Each subject will receive 15 individual rehabilitation sessions, each lasting 60 minutes, conducted 3 to 5 times per week over a period of 5 to 3 weeks, depending on the weekly frequency. Each participant will perform task-oriented exercises.
214858505|NCT06927908|PROCEDURE|Partial Cardiac Denervation|Expose the ligament of Marshall (LOM) between the left atrial appendage and left pulmonary veins, and transect it using an electrocautery knife. Expose the fatty pad along the Waterston groove between the right pulmonary veins and the right atrium, and completely resect it down to the myocardial surface, extending the superior margin beyond the ostium of the right superior pulmonary vein and the inferior margin to the inferior vena cava.
214858506|NCT00885014|BEHAVIORAL|CBT|Telephone cognitive-behavioral therapy
214858507|NCT00885014|BEHAVIORAL|EAP|Employees Assistance Program
214858508|NCT05565339|DEVICE|PMEIs|"To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed.~To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated."
214858509|NCT01706874|OTHER|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
214858510|NCT06912906|PROCEDURE|BIPAPasynchro: byphaisc positive pressure modality without any synchronisation|Patients will be switched to byphaisc positive pressure modality without any synchronisation (BIPAPasynchro) as soon as they are considered to be ready to initiate the weaning phase from mechanical ventilation. Lausanne adult intesive care physicians will be provided a protocol to help guide them with the setting of BIPAPasynchro, as this is different from standard clinical pratice.
214858511|NCT06928285|OTHER|Technology Enriched Rehabilitation|The intervention is an 8-week long rehabilitation programme delivered entirely through technology, including virtual reality (immersed and non-immersed), treadmills, weight suspension and movement resistance, and power assistance equipment located in a gym-like space on a university campus. Individual programs are designed, supervised, and reviewed by a physiotherapist using principles of intensity, feedback, cognitive engagement, and aerobic activity to address the goals identified by the participant and scores from outcome measures at baseline. Participants should attend a minimum of two times per week and can more frequently for the two hour group based circuit class.
214907043|NCT02380586|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
214907044|NCT00170781|DRUG|Lumiracoxib|
214907045|NCT03205319|DEVICE|e-learning|The e-learning for patients is a user friendly, audiovisual based, online-accessible program, designed especially for this study. The e-learning will contain information on dyspepsia and advice on lifestyle interventions
214858512|NCT06927323|OTHER|Otago exercise program|The Otago Exercise Program is composed of strength training and balance training. Strength training consisted of flexion and extension exercises of the knee, ankle, and toe joints, as well as hip opening exercises to strengthen the sides of the pelvis. Balance training consisted of walking backwards, walking in a figure of eight, heel-toe walking, standing on one leg, walking on the heels, walking on the toes, heel-toe walking backwards, standing up from a sitting position, and walking up stairs. Otago exercise program will be performed with action observation train will be instructed to watch a video on a 22-inch screen positioned 1 meter away from them, while comfortably seated in a chair with armrests. They are not allowed to follow along or engage in any movement while watching the video.
214858513|NCT06927531|OTHER|sacral massage|During labor, pregnant women will be given effleurage (stroking) and vibration (vibration) techniques to the sacral region in a comfortable position during contractions, once an hour for a maximum of 10 minutes.
214858514|NCT06927531|OTHER|pilates ball|During labor, pregnant women will be given pelvic oscillation movements (a full rotation of the hips, going right/left, coming forward and backward, lightly bouncing on a ball while holding onto the headboard) once an hour during the active phase of labor.
214858515|NCT06928363|DRUG|KY-0301|KY-0301 is an antibody-drug conjugate (ADC) targeting both EGFR and c-Met, developed independently by Novatim Immune Therapeutics (Zhejiang) Co., Ltd
214858516|NCT06927063|DIAGNOSTIC_TEST|blood-based protein biomarker assessments|Assessment of multiple blood-based biomarkers of different cellular origin and inflammatory mediators
214858517|NCT06927063|DIAGNOSTIC_TEST|blood-based metabolomic/lipidomic biomarker assessments|Assessment of multiple blood-based TBI-related metabolomic and lipidomic biomarkers
214858518|NCT06927063|DIAGNOSTIC_TEST|Diffusion-weighted magnetic resonance imaging (brain)|Diffusion-weighted magnetic resonance imaging
214858519|NCT06927063|DIAGNOSTIC_TEST|Structural magnetic resonance imaging (brain)|Structural magnetic resonance imaging
214858520|NCT06927063|DIAGNOSTIC_TEST|PET imaging (brain)|Positron emission tomography imaging
214858521|NCT06927063|PROCEDURE|Standard colonoscopy with pinch biopsies|Standard colonoscopy including pinch biopsies from the bowel wall at several levels (terminal ileum, ascending colon, transverse colon, descending colon, and rectosigmoideum) for histology, microbiome analysis and metabolomics
214858522|NCT06927063|DIAGNOSTIC_TEST|Fecal microbiome assessments|Fecal microbiome assessments (DNA)
214858523|NCT03261102|BIOLOGICAL|Adalimumab|
214858524|NCT03755336|OTHER|Administered Slip Perturbations|Participants will be exposed to a series of 12 unannounced slip perturbations while walking overground. These perturbations will be delivered at 3 different times within the gait cycle - early phase, middle phase, and late phase.
214858525|NCT01777919|DRUG|Temozolomide|already included
214858526|NCT01777919|DRUG|Disulfiram|already included
214858527|NCT01777919|DRUG|Copper|already included
214858528|NCT05060380|OTHER|Exercise training|Progressive muscle resistive exercise will be performed by the experimental group only. Control group will maintain their normal level of daily activity.
214858529|NCT05296265|BEHAVIORAL|VR treatment for phantom limb pain|8 twice-weekly interventions of 1 hour; baseline, pre-intervention; immediately after the end of the in intervention; 1 week after the end of the intervention; 8 weeks after the end of the intervention
214858530|NCT06422130|OTHER|Pregnant women and their offspring without intervention|Pregnant women and their offspring with those exposures of interest determined in specific research based on the database
214290535|NCT05109039|DIETARY_SUPPLEMENT|Creatine|Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
214858531|NCT03821935|DRUG|Livmoniplimab|Liquid for intravenous infusion.
214858532|NCT03821935|DRUG|Budigalimab|Lyophilized powder for solution for intravenous infusion.
214858533|NCT04989803|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
214858534|NCT04989803|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
214858535|NCT04989803|BIOLOGICAL|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
214858536|NCT04989803|BIOLOGICAL|KITE-753|A single infusion of CAR-transduced autologous T cells administered intravenously
214858537|NCT05633706|DEVICE|fluid biopsy capsule|Collection of a fluid biopsy from the small intestine via ingestible capsule
214858538|NCT02418143|DEVICE|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
214858539|NCT03664648|BIOLOGICAL|HEPLISAV-B|This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
214858540|NCT00285948|DEVICE|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
214858541|NCT04041622|DIAGNOSTIC_TEST|Endoscopy and biopsy|Participants with a positive celiac serology are assessed by endoscopy and duodenal biopsy
214858542|NCT04845074|PROCEDURE|TSA-group|Anatomical total shoulder arthroplasty followed by standard rehabilitation.
214907046|NCT04088812|OTHER|Placebo meat derivative + Placebo satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water
214290536|NCT05109039|DIETARY_SUPPLEMENT|Placebo|Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
214290537|NCT03992157|DEVICE|ECG telemetry|ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
214290538|NCT00337506|DRUG|Dexamethasone|
214290539|NCT00337506|DRUG|velcade|
214290540|NCT02478801|DIETARY_SUPPLEMENT|amino acids intake|amino acids intakes will be varied at 0.2-2.8 g/kg/day
214907047|NCT04088812|OTHER|Placebo meat derivative + Satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water
214907048|NCT04088812|OTHER|Experimental meat derivative + Placebo satiating control|Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water
214290541|NCT01018368|DRUG|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
214290542|NCT01018368|DRUG|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
214858543|NCT04845074|OTHER|Exercise-group|The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
214858544|NCT03174951|DRUG|IVIg|Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
214858545|NCT04626453|BEHAVIORAL|2-month home moderate-intensity exercise|The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
214858546|NCT06133803|DRUG|Lovenox|A low-molecular-weight heparin, 40mg daily injection.
214858547|NCT06133803|DRUG|Aspirin|Aspirin 81mg daily tablet.
214858548|NCT06133803|PROCEDURE|Embryo transfer|Embryo transfer
214858549|NCT05568979|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
214858550|NCT05568979|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
214858551|NCT03340064|DRUG|Levetiracetam|levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)
214858552|NCT02151812|DEVICE|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
214858553|NCT02151812|DEVICE|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
214858554|NCT01475006|DRUG|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
214858555|NCT04325152|DEVICE|FCSEMS plus Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
214858556|NCT04325152|DEVICE|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
214858557|NCT04798365|BEHAVIORAL|Intervention group|medical education and distribution of educations materials
214858558|NCT01369017|DRUG|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
214858559|NCT01369017|DRUG|Placebo|Injection of NS
214858560|NCT00997139|DRUG|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
214858561|NCT00313443|PROCEDURE|Fat tissue needle aspiration|Small fat tissue sampling performed by needle aspiration.
214858562|NCT00787579|DEVICE|Bifocal spectacles|+1.50D bifocal spectacles
214858563|NCT00787579|DEVICE|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
214858564|NCT06360068|DRUG|Sulfasalazine Tablets|All subjects who meet the inclusion/exclusion criteria will be given sulfasalazine 750mg/dose, twice a day. The dosage will be increased to 1000mg/dose within one month, twice a day if the patient tolerates well.
214858565|NCT03017118|DIETARY_SUPPLEMENT|Turmeric|Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
214858566|NCT03017118|OTHER|Placebo|Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
214858567|NCT01651143|DRUG|SAR100842|"Pharmaceutical form: tablets~Route of administration: oral"
214858568|NCT01651143|DRUG|Placebo (for SAR100842)|"Pharmaceutical form: tablets~Route of administration: oral"
214858569|NCT04097171|OTHER|Diet|Participants will consume each diet for 14 days in a crossover design.
214858570|NCT04386174|OTHER|Neurofeedback|Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
214858571|NCT00968760|PROCEDURE|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
214858572|NCT00968760|PROCEDURE|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
214858573|NCT00968760|PROCEDURE|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
214858574|NCT00968760|DRUG|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10\^6 U/m\^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
214858575|NCT00968760|DRUG|Carmustine|300 mg/m\^2 IV over 1 hour on Day -6
214858576|NCT00968760|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours every 12 hours on Days -5 to -2
214858577|NCT00968760|DRUG|Cytarabine|200 mg/m\^2 by vein over 1 hour every 12 hours on Days -5 to -2.
214290543|NCT02683889|DRUG|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
214290544|NCT01948050|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|
214290545|NCT02651298|DEVICE|Fractional Co2-laser|laser treatment
214858578|NCT00968760|DRUG|Melphalan|140 mg/m\^2 IV over 30 minutes on Day -1
214858579|NCT03582761|BIOLOGICAL|EV71 vaccine|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
214858580|NCT05253365|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
214858581|NCT00856973|DRUG|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
214858582|NCT00856973|DRUG|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
214858583|NCT00856973|DRUG|Placebo|1 tablet per day for 12 weeks
214858584|NCT03257033|DRUG|Gemcitabine|Chemotherapy
214858585|NCT03257033|DRUG|nab-paclitaxel|Chemotherapy
214858586|NCT03257033|DEVICE|RenovoCath|Intra-arterial catheter
214858587|NCT05079386|DEVICE|New Voice Prosthesis|Replacement of the current prosthesis with the experimental device and use the New Voice Prosthesis for the duration of two weeks with the option of leaving the device in situ until replaced for device failure or other reason, with a maximum of 12 months.
214858588|NCT02664363|BIOLOGICAL|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
214858589|NCT02813057|PROCEDURE|Stoppa inguinal hernia repair|Stoppa inguinal hernia repair
214858590|NCT02813057|PROCEDURE|Total extraperitoneal inguinal hernia repair|Total extraperitoneal inguinal hernia repair
214858591|NCT00865618|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
214858592|NCT00865618|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
214858593|NCT00409318|DRUG|Etanercept|50 mg SC q week
214858594|NCT00409318|DRUG|Placebo|SC q week
214858595|NCT03075319|PROCEDURE|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
214858596|NCT03075319|PROCEDURE|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
214858597|NCT03561441|DRUG|Tailored aggressive hydration|"1. Hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg for 1 hour after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the upper normal limit (UNL), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
214858598|NCT03561441|DRUG|Tailored standard hydration|"1. Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
214290546|NCT00909116|PROCEDURE|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
214290547|NCT02099357|DIETARY_SUPPLEMENT|Creatine|Daily supplementation with 3g of monohydrate creatine during 8 weeks
214290548|NCT02099357|DIETARY_SUPPLEMENT|Placebo|
214290549|NCT02099357|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D supplementation with 25000 IU each two weeks during eight weeks
214858599|NCT02431819|DEVICE|contention socks|Patients wear contention socks during 15 days.
214858600|NCT05795179|BEHAVIORAL|Cold-Pressor Task (CPT)|CPT is a physiological stress task in which participants continuously submerge their hand and forearm in ice-water (0-4°C) for 3 minutes.
214858601|NCT05795179|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges.
214858602|NCT05795179|BEHAVIORAL|Modified Non-Stress CPT|The modified non-stress CPT involves participants continuously submerging their hand and forearm in warm water for 3 minutes.
214907049|NCT06284369|BEHAVIORAL|Developing, Evaluating and Testing Video Messages for a Smoking Cessation Campaign|To explore how smokers reacted to the gain-framed and loss-framed video ad
214907050|NCT06284369|BEHAVIORAL|Health Message Framing|Gain- framed messages in health communication are constructed by framing a particular outcome as either a benefit or a cost, relative to a specific reference poin
214290550|NCT01314443|OTHER|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
214290551|NCT01314443|DIETARY_SUPPLEMENT|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
214290552|NCT01314443|OTHER|Placebo|Participants will take placebo for 7 days
214290553|NCT01314443|BEHAVIORAL|Smoking cessation|Participants will quit smoking without any pharmacological aids
214290554|NCT01072812|DRUG|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
214858603|NCT05795179|BEHAVIORAL|Modified Non-Stress TSST|For the modified non-stress TSST, participants are asked to prepare for a speech that they will practice alone to themselves and complete math problems alone on a piece of scrap paper.
214858604|NCT05795179|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|Participants will complete the self-control task in the fMRI scanner.
214858605|NCT04125121|DRUG|Sevoflurane-propofol|General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
214858606|NCT03667079|OTHER|integrated delivery of deworming and vaccination|integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)
214858607|NCT03667079|OTHER|Mass deworming only|Delivery of mass deworming to people only
214858608|NCT03667079|OTHER|Mass vaccination of dogs|Delivery of mass vaccination of dogs only
214858609|NCT01192984|BIOLOGICAL|KW-0761|Intravenously 8 times at 1-week intervals
214858610|NCT01432418|OTHER|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
214858611|NCT01681602|OTHER|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
214858612|NCT03439852|BEHAVIORAL|Light-to-Moderate Physical Activity / Sedentary Time|12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
214858613|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock|CONTROL
214858614|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock|TEST
214858615|NCT04556552|DEVICE|Non invasive VN stimulation (nVNS)|"Stimulation of vagus nerve with active device. Participants will be administered nVNS using the electroCore GammaCore-S non-invasive VNS device. The intensity of the stimulus will be adjusted by the user, to the maximum tolerable level to ensure nVNS without causing excessive pain, the burst frequency to 5 kHz, and the envelope frequency to 25 Hz.~The duration of delivery will be 2 minutes, and the beginning will coincide with initiation of acquisition of the HR-PET scan which will be 90 seconds in duration; following an additional 8 minutes, a second VNS delivery will be administered, in conjunction with which another scan will be obtained."
214858616|NCT04556552|DRUG|Oxygen (15-O) Water|Injection of radiolabelled water. H2\[15-O\] is a radioactive material. Each patient will have eight H2\[15-O\] blood flow scans. For each O-15 water scan 20 mCi of H2\[15O\] will be injected as an intravenous bolus.
214858617|NCT04556552|DEVICE|Sham Stimulation|"Sham stimulation of vagus during opioid cue exposure. Each subject in the SHAM group will undergo the action of administering the intervention, but the device will be programmed such that the stimulation will not activate the vagus nerve."
214858618|NCT00033813|DRUG|Oxatomide (tinset)|
214858619|NCT05545618|DIAGNOSTIC_TEST|CCTA and 18F-FDG-PET/CT|18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days
214858620|NCT03734211|DRUG|Evolocumab|420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
214858621|NCT03734211|DRUG|Placebo|Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
214858622|NCT05962502|DRUG|Cetuximab and irinotecan|chemotherapy plus targeted therapy
214290555|NCT03097874|BEHAVIORAL|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
214858623|NCT02526511|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
214290556|NCT03097874|BEHAVIORAL|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
214476455|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.1 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.1 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
214858624|NCT02526511|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
214858625|NCT02526511|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
214858626|NCT02526511|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
214858627|NCT05892484|DEVICE|Thermal Imaging|Thermal Imaging device used to evaluate fracture in those presenting with proposed wrist fracture in the emergency department.
214858628|NCT05892484|DIAGNOSTIC_TEST|X-RAY|Routine X-RAY
214858629|NCT04802902|OTHER|home-based hospitalization|management in a hospital-at-home programme of patients treated by immunotherapy and chimiotherapy combo for bronchial cancer
214858630|NCT04774887|BIOLOGICAL|HPV vaccine, Merck|Vaccination against HPV will be offered to 900 children/grandchildren aged 9 through 18 of women attending the Community Meetings.
214858631|NCT01215513|DRUG|Degarelix|
214858632|NCT00054548|BIOLOGICAL|oblimersen sodium|Given IV
214858633|NCT00054548|DRUG|paclitaxel|Given IV
214858634|NCT00054548|OTHER|laboratory biomarker analysis|Correlative studies
214858635|NCT00054548|OTHER|pharmacological study|Correlative studies
214858636|NCT05732974|OTHER|Resected non small cell lung cancer|plasma sample, tissue sample and computed tomography scan images
214858637|NCT02016261|DRUG|Fluvoxamine|The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
214858638|NCT05001464|DEVICE|reflectance pulse oximeter|Wearing reflectance pulse oximeter at the same time on the night of PSG examination
214858639|NCT05807516|OTHER|Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)|Combined both retrospective and prospective observational design
214858640|NCT00712426|DRUG|Creatine Monohydrate|Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
214858641|NCT00712426|DRUG|Placebo|Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
214858642|NCT00709839|DRUG|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
214858643|NCT00709839|DRUG|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
214858644|NCT05174117|COMBINATION_PRODUCT|single irradiation|46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
214858645|NCT05174117|COMBINATION_PRODUCT|Double irradiation|46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
214858646|NCT02586142|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
214858647|NCT02586142|OTHER|Stretching exercise|After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
214858648|NCT00959361|BEHAVIORAL|pharmaceutical care|consultation with the pharmacists and usual care
214858649|NCT01825889|DRUG|Evacetrapib|
214858650|NCT03972449|BEHAVIORAL|BEAT-Speech|BEAT-Speech integrates beatboxing techniques within speech-therapy services for individuals with speech sound disorders.
214858651|NCT03972449|BEHAVIORAL|Traditional Articulation Approach|The traditional approach to treating speech sound disorders focus on one or two sounds at a time until they are mastered by the client. Perceptual and production training are used with target starting at simple (isolation) and moving to more complex (sentences). A variety of cues such as shaping and phonetic placement cues are used.
214858652|NCT00044109|DEVICE|Magnets|
214858653|NCT04524052|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
214858654|NCT04524052|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
214858655|NCT01857960|BEHAVIORAL|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
214858656|NCT00793780|DRUG|Naltrexone 25mg|Naltrexone 25mg caplets taken orally once a day for 8 weeks
214858657|NCT00793780|OTHER|Placebo|Placebo caplet (inactive substance) taken orally once a day for 8 weeks
214858658|NCT02858492|DRUG|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
214858659|NCT02858492|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
214858660|NCT02737982|PROCEDURE|percutaneous coronary intervention|coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion
214858661|NCT05837572|OTHER|Standardized meal|"Assessment of the validity of the ES-LFPQ: Each participant will complete the ES-LFPQ in before (fasted state) and after a standardized meal (fed state).~Evaluation of the reproducibility of the ES-LFPQ: With at least one week of difference between tests, each participant will repeat the same protocol performed in the previous visit and under the same conditions."
214858662|NCT01211704|DRUG|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
214858663|NCT01211704|DRUG|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
214858664|NCT00432302|DRUG|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg \[14C\]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
214858665|NCT00044421|DRUG|Ruboxistaurin mesylate|
214858666|NCT03365167|RADIATION|LANAP (Laser Assisted New Attachment Procedure)|radiation of Nd:YAG laser in periodontal pocket
214858667|NCT03365167|RADIATION|LANAP off|radiation of Nd:YAG laser in off mode in periodontal pocket
214858668|NCT04404946|OTHER|phenylephrine infusion|in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
214858669|NCT04404946|OTHER|norepinephrine infusion|in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
214858670|NCT04404946|OTHER|placebo infusion|in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
214858671|NCT00010192|BIOLOGICAL|rituximab|Given IV
214858672|NCT00010192|BIOLOGICAL|aldesleukin|Given SC
214858673|NCT00010192|OTHER|laboratory biomarker analysis|Correlative studies
214858674|NCT00010192|OTHER|pharmacological study|Correlative studies
214858675|NCT03838861|BEHAVIORAL|NEMO: NEw MOdel of follow-up|The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
214858676|NCT03783273|DIETARY_SUPPLEMENT|Vitamin D3|Single dose vitamin D3
214858677|NCT03783273|COMBINATION_PRODUCT|Whey protein-complex|Whey protein complex-bound vitamin D3
214858678|NCT03783273|OTHER|Water|500 mL water
214858679|NCT03783273|OTHER|Milk|500 mL milk
214858680|NCT03783273|OTHER|Juice|500 mL juice
214858681|NCT05649241|DRUG|Nicotine patch|Nicotine replacement therapy patch
214858682|NCT05649241|DRUG|Nicotine gum|Nicotine replacement therapy gum
214858683|NCT05649241|BEHAVIORAL|Medication Therapy Management|Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
214858684|NCT02452541|OTHER|Prognostic tests|"* Brain CT-Scan on day 1, 3 and 7~* Brain MRI on day 7~* SomatoSensory Evoked Potentials on day 7~* Electroencephalogram on day 7~* Serum biomarkers on day 1, 3 and 7~* Daily clinical exams"
214858685|NCT01097941|BIOLOGICAL|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
214858686|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
214858687|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
214858688|NCT00937378|DRUG|SER120|Nasal Spray, once a day
214858689|NCT00937378|DRUG|Placebo|Nasal Spray
214858690|NCT06444945|DEVICE|Heating pad|Heating pad will be used for heating purpose.
214858691|NCT06444945|DEVICE|Transcutaneous electrical nerve stimulation(TENS)|TENS is used for symptomatic pain relief
214858692|NCT06444945|PROCEDURE|Mulligan mobilization with movement (MWM)|It provides short term pain relief and to restore pain-free, functional movements by achieving full range at the joint
214858693|NCT06444945|PROCEDURE|Kaltenborn joint mobilization|The purpose of joint mobilization is to restore normal, painless joint function. In restricted joints, this involves the restoration of joint play to normalize the roll-gliding that is essential to active movement.
214858694|NCT06444945|PROCEDURE|Resistance Training exercise|Resistance training increases muscle strength by making your muscles work against a weight or force.
214858695|NCT05199168|PROCEDURE|intraoperative nerve monitoring|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
214858696|NCT03111914|DIAGNOSTIC_TEST|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
214858697|NCT01428050|DRUG|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
214858698|NCT01428050|DRUG|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
214858699|NCT02718508|BEHAVIORAL|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
214858700|NCT00926224|DEVICE|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
214858701|NCT04425538|DRUG|Infliximab|Either infliximab or infliximab-abda will be used at the discretion of the investigator
214858702|NCT04030065|DRUG|Omega 3 fatty acid|10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
214858703|NCT04259463|PROCEDURE|Third molars extraction|Third molars extractions with concious sedation or general anesthesia
214858704|NCT03512132|BIOLOGICAL|Blood samples|5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
214858705|NCT03512132|BIOLOGICAL|Urine sample|Urine sample on an empty stomach
214858706|NCT01271751|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
214858707|NCT01271751|DRUG|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
214858708|NCT01418963|DRUG|RO5285119|single and multiple ascending oral doses
214858709|NCT01418963|DRUG|placebo|single and multiple oral doses
214858710|NCT00276822|OTHER|communication intervention|Patient Education Programs to include surveys, questionnaires, interviews, and videos.
214858711|NCT03044717|OTHER|Nutrition survey|Survey will be done prior to the initiation of the education
214858712|NCT03044717|OTHER|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
214858713|NCT03044717|OTHER|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
214858714|NCT02188511|OTHER|Group A|90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to \< 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
214858715|NCT02188511|OTHER|Group B|On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
214858716|NCT02188511|OTHER|Group C|On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
214858717|NCT02188511|OTHER|Group D|On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
214907051|NCT02371538|DIETARY_SUPPLEMENT|Donor Breastmilk|Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
214907052|NCT03514732|DRUG|MELATONIN (MELATL07959)|Pharmaceutical form:Capsule Route of administration: Oral
214907053|NCT03695900|OTHER|Targeting SpO2 at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours
214858718|NCT02188511|OTHER|Group E|"On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).~Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine."
214858719|NCT02833545|DEVICE|Ozone gas|Injection of ozone gas intra articularly
214858720|NCT02833545|DRUG|Steroid injection|Injection of steroids (diprospan) intra articularly
214858721|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine|As a experimental vaccine for 6 months to 5 years old.
214858722|NCT06314685|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 6-11 months and 12-23 months.
214858723|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 2-5 years.
214858724|NCT01352130|DRUG|Ondansetron|Intravenous Ondansetron 8 mgs
214858725|NCT01352130|DRUG|Granisetron|Intravenous Granisetron 1 mgs
214858726|NCT04590066|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
214858727|NCT01327144|DRUG|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
214858728|NCT01327144|DRUG|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
214858729|NCT03376230|OTHER|Collect of blood, urines, and intestinal biopsies|
214858730|NCT00002639|DRUG|chemotherapy|
214858731|NCT00002639|DRUG|suramin|
214858732|NCT01445210|PROCEDURE|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
214858733|NCT01445210|PROCEDURE|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
214858734|NCT00719771|DEVICE|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
214858735|NCT02438852|OTHER|Placebo|Given IV
214858736|NCT02438852|OTHER|Questionnaire Administration|Ancillary studies
214858737|NCT02438852|DRUG|Ropivacaine Hydrochloride|Given IV
214858738|NCT06456736|OTHER|None, non-interventional study|Not applicable, non-interventional study
214858739|NCT03292536|DRUG|Merestinib|"\*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks"
214858740|NCT02040779|DRUG|Beclomethasone dipropionate breath-actuated inhaler|Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
214858741|NCT02040779|DRUG|Placebo breath-actuated inhaler|Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
214858742|NCT02040779|DRUG|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
214858743|NCT02132637|DRUG|Insulin Peglispro|Administered SQ
214858744|NCT02132637|DRUG|Insulin Glargine|Administered SQ
214858745|NCT02084602|DRUG|Artesunate|Orally administration of artesunate 4mg/Kg by three days
214858746|NCT02084602|DRUG|Mefloquine|Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
214858747|NCT00929890|BEHAVIORAL|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
214476456|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.15 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.15 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
214858748|NCT00929890|BEHAVIORAL|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
214858749|NCT03717714|DIETARY_SUPPLEMENT|Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
214858750|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 750 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
214858751|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
214858752|NCT03262727|DRUG|BMS-986165|Oral administration of specified dose on specified days
214858753|NCT03262727|DRUG|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
214858754|NCT01936519|DRUG|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
214858755|NCT01936519|DRUG|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
214858756|NCT05550883|OTHER|Aerobic exercise|The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.
214858757|NCT05550883|DRUG|Fibromyalgia Agents|tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
214858758|NCT03949244|DRUG|Latanoprost 0.005%|Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
214858759|NCT03949244|DRUG|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
214858760|NCT03949244|DRUG|Normal saline 0.9%|Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
214858761|NCT03949244|DIAGNOSTIC_TEST|Nailfold capillaroscopy|An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
214858762|NCT00605735|DRUG|BMS-582949|Tablets, Oral, 300 mg, once daily, 12 weeks
214858763|NCT00605735|DRUG|Placebo|Tablets, Oral, placebo, once daily, 12 weeks
214858764|NCT01916746|PROCEDURE|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
214858765|NCT04831372|PROCEDURE|Off Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a standard operating room table
214858766|NCT04831372|PROCEDURE|On Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a traction table
214858767|NCT02182869|DRUG|Combivent® HFA inhalation aerosol|
214858768|NCT02182869|DRUG|Combivent® CFC inhalation aerosol|
214858769|NCT04467268|BEHAVIORAL|Sleep extension|The sleep extension programme was designed around four alternative assumptions: 1) that among this group of habitual short sleepers, extending time in bed (TIB) would represent a significant behavioral change to established night-time and daytime routines; 2) that for practical purposes (accommodating personal, family and work schedules) extended time in bed is best anchored against typical rise-times; 3) that sleep onset may represent a particular challenge for those advancing habitual bed-times by over 1 hour each night; and 4) that in consenting to the trial, participants were motivated to make and sustain behavioral change.
214858770|NCT02017730|DRUG|BMS-986020|
214858771|NCT02017730|DRUG|[11C]BMT-136088|
214858772|NCT03687658|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
214858773|NCT00127036|DRUG|XELOX|XELOX: Oxaliplatin 130 mg/m\^2 intravenously (IV); Capecitabine 825 mg/m\^2 by mouth (po)
214858774|NCT00127036|DRUG|XELIRI|XELIRI: Irinotecan 240 mg/m\^2 IV; Capecitabine 825 mg/m\^2 by mouth (po)
214858775|NCT00127036|DRUG|Bevacizumab|7.5 mg/kg intravenously (IV)
214858776|NCT04126421|DEVICE|Prosthesis component (acetabular cup) E1 cup|Semented acetabuar cup With E1 cup
214858777|NCT04126421|DEVICE|Prosthesis component (acetabular cup) Marathon cup|Semented acetabuar cup With Marathon cup
214858778|NCT03195153|DRUG|Atorvastatin 80mg|30 DAYS OF atorvastatin 80 mg
214858779|NCT03195153|DRUG|ALLOPURINOL 300 MG|30 DAYS OF ALLOPURINOL 300 MG
214858780|NCT03195153|DRUG|Atorvastatin 80mg AND allopurinol 300 mg|30 days of atorvastatin and allopurinol 300 mg
214858781|NCT00635115|DEVICE|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
214858782|NCT00635115|DEVICE|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
214858783|NCT03233425|BEHAVIORAL|multiprofessional group therapy|Behavioural therapy of lifestyle including activity, family and eating habits
214858784|NCT02613325|DEVICE|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
214858785|NCT02613325|PROCEDURE|Standard of care surgical excision|
214858786|NCT02613325|DEVICE|Single cell photoacoustic microscopy|
214858787|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
214858788|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
214858789|NCT00626717|PROCEDURE|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
214858790|NCT00626717|PROCEDURE|Sham treatment|Fluorescein eye drops. Exposure with blue light
214858791|NCT00548938|DRUG|Gliadel wafer|Implanted at surgery
214858792|NCT00548938|DRUG|Temozolomide|During External Beam Radiation
214858793|NCT00548938|RADIATION|External Beam Radiation Therapy|60 Gy
214858794|NCT04415736|OTHER|No intervention, observational study|
214858795|NCT04763018|DEVICE|iTEAR100|Neurostimulation external nasal nerve to stimulate tear production
214858796|NCT04309318|PROCEDURE|Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
214858797|NCT04309318|PROCEDURE|High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
214858798|NCT02070302|DRUG|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
214858799|NCT02070302|DRUG|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
214858800|NCT02979236|DEVICE|STENTYS Xposition S|
214858801|NCT01431911|DRUG|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
214858802|NCT01431911|DRUG|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
214858803|NCT03656874|OTHER|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care
214858804|NCT00584844|BIOLOGICAL|Live F tularensis Vaccine|Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (\< 1:20).
214858805|NCT00797329|OTHER|chart review|"* cholesterol~* cognitive profiles~* violent behavior"
214858806|NCT01124357|DEVICE|NovaSure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
214858807|NCT01124357|DEVICE|thermachoice|ThermachoiceTM III thermal balloon ablation
214858808|NCT01195103|DRUG|Fospropofol disodium|10 mg/kg bolus
214858809|NCT01195103|DRUG|Fospropofol disodium|6.5 mg/kg bolus
214858810|NCT01195103|DRUG|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients \<60 kg; 1.5 mg for patients ≥60 kg to \<90 kg; or 2 mg for patients ≥90 kg
214858811|NCT01195103|DRUG|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
214858812|NCT03760250|DRUG|Imiquimod 5% cream|Imiquimod 5% Cream application to keloid skin area 5-times per week for 6 weeks, starting 1-week before keloid excision
214858813|NCT02302313|DEVICE|CO2 laser and ANI monitor|Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
214858814|NCT06014918|DEVICE|A new smart device application (Smart APS)|The application sends alarms to patients to enter their pain intensity and opioid-related side effects at the times set by the researcher. Additional entries for severe pain or opioid side effects are also available at any other time. Researchers can monitor the results in real-time via an integrated web program. If a red flag sign is observed during regular office hours, an anesthesiologist participating in the research will visit the patient for assessment and intervention. In addition, patients can watch pre-made perioperative pain-related educational videos through the smart APS.
214858815|NCT04629768|DEVICE|PuraStat|Purastat is applied to the EMR defect
214858816|NCT06304025|BIOLOGICAL|Wharton's jelly mesenchymal stem cells (WJ-MSCs)|Four doses of 1x10 6 of thawed allogeneic WJ-MSCs or expanding allogeneic WJ-MSCs / kg at 1, 4, 11, and 18 days
214858817|NCT03479463|BIOLOGICAL|Dehydrated human amnion/chorion membrane|Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
214858818|NCT01776463|DRUG|Z-360|
214858819|NCT01776463|DRUG|placebo|
214858820|NCT03710720|BEHAVIORAL|TIPS app|Psycho-educational electronic application
214858821|NCT03710720|BEHAVIORAL|Trauma Focused-Cognitive Behavioral Therapy|Effective form of trauma therapy for adolescents
214858822|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane blend|1.8 gram per day of lions mane, consisting of 3 x 600mg capsules
214858823|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane and reishi blend|1.8 gram per day of lions mane and reishi blend, consisting of 3 x 600mg capsules
214858824|NCT06406946|DIETARY_SUPPLEMENT|Placebo|1.8-gram microcrystalline cellulose placebo powder, 3x600mg capsules
214858825|NCT05885191|OTHER|2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture|Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours. The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.
214858826|NCT05483387|DEVICE|Treatment with HBS 2 Resorb Mg|Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
214858827|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
214858828|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
214858829|NCT04355949|DIAGNOSTIC_TEST|Serum vitamin D, vitamin B12, folic acid|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
214858830|NCT00857259|DRUG|Everolimus|5 mg oral tablet
214858831|NCT00857259|DRUG|Ranibizumab|0.5 mg administered by intravitreal injection
214858832|NCT02701413|DEVICE|ApexM (Stimulation) Device|Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
214858833|NCT02701413|DEVICE|Sham Device|A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
214858834|NCT01370213|DRUG|Preparative Regimen|"Preparative Regimen:~1\) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,"
214858835|NCT01370213|BIOLOGICAL|NK Cells|CD3\^- CD19\^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
214858836|NCT01370213|DRUG|Interleukin-2|Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
214907054|NCT03695900|OTHER|Targeting SpO2 at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
214858837|NCT01370213|BIOLOGICAL|CD34 Graft/Anti-thymocyte globulin|Single donor filgrastim mobilized CD34+ selected peripheral blood stem cell graft (minimum cell dose of 5 x 10\^6/kg) on day 0. Rabbit anti-thymocyte globulin (ATG) will be administered on day -1 (0.5 mg/kg) and day +1 and +2 (2.5 mg/kg) pretransplant per institutional guidelines. ATG dosing not identical for all patients.
214858838|NCT01370213|BIOLOGICAL|Donor TCR α/β-depleted Graft/ATG|Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10\^6/kg) on day 0. ATG will be administered on days -6 and -5 (3mg/kg) for most patients.
214858839|NCT04026685|DRUG|Phenylephrine infusion|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
214858840|NCT04026685|DRUG|Phenylephrine infusion and Ringer-Acetate bolus|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
214858841|NCT05146349|OTHER|Minnesota RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
214858842|NCT00887328|DRUG|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
214858843|NCT00887328|DRUG|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
214858844|NCT03804398|DEVICE|compliance guided an optimal Positive End-Expiratory Pressure|The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
214858845|NCT03804398|DEVICE|PEEP level of 5 cmH2O|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
214858846|NCT01227655|DRUG|BIA 9-1067|Capsules will be used.
214858847|NCT01227655|DRUG|Placebo|comparator
214858848|NCT01227655|DRUG|Levodopa|
214858849|NCT01227655|DRUG|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
214858850|NCT01227655|DRUG|Benserazide|DOPA decarboxylase inhibitor
214858851|NCT01095679|DRUG|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
214858852|NCT01095679|DRUG|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
214858853|NCT05291455|DRUG|Lacosamide|lacosamide will be given
214858854|NCT05291455|DRUG|Phenobarbital|phenobarbital will be given
214858855|NCT04535752|DRUG|ANX009|Single or multiple ascending dose
214858856|NCT04535752|DRUG|Placebo|Single or multiple ascending dose
214858857|NCT04445220|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
214858858|NCT00472797|DRUG|Rebif New Formulation Non Titrated|human interferon beta 1a - Rebif New Formulation
214476457|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.2 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.2 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
214476458|NCT04681638|DRUG|Pathogen-Reduced Plasma|The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL\*kg\*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
214858859|NCT00472797|DRUG|Rebif New Formulation Titrated|Human interferon beta 1a Rebif New Formulation
214858860|NCT05351814|OTHER|Exercise|While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
214858861|NCT04647669|DRUG|Remdesivir|200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
214858862|NCT04647669|DRUG|Acalabrutinib|100 mg capsules twice daily every 12 h for 10 days taken with or without food.
214858863|NCT04647669|DRUG|Interferon beta-1a|Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
214858864|NCT04647669|OTHER|Standard of Care|Treatment according to local hospital protocol
214858865|NCT03077906|OTHER|Medical Files data extraction|Medical Files data extraction
214858866|NCT05747521|DRUG|Anrotinib hydrochloride combined with adriamycin|To evaluate the efficacy of anrotinib hydrochloride combined with doxorubicin in the neoadjuvant treatment of high-grade soft tissue sarcoma
214858867|NCT04297995|DRUG|HLX10|Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.
214858868|NCT04297995|DRUG|HLX07|Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.
214858869|NCT04297995|DRUG|HLX07 placebo|HLX07 placebo 1000 mg every three weeks
214858870|NCT04297995|DRUG|Cisplatin/Carboplatin|Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.
214858871|NCT04297995|DRUG|5-FU|5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.
214858872|NCT02496819|OTHER|Meta-cognitive self-regulated learning intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
214858873|NCT02496819|OTHER|Sensory integration intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
214858874|NCT02496819|OTHER|Activity-based intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
214858875|NCT00590278|DRUG|Tomudex|
214858876|NCT00590278|PROCEDURE|Radiotherapy|
214858877|NCT00590278|PROCEDURE|Haematology|
214858878|NCT00590278|PROCEDURE|Biochemistry|
214858879|NCT00488670|DRUG|Escitalopram|See Detailed Description.
214858880|NCT03876977|PROCEDURE|Robotic laparoscopic decompression of pudendal nerve entrapment|"Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance"
214858881|NCT01621191|DRUG|Duloxetine|Administered Orally
214858882|NCT04072016|DEVICE|Beacon Aqueous Microshunt|The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.
214858883|NCT00988689|OTHER|Dietary Intervention|soup with or without starch
214858884|NCT00148330|DRUG|Triamcinolone acetate|When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\]) was injected into the vitreous under sterile conditions in a minor procedures area.
214858885|NCT03664895|DRUG|Leuplin or zoladex|OFS(Leuplin or zoladex) add on to TMX
214858886|NCT01283594|DRUG|Tozadenant (SYN115) 60 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID."
214858887|NCT01283594|DRUG|Placebo|White-coated, modified-oval placebo tablets.
214858888|NCT01283594|DRUG|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
214858889|NCT01283594|DRUG|Tozadenant (SYN115) 120 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID."
214858890|NCT01283594|DRUG|Tozadenant (SYN115) 180 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID."
214858891|NCT01283594|DRUG|Tozadenant (SYN115) 240 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID."
214858892|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
214858893|NCT01704794|DRUG|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
214858894|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
214858895|NCT03418090|DRUG|129Xe MRI|Evaluation of pulmonary function
214858896|NCT03418090|DRUG|133XE scintigraphy|Evaluation of pulmonary function
214858897|NCT03529461|DEVICE|Non-invasive positive pressure ventilation through nasal mask|Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
214858898|NCT03529461|DEVICE|Rescue non-invasive positive pressure ventilation through nasal mask|If desaturation below 90 %, nasal cannula removed and non invasive positive pressure nasal mask connected to machine: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
214858899|NCT03529461|OTHER|Secondary rescue maneuvers|If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat \> 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase \> 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
214858900|NCT06285422|DRUG|SC262|SC262 is an allogeneic CAR -T cell therapy
214476459|NCT04681638|DRUG|Crystalloid Solutions|The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL\*kg\*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
214476460|NCT06612723|OTHER|high-intensity gait training|Individuals will perform up to 40 minutes of walking practice during 60 minute sessions while targeting heart rates of at least 70% heart rate reserve.
214858901|NCT02281331|DIETARY_SUPPLEMENT|Supplement|supplement/placebo plus exercise training
214858902|NCT01071447|OTHER|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
214858903|NCT02003911|DRUG|Azithromycin|Azithromycin suspension (200mg/5mL)
214858904|NCT02003911|DRUG|Placebo|
214858905|NCT01782482|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
214858906|NCT01782482|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color
214858907|NCT05507593|BIOLOGICAL|DLL3-CAR-NK cells|Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
214858908|NCT05051501|DIETARY_SUPPLEMENT|Probiotics C2P|Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.
214858909|NCT00511992|DRUG|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"
214858910|NCT00511992|DRUG|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
214858911|NCT00511992|DRUG|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
214858912|NCT06085716|BEHAVIORAL|Psychoeducational Intervention|Participants in the PI group will complete the educational sessions only.
214858913|NCT06085716|DRUG|Open Label Placebo|This group will only take placebo capsules every day.
214858914|NCT06085716|BEHAVIORAL|Psychoeducational Intervention+Placebo|This group will take the placebo capsules every day, as well as completing the educational sessions.
214858915|NCT02974036|OTHER|Patient education for osteoarthritis|Group sessions and optional supervised exercise.
214858916|NCT00038649|DRUG|Gleevec|400 mg orally twice daily
214858917|NCT03831763|DEVICE|ColdZyme|"ColdZyme® Mouth Spray is a CE-marked medical device with the following composition: glycerol, water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme® Mouth Spray consists of a 20 ml bottle, pump, spray nozzle and protective cap."
214858918|NCT03785535|DEVICE|Vibrotactile stimulation|The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
214858919|NCT02701166|DRUG|Bezafibrate|bezafibrate 400mg per day
214858920|NCT02701166|DRUG|Placebo|placebo 400mg per day
214858921|NCT06304649|DEVICE|Cast or brace alternative|Waterproof alternative to a cast or brace for broken bones
214858922|NCT02006537|DRUG|GSK2256294|GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
214858923|NCT01405131|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
214858924|NCT01405131|DRUG|methylprednisolone|tablets 32 mg single dose
214858925|NCT00393120|DRUG|INCB009471|100mg SR (sustained release) orally once daily
214858926|NCT00393120|DRUG|INCB009471|300mg SR (sustained release) orally once daily
214858927|NCT00393120|DRUG|Placebo comparator|Orally once daily
214858928|NCT04960319|DEVICE|Intravascular Lithotripsy|Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.
214858929|NCT01700426|DRUG|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
214858930|NCT01700426|OTHER|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
214858931|NCT04572282|DEVICE|Mentora app|Remote monitoring mobile app
214858932|NCT01345994|PROCEDURE|electro-acupuncture|acupuncture stimulation with electricity
214858933|NCT04068974|DRUG|Camrelizumab (SHR-1210)|Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway.
214858934|NCT04068974|DRUG|Apatinib|Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
214858935|NCT04178265|OTHER|Electroacupuncture|needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints.
214858936|NCT03663439|PROCEDURE|modified shell technique|divided block of bone into two shells and grafting one shell in anterior maxilla
214858937|NCT04203875|DRUG|Orencia® (Abatacept)|Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
214858938|NCT06031987|DEVICE|CareSens N (iSENS)|Control group is asked to perform SMBG (4 times or more per day).
214858939|NCT06031987|DEVICE|Freestyle Libre (Abbott)|CGM group is asked to scan CGM (4 times or more per day).
214858940|NCT05994820|BEHAVIORAL|Happy Baby Programme -Vaccine Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi.
214858941|NCT05994820|BEHAVIORAL|Happy Baby Programme- Vaccine ++ Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi as part of a holistic healthy baby approach that includes nutrition and sanitation.
214858942|NCT05750147|OTHER|Blood Sample Collection|Blood for DNA and biomarker analysis
214858943|NCT05574231|PROCEDURE|Periodontal treatment|It includes surgical and non-surgical procedures depending on patient as well as tooth level.
214858944|NCT02980250|DRUG|Low dose|0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
214858945|NCT02980250|DRUG|normal dose|0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
214858946|NCT02980250|DRUG|over dose|0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
214858947|NCT02980250|DRUG|Glucose|Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
214858948|NCT02614313|PROCEDURE|Open breath test with fructose|Open randomised fructose 35g during breath test
214858949|NCT02614313|PROCEDURE|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
214858950|NCT02614313|PROCEDURE|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
214858951|NCT02614313|PROCEDURE|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
214858952|NCT03475628|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
214858953|NCT01135628|OTHER|Auxiliary Treatment|Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
214858954|NCT01135628|DIETARY_SUPPLEMENT|Hyperproteic and fiber-rich diet|Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
214858955|NCT01135628|DRUG|Nitazoxanide|Nitazoxanide tablets 400 mg, bid, orally for 6 months
214858956|NCT05264961|BEHAVIORAL|voice therapy|sessions of voice therapy
214858957|NCT06167954|DEVICE|EXPLORER|8 sessions of use of the device in the home and the community of the participants
214858958|NCT03941353|OTHER|Usual care|Benchmark study with retrospective patient analysis evaluating the actual care patients with a fragile hip fracture receive
214858959|NCT01321008|RADIATION|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
214858960|NCT01321008|DRUG|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
214858961|NCT01321008|DRUG|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
214858962|NCT01321008|DRUG|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
214858963|NCT01321008|DRUG|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
214858964|NCT03688178|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
214858965|NCT03688178|DRUG|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)
214858966|NCT03688178|BIOLOGICAL|Varlilumab|Varlilumab is an agonist anti-CD27 monoclonal antibody
214858967|NCT03688178|BIOLOGICAL|Td|A single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally
214858968|NCT03688178|BIOLOGICAL|Unpulsed DCs|Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
214858969|NCT00402220|DRUG|TMS|Active Transcranial Magnetic Stimulation
214858970|NCT00402220|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
214476461|NCT06612723|BEHAVIORAL|Physical activity coaching|Individuals will receive feedback on the minutes of walking activity performed on non-training days and provided coaching strategies to increase this metric.
214858971|NCT02283450|DRUG|Qiliqiangxin Capsule|
214858972|NCT02114957|DIETARY_SUPPLEMENT|800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0|
214858973|NCT02477774|DEVICE|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
214476462|NCT00761124|BEHAVIORAL|Intervention Session|A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
214858974|NCT01184248|BEHAVIORAL|Sound stimulation|Listening to sound stimuli at the lowest audible level.
214858975|NCT01381263|BEHAVIORAL|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
214858976|NCT01381263|OTHER|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
214858977|NCT01727986|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
214858978|NCT03356886|PROCEDURE|Spinal Manipulative Technique|1\) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
214858979|NCT03356886|BEHAVIORAL|Pain Neuroscience Education|All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
214858980|NCT03399318|DRUG|Acetaminophen|"30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments"
214858981|NCT03399318|DRUG|Ibuprofen|10 mg/kg Q6 hours for the Aggressive Antipyretic Arm
214858982|NCT03399318|DRUG|placebo for acetaminophen|"placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo"
214858983|NCT03399318|DRUG|placebo for ibuprofen|placebo for ibuprofen
214858984|NCT03581513|PROCEDURE|Deferred or Immediate Stent Implantation|IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.
214858985|NCT00531349|PROCEDURE|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
214858986|NCT00531349|DRUG|Sevoflurane|General anesthesia
214858987|NCT02171390|DRUG|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
214858988|NCT02171390|DRUG|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
214858989|NCT05212064|DEVICE|high-flow oxygen nasal cannula therapy|Heated and humidified oxygen of 40L/minute through high-flow nasal cannula (HFNC) therapy machine.
214858990|NCT05212064|OTHER|nasal cannula oxygen therapy|Heated and humidified oxygen of 6L/minute through high-flow nasal cannula (HFNC) therapy machine.
214858991|NCT04130659|COMBINATION_PRODUCT|MARIAL® + PPI (generic Omeprazole)|"MARIAL® administration: 1 stick twice daily after meals from day 1 to 28.~Omeprazole administration: 20 mg cps once daily from day 1 to day 28"
214858992|NCT04130659|DRUG|PPI alone (generic omeprazole)|Omeprazole administration: 20 mg cps once daily from day 1 to day 28
214858993|NCT04130659|DEVICE|MARIAL® alone|MARIAL® administration: 1 stick twice daily after meals from day 29 to month 6.
214858994|NCT01520636|PROCEDURE|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
214858995|NCT01520636|PROCEDURE|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
214858996|NCT00838942|BEHAVIORAL|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
214858997|NCT02790307|DEVICE|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
214858998|NCT03501537|PROCEDURE|Free gingival graft obtained from the palate and debridement of the peri-implant lesion|granulation tissue debridement and grafting of a free gingival strip obtained from the palate
214858999|NCT02408328|DRUG|Caffeine citrate|Loading dose and continues use of caffeine until 44 weeks postmenstrual age
214859000|NCT02408328|DEVICE|Home monitor|Use of home monitor until 44 weeks postmenstrual age
214859001|NCT02408328|OTHER|Continued inpatient monitoring until apnea resolution|Continued inpatient monitoring until apnea resolution
214859002|NCT06107478|OTHER|Self-report questionnaires (only for parents)|"Quantitative part (all investigating centers): When they come to the various timepoints (T0, T1, T2), participants will be asked to fill in self-questionnaires, either electronically or on paper. If they are unable to come to the center at T1 and/or T2, they will be offered the option of completing the self-questionnaires online. These can also be sent by e-mail or postal mail and received by the same means if necessary.~The tools:~* Quality of life: Pediatric Quality of Life Inventory~* Anxiety: Edmonton Symptom Assessment System; Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale~* Depression: Edmonton Symptom Assessment System; PROMIS depression scale~* Parent-child relationship: Ad hoc questionnaire~* Parent-caregiver relationship: Enabling Practices Scale Socio-demographic data on parents and children, data relating to supportive care will be collected at inclusion. Massage habits will be collected at T1 and T2."
214859003|NCT06107478|OTHER|Interview (only for parents)|"Qualitative part (exclusively at CLB):~Participants (parents) in the qualitative part of the study will be asked to complete a self-administered questionnaire on socio-demographic data when they come to the center at T0. Clinical data will also be collected at T0. At T1, an interview will be organized with a researcher dedicated to the study. Qualitative interviews will preferably take place face-to-face, although videoconferencing may be used in certain circumstances."
214859004|NCT06107478|OTHER|Clinical data collection (only concerning Children)|The children's medical data (patients) will be collected in a Case Report Form (CRF; e.g. type of cancer, date of diagnosis, anti-cancer treatments received, symptoms) at T0.
214859005|NCT04888676|PROCEDURE|Class II Restoration|A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
214859006|NCT02749292|DRUG|Rituximab|re-dosing dependent on interventional arm parameter.
214859007|NCT05116748|BIOLOGICAL|COVID19 mRNA vaccine|Administration of COVID19 mRNA vaccine
214859008|NCT02458092|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
214859009|NCT02458092|BIOLOGICAL|Rabipur|Rabipur is a licensed rabies vaccine.
214859010|NCT01825122|DRUG|Nadolol|
214859011|NCT01825122|DRUG|Placebo|
214859012|NCT03022474|BEHAVIORAL|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
214859013|NCT03595163|DRUG|Sevoflurane|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
214859014|NCT03595163|DRUG|Propofol|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
214859015|NCT03329534|OTHER|Gluten free diet|A month long gluten free diet
214859016|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
214859017|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
214859018|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
214859019|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
214859020|NCT01387763|DRUG|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
214907055|NCT00907361|DEVICE|MRI with pacemaker or ICD|The aim of the present protocol is to prospectively determine the adverse event rate of non-thoracic MRI for patients with implanted cardiac devices by collecting pre- and post-MRI device interrogations in a multi-center registry.
214859021|NCT00251641|DRUG|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
214859022|NCT00251641|DRUG|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a \<25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
214859023|NCT01797484|DRUG|Ranolazine|Improvement of myocardial microcirculation
214859024|NCT05681312|DRUG|systemic proteolytic enzyme (Tibrolin)|Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)
214859025|NCT05681312|DRUG|Amoxicillin 500mg+metronidazole 500mg+ doliprane 100mg|Amoxicillin is given with metronidazole 500mg 1\*3' Doliprane 1000mg is given 1\*1
214859026|NCT02093221|BIOLOGICAL|180 mg/kg Alpha1-PI|
214859027|NCT02093221|BIOLOGICAL|90 mg/kg Alpha1-PI|
214859028|NCT02093221|BIOLOGICAL|Placebo|
214859029|NCT02147249|DRUG|antibiotic treatment|Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
214859030|NCT03516136|DEVICE|EndoFast Reliant SCP|POP repair procedure with the EndoFast Reliant SCP system
214859031|NCT01421121|BIOLOGICAL|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
214859032|NCT01421121|BIOLOGICAL|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
214859033|NCT01421121|BIOLOGICAL|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
214859034|NCT01421121|BIOLOGICAL|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
214859035|NCT01421121|BIOLOGICAL|Placebo|0.5ml placebo, two doses, 28 days interval
214859036|NCT05099484|DRUG|The MedMilk study|This observational, pragmatic PK study will enroll lactating women who are taking medications that were prescribed by their treating medical provider or as an over-the-counter medication.
214859037|NCT01348984|DRUG|transdermal fentanyl patch|TFP = transdermal fentanyl patch (50 microgram/hour)
214859038|NCT01348984|DRUG|placebo patch|group 2 = placebo patch
214859039|NCT02172352|DRUG|Ba 679 BR low dose|
214859040|NCT02172352|DRUG|Ba 679 BR middle dose|
215033613|NCT05078437|BEHAVIORAL|Medication therapy management|The proposed deprescribing intervention is using a patient-centered framework by: (1) balancing the risks and benefits, and addressing the specific needs of each individual patient, (2) considering the individual patient and the caregiver's preferences and values, and (3) empowering the patient and the caregiver to take responsibility and fully participate in the decision-making process as equal team players.
215033614|NCT01923038|PROCEDURE|First arm: patients ventilated with zero end expiratory pressure|
215033615|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure|
215033616|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
214476463|NCT00761124|BEHAVIORAL|Printed Material|General prostate cancer pamphlet
214476464|NCT06288386|DEVICE|GrandioSO Heavy Flow|Attachment will be performed with GrandioSO Heavy Flow.
214476465|NCT06288386|DEVICE|Filtek Z350XT Flowable|Attachment will be performed with Filtek Z350XT Flowable.
214859041|NCT02172352|DRUG|Ba 679 BR high dose|
214859042|NCT02172352|DRUG|Placebo inhalation powder|
214859043|NCT06098287|DEVICE|Residential mechanical ventilation system (Exhaust)|Exhaust-only ventilation system
214859044|NCT06098287|DEVICE|Residential mechanical ventilation system (CFIS) and air filtration upgrades|Central-fan-integrated-supply ventilation system and air filtration upgrades (MERV 10)
214859045|NCT06098287|DEVICE|Residential mechanical ventilation system (ERV) and air filtration upgrades|Balanced energy recovery ventilation system and air filtration upgrades (MERV 10)
214859046|NCT00384878|DRUG|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
214859047|NCT00000607|DEVICE|Left ventricular assist device|A type of implantable heart pump
214859048|NCT00000607|DEVICE|Optimal medical therapy|(non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
214859049|NCT04458493|BEHAVIORAL|satiety|satiety ratings, appetite and desire to eat (10-point visual analogue scale) will be measured at 30, 60 and 120 minutes after each meal replacement drink
214859050|NCT04458493|DIETARY_SUPPLEMENT|Dietary Supplement: Generation UCAN supplementation|meal replacement, Generation UCAN supplement, 400ml, 20% solution
214859051|NCT01312311|DRUG|Docetaxel, Cisplatin|Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1
214859052|NCT02387593|DEVICE|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
214859053|NCT04923711|BEHAVIORAL|Moderate intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 60-69% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 50-59% reserve heart rate or the heart rate at the anaerobic threshold."
214859054|NCT04923711|BEHAVIORAL|High intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 70-85% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 60-70% reserve heart rate or the heart rate at the anaerobic threshold."
214859055|NCT05010733|DEVICE|Total hip arthroplasty using the Exeter V40 cemented femoral stem|Consists of applying a cement layer of at least 2 millimeters surrounding an undersized prosthetic stem, so that this layer of cement fits between the femoral medullary canal and the prosthetic's femoral stem.
214859056|NCT05010733|DEVICE|Total hip arthroplasty using the Müller Straight Stem|Consists of applying a thin layer of cement, so that the prosthetic's femoral stem fills as much as possible the femoral medullary canal.
214859057|NCT06310928|OTHER|Thermal Blanket|Thermal blankets, a passive heating blanket, have a silver surface to prevent heat loss through radiation. Thermal insulation is achieved thanks to the fact that they are covered with a reflective surface to reflect light radiation, i.e. thermal radiation. It is a cost-effective, easy-to-clean, flexible material that takes the desired shape. Thermal blankets generate heat by providing thermal insulation with infrared radiation and can provide thermal vasodilation or thermotherapy. In 2013, Lima et al. used infrared thermal blankets to provide thermal vasodilation and as a result, it was found to reduce vascular resistance. Therefore, FORCLAZ brand blanket, also known as emergency blanket, used in natural disaster management, peripheral vascular resistance studies and hypothermia prevention studies was used in this study.
214859058|NCT03356028|BEHAVIORAL|Child and adolescent psychiatry and Epidemiology|psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
214859059|NCT03356028|OTHER|salivary biological collection|Saliva sampling will be done using a specific kit
214859060|NCT03356028|BEHAVIORAL|qualitative analysis of the discourse|two semi-structured interviews, the first with the teenager alone, the second with the lone parents
214859061|NCT03356028|BEHAVIORAL|Parenthood|Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial
214859062|NCT03356028|BEHAVIORAL|Cognitive alterations|Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents
214859063|NCT03356028|BEHAVIORAL|Impact on schooling|collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child
214859064|NCT03356028|BEHAVIORAL|Sleep disorders and associated somatizations|Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
214859065|NCT03987347|OTHER|Observational|People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
214859066|NCT06859853|DRUG|Placebo|Sub cutaneous injection on the abdomen by a qualified member of study staff.
214859067|NCT06859853|DRUG|Subcutaneous single and mutiple dose|Sub cutaneous injection on the abdomen by a qualified member of study staff.
214859068|NCT00188227|DRUG|Midazolam (sedative)|
214859069|NCT00188227|DRUG|Piritramid (analgetic)|
214859070|NCT00188227|BEHAVIORAL|Cognitive exercises|
214859071|NCT06617273|DEVICE|Ophthalmosurgical handpiece with active anterior chamber pressure sensing and regulation|Cataract surgery in patients with diabetic retinopathy using active anterior chamber pressure sensing and regulation
214859072|NCT04072276|BIOLOGICAL|EV71 vaccine|EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study
214859073|NCT00257920|DRUG|Zemplar® injection|6 mcg QOD
214859074|NCT00257920|DRUG|Hectorol® injection|3.6 mcg QOD
214859075|NCT04576182|BEHAVIORAL|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
214859076|NCT04576182|BEHAVIORAL|Emotions-Focused treatment|Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
214476466|NCT06177613|PROCEDURE|Blank culture transfer|A maximum of 0.1 ml of gassed embryo culture medium preheated to 37°C is injected into the uterine cavity transcervically using an embryo transfer catheter placed just beyond the internal os, two to 3 days before transfer of the thawed embryo
214859077|NCT00449982|DRUG|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
214859078|NCT05758220|DEVICE|MRI|Structural MRI volumetry, resting functional MRI \& MR spectroscopy
214859079|NCT03508687|DRUG|300mg Gemcabene|300mg Gemcabene
214859080|NCT03508687|DRUG|600mg Gemcabene|600mg Gemcabene
214859081|NCT05877391|BEHAVIORAL|SGM Communication Intervention|Evaluate the feasibility and acceptability of the SGM communication intervention by hospice staff. I will pilot test the training with hospice staff to refine the content and delivery of the training. Outcomes in the pilot clinical trial will include feasibility, acceptability, and staff satisfaction with training.
214859082|NCT03915665|DRUG|Chlorhexidine|Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
214859083|NCT03915665|DEVICE|Air-powder|Erythritol powder using air-powder device
214859084|NCT01528020|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
215033617|NCT06149182|BEHAVIORAL|Life stress interview according to EAET|This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.
214476467|NCT06177613|PROCEDURE|Sham transfer|An intermediate transfer step is added two or three days before the planned transfer of the frozen embryo but with an empty catheter.
214476468|NCT01420770|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
214476469|NCT06611891|DRUG|68Ga-DOTATOC|Slow direct intravenous injection
214859085|NCT01528020|BEHAVIORAL|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
214859086|NCT05623631|OTHER|Survey|Surveys were distributed using REDCap, and participants were asked to complete these within 5 weeks of receiving the invitation.
214859087|NCT02235220|OTHER|Composite resin restoration|"Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.~A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted."
214859088|NCT01200940|OTHER|Sucralose|sucralose will be given at doses of 68 mg (equivalent to one 12 oz soda) 170 mg (equivalent to two and one-half 12 oz sodas, and 250 mg (equal to 100% of the FDA s acceptable daily intake for a 50kg individual).
214859089|NCT01200940|OTHER|Aspartame|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
214859090|NCT01200940|OTHER|Acesulfame-Potassium|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
214859091|NCT01200940|OTHER|Control|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
214859092|NCT03647631|PROCEDURE|sentinel lymph node biopsy|Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.
214859093|NCT00453817|DRUG|ferucarbotran (iron-based MRI contrast agent)|islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
214859094|NCT00453817|PROCEDURE|Islet transplantation|intraportal percutaneous islet transplantation
214859095|NCT00453817|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
214859096|NCT06449755|DIAGNOSTIC_TEST|Radiologic examination|Posoperative first week, month and third month On the x-ray of Hand AP view: metacarpal shortening On the x-ray of Hand 30 degree pronation view: dorsal angulation
214859097|NCT06449755|PROCEDURE|Grip Strength|Postoperative first month and third month grip streng compare with Cambry hand dinamometer.
214859098|NCT06449755|OTHER|Quick DASH Questionnaire|Quick DASH is an 11-question questionnaire that assesses upper extremity functionality.
214859099|NCT05311761|OTHER|CogMe Personal Assistant (PA)|Twice a day, in the morning and evening, the electronic tablet with the CogMe PA will be given to the patient by the research assistant. Patients will be asked to respond to a short question and answer (Q\&A) session of approximately 5-10 minutes duration. This intervention will continue throughout the hospitalization period, estimated at approximately 5 days.
214859100|NCT05449509|DIAGNOSTIC_TEST|Abdominal aortic Duplex ultrasound|All patients will undergo bedside Duplex ultrasound in order to measure infrarenal abdominal aortic diameter.
214859101|NCT00004313|DRUG|dehydroepiandrosterone|
214859102|NCT00821366|BEHAVIORAL|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
214859103|NCT00821366|DIETARY_SUPPLEMENT|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
214859104|NCT00821366|DRUG|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
214859105|NCT04629859|PROCEDURE|mandibular setback and maxillary advancement|12 patients will undergo mandibular setback and maxillary advancement
214859106|NCT04629859|PROCEDURE|mandibular setback|12 patients will undergo mandibular setback
214859107|NCT00631852|DRUG|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
214859108|NCT03532633|PROCEDURE|cord blood|collection of cord blood
214859109|NCT03532633|PROCEDURE|blood sample infant|collection of remnant of clinically indicated blood sample
214859110|NCT03532633|PROCEDURE|blood sample mother|collection of remnant of clinically indicated blood sample. If not available blood sample is taken after mother agreed
214859111|NCT03532633|PROCEDURE|breast milk|collection of breast milk 1/week during neonatal care (maximum 8 weaks)
214859112|NCT05859399|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
214859113|NCT00621036|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
214859114|NCT00621036|BIOLOGICAL|sargramostim|
214859115|NCT00621036|DRUG|methotrexate|
214859116|NCT00621036|DRUG|thiotepa|
214859117|NCT00621036|RADIATION|radiation therapy|
214859118|NCT01861236|DRUG|Firmagon® (degarelix)|Monthly subcutaneous injections
214859119|NCT05590156|PROCEDURE|Conventional Rehabilitation|Conventional treatment for the upper extremity will be applied according to the patient's individual needs. A physiotherapist will apply this method in the clinic for 60 minutes. The duration of treatment is 60x3x8 minutes/day/week. Other methods will be applied in addition to the conventional treatment program.
214859120|NCT05590156|DEVICE|Robotic Rehabilitation (ExoRehab X)|Robotic Rehabilitation
214859121|NCT05590156|PROCEDURE|Action Observation Therapy (AOT)|Action Observation Therapy (AOT)
214859122|NCT00378651|PROCEDURE|Neck Auscultation|
214859123|NCT06537804|RADIATION|Screening by low-dose CT scan|Screening for lung cancer by low-dose CT scan
214859124|NCT04571892|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
214859125|NCT04121650|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
214859126|NCT04952532|OTHER|Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)|The proposed study aims to collect pilot data to test the feasibility and acceptability of adjunctive neuroplasticity-based cognitive remediation on key treatment targets. The intervention will be delivered via telehealth to a sample of 36 Veterans with MDD and a history of a suicide attempt. The intervention will be delivered in 20 90-min sessions (2x/week for 10 weeks). Pre-, post, and follow-up assessments will be conducted to assess changes in neurocognitive, clinical, social, and real-world functioning.
214859127|NCT00534794|DRUG|Elestat|Elestat BID for 2 days
214859128|NCT00534794|DRUG|Pataday|Pataday QD for 2 days
214859129|NCT04873531|DRUG|Neostigmine|"For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
214859130|NCT04873531|DRUG|Normal saline|"For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
214859131|NCT04323020|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
214859132|NCT00112346|DRUG|Cetuximab + platinum + gemcitabine|Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
214859133|NCT00112346|DRUG|Platinum + Gemcitabine|Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
214859134|NCT00767065|RADIATION|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate \<70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
214859135|NCT00767065|OTHER|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
214859136|NCT02635217|DEVICE|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
214859137|NCT02635217|DEVICE|room air insufflation|using standard care room air will be infused on demand
214859138|NCT02635217|PROCEDURE|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
214859139|NCT02635217|PROCEDURE|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
214859140|NCT06204419|DRUG|XH-S002 （A）|XH-S002 powder will be administered orally as per assigned treatment regimen.
214859141|NCT06204419|OTHER|Placebo（B）|XH-S002 Placebo (matched) will be administered orally as per assigned treatment regimen.
214859142|NCT03822364|DRUG|009-1|Inhaled apomorphine via Staccato aerosol, Dose 1
214859143|NCT03822364|DRUG|active comparator|commercially available apomorphine injector
214859144|NCT03822364|DRUG|009-0|Inhaled placebo via Staccato device
214859145|NCT03822364|DRUG|009-2|Inhaled apomorphine via Staccato aerosol, Dose 2
214859146|NCT03822364|DRUG|009-3|Inhaled apomorphine via Staccato aerosol, Dose 3
214859147|NCT03822364|DRUG|009-4|Inhaled apomorphine via Staccato aerosol, Dose 4
214859148|NCT03822364|DRUG|009-5|Inhaled apomorphine via Staccato aerosol, Dose 5
214859149|NCT05495113|DEVICE|YMS-201B (Device: Mind STIM)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
214859150|NCT05495113|DEVICE|Sham stimulation using YMS-201B|Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
214859151|NCT03866018|OTHER|Adapted physical activity|12 sessions of one hour of adapted physical activity.
214859152|NCT00238849|DRUG|Oxaliplatin|
215033618|NCT06149182|BEHAVIORAL|"Psychiatric interview according to region stockholm - basutredning"|This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders
215033619|NCT01416337|DRUG|GSK1120212|2 mg single dose tablet on Day 1 of study
215033620|NCT01416337|DRUG|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
215033621|NCT03089294|DEVICE|Aries ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
214859153|NCT05582252|OTHER|Non-Invasive saliva sampling|"There are two types of intervention in this ambidirectional study.~1. Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~2. ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records."
214859154|NCT00287859|DRUG|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
214859155|NCT04435106|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
214859156|NCT04435106|DRUG|Standard of Care|Study participants received Standard of Care
214859157|NCT03902652|PROCEDURE|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
214859158|NCT03902652|PROCEDURE|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
214859159|NCT05465642|OTHER|Collect stool and blood samples from patients|Collect stool and blood samples from patients
214859160|NCT02728752|DRUG|Octagam 10%|Patients to be treated with Octagam 10%
214859161|NCT02728752|OTHER|Placebo|Patients to be treated with a Placebo
214859162|NCT03097588|DRUG|Netupitant|300 mg, Given PO, QD
214859163|NCT03097588|DRUG|Palonosetron Hydrochloride|0.5 mg, Given PO, QD
214859164|NCT03097588|OTHER|Questionnaire Administration|Ancillary studies
214859165|NCT03021252|DEVICE|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
214859166|NCT03021252|DEVICE|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
214859167|NCT00838708|DRUG|SRD174 Cream|topical SRD174 Cream
214859168|NCT00838708|OTHER|vehicle cream|topical vehicle cream
214859169|NCT06682962|DEVICE|Transcorneal electrical stimulation (TES) with the OkuStim 2 System|Retinal stimulation is achieved through transcorneal current application: using a thread electrode, a weak current (≤ 1mA) is introduced onto the surface of the eye, which spreads through the eye towards the retina.
214859170|NCT03493776|BIOLOGICAL|VZV subunit vaccine|VZV subunit vaccine
214859171|NCT03146182|BEHAVIORAL|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
214859172|NCT03146182|BEHAVIORAL|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
214859173|NCT02782494|OTHER|Examination of latent TB by QuantiFERON-TB|Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
214859174|NCT02099604|DRUG|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
214859175|NCT05897268|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
214859176|NCT05897268|DRUG|Tislelizumab|a PD-1 immune check inhibitor
214859177|NCT05897268|DRUG|Lenvatinib|Lenvatinib capsules
214859178|NCT03456960|DRUG|TAK-438ASA|TAK-438ASA tablet.
214859179|NCT03456960|DRUG|TAK-438|TAK-438 tablet.
214859180|NCT03456960|DRUG|Aspirin|Aspirin enteric-coated tablet.
214859181|NCT04757701|OTHER|Social Behavioral surveys, interviews, and focus groups|Surveys with dentists/hygienists, interviews/focus groups with service learning center directors and key staff at federally qualified health centers.
214859182|NCT03200691|RADIATION|3-DCRT or IMRT radiation|Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.
214859183|NCT03200691|DRUG|anti-PD-1 antibody SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
214859184|NCT01576094|DRUG|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
214907056|NCT03309137|DEVICE|Chlorhexidine flush|"1. For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.~   After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.~2. Discard the syringe and device in biohazard waste.~3. Blue Cap the IV as per routine practice."
214859185|NCT01576094|DRUG|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
214859186|NCT06310265|OTHER|Retrospective observational study|Our study includes child earthquake victims, regardless of gender, between the ages of 0-18, who applied to our clinic within six months after the February 6, 2023 earthquake and underwent surgery.
214859187|NCT05387174|BEHAVIORAL|: Nursing intervention in two risk factors of the Metabolic Syndrome, abdominal obesity and arterial hypertension and quality of life in the climacteric period.|Nursing intervention with technological support (Metamorphosis) in two risk factors of Metabolic Syndrome, abdominal obesity and hypertension and quality of life in the climacteric period, developed in 3 months, in the experimental group that includes individual nursing counseling, group education virtually and physical activity sessions for 12 weeks virtually.
214859188|NCT00653991|BEHAVIORAL|SOLVE-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
214859189|NCT04300829|DRUG|cicaderma + simple hygiene rules|Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
214859190|NCT04300829|OTHER|Simple hygiene rules and a maximum of one topical treatment|Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment
214859191|NCT04429529|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)
214859192|NCT04429529|OTHER|0.9% Saline|Placebo
214859193|NCT04851431|BEHAVIORAL|one-to-one peer mentoring|Weekly meetings with a peer family caregiver
214859194|NCT05467163|DEVICE|Biventricular pacemaker implantation|Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.
214859195|NCT05467163|DEVICE|Conduction system pacing device implantation|Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.
214859196|NCT05467163|PROCEDURE|AV node ablation|Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
214859197|NCT02794857|DRUG|NP001|
214859198|NCT02794857|DRUG|Placebo|
214859199|NCT02947074|BEHAVIORAL|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
214859200|NCT03757273|PROCEDURE|FFF with CAD/CAM customized cutting guide|This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton and lower legs. the CT scan will be sent to the modeling company for producing autoclavable 3D models and cutting guides of the mandible and fibula to be used during the workflow as well as a model of the final reconstructed mandible. Surgery will be performed by two surgical teams, one for cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, osteotomy guides secured; cuts then accomplished as planned virtually. fibular flap is harvested and cutting guides secured to replicate osteotomies and reshaping as planned to conform with remaining mandible. fixation and pedicle anastomosis is performed. Finally, the operation completed with soft tissue reconstruction.
214859201|NCT03757273|PROCEDURE|FFF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton. the C.T scan will be sent to the modeling company for planning three-dimensional model of the mandible. autoclavable model will be prepared for mandible to be used during the workflow for plate reshaping and positioning to conform with the remaining mandible.~Surgery will be performed by two surgical teams, one in charge of cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, and resection/ reconstruction then performed in conventional surgical manner with microvascular anastomosis. Finally, the operation will be completed with soft tissue reconstruction."
214859202|NCT01947231|OTHER|Global Postural Re-education|Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
214907057|NCT03047187|DIAGNOSTIC_TEST|ACLR|"* quadriceps and hamstring isometric muscles test~* single hop for distance~* IKDC, KOOS, Tampa and ACL-RSI Questionnaires"
214907058|NCT03160937|OTHER|Manual therapy|The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
214476470|NCT06612346|DEVICE|Minimally Invasive Micro Trabeculostomy|The MINT system is a surgical device designed to create a trabeculostomy within the eye.
214476471|NCT06612151|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.
214859203|NCT01947231|OTHER|Standard manual physical therapy|Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
214859204|NCT01298713|DRUG|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
214859205|NCT01298713|DRUG|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
214859206|NCT04715360|COMBINATION_PRODUCT|autologous activated platelet-rich plasma|Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
214859207|NCT04715360|DRUG|Avigan|Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
214859208|NCT00891839|DRUG|Bendamustine|Bendamustine at 90 mg/m\^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
214859209|NCT00891839|DRUG|Rituximab|Patients receive 375 mg/m\^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
214859210|NCT04774952|DRUG|RMC-5552|RMC-5552 for IV administration
214859211|NCT05419115|DRUG|SQIN-Furosemide|The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8). SC infusion will be performed using the SQIN-Infusor which will deliver 2.7 mL of the SQIN-Furosemide formulation (80mg) over approximately 5 hours, using a biphasic delivery profile.
214859212|NCT05419115|DEVICE|SQIN-Infusor|The investigational device (SQIN-Infusor) is an on-body delivery system that consists of a RU, DU, plus a charger (Figure 2). For the purpose of SUBCUT-HF II trial, the RU will be used for multiple infusions for a single participant. The DU will be used only once per infusion and disposed of. The RU must be charged after each use and will not restart for the next infusion without charging. Charging takes up to 15 minutes. SQIN-Infusor is a bespoke system, adapted from the design of a SC insulin pump. The RU consists of the drive-unit, the controllers, the rechargeable battery, and the user interface.
214859213|NCT00877357|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
214859214|NCT06309446|DEVICE|Zoralan Wound|Topical application of approximately 0.2 g per test field (approx. 1.2 cm in diameter each) once daily during a 12-day treatment period (11 treatments).
214859215|NCT04887246|BIOLOGICAL|COVID-19 vaccines|COVID-19 vaccines available at Colombia
214859216|NCT02337140|DEVICE|Pacemaker SORIN Group KORA DR|
214859217|NCT02337140|PROCEDURE|transcatheter aortic valve implantation (TAVI)|
214859218|NCT03828448|DRUG|Ublituximab|\- anti-CD 20 monoclonal antibody administered via IV infusion
214859219|NCT03828448|DRUG|Umbralisib|\- PI3K Delta Inhibitor oral daily dose
214859220|NCT05506722|DEVICE|Testes shocker|It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
214859221|NCT01565265|DRUG|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
214859222|NCT01565265|DRUG|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
214859223|NCT06453239|DIAGNOSTIC_TEST|Pro-Neurotensin level as a Serum Biomarker|Pro-Neurotensin mediates the development of fatty liver disease. Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation to food lipid content.
214859224|NCT06126965|DRUG|KX-826-（5%） BID|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized active drug would be administered to the scalp once in the morning and once in the evening.
214859225|NCT06126965|OTHER|Placebo|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized matching placebo would be administered to the scalp once in the morning and once in the evening.
214859226|NCT02037165|DRUG|Placebo to BI 1026706|Placebo tablet
214859227|NCT02037165|DRUG|Pregabalin|Pregabalin hard capsule
214859228|NCT02037165|DRUG|BI 1026706|BI 1026706 oral solution
214859229|NCT02037165|DRUG|Celecoxib|Celecoxib hard capsule
214859230|NCT01145131|OTHER|Intact or minced beef meat|135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
214859231|NCT01440439|DRUG|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
214859232|NCT01440439|DRUG|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
214859233|NCT03591939|DIAGNOSTIC_TEST|laboratory test|role of T- regulatory cells in the patients of diabetic nephropathy
214859234|NCT00532935|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period
215033622|NCT05368519|DEVICE|Brijjit®|Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
214859235|NCT00532935|DRUG|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.
214859236|NCT05391334|DEVICE|Qumea|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
214859237|NCT04977063|DEVICE|Atmo gas capsule|The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
214859238|NCT04977063|DEVICE|SmartPill|The SmartPill measures the capsules location and motility/transit times through pH sensing
214859239|NCT04750135|DRUG|metformin 500 mg TID Oral Tablet|biguanides derivatives
214859240|NCT04750135|DRUG|Placebo|Placebo
214859241|NCT05290324|DRUG|Midazolam|Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
214859242|NCT05980286|BEHAVIORAL|Piano Improvisation|Piano Improvisation taught by a professional instructor for 16 weeks.
214859243|NCT05980286|BEHAVIORAL|Music Listening|Music Listening facilitated by a professional instructor for 16 weeks.
214859244|NCT06222541|BEHAVIORAL|"Nudges in Web-Based Supermarket"|"While shopping in the web-based supermarket, participants assigned to the nudge arm will see retail nudges to discourage sugary drink purchases and promote healthier substitutes."
214859245|NCT00926016|DRUG|Pioglitazone (Actos)|pioglitazone 45 mg a day
214859246|NCT01474902|DRUG|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
214859247|NCT01124708|DRUG|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
214859248|NCT01124708|DRUG|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
214859249|NCT06058221|DEVICE|simultaneous videolaryngoscopy|Two specialists perform tracheal intubation, one using a video laryngoscope to expose the vocal cords and the other using a fiberoptic bronchoscope.
214859250|NCT06058221|DEVICE|supraglottic airway|After inserting the supraglottic airway, the specialist performs intubation using a fiberoptic bronchoscope through the supraglottic airway.
214859251|NCT01300923|DRUG|Acamprosate|
214859252|NCT01235702|BEHAVIORAL|12-week lifestyle modification|
214859253|NCT06327802|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the Beck, Zarit, HAD, FAS CARERQOL-7D questionnaires
214859254|NCT01568866|DRUG|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
214859255|NCT01568866|DRUG|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
214859256|NCT01568866|DRUG|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
214859257|NCT06142370|OTHER|Descriptive|The patients will be asked by the recruiting physicians to perform a clinical examination looking for the LCV, which will take a total of five seconds. This is a self-test and not part of a regular clinical examination
214859258|NCT03340870|DRUG|Sonazoid™|Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
214859259|NCT03376542|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
214859260|NCT01698775|DRUG|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
214859261|NCT01698775|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
214859262|NCT01698775|DRUG|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
214859263|NCT01698775|DRUG|Placebo to glipizide|Matching placebo to glipizide daily
214859264|NCT01698775|BIOLOGICAL|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
214476472|NCT06612151|DRUG|topotecan hydrochloride for injection|Topotecan hydrochloride will be administered intravenously per prescribing information.
214859265|NCT01377675|OTHER|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
214859266|NCT01869478|DRUG|Intravenous Thrombolysis|
214859267|NCT01869478|DEVICE|Endovascular Arterial Reperfusion|
214859268|NCT01078337|PROCEDURE|bone marrow aspiration|
214859269|NCT01078337|PROCEDURE|peripheral blood sampling|
214859270|NCT01366378|DRUG|methylnaltrexone|
214859271|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3|600 IU Vitamin D3 capsule daily
214859272|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
214859273|NCT00571285|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given once a week
214859274|NCT03437915|RADIATION|NIBB: accuboost|28.5 Gy delivered in 5 daily fractions
214859275|NCT03437915|PROCEDURE|Partial mastectomy|4-12 weeks post NIBB
214859276|NCT01244061|DRUG|Varenicline|Varenicline 1mg twice daily
214859277|NCT01244061|DRUG|Placebo|Matched placebo twice daily
214859278|NCT02494102|DRUG|Modafinil|Atypical Psychomotor stimulant
214859279|NCT02494102|DRUG|Placebo|
214859280|NCT01706848|OTHER|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
214859281|NCT01706848|OTHER|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
215033623|NCT01767987|DRUG|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
214859282|NCT06690008|PROCEDURE|Experimental group|SDF application
214859283|NCT05777824|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
214859284|NCT05777824|RADIATION|postoperative radiaotherapy|postoperative radiotherapy (60Gy or 50Gy)
214859285|NCT06490120|OTHER|sampling method|feasibility outcomes will be compared between the 3 groups
214859286|NCT02384850|DRUG|Selinexor|Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
214859287|NCT02384850|DRUG|Oxaliplatin|85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
214859288|NCT02384850|DRUG|5-FU|400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
214859289|NCT02384850|DRUG|Folinic Acid|400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
214859290|NCT00646620|DRUG|budesonide/formoterol (Symbicort)|
214859291|NCT00646620|DRUG|fluticasone/salmeterol (Advair Diskus)|
214859292|NCT00646620|DRUG|albuterol (Ventolin)|
214859293|NCT06094452|OTHER|Computerized Cognitive Training|Participants in intervention group will receive a multidomain, adaptive computerized cognitive training program (www.66nao.com) and will be required to complete at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks. Multidomain coverage paradigms include working memory, calculation, processing speed, attention, executive function, and short-term and long-term memory.
214859294|NCT06094452|OTHER|Treatment As Usual|Patients in control group will receive TAU for 24 weeks, which includes (1) regular medication management from the Memory Clinic, if applicable; (2) basic health education at each follow-up (face to face) and twice per month on the internet .
214859295|NCT04810442|OTHER|Nap|45-minute nap between scanning procedures
214859296|NCT02013375|PROCEDURE|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
214859297|NCT02013375|DRUG|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
214859298|NCT02013375|RADIATION|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
214859299|NCT02013375|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
214859300|NCT02013375|DRUG|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
214859304|NCT02219971|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
214859305|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) + placebo|Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
214859306|NCT03090997|DIETARY_SUPPLEMENT|resveratrol (500 mg / day) + placebo|Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
214859307|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) and resveratrol (500 mg / day)|Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
214859308|NCT01764282|BEHAVIORAL|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
214859309|NCT01475084|DEVICE|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|"The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way."
214476473|NCT06612125|OTHER|volume controlled ventilation|Pediatric patients in the VCV group (n= 30) received volume-controlled ventilation, target tidal volume was set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
214859310|NCT05882279|OTHER|No Intervention|This is a non-interventional study.
214859311|NCT05533398|OTHER|Stress ball use|They were asked to use the ball for at least 10 minutes during the dialysis treatment and when they felt stressed or unwell at home/work. Patients with arteriovenous fistula or arteriovenous graft were instructed to use the stress ball with the other hand, where there was no vascular access.
214859312|NCT04078880|DIETARY_SUPPLEMENT|Sucrosomial iron plus ascorbic acid|A number of 41 subjects are supplemented with 30 mg of iron plus 70 mg of ascorbic acid daily for 30+/-5 days before orthopedic surgery.
214859313|NCT04037930|BEHAVIORAL|multiple implant surgery|Patients older than 30 years who will undergo elective dental implant surgery.
214859314|NCT05473819|DRUG|Buffered Local Anesthesia|"Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe \[Tyco Healthcare, tyco.com\] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present."
214859315|NCT05473819|DRUG|Conventional Unbuffered Local Anesthesia|The control group will receive the unbuffered conventional anaesthetic solution
214859316|NCT00551382|DRUG|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
214859317|NCT00551382|DRUG|Placebo|Look alike tablets or granules 1 per day for 12 weeks
214859318|NCT00586482|DRUG|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
214859319|NCT00586482|DRUG|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
214859320|NCT00586482|BEHAVIORAL|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
214859321|NCT02932228|OTHER|ImPACT|"The ImPACT team offers the following services:~* An intensive intake process, including a home visit if deemed appropriate~* Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs~* After-hours access to on-call team member in order to avoid unnecessary emergency care~* Optimization of chronic condition management using evidence-based protocols~* Navigation of transitions between hospital and home~* Coordination of specialty care, including contact with specialists when indicated~* Rapid response to signs of health status deterioration or other stressful events~* Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment"
214859322|NCT01068379|PROCEDURE|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
214859323|NCT01068379|PROCEDURE|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
214859324|NCT04451603|PROCEDURE|Surgery|Surgical resection of the liver
214859325|NCT04451603|RADIATION|Radiation therapy|Y-90 radioembolization therapy is the main treatment
214859326|NCT04451603|DRUG|Drug treatment|Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
214859327|NCT00072072|DRUG|celecoxib|
214859328|NCT00072072|DRUG|erlotinib hydrochloride|
214859329|NCT04945772|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
214859330|NCT04945772|PROCEDURE|Sham Injection|Sham Injection
214859331|NCT06394674|DRUG|Furmonertinib|Drug: Furmonertinib
214859332|NCT04542265|COMBINATION_PRODUCT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
214859333|NCT04337684|DRUG|Long Term Follow-Up|"Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up."
214859334|NCT04520932|PROCEDURE|Radiofrequency ablation|RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.
214859335|NCT06437600|PROCEDURE|Immediate angioplasty|See arm/group descriptions.
214859336|NCT06421701|DRUG|anti-CD19 CAR-NK cells|Patients will receive Fludarabine and Cyclophosphamide for lymphodepletion conditioning. Anti-CD19 CAR-NK cells will be infused on Day 0, 3, and 6.
214859337|NCT02673879|OTHER|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
214859338|NCT02673879|OTHER|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated
214859339|NCT03344978|OTHER|Cardboard Cot Care|Infant maintained in reflective film-lined cot for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. Infant may be moved to incubator or radiant warmer. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
214859340|NCT03344978|OTHER|Incubator Care|Infant maintained in standard incubator for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
214859341|NCT04835649|OTHER|Exercise|Both groups will receive exercise-based training
214859342|NCT00821873|OTHER|CR Plug|CR Plug will be placed in the harvest site
214859343|NCT00001045|DRUG|Nevirapine|
214859344|NCT00001045|DRUG|Zidovudine|
214859345|NCT00001045|DRUG|Didanosine|
214859346|NCT03569150|OTHER|Cultural adaptation/implementation COMFORT CC|The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
214859347|NCT02704780|DRUG|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
214907059|NCT07059793|DEVICE|MITRIS RESILIA Mitral Valve|Surgical replacement of native or prosthetic mitral valve.
214907060|NCT04762160|DRUG|Tazemetostat|Study Drug
214907061|NCT04762160|COMBINATION_PRODUCT|Rituximab|Partner Drug
214907062|NCT00056927|BEHAVIORAL|Anti-smoking Socialization Program|
214859348|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-coated balloon|"SeQuent Please (BBraun) + tailored antithrombotic regimen:~1. Stable patients without OAC: perioperative SAPT (preferably) or perioperative DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative SAPT (preferably) or perioperative DAPT and lifelong OAC~3. ACS patients without OAC: 1-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 1-month SAPT and lifelong OAC"
214859349|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-eluting stent|"Biofreedom (Biosensors), Synergy (Boston Scientific), Ultimaster Tansei (Terumo) and Integrity Onyx (Medtronic), Xience Pro S (Abbott) or Promus Elite (Boston Scientific) or any other DES can also be used provided that it has a CE mark for 1-month DAPT, combined with tailored antithrombotic regimen:~1. Stable patients without OAC: 1-month DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and life-long OAC~3. ACS patients without OAC: 3-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and lifelong OAC"
214859350|NCT03310411|DRUG|Lasmiditan|Administered orally
214859351|NCT03310411|DRUG|Sumatriptan|Administered orally
214859352|NCT03310411|DRUG|Placebo for Lasmiditan|Administered orally
214859353|NCT03310411|DRUG|Placebo for Sumatriptan|Administered orally
214859354|NCT01300910|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
214859355|NCT01300910|PROCEDURE|Male circumcision|A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
214859356|NCT00794755|DIETARY_SUPPLEMENT|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
214859357|NCT00794755|DIETARY_SUPPLEMENT|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
214859358|NCT01440036|PROCEDURE|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
214859359|NCT02968836|DIETARY_SUPPLEMENT|Blend of amino acids|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
214859360|NCT02968836|DIETARY_SUPPLEMENT|Maltodextrin only|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
214859361|NCT04600778|OTHER|placebo|placebo
214859362|NCT04600778|DRUG|Cavosonstat 5 mg|Cavosonstat (low dose)
214859363|NCT04600778|DRUG|Cavosonstat 10 mg|Cavosonstat (medium dose)
214859364|NCT04600778|DRUG|Cavosonstat 25 mg|Cavosonstat (high dose)
214859365|NCT01860911|DRUG|Insulin|
214859366|NCT01860911|DRUG|NG-monomethyl-L-arginine|
214859367|NCT03983083|BEHAVIORAL|Physical activity|Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
214859368|NCT04029311|DEVICE|Nuance Pro|Study compares Nuance Pro plus Automatic Positive Airway Pressure (autoPAP) vs TAP PAP plus autoPAP
214859369|NCT04029311|DEVICE|autoPAP|autoPAP
214859370|NCT04029311|DEVICE|TAP PAP|TAP PAP
214859371|NCT03802253|BEHAVIORAL|Time Restricted Feeding(TRF)|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm) in the first 6 months. 6 months later, Participants will receive a diet of 1200-1500kcal/d without a restriction of feeding time.
214859372|NCT03802253|BEHAVIORAL|Reduced Calorie Diet (RCD)|Participants will receive a diet of 1200-1500kcal/d and keep their usual eating pattern.
214859373|NCT04601298|OTHER||
214859374|NCT00452517|PROCEDURE|Percutaneous Coronary Intervention|
214859375|NCT03623386|OTHER|PD neurofeedback|PD-neurofeedback subjects will practice motor imagery in the MRI scanner and receive neurofeedback on their performance. There will be a total of 10-12 neurofeedback sessions on two separate days. Subjects will continue practicing motor imagery at home every day throughout the study period for 4-6 weeks.
214859376|NCT03623386|OTHER|PD control|PD-control subjects will practice visual imagery (e.g., of scenery, objects, etc., but not of movement) in the MRI scanner and will not receive neurofeedback on their performance. Subjects will continue practicing visual imagery at home every day throughout the study period for 4-6 weeks.
214859377|NCT03282630|PROCEDURE|Sphenopalatine ganglion acupuncture|"* active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~* sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment."
214859378|NCT02903992|RADIATION|Dual-energy X-ray absorptiometry (DXA)|Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
214859379|NCT05080426|BEHAVIORAL|Family Supportive Supervisor Training 2.0|FSST 2.0 is a workplace intervention package designed to increase supervisors' family and leave supportive behaviors and leave supportive behaviors. The package includes Workplace Assessment tool, 2 45-60 minute online training modules (family-supportive supervisor training and supervisors' leave supportive behavior training), a webinar, behavior training, and individualized feedback reports.
214859380|NCT05502692|BEHAVIORAL|CHARACTERISE|Cohort 1 Cohort 2
214859381|NCT02636426|DRUG|sorafenib|In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
214859382|NCT05347381|DRUG|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
214859383|NCT04271735|DIETARY_SUPPLEMENT|Niagen|Participants will take two capsules of nicotinamide riboside (NR) by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.
214859384|NCT04271735|OTHER|Placebo|Placebo capsule to match the active supplement. Participants will take two capsules, twice daily for a total of 4 weeks.
214859385|NCT05417035|DRUG|Nebido|To evaluate if traditional treatment induces puberty similary to newer treatment
214859386|NCT00515541|DRUG|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
214859387|NCT04353765|DRUG|Cabozantinib monotherapy|Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
214859388|NCT04353765|DRUG|All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC|As per authorized FDA label in advanced RCC
214859389|NCT05133791|DRUG|Annexin A5|Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
214859390|NCT04964518|DRUG|APG 2575 ramp up arm|APG2575 ramp up + Azacitidine
214859391|NCT06385561|DRUG|Tramadol|Tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200 mg)
214859392|NCT06385561|DRUG|Placebo|Placebo is administered orally twice daily.
214859393|NCT06337253|DRUG|Sulfadoxine/pyrimethamine plus amodiaquine|Seasonal Malaria Chemoprevention with SPAQ has not been trialed or introduced in Malawi yet. This intervention trial is different from others because of the location and because, traditionally, a full round of SMC with SPAQ that involves between 3-5 cycles is administered. Our trial is the first one that will only distribute one cycle of SMC with SPAQ. The data collected during the 42 days after SMC distribution will be used to estimate the medicines chemoprevention effectiveness at preventing malaria in children aged 3-59 months. This data, together with the resistance markers data will then be fed into a dynamical model that collaborators at Imperial College London have developed that will predic the potential impact of upscaling SMC in similar geographies.
214859394|NCT00922272|DRUG|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
214859395|NCT00922272|DRUG|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
214859396|NCT04910516|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage fo
214290557|NCT05560984|COMBINATION_PRODUCT|cervical internal os plasty|A long Allis forceps will be passed through the uterine incision and used to grasp the anterior lip of the cervix, pulling the cervix upwards into the uterine cavity. An assistant sometimes needs to elevate the cervix upwards from the vaginal aspect. The anterior lip of the cervix will be sutured to the anterior wall of the lower uterine segment using two or three simple interrupted absorbable stitches (Vicryl or Vicryl rapid no. 0). This aids to compress the bleeding sites of the placental bed and support the very thin lower uterine segment. If the placenta was implanted posteriorly and the bleeding areas will be mainly from the posterior wall of the uterus, the same procedure could be repeated using the posterior lip of the cervix. A Hegar dilator (size 12) will be inserted in a retrograde manner from the abdominal aspect toensure patency of the cervical canal .
214859397|NCT03609723|PROCEDURE|CABG|CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
214859398|NCT02384135|OTHER|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
214859399|NCT00228514|DRUG|Rosuvastatin|
214859400|NCT00228514|PROCEDURE|Positron emission tomography|
214859401|NCT04619095|DIETARY_SUPPLEMENT|Psyllium|See the information already included in the arm descriptions.
214859402|NCT04619095|DIETARY_SUPPLEMENT|Placebo|See the information already included in the arm descriptions.
214859403|NCT02588950|DRUG|U-500R|
214859404|NCT01830634|BEHAVIORAL|Theraband with strengthening and stretching exercise|"Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day."
214859405|NCT03188718|DEVICE|WatchPAT Intervention|Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
214859406|NCT01374139|DRUG|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
214859407|NCT01374139|DRUG|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
214859408|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
214859409|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
214859410|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
214859411|NCT04498741|DRUG|Tacrolimus|Subjects will receive tacrolimus once daily on Day 1 and Day 24
214859412|NCT04498741|DRUG|Dabigatran|Subjects will receive dabigatran once daily on Day 1 and Day 13
214859413|NCT04498741|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Day 1 and Day 13
214859414|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
214859415|NCT04498741|DRUG|Midazolam|Subjects will receive midazolam once daily on Day 1 and Day 16
214859416|NCT01417819|OTHER|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
214907063|NCT00648882|DRUG|LEVOTHYROXINE SODIUM TABLETS,|2x300mcg, single dose fasting
214290558|NCT02069743|OTHER|ePAL Mobile Application|A mobile application designed to help cancer patients better self-manage cancer pain.
214859417|NCT04912115|DRUG|Ketamine|Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).
214290559|NCT03415841|DEVICE|mHealth remote monitoring devices|"Blood Pressure and wearable vital signs monitor, Biovotion and Kardia mobile application"
214859418|NCT04912115|DRUG|Midazolam|Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.
214859419|NCT05638841|OTHER|After radiofrequency ablation of atrial fibrillation|This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
214859420|NCT03911921|DRUG|RSYRT decoction|Compound granules of traditional Chinese medicine
214859421|NCT03911921|DRUG|Astragalus membranaceus|One herb
214859422|NCT04233086|OTHER|No intervention, observational only|No intervention, observational only
214859423|NCT02035839|DEVICE|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
214859424|NCT02035839|DEVICE|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
214859425|NCT02035839|DEVICE|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
214859426|NCT04252222|DEVICE|Videolaryngoscopy with VL3|Tracheal Intubation aided by VL3 Videolaryngoscope
214859427|NCT03114696|DIETARY_SUPPLEMENT|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
214859428|NCT03114696|DIETARY_SUPPLEMENT|Placebo|1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
214859429|NCT03384017|OTHER|Transcutaneous Spinal Cord Stimulation and Gait Training|"TSCS will be applied using a midline electrode placed on the skin between spinous process T11 -T12 and two electrodes placed symmetrically on the skin over the lower abdomen as anodes. A symmetrical biphasic rectangular waveform, at 50 Hz and 1 millisecond, is used to provide 30 continuous minutes of stimulation.~Subjects will participate in 24 two-hour sessions of physical therapy over eight weeks. In each session, subjects will receive TSCS continuously for 30 minutes, using the parameters outlined above. During stimulation, subjects will participate in strengthening, segmental task practice, and gait-based interventions. Participation in gait training will continue following the stimulation period for the duration of the session."
214859430|NCT03678324|OTHER|Functional MRI and fast bound-pool fraction imaging|"Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.~Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey."
214859431|NCT01034787|DRUG|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
214859432|NCT06165666|OTHER|Approach by functional objectives|The therapeutic approach that will be administered to the EG will be based on the training of specific tasks aimed at functional objectives. Each session will begin with activities to activate the muscles of the trunk, pelvis and lower limbs, to modify atypical movement patterns and prepare the muscles for a more effective contraction. Subsequently, activity training will be carried out in a functional and meaningful context, aimed at specific and significant functional objectives for the participant and previously agreed upon with them.
214859433|NCT06165666|OTHER|Treatment protocol|The therapeutic approach of the participants assigned to the CG will be aimed at maintaining joint ranges and transfer work, passive mobilization of the paretic lower and upper limb, maintenance of sitting posture with/without assistance, transfer from sitting to standing, from standing to sitting. and coordination work. Subsequently, initiation of walking with a support product and/or help, if possible.
214859434|NCT05043623|DEVICE|Rhinoswab Junior|Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages
214859435|NCT05043623|DEVICE|Combined nose and throat swab|Combined nose and throat swab (standard of care)
214859436|NCT05043623|DEVICE|Saliva swab|Saliva swab
214859437|NCT05043623|DIAGNOSTIC_TEST|Abbott Panbio™ COVID-19 antigen self-test kit|COVID-19 antigen self-test kit for the screening of active COVID-19 infection. It is a single-use, in vitro, visually read rapid immunoassay that uses a human nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen. It is intended to be used manually by untrained lay users (self testing) in a private setting.
214859438|NCT02479542|OTHER|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
214859439|NCT02479542|DEVICE|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
214907064|NCT00648882|DRUG|SYNTHROID® 300 mcg Tablets|2x300mcg, single dose fasting
214290560|NCT05000125|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
214290561|NCT05611203|PROCEDURE|An Oropharyngeal swab|An Oropharyngeal swab performed for diagnostic purposes
214859440|NCT03826498|BIOLOGICAL|CP CB-MNC injection|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
214859441|NCT03826498|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training etc.
214859442|NCT04129320|BIOLOGICAL|enoblituzumab|anti-B7-H3 antibody
214859443|NCT04129320|BIOLOGICAL|MGA012|anti-PD-1 antibody
214859444|NCT04129320|BIOLOGICAL|MGD013|PD-1 X LAG-3 bispecific DART protein
214859445|NCT04375852|DIAGNOSTIC_TEST|Detection of autoantibodies|Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
214859446|NCT03832699|DRUG|Dydrogesterone 10 MG|Oral progesterone 10 mg TID
214859447|NCT03832699|DRUG|Endometrin 100Mg Vaginal Insert|Vaginal Endometrin 100 mg twice daily
214859448|NCT02072824|DRUG|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
214859449|NCT02072824|DRUG|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
214859450|NCT02072824|DRUG|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
214859451|NCT03084367|DIAGNOSTIC_TEST|iFR pullback|iFR pullback assessment post angiographically successful PCI
214859452|NCT02564081|OTHER|Static Stretching lower limb|
214859453|NCT02564081|OTHER|Static stretching Cervical|
214859454|NCT03413137|PROCEDURE|Transperineal mpMRI-US Fusion prostate biopsy|mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).
214859455|NCT03413137|PROCEDURE|Transrectal mpMRI-US Fusion prostate biopsy|using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.
214859456|NCT03863093|DEVICE|Electro Medical Systems AIRFLOW®|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
214859457|NCT03863093|DEVICE|Electro Medical Systems Piezo|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
214859458|NCT02148861|DRUG|Insulin icodec|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
214859459|NCT02148861|DRUG|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
214859460|NCT02148861|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
214290562|NCT00010374|DEVICE|NeuRx DPS|Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.
214859461|NCT03251274|OTHER|machine bathing|machine bathing 20-min duration at evening
214290563|NCT03305198|BIOLOGICAL|Capillary blood sampling from the earlobe|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
214290564|NCT02664454|OTHER|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care"
214290565|NCT03791476|DRUG|rhC1INH|C1 esterase inhibitor
214290566|NCT03791476|OTHER|Saline Solution|saline solution
214859462|NCT03251274|OTHER|traditional bathing|traditional bathing
214859463|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
214859464|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Current Adhesive|single application
214859465|NCT00841906|DEVICE|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
214859466|NCT00841906|DEVICE|Alice PDx with written and verbal instructions|Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
214859467|NCT00345059|DRUG|docetaxel|
214859468|NCT00345059|DRUG|vinorelbine|
214290567|NCT04326907|PROCEDURE|Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy|Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
214859469|NCT00345059|DRUG|gemcitabine|
214859470|NCT00345059|DRUG|capecitabine|
214859471|NCT05211999|BEHAVIORAL|Precede-Proceed Model Based Simulation Experience|The program was created on the basis of the PRECEDE-PROCEED Model.The program consists of eight phases. It will be carried out with theoretical training and simulation experience in the experimental group. In the control group, theoretical training will be given. Results will be followed.
214859472|NCT05211999|BEHAVIORAL|Control Group|No intervention in control group just theoretical education was done for them.
214859473|NCT02290275|DIETARY_SUPPLEMENT|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
214859474|NCT02290275|OTHER|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
214859475|NCT02290275|DIETARY_SUPPLEMENT|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
214859476|NCT06492200|OTHER|Psyllium husks|Patients in the intervention group will receive nutritional counseling and will be asked to take 10g (one tablespoon) of ground psyllium husks daily to significantly increase the fiber content of their diet.
214859477|NCT03962582|DEVICE|Matrix back|The Matrix back will replace the individual's back and the measures will be taken.
214859478|NCT04823962|DRUG|rhGM-CSF + hydrogel|The active substance: molgramostim (rhGM-CSF)
214859479|NCT04823962|DRUG|Placebo hydrogel|Placebo hydrogel
214859480|NCT04823962|OTHER|Standard care|Compression therapy and neutral dressings
214859481|NCT03798665|DRUG|Pegfilgrastim（PEG-rhG-CSF）|From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency
214859482|NCT00903448|DRUG|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
214859483|NCT00903448|DRUG|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
214665282|NCT05170360|DIAGNOSTIC_TEST|Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:|"1. Assessment of smoking exposure:~   Serum cotinine will be measured by using serum cotinine ELISA kits~2. Assessment of heavy metal exposure:~   Lead and cadmium will be measured using Graphite Tube Atomizer.~3. Assessment of organophosphorus exposure:~   By measuring pseudocholinesterase level by spectrophotometer~4. Mutational analysis of the KRAS and BRAF genes:~the tissue samples will be used to determine the mutation in k-ras and BRAF genes by RCR"
214665283|NCT03182738|BEHAVIORAL|VIP app without HIV-related symptom strategies.|The control group will receive the VIP app without HIV-related symptom strategies
214665284|NCT03182738|BEHAVIORAL|VIP app that delivers HIV-related symptom strategies.|The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
214665285|NCT04329026|DEVICE|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
214665286|NCT04329026|DEVICE|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
214665287|NCT03934762|BIOLOGICAL|Placebo|A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.
214665288|NCT03934762|BIOLOGICAL|Natural Aloe Vera|Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
214665289|NCT03934762|BIOLOGICAL|Aloe vera soup|Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
214665290|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using a vial and syringe.
214665291|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using AI.
214665292|NCT01043640|DRUG|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
214665293|NCT01043640|DRUG|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
214665294|NCT01043640|DRUG|Busulfan|Administered every 6 hours: If \< or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If \> 12 kg then 0.8 mg/kg/dose IV
214859484|NCT05712525|DIAGNOSTIC_TEST|G-Tech Wireless Patch System (WPS)|Noninvasive monitoring of myoelectrical signals
214859485|NCT04340817|DIAGNOSTIC_TEST|Proteomics|Mass-spectometry proteomics
214859486|NCT04340817|DIAGNOSTIC_TEST|Transcriptomics|Next generation sequencing
214859487|NCT04340817|GENETIC|Genomics|Targeted genetics
214859488|NCT00206765|DRUG|Risperidone|
214859489|NCT00206765|DRUG|Paroxetine|
214859490|NCT03632317|DRUG|Panobinostat|30 mg/m\^2
214859491|NCT03632317|DRUG|Everolimus|3.0 mg/m\^2
214859492|NCT01739296|OTHER|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
214859493|NCT01739296|OTHER|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
214859494|NCT01075841|DRUG|Cetuximab|Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. where Erbitux is used in combination with platinum-based therapy for the treatment of subjects with recurrent and/or metastatic SCCHN) according to the approved national label as in routine clinical practice under the supervision of an investigator experienced in the use of antineoplastic medicinal products.
214859495|NCT01626521|OTHER|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
214859496|NCT02212002|DRUG|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
214665295|NCT01043640|PROCEDURE|Allogeneic stem cell transplantation|Administered \> 24 hours after last dose of busulfan.
214665296|NCT01043640|DRUG|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV\_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~* If body weight is ≤ 40 kg dosing will be 3 times daily~* If body weight is \> 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
214859497|NCT00225121|DRUG|PF-00299804|investigational drug by oral route (escalating doses depending on safety) administered until progression
214859498|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
214859499|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
214859500|NCT04111406|DRUG|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
215033624|NCT01767987|DRUG|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
215033625|NCT03232567|BIOLOGICAL|NasoVAX|Single ascending dose study
215033626|NCT05837481|BEHAVIORAL|Meditation|Guided meditation utilizing breath awareness, body scan and visualization techniques
214859501|NCT04111406|DRUG|Protocol based|"Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~1. insertion at mid-level of surgical insertion~2. insertion depth is 3-5 cm in space, not more than 5 cm~3. using benzoin tincture and transparent dressing to fix catheter~4. test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~5. After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage"
214859502|NCT02002000|DRUG|vitamin D (cholecalciferol)|Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
214859503|NCT02002000|DRUG|Placebo, similar in appearance and taste to cholecalciferol|Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
214859504|NCT04859842|OTHER|Pulse Electromagnetic Field|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with PEMF in prone position. Each session will be 45 minute long with a 15 minute PEMF therapy and a 30 minute conventional therapy program.
214859505|NCT04859842|OTHER|Interferential Current|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with Interferential current in prone position. Four interferential electrode will be placed on low back region. Each session will be 45 minute long with a 15 minute interferential current and a 30 minute conventional therapy program.
214859506|NCT04859842|OTHER|Sham|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with conventional therapy and sham electrotherapy. Sham application will be performed on prone position with four electrodes and electrodes will stay for 15 minutes on this region.
214859507|NCT05767606|BIOLOGICAL|NVX|Administration of NVX
214859508|NCT05767606|BIOLOGICAL|PCV20|Administration of PCV20
214859509|NCT05767606|BIOLOGICAL|Placebo|No intervention
214859510|NCT00728442|DEVICE|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
214859511|NCT05387707|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablets administered twice daily
214859512|NCT05387707|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablets administered twice daily
214859513|NCT05387707|DRUG|TCS Cream|TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
214859514|NCT05387707|DRUG|Placebo|Oral Placebo tablets administered twice daily
214859515|NCT05387707|DRUG|Vehicle Cream|Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
214859516|NCT01816815|DRUG|BAY1002670|
214859517|NCT01816815|DRUG|Placebo|
214859518|NCT02957188|OTHER|13C eicosapentaenoic acid and 13C arachidonic acid|Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
214859519|NCT02667288|DRUG|A-101 Solution|
214859520|NCT06219993|PROCEDURE|robot-assisted modified Kasai portoenterostomy|"1. A 1.0 cm incision was made around the umblilicus for the camera port. 1.Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis.~2. dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot."
214859521|NCT06219993|PROCEDURE|traditional open Kasai portoenterostomy|Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).
214859522|NCT00912093|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
214859523|NCT00912093|DRUG|Placebo|Single subcutaneous injection of matching placebo
214859524|NCT01314378|BEHAVIORAL|Mindfulness Training|Eight session intensive behavioral training program for smokers
214859525|NCT01314378|BEHAVIORAL|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
214859526|NCT02470793|PROCEDURE|Descemet Stripping Automated Endothelial Keratoplasty|Descemet Stripping Automated Endothelial Keratoplasty
214859527|NCT02470793|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Descemet Membrane Endothelial Keratoplasty
214859528|NCT00700609|BEHAVIORAL|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
214859529|NCT01672944|OTHER|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
214859530|NCT01672944|OTHER|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
214859531|NCT04058574|DEVICE|Proprioception measurement on isokinetic dynamometer|Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
214859532|NCT05029401|DRUG|DMX-1002|Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)
214859533|NCT05029401|DRUG|Placebo|Matching placebo to the IMP (DMX-1002)
214859534|NCT05312242|DIETARY_SUPPLEMENT|United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) MMS|Introduction of UNIMMAP MMS along with novel counseling strategies to increase acceptability and adherence to prenatal supplementation
214859535|NCT05312242|DIETARY_SUPPLEMENT|Iron Folic Acid Supplement|Standard of Care Intervention
214859536|NCT01280409|DRUG|Metformin|Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks
214665297|NCT01043640|DRUG|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC\>500 x 10\^6 neutrophils/L x 3 days and chimerism \>90%), whichever is later.
214665298|NCT03835663|DIAGNOSTIC_TEST|No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes|Standard upper GI endoscopy with biopsies
214665299|NCT00304473|DRUG|Quetiapine fumarate|
214665300|NCT04421651|BEHAVIORAL|Dance Movement Therapy group|DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks.
214665301|NCT01912118|DRUG|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
214859537|NCT01280409|DRUG|Placebo|Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
214859538|NCT04171271|BEHAVIORAL|Activating kinesthetic motor imagery training|Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
214859539|NCT04171271|BEHAVIORAL|Relaxing kinesthetic motor imagery training|Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
214859540|NCT04397445|DRUG|Ranitidine|Ranitidine 300 mg
214859541|NCT04397445|DRUG|Placebo|Oral placebo tablet
214859542|NCT04397445|OTHER|Low nitrite/NDMA meals|Meals containing low levels of nitrites and NDMA
214859543|NCT04397445|OTHER|High nitrite/NDMA meals|Meals containing higher levels of nitrites and NDMA
214859544|NCT00358293|DRUG|Tizanidine (sublingual or oral)|
214859545|NCT04666415|OTHER|Osteopathic treatment|Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
214859546|NCT03921151|DRUG|Mirtazapine 15 MG Oral Tablet|The intervention will be a 15mg of mirtazapine oral tablet given to participants prior to their treatment scan and assessments. In order to ensure that biases or social desirability do not contaminate baseline assessments, all participants will also be given a tablet consisting of dextrose in gelatin prior to their baseline scan and assessment.
214859547|NCT02214368|OTHER|Early application of NIV|"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
214859548|NCT02214368|DEVICE|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
214859549|NCT02214368|DRUG|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."
214859550|NCT02214368|OTHER|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate\>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2\> 0.5 or breathing at least 10 L/min oxygen.
214859551|NCT01207648|DRUG|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
214859552|NCT04273581|DRUG|placebo|100mg/d，qn，for 14 days.
214859553|NCT04273581|DRUG|Thalidomide|100mg/d，qn，for 14 days.
214859554|NCT04530240|PROCEDURE|Liver Transplantation|Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
214665302|NCT01912118|DRUG|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
214859555|NCT00003144|DRUG|amifostine trihydrate|
214859556|NCT00003144|DRUG|cisplatin|
214859557|NCT00003144|DRUG|gemcitabine hydrochloride|
214859558|NCT03219931|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|This is the active product containing 108 viable cells/strain
214859559|NCT03219931|DRUG|Placebos|This is the placebo product containing a similar product without bifidobacterium inside.
214859560|NCT00941057|DRUG|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
214859561|NCT00941057|DRUG|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
214859562|NCT00941057|DRUG|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
214859563|NCT06271720|OTHER|visceral manipulation|"visceral manipulation: A palpation technique will be applied till the barrier is felt and it will be applied until release is felt.~integrated neuromuscular inhibition: ischemic compression will be applied to trigger point of upper trapezius"
214859564|NCT06271720|OTHER|integrated neuromuscular inhibition|It involves applying direct sustained digital pressure to the TrP with sufficient force over dedicated time duration, to slow down the blood supply and relieve the tension within the involved muscle. The pressure is gradually applied, maintained and the gradually released
214859565|NCT03828266|OTHER|No intervention|Patients will undergo routine clinical practice. There is no additional intervention.
214859566|NCT01254474|DEVICE|Cardiac chambers mapping with MAP 4|
214859567|NCT00085774|DRUG|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
214859568|NCT00085774|DRUG|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
214859569|NCT00085774|DRUG|placebo aerosol by HFA|placebo HFA
214859570|NCT04613674|DRUG|Camrelizumab Plus Chemotherapy|camrelizumab+chemotherapy
214859571|NCT04613674|DRUG|placebo+chemotherapy|placebo+chemotherapy
214859572|NCT03187366|OTHER|Bottom-up intervention|Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
214859573|NCT03983174|PROCEDURE|Drainage seton with flap|Seton is placed around the external sphincter then mucosal advancement flap will be constructed
214859574|NCT03983174|PROCEDURE|EAS sparing seton|Rerouting of the seton around the internal sphincter only sparing the external sphincter
214859575|NCT03390348|DEVICE|LENA Recorder|Use of the LENA recorder to document crying and fussing
214859576|NCT00270257|DRUG|Buprenorphine/Naloxone|Oral tablet
214859577|NCT03667014|DRUG|Dupilumab|Dupilumab treatment
214859578|NCT03501914|BEHAVIORAL|Mindfulness|A mindfulness program based on mindfulness-based principles developed by colleagues in Manchester will be adapted to be accessible for people with intellectual disabilities (ID) in Pakistan. This intervention will be translated into Urdu afterwards focus group will be conducted to get the views from people with ID, thei care takers and other stake holders to adapt and culturally modify the program. It will include some mindfulness based exercises i.e.welcome \& introduction, exploring senses, its all in the mind, Mindful eating, breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking.
214859579|NCT04188314|DRUG|Desflurane|The intervention group will receive desflurane for maintenance of anaesthesia, and the quality of recovery score will be compared post-operatively with the control group who received isoflurane.
214859580|NCT04188314|DRUG|Isoflurane|The control group will receive Isoflurane for maintenance of anesthesia. The quality of recovery score will be compared post-operatively with patients in the intervention group who received desflurane.
214859581|NCT03018210|PROCEDURE|Surgical repair of the rotator cuff|
214859582|NCT02319395|GENETIC|Blood Sampling and DNA collection|"One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or coding SNP  (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate."
214859583|NCT02799238|BIOLOGICAL|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
214859584|NCT02799238|RADIATION|Radiotherapy|Radiotherapy 5 days/week for 6 weeks
214859585|NCT02799238|DRUG|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
214859586|NCT01781819|PROCEDURE|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
214859587|NCT01630681|BEHAVIORAL|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
214859588|NCT03001219|DRUG|Anti-TNF-alpha|Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
214859589|NCT03001219|DRUG|Methotrexate|Participants will continue their pre-trial methotrexate therapy at a stable dose.
214859590|NCT03001219|DRUG|Placebo|Participants will receive intravenous infusion of placebo.
214859591|NCT03001219|DRUG|RO7123520|Participants will receive intravenous infusion of RO7123520.
214859592|NCT02302664|PROCEDURE|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
214859593|NCT02302664|PROCEDURE|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
214859594|NCT00001993|DRUG|Butyldeoxynojirimycin|
214859595|NCT00001993|DRUG|Zidovudine|
214859596|NCT05033574|DIAGNOSTIC_TEST|Biochemical study of hormone levels|Biochemical study of the level of follicle-stimulating hormone, luteinizing hormone, estradiol, total testosterone, prolactin, 17-hydroxyprogesterone, dehydroepiandrosterone sulfate, cortisol, insulin, thyroid-stimulating hormone, tetraiodothyronine, thyr
214859597|NCT05033574|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys
214859598|NCT05033574|RADIATION|Radiography of the hands|Determination of bone age using radiography of the hands
214859599|NCT05033574|BEHAVIORAL|Consultation of a medical psychologist|Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence
214859600|NCT02860065|DRUG|CPC-201|solifenacin and donepezil
214859601|NCT02860065|OTHER|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
214859602|NCT01043120|DRUG|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
214859603|NCT01043120|DRUG|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
214859604|NCT03733210|DRUG|Panitumumab-IRDye800|30 mg administered intravenously (IV)
214859605|NCT03733210|DRUG|89-Zirconium (Zr-89) Panitumumab|0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
214859606|NCT03733210|DEVICE|Pinpoint IR IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
214859607|NCT03733210|DEVICE|SPY-PHI IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
214859608|NCT03733210|DEVICE|Explorer Air camera|Fluorescence camera manufactured by SurgVision
214859609|NCT03733210|DEVICE|PDE-NEO II camera|Medical infrared camera manufactured by Hamamatsu Photonics KK
214859610|NCT03733210|DEVICE|FIS-00 fluorescence imaging system (FIS)|Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
214859611|NCT03733210|DEVICE|Da Vinci Firefly Imaging System|Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
214859612|NCT03733210|DEVICE|IGP-ELVIS-v4 Macroscopic Specimen Imager|Macroscopic specimen imager manufactured by LI-COR Biosciences
214859613|NCT03733210|DEVICE|Vevo 3100 LAZR-X|Photoacoustic ultrasound imaging system manufactured by VisualSonics
214859614|NCT03733210|DEVICE|Pearl Triology Imaging System|Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
214859615|NCT03733210|DEVICE|Odyssey CLx Imaging System|Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
214859616|NCT03733210|DEVICE|Leica fluorescence microscope|Fluorescence microscope manufactured by Leica
214859617|NCT01237925|DRUG|Dexchlorpheniramine 1% gel|Small amount applied over the lesion twice a day for 7 days
214859618|NCT01237925|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
214859619|NCT02621034|PROCEDURE|Control|K-file hand instrumentation
214859620|NCT02621034|PROCEDURE|Reciproc|reciprocating rotary instrument
214859621|NCT02621034|PROCEDURE|One shape|full rotation protocol
214859622|NCT04683666|PROCEDURE|Bariatric surgery|Laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), as primary bariatric procedures, were performed. \^Postoperative complications were assessed.
214859623|NCT00999765|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|eight-week (two hours a week) group therapy (8-12 patients per group)
214859624|NCT05561530|DRUG|ALG-125755|single or multiple doses of ALG-125755
214859625|NCT05561530|DRUG|Placebo|single or multiple doses of placebo
214859626|NCT06026020|OTHER|Biological samples collection|Samples of blood, faeces, saliva are collected for analysis.
214859627|NCT02293330|DRUG|continuous infusion of levobupivacaine|continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
214859628|NCT02293330|DRUG|Intermittent bolus infusion of levobupivacaine|Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
214859629|NCT00977730|DIETARY_SUPPLEMENT|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
214859630|NCT00977730|DIETARY_SUPPLEMENT|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
214859631|NCT00727948|DRUG|Aspirin|325 mg tablets, once daily for 45 days
214859632|NCT00574925|DRUG|Esomeprazole|
214859633|NCT04941339|DRUG|MRG002|Administrated intravenously
214859634|NCT01939925|OTHER|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
214859635|NCT01939925|OTHER|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
214859636|NCT03970486|PROCEDURE|Dry needling|For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.
214859637|NCT01787539|DRUG|Postoperative Chemotherapy|"Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery."
214859638|NCT00686530|PROCEDURE|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
214859639|NCT00686530|PROCEDURE|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
214859640|NCT03121430|DEVICE|Drug eluting peripheral vascular stent system|Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
214859641|NCT03121430|DEVICE|Nitinol Stent System|Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
214859642|NCT05214963|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode
214859643|NCT05214963|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode
214859644|NCT01246622|DRUG|cytarabine|Given IV
214859645|NCT01246622|DRUG|lenalidomide|Given PO
214859646|NCT02271139|DRUG|Alectinib|Alectinib 600 mg administered orally with food.
214859647|NCT02963441|DEVICE|LumineticsCore (formerly IDX-DR)|Prospective analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
214859648|NCT02955017|BEHAVIORAL|traditional follow_up|"* Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~* Two days of a complete medical check at 9 and 15 months"
214859649|NCT02955017|BEHAVIORAL|"distance follow-up new technologies"|"* Multidisciplinary support with long distance monitoring Mobile apps.~* Two days of a complete medical check at 9 and 15 months"
214859650|NCT02399735|BIOLOGICAL|Low Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
214859651|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
214859652|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×8 times|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
214859653|NCT00345735|DRUG|Fentanyl|
214859654|NCT01530763|DRUG|Ceftaroline fosamil|"Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children \< 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)"
214859655|NCT01530763|DRUG|Ceftriaxone|"Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)"
214859656|NCT01530763|DRUG|amoxicillin clavulanate|"Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)"
214859657|NCT01338649|DEVICE|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
214859658|NCT01338649|DEVICE|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
214859659|NCT06219590|PROCEDURE|Acetylcholine Iontophoresis|Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
214859660|NCT06219590|PROCEDURE|Shame Acetylcholine Iontophoresis|Shame Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
214859661|NCT02603302|RADIATION|Dose Escalation Radiotherapy|RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
214859662|NCT02603302|PROCEDURE|Delayed surgery|Surgery after 8 weeks with TME (total mesorectal excision)
214859663|NCT01140490|PROCEDURE|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
214290568|NCT02526472|PROCEDURE|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
214665303|NCT00527202|DRUG|botulinum toxin A|Botulinum toxin A versus saline in parallel groups
214859664|NCT02926820|BEHAVIORAL|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
214859665|NCT03290365|DRUG|platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
214859666|NCT03290365|DRUG|platelet rich plasma + normal saline|The normal salin as the placebo intervention was injection control group.
214859667|NCT04871763|OTHER|Retainers' Cleansing with Geldis®|Patients will clean their essix retainers with Geldis® using a toothbrush every night for 2 months.
214859668|NCT04871763|OTHER|Retainers' Cleansing with tablets|Patients will leave their essix retainers in a glass with water and Polident tablets every night for 2 months.
214859669|NCT04871763|OTHER|Retainers' cleansing with water|Patients will brush their essix retainers with a toothbrush under water every night for 2 months.
214859670|NCT00361335|DRUG|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
214859671|NCT00361335|DRUG|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
214859672|NCT00361335|DRUG|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
214859673|NCT05469217|OTHER|fMRI brain imaging|Structural MRI of gray and white matter, functional MRI during performance of the N-back task
214859674|NCT04969718|OTHER|LEADS Plus educational posters|This intervention covers depression and its symptoms, the link between depression and suicide, the risk and protective factors associated with suicide, the warning signs of suicide, seeking help and overcoming barriers to seeking help, and school and community suicide prevention resources. Six educational posters will also be displayed in class rooms
214859675|NCT04969718|OTHER|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers, originally developed in the USA which to train teachers/school staff to identify the suicide risk in students and encourage students at risk of suicide to seek professional help. Six educational posters will also be displayed in classrooms.
214859676|NCT04969718|OTHER|Screening by Professionals programme plus educational posters|This is an indicated or selective intervention which is based on students' responses to the baseline questionnaires. Participating health professionals review students' responses to the questionnaires used in the study and students whose scores meet pre-established cutoff points will be invited to participate in a professional mental health clinical assessment and if needed, referred to clinical services. Six educational posters will also be displayed in classrooms.
214859677|NCT04969718|OTHER|educational posters|Six educational posters will be displayed in all schools in this cluster.
214859678|NCT04969718|OTHER|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents), originally developed in the USA which to train parents to support the young people at risk of suicide. Six educational posters will also be displayed in classrooms.
214859679|NCT04327713|DIETARY_SUPPLEMENT|fish oil supplement|daily fish oil supplement vs. placebo
214859680|NCT02774096|DRUG|xenon|
214859681|NCT03449836|COMBINATION_PRODUCT|Streptococcus salivarius 24SMBc + Strept. oralis 89a|nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
214859682|NCT03449836|COMBINATION_PRODUCT|fluticasone + mometasone|nasal spray based on fluticasone + mometasone
214859683|NCT03449836|OTHER|placebo|nasal spray based on isotonic solution
214859684|NCT00006235|DRUG|carboplatin|
214859685|NCT00006235|DRUG|pegylated liposomal doxorubicin hydrochloride|
214859686|NCT04205019|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
214859687|NCT04004143|OTHER|No intervention|No intervention.
214859688|NCT04192279|DIAGNOSTIC_TEST|lactate clearance|Lactate clearance rate was monitored within 6 hours after admission
214859689|NCT04852900|OTHER|Decompression with 30%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
214859690|NCT04852900|OTHER|Decompression with 40%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
214859691|NCT04852900|OTHER|Decompression with 50%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
214859692|NCT05194878|DRUG|neoadjuvant chemotherapyI|mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
214859693|NCT05194878|PROCEDURE|Colectomy|Radical colectomy
214859694|NCT05194878|DRUG|adjuvant chemotherapy|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
214859695|NCT00601809|OTHER|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
214859696|NCT00601809|DRUG|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
214859697|NCT01327261|DRUG|Levodopa + benserazide|Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
214290569|NCT02526472|PROCEDURE|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
214859698|NCT05065983|BIOLOGICAL|CHIKV VLP, adjuvanted|Adjuvanted formulation includes aluminum hydroxide
214859699|NCT00986180|DRUG|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
214859700|NCT00986180|DRUG|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
214859701|NCT03318276|DRUG|SID142|SID142 is administrated to patients with PAD for 12 weeks
214859702|NCT03318276|DRUG|Rinexin® Tab|Rinexin® Tab is administrated to patients with PAD for 12 weeks
214290570|NCT02424747|OTHER|Acute Kidney Injury|"We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission."
214859703|NCT01074762|BEHAVIORAL|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
215033627|NCT05361616|DEVICE|PBM Ortho|The device will be used by the patients at home for one 8 minutes per day (4 minutes each upper and lower) for 7 days.
214290571|NCT02504008|DRUG|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
214290572|NCT02504008|DRUG|Placebo|Once weekly for 6 weeks
214290573|NCT04262505|BEHAVIORAL|Mediterranean Diet Group|Participants will be advised to follow a traditional Mediterranean diet
214859704|NCT01765582|DRUG|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m\^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
214859705|NCT01765582|DRUG|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
214859706|NCT01765582|DRUG|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
214859707|NCT01765582|DRUG|irinotecan|Participants will receive IV infusion of 165 mg/m\^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m\^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
214859708|NCT01765582|DRUG|folinic acid|Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.
214859709|NCT01765582|DRUG|oxaliplatin|Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
214859710|NCT00729274|DRUG|normal saline solution|Two 4ml nebulizations with 30 minute interval
214859711|NCT05757882|OTHER|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water.
214859712|NCT05757882|OTHER|2 hours of fasting time|Oral intake is not allowed for 2 hours before sedation including water.
214859713|NCT01691820|PROCEDURE|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
214859714|NCT01691820|PROCEDURE|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
214859715|NCT01691820|PROCEDURE|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
214859716|NCT00074776|DRUG|Lithium|Participants will receive lithium.
214859717|NCT00074776|DRUG|Lamotrigine|Participants will receive lamotrigine.
214859718|NCT05467046|DEVICE|Smartwatch system|The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
214859719|NCT02668926|DRUG|Lisdexamfetamine, d-amphetamine, Placebo|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
214859720|NCT02668926|DRUG|d-amphetamine, Placebo, Lisdexamfetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
214859721|NCT02668926|DRUG|Placebo, Lisdexamfetamine, d-amphetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
214859722|NCT03261960|DRUG|BLI4700|Oral bowel preparation
214859723|NCT03261960|DRUG|Magnesium bowel preparation|Oral bowel preparation
214859724|NCT04768166|DRUG|Miglustat 100 MG|100mg/TID in 4w then 200mg/TID in 8 w
214859725|NCT04493320|DRUG|Carbidopa/levodopa|150-450mg carbidopa/levodopa 3 times daily
214859726|NCT04493320|DRUG|Placebo|Carbidopa/levodopa-matched placebo tablet 3 times daily
214290574|NCT04262505|BEHAVIORAL|Healthy Eating Group|Participants will be advised to follow the Healthy Eating Guidelines in Ireland
214290575|NCT00449046|DRUG|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
214290576|NCT03973840|DRUG|Testosterone Undecanoate|dose was given orally and allowed to reach steady state
214859727|NCT05746065|DRUG|PrEP|Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.
214859728|NCT06431165|DRUG|Lidocaine IV|After confirming patient history, type of operation and patient group allocation, standard ASA monitoring will be attached to the patient then the I.V induction of anesthesia will be commenced using standard doses of Propofol \&Tracrium in addition to 1 μg/kg Fentanyl and 1 ml/10 kg from the bolus Lidocaine syringe followed after 3 minutes by endotracheal intubation, then the Lidocaine infusion Syringe will be attached to a separate I.V line at an infusion rate of 1 ml/10 kg/h. The patient will receive 1 gm of I.V paracetamol and the surgery will be allowed to proceed.
214859729|NCT04070586|DEVICE|4DCBCT images|Images are acquired and assessed offline
214859730|NCT02745886|DRUG|metformin 0.85 twice daily for 6 months|
214859731|NCT02745886|BEHAVIORAL|Calorie restriction|
214859732|NCT03205930|BIOLOGICAL|Neo-MASCT|The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
214859733|NCT05369286|DRUG|"MAX-40279-01 and Toripalimab"|"MAX-40279-01combined with Toripalimab"
214859734|NCT05676086|BEHAVIORAL|indoor light intervention|"Persons allocated to the indoor light intervention arm will be given a lamp to be placed at home with specific instructions to install it in a room where they spend most of their time, in order to supplement the existing indoor lighting. Thus, all people of the intervention arm will be equipped with the LUMIE Halo lamp. Utilizing both warm-white and cool-white LEDs, Lumie Halo delivers 10,000 lux at 20 cm at maximum brightness in Day Mode. The touch slider allows the user to adjust the brightness while mixing the color temperature of the light."
214859735|NCT05676086|BEHAVIORAL|no indoor light|Persons allocated to the control group will receive no indoor light supplementation and will undergo assessment procedures only. Exposure to the outdoor intervention will be taken into account in the analysis in three ways, (1) by locating the distance between people's home and the modified outdoor light, (2) by a question about the awareness of the change in outdoor light, timing, and duration of exposure and what they think of it, and (3) by recording the amount of light exposure over the 24 hours during two weeks at baseline and after the 1-year light interventions
214859736|NCT01608386|PROCEDURE|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
214859737|NCT02195466|DRUG|Tipranavir (TPV)|500 mg bid on days 7-14
214859738|NCT02195466|DRUG|Ritonavir (RTV)|200 mg bid on days 7-14
214859739|NCT02195466|DRUG|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
214859740|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of 5% dextrose in water (D5W) and administered subcutaneously as a single injection.
214859741|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of D5W, mixed with 0.5 mL of Montanide, and administered subcutaneously as a single injection.
214859742|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) and 1.4 mg of poly-ICLC were emulsified in 1.0 mL of Montanide and administered subcutaneously as two injections.
214859743|NCT00425334|DRUG|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
214859744|NCT00425334|DRUG|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
214859745|NCT02893202|OTHER|Therapeutic Horseback riding|An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
214859746|NCT00000408|PROCEDURE|Patient education evaluation|
214859747|NCT01988506|DRUG|Interleukin 2|Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
214859748|NCT06258759|BIOLOGICAL|autologous platelet-rich plasma supplement|the semen of the additional autologous platelet-rich plasma supplement group will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
214859749|NCT06258759|BIOLOGICAL|no autologous platelet-rich plasma supplement|the semen mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
214859750|NCT02773459|DRUG|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
214859751|NCT00755859|DRUG|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
214859752|NCT00755859|DRUG|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
214859753|NCT00173875|DRUG|Iressa|
214859754|NCT02887300|BEHAVIORAL|Mantra Meditation|"Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
214859755|NCT00435396|BIOLOGICAL|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
214859756|NCT05102136|DRUG|REGN9933|Administered intravenously (IV) or subcutaneous (SC) per the protocol
214859757|NCT05102136|DRUG|Placebo|Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol
214859758|NCT00714493|BIOLOGICAL|Infliximab|3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
214859759|NCT05005871|OTHER|Quadratus lumborum block after C-section surgery as postoperative pain management|To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.
214859760|NCT02372071|DEVICE|BiliCare|Two measurements with the BiliCare device
214859761|NCT01297387|OTHER|PTA BPG procedure,|Surgery PTA or BPG Procedure, according usual local clinical practice
214859762|NCT05824247|DEVICE|68Ga-FAPI-PET-CT|a new technology that using Fibroblast activation protein （FAP）inhibitor as the tracer of PET-CT
214859763|NCT00506129|DRUG|Fludarabine|25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
214859764|NCT00506129|DRUG|Melphalan|70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
214859765|NCT00506129|PROCEDURE|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
214859766|NCT00506129|DRUG|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
214859767|NCT06004219|BEHAVIORAL|Peer counseling group|A community advisory board (CAB) will be set up for need assessment and to design the peer support program. Virtual meetings will be held quarterly for year 1 and 2. The group will consist of (up to 12 members) and will include at least 2 patient partners (patients with a recently diagnosed ulcer), 2 peer pals (patients with a healed DFU), family members or caregivers (limited to only 1 person per family represented on the CAB), healthcare workers (podiatrist, nurse, or case manager), medical equipment company representatives, and others. We will ask them about potential barriers at the first meeting, have flexible meeting times, and intentionally limit the number of healthcare providers. At the last meeting, we will seek feedback and input from the CAB. In addition, this group will have the opportunity to participate in a focus group which will be moderated with a trained, bilingual assistant and will last 40-60 minutes.
214859768|NCT05227300|DRUG|Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
214859769|NCT05227300|DRUG|2% lidocaine with 1:100,000 epinephrine|Septodont's standard formulation of 2% lidocaine with epinephrine
214859770|NCT01483053|DRUG|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
214290577|NCT00192829|PROCEDURE|Blood sample withdrawal|
214290578|NCT02875860|DEVICE|GoldBal2 detachable balloon|Placement of the balloon using the plug/unplug method.
214290579|NCT02875860|DEVICE|Baltaccidbpe100 Delivery Catheter|The catheter assists with implanting the balloon in the plug/unplug method.
214859771|NCT01483053|DRUG|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
214859772|NCT03940794|OTHER|Verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. A transabdominal Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
214859773|NCT01261286|DRUG|verapamil|
214859774|NCT04989712|OTHER|Exposure|Participants randomised to one of the three exposures
214859775|NCT05876455|PROCEDURE|Conventional Subgingival Instrumentation|On the conventional non-surgical periodontal therapy side, a power-driven piezo-electric ultrasonic scaling device with scaling tips will be used the majority of the time to debride subgingival biofilm and calculus, and manual standard Gracey curette instruments (Gracey curettes Hu-Friedy, Chicago, IL, USA) will be used to remove residual deposits from the root surface.
214859776|NCT05876455|PROCEDURE|minimally invasive non-surgical periodontal therapy|minimally invasive non-surgical periodontal therapy will undergo careful scaling and root planing under magnification (use of 3.5 X magnification loupes) with mini curettes and using an ultrasonic device with specific thin and delicate tips. These instruments will be carefully inserted through the periodontal pocket of the affected tooth to reach the root surface for debridement. Caution will be taken to preserve the stability of soft tissues.
214859777|NCT03306524|DEVICE|SIPPV_VG_0_08|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes
214859778|NCT03306524|DEVICE|SIPPV_VG_0_16|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes
214859779|NCT03306524|DEVICE|SIPPV_VG_0_24|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes
214859780|NCT03306524|DEVICE|SIPPV_VG_0_32|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes
214859781|NCT03306524|DEVICE|SIPPV_VG_0_40|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes
214859782|NCT03306524|DEVICE|PSV_VG_0_08|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
214859783|NCT03306524|DEVICE|PSV_VG_0_16|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
214859784|NCT03306524|DEVICE|PSV_VG_0_24|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
214859785|NCT03306524|DEVICE|PSV_VG_0_32|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
214859786|NCT03306524|DEVICE|PSV_VG_0_40|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
214859787|NCT03161964|DRUG|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
214859788|NCT03161964|DRUG|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
214859789|NCT00004800|BIOLOGICAL|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
214859790|NCT00004800|BIOLOGICAL|diphtheria-tetanus vaccine|
214859791|NCT03544996|COMBINATION_PRODUCT|TD Insulin|Human Insulin USP formulated in a solution capable of transdermal delivery.
214859792|NCT04583449|BEHAVIORAL|Mental imagery|"Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery)."
214859793|NCT02736877|PROCEDURE|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
214859794|NCT02736877|PROCEDURE|Conventional Microscope|corneal transplantation guided by Conventional Microscope
214859795|NCT04068415|OTHER|Constipation risk assessment scale|questionnaires
214859796|NCT00325377|PROCEDURE|MME Procedure|
214859797|NCT00557076|BEHAVIORAL|Familiar Auditory Sensory Training|Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
214859798|NCT00557076|BEHAVIORAL|Sham Auditory Sensory Training|The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
214859799|NCT00573404|DRUG|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
214859800|NCT00573404|DRUG|sunitinib malate|
214859801|NCT00573404|OTHER|pharmacological study|
214859802|NCT00593632|DIETARY_SUPPLEMENT|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
214859803|NCT04650152|DRUG|Tricor (fenofibrate), 145 mg, film-coated tablet|Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
214859804|NCT02551432|DRUG|pembrolizumab, paclitaxel|pembrolizumab, paclitaxel
214859805|NCT03816215|BEHAVIORAL|Volunteer experience|Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
214859806|NCT02468063|DRUG|Low dose terlipressin|Terlipressin-2mg (low dose )
214859807|NCT02468063|DRUG|Noradrenaline|Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
214859808|NCT02468063|DRUG|Noradrenaline|Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
214859809|NCT01799122|DEVICE|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
214859810|NCT01725321|OTHER|Narrow band imaging|Colonoscopy with new narrow band imaging
214859811|NCT02408068|DRUG|Dexamethasone|Dexamethasone used to suppress endogenous cortisol secretion
214859812|NCT02408068|DRUG|Chronocort: fasted|single dose of 20mg modified release hydrocortisone in the absence of food
214859813|NCT02408068|DRUG|Immediate release hydrocortisone: fasted|single dose of 20mg immediate release hydrocortisone in the absence of food
214859814|NCT02408068|DRUG|Chronocort: fed|single dose of 20mg modified release hydrocortisone in the presence of food
214859815|NCT03041324|BIOLOGICAL|SB-913|Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
214859816|NCT02321735|BEHAVIORAL|Quality of life questionaire|Patients will participate in a QOL questionaire followed by a phone interview
214859817|NCT04809935|DRUG|98% dehydrated alcohol|"* coeliac plexus is identified and punctured~* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol."
214859818|NCT04809935|DEVICE|19G EUSRA needle, Taewoong Medical, Korea|"* 10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~* Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan"
214859819|NCT05778552|DEVICE|Home-based pelvic muscle training devices or traditional PFMT at hospital|Performed home-based pelvic muscle training devices at home or traditional PFMT at hospital
214859820|NCT05950230|DIAGNOSTIC_TEST|Assess Periodontal Health Status|"For all patients who are suitable for the study, the following clinical evaluation parameters will be recorded:~* Plaque index (PI)(Silness and Löe, 1964).~* Sulcus bleeding index(BOP)(Perez et al., 2008).~* Probing depth (PD) (Polson et al., 1980).~* Clinical attachment level (CAL) (Glavind and Löe, 1967).~* Standardized Periapical Radiograph."
214859821|NCT05950230|OTHER|Collecte GCF samples by paperstrip|GCF samples will be collected from all participating individuals to assess the levels of MMP-8 from the deepest periodontal pocket in the area. The sample areas will be insulated with cotton rolls, saliva contamination will be prevented, all supragingival plaque will be eliminated. The paper strips will placed into the periodontal pocket until resistance is felt and then permitted to remain for 30s(Offenbacher et al., 1984, Megson et al., 2010).
214859822|NCT04412265|OTHER|Relation between frailty and clinical outcomes in elderly patients with COVID-19.|"To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration."
214859823|NCT00942435|DRUG|YM150|oral
214859824|NCT00942435|PROCEDURE|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
214859825|NCT01549106|DRUG|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
214859826|NCT01549106|DRUG|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
214859827|NCT01983709|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10\^6 cells/kg or a maximum dose of 1 x 10\^8 total cells IV 4 days prior to undergoing a planned prostatectomy.~The remaining subjects will receive a single dose of 2 x 10\^6 cells/kg or a maximum dose of 2 x 10\^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy."
214859828|NCT05437367|OTHER|Scapular Stabilization exercises|Therapeutic exercises
214859829|NCT05437367|OTHER|Postural correction exercises|Therapeutic exercises
214859830|NCT05405972|BEHAVIORAL|The Connected Family Series - For Foster Families|A 4-week program involving videos and activities for both the parent and child in the home.
214859831|NCT01053234|DIETARY_SUPPLEMENT|Standardised meals|
214859832|NCT00211965|BIOLOGICAL|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
214859833|NCT00211965|BIOLOGICAL|placebo|single dose IM
214859834|NCT00144911|DRUG|Salmeterol|
214859835|NCT00144911|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
214859836|NCT04580121|DRUG|RO7283420|RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
214859837|NCT04580121|DRUG|RO7283420|RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
214859838|NCT04580121|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.
214859839|NCT04580121|DRUG|Dasatinib|Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily \[BID\] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.
214859840|NCT04580121|DRUG|Dexamethasone|20 mg IV of dexamethasone will be administered as pre-medication at least 60 minutes prior to the all RO7283420 infusions or injections during cycle 1.
214859841|NCT04580121|DRUG|Paracetamol/acetaminophen|500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
214859842|NCT04580121|DRUG|Diphenhydramine|25 mg or 50 mg of diphenhydramine will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
214859843|NCT06148064|OTHER|Collaplug with low level laser|Immediate implant placement with applying a collaplug material in the jumping gap followed by low level laser application using Siro laser (660 nm, avg. power density: 0.5-WATT) circular spot diameter and area: 0.71 cm/0.4cm2) applied in six points in contact mode with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before bone perforation and after suturing.
214859844|NCT06148064|OTHER|Collaplug|Implant of suitable diameter and height was placed in the fresh extracted socket immediately after extraction and the jumping gap was augmented by the collaplug followed by healing abutment placement.
214859845|NCT02277678|DRUG|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
214859846|NCT02277678|DRUG|Opioid administration morphine|
214859847|NCT06085118|OTHER|Pepticate® Syneo®|Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
214859848|NCT05829213|PROCEDURE|"arch-bridge-type esophagogastric reconstruction after proximal gastrectomy"|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. Creating the seromuscular flap (arch-bridge)~4. The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis."
214859849|NCT03358745|OTHER|Standard meal, bread/butter as starter|Reference lunch. Bread and butter are eaten during the first 15 min. Soup, cheese and salad are eaten within the following 15 min.
214859850|NCT03358745|OTHER|Standard meal with soup as starter|Lunch meal in which soup is eaten during the first 15 min. Bread, butter, cheese and salad are eaten within the following 15 min.
214859851|NCT03358745|OTHER|Standard meal with cheese as starter|Lunch meal in which cheese is eaten during the first 15 min. Bread, butter, soup and salad are eaten within the following 15 min.
214859852|NCT03358745|OTHER|Standard meal with salad as starter|Lunch meal in which salad is eaten during the first 15 min. Bread, butter, soup and cheese are eaten within the following 15 min.
214859853|NCT02623348|BEHAVIORAL|pedometer|pedometer-based physical activity recommendations
214859854|NCT02571166|BIOLOGICAL|HSV529|Live, Replication-defective HSV-2 virus
214859855|NCT02571166|DRUG|Valacyclovir|500 mg orally, once daily for 4 weeks
214859856|NCT02870179|DEVICE|Pulse Oximeter|Measurement of physiological parameters
214859857|NCT05870137|DEVICE|HoloLens2TM|Participants assigned to Mixed Reality-supported care used the HoloLens2 device, which provided support using technology that was permitted by the device. This support included remote assistance and holographic versions of patient-specific investigation results, such as radiological findings, biochemistry, and guidelines for completing the procedure (insertion of chest drain).
214859858|NCT05870137|OTHER|Standard care|The standard care for the intervention involved participants performing the invasive technical procedure to treat a tension pneumothorax using their standard clinical skills and knowledge, without the aid of the HoloLens2 device. The participants in the standard care group did not receive any additional support or guidance beyond what is typically available in a clinical setting. The goal of the study was to compare the effectiveness of the standard care approach with the use of Mixed Reality-supported care using the HoloLens2 device.
214859859|NCT05537194|DRUG|dihydropyridine calcium channel inhibitors use|administration of dihydropyridine calcium channel inhibitors
214859860|NCT04289597|DIAGNOSTIC_TEST|Distance between hyoid bone-skin (DSHB)|Distance between hyoid bone-skin
214859861|NCT04289597|DIAGNOSTIC_TEST|Vocal cord anterior commissura-skin distance (DSAC)|Vocal cord anterior commissura-skin distance
214859862|NCT04289597|DIAGNOSTIC_TEST|minimum distance of the trachea to the skin at the level of suprasternal notch|Distance of the trachea to the skin at the level of suprasternal notch
214290580|NCT02875860|OTHER|Standardized postnatal care|After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
214859863|NCT04289597|DIAGNOSTIC_TEST|Thyroid isthmus-skin distance (DSI)|Thyroid isthmus-skin distance
214859864|NCT04289597|DIAGNOSTIC_TEST|Skin-epiglottic distance (DSE)|Skin-epiglottic distance
214859865|NCT01877044|DIETARY_SUPPLEMENT|NAXUS|
214859866|NCT01877044|DIETARY_SUPPLEMENT|Placebo|
214859867|NCT04414462|OTHER|exergaming training|"* HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)"
214290581|NCT00162656|DRUG|half cyclophosphamide|
214290582|NCT00162656|DRUG|without COPADM3|
214290583|NCT00162656|DRUG|mini CYVE, without 3 maintenance courses|
214290584|NCT00162656|DRUG|LMB B|
214290585|NCT00162656|DRUG|LMB C|
214290586|NCT01835067|DRUG|Ranibizumab|Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
214290587|NCT01835067|DRUG|C3F8 Gas|Single intravitreal injection of 0.3 mls C3F8
214290588|NCT01835067|DRUG|tPA|Single intravitreal injection of 50 micrograms tPA in 0.05 mls
214859868|NCT04414462|OTHER|training - Group II|"* Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks."
214859869|NCT04021849|OTHER|Face-to-face Class|The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation
214859870|NCT04021849|OTHER|Asynchronous Virtual Class|Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
214859871|NCT02666352|DRUG|Uprifosbuvir|A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
214859872|NCT02666352|DRUG|Ruzasvir|A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
214859873|NCT00250900|BEHAVIORAL|Prescription Fill Status|
214859874|NCT05284461|DEVICE|dental implant with transepithelial abutments manufactured by Galimplant Dental System (Spain)|Dental implants with transepithelial abutments with distinct morphology
214859875|NCT03409393|OTHER|The COPUS intervention|The COPUS intervention consists of 8 weeks of High-Intensity Functional Training (HIFT). The frequency of the training is 3 sessions per week and the duration is one hour per session. The intervention is group-based and supervised. Each training session includes warm-up (15 min), followed by 30 minutes of HIFT based on a range of varied functional exercises, including elements of strength training and aerobic exercise. The sessions are supervised by a trained physiotherapist and exercise physiologist supported by 2 two trained bachelor students in Sports Science.
214859876|NCT03409393|OTHER|Usual Care (OPUS treatment)|Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.
214859877|NCT02078336|DRUG|Midazolam Mylan|
214859878|NCT02078336|DRUG|Lorazepam Mylan|
214859879|NCT02078336|DRUG|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
214859880|NCT04016961|OTHER|AAT - Dog|therapy dog added to inpatient PT and OT session
214859881|NCT04016961|OTHER|TAU - No Dog|PT and OT as usual without the addition of therapy dog
214859882|NCT01406392|DRUG|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
214859883|NCT01406392|DRUG|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
214859884|NCT06654063|PROCEDURE|non-surgical periodontal therapy (SRP)|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage."
214859885|NCT06654063|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP)+ Omega-3|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA)~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Patients will start taking Omega-3 supplements on the day of SRP procedure."
214859886|NCT06654063|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP)+ Vitamin D|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Serum vitamin D levels will be assessed at baseline and 6 weeks after intervention in all groups."
214859887|NCT02580084|PROCEDURE|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
214859888|NCT02580084|PROCEDURE|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
215033628|NCT06564857|DRUG|Remifentanil|Age \< 70 years: Bolus of 4 μg/kg Ideal Body Weight remifentanil at anaesthesia induction; Age \>= 70 years: Bolus of 2 μg/kg ideal Body Weight remifentanil at anaesthesia induction
215033629|NCT06564857|DRUG|Rocuronium|Bolus of 0.6 mg/kg Ideal Body Weight rocuronium at anaesthesia induction
215033630|NCT00514189|BIOLOGICAL|Autologous Dendritic Cells|The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
215033631|NCT00103844|DRUG|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
215033632|NCT00103844|DRUG|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
215033633|NCT03271333|OTHER|lung function tests|Patients hospitalized realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes)
215033634|NCT04544280|DRUG|Xeomin Injectable Product|Intramuscular injection
214859889|NCT04467359|OTHER|ERAS|Optimize physical conditions; Fasting solid diet 6h before surgery, fasting clear fluid 2 h before surgery; If there is no chief complaint of dizziness, nausea or other discomfort after the operation, warm water (no more than 100ml) can be immediately drunk. Pain management; Encourage patients to engage in early activities under the premise of effective pain control; If no dural puncture and other complications occur, the patient has no chief complaints of headache, dizziness, nausea and other discomfort, and there is no need to lie supine, the comfortable position such as semi-supine lateral supine position can be taken immediately (avoid 90-degree upright position for patients with hip joint); Prevention of thrombosis; Prevention and treatment of nausea and vomiting; Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the operation.
214859890|NCT04467359|OTHER|Perioperative routine rehabilitation nursing|Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation
214859891|NCT03971487|BEHAVIORAL|Psychosis and cognitive assessments|Administration of MINI, PANSS and Quality of Living scales
214859892|NCT03971487|BEHAVIORAL|Physical and neuro-cognitive evaluations|Physical, neurological and cognitive evaluations.
214859893|NCT03971487|DIAGNOSTIC_TEST|Safety labs and electrocardiogram|Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
214859894|NCT03971487|BIOLOGICAL|Ocrelizumab infusion|Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
214859895|NCT02138136|DRUG|Lubiprostone|12 or 24 mcg soft capsules for oral administration
214859896|NCT04192123|DEVICE|HM242|HM242-Solution and HM242-Gel will be topically applied in an occlusive patch for 48h on healthy skin on the subject's outer part of the upper arm.
214859897|NCT03808662|RADIATION|Sterotactic Body Radiotherapy/SBRT|In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
214859898|NCT03808662|DRUG|Standard of care|Standard of care per physician discretion
214859899|NCT02593448|PROCEDURE|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~1. 30 minutes after anaesthesia induction,~2. directly after the sternotomy,~3. during CPB - 20 minutes after aortic cross-clamping ,~4. 40 minutes after aortic cross-clamping,~5. 20 minutes after the release of the aortic cross-clamp,~6. 45 minutes after weaning of CPB."
214859900|NCT02593448|PROCEDURE|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
214859901|NCT02593448|PROCEDURE|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
214859902|NCT04940949|DRUG|Lu AF90103|Lu AF90103 - powder for solution for infusion
214859903|NCT04940949|DRUG|Placebo|Placebo - powder for solution for infusion
214859904|NCT06051565|DRUG|Polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
214859905|NCT03792360|DRUG|SVF (Stromal Vascular Fraction)|The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
214290589|NCT05487638|OTHER|Nursing Education and Counseling Service Provided to Patients by Video Calling on the Phone|Nursing Education and Counseling Services were provided to the patients by video calling on the phone for the problems they may encounter in the postoperative period.
214290590|NCT00499018|DRUG|Rituximab|375 mg/m2 day 1
214859906|NCT04882566|OTHER|Paleolithic Diet|Advice to follow Paleolithic Diet for Inflammatory bowel disease Patients
214859907|NCT04982874|DRUG|Furosemide 40 mg|Administered with 240 mL of water
214859908|NCT04982874|DRUG|Lasix® 40 mg Tablet|Administered with 240 mL of water
214859909|NCT05120323|BEHAVIORAL|vDOT Intervention Group|The vDOT intervention group will submit video clips of doses of inhaled controller asthma medication via the Emocha® smartphone application with each prescribed dose of inhaled controller medication. Each video will include a date and time stamp of the medication dose. Participant videos will be evaluated by trained personnel using an inhaler technique checklist to score each dose and create a report detailing the steps that were taken to complete the medication dose.
214859910|NCT05770921|DEVICE|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
214859911|NCT03370874|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
214859912|NCT03370874|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to diabetic foot ulcer
214290591|NCT00499018|DRUG|Ciclofosfamide|1200 mg/m2 day 1
214290592|NCT00499018|DRUG|Doxorubicina|70 mg/m2 day 1
214290593|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
214859913|NCT05614557|DEVICE|Stratacel|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
214859914|NCT05614557|DEVICE|Stratamed|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
214859915|NCT05520320|DEVICE|Hypothermic oxygenated machine perfusion (any device)|After static cold storage, all grafts included in this study are subjected to \>1 hour of hypothermic oxygenated machine perfusion at 4-12°C with an acellular perfusion solution.
214859916|NCT05007314|BEHAVIORAL|Biocriminological Evidence|Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.
214859917|NCT00407693|DRUG|[C-11]PRB28|
214859918|NCT04527653|DEVICE|Tixel|Non-invasive thermo-mechanical treatment
214859919|NCT05757323|OTHER|infant formula based on hydrolyzed protein|infant formula based on hydrolysed protein
214859920|NCT05757323|OTHER|infant formula based on intact protein|infant formula based on intact protein
214859921|NCT00568815|DRUG|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
214859922|NCT01389583|DRUG|AUY922|70 mg/m2 60-min i.v. infusion weekly
214859923|NCT04145583|DRUG|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
214859924|NCT04145583|DRUG|voriconazole +HSK3486|Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
214859925|NCT04928274|OTHER|ball attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
214859926|NCT04928274|OTHER|locator attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
214859927|NCT04928274|OTHER|telescopic attachment to retain mandibular over denture|each patient in group receive 3 telescopic attachment for over denture retention
214859928|NCT00706381|DRUG|Sincalide|
214859929|NCT00706381|DRUG|Ursodiol|
214859930|NCT00706381|PROCEDURE|Fat Meal|600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate
214859931|NCT00706381|PROCEDURE|Carb meal|600 calorie meal containing 100% carbohydrate
214859932|NCT00706381|DRUG|Placebo|IV and/or oral placebo
214859933|NCT00276952|DRUG|Gonyautoxin|
214859934|NCT00954330|PROCEDURE|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
214859935|NCT00954330|DEVICE|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
214859936|NCT00054912|BIOLOGICAL|EP2101|
214859937|NCT02477163|OTHER|Ayurveda treatment|"1. Gokshuradi Guggulu (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) - 1 g, 3 times in a day after food with warm water.~2. Varunadi kvath (ingredients: Varuna tvak + Bilva moola + Apamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) - 40 ml 2 times in a day after food.~3. Rasayan Churna (powder of Gokshura + Amalaki + Guduchi in equal quantities ) - 3 g, 3 times a day with water.~4. Bhumyamalaki (Tamalaki Rasayan) tablet - 1 g, 2 times in a day after food with water.~5. Uricare (of Punarvasu Pharmacy, Petlad road, Nadiad) tablet - 1 g, 3 times in a day after food with warm water.~6. Niruha Basti (procto-colonic administration of ayurvedic medicine) with Punarnavadi kvath (decoction) - in the morning, before one hour of the lunch."
214859938|NCT06074484|DRUG|RC48-ADC|4 preoperative cycles of RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 6 cycles of postoperative RC48-ADC（2.0 mg/kg，intravenous (IV) infusion，Q3W）
214859939|NCT06074484|DRUG|AK104|4 preoperative cycles of AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 14 cycles of postoperative AK104（10 mg/kg，intravenous (IV) infusion，Q3W）
214859940|NCT00587600|PROCEDURE|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
214859941|NCT00587600|PROCEDURE|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
214859942|NCT01930955|DRUG|Amoxicillin|β-lactam antibiotics
214859943|NCT05243953|DRUG|Levcromakalim|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
214859944|NCT05243953|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
214859945|NCT05530148|BEHAVIORAL|Martial Arts Training Group|Participants in the experimental intervention group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, they will be instructed in the three exercises practiced in the experimental group, known as hubud, chi sau and padwork. Hubud is a turn-based, partnered, coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Chi Sau is a simultaneous contact drill from Chinese Kung Fu, specifically the Wing Chun school. Padwork is an amalgam of punching and kicking combinations used against focus pads or padded sticks to improve coordination, most commonly seen in kickboxing and Muay Thai. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of these exercises by the end of their participation in this intervention.
215033635|NCT01469247|RADIATION|Radiation Therapy|Starting Dose 24 Gy in 2 Gy fractions.
215033636|NCT04942145|DEVICE|virtual reality in dental patients|"The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires"
215033637|NCT02164110|BIOLOGICAL|Euvichol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
214290594|NCT00499018|DRUG|Prednisone|100 mg day g 1-5
214859946|NCT05530148|BEHAVIORAL|Flexing, Toning and Balance|Participants in the active comparator group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, participants will start with a 5-minute warmup of basic joint mobilization exercises and dynamic stretching techniques. After this, participants will engage in a mild intensity circuit of exercises using resistance bands, bodyweight exercises and stability/balance exercises for approximately 50 minutes. The last 5 minutes of the session will be left for cooldown exercises and light stretching. Heartrate will be monitored regularly in order to prevent these exercises exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
214859947|NCT00254228|DEVICE|Electrotactile sensory substitution|
214859948|NCT04271553|OTHER|Video|In addition to standard workflow, participants will also receive the PFO bundle which consists of: 1) A cartoon video of about 6 minutes duration illustrating the events occurring during admission, anaesthesia and surgery and 2) Sets of activity sheets which have been tailored for different age groups. Families would be encouraged to complete activity sheets together.
214859949|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
214859950|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
214859951|NCT05410054|OTHER|no intervention|observational research
214859952|NCT00995085|DRUG|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
214859953|NCT05946954|PROCEDURE|Immediate Dentoalveolar Restoration|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
214859954|NCT05946954|PROCEDURE|Ice cream cone technique|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
214859955|NCT04593017|DIETARY_SUPPLEMENT|Active Probiotic|Lactobacillus Reuteri (DSM 17938 and ATCC PTA 4659
214859956|NCT04593017|OTHER|Placebo Probiotic|Placebo
214859957|NCT05213143|DRUG|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.
214859958|NCT04088266|COMBINATION_PRODUCT|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA®
214859959|NCT02969993|OTHER|Questionnaires|evaluating the voice outcome by the fullfilment of the voice handicap index
214859960|NCT02545647|DEVICE|BRYGB|65 patients undergo a banded RYGB
214859961|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose level 1 or 2|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
214859962|NCT03736928|OTHER|placebo|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
214859963|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 3|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
214859964|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 4|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
214859965|NCT04206228|DRUG|Intravenous iron isomaltoside|"The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min)."
214859966|NCT04206228|DRUG|Placebo|The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
214859967|NCT03662906|OTHER|Electroacupuncture|"Bilateral BL32 and BL 33 will be inserted to a depth of 70-95 mm with an angle of 20-30° inward and downward into the second and third sacral foramen. Bilateral BL35 will be inserted to a depth of 60-70 mm with a slightly superolateral direction using needles (0.30 mm in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a depth of 25-30 mm using needles (0.30 mm in diameter, 40 mm in length). The electric stimulators (6805-D electroacupuncture apparatus, Guangzhou Jiayu Medical Company, China) will connect the bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 5-10 mA for BL 32 and BL 33 and an intensity of 1-5 mA for SP 6 will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
214907065|NCT02540382|DEVICE|covered stent|A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions\* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
214859968|NCT03662906|OTHER|Sham electroacupuncture|"Sham BL 23, BL32 and BL33 which are 2 cm lateral to BL23, BL33 and BL35 will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. Sham SP 6 which is at the midpoint between the spleen meridian and the kidney meridian will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. The electric stimulators (SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China) will connect bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 0.1-0.3mA will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
214859969|NCT02662088|PROCEDURE|laparoscopic-lavage|
214859970|NCT04080609|DRUG|Dorzagliatin|GKA currently under clinical development
214859971|NCT06417333|DEVICE|xiaomi mi band 7 smart wristband|Patients with mild dementia have been distributed xiaomi mi band 7 smart wristbands for health data collection
214859972|NCT05338021|PROCEDURE|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
214859973|NCT03261882|OTHER|Nativity|Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
214859974|NCT03096847|DRUG|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
214859975|NCT03096847|DRUG|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
214859976|NCT03096847|DRUG|goserelin|Premenopausal patients additionally received goserelin 3.6mg as monthly implant
214859977|NCT02145312|DRUG|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
214859978|NCT01090999|OTHER|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
214859979|NCT02014077|PROCEDURE|VATS ( Video-Assisted Thoracoscopy )|the patients were randomized to a Video-Assisted thoracoscopy( VATS )for retained haemothorax
214859980|NCT02014077|PROCEDURE|Thoracostomy Tube reinsertion|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
214859981|NCT02239198|OTHER|Nutrition bar|The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
214859982|NCT05748327|DEVICE|Alcasite restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), conditioning with primer, mixing alcasite capsula, place restoration, polymerizing and finishing
214859983|NCT05748327|DEVICE|Bulk fill glass hybrid restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), mixing bulk fill glass hybrid capsula, conditioning, place restoration, apply coating, polymerizing and finishing
214859984|NCT02714231|DRUG|diclofenac sodium (cataflam)|The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
214859985|NCT02714231|DRUG|hyoscine butyl bromide (buscopan)|The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
214859986|NCT00671073|DRUG|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
214859987|NCT00671073|DRUG|Placebo|Placebo, oral administration, once daily for 12 weeks
214859988|NCT00671073|DRUG|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
214859989|NCT00671073|DRUG|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
214859990|NCT01640873|DRUG|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
214859991|NCT01640873|DRUG|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
214859992|NCT03746548|DEVICE|Adhear|Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
214859993|NCT03746548|DEVICE|Contact Mini (CM)|Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
214859994|NCT02212912|BEHAVIORAL|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
214859995|NCT02212912|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
215033638|NCT02164110|BIOLOGICAL|Shanchol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
214859996|NCT01303536|DRUG|Ondansetron|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
214859997|NCT03891017|OTHER|vacuum casting|Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
214859998|NCT03891017|OTHER|hydrostatic casting|Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
214859999|NCT02192164|BEHAVIORAL|smoking questionnaire|patients fill in a smoking questionnaire about their smoking habits
214860000|NCT04870723|BEHAVIORAL|eHealth for Covid-19 prevention and support|3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
214860001|NCT02814435|OTHER|Questionnaire|The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
214860002|NCT02814435|OTHER|Computerised contrast sensitivity function test|This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
214860003|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program A|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
214860004|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program B|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
214860005|NCT03329079|BEHAVIORAL|Mobile Technology Plus|The intervention group MT+ will receive the premium-version mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
214860006|NCT03329079|BEHAVIORAL|Mobile Technology|The comparison group MT will receive the basic-version mobile phone app only to self monitor eating, activity, and weight.
214860007|NCT01844999|BEHAVIORAL|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
214860008|NCT01844999|BEHAVIORAL|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
214860009|NCT00359788|DRUG|tiotropium|
214860010|NCT00359788|DRUG|Combivent (Ipratropium/Albuterol)|
214860011|NCT03946254|OTHER|Effect of strength training on executive functions in elderly people with mild cognitive impairment.|Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group
214860012|NCT00673933|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
214860013|NCT02463305|DRUG|Creatine monohydrate|21 grams creatine monohydrate total per day
214860014|NCT02463305|OTHER|Placebo|7 grams of dextrose dissolved in 500mL water, taken three times daily
214860015|NCT00940797|DRUG|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
214860016|NCT00940797|DRUG|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
214860017|NCT05709483|DRUG|Aspirin|Platelet assays including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, Thromboxana A2 levels- will be measured at baseline and 1 hour after administration of single-dose enteric-coated 81 mg aspirin
214860018|NCT03760614|DRUG|Entinostat|Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
214860019|NCT03760614|DRUG|FOLFOX regimen|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.
214860020|NCT04915014|PROCEDURE|sleeve gastrectomy with transit bipartition (SG +TB)|In case of a first intention procedure, a typical sleeve gastrectomy is performed, calibrated on a 36 French bougie, stapling starting 4 to 6 cm from the pylorus. Antecolic gastroileal anastomosis is performed 250 cm from the ileocecal transition, on the antrum using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 120 cm from the ileocecal junction. Thus, alimentary limb is 130cm and common limb 120cm.
215033639|NCT04179344|OTHER|Integrated e-healthcare services (IeHS) web-based app|Each participant is asked to complete study tasks using the IeHS web-based app as a part of IeHS simulation. This activity is followed by user experience survey, and an in-depth interview to explore user satisfaction on the IeHS web-based app
215033640|NCT01771497|DEVICE|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
214860021|NCT04915014|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|A small gastric pouch (30 cc) is performed. Antecolic gastroileal anastomosis is performed 200 cm from the Treitz junction, using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 50 cm from the Treitz junction. Thus, alimentary limb is 150cm and biliary limb 50cm.
214860022|NCT01473550|BEHAVIORAL|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
214860023|NCT01678651|PROCEDURE|Stimulation with human FSH|Human FSH
214860024|NCT01678651|PROCEDURE|Stimulation with recombinant FSH|Recombinant FSH
214860025|NCT04365179|DRUG|Nerofe|"Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1."
214860026|NCT00896324|BEHAVIORAL|Cognitive Rehabilitation|The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
214860027|NCT00896324|BEHAVIORAL|Active Neurofeedback Training|Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
214860028|NCT00896324|BEHAVIORAL|Neurofeedback Training (placebo / Sham)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
214860029|NCT04932941|DRUG|MP1032|Hard gelatin capsules for oral administration.
214860030|NCT04932941|DRUG|Placebo|Placebo capsules matched to MP1032 for oral administration.
214860031|NCT03637335|COMBINATION_PRODUCT|irradiation + carboplatin|30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin
214860032|NCT03637335|COMBINATION_PRODUCT|irradiation + placebo|30 Gy en 10 fractions de 3 Gy + 10 injections of placebo
214860033|NCT04177641|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
214860034|NCT04177641|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
214860035|NCT00892788|BEHAVIORAL|contingency management|Prize-based contingency management for weight loss
214860036|NCT00892788|BEHAVIORAL|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
214860037|NCT06483087|BEHAVIORAL|Animated Education Program|Eight minutes animated vedio; presented individually to children in their rooms. The vedio explains specific aspectsof the cardiac cathetrization procedure.
214860038|NCT04254640|DRUG|Cladribine Injection|Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
214860039|NCT04254640|DRUG|Aclarubicin|aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
214860040|NCT04254640|DRUG|G-CSF|G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
214860041|NCT04254640|DRUG|cytarabine|cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
214860042|NCT04732988|DRUG|HSG4112|Once-daily oral administration
214860043|NCT04732988|DRUG|Placebo|Once-daily oral administration
214860044|NCT06289829|DRUG|remifentanil of the assigned dose|Ambu Auragain will be inserted after general anesthesia is induced with remimazolam and remifentanil. Each patient will be assigned with a certain dose of remifentanil, according to whether the previous patient's LMA insertion process was successful or not.
214860045|NCT06289829|DEVICE|Ambu Auragain for airway management|Ambu Auragain, a type of laryngeal mask airway, will be inserted into every patient after general anesthesia has been induced.
214860046|NCT04134026|DRUG|HIF-PHI|Drug will be dosed orally three times a week.
214860047|NCT04134026|DRUG|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
214860048|NCT00766155|DRUG|capecitabine|Given orally
214860049|NCT00766155|DRUG|oxaliplatin|Given IV
214860050|NCT06451393|DRUG|Neoadjuvant chemotherapy with radical tumor resection surgery|All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).
214860051|NCT03421041|DRUG|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet，0.75mg/tablet
214860052|NCT00449319|PROCEDURE|Identification of appropriate therapies according to risks factors|
214860053|NCT00449319|DRUG|Daunorubicine|
214860054|NCT00449319|PROCEDURE|Transplant|
214860055|NCT03336957|PROCEDURE|periodontal treatment|non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
214860056|NCT02441244|DRUG|Visbiome|Visbiome probiotic
214860057|NCT02441244|OTHER|Placebo|Placebo
214907066|NCT02540382|DEVICE|bare stent|"A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.~The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.~The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.~It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions."
214860058|NCT03285789|OTHER|Passing tests in dyslexics with reduced eva|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30."
214860059|NCT03285789|OTHER|Passing tests in controls|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30."
214860060|NCT03582280|DRUG|Amorphous Calcium Carbonate (ACC) - Amor|Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
214860061|NCT01286389|OTHER|medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
214860062|NCT01286389|BEHAVIORAL|caloric restriction|Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
214860063|NCT03721731|DEVICE|Obesity treatment with a Plication device|Plicating the stomach to treat obesity
214860064|NCT02150759|DRUG|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
214860065|NCT02150759|DRUG|Fentanyl|add dexmedetomidine during position change
214860066|NCT02150759|DRUG|Ketamine|add dexmedetomidine during position change
214860067|NCT00002006|DRUG|Zidovudine|
214860068|NCT00002006|DRUG|Sargramostim|
214860069|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
214860070|NCT01929031|DRUG|ibuprofen|tablet.
214860071|NCT01929031|DRUG|ibuprofen|tablet
214860072|NCT01929031|DRUG|caffeine|tablet
214860073|NCT01929031|DRUG|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
214860074|NCT01929031|DRUG|placebo|tablet
214860075|NCT01929031|DRUG|placebo|tablet
214860076|NCT01929031|DRUG|caffeine|tablet
214860077|NCT01929031|DRUG|ibuprofen|tablet
214860078|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
214860079|NCT03944681|DRUG|Droperidol Injectable Solution|An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
214860080|NCT03352375|DEVICE|Orotracheally intubation|Interventions used for airway safety and ventilation during surgical procedures
214860081|NCT03352375|DEVICE|Laryngeal Mask Airway|Interventions used for airway safety and ventilation during surgical procedures
214860082|NCT05684471|PROCEDURE|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients in this group will be administered SFIB with 50 mL of local anesthetic solution (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
214860083|NCT05684471|PROCEDURE|Ultrasound Guided Anterior Quadratus Lumborum Block|Patients in this group will be administered anterior QLB with 40 mL of local anesthetic (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
214860084|NCT00321594|DRUG|belinostat|Given IV
214860085|NCT04352270|OTHER|AD printed educational materials|Printed educational materials in Spanish and English about coping with Atopic Dermatitis, specifically geared towards children and parents will be given to participants.
214860086|NCT04352270|OTHER|AD educational videos|Short, educational videos in English and Spanish about coping with Atopic Dermatitis, specifically geared towards children and parents will be developed. There will be Spanish and English versions of the videos, minimal text, comprehensive language, animations, and it will be administered via user friendly platforms or websites.
214860087|NCT03478228|OTHER|Multi-Sensory Training|
214860088|NCT06225557|OTHER|ERAS community recommendation|Enhanced recovery techniques including opioid sparing anesthesia in elective cesarean section
214860089|NCT06225557|OTHER|Traditional postoperative care|Usual anesthesia and analgesia in elective cesarean section.
214860090|NCT02394730|DRUG|vorapaxar|2.5mg of vorapaxar taken orally once daily for 12 weeks
214860091|NCT02394730|DRUG|Placebo|Sugar pill taken orally once daily for 12 weeks
214860092|NCT05512520|COMBINATION_PRODUCT|Intensity-modulated radiotherapy concurrent with capecitabine|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks.
214860093|NCT03110601|DEVICE|Control - Conventional SCS|Conventional SCS Parameters
214860094|NCT03110601|DEVICE|Test - Stimgenics SCS|Stimgenics SCS Parameters
214860095|NCT01363804|DRUG|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
214860096|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Amino Acid daily for 13 days|A 30 mg zinc amino acid supplement is taken p.o. in the fasted state for 13 days.
214860097|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Gluconate daily for 13 days|A 30 mg zinc gluconate supplement is taken p.o. in the fasted state for 13 days.
214860098|NCT00804817|BEHAVIORAL|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
214290595|NCT00499018|DRUG|Pegfilgrastim|6 mg day +1
214860099|NCT00804817|BEHAVIORAL|SCION-HSCT program|"Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
214860100|NCT00577902|OTHER|Observation|Head and neck cancer patients receiving chemoradiation
214860101|NCT02497118|DRUG|Endostatin|Endostatin,7.5mg/m\^2,intravenous, d1-14;
214860102|NCT02497118|DRUG|Vinorelbine|vinorelbine,25mg/m\^2,intravenous, d1, d8;
214860103|NCT02497118|DRUG|Cisplatin|Cisplatin，75mg/m\^2 intravenous,divide into d1-3
214860104|NCT01851018|RADIATION|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
214860105|NCT01851018|RADIATION|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
214860106|NCT03784521|DEVICE|In-line filtration|In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.
214860107|NCT03784521|DEVICE|Standard care|Patients are treated with standard intravenous solutions and vascular access management
214860108|NCT05060432|DRUG|EOS-448|Anti-TIGIT monoclonal antibody
214860109|NCT05060432|DRUG|pembrolizumab|Anti-PD-1 monoclonal antibody
214860110|NCT05060432|DRUG|inupadenant|A2A receptor antagonist
214860111|NCT05060432|DRUG|Dostarlimab|Anti-PD-1 monoclonal antibody
214860112|NCT05060432|DRUG|SOC chemotherapies|SOC chemotherapies in 1L mNSCLC
214860113|NCT01099059|DRUG|Amantadine|Amantadine 100-150 mg depending on weight (100 mg/day for \<30 Kg and 150 mg/day for \>30 Kg)
214860114|NCT01099059|DRUG|ritalin|ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)
214860115|NCT02860442|BEHAVIORAL|Smartphone brief intervention (SP-BI)|"Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan."
214860116|NCT02860442|OTHER|Enhanced Usual Care (EUC)|Those assigned to EUC will receive an informational brochure with resources available to members of the military related to mental health and alcohol use. They will be contacted to complete 4-, 8-, and 12-month follow-up assessments.
214860117|NCT02384252|OTHER|functional tissu atrial analysis|
214860118|NCT05226559|PROCEDURE|Multimodal Physical therapy approach plus usual care|HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
214860119|NCT05226559|DRUG|Usual care|Standard pharmacological treatment alone.
214860120|NCT06425770|PROCEDURE|indirect digital impression and 3D printed cast|the provisional restoration will be scanned with intraoral scanner extraorally, based on which a virtual model will be created, from which a 3D printed cast will be created with manually fabricated gingival mask based on the provisional restoration
214860121|NCT06425770|PROCEDURE|direct digital impression|the emergence profile will be directly scanned with intraoral scanner at 0, 2, 10, and 20 minutes after removing the provisional restoration
214860122|NCT06425770|PROCEDURE|conventional impresion and cast|conventional impression with elastomer (silicon), from which a high-precision epoxi-resin cast with gingival mask will be created
214860123|NCT04216615|BEHAVIORAL|preoperative anxiety|patients who are anxious
214860124|NCT02654171|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
214860125|NCT02654171|DRUG|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
214860126|NCT00324311|DRUG|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
214860127|NCT02287493|OTHER|Pharmacokinetic Analysis|
214860128|NCT05289128|DEVICE|Experimental group|10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
214860129|NCT05289128|DEVICE|Sham Control|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
214860130|NCT04001920|OTHER|Training program|12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
214290596|NCT00499018|DRUG|Mitoxantrone|8 mg/m2/days 1-3
214860131|NCT01953939|OTHER|Prosthetic Limb Users|There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
214860132|NCT00192855|DRUG|Entacapone|Entacapone 600mg BID
214860133|NCT02775136|DEVICE|HS-1000 recording|
214860134|NCT03510182|DEVICE|transcranial direct current stimulation|
214860135|NCT02185313|OTHER|visual stimulus to follow|
214860136|NCT03627741|DRUG|Triamcinolone Acetonide|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
214860137|NCT05762484|PROCEDURE|Nd:YAG laser hair removal|Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.
214860138|NCT05762484|DRUG|Clindamycin 1 % Topical Lotion|Clindamycin 1% lotion if needed
214860139|NCT04994938|OTHER|Diet Intervention|Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.
214860140|NCT04994938|OTHER|Exercise Intervention|Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
214860141|NCT06928948|PROCEDURE|Femur replacement|Reconstruction using the Limb Preservation System™ for segmental resection of the distal femur.
214860142|NCT06877611|DRUG|S-4321|S-4321 via subcutaneous or intravenous administration
214860143|NCT06877611|OTHER|Placebo|Placebo via subcutaneous or intravenous administration.
214860144|NCT06855030|OTHER|Scoliosis Specific Exercise|In the first session, the individual and their family will learn about AIS, the specific curvature, and the treatment process. They will also be taught correct posture and active self-correction, which means finding the best alignment in three planes. Once the individual becomes confident in their self-correction, they will start exercises. In the SEAS method, exercises begin in a sitting position, and as the individual improves, the exercises will be made more challenging and suited to their level. The rehabilitation protocol includes exercises in standing, squatting, single-leg stance, and on the floor. In each session, previous exercises will be reviewed, and new ones will be added. Individuals will be reminded to practice active self-correction during exercises and daily activities. In literature, there is no fixed protocol for exercise duration and frequency, but it is recommended to do exercises 2-3 times a week for 45 minutes or 20 minutes daily.
214860145|NCT06855030|OTHER|Basic Body Awareness Therapy|"Body awareness movements will be performed in lying, sitting, and standing positions. Then, they will be varied by incorporating walking, running, and voice use. The patient will be asked to perform these movements with a specific rhythm and coordination. BBAT aims to enhance body awareness and create a more realistic body image by normalizing posture, balance, and muscle tension. The training process will involve gradually increasing awareness of the relationship with the floor, the vertical axis, centering, breathing, and flow. During this therapy process, the goal is to improve the individual's awareness of themselves and their surroundings, helping them adopt the here and now experience and later apply it in daily life. At the end of each session, time will be given for the patient to respond to their experience and express their thoughts. There is variability in the application duration in the literature."
214860146|NCT06929039|DRUG|Abatacept|Test Product (A) (Kashiv's Abatacept): KSHB002 (Abatacept) Injection, 125 mg/mL - Manufactured by: Kashiv Bioscience's LLC, USA.
214860147|NCT06929039|DRUG|Abatacept|Reference Product (B) (US-licensed ORENCIA): 'ORENCIA' (abatacept) injection 125 mg/mL - Manufactured for: Bristol-Myers Squibb Company Princeton, NJ 08543 USA.
214860148|NCT06929039|DRUG|Abatacept|Reference Product (C) (EU-authorized ORENCIA): 'ORENCIA' 125 mg solution for injection (abatacept) - Marketing Authorization Holder: Bristol-Myers Squibb Pharma EEIG, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland.
214860149|NCT01195272|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
214860150|NCT01893645|DEVICE|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
214860151|NCT00018811|BEHAVIORAL|Relaxation training & thermal biofeedback|
214860152|NCT00018811|BEHAVIORAL|Surface EMG biofeedback|
214860153|NCT05397548|DIAGNOSTIC_TEST|Measurement of levels of circulating exosomal lncRNA-GC1|Each participant was enrolled to assess the levels of circulating exosomal lncRNA-GC1
214860154|NCT05250674|DEVICE|CEM-guided biopsy|"The evaluation population consists of adult women, presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination (with no clear ultrasound or mammography correlation) and considered eligible for this procedure as per standard of care.~Eligible subjects undergo the clinically indicated breast biopsy procedure using the Pristina Serena Bright ® CEM-guided biopsy. Region of interest location is determined by using stereotactic pairs of CEM images after injection of iodinated contrast media. All necessary equipment and instrumentation, medications, or other devices required to complete the subject's clinically indicated procedure shall be used and are not expected to be influenced by evaluation participation."
214860155|NCT06128720|DEVICE|Hyperbaric Oxygen|Participant will undergo 60 minutes of Hyperbaric oxygen at 1.5ATA while breathing 100% oxygen
214860156|NCT06128720|DEVICE|Sham Hyperbaric Oxygen|Participant will undergo 60 minutes of Sham Hyperbaric Oxygen at atmospheric pressure while breathing room air.
214860157|NCT06112184|OTHER|SK-M11/3A1 Digital health program|Digital Health program with participants using an autoinjector delivered via the Sidekick mobile application (app)
214860158|NCT06169657|DEVICE|Body-weight-supported treadmill training (BWSTT)|Walking on a treadmill in a harness with body weight support as needed
214860159|NCT06169657|DEVICE|EksoNR exoskeleton gait training|Walking in the EksoNR exoskeleton
214860160|NCT06169657|DEVICE|Overground gait training|Walking overground in a harness with body weight support as needed
214860161|NCT06253052|BEHAVIORAL|Additional pre-OP-visit|OP-schedule is closely monitored and patients will be visited to support and encourage them in drinking clear fluids.
214860162|NCT06253052|BEHAVIORAL|Liberal fasting regime|Patients may drink up to 200 ml clear fluids between 2 h prior to the surgery and the call to operation room.
214290597|NCT00499018|DRUG|ARA-C|2000 mg/m2/12h day 1 - 3
214290598|NCT00499018|DRUG|Lenograstim|5 μg/Kg/days +2
214860163|NCT04082429|DRUG|Concizumab|When patients are randomised/allocated to concizumab prophylaxis, they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week (Wk) 0) (arm 2, 3 and 4) or visit 9a (Wk 24) (arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (Wk 6) or 9a.3 (Wk 30) and will be based on the concizumab exposure level measured at the previous visit 4a (Wk 6) or 9a.2 (Wk 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual replacement therapy until visit 9a (week 24; end of main part). In the extension part, patients in arm 1 will receive daily concizumab subcutaneous injections.
214860164|NCT02664545|DEVICE|BEAR Scaffold|A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.
214860165|NCT02664545|PROCEDURE|Tendon Graft|A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
214860166|NCT05395715|PROCEDURE|Electrical stimulation|Patients with cubital tunnel syndrome will receive either surgery and sham stimulation, or conditioning electrical stimulation 7 days prior to surgery
214860167|NCT04905290|DEVICE|Left ventricular coronary sinus (BiV) configuration|For subjects with a pacemaker, pacing of the left ventricular coronary sinus only. For subjects with a defibrillator, biventricular pacing of the left ventricular coronary sinus and the right ventricle. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay. Patients with a defibrillator will receive two additional delays LV precedes default by 30ms and LV precedes default by 60ms.
214860168|NCT04905290|DEVICE|Conduction system pacing-only configuration|Conduction System Pacing (CSP) of the left bundle branch. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, and default - 60ms AV delay.
214860169|NCT04905290|DEVICE|Conduction System Pacing Optimized Therapy (CSPOT) configuration|A combination of Left Ventricle pacing and Conduction System Pacing of the left bundle branch. During the acute protocol, the eight delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay, CSP precedes default by 30ms, LV precedes default by 30ms and LV precedes default by 60ms.
214860170|NCT03295318|BIOLOGICAL|Non-adjuvanted study formulation NmCV-5|Non-adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
214860171|NCT03295318|BIOLOGICAL|Adjuvanted study formulation NmCV-5|Adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Alum as adjuvant with Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine
214860172|NCT03295318|BIOLOGICAL|Menactra|Menactra is available as ready to used solution containing polysacchride antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine.
214860173|NCT06579261|OTHER|Core Shamanism|Each Shamanic intervention session, led by the shamanic practitioner, will include classical music as a control, followed by repetitive drumming and/or rattling music which the participant and shamanic practitioner will listen to for 15-30 mins. Following listening to drumming, the patient will then talk with the shamanic practitioner to debrief the experience of each session. Participants will also listen to classical music as a control stimulus.
214860174|NCT04319718|COMBINATION_PRODUCT|MK-2048 High Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and either 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)"
214860175|NCT04319718|COMBINATION_PRODUCT|MK-2048 Low Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)"
214860176|NCT02739945|PROCEDURE|Cubital tunnel release|The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
214860177|NCT06483347|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
214860178|NCT01288053|BIOLOGICAL|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
214860179|NCT06316648|DIETARY_SUPPLEMENT|whey intake group|It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink.
214860180|NCT06316648|PROCEDURE|control group|The patients were left fasting after 00:00.
214860181|NCT04201886|OTHER|serum calprotectin|serum calcium binding leucocyte protein
214860182|NCT05920733|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
214860183|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
214860184|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
214860185|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
214860186|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
214860187|NCT02068092|DRUG|Hydroxytyrosol|
214860188|NCT03684187|BEHAVIORAL|Mindfulness Based Intervention|"Mindfulness - Based Intervention (MBI) Course:~The 8-week MBI program is comprised of an orientation session, 8 separate weekly sessions of 2.5 hours and also a 7.5 hour retreat session on a weekend day. The orientation session will include an introductory session, description of the course and will include completion of stress surveys. During the orientation session, there will be explanation to the patients of objectively the basis of mindfulness teaching. The role of the stress surveys that are conducted are to assess an individual's degree of stress prior to the initiation of any mindfulness practice teaching.~Subjects will also be asked to wear a BodyGuard 2 (BG2) for parts of the study, on average of 7 days at baseline, end of the control phase, end of intervention phase, and end of 48 week follow up period. This will track subjects heart rate (HR), HR variability, VO2, energy expenditure and activity."
214860189|NCT04786548|DRUG|Celecoxib|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
214860190|NCT03502525|BEHAVIORAL|Break the Cycle Intervention|The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting. The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
214860191|NCT03502525|BEHAVIORAL|Bacterial Infection Prevention|Bacterial Infection Prevention is an attention control intervention. The content of Bacterial Infection Prevention is representative of the infection prevention information injection drug users ought to receive, and sometimes do, when they engage with service providers, such as syringe exchange programs. Bacterial Infection Prevention does not use Motivational Interviewing principles, but is more informational/educational in nature. This intervention focuses on bacterial infection risks that accompany injection drug use, with a special focus on risk reduction, identification, and treatment of abscesses and endocarditis.
215033641|NCT03038087|DEVICE|SENSE Device|"The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~1. A molded plastic headpiece containing the antenna array, and~2. A processing control unit.~The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device."
214860192|NCT06158048|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214860193|NCT06158048|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
214860194|NCT04196972|OTHER|Communication Intervention|Receive ECHO telementoring intervention
214860195|NCT04196972|OTHER|Questionnaire Administration|Ancillary studies
214860196|NCT04196972|OTHER|Waiting List|Placed on wait-list
214860197|NCT03607708|OTHER|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
214860198|NCT03607708|OTHER|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
214860199|NCT05948592|BIOLOGICAL|TP-102|Patients randomised to TP-102 will receive 1 (one) mL of IP solution, applied topically per cm3 of target ulcer. The titre of each bacteriophage in TP-102 is 1x109 PFU/mL (\>1x108 PFU/mL and \<1x1010 PFU/mL). All patients randomised to TP-102 will receive the same concentration per mL. TP-102 will be applied to the target ulcer using a syringe without a needle. The volume of TP-102 to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
214860200|NCT05948592|OTHER|Placebo|Patients randomised to placebo, the volume calculated to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
214860201|NCT04737421|DEVICE|NobelActive TiUltra implant|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
215033642|NCT01202162|DRUG|Desflurane|Administratino of Desflurane
215033643|NCT01202162|DRUG|Administration of Sevoflurane|Administration of Sevoflurane
214860202|NCT04737421|DEVICE|NobelParallel CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
214860203|NCT04737421|DEVICE|NobelReplace CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
214860204|NCT04737421|DEVICE|Nobel Biocare N1 TiUltra TCC implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
214860205|NCT06499831|DIAGNOSTIC_TEST|0-(2-18F-Fluoroethyl)-L-Tyrosine|0-(2-18F-Fluoroethyl)-L-Tyrosine positron emission tomography (FET) is an amino acid agent derived from tyrosine that is able to cross the blood brain barrier. It has been studied primarily in diagnosis and detection of tumor recurrence in glioblastomas with emerging evidence for its use in brain metastases. Compared to conventional MRI, FET-PET has been shown to delineate geographically distinct tumor volume in newly diagnosed GBM suggesting the complementarity of the two modalities.
214860206|NCT02842333|OTHER|Additional biological samples|Blood samples
214290599|NCT00499018|DRUG|BCNU|300 mg/m2 day -7
214290600|NCT00499018|DRUG|ARA-C|200 mg/m2/12 days -6,-5,-4,-3
214860207|NCT06084832|BIOLOGICAL|blood microsampling|blood microsampling for the measure of Phosphatidylethanol
214860208|NCT06287801|OTHER|Annual Wellness Visit|Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.
214860209|NCT06287801|OTHER|Geriatric Resources and Assessment for the Care of Elders|The practice will initiate the Geriatric Resources and Assessment for the Care of Elders (GRACE) program for Medicare beneficiaries deemed by study algorithm as high-risk and meeting other study criteria (see below). After completion of the in-home structured annual wellness visit (AWV) and GRACE assessment by the NP/SW team, responses will be reviewed and applied to construct an individualized care plan using the GRACE protocols inclusive of advance care planning, health maintenance, medication management, assistance with any difficulty walking, falls, dementia, depression, chronic pain, malnutrition, weight loss, urinary incontinence, visual impairment, hearing impairment, or caregiver burden.
214860210|NCT04155034|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214860211|NCT04155034|RADIATION|Prophylactic Cranial Irradiation|Undergo PCI
214860212|NCT05447923|OTHER|Educational Intervention|Undergo education for colorectal cancer screening
214860213|NCT05447923|OTHER|Fecal Immunochemical Test|Undergo FIT testing
214860214|NCT05447923|BEHAVIORAL|Patient Navigation|Undergo patient navigation for positive FIT results
214860215|NCT05447923|OTHER|Questionnaire Administration|Complete questionnaire about colorectal cancer screening and healthcare
214860216|NCT03994055|OTHER|Omega-3 fatty acids|Diet will include foods rich in omega-3 fatty acids.
214860217|NCT03994055|OTHER|Antioxidants|Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.
214860218|NCT03994055|OTHER|Soluble fiber|Diet will include foods rich in soluble fiber.
214860219|NCT03994055|OTHER|Probiotics|Diet will include foods rich in probiotics.
214860220|NCT03994055|OTHER|Lactose restriction|Diet will be restricted to 5g lactose/day
214860221|NCT03994055|OTHER|Fiber restriction|Diet will be restricted to 20g fiber/day
214860222|NCT03994055|OTHER|Fat restriction|Diet will be restricted to 20% total energy intake
214860223|NCT01870882|BEHAVIORAL|Attentional retraining|
214860224|NCT01870882|BEHAVIORAL|Control condition|
214860225|NCT05935436|DEVICE|Cardiac Shock Wave Therapy|When operating CSWT, it is necessary to determine the target myocardium for treatment, adjust the height of the water bladder, set the energy that the patient can tolerate, and then start the treatment. During the treatment, the vital signs of the subjects should be detected.
214860226|NCT05791682|DRUG|Sealant, Fissure|FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
214860227|NCT06080841|DIETARY_SUPPLEMENT|Curcumin|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.
214860228|NCT06080841|DIETARY_SUPPLEMENT|Curcumin + Piperine|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.
214860229|NCT04476862|DRUG|Cerliponase Alfa|Commercially available product provided to patient by participating clinic site.
214860230|NCT04476862|DEVICE|Administration Kit|Commercially available administration kit provided to the patient by participating clinic site.
214860231|NCT04502758|DEVICE|MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.
214907067|NCT02976129|DRUG|V565|Daily dosing of V565 three times a day orally for 6 weeks
214907068|NCT02976129|DRUG|Placebo|Daily dosing of placebo three times a day orally for 6 weeks
214907069|NCT04924192|DRUG|TQB3616 capsules|A CDK4/6 kinase inhibitor
214907070|NCT04924192|DRUG|Anlotinib Hydrochloride capsules|A multi-target receptor tyrosine kinase inhibitor
214290601|NCT00499018|DRUG|VP-16|100 mg/m2/12h days -6,-5,-4,-3
214290602|NCT00499018|PROCEDURE|ASCT|PBSC Reinfusion
214290603|NCT00499018|DRUG|Ciclofosfamide|750 mg/m2 day 1
214290604|NCT00499018|DRUG|Doxorubicina|50 mg/m2 day 1
214860232|NCT04502758|DEVICE|Sham MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.
214860233|NCT01045421|DRUG|MLN8237 (Alisertib)|"Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."
214860234|NCT06196021|OTHER|Intra-articular hyaluronic acid injection|"Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid."
214860235|NCT00207779|DEVICE|heparin impregnated central venous catheters|
214860236|NCT04922684|BEHAVIORAL|Mimic facial expressions|16 times (4 times a week, last 4 weeks) of mimicking facial expressions.
214860237|NCT06454942|DIETARY_SUPPLEMENT|Nutrient-fortified egg|Consumption of nutrient-fortified eggs with habitual diet
214860238|NCT06454942|DIETARY_SUPPLEMENT|Regular egg with habitual diet|Consumption of regular egg with habitual diet
214860239|NCT04637126|OTHER|Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography|Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
214860240|NCT00146406|BEHAVIORAL|Project Connect|
214860241|NCT02221037|DRUG|GSK2862277|"It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
214860242|NCT02221037|DRUG|Placebo|"It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
214860243|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04+PreforPro|One 15mg capsule taken orally each day
214860244|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04|One 15mg capsule taken orally each day
214860245|NCT04511221|OTHER|Placebo|One 15mg capsule taken orally each day
214860246|NCT05000970|DEVICE|blood pressure cuff PLUS tablet|all arms
214860247|NCT05000970|OTHER|Telehealth Consult|Telehealth consult with an RN
214860248|NCT03044041|DRUG|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
214860249|NCT00306943|BIOLOGICAL|Influsplit SSW®|
214860250|NCT02872792|DEVICE|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
214860251|NCT02872792|OTHER|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
214860252|NCT03421158|BEHAVIORAL|breastfeeding|Newborns were breastfed during the procedure
214860253|NCT03421158|DIETARY_SUPPLEMENT|oral sucrose|Newborns were given oral sucrose during the procedure
214860254|NCT03421158|BEHAVIORAL|Skin-to-Skin contact|Newborns were placed in direct contact with their mothers during the procedure
214860255|NCT03421158|BEHAVIORAL|Non-nutritive sucking|newborns were given a pacifier to suck on during the procedure
214860256|NCT03880435|DEVICE|Hyalobarrier® gel endo|Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
214860257|NCT02307266|BEHAVIORAL|Standard of care + supplementary education|
214860258|NCT02307266|BEHAVIORAL|Standard of care + additional visits|
214860259|NCT02307266|BEHAVIORAL|Standard of care|
214860260|NCT04864405|OTHER|Morning administration of endocrine therapy|Endocrine therapy administered within one hour of patient wake up time
214860261|NCT04864405|OTHER|Evening administration of endocrine therapy|Endocrine therapy administered within one hour of the patient bed time
214860262|NCT00687089|OTHER|Sexual, cognitive functional tests and measurement weight|
214860263|NCT01453894|BEHAVIORAL|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
214860264|NCT02453776|DRUG|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
214860265|NCT06214169|DRUG|Cisatracurium Besylate|Addition of cisatracurium to plain lignocaine for IVRA.
214860266|NCT06214169|DRUG|Lignocaine|Plain Lignocaine for IVRA
214860267|NCT02454660|BEHAVIORAL|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
214860268|NCT06084962|BIOLOGICAL|DeepTag-GPRC5D Targeted CAR T-cells|Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion
214907071|NCT04924192|DRUG|Irinotecan Hydrochloride for Injection|An inhibitor of DNA topoisomerase Ⅰ
214860269|NCT05842421|DEVICE|optical coherence tomography, in vivo reflectance confocal microscopy, 3D total body photography|each lesion is in addition to examination with dermoscopy examined with optical coherence tomography, in vivo reflectance confocal microscopy, each patient is photographed with 3D total body photography
214860270|NCT00754403|DRUG|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
214860271|NCT00754403|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
214860272|NCT02161250|DIETARY_SUPPLEMENT|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
214860273|NCT02161250|DIETARY_SUPPLEMENT|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
214860274|NCT05340543|PROCEDURE|Confocal optical coherence tomography - OCTAVE|"An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function"
214860275|NCT02149290|DEVICE|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
214860276|NCT00256984|PROCEDURE|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
214860277|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
214860278|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
214860279|NCT02475941|OTHER|Non Weight bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
214860280|NCT02475941|OTHER|Early Weight Bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
214860281|NCT02124941|DRUG|N-acetyl cysteine|Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
214860282|NCT02124941|DIAGNOSTIC_TEST|[18F]FDG PET scan|All subjects will undergo \[18F\]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
214860283|NCT02124941|DIAGNOSTIC_TEST|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans at 7T, including before and after two-weeks of placebo and NAC administration.
214860284|NCT02124941|DIAGNOSTIC_TEST|[11C]APP311 PET scan|All subjects will undergo \[11C\]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
214860285|NCT01164345|DRUG|Plerixafor|Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
214860286|NCT01783249|OTHER|Stationary Exercise cycling|Stationary exercise cycling
214860287|NCT04299906|DEVICE|Solaris Vascular Stent Graft|Solaris Vascular Stent Graft for treatment of Iliac Lesions
214860288|NCT01956695|DRUG|Lenalidomide|
214860289|NCT01956695|DRUG|Rituximab|
214860290|NCT02279693|OTHER|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
214860291|NCT02279693|OTHER|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
214860292|NCT02279693|RADIATION|IGRT Associated With IMRT|
214860293|NCT03548649|DEVICE|exoskeleton robot training|subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
214860294|NCT05425693|OTHER|Hybrid Warm-up|Dynamic + stretching exercises
214860295|NCT05425693|OTHER|Dynamic Warm-up|Dynamic exercises
214860296|NCT05425693|OTHER|Stretching Warm-up|Stretching exercises
214860297|NCT01374126|DRUG|Artesunate|Artesunate alone
214860298|NCT01374126|DRUG|Azithromycin + Artesunate|Combination of azithromycin + artesunate
214860299|NCT00300625|PROCEDURE|Application of the San Francisco Syncope Rule|
214860300|NCT01301586|DRUG|Doxycycline and S-equol|Oral doxycycline and s-equol twice a day
214860301|NCT01301586|DRUG|Doxycycline|ORAL DOXYCYCLINE TWICE A DAY
214860302|NCT00006438|DEVICE|Shoes with Rocker Soles|
215033644|NCT02725684|OTHER|Observational study, no intervention|Observational study, no intervention
215033645|NCT06209866|DEVICE|PTA|Percutaneous Trans lumenal Angioplasty
214860303|NCT02470390|DRUG|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
214860304|NCT02835781|OTHER|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
214860305|NCT05157867|OTHER|Amylase trypsin inhibitors|Intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (wheat), dissolved in physiological saline.
214860306|NCT05157867|OTHER|Placebo|Intraduodenal administration of placebo (physiological saline).
214860307|NCT02766374|BEHAVIORAL|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
214860308|NCT02766374|BEHAVIORAL|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
214860309|NCT01995266|DRUG|Asunaprevir|
214860310|NCT01995266|DRUG|Daclatasvir|
214860311|NCT01006226|DRUG|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
214860312|NCT04795830|COMBINATION_PRODUCT|Bioceramic root repair material as pulp dressing in pulpotomy in primary molars|BC RRM-F, a novel premixed bioceramic-based putty, can be used as a pulp dressing to promote pulp healing and repair with an added convenience for the pediatric patient. The aim of the present study is to evaluate the efficacy of a bioceramic root repair material as pulp dressing in pulpotomy in primary molars. The success of this material as pulpotomy dressing in primary molars will be evaluated clinically and radiographically in comparison to mineral trioxide aggregate pulpotomy. Both materials will be compared in terms of ease of handling, time to perform procedure and convenience of application. Each material's success will be evaluated by comparing its performance with or without the added peripheral seal of a stainless steel crown.
214860313|NCT04795830|COMBINATION_PRODUCT|Mineral Trioxide Aggregate as pulp dressing in primary molars (MTA)|MTA's sealing ability, biocompatibility, ability to stimulate hard tissue formation and its regenerative ability when used in contact with pulp tissues has made MTA pulpotomy the new gold standard as opposed to formocresol pulpotomy in treating the amputated pulp stumps of primary molars.
214860314|NCT03758404|BIOLOGICAL|adeno-associated virus vector AAV- CNGA3|Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene
214860315|NCT01673243|OTHER|Questionnaire|Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
214860316|NCT00226421|DRUG|Oxymorphone Extended Release|
214860317|NCT03596151|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
214860318|NCT05802251|DIAGNOSTIC_TEST|Ultrasonographic parameters|cervical length. placental thickness. distance placental edge from internal os of the cervix
214860319|NCT00222989|DRUG|PPI|
214860320|NCT04094376|OTHER|receiving operation during the day or at night|eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
214860321|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given intravenously only once at dose of 10 mg
214860322|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
214860323|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
214860324|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
214860325|NCT01066091|OTHER|Mashed potatoes|Mashed potatoes: Potatoes + Skim milk powder
214860326|NCT01066091|OTHER|Mashed potatoes + Oleic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
214860327|NCT01066091|OTHER|mashed potatoes + Palmitic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
214860328|NCT05948514|OTHER|The complications related to central venous access device|The complications related to central venous access device were collected when occurs : from time of catheter insertion, until first complication, or removal for another type of catheter, or until death.
214860329|NCT02064114|PROCEDURE|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
214860330|NCT02064114|PROCEDURE|control group|Followed for a period of 3,6 and 12 months after the procedure.
214860331|NCT02514850|DRUG|Biochaperone Combo|Injection of BioChaperone Combo
214860332|NCT02514850|DRUG|Humalog Mix25|Injection of Humalog Mix25
214860333|NCT02514850|DRUG|Humalog|Injection of Humalog
214860334|NCT02514850|DRUG|Lantus|Injection of Lantus
215033646|NCT05022719|DEVICE|PillCam Colon2 procedure with MB-MMX|Subjects will undergo a bowel preparation (single dose, 4L PEG), including 200 mg Methylthioninium chloride, corresponding to eight 25 mg MB-MMX tablets and 1 tab of Resolor (Prucalopride 1mg). An experienced Gastroenterologist will read the CCE procedure and complete a subjective questionnaire, to evaluate mucosal enhancement during a CCE procedure, when using MB-MMX as a contrast-enhancement technique.
214860335|NCT02514850|DRUG|Placebo|Injection of saline 0.9% solution
214860336|NCT01700036|DRUG|Alpha-1-Antitrypsin (AAT)|AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
214860337|NCT04190719|OTHER|multimodal prehabilitation|"Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~* Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~* An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~* Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics"
214860338|NCT00062543|PROCEDURE|Hepatic artery infusion of CD34+ cells|Donor's cells infused directly into liver through a groin catheter (hepatic artery).
214860339|NCT00062543|DEVICE|Cobe Spectra|Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
214860340|NCT04006483|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
214860341|NCT04006483|DRUG|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
214860342|NCT04006483|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
214860343|NCT04414761|DRUG|Progesterone|oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
214860344|NCT04414761|DRUG|GnRH Antagonist|GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
214860345|NCT03074253|DIAGNOSTIC_TEST|Echocardiography|Patients are undergoing echocardiography
214860346|NCT03074253|DIAGNOSTIC_TEST|magnetic resonance imaging|Patients are undergoing magnetic resonance imaging
214860347|NCT03074253|DIAGNOSTIC_TEST|computed tomography|Patients are undergoing computed tomography
214860348|NCT03074253|DIAGNOSTIC_TEST|blood withdrawl|Peripheral blood samples are being collected from all patients
214860349|NCT04166448|OTHER|Fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
214860350|NCT03957330|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
214860351|NCT04390295|DRUG|Placebo|Once daily, 24 weeks
214860352|NCT04390295|DRUG|SHR3824|Once daily, 52 weeks
214860353|NCT04390295|DRUG|metformin|Three times daily, 52 weeks
214860354|NCT01850186|DEVICE|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
214290605|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
214860355|NCT01850186|DRUG|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
214860356|NCT00679926|DRUG|Once daily|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
214860357|NCT03996148|DRUG|Remifentanil, Propofol, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
214476474|NCT06612125|OTHER|pressure controlled ventilation|Pediatric patients in the PCV group(n=30) received pressure-controlled ventilation. The initial parameters will be as follows: the peak inspiratory pressure (PIP) will set to provide a tidal volume of 7 ml/kg , respiratory rate will be 16 breaths/min, inspiratory to expiratory ratio was 1:2 with an upper limit of PIP of 20 cm H2O.
214476475|NCT06612125|OTHER|pressure controlled volume grantanteed ventilation|Pediatric patients in the PCV-VG group (n=30)will be conducted with pressure-controlled volume-guaranteed ventilation, target tidal volume will set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
214860358|NCT03996148|DRUG|Remifentanil, Dexmedetomidine, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
214860359|NCT03996148|DRUG|Remifentanil and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
214860360|NCT01103726|DRUG|PF-02545920|1 and 5 mg tablets, 6 mg single dose
214860361|NCT01103726|DRUG|placebo|matching placebo tablets, single dose
214860362|NCT01103726|DRUG|PF-02545920|1 mg tablets, 3 mg single dose
214860363|NCT01103726|DRUG|PF-02545920|5 mg tablets, 15 mg single dose
214860364|NCT01103726|DRUG|Placebo|matching placebo tablets, single dose
215033647|NCT02501447|BEHAVIORAL|Guided audio-visual relaxation|
215033648|NCT06544720|BIOLOGICAL|SCG142 TCR-T cells|Monotherapy of SCG142
215033649|NCT05006495|PROCEDURE|C3 laminectomy|C3 laminectomy preserving semispinalis cervicis inserted into the axis.
215033650|NCT05006495|PROCEDURE|C3 laminoplasty|Conventional C3-6 laminoplasty, resulting in injury of semispinalis cervicis.
215033651|NCT03137823|DIAGNOSTIC_TEST|throat culture|throat culture - from the tonsills and from the bucal surface
215033652|NCT03161873|DEVICE|Ava|Ava is a fertility monitoring bracelet that collects various physiological parameters
214860365|NCT03827746|OTHER|Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale|"Tampa Kinesiophobia Scale: The TSK is a 17-item self report checklist using a 4-point Likert scale that was developed as a measure of fear of movement or (re)injury.~Berg-Balance Test: 14-item scale designed to measure balance of the older adult in a clinical setting.~International Physical Activity Questionnaire-Short Form: This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.~Falls Efficacy Scale: A 16- item self-administered questionnaire designed to assess fear of falling in mainly older population"
214860366|NCT00299026|DEVICE|NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System|
214860367|NCT04342468|OTHER|non-interventional|No intervention
214860368|NCT00604123|DRUG|JNJ-17166864|JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
214860369|NCT00604123|DRUG|Placebo|Placebo nasal spray twice daily for 2 weeks.
214860370|NCT05483595|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 10ml
214860371|NCT00258050|DRUG|Midazolam|Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
214860372|NCT00258050|DRUG|Lapatinib|Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
214860373|NCT04602910|DEVICE|a web-based shared decision-making tool|Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
214860374|NCT02261350|DIETARY_SUPPLEMENT|Food fortification|
214860375|NCT02261350|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|
214860376|NCT02603718|OTHER|Rehabilitation treatment|
214860377|NCT01996943|DRUG|Ethanol|6% volume/volume ethanol in 0.45% saline solution.
214860378|NCT01996943|DRUG|Placebo|"The placebo with be 0.45% saline solution (half normal saline)."
214860379|NCT03917017|DEVICE|Radiomics and Watson artificial intelligence|"The artificial intelligence platform developed by IBM Watson can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.~The imaging histology can be used to conduct intraoperative navigation surgical resection and treatment monitoring, and established a prognosis model to predict the prognosis of patients by grading the results of postoperative follow-up and microvascular invasion of pathological liver cancer, so as to better achieve accurate diagnosis and treatment of the disease."
214860380|NCT01126411|PROCEDURE|immunoadsorption / immunglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
214860381|NCT01468805|PROCEDURE|Cockroach mitigation/extermination|
214860382|NCT00863395|PROCEDURE|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
214860383|NCT02796118|DRUG|ASP2151|Oral
214860384|NCT02796118|DRUG|Placebo|Oral
214860385|NCT03573505|DRUG|BG00011|Administered as specified in the treatment arm.
214860386|NCT03573505|DRUG|Placebo|Administered as specified in the treatment arm.
214860387|NCT00316147|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
214860388|NCT03222583|DRUG|Placebo|Matching placebo tablet for oral administration
214860389|NCT03222583|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
214860390|NCT05056883|DRUG|K-237 0.3-0.4mg/kg (once daily)|Ivermectin 3mg tablet
214860391|NCT05056883|DRUG|Placebo 0.3-0.4mg/kg (once daily)|Placebo 3mg tablet
214860392|NCT04280705|OTHER|Placebo|The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.
214860393|NCT04280705|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
214860394|NCT01740635|DEVICE|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
214860395|NCT05145179|DRUG|SSGJ-705|0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
214860396|NCT02802449|DRUG|25 Hydroxy- Vitamin D3 [25 (OH) D3]|Two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
214860397|NCT02802449|DRUG|Placebo|
214860398|NCT04268316|DEVICE|Virtual Reality Behavioral Activation|"Participants will choose four activities to complete in virtual reality over the course of the week. These activities are video 360 and range from viewing animals, to viewing nature scenes, to traveling to a different location in the world, to viewing adrenaline-pumping activities."
214860399|NCT04268316|BEHAVIORAL|Behavioral Activation in real-life|Participants will choose four pleasurable and/or mastery activities to complete over the course of the week in real life.
214860400|NCT02216513|DRUG|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
214860401|NCT02216513|DRUG|placebo|normal saline IV for 4 hours for 5 consecutive days
214860402|NCT03145636|DEVICE|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
214860403|NCT03145636|OTHER|vBloc Achieve Weight Management Program|Remotely accessible web-based program to add additional support to subjects with vBloc therapy
214860404|NCT03145636|OTHER|Control Weight Management (CWM) program|In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
214860405|NCT01463735|DIETARY_SUPPLEMENT|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
214860406|NCT00845819|DRUG|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) \& nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
214860407|NCT00845819|DRUG|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
214860408|NCT00746018|DEVICE|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
214860409|NCT05557032|PROCEDURE|cardiopulmonary resuscitation|pulse checks during cardiopulmonary resuscitation
214860410|NCT05530187|DEVICE|Electronic Patient-reported Outcomes-based Model of Care|Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
214860411|NCT00605761|DRUG|SB656933|50 mg treatment
214860412|NCT00605761|DRUG|SB656933|150 mg treatment
214860413|NCT01375153|DRUG|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
214860414|NCT01375153|DRUG|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
214860415|NCT01030653|DRUG|Voriconazole low dose|Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
214860416|NCT01030653|DRUG|Voriconazole high dose|Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
214860417|NCT03183648|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
214860418|NCT02564146|DRUG|nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
215033653|NCT04661527|DRUG|Sarilumab|Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.
215033654|NCT05501899|DRUG|Levocarnitine|Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
214860419|NCT02564146|DRUG|gemcitabine mono and nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
214860420|NCT05672823|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.
214860421|NCT03370016|PROCEDURE|Amount of Pneumoperitoneum Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
214860422|NCT01405716|BEHAVIORAL|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
214860423|NCT01405716|BEHAVIORAL|Health Education|8-week health education program
214860424|NCT04141124|OTHER|breathing exercise/HRV-biofeedback|5 min of relaxing breathing, coupled with biological feedback.
214860425|NCT04141124|OTHER|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
214860426|NCT04141124|OTHER|Control|5 minutes of reading fictitious biological medical results
214860427|NCT04059458|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.
214860428|NCT04059458|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
214860429|NCT00003224|BIOLOGICAL|QS21|vaccine adjuvant
214860430|NCT00003224|BIOLOGICAL|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
214860431|NCT00003224|BIOLOGICAL|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
214860432|NCT00003224|BIOLOGICAL|p946/tet-p|This peptide is a longer version of p946 (gp100 \[280-288\]) sythesized colinearly with the tetanus helper peptide (Tet-p)
214860433|NCT00003224|BIOLOGICAL|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
214860434|NCT04156958|DRUG|Fruquintinib|Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
214860435|NCT02337023|RADIATION|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
214860436|NCT04808310|DEVICE|Quantitative flow ratio|Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)
214860437|NCT04808310|DIAGNOSTIC_TEST|Assessment of angiographic severity of the stenosis|The indication to coronary stent intervention will be based on angiography
214860438|NCT03286010|BEHAVIORAL|Women@Heart Program|The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
214860439|NCT02767895|BEHAVIORAL|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
214860440|NCT03986138|DRUG|gadopiclenol|Single intravenous bolus injection
214860441|NCT03986138|DRUG|Gadobutrol 1 MMOLE/ML Intravenous Solution|Single intravenous bolus injection
214860442|NCT06231264|DEVICE|transcutaneous electrical acustimulation at treatment sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.
214860443|NCT06231264|DEVICE|transcutaneous electrical acustimulation at sham sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
214860444|NCT02777814|DRUG|Entecavir|anti hepatitis B virus
214860445|NCT01510548|BIOLOGICAL|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
214860446|NCT05855616|DEVICE|"Group chlorhexidine dressing"|Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.
214860447|NCT05855616|OTHER|"Group solution"|Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
214860448|NCT02494934|BEHAVIORAL|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
214860449|NCT02494934|BEHAVIORAL|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
214860450|NCT04214717|COMBINATION_PRODUCT|DC-CIK combined with Chemotherapy|Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months.
214860451|NCT04214717|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
214860452|NCT04032158|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
214860453|NCT04032158|DRUG|Avonex®|Participants received avonex® IM injection once a week.
214860454|NCT04032158|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to Avonex® once a week.
214860455|NCT04032158|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
214860456|NCT05032521|BIOLOGICAL|collection of biological data|collection of biological data
214860457|NCT05032521|OTHER|collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data|These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.
214860458|NCT05032521|PROCEDURE|Standard treatment|usual management based on the use of drugs according to international recommendations
214860459|NCT05032521|PROCEDURE|stratified treatment according to algorithm|management based on arteriovenous CO2 gradient Stratification of drug use
214860460|NCT01772264|DRUG|PF-05089771|titration from 150mg BID to 450mg BID
214860461|NCT01772264|DRUG|Placebo|matched placebo
214860462|NCT05222542|OTHER|Sampling of plasma and cerebrospinal fluid at specified time points|Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
214860463|NCT02276079|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 - 0.7 × age).
214860464|NCT02276079|BEHAVIORAL|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
214860465|NCT00059787|DRUG|paclitaxel|Given IV
214860466|NCT00059787|DRUG|carboplatin|Given IV
214860467|NCT00059787|DRUG|erlotinib|Given PO
214860468|NCT02253836|DRUG|Tipranavir|TPV
214860469|NCT02253836|DRUG|Ritonavir|RTV
214860470|NCT02253836|DRUG|Atazanavir|TAZ
214860471|NCT00010608|BEHAVIORAL|Transcendental Meditation|a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
214860472|NCT00010608|BEHAVIORAL|Health Education|didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
214860473|NCT03342599|DIETARY_SUPPLEMENT|Alpha Lipoic Acid Supplement|Alpha lipoic acid ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
214860474|NCT03342599|DIETARY_SUPPLEMENT|Placebo|Cellulose fiber ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
214860475|NCT02135653|RADIATION|Radiotherapy|
214860476|NCT02135653|OTHER|Eischens Yoga|
214860477|NCT02340845|BIOLOGICAL|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
214860478|NCT02726893|OTHER|no intervention|
214860479|NCT00725530|DEVICE|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
214860480|NCT00725530|DEVICE|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
214860481|NCT02882685|PROCEDURE|Roux-en-y gastric bypass|
214860482|NCT02882685|PROCEDURE|Single anastomosis gastric bypass|
214860483|NCT05018520|DRUG|Six Courses of R-CHOP Plus Two Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 2 courses)
215033655|NCT02786407|DRUG|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
215033656|NCT02786407|DRUG|Placebo|In these studies,patients received placebo administered to 20 injection sites
214860484|NCT05018520|DRUG|Four Courses of R-CHOP Plus Four Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 4 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 4 courses)
214860485|NCT02050425|DEVICE|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
214860486|NCT02050425|DEVICE|CPAP|Patients continue therapeutic CPAP therapy
214860487|NCT00453557|DRUG|rhGH|
214860488|NCT01660464|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
214860489|NCT01646047|DIETARY_SUPPLEMENT|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
214860490|NCT01646047|DIETARY_SUPPLEMENT|multi-component dietary supplement|placebo capsules
214860491|NCT06063759|DEVICE|VitalDetect|measurement of microcirculating blood flow, SpO2 (mmHg or %), heart rate (beats/min)
215033657|NCT03139721|DEVICE|Mosaic model 305, model 310, and ultra model 305|Aortic or mitral valve replacement
215033658|NCT02284893|DRUG|Saxagliptin|administered orally once daily
215033659|NCT02284893|DRUG|Dapagliflozin|administered orally once daily
215033660|NCT02284893|DRUG|Sitagliptin|administered orally once daily
214860492|NCT03535675|DRUG|Muscadine Plus|Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
214860493|NCT03535675|DRUG|Placebos|The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
214860494|NCT00307606|DRUG|Solu-medrol 125 mg|
214860495|NCT00103311|DRUG|ispinesib|Given IV
214860496|NCT00103311|OTHER|laboratory biomarker analysis|Correlative studies
214860497|NCT01196078|DRUG|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
214860498|NCT01196078|DRUG|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
214860499|NCT05986331|DRUG|BCD-201|up to 8 treatment cycles
214860500|NCT05986331|DRUG|Keytruda|up to 8 treatment cycles
214860501|NCT03928314|DRUG|ORIC-101|ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle
214860502|NCT03928314|DRUG|Nab-paclitaxel|75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle
214860503|NCT03063879|DRUG|Sofosbuvir 400 mg and daclatasvir 60 mg|Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness \< 12 KPa) or 24 weeks if cirrhotic
214860504|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
214860505|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
215033661|NCT02284893|DRUG|Placebo matching with Saxagliptin|administered orally once daily
214860506|NCT04029987|PROCEDURE|Control|Conventional analgesia
214860507|NCT00225537|DRUG|4-Methylumbelliferone (Heparvit®)|
214860508|NCT04324593|DEVICE|Peripheral intravenous analysis (PIVA) algorithm|An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
214860509|NCT02133586|OTHER|Ozone|Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
214860510|NCT02133586|OTHER|Nitrogen dioxide|Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
214860511|NCT00771381|DRUG|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
214860512|NCT00771381|DRUG|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
214860513|NCT02159781|PROCEDURE|periodontal treatment - scaling and root planning|
214860514|NCT05717855|DIAGNOSTIC_TEST|Displaying optic chiasm for screening septooptic dysplasia|Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia with ultrasound between 16-20 weeks of gestation
214860515|NCT04413136|BEHAVIORAL|Web-ORLA|
214860516|NCT04413136|BEHAVIORAL|Control|
214860517|NCT00003436|DRUG|amsacrine|
214860518|NCT00003436|DRUG|asparaginase|
214860519|NCT00003436|DRUG|cytarabine|
214860520|NCT00003436|DRUG|daunorubicin hydrochloride|
214860521|NCT00003436|DRUG|etoposide|
214860522|NCT00003436|DRUG|methotrexate|
214860523|NCT00003436|DRUG|mitoxantrone hydrochloride|
214860524|NCT00003436|DRUG|therapeutic hydrocortisone|
214860525|NCT00003436|PROCEDURE|allogeneic bone marrow transplantation|
214860526|NCT03516396|BEHAVIORAL|Training Plus|Training plus enhanced community development activities
214860527|NCT03516396|BEHAVIORAL|Training Only|Training Only (livestock management and child nutrition) for 24 months then add community development inputs
214860528|NCT03516396|BEHAVIORAL|No Inputs then Community development and training|No inputs for 24 months then add community development and training
214860529|NCT04270136|PROCEDURE|total mastectomy|breast cancer non conserving surgery
214860530|NCT05017259|DIETARY_SUPPLEMENT|calorie restriction diet|The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
214860531|NCT00787397|BEHAVIORAL|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
214860532|NCT05389982|OTHER|mHealth (GetWell)|GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.
214860533|NCT05389982|OTHER|Standard Care|Office based pathway
215033662|NCT02284893|DRUG|Placebo matching with Dapagliflozin|administered orally once daily
215033663|NCT02284893|DRUG|Placebo matching with Sitagliptin|administered orally once daily
214860534|NCT04460196|OTHER|survey|Each admitted patient will complete a questionnaire
214860535|NCT03869203|OTHER|Enhanced recovery after surgery (ERAS)|The patients in the ERAS group were given a pre-treatment drug \[300 mg (gabapentin, Neurontin 300mg) and 10 mg oxycontin (oxycontin, Oxycontin CR 10mg) and 2 mg prednisolone (prednisolone 10 mg, Solondo 5mg)\] on the evening before surgery. And pre-operative fasting should not exceed 6 hours, and clear liquid fasting should not exceed 2 hours. In addition, 400 ml of oral carbohydrate should be taken 2 to 4 hours before surgery to ensure adequate blood sugar and encourage regular diet (light meal) as soon as possible within a tolerable range after surgery. The initial pain after surgery is actively controlled by oral drugs such as celebrex and IR codon, and injections such as tramadol and demerol. On the first postoperative day, the urinary catheter is removed and CPM (continuous passive motion) rehabilitation is started.
214860536|NCT01403064|BIOLOGICAL|ALD518|IV
214860537|NCT01403064|DRUG|0.9% saline|IV Infusion
214860538|NCT02945670|BEHAVIORAL|Focus Group|We had recruited 64 women and completed 7 focus group sessions
214860539|NCT01718470|PROCEDURE|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
214860540|NCT01718470|PROCEDURE|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
214860541|NCT00393471|DRUG|Etanercept|
214860542|NCT00929331|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
214860543|NCT03537274|BIOLOGICAL|PEG-Intron|PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
214860544|NCT03537274|BIOLOGICAL|Interferon Alfa-2B|Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
214860545|NCT04572126|BEHAVIORAL|Mindfulness Intervention|The mindfulness intervention includes strategies to cope with substance cravings based on previously published mindfulness techniques. Examples of strategies presented include paying close attention to sensations, acceptance of cravings, and self-kindness.
214860546|NCT04572126|BEHAVIORAL|Control Intervention|The control intervention instructs participants to utilize their own, previously used strategies to cope with substance cravings.
214860547|NCT01969448|PROCEDURE|Inframammary Fold Incision or Lateral Radial Incision|
214860548|NCT01969448|PROCEDURE|Lateral Radial Incision|
214860549|NCT01969448|PROCEDURE|Inframammary Fold Incision|
214860550|NCT01969448|DEVICE|Laser-assisted fluorescence angiography|
214860551|NCT01969448|DRUG|Indocyanine Green|
214860552|NCT04250948|DRUG|JS001|JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.
214860553|NCT04250948|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w
214860554|NCT04250948|DRUG|S1|S-1: 40\~60mg Bid，d1\~14, q3w
214860555|NCT04250948|DRUG|Capecitabine|Capecitabine: 1000mg/m2 Bid，d1-14, q3w
214860556|NCT02000401|DRUG|Ketorolac Tromethamine|
214860557|NCT01521416|OTHER|Data collection|"Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated."
214860558|NCT02876783|OTHER|Observational - No intervention|
214860559|NCT04688931|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
214860560|NCT04688931|PROCEDURE|TURBT|The current standard of care for treatment of LG-IR-NMIBC is TURBT under general anesthesia.
214860561|NCT03743740|OTHER|Spinal stabilization exercise|The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.
214860562|NCT04724044|DRUG|Tablets|Oral tablets of similar appearance to active study drug
214860563|NCT04724044|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
214860564|NCT06019520|DRUG|N-Acetylcysteine|Patients in the NAC arm will receive1200 mg of NAC (water-soluble granule Preparation) administered orally once daily at night for 7 consecutive days (1 days before chemotherapy, on the day of chemotherapy, and 5 days after chemotherapy) in each cycle of chemotherapy.
214860565|NCT06019520|DRUG|Chemotherapy|Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
214860566|NCT06124274|BEHAVIORAL|Protein tracer drink|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13 Carbon(13C)\]-leucine.
214860567|NCT00121316|DRUG|Pimecrolimus|Pimecrolimus Cream 1 %
214860568|NCT00121316|DRUG|Placebo|Vehicle cream (placebo cream)
214860569|NCT00422981|DRUG|AL-108|5 mg QD
214860570|NCT00422981|DRUG|AL-108|15 mg BID
214860571|NCT00422981|DRUG|Placebo|Placebo
214860572|NCT01898325|DEVICE|Fibroscan|Fibroscan
214860573|NCT00450619|RADIATION|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
214860574|NCT00450619|BIOLOGICAL|Sargramostim|100 mcg/injection x 4 days given subcutaneously
214860575|NCT00450619|BIOLOGICAL|Recombinant vaccinia-TRICOM vaccine|2 x 10\^8 PFU given subcutaneously on day 1.
214860576|NCT00450619|BIOLOGICAL|Recombinant fowlpox-TRICOM vaccine|1 x 10\^9 PFU given subcutaneously on days 15 and 29
214860577|NCT00531141|OTHER|examination only|OCT performed twice
214860578|NCT03750435|PROCEDURE|AF ablation or left-sided AT ablation|According to the type of AF/AT, single or double transseptal and subsequent catheter ablation in the left atrium using radiofrequency will be performed.
214860579|NCT02613013|DEVICE|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
214860580|NCT02613013|DEVICE|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
214860581|NCT02613013|DRUG|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
214860582|NCT02613013|PROCEDURE|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
214860583|NCT02613013|DRUG|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
214860584|NCT02613013|PROCEDURE|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris \>0.1mm. and patency was determined by direct visualization of the posterior chamber.
214860585|NCT05129436|DRUG|Vaxigrip Tetra 2020/2021|vaccine against seasonal influenza
214860586|NCT05778136|OTHER|Resistance training|Supervised resistance training. 2 sessions/week for 12 weeks. The exercises are one-legged leg-press and one-leg knee extension. Resistance training start-up phase comprises 3 sets of 10 repetitions in each of the two exercises with 50% of 1RM. Resistance training progressive phase comprises 3 sets (leg-press) of 5-8 repetitions (70-90% 1 RM) and 6 sets (knee extension) of 8 repetition (75% 1RM). Rest between sets: 3 minutes
214860587|NCT01130636|DRUG|Oseltamivir|Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
214860588|NCT02034058|DEVICE|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
214860589|NCT05222503|DEVICE|Knee Brace + OPUM Digital Knee|Knee Brace + OPUM Digital Knee
214860590|NCT05222503|DEVICE|Knee Brace|Knee Brace without OPUM Digital Knee
214860591|NCT05232084|DRUG|Bupivacaine + Fentanyl|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
214860592|NCT05367479|DRUG|Antibiotic|Peri-operative, intravenous antibiotic for surgical site infection
214860593|NCT02369900|DRUG|Esmolol|
214860594|NCT02369900|OTHER|Saline|
214860595|NCT03309007|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
214860596|NCT03309007|DRUG|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
214860597|NCT05854888|PROCEDURE|Perineal Massage and Warm Compresses (PeMWaC)|Perineal Massage was performed in the II Hodge Plan, between maternal contractions and regardless of maternal position. Warm Compresses were applied by the midwife between Hodge plans III and IV, during pushing and regardless of maternal position.
214860598|NCT05854888|PROCEDURE|Control Group (Hands-on)|"The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum."
214290606|NCT03730493|BEHAVIORAL|Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
214860599|NCT00587015|DRUG|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
214860600|NCT04943978|OTHER||just observational blood and liver sampling
214860601|NCT03899311|OTHER|protein-sparing modified fast diet|a PSMF diet follow the usual care format in the Center
214860602|NCT02963311|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
214860603|NCT02963311|DRUG|Standard of Care|Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
214860604|NCT00455611|DEVICE|CPAP (Continuous Positive Airway Pressure)|
214860605|NCT06408883|DEVICE|Vibrabot capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
214860606|NCT06418685|DEVICE|Treatment with Vibrating Capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
214860607|NCT02982798|DRUG|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
214860608|NCT02982798|DRUG|JLP-1310|administration of JLP-1310
214860609|NCT02018783|PROCEDURE|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
214860610|NCT02018783|PROCEDURE|Sensodyne|Digital application for 60 seconds.
214860611|NCT02018783|PROCEDURE|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
214860612|NCT02018783|PROCEDURE|Cocorico|Digital application for 60 seconds
214860613|NCT01211080|DRUG|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
214860614|NCT03106831|DRUG|Pituitrin infusion|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
214860615|NCT03106831|DRUG|Norepinephrine infusion|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
214860616|NCT05019820|OTHER|Knee strengthening exercises with isokinetic dynamometer|18 sessions of strengthening exercises around the knee with an isokinetic dynamometer 3 days a week
214860617|NCT05019820|OTHER|Strengthening around the knees with home exercise programe|18 sessions of strengthening exercises for the muscles around the knee at home, 3 days a week
214860618|NCT01234792|DRUG|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
214860619|NCT01234792|DRUG|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
214860620|NCT01234792|DRUG|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
214860621|NCT03752944|PROCEDURE|lefort I osteotomy for maxillary advancement|fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.
214860622|NCT04597294|COMBINATION_PRODUCT|FLOT + HIPEC + Surgery|HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy
214860623|NCT04597294|COMBINATION_PRODUCT|FLOT + Surgery|Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery
214860624|NCT01295294|DRUG|Tranexamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
214860625|NCT01295294|DRUG|Mefenamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
214860626|NCT01295294|DRUG|Placebo|3 times daily per oral during bleeding/spotting episodes
214860627|NCT01295294|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|In vitro release rate 20 microgram/24 hours. Intrauterine system
214860628|NCT03707665|DIAGNOSTIC_TEST|Compression ultrasound testing|Compression ultrasound testing, screening technique for diagnosing deep venous thrombosis
214860629|NCT02836626|PROCEDURE|deep fascial mobilization|Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
214860630|NCT02836626|PROCEDURE|superficial fascial mobilization|This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
214860631|NCT06255301|DIAGNOSTIC_TEST|EYEPRIM|Collection of conjunctival impressions using the EC(European Conformity )-marked EYEPRIM device . This device enables cells to be collected the superficial ocular surface cells by applying a membrane for few seconds to the ocular surface.
214860632|NCT03239886|OTHER|imatinib discontinuation|imatinib discontinuation
214860633|NCT02897986|DRUG|administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination|
214860634|NCT02375139|DRUG|DA-1229_01|complex single administration
214860635|NCT02375139|DRUG|E+M|co-administration of 2 drugs
214860636|NCT02788786|DRUG|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
214860637|NCT02788786|DRUG|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
214860638|NCT02788786|DRUG|Salt and Water|salt and water mix oral rinse
214860639|NCT05162365|BIOLOGICAL|IBI314|Low/medium/high dose, intravenously, once, on Day 1
214860640|NCT05162365|OTHER|Placebo|Placebo, intravenously, once, on Day 1
214860641|NCT03426566|OTHER|retrospective observational study with no intervention|no intervention
214860642|NCT03054558|OTHER|Pelvic ultrasound both two dimensional and three dimentional|
214860643|NCT04641065|OTHER|Music listening|An expert on the particular type of music will do the selection of the playlist of Traditional Turkish Military music, and this playlist will be listened to the patients by the researchers.
214860644|NCT03438825|PROCEDURE|Mitral valve replacement/repair|Mitral valve replacement/repair: standard of care operation of the mitral valve due to severe insufficiency
214860645|NCT05914935|DRUG|Recombinant L-IFN adenovirus injection|The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
214860646|NCT00212121|RADIATION|high dose boost|high dose boost
214860647|NCT00212121|PROCEDURE|boost|low dose versus high dose
214860648|NCT02933021|OTHER|Blood sample taken|
214860649|NCT02933021|OTHER|Answering a lifestyle questionnaire|
214860650|NCT02933021|OTHER|Follow-up phone call from researcher (two years after first visit)|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
214860651|NCT06625918|DEVICE|Ultraviolet B exposure to produce vitamin D synthesis|Exposure using a UV skin care device on vitamin D production and immune response in healthy adults
214860652|NCT03377764|PROCEDURE|Landmark Technique Control group|Spinal Anesthetic
214860653|NCT03377764|PROCEDURE|Neuroaxial block using Ultrasound Guidance|Ultrasound guided Spinal Anesthetic
214860654|NCT00467636|PROCEDURE|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
214860655|NCT00467636|DRUG|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI \> 30 = 0.2 unit/kg)
214860656|NCT03728218|DEVICE|Contact lenses (Orthokeratology)|Contact lenses
214860657|NCT03728218|DEVICE|Contact lenses (Soft Multifocal)|Contact lenses
214860658|NCT05334264|PROCEDURE|Cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
214860659|NCT00874003|DRUG|mirtazapine|oral tablet, 30 mg daily
214860660|NCT00874003|DRUG|placebo|oral tablet, 1 daily
214860661|NCT04398264|OTHER|COVID-19 positive via testing|Pregnant women admitted to Obstetric Units undergo RT-PCR testing for the detection of SARS-Cov2 (COVID-19 infection)
214860662|NCT02232490|BIOLOGICAL|hepcortespenlisimut-L|hepcortespenlisimut-L (V5) is given in experimental arm
214860663|NCT02232490|BIOLOGICAL|Placebo|
214860664|NCT05038579|PROCEDURE|Musiquence|The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
214860665|NCT00845806|OTHER|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
214860666|NCT01679106|OTHER|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
214860667|NCT01679106|OTHER|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
214860668|NCT00333879|DEVICE|Virtual Sound System|Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
214860669|NCT03311100|OTHER|immunohistochemistry assay|biomarkers expression
214860670|NCT03045159|BEHAVIORAL|Strong Families Strong Forces|Parenting program
214860671|NCT03045159|BEHAVIORAL|Strong Parents|self-care program
214860672|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 + fish oil/fish oil placebo|Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
214860673|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 placebo + fish oil/fish oil placebo|Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
214860674|NCT02044796|DRUG|Cladribine|Given IV
214860675|NCT02044796|DRUG|Cytarabine|Given IV
214860676|NCT02044796|BIOLOGICAL|Filgrastim|Given SC
214860677|NCT02044796|OTHER|Laboratory Biomarker Analysis|Correlative studies
214860678|NCT02044796|DRUG|Mitoxantrone Hydrochloride|Given IV
214860679|NCT04102852|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG ATCC 53103|probiotic administration at two different doses for 1 month
214860680|NCT02824718|DRUG|Teriparatide|human recombinant parathormone
214860681|NCT02824718|DRUG|Thiazide|Diuretic
214860682|NCT02824718|DRUG|Potassium sparing diuretic|Diuretic
214860683|NCT02824718|DRUG|Alfacalcidol|Belongs to the class of vitamin D and analogues
214860684|NCT04408599|DRUG|NC410|NC410 is an experimental antibody drug that may make the immune response more active against cancer
214860685|NCT00713999|DRUG|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
214860686|NCT00132171|DRUG|Sequential therapy|
214860687|NCT01016093|DRUG|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
214860688|NCT01016093|DRUG|Placebo|Placebo
214860689|NCT02721693|DEVICE|Treadmill exercise test|Patients are subjected to an incremental exercise test to exhaustion on a treadmill
214860690|NCT04976998|DIAGNOSTIC_TEST|imaging|imaging by ultrasonography and nerve conduction studies will be done for both grups
214860691|NCT06156345|DEVICE|Conservative with Denneroll|Denneroll cervical traction orthodontic traction for 3 to 15 minutes once daily with conservative management of stretching and relaxation.
214860692|NCT06156345|OTHER|Conservative|conservative management of stretching and relaxation with placebo traction.
214860693|NCT00263991|DEVICE|EEC-techniques|
214860694|NCT01968694|DRUG|IV Lidocaine|
214860695|NCT01968694|DRUG|IV diphenhydramine|
214860696|NCT01101204|DRUG|Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg|Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
214860697|NCT02163486|DEVICE|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
214860698|NCT02163486|DEVICE|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
214860699|NCT06132217|DRUG|Simmitinib|Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
214860700|NCT06132217|DRUG|SG001|Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
214860701|NCT00523224|PROCEDURE|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
214860702|NCT00523224|BIOLOGICAL|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
214860703|NCT02836496|DRUG|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
214860704|NCT02836496|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
214860705|NCT02836496|DRUG|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
214860706|NCT02836496|DRUG|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
214860707|NCT00354341|DRUG|Epoetin beta|
214860708|NCT03958123|DRUG|100 μg cebranopadol|Encapsulated 100 μg cebranopadol tablet.
214860709|NCT03958123|DRUG|200 μg cebranopadol|Encapsulated 200 μg cebranopadol tablet.
214860710|NCT03958123|DRUG|400 μg cebranopadol|Encapsulated 400 μg cebranopadol tablet.
214860711|NCT03958123|DRUG|Placebo to cebranopadol encapsulated tablets|Matching placebo to cebranopadol encapsulated tablet.
214860712|NCT03958123|DRUG|400 mg Moxifloxacin|Encapsulated 400 mg moxifloxacin tablet.
214860713|NCT03958123|DRUG|Placebo to moxifloxacin encapsulated tablets|Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
214860714|NCT05549908|BIOLOGICAL|rabies vaccine|The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared
214860715|NCT03438214|DRUG|Vancomycin Continuous infusion|Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L
214860716|NCT03438214|DRUG|Vancomycin Intermittent infusion|Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.
214860717|NCT04483635|DIETARY_SUPPLEMENT|Placebo|Weekly oral dose of placebo
214860718|NCT04483635|DIETARY_SUPPLEMENT|Vitamin D|Weekly oral dose of Vitamin D
214860719|NCT01400919|DEVICE|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
214860720|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
214860721|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
214860722|NCT00251719|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
214860723|NCT02047175|DRUG|Telmisartan/S-Amlodipine|Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days
214860724|NCT02047175|DRUG|Rosuvastatin|Rosuvastatin 20mg 1T PO, QD for 5days
214860725|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days
214860726|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
214860727|NCT04236570|DEVICE|Thermode(hot plate) and cold water bath|Standardized protocol will consisted of stimulus test (TS) generated by thermode and conditioning stimulus (CS) using cold water bath.
214860728|NCT04236570|DEVICE|TENS(transcutaneous electrical nerve stimulation)|TENS protocol will consisted of test stimulus (TS) and conditioning stimulus (CS) both generated by TENS
214860729|NCT00073242|DRUG|Leptin|leptin administration
214860730|NCT00073242|BEHAVIORAL|Dietary modification|Subjects lose 10% of body weight via dietary restriction
214860731|NCT00073242|DRUG|T3 repletion|administer T3
214860732|NCT01660399|DRUG|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
214860733|NCT01660399|DRUG|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
214860734|NCT03324932|DRUG|Denosumab Injection|AI intake + denosumab injection per 6 months VS only AI intake
214860735|NCT03822832|DRUG|BI 655130|Solution for infusion
214860736|NCT03822832|DRUG|Placebo|Solution for infusion
214860737|NCT06174870|OTHER|Inspiratory muscle training|Inhale against 60% of Maximal inspiratory pressure 30breaths/day 5days/week for 6 weeks
214860738|NCT05340777|DEVICE|Training Obstetric staff on Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to ensure staff are trained on the newly registered and provided medical device. We will gather feedback on how to improve the training curriculum from participants. We will also gather information from the healthcare workers immediately post-use of an Ellavi UBT device following their management of a refractory PPH case. These surveys will help us to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of PPH care.
214860739|NCT02502773|DRUG|Hydroxethyl starch|
214860740|NCT03002662|OTHER|colonoscopy|
214860741|NCT03168594|DRUG|irinotecan cisplatin|Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
214860742|NCT03168594|DRUG|Etoposide cisplatin|Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
214860743|NCT01732874|DRUG|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
214860744|NCT01732874|DRUG|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
214860745|NCT03097835|DRUG|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
214860746|NCT03097835|DRUG|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
214860747|NCT03097835|OTHER|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
214860748|NCT04383236|OTHER|Probiotics|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
214860749|NCT04383236|DRUG|Oracure oral gel|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
214860750|NCT06398821|DIETARY_SUPPLEMENT|G3P-01|Nutritional supplement to promote healthy aging
214860751|NCT06398821|DIETARY_SUPPLEMENT|Placebo|Placebo
214860752|NCT06187493|DRUG|lisinopril, enalapril|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
214860753|NCT06187493|DRUG|dapagliflozin, empagliflozin|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
214860754|NCT03326609|DRUG|Ropivacaine|Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
214860755|NCT02737332|DRUG|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
214860756|NCT02737332|DRUG|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
214860757|NCT01340105|PROCEDURE|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
214860758|NCT01340105|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
214860759|NCT02775474|DRUG|Use of Intraoperative Intravenous Methadone|The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
214860760|NCT02775474|DRUG|Use of Intraoperative Intravenous Fentanyl|The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
214860761|NCT05420974|PROCEDURE|NIR fluorescence imaging of the vascular perfusion of the meniscus using ICG|NIR fluorescence imaging of vascular perfusion using the Arthrex NIR fluorescence scope and Indocyanin Green
214860762|NCT06126068|DRUG|Use of magnesium sulfate to prevent and stop fits in pre-eclampsia and Eclampsia|Loading dose magnesium sulfate versus the Pritchard regimen
214860763|NCT04570540|DIAGNOSTIC_TEST|Sleep Study|Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry
214860764|NCT04570540|DIAGNOSTIC_TEST|Pulmonary Function Test|Bodyplethysmographic assessment
214860765|NCT04570540|DIAGNOSTIC_TEST|Hypercapnic ventilatory response|Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag
214860766|NCT04570540|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations
214860767|NCT02631967|PROCEDURE|Kono anastomosis|Kono anastomosis
214860768|NCT02631967|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
214860769|NCT00757757|DRUG|MCS110|Anti-M-CSF antibody
214860770|NCT04029441|OTHER|the eradication Hp|the eradication of Hp based on antimicrobial susceptibility test
214860771|NCT04253496|OTHER|Tumor samples and MRI|We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
214860772|NCT00759135|DRUG|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
214860773|NCT00759135|DRUG|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
214860774|NCT00759135|DRUG|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
214860775|NCT00846521|DRUG|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
214860776|NCT00153608|BIOLOGICAL|WT1 126-134 peptide|
214860777|NCT01792219|OTHER|Interprofessional collaboration in health care module|An educational module
214860778|NCT00257218|BEHAVIORAL|Life style modification|
214860779|NCT01246011|DRUG|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
214860780|NCT04406597|DEVICE|the New Tissue Containment System|Laparoscopic Ovarian Cystectomy using the New Tissue Containment System
214860781|NCT01376193|DRUG|Naratriptan|Collection of safety data
214860782|NCT03947671|DEVICE|Rapr Rounds Hyper/Hypothermia Wraps|Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature
214860783|NCT03947671|DRUG|Acetaminophen|Acetaminophen will be administered as it would be per standard of care
214860784|NCT02494609|DRUG|sotagliflozin|400 mg sotagliflozin
214860785|NCT02494609|DRUG|oral contraceptive|0.25 mg norgestimate/0.035 mg ethinyl estradiol
214860786|NCT02494609|DRUG|oral contraceptive + sotagliflozin|0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
214860787|NCT00057083|OTHER|Telemedicine Care|
214860788|NCT04392583|DEVICE|ENTACT Septal Staple system|The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
214860789|NCT01672112|DRUG|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
214860790|NCT01672112|DRUG|Codeine|Oral Codeine 60mg 6hrly/prn
214860791|NCT03239912|DEVICE|Twin-block appliance|Functional treatment will be achieved using the Twin-block appliance
214860792|NCT03239912|OTHER|Low level laser|Functional treatment will be combined with low-level laser therapy on the TMG region
214860793|NCT03427502|DRUG|Bupivacaine-epinephrine|10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline
214860794|NCT03427502|DRUG|normal saline|normal saline
214860795|NCT06095336|OTHER|telerehabilitation|The individuals included in the research will be divided into three groups. Group 1 (experiment): This is the exercise group followed by the telerehabilitation method. Group 2 (experiment): This is the group where traditional physical therapy methods will be applied. The 3rd group will be taken as the control group, there will be no intervention and they will be asked to continue their daily lives.
214860796|NCT03305406|OTHER|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
214860797|NCT03305406|OTHER|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
214860798|NCT02177656|BEHAVIORAL|Motivational Interviewing tailored intervention|MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
214860799|NCT01527084|PROCEDURE|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
214860800|NCT03565393|COMBINATION_PRODUCT|Fibersol-2|A placebo-controlled, randomized; double-blind 2 arm trial
214860801|NCT03580083|GENETIC|RGX-111|Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette
214860802|NCT05279365|BIOLOGICAL|Pfizer/BioNTech (BNT162b2)|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
214860803|NCT05279365|BIOLOGICAL|Moderna|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
214860804|NCT02303041|DRUG|Buparlisib|Administered orally at starting dose of 80 mg/day
214860805|NCT02303041|DRUG|Sonidegib|Administered orally at starting dose of 200 mg/day
214860806|NCT02908035|DRUG|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
214860807|NCT02908035|DRUG|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
214860808|NCT00428636|PROCEDURE|ileostomy|
214860809|NCT05549518|OTHER|Core stabilization + Traditional Physical Therapy|"In addition to the traditional physical therapy training, core stabilization exercises will be applied 3 days a week for 6 weeks, and 20 minutes in each session under the supervision of a physiotherapist. Core stabilization exercises; will gradually progress from easy exercises to difficult ones. Exercises will be performed in supine, hook position, sitting position, on stable and mobile surfaces. Exercises will progress from 1 set to 3 sets, from 7 to 10 reps, contractions from 3 seconds to 10 seconds. All exercises will be performed with breathing control.~The exercises will be progressed by gradually increasing them every week."
214860810|NCT05549518|OTHER|Traditional Physical Therapy|"Traditional physical therapy training will be given for 40 minutes each session, 3 times a week for 6 weeks under the supervision of a physiotherapist. As a traditional physical therapy program, a rehabilitation program that increases mobility and daily living activities will be applied to patients.~* Joint range of motion exercises~* Stretching exercises~* Strengthening exercises~* Bobath-based neurophysiological approaches~* Task-oriented training~* 15 minutes of neuromuscular electrical stimulation (NMES) application"
214860811|NCT02140307|BEHAVIORAL|Relaxation Response-based Mental Health Promotion (RR-MHP)|"The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship)."
214860812|NCT00363753|DRUG|aspirin versus clopidogrel|
214860813|NCT00975403|DEVICE|Dead space breathing|Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
214860814|NCT00975403|DEVICE|Room air breathing|Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
214860815|NCT03994718|OTHER|Music intervention|The music therapist will work with subjects for up to 60 minutes each session.
214860816|NCT03994718|OTHER|Visual arts intervention|The visual artist will work with subjects for up to 60 minutes each session.
214860817|NCT03994718|OTHER|Creative writing intervention|The creative writer will work with subjects for up to 60 minutes each session.
214860818|NCT01884428|DRUG|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
214860819|NCT01884428|DRUG|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
214860820|NCT01884428|DRUG|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
214860821|NCT01884428|DRUG|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
214860822|NCT01884428|DRUG|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
214860823|NCT00953641|DRUG|Misoprostol|Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
214860824|NCT00953641|DRUG|Placebo|Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
214860825|NCT03979820|DRUG|BI 1467335|Film-coated tablet
214860826|NCT03979820|DRUG|Placebo|Film-coated tablet
214860827|NCT03979820|DRUG|Phenelzine sulfate|Film-coated tablet
214860828|NCT03979820|DRUG|Tyramine|Capsules
214860829|NCT00971958|PROCEDURE|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
214860830|NCT00971958|DEVICE|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
214860831|NCT00971958|DEVICE|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
214860832|NCT00971958|DEVICE|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
214860833|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder \[one 20 U, two 20 U and one 40 U cartridges)
214860834|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder \[one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)\])
214860835|NCT04463303|OTHER|lung ultrasound|patient with or without weaning induced pulmonary adema
214860836|NCT04780841|DRUG|RDX013|RDX013 is an experimental drug that is a potassium secretagogue
214860837|NCT04780841|DRUG|Placebo|Placebo treatment that looks identical to experimental treatment
214860838|NCT01077466|DRUG|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
214860839|NCT04514965|OTHER|Blood sampling|Blood sampling
214860840|NCT04514965|DEVICE|Fibroscan|Measurement of liver stiffness
214860841|NCT04514965|OTHER|Question|Question about pruritus
214860842|NCT02546336|DEVICE|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
214860843|NCT00973401|OTHER|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
214860844|NCT02017548|BEHAVIORAL|Life-extension default advance directive|
214860845|NCT02017548|BEHAVIORAL|Comfort default advance directive|
214860846|NCT00914914|DRUG|p28|p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
214860847|NCT00160641|BIOLOGICAL|Certolizumab Pegol|"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
214860848|NCT03435718|DRUG|Oxfendazole|oral suspension
214860849|NCT03435718|DRUG|Albendazole|tablet
214860850|NCT05297695|DRUG|Triple therapy for H. pylori infection|Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
214860851|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with Listerine|
214860852|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with CHX|
214860853|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with serum|
214860854|NCT03895723|PROCEDURE|laparoscopic and robotic liver resection|laparoscopic and robotic procedure for liver resection
214860855|NCT03895723|PROCEDURE|open surgery|using open surgery procedure for liver resection
214860856|NCT03361852|DRUG|Rituximab|Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
214860857|NCT03361852|BIOLOGICAL|Neo Vax|"Neo Vax is an experimental viral mimic and an activator of immunity."
214860858|NCT03361852|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
214860859|NCT05845294|PROCEDURE|Routine Care|Routine care for patients undergoing colorectal cancer stoma
214860860|NCT05845294|PROCEDURE|Short-term structured psychological Care|Short-term structured psychological care for colorectal cancer stoma patients based on conventional care
214860861|NCT03511274|BEHAVIORAL|Hygiene based educational film|Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
214860862|NCT06213714|DEVICE|5G Tele-Robotic-Assisted PCI|The 5G Tele-Robotic-Assisted VRS100 system is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
214860863|NCT02030314|DRUG|Chlorthalidone|treatment of resistant hypertension in kidney transplant patients
214860864|NCT06102408|OTHER|second line investigations for uveitis etiological workup|Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
214860865|NCT02519621|DEVICE|NPWT PRO without irrigation|NPWT PRO without irrigation.
214860866|NCT02519621|DEVICE|NPWT PRO with irrigation|NPWT PRO with irrigation (saline)
214860867|NCT02519621|DEVICE|KCI Ulta|KCI Ulta NPWT without irrigation
214860868|NCT05302570|RADIATION|Hypofractionated Proton Beam Therapy|5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
214860869|NCT04691310|DEVICE|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
214860870|NCT04309253|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
214860871|NCT04309253|DRUG|AV45|F-18 AV45 PET Imaging
214860872|NCT03692143|DRUG|Teriparatide|subcutaneous injection of teriparatide(20 mg) once daily
214860873|NCT03692143|PROCEDURE|PVP|With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously
214860874|NCT03692143|DRUG|Alendronate|Alendronate Sodium, oral, 70mg, once a week
214860875|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas."
214860876|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal."
214860877|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation."
214860878|NCT01550276|OTHER|Placebo control|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
214860879|NCT02549794|PROCEDURE|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
214860880|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
214860881|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
214860882|NCT03748394|BEHAVIORAL|Work-directed rehabilitation|Each participant starts with a meeting together with an occupational therapist or a physical therapist, focusing on the participant's resources and obstacles for functioning well at work. A plan is designed and carried out over 8 weeks, including 1-4 different treatment modules of occupational and physical therapy, to support the person's ability to function at work
214860883|NCT03748394|BEHAVIORAL|Physical activity|In a meeting with a physical therapist, each participant receives advice on physical activity to support mental health, according to national recommendations. The participant is offered to train at a local gym during 8 weeks.
214860884|NCT05636566|DRUG|Sevoflurane|inhalational anaesthesia for maintenance
214860885|NCT05636566|DRUG|Propofol infusion for maintance|propofol infusion after induction for maintenance of anaesthesia
214860886|NCT05636566|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia
214860887|NCT02311920|BIOLOGICAL|Ipilimumab|Given IV
214860888|NCT02311920|OTHER|Laboratory Biomarker Analysis|Correlative studies
214860889|NCT02311920|BIOLOGICAL|Nivolumab|Given IV
214860890|NCT02311920|DRUG|Temozolomide|Given PO
214860891|NCT04764630|DRUG|Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min
214860892|NCT04764630|DRUG|Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
214860893|NCT04764630|DRUG|Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
214860894|NCT05485519|DRUG|Dexmedetomidine|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
214860895|NCT05485519|DRUG|Midazolam|(1 mcg/kg/minute. up to a maximum of 5 mcg/kg/minute.
214860896|NCT00970008|OTHER|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
214476476|NCT06611644|OTHER|Erector Spinae Plane Block|Patients in this group will receive an Erector Spinae Plane (ESP) block in addition to standard postoperative care. The ESP block will be performed under ultrasound guidance. A needle will be advanced in-plane or out-of-plane, targeting the lateral aspect of the T6 transverse process. Local anesthetic (20 to 30 ml) will be injected into the fascial plane between the erector spinae muscle and the transverse process. This block is intended to provide postoperative analgesia by blocking the transmission of pain through the thoracic spinal nerves.
214860897|NCT00970008|OTHER|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
214860898|NCT00970008|OTHER|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
214860899|NCT00970008|OTHER|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
214860900|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
214860901|NCT00899470|DRUG|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
214860902|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
214860903|NCT00899470|DRUG|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
214860904|NCT05873361|OTHER|Questionnaire|The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
214860905|NCT05480592|DRUG|HS-10380|Administered orally as a tablet
214860906|NCT05480592|DRUG|Placebo|Administered orally as a tablet
214860907|NCT03138447|DEVICE|Basal Insulin Titration Application|"Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose."
214860908|NCT03442959|OTHER|Data record|characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
214860909|NCT05816200|DEVICE|Low-Level Light Therapy|Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.
214907072|NCT06244329|DEVICE|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain. TMS uses a small electromagnetic coil controlled by a computer program to deliver short, powerful pulses of magnetic energy focused precisely on parts of the brain's pre-frontal cortex. High-frequency repetitive TMS can enhance the excitability of the stimulated region.
214907073|NCT02475473|OTHER|Exercise Training|Chronic High-Intensity Resistance Training
214860910|NCT05816200|DEVICE|Transcutaneous Electric Nerve Stimulation|Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
214860911|NCT01366443|PROCEDURE|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
214860912|NCT01366443|PROCEDURE|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
214860913|NCT01366443|PROCEDURE|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
214860914|NCT00821002|DRUG|Latanoprost|Comparison of punctal plug placement between upper and lower puncta
214860915|NCT02923414|DEVICE|Standard escalating shocks|125 J, 150 J, 200 J
214860916|NCT02923414|DEVICE|High energy shock protocol|360 J, 360 J, 360 J.
214860917|NCT01839630|DRUG|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
214860918|NCT05388240|OTHER|Education via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources."
214860919|NCT05388240|OTHER|Education and Exercise via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources. The app will also be used to help guide participants through an eight-week shoulder exercise program, together with physical therapy remote support."
214860920|NCT05115591|DIAGNOSTIC_TEST|Spinal Ultrasound|Spinal Ultrasound is performed by an observer who records ultrasound characteristics of the intervertebral space chosen by the anesthetist who will practice spinal anesthesia
214860921|NCT05115591|PROCEDURE|Spinal Anesthesia|Spinal anesthesia is performed by an anesthetist after the observer recorded ultrasound characteristics of the intervertebral space chosen by the anesthetist, who is blinded to the ultrasound evaluation.
214860922|NCT00369382|DRUG|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
214860923|NCT00369382|DRUG|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
214860924|NCT01957566|PROCEDURE|APS|
214860925|NCT03554603|BEHAVIORAL|Modified Report|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important.
214860926|NCT00469768|DRUG|dapivirine reservoir intravaginal ring|a silicone elastomer reservoir ring containing 25mg of dapivirine
214860927|NCT00469768|DRUG|dapivirine matrix intravaginal ring|a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
214860928|NCT00469768|OTHER|placebo intravaginal ring|a silicone elastomer intravaginal ring containing no dapivirine
214860929|NCT06346002|BEHAVIORAL|Mindfulness-based intervention|The MBI program implemented comprised ten weekly sessions. Please refer to the arm/group descriptions for further details.
214860930|NCT03870113|BIOLOGICAL|Vaccinated group|Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
214860931|NCT01673698|DEVICE|ReShape Duo balloon|
214860932|NCT01673698|OTHER|Diet counseling|
214860933|NCT01673698|OTHER|Exercise counseling|
214860934|NCT00507546|DRUG|Ramelteon|8 mg nightly
214860935|NCT00507546|DRUG|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
214860936|NCT04235452|DIAGNOSTIC_TEST|Somatosensory evoked potential|"Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out."
214860937|NCT04083586|OTHER|All investigations; laboratory and radiological, needed for diagnosis|mri brain, ct brain, drug screening
214860938|NCT00578981|BEHAVIORAL|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
214860939|NCT04683419|DEVICE|Modified Thoracoscopic pleural Cryobiopsy|"Thoracoscopic pleural biopsy will be taken with a modified technique raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe"
214860940|NCT03764436|BEHAVIORAL|LEAPS-NCHD Program|The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.
214860941|NCT04798118|PROCEDURE|toilet bronchoscope|Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done
214860942|NCT00448136|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
214860943|NCT00448136|DRUG|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
214860944|NCT00448136|DRUG|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
214860945|NCT00448136|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
214860946|NCT02268266|DEVICE|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
214860947|NCT03077321|BEHAVIORAL|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
214860948|NCT03077321|BEHAVIORAL|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
214860949|NCT00609466|DRUG|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
214860950|NCT00609466|DRUG|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
214860951|NCT00609466|DRUG|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
214860952|NCT04684303|PROCEDURE|Lumbar medial branch radiofrequency ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
214860953|NCT04684303|PROCEDURE|Lumbar medial branch cryo ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
214860954|NCT06456437|DEVICE|Post-conditioning Balloon dilation and contraction|The balloon was filled at a pressure of no more than 4 atm at the original occlusion of the vessel to block blood flow for 2 minutes (confirmed by angiography), and then contracted to reperfuse the blood flow for 2 minutes, and the above steps were repeated 4 times to complete the in situ ischaemic post-acclimatisation intervention.
214860955|NCT03512262|DRUG|Abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
214860956|NCT03512262|DRUG|Placebo|Abaloparatide-matched placebo.
214860957|NCT01148641|DIETARY_SUPPLEMENT|LNS|Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.
214860958|NCT00453427|DRUG|Alemtuzumab (Campath-1H)|The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (\> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.
214860959|NCT05203666|OTHER|percutaneous removable interspinous process|percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
214860960|NCT02198326|DRUG|BIBN 4096 BS- in single rising doses|
214860961|NCT02198326|DRUG|Placebo|
214860962|NCT03407430|DRUG|Pregabalin|During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.
214860963|NCT03407430|DRUG|Placebo|During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
214860964|NCT06168435|OTHER|eIMPAQc|e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard.
214860965|NCT05968534|BEHAVIORAL|MOSAIC Plus|"This is a single-arm study. Participants will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
214860966|NCT04445779|DIETARY_SUPPLEMENT|Coenzyme Q10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.
214860967|NCT02819141|DRUG|Dexmedetomidine|Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
214860968|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein + MIX)|Protein supplement as needed + 750 mg vitamin C, 15 g. arginine, 35 mg. zinc and two multivitamin tablets, by mouth every day for 35 days.
214860969|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein)|Protein supplement as needed
214860970|NCT02794155|DRUG|HDV Insulin Lispro|HDV Insulin Lispro: \~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
214860971|NCT02794155|DRUG|Insulin LISPRO|Insulin Lispro: no bound insulin
214860972|NCT00770536|DRUG|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
214860973|NCT00770536|DRUG|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
214860974|NCT00770536|DRUG|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
214860975|NCT00770536|DRUG|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
214860976|NCT04901013|OTHER|Affinity|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM).
214860977|NCT03502707|BIOLOGICAL|Placebo|Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
214860978|NCT03502707|BIOLOGICAL|RSV preF Protein 50 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
214860979|NCT03502707|BIOLOGICAL|RSV preF Protein 150 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
214860980|NCT03502707|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1\*10\^11 vp.
214860981|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
214860982|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
214860983|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
214860984|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
214860985|NCT03502707|BIOLOGICAL|Selected Regimen|A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
214860986|NCT06424067|DRUG|Fingolimod 0.5 milligram (mg) [Gilenya]|Oral fingolimod will be administered at a dose of 0.5 mg once a day.
214860987|NCT05753306|DRUG|Cisplatin|Given via HIPEC
214860988|NCT05753306|PROCEDURE|Computed Tomography|Undergo CT scan or PET/CT
214860989|NCT05753306|PROCEDURE|Gastrectomy|Undergo robotic gastrectomy
214860990|NCT05753306|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214860991|NCT05753306|PROCEDURE|Positron Emission Tomography|Undergo PE/CT
214860992|NCT05753306|OTHER|Questionnaire Administration|Complete questionnaire
214860993|NCT05753306|DRUG|Paclitaxel|Given via HIPEC
214860994|NCT05753306|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
214860995|NCT04701411|BIOLOGICAL|Darvadstrocel|Darvadstrocel perilesional injection.
214860996|NCT06958926|PROCEDURE|Radical surgery for colon and rectum cancer|Radical surgery for colon and rectum cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.
214860997|NCT06958926|PROCEDURE|Radical surgery for colorectal cancer|Radical surgery for colorectal cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.
214860998|NCT06837233|DRUG|Pumecitinib Nasal Spray 0.3%|2 sprays in each nostril, twice daily for 14-day treatment period.
214860999|NCT06837233|DRUG|Pumecitinib Nasal Spray 0.6%|2 sprays in each nostril, once daily for 14-day treatment period.
214861000|NCT06837233|DRUG|Placebo (twice daily)|2 sprays in each nostril, twice daily for 14-day treatment period.
214861001|NCT06837233|DRUG|Pumecitinib nasal spray 0.6%(twice daily)|2 sprays in each nostril, twice daily for 14-day treatment period.
214861002|NCT06837233|DRUG|Placebo|2 sprays in each nostril, once daily for 14-day treatment period.
214861003|NCT04055818|DRUG|Nicotinamide|Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
214861004|NCT03340753|DRUG|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
214861005|NCT03340753|DRUG|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
214861006|NCT04551911|DRUG|Rayaldee|30 mcg calcifediol Extended-Release (ER) Capsule
214861007|NCT04551911|DRUG|Placebo|0 mcg calcifediol Extended-Release (ER) Capsule
214861008|NCT03971149|BEHAVIORAL|EMPOWER|EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
214861009|NCT04158960|BEHAVIORAL|Equine-assisted activities|Participants performed riding-related activities on and off of a horse once per week for 8 weeks
214861010|NCT04158960|BEHAVIORAL|GaitWay program|Participants performed riding-related activities on and off of a horse, along with brain-building activities including balance tasks, swinging, spinning, music therapy, and sensory tasks, all once per week for 8 weeks
214861011|NCT00354250|DRUG|ispinesib|Given IV
214861012|NCT00885521|OTHER|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
214861013|NCT05441995|OTHER|Cryotherapy|Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
214861014|NCT05050890|OTHER|ctDNA level during neoadjuvant chemotherapy|ctDNA samples will be collected from patients at baseline, during neoadjuvant therapy (every 15 days) and before the surgical procedure
214861015|NCT03805503|DRUG|Chloroprocaine 1% Injectable Solution|"standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg.~Efficacy of the analgesia will be evaluated:~Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia.~Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed."
214861016|NCT03416803|RADIATION|Radiotherapy|Radiotherapy
214907074|NCT04366492|OTHER|Prevalence of blood borne viral infections (HBV/HCV/HIV)|rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire
214861017|NCT03362918|BEHAVIORAL|High Intensity Interval Training|"The exercise prescription is as follows:~Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.~Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles~* High intensity for most individuals will occur at approximately 90% of maximum heart rate. Using the rating of perceived exertion scale, participants should be exercising at a 9/10, which is very difficult to maintain the intensity and results in only being able to speak a few words at a time.~* Low intensity is defined as light activity and rated as 2-3/10 on the rating of perceived exertion scale. Participants should be able to carry on a conversation and maintain the pace for hours.~Duration: 30 minutes Frequency: 3 times per week"
214861018|NCT03362918|BEHAVIORAL|Continuous Aerobic Exercise Training|"The exercise prescription for the continuous aerobic exercise group is as follows:~Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.~Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.~Duration: 50 minutes Frequency: 3 times per week"
214861019|NCT02063243|PROCEDURE|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
214861020|NCT01030341|DEVICE|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
214861021|NCT00614809|DRUG|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
214861022|NCT04453098|BEHAVIORAL|3-week residential program based on a tryptic (diet,|"3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education)."
214861023|NCT05692050|DRUG|Epcoritamab|Subcutaneous Injection
214861024|NCT02637375|DRUG|Ganetespib|
214861025|NCT02637375|DRUG|Paclitaxel|
214861026|NCT02637375|DRUG|Doxorubicin|
214861027|NCT02637375|DRUG|Cyclophosphamide|
214861028|NCT01884311|BIOLOGICAL|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
214861029|NCT01764230|DRUG|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
214861030|NCT00507286|DRUG|combination of various doses of sildenefil and alprostadil|
214861031|NCT03400072|OTHER|Unsupervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
214861032|NCT03400072|OTHER|Supervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
214861033|NCT05717504|DEVICE|Implantable Loop Recorder|Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
214861034|NCT05717504|OTHER|Quality of life survey|A quality of life survey will be performed at the end of the follow-up period. The survey will be done over the phone or in person if the follow-up visit is in person.
214861035|NCT01752686|DRUG|carboplatin|carboplatin as adjuvant chemotherapy
214861036|NCT00423995|DRUG|Loratadine/montelukast combination|
214861037|NCT03098914|OTHER|Cohort Study； pathogen； clinical features|Cohort Study； pathogen； clinical features
214861038|NCT01864850|RADIATION|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
214861039|NCT01864850|RADIATION|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
214861040|NCT03034655|DEVICE|CDP|Vestibular rehabilitation using CDP
214861041|NCT03034655|DEVICE|Mobile posturography|Vestibular rehabilitation using mobile posturography
214861042|NCT03034655|OTHER|10 sessions|Vestibular rehabilitation, ten sessions
214861043|NCT03034655|OTHER|5 sessions|Vestibular rehabilitation, five sessions
214861044|NCT05154630|DRUG|TQB2858 injection|TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
214861045|NCT02731417|OTHER|acupuncture|Acupuncture for women with post partum urinary retention
214861046|NCT02731417|DEVICE|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
214861047|NCT04738474|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"Develops personal resilience resources through 1:1 sessions with a PRISM coach."
214861048|NCT04738474|OTHER|Usual Care|No additional study-specific interaction with subjects. Subjects continue to receive usual medical care.
214861049|NCT05376709|DIETARY_SUPPLEMENT|Short-Term Calorie Reduction|Align with the R-CHOP regimen, patients in the experimental group will first perform water fast 24 hours before (day 0) and during the first day of R-CHOP (day 1) when they receive Rituximab, Vincristine, Doxorubicin, cyclophosphamide, and prednisolone. On day 2, they will resume normal calorie intake until the day before the next cycle of chemotherapy. While each cycle of R-CHOP takes 21 days, most patients will receive a total of 6-8 cycles over four to six months.
214861050|NCT00915928|DRUG|Perindopril|2,5 mg daily for 3 months
214861051|NCT00915928|DRUG|Placebo|Placebo dayli for 3 months
214861052|NCT03867461|PROCEDURE|Venous Sinus Stenting|Venous sinus stenting is performed under general anesthesia. Patients are loaded with aspirin and clopidogrel before the procedure. After induction, the right femoral vein is accessed and an 8 F sheath is placed. Intravenous heparin is administered. A 0.070-0.088 guide catheter is navigated into the ipsilateral jugular vein near the jugular bulb. Pre-stenting manometry is performed in every patient. To do so, a Renegade Hi-Flo microcatheter is navigated into the superior sagittal sinus and then used to measure ipsilateral venous pressures across the site of outflow obstruction (this will be the time point where the study intervention will be performed).
214861053|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range
214861054|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (100-110 mmHg range)|Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
214861055|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (60-80 mmHg range)|Mean arterial pressure will be adjusted to fall in the 60-80 mmHg range
214861056|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the 24-26 mmHg range
214861057|NCT05579483|DIETARY_SUPPLEMENT|Prebiotics|The prebiotics consists of three non-digestible carbohydrates (40% acacia gum, 20% partially hydrolyzed guar gum, and 40% resistant starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
214861058|NCT05579483|DIETARY_SUPPLEMENT|Placebo|The placebo consists of two digestible carbohydrates (20% maltodextrin and 80% corn starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
214861059|NCT04996563|OTHER|Video|A brief educational video, approximately 9 minutes in duration, on pelvic organ prolapse is sent electronically to patients to view prior to their initial visit in order to provide early access to information. The video was created to educate patients on the following key components of prolapse: the clinical condition, associated symptoms, common risk factors, evaluation and diagnosis, non-surgical treatment options, and surgical treatment options. Simple drawings and animations are included as visual aids to enhance the ability to conceptualize prolapse and its management options.
214861060|NCT00634881|BIOLOGICAL|Alemtuzumab i.v.|"Alemtuzumab will be administered once per week as a 2 h infusion~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
214861061|NCT00634881|BIOLOGICAL|Alemtuzumab s.c.|"Alemtuzumab will be administered once per week subcutaneously~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
214861062|NCT01338948|PROCEDURE|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
214861063|NCT02875158|PROCEDURE|Cyclophotocoagulation protocol|"* Intravenous route is installed~* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~* Pars plana measurement using transillumination (if needed)~* Laser treatment applied approximately 1mm post to limbus~* Dexamethasone 0,5 mg subconjunctival injection~* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h"
214861064|NCT02875158|PROCEDURE|Conventional cyclophotocoagulation|1250 mW for 4 seconds.
214861065|NCT02875158|PROCEDURE|Modified cyclophotocoagulation|2000 mW for 2 seconds.
214861066|NCT04746911|DRUG|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
214861067|NCT02648295|PROCEDURE|Effects of IV TXA on TEG in patients undergoing THA or TKA|Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.
214861068|NCT03420664|DEVICE|Orthosis VACOped|Orthosis for lower limb immobilisation
214861069|NCT03420664|DEVICE|Below knee cast|Below knee cast for lower limb immobilisation
214861070|NCT00006239|DRUG|sodium phenylbutyrate|
214861071|NCT00006239|DRUG|tretinoin|
214861072|NCT00060138|BIOLOGICAL|monoclonal antibody CAL|
214861073|NCT00060138|DRUG|zoledronic acid|
214861074|NCT06486961|DEVICE|BeatMove Application|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
214861075|NCT06486961|DEVICE|BeatMove Application without synchronized music|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
214861076|NCT06486961|DEVICE|BeatMove Application without music|The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
214861077|NCT03047798|DRUG|Mouthrinse|"A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen."
214861078|NCT00022542|DRUG|ixabepilone|Given IV
214861079|NCT00147953|DRUG|Rituximab|
214861080|NCT00147953|PROCEDURE|Total nodal irradiation|
214861081|NCT00005634|DRUG|vorinostat|
214861082|NCT02031458|DRUG|Atezolizumab|1200 mg IV every 3 weeks
215033664|NCT06222021|GENETIC|Genetic analysis of polymorphism of membrane receptors involved in lactate transport|The DNA extracted from the blood samples (through extractor MagCore) will then undergo gene sequencing by Sanger sequencing and/or Custom NGS (Next Generation Sequencing) panels and will be used to identify nucleotide variants within genes involved in lactate transport (MCT-1/4, GPR81).
215033665|NCT04560530|RADIATION|Non-enhanced CT scan of the chest|Non-enhanced CT scan of the chest with multi-slice CT scan machine.
214290607|NCT01693575|DEVICE|Pupil expansion with APX 100 device|Patients with small pupils (\<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
214290608|NCT00022620|DRUG|paclitaxel|
214861083|NCT06632561|DRUG|Empagliflozin 10 mg|Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months
214861084|NCT06632561|DRUG|Placebo|Sugar pills one tablet daily for 6 months
214861085|NCT02390687|DRUG|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
214861086|NCT02390687|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
214861087|NCT02637661|OTHER|earlobe crease positive|
214861088|NCT02637661|OTHER|earlobe crease negative|
214861089|NCT05368311|OTHER|Dietary recommendations including protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations and 2 protein enriched bars per day to be eaten 45 minutes before lunch and dinner.
214861090|NCT05368311|OTHER|Dietary recommendations without protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations.
214861091|NCT01250197|DRUG|AR-12286|Ophthalmic Solution
214861092|NCT02885597|DRUG|Juanbi pill|4g, twice a day, 3month, oral
214861093|NCT02885597|DRUG|Juanbi pill placebo|4g, twice a day, 3month, oral
214861094|NCT02885597|DRUG|Methotrexate|5mg, once a week, 3 month, oral
214861095|NCT03990597|OTHER|Placebo Administration|Applied topically
214861096|NCT03990597|OTHER|Questionnaire Administration|Ancillary studies
214861097|NCT03990597|DRUG|Wound Dressing Material|Applied StrataXRT topically
214861098|NCT06104995|OTHER|Interventional video|The educational video comprises of health care professionals explaining the durability of the back against the popular belief that the back is fragile and the multifactorial nature of back pain.
214861099|NCT06104995|OTHER|Control video|The control video is a neutral video with no content addressing back beliefs (fragility and need for protection).
214861100|NCT04106167|GENETIC|Allogeneic natural killer (NK) cell|No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
214861101|NCT05910476|DRUG|a high dose of statin/ezetimib|"In randomization, 100 patients will proceed with Rosuvastatin/Ezetimib 20/10 mg and 100 patients will proceed with Atovastatin/Ezetimib 40/10 mg.~A new generation of drug elution stents can be inserted and later registered, and if the patient agrees to participate in the study, they are randomly assigned after stent implantation."
214861102|NCT03617757|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.
214861103|NCT03617757|DIAGNOSTIC_TEST|HbA1c|2mL blood will be taken for analysis of HbA1c.
214861104|NCT04478630|OTHER|Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract|Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).
214861105|NCT03482700|BEHAVIORAL|Intervention Arm|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
214861106|NCT03482700|BEHAVIORAL|Control Arm|Usual standard of care
214861107|NCT06160700|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|MoCA is a method for evaluating cognition. This assessment will be conducted at baseline, month 3, and month 6.
214861108|NCT03487952|OTHER|Questionnaire Administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.
214861109|NCT04540354|DRUG|Optimal Medical Therapy (OMT)|Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.
214861110|NCT04540354|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
214861111|NCT00609518|DRUG|pemetrexed|500 mg/m\^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
214861112|NCT00609518|DIETARY_SUPPLEMENT|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
214861113|NCT00609518|DIETARY_SUPPLEMENT|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
214861114|NCT00609518|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
214907075|NCT04823065|DRUG|Loperamide Pill|4 mg Imodium, per os
214290609|NCT03043027|DRUG|liposomal bupivicaine|local anesthetic
214861115|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
214861116|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
214861117|NCT00006267|DRUG|rubitecan|
214861118|NCT06055530|DIAGNOSTIC_TEST|Artificial Intelligence Digital Pathology|School aged children will be asked to leave a stool sample. The samples will be prepared with the Kato-Katz method and scanned and processed by an artificial intelligence digital pathology system to determine the infection level of soil transmitted helminths and schistosomiasis. The samples will also be analyzed by a human microscopist for comparison.
214861119|NCT02382055|BEHAVIORAL|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
214861120|NCT02382055|BEHAVIORAL|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
214861121|NCT02382055|BEHAVIORAL|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
214861122|NCT03213730|OTHER|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
214861123|NCT03213730|OTHER|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
214861124|NCT02180178|OTHER|observational only- no intervention|
214861125|NCT02381626|DEVICE|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
214861126|NCT02381626|BEHAVIORAL|questionnaires|
214861127|NCT02381626|OTHER|Log-book|PM and biological measurements
214861128|NCT02381626|OTHER|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
214861129|NCT03324321|OTHER|Hypocapnia via Hyperventilation Protocol|90 seconds of hyperventilation using a metronome to lower levels of -5mmHg and -10mmHg below baseline EtCO2
214861130|NCT05052242|DIAGNOSTIC_TEST|primary angle closure disease|2 swept source OCT biometers, IOL Master700 and Anterion
214861131|NCT00292188|DRUG|pregabalin|pregabalin
214861132|NCT00292188|DRUG|Placebo|placebo
214861133|NCT03214341|RADIATION|MRI diffusion|using MRI diffusion to differentiate between benign and malignant mediastinal masses
214861134|NCT00665938|OTHER|Infant formula|"Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics"
214861135|NCT00824616|DRUG|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
214861136|NCT00824616|DRUG|Placebo|Placebo tablets, taken 3 times daily.
214861137|NCT00824616|DRUG|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
214861138|NCT00206492|DRUG|Iressa|Iressa
214861139|NCT00206492|DRUG|Tamoxifen|Tamoxifen
214861140|NCT04449757|DRUG|Bicarbonated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
214861141|NCT04449757|DRUG|Lactated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
214861142|NCT00676325|PROCEDURE|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
214861143|NCT00676325|DEVICE|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
214861144|NCT00676325|PROCEDURE|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
214861145|NCT06190535|DRUG|Etamsylate|Enteral administration of Etamsylate as solution galenic form
214861146|NCT01796912|OTHER|Lipoprotein Apheresis|Weekly lipoprotein apheresis for 3 months
214861147|NCT01796912|OTHER|Sham Apheresis|Weekly sham (placebo) apheresis for 3 months
214290610|NCT03043027|DRUG|Bupivacaine|local anesthetic
214290611|NCT03043027|DRUG|Saline Solution|saline injection
214861148|NCT03814525|RADIATION|Photobiomodulation|PBM will be applied with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
214861149|NCT03814525|RADIATION|Placebo Photobiomodulation|The person responsible for applying the PBM will simulate the irradiation by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off
214861150|NCT02113553|DRUG|Triptorelin|Triptorelin administered once every 28 days in addition to chemotherapy
214861151|NCT06406517|DRUG|Gadopiclenol|Gadopiclenol is an FDA-approved gadolinium-based contrast agent (GBCA) for neurological and abdominal contrast-enhanced MRI. Participants will receive this contrast agent at one of three different doses prior to undergoing a congenital heart cardiac MRI/MRA. This contrast agent will be compared to gadobenate dimeglumine, the standard-of-care.
214861152|NCT06406517|DRUG|Gadobenate dimeglumine|Gadobenate dimeglumine is an FDA-approved GBCA that is used in standard clinical practice at UCSD for contrast-enhanced MRI/MRA studies, including cardiac MRI/MRA. This contrast agent is the standard of care to which gadopiclenol will be compared.
214861153|NCT00349557|DRUG|bevacizumab, bicalutamide and goserelin|
214861154|NCT00349557|PROCEDURE|intensity modulated radiation therapy (IMRT)|
214861155|NCT02681224|OTHER|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
214861156|NCT02681224|OTHER|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
214861157|NCT02681224|OTHER|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
214861158|NCT02681224|OTHER|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
214861159|NCT01264042|DIETARY_SUPPLEMENT|Ferrous Sulfate|60 mg with 200 mL water, single administration
214861160|NCT04973553|OTHER|upper limb rehabilitation|the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.
214861161|NCT05892146|DRUG|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
214861162|NCT05892146|DRUG|Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
214861163|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5\*10\^10 vp/0.5 milliliter (mL).
214861164|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1\*10\^11 vp/0.5 milliliter (mL).
214861165|NCT02926430|DRUG|Placebo|Participants will receive placebo as formulation buffer.
214861166|NCT00700323|DIETARY_SUPPLEMENT|PS-Omega3 conjugate supplementation|
214861167|NCT00700323|DIETARY_SUPPLEMENT|placebo|
214861168|NCT02400424|RADIATION|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
214861169|NCT00233506|DRUG|CpG 7909|
214861170|NCT02740829|DRUG|Intranasal glucagon|Glucagon will be administered via a nasal dispenser
214861171|NCT02740829|DRUG|Intranasal placebo|Placebo
214861172|NCT03275766|OTHER|DLPFC facilitatory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
214861173|NCT03275766|OTHER|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
214861174|NCT03275766|OTHER|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
214861175|NCT03275766|OTHER|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
214861176|NCT05320848|BEHAVIORAL|cardiac rehabilitation|Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.
214861177|NCT03847103|OTHER|Robotic-assisted Therapy with Bilateral Practice|40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.
214861178|NCT03847103|OTHER|Unilateral Task-specific Training|40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.
214861179|NCT03847103|OTHER|Sensorimotor Stimulation Program|10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
214861180|NCT04866849|OTHER|examination|"The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
214861181|NCT02592109|BEHAVIORAL|Enhanced Counseling using CFR based on Linear Programming|
214861182|NCT02439671|BEHAVIORAL|McGill Transition Support Program|"The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~* Social communication (e.g. listening, perspective taking)~* Self-determination (e.g. problem-solving, self-advocacy)~* Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages."
214861183|NCT04813315|OTHER|Kendall exercise|consist of stretch of pectoralis major and neck extensor strengthening of deep neck flexors and scapular retractor
214861184|NCT04813315|OTHER|Gong's mobilization|it is combination of glide along the facet joint and concurrent movement of cervical spine
214861185|NCT03192865|PROCEDURE|diaphragmatic assessment using ultrasounds.|A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
214861186|NCT06111274|DRUG|Pimicotinib (ABSK021)|The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
214861187|NCT03754374|OTHER|access to healthcare|use or non-use of dedicated health facilities
214861188|NCT05887895|DRUG|INS062 injection、INS068 injection、HR20014 injection|"INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects."
214861189|NCT00971841|DRUG|Paclitaxel|
214861190|NCT02920918|DRUG|Canagliflozin|
214861191|NCT02920918|DRUG|Sitagliptin|
214861192|NCT03814616|DRUG|Pyronaridine tetraphosphate 180mg:artesunate 60mg|ACT
214861193|NCT03952234|DRUG|L-Citrulline|To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
214861194|NCT02201238|DRUG|Diclofenac sodium|Diclofenac sodium
214861195|NCT02201238|DRUG|Menthol|Menthol
214861196|NCT02409602|OTHER|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
214861197|NCT00974974|DRUG|IPX066|extended-release carbidopa-levodopa capsules
214861198|NCT00974974|DRUG|IR CD-LD|immediate-release carbidopa-levodopa tablets
214861199|NCT04648566|PROCEDURE|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
214861200|NCT04648566|PROCEDURE|Intrauterine administration of sperm washing medium|Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
214861201|NCT01959035|DRUG|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
214861202|NCT02317718|OTHER|monitor reproductive outcome|
214861203|NCT01527136|DRUG|entolimod|Given IM or SC
214861204|NCT01527136|OTHER|pharmacological study|Correlative studies
214861205|NCT01527136|OTHER|laboratory biomarker analysis|Correlative studies
214861206|NCT03254602|DEVICE|Intense Therapeutic Ultrasound Treatment|
214861207|NCT05937984|DEVICE|Active Controlled Transcranial Magnetic Stimulation (cTMS)|cTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of cTMS requires 9 minutes in total.
214861208|NCT05937984|DEVICE|Sham Controlled Transcranial Magnetic Stimulation (cTMS)|A sham coil will be utilized for the sham cTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham cTMS will be identical to Active cTMS.
214861209|NCT01031459|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
214861210|NCT01631175|BEHAVIORAL|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
214861211|NCT05737316|BEHAVIORAL|Combat PD|CombatPD is an aerobic exercise programme hosted on a mobile application that pairs with motion sensors and heart rate monitor, which connects to a web-based portal for remote monitoring. The wearable sensors consist of (i) 2 motion sensors worn across one thigh and attached to an exercise ring which is held by the participant during the exergame and (ii) 1 heart rate sensor worn across the participant's chest. They will receive once weekly physiotherapy sessions at the study site for the first 4 weeks where they will be guided through the use of the CombatPD. Participants will be instructed to perform 2 sessions of 30-minute exergames in addition to a session of 30-minute brisk walking every week for 12 weeks at home. They will be instructed to exercise at a target heart rate zone at moderate intensity (i.e., 40% - 60% Heart Rate Reserve), which will be gradually increased.
214861212|NCT05737316|BEHAVIORAL|Usual Care|Participants in the control group (usual care) will receive once weekly physiotherapy sessions for first 2 weeks and another session at week 6 where they will be taught home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises , as well as brisk walking techniques. Participants in the control group will be instructed to perform these home exercises twice a week, in addition to a 30-minute brisk walk for 12 weeks.
214861213|NCT03340142|DEVICE|VIVO™|Diagnose the area of a PVC or VT onset
214861214|NCT05219461|DRUG|Single dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
214861215|NCT05219461|DRUG|Single dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
214861216|NCT05219461|DRUG|Single dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
214861217|NCT05219461|DRUG|Multiple dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
214861218|NCT05219461|DRUG|Multiple dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
214861219|NCT05219461|DRUG|Multiple dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
214861220|NCT05070871|DIETARY_SUPPLEMENT|Hydrolyzed Collagen|Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.
214861221|NCT05070871|OTHER|Placebo|Pure maltodextrin.
214861222|NCT05070871|DIETARY_SUPPLEMENT|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.
214861223|NCT00334061|DEVICE|Penumbra System|
214861224|NCT03592576|DRUG|Navitoclax|Tablet, Oral
214861225|NCT03592576|DRUG|Venetoclax|Tablet, Oral
214861226|NCT01335373|DRUG|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
214861227|NCT00776165|BIOLOGICAL|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
214861228|NCT00776165|BIOLOGICAL|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
214861229|NCT04539886|DEVICE|CellFX System|CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
214861230|NCT04539886|DEVICE|Intralesional Electrodesiccation|Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
214861231|NCT01620619|OTHER|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
214861232|NCT01620619|PROCEDURE|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
214861233|NCT03150849|DIAGNOSTIC_TEST|C-X-C Chemokine Receptor 4|marker assessed by flowcytometry in a blood sample
214861234|NCT01194336|DRUG|Huperzine A|dosage form: tablet dose frequency: once only
214861235|NCT01194336|DRUG|Donepezil|dosage form: tablet dosage frequency: once only
214861236|NCT01194336|DRUG|Galantamine|dosage form: tablet dosage frequency: once only
214861237|NCT01194336|OTHER|Placebo|dosage form: tablet dosage frequency: once only
214861238|NCT00107549|BIOLOGICAL|rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])|Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
214861239|NCT00107549|BIOLOGICAL|rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])|Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
214861240|NCT04163978|DRUG|Nitric Oxide|in situ 240mL nitric oxide releasing sinus irrigation solution
214861241|NCT04163978|DRUG|Budesonide|Saline based sinus irrigation 1mg Budesinide solution
214861242|NCT02423356|PROCEDURE|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
214861243|NCT00896909|GENETIC|gene expression analysis|
214861244|NCT00896909|GENETIC|mutation analysis|
214861245|NCT00896909|GENETIC|polymerase chain reaction|
214861246|NCT00896909|OTHER|diagnostic laboratory biomarker analysis|
214861247|NCT00666783|DRUG|palonosetron|receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
214861248|NCT00666783|DRUG|Granisetron|receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
214861249|NCT00688376|DRUG|Donepezil hydrochloride|"During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
214861250|NCT00688376|DRUG|Placebo|"During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
214861251|NCT00858962|DRUG|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
214861252|NCT02181426|DRUG|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
214861253|NCT01423136|DEVICE|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
214861254|NCT02252718|OTHER|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (\<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
214861255|NCT04481321|BIOLOGICAL|Biological/Vaccine|
214861256|NCT04404452|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart and lung sounds using electronic stethoscopes
214861257|NCT03477552|DEVICE|Accuvein V400 device|Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network
214861258|NCT03477552|OTHER|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
214861259|NCT04213352|OTHER|Wrist Splint|Neutral position and volar supported wrist orthosis which limits the flexion and deviation while allowing pronation, supination, and extension of the wrist.
214861260|NCT04213352|OTHER|Rigid Taping|Rigid taping in the neutral position will be performed to allow pronation, supination, and extension of the wrist while limiting the flexion and deviation.
215033666|NCT04814914|OTHER|KB109 + Self Supportive Care|KB109 is a novel glycan
215033667|NCT04814914|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
215033668|NCT04576559|OTHER|Modified dental visual aids|Modified Dental visual aids in the form of pictures created by the main investigator
215033669|NCT04576559|OTHER|Regular dental visual aids|Regular dental visual aids
214861261|NCT00017537|BIOLOGICAL|MVF-HER-2(628-647)-CRL 1005 vaccine|
214861262|NCT05693207|DEVICE|EMG|wearables EMG
214861263|NCT02912585|BIOLOGICAL|Oropharyngeal administration of own mother's colostrum|
214861264|NCT02912585|OTHER|Oropharyngeal administration of sterile water (placebo)|
214861265|NCT02912585|BIOLOGICAL|Oropharyngeal administration of donor human milk|
214861266|NCT02871271|DIETARY_SUPPLEMENT|IQP-AS-121|
214861267|NCT00930371|OTHER|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
214861268|NCT00930371|OTHER|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
214861269|NCT01988961|BIOLOGICAL|Golimumab|SC injections
214861270|NCT02641197|DEVICE|AngioDefender|"Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.~Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators."
214861271|NCT00902720|OTHER|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
214861272|NCT02845765|DEVICE|Dynamic Vessel Analyzer (DVA)|
214861273|NCT02845765|DRUG|Phosphodiesterase type 5 Inhibitor (PDE5I)|
214861274|NCT04492020|DRUG|Ubrogepant 100 mg|For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
214861275|NCT04492020|DRUG|Placebo|For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
214861276|NCT03858192|PROCEDURE|Colorectal surgery procedure|Elective admission for colorectal surgery
214861277|NCT03858192|PROCEDURE|Emergency abdominal surgery|Emergency admission necessitating emergency surgery
214861278|NCT03858192|DRUG|Antibiotics|Treatment for infection and reason for admission
214861279|NCT06064292|DEVICE|INSPIRATORY MUSCLE TRAINING|After finishing the 8-week intervention period with IMT, CP patients stopped training with IMT and continued with their daily normal activities. During the following 24 weeks (without IMT), three evaluations of the respiratory parameters analyzed in the trial were made (MIP, MEP, FEV1, PEF). The first evaluation was made 4 weeks after the intervention was completed, the second 12 weeks and the third 24 weeks after finishing IMT.
214861280|NCT02982031|PROCEDURE|shamrock|This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
214861281|NCT02982031|PROCEDURE|paramedian transverse scan|The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
214861282|NCT02929446|PROCEDURE|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
214861283|NCT02929446|PROCEDURE|Mobilisation and breathing exercises|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
214861284|NCT03199430|DIETARY_SUPPLEMENT|Epigallocatechin gallate|
214861285|NCT03199430|DIETARY_SUPPLEMENT|Placebo|1450mg Corn Flour
214861286|NCT02253030|DEVICE|Optical Coherence Tomography|
214861287|NCT03317886|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
214861288|NCT06238596|PROCEDURE|rehabilitation|The rehabilitation intervention will be led by a Physiotherapist and will include: a 12 weeks standardized multicomponent exercise (aerobic, resistance, balance and flexibility, and impact exercise if indicated), supervised by the physiotherapist, on an outpatient basis or in telerehabilitation. This program will be adapted to single patient needs. Every exercise session will last almost 60 minutes and patients will be supervised twice a week. One more exercise session per week will be self-managed by patients.
214861289|NCT03474250|DIAGNOSTIC_TEST|Magnetic Resonance test for kidney|Magnetic Resonance test for kidney
214861290|NCT04790838|DRUG|Test|2 inhalations of Test and Reference product in each study period
214861291|NCT04790838|DRUG|Reference|2 inhalations of Test and Reference product in each study period
214861292|NCT01305395|DRUG|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
214861293|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
214861294|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
214861295|NCT01305395|DRUG|Sirolimus|Will start sirolimus after they develop CAV by angiogram
214861296|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
214861297|NCT04690517|PROCEDURE|tracheal ultrasound|When checking tracheal ultrasound, several signs are used in judgements. Direct signs include reverberation artifact and double ring sign. Indirect sign means checking the bilateral lung sliding.
214861298|NCT01691924|DRUG|PBF-509|
214861299|NCT01691924|DRUG|Placebo|
214861300|NCT02263235|BIOLOGICAL|administration of stable isotope-labelled leucine-|\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
214861301|NCT02263235|OTHER|collection of CSF, blood, urine, saliva|\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
214861302|NCT02774135|OTHER|direct occupational therapy intervention|Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
214861303|NCT00063635|DRUG|Metformin|500 mg, twice daily
214861304|NCT00063635|DIETARY_SUPPLEMENT|Vitamin E|400 IU, twice daily
214861305|NCT00063635|DRUG|Matching placebo|Twice daily
214861306|NCT03795896|DIAGNOSTIC_TEST|Optic nerve sheath diameter|The intracranial pressure will be measured by the optic nerve sheath diameter and after giving the mannitol osmotherapy the intracranial pressure will be monitored by the optic nerve sheath diameter
214861307|NCT02599636|OTHER|None intervention|Investigators will study the usual medical assistance
214861308|NCT01663935|DRUG|Levodopa/carbidopa|This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
214861309|NCT05089318|DIETARY_SUPPLEMENT|Flexofytol PLUS|2 tablets in the morning and in the evening for minimum 6 weeks.
214861310|NCT02059018|DRUG|COX-inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
214861311|NCT02059018|DRUG|Nitroglycerin|Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
214861312|NCT02059018|DRUG|COX-inhibitor + Nitroglycerin|Combination of COX-inhibitor and nitroglycerin interventions.
214861313|NCT02792959|DEVICE|Functional Imaging previous the second course|Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
214861314|NCT02792959|DEVICE|Functional Imaging previous the surgery|Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
214861315|NCT05322499|DRUG|Camrelizumab|200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);
214861316|NCT05322499|DRUG|Irinotecan|100-125mg/m2，d1，d8；q21d
214861317|NCT05322499|DRUG|Paclitaxel|135-175mg/m2，d1，Q3W
214861318|NCT05322499|DRUG|Paclitaxel-albumin|100-135mg/m2, d1、d8，Q3W
214861319|NCT05322499|DRUG|Docetaxel|60-75mg/m2，d1，Q3W
214861320|NCT05322499|DRUG|Anlotinib|12mg，qd，d1-d14，q3w
214861321|NCT05050006|BIOLOGICAL|ITIL-168|ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
214861322|NCT00562575|DRUG|SLx-4090|
214861323|NCT00562575|DRUG|Placebo|
214861324|NCT05912907|OTHER|potassium nitrate in polycarboxilate cement|5% potassium nitrate in polycarboxylate; pre-weighed 95 mg zinc oxide powder and 5mg of KNO3 will be placed on a glass slab followed by mixing by polyacrylic acid (liquid) in a 1:1 P/L ratio
214861325|NCT06360315|OTHER|Incentive letter for pneumococcal vaccination to the patient and to the GP|Incentive letter for pneumococcal vaccination to the patient and to the GP
214861326|NCT00554307|DEVICE|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
214861327|NCT02075671|DRUG|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
214861328|NCT02075671|DEVICE|Blu-U Light Therapy|Intervention used in experimental and sham arms
214861329|NCT02075671|OTHER|Placebo vehicle only|Intervention only includes the placebo vehicle solution
214861330|NCT00376311|DRUG|oral salmon calcitonin|
214861331|NCT00038987|BIOLOGICAL|Wetvax (APSV)|
214861332|NCT00040053|DRUG|Ondansetron|
214861333|NCT06168877|DIAGNOSTIC_TEST|Execution of 18F-FDG PET/CT and contrast-enhanced CT scan.|PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer).
214861334|NCT05941689|DEVICE|AI-assisted colonoscopy|AI can not only detect suspicious lesions timely, and label them in the field of view of the colonoscopy, but also monitor withdrawal speed and calculate the clean withdrawal time automatically.
214861335|NCT01524614|PROCEDURE|nasal mask|nasal mask use instead of face mask
214861336|NCT03914950|DIAGNOSTIC_TEST|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas."
214861337|NCT04101500|DRUG|Compound Ipratropium Bromide Solution(C1) for Inhalation|The patient's condition and basic condition were the same in the experimental group and the control group.
214861338|NCT04101500|DRUG|Compound Sodium Chlolate and Aminophylline Tablets(C2)|Applied only to the experimental group.
214861339|NCT04101500|DRUG|Placebo Tablets|Applied only to the control group.
214861340|NCT04202809|DRUG|Durvalumab|Durvalumab is given earlier as registered, during chemotherapy and radiotherapy in treatment Arm A
214861341|NCT00119067|BIOLOGICAL|Anthrax Vaccine Adsorbed|
214861342|NCT00119067|BIOLOGICAL|Saline injection|
214861343|NCT05206292|DIAGNOSTIC_TEST|Sulfitest|Urine strip to detect the presence of sulfites in urine. Immediate result.
214861344|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair|This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
214861345|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair with Allograft Augmentation|Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
214907076|NCT04823065|DRUG|hyoscine-n-butylbromide|3 X 20 mg Buscopan, intravenous
214861346|NCT03340363|BEHAVIORAL|environmental change|"1. Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~2. Offer healthy default ingredients (bundled ingredients promoted with recipes).~3. Promote recipe ingredients with prominently displayed signage and images.~4. Promote recipes in multiple locations throughout the store."
214861347|NCT03340363|BEHAVIORAL|messaging|Short, behavioral messages sent to participants via text message or email each week to promote the in-store environmental changes
214861348|NCT03155386|OTHER|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~* The intensity of lesion enhancement~* The presence and type of artefacts on the recombined images.~* The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
214861349|NCT05344430|PROCEDURE|cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy|We will be conducting cone beam computer tomography for percutaneous transthoracic needle biopsies.
214861350|NCT03674086|DEVICE|eAdjust 0.2 hearing aid smartphone application (or app)|The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.
214861351|NCT04727814|OTHER|Computer-aided detection system overlaid colonoscopy videos analysis|Analysis of computer-aided detection system overlaid videos from colonoscopies performed with water exchange or air insufflation method.
214861352|NCT04229524|PROCEDURE|Fluorescence angiography|After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least\> 30.
214861353|NCT00242619|DRUG|rosiglitazone|Rosiglitazone was administered at two different doses over the 12-week period.
214861354|NCT04199013|DRUG|Ropivacaine 0.75% Injectable Solution|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
214861355|NCT04199013|DRUG|Fentanyl Citrate|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
214861356|NCT02143635|DRUG|HDM201|
214861357|NCT02143635|DRUG|ancillary treatment|
214861358|NCT06088056|DRUG|Combination use of SRT with T-DXd|"Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg"
214665304|NCT01251523|BEHAVIORAL|PACE|The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
214861359|NCT02517437|DRUG|Suprascapular & axillary blocks|After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
214861360|NCT02517437|DRUG|Interscalene block|After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
214861361|NCT02693093|DRUG|NI-03|
214861362|NCT02693093|DRUG|Placebo|
214861363|NCT00327288|DRUG|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
214861364|NCT00327288|DRUG|docetaxel|IV once every 21 days for duration of study
214861365|NCT01390285|DEVICE|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
215033670|NCT04769284|OTHER|Mental health student|"An ad-hoc questionnaire was designed that included sociodemographic variables related to the characteristics of the students. The variables sex, age, degree, employment situation, coexistence situation, economic situation, origin environment, country of origin, time of residence in the Spanish State were collected.~Personal variables:~* Gender stereotypes: Short version of the Bem Sex Rol Inventory (BRSI).~* International Physical Activity Questionnaire (IPAQ)~* Abbreviated Goldberg Anxiety Scale EADG~* Modified version of EPP-10 related to COVID-19 (EPP-10-C)"
214861366|NCT01390285|DEVICE|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
214861367|NCT01330771|DRUG|hMG-HP/r-FSH|
214861368|NCT05418166|DRUG|Evolocumab|evolocumab 140mg subcutaneous injection after regular take Ticagrelor and Aspirin for 5 days.
214861369|NCT00822341|DRUG|TG-0054|0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion
214861370|NCT05797818|DEVICE|Methylene Blue Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- Methylene Blue (0.01%) + 4 minutes of light treatment"
214861371|NCT05797818|DEVICE|Chlorhexidine Gluconate Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- Chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
214861372|NCT05797818|DEVICE|Methylene Blue + Chlorhexidine Gluconate|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- Methylene blue (0.01%) + chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
214861373|NCT05797818|DEVICE|Light Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- 4 minutes of light treatment only"
214861374|NCT01948713|OTHER|Strengthening of pelvic floor muscles.|Kegel exercises kinesiotherapy
214861375|NCT01948713|OTHER|Strengthening of hip muscles.|Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
214861376|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
214861377|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
214861378|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
214861379|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
214861380|NCT01008852|DRUG|Placebo|Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
214861381|NCT00003875|DRUG|busulfan|Given PO or IV
214861382|NCT00003875|DRUG|etoposide|Given IV
214861383|NCT00003875|BIOLOGICAL|aldesleukin|Given SC
214861384|NCT00003875|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous or syngeneic stem cell rescue
214861385|NCT03282474|DRUG|Sofosbuvir|Sofosbuvir 400 MG Oral Tablet \[Sovaldi\]
214861386|NCT02257463|DRUG|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
214861387|NCT02257463|OTHER|peripheral muscles exercise training|
214861388|NCT02257463|DEVICE|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
214861389|NCT00006466|DRUG|beta alethine|
214861390|NCT04236726|OTHER|Questionnaire|HRQoL questionnaires
214861391|NCT02967796|DIETARY_SUPPLEMENT|Proteochoc|
214861392|NCT00003708|DRUG|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
214861393|NCT03591523|DIAGNOSTIC_TEST|Quantitative MR angiography|Quantitative MR angiography: A standard axial 3-dimensional time-of-flight (TOF) MRA of intracranial and cervical arteries will be obtained. Then, the acquired images will be transmitted to the workstation to reconstruct 3D surface-rendered vessel images. After determining optimal perpendicular scan plane and setting the baseline coordinates , retrospectively gated, fast 2-dimensional phase-contrast sequence will be performed. Velocity encoding will be automatically adjusted by NOVA software.
214861394|NCT03591523|DIAGNOSTIC_TEST|Duplex sonography|Duplex sonography of cervical arteries will be performed using 5 - 12 MHz linear duplex probe and transcranial color-coded duplex sonography will be performed using 2 - 5 MHz transcranial duplex probe. Peak systolic velocity, end diastolic celocity, mean blood flow velocity and arterial diameter will be measured with automatic calculation of blood flow velocity in each arterial segment.
214861395|NCT02263781|PROCEDURE|Blood draw|Blood draw
215033671|NCT05093608|DRUG|Selinexor Pill|Selinexor 60 mg or 80 mg (oral table) will be administered once a week.
215033672|NCT05093608|DRUG|Bevacizumab|Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.
215033673|NCT05093608|DRUG|Atezolizumab|Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.
215033674|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
215033675|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
215033676|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
214861396|NCT02263781|PROCEDURE|muscle biopsy|Muscle biopsy during planned anesthesia/surgery
214861397|NCT06389643|PROCEDURE|Four-point scleral fixation of Akreos AO60 IOL|Intrascleral tunnels were marked at a distance of 2 mm from the corneal limbus, 6 mm apart (4 in number) after retrobulbar anesthesia. Next corneal incisions were performed. An artificial lens was then implanted into the anterior chamber. The 6-0 polypropylene suture was introduced into the anterior chamber through openings in the cornea. The next stage was to perform a sclerotomy using a 30G needle. Then the needle was passed through the hole in the haptic and 6-0 polypropylene suture was inserted into the needle hole and guided outside. The other end of the suture, passed through the opening in the haptic, was placed in the lumen of the needle and carried out through another sclerotomy and then externalised. This maneuver was repeated with another haptics as well. Correct position of the IOL in the eye was achieved by pulling on the ends of the monofilament. The ends of sutures were trimmed and cauterized. The melted tips of the sutures were then fixed subconjunctivally.
214861398|NCT06389643|PROCEDURE|Sutureless scleral fixation of AcrySof MA60AC IOL with Yamane technique|The surgery was performed under retrobulbar anesthesia. The first step of the procedure was to mark the locations of the intrascleral tunnels (2 mm from the corneal limbus) and locate them at a distance of 180° from each other to prevent the lens from tilting in the eyeball. Openings in the cornea were done. Three-piece IOL was implanted into the anterior chamber. The first sclerotomy was performed through the conjunctiva using a 30G needle 2 mm from the limbus. One of the haptics was inserted into the needle lumen and then brought out. Same procedure was performed with another haptic at a distance of 180°. The next step was to perform cautery of the tips of the haptics, obtaining a 0.3 mm collar that prevents the risk of the haptic coming out of the tunnel and displacing the lens inside the eyeball. The tips of the haptics were finally gently inserted into the scleral canals and covered with conjunctiva.
214861399|NCT01780987|DRUG|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
214861400|NCT01780987|DRUG|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
214861401|NCT01780987|DRUG|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
214861402|NCT05765630|BIOLOGICAL|BLOOD SAMPLES|BLOOD SAMPLES
214861403|NCT03698448|DRUG|OligoG Dry powder for inhalation|10 capsules Dry Powder for Inhalation, BID
214861404|NCT02547155|PROCEDURE|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
214861405|NCT02547155|PROCEDURE|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
214861406|NCT00296634|DRUG|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
214861407|NCT00296634|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
214861408|NCT00920517|BIOLOGICAL|rDEN2/4delta30(ME) vaccine|10\^3 PFU dose
214861409|NCT00920517|BIOLOGICAL|Placebo|placebo for rDEN2/4delta30(ME) vaccine
214861410|NCT06632522|DRUG|radiotherapy combined with Camrelizumab and Apatinib|Camrelizumab is administered intravenously (without preventive medication), with a fixed dose of 200mg, with an infusion of 30 min (not less than 20 min and not more than 60 min) every three weeks. Apatinib, 250 mg, taken orally within half an hour after meals, QD, continuously.
214861411|NCT06168786|DRUG|Fruquintinib|Fruquintinib:5mg ,qd,po, d1-d14, q3w
214861412|NCT06168786|DRUG|Cadonilimab|Cadonilimab:10mg/kg, ivgtt, d1, q3w
214861413|NCT06168786|RADIATION|SBRT|SBRT:8-10Gy×5F，qod， in 10 days
214861414|NCT05291039|DRUG|Infliximab|group 1 (n=20): patients will receive IFX
214861415|NCT05291039|DRUG|Adalimumab|group 2 (n=20): patients will receive ADA
214861416|NCT00179816|DRUG|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
214861417|NCT00188110|PROCEDURE|Water-Enema Computed Tomography|
214861418|NCT04569396|DIAGNOSTIC_TEST|Biochemistry analysis|Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.
214861419|NCT04569396|DIAGNOSTIC_TEST|NAFLD fibrosis score|NAFLD fibrosis score was determined among the study subjects before and after the surgery.
214861420|NCT04569396|OTHER|BMI measurement|BMI was measured among the study subjects before and after the surgery.
214861421|NCT04569396|DIAGNOSTIC_TEST|Fibrosis 4 Index|Fibrosis 4 Index was determined among the study subjects before and after the surgery.
214861422|NCT04569396|DIAGNOSTIC_TEST|Fatty Liver Index|Fatty Liver Index was determined among the study subjects before and after the surgery.
214861423|NCT03499210|DEVICE|ReWalk ReStore device|The ReWalk ReStore device is intended to be used to perform ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia/hemiparesis due to stroke.
214290612|NCT05643768|BEHAVIORAL|Inspiratory muscle strength training (IMST)|30 breaths/day, 5 days/week, 6 weeks
214290613|NCT03388060|PROCEDURE|Ultrasound guided SWL|Ultrasound guided SWL for radiolucent renal stone
214861424|NCT04168190|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
214861425|NCT04168190|BIOLOGICAL|Pneumovax™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
214861426|NCT02637635|PROCEDURE|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
214861427|NCT02637635|PROCEDURE|Expander prosthesis|breast reconstruction with expander prosthesis.
214861428|NCT00992524|DRUG|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
214861429|NCT00992524|DRUG|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
214861430|NCT02841813|OTHER|No intervention|No intervention
214861431|NCT06155318|DIAGNOSTIC_TEST|68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included|Patients meeting the inclusion criteria will undergo 68Ga-DOTATOC PET(PET/MRI or PET/CT) as part of their routine work-up, according to the referral clinicians' indication.PET/MRI will be performed on a 3.0T time of flight PET/MRI. Simultaneous PET/MRI will start approximately 60 minutes after the injection of 68Ga-DOTATOC.
215033677|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
214861432|NCT01796613|DEVICE|Vaginal Ring - intermittent regimen|NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
214861433|NCT01796613|DEVICE|Vaginal Ring - continuous regimen|NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
214861434|NCT05041621|DEVICE|Sensor augmented MDI therapy plus mobile application|"Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions.~All participants will be asked to complete the:~(i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention.~(ii) mHealth usability questionnaire (MAUQ) at post-intervention."
214861435|NCT03466437|DEVICE|Glass-fiber post and composite resin restoration|Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication
214861436|NCT03466437|DEVICE|Glass-fiber post and metalceramic crown|Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
214861437|NCT03466437|DEVICE|Cast-metal post and metalceramic crown|Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
214861438|NCT00336245|DEVICE|Copper T Intrauterine Contraceptive Device|
214861439|NCT00336245|DRUG|Hormonal Contraception|
214861440|NCT05268068|DRUG|Risankizumab|Intravenous (IV) Infusion
214861441|NCT05268068|DRUG|Risankizumab|Subcutaneous (SC) Injection
214861442|NCT01022944|PROCEDURE|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
214861443|NCT01022944|PROCEDURE|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
214861444|NCT03141866|OTHER|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
214861445|NCT03141866|OTHER|Exercise Intervention 2: Machine-based resistance training intervention|Specialised, chair-based, pneumatic resistance training equipment for older adults.
214861446|NCT06072365|OTHER|nutritional intake questionnaire|patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after
214861447|NCT00283023|PROCEDURE|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
214665305|NCT01251523|BEHAVIORAL|PACE Plus|In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
214861448|NCT01094418|OTHER|Nerve conduction studies ( NCS) of the peripheral nerves|"Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.~NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves."
214861449|NCT02502279|DEVICE|Engström Datex-Ohmeda ICU Ventilator|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
214861450|NCT02502279|DEVICE|Postoperative CPAP mask|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
214861451|NCT03638778|DRUG|Semaglutide 3 mg|Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.
214861452|NCT03638778|DRUG|Semaglutide 7 mg|Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.
214290614|NCT03388060|PROCEDURE|Dissolution therapy|Alkalinization dissolution therapy for radiolucent renal stone
214290615|NCT03388060|PROCEDURE|Combined ultrasound guided SWL and dissolution therapy|Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
214290616|NCT05195827|DRUG|PRM-125|Antihypertensive
214861453|NCT03638778|DRUG|Semaglutide B 3 mg|Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.
214861454|NCT03638778|DRUG|Semaglutide B 7 mg|Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.
214861455|NCT03638778|DRUG|Semaglutide C 3 mg|Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.
214861456|NCT03638778|DRUG|Semaglutide C 7 mg|Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.
214861457|NCT03638778|DRUG|Semaglutide D 3 mg|Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.
214861458|NCT03638778|DRUG|Semaglutide D 7 mg|Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.
214861459|NCT03587389|BIOLOGICAL|Rotarix vaccine|In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.
214861460|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months
214861461|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by only one phone call
214861462|NCT05875792|DEVICE|EvolvRehab - MoveWell|The Intervention has been developed and has a CE mark and has medical device level 1 approvals in the UK. It will be developed with patients in Phase 1 and will consist of initial staff training \[training package\]. Exercise prescription will be encouraged, in line with usual care, for the either one week (stage 1, phase 2) or six weeks (stage 2, phase 2). Individuals will be able to continue using the EvolvRehab - MoveWell system beyond 6 weeks from stage 2, phase 2, and technical support will continue until the end of the study completion, participants will not be limited in the additional activity that can be performed during this time, and encouraged to do as much as they wish, except if needed for clinical reasons. The intervention will be supported by the clinical team in keeping with routine care. The research therapist will attend clinical visits and support as required. The number of visits will be recorded, and will hopefully reduce to zero over the study.
214861463|NCT02322463|DRUG|Arab children|Treatment with Oxycodone
214861464|NCT00202423|DRUG|Sativex|
214861465|NCT02393443|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
214861466|NCT02393443|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
214861467|NCT01070771|DEVICE|Radi pressure wire (pressure wire assessment)|Intracoronary insertion of pressure wire at the time of diagnostic angiography.
214861468|NCT04111393|PROCEDURE|transoral specimen extraction|transoral specimen extraction during laparoscopic gastric resection
214861469|NCT00870597|PROCEDURE|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
214861470|NCT00870597|PROCEDURE|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
214861471|NCT05750862|PROCEDURE|Marking of the intended axis of IOL-Implantation manually with an ink and marking device on the surface of the eye|The marking of the intended implantation axis of the interocular lens will be marked in all patients with topography guided in the corneal stroma with laser and in addition manually with a caliper and ink on the corneal surface
214861472|NCT05713968|OTHER|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
214861473|NCT05713968|OTHER|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2 examined by HRIM
214861474|NCT05890495|DRUG|Lidocaine topical|4% aqueous solution
214861475|NCT05890495|DEVICE|Tampon|Tampon with plastic applicator provided
214861476|NCT02816099|BIOLOGICAL|Prise de sang|
214861477|NCT03525652|BIOLOGICAL|Therapeutic vaccine|The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.
214861478|NCT03525652|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
214861479|NCT04605003|DEVICE|Novel rig-S|A new device created to hold the high level disinfectant and automatically indicate when sterilisation process has been completed
214861480|NCT04605003|DEVICE|Conventional Autoclave machine|The gold standard device to clean all medical instruments
214861481|NCT04536532|DRUG|HEC121120 tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
214861482|NCT04536532|DRUG|HEC121120 placebo tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
214861483|NCT04536532|DRUG|entecavir tablets|Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
214861484|NCT04536532|DRUG|entecavir placebo tablets|Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
214861485|NCT04300283|BEHAVIORAL|Hypnosis|See previous description
214861486|NCT03994497|OTHER|Blood samples|Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
214861487|NCT02293291|DIETARY_SUPPLEMENT|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI"
214861488|NCT00143429|DRUG|Xalatan|
214861489|NCT06205472|RADIATION|Adjuvant SIB radiotherapy|Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions,mainly depending on the dose constraints of OARs.
214861490|NCT01775969|OTHER|Text Message|A text message with instructions is sent to the patient
214665306|NCT05669521|DRUG|TK-112690|TK112690 treatment Post 5-FU chemotherapy
214665307|NCT05669521|DRUG|Placebo|Placebo treatment Post 5-FU chemotherapy
214861491|NCT01775969|OTHER|Voicemail|A voicemail with instructions is sent to the patient
214861492|NCT03651466|DRUG|Gx-G6|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
214861493|NCT03651466|DRUG|Placebo|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
214861494|NCT00629265|DEVICE|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
214861495|NCT01917448|DRUG|Morphine|spinal morphine 0.15 mg
214861496|NCT01917448|OTHER|control|Patient receive only local infiltration without spinal analgesia
214861497|NCT01913925|OTHER|Tyrosine-Containing Food Bar|
214861498|NCT01913925|OTHER|Placebo Bar|
214861499|NCT00999648|OTHER|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
214861500|NCT00999648|OTHER|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
214861501|NCT04465630|DEVICE|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
214861502|NCT06206200|OTHER|Cognitive dual task training (intervention group)|Simultaneously performing cognitive tasks and motor rehabilitative exercises.
214861503|NCT06206200|OTHER|Standard of care physiotherapy (control group)|The current best physical therapy treatment for patients with anterior cruciate ligament reconstruction based on existing scientific evidence.
214861504|NCT04002336|BEHAVIORAL|Traditional Voice therapy|Traditional method of voice therapy
214861505|NCT04002336|BEHAVIORAL|Voice Therapy App|Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
214861506|NCT03024736|OTHER|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in~the treatment of opioid-maintained pregnant women"
214861507|NCT00649818|DRUG|Lorazepam Tablets 2 mg|2mg, single dose fasting
214861508|NCT00649818|DRUG|Ativan Tablets 2 mg|2mg, single dose fasting
214861509|NCT04050150|BEHAVIORAL|Arm training in standing|Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
214861510|NCT01169532|DRUG|ridaforolimus|Given PO
214861511|NCT01169532|DRUG|vorinostat|Given PO
214861512|NCT01169532|PROCEDURE|biopsy|Optional correlative studies
214861513|NCT01169532|OTHER|pharmacological study|Correlative studies
214861514|NCT01169532|OTHER|laboratory biomarker analysis|Correlative studies
214861515|NCT01775865|DRUG|Salsalate|4 weeks of daily salsalate
214861516|NCT01775865|DRUG|Placebo (for salsalate)|4 week of daily placebo
214861517|NCT01617694|DRUG|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
214861518|NCT01617694|DRUG|Normal Saline|
214861519|NCT01415765|DRUG|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
214861520|NCT01415765|DRUG|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
214861521|NCT01415765|DRUG|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
214861522|NCT01415765|DRUG|Vincristine|CIV on days 1-4 of every 21 day cycle
214861523|NCT01415765|DRUG|Cyclophosphamide|IV on day 5 of each 21 day cycle
214861524|NCT01415765|DRUG|Doxorubicin|CIV on days 1-4 of each 21 day cycle
214861525|NCT01415765|DRUG|Rituximab|IV on day 1 of each 21 day cycle
214861526|NCT01415765|DRUG|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
214861527|NCT02660528|DRUG|Tocilizumab|Subcutaneous tocilizumab
214861528|NCT01521182|OTHER|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
214861529|NCT01521182|OTHER|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
214861530|NCT03726281|DRUG|Nivolumab|Nivolumab 240 mg, IV
214861531|NCT06469489|OTHER|Liver Disease of all etiologies|No intervention
214861532|NCT04355663|BEHAVIORAL|Motor program activating therapy|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
214861533|NCT04355663|BEHAVIORAL|Vojta's reflex locomotion|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
214861534|NCT04355663|BEHAVIORAL|Functional electric stimulation|Pacients uderwent two months' therapy. They used the whole time Functional electric stimulation during activities of daily living and underwent 2 individual sessions of Motor program activating therapy.
214861535|NCT03164421|DRUG|N-Acetylcysteine|N-Acetylcysteine in clomiphene resistant pcos women
214861536|NCT03164421|DRUG|L-carnitine|L-carnitine in clomiphene resistant pcos women
214861537|NCT02189980|OTHER|Aromatherapy blend|A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils
214861538|NCT02189980|OTHER|Duration of effectiveness of the essential oil blend|Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.
214861539|NCT02189980|OTHER|Participant comfort using the nasal clip delivery system|Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
214861540|NCT02450955|OTHER|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
214861541|NCT02450955|OTHER|Occiput-Atlas-Axis Technique|This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
214861542|NCT02748811|OTHER|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
214861543|NCT06502197|PROCEDURE|Silastic Stenting|Drill-out frontal sinus procedures, are a well-established surgical intervention in the management of CRS, involves extensive sinus surgery with the creation of a large, surgically exposed area of raw bone. This raw bone, left exposed postoperatively, poses a unique challenge in the context of mucosal healing. Silastic stents, inserted into the sinus cavities, offer a promising solution by providing structural support and facilitating mucosal re-mucolisation in this critical period of postoperative recovery.
214861544|NCT05162651|BEHAVIORAL|Contingency-management|In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.
214861545|NCT05162651|OTHER|Enhanced usual care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.
214861546|NCT02931045|DRUG|Ticagrelor|Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
214861547|NCT02931045|DRUG|Clopidogrel|Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
214861548|NCT00466973|DEVICE|Dry bipolar radiofrequency (RF) clamp|Specified device used for ablation during standard surgical procedure
214861549|NCT00466973|DEVICE|Unipolar microwave antenna|Specified device used for ablation during standard surgical procedure
214861550|NCT00466973|DEVICE|Unipolar cryothermic probe|Specified device used for ablation during standard surgical procedure
214861551|NCT00466973|DEVICE|Irrigated unipolar RF antenna|Specified device used for ablation during standard surgical procedure
214861552|NCT00466973|DEVICE|Irrigated bipolar RF clamp|Specified device used for ablation during standard surgical procedure
214861553|NCT00466973|DEVICE|Hi-intensity focused ultrasound wand|Specified device used for ablation during standard surgical procedure
214861554|NCT00876018|OTHER|Nutritional supplement|Fortified nutritional powder
214861555|NCT00876018|OTHER|Placebo|Un-fortified nutritional powder
214861556|NCT02918747|DRUG|pegaspargase|"P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four."
214861557|NCT02918747|DRUG|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
214861558|NCT02918747|DRUG|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
214861559|NCT02918747|DRUG|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
214861560|NCT02918747|DRUG|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
214861561|NCT02918747|DRUG|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
214861562|NCT02918747|DRUG|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
214861563|NCT02918747|DRUG|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
214861564|NCT02918747|RADIATION|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
214861565|NCT05195866|DIAGNOSTIC_TEST|CRP POCT (C-reactive protein point of care test)|"CRP POCT equipment will be supplied at healthcare centers, along with a short training in use and interpretation supporting the clinical evaluation of the child. It will be communicated that CRP levels less than 10 indicate that the disease is not severe, and antibiotics is most likely not needed, if between 10 and 50, that antibiotics might be needed, and if more than 50 that it is likely that they are needed. With CRP between 10-50 the HCW are instructed to take the clinical picture into account together with the value of the test.~The training will also include knowledge of CRP pharmacodynamics and cases where a low CRP might need to be interpreted cautiously, e.g. a history of fever lasting less than 24 hrs. HCWs will be instructed to use CRP POCT for all patients in the intervention group and use the information to guide diagnosis and treatment choice. We will use Aidian (Copenhagen, Denmark) QuickRead go CRP POCT set-up."
215033678|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
215033679|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
215033680|NCT01985789|DRUG|Diphenhydramine|
215033681|NCT01985789|DRUG|cetirizine|
215033682|NCT01985789|DRUG|desloratadine|
215033683|NCT01985789|DRUG|placebo|
215033684|NCT02444754|OTHER|Medical Chart Review|Obtain medical data
214861566|NCT01516866|PROCEDURE|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
214861567|NCT05009966|DRUG|SYSA1801 for injection|SYSA1801 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
214861568|NCT00387920|DRUG|sunitinib malate|Given orally
214861569|NCT00387920|OTHER|pharmacological study|Correlative studies
214861570|NCT00387920|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
214861571|NCT00387920|OTHER|laboratory biomarker analysis|Correlative studies
214861572|NCT05622292|DEVICE|HARKIT I-Care Application|HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
214861573|NCT01774825|DIETARY_SUPPLEMENT|IQP-CL-101|2 softgels twice a day
214861574|NCT01774825|OTHER|Placebo|2 softgels twice a day
214861575|NCT04919941|OTHER|A Guide to Conservative Care|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
214861576|NCT01230892|DRUG|Nebivolol|10 mg PO qday
214861577|NCT01230892|DRUG|Atenolol|100 mg PO qday
214861578|NCT01687582|DRUG|GLP-1 analog|GLP-1 analog treatment
214861579|NCT04243408|OTHER|Autologous umbilical cord blood transfusion|single dose of an autologous umbilical cord blood transfusion
214861580|NCT04243408|OTHER|placebo|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
214861581|NCT01983319|DEVICE|active anodal transcranial Direct Current Stimulation (tDCS)|Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
214861582|NCT01983319|DEVICE|sham transcranial Direct Current Stimulation|sham transcranial Direct Current Stimulation 30 min with CIMT
214861583|NCT01983319|BEHAVIORAL|Constraint Induced Movement Therapy (CIMT)|2 weeks of CIMT
214861584|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
214861585|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
214861586|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
214861587|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
214861588|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp once daily for 24 weeks
214861589|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily for 24 weeks
214861590|NCT01519102|DEVICE|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
214861591|NCT03986450|OTHER|Enhanced recovery after surge(ERAS) protocol|"The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~1. Preoperative care:~   Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~2. Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization"
214861592|NCT00679913|PROCEDURE|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
214861593|NCT00679913|PROCEDURE|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
214861594|NCT06437106|BEHAVIORAL|A blanket impregnated with the mother's odor|Intervention group 1 consists of premature babies who receive a blanket impregnated with the mother's odor.
214861595|NCT06437106|BEHAVIORAL|blanket without mother's smell|Intervention group two consists of preterm infants who receive blanket without mother's odor.
214861596|NCT06437106|BEHAVIORAL|control group|The control group includes premature babies who are not subjected to any intervention and receive the usual care.
214861597|NCT01597219|PROCEDURE|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 \& +4
214861598|NCT01597219|PROCEDURE|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 \& -2 Stem cell transplant day 0
214861599|NCT00287313|DRUG|Vitamin K|
214861600|NCT02658513|OTHER|Lancet blood sampling|Blood samples will be obtained using a finger-prick (lancet) technique.
214861601|NCT02658513|OTHER|Standard intravenous blood sampling|Blood samples will be obtained using a standard intravenous technique.
214861602|NCT01006564|OTHER|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
214861603|NCT01006564|OTHER|Other|Insertion of gold seeds into prostate for image registration.
214861604|NCT00725621|BIOLOGICAL|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
214861605|NCT00428779|PROCEDURE|running during 24 hours without sleep|patients running during 24 hours without sleep
214861606|NCT00428779|OTHER|no sleeping|patients without sleep during 24 hours
214861607|NCT00517959|RADIATION|Stereotactic Conformal radiotherapy|SCRT
214861608|NCT00517959|RADIATION|Conventional radiotherapy|
214861609|NCT01189500|DRUG|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
214861610|NCT01189500|DRUG|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
214861611|NCT04792359|DEVICE|Equinometer|Measurement of dorsiflexion of the ankle will be reproduced three times on each ankle in two positions, with a force applied
214861612|NCT03939988|RADIATION|Photobiomodulation|Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
214861613|NCT03939988|RADIATION|Placebo photobiomodulation|In the placebo group, the same procedures will be made, but the laser will be turned off.
214861614|NCT00043537|BEHAVIORAL|Social Effectiveness Therapy for Children (SET-C)|
214861615|NCT00043537|DRUG|Fluoxetine|
214861616|NCT00043537|DRUG|Pill Placebo|
214861617|NCT05672693|OTHER|Several Calculation Formulas of Intraocular Lens|Comparison of the accuracy of several intraocular lens calculation formulas
214861618|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
214861619|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
214861620|NCT00062751|DRUG|Letrozole|Letrozole 2.5 mg daily
214861621|NCT05028231|PROCEDURE|Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|Each patient will complete 2 cycles of neoadjuvant therapy. After evaluating the curative effect, decide whether to operate or not. Patients with and without surgery enter the survival follow-up period.
214861622|NCT01319786|OTHER|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
214861623|NCT01319786|OTHER|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
214861624|NCT02963402|DRUG|Tocilizumab|
214861625|NCT02963402|DRUG|Adalimumab|
214861626|NCT04078438|DEVICE|neurofeedback augmentation|"Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study."
214861627|NCT04078438|DRUG|treatment as usual|The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
214861628|NCT04078438|OTHER|psychotherapy placebo sessions|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
214861629|NCT04920903|DRUG|COR588|Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
214861630|NCT04920903|DRUG|Placebo|Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
214861631|NCT02307643|DRUG|MT-1303 Low dose|
214861632|NCT02307643|DRUG|MT-1303 High dose|
214861633|NCT03589521|BEHAVIORAL|ABCT_Military|15 Weekly Couple Therapy Sessions
214861634|NCT01606059|DRUG|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
214861635|NCT01606059|DRUG|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
214861636|NCT05195749|DRUG|101-PGC-005 ('005) + SOC|Three consecutive days of '005 administration
214861637|NCT05195749|DRUG|Placebo + SOC|Three consecutive days of placebo administration
214861638|NCT03345394|BEHAVIORAL|Contingency Management|Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples
214861639|NCT03345394|BEHAVIORAL|Standard treatment|Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program
214861640|NCT04013945|DIETARY_SUPPLEMENT|Superba Boost (Active)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Superba Boost.
214861641|NCT04013945|DIETARY_SUPPLEMENT|Vegetable oil (Placebo)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Placebo.
215033685|NCT02444754|OTHER|Questionnaire Administration|Complete demographics questionnaires
215033686|NCT02444754|OTHER|Survey Administration|Complete surveys
214861642|NCT02593435|GENETIC|NGS test|"To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2."
214861643|NCT04142008|DEVICE|Walk with Me app|For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
214861644|NCT01144364|DRUG|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
214861645|NCT05084664|DEVICE|electrical stimulation|premodulated current+ exercises
214861646|NCT05084664|DEVICE|electrical stimulation|diadynamic current+ exercises
214861647|NCT04108247|DRUG|Abiraterone+SHR3162|Participants will receive Abiraterone combined with SHR3162 orally
214861648|NCT02079168|DRUG|RXI-109|
214861649|NCT02079168|DRUG|Placebo|
214861650|NCT01635062|DRUG|Calcitriol|Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
214861651|NCT01635062|DRUG|Placebo|Subjects will receive placebo for 3 weeks.
214861652|NCT02880020|BIOLOGICAL|Ipilimumab|Given IV
214861653|NCT02880020|OTHER|Laboratory Biomarker Analysis|Correlative studies
214861654|NCT02880020|BIOLOGICAL|Nivolumab|Given IV
214861655|NCT05518266|PROCEDURE|US-guided Parasternal block|Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance
214861656|NCT05518266|PROCEDURE|Surgeon-delivered parasternal block|Just before wiring of the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
214861657|NCT05199766|DRUG|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease|This is an open-label, single-arm, single-stage phase II trial of voxelotor in patients with sickle-cell disease. Voxelotor 500mg tablets. Voxelotor will be administered as 500mg tablets orally once daily. The participant should always take all 3 tablets in a row at the same time each day, unless the study doctor has instructed them to adjust the dose.
214861658|NCT04698148|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
214861659|NCT04698148|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
214861660|NCT04698148|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
214861661|NCT04757038|DEVICE|Intradiscal injection|The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided.
214861662|NCT00040248|DRUG|Daclizumab|
214861663|NCT02307214|OTHER|BaroReflex Sensitivity, endothelial function measurement|no other
214861664|NCT01631513|DRUG|Nucynta ER|100 to 250 mg every 12 hours
214861665|NCT04734119|OTHER|Pre operative evaluation and anesthesia administration by the same anesthesiologist|Pre operative evaluation and anesthesia administration by the same anesthesiologist (instead of two different anesthesiologists, as routinely performed in our medical center)
214861666|NCT04048941|PROCEDURE|One Needle Hand Acupuncture with Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
214861667|NCT04048941|PROCEDURE|One Needle Hand Acupuncture without Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.
214861668|NCT04048941|PROCEDURE|Control Acupuncture with Movement|Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
214861669|NCT00390702|DEVICE|transcatheter implantation of a VSD occluder (Nitinol coil)|transcatheter implantation, by first performing a arterial-venous loop through the defect
214861670|NCT01301508|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
214861671|NCT01301508|DRUG|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
214861672|NCT01301508|DRUG|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
214861673|NCT01301508|DRUG|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
214861674|NCT02547402|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
214861675|NCT02547402|DRUG|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
214861676|NCT02547402|DRUG|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
214861677|NCT05173038|BEHAVIORAL|second ejaculate|group patients received IUI for pregnancy assistance 1 hour after the first sperm extraction. The two semen were mixed and treated.
214861678|NCT00851643|BIOLOGICAL|Octavalent HPV with 15 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
214861679|NCT00851643|BIOLOGICAL|Octavalent HPV with 30 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
214861680|NCT00851643|BIOLOGICAL|Octavalent HPV with 60 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
214861681|NCT00851643|BIOLOGICAL|Octavalent HPV with 120 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
214861682|NCT00851643|BIOLOGICAL|Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
215033687|NCT03455686|OTHER|Hyperpolarized 129Xe MRI|Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
214861683|NCT01681966|DRUG|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
214861684|NCT01832675|DRUG|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
214861685|NCT01832675|DRUG|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
214861686|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to maintain a sedation depth between 80-90 value, which corresponds to light sedation definition.
214861687|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to monitor sedation depth.
214861688|NCT06088849|PROCEDURE|Venipuncture|The lactating mother will be asked to collect milk samples and donate 2 blood samples, which is not a part of their normal follow-up/treatment. We will also aks the parents if we can collect a blood sample fo the infant (0-6 months).
214861689|NCT01019707|DRUG|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
214861690|NCT01019707|DRUG|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
214861691|NCT03102593|DRUG|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
214861692|NCT03102593|OTHER|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
214861693|NCT02707861|DRUG|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
214861694|NCT02707861|DRUG|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
214861695|NCT00552383|PROCEDURE|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff \[this includes 3 of the investigators\], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
214861696|NCT00974961|DRUG|bupivacaine, levobupivacaine|intrathecal injection 15\~20mg(for Levobupivacaine) or 10\~15mg(for Bupivacaine) once
214861697|NCT01940497|DRUG|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
214861698|NCT01940497|DRUG|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
214861699|NCT01940497|DRUG|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
214861700|NCT01940497|DRUG|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
214861701|NCT00166153|DRUG|Mycophenolate Mofetil|
214861702|NCT01641133|BIOLOGICAL|Synflorix (3-Dose)|3 doses administered intramuscularly
214861703|NCT01641133|BIOLOGICAL|Synflorix (2-Dose)|2 doses administered intramuscularly
214861704|NCT01641133|BIOLOGICAL|Synflorix (Single Dose)|1 dose administered intramuscularly
214861705|NCT01641133|BIOLOGICAL|Prevenar 13 (Single Dose)|1 dose administered intramuscularly
214861706|NCT01641133|BIOLOGICAL|Prevenar 13 (2-Dose)|2 doses administered intramuscularly
214861707|NCT04554797|OTHER|Regional Hypothermia|Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
214861708|NCT00034983|DRUG|aprepitant|
214861709|NCT00034983|DRUG|Comparator: paroxetine HCL|
214861710|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
214861711|NCT01012557|BIOLOGICAL|Focetria|3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
214861712|NCT01012557|BIOLOGICAL|Focetria|15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
214861713|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
214861714|NCT01586403|BIOLOGICAL|Dose 1|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight. Subject in cohort 1 will receive 2.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
214861715|NCT01586403|BIOLOGICAL|Dose 2|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 2 will receive 7.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
214861716|NCT01586403|BIOLOGICAL|Dose 3|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 3 will receive 2.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
214861717|NCT01586403|BIOLOGICAL|Dose 4|Subjects then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
214861718|NCT03504995|DEVICE|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
214861719|NCT04186598|DEVICE|CPAP mask system|Intervention group will receive 15cm of H2O of positive end expiratory pressure
214861720|NCT04186598|DRUG|Nifedipine 30 MG|All participants will receive this intervention
214861721|NCT04186598|DEVICE|CPAP mask system without PEEP|Placebo group will receive high flow oxygen via altered CPAP mask system without providing any positive end expiratory pressure
214861722|NCT04681651|DRUG|Normobaric Hyperoxia|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
214861723|NCT04681651|DRUG|Sham Normobaric Hyperoxia|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；
214861724|NCT04681651|PROCEDURE|Endovascular Thrombectomy|EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
214861725|NCT04310488|OTHER|The Centre of excellence self-administered (CESAM) questionnaire items|Complete a self-administered questionnaire within two days of their museum visit.
214861726|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
214861727|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
214861728|NCT03977831|PROCEDURE|Radical Cystectomy|Participants are randomly and blinded assigned
214861729|NCT00429520|DRUG|Hyaluronic acid filler/IMD1 basic|
214861730|NCT05571072|OTHER|Opioid calculator|Our research group previously created an Opioid calculator that can be used to predict the number of opioids needed post-operatively based on patient health history and characteristics.
214861731|NCT05571072|OTHER|Standard opioid prescription|Patients will receive prescription for post-operative opioids based on what the attending surgeon usually provides.
214861732|NCT04161183|DEVICE|Extracoporeal shock wave therapy|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks
214861733|NCT04161183|DEVICE|Placebo|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks
214861734|NCT05487365|DEVICE|Comunicare Solutions Smartphone Application|The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.
214861735|NCT05487365|OTHER|Completing a quality of life (QOL)-questionnaire|Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
214861736|NCT00732420|DRUG|topotecan|Topoisomerase I inhibition.
214861737|NCT00732420|DRUG|pazopanib|Tyrosine kinase inhibitor
214861738|NCT00116519|DRUG|PPAR alpha|
214861739|NCT00116519|DRUG|placebo|
214861740|NCT05365841|DRUG|Mepolizumab 100 MG|Patients with SEA eligible to receive anti-IL5 treatment, which is a biologic treatment for SEA
214861741|NCT04899817|DRUG|Granisetron|The drug is given after induction of general anesthesia
214861742|NCT05814003|DRUG|hydroxylate flavones solid dispersion application|this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing
214861743|NCT05814003|OTHER|Placebo|Dough inert material without any therapeutic action
214861744|NCT03322384|DRUG|epacadostat|Epacadostat will be administered orally, in pill form, twice daily until disease progression.
214861745|NCT03322384|DRUG|SD-101|Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
214861746|NCT03322384|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
214861747|NCT04323241|OTHER|Controlled cord traction|In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
214861748|NCT04320550|DIAGNOSTIC_TEST|abdominal ultra sound|non invasive tests to exclude pathological causes
214861749|NCT01955213|DRUG|methylnaltrexone|Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
214861750|NCT03594695|DIAGNOSTIC_TEST|HSCRP and NLR|hs-CRP levels and NLR values will be studied from routine blood samples.
214861751|NCT02213913|DRUG|lenalidomide|Given PO
214861752|NCT02213913|DRUG|etoposide|Given IV
214861753|NCT02213913|DRUG|prednisone|Given PO
214861754|NCT02213913|DRUG|vincristine sulfate|Given IV
214861755|NCT02213913|DRUG|doxorubicin hydrochloride|Given IV
214861756|NCT02213913|DRUG|cyclophosphamide|Given IV
214861757|NCT02213913|BIOLOGICAL|rituximab|Given IV
214861758|NCT02213913|OTHER|quality-of-life assessment|Ancillary studies
214861759|NCT02213913|OTHER|laboratory biomarker analysis|Correlative studies
214861760|NCT04704141|DRUG|Hormone replacement therapy|A hormone replacement regimen using any medication of a number of standard treatment options
214861761|NCT03736213|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I
214861762|NCT03736213|BEHAVIORAL|Ultrasound biofeedback|In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
214861763|NCT00444457|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
214861764|NCT00444457|BIOLOGICAL|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
214861765|NCT05077436|DRUG|Vamifeport Formulation 1|Vamifeport Formulation 1 is available as 60 mg oral capsules
214861766|NCT05077436|DRUG|Vamifeport Formulation 2|Vamifeport Formulation 2 is available as 60 mg oral capsules
214861767|NCT03083236|OTHER|Standard PBI|Standard Parent Based Intervention (PBI)
214861768|NCT03083236|OTHER|Enhanced|Enhanced Parent Based Intervention (EPBI)
214861769|NCT02881164|OTHER|Low glycemic index|Subjects intake a low glycemic index breakfast
214861770|NCT02881164|OTHER|High glycemic index|Subjects intake a high glycemic index breakfast
214861771|NCT01112943|OTHER|Acupuncture|Acupuncture on predefined points for 20min once a week over seven weeks
214861772|NCT01112943|OTHER|Pulmonary Rehabilitation|a seven week pulmonary rehabilitation course
214861773|NCT01112943|OTHER|Pulmonary Rehabilitation|Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
214861774|NCT01876550|DRUG|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
214861775|NCT01876550|DRUG|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
214861776|NCT01876550|DRUG|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
214861777|NCT05620602|OTHER|Remedial treatment within 3 months|"The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
214861778|NCT05620602|OTHER|Remedial treatment within 3 to 6 months|"The interval between the time of this treatment and the last day of the last therapy is 3-6 months.~Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
214861779|NCT05620602|OTHER|Remedial treatment within 6 to 12 months|"The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
214861780|NCT05620602|OTHER|Remedial treatment after 12 months|"The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
214861781|NCT02216318|OTHER|blue light|
214861782|NCT00982449|OTHER|FIAU-PET-CT-2|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
214861783|NCT00982449|OTHER|FIAU-PET-CT-4|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
214861784|NCT03828136|DEVICE|Novum Vitrium® Cervical Interbody Device|For spinal fusion procedure at one level (C3 to T1) of the cervical spine.
214861785|NCT03828136|DEVICE|Allograft Ring or Block|Standard of Care
214861786|NCT00602277|OTHER|Laboratory Biomarker Analysis|Correlative studies
214861787|NCT00602277|BIOLOGICAL|Wild-type Reovirus|
214861788|NCT05314894|BEHAVIORAL|Education|Giving training to the students in the initiative group to quit smoking in three sessions, sending messages via whatsapp program and telephone counseling
214861789|NCT04216758|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
214861790|NCT04216758|DRUG|Gemcitabine|Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
214861791|NCT04216758|DRUG|tegafur|Patients secondly receive tegafur Body surface area \< 1.25 m\^2, 60 mg/d;Body surface area ≥ 1.25 m\^2 to \< 1.5 m\^2, 80 mg/d;Body surface area ≥ 1.5 m\^2, 100 mg/d (po) on days 1-21 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
214861792|NCT04120584|DEVICE|Forma Eye Applicator|"Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment."
214861793|NCT05161650|DIETARY_SUPPLEMENT|Ketone monoester (3-OHB)|Commercially available ketone supplement
214861794|NCT05161650|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
214861795|NCT02622451|BEHAVIORAL|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
214861796|NCT02622451|BEHAVIORAL|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
214665308|NCT00296322|DRUG|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
214861797|NCT01411865|OTHER|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
214861798|NCT01411865|OTHER|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
214861799|NCT01547949|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|
214861800|NCT01547949|DIETARY_SUPPLEMENT|placebo cherry fruit drink|
214861801|NCT05808673|BIOLOGICAL|Post-change CMAB807X|for subcutaneous injection only
214861802|NCT05808673|BIOLOGICAL|Pre-change CMAB807X|for subcutaneous injection only
214861803|NCT05808673|BIOLOGICAL|Xgeva®|for subcutaneous injection only
214861804|NCT05665920|RADIATION|Ultra-hypofractionated whole breast radiotherapy|Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
214861805|NCT05665920|RADIATION|Standard Radiation|Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
214861806|NCT06880783|OTHER|manual diaphragm release technique|The participant should be supine with relaxed limbs, and the therapist should position themselves at the head, making manual contact with the pisiform, hypothenar region, and fingers. The therapist should gently pull the contact towards the head, deepen it during exhalation, and gradually increase the depth.
214861807|NCT06880783|OTHER|deep breathing exercises|Participants in a crook laying position are instructed to inhale through the nose, lift the abdomen, and let out through the mouth, breathing six breaths per minute for 30 minutes.
214861808|NCT06723639|PROCEDURE|A new two-layer surgical technique|A new double row suturing technique attempting to restore the length of the distinct soleus and gastrocnemius portions of the Achilles tendon.
214861809|NCT06723639|OTHER|Standard non-surgical treatment|Standard non-surgical treatment
214861810|NCT06745102|DIETARY_SUPPLEMENT|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo or 0.75 mg soluble Xanthohumol)
214861811|NCT06745102|DIETARY_SUPPLEMENT|Iso-alpha Acids|Participants receive a study drink supplemented with Iso-alpha Acids (0 mg = Placebo or 45 mg Iso-alpha Acids)
214861812|NCT06745102|DIETARY_SUPPLEMENT|Xanthohumol + Iso-alpha Acids|Participants receive a study drink supplemented with Xanthohumol and Iso-alpha Acids (0 mg = Placebo or 0.75 mg + 45 mg soluble Xanthohumol + Iso-alpha Acids)
214861813|NCT06281951|DRUG|Fentanyl - Inhalation by facial nebulization|3 administrations based on a weight-dependent threshold (40 µg per administration for a weight \< 70kg and 50 µg per administration for a weight ≥ 70kg).
214861814|NCT06281951|DRUG|Fentanyl - Nebulisation|3 administrations based on a weight-dependent threshold (20 µg/administration and for a weight \< 70kg and 30 µg/administration for a weight ≥ 70kg). The dose of each bolus will be distributed at equivalent volume in both nasal pits
214861815|NCT06927843|DEVICE|point of care test|DPP Syphilis Screen and Confirm antibody point-of-care-test (POCT)
214861816|NCT06846242|OTHER|Assessment|The group in which the assessments will be made.
215033688|NCT04502914|PROCEDURE|Open-to-air strategy|In open-to-air management, the wound will be washed with a chlorhexidine solution and leave the wound open, or portion of the wound assigned to OTA, to the environment. An electric heat lamp (model no. 53103, 250W, Brandt Industries LLC, Bronx, NY) will be placed at as close to 1 yard (0.91 m) as possible from the wound after daily wound care for 24 hours (+/- 6 hours) to promote drying. However, to prevent excessive drying an hourly spritz of topical solution, e.g., DuoDERM® Hydroactive® gel (ConvaTec Oklahoma City, OK) will be used at the bedside.
214861817|NCT06319079|DIETARY_SUPPLEMENT|Fortified powder milk|Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.
214861818|NCT06319079|OTHER|Powder milk|Commercial powder milk constitutes dehydrated commercially available cow's milk, which is fortified with Vitamins A and D by law.
214861819|NCT03596931|DRUG|Statins (Cardiovascular Agents)|Prescribed with statins
214861820|NCT06779292|DIAGNOSTIC_TEST|Large Language Model Diagnosis|Using the large language model for diagnosing emergency neurology conditions.
214861821|NCT06923332|OTHER|High Fiber bar with Inulin|Bar with inulin - high fiber
214861822|NCT06923332|OTHER|Low fiber bar - no inulin|Bar without inulin - low fiber
214861823|NCT06237803|OTHER|storage of biological samples|collect and store biological samples
214861824|NCT06922383|DRUG|arfolitixorin (ARFOX + bevacizumab)|Every 14 days during treatment phase, Bevacizumab will be administered as an i.v. infusion of 5 mg/kg, Oxaliplatin will be administered as an 85 mg/m2 i.v. infusion, 5-FU will be administered as a 400 mg/m2 i.v. bolus + a 2,400 mg/m2 i.v. infusion and Arfolitixorin will be administred as an i.v. infusion.
214861825|NCT01489618|BIOLOGICAL|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
214861826|NCT01489618|BIOLOGICAL|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
214861827|NCT05287347|DIAGNOSTIC_TEST|Blood Specimen|"Blood samples will be collected from study participants at one time-point in the study, for the following:~1. tumor markers CEA and CA 19-9: 2 ml blood will be collected.~2. glycomics: 0.5 cc blood will be collected~3. ctDNA: 20 cc blood will be collected"
214861828|NCT02390349|OTHER|Placebo|
214861829|NCT02390349|DIETARY_SUPPLEMENT|Curamin|
214861830|NCT02390349|DIETARY_SUPPLEMENT|CuraMed|
214861831|NCT06227013|BEHAVIORAL|Whistleblowing intervention|the participated nurses will receive session about Whistleblowing
214861832|NCT02518919|OTHER|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
214861833|NCT02518919|OTHER|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
214861834|NCT03554213|BIOLOGICAL|Typhoid Conjugate Vaccine|Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited
214861835|NCT03760003|DRUG|ABX464 25mg|ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks
214861836|NCT03760003|DRUG|ABX464 50mg|ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
214861837|NCT03760003|DRUG|ABX464 100mg|ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
214861838|NCT03760003|DRUG|Placebo|Two capsules of placebo once daily for 16 weeks
214861839|NCT03237949|BEHAVIORAL|Phone counseling|Four telephone counseling sessions using a motivational interviewing approach
214861840|NCT03237949|BEHAVIORAL|Text message|30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
214861841|NCT01615237|BEHAVIORAL|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
214861842|NCT01615237|BEHAVIORAL|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
214861843|NCT01615237|BEHAVIORAL|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
214861844|NCT03882528|BIOLOGICAL|Plasmodium falciparum malaria parasite|Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
214861845|NCT02385253|BEHAVIORAL|Educational training program|"The educational training program (intervention) consists of four sequential phases:~1. Knowledge Acquisition~2. Skills Assessment~3. Deliberate Practice~4. Clinical Proficiency"
214861846|NCT02755077|PROCEDURE|Head rotation during mask ventilation|Patient's head position is axially rotated 45 degrees to the right.
214861847|NCT05530343|DIAGNOSTIC_TEST|Seattle protocol|Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.
214861848|NCT05530343|DIAGNOSTIC_TEST|WATS3D brushings|Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.
214861849|NCT02960061|DRUG|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
214861850|NCT02960061|PROCEDURE|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
214861851|NCT02960061|DRUG|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
214861852|NCT02960061|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
214861853|NCT05623072|DEVICE|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in vmPFC
214861854|NCT05623072|DEVICE|Sham tDCS|20 min, vmPFC Sham tDCS
214861855|NCT02917330|OTHER|Stretching and progressive strength training|Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
214861856|NCT00033124|BEHAVIORAL|Behavior Therapy|
214861857|NCT01874795|DEVICE|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
214861858|NCT01874795|DEVICE|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
214861859|NCT03525158|BEHAVIORAL|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
214861860|NCT00221611|DRUG|Administration of intrathecal baclofen|
214861861|NCT02733315|BEHAVIORAL|Diabetes Conversation Map Program|"The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants."
214861862|NCT00653965|DRUG|Rosuvastatin|
214861863|NCT00653965|DRUG|Atorvastatin|
214861864|NCT00580216|DRUG|Idrabiotaparinux sodium|"Pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
214861865|NCT00580216|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
214861866|NCT00580216|DRUG|Placebo (for idrabiotaparinux)|"Matching pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
214861867|NCT00580216|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
214861868|NCT00580216|DRUG|Avidin|"Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes"
214861869|NCT00580216|DRUG|Placebo (for avidin)|"Vial containing 105 mg of matching lyophilized powder for dissolution~Intravenous infusion for 30 minutes"
214861870|NCT05619055|OTHER|Routine treatment|Antibiotics, intravenous fluids and symptomatic supportive treatment.
214861871|NCT05921513|PROCEDURE|Free Gingival Graft Procedure|This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.
214861872|NCT02227147|DRUG|rhNGF 20µg/ml|
214861873|NCT02227147|OTHER|Placebo|Formulation containing antioxidant
214861874|NCT02000661|DEVICE|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
214861875|NCT03934320|OTHER|FAMCAT|The intervention is a computer-based software algorithm (FAMCAT) for use in general practice with a family history questionnaire.
214861876|NCT00324766|DRUG|levosimendan|1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
214861877|NCT00324766|DRUG|placebo,|24 h, infusion
214861878|NCT02923674|BEHAVIORAL|Weight loss|All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.
214861879|NCT02923674|BEHAVIORAL|Exercise|Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.
214861880|NCT02923674|BEHAVIORAL|Sitless|Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level \<3).
214861881|NCT05991830|PROCEDURE|General anesthesia|Older adults during elective surgery under general anesthesia with propofol, frontal EEG will recorded and a baseline plasma sample will be taken
214861882|NCT02717858|DRUG|liraglutide|Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
214861883|NCT02717858|DRUG|placebo|Injected s.c./subcutaneously (under the skin) once daily.
214861884|NCT03709823|DRUG|Cytisine|film coated tablet containing 1.5 mg cytisine in a single tablet
214861885|NCT03709823|DRUG|Placebo Comparator|1.5 mg cellulose powder to match final weight of the cytisine tablet
214861886|NCT03709823|BEHAVIORAL|Behavioral support|12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
214861887|NCT05998941|DRUG|TQB2868 injection|TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
214861888|NCT05998941|DRUG|Paclitaxel injection|Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
214861889|NCT05998941|DRUG|Cisplatin injection|Cisplatin injection can inhibit the DNA replication process of cancer cells
214861890|NCT05998941|DRUG|Carboplatin injection|Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
214861891|NCT05998941|DRUG|Bevacizumab injection|Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).
214861892|NCT04476719|DRUG|ATAFENOVIR 200 MG KAPSUL|A 200 mg capsule 0ral administration with 240 ml water
214861893|NCT04476719|DRUG|ARBIDOL 100 MG KAPSUL|Two 100 mg capsules will be administrated with 240 ml water orally.
214861894|NCT02716935|DIETARY_SUPPLEMENT|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
214861895|NCT02716935|DIETARY_SUPPLEMENT|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
214861896|NCT00283790|DRUG|zolpidem tartrate|
214861897|NCT01055132|DEVICE|Etafilcon A toric contact lens|contact lens to correct astigmatism
214861898|NCT01055132|DEVICE|Nelfilcon A toric contact lens|contact lens to correct astigmatism
214861899|NCT00158600|BIOLOGICAL|alglucosidase alfa|IV infusion of 20mg/kg; qow for 78 weeks.
214861900|NCT00158600|DRUG|Placebo|Placebo Comparator; qow for 78 weeks.
214861901|NCT01466452|DRUG|Aspirin|single-dose aspirin in 100 mg 1 tablet every 24 hours
214861902|NCT01466452|DRUG|Aspirin|single-dose aspirin 200 mg 1 tablet every 24 hours
214861903|NCT01466452|DRUG|Aspirin|double-dose aspirin 100 mg 1 tablet every 12 hours
214861904|NCT00805753|DRUG|ACTH|comparison of different dosages of drug
214861905|NCT02067429|PROCEDURE|Limbal Relaxing Incisions|
214861906|NCT02067429|DEVICE|Toric Intraocular Lens|
214861907|NCT04670666|DRUG|MADALENA ASSOCIATION|Madalena association coated tablet.
214861908|NCT04670666|DRUG|METFORMIN|Metformin 1000 mg extended-release tablet.
214861909|NCT04670666|DRUG|EMPAGLIFLOZIN + LINAGLIPTIN|Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
214861910|NCT04670666|OTHER|MADALENA ASSOCIATION PLACEBO|Madalena association placebo tablet.
214861911|NCT04670666|OTHER|METFORMIN PLACEBO|Metformin placebo tablet.
214861912|NCT04670666|OTHER|EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO|Empagliflozin + linagliptin placebo tablet.
214861913|NCT01021358|DRUG|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
214861914|NCT01021358|DRUG|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
214861915|NCT01219413|DRUG|Aliskiren, Perindopril|Rasilez 300 mg Prestarium 10 mg
214861916|NCT00523536|BEHAVIORAL|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
214861917|NCT02618408|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
214861918|NCT02618408|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
214861919|NCT02618408|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
215033689|NCT04502914|PROCEDURE|Traditional closed-wound management|In traditional closed-wound management, once a day the wound will be washed with a chlorhexidine solution and closed with a non-adherent dressing such as ADAPTIC® (Acelity, San Antonio, TX) soaked in topical antimicrobial solutions, ointments, and creams designed to promote wound healing.
215033690|NCT00105066|DRUG|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
214861920|NCT04866732|BEHAVIORAL|Physical Activity Cardiac Health Program|The investigators anticipate that the physical activity program will include the following components: a) physical activity component - the investigators propose an incremental physical activity component whereby participants will gradually increase their physical activity ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to Cardiovascular disease risk factors prevention; c) daily diary, which will be used to document record about any barriers for completing various components of the intervention; d) problem-solving sessions whereby participants will meet once a week with the investigators to talk about the barriers and facilitators of their weekly activity and any adherence issues.
214861921|NCT03365752|DRUG|Chloroprocaine|A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
214861922|NCT03365752|DRUG|Mepivacaine|A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
214861923|NCT03365752|DRUG|General Anesthetics|General anesthetics will be administered intravenously
214861924|NCT03063840|DEVICE|Microwave ablation|Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
214861925|NCT05628519|BEHAVIORAL|Captain Sonar Exposition|Captain SonarTM is a naval battle game where two teams each composed of four participants clash. Each player has a well-defined role and it is imperative to communicate in a closed loop to advance in the game. This game also includes components similar to support for Trauma care: stress, speed of action, central communication and teamwork of four protagonists (Team Leader- Captain, intern-Second, nurse-Mechanic, Caregiver-Detector). This short video describes the rules and the Game progress: https://vimeo.com/173614346.
214861926|NCT05628519|BEHAVIORAL|Monopoly Exposition|Participant will be invited to play to Monopoly during 60 min
214861927|NCT00398996|DRUG|Early versus intermediate versus late initiation of ART|Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
214861928|NCT06478264|DRUG|Etoposide|100mg/m\^2, intravenous infusion for 1-3 days,21 days/cycle, 4 cycles
214861929|NCT06478264|DRUG|Cisplatin|25mg/m\^2 ,intravenous infusion for 1-3 days ,21 days/cycle, 4 cycles
214861930|NCT06478264|DRUG|Carboplatin|Carboplatin (AUC = 5) on 1 Day,21 days/cycle, 4 cycles ;
214861931|NCT06478264|DRUG|Adebrelimab|1200mg adebrelimab was given intravenously on 2 day after chemotherapy,21 days/cycle, continuous use.
214290617|NCT01881776|PROCEDURE|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
214290618|NCT03144388|PROCEDURE|Variable Stepping Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
214290619|NCT03144388|PROCEDURE|Variable Non-specific Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
214290620|NCT02190084|DEVICE|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
214861932|NCT06478264|RADIATION|radiotherapy|Stage I-IVa , prescription dose: PTV 50Gy/25f. Stage IVb ,prescribed dose: PTV 30Gy/10f.
214861933|NCT02637921|OTHER|Hypoxia|21 days confinement in normobaric hypoxic (FiO2 = 14%)
214861934|NCT02637921|OTHER|Ambulatory|Participants hava a standardized activity level throughout the intervention
214861935|NCT02637921|OTHER|Normoxia|21 days confinement in normobaric normoxic (FiO2 = 21%) environment
214861936|NCT02637921|OTHER|Bed Rest|Participants remain on supine bed rest throughout the intervention
214861937|NCT02637921|OTHER|Standardised nutritional intake|Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
214861938|NCT02865252|OTHER|MWM Treatment|
214861939|NCT02865252|OTHER|MWM Sham|
214861940|NCT01965470|OTHER|Combination Prevention|
214861941|NCT01965470|OTHER|Enhanced Care|
214861942|NCT02953470|BEHAVIORAL|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
214861943|NCT02953470|BEHAVIORAL|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
214861944|NCT02575911|DEVICE|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
214290621|NCT03198533|DEVICE|Triathlon PA|Implantation of Knee Prosthesis
214290622|NCT03198533|DEVICE|Triathlon Pressfit|Implantation of Knee Prosthesis
214290623|NCT01668550|DRUG|AZD0424|"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."
214861945|NCT02575911|PROCEDURE|LASIK surgery|
214861946|NCT01333371|PROCEDURE|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
214861947|NCT02589483|PROCEDURE|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
214861948|NCT02589483|DEVICE|Hemopatch|The rectal anastomosis reinforced with Hemopatch
214861949|NCT01249365|BIOLOGICAL|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
214861950|NCT03069950|DRUG|Floxuridine (FUDR)|5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
214861951|NCT03069950|DRUG|Irinotecan (CPT-11)|Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
214861952|NCT03069950|DRUG|FLUOROURACIL|5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
214861953|NCT03069950|DRUG|PANITUMUMAB|Panitumumab (6 mg/kg IV over 60 min)
214861954|NCT03069950|DRUG|DEXAMETHASONE|flat dose of 25 mg on Day 1
214861955|NCT03069950|DRUG|Leucovorin|Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
214861956|NCT04402775|OTHER|Tourniquet|A tourniquet will be used during surgery
214290624|NCT03484481|DIETARY_SUPPLEMENT|Oral Nutritional Support; Nutrena|Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. \]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
214290625|NCT03484481|DIETARY_SUPPLEMENT|Intradialytic Parenteral Nutrition; Kabiven central|Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
214861957|NCT03074773|DRUG|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
214861958|NCT03074773|DEVICE|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
214861959|NCT03074773|PROCEDURE|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
214861960|NCT03074773|DRUG|Bupivacaine|it is an amino amide local anesthetic drug
214861961|NCT03074773|OTHER|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
214861962|NCT03900065|PROCEDURE|Preconditioning|Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
214861963|NCT04905030|BEHAVIORAL|Information T1|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in non-scientific, non-statistical terms and is emotionally charged: the consequences of cervical cancers are portrayed by testimonies of cancer survivors from Sweden.
214861964|NCT04905030|BEHAVIORAL|Information T2|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in scientific terms and incidence and mortality statistics are reported. The information is not emotionally charged but rather aseptic.
214861965|NCT04905030|BEHAVIORAL|Information C|A4 information sheet containing a reminder of the upcoming HPV vaccination, and information on the history and characteristics of the Swedish national vaccination program.
214861966|NCT04974866|DRUG|EGFR-TK Inhibitor|epidermal growth factor receptor tyrosine kinase inhibitors
214861967|NCT00517179|DRUG|Vardenafil 10mg|
214861968|NCT05668078|DIAGNOSTIC_TEST|Rapid Antigen Testing (RAT) for COVID-19|COVID-19 RAT intervention done among the school students to see if RAT test can play a role in reducing absenteeism. School type-1-only for symptomatic participants, School type-2-Serial testing at three days interval for all participants and School type-3 got no testing.
214861969|NCT04514536|DEVICE|Health monitors|"* The connected scale (iHealth HS2) measures weight from 5 to 180kg and BMI.~* The connected actimeter (iHealth AM4) monitors activity (number of steps, distance, calories), sleep (automatic sleep recognition, effective sleep time, number of awakenings) and swimming (automatic activity recognition, session duration, swim type recognition and number of laps).~* The connected blood pressure monitor (iHealth Track KN-550BT)is a medical device that measures blood pressure and pulse rate.~* The activity monitor (manufactured by RF Track) consists of a housing that can be positioned as a pendant or at the hip. It includes an accelerometer, gyroscope, magnetometer, barometer, radio transceiver, and led. The sensor records the raw signals.~* The touchpad allows the subject to connect to the Calliope app. This app allows the data recovery, storage, analysis, visualization, and all the required settings for the platform to work together."
214861970|NCT05068089|PROCEDURE|Nissen fundoplication|Nissen fundoplication, numbers, reasons and length of hospitalizations, gastrointestinal symptoms and survival
214861971|NCT05068089|BIOLOGICAL|Enteral nutrition|Type and switch of enteral nutrition formula (tube, PEG, PEJ)
214861972|NCT05325307|OTHER|Acupressure|The experimental group will start with HT7 points and continue LI4 and EX-NH3 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
214861973|NCT05325307|OTHER|Placebo acupressure|In the placebo acupressure group , the points 1.5 cm away from the HT7, LI4, and EX-NH3 points will be applied for an average of 15 minutes. Less pressure will be applied.
214861974|NCT02594085|OTHER|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
214290626|NCT00560079|DRUG|Allopurinol|Allopurinol 600mg/day bid for 28 days
214861975|NCT02594085|OTHER|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
214861976|NCT02594085|OTHER|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
214861977|NCT02594085|OTHER|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
214861978|NCT02594085|OTHER|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
214861979|NCT02594085|OTHER|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
214861980|NCT03595085|PROCEDURE|catheter directed fragmentation and thrombolysis|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery. After ensuring initial flow, Initial bolus dose of streptokinase (250.000 international unit) will be given over 10 min followed by continuous infusion of (100.000 international unit per hour)for 24 hours
214861981|NCT03595085|DRUG|Streptokinase|intravenous streptokinase at a dose of 250 000 international unit as a loading dose over 30 minutes, followed by 100 000 international unit per hour over 12-24 hours
214861982|NCT02045082|PROCEDURE|Corneal sampling|Slit lamp corneal sampling with a Swab
214861983|NCT01460901|BIOLOGICAL|GD2 CAR modified Tri-virus specific cytotoxic t-cells|This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
214861984|NCT01857765|BEHAVIORAL|Rehabilitation|Range of motion stretching exercises
214861985|NCT01857765|BEHAVIORAL|Follow-up|Follow-up with surgeon's clinic
214861986|NCT01322126|DEVICE|ultrasound probe|we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
214861987|NCT02766426|BEHAVIORAL|Lifestyle change program|"Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.~The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week."
214861988|NCT04775186|PROCEDURE|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
214290627|NCT00560079|DRUG|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
214290628|NCT00560079|DRUG|Placebo|Placebo
214290629|NCT03297996|DIAGNOSTIC_TEST|Mobio PowerSoil DNA Isolation Kit|16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
214861989|NCT00996138|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
214861990|NCT05263622|OTHER|Split-mouth administration for group B|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q1 and Q3) and with Mectron handpiece (quadrants Q2 and Q4)~* Calculus removal with EMS ultrasound handpiece (Q1 and Q3) and with Mectron handpiece (Q2 and Q4)"
214861991|NCT05263622|OTHER|Split-mouth administration for group A|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q2 and Q4) and with Mectron handpiece (quadrants Q1 and Q3)~* Calculus removal with EMS ultrasound handpiece (Q2 and Q4) and with Mectron handpiece (Q1 and Q3)"
214861992|NCT01834430|DIETARY_SUPPLEMENT|enteral nutrition|
214861993|NCT04488835|OTHER|Electromagnetic field therapy and transcutaneous electrical nerve stimulation|Both groups received conventional physical therapy treatment protocol. Moreover, group (A) has an additional TENS application and group (B) had PEMFS application. TENS and the PEMFT were applied once daily, three times per week for 20 minutes for each session. Assessment performed pre and post intervention using visual analogue scale (VAS) and estimation of the carbamazepine intake (CMI).
214861994|NCT02566993|DRUG|Lurbinectedin (PM01183)|
214861995|NCT02566993|DRUG|Doxorubicin (DOX)|
214861996|NCT02566993|DRUG|Cyclophosphamide (CTX)|
214861997|NCT02566993|DRUG|Vincristine (VCR)|
214861998|NCT02566993|DRUG|Topotecan|
214861999|NCT05337774|DRUG|[18F]PI-2620|The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
215033691|NCT00105066|DRUG|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
215033692|NCT05577741|BEHAVIORAL|Multisensory virtual reality pod (SENSIKS©)|Six sessions of 20 minutes of mindfulness.
215033693|NCT05577741|BEHAVIORAL|Cognitive bike (Vélo-cognitif®)|Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
214862000|NCT02356003|DEVICE|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
214862001|NCT03086837|BEHAVIORAL|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
214862002|NCT02820649|OTHER|Sleep deprivation|40 hours of continuous wakefullness
214862003|NCT01912274|DRUG|Pracinostat|Elderly newly diagnosed patients will all receive pracinostat
214862004|NCT01912274|DRUG|Azacitidine|Elderly newly diagnosed patients will all receive azacitadine
214862005|NCT06428318|DIAGNOSTIC_TEST|Conventional Sputum culture|Sputum culture was done to patients and they received Antibiotics According to its results
214862006|NCT06428318|DIAGNOSTIC_TEST|BioFire Pneumonia Panel (BFPP)|BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
214862007|NCT00298779|DRUG|omeprazole and bortezomib|
214862008|NCT04276844|DIAGNOSTIC_TEST|Ultrasonography using the two-dimensional (2D) mode|Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.
214862009|NCT04276844|DIAGNOSTIC_TEST|Respiratory Functional Explorations|Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV) and total lung capacity (TLC) measured at day 7
214862010|NCT06127368|DRUG|GB-5001A|Depending on the cohort, volume will be varied to administer, and the dosage and route of administration may be varied.
214862011|NCT06127368|DRUG|GB-5001D|Depending on the cohort, volume will be varied to administer.
214862012|NCT06127368|DRUG|Oral cohort|Single dose of Aricept tablet.
214862013|NCT03776721|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs.
214862014|NCT03776721|PROCEDURE|Fat graft|30mL harvested lipoaspirate is injected at the affected axillary site.
214665309|NCT04599426|BIOLOGICAL|Allogeneic NK cell regimen group|"10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15 ."
214862015|NCT03776721|PROCEDURE|Sham graf (Saline injection)|30mL saline is injected at the affected axillary site.
214665310|NCT00527449|DRUG|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
214665311|NCT00019955|PROCEDURE|laparoscopic surgery|
214665312|NCT00019955|PROCEDURE|radiofrequency ablation|
214862016|NCT03776721|BIOLOGICAL|Stem cell injection|4mL stem cell suspension injected at the affected axillary site.
214862017|NCT03776721|PROCEDURE|Saline injection|4mL saline injected at the affected axillary site.
214862018|NCT03748849|PROCEDURE|Physiotherapy|
214862019|NCT00952549|PROCEDURE|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
214862020|NCT01622374|BEHAVIORAL|Music|Ten minutes of music or silence were applied prior to dental procedures
214862021|NCT06332729|DEVICE|universal exercis unit|Universal exercise unit (UEU) consists of system of pulleys, suspensions, belts for supporting and elastic cords. UEU is based on the concept of unloading the body against gravity and to perform movement of weak part of the body. Therapist's hands are free to provide adequate support as required by the patient during exercise training Universal exercise unit, therapy sessions extended are from three to four hours Children and adults have neurological conditions can used. Spider cage is made of metal could be depending on population pediatric or adults. Elastic resistance of cords used to increase strengthen of muscle
214862022|NCT06332729|DEVICE|functional electrical stimulation|Functional electrical stimulation (FES) is defined as the electrical stimulation of muscles that have impaired motor control to produce a contraction to obtain functional useful movement
214862023|NCT02664233|BEHAVIORAL|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
214862024|NCT01716689|DRUG|oral cyclophosphamide|50mg daily
214862025|NCT03731871|DIAGNOSTIC_TEST|Ultrasonography|ultrasound to evaluate parameters of fetal maturity during pregnancy
214862026|NCT02363608|OTHER|standard post surgery care|
214862027|NCT02363608|BEHAVIORAL|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
214862028|NCT02363608|BEHAVIORAL|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
214862029|NCT00297856|BIOLOGICAL|Boostrix®|Single dose
214862030|NCT00297856|BIOLOGICAL|Td (Tetanus diphtheria) vaccine|Single dose
214862031|NCT01708590|DRUG|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
214665313|NCT00019955|PROCEDURE|thermal ablation therapy|
214665314|NCT03506503|PROCEDURE|Nanofat grafting|hair loss area will be treated by processed autologous Nanofat grafting
214665315|NCT04048577|DRUG|Dosing Interruption of Natalizumab|Planned 12 week dosing interruption of natalizumab
214665316|NCT01660815|DRUG|florbetapir (18F)|IV injection, 370 MBq (10mCi), single dose
214665317|NCT00030784|DRUG|ifosfamide|
214665318|NCT00030784|DRUG|pegylated liposomal doxorubicin hydrochloride|
214862032|NCT01708590|DRUG|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
214862033|NCT01708590|DRUG|placebo|Placebo administered subcutaneous (SC)
214862034|NCT00760565|DRUG|RO4905417|3mg/kg iv every 28 days for 3 infusions
214862035|NCT00760565|DRUG|RO4905417|20mg/kg iv every 28 days for 3 infusions
214862036|NCT00760565|DRUG|RO4905417|7mg/kg iv every 28 days for 3 infusions
214862037|NCT00760565|DRUG|placebo|3mg/kg iv every 28 days for 3 infusions
214862038|NCT00760565|DRUG|placebo|7mg/kg iv every 28 days for 3 infusions
214862039|NCT00760565|DRUG|placebo|20mg/kg iv every 28 days for 3 infusions
214862040|NCT05476107|DRUG|AMT-126|Single or daily dosing at doses A, B, C, D, E, F; G, H, and I
214862041|NCT05476107|DRUG|Placebo|Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
214862042|NCT05476107|OTHER|Radioactive Tablet (Part 2 Only)|Single dose in two periods in Part 2 (optional)
214862043|NCT04787393|DEVICE|Heartfelt device|The Heartfelt device uses a system of scanner in a compact device to generate depth images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit, For the measurements to take place, the participant walks in the field of view of the device, measurments are only taken when the patients has bare feet and no slippers/shoes, so the location of the device in the home is choosen to match this requirement. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.
214862044|NCT04787393|DEVICE|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records if they wish to do so.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.~The data from the scales will be reviewed retrospectively, as the comparison in this study is with standard care, not with enhanced provision of care, which would be the case if we were using automatic reporting of weights."
214862045|NCT06110728|BEHAVIORAL|Habit Change|Participants assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Goals can include things like reaching a step goal, sleeping for a certain number of hours, or making healthy food choices.
214862046|NCT01182558|OTHER|Hypothenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
214862047|NCT01182558|OTHER|Thenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
214862048|NCT01182558|OTHER|EDB muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
214862049|NCT01182558|OTHER|Relaxation of muscle|The muscle on the opposite side will be maintained at rest.
214862050|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
214862051|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
214862052|NCT03127644|DRUG|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
214290630|NCT05013567|DRUG|Ibuprofen gel|Ibuprofen gel 5% topically four times a day
214862053|NCT02536326|DEVICE|LEPU Renal Denervation System|LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
214862054|NCT01795274|RADIATION|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
214862055|NCT04738682|OTHER|Digital dietary registration|"The purpose of the intervention is to test whether digital dietary registration can yield more precise and consistent data, than conventional pen and paper based registration.~Furthermore a subjective evaluation of the use of digital registration will be conducted by the staff upon completion of the intervention. The format will be individual interviews held by the investigators."
214862056|NCT04738682|OTHER|Conventional dietary registration|The conventional way of doing dietary registration. This is done by a paper form, with the dietary options listed. The form is then filled in and logged by staff working in the afternoon.
214290631|NCT05013567|OTHER|Placebo|Placebo gel topically four times a day
214862057|NCT04587063|BEHAVIORAL|Fear Appeals|Email
214862058|NCT04587063|BEHAVIORAL|Message about Future Healthcare Costs|Email
214290632|NCT02542878|DEVICE|Foam roller|A bout of 60 seconds of myofascial release with foam roller
214862059|NCT04587063|BEHAVIORAL|Endorsement from a Doctor|Email
214862060|NCT04587063|BEHAVIORAL|Comparison Table|Email
214862061|NCT04587063|BEHAVIORAL|Highlighting Cost Savings and Convenience|Email
214862062|NCT01599065|OTHER|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
214862063|NCT03908762|DEVICE|iSage App with connected glucometer|Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.
214862064|NCT03908762|BEHAVIORAL|Magnet|Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.
214862065|NCT04710966|PROCEDURE|arthroscopic debridement|For the arthroscopic debridement, only stump refreshing and surrounding soft tissue cleaning were performed.
215033694|NCT05577741|OTHER|Standard treatment|Standard of care treatment
214290633|NCT01586390|OTHER|Functional treatment for ankle sprain using ankle cast|Functional treatment for ankle sprain using ankle cast
214290634|NCT01586390|OTHER|Ankle sprain treated with removable ankle support|Ankle sprain functionally treated with removable and adjustable ankle support
214290635|NCT03892109|OTHER|No Cord impression material|the no cord self- retracting impression material placed directly in the tray
214862066|NCT04710966|PROCEDURE|arthroscopic repair|For the arthroscopic repair, we converted partial tears into full-thickness tears and sutured them.
214862067|NCT02032706|DEVICE|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
214862068|NCT04972123|DRUG|CPC - Capsaicin, Phenylephrine, Caffeine|CPC is a combination of Capsaicin, Phenylephrine and Caffeine
214862069|NCT04972123|DIAGNOSTIC_TEST|Tilt Table Test|Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).
214862070|NCT04972123|DRUG|Placebo|Placebo for CPC
214862071|NCT05912283|DEVICE|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
214862072|NCT05912283|DEVICE|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
214862073|NCT05912283|DEVICE|Control Latex Condom|Commercial natural rubber latex condom
214862074|NCT03762486|OTHER|TENS|4 electrodes were placed 2-3 cm lateral to the incision of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
214862075|NCT03762486|OTHER|TAES|4 electrodes were placed at the ST25, P6, ST36, and LI4 acupuncture points of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
214862076|NCT01186601|DRUG|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
214862077|NCT05102214|DRUG|HLX301|A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, HLX301 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
214862078|NCT06262802|DEVICE|Active decompression|Intracystic active negative pressure
214862079|NCT05493137|OTHER|No intervention will be provided|No intervention will be provided, this is an observational study
214862080|NCT03343652|DRUG|Nivolumab|3 mg/kg IV infusion on day 1,14 up to 3 cycles
214290636|NCT03892109|DEVICE|cord|Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.
214290637|NCT03892109|OTHER|Gingitrac|packed into the sulcus
214665319|NCT03547050|OTHER|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
214665320|NCT03547050|OTHER|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
214665321|NCT05523492|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|All clients will receive the Culturally Enhanced Wellbeing Course. The Course was originally developed at Macquarie University in Australia and was then culturally enhanced by the Online Therapy Unit in Saskatchewan Canada. The course is a trans-diagnostic Internet-delivered cognitive behaviour therapy intervention targeting symptoms of depression and anxiety. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in order over 8 weeks. Therapists will spend \~15 mins. per week/per client offering support via emails and or phone calls.
214665322|NCT01748227|BEHAVIORAL|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
214665323|NCT02204865|DEVICE|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
214665324|NCT00874380|OTHER|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
214862081|NCT03343652|DRUG|Bendamustine Hydrochloride|90 mg/kg IV infusion on day 1 up to 3 cycles
214862082|NCT01156142|DRUG|doxepin hydrochloride|Oral rinse
214862083|NCT01156142|OTHER|placebo|Oral rinse
214862084|NCT02451332|BIOLOGICAL|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
214862085|NCT00893737|DRUG|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
214665325|NCT01955616|DRUG|RM-131|
214665326|NCT01955616|DRUG|Placebo|
214665327|NCT01243931|DRUG|OCT-guided laser phototherapeutic keratectomy|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
214862086|NCT02115932|OTHER|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
214862087|NCT03903809|DRUG|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
215033695|NCT04417985|DEVICE|18F-FDG PET/CT, MRI|
214665328|NCT01642355|BEHAVIORAL|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
214862088|NCT03903809|DRUG|ESPO|Participants received ESPO by subcutaneous injection weekly. The starting dose was 6000 IU and was adjusted according to the instruction to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
214665329|NCT01642355|BEHAVIORAL|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
214665330|NCT02059824|DEVICE|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
214665331|NCT04579861|OTHER|Prospective data collection following gynaecological oncology surgery|Prospective data collection and entry on database following gynaecological oncology surgery
214665332|NCT01486238|DRUG|Macugen® pegaptanib sodium|"Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert."
214665333|NCT06116305|OTHER|No intervention|No intervention
214665334|NCT03963973|DRUG|RDN-929 oral capsule|low, medium and high dose
214665335|NCT03963973|DRUG|Placebo oral capsule|matching placebo dose
214665336|NCT03384992|OTHER|Diaphragmatic breathing and relaxation|Education on physiological effects of anxiety, instructions in diaphragmatic breathing and relaxation techniques, and audio-recordings 5-15 minutes in length that provide guided relaxation exercises (autogenic, imagery-based and progressive muscle relaxation).
214665337|NCT03384992|OTHER|Cognitive restructuring|Education on the thought-emotion connection and exercises designed to better understand cognitions associated with increased anxiety and tools to evaluate and replace anxiety-generating cognitions. Includes an interactive tool (thought record) participants complete to facilitate this process.
214665338|NCT03384992|OTHER|Scheduled worry practice|Education on the association between avoidance and increased anxiety, and instructions on actively thinking about feared events to reduce avoidance and engage healthy coping strategies. Interactive tool includes a video-based guided worry practice session and an interactive worksheet and timer.
214665339|NCT03384992|OTHER|Telephone coaching|BCS will receive 5 TeleCoaching calls over a period of 4 weeks, to include one introductory phone call, followed by 4 calls focused each week on the current CSM; if the participant is not randomized to a CSM, TeleCoaching will provide reflective listening and encouragement.
214665340|NCT03384992|OTHER|Usual care|Includes general health, diet-general information and diet-BCSS (breast cancer survivor-specific) information.
214665341|NCT02712775|DRUG|Minocycline (yes/no)|
214665342|NCT02712775|DRUG|Placebo|Saline
214665343|NCT02180386|BEHAVIORAL|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
214665344|NCT02087566|DRUG|600 mg linezolid|
214665345|NCT04073615|DRUG|Rivoceranib|Film-coated tablets
214665346|NCT04073615|DRUG|Trifluridine/Tipiracil|Film-coated tablets
214665347|NCT04352829|OTHER|VIDEO-TRAINING-SESSION ABOUT MDI USE|The steps were demonstrated with the brochure that illustrated correct inhalation techniques and were prepared by Turkish Respiratory Research Society-Inhalation Treatment Study Group in line with the literature and were described with a video that was designed by Turkish National Society of Allergy and Clinical Immunology (25). The video is provided with a free access on the webpage of Turkish National Society of Allergy and Clinical Immunology.The video included images that explained the steps about what to do before MDI use, how to use the device and the issues to which attention should be paid during the use of the device and focused on the skill-steps that should gradually be performed about MDI use.
214665348|NCT03252782|DEVICE|Herbst Appliance|Acrylic Splint Herbst Appliance
214665349|NCT03252782|DEVICE|Distal Jet Appliance|Anterior Median Palate Implant Borne Distal Jet Appliance
214665350|NCT00343902|DRUG|Crataegus Special Extract WS 1442|
214665351|NCT04460430|DRUG|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
214665352|NCT03571464|DEVICE|GGRO Mobile App|"GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards)."
214665353|NCT06487156|DRUG|Nivolumab + ipilimumab|As per product label
214665354|NCT00674531|PROCEDURE|Artery resection|Artery resection
214862089|NCT00566007|PROCEDURE|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
214862090|NCT00566007|DRUG|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
214665355|NCT01225354|DRUG|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
214665356|NCT01091129|DEVICE|miraDry System (treatment with energy)|Treatment with microwave energy delivery device as specified by manufacturer's instructions
214862091|NCT00566007|DRUG|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
214862092|NCT05173675|BEHAVIORAL|Empathy in Action for life with diabetes.|"In Phase 1 (Months 1-6) participants receive (Program):~1. Empathetic communications: A dedicated partner (lightly-trained lay person) who communicates with them via phone with timing and frequency defined by the participant within certain parameters. Two letters mailed during the 6 months that compile anonymized learnings from all participants in the callers panel of 10-20 participants, written as a newsletter to share back with the participant.~2. Material Incentives: One choice of health tool (weight scale or pedometer) selected with the caller in week 1 and expected to be received in weeks 3-5. Two small recognition gifts (valued at US$25) chosen by the caller based on their understanding of the participants preferences, and sent at month 2.5 and 4.5.~3. Educational Materials: Printed DM management educational materials mailed right after enrollment and randomization, and expected to be received in weeks 1-2."
214862093|NCT05173675|BEHAVIORAL|Control Phase 2 Materials Only|"1. Material Incentives:~   a. Choice of health tool (weight scale or pedometer) and 2 health promoting gifts chosen by the caller at the end of their 6 month measurement visit.~   i. Health tool is mailed out within the 7th month ii. Health promoting gifts are mailed out in the 8th and 10th month~2. Educational Materials a. The same educational materials mailed to participants in the intervention arm Program will be mailed to control arm participants after they complete their 6 months visit"
214862094|NCT02140411|DRUG|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
214862095|NCT00002444|DRUG|Nitazoxanide|
214862096|NCT02369991|PROCEDURE|Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique
214862097|NCT03749486|PROCEDURE|Cataract surgery|Cataract surgery will be done following ArcScan measurement
214862098|NCT04709367|OTHER|3D optical scan|The clinical protocol consisted of four test sessions in four different days for an overall duration of 3 weeks. During the 1st session, amputees' residual limb volume was measured 7 times at intervals of 10 minutes after the prosthesis removal. During the subsequent sessions, the residual limb volume was measured immediately after the prosthesis doffing and after the amputee's stabilization time, before and after 15-min of walking on a treadmill, both in the morning and in the afternoon.
214862099|NCT01016886|DRUG|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
214862100|NCT03584724|DRUG|Norflo Oro|Norflo Oro is highly bioavailable curcumin complexed into phytosomes
214862101|NCT03584724|DRUG|Placebo for Norflo Oro|Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
214862102|NCT06284603|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session includes exposure of 60 minutes to 100% oxygen at 2.5 atmosphere absolute (ATA), with 5-minute air breaks every 20 minutes
214862103|NCT03981419|BIOLOGICAL|GRF6021|for IV infusion
214862104|NCT03981419|OTHER|Placebo|for IV infusion
214862105|NCT00985179|BEHAVIORAL|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
214862106|NCT03562559|OTHER|Measurements Using Ultrasound|Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
214862107|NCT02337959|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
214862108|NCT01330459|DRUG|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
214862109|NCT01330459|DRUG|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
214862110|NCT01330459|DRUG|Ibuprofen|800 mg oral ibuprofen
214862111|NCT01330459|DRUG|Lorazepam|2 mg oral lorazepam
214862112|NCT01330459|DRUG|Lidocaine|20 ml 1% buffered lidocaine, injected
214862113|NCT00895947|DRUG|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
214862114|NCT00895947|OTHER|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
214862115|NCT01231399|DRUG|fluorouracil|Given IV
214862116|NCT01231399|DRUG|leucovorin calcium|Given IV
214862117|NCT01231399|DRUG|oxaliplatin|Given IV
214862118|NCT01231399|DRUG|everolimus|Given orally
214862119|NCT01231399|OTHER|laboratory biomarker analysis|Correlative studies
214862120|NCT01231399|OTHER|immunohistochemistry staining method|Correlative studies
214862121|NCT01231399|GENETIC|microarray analysis|Correlative studies
214862122|NCT00760851|OTHER|probiotic strain Bb-12|10\^9 CFU Bb-12 per 4 oz yogurt
214862123|NCT00760851|OTHER|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
214290638|NCT05634460|DRUG|potassium hydroxide|Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
214862124|NCT00192244|BIOLOGICAL|CAIV-T, Liquid|
214862125|NCT01531829|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
214665357|NCT00356915|DRUG|Itraconazole 100mg capsules|Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
214665358|NCT00356915|DRUG|Itraconazole 200mg tablets|Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
214862126|NCT01531829|DRUG|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
215033696|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
214862127|NCT02001220|PROCEDURE|Once daily screening|"In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.~The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre."
214862128|NCT02001220|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
214862129|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+virtual reality+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.frequency:Stimulation perform for 30 minutes per day for 4 weeks .~duration 600 pulses (intratrain pulse) frequency =20 Hz ; Pulse duration =0.3ms ,lasting 30 seconds each time ,stimulating once every 5 minutes"
214862130|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.Stimulation perform for 30 minutes per day for 4 weeks .~Routine physical therapy Stretching Areas :upper chest ,neck flexors ,shoulder flexor and adductors ,elbow and wrist flexors 10 minute per session,and stretches will held for 10s -30swith four repetition of each.30 minutes per day for 4 weeks Upper extremity Proprioception ,coordination,speed and agility increase such as followReach and grasp Handle turning simulated eating task Inserting object Opening bottle strenghtening exercise Muscles biceps brachii brachialis Coracobrachialis triceps brachii wrist extensors 10 minute per session for 4 weeks"
214862131|NCT05637619|DEVICE|Monolithic Zirconia|Maxillary or/and mandibular screw retained zirconia monolithic prostheses supported by at least 4 implants
214862132|NCT05637619|DEVICE|Hybrid-Acrylic|Maxillary or/and mandibular screw retained hybrid prostheses supported by at least 4 implants;
214862133|NCT05637619|BEHAVIORAL|Dentate Patients|Dentate Patients with natural dentition or tooth supported crowns
214862134|NCT00173550|PROCEDURE|Hysterectomy and Bilateral salpingo-oophorectomy|
214862135|NCT05934955|DRUG|BI 1839100|BI 1839100
214862136|NCT05934955|DRUG|Placebo matching BI 1839100|Placebo matching BI 1839100
214862137|NCT03494335|OTHER|Online surveys|The investigators are recruiting health care providers for these surveys that are involved in or use imaging.
214862138|NCT05472662|DRUG|Placebo 152a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
214862139|NCT05472662|DRUG|Placebo 134a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant
214862140|NCT04620135|DRUG|Netarsudil ophthalmic solution 0.02%|Topical sterile ophthalmic solution Other Name: Rhopressa®
214862141|NCT04620135|DRUG|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|Other Name: Glanatec®
214862142|NCT02452983|DRUG|Sertraline|
214862143|NCT02452983|PROCEDURE|Bone Marrow Aspirate/Biopsy|
214862144|NCT00835965|DRUG|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
214862145|NCT00835965|DRUG|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
214862146|NCT00835965|DRUG|Placebo Dexamethasone|
214290639|NCT05678309|OTHER|Blood samples|"At inclusion :~* 52.5 ml of blood :~* 24 ml plasma~* 20 ml serum~* 6 ml DNA~* 2.5 ml RNA"
214665359|NCT00356915|DRUG|Placebo tablets|Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
214862147|NCT02343783|OTHER|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
214862148|NCT05669183|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is mainly used for circulatory support in patients with severe cardiopulmonary failure. VA ECMO drains the blood from the venous system followed pumping the blood back into the arterial vascular compartment after oxygenation. It can be divided into two cannulation strategies for VA ECMO support, namely peripheral VA ECMO and central VA ECMO based on the arterial cannulation site. Peripheral VA ECMO is established via the femoral artery (FA), whereas axillary artery (AX) is an arterial cannulation site in central VA-ECMO.
214862149|NCT04934449|DEVICE|Occlusal splint|Using occlusal splints during sleep for 2 months
214862150|NCT03267875|PROCEDURE|Blood Test|draw out 2 blood tubes from a patient
214862151|NCT00390130|DRUG|Pentacel (DPTaP+Hib)|
214862152|NCT00390130|DRUG|Prevnar (conjugated pneumococcal vaccine)|
214862153|NCT01805830|DRUG|MP513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
214862154|NCT01805830|DRUG|Placebo|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
214862155|NCT04146506|OTHER|Muscle stretching exercises|Muscle stretching exercises consisting of static stretching exercises of the knee flexors
214862156|NCT04988152|BIOLOGICAL|sotrovimab|sotrovimab IV infusion, single dose
214862157|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
214862158|NCT04988152|BIOLOGICAL|sotrovimab|Sotrovimab IM injection, single dose
214862159|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
214862160|NCT06458842|DRUG|Ketamine|
214862161|NCT06458842|OTHER|Placebo|
214862162|NCT02005887|DRUG|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
214862163|NCT02005887|DRUG|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
214862164|NCT02005887|DRUG|letrozole|Letrozole 2.5 mg orally every day for 6 cycles
214862165|NCT04746300|PROCEDURE|Biopsy|A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing
214862166|NCT04746300|PROCEDURE|Blood sample|Blood samples will be taken for additional translational research
214862167|NCT02705404|GENETIC|Multifocal Tissue Banking|
214862168|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire at inclusion in registry
214862169|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
214862170|NCT00000476|DRUG|digitalis|
214862171|NCT01550744|DRUG|Ustekinumab 45 mg|Form = Injection, route = subcutaneous
214862172|NCT01550744|DRUG|Ustekinumab 90 mg|Form = Injection, route = subcutaneous
214862173|NCT01550744|DRUG|Placebo|Form = Injection, route = subcutaneous
214862174|NCT01457261|DRUG|Salbutamol|Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
214862175|NCT01534923|BEHAVIORAL|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
214862176|NCT01660334|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
214862177|NCT05376852|COMBINATION_PRODUCT|based decitabine and olverembatinib（HQP1351)chemotherapy|"AP-CML treated with decitabine 10mg/m2 d1-5 intravenously (IV) over 60 minutes on days 1-5 and HQP1351 40mg qod every 28 days.After completion of HQP1351 lead-in, patients will receive HQP1351 PO qod on days 1-28 of subsequent cycles.~BC-CML:treated with decitabine 20mg/m2 d1-5 IV on days 1-5 and HQP1351 40mg qod every 28 days,with or without other chemotherapy Drugs"
214862178|NCT04184661|OTHER|blood sample|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
214862179|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
214862180|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
214862181|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
214862182|NCT00311311|DRUG|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
214862183|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
214862184|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
214862185|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
214862186|NCT01957228|PROCEDURE|bone biopsies|
214862187|NCT00344851|DRUG|metformin, exenatide or combined (metformin & exenatide )|
214862188|NCT01610453|PROCEDURE|ultrasound examination|transabdominal and transperineal ultrasound examinations
214862189|NCT00264368|DRUG|intravenous (IV) ganciclovir|
214862190|NCT04872972|OTHER|Simulation based learning|Faculty development courses on simulation based learning
214862191|NCT02440113|DEVICE|Nellix|Nellix Implantation
214862192|NCT04153383|DRUG|Milrinone Injection|giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV
214862193|NCT00080405|DRUG|Bortezomib|
214862194|NCT03214874|DRUG|Demadex 20mg Tablet|Immediate Release (IR) Torsemide
214862195|NCT03214874|DRUG|ER Torsemide 20mg Tablet|Extended Release Torsemide 20 mg tablet given once daily
214862196|NCT02996760|DRUG|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
214862197|NCT00988065|DRUG|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
214862198|NCT00988065|DRUG|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
214862199|NCT00988065|DRUG|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
214862200|NCT00988065|DRUG|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
214862201|NCT01475058|BIOLOGICAL|allogeneic cytomegalovirus-specific cytotoxic T lymphocytes|Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV
214862202|NCT06303973|DEVICE|IOE|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214862203|NCT06303973|DEVICE|PNG|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214862204|NCT05438498|DRUG|Evusheld (tixagevimab+cilgavimab) IM or IV|Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
214862205|NCT05142098|DRUG|Dexamethasone|Intramuscular
214862206|NCT05142098|DRUG|Etoricoxib 60 mg|Orally
214862207|NCT04890951|PROCEDURE|Hysteropexy|Uterine preservation through suspension
214862208|NCT04890951|PROCEDURE|Hysterectomy and vaginal vault suspension|Uterine removal and sewing the vagina upwards
214862209|NCT01229735|DRUG|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
214862210|NCT01229735|DRUG|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
214862211|NCT02685202|DEVICE|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
214862212|NCT05286723|OTHER|Multicomponent Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
214665360|NCT01627704|DRUG|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
214862213|NCT03241381|DIAGNOSTIC_TEST|vitamin D serum assay study and control groups|Serum- vitamin D assay
214862214|NCT03241381|DIAGNOSTIC_TEST|Photometry|Serum- Hemoglobin assay
214862215|NCT03241381|OTHER|Russels periodontal index|Clinical examination for periodontitis
214862216|NCT02747862|OTHER|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP \[i.e. identifiable APC mutation\], and/or a compatible family history or personal adenoma burden of \> 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
214862217|NCT03956836|DIAGNOSTIC_TEST|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC
214862218|NCT05816369|OTHER|Taste session of five ONS flavors|Patients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).
215033697|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
214665361|NCT05152212|BIOLOGICAL|LVGN7409|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
214862219|NCT00968292|DEVICE|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
214862220|NCT00520286|DRUG|Modafinil|200 mg or 400 mg /daily
214862221|NCT00520286|DRUG|Placebo|Placebo / daily
214862222|NCT03880916|DRUG|Duloxetine|"1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
214862223|NCT03880916|DRUG|Placebo|Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
214862224|NCT06484634|DRUG|Low molecular weight heparin|A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
214862225|NCT03752463|DRUG|DAOI-A group|DAOI with A dose
214862226|NCT03752463|DRUG|DAOI-B group|DAOI with B dose
214862227|NCT03752463|DRUG|DAOI-C group|DAOI with C dose
214862228|NCT03752463|DRUG|Placebo oral capsule|Placebo
214862229|NCT05711836|GENETIC|HLA-genotyping|HLA genotyping in DNA samples from peripheral blood of patients and controls
214862230|NCT04997941|DRUG|Tamoxifen Oral Product|Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
214862231|NCT04997941|DIAGNOSTIC_TEST|Assessment of Ki-67|Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
214862232|NCT04997941|PROCEDURE|Surgery|The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
214862233|NCT01878162|OTHER|Exercise|
214862234|NCT03203486|OTHER|Mediterranean Diet|Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
214862235|NCT04412148|DRUG|Triamcinolone Acetonide|intralesional injection of triamcinolone acetonide every 2 weeks for 6 sessions
214862236|NCT04412148|OTHER|saline|intralesional injection of saline
214862237|NCT00227786|BEHAVIORAL|smoking cessation intervention|
214862238|NCT00227786|OTHER|counseling intervention|
214862239|NCT02109510|DRUG|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
214665362|NCT00509106|DRUG|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
214862240|NCT02109510|DRUG|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
214862241|NCT02109510|PROCEDURE|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
214862242|NCT00128414|DRUG|Colchicine (for 6 months)|colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.
214862243|NCT00128414|DRUG|Placebo|Tablets identical in colour, shape, and taste were provided in blister packs.
214862244|NCT03080415|DRUG|Combined Therapy SOF and DCV|"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"
214862245|NCT01484613|DEVICE|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
214862246|NCT03275818|DRUG|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
214862247|NCT01715064|BEHAVIORAL|Exercise|1 hour of moderate-intensity exercise
214862248|NCT00856219|DIETARY_SUPPLEMENT|Enteral Continuous|Continuous Tube Feeding for 72 hours
214862249|NCT00856219|DIETARY_SUPPLEMENT|Enteral Intermittent|Intermittent Tube Feedings
214862250|NCT00856219|DIETARY_SUPPLEMENT|Parenteral Continuous|Parenteral Continuously for 72 hours
214862251|NCT00005595|DRUG|arsenic trioxide|
214862252|NCT03108092|OTHER|STRIP intervention|The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up
214862253|NCT03108092|OTHER|Control|Standard care in the department where the trial is conducted
214862254|NCT00725751|BIOLOGICAL|Pegylated interferon alfa-2b (PegIFN-2b)|PegIFN-2b administered according to European labeling.
214862255|NCT00725751|DRUG|Ribavirin|Ribavirin administered according to European labeling.
214862256|NCT02570516|PROCEDURE|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
214862257|NCT01167959|PROCEDURE|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
214862258|NCT01167959|BEHAVIORAL|Prodimed dietary intervention|3 months of using the prodimed diet
214862259|NCT02041910|BIOLOGICAL|Stem Cells|MSCs injection intratesticular
214862260|NCT02041910|BIOLOGICAL|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
214862261|NCT00195234|BIOLOGICAL|HIV CTL MEP 1000 micrograms, 19 months per subject|
214862262|NCT00069836|DRUG|Rosiglitazone/metformin|
214862263|NCT01379001|DRUG|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
214862264|NCT01379001|DRUG|Placebo|IM or PO placebo
214862265|NCT01379001|DRUG|Donepezil|donepezil 5mg PO x 1
214862266|NCT02987101|PROCEDURE|Liposuction|Adipose tissue is harvested by liposuction from either abdomen or thighs.
214862267|NCT02987101|OTHER|Standard wound care|Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
214862268|NCT02987101|DRUG|Adipose-Derived Regenerative Cells|Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
214862269|NCT04390542|BEHAVIORAL|Psychoeducation|"6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning"
214862270|NCT02400242|DRUG|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
214862271|NCT02400242|DRUG|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
214862272|NCT02400242|DRUG|Dexamethasone|40 mg qd on days 1, 8, 15, 22
214862273|NCT05296538|OTHER|Broad-Minded Affective Coping Intervention|The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.
214862274|NCT05296538|OTHER|Risk Assessment and Signposting|A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
214862275|NCT03544619|OTHER|Neuropathic Pain Symptom Inventory|Investigators will use the Neuropathic Pain Symptom Inventory for assessing neuropathic symptoms
214862276|NCT04422353|OTHER|Video Dance classes|The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
214862277|NCT04422353|OTHER|Unsupervised physical activities|The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
214862278|NCT02787408|DEVICE|EW Tricuspid Transcatheter Repair System|Treatment with the EW Tricuspid Transcatheter Repair System
214862279|NCT00001586|BIOLOGICAL|Rituximab|Rituxan
214862280|NCT00001586|DRUG|Fludarabine phosphate|Fludara
214862281|NCT00001586|OTHER|Leukemic or stroma cells|Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
214862282|NCT04293978|BEHAVIORAL|CalmPlace|Self-contained VR application allowing the user to build and custom a relaxation session, with options to vary session length (9-20 minutes), music/sound, relaxation exercises, and specific nature environment (three available) including time of day and events (e.g. rain). Delivered using an Oculus Go devices in kiosk-mode.
214862283|NCT00364806|DRUG|Prochlorperazine|
214862284|NCT00364806|DRUG|Metoclopramide|
214862285|NCT02289235|DRUG|Ginger|Ginger powder capsule 1000 mg twice daily for 3 months
214862286|NCT02289235|DRUG|Placebo|Placebo powder 2 capsules twice daily for 3 months
214862287|NCT00985712|DRUG|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
214862288|NCT00985712|DRUG|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
214862289|NCT00985712|DEVICE|HumaPen Memoir|subcutaneously, daily for 24 weeks
214862290|NCT00985712|DEVICE|HumaPen Luxura|subcutaneously, daily for 24 weeks
214862291|NCT04819399|DRUG|Catumaxomab|"Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~1. cohort 50 µg~2. cohort 70 µg~3. cohort 100 µg~Part II will be treated at recommended dose"
214862292|NCT00663767|DRUG|Placebo; oral|dose 1, dose 2
214862293|NCT00663767|DRUG|Placebo; oral|dose 1
214862294|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels
214862295|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels; dose 2
214862296|NCT00663767|DRUG|Celecoxib, COX-2 inhibitor; oral|dose 1
214862297|NCT00663767|DRUG|Placebo; oral|dose 2
214862298|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
214862299|NCT01889212|OTHER|11C-erlotinib PET/CT|
214907077|NCT04872686|DRUG|0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient|"Number of participants 768 COVID-19 positive, moderately ill admitted patient who will receive intervention~Step 1: Enrollment of the study populations by applying inclusion and exclusion criteria Step 2: Randomization to allocate experimental and controlled group by using table of random number Step 3: Application of 0.6% PVP-I spray to experimental group and distilled water to control group Step 4: Follow up (waiting for 2-5 minutes) Step 5: Collection of nasopharyngeal and oropharyngealsawab for RT-PCR test for both group Step 6: Observation of the patients for 30 minutes for possible early adverse effects (if any) and subsequent management (if needed).~Step 7: Analysis data collection, data processing and analysis by using SPSS software."
214862300|NCT04978064|BEHAVIORAL|e-health psychological counselling|"Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application My Plan. The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.~Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study)."
214862301|NCT04056975|BIOLOGICAL|Recombinant Anti-CD19m-CD3 Antibody Injection|Intravenous Infusion
214862302|NCT01131962|PROCEDURE|Endoscopic control of hematemesis|Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
214862303|NCT05329298|DRUG|BPI-361175|Subjects will receive BPI-361175 until disease progression
214862304|NCT00074737|DRUG|cenersen|cenersen with standard of care
214862305|NCT00074737|DRUG|Idarubicin|standard of care for AML
214862306|NCT00074737|DRUG|Cytarabine|standard of care Ara-C and High dose Ara-C
214862307|NCT00015028|DRUG|Buprenorphine/naloxone|
214862308|NCT05315635|OTHER|Questionnaire|"Patients treated for substance use disorders and patients treated for eating disorders will have to complete self-questionnaires and a clinical psychiatric (MINI) at the inclusion.~Patients suffering from substance use disorder will be assessed 3 weeks after inclusion.~Questionnaires are :~* Modified Yale Food Addiction (mYFAS 2.0) and Impulsive Behavior Scale (UPPS-P)~* Trait Meta-Mood Scale (TMMS), Hospital Anxiety and Depression Scale (HADs), Emotional Appetite Questionnaire (EMAQ), Perceived Stress Scale (PSS-10), Multidimensional Assessment of Interoceptive Awareness (MAIA) and Five Facet Mindfulness Questionnaire (FFMQ)~* Mini International Neuropsychiatric Interview (MINI), Eating Disorder Examination-Questionnaire (EDE-Q), Rosenberg's Self Esteem (RSE) and Ruminative Response Scale for Eating disorders (RRS-ED)~* Pittsburgh Sleep Quality Index (PSQI) and Montreal Cognitive Assessment (MoCA)"
214862309|NCT01254682|DEVICE|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
214862310|NCT01254682|PROCEDURE|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
214862311|NCT02056470|DEVICE|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
214862312|NCT02056470|DEVICE|Total Knee Replacement|total Knee replacement implant
214862313|NCT02056470|DEVICE|Freedom Total Knee System|Total Knee replacement implant
214862314|NCT04555304|DRUG|KH903 + Paclitaxel|KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
214862315|NCT04555304|DRUG|Placebo + Paclitaxel|Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
214862316|NCT01908790|DEVICE|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
214862317|NCT01908790|DEVICE|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
214862318|NCT00305552|DRUG|THALIDOMIDE|THALIDOMIDE
214862319|NCT04376528|DRUG|Cyclosporin A|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with cyclosporin A)
214862320|NCT04376528|DRUG|Mycophenolate Mofetil|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with mycophenolate mofetil )
214862321|NCT04712149|DEVICE|Weekly digital follow up|weekly digital follow-up by sending a questionnaire to patients and sending alerts based on the questionnaire to the care team
214862322|NCT05086718|OTHER|Endoscopic ear surgery|Endoscopic approach without posterior meatal flap elevation will be employed in the ear with dry chronic suppurative otitis media. Tympanoplasty utilizing composite cartilage-fascia graft will be performed. After three months of time period successful outcome will be taken as closure of air bone gap on pure tone audiometry.
214862323|NCT00000813|BIOLOGICAL|ALVAC-HIV gp160MN (vCP125)|
214862324|NCT00000813|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
214862325|NCT00000813|BIOLOGICAL|rgp120/HIV-1 SF-2|
214862326|NCT03560921|DIAGNOSTIC_TEST|urinary NGAL|measurement urinary NGAL using the ARCHITECT technique
214862327|NCT05702879|DRUG|Ozanimod|Start of standard therapy
214862328|NCT05702879|DRUG|TNF Inhibitor|Start of standard therapy
214862329|NCT05702879|DRUG|Steroids|Start of standard therapy
214862330|NCT05702879|DRUG|Vedolizumab|Start of standard therapy
214862331|NCT05702879|DRUG|Ustekinumab|Start of standard therapy
215033698|NCT03802019|OTHER|LNC Cigarettes + Colored Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.
215033699|NCT03802019|OTHER|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive their own preferred brand of cigarette (i.e., control).
214862332|NCT06237387|OTHER|Periodontal examination|Determining the patient's oral hygiene status and the severity of gingivitis. For this purpose, the non-invasive Löe-Silness plaque and gingival index system will be used.
214862333|NCT04277871|BEHAVIORAL|Pelvic floor muscles training (PFMT) combined with yoga|All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
214862334|NCT06041841|DRUG|LB54640|LB54640 QD Oral
214862335|NCT02581007|DRUG|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
214862336|NCT02581007|DRUG|Melphalan|
214862337|NCT02581007|DRUG|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
214862338|NCT02581007|PROCEDURE|peripheral blood stem cell transplant|
214862339|NCT04781036|DRUG|4%Chlorhexidine|4%Chlorhexidine was given to participants with foot odor for 2 weeks
214862340|NCT06922409|DEVICE|Naturalistic Light Intervention|Naturalistic light as an Intervention A 24-hour naturalistic lighting scheme is implemented in all areas and rooms in the unit at Rigshospitalet Glostrup with a computer-controlled lighting scheme (ChromaViso, Denmark). The naturalistic lighting scheme is constantly running. The lighting imitate the sunlight rhythm following the principles of Lucas et al.
214862341|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
214862342|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
214862343|NCT04560465|DRUG|Tranexamic acid|intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
214862344|NCT04999930|DEVICE|Aerochamber|efficacy and patients satisfaction
214862345|NCT00530686|DRUG|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
214862346|NCT04800341|OTHER|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
214862347|NCT00653484|BEHAVIORAL|Physical Activity|
214862348|NCT00653484|BEHAVIORAL|Energy Restriction|
214862349|NCT00653484|BEHAVIORAL|Physical Activity and Energy Restriction|
214862350|NCT02540317|BEHAVIORAL|Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
214862351|NCT03323723|DEVICE|SUI Device|Pessary SUI device
214862352|NCT04131049|OTHER|High GI calculated by CC (CHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
214862353|NCT04131049|OTHER|Low GI calculated by CC (CLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
214862354|NCT04131049|OTHER|High GI calculated by FII (FHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
214862355|NCT04131049|OTHER|Low GI calculated by FII (FLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
214862356|NCT03335579|COMBINATION_PRODUCT|inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil|Different combination of opioids and anesthetics
214862357|NCT03415984|DIAGNOSTIC_TEST|Color retinography|Color retinography
214862358|NCT03415984|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography
214862359|NCT03415984|DIAGNOSTIC_TEST|Fundus autofluorescence imaging|Fundus autofluorescence imaging
214862360|NCT02021370|DRUG|BAY85-3934|25mg Tablet
214862361|NCT02021370|DRUG|Placebo|Matching placebo tablet
214862362|NCT05192759|DEVICE|Transcranial Magnetic Stimulation|The stimulations were performed by MagStim Rapid2.
214862363|NCT02167542|DEVICE|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2\>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
214290640|NCT05678309|OTHER|skin swab sample|At inclusion a skin swab sample will be collected
214290641|NCT05678309|OTHER|skin biopsy sample|At inclusion a skin biopsy sample will be collected
214862364|NCT02167542|DEVICE|CPAP valve (Boussignac)|"Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2\>92%."
214862365|NCT03325400|OTHER|Toothpaste non-fluoride and fluoride|"Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation."
214862366|NCT03458637|BEHAVIORAL|LITE Program and Usual Care|Family based lifestyle Intervention
214862367|NCT03458637|BEHAVIORAL|Usual Care|Usual care consisting of 3 visits to weight management clinic
214862368|NCT00109759|BIOLOGICAL|RagweedMATAMPL|
214862369|NCT00109759|DRUG|Placebo|
214862370|NCT01427842|DRUG|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
214862371|NCT01092078|BEHAVIORAL|MINT|Motivational interviewing for lifestyle changes associated with treating hypertension
214862372|NCT01092078|BEHAVIORAL|Patient Navigation|Patient navigation for colonoscopy.
214862373|NCT04515537|DIETARY_SUPPLEMENT|Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),|Patient use 2 capsules 3 time a day by oral.
214862374|NCT04515537|PROCEDURE|Infiltrtion of SVf|After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF
214862375|NCT01589861|DRUG|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
214862376|NCT02182128|DRUG|BIBF 1120|
214862377|NCT00223353|OTHER|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
214862378|NCT00963079|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
214862379|NCT00963079|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
214862380|NCT06264791|OTHER|Stress|To manipulate stress, we follow the personalized imagery script procedure developed by Sinha and colleagues. Participants randomly assigned to the stress condition will be interviewed about one week prior to the lab session. They will share a detailed description of a stressful event from their life (last 12 months) with the interviewer. Based on this interview, the experimenter will write a script (\~500 words), that will then be audiotaped. Participants will listen to this personalized audiotape during the experiment, and will be asked to imagine this event as vividly as possible. Participants randomly assigned to the no stress condition will listen to a generic audiotape that describes a non-stressful event (\~500 words). They will not be interviewed. During the lab session, participants will first complete a 3-min color counting task. The participant will then listen to the audiotape (personalized stressful audiotape in stress condition, generic non-stressful audiotape in no stress c
214862381|NCT06264791|OTHER|Alcohol|Intoxication: Participants randomly assigned to the alcohol condition will be administered 100-proof Vodka mixed with orange juice (1:3 ratio) to induce a BAC of .06% (based on Widmark's formula). They will be breathalyzed every 5 minutes until they reach peak BAC, at which point they will continue with the experiment. Participants randomly assigned to the no alcohol condition will be administered water mixed with orange juice (1:3 ratio). Each participant in the no alcohol condition will be yoked to a participant in the alcohol condition and will complete the same number of breath tests. Once participants in the alcohol condition reach peak BAC and participants in the no alcohol condition performed the same number of breath tests as the participant they are yoked to, participants will continue to the stress induction.
214862382|NCT05260164|DEVICE|HIFEM+RF|Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
214862383|NCT00157859|DRUG|Chloroquine and sulphadoxine-pyrimethamine|
214862384|NCT04887233|OTHER|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
214862385|NCT04887233|OTHER|Placebo|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
214862386|NCT04622397|DRUG|Tranexamic acid injection|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
214862387|NCT04622397|DRUG|Saline|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
214862388|NCT03123861|DRUG|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
214862389|NCT03123861|DRUG|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
214862390|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with the implementation of modified ERAS program|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1\) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Low-pressure pneumoperitoneum (8-9 mmHg)~2. Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~3. PONV prophylaxis in patients of risk~Postoperative care~1. Early mobilization (2 h after surgery)~2. Early fluid intake (2 h after surgery)~3. Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
214862391|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with standard perioperative treatment|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1\) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Standard CO2 pressure (12-14 mmHg)~2. No additional anesthesia~Postoperative care~1. Mobilization in 4-6 h after surgery~2. Fluid intake in 6 hours~3. Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
214862392|NCT02527928|OTHER|None intervention|
214862393|NCT05600881|DRUG|Methylphenidate|Participants will take their regular medication or a placebo (vitamin C)
214862394|NCT00000824|DRUG|Lymphocytes, Activated|
214862395|NCT01921491|PROCEDURE|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
214862396|NCT01921491|DEVICE|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
214862397|NCT02196740|DRUG|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
214290642|NCT05678309|OTHER|Questionnaires|At inclusion, at 6 months and every year, the patient will respond to 5 questionnaires : Brest questionnaire, 5-D itch scale, Dermatology Life Quality Index, Itchy Quality of Life and Hospital Anxiety and Depression Scale
214290643|NCT04176978|DRUG|Rosuvastatin|Patient in this group will receive Rosuvastatin 20mg daily.
214862398|NCT02196740|DRUG|creosote|Pulp removal,Root canal irrigation and disinfection
214862399|NCT05134194|DRUG|Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
214862400|NCT05134194|DRUG|Capecitabine/eribulin/gemcitabine/vinorelbine|Capecitabine or eribulin or gemcitabine or vinorelbine
214862401|NCT02206620|DRUG|Donepezil|
214862402|NCT02575274|PROCEDURE|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
214862403|NCT02040311|DRUG|Topiramate 96 mg daily|
214862404|NCT02040311|DRUG|Topiramate 192 mg daily|
214862405|NCT02040311|DRUG|Placebo|
214862406|NCT01551147|DRUG|ONO-6950|200 mg QD for 8 days
214862407|NCT01551147|DRUG|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
214862408|NCT01551147|DRUG|Montelukast|10 mg Montelukast QD for 8 days
214862409|NCT05960474|OTHER|Outcomes for Patients with CMD|Our objective is to perform a retrospective/prospective descriptive study on the short term to longterm (up to 5 years of follow-up) outcomes of patients with coronary microvascular disease diagnosis invasively
214862410|NCT04333381|OTHER|Educational and organizational intervention|"Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~1. The educational intervention will consist:~   Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~2. The organizational intervention will consist:~   * Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~  * Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~  * Review organizational strategies and definition of new improvement measures~  * Audit the delays in STEMI~  * Periodic multi-disciplinary update sessions"
214862411|NCT04333381|OTHER|Common Practice|Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
214862412|NCT02286219|DRUG|FS102|Experimental
214862413|NCT02992626|OTHER|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
214862414|NCT02992626|OTHER|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
214862415|NCT01346774|DRUG|Cranberry powder capsules|2 cranberry powder capsules twice a day
214862416|NCT01346774|DRUG|Placebo powder capsules|2 placebo capsules twice a day
214862417|NCT05031247|OTHER|Wellbeing Program|The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
214862418|NCT05445726|DEVICE|CPM Device|CPM device used in tangent with reference ECG for validation
214862419|NCT05010044|BEHAVIORAL|mindfulness-based cognitive therapy (MBCT)|Mindfulness- Based Cognitive Therapy (MBCT) It involves practicing to be present 'in the moment' and an attitude of non- judgmental acceptance with the aim to maintain awareness, disengaging oneself from strong attachment and thereby developing a greater sense of emotional balance and well-being.
214862420|NCT05010044|OTHER|Antipsoriatic treatment|The routine drug therapy for psoriasis.
214862421|NCT01713231|DIETARY_SUPPLEMENT|standard-dose vitamin D (400IU per day)|
214862422|NCT01713231|DIETARY_SUPPLEMENT|high-dose vitamin D (2000 IU per day)|
214862423|NCT05282979|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
214862424|NCT02170948|DRUG|Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
214862425|NCT05266820|DRUG|Thalidomide|For the experimental group, the intervention was thalidomide（100mg PO Bid)
214862426|NCT05266820|DRUG|TAS-102|TAS-102
214862427|NCT01949948|DRUG|Tenecteplase|0.4 mg/kg single bolus intravenously
214862428|NCT01949948|DRUG|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
214862429|NCT03580122|DRUG|Arginine Aspartate|Asparten
214862430|NCT01197430|OTHER|exercise training|
214290644|NCT04176978|OTHER|Treat-to-target strategy|Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
214290645|NCT04044716|DEVICE|Auricular acupressure|Trained nurses in auricular acupressure will place acupressure beads on 5 acupoints on each ear (cingulate gyrus, thalamus, omega-2, point zero, and Shen Men). The nurse will do the initial activation of the acupressure site by applying pressure for 30 seconds to each point until the participant reports tingling or moderate degree of pressure. Participant will be given instructions to do this three times a day for a total of 5 days. Acupoints were selected based on recommendation of faculty acupuncturist.
214862431|NCT01435226|DRUG|GS-5885|"Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD"
214862432|NCT01435226|DRUG|GS-9451|"Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD"
214862433|NCT01435226|DRUG|tegobuvir|tegobuvir 30 mg BID
214862434|NCT01435226|DRUG|placebo to match tegobuvir|tegobuvir placebo BID
214862435|NCT01435226|DRUG|placebo to match RBV|Ribovirin placebo BID
214862436|NCT01435226|DRUG|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
214862437|NCT00093002|DRUG|Fulvestrant|250 mg \& 500 mg intramuscular injection
214862438|NCT03282149|BIOLOGICAL|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
214862439|NCT00502801|DRUG|doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
214862440|NCT03095573|DEVICE|Lateral-viewing CapsoCam device|Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
214862441|NCT03095573|DEVICE|Axial-viewing capsule|Small bowel capsule endoscopy examination with the Axial-viewing capsule device
214862442|NCT01506544|DRUG|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
214862443|NCT00561314|OTHER|questionnaire administration|
214862444|NCT00561314|PROCEDURE|biopsy|
214862445|NCT00561314|PROCEDURE|high-intensity focused ultrasound ablation|
214862446|NCT00561314|PROCEDURE|magnetic resonance imaging|
214862447|NCT00561314|PROCEDURE|quality-of-life assessment|
214290646|NCT04044716|OTHER|Standard of care pain management|The participant post-operative pain will be managed following the standard protocol by the treating physician.
214862448|NCT01565616|DRUG|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV"
214862449|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
214862450|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
214862451|NCT00759720|DRUG|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
214862452|NCT05886439|DRUG|LK101 injection (personlized neoantigen pulsed DC vaccine )|LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.
214862453|NCT05886439|DRUG|Pembrolizumab|Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.
214862454|NCT05886439|DRUG|Durvalumab|Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
214862455|NCT04691050|PROCEDURE|OrthoMTA (BioMTA)|Primary second molars without successors in which traditional root canal treatment with gutta-percha could not be performed was treated with OrthoMTA
214862456|NCT02243839|DRUG|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
214290647|NCT02389010|BIOLOGICAL|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
214290648|NCT02389010|OTHER|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
214665363|NCT00509106|DRUG|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
214862457|NCT02243839|PROCEDURE|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
214862458|NCT00145639|DRUG|Ifosfamide, Carboplatin, Doxorubicin|See Detailed Description for treatment plan.
214862459|NCT00145639|PROCEDURE|Limb Sparing|See Detailed Description for treatment plan.
214862460|NCT04705870|DEVICE|cerebral MRI|"MRI of routine care in the context of MS includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~* SWI EPI 0.6 iso (7 minutes)~The sequences added by the search are:~* SWI non EPI QSM 6 echo (10 minutes)~* SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)~* SWI EPI to TR equivalent to SWI non EPI (6 minutes)"
214862461|NCT06415617|OTHER|Psychoeducation|"The content of psychoeducation is based on Five Ways of Well-being which covers Be active, Connect, Take Notice, Keep learning and Giving . The participants will be engaged in psychoeducation through group discussion, individualised goal setting and reflective exercises."
214862462|NCT06415617|OTHER|Attention control|The content of the sessions mainly focuses on physical health information, such as healthy eating, physical exercise, prevention of falls, and pain management.
214862463|NCT05246033|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
214862464|NCT05246033|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
214862465|NCT02116699|OTHER|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
214862466|NCT02116699|OTHER|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
214862467|NCT02031016|DRUG|Fentanyl|"fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
214862468|NCT02031016|DRUG|Remifentanil|starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
214862469|NCT02031016|DRUG|Fentanyl|fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
214862470|NCT05241717|BEHAVIORAL|Web-based Management of Adolescent Pain (WebMAP)|Participants will be asked to complete one module per week, which are approximately 20 minutes in length. Survivors and parents will be asked to spend approximately 4.5 hours each over the course of the intervention on WebMAP including 4 hours to complete the modules and 30 minutes total corresponding with a coach. Each week, patients log into WebMAP to learn a new skill and practice that skill for 1 week to allow time for skills acquisition. WebMAP consists of two separate, password-protected programs including one for adolescents and one for parents (http://webmap2.com).
214862471|NCT03149458|OTHER|dance|dance program
214862472|NCT03149458|OTHER|control|upper limb rehabilitation
214862473|NCT01154959|DRUG|Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol|Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
214862474|NCT05042934|PROCEDURE|Fine-Needle Aspiration|Undergo fine-needle aspiration
214862475|NCT05042934|DRUG|Irinotecan|Given IV
214862476|NCT05042934|DRUG|Irinotecan Hydrochloride|Given IV
214862477|NCT05042934|DRUG|Lurbinectedin|Given IV
214862478|NCT00161798|BIOLOGICAL|Tick-borne encephalitis vaccine|
214862479|NCT03813693|OTHER|towels impregnated with 2% chlorhexidine gluconate|"The first TICHG should be used on the neck, chest and abdomen; The second TICHG should be used on the right upper limb, start at the shoulder; The third TICHG was intended for the upper left limb; The fourth TICHG should be used on the neck and chest; The fifth TICHG was for the right lower limb; The sixth TICHG should be used on the lower left limb.~2\) Time of application: use six TICHGs the night before surgery and the six remaining on the morning of surgery.~3\) After the hygiene of each member, discard the TICHG. After use of TICHG, allow the product to dry on the skin. Do not use bath towels to dry yourself and wear clean clothes."
214862480|NCT03813693|OTHER|chlorhexidine gluconate 2% liquid|Spread the product on the skin during the bath and massage for 3 minutes, so that it is distributed equally to all parts of the body (except the face, hair and intimate area). Then rinse with water and dry with a clean, dry towel, and wear clean clothes.
214862481|NCT02055443|OTHER|12-lead holter monitor application|"\-- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.~* The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.~* After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan."
214862482|NCT01733147|DRUG|Omega-3 polyunsaturated fatty acids|3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
214862483|NCT01733147|DRUG|Placebo|3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
214862484|NCT03359824|OTHER|Exercise|
214862485|NCT04586153|DRUG|Meplazumab for Injection|humanized antibody target CD147
214862486|NCT04586153|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
214862487|NCT04320979|RADIATION|internal mammary nodal irradiation|chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
214862488|NCT04320979|RADIATION|no internal mammary nodal irradiation|chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
214862489|NCT03212521|DRUG|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
214862490|NCT02505490|OTHER|Television|The purpose is to determine whether television impacts liking of food.
214862491|NCT02505490|OTHER|No Television|The purpose is to determine whether the lack of television impacts liking of food.
214862492|NCT01401049|DRUG|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
214862493|NCT01401049|DRUG|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
214862494|NCT03082664|DEVICE|PICO Single Use Negative Pressure Wound Therapy|The PICO device will be placed over the closed cesarean section incision.
214862495|NCT00554775|DRUG|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
214862496|NCT00554775|DRUG|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
214862497|NCT03054259|DRUG|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
214862498|NCT03054259|DRUG|Methylprednisolone|100mg infusion on days 1 and 15
214862499|NCT03054259|DRUG|Normal Saline|250ml infusion on days 1 and 15
214862500|NCT00222352|DIAGNOSTIC_TEST|Point of Care cTnL testing|"The study design will be a phase IV prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. The experimental group of interest will be patients receiving the POC cTnI test, and the control group will be patients receiving the central laboratory cTnI test.~The treating physician will be blinded to the randomization and will receive only the POC results from half the study patients and only the laboratory results for the remaining half."
214862501|NCT01668693|OTHER|ERA (Endometrial Receptivity Array)|"The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction."
214862502|NCT01668693|OTHER|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
214862503|NCT01668693|OTHER|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
214862504|NCT03597360|RADIATION|CT scan|Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
214862505|NCT00906984|DEVICE|TheraSphere|Given IV
214862506|NCT05862194|DRUG|Lazertinib|Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
214862507|NCT05862194|DRUG|Platinum-based Chemotherapy|Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
214862508|NCT03499002|OTHER|Simulated Learning Environment|Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
214862509|NCT04294420|BEHAVIORAL|Patient education program|The education program provides information and guidance concerning aetiology, diagnostics and treatment of pain-predominant functional gastrointestinal disorders. The patient education program will be provided in a group setting and the children will participate along with one of their parents. The participants (n=20) will be divided into two groups consisting of ten child-parent pairs. Two lectures will be held, two weeks apart, two hours per lecture. Represented teachers are physician, psychologist and dietician.
214862510|NCT06440187|DRUG|Gemcitabine+ nivolumab|Gemcitabine+ nivolumab q 2wks
214862511|NCT03772431|OTHER|Female Voice|The survey was narrated by a female voice
214862512|NCT03772431|OTHER|Motivational Introduction|The survey introduction was worded to include motivational content
214862513|NCT03772431|OTHER|Male Voice|The survey was narrated by a male voice
214862514|NCT03772431|OTHER|Informational Introduction|The survey introduction was worded to include informational content
214862515|NCT01349582|PROCEDURE|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
214290649|NCT01645696|DEVICE|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
214862516|NCT01349582|OTHER|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
214862517|NCT01349582|PROCEDURE|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
214862518|NCT01349582|PROCEDURE|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
214862519|NCT01349582|PROCEDURE|surgical clipping|clipping of the aneurysm following invasive brain surgery
214862520|NCT05985733|OTHER|Biochemical analysis|Oxidative stress and inflammation markers were analyzed in serum and saliva of TMD and healthy subjects.
214862521|NCT05370755|DRUG|ICP-189|Administered orally
214862522|NCT03356574|PROCEDURE|Single-ventricle palliation surgery|Single-ventricle palliation surgery
214290650|NCT01645696|DEVICE|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
214290651|NCT01645696|DEVICE|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
214862523|NCT03274674|OTHER|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
214862524|NCT02441582|OTHER|Telemetry|
214862525|NCT02441582|OTHER|Non-telemetry|
214862526|NCT04516512|BIOLOGICAL|Blood draw|For each participants to the research a peripherical blood draw will be performed
214290652|NCT04386980|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
214290653|NCT04386980|DRUG|Placebo|Diluent in normal saline
214862527|NCT00191633|DRUG|Atomoxetine|
214862528|NCT01602965|PROCEDURE|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
214862529|NCT01602965|PROCEDURE|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
214862530|NCT04476966|DRUG|Bladogra|1 tablet contains 25 mg Mirabegron
214290654|NCT02916342|PROCEDURE|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
214290655|NCT02916342|PROCEDURE|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
214862531|NCT04476966|DRUG|Myrbetriq (first dosing)|1 tablet contains 25 mg Mirabegron
214862532|NCT04476966|DRUG|Myrbetriq (second dosing)|1 tablet contains 25 mg Mirabegron
214862533|NCT05480826|GENETIC|study of the transmission of genetic variants|the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA
214862534|NCT01669473|OTHER|EHR Based Strategy to promote Safe and Appropriate Drug Use|"The printed tools presented in the intervention include:~1. Medication Review: a consolidated list of the medications a patient is currently taking.~2. Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~3. Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen"
214862535|NCT06426173|OTHER|Resistance Training Program|The resistance training program will be individualized and divided into four stages of increasing complexity. It will be conducted for approximately 40 minutes per day, three times a week, for 12 weeks, under supervision. Each patient will begin the program at the stage corresponding to their functional capacity. The resistance load will be set at 50% of the maximum resistance (1RM) obtained in the initial assessment. Throughout all stages of the exercise program, the target intensity will range from light (≤ 12) to moderate (≤ 15) on the Borg scale.
214862536|NCT06426173|OTHER|Standard Treatment Group|Patients will receive the standard treatment provided by the hospital inpatient unit, which includes guidance on reducing sedentary time, encouragement to walk, and performance of active and breathing exercises when necessary.
214862537|NCT01272726|BEHAVIORAL|Education|Education on the genetics of ADHD and treatment options for ADHD
214862538|NCT04226573|OTHER|Preoperative anxiety levels|"Serums were separated from blood samples taken from all patients in the study, Using the anti-human TNF-α and IL-6 enzyme-linked immunosorbent assay (ELISA) kits in the Elisa device, the TNF-α and IL-6 cytokines will be measured to determine their concentration.~No routine blood will be drawn during the procedures. Preoperative anxiety levels will be evaluated with STAI-Continuity and STAI-Statefulness scale."
214862539|NCT02033330|DIETARY_SUPPLEMENT|phenolics form orange peel|
214862540|NCT00004734|DRUG|pyridoxine|
214862541|NCT00004734|DRUG|cyanocobalamin|
214862542|NCT00004734|DRUG|folic acid multivitamin|
214862543|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal renal function.
214862544|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with severe renal impairment.
214862545|NCT00697684|DRUG|Antithymocyte Globulin|
214862546|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
214862547|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
214862548|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
214862549|NCT00712205|DRUG|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
214862550|NCT00712205|DRUG|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
214862551|NCT01662349|DEVICE|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
214862552|NCT05485220|OTHER|Aerobic exercise|Aerobic exercise group: Peak workload will be determined by performing an exercise test on the patients. Training will be given at 60-70% of the peak workload for 45 minutes with an arm ergometer 3 days a week for 8 weeks.
214862553|NCT05485220|OTHER|High-intensity interval training|High-intensity interval training Group: Peak workload will be determined by performing an exercise test on the patients and arm ergometer HIIT will be done with a total of 45 minutes, 90-95% of the peak workload for 30 seconds, 60 seconds in between, active recovery at 40-50% workload, 3 days a week for 8 weeks.
214862554|NCT01469260|OTHER|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
214862555|NCT02156141|OTHER|Supervised high intensity training|8 weeks of supervised training
214862556|NCT02156141|OTHER|Optional training|8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
214862557|NCT02156141|OTHER|Control period|8 weeks with no training.
214862558|NCT02156141|OTHER|Unsupervised High intensity training|8 weeks of unsupervised high intensity training.
214862559|NCT01690221|DRUG|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
214862560|NCT01690221|DRUG|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
214862561|NCT06729138|OTHER|Resisted Sprint Training|In this intervention, participants will perform 16 sessions of resisted sprint training with external loads using a sled over eight weeks. In these 16 sessions the intensity will vary in both the distance to be covered and the load to be moved.
214862562|NCT06729138|OTHER|Sprint Training|In this intervention, participants will perform 16 sessions of sprint training over eight weeks. In these 16 sessions the intensity will vary in the distance.
214862563|NCT06727877|DIAGNOSTIC_TEST|Ability of early digestive microbiota analysis (using artificial intelligence) to predict the occurrence of NEC diagnosed according to the Bell classification.|"The test gives us a dichotomous response (yes/no) for each stool. We will systematically analyze two stools per child, and in the event of a discrepancy, we will analyze a third to classify the child as being at risk of NEC or not.~The analysis model consists of a deep neural network that has been trained and optimized on data from international cohorts. In a local pilot study (N=20), it enabled accurate prediction for 90% of newborns."
215033700|NCT02886364|BEHAVIORAL|Adapted Safe Childbirth Checklist|The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
214862564|NCT06925204|OTHER|Observation|Based on the patient's specific clinical condition, the appropriate examination and treatment in accordance with the conventional diagnosis and treatment standards of CP will be performed, including but not limited to: CT, MRI, endoscopic ultrasound (EUS) with or without biopsy, endocrine hormone testing (such as oral glucose tolerance test or mixed meal tolerance testing), pancreatic exocrine function tests (such as fecal elastase-1 test), extracorporeal shock wave lithotripsy (ESWL), endoscopic retrograde cholangiopancreatography (ERCP), and pancreatic enzyme replacement therapy. Patients were followed up regularly.
214862565|NCT05524961|DEVICE|Bright light therapy|Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks
214862566|NCT05524961|DEVICE|Inactivated negative ion generator|Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
214862567|NCT05524961|DEVICE|Inactivated negative ion generator|Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
214862568|NCT03531398|OTHER|Metabolic test meal challenge|Metabolic test meal challenge
214862569|NCT06456879|OTHER|extra-coronal restoration type|primary molar crown type
214862570|NCT04441645|OTHER|Acupressure|acupressure once per day, five times per week, a total of 12 weeks
214862571|NCT06785480|DEVICE|Computer Controlled Local Anesthetic Delivery (CCLAD)|Administering local anesthesia with 1.2ml Septanest normal (4% articaine, 1/200000 adrenaline) with CCLAD. The CCLAD device is set to 60sec/ml in continuous mode.
214862572|NCT06785480|DEVICE|Conventional metallic syringe|A conventional metallic syringe is used to administers local anesthesia with 1.2ml Septanest normal (4% articaine, 1/200000 adrenaline).
214862573|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
214862574|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
214862575|NCT00321737|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
214862576|NCT06928220|PROCEDURE|cystectomy with ileal conduit, using mechanical bowel anastomosis|"An ileal conduit will be the new storage area for urine once the bladder is removed.~GIA Device will be used to perform bowel anastomosis"
214862577|NCT06928220|PROCEDURE|cystectomy with ileal conduit, using manual bowel anastomosis|"An ileal conduit will be the new storage area for urine once the bladder is removed.~Vycryl suture will be used to perform manual bowel anastomosis"
214862578|NCT06927765|OTHER|No abdominal drain is placed|No abdominal drain is placed
214862579|NCT06928688|DIETARY_SUPPLEMENT|Saskatoon berry powder|After oral intake of SB powder, dried whole SB fruit or glucose drink, finger tip blood glucose will be measured 15, 30, 45, 60, 90 and 120 minutes after the consumption.
214862580|NCT06927895|BEHAVIORAL|Educational Intervention|"The research-specific educational intervention is the enhancement of communications and SDM in AE management.~To this end, interventions will include pre-recorded videos that address:~1. SDM methodologies (\~30 minutes)~2. Simulated case role play interactions between a standardized patient actor and clinician participant (\~60 minutes)~3. In depth presentation on AEs associated with HER2-targeted ADC treatments, and the management of these AEs (\~45 minutes)~Clinician participant educational intervention videos and patient participant educational intervention videos will be slightly different, as they are each presented from their specific perspectives."
214862581|NCT06928623|OTHER|Surveys|In the present study, no intervention will be carried out, with the recruited subjects only completing the questionnaires set out in the study variables.
214862582|NCT06927479|OTHER|Training about Electronic Decision Support System|"1. System Registration and Usage~2. Pressure Ulcer Prevention~3. Urinary Infection Prevention~4. Nutrition and Hydration Management~5. Physical Activity and In-Bed Mobilization~6. Emergency Management and Reporting~7. Continuous Monitoring and Feedback"
214862583|NCT06928103|OTHER|Dynamic stretching|dynamic stretching: teach the participants movements that they can perform to warm up their soft tissues.
214862584|NCT06928103|OTHER|Static stretching and dynamic stretching|Static stretching: help patients do the movement that they\&amp;amp;#39;re limited to stretch their soft tissue; Dynamic stretching: teach the participants movements that they can perform to warm up their soft tissues
214862585|NCT06928103|OTHER|Dynamic stretching and foam rolling|Dynamic stretching: teach the participants movements that they can perform to warm up their soft tissues; Foam rolling: Teach the participants how to use a massage ball so that they can perform movements to warm up their soft tissues
214862586|NCT06928883|DEVICE|Sirolimus drug eluting ballooon therapy|Non-flow limiting vulnerable coronary plaques are treated using sirolimus drug eluting balloon therapy additional to guidelines directed medical therapy.
214862587|NCT06928883|DRUG|Optimal guidelines-directed medical therapies (GDMT)|Optimal guidelines-directed medical therapies (GDMT) to reduce plaque burden and vulnerability for non-flow limiting vulnerable plaques
214862588|NCT06928311|OTHER|Exercise Environment|This intervention focused around the environmental design of the exercise room.
214862589|NCT06927011|BEHAVIORAL|Capscan|"Participants will be asked to swallow 2 small devices (called Capscan), which will collect samples of intestinal fluid as they move through participants small intestine and colon. This device is not FDA approved but has been deemed to have no significant risk. The investigator can explain how it is designed to work. Participants will also answer surveys about participants quality of life.~Participants in this study will be over after all study procedures are completed."
214907078|NCT04872686|DRUG|0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|"Number of participants 20 asymptomatic to mild COVID -19 patients having multiple comorbidity who will receive intervention~Step 1: Selection of 20 patients randomly with no or mild symptoms and obtain their consent for the further tests.~Step 2: Collection of 2nd, 3rd and 4th sample from nasopharynx and oropharynx hourly Step 3: Data collection, data processing and analysis by using SPSS software"
214907079|NCT04872686|DRUG|0.6% PVP-I Oral and nasal spray to healthy volunteer|"Number of participants 10 healthy individual who accept intervention 0.6% PVP-I oronasal spray~Step 1: Selection of 10 healthy volunteers randomly who will be selected for using 0.6% PVP-I Oro-Nasal spray 2 puff inside both nostrils and mouth 3 to 4 times a day for one month.~Step 2: Collection of blood \& urine of participants on day 0, 10, 20, 30 for determination of any change in biochemical marker (thyroid, kidney and liver functions will be done) Step 3: Data collection, data processing and analysis by using SPSS software"
214862590|NCT06928077|BEHAVIORAL|ROC-Stand training with specific environmental features|A licensed, independent therapist along with caregivers will conduct the training program in a public space at the university. The initial phase of the training will concentrate on developing the participants' understanding of cause-and-effect in relation to the control system and the movement of the car, focusing on specific public spaces such as hallways, convenience stores, gardens, and museums. Following this, the therapist will collaborate with caregivers to direct the participants' gaze towards specific physical structures and objects. Furthermore, the therapist will guide and coach caregivers on how to lead the participants in engaging with these environmental features through various exploratory actions, as supported by previous evidence. These actions include touching, hitting, squeezing, pointing, holding objects with one or two hands, object touching own body, fingering, banging, manipulating, and transferring objects.
214862591|NCT06928077|BEHAVIORAL|ROC-Stand training without specific environmental features|The initial phase of training will also focus on teaching participants about cause-and-effect as it pertains to the control system and movement of the car. This phase will include goal-oriented driving activities, such as traveling 200 meters to reach a preferred toy or to interact with someone, and engaging in games like hide-and-seek in various public spaces including hallways, convenience stores, gardens, and museums. The training, without a specific emphasis on environmental features, will highlight the use of upper limbs in functional tasks during driving sessions, and incorporate a range of motor skills to enhance mobility and socialization during natural play sessions. The details of the program will also be established through collaborative discussions between the family and the treating therapist. These discussions will take into account clinical observations of the participant's performance in previous sessions.
214862592|NCT06928077|BEHAVIORAL|Conventional therapy|The overarching goal of this training is to support developmental progress and improve mobility, socialization, and upper limb functionality in everyday tasks. Participants in this group will have the opportunity to walk in the same public space used by the ROC training groups, allowing interaction with both the therapist and caregivers based on their individual motor capabilities.
214862593|NCT04772391|OTHER|Exercise Sessions|Participant will complete up to 8 exercise sessions
214862594|NCT02283294|DRUG|Apixaban|
214862595|NCT02283294|DRUG|Warfarin|
214862596|NCT05476614|OTHER|Yoga (Robot-instructed)|Yoga that is instructed by a social robot
214862597|NCT05476614|OTHER|Yoga (Human-instructed)|Yoga that is instructed by a human
214862598|NCT02123212|OTHER|Mailer|Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
214862599|NCT02123212|OTHER|In-person recruitment|UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
214862600|NCT02123212|OTHER|EHR Alert|EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
214862601|NCT05344248|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Subcutaneous injection
214862602|NCT05344248|BIOLOGICAL|JS005 placebo|Subcutaneous injection
214862603|NCT06928428|BEHAVIORAL|Metacognitive therapy, blended format|Blended metacognitive therapy (bMCT): New about this treatment is that it is given both via the internet and through meetings with a therapist. Participants work with the treatment independently via an internet platform and meets their therapist for therapy sessions up to 6 times during the course of the treatment. Key components of the original manual are retained, but adapted to better fit the digital format. A handbook for therapists is developed to facilitate the implementation of the blended format and optimize execution. The digital parts of the treatment for depression and GAD consist of 10 interactive modules located in the Support and Treatment (SoB) platform. The sessions are divided in a flexible way between physical and digital sessions that therapist and patient agree on. The patient has access to all modules but receive instructions from their therapist which module is relevant for each week. During the treatment, the patient can write text messages to his/her therapist.
214290656|NCT04809207|OTHER|CF Wellness Program Sessions|The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.
214290657|NCT01529879|DEVICE|New Abutment Connection implant|New abutment connection implant
214862604|NCT06926998|DRUG|9MW2821+other anticancer therapy|Subjects will receive intravenous (IV) infusion of 9MW2821 +other anticancer therapy as per protocol
214907080|NCT04872686|OTHER|Oral and nasal spray by distilled water to control group|Placebo comparator: Distilled Water Oral and Nasal spray will be provided by Distilled water to control group
215033701|NCT00105898|PROCEDURE|Web-based care management|Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
215033702|NCT00105898|PROCEDURE|Telephone and face-to-face care management|Participants interact with a care manager via face-to-face and telephone contact
215033703|NCT00105898|PROCEDURE|Internet access alone|Participants are given internet access and encouraged to seek diabetes information to help in their self management
214862605|NCT06910696|DRUG|Regional Anesthetic Injection|The probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe was moved 3 cm laterally from the midline. The erector spinae musclewill be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution will be injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine will be administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered
214862606|NCT06910696|DRUG|Regional Anesthetic Injection|The probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probewill be moved laterally to identify the longissimus and iliocostalis muscles . The needlewill be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine will be administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered
214862607|NCT06926816|GENETIC|Natera® Empower™ hereditary cancer panel test|The test will be the Natera® Empower™ hereditary cancer panel test and will be collected by saliva.
214862608|NCT06926816|OTHER|Specialist Referral|Participants with actionable pathogenic variants will be referred to the appropriate specialists (e.g., medical oncologist, gynecologic oncologist, breast surgeon) to discuss risk-reduction strategies and offered genetic counseling
214862609|NCT06927258|DRUG|changyanning granules|From one day before the procedure to five days postoperatively, patients in the experimental group will be administered Chanyanning granules.
214862610|NCT06927258|DRUG|Placebo|control
214862611|NCT06928701|DIETARY_SUPPLEMENT|omega-3 (n-3 Lc-PUFA), EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) plus a source of palmitoleic acid (hexadecenoic acid)|Nutritional supplements
214862612|NCT06928181|OTHER|Blood Flow Restriction Training|BFR training involves the application of blood flow restriction during passive or active movement interventions to elicit an additional metabolic stimulus. The cuffs are applied as proximally as possible on the thigh, and a pressure is exerted during the movement that partially restricts venous return from the limb, resulting in venous pooling. Venous occlusion is achieved using a cuff system commonly employed in resistance training (Delfi Medical Innovations Inc., Vancouver, Canada; CE-certified). The pressure applied is individually determined at the start of each training session based on the participant's arterial occlusion pressure, measured via duplex ultrasonography. For this measurement, the participant rests in a supine position while the cuff is gradually inflated until no blood flow is detectable in the limb (i.e., occlusion pressure). For the BFR intervention, 60-80% of this occlusion pressure is subsequently applied. The exercise protocol consists of daily
214862613|NCT06928181|OTHER|Sham-BFR|Patients in the control group (CG) follow the same exercise protocol as those in the BFR intervention group; however, the cuff is only inflated to a minimal pressure of 20 mmHg. This pressure does not induce any relevant venous stasis, nor can any local or systemic metabolic effects be expected.
214862614|NCT06927271|OTHER|phone call based intervention|The phone call based intervention seek to educate patients about hypertension and the medications used. It also seeks to remind patients to take their medications. This will be done thrice weekly
214862615|NCT06927271|OTHER|Video based intervention|The video based intervention seek to educate patients about hypertension and the medications used. It also seeks to remind patients to take their medications. This will be done thrice weekly
214862616|NCT06927271|OTHER|Usual Care|The usual care concerns the care the participants receive from the health facility. Participants in this group would neither receive the phonecall or video based interventions.
214862617|NCT06929013|BIOLOGICAL|Blood sampling|Inclusion (baseline): 28 mL Incision (surgery): 18 mL End surgery: 18 mL H+12 after end surgery: 18 mL H+4 after end surgery: 18 mL H+48 after end surgery: 18 mL H+72 after end surgery: 18 mL D+7 after end surgery: 18 mL D+14 after surgery: 18 mL 4 to 6 weeks after surgery:28 mL
214862618|NCT06928636|BEHAVIORAL|Supper Heroes online environmentally friendly eating intervention for families|Families randomized to the intervention group will complete a 7-week Supper Heroes program that includes activities focused on making more meals at home, reducing food waste, and eating more plant-based foods.
214862619|NCT06928636|BEHAVIORAL|Monthly emails about environmentally friendly habits|Families randomized to the control group will receive monthly emails for 6 months about environmentally friendly habits.
214862620|NCT06296654|BEHAVIORAL|Empowerment-Based Interventions|The Empowerment-Based Interventions was used for the study group. It is an integrative educational program under the patient-centered care approach emphasizing collaborative patient interaction. The EBI was implemented through structured (a) small-group d
214862621|NCT06296654|BEHAVIORAL|Standard Health Education|Patients in the control group received standard health education from SCD clinics in the HC. The clinic employs a multidisciplinary team, including a nurse, a physician, a health record clerk, a laboratory technician, a social worker, and a health promotion specialist, to provide integrated patient health services. It consists of both preventative and curative services. The nurses at the health center provide patients with information regarding factors that may cause vaso-occlusion and precipitate VOCs when to seek emergency care and educate patients on the significance of regular medical examinations and screening using different standardized audiovisual aids.
214862622|NCT02287129|DRUG|Oxaliplatin|130 mg/m2
214862623|NCT02287129|DRUG|Epirubicin|50 mg/m2
214862624|NCT02287129|DRUG|Capecitabine|625 mg/m2
214862625|NCT02287129|DRUG|5-FU|200 mg/m2
214862626|NCT02287129|DRUG|Carboplatin|2 mg/ml min
214862627|NCT02287129|DRUG|Paclitaxel|50 mg/m2
214862628|NCT02287129|RADIATION|radiation|total dosage 41,4 Gy
214862629|NCT02287129|PROCEDURE|Biopsy|translational analysis
214862630|NCT01769339|DRUG|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
214862631|NCT03801538|DRUG|Peginterferon Alfa|Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
214862632|NCT03801538|DRUG|Nucleoside Analog (Substance)|Patients do not need to change their NAs treatment.
214862633|NCT06919796|BIOLOGICAL|COMIRNATY®|COVID-19 Vaccine, mRNA suspension
214862634|NCT06926725|DEVICE|Cavitation : Study group A only will receive one session per week for three months (total 12 sessions ). Ultrasound treatments are performed using an applicator head with diameter 7 cm . Intensity :|"Cavitation :~Study group A only will receive one session per week for three months (total 12 sessions ).~Ultrasound treatments are performed using an applicator head with diameter 7 cm .~Intensity : 0.1-0.5 w/cm2 (low) Frequency : 30-40 KHZ (low) Duration : 30 minutes"
214862635|NCT06926725|OTHER|high intenisty exercise|"type: alternate high intensity exercise (aerobic or strength training) with recovery stages Intensity: high intensity (75%-95% HRmax) or RPE(14-16 hard to very hard ) ( according to patient tolerance), followed by active or passive recovery stage (30%-60% HRmax) or RPE(7-11 extremely light to light) .~frequency : 3 days per week for three months (with no more than 2 consecutive days between sessions) Duration: 10 seconds to 4 minutes high intensity ,12 seconds to 5 minutes active or passive recovery .(according to patient tolerance) 5 minutes warm up pre exercise . 5 minutes cool down post exercise . Progress gradually. total duration :20-40 minutes (according to patient tolerance and progression)"
214862636|NCT06926725|DIETARY_SUPPLEMENT|Diet|In all groups (both study groups A\&B and control group).
214862637|NCT06927414|DEVICE|Functional lens|Diffractive Optical Element, D.O.E, technology for controlling myopia progression in children and adolescents. and H.A.L.T, highly aspheric lenslet technology) for controlling myopia progression in children and adolescents.
214862638|NCT06927986|DRUG|SYS6010|SYS6010,Q3W
214862639|NCT06927986|DRUG|Pemetrexed|Pemetrexed injection 500 mg/m\^2 administered via intravenous infusion，Q3W
214290658|NCT01529879|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
214290659|NCT01891695|RADIATION|39.6 Gy radiation|
214862640|NCT06927986|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 administered via intravenous infusion，Q3W
214862641|NCT06927986|DRUG|Carboplatin|Carboplatin (AUC=5, Calvert formula) administered via intravenous infusion，Q3W
214862642|NCT00221962|DRUG|Aripiprazole|Open label
214862643|NCT06927232|DRUG|Azacitidine (AZA)|Azacitidine 75mg/m/ day \*5 days, 28 days for 1 course
214862644|NCT06927232|DRUG|Luspatercept|Luspatercept 1.0 mg/kg subcutaneously every 3 weeks, adjusted according to hemoglobin, up to 1.75mg/kg. If hemoglobin ≥120g/L, luspatercept can be discontinued.
214862645|NCT00290251|DRUG|ulipristal acetate 20 mg|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
214862646|NCT00290251|DRUG|ulipristal acetate 10 mg|10 mg given daily for three menstrual cycles or 90 - 102 days
214862647|NCT00290251|DRUG|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
214862648|NCT05788575|PROCEDURE|surgery|any surgery that an inpatient has undergone
214862649|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
214862650|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
214862651|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
214862652|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
214862653|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
214862654|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
214862655|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
214862656|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
214862657|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
214862658|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
214862659|NCT01512706|BIOLOGICAL|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
214862660|NCT01512706|BIOLOGICAL|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
214862661|NCT01512706|BIOLOGICAL|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
214862662|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
214862663|NCT01512706|BIOLOGICAL|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
214862664|NCT00468429|DRUG|Subconjunctival Bevacizumab|
214862665|NCT01745211|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser with array handpiece
214290660|NCT01533025|PROCEDURE|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
214862666|NCT01295866|DEVICE|nasal nitric oxide|
214862667|NCT01030354|DIETARY_SUPPLEMENT|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
214862668|NCT01030354|DIETARY_SUPPLEMENT|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
214862669|NCT05925777|DEVICE|THEAL (Mectronic, Bergamo)|laser therapy high intensity
214862670|NCT06267547|OTHER|HAIL Online Platform|The HAIL online platform was developed based on feedback from our focus groups with older adults affiliated with BMA churches (conducted per IRB Protocol 2020P003100). Specifically, the HAIL online platform has a landing page where participants can access the links to the F\&S! exercise sessions, complete the exercise log, obtain tips from an exercise instructor, as well as view study announcements. The landing page has a navigation bar on the left to access 1) the study assessments; 2) the F\&S! exercise program participant manual; and 3) information on how to contact study staff. The goal of this adjunctive HAIL online platform is to support the continuation of exercise in the follow-up period once the 8-week F\&S! exercise program is over. We conducted an open trial (per IRB protocol 2022P001782) to assess the feasibility and acceptability of the HAIL online platform adjunct to the F\&S! program, which yielded positive results.
214862671|NCT06267547|BEHAVIORAL|Fit and Strong! Program|The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
214862672|NCT06964750|BEHAVIORAL|Exercise|Groups will practice the exercises by different method for 6 week
214862673|NCT06964750|BEHAVIORAL|home based exercise|Participant were practice for 6 weeks home based exercises.
214862674|NCT03673332|DRUG|immune-checkpoint inhibitors therapies|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
214862675|NCT04011215|OTHER|wool clothing|superfine merino wool ensembles for baby/child wear
214862676|NCT04011215|OTHER|standard clothing|Standard clothing refers to the clothing normally worn by the infant/child. This will not be superfine merino wool as superfine merino is not generally available for baby wear. The exact nature of the standard clothing will be recorded by investigators. From previous data we expect it to be primarily cotton.
214862677|NCT04209686|DRUG|Paclitaxel|"1. Patients will receive treatment on Day 1 and 8 starting with cycle 2.~2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~3. Drug - Paclitaxel - 80mg IV"
214862678|NCT04209686|DRUG|Olaparib|"1. Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~2. Drug - 100 mg or 300mg"
214862679|NCT04209686|DRUG|Pembrolizumab|"1. Patients will receive treatment every 21 days.~2. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~3. Drug - 200mg IV"
214862680|NCT05759806|DEVICE|Nephronyx system (Perfuser)|Temporary deployment of the Nephronyx system (Perfuser)
214862681|NCT03649685|DEVICE|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
214862682|NCT03649685|DEVICE|shame rTMS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
214862683|NCT04062448|DRUG|Ibrutinib|Ibrutinib 420 mg will be administered orally.
214862684|NCT04062448|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered intravenously.
214862685|NCT05731713|BEHAVIORAL|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
214862686|NCT05178017|DIAGNOSTIC_TEST|Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program|The LEAP program is based on the in-vitro Leukocyte Activation Assay (LAA-MRT) results and initially prepared with the least immune reactive foods and chemicals, and subsequent foods will be added depending on the degree of immune reactivity in a nutritionally balanced manner.
214862687|NCT04008368|DEVICE|CliniMACS CD34 Reagent|Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
214862688|NCT02477930|OTHER|No interventions are done|No intervention is done. This is a registry study.
214862689|NCT05913050|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
214862690|NCT05913050|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
214862691|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
214862692|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2\*10\^10 viral particles on Day 1
214862693|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8\*10\^10 viral particles on Day 1
214862694|NCT02543567|BIOLOGICAL|MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57
214862695|NCT02543567|BIOLOGICAL|MVA-BN-Filo 5*10^7 Inf. U.|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5\*10\^7 Inf. U. once on Day 57
214862696|NCT02543567|BIOLOGICAL|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
214862697|NCT05101486|BIOLOGICAL|Ad26.RSV.PreF-based Vaccine|Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.
214862698|NCT02788045|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
214862699|NCT02788045|BIOLOGICAL|Ad26.Mos4.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5mL injection administered intramuscularly.
214862700|NCT02788045|BIOLOGICAL|Clade C gp140|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
214862701|NCT02788045|DRUG|Placebo|Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
214862702|NCT06502457|DRUG|painkiller|The control group will receive a painkiller adapted to the service protocol after the fetal heart rate has been recorded.
214862703|NCT06502457|OTHER|hypnosis group|"The hypnosis group will receive a hypnosis session after the fetal heart rate has been recorded. Automated measurement of blood pressure and maternal heart rate will take place during the session in order to objectively assess the impact of the session on the mother.~Patients in the hypnosis group will then have access to the virtual reality headset on request throughout the latency or maturation phase, and will also be able to benefit from a painkiller in accordance with the service protocol if they so request."
214862704|NCT06189118|BEHAVIORAL|Online Mindfulness Based Cognitive Therapy or Health Education Program|12 hours of online group training of Mindfulness Based Cognitive Therapy OR 12 hours of online group training of Health Education Program will be provided via teleconferencing. Additional both groups will perform daily home practice.
214862705|NCT06570928|OTHER|Cannabis|0,2 ml of CBD:THC (50 mg:5 mg)
214862706|NCT06570928|OTHER|Placebo|Product vehicle, medium chain triglycerides (MCT)
214862707|NCT05870800|DRUG|Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2|Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)
214862708|NCT05870800|DRUG|Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPOX Q3 weeks x 4 cycles (12 weeks)
214862709|NCT05870800|DRUG|Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPOX Q3 weeks x 4 cycles (12 weeks)
214862710|NCT05312398|DRUG|Cetuximab|"I LINE:~\- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter~II LINE:~\- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line~THIRD LINE:~\- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
214862711|NCT05312398|DRUG|FOLFIRI|"I LINE:~\- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter"
214862712|NCT05312398|DRUG|FOLFOX regimen|"II LINE:~\- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line"
214862713|NCT05312398|DRUG|Irinotecan|"III LINE:~\- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
214862714|NCT05703347|BEHAVIORAL|Fixed sleep goal|Investigators will determine if a fixed guideline-based goal (≥9 hours per night) is more efficacious for increasing sleep duration.
214862715|NCT05703347|BEHAVIORAL|Personalized sleep goal|Investigators will determine if a personalized goal (≥9 hours per night, but can be lowered to a personalized level, capped at +30 minutes per night above baseline) is more efficacious for increasing sleep duration.
214862716|NCT05703347|BEHAVIORAL|Digital sleep health messaging without virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.
214862717|NCT05703347|BEHAVIORAL|Digital sleep health messaging with virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. The participants will be randomized to additionally receive virtual study visits where doctoral-level psychology trainees will be trained to implement evidence-based behavioral sleep health guidance.
214862718|NCT05703347|BEHAVIORAL|Inactive Parent-Directed Loss-Framed Incentive|No parental incentive
214862719|NCT05703347|BEHAVIORAL|Active Parent-Directed Loss-Framed Incentive|Parents will receive a financial incentive when their child achieves their sleep goal. The incentive will be loss-framed; parents will receive an endowment of $10 at the start of each intervention week, in a virtual bank account; Investigators will deduct $2 each weeknight the sleep duration goal is not met; the funds remaining in the virtual account will be dispensed each Sunday. The weekly endowment-payment approach allows for fresh starts each week. The incentive will be directed at parents as a method to enhance engagement. Investigators will ask parents at baseline and at the end of each month to rate their perceived support in helping their child to meet their sleep duration goal.
214862720|NCT05703347|BEHAVIORAL|Inactive Supportive Feedback|No supportive feedback
215033704|NCT05036343|DEVICE|InPen®|A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
214862721|NCT05703347|BEHAVIORAL|Active Supportive Feedback|Participants will receive a weekly performance summary message each Sunday during the intervention period, with supportive feedback included to motivate children to maintain their good performance in the week ahead, or to try and improve upon a weak or moderate performance in the week ahead. Investigators will ask children will complete an online survey each Sunday to measure how motivated they are to achieve their sleep goal in the week ahead.
214862722|NCT04901429|PROCEDURE|Truncal vagotomy|Truncal vagotomy will be performed in 50% of patients during other routine procedure.
214862723|NCT06135064|DEVICE|Diadem|The device delivers low-intensity ultrasonic waves into specified brain targets.
214862724|NCT05608837|DRUG|OCS-01|One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
214862725|NCT02111941|OTHER|Laboratory Biomarker Analysis|Correlative studies
214862726|NCT02111941|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
214862731|NCT02912845|DRUG|KamRAB - HRIG|wound infiltration or IM injection
214862732|NCT01463215|DRUG|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
214862733|NCT01910012|DRUG|ADI-PEG 20|
214862734|NCT03516253|DIETARY_SUPPLEMENT|Fish oil + EPO|Supplementation with both fish oil and EPO
214862735|NCT04034537|DIAGNOSTIC_TEST|cPSTA|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
214862736|NCT01195792|DRUG|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
214862737|NCT01195792|DRUG|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
214862738|NCT03188666|DRUG|REGN2477|Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
214862739|NCT03188666|DRUG|Matching placebo|Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
214862740|NCT02208986|DRUG|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
214862741|NCT00388401|DRUG|Alvimopan|
214862742|NCT03288181|DEVICE|Muscle Stretch|The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
214862743|NCT01400802|BIOLOGICAL|Insulin Lispro|Dosage form- Subcutaneous Injection
214862744|NCT03696953|BIOLOGICAL|Florajen3|Probiotic combination product One capsule daily by mouth.
214862745|NCT05892289|PROCEDURE|Robotic assisted proximal gastrectomy with double-flap technique|Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p and 11d).The double-flap technique is used for the digestive tract reconstruction.
214290661|NCT01454622|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
214862746|NCT05104476|DRUG|Lu AF82422|Solution for infusion
214862747|NCT05104476|DRUG|Placebo|Solution for infusion
214862748|NCT06274164|DIAGNOSTIC_TEST|Electroencephalography/Polysomnography (EEG/PSG)|Instigators will determine if subjects are candidate for the procedure. A sleep study records the brain electrical waves, the oxygen level in the blood, heart rate breathing, as well as eye and leg movements. Subjects will need to be admitted overnight for the sleep study.
214862749|NCT06274164|PROCEDURE|Skin Biopsy|A special 3-4 mm (0.12 inches) wide circular tool will be used to remove a small section of skin including deeper layers. A numbing cream or injectable anesthetic (i.e. lidocaine) will be applied to the area before the procedure. Sample will be used to create a cell line. This means that investigators would treat the cells from the sample in a way that allows to grow them in the laboratory. Investigators will then use these cells in research.
214862750|NCT06274164|DIAGNOSTIC_TEST|Blood draw|A single blood sample of 15 cc (not exceeding 3 cc per kg) (\~3 teaspoons) will be collected for metabolomics (biomarker) study. From available family members, same amount of blood will be obtained to use as a control sample.
214862751|NCT06491511|PROCEDURE|Transcutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
214862752|NCT06432660|OTHER|Data collection|Information about radiation therapy via eye plaque brachytherapy and follow up
214862753|NCT05557357|PROCEDURE|Electroacupuncture (EA)|"Electroacupuncture (EA) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are Tinggong (SI19) and Yifeng (TE17) of the affected side, Baihui (GV20) and Yintang (GV24+), bilateral posterior temporal line (MS11), and Zhongzhu (TE3) and Zusanli (ST36) of the affected side.~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11."
215033705|NCT01771354|BIOLOGICAL|Engerix B Vaccine|
215033706|NCT01771354|BIOLOGICAL|Placebo|
215033707|NCT03880357|DRUG|Betamethasone Scalp Suspension 0.064%;0.0005%|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
214290662|NCT01454622|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
214862754|NCT05557357|PROCEDURE|Electroacupuncture Combined With Warm Needling (EAWN)|"Electroacupuncture combined with warm needling (EAWN) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are SI19 and TE17 (affected side), GV20 and GV24+, bilateral MS11, and TE3 and ST36 (affected side).~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.~For warm needling (WN), two moxa sticks will be ignited and attached one by one to the needle handle of each acupoint of SI19 and TE17."
214862755|NCT05557357|OTHER|Waitlist Control|No treatment will be provided during the 10-week waiting period after baseline assessment.
214862756|NCT04908683|BIOLOGICAL|Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF|Participants will receive a single IM injection of an RSV vaccine.
214862757|NCT04908683|BIOLOGICAL|Placebo|Participants will receive a single IM injection of matching placebo.
214862758|NCT05748483|DRUG|Atogepant|Oral Tablet
214862759|NCT05748483|DRUG|Placebo for Atogepant|Oral Tablet
214862760|NCT05748483|DRUG|Topiramate|Oral Capsule
214862761|NCT05748483|DRUG|Placebo for Topiramate|Oral Capsule
214290663|NCT03037411|DEVICE|Peripheral stenting|stent implantation during the index procedure
214862762|NCT06639854|PROCEDURE|Hematopoietic Cell Transplant|"Participants choices may include to receive standard post-transplant virus prevention with letermovir or other standard drugs without being part of this study. Participants may choose to receive other investigational therapy, if available.~These alternative treatments have risks and benefits that may be the same or different than those in this research study."
214862763|NCT06639854|DRUG|Letermovir|Given by PO
214862764|NCT06323850|BEHAVIORAL|Intervention Phase|After participants have been enrolled, they will be assigned to one of the trainer-pairs and will work with them to schedule the first two sessions. Most clients will be able to schedule one virtual session per week and one ride along session per week for the first five weeks, with the remaining three weeks allotted to practice ride-along sessions and module repetition (as needed). The additional time also provides a buffer if subjects are unavailable for a week during the intervention phase.
214862765|NCT06323850|BEHAVIORAL|Virtual Training Sessions|Virtual sessions will take place over Zoom each session lasting 20-30 minutes. Each of the five virtual sessions will be aligned with the five online modules. For each module, exercises are built in to test comprehension. If the participant does not complete an exercise accurately, the lead trainer will explain why the response was incorrect and prompt them to repeat the video modeling exercise. The support training partner will take notes to support the formative assessment process and complete fidelity checks.
214862766|NCT06323850|BEHAVIORAL|Ride-Along Training Sessions|The first ride-along session will be the baseline session for assessing level of independence (number of cues needed) and safety. The participant will have up to 8 ride-along sessions to reach full independence (no cues needed) and full marks on the safety assessment. The lead trainer will provide the cues as needed to complete each step of the Rideshare process.
214862767|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the general population
214862768|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_cirrhosis|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population with liver cirrhosis
214862769|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_no_cirrhosis|neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population without liver cirrhosis
214862770|NCT04649073|BIOLOGICAL|OPC-415|OPC-415 (up to 1×10\^7cells/kg) On 2 days
214862771|NCT05102981|PROCEDURE|emergency procedure|The difference between groups is the timing or type ie emergency as opposed to planned
214862772|NCT04848038|BEHAVIORAL|Exercise|Standard public health exercise recommendations
214862773|NCT02205762|DRUG|Prednisone|Stratum I
214862774|NCT02205762|DRUG|Vinblastine|Stratum I
214862775|NCT02205762|DRUG|mercaptopurine|Stratum I
214862776|NCT02205762|DRUG|INDOMETHACIN|Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
214862777|NCT02205762|DRUG|Methotrexate|fixed dose weekly orally for total treatment duration of 24 months.
214862778|NCT02205762|DRUG|Cytosine Arabinoside|
214862779|NCT02205762|DRUG|2-chlorodeoxyadenosine|
214862780|NCT02205762|PROCEDURE|hematopoietic stem cell transplantation (RIC-HSCT)|
214862781|NCT02205762|BIOLOGICAL|Intravenous immunoglobulin|
214862782|NCT06210399|PROCEDURE|Extracorporeal Shockwave Therapy|3 to 6 shock wave treatment sessions will be performed (PiezoWave 2 Control Unit Generator, classification 93/42/EEC class IIb), with a frequency of two sessions per week.
214862783|NCT05801965|DEVICE|A digital solution for patients with Cancer|A digital program that provides holistic lifestyle intervention as well as disease education.
214862784|NCT05801965|OTHER|Standard of care for patients with Cancer|Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
214862785|NCT03928158|DRUG|LCZ 696|50-100-200 mg tablet
215033708|NCT03880357|DRUG|Taclonex®|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
215033709|NCT03880357|DRUG|Placebo topical suspension|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
215033710|NCT01416350|DRUG|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
214862786|NCT03928158|DRUG|Valsartan|40-80-160 mg tablet
214862787|NCT03047473|BIOLOGICAL|avelumab|add on of avelumab 10mg/kg IV to standard therapy
214862788|NCT05646316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214862789|NCT05646316|PROCEDURE|Diagnostic Imaging Testing|Undergo imaging
214862790|NCT05646316|PROCEDURE|Excisional Biopsy|Undergo sentinel lymph node excision
214862791|NCT05646316|DRUG|Indocyanine Green Solution|Given via injection
214862792|NCT05646316|PROCEDURE|Minimally Invasive Surgery|Undergo minimally invasive hysterectomy
214862793|NCT05646316|PROCEDURE|Pelvic Lymphadenectomy|Undergo pelvic lymphadenectomy
214862794|NCT05646316|OTHER|Questionnaire Administration|Ancillary studies
214862795|NCT05646316|PROCEDURE|Sentinel Lymph Node Mapping|Undergo sentinel lymph node mapping
214862796|NCT06235307|OTHER|motivational interviewing|Upon entry into the program, all patients will be seen for an assessment of their physical condition at the premises of Amiens Métropole by a teacher in adapted physical activity (APA) in order to be assessed and directed to a club or a approved associations. The EM group will also benefit from a motivational interview at 0 and 3 months by a doctor trained in the technique. The entire cohort will complete the SF12 (perception of quality of life) and IPAQ (current level of physical activity) questionnaires at 0 and 6 months during the usual appointments with the APA teacher.
214862797|NCT05468359|DRUG|Atezolizumab|Atezolizumab intravenously, every 3 weeks, Day 1
214862798|NCT05468359|DRUG|Sorafenib|Sorafenib by mouth every 12 hours, Days 1-21
214862799|NCT05468359|DRUG|Bevacizumab|Bevacizumab intravenously, every 3 weeks, Day 1
214862800|NCT05468359|DRUG|Cyclophosphamide|Low-dose cyclophosphamide by mouth once daily, Days 1-21
214862801|NCT06204887|PROCEDURE|Manual dynamic activation|The root canals were filled with irrigation solutions. A main gutta percha cone was positioned 1 mm shorter than the working length and 2 mm coronal-apical direction movement was performed at a rate of 100 strokes per minute during 60 s.
214862802|NCT06204887|PROCEDURE|Passive ultrasonic activation|A non-cutting ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) coupled to an ultrasonic device (DTE S6 Led, Guilin Woodpecker Co., Guilin, Guangxi, China) (mode: E, setting: 6) was used according to the manufacturer's recommendations.
214862803|NCT06204887|PROCEDURE|Laser activation|A 2940 nm Er:YAG-laser device (Lightwalker, Fotona, Ljubljana, Slovenia), equipped with a handpiece (H14, Fotona) holding a 8.5 mm long and 600 µm diameter-tapered fiber tip (SWEEPS 600, Fotona) was used for irrigation activation. The device was set to AutoSWEEPS mode with two ultrashort micropulse durations (25 μs) continuously varying at 0.3 W, 20 mJ, 15 Hz settings. The air and water sprays were turned off.
214862804|NCT05464667|RADIATION|Radiation Therapy (RT)|"Dose Escalation: 4 Cohorts - 30 GY in 5 fractions (baseline treatment with 0 boost dose to GTV), 35, 40, 50 Gy in 5 fractions (Par 1)~Dose Expansion: Maximum Tolerated Dose determined during dose escalation (Part 2)"
214862805|NCT04523610|BEHAVIORAL|Telehealth phone calls|The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).
214862806|NCT04523610|OTHER|Volunteer of TIP-OA Program|Participant is a volunteer of the TIP-OA Program
214862807|NCT04523610|OTHER|Stakeholder of TIP-OA Program|Participant is a stakeholder of the TIP-OA Program
214862808|NCT02935686|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV at a dose of 5\*10\^10 viral particles (vp), administered intramuscularly.
214862809|NCT02935686|BIOLOGICAL|Clade C gp140 plus adjuvant|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.
214862810|NCT02935686|BIOLOGICAL|Clade C gp140/Mosaic gp140 plus adjuvant|Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.
214862811|NCT02935686|OTHER|Placebo|Placebo Containing 0.9 percent normal saline, administered intramuscularly.
214862812|NCT02935686|BIOLOGICAL|gp140 HIV Bivalent Vaccine|gp140 HIV Bivalent Vaccine is adjuvanted protein co-formulation with a dosage strength of 80 mcg Clade C protein, 75 mcg Mosaic protein and 425 mcg aluminum (as aluminum phosphate adjuvant).
214862813|NCT05422703|DEVICE|Kinesio tape|Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).
214862814|NCT05422703|OTHER|Gauze pack|Place gauze pack over surgical site for one hour after surgery.
214862815|NCT05422703|DEVICE|ice pack|Ice packs will be applied for 6 hours after surgery in all patients
214862816|NCT05422703|PROCEDURE|Manual therapy|passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.
214862817|NCT05422703|DRUG|Analgesic|NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
214862818|NCT05422703|DRUG|Proteolytic enzymes|1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
214862819|NCT05422703|DRUG|Mouth wash|use 0.12% chlorhexidine or povidone iodine mouthwash daily
214862820|NCT05422703|DIETARY_SUPPLEMENT|Soft cold diet|For the day of surgery
214862821|NCT06228794|OTHER|Peripheral blood test|We will draw 2-5 mL of peripheral blood and utilize multiparameter flow cytometry to measure the level of circulating plasma cells.
214862822|NCT05034120|DRUG|XZP-3621|Administer a single dose of XZP-3621 tablet after a low-fat meal.
214862823|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
214862824|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9) : Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after on an empty stomach in a single dose on Day19.
215033711|NCT01416350|DRUG|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
214862825|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
214862826|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9) : Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
214862827|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
214862828|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day19.
214862829|NCT06330194|DEVICE|2nd Generation Automated Insulin Delivery (AID) system|The AID system will initially commence delivery by insulin pump post-randomisation without the AID in operation and with predictive low glucose suspend activated for a period of two weeks. Once safety has been established, the autocorrect function can be activated and the setpoint reduced to 5.5 mmol/L. Throughout the study insulin pump uploads will be reviewed twice weekly initially and at least weekly thereafter.
214862830|NCT03947736|DIAGNOSTIC_TEST|cfDNA was detected by dPCR|Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.
214862831|NCT04100564|DEVICE|Supraglottic airway device|Initial advanced airway management with a supraglottic device
214862832|NCT04100564|OTHER|Standard airway management|Initial advanced airway management with standard care method
214862833|NCT06383052|DRUG|177Lu-NYM032 injection|Radionuclide 177Lu will be used as a therapeutic nuclide for this study. The precursor of NYM032 will be labeled with 177Lu to form the chelation product, 177Lu-NYM032 injection which will be used in this study as a intravenous injection dose of 177Lu-NYM032. The radiation dose is chosen within the range of 50-200 mCi for an individual patient at every dose.
214862834|NCT02556372|DRUG|JKB-122|Orally administered capsules of JKB-122 which will be taken once daily with dose escalation from 5mg up to 40mg depending on the monthly response.
214862835|NCT02934763|DRUG|Propranolol|propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
214862836|NCT02934763|DRUG|Saline|Saline as placebo
214862837|NCT02884349|PROCEDURE|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
214862838|NCT00229736|GENETIC|AAV-hAADC-2|9 x 10\^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
214862839|NCT00229736|GENETIC|AAV-hAADC-2|3 x 10\^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
214862840|NCT04669470|PROCEDURE|bariatric endoscopy, mainly intragastric baloons, plication of stomach too|bariatric endoscopy, mainly intragastric baloons, plication of stomach too
214862841|NCT03592342|DRUG|Clobetasol Propionate|Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
214862842|NCT00031122|OTHER|No Intervention|There is no intervention in this study
214862843|NCT00640679|DRUG|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
214862844|NCT00640679|DRUG|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
214862845|NCT01917864|BEHAVIORAL|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
214862846|NCT06433635|DRUG|Cariprazine|"1. Cariprazine monotherapy outperformed placebo in improving depressive symptoms in most large randomized control trials (RCT). Pooled data showed higher remission rates (30.2%) with cariprazine (1.5 mg and 3 mg/day) compared to placebo (20.9%). Its efficacy extends to bipolar I depression, including mixed features and anxiety.~2. Common adverse effects include nausea (8%) and akathisia (7%). Somnolence and sedation were slightly more common with cariprazine than placebo.~3. Results from a large RCT evaluating cariprazine for bipolar disorder maintenance treatment (NCT03573297) are awaited. An open-label trial reported reduced manic symptoms over 16 weeks.~4. Cariprazine is a D3-preferring partial agonist for D3 and D2 receptors. It antagonizes 5-HT2A and 5-HT2B receptors and partially agonizes 5-HT1A receptors. Affinity for 5-HT1C and histamine 1 receptors is low to moderate."
214862847|NCT06433635|DRUG|Aripiprazole/Escitalopram combination|"1. 40-70% of bipolar patients use antidepressants, often with antipsychotics or mood stabilizers. Aripiprazole lacks efficacy in bipolar depression but is used for mania. Escitalopram, studied alongside mood stabilizers, showed some efficacy.~2. Aripiprazole in bipolar depression trials led to higher rates of akathisia, insomnia, nausea, fatigue, and impulse control disorders. Escitalopram's is generally safe but adverse effects include nausea, diarrhea, insomnia, dry mouth, ejaculatory dysfunction and dizziness.~3. Aripiprazole monotherapy in bipolar I patients reduced relapse rates and delayed relapse time, but not for depressive episodes.~4. Aripiprazole acts as a partial agonist at D2, D3, 5-HT1A, and 5-HT2C receptors, with antagonistic effects on α1 and possibly H1 receptors. Escitalopram is highly selective for the serotonin transporter, with no significant activity at other receptors."
215033712|NCT01416350|DRUG|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
215033713|NCT03473587|BEHAVIORAL|Motivational interview|A lay health advisor will engage the subject in a motivational interview to promote the importance of colorectal cancer screening
214862848|NCT06433635|DRUG|Quetiapine|"1. Both immediate and extended-release quetiapine monotherapies showed superiority over placebo in acute BD depression across three 8-week randomized trials, confirmed by meta-analysis. Quetiapine exhibited significantly higher remission rates (52.8%) compared to placebo (34.7%) and improved various aspects of life, including quality of life, clinical global impression, sleep, functioning, and anxiety.~2. Common adverse events of quetiapine include sedation, hypotension, increased appetite, weight gain, dyslipidemia, and elevated glucose levels, particularly in a population already at risk.~3. Four studies examined quetiapine's maintenance effects in patients with manic, mixed, or depressive episodes. Overall, quetiapine prolonged the time to recurrence for both depressive and manic episodes."
214862849|NCT06433635|DRUG|Lurasidone|"1. Lurasidone, either alone or with lithium/valproate, proved more effective than placebo for acute BD depression in two 6-week randomized trials. Remission rates were significantly higher with lurasidone monotherapy (40.9%) and in combination (50.3%) compared to placebo (24.7% and 35.4% respectively). Lurasidone also improved anxiety, quality of life, and disability.~2. Common mild adverse events included nausea, headache, akathisia, somnolence, sedation, dry mouth, and vomiting. Weight gain, dyslipidemia, and increased glucose levels were not observed.~3. In a 6-month double-blind discontinuation study post-acute treatment response, lurasidone combined with lithium/valproate prolonged time to depressive episode recurrence compared to placebo (hazard ratio: 0.68). Although not statistically significant due to low placebo recurrence and shorter follow-up, it hints at maintenance efficacy."
214862850|NCT06489457|DRUG|Semaglutide|Semaglutide subcutaneous injection once weekly titrated to 1 mg in concordance with Summary of product characteristics (SmPC) (0.25 mg once weekly in the first month, 0.5 mg once weekly in the second month and 1 mg once weekly from the third month onward)
214862851|NCT06489457|DRUG|Testosterone Undecanoate|Testosterone Undecanoate intramuscular injection 1000 mg once per 10-12 weeks
214862852|NCT01264731|BIOLOGICAL|MELITAC 12.1|Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants in cohort 1 will receive MELITAC 12.1 (100 mcg each of the12-MP and 200 mcg of Peptide-tet) administered subcutaneously (1 ml) and intradermally (1 ml) in Montanide ISA-51 VG adjuvant at a single vaccination site.
214862853|NCT01264731|DRUG|Imiquimod|Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.
214862854|NCT04957836|OTHER|reversal with sugammadex|reversal with sugammadex for immediate extubation in the operating room
214862855|NCT00218166|DRUG|GABA Agonists|GABA drugs administered acutely by mouth
214862856|NCT04141358|DIAGNOSTIC_TEST|Advanced ultrasound measurements|"Clinical interventions and procedures:~* Consent at 0 week~* Clinical data collection at 0 week~* Strain for native artery at 0 week~* Young's modulus for native artery at 0 week~* Intimal medial thickness for native artery at 0 week~* Ultrasound blood volume flow measurement at 0 week~* Vessel diameter at 0 week~* Blood pressure at 0 week~* BMI at 0 week~* Intra-operative blood volume flow measurement at AVF surgery time~* Strain for native artery at 6 weeks~* Young's modulus native artery at 6 weeks~* Intimal medial thickness native artery arteries at 6 weeks~* Ultrasound blood volume flow measurement at 6 weeks~* Vessel diameter at 6 weeks~* Blood pressure at 6 weeks~* BMI at 6 weeks"
214862857|NCT04265339|OTHER|Smoking cessation|Participants are required to quit smoking
214862858|NCT04006314|OTHER|Autologous platelet rich plasma and dextrose solution.|"Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves."
214862859|NCT04336514|DEVICE|Semi-compressed felt pad (SCF)|Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
214862860|NCT02715934|OTHER|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
214862861|NCT02715934|OTHER|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
214862862|NCT01816919|OTHER|collecting breath samples|
214862863|NCT00062010|BIOLOGICAL|interferon alpha|Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
214862864|NCT00062010|DRUG|13-cis-retinoic acid|13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
214862865|NCT00062010|DRUG|paclitaxel|paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
214862866|NCT02856880|OTHER|Test zinc-IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w IPMP and 1426ppm fluoride as sodium fluoride.
214862867|NCT02856880|OTHER|Test zinc non- IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride, 0% w/w IPMP and 1426ppm fluoride as sodium fluoride.
214862868|NCT02856880|OTHER|Positive control|Positive control toothpaste containing 0.454% w/w stannous fluoride (Fluoride Toothpaste (1100ppm Fluoride as stannous fluoride)).
214862869|NCT02856880|OTHER|SLS negative control|Negative control toothpaste containing 2.0% SLS, 0.65% Tegobetain and 1150 ppm fluoride as sodium fluoride
214862870|NCT02856880|OTHER|non-SLS negative control|Negative control toothpaste containing 1426 ppm fluoride as sodium fluoride
214862871|NCT05741515|OTHER|Vestibular Balance Therapy|see intervention arm description
214862872|NCT05741515|OTHER|Sham Intervention|see sham intervention arm description
214862873|NCT05354830|OTHER|Foot Massage|Foot Massage
214862874|NCT01289444|BEHAVIORAL|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care \& when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care \& prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
214862875|NCT01289444|BEHAVIORAL|Healthy Living Control|"Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~3\. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides."
214862876|NCT03416244|DRUG|Nivolumab|Nivolumab 240 mg IV fixed dose every two weeks
214862877|NCT03416244|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
214862878|NCT00573157|DRUG|Atacicept|Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
214862879|NCT00573157|DRUG|Mycophenolate mofetil|MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
214862880|NCT00573157|DRUG|Placebo|Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
214862881|NCT00573157|DRUG|Corticosteroids|High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
214862882|NCT05567484|DRUG|Itraconazole|100 mg two capsules of itraconazole were given twice daily to 30 patient group A for one week per month.baseline LFTs were also monitered
214862883|NCT04317183|DRUG|chamomile topical oral gel|Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.
214862884|NCT04317183|DRUG|Miconazole Topical Gel|topical anti fungal agent
214862885|NCT04317183|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
214862886|NCT04317183|DRUG|Oracure gel|Topical analgesic gel
214862887|NCT03557528|PROCEDURE|Laparoscopic colorectal resection|Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
214862888|NCT02944383|DRUG|Gemcabene|Gemcabene tablets administered orally once daily, for 12 weeks.
214862889|NCT02944383|DRUG|Placebo|Placebo tablets administered orally once daily, for 12 weeks.
214862890|NCT01632111|OTHER|Lung function measurement|Spirometry
214862891|NCT02646930|PROCEDURE|Endometrial biopsy|Endometrial biopsy in women undergoing first IVF cycle
214862892|NCT05960318|DEVICE|KalobaNaso spray|Nasal spray, 2 puff per nostril, 3 times a day
214862893|NCT05960318|DEVICE|KalobaNaso junior spray|Nasal spray, 1 puff per nostril, 3 times a day
214862894|NCT02823860|OTHER|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
214862895|NCT00055614|DRUG|topotecan hydrochloride|
214862896|NCT00055614|PROCEDURE|adjuvant therapy|
214862897|NCT01183221|DRUG|Syntocinon|One dose of 24 IU (3 sprays/nostril)
214862898|NCT01183221|DRUG|Placebo|Intranasal Placebo
214862899|NCT02674321|DRUG|SD-809|
214862900|NCT05367336|DRUG|Morphine|second group will be receiving morphine
214862901|NCT05367336|DRUG|Fentanyl|third group receiving fentanyl
214862902|NCT00003538|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
214862903|NCT00003538|PROCEDURE|allogeneic bone marrow transplantation|
214862904|NCT01551641|OTHER|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
214862905|NCT01551641|DRUG|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
214862906|NCT01551641|OTHER|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
214862907|NCT04461561|GENETIC|end-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
214862908|NCT00167687|DRUG|prazosin|"Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg"
214862909|NCT03249974|DEVICE|Enlite sensor communicating with Minimed 640G pump|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
214862910|NCT03572166|DIAGNOSTIC_TEST|Arginine infusion|Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
214862911|NCT03572166|DIAGNOSTIC_TEST|Hypertonic saline infusion|Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
214862912|NCT01935466|DRUG|Pioglitazone|Ever users of Pioglitazone
214862913|NCT01957072|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of~1. feedback via a web-based food diary~2. 'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails."
214862914|NCT04243434|DRUG|Vincristine Sulfate Liposome|Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.
214862915|NCT04243434|COMBINATION_PRODUCT|CHOP|CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
214862916|NCT04243434|COMBINATION_PRODUCT|R-CHOP|R-CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
214862917|NCT02878941|PROCEDURE|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
214862918|NCT03861403|DRUG|TRX518|Administered by IV infusion
214862919|NCT03861403|DRUG|Cyclophosphamide|Administered by IV infusion
214862920|NCT03861403|DRUG|Avelumab|Administered by IV infusion
214862921|NCT02931903|OTHER|Vita Enamic (hybrid dental ceramic)|Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,
214862922|NCT02931903|OTHER|lithium disilicate glass-ceramic|All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
214862923|NCT06151496|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
214862924|NCT06151496|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
214862925|NCT03621059|BEHAVIORAL|habit reversal training (HRT)|"The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)"
214862926|NCT03275636|BIOLOGICAL|Peripheral blood stem cells|Hematopoietic stem cell transplantation with PBSC
214862927|NCT04267107|OTHER|Individual Managing Fatigue Program|The Individual Managing Fatigue Program includes six weekly sessions that focus on sleep, communication and body mechanics, activity stations, priorities and standards, and balancing daily schedule. Each session includes three parts: 1) a pre-session activity 2) in-session activities/information and 3) homework. Prior to coming to each session, participants will be asked to complete activities that will help them prepare for the in-session discussions. During each session participants will discuss and practice the topics most important to them. Based on their discussions, participants and therapists will decide on activities to complete during each session and as homework. The therapist will help the participant begin the homework at the end of each session, and the participant will finish it outside of the session at home. At the beginning of the following session, the therapist and participant will review the homework.
214862928|NCT04069871|DEVICE|trans-cutaneous electrical nerve stimulation.|• Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
214862929|NCT04069871|DEVICE|Sham TENS|Patients in the control group will receive sham TENS.
214862930|NCT00266071|BEHAVIORAL|Cutaneous response|
214862931|NCT02422771|OTHER|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
214862932|NCT05874583|DRUG|Combined route administration of Tranexamic acid|tranexamic acid in topical route administration
214862933|NCT05874583|DRUG|Intravenous route Tranexamic acid injection|Intra venous route administration
214862934|NCT04848311|PROCEDURE|lymph nodes dissection at 253 station assisted by ICG|In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
214862935|NCT04022928|OTHER|PRP|, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
214862936|NCT04132583|DRUG|Deflox®|Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
214862937|NCT04132583|DRUG|Cataflam DD®|Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
214862938|NCT03970928|DEVICE|PVI|A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
214862939|NCT05803928|DRUG|lenvatinib + anti-PD-1 antibodies|A ablation treatment group B ablation+ lenvatinib + anti-PD-1 antibodies treatment group
214862940|NCT05803928|PROCEDURE|ablation|radiofrequency ablation or microwave ablation
214862941|NCT00292487|DRUG|Iopamidol 370 mgI/mL|
214862942|NCT03410251|PROCEDURE|Socket preservation|"Teeth were extracted atraumatically and without flap release in patients who have received prophylactic antibiotherapy and local anaesthesia. After checking the integrity of the buccal and palatal bone plate, biomaterial (Bio-Oss®) was introduced into the socket. A connective tissue graft harvested from the palate was inserted and sutured in buccal and palatal pouches in order to cover the socket.~chlorhexidine spray (0.12%) twice a day and Ibuprofen 600 mg three times/ day were prescribed whereas antibiotics were continued for 5 days. Tooth brushing was banned at the extraction site for 10 days and sutures were removed 10 days after surgery."
214862943|NCT04551833|DRUG|Levobupivacaine|Tramadol versus Dexamethasone as adjuvant to Levobupvacain
214862944|NCT00684489|DRUG|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
214862945|NCT00684489|DRUG|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
214862946|NCT05464043|DIAGNOSTIC_TEST|evaluation of second line glucose homeostasis|blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
214862947|NCT04162054|OTHER|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).
214862948|NCT02433262|OTHER|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
214862949|NCT02433262|OTHER|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
214862950|NCT05533762|DEVICE|arch insole and sham insole|children wear insoles on feet
214862951|NCT04054960|DEVICE|Active tPCS|Active anodal tPCS will be given for 20 mins to motor cortex (M1) or supplementary motor area (SMA), based on our quantitative EEG findings.
214862952|NCT04054960|DEVICE|Sham tPCS|For the sham condition, the electrode placement will be the same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation.
214862953|NCT04054960|DRUG|Levodopa tablet|We will give 3 tablets of Levodopa-Carbidopa (100/25).
214862954|NCT03166423|DRUG|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
214862955|NCT03166423|DEVICE|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
214862956|NCT04920643|PROCEDURE|Ultrafiltration|Ultrafiltration is used during cardiac surgery with cardiopulmonary bypass to remove both fluid and small molecules such as inflammatory cytokines from the patient's circulation.
214862957|NCT02567643|RADIATION|Stereotactic Radiosurgery|
214862958|NCT05326321|OTHER|Study Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
214862959|NCT02254213|OTHER|EEG recording|A short EEG recording is performed 10 times over the span of three months.
214862960|NCT03589586|OTHER|DermACELL AWM|DermACELL AWM is a sterile, ready to use acellular dermal matrix
214862961|NCT00662948|DRUG|Rituximab|375 mg/m2 every 8 weeks during 24 months
214862962|NCT00662948|DRUG|Ibritumomab tiuxetan|One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
214862963|NCT03139786|OTHER|Study the natural history of bicuspid|Study the natural history of bicuspid
214862964|NCT04190810|BEHAVIORAL|Inhibition|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
214862965|NCT04190810|BEHAVIORAL|Classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
214862966|NCT04190810|BEHAVIORAL|Control|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
214862967|NCT02427035|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
214862968|NCT02427035|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
214862969|NCT02203214|DEVICE|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
214862970|NCT04645810|PROCEDURE|High-Dose-Rate Brachytherapy|High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
214862971|NCT06060808|GENETIC|gene polymorphism|gene polymorphism of NFKBIA and PTPN22 genes
214862972|NCT00807248|DRUG|Escitalopram placebo|Once daily before bedtime for 8 weeks
214862973|NCT00807248|DRUG|Gaboxadol placebo|Once daily before bedtime for 8 weeks
214862974|NCT00807248|DRUG|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
214862975|NCT00807248|DRUG|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
214862976|NCT00807248|DRUG|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
214862977|NCT01685411|DRUG|Allopurinol|Day -8 (prior to transplant): Per institutional guidelines
214862978|NCT01685411|DRUG|Keppra|Day -8 (prior to transplant): Per institutional guidelines
214862979|NCT01685411|DRUG|Busulfan|Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
214862980|NCT01685411|DRUG|Cyclophosphamide|Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
214862981|NCT01685411|DRUG|Tacrolimus|All patients (regardless of allograft source) will receive tacrolimus therapy beginning on day -3. Dosing will be monitored and altered as clinically appropriate per institutional pharmacy guidelines. Dose adjustments will be made on the basis of toxicity and/or low tacrolimus levels. Taper at day +100 for matched sibling donor (MSD) recipients, and day +180 for non-MSD recipients. Taper to zero by 10% weekly dose reduction over approximately 10 weeks.
214862982|NCT01685411|DRUG|Mycophenolate mofetil|Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (\> or = 40 kg) or 15 mg/kg 3 times per day (\< 40 kg) for up to 30 days unless no engraftment.
214862983|NCT01685411|BIOLOGICAL|Allogeneic hematopoietic stem cell transplant|Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
214862984|NCT01685411|BIOLOGICAL|Filgrastim|Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is \>2500 x 10\^9/L or per institutional guidelines.
214862985|NCT01685411|BIOLOGICAL|antithymocyte globulin|Administered per institutional guidelines for recipients of umbilical cord blood transplant.
214862986|NCT04901598|OTHER|Running anaerobic sprint test and aerobic test|subjects walk a mile with maximum steps and their heart rate will not exceed 180 beats per minute during the test and the execution time will not be less than 9 minutes (RAST test)
214862987|NCT06442423|DRUG|Psilocybin|Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.This is an open-label clinical trial with a single treatment arm. This is an open-label clinical trial with no blinding.
214862988|NCT00813566|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
214862989|NCT00813566|DRUG|3'-deoxy-3'-[18F]fluorothymidine (FLT)|Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
214862990|NCT00813566|DRUG|[15O]-H2O|Brain scan with imaging agent to determine tumor blood flow
214862991|NCT00813566|DRUG|[11C]Acetate|Brain scan with imaging agent to determine growth activity of tumor
214862992|NCT02689050|DEVICE|Needle based confocal laser endomicroscopy (nCLE)|During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
214862993|NCT02504671|DRUG|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
214862994|NCT02504671|DRUG|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
214862995|NCT02504671|DRUG|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
214862996|NCT02504671|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
214862997|NCT06016036|DRUG|SAL-0951|"SAL-0951：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
214862998|NCT06016036|DRUG|Placebo|"SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
214862999|NCT02242916|RADIATION|Photon therapy versus proton therapy|
214863000|NCT02242916|RADIATION|Photon therapy versus C-ion therapy|
214863001|NCT04842565|DRUG|Sintilimab|Sintilimab (200mg ivdrip D1 Q3W)
214863002|NCT04842565|DEVICE|TACE|TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.
214863003|NCT04959591|DRUG|intravenous acetaminophen|experimental(pre): administration of IV acetaminophen
214863004|NCT04959591|DRUG|intravenous acetaminophen|experimental(post): administration of IV acetaminophen
214863005|NCT04959591|DRUG|Placebo|placebo comparator: administration of normal saline
214863006|NCT00599521|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
214863007|NCT00599521|DRUG|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
214863008|NCT02860221|DRUG|Tranexamic acid (TXA)|IV and topical administration
214863009|NCT02860221|DRUG|Epinephrine|
214863010|NCT00197288|BIOLOGICAL|Influenza|
214863011|NCT04602715|DRUG|MET-2|Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
214863012|NCT04602715|DRUG|Placebo|Placebo Control
214863015|NCT02789397|DRUG|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
214863016|NCT02789397|DRUG|Placebos|IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
214863017|NCT03279497|BEHAVIORAL|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
214863018|NCT03279497|BEHAVIORAL|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
214863019|NCT02948153|OTHER|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
214863020|NCT04227353|BEHAVIORAL|HEAL ABC|Participants will be assigned their first booklet based on the one they perceive to be the easiest for setting an incremental goal and achieving it. After the participant achieves successful behaviour change, he or she can move more confidently to the next booklet. Support will be provided every two weeks over the phone for 12 weeks. During the follow-up period, participants will use the follow-up booklet which helps them to continue with changes they have made and encourage them to set new goals.
214863021|NCT04131777|DEVICE|Radiofrequency (RF) catheter|A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation
214863022|NCT00004151|DRUG|acridine carboxamide|
214863023|NCT00811356|DRUG|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
214863024|NCT00002353|BIOLOGICAL|P3C541b Lipopeptide|
214863025|NCT05250648|DRUG|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
214863026|NCT05250648|PROCEDURE|complete cytoreductive surgery without HIPEC|in the arm without HIPEC, only complete cytoreductive surgery will be performed
214863027|NCT04706286|DRUG|CKD-501, D759, D150|CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
214863028|NCT04706286|DRUG|CKD-393 0.5/100/1000 mg|CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
214863029|NCT02933268|DIETARY_SUPPLEMENT|High water intake|High water intake aimed at achieving an urine osmolality \< 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
214863030|NCT02933268|OTHER|Ad libitum water intake|Water intake guided by thirst
214863031|NCT00555386|DIETARY_SUPPLEMENT|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
214863032|NCT05382169|OTHER|Determine the presence of mast cell activation syndrome|"Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) :~* At least two clinical signs compatible with MAS before the first consultation (V1)~* Improvement of symptoms on antihistamines within 2 months of initiation of treatment~* Significant increase in tryptase during crisis~Mast cell activation syndrome will be possible if :~* At least two clinical signs consistent with MAS before the first consultation (V1)~* Improvement of symptoms with antihistamines within 2 months of initiation of treatment~* No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely."
214863033|NCT01293539|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (\>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle."
214863034|NCT05903014|DRUG|n-acetylcysteine|we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
214863035|NCT05903014|BEHAVIORAL|Motivational Enhancement Therapy|Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
214863036|NCT00887055|DEVICE|CRT device|
214863037|NCT03429517|DIAGNOSTIC_TEST|Lipogram|liporgram samples
214863038|NCT00267449|DEVICE|SoftScan Optical Breast Imaging System|
214863039|NCT00418301|OTHER|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
214863040|NCT04493866|OTHER|Messages to departmental employees to improve quality of consent form completion|All interventions directed to members of the plastic surgery department: Intervention 1: Poster illustration common mistakes on consent forms. Intervention 2: Group message explaining Quality Improvement Project to the department. Intervention 3: Email from Consultant lead in support of project. Intervention 4: Further group message illustrating gains and ongoing goals of the project.
214863041|NCT02910674|DEVICE|Dario Blood Glucose Monitoring System|Accuracy with usability assessment
214863042|NCT03547700|DRUG|Romidepsin|Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
214863043|NCT03547700|DRUG|Ixazomib|Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
214863044|NCT01687478|DRUG|Olanzapine|Administered Orally
214863045|NCT01687478|DRUG|Fluoxetine|Administered Orally
214863046|NCT01687478|DRUG|Placebo|Administered Orally
214863047|NCT01546935|DRUG|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
214863048|NCT05479916|DIETARY_SUPPLEMENT|Low glycated milk protein|40 grams of protein dissolved in 600 mL of water
214863049|NCT05479916|DIETARY_SUPPLEMENT|High glycated milk protein|40 grams of protein dissolved in 600 mL of water
214290664|NCT00276744|BIOLOGICAL|cetuximab|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
214863050|NCT00742066|DRUG|Irbesartan|Single dose 600mg orally
214863051|NCT00742066|DRUG|Felodipine|single dose 10mg Felodipine ER
214863052|NCT00742066|DRUG|Placebo|Single dose tablet orally
214863053|NCT04120038|DEVICE|Self-Management for Amputee Rehabilitation using Technology [SMART]|Participants will complete a 6-week tablet-based education program for individuals with LLA that will provide them with self-management education.
214863054|NCT03544710|OTHER|preoperative bathing with antiseptic|"Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
214863055|NCT04641078|DRUG|Darolutamide|600 mg BID
214863056|NCT04641078|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
214863057|NCT01242995|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
214863058|NCT00914953|DRUG|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
214863059|NCT03126357|OTHER|Product A|Usual Brand Cigarette
214863060|NCT03126357|OTHER|Product B|FT21039 an electronic tobacco vapor product
214863061|NCT03126357|OTHER|Product C|FT21092 an electronic tobacco vapor product
214863062|NCT03126357|OTHER|Product D|FT21018 an electronic tobacco vapor product
214863063|NCT03126357|OTHER|Product E|4mg nicotine gum
214863064|NCT03828916|OTHER|NuShield|SOC surgery with the addition of NuShield
214863065|NCT01714375|DEVICE|QuietDose Device|"The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss."
214863066|NCT03762499|DIAGNOSTIC_TEST|Echocardiography scan|Non-invasive ultrasound imaging of the heart.
214863067|NCT04322149|DRUG|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
214863068|NCT03040557|DEVICE|Flexible footwear|\- Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
214863069|NCT03040557|DEVICE|Orthopedic insole|\- Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
214863070|NCT01700049|DRUG|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
214863071|NCT05909930|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 6 months at home, with a frequency of 1-3 sessions per week at the hospital.
214863072|NCT05909930|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
214290665|NCT00276744|DRUG|capecitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
214863073|NCT03534843|PROCEDURE|Liver resection|Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
214863074|NCT03534843|OTHER|Transcatheter arterial embolization|Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
214863075|NCT00850434|DEVICE|Modified AutoSet Algorithm|"The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm"
214863076|NCT00850434|DEVICE|Standard AutoSet Algorithm|The standard AutoSet used for treatment of OSA
214863077|NCT05394311|OTHER|sports based mental health promotion program|sports related programs
214863078|NCT05189886|PROCEDURE|Double Balloon Valvuloplasty in TAVR|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
214863079|NCT00871273|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
214863080|NCT01206101|DRUG|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
214863081|NCT01206101|DRUG|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
214863082|NCT01906892|OTHER|Group drumming (participatory)|Active participation in group drumming workshops
214863083|NCT01906892|OTHER|Group drumming (live)|Listening to live performances of group drumming
214863084|NCT01906892|OTHER|Group drumming (recorded)|Listening to recorded performances of group drumming
214863085|NCT01906892|OTHER|Comparative activity|Taking part in a literary-based activity
214863086|NCT01248013|BEHAVIORAL|gut focused hypnotherapy|7 session hypnotherapy protocol designed for irritable bowel syndrome
214863087|NCT00037024|PROCEDURE|fatigue assessment and management|
214863088|NCT00037024|PROCEDURE|nutritional support|
214863089|NCT00037024|PROCEDURE|physical therapy|
214863090|NCT00037024|PROCEDURE|psychosocial assessment and care|
214863091|NCT00037024|PROCEDURE|quality-of-life assessment|
214863092|NCT04653272|OTHER|Questionnaire|Patients will be evaluated identically to routine care with reference tests (Lysholm-Tegner, and Knee injury and Osteoarthritis Outcome Score (KOSS) and, IKDC (Evaluation of knee ligament injuries). This is filled in without any external help. The questionnaire includes the Lysholm-Tegner (young adult group), IKDC and KOOS scores (young and senior adult groups).
214863093|NCT02154295|DEVICE|Infraredx Test Catheter|
214863094|NCT02468622|OTHER|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
214863095|NCT03745157|DRUG|Insulin Degludec/Insulin Aspart|Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
214863096|NCT02033057|PROCEDURE|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
214863097|NCT03019159|DEVICE|Teleconsulting|
214290666|NCT00276744|DRUG|docetaxel|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
215033714|NCT03473587|BEHAVIORAL|Standard of care|A lay health advisor will provide the subject with a brochure promoting the importance of colorectal cancer screening
214863098|NCT03426137|DRUG|Oxycodone|5mg Oxycodone in oral solution given every 3 hours
214863099|NCT03426137|DRUG|Ketorolac|toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
214863100|NCT03426137|OTHER|Placebo|Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
214863101|NCT03507647|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"MBCT is a manualised group skills-training program (Segal, Williams \& Teasdale 2012) consisting of eight weekly sessions of 2.5 hours, plus one day of silent practice. The program includes both formal and informal meditation exercises. Cognitive techniques that are part of the program are education, monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan.~The MBCT treatment will be adapted to address the needs of patients with a bipolar disorder. A few examples of these adaptations are: (more) psychoeducation about manic symptoms in addition to the psychoeduction about depression; introducing the 3-minute breathing space earlier in the programme and more often during sessions, especially when strong emotions are present; repeatedly bringing the focus to self-care; and making use of the mindful movement (yoga) exercises more frequently."
214863102|NCT03507647|OTHER|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse). Usual care will not be restricted, except for proscribing high-frequency psychological interventions such as (group) cognitive behavioral therapy, for practical and methodological reasons.
214863103|NCT02677181|DRUG|ATG|rabbit ATG（Sanofi）
214863104|NCT02677181|DRUG|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
214863105|NCT02677181|DRUG|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
214863106|NCT02677181|DRUG|Methotrexate|short-term methotrexate
214863107|NCT00209105|DRUG|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
214863108|NCT00209105|BEHAVIORAL|Psychosocial stress induction|Laboratory stress induction, no drug administration
214863109|NCT00209105|PROCEDURE|Brain imaging of sad mood , self-reference, reward|Brain imaging
214863110|NCT00209105|BEHAVIORAL|Acoustic startle|No drugs involved
215033715|NCT02733757|DRUG|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
215033716|NCT00031733|BIOLOGICAL|MART-1 antigen|
215033717|NCT00031733|BIOLOGICAL|gp100 antigen|
215033718|NCT00031733|BIOLOGICAL|incomplete Freund's adjuvant|
214290667|NCT00276744|DRUG|Erlotinib|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
215033719|NCT00031733|BIOLOGICAL|recombinant interleukin-12|
215033720|NCT00031733|BIOLOGICAL|sargramostim|
215033721|NCT00031733|BIOLOGICAL|tyrosinase peptide|
215033722|NCT00031733|DRUG|alum adjuvant|
215033723|NCT00031733|PROCEDURE|adjuvant therapy|
215033724|NCT03577457|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
214290668|NCT00276744|DRUG|Gemcitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
214863111|NCT04604743|BEHAVIORAL|Intervention, TBN|The intervention will target adolescents aged 15-17 years who have not received at least one dose of the HPV vaccine. The intervention has yet to be named; this will occur through the conduct of Aim 1. Our intervention, when developed, will improve knowledge of HPV, COVID-19, the HPV vaccine, and the COVID-19 vaccine (Information), reduce stigma and distrust improving motivation (Motivation), leading to improved vaccine confidence and higher vaccination rates and lower vaccine hesitancy (Behavioral Skills). Each one of these three change objectives will be encapsulated in its own Zoom-based session with the near peer interventionist. We anticipate that each modular session will be no longer than seven minutes; thus, the entire three module intervention will be no longer than twenty-one minutes long.
214863112|NCT00709436|DRUG|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
214863113|NCT00709436|DRUG|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
214863114|NCT02631018|BEHAVIORAL|Standard Weight Loss Intervention|18 session, group-based, 6-month, standard behavioral weight loss intervention
214863115|NCT02631018|BEHAVIORAL|Physical Activity Enhanced Weight Loss Intervention|18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
214863116|NCT01841775|DRUG|interferon α 2b + ribavirin|"1. interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks~2. ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks"
214863117|NCT04304365|OTHER|Follow-up clinic visit|Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.
214863118|NCT04304365|OTHER|Text message|Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.
214863119|NCT04304365|OTHER|Low Sensitivity Pregnancy Test (LSPT)|Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
214863120|NCT00307034|BIOLOGICAL|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
214863121|NCT00307034|BIOLOGICAL|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
214863122|NCT00307034|BIOLOGICAL|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
214863123|NCT02239341|OTHER|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
214863124|NCT02239341|OTHER|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
214863125|NCT02667171|BEHAVIORAL|Supervised COPD Rehabilitation (control group)|"The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).~Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises."
214863126|NCT02667171|BEHAVIORAL|Online COPD rehabilitation (experimental)|"Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.~Educations consists same information as for the control group."
214863127|NCT01867944|BEHAVIORAL|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
214863128|NCT01867944|BEHAVIORAL|Educational Control|Education on conventional treatment options for chronic constipation.
214863129|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally|Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
214863130|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally|Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
214863131|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
214863132|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
214863133|NCT00667810|DRUG|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
214863134|NCT01983917|BEHAVIORAL|Diabetes Mobile Application|
214863135|NCT01527617|OTHER|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
214863136|NCT01527617|OTHER|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
214863137|NCT03514641|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
214863138|NCT03514641|DRUG|Placebo|Placebo (inactive) tablet to match the active drug
214863139|NCT02960919|DRUG|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
214863140|NCT02960919|DRUG|parenteral ampicillin/ penicillin|
214863141|NCT02960919|DRUG|gentamicin|
214290669|NCT00276744|DRUG|Irinotecan|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
214863142|NCT00094003|DRUG|NS-9 [Poly I: Poly C]|
214863143|NCT06410170|DEVICE|MIRA Device|At home diagnostic testing
214863144|NCT02038907|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
214863145|NCT02038907|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
214863146|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6)|0.5 mL suspension for injection x 2 with 2 months interval
214863147|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
214863148|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
214863149|NCT03294486|DRUG|Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)|"Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:~* Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu~* Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.~  5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L."
214863150|NCT04701515|OTHER|Chart review|Chart review
214863151|NCT04596228|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
214863152|NCT02513511|PROCEDURE|laryngoscopy under hypnosis|patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
214863153|NCT01653561|DRUG|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
214863154|NCT00129051|PROCEDURE|Tomotherapy|
214863155|NCT04781101|OTHER|conventional therapy|Conventional therapy sessions that were planned by a physiotherapist for the children were conducted by a physiotherapist experienced in paediatrics. The therapy sessions mainly focused on functions such as the regulation of muscle tone, correction of posture, elimination of stiffness, muscle strengthening, balance/coordination training and mobilisation (Figure 2). The sessions were planned to last 40 minutes.
214863156|NCT04781101|OTHER|RoboGait®|The RoboGait®-assisted gait system was used for the robot-assisted gait training. In addition to conventional therapy, 16 robot-assisted gait training sessions were conducted, each lasting 25 minutes for 2 days a week (400 minutes in total). Gait speed was 1.5 km/h in all sessions. Considering conditions such as joint limitations and spasticity, gait training was performed with patients bearing 45% to 75% of their weight.
214863157|NCT04215848|DRUG|Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.
214863158|NCT04215848|DRUG|Budesonide 200Mcg Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily
214863159|NCT04814030|DRUG|PD-1 inhibitor|Transarterial hepatic chemoembolization and FOLFOX-based infusion
214863160|NCT00595686|DRUG|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
214863161|NCT02564419|DEVICE|Medtronic Activa PC+S|Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
214863162|NCT03559621|BEHAVIORAL|mobile-based lifestyle intervention|one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
214863163|NCT00755404|DRUG|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
214863164|NCT00755404|DRUG|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
214863165|NCT05665114|DRUG|QN-030a|NK cell therapy
214863166|NCT05665114|DRUG|Cyclophosphamid|Lympho-conditioning Agent
214863167|NCT05665114|DRUG|Fludarabine|Lympho-conditioning Agent
214863168|NCT05665114|DRUG|Cytarabine|Lympho-conditioning Agent
214863169|NCT05665114|DRUG|VP-16|Lympho-conditioning Agent
214863170|NCT03311035|PROCEDURE|Seton|The identification of the primary tract of the fistula and the placement of the thread can be performed in one single step. a non-absorbable, braided thread is inserted . After excision of the external opening and the extrasphincteric parts of the fistula, the thread is grasped and is pulled out of the anus .The thread is cut in two parts. The mucosa is incised over the muscular bridge . One thread is tied snugly around the muscle; the other is tied loosely .The snugly tied seton has to be replaced after 14 days to provide appropriate tension to cut slowly trough the muscle. This can easily be achieved with the second loosely tied seton . A new thread is folded in the middle and connected to the opened sling of the loose seton using a special knot shown in.The old thread is removed and in the same maneuver two new setons are placed. Again, one thread is tied snugly around the remaining portion of the sphincter muscle; the other is tied loosely .
215033725|NCT03577457|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
215033726|NCT03577457|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
215033727|NCT03577457|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
214863171|NCT03311035|PROCEDURE|LIFT technique|The internal opening was identified . The intersphincteric plane was entered via a curvilinear incision corresponding to the site of the internal opening at the intersphincteric groove. The intersphincteric plane was developed by meticulous scissor and diathermy dissection up to the tract. Once identified, a small, right-angled clamp was hooked underneath or a tape passed round it. the tract was then transfixed close to the internal sphincter with 2/0 polyglactin suture . Saline was gently injected through the external opening to confirm that the tract was no longer patent and it was then divided distal to the point of ligation . After light traction, a segment of the distal tract was excised and, if needed, any defect in the external sphincter was closed. The intersphincteric incision wound was re-approximated loosely with interrupted 2/0 Vicryl. Partial core-out of the fistula tract was performed from the external opening to the external sphincter.
214863172|NCT04921020|OTHER|Photography|Facial photographs and blinking videos are taken
214863173|NCT03178565|OTHER|Mechanical insufflation-exsufflation|The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
214863174|NCT03178565|OTHER|Standard Respiratory Physiotherapy|Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
214863175|NCT02655744|RADIATION|Standard treatment protocol with combined chemoradiation|
214863176|NCT01335386|DRUG|KLYX|
214863177|NCT01335386|DRUG|Glycerine|
214863178|NCT02878486|DEVICE|Jawbone Up|Jawbone Up is a wrist wore water resistant activity monitor.
214863179|NCT02878486|BEHAVIORAL|Physical Activity Education|A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
214863180|NCT02878486|DEVICE|ActivPAL|Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
214863181|NCT02815449|OTHER|Meals prepared with iron fortified cube with Low stabilizer level|Meals prepared with iron fortified cube with Low stabilizer level
214863182|NCT02815449|OTHER|Meals prepared with iron fortified cube with Medium stabilizer level|Meals prepared with iron fortified cube with Medium stabilizer level
214863183|NCT02815449|OTHER|Meals prepared with iron fortified cube with High stabilizer level|Meals prepared with iron fortified cube with High stabilizer level
214863184|NCT01713049|DRUG|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
214863185|NCT00003851|BIOLOGICAL|proteolytic enzymes|
214863186|NCT00003851|DRUG|gemcitabine hydrochloride|
214863187|NCT00003851|PROCEDURE|Gonzalez regimen|
214863188|NCT01239875|BIOLOGICAL|dendritic cell vaccine therapy|Given intratumorally
214863189|NCT01239875|PROCEDURE|cryotherapy|Undergo cryoablation
214863190|NCT01239875|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
214863191|NCT01239875|OTHER|laboratory biomarker analysis|Correlative studies
214863192|NCT01239875|OTHER|immunoenzyme technique|Correlative studies
214863193|NCT01239875|OTHER|immunohistochemistry staining method|Correlative studies
214863194|NCT01239875|BIOLOGICAL|autologous dendritic cell-tumor fusion vaccine|Given intradermally
214863195|NCT00145275|DRUG|zoledronic acid|
214863196|NCT00185666|PROCEDURE|Stereotactic radiosurgery|
214863197|NCT04296058|OTHER|microvessel density|the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
214863198|NCT05806619|OTHER|histopathological analysis; morphological and non-morphological magnetic resonance|The surgical material removed during surgery was subjected to histological analysis. Morphological and non-morphological magnetic resonance examination before the neurosurgical surgery, according to clinical practice.
214863199|NCT02894281|DEVICE|pupillary light reflex|measure with infra-red cameras
214863200|NCT00628537|DEVICE|BION stimulation|"BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises."
214863201|NCT00807677|DRUG|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
214863202|NCT05803174|DIAGNOSTIC_TEST|blood sample|"Blood collection Circulating serum concentrations of melatonin and dopamine were determined from fasting blood samples. Participants were required to fast from 10 pm the previous evening. A 5 mL serum blood sample was collected from the antecubital vein between 8.30 am and 10 am.~Tear collection Tear samples were collected using Schirmer's strip without anesthesia between 8:30-10:00am. Tears were extracted in 200 μl of 1 X Phosphate Buffered Saline with 0.1% Tween-20 (PBST).~Saliva collection Saliva samples were collected via the passive drool method with subjects in a seated position. Subjects were asked to rinse their mouth with water 10 minutes prior to saliva collection and to refrain from using lip makeup during the sampling period."
214863203|NCT01141244|DRUG|temsirolimus|Given IV
214863204|NCT01141244|DRUG|temozolomide|Given orally
214863205|NCT01141244|DRUG|irinotecan hydrochloride|Given IV
214863206|NCT01141244|OTHER|laboratory biomarker analysis|Correlative studies
214863207|NCT05702671|DIAGNOSTIC_TEST|Total Immunoglobulin E, Obtained From Fingerstick Sample|The Kenota 1 System is intended to be a specialized tool in a professional allergist setting. It will help streamline the patient testing process by bringing quantitative, minimally invasive fingerstick IgE blood testing to the allergy clinic.
214863208|NCT01328665|OTHER|Expressive Writing|Writing intervention for cognitive appraisal of stressor.
214863209|NCT06024889|DRUG|Furosemide Injection|Intravenous administration of 80 mg furosemide is followed by assessing blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS\*, and ultrasound examination of heart and lungs, including assessment of filling pressures with doppler and strain analysis. These measurements are repeated at multiple time points until 6 hours have elapsed.
214863210|NCT03791723|DRUG|Sacubitril-Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
214863211|NCT03791723|DRUG|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
214863212|NCT02444923|DEVICE|Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
214863213|NCT02444923|DEVICE|Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
214863214|NCT05644015|OTHER|escape room game|Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
214863215|NCT00045188|DRUG|imatinib mesylate|Given PO
214863216|NCT00045188|OTHER|laboratory biomarker analysis|Optional correlative studies
214863217|NCT00003960|DRUG|busulfan|
214863218|NCT00003960|DRUG|cyclophosphamide|
214863219|NCT00003960|DRUG|methylprednisolone|
214863220|NCT00003960|PROCEDURE|allogeneic bone marrow transplantation|
214863221|NCT00003960|PROCEDURE|in vitro-treated bone marrow transplantation|
214863222|NCT01059266|DRUG|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
214863223|NCT00730223|DRUG|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
214863224|NCT03425695|DEVICE|CheseeTM Diode Laser|low level laser therapy was utilized adjunct with free gingival graft.
214863225|NCT03425695|OTHER|Clinical examination|"The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery."
214863226|NCT06289803|DEVICE|probe confocal laser endomicroscopy|probe confocal laser endomicroscopy will be used to identify the tumor behavior
214290670|NCT00276744|DRUG|mitomycin C|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
214863227|NCT03274882|DRUG|S95005|The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
214863228|NCT01320748|BEHAVIORAL|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
214863229|NCT01320748|BEHAVIORAL|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
214863230|NCT05759936|DIETARY_SUPPLEMENT|500mg seaweed|4 week supplementation of 1 capsule per day of seaweed
214290671|NCT00276744|DRUG|rapamycin|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
214863231|NCT05759936|OTHER|Placebo|4 week placebo supplement of 1 capsule per day
215033728|NCT05990686|DRUG|Tramadol Hydrochloride|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)"
215033729|NCT05990686|DRUG|Fentanyl injection|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~."
215033730|NCT05233839|OTHER|Telerehabilitation|Application based video home exercise for the degenerative meniscus injury
215033731|NCT05233839|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the degenerative meniscus injury
215033732|NCT00184392|PROCEDURE|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
214863232|NCT03641521|BEHAVIORAL|Parent-led behavioral strategies|Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
214863233|NCT00030979|DRUG|Donepezil|
214863234|NCT01051219|DRUG|Losartan|50 milligrams to be taken orally, daily
214863235|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 1|Free mobile mental health application that focuses on meditation
214863236|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 2|Free mobile mental health application that assists with coping with COVID-19
214863237|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 3|Free mobile mental health application that focuses on positive psychology.
214863238|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 4|Free mobile application that addresses mental health issues through mood tracking
214863239|NCT00423475|DRUG|goserelin acetate|
214863240|NCT00423475|PROCEDURE|adjuvant therapy|
214863241|NCT00423475|RADIATION|radiation therapy|
214863242|NCT06128070|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214863243|NCT06128070|PROCEDURE|Chest Computed Tomography|Undergo chest CT
214863244|NCT06128070|PROCEDURE|Echocardiography|Undergo ECHO
214863245|NCT06128070|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
214863246|NCT06128070|DRUG|Methotrexate|Given IV
214863247|NCT06128070|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214863248|NCT06128070|DRUG|Ruxolitinib Phosphate|Given PO
214863249|NCT06128070|DRUG|Tacrolimus|Given IV
214863250|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
214863251|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
214863252|NCT01732484|PROCEDURE|intraocular lens implantation|
214863253|NCT05402774|DIAGNOSTIC_TEST|point-of-care ultrasound|point-of-care ultrasound
215033733|NCT03815344|DRUG|Standard|20 units diluted in 100mL of Normal Saline injected laparoscopic needle
215033734|NCT03815344|DRUG|Standard-vaginal misoprostol|20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
214863254|NCT02808949|DRUG|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
214863255|NCT02890836|DRUG|Antihypertensiva, mainly Metyldopa|
214863256|NCT04804865|OTHER|prognostic assessment|determination of a prognostic score with 3 clinical and 5 biological parameters.
214863257|NCT02041156|OTHER|aerobic and resistance training|
214863258|NCT02041156|OTHER|aerobic combined with balance training|
214863259|NCT00889369|DRUG|Duloxetine|Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
214863260|NCT04856423|DIAGNOSTIC_TEST|The us-qFIT and colonoscopy with pathological examination|Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
214863261|NCT01517230|BEHAVIORAL|Local radio campaign to reduce under-five child mortality|"The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years."
214863262|NCT03893435|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
214863263|NCT04259983|OTHER|Maximal exercise test|The maximal exercise test will be performed on an electronically braked bicycle ergometer.
214863264|NCT04259983|OTHER|Endothelial dysfunction assessment|Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.
214863265|NCT04259983|OTHER|Arterial stiffness assessment|Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.
214863266|NCT00019786|DRUG|isolated perfusion|
214863267|NCT00019786|DRUG|melphalan|
214863268|NCT00019786|PROCEDURE|conventional surgery|
214863269|NCT02166814|DRUG|Fimasartan and Rosuvastatin|
214863270|NCT02166814|DRUG|Fimasartan|
214863271|NCT02166814|DRUG|Rosuvastatin|
214863272|NCT03473626|DRUG|Alicaforsen|Alicaforsen tablet
214863273|NCT02272634|DRUG|YPL-001 80 mg|twice daily \[BID\]
214863274|NCT02272634|DRUG|YPL-001 160 mg|twice daily \[BID\]
214863275|NCT02272634|DRUG|Placebo|twice daily \[BID\]
214863276|NCT00291980|BIOLOGICAL|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
214863277|NCT00291980|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
214863278|NCT05070546|BIOLOGICAL|Ad26.RSV.preF-based Vaccine|Participants will receive a single IM injection of an RSV vaccine.
214863279|NCT05070546|OTHER|Placebo|Participants will receive a single IM injection of matching placebo.
215033735|NCT01912573|DRUG|Intranasal (IN) naloxone|
215033736|NCT01912573|DRUG|Intravenous (IV) naloxone|
215033737|NCT01912573|DRUG|Intramuscular (IM) naloxone|
215033738|NCT01912573|DRUG|Intraosseus (IO) naloxone|
215033739|NCT02421094|DRUG|GR-MD-02|GM-MD-02 active
215033740|NCT02421094|DRUG|Placebo|Placebo
215033741|NCT03346837|DRUG|BMS-986205|BMS-986205
215033742|NCT03346837|DRUG|Itraconazole|Oral solution
214863280|NCT01843036|OTHER|Durham Connects|Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived areas of family functioning across 4 domains (i.e. - healthcare, parenting/childcare, family violence/safety, and maternal well-being). For each domain found to be at risk, the nurse intervenes directly to support the mother (mild risk) or connects the mother with matched community resources as needed to address individualized long-term family needs (moderate or severe risk).
214863281|NCT03759119|BEHAVIORAL|Tummy time and parent education|Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.
214863282|NCT03759119|BEHAVIORAL|Parent education only|"Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~* Complete educational session with primary investigator.~* Adherence during the four-week intervention period will be measured remotely through the PT Pal® application."
214863283|NCT00045175|DRUG|7-hydroxystaurosporine|
214863284|NCT00045175|DRUG|topotecan hydrochloride|
214863285|NCT01941355|BEHAVIORAL|Exercise training component|The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
214863286|NCT01941355|BEHAVIORAL|Psycho-educative component|The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
214863287|NCT01359644|DRUG|PSI-7977|Tablets, oral, 400 mg, once daily
214863288|NCT01359644|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily
214863289|NCT01359644|DRUG|Ribavirin|Tablets, oral, 200 mg
214863290|NCT01763814|PROCEDURE|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
214863291|NCT01763814|PROCEDURE|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
214863292|NCT01763814|PROCEDURE|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
214863293|NCT05028049|DRUG|Sufentanil injection|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
214863294|NCT05028049|DRUG|Remifentanil Hydrochloride|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
214863295|NCT05028049|OTHER|plain areas|Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
214863296|NCT05028049|OTHER|plateau areas|Patients should be long staying residents in plateau areas (altitude level\>3000 meters above sea level)
214863297|NCT03306953|PROCEDURE|Rectus muscle approximation|The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
214863298|NCT04629261|BEHAVIORAL|Use of ECOBICI (public bicycle sharing program)|Use of ECOBICI program with and without incentive.
215033743|NCT03346837|DRUG|Rifampin|Tablet
214863299|NCT00516009|DRUG|DEXAMETHASONE|
214863300|NCT00516009|OTHER|PLACEBO|
214863301|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis|Will be performed education in pain neurosciences and clinical hypnosis, in 4 sessions during 4 weeks
214863302|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis plus osteopathic manipulative treatment|Will be performed education in pain neurosciences and clinical hypnosis, and only for this group will be delivered osteopathic manipulative treatment, in 4 sessions during 4 weeks
214863303|NCT04761874|OTHER|Telestroke|In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
214863304|NCT02130882|DRUG|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
214863305|NCT02130882|OTHER|Placebo|A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
214863306|NCT00188487|DEVICE|magnetic resonance imaging (MRI) of the thorax|
214863307|NCT03933436|OTHER|Iodine swabs.|Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
214863308|NCT03933436|OTHER|Saline flush.|Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
214863309|NCT05238818|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocyte Injection (GT202)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. T cells then are manufactured to express mbIL-12. After lymphodepletion, patients are infused with GT202 followed by IL-2.
214863310|NCT03891186|BEHAVIORAL|Metacognitive Training in Schizophrenia (MCT)|"MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual Metacognitive Training for Psychosis (MCT) that is currently available in 35 languages (available in www.uke.de/mkt)."
214863311|NCT03891186|OTHER|Treatment As Usual (TAU)|In both groups will be maintained the TAU.
214863312|NCT01844739|DRUG|NVN1000 4% Gel|Applied topically twice daily
214863313|NCT01844739|DRUG|Vehicle Gel|Applied topically twice daily
214863314|NCT03424512|BEHAVIORAL|Group Metacognitive Therapy|Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
214863315|NCT03989622|OTHER|evaluation of the visual field on the ground|evaluation of the visual field on the ground
214863316|NCT05066763|OTHER|Non-interventional|non-interventional
214863317|NCT03508414|BEHAVIORAL|ketogenic diet|Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.
214863318|NCT03508414|BEHAVIORAL|Intermittent therapeutical fasting|Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.
214863319|NCT03508414|BEHAVIORAL|Active comparator|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
214863320|NCT01604590|RADIATION|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
214863321|NCT02365870|DRUG|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
214863322|NCT02365870|DRUG|placebo|Participants will receive a placebo transdermal patch to be worn daily
214863323|NCT03113513|PROCEDURE|fixation of the vaginal apex|In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
214863324|NCT04312529|OTHER|Isokinetic test + EMG|Isokinetic test:The isokinetic device is used to evaluate the strength of a subject. The test will be performed in two positions. This will determine the best position to activate shoulder muscles EMG (electromyography):it's a device that measures the electrical activity of muscles. This will allow us to record the maximum activity of the shoulder muscles during force tests.
214863325|NCT03341819|PROCEDURE|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
214863326|NCT03341819|PROCEDURE|Urinary Catheterization|Urinary catheterization is a latex, polyurethane, or silicone tube known as a urinary catheter is inserted into a patient's bladder via the urethra. Catheterization allows the patient's urine to drain freely from the bladder for collection.
214863327|NCT03043859|BEHAVIORAL|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
214863328|NCT05739344|BEHAVIORAL|Cognitive behavioral approach based resilience development program for schizophrenic individuals|The intervention will be administered as sessions of 2 hours once a week.
214863329|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal and postpartum phases
214863330|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
214863331|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
214863332|NCT01120041|BEHAVIORAL|health education|Traditional health education given during the prenatal phase and the postpartum phase
214863333|NCT01690741|DRUG|Nerofe|Nerofe administered intravenously 3x/week
214863334|NCT04373044|DRUG|Baricitinib|Given PO
214863335|NCT04373044|DRUG|Hydroxychloroquine|Given PO
214863336|NCT04373044|DRUG|Placebo Administration|Given Po
214863337|NCT06179927|OTHER|QT voice|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes made via tablet. In the scenario, the depictions will be presented in color. They, guided by QT Robot's narrator voice, will have to choose from two or three alternatives the one that represents the appropriate mental state by selecting it on the tablet. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
214863338|NCT06179927|OTHER|Image stimuli|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the control group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes on paper. They, guided by the narrator's voice of the operator will have to choose from two or three alternatives the one that represents the appropriate mental state by indicating it on the paper. Consequently, feedback will be provided by the operator to return information to the subject on the accuracy of the response.
214863339|NCT00044967|GENETIC|microsatellite instability analysis|
214863340|NCT06052930|DEVICE|HTC Vive™ Pro|"A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week.~Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session)."
214863341|NCT01642459|OTHER|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
214863342|NCT01642459|OTHER|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
214863343|NCT02029586|DRUG|MB12066 200mg|oral administration, 100mg bid
214863344|NCT02029586|DRUG|Placebo|oral administration, 100mg bid
214863345|NCT02667015|BEHAVIORAL|Psychotherapy (Anxiety Sensitivity Intervention)|3 week, 6-session psychotherapy targeting anxiety sensitivity
214863346|NCT00669071|DRUG|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
214863347|NCT00669071|DRUG|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
214863348|NCT00543608|DRUG|iclaprim|
214863349|NCT00543608|DRUG|vancomycin|
214863350|NCT01201941|OTHER|e-Chasqui|"The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests."
214863351|NCT05033912|DRUG|CST-2032, matching placebo for CST-2032, CST-107|CST-2032 and matching placebo oral liquid; CST-107 white capsules
214665364|NCT00509106|DRUG|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
214665365|NCT02318602|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
214863352|NCT03358784|PROCEDURE|Hemi-shoulder Arthroplasty|Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus
214863353|NCT03358784|PROCEDURE|PHILOS Plate|PHILOS plate treating three or four-part fractures of proximal humerus
214863354|NCT00556023|DRUG|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
214863355|NCT01194973|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
214863356|NCT01634282|DRUG|OPC-262|Orally administered once daily
214863357|NCT02031952|PROCEDURE|hepatectomy combined with lymphadenectomy|
214863358|NCT02031952|PROCEDURE|hepatectomy alone|
214863359|NCT04477772|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|Part A: including dose escalation (1mg/kg JS004; 3mg/lg JS004; 10mg/kg JS004), dose expansion (3mg/kg JS004 and 200mg JS004) and indication expansion. Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
214863360|NCT04477772|BIOLOGICAL|Drug：JS001, Intravenous infusion|Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
214863361|NCT01831453|DRUG|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
214863362|NCT01831453|DRUG|placebo|soft gelatinous capsules filled with isopropylmyristate oil
214863363|NCT02114476|DEVICE|progestin implant|two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
214863364|NCT02114476|DEVICE|Placebo|
214863365|NCT03844789|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Eligible participants will be use the t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology \& Dexcom G6 CGM
214863366|NCT03844789|DEVICE|Control Group|Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
214863367|NCT06233357|DRUG|treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)|IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
214290672|NCT00276744|PROCEDURE|conventional surgery|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
214665366|NCT03736044|DRUG|TNF-blockers suspension in patients with rheumatoid arthritis|in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
214665367|NCT04300348|DEVICE|Heel2Toe|Heel to Toe (Heel2Toe) is a device that clips on the shoe and provides an instant auditory feedback (a beep) for each correct step characterized by putting the heel first and it provides data on gait parameters
214290673|NCT00970060|BEHAVIORAL|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
214290674|NCT03138278|OTHER|Telephone support on demand|Dedicated phone number for help and advice for caregivers
214863368|NCT00359632|DRUG|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
214290675|NCT03060629|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
214290676|NCT03060629|BIOLOGICAL|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
214290677|NCT03060629|BIOLOGICAL|Placebo|Participants will receive matching placebo.
214290678|NCT02097004|BIOLOGICAL|Peginterferon alfa-2a|once weekly 180 μg subcutaneous injection for 48 weeks
214290679|NCT02097004|BIOLOGICAL|HBV vaccination|1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
214665368|NCT04300348|OTHER|No-feedback control group|The control group will follow the same protocol as the Heel2Toe group but the device will not be in feedback mode just in data acquisition mode.
214665369|NCT00942006|DRUG|doxycycline|100 mg bid, 14 days
214665370|NCT00942006|DRUG|ceftriaxone|2g x 1 iv, 14 days
214665371|NCT04147949|DRUG|AV-101|Oral capsules taken twice daily for 14 days
214665372|NCT04147949|DRUG|Placebo|Oral capsules taken twice a day for 14 days
214665373|NCT00693706|BIOLOGICAL|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
214665374|NCT00693706|BIOLOGICAL|Fluarix|IM injection on Day 0
214863369|NCT00359632|DRUG|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
214863370|NCT02448849|BIOLOGICAL|Percutaneous injection|percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.
214863371|NCT02448849|OTHER|Percutaneous injection|Percutaneous implantation of placebo in patients with nonunion fracture.
214863372|NCT04328571|DIETARY_SUPPLEMENT|OLE enzymatically treated|OLE (Olive leaf extract ) enzymatically treated + maltodextrin
214863373|NCT04328571|DIETARY_SUPPLEMENT|OLE + probiotic|OLE (Olive leaf extract) co-administered with probiotic
214863374|NCT04328571|DIETARY_SUPPLEMENT|OLE|OLE (Olive leaf extract) + maltodextrin
214863375|NCT05143151|BIOLOGICAL|CD276 CAR-T cells|CD276 CAR-T cells infusion
214863376|NCT00937651|DRUG|Placebo|Placebo
214863377|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 20 mg|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
214863378|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 60 mg|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
214863379|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 180 mg|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
214863380|NCT05801653|DIETARY_SUPPLEMENT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
214863381|NCT00004153|GENETIC|reverse transcriptase-polymerase chain reaction|
214863382|NCT00004153|PROCEDURE|sentinel lymph node biopsy|
214863383|NCT05116488|DIAGNOSTIC_TEST|ECG(electrocardigraph)|Detection of electrocardiographic Brugada patterns using high precordial leads positioning as placing the precordial leads in the second intercostal space has been proposed to add sensitivity to the ECG diagnosis of Brugada syndrome.
214863384|NCT03982576|OTHER|Nicotine replacement therapy (NRT)|4 weeks of Transdermal nicotine patches or nicotine gum
214863385|NCT03982576|BEHAVIORAL|CS-CBT intervention|4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks
214863386|NCT03982576|BEHAVIORAL|Path2Quit|Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).
214863387|NCT03982576|BEHAVIORAL|Relapse prevention program|4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov
214863388|NCT03982576|BEHAVIORAL|SmokefreeTXT|NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
214863389|NCT04594174|PROCEDURE|Fluid administration|"Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP \<65 mm Hg or a Systolic Blood Pressure \<90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase."
214290680|NCT02097004|DRUG|Entecavir|Continue Entecavir(0.5mg) for 100 weeks
214665375|NCT05025943|OTHER|Diet intervention|The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.
214863390|NCT03358160|BEHAVIORAL|Action discrimination tasks.|The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
214863391|NCT01742780|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
214863392|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
214863393|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
214863394|NCT02555020|DIETARY_SUPPLEMENT|Allocated to MN NPO group,|Patients received NPO from MN.
214290681|NCT03627247|BEHAVIORAL|Cognitive Behavioral Stress Management|Interactive activities (e.g., role-playing, use of physical props to introduce concepts related to coping and stress) were designed for each class to optimize participant engagement and understanding of the course material while tailoring class content to the stressors commonly reported by participants. Each week, participants were given coping and relaxation skills to practice at home (e.g., cognitive reappraisal, diaphragmatic breathing) and were asked to record their experiences on an activity log that was collected and discussed in class the following week. Course content was taught from a detailed training manual (Urizar \& Kofman, 2012).
214863395|NCT03509714|DIETARY_SUPPLEMENT|Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)|2 Pills to be taken orally per day during their entire menstrual cycle
214863396|NCT03509714|DIETARY_SUPPLEMENT|rice flour (Placebo)|250 mg rice flour (Placebo)
214863397|NCT01393184|DRUG|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
214863398|NCT02743143|BEHAVIORAL|Exercise therapy|
214863399|NCT02743143|OTHER|Follow-up care as usual|
214863400|NCT03380533|DRUG|Buprenorphine|Buprenorphine 10mg transdermal patch used during the first five postoperative days after arthroscopic rotator cuff repair
214863401|NCT03380533|DRUG|Placebo Patch|Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
214863402|NCT03380533|DRUG|Multimodal Oral Scheme|Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
214863403|NCT03380533|DRUG|Tramadol|Tramadol 50mg tablet that the patient consumes every 8 hours during the first five days
214863404|NCT03380533|DRUG|Placebo Tablet|Placebo tablet that the patient consumes every 8 hours during the first five days
214863405|NCT02615171|BEHAVIORAL|Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
214863406|NCT02615171|BEHAVIORAL|Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity|Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
214863407|NCT06609252|OTHER|Breast milk odour|On the day of the study, the mothers of the babies will be contacted and fresh breast milk will be obtained from the mother of each baby. In the study, a sterile sponge will be used to smell the breast milk to the baby. Breast milk will be taken as 2 ml, dripped onto a sterile sponge and held 10 cm away from the baby's nose and sniffed 2 minutes before the examination.
214863408|NCT06609252|OTHER|Mother voice|Mothers of premature babies in the mother voice group will be given a voice recorder on the day of the study and will be encouraged to express their feelings and thoughts and say what they want to say to their babies and will be asked to talk to their babies as they wish. The mother's voice, which is recorded 2 minutes before the procedure, will be placed approximately 30 cm away from the baby's ear and a loudspeaker will be placed at the foot end so that the baby can listen to the sound.
214863409|NCT02617524|DEVICE|Valve Medical Dedicated Sheath version 00|The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
214290682|NCT04847947|DRUG|Cholecalciferol|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks
214863410|NCT04338217|DEVICE|Bionator|This is a functional appliance that is used to overcome the functional problems and to correct the open bite deformity
214863411|NCT04338217|DEVICE|Removable Appliance with Posterior Bite Planes|This is a one-jaw appliance that is used in conjunction with a tongue crib to control the faulty positions of the tongue and to help in closing the open bite through the use of posterior bite planes.
214863412|NCT04375865|DRUG|AD-2111|celecoxib 200mg
214863413|NCT04375865|DRUG|AD-2112|Tramadol 150mg
214290683|NCT04847947|DRUG|Placebo|Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
214665376|NCT05025943|OTHER|Control group|The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.
214863414|NCT03816813|OTHER|blood and saliva sampling|blood and saliva sampling
214863415|NCT04960306|BIOLOGICAL|Fecal filtrate transplantation|"Patients will receive 5-8 encapsulated lyophilized fecal filtrate transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
214863416|NCT04960306|BIOLOGICAL|Conventional fecal microbiota transplantation|"Patients will receive 5-8 encapsulated lyophilized conventional fecal microbiota transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
214863417|NCT00016718|DRUG|Didanosine (ddI)|Antiretroviral Didanosine (ddI) : 240 mg/m\^2 up to a maximum of 400 mg once daily
214863418|NCT00016718|DRUG|Efavirenz (EFV)|Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
214863419|NCT00016718|DRUG|Emtricitabine (FTC)|Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
214863420|NCT00621049|DRUG|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
214863421|NCT00621049|DRUG|Docetaxel/Carboplatin|"Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
214863422|NCT00888459|DRUG|nicotine replacement therapy|4 mg nicotine lozenges, ad lib, for 12 weeks.
214863423|NCT00888459|DRUG|placebo NRT|Placebo nicotine lozenges
214863424|NCT01593033|DIETARY_SUPPLEMENT|Fish oil and Micronutrient Supplementation|"0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months"
214863425|NCT01593033|DIETARY_SUPPLEMENT|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
214863426|NCT01593033|DRUG|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
214863427|NCT05897918|DRUG|Tranexamic Acid 500 MG|Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions
214863428|NCT05622136|DRUG|Regorafenib Oral Product|Dose escalation strategy
214863429|NCT05736536|BEHAVIORAL|Chance2Act|A Health education package that has been developed based on Transtheoretical Model to encourage behaviour change for weight loss among overweight/obese type 2 diabetes adults.
214863430|NCT05811702|OTHER|A randomized acute controlled trial of twenty-eight healthy overweight or obese women|A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks. Our primary outcome of this study to investigated the effective diets HFKD and LFD on reduction of body weight, the percentage of body fat
214863431|NCT01000493|DRUG|orvepitant|Neurokinin-1 (NK-1) antagonist
214863432|NCT01000493|OTHER|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
214863433|NCT01045915|BIOLOGICAL|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
214863434|NCT00630890|RADIATION|External beam radiation and Cyberknife radiosurgery boost and capecitabine|External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
214863435|NCT00932139|PROCEDURE|Electro-acupuncture control|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
214863436|NCT00932139|PROCEDURE|Electro-acupuncture test|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA. At end of 8-week treatment, 24 hours blood pressure and heart rate will be measured.
214863437|NCT04102631|DIAGNOSTIC_TEST|colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
214863438|NCT04102631|DIAGNOSTIC_TEST|colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
214863439|NCT03480126|OTHER|Herbal Teas|Steeped tea ingested 3 times a day for 3 mos
215033744|NCT05356715|PROCEDURE|Ultrasound guided bilateral ESBP|Patients in group A will be positioned in the lateral position , ESPB will be done under complete aseptic conditions , using , linear ultrasound probe(Philips HD11XE Ultrasound System) , to locate the ESP at the level of the fifth dorsal vertebrae , 22 G spinal needle will be used to inject 20 ml of 0.25% of bupivacaine in the ESP bilaterally, block will done by an expert anesthesiologist , who will not be included in the data collection
215033745|NCT01139151|DRUG|3 Day Thiarabine|Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3
214290684|NCT03566147|BIOLOGICAL|Human primary Retinal Pigment Epithelial (HuRPE) cells|HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
214290685|NCT02490228|PROCEDURE|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
214290686|NCT05541172|DRUG|Testosterone Undecanoate|Testosterone undecanoate (1000 mg/4 ml) will be administered at a dose of 1 ml every 12 weeks for 6 months, 2 ml every 12 weeks for 6 months, 3 ml every 12 weeks for 6 months and 4 ml every 12 weeks for 6 months.
214290687|NCT00060008|RADIATION|fludeoxyglucose F 18|
214290688|NCT00060008|RADIATION|gadopentetate dimeglumine|
214290689|NCT00299910|DRUG|Montelukast|
214290690|NCT02160574|DRUG|ChloraPrep|The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
215033746|NCT01139151|DRUG|5 Day Thiarabine|Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
215033747|NCT02774694|DEVICE|"nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)"|"measurement of the NFR threshold using the Paintracker device"
214290691|NCT02160574|DRUG|0.1% Sodium Lauryl Sulfate|The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
214290692|NCT02160574|DRUG|0.9% Physiological Saline|The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
214863440|NCT02701231|DEVICE|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
214863441|NCT02701231|DRUG|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
214863442|NCT02701231|DEVICE|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
214863443|NCT02009748|DIETARY_SUPPLEMENT|Vitamin D supplementation|oral administration of colecalciferol 2.800 IU once daily
214863444|NCT02009748|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo (vehicle) once daily
214863445|NCT03223948|DEVICE|'Optiflow'|High flow nasal oxygen delivery device 'Optiflow'
214863446|NCT03347136|DEVICE|CPAP|
214863447|NCT03347136|DEVICE|NIPPV|
214863448|NCT03045237|OTHER|physical exercises classes|3 physical exercises classes, one of them in the pool.
214863449|NCT01408628|BEHAVIORAL|Internet Insulin Education|"Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of \< 7.0% using an established treat-to-target algorithm."
214863450|NCT04160845|PROCEDURE|cardiac surgery|cardiac surgery with hypothermic cardiopulmonary bypass
214863451|NCT05768126|DRUG|Rivastigmine Transdermal Product|The patches will be administered (first four weeks 4.6 mg and then 9.5. mg).
214863452|NCT05768126|OTHER|Sham|The sham patches will be administered during the same period of time as the rivastigmine.
214863453|NCT01941940|DRUG|Tocilizumab|Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
214863454|NCT01941940|DRUG|DMARDs|Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
214863455|NCT01846117|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside, vitamin D|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
214863456|NCT00750308|DRUG|Ramipril|Ramipril 10 mg per day for three weeks
214665377|NCT04242537|DEVICE|High flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a high flow nasal cannula with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
214863457|NCT00750308|DRUG|Tadalafil|tadalafil 10 mg every other day for three weeks
214863458|NCT00750308|DRUG|placebo|placebo matching ramipril
214863459|NCT00750308|DRUG|placebo|placebo matching tadalafil
214863460|NCT02169349|OTHER|laboratory biomarker analysis|
214863461|NCT02169349|OTHER|Next Generation Sequencing|
214863462|NCT02169349|GENETIC|DNA Analysis|
214863463|NCT03143478|DEVICE|M-MARK|"M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.~A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.~During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist."
214863464|NCT02274207|DEVICE|NPWT application|NPWT mode is cyclic mode : -125\~-50 mmHg
214863465|NCT03875937|DRUG|Tranexamic 1 gram|To be administered intramuscularly (2 injections)
214863466|NCT00399971|PROCEDURE|Ex Vivo Immunotherapy|Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
214863467|NCT00399971|DRUG|Ex vivo immunotherapy|i.v. infusions, once a week, at least 6 to 12 months
214863468|NCT02218112|PROCEDURE|bariatric surgery (gastric bypass)|
214863469|NCT00281476|DRUG|Simvastatine|
214863470|NCT04882319|DRUG|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously
214863471|NCT04882319|DRUG|HP-5000 Placebo Patch|HP-5000, placebo and saline will be administered simultaneously
214863472|NCT04882319|DRUG|Saline Patch|HP-5000, placebo and saline will be administered simultaneously
214863473|NCT00513682|DRUG|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
214863474|NCT03797820|OTHER|Our study type is observational|Our study type is observational
214863475|NCT03316326|DRUG|Tegafur-gimeracil-oteracil potassium|40 mg bid, D1-14
214863476|NCT03316326|DRUG|Oxaliplatin|85 mg/m2, D1
214863477|NCT03316326|DRUG|Irinotecan|150 mg/m2, D8
214863478|NCT02452996|DRUG|GNbAC1|Single dose of IMP, IV infusion
214863479|NCT02523196|DRUG|HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)|The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
214863480|NCT02523196|DEVICE|Hepatic Venous Pressure Gradient (HVPG)|Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
214863481|NCT03903458|DRUG|Tinostamustine|First-in-human administration of the combination of Tinostamustine and Nivolumab.
214863482|NCT03412786|BIOLOGICAL|Bcl-Xl_42-CAF09b vaccine|The vaccine consists of 0.05 mg peptide (bcl-xl\_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion
214863483|NCT04149886|PROCEDURE|cardiac ganglion plexus ablation(cardioneuroablation)|Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
214863484|NCT04149886|DEVICE|Permanent pacemaker implantation|DDD permanent pacemaker will be implanted in the paticipants.
214863485|NCT01372241|BEHAVIORAL|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
214863486|NCT03639519|DRUG|Ascorbic Acid 500Mg Chew Tab|Ascorbic acid will be administered at the night before surgery and will be continued for five days
214863487|NCT03639519|OTHER|Carbonated orange beverage|The carbonated orange beverage will be administered at the night before surgery and will be continued for five days
214863488|NCT05790421|OTHER|Foot Muscle Energy Technique|Starting from the preparation position, at the restriction barrier, the patient is asked to exert a small effort (no more than 20% of available strength) towards plantarflexion, against unyielding resistance, with appropriate breathing. The patient produces isometric effort contracts either gastrocnemius or soleus (depending on whether the knee is unflexed or flexed). This contraction is held for 7-10 seconds together with a held breath. The exercise was repeated until the full range of movement was obtained.
214863489|NCT05790421|OTHER|Conventional Physical Therapy Program|Graduated active resisted range of motion exercises for both UL and LL and graduated gait training
214863490|NCT04832321|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan man with different profiles of illness severity, treatment, and treatment response.
214863491|NCT03022058|DEVICE|Ear-EEG system|Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
214665378|NCT04242537|DEVICE|Low flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a low flow nasal cannula coupled with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
214665379|NCT06356740|BIOLOGICAL|Blood sample|"blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum."
214863492|NCT01193738|PROCEDURE|osteopathic compression of Pterygopalatine node|osteopathic compression of Pterygopalatine node
214863493|NCT05306171|BEHAVIORAL|Online training for healthcare professionals|"The online training (4 modules) will use the technique of hybrid learning, combining meetings that will require the presence of participants and mediator at the same time and platform (live) with recorded meetings (interviews with experts) that will be watched by the participants at any time (from a distance).~Module 1: Self Care; Module 2: Stress and anxiety management; Module 3: Relationships; Module 4: Communication."
214863494|NCT01484418|BEHAVIORAL|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
214863495|NCT01484418|BEHAVIORAL|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
214863496|NCT00041249|DRUG|brostallicin|
214863497|NCT03660436|DRUG|BMS-986165|Specified dose on specified days
214863498|NCT03660436|DRUG|MMF|Specified dose on specified days
214863499|NCT01121666|DRUG|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
214863500|NCT03546803|OTHER|3M™ Cavilon™ Advanced Skin Protectant|liquid skin protectant on skin to protect from radiation dermatitis
214863501|NCT03176459|DRUG|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
214863502|NCT03176459|DRUG|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
214863503|NCT03235661|DEVICE|BiPAP|BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
214863504|NCT03235661|DEVICE|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
214863505|NCT01179126|PROCEDURE|complete multivessel revascularization|After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
214863506|NCT01179126|PROCEDURE|stress echocardiography and revascularization if required|after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
214863507|NCT00777127|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
214863508|NCT00777127|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
214863509|NCT04450147|BEHAVIORAL|Tai Chi/Qigong vs. Walking/Stretching|Both interventions can be thought of as a form of movement and exercise.
214863510|NCT06077487|DRUG|Ketamine|Given orally (PO)
214863511|NCT06077487|DRUG|Ketamine Injectable Product|Given intramuscularly (IM)
214863512|NCT06077487|BEHAVIORAL|Meaning and Purpose therapy|In-person sessions
214863513|NCT06077487|OTHER|Placebo|Given PO or IM
214863514|NCT06077487|OTHER|Questionnaires|Questionnaires will be given over the course of the study
214863515|NCT04990609|DEVICE|Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)|Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) consists of the application of an alternating current with a frequency of 350-500 kilohertz (kHz) to the target tissue via a special electrode located at the tip of an echoendoscope. The alternating current causes the vibratory movement of ionic particles in the abutting and adjoining tissue and results in the generation of heat. However, RFA induces not only local disruption of the tumor by heat, but it also produces localized coagulation necrosis of the tumor; which induces the release of large amounts of cellular debris. This cellular debris represents a source of tumor antigens that can trigger a host adaptive immune response against the tumor.
214863516|NCT04990609|DRUG|Neoadjuvant Chemotherapy (NAC)|The NAC regimen will be determined clinically by the participant's physician \[possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)\].
214863517|NCT06485960|OTHER|ESDAM validation|"* 3\* 24-Hour Dietary Recalls~* Experience Sampling Dietary Assessment Method (mobile application)~* Continuous Blood Glucose Monitoring~* Doubly-labeled water administration~* Blood drawings (Erythrocyte Membrane Fatty Acid composition, Carotenoids)~* Urine sampling (Doubly-labeled water, urinary nitrogen)"
214863518|NCT02579161|DRUG|cephalosporins|Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed
214863519|NCT02579161|DRUG|Fluoroquinolones|If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance
214863520|NCT02579161|DRUG|Clindamycin|If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.
214863521|NCT02579161|DRUG|Ampicillin/Gentamicin|5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
214863522|NCT00759902|DRUG|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
214863523|NCT00759902|DRUG|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
214863524|NCT00134043|DRUG|vorinostat|Given orally
214863525|NCT02609412|OTHER|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
214863526|NCT02609412|OTHER|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
214290693|NCT02160574|OTHER|ZuraPrep without IPA|Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
214290694|NCT01288105|DEVICE|Optical coherence tomography|Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom \>95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with \<95% stent strut coverage will receive perioperative bridging.
214665380|NCT06356740|DRUG|Treatment :Abacavir 600 mg/lamivudine 300 mg|Patients randomised to the experimental arm will be required to take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.
214863527|NCT02609412|DEVICE|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
214863528|NCT03722095|DEVICE|active tDCS|A current of 2 milliampère (mA) through electrodes of 5x5cm.
214863529|NCT03722095|DEVICE|sham tDCS|Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
214863530|NCT03722095|DEVICE|iTBS|54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
214863531|NCT01754116|DRUG|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
214863532|NCT01754116|DRUG|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
214863533|NCT01754116|DRUG|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
214863534|NCT01754116|DRUG|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
214863535|NCT01754116|DRUG|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
214665381|NCT06356740|OTHER|Lupus Impact Tracker questionnaire|Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).
214665382|NCT04425655|DRUG|Fludarabine|30mg/m2 days 1 through 5
214665383|NCT04425655|DRUG|Vyxeos|100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
214665384|NCT01596491|PROCEDURE|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
214665385|NCT06229509|DEVICE|Effective noninvasive ventilation|Noninvasive ventilation set to alleviate dyspnea Inspiratory aid set according to a preliminary test (aiming for a diminution of 2 points in Borg score)
214665386|NCT06229509|DEVICE|Sham noninvasive ventilation|Noninvasive ventilation set with an insufficient inspiratory aid to alleviate dyspnea
214665387|NCT00488631|BIOLOGICAL|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
214863536|NCT04882423|OTHER|grilled hamburger (7 oz) with no vegetables|Test meal 1: grilled hamburger (7 oz) with no vegetables
214863537|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)|Test meal 2: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
214863538|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)|Test meal 3: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
214863539|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).|Test meal 4: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
214863540|NCT05989724|DRUG|SON-DP|Solution for IV administration
214863541|NCT02327117|DRUG|Tranexamic Acid|
214863542|NCT02327117|DRUG|Normal saline|
214863543|NCT02128217|DRUG|Sofosbuvir|Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
214665388|NCT00488631|BIOLOGICAL|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
214665389|NCT00488631|BIOLOGICAL|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
214863544|NCT02128217|DRUG|Ribavirin|Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
214863545|NCT02128217|DRUG|Ledipasvir/Sofosbuvir|Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
214863546|NCT05071313|BIOLOGICAL|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as single IM injection.
214863547|NCT05071313|BIOLOGICAL|Quadrivalent High-dose Influenza Vaccine|Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.
214863548|NCT05071313|BIOLOGICAL|Placebo|Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.
214863549|NCT03911050|DIETARY_SUPPLEMENT|Apple consumption|Apple blends (600 g) One single dose
214863550|NCT03911050|DIETARY_SUPPLEMENT|Control group|Breakfast without any apple-related products
214863551|NCT06074081|OTHER|motor relearning program|MRP is a therapy to regain particular motor function and neglecting accessory movements by engaging cognitive behavior .
214863552|NCT06074081|OTHER|mirror therapy|Mirror therapy enhance functional activities in patient with hemiplegic stroke. For betterment of result high quality methodological studies and larger sample size is required.
214863553|NCT02733081|PROCEDURE|Simplified IUD Insertion|IUD Insertion with no bimanual pelvic exam or uterine sounding.
214863554|NCT01211418|BEHAVIORAL|Integrative Meditation|"Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.~Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB \& IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.~Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study."
214863555|NCT01211418|BEHAVIORAL|Supportive Counseling|"NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.~The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion."
214863556|NCT00541970|BIOLOGICAL|Cervarix|Intramuscular injection, different dosing /schedule
214863557|NCT00541970|DRUG|Placebo|Intramuscular injection, different dosing /schedule
214863558|NCT00057993|BIOLOGICAL|trastuzumab|
214863559|NCT00057993|DRUG|exemestane|
214863560|NCT00321828|BIOLOGICAL|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
214863561|NCT00321828|DRUG|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
214863562|NCT00321828|DRUG|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
214863563|NCT00321828|DRUG|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
214863564|NCT01461226|BEHAVIORAL|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
214863565|NCT01461226|BEHAVIORAL|Usual care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
214863566|NCT00304226|DRUG|valsartan|
214863567|NCT00304226|DRUG|amlodipine|
214863568|NCT04438226|PROCEDURE|Surgical approach|The surgical approach of hemiarthroplasty after femoral neck fracture
214863569|NCT05102292|DRUG|HLX208|HLX208 450mg bid po
214863570|NCT06356363|OTHER|Data collection|data collection
214863571|NCT01452711|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
214863572|NCT01452711|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
214863573|NCT01452711|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
214863574|NCT01452711|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
214863575|NCT02756026|DIETARY_SUPPLEMENT|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
214863576|NCT04987242|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
214863577|NCT04987242|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
214863578|NCT00494039|PROCEDURE|Radioactive seed implant to prostate|
214863579|NCT02058212|DRUG|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
214863580|NCT01002014|PROCEDURE|Nipple Sparing Mastectomy|Skin sparing mastectomy with preservation of the nipple areolar complex
214863581|NCT04763564|DRUG|Liraglutide Pen Injector|Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.
214863582|NCT04763564|DRUG|Placebo Pen Injector|Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
214863583|NCT02086630|BEHAVIORAL|Heart to Heart|
214863584|NCT00343343|DEVICE|NovoFine® needle 6 mm|
214863585|NCT00343343|DEVICE|NovoFine® needle 4 mm|
214863586|NCT03912441|BIOLOGICAL|BCD-147|Bispecific anti-HER2 monoclonal antibody
214863587|NCT00858143|OTHER|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
214863588|NCT05726175|DRUG|Disitamab Vedotin|Disitamab Vedotin(RC48)：2.0mg/kg, iv, day1, q3weeks, 6 cycles in total;
214863589|NCT05726175|DRUG|Penpulimab|Penpulimab(AK105)：200mg, iv, day1, q3weeks, 6 cycles in total;
214863590|NCT06406270|OTHER|Fava|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with fava bean food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
214863591|NCT06406270|OTHER|Buckwheat|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with buckwheat food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
214863592|NCT03591393|DIAGNOSTIC_TEST|questionnaire|"Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire."
214863593|NCT03529578|PROCEDURE|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
214863594|NCT00299845|DRUG|Lansoprazole|
214863595|NCT03668561|DEVICE|Caligaloc|15 days of wearing of the Caligaloc orthosis
214863596|NCT01706237|DEVICE|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
214863597|NCT04785859|DIAGNOSTIC_TEST|BPD prediction|"The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time."
214665390|NCT00488631|BIOLOGICAL|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
214863598|NCT06432049|OTHER|restoration for endodontically treated molar|prefabricated stainless steel crown or endocrown
214863599|NCT01495156|DRUG|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."
214665391|NCT05219812|DRUG|BAY2395840|Tablet, intake orally.
214665392|NCT05219812|DRUG|Placebo for BAY2395840|Tablet, intake orally.
214665393|NCT01873950|DRUG|Ranolazine|
214665394|NCT01873950|DRUG|Dofetilide|
214665395|NCT01873950|DRUG|Verapamil|
214665396|NCT01873950|DRUG|Quinidine sulfate|
214665397|NCT01873950|DRUG|Placebo|
214863600|NCT01495156|DRUG|Placebo/Adjunctive SGA treatment|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."
214863601|NCT00852969|DRUG|Niacin|1000 mg tablets once per day
214863602|NCT00852969|DRUG|Active Placebo|100 mg Niacin tablets once per day
214863603|NCT03853148|BEHAVIORAL|Otago|Exercise program for strength and balance
214863604|NCT03853148|BEHAVIORAL|Gentle yogic breathing|yogic breathing
214863605|NCT03853148|BEHAVIORAL|Behavioral Activation|Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
214863606|NCT03853148|BEHAVIORAL|Caregiver Gentle yogic breathing|yogic breathing
214863607|NCT02537366|DRUG|Dexmedetomidine|
214863608|NCT02537366|DRUG|Placebo|
214863609|NCT03865186|BEHAVIORAL|Psychoeducation Program|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
214863610|NCT03865186|BEHAVIORAL|no intervention|
214863611|NCT02440022|COMBINATION_PRODUCT|Lutonix DCB|
214863612|NCT02440022|DEVICE|Standard Balloon Angioplasty Catheter|
214863613|NCT02440022|PROCEDURE|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
214863614|NCT00658658|BIOLOGICAL|Panitumumab|Panitumumab administered by intravenous infusion
214863615|NCT04335526|DRUG|Cholestyramine Resin|Change bile acid pool by cholestyramine treatment
214863616|NCT05495958|DRUG|Topical Vitamin D eye drop|25 Microgram/cc or 1000 IU
214863617|NCT05495958|DRUG|Topical placebo eye drop|The same-shape packed drop without vitamin D
214863618|NCT04644835|DEVICE|Low Energy Shock Wave Treatment|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
214863619|NCT04644835|DEVICE|Sham Treatment|The patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
214476477|NCT06611644|OTHER|SPSIPB blcok|Patients in this group will receive a Serratus Posterior Superior Intercostal Plane (SPSIP) block along with standard postoperative care. The SPSIP block will be performed under ultrasound guidance, where the needle is advanced between the second and third ribs towards the medial aspect of the scapula. Local anesthetic 20 to 30 ml) will be injected into the fascial plane between the serratus posterior superior muscle and the intercostal muscles after confirming needle placement with hydrodissection using 1-2 ml of saline. This block is intended to provide broad analgesia across the upper thoracic dermatomes, from C3 to T7, to control postoperative pain.
214863620|NCT00678041|DRUG|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
214863621|NCT00678041|DRUG|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
214863622|NCT05968443|DEVICE|ophthalmic surgery|any ophthalmic surgery using Dafilon® suture
214863623|NCT02358343|BEHAVIORAL|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
214863624|NCT02358343|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
214863625|NCT02358343|DRUG|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
214863626|NCT02861079|DEVICE|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
214863627|NCT02861079|DRUG|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
214863628|NCT02015559|DRUG|mucoadhesive oral wound rinse|Given PO
214863629|NCT02015559|OTHER|laboratory biomarker analysis|Correlative studies
214863630|NCT05447000|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring anxiety levels with mindfulness program
214863631|NCT05447000|BEHAVIORAL|Deep Relaxation Exercises intervention|Deep Relaxation Exercises intervention: Monitoring anxiety levels with deep Relaxation Exercises intervention
214863632|NCT05447000|OTHER|No Intervention|No Intervention
214863633|NCT04317209|DRUG|SHR0410|administered intravenously
214863634|NCT04317209|DRUG|Placebo|administered intravenously
214863635|NCT05404607|OTHER|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
214863636|NCT05404607|OTHER|Fascial distortion method|27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
214863637|NCT05332028|DRUG|bupivacaine|Block applications
214863638|NCT05332028|DEVICE|22 gauge 100 mm needle|Block applications
214863639|NCT05332028|DRUG|Propofol|Routine general anesthesia protocol
214863640|NCT05332028|DRUG|fentanyl|patient-controlled analgesia
214863641|NCT00281671|DRUG|nesiritide|nesiritide 0.015 mcg/kg/hour x 10 hours
214863642|NCT00281671|DRUG|Placebo|0.9% sodium chloride infusion
214863643|NCT06037837|PROCEDURE|Robotic Surgery|Surgeons will perform and participants will undergo robotic surgery according to the standard of care. No additional interventions will be performed on participating participants.
214863644|NCT00090610|DRUG|Docetaxel|"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
214863645|NCT00090610|DRUG|Carboplatin|"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
214863646|NCT00788749|DRUG|Prednisolone|tablets 25 mg/day
214863647|NCT00788749|DRUG|Placebo|tablets once daily
214863648|NCT00788749|OTHER|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
214863649|NCT00788749|OTHER|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
214863650|NCT02444793|DRUG|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
214863651|NCT02444793|DRUG|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
214863652|NCT05526261|PROCEDURE|Hemithyroidectoy|Hemithyroidectomy it is a surgical procedure where half of the thyroid gland is operated.
214863653|NCT03686449|PROCEDURE|Non-cultured Autologous Keratinocyte Suspension|New method for treatment of post-burn raw area
214863654|NCT03686449|PROCEDURE|Adipose-Derived Stem cell-Keratinocyte Suspension|New method for treatment of post-burn raw area
214863655|NCT03686449|PROCEDURE|Split skin graft|Traditional method for treatment of post-burn raw area
214863656|NCT03576183|BIOLOGICAL|VLA1701|VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
214863657|NCT03576183|BIOLOGICAL|Placebo|buffer component of VLA1701
214863658|NCT03576183|OTHER|Challenge Strain|LSN03-016011/A
214863659|NCT02562105|PROCEDURE|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
214863660|NCT03220061|BEHAVIORAL|music therapy|
214863661|NCT00069511|DRUG|UT-231B|
214863662|NCT02711683|DRUG|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
214863663|NCT02711683|DRUG|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
214863664|NCT06633718|DRUG|Meropenem and Pralurbactam|3g，q8h，120min infusion
214863665|NCT06633718|DRUG|Saline|100mL，q8h，60min infusion
214863666|NCT06633718|DRUG|Ceftazidime-avibactam|2.5g，q8h，120min infusion
214863667|NCT06633718|DRUG|Metronidazole|0.915g，q8h，60min infusion
214863668|NCT00042458|DRUG|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
214863669|NCT00042458|DRUG|Placebo|The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
214863670|NCT00237913|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
214863671|NCT00237913|DRUG|Olanzapine or Quetiapine or Risperidone|Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
214863672|NCT04498403|DRUG|Crisaborole 2%|Crisaborole 2% ointment
214863673|NCT05211661|DIAGNOSTIC_TEST|Respiratory Muscle Testing|Comprehensive assessment of respiratory muscle function. Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
214863674|NCT05903456|PROCEDURE|TACE（transcatheter arterial chemoembolization）|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
214863675|NCT05903456|DRUG|lenvatinib|Ronvastinib is an orally administered multi-receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2, and VEGF-3, in addition to inhibiting other pro-angiogenic and oncogenic signaling pathways associated with tumor proliferation ，has been approved as a first-line treatment for liver cancer
214863676|NCT05903456|DRUG|Icaritin soft capsules|Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials. It is a new type of small molecule immunomodulator. It is a 1.2 class of innovative Chinese medicine with global independent intellectual property rights. By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role. At present, it has been approved for first-line treatment of advanced liver cancer, with good efficacy and safety.
214863677|NCT04830059|BEHAVIORAL|Exercise|Two types of exercise intervention and control group
214863678|NCT04830059|BEHAVIORAL|Air purification|Air purification in order to reduce the PM2.5 and PM10
214863679|NCT04731337|DEVICE|Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the tip of the upper and lower canine teeth.
214863680|NCT01674153|PROCEDURE|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
214863681|NCT01951885|DRUG|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
214863682|NCT01951885|DRUG|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
214863683|NCT01951885|DRUG|Mycophenolate mofetil|Patients will receive Mycophenolate beginning on day +1. Patients \>40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients \< 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol
214863684|NCT01951885|DRUG|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
214863685|NCT05192694|PROCEDURE|Computed tomography|Positron Emission Tomography
214863686|NCT01546376|RADIATION|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
214863687|NCT01546376|OTHER|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
214863688|NCT01167322|DRUG|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
214863689|NCT06400134|OTHER|Cognitive Function|The Standardized Mini Mental Test (SMMT) was used to evaluate the cognitive status of the geriatric individuals'. In the test, which has a total score of 30, those with a score of 24 or less are recommended to be evaluated for dementia.
214863690|NCT06400134|OTHER|Physical Performance|The Brief Physical Performance Battery (BPPB) was used to assess the physical performance of geriatric individuals. All three physical performance measures (balance, walking speed, getting up from the chair) were scored between 0-4 according to the duration of the activity, these scores were summed and the total score was determined between 0 (poor) and 12 (very good).
214863691|NCT06400134|OTHER|Grip Strength|Muscle strength was assessed with a hand grip dynamometer. In the geriatric individuals, less than 30 kg for men and less than 20 kg for women was considered as low hand grip strength.
214863692|NCT06400134|OTHER|Walking speed|Walking speed was assessed with the 6-metre walk test. Speed was calculated by dividing each known distance by the time it took for each individual, on each trial, to walk from the start to the end points marked on the floor and then converting to m/s.
214863693|NCT06400134|OTHER|Mobility|The Time up Go test (TUG) was used for mobility. The risk of falling increases with increasing duration.
214863694|NCT06400134|OTHER|Fraility|Frailty assessment was performed using the FRAIL scale.The scale was scored by giving 0 or 1 point according to the answer given. The higher the score, the greater the fraility.
214863695|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392103A|intramuscular vaccination according to protocol schedule
214863696|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392105A|intramuscular vaccination according to protocol schedule
214863697|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392106A|intramuscular vaccination according to protocol schedule
214863698|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392019A|intramuscular vaccination according to protocol schedule
214863699|NCT01160172|DRUG|Saline placebo|intramuscular vaccination according to protocol schedule
214863700|NCT03465124|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order. Contralateral eye will receive conventional cataract surgery
214863701|NCT03465124|OTHER|Manual Cataract Surgery|conventional cataract surgery as control
214863702|NCT06318286|DRUG|Lenvatinib|Induction treatment: lenvatinib, 8 mg QD on Day 1 of a 21-day cycle for 4-6 cycles. Maintenance treatment: Lenvatinib, 20 mg QD may be given for up to a total of 35 cycles.
214863703|NCT06318286|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 will be given by intravenous (IV) infusion on Day 1 of a 21-day cycle for 4-6 cycles.
214863704|NCT06318286|DRUG|Cisplatin/Carboplatin|Carboplatin (AUC 5 mg/mL/min) or Cisplatin (75 mg/m2) will be given by IV infusion on Day 1 of a 21-day cycle for 4-6 cycles.
214863705|NCT06318286|DRUG|Pembrolizumab|Pembrolizumab, 200 mg will be given by IV infusion on Day 1 of a 21-day cycle for up to a total of 35 cycles.
214863706|NCT04441710|OTHER|Questionnaire|Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
214863707|NCT03074123|DIAGNOSTIC_TEST|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
214863708|NCT00866658|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
214863709|NCT00866658|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
214863710|NCT00866658|DEVICE|Pen auto-injector|
214863711|NCT00866658|DRUG|Sulfonylurea|Sulfonylurea if given, to be continued at a stable dose.
214863712|NCT00866658|DRUG|Basal Insulin|To be continued at a stable dose.
214863713|NCT05476653|OTHER|MRI procedure|Pulmonary MRI based on a 1.5 T machine (Siemens VIDA) or a 3T machine (Siemens SOLA) without the use of contrast product according to a protocol based on a 3D-UTE sequence acquired in free breathing but with a respiratory synchronization system in association with weightings in T1 and T2.
214863714|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|Single 200 mg dose of vepdegestrant registrational (200 mg strength) tablet.
214863715|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|Single 200 mg dose of vepdegestrant variant (200 mg strength) tablet.
214863716|NCT06221267|DRUG|Rimegepant|No intervention. The study will record the usage, timing, frequency, and dosage of rimegepant in a real-world clinical setting.
214863717|NCT06209411|BEHAVIORAL|Home Based Testing|Community Health Workers (CHWs) will offer at home OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
214863718|NCT06209411|BEHAVIORAL|Clinic Based Screening|Community Health Workers (CHWs) will offer referral to clinic based OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
214863719|NCT01276301|DRUG|Verapamil|single dose verapamil
214863720|NCT01276301|DRUG|BI 10773|single dose BI 10773
214863721|NCT01276301|DRUG|BI 10773|single dose BI 10773
214863722|NCT04283201|OTHER|Physical activity|Moderate activity 150 min per week
214863723|NCT04283201|OTHER|Macronutrient modification|Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
214863724|NCT03550001|PROCEDURE|Injection CNP before NAT|Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy
214863725|NCT00798148|DRUG|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
214863726|NCT03659526|DIAGNOSTIC_TEST|Deformation imaging|Deformation parameters derived using myocardial velocity imaging or speckle tracking
214863727|NCT06251492|RADIATION|Stereotactic body radiotherapy|8 Gray x 3 for 2 cycles
214863728|NCT06251492|DRUG|Adebrelimab|Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
214863729|NCT06633068|DRUG|Adding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block|Adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries
214863730|NCT01258712|DRUG|Tocilizumab + methotrexate(MTX)|Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
214863731|NCT01258712|DRUG|Tocilizumab placebo + methotrexate(MTX)|Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
214863732|NCT03328195|DEVICE|Neuro RX Gamma synchronous|Twenty minute treatment, six days per week for 12 weeks
214863733|NCT03328195|DEVICE|Sham|Twenty minutes, six days per week for 12 weeks with sham device
214863734|NCT03328195|DEVICE|Neuro RX Gamma asynchronous|Twenty minutes, six days per week for 12 weeks with sham device
214863735|NCT06102681|OTHER|intervention group|we will measure, consider and compare patients pain level, quality of life and recovery process. For these aims we will use numeric pain scale, nottingham health profile and postoperative recovery index.
214863736|NCT05834530|OTHER|3D Printed Complete Dentures|Denture bases printed from a pre-polymerized block via additive technique, using photon S desktop 3D printer\* that relies on SLA technology and post cured by post curing unit.
214863737|NCT01859130|DEVICE|Zimmer Persona Total Knee System|
214863738|NCT03996629|OTHER|Patient education and compliance|When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
214863739|NCT00000326|DRUG|Heroin Dependence|
214863740|NCT05373121|BEHAVIORAL|Online Peer Support|Signposting to online peer support groups and forums
214863741|NCT00933348|DRUG|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
214863742|NCT00933348|DRUG|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
214863743|NCT06632249|OTHER|Practice with the virtual reality game|4 weeks of practice with the virtual reality game, totalling 20 sessions, 5 supervised in the laboratory and 15 at home with remote monitoring.
214863744|NCT01959854|DEVICE|carboxymethylcellulose|0.25% carboxymethylcellulose preservative free
214863745|NCT01959854|DEVICE|xanthan gum|0.2% xanthan gum preservative free
214863746|NCT06633107|BEHAVIORAL|Cardiac、rehabilitation、exercise|"Routine cardiac rehabilitation treatment + corresponding rehabilitation exercise therapy prescription according to the condition: (1) slow walking + stairs climbing + standing aerobic exercise for patients with cardiac function level I; Grade II patients should take slow walking + standing aerobics; Grade III patients undergo bedside chair aerobics; Class IV aerobic exercises on bed.~After discharge aerobic exercise with the help of community exercise equipment. The duration is gradually increased from 10-20min to 30-40min each time; Gradually increase the intensity from 55% to 60% of the maximum heart rate and not exceed 85% (maximum heart rate (times / min) = 220 - age (years)); The frequency gradually increased from 3 days/week to 5 days/week"
214863747|NCT03954314|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
214863748|NCT01914055|DEVICE|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
214863749|NCT01914055|DEVICE|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
214863750|NCT00166036|DRUG|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
214863751|NCT00166036|DRUG|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
214863752|NCT01462318|DRUG|Midazolam|5 mg
214863753|NCT01462318|OTHER|Caffeine|200 mg
214863754|NCT01462318|DRUG|S-warfarin|10 mg
214863755|NCT01462318|OTHER|Vitamin K|10 mg
214863756|NCT01462318|DRUG|Omeprazole|40 mg
214863757|NCT01462318|DRUG|Dextromethorphan|30 mg
214863758|NCT01462318|BIOLOGICAL|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
214863759|NCT03827564|DEVICE|Intranasal Tear Neurostimulator (ITN) [TrueTear®]|The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
214863760|NCT00326287|DRUG|Ceftobiprole medocaril|
214863761|NCT00326287|DRUG|Ceftriaxone with or without Linezolid|
214863762|NCT02799030|DRUG|BF-200 ALA 1%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
214863763|NCT02799030|DRUG|BF-200 ALA 3%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
214863764|NCT02799030|DRUG|BF-200 ALA 10%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
214863765|NCT05562908|PROCEDURE|Pedicled|Surgical procedure: A prior marking was made on both sides of the LIMA and its veins with bi-polar technique. Hereafter the LIMA and its veins were dissected free with scissor and forceps. Clips were added to all side branches. When the full length of LIMA was obtained, the LIMA and its veins were divided distally by adding clips on the peripheral part of the vessels and proximately dividing by scissor. A vessel-clamp was placed distally and the pedicled LIMA placed in the jugular cavity with a cloth containing papaverine.
214863766|NCT05562908|PROCEDURE|Surgical skeletonised|Surgical procedure: The fascia of the LIMA was opened with a scissor. Hereafter the LIMA was dissected free with scissor and forceps, clips on all LIMA side-branches and divided by scissor. When the full length of LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
214863767|NCT05562908|PROCEDURE|Thunderbeat skeletonised|Surgical procedure: With Thunderbeat the fascia of LIMA was opened. The LIMA was dissected free with Thunderbeat including all side-branches. When the full length of the LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
214863768|NCT00891371|DRUG|lanreotide (Autogel formulation)|Autogel 120mg
214863769|NCT02238626|DRUG|Placebo (for MN-166)|
214863770|NCT02238626|DRUG|MN-166|
214863771|NCT02238626|DRUG|riluzole|Patient is given 50 mg riluzole twice daily.
214863772|NCT00197392|DEVICE|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
214863773|NCT00197392|DEVICE|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
214863774|NCT05969379|GENETIC|Analysis of biomarkers and their correlation with clinical characteristics and outcome|"This is a non-interventional study involving clinical data, neuroimaging analysis, and biological samples. Demographics and clinical data are collected in the database of the French Reference Centre. Additional or missing data will be obtained by contacting the referral physicians. All the neuroimages available will be analysed by dedicated software. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids). Additional samples for genetic testing will be collected upon explicit written consent."
214863775|NCT02622113|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
214863776|NCT02622113|DRUG|Insulin|
214863777|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and delivery of systemic oxygen|CXL is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
214863778|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and without additional oxygen therapy|corneal collagen cross linking with accelerated protocol without additional oxygen therapy
214863779|NCT04343326|PROCEDURE|perform Conventiona corneal collagen cross linking|Conventional CXL using 30 mW/CM2 UV-A ablation for 30 minutes
214863780|NCT00322504|PROCEDURE|Accupuncture|
214863781|NCT03829696|DRUG|Mifeprex® (Mifepristone 200 mg)|Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
214863782|NCT03829696|DRUG|Misoprostol 800 mcg|Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
214863783|NCT03829696|DRUG|ella® (ulipristal acetate emergency contraception 30 mg)|Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
214863784|NCT03829696|DIAGNOSTIC_TEST|AccuHome® Pregnancy OTC Test|Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
214863785|NCT02969941|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
214863786|NCT01562340|OTHER|Pomegranate juice|Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
214863787|NCT01562340|OTHER|Pomegranate fruit extract|Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
214863788|NCT00672165|BIOLOGICAL|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
214863789|NCT00774696|DRUG|clarithromycin 500mg tablets|
214863790|NCT03792724|DRUG|Urelumab + Nivolumab|Treatment with intratumoral urelumab after which Nivolumab will be given.
214863791|NCT05034341|OTHER|Multimodal Prehabilitation|"In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free."
214863792|NCT05034341|OTHER|Standard Pre-Surgical Clinical Care|"* Education related to preoperative activity and home-based exercise program.~* Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment."
214863793|NCT03265613|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
214863794|NCT05389683|BEHAVIORAL|Elimination Diet|An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.
214863795|NCT01946360|DEVICE|Methacetin Breath Test in ACLF and ALF patients|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
214863796|NCT00470457|BIOLOGICAL|Allergen specific immunotherapy|
214863797|NCT01076686|DRUG|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
214863798|NCT00186758|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -"
214863799|NCT02244918|DRUG|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
214863800|NCT02244918|BEHAVIORAL|Smoking Cessation Counseling|
214863801|NCT04650503|OTHER|No intervention|No intervention
214863802|NCT04442490|DRUG|SAGE-217|SAGE-217 oral capsules.
214863803|NCT04442490|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
214863804|NCT03142906|DIAGNOSTIC_TEST|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
214863805|NCT01216696|DRUG|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
214863806|NCT05154435|DRUG|mostcare hemodynamic monitor|mostcare hemodynamic monitoring integrated into the radial artery catheter. According to the data obtained, intraoperative fluid management was arranged with certain algorithms.
214863807|NCT01449279|DRUG|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
214863808|NCT01449279|RADIATION|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
214863809|NCT00505375|DRUG|CTLA-4 Ig|Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
214863810|NCT00505375|OTHER|Placebo|Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
214863811|NCT05579275|BIOLOGICAL|JCXH-212 Injection|Based on the development principle of NCV, a community-type tumor neoantigen mRNA vaccine, JCXH-212 injection, has been developed that can be applied to patients with malignant solid tumors. NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity, and these T cells can inhibit and kill tumor cells in cancer patients, thus prolonging the survival of cancer patients.
214863812|NCT05631353|DEVICE|Carriere Motion Appliance|"Patient will be randomly allocated into two groups:~Group I: conventional mandibular anchorage using passive lingual arch. Group II: anchorage by direct mini-screws. In the group I, Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally with passive lingual arch in the lower arch as anchorage means.~In the group I, Class II elastics will be attached from the maxillary canine to mandiular miniscrews bilaterally.~For each patient, two CBCT radiographs will be obtained: one preoperatively and another after completion of distalization."
214863813|NCT04821531|OTHER|PT Pal|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength balance and mobility
214863814|NCT04821531|OTHER|Exercise Manual|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength, balance and mobility
214863815|NCT03347422|DRUG|sutimlimab (BIVV009)|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
214863816|NCT03347422|DRUG|placebo|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
214863817|NCT02255825|GENETIC|Whole Genome Sequencing|Whole genome sequencing in a CLIA lab and return of results.
214863818|NCT02255825|PROCEDURE|Amniocentesis|Note: this is being performed on all subjects as a clinical (not research) procedure
214863819|NCT02255825|OTHER|Psychosocial assessment|Use of EPDS and STAI for assessment of maternal and paternal mood
214863820|NCT00070057|DRUG|celecoxib|Given orally
214863821|NCT00070057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214863822|NCT00070057|OTHER|pharmacological study|Correlative studies
214863823|NCT00070057|OTHER|laboratory biomarker analysis|Correlative studies
214863824|NCT06394843|OTHER|Ultrafiltration|Patients are selected depending on need of ultrafiltration
214863825|NCT00334100|BEHAVIORAL|Exercise|Treadmill exercise
214863826|NCT03244943|PROCEDURE|Non surgical periodontal Treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
214863827|NCT06230718|OTHER|Motor Imagery (MI)|mental process where an individual visualizes or imagines themselves performing a movement without actually executing it physically. This cognitive process involves the mental rehearsal of motor actions, engaging similar neural pathways that are used when physically performing the action.
214863828|NCT06230718|OTHER|Action Observation (AO)|rehabilitation technique based on the principle of observing actions to improve motor function and learning. This approach is rooted in the concept of the mirror neuron system, a group of neurons that are activated both when a person performs an action and when they observe the same action performed by others.
214863829|NCT06230718|OTHER|Control condition- placebo|Recording with images of landscapes without the presence of any person or animal that could evoke MI or OA.
214863830|NCT04603170|OTHER|DRUG|taking drug medication prescribed by psychiatrists for at least one month
214863831|NCT05355649|DEVICE|PREGNOLIA SYSTEM|"The Pregnolia System is composed of two products: an active device (Pregnolia Control Unit) and a single-use sterile probe (Pregnolia Probe).~The intended use of the Pregnolia System is to provide information about the mechanical properties of the uterine cervix by assessing the tissue stiffness through a proxy parameter (the closing pressure, denominated CSI, or Cervical Stiffness Index, in mbar). The Pregnolia System is intended to be used in conjunction with the information obtained from the clinical evaluation of the patient and in addition to other standard examinations."
214863832|NCT00497952|BIOLOGICAL|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
214863833|NCT02894437|OTHER|qualitative interviews|semi-structured interviews as a conceptual frame work
214863834|NCT03627507|BIOLOGICAL|Hepa-B|Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine. This bulk is formulated to prepare finished dosage to manufacture large scale in fully GMP compliant plant. Incepta has conducted preclinical study at Bioneed, India. After successful completion of preclinical study, this non inferiority clinical trial with innovator product is needed for Licensure in Bangladesh.
214863835|NCT03627507|BIOLOGICAL|Engerix B|.'Engerix B' is a recombinant DNA hepatitis B vaccine. It is sterile suspension of purified surface antigen of hepatitis B virus obtained by culturing genetically yeast cells (Saccharomyces cerevisiae cells), which carry the gene that codes for HBsAg
214863836|NCT00842478|PROCEDURE|Toothbrushing|
214863837|NCT03976583|DRUG|Cpp-Acp|Remineralising agent
214665398|NCT02712502|DRUG|Levofloxacin|"* Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~* Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
214665399|NCT02712502|DRUG|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
214665400|NCT03615027|BEHAVIORAL|Dementia-specific advance care planning|see detailed description
214863838|NCT03976583|OTHER|Pearl powder|Natural product
214863839|NCT02746471|DEVICE|Reveal LINQ|
214863840|NCT05190809|PROCEDURE|Goldilocks mastectomy and fat transfer|Skin sparing mastectomy (Goldilocks mastectomy), then autologous fat grafting in the medial and lateral breast pillars as well as the inferior dermal flap
214863841|NCT03868462|DEVICE|Optos P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
214665401|NCT05786170|DIAGNOSTIC_TEST|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging
214665402|NCT04603248|DRUG|Nivolumab|Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
214665403|NCT03457298|DEVICE|Ossix Volumax|Ossix Volumax is intended to be used for Lateral ridge augmentation
214665404|NCT03457298|DEVICE|FDBA with collagen membrane|freeze-dried bone allograft (FDBA) with collagen membrane
214665405|NCT00816803|PROCEDURE|Autologous bone marrow transplant|
214665406|NCT00816803|PROCEDURE|Physical therapy|
214863842|NCT03868462|DEVICE|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
214863843|NCT05944601|BEHAVIORAL|Virtual and computer-based cognitive remediation training|Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).
214863844|NCT01484262|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
214863845|NCT01484262|DRUG|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
214863846|NCT00910091|DRUG|BN83495|BN83495 will be administered as a 40 mg tablet once a day orally
214863847|NCT00910091|DRUG|Megestrol Acetate (MA)|MA will be administered orally as 160mg daily
214863848|NCT00784186|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
214863849|NCT00784186|DRUG|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
214863850|NCT00784186|DRUG|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
214863851|NCT00749736|DIETARY_SUPPLEMENT|cholecalciferol|"4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm."
214863852|NCT00749736|DIETARY_SUPPLEMENT|doxercalciferol|1 mcg of doxercalciferol per day
214863853|NCT00749736|DIETARY_SUPPLEMENT|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm."
214863854|NCT00002679|BIOLOGICAL|filgrastim|
214863855|NCT00002679|DRUG|cyclophosphamide|
214863856|NCT00002679|DRUG|doxorubicin hydrochloride|
214863857|NCT00002679|DRUG|paclitaxel|
214863858|NCT00002679|DRUG|tamoxifen citrate|
214863859|NCT00002679|RADIATION|radiation therapy|
214476478|NCT06611644|OTHER|Control|Patients in the control group will receive standard postoperative pain management without any regional block intervention. This will include the administration of systemic analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs). Opioid analgesics will be administered as needed based on the patient's pain level. Pain management will be conducted according to the standard protocol followed for breast surgery patients.
214476479|NCT06612112|OTHER|No Interventions|No Interventions
214665407|NCT03785080|OTHER|restart NOAC very early|withhold NOAC less than 24 hours Post OGD
214665408|NCT03785080|OTHER|restart NOAC early|withhold NOAC for 72 to 84 hours Post OGD
214665409|NCT04808687|DRUG|Nab paclitaxel and S-1|Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area \< 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 \< 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
214665410|NCT03693872|DRUG|Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
214665411|NCT03693872|DRUG|Dopaminergic Agonist + Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
214863860|NCT05237518|DEVICE|EarlySense Noomi system|The EarlySense device is intended for continuous contact-free monitoring of heart rate and respiration rate at home, or in professional healthcare settings. The system is intended for remote monitoring of patients by healthcare professionals and is indicated mainly for elderly population monitoring.
214665412|NCT04767425|RADIATION|Brachytherapy|• 3D image-based cervical cancer brachytherapy will be delivered as 4 sessions x 7 Gy High Dose Rate (HDR) brachytherapy
214665413|NCT01318616|OTHER|Strength training of the hip adductors|Adductor strength training
214665414|NCT01539629|DEVICE|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
214665415|NCT05762341|OTHER|PRESSURE INJURY PREVENTION TRAINING|PREVENTION OF PRESSURE INJURY TO FACE TO FACE TRAINING
214665416|NCT03834948|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
214665417|NCT03834948|DRUG|AO-176 + Paclitaxel|Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel
214665418|NCT03834948|DRUG|AO-176 + Pembrolizumab|Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab
214665419|NCT01994343|OTHER|Global posture reeducation|An assessment of the women is performed using global posture reeducation.
214665420|NCT04874272|OTHER|Chaplain led post-code debrief|an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain
214665421|NCT01876589|DEVICE|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
214665422|NCT01876589|DEVICE|Xience Prime|Drug eluting metallic stent
214665423|NCT01663649|BEHAVIORAL|Deprexis|web-based treatment program for depression
214665424|NCT01663649|BEHAVIORAL|Wait-list|the wait-list group receives Deprexis after 6 month
214665425|NCT03797287|DEVICE|Tensor Tunnler|Create the bone tunnels during the arthroscopic rotator cuff repair procedure
214665426|NCT03797287|PROCEDURE|Anchor Rotator Cuff Repair|The suture anchors (Smith and Nephew PEEK Helicoil Anchor) are inserted in bone and the sutures are then used to sew the tendons to bone arthroscopically.
214665427|NCT04758793|OTHER|blood samples|3 citrated tubes and 3 EDTA tubes
214665428|NCT04758793|OTHER|biopsy of abdominal paroie|a muscle biopsy will be performed on the incision area
214863861|NCT02212288|OTHER|Blood sample|Blood samples are for metabolic and genetic and biological investigation
214863862|NCT02212288|OTHER|Urine sample|Urine sample for biological investigation
214863863|NCT02218125|BIOLOGICAL|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
214863864|NCT02218125|BIOLOGICAL|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
214863865|NCT00244530|DRUG|Nifedipine|
214863866|NCT04870138|DRUG|Azithromycin|Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.
214665429|NCT05018338|DEVICE|Brain shift monitoring|For use to monitor brain shift during craniotomy
214863867|NCT04870138|DRUG|Ceftriaxone|Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.
214863868|NCT04870138|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.
214863869|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of wild-type (WT) Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
214863870|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA7527|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of isogenic LptA mutant Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
214863871|NCT06445634|OTHER|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis in Glaucoma Patients with Secondary Synechial Angle Closure
214863872|NCT00208806|OTHER|congestive heart failure patients|observational echo data on congestive heart failure patients
214863873|NCT00798187|BEHAVIORAL|Group Meetings|10 weekly group meetings lasting 2 hours.
214863874|NCT00798187|BEHAVIORAL|Questionnaire|Surveys
214863875|NCT04594707|DRUG|PRM-151 (Zinpentraxin Alfa)|"Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.~Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo."
214476480|NCT06210009|OTHER|DASH-Style Diet|Participants will be randomized to a DASH-style diet
214665430|NCT02201810|BEHAVIORAL|Rate reduction intervention|
214863876|NCT02691793|DRUG|Sunitinib|sunitinib 37.5mg QD
214863877|NCT03080753|DEVICE|Sphinkeeper|Intersphincteric implants in the anal sphincter
214863878|NCT02403453|DEVICE|Rhine Cervical Disc|RHINE Cervical Disc
214863879|NCT03269331|BEHAVIORAL|CTEP EBP Immersion|36 continuing ed credits, virtual library access, collaboration with expert mentors
214863880|NCT04439695|BIOLOGICAL|Low dose|Low dose of KBP-V001
214863881|NCT04439695|BIOLOGICAL|Intermediate dose|Intermediate dose of KBP-V001
214863882|NCT04439695|BIOLOGICAL|High dose|High dose of KBP-V001
214863883|NCT04439695|BIOLOGICAL|Placebo|Buffered Saline Solution
214863884|NCT05986721|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
214863885|NCT05986721|DRUG|Placebo|Placebo oral tablet
214863886|NCT01155024|DEVICE|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
214863887|NCT01155024|DEVICE|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
214863888|NCT06197958|OTHER|eccentric exercises|eccentric exercises like walking down stairs, lowering a weight during shoulder press, the downward motion of squatting, the downward motion of a push-up, lowering the body during a crunch, lowering the body during a pull-up 3 sets with 10 RM (repetition maximum) for six week training.
214290695|NCT00272467|DRUG|Rebamipide|"1. Brand name: Mucosta® Tab.~2. Generic name: Rebamipide.~3. Chemical name:~   (±)-2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinon-4-yl\]propionic acid.~4. Formulation: Tablet (White, film-coated tablet).~5. Strength: One tablet contains rebamipide 100mg.~6. Storage condition: 15℃\~25℃.~7. Manufacturer: Korea Otsuka Pharmaceuticals"
214665431|NCT02201810|BEHAVIORAL|Recycling Group|
214665432|NCT02201810|BEHAVIORAL|Choice Group|
214665433|NCT02201810|BEHAVIORAL|Proactive QL|
214665434|NCT00117078|DRUG|Aranesp®|
214665435|NCT01152138|DEVICE|Open cells stent|Cobalt Chromium Stent with open cell design
214665436|NCT01152138|DEVICE|Closed Cells Stent|Cobalt Chromium stent with closed cell design
214665437|NCT00226642|DRUG|Sertralin|
214665438|NCT00226642|BEHAVIORAL|Cognitive-behavioral therapy|
214665439|NCT00226642|DRUG|Placebo|
214665440|NCT00226642|BEHAVIORAL|Non-specific supporting group therapy|
214863889|NCT06197958|OTHER|concentric exercises|concentric exercises like walking upstairs, pushing up in a bench press, the beginning portion of a deadlift when you lift the barbell off the ground, sitting up in a sit up, pushing up from a lowered push-up and standing up in a back squat 3 sets with 10 RM.
214863890|NCT02521935|DEVICE|Complete traditional dentures|"Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination \& diagnosis \& initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments"
214863891|NCT02521935|DEVICE|Complete CADCAM dentures|"Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, \& tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage"
214863892|NCT03009916|DRUG|"cholestagel® (Colesevelam)"|3750mg
214863893|NCT03009916|DRUG|Placebos|3750mg
214863894|NCT03198975|DIAGNOSTIC_TEST|Magnetic resonance image|Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
214863895|NCT04178070|BIOLOGICAL|GB224 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
214863896|NCT04178070|BIOLOGICAL|GB224 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
214863897|NCT04178070|BIOLOGICAL|GB224 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
214863898|NCT04178070|BIOLOGICAL|GB224 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
214863899|NCT04178070|BIOLOGICAL|GB224 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
214863900|NCT04178070|BIOLOGICAL|GB224 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
214863901|NCT04178070|OTHER|Placebo, 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
214863902|NCT04178070|OTHER|Placebo, 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
214863903|NCT04178070|OTHER|Placebo, 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
214863904|NCT04178070|OTHER|Placebo, 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
214863905|NCT04178070|OTHER|Placebo, 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
214863906|NCT04178070|OTHER|Placebo, 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
214863907|NCT01593696|BIOLOGICAL|Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)|Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
214863908|NCT03327636|DEVICE|Echopulse|This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
214863909|NCT03751956|DRUG|HSK3486|The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
214863910|NCT02633488|DRUG|Placebos|A 12 week single blind placebos
214863911|NCT02633488|DRUG|metformin|A 12 week single blind metformin
214863912|NCT05535985|DEVICE|acupuncture|treatment of pain or disease by inserting the tips of needles at specific points on the skin
214863913|NCT05535985|DEVICE|placebo acupuncture|placebo acupuncture
214863914|NCT03335293|DRUG|100 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
214863915|NCT03335293|OTHER|normal saline|placebo comparator
214863916|NCT03335293|DRUG|200 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
214863917|NCT00002785|BIOLOGICAL|filgrastim|
214863918|NCT00002785|DRUG|asparaginase|
214863919|NCT00002785|DRUG|cyclophosphamide|
214863920|NCT00002785|DRUG|cyclosporine|
214863921|NCT00002785|DRUG|cytarabine|
214863922|NCT00002785|DRUG|daunorubicin hydrochloride|
214863923|NCT00002785|DRUG|dexamethasone|
214863924|NCT00002785|DRUG|etoposide|
214863925|NCT00002785|DRUG|leucovorin calcium|
214863926|NCT00002785|DRUG|mercaptopurine|
214863927|NCT00002785|DRUG|mesna|
214863928|NCT00002785|DRUG|methotrexate|
214863929|NCT00002785|DRUG|methylprednisolone|
214863930|NCT00002785|DRUG|pegaspargase|
214863931|NCT00002785|DRUG|prednisone|
214863932|NCT00002785|DRUG|therapeutic hydrocortisone|
214863933|NCT00002785|DRUG|vincristine sulfate|
214863934|NCT00002785|PROCEDURE|allogeneic bone marrow transplantation|
214863935|NCT00002785|RADIATION|low-LET cobalt-60 gamma ray therapy|
214863936|NCT00002785|RADIATION|low-LET photon therapy|
214863937|NCT02866045|PROCEDURE|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
214863938|NCT02866045|PROCEDURE|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
214863939|NCT00365131|DRUG|Cerezyme (imiglucerase for injection)|
214863940|NCT04644822|DIAGNOSTIC_TEST|[18F] PSMA-1007 Injection|a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.
214863941|NCT03355014|DRUG|Combination of gemigliptin/metformin HCl sustained release 50/1000mg|Gemigliptin/Metformin HCl extended release 25/500mg 2tablets
214863942|NCT03355014|DRUG|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg|Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
214863943|NCT03816514|PROCEDURE|SpHb monitoring|Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring
214863944|NCT03816514|PROCEDURE|Conventional management|Conventional management without SpHb monitoring
214863945|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
214863946|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR after treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
214863947|NCT01936623|BEHAVIORAL|Computerized Brief Intervention|No additional information needed.
214863948|NCT01374295|OTHER|video|watch a 3 minute video
214863949|NCT01374295|OTHER|standard education|Receives standard verbal education from healthcare provider
214863950|NCT01439750|DRUG|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
214863951|NCT01439750|DRUG|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
214863952|NCT01439750|DRUG|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
214863953|NCT00986713|DRUG|Amphotericin B|Aerosolized Amphotericin B,2mg/day or 10mg/day
214863954|NCT04859621|DRUG|Vitamin D3 4000 IU|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
214863955|NCT04859621|DRUG|Vitamin D3 2000 IU|Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
214863956|NCT04859621|DRUG|Placebo|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
214665441|NCT01697332|DRUG|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
214863957|NCT04859621|OTHER|standard antibiotic therapy|standard antibiotic therapy
214665442|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
214863958|NCT03167723|DEVICE|Chest tube placement|Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
214863959|NCT06157203|DEVICE|Uterine electromyography|electromyographic and fetal electrocardiographic recordings will be obtained during threatened labor
214863960|NCT00250796|DRUG|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
214863961|NCT00250796|DRUG|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
214863962|NCT02122406|OTHER|Hospital Anxiety and Depression Scale (HADS) questionnaire|Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
214863963|NCT01175811|DRUG|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
214863964|NCT01175811|DRUG|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
214863965|NCT01175811|DRUG|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
214863966|NCT04873765|BIOLOGICAL|Pegfilgastrim Megalabs|Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
214863967|NCT04873765|BIOLOGICAL|Pegfilgastim Amgen|Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
214863968|NCT05291065|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
214863969|NCT05291065|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
214863970|NCT05291065|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
214863971|NCT03579966|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
214863972|NCT03816566|DEVICE|patch|A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.
214863973|NCT02620150|DRUG|Escitalopram|10 week trial
214863974|NCT02620150|OTHER|Placebo|10 week trial
214863975|NCT00997568|DEVICE|PET-511BTM|Transesophageal Transducer
214863976|NCT01340768|DRUG|Sitagliptin|One 100 mg tablet taken orally once daily
214863977|NCT01340768|DRUG|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
214863978|NCT01340768|DRUG|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
214863979|NCT02203422|DRUG|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
214863980|NCT02203422|DRUG|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
214863981|NCT03778658|BEHAVIORAL|Physical Activity Intervention|Participants will engage in a multimodal aerobic and strength training intervention.
214863982|NCT01150318|DRUG|Administration of 131 iodine|100 mCi 131 iodine irradiation
214863983|NCT00476554|DRUG|Sapacitabine|Sapacitabine
214863984|NCT03052959|BEHAVIORAL|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
214863985|NCT03052959|OTHER|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
214863986|NCT05385159|DRUG|AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION|Adipose tissue removal, ADSVF production and injection of ADSVF will be done on the same day during a short hospital stay
214863987|NCT05385159|DRUG|Placebo|Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.
214863988|NCT01166906|DEVICE|pain blocking|pain blocking
214863989|NCT01194518|BEHAVIORAL|Lifestyle Intervention Program|
214863990|NCT01584206|DRUG|Ezetimibe|10mg ezetimibe/day, at least 4 months
214863991|NCT04183075|DIETARY_SUPPLEMENT|FontActiv Superprotein/Hypercaloric Fiber|The product under study has a liquid presentation, in 200 ml bottles, ready to take
214863992|NCT04183075|DIETARY_SUPPLEMENT|Carbohydrates and C Vitamin|The control product will be prepared with equal presentation and taste as similar as possible tan study product
214863993|NCT04258475|DRUG|Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.|Raltegravir will be dosed in a fasted state in all periods. Participants will take Raltegravir along with other ART medication.
214863994|NCT04258475|DRUG|Calcium carbonate antacid tablet|PK analysis of different doses of calcium carbonate antacid in patients undergoing ART treatment for HIV using Raltegravir.
214863995|NCT05410132|OTHER|Internet-delivered Mindfulness Based Training (iMBT)|"The iMBT developed for this study will be adapted from our team's previous study and the manual of mindfulness based cognitive therapy. The program is designed to be brief in nature, for example, participants will be asked to practice meditations for 15 minutes a day instead of the original 45 minutes a day, and each module is shortened to approximately 1 hour instead of the original 2.5 hours.~This iMBT is comprised of six weekly modules on education about mindfulness, guidance on using mindfulness skills to manage symptoms, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and graphics are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice."
214863996|NCT05001932|PROCEDURE|Cataract surgery|Randomized Clinical Trial
214863997|NCT02377518|RADIATION|Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media|
214863998|NCT00437632|DRUG|GSK598809|GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
214863999|NCT00437632|DRUG|Placebo|Subjects will receive matching placebo capsules to GSK598809 orally with water.
214864000|NCT00437632|DRUG|Caffeine|Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
214864001|NCT03886987|DEVICE|Blue Non Sterile Powder Free Nitrile Examination Gloves|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
214864002|NCT05016193|DEVICE|Axem Home Prototype Device|The Axem Home prototype device is a rehabilitation system designed to be used independently by a stroke survivor to facilitate physical rehabilitation exercises in their home environment. The device uses a functional near-infrared spectroscopy (fNIRS) headband that measures the hemodynamic response to rehabilitation exercises and displays this brain activity information to the user.
214864003|NCT05016193|BEHAVIORAL|Rehabilitation Exercise Program|Individual exercise program prescribed by a therapist in the Early Supported Discharge Program.
214864004|NCT06300671|OTHER|Foot Posture Index-6|Foot Posture Index 6 (API-6) is a clinical diagnostic tool that broadly measures whether a foot is in neutral, supination or pronation posture. During the evaluation, individuals' static standing postures in a comfortable position are observed and scored. When using API-6, researchers visually evaluate the foot according to 6 criteria, each rated on a 5-point (-2 to +2) Likert scale. Each item is scored between -2 (supination) and +2 (pronation) and 0 (for neutral position), with the total score being between -12 (high degree of supination) and +12 (high degree of pronation). The grouping of reference values showing foot posture can be summarized as follows; Neutral position from 0 to +5, pronation position from +6 to +9, hyperpronation position from +10 to +12, supination position from -1 to -5, and supination position from -6. It shows a high degree of supination position up to -12. Higher scores represent a more pronated foot posture.
214864005|NCT04842773|DIAGNOSTIC_TEST|Ultrasound measurement|Ultrasound measurement of sarcopenia in an elderly population
214864006|NCT02431182|BEHAVIORAL|Memory Training Workshop|"1. Presentation of the workshop: Objectives and Methodology~2. Explanation of the different types of memory and its implication in normal life~3. Strategies for gathering and codification of the information~4. Strategies for selection and storage the information~5. Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory~6. Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences~7. Strategies for recuperation according to the individual profile. Improving self-esteem~8. Strategies for recuperation Social skills.~9. Personal and social skills~10. New contexts and opportunities~11. Evaluation of the workshop"
214665443|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
214476481|NCT06210009|OTHER|Western-Style Diet|Participants will be randomized to a Western-style diet
214665444|NCT00683943|DRUG|Lithium Carbonate|
214864007|NCT04351048|PROCEDURE|Stepwise Excavation|"* stepwise excavation includes selective caries removal to soft dentine on pulpal wall in the first stage of the excavation and~* after six months, the second stage of intervention includes re-entring the cavities and wall selective removal to firm dentine on pulpal wall."
214864008|NCT04351048|PROCEDURE|One Step Excavation|\*one step excavations is completed in the first stage via performing selective removal to soft dentine on pulpal wall of the cavities.
214864009|NCT01476592|DIETARY_SUPPLEMENT|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
214864010|NCT03669939|OTHER|Communication Strategy|Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
214864011|NCT03669939|OTHER|Standard of Care|The standard information about the CDC Guidelines and no other information that is available through the study.
214864012|NCT05304286|BEHAVIORAL|Acceptance and Commitment Therapy|The aim of ACT is to address avoidance behaviors by increasing openness to difficult experiences, such as pain, and to develop an awareness of behavioral options that will aid to facilitate behavior change processes that are in accord with living a values-based life.
214864013|NCT05816057|BIOLOGICAL|semaglutide injection|The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.
214864014|NCT05638958|DEVICE|Immediate post-extractive Implant placement|Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.
214864015|NCT05721118|DIAGNOSTIC_TEST|CBCT and DXA exams performed in current practice in Nantes University Hospital|40 patients will be enrolled in order to study DXA/CBCT acquisitions of 16 osteoporotic women vs 34 osteopenic/healthy women (Estimated osteoporotic rate = 20%)
214864016|NCT03967535|DEVICE|MRI Brain Imaging|Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
214864017|NCT03967535|BEHAVIORAL|Mental Health Assessment and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
214864018|NCT05492253|OTHER|Infant fruit|Infants will be fed prune puree
214864019|NCT05492253|OTHER|Infant vegetable|Infants will be fed carrot puree
214864020|NCT05492253|OTHER|Infant meat|Infants will be fed beef puree
214864021|NCT05492253|OTHER|Infant grain|Infants will be fed oatmeal cereal
214864022|NCT03850951|DEVICE|Lingual appliances|Patients with moderate crowding will be treated without extraction using lingual appliances.
214864023|NCT03850951|DEVICE|Labial appliances|Patients with moderate crowding will be treated without extraction using labial appliances.
214864024|NCT02651779|PROCEDURE|Open reduction and internal plate fixation|
214864025|NCT02651779|OTHER|Closed reduction and plasterimmobilisation|
214864026|NCT04419792|OTHER|Assessment of physical performance variables|"Other:~Assessment of physical performance indices using the following outcome measures:~Cardiopulmonary fitness: YMCA submaximal bike test Upper Body: ACSM press up test, Dynamometry Lower body: Wall squat test, Countermovement jump test"
214864027|NCT00950963|BEHAVIORAL|Phone Counseling|Patient were contacted on a periodic basis via telephone to address there diabetes care.
214864028|NCT00950963|OTHER|Standard Clinical Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
214864029|NCT06295848|BEHAVIORAL|Exercise|An individual program will be organized for each patient according to the exercise test result. Since the patients have both arthritis and HTN, aerobic exercises will be given at moderate intensity (40-60% VO2 reserve) according to ACMS recommendations. Xrcise Runner Med treadmill and Xrcise Care 2.5.8.3 software will be used for aerobic exercises. Resistant exercises will be given under the supervision of a physiotherapist, calculating 1 repetitation maximum (1-RM) in the main muscle groups.Patients will perform isotonic exercises with 3 sets of 15 repetitions with a resistance of 60% of 1-RM. The education sessions will be conducted by a multidisciplinary team of health professionals (nurse, physiotherapist and dietician) under the leadership of a clinician experienced in CR. Education topics will consist of 60-minute sessions covering heart-healthy eating, setting health-related goal, exercise, diet, healthy weight loss, smoking cessation, and stress/coping.
214864030|NCT02447796|DRUG|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
214864031|NCT02447796|DRUG|Dexmedetomidine|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
214864032|NCT00627315|PROCEDURE|Gastric bypass|NOTE: Surgery will not be paid by the study
214864033|NCT00627315|PROCEDURE|Gastric banding|NOTE: Surgery will not be paid by the study
214864034|NCT01776697|DRUG|pelubiprofen (30mg) tablet IR|
214864035|NCT01776697|DRUG|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
214864036|NCT03508505|DEVICE|Venoarterial extracorporeal oxygenation|Veno-arterial extracorporeal oxygenation (VA-ECMO) is inserted in the acute setting in case of cardiac low output after adult cardiac surgery in order to provide cardiopulmonary support to recovery or as bridge to transplantation.
214864037|NCT02161822|DRUG|simvastatin|simvastatin 80mg qd for 5weeks
214864038|NCT00848107|DRUG|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
214864039|NCT05965115|DIAGNOSTIC_TEST|Sample of Blood|All participants will receive M-protein screening by serum electrophoresis. Individuals with detected M-protein will undergo further diagnostic tests to determine their accurate diagnosis. Patients with monoclonal gammopathy of undetermined significance (MGUS) would be carefully assessed and followed up.
214864040|NCT00237783|DRUG|dialysate sodium (140 mmol/L)|
214864041|NCT00237783|DRUG|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
214864042|NCT00326963|DRUG|Background ARVs|As prescribed
214864043|NCT00326963|DRUG|PI|As prescribed
214864044|NCT00326963|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
214864045|NCT00859586|DEVICE|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
214864046|NCT05967052|DRUG|Pregabalin|Pregabalin pharmacotherapy
214864047|NCT05967052|BEHAVIORAL|Independent walking training|Independent walking training
214864048|NCT05967052|DRUG|Placebo|Placebo
214864049|NCT05967052|BEHAVIORAL|Gradual movement therapy in the ward|Gradual movement therapy in the ward
214864050|NCT05967052|BEHAVIORAL|Telerehabilitation|Telerehabilitation
214864051|NCT05967052|BEHAVIORAL|Psychotherapy|Psychotherapy
214864052|NCT00231647|DRUG|topiramate|
214864053|NCT01398215|PROCEDURE|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
214864054|NCT06504420|DRUG|Sirolimus|Subjects will receive Sirolimus 1.5mg/d for 48 weeks in addition to their ongoing APS treatment regimen
214864055|NCT06504420|DRUG|Placebo|Subjects will receive Placebo 1.5mg/d for first 24 weeks and Sirolimus 1.5mg/d for next 24 weeks in addition to their ongoing APS treatment regimen
214665445|NCT03436589|BEHAVIORAL|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
214665446|NCT03306147|BEHAVIORAL|Pain education with follow up encounters|Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
214864056|NCT04849962|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
214864057|NCT04849962|OTHER|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
214864058|NCT02008786|DRUG|ramipril|5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
214864059|NCT02008786|DRUG|rosuvastatin|10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
214864060|NCT02008786|DRUG|placebo|Placebo
214864061|NCT03906396|DEVICE|Xbox 360 Kinect|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant. Games uses for the activity are Sports Kinect and Sports Kinect 2. Xbox 360 Kinect - the players themselves become the ''game controller'' via their body movements and gestures, Kinect-enabled game titles lend themselves comfortably to the class of exercise games.
214864062|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate and Vitamin C|28 mg iron 240 mg vitamin C
214864063|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate|28 mg iron
214864064|NCT04469010|DIETARY_SUPPLEMENT|Placebo|Matched placebo
214864065|NCT02053935|DRUG|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
214864066|NCT04425135|DRUG|Camrelizumab|200mg,D1,ivgtt, Q3w.
214864067|NCT04425135|DRUG|Apatinib|250mg,Qd,Q3W.
214864068|NCT04425135|DRUG|Pemetrixed|500 mg/m2,D1,ivgtt, Q3w.
214864069|NCT04425135|DRUG|Carboplatin|AUC=5\~6,D1,ivgtt, Q3w.
214665447|NCT01733329|DRUG|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
214864070|NCT06138236|DRUG|Collagen hydrolyzed peptides|infiltration near the heal spur of 2ml of Arthrys
214864071|NCT02992418|BIOLOGICAL|CYD Dengue Vaccine|0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively
214864072|NCT02992418|BIOLOGICAL|Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed|0.5 mL, intramuscularly (IM) at Month 1.
214864073|NCT02992418|BIOLOGICAL|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Day 0.
214864074|NCT01830205|DRUG|Daclatasvir|
214864075|NCT03915353|OTHER|No Intervention|No Intervention
214864076|NCT03246126|DEVICE|Valiant™Thoracoabdominal Stent Graft System|The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
214864077|NCT01996618|DRUG|Ranolazine|After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
214864078|NCT06189547|OTHER|different prior cancer history type|different types of prior cancer history
214864079|NCT05943808|OTHER|Book reading|subjects are given an acupuncture textbook to read for 30 minutes
214864080|NCT05943808|OTHER|VR pre-recorded video watching|subjects are given an pre-recorded VR video to watch for 30 minutes
214864081|NCT00005399|OTHER|No interventions|No interventions
215033748|NCT06408376|PROCEDURE|Physiological cord clamping|Immediately after birth, the newborn with prenatal diagnosis of CDH will be placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact and intubated. The patient will be gently ventilated (PIM 15/25 - PEEP 4 - Fio2 50%), until saturation \>85% and HR\>100 or 10 timed minutes have elapsed, whichever occurs first, the umbilical cord will be clamped.
215033749|NCT02320656|OTHER|Blood sampling|Longitudinal (3 stages of the disease)
214864082|NCT01992523|DRUG|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
214290696|NCT00272467|DRUG|Omeprazole|"1. Brand name: Losec® Cap.~2. Generic name: Omeprazole.~3. Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃\~25℃. 7) Manufacturer: AstraZenaca Korea."
214864083|NCT01992523|DRUG|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
214864084|NCT05626439|DRUG|Staccato alprazolam|Study participants will receive single dose of Staccato alprazolam by inhalation at pre-specified time points.
214864085|NCT05626439|DRUG|Oral alprazolam|Study participants will receive single dose of oral alprazolam at pre-specified time points.
214864086|NCT00144664|DRUG|MRA(Tocilizumab)|
214864087|NCT00067899|DRUG|Vitamin E with and without Vitamin C|
214864088|NCT02758522|DRUG|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
214864089|NCT02758522|DRUG|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
214864090|NCT02758522|DRUG|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
214864091|NCT00172536|BEHAVIORAL|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
214864092|NCT00172536|OTHER|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
214864093|NCT01684436|DEVICE|Punctal Plug|Punctal plugs inserted into the study eye on Day 1.
214864094|NCT00476983|DRUG|saquinavir/ritonavir plus truvada|SQV/r 1500/100 mg OD + Truvada OD for 2 years
214864095|NCT05006768|DRUG|Barcimiant|1 tablet contains 4 mg Barcitinib
214864096|NCT05006768|DRUG|Olumiant (first dose)|1 tablet contains 4 mg Barcitinib
214864097|NCT05006768|DRUG|Olumiant (second dose)|1 tablet contains 4 mg Barcitinib
214864098|NCT00737763|DRUG|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
214290697|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
214290698|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
214290699|NCT00755092|BEHAVIORAL|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
214290700|NCT00755092|BEHAVIORAL|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
214290701|NCT04031937|OTHER|Psychomotor assessment|the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
214290702|NCT01917474|DIETARY_SUPPLEMENT|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
214864099|NCT00737763|DRUG|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
214864100|NCT03791710|PROCEDURE|autologous fat grafting|regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound
214864101|NCT03791710|DRUG|Topical Cream|serial dressing with topical agents e.g Silver Sulphadiazine
214864102|NCT03791710|PROCEDURE|split thickness skin grafting|depridment and split thickness skin grafting
214864103|NCT05941455|DEVICE|Venus-Neo Surgical Aortic Valve|Implant of a Venus-Neo Surgical Aortic Valve
214864104|NCT05652738|DEVICE|Passive cooling application|Passive cooling application for asphyxiated neonates and their effect on myocardial function and hemodynamics
215033750|NCT02320656|OTHER|Bone marrow aspirate|Longitudinal (3 stages of the disease)
214864105|NCT05652738|DEVICE|cooling using Blanket roll III|standard care using Blanket roll III in asphyxiated neonates and their effect on myocardial function and hemodynamics
214864106|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
214864107|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
214864108|NCT00132028|DRUG|vorinostat|Given orally
214864109|NCT00132028|OTHER|laboratory biomarker analysis|Correlative studies
214864110|NCT00888056|PROCEDURE|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
214864111|NCT05490485|DRUG|Camrelizumab|Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma
214864112|NCT02240030|DRUG|CVT-301 Low Dose|
214864113|NCT02240030|DRUG|CVT-301 High Dose|
214864114|NCT02240030|OTHER|Placebo|
214864115|NCT04467801|DRUG|Ipatasertib|Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.
214665448|NCT01733329|DRUG|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
214864116|NCT02909946|BEHAVIORAL|Multi-modal Infection Control Program|"1. Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~2. Hand hygiene education to residents and families (resident-level intervention).~3. Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~4. Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~5. Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
214864117|NCT00978263|DRUG|metformin-based Oral Antidiabetic Drugs|
214864118|NCT00978263|DRUG|Glargine|
214864119|NCT00437840|DRUG|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
214864120|NCT00437840|DRUG|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
214864121|NCT04607330|OTHER|High protein liquid|After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
214864122|NCT00328016|BEHAVIORAL|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
214864123|NCT00328016|DEVICE|RESPeRATE|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
214864124|NCT01921621|BEHAVIORAL|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
214864125|NCT01921621|BEHAVIORAL|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
214864126|NCT01921530|PROCEDURE|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
214864127|NCT01921530|PROCEDURE|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
214864128|NCT02731326|DEVICE|AliveCor|"The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, AliveECG. It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor cloud."
214864129|NCT02731326|BEHAVIORAL|Behavioral Altering Messaging|Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number
214864130|NCT03670290|PROCEDURE|Fascia iliaca compartment catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
215033751|NCT02320656|OTHER|Skin biopsy|Single biopsy (optional)
215033752|NCT02320656|OTHER|Buccal swab|Single sampling.
214665449|NCT03950986|OTHER|Modified clinical reminders|Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
214864131|NCT03670290|PROCEDURE|epidural catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
214864132|NCT03670290|PROCEDURE|patient controlled analgesia|Patient will evaluate and if VAS score \>3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
214864133|NCT01920607|DEVICE|magnetic anal sphincter|
214864134|NCT01920607|DEVICE|sacral nerve stimulation|
214864135|NCT00150943|DEVICE|Renal artery stent|
214864136|NCT02802774|OTHER|Plaster Splint|The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
214864137|NCT02802774|OTHER|Velcro Brace|The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
214864138|NCT02802774|OTHER|Soft Dressing|Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
214864139|NCT03262506|OTHER|Computerized cognitive training|The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
214864140|NCT02068521|DRUG|somavaratan|Subcutaneous injection
214864141|NCT00853086|DRUG|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
214864142|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 24 weeks
214864143|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.0 mcg/kg QW SC for 24 weeks
214864144|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 16 weeks
214864145|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 24 weeks
214864146|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 16 weeks
214864147|NCT05789693|BEHAVIORAL|Physical activity changes|Previously an initial measure (qualitative and qualitative) will be made to know the little active adolescents. At the end of the physical activity program a retention measure will be carried out to know the scope and persistence of the variables analyzed. The intervention will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where there will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all.
214864148|NCT02689245|DRUG|Tenofovir|
214864149|NCT02689245|DRUG|Fecal Microbiota Transplantation (FMT)|
214864150|NCT01616953|BIOLOGICAL|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
214864151|NCT01616953|PROCEDURE|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
214864152|NCT02902783|OTHER|Data Collection|Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
214864153|NCT04315870|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
214864154|NCT06227156|DRUG|Disitamab Vedotin Injection|2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle
214864155|NCT03535779|BIOLOGICAL|Hepatitis B|The Hepatitis B virus, is a double stranded DNA virus that prevents Hepatitis B in the population
214864156|NCT03535779|BIOLOGICAL|Tetanus Toxoid|The Tetanus vaccine, also known as tetanus toxoid (Td/IVP), is an inactive vaccine used to prevent tetanus in the population
214864157|NCT05863143|BEHAVIORAL|Nutritional and Exercise|Provide Nutritional Education Program and Falls Module Exercise (FME) to the intervention group
214864158|NCT06007131|DEVICE|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
214864159|NCT03206580|OTHER|Concentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
214864160|NCT03206580|OTHER|Concentric-Eccentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
214864161|NCT02309775|OTHER|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
214864162|NCT00545207|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
214864163|NCT00545207|DRUG|Placebo|po monthly for 2 years
214864164|NCT05167604|DRUG|Adjuvants, Pharmaceutic|Patients with stage IB-IIA NSCLC after curative surgery were treated with adjuvant chemotherapy. The blood samples of the patients before and after adjuvant chemotherapy will be collected to examine the MRD status
215033753|NCT03430999|DRUG|Calmangafodipir|Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg
215033754|NCT03430999|DRUG|Placebo|Placebo
215033755|NCT03820076|OTHER|AZT-04|Staphylococcus epidermidis
214864165|NCT05466006|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), SCTG will be harvested from the palate and sutured to the flap. Simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
214864166|NCT05466006|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix (VCXM)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), VCMX will be sutured to the flap and simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
214864167|NCT01222286|DRUG|IPH2101|0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
214864168|NCT04093635|DEVICE|Negative Pressure Wound Therapy|VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
214864169|NCT02500641|DRUG|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration \> 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
214864170|NCT02500641|DRUG|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
214864171|NCT02500641|DRUG|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
214864172|NCT02500641|DRUG|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
214864173|NCT02500641|DRUG|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
214864174|NCT04694183|DRUG|Camrelizumab|200mg, intravenous drip administration, d1, every 3 weeks.
214864175|NCT04694183|DRUG|S-1|Oral, d1-14, every 3 weeks.
214864176|NCT04694183|DRUG|Oxaliplatin|130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
214864177|NCT04694183|DRUG|Paclitaxel|Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).
214864178|NCT00543946|DRUG|GAP-134|24-Hour IV infusion, SAD
214864179|NCT05555563|OTHER|MTAD irrigation|Final irrigation protocol was performed using 5 ml MTAD (n=50).
214864180|NCT01031953|DRUG|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
214864181|NCT01031953|DRUG|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
214864182|NCT01031953|OTHER|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
214864183|NCT01031953|PROCEDURE|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
214864184|NCT03744702|DRUG|Ascorbic Acid|Patients will receive IV ascorbic acid.
214864185|NCT03453671|BEHAVIORAL|Mindfulness|Participants will use mindfulness techniques while exercising
214864186|NCT03453671|BEHAVIORAL|Distraction|Participants will distract themselves while exercising
214864187|NCT03453671|BEHAVIORAL|Self-monitoring|Participants will use associative attentional focus while exercising
214864188|NCT00000723|DRUG|Methotrexate|
214864189|NCT00000723|DRUG|Leucovorin calcium|
214864190|NCT00000723|DRUG|Zidovudine|
214864191|NCT00000723|DRUG|Dexamethasone|
214864192|NCT00090181|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
214864193|NCT00090181|DRUG|Comparator: diclofenac / Duration of Treatment: 4 weeks|
214864194|NCT04582461|DEVICE|multislice computed tomography|All patients will undergo a preoperative multiphasic multidetector CT scan before surgery.The unenhanced scan will be used to generate a CT reconstruction of the upper abdomen (from the diaphragm to the kidneys) with a 5mm thickness. Two different radiologists (D.F. and D.I.), blinded to patient information, measured total fat volume (TFV), visceral fat volume (VFV), and analyzed pixels with densities in the - 190 hounsfield units (HU) to - 20 HU range. the ratio between the density of the pancreas over the density of the spleen will be calculated and the maximum diameter of the pancreatic duct will be measured using the arterial phase in order to better identify the entire length of the duct.
214864195|NCT02546401|DRUG|Insulin Aspart|Injection of Insulin Aspart before or after meals
214864196|NCT00643565|DRUG|Standard chemotherapy|As prescribed
214864197|NCT00643565|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
214864198|NCT06162130|DIAGNOSTIC_TEST|Eccentric quadriceps exercises|The activation of the vastus medialis, vastus lateralis, and rectus femoris muscles will be measured using surface electromyography (sEMG) during four distinct quadriceps eccentric exercises: Reverse Nordic, Pistol squat, Suspension-based Bulgarian split squat, and Bulgarian split squat. Participants will be instructed to perform three successful repetitions for each exercise. A 30-second break will be provided between each repetition, and there will be a minimum of 10 minutes of rest between each of the four exercises. Due to the belief that fatigue could impact exercise performance, the modified Borg scale will be used to ensure that fatigue does not occur before each exercise. Exercise recording will commence when scores reported using the modified Borg scale are 1 or lower.
214864199|NCT02317614|BEHAVIORAL|SteadyRx|The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
214864200|NCT05237336|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~* to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~* To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~* To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~* To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences."
214864201|NCT05237336|BEHAVIORAL|Counselling as usual|Control group, Counselling as usual
214864202|NCT02310711|OTHER|Standard of Care|"Standard of care for early stage breast cancer is breast conserving therapy at this center.~Other concomitant standard of care treatment • Radiation therapy to the whole breast~o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions"
214864203|NCT01355159|DRUG|Folic Acid 4 mg|Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
214864204|NCT01355159|DRUG|Placebo|Placebo x 4 tablets will be taken daily by oral administration.
214864205|NCT00360737|BIOLOGICAL|Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)|Biological/Vaccine NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from pooled plasma obtained from horses that have been immunized against one of seven botulinum antitoxins (A-G). .
214864206|NCT04178161|DEVICE|Laser treatment|Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
214864207|NCT04700280|DRUG|GLPG3970|GLPG3970 film-coated tablet.
214864208|NCT04700280|DRUG|Placebo|Placebo film-coated tablet.
214864209|NCT04627480|DEVICE|Fisher Wallace Neurostimulation Device|a Cranial Electrotherapy Stimulator Device (CES).
214864210|NCT00352235|DRUG|KRN7000|
214864211|NCT06273787|OTHER|diaphragmatic release|diaphragmatic myofascial release for 1 months 3 sessions per week
214864212|NCT05617937|OTHER|Massage|The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
214864213|NCT06202924|BEHAVIORAL|Static balance assessment|Biodex stabilometer device will be used to evaluate the static balance of the participants.
214864214|NCT06202924|BEHAVIORAL|Dynamic balance assessment:|Individuals' dynamic balance performances were evaluated with the Y balance test. Y balance test is a test method with proven validity and reliability in athletes and healthy subjects. (Intra-class correlation 0.99-1, Inter-class correlation 0.85-0.91).
214864215|NCT06202924|BEHAVIORAL|Isokinetic strength evaluation:|Quadriceps muscle strength of the participants will be evaluated with an isokinetic dynamometer. Isokinetic dynamometers are considered the gold standard in muscle strength measurements. These devices have the ability to objectively report the amount of force produced by individuals at predetermined angular speed and joint range of motion.
214864216|NCT02907541|OTHER|QI4U learning|Learners will have access to 8 QI methods modules on QI4U
214864217|NCT02907541|OTHER|Facilitated learning|Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
214864218|NCT02907541|OTHER|QI4U and Facilitated learning|Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
214864219|NCT06446141|OTHER|Osteopathic technique|Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed.
214864220|NCT04158336|DRUG|ZN-c3|ZN-c3 is a study drug
214864221|NCT02448121|PROCEDURE|Autologous bone marrow stem cell graft|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
215033756|NCT05759403|DIAGNOSTIC_TEST|Cortical excitability using transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.
215033757|NCT02878785|DRUG|Decitabine|DNA methyltransferase inhibitor
215033758|NCT02878785|DRUG|talazoparib|poly ADP ribose polymerase (PARP) inhibitor
214665450|NCT05970887|BIOLOGICAL|bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine|The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.
215033759|NCT01483560|DRUG|Metformin|3 years treatment duration
215033760|NCT01483560|DRUG|Placebo|3 years duration
214864222|NCT04799678|OTHER|Recording voice samples|A maximum of 9 voice sample recording session will be carried out on their phones and take less than 2 minutes each
214864223|NCT03827928|BEHAVIORAL|Yoga/meditation|A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
214864224|NCT00342836|PROCEDURE|Akt levels|
214864225|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8\_TCID50
214864226|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8\_TCID50
214864227|NCT00686582|PROCEDURE|Blood Draw Only|
214864228|NCT05566548|DIAGNOSTIC_TEST|Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species|It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.
214864229|NCT00741936|DRUG|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
214864230|NCT00741936|DRUG|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
214864231|NCT02015689|BEHAVIORAL|Benefits to Child|CDC VIS + message emphasizing benefits to child of MMR vaccine
214864232|NCT02015689|BEHAVIORAL|Benefits to Society|CDC VIS + message emphasizing benefits to society of MMR vaccine
214864233|NCT02015689|BEHAVIORAL|Benefits to Child and Society|CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine
214864234|NCT02015689|BEHAVIORAL|CDC VIS|CDC Vaccine Information Statement (VIS)
214864235|NCT05120102|DEVICE|Diode laser|K2 diode laser of 980nm wavelength
214864236|NCT03035552|BEHAVIORAL|Pacifier activated music player|Therefore the immediate goal of the current proposal is to demonstrate that intensive NNS-training using reinforcement with mother's voice can improve the oral feeding outcomes of infants with CCHD using a randomized controlled trial (RCT) design, with wait-list controls to ensure that infants in the trial all benefit from a treatment with only demonstrated positive effects. Establishment of optimal NNS patterns in the first 6 months after birth in these infants will improve downstream feeding skills and may promote better motor and language outcomes by one year of age.
214864237|NCT01679587|DRUG|Molidustat (BAY85-3934)|20 mg molidustat as a single tablet
214864238|NCT01679587|DRUG|Placebo|Single oral dose of matching placebo will be given in each treatment arm
214864239|NCT02941276|DEVICE|Active Electrostimulator device|Patients who will receive a fully functioning device
214290703|NCT01917474|DIETARY_SUPPLEMENT|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
214665451|NCT05970887|BIOLOGICAL|quadrivalent influenza vaccine|The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
214864240|NCT02941276|DEVICE|Sham Electrostimulator device|Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
214864241|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
214864242|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
214864243|NCT02450526|DRUG|Placebo|50 Units
214864244|NCT02450526|DRUG|Placebo|20 Units
214864245|NCT01468376|DIETARY_SUPPLEMENT|GLU-01|14 day dosing
214864246|NCT01468376|DIETARY_SUPPLEMENT|GLU-02|14 day dosing
214864247|NCT01468376|DIETARY_SUPPLEMENT|GLU-03|14 day dosing
214864248|NCT01468376|DIETARY_SUPPLEMENT|GLU-04|14 day dosing
214864249|NCT01468376|DIETARY_SUPPLEMENT|GLU-05|14 day dosing
214864250|NCT01468376|DIETARY_SUPPLEMENT|GLU-06|14 day dosing
214864251|NCT03992794|DIAGNOSTIC_TEST|Measurement of MR-proADM|It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
214290704|NCT02258698|PROCEDURE|Cardiac surgery|Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
214864252|NCT04921124|DRUG|Teriparatide|PTH(1-34) cartridge and pen device
214864253|NCT05496335|DRUG|AGN-151586|Intramuscular Injection
214864254|NCT05496335|DRUG|BOTOX|Intramuscular Injection
214864255|NCT05496335|DRUG|Placebo|Intramuscular Injection
214864256|NCT05372133|DRUG|Morphine|Children will be provided with morphine for at-home pain management following supracondylar fracture repair
214864257|NCT00000651|DRUG|Zidovudine|
214864258|NCT00000651|DRUG|Zalcitabine|
214864259|NCT01970865|DRUG|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
214864260|NCT01970865|DRUG|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
214864261|NCT03642782|DEVICE|Electroretinogram Pattern (Diopsys® NOVA System)|it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
214864262|NCT01576874|DRUG|Oxytocin|40 IUs of oxytocin administered intranasally one time
214864263|NCT01576874|DRUG|placebo|placebo administered intranasally one time
214864264|NCT02520752|DRUG|INC280|
214864265|NCT02520752|DRUG|Midazolam|
214864266|NCT02520752|DRUG|Caffeine|
214864267|NCT01855074|DRUG|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
215033761|NCT00749346|DEVICE|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
214864268|NCT05258331|GENETIC|CT303|"1. Cohort 1 : Single-dose administration, intravenous injection~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg~2. Cohort 2 : Multiple-dose administration, intravenous injections (Week 0, Week 4)~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg"
214864269|NCT02349620|BIOLOGICAL|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
214864270|NCT03880773|DEVICE|Stapler|for transection of the pancreas and pancreatic stump treatment
214864271|NCT03880773|DEVICE|ultrasonic shears|for transection of the pancreas and pancreatic stump treatment
214864272|NCT00601666|DRUG|Zolpidem|
214864273|NCT01747720|DIETARY_SUPPLEMENT|Vitamin D3|Given orally
214864274|NCT01747720|DIETARY_SUPPLEMENT|Placebo|
214864275|NCT05697926|OTHER|No intervention|This is a preclinical study. No intervention will be performed.
214864276|NCT02724865|DEVICE|Somnodent® (Oral appliance therapy)|
214864277|NCT02724865|DEVICE|Herbst® (Oral appliance therapy)|
214864278|NCT05560789|BEHAVIORAL|Physical activity (cycling on a stationary bicycle ergometer or walking on a treadmill)|At time 0, exercise will be initiated and intensity will be increased at 2 minute intervals to achieve low intensity for 30 minutes (as defined by heart rate target 50-55% of maximum heart rate determined as 220-age). Next, intensity will be increased at 2 minute intervals until the heart rate target for moderate intensity exercise is achieved (55-65% of max heart rate), or the total duration of exercise of up to 60 minutes is achieved.
214864279|NCT04610463|DIAGNOSTIC_TEST|Cardiac flow measurement|Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
214864280|NCT00002040|DRUG|Fluconazole|
214665452|NCT01153490|BEHAVIORAL|Behavioral Intervention|Substance-related
214864281|NCT05134896|DEVICE|Spatial light modulator|This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.
214864282|NCT01298401|BIOLOGICAL|ganitumab|
214864283|NCT01298401|DRUG|capecitabine|
214864284|NCT01298401|DRUG|gemcitabine hydrochloride|
214864285|NCT01298401|RADIATION|3-dimensional conformal radiation therapy|
214864286|NCT00026286|DRUG|conjugated estrogens|
214864287|NCT00026286|DRUG|medroxyprogesterone|
214864288|NCT01150890|BIOLOGICAL|Brodalumab|Administered as as an intravenous (IV) infusion over at least 30 minutes.
214864289|NCT01150890|DRUG|Placebo|Administered as as an intravenous (IV) infusion over at least 30 minutes.
214864290|NCT02643017|DRUG|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
214665453|NCT00661375|DRUG|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
214864291|NCT02643017|DRUG|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
214665454|NCT04735029|DEVICE|Thermal gun|"Thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
214864292|NCT02299817|DRUG|Denosumab|"Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.~Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.~Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast."
214864293|NCT02299817|DRUG|Placebo|Placebo
214864294|NCT02715206|BEHAVIORAL|keepin' it REAL classic|keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
214864295|NCT02715206|BEHAVIORAL|keepin' it REAL rural|keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
214864296|NCT02715206|BEHAVIORAL|control|control group continues to teach whatever prevention curriculum they were using prior to study
214864297|NCT01859806|PROCEDURE|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
214864298|NCT01859806|PROCEDURE|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
214864299|NCT02647736|OTHER|Hypertonic saline infusion|
214864300|NCT01547364|DRUG|Saline|Injection of 10 ml of normal saline into the caudal epidural space
214864301|NCT01547364|DRUG|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
214864302|NCT05163197|PROCEDURE|Transperineal Laser Ablation of Prostate Cancer|Minimal invasive transperineal laser ablation treatment for prostate cancer
214864303|NCT02289859|PROCEDURE|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
214864304|NCT02289859|PROCEDURE|Wound Closure without Undermining|One side of the wound will remain un-undermined.
214864305|NCT02381951|DEVICE|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
214864306|NCT03120533|DRUG|Iontophoresis of treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site
214864307|NCT03120533|DRUG|Iontophoresis of placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
214864308|NCT01822574|PROCEDURE|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
214864309|NCT01822574|PROCEDURE|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
214864310|NCT01822574|PROCEDURE|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
214864311|NCT03071094|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4
214864312|NCT03071094|DRUG|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
214864313|NCT02074592|BEHAVIORAL|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
214864314|NCT02074592|BEHAVIORAL|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
214864315|NCT02312063|DRUG|Sitagliptin|
214864316|NCT02312063|DRUG|Glimepiride|
214864317|NCT01382745|DRUG|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
214864318|NCT01382745|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
214864319|NCT03848247|OTHER|Injection of Isotonic saline|Half the participants will be injected in a neck muscle with isotonic saline (Control group) and the other half will get NGF (Neck pain group).
214864320|NCT03848247|OTHER|Injection of NGF|Half the participants will be injected in a neck muscle with NGF (Neck pain group).
214864321|NCT04204759|DEVICE|Transcranial direct current stimulation|Non-invasive stimulation will be conducted using a tDCS device (StarStim, Neuroelectrics, Spain).
214864322|NCT04204759|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
214864323|NCT01079832|RADIATION|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
214864324|NCT01079832|PROCEDURE|quality-of-life assessment|Ancillary studies
214864325|NCT06928025|PROCEDURE|Preoperative Education|animation-based education for elderly patients before coronary artery bypass graft surgery Before coronary artery bypass graft surgery, the scenario prepared based on the literature information including introduction of the service, preparation for surgery, monitoring, drug treatment and applications, deep breathing and cough exercise, spirometer use, operation time, postoperative period and care, patient pain management and intubation process will be given as animation-based video training. The effects of this on postoperative pain, fear, anxiety and self-care management will be evaluated.
214864326|NCT06928584|RADIATION|Conventional Radiotherapy|50Gy/25Fx irradiation or 39Gy/30Fx bid reirradiation (previous pelvic radiation)
214864327|NCT06928584|DRUG|Capecitabine|1000mg/m2 d1-14 q3w
214864328|NCT06928584|DRUG|5-fluorouracil|400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
214864329|NCT06928584|DRUG|folinic acid|400 mg/m2 q2w
214864330|NCT06928584|DRUG|Oxaliplatin|130 mg/m² q3w or 85 mg/m² q2w
214864331|NCT06928584|DRUG|Irinotecan|180 mg/m² q2w and 200 mg/m² q3w
214864332|NCT06928584|DRUG|Cetuximab|500 mg/m² q2w
214864333|NCT06928584|DRUG|Bevacizumab|5 mg/kg q2w or 7.5mg/kg q3w
214864334|NCT06928584|RADIATION|Hypofractionated radiotherapy|25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (previous pelvic radiation)
214864335|NCT06928584|DRUG|PD-1 antibody|200mg IV q3w
214864336|NCT06928064|PROCEDURE|Prediction of Postoperative Pain Severity Using Pain Sensitivity Questionnaire Applied in Preoperative Period in Patients Undergoing Breast-Conserving Surgery (Lumpectomy).|": This study included 74 patients over the age of 18 with American Society of Anesthesiologists (ASA) scores of I, II, or III, who were scheduled to undergo breast-conserving surgery. Ethical approval from the local ethics committee and written informed consent from each patient were obtained. Patient data, including age, ASA score, and comorbidities, were collected, and contact details were recorded for postoperative follow-up.~The PSQ was administered to all patients during the preoperative period to assess their pain sensitivity. Anesthesia induction and maintenance followed a standardized protocol on the day of surgery. The intraoperative analgesic consumption and the duration of the surgery were documented. Postoperative assessments were conducted 24 hours after the surgery in the general surgery ward, where analgesic use and short pain inventory scores were recorded. Patients were followed up one month postoperatively, and their pain levels were assessed using the Numeric Rating"
214864337|NCT06928805|OTHER|Balloon inflation exercise|Balloon inflation exercise was applied in addition to the forward-leaning position.
214864338|NCT06928805|OTHER|Pursed-lip breathing exercise|The pursed-lip breathing exercise was applied in addition to the forward-leaning position.
214864339|NCT06928805|OTHER|Control (Standard treatment)|Standard practice is implemented in the institution where the study is conducted.
214864340|NCT06926777|DIAGNOSTIC_TEST|Nerve Conduction Study|"This study involves two diagnostic interventions for evaluating CTS:~Ultrasound Examination (Diagnostic Intervention)~1. A high-frequency ultrasound probe will be used to assess the median nerve at the wrist.~2. Parameters measured include cross-sectional area, flattening ratio, and echogenicity.~The goal is to determine if ultrasound can accurately diagnose CTS compared to NCS.~NCS (Diagnostic Intervention)~1. Surface electrodes will be placed on the skin to stimulate and record median nerve conduction.~2. Parameters such as latency, conduction velocity, and amplitude will be recorded.~3. NCS serves as the gold standard for diagnosing CTS and will be used for comparison with ultrasound results.~Each participant will undergo both ultrasound and NCS, allowing researchers to compare their effectiveness in diagnosing CTS."
214864341|NCT03982199|BIOLOGICAL|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.
214864342|NCT03982199|BIOLOGICAL|Placebo|Participants will receive a single IM injection of placebo control on Day 1.
214864343|NCT00594646|DRUG|TRUVADA + Raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
214864344|NCT06927349|DRUG|BA1301|BA1301 is administered intravenously once every three weeks.
214864345|NCT06927128|DRUG|Gemcitabine, Cisplatin|Gemcitabine (1000mg/m²) and cisplatin (70mg/m²). Gemcitabine is used on the 1st and 8th days of a 21 - day cycle, and cisplatin is used on the 2nd day of the cycle. A total of 3 - 4 cycles are carried out.A dose reduction to 60% of the original dose (adjusted to 0.6 times the initial dose) will be implemented if deemed clinically necessary, contingent upon meeting either of the following criteria: 1) occurrence of grade 3 or higher treatment-related adverse events as per CTCAE v5.0 guidelines, or 2) evidence of renal impairment manifested by a ≥40% decline in glomerular filtration rate (GFR) from baseline measurements.
214864346|NCT06926751|DRUG|Telpegfilgrastim Injection|subcutaneous injections of Telpegfilgrastim (33 μg/kg, single dose) 24 hours after each chemotherapy cycle
214864347|NCT06926751|DRUG|filgrastim|subcutaneous injections of Filgrastim (5 μg/kg/day, multiple doses) 24 hours after each chemotherapy cycle
214864348|NCT06927453|PROCEDURE|Acrylic splint|The HAM particulate material will be packed into the extraction socket then the HAM will be tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 5-0 resorbable suture material. The surgical site covered with the custom acrylic splint.
214864349|NCT06927453|PROCEDURE|No splint|The HAM particulate material will be packed into the extraction socket then the HAM will be tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 5-0 resorbable suture material. The surgical site will not be covered
214864350|NCT06895343|DRUG|ABBV-701|Subcutaneous
214864351|NCT06895343|DRUG|Placebo|Subcutaneous
214864352|NCT02984774|PROCEDURE|Cystectomy|Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
214864353|NCT02984774|PROCEDURE|Endometrial sampling|Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
214864354|NCT02984774|PROCEDURE|Peripheric blood sampling|4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
214864355|NCT02984774|PROCEDURE|Ovarian tissue sampling|2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
214864356|NCT06927024|DEVICE|Active taVNS|Active taVNS delivered via the TENS Device 7000.
214864357|NCT06927024|DEVICE|Sham taVNS|Sham taVNS delivered via the TENS Device 7000.
214864358|NCT06927960|DRUG|AH-001 or placebo|SAD: Subjects are planned to receive a single dose of AH-001 or placebo once MAD: Subjects are planned to receive a single daily dose of AH-001 or placebo for 7 consecutive days
214864359|NCT06927336|DRUG|XinNaoJing injection|XingNaoJing injection is a kind of traditional Chinese medicine preparation, which has the effects of clearing heat and detoxifying, cooling blood and activating blood circulation, resuscitating the brain. In recent years, it has been often used in the treatment of related symptoms caused by qi and blood disturbance and cerebral blood stasis, and has achieved certain results. Xingnaojing injection contains Yujin to resuscitate phlegm, invigorate blood circulation and promote qi; Zhizi dissipates blood stasis and cleans heat; Both are subject medicine. Natural musk cleans the brain, Shujin Tongluo, Jun medicine; Borneol awaken awaken, for adjuvant. Small doses of musk restored brain function and improved cerebral circulation. Xingnaojing injection can promote the recovery of consciousness, reduce the level of plasma β-endorphin, and restore brain function. Borneol bi-dimensionally regulates the central nervous system, calms, prolongs the level of arousal, and protects the brain tissue.
214864360|NCT06927336|DEVICE|tDCS|tDCS stimulated the cerebellum for 20 minutes, once a day, 5 times a week, a total of 10 times, and the stimulation intensity was 2mA.
214864361|NCT03544879|BEHAVIORAL|Yoga Intervention|The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.
214864362|NCT03544879|BEHAVIORAL|Healthy Aging Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works \& What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
214864363|NCT06915987|BEHAVIORAL|Exercise Intervention|Exercise snack group will be higher intensity movements designed to elevate heart rate while active movement break will have low intensity / stretching exercises assigned to them.
214864364|NCT06927570|DRUG|HS-20122（Phase 1a：Dose Escalation）|Intravenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214864365|NCT06927570|DRUG|HS-20122（Phase 1b：Dose Expansion ）|travenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214864366|NCT05673213|OTHER|Three-stair positioning pillows group|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with three-stair positioning pillows. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
214864367|NCT06928233|PROCEDURE|blood sampling|Blood sampling for experimental analyses.
214864368|NCT03907462|BEHAVIORAL|SMART 2.0|SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
214864369|NCT02182791|DRUG|Nevirapine|
214864370|NCT02182791|DRUG|EE/NET|
214864371|NCT02140866|OTHER|Hand Exercise|
214864372|NCT02140866|OTHER|Compensatory Intervention Program (CIP)|
214864373|NCT02053675|DRUG|Vasopressin infusion|
214864374|NCT05397743|OTHER|Quality of Life|Questionnaire Perceived stress scale (PSS) + Questionnaire Short form 36 (SF-36) + Questionnaire Visual functioning questionnaire 25 (VFQ-25)
214864375|NCT06214988|PROCEDURE|selective approach defunctioning stoma|With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.
214864376|NCT05382221|OTHER|Comprehensive Chronic Care|Those randomized to CCC will receive smoking treatment offers via the following routes: 1) Four Outreach Calls from a Health Counselor at 4, 8, 12, and 14 months post-study enrollment; 2) Four texts and/or mailings (depending on healthcare system preferences) over 14 months. These outreach contacts will offer cessation treatment or reduction treatment.
214864377|NCT05382221|OTHER|Standard Care|one offer of cessation treatment annually
214864378|NCT06262191|DEVICE|Differential and adjustable stiffness AFO (DAS-AFO)|Walking with a differential and adjustable stiffness AFO (DAS-AFO)
214864379|NCT06299956|OTHER|Supervised exercise therapy|Walking on a treadmill at increasing elevation and pace.
214864380|NCT04267302|OTHER|Baby Bouncer|Fischer Price baby bouncer.
214864381|NCT04267302|OTHER|Infant t-shirts with Language Environment Analysis (LENA) audio recorders|Infant t-shirts with wearable LENA audio recorders for 2-8 hours of recordings of vocal interaction, crying and turn-taking.
215033762|NCT00874601|DRUG|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
214864382|NCT04267302|OTHER|Baby Carrier|Ergobaby Baby carrier.
214290705|NCT04236830|DRUG|Silver diamine fluoride/ potassium iodide|Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.
214864383|NCT03107026|DRUG|dasotraline 4mg|dasotraline 4mg tablet once daily
214864384|NCT03107026|DRUG|dasotraline 6mg|dasotraline 6mg tablet once daily
214864385|NCT03107026|DRUG|Placebo|Placebo tablet once daily
214864386|NCT01721811|OTHER|Hyperoxia|
214864387|NCT01721811|OTHER|Glucose|
214864388|NCT00912483|BIOLOGICAL|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
214864389|NCT00912483|BIOLOGICAL|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
214864390|NCT05643248|DRUG|NEX-20A|Subcutaneous prolonged-release injection
214864391|NCT05362734|BEHAVIORAL|obstetric outcomes after fresh versus cryopreserved embryo transfer|measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate
214864392|NCT05191017|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
214864393|NCT05191017|DRUG|Enzalutamide|Enzalutamide
214864394|NCT01685450|DEVICE|Echodia® hand-held equipment|
214864395|NCT06273839|DRUG|Tafamidis 61 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
214864396|NCT06273839|DRUG|Tafamidis 70 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
214864397|NCT06273839|DRUG|Tafamidis 61 mg free acid capsule (Reference)|Tafamidis 61 mg free acid capsule (Reference)
214864398|NCT00081536|DRUG|Aroplatin (Liposomal NDDP) in combination with capecitabine|
214864399|NCT06020287|PROCEDURE|the robot-assisted laparoscopic radical prostatectomy|We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.
214864400|NCT05900128|BEHAVIORAL|workshop|Patients will receive workshops and they will encourage to practice physical activity
214864401|NCT05900128|OTHER|no workshop|patients won't receive educative workshops
214864402|NCT01878461|DRUG|Vehicle|
214864403|NCT01878461|DRUG|M518101|
214864404|NCT04819048|DEVICE|Low-Level Laser Therapy+acupuncture|"The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.~The needles using are disposable, sterile, individually packed, and made of stainless steel (Hua Tuo; Suzhou Medical Supplies Factory Co, Ltd,Suzhou, China), in sizes 0.25 mm ×40 mm.Asepsis of the skin will be performed with cotton wool and 75% alcohol."
214864405|NCT04819048|DEVICE|Low-Level Laser Therapy|The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.
214864406|NCT03748030|RADIATION|Confirmed Left-Sided Breast Cancer|Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
214864407|NCT00142233|DIETARY_SUPPLEMENT|ANTOX (vers.)1.2|"300 µg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine per day (for patients of 10 years and older)~150 µg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine per day (for patients aged between 5 and 9 years)"
214864408|NCT00142233|DRUG|Magnesium|"15 mmol per day (for patients of 10 years and older)~7,5 mmol per day (for patients aged between 5 and 9 years)"
214864409|NCT00142233|OTHER|Placebo ANTOX (vers)1.2|Placebo ANTOX (vers)1.2
214864410|NCT00142233|OTHER|Placebo Magnesiocard (2.5 mmol)|Placebo Magnesiocard (2.5 mmol)
214864411|NCT00004553|PROCEDURE|Electromyography|
214864412|NCT01948466|BEHAVIORAL|Commercials|These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
214864413|NCT04105426|DIETARY_SUPPLEMENT|Antioxidants|one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
214864414|NCT04105426|DIETARY_SUPPLEMENT|Placebo|one placebo tablet three times per day for 3 months.
214864415|NCT05445661|DEVICE|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
214864416|NCT05445661|OTHER|Normal Saline|Sham Comparator
214864417|NCT03929276|DEVICE|high-intensity laser therapy & exercises|A total of 15 sessions of high-dose laser treatment- i Lux Laser (Mectronic Medicale, Italy)- (in the first phase, 8 Watt for the analgesic effect; in the second phase, 12 Watt in burst mode for the biostimulation effect; and finally in the third phase with 8 Watt) will be applied.
214864418|NCT03929276|DEVICE|Shame laser & exercises|Sham laser treatment (the same device to be used, 0 watts) will be given.
214864419|NCT03929276|OTHER|exercise|Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
215033763|NCT01219257|BIOLOGICAL|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
215033764|NCT03549962|PROCEDURE|TKA|Total Knee Arthroplasty
215033765|NCT03701243|PROCEDURE|mNT-BBAVF|Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.
215033766|NCT03701243|PROCEDURE|RCAVF|Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
214290706|NCT04236830|DRUG|Silver diamine fluoride|Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.
214864420|NCT00244478|DIETARY_SUPPLEMENT|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
214864421|NCT00244478|DIETARY_SUPPLEMENT|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
214864422|NCT03361930|DEVICE|Ankle-foot orthosis|"Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured."
214864423|NCT01216618|DEVICE|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
214864424|NCT05748106|DEVICE|Ultrasound-based imaging|Ultrasound-based imaging
214864425|NCT01879930|DRUG|doxycycline|"Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100"
214864426|NCT01879930|DRUG|placebo|"Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group"
214864427|NCT01034254|BIOLOGICAL|influenza vaccine|Pregnant women will receive FDA approved influenza vaccine.
215033767|NCT01413438|PROCEDURE|Craniotomy|
215033768|NCT05977998|DRUG|Paclitaxel|Given by IP (Intraperitoneal injection)
215033769|NCT05977998|DRUG|Dexamethasone|Given by IV (vein)
215033770|NCT05977998|DRUG|Diphenhydramine|Given by IV (vein)
215033771|NCT05977998|DRUG|Famotidine|Given by IV (vein)
214665455|NCT04735029|OTHER|Heat pack|A hydrocollator heat pack used to simulate traditional thermal therapy
214665456|NCT03216616|BEHAVIORAL|Cognitive Behavioural Therapy|
214864428|NCT01034254|BIOLOGICAL|saline placebo|Vaccination of pregnant women with saline placebo.
214864429|NCT04029753|BEHAVIORAL|Walk out from operating room|After the surgery of laparoscopic radical gastrectomy, patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb.
214864430|NCT04885153|DRUG|Fenofibrate|Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.
214864431|NCT04885153|DRUG|Placebo|Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
214864432|NCT04365218|DRUG|MEDI8367|Subjects will receive subcutaneous (SC) single dose of MEDI8367, depending upon dose escalation strategy and Safety Review Committee results. The maximum dose will not exceed 600 mg. The dose will be administered as a single injection or multiple injections in the abdomen region.
214864433|NCT04365218|DRUG|Placebo|Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.
214864434|NCT05522985|DRUG|Triprilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
214864435|NCT04331938|DRUG|Regional anesthetic SPG block-bilateral|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
214864436|NCT02049450|DRUG|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
214864437|NCT03771248|DEVICE|peek telescopic partial denture|removable partial denture
214864438|NCT00002865|BIOLOGICAL|filgrastim|
214864439|NCT00002865|DRUG|cyclophosphamide|
214864440|NCT00002865|DRUG|cytarabine|
214864441|NCT00002865|DRUG|dexamethasone|
214864442|NCT00002865|DRUG|doxorubicin hydrochloride|
214864443|NCT00002865|DRUG|etoposide|
214290707|NCT04236830|DRUG|Resin modified glass ionomer cement|Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
214290708|NCT02612974|BIOLOGICAL|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
214864444|NCT00002865|DRUG|ifosfamide|
214864445|NCT00002865|DRUG|leucovorin calcium|
214864446|NCT00002865|DRUG|mesna|
214864447|NCT00002865|DRUG|methotrexate|
214864448|NCT00002865|DRUG|therapeutic hydrocortisone|
214864449|NCT00002865|DRUG|vincristine sulfate|
214864450|NCT00002865|RADIATION|low-LET cobalt-60 gamma ray therapy|
214864451|NCT00002865|RADIATION|low-LET photon therapy|
214864452|NCT00471289|DEVICE|PTA with placement of paclitaxel-eluting stent|PTA with placement of paclitaxel-eluting stent
214665457|NCT00264277|DRUG|Vitamin K antagonist (Coumarin anticoagulants)|
214665458|NCT01774942|PROCEDURE|Procedure/Surgery|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
214665459|NCT00302692|DRUG|Esmolol|
214665460|NCT00302692|DRUG|Metoprolol|
214665461|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)|The COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)was manufactured by Sinovac Research\& Development Co., Ltd.1200SOU inactivated SARS-CoV-2 Omicron strain in 0.5ml of aluminium hydroxide solution per injection.
214864453|NCT00471289|DEVICE|PTA|PTA
214864454|NCT00411957|DRUG|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
214864455|NCT06186934|DRUG|the standard-dose group (4 g/day)|Patients with chronic kidney disease undergoing hemodialysis and controlling hyperphosphatemia
214864456|NCT04736043|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.
214864457|NCT02675439|DRUG|ADU-S100|
214864458|NCT02675439|BIOLOGICAL|ipilimumab|
214864459|NCT03888781|DEVICE|Echocardiography|An echocardiogram (also called an echo) is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of your heart. These echoes are turned into moving pictures of your heart that can be seen on a video screen.
214864460|NCT00577395|DRUG|placebo|oral tablet once a month for 12 months
214864461|NCT00577395|DRUG|risedronate|tablet, 150 mg once a month for 12 months
214864462|NCT05202730|PROCEDURE|New local anesthesia injection site and new local anesthetic drug formulation.|The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.
215033772|NCT06377319|DIAGNOSTIC_TEST|Cardiac Output Response to Stress (CORS) test|Cardiac Output Response to Stress (CORS) is a novel, non-invasive, easy-to-use test developed by the Newcastle and Coventry Universities. CORS test measures heart function (cardiac output) at rest and in response to short step-exercise using validated electrical signal processing bioreactance technology, similar to an ECG.
214864463|NCT03364166|PROCEDURE|surgical excision|"* Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~* A neck dissection will be done in all cases of negative or positive neck lymph node.~* Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery."
214864464|NCT02562339|BEHAVIORAL|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
214864465|NCT00273039|DRUG|paroxetine|
214864466|NCT04242914|DRUG|Ketamine|Intravenous Ketamine, dose 0.5mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
214864467|NCT04242914|DRUG|Midazolam|Intravenous Midazolam, dose 0.03mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
214864468|NCT06082895|BEHAVIORAL|Birth self-efficacy enhancement training based on motivational interviewing method|Birth self-efficacy enhancement training based on motivational interviewing method
214864469|NCT00429195|BEHAVIORAL|Dietary Fatty Acid Modification|
214864470|NCT05078164|BEHAVIORAL|Bridging the Gap (BTG)|"Bridging the Gap: Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program: The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
214864471|NCT02527538|DEVICE|Pleth|apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
214864472|NCT01404078|DRUG|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
214864473|NCT01404078|DRUG|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
214864474|NCT00554190|DEVICE|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
214864475|NCT00554190|DEVICE|Merogel Injectable|Bioresorbable hyaluronic acid product
214864476|NCT04775849|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed uni- or bilateral
214864477|NCT05479656|OTHER|Training program|8-week rehabilitation program aimed at increasing trunk and lower limb motor control on balance and walking abilities, and accomplishment of activities of daily living.
214864478|NCT05282225|BEHAVIORAL|MI- Safety Plan|"The MI-enhanced safety plan (MI-SP) component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy"
214864479|NCT05282225|BEHAVIORAL|Texts messages|For participants randomized to receive supportive text messages (Texts), text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
214864480|NCT05282225|BEHAVIORAL|Monitoring|Adolescent participants will complete daily surveys for 4 weeks (including assessment of suicidal ideation, behavior, and other relevant risk and protective factors) and these will be monitored daily to identify presence of heightened suicidal ideation and presence of suicidal behavior. In addition, daily surveys will be used to determine if adolescents are sufficient responders to Phase 1 intervention.
214864481|NCT05282225|BEHAVIORAL|Portal follow-up|This will be part of Phase 2. The portal follow-up will similarly address content offered in the booster call. For the adolescent, the focus will be on revisiting and adjusting the safety plan, addressing barriers to safety plan adherence, as well as enhancing motivation and self-efficacy to use healthy coping. For the parent, portal communication will focus on revisiting safety recommendations provided as part of MI-SP, addressing barriers in implementing safety recommendations and in supporting the adolescent's safety plan use, as well as enhancing parents' motivation and self-efficacy in these areas. The portal will enable additional asynchronous contacts up to 3 weeks to provide added support and problem solving, based on identified barriers and concerns, to promote post-discharge behavior change. Counselors will initiate approximately 6 contacts with adolescents and, separately, with parents over 3 weeks as soon as non-response is detected.
214864482|NCT05282225|BEHAVIORAL|Booster call|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, is to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
214864483|NCT00616798|DRUG|RO4917838|10mg po daily
214864484|NCT00616798|DRUG|RO4917838|30mg po daily
214864485|NCT00616798|DRUG|RO4917838|60mg po daily
214864486|NCT00616798|DRUG|Placebo|po daily
214864487|NCT00616798|DRUG|Standard antipsychotic therapy|As prescribed
214864488|NCT03781401|DEVICE|Ambulatory blood pressure monitoring|
214864489|NCT03788304|DEVICE|non-invasive ventilation|conventional NIV
214864490|NCT03788304|DEVICE|high flow nasal cannula|HFNC ventilation
214864491|NCT00853463|BEHAVIORAL|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
214864492|NCT04053049|OTHER|Diet|Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
214864493|NCT04820530|DRUG|Iptacopan (LNP023)|Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
214864494|NCT00569530|DRUG|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
214864495|NCT00569530|DRUG|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
214864496|NCT04709835|DRUG|AT-527|Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.
214864497|NCT04709835|DRUG|Placebo|The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
214864498|NCT06634017|BIOLOGICAL|Platelet rich fibrin|Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
214864499|NCT00169481|BIOLOGICAL|Pneumococcal (vaccine)|
214864500|NCT01832207|DEVICE|Transcutaneous electrical nerve stimulation|
214864501|NCT01832207|DEVICE|Placebo transcutaneous electrical nerve stimulation|
214864502|NCT03545230|PROCEDURE|":Four Not Techniques"|":Four Not Techniques~1. Not enter posteriorly~2. Not too much dissection the muscle around the lateral condyle during surgery~3. Not perfect anatomical reduction~4. Not using bone graft."
214864503|NCT06336395|DRUG|Prednisolone|Oral
214864504|NCT06336395|DRUG|Dexamethasone|Oral
214864505|NCT06336395|DRUG|Vincristine|Intravenous
214864506|NCT06336395|DRUG|Methotrexate|Oral/ intrathecal/intravenous/subcutaneous
214864507|NCT06336395|DRUG|L-Asparaginase|Intramuscular
214864508|NCT06336395|DRUG|Pegylated asparaginase|Intravenous
214864509|NCT06336395|DRUG|Erwinase|Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)
214864510|NCT06336395|DRUG|Dasatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
214864511|NCT06336395|DRUG|Imatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
214864512|NCT06336395|DRUG|Cyclophosphamide|Intravenous
214864513|NCT06336395|DRUG|Cytarabine|Subcutaneous/ Intravenous
214864514|NCT06336395|DRUG|Mercaptopurine|Oral
214864515|NCT06336395|DRUG|Thioguanine|Oral
214864516|NCT06336395|DRUG|Rituximab|Intravenous
214864517|NCT06336395|DRUG|Doxorubicin|Intravenous
214864518|NCT06336395|DRUG|Fludarabine|Intravenous
214864519|NCT01630577|OTHER|volume expansion using modified gelatin|Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
214864520|NCT04325204|BEHAVIORAL|Faith-based Home Activity Toolbox (Faith-HAT)|"They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project."
214864521|NCT06083012|DEVICE|Cardiac mapping|"All patients enrolled are treated for their atrial fibrillation/tachycardia via a catheter ablation procedure using VX1/Volta AF-Xplorer/Volta AF-Xplorer II software (used in accordance with its approved indication as per of its IFU) during the mapping phase to identify areas of interest specific to the patient.~The ablation approach is free and chosen by the operator according to his standard practice. The two main phases of the ablation procedure are:~* 3D mapping of the atria and location of areas of interest;~* Catheter ablation at the operator\&amp;#39;s discretion."
214864522|NCT06168279|PROCEDURE|hand occlusal articulation|The upper and lower cast will be scanning separately then will be articulated manually in the final occlusion then scanned after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
214864523|NCT06168279|PROCEDURE|digital occlusal articulation|Both upper and lower casts will be scanning separately, then the 3D casts will be articulating by using 3d virtual program to obtained the final occlusion after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
214864524|NCT03557879|GENETIC|Exome sequencing|DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)
214864525|NCT00820443|DEVICE|Ceramic on metal prosthesis|Ceramic femoral head with a metal acetabular component
214864526|NCT04711902|DRUG|AIN457|Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
214864527|NCT04711902|OTHER|Secukinumab Placebo|Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
214864528|NCT06355102|OTHER|Conventional treatment and care|Conventional treatment and care
214864529|NCT05643053|OTHER|thomas fixation|Use of the thomas tube holder for endotracheal tube fixation in patients operated in the prone position
214864530|NCT05643053|OTHER|elastic band|Use of the elastic band for endotracheal tube fixation in patients operated in the prone position
214864531|NCT05643053|OTHER|normal fixation adhesive tape|Use of the adhesive tape for endotracheal tube fixation in patients operated in the prone position
214864532|NCT05643053|OTHER|reinforced adhesive tape fixation|Use of the reinforced adhesive tape fixation for endotracheal tube fixation in patients operated in the prone position
214864533|NCT04556851|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
214864534|NCT04556851|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
214864535|NCT04556851|DRUG|Placebo|Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
214864536|NCT00138554|DRUG|vildagliptin|
214864537|NCT00138554|DRUG|pioglitazone|pioglitazone 45 mg qd
214864538|NCT05063435|DIAGNOSTIC_TEST|Carotid ultrasonography|"1. Study takes 10 - 15 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The ultrasound probe will be placed on one side of the neck to capture images of the carotid artery. When images from one side have been captured, the probe will be moved to the other side of the neck to capture images from the other carotid artery.~4. Blood pressure and heart rate will be obtained during the study~5. Results will be anonymized, digitized and stored on CD with unique identifier"
214864539|NCT05063435|DIAGNOSTIC_TEST|Echocardiography, transthoracic|"1. Study takes 15 - 20 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The technician will apply an ultrasound probe to the chest. Images and movies will be acquired.~4. Results will be digitized and stored on CD"
214864540|NCT05063435|PROCEDURE|Venipuncture|"1. 10 mL of blood total will be drawn (5 mL in a blue top citrate tube, 5 mL in a purple top EDTA tube). Measurements of cytokines, clusterin, lipidomics, cathepsin S protease, and elastin (previously identified potential biomarker candidates) will be performed.~2. Blood will preferably be drawn via venipuncture, but if patient has a port-a-cath already implanted and is having blood drawn via port-a-cath for clinically required reasons, then study-related blood draw via port-a-cath can take place concurrently with clinically required blood draws."
214864541|NCT02077218|PROCEDURE|computed tomography|Undergo cardiac CT
214864542|NCT02077218|OTHER|cytology specimen collection procedure|Undergo collection of blood samples
214864543|NCT02077218|OTHER|laboratory biomarker analysis|Correlative studies
214864544|NCT02077218|OTHER|questionnaire administration|Ancillary studies
214864545|NCT05501990|BEHAVIORAL|Health intervention based on intelligent applet|Patients are jointly managed by a MDT team based on the applet. The supportive intervention based on the applet mainly includes three parts: Nutrition, psychology, and patient management which includes four main parts: Cancer patient education, self-management, patient community, and real-time communication.
214864546|NCT05177302|OTHER|HAGOS-C|The subjects will be instructed to complete HAGOS-C at the initial contact and again after 1 week and 4 month for reliability and responsiveness test, respectively
214864547|NCT05177302|OTHER|SF-36v2|The subjects will be instructed to complete SF-36v2 at the initial contact to determine the validity of HAGOS-C
214864548|NCT05349643|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
214864549|NCT04710979|BEHAVIORAL|Yoga Intervention|This group will have in-person, 60 minute yoga sessions three times per week for 12 weeks. These sessions will also include a sharing circle to provide group feedback as to how the practice felt and integration into ones' daily life. There will be biweekly themes established for these sessions (i.e. common yoga poses, importance of breath) and biweekly in-person workshops will be offered. These will be specialty classes for participants to experience additional exposure to meditation and breathing. They will be a longer format so participants can delve deeper into yogic philosophy and practice. There will also be a private Facebook group for participants to connect with each other and for the research staff to maintain contact and share information with the participants (eg. weekly reminder for yoga sessions and workshops).
214864550|NCT04637932|PROCEDURE|Percutaneous Dilatation Tracheostomy|pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure.
214864551|NCT00501098|DRUG|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
214864552|NCT01446328|DRUG|Amisulpride|Tablets, dose range 50-1200 mg/ day
214864553|NCT01446328|DRUG|Aripiprazole|Tablets, dose range 5-30 mg/ day
214864554|NCT01446328|DRUG|Olanzapine|Tablets, dose range 2.5-20 mg/ day
214864555|NCT01775449|BEHAVIORAL|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
214864556|NCT01966588|OTHER|Blood samples for whole genomic/transcriptomic sequencing|Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
214864557|NCT01966588|OTHER|UKU Side Effect Rating Scale|Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
214864558|NCT00521417|BEHAVIORAL|short-term dynamic therapy|
214864559|NCT00521417|BEHAVIORAL|long-term dynamic therapy|
214864560|NCT00026221|BIOLOGICAL|Recombinant Interferon Alfa|Given SC
214864561|NCT00026221|BIOLOGICAL|Bevacizumab|Given IV
214864562|NCT03178526|DRUG|Lovastatin gel|Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
214864563|NCT03178526|DRUG|Placebo|placebo gel
214864564|NCT02459496|BEHAVIORAL|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
214864565|NCT04766190|BEHAVIORAL|Group 2: The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
214864566|NCT04766190|BEHAVIORAL|Group 1: Usual Care|Patients randomized to this arm will receive usual care.
214864567|NCT04766190|BEHAVIORAL|Group 3: The DISCO App + Booster|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. Then, 2 months later they will receive an intervention booster in the form of an individually-tailored email to remind patients of the contents of the intervention.
214864568|NCT02075827|BEHAVIORAL|Competitive video game|1 hour playing video game
214864569|NCT02075827|BEHAVIORAL|Little Big Planet|1 hour playing video game
214864570|NCT03265366|DEVICE|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
214864571|NCT03265366|DEVICE|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
214864572|NCT05296486|PROCEDURE|phacovitrectomy surgery with silicone oil tamponade|Patients in this study will receive phacovitrectomy surgery with silicone oil tamponade.
214864573|NCT05296486|PROCEDURE|phacovitrectomy surgery with gas tamponade|Patients in this study will receive phacovitrectomy surgery with gas tamponade
214864574|NCT05296486|PROCEDURE|phacovitrectomy surgery with balanced saline solution tamponade|Patients in this study will receive phacovitrectomy surgery with balanced saline solution tamponade
214864575|NCT05296486|PROCEDURE|phacoemulsifacation surgery without vitrectomy|Patients in this study will receive phacoemulsifacation surgery without vitrectomy.
214864576|NCT01339663|DRUG|cyclophosphamide|Given IV
214864577|NCT01339663|BIOLOGICAL|aldesleukin|Given SC
214864578|NCT01339663|BIOLOGICAL|autologous tumor cell vaccine|Receive T-APC via IV
214864579|NCT01339663|OTHER|laboratory biomarker analysis|Correlative studies
214290709|NCT03478267|DIAGNOSTIC_TEST|AChE levels|AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
214290710|NCT03793738|PROCEDURE|Anterior component separation|
214864580|NCT01339663|OTHER|immunologic technique|Correlative studies
214864581|NCT01339663|OTHER|immunohistochemistry staining method|Correlative studies
214864582|NCT01339663|GENETIC|polymerase chain reaction|Correlative studies
214864583|NCT01339663|BIOLOGICAL|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
214864584|NCT06394349|COMBINATION_PRODUCT|PRP+308nm|PRP+308nm
214864585|NCT06394349|COMBINATION_PRODUCT|NS+308nm|NS+308nm
214864586|NCT03296436|BIOLOGICAL|NEOX® CORD 1K®|NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
214864587|NCT02998970|DRUG|Empagliflozin|single oral tablet once daily.
214864588|NCT02998970|DRUG|Placebo|single oral tablet once daily.
214864589|NCT06032962|PROCEDURE|salpingectomy|surgical removal of the fallopian tubes
214665462|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
214864590|NCT01289665|PROCEDURE|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
214864591|NCT01289665|PROCEDURE|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
214864592|NCT05430126|DRUG|Protein Kinase Inhibitor|This retrospective pharmacovigilance study will include protein kinase inhibitor and exclude those drugs known to cause hepatotoxicities
214864593|NCT01561430|DRUG|LY2886721|
214290711|NCT03793738|PROCEDURE|Posterior component separation|
214290712|NCT04973826|DRUG|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
214290713|NCT00627120|DRUG|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
214290714|NCT00738595|DRUG|EVT 302|EVT 302 5 mg once daily
214290715|NCT00738595|DRUG|Placebo|Placebo to match EVT 302, 5 mg
214290716|NCT00738595|DRUG|EVT 302 plus open label Nicotine replacement|Double-blind EVT 302 plus open label nicotine replacement
214864594|NCT01561430|DRUG|Placebo|
214864595|NCT03972267|PROCEDURE|Free gingival graft|Free Gingival Graft removal from the palate donor area for socket preservation
214864596|NCT03972267|DEVICE|Enamel Matrix Derivate|EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
214864597|NCT00879892|DRUG|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
214864598|NCT00879892|OTHER|Hypothermia|24 hour, target core temperature 33
214864599|NCT01145430|OTHER|Laboratory Biomarker Analysis|Correlative studies
214864600|NCT01145430|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214864601|NCT01145430|OTHER|Pharmacological Study|Correlative studies
214864602|NCT01145430|DRUG|Veliparib|Given PO
214864603|NCT00111423|DRUG|Pegsunercept (PEG sTNF-RI)|
214864604|NCT02905214|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
214864605|NCT06073210|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
214864606|NCT06073210|BEHAVIORAL|Action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a action observation intervention (observing movements without actually doing them).
214290717|NCT00738595|DRUG|Placebo plus open label Nicotine Replacement|Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
214864607|NCT06073210|BEHAVIORAL|Sham action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a sham action observation intervention (observing space planets).
214864608|NCT03683524|DRUG|Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
214864609|NCT03683524|DRUG|Current ART|To continue with their current ART
214864610|NCT06155058|PROCEDURE|SYREBO|Serial ADL training of upper extremities with robotic aid
214864611|NCT06155058|PROCEDURE|Conventional Mirror Method|Serial ADL training of upper extremities assisted by physical therapist
214290718|NCT03790488|DRUG|JTX-4014|Specified dose on specified days
214864612|NCT02984618|PROCEDURE|Sphenopalatine ganglion block|Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
214864613|NCT02984618|PROCEDURE|Epidural blood patch|Autologous sterile blood (20ml) will be infused in the lombar epidural space.
214864614|NCT04198636|DRUG|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
214864615|NCT04198636|DRUG|Xgeva 120 MG in 1.7 ML Injection|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
214864616|NCT03058419|DRUG|JNJ-54175446 150 mg|Subjects will receive JNJ-54175446 150 mg capsules orally (1\*100 mg + 1\*50 mg) under fasted conditions on Day 7, 9, 10 and 11.
214864617|NCT03058419|DRUG|JNJ-54175446 600 mg|Subjects will receive JNJ-54175446 600 mg (6\*100 mg capsules) orally on Day 8.
214864618|NCT03058419|DRUG|Midazolam 2 mg|Subjects will receive midazolam 2 mg oral emulsion \[2 (milligram per milliliter (mg/mL)\] as a drug cocktail on Day 1, 7 and 11.
214290719|NCT04690491|OTHER|follicular cyclus|Days of cyclus 6-12
214290720|NCT04690491|OTHER|luteal cyclus|Days of cyclus 20-24
214864619|NCT03058419|DRUG|Warfarin 10 mg|Subjects will receive warfarin 10 mg tablets (2\*5 mg) orally as a drug cocktail on Day 1, 7 and 11.
214864620|NCT03058419|DRUG|Caffeine 50 mg|Subjects will receive caffeine 50 mg tablet (1\*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
214864621|NCT03058419|DRUG|Dextromethorphan 30 mg|Subjects will receive dextromethorphan 30 mg capsule (1\*30 mg) orally as a drug cocktail on Day 1, 7 and 11.
214864622|NCT03058419|DRUG|Bupropion 150 mg|Subjects will receive Bupropion 150 mg tablet (1\*150 mg) orally as a drug cocktail on Day 1, 7 and 11.
214864623|NCT03058419|DRUG|Omeprazole 20 mg|Subjects will receive omeprazole 20 mg capsule (1\*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
214864624|NCT03230799|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
214864625|NCT03230799|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
214864626|NCT02868918|DRUG|biodentine|tricalcium silicate cement used to replace the carious dentin
214864627|NCT02868918|DRUG|glass ionomer cement|high viscosity glass ionomer used as a base material
214864628|NCT02868918|DEVICE|DigoraH optium|digital Xray for follow up
214864629|NCT02570113|DEVICE|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
214864630|NCT04316507|PROCEDURE|Genetic Counselling and Testing|Oncologist-initiated brief genetic counselling and testing
214290721|NCT00824512|DRUG|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
214290722|NCT00824512|DRUG|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
214290723|NCT03355040|OTHER|induction of labour|induction of labour
214665463|NCT01078753|DRUG|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
214665464|NCT01078753|DRUG|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
214665465|NCT00462423|DRUG|Avastin|Avastin 10 mg/kg IV every 2 weeks (without rest period).
214665466|NCT00462423|DRUG|Abraxane|Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
214864631|NCT04100785|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
214864632|NCT06358170|BEHAVIORAL|Circuit Training Combine with Square-Stepping Exercise|Circuit Training Combine with Square-Stepping Exercise
214864633|NCT02564211|DRUG|Ipragliflozin|one 50 mg tablet QD
214864634|NCT02564211|DRUG|Sitagliptin|one 50 mg tablet QD
214864635|NCT00982176|OTHER|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
214864636|NCT03102801|DRUG|Humulin S|Humulin S used to induce hypoglycaemia
214864637|NCT01908816|DRUG|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
214864638|NCT05209217|DRUG|Ketamine|Intranasal administration of their customary prescribed dose
214864639|NCT00658749|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
214864640|NCT00658749|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
214864641|NCT02296021|DRUG|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
214864642|NCT02296021|DRUG|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
214864643|NCT02296021|DRUG|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
214864644|NCT02296021|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
214864645|NCT02296021|DRUG|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
214864646|NCT04162132|DEVICE|Smartphone app|Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
214864647|NCT00183937|DRUG|PS 341|PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
214864648|NCT00183937|DRUG|Docetaxel|Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
214864649|NCT04719520|BEHAVIORAL|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
214864650|NCT00567866|DRUG|Quetiapine|50 or 100 mg of quetiapine orally
214864651|NCT01533766|DRUG|CombiflexOmega|intravenously over 5 days infusion
214864652|NCT01533766|DRUG|SmofKabiven|intravenously over 5 days infusion
214864653|NCT05042050|BEHAVIORAL|A-iMAPS|Imagery therapy targeting Psychosis-Related PTSD
214864654|NCT01081535|DRUG|ketorolac, fentanyl|intravenous PCA
214864655|NCT05183217|BEHAVIORAL|Online Continence promotion program without tailoring|The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive automated weekly reminders reminding them to re-visit the program, regardless of their individual user activity.
214864656|NCT05183217|BEHAVIORAL|Online Continence promotion program with tailoring|"The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive tailored output (personalized cues, emphasis on relevant content, individualized and tailored reminders about their goals) based on a computer algorithm incorporating unique user inputs (individual factors). Inputs will be reassessed every 2 weeks for retailoring so that personalization evolves over the course of the intervention."
214864657|NCT04619719|DEVICE|Hyperbaric Oxygen Therapy (HBOT)|Patients assigned to the treatment arm will receive up to 5 treatments of hyperbaric oxygen therapy administered daily at 2.0 atmospheres for 90 minutes per session.
214864658|NCT04902092|BEHAVIORAL|High Intensity Interval Training|Exercise sessions will commence with an initial 3-week accustomization period whereby training load will increase incrementally from 2 x 45min sessions with effort peaking at 60% VO2 max (week 1) increasing to 3 x 45minute with effort peaking at 80% VO2max (week 3). Participants will transition to the full HIIT protocol for the remaining weeks. The HIIT component will comprise a work-rest ratio of ≥1:1minutes, with alternating exertion epochs at \>80% VO2max and \<60% VO2max. As VO2max is likely to increase as fitness improves toward the end of the 3-month program, adjustments to HIIT will be made by the exercise physiologist based on real-time heart rate monitoring, ensuring greater accuracy in participants achieving their heart rate targets.
214864659|NCT04902092|BEHAVIORAL|Strength and Resistance Training|Exercise sessions will comprise a combination of strength, coordination and mobility exercises. The strength component will consist of 2-3 sets of resistance exercises at ≤70% of a predicted 1 repetition maximum, targeting all body segments. Heart rate tracking will occur to ensure participants do not exceed 70% v02 (or exceed Lactate Threshold).
214864660|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
214864661|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
214864662|NCT01571076|OTHER|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
214864663|NCT01571076|OTHER|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
214864664|NCT04053686|BEHAVIORAL|Breaks|3-min breaks every half hour at work
214665467|NCT00349128|DRUG|fenofibrate and metformin combination (drug)|
214864665|NCT01371266|DIETARY_SUPPLEMENT|Honey|60.7 grams orally daily times 14 days
214864666|NCT01371266|DIETARY_SUPPLEMENT|High Fructose Corn Syrup 55 (HFCS 55)|65.7 gram daily orally times 14 days
214864667|NCT01371266|DIETARY_SUPPLEMENT|CHO (sugar)|50 grams daily orally times 14 days
214864668|NCT03201250|DRUG|Cabozantinib|"Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)"
214864669|NCT00148824|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (vaccine)|
214864670|NCT00148824|BIOLOGICAL|23-valent pneumococcal conjugate vaccine (vaccine)|
214864671|NCT04040608|OTHER|Influence of screen sizes on responses to visual analog scales of stress|"An open questionnaire will be created by the Clinical Research Direction. The questionnaire will be opened by the examinator who will fulfill the anonymized identification of participants and the type of screens. In a dedicated room at the LaPSCo, the participants will answer the same VAS on four different sizes/types of screens (24-inch screen, laptop, tablet, smartphone) and on paper. Saliva will be collected after answering questionnaires. Heart rate variability and skin conductance will be measured with the use of a wrist watch during 15 minutes, from the entrance in the room to the completion of questionnaires.~The participant will undergo the same examination within a week (15 minutes)."
214864672|NCT05691686|OTHER|Finely milled whole wheat-legume bread|The intervention examines the effect of finely milled wheat-legume bread in subjects with normal body weight.
214864673|NCT05691686|OTHER|Less processed whole wheat-legume bread|The intervention examines the effect of less processed whole wheat-legume bread in subjects with normal body weight.
214864674|NCT05691686|OTHER|Less processed whole wheat bread|The intervention examines the effect of less processed whole wheat bread in subjects with normal body weight.
214864675|NCT05691686|OTHER|White wheat bread|The intervention examines the reference food product in subjects with normal body weight.
214864676|NCT03121287|OTHER|Imaging Biomarkers|Whole lung volumetric CT scans
214864677|NCT03121287|OTHER|Pulmonary|Pulmonary Function Tests \& 6 minute hall walk
214864678|NCT03121287|OTHER|Imaging|Cardiac MRI
214864679|NCT03121287|OTHER|Specimen Collection|Blood draw
214864680|NCT02070874|BEHAVIORAL|telehealth enhanced pain management|
214864681|NCT03357965|OTHER|Questionnaire|Women who had gave birth in 6 weeks
214864682|NCT01874067|DEVICE|Arthritis glove|Isotoner three-quarter finger arthritis glove
214864683|NCT03590392|BIOLOGICAL|ChAdOx1 Chik|ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
214864684|NCT03205891|DRUG|Brentuximab Vedotin|1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.
214864685|NCT03205891|DRUG|TAK228|Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
214864686|NCT03205891|DEVICE|Glucose Monitor|Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
214864687|NCT00415194|DRUG|pemetrexed|500 mg/m\^2, IV, every 21 days, six 21 day cycles
214864688|NCT00415194|DRUG|cisplatin|75 mg/m\^2, administered IV, every 21 days, six 21 day cycles
214864689|NCT00415194|DRUG|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
214864690|NCT05067530|DRUG|Palbociclib|CDK4/6 inhibitor
214864691|NCT05067530|DRUG|Paclitaxel|Chemotherapy
214864692|NCT05067530|DRUG|Carboplatin|Chemotherapy
214864693|NCT01297465|DRUG|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
214864694|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
214864695|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
214864696|NCT01297465|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles \>= 18 mm).
214864697|NCT06162104|OTHER|No intervention|No intervention
214864698|NCT00969540|DEVICE|Active Mattress Cover|Active Mattress Cover
214864699|NCT00969540|DEVICE|Placebo Mattress Cover|Placebo Mattress Cover
214864700|NCT00270348|DRUG|ciclesonide|
214864701|NCT04616339|DRUG|PF-06882961 100 mg|"PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)"
214864702|NCT02743234|OTHER|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
214864703|NCT02743234|DRUG|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
214864704|NCT02743234|DRUG|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
214864705|NCT01593514|BIOLOGICAL|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
214864706|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
214864707|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
214864708|NCT01593514|BIOLOGICAL|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
214864709|NCT01593514|BIOLOGICAL|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
214864710|NCT00986063|GENETIC|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
214864711|NCT00986063|OTHER|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
214864712|NCT02714517|OTHER|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
214864713|NCT02714517|OTHER|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
214864714|NCT03956810|OTHER|On-demand transportation|On-demand scheduling via telephone, web portal, or the broker's mobile application.
214864715|NCT03956810|OTHER|Usual transportation|Usual transportation scheduling via call-center.
214864716|NCT00378612|DEVICE|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
214864717|NCT02397408|DRUG|Carbon C 11 Choline|Given intravenously (IV) prior to imaging
214864718|NCT02397408|DRUG|Fluorine F 18 Choline|Given intravenously (IV) prior to imaging
214864719|NCT02397408|PROCEDURE|Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)|Undergo whole-body PET/MR imaging
214864720|NCT00369655|BIOLOGICAL|ziv-aflibercept|
214864721|NCT05621408|BEHAVIORAL|Attention Training Technique|Attention Training Technique is a six weeks psychological intervention provided by trained professionals
214864722|NCT05886010|DEVICE|prototypes 1 everyday|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214864723|NCT05886010|DEVICE|prototypes 1 every week|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214864724|NCT05886010|DEVICE|prototypes 1 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214864725|NCT05886010|DEVICE|prototypes 2 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214864726|NCT05886010|DEVICE|prototypes 3 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214864727|NCT00573781|DIETARY_SUPPLEMENT|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
214864728|NCT00573781|DIETARY_SUPPLEMENT|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
214864729|NCT00573781|DIETARY_SUPPLEMENT|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
214864730|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing to start with home respiratory polygraphy
214864731|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
214864732|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
214864733|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
214864734|NCT04662138|DRUG|directly acting antivirals|Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
214864735|NCT05029830|COMBINATION_PRODUCT|investigations like MRI..|• Multiple Sclerosis Quality of Life-54 (MSQOL-54) Can be considered as the most known disease-specific instrument for the evaluation of quality of life in patients with multiple sclerosis (MS). It was developed to combine generic quality of life aspects of the SF-36 with MS-targeted dimensions and ratings for the overall quality of life. Therefore, 18 disease-specific items were added to the original 36 items of the SF-36. The 54 items are divided into 12 multi-item and 2 single-item scales. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales
214864736|NCT01683838|DRUG|Fampridine-SR|25mg bid (twice daily)
214864737|NCT01683838|DRUG|Placebo|Placebo
214864738|NCT02881138|DRUG|RC48-ADC|
214864739|NCT01646138|BIOLOGICAL|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
214864740|NCT05634850|DEVICE|Kinder|Participants will test at their urine with at home with in the device. Results are sent via an app back to the clinic for reporting.
214864741|NCT00256438|DEVICE|Transcranial Direct Current Stimulation|
214864742|NCT04657796|DEVICE|High Flow Nasal Cannula|use of high flow nasal cannula as a weaning mode from invasive mechanical ventilation to deliver oxygen
214864743|NCT04049617|DRUG|Evixapodlin|Tablets administered orally.
214864744|NCT05157958|BIOLOGICAL|ALLO-ASC-SHEET|Weekly administration
214864745|NCT05157958|OTHER|Vehicle Control|Weekly administration
214864746|NCT03551496|COMBINATION_PRODUCT|Drug Eluting Stent - Below the Knee|Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
214864747|NCT03551496|DEVICE|Standard PTA Control Arm|The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
214864748|NCT00986518|BIOLOGICAL|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
214864749|NCT05298319|DEVICE|high flow nasal cannula|The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.
214864750|NCT02903719|DRUG|Ropivacaine|All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
214864751|NCT02413216|BEHAVIORAL|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
214864752|NCT02413216|OTHER|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
214864753|NCT02882243|DEVICE|FLXfit Cage for fusion|Evaluating patient outcomes and radiographic outcomes
214864754|NCT02430779|PROCEDURE|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
214864755|NCT02430779|DEVICE|NanoKnife|
214665468|NCT03543371|DIAGNOSTIC_TEST|Neuropsychological assessment|Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A \& B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
214864756|NCT04340921|BIOLOGICAL|COVID-19 exposure|Observation only
214864757|NCT06483321|DIETARY_SUPPLEMENT|Creatine Supplementation|"Normocaloric vegan diet supplemented with 0.1 g/kg/day of creatine monohydrate~Normocaloric diet based solely on foods of plant sources with creatine supplementatio (0.1 g/kg/day)"
214864758|NCT06483321|DIETARY_SUPPLEMENT|Placebo|Normocaloric vegan diet supplemented with 0.1 g/kg/day of placebo (maltodextrin)
214864759|NCT04413864|OTHER|Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration|"Assigned Interventions:~* Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~* CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)"
214864760|NCT00222521|DRUG|Glargine insulin|
214864761|NCT05841303|DRUG|Vit C|Vit c is proven to be an anti-inflammatory and antioxidant agent. also play a great role in collagen biosynthesis (collagen type I), as it helps in fibroblasts proliferation. It reduces the potentiality of scaring via inhibiting cross-linking of collagen fibers and fibrosis. It acts as a cofactor in hydroxyproline synthesis to produce collagen type IV and improves endothelial cell vitality and function..
214864762|NCT05841303|OTHER|injectable PRF|5 ml of peripheral blood from each patient , blood will be transferred to a glass coated plastic vacutainer tube without anticoagulant. Then this tube will immediately centrifuged at 700 rpm for 3 mins \[Centrifuge Machine 5000rpm.After centrifugation, two fluid layers will formed, upper being yellow fluid layer (i-PRF) while lower layer containing red blood cells. Yellow fluid layer containing i-PRF will be immediately aspirated using micro needle to be injected for management of gingival phenotype
214864763|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
214864764|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
214864765|NCT01524679|DRUG|Pegylated interferon alfa-2a plus nucleos(t)ide(s)|Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
214864766|NCT03835143|PROCEDURE|subinguinal varicocelectomy|varicocele ligation done at the level of subinguinal region
214864767|NCT00045903|BEHAVIORAL|Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|
214864768|NCT00045903|BEHAVIORAL|Stress Management Therapy (Cognitive Behavior Therapy)|
214864769|NCT01984203|OTHER|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
214864770|NCT01984203|OTHER|Progressive Heavy Strength Exercises|"All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.~Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
214864771|NCT04737070|BIOLOGICAL|Prenatal test for Trisomy 21 screening|prenatal routine test for Trisomy 21 screening (blood test + nuchal translucency test)
214864772|NCT00152737|PROCEDURE|Exercise test with Transcutaneous oxygene pressure|Ce marked devices
214864773|NCT00152737|PROCEDURE|Ankle and arm pressure values|one test before and one test after surgery
214864774|NCT00801099|DRUG|Amoxicillin/Clavulanic Acid|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
214864775|NCT04631952|BEHAVIORAL|Online exercise|SMS messeages on encouraging active lifestyle and online exercise video will be sent to the participant weekly for 8 weeks.
214864776|NCT04631952|BEHAVIORAL|SMS message|SMS messeages on encouraging active lifestyle will be sent to the participant weekly for 8 weeks.
214864777|NCT01551888|DRUG|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
214864778|NCT01551888|DRUG|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
214864779|NCT03895671|DRUG|Ponatinib|"Induction phase (first three cycles)~\- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~* Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~* Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day"
214864780|NCT03895671|DRUG|Azacitidine|"Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~\- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%\<MR4≤0.01%;"
214864781|NCT03208361|DRUG|Penicillin V|
214665469|NCT03193268|OTHER|Single-blind RTC of PD patients|The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
214665470|NCT03193268|OTHER|cycling|Patients must undergo a daily exercise cycle of 1 hour during the intervention
214665471|NCT01565525|BEHAVIORAL|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
214864782|NCT03208361|DRUG|Amoxicillin|
214864783|NCT02991677|BEHAVIORAL|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
214864784|NCT02991677|OTHER|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
214864785|NCT02991677|BEHAVIORAL|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
214864786|NCT03474497|DRUG|IL-2|• A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.
214864787|NCT03474497|DRUG|Pembrolizumab|Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.
214864788|NCT03474497|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the second cycle of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1-2 of cycle 2 and will not be repeated in future cycles.
214864789|NCT02789553|OTHER|First starch meal then meal with glucose syrup|Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
214864790|NCT02789553|OTHER|First meal with glucose syrup then starch meal|Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
214864791|NCT05497193|DRUG|perampanel|China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.
214864792|NCT06314789|DIAGNOSTIC_TEST|doing lung ultrasonography|In the study, both LUS imaging and scoring will be performed in the delivery room within the first 30 minutes and LUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients.
214864793|NCT04602065|DRUG|IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)|IBI318, 300mg, Q2W, Intravenous influsion.
214864794|NCT00140426|DRUG|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
214864795|NCT00140426|DRUG|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
214864796|NCT01760525|DRUG|CGM097|Patients treated with CGM097
214864797|NCT02323516|DRUG|Acetylsalicylic acid + loperamide|In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
214864798|NCT02323516|DRUG|diosmectite + loperamide|In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
214864799|NCT04603235|BEHAVIORAL|Manual-based Art Therapy|This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
214864800|NCT02149108|DRUG|Nintedanib (BIBF 1120)|
214864801|NCT02149108|DRUG|Placebo|
214864802|NCT02149108|DRUG|BSC|
214864803|NCT02149108|DRUG|BSC|
214864804|NCT02175316|DEVICE|Enhanced External Counterpulsation|Enhanced External Counterpulsation
214864805|NCT04047914|DEVICE|Antimicrobial Photodynamic therapy|"Application 0.01% methylene blue with sterile swabs in each nostril with a 10-minute pre-irradiation~• Light-emitting diode (λ = 660 nm), for 300 seconds, with an irradiance of 400 mW / cm2"
214864806|NCT04047914|DRUG|Mupirocin ointment|Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
214864807|NCT03716414|PROCEDURE|SLN mapping|"Intra-operative SLN mapping with indocyanine green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and Arms Assigned Interventions another 1ml will be injected superficially (2mm-depth).~The time between the injection and the search for SLN must be as soon as possible."
214864808|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
214864809|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
214864810|NCT02775708|DEVICE|Pillcam endoscopy system|
214864811|NCT02981303|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
214864812|NCT02981303|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
214864813|NCT05578196|DRUG|fecal bacteria solution|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
214864814|NCT05578196|DRUG|physiological saline solution|physiological saline solution 20ml
214864815|NCT00152178|DRUG|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
214665472|NCT01565525|BEHAVIORAL|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
214864816|NCT00152178|DRUG|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
214864817|NCT02895607|PROCEDURE|Ambulatory care among eligible patients|"The management of Anterior Cruciate Ligament (ACL) Reconstruction reconstruction in outpatient will be proposed in consultation with the surgeon.~After an explanation of the course of treatment a fact sheet on the protocol will be provided to the patient and his doctor to the patient to decide its support in CA (ambulatory surgery) or HC (conventional hospitalization)."
214864818|NCT00040183|DRUG|Tarceva (erlotinib HCl, OSI-774)|
214864819|NCT00567047|DRUG|vildagliptin|
214864820|NCT02393248|DRUG|Pemigatinib|
214864821|NCT02393248|DRUG|Gemcitabine|
214864822|NCT02393248|DRUG|Pembrolizumab|
214864823|NCT02393248|DRUG|Docetaxel|
214864824|NCT02393248|DRUG|Trastuzumab|
214864825|NCT02393248|DRUG|Retifanlimab|
214864826|NCT02393248|DRUG|Cisplatin|
214864827|NCT02555748|DRUG|Pazopanib|
214864828|NCT02555748|DRUG|Sunitinib|
214864829|NCT01096030|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
214864830|NCT02435095|DRUG|Maintenance treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
214864831|NCT02435095|DRUG|Intermittent treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
214864832|NCT06351475|OTHER|Intra-operative albumin administration|Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
214864833|NCT06351475|OTHER|Control|Ringer lactate
214864834|NCT02728570|OTHER|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
214864835|NCT02728570|OTHER|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
214864836|NCT00987389|PROCEDURE|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
214864837|NCT00987389|OTHER|No Plasma Exchange|No plasma exchange.
214864838|NCT00987389|DRUG|Glucocorticoids [Standard Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
214864839|NCT00987389|DRUG|Glucocorticoids [Reduced Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
214864840|NCT04048044|DEVICE|Exposure to GHz electromagnetic energy (RejuvaMatrix)|75 decibels of 54 to 78 GHz daily for 60 minutes
214864841|NCT04514068|PROCEDURE|Acupuncture|In each session, acupuncture are applied unilaterally or bilaterally on P6 acupoint. Each acupuncture needle will be stimulated by transcutaneous electric device.
214864842|NCT04514068|PROCEDURE|Sham acupuncture|Sham acupuncture
214864843|NCT04877886|DIAGNOSTIC_TEST|Ultrasound with IV contrast|To compare the efficiency over the ultrasound scan within contrast
214864844|NCT04877886|DIAGNOSTIC_TEST|CT with IV contrast|CT with IV contrast
214864845|NCT04877886|DIAGNOSTIC_TEST|Ultrasound without IV contrast|Ultrasound without IV contrast
214665473|NCT01576471|BIOLOGICAL|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
214665474|NCT01576471|BIOLOGICAL|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
214665475|NCT06278636|DIAGNOSTIC_TEST|Laparoscopi ultrasound examination|Analysis of feasibility and fellow surgeons learning curve in minimally invasive gynecological procedures
214665476|NCT05343910|OTHER|Aroma massage|The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
214864846|NCT04877886|DIAGNOSTIC_TEST|CT without IV contrast|CT without IV contrast
214864847|NCT00507130|BIOLOGICAL|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
214864848|NCT00507130|BIOLOGICAL|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
214864849|NCT00507130|BIOLOGICAL|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
214864850|NCT00507130|OTHER|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
214864851|NCT00374426|DRUG|sertraline|
214864852|NCT01597466|DEVICE|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
214864853|NCT01597466|PROCEDURE|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
214864854|NCT00006055|DRUG|anti-thymocyte globulin|
214864855|NCT00006055|DRUG|cyclophosphamide|
214864856|NCT00006055|DRUG|cyclosporine|
214864857|NCT00006055|DRUG|filgrastim|
214864858|NCT00006055|DRUG|methylprednisolone|
214864859|NCT00006055|DRUG|prednisone|
214864860|NCT00006055|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplantation|
214864861|NCT02140723|RADIATION|preoperative short course radiation|
214864862|NCT05040438|BIOLOGICAL|Vax-NK/HCC|autologous NK cells expanded ex vivo.
214864863|NCT01772758|DRUG|BH4 5mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
214476482|NCT06611605|BEHAVIORAL|Storytelling with metaphor toys|"There is evidence of the effectiveness of various methods such as using different types of balls as tactile stimulation and active distraction methods during the management of pain, anxiety, and fear, watching cartoons, using virtual reality (VR) as a method of distracting attention, and using virtual reality hypnosis (VRH). However, no scientific study has been found on storytelling with a metaphoric toy during venous blood collection.~Before the children in the intervention group start the blood collection process, the story will be told to the child by the researcher in the waiting room of Akdeniz University Hospital Blood Collection Unit. The child and the parent will be together during the story telling. Expert opinions were received from five academics who completed their doctorate in Child Health and Disease Nursing for the content of the story."
214864864|NCT01772758|DRUG|BH4 20mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
214864865|NCT01772758|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
214864866|NCT03024658|OTHER|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
214864867|NCT04099550|DEVICE|RT-CGM|The group was monitored blood glucose initial 1-week with a RT-CGM.
214864868|NCT04099550|OTHER|SMBG|The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
214864869|NCT04525235|COMBINATION_PRODUCT|phenotyping cocktail|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
214864870|NCT04525235|DRUG|rifampicin|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
214864871|NCT00080938|DRUG|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
214864872|NCT00080938|RADIATION|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
214864873|NCT06279559|BEHAVIORAL|Music-therapy|10 sessions of online music therapy held by expert music therapists
214864874|NCT00787059|DRUG|Ad5.hAC6|Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10\^9 vp to 10\^12 vp in 5 dose groups
214864875|NCT00787059|DRUG|Sucrose (3%)|
214864876|NCT03216018|BEHAVIORAL|"Prevention program: In Favor of Resilient Self"|"Prevention program: In Favor of Resilient Self"
214864877|NCT04561375|DRUG|Sufentanil|30 µg tablet of sublingual sufentanil
214864878|NCT04561375|DRUG|Fentanyl|50 µg fentanyl
214864879|NCT04319185|OTHER|Assistance to perform Peritoneal Dialysis (PD) at home|The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
214864880|NCT02861742|OTHER|Delivery of questionnaires|After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
214864881|NCT02861742|BEHAVIORAL|Questionnaire T1 to fill|T1 is to fill before chemotherapy.
214864882|NCT02861742|BEHAVIORAL|Questionnaire T2 to fill|T2 is to fill after the 6th cycle of chemotherapy.
214864883|NCT02861742|BEHAVIORAL|Questionnaire T3 to fill|T3 is to fill at the end of radiotherapy.
214864884|NCT02861742|BEHAVIORAL|Questionnaire T4 to fill|T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
214864885|NCT02861742|BEHAVIORAL|Questionnaire T5 to fill|T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
214864886|NCT00441506|DRUG|daily interruption of sedatives|
214864887|NCT05036356|OTHER|Headspace App|"A mobile-application (app) focusing on teaching and sustaining mental well-being."
214864888|NCT03779737|BEHAVIORAL|Muscular Resistance training|
214864889|NCT03779737|BEHAVIORAL|Cardiorespiratory training|
214864890|NCT03779737|BEHAVIORAL|Habitual training|
214864891|NCT01025271|DRUG|Daptomycin|one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
214864892|NCT01312571|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
214864893|NCT01312571|BEHAVIORAL|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
214864894|NCT06035471|DIAGNOSTIC_TEST|MeD-seq|MeD-seq analyse: DNA treatment bisulfite --\> unmethylated C-nucleotide trabsformed in uracil.--\> PCR --\> next generation sequencing (NGS) --\> localization methylated nucleotides (enzym LpnPI).
214864895|NCT01386151|DRUG|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
214864896|NCT01386151|DRUG|Saline placebo|Normal (0.9%) saline will be used as a placebo.
214864897|NCT00654966|DRUG|Urotensine II|A few drops of the drug will be administered to the skin by iontophoresis.
214864898|NCT00654966|DRUG|Soluble epoxide hydrolase|A few drops of the drug will be administered to the skin by iontophoresis.
214864899|NCT00121472|DEVICE|Thoratec HeartMate II Left Ventricular Assist System (LVAS)|Implantation of ventricular assist device to provide hemodynamic support
214665477|NCT02913625|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
214864900|NCT02934659|DEVICE|Atlas(TM) Knee System|The Atlas System is an extra-capsular knee implant designed to unload the medial knee.
214864901|NCT01334983|BEHAVIORAL|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
214864902|NCT02538848|DRUG|HTD4010|injectable solution
214864903|NCT05473962|DIAGNOSTIC_TEST|assessment and quantification of symptoms related to post-traumatic stress.|Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
214864904|NCT03651258|BEHAVIORAL|Implementation of ALIJEU|"The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay."
214864905|NCT04935424|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.
214864906|NCT01123135|DRUG|Vaginal ERT|1gm of estrogen vaginal cream \[EVC\] at bed time 3 times a week
214864907|NCT01123135|DRUG|Placebo|Placebo
214864908|NCT00296231|OTHER|Nasal high frequency ventilation|use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
214864909|NCT04898855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Treatment includes sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
214864910|NCT04040023|DRUG|Iron and vitamin Deficiencies Correction Program|"Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation"
214864911|NCT04040023|OTHER|PBMi: Training program to improve transfusion practices|Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
214864912|NCT05545358|OTHER|Questionnaires|Short-Form McGill Pain Questionnaire (SF-MPQ) Pain Disability Index (PDI) Prosthesis Evaluation Questionnaire (PEQ) Psychological Inflexibility to Pain Scale (PIPS) Chronic Pain Acceptance Questionnaire (CPAQ) Cognitive Difficulties Scale (CDS) Amputee Body Image Scale (ABIS) Trinity Amputation and Prosthesis Experience Scales (TAPES) Pain Catastrophizing Scale (PCS) Hospital Anxiety and Depression Scale (HAD) Credibility/Expectancy Questionnaire (CEQ) Short-Form Edinburgh Handedness Inventory (SF-EHI) Patient's Global Impression of Change (PGIC)
214864913|NCT05545358|DEVICE|Brain and Spinal Cord functional Magnetic Resonance Imaging|Brain and Spinal Cord functional Magnetic Resonance Imaging
214864914|NCT05545358|OTHER|Proprioceptive training|Proprioceptive muscular training via a mechanical vibration of low amplitude and frequency between 60 and 80 Hz applied to the tendons.
214864915|NCT04992429|PROCEDURE|SphinkeeperTM|The SphinkeeperTM includes up to 10 self-expandable prostheses, which get inserted into the intersphincteric place. They are made of inert Hyexpan (polyacrylonitrile)
214864916|NCT04810286|PROCEDURE|3d-Printing Myofunctional Appliance|To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.
214864917|NCT03507023|DIETARY_SUPPLEMENT|Metabolaid®|500 mg per day, in fasting conditions.
214864918|NCT03507023|DIETARY_SUPPLEMENT|Placebo|500 mg per day, in fasting conditions.
214864919|NCT00338455|DRUG|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
214864920|NCT00338455|DRUG|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
214864921|NCT06216223|PROCEDURE|treatment of anal diseases in inflammatory bowel patients|treatment of anal diseases in inflammatory bowel patients
214864922|NCT06216223|DEVICE|Laser|laser
214864923|NCT06216223|PROCEDURE|traditional surgery|traditional surgery
214864924|NCT02266134|BEHAVIORAL|Tailored Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
214864925|NCT02266134|BEHAVIORAL|Standard Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
214864926|NCT02951468|PROCEDURE|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed \[14\]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
214864927|NCT04260438|DRUG|CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T|single oral administration under fed condition
214864928|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 1 Tab. 1T|single oral administration under fed condition
214864929|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 2 Tab. 1T|single oral administration under fed condition
214864930|NCT04035915|PROCEDURE|Limited driving pressure|Keep driving pressure \<15 cmH2O
214864931|NCT04035915|PROCEDURE|Conventional mechanical ventilation strategies|Keep tidalvolume \</= 8
214864932|NCT01715792|OTHER|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
214864933|NCT06593639|OTHER|Prehabilitation before surgery|Prehabilitation multimodal program will start about 4 weeks before the surgery and will be continued until 2 weeks after the surgical intervention. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
214864934|NCT06593639|OTHER|Prehabilitation before and during CRT|Prehabilitation multimodal program will start about 4 weeks CRT and will be continued in parallel until 2 weeks after the end. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
214864935|NCT01716624|DRUG|Oxybutynin|standard oral therapy
214864936|NCT01716624|DRUG|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
214864937|NCT05924854|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints). Equipment used in the trial included:~1. Huatuo brand copper filiform needle (diameter: 0.35×50mm), Suzhou Medical Supplies Factory, Food and Drug Administration firearms production: Suzhou Food and Drug Administration firearms production No. 20010020.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675"
214864938|NCT00751907|DRUG|atorvastatin|40mg daily for 4 months
214864939|NCT00751907|DRUG|Placebo|Matching placebo daily for 4 months
214864940|NCT00460538|DIETARY_SUPPLEMENT|Lectranal|"Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
214864941|NCT00460538|DIETARY_SUPPLEMENT|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
214864942|NCT00006243|BIOLOGICAL|tyrosinase peptide|Given SC
214864943|NCT00006243|BIOLOGICAL|MART-1:27-35 peptide vaccine|Given SC
214864944|NCT00006243|BIOLOGICAL|gp100 antigen|Given SC
214864945|NCT00006243|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
214864946|NCT00006243|BIOLOGICAL|sargramostim|Given SC
214864947|NCT00006243|OTHER|laboratory biomarker analysis|Correlative studies
214864948|NCT02344719|DRUG|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
214864949|NCT02344719|PROCEDURE|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
214864950|NCT02344719|PROCEDURE|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
214864951|NCT02344719|DRUG|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
214864952|NCT01437943|DRUG|Aliskiren|Take 1 tablet (150 mg) by mouth daily for 180 days
214864953|NCT01437943|DRUG|Placebo|Take 1 tablet (0 mg) daily for 180 days.
214864954|NCT03821870|DIAGNOSTIC_TEST|Inditreat|Tumoroid formation and drug sensitivity analysis
214864955|NCT03821870|DRUG|Experimental drug|Second line treatment based on drug sensitivity analysis
214864956|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
214864957|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
214864958|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
214864959|NCT01471119|BIOLOGICAL|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
214864960|NCT03667209|OTHER|Pain neuroscience education (PNE) and traditional exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
214864961|NCT03667209|OTHER|Pain neuroscience education (PNE) and suspension exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises. delivered in suspension.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
214476483|NCT04923776|DRUG|Carboplatin|The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
214864962|NCT06160297|PROCEDURE|Modified Otago Exercise|"The exercises are as follows;~Warm-up exercises (5 min)~Strengthening exercises (weight attached to ankle)~* Knee extension while sitting on a chair~* Knee flexion while standing with support from a chair~* Hip abduction while standing with support from the chair~Strengthening exercises (weight removed from ankle)~* Standing on tiptoe with support from a chair~* Rising on the heels with support from a standing chair~Balance Exercises (progressively, with support - without support)~* Mini squats~* Toe walking~* Walking on heels~* Tandem stance~* Tandem walking~* Walking backwards (10 steps)~* Standing on one leg~* Assisted side walking~* Side walking without support~* Sit and stand on the chair~* Figure eight walking"
214864963|NCT06160297|PROCEDURE|Neuromuscular Exercise|"* Proprioceptive stabilization of the knee with ball~* Bridging with ball~* Stepping forward, sideways and backwards by holding on to a fixed support while standing~* Doing the same movements with the support leg on a different surface~* Hip abduction-adduction with resistance band~* Knee flexion-extension with resistance band~* Climbing and descending steps by taking steps~* Balancing on the step~* Standing up from the chair"
214864964|NCT03112785|DEVICE|Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)|The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
214864965|NCT06010537|DRUG|polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.
214864966|NCT05669963|DRUG|lactoferrin|"study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month."
214864967|NCT05828576|DIAGNOSTIC_TEST|MRI|Patients will be asked for two additional control visits in the hospital. Overview of measurements: Included subject will visit the UMCU at two occasions. The first MRI scan will be the baseline MRI, and the second MRI will take place after 2 years of follow-up. Additional follow-up data will be collected through medical records reporting on regular follow-up.
214864968|NCT04116762|DEVICE|TissuePatchDS-P™|The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue
214864969|NCT04116762|DEVICE|Surgical Drain|A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
214864970|NCT06022900|BEHAVIORAL|Online training group|online health education with video call
214864971|NCT06022900|BEHAVIORAL|Face-to-face training group|Face-to-face health education with home visit
214864972|NCT02395952|DRUG|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
214864973|NCT02395952|DEVICE|Acuvue Oasys Bandage Contact Lens|
214864974|NCT02395952|DEVICE|Ambiodisk|
214864975|NCT02395952|DEVICE|Prokera|
214864976|NCT05310162|BEHAVIORAL|Food, fun and family|"The intervention consists of a series of change of habits in the way children eat, the reduction of the recreational time of screens and healthy habits of physical activity. This intervention, which is called Food, Fun \& Family (FFF), is aimed at parents and has been shown to be effective in reducing the consumption of empty calories by children. It teaches parents skills to reduce their daily energy intake of added sugars and saturated fats, it also seeks to reduce screen time.~The intervention contains information and recommendations, through guides, in which precise instructions are given about how to maintain a healthy environment at home."
214864977|NCT05310162|BEHAVIORAL|Counseling|"Simple verbal instructions will be given in the consultation to reduce the time of use of screens and refined sugar.~For refined sugar reduction, parents will be told to avoid sugary drinks, add sugar to drinks (juices, milk, etc.), and avoid snacks and sweets. It will also be indicated that the screen time should be less than two hours a day and in no case use them two hours before sleeping."
214864978|NCT06406218|BEHAVIORAL|Phase I Cardiac Rehabilitation Exercise Training|"A) In the morning, take a supine position and perform straight leg raises with each leg individually, lifting to a height of 30° and holding for 3-5 seconds. Raise both arms to the side of the head to a 90° angle and hold for 5-10 seconds. Inhale deeply when exerting force and exhale slowly when lowering. Alternate between leg lifts and arm raises, performing 5 sets per session. Adjust intensity based on individual condition and may be repeated. In the afternoon, sit beside the bed for 5 minutes. B) After transitioning to secondary care according to the patient's condition, stand beside the bed for 5 minutes in the morning; in the afternoon, march in place beside the bed for 5 minutes. C) Walk beside the bed for 10 minutes per session, twice a day. D) Move around and doing activities under supervision inside the ward, 10 minutes per session, twice a day.~Spend approximately one day at each level, gradually progressing the exercise to the patient's tolerance level."
214864979|NCT05097313|DIETARY_SUPPLEMENT|Yeast β-glucan fiber|The study is designed to determine if β-glucan is safe and if it presents an antioxidant and immunomodulatory response in healthy adults in Colombia.
214864980|NCT05097313|OTHER|Placebo|oral consumption of 200 mg (one capsule) or 400 mg (two capsules) of soy protein powder for 84 days.
214864981|NCT04732910|DRUG|Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor|observational
214864982|NCT04647721|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
214864983|NCT04647721|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection.
214864984|NCT01265810|OTHER|supersaturated calcium-phosphate|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
214864985|NCT01265810|OTHER|sodium chloride 0.9 %|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
214864986|NCT02664714|OTHER|PFMT|Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
214864987|NCT06532604|DEVICE|Electroretinography (ERG)|ERG are specifically carried out for research. They are performed in Nancy with the MonPackOne device developed by Metrovision for participants at center n°1, and in Paris with the RETeval device developed by LKS Technologie for participants at center n°2. Both devices comply with ISCEV standard and are CE marked. They enable the reccord of Pattern ERG, Flash ERG and Multifocal ERG using corneal and skin electrodes, or Sensor Strip skin electrodes only, for the Nancy and Paris centers respectively.
214864988|NCT04824248|BEHAVIORAL|Pain Neuroscience Education|Increase pain coping skills and educating the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.
214864989|NCT04824248|BEHAVIORAL|Cognition-targeted exercise therapy|Daily (physical) activity and exercise therapy. To confront the patient with movements and activities that are feared, avoided and/or painful using a gradual and cognition-targeted approach.
214864990|NCT04824248|BEHAVIORAL|Behavioral weight reduction program|Changes in diet, behavior and a physical exercise to reach weight loss. It will include a lifestyle approach, incorporating behavioral theories and constructs to assist and facilitate healthy energy balance related behavior.
214864991|NCT04117360|OTHER|Orthognathic surgery and Orthodontics|This study is observational. All subjects identified to participate will be undergoing orthognathic jaw surgery and orthodontic treatment.
214864992|NCT05855486|DEVICE|Saline eye drops|Ocular drops used to facilitate the removal of ocular secretions in pediatric subjects
214864993|NCT05987917|DEVICE|BTL-785-2|Treatment with BTL-785 device (BTL-785-2 applicator) for non-invasive facial rejuvenation
214864994|NCT05987917|OTHER|No Treatment|The subject who will serve as control will not be treated with the study device.
214864995|NCT00043758|DRUG|Tolvaptan|
214864996|NCT06483542|OTHER|bioenergetic balance|Bioenergetic balance is calculated for all patients who had a resting energy expenditure measurement with indirect calorimetry.
214864997|NCT06036888|OTHER|questionaries completion|Answer to the DASH and SF-12 questionaries, for an estimated duration of 15 minutes.
214864998|NCT06276036|OTHER|Identification of specific markers|Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
214864999|NCT04771403|DEVICE|FMPD AP algorithm|The Fading Memory Proportional Derivative (FMPD) insulin infusion algorithm determines insulin delivery rates based on proportional error, defined as the difference between the current CGM level and the target CGM level, and the derivative error, defined as the rate of change of the CGM. The FMPD algorithm utilizes derivative and proportional glucose errors to determine delivery rates of insulin.
214865000|NCT04771403|DEVICE|MPC AP system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
214865001|NCT04771403|DEVICE|Dexcom G6 Continuous Glucose Monitoring (CGM) System|The Dexcom G6 CGM measures interstitial glucose through a sensor transmitter. This glucose value is reported to the MPC algorithm during this intervention.
214865002|NCT00763438|DRUG|Sertindole|Flexible dose
214865003|NCT00045539|DRUG|leucovorin calcium|
214865004|NCT00045539|DRUG|methotrexate|
214865005|NCT00045539|DRUG|thiotepa|
214865006|NCT02125253|DRUG|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
214865007|NCT02125253|DRUG|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
214865008|NCT02125253|DRUG|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
214865009|NCT06822049|DRUG|Combination Nicotine Replacement Therapy (patch and lozenge)|All participants receive 8 weeks of combination nicotine replacement therapy - long-acting transdermal patch and short-acting lozenge.
214476484|NCT04923776|DRUG|Etoposide|The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
214865010|NCT06006897|OTHER|Physical Evaluations of post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis with post-COVID-19 individuals. The data to be obtained from all these evaluations will be collected from the individuals at one time and over a period of approximately 1 hour at the most. Step count tracking with pedometer will be done for each individual for 3 days.
214865011|NCT06006897|OTHER|Physical evaluations of non-post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis without post-COVID-19 individuals.
214476485|NCT04923776|DRUG|Atezolizumab|The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
214865012|NCT06973512|DEVICE|deep brain stimulation and stereoelectroencephalography|Deep brain stimulation guided by stereoelectroencephalography
214865013|NCT06969313|OTHER|Structured Questionnaire on Telemedicine Needs|Participants will complete a structured questionnaire designed to assess their telemedicine needs, expectations, and current knowledge. The questionnaire includes items on demographics, osteoporosis management, and telemedicine service expectations. No clinical or pharmacological intervention will be applied.
214865014|NCT06973083|PROCEDURE|FASTER-assisted ESD|The patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system.
214865015|NCT06973083|PROCEDURE|Conventional ESD|The patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern.
214865016|NCT05957809|OTHER|Structured exercise training|"This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks. • Warm-up program - 10 minutes~* Strength training on unstable surfaces - 25-30 minutes~* High repetition muscular endurance training - 25-30 minutes~* Cool-down program - 10 minutes"
214865017|NCT06968182|DIETARY_SUPPLEMENT|Sodium Chloride|During the examination day after a baseline period, from 11.00 AM to 11.30 AM, a sustained infusion of 1 L isotonic NaCl, was administered.
214865018|NCT05084963|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
214865019|NCT05084963|DRUG|Placebo|Matching placebo for IRL201104
214865020|NCT05357755|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as delayed release tablets.
214865021|NCT05357755|DRUG|Placebo|Matching placebo will be administered orally as delayed release tablets.
214865022|NCT05442866|DEVICE|Virtual reality experience for 10 minutes|Each 10-minute VR session will be self-administered (by each participant) using the Facebook (Facebook Inc., Menlo Park, CA) Meta Quest 2 VR and Touch controllers. This equipment was selected because it is portable, has built in audio, and has clear graphics at a lower price than VR setups that require a computer to generate graphics. The headset has an optional eyeglass spacer to allow participants to wear corrective eyeglasses during the VR session if appropriate. The hand controllers facilitate immersive, interactive VR experiences. The VR software, Nature Treks VR application (https://naturetreksvr.com) that features ten non-violent, nature-based experiences in peaceful environments (e.g. forest, river, beach, etc.) that can be played in a seated or fixed position.
214865023|NCT06014073|BIOLOGICAL|TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)|"Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (1 × 10\^7 cells/kg); Phase 2 : dose of RP2D.~No more than 2 × 10\^5 per kilogram of allogenic residual CD3+T cells harbouring in grafts can only be released for recipient infusion."
214865024|NCT06014073|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
214865025|NCT06014073|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
214865026|NCT06700109|DEVICE|Neural Ice|This therapy will be injected around the superolateral, superomedial, and inferomedial genicular nerves.
214865027|NCT06700109|DRUG|Triamcinolone acetate|A single dose of Triamcinolone 40mg injected directly into the joint space.
214865028|NCT04838522|OTHER|No Intervention|This is a non-interventional study.
214865029|NCT03819049|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
214865030|NCT03819049|BIOLOGICAL|ExPEC4V|Participants will receive a single IM injection of ExPEC4V on Day 1.
214865031|NCT03819049|BIOLOGICAL|Prevnar 13|Participants will receive a single IM injection of Prevnar 13 on Day 1.
214865032|NCT03819049|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo on Day 1.
214665478|NCT02913625|OTHER|Ultrasound guided infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
214865033|NCT06249776|DEVICE|Supernova revascularization device|Mechanical Thrombectomy
214865034|NCT06572631|BIOLOGICAL|Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001|Given IV
214865035|NCT06572631|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214865036|NCT06572631|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214865037|NCT06572631|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214865038|NCT06572631|PROCEDURE|Computed Tomography|Undergo PET/CT
214865039|NCT06572631|DRUG|Cyclophosphamide|Given IV
214865040|NCT06572631|DRUG|Decitabine|Given IV
214865041|NCT06572631|PROCEDURE|Echocardiography|Undergo ECHO
214865042|NCT06572631|DRUG|Fludarabine|Given IV
214865043|NCT06572631|PROCEDURE|Leukapheresis|Undergo leukapheresis
214865044|NCT06572631|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214865045|NCT06572631|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214865046|NCT05841732|OTHER|Usual Care|Education; Pain Medication, imaging, referrals to other health services, other health care appointments
214865047|NCT05841732|OTHER|MyBack Program|A tailored exercise and behavioural change program
214865048|NCT01638650|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
214865049|NCT01638650|DRUG|ritonavir|100 mg bid orally, Days 1-14
214865050|NCT01638650|DRUG|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
214865051|NCT05500716|OTHER|Auricular Non-Invazive Vagus Nerve Stimulation + Traditional Rehabilitation Program for TMD|"In this application, vagus nerve stimulation is applied to the patients in addition to the traditional rehabilitation program. In our research, vagal nerve stimulation will be applied with the Vagustim Device and all applications will be applied at a frequency of 10 Hz, a pulse amplitude of 300 microseconds and for 20 minutes."
214865052|NCT05500716|OTHER|Traditional Rehabilitation Program|This intervention includes: Deep Friction Massage, Myofascial Trigger Point Compression Therapy, Temporomandibular Joint Mobilization, Rocabado Exercises, Muscle-Energy Techniques.
214865053|NCT04180176|OTHER|Blood Draw|Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
214865054|NCT00535587|BEHAVIORAL|Exercise|
214865055|NCT00535587|DRUG|pyridostigmine|
214865056|NCT00535587|DRUG|Placibo|
214865057|NCT00535587|BEHAVIORAL|Attention Control|
214865058|NCT01912638|DEVICE|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
214865059|NCT01912638|DRUG|Provisc|Provisc is an cohesive viscoelastic.
214865060|NCT01956019|DEVICE|MRI scanning|
214865061|NCT04944719|DIAGNOSTIC_TEST|nasopharyngeal aspirate|nasopharyngeal aspirate to determinate colonization by streptococcus pneumoniae
214865062|NCT02859948|DRUG|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
214865063|NCT00183885|DRUG|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
214865064|NCT01567748|PROCEDURE|BP Measurements at aorta, radial and femoral locations|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
214476486|NCT04923776|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
214476487|NCT06566716|DIAGNOSTIC_TEST|CleoDX ovarian cancer test|A diagnostic test to assist in predicting risk of malignancy prior to surgery for patients with an adnexal mass.
214865065|NCT05294419|DEVICE|CVD Integrated Risk Test|CVD IRT (IVD regulations with a software device)
214865066|NCT01168765|BEHAVIORAL|Tu Salud Si Cuenta Behavioral Intervention|A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
214865067|NCT01568320|DEVICE|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
214865068|NCT01078129|BEHAVIORAL|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
214865069|NCT01078129|BEHAVIORAL|non-CRT|waiting list
214865070|NCT01847820|DEVICE|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
214865071|NCT05314114|PROCEDURE|No axillary surgery|No axillary surgery
214865072|NCT00306150|DRUG|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
214865073|NCT00306150|DRUG|Placebo|Placebo is used according to the description of Arm 1
214865074|NCT02833376|OTHER|alcohol antisepsis|
214865075|NCT02833376|OTHER|chlorhexidine antisepsis|
214865076|NCT02680431|OTHER|Blood sample|10 mL venous blood sample for analysis of plasma
214865077|NCT05249530|OTHER|Chiropractic spinal adjustment|Chiropractic spinal adjustment
214865078|NCT05249530|OTHER|Non-force simulation|Non-force simulation
214865079|NCT03583632|OTHER|visual acuity testing|testing of visual ycuity by ETDRS charts
214865080|NCT03583632|DEVICE|optical coherence tomography|optical coherence tomography generates sectional slides of the retinal tomography with light
214865081|NCT00816361|DRUG|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
214865082|NCT00436904|DRUG|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
214865083|NCT00436904|DRUG|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
214865084|NCT00546572|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
214865085|NCT00546572|BIOLOGICAL|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
214865086|NCT01394952|DRUG|Dulaglutide|Administered subcutaneously
214865087|NCT01394952|DRUG|Placebo|Administered subcutaneously
214865088|NCT01986010|BIOLOGICAL|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
214865089|NCT01986010|BIOLOGICAL|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
214865090|NCT01986010|BIOLOGICAL|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
214865091|NCT01986010|BIOLOGICAL|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
214865092|NCT01986010|BIOLOGICAL|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
214865093|NCT01986010|BIOLOGICAL|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
214865094|NCT01986010|OTHER|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
214865095|NCT01986010|BIOLOGICAL|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
214865096|NCT01986010|OTHER|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
214865097|NCT00093600|DRUG|cytarabine|
214865098|NCT00093600|DRUG|daunorubicin hydrochloride|
214865099|NCT00093600|DRUG|midostaurin|
214865100|NCT06412588|DRUG|Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days|Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.
214865101|NCT06412588|DRUG|Vonoprazan+Amoxicillin|Group B: Patients were treated with oral Vonoprazan 20mg, bid + amoxicillin 1.0g, bid for 14 days.
214865102|NCT06412588|DRUG|Vonoprazan+doxycycline|Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.
214865103|NCT01587937|OTHER|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
214865104|NCT04727437|OTHER|No treatment|Withholding anticoagulation for at least 3 months.
214865105|NCT04727437|DRUG|Warfarin|anticoagulation drug given for at least 3 months.
214865106|NCT04727437|DRUG|direct oral anticoagulants|anticoagulation drug given for at least 3 months.
214865107|NCT04727437|DRUG|Low molecular weight heparin|anticoagulation drug, subcutaneous injection given for at least 3 months.
214865108|NCT02410356|DRUG|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
214865109|NCT02410356|DRUG|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
214865110|NCT01472328|PROCEDURE|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
214865111|NCT01472328|PROCEDURE|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
214865112|NCT05832528|OTHER|Low-FODMAP diet|6-week Low-FODMAP diet in patients with functional dyspepsia
214865113|NCT05456711|DIAGNOSTIC_TEST|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
214865114|NCT02838511|OTHER|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
214476488|NCT05439200|DEVICE|Asynchronous 3D movies|3D movies streamed at home for viewing on a handheld lenticular 3D screen
214476489|NCT05439200|DEVICE|Patching|Adhesive patch to cover the fellow eye
214665479|NCT04925115|OTHER|Brisk walking|"* Warm up and cool down (10 minutes before physical activity)~* Brisk walking ( 30 minutes each session for 5 days in a week)"
214665480|NCT04459962|DIAGNOSTIC_TEST|Breath Test & Cheek Swab|Breath Sample and Cheek Swab of participants will be used for machine learning (NBT - Nanobiotechnology Biomarkers Tagging) system to develop a profile which can be used later on for Covid-19 Diagnosis.
214665481|NCT00283010|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
214865115|NCT02838511|OTHER|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
214865116|NCT04368611|PROCEDURE|start with fundus|fundus first dissection then complete cholecystectomy as usual
214865117|NCT04368611|PROCEDURE|calot first dissection|start dissection by calot approach
214865118|NCT03297528|DRUG|donor lymphocyte infusion|Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
214865119|NCT01335997|DRUG|ER niacin/laropiprant (ERN/LRPT)|ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
214865120|NCT01335997|DRUG|ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)|ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
214865121|NCT01335997|DRUG|Simvastatin (SIM)|Simvastatin 10 mg oral tablet taken once daily
214865122|NCT01335997|DRUG|Placebo Run-In|Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
214865123|NCT01335997|DRUG|SIM-matching placebo|Placebo for simvastatin 10 mg oral tablet taken once daily
214865124|NCT05666219|DRUG|Aminophylline Injection|Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.
214865125|NCT03003273|OTHER|stoppage of antibiotics|antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.
214865126|NCT03003273|OTHER|amoxycillin/clavulanic acid|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
214865127|NCT03003273|OTHER|levofloxacin|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
214865128|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
214865129|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
214865130|NCT01066689|DRUG|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
214665482|NCT00283010|OTHER|Educational DVDs|
214865131|NCT01066689|DRUG|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
214865132|NCT01923623|DRUG|Ropivacaine block|
214865133|NCT06077331|DRUG|HS-10374 tablets 1mg|Administered orally QD for 12 weeks
214865134|NCT06077331|DRUG|HS-10374 tablets 5mg|Administered orally QD for 12 weeks
214865135|NCT06077331|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 12 weeks
214865136|NCT02043665|BIOLOGICAL|CVA21/pembrolizumab|
214865137|NCT03386565|DRUG|sodium chloride solution|intraoperative IV infusion
214865138|NCT03386565|DRUG|Lidocaine|intraoperative IV infusion
214865139|NCT00512382|DEVICE|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
214865140|NCT04740814|DRUG|Certolizumab pegol|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study."
214865141|NCT02187510|PROCEDURE|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
214865142|NCT02187510|PROCEDURE|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
214865143|NCT05435716|DEVICE|C-wave™ peripheral seismic waveguide system|In the experimental group, if the target lesions did not show flow-limiting dissection or severe elastic retraction, drug-coated balloon was subsequently performed after lumen preparation by peripheral seismic catheterization system (IVL). If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
214865144|NCT05435716|DEVICE|Peripheral vascular balloon dilatation catheter (PTA)|Subjects in the control group received balloon dilatation catheter in peripheral blood for lumen preparation, and if the target lesions did not show flow-limiting interlayer or severe elastic retraction, drug-coated balloon therapy was subsequently performed. If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
214865145|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable \& 2 fruit \& 2 berry capsule
214865146|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable \& fruit \& placebo capsule
214865147|NCT00952536|DIETARY_SUPPLEMENT|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
214865148|NCT03982472|OTHER|transcutaneous electric stimulation|transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
214865149|NCT05367726|OTHER|patients having had skin coverage of the knee|the cutaneous cover is not always optimal to protect the prosthesis, an act of reconstructive plastic surgery is then necessary
214865150|NCT04489758|DIAGNOSTIC_TEST|X-ray velocimetry analyzed by 4Dx XV Ventilation Analysis|Fluoroscopy will be performed for a complete tidal breath and full exhalation at 5 angles (AP, +/- 36 degrees from AP, and +/- 72 degrees from AP) while the patient's arms are raised overhead. 4Dx XV Ventilation Analysis software will be used to analyze these images. Both groups will also undergo pulmonary function testing and take a questionnaire regarding respiratory symptoms.
214865151|NCT01763684|DEVICE|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
214865152|NCT01763684|PROCEDURE|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
214865153|NCT04340609|BIOLOGICAL|Mesenchymal Stem Cells|The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
214865154|NCT01339481|DRUG|abatacept|Intravenous Infusion
214865155|NCT04906083|DRUG|Avatrombopag|"Avatrombopag:~PLT：30\~50×10\^9/L patients, 40 mg/d; PLT：\<30×10\^9/L patients, 60 mg/d."
214865156|NCT04906083|DRUG|Standard medical treatment|Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
214865157|NCT06405217|DRUG|Recombinant Human Thyroid Stimulating Hormone|Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days
214865158|NCT00673244|DRUG|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
214865159|NCT04763694|DEVICE|Multifocal soft contact lenses|Myopic subjects wore multifocal soft contact lenses for 12 months
214865160|NCT01011179|BEHAVIORAL|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
214865161|NCT01011179|BEHAVIORAL|Self-Management|"Adolescents' own best efforts at managing their JIA"
214865162|NCT05986253|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
214865163|NCT05986253|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin solution
214865164|NCT04953572|GENETIC|autologous peripheral blood mesenchymal stem cell|Transplantation of autologous peripheral blood mesenchymal stem cell
214865165|NCT04953572|PROCEDURE|Microfracture|Microfracture
214865166|NCT04953572|COMBINATION_PRODUCT|Microfracture + collagen membrane|Microfracture plus collagen membrane transplantation
214865167|NCT04953572|PROCEDURE|Autologous osteochondral transplantation|Autologous osteochondral transplantation
214865168|NCT03290703|DRUG|GDC-0853|Participants will receive different formulations of GDC-0853 tablet.
214865169|NCT03290703|DRUG|Rabeprazole|Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
214865170|NCT00157079|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|
214865171|NCT04453202|BIOLOGICAL|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
214865172|NCT04453202|OTHER|Placebo|Participants will receive a single IM injection of placebo on Day 1.
214865173|NCT02870400|DRUG|REGN2477|Participants will receive ascending doses of REGN2477
214865174|NCT02870400|DRUG|Placebo|Participants will receive matching placebo
214865175|NCT01483469|DRUG|RO4917523|orally daily, 14 days
214865176|NCT01483469|DRUG|RO5011232|\[11C\]-RO5011232 intravenously
214865177|NCT03565458|DRUG|Gemigliptin|zemiglo 50mg,LG Chem
214865178|NCT03565458|DRUG|Dapagliflozin|forxiga, dapagliflozin 10mg
214865179|NCT03565458|DRUG|Empagliflozin|jardiance 25mg, empagliflozin
214865180|NCT02931006|OTHER|water|
214865181|NCT02931006|OTHER|bovine milk|
214865182|NCT04952636|PROCEDURE|arthroscopic Cuistow|peforming the Cuistow Procedure under arthroscopy
214865183|NCT04952636|PROCEDURE|open Cuistow|peforming the Cuistow Procedure with the traditional open process
214865184|NCT01157897|BIOLOGICAL|VMP001|Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
214865185|NCT01157897|OTHER|P. vivax sporozoite challenge|P. vivax sporozoite challenge
214865186|NCT04472247|DIAGNOSTIC_TEST|Continuous EEG and EMG monitoring, with derived variables|All patients are monitored during their ICU stay by frontal EEG and EMG measuring devides, which are already in clinical use.
214865187|NCT05528835|PROCEDURE|Frozen embryo transfer|All women in both groups will receive oral estradiol valerate 8 mg/ day from the second day of the menstrual cycle. Endometrial thickness will be assessed by vaginal ultrasonography at the tenth day of treatment. When endometrial thickness reached ≥ 7 mm all subjects, in addition to estrogen, they will receive progesterone vaginal suppositories 400 mg twice daily and 100 mg of progesterone intramuscularly daily. Frozen thawed embryo transfer will be at day 6 of progesterone. Estrogen and progesterone will be continued until 9-10 weeks of gestation
214865188|NCT04059224|DRUG|Trametinib|Trametinib 2 mg once a day by mouth.
214865189|NCT04059224|DRUG|Dabrafenib|Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
214865190|NCT04644874|DIAGNOSTIC_TEST|Geriatric 8|The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.
214865191|NCT04644874|DIAGNOSTIC_TEST|modified Geriatric 8|The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.
214865192|NCT04644874|DIAGNOSTIC_TEST|30 second chair stand test|Repetitions within 30 seconds
214865193|NCT04644874|DIAGNOSTIC_TEST|Handgrip Strength Test|Measured in kilograms
214865194|NCT03276221|BEHAVIORAL|Abstinence|Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
214865195|NCT03659097|PROCEDURE|periodontally accelerated osteogenic orthodontics|Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
214865196|NCT03809988|DRUG|Palbociclib|Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
214865197|NCT03809988|DRUG|Endocrine therapy|Endocrine therapy alone (letrozole or fulvestrant)
214865198|NCT05445674|COMBINATION_PRODUCT|Plasma Exchange Procedure|Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline
214865199|NCT05445674|OTHER|Sham Plasma Exchange Procedure|For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
214865200|NCT02912650|DRUG|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
214865201|NCT02912650|DRUG|Ibuprofen 250 mg|2 caplets of Ibuprofen 125 mg
214865202|NCT02912650|DRUG|Acetaminophen 650 mg|2 tablets of Acetaminophen 325 mg
214865203|NCT02912650|DRUG|Placebo|2 caplets of Placebo
214865204|NCT03966482|BEHAVIORAL|Group before-after|The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
214865205|NCT01246362|DRUG|Control|Given placebo
214865206|NCT01246362|DRUG|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
214865207|NCT05477160|DRUG|STAR-0215 (SC)|STAR-0215 will be administered as an SC bolus injection.
214865208|NCT05477160|DRUG|Placebo (SC)|Placebo will be administered as an SC bolus injection.
214865209|NCT05477160|DRUG|STAR-0215 (IV)|STAR-0215 will be administered as an IV bolus injection.
214865210|NCT05477160|DRUG|Placebo (IV)|Placebo will be administered as an IV bolus injection.
214865211|NCT04439773|DRUG|placebo|the control group will be given the same volume of saline.
214865212|NCT04439773|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
214865213|NCT01720199|OTHER|Diario della Salute (DDS)|"DDS is composed by~1. tools for children and their parents on health and social and emotional well-being issues:~   1. a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~  2. a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~2. five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers."
214865214|NCT00663832|DRUG|LBH589 (i.v. panobinostat)|"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"
214865215|NCT02562482|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).
214865216|NCT02562482|OTHER|VRC-PBSPLA043-00-VP|VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
214865217|NCT00939120|DRUG|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
214865218|NCT00939120|DRUG|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
214865219|NCT00939120|DRUG|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
214865220|NCT01674413|DRUG|Adalimumab|Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
214865221|NCT01674413|DRUG|Adalimumab PRN|"160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with~* PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,~* Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is \< 167 mcg/gram of stool."
214865222|NCT01674413|DRUG|Placebo|1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
214865223|NCT00916136|PROCEDURE|Femoral Traction|Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
214865224|NCT02593513|DEVICE|Daifert|
214865225|NCT02593513|PROCEDURE|Control Group|Control - Morphological Assessment
214865226|NCT03528473|OTHER|Exercise|"The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.~Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.~Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines."
214865227|NCT05624827|DIAGNOSTIC_TEST|Testing DNA methylation test for predicting prognosis of untreated CIN 2|After being diagnosed with CIN 2, patients will first be contacted by telephone and invited to participate in the study. If patients agree to participate in the research, they will sign a consent to participate in the research. After that, we will perform a colposcopy and take a cervical swab for analysis with the QIAsure Methylation Test Kit (Qiagen, Gaithersburg, USA), which will determine the methylation of tumor suppressor genes FAM19A4 and has-mir-124. Patients will complete a questionnaire. The total duration of tracking in both groups will be two years. The QIAsure Methylation Test will be performed to analyze methylation. It is a methylation-specific PCR test that detects hypermethylation of the tumor promoter suppressor genes FAM19A4 and has-mir-124. The samples on which we will use this test are bisulfite-converted DNA obtained by triage test for high-risk HPV - Hybrid Capture 2 HPV DNA Test (hc2, Qiagen, Gaithersburg, USA).
214865228|NCT00433316|DRUG|ropivacaine|1% ropivacaine
214669994|NCT01122810|PROCEDURE|Coronary scanner|The ECG-gated contrast-enhanced multidetector computed tomography coronary angiography will be performed with a 64 or 256-row CT Philips, Brilliance. The contrast medium mean quantity used is 80-100 ml. The CT scan parameters, adapted to the patient's weight, include 120 kV, 800mA, 0.625 mm slice thickness, 0.42-s rotation time and 0.2 pitch. To determine X-Ray exposure, Dose Length Product (Gycm) will be measured. Reconstruction will be performed at 40 and 75 % of the cycle using ECG gating. A semi quantitative analyse of coronary narrowing will be performed blindly to coronary angiogram results by two experienced radiologists. The CT quality will be determined using a quality scale from 1 to 5. A Calcification score will also be determined. A segment analyse will be performed according to AHA classification. Only more than 1.5 mm diameter vessel segments will be analysed.
214865229|NCT00433316|DEVICE|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
214865230|NCT00598624|DRUG|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
214865231|NCT01040884|OTHER|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
214865232|NCT00110162|DRUG|antiandrogen therapy|
214865233|NCT00110162|DRUG|releasing hormone agonist therapy|
214865234|NCT00110162|PROCEDURE|orchiectomy|
214865235|NCT04962984|PROCEDURE|blood sampling|additional blood sampling for coagulation tests
214865236|NCT03712982|BEHAVIORAL|Attention to Variability - Patient Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
214865237|NCT03712982|BEHAVIORAL|Attention to Variability - Partner Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology in their partner that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
214865238|NCT03712982|BEHAVIORAL|Attention to Variability - Patient & Partner|Same as patient and partner only conditions, just that in this condition both the patient and partner do their corresponding intervention rather than only one of them.
214865239|NCT03712982|OTHER|Infertility Stories - Reading|Reading Stories About Others' Infertility Experiences
214865240|NCT00210236|PROCEDURE|Conventional surgery|
214865241|NCT02435836|DRUG|Aripiprazole|
214865242|NCT00002321|DRUG|Aldesleukin|
214865243|NCT02963870|OTHER|Security Plan|This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
214865244|NCT02041091|DRUG|Tabalumab Auto-Injector|Administered SC
214865245|NCT02041091|DRUG|Tabalumab Prefilled Syringe|Administered SC
214865246|NCT00922987|DRUG|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
214865247|NCT06213870|DIAGNOSTIC_TEST|Surgical criteria|"In the MRI group, patients with FVH-DWI mismatch underwent EVT surgery or were otherwise treated with medication.~In the perfusion group, patients who meet the criteria of DEFUSE3 will receive EVT surgery, otherwise receive medication."
214865248|NCT05091307|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as an IM injection.
214865249|NCT05091307|OTHER|Placebo|Placebo will be administered as an IM injection.
214865250|NCT05091307|BIOLOGICAL|Influenza Vaccine|Influenza vaccine high and standard dose will be administered as IM injection.
214865251|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1\*10\^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
214865252|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5\*10\^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
214865253|NCT03303625|DRUG|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
214865254|NCT02267668|BEHAVIORAL|STEP|Physical therapists guide participants through novel set of assigned exercises
214865255|NCT02267668|BEHAVIORAL|Control|Participants self-guide through standard exercises
214865256|NCT01167257|DRUG|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
214865257|NCT01167257|DRUG|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
214865258|NCT06402370|DIAGNOSTIC_TEST|PET scan|\[18F\]Vizamyl
214865259|NCT05854394|BEHAVIORAL|Multimodal prehabilitation management Multimodal prehabilitation management|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including drug treatment recommendations for chronic disease, quit smoking and abstinence).
214865260|NCT00045292|DRUG|acyclovir|
214865261|NCT00045292|DRUG|acyclovir sodium|
214865262|NCT00045292|DRUG|valacyclovir|
214865263|NCT03153761|OTHER|CSD170201AA|A moist snuff product
214865264|NCT03153761|OTHER|CSD170201AB|A moist snuff product
214865265|NCT00193466|DRUG|Rituximab|
214865266|NCT00193466|DRUG|Fludarabine|
214865267|NCT00193466|DRUG|CAMPTH-1H|
214865268|NCT04136457|OTHER|Endurance training|Subjects perform a period of endurance training
214865269|NCT04136457|OTHER|Resistance training|Subjects perform a period of resistance training
214865270|NCT04136457|OTHER|Sprint training|Subjects perform a period of sprint training
214865271|NCT00788138|DIETARY_SUPPLEMENT|Vitamin D3|250,000 IU of vitamin D3
214865272|NCT00788138|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
214865273|NCT00963781|DEVICE|Medtronic Endeavor Stent|The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
214865274|NCT00963781|DRUG|Reduced duration (6 months) DAPT|
214865275|NCT04607161|OTHER|no intervention|no intervention
214865276|NCT04430478|DIAGNOSTIC_TEST|Volume flow guided angioplasty|Volume flow measurements using DUS will be obtained at the end of each balloon dilation, at 24 hours, 6 months, and one year after index procedure.
214865277|NCT02048930|DEVICE|Budesonide Easyhaler|
214865278|NCT02048930|DEVICE|Budesonide dry powder inhaler|
214865279|NCT02492880|DEVICE|Precision Spectra™ SCS system programming features|Precision Spectra™ SCS system programming features using the CoverEdge surgical lead.
214865280|NCT03363399|DIAGNOSTIC_TEST|Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection. The samples will be stored at 4°C overnight.~Blood samples containing at least 105 neutrophils will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8-color flow cytometer and analyzed using Becton Dickinson (BD) Fluorescence-activated cell sorting (FACS) Diva Software version 6. Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
214865281|NCT06632392|OTHER|Simulation training|Theory and simulation training
214865282|NCT06632392|OTHER|Theory training|Theory training
214865283|NCT03533738|OTHER|Food sequence 1|Vegetables first then meat \& rice together
214865284|NCT03533738|OTHER|Food sequence 2|Meat first then vegetables \& rice together
214865285|NCT03533738|OTHER|Food sequence 3|Vegetables first then meat followed by rice
214865286|NCT03533738|OTHER|Food sequence 4|Vegetables first followed by meat and rice together
214865287|NCT03533738|OTHER|Food sequence 5|Rice first followed by vegetables \& meat together
214865288|NCT05331196|DIAGNOSTIC_TEST|Preoperative cardiopulmonary exercise tetsing|Patients underwent a cardiopulmonary exercise test prior to surgery.
214865289|NCT06035263|OTHER|FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME|the prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.
214865290|NCT06035263|OTHER|Health education programme:|"instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group."
214865291|NCT04522115|OTHER|exercises|"Group(1) aerobic training: Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.~Group(2) resistance exercise: training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated."
214865292|NCT02771795|DRUG|Herceptin (trastuzumab)|Intravenous administration
214865293|NCT02771795|DRUG|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
214865294|NCT02906930|DRUG|semaglutide|Oral administration once daily.
214865295|NCT02906930|DRUG|placebo|Oral administration once daily.
214865296|NCT05268263|DEVICE|Artificial Intelligence Algorithm|The enrolled population will include patients with a history of lung pathologies. Artificial intelligence-based models are developed for classification of wheezes, crackles and normal lung sounds. These AI models will be tested and assessed on local lung sounds clinical data.
214865297|NCT05483725|BIOLOGICAL|Booster dose of mRNA vaccine|Administration of SARS-CoV-2 mRNA vaccine.
214865298|NCT03621358|OTHER|Control gummy with free flavour (without encapsulating)|12 g/day (3 gummies)
214865299|NCT03621358|OTHER|Experimental gummy with 50% free/50% encapsulated flavour|12 g/day (3 gummies)
214865300|NCT03621358|OTHER|Experimental gummy with 100% encapsulated flavour|12 g/day (3 gummies)
214865301|NCT01736241|DRUG|LY3053102|
214865302|NCT01736241|DRUG|Placebo|
214865303|NCT03123536|DEVICE|Point-of-care Ultrasound|Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
214865304|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology Pro|"The Tandem t:slim X2 with Control-IQ Technology Pro is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is very similar to the commercially available t:sli X2 with Control-IQ but modified to accept the lower weight and Total Daily Insulin of the studied population."
214865305|NCT04796779|DEVICE|Standard Care (SC)|Standard of Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study Dexcom G6 CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump without hybrid closed-loop control capabilities (low-glucose suspend or predictive low-glucose suspend functionality is permitted).
214865306|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology V1.5|"The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features."
214865307|NCT00814918|DRUG|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
214865308|NCT00814918|DRUG|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
214865309|NCT00622466|DRUG|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
214865310|NCT00622466|DRUG|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
214865311|NCT01659866|DRUG|Ciprofloxacin|500 mg orally 2 hours before prostate biopsy
214865312|NCT01659866|DRUG|trimethoprim-sulfamethoxazole|1 double strength tablet orally 2 hours before the procedure and again 12 hours later
214865313|NCT01659866|DRUG|cefuroxime|500 mg orally 2 hours before the procedure then again 12 hours later
214865314|NCT01659866|DRUG|ceftriaxone|500 mg intramuscularly 2 hours before the procedure
214865315|NCT01659866|DRUG|gentamicin|2 mg/kg intramuscularly 2 hours before the procedure
214865316|NCT01659866|DRUG|amikacin|5 mg/kg intramuscularly 2 hours before the procedure
214865317|NCT01659866|DRUG|aztreonam|500 mg intramuscularly 2 hours before the procedure
214865318|NCT01659866|DRUG|imipenem|500 mg intramuscularly 2 hours before the procedure
214865319|NCT01659866|DRUG|ceftriaxone|2000 mg intravenously 1 hour before the procedure
214865320|NCT01659866|DRUG|gentamicin|2 mg/kg intravenously 1 hour before the procedure
214865321|NCT01659866|DRUG|amikacin|5 mg/kg intravenously 1 hour before the procedure
214865322|NCT01659866|DRUG|aztreonam|2000 mg intravenously 1 hour before the procedure
214865323|NCT01659866|DRUG|imipenem|1000 mg intravenously 1 hour before the procedure
214865324|NCT02902536|OTHER|No interventions|
214865325|NCT06049836|OTHER|Holograms|Clinical decision making based on visualising liver 3D holographic augmented reality liver models
214865326|NCT06049836|OTHER|PDF|Clinical decision making based on visualisation of 3D liver rendering on computer monitors on a PDF file
214865327|NCT01633736|OTHER|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
214865328|NCT01425918|BEHAVIORAL|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
214865329|NCT01425918|BEHAVIORAL|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
214865330|NCT02286596|DEVICE|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
214865331|NCT02286596|DEVICE|dextran sulfate adsorption|Lipid apheresis for 3 hours
214865332|NCT00037102|DRUG|interferon beta 1a|
214865333|NCT00037102|DRUG|methotrexate|
214865334|NCT02916043|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
214865335|NCT02134743|PROCEDURE|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
214865336|NCT05569603|BEHAVIORAL|Chronobiology-guided lifestyle interventions|1\) timed bright light exposure using blue-enriched white light glasses, 2) recommendations for meal timing, and 3) sleep hygiene education
214865337|NCT00058721|DRUG|I-123-5-IA85380|
214865338|NCT03300544|DRUG|Capecitabine|Given PO
214865339|NCT03300544|DRUG|Fluorouracil|Given IV
214865340|NCT03300544|DRUG|Leucovorin|Given IV
214865341|NCT03300544|DRUG|Oxaliplatin|Given IV
214865342|NCT03300544|RADIATION|Radiation Therapy|Undergo chemoradiation
214865343|NCT03300544|BIOLOGICAL|Talimogene Laherparepvec|Given intralesionally
214865344|NCT01294826|DRUG|AUY922|Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
214865345|NCT01294826|DRUG|Cetuximab|Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
214865346|NCT03994601|DRUG|BMS-986288|Specified dose on specified days
214865347|NCT03994601|DRUG|Nivolumab|Specified dose on specified days
214865348|NCT03994601|DRUG|Regorafenib|Specified dose on specified days
214865349|NCT04585789|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
214865350|NCT04585789|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
214865351|NCT04585789|DRUG|Entecavir (ETV)|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
214865352|NCT04585789|DRUG|Tenofovir disoproxil|Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
214865353|NCT04585789|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
214865354|NCT04585789|DRUG|PegIFN-alpha-2a (Optional)|PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
214865355|NCT00769093|DRUG|Ferumoxytol|2 mg/kg
214865356|NCT01753466|DIETARY_SUPPLEMENT|Hydration|
214865357|NCT00894738|PROCEDURE|Testing (MRS, US, DEXA, blood tests)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
214865358|NCT00778024|DRUG|fluoxetine HCL 40 mg capsules|
214865359|NCT01383135|DRUG|F18-FPPRGD2|Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
214865360|NCT00866736|DRUG|dasatinib|100mg QD
214865361|NCT00070096|DRUG|ixabepilone|
214865362|NCT05134506|BEHAVIORAL|Dance for PD® classes|The intervention consisted of 16 60-min classes, performed twice weekly over a period of 8 weeks and instructed by a single researcher who had the approval to use it for research reasons.
214865363|NCT01904617|OTHER|Dextrose|
214865364|NCT01904617|OTHER|Normal Saline|
214865365|NCT01884818|OTHER|Manipulation vs. TNS thoracic pain|
214865366|NCT01612299|DRUG|Zortress® /Everolimus|"Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml \>6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 \&2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml \>6 mo post transplant 4-7 ng/ml."
214865367|NCT01560481|DRUG|Step A: metformin glycinate 620 mg single dose|metformin glycinate 620 mg single dose
214865368|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg single dose|metformin glycinate 1240 mg single dose
214865369|NCT01560481|DRUG|Step A: metformin glycinate 2480 mg single dose|metformin glycinate 2480 mg single dose
214865370|NCT01560481|DRUG|Step A: metformin hydrochloride 1000 mg single dose|metformin Chlorhydrate 1000 mg single dose
214865371|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg,food intake|metformin glycinate 1240 mg, intake of food
214865372|NCT01560481|DRUG|Step B: metformin glycinate 620 mg BID|metformin glycinate 620 mg BID, 8 days
214865373|NCT01560481|DRUG|Step B: metformin hydrochloride 500 mg BID|metformin Chlorhydrate 500 mg BID, 8 days
214865374|NCT01154816|DRUG|Alisertib|Given orally
214865375|NCT01154816|OTHER|Laboratory Biomarker Analysis|Correlative studies
214865376|NCT01154816|OTHER|Pharmacological Study|Correlative studies
214865377|NCT06348706|DRUG|Dipeptidyl peptidase 4 (DPP-4) inhibitor|Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.
214865378|NCT05876988|DEVICE|Chinese acupuncture|"Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment."
214865379|NCT03397771|DRUG|Litoxetine|oral study medication provided in a dose titration manner
214865380|NCT03397771|DRUG|placebo|placebo medication provided in a dose titration manner
214865381|NCT05477498|DRUG|Ferric carboxymaltose|Application of FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection.
214865382|NCT05477498|DRUG|Placebo|Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
214865383|NCT04062656|DRUG|Nivolumab|Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes
214865384|NCT04062656|DRUG|relatlimab|relatlimab (80mg flat dose) administered IV over 60 min
214865385|NCT04062656|DRUG|Oxaliplatin|Oxaliplatin 85mg/m² IV over 1 h
214865386|NCT04062656|DRUG|Docetaxel|Docetaxel 50mg/m² IV over 1 h
214865387|NCT04062656|DRUG|5-Fluorouracil (5-FU)|5-fluorouracil 2600mg/m² IV over 24h
214865388|NCT04062656|DRUG|Folic acid (FA)|Folic acid 200mg/m² IV over 30 min
214865389|NCT06130098|OTHER|control group|"Training by the clinical nurse before discharge. Prepare an educational brochure and give it to patients. Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale During the routine check-up in the first week, evaluates the development of complications without knowing which group the patient is in.~Within the first week and at the end of the fourth week, the wound site is evaluated by the physician for the development of complications, . Patients who cannot come for a check-up should send a photo of the wound area to the researcher via WhatsApp application, and the photo will be forwarded to the clinician who performed the surgery and the physician will record the complication situation. It is planned to receive complication development and wound site evaluation results from the physician system.~At the end of the fourth and sixth weeks after discharge, the EQ-5D-5L and OKS scale must be filled in again by the patients."
214865390|NCT06130098|OTHER|experimental group|"Providing training before discharge Prepare an educational brochure and give it to patients. You will be contacted by phone at the end of the first, second, third and fourth weeks after discharge.~Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale Evaluating the wound site in terms of complications within the first week and at the end of the fourth week. It is planned to receive complication development and wound site evaluation results from the system.~After the first check-up, calling the patients in the study group at the end of the first week after discharge.~Providing training on the subjects included in the training brochure in the first phone call and recording any existing problems.~In the fourth meeting, tele-nursing service will be provided through the Telephone Counseling Protocol.~EQ-5D-5L and OKS forms must be filled out again by patients at the routine check-up at the end of the fourth and sixth weeks after discharge."
214865391|NCT02936453|PROCEDURE|Device implantation|"* Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~* Implantation of Activa RC neurostimulator"
214865392|NCT03417193|DRUG|opioid free Anesthesia vs Opioid based Anesthesia|Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
214865393|NCT02331329|DEVICE|NICOM cardiac output measurement|
214865394|NCT02331329|DEVICE|Cardiac MRT cardiac output measurement|
214865395|NCT06169189|BEHAVIORAL|global warming-climate change based education|The experimental group will be given 8 weeks of global warming-climate change based training. No intervention will be applied to the control group.
214865396|NCT03801265|PROCEDURE|Lumbar plexus block|Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
214865397|NCT03801265|PROCEDURE|Quadratus lumborum type 3 block|Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
214865398|NCT03801265|DRUG|Ropivacaine injection|0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
214865399|NCT06345365|DRUG|mitoxantrone liposome, Ara-Cytarabine and azacitidine|Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7
214865400|NCT06345365|DRUG|Daunorubicin,Ara-Cytarabine, azacitidine|Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3; Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;
214865401|NCT00601874|DRUG|Pilocarpine|
214865402|NCT04968665|DIAGNOSTIC_TEST|gait testing, functional MRI|diagnostic tests including the gait testing and functional MRI
214865403|NCT01727466|BEHAVIORAL|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
214865404|NCT04078126|COMBINATION_PRODUCT|BFF|Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
214865405|NCT04078126|COMBINATION_PRODUCT|Symbicort Turbuhaler|Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
214865406|NCT04793048|DEVICE|a noninvasive intraoral electrotherapy device|a noninvasive intraoral electrotherapy device to treat periodontal disease at-home for 20 minutes a day
214865407|NCT04793048|DEVICE|a sham device|a sham device to be used at-home for 20 minutes a day
214865408|NCT04811586|PROCEDURE|coronary revascularization|to improve the blood supply for coronary arteries by using either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
214865409|NCT03321630|DRUG|Lenvatinib|Lenvatinib 20 mg orally each day on days 1-7
214865410|NCT03321630|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
214865411|NCT04013230|BEHAVIORAL|Usual care|Visit doctor and nurse at the clinic.
214865412|NCT04013230|BEHAVIORAL|Web-COP|Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
214865413|NCT00130455|DRUG|escitalopram|
214669995|NCT04385901|BEHAVIORAL|Therapy Intervention|Patients receive 2-4 visits (based on patient presentation and need) of physical therapy, up to 4 visits of occupational therapy, up to 4 visits of speech therapy based on need. Treatment focuses on physical strengthening, pulmonary strengthening/breathing exercises, and cognitive rehabilitation.
214865414|NCT05224310|PROCEDURE|PECS block, SAP block|performing either PECS block or SAP block
214865415|NCT02669758|DRUG|ALKS 3831|Tablets were administered for daily dosing
214865416|NCT06013839|DRUG|talfirastide|TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).
214865417|NCT04573764|DIETARY_SUPPLEMENT|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|"The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded."
214865418|NCT04573764|DIETARY_SUPPLEMENT|Placebo|Taste-matched water
214865419|NCT03422367|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
214865420|NCT00072592|DRUG|Rituximab|
214865421|NCT03281863|DIAGNOSTIC_TEST|C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate|Throat culture to detect the causative organism
214865422|NCT06483139|PROCEDURE|Plasma exchange|Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
214865423|NCT06483139|DRUG|Daratumumab|Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
214865424|NCT02455050|DRUG|Carboxymethylcellulose Sodium Based Eye Drops|1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.
214865425|NCT02455050|DRUG|Systane® Gel Drops|1 to 2 drops of Systane® Gel Drops in each eye.
214865426|NCT02455050|DRUG|Genteal® Lubricant Gel Drops|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
214865427|NCT06299917|OTHER|WORK-ON|The intervention includes three parts: 1) a coordinating occupational therapist, 2) four group sessions and 3) Individual consultations based on the agreed upon goals.
214865428|NCT03545035|DRUG|idelalisib and rituximab|patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
214865429|NCT02325518|DRUG|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
214865430|NCT02325518|DRUG|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
214865431|NCT02325518|DRUG|Subject's habitual PGA monotherapy|
214865432|NCT00103818|DRUG|gaboxadol|Duration of Treatment: 3 months
214865433|NCT00103818|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 3 months
214865434|NCT00631449|DRUG|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
214865435|NCT00631449|DRUG|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
214865436|NCT00586352|OTHER|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
214865437|NCT04847349|DIETARY_SUPPLEMENT|OL-1, standard dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
214865438|NCT04847349|DIETARY_SUPPLEMENT|OL-1, high dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
214865439|NCT04847349|DIETARY_SUPPLEMENT|Placebo|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.
214865440|NCT04086836|DEVICE|TAVR|Patient recieving a TAVR
214865441|NCT04193306|DRUG|Alirocumab|Alirocumab 150 mg s.c. every 2 weeks
214865442|NCT04193306|OTHER|Placebo|Placebo s.c. every 2 weeks
214865443|NCT03393806|DRUG|GSK3772847|GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.
214865444|NCT03393806|DRUG|Placebo|Commercially sourced sterile normal saline will be provided as Placebo
214865445|NCT02552056|OTHER|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
214865446|NCT06387485|DEVICE|3D Printed Anatomic Model|Patient-specific 3D printed anatomic model for pre-surgical planning
214865447|NCT06387485|DIAGNOSTIC_TEST|CT/MRI|Standard imaging type for bony tumors
214865448|NCT01675661|DRUG|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
214865449|NCT01675661|DRUG|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
214865450|NCT01151228|OTHER|Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.|Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
214865451|NCT04809883|DIAGNOSTIC_TEST|Endoflip measurement of gastric and pyloric function|Endoflip device to measure gastric and pyloric functions
214865452|NCT03485183|DEVICE|White/Pink Noise|White and/or pink noise will be played from 2200 to 0700 using the PicTek® white noise machine.
214865453|NCT03485183|OTHER|Control Group|Standard of care including lights on during the day and off at night, getting the patient out of bed for meals, presence of a large wall clock in the room, updating the whiteboard with current day, consistent reorientation of patient, geriatrician consults as needed, and pain management.
214865454|NCT02620644|DEVICE|OCT Retinal GCC|measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
214865455|NCT03512860|DRUG|E4/DRSP|Administered as specified in the treatment arm.
214865456|NCT03512860|DRUG|VAL|Administered as specified in the treatment arm.
214865457|NCT02941757|BEHAVIORAL|Mediterranean diet Intervention|"1. Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~2. Peer-education and support~3. Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~4. Email or text message encouragement and reminders during the intervention."
214865458|NCT02890030|BEHAVIORAL|Questionnaire|"* Neurotoxicity~* Medications of interest~* General health~* Family history"
214865459|NCT04765384|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
214865460|NCT03202524|BIOLOGICAL|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.
214865461|NCT03202524|BIOLOGICAL|Albumin|Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care
214865462|NCT02554136|DRUG|HGP0918|
214865463|NCT02554136|DRUG|HGP0816|
214865464|NCT02554136|DRUG|HGP0918 + HGP0816|
214865465|NCT01971970|BIOLOGICAL|Infliximab|Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
214865466|NCT01971970|BIOLOGICAL|Adalimumab|ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
214865467|NCT05107388|DEVICE|FreeStyle Libre Pro|Measurements of interstitial glucose variations with FreeStyle Libre Pro
214865468|NCT06437483|PROCEDURE|Sustained Natural Apophyseal Glides|"SNAGs:~Therapist will apply an antero-superior accessory glide to the superior spinous process of the involved motion segment (between C3 to C7) by pushing it towards the direction of eyeball at approximately a 45 degree angle, using the thumb. The other thumb will reinforce the glide. Painless accessory glide will be maintained and subject will slowly turn their head towards the painful or restricted side (that elicited symptoms) and sustain the position for a few seconds. In case of symptom-free, the subject will apply overpressure at the end of restricted range of motion. The glide will be maintained till the head returns to the midline.~Each session will consist of three sets of six to ten repetitions."
214476490|NCT04817176|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|Experimental Arm: The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
214865469|NCT06437483|PROCEDURE|Kinesiotaping|"Kinesiotaping (KT):~Subject will be in comfortable sitting position. Neck of the subject will be thoroughly cleaned with alcohol and sterile gauze pads before the application of Kinesiotape.The layers of KT will be applied in the form of two strips i.e. Y strip and I strip. and applied over the neck in a position of cervical flexion and contralateral rotation and, pasted up and over either ridge of the spine covering the cervical muscles.It extends from T1-T2 to either side of C1-C2.The second layer is I-strip:The overlaying I-strip will be placed perpendicular to the Y-strip, It will be stretched from the both ends, and the middle portion of the tape will be applied first after which tension is released and ends are applied without tension."
214865470|NCT06437483|PROCEDURE|Conventional Treatment|Hot pack (moist heat) and TENS will be applied, each for 10 minutes.
214865471|NCT03528083|OTHER|Bronchiolitis quality improvement|Patients in the intervention group will undergo a quality improvement process to improve care quality for bronchiolitis at our hospital.
214476491|NCT04817176|OTHER|Ketogenic Nutrition Program|Active Comparator Arm: 6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
214865472|NCT02335983|DRUG|Carfilzomib|Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
214865473|NCT02335983|DRUG|Lenalidomide|Administered orally once daily on days 1-21 of each 28-day cycle.
214865474|NCT02335983|DRUG|Dexamethasone|Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
214865475|NCT01041183|DRUG|intravenous ramosetron|0.3 mg IV ramosetron (group I)
214865476|NCT01041183|DRUG|oral ramosetron|0.1 mg oral ramosetron (group II)
214865477|NCT01041183|DRUG|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
214865478|NCT05134753|BIOLOGICAL|Advanced PRF|Advanced PRF will be placed for patients undergoing sinus augmentation
214865479|NCT05134753|BIOLOGICAL|Control|PRF will be placed for patients undergoing sinus augmentation
214865480|NCT02190474|BEHAVIORAL|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
214865481|NCT02757365|DRUG|aspirin|
214865482|NCT02757365|DRUG|Levofloxacin|
214865483|NCT02069431|DRUG|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
214865484|NCT02069431|OTHER|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
214865485|NCT03043976|DEVICE|Actigraph GT9X Link device|"Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased"
214865486|NCT01819974|OTHER|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
214865487|NCT02437240|BEHAVIORAL|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
214865488|NCT02437240|BEHAVIORAL|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
214865489|NCT02195089|DRUG|BLS_ILS_E710c 500mg|\- 2 capsules per day for 20 days (week 1,2,4 \& 8)
214865490|NCT02195089|DRUG|BLS_ILB_710c 1000mg|\- 4 capsules per day for 20 days (week 1,2,4 \& 8)
214865491|NCT02195089|DRUG|BLS_ILS_E710c 1500mg|\- 6 capsules per day for 8 weeks (week 1,2,4 \& 8)
214865492|NCT06436040|OTHER|Pathological response assessment|The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.
214865493|NCT02928367|OTHER|rectal swab|rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)
214865494|NCT02928367|OTHER|nasopharyngeal swab|nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)
214865495|NCT02928367|OTHER|blood draw|blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
214865496|NCT00655876|DRUG|cetuximab|Weekly with external beam radiation therapy for a total of six doses. The initial dose of cetuximab is 400 mg/m\^2 intravenously administered over 120 minutes on day 1, followed by weekly infusions of 250 mg/m\^2 intravenously over 60 minutes on days 8, 15, 22, 29, and 36. The infusion rate of cetuximab must never exceed 5 mL/min.
214865497|NCT00655876|DRUG|cisplatin|Weekly with external beam radiation therapy for a total of six doses. Patients receive 25 mg/m\^2 as an intravenous infusion over 30-60 minutes on days 1, 8, 15, 22, 29 and 36.
214865498|NCT00655876|DRUG|paclitaxel|Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m\^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.
214865499|NCT00655876|RADIATION|radiation therapy|1.8 Gy daily for 28 days (over 5-6 weeks) for a total dose of 50.4 Gy.
214865500|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
214865501|NCT01831765|DRUG|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
214865502|NCT01831765|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
214865503|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
214865504|NCT00767169|DEVICE|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
214865505|NCT03967496|PROCEDURE|Types of Anesthesia|"General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively."
214865506|NCT03967496|PROCEDURE|Access of Surgery|Type of surgical access
214865507|NCT03967496|OTHER|Comorbidities|A patient may have more than one comorbidity
214865508|NCT03967496|DRUG|Preoperative Medication|Preoperative medications
214865509|NCT03967496|DIAGNOSTIC_TEST|Routine blood test|Preoperative and Intraoperative Investigations
214865510|NCT01267721|PROCEDURE|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
214865511|NCT01570803|DEVICE|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
214865512|NCT01570803|DEVICE|Complete SE Stent|same to SMART CONTROL Stent
214865513|NCT01775852|BEHAVIORAL|ACT-IM|1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
214865514|NCT02118090|DRUG|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
214865515|NCT02118090|DRUG|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
214865516|NCT05084703|OTHER|Functional tests|"* Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~* Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test"
214865517|NCT00977379|RADIATION|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
214865518|NCT00977379|DRUG|Capecitabine|825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
214865519|NCT00977379|DRUG|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
214865520|NCT00556400|DRUG|Lo-Ovral Oral Contraceptive Pills|
214865521|NCT00556400|DRUG|Placebo - sugar pill|
214865522|NCT04317859|BEHAVIORAL|Behavioural Activation|Behavioural Activation (BA) is a therapy previously shown to be effective in depressive disorders. This form of therapy involves modification of activities in order to change perceptions of specific situations, thereby improving mood. The BA treatment program will consist of 18 two-hour visits over 14 weeks (twice weekly group visits for the first 8 weeks, followed by two individual visits over 6 weeks).
215033773|NCT04881084|OTHER|Digital storytelling group|Participants (intervention- group 1) will watch digital stories, short videos describing the experience of recovering from mental illness created as part of this project. Participants in the control group (group 2) will watch social marketing and/or fundraising campaigns on similar topics and complete a few questionnaires. The following standardized scales will be used: The Level of Familiarity Scale (LOF) (which will be used only before exposure to movies); Toronto Empathy Questionnaire (16 items; internal consistency coefficient .79; test-retest reliability coefficient .73), Compassionate Love Scale (21 items; Cronbach's alpha: .95; item-to-total correlations ranging from .46 to .81), Dispositional Positive Emotions Scale (DPES) (5 items; Cronbach's alpha for the compassion subscale: .80; inter-scale correlations: .44), Self-Stigma of Mental Illness Scale-Short Form (SSMIS-SF) (20 items; Cronbach's alpha: 0.91); Difference and Disdain Scales for Public Stigma (DDSPS) (9 items).
214476492|NCT06657248|DEVICE|univation® XF Pro|Primary medial unicompartmental knee arthroplasty
214865523|NCT06452875|PROCEDURE|Primary Needle Knike Fistulotomy|"After verifying the eligibility of the papillary morphology (excluding flat or diverticular papillae according to Viana's classification), access to the bile duct will be initiated using the primary needle knife fistulotomy technique. After the first contact of the needle knife with the papilla, the endoscopist will have a total of 8 minutes, after which he can change to other cannulation techniques (eg standard cannulation methods through the papillary orifice) or even stop the procedure.~During ERCP all patients will be submitted to PEP prophylaxis with indomethacin. Also as a prophylactic PEP measure a pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct. For the purpose of this study, a dedicated form (attached) will be created with the various variables to be analyzed."
214865524|NCT05136300|BEHAVIORAL|Pulmonary rehabilitation|"Patients in the intervention group will receive physical therapy, scheduled pain monitoring and coaching by a social worker.~The intensity of the rehabilitation training program will be determined separately for each patient by a steepramp and 1-repetition test within 3 weeks post-operative. The intervention group will be trained and educated in 2 sessions of 2 hours per week, for a period of 3 months."
214865525|NCT03462849|OTHER|increase in positive end expiratory pressure|increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O
214865526|NCT04173832|DRUG|Tianqi Pingchan Granule Combined With Amantadine|Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
214865527|NCT04173832|DRUG|Placebo Combined With Amantadine|Placebo and Amantadine are given to patients simultaneously
214865528|NCT02826837|DRUG|LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab|"The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
214865529|NCT01987037|BEHAVIORAL|neuropsychomotor assessment|Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
214865530|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 6 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
214865531|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 8 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
214865532|NCT01633411|DEVICE|CryoBalloon Focal Ablation System - 10 seconds|"Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
214865533|NCT00706511|DEVICE|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
214865534|NCT02605993|BIOLOGICAL|Ravulizumab|All treatments were given as IV infusions.
214865535|NCT01454271|PROCEDURE|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
214865536|NCT02603393|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
214865537|NCT02603393|DRUG|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
214865538|NCT02603393|DRUG|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
214865539|NCT00927693|OTHER|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
214865540|NCT05872893|DRUG|Ondansetron|Patients will receive age-adjusted doses of ondansetron 5mg/m2
214865541|NCT05872893|DRUG|Dexamethasone|Patients will receive dexamethasone 4mg/m2
214865542|NCT00077545|DRUG|triapine|Given IV
214865543|NCT00077545|DRUG|cisplatin|Given IV
214865544|NCT04509882|DRUG|bear bile pill|Bear bile pill (15 pills) taken orally three times a day after meals with water.
214865545|NCT04509882|DRUG|placebo|Placebo(15 pills) taken orally three times a day after meals with water.
214865546|NCT00440960|DRUG|propofol|
214865547|NCT00440960|DRUG|midazolam|
214865548|NCT00440960|DRUG|alfentanil|
214476493|NCT05100706|DRUG|Continuous adductor canal block (CACB)|Ropivacaine 0.2% infusion through adductor canal catheter
214669996|NCT05126615|DRUG|Auriculotherapy|Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
214865549|NCT00440960|DRUG|lidocaine|
214865550|NCT01041066|DRUG|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
214865551|NCT01041066|DRUG|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
214865552|NCT00468260|DRUG|Patupilone|
214865553|NCT02711735|BIOLOGICAL|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
214865554|NCT02711735|BIOLOGICAL|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
214865555|NCT02080013|OTHER|radiofrequency|ClosureFAST
214865556|NCT04234932|DRUG|Netarsudil Ophthalmic|Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
214865557|NCT00668161|BEHAVIORAL|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
214865558|NCT01342107|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.
214865559|NCT01342107|DEVICE|Soft contact lens|Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
214865560|NCT01342107|DEVICE|Blister pack solution|Commercially approved storage solution as found in the contact lens blister pack.
214865561|NCT05515692|PROCEDURE|Biospecimen Collection|Correlative studies
214865562|NCT05515692|PROCEDURE|Computed Tomography|Undergo radiotherapy simulation using CT
214865563|NCT05515692|COMBINATION_PRODUCT|Electron Beam Therapy|Undergo electron beam radiotherapy
214865564|NCT05515692|PROCEDURE|High Frequency Ultrasound Imaging|Undergo HFUS
214865565|NCT05515692|OTHER|Questionnaire Administration|Ancillary studies
214865566|NCT05515692|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo radiotherapy simulation using clinical setup
214865567|NCT05515692|PROCEDURE|Skin Biopsy|Undergo biopsy
214865568|NCT06213935|DRUG|Norepinephrine|after spinal anesthesia, norepinephrine will be injected intravenous as bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min to prevent post spinal hypotension
214865569|NCT06213935|DRUG|Midodrine|10 mg tablets of midodrine 1 hour before spinal anesthesia to prevent post spinal anesthesia hypotension
214865570|NCT05979649|BEHAVIORAL|behavioral corrective tasks|"After each personalized conversation, the interveners will, based on a clear understanding of the participants' completion status and personal experiences with the previous behavioral corrective tasks, assist in formulating future behavioral corrective tasks for the next two weeks. These tasks will be selected from our designated To Do List, requiring at least one task from each category: social support, coping strategies, and emotional intelligence."
214865571|NCT05979649|OTHER|Counselling on psychological knowledge|Counselling on psychological knowledge includes weekly personalized feeds, as well as the methods and techniques for coping with challenges provided by the interveners.during personalized conversations with the participants.
214865572|NCT05979649|OTHER|placebo-controlled study|"feel-good articles without professional psychological knowledge will be sent to the control group participants weekly."
214865573|NCT05979649|OTHER|Peer Interventionist Training|The training is a one-day course, encompassing a broad range of topics, including but not limited to counseling techniques and specialized medical psychology knowledge.
214865574|NCT02376543|DEVICE|19 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
214865575|NCT02376543|DEVICE|22 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
214865576|NCT01454908|DEVICE|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
214865577|NCT04889287|DRUG|Elinzanetant (BAY3427080)|Once daily over 12 days
214865578|NCT04889287|DRUG|Rosuvastatin|Single doses on Day 1, Day 8, and Day 13
214865579|NCT00759187|DRUG|Fluoride|Brush twice daily
214865580|NCT00759187|DRUG|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
214865581|NCT00759187|DRUG|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
214865582|NCT01568970|BEHAVIORAL|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
214865583|NCT01568970|BEHAVIORAL|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
214865584|NCT02674906|DRUG|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
214865585|NCT02674906|DRUG|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
214865586|NCT02808156|OTHER|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
214865587|NCT02808156|OTHER|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
214865588|NCT05982288|OTHER|Virtual Reality Software|Training of intensive care nurses with virtual reality software
214865589|NCT00317707|DRUG|N-3 Polyunsaturated Fatty Acids|Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
214865590|NCT00317707|DRUG|Placebo: Olive oil|Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
214865591|NCT03454178|DIAGNOSTIC_TEST|WatchBP Office (BP measurement machine)|BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
214865592|NCT04975009|BEHAVIORAL|Fear conditioning|Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
214865593|NCT01996683|DRUG|desferal, ferriprox, blood transfusion|"Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation"
215033774|NCT04881084|OTHER|Social marketing/fundraising group|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
215033775|NCT00000884|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
214865594|NCT01470911|DRUG|SB010|"Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL."
214865595|NCT01470911|DRUG|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
214865596|NCT05545371|BIOLOGICAL|immunization procedures|The subjects were vaccinated with rabies vaccine according to different immunization procedures
214865597|NCT03122197|DRUG|Letrozole Oral Tablet|Administration: Letrozole will be given orally once daily.
214865598|NCT03122197|DRUG|Temozolomide|50 mg/m2 TMZ administered orally once daily
214865599|NCT04620928|BEHAVIORAL|Concepts|Images and sounds that are characteristic of various common objects.
214865600|NCT06158022|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214865601|NCT06158022|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
214865602|NCT04273841|DIETARY_SUPPLEMENT|Military Energy Gum|Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
214865603|NCT04273841|DIETARY_SUPPLEMENT|Placebo Gum|Pellet form placebo gum
214865604|NCT01974440|DRUG|Bendamustine|90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
214865605|NCT01974440|DRUG|Rituximab|375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
214865606|NCT01974440|DRUG|Cyclophosphamide|750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
214865607|NCT01974440|DRUG|Doxorubicin|50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
214865608|NCT01974440|DRUG|Vincristine|1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
214865609|NCT01974440|DRUG|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
214865610|NCT01974440|DRUG|PCI-32765 (Ibrutinib)|560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
214865611|NCT01974440|DRUG|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
214865612|NCT00762437|DEVICE|Zeltiq Dermal Cooling Device|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214865613|NCT06260332|BEHAVIORAL|Supportive Care (Fitbit)|Wear Fitbit, Use Fitbit application, Receive educational materials, attend coaching calls, Ancillary studies
214865614|NCT06337097|DIAGNOSTIC_TEST|Troponin surveillance|Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.
214865615|NCT06337097|OTHER|Standard of care|Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.
214865616|NCT05301153|DIAGNOSTIC_TEST|real time PCR , ELISA|Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39. Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA
214865617|NCT02387983|DRUG|Posaconazole|Posaconazole 300 mg solid oral tablet
214865618|NCT05403255|OTHER|evaluation of the quality of life with questionnaires|"Questionnaire data will be collected among patients and their parents during follow-up consultations.~Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France."
214865619|NCT05817929|OTHER|blood sample|5 ml blood sample will be withdrawn at the surgery start and at the surgery end
214865620|NCT03569228|DEVICE|Study 1 - ITE hearing aids|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
214865621|NCT03569228|DEVICE|Study 1 - BTE hearing aids|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
215033776|NCT00000884|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
215033777|NCT00000884|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
215033778|NCT03610698|BEHAVIORAL|LEAF Positive Emotion Intervention|5-week online intervention teaching 8 positive emotions skills for caregivers
215033779|NCT03610698|OTHER|Emotion Reporting Control Condition|Daily reporting of emotions for participants assigned to the control condition.
214865622|NCT03569228|DEVICE|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
214865623|NCT03569228|DEVICE|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
214865624|NCT03569228|DEVICE|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
214865625|NCT03569228|DEVICE|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
214865626|NCT06354998|BIOLOGICAL|Investigational mRNA-1273.815|Sterile solution for injection
214865627|NCT06354998|BIOLOGICAL|Licensed Spikevax Vaccine|Commercially available formulation
214865628|NCT02974647|DRUG|Ruxolitinib|
214865629|NCT03690882|OTHER|systematic review of medical imaging|
214865630|NCT05372783|DRUG|STI-9199|STI-9199 is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
214865631|NCT05372783|DRUG|Placebo|Diluent solution
214865632|NCT05682846|DRUG|Sodium glycerophosphate pentahydrate solution|Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
214865633|NCT04636242|PROCEDURE|Skin Biopsy|A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
214865634|NCT04636242|DRUG|5 Aminolevulinic Acid + Phototherapy|5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
214865635|NCT05380076|OTHER|Mindfulness meditation|6 minutes of watching a video tape made for the study that inspire mindfulness like meditation just before entering the examination circuit.
214865636|NCT05380076|OTHER|Mobilization of inner resources|6 minutes of watching a video tape made for the study that provide psychological stimulation just before entering the examination circuit
214865637|NCT05380076|OTHER|Biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.
214865638|NCT01555008|DRUG|LX4211|Subjects will receive LX4211 once daily for 7 days
214865639|NCT01555008|DRUG|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
214865640|NCT03227614|BEHAVIORAL|Support Person Intervention|The patient participant will have a support person of her choice accompany her during her abortion procedure.
214865641|NCT01551225|DRUG|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
214865642|NCT03107143|DEVICE|Q2 System|
214865643|NCT02684708|DRUG|cyclophosphamide, vincristine, prednisone, dacarbazine|28-day chemotherapy cycle
214865644|NCT02684708|DRUG|cyclo, vcr, pred, dacarb,etop and doxo|21-day chemotherapy cycle
215033780|NCT05713266|DEVICE|MouthLabTM|Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple clinically meaningful parameters such as temperature, blood pressure, heart rate, heart rate variability, pulse rate, SpO2, single-lead ECG, respiratory rate, breathing pattern, and basic lung functions in 60 seconds.
215033781|NCT01720550|DRUG|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
214476494|NCT05100706|DRUG|Sham continuous adductor canal block (ShACB).|NaCl 0.9% infusion through adductor canal catheter
214669997|NCT05126615|BEHAVIORAL|Chronic Post-Surgical Pain evaluation|"Different questionnaires :~BPI : Brief Pain Inventory DN4"
214865645|NCT02735850|DRUG|L19-IL2|L19-IL2 added to SBRT
214865646|NCT02735850|RADIATION|SBRT|
214865647|NCT02735850|OTHER|No intervention|
214865648|NCT00589030|RADIATION|brachytherapy|The target dose of TheraSphere® is 80-150Gy
214865649|NCT00589030|RADIATION|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
214865650|NCT02390141|DRUG|ZP4207|
214865651|NCT02390141|DRUG|Placebo|
214865652|NCT03724526|BEHAVIORAL|Text messaging|"Intervention-Text messaging: Participants will receive regular text messages for 12 months. Each participant will receive 6 text messages per week. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week.~Control: The control group will receive the usual care."
214865653|NCT04752046|PROCEDURE|maxillary cancer resection|patient with maxillary cancer will resected and reconstructed
214865654|NCT00944268|DRUG|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
214865655|NCT02440568|DRUG|Cytarabine|Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
214865656|NCT02440568|DRUG|Idarubicin|Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
214865657|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 0.625mg/m\^2
214865658|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 1.25mg/m\^2
214865659|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 2.0mg/m\^2
214865660|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 3.0mg/m\^2
214865661|NCT01948986|DRUG|Ertugliflozin|Single oral administration of 3 X 5 mg tablets.
215033782|NCT01720550|DRUG|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
214865662|NCT05335733|DIAGNOSTIC_TEST|Intraoral examination, saliva, dental plaque and serum collection.|"Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit."
214865663|NCT02833701|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
214865664|NCT02833701|BIOLOGICAL|Bevacizumab|Given intravenously (IV)
214865665|NCT02833701|OTHER|Laboratory Biomarker Analysis|Correlative studies
214865666|NCT02833701|OTHER|Quality-of-Life Assessment|Ancillary studies
214865667|NCT04659252|OTHER|n/a - samples collected along routine care samples only|This is a non-interventional study.
214865668|NCT00569621|DRUG|Moxaverine|intravenous administration
214865669|NCT00569621|DRUG|physiological saline|intravenous administration
214865670|NCT02553902|DEVICE|Sleep position trainer|
214865671|NCT02553902|DEVICE|Mandibular advancement device|
214865672|NCT02553902|DEVICE|Continuous positive airway pressure|
214865673|NCT05656521|DRUG|101-PGC-005|'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
214865674|NCT05656521|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
214865675|NCT03907384|BEHAVIORAL|Mat Pilates training|This group completed 12-weeks of training
214865676|NCT04263402|DRUG|Methylprednisolone|Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(\<40mg/d intravenous drip for 7 days).
214865677|NCT04263402|DRUG|Methylprednisolone|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40\~80mg/d intravenous drip for 7 days).
214865678|NCT02550730|BEHAVIORAL|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
214865679|NCT02550730|OTHER|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
214865680|NCT00548171|BIOLOGICAL|Boostrix™|Intramuscular injection, 1 dose
214865681|NCT02548611|DRUG|Prasugrel|see arm description
214865682|NCT02548611|DRUG|Clopidogrel|see arm description
214865683|NCT03446911|RADIATION|SABR|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy.
214865684|NCT03446911|COMBINATION_PRODUCT|SABR + pembrolizumab|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy + 2 rounds of pembrolizumab
214865685|NCT01216852|DRUG|Losartan Potassium|100 mg tablet
214865686|NCT01103466|DEVICE|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
214865687|NCT01103466|DEVICE|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
214865688|NCT01103466|DEVICE|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
214865689|NCT03966248|OTHER|Chinese Tuina therapy|"1. The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~2. The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~3. Massage the spleen and stomach meridians of the affected lower extremes;~4. Roll the soft tissues around the affected knee;~5. Relax the gastrocnalis muscle~6. The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~7. Push the patella and do the passive movement of the affected knee;~8. Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
214865690|NCT03966248|OTHER|Physical Manual therapy|"1. Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~2. Activity training: Mainly about the knee joint flexion and extension movement training.~3. Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
214865691|NCT01019928|DRUG|AZD1386|95 mg, oral solution, single dose
214865692|NCT01019928|DRUG|Placebo to AZD1386|Placebo, oral solution, single dose
214865693|NCT02331368|PROCEDURE|Autologous Stem Cell Transplant|
215033783|NCT04205786|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12, orally, 2500 mcg, daily, for 90 days
214669998|NCT04837404|PROCEDURE|Ultrasound guided femoral access for complex PCI|Ultrasound guided femoral access for complex PCI
214669999|NCT04837404|PROCEDURE|Fluoroscopy guided femoral access for complex PCI|Fluoroscopy guided femoral access for complex PCI
214865694|NCT02331368|DRUG|Melphalan|140-200 mg/m\^2
214865695|NCT02331368|DRUG|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
214865696|NCT02331368|DRUG|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
214865697|NCT04300010|DRUG|5% Topical Benzoyl Peroxide Gel|Gel treatment used to treat acne
214865698|NCT04300010|DEVICE|Blue Light Therapy|Blue light therapy treatment for acne
214865699|NCT02838810|DRUG|peginterferon alfa|peginterferon alfa-2b or peginterferon alfa-2a
214865700|NCT02838810|DRUG|Nucleoside analogues|Nucleoside analogues
214865701|NCT06967714|BEHAVIORAL|Exercise|25 min cycling exercise at 75% of hear rate reserve. Physical use of one upper-limb will be restricted with a sling.
214865702|NCT05873010|DIAGNOSTIC_TEST|Manual Compression and Stretching|Manual Compression and Stretching for The Myofascial Trigger Points
214865703|NCT03073785|DRUG|Capecitabine|Given by mouth (PO)
214865704|NCT03073785|DRUG|Fluorouracil|Given Intravenously (IV)
214865705|NCT03073785|OTHER|Laboratory Biomarker Analysis|Correlative studies
214865706|NCT03073785|OTHER|Pharmacological Study|Correlative studies
214865707|NCT03073785|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
214865708|NCT03073785|DRUG|Zoledronic Acid|Given IV
214865709|NCT03670264|BEHAVIORAL|Quitline Incentive|The incentive structure emphasizes engaging with the quitline, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the quitline, for maintaining involvement in the quitline program (compensation per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
214865710|NCT03670264|BEHAVIORAL|Tobacco Cessation Incentive|The incentive payment structure emphasizes quitting regardless of engagement with the quitline (though the quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
214865711|NCT03670264|BEHAVIORAL|Way to Health (WTH) Platform|The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
214865712|NCT03670264|BEHAVIORAL|Quitline Delivered Treatment|The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
214865713|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
214865714|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
214865715|NCT01401621|BEHAVIORAL|Control|No scratch-off element
214865716|NCT02214784|DEVICE|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
214865717|NCT02214784|DEVICE|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
214865718|NCT02352545|DRUG|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
214865719|NCT05240170|DEVICE|RIRS|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
214865720|NCT05240170|DEVICE|SWL|Patients who underwent SWL at our institution in the past five years. According to (a) the type of renal anomaly (rotation, position, or rotation/position anomaly), (b) the size of the stone (±5 mm), (c) location of the stone (lower polar or non-lower polar), and (d) density of the stone (\>800 HU or ≤800 HU), matched cases will be selected for comparison.
214865721|NCT05051202|OTHER|Sugars from Fiber|Proprietary blend of Sugars from Fiber baked into 50 g flapjack
214476495|NCT06586320|DRUG|150% of their routine home dopaminergic medications dose right in the clinic|IPD subjects will be informed head of time not to take their dopaminergic medications and other Parkinson's non-dopaminergic medications such as anticholinergics, NMDA inhibitors, and adenosine blockers for at least 12 hours prior to their initial procedure. Immediately, after conducting both hand movement and eye movement tests, the patient will take 150% of their routine home dopaminergic medications dose right in the clinic. They will also take their non-dopaminergic medications doses similar to home dose with no change. This will be under the supervision of their treating movement disorders specialist and study PI.
214865722|NCT05051202|OTHER|Resistant Maltodextrin|Resistant Maltodextrin baked into 50 g flapjack
214865723|NCT04016441|OTHER|Survey|Participants will complete a survey online
214865724|NCT02302859|DRUG|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
214865725|NCT02302859|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
214865726|NCT02302859|OTHER|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
214865727|NCT02302859|BEHAVIORAL|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time."
214865728|NCT02302859|OTHER|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
214865729|NCT02302859|DEVICE|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
214865730|NCT03003949|DRUG|Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release|Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
214865731|NCT03003949|DRUG|Placebo Patch|Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
214865732|NCT03003949|DRUG|Progesterone Capsule|Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week
214865733|NCT03003949|DRUG|Placebo Oral Capsule|Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.
214865734|NCT00397059|DRUG|Escitalopram|
214865735|NCT05476952|PROCEDURE|"he patients who are administered rocuronium according to LBW were categorized as LBW, and The group number for those administer according to TBW was categorized as K."|Patients will be divided equally and validly by the one who will be placed in opaque sealed envelopes on a self-paid basis. One group will be given 0.6 mg/kg rocuronium on an LBW basis (Curon ® 50 mg/5 mL \[Mustafa Nevzat, Istanbul, Turkey\]), and the other group will be given 0.6 mg/kg rocuronium on a TBW basis.
214865736|NCT05813314|COMBINATION_PRODUCT|BMN 111 administration via Injector Pen|BMN 111 Injection will be given using an injector pen
214865737|NCT05813314|DRUG|BMN 111 administration via vial and syringe|BMN 111 Injection will be given using vial and syringe
214865738|NCT05735041|BEHAVIORAL|Multi-domain cognitive digital therapy|Patients in the cognitive digital therapy group received multi-dimensional targeted cognitive function training electronically, involving attention, memory, executive function, thinking, processing speed and perception. The system will adjust the training difficulty and training plan adaptively according to the patient's current training time and performance, and train the patient's weak cognitive ability as far as possible. The patients had the same total amount of training each day.
214865739|NCT05735041|BEHAVIORAL|Basic cognitive therapy|The training content of the positive control group was cognitive training tasks with weak difficulty or no difficulty change. The patients underwent cognitive function training with fixed programs, including 15 training items, and the internal difficulty of the training items remained constant without change. The system presents the training content randomly according to the training scheme. The patients had the same total amount of training each day.
214865740|NCT06148168|DRUG|Bupivacaine plus normal saline|"Unlike specific peripheral nerve blocks, TAP block is a non-dermatomal field block. Even with the same US-guided technique, the extent of spread of local anesthetics can be variable due to individual anatomical variations (18). In order to perform the blocks, abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest .Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
214865741|NCT06148168|DRUG|Bupivacaine plus normal saline containing MgSO4|Bupivacaine plus normal saline containing MgSO4
214865742|NCT04671186|DIETARY_SUPPLEMENT|Culturelle (Lactobacillus rhamnosus strain GG)|Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily
214865743|NCT04671186|OTHER|Placebo|Placebo group will take 1 capsule of placebo orally once daily
214865744|NCT04376762|DRUG|Fibrinogen|Fibrinogen Concentrate (Human) Injection \[Fibryga\] (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
214865745|NCT04376762|DRUG|Cryoprecipitate|Cryoprecipitate group (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
214865746|NCT00300508|DRUG|Anastrozole|
214865747|NCT04555850|DRUG|Recombinant Human Thymosin β4|Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
214865748|NCT04555850|OTHER|Placebo|3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
214865749|NCT01798355|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
214865750|NCT01798355|BEHAVIORAL|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
214865751|NCT04713150|OTHER|No Intervention|No Intervention
214865752|NCT06008743|BEHAVIORAL|Belt Accelerations|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control. The speed of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg.
214865753|NCT06008743|BEHAVIORAL|Belt accelerations combined with an exoskeleton|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control, and using a hip exoskeleton. The velocity of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg. At the same time, they will be interacting with a wearable motion assistive device (i.e., exoskeleton). The exoskeleton will apply forces to the leg to resist hip extension during accelerations, reducing hip extension relative to the values of that participant at baseline.
214865754|NCT06008743|BEHAVIORAL|Variable Stiffness treadmill|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with identical speed control. A variable stiffness mechanism under one belt will change the vertical stiffness of one side of the treadmill for one or multiple steps. The walkers will be informed before stepping on the softer surface on one side, which can be either the left or the right side.
214865755|NCT03021109|DEVICE|Measurement of inferior vena cava diameters with ultrasound|The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
215033784|NCT04205786|OTHER|Blood collection|"Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~1. Serum B12 levels~2. CRP~3. Homocysteine level~4. MMA"
214865756|NCT05437926|DEVICE|Arrhythmia Analysis Software (software) which runs on a mobile application (Huawei Phone) and uses input from a wearable device (smart watch or smart band).|Subjects with or without cardiac arrhythmias and of light skin tone (melanin index \<150) or dark skin tone (melanin index \>350). Subjects will be divided based on their heart rhythm in three groups: approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
214865757|NCT03415061|DRUG|Regular Insulin, Human 100 UNT/ML|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
214865758|NCT03415061|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
214865759|NCT04948164|DRUG|sumatriptan 85mg and naproxen sodium 500mg|Subjects took 1 tablet of the study drug (each containing sumatriptan 85mg and naproxen sodium 500mg) within 1h of an acute migraine attack of mild severity, and if the headache progressed to moderate severity within 2 hours, they could take the remedial drug phenol chai (each containing acetaminophen 500mg and caffeine 65mg).
214865760|NCT04948164|DRUG|Placebo|"subjects were given one tablet of placebo within 1 h of an acute migraine attack with mild severity, and if the headache progressed to moderate severity within 2 hours, they were given the remedial drug phenol chai (each tablet contains acetaminophen 500 mg and caffeine 65 mg)."
214865761|NCT03285308|DRUG|Placebo|Placebo injected subcutaneously twice daily.
214865762|NCT03285308|DRUG|Relamorelin|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily.
214865763|NCT04301908|DRUG|interferon|Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
214865764|NCT02283983|OTHER|mittens and booties|
214865765|NCT02283983|OTHER|cooling helmet|
214865766|NCT05802732|DIAGNOSTIC_TEST|Stool Antigen test|Correlation between the result of endoscopic biopsy and stool antigen test
214865767|NCT04796753|OTHER|Basketball Injury Defense|To establish a specific evaluation protocol for youth basketball players.
214865768|NCT01470495|OTHER|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
214865769|NCT01470495|OTHER|RFA|treat Recurrent HCC with RFA
214865770|NCT00735605|OTHER|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
214865771|NCT00735605|PROCEDURE|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
214865772|NCT00735605|OTHER|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
214865773|NCT02654860|DRUG|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
214865774|NCT02654860|DRUG|Placebo injection containing Saline solution 0.9%|Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
214865775|NCT02654860|DRUG|Hyperbaric Bupivacaine HCl 0.5%|NIMP, spinal anaesthetic before the surgical procedure
214865776|NCT02191631|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
214865777|NCT04530708|RADIATION|Thoracic radiotherapy|36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
214865778|NCT01169428|BEHAVIORAL|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
214865779|NCT01169428|BEHAVIORAL|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors \[e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information \& education\]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
214865780|NCT04012151|OTHER|Physical measurement|Parturients of gestational week \>= 32 weeks will have their arms and fingers measured to generate the conicity index.
214865781|NCT04012151|OTHER|Cuff size fitting|Fit on arm cuff and finger cuff as selected by investigators based on the measurement.
214865782|NCT00168311|DEVICE|Transcranial Magnetic Stimulation|Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.
214865783|NCT00168311|DEVICE|sham TMS|
214865784|NCT02353052|OTHER|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
215033785|NCT04205786|OTHER|Brief Pain Inventory - Short Form survey|Brief Pain Inventory - Short Form survey
214865785|NCT04760392|BEHAVIORAL|Goal-directed mobilization|"* A short educational intervention with handout of a leaflet on GDM.~* Definition of personal mobility goal level.~* Communication of the mobility goal level to involved stakeholders.~* Regular reassessment of the mobility goal level and booster sessions by physiotherapists."
214865786|NCT04076488|OTHER|Dividat Fit|tablet based, remote assisted home-training
214865787|NCT04784910|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
214865788|NCT04784910|DRUG|Lansoprazole 15 mg|Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks
214865789|NCT04784910|DRUG|DWP14012 20mg placebo|DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
214865790|NCT04784910|DRUG|Lansoprazole 15 mg placebo|Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks
214865791|NCT00004450|DRUG|glyceryl trierucate|
214865792|NCT00004450|DRUG|glyceryl trioleate|
214865793|NCT00004450|DRUG|interferon beta|
214865794|NCT00004450|DRUG|thalidomide|
214865795|NCT02158312|DEVICE|Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)|2 mA for 20 minutes transcranial direct current stimulation
214865796|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
214865797|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
214865798|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
214865799|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
214865800|NCT04405895|OTHER|Breakfast Diet|Breakfast Diet (3Mdiet) consist on high-energy breakfast and reduced in energy and carbohydrate (CH) dinner. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 3Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 3Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
214865801|NCT04405895|OTHER|Allday Diet|Allday Diet (6Mdiet) consist in 6 small meals: breakfast, lunch and dinner and 3 snacks, with calories and carbohydrates (CH) evenly distributed throughout the day. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 6Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 6Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
214865802|NCT03452332|BIOLOGICAL|Durvalumab|Given IV
214865803|NCT03452332|OTHER|Laboratory Biomarker Analysis|Correlative studies
214865804|NCT03452332|RADIATION|Stereotactic Radiosurgery|Undergo SABR
214865805|NCT03452332|BIOLOGICAL|Tremelimumab|Given IV
214865806|NCT02027675|OTHER|High fat poor micronutrient meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
214865807|NCT02027675|OTHER|Mediterranean meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
214865808|NCT04857463|OTHER|Nutritional supplement drink|At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.
214865809|NCT04857463|OTHER|Nutritional education|At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
214865810|NCT01718548|DIETARY_SUPPLEMENT|Cordyceps Sinensis (CS) and Lingzhi|
214865811|NCT01718548|DIETARY_SUPPLEMENT|Tea and Flour|Placebo
214865812|NCT02468752|DRUG|Oxygen|
214865813|NCT02468752|OTHER|Air|
214865814|NCT00920894|DIETARY_SUPPLEMENT|plant stanol ester|the effect of plant stanol esters on plasma lipids
214865815|NCT05291832|OTHER|Brain.fm Music|Experimental arm
214865816|NCT05291832|OTHER|Spectrally-matched Noise|Active control arm
214865817|NCT06214533|DRUG|Ropivacaine 0.5%|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.
214865818|NCT06214533|DRUG|Normal Saline|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.
215033786|NCT04205786|OTHER|FACT-ES Trial Outcome Index (Version 4)|FACT-ES Trial Outcome Index (Version 4)
214290724|NCT06406985|BEHAVIORAL|Weight-loss through dietary and lifestyle changes|Weight-loss participants will complete one online, self-paced education session each week for 12 weeks. Education sessions focus on topics such as self-monitoring weight, meal routines, and dietary habits with an emphasis on protein and fiber intake. During these 12 weeks, participants will receive weekly messages from nutrition coaches as well as a monthly nutrition coaching call. After the first 12 weeks, participants will enter a follow-up period where nutrition coaching messaging will occur as needed and with the opportunity to still participate in a monthly nutrition coaching call. Participants are asked to weigh daily on a provided WiFi scale that automatically uploads their weight data to a website for researchers and coaches to monitor. Participants will also submit food records and self-reported weight and hip circumferences.
214865819|NCT01095042|BEHAVIORAL|emotion|Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
214865820|NCT04950959|DEVICE|Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T|The system is used for trajectory planning and is intended to assist the physician in the positioning of an instrument, such as a needle, where CT imaging is used for target trajectory planning and intraoperative tracking. The XACT ACE Robotic System uses a computerized quantitative guidance system, which provides real-time, accurate needle guidance, including advancement and steering of the needle from the entry point on the subject's body to the target point within the body.
214865821|NCT06139393|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.
214865822|NCT06139393|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
214865823|NCT05701644|DRUG|C1K 150mg|Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
214865824|NCT05701644|DRUG|C1K 300mg|Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
214865825|NCT05701644|DRUG|Placebo with the same volume of C1K 300mg|Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15
214865826|NCT05701644|DRUG|C1K 600mg|Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
214865827|NCT05701644|DRUG|Placebo with the same volume of C1K 600mg|Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15
214865828|NCT05701644|DRUG|C1K 900mg|Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
214865829|NCT05701644|DRUG|Placebo with the same volume of C1K 900mg|Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15
214865830|NCT05701644|DRUG|C1K 1200mg|Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
214865831|NCT05701644|DRUG|Placebo with the same volume of C1K 1200mg|Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
214865832|NCT02540759|DIETARY_SUPPLEMENT|Buglossoides oil|
214865833|NCT02540759|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|
214865834|NCT03092063|BEHAVIORAL|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
214865835|NCT03092063|BEHAVIORAL|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
214865836|NCT03092063|BEHAVIORAL|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
214865837|NCT03092063|BEHAVIORAL|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
214290725|NCT02677467|BIOLOGICAL|Blood-pressure variability|Day to Night Blood pressure variability
214865838|NCT05114382|PROCEDURE|EP Procedure|Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
214865839|NCT00001026|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
214865840|NCT00001026|BIOLOGICAL|rgp120/HIV-1IIIB|
214865841|NCT00001026|BIOLOGICAL|rgp120/HIV-1MN|
214865842|NCT00001026|BIOLOGICAL|rgp120/HIV-1 SF-2|
214865843|NCT00001026|BIOLOGICAL|HIVAC-1e|
214290726|NCT01412359|DRUG|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
214290727|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
214290728|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
214290729|NCT01782495|DRUG|ribavirin|tablet
214290730|NCT00229060|DRUG|doripenem|
214290731|NCT01584102|BEHAVIORAL|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
214290732|NCT01584102|BEHAVIORAL|group fitness classes only|15 weeks biweekly group fitness
214290733|NCT01995032|DRUG|750 mg metformin and 7.5 g L-citrulline daily p.o.|
214865844|NCT02991170|PROCEDURE|unipolar or bipolar radiofrequency ablation+CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
214865845|NCT02991170|PROCEDURE|CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
214670000|NCT03863444|OTHER|Prenatal Preparation Education|Intervention, provided by researchers, includes video, counseling, and skill practices. Video contains (1) Newborn Reaction, including rooting reflex, correct latch-on posture, assuring newborn having enough milk intakes; (2) Newborn Care, including holding, dipper-changing, clothes-changing, and swaddle the newborn; and (3) Partner Support, including the importance of partner support and the content how partner provide support to the postpartum women. After watching the video, the researcher will provide participants counseling, and then each pair of participants will have skill practice.
214865846|NCT00242736|DRUG|Esomeprazole|
214865847|NCT04173299|PROCEDURE|early tips|patients with early tips
214865848|NCT02459548|OTHER|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
214865849|NCT02459548|OTHER|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
214865850|NCT00671138|BIOLOGICAL|Necator americanus|10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12
214865851|NCT00671138|OTHER|Sham inoculation|A diluted amount of McIlhenny \& Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
214865852|NCT00424775|DRUG|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
214865853|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|400 IU daily (low dose)
214865854|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|2000 IU daily (high dose)
214865855|NCT04775420|DIAGNOSTIC_TEST|Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)|MPV and NLR are easily accessible and inexpensive tests
214865856|NCT01898650|OTHER|MR scan|
214865857|NCT04416620|OTHER|The PCOS pharmaceutical care service|"The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects."
214865858|NCT04339920|DIAGNOSTIC_TEST|Spermine Measuring Device|The Spermine Measuring Device (SMD) is a simple device, with automatic urine aspiration and also spermine level assessment. First about 30 cc urine will be freshly collected by a prepared collection device. Then the cap of the SMD will be removed and the aspiration tip of the device will be immersed into the urine specimen. After firmly pressed on the device, a small sample of urine will be aspirated into the SMD. The device will then automatically assess the urine spermine level. The result will then be read at a indicator window after about 5 minutes. If the level was below a pre-set cutoff, i.e. suggestive of having increase risk of prostate cancer, the indicator window will turn into red colour. However, if the spermine level is higher than the cutoff value, i.e. low risk of having cancer, the indicator window will turn blue.
214865859|NCT01791153|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
214865860|NCT01791153|DRUG|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
214865861|NCT01791153|DRUG|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
214865862|NCT01791153|DRUG|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
214865863|NCT01791153|DRUG|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
214865864|NCT01791153|DRUG|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
215033787|NCT04205786|OTHER|Questionnaire to Assess Adherence to Aromatase Inhibitors|Questionnaire to Assess Adherence to Aromatase Inhibitors
215033788|NCT04205786|OTHER|Demographics Questionnaire|Demographics Questionnaire
214290734|NCT01995032|DRUG|Placebo|
214290735|NCT00071513|BEHAVIORAL|CAST-T/HSTS|Skills training small group.
214865867|NCT01483859|OTHER|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
214865868|NCT02876926|BEHAVIORAL|"Smart home-based test for HIV"|A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.
214865869|NCT02876926|BEHAVIORAL|Home-based testing only|A standard home-based HIV test kit.
214865870|NCT02876926|BEHAVIORAL|Reminder letters for clinic-based testing|Letters reminding patients to get tested at a free clinic location
214865871|NCT04557306|BIOLOGICAL|CBT101 cells, every 2 weeks|CBT101 cells, every 4 weeks
214865872|NCT04557306|BIOLOGICAL|CBT101 cells, every 4 weeks|CBT101 cells, every 4 weeks
214865873|NCT00975286|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214865874|NCT00975286|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214865875|NCT00975286|DRUG|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
214865876|NCT00975286|DEVICE|Pen auto-injector|Lantus® SoloStar® OptiClik®
214865877|NCT00975286|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
214865878|NCT00975286|DRUG|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
214865879|NCT00027079|DRUG|ondansetron (Zofran)|
214865880|NCT00027079|DRUG|naltrexone (ReVia)|
214865881|NCT00027079|BEHAVIORAL|Cognitive Behavioral Therapy|
214865882|NCT01487070|DRUG|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only."
214865883|NCT02357342|DRUG|Sirolimus|intravitreal injection
214865884|NCT02357342|DRUG|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
214865885|NCT02373670|BEHAVIORAL|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
214865886|NCT02373670|BEHAVIORAL|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
214290736|NCT00071513|BEHAVIORAL|Brief Intervention|Assessment of needs and referral to services as needed.
214290737|NCT06069284|OTHER|No intervention|No intervention
214290738|NCT01904591|DIETARY_SUPPLEMENT|Selenium|"Selenium 50 micrograms daily per oral~1 year of treatment"
214290739|NCT01904591|DIETARY_SUPPLEMENT|Vitamin E|"Vitamin E 400 international units daily per oral~1 year of treatment"
214290740|NCT02949102|DIETARY_SUPPLEMENT|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
214290741|NCT02949102|DIETARY_SUPPLEMENT|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
214290742|NCT05174260|DEVICE|perfusion index, pleth variable index|a clip will be attached to the patient's finger and the perfusion index and pvi will be measured
214865887|NCT02620215|DEVICE|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
214865888|NCT02620215|DRUG|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
214865889|NCT03959215|BEHAVIORAL|Back in the Game|"A six-month programme of cognitive-behavioural therapy delivered by smartphone application. The intervention commences in the first week after ACL reconstruction. The smartphone app is delivered in parallel with usual rehabilitation care.~Usual rehabilitation care: all participants will be referred to physiotherapy following ACL reconstruction. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the treatment aims is at the clinical discretion of the treating physiotherapist."
214865890|NCT03959215|OTHER|Usual rehabilitation care|Following ACL reconstruction, as per routine clinical practice, all participants will be referred to physiotherapy. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the required treatment aims is at the clinical discretion of the treating physiotherapist.
214865891|NCT02972177|PROCEDURE|Radiofrequency ablation|Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.
214865892|NCT02972177|PROCEDURE|Microwave ablation|Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
214865893|NCT01674647|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
214865894|NCT01674647|DRUG|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
214865895|NCT03359577|DIETARY_SUPPLEMENT|Psorax35|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
214865896|NCT03359577|DIETARY_SUPPLEMENT|MCT oil|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
214865897|NCT05393505|DRUG|Meropenem Injection|Given if patient has no known allergies at 1 g IV bolus within 1 hour of ED registration, then every 8 hours
214865898|NCT05393505|DRUG|Levofloxacin|Given if patient is allergic to beta lactam at 500 g IV in 100 mL 0.9% sodium chloride solution, infused over 1 hour started within 1 hour of ED registration, then every 24 hours. If the patient can tolerate oral drugs, 500 mg daily after the first IV dose.
214865899|NCT05393505|DRUG|Amoxicillin Clavulanate|Given if patient has no known allergies at 1.2 g IV bolus within 1 hour of ED registration, then every 8 hours. If the patient can tolerate oral drugs, 1 g twice daily after the first IV bolus.
214865900|NCT05393505|DRUG|Antibiotic|"Any antibiotic for empirical therapy of common infections as recommended by the fifth version of Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) guideline, with reference to previous bacterial sensitivity pattern"
214865901|NCT06863545|DRUG|PCSK9 inhibitors and background lipid-modifying therapy|Patients will receive subcutaneous injections of PCSK9 inhibitors and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with PCSK9 inhibitors administered every 2 weeks. After the first 12 months, patients will discontinue the PCSK9 inhibitors but continue background LMT for the remainder of the trial.
214865902|NCT06863545|DRUG|Placebo plus background lipid-modifying therapy|Patients will receive subcutaneous injections of placebo and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with placebo administered every 2 weeks. After the first 12 months, patients will discontinue the placebo but continue background LMT for the remainder of the trial.
214865903|NCT05755152|OTHER|polyphenol-lecithin precipitate (PLP)|Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).
214865904|NCT05755152|OTHER|control formulation|Chewing gum made with material produced from conventional technology (e.g cranberry extract).
214865905|NCT03196414|BIOLOGICAL|CART-138/BCMA/19/more|Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
214865906|NCT00503711|DRUG|Vandetanib|100 mg every other day, 100mg once daily
214865907|NCT00503711|DRUG|Vandetanib 300 mg|300mg once daily
214865908|NCT05697055|DRUG|Azvudine|5mg orally, once a day, for no more than 14 days
214865909|NCT05697055|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR \< 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
214290743|NCT04347044|OTHER|Pulmonary Rehabilitation|Exercise training+ Optimal medication and clinical follow-up
214865910|NCT02487381|DRUG|delta-9-tetrahydrocannabinol|
214865911|NCT02487381|DRUG|Cannabidiol|
214865912|NCT02487381|DRUG|Placebo|
214865913|NCT02736682|DRUG|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
214865914|NCT02736682|DRUG|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
214865915|NCT04917718|DRUG|Conversion from IR Tacrolimus to XR Tacrolimus|All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus
214865916|NCT03255512|DRUG|Vericiguat (BAY1021189)|2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet
214865917|NCT03255512|DRUG|Placebo|Matching placebo
214865918|NCT03255512|DRUG|Isosorbide mononitrate (ISMN)|30 mg/tablet or 60 mg/tablet
214290744|NCT04347044|OTHER|Standart care|Optimal medication and clinical follow-up
214290745|NCT04853511|DEVICE|OCT-FLIM (optical coherence tomography-fluorescence life time)|comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
214865919|NCT03052413|DIETARY_SUPPLEMENT|Nutrafol|Eligible subjects will receive Nutrafol® to take daily for 180 days
214865920|NCT03052413|DIETARY_SUPPLEMENT|placebo|Eligible subjects will receive Placebo to take daily for 180 days
214865921|NCT02812979|DEVICE|Airvo2 with Aerogen Solo|Nebulization of salbutamol with Airvo 2 and Aerogen solo
214865922|NCT02812979|DEVICE|Mask|Usual nebulization of salbutamol with mask
214865923|NCT02812979|DEVICE|arm control Airvo2 without nebulization of salbutamol|Airvo2 with Aerogen Solo. No nebulization of salbutamol
214865924|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 75 mg/capsule|Take 2 capsules per day at any time.
214865925|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 40 mg/capsule|Take 2 capsules per day at any time.
214865926|NCT05683327|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules per day at any time.
214865927|NCT01727882|BEHAVIORAL|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
214865928|NCT01727882|BEHAVIORAL|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
215033789|NCT02928835|DEVICE|Knee flexion Dynasplint orthosis|Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
215033790|NCT02205320|BIOLOGICAL|DRL_PG|
215033791|NCT02205320|BIOLOGICAL|Pegfilgrastim Form A|
215033792|NCT02205320|BIOLOGICAL|Pegfilgrastim Form B|
215033793|NCT06494046|OTHER|Non-Interventional Study|Non-Interventional Study
215033794|NCT00005830|DRUG|Doxorubicin Hydrochloride|Given IV
214865929|NCT03267420|DIAGNOSTIC_TEST|BpTRU First, Unattended Omron Second|"Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted."
214865930|NCT03267420|DIAGNOSTIC_TEST|Unattended Omron First, BpTRU Second|"Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings."
214865931|NCT03267420|DIAGNOSTIC_TEST|Partially Attended Omron First, Unattended Omron Second|"Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted."
214865932|NCT04346966|OTHER|Study Group|Video Based Exercises 64 young adults aged 18-40, who are socially isolated due to coronavirus, will be included in this group. A video-based exercise protocol was created for individuals to participate in the study. Each exercise session is planned as 30 minutes 7 days a week for 6 weeks. The protocol was planned to start with warm-up exercises and end with cooling exercises. The exercise protocol has also been determined as a combination of aerobic exercises, strengthening and posture exercises. Individuals will be classified at 4 levels according to their physical activity levels and will be shared with volunteers according to their level of exercise. Volunteers will be evaluated before and after 6 weeks of exercise.
214865933|NCT01490866|DRUG|Axitinib|5-mg tablets PO BID
214865934|NCT01490866|DRUG|Bevacizumab|5 mg/kg Days 1 and 15; IV
214865935|NCT01490866|DRUG|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
214865936|NCT01490866|DRUG|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
214865937|NCT01490866|DRUG|Leucovorin|400 mg/m2 Days 1 and 15; IV
214865938|NCT01490866|DRUG|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
214865939|NCT05927831|DRUG|Grape Seed Extract|Grape seed extract will be applied in the form of a gel on the tooth surface
214865940|NCT05927831|DEVICE|Low-level laser therapy|The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode
214865941|NCT02038231|BEHAVIORAL|Parenting Mindfully Program|see Arm Description.
214865942|NCT02038231|OTHER|Parent Education Program|See Arm Description.
214865943|NCT00209989|DRUG|Zarnestra|ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
214865944|NCT00209989|PROCEDURE|standard Radiation therapy|Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
214865945|NCT06332001|OTHER|Experimental Group|Listening of music of patient's choice during WB-MRI
214865946|NCT06332001|OTHER|Control Group|Standard care condition during WB-MRI
214865947|NCT02943967|PROCEDURE|CXL + PRK group|Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
214865948|NCT02943967|PROCEDURE|PRK group|Photorefractive keratotomy alone was performed in contra lateral eyes
214865949|NCT03433716|OTHER|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
215033795|NCT00005830|DRUG|Cisplatin|Given IV
214865950|NCT04283916|DRUG|Botulinum Toxins|Botulinum toxin injection to abdominal wall
214865951|NCT04171024|DEVICE|Sham electrical stimulation|A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
214865952|NCT04171024|DEVICE|Transcutaneous diaphragm electrical stimulation|A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
214865953|NCT01665924|DRUG|GLPG0634 100mg capsule once a day for 10 days|
214865954|NCT02575612|PROCEDURE|vacuum-assisted biopsy|Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (\> 50 ultrasound guided minimal invasive biopsies per year, \> 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
214865955|NCT02251119|DRUG|Tipranavir|
214865956|NCT02251119|DRUG|Ritonavir|
214865957|NCT02251119|DRUG|Loperamide|
215033796|NCT00005830|RADIATION|Radiation Therapy|Undergo radiation therapy
215033797|NCT01957384|DEVICE|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
215033798|NCT01957384|DEVICE|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
214865958|NCT01051713|BEHAVIORAL|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
214865959|NCT01051713|BEHAVIORAL|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
214865960|NCT01782508|DRUG|imatinib|a selectively inhibits the KIT protein tyrosine
214865961|NCT01782508|DRUG|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
214865962|NCT03088618|PROCEDURE|Nasal septoplasty|Type of surgery
214865963|NCT02672202|DRUG|Duloxetine|"* 60 mg/d - twice before surgery and once a day for post operative days 3-7~* 30 mg/d - once a day for post operative days 1-2"
214865964|NCT02672202|DRUG|Pregabalin|"* 75 mg/d - twice a day for post operative days 1-2~* 150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery"
214865965|NCT02672202|DRUG|Placebo|"* non-active - twice before surgery~* non-active - twice a day for post operative days 1-7"
214865966|NCT05044884|OTHER|Otago Exercise training|"1. Warm-up exercises. Chair March, Arm swings ( 30 second), Head movement, neck movement, back extension, trunk movement, ankle movement (repeat 5 times).~   Back of thigh stretch, calf stretch, (hold for 8 seconds).~2. Strengthening exercises Front knee strengthening, back knee strengthening, side hip strengthening (2 or more sets of 10 reps) Calf raises, toe raises (repeat this exercises 10 to 20 times)~3. Balance improvement exercises Knee bends, heel-toe standing, heel toes walking, one leg stand ( start with 5 sec move up to 10 sec) Side walk, heel walking, sit to stand, backwards walking, heel toes walking backwards, walking and turning around, stair walking (10 steps).~4. Cool-down session Back of thigh stretch, calf stretches ( 10 to 20 sec hold, 1 to 3 reps)~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles."
214865967|NCT05044884|OTHER|Circuit training|"1. Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~2. Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~3. Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~   Sit on floor and stand up with assistance and then without assistance.~4. Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles"
214865968|NCT01181271|DRUG|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
214865969|NCT01181271|DRUG|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
214865970|NCT01181271|DRUG|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
214865971|NCT01181271|DRUG|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
214865972|NCT01181271|OTHER|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
214865973|NCT01181271|DRUG|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
214865974|NCT01181271|DRUG|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
214865975|NCT01181271|DRUG|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
214865976|NCT01181271|OTHER|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10\^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10\^6/kg of recipient's actual body weight
214865977|NCT01181271|DRUG|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
214865978|NCT01181271|DRUG|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
214865979|NCT01181271|DRUG|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
214865980|NCT02885649|DRUG|Enzalutamide|Given PO
214865981|NCT02885649|OTHER|Laboratory Biomarker Analysis|Correlative studies
214865982|NCT02885649|PROCEDURE|Nephrectomy|Undergo partial or radical nephrectomy
214865983|NCT04624347|BEHAVIORAL|Access to video and movement curves|intervention of caregivers with access to videos and motion curves of the premature infant
214865984|NCT05507762|BIOLOGICAL|UC-MSCs|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively"
214865985|NCT05507762|BIOLOGICAL|Saline solution|Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
214865986|NCT03512951|OTHER|Digital signal processing algorithms|The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).
214865987|NCT03489161|DRUG|Buprenorphine|buprenorphine/naloxone 4mg/1 mg for Clinical Opioid Withdrawal Scale (COWS) scores between 8 and 12, or 8mg/2mg S/L ≥ 12 by the sublingual route
214865988|NCT01264159|DEVICE|Lung impedence-guided therapy|
214865989|NCT01264159|OTHER|Usual treatment of patients with developing acute heart failure|
214865990|NCT02083237|BEHAVIORAL|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
214865991|NCT01625130|DIETARY_SUPPLEMENT|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
214865992|NCT01625130|DIETARY_SUPPLEMENT|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
214865993|NCT02351583|DEVICE|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
214865994|NCT02351583|DEVICE|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
214865995|NCT00005965|DRUG|bryostatin 1|
214865996|NCT00005965|DRUG|cisplatin|
214865997|NCT04156620|DRUG|Secukinumab|The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)
214865998|NCT04156620|DRUG|Placebo|The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
214865999|NCT02980874|DRUG|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
214866000|NCT02980874|DRUG|suprachoroidal sham|suprachoroidal sham procedure
214866001|NCT02980874|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
214866002|NCT02251691|DRUG|Advagraf|Compare the drug compliance between once daily or twice daily regimen
214866003|NCT02251691|DRUG|Prograf|Compare the drug compliance between once daily or twice daily regimen
214290746|NCT01150864|DEVICE|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
214290747|NCT02260921|DEVICE|iovera°|
214290748|NCT02260921|DEVICE|Sham Comparator|
214866004|NCT05303376|BIOLOGICAL|IBIO123|5 or 10 mg
214290749|NCT02921854|OTHER|Blood withdrawal|For each patient, 3 blood withdrawals of 25 ml each will take place during treatment
214866005|NCT05303376|OTHER|Placebo|matching placebo
214866006|NCT04298060|DRUG|DAS181|SD (4.5mg/day), HD (9mg/day)
214866007|NCT04298060|DRUG|Placebo|Placebo 0mg/day
214866008|NCT02024373|DRUG|Atorvastatin|20 mg (every evening orally) for 8 weeks
214866009|NCT02024373|DRUG|placebo|20 mg (every evening orally) for 8 weeks
214866010|NCT02722148|DEVICE|Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
214866011|NCT00539357|DEVICE|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
214866012|NCT02516904|DRUG|CD101 IV|antifungal
214866013|NCT02516904|DRUG|Placebo|normal saline
214866014|NCT05221424|OTHER|Patient Education|"The training program about hypertension prepared according to the Roy Adaptation Model was performed in a room in the cardiology outpatient clinic of a state hospital. The training content was shaped according to 4 (four) basic areas of the Roy Adaptation Model (physiological field, self-concept field, role function field and interdependence field). The training taught to each patient individually and interactively with the support of powerpoint presentation lasted for averagely 45-50 minutes. A Hypertension Training Booklet was prepared according to the Roy Adaptation Model in order to be used during the training and to strengthen the training."
214290750|NCT01244425|DRUG|Fibrin Sealant (FS) VH S/D 500 s-apr|Dosage form: spray application; dosage frequency: single application
214290751|NCT01244425|OTHER|Manual compression|Dosage form: surgical gauze swab; dosage frequency: single application
214290752|NCT02863029|PROCEDURE|Flexible Sigmoidoscopy|A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
214290753|NCT02502643|DRUG|OK-432 pleurodesis|1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
214290754|NCT02502643|DRUG|normal saline pleurodesis|Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
214290755|NCT03957304|DRUG|Dexmedetomidine|Intranasal dexmedetomidine
214290756|NCT01490229|DRUG|Ezetimibe|os, 10 mg, once daily, 1 year
214290757|NCT01490229|DRUG|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
214866015|NCT03570086|DIAGNOSTIC_TEST|diagnostic|using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
214866016|NCT05077371|BEHAVIORAL|Peer support program|The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.
214866017|NCT04274023|DRUG|TSR-042|TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
214866018|NCT00862238|BEHAVIORAL|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, \& C
214866019|NCT00862238|OTHER|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, \& C
214866020|NCT05032313|DIAGNOSTIC_TEST|IUO CLPD Limited Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .
214866021|NCT01753336|BIOLOGICAL|Botulinum toxin type A|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
214866022|NCT05957419|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
214866023|NCT03721536|DIAGNOSTIC_TEST|hemodynamic parameters|vital signs on the monitor including heart rate, mean arterial pressure, peripheral oxygen saturation and End-tidal Carbon Dioxide
214866024|NCT03721536|DIAGNOSTIC_TEST|arterial blood gase|Arterial blood gas including partial oxygen pressure and partial carbon dioxide pressure is an important routine investigation to monitor the acid-base balance of patients, effectiveness of gas exchange, and the state of their voluntary respiratory control.
214866025|NCT01501136|OTHER|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
214866026|NCT01501136|OTHER|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
214866027|NCT01501136|OTHER|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
214866028|NCT01501136|OTHER|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
214866029|NCT01501136|RADIATION|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
214866030|NCT03896984|DRUG|Radium-223 (Xofigo, BAY88-8223)|Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
214866031|NCT03896984|DRUG|Abiraterone|Abiraterone is a CYP17 inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2011, and for patients with metastatic high-risk castration-sensitive prostate cancer in 2018.
214866032|NCT03896984|DRUG|Enzalutamide|Enzalutamide is an androgen receptor inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2012, with warning and precautions added in 2017 regarding the risk of seizure and encephalopathy.
214866033|NCT03025490|DEVICE|Capnographic monitoring|Capnographic monitoring is used during the sedation.
214866034|NCT02103270|DRUG|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
214866035|NCT02103270|DRUG|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
214866036|NCT02103270|DRUG|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
214866037|NCT05372874|DRUG|Direct Acting Antivirals|hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
214866038|NCT03936673|PROCEDURE|Percutaneous nephrostomy|
214866039|NCT03138226|PROCEDURE|uterus transplantation|
214866040|NCT00446199|DRUG|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
214866041|NCT00446199|DRUG|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
214866042|NCT00446199|DRUG|Estradiol (E2 0.3mg)|One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
214866043|NCT00446199|DRUG|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
214866044|NCT00317252|DRUG|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
214290758|NCT02319889|RADIATION|Stereotactic Body Radiotherapy|Undergo SBRT
214866045|NCT00819975|DIETARY_SUPPLEMENT|Casein|
214866046|NCT00819975|DIETARY_SUPPLEMENT|Whey Isolate|
214866047|NCT00819975|DIETARY_SUPPLEMENT|Whey Hydrolysate|
214866048|NCT00819975|DIETARY_SUPPLEMENT|Alphalact-Albumin|
214866049|NCT04696107|BEHAVIORAL|Psychoeducative intervention|"This workshop is centred in psychoeducational and training action in emotional self-regulation in a group modality and participatory character, aimed at patients with mCNCP to acquire basic knowledge in:~* Neurology and psychoneuroimmunology.~* The role of beliefs in our manifestation of the disease.~* Body language and modulation of pain perception.~* Relaxation body-mind techniques.~* Creative visualization for pain management.~* Mirror feed-back.~The workshop will take place at the Hospital San Juan de Dios del Aljarafe, in four weeks, once a week, three hours each. Until now, the attendance was 24 patients per workshop. After the pandemic, we will reduce to 15 to increase safety distance. We will also conduct a telephone survey of each patient on symptoms of Covid infection in the 24 hours prior to the workshop."
214866050|NCT00727727|DRUG|Piribedil|
214866051|NCT03801382|DEVICE|IntelliSpace Cognition (ISC)|Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
214866052|NCT03801382|DIAGNOSTIC_TEST|Paper-Pencil Tests|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
214866053|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for patient
214866054|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for healthy volunteers
214866055|NCT04884867|BEHAVIORAL|CBT-based supportive skills delivered by phone by lay coaches|8-10 weekly coaching sessions delivered by telephone
214866056|NCT04331444|DEVICE|CGM|Using the CGM during the entire study period of 12 months.
214866057|NCT04331444|BEHAVIORAL|training course|The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.
214866058|NCT04331444|BEHAVIORAL|Peer-support|The peer-support will be facilitator-led by the primary investigator with peer exchange in group sessions (3 sessions over the study period, 3 hours per session) with 6-8 participants in every group.
214866059|NCT04188301|DRUG|IVM w/ ALB|Participants will be given a single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)
214866060|NCT04188301|DRUG|Single dose of IDA|Participants will be given a single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
214866061|NCT04188301|DRUG|Three daily doses of IDA|Participants will be given one daily dose for 3 days of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
214866062|NCT01200264|DRUG|apremilast|apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
214290759|NCT02319889|DRUG|Carboplatin|Given IV
214290760|NCT02319889|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
214476496|NCT06586320|DEVICE|Evaluation of mathematical models|Evaluation of performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras
214866063|NCT01204450|DRUG|Temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
214866064|NCT01204450|DRUG|Valproic Acid|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
214866065|NCT05499013|DRUG|SLN124|SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
214866066|NCT05499013|DRUG|Placebo|sodium chloride, solution for injection
214866067|NCT00239655|DRUG|MK0812|
214866068|NCT00486564|DRUG|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
214866069|NCT03035721|DIETARY_SUPPLEMENT|Low protein formula|Infants were enrolled to receive low protein formula (energy: 65 kcal/100 mL, protein: 1.2 g/100 mL, protein-to-energy ratio:1.9 g/100 kcal, carbohydrates: 8 g/100 mL, fat: 3.1 g/100 mL) for the firsts 4 months of life.
214866070|NCT03035721|DIETARY_SUPPLEMENT|Standard protein formula|Infants were enrolled to receive standard protein formula (energy: 68 kcal/100 mL, protein: 1.7 g/100 mL, protein-to-energy ratio:2.5 g/100 kcal, carbohydrates: 7.1 g/100 mL, fat: 3.5 g/100 mL) for the firsts 4 months of life.
214866071|NCT03480438|DRUG|Blinatumomab|Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.
214866072|NCT05137470|OTHER|This is an observational study|This is an observational study
214866073|NCT02511899|DIETARY_SUPPLEMENT|Mango fruit powder|Dietary supplement; Mango fruit powder
214866074|NCT04191837|OTHER|Self-administered acupressure treatment group|Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.
214866075|NCT04191837|OTHER|Knee health education control group|Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
214476497|NCT06606262|PROCEDURE|Tonsillotomy|Bilateral partial removal of the palatine tonsils to a level between the pharyngeal pillars and the tonsillar capsule. Surgery will be performed under general anesthesia using monopolar electrocautery.
214866076|NCT02434432|BEHAVIORAL|music therapy selected by mothers|mothers' choice of music
214866077|NCT02434432|BEHAVIORAL|Music therapy recorded lullaby|recorded lullaby
214866078|NCT03500653|DIETARY_SUPPLEMENT|Curcumin|4 gr curcumin
214866079|NCT03500653|DIETARY_SUPPLEMENT|Placebo|4 gr placebo
214866080|NCT03056820|OTHER|25° head-up position|Participant will be positioned at 25° angle for procedure.
214866081|NCT03056820|OTHER|55° head-up position|Participant will be positioned at 55° angle for procedure.
214866082|NCT03693573|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
214866083|NCT03693573|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
214866084|NCT06420791|OTHER||
214866085|NCT06253026|OTHER|Search and rescue mission|Air search and rescue missions lasting 15 consecutive days
214866086|NCT02242565|DEVICE|ShangRing|ShangRing device for male circumcision
214866087|NCT04805918|BEHAVIORAL|VIPP-SD|Parenting program
214866088|NCT05191303|DEVICE|Mobile intervention of breastfeeding counseling|The mobile intervention of breastfeeding counseling includes an evidence-based information of breastfeeding, which is based on Ten steps of breastfeeding of Baby Friendly Hospital Initiative (BFHI) and Finnish Institute for Health and Welfare recommendation. The links provide more information and videos related to breastfeeding topic. The mobile intervention of breastfeeding counseling allows the client to write comments or notes that can be used in counseling at maternity clinic or hospital. The mobile intervention of breastfeeding counseling also provides an e-mail to non-urgent questions related to breastfeeding. Questions will be answered within 3 or 4 days by a lactation consultant (IBCLC).
214866089|NCT01296659|DRUG|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
214866090|NCT02584400|DRUG|Injection with the hypoxia tracer [18F]HX4,|The \[18F\]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) \[18F\]HX4 via a bolus IV injection.
214866091|NCT06182176|DRUG|Sulphadoxine-pyrimethamine and Amodiaquine|The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).
214866092|NCT05646420|OTHER|Blood sampling|A blood sample of 15 ml will be collected for each patient.
214866093|NCT00496535|DRUG|TNFerade biologic|
214866094|NCT04275765|BEHAVIORAL|Arm 2:Behavioral Intervention with nudges & Facebook interaction|Participants will receive nudges and be enrolled to Facebook group for self-learning.
214866095|NCT04275765|OTHER|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
214866096|NCT00220987|OTHER|Intensive Insulin Therapy|Maintain blood glucose 4.5 - 6.o mmol/L
214866097|NCT00220987|OTHER|Conventional Insulin therapy|Maintain blood glucose 8-10mmol/L
214866098|NCT03511443|DIAGNOSTIC_TEST|hsRDT|Testing highly sensitive RDT detection for low parasitemia
214866099|NCT01080443|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
214866100|NCT00147849|BEHAVIORAL|mailing of printed educational materials|
214866101|NCT00147849|BEHAVIORAL|a combination of interactive educational meetings, educational outreach visits, and reminders|
214866102|NCT00147849|BEHAVIORAL|identification of local opinion leaders and establishment of local consensus processes|
214866103|NCT04128280|PROCEDURE|TUDP|a surgery: transurethral dilation of prostate with a columnar balloon
214866104|NCT04128280|PROCEDURE|TUIB|a surgery: transurethral incision of bladder neck
214866105|NCT06322173|DIAGNOSTIC_TEST|NGS Analysis|An analytical pipeline with NGS technology developed in the GENRES study will be used for the identification of infecting microorganisms and the drug resistance they carry. For this purpose, a sequencing method will be identified and adopted that can obtain gene sequences of approximately 75 bp in length and on the Illumina MiSeq platform. Furthermore, IT software and bioinformatics analyzes with specific quality control parameters (pre- and post-alignment of reads) will be identified and adopted in order to develop an IVD system that includes a complete package of sequencing kits and software.
214866106|NCT04831463|BEHAVIORAL|Increasising Health Awareness Program for Immigrant Men|The IHAPIM program is a health promotion intervention. The aim of intervention improve health perception and responsibilitiy
214866107|NCT01104779|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
214866108|NCT01104779|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
214866109|NCT00644449|OTHER|placebo|placebo
214866110|NCT00644449|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
214866111|NCT00644449|OTHER|placebo|placebo
214866112|NCT00644449|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
214866113|NCT03632967|DEVICE|Tricinch Coil System Implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
214866114|NCT04555681|DIAGNOSTIC_TEST|Collection of subgingival dental plaque|Identification and quantification using q-PCR of the 21 bacteria most frequently found in the dental plaque (including the periopathogenic bacteria) and Candida albicans.
214866115|NCT01124344|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
214866116|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
214866117|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
214866118|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
214866119|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
214866120|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
214866121|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
214290761|NCT01259505|BIOLOGICAL|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
214476498|NCT06606262|PROCEDURE|Tonsillectomy|"Bilateral extracapsular removal of palatine tonsils. Surgery will be performed under general anesthesia using cold knife dissection."
214866122|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
214866123|NCT00125411|DRUG|satraplatin and docetaxel|"Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.~Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush."
214866124|NCT06929052|DEVICE|ADL-018 Autoinjector|Test product (A): ADL-018 Injection 150 mg/mL solution in a single dose pre-filled autoinjector manufactured/supplied by Kashiv BioSciences LLC, USA.
214866125|NCT06929052|DRUG|ADL-018 Injection|Reference Product (B): ADL-018 Injection 150mg/mL solution in a single dose pre-filled syringe manufactured/supplied by Kashiv BioSciences LLC, USA
214866126|NCT01648504|OTHER|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
214866127|NCT06929000|OTHER|the supine head-lateral position group|the supine head-lateral position group: during the perioperative period, keep the patient's head tilted to the left or right
214866128|NCT06929000|OTHER|the adjustable headrest group|the adjustable headrest group: placing an adjustable pillows on the patient's head to align the patient's external auditory canal horizontally with the sternum
214866129|NCT06929000|OTHER|the supine head-straight position group|the supine head-straight position group: during the perioperative period, keep the patient's head upright
214866130|NCT06928129|DIAGNOSTIC_TEST|BinaxNOW™ COVID-19/Flu A&B Combo Self-Test|"Diagnostic Test: BinaxNOW™ COVID-19/Flu A\&B Combo Self-Test~The BinaxNOW™ COVID-19/Flu A\&B Combo Self-Test is a visually read lateral flow in vitro immunoassay for the qualitative detection and differentiation of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B directly in anterior nasal swab specimens from individuals with signs and symptoms of respiratory infection."
214866131|NCT03926481|BEHAVIORAL|Evaluate Healthy Lifestyle Program on cognitive outcomes|The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
214866132|NCT04262661|DRUG|NNC0472-0147|Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
214866133|NCT04262661|DRUG|insulin glargine|Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.
214866134|NCT04262661|DRUG|Placebo (NNC0472-0147)|Part 1: A single dose of placebo, dose increased in each cohort.
214866135|NCT01829087|DRUG|Botox|
214866136|NCT01829087|DRUG|placebo|
215033799|NCT01957384|DEVICE|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|"Standard Care was the subject usual ostomy appliance and had to be one of the following:~* Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,~* Dansac: Nova 1 \& Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate~* Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate~* ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate~* B. Braun: Flexima Active \& Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate"
214866137|NCT05460559|PROCEDURE|Group A (p-PCNL) procedure|In lithotomy position, ureteric catheter will be inserted allowing injection of contrast to obtain a pyelogram. Shifting the patients in prone position will be done. Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
214866138|NCT05460559|PROCEDURE|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
214866139|NCT02288390|PROCEDURE|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
214866140|NCT04797429|OTHER|Peer Support Intervention via Instant Messaging Service Tool (IMS-Tool)|Peer Support via the IMS-tool increases diabetes self-management, improves self-efficiacy, adherence and glycaemic control
214866141|NCT04797429|OTHER|antidiabetic therapy according to the current guidelines|In contrast, the control group has to manage their diabetes mellitus type 2 with standard support and without online exchange.
214866142|NCT06112431|OTHER|Intervention|Participants randomized to the Intervention Arm and referred to ophthalmology will receive assistance from a Study Coordinator with scheduling in-office eye exam appointment and arranging transportation to these appointments over 2 years at either Columbia Ophthalmology, Harlem Hospital, or their own eye care provider.
214866143|NCT06112431|OTHER|Usual Care|Consented participants randomized to the Usual Care Arm will receive all the basic level of services including the eye health screening, optometric exam if they fail the screening, and eyeglasses at no charge. Those who require referral to ophthalmology will be scheduled for the initial in-office eye exam and their outcomes will be tracked. No additional support will be provided the Usual Care participants during the study. The Usual Care Arm represents a realistic choice currently available for participants following eye health screening.
214866144|NCT06459037|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214866145|NCT04997200|BEHAVIORAL|One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
214866146|NCT06336538|OTHER|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is a group-based psychological intervention for depression that combines mindfulness training with cognitive therapy.
214866147|NCT03548064|OTHER|Placebo|Placebo
214866148|NCT03548064|OTHER|Placebo|Placebo
214866149|NCT03548064|OTHER|Placebo|Placebo
214866150|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
214866151|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
214866152|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
214866153|NCT05904769|DEVICE|LIFELEAF Smartwatch|Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.
214866154|NCT05011123|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection - Subcutaneous
214866155|NCT05011123|BIOLOGICAL|Yellow fever vaccine|Powder and diluent for suspension for injection - Subcutaneous
214866156|NCT06726161|DIAGNOSTIC_TEST|RYZ811|Ga-68
214866157|NCT06726161|DRUG|RYZ801|Ac-225
214866158|NCT05740982|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.
214866159|NCT03117036|DRUG|Chemotherapy|Systemic chemotherapy with curative intent
215033800|NCT03248752|BEHAVIORAL|Fitbit use and reports|Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.
214866160|NCT06953245|OTHER|Non-Interventional Study|Non-interventional study
214866161|NCT04221789|OTHER|TB treatment assistant|Cell phone app to support self administered treatment and monitor adherence
214866162|NCT05137314|DRUG|PLG0206|PLG0206 is an engineered antibacterial peptide (EAP)
214866163|NCT04193475|OTHER|Analysis|No intervention planned. Novel analysis of echocardiographic data.
214866164|NCT03778060|DEVICE|Cala TWO stimulator|Treatment intervention will consist of subjects undergoing 40 minute sessions of transcutaneous stimulation with the Cala TWO stimulator twice daily for 3 months to reduce hand tremors prior to their undergoing deep brain stimulation 'surgery for treatment of essential tremor at Mayo Clinic.
214866165|NCT04732221|DRUG|Frespaciguat|Frespaciguat (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
214866166|NCT04732221|DRUG|Placebo to Frespaciguat|Placebo administered as dry powder inhalation
214866167|NCT04578665|BEHAVIORAL|Behavioral Interaction Conditions|The participants will be single-blinded and complete a tracking task as either: solo task, collaboration task (both participants work on a common task synchronously to achieve a goal; this is a summative effort to achieve the goal), competition task (each participant has to achieve a goal at the expense of his or her partner, therefore maximizing effort or error of the partner in reaching the goal), or cooperation task (an asymmetric partnership with an active partner and a passive partner working towards a goal).
214866168|NCT04578665|DEVICE|Haptic Impedance Level|The subjects will complete their task at 3 impedance levels: high (a virtual stiffness 160-200 N/m and damping 0\~10 Nm/s; this will be a stiff connection in which the subjects feel like they are connected via rigid links and each subject will perceive the other partner's movement directly), medium (a virtual stiffness 100-140 N/m and damping 0\~10 Nm/s; this will be a spring like-connection in which the subjects feel like they are connected with a spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two participants), and soft (a virtual stiffness 40-80 N/m and damping 0\~10 Nm/s; this will be a spring like connection in which the subjects feel like they are connected with a loose spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two subjects, however, this force will be smaller than that of the medium impedance).
214866169|NCT04578665|BEHAVIORAL|Skill Level of Partner|There will be two skill levels: novice (a participant who has no prior experience with the trajectory tracking experiment; in testing with the clinical populations, the investigators will assign this condition to the clinical participant) and expert (a participant who is experienced with the trajectory tracking experiment and who can achieve a tracking error \[difference of the desired trajectory and actual trajectory\] below a certain threshold; in testing with the clinical population, the investigators will assign this condition to the therapist). Participants will start experimentation paired as novice-novice, and at the end of the session may be invited to continue additional sessions to be paired as the expert in a novice-expert dyad.
214866170|NCT04578665|DEVICE|Robot Controller Showcase|The subjects will complete 10 training sessions per assistive robot for the researchers to observe motor learning and functional outcomes.
214866171|NCT03747601|DEVICE|Temporal Interference (TI) Stimulation|2-4 Temporal Interference stimulation sessions. The device is an experimental non-invasive electrical brain stimulator that functions similar to existing non-significant risk devices for electrical stimulation, including human non-invasive brain stimulation. Briefly, the device produces alternating current electrical stimulation in a kilohertz (kHz) range and results in less net charge applied within the brain. The device is powered by rechargeable 20 volt (V) battery (i.e. there is no connection to building power supply). The current is hardwired and limited to 5 milliamp (mA) via internal resistors. It includes extra safety features such as onboard fuses to limit any abrupt high current, and an emergency stop button which effectively insulates the subject and resets the device. The device was tested and characterized at all the required load conditions.
214866172|NCT06099444|DEVICE|Conventional High Intensity Gait Training|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity. The participants will complete 18 training sessions.
214866173|NCT06099444|DEVICE|Standard FES to the Tibialis Anterior (TA)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while wearing a FES stimulator on the tibialis anterior muscle of their more affected leg. Stimulation will be triggered prior to swing phase to combat drop foot. The participants will complete 18 training sessions.
214866174|NCT06099444|DEVICE|Synergy-Based Multichannel FES (MFES)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while FES is applied to multiple muscles of the leg throughout the gait cycle based on the healthy muscle synergies. The goal will be to have the FES applied for at least 20 minutes of each gait training session. The participants will complete 18 training sessions.
214866175|NCT06099444|DEVICE|Muscle Synergy Visual Biofeedback|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while receiving visual feedback of the similarity of their muscle synergies to healthy muscle synergies. They will be instructed to try to optimize the similarity score. The participants will complete 18 training sessions.
214866176|NCT06541002|BEHAVIORAL|SHIFT Intervention Group|Participants assigned to SHIFT will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and start using SHIFT at their desired pace over 8 weeks to complete five modules.
214866177|NCT06541002|BEHAVIORAL|Enhanced Usual Care Group|Participants assigned to the enhanced usual care group will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and maybe referred to a psychologist, urologist, or gynecologist at the participants' request or at the discretion of the HCT clinician.
214866178|NCT05874193|DRUG|Belantamab mafodotin|Belantamab mafodotin 2.5mg/kg in 42-day cycles. Every 6 weeks until PD, unacceptable toxicity or withdrawal of consent, whichever comes first
214866179|NCT03919877|OTHER|Dietary|Dietary counseling based on results of CGM analyses.
214866180|NCT03811613|OTHER|Transcranial photobiomodulation|Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)
214866181|NCT06242704|BEHAVIORAL|Working Memory Training|A multi-session computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
214866182|NCT06242704|BEHAVIORAL|Working Memory|A multi-session control computer training condition that is designed to not engage working memory among at-risk adolescents in a traditionally underserved area.
214866183|NCT05327816|BIOLOGICAL|RSV preF-based Vaccine|RSV preF-based vaccine will be administered as intramuscular injection.
214866184|NCT05327816|DRUG|Placebo|Placebo will be administered as intramuscular injection.
214866185|NCT05428826|DRUG|Prednisone|Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
214866186|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Active|"Treatment protocol:~* EFD 0.096 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
214866187|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Sham|"Treatment protocol:~* EFD 0 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
214866188|NCT05122377|DRUG|3M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
214866189|NCT05122377|DRUG|1M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
214866190|NCT00112866|DRUG|cilengitide|Given IV
214866191|NCT00112866|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection
214866192|NCT00112866|OTHER|pharmacological study|Correlative studies
214866193|NCT00112866|OTHER|laboratory biomarker analysis|Correlative studies
214866194|NCT00388076|DRUG|Pazopanib|pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
214866195|NCT00388076|DRUG|Lapatinib|Lapatinib in combination with pazopanib and paclitaxel in Part 3
214866196|NCT00388076|DRUG|paclitaxel|in combination with pazopanib
214866197|NCT00388076|DRUG|carboplatin|in combination with pazopanib
214866198|NCT04487938|OTHER|No intervention utilised|No intervention utilised
214866199|NCT02845141|PROCEDURE|Actifuse|bone tunnel filled with Actifuse
214866200|NCT02845141|PROCEDURE|bone graft|bone graft to fill bone tunnel
214866201|NCT06276049|OTHER|custom GPT supported self-directed learning|"The intervention in our study involved a LearnGuide utilization guide course along with a 12-week integrated training program that incorporated LearnGuide. In the first two-hour session, instructional staff introduced LearnGuide through a hands-on demonstration, teaching students how to use ChatGPT effectively by crafting high-quality prompts. The team emphasized LearnGuide's role as an AI facilitator in self-directed learning (SDL). Following the introduction, students were assigned various tasks including online learning, literature reviews, case analyses, and Problem-Based Learning (PBL) activities. Over the 12-week SDL phase with LearnGuide, students were required to complete at least one of these tasks weekly. This setup allowed students to consult mentors for any LearnGuide-related questions, enhancing their learning experience."
214290762|NCT05812612|DRUG|ursodeoxycholic acid|To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
214290763|NCT02619955|OTHER|samples with DNA|
214476499|NCT06296810|DEVICE|aDBS|adaptive deep brain stimulation
214866202|NCT03422939|OTHER|there was no intervention, only separate analyses|We only conducted separate analyses to see if responses differed according to level of experience.
214866203|NCT05122936|COMBINATION_PRODUCT|XRXPY-based Obesity Wellness Intervention(SOWI)|It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
214866204|NCT05673330|OTHER|Spinal Mobilizations|"1. Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~2. Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks"
214866205|NCT05673330|OTHER|Myofascial Release Technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
214866206|NCT00496353|DRUG|MK2461|MK2461 treatment, bid, 28-day
214866207|NCT02512653|BIOLOGICAL|Cupressus arizonica|Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
214866208|NCT06295640|OTHER|Oral glucose tolerance test with double-tracer dilution and intranasal insulin spray|Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Intranasal insulin will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
214866209|NCT06295640|OTHER|Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray|Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Placebo spray will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over ten minutes starting at time point -15 minutes on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
214866210|NCT04305587|DRUG|PF-07081532|Investigational Drug once daily for up to 42 days; multiple ascending dose design.
214866211|NCT04305587|OTHER|Placebo|Placebo once daily for up to 42 days.
214866212|NCT04305587|DRUG|Clopidogrel|Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
214866213|NCT01367665|DRUG|vismodegib|150 mg once daily until disease progression or unacceptable toxicity
214866214|NCT01589965|BEHAVIORAL|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
214866215|NCT06006065|BEHAVIORAL|Upper limb somatosensory discrimination therapy|"Participants will receive three 45 minute sessions of upper limb somatosensory discrimination therapy per week for a period of 8 weeks.~Each session includes 30 minutes of component-based training, including graded practice of three components of somatosensation (i.e., tactile object recognition, texture discrimination and proprioception). Next, 15 minutes of occupation-based practice will be completed to enhance transfer to a functional context. This includes repetitive and structured practice of self-chosen activities of daily living, while attention is designated to the somatosensory aspects necessary for successful task completion (e.g., identification of button based on touch)."
214866216|NCT06006065|BEHAVIORAL|Upper limb motor therapy|Participants in the control group will receive an equal amount of motor training, including 30 minutes of unimanual motor tasks and 15 minutes of bimanual goal directed training. The unimanual motor tasks will be selected based on the main difficulties of the child (e.g., grip strength, supination). Bimanual goal directed training includes whole task practice of self-chosen activities of daily living. All therapy sessions will be performed under supervision of a trained physical and/or occupational therapist. Therapy adherence and progression will be closely monitored by the therapist.
214866217|NCT00182468|OTHER|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
214866218|NCT02752906|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
214866219|NCT02752906|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
214866220|NCT04229459|DRUG|Cisplatin|Cisplatin 100mg/m2 IV on day 1 of induction chemotherapy, 75mg/m2 IV on day 1 and 29 of chemoradiation
214866221|NCT04229459|DRUG|5-FU|5-FU 1000mg/m2/d IV on days 1-5 of induction chemotherapy, 1000mg/m2/d IV on days 1-4 and days 29-32 of chemoradiation
214866222|NCT04229459|RADIATION|Radiation therapy|1.8 Gy/fraction, 5 days a week for a total of 28 days
214866223|NCT04229459|DRUG|Cetuximab|Cetuximab 400mg/m2 IV on day 1 followed by 250mg/m2 IV weekly on induction chemotherapy, 250mg/m2 IV weekly on chemoradiation, 500mg/m2 IV on day 1 of each treatment cycle, every two weeks during immunotherapy
214866224|NCT04229459|DRUG|Nivolumab|Nivolumab 3mg/kg IV on day 1 of each treatment cycle, every two weeks during immunotherapy
214866225|NCT04899388|PROCEDURE|Pericapsular Nerve Block|regional anaesthia
214866226|NCT04899388|PROCEDURE|Lumbar Erector Spinae Plane Block|regional anaesthia
214866227|NCT04899388|DRUG|Fentanyl|intavenous
214866228|NCT00822406|DRUG|homeopathic medicine|individualized homeopathic medicine
215033801|NCT03248752|BEHAVIORAL|Partner engagement|Participants will be connected with their partner in the Fitbit app and therefore have the ability to access their partner's progress. Participants' Weekly Progress Reports will be automatically forwarded to their partner. Participants will engage in a weekly discussion on the topic of their Weekly Progress Reports.
214866229|NCT00822406|DRUG|placebo|placebo - 6 months
214866230|NCT04759053|PROCEDURE|FNB|Fine needle aspiration from the nodules
214866231|NCT04759053|PROCEDURE|Core biopsy|Core biopsy from thyroid nodules
214476500|NCT06862076|PROCEDURE|Lung Function Prehabilitation|Participants assigned to the prehabilitation group received personalized exercise prescriptions, including aerobic training, muscle strengthening, and inspiratory muscle training with a threshold device. The prehabilitation program was conducted at the participants' homes for a minimum duration of two weeks. Adherence was monitored through logbook entries and video call evaluations to ensure correct implementation of the prescribed exercises.
215033802|NCT02006511|DEVICE|Incisional Neg Pressure Wound Therapy (Prevena™)|Negative pressure wound therapy dressing applied over closed surgical incision
214476501|NCT06860282|DRUG|Remdesivir|Intravenous remdesivir 100 mg
214476502|NCT06860282|DRUG|CX2101A|CX2101A enteric-coated tablet
215033803|NCT02006511|OTHER|Standard of Care wound therapy|Gauze type dressing.
214476503|NCT06860282|DRUG|Placebo|CX2101A placebo enteric-coated tablet
214476504|NCT06860217|OTHER|Robotic Nipple-Sparing Mastectomy|Patient will undergo to nipple sparing mastectomy and breast reconstruction, conducted using robot
214866232|NCT00106067|BEHAVIORAL|coping and communication support (CCS) intervention|"Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.~The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families."
214866233|NCT01539135|DRUG|Methylene Blue|20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
214866234|NCT03521466|BEHAVIORAL|Smoking Cessation Counseling|Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
214866235|NCT00002282|DRUG|Clotrimazole|
214866236|NCT00002282|DRUG|Fluconazole|
214866237|NCT01717716|DIETARY_SUPPLEMENT|water with Sucralose|
214866238|NCT01717716|DIETARY_SUPPLEMENT|water with HFCS|
214866239|NCT01717716|DIETARY_SUPPLEMENT|water with glucose|
214866240|NCT01717716|DIETARY_SUPPLEMENT|water with sucrose|
215033804|NCT01283672|OTHER|Controlled diet with whole grain barley, whole grain oats, or low grain diet|Participants will consume a standardized diet for 3 days prior to the treatment intervention meal. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. Participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
214866241|NCT03673657|DIETARY_SUPPLEMENT|Early Nutrition Intervention from the start of CCRT|Nutrition counseling and oral nutritional supplements from the start of radiotherapy; weekly counseling sessions; daily energy intake of approximately 30 kcal/kg.
214866242|NCT03673657|RADIATION|Thoracic radiotherapy|Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy
214476505|NCT04707768|DRUG|Vadadustat|oral tablets
214476506|NCT04707768|DRUG|Mircera®|intravenous administration
214476507|NCT06862141|DEVICE|bendable suction ureteral access sheath|flexible ureteroscopy will be done using bendable suction ureteral access sheath
214866243|NCT03673657|DRUG|Weekly DP chemotherapy concurrent with thoracic radiotherapy|Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
214866244|NCT03097510|BEHAVIORAL|Transcendental meditation|The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
214866245|NCT01480843|DRUG|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
214866246|NCT02743338|BEHAVIORAL|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
214866247|NCT02743338|BEHAVIORAL|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
214866248|NCT02743338|BEHAVIORAL|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
214866249|NCT04791878|DRUG|Mesenchymal stem cells|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
214866250|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
214866251|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
214866252|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
214866253|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
214866254|NCT01451086|BIOLOGICAL|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
214866255|NCT01451086|BIOLOGICAL|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
214866256|NCT01560650|DEVICE|CRRT|Difference dose of CRRT
214866257|NCT00072020|DRUG|zoledronic acid|
214866258|NCT00072020|PROCEDURE|adjuvant therapy|
214866259|NCT00072020|PROCEDURE|neoadjuvant therapy|
214866260|NCT04015323|DEVICE|Interferential current|An electrotherapy current with different carrier frequencies
214866261|NCT00673153|DRUG|gemtuzumab ozogamicin|Given IV
214866262|NCT00673153|DRUG|vorinostat|Given orally
214866263|NCT00673153|OTHER|laboratory biomarker analysis|Correlative studies
214866264|NCT00505089|DRUG|ACZ885|
214866265|NCT00505089|DRUG|ACZ885|
214866266|NCT00505089|DRUG|ACZ885|
214866267|NCT00505089|DRUG|ACZ885|
214866268|NCT01998672|DRUG|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
214866269|NCT01998672|DRUG|Placebo|Drinking solution
214866270|NCT05244395|OTHER|Duchenne Muscular Dystrophy Gait Assessment Scale|a special gait assessment scale for Duchenne Muscular Dystrophy patients
214866271|NCT00003916|RADIATION|radiation therapy|
214866272|NCT00003916|RADIATION|stereotactic radiosurgery|
214866273|NCT01345175|DRUG|Rifaximin|Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
214866274|NCT01345175|DRUG|Placebo|Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
214866275|NCT00642694|DRUG|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
214866276|NCT00642694|DRUG|Ramelteon|Ramelteon 8 mg qd
214866277|NCT00642694|OTHER|Placebo|Matching placebo qd
214866278|NCT05752682|DIAGNOSTIC_TEST|Diagnostic pathway|Each included patient will undergo to the faint and fall protocol, to assess the effectiveness of a patients' flow pathways developed in accordance with the most recent guidelines on syncope of the European Society of cardiology and of guidelines on falls of the American and British Geriatrics Societies.
214866279|NCT03688282|DEVICE|Wearable vibration belt|The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
214476508|NCT06862141|DEVICE|conventional suction ureteral access sheath|flexible ureteroscopy will be done using conventional suction ureteral access sheath
214476509|NCT06860841|DRUG|D-Chiro-Inositol Combined with Metformin|D-chiro-Inositol will be administered for 14 days,1 cp after lunch and 1 cp after dinner in addition to preexisting metformin therapy
214866280|NCT03688282|DEVICE|Sham, wearing belt|The device is worn, for a specified time. It will not be turned on during this period. It is only sham.
214866281|NCT01985074|BEHAVIORAL|Case-management intervention|The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
214866282|NCT04112173|BEHAVIORAL|perturbation-based fall-recovery training|Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
214476510|NCT06860841|DRUG|Placebo in combination with metformin|placebo will be administerd for 14 days, 1 cp after lunch and 1 cp after dinner in addition to pre-existing metformin therapy
214866283|NCT05521139|DIAGNOSTIC_TEST|drug sensitivity results|drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
214866284|NCT05379816|PROCEDURE|5% DW perineural injection|5% DW perineural injection to intercostal nerve
214866285|NCT04009512|DEVICE|Valiant Thoracoabdominal Stent Graft System|This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
214866286|NCT03250559|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic kidney stone extraction technique.
214866287|NCT03712215|OTHER|Rehabilitation|diaphragmatic electrical stimulation
214866288|NCT04575766|DRUG|FT-7051|"Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable.~Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level."
214866289|NCT02519335|DRUG|Dexrazoxane|Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
214866290|NCT03876418|DIAGNOSTIC_TEST|Intra-abdominal Pressure|Aggressive screening, prevention and treatment of intra-abdominal hypertension
214866291|NCT02109419|OTHER|HHT-G|Helping Hands Technology global cognitive function assessment
214866292|NCT02109419|OTHER|HHT-D|Helping Hands Technology depression assessment
214866293|NCT02109419|OTHER|Geriatric Depression Scale (DGS)|Geriatric Depression Scale (DGS)
214866294|NCT02109419|OTHER|MMSE|Mini Mental State Exam
214866295|NCT02740387|DRUG|OTO-104|
214866296|NCT03320200|OTHER|CNS-focused treatment|The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
214866297|NCT03320200|OTHER|Standard Care Treatment|The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
214866298|NCT04275206|OTHER|Harkány medicinal water|The aim is to prove the effectiveness of Harkány medicinal water on patients suffering from psoriasis and rheumatoid arthritis. The control group is treated with tap water.
214866299|NCT04275206|OTHER|Tap water (placebo control)|The control group is treated with tap water.
214866300|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 1500 mg
214866301|NCT04505137|OTHER|GMA301 Placebo Injection|GMA301 Injection without GMA301 administered as a single intravenous dose
214866302|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 2000 mg
214866303|NCT01259115|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
214866304|NCT01259115|DRUG|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
214866305|NCT01259115|DRUG|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
214866306|NCT02889471|PROCEDURE|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
214866307|NCT02889471|PROCEDURE|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
214866308|NCT00006083|DRUG|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
214866309|NCT00006083|OTHER|placebo|placebo injected subcutaneously daily
214866310|NCT04428515|DEVICE|Photoacoustic Imaging System|Photoacoustic Imaging investigate changes of measured PA markers and compare these to radiological assessment of response of lymph node involvement to chemoradiation therapy for head and neck cancer
214866311|NCT04948060|OTHER|Enhanced lung cancer screening services|A theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings
214866312|NCT01270165|DRUG|telbivudine|600mg, oral daily over 12 months
214866313|NCT03560986|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
214866314|NCT03560986|DRUG|Placebo|Glass vials with matching placebo.
214866315|NCT02807168|OTHER|NT-proBNP (Cardiac Biomarkers)|
214866316|NCT00708786|DEVICE|ICD|Ventricular arrhythmia treatment
214866317|NCT00708786|DEVICE|CRT-D|Ventricular arrhythmia treatment
214866318|NCT02355483|DEVICE|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
214866319|NCT03806374|DRUG|Ketamine|ketamine
214866320|NCT03806374|DRUG|Propofol|propofol
214866321|NCT03806374|DRUG|Fentanyl|fentanyl
214866322|NCT03806374|DRUG|Cisatracurium|cisatracurium
214866323|NCT03806374|DRUG|Lidocaine|lidocaine
214866324|NCT02524730|DEVICE|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
214866325|NCT03633734|DRUG|Sequential Treatment|One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
214866326|NCT00152724|DEVICE|pressure strain system, iontophoresis|
214866327|NCT00152724|DRUG|scopolamin|
214866328|NCT00152724|DRUG|emla|
214866329|NCT00152724|DRUG|capsaicin|
214866330|NCT00152724|DRUG|aspirin|
214866331|NCT00152724|DRUG|clopidogrel|
214866332|NCT00152724|DRUG|celecoxib|
214866333|NCT00152724|DRUG|indomethacin|
214290764|NCT03705676|BEHAVIORAL|Rapid Arm Movements|240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
214866334|NCT00152724|DRUG|acetylcholine|
214866335|NCT00152724|DRUG|sodium nitroprusside|
214866336|NCT00152724|DRUG|brethyllium|
214866337|NCT00152724|DEVICE|general and local heating|
214866338|NCT04120090|DRUG|low dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 10 mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 5mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 2.5mg twice daily.
214866339|NCT04120090|DRUG|high dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 20mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 10mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 5mg twice daily
214866340|NCT06490237|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression, vestibular neurotomy, meningioma or schwannoma removal), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests in noise and in silence. During the operation, stimuli are delivered in silence and in noise, under the same conditions as during the preoperative auditory exploration."
214866341|NCT00667901|DRUG|riluzole|
214866342|NCT00667901|GENETIC|protein expression analysis|
214866343|NCT00667901|GENETIC|reverse transcriptase-polymerase chain reaction|
214866344|NCT00667901|GENETIC|western blotting|
214866345|NCT00667901|OTHER|immunohistochemistry staining method|
214866346|NCT00667901|OTHER|laboratory biomarker analysis|
214866347|NCT00667901|OTHER|pharmacological study|
214866348|NCT00667901|PROCEDURE|neoadjuvant therapy|
214866349|NCT00667901|PROCEDURE|therapeutic conventional surgery|
214866350|NCT03256331|DRUG|BEL-X-HG|"This study will be carried out in 2 parts:~1. A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment~2. A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment~Escalating dose levels of BEL-X-HG in 5 study cohorts and one modified dose will be as follows:~* Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)~* Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)~* Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)~* Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid) Modified dose level Cohort 5: Dose level 5 - 1.5 g/day (0.75g bid) This re-escalation is allowed only when dose de-escalates from Dose level 3 to Dose level 2, and 1 DLT in 6 evaluable subjects of Dose level 2."
214866351|NCT05321225|DIAGNOSTIC_TEST|the level of biomarker in bood|Elisa is used to test the level of biomarker in blood.
214866352|NCT04471025|PROCEDURE|USG guided infraclavicular block|USG guided infraclavicular block was applied to patients either by conventional two-person technique or by one person Jedi technique according to the allocated group. On Group I single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm. On Group II, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic.
214866353|NCT03995186|BEHAVIORAL|Behavioural activation|4-week programme based on the behavioural activation treatment provided in the NHS IAPT services. The programme includes psychoeducation on the relationship between activity and depression, examining the depressed person's level of activity, helping them identify activities they would like to increase and supporting them in the planning and conduct of those activities.
214866354|NCT03995186|BEHAVIORAL|Activity monitoring|4-week programme where participants simply monitor their general daily activities in a diary.
214866355|NCT00654758|DRUG|M200 (Volociximab), Carboplatin, Paclitaxel|Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
214866356|NCT04689919|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
214866357|NCT01383213|OTHER|Oxygen therapy|patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation
214866358|NCT01383213|OTHER|Helmet CPAP|patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
214866359|NCT05379049|BIOLOGICAL|Infliximab: Adalimumab; Etanercept;|Therapeutic drug monitoring, evaluation of clinical outcomes and laboratory analysis of biomarkers
214866360|NCT00593736|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
214866361|NCT00593736|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
214866362|NCT00593736|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
214866363|NCT00593736|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
214866364|NCT05442710|BIOLOGICAL|ARTICE|Extracorporal treatment with purified granulocyte concentrate
214866365|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
214866366|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
214866367|NCT02117700|OTHER|Placebo twice/day|Placebo capsules twice/day for 16 weeks
214866368|NCT03472417|DEVICE|Active partial rebreathing device|
214866369|NCT03472417|DEVICE|Dummy partial rebreathing device|
214866370|NCT01268332|DRUG|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
214866371|NCT01868893|DRUG|Obinutuzumab|
214866372|NCT01868893|DRUG|Chlorambucil|
214866373|NCT05316883|DRUG|Clozapine|clinical doses adjusted to sideeffects and clinical effect
214866374|NCT01857271|DRUG|Erlotinib Hydrochloride|Given PO
214866375|NCT01857271|PROCEDURE|Therapeutic Conventional Surgery|Undergo thoracotomy
214866376|NCT01857271|OTHER|Laboratory Biomarker Analysis|Correlative studies
214866377|NCT03002129|OTHER|fluid challenge|At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
214866378|NCT04581174|DIAGNOSTIC_TEST|24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated|Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
214866379|NCT00967291|DRUG|ifosfamide|2,500 mg/mq on days 1-3 every 28 days
214866380|NCT00967291|DRUG|mitomycin C|8 mg/mq on day 1 every 28 days
214866381|NCT01905748|OTHER|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
214866382|NCT03244501|OTHER|Active tSMS|A cylindrical neodymium magnet is placed above the scalp.
214866383|NCT03244501|OTHER|Sham tSMS|A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
214866384|NCT03031886|OTHER|low glycaemic index intervention|Low GI sweetener would be added to the treatment meals. 30 grams of isomaltulose to dinner and breakfast and 20 grams of isomaltulose to lunch and snack.
214866385|NCT03031886|OTHER|high glycaemic index intervention|High GI sweetener would be added to the treatment meals. 30 grams of sucrose to dinner and breakfast and 20 grams of sucrose to lunch and snack.
214866386|NCT02878122|PROCEDURE|Cancer treatment|Chemotherapy and laparoscopic surgery
214866387|NCT04364425|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide
214290765|NCT03705676|DEVICE|Unpleasant stimulus|An unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization).
214290766|NCT03705676|DEVICE|Vibrotactile stimulus|In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
214866388|NCT04364425|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
214866389|NCT04364425|DRUG|Normal saline|Ultrasound guided injection using 15ml or 12 ml of normal saline
214866390|NCT06633822|DIAGNOSTIC_TEST|Digital planning|The digital methodology will consist of obtaining a digital scan and a computed tomography (CBCT) that will be aligned using a digital program for the elaboration of a digital wax-up and fabrication of a printed surgical template.
214866391|NCT06633822|DIAGNOSTIC_TEST|Analogic planning|The analog wax-up will be elaborated based on a silicone impression and periapical radiographs with parallel technique, which will allow us to elaborate an essix-type surgical splint.
214866392|NCT06264401|OTHER|Alendronate|control group received (Alendronate) 70 mg 1 tab every week.
214866393|NCT06264401|OTHER|treatment exercises|the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program, each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 minutes.
214866394|NCT03056586|DEVICE|vaginal pessary|A vaginal pessary will be inserted at the end of the operation, for genital prolapse, and will be sutured to the vaginal wall. The pessary will stay in the vagina for 4 weeks.
214866395|NCT03009630|PROCEDURE|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
214866396|NCT03009630|DEVICE|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
214866397|NCT02141425|DRUG|ASP015K|oral
214866398|NCT02141425|DRUG|Placebo|oral
214866399|NCT01783548|DRUG|BDP Nasal Aerosol|
214866400|NCT01783548|DRUG|Placebo|
215057155|NCT04120844|BEHAVIORAL|Motivational interviewing (MI)-based patient empowerment program (PEP)|Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
214290767|NCT02516683|OTHER|Shigella sonnei infection|A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
214290768|NCT02749981|PROCEDURE|blood and tissue sampling|
214290769|NCT00240162|DRUG|PTK787/ZK 222584|
214290770|NCT03861351|DEVICE|Mini WELL Toric Ready intraocular lens|The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
214866401|NCT02532725|PROCEDURE|Cardiopulmonary Exercise Stress Test|Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.
214866402|NCT02532725|PROCEDURE|Climatic-Controlled Cardiopulmonary Exercise Stress Test|Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.
214866403|NCT02532725|PROCEDURE|Body Composition Evaluation|Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.
214670001|NCT03863444|OTHER|Routine care|Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
214670002|NCT01326598|DEVICE|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
214866404|NCT02532725|PROCEDURE|Pre-Exercise Risk Assessment|Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
214866405|NCT03493386|DRUG|Daprodustat 2 mg tablet|Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.
214866406|NCT03493386|DRUG|Daprodustat 4 mg tablet|Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.
214866407|NCT01097525|PROCEDURE|WFG PRK|
214866408|NCT01097525|PROCEDURE|WFG LASIK|
214866409|NCT01097525|PROCEDURE|WFO PRK|
214866410|NCT01097525|PROCEDURE|WFO LASIK|
214866411|NCT02923986|DRUG|BP1001 (varying dose)|BP1001 (varying dose)
214866412|NCT02923986|DRUG|BP1001 (fixed dose)|BP1001 (fixed dose)
214866413|NCT02923986|DRUG|Dasatinib|Dasatinib
214866414|NCT04221139|BEHAVIORAL|Virtual Reality games|Participants will play the following four virtual reality games for 15 minutes each: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
214866415|NCT05760586|DRUG|Tovorafenib|Oral RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL)
214866416|NCT03499886|DRUG|Ketamine Hydrochloride 50Mg/1mL Solution for Injection|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
214866417|NCT03499886|DRUG|Ketamine Hcl 50Mg/Ml Inj|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
214866418|NCT04589416|OTHER|Dental adhesive materials.|It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
214866419|NCT01140555|DEVICE|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
214866420|NCT00149812|BEHAVIORAL|Family Functioning Intervention|
214866421|NCT02599038|DIETARY_SUPPLEMENT|Serine supplementation|Serine supplementation (200 mg/kg/day)
214866422|NCT03598335|DEVICE|Ultrasound|Ultrasound imaging of women arriving at clinic for routine care
214866423|NCT04605224|BEHAVIORAL|Culinary class|This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
214866424|NCT03682458|GENETIC|Study of Neurodegenerative Diseases Induced Stem Cells|The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
214866425|NCT03321435|OTHER|placenta previa patient|women had placenta previa either major or minor degree
215057156|NCT04120844|BEHAVIORAL|Traditional lecture style health education|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
214866426|NCT03321435|OTHER|normal women|those women had not placenta previa
214670003|NCT00878046|DEVICE|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
214670004|NCT03412630|RADIATION|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
214670005|NCT02183467|DRUG|BI 1356, low dose|
214670006|NCT02183467|DRUG|BI 1356, high dose|
214670007|NCT02183467|DRUG|Placebo|
214670008|NCT02183467|DRUG|Moxifloxacin|
214866427|NCT03804502|DEVICE|TearCare|The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
214866428|NCT04333108|DRUG|Masitinib|Masitinib 6 mg/kg/day
214866429|NCT04333108|OTHER|Placebo|Matching placebo
214866430|NCT04333108|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
214866431|NCT06107504|DRUG|Sucralfate|2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
214866432|NCT00988442|BEHAVIORAL|Enhanced nursing telephone support|Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.
214866433|NCT00988442|BEHAVIORAL|Standard care|Usual ACTG site care.
214866434|NCT04167293|RADIATION|stereotactic body radiotherapy|Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
214866435|NCT04167293|DRUG|Sintilimab|Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
214866436|NCT03982979|DEVICE|HM3 LVAS|HeartMate® 3 (HM3) Left Ventricular Assist System (LVAS)
214866437|NCT05073952|PROCEDURE|Connective tissue graft|Implants will be placed with a flap and a connective tissue graft.
214866438|NCT05073952|PROCEDURE|Flapless|Implants will be placed with a flapless approach
214866439|NCT02468570|OTHER|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
214866440|NCT04257552|BEHAVIORAL|Healthy Beyond Pregnancy|Web-based application grounded in tenants of behavioral economics.
214866441|NCT04257552|BEHAVIORAL|Pre-Scheduled Postpartum Visit|Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
214866442|NCT04257552|OTHER|Attention Control|Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
215033805|NCT04017858|BEHAVIORAL|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).|"Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis"
214866445|NCT00918840|BIOLOGICAL|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
214866446|NCT00918840|BIOLOGICAL|Placebo|Dextrose/glucose solution
214866447|NCT00918840|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
214866448|NCT00894101|DRUG|[F-18] FLT|10 mCi \[F-18\] FLT and 10 mCi \[F-18\] FDG will be used for PET imaging.
215033806|NCT04017858|BEHAVIORAL|Patients will be submitted to total knee replacement.|"Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively"
214866449|NCT03308266|DIAGNOSTIC_TEST|electromyography|
214866450|NCT04755257|DEVICE|Isokinetic test|Using IsoMed 2000 device (D. \& R. Ferstl GmbH, Hemau, Germany) we conducted the isokinetic test of concentric (CON) and eccentric (ECC) shoulder internal (IR) and external (ER) strength at the angular velocity of 60˚/s in both Method I (scapular position) and Method II (25⁰ Abd and 20⁰ ER). There were seven days between the testing sessions, and both tests were conducted at the same time of day. The same examiner with experience in performing isokinetic testing with IsoMed 2000 tested all subjects in both testing sessions.
214866451|NCT05509738|BEHAVIORAL|SMS Text Messaging|"The text message-based healthcare assistance includes 1) message reminders and 2) a daily achievement reflection. The delivery schedule is as below.~1. Message reminders:~   The investigators will send participants two text reminders per day, one in the morning and one in the afternoon, from Monday to Friday, with the information on helping their child achieve healthy bladder goals.~2. Daily achievement reflection:~The investigators will send participants a text message with a survey link to reflect their and their children's daily goal achievement Monday to Friday evenings. Timely feedback (e.g., inspirational and compliment messages) will be provided based on participants' responses."
214866452|NCT03557424|DRUG|Polyglucosamine Glucomannan normal dose (Verum)|Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
214866453|NCT03557424|DRUG|Polyglucosamine Glucomannan high dose (Verum)|Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
214866454|NCT03557424|DRUG|Placebo Comparator: Placebo|Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
214670009|NCT06340204|DRUG|Irinotecan Hydrochloride Liposome Injection|Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).
214866455|NCT00467935|DRUG|intravitreal injection Lucentis (ranibizumab)|intravitreal injection Lucentis (ranibizumab)
214866456|NCT01830218|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
214866457|NCT04023643|OTHER|Ventilation Weaning|Use of different weaning strategies
214866458|NCT05502965|OTHER|dietary pattern|Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.
214866459|NCT05502965|OTHER|EEN|All energy and nutrients are obtained from exclusive enteral nutrition.
214866460|NCT03249337|DRUG|Ripasudil hydrochloride hydrate 0.4% ophthalmic solution|"the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment"
214866461|NCT05297578|BIOLOGICAL|24-Valent Pneumococcal Conjugate Vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
214866462|NCT05297578|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
214866463|NCT03456583|DEVICE|Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
214866464|NCT04005365|DRUG|Propranolol|add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
215033807|NCT05176067|RADIATION|Thoracic Three-dimensional Radiotherapy|Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
215033808|NCT00661856|DIETARY_SUPPLEMENT|Soy protein|25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
214866465|NCT06552065|OTHER|collagen with silk fibroin membrane|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.~An immediate implant with collagen membrane ( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures"
214866466|NCT06552065|OTHER|cross linked collagen membrane|A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.
214866467|NCT04422119|PROCEDURE|Multi-Foam dressing|Application of a multi-layer foam dressing with Safetac in surgical wound
214866468|NCT04422119|PROCEDURE|Usual care|Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
214866469|NCT00015340|DRUG|Buprenorphine/naloxone|
215033809|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (25 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
214866470|NCT01113944|BEHAVIORAL|Program 1|
214866471|NCT01113944|BEHAVIORAL|Program 2|
214866472|NCT05076240|PROCEDURE|FilmArray® analysis|FilmArray® multiplex PCR analysis to diagnose ventilator associated pneumonia in COVID-19 ARDS
214866473|NCT01087489|DRUG|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
214866474|NCT01087489|DRUG|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
214866475|NCT02374489|DRUG|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
214866476|NCT02640092|DRUG|[18F]GTP1|Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.
214866477|NCT02770885|DRUG|Dulaglutide|Treatment with dulaglutide for 3 weeks.
214866478|NCT02770885|DRUG|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
214866479|NCT00056394|BEHAVIORAL|Comprehensive Coping Skills Training|10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.
214866480|NCT00056394|BEHAVIORAL|Arthritis Education Sessions|10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.
214866481|NCT00056394|BEHAVIORAL|Standard Care|Usual care from participants' rheumatologists but no treatment sessions.
214866482|NCT04849065|DRUG|MNC (Mononuclear cells)|"* Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)~* Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)"
214866483|NCT04849065|DRUG|Placebo / Saline|\- Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
214866484|NCT04735757|OTHER|Contrast-enhanced MRI|Contrast-enhanced MRI
214866485|NCT04735757|OTHER|Measurement of respiratory muscle force|Measurement of the maximum inspiratory and expiratory pressure.
215033810|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (40 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
214866486|NCT02912169|PROCEDURE|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
214866487|NCT02912169|BIOLOGICAL|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
214866488|NCT00346463|DRUG|Allopurinol|
214866489|NCT05851625|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
215033811|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
215033812|NCT06473246|DIETARY_SUPPLEMENT|CBD Broad Extract (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
214670010|NCT02031146|PROCEDURE|Lumbar puncture|
214670011|NCT01284556|DRUG|Phenobarbital|tablet
214866490|NCT05851625|DEVICE|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
214866491|NCT00117325|DRUG|GW685698X|Aqueous Nasal Spray 100mcg
214866492|NCT02208674|OTHER|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
214866493|NCT05951855|DRUG|Selinexor|Selinexor 60mg/day, weight≥70kg (40mg/day, weight\<70kg) orally on d1,4,8,11,
214866494|NCT05951855|DRUG|Chidamide|Chidamide 10mg/day, orally on day 1 to 28
214866495|NCT03184155|DRUG|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
214866496|NCT03184155|DRUG|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
214866497|NCT00416650|DRUG|erlotinib hydrochloride|All patients will receive 150 mg orally daily
214866498|NCT06344936|DRUG|HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules|Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice
215033813|NCT06473246|DIETARY_SUPPLEMENT|Placebo|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
215033814|NCT05743309|BEHAVIORAL|Video call sessions|Investigators made video call sessions with the participants.
215033815|NCT04883138|DRUG|GIGA-2050|Recombinant Hyperimmune Polyclonal Antibody
214866499|NCT05830149|OTHER|Cryoinsufflation|In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
214866500|NCT05830149|OTHER|Deroofing|Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
214866501|NCT05748249|DRUG|Vertistop® D|Vitamin D supplementation
214866502|NCT03956121|OTHER|injection of magnesium sulfate|The intervention consists to perform a study of the usual fetal heart rate with, in addition, comparison analysis of the short-term variability before and after injection of magnesium sulfate in the exposed group. Two successive short-term variability analyzes will be performed in fetuses of the control group.
214866503|NCT04728503|BEHAVIORAL|5-Minute Mindful Movement Video|5 minute video includes a brief verbal introduction to mindfulness and then guides participants through a mindful movement exercise to facilitate grounding in the present moment and activation of the parasympathetic nervous system.
214866504|NCT04728503|BEHAVIORAL|Written Educative Materials|1 page written educative material about the benefits of mindfulness to serve as a control.
214866505|NCT04664790|DEVICE|Hyperbaric Oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
214866506|NCT04664790|BEHAVIORAL|Cognitive training|Neuropsychologist guided BrainHQ training
214866507|NCT03361475|BEHAVIORAL|SME App|"The features in the App could be used in the future by linking with some platforms / existing services so that more SME messages can be sent to the students for sharing. One school workshop will be held to promote SME and introduce the function of SME App for students to download and use immediately to connect family members.~SME App promotes SME via:~* Express gratitude to family members (sharing)~* Deliver positive messages regularly (mind)~* Record physical and other joyful activities (enjoyment)~* Increase knowledge and understanding of adolescent mental health problem (in particular the anxiety disorders)"
214866508|NCT01265433|BIOLOGICAL|Galinpepimut-S + Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self administered) subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
215033816|NCT04017208|DRUG|ASP2713|Administered intravenously
215033817|NCT04017208|DRUG|placebo|Administered intravenously
215033818|NCT00099814|PROCEDURE|Two different loop designs which deliver distinctive forces|
215033819|NCT05492045|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
215033820|NCT05492045|DRUG|Other|Standard treatment of NSCLC.
214290771|NCT06248892|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214670012|NCT01284556|DRUG|Placebo tablet|tablet
214670013|NCT01754896|OTHER|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
215033821|NCT04748237|DIAGNOSTIC_TEST|Coronary computed tomopraphic angiography|CCTA as soon as possible, preferably within 24 hours, but not later than within 21 days.
215033822|NCT02259231|DRUG|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
215033823|NCT02259231|DRUG|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
215033824|NCT02259231|DRUG|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
215033825|NCT02259231|DRUG|Omaveloxolone Capsules (10 mg/capsule)|Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
215033826|NCT02259231|DRUG|Omaveloxolone Capsules (50 mg/capsule)|Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
215033827|NCT06293898|DRUG|BL-M07D1|"Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 by intravenous infusion every 3 weeks.~Other Names:~BL-M07D1"
215057157|NCT00669825|DRUG|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
215057158|NCT00669825|DRUG|Placebo|Placebo to be administered via intragastric tube
214866509|NCT01265433|BIOLOGICAL|Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self-administered)subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
214866510|NCT05420870|BEHAVIORAL|exercise|"Six weeks of exercise intervention~To meet weekly 150 min of moderate to vigorous physical activity and twice weekly strength exercise General description of the exercise program~Main goal of the supervised exercise (1 hour per session, twice a week) are three folds. 1) Instruct participants to correctly perform prescribed exercises. 2) Encourage participants to be compliant to exercise program. 3) Participants were encouraged to hand in their exercise diary~Main goal of the home-based exercise is to perform calisthenics exercise daily. Participants were encouraged to perform at least one set of exercise (8-12 different exercises) and stretching (At least 3 days per week, but preferably most of the days) daily~Basic 8 exercises which increase ROM and strength of shoulder, lower back, Hip, Knee and ankle Additional 4 exercise to increase core strength and stability"
214866511|NCT03265418|DEVICE|BioXmark liquid fiducial markers|Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
214866512|NCT03265418|OTHER|Imaging|"As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy."
214866513|NCT03265418|PROCEDURE|surgery or wait-and-see|"As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol."
214866514|NCT01468818|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
214866515|NCT01468818|DRUG|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
214866516|NCT01468818|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
214866517|NCT04360096|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
214866518|NCT04360096|DRUG|Placebo|Normal Saline Inhalation
214866519|NCT04360096|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
214866520|NCT01714232|DEVICE|Contour® PLUS BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214866521|NCT01714232|DEVICE|OneTouch® SelectSimple™ BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214866522|NCT01714232|DEVICE|Accu-Chek® Performa BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
215033828|NCT06821841|BEHAVIORAL|Online Physical Activity Group|The online physical activity group will consist of four 45-60-minute sessions, which participants allocated to this group will be asked to commit to. These sessions will be delivered online and occur for 4 weeks. Discussions within the sessions will incorporate motivational interviewing, focussing on the benefits of physical activity, current physical activity levels, barriers to physical activity and overcoming these, motivation to complete physical activity, and goal setting. Participants allocated to this group will receive weekly reminders to promote attendance. Participants will also be asked to complete a weekly physical activity log that includes detail about the type of physical activity they completed, the duration, intensity, context and comments.
215033829|NCT06821841|BEHAVIORAL|Information Leaflet|Participants will receive an information leaflet that includes information about menopause (e.g. definition, symptoms), the benefits of physical activity for menopause, recommended weekly physical activity levels (based on CMO guidelines), examples of physical activity, and signposting to online resources. Participants will be able to use the information leaflet as they wish, and complete a weekly physical activity log that includes detail about the type of physical activity completed, the duration, intensity, context and comments.
214866523|NCT01714232|DEVICE|Accu-Chek® Active BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214866524|NCT01714232|DEVICE|Freestyle Freedom® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
214866525|NCT06244849|BIOLOGICAL|Blood samples|A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine
214866526|NCT06244849|BIOLOGICAL|Stool simple|A fresh stool sample will be collected and conserved at room temperature until shipment
214866527|NCT06244849|BIOLOGICAL|Ileocolonic biopsies|An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed
214866528|NCT01607307|DRUG|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
214866529|NCT01607307|DRUG|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
214866530|NCT01212588|DRUG|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
214866531|NCT01212588|DRUG|Placebo|3 tablets once daily for seven days
214866532|NCT06455007|DRUG|Propolis|Propolis 3x10 drops (7 days)
214866533|NCT02430285|PROCEDURE|Endoscopic Ultrasound|Endoscopic Ultrasound
214866534|NCT02430285|DEVICE|Olympus 180 series echoendoscope|
214866535|NCT00935688|OTHER|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
214866536|NCT03715361|DIAGNOSTIC_TEST|SL-ECG|additional SL-ECG measurement
214866537|NCT02338193|DRUG|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
214866538|NCT02338193|DRUG|DAPA|10 mg dapagliflozin QD for 20-24 weeks
214866539|NCT02338193|DRUG|MET XR|1000 mg Metformin XR BID for 20-24 weeks
214866540|NCT00540683|DEVICE|Diffuse Optical Spectroscopy|Muscle properties
214866541|NCT05174494|DIAGNOSTIC_TEST|Evaluation of serum CRP and NT-proBNP|All patients were evaluated to 6-months post-treatment reduction of serum CRP and NT-proBNP
214866542|NCT03283462|DIETARY_SUPPLEMENT|Mitopure|Mitopure (Urolithin A) containing softgels
214866543|NCT03283462|DIETARY_SUPPLEMENT|Placebo|Placebo containing softgels
214866544|NCT01568060|OTHER|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
214866545|NCT00151138|DRUG|Atenolol (drug), Lisinopril (drug)|
214866546|NCT00357123|DRUG|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
214866547|NCT02276014|DIETARY_SUPPLEMENT|Beta-carotene|
214866548|NCT04896814|PROCEDURE|Transcutaneous tibial nerve stimulation|The participant will be placed in the supine position with the soles of the feet together and the knees flexed and abducted at 90º. Two adhesive electrodes will be used for each leg. First one: 32 mm of diameter that will be placed in the posterior tibial nerve, that is, 4-5 cm cranial to the internal malleolus, between the posterior edge of the medial border of the tibia and the soleus tendon. Second one: 50x50 mm to be placed in the ipsilateral calcaneus. The electrodes will be connected to the NeuroTracTM PelviTone stimulation device. The stimulation range will be selected according to the tolerable pain limit for the patient, between 0.5 and 20 mA (adjustable in 1 mA levels).The intensity elevation will be allowed each time the patient perceives the fading of the previous sensation due to accommodation. Under no circumstances should the stimulation cause a painful feeling.
214866549|NCT04896814|PROCEDURE|Placebo|The participant will be placed in the same position. Two 50 x 50 mm adhesive electrodes will be placed on the external face of the thigh, on a single leg. This area is outside the territory of the posterior tibial nerve. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied. This simulated current being considered to be insufficient to achieve therapeutic effects in the body and to be outside of the usual ranges described in electrotherapy manuals regarding pain management. The intensity will be selected according to the paint limit level of the patient, between 0.5 and 60 mA (adjustable in 0.1 mA levels), where a low or moderate sensation of the patient will be sought, without muscle contraction.
214670014|NCT01754896|OTHER|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
214866550|NCT01735955|DRUG|Nilotinib|Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
214866551|NCT02971735|OTHER|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
214866552|NCT01906450|DRUG|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
214866553|NCT01906450|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
214866554|NCT03194841|OTHER|Heart failure application|A mobile phone application that allowed for input of physiologic data, qualitative question input and education retrieval along with SMS use.
214866555|NCT05084716|BEHAVIORAL|Enhanced PrEP provision|At the intervention site during healthcare facility outreach events, all community members will be offered the opportunity to attend intervention workshops where they can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Check-in reminder calls will be conducted systematically with PrEP users. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter.
214866556|NCT04271579|PROCEDURE|Salvage Lymphnode dissection|"A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)"
214866557|NCT02890654|OTHER|First time measure|"* Initial Interview~* Initial Survey,~* Quality of life Scale~* Kinesitherapy Review~* Anxiety Scale"
214866558|NCT02890654|OTHER|Second time measure|"* Kinesitherapy review~* Second survey including numeric scale of pain~* Anxiety scale~* Scoliosis Research Society 22 quality of life scale"
214866559|NCT02890654|OTHER|Third time measure|"* Scoliosis Research Society 22 quality of life Scale~* Anxiety scale~* Numeric scale of pain~* Kinesitherapy review"
214866560|NCT02476240|BEHAVIORAL|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
214866561|NCT00362544|DRUG|Ambisome|
214866562|NCT05042544|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
214866563|NCT01930565|OTHER|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
214866564|NCT01930565|OTHER|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
214866565|NCT00879957|DRUG|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
214866566|NCT00879957|DRUG|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
215033830|NCT05079334|BEHAVIORAL|MeTree Questionnaire|"MeTree is a patient driven risk assessment program with Clinical Decision Support (CDS) that enables collection of a three plus generation family health history (FHH) on 128 conditions. CDS is provided in a report with a pedigree and tailored evidence-based guidelines. While patient drive, MeTree also includes a provider-facing report with additional references. These reports promote engagement by both patients and providers and enhance shared decision-making.~MeTree first generates information imported from the participant's EHR record. These data include basic demographic information, any recent lab results, and any listed diseases or conditions from the EHR. Next, MeTree gives the participant an opportunity to fill out a family history tree. The more information the participant provides on their own health and their family member's health, the better MeTree can provide recommendations from current literature."
215033831|NCT00496119|RADIATION|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
215033832|NCT00496119|RADIATION|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
215057159|NCT01521923|BIOLOGICAL|Certolizumab Pegol + Methotrexate (MTX)|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week."
214866567|NCT03503526|BEHAVIORAL|Receptive music therapy|12 weekly trauma-focused Group therapy sessions of a length of 2.5 hours. The core element is receptive music psychotherapy with music listening, art making, and other art based methods.
214866568|NCT03373773|PROCEDURE|Foley catheter removal|After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
214866569|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of single fertilized embryo through IVF
214866570|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of double fertilized embryo through IVF
214670015|NCT01754896|OTHER|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
214866571|NCT00001110|PROCEDURE|Bronchoalveolar lavage|
214866572|NCT01846910|BEHAVIORAL|Tooth Whitening|1\. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
214866573|NCT01846910|BEHAVIORAL|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
214866574|NCT02176408|BEHAVIORAL|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
214866575|NCT02176408|BEHAVIORAL|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
214866576|NCT02176408|BEHAVIORAL|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
214866577|NCT03204708|DEVICE|catheter|catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
214866578|NCT03204708|DRUG|iv analgesia|patients were given 100 ml of tramadol 30 minutes before extubation
214866579|NCT05428410|OTHER|IL-4R|IL-4R was injected subcutaneously.
214866580|NCT05428410|OTHER|Placebo|Placebo was injected subcutaneously.
214866581|NCT00650208|DRUG|Lamotrigine Tablets 25 mg|2x25mg, single dose fasting
214866582|NCT00650208|DRUG|Lamictal® Tablets 25 mg|2x25mg, single dose fasting
214866583|NCT03934411|DRUG|Tramadol|The subjects will orally ingest 100 mg tramadol retard actavis
214866584|NCT03934411|OTHER|Placebo|The subjects will orally ingest 100 mg calcium powder
214866585|NCT06132932|DRUG|WX390|Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
214866586|NCT05568901|BEHAVIORAL|Lethal means counseling|"Lethal means counseling is a type of safety education that advises securement or removal of potentially hazardous household items such as medications, knives, and firearms. Counseling provided by study team was derived from the Suicide Prevention Resource Center's Counseling on Access to Lethal Means training module and the Store It Safe campaign from the Ohio Chapter of the American Academy of Pediatrics (AAP). Guidance focused on securement of dangerous items in the household, such as medications and firearms, with locking devices-or more preferably removing these items from the home, even if temporarily."
214866587|NCT05568901|BEHAVIORAL|Provision of Cable-style gun locks|Caregivers were provided 2 (two) SnapSafe Cable Padlock (Item No. 75281), advised on how to use these devices to store firearms safely (including instructions from within the package of the provided gun locks) and were advised to store keys away from the firearm in a location that children would not have access
214866588|NCT04708548|OTHER|Health-related Quality of Life|Health-related quality of life (HRQOL) is an individual's or a group's perceived physical and mental health over time.
214866589|NCT04708548|OTHER|Psychological Distress|Measured of the distress experienced by patients
215033833|NCT05164653|DRUG|Sacubitril Valsartan Sodium Hydrate|"Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation."
215033834|NCT05164653|DRUG|Standard treatment|Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
214866590|NCT04708548|OTHER|Fatigue|Measure of the extreme tiredness resulting from mental or physical exertion or illness
214866591|NCT04708548|OTHER|Cognitive Functioning|Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention. This will be measured through self-report and cognitive testing.
214866592|NCT03514849|PROCEDURE|prophylactic cranial irradiation (PCI)|Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.
214866593|NCT03514849|PROCEDURE|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
214866594|NCT03514849|DRUG|postoperative adjuvant chemotherapy|If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
215057160|NCT01521923|BIOLOGICAL|Placebo + Methotrexate (MTX)|"1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week."
215057161|NCT02706418|PROCEDURE|Clinical Massage Therapy|
214866595|NCT01434186|DRUG|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
214866596|NCT01434186|DRUG|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
214866597|NCT01434186|DRUG|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
214866598|NCT01434186|DRUG|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
214866599|NCT04380363|DEVICE|Honda Walk Assist (HWA) device|Use of HWA for 2 months in the home setting
214866600|NCT04380363|OTHER|SRALab fitness center membership|Membership to Shirley Ryan AbilityLab fitness center for 2 months
214866601|NCT00405886|DRUG|Neramexane|Oral tablets, duration: 16 weeks
215033836|NCT03815552|DEVICE|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with diabetes for the operating life of the sensor.The System comprises a sensor and a transmitter. The small sensor will be subcutaneously inserted in the arm.The transmitter reads glucose data from the subcutaneous sensor.
215033837|NCT03979001|OTHER|complete ophthalmological examination|"collection:~* ophthalmological history and current treatments~* occular tension measurement~* measurement of visual acuity (Snellen chart)~* Axial length measurement~* Photograph of the posterior segment of the eye~* 3x3 and 6x6 macular and papillary OCT angiography"
215033838|NCT05826665|OTHER|Persistent AF ablation assisted with the STAR Apollo Mapping System|This exploratory hypothesis generating data set will be collected during standard AF ablation procedures using FDA cleared technologies as described in their Instructions for Use (IFU). No randomization or experimental protocols will be used during this study, and all follow up will be performed as per the center's standard of care(SOC).
215033839|NCT06638736|OTHER|Wound Closure with sutures vs staples|Closure of the wound with either sutures or staples depending upon the study arm
215033840|NCT06639334|OTHER|Fasttrack pathway for THA/HE prosthesis reduction|"The purpose of this study is to design a fast-track pathway for patients referred to the University Hospital of Southern Denmark, Esbjerg, with high probability of having a dislocated hip prosthesis with the primary aim to reduce the time from arrival to reduction and the total hospitalization time.~The intervention is changed logistic and work pathways at the hospital that should reduce time to reduction significantly. For detailed description we refer to the uploaded protocol."
214866602|NCT00405886|DRUG|Placebo|Oral tablets, duration: 16 weeks
215033841|NCT06639334|OTHER|Standard pathway for THA/HE prosthesis reduction|Standard treatment for a dislocated THA/HA at our institution is education in general anesthesia at the operating theater. For detailed description we refer to the uploaded protocol.
215033842|NCT06637150|DRUG|Dalpicilib|Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.
215033843|NCT06637150|DRUG|endocrine therapy|standard endocrine therapy
214866603|NCT03599830|OTHER|Cognitive test passations|"Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences"
214866604|NCT01762930|DRUG|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
214866605|NCT00831766|DRUG|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
215033844|NCT06210893|OTHER|The cricoid cartilage is located.|The cricoid cartilage is located.
215033845|NCT05371379|BIOLOGICAL|CM338 Injection|A humanized monoclonal antibody.
215033846|NCT06643572|DEVICE|Virtual reality simulator|This virtual reality simulator allows for the simulation of a lumbar transforaminal epidural steroid injection using the patient's 3D lumbar images.
215033847|NCT03126630|BIOLOGICAL|Anetumab Ravtansine|Given IV
215033848|NCT03126630|OTHER|Laboratory Biomarker Analysis|Correlative studies
214866606|NCT00831766|DRUG|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
214866607|NCT00831766|DRUG|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
214866608|NCT05604248|OTHER|Intervention|Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil
214866609|NCT03517696|PROCEDURE|Membrane sweeping|Participants assigned to membrane sweeping will have an additional exam during their initial evaluation in which the membranes will be separated from the cervix and lower part of the uterus with a finger inserted into the cervical os. This would be done with at least one rotation counterclockwise and one rotation clockwise.
215033849|NCT03126630|BIOLOGICAL|Pembrolizumab|Given IV
215033850|NCT03126630|OTHER|Pharmacological Study|Correlative studies
215033851|NCT00847730|DEVICE|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
215033852|NCT05908500|BEHAVIORAL|CPR Training|Various durations and frequencies of CPR training
215033853|NCT05908500|DEVICE|CPR Manikin Type|Various types of CPR manikins are compared
215033854|NCT06171802|DRUG|Empagliflozin|10 mg empagliflozin daily for six months
215033855|NCT06171802|DRUG|Placebo|Placebo capsule once daily for six months
215033856|NCT05191485|OTHER|Qualitative interviews|We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA\_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.
215033857|NCT06845436|BEHAVIORAL|Exercise|Combined exercise group subjects will undergo weekly three sessions of both HIIT and resistance training for sixteen weeks. The HIIT session will involve four four-minute high-intensity intervals with an intensity of at 80-95% of the HRmax interspersed with two-minute active recovery intervals with intensity of 40% to 60% of the HRmax.
215057162|NCT05895877|DRUG|Goofice®|Once daily before breakfast.
215057163|NCT05895877|DRUG|Goofice® Placebo|Once daily before breakfast.
215033858|NCT06845436|OTHER|routine physical activity|The control group subjects will be instructed not to change their usual daily physical activities routine and instructed to abstain from practicing any exercise regimens during the 12-week study period.
215033859|NCT06852898|OTHER|Chiropractic Care|Chiropractic Care is the active comparator arm / intervention. All subjects will receive chiropractic care.
215033860|NCT06852898|OTHER|Radial Extracorporeal Shockwave Therapy (ESWT) - Radial Pulse Therapy|This intervention is answering the question: Does on radial ESWT have additive therapeutic effects on the recovery of acute lower back pain symptoms - better or earlier reduction in pain intensity or improvement in physical function - than chiropractic care / manual therapy alone? Subjects will be randomly assigned to receive chiropractic care and ESWT or only chiropractic care.
215033861|NCT05736471|DIAGNOSTIC_TEST|Computational dissociation of the causes of cognitive rigidity in depression|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
215033862|NCT04341012|DIAGNOSTIC_TEST|Collection of breath sample|Analysis of volatile organic compounds in breath
215033863|NCT04606849|OTHER|Physician Survey|Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.
215033864|NCT04606849|DEVICE|ePNa-CheXED|ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in \<1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
215033865|NCT05499819|OTHER|Canned black beans, drained and rinsed|Canned black beans, drained and rinsed and consumed in a tortilla wrap
215033866|NCT05499819|OTHER|Canned red kidney beans, drained and rinsed|Canned red kidney beans, drained and rinsed, drained and rinsed and consumed in a tortilla wrap
215033867|NCT05499819|OTHER|Extra-lean ground beef|Extra-lean ground beef, pan-fried and consumed in a tortilla wrap
215033868|NCT03607500|BEHAVIORAL|caloric intake reduction|The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
215033869|NCT01456403|OTHER|Histological validation|3D ultrasound, PET/CT, MRI, contrast ultrasound
215033870|NCT06506513|OTHER|High-intensity interval training|High-intensity interval training
215033871|NCT06506513|OTHER|Moderate intensity exercise training|Moderate intensity exercise training
215033872|NCT06506513|OTHER|Low intensity exercise training|Low intensity exercise training
215033873|NCT04858997|DRUG|Palbociclib|Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
215033874|NCT04858997|DRUG|AI|AI, orally once daily (continuously)
215033875|NCT00091897|DRUG|Rituximab|
215033876|NCT00091897|DRUG|rituximab or placebo|A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
215033877|NCT05795764|BEHAVIORAL|Crisis Response Planning|Crisis Response Planning (CRP) is a brief psychotherapeutic intervention.
215033878|NCT05795764|BEHAVIORAL|Treatment as Usual|Standard care provided for patients at risk for suicide
215033879|NCT06475820|DRUG|Baricitinib|"GVHD prevention using a combination of post-transplantation cyclophosphamide~Prevention of GVHD:~Cyclophosphamide 80 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +60, +90 Vedolizumab 10 mg/kg/day, max. 300 mg on the days 0, +14, +28, +60 Baricitinib 4 mg/day per os (patient age \> 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day."
215033880|NCT03701334|DRUG|Ribociclib|Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle
215033881|NCT03701334|OTHER|Endocrine Therapy|ET will be administered according to the local clinical guidelines and current local prescribing information
214670016|NCT01754896|OTHER|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
214670017|NCT02420652|DRUG|Aspirin|Given PO
215033882|NCT00005626|DRUG|Irinotecan|Irinotecan as outlined in treatment arm
215033883|NCT05132491|OTHER|TECH-Prep Intervention|Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.
215033884|NCT04507269|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
215033885|NCT04507269|DRUG|Placebo|Saline given by subcutaneous injection
215033886|NCT01080235|OTHER|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
215033887|NCT01080235|OTHER|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
215033888|NCT06463730|BEHAVIORAL|Serious games|Custom games played using the Equio system, non-custom Wii Fit games played using the Nintendo Wii Balance Board
215033889|NCT03662451|PROCEDURE|Robotic assisted hysterectomy|Periumbilical single incision vs multiple abdominal incisions for hysterectomy
215033890|NCT06129955|DRUG|Pucotenlimab Combined With Lenvatinib|Patients treated by Pucotenlimab combined with Lenvatinib for 3 months before surgery
215033891|NCT05051228|DEVICE|CardioFlux|Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
215033892|NCT02120261|DRUG|Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
215033893|NCT02120261|DRUG|Lidocaine Hydrochloride|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
215033894|NCT02120261|DRUG|Triamcinolone acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
215033895|NCT06570070|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
215033896|NCT06570070|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
215033897|NCT06570070|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
215033898|NCT06570070|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
215033899|NCT06570070|BEHAVIORAL|Counselor individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
215033900|NCT02071589|DRUG|Nifedipine soft gelatine capsules|3 Adalat capsules of 10 mg each one
215033901|NCT02071589|DRUG|Nifedipine oral solution|6 mL of Nife Par solution
215033902|NCT04103931|BEHAVIORAL|"Treatment Choices for Aortic Stenosis Decision Aid"|"A decision aid, titled Treatment Choices for Aortic Stenosis, produced by the American College of Cardiology that contains information for patients deciding between TAVR and surgery to treat their aortic stenosis."
215033903|NCT05143814|DEVICE|3D Printed Mask Adapter Designed from Facial 3D scans for Fit testing.|Given the high level of fit test failures, without the provision of improved fits of masks, patient care will be highly curtailed for frontline staff at risk of SARS-CoV-2. Therefore, a reusable bespoke mask adapter used with a soft FFP3 disposable mask might be an economical solution to address the passing of fit testing. Currently, this is a major challenge in delivery of healthcare and urgent action is needed.
215033904|NCT06064617|DEVICE|Contact Lens|Coopervision Biofinity Multifocal Lens
215033905|NCT01013571|DRUG|insulin glargine|pre-filled disposable pen, in package of 5.
215033906|NCT01013571|DRUG|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
215033907|NCT03070665|DRUG|Norepinephrine|Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
215033908|NCT00071032|BIOLOGICAL|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
215033909|NCT00071032|BIOLOGICAL|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
215033910|NCT02784587|PROCEDURE|Stellate Ganglion Block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
215033911|NCT05752032|GENETIC|ICM-203|Long term follow-up
215033912|NCT05752032|DRUG|Placebo|Long term follow-up
215033913|NCT05580705|OTHER|Routine Physical Therapy|The Routine Physiotherapy treatment will include Transcutaneous Electrical Nerve Stimulation, Hot pack, Range of Motion (ROM) Exercises and Muscle Strengthening Exercises
215033914|NCT05580705|OTHER|Vibration Therapy|Vibration Therapy will include a vibration device of brand Manipol, model number RK-001. It has 360 degree off-centered axis with a frequency of 2500 times per minute. It will be applied on sole of the foot for about 15 mins.
215033915|NCT03381326|PROCEDURE|blood and FFPE sample collection|blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection
215033916|NCT01907893|BEHAVIORAL|Trauma Collaborative Care Plus Treatment as Usual|
215033917|NCT05974540|DIAGNOSTIC_TEST|Determination of cricothyroid membrane|"After the patient's head is extended, the pediatric surgeon will be asked to mark the cricothyroid membrane with a pencil using traditional inspection and palpation methods. Then, the cricothyroid membrane will be determined by the Anesthesiology and Reanimation specialist by USG method and the difference will be determined. Demographic and morphometric characteristics of the patients will be recorded. In addition, the length of the cricothyroid membrane, the distance between the cricoid cartilage and the skin, the distance between the cricoid cartilage and the 2nd tracheal ring will be measured by USG.~Mallampati classes of patients with intubation, Cormack-Lehane (CL) glottic appearance grades, Likert scale with intubation difficulties (1: very easy, 2: easy, 3: medium, 4: difficult) will also be recorded."
215033918|NCT05947838|PROCEDURE|Circulating tumoral DNA directed neoadjuvant therapy arm|Given by IV (vein)
215033919|NCT05878795|BEHAVIORAL|WET-SP|WET-SP will consist of 5 treatment sessions; the first session lasting about one hour and each subsequent session lasting approximately 40 minutes. Each session will include a 30-minute written exposure exercise. The participant will be given general instructions for completing the narrative writings and specific instructions for completing the first session. Participants will be instructed to write about the same suicidal crisis during each session. The therapist will emphasize the importance of delving into their deepest emotions surrounding the suicidal crisis as well as the importance of writing detailed information about the crisis. Following writing, the therapist and the participant will process the writing experience. Subsequent sessions involve the therapist iteratively providing feedback to the patient regarding their writing from the previous session.
215033920|NCT05878795|BEHAVIORAL|TAU|TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.
215033921|NCT05136495|OTHER|caffeinated coffee - decaffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
215033922|NCT04104789|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
215033923|NCT04104789|DRUG|Articaine Injection|Local anesthetic
215033924|NCT05561387|DRUG|Bortezomib|Given SC
215033925|NCT05561387|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
215033926|NCT05561387|DRUG|Dexamethasone|Given PO
215033927|NCT05561387|DRUG|Lenalidomide|Given PO
215033928|NCT05561387|OTHER|Quality-of-Life Assessment|Ancillary studies
215033929|NCT05561387|OTHER|Questionnaire Administration|Ancillary studies
215033930|NCT06196138|OTHER|Gum|In the postoperative period, starting from the 4th hour, chewing gum is done 3 times a day, morning, noon and evening, for 30 minutes each, until the patient passes the first flatus.
215033931|NCT06196138|OTHER|Hot Compress|Starting from the 1st postoperative day, patients will receive hot application (to the lumbar region) for 10 minutes in the morning and evening. The hot application is applied by wrapping 2 towels in a water bag containing 55 ± 2 °C hot water. The water bag is applied to the lumbar region for 10 minutes with the patient in the supine position. The application is continued until the patient passes the first flatus.
215033932|NCT06071104|PROCEDURE|Anterior segment ophthalmic surgery|Cataract surgery during which the crystalline lens (often cloudy) is broken into small pieces and gently removed from the eye with suction (phacoemulsification)
215033933|NCT06071104|DEVICE|UNITY VCS|UNITY Vitreoretinal Cataract System (VCS) with console, remote control, foot controller, UNITY Cataract FMS Pack, and UNITY Anterior Vitrectomy Kit
215033934|NCT05866081|DEVICE|Standard of care stent placement|Participants will have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
215033935|NCT05866081|OTHER|No stent placement|Participants not have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
215033936|NCT05866081|OTHER|Surveys|"All participants in the trial cohort and observational arms will be asked to complete survey instruments (evaluating their pain, quality of life, and experiences following ureteroscopy, as well as surveys evaluating their opinions and preferences around ureteral stenting, etc.).~Participants will also have routine clinical data (preoperative, perioperative, and postoperative) to be collected and analyzed for research purposes."
215033937|NCT06419361|DRUG|[68Ga]Ga-Sa-DABI-4|Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
215033938|NCT03518060|DRUG|JULUCA|JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
215033939|NCT05078112|DEVICE|Sleep sensor technology|Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output to soothe them to sleep. The device will give this output for first 10 nights, then wean the output the child receives over 10 nights.
215033940|NCT05136846|DRUG|Carboplatin|Given IV
215033941|NCT05136846|BIOLOGICAL|Durvalumab|Given IV
215033942|NCT05136846|DRUG|Paclitaxel|Given IV
215033943|NCT05136846|DRUG|Papaverine|Given IV or SC
215033944|NCT05136846|RADIATION|Radiation Therapy|Undergo RT
215033945|NCT05136846|DRUG|Pemetrexed|Given IV
215033946|NCT05136846|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
215033947|NCT05136846|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215033948|NCT05136846|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215033949|NCT05136846|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
215033950|NCT05136846|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo brain MRI
215033951|NCT05136846|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215033952|NCT03241615|OTHER|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
214290772|NCT06248892|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214670018|NCT02420652|OTHER|Laboratory Biomarker Analysis|Correlative studies
215033953|NCT04766567|PROCEDURE|Cesarean section with cesarean myomectomy (serosal)|Serosal or endometrial myomectomy performed during cesarean section
215033954|NCT04766567|PROCEDURE|Cesarean section without myomectomy|Cesarean delivery without performing myoemctomy
215033955|NCT06113367|OTHER|Evaluation of anti-PD-(L)1 immunotherapy efficacy|Non Applicable, research on data
215033956|NCT01427478|DRUG|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
215033957|NCT01427478|DRUG|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
214670019|NCT02420652|DRUG|Metformin Hydrochloride|Given PO
214866610|NCT05080101|OTHER|Conventional Therapy Program|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
214866611|NCT05080101|OTHER|Basic Body Awareness Therapy Group Program|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
214866612|NCT03630107|OTHER|WO 5101 Shampoo for Scalp and Hair|Wash the hair at least three times a week for a period of four weeks
215033958|NCT04614532|DIAGNOSTIC_TEST|cognitive assessment|"global cognitive assessment :~* Mini Mental State~* Evaluation of manual laterality~* Hospital Anxiety and Depression scale~* 5 words of Dubois~* Trail Making Test~* short battery of the praxies~* neuropathic pain scale (DN4 in french)~* Analog Visual Scale for pain~* Fast Front End Efficiency Battery"
214866613|NCT00752011|DRUG|TAS-106|Starting dose 2.0 mg/m\^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
214866614|NCT00752011|DRUG|Carboplatin|Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
215033959|NCT04614532|OTHER|Cold Pressor Test|"consists of the complete immersion of the participant's arm in a basin of cold water maintained at a temperature.~The test will be divided into two conditions (pain, no pain). In the first, the container will be filled with cold water. In the second, the water in the container will be at room temperature. The investigators will test each arm. During the immersion of the arm, participants will have to remain silent and remove their arm when the ordeal becomes too painful for the painful condition.~For the non-painful condition, the immersion time will be determined according to the results of the pre test."
215033960|NCT04614532|OTHER|digital sensor of Nociception Level Index|placed on the contralateral index finger with the arm immersed in the tank to measure the variation of physiological parameters.
215033961|NCT00220792|BEHAVIORAL|Brief supportive-expressive group therapy|
215033962|NCT05242367|DEVICE|Modius Spero active device|Battery powered non-invasive neurostimulation device
215033963|NCT05242367|DEVICE|Sham device|Placebo comparator sham device (no active stimulation)
215033964|NCT05185622|DRUG|Vamorolone|Oral administration of vamorolone for 12 weeks.
214670020|NCT02420652|OTHER|Placebo|Given metformin hydrochloride placebo PO
214866615|NCT04140435|DEVICE|EUS-guided through-the-needle microbiopsy forceps (Moray)|"EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology."
214670021|NCT02420652|OTHER|Placebo|Given aspirin placebo PO
214866616|NCT00110526|GENETIC|Ad.hIL-12|Ad.hIL-12 intraprostatic injection IND
214866617|NCT00430820|PROCEDURE|per intervention|per intervention
214866618|NCT02208635|OTHER|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (\~30 µg Zn/g).
214866619|NCT02208635|OTHER|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of \~60 µg Zn/g).
214866620|NCT02208635|OTHER|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (\~15 µg Zn/g maize).
214866621|NCT04020757|DEVICE|variation in dialysis bicarbonate|35 mEq/L dialysate bicarbonate for one week, followed by 30 mEq/L for one week, followed by 35mEq/L for one week with nutritional supplement during dialysis
214866622|NCT04020757|DIETARY_SUPPLEMENT|Zone Perfect bar|16g protein supplement given during first 30 mins of dialysis on last testing day
215033965|NCT06063876|PROCEDURE|Induction of experimental peri-implant mucositis|Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.
215033966|NCT06063876|PROCEDURE|Resolution of experimental peri-implant mucositis|Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.
215033967|NCT06564740|DRUG|Stem Cell|UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg.
215033968|NCT06564740|OTHER|Control|In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to these patients will continue to be administered.
215033969|NCT04648085|DEVICE|Trigeminal Nerve Stimulation|Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
215033970|NCT03005886|PROCEDURE|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
214866623|NCT01162746|DRUG|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
214866624|NCT01162746|DRUG|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
214866625|NCT00971776|DEVICE|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
214866626|NCT02229123|DRUG|Intravenous Levetiracetam|Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
214866627|NCT04300140|DRUG|Batiraxcept|Batiraxcept is experimental drug
214866628|NCT04300140|DRUG|Cabozantinib (Cabo)|Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC
214866629|NCT04300140|DRUG|Nivolumab|Nivolumab is standard of care in the first line treatment of ccRCC
214866630|NCT01751932|DEVICE|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
214866631|NCT03713775|OTHER|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
214866632|NCT03713775|OTHER|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min), together with supporting written information.
214866633|NCT06483568|BEHAVIORAL|Pathways to Happiness Intervention|Four weeks of activities including a gratitude journal, random acts of kindness, self-compassionate letter, and capitalizing on positive events activities.
214866634|NCT06483568|BEHAVIORAL|Personal Organization Activities|"Four weeks of activities including a completed tasks journal, weekly task burst, productivity letter, and talking to others about task activities."
214866635|NCT05200897|DEVICE|Transdermal trigeminal electrical neuromodulation(Cefaly)|The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes
214866636|NCT03260985|OTHER|Feedback Report|A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
215033971|NCT03005886|PROCEDURE|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
215033972|NCT03005886|PROCEDURE|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
215033973|NCT03352947|DRUG|Dabrafenib|150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
215033974|NCT03352947|DRUG|Trametinib|Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
215033975|NCT03463187|BIOLOGICAL|SHR-1314|Administered subcutaneously
214866637|NCT02852720|DRUG|Levobupivacaine|After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.
214866638|NCT02852720|PROCEDURE|Spinal anesthesia|Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.
214866639|NCT02852720|PROCEDURE|Peripheral vein canulation|An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling
214866640|NCT02852720|PROCEDURE|Ultrasonography|TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.
214866641|NCT02852720|DEVICE|Holter|A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
214866642|NCT02767882|DRUG|Dexamethasone|Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
214866643|NCT02767882|DRUG|Saline|Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
214866644|NCT05563376|DIAGNOSTIC_TEST|Univentricular Hearts|Prevention when factors are recognized
215033976|NCT03463187|DRUG|Placebo|Administered subcutaneously
215033977|NCT06114628|DRUG|GSK3036656|Oral daily dosage of 20mg.
215033978|NCT06114628|DRUG|BTZ-043|Oral daily dosage of 1000mg.
214670022|NCT00204893|DRUG|calcium formate|Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
214670023|NCT02463591|DRUG|Beriplex|Beriplex 50 IU/Kg i.v. , single dose.
214670024|NCT03524872|DEVICE|Original CAD/CAM prosthetic abutment|Original (Sweden\&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.
214866645|NCT03576482|OTHER|Transport on foot|Patients go to operating room walking with their families and with their normal clothes
215033979|NCT06114628|DRUG|Bedaquiline (B)|Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
215033980|NCT06114628|DRUG|Delamanid (D)|Oral daily dosage of 300mg.
215033981|NCT06114628|DRUG|Pretomanid (Pa)|Oral daily dosage of 200mg.
215033982|NCT06114628|DRUG|Moxifloxacin (M)|Oral daily dosage of 400mg.
215033983|NCT06114628|DRUG|Linezolid (L)|Oral daily dosage of 600mg for the first 8 weeks.
214866646|NCT03963986|DEVICE|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
214866647|NCT02188186|DRUG|Initial triple combination|Initial triple combination arm
215033984|NCT06114628|DRUG|Pyrazinamide (Z)|Oral daily dosage of 1200mg-2000mg depending on weight.
215033985|NCT06114628|DRUG|Rifampicin (R)|Oral daily dosage of 450mg-750mg depending on weight.
215033986|NCT06114628|DRUG|Isoniazid (H)|Oral daily dosage of 225mg-375mg depending on weight.
215033987|NCT06114628|DRUG|Ethambutol (E)|Oral daily dosage of 825mg-1375mg depending on weight.
215033988|NCT05609825|DRUG|LY3875383|Administered SC.
215033989|NCT05609825|DRUG|Placebo|Administered SC.
214670025|NCT03524872|DEVICE|Compatible CAD/CAM abutment|Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.
214866648|NCT02188186|DRUG|Conventional treatment|Conventioanl treament with dose escalation
214866649|NCT04098900|DIAGNOSTIC_TEST|Click Sexual Health Test|The Click Device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
214866650|NCT00714961|DRUG|Clopidogrel (SR25990)|plus acetylsalicylic acid (ASA)
214866651|NCT00714961|DRUG|Placebo|plus acetylsalicylic acid (ASA)
214866652|NCT03671616|BIOLOGICAL|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
215033990|NCT02394067|OTHER|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
215033991|NCT02516813|DRUG|M3814 100 mg|Participants received 100 mg of M3814 as capsule or tablet orally once daily.
215033992|NCT02516813|DRUG|M3814 200 mg|Participants received 200 mg of M3814 as capsule or tablet orally once daily.
215033993|NCT02516813|DRUG|M3814 300 mg|Participants received 300 mg of M3814 as capsule or tablet orally once daily.
215033994|NCT02516813|DRUG|M3814 400 mg|Participants received 400 mg of M3814 as capsule or tablet orally once daily.
215033995|NCT02516813|DRUG|M3814 50 mg|Participants received 100 mg of M3814 as capsule orally once daily.
215033996|NCT02516813|RADIATION|Fractionated RT|Participants received fractionated palliative RT (3 Gray \[Gy\] \* 10 in Arm A and 2 Gy \* 33 to 35, 5 fractions per week \[F/W\]) in Arm B and received a single high dose of RT (10-25 Gy) capsule on Day 1 given on Lesion 1 and a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2 in ancillary CPoP part.
215033997|NCT02516813|DRUG|Cisplatin|Participants received Cisplatin twice at a dose of 100 mg/m\^2 or weekly at a dose of 40 mg/m\^2.
215033998|NCT05315752|PROCEDURE|Bariatric surgery|"Bariatric surgery includes (but is not limited to)~* Gastric bypass: surgical bypass of the entire stomach, duodenum and approximately 1 m of the proximal small intestine~* Sleeve: a large part of the stomach is removed laparoscopically, the open vertical edges are put back in place to leave a sleeve-like tube.~Bariatric surgery is considered a treatment option~* for patients with a BMI \>40 kg/m 2 , assuming the patient has previously participated successfully in a group weight management programme (weight loss \>7%) or~* for patients with a BMI of 35-40 kg/m 2 when the obesity is associated with type 2 diabetes or hypertension, or OAS (with CPAP therapy) or severe musculoskeletal disease"
215033999|NCT02929732|OTHER|Sympathetic nervous activity measurement|Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
215057164|NCT03174405|DRUG|Avelumab|"All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)"
214670026|NCT03524872|PROCEDURE|Local anesthesia|Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).
214670027|NCT03524872|DRUG|Painkillers|Patients will be prescribed ibuprofen 600 mg three times per day for five days
214670028|NCT03524872|DRUG|Mouthwashes|Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
214670029|NCT03524872|DEVICE|Implant placement|Dental implants (Sweden \& Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
214866653|NCT03581409|DRUG|Aspirin|Aspirin protect tablet
214866654|NCT03581409|DRUG|Prasugrel|Prasugrel tablet
214866655|NCT03581409|DRUG|Clopidogrel|Clopidogrel 75mg tablet
214866656|NCT03581409|DRUG|Cilostazol|Cilostazol tablet
214866657|NCT06002841|BIOLOGICAL|intravenous treatment with EVs|intravenous treatment with extracellular vesicles
214866658|NCT06002841|BIOLOGICAL|intravenous treatment with placebo solution|intravenous treatment with placebo solution (without extracellular vesicles)
214866659|NCT01381666|DRUG|INS316 solution for inhalation|inhalation via nebulizer given for 2 doses for 60 minutes each
214866660|NCT01381666|DRUG|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
214866661|NCT05668130|PROCEDURE|Sacrospinous ligament fixation|Women with stage II or higher pelvic organ prolapse with apical compartment involvement planned for surgical management will be randomised to either sacrospinous ligament fixation arm or uterosacral ligament suspension arm. those raandomized to sacrospinous ligament fixation arm will undergo unilateral (right) sided sacrospinous ligament fixation of apex as a part of pelvic organ prolapse surgery.
214866662|NCT05668130|PROCEDURE|Uterosacral Ligament Suspension|Similarly women randomised to uterosacral ligament suspension arm will undergo modified high uterosacral ligament suspension of apex. Both arms will be followed up in 6 months and 12 months for anatomical and functional outcome.
214866663|NCT05910112|PROCEDURE|Pleural interventions|eg thoracocentesis, chest drain, indwelling pleural catheters, thoracoscopy
214866664|NCT03570671|DIAGNOSTIC_TEST|Spasm positive|"Investigators define the positive criteria for VSA on MDCTA as follows:~1. Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or~2. Diffuse small diameter (\< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT."
214866665|NCT03570671|DIAGNOSTIC_TEST|Spasm negative|Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.
214866666|NCT02906761|DRUG|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
214866667|NCT02906761|DRUG|Placebo|Placebo (2 tablets) twice daily for 6 months
214866668|NCT04709211|PROCEDURE|Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca block using 50 ml 0f Bupivacaine 0.25%
214866669|NCT04709211|PROCEDURE|Anterior Quadratus Lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using 50 ml 0f Bupivacaine 0.25%
214866670|NCT04709211|DRUG|bupivacaine|bupivacaine
215034000|NCT06597513|DRUG|auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab|"Induction:~Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.~Those without disease progression will advance to consolidation treatment.~Consolidation:~Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.~After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.~Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.~Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.~Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.~Maintenance:~Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision."
215034001|NCT01200134|OTHER|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
215034002|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread mixed with fermented brown seaweed|5-day intake period
215034003|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread|5-day intake period
215034004|NCT05639725|PROCEDURE|maxillary Ist premolar extraction|Procedure/Surgery: Patients will undergo bilateral maxillary 1st premolars extraction before bonding followed by leveling \& alignment.
214670030|NCT05734872|DEVICE|Virtual Reality Technology|Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
215034005|NCT05639725|PROCEDURE|SURGICAL|Surgery:After leveling and alignment,placement of zygomatic miniplates in bilaterally
215034006|NCT04497155|DRUG|Norepinephrine|Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure \<100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
215034007|NCT05434468|OTHER|Sustained neutral apophyseal glides|gong mobilization
215057165|NCT00113672|BEHAVIORAL|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
214670031|NCT05734872|OTHER|Routine mental health course training|Conduct mental health education for patients by making a speech.
214670032|NCT00772460|DEVICE|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
214670033|NCT04569539|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
214866671|NCT03893565|DRUG|GSK2831781 - Double Blind Phase|GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
214866672|NCT03893565|DRUG|Placebo|Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
214866673|NCT03893565|DRUG|GSK2831781 - Open Label phase|GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
214866674|NCT00446901|DIETARY_SUPPLEMENT|Selenium|Selenized yeast, 300 ug/day
214866675|NCT02707445|DRUG|Clopidogrel|Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
214866676|NCT02811432|OTHER|Kangaroo mother care|Skin-to-skin care (target: at least 18 hours per day)
214866677|NCT02811432|OTHER|Standard care|Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
214866678|NCT02332837|BEHAVIORAL|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
214866679|NCT02332837|BEHAVIORAL|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
214866680|NCT02332837|BEHAVIORAL|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
214866681|NCT02697240|DRUG|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
214866682|NCT02681211|OTHER|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
214866683|NCT02681211|DRUG|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
215034008|NCT02755350|DRUG|Truvada|Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
215034009|NCT05361798|DRUG|M9241|In the safety lead in, M9241 will be given in de-escalating doses (starting dose 16.8 mcg/kg, and de-escalated if needed to 12 mcg/kg, or 8 mcg/kg) every 4 weeks for 3 doses. Within 4 weeks after completing SBRT, those participants receiving immunotherapy agents will receive M9241 by subcutaneous injection at dose determined during the safety lead in every 4 weeks for 3 doses.
215034010|NCT05361798|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy
215034011|NCT06001723|BEHAVIORAL|Forest Therapy|Forest healing activities are guided by professionals, allowing participants to engage in a two-hour sensory experience within the forest environment. This includes activities such as stacking leaves and stones, closing their eyes to listen to sounds, engaging in physical stretches, blindfolded tree identification, connecting with tree companions, creating earth mandalas, and partaking in tea ceremonies and sharing insights.
215034012|NCT04556045|BEHAVIORAL|Exercise therapy|The exercise therapy intervention will last 4 weeks. Each participant assigned to this intervention will receive a personalized ET regimen, including in-person, supervised exercise sessions; other activities to be followed at home. Participants will exercise between one and seven times per week depending on their tolerance to the treatment and exercise program.
215034013|NCT04470037|DRUG|DAAOI-P|DAAOI-P 250-1500mg
215034014|NCT04470037|DRUG|Placebo|starch pill
215034015|NCT06183593|OTHER|Radiofrequency application|Radiofrequency stimuli will be applied at pain threshold intensity. Arm and leg will be stimulated.
215034016|NCT06183593|OTHER|Pinprick stimuli|Pinprick stimuli will be administered at varying speeds and forces using an automated device
215034017|NCT05697380|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted.
215034018|NCT03657485|DIETARY_SUPPLEMENT|containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A|we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
214866684|NCT02681211|DRUG|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
214866685|NCT02681211|DRUG|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
214866686|NCT02681211|DRUG|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
214866687|NCT05875103|DIAGNOSTIC_TEST|linguistic processes|"Linguistic processes are assessed by performance score on the following tests:~* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)~* vocabulary test (Mill Hill - Deltour, 1993),~* repetition tests (Gremots - Bézy et al., 2016),~* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)~* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),~* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),~* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)"
214866688|NCT04257149|DIAGNOSTIC_TEST|Hemorrhagic stroke group (group A)|Group A: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
214866689|NCT04257149|DIAGNOSTIC_TEST|Ischemic stroke group (group B)|Group B: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
214866690|NCT04257149|DIAGNOSTIC_TEST|Stroke mimic group (group C)|Group C: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
214866691|NCT06014905|DRUG|Hyperpolarized carbon C 13 pyruvate|Given Intravenously (IV)
214866692|NCT06014905|PROCEDURE|Magnetic Resonance Image (MRI)|Imaging procedure
214866693|NCT06014905|OTHER|Saline|Given IV
214866694|NCT00997204|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
214866695|NCT05008601|DEVICE|Wrist-word optical heart rate and ECG measurement device|Aino ECG: wrist-word optical heart rate and ECG measurement device
214866696|NCT00513136|BEHAVIORAL|Group based mind body medicine intervention|Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns
214866697|NCT00513136|BEHAVIORAL|Group-based mind body medicine intervention + family focus|In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
214866698|NCT04380090|DRUG|Propylene Glycol|Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
214866699|NCT04380090|DRUG|Docusate Sodium|Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
214866700|NCT04585880|OTHER|Virtual Collaborative Care Clinic|The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
214866701|NCT05659693|BEHAVIORAL|digital literacy education specific to menopause|Education; It is planned as 5 sessions in the form of presentation, homework, scenario and sending reminder messages. The training is planned to last approximately 20 minutes with a power point presentation prepared by the trainer. The survey will be evaluated in the first session. Women will be told what digital literacy is, why it is important, how to verify information and resources, security of accounts, resources, money and devices, access to information, understanding and valuing information. A screening and access to information session will be held with a scenario prepared on menopausal symptoms, taking into account the variables of information and resource security, access to information, understanding and valuing information, with examples on the digital platform. The woman will be given a scenario homework on menopausal symptoms. Interim evaluation will be made in the fourth week of the training. The final evaluation will be made in the fifth session.
215034019|NCT05607849|OTHER|The decidons ensemble (let's decide together) leaflet and the discutons-mammo.fr (let's talk about breast cancer screening) online tool.|"The leaflet will include a link to access the discutons-mammo.fr DA aid tool, and will inform women about shared decision-making.~The GPs of women who are sent the leaflet will also be sent a letter encouraging shared decision-making. This material will be sent 3 months after women have received their breast cancer screening invitation letter.~Data related to primary and secondary objectives will be collected by questionnaire from the 2 groups. The questionnaire will be sent 2 months after participants are informed about the tool."
215034020|NCT02757768|DRUG|Mirabegron|Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
215034021|NCT02757768|DRUG|Placebo|Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
215034022|NCT02757768|DRUG|Tamsulosin Hydrochloride|Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
215034023|NCT06659900|OTHER|CORE Plus (+)|CORE PLUS intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.
215034024|NCT06659900|OTHER|CORE|CORE intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
215034025|NCT06662513|OTHER|No Intervention: Observational Cohort|No intervention - retrospective observational study
215034026|NCT06658067|DEVICE|Continuous Glucose Monitor (CGM)|The first CGM sensor will be applied as directed during the first visit with a brief training by staff. Participant will be instructed to remove and replace the device every 14 days for the remainder of the 3-month trial period. Participant will also be instructed to scan the sensor three times daily. Compliance may be tracked via remote accessing of the blood glucose log on the online FreeStyle portal. CGM models used will include the Abbott FreeStyle Libre 2 and 3 and Dexcom G5, G6 and G7.
215034027|NCT05218434|DRUG|AX-158|Oral administrations of AX-158
215034028|NCT06990555|OTHER|Neutral White Cast|This intervention consists of receiving a cast of neutral white color.
215034029|NCT06990555|OTHER|Color Wrapped Cast|This intervention consists of receiving a cast of color that is the choice of the participant.
215034030|NCT06990555|OTHER|Cast with Cast Art|This intervention consists of receiving a cast with art at the request of the participant, to include drawing, multiple colors, glitter, and any artwork.
215034031|NCT06078189|DEVICE|HORUS|"The trapezium-metacarpal arthroplasty consists of the installation of a bipolar prosthesis composed of a metacarpal implant and a trapezial implant articulated through a metacarpal head."
215034032|NCT06674564|DIETARY_SUPPLEMENT|Zinc Acetate 50 Mg Oral Capsule|zinc suppose to improve immunity and wound healing after laryngectomy
215034033|NCT06674564|DIETARY_SUPPLEMENT|Probiotic|probiotics lowering infections rates and improving outcomes after surgery
215034034|NCT06999278|DRUG|Levothyroxin|Levothyroxin 50ug/d from randomization until delivery
215034035|NCT06999278|DRUG|Placebo|Placebo to levothyroxin
215034036|NCT06673784|DIAGNOSTIC_TEST|ophthalmic saline eye drops|for optical examination
215034037|NCT06673784|DRUG|Saline|Most one natural and not effects on study
215034038|NCT06675734|DRUG|diclofenac sodium solution|The experimental group consisted of patients in whom diclofenac sodium was administered IM and the control group consisted of patients in whom diclofenac sodium was administered orally only.
215034039|NCT07010861|OTHER|Expressive Art Therapy|As a strategy for coping with trauma, art production creates therapeutic effects on the individual with its sensory and physical aspects (Chapman, 2013; King-West and Hass-Cohen, 2008). When verbal expression is insufficient or carries the risk of re-traumatization, expressive art therapy offers a safe space through non-verbal expression (Talwar, 2007). It is stated that art production is effective in repairing self-integrity ruptures that occur in traumatic experiences (Harris, 2009). Through creative processes, the individual can restructure both internally and externally. Expressive art therapy, especially when applied in a group environment, creates a psychotherapeutic effect by providing participants with the opportunity to express their emotions, imagination and unconscious processes (Malchiodi, 2012; Kim et al., 2021). The commitment and reflective understanding that occur in group psychotherapy are among the factors that give hope and strength (Robb, 2017).
215034040|NCT07010653|DEVICE|Higroscopic Cervical ripening|Participants assigned to the Dilapan-S group will have 3 to 5 rods inserted under aseptic conditions. Placement will follow manufacturer instructions, and rods will remain in place for up to 12 hours unless spontaneous labor or device expulsion occurs earlier. Upon removal, cervical status will be assessed, and induction will continue with prostaglandins or oxytocin based on standard care.
215034041|NCT07010653|DEVICE|Cervical ripening via CRB|Double Balloon Catheter (CRB) Participants randomized to CRB will undergo insertion of a double balloon catheter with inflation of each balloon (approximately 80 mL saline each) according to established protocols. The catheter will remain for up to 12 hours or until spontaneous labor or expulsion. Post-removal management will mirror that of the Dilapan-S group.
215034042|NCT07010848|OTHER|Core stability training|Core stability Training consists in the activation of trunk.
215034043|NCT07010718|DRUG|Scented Oil|inpatient-safe aromatherapy (scented oil)
214866702|NCT05674903|DEVICE|Verum stimulation with Diadem prototype|Diadem prototype device delivers focused low-intensity ultrasound stimulation
215034044|NCT07010718|DEVICE|Ear Plugs|ingestible-safe ear plugs (noise blocking)
215034045|NCT07010718|DEVICE|Eye Mask|inpatient-safe eye mask (light blocking).
215034046|NCT07010718|BEHAVIORAL|Video based safety check|video based safety checks will be conducted as long as participants are in bed and asleep
215034047|NCT07010718|BEHAVIORAL|In person safety check|In person safety checks will be conducted every 30 minutes
215034048|NCT06624995|OTHER|chatbot education|elderly patients interacted with Chatbot to discuss general postoperative complication related inquiries
215034049|NCT07011407|OTHER|Maximal Exercise Test|"Healthy participants will be situated on a cycle ergometer fitted with a 12-lead ECG or chest-strap heart rate monitor. Data from the questionnaire will be stored in a study site file in a locked cabinet in an office. Baseline readings will be obtained whilst on the bike for 3 minutes before the subject embarks on a 3-minute warm-up at 50 Watts (W). The workload (watts) on the bike is then increased to a workload that corresponds to a heart rate of 120 bpm (gentle exercise). The workload will then be increased by 25-50W every three minutes until volitional exhaustion. Between each stage, there will be a 30s rest period where the participant will be cycling with minimal resistance (freewheeling) but will be otherwise stationary on the cycle ergometer. Still images of the face and facial video recordings will be taken during a 30s rest period between increases in exercise intensity. A finger-prick blood sample (glucose \& lactate) will be taken at the beginning and every 3 minutes."
215034050|NCT07010614|DEVICE|Intracranial electrodes|Intracranial electrodes will be used for the delivery of invasive electrical brain stimulation.
215034051|NCT07010614|DEVICE|TMS|TMS will be used for the delivery of noninvasive brain stimulation
215034052|NCT07010614|DEVICE|TMS sham|Sham TMS will be used as a comparator for noninvasive brain stimulation
215034053|NCT07010068|DIETARY_SUPPLEMENT|TGF-β2-enriched food for special medical purposes|"The experimental treatment is Modulen-IBD®, a food for special medical purpose, polymeric, enriched with TGF-beta. If the patient refuses the experimental supplementation, NGT will be proposed to ensure the correct intake of Modulen-IBD® supplementation.~If the patient refuses, not tolerates, or there are contraindications to NGT placement, best supportive therapy will be warranted as reported below (BST)."
215034054|NCT07010068|DIETARY_SUPPLEMENT|BST|Best Nutritional Supportive Treatment as per center's policy according to EBMT Handbook 2024
215034055|NCT06683677|DEVICE|High-Flow Nasal Cannula|The intervention involves administering High-Flow Nasal Cannula therapy to extremely preterm infants immediately after birth.
215034056|NCT07011108|OTHER|No intervention (observational study)|no intervention
215034057|NCT06691360|DRUG|AK137|IV infusion, specified dose on specified days.
215034058|NCT06687733|GENETIC|NGGT002|adeno-associated viral vector with human phenylalanine hydroxylase gene
214866703|NCT05674903|DEVICE|Sham stimulation with Diadem prototype|Diadem prototype device delivers active sham, unfocused low-intensity ultrasound stimulation
214866704|NCT05909865|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
214866705|NCT05909865|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
215034059|NCT04255563|DEVICE|DCB treatment|DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
215034060|NCT07010393|DRUG|Dabrafenib|150 mg orally twice daily; ≤4 × 28-day cycles
215034061|NCT07010393|DRUG|Trametinib|2 mg orally once daily; same duration
215034062|NCT07010393|DRUG|Selpercatinib|160 mg orally twice daily; ≤4 cycles
215034063|NCT07010393|DRUG|Pralsetinib|retrospective, 400 mg orally once daily; ≤4 cycles
215034064|NCT07010393|DRUG|Lenvatinib|24 mg orally once daily; ≤4 cycles
215034065|NCT07010393|DRUG|Larotrectinib|Larotrectinib 100 mg orally twice daily, continuous 28-day cycles.
215034066|NCT07010393|DRUG|Anlotinib|12 mg orally once daily; 2 weeks on / 1 week off, ≤4 cycles (alternative)
215034067|NCT07010393|DRUG|Pembrolizumab|200 mg IV infusion every 3 weeks; ≤4 cycles
215034068|NCT07010393|DRUG|Sintilimab|200 mg IV infusion every 3 weeks; ≤4 cycles
215034069|NCT07010393|DRUG|Cabozantinib|Cabozantinib 60 mg orally once daily, continuous 28-day cycles.
215034070|NCT07010393|DRUG|Bemosuzumab|China PD-L1 antibody bemosuzumab 900 mg IV every 2 weeks (14-day cycle).
215034071|NCT07010393|PROCEDURE|Conversion Surgery|Conversion Surgery if resectable
215034072|NCT07009899|DRUG|Linvoseltamab|Linvoseltamab is a human IgG4-based bsAb that binds to CD3, a T-cell antigen associated with the TCR complex, and BCMA, which is expressed on the surface of malignant MM B-lineage cells, as well as late-stage B cells and plasma cells.
215034073|NCT06607770|DRUG|Karelizumab+Apatinib|Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.
215034074|NCT06625710|DRUG|GV1001|Lyophilized peptide from hTERT
215034075|NCT06625710|DRUG|Placebo|0.9 % Normal Saline
215034076|NCT02371187|DRUG|Dapagliflozin|Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
215034077|NCT02371187|DRUG|Placebo|Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
215034078|NCT03462121|DRUG|RPh201|RPh201 is a well-defined extract from a botanical source
215034079|NCT03462121|OTHER|Placebo|Inactive placebo consisting of the therapeutic vehicle
215034080|NCT06022887|BEHAVIORAL|TRE|daily ad libitum food intake, 8-h 12pm - 8pm, 8 wks active weight loss phase;
215034081|NCT06022887|BEHAVIORAL|MBSR|Completed 30 sessions of a Mindfulness-Based Stress Reduction (MBSR) interventions for 8 weeks
215034082|NCT02117076|DRUG|Gabapentin immediate release|up to 1200 mg per day
215034083|NCT02117076|DRUG|Gabapentin enacarbil extended release|up to 1200 mg per day
215034084|NCT05918146|DRUG|Dextrose|Dextrose injection plus physical therapy
215034085|NCT05918146|DRUG|Normal saline|Normal saline injection plus physical therapy
215034086|NCT04701710|DRUG|Ivermectin / Iota-Carrageenan|The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
215034087|NCT05406531|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
215034088|NCT05406531|BEHAVIORAL|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
215034089|NCT05406531|BEHAVIORAL|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
215034090|NCT00005819|DRUG|cisplatin|Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
215034091|NCT00005819|DRUG|fenretinide|Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
215034092|NCT00005819|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
215034093|NCT00414557|PROCEDURE|Quadriceps strengthening|
214665483|NCT00336362|DRUG|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
214665484|NCT02500550|BIOLOGICAL|ATIR101|T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
214665485|NCT02500550|PROCEDURE|Haploidentical hematopoietic stem cell transplantation (HSCT)|"CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:~* Total Body Irradiation (TBI) regime~* Non-TBI regime~(See below for details)"
214866706|NCT01653717|PROCEDURE|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
214866707|NCT01653717|DRUG|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
214866708|NCT01653717|DRUG|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
214866709|NCT01653717|PROCEDURE|T-cell Infusion|Beginning dose of genetically modified cells is \> 5x10\^7/m2 but less than or equal to 5 x10\^8/m2 infused on Day 0.
214866710|NCT05788289|DRUG|Tafasitamab|Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
214866711|NCT05788289|DRUG|Lenalidomide|Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
214866712|NCT05203718|BEHAVIORAL|Food Response Training (FRT)|All patients will complete the 12-week FRT intervention consisting of one in-person session (during the baseline visit) and three weekly sessions at home, one delivered via video conference (WebEx) and two self-guided. Food Response Training (FRT) is a computer-based attention bias modification intervention. The intervention will be delivered on a computer or smart device (e.g. iPhone). Patients will use the FoodTrainer application available for Android and iPhone (https://www.exeter.ac.uk/foodt/about/).
214866713|NCT01758055|BIOLOGICAL|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
214866714|NCT02880657|DIETARY_SUPPLEMENT|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
214866715|NCT02880657|DIETARY_SUPPLEMENT|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
214866716|NCT02039466|PROCEDURE|volume controlled ventilation|
214866717|NCT02039466|PROCEDURE|pressure controlled ventilation|
214866718|NCT04795908|DEVICE|Transcranial Magnetic Stimulation|rTMS will be delivered using a MagStim Super Rapid2 TMS therapy system.
215034094|NCT00657683|BIOLOGICAL|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
215034095|NCT00657683|BIOLOGICAL|Placebo|1 dose of placebo
215034096|NCT03864705|DIAGNOSTIC_TEST|Measurement of plasma metformin levels|Subjects on chronic metformin therapy will have their plasma metformin levels measured during a regular check-up with glycated hemoglobin assessment.
215034097|NCT03420820|BIOLOGICAL|Bacterial Culture Swab|Culture swabs will be obtained before application of PI and after injection.
214665486|NCT02500550|PROCEDURE|TBI regime|"* Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)~* Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
214665487|NCT02500550|PROCEDURE|Non-TBI regime|"* Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1~* ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
214665488|NCT02333708|OTHER|Blood sample|
214665489|NCT02852629|OTHER|observational study|
214665490|NCT01626040|DRUG|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
214665491|NCT04143022|DEVICE|acupuncture press needle|Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
214665492|NCT02599012|DRUG|Ferinject®|intravenous Ferinject 1000mg injection
214665493|NCT04038333|OTHER|No intervention|This is an observational study without any interventions.
214866719|NCT04795908|BEHAVIORAL|Comprehensive behavioral intervention|Patients will receive CBIT with a therapist trained in CBIT. Each session will last about an hour and will be delivered remotely via telemedicine. Sessions will be tailed to the patient's individual needs.
214866720|NCT00762931|DEVICE|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
214866721|NCT00657228|DRUG|Intravenous heparin|"Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.~To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone."
214866722|NCT00657228|DRUG|Saline|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
214866723|NCT01802749|DRUG|Bevacizumab|
214866724|NCT01802749|DRUG|Paclitaxel|
214866725|NCT01802749|DRUG|Carboplatin|
214866726|NCT01802749|DRUG|pegylated liposomal doxorubicin|
214866727|NCT01802749|DRUG|Gemcitabine|
214866728|NCT02508753|DRUG|CXA-101/tazobactam|1000/500 mg single IV dose administered over 60 minutes
214866729|NCT02508753|DRUG|CXA-101/tazobactam|3000/1500 mg single IV dose administered over 60 minutes
214866730|NCT02508753|DRUG|Moxifloxacin|400 mg tablet
214866731|NCT02508753|DRUG|placebo|single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
214866732|NCT00115297|DRUG|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
214866733|NCT00115297|DRUG|Placebo|Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.
214866734|NCT00085423|BIOLOGICAL|aldesleukin|‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course
214866735|NCT00085423|BIOLOGICAL|sargramostim|GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.
214866736|NCT00085423|DRUG|cyclophosphamide|Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
214866737|NCT00085423|DRUG|fludarabine phosphate|Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
214866738|NCT04526886|OTHER|Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy|Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy
214866739|NCT02800213|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
214866740|NCT02800213|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
214866741|NCT00536263|DRUG|pegylated interferon alpha-2b|1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
214866742|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 24 weeks
214866743|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 48 weeks
214665494|NCT05076968|PROCEDURE|Complete denture fabrication|Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery
214665495|NCT05123157|OTHER|NO intervention|"N/:~NO intervention"
214665496|NCT06392815|DIAGNOSTIC_TEST|Cu DOTATATE PET|The primary endpoint of the study is diagnostic performance for detecting LNB by 64Cu-DOTATATE-PET/CT/MRI measured as the difference in uptake between patients with definite LNB and patients without LNB. The primary read-out from 64Cu-DOTATATE-PET/CT/MRI is SUV in CNS and reference organs
214665497|NCT03724708|DEVICE|IUD|IUD insertion
214665498|NCT04516681|DRUG|Ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
214665499|NCT04516681|DRUG|FOLFOX Protocol|Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks
214665500|NCT04516681|DRUG|Adebrelimab|20mg/Kg intravenously every 3 weeks
214866744|NCT03392493|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.
214866745|NCT03392493|BEHAVIORAL|Standard treatment|Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.
214866746|NCT00195637|DRUG|Immune Globulin|
214866747|NCT03695861|DIAGNOSTIC_TEST|Whole-body 18F-FDG PET-CT scan|A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
214866748|NCT01172483|PROCEDURE|general practice in primary care and education|education of chronic disorders in PC
214866749|NCT01172483|OTHER|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
214866750|NCT04371328|OTHER|RECOP unit patient|"All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.~30 days after inclusion, virological status and mortality will be collect"
214866751|NCT03123510|DIETARY_SUPPLEMENT|Bifidobacterium spp plus bimuno- galacto-oligosaccharides|Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
214866752|NCT03123510|DIETARY_SUPPLEMENT|Placebo|Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
214866753|NCT03450395|OTHER|Hot Cereal|Intervention involves consumption of one hot cereal in the beginning of each day
214866754|NCT03720379|DEVICE|Fluor Protector S|. All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
214866755|NCT03720379|DEVICE|Placebo|All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
214866756|NCT06152952|PROCEDURE|The rhomboid flap approach|"The rhomboid flap Approach :~The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers~The deep suturing approach :~A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. T then the deep fascia will be approximated and the wound will be closed"
214866757|NCT01520532|OTHER|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
214866758|NCT00273390|DRUG|Remicade (infliximab)|
214866759|NCT01321619|DRUG|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
214866760|NCT01321619|DRUG|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
214866761|NCT01859767|DRUG|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
214866762|NCT03842579|OTHER|Resistance training|Supervised progressive explosive type heavy-resistance training two times per week
214866763|NCT03842579|OTHER|High-protein diet|Daily supplementation with milk-based protein-rich products
214866764|NCT03842579|OTHER|Recommendations|Provided with the official national recommendations on nutrition
214866765|NCT02651454|DRUG|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
214866766|NCT02651454|DRUG|Chowiseungcheng-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
214866767|NCT02651454|DRUG|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
214866768|NCT03734666|BEHAVIORAL|Mindfulness Based Relapse Prevention - Smoking and Alcohol|Mindfulness Based Relapse Prevention (MBRP) is a treatment for preventing relapse in addictive disorders that integrates mindfulness meditation with standard relapse prevention practices.
214866769|NCT03734666|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a form of therapy that aims to help individuals modify problematic emotions, behaviors, and thoughts.
215034098|NCT01564329|DRUG|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
214866770|NCT00026364|DRUG|fluorouracil|
214866771|NCT00026364|DRUG|gefitinib|
214866772|NCT00026364|DRUG|irinotecan hydrochloride|
214866773|NCT00026364|DRUG|leucovorin calcium|
214866774|NCT01592305|DRUG|atazanavir|multiple oral doses
215034099|NCT00618787|DEVICE|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
215034100|NCT00618787|DEVICE|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
215034101|NCT03334955|PROCEDURE|Laparoscopic ovarian drilling|A specially designed monopolar electrocautery probe was used to penetrate the ovarian capsule at 4 points, with the aid of a short burst of monopolar diathermy. The probe (which has a distal stainless steel needle measuring 10 mm in length and 2 mm in diameter) was applied to the surface of the ovary at a right angle to avoid slippage and to minimize surface damage. A monopolar coagulating current at a 40 W power setting was used. The needle was pushed through the ovarian capsule for about 4 mm depth into the ovarian tissue and electricity was activated for 4 seconds.
215034102|NCT04514835|DRUG|Cisplatin+Capecitabine+Sintilimab|"The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months."
215034103|NCT06301113|DIETARY_SUPPLEMENT|CBD infused candy|300 Nano mg CBD Candy cherry flavor
215034104|NCT06301113|DIETARY_SUPPLEMENT|Sugar free Candy|Raspberry flavored sugar free candy
215034105|NCT01107886|DRUG|Saxagliptin|5 mg or 2.5 mg once daily
215034106|NCT01107886|DRUG|Placebo|
215034107|NCT03761550|COMBINATION_PRODUCT|pMDT(Process Implementation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
215034108|NCT02007460|BEHAVIORAL|Exercise|multidirectional unilateral hopping exercise
215034109|NCT04392076|PROCEDURE|Image Guided Ablation|Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
215034110|NCT05512338|OTHER|Treatment|ACT-informed interventions combined with standard physiotherapy methods.
215034111|NCT05512338|OTHER|Active control group|Standard physiotherapy methods.
215034112|NCT03027596|PROCEDURE|Remote ischemic conditioning|
215034113|NCT03772925|DRUG|Belinostat|Given IV
214866775|NCT01592305|DRUG|danoprevir|multiple oral doses
214866776|NCT01592305|DRUG|ritonavir|multiple oral doses
214866777|NCT01592305|DRUG|tenofovir disoproxil fumarate|single oral doses
215034114|NCT03772925|DRUG|Pevonedistat|Given IV
214866778|NCT03303183|DEVICE|Standard Impression technique|Silicone impression technique
214866779|NCT03303183|DEVICE|Direct Ear Scanner|Direct Ear Scanner to scan the ear anatomy
214866780|NCT00239044|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
214866781|NCT00753220|BIOLOGICAL|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10\^7, 7.5 x 10\^7 or 1.0 x 10\^8 cells"
214866782|NCT00753220|DRUG|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)
214866783|NCT03148561|DRUG|Misoprostol|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
214866784|NCT02773199|OTHER|Preoperative Fasting for 8 hours|Patients will be exposed to preoperative fasting
215034115|NCT06896903|DIAGNOSTIC_TEST|Coronary reactivity testing with and without nitrates|CRT will be performed in the left and right coronary arteries. Measurements will be obtained in each of the coronaries first without intracoronary nitrates followed by a dose of 200-500 mcg of intracoronary nitrates and repeat measurements.
215034116|NCT06835959|BEHAVIORAL|Moms@Home|Participants will use a storytelling mobile health app for daily home-based blood pressure monitoring and symptom/medication adherence tracking.
215034117|NCT06835959|BEHAVIORAL|Enhanced Standard of Care|Participants will use a paper journal daily to track home-based blood pressure values
215034118|NCT05046730|DEVICE|Ileostomy Reversal using Self Forming Magnets (SFM)|The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
215034119|NCT03272932|OTHER|No intervention|No intervention
215034120|NCT05301764|COMBINATION_PRODUCT|LVGN6051 and Anlotinib|"LVGN6051: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. Anlotinib: Rout of administration is oral. The initial dose of anlotinib was 12 mg for subjects with body surface area ≥ 1.5m2 and 10 mg for subjects with body surface area \< 1.5m2. If the subjects in the combined treatment group were not tolerated, the dose of anlotinib was reduced to 10 mg for subjects with body surface area ≥ 1.5m2 and 8 mg for subjects with body surface area \< 1.5m2.~One cycle is 3 weeks, including oral for 2 weeks and withdrawal for 1 week."
215034121|NCT06089317|DRUG|TCM ultrasonic atomization treatment with herbal Compound Decoction (CD)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the CD group is TCM compound decoction.~The prescription of atomization solution in the CD group contains Honeysuckle flower (金銀花) 5g, Chrysanthemum flower (菊花) 5g, Pale betterflybush flower (密蒙花) 5g, Mild mint herb (薄荷) 5g, Barbary wolfberry fruit (枸杞子) 10g, and Ophiopogon japonicus (麥冬) 5g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
215057166|NCT00113672|BEHAVIORAL|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
214866785|NCT02773199|OTHER|Preoperative Fasting for more than 12 hours|Patients will be exposed to preoperative fasting
214866786|NCT02773199|DRUG|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
214866787|NCT00944749|DRUG|h-ATG (ATGAM )|
214866788|NCT00944749|DRUG|Cyclosporine (Gengraf )|
215034122|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
215034123|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
215057167|NCT00113672|BEHAVIORAL|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
214665501|NCT00763893|DRUG|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
214665502|NCT00763893|DRUG|Losartan|50 mg/day if \< weight 50 kg 100 mg/day if weight \> 50 kg
214665503|NCT03133715|PROCEDURE|laparoscopic repair|surgical repair of ventral hernia using laparoscopic repair
214665504|NCT03133715|PROCEDURE|robot-assisted repair|surgical repair of ventral hernia using robot-assisted repair
214665505|NCT02464631|DRUG|Sofosbuvir + Ribavirin 1|
214665506|NCT02464631|DRUG|Sofosbuvir + Ribavirin 2|
214665507|NCT02464631|DRUG|Sofosbuvir + Ribavirin 3|
214665508|NCT00410891|DRUG|gatifloxacin|
214665509|NCT01946009|DRUG|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.|
214665510|NCT03210844|PROCEDURE|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
214866789|NCT06412237|DEVICE|RELab tenoexo|The RELab tenoexo is a fully wearable and portable RHO developed at the Rehabilitation Engineering Laboratory (RELab) at ETH Zurich.
214866790|NCT03697265|DRUG|Sepranolone (UC1010) low dose|Subcutaneous (SC) administration
214866791|NCT03697265|DRUG|Sepranolone (UC1010) high dose|Subcutaneous (SC) administration
214866792|NCT03697265|DRUG|Placebo|Subcutaneous (SC) adminstration
214866793|NCT03916523|PROCEDURE|Sustained lung inflation|"Preterm infants will receive a total of 15 sustained lung inflations during the first 4 days of life as follows:~1. On day 1 of life (a total of 6 sustained lung inflations, 20 cmH2O for 21 seconds each) once at enrollment and then once every 4 hours~2. On day 2 of life (a total of 3 sustained lung inflations, 15 cmH2O for 21 seconds each) once every 8 hours.~3. On day 3 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours.~4. On day 4 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours."
214665511|NCT05981950|DIAGNOSTIC_TEST|artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
214665512|NCT04252378|PROCEDURE|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
214665513|NCT04252378|PROCEDURE|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
214665514|NCT02379858|DRUG|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
214665515|NCT02379858|DRUG|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
214665516|NCT00155402|DRUG|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
214665517|NCT00796783|DRUG|Cushing's syndrome confirmation|
214665518|NCT00567931|DRUG|1-methyl-d-tryptophan|Given orally
214665519|NCT00567931|OTHER|pharmacological study|Correlative studies
214665520|NCT00567931|OTHER|laboratory biomarker analysis|Correlative studies
214665521|NCT03314168|OTHER|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
214665522|NCT03314168|OTHER|Control group|The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
214665523|NCT01843556|DRUG|E2022 Tape Formulation|E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
214665524|NCT05537181|DEVICE|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
214665525|NCT01177215|PROCEDURE|Thoracic Surgery|Wedge Resection Segmental Resection Lobectomy
214866794|NCT03916523|PROCEDURE|Continuous positive airway pressure (CPAP)|Preterm infants will receive CPAP for respiratory support.
214866795|NCT03916523|PROCEDURE|Mechanical ventilation|Preterm infants in this group will receive mechanical ventilation for respiratory support
214866796|NCT06218121|DIAGNOSTIC_TEST|Instrumental and Functional Tests that Assess Functional Capacity|The correlation between all functional, ultrasound, nutritional, and psychological variables will be analyzed. Through GLIM diagnosis, anthropometric data (weight, height, BMI) as well as analytical data including inflammation information (CRP and albumin) will be used to reach a diagnosis that allows comparison/correlation with the rest of the variable parameters.
214665526|NCT02016066|DRUG|CR6261|CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
214665527|NCT02016066|DRUG|Placebo|Placebo will be administered as a single 2-hour intravenous infusion
214665528|NCT04650633|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
214665529|NCT01559103|BIOLOGICAL|MEDI5117|Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
214665530|NCT01559103|BIOLOGICAL|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
214665531|NCT03655444|DRUG|Abemaciclib|Abemaciclib is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
214665532|NCT03655444|DRUG|Nivolumab|Nivolumab is commercially available
214665533|NCT03655444|PROCEDURE|Tumor biopsy|"* Phase II patients only~* If the patient consents, fresh tumor tissue will be collected at baseline and then during Cycle 2 (between days 8-22) of abemaciclib and nivolumab."
214665534|NCT03655444|PROCEDURE|Peripheral blood|"* Phase II patients only~* Peripheral blood will be collected at baseline, at the end of the Lead In (cycle 1 day 1 prior to treatment), during cycle 2 (between days 8-22), and during cycle 3 (between days 21-28). If patient does not have progression after cycle 3, patient will also have peripheral blood collected at time of progression."
214665535|NCT03655444|OTHER|EORTC QLQ-30|"* Phase II patients only~* Screening , Cycle 2 D1, Cycle 4 D1, and End of treatment (EOT)"
214665536|NCT04003610|DRUG|Pemigatinib|13.5 mg once a day orally
214665537|NCT04003610|DRUG|Pembrolizumab|200 mg Q3W intravenously
214665538|NCT04003610|DRUG|Gemcitabine|1000 mg/m\^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle
214665539|NCT04003610|DRUG|Carboplatin|Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle
214665540|NCT03502122|OTHER|VR rehabilitation for motor function|rehabilitation for motor function
214665541|NCT01368796|BIOLOGICAL|Agriflu|0.5mL dose IM vaccination
214665542|NCT01368796|BIOLOGICAL|Fluad|0.5mL dose of vaccine given IM
214665543|NCT01368796|BIOLOGICAL|Intanza|0.5mL dose vaccine given IM
214665544|NCT01368796|BIOLOGICAL|Vaxigrip|0.5mL dose vaccine given IM
214665545|NCT05547945|BEHAVIORAL|Health Promotion Program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
214665546|NCT05547945|BEHAVIORAL|Control group|The control group received as usual care.
214866797|NCT01193036|BEHAVIORAL|Part 1: Interview + Questionnaires|Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
214866798|NCT01193036|BEHAVIORAL|Part 2: Multiple Questionnaires|Questionnaires to be repeated about every 2 weeks for 1 year.
214866799|NCT00181220|DRUG|valproic acid|
214866800|NCT00769626|OTHER|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
214866801|NCT00769626|OTHER|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
214866802|NCT03996161|OTHER|patient position|After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.
214665547|NCT01523821|DRUG|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]|Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days
214665548|NCT02310373|OTHER|Nicotine free hookah smoking|Subjects will smoke waterpipe in a controlled research environment
214665549|NCT01917123|DRUG|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
214866803|NCT02852642|OTHER|Exercise|Plyometric training
214866804|NCT06339320|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG)|The ESG procedure uses the Apollo OverStitch endoscopic suturing device, which has received FDA authorization as a minimally invasive procedure to facilitate weight loss for adults with who have been unable to lose weight or maintain weight loss through more conservative measures such as diet and exercise. This procedure involves endoscopic suturing to reduce the volume of the stomach endoscopically by approximately 70% to 80% its original size. Using the Apollo OverStitch or APOLLO ESG and ESG SX Systems, the ESG procedure is performed be folding the stomach in on itself (endoscopically) and placing full-thickness sutures through the wall of the stomach to maintain this narrow, smaller size. Following the procedure, the new stomach appears similar to the surgical sleeve stomach, although the procedure is considered less invasive with fewer complications compared to a surgical sleeve gastrectomy.
214866805|NCT06339320|DEVICE|Apollo OverStitch endoscopic suturing device|Apollo ESG is the first and only device to be authorized by the FDA to perform the ESG procedure to facilitate weight loss in patients with obesity (BMI 30 to 50 kg/m2). The FDA identifies this generic type of device as an Endoscopic suturing device for altering gastric anatomy for weight loss.
214866806|NCT00560430|DRUG|telmisartan|80 mg per day, orally, weeks 1-14
214866807|NCT00560430|DRUG|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
214665550|NCT01798914|DRUG|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
214665551|NCT05740150|DEVICE|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
214665552|NCT05740150|DEVICE|Heparin lock (heparin 100 IU/mL)|The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
214665553|NCT02814721|DEVICE|Sonic Window ultrasound device|
214665554|NCT00872222|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
214665555|NCT05937477|OTHER|Fitbit smartwatch|Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
214665556|NCT02502864|DRUG|Standard of Care: Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m\^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
214665557|NCT02502864|DRUG|Standard of Care: Cyclophosphamide|Cycle 1: 600 mg/m\^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
214665558|NCT02502864|OTHER|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
214665559|NCT04096534|PROCEDURE|Normotonic partial nephrectomy|partial nephrectomy performing with avoidance of hypotension: mean blood pressure more or equal 65 mm Hg
214665560|NCT04096534|PROCEDURE|Hypotonic partial nephrectomy|partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: mean blood pressure less than 65 mmHg
214665561|NCT04522869|BIOLOGICAL|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
214665562|NCT06003959|OTHER|Routine nursing care|Preterm infants in the control group did not receive any intervention other than the routine feeding protocol applied in the clinic.
214665563|NCT06003959|OTHER|breastfeeding support system|The body weight of preterm infants in the experimental group was measured and recorded each morning before their first feeding. Mothers of these infants were asked to complete the Mother-Infant Attachment Scale (MIAS) prior to the procedure. The physician determined the appropriate amount of breast milk the infant should receive during feeding. Before each feeding, the neonatal nurse ensured the sterile preparation of the milk and transferred it to the Breastfeeding Support System. The mothers were then prepared for the procedure, with the neonatal nurse explaining how the breastfeeding support system worked. Once both the mother and baby were ready, the baby was placed at the mother's breast. After feeding, the mothers were asked to complete the MIAS again.
214665564|NCT03772327|DEVICE|"Adheretech smart bottle"|"A smart pill bottle that measures the exact number of pills in the bottle in real-time, sends this HIPAA-compliant data to a central server, and based on the results, can remind participants to take their medication through a phone call or text message."
214866808|NCT00560430|DRUG|placebo|placebo; orally weeks 1-14
214866809|NCT00456430|DRUG|Escitalopram|10 mg a day of escitalopram by mouth per day for 4 weeks. Dose may be increased to 20 mg a day after the 4th week depending on tolerance and treatment response.
214866810|NCT03961022|DIETARY_SUPPLEMENT|Polyherbal supplement: ReWin(d) vs Placebo|Supplementation during 4 weeks + 72 hours post acute exercice
214665565|NCT03772327|BEHAVIORAL|Routine adherence counseling|Participants will be provided with routine adherence counseling
214665566|NCT04576312|DRUG|UNI911 inhalation 1% and intranasal spray 1%|Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.
214866811|NCT04751292|OTHER|Exposure to high altitude|permanence at high (\>2500 m) altitude; permanence is defined as being born and living at high altitude with the total time spent at lower altitudes not exceeding 2 years in the past 10 years
214866812|NCT00395174|BIOLOGICAL|Influenza Vaccination|0.5mL dose for intramuscular injection
214866813|NCT03817801|DEVICE|NSE balloon|NSE (Goodman®) predilation + DCB (Sequent® Please) treatment
214866814|NCT03817801|DEVICE|NC balloon|NC balloon predilation + DCB (Sequent® Please) treatment
214866815|NCT02872363|OTHER|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
214866816|NCT02872363|OTHER|Intervention B - Priority|"SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
214866817|NCT00677079|DRUG|Iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
214665567|NCT04576312|DRUG|Placebo|The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
214665568|NCT06491134|DRUG|Liposomal Irinotecan Hydrochloride|liposomal irinotecan With Cisplatin and Concurrent Radiotherapy
214665569|NCT05212051|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
214665570|NCT05212051|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
214665571|NCT03588689|PROCEDURE|Continuous fascia iliaca block|Regional nerve block performed under ultrasound guidance. A catheter will be left in place to allow ongoing infusion of local anesthetic.
214665572|NCT03588689|DRUG|Ropivacaine|Ropivacaine local anesthetic will be used for the fascia iliaca block
214665573|NCT03700957|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|100 milligrams of Docosahexaenoic Acid
214665574|NCT03700957|OTHER|placebo|placebo
214665575|NCT00629395|BEHAVIORAL|Captain's Log Computer Program|12 Computer Program
214866818|NCT06167590|DIAGNOSTIC_TEST|GAPsy protocol|Each participant will undergo a 7 T multimodal neuroimaging session, including T1-weighted, 1H-MRS and fMRI. Each participant will also be assessed through a structured clinical interview (SCID-I e SCID-II) and will be administered scales such as HAM-A, HAM-D, BPRS and MADRS.
214866819|NCT02489019|DRUG|Sodium chloride|Sodium chloride will be used as a placebo comparator in this trial
214866820|NCT02489019|DRUG|Fentanyl|Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
214866821|NCT00626314|BIOLOGICAL|myoblast|autologous myoblast
214866822|NCT00626314|BIOLOGICAL|sham|sham injection procedure
215034124|NCT06089317|DRUG|Placebo TCM ultrasonic atomization treatment (PA)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
214866823|NCT00309764|BEHAVIORAL|Telemedicine|
214866824|NCT00238875|PROCEDURE|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
214866825|NCT03195036|BEHAVIORAL|Home-based ECD services|Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program.
214866826|NCT05884879|BEHAVIORAL|Tinnitus simulation|The control group will perform speech perception tests and listening effort tests in the absence and presence of a simulated tinnitus percept using a bone vibrator.
214866827|NCT04019184|DRUG|L-Alanyl/L-Glutamine|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
214866828|NCT04019184|DRUG|Placebo|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
215034125|NCT06089317|DRUG|Artificial Tears (AT)|The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
215034126|NCT04848506|DRUG|Aficamten (5 - 20 mg)|Aficamten tablets administered orally. During titration phase, clinic visits will occur approximately every 2-6 weeks. In the maintenance phase clinic visits will occur every 24 weeks, with safety check-in occurring every 12 weeks between visits by phone or, if desirable, in the clinic.
215034127|NCT06510621|PROCEDURE|Socket-Shield Technique|A high-speed turbine was used to cut the tooth crown 1.5-2 mm from the buccal gingival margin. The tooth was then divided along the long axis, approximately 2 mm from the buccal side(Figure 1c, 1d). The palatal roots were removed using minimally invasive elevation and extraction forceps. Next, the buccal socket-shield was trimmed to approximately 4-6 mm in height (1 mm from the buccal gingival margin)\[18\], 3-4 mm in width, and 1-1.5 mm in thickness\[19,20\]. The trimming process required with clear visualization of the shield and calibration by periodontal probe. Finally, the socket-shield was removed by minimally invasive forceps when the adjacent tooth moved proximate to the shield during the process of closing orthodontic gap.
215034128|NCT02445911|DRUG|KQ-791|Capsules administered orally
215034129|NCT02445911|DRUG|Placebo|Capsules administered orally
215034130|NCT06919887|OTHER|EMMII|The tool/app, consists of educational components designed to enable women to more effectively identify menopause symptoms and feel confident in seeking treatment to address their symptoms. The tool/app also produces a tailored menopause discussion guide for patients to bring to their primary care appointment.
215034131|NCT06919887|OTHER|Comparison Group|Receive educational menopause pamphlet describing menopause symptoms and evidence-based treatment options.
214866829|NCT00914459|BIOLOGICAL|Moroctocog alfa ( AF-CC)|Dosing is at the discretion of the Investigator
215034132|NCT04309682|PROCEDURE|crestal sinus approach technique|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.
215034133|NCT04309682|PROCEDURE|Lateral sinus approach|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place
214665576|NCT04324853|DIAGNOSTIC_TEST|Microscopy ( Urine filtration), UCAA test, qPCR,|Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma.Schistosomiasis is prevalent in tropical and subtropical areas, especially in poor communities without access to safe drinking water and adequate sanitation.
214866830|NCT00914459|PROCEDURE|Laboratory tests|Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
214866831|NCT05901259|DEVICE|Exopulse Mollii Suit|The registry is designed to demonstrate the impact of Exopulse Mollii Suit on improvement of muscle relaxation, muscle activation, local blood circulation and/or chronic pain relief. The subjects included use the suit for 60 minutes every other day, unless other is specified by the Investigator, in their home environment for up to a maximum of 12 consecutive weeks. Qualitative and quantitative measures will be collected at baseline (T0), after 60 minutes stimulation (T1), after 4 weeks (T4) and at the end of the 12-week intervention period (T12).
214866832|NCT00453778|DRUG|FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)|
214866833|NCT04219683|PROCEDURE|Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap|Using Free Fibula Flap for reconstruction of mandibular segemental defect
214866834|NCT03722355|RADIATION|Conventional RT|Radiation therapy
214866835|NCT03722355|RADIATION|Hyperfractionated RT|Radiation therapy
214866836|NCT03722355|DRUG|Carmustine|Chemotherapy
214866837|NCT03605654|BIOLOGICAL|MDR-102|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
214866838|NCT03605654|DRUG|Immunosuppressive Agents|Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
214866839|NCT01661179|DRUG|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
214866840|NCT05210244|DIETARY_SUPPLEMENT|Beetroot Juice (BJ) acute supplementation|One serving of 70 mL of BJ (6.4 mmol of NO3) 3h before initiating the testing session
214866841|NCT05210244|DIETARY_SUPPLEMENT|Placebo Juice (PLA) acute supplementation|One serving of 70 mL of juice (0.005 mmol of NO3) 3h before initiating the testing session
214866842|NCT01946191|BEHAVIORAL|24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.|Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.
214866843|NCT01946191|BEHAVIORAL|Online self-monitoring|Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
214866844|NCT01946191|BEHAVIORAL|Real-time updates to Primary Care physicians|Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
214866845|NCT05215080|DIETARY_SUPPLEMENT|Organic Formula Milk|Organic formula milk is given to the infants three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
214866846|NCT03063762|DRUG|Atezolizumab|"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
214866847|NCT03063762|DRUG|Bevacizumab|"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
214866848|NCT03063762|DRUG|RO6874281|"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
214866849|NCT00204165|PROCEDURE|MRI of the small bowel|
214866850|NCT01019473|DRUG|AFQ056|
214866851|NCT01019473|DRUG|Placebo|
214866852|NCT04335175|OTHER|None - observational study|None - observational study
214866853|NCT03118570|DRUG|setrusumab|Intravenous infusion
214866854|NCT03118570|DIETARY_SUPPLEMENT|Calcium|tablets
214866855|NCT03118570|DIETARY_SUPPLEMENT|Vitamin D|capsules
214866856|NCT03118570|DRUG|zoledronic acid (optional)|Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
214866857|NCT04732936|DEVICE|Temporary Peripheral Nerve Stimulator|Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.
214866858|NCT00173537|PROCEDURE|for BMPR II study|
214866859|NCT00173537|GENETIC|BMPRII|
214866860|NCT02010788|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
214866861|NCT03970837|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.
214866862|NCT03970837|DRUG|Tofacitinib|Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.
214866863|NCT03970837|DRUG|Placebo|Placebo matching GSK3196165 and Tofacitinib was administered.
214866864|NCT04866277|OTHER|Fast-track referral for reference services|Activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study.
214866865|NCT03036553|OTHER|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
214866866|NCT05726760|BEHAVIORAL|Seeking informed consent for participation in the study.|The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. The Anaesthetist or researcher will conduct this process. A patient information leaflet will be provided for the parturients.
214866867|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
214866868|NCT05726760|DEVICE|Covidien Mon-a-Therm skin temperature probes will be applied to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher will conduct the intervention in theatre. The probes will be removed in the recovery ward.
214866869|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the ear.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
214866870|NCT06231394|OTHER|multimodal pelvic floor rehabilitation|A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.
214866871|NCT02811263|DRUG|Normal saline placebo|Equal volume of normal saline to be used as placebo
214866872|NCT02811263|DRUG|Erythropoietin|Epogen drawn from commercially available single dose 4000U/mL vials
214866873|NCT03330912|DEVICE|Neutral seat height|Seat height set relative to participant's leg length with neutral set at the measured lower leg length
214866874|NCT03330912|DEVICE|Very low seat height|"Seat height set relative to participant's leg length, 2 below the measured lower leg length"
214866875|NCT03330912|DEVICE|Low seat height|"Seat height set relative to participant's leg length, 1 below the measured lower leg length"
214866876|NCT03330912|DEVICE|Very high seat height|"Seat height set relative to participant's leg length, 2 above the measured lower leg length"
214866877|NCT03330912|DEVICE|High seat height|"Seat height set relative to participant's leg length, 1 above the measured lower leg length"
214866878|NCT05136118|PROCEDURE|TAPB|TAPB will be given to parturients whether by the modified surgeon assisted approach or by the ultra-sound guided approach.
215034134|NCT06308315|OTHER|Rhythmic balance visual auditory exercise + Routine physical therapy|"5 minute warm-up activities.~Bal-A-Vis-X training includes:~1. Ball Rectangle; A and B hold one ball in each hand, simultaneously bounce right balls to patient left hand; while balls bounce, clap left balls on right hand; catch patient ball with left hand; continue pattern. Bounces must be simultaneous. (10 minutes)~2. Ball rectangle in which one hand has to toss a ball to a partner and the other hand catch an incoming bag from the partner and 2 ball drop/pass/catch, two-foot jumping forward, tandem walking on ground. (10 minutes)~Routine Physical therapy treatment includes:~Range of Motion exercises, Stretching, Strength, balance training for 15 minutes~5 minute cool-down activities."
215034135|NCT06308315|OTHER|Strength Training + Routine Physical Therapy|"The expert managed sessions based on:~5 minute warm-up activities. 5 minute cool-down activities. Strength training includes 5 tasks for 20 minutes~1. core strengthening,~2. upper and lower limbs strength in both static positions as well as with dynamic movements~3. standing long jump,~4. knee push-ups,~5. sit-ups~Routine Physical therapy treatment will be given for 15 minutes.~It includes:~Range of Motion exercises, Stretching, Strength, balance training."
215034136|NCT04699877|DRUG|Gilteritinib|Oral
215034137|NCT06054542|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the DESQ
215034138|NCT00583583|DEVICE|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
215034139|NCT01649869|OTHER|Placebo|Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
215034140|NCT01649869|DRUG|Valganciclovir|Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
215034141|NCT02776735|DRUG|Sarilumab|Pharmaceutical form:Solution Route of administration: Subcutaneous
215034142|NCT05395338|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
215034143|NCT05913687|DIAGNOSTIC_TEST|AIDP|Machine learning algorithm of imaging data
215034144|NCT03533569|PROCEDURE|Intra-articular corticosteroid injection|Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection
215034145|NCT03449472|DRUG|Quetiapine|Patients are tested for their normal prescription quetiapine medication
215034146|NCT06146062|DRUG|Mesenchymal Stromal Cells (MSC)|3 injections one week apart
215034147|NCT06146062|DRUG|placebo|3 injections one week apart
215034148|NCT06524180|DEVICE|Telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
215034149|NCT06524180|OTHER|Usual care|Participants will be followed up as usual by face-to-face consultation with the doctors
214665577|NCT04324853|DIAGNOSTIC_TEST|Microscopy (Kato Katz, Coproculture, Harada Mori, MIF), qPCR,|Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities. They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.
214866879|NCT01207505|BEHAVIORAL|Enhancing Emotion Regulation|12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
214866880|NCT00000660|DRUG|Etoposide|
214866881|NCT00907127|BEHAVIORAL|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
215034150|NCT03224845|BEHAVIORAL|Cognitive behavioural skills training|The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
215034151|NCT03556891|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
215057168|NCT00113672|BEHAVIORAL|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
214866882|NCT05931666|OTHER|Gong Mobilization|"Patients are treated with Gong mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
214866883|NCT05931666|OTHER|Kaltenborn Mobilization|"Patients are treated with Kaltenborn mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
214866884|NCT02833766|DRUG|anti-EGFR-IL-dox|First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
214866885|NCT04979273|DRUG|Dextrose 40 % in Water|injection of adrenaline 1:20.000, followed by dextrose 40% spray
214866886|NCT04979273|DRUG|Adrenaline 1 Mg/mL Solution for Injection|injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
214866887|NCT04979273|PROCEDURE|argon plasma coagulation|Thermocoagulation
214866888|NCT04979273|PROCEDURE|Hemoclip|Hemoclip
214866889|NCT03370731|PROCEDURE|adenotonsillectomy|Resection of adenoidal tissue or hypertrophy tonsils by radiofrequency ablation or other methods.
214866890|NCT03370731|OTHER|Nonsurgical management|Nasal Irrigation or inhaled corticosteroids, etc.
214866891|NCT03947424|DEVICE|LP Er:YAG|LP Er:YAG applied to oral mucosa
214866892|NCT03947424|DEVICE|SMOOTH mode Er:YAG|SMOOTH mode Er:YAG applied to oral mucosa
214866893|NCT03947424|DEVICE|sham|Er:YAG laser applied to oral mucosa with no energy
214866894|NCT05918224|DRUG|Streptococcus salivarius K12|The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
214866895|NCT05918224|DRUG|Streptococcus salivarius K12 simulants|Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
214866896|NCT04979286|OTHER|Kinesiotaping|"Y strip kinesiotaping will be applied to both the gastrocnemius muscles while keeping the participant's ankle in full dorsiflexion. The tape will start from the plantar surface of the toe and continue proximally. The medial Y tail will be applied along the medial border of the gastrocnemius and the lateral Y tail along the lateral border of the gastrocnemius, at approximately 20% tension from the resting length. End points will end just below the popliteal crease."
214866897|NCT04979286|OTHER|Placebo Kinesiotaping|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
215034152|NCT05894655|BEHAVIORAL|COVID-19 walk-up, on-site testing strategy|This strategy is a no-appointment, walk-up point-of-care PCR and rapid testing strategy for clinic patients and community members. It will be offered 5 days/week for 7 hours during the first 3 months of the trial at Clinic 1. The intensity will decrease over the trial ending with 1 SYH Medical Assistant overseeing the testing protocol. Bilingual research staff will be trained to oversee onsite testing.
215034153|NCT05894655|BEHAVIORAL|Community Health Worker (CHW) leading testing navigation and general preventive care reminders|This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.
215034154|NCT05894655|BEHAVIORAL|No-cost self-testing kit vending machines|This strategy includes vending machines that will provide interactive instructions for accessing free self-testing COVID-19 kits located outside of clinics for patients and community members to use anytime. The vending machines will be available 24 hours/day, 7 days a week.
215034155|NCT05459753|RADIATION|(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET|Participants will receive an injection of 8 mCi \[18F\]FEOBV PET tracer and undergo a CT of the head.
215034156|NCT05459753|RADIATION|Dihydrotetrabenazine (DTBZ) PET|Participants will receive an injection of 15 mCi \[11C\]DTBZ PET tracer and undergo a CT of the head.
215034157|NCT06439771|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
214866898|NCT06104241|BIOLOGICAL|BGT007 Injection|BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10\^7 cells,1.0 ×10\^8 cells, 3.0× 10\^8 cells,1.0 × 10\^9 cells,3.0 ×10\^9 cells.
214866899|NCT05320341|PROCEDURE|TIVA|During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
214866900|NCT05320341|PROCEDURE|SEVO|During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
215034158|NCT06168773|DRUG|Haloperidol Injection|to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.
215034159|NCT00190957|DRUG|Atomoxetine|
215034160|NCT00190957|DRUG|placebo|
215034161|NCT06213480|DIETARY_SUPPLEMENT|Synbiotic Group|"WBF-038: Noninfectious and nonhazardous lyophilized commensal bacteria (probiotics). Contains no genetically modified organisms (GMOs) and contains no animal ingredients or by-products, and were originally isolated from human sources. The (probiotic) strains are grown in a FDA registered food facility, adhering to Good Manufacturing Practice (GMP) conditions.~Probiotic Ingredients:~Clostridium butyricum WBSTR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WBSTR-0001, and Bifidobacterium infantis~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
215034162|NCT06213480|OTHER|Placebo Group|Ingredients: Chicory inulin and oligofructose (prebiotic fiber, hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation).
215057169|NCT02744495|DRUG|Betamethasone|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
214866901|NCT04334486|OTHER|Super Smash Brothers Melee (Gamecube)|10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
214866902|NCT00317421|DRUG|Sildenafil citrate|
214866903|NCT01425723|BIOLOGICAL|rFIXFc|Administered as specified in the treatment arm.
214866904|NCT00186043|DRUG|Quetiapine/Seroquel|Quetiapine/Seroquel
214866905|NCT00186043|DRUG|Placebo|Placebo
214866906|NCT02567318|DEVICE|MRI-scan|Magnetic resonance imaging scan of the brain
214866907|NCT01689818|OTHER|exercise training|exercise training program which included aerobic exercise for 3 times per week.
214866908|NCT01142479|DRUG|Chinese herbal medicine decoction|100 ml /Qd for 6 weeks(42 days)
214866909|NCT04874636|DRUG|LY3556050|Administered orally
214866910|NCT04874636|DRUG|Placebo|Administered orally
214866911|NCT01046266|DRUG|RO5083945|700mg iv weekly
214866912|NCT01046266|DRUG|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
214866913|NCT04154306|DIETARY_SUPPLEMENT|Red clover|2 weeks of Red clover
214866914|NCT04154306|DIETARY_SUPPLEMENT|Placebo|2 weeks of Placebo
214866915|NCT02240342|DRUG|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
214866916|NCT03566576|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
214866917|NCT03566576|DRUG|Pemetrexed|Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
214866918|NCT03566576|DRUG|Docetaxel|Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
214866919|NCT00283491|BEHAVIORAL|Active Lactobacillus plantarum 299v|10\^11 cfu/meal in 2 meals on 2 consecutive days
214866920|NCT00283491|DIETARY_SUPPLEMENT|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
214866921|NCT02849327|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
214866922|NCT02849327|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
214866923|NCT03533127|DRUG|LY01008|LY01008+Carboplatin/Paclitaxel
214866924|NCT03533127|DRUG|Bevacizumab|Bevacizumab + Carboplatin/Paclitaxel
214866925|NCT00872482|DRUG|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
214866926|NCT01362127|DRUG|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
215034163|NCT05627921|DEVICE|Extracorporeal Shock Wave Therapy|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used. rESWT will be applied with a soft applicator. The soft applicator is designed for application to sensitive and painful areas and applications will be painless.Shock waves will be applied at 1500/beat, 8 Hz, 0.030 Mj/mm2, 2 bar per muscle.
215034164|NCT05627921|DRUG|Botilinum Toxin injection|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex.
215034165|NCT02354573|DRUG|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
215034166|NCT00663078|BEHAVIORAL|Brief CBT Group therapy|CBT based therapy also expert patient programme
214665578|NCT03441126|OTHER|Multicenter Quality Improvement program|Participating institutions will not participate in an intervention study. Sites will design and implement local QI programs to improve care within their unit. Local healthcare teams, who are interested in directly and immediately improving patient outcomes, will devise customized tools. The Bright STAR Team will assess the impact of these local QI initiatives on patient health outcomes, using data that are collected as part of the QI programs or through routine clinical care.
214866927|NCT01362127|RADIATION|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
214866928|NCT04940260|DIAGNOSTIC_TEST|Renal function|measure eGFR at one year post partum
214866929|NCT04940260|DIAGNOSTIC_TEST|proteinuria|measure urine protein creatinine ratio at one year postpartum
214866930|NCT04691180|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given intravenously
214866931|NCT04691180|DRUG|Placebo|Placebo given intravenously
214866932|NCT05145582|BEHAVIORAL|The Self-Guided PSP Wellbeing Course|An unguided version of a transdiagnostic ICBT program that has shown promising initial outcomes in prior research (https://doi.org/10.2196/27610).
214866933|NCT05145582|BEHAVIORAL|Online Discussion Forum|An online discussion forum designed to provide an opportunity for participants to support one another in their use of the ICBT program.
214866934|NCT03015727|DRUG|Docetaxel|3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.
214866935|NCT03015727|DRUG|Cisplatin|3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.
214866936|NCT03015727|RADIATION|IMRT/TOMO|intensity modulated radiation therapy or tomotherapy
214866937|NCT03015727|DRUG|Chemotherapy|2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
214866938|NCT04971265|BEHAVIORAL|Low SES/High Supports|Participant will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
214866939|NCT04971265|BEHAVIORAL|Low SES/ Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
214866940|NCT04971265|BEHAVIORAL|High SES/High Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
215034167|NCT02845414|DRUG|CD133KDEL (dCD133KDEL)|Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
214866941|NCT04971265|BEHAVIORAL|High SES/Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
214866942|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)|Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
214866943|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)|Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
214866944|NCT06314880|BIOLOGICAL|Placebo control|Placebo control. 20 people/group.
214866945|NCT06157762|PROCEDURE|Erector spinae plane block|ultrasound guided lumbar erector spinae plane block
214866946|NCT06157762|PROCEDURE|Erector spinae plane block performed by surgeon|Erector spinae plane block performed by surgeon
214866947|NCT05174676|DEVICE|Dextreme|"A unique robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the movement.~The setting of stroke patients in a simulated environment enhances patient motivation and participation. The completion of games (tasks) is a great indicator for the patients that they are progressing in the treatment and are on their way to recovery."
214866948|NCT03683368|DEVICE|YpsoPump Orbit soft|Insulin infusion sets will be used for up to 7 days or until failure
214866949|NCT03683368|DEVICE|YpsoPump Orbit micro|Insulin infusion sets will be used for up to 7 days or until failure
214866950|NCT00415844|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
215034168|NCT00692328|BEHAVIORAL|Levodopa or acupuncture|Comparison of subject expectancy of receiving levodopa or acupuncture.
215034169|NCT03552029|DRUG|Quizartinib|20 or 30 mg tablets for oral administration
215034170|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration
215034171|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
215034172|NCT01198691|DEVICE|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
215034173|NCT01198691|DEVICE|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
215034174|NCT02299245|DRUG|rosuvastatin|different dose of rosuvastatin treatment
215034175|NCT04918082|OTHER|Quality of life questionnaires|Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.
215034176|NCT03325322|DIETARY_SUPPLEMENT|Fisetin|Flavonoid family
215034177|NCT03325322|DRUG|Placebo oral capsule|Placebo
215034178|NCT01282398|DRUG|Simvastatin|The experimental group will take 40 mg each 24 hours for at least two years.
215034179|NCT01282398|DRUG|placebo|the control group wiil take placebo pills for at least two years.
215034180|NCT03468998|DEVICE|Socket Grafting with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
215034181|NCT03468998|DEVICE|Socket Grafting with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
215034182|NCT03468998|DEVICE|Lateral ridge augmentation with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
214866951|NCT04427644|PROCEDURE|Laparascopic Sleeve Gastrectomy|Operations performed for complciation of laparascopic sleeve gastrectomy
214866952|NCT04427644|PROCEDURE|İnterventional radiologic drainage|İnterventional radiologic drainage of gastric leakage
214866953|NCT04427644|DIAGNOSTIC_TEST|Complte Blood Count and Biochemical evaluation|blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
214866954|NCT04427644|DIAGNOSTIC_TEST|Computed tomography|Admitted to observe leakage
215034183|NCT03468998|DEVICE|Lateral ridge augmentation with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
215034184|NCT05465304|DRUG|Azithromycin|The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
215034185|NCT06305403|DIAGNOSTIC_TEST|serum creatinin level|Serum creatinine and urine amounts will be checked for five days.
215034186|NCT01765400|DRUG|Prasugrel 10 mg daily x 2 weeks|
215034187|NCT01765400|DRUG|Clopidogrel 75 mg daily x 2 weeks|
215034188|NCT01893086|PROCEDURE|LH alone|LH, laparoscopic hysterectomy
215034189|NCT01893086|PROCEDURE|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
215034190|NCT04236076|DEVICE|PulseHaler|PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.
215034191|NCT04236076|DEVICE|Sham - control|Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
215034192|NCT02798757|DRUG|Dapagliflozin|Urine samples will be collected for 1HNMR spectroscopies
215034193|NCT01055340|DRUG|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
215034194|NCT01055340|DRUG|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
215034195|NCT01055340|DRUG|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
215034196|NCT01467557|DEVICE|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
215034197|NCT01467557|DEVICE|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
215034198|NCT05271357|PROCEDURE|Bilateral TMS|Stimulation begins with continuous TBS to the right dorsolateral prefrontal cortex (DLPFC) (120 seconds of uninterrupted bursts; 600 pulses per session) followed by intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds per hemisphere.
214866955|NCT03476863|PROCEDURE|Alveolar Recruitment Maneuver|Patients in the Experimental Group will be submitted to ARM, immediately after abdominal desinflation of the pneumoperitoneum (PNP). The ARM will be performed with PEEP of 15 cmH2O for thirty seconds, 20 cmH2O for thirty seconds, 25 cmH2O for thirty seconds, 30 cmH2O for one minute and a inspiratory plateau pressure of 15 cmH2O above PEEP, totaling two minutes and thirty seconds.The data of the TIE will be continuously recorded and the hemodynamic and respiratory function variables such as heart rate (HR), respiratory rate (RF), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2) and final gas expiratory pressure carbon dioxide (PETCO2) will be recorded in several moments: immediately after the monitoring, and the patient is still on spontaneous ventilation, 5min after orotracheal intubation, after the installation of the pneumoperitoneum, before and after the execution of the MRA and in the Post-OP, in the first 24h, along with new lung function tests.
214866956|NCT03476863|PROCEDURE|Conventional mechanical ventilation|Immediately after intubation, patients will undergo mechanical ventilation with the ventilator (Dixtal DX 5020) in volume controlled mode with an ideal tidal volume of 7 ml / kg body weight, a set frequency to maintain a carbon dioxide of 35-42 mmHg, and an inspiratory / expiratory ratio of 1: 2. The inspiratory oxygen fraction (FIO2) will be 0.5.
214866957|NCT04557202|DRUG|Tamsulosin Oral Capsule|To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.
214866958|NCT04557202|DRUG|Placebo|Placebo - control group
214866959|NCT00228423|DRUG|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel
214866960|NCT00228423|DRUG|water pill daily|Daily dose of water pill (placebo)
214866961|NCT06438536|BEHAVIORAL|Virtual Reality-based Social Cognitive Training|Virtual reality assisted social cognitive training embedded in cognitive behavioral therapy, that aims at enhancing social cognition and daily life functioning.
214866962|NCT02642536|BEHAVIORAL|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
214866963|NCT02642536|BEHAVIORAL|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
214866964|NCT04076384|BEHAVIORAL|Guided Self-Determination|Structured team-based consultations
214866965|NCT04076384|BEHAVIORAL|Standard care|Standard consultations
214866966|NCT01918540|PROCEDURE|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
214866967|NCT01918540|PROCEDURE|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
214476511|NCT06857409|PROCEDURE|pulsed radiofrequency|All patients will be monitored with electrocardiography, non-invasive blood pressure, and peripheral oxygen saturation, and peripheral intravenous vascular access will be performed before the procedure. Patients will be placed in a sitting position. The physician will stand behind the patient for the posterior approach. The skin area to be injected will be prepared and covered in a sterile manner using a povidone-iodine-based solution. The operator will use ultrasound (a TOSHIBA Aplio 500 Ultrasound) guidance to perform suprascapular nerve radiofrequency. The suprascapular notch will be visualized. A twenty-two gauge, 10 cm long, and 10 mm active-tipped radiofrequency cannula will be introduced to the suprascapular notch. Motor stimulation will be performed at 2 Hz at a setting of 1 V, and sensory stimulation will be performed at 50 Hz at a setting of 0.5 V. After the needle tip confirmation, pulsed radiofrequency will be applied to the suprascapular nerve for 360 seconds.
214866968|NCT01918540|DEVICE|MS-30 femoral stem|This is the stem used in the study.
214866969|NCT05294939|DIETARY_SUPPLEMENT|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
214866970|NCT05294939|DIETARY_SUPPLEMENT|Control product consumption|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, 90g of carbohydrates should be consumed every hour.
214866971|NCT05031689|BIOLOGICAL|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
214476512|NCT03579836|DRUG|BEY1107|Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
214476513|NCT03579836|COMBINATION_PRODUCT|Gemcitabine|Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
214476514|NCT04293523|DRUG|ELOCTA|Extended half-life factor VIII product
214476515|NCT06752473|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
214866972|NCT05031689|BIOLOGICAL|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract|Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
214866973|NCT04917653|DEVICE|Heart rhythm monitoring with wearable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel."
215034199|NCT05271357|PROCEDURE|Unilateral TMS|Stimulation involves only intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds.
214476516|NCT06614738|OTHER|Sampling of feces and duodenal fluids|"* Blood sampling (plasmotheque and serotheque): 2 tubes (EDTA (5mL) and dry (5mL)) during hospitalization~* Fecal sampling (fecal library): A stool sample (approx. 2g) will be taken 48 hours before the endoscopy at home for outpatient or during hospitalization~* Duodenal aspiration fluid (6-10 mL in total): before and after mucosal lavage with sterile isotonic saline on the day of endoscopy.~* Food and Lifestyle Questionnaire (FFQ) during inclusion"
214476517|NCT06781034|OTHER|None, pure observational study|None, pure observational study
214476518|NCT06857630|OTHER|Observational|Postoperative acute kidney injury and hemoglobin level relationship observation
214866974|NCT04917653|OTHER|Blood samples and biomarkers|"Several blood samples will be collected during the study protocol in pre-defined times before and after the cardioversion intervention.~Atrial peptides and cardiac troponins will be analyzed and kinetics estimated to predict the duration of early-onset AF period."
214866975|NCT03647683|OTHER|Self-Compassion|"Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus."
214866976|NCT03647683|OTHER|Acceptance|"Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
214866977|NCT03647683|OTHER|Distraction|"Participants are introduced to the concept of distraction. Distracting oneself from the present situation helps with not perceiving pain, painful thoughts or feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
214866978|NCT03647683|OTHER|Heat pain|Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
214866979|NCT00786994|DRUG|Oleogel-S10 100 mg/g|topical use once or twice daily
214866980|NCT00786994|DRUG|Placebo (petroleum jelly)|topical use once or twice daily
214866981|NCT05865821|PROCEDURE|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
214866982|NCT05865821|OTHER|No pressure drain|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
214866983|NCT03524989|DEVICE|Hyperbaric Oxygen Therapy|40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.
214866984|NCT03524989|DEVICE|SHAM treatment|40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
214866985|NCT03823495|OTHER|12-week PAP|It is a non-drug intervention, using exercises to reduce elderlies chronic pain.
214866986|NCT01709253|RADIATION|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
214866987|NCT06309654|BEHAVIORAL|12-week home-based circuit training (HBCT)|Participants in the exercise group performed HBCT three times per week on non-consecutive days for 12 weeks. The first session was conducted at USM Hospital and participants were instructed how to perform the prescribed exercises in a correct form. In each session, participants performed seven exercises (two aerobic- and five resistance-based) in a circuit fashion, using bodyweight movements and adjustable dumbbells for varied weights, activating all the major muscle groups. In weeks 1-6, participants executed 15 repetitions for 2 rounds with 1 min passive rest between exercises and rounds. In weeks 7-12, participants executed 30 repetitions for 4 rounds with the same rest as prescribed in weeks 1-6. Each round lasted 10-15 min and the total session duration was 20-60 min, aiming to help participants adapt gradually to increasing training volume.
214866988|NCT06309654|BEHAVIORAL|Standard of care (CONT)|"Providing education about the nature of OA, its progression, and strategies for symptom management.~Empowering individuals with self-management techniques, such as joint protection strategies, activity modification, and lifestyle changes (e.g., weight management, exercise)."
214866989|NCT04839081|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
214866990|NCT06272747|DRUG|XH-S003|IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
214866991|NCT06272747|DRUG|Placebo|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
214866992|NCT06384534|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
214866993|NCT06384534|OTHER|6-minute walk distance test with supplemental oxygen|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
214866994|NCT05849038|DRUG|Baricitinib|Patients will receive baricitinib at a dose of 2 mg oral daily.
214866995|NCT05849038|OTHER|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.
214866996|NCT06193928|DRUG|Livmarli|The recommended dosage is 380 mcg/kg once daily.
214866997|NCT06193928|DRUG|Livmarli|The recommended dosage us 570 mcg/kg twice daily.
214866998|NCT04018664|DRUG|Nalbuphine HCl solution|nalbuphine solution administered at various strengths
214866999|NCT04018664|DRUG|Placebo solution|Placebo
214867000|NCT03845296|DRUG|Rucaparib|Given PO
214867001|NCT04810871|PROCEDURE|Brain Surgery|Undergo surgery
214867002|NCT05104073|BEHAVIORAL|Intervention|Provided with educational materials, guidelines and instructions.
214867003|NCT04270175|DRUG|Daratumumab SC|Given as 1800mg via injection
214867004|NCT04270175|DRUG|Pomalidomide|Given as 4mg oral capsule
215034200|NCT02729415|PROCEDURE|Stromal Vascular Fraction Cells (SVF Cells) Injection|The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
215034201|NCT02729415|PROCEDURE|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
215034202|NCT02729415|OTHER|Hair Measurements|Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
215034203|NCT00149357|OTHER|Thrombophilia Testing|TP testing in Group 1 and 3 only
215034204|NCT02853292|BIOLOGICAL|urine collection|
215034205|NCT00633126|DRUG|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
214867005|NCT04270175|DRUG|Dexamethasone|Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.
214867006|NCT06577532|DRUG|ABO2102|mRNA encoding mutant KRAS neoantigens, administrated intramuscularly
214867007|NCT06577532|DRUG|Toripalimab|Anti-PD-1 antibody, administered intravenously
214867008|NCT00671918|DRUG|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
214867009|NCT05804916|DEVICE|Surface Guided Radiation Therapy (SGRT)|SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection
215034206|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
215034207|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
215034208|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
215034209|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
215034210|NCT02749916|OTHER|Methods of carotid wall imaging|
215034211|NCT05577156|BEHAVIORAL|Self-questionnaires and semi-structured interview|Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions
215034212|NCT02700438|DRUG|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
215034213|NCT02700438|PROCEDURE|Urgent PC Neuromodulation System®|Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.
215034214|NCT06424002|BIOLOGICAL|Mosquirixs|RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01. Three doses of the vaccine will be administered, each with one month interval.
215034215|NCT06424002|DRUG|artemether-lumefantrine|A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
215034216|NCT03243721|DIAGNOSTIC_TEST|7T MRI|A high field MRI that will take approximately one hour.
215034217|NCT03243721|DIAGNOSTIC_TEST|Neurocognitive testing|A series of tests to assess memory, verbal skills, and visuospatial skills.
215034218|NCT03926455|BIOLOGICAL|Typhax (investigational typhoid fever candidate vaccine)|
215034219|NCT03926455|BIOLOGICAL|Placebo|Placebo is administered to the control group on Day 0 and 28
214867010|NCT05575258|OTHER|44-Day Diet Conventionally Sourced - YELLOW Diet|Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.
214867011|NCT05575258|OTHER|44-Day Diet Agro-Ecologically Sourced - GREEN Diet|Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
215034220|NCT03926455|BIOLOGICAL|Active Comparator Typhim Vi|A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28
215034221|NCT03978598|DRUG|Etonogestrel|Immediate v. Standard insertion.
215034222|NCT03978598|DEVICE|Nexplanon|Implant.
215057170|NCT02744495|DRUG|Droperidol|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
214867012|NCT04326621|OTHER|Pressure Release Technique (PRT)|A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
214867013|NCT04326621|OTHER|Control|exercises
214867014|NCT05256524|DRUG|The effect of LMWH|Quantified by aFXa-levels
214867015|NCT05256524|DIAGNOSTIC_TEST|Monitoring frequency of aFXa-levels|The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking
214867016|NCT01200992|BIOLOGICAL|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
214867017|NCT01200992|BIOLOGICAL|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
214867018|NCT03402555|OTHER|Stool pattern|Collection of stool images
215034223|NCT03100526|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
214867019|NCT03543436|DRUG|Temocillin|Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .
214867020|NCT03543436|DRUG|meropenem or imipenem|Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)
214867021|NCT02155543|DRUG|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
214867022|NCT02155543|DRUG|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
214867023|NCT02155543|DRUG|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
214867024|NCT02155543|DRUG|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
214867025|NCT00104143|DRUG|A4I Antagonist|
214867026|NCT02098239|DRUG|G17DT|
214867027|NCT01466010|PROCEDURE|surgical removal of osteoid osteoma|surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
214867028|NCT02213510|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
214867029|NCT02213510|DEVICE|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
214867030|NCT02263950|DRUG|Artemether|Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
214867031|NCT00773630|DRUG|Cilostazol|100 mg Cilostazol
214867032|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 1|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts.
215034224|NCT04451798|DEVICE|Impella CP microaxial pump|ramp test
215034225|NCT02297516|DRUG|Azzalure or Dysport|Glabellar lines
215034226|NCT02297516|DEVICE|Restylane or Emervel filler|Facial tissue augmentation
215034227|NCT02297516|DEVICE|Restylane Skinbooster|Facial skin rejuvenation
215034228|NCT01444105|DEVICE|iStent|Implantation of two iStent devices
214476519|NCT03525587|OTHER|"Use of MAGHD App/MAGHD Framework"|Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).
214867033|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 2|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts. This version also contains audio materials.
214867034|NCT04890301|BEHAVIORAL|CT guided biopsy for pulmonary nodule|"The technical process of the experimental group: ① design of puncture path, positioning and fixation of patients; ② puncture point positioning; ③ installation of navigation frame and template; ④ percutaneous lung biopsy guided by PT combined with CT.~The technical process of the active comparator group: ① planning puncture path, positioning and fixation of patients; ② positioning puncture point; ③ CT guided percutaneous lung biopsy.~The operation related information, complications and postoperative pathological results were collected."
214867035|NCT00125840|DRUG|clofarabine (IV formulation)|
214867036|NCT04113863|DRUG|all-trans retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
214867037|NCT04113863|DRUG|Anastrozole 1mg|Anastrozole will be administered orally at the dosage of 1 mg/die.
215034229|NCT01444105|OTHER|SLT|Laser treatment
215034230|NCT05795907|DRUG|SAR443820|Capsule / Oral
215034231|NCT05795907|DRUG|Placebo|Matching Capsule / Oral
215034232|NCT01605994|DRUG|BMS-933043|
215034233|NCT01605994|DRUG|Placebo matching with BMS-933043|
215034234|NCT01605994|DRUG|Antacid Buffer Predose Solution|
215034235|NCT03835078|DEVICE|methafilcon A contact lenses|Bilateral daily wear of methafilcon A contact lenses
215034236|NCT03835078|DEVICE|fanfilcon A contact lenses|Bilateral daily wear of fanfilcon A contact lenses
215034237|NCT01145950|DRUG|LBEC0101|Etanercept 25mg, single dose
215034238|NCT01145950|DRUG|Enbrel|Etanercept 25mg, single dose
215034239|NCT02383160|DEVICE|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
215034240|NCT02383160|DEVICE|Sham device|Placebo device with no active therapy
215034241|NCT02491879|DRUG|Ketoprofen|2.5% Ketoprofen gel with a 2 g local use
215034242|NCT02491879|OTHER|Placebo|Placebo gel with a 2 g local use
215034243|NCT02332928|DRUG|Melatonin|Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
215034244|NCT02332928|DRUG|Placebo|Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
215034245|NCT04243265|PROCEDURE|MPFL reconstruction with fascia lata allograft|Reconstruction of MPFL using a fascia lata allograft. The rationale for this technique is to stabilize the patella and limit medium to long-term patellofemoral arthritic degeneration by restoring the MPFL in the most anatomical way possible, not using a tubular graft but an aponeurosis with biomechanical characteristics similar to the native MPFL. The MPFL reconstruction can be used alone or in association with the realignment of the extensor apparatus by transposition of the anterior tibial tuberosity, managing to correct most of the recurrent patellofemoral instabilities. Only in very serious particular cases is it necessary to perform more invasive additional procedures with a more uncertain clinical result (such as Trocleoplasty).
215034246|NCT01190319|OTHER|Strawberry Beverage|Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder
215034247|NCT01190319|OTHER|Placebo|Placebo beverage, 8 weeks
215034248|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
215034249|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
215034250|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
215034251|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
215034252|NCT01425814|DRUG|Reference|Dry powder inhalation (capsule),single dose
215034253|NCT01425814|DRUG|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
215034254|NCT05586295|OTHER|Placebo|Microcrystalline α-cellulose, shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, palm wax.
215034255|NCT05586295|OTHER|EX plus|Furanthiamine hydrochloride (vitamin B1), pyridoxine hydrochloride (vitamin B6), cyanocobalamin (vitamin B12), DL-alpha-tocopheryl acetate 50% (DL-alpha-tocopheryl acetate, sucrose, caprylic acid) Sodium alkenyl succinate starch, corn starch, water, sodium aluminosilicate), shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, γ-oryzanol (γ-oryzanol, rice bran powder ), sucrose, silica, inositol, taurine, talc, oxidized starch, gelatin, magnesium stearate, calcium panpolyate, microcrystalline α-cellulose, riboflavin (vitamin B2), palmar wax.
215034256|NCT03386162|DRUG|Alpelisib|fulvestrant (500 mg intramuscular \[as two 5 mL injections\] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
214867038|NCT05456555|PROCEDURE|Flapless with Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.
214867039|NCT05456555|PROCEDURE|Flapless without Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
215034257|NCT03386162|DRUG|Chemotherapy|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
215034258|NCT04768153|BIOLOGICAL|Serology|Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
215034259|NCT05542888|PROCEDURE|Sacroiliac joint mobilization|Sacroiliac joint mobilization will be performed with the patient in side lying position in which grade I,II pain relief mobilization will be given in PA direction.It will be given as 1 set of 30 oscillations per session, 3 times per week for 4 weeks.
215034260|NCT05542888|PROCEDURE|Standard therapy|Postural education, Hot pack, Antenatal exercises
215034261|NCT04445103|DIAGNOSTIC_TEST|Assessment of cardiac function|Echocardiographic examination and assessment of cardiac biomakers
215034262|NCT00064857|DRUG|Pycnogenol|
215034263|NCT01999530|DRUG|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
215034264|NCT00614224|BEHAVIORAL|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
215034265|NCT00800644|PROCEDURE|CT or MRI + Blood Test|"During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover."
215034266|NCT04077502|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
215034267|NCT05849558|DRUG|Ursoplus|Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)
215034268|NCT05849558|DRUG|UDCA 250mg|UDCA 250mg alone
215034269|NCT05849558|OTHER|Placebo|Placebo alone
215034270|NCT00331721|DRUG|Enecadin|Dose escalating
215034271|NCT00331721|DRUG|Placebo|Placebo comparator
215034272|NCT03699202|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
215034273|NCT03699202|DRUG|Placebo|The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
215034274|NCT05640427|DRUG|Dexmedetomidine|Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.
215034275|NCT05640427|DRUG|normal saline|The same capacity of 0.9% normal saline was used in group C
215034276|NCT01229566|DRUG|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
215034277|NCT03367104|DEVICE|ECG Belt|Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.
215034278|NCT03319641|DIAGNOSTIC_TEST|PSMA-PET/CT scan|perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
215034279|NCT01418456|DRUG|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
215034280|NCT05242289|DEVICE|CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
215034281|NCT01192074|DEVICE|Ultrasound|Preprocedure ultrasound examination of the spine
215034282|NCT03515421|DEVICE|Frazier 3 Verio|In vitro diagnostic device (IVDD)
215034283|NCT03515421|DEVICE|Frazier 3 UltraPlus|In vitro diagnostic device (IVDD)
215034284|NCT00002673|PROCEDURE|infection prophylaxis and management|
215034285|NCT03401866|DIAGNOSTIC_TEST|DSC-MRI|"The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes."
215034286|NCT01451021|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
215034287|NCT00757068|BEHAVIORAL|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
215034288|NCT00757068|BEHAVIORAL|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
215034289|NCT05835648|DIETARY_SUPPLEMENT|Nutrasumma|On the basis of daily diet, dietary fiber supplement (Nutrasumma) was given once a day, 1 strip each time, before meals, and the intervention lasted for 3 months.
215034290|NCT04602845|DRUG|Fentanyl|50ug Fentanyl intravenously
215034291|NCT04602845|DRUG|Flurbiprofen|50mg Fentanyl intravenously
215034292|NCT04602845|DRUG|Midazolam|2.5mg midazolam in 2ml normal saline intravenously
215034293|NCT04602845|DRUG|Remimazolam|3mg Remimazolam in 2ml normal saline intravenously
215034294|NCT00240877|BIOLOGICAL|AV024|0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
215034295|NCT00240877|OTHER|Placebo|Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
215034296|NCT04513236|OTHER|Pre-survey incentive|An incentive of is given in the form of airtime to motivate participants to complete the survey. Participants were sent 0.1X before the were sent a mobile phone survey and an additional 1X after completing the survey.
215034297|NCT04513236|OTHER|Post-survey incentive|An incentive in the form of airtime to motivate participants to complete the survey. Participants were given Bangladeshi Taka or Ugandan Shillings worth of certain airtime for completing the survey.
215034298|NCT01202695|DRUG|AVP-21D9|intravenously, single dose
215034299|NCT01202695|DRUG|Placebo|Placebo comparator
215034300|NCT00355043|DRUG|Zinc sulphate 20 mg|
215034301|NCT01421056|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 24 weeks
215034302|NCT01421056|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
215034303|NCT01421056|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
215034304|NCT06489015|DRUG|Recombinant Human Serum Albumin|Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.
215034305|NCT03823989|DRUG|Promitil|The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
215034306|NCT03823989|RADIATION|EBR|A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
215034307|NCT05299515|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately four weekly core sessions (approximately 30 minutes-1 hour) with two additional sessions to reinforce core content, and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to assist in their retention and persistence in methadone treatment and incorporating value-driven, substance-free, rewarding activities into their daily life."
215034308|NCT05477888|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,the Penn State Electronic Cigarette Dependence Index (PS-ECDI ).
215034309|NCT05242939|OTHER|Video game|The child will be allowed to play the game they want to play throughout the entire procedure, starting 5 minutes before the inhalation therapy. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
215034310|NCT05242939|OTHER|Watching cartoons|The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
215034311|NCT00108381|BEHAVIORAL|tailored cognitive behavior therapy|tailored psychological treatment
215034312|NCT00108381|BEHAVIORAL|standard care|standard psychological treatment
214476520|NCT06513182|OTHER|No Alexis orthopaedic protector|No Alexis orthopaedic protector will be used during the course of the surgery.
214476521|NCT06513182|DEVICE|Alexis orthopaedic protector|Alexis orthopaedic protector will be inserted after making an initial superficial approach to the shoulder.
215034313|NCT01818778|OTHER|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
215034314|NCT01818778|OTHER|Standard Friendly Visit|"Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident."
215034315|NCT01142180|PROCEDURE|TAE|The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
215034316|NCT01142180|PROCEDURE|No TAE|No TAE procedure will be performed after endoscopic treatment
215034317|NCT02663362|OTHER|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
215034318|NCT00575224|DRUG|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
215034319|NCT00378092|DRUG|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
215034320|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
214476522|NCT04483739|DRUG|Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
214867040|NCT03398070|OTHER|Standard of Care|"The standard of care interventions for Functional Neurological Disorders (FND) include:~1. delivery of a rule-in diagnosis~2. providing educational materials~3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~4. referring to FND-related cognitive behavioral therapy (CBT)~5. psychotropic medication management based on standard psychiatric care"
214867041|NCT01509703|PROCEDURE|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
214867042|NCT06232798|OTHER|a dual energy catheter (RF and PFA) or PFA catheter only will be to treat PeAF,Cardiac Pulsed Electric Field Ablation Catheter|This study will be used two catheters, the contact force sensing catheter able to deliver both RF and PFA energy, this catheter provides both the radiofrequency (RF) energy and pulsed field ablation (PFA) energy to the catheter through the toggling of the two energy sources on the generator monitor. Another catheter is PFA catheter only.
214867043|NCT06232798|OTHER|catheter ablation|catheter ablation
214867044|NCT02470533|RADIATION|Radiation therapy|6 fractions of 8-9Gy
214867045|NCT02470533|DEVICE|chemoembolization|Up to 4 sessions
214867046|NCT06425497|OTHER|The dosage of dnDSA|Flow cytometric analysis using FlowPRA Screening Test and/or Luminex Single Antigen Beads class I and II- IgG (cut- positivity off = MFI\> 1000)
214867047|NCT04773301|DRUG|Levobupivacaine|Local anaesthetic drug belonging to the amino amide group. It is the S-enantiomer of bupivacaine
214867048|NCT04773301|DRUG|Ropivacaine|Local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer.
214867050|NCT02873741|PROCEDURE|Perianal and Digital Anorectal Exam|The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.
214867051|NCT02873741|PROCEDURE|Cervical Swabs|A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.
214867052|NCT02873741|PROCEDURE|Anal Swabs|The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.
214867053|NCT02873741|PROCEDURE|High Resolution Anoscopy (HRA)|High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
214867054|NCT01385449|PROCEDURE|interscalene catheter|interscalene catheter
214867055|NCT01385449|PROCEDURE|interscalene block|interscalene block
214867056|NCT00620399|OTHER|lumbar corset|
214867057|NCT00828737|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
214867058|NCT05958888|BEHAVIORAL|Text only sodium label|"Warning: High in sodium. is shown in a black square label on the can of soup."
214867059|NCT05958888|BEHAVIORAL|Icon sodium label|"Warning: High in sodium. is shown beneath a yellow triangle icon with an exclamation mark all in a black square label on the can of soup."
214867060|NCT05958888|BEHAVIORAL|Pictorial sodium label|"Warning: High in sodium. is shown beneath an image of a spilled salt shaker, all in a black square label on the can of soup."
214867061|NCT05958888|BEHAVIORAL|Barcode label|Barcode is shown in white square label on the can of soup
214867062|NCT06548815|DRUG|GZR4|Ascending single doses - 4 dose levels.
214867063|NCT06548815|DRUG|Placebo|Ascending single doses - 4 dose levels.
214867064|NCT02024113|OTHER|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
214867065|NCT03190213|DRUG|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
214867066|NCT04903951|DEVICE|Adaptive Servoventilation (ASV) therapy|Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated
214867067|NCT04903951|OTHER|Best medical treatment|Best medical treatment for stroke, including rehabilitation
214867068|NCT06355011|DEVICE|Total Elbow Replacement|Total elbow replacement is a procedure that involves replacing the elbow joint with an implanted device to alleviate pain and improve function.
214867069|NCT03244644|DRUG|RBX2660|RBX2660 is a rectally administered microbiota suspension
214867070|NCT03244644|DRUG|Placebo|Placebo is normal saline solution administered rectally
215034321|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
215034322|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
215034323|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
215034324|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
215034325|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
215034326|NCT02243358|DRUG|Folfox6|
214476523|NCT04483739|DRUG|Isatuximab Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
214476524|NCT04857827|DRUG|QLS-101|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
214476525|NCT04857827|DRUG|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
214476526|NCT06865157|OTHER|Healthy Wallet|The Healthy Wallet program is a mobile-based initiative designed to promote healthy eating among low-income families by incentivizing the purchase of fruits and vegetables at open markets. Over a two-month period, 30 families received monthly benefits to use at a designated open market.
214867071|NCT03244644|DRUG|Open label RBX2660 (only for confirmed CDI recurrence)|RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
214867072|NCT01931696|DEVICE|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
214867073|NCT01931696|DEVICE|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
214867074|NCT01879163|BIOLOGICAL|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
214867075|NCT01879163|BIOLOGICAL|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
214867076|NCT01997216|DEVICE|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
215034327|NCT02243358|DRUG|Gemcitabine|
215034328|NCT02243358|RADIATION|Radiation Therapy|
215034329|NCT02243358|PROCEDURE|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
215034330|NCT03808935|DRUG|Medical Cannabis|The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.
215034331|NCT03808935|DRUG|Placebo|The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
215034332|NCT00968409|RADIATION|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
215034333|NCT00968409|OTHER|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
215034334|NCT00968409|OTHER|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
215034335|NCT00968409|DRUG|F18-FFNP|injection of F18-FFNP
215034336|NCT06156150|BIOLOGICAL|tumor vaccine|DC vaccine produced by the Team
215034337|NCT00710099|DRUG|sildenafil|systemic absorption of sildenafil
214867077|NCT01997216|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
215034338|NCT00710099|DRUG|nitroprussiate iontophoresis|nitroprussiate iontophoresis
215034339|NCT01323608|DRUG|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
215034340|NCT01323608|DRUG|Placebo|Placebo
215034341|NCT03278561|PROCEDURE|Sputum induction|Sputum induction according to the ERS protocol
215034342|NCT03278561|PROCEDURE|Blood sample|A blood sample of 100ml will be taken.
215034343|NCT04989361|PROCEDURE|Soluble Hyaluronic Acid Microneedle|The soluble hyaluronic acid microneedle eye mask is a nanometer-sized microneedle made of water-soluble hyaluronic acid, which can directly inject the active ingredients into the dermis, and after being absorbed and dissolved by the skin, it can achieve the purpose of improving the water content and elasticity of the skin.
215034344|NCT04989361|PROCEDURE|Non-fractional laser|he non-ablative fractional laser use 1565nm fiber laser, which acts on the target base in the dermis-water. The beam penetrates the epidermis and acts on the dermis. Using the principle of focal light and heat, the tissue cells are heated to initiate the repair process, which promotes increased collagen synthesis, thereby Achieve the effect of firming the skin and improving wrinkles.
215034345|NCT04442009|OTHER|Group SCPB|In group SCBP, SCBP block will be performed. Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
215034346|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
215034347|NCT00573768|DRUG|Placebo|Vehicle 2 times daily
215034348|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
214867078|NCT04087434|DEVICE|Brain Gauge Prospective and Healthy Control|The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
214867079|NCT01811316|OTHER|Probiotics|
214867080|NCT04241315|DRUG|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
214867081|NCT04241315|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
215034349|NCT03243084|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
215034350|NCT03243084|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
215034351|NCT01785030|DRUG|50% Nitrous oxide|
215034352|NCT04470414|DIAGNOSTIC_TEST|IgG antibodies immunoassay|Assessment of IgG level will be done by quantitative assessment of IgG in the serum of recovered persons by Chemiluminescence Immunoassay (CLIA).
215034353|NCT04587492|DRUG|Nusinersen|Treatment with nusinersen
215034354|NCT05383261|OTHER|exercise|aerobic and resisted ex
215034355|NCT04541615|PROCEDURE|Online course with proficiency test|Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
215034356|NCT04541615|PROCEDURE|Online course|Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
215034357|NCT04541615|PROCEDURE|Standard training group|After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
215034358|NCT04541615|PROCEDURE|Apprenticeship group|Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
215034359|NCT04703140|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|2 nasopharyngeal swabs taken for PCR and COVIDISC
215034360|NCT01239940|DEVICE|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
215034361|NCT01239940|DEVICE|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
215034362|NCT04037215|OTHER|STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|"Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~* children controls not achieved with normal BMI;~* children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders."
214867082|NCT05353387|OTHER|Motivational Interviewing|Motivational Interviewing will be carried out in 3 different sessions, each to be conducted one week apart. 6 weeks after the last interview, first follow up would be conducted through phone communication and 6 weeks after the first follow up, a face-to-face interview would be conducted for the scales to be applied to the participants again.
214867083|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
214867084|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
214867085|NCT03906552|OTHER|nonpharmalogocial methods|neonates received acupressure (acupressure group) or massage (massage group) before heel lancing procedure
214867086|NCT02657265|DEVICE|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
214867087|NCT02657265|DEVICE|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
214867088|NCT03929991|OTHER|Observational|To record social and clinical characteristics
215034363|NCT00970398|OTHER|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
214867089|NCT02929524|DRUG|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
214867090|NCT02929524|DRUG|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
214867091|NCT01998724|BEHAVIORAL|Tai Chi|24 week tai chi intervention designed for individuals with COPD
214867092|NCT01998724|BEHAVIORAL|Group Walking|24 week group walking intervention
214867093|NCT00394524|DEVICE|Glucommander|Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG- 60).
215034364|NCT00970398|OTHER|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
215034365|NCT04958603|PROCEDURE|"L type release surgery"|Lateral release of the lateral support belt
215034366|NCT05263804|OTHER|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection|No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
215034367|NCT05263804|OTHER|Cardiac MRI with gadolinium injection - Ancillary Study|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
215034368|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
215034369|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
215034370|NCT04722666|DRUG|MIJ821 Intravenous Injection|MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
215034371|NCT04722666|DRUG|Placebo Intravenous Injection|40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
215034372|NCT06456840|DIAGNOSTIC_TEST|ULTRASOUND|Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.
215034373|NCT01741129|DEVICE|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
215034374|NCT01741129|DEVICE|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
215034375|NCT01807884|PROCEDURE|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
215034376|NCT01807884|OTHER|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
215034377|NCT01006733|GENETIC|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
215034378|NCT01006733|DRUG|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
215034379|NCT06637943|DIAGNOSTIC_TEST|POC viscoelastic test|applying viscoelastic test (Rotem or TEG tests) to 1 ml arterial blood sample
215034380|NCT06637943|DIAGNOSTIC_TEST|standard central laboratory test|applying central laboratory test to arterial blood sample
215034381|NCT01137890|DRUG|Zonisamide|Eight capsules administered daily in split doses at 22:00 and 09:00.
215034382|NCT01137890|DRUG|Placebo|capsules administered in split doses at 22:00 and 09:00.
215034383|NCT01137890|DRUG|Cocaine Hydrochloride|Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
214867094|NCT00394524|OTHER|Standard insulin infusion algorithm|Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving \>80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
214867095|NCT00492986|DRUG|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
214867096|NCT01398514|DRUG|Escitalopram|Escitalopram 10mg/day or matched pill placebo
215034384|NCT01137890|BEHAVIORAL|Neurocognitive and Performance Battery|Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
215034385|NCT01137890|BEHAVIORAL|Smoking Assessments|Participants answer questions about smoking and smoking behaviors are monitored.
214665579|NCT03643692|DEVICE|ARISES|The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
214665580|NCT03831087|DIAGNOSTIC_TEST|TAVR-CMR|CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
214665581|NCT03831087|DIAGNOSTIC_TEST|TAVR-CT|CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
214665582|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
214665583|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
214665584|NCT00246259|DRUG|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
214665585|NCT00246259|DRUG|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
214665586|NCT05971797|BEHAVIORAL|REBT|During REBT in patients with osteoarthritis and concomitant diseases with diagnosed depression or anxiety before arthroplasty the patients learn how to manage their irrational or unhealthy emotions, thoughts, and behaviors.
214665587|NCT01770340|BIOLOGICAL|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
214867097|NCT05808153|RADIATION|radiotracer injection|MRI with radiotracer injection
214867098|NCT01710553|OTHER|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
214867099|NCT01710553|OTHER|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
214867100|NCT06493604|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
214867101|NCT06493604|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered six times over two consecutive days
214867102|NCT04310618|OTHER|No intervention|No intervention
214867103|NCT05411588|DRUG|PF-07275315|Active drug
214867104|NCT05411588|DRUG|Placebo|Placebo
214867105|NCT01070459|BEHAVIORAL|Aerobic exercise group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
214867106|NCT01070459|BEHAVIORAL|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
214867107|NCT01070459|BEHAVIORAL|Follow-up first aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
214665588|NCT01770340|PROCEDURE|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
214665589|NCT05623566|DEVICE|Picterus Jaundice Pro|In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
214867108|NCT01070459|BEHAVIORAL|Follow-up control group|No intervention will be offered in a period of 9 months after the passive mobilisation programme
214867109|NCT01070459|BEHAVIORAL|Follow-up second aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
214867110|NCT03537599|BIOLOGICAL|Daratumumab|Given IV
214867111|NCT03537599|PROCEDURE|Donor Lymphocyte Infusion|Given via infusion
214867112|NCT03537599|OTHER|Laboratory Biomarker Analysis|Correlative studies
214867113|NCT04799873|DRUG|AAT( Alpha 1 Antitrypsin)|AAT administration based on clinical indication
214867114|NCT06445114|DRUG|Cisplatin|"Low risk pathology with post-op HPV DNA (-): cisplatin-based chemoradiation with 30 Gy in 15 fractions and 3 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, and 15 of radiation.~Low risk pathology with post-op HPV DNA (+): cisplatin-based chemoradiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (-), excluding patients with both 5 LN+ and ENE+ or pre-op HPV DNA≤12 copies/mL: cisplatin-based radiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (+) OR pre-op HPV DNA≤12 copies/mL OR both 5 or more LN+ and ENE+: cisplatin-based radiation with 50 Gy in 25 fractions with 5 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, 22, and 29 of radiation."
214867115|NCT01007942|DRUG|everolimus|Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
214867116|NCT01007942|DRUG|Placebo|Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
215034386|NCT05148338|OTHER|Comprehensive risk factor treatment|"1. Apnea screening with Home Sleep Apnea Test. Referral to sleep physician if apnea-hypopnea index (AHI) is greater than 5~2. Weight management counseling by dietician if body mass index (BMI) is above 27 kg/m2~3. Physical activity program under supervision of physiotherapist at a specialized cardiac rehabilitation centre if BMI is over 27 or if there are complaints during exercise~4. Smoking cessation at specialized outpatient clinic~5. Blood pressure control, lipid management, glycaemic control, alcohol intake reduction by specialized AF nurse~6. Motivation and education through a digital health platform"
215034387|NCT05148338|OTHER|Standard of care|Standard usual care: Treatment by cardiologist conform existing guidelines
214867117|NCT01007942|DRUG|vinorelbine|intravenous vinorelbine (25 mg/m2 weekly)
214867118|NCT01007942|DRUG|trastuzumab|intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
214867119|NCT02275130|PROCEDURE|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
215034388|NCT06564129|DEVICE|electroencephalography|Fifty-nine EEG electrodes conforming to international standard points were placed using a saline electrode EEG cap (Gelfree, Prysmian, China), and an accompanying portable multimodal EEG acquisition system (Neurohub, Prysmian, China) was used. EEG data were collected using collect software (Brycon, China).
215034389|NCT06563882|OTHER|Home-based exercise program|"The program will comprise of six exercises aimed at improving the mobility of the thoracic spine and shoulders, strengthening the extensor muscles of the spine, and enhancing the flexibility of the chest and anterior shoulders. Progression within the program will involve increasing exercise duration or repetitions/sets, along with implementing postural corrections in compound exercises. Participants will be instructed to perform the exercises at least three times a week.~To heighten participants awareness of their daily posture, they will receive a daily scheduled message via WhatsApp reminding them to focus on their posture. Once a week, participants will be asked to submit a home exercise tracking report to monitor their adherence to the program. Additionally, exercises execution will be reviewed every two weeks, and adjustments to the program will be made accordingly."
215034390|NCT06563882|OTHER|No intervention|No intervention
215034391|NCT05533463|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
215034392|NCT02090764|DRUG|Ozenoxacin|
215034393|NCT02090764|DRUG|Placebo|
215034394|NCT01598155|PROCEDURE|Group 1 - Supragingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient."
215034395|NCT01598155|PROCEDURE|Group 2 - Supra- and subgingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing of coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;~* Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged."
215034396|NCT02384421|DEVICE|Adaptive DBS (Activa PC+S Neurostimulator)|
215034397|NCT02384421|DEVICE|Continuous DBS (Activa PC+S Neurostimulator)|
215034398|NCT00737789|DRUG|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
215034399|NCT00737789|DRUG|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
215034400|NCT05072379|DEVICE|colostomy self-care app|The study will use mixed methods as the study design in which content analysis will be used to identify the content suited for the App based on interviews with participants. A systematic research and development process will be utilized to design the text, videos, and images in the App's simulations to provide accurate, consistent, and complete knowledge of the skills needed for colostomy self-care and contending with any potential emergency.
215034401|NCT05769114|PROCEDURE|Surgical stabilization|Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
215034402|NCT04755647|DRUG|Nitric Oxide-Releasing Solution|Active antimicrobial
215034403|NCT04755647|DRUG|Saline solution, hypotonic|Placebo
215034404|NCT03586531|PROCEDURE|renal biopsy|Renal biopsy samples will be obtained by a percutaneous method using a spring-loaded Trucut® biopsy needle under real time ultrasound guidance. Biopsy samples will be processed for light microscopy with special staining will be done: Schiff periodic acid, Masson trichrome and methenamine silver.and immunofluorescence studies to evaluate IgA, IgG, IgM, complement C1q and C3, fibrin, and kappa and lambda light chain deposits.
215034405|NCT03060889|DRUG|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
215034406|NCT04485702|DRUG|Midazolam injection|2mg IV
215034407|NCT04485702|DRUG|Ketamine Injectable Product|6mg IV
215034408|NCT04485702|DRUG|MELT-100|midazolam 3mg and ketamine 25mg SL tablet
215034409|NCT03274765|DIAGNOSTIC_TEST|Dosage of oestradiol|"The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech).~This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation."
214867120|NCT02275130|DEVICE|Radiesse Voice (Calcium Hydroxyapatite)|
214867121|NCT00266396|BEHAVIORAL|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
214867122|NCT00266396|BEHAVIORAL|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
214867123|NCT04549935|DRUG|Dextenza|Dextenza 0.4mg
214867124|NCT04549935|DRUG|Topical Prednisolone|Standard of care topical drop treatment
214867125|NCT01020344|PROCEDURE|Lung volume reduction surgery|Lung volume reduction surgery
214867126|NCT02301195|OTHER|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
214867127|NCT02301195|OTHER|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
214867128|NCT04170556|DRUG|Regorafenib|Regorafenib 160 mg/day 3 weeks on and 1 week off
214867129|NCT04170556|DRUG|Nivolumab|Nivolumab at the dose of 1.5 mg/kg, 3 mg/kg or 240 mg/infusion every 2 weeks. Dose will be adjusted depending on the incidence of adverse events
214867130|NCT01104909|PROCEDURE|Clinical|Each patient will be submitted a clinical evaluation, considering signals of overload.
214867131|NCT01104909|DEVICE|electrical bioimpedance|From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
214867132|NCT02713386|DRUG|Carboplatin|Given IV
214867133|NCT02713386|DRUG|Paclitaxel|Given IV
214867134|NCT02713386|DRUG|Ruxolitinib Phosphate|Given PO
215034410|NCT01707537|BIOLOGICAL|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
215034411|NCT06387381|DRUG|68Ga-PSFA|Each subject receives a single intravenous injection of 68Ga-PSFA.
215034412|NCT00000628|DRUG|L-697,661|
215034413|NCT00000628|DRUG|Zidovudine|
215034414|NCT00182143|DRUG|LMWH (Fragmin, dalteparin)|Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
215034415|NCT00182143|DRUG|Unfractionated Heparin|5000 IU BID
215034416|NCT00529048|OTHER|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
215034417|NCT00529048|OTHER|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
215034418|NCT00529048|OTHER|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
215034419|NCT02300233|DRUG|Volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
215034420|NCT02300233|DRUG|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
215034421|NCT00833690|DRUG|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
215034422|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
215034423|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
215034424|NCT03567694|DRUG|HA115|Test Drug
215034425|NCT03567694|DRUG|Placebo|Placebo
214665590|NCT06061445|COMBINATION_PRODUCT|Radiotherapy combined with TKI and Anti-PD-1 Antibody|After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.
214867135|NCT02713386|PROCEDURE|Therapeutic Conventional Surgery|Undergo TRS
214867136|NCT05083585|BIOLOGICAL|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.
214867137|NCT01751035|BEHAVIORAL|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
214867138|NCT01751035|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
215034426|NCT04679454|RADIATION|Phase I|To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
215034427|NCT04679454|RADIATION|Phase II|The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
215034428|NCT01486303|PROCEDURE|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
215034429|NCT06275867|OTHER|Free high-quality care|Participants are able to take their child to receive free consultations and treatment in a network of contracted private healthcare providers.
215034430|NCT06275867|OTHER|Close distance|The network of contracted providers is located close to where participants live.
215034431|NCT06275867|OTHER|Far distance|The network of contracted providers is located far to where participants live.
215034432|NCT03896646|PROCEDURE|Computed Tomography|Undergo SPECT/CT HIDA scan
215034433|NCT03896646|OTHER|Hepatobiliary Iminodiacetic Acid Scan|Undergo SPECT/CT HIDA scan
215034434|NCT03896646|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT HIDA scan
215034435|NCT03896646|RADIATION|Yttrium Y 90 Glass Microspheres|Undergo radioembolization with yttrium Y 90 glass microspheres
215034436|NCT03896646|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere radioembolization
215034437|NCT02236910|OTHER|Lu-DOTA-TATE|
215034438|NCT04128748|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
215034439|NCT04128748|DRUG|Quizartinib|Given PO
215034440|NCT04306926|DRUG|TQB2450|TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
215034441|NCT04306926|RADIATION|SBRT|Give according to the location of the lesion and clinical condition.
215034442|NCT06353906|DRUG|Carboplatin/Paclitaxel|Induction: three cycles of intravenous carboplatin AUC5 (max 750 mg) and paclitaxel 175 mg/m2, during cycle 1, 2 and 3 (day 1, 22, 43)
215034443|NCT06353906|DRUG|Pembrolizumab|"Induction: two cycles of intravenous pembrolizumab 400 mg during cycle 1 and 3 (day 1 and 43)~Adjuvant: up to seven cycles of fixed-dose intravenous pembrolizumab 400 mg, on day 1 every 6 weeks within 3-9 weeks after surgery"
214867139|NCT02016313|OTHER|physiotherapy|
214867140|NCT03929757|BIOLOGICAL|Ad26.ZEBOV|Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.
214867141|NCT03929757|BIOLOGICAL|MVA-BN-Filo|Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.
214867142|NCT03929757|BIOLOGICAL|MenACWY|Participants will receive 0.5 mL IM injection of MenACWY.
214867143|NCT04941521|DRUG|Exenatide 2 mg [Bydureon]|Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
214867144|NCT04941521|BEHAVIORAL|Drug Counseling|Once weekly drug counseling sessions for cocaine use with trained masters-level therapists.
215034444|NCT06353906|PROCEDURE|Partial or total penectomy with inguinal and/or pelvic lymph node dissection|Resection of part or all of the penis with complete removal of suspect lymphnodes in the inguinal and/or pelvic area
215034445|NCT05763771|BEHAVIORAL|Smart Phone App|Collection of data
215034446|NCT05763771|OTHER|NIcotine Patches|Place on the skin
215034447|NCT04533750|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214867145|NCT03734406|OTHER|Videoclips|The images contained in the videoclips show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
214867146|NCT04792775|BEHAVIORAL|PE+ER|PE includes the following components: a) psychoeducation about the common reactions to traumatic events and presentation of the treatment rationale b) repeated in vivo exposure to traumatic stimuli, c) repeated, prolonged, imaginal exposure to traumatic memories, and d) relapse prevention strategies and further treatment planning (session 12). DBT Emotion Regulation Skills is integrated as part of this intervention. DBT training provides skills to understand, name, experience and tolerate emotions, as well as skills to change negative emotional responses and to reduce vulnerability to emotion dysregulation (Linehan et al., 2015). The current project includes an adapted 3- session individual emotion regulation skills training intervention to be implemented concurrently with PE which consists of initial teaching/instruction and brief skills review for the remainder of PE treatment.
215034448|NCT04533750|OTHER|Fludeoxyglucose F-18|Given IV
215034449|NCT04533750|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215034450|NCT04533750|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215034451|NCT04533750|DRUG|Peposertib|Given PO
215034452|NCT04533750|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215034453|NCT05327257|DEVICE|iTBS rTMS|Repetitive transcranial magnetic stimulation (rTMS) intermittent Theta Burst Stimulation (iTBS)
215034454|NCT06096337|DEVICE|FARAPULSE™ Pulsed Field Ablation (PFA) System|Subjects will undergo a pulsed field ablation procedure using the FARAPULSE™ Pulsed Field Ablation (PFA) System for the isolation of pulmonary veins and posterior wall.
214867147|NCT02796937|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
215034455|NCT06096337|DRUG|Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone|Anti-Arrhythmic Drugs (AADs) including, Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone will be prescribed and monitored in accordance with local clinical practice and already established guideline-directed therapy for patients with persistent atrial fibrillation (AF).
214867148|NCT00463242|DRUG|Agomelatine|Either 25 mg or 50 mg agomelatine orally once daily
214867149|NCT00463242|DRUG|paroxetine|
214867150|NCT00463242|DRUG|placebo|
214867151|NCT06063265|BEHAVIORAL|Integrated Attention Training Program|Integrated Attention Training Program (IATP) specifically aims at training attentional control, which involves the coordination of complex behaviours, such as planning, reasoning, selection and information inhibition.
214867152|NCT03944174|PROCEDURE|Fixation of unstable pelvic fractures|Percutaneous fixation of both iliac bones through the sacrum using one screw
214867153|NCT00114166|DRUG|topotecan hydrochloride|
214867154|NCT00150891|PROCEDURE|Kidney transplantation|
214867155|NCT00150891|DRUG|cyclosporine A|
214867156|NCT00150891|DRUG|tacrolimus|
214867157|NCT00150891|DRUG|azathioprine|
214867158|NCT00150891|DRUG|mycophenolate mofetil|
215034456|NCT06645314|BIOLOGICAL|Group A|3.0 × 10 \^ 9 BST06 cells, intravenous infusion，at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
215034457|NCT06645314|BIOLOGICAL|Group B|3.0 × 10 \^ 10 BST06 cells, intravenous infusion, at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
215034458|NCT06645431|BEHAVIORAL|Water Intake|Previous studies have not observed blood glucose with adequate vs. low water intake in a free-living situation. The use of continuous glucose monitors allows this.
215034460|NCT04752566|BIOLOGICAL|Eculizumab|Eculizumab will be administered via IV infusion once a week for 4 weeks.
215034461|NCT04752566|DRUG|Placebo|Placebo will be administered via IV infusion once a week for 4 weeks.
215034462|NCT05921786|DEVICE|Electrophysiological system|Electrophysiological system is used for examining voltage variation in biological samples. And multiphoton microscopy is a common type of nonlinear optical microscope.
215034463|NCT05921786|DEVICE|Multiphoton microscope|Multiphoton microscope acquires high-resolution image based on nonlinear optics and can be used for detect biological specimens.
215034464|NCT05933811|PROCEDURE|exploratory laparoscopy|Laparoscopic exploration for impalpable maldescended testis in pediatric age group
215034465|NCT00283166|BEHAVIORAL|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
215034466|NCT05878704|DRUG|GBT021601|Oral
215034467|NCT02588014|OTHER|Magnetoencephalography|Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
215034468|NCT05291533|OTHER|Virtual Reality (VR) Mindfulness Program|The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
215034469|NCT05971407|DEVICE|Remote Ischaemic Preconditioning|RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
215034470|NCT05971407|DEVICE|Sham Remote Ischaemic Preconditioning|Sham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
215034471|NCT06498050|DRUG|intravitreal injection of Brolucizumab 6 mg in study eye|After disinfecting the conjunctival sac and administering a topical anesthetic, an intravitreal injection of Brolucizumab at a dose of 6 mg is given.
215034472|NCT04474873|PROCEDURE|erector spinae block|we administer 15 cc of 0.5% bupivacaine between the erector spine muscle and the transverse process. The distribution of bupivacain was observed on ultrasound.
215034473|NCT02661815|DRUG|Paclitaxel|Please see arm/group description.
215034474|NCT02661815|DRUG|Ricolinostat|Please see arm/group description.
215034475|NCT02661815|DRUG|Bevacizumab|Please see arm/group description.
214867159|NCT00001365|DRUG|dextromethorphan|
215034476|NCT00989495|DEVICE|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
215034477|NCT05054101|OTHER|Real-time assessment using the VieCovid2020 smartphone application|a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
215034478|NCT00374179|DRUG|CT-322|IV solution, weekly or bi-weekly
215034479|NCT02247921|OTHER|Rehabilitation|Patients recruited into the intervention arm will have their family-nominated caregivers trained by a trained nurse and guided by a culturally appropriate and easy-to-understand rehabilitation manual to be given to caregivers at the last session, shortly before hospital discharge to reduce contamination. The training sessions will take at least 90 minutes per day for 2 or 3 days.The nurse will call the patients and caregivers at 2, 4, and 8 weeks after hospital discharge to monitor progress and offer guidance on rehabilitation.Duration of the standardized yet individualized intervention by nurses will be 8 weeks; however, trained caregivers are expected to deliver the rehabilitation services to patients as long as they are needed.
215034480|NCT03209258|OTHER|Care bundle of active management|"1. Intensive BP lowering to systolic target of \<140mmHg;~2. Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;~3. Treatment of pyrexia to a target body temperature ≤37.5 ℃;~4. Reversal of anticoagulation to target INR \<1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).~As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets."
215034481|NCT03209258|OTHER|Usual care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
215034482|NCT03470051|DIAGNOSTIC_TEST|QT Ultrasound|All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.
215034483|NCT05836909|DIETARY_SUPPLEMENT|Swisse plus cholesterol capsule|Swisse plus cholesterol capsule per day orally for 12 weeks
215034484|NCT05836909|DIETARY_SUPPLEMENT|Placebo|Placebo
215034485|NCT04743232|OTHER|Decision tool for clinicians|Clinical decision aid, using a structured approach to advanced care directives and a comprehensive view of available risk scores.
215034486|NCT02102945|PROCEDURE|Computed tomography perfusion|Computed tomography perfusion of the head
215034487|NCT02583841|PROCEDURE|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
215034488|NCT00189475|DRUG|Montelukast|
215034489|NCT00189475|DRUG|Placebo|
215034490|NCT02474498|DRUG|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
215034491|NCT02474498|DEVICE|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
215034492|NCT02474498|PROCEDURE|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
215034493|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement with a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink with cooling sensation flavour
214867160|NCT00301093|BIOLOGICAL|GM-K562 cell vaccine|Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations
214867161|NCT00301093|DRUG|imatinib mesylate|Participants will continue on current dose
214867162|NCT01049711|DRUG|erythropoietin|
214867163|NCT03614897|BEHAVIORAL|Education|Education on guidelines for care of individuals at risk of falling
214867164|NCT01191983|DRUG|Methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
214867165|NCT02770677|OTHER|Modified Dantien Salee Yoga Training Program|The intervention aims to improve pulmonary function and functional fitness.
214867166|NCT03251495|DRUG|Vaxchora|Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
214867167|NCT01155453|DRUG|BKM120|
215034494|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement without a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink without cooling sensation flavour
214665591|NCT06105138|DIETARY_SUPPLEMENT|200mg Cannabidiol oral solution|"200mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
214867168|NCT01155453|DRUG|GSK1120212|
214665592|NCT06105138|DIETARY_SUPPLEMENT|30mg Cannabidiol oral solution|"30mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
215034495|NCT03178682|DIAGNOSTIC_TEST|ultrasound parameters|ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss.
215034496|NCT05293262|PROCEDURE|Endourological surgery|Includes ureteral stent insertion, ureteroscopies and retrograde intrarenal surgeies
215034497|NCT00654355|DRUG|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
215034498|NCT02160431|BEHAVIORAL|CBT for pediatric OCD|Participants complete standard CBT for OCD as delivered in the POTS study .
215034499|NCT06264154|OTHER|E-cigarettes|All participants are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. Participants will receive an e-cigarette device and flavored nicotine pods according to their randomly assigned flavor.
215034500|NCT04078243|DEVICE|CardioMEMS HF System|The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
215034501|NCT01728246|DRUG|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
215034502|NCT01728246|DRUG|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
215034503|NCT00773188|DRUG|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
215034504|NCT00773188|DRUG|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
215034505|NCT00773188|DRUG|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
215034506|NCT00502918|DEVICE|CLM - HA Continuous Monitoring System Heart Application|
215034507|NCT04747041|COMBINATION_PRODUCT|CYSCONTROL/PHYTOCYST Herbal tea|Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
215034508|NCT05708859|DRUG|Tirzepatide|Tirzepatide 15mg Subcutaneous Solution
215034509|NCT05708859|DRUG|Placebo|Volume matched Subcutaneous Solution
214867169|NCT04145453|BEHAVIORAL|Intervention genotype personalized nutritional recommendations|Participants will receive personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the beginning of study
214867170|NCT04145453|BEHAVIORAL|Control Group 1 personalized nutritional recommendations|Participants will receive genotype personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the end of study
214867171|NCT04145453|BEHAVIORAL|Control Group 2 general nutritional recommendations|Participants will receive general nutritional recommendations to increase fruit and vegetables consumption
214867172|NCT04040322|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
214867173|NCT04040322|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
214867174|NCT00466453|BEHAVIORAL|knowledge-adaptive Web-based instruction|
214867175|NCT05990153|OTHER|Myofascial Release (MR)|Myofascial release therapy is a type of gentle, constant massage that releases tightness and pain throughout myofascial tissues.
215034510|NCT06317935|OTHER|ArmeoSenso|ArmeoSenso is an upper extremity virtual reality application with three motion sensors and one hand grip sensor. The device detects the person's body, arm, forearm and hand movements and displays the reflection of the movements on the screen. The application includes studies on upper extremity functions.
215034511|NCT06317935|OTHER|Traditional Rehabilitation|It includes traditional occupational therapy and physiotherapy approaches.
214867176|NCT05990153|DRUG|clinical practice drug treatment|drug treatment according to the medical indications of clinical practice
214867177|NCT05990153|OTHER|Manual therapy (MT)|The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
214867178|NCT05990153|OTHER|Therapeutic exercise (TE)|The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
214867179|NCT02195453|DRUG|Yangzhengxiaoji Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po."
214867180|NCT02195453|DRUG|Placebo Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po."
215034512|NCT04440774|BIOLOGICAL|CHIK low dose|A single dose of 5x10\^9 vp ChAdOx1 Chik
214867181|NCT05898321|DRUG|Zoladex|Patients with fibroid remained will be enrolled and divided into three groups. one group wii be administrated with Zoladex (3.60mg/28 days) for three to six months.
214867182|NCT05898321|DRUG|Mifepristone Oral Tablet|Patients with fibroid remained will be enrolled and divided into three groups. one group will be administrated with mifepristone(10.0mg/d) for three to six months.
214867183|NCT03056157|BEHAVIORAL|Adaptive Disclosure for Moral Injury and Loss|AD-MIL is a manualized, 12-session individual psychotherapy designed to improve functioning and to reduce PTSD symptoms by facilitating Veterans doing corrective things in their life to heal and repair traumatic loss and moral injuries. The change agents are: (1) emotional-processing of traumatic loss and moral injuries and motivating a healing and action plan by writing therapeutic letters (e.g., to a lost unit member, to victims of personal transgressions, to people who transgressed); (2) skills training and behavioral contracting to improve functioning and targeting moral injury- and traumatic loss-related psychological and behavioral obstacles to positive and potentially habilitative engagements in occupational, relationship, and family roles; and (3) teaching self- and other-compassion and mindfulness. The goal is to redress the functional impact of moral emotions (anger, shame).
214867184|NCT03056157|BEHAVIORAL|Present Centered Therapy|Participants randomized to the PCT arm will receive 12 sessions of therapy focused on day-to-day functional problems with no focus on trauma or re-visiting past experiences
214867185|NCT02077439|DEVICE|Hand Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
214867186|NCT02077439|DEVICE|Hand and Arm Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
214867187|NCT02077439|OTHER|Conventional therapy|Training for 20 sessions for one hour, 3-5 times per week.
214867188|NCT02879357|BEHAVIORAL|Training|"1. Clinician training~2. System for patient selection~3. System of triggering and tracking conversations~4. Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~5. Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
214867189|NCT02286310|OTHER|Kinetic Chain Exercises|Exercises include kinetic chain segments.
215034513|NCT04440774|BIOLOGICAL|CHIK mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Chik
214867190|NCT02286310|OTHER|Traditional Exercises|Stretching, strengthening exercises.
215034514|NCT04440774|BIOLOGICAL|CHIK high dose|A single dose of 5x10\^10 vp ChAdOx1 Chik
215034515|NCT04440774|BIOLOGICAL|ZIKA low dose|A single dose of 5x10\^9 vp ChAdOx1 Zika
215034516|NCT04440774|BIOLOGICAL|ZIKA mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Zika
215034517|NCT04440774|BIOLOGICAL|ZIKA high dose|A single dose of 5x10\^10 vp ChAdOx1 Zika
215034518|NCT04440774|BIOLOGICAL|Saline placebo|A single dose of isotonic saline solution (0.9%)
215034519|NCT05703230|OTHER|Structured preoperative multidisciplinary team meeting|"The intervention to be investigated is the introduction of a preoperative structured multidisciplinary team (sMDT) meeting for high risk noncardiac surgical patients, which is attended by at least the treating surgical specialist, an anesthesiologist and another medical consultant with expertise relevant for the patients comorbidities and preferences. In the preoperative sMDT meeting, at least the following questions will be discussed as recommended by the Dutch Perioperative Guideline:~* Is the proposed surgical intervention appropriate care for the patient?~* Is the risk/benefit ratio of the proposed surgical intervention acceptable for the patient?~* Should the patient's condition be optimized before undergoing the proposed surgical intervention?"
214867191|NCT02336035|PROCEDURE|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
214867192|NCT06192836|PROCEDURE|Manual Removal 1|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
214867193|NCT06192836|PROCEDURE|Manual Removal 2|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
214867194|NCT06192836|PROCEDURE|Controlled Cord Traction 1|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
214867195|NCT06192836|PROCEDURE|Controlled Cord Traction 2|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
215034520|NCT02918448|OTHER|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
215034521|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 25mg|To evaluate the efficacy and safety of TQA2225/AP025 (25mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
215034522|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 50mg|To evaluate the efficacy and safety of TQA2225/AP025 (50mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
215034523|NCT06570122|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
215034524|NCT06570122|OTHER|Health warning leaflet|The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.
215034525|NCT06570122|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
215034526|NCT02244515|DRUG|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
215034527|NCT01983111|DRUG|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
214665593|NCT06105138|DIETARY_SUPPLEMENT|Placebo|"Placebo administered in the laboratory prior to a standard dose of alcohol.~The placebo was made up for the study and contained reverse-osmosis water, gum arabic, MCT (Medium Chain Triglyceride) oil, citric acid, plus the addition of a natural food color, used at \<0.1%."
215034528|NCT01983111|DRUG|tramadol/acetaminophen|"Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
215034529|NCT01777061|DRUG|[11C]Acetate|intravenous injection of an average of 40 mCi of \[11C\]Acetate
214867196|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 1|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed after placental delivery"
214867197|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 2|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. Additional uterine massage for one minute duration will be performed after uterine incision is closed"
215034530|NCT06048029|PROCEDURE|laparscopic Cholecystectomy in children|Evaluate preoperative and operative risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy
214867198|NCT04325763|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214867199|NCT04325763|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
215034531|NCT03502200|DEVICE|JUUL|Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.
215034532|NCT03502200|OTHER|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.
215034533|NCT00855335|DRUG|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
215034534|NCT00855335|DRUG|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
215034535|NCT00855335|DRUG|Etravirine|200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
215034536|NCT00855335|DRUG|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
215034537|NCT00855335|DRUG|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
215034538|NCT04627714|OTHER|Adapted Physical Activity|Intervention consists in 1h30/week of adapted fencing
215034539|NCT05284578|OTHER|Self-compassionate writing intervention|Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
215034540|NCT05284578|OTHER|Expressive writing intervention|Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
215034541|NCT05284578|OTHER|Control writing task|Participants assigned to this condition were asked to engage in a neutral time management writing task.
215034542|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging with physical grid using conventional processing|X-ray imaging with physical grid using conventional processing
215034543|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using conventional processing|X-ray imaging without physical grid using conventional processing
215034544|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using experimental SimGrid offline processing|X-ray imaging without physical grid using experimental SimGrid offline processing
215034545|NCT05126303|DRUG|RMC-035|Concentrate for Solution for Infusion
215034546|NCT05126303|DRUG|Placebo|Concentrate for Solution for Infusion
214867200|NCT04325763|DRUG|TQB2450(blank)|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
214867201|NCT04325763|DRUG|Anlotinib(blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
214867202|NCT04638335|BIOLOGICAL|Blood test|blood test for Anti-HAV antibodies
214867203|NCT04041349|DRUG|mouse nerve growth factor|mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
214867204|NCT04096508|BEHAVIORAL|Music listening|Patients sit comfortably in a chair for 20 min listening music before the procedure.
214867205|NCT03218059|PROCEDURE|Methotrexate Combined With Transvaginal Surgery|The methods of treatment of CSP
215034547|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
215034548|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
215034549|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor|"Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10\^8 cells will be given up to 3x10\^11 anti-MART-1 F5 TCR engineered TIL or PBL."
215034550|NCT00509288|DRUG|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
215034551|NCT00509288|DRUG|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
215034552|NCT00509288|BIOLOGICAL|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e\^11 (with a minimum of 5x10e\^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
215034553|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
215034554|NCT05095922|DRUG|Heart-Protecting Musk Pill|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
215034555|NCT05095922|DRUG|Valsartan Capsules|Valsartan Capsules(capsule, 80mg, once a day, 3 months）
214665594|NCT03632642|DRUG|Benzylpenicillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
214867206|NCT01157559|DRUG|Ziprasidone|8 week prospective study
214867207|NCT06033300|BIOLOGICAL|blood sample|blood sample
214867208|NCT03554044|DRUG|Anastrozole|Given PO
214867209|NCT03554044|DRUG|Exemestane|Given PO
214867210|NCT03554044|DRUG|Fulvestrant|Given IM
214867211|NCT03554044|DRUG|Letrozole|Given PO
214867212|NCT03554044|DRUG|Paclitaxel|Given IV
214867213|NCT03554044|BIOLOGICAL|Talimogene Laherparepvec|Given IT
214867214|NCT03554044|DRUG|Tamoxifen|Given PO
214867215|NCT03554044|DRUG|Nab paclitaxel|Given IV
214867216|NCT03554044|DRUG|Gemcitabine|Given IV
214867217|NCT03554044|DRUG|Carboplatin|Given IV
214867218|NCT00331240|DRUG|travoprost/timolol fixed combination|
214867219|NCT00331240|DRUG|placebo (artificial tears)|
214867220|NCT00806286|DRUG|CS7017 tablets|CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
214867221|NCT00806286|DRUG|Paclitaxel|Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks
214867222|NCT00806286|DRUG|Carboplatin|IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
214867223|NCT00806286|DRUG|Placebo Tablets|Placebo tablets matching CS-7017 tablets
214867224|NCT03527381|DRUG|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
214867225|NCT03527381|OTHER|Standard CPB|Standard CPB protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit during cardiac surgery.
214867226|NCT03257514|DRUG|alpha lipoic acid drug (thioctic acid acid)|Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
215034556|NCT05095922|DRUG|Calcium Dobesilate Capsules|Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
214867227|NCT03257514|DRUG|Placebo Oral Tablet|placebo oral drug have the same shape of thiotacid tablet
214867228|NCT03402750|BEHAVIORAL|Meds to Beds|Medications will be delivered to patient bedside before discharge
214867229|NCT03402750|BEHAVIORAL|Electronic Prescription|Patient or surrogate can pick up medication from pharmacy
214867230|NCT06015243|DRUG|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
214867231|NCT04914858|OTHER|Education|Its validity and reliability is a reliable scale in Turkey
214867232|NCT00146341|DRUG|Telmisartan/HCTZ|
214867233|NCT00146341|DRUG|Telmisartan|
214867234|NCT02416024|DEVICE|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
214867235|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
214867236|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
214867237|NCT02621918|OTHER|Progressive resistance training|
214867238|NCT02621918|OTHER|Aerobic training|
214867239|NCT02621918|OTHER|Placebo training|
214867240|NCT03469336|DRUG|PF-06763809|Three different concentrations will be administered to three different treatment fields: 2.3%, 0.8% and 0.23%
214867241|NCT03469336|OTHER|Vehicle|Vehicle matching PF-06763809.
214867242|NCT03469336|DRUG|Calcipotriene/calcipotriol|Calcipotriene/calcipotriol 50 ug/mL solution
214867243|NCT03469336|DRUG|Betamethasone|Betamethasone 1 mg/g solution
214867244|NCT02628743|DRUG|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
214867245|NCT06320808|OTHER|FDA template PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
214867246|NCT06320808|OTHER|Decision Critical PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template and modified, according to decision science principles, to include benefit information, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
214867247|NCT06320808|OTHER|Standard Information|The intervention is an information format viewed by participants. This patient medication information format is the current standard of care patient medication information that is included with the drug. No drug or device is included as part of this intervention.
214867248|NCT02534844|DRUG|Parts A/B: Adrabetadex|900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
214867249|NCT02534844|OTHER|Parts A/B: Sham Control|No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
214867250|NCT04142957|OTHER|COPD Pal|'COPD Pal' aims to allow people with COPD to track and manage their condition. It enables patients to log symptoms (e.g. COPD assessment Test), wellness (e.g. quality of life such as EQ-5D), and medications, to help them become more engaged in their own care.
214867251|NCT00003174|DRUG|bryostatin 1|
214867252|NCT00003174|DRUG|cladribine|
214867253|NCT04060043|DRUG|Goserelin Acetate|The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
214867254|NCT02183207|PROCEDURE|Percutaneous Endoscopic Gastrostomy|Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
215034557|NCT03127930|BEHAVIORAL|Intervention|Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
214665595|NCT03632642|DRUG|Flucloxacillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
214867255|NCT02958982|DRUG|RP3128|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
214867256|NCT02958982|DRUG|Placebo|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
214867257|NCT03870282|BEHAVIORAL|Sleep Extension|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
214867258|NCT02642848|PROCEDURE|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
214867259|NCT02642848|PROCEDURE|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
214867260|NCT02642848|PROCEDURE|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
214867261|NCT05227911|PROCEDURE|Abdominal Surgery|Abdominal surgery (laparotomy or laparoscopy) ,which includes proper inspection of the abdominal cavity.
214867262|NCT02390609|DRUG|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
214867263|NCT02390609|DRUG|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
214867264|NCT02390609|DRUG|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
214867265|NCT02390609|DRUG|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
214867266|NCT02390609|DRUG|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
214867267|NCT02390609|DRUG|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
214867268|NCT02192320|DRUG|Atorvastatin|20 mg (every evening orally) for 5 weeks
214867269|NCT02192320|DRUG|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
214867270|NCT03881020|DRUG|Silver diamine Fluoride 38%|In the intervention group 38% Silver Diamine Fluoride will be applied to the surface of the isolated lesion for a period of 1 minute followed by glass ionomer restoration at the same visit.
214867271|NCT03881020|PROCEDURE|Conventional atraumatic restorative treatment|In the active comparator group caries will be removed from primary molars using sharp excavators then teeth will be restored using glass ionomer filling material at the same visit.
214867272|NCT04636060|DIETARY_SUPPLEMENT|Eisen|Treatment with low-dose iron in the form of tablets containing 6mg of iron. Treatment consists of twice-daily oral administration of iron-tablets for 8 weeks in total.
214867273|NCT05918731|BEHAVIORAL|Self Management|"A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file."
214867274|NCT04645966|BIOLOGICAL|MenABCWY|Neisseria meningitis groups A, B, C W, and Y vaccine
214867275|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (60-µg Dose)|Trumenba (half dose) - Meningococcal Group B vaccine
214867276|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (120-µg Dose)|Trumenba - Meningococcal Group B vaccine
214867277|NCT04645966|BIOLOGICAL|Bexsero|Bexsero - Meningococcal Group B vaccine
214867278|NCT04645966|DRUG|Prophylactic Liquid Paracetamol (PLP)|PLP administration during primary vaccinations 1 and 2
214867279|NCT04645966|BIOLOGICAL|Nimenrix|Nimenrix - Meningococcal Group A, C, W and Y vaccine
214867280|NCT04645966|OTHER|Placebo|Normal Saline
214867281|NCT04645966|DRUG|Scheduled Liquid Paracetamol (SLP)|SLP administration after primary vaccinations 1 and 2.
214867282|NCT04645966|DRUG|Therapeutic Liquid Paracetamol (TLP)|TLP administration after primary vaccinations 1 and 2
214867283|NCT02357563|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
214867284|NCT02357563|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
214665596|NCT03133767|DRUG|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
214867285|NCT01020955|DRUG|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
214867286|NCT01020955|DRUG|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
214867287|NCT00201955|DRUG|Rebamipide|
214867288|NCT04938323|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
214867289|NCT04938323|DRUG|Placebo|.1 mL of diluent (saline) given intradermally at baseline
214867290|NCT01604135|DEVICE|Corneal Collagen Crosslinking|Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
214867291|NCT03825341|DRUG|Hydroxyurea|Drug: Hydroxyurea oral liquid dose administered will be 20mg/kg/day or infants's usual daily dose.
214665597|NCT03133767|DRUG|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
214665598|NCT04233424|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
214867292|NCT03825341|DRUG|Hydroxyurea Oral Capsule|Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
214867293|NCT04248218|BEHAVIORAL|Active Rehabilitation Group/Case|If the patient is in the active rehabilitation group, the patient will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. In addition, they will also watch a two-minute video by the PI and research team reinforcing the active rehabilitation instructions.
214867294|NCT04146116|DRUG|intranasal povidone-iodine|povidone-iodine USP, 10% w/w antiseptic
214867295|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
214867296|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
214867297|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
214867298|NCT04013321|DEVICE|SleepScore Max coaching feature|The SleepScore max is a non-contact sleep tracking device. The app has an integrated feedback coaching feature to improve sleep.
214867299|NCT04013321|BEHAVIORAL|Online CBTi|Online Cognitive Behavioral Therapy for insomnia is a user guided program to track sleep, receive sleep coaching, and initiate behavioral techniques such as tailored sleep scheduling and sleep hygiene to help improve sleep.
214867300|NCT04645264|DEVICE|Foley Catheter|The patient is catheterized during surgery.
214867301|NCT03272464|DRUG|Trametinib|Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
214867302|NCT03272464|DRUG|Dabrafenib|Dabrafenib may work by stopping your cancer cells from duplicating.
214867303|NCT03272464|DRUG|INCB039110|Itacitinib may work by stopping your tumor cells from living and growing.
214867304|NCT00057421|DRUG|prednisolone|
214867305|NCT00829803|DEVICE|SNAP monitor; Bispectral Index Monitor (BIS Monitor)|Intended to monitor the state of the brain by data acquisition of EEG signals.
214867306|NCT05131243|PROCEDURE|Chemotherapy time|6 months of chemotherapy
214867307|NCT05131243|PROCEDURE|Chemotherapy time|3 months of chemotherapy
214867308|NCT00002608|DRUG|cisplatin|
214867309|NCT00002608|DRUG|doxorubicin hydrochloride|
214867310|NCT00002608|DRUG|tamoxifen citrate|
214867311|NCT00002608|PROCEDURE|conventional surgery|
214867312|NCT00002608|RADIATION|radiation therapy|
214867313|NCT02116608|DRUG|Betadine|Apply locally as needed.
214867314|NCT02116608|DRUG|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
214867315|NCT02116608|DRUG|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
214867316|NCT04283500|DRUG|Buprenorphine Naloxone|Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
214867317|NCT03468075|DRUG|Ascorbate|Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
214867318|NCT03468075|DRUG|Gemcitabine|Administered on Days 1, 8 and 15, after the infusion of ascorbate
214867319|NCT01788618|OTHER|Cognitive exams|"Psychopathological assessment (T0 and T3):~* Scale of Spielberger~* The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~\- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)"
214867320|NCT01788618|OTHER|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
214867321|NCT01788618|OTHER|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
214867322|NCT01788618|OTHER|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
214867323|NCT00348452|DRUG|tramadol HCl ER; celecoxib|
214867324|NCT01008332|BIOLOGICAL|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
214867325|NCT01008332|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
214867326|NCT02330536|DEVICE|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
214867327|NCT05552170|OTHER|day-case surgery|Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
214867328|NCT00006199|DRUG|R115777 (farnesyl transferase inhibitor)|
214867329|NCT00006199|DRUG|Topotecan|
214867330|NCT03599271|DEVICE|Drug-Coated Device|3000 mcg mometasone furoate-coated sinus dilation device
214867331|NCT03599271|DEVICE|Control Device|Sinus dilation device without drug
214867332|NCT02006693|DEVICE|XEN® Gel Stent|The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
214867333|NCT02006693|PROCEDURE|Cataract Surgery|Participants diagnosed with a cataract elected to have cataract surgery.
214867334|NCT06207188|OTHER|Non-Interventional Study|Non-interventional study
214867335|NCT03682224|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site
214867336|NCT03682224|DRUG|Bupivacaine-Epinephrine|Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
214867337|NCT01119508|DRUG|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
214665599|NCT04233424|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
214867338|NCT01119508|DRUG|Temozolomide|Induction Phase, 200 mg/m\^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
214867339|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
214867340|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"
214867341|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a standard dose of Biolimus A9TM
214867342|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a low dose of Biolimus A9TM
214867343|NCT01172119|DEVICE|Tuxus Liberte Drug Eluting Stent|Standard paclitaxel dose Taxus Liberte DES
214867344|NCT02312518|DEVICE|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
214867345|NCT02312518|OTHER|Usual and Customary Practice|Usual and Customary Practice for non-healing venous leg ulcers
214867346|NCT06317090|PROCEDURE|guided bone regeneration|a non-resorbable membrane was used as a space maintainer, filled with a particulated bone graft.
214867347|NCT02013479|DIETARY_SUPPLEMENT|SelenoPRECISE|Produced by Pharma Nord ApS, Vejle, Denmark
214867348|NCT02013479|DIETARY_SUPPLEMENT|Placebo|Produced by Pharma Nord ApS, Vejle, Denmark
214867349|NCT00190190|PROCEDURE|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
214867350|NCT00190190|PROCEDURE|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
214867351|NCT01910779|PROCEDURE|100 joule as first biphasic shock energy|
214867352|NCT01910779|PROCEDURE|120 joule as first biphasic shock energy|
214867353|NCT02498106|DIETARY_SUPPLEMENT|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins \[B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene\] and minerals \[Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese\]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid \[EPA\] and docosahexaenic acid \[DHA\])
214867354|NCT00271154|DEVICE|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
214867355|NCT05109806|BEHAVIORAL|problem prevention therapy with CHD|The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
214665600|NCT03517436|DEVICE|TAVR with CENTERA THV|TAVR with the Edwards CENTERA THV System
214867356|NCT05254600|BEHAVIORAL|RISE for Nurse Leaders Program|Psychoeducational sessions designed to impact resilience, insight, self-compassion, and empowerment
214867357|NCT02734654|PROCEDURE|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
214867358|NCT04832516|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
214867359|NCT04832516|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
214867360|NCT01928706|OTHER|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
214867361|NCT01928706|OTHER|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
214867362|NCT06149715|DEVICE|Bottle Filter|The household is given a Sawyer Squeeze Water Filtration System.
214867363|NCT06149715|DEVICE|Bucket Filter|The household is given a Sawyer International Bucket System, which is a Squeeze Water Filtration System that is integrated with a hose and bucket.
214867364|NCT06149715|DEVICE|Tap Filter|The household is given a Sawyer Tap Water Filtration System.
214867365|NCT05597137|DIETARY_SUPPLEMENT|Zinc Gluconate|Each participant should receive a regular zinc diet for weeks 1-2 and take zinc supplements for weeks 3-4.
214867366|NCT00001474|DRUG|Interleukin-2|
214867367|NCT06468293|OTHER|Psychological support|Psychological support intervention
214867368|NCT05369468|DRUG|dexmedetomidine as adjuvant with bupivacaine|to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
215034558|NCT00823173|BIOLOGICAL|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
214867369|NCT05369468|DRUG|Bupivacain only|to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
214867370|NCT01799525|PROCEDURE|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
214867371|NCT03872934|BEHAVIORAL|implant anxiety|to determine the type of music that reduces anxiety in patients undergoing implant surgery.
214867372|NCT01894035|DRUG|Iloprost (Ventavis, BAYQ 6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
214867373|NCT00749021|DRUG|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
214867374|NCT00749021|DRUG|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
214867375|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
214867376|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
214867377|NCT04053465|OTHER|Heat acclimation|14 days of aerobic exercise in a hot environment
214867378|NCT04053465|OTHER|Exercise in a cool environment|14 days of aerobic exercise in a cool environment
214867379|NCT00001049|DRUG|Zidovudine|
214867380|NCT00001049|DRUG|Didanosine|
214867381|NCT04576299|OTHER|Group 1|Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
214867382|NCT03595631|OTHER|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
214665601|NCT05320939|DRUG|Mepolizumab 100 MG|30 subjects (≥ 300 eosinophils/ul) will receive mepolizumab 100 mg subcutaneously every 4 weeks for 5 complete doses.
214665602|NCT00976755|DRUG|everolimus|"Everolimus:~10mg daily"
214665603|NCT04730895|DRUG|Oral 13 cis retinoic acid|Dose of 0.5 mg/kg/day in 2 divided doses orally for 14 days
214665604|NCT04730895|DRUG|Aerosolized 13 cis retinoic acid|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day
214867383|NCT03595631|OTHER|Physical Therapy plus Neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
214867384|NCT01103622|DRUG|AZD1656|Oral tablet bd, step-wise increased dosage
214867385|NCT01103622|DRUG|Digoxin|Oral tablet od on Day 4
214867386|NCT01103622|DRUG|Placebo|Oral tablet bd, step-wise increased dosage
214867387|NCT00548509|DRUG|Menatetrenone (Vitamin K2)|
214867388|NCT02925507|OTHER|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
214867389|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.once a week，for a total of six times.
214867390|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.
214867391|NCT02013011|PROCEDURE|recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only|application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
214867392|NCT05658978|OTHER|Neuromuscular training|Neuromuscular training Length: 12 weeks; Training duration: 90 minutes; Intensity: 70-95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
214867393|NCT05658978|OTHER|Control group|The Control group continues previous regular exercises for 12 weeks with a duration of 90 minutes and three days per week.
214867394|NCT05321511|DRUG|Triptorelin acetate (a-GnRH)|Adminsitration of triptoreline acetate 0.2 mg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
214867395|NCT05321511|DRUG|Ovitrelle® (hCG)|Adminsitration of coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
214867396|NCT05321511|DRUG|Decapeptyl 0.1 mg® (a-GnRH) and Ovitrelle® (hCG) used together|Adminsitration of triptoreline acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
214867397|NCT02776579|OTHER|Girls-only resistance training|
214867398|NCT01521065|DEVICE|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
214867399|NCT00002883|DRUG|cisplatin|
214867400|NCT00002883|DRUG|fluorouracil|
214867401|NCT00002883|PROCEDURE|adjuvant therapy|
214867402|NCT00002883|PROCEDURE|conventional surgery|
214867403|NCT00002883|PROCEDURE|neoadjuvant therapy|
214867404|NCT04136691|OTHER|simulation training|Burn patient scenario was performed with the intervention group.
214867405|NCT06077383|DIETARY_SUPPLEMENT|Weizmania Coagulans BC99|Probiotics group subjects take probiotics every day for 8 weeks.
214867406|NCT04515082|DIAGNOSTIC_TEST|Stool-based SDC2 and SFRP2 DNA methylation test|A diagnostic device measuring syndecan 2 (SDC2) and secreted frizzled-related protein 2 (SFRP2) methylation status in stool DNA to detect colorectal cancer
214867407|NCT04515082|DIAGNOSTIC_TEST|FIT|Fecal immunochemical test
214867408|NCT05690503|DRUG|CI-581a|Medication infusion intravenously over 90 minutes.
214867409|NCT05690503|DRUG|CI-581b|Medication infusion intravenously over 90 minutes.
214867410|NCT01557361|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
215034559|NCT03102086|PROCEDURE|Scaling|Scaling of dental calculus
215034560|NCT01334879|DRUG|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
214867411|NCT01557361|OTHER|Standard RRT initiation|"Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~1. Serum potassium ≥6.0 mmol/L, or~2. Serum bicarbonate ≤ 10 mmol/L, or~3. Evidence of severe respiratory failure, based on a PaO2/FiO2 \<200 and bilateral infiltrates on the chest x-ray, or~4. By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization"
214867412|NCT02507544|DRUG|TRX-818 capsules|
215034561|NCT02870426|PROCEDURE|Frontal Craniotomy and retrieval of OBs|For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique. For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
214867413|NCT05121792|BEHAVIORAL|Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy|The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.
214867414|NCT04832893|DIAGNOSTIC_TEST|steady intensity aerobic test of 30 minutes long|the use of different type of masks during an aerobic exercise
214867415|NCT03317834|DEVICE|Navio ™ Robotic-assisted Surgical System|Total Knee Replacement
214867416|NCT05301413|BEHAVIORAL|Culturally Tailored Diabetes Prevention Program|This intervention includes a culturally tailored DPP curriculum, class procedures, and handouts
214867417|NCT05301413|BEHAVIORAL|Culturally Tailored DPP Enhanced with Socioeconomic Supports|This intervention includes the culturally tailored DPP curriculum, class procedures, and handouts along with promotional items for class participation, opportunities to attend class in-person or virtually through a digital platform, and assistance from a community health worker to provide linkage to health care services and community resources
214867418|NCT05301413|BEHAVIORAL|Diabetes Prevention Program|This is the CDC TD2 evidence-based Diabetes Prevention Program
214867419|NCT04751084|DRUG|Buscopan 20 milligrams/ML Injectable Solution|cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
214867420|NCT02192749|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
214867421|NCT02257541|DRUG|BGJ398|
214867422|NCT02257541|DRUG|Imatinib Mesylate|
214867423|NCT01459562|DRUG|NI-0501|
214867424|NCT01459562|DRUG|Placebo|
214867425|NCT05986591|COMBINATION_PRODUCT|Test Product - Tiotropium Bromide Inhalation Powder 18 mcg|Test Product
214867426|NCT05986591|COMBINATION_PRODUCT|Spiriva Handihaler (Tiotropium Bromide) 18 mcg|RLD
214867427|NCT05986591|COMBINATION_PRODUCT|Placebo|Placebo Product
214867428|NCT04600102|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
214867429|NCT02829294|DEVICE|E002 - cerumen removal aid|topical treatment
214867430|NCT00040768|DRUG|bortezomib|Given IV
214867431|NCT00837772|DEVICE|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
215034562|NCT02870426|PROCEDURE|OB Retrieval During Anterior Cranial Surgery|Group 2: The patients routine anterior cranial surgery would proceed as planned without change to the surgical procedure. In the event that the ON had to be sacrificed for the purposes of surgery the OB of the concomitant nerve would be retrieved.
215034563|NCT03795142|BIOLOGICAL|BGB149|Single Ascending Dose
215034564|NCT03795142|BIOLOGICAL|Placebo|Matching placebo
214665605|NCT04730895|COMBINATION_PRODUCT|13 cis retinoic acid doses orally in combination with spike protein based vaccine|Dose of 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
214867432|NCT00837772|DEVICE|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
214867433|NCT03055650|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
214867434|NCT01140503|DRUG|Apremilast|Apremilast 20mg PO BID
215034565|NCT02903862|BEHAVIORAL|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support \& assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
214867435|NCT01442428|DRUG|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
214867436|NCT01442428|DRUG|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
214867437|NCT01442428|DRUG|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
214867438|NCT01442428|DRUG|Placebo|Atorvastatin placebo
214867439|NCT02553083|DRUG|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
214867440|NCT02553083|DRUG|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
214867441|NCT02553083|DRUG|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
214867442|NCT02553083|DRUG|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
214867443|NCT02553083|DRUG|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
214867444|NCT02553083|DRUG|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
215034566|NCT02903862|DEVICE|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
214867445|NCT03885479|DIAGNOSTIC_TEST|ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
214867446|NCT06050161|DEVICE|Articulating laparoscopic instrument|The Artisential articulating laparoscopic instrument will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
214867447|NCT06050161|DEVICE|Conventional laparoscopic instrument|Conventional laparoscopic instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
214867448|NCT06050161|DEVICE|Robotic surgical instrument|Robotic surgical instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
214867449|NCT06059664|DRUG|Finerenone Oral Tablet|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
214867450|NCT06059664|DRUG|Placebo|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
214867451|NCT05459454|DEVICE|A digital health program for patients with Breast Cancer|A digital solution that supports healthy lifestyle changes, provides disease and side effect education as well as daily tasks for patients diagnosed with breast cancer.
214867452|NCT04801667|BIOLOGICAL|Coronavac|The CoronaVac is manufactured by Sinovac Life Sciences Co., Ltd. This vaccine contains the inactivated SARS-CoV-2 virus antigen and is administered intramuscularly.
214867453|NCT04641793|DEVICE|Motion and Emg Control|"We will consider two methods for integrating motions and EMG signals:~1. Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.~2. Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty."
214867454|NCT06989840|DRUG|TVB-3567|Orally administered capsule
214867455|NCT06989840|DRUG|Placebo|Orally administered capsule
215034567|NCT00875446|DRUG|PLACEBO|Placebo
215034568|NCT00875446|DRUG|GSK1223249|I.V Infusion
215034569|NCT04139291|OTHER|Complex decongestive therapy phase 1|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
215034570|NCT00938574|DRUG|Atu027|
215034571|NCT01350076|DRUG|conventional liberal fluid regimen|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
214665606|NCT04730895|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
214867456|NCT00004890|BIOLOGICAL|aldesleukin|
214867457|NCT00004890|DRUG|Biomed 101|
214867458|NCT01613950|DRUG|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
214867459|NCT01613950|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
214867460|NCT01687348|DRUG|lidocaine aguettant|
214867461|NCT00273234|PROCEDURE|Autologous Platelet Gel (APG)|
214867462|NCT02098421|DRUG|Oxytocin|Use of oxytocin while the Foley bulb is in place
214867463|NCT04154150|DRUG|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
215034572|NCT01350076|DRUG|restricted fluid regimen|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
215034573|NCT05809089|DEVICE|High flow nasal cannula (HFNC)|"High-flow nasal cannula device was utilized. Humidifier temperature was set at 37°C via large-bore bi-nasal prongs, and inspired oxygen (FiO2) was adjusted to maintain oxygen saturation by pulse oximetry (SpO2) ≥ 90%.The flow was initially set at 10 L/min and titrated upward in 5 L/min steps until patients experienced discomfort.~Patient will be evaluated every 8 hours and discontinued the device for eating, drinking and coughing up secretion and returned back to the device for 72 hours."
215034574|NCT05809089|DEVICE|Noninvasive ventilation (NIV)|Patients initiated NIV; Inspiratory positive airway pressure (IPAP) was initiated at 10-12 cmH2O, and expiratory positive airway pressure (EPAP) started at 4-5 cmH2O. FIO2 was adjusted to maintain SpO2 ≥ 90%. The same protocol as done in HFNC, patient will be evaluated every 8 hours and discontinued the device and returned back to the device for re- evaluation within 72 hours
215034575|NCT01731145|DEVICE|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
215034576|NCT04972279|BEHAVIORAL|Digital message (text + image)|"Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
215034577|NCT05405270|DRUG|Imiquimod|Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
214867464|NCT04154150|BEHAVIORAL|Cognitive training|8 sessions of computer-based cognitive training
214867465|NCT04154150|BEHAVIORAL|Sham Training|8 sessions of computer-based sham training
214867466|NCT04385966|PROCEDURE|Interscalene brachial plexus block|Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
214867467|NCT04385966|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|"Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999)."
214867468|NCT01742520|DRUG|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
214867469|NCT01742520|DRUG|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
214867470|NCT02245061|OTHER|paired pulses cortical electrical stimulation|
214867471|NCT00146887|PROCEDURE|coronary catheterization|
214867472|NCT05190653|OTHER|Early palliative and supportive care|The intervention itself will be predominantly the provision of education and information. It is possible that patients in the intervention arm may receive treatment recommendations to help manage symptoms.
215034578|NCT05405270|DIAGNOSTIC_TEST|3x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
215034579|NCT05405270|OTHER|Expectative management|Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
215034580|NCT05405270|DIAGNOSTIC_TEST|2x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
214867473|NCT05444322|DRUG|RD14-01 cell infusion|Autologous CAR T cells
214867474|NCT04135196|OTHER|voluntary forearm loading task|voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
214867475|NCT05056610|OTHER|food antigens on duodenal mucosa|Administration of food antigens on duodenal mucosa and determining the response through confocal laser endomicroscopy
214867476|NCT05161806|DRUG|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
215034581|NCT04380142|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
214476527|NCT06864910|DEVICE|anodal transcranial Direct Current Stimulation|Transcranial direct current stimulation was administered following standard procedures using a neuroConn DC-Stimulator Plus device (neuroCare Group GmbH, Munich, Germany) with the anode placed at F3 (left DLPFC) and the cathode over the right supraorbital region (Fp2) using 5x7cm electrodes. The anodal tDCS intervention involved daily sessions (between 10-11 a.m.) for 10 consecutive days, wherein a direct current (DC) of 2 mA was administered for 20 minutes (with additional ramp-up and ramp-down phase of 20 seconds each at the beginning and end of the session respectively), adhering to stringent safety measures . None of the participants reported significant adverse effects.
214867477|NCT05161806|DEVICE|Prefilled Syringe (PFS)|Prefilled Syringe (PFS)
214867478|NCT00809159|BIOLOGICAL|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
214867479|NCT00809159|DRUG|Placebo|Placebo to AIN457
214867480|NCT03316378|DRUG|Ropivacaine injection|single dose, subcutaneous injection
214867481|NCT03201211|BIOLOGICAL|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
215034582|NCT04380142|DRUG|Placebo for Levodopa/Carbidopa (LD/CD)|Oral capsule
215034583|NCT04380142|DRUG|Levodopa/Carbidopa (LD/CD)|Oral encapsulated tablet
215034584|NCT04380142|DRUG|Placebo for ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
215034585|NCT02908178|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
215034586|NCT03270995|BEHAVIORAL|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
215034587|NCT03270995|BEHAVIORAL|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
215034588|NCT03145220|DRUG|EA-230|Active intervention
215034589|NCT03145220|OTHER|Placebo (NaCl)|Placebo intervention
215034590|NCT00895804|DRUG|MDMA|capsule, 1.6 mg/kg body weight, single dose
215034591|NCT00895804|DRUG|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
214867482|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214867483|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214867484|NCT03201211|DRUG|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214867485|NCT03175289|OTHER|Best Practice|Undergo therapy session conducted by a speech pathologist
214867486|NCT03175289|OTHER|Educational Intervention|Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
214867487|NCT03175289|OTHER|Exercise Intervention|Perform prescribed home exercises
214867488|NCT03175289|OTHER|Expiratory Muscle Strength Training|Participate in EMST
214867489|NCT03175289|OTHER|Quality-of-Life Assessment|Ancillary studies
214867490|NCT03175289|OTHER|Questionnaire Administration|Ancillary studies
214867491|NCT05100979|OTHER|The Art of Medicine Series|The Art of Medicine Series is a smartphone-based educational tool focused on teaching communication strategies to clinicians and patients.
214867492|NCT01693627|DEVICE|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
214867493|NCT01693627|DEVICE|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
214867494|NCT01693627|DEVICE|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
214867495|NCT01693627|DEVICE|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
214867496|NCT01083810|DRUG|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
214867497|NCT03347760|DRUG|DOTATOC-68Ga PET initial|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
214867498|NCT03347760|DRUG|DOTATOC-68Ga PET at 6 months|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
214867499|NCT03347760|BIOLOGICAL|blood sample|blood tests will be carried out during the control visit to ensure that biological parameters are normalized
214867500|NCT04407091|DRUG|14C]AZD4831 Oral Solution|10 mg dose of \[14C\]AZD4831 Oral Solution
214867501|NCT01629966|DRUG|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
214867502|NCT01629966|DRUG|Vilazodone|Vilazodone, 20mg, oral administration once per day.
215034592|NCT02395276|DEVICE|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
214476528|NCT06864559|OTHER|To Compare 3 different suture materials used in oral surgery|To compare bacterial colonization, tissue reaction and clinical characteristics such as wound healing and patient postoperative outcomes in 3 different suture materials used in oral surgery.
214867503|NCT01629966|DRUG|Vilazodone|Vilazodone, 40mg, oral administration once per day.
214867504|NCT02107326|DEVICE|Webdia Software|
214867505|NCT03344926|BEHAVIORAL|ACTsmart|"Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~1. education about pain behaviors, exposure and acceptance and commitment therapy~2. education about pain physiology~3. exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~4. value based exposure in the participant's daily life"
214867506|NCT04860596|BEHAVIORAL|collaborative health management model|nursing education program
214867507|NCT00004755|DRUG|allopurinol|
214867508|NCT00004755|DRUG|glucantime|
214867509|NCT05596721|DRUG|Azithromycin|Treat patient with azithromycin for 12w.
214867510|NCT05596721|DRUG|ICS/LABA|Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
214867511|NCT00609388|DRUG|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
215034593|NCT05766605|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
215034594|NCT05766605|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
214867512|NCT00609388|OTHER|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
214867513|NCT04063488|DRUG|Metreleptin|This is an observational study in which the subjects will serve as their own controls. Study testing will be conducted at baseline (pre-treatment) and for 2 years, post-treatment with metreleptin.
214867514|NCT04395651|DEVICE|PET/CT|It is a prospective clinical study that will include patients known to have lung cancer and referred to nuclear medicine unit to perform 18F-FDG PET/CT for staging and therapy planning as well as patients referred for assessment of response of therapy and restaging.
214867515|NCT05981820|DIETARY_SUPPLEMENT|Creatine|To observe the effects of creatine in the study, 10 g of creatine supplementation was taken only on training days during the study period. Participants used 10 g of creatine monohydrate by dissolved in 200 ml of water. Creatine supplementation was taken in two doses of five grams, 30 minutes before and after training.
214867516|NCT05981820|OTHER|HIIT training|"In the first three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 4 sets of 12x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets~In the last three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 5 sets of 20x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets"
214867517|NCT01045174|DEVICE|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
215034595|NCT05766605|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
214867518|NCT05706194|DIAGNOSTIC_TEST|Early neurological prognostication with biomarkers, EEG and CT|Biomarker samples collected at 12, 24, 48 and 72 h after randomisation, CT and EEG performed as early as possible after 24 h post randomisation in patients still unconscious (defined as not awake and able to follow verbal commands)
214867519|NCT00836329|BEHAVIORAL|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
214867520|NCT00836329|BEHAVIORAL|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
214867521|NCT00477295|DRUG|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
214867522|NCT00477295|DRUG|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
215034596|NCT05766605|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
215034597|NCT05766605|DRUG|Oxaliplatin, Leucovorin, fluorouracil|"Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions"
215034598|NCT05766605|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
215034599|NCT00460213|DRUG|Valsartan 80mg daily|
215034600|NCT00460213|DRUG|Valsartan 160mg daily|
215034601|NCT04870047|DEVICE|Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device|Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.
215034602|NCT06513247|DIAGNOSTIC_TEST|screening for Islet autoantibody|IAA, GADA, IA-2A, Zn-transporter 8 autoantibodies
215034603|NCT06513247|DIAGNOSTIC_TEST|HLA phenotype and genetic risk score|using DBS filter paper
215034604|NCT04716894|DRUG|BI 474121|BI 474121 oral solution
215034605|NCT04716894|DRUG|Itraconazole|Itraconazole oral solution
215034606|NCT01378143|DRUG|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
215034607|NCT04115306|DRUG|PMD-026|Investigational Drug
215034608|NCT04115306|DRUG|fulvestrant|SERDs
215034609|NCT05446064|BEHAVIORAL|Stigma-reduction intervention|The intervention is modularized into four weekly 1-hour group sessions, led by a trained facilitator who provides psychoeducation to promote awareness and understanding of HIV stigma and teach CBT-based coping skills. Each group session will last 45-60 minutes. Participants are introduced to the general CBT model of HIV stigma and encouraged to track thoughts, feelings, and behavioral responses when encountering external stigma or adverse events. The participants further learn to differentiate effective and ineffective coping strategies and practice applying new coping skills to reduce internalized HIV stigma. The interventionist will follow the intervention manual to deliver the intervention and assign homework for group members to practice on their own. In the following sessions, the interventionist will review progress with participants, guide participants through exercises, and identify additional problems to be addressed in subsequent sessions.
215034610|NCT05292703|OTHER|Participatory activity based on art and olfactory stimulation|practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities.
214476529|NCT06863532|DRUG|Cofrogliptin+SGLT2i+Metformin|The cofrogliptin add-on group will continue their existing SGLT2i plus metformin regimen and dosing, with the add-on of cofrogliptin over 24 weeks of triple combined therapy.
214476530|NCT06863532|DRUG|Metformin dose escalation|The metformin dose escalation group will have their metformin dose gradually increased to the target dose.
215034611|NCT05292703|OTHER|practicing art virtually in conjunction with olfactory identification|"For the remote group, , they will receive the connection link to the internet application and an individual connection code.~The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop.~The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks."
215034612|NCT03464266|COMBINATION_PRODUCT|FTC/TDF and DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
214476531|NCT06863584|DRUG|Lenalidomide (Revlimid)|10mg po for 21 days, followed by a 7-day rest period.
214476532|NCT06863584|RADIATION|SBRT|PTV 30Gy/5f and/or PGTV 35Gy/5F.
215034613|NCT03464266|DRUG|FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
215034614|NCT03464266|DRUG|DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
215034615|NCT03464266|OTHER|Neither DMPA nor FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
215034616|NCT00037882|DRUG|PEG-Intron|Once weekly injection.
215034617|NCT03014258|BIOLOGICAL|NF54 P. falciparum malaria challenge|Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
215034618|NCT04943679|DRUG|Anti-PD-1/PD-L1|Intravenous injection for up to 2 years
215034619|NCT04943679|DRUG|PEG-Interferon Alfa|3 µg/kg every week by subcutaneous injection for up to 2 years
215034620|NCT01280331|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
215034621|NCT01280331|DRUG|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
215034622|NCT01280331|DRUG|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
215034623|NCT04778566|DIAGNOSTIC_TEST|Cologuard test|Cologuard is a stool-DNA screening test for detecting colon cancer
215034624|NCT06099002|OTHER|Changed Medical research Council,Mini Mental Test, Quadriceps Femoris muscle strength measurement,2 min walking test, fall effectiveness scale,Fall risk self-assessment scale|"All individuals were given a respiratory function test to evaluate respiratory functions before and after training Modified Medical research Council to evaluate dyspnea, Mini Mental Test to evaluate cognitive status~, Berg Balance Test to evaluate balance, 2-minute walk test to evaluate walking speed. A hand dynamometer will be used to measure QuadricepsFemoris muscle strength, Fall efficiency scale Fall risk self-assessment scale will be used to evaluate falls."
215034625|NCT03483701|BEHAVIORAL|Cognitive Remediation Therapy|The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
215034626|NCT00572819|DRUG|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
215034627|NCT00572819|DRUG|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
214867523|NCT04269564|DEVICE|stepwise PEEP|"* a PEEP of 4 cmH2O will be used after intubation till 5 minutes after pneumoperitonium, and adjusted in a step wise approach after lung ultrasound by adding 2 cmH2O, repeating ultrasound 5 minutes after every change in peep till no lung collapse is detected by lung ultrasound with a maximal peep of 10 cmH2O, or if hemodynamic instability occurs.~* Lung ultrasound examination will be performed at a minimum three times in each patient; the first will be performed 1 min after starting mechanical ventilation of the lungs, 5 minutes after pneumoperitonium, 5 min after every peep increase in stepwise peep group and the last time at the end of the surgery.~We define anaesthesia-induced atelectasis to be significant if any region has a consolidation score of ≥ 2."
214476533|NCT06863909|BEHAVIORAL|Journaling|In the journaling condition, participants will be asked to keep a therapy journal twice a day in addition to the content of the cognitve behavioral therapy. At the beginning of the day, patients are to set a daily goal that aligns with their therapy goals (e.g., remaining calm when negative thoughts arise), and at the end of the day, they will reflect on the day itself and the work done on their therapy goals.
214665607|NCT04730895|BIOLOGICAL|Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Dose of 5-7.5x10\^10vp of spike protein based vaccine such as ChAdOx1 nCoV-19 in deltoid of non-dominant arm, 28 days apart
214867524|NCT04840966|DIAGNOSTIC_TEST|Flavor test|A simplified self-administrable flavor test has been proposted to all the enrolled subjects
215034628|NCT05007132|BIOLOGICAL|Panitumumab 20 milligram/ML|Participants receive Panitumumab at 6mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
215034629|NCT05007132|BIOLOGICAL|Bevacizumab|Participants receive bevacizumab at 5 mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
215034630|NCT05007132|DRUG|Trifluridine/Tipiracil Hydrochloride|Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
215034631|NCT06186310|OTHER|Aquatic Therapy Group|After the initial evaluations, patients will be given aquatic exercises including personalized strengthening, balance and breathing exercises accompanied by a physiotherapist 3 days a week for total 5 weeks. At the same time, the exercises taught as a home program will be asked to be repeated every day for 5 weeks.
215034632|NCT06186310|OTHER|Conventional Physical Therapy Group|After the initial evaluations, patients in the control group will be taught passive, active, actively assisted or resistant upper and lower extremity exercises as a home program, appropriate to each patient's functional level and muscle strength. Subjects will be asked to perform the exercises every day for 5 weeks, not exceeding an average of 45 minutes, 5 to 10 repetitions of each exercise, depending on fatigue.
215034633|NCT03773484|BEHAVIORAL|Opioid naive|Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days
214867525|NCT04840966|OTHER|Self-assesment questionnaire|"Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to no smell/flavor perception and 10 corresponding to excellent smell/flavor perception."
215034634|NCT03773484|BEHAVIORAL|At-risk for long term use|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days
215034635|NCT03773484|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days
215034636|NCT02578251|DRUG|Paracetamol|
215034637|NCT02578251|DRUG|Pethidine|
215034638|NCT05229016|BEHAVIORAL|Reflection on health-related experiences|This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
214867526|NCT06455436|DEVICE|Standard healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive a standard healing abutment
214867527|NCT06455436|DEVICE|Individualized healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive an individualized healing abutment
214867528|NCT02244879|DIETARY_SUPPLEMENT|resveratrol|arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
214867529|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC+NOL|Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
214867530|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC|Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
214867531|NCT06309277|DRUG|GM-1020|N-methyl-D-aspartate (NMDA) receptor antagonist
214867532|NCT05124197|OTHER|prone position|extension of prone position duration
214867533|NCT01157780|DRUG|Lovaza (fish oil)|Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
215034639|NCT02002715|DRUG|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
214867534|NCT01965392|OTHER|Health education intervention|'Health education intervention'
215034640|NCT05460286|OTHER|Chiropractic Manipulation|20 participants with low back pain existing more than 3 months was included in the CSMT group. Lumbar region chiropractic HVLA (High Velocity, Low Amplitude) spinal manipulation and/or sacroiliac joint chiropractic HVLA manipulation were applied to participants. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
214867535|NCT02122120|DIETARY_SUPPLEMENT|HEN|Patients with tube feeding with FSMP for at least twelve months
214867536|NCT00234182|DRUG|Interferon alpha-2b|
214867537|NCT04568031|DRUG|AZD1222|For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
214867538|NCT04568031|DRUG|0.9% (w/v) saline|For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
214867539|NCT03287973|BEHAVIORAL|Lifestyle modification|A caloric reduction of 10-20% in daily energy intake from the patient's usual diet (i.e. a deficit ≥ 200 calories per day) will be set as the general initial goal, which will be adjusted subsequently based on changes in body weight with target body mass index (BMI) towards 23 kg/m2.
214867540|NCT03287973|DEVICE|Continuous positive airway pressure (CPAP)|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
214867541|NCT01180439|DEVICE|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
214867542|NCT04430855|DRUG|Upadacitinib|Tablet; Oral
214867543|NCT04430855|DRUG|Placebo|Tablet; Oral
215034641|NCT05460286|OTHER|Spinal Decompression Device Treatment|20 participants with low back pain existing more than 3 months was included in the SD group. Lumbar region spinal decompression (traction) device therapy was applied to participants, and as a standard of treatment was given a hot pack for 15 minutes before applying and a cold pack for 10 minutes after applying. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
215034642|NCT01889251|DRUG|Ocriplasmin|
215034643|NCT01889251|DRUG|Sham injection|
215034644|NCT02009267|DEVICE|Patient controlled analgesia|A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
214665608|NCT04378426|DRUG|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50% nitrous oxide and 50% oxygen plus intravenous saline
214867544|NCT01826786|DRUG|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
214867545|NCT01826786|DRUG|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
214867546|NCT02375919|OTHER|PERC based Strategy|work up for diagnosis of PE includes calculation of PERC
215034645|NCT02009267|PROCEDURE|Continuous thoracic epidural infusions|Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation-including the sensation of pain-by blocking the transmission of signals through nerve fibers in or near the spinal cord.
215034646|NCT02009267|PROCEDURE|Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
215034647|NCT01533623|DEVICE|Mandibular Advancement Device|Nightly wearing time
215034648|NCT03584490|OTHER|Computerized Talking Touchscreen|"The intervention is a computerized talking touchscreen designed to aid people with low health literacy.~All Participants in both arms will complete a battery of health questionnaires. One group will complete questionnaires in traditional pen-and-paper format. The other group will receive the computerized talking touchscreen, which reads questions to participants on demand."
215034649|NCT03584490|OTHER|Phone Administration of Questionnaires|This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.
215034650|NCT01006148|BIOLOGICAL|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
215034651|NCT02740985|DRUG|AZD4635|AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
215034652|NCT02740985|DRUG|Durvalumab|Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
215034653|NCT02740985|DRUG|Abiraterone Acetate|"Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets."
215034654|NCT02740985|DRUG|Enzalutamide|"Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules."
215034655|NCT02740985|DRUG|Oleclumab|Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
215034656|NCT02740985|DRUG|Docetaxel|"Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice."
215034657|NCT01530516|DEVICE|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
215034658|NCT01530516|DEVICE|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
214867547|NCT03704402|OTHER|Alcohol policy|Introduction of new mutual alcohol policy
214867548|NCT06229821|DEVICE|Intrapulmonary Percussive Ventilation|IPV applied at increasing intervals, starting every 6 hours, and ending at every 24 hours, for a total of 7 days.
214867549|NCT05020613|PROCEDURE|Procedure: Early removal group|Participants assigned this arm will have their urethral catheters removed at 2 days after low anterior resection of the rectum
214867550|NCT05020613|PROCEDURE|Procedure: Late removal group|Participants assigned this arm will have their urethral catheters removed after 48.th hours after Low anterior resection of the rectum
214907081|NCT03945227|DRUG|standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001|drug: standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
214476534|NCT06863909|BEHAVIORAL|Treatment as Usual (TAU)|Patients in this arm receive standard treatment (cognitive behavioral therapy) for their individual diagnosis. The study participation spans a period of 24 sessions (short-term psychotherapy KZT1\&2), during which the severity of symptoms will be assessed at the beginning of each session (duration approx. 2 minutes). Additionally, participants will be asked to answer some questions about basic documentation (diagnoses, symptoms) at the beginning and end of the study (duration approx. 20 minutes).
214476535|NCT06861738|DRUG|Paracetamol (acetaminophen)|oral paracetamol 500mg three times per day
214476536|NCT06861738|DRUG|Paracetamol Placebo|placebo tab three time per day
214476537|NCT06400719|BIOLOGICAL|AVT16|Single intravenous administration of 300mg of AVT16
214665609|NCT04378426|DRUG|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
214867551|NCT01544738|OTHER|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
214867552|NCT01544738|OTHER|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
214867553|NCT02497313|DRUG|Isotonic saline|
214867554|NCT02497313|DRUG|Metformin placebo|
214867555|NCT02497313|DRUG|Cholecystokinin|
214867556|NCT02497313|DRUG|Metformin|
214867557|NCT02273336|OTHER|cytology specimen collection procedure|Undergo tissue and blood sample collection
214867558|NCT02273336|OTHER|laboratory biomarker analysis|Correlative studies
214867559|NCT03134443|DRUG|Andrographolide sulfonate|Routine treatment for acute tonsillitis + Xiyanping injection
214867560|NCT03134443|DRUG|Andrographolide sulfonate simulation|Routine treatment for acute tonsillitis + Xiyanping injection simulation
214867561|NCT06048666|BIOLOGICAL|Intra ovarian by platelet rich plasma|On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide.
214867562|NCT00427713|DRUG|capecitabine|
214867563|NCT00427713|DRUG|oxaliplatin|
214867564|NCT00427713|PROCEDURE|adjuvant therapy|
214867565|NCT00427713|PROCEDURE|standard follow-up care|
214867566|NCT02754466|OTHER|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
214867567|NCT02754466|OTHER|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
214867568|NCT00545675|DRUG|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
214867569|NCT00545675|DRUG|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
214867570|NCT05060133|PROCEDURE|Orthognathic Surgery|Surgical corrections of dentofacial deformities and malocclusions.
214867571|NCT03939299|PROCEDURE|OCT|Patients with coronary chronic total occlusion received successful stenting. Optimal coherence tomography imaged immediately and at 9-12 months after the index procedure to explore long-term vascular response and healing profile.
214867572|NCT05068375|DIAGNOSTIC_TEST|Thrombophilia screening|Genetic thrombophilia and acquired thrombophilia screening
214665610|NCT04378426|DRUG|Nitrogen|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
214867573|NCT04310956|DEVICE|Y-Knot all-suture anchor|Y-knot all-suture anchor will be implanted to participants
214867574|NCT04310956|DEVICE|Biocomposite suture anchor|Biocomposite suture anchor will be implanted to participants
214867575|NCT04359576|DIAGNOSTIC_TEST|Primary and secondary hemostasis|Focus on platelet aggregation, primary and secondary hemostasis parameters
214867576|NCT01102062|DIETARY_SUPPLEMENT|orange juice|
214867577|NCT04001101|COMBINATION_PRODUCT|RT and Anti-PD-1|limited metastatic site radiation
214867578|NCT04001101|DRUG|Anti-PD-1|anti-PD-1 therapy alone
214867579|NCT06526455|DRUG|Vonoprazan|oral drug 3-56 days after ESD.
214867580|NCT06526455|DRUG|Esomeprazole|oral drug 3-56 days after ESD.
214867581|NCT03050008|OTHER|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
214867582|NCT03050008|OTHER|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound.
214867583|NCT00777413|DRUG|Minocycline 100mg Tablets|
214867584|NCT04614623|DEVICE|AHCL pump|Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia
214867585|NCT04614623|OTHER|Video conferencing Application|Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
214867586|NCT02099695|DRUG|Oxybutynin|The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
214867587|NCT02099695|DRUG|Placebo|The quantity of tablets will increase due to the absence/ lack of therapeutic response.
214867588|NCT04625595|DRUG|350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
214867589|NCT04625595|DRUG|700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
214867590|NCT04625595|DRUG|1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
214665611|NCT04378426|DRUG|Oxygen|inhaled gas
214867591|NCT04625595|DRUG|1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
214867592|NCT04068636|PROCEDURE|Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.|Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
214867593|NCT00106236|BEHAVIORAL|exercise|
214867594|NCT00955136|DEVICE|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
214867595|NCT05228821|DRUG|Voxelotor Oral Tablet|During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
214867596|NCT02165865|PROCEDURE|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
214867597|NCT00808964|DRUG|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
214867598|NCT00390221|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|SC injection
214867599|NCT00390221|DRUG|Placebo|Placebo SC injection
214867600|NCT04791475|PROCEDURE|adding Dexmedetomidine and dexamethasone to bupivacaine in USG guided supraclavicular brachial plexus block.|The linear transducer probe (frequency 4 -12 Hz) of USG machine will be used. A superficial skin wheal will be made by 2ml of 1% lignocaine subcutaneously at the point of needle insertion. USG guided Brachial plexus block will be performed by supraclavicular route via the subclavian perivascular approach in in-plane technique from lateral to medial using 22 gauge spinal needle. Study Drug will be administered via Pressure Monitoring line connected to syringe according to the allocated group with repeated aspiration and incremental dosing. • Intercostobrachial nerve block will be performed to alleviate the tourniquet pain. A 25 G needle will be inserted at the level of axillary fossa. The entire width of the medial aspect of arm, starting at the deltoid prominence and proceeding inferiorly, will be infiltrated with 5ml of 1% Lignocaine with Epinephrine (1:4,00,000) to raise a subcutaneous wheal. •
214665612|NCT04378426|DRUG|Saline|Placebo infusion
214867601|NCT06462859|OTHER|Sensory Integration Therapy Group|The experimental group received sensory integration therapy in addition to the NDT program. The NDT program is customized for each child, featuring a unique blend of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. Participants attended 45-minute NDT and sensory integration sessions three times a week for 8 weeks. Sensory integration therapy, visual perception activities (block design, shape recognition in pictures, puzzles, matching geometric shapes and letters, numbers and classification exercises), body awareness activities (showing body parts, drawing life-size drawings, turning left and right, recognizing body parts by touching ), tactile perception exercises (feeling and touching various textures and shapes) and visual-motor coordination training (eye tracking exercises, activities with moving objects and panel activities).
214867602|NCT06462859|OTHER|Neurodevelopmental Treatment Group|The NDT program is customized for each child, featuring a mix of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. He attended 45-minute NDT sessions three times a week for 8 weeks. There is no treatment or medication other than NDT.
214867603|NCT03727659|BEHAVIORAL|SHADE therapy + CONNECT FaceBook support|"See study arms description."
214867604|NCT02533375|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
214867605|NCT06123442|BEHAVIORAL|Cognitive Resilience Intervention|Participants will have 12 weeks to complete the program, and then before the post-assessment, there will be a one-month feedback period \[22\]. This includes twelve components: 1) preliminary routine, 2) significance of knowing yourself, 3) interpreting events and stressors, 4) taking autonomy over events, 5) practicing mindfulness and self-compassion, 6) learning adaptation skills, 7) building connection , 8) purpose in life and personal growth, 9) Regulation and disclosure of emotions, 10) practicing gratitude, and 11) positive Communication both intra and interpersonal, 12) overcoming obstacles and moving forward (in the context of current problems) and the conclusion/retrospection are addressed in 12 sessions while closure and post assessment will be done after a month
214867606|NCT05376670|DRUG|Intravesical aminoglycoside instillations|Overnight instillation of an aminoglycoside (CIC), varying treatment regimens
214867607|NCT05259878|OTHER|Adverse Childhood Events|"• The Adverse Childhood Events (ACE) scale is a validated 10-item binary questionnaire (yes or no) that retrospectively measures domains of physical, emotional, and sexual abuse in the first 18 years of life. Scores range from 0 to 10 with higher scores indicating more adverse experiences during patients' childhood."
214867608|NCT00429156|DEVICE|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
214867609|NCT00429156|DEVICE|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
214867610|NCT01270737|DIETARY_SUPPLEMENT|Whole soy (soy flour)|40g soy flour per day for six months
214867611|NCT01270737|DIETARY_SUPPLEMENT|daidzein|66mg daidzein per day for six months
214867612|NCT01270737|DIETARY_SUPPLEMENT|milk powder|40g low-fat dry milk per day for six months
214867613|NCT02823483|OTHER|Sunscreen Lotion (BAY987521)|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
214867614|NCT02823483|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
215034659|NCT06379100|DEVICE|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
215034660|NCT00085839|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
214867615|NCT04040153|BEHAVIORAL|Guiding Good Choices|Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
214867616|NCT00495547|DRUG|Azacitidine|Azacitidine
214867617|NCT00495547|DRUG|Beta Erythropoietin|Beta Erythropoietin
214867618|NCT05341297|BEHAVIORAL|ParentKIT|The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
214867619|NCT00003079|DRUG|bryostatin 1|
214867620|NCT00003079|DRUG|cytarabine|
214867621|NCT00539227|PROCEDURE|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
214867622|NCT00539227|BEHAVIORAL|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
214867623|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical short cavity tunable laser
214867624|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
214867625|NCT00368901|DRUG|Darbepoetin alfa|Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
214867626|NCT01412372|DRUG|Mesalamine|2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
215034661|NCT00085839|DRUG|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
215034662|NCT05645380|DRUG|Carboplatin|AUC=6, IV
215034663|NCT05645380|DRUG|Docetaxel|75 mg/m2, IV
215034664|NCT05645380|DRUG|Doxorubicin|60 mg/m2, IV
215034665|NCT05645380|DRUG|Cyclophosphamide|600 mg/m2, IV
215034666|NCT05645380|DRUG|Pembrolizumab|200 mg, IV
214476538|NCT06770686|OTHER|Intervention Group|"A nursing care bundle will be applied to patients in the intervention group. The implementation status of the nursing interventions included in the care bundle for each patient will be observed by the researcher and recorded on the Care Bundle Observer Form. Recording of the applications performed on the monitoring form will be encouraged."
214476539|NCT06770686|OTHER|Control Group|They will receive standard care
214476540|NCT02396823|BEHAVIORAL|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
214867627|NCT01412372|DRUG|Placebo|This is an inactive pill
214867628|NCT02351544|DRUG|Botulinum Toxin Type A|
214867629|NCT02351544|PROCEDURE|Surgery|
214867630|NCT02351544|OTHER|Daily headache diary|
214867631|NCT02351544|OTHER|Migraine Disability Assessment Test (MIDAS)|
214867632|NCT02351544|OTHER|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
214867633|NCT02351544|OTHER|Migraine-Specific Quality of Life Questionnaire (MSQ)|
214867634|NCT05600504|OTHER|no intervention|no intervention
214867635|NCT01700166|BIOLOGICAL|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
214867636|NCT04673513|OTHER|Psychotherapy|In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.
214867637|NCT03905564|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
214867638|NCT03905564|DRUG|Diclegis (Registered Trademark)|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).
214867639|NCT05197218|DIETARY_SUPPLEMENT|Prebiotic|Combination of a polyphenol rich extract of chokeberry (Aronia melanocarpa) and a polyphenol rich extract of cranberry (Vaccinium macrocarpon Aiton) will be administered for 18 days.
214867640|NCT06417138|OTHER|biological and targeted synthetic disease modifying anti rheumatic drugs (bDMARDs) and (tsDMARDs)|This is a registry-based study. It is an observational, retrospective trial. There is/are no interventional drug(s).
214867641|NCT01431859|BIOLOGICAL|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
214867642|NCT01431859|OTHER|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
214867643|NCT02876575|DEVICE|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
214867644|NCT03041649|OTHER|GT button change - Mic-Key|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
215034667|NCT03682484|DRUG|MA-0211|oral
215034668|NCT03682484|DRUG|Placebo|oral
215034669|NCT03342222|DEVICE|Interference Screws|tibial fixation for ACL reconstruction
215034670|NCT04653376|PROCEDURE|Tonsillectomy surgery|The tonsillectomy procedure was performed under general anesthesia using the classical dissection method. Extracted tonsil tissue samples were sent to the medical genetics department in tubes to investigate the ER stress and apoptosis.
215034671|NCT00409656|DRUG|Basiliximab|
215034672|NCT05136027|OTHER|Combined training|Low-intensity interval training and resistance exercise
214867645|NCT03041649|OTHER|GT button change - Mini One|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
214867646|NCT00199771|DRUG|7.5% NaCl in 6% dextran 70 solution|
215034673|NCT01172782|DRUG|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
214867647|NCT04559971|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
215034674|NCT06107699|OTHER|Patient Navigation|Assigned a Patient Navigator to provide information on transitional care and community resources.
215034675|NCT05880355|DRUG|Dapansutrile|Oral inhibitor of NLRP3
214867648|NCT04559971|DRUG|Placebo|Sodium chloride for s.c. injection
214867649|NCT03787576|DEVICE|Cataract surgery|Evaluation of patient satisfaction after bilateral cataract surgery with multifocal intraocular lens implantation
214867650|NCT00193427|DRUG|Docetaxel|30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
215034676|NCT05880355|OTHER|Placebo|Non-active placebo
215034677|NCT06529237|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
215034678|NCT06529237|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|Routine malaria rapid diagnostic tests
215034679|NCT05216380|BEHAVIORAL|ActivityLink|"ActivityLink is an implementation program using:~1. Didactic and experiential training sessions for clinic staff to conduct referrals~2. Secure electronic referral webform to refer patients using their email address and phone number~3. Messaging sent to the patient and provider that they have been referred to a program~4. Clinic visual cues (flyers and paper prescription pad) to reinforce referrals~5. Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot"
215034680|NCT02628535|BIOLOGICAL|MGD009|B7-H3 x CD3 DART protein
215034681|NCT04312022|DIETARY_SUPPLEMENT|Berry extract|Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)
215034682|NCT04312022|OTHER|Placebo|Placebo (flour capsule)
215034683|NCT01344226|DRUG|loteprednol 0.5% ophthalmic solution|Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.
215034684|NCT05335434|DEVICE|THOR LX2.3 with LED Lollipop|The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration
215034685|NCT02914938|DRUG|ME-401|60 mg
215034686|NCT02914938|DRUG|Rituximab|IV infusion 375 mg/m2
215034687|NCT02914938|DRUG|Zanubrutinib|80 and 160 mg bid
215034688|NCT00201279|DRUG|13-cis Retino Acid|
215034689|NCT04825600|DIAGNOSTIC_TEST|anti-Toxoplasma gondii IgG and IgM dosage|blood sample performed to check the toxoplasma serological diagnosis
215034690|NCT04825600|DIAGNOSTIC_TEST|cellular test|blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis
214290773|NCT06248892|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214867651|NCT00193427|DRUG|Gemcitabine|1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
214867652|NCT00193427|DRUG|Carboplatin|AUC = 1.5 weekly x 7
214867653|NCT00193427|RADIATION|Radiation|To 63 Gy
214867654|NCT01072474|PROCEDURE|Capnography|Capnographic monitoring
214867655|NCT01072474|PROCEDURE|Standard monitoring|Standard monitoring
214867656|NCT04099173|BEHAVIORAL|Brief Mindfulness Based Intervention|This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
214867657|NCT04213976|PROCEDURE|Ileostomy|Use of an ileostomy to decompress the proximal bowel, perfored either as a conventional loop ileostomy or as described by Santulli et al. or by Bishop and Koop.
214867658|NCT03170427|DEVICE|Impedance cardiography|hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine
215034691|NCT04118764|DEVICE|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
215034692|NCT04118764|DRUG|Definity|Definity microbubbles (10 μl/kg) will be used in conjunction with the ultrasound transducer to temporarily open the blood brain barrier.
215034693|NCT04118764|OTHER|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|MRI scans will be completed at baseline and immediately after the focused ultrasound treatment to confirm BBB opening and safety. A follow-up MRI will be performed three days after treatment to confirm BBB closure, only in the case of successful BBB opening.
215034694|NCT04118764|OTHER|Positron Emission Tomography (PET)|A follow-up PET scan will be performed three days after treatment to determine amyloid plaque load.
215034695|NCT04118764|OTHER|Amyvid|To be used during the PET scan to determine uptake of Amyvid within the treated area.
215057171|NCT02364804|DRUG|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
215057172|NCT04034719|OTHER|portage scarf|Parents will be carried their newborn with the portage scarf provided by the department.
214290774|NCT03785002|OTHER|Strength training|24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
214867659|NCT03170427|DIAGNOSTIC_TEST|Sensory levels|Sensory levels are checked using ice test cold
214867660|NCT03170427|DIAGNOSTIC_TEST|Motor block|motor block is measured by modified Bromage scale
214867661|NCT03170427|DIAGNOSTIC_TEST|Sensory level|Sensory levels are checked using touch with alcohol puffs
214867662|NCT02683265|DRUG|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
214867663|NCT02683265|DRUG|Placebo|Placebo capsules
214867664|NCT04241991|RADIATION|Active laser|Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
214867665|NCT04241991|RADIATION|Placebo laser|Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
214867666|NCT04682730|BEHAVIORAL|Deliberative Loop|"The investigators will give background information to the stakeholders before they engage in the Deliberative session.~Stakeholders from a given clinic will come together for a Deliberative session (i.e., facilitated conversation), enabling them to hear the full range of perspectives held by their fellow colleagues and to share their own perspective regarding how best to implement the guideline in small-group discussions.~Following the Deliberative session, each stakeholder will have the opportunity to record their opinions regarding possible implementation interventions. The investigators will share these opinions with the clinic's decision-makers to help guide their decision-making about which implementation interventions to deploy. If a stakeholder happens to be absent the day of their clinic's Deliberative session, they will still have the opportunity to complete the survey."
214867667|NCT02261844|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 1 gm po x 10 days prior to liver resection
214867668|NCT02261844|DRUG|Placebo|Placebo 1 pill daily X 10 days
214867669|NCT01233921|BIOLOGICAL|palifermin|Given IV
214867670|NCT01233921|OTHER|flow cytometry|Correlative studies
214867671|NCT01233921|OTHER|laboratory biomarker analysis|Correlative studies
214867672|NCT01233921|OTHER|pharmacological study|Correlative studies
214867673|NCT03258853|DEVICE|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
214867674|NCT03258853|OTHER|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
214867675|NCT00402454|DRUG|isoniazid, rifampin + isoniazid or rifampin + pyrazinamide|
214867676|NCT03709459|DRUG|Doxycycline|Participants will be asked to take Doxycycline 100mg/day for 12months duration
214867677|NCT05971654|DRUG|azithromycin|azithromycin.:500 mg PO once for 5 days every month
215057173|NCT04034719|OTHER|usual practice|Parents will be carried their newborn as their usual practice.
214290775|NCT03785002|OTHER|Protein intake|Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
214290776|NCT01923493|OTHER|tuina|Patients in the tuina group will receive a tuina therapy (also known as Chinese massage). A Chinese massage lasts about 20 to 30 minutes. A series of 6 sessions with 2 treatments per week is applied.
214867678|NCT03906162|BEHAVIORAL|Motivational interviews|"During the 12-week intervention, the participants will receive seven telephone calls from a physical therapist. The interviews will be held in week 1, 2,3,5,7,9, and 12.~The telephone call will consist of a motivational interview focused on enhancing the daily level of physical activity in the participants.~MI is a form of counselling aiming at prompting increases in self-efficacy, which may leave people more open to and invested in changing their behaviours and shows potential for significant effects for exercise behaviour change.~In addition to the telephone based motivational interviews, the experimental group will also receive the base intervention which is described in detail under the control intervention paragraph."
214867679|NCT03906162|BEHAVIORAL|Base intervention|"The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity."
214867680|NCT06284577|DIETARY_SUPPLEMENT|Multistrain Probiotic|Participants will recieve a multi-strain probiotic daily for 6 months
214867681|NCT06284577|DIETARY_SUPPLEMENT|Placebo - maltodextrin|Participants will recieve placebo/ maltodextri daily for 6 months
214867682|NCT00818129|DRUG|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
214867683|NCT00818129|DRUG|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
214867684|NCT03870477|DEVICE|THP Hip Fracture Plating System with telescoping lag screws|The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
215057174|NCT01283776|DRUG|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
215034696|NCT06239376|PROCEDURE|GnRHa+AI - AC|"Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA."
215034697|NCT06239376|PROCEDURE|Artificial cycle|The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises estradiol 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
214867685|NCT04565613|DIETARY_SUPPLEMENT|Enteral protein supplementation|"The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue."
214867686|NCT06514690|OTHER|Sedation|Different degrees of intravenous sedation according to the Ramsay scale
214867687|NCT05285670|BEHAVIORAL|Digital counseling plus interactive two-way SMS dialogue|We will utilize a digital counseling tool on a tablet to provide initial reproductive life planning counseling while waiting for an HIV care provider. We will then use Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women following enrollment and for up to 2 years. Women will receive automated theoretically grounded SMS messages targeting the appropriate reproductive health needs and will have the capability to respond and spontaneously message a nurse based at the clinic. . Automated SMS will be delivered at times and in languages based on patient preferences, weekly the first 3 months, every other week in months 4-12, and monthly during the last year of the trial. If there is a change in the reproductive health needs, more frequent messaging will be re-initiated at the same frequency as enrollment.
215034698|NCT03211416|OTHER|Laboratory Biomarker Analysis|Correlative studies
215034699|NCT03211416|BIOLOGICAL|Pembrolizumab|Given IV
215034700|NCT03211416|DRUG|Sorafenib Tosylate|Given PO
215034701|NCT06413212|DIAGNOSTIC_TEST|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.|Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
215034702|NCT05008614|PROCEDURE|Erector spinae plane block group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)"
215034703|NCT05008614|PROCEDURE|Thoracic epidural analgesia group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)"
215034704|NCT02302222|DEVICE|Customizable Dressing with ActiV.A.C. Therapy Unit|
215034705|NCT02302222|DEVICE|Standard of Care Dressing|
215034706|NCT05974800|BEHAVIORAL|Emergency department caregivers interview|The interview focuses on several parts of the emergency care process: The first part is regarding the actions that are executed during an emergency department visit. We will establish which actions are executed and why. The second part is regarding the suspected outcome for the patient. The third part will be about any potential improvements to the emergency care process for the patient.
215034707|NCT01950520|DRUG|Propranolol|Propanolol 160mg, oral, by mouth (Cohort 1 only)
215034708|NCT01950520|DRUG|Pindolol|Pindolol 20mg, oral, by mouth (Cohort 1 only)
215034709|NCT01950520|DRUG|Dantrolene|Dantrolene 100mg, oral, by mouth (Cohort 1 only)
215034710|NCT01950520|DRUG|Magnesium Sulfate|Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)
215034711|NCT01950520|DRUG|Caffeine|Caffeine 200mg, oral, by mouth (Cohort 2 only)
215034712|NCT01950520|DRUG|Qsymia|Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)
215034713|NCT01950520|DRUG|Topiramate|Topiramate 200mg, oral, by mouth (Cohort 2 only)
215034714|NCT01950520|BEHAVIORAL|Phentermine|Phentermine 37.5mg, oral, by mouth (Cohort 2 only)
215034715|NCT01950520|DRUG|Naltrexone|Naltrexone 100mg, oral, by mouth (Cohort 2 only)
215034716|NCT01950520|DRUG|Mirabegron 50mg|Mirabegron 50mg, oral, by mouth (Cohort 3 only)
215034717|NCT01950520|DRUG|Mirabegron 200mg|Mirabegron 200mg, oral, by mouth (Cohort 3 only)
215034718|NCT01950520|DRUG|Placebo Cohort 1|Placebo, oral, by mouth (Cohort 1 only)
215034719|NCT01950520|DRUG|Placebo Cohort 2|Placebo, oral, by mouth (Cohort 2 only)
214665613|NCT03664726|BEHAVIORAL|Episodic Future Thinking|Participants will be instructed to use their episodic future cues as they engage in different decision making tasks.
215034720|NCT01950520|DRUG|Placebo for Mirabegron|Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
215034721|NCT04908046|DRUG|HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .|"Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
215034722|NCT04212442|BEHAVIORAL|Independent Living Program for Affordable Housing.|"Two-month program intended to increase physical activity and function, including the following 4 steps:~1. Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~2. Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~3. Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~4. The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches."
215034723|NCT04809064|PROCEDURE|Arthroscopic Bankart repair procedure|Bankart repair with remplissage consists of arthroscopic anterior inferior capsulolabral repair with arthroscopic infraspinatus tenodesis to the posterior humeral head.
215034724|NCT04809064|PROCEDURE|Open Bankart|Open Bankart repair consists of anterior capsulorrhaphy with labral repair.
215034725|NCT04809064|PROCEDURE|Latarjet|Latarjet consists of open transfer of the coracoid to the anterior glenoid bone deficiency.
214867688|NCT04995705|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components."
214867689|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
214867690|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
214867691|NCT00105976|DRUG|MM-093|
214867692|NCT01725776|DRUG|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
214867693|NCT05341882|BEHAVIORAL|Mindfulness|Participants took part in a live, facilitated Zoom-delivered training that involved learning mindfulness and education about moral injury. The participants were interviewed regarding the program.
214867694|NCT05341882|BEHAVIORAL|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
214867695|NCT03810755|OTHER|Personalized Supervised physical activity|personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
214867696|NCT05498402|DEVICE|i-gel ® device|Ventilations will be delivered through an i-gel ® device
215034726|NCT04809064|OTHER|Post-Operative Rehabilitation|Post-operative rehabilitation will be conducted following surgical procedure-specific rehabilitation guidelines and will be progressed based on individual needs.
215034727|NCT03858777|DIAGNOSTIC_TEST|cell free DNA|All groups will have blood draws and cfDNA measured
214867697|NCT05498402|DEVICE|bag-valve-mask ventilation|Ventilations will be delivered using a bag-valve-mask
214867698|NCT03378050|BEHAVIORAL|HEART|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training."
214867699|NCT03378050|OTHER|Usual Care|"Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
214867700|NCT05975138|PROCEDURE|implant insertion|a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus
214867701|NCT01709838|DRUG|deferasirox|Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
214867702|NCT01674127|DRUG|Methyldopa|
214867703|NCT01674127|DRUG|Placebo|
214867704|NCT03564444|BIOLOGICAL|Bivalent influenza vaccine|A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.
214867705|NCT03564444|OTHER|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
214867706|NCT02314091|PROCEDURE|onlay mesh hernioplasty|
215034728|NCT04623593|PROCEDURE|ACDF|Standard operative treatment for anterior cervical discectomy. Through a right or left-sided approach the disc space contents are resected. The endplates are prepared with curettes and the disc space contents are removed. The posterior longitudinal ligament is opened. The dura is visualized to ensure adequate decompression. A cage is implanted in the disc space. The disc removal and cage implantation can be performed at a single level or at multiple levels. The wound is closed in layers, after a prevertebral wound drain is placed.
215034729|NCT04623593|PROCEDURE|ACDA|The start of the procedure is the same as in the ACDF group. After the discectomy, a cervical disc prosthesis is placed in the disc space instead of a cage, in accordance with the manufacturer's protocol for implantation and endplate preparation. The disc removal and arthrodesis implantation can be performed at a single level or at multiple levels. Wound closure is similar to the ACDF procedure.
215034730|NCT06645171|DIETARY_SUPPLEMENT|Fibre drink|One drink will be tested
214867707|NCT00295295|DEVICE|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
214867708|NCT00295295|OTHER|Standing|Standing 10 min/day
214867709|NCT04625426|DEVICE|3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant|Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant
214867710|NCT04625426|DEVICE|Conveen EasiCleanse and Conveen Critic Barrier|Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
214867711|NCT04625426|DEVICE|Standard cleansing and Conveen Critic Barrier|Hospital's standard care for IAD management
214867712|NCT05813366|OTHER|Acupuncture|Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.
214867713|NCT05813366|OTHER|Tryptophan-Rich Diet|"All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed."
214867714|NCT05813366|OTHER|Vitamin B6 Supplementation|All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.
214867715|NCT04223531|DRUG|Normal Saline 0.9% Infusion Solution Bag|Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
214867716|NCT00969631|DRUG|metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
214867717|NCT00969631|PROCEDURE|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
214867718|NCT03775720|BEHAVIORAL|Dietary advice|Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
214867719|NCT00968786|DEVICE|Home monitoring|automated measuring devices for patients using at home
214867720|NCT05061186|OTHER|Resistive Expiratory muscle Training Group|"Mild Resistive Expiratory Technique \[Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day\] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
214867721|NCT05061186|OTHER|Conventional Breathing Exercise Group|"Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)"
214867722|NCT01391741|OTHER|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
214867723|NCT01391741|OTHER|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
214867724|NCT01712737|OTHER|Dietary intervention|
214867725|NCT04452253|DIETARY_SUPPLEMENT|PS128|PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128
215034731|NCT03781570|BEHAVIORAL|Placebo Cream|"In the Placebo intervention, participants are given an inert cream with instructions that it is Prodicaine, an effective pain-relieving drug. The cream is applied to two fingers on the left hand."
215034732|NCT03781570|BEHAVIORAL|Control Cream|"In the Control intervention, participants are given an inert cream with instructions that it is a control cream with no effects . The cream is applied to two fingers on the left hand."
214867726|NCT04452253|DIETARY_SUPPLEMENT|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
214867727|NCT04452253|DIETARY_SUPPLEMENT|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.
214867728|NCT04452253|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
214867729|NCT05899751|DRUG|High-dose methotrexate|High-dose methotrexate
214867730|NCT05899751|DRUG|Glucarpidase|Glucarpidase
215034733|NCT01107496|DRUG|IR Viloxazine|"One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1.~Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6."
215034734|NCT01107496|DRUG|Placebo|Placebo capsules administered orally 3 times a day
215034735|NCT06063551|PROCEDURE|Testicular Biopsy|Testicular biopsy for clinical storage and laboratory research.
214867731|NCT05094245|PROCEDURE|Stellate Ganglion Block Group|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
214867732|NCT00324480|DRUG|alvocidib|Given IV
214867733|NCT00324480|DRUG|vorinostat|Given orally
214867734|NCT00324480|OTHER|pharmacological study|Correlative studies
215034736|NCT03709472|BEHAVIORAL|Computer Assisted CIFFTA|This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
215034737|NCT03709472|BEHAVIORAL|Behavioral: Traditional face-to-face treatment-no technology|Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
215034738|NCT05644301|DRUG|Celecoxib|Oral capsule, 200 mg, twice daily, for 12 weeks
214867735|NCT01573169|DRUG|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
214867736|NCT01573169|OTHER|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
214867737|NCT02439931|BEHAVIORAL|Remote psychosocial intervention|
214867738|NCT01540773|DRUG|Amino acid supplement|An orally administered supplement of the proprietary amino acid derivative
215034739|NCT05644301|DRUG|Minocyclin|Oral capsule, 100 mg, twice daily, for 12 weeks
215034740|NCT05644301|DRUG|Placebo|Oral capsule, no active substance, twice daily, for 12 weeks
215034741|NCT05826054|DIETARY_SUPPLEMENT|Montbretin A|The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA).
215034742|NCT02056769|RADIATION|CT Perfusion|Quantitative CT Perfusion imaging
215034743|NCT06479707|BEHAVIORAL|Digital Literacy Intervention|This intervention consists of 4-6 home visits with 3-4 interim phone calls based on the participant's individual digital literacy needs and goals. Each participant will receive internet connectivity (if not already available), a tablet (if not already available) and tailored action plans co-developed by the participant and the interventionist.
215034744|NCT06464640|DEVICE|"Online Interactive Podcast Program Living with Type 1 Diabetes to Grown-Up"|The podcast content was designed based on the results of previous research.Subjects will be randomly assigned to either the experimental group (N=44) or the comparison group (N=44). Comparative analyses will focus on variations in disease control, emotional disturbance,confidence in self-management, self-care behaviors, diabetes knowledge,interpersonal disturbance, and family conflict at baseline, and post-interventions of immediate, 3-month, and 6-month periods.
215034745|NCT06464640|DEVICE|E-book|Participants in the active control group will use Ebook.According to the research results from the project leader\&#39;s app effectiveness evaluation (Chiang, 2020-2022), the e-book did not show significant effects on blood sugar control, disease management confidence, self-care behaviors, disease-related knowledge, or interpersonal distress. Therefore, the active control group received a sham treatment in the form of an e-book. The research team extracted content from the CEO APP e-book, with an expert validity of 0.91, and reorganized it into an electronic health education manual titled \&#34;Transitioning from Adolescence to Early Adulthood: The Ins and Outs of Type 1 Diabetes.\&#34;
215034746|NCT03141970|DRUG|Prednisolone|Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
215034747|NCT03659721|BEHAVIORAL|FACAM|Support person
215034748|NCT03659721|BEHAVIORAL|Care as Usual|Usual care
215034749|NCT03659721|BEHAVIORAL|COS-P|Attachment based therapy
215034750|NCT06499961|BEHAVIORAL|Digital version of Holistic Healthy Life Education|Participants need to attend a two-day workshop related to (1) health risk appraisal and self-care; (2) exercise, fitness and self-acupressure; (3) emotion and stress management; (4) the whole food plant-based (WFPB) diet; and (5) meditation and mindfulness practices, led by a multi-disciplinary team. Before the intervention commences, they will take pre-blood test and further receive the e2HLE with Hera Leto for three months. During the intervention, participants will attend (1) nine weekly workshops pertaining to WFPB diet, exercise, fitness and self-acupressure, and meditation and mindfulness and followed by weekly tele-counselling sessions; (2) three process evaluation practice sharing sessions in the format of focus group, making up a total of twelve sessions. The process evaluation practice sharing sessions will be audio-recorded; (3) mutual support networking platform will be held between case managers and participants within Hera Leto system.
215034751|NCT06499961|OTHER|Waitlist control|usual care first, then switch to receive the intervention
214290777|NCT01923493|OTHER|no intervention|Patients in the no intervention waiting list group will not receive a study intervention. They will continue their respective pre-study therapy during the study period.
214867739|NCT01540773|DRUG|Placebo|A non-active orally administered supplement of the proprietary amino acid derivative
214867740|NCT00192270|BIOLOGICAL|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10\^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of \~3 x 10\^7 TCID50 per dose.
214867741|NCT04776837|BEHAVIORAL|Observational Cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
214867742|NCT03753763|DRUG|Safinamide Methanesulfonate|100 mg (free base)
214867743|NCT03753763|DRUG|Safinamide Methanesulfonate matching placebo|100 mg placebo
215034752|NCT02025218|DRUG|Gefitinib standard dose|
214867744|NCT05346783|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
214867745|NCT05346783|OTHER|Placebo (vehicle)|1 drop 6 times a day
214867746|NCT05346783|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
214867747|NCT00389831|DRUG|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
214867748|NCT00389831|OTHER|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
214867749|NCT05058534|DEVICE|Multiline Neo®|Multiperfusion neonatal system
215034753|NCT02496000|DRUG|ORMD-0801|Oral Insulin
215034754|NCT02496000|DRUG|Placebo Comparator|Placebo
215034755|NCT05040932|DRUG|YH004|IV infusion once every 3 weeks (Q3W).
215034756|NCT01150370|DEVICE|The PrePex a novel device for adult male circumcision|The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
215034757|NCT02255656|DRUG|alemtuzumab GZ402673|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
215034758|NCT05806528|OTHER|Ultrasound|Use ultrasound to make placental invasion index
215034759|NCT06461507|OTHER|Janda's Approach|For Tightened Structures Stretching applied toIliopsoas and Erector spinal muscles (5 repetitions of stretching with 30-s hold for each muscle). For Strengthening of Weakened Structures; Glute bridge and Abdominal crunch(10 repetitions of each).
215034760|NCT02229682|RADIATION|Mild-dose IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
215034761|NCT03852420|DEVICE|LUMINIZE RF Balloon Catheter|Ablation Therapy with the LUMINIZE RF Balloon Catheter
215034762|NCT03543423|OTHER|Oral glucose tolerance test|Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG
215034763|NCT03543423|OTHER|Liquid mixed meal test|A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).
215034764|NCT01555580|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
215034765|NCT05100095|DRUG|Radiation therapy|Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
215034766|NCT05446207|OTHER|Routine Physiotherapy and Task-oriented Training|The routine physiotherapy treatment will include TENS and Hot pack. The task oriented training for lower extremity will include walking training on the ground, equal weight bearing sit-to-stand exercises, resistance exercises e.g. leg press, leg extension, and leg curl and reaching tasks for improving balance. There will be a rest period of 5 minutes between each set of training.
215034767|NCT05446207|OTHER|Music Therapy and Task oriented Training with Routine Physiotherapy|Relaxing Music will be provided through headphones having voice cancellation property for 15 minutes.
215034768|NCT04269863|DRUG|Aspirin|control - 81mg. treatment - 81-325mg.
215034769|NCT04736355|DRUG|DAOIB|oral, for 24 weeks
215034770|NCT04736355|DRUG|Placebo|oral, for 24 weeks
215034771|NCT06381960|DRUG|Fuzheng Quxie Recipe|Treatment group: Fuzheng Quxie Recipe (Yifei Sanjie Recipe) ingredients: Sheng Huang Qi 15g, Jiao Bai Zhu 15g, Bai Fu Ling 15g, Bei Sha Shen 15g, Zhe Mai Dong 15g, Dang Shen 15g, Shu Yang Quan 15g, Xia Ku Cao 15g, Sheng Mu Li 15g, Shi Jian Chuan 15g, Shi Shang Bai 15g, and Hai Zao 15g. Combined with basic chemotherapy after lung cancer.
215034772|NCT06381960|DRUG|Fuzhengquye Fang Recipe simulant|Control group: Fuzhengquye Fang Recipe simulant, which was prepared into control group placebo drug according to 5% of the drug content in the treatment group. Combined with basic chemotherapy after lung cancer.
215034773|NCT01877278|DEVICE|Wearable pulsed electromagnetic fields|
214665614|NCT03664726|BEHAVIORAL|Episodic Recent Thinking|Participants will be instructed to use their episodic recent cues as they engage in different decision making tasks.
214867750|NCT06072495|OTHER|real time MRI|ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects
214867751|NCT00249691|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
214867752|NCT00249691|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
214867753|NCT03433755|DRUG|evolocumab|Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
214867754|NCT03433755|DRUG|placebo|Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
214867755|NCT01850095|DRUG|treatment azelaic acid (azelan)|treatment for 6 months
214867756|NCT01850095|DRUG|dorspirenone/ethynil estradiol|
214867757|NCT00000117|DRUG|Immunoglobulin|
214867758|NCT00044980|PROCEDURE|nutritional support|
214867759|NCT00044980|PROCEDURE|quality-of-life assessment|
214867760|NCT03894748|DRUG|Botulinum Toxin Type A|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
214867761|NCT03485053|DRUG|IOP Injection / MPB-1514|Dilute with 5% Dextrose solution (D5W)
214867762|NCT05486455|DIAGNOSTIC_TEST|Low-dose chest CT scan|baseline, 1-year, 3-year and 5-year low-dose CT scan
214867763|NCT01176214|PROCEDURE|Early tracheostomy|"Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset."
214867764|NCT01176214|PROCEDURE|Late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
214867765|NCT00303394|DRUG|IL-1Ra|
215034781|NCT01480830|DEVICE|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
215034782|NCT06973876|BEHAVIORAL|Pain-Sensitive Teleyoga Primer|The 5-session Pain-Sensitive Teleyoga Primer will be delivered synchronously to participants who will practice from their home. The purpose of the 5-session primer is two-fold: (1) it allows trained yoga instructors to determine physical abilities and limitations of patient participants so that pose modifications may be taught and (2) it provides education to participants on pain neuroscience, breathwork, relaxation, mindfulness, and interoception so that they may apply this knowledge to maximize the benefits of whichever yoga condition they are randomized to. Each session will last approximately 75 minutes. Participants will be provided with a supplementary handout to reinforce content from the sessions.
215034783|NCT06973876|BEHAVIORAL|Synchronous Teleyoga|Participants randomized to receive synchronous teleyoga will be provided information so that they can attend VAPORHCS virtual yoga offerings. They will be encouraged to attend one class per week during the 12 weeks between randomization and follow-up assessment. Attendance will be tracked via a signed note in the medical record. Each session will last approximately 30-60 minutes.
215034784|NCT06973876|BEHAVIORAL|Asynchronous Teleyoga|Participants randomized to receive asynchronous teleyoga will be provided information so that they can access to the digital library of yoga videos on Ompractice, an existing partner with VA Medical Centers. Ompractice contains a suite of yoga video content, and participants will be encouraged to complete one class per week during the 12 weeks between randomization and follow-up assessment. Attendance will be tracked by Ompractice and shared with VAPORHCS.
215034785|NCT04619628|BIOLOGICAL|COVI-VAC|intranasal, live attenuated vaccine against SARS-CoV-2
215034786|NCT04619628|OTHER|Placebo|normal saline
215034787|NCT03014505|BIOLOGICAL|FMT|Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1
215034788|NCT03014505|OTHER|traditional treatments|traditional treatments for Decompensated Cirrhosis in part 2
215034789|NCT01757496|DEVICE|Cough Assist|
215034790|NCT05535569|DRUG|Nivolumab, Paclitaxel|Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
215034791|NCT06269315|OTHER|Cleaning product exposure|Exposure of a small amount of a different household cleaner, hand disinfectant, their ingredients, and control with proper dilution on forearm of donors
215034792|NCT04731597|DRUG|drug interaction|when two drugs are taken together
215034793|NCT06575894|BEHAVIORAL|Adapted Facilitation|Home visiting supervisor trained in adapted facilitation will employ interactive problem-solving focused on supporting the home visitors to implement Mothers and Babies - working with pregnant people, challenges with resources, additional training needs, etc. - based on understanding the individual communities, contexts, and recipients' and home visitors' needs over the course of the project.
215034794|NCT06575894|BEHAVIORAL|Standard Implementation|Standard Mothers and Babies training includes ongoing implementation support from the Mothers and Babies training team
215034795|NCT06460532|OTHER|Baseline treatment|Transcutaneous Electric Nerve Stimulation (TENS) of Care Vision company will be applied, with a pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the suboccipital region and the trapezius bilaterally.
215034796|NCT06431581|BEHAVIORAL|m-Health intervention (educational video, SMS and reminder phone call)|Pregnant women meeting the inclusion criteria and assigned to the intervention group will receive m-health intervention that includes a tailored educational video regarding perinatal care targeting positive birth outcomes and infant health, SMS messages, and reminder phone calls for follow-up
214476541|NCT06668636|BEHAVIORAL|ED-PATCH|Participants will access ED-PATCH using their personal mobile device and use it to track important information throughout their visit. The summary will be checked by a healthcare provider and corrected, if necessary, before being locked and sent to the patient or caregiver to keep for their own records.
214867766|NCT06928090|DRUG|DTG + 3TC FDC|None(Non-interventional, retrospective chart review, single-arm study )
214867767|NCT03202901|DIETARY_SUPPLEMENT|B-turmactive|"The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
215034797|NCT05678465|PROCEDURE|Non-fixation of the mesh|3D-shaped, anatomical, standard, polypropylene mesh without fixation.
215034798|NCT05678465|PROCEDURE|Fixation of the mesh|Glue fixation of lightweight, macroporous, polypropylene mesh.
214476542|NCT02518048|DRUG|LEO 90100 Aerosol foam|
214476543|NCT02518048|DRUG|Betesil® 2.25 mg|
214476544|NCT06608199|BIOLOGICAL|pneumococcal disease prevention|2P+1 programme of PCV13
214476545|NCT06745960|DEVICE|electrical muscle stimulation device (EMS gymna)|muscle stimulant device
215034799|NCT04317742|DEVICE|Sleep Healthy Using the Internet (SHUTi) Intervention Group|"SHUTi is a fully automated, interactive and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is presented in six Cores, metered out over time."
214867768|NCT03202901|DIETARY_SUPPLEMENT|Placebo|"The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
214867769|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 100% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
214867770|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 50% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
214290778|NCT06361030|DRUG|surufatinib combined with gemcitabine plus nab-paclitaxel|"Surufatinib capsules: oral, once daily. Combination treatment period: 200 mg each time, every 4 weeks for a treatment cycle(Q4W). If all the chemotherapy drugs were stopped during the maintenance treatment period, only surufatinib was left, the dose of Surufatinib could be increased to 300 mg per dose according to the patient\&#39;s condition.~Gemcitabine: iv, 1000 mg/m2, days 1, 8, and 15 of each treatment cycle, Q4W. Paclitaxel (albumin-bound), iv, 125mg/m2, on days 1, 8 and 15 of each treatment cycle, Q4W.~All they will be used until disease progression, death, intolerable toxicity, initiation of new antineoplastic therapy, withdrawal of consent, loss to follow-up, or any other protocol-specified event requiring treatment discontinuation or study closure, whichever occurred first.~But If surgical resection was performed, they will be only maintained for 6 months after surgery."
214867771|NCT00121160|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM) group intervention|Participants will meet in closed, structured groups of 4 to 6 women for ten weekly, 2-hour group sessions. The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Group members and group leaders are used as role models for effective coping and the use of social support. The groups also encourage emotional expression and provide an opportunity to practice techniques learned in the group and experience social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Each week participants also experience a different relaxation technique. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
214867772|NCT06927752|DEVICE|PelviGYNious|Patient received PelviGYNious implant.
214867773|NCT06927752|DEVICE|EndoGYNious|Patient received EndoGYNious implant.
214867774|NCT06926712|DRUG|Vitamin E|dose of vitamin E in an appropriate dose for age during hospital stay for intervention group
214867775|NCT06928961|OTHER|Patient portal with patient-reported outcome measure administration, appointment calendar and reminders, access to lab test results, and educational material|Patients in the intervention will be trained to register on and use the patient portal. The following portal features will be used and studied in this project: the appointment calendar, PROMs administration, reminders (e.g., for appointments), educational materials, and access to personal lab results. Educational materials in the portal will include information on what to expect during HIV clinic visits, how to interpret HIV lab reports, and instructional videos on using the portal. Prior to visiting their HIV physician, patients will have continuous access to several portal features (calendar, education, and lab results, if applicable), and receive reminders (within 48 hours) of their clinic appointment and to complete the PROMs. Physicians will acquire their patients' PROM scores via the patient portal and receive training on how to do so. Patients and physicians are expected to review the PROM results and consider them during each clinic visit.
214867776|NCT00240942|DRUG|Letrozole|
214867777|NCT00486616|DEVICE|electrical impedance tomography|
214867778|NCT00486616|PROCEDURE|double-lumen tube placement|
214867779|NCT05463263|DRUG|STP938|Small molecule
214867780|NCT02375620|BIOLOGICAL|PEG-somatropin|
214867781|NCT06218030|DRUG|L-methylfolate|Oral administration of L-methylfolate 15 mg per day for 8 weeks. The study drug will be given in addition to the standard of care (SOC) for GAD.
214867782|NCT05052515|DIETARY_SUPPLEMENT|Dihydromiricetin, Vitamin C, E and Choline|Patients with MASLD will be randomly allocated to receive capsules with Dihydromiricetin, Vitamin C, E and Choline
214867783|NCT05052515|OTHER|Placebo|Patients with MASLD will be randomly allocated to receive placebo capsules
214867784|NCT06451926|OTHER|Escape room game|Educational escape rooms are live action games where teams use content knowledge to complete tasks and puzzles to reach a final goal, such as escaping from a room or completing a final puzzle
214867785|NCT04685109|DEVICE|Alocross 0.2% Unit Dose|Eye Drops
214867786|NCT04685109|DEVICE|Vismed|Eye drops
215034800|NCT04317742|DEVICE|Online Patient Education (PE) Control Group|The online PE program provides static information about: insomnia symptoms; the impact, prevalence, and causes of insomnia; when to see a doctor; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
214290779|NCT02740764|OTHER|Optimization of drug prescribing|The patients included in this group will have the intervention. The optimization of drug prescribing consists to a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital and sent to the referring physicians of patients, who can accept or not the recommendations.
215034801|NCT06642116|DEVICE|OCEAN|Biodegradable nasal dressing
215034802|NCT06640699|OTHER|exercise|exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.
215034803|NCT06637059|OTHER|observational study|observation alone
215034804|NCT06638918|DEVICE|Virtual Reality|The virtual reality (VR) intervention administers graded motor imagery (GMI) treatment for phantom limb pain. It consists of three stages: left right sorting task (a sorting task where participants sort images of left and right feet), explicit motor imagery (a series of guided imagery exercises administered via audio to facilitate focus on the phantom limb), and the limb simulation task (where participants perform a series of exercises with virtual legs to create the illusion of movement in their phantom limb). The limb simulation stage can also be conducted with leg trackers to generate a higher degree of illusion in the virtual legs.
214867787|NCT04941729|DEVICE|OR3O™ - Dual Mobility System|OR3O™ Dual Mobility System is comprised of a diffusion-hardened, oxidized zirconium acetabular liner (OR3O™ Liner), and an insert of highly cross-linked polyethylene (OR3O™ XLPE Insert).
215034805|NCT06641518|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|a therapeutic modality employing electric current to relieve pain by activating peripheral nerves. The evolution of TENS units alongside technological advancements has led to user-friendly interfaces and enhanced portability, with units now small enough to be carried in a pocket.
214867788|NCT04941729|DEVICE|Conventional|A conventional, single-bearing design Total Hip System comprised of R3™ Acetabular Shell with XLPE liner and a Smith \& Nephew Oxinium (Ox) femoral head.
214867789|NCT05676918|BEHAVIORAL|Positive Psychology Intervention|PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
214867790|NCT05676918|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
214867791|NCT03145077|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
214867792|NCT03145077|OTHER|Questionnaire Administration|Ancillary studies
214867793|NCT03964532|DRUG|Talazoparib|Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
214867794|NCT03964532|DRUG|Avelumab|Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
214867795|NCT03190330|DRUG|Ibrutinib 420 mg|Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
215034806|NCT06637813|OTHER|Blood sampling for evaluation of biomarkers|Non-routine diagnostic test evaluations
215034807|NCT06645275|GENETIC|POCT test|Patients undergo POCT testing on the day of warfarin administration, and based on the POCT results, the initial and maintenance doses of warfarin are determined according to the IWPC algorithm.
215034808|NCT06187714|PROCEDURE|caudal block rate|optic nerve sheath diameter measurement according to caudal block rate
215034809|NCT01716702|BEHAVIORAL|Couples Prostate Cancer Support Group|"The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
215034810|NCT01969058|DRUG|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
215034811|NCT03716973|DEVICE|High Density Programming|Patients implanted with Medtronic spinal cord stimulator will have high density programming.
215034812|NCT06358508|DEVICE|Sapphire 3 Coronary Dilatation Catheter|To pre-dilate Chronic Total Occlusion (CTO) lesions in coronary arteries during the subject's index procedure with Sapphire 3 0.85mm, 1.0mm, and 1.25mm diameter Coronary Dilatation Catheters.
215034813|NCT05289544|BEHAVIORAL|Phone-Based Walk With Ease|6 week phone-delivered Walk With Ease Program
215034814|NCT00883311|DEVICE|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
215034815|NCT02314195|DRUG|Selective serotonin re-uptake inhibitor|A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
215034816|NCT02314195|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
215034817|NCT02314195|OTHER|Music therapy|12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
215034818|NCT04305756|DRUG|Enoxaparin|Low molecular weight heparin
215034819|NCT03910972|BIOLOGICAL|Sm-TSP-2/Alhydrogel® vaccine|The Sm-TSP-2/Alhydrogel® candidate vaccine contains recombinant Sm-TSP-2 adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10mM imidazole buffer containing 2mM phosphate and 15% sucrose, with pH 7.4 ± 0.1. The final concentrations of Sm-TSP-2 and Alhydrogel® in the drug product are 0.1mg/ml and 0.8mg/ml respectively.
215034820|NCT03910972|BIOLOGICAL|Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701|The Sm-TSP-2/Alhydrogel® candidate vaccine co-administered with the immunostimulant, AP 10-701. b) AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist. Point-of-injection formulations with this immunostimulant will be prepared immediately prior to vaccination by adding an appropriate volume of AP 10-701 to Sm-TSP-2/Alhydrogel® and withdrawing an appropriate volume to administer the desired amount of Sm-TSP-2 plus 5µg GLA-AF.
215034821|NCT03910972|BIOLOGICAL|ENGERIX-B Hepatitis B Vaccine|Recombinant hepatitis B vaccine containing 10 mcg recombinant hepatitis B surface antigen per dose
215034822|NCT04977232|DRUG|Escitalopram|Selective serotonin reuptake inhibitors (SSRI) were most commonly used first line pharmacotherapy for depression.
215034823|NCT04977232|BEHAVIORAL|Game intervention|Participants will be instructed to play the commercial video game for about 30-60 minutes at least three times per week.
215034824|NCT01527955|OTHER|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
214290780|NCT01202474|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day
214867796|NCT03190330|DRUG|Ibrutinib 560 mg|Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
214867797|NCT06559176|BIOLOGICAL|PM359|Single dose of PM359 administered autologously by intravenous (I.V.) infusion following myeloablative conditioning with busulfan
215034825|NCT05024162|DIAGNOSTIC_TEST|MRT Accuracy|Predicted Grade Group (GG) by the MRI-based Radiomics Tool (MRT) at each Magnetic Resonance Imaging of the Prostate (MRI-P)
215034826|NCT05024162|DIAGNOSTIC_TEST|MRT Stability|MRT's predicted GG at second MRI-P.
214867798|NCT06145737|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)|"One on one virtual self-management program for cognitive dysfunction associated with Multiple Sclerosis (MS).~HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-MS is an adaptation of the HOBSCOTCH program for people with MS and incorporates education about multiple sclerosis and cognition into the education module."
214867799|NCT04295473|PROCEDURE|Reduced port laparoscopic gastrectomy|The ports were reduced in the surgery of intervention arm.
214867800|NCT06314048|OTHER|CGM and RPM|1\. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
214867801|NCT06488001|DRUG|pantoprazole|Pantoprazole 40mg given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
214867802|NCT06488001|DRUG|Placebo|Placebo given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
215034827|NCT04416711|BEHAVIORAL|Personalized Feedback|The personalized feedback consists of four components: normative feedback, risk/protective feedback, decisional balance/goal setting, and protective strategy review. Personalized feedback targets include readiness to change, perceptions of risk, and misperceptions of peer attitudes/behaviors.
215034828|NCT04416711|BEHAVIORAL|Cognitive Skills Training|We will address three cognitive targets: focus on affective cues, focus on non-affective cues, and over-perception of sexual interest. The first module targets enhanced focus on women's affective cues and reduced over-perception of sexual interest. We will introduce the role of men's sexual-perception skills in satisfying social and sexual interactions with women, as well as problematic sexual behavior including RSB and SAB. Next, we will instruct participants that affective information is the best-available nonverbal information about how a woman is feeling about a specific man. This instruction will focus on distinguishing four primary dating relevant cues: sexual-interest, friendliness, sadness, and rejection. More detailed focus on each cue will emphasize the increased difficulty of reading these cues with a new partner and under the influence of alcohol and sexual arousal, as well as the importance of checking verbally on assumptions about a woman's current sexual interest.
215034829|NCT04416711|OTHER|Services As Usual|These participants will receive services as usual
215034830|NCT01737723|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
215034831|NCT03661099|DIAGNOSTIC_TEST|colonoscopy|endoscopists' performance outcome
215034832|NCT05972785|DRUG|Calcium channel blocker|Drugs with ATC code C08 will be categorised as calcium channel blockers.
215034833|NCT05972785|DRUG|Beta blocker|Drugs with ATC code C07 will be categorised as beta-blockers.
215034834|NCT05972785|DRUG|Diuretic|Drugs with ATC code C03 will be categorised as diuretics.
215034835|NCT05972785|DRUG|RAS|Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
215034836|NCT05972785|DRUG|Other AHT|Drugs with ATC code C02 will be categorised as other antihypertensives.
215034837|NCT05972785|DRUG|None AHT|None AHT
214867803|NCT04351737|DRUG|Intracanalicular Dexamethasone, (0.4 mg) Insert|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.
214867804|NCT04351737|DRUG|Prednisolone Acetate|To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
214867805|NCT05413915|DRUG|Asciminib|Tyrosine kinase inhibitor
214867806|NCT05413915|DRUG|Imatinib|Tyrosine kinase inhibitor
214867807|NCT04197258|OTHER|Peer support|"The intervention studied is the psycho-social support by a peer-helper to the patients and their main informal caregiver during the return home following a stay in rehabilitation center for a stroke.~Peer support intervention will be based on evidence, Bandura's social learning and social support theory, and the results of our ongoing study of the needs of patients and their caregivers as a result of returning home (Stroke69). It will include a meeting before the discharge and a regular follow-up for 6 months (face-to-face meetings, virtual or by phone), adapted to the needs of the patient and his caregiver, taking into account the social environment and in connection with the devices existing sanitary and social."
215034838|NCT06565091|DEVICE|Measurements of physiological parameters of the anterior chamber|Acquisition by the investigational device
215034839|NCT06565091|DEVICE|Measurements of the Axial biometry|Acquisition by the investigational device
215034840|NCT06053372|DEVICE|Apple Watch|Wearable monitor for heart rate and arrhythmia detection
215034841|NCT01558167|DRUG|Bendamustine, Rituximab, Lenalidomide|"Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~* Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~* Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~* Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~* Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~* Dose level 5: maximal tolerated dose"
214290781|NCT01202474|DRUG|INSULIN GLARGINE|Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
214867808|NCT05960266|BIOLOGICAL|Polvac Grass+Rye|Aqueous suspension of a co-precipitate of allergen extract and tyrosine
215034842|NCT04976855|DRUG|INDV-2000|Capsule for oral administration
215034843|NCT04976855|DRUG|Placebo|Capsule for oral administration
215034844|NCT04976855|DRUG|SUBOXONE® sublingual film|Administered either under the tongue (sublingual) or between the gum and cheek (buccal)
215034845|NCT00291837|DRUG|CT-2106|
215034846|NCT04953026|DIAGNOSTIC_TEST|Diagnositic test|The results of shoulder arthroscopy were taken as the gold standard, and MRI examination was taken as the research object.
215034847|NCT00287560|DRUG|propofol (drug)|
214867809|NCT04141098|DEVICE|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
214867810|NCT00006721|BIOLOGICAL|rituximab|Given IV
214867811|NCT00006721|DRUG|cyclophosphamide|Given IV
214867812|NCT00006721|DRUG|doxorubicin|Given IV
214867813|NCT00006721|DRUG|prednisone|Given orally
214867814|NCT00006721|DRUG|vincristine|Given IV
214867815|NCT00006721|RADIATION|tositumomab|Given IV
214867816|NCT04582279|DIAGNOSTIC_TEST|Lung ultrasound|The lung ultrasound will be performed by a trained pulmonologist by gently pressing a probe to various areas of your chest. This is a non-invasive procedure and you should not feel any pain. The ultrasound will take less than 10 minutes.
214867817|NCT05705128|DRUG|Dexmedetomidine|Dexmedetomidine will be given with bupivaciane for postoperative pain control
214867818|NCT02081209|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214867819|NCT05376696|BEHAVIORAL|Set For Variability|This intervention will focus on training students to use a sound variation of grapheme correspondence rule in order to read an irregular spelling word correctly.
214867820|NCT05376696|BEHAVIORAL|Current Best Practices|This active control intervention will focus on training students to use grapheme-phoneme correspondence rules and sight words in the absence of set-for-variability component
214290782|NCT02374801|DEVICE|"SonR automatic optimization feature turned ON (AV+VV)."|
214867821|NCT06193772|BEHAVIORAL|Internet-delivered psychodynamic therapy (IPDT)|"IPDT consists of 8 therapist-supported self-help modules delivered over 10 weeks on a secure online platform. Modules consist of texts and video followed by assignments which they send to their therapist and receive feedback within a few days. The intervention IPDT adapted starts with therapist feedback about the patient's predicted progress and continues with adapting the treatment to the individual adolescent, for example adding text chat sessions."
214867822|NCT05927610|DIAGNOSTIC_TEST|Lumber Puncture|During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).
214867823|NCT05205772|DEVICE|transcranial magnetic stimulation|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes."
214867824|NCT05768178|DRUG|Vemurafenib|Patients will receive vemurafenib at a dose of 960 mg orally (4 tablets of 240 mg) on a twice daily schedule throughout a 28-day cycle. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
214867825|NCT05768178|DRUG|Cobimetinib|Patients will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
214867826|NCT05297760|BIOLOGICAL|Polvac Grass+Rye|Suspension of micro crystalline tyrosine with grass and rye pollen allergen
214867827|NCT05297760|DRUG|Saline 0.9%|Physiological saline solution for use as vehicle for the biological drug (Polvac Grass+Rye) or as placebo.
214867828|NCT04731155|DRUG|PCSK9 inhibitor （Alirocumab）plus standard medications|PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
214867829|NCT04731155|DRUG|standard medications|standard medications was giving to subjects according guidelines
214867830|NCT06531395|DRUG|Abiprubart|humanized monoclonal antibody
214867831|NCT06531395|DRUG|Placebo|sterile preservative-free solution
214867832|NCT04696029|DRUG|Difluoromethylornithine|"DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C)."
214867833|NCT06378749|BEHAVIORAL|PreCharge|PreCharge is an intervention for Hereditary Cancer Syndrome Previvors that administers brief assessments and uses multivariate algorithms and tailoring technology to provide timely, individualized, bi-directional text messages to improve resilience and coping. The program uses proven approaches to behavior change tailoring to increase resilience by promoting a positive mindset, strong social connections, and a deep sense of meaning and purpose. It will also proactively provide access to online tools prior to medical appointments to address scanxiety (e.g., management of emotion tips; mindfulness meditation; communication scripts; breathing exercises). At any time, users will be able to text a trigger word to indicate that they need extra support and will receive just-in-time assistance via text message.
214867834|NCT06556251|DEVICE|PIPPEP App|"Digital platform with psichoeducative content in infographics, animated and testimonial videos about:~* psychotic and comorbid symptoms, substance use, available treatments, healthy lifestyle habits, social and health emergency resources and outpatient clinics for young people.~* Regular self-completed questionnaires to measure alarm symptoms, side effects of pharmacological treatment, emotional state, and treatment adherence. There will be a feedback for patients in the form of graphs of the evolution of the different types of questionnaires.~* A bidirectional messaging service with the professional reference team, allowing better accessibility in non-urgent cases.~* A gamification system to encourage use of the application, which includes points, rewards, a leaderboard and mini-games.~* A folder where patients can keep documents they find useful (personal reports, relapse prevention plan, crisis plan)."
214867835|NCT04441619|BEHAVIORAL|Delayed onset muscle soreness.|Participants will perform a fatiguing exercise protocol for the upper extremity (biceps muscles)
214867836|NCT06110156|BEHAVIORAL|Patient-tailored deprescribing assessment and intervention|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
214867837|NCT03782415|DRUG|MN-166|MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
214867838|NCT03782415|DRUG|Temozolomide|Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
214867839|NCT05217459|DEVICE|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
215034848|NCT05493410|OTHER|TREATMENT GROUP (TG)|In addition to muscle strengthening and aerobic exercise, patients from the TG will undergo IMT for six weeks, performing two sets of 30 repetitions daily using the device POWERbreathe classic medic® (POWERbreathe International Ltd., Southam, United Kingdom). MIP will be measured in all patients before the intervention as described earlier, and patients will exercise at 40% MIP in the first week and 60% MIP in the subsequent five weeks. The patients will be instructed to inhale using the diaphragm muscle, trying to expand the rib cage to avoid using accessory muscles A nose clip will be used to ensure patients breathe exclusively through the training device.
215034849|NCT05493410|OTHER|CONTROL GROUP (CG)|"For six weeks the CG will perform muscle strengthening through a sit and stand up from a chair routine, abduction of upper and lower limbs, and rowing; three sets of 10 repetitions of each exercise will be performed. Elastic tubes will be used, with elasticity defined by color and indicating the greatest resistance the participant can endure with an effort between 4 and 8 on the OMNI-RES scale for perceived exertion.~In addition, aerobic exercise will be performed, through walking on flat terrain for five minutes in the first week, 10 minutes in the second week, and 20 minutes in the subsequent week, with intensity between 40-60% of the reserve heart rate and respecting the patients' symptoms.~Aerobic training intensity will be calculated by the modified BORG exertion scale maintaining a score between 6 and 7 - with the progression respecting the patients' symptoms - and by the reserve heart rate."
215034850|NCT05095467|PROCEDURE|HIPEC|The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.
215034851|NCT05095467|DRUG|Paclitaxel-albumin|albumin paclitaxel D1, D8; S-1: D1-D14
215034852|NCT05095467|DRUG|Tegafur-gimeracil-oteracil potassium|40mg bid(BSA\<1.5 m2) ，60mg bid(BSA\>=1.5 m2); D1-D14, po, bid.
215034853|NCT05095467|PROCEDURE|Surgery+HIPEC|gastrectomy with D2 lymphadenectomy+HIPEC procedure
215034854|NCT00060125|DRUG|tipifarnib|Given orally
215034855|NCT00060125|OTHER|laboratory biomarker analysis|Correlative studies
215034856|NCT05386966|OTHER|questionnaire|Patient demographic data ( age, gender, residence , work ,Level of education) .Detailed history about the trauma (type, site , manner , mechanism of injury , actual cause of assault , post traumatic period till arrival to hospital ) .Clinical assessment ( Rapid neurological assessment , assesment of Scalp injury ,Presence of other body trauma ,Degree of severity of head injury according to GCS , Radiological finding. Treatment (Conservative or operative intervention ) .Follow up and outcome at the time of discharge by using the GOS .Expected time for healing (\<20 day or \>20 day ).Expectance for permanent infirmity
215034857|NCT02946697|BEHAVIORAL|Social support intervention|The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
215034858|NCT06195956|OTHER|exercise|Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months
215034859|NCT03100279|BEHAVIORAL|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, \& Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
215057175|NCT01236066|OTHER|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children \<5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
214290783|NCT04575922|DRUG|Nivolumab|Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.
214867840|NCT06138899|OTHER|Club 25|The Club 25 donation program will involve students pledging to donate blood 25 times in their lifetime. In order to achieve this objective, students also pledge to lead a healthy lifestyle, to avoid acquiring HIV and other TTIs and to continue donating blood after leaving school. The Club 25 donation program includes activities in-between blood donation events as well as peer leadership and peer education in schools and in communities.
214867841|NCT02664935|DRUG|AZD4547|FGFR Inhibitor
214867842|NCT02664935|DRUG|Vistusertib|MTORC1/2 Inhibitor
214867843|NCT02664935|DRUG|Palbociclib|CDK4/6 Inhibitor
214867844|NCT02664935|DRUG|Crizotinib|ALK/MET/ROS1 Inhibitor
214867845|NCT02664935|DRUG|Selumetinib|MEK Inhibitor
214867846|NCT02664935|DRUG|Docetaxel|Taxane, anti-mitotic cytotoxic chemotherapy
214867847|NCT02664935|DRUG|AZD5363|AKT Inhibitor
214867848|NCT02664935|DRUG|Osimertinib|EGFRm+ T790M+ Inhibitor
214867849|NCT02664935|DRUG|Durvalumab|Anti-PDL1
214867850|NCT02664935|DRUG|Sitravatinib|VEGFR Inhibitor
214867851|NCT02664935|DRUG|AZD6738|ATR inhibitor
214867852|NCT04702542|DRUG|Enteral oxygen therapy|Enteral oxygen therapy during the rehabilitation period of patients with CGDP.
214867853|NCT05619146|DEVICE|Motor-assisted arms and legs cycling|The participants will complete 60min of active cycling training paradigm, 5 times a week, for 12 weeks. The cycling ergometer will be used to provide motorized assistance during simultaneous arms and legs cycling to the participant while they are seated.
214867854|NCT05538065|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
214867855|NCT05538065|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
214867856|NCT05538065|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
214867857|NCT04424511|DRUG|Placebo|Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
214867858|NCT04424511|DRUG|Azithromycin|Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
214867859|NCT05949164|BEHAVIORAL|Insomnia|The primary exposure is insomnia
214867860|NCT05634057|DRUG|Anisodamine hydrobromide combined with heparin|The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
214867861|NCT06364696|DRUG|ASP4396|Intravenous (IV) infusion
215057176|NCT01175876|DEVICE|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
214290784|NCT04575922|DRUG|Ipilimumab|Administered into vein by intravenous infusion day 1 of each 6 week study cycle.
214867862|NCT06168409|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~• 2 mg per tablet."
214867863|NCT06168409|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
214867864|NCT01565655|DRUG|peficitinib|oral
214867865|NCT01565655|DRUG|Placebo|oral
214867866|NCT05199311|DRUG|Carfilzomib|20 mg/m2 C1D1; 56 mg/m2 thereafter
214867867|NCT05199311|DRUG|Iberdomide|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
214867868|NCT05199311|DRUG|Oral Dexamethasone|40 mg (\<=75 years old); 20 mg (\>75 years old)
214867869|NCT06616896|DEVICE|vibration|Each participant will randomly receive four different vibration conditions (2 frequencies × 2 vibration modes = 4 conditions) in a different order. Considering that the current research range of local vibration frequency is 10 to 150 Hz the frequencies with low and high frequencies (30/60Hz) will be selected. The location chosen for this study is the quadriceps muscle belly. Two-minute vibrations will improve muscle strength without any fatigue side effects. Two vibration modes include providing a two-minute continuous vibration intervention and only providing vibration during the rest position before executing the functional test.
214867870|NCT03226028|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlists of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
214867871|NCT05635383|OTHER|PERIPHERAL NERVE BLOCK|Observation of rebound pain after peripheral nerve block application
214867872|NCT04170751|DRUG|16 mcg / cc of norepinephrine(group N)|In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
214867873|NCT04170751|DRUG|0.4 unit / cc of vasopressin(group V)|In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
214867874|NCT04197817|DRUG|JS002|JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design
214867875|NCT04197817|DRUG|Placebo|Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
215034860|NCT03100279|BEHAVIORAL|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
215034861|NCT01606241|DRUG|Cyclophosphamide|Given PO
215034862|NCT01606241|OTHER|Laboratory Biomarker Analysis|Correlative studies
215034863|NCT01606241|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
215034864|NCT05318287|BEHAVIORAL|Walk with Me|Walk with Me is a perinatal grief mobile application to provide supportive care to bereaved parents. The application includes modules to guide bereaved parents through strategies to help support them through their grieving.
215034865|NCT05185453|BEHAVIORAL|Strengthening Connections for Change|Strengthening Connections for Change is a 12-session curriculum designed to strengthen adolescent-adult support networks, build leadership skills, foster community engagement, and challenge attitudes and behaviors that foster violence involvement. During the program, youth ages 13-17 years invite their self-identified key adult supports to jointly participate in programming including youth-focused, adult-focused and jointly focused activities. Towards the end of programming participants design and carry out a community project to strengthen intergenerational connections and promote community engagement.
215034866|NCT05185453|BEHAVIORAL|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
215034867|NCT06596525|OTHER|Conventional physical therapy|"Conventional physical therapy program will include:~1. Stretching exercises (forearm pronators, ulnar deviators, shoulder internal rotators, hip flexors and adductors, and hamstring muscle groups)~2. Strengthening exercises (ankle dorsiflexors, knee extensors, and hip flexor muscle groups)~3. Posture exercises~4. Balance and proprioception exercises~5. Walking training, obstacle crossing training, stair climbing and descending exercises"
215034868|NCT06596525|OTHER|Barefoot Whole Body Vibration Training (WBVTb)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will be barefoot. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
215034869|NCT06596525|OTHER|Shod Whole Body Vibration Training (WBVTs)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will wear everyday sports shoes. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
215034870|NCT06596525|OTHER|Sham Whole Body Vibration Training (WBVTsh)|"During Sham WBVT; the same exercises that the intervention groups will receive on the vibration platform will be performed on the platform for the same duration (3 days per week for 15 minutes each session, over a period of 4 weeks) without the platform being activated."
215034871|NCT06983665|DRUG|Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.)|Single intravenous administration of 2.0 mg/kg in each period.
215034872|NCT06983665|DRUG|Reference product (AmBisome®, Astellas Pharma US Inc.)|Single intravenous administration of 2.0 mg/kg in each period.
215034873|NCT04652765|DRUG|Camostat Mesilate|Camostat 600mg by mouth four times a day, for a total of 7 days
215034874|NCT04652765|DRUG|Bicalutamide 150 mg|Bicalutamide 150mg by mouth once daily, for a total of 7 days
215057177|NCT01175876|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
214867876|NCT03963024|DRUG|"Conditioning treatment Treosulfan-TMI"|Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0\* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)
214867877|NCT03963024|PROCEDURE|SCT|Stem Cell Transplant
214290785|NCT04575922|RADIATION|Radiation Therapy|3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
214476546|NCT06745960|OTHER|physical therapy program|neck exercises
214867878|NCT03963024|DRUG|GvHD prophylaxis|Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)
214867879|NCT06647394|PROCEDURE|Matrix Dressing|extracellular matrix dressing soaked in 4% topical lidocaine to the skin graft donor site
214867880|NCT04391530|BEHAVIORAL|emotional freedom technique, breathing therapy|emotional freedom technique, breathing therapy
214867881|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill|Pomegranate extract pill
214867882|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill placebo|Pomegranate pill placebo
214867883|NCT03465826|BEHAVIORAL|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
214867884|NCT03465826|BEHAVIORAL|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
214867885|NCT02808689|BEHAVIORAL|Lifestyle Factors|Will look at nutrition and exercise that influence long-term health and chronic diseases.
214867886|NCT02808689|OTHER|Customized use of Dietary Supplements|Reduce ongoing biologic imbalances from deficiencies in dietary oxidants/ antioxidants via vitamin supplementation. Approach is customized based on results for laboratory testing.
214867887|NCT02808689|OTHER|Currently Accepted Asthma Care Guidelines|Use of asthma care guidelines set forth by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) and Global Initiative for Asthma
214867888|NCT03898089|OTHER|Core Stability Exercise|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks. Traditional physiotherapy methods will be applied to all participants. Traditional physiotherapy will include heat modality (a hot pack for 15 minutes), electrotherapy (transcutaneous electrical nerve stimulation (TENS), a 50 Hz conventional TENS with a pulse duration \<150 microseconds).Each training session will be lasted 60 min, starting with a 10-min warm up program mainly consisting of core strength exercises and ending with a 5-min cool-down program (stretching). Progression of exercises will be tailored to individual patients' ability, fatigue and pain. Exercises will be designed from 1 set to 3 sets, from 8 to 15 repetitions and contractions from 5 seconds to 10 seconds.
214867889|NCT03898089|OTHER|Core Stability Exercise plus Myofascial Release Technique Group|In addition to the core stabilization exercise group myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks. The myofascial relaxation technique will be performed along the superficial back line (plantar fascia gastrocnemius muscles, hamstring muscles, sacrolumbar fascia, erector spinae muscles) bilaterally. Myofascial relaxation will be done to the anatomical structures indicated by roller massage technique. Applications will be made in 3 sets of 30sec for each zone (1 min rest between sets) and 7/10 according to VAS.
214867890|NCT01806766|PROCEDURE|Ceramic on Ceramic bearing|cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
214867891|NCT01806766|PROCEDURE|Ceramic on Highly crosslinked polyethylene bearing|Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
214867892|NCT00186095|PROCEDURE|autologous followed by nonmyeloablative allogeneic transplant|
214867893|NCT02183181|DRUG|Meloxicam capsule|
214867894|NCT02183181|DRUG|Meloxicam tablet|
214867895|NCT04645836|BEHAVIORAL|New management mode|"New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
214867896|NCT06408948|DRUG|[14C]SHR7280|Patients will receive single dose of orally \[14C\]SHR7280 on Day 1.
214867897|NCT04465695|DRUG|Interferon beta-1b|Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days
214867898|NCT04465695|DRUG|Clofazimine|Oral 100mg twice daily on day 1, then 100mg daily for 2 days
214867899|NCT05699486|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
214867900|NCT05699486|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
214867901|NCT00191113|DRUG|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
214867902|NCT00191113|DRUG|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
214867903|NCT00191113|DRUG|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
214867904|NCT06213272|BEHAVIORAL|Phono-Motor Therapy|The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
214867905|NCT06213272|BEHAVIORAL|Aerobic Exercise Training (AET)|Stationary ergometer cycling at 60% heart rate range for 20 minutes, plus 5 minutes of warm up and cool down.
214867906|NCT06213272|BEHAVIORAL|Stretching|Light stretching activities targeting the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
214867907|NCT04129229|DEVICE|LinguaFlex Tongue Retractor (LTR)|The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
214867908|NCT05460481|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
214290786|NCT01299792|OTHER|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
214290787|NCT03806140|BEHAVIORAL|text messages|receive about one health-related text message a day for 16 weeks
214867909|NCT03052010|OTHER|Integrated PrEP as a bridge to ART HIV-1 prevention strategy|The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
214867910|NCT03052010|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
214867911|NCT03052010|DRUG|ART|ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
214867912|NCT04996550|DRUG|Carvedilol|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
214867913|NCT04996550|DRUG|Metoprolol Succinate|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
214867914|NCT04055038|DRUG|Platinum-Based Drug|Reintroduction of platinum-based chemotherapy
214867915|NCT04055038|DRUG|Conventional chemotherapy|Conventional chemotherapy
215034875|NCT06570005|OTHER|Water Quality Assurance Fund|"* At the water system level: Written legal agreements between water systems, centralized laboratories, and the organization facilitating the Assurance Fund will provide water systems with regular water quality testing and provide laboratories a guarantee of payments if water systems fail to pay for testing services on time (for up to three concurrent unpaid invoices). Regular debrief meetings will be held with water operators and local government authorities to discuss test results and water treatment options, and to encourage water systems to share water quality information with their consumers. Technical guidance to improve water treatment will be provided, if requested by water system operators or local government authorities.~* At the community level: Community engagement, primarily at the onset, to inform the community about the water quality testing program and answer questions."
215034876|NCT06183021|PROCEDURE|Vital pulp cryotherapy|Shaved ice made from sterile distilled water will be applied around the treated tooth especially in contact with amputated pulp tissue until totally dissolves.
215034877|NCT06183021|PROCEDURE|Intracanal cryotherapy|After mechanical preparation, a 5-minute final irrigation with 20 mL cold saline (2.5 Centigrade degrees) will be applied using a negative pressure irrigation technique per canal.
215034878|NCT00391716|DRUG|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
215034879|NCT00391716|BEHAVIORAL|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
215034880|NCT00391716|DRUG|placebo|lactose capsule compounded to mimic gabapentin capsules
215034881|NCT00391716|DRUG|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
215034882|NCT03403738|BEHAVIORAL|Bounce Back Now|web/smartphone-based intervention for disaster victims
215034883|NCT03403738|BEHAVIORAL|enhanced usual care|enhanced usual care with list of resources
215034884|NCT02410187|RADIATION|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
215034885|NCT02410187|DRUG|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|"Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT."
215034886|NCT02410187|RADIATION|palliative RT|fraction size of RT = \< 3 Gy
215034887|NCT00349986|DRUG|Insuline glargine|
215034888|NCT01045733|DEVICE|AcrySof IQ Toric IOL|AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
215034889|NCT01045733|DEVICE|AcrySof IQ Aspheric IOL|AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
215034890|NCT01045733|PROCEDURE|Limbal Relaxing Incision (LRI)|An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
215034891|NCT03777605|DRUG|Nitroglycerin 0.4 MG|"The study evaluate absorption rate of nitroglycerine 0.4 milligrams as tablets or a quickly absorbable capsuel NTG1523 determined by T-max and area under the response curve in the blood of NTG as well as from clinical effects.~Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: The applicant's rights in a biomedical research project"
214290788|NCT06242951|DIAGNOSTIC_TEST|VO2 max assessment|Measurement of the maximum oxygen consumption (VO2max) by a cardiopulmonary exercise test (CPET)
214290789|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 intravenously
214867916|NCT02087995|DEVICE|Continuous Glucose Monitoring|A prescribed clinic session day for participating subjects.
214867917|NCT05498181|DRUG|Sacubitril-valsartan|sacubitril/valsartan
214867918|NCT05498181|DRUG|Placebo|Placebo
214867919|NCT02590250|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
214290790|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 intravenously
214290791|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 subcutaneously
214290792|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 subcutaneously
214290793|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
215034892|NCT03331887|PROCEDURE|E-max CAD endocrown|endocrown used to restore endodontically treated teeth with E-max CAD endocrowns
215034893|NCT03331887|PROCEDURE|E-max CAd crowns retained with fiber reinforced composite post|fiber reinforced composite post need to restore endodontically treated tooth with E-max crown
215034894|NCT00414154|BEHAVIORAL|Group based multidisciplinary patient education programme|
215034895|NCT06599320|OTHER|Oral rehabilitation with dental implants|Patients rehabilitated with implant-supported fixed partial dental prostheses
214867920|NCT06017310|DIAGNOSTIC_TEST|Evaluate the performance of IFN I/III|Evaluate the response in diagnosing non-respiratory viral infection.
214867921|NCT05176795|OTHER|Stool sample|Comparaison of the gut microbiota composition
215034896|NCT06816823|BIOLOGICAL|CL-NK-001|Dose level 1 (5 × 10\^8 cells); dose level 2 (15 × 10\^8 cells); dose level 3 (30 × 10\^8 cells); additional dose levels (investigator's discretion).
215034897|NCT06303453|OTHER|Balance exercises|Balance exercises includes active movements (flexion, extension, abduction, adduction) of one upper extremity and lower extremity, trunk movements (bending forward and rotation), raising heel, raising toes and raising heel. Every move in each session will be hold for 30 seconds. The part B comprises of training i.e., holding positions in standing posture which include moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand and throwing the ball against the wall with foot.
215034898|NCT06303453|OTHER|Resisted exercises|"The resistance training protocol include shoulder flexion and extension with 1 kg weight, shoulder pulley with 2 kg weight, arm curls with 1 kg weight, wall push-ups, bridging, hip abduction and adduction against resistance band, knee extensions and flexion in sitting position with resistance applied by contralateral limb, knee adduction and abduction with resistance band, mini squats, strengthening exercise for toes flexor and extensor (22), resisted inversion and eversion and straight leg raise (SLR) with 1 kg ankle weight (10).~Every move in each session comprises of 2 sets of 3 reps each and 1 set will be added at 4th and 8th week."
215034899|NCT02457793|DRUG|Cobimetinib|Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
215034900|NCT02457793|DRUG|GDC-0994|GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
215034901|NCT03997500|DRUG|normal saline|a bolus of normal saline was given followed by normal saline infusion
215034902|NCT03997500|DRUG|Norepinephrine|a bolus of norepinephrine was given followed by norepinephrine infusion
215034903|NCT04316143|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat
215034904|NCT06239649|PROCEDURE|Genicular nerve Radiofrequency Ablation block|Genicular nerve Radiofrequency Ablation block
215034905|NCT05849844|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure
215034906|NCT06669039|DEVICE|Computer-controlled Local Anesthetic delivery system|Local anesthesia will be delivered using Computer-controlled Local Anesthetic delivery system.
215034907|NCT06669039|PROCEDURE|Inferior Alveolar Nerve Block|Local anesthesia will be delivered using the conventional syringe
215034908|NCT06503510|OTHER|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
215034909|NCT06503510|OTHER|Cowhage|Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.
215034910|NCT06503510|OTHER|bovine adrenal medulla (BAM8-22)|A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
215034911|NCT02322840|DEVICE|Twelve TMVR Implant|Implantation of the Twelve TMVR System -Apical
215034912|NCT02322840|DEVICE|Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System|Implant of Intrepid valve -Transfemoral
214290794|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
214290795|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given 2 doses intravenously
214290796|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given 2 doses intravenously
214290797|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given doses of PF-06817024 intravenously
214290798|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given doses of Placebo intravenously
215034913|NCT00934180|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
215034914|NCT00934180|DRUG|Zofran®|1 x 8 mg ODT
215034915|NCT05497934|DRUG|Glycerol|In this study, 99.5% pure glycerol will be used as an optical clearing agent. The glycerol will be applied topically to the tympanic membrane.
214290799|NCT04073589|BIOLOGICAL|ARGX-113 with rHuPH20|subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
214290800|NCT05042167|OTHER|Resistance exercise|4 total resistance exercises that target all major muscle groups.
214290801|NCT05471622|BEHAVIORAL|Nudge for PHPC Referral|The case manager and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for Penn Home Palliative Care (PHPC) upon hospital discharge will be asked to refer their patient for these home palliative care services.
214290802|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
214290803|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
214290804|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
214290805|NCT01366170|GENETIC|microarray analysis|
214290806|NCT01366170|GENETIC|protein expression analysis|
214290807|NCT01366170|GENETIC|western blotting|
214290808|NCT01366170|OTHER|flow cytometry|
214867922|NCT03309995|DEVICE|Lozenges|The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
214867923|NCT03309995|DEVICE|Placebo lozenges|Placebo lozenges
215034916|NCT06613477|DRUG|PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease|Table 3: Digoxin dosing regimen based on optimized Cmin,ss Dose to be given twice daily (mcg/kg/dose) PNA\<30 days 30 days \< PNA \< 180 days eGFR≤40 1.4 1.4 40\<eGFR≤60 1.6 1.6 eGFR\>60 1.9 2.8
215034917|NCT00835172|DRUG|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
215034918|NCT00835172|DRUG|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
215034919|NCT04890509|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
215034920|NCT04890509|OTHER|SoC|The SoC will be administered based on local guidelines.
215034921|NCT06541197|OTHER|Robotic rehabilitation combined with Functional Electrical Stimulation (FES) bicycle ergometry group|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks. For FES bicycle ergometry, a current-controlled six-channel stimulator (RT 300-SLSA; Restorative Therapies, Baltimore, MD, USA) will be used. The quadriceps, hamstring and tibialis anterior muscles will be stimulated bilaterally with six channels through 3 × 4 cm2 adhesive surface electrodes. Stimulation intensity will be adjusted according to palpable muscle contraction and sensory discomfort felt by patients with incomplete SCI. The pedaling cadence range will be set to 40-50 rotations per minute. FES bicycle ergometry will be performed in 30-minute sessions for 4 weeks for a total of 20 sessions before robotic rehabilitation.
215034922|NCT06541197|OTHER|Robotic rehabilitation|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks.
214867924|NCT05585879|DEVICE|Pure-Vu EVS|"Subjects will be enrolled until 115 inadequate bowel prep cases via SOC are accrued and subsequently treated with Pure-Vu EVS. Inadequate OCs defined as such if any of the following are met:~* Boston Bowel Preparation Score (BBPS) \< 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~* Inability to identify \> 5mm polyps"
214867925|NCT04129359|BEHAVIORAL|FamilieTrivsel|FamilieTrivsel is a modular internet-based low-cost and brief psychoeducation intervention based on the Robusthed (Resilience) programme (RP). Mentalisation approaches are used to increase resilience and ability to handle the challenges of life. The programme is licence free and can be used with low or high intensity and it can be combined with any other interventions. RP provides simple explanations and tools that can be used to discover, understand and regulate one's own thoughts and feelings by activating mental and physical resources and it provides examples and exercises that may promote communication about mental states between parents and the child. The content has been developed to include video-based training sessions based on different stages of pregnancy and early childrearing. RP appears suitable for use in general practice, where the GP sees young parents regularly and thus can direct patients towards components of the programme when need appears greatest.
214867926|NCT04129359|OTHER|enhanced care as usual|Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice
215034923|NCT06672341|DIAGNOSTIC_TEST|Endometrial Cytology Testing|Endometrial Cytology Examination Liquid-based endometrial cytology is an emerging minimally invasive screening technique. This method involves collecting endometrial cells and tissues from the uterus and its downstream anatomical structures. The samples are preserved and analyzed using either liquid-based cytology techniques or tissue smear methods to reach a pathological diagnosis. Compared to invasive procedures such as fractional curettage, liquid-based cytology offers advantages in the screening of endometrial cancer, including being minimally invasive, convenient, and low-risk.
214867927|NCT01354379|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
214867928|NCT01354379|BIOLOGICAL|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
215034924|NCT06672341|DIAGNOSTIC_TEST|Cervical Methylation Testing|Cervical Cell Methylation Testing Cervical cell methylation testing is another promising method for methylation-based screening of endometrial cancer. This approach targets specific genes that undergo methylation in the early stages of endometrial cancer. The combined methylation analysis of four genes (CD01, BHLHE22, ACTB, and SEPTIN9) uses menstrual blood or vaginal secretions as samples, offering advantages such as safety, non-invasiveness, and self-collection. This method has shown high sensitivity and specificity for the early detection of endometrial cancer. Ongoing research suggests that the sensitivity and specificity of cervical cell methylation testing can reach 93.2% and 96%, respectively, although this data is yet to be published.
215034925|NCT06671119|DEVICE|Gastric Mucosal Ablation (GMA)|Endoscopic Gastric Mucosal Ablation (GMA) after sleeve gastrectomy
215034926|NCT06516198|OTHER|Auricular Acupressure|Seeds will be placed during the clinic visit by the acupuncturist or the research associate according to the group the patient was assigned to. The care partner will observe the placement. A photograph of the seed placement will be taken and given to the care partner and to the patient after the relevant points are labeled by number or letter. The method of pressing is demonstrated for 1 one of the seeds, the care partner practices pressing on 2 other seeds, and the patient practices pressing on the remaining 2 seeds. Pressing consists of applying pressure, gradually increasing the pressure until the patient expresses discomfort, and maintaining that pressure until 2 minutes have passed. After pressing has been performed for each seed, the seeds are removed in clinic prior to clinic discharge.
215034927|NCT06675916|PROCEDURE|PENG Block with lidocaine hydrochloride|Intervention is ultrasound-guided PENG block analgesia with lidocaine hydrochloride
215034928|NCT06675916|PROCEDURE|Intra-articular infiltration with lidocaine hydrochloride|Intervention is intra-articular analgesia with lidocaine hydrochloride
215034929|NCT06675786|DEVICE|I.V. House UltraDressing|I.V. House UltraDressing (I.V. House, Inc., St. Louis, MO, USA) will be applied according to the manufacturer's instructions and secured with an anti-slip tape without the need for further taping. It is intended to prevent complications such as catheter-related displacement, phlebitis, infiltration, extravasation, catheter occlusion, and folding of PVCs.
214867929|NCT02205190|DRUG|Fimasartan|
214290809|NCT01366170|OTHER|immunohistochemistry staining method|
214290810|NCT01366170|OTHER|laboratory biomarker analysis|
214290811|NCT01366170|OTHER|mass spectrometry|
214290812|NCT04019665|OTHER|MMSE (mini mental state examination)|mini mental state examination takes place during the consultation. The consultation is a general or post-emergency geriatric consultation.
214867930|NCT02205190|DRUG|Rosuvastatin|
214867931|NCT02205190|DRUG|Fimasartan/Rosuvastatin combination|
214867932|NCT02068235|DRUG|Ponesimod 5mg i.v.|
214867933|NCT02068235|DRUG|Ponesimod i.v.|Dose and infusion rate will be adjusted according to the results of the pilot phase
214867934|NCT02068235|DRUG|Ponesimod 10 mg tablet|
214867935|NCT00003602|DRUG|cytarabine|
214867936|NCT00003602|DRUG|etoposide|
214867937|NCT00003602|DRUG|idarubicin|
214867938|NCT00003602|DRUG|mitoxantrone hydrochloride|
214867939|NCT02598687|DRUG|TH-302|TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
214867940|NCT02598687|OTHER|HX4 scan|HX 4 scan day 1 and day 8
214867941|NCT02598687|DRUG|Carboplatin|2mg/ml/min
214867942|NCT02598687|DRUG|Paclitaxel|50 mg/m2
214867943|NCT02598687|RADIATION|Radiotherapy|23 x 1.8 Gy
214867944|NCT02598687|PROCEDURE|surgery|minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
214867945|NCT00991705|DRUG|Atorvastatin|
214867946|NCT00991705|DRUG|Fimasartan|
214867947|NCT02591186|PROCEDURE|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
215034930|NCT06673888|OTHER|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) is utilized for a variety of purposes, as luting agents, liners/bases, and restorative materials. The RMGI is more aesthetically pleasing than the conventional glass ionomer while maintaining the clinical benefits of the former, such as the release of fluoride, recharging capabilities, prevention of decalcification of hard tooth tissue, inhibition of bacterial acid metabolism, and ease of clinical operation.
215034931|NCT06673888|OTHER|alkasite based restorative material|Cention forte is bioactive restorative material which has the ability to remineralize hard dental tissues through calcium and fluoride release and can also neutralize bacterial acids through hydroxide ions release.
215034932|NCT06673992|OTHER|This study does not involve any interventions|This study does not involve any interventions
215034933|NCT06673875|PROCEDURE|conservative treatment of stress urinary incontinence - pelvic floor muscle training|evaluation of pelvic floor muscle rehabilitation to change the clinical severity of urinary incontinence
215034934|NCT06673875|DEVICE|vaginal device Aniball INCO|"the firt group - the pelvic floor muscle training with vaginal device Aniball INCO according manual after education by the urogynecologist, who is educated in pelvic floor dysfunction.~the second group - the pelvic floor muscle training without vaginal device, the education was performed by certified physiotherapist trained in pelvic floor disorder."
215034935|NCT06997926|PROCEDURE|blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
215034936|NCT07004439|DEVICE|RefluxStop™ implantation|Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use
215034937|NCT07004049|DRUG|Colistin/Polymyxin B + Sulbactam|For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand and Singapore
215034938|NCT07004049|DRUG|Colistin/Polymyxin B + Tigecycline/Eravacycline|For carbapenem-resistant Acintobacter, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand and Singapore
215034939|NCT07004049|DRUG|Colistin/Polymyxin B + Meropenem|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia and Singapore
215034940|NCT07004049|DRUG|Ceftazidime-avibactam + Sulbactam|For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand, Singapore and Australia.
215034941|NCT07004049|DRUG|Ceftazidime-avibactam + Fosfomycin|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Malaysia, Thailand and Singapore
215034942|NCT07004049|DRUG|Ceftazidime-avibactam|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.
214867948|NCT05339334|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days
214290813|NCT04019665|OTHER|SAGE (Self-Administered Gerocognitive Exam)|SAGE test contains a series of questions that assess the cognitive functioning. Sage was developed by the Ohio State University Wexner Medical Center. it's an online, at-home, self-screening dementia tool that has been scientifically evaluated, and it's demonstrated good results in accurately identifying cognitive deficits.
214867949|NCT00284024|DRUG|domperidone|
214867950|NCT06328179|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；|VHEA -Induction Phase Regimen/Consolidation therapy after remission
214867951|NCT03786718|OTHER|Patient-facing Diabetes Dashboard|The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
214867952|NCT05258903|PROCEDURE|Ulnar artery cannulation|Ulnar artery will be cannulated under USG guidance
214867953|NCT05258903|PROCEDURE|Radial artery cannulation|Radial artery will be cannulated under USG guidance
214867954|NCT03987321|DEVICE|Infrarenal vena cava filter placement|Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
214867955|NCT06349590|DIETARY_SUPPLEMENT|High-fiber/low-fat meals|Meals with Low fat/High fiber
214867956|NCT00368979|DRUG|Dutasteride|once daily
214867957|NCT00368979|DRUG|Placebo|once daily
214867958|NCT05408936|DRUG|SGLT2 inhibitor|Patients receive an SGLT2 inhibitor as part of theirn routine care.
214867959|NCT05013437|DRUG|Evomela|16 mg/m\^2 Evomela administered one time via a central line
214867960|NCT05013437|DEVICE|Next Generation Sequencing|Next Generation Sequencing
214867961|NCT05013437|DRUG|Prochlorperazine|10mg once intravenous (IV) within 30 minutes before Evomela
214867962|NCT05013437|DRUG|Acetaminophen|650 mg once orally within 30 minutes before Evomela
214867963|NCT05013437|DRUG|Diphenhydramine|50 mg once intravenously within 30 minutes before Evomela
214867964|NCT01853800|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|
214867965|NCT00945100|DEVICE|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
214867966|NCT00945100|DEVICE|Eye Patch|2 hours patching daily
214867967|NCT05938907|OTHER|concentrated growth factor|Implanting concentrated growth factor into the area of root apical bone defect
214867968|NCT05938907|OTHER|bone substitute|Implanting bone substitute into the area of root apical bone defect
215034943|NCT07004049|DRUG|Ceftazidime-avibactam + Aztreonam|For carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.
215034944|NCT07004049|DRUG|Ceftazidime-avibactam + Colistin/Polymyxin B|For carbapenem-resistant Pseudomonas aeruginosa in China, Malaysia, Thailand, Singapore and Europe.
214867969|NCT05938907|COMBINATION_PRODUCT|concentrated growth factor + bone substitute|Implanting concentrated growth factor + bone substitute into the area of root apical bone defect
214867970|NCT05252598|DRUG|Psilocybin|1mg encapsulated psilocybin
214867971|NCT05252598|DRUG|Inonotus Obliquus Whole Extract|1mg encapsulated chaga mushroom
215034945|NCT07004049|DRUG|High-dose meropenem|For carbapenem-resistant Enterobacterales infection in Europe
215034946|NCT07004049|DRUG|Meropenem + Fosfomycin|For carbapenem-resistant Enterobacterales in Europe
215034947|NCT07004049|DRUG|Meropenem-vaborbactam|For carbapenem-resistant Enterobacterales infection in Europe
215034948|NCT07004049|DRUG|Cefiderocol|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Europe and Australia.
215034949|NCT07004049|DRUG|Ceftolozane-tazobactam|For carbapenem-resistant Pseudomonas aeruginosa in Europe and Australia.
215034950|NCT07004049|DRUG|Ceftolozane-tazobactam + Meropenem|For carbapenem-resistant Pseudomonas aeruginosa in Europe.
215034951|NCT07005375|BEHAVIORAL|thermal mineral water bath|One group will bathe in a pool filled with 36°C thermal mineral water of the Palatinus Spa for 3 weeks, 5 days a week, for a total of 15 sessions, 20 minutes per session. Bathing in the thermal mineral water takes place in the medicinal water pool. The control group does not receive balneotherapy. Both groups can continue their usual training plan.
215034952|NCT06674590|PROCEDURE|Proprioceptive Neuromuscular Facilitation|PNF of 30 minutes duration will given in a single session. Pelvic anterior elevation and posterior depression of the hemiplegic side. rhythmic initiation slow reversal agonistic reversals Pelvic anterior depression and posterior elevation of the hemiplegic side. The first diagonal (D1): Flexion and extension The second diagonal (D2): Flexion and extension 4 session per week
215034953|NCT06674590|PROCEDURE|Motor Relearning Program|Motor Relearning Programme (MRP) This is a task-oriented approach to help the control of movement, focusing on the relearning of daily activities.
215034954|NCT06675838|BEHAVIORAL|Time Management and Procrastination Behavior Management Training|"Intervention Content~Training Program Name: Time Management and Procrastination Behavior Management Training Duration: 3 sessions of 1 hour each, 5-day program Target Audience: Intern Nurses~Training Content:~Fundamentals of Time Management:~Definition and importance of time management. Key principles for effective use of time (prioritization, time blocking, planning).~Understanding Procrastination Behavior:~Definition and reasons for procrastination behavior. Effects of procrastination on student success.~Time Management Strategies:~Task Prioritization: Differentiating between urgent and important tasks. Time Blocking: Completing specific tasks in designated time slots. Daily Planning: Organizing daily tasks and activities.~Managing Procrastination Behavior:~Identification and analysis of procrastination habits. Coping strategies for procrastination (e.g., goal setting, increasing motivation, self-rewarding).~Effective Teaching Techniques:~Presentations and Information Sharing"
215034955|NCT03077061|PROCEDURE|Open flap debridement|Open flap debridement using saline as irrigation
215034956|NCT03077061|DEVICE|Bone replacement graft|Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
214867972|NCT06633432|OTHER|Acupuncture|Administer medication at each acupoint a total of three times: (1) the night before surgery, (2) the night of surgery, and (3) the first night after surgery. In the acupuncture group, the acupuncture and moxibustion successively acupunctured four points with a depth of 10-20mm. Select the specific depth based on the subject\&#39;s body type (tall, short, fat, thin). After the puncture, the acupuncture and moxibustion lifted and twisted the needle handle, and then retained the needle for 20 minutes.
215034957|NCT05317858|DEVICE|Blood Brain Barrier Opening - Oncology|BBB opening via Exablate Type 2 system with microbubble resonators on the day of ICI infusion to treat brain metastases.
215034958|NCT05317858|DRUG|Pembrolizumab|Pembrolizumab infusion
215034959|NCT05317858|DRUG|Atezolizumab|Atezolizumab infusion
215034960|NCT05317858|DRUG|Cemiplimab|Cemiplimab infusion
215034961|NCT05317858|DRUG|Nivolumab|Nivolumab infusion
215034962|NCT05317858|DRUG|Iptilimumab|Iptilimumab infusion
215034963|NCT07010029|DEVICE|Coronary Sinus Reducer|Patients will undergo implantation of Coronary Sinus Reducer
215034964|NCT07009730|PROCEDURE|Bypassing Agents|Cardiopulmonary bypass surgery, pulsatile flow
214867973|NCT06633432|OTHER|Sham-acupuncture stimulation|The sham acupuncture group received non skin breaking comfort needles at the corresponding points for acupuncture and moxibustion and retained the needles for 20 minutes. Non transdermal comfort needles can cause patients to experience a needle like sensation similar to piercing the skin, but in reality, they do not break the skin.
214867974|NCT00375895|DRUG|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
215034965|NCT06674330|OTHER|concentration of teicoplanin|post analysis of concentration of teicoplanin
215034966|NCT07011433|DIAGNOSTIC_TEST|Inflammatory Biomarker Evaluation|Venous blood samples are collected from subjects and analyzed for inflammatory biomarkers, including CD64, presepsin, IL-6, and IL-8, using a Luminex multiplex assay. Results are used for research purposes only and do not affect clinical management.
215034967|NCT03274466|DEVICE|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
215034968|NCT03274466|DEVICE|Standard of Care Dressing|A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
215034969|NCT03057340|BIOLOGICAL|Dribble vaccine|DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
215034970|NCT01096251|BEHAVIORAL|CBT vs BST|The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
214665615|NCT03664726|BEHAVIORAL|Scarcity Narrative|Participants will read a narrative to induce a scarcity mindset, in which they are asked to imagine a scenario in which they have lost their job and have no current secondary income.
215034971|NCT05604703|DIAGNOSTIC_TEST|Periodontal classification|300 patients will be classified according to 1999 armitage and 2018 new periodontal classification and compared.
214867975|NCT03724214|COMBINATION_PRODUCT|Pre-hospital interventional care bundle|"The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment.~Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres.~Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol."
214867976|NCT03724214|COMBINATION_PRODUCT|In-hospital interventional care bundle|"In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme.~In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available."
214867977|NCT02516943|OTHER|Control|The patient's ABGs were test according to a 4 - hour routine
215034972|NCT02229357|BIOLOGICAL|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
215034973|NCT05589909|DIAGNOSTIC_TEST|IL27, PCT, CRP, Blood culture|magnetic bead multiplex platform
214867978|NCT02516943|OTHER|Guideline|The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
214867979|NCT06505070|BEHAVIORAL|Recreational Games|"40 individuals in the intervention group were introduced to 15 games. Researchers conducted these sessions and provided participants with instructions and rules for the games. Then, they were asked to rate the games from 1 to 10. In this form, the elderly individuals evaluated the games by determining the minimum 1 and maximum 10 points according to their interest and willingness to play. Thus, it was ensured that individuals freely choose the games they want to play. As a result, bingo, matching pairs, word challenges and hot-cold games, which received the highest scores from the participants, were selected to be played."
215034974|NCT01926860|BIOLOGICAL|Prevenar13|
215034975|NCT01926860|BIOLOGICAL|Hepatitis A vaccine|
215034976|NCT04670796|DRUG|HLX02|subject receive one dose of HLX02
215034977|NCT04670796|DRUG|EU-sourced Trastuzumab (Herceptin®)|subject receive one dose of EU-sourced Trastuzumab (Herceptin®)
215034978|NCT04670796|DRUG|US-licensed Trastuzumab (Herceptin®)|subject receive one dose of US-licensed Trastuzumab (Herceptin®)
215034979|NCT01595477|BEHAVIORAL|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
215034980|NCT01312480|OTHER|5A's Model|"The smoking cessation intervention is based on the 5A's model, which includes the following elements:~1. Ask if the patient smokes.~2. Advise every patient to quit.~3. Assess readiness to quit.~4. Assist in quitting and finding services.~5. Arrange for cessation services and follow-up."
215034981|NCT01312480|OTHER|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
215034982|NCT06288568|OTHER|No intervention|No intervention
215034983|NCT06571942|DRUG|Vilanterol / Umeclidinium (25/62.5 mcg)|One inhalation daily from Ellipta device for three months
215034984|NCT06571942|DRUG|Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)|One inhalation daily from Ellipta device for three months
215034985|NCT06571942|DRUG|Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg|Two inhalations twice daily form pMDI device for three months
215034986|NCT06571942|DRUG|Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg|Two inhalations twice daily form pMDI device for three months
214867980|NCT04086407|DEVICE|Dual-axis inclinometer attached to the subject's forehead with tape|This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
214867981|NCT02668588|DRUG|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
214867982|NCT02668588|DRUG|extended release of placebo|1 intramuscular injection of extended release of placebo
215034987|NCT02238301|OTHER|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
215034988|NCT02238301|OTHER|Bold + ASL sequence|"A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
215034989|NCT04389463|OTHER|No intervention|No description
215057178|NCT04774588|OTHER|VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.|1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
215034990|NCT02695836|OTHER|Initial face-to-face dissemination workshop|Managers and directors of care will receive a printed report (tailored to their facility) on their facility's performance and performance of each unit (microsystem) within that facility. The workshop will include a presentation of the feedback reports with a particular focus on the core set of actionable context targets (Formal Interactions, Evaluation, Social Capital, Organizational Slack (OS) - Time) in the face-to-face workshops. Following the presentation, participants will discuss their reports in facilitated, round-table group discussions to a) help with interpretation of the results overall, b) draw attention to elements of context that are modifiable, c) encourage microsystem teams to work on improving the more modifiable areas
215034991|NCT02695836|OTHER|Face-to-face goal setting workshop|Sessions will build on the dissemination workshops and will be held three months after. Feedback reports on Formal Interactions, Evaluation, Social Capital, and Organizational Slack (OS) - Time will be discussed. Small group activities will take place including: a) reflecting on context data, b) performance goal setting using the 'tell and sell' method, which capitalizes on the workshop leaders' perceived expertise about what goals are achievable, c) establishing a series of proximal learning goals that will provide teams with explicit strategies for attaining performance goals set in (b). An action plan and instructions for reporting back at the Virtual Support Workshop will be provided.
215034992|NCT02695836|OTHER|Virtual support workshops|On virtual support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges.
215034993|NCT02695836|OTHER|Face-to-face support workshops|On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.
215034994|NCT02695836|OTHER|On-demand email and telephone support|Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
215034995|NCT05755984|DIAGNOSTIC_TEST|3D printed model|scan
215034996|NCT00410683|OTHER|clinical observation|
215034997|NCT00410683|PROCEDURE|adjuvant therapy|
215034998|NCT00410683|RADIATION|3-dimensional conformal radiation therapy|
215034999|NCT02647502|OTHER|Diet|Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
215035000|NCT05215145|BEHAVIORAL|Baby Navigator Bundle|The Baby Navigator Bundle includes 1) Baby Navigator, an online collection of resources: videos, growth charts, milestones, short articles, checklists, tools, and tips to help families promote early learning. Tools are customized to the child's age (in months). Baby Navigator can be found at https://babynavigator.com. 2) Social Communication (SoCo) Growth Charts is a self-guided app for parents of babies from birth to 24 months. Parents can watch video clips of early milestones and chart their child's social communication development. 3) Baby Navigator Webinars are held twice a month. Parents can learn how to support their child's growth from birth to 24 months. Content and videos focus on social communication milestones. Expert-led sessions cover a range of topics: gestures and sounds babies need to learn to talk, everyday activities that encourage learning, getting ahead of the Terrible Twos, and how Baby Navigator can help families.
215035001|NCT05215145|BEHAVIORAL|Baby Navigator Bundle + Individual-ESI|Continued Baby Navigator Bundle. Addition of ESI mobile coaching. ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that session's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are also invited to and guided through the Autism Navigator How-To Guide for Families online course.
215035002|NCT03336229|BEHAVIORAL|Exercise intervention|Graduated walking programme, strengthening exercises and respiratory muscle training.
215035003|NCT06535854|DEVICE|Prevail DCB|The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.
215035004|NCT06535854|DEVICE|Agent DCB|The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
215035005|NCT06548711|OTHER|Transcutaneous Acupoint Electrical Stimulation (TAES)|Transcutaneous acupoint electrical stimulation (TAES) is a non-invasive treatment method that delivers gentle electrical pulses through the skin to specific acupuncture points on the body. This technique aims to mimic the effects of traditional acupuncture, providing a convenient and painless method of treatment.
215035006|NCT02499926|DIETARY_SUPPLEMENT|Arginine|"Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals."
215035007|NCT02499237|DRUG|Denosumab|Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
215035008|NCT02499237|DRUG|Zoledronic acid|Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
215035009|NCT00730327|DEVICE|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
215035010|NCT00730327|OTHER|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
215035011|NCT02705963|DRUG|Trametinib|Each tablet is 2mg trametinib to be taken orally once daily.
214867983|NCT05337371|DEVICE|ECG patch (Philips ePatch® 2.0)|The ECG patch will be put on the patients chest to monitor cardiac activity for a total time period of 14 days after cardiac arrest.
214867984|NCT01596660|DRUG|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
214867985|NCT01596660|DRUG|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
214867986|NCT05021718|OTHER|Strengthening exercises|Back and hip strengthening exercises. The intensity of exercises was based on the exercise tolerance and pain thresholds of the individual subjects.
214867987|NCT05021718|DRUG|Pharmacological therapy|Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks
214867988|NCT05021718|OTHER|Hot compression|Hot moist compression from week 4 to week 6.
214867989|NCT05021718|BEHAVIORAL|Activities to daily living instructions|"* Avoid forward bending.~* Avoid heavy weightlifting.~* Avoid prolong standing.~* Avoid prolong sitting.~* Use a plain firm bed.~* Lie down in a supine position."
214867990|NCT02684630|DEVICE|Trima Accel System|Platelet Apheresis Procedure
214867991|NCT04593576|OTHER|Physical activity protocol/out door sports|"Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week."
214867992|NCT04593576|OTHER|Intensive table teaching speech therapy|Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
214867993|NCT01531439|DRUG|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
214867994|NCT01531439|DRUG|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
214867995|NCT03268707|DEVICE|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
214867996|NCT03268707|OTHER|Conventional follow up|Conventional follow up at physician practice
214867997|NCT03624959|DRUG|Ozanimod|ozanimod
214867998|NCT03624959|DRUG|Gemfibrozil|Gemfibrozil
214867999|NCT03624959|DRUG|Itraconazole|Itraconazole
214868000|NCT03624959|DRUG|Rifampin|Rifampin
214868001|NCT03796598|DRUG|Fecal Microbial transplant Capsules|Oral capsules of FMT
214868002|NCT03796598|DRUG|Fecal Microbial Transplant Enema|FMT enema
214868003|NCT03796598|OTHER|Placebo|Placebo
214868004|NCT02131350|PROCEDURE|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
215035012|NCT02705963|DRUG|Trametinib|Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
214868005|NCT02131350|DRUG|Ranibizumab|
214868006|NCT04358055|DEVICE|WET® gel|In each application, a puff should be administered in each nostril every two seconds, with minimal inspirations, up to a sensation of lubrication in the external conduct is perceived. Then the patient should proceed with short inspirations and light touching of ala of the nose, to favour the distribution of the gel. A maximum of 4 erogations (2/nostril) is allowed in each application session.
214868007|NCT02904941|BIOLOGICAL|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
214868008|NCT02904941|DEVICE|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
214868009|NCT02904941|PROCEDURE|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
214868010|NCT01570686|DRUG|Aliskiren|Aliskiren 300 mg once daily
214868011|NCT00801359|PROCEDURE|Phacoemulsification|
214868012|NCT00801359|DRUG|BSSPlus solution|
214868013|NCT00801359|DRUG|Lactated Ringer's solution|
214868014|NCT05035342|BIOLOGICAL|Fecal Microbiota Transplantation (FMT) capsules|Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).
214868015|NCT05035342|BIOLOGICAL|Placebo capsules|"The placebo FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules."
214868016|NCT01916590|DRUG|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
214868017|NCT01916590|DRUG|placebo|
214868018|NCT00486317|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
214868019|NCT02208232|PROCEDURE|cataract surgery|cataract surgery with implantation of intraocular lens
214868020|NCT03279211|OTHER|Whey Protein Isolate 894 Fonterra|30 g of protein powder diluted in water
214868021|NCT03279211|OTHER|Zein Sigma-Aldrich W555025|30 g of protein powder diluted in water
214868022|NCT03279211|OTHER|Protein-free test-meal|No protein included in the drink made of water and flavour/sugar
214868023|NCT00097877|DRUG|biphasic insulin aspart|
214868024|NCT00097877|DRUG|insulin glargine|
215035013|NCT02705963|DRUG|Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)|Combined oral contraceptive to be taken orally once daily.
215057179|NCT04103151|DEVICE|Single lead ECG|Heart Rate Variability will be monitored using a single lead electrocardiogram
215057180|NCT02144402|OTHER|infant formula with DHASCO|
215035014|NCT06153264|OTHER|neurodynamic mobilization exercise|Upper extremity neurodynamic mobilization exercises and upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
214868025|NCT05763186|OTHER|Sampling|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
214868026|NCT05763186|OTHER|Sampling and rinsing|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
214868027|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
214868028|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
214868029|NCT05686083|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
214868030|NCT05686083|DIETARY_SUPPLEMENT|Novel ketone di-ester|Novel ketone di-ester
214868031|NCT00000386|BEHAVIORAL|Exposure and Response Prevention|
214868032|NCT00000386|BEHAVIORAL|Family Treatment Program|
214868033|NCT00000386|BEHAVIORAL|Relaxation Training|
214868034|NCT00000386|BEHAVIORAL|Behavior therapy|
214868035|NCT00000386|BEHAVIORAL|Family Counseling|
214868036|NCT02901964|OTHER|Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
214868037|NCT02901964|OTHER|Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
214868038|NCT06430359|DIAGNOSTIC_TEST|urine and blood test|3 urine collections of an 8h period. One blood sample for liver function test and copper assessment
214868039|NCT01299259|BEHAVIORAL|Text Message Reminders|Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
214868040|NCT02815358|OTHER|Segmental Stabilization Exercises|The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.
214868041|NCT02815358|OTHER|Home Exercises|Home exercises include passive stretching and active mobilization of the spine.
214868042|NCT03884452|DRUG|Atorvastatin|Tablets taken orally once daily in the morning
215035015|NCT06153264|OTHER|strengthening exercises|upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks
215035016|NCT04394494|OTHER|Motor Imagery. Imaging doing Extension exercises without actually doing them.|This study will compare imagining doing specific extension based exercises for LBP vs. actually performing the exercises. This intervention will be just imaging doing the exercises.
214290814|NCT04667650|OTHER|Use of nomogram for predictions of Ocular Mysathenia Gravis generalization|The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.
214290815|NCT04111484|OTHER|Adrenomedullin|Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
214290816|NCT04111484|OTHER|Saline|Placebo
214290817|NCT05173402|DEVICE|dentoalveolar compensation method|orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw
214290818|NCT05173402|DEVICE|face mask|orthopedic treatment was performed using a face mask.
214868043|NCT03884452|DRUG|Simvastatin|Tablets taken orally once daily in the morning or evening
214868044|NCT03884452|DRUG|Ezetimibe|Tablet taken orally once daily in the morning or evening
214868045|NCT03884452|DRUG|Placebo for Ezetimibe|Tablets taken orally once daily in the morning or evening
214868046|NCT01108406|DEVICE|Sonitus SoundBite System|Non Surgical Bone Conduction Device
214868047|NCT01108406|DEVICE|SoundBite Hearing System|
214868048|NCT04137016|OTHER|Mobile application|
214290819|NCT00019578|PROCEDURE|Sterotactic radiosurgery|
214290820|NCT01411111|DRUG|Rosuvastatin 10 mg|days 1-14
214290821|NCT01411111|DRUG|GSK2190915 30mg|1x30mg tablet, days 8-14
214290822|NCT01411111|DRUG|GSK2190915 100mg|1x100mg tablet, days 8-14
214290823|NCT00751751|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
214868049|NCT05211414|BEHAVIORAL|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
214868050|NCT01455311|PROCEDURE|EUS Guided Fine Needle Aspiration|EUS-guided fine needle aspiration of the cyst fluid
214868051|NCT01455311|PROCEDURE|EUS Guided EchoBrush Sampling|EUS-guided brushing of the cyst wall
215035017|NCT04394494|OTHER|Control: Physically performing extension based exercises.|This study will compare imagining doing specific extension based exercises for LBP vs. actually doing them. This intervention will be actually, physically performing the exercises.
215035018|NCT04448951|OTHER|transcriptomics|transcriptomics
215057181|NCT02144402|OTHER|infant formula with DHASCO-B|
215035019|NCT04448951|OTHER|flow-cytometry|peripheral blood myeloid cells and lymphocytes flow-cytometry
214868052|NCT04310969|DEVICE|MiBoFlo Thermoflo|Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.
215035020|NCT04448951|OTHER|cytokines|peripheral blood cytokine analysis
215035021|NCT00925275|DRUG|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
215035022|NCT03773419|BEHAVIORAL|Texting Intervention (T-WRITE)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using a cellular phone
215035023|NCT03773419|BEHAVIORAL|HandWriting Intervention (ORLA+WTG)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using pen and paper
215035024|NCT04868422|DEVICE|Telemonitoring via wireless internet-based system|
215035025|NCT02552225|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
215035026|NCT02552225|OTHER|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
215035027|NCT03035747|PROCEDURE|conventional surgery|high ligation and stripping of incompetent saphenous veins
214868053|NCT04310969|PROCEDURE|forceful expression of the meibomian glands|Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
214868054|NCT04310969|DEVICE|LipiFlow|LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
215035028|NCT03035747|PROCEDURE|endovenous laser ablation|endovenous laser ablation of incompetent saphenous veins
215035029|NCT03035747|PROCEDURE|sclerotherapy|ultrasound guided or catheter or or any other methods sclerotherapy of incompetent saphenous or varicose veins
215035030|NCT03035747|PROCEDURE|endovenous radiofrequency ablation|endovenous radiofrequency ablation of incompetent saphenous veins
215035031|NCT03035747|PROCEDURE|phlebectomy|hooks phlebectomy of varicose veins
215035032|NCT02085863|DRUG|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
215035033|NCT02085863|DRUG|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
215035034|NCT04423432|OTHER|Lower Extremity Resistance Exercise Training|3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)
215035035|NCT04423432|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~1. AROM isolated knee extension and knee flexion~2. Isometric isolated knee extension and knee flexion~3. Isometric terminal knee extension~4. Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)"
215035036|NCT04423432|DEVICE|Electrotherapy + Heating|Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes
215035037|NCT04423432|PROCEDURE|Joint Mobilization|"1. Tibio-femoral Anterior Glide~2. Tibio-femoral Posterior Glide~3. Patellofemoral Joint Mobilization"
215035038|NCT04423432|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
215035039|NCT04423432|DIETARY_SUPPLEMENT|Glucoseamine/ Chondritin Sulfate Supplementation|Glucoseamine/ Chondritin Sulfate Supplementation (500mg+400mg/day)
214868055|NCT00442039|DRUG|Lithium Carbonate|The starting dose of lithium was 300 mg for patients weighing \< 20 kg
214868056|NCT00442039|DRUG|Lithium Carbonate|"The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability"
214868057|NCT00442039|DRUG|Lithium Carbonate|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
214868058|NCT00442039|DRUG|Placebo|During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
215035040|NCT02989857|DRUG|AG-120|Tablet administered orally
215035041|NCT02989857|DRUG|Placebo|Tablet administered orally
215035042|NCT01163942|DRUG|G-CSF|Yes/no addition of G-CSF
215035043|NCT01163942|DRUG|Early retreatment with ATG|Yes/no early retreatment with ATG
215035044|NCT00043602|BEHAVIORAL|Standard interpersonal psychotherapy (IPT)|Participants will receive 12 sessions of IPT over 12 weeks.
215035045|NCT00043602|BEHAVIORAL|Clinician managed interpersonal psychotherapy (CM-IPT)|Participants will receive 12 sessions of CM-IPT over 1 year.
215035046|NCT01880463|DRUG|Omega-3 fatty acids (fish oil)|
215035047|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3|
215035048|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
215035049|NCT01880463|DRUG|Fish oil placebo|
215035050|NCT02682056|DEVICE|Microneedle patch|The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
215035051|NCT02682056|DEVICE|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
215035052|NCT02682056|DEVICE|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
215035053|NCT02746315|DRUG|HS-20004|
215035054|NCT02746315|DRUG|Placebo|
215035055|NCT00664950|DEVICE|sliding hip screw|surgical repair of hip fracture using conventional sliding hip screw
215035056|NCT00664950|DEVICE|IntertAn IM nail|interTAN IM nail
215035057|NCT04942002|DRUG|Methylprednisolone Acetate 40 MG/ML [Depo-Medrol]|Retrobulbar injection performed by care provider
214868059|NCT01209130|DRUG|DCDT2980S|Intravenous repeating dose
214868060|NCT01209130|DRUG|rituximab|Intravenous repeating dose
214868061|NCT01036139|DRUG|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
214868062|NCT05213455|BIOLOGICAL|booster vaccine for COVID 19|The effect of Booster vaccine will be seen in participants in terms of antibody response IgG
214868063|NCT02029014|DEVICE|LAA closure system|
214868064|NCT00000114|DRUG|Vitamin E|
214868065|NCT00000114|DRUG|Vitamin A|
214868066|NCT00128050|DRUG|rFactor VIIa (Eptacog alfa, NovoNordisk)|rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
214868067|NCT00128050|DRUG|rFVIIa|Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
214868068|NCT00128050|OTHER|Sodiun chloride 0.9%|Bolus injection of sodium chloride 0.9% after surgical hematoma removal
214868069|NCT01774552|DEVICE|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
214868070|NCT01915706|PROCEDURE|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
214868071|NCT01136967|DRUG|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
215035058|NCT04942002|DRUG|Placebo Comparator: Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution by care provider
215035059|NCT03873545|PROCEDURE|Cryopreserved Osteochondral Allograft|This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.
215035060|NCT01882816|RADIATION|IMRT|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC
215035061|NCT01882816|DEVICE|DWI MRI|The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.
215035062|NCT01882816|DRUG|Doxorubicin|Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
215035063|NCT01882816|OTHER|Modified Barium Swallow Impairment Profile (MBSImP)|The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.
214868072|NCT02346591|BEHAVIORAL|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
214868073|NCT02346591|BEHAVIORAL|Online stress management information|Online educational information about stress management
214868074|NCT02885181|DRUG|GS-9876|One tablet administered orally once daily
214868075|NCT02885181|DRUG|Filgotinib|Two tablets administered orally once daily
214868076|NCT02885181|DRUG|GS-9876 placebo|One tablet administered orally once daily
214868077|NCT02885181|DRUG|Filgotinib placebo|Two tablets administered orally once daily
214868078|NCT02885181|DRUG|Methotrexate|Background therapy with methotrexate administered orally or parenterally once weekly
214868079|NCT00570895|DIETARY_SUPPLEMENT|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
214868080|NCT02618135|OTHER|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
215035064|NCT04548908|DIAGNOSTIC_TEST|Serelogy testing, RT PCR|Serology testing for all the participants and RT PCR for participants with symptoms
215035065|NCT00002325|DRUG|Fluconazole|
214290824|NCT00751751|DRUG|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
214290825|NCT04446546|PROCEDURE|Vascular access by pass using a cold stored venous allograft|Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft
214290826|NCT00070174|DRUG|asparaginase|
214290827|NCT00070174|DRUG|busulfan|
214290828|NCT00070174|DRUG|cyclophosphamide|
214290829|NCT00070174|DRUG|cyclosporine|
214290830|NCT00070174|DRUG|cytarabine|
214290831|NCT00070174|DRUG|daunorubicin hydrochloride|
214290832|NCT00070174|DRUG|etoposide|
214290833|NCT00070174|DRUG|gemtuzumab ozogamicin|
214290834|NCT00070174|DRUG|methotrexate|
214290835|NCT00070174|DRUG|mitoxantrone hydrochloride|
214290836|NCT00070174|PROCEDURE|allogeneic bone marrow transplantation|
214290837|NCT01661439|DRUG|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
214868081|NCT02618135|OTHER|Control Group|"Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology."
214868082|NCT06548308|DIAGNOSTIC_TEST|Corneal Incision|Astigmatism will be assessed by objective and subjective refraction by using the Autorefrectometer and retinoscop.Autorefrectometer uses to acsess the refracive state of eye by which we measure the astigmatim in patients eyes .Then after ctaract surgry in the next followup we will again use autorefrectometer to take readings and these both will be compared on visits among patients undergoing two procedures.
214868083|NCT06548308|OTHER|Toric Intraocular|Two cataract surgery techniques will be used .1 : Toric IOL lenses designed with a unique shape to help provide clear vision at all distances for individuals with astigmatism compared to give better results specially in astigmatic patients.2: Corneal Inscion is which eye surgeon makes a very small opening on the eye, next to the outer corner. to remove the catract during surgry .
214868084|NCT01152151|DEVICE|Postal reminder letters|Postal reminder letters if adherence is not obtained (up to four)
214868085|NCT01152151|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
214868086|NCT01152151|DEVICE|Reminder letters|up to four reminder letters in september - december 2010
214868087|NCT00000693|DRUG|Zidovudine|
214868088|NCT00000693|DRUG|Acyclovir|
214868089|NCT03327792|DRUG|Mavoglurant|200 mg Mavoglurant
214868090|NCT03327792|DRUG|Placebo|Placebo
214868091|NCT03624686|OTHER|peripheral blood|draw peripheral blood
214868092|NCT05546112|DEVICE|Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B|A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve
214868093|NCT05546112|DEVICE|Sham Stimulation using YPS-401B|A device that is attached in the same way as a real medical device, but actually applies a shum stimulus
214868094|NCT05395455|PROCEDURE|Non-surgical periodontal treatment|Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
214868095|NCT00050323|DRUG|Allogeneic DCs and Autologous RCC Tumor Derived Cells|
214868096|NCT02299024|BEHAVIORAL|Additional Opioid Information|Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
214868097|NCT05268835|DRUG|Dalacin C|The objective of the intervention is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars
214868098|NCT00592618|DRUG|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
214868099|NCT00996775|BEHAVIORAL|brief alcohol intervention|this intervention consists of brief assessment and feedback
215035066|NCT03361449|OTHER|Flamingo exercise|Flamingo exercise
215035067|NCT03361449|OTHER|training with kinesthetic ability trainer|training with kinesthetic ability trainer
215035068|NCT00066040|DRUG|Cervitec chlorhexidine varnish|
215035069|NCT00066040|DRUG|Duraphat fluoride varnish|
215035070|NCT00066040|DRUG|xylitol gum from Fennobon, Finland|
215035071|NCT06253650|DRUG|Experimental|6 cycles of: T-DXd at the dose of 6.4 mg/kg intravenous every 3 weeks plus capecitabine 1000 mg/sqm BID orally on days 1-14 every 3 weeks or 5-fluorouracil 600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks as per Investigator's choice
215035072|NCT06253650|DRUG|Control|4 cycles of: 5-fluorouracil 2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks, leucovorin 200 mg/m2 intravenous infusion on day 1 every 2 weeks, oxaliplatin 85 mg/m2 intravenous infusion on day 1 every 2 weeks, and docetaxel 50 mg/m2 intravenous infusion on day 1 every 2 weeks.
215035073|NCT01680211|DIETARY_SUPPLEMENT|Salacia bark extract|
214290838|NCT05229237|DRUG|Conbercept|Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.)
214290839|NCT02973217|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|
214290840|NCT02325375|PROCEDURE|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
214665616|NCT03664726|BEHAVIORAL|Neutral Narrative|Participants will read a narrative in which they are asked to imagine a scenario in which they have been transferred between departmental jobs, with little change in salary/commute.
214868100|NCT00996775|BEHAVIORAL|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
214868101|NCT01782300|BIOLOGICAL|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
214868102|NCT01782300|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
214868103|NCT01086397|PROCEDURE|Urine sample collection|All subjects have non-invasive urine sample collection performed
214665617|NCT03032744|OTHER|Asthma Assessment & Management|Asthma Assessment \& Management based on NAEPP-EPR3 guidelines
214665618|NCT03032744|OTHER|Asthma Education|Asthma education on medications
214868104|NCT01302522|BEHAVIORAL|Mental practice|All patients in the study will be administered a regimen of locomotor therapy (rehabilitative therapy working on walking). Half of the patients will also be administered a regimen in which they mentally rehearse the exercises that they have just physically performed.
214868105|NCT02767830|BEHAVIORAL|Excercise and Nutrition Program|
214868106|NCT00375830|PROCEDURE|Bone scan|Scan to diagnose a number of bone conditions including cancer or metastasis
214868107|NCT00375830|DRUG|99mTc-methyl diphosphonate|Radiolabel for bone scan procedures
214868108|NCT00375830|PROCEDURE|Positron Emission Tomography (PET) scan|Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F
214868109|NCT00375830|DRUG|18F-Fludeoxyglucose (18F-FDG)|Radiolabel for positron emission tomography scan procedures
214868110|NCT00375830|PROCEDURE|Computed Tomography (CT) scan|Scan to detect \& analyze X-rays
215035074|NCT01680211|DIETARY_SUPPLEMENT|Salacia leaf extract|
215035075|NCT01680211|DIETARY_SUPPLEMENT|Sesame seed extract|
215035076|NCT01680211|BEHAVIORAL|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
215035077|NCT01680211|OTHER|Placebo|
214868111|NCT00375830|DRUG|18F-Sodium Fluoride (18F-NaF)|Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.
214868112|NCT00375830|PROCEDURE|Whole Body Magnetic Resonance Imaging (WB-MRI) scan|Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.
214868113|NCT00375830|DRUG|Gadopentetate dimeglumine|A gadolinium-based contrast agent for MRI
214868114|NCT00375830|DRUG|Gadofosveset|A gadolinium-based contrast agent for MRI
214868115|NCT00375830|DRUG|Gadobutrol|A gadolinium-based contrast agent for MRI
214868116|NCT04024839|OTHER|Active Isolated Stretch|In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.
214868117|NCT04024839|OTHER|Post Isometric Relaxation|In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
214868118|NCT01234922|DRUG|lisinopril|Given orally
214868119|NCT01234922|DRUG|losartan potassium|Given orally
214868120|NCT01234922|OTHER|laboratory biomarker analysis|Correlative studies
215035078|NCT03735355|PROCEDURE|Surgery|Surgical resection of fibrostenotic area
215035079|NCT03735355|PROCEDURE|TTS balloon dilation|Dilation of a stricture using TTS balloon
215035080|NCT01400711|OTHER|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
215035081|NCT01400711|OTHER|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
214868121|NCT01234922|DRUG|benazepril hydrochloride|Given orally
215035082|NCT01090596|DRUG|Naproxen|500mg naproxen, twice daily for 7 days
215035083|NCT01090596|DRUG|Placebo|1 tab,twice a day for a seven days
214868122|NCT01234922|DRUG|ramipril|Given orally
214868123|NCT04226326|OTHER|Directly measure microvascular function using direct coronary flow measurements|The study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. Evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. The overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with CTO.
214868124|NCT05893810|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares
215035084|NCT01212900|DRUG|Statins, HMG CoA|Statin therapy
215035085|NCT01480687|DIETARY_SUPPLEMENT|DHA-EPA|1800 mg/day
215035086|NCT01480687|DRUG|Ciprofibrate|100 mg/day
215035087|NCT01511133|PROCEDURE|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
214665619|NCT03032744|OTHER|Controller medication at school|Students will receive the morning dose of their daily preventive asthma medication at school on school days.
214868125|NCT04122066|DRUG|sofosbuvir \daclatsvir|study the effect of the new oral antihepatitis C drugs on the respiratory system
214868126|NCT05826795|PROCEDURE|Early goal-directed therapy (EGDT)|The principle of hemodynamic optimization to achieve the defined goals.
215035088|NCT01511133|PROCEDURE|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
215035089|NCT00003287|DRUG|FOLFOX regimen|
215035090|NCT00003287|DRUG|fluorouracil|
215035091|NCT00003287|DRUG|leucovorin calcium|
215035092|NCT00003287|DRUG|oxaliplatin|
214868127|NCT03466255|OTHER|Ultrasound|Contrast-enhanced ultrasound (CEUS)
214868128|NCT04066595|DRUG|Cabozantinib|60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
214868129|NCT05149859|OTHER|Observational|(no intervention)
214868130|NCT02449096|DEVICE|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
214868131|NCT02449096|OTHER|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
214868132|NCT04471337|DRUG|BAY1817080|BAY1817080 will be administered orally as tablet.
214868133|NCT00123474|DRUG|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
214868134|NCT00123474|DRUG|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
214868135|NCT00123474|DRUG|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
214868136|NCT00123474|DRUG|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
214868137|NCT01059344|DRUG|Mesalamin|4.8g/day, 800 mg tablets
214868138|NCT05386940|OTHER|PKN1 level|different PKN1 level after on-pump cardiac surgery
215035093|NCT04120467|OTHER|Dance|"One group will receive a 60-minute dance class weekly over a 6 weeks period. A physiotherapist - dance teacher will lead the classes, supported by at least one volunteer.~The class structure will consist of five components: warm up (10 minutes), technical exercises (10 minutes), improvisation (15 minutes), a short routine (15 minutes) and a cool down/feedback time (10 minutes). Dance exercises will be targeting flexibility, balance, endurance, upper and lower limbs functions, interaction between dancers, perception and memory. Using choreography or short routine, the class will include repeating the dance moves - which fosters memorization - and also the additional challenge of remembering a sequence of moves.~Given the great variability of each participant's functional ability, the complexity and the intensity of the dance exercises will progress according to each participant's capacity, in order to fulfill an appropriate challenge at moderate treatment intensity."
214868139|NCT02345629|PROCEDURE|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
214868140|NCT02345629|BEHAVIORAL|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
214868141|NCT02345629|PROCEDURE|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
214868142|NCT02345629|PROCEDURE|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
214868143|NCT02902367|OTHER|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
214868144|NCT02902367|OTHER|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
214868145|NCT02174380|OTHER|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
214868146|NCT04808180|OTHER|Biorepair Shock Treatment|Teeth from this group will undergo the application of Biorepair Toothpaste for the first 7 days of the month for 9 months (1 application per day that lasts 10 minutes).
214868147|NCT04808180|OTHER|No treatment|Teeth from this group will not be treated with the experimental toothpaste.
214868148|NCT00742924|DRUG|cisplatin|Given IV
214868149|NCT00742924|DRUG|dexrazoxane hydrochloride|Given IV
215035094|NCT04120467|OTHER|Standard rehabilitation|The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
215035095|NCT02260037|DRUG|Epinastine nasal|
215035096|NCT02260037|DRUG|Placebo|
215035097|NCT01168596|DRUG|Rasagiline|"Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
215035098|NCT01168596|DRUG|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
215035099|NCT00649584|DRUG|SGN-35|IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
215035100|NCT00649584|DRUG|gemcitabine|IV; 1000 mg/m2 weekly 3 out of 4 weeks
215035101|NCT05157360|DRUG|HAT|hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
215035102|NCT05157360|DRUG|Placebo|normal saline solution
215035103|NCT06529432|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose
215035104|NCT06529432|DRUG|Bupivacaine Hydrochloride Injection|Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose
215035105|NCT01676233|DRUG|insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
215035106|NCT01676233|DRUG|insulin glargine- new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
214868150|NCT00742924|DRUG|doxorubicin hydrochloride|Given IV
214868151|NCT00742924|DRUG|etoposide|Given IV
214868152|NCT00742924|DRUG|ifosfamide|Given IV
214868153|NCT00742924|DRUG|leucovorin calcium|Given IV or orally
214868154|NCT00742924|DRUG|methotrexate|Given IV
214868155|NCT00742924|DRUG|zoledronic acid|Given IV
214868156|NCT00742924|PROCEDURE|adjuvant therapy|
214868157|NCT00742924|PROCEDURE|neoadjuvant therapy|
214868158|NCT00742924|PROCEDURE|therapeutic conventional surgery|Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
214868159|NCT00742924|BIOLOGICAL|filgrastim|Given SC
214868160|NCT00742924|DRUG|Mesna|Given IV
214868161|NCT02752763|DRUG|%40 diluted Autologous serum|Serum that obtained after centrifugation of blood sample
214868162|NCT02752763|DRUG|Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)|Preservative free artificial tears is a group naming for drops commonly used for drye disease
214868163|NCT00660400|DRUG|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M\^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
215035107|NCT00794430|DRUG|V3381|100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
215035108|NCT00794430|DRUG|Placebo|Capsule, bid, for 13 weeks
215035109|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor \> 12 weeks as needed for up to 3 years.
215035110|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor \> 12 weeks as needed for up to 3 years.
215035111|NCT00004200|DRUG|prinomastat|
215035112|NCT00004200|DRUG|temozolomide|
215035113|NCT00123630|DRUG|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
215035114|NCT00123630|DRUG|Placebo|Placebo given IV once every 2-4 weeks based on weight
215035115|NCT00318682|DEVICE|FIBROSCAN|diagnostic examination of the hepato fibrosis
215035116|NCT06406933|DRUG|Carbomer Gel/Jelly|The drug is for dry eye syndrome by providing temporary relief from discomfort and irritation.
215035117|NCT06247137|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with components of natural origin: artichoke, bergamot, folic acid, astaxanthin, Chromium picolinate and excipients.~Oral administration: 1 tablet/day at evening meal"
215035118|NCT06247137|OTHER|Placebo|"Placebo (microcrystalline cellulose, calcium carbonate, magnesium stearate, silica dioxide and iron oxides).~Oral administration: 1 tablet/day at evening meal."
215035119|NCT04781179|BEHAVIORAL|CM-II|It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique
215035120|NCT04781179|BEHAVIORAL|Psychoeducation|It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation
215035121|NCT02329808|PROCEDURE|blood drawing|The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
215035122|NCT00371124|DRUG|Atropine Eye drops|
215035123|NCT06300775|DEVICE|modified hyrax|Appliance used for rapid maxillary expansion
215035124|NCT06300775|DEVICE|quad helix|device use for slow maxillary expansion
215035125|NCT01900366|PROCEDURE|Fat Biopsy|Fat biopsy
214868164|NCT00660400|PROCEDURE|Allogeneic Hematopoietic Cell Transplantation (HCT)|"Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~* Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~* The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~* All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant."
214868165|NCT05308082|BEHAVIORAL|Dance Movement Therapy (DMT)|The main Dance Movement Therapy (DMT) methods were dance-movement improvisations, body awareness exercises, and reflection through drawing/painting, writing, and verbalization. There was an orientation to personal space and body awareness, interaction in pairs, and interaction in the whole group. The themes included exploration of boundaries, somatic resources, symbols, pleasant and unpleasant emotions, mindfulness, and body awareness, enriched movement experiences, and safety and touch. In the present study, it consists of six sessions, including (1) Movement for Self-expression, (2) Movement for Emotional Health I, (3) Movement for Emotional Health II, (4) Movement for Connection \& Creativity, (5) Embracing your Dancing Child, and (6) Movement for Self-compassion.
214868166|NCT05640219|DEVICE|laparoscopic trocar 12mm|long laparoscopic trocar 12mm (36 french) with central hole from its tip till its handle with transparent sheath
214868167|NCT04312386|OTHER|OPTIMAT|Baseline menue, not optimized
214868168|NCT02592135|OTHER|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
215035126|NCT00203190|DRUG|Topiramate|
215035127|NCT00853853|DEVICE|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
215035128|NCT00853853|PROCEDURE|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
215035129|NCT01969734|DEVICE|Zephyr endobronchial valve placement|
215035130|NCT02965781|DRUG|SADBE|Topical solution
215035131|NCT02965781|OTHER|Placebo|Topical solution
215035132|NCT06486909|DIAGNOSTIC_TEST|Cerebrospinal Fluid (CSF) Sample|Samples for glucose in CSF will be taken upon EVD/LD placement until EVD/LD removal (within the first 14 days).
215035133|NCT06486909|DIAGNOSTIC_TEST|Blood Serum Sample|Samples for glucose in blood serum will be completed every day, for the first 14 days.
215035134|NCT01175122|BIOLOGICAL|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
215035135|NCT06527885|DRUG|Lurasidone|Patients treated with Lurasidone in according to routine clinical practice, in Italy
215035136|NCT00366457|DRUG|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
214290841|NCT04119492|BEHAVIORAL|CO-OP Treatment Group|"Cognitive Orientation to Occupational Performance (CO-OP) is a cognitive approach to solving functional motor problems (Polatajko et al., 2001). Therapists teach children a global problem-solving strategy (Goal-Plan-Do-Check) as means to develop specific strategies for overcoming motor problems; the strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists trained in CO-OP will see children for one hour, once weekly for 10 weeks. Parents or caregivers will be encouraged to attend treat¬ment sessions so therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select 3 functional motor goals to be addressed during treatment."
214290842|NCT06969651|BEHAVIORAL|Black-Food|Ads featuring a Black person with a food product
215035137|NCT00366457|DRUG|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
215035138|NCT00366457|DRUG|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
215035139|NCT02538614|DRUG|Idelalisib|Tablets administered orally twice daily
215035140|NCT02538614|DRUG|BI 836826|Intravenous administration as a rate-controlled infusion
214290843|NCT06969651|BEHAVIORAL|White-Food|Ads featuring a White person with a food product
214290844|NCT06969651|BEHAVIORAL|Black-Non Food|Ads featuring a Black person with a non-food product
214290845|NCT06969651|BEHAVIORAL|White-Non Food|Ads featuring a White person with a non-food product
214290846|NCT06969651|BEHAVIORAL|Food-Many Likes|"Ads with Many likes featuring a food product"
214290847|NCT06969651|BEHAVIORAL|Non Food-Many Likes|"Ads with Many likes featuring a non-food product"
214868169|NCT01989962|OTHER|E4E intervention|The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
214868170|NCT03628625|DRUG|Letrozole 2.5mg|total dose 7.5 mg per day for 3 days
214868171|NCT03628625|DRUG|Placebo|Folic acid for 3 days
214868172|NCT03628625|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
214868173|NCT02256527|OTHER|Observational|compare data
214868174|NCT02150135|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
214868175|NCT03839030|OTHER|MBHP-Educa|This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
214868176|NCT00024284|DRUG|carboplatin|
214868177|NCT00024284|DRUG|irinotecan hydrochloride|
214868178|NCT05367583|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
214868179|NCT01025115|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
214868180|NCT01025115|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
215035141|NCT01098747|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
215035142|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
215035143|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
215035144|NCT01098747|DRUG|Placebo|Single-dose of placebo
215035145|NCT06469983|DEVICE|ErigoBasic or ErigoPro®|Static bed with integrated robotic stepper (ErigoBasic) and optionally integrated with Functional Electrical Stimulation (FES ErigoPro®). The Erigo is a robot designed to be used for early functional mobilisation of patients with neurological manifestations or who are bedridden, even in intensive care. It is a tilt table equipped with an integrated passive stepper controlled by microprocessors that generate physiological leg movements: the patient's thighs are secured by straps to the movement mechanisms and the feet are secured to plates equipped with shock absorbers, while the upper body is held in place by a sling integrated into the table. Erigo provides active functions: gradual elevation in orthostatism up to 90°, controlled and independent mobilisation of the lower limbs, and functional stimulation.
215035146|NCT06469983|BEHAVIORAL|Traditional Verticalization|gradual verticalization (from supine position up to maximum 90°, in 3 steps), depending on the patient's vital signs compliance, using a traditional standing device (i.e., non-robotic traditional tilt table)
215035147|NCT01876498|PROCEDURE|Xiaflex surgery|Xiaflex surgery
215035148|NCT02692196|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|
214868181|NCT06551571|OTHER|Intrapartum Care Model|\- The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations
214868182|NCT03437226|DRUG|Levosimendan 2.5 MG/ML|Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
214868183|NCT03437226|DRUG|Placebos|Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
214868184|NCT03490760|DRUG|Durvalumab|Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks
214868185|NCT03490760|RADIATION|Radiation Therapy|24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
214868186|NCT00711438|BEHAVIORAL|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
214868187|NCT00711438|BEHAVIORAL|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
215035149|NCT01203007|DIETARY_SUPPLEMENT|Tailored diet|Tailored diet according to demonstrated food sensitivity, 6 months
215035150|NCT01203007|DIETARY_SUPPLEMENT|Low antigen content diet|Low-antigen content diet for one month
215035151|NCT04868292|DRUG|SPR206|Three 100 mg SPR206 intravenous doses administered every 8 hours
215035152|NCT04983784|BEHAVIORAL|walking|walking for 12 weeks at home
215035153|NCT04983784|OTHER|Routine care|Routine care
215035154|NCT00726908|DIETARY_SUPPLEMENT|Low carbohydrate|43% CHO
215035155|NCT00189423|DEVICE|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|"The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR."
214290848|NCT06969651|BEHAVIORAL|Food-Few Likes|"Ads with Few likes featuring a food product"
214868188|NCT05462171|DIAGNOSTIC_TEST|Questionnaires|Participants will be asked to complete validated questionnaires (the five-item International Index of Erectile Function - IIEF-5, Premature Ejaculation Diagnostic Tool - PEDT, International Prostate Symptom Score - IPSS, Overactive Bladder - Validated 8-question Screener - OAB-V8, Hospital Anxiety and Depression Scale - HADS, Athens Insomnia Scale - AIS).
214868189|NCT06443411|OTHER|Monitoring of cerebral hemodynamics|A specially designed pair of goggles will be put on the patient's head. The closed eyelids, along with the surrounding tissues, will be in contact with a thin, elastic, non-allergic film used to seal water filled inside the goggles. Pulse waves, including those originating from cerebrospinal fluid pulsation, will be transmitted from the eyelids to the water, where they will be detected by a pressure sensor and recorded with a laptop.
214868190|NCT00528411|DRUG|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
214868191|NCT00528411|DRUG|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
214868192|NCT00528411|DRUG|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
214868193|NCT02644005|DEVICE|Smart Vent Control|Smart Vent Control (SVC) was designed to automatically control the following ventilator settings: mechanical breathing frequency, inspiratory pressure, pressure support, inspiratory time, trigger sensitivity. SVC adjusts the ventilator settings with the aim to keep a patient stable in a target zone (TZ). Numerous predefined TZs exist that can be set according to the current therapeutic situation. All TZs are adoptable by the user for each individual patient and consist of upper and lower limits for tidal volume and for the partial pressure of end-tidal carbon dioxide (PetCO2). Based on these limits, the system classifies the current quality of ventilation, called Classification of Ventilation, and derives new ventilator settings accordingly. SVC is available as a software option on Zeus Infinity Empowered anesthesia machines (Drägerwerk AG \& Co. KGAa, Lübeck, Germany) and is approved as a medical product according to 93/42/European Economic Community.
214868194|NCT00252200|DRUG|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
214868195|NCT05729685|OTHER|Interval training|"The interval training group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the new PTV achieved during mid-testing as a result of training."
214868196|NCT05729685|OTHER|Continuous training|The continuous group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains.
214868197|NCT04769414|DRUG|Gemcitabine fluorouracil|"chemotherapy protocol given as:~* Gemcitabine 1000mg/m2 IV short infusion~* Leucovorin 400 mg/m2 IV short infusion~* Flourouracil 400 mg/m2 direct IV shot~* Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly"
214868198|NCT05949710|BEHAVIORAL|aerobic exercise(AE)|The participants will receive AE three times per week.
214868199|NCT04026386|BEHAVIORAL|Center Based or In Home Early Intervention Program|This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
214868200|NCT02643355|DRUG|Olanzapine|
214868201|NCT02643355|DRUG|Clonidine|
214868202|NCT00025012|DRUG|isotretinoin|
214868203|NCT04856410|OTHER|Spaceflight|Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.
214868204|NCT04856410|OTHER|Controls|No intervention
214868205|NCT04318223|DRUG|Palbociclib|Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
214868206|NCT03277118|DEVICE|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
214868207|NCT06505941|DRUG|umbilical cord mesenchymal stem cell|umbilical cord mesenchymal stem cell
214868208|NCT06505941|DRUG|Placebo|non-cell-containing placebo
214290849|NCT06969651|BEHAVIORAL|Non Food-Few|"Ads with Few likes featuring a non-food product"
215035156|NCT00189423|PROCEDURE|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
215035157|NCT05685784|DEVICE|Bytelfies kit - sensor dot|"Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.~GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.~PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand"
215035158|NCT04955548|PROCEDURE|arthroscopic micro-fracture with autologous adipose gel|Fully cut the adipose tissue taken out under the arthroscopy, transfer the cut adipose tissue to a syringe connected with a double pass, push back and forth through the syringe to physically emulsify the adipose, and centrifuge to obtain the autologous adipose gel, and inject it into the lesion
215035159|NCT04955548|PROCEDURE|arthroscopic micro-fracture|Surgeons routinely perform international standard micro-fracture surgery to repair cartilage damage
214290850|NCT03906838|DRUG|Ropivacaine injection|Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
214868209|NCT05736653|DEVICE|Task-specific PCMS|120 pairs of TMS and PNS volleys will be administered during electromyography-triggered functional electrical stimulation (FES)-assisted task-specific training (task-specific PCMS). In the task-specific PCMS, participants will first grasp a spherical ball when prompted by an auditory 'Ready' cue, and upon seeing a visual 'Go' cue will voluntarily extend the wrist and fingers to release the ball. After the 'Go cue', our customized stimulation delivery algorithm triggers the TMS and PNS only when the extensor digitorum communis (EDC) muscle activity exceeds a pre-determined threshold. The algorithm will then trigger FES to EDC after detecting EDC activity (\~2 ms after PNS) for the next 2 seconds, allowing the pairing of PCMS (TMS and PNS) with the voluntary movement of EDC without the confounding effects of FES.
214868210|NCT05736653|DEVICE|Task-specific sham-PCMS|120 pairs of sham-PCMS stimuli will be administered during task-specific practice. The TMS coil will be placed \~10 cm behind the participant's head, and PNS electrodes will be placed in the same position as for task-specific PCMS, but no stimulation will be delivered. Like the task-specific PCMS condition, participants will perform the same grasp and release a ball task in an identical manner. FES will be delivered after detecting voluntary EDC activity, similar to the task-specific PCMS condition.
214868211|NCT05736653|DEVICE|PCMS-rest|120 pairs of TMS and PNS volleys will be administered with the EDC muscle at rest every 10 s (\~20 min, 0.1 Hz). TMS will be used to elicit motor-evoked potentials (MEPs). Antidromic activation of spinal motor neurons will be elicited by supramaximal peripheral nerve stimulation (PNS) applied to the radial nerve near the elbow. Volleys will be timed to arrive in the spinal cord based on central and peripheral conduction times calculated for each subject so that the pre-synaptic terminal is depolarized via TMS \~1-2 ms before spinal motor neurons are depolarized via PNS at a pulse duration of 200us. We will also perform stimulation of the cervical roots (C-root) by placing the coil behind the neck and stimulating the C-root (C6 and C7 vertebrae), which innervate the finger extensor muscles. Conduction times will be calculated from latencies of the primary motor area (M1) MEP, C-root, and M-wave.
214868212|NCT03122288|BEHAVIORAL|Individualized Cognitive Training|These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).
214868213|NCT03122288|OTHER|No-Contact Control|This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
214868214|NCT03495349|OTHER|safety and effectiveness of the usual treatments of diabetic foot infections|clinical and biological follow-up necessary to assess the safety and effectiveness of the medical treatments, MOS-SF survey (36-Item Short Form Survey) to study the quality of life.
214868215|NCT03335215|OTHER|cognitive remediation|The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context. The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
214868216|NCT00237653|DRUG|Valganciclovir|
214868217|NCT02513030|PROCEDURE|Defibrillation testing during ICD replacement|
214868218|NCT02135471|DRUG|acellular dermal matrix graft|On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
214868219|NCT02135471|DRUG|enamel matrix derivative|On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
214868220|NCT01715571|DEVICE|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary."
214868221|NCT04420273|BEHAVIORAL|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
214868222|NCT04420273|BEHAVIORAL|Active control:Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
214868223|NCT01687972|COMBINATION_PRODUCT|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
214868224|NCT01687972|COMBINATION_PRODUCT|Absorbable sutures|placement of absorbable sutures at cesarean section
215035160|NCT03302767|OTHER|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
215035161|NCT01638507|DEVICE|Resolute Integrity Stent|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
215035162|NCT04622592|BIOLOGICAL|Instramuscular vaccine|On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
215035163|NCT01502384|OTHER|neurological examination|motor and cognitive functions
215035164|NCT02996396|DEVICE|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
215035165|NCT01497197|DRUG|GONAL-f®|GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen.
215035166|NCT01497197|DRUG|Luveris®|Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
215035167|NCT01497197|BIOLOGICAL|Recombinant human chorionic gonadotropin (r-hCG)|A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
214868225|NCT00000139|BEHAVIORAL|Stress|
214868226|NCT00000139|DRUG|Acyclovir|
214868227|NCT03144310|OTHER|lung ultrasound|lung ultrasound and blood gas
214868228|NCT04534907|COMBINATION_PRODUCT|The combination of exposure and response prevention (ERP) and VR|The combination of exposure and response prevention (ERP) and VR aimed to investigate the combination of an immersive virtual reality environment (VRE) alongside therapist delivered CBT to reduce anxiety when the OCD patients were induced by virtual scene.Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get VR+ERP session twice a week. From the fourth week to the seventh week, patients weill get VR+ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
214868229|NCT04534907|BEHAVIORAL|Traditional ERP|Patients will achieve the exposure based CBT for total 10 times excluding 8 sessions of ERP. Structured protocol described by Foa et al., 2012. Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get ERP session twice a week. From the fourth week to the seventh week, patients weill get ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
214868230|NCT04524364|DEVICE|Pulsed Field Ablation (PFA) Therapy|Participants will undergo PFA therapy with a compatible ablation catheter when used with Multi-Channel irreversible electroporation (IRE) Generator (deliver trains of high-voltage bipolar pulses of short duration on separate channels to a multi-electrode ablation catheter) and Circular IRE Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with an IRE Generator, for cardiac ablation).
214868231|NCT04007432|OTHER|pulse oxymeter|Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
214868232|NCT06160193|BEHAVIORAL|Brief behavioral parent training with optional care as usual|A brief behavioral parent training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of 120 minutes, and a third session of 60 minutes, in which the training will be evaluated and maintenance training will be provided.
214868233|NCT06160193|OTHER|Care as usual|Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
214868234|NCT05626855|DRUG|Apitegromab|Apitegromab (SRK-015) is an investigational, fully human immunoglobulin G4 monoclonal antibody that specifically binds to human proforms (i.e., inactive precursor forms) of myostatin, pro- and latent- myostatin, with high affinity, inhibiting activation of myostatin, a negative regulator of muscle growth and strength.
214868235|NCT05124977|DRUG|Antimicrobial Stewardship|Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
214868236|NCT05124977|DRUG|Standard management|Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
214868237|NCT03706833|DEVICE|Edwards PASCAL System|Transcatheter mitral valve repair with the Edwards PASCAL System
214868238|NCT03706833|DEVICE|Abbott Mitraclip System|Transcatheter mitral valve repair with the Abbott Mitraclip System
214868239|NCT06966050|BEHAVIORAL|Quality-of-life Questionnaire|Participants will be asked to fill out a quality-of-life questionnaire, which will take about 10-15 minutes to complete.
214868240|NCT05438459|BIOLOGICAL|Phase I part|Administration of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination.
214868241|NCT05438459|BIOLOGICAL|Phase II part|Randomized into group of administration of GAIA-102 as a monotherapy or GAIA-102 or pembrolizumab in combination, group of standard treatment
214868242|NCT03806842|DEVICE|Easytech group|total shoulder replacement
214868243|NCT00752830|DRUG|AZD0328|Oral capsule, single dose
214868244|NCT03185442|DEVICE|Pulsed Radiofrequency|Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
214868245|NCT06633250|OTHER|Test Formula|Hydrolyzed rice protein formula
214868246|NCT06633250|OTHER|Control Formula|Commercially available extensively hydrolyzed cow's milk formula
214868247|NCT06968325|DEVICE|AI-based TruRoot group:|Participants in this group will receive clear aligner treatment designed using an artificial intelligence (AI)-based system called TruRoot
214868248|NCT06968325|DEVICE|Conventional clear aligner group|Participants in this group will receive clear aligner treatment planned manually by expert orthodontists based only on intraoral scans.
214868249|NCT00826449|DRUG|Dasatinib|Starting dose of 70 mg by mouth daily for 21 day cycle.
214868250|NCT00826449|DRUG|Erlotinib|150 mg by mouth daily every 21 day cycle.
214868251|NCT03490448|BEHAVIORAL|aerobic exercise and appropriate caloric control|The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
214868252|NCT02994940|DRUG|Acetaminophen|already included in arm/group descriptions
214290851|NCT05993468|OTHER|TMC Treatment Approach|The TMC approach consists of 16 weekly group sessions, each lasting 2 hours. The first 10 sessions focus mainly on building mindfulness capacities, and the last 6 sessions on developing compassion toward self and others. Between sessions, participants are encouraged to do exercises with the support of audio files. The approach was developed with a transdiagnostic perspective, including clients with a variety of trauma-related symptoms.
214868253|NCT03233230|DRUG|M2591 25 mg QD|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
214868254|NCT03233230|DRUG|M2951 75 mg QD|Participants received 75 mg of M2951 orally QD for 12 weeks.
214868255|NCT03233230|DRUG|M2951 50 mg BID|Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
214868256|NCT03233230|DRUG|Placebo|Participants received placebo matched to M2951 orally for 12 weeks.
214868257|NCT02930486|DEVICE|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
214868258|NCT02930486|DEVICE|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
214868259|NCT00475150|DRUG|cediranib maleate|Given orally
214868260|NCT00475150|OTHER|laboratory biomarker analysis|Correlative studies
214868261|NCT02327741|DRUG|plavix|taking plavix more than 12 months
214868262|NCT02327741|DRUG|plavix|taking plavix less than 12 months
214868263|NCT02987959|DRUG|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
214868264|NCT00134693|DRUG|Prednisolone|
214868265|NCT00134693|DRUG|SB-681323|
214868266|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
214868267|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
214868268|NCT05581290|DEVICE|AI-Flex|A flexible multi-modal bio-sensing device with integrated AI capability used to measure ECG (heart's electrical activity), body temperature, and PPG (blood volume in tissue); primarly mounted on the wrist and chest.
214868269|NCT00392236|DEVICE|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
215035168|NCT04256850|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Teaches acceptance, mindfulness, and values-based skills
214290852|NCT03532334|DIAGNOSTIC_TEST|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
214290853|NCT01259908|PROCEDURE|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
214868270|NCT00392236|BEHAVIORAL|Treatment as usual|Participants will receive treatment as usual.
214868271|NCT04126213|BIOLOGICAL|RSV MAT 60 µg|One single dose of RSV MAT 60 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
214868272|NCT04126213|BIOLOGICAL|RSV MAT 120 µg|One single dose of RSV MAT 120 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
214868273|NCT04126213|DRUG|Placebo|One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
214868274|NCT02853370|DRUG|Bendamustine and Rituximab|
214868275|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - upon admission|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
214868276|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - 24 hours after injury|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
214868277|NCT04390659|PROCEDURE|myomectomy|The myomectomy was done by conventional technique but timing of myomectomy either before or after delivery of the baby varied between different cases .Infusion of oxytocin during the operation and for 24 h later.
214868278|NCT02196701|DRUG|Adalimumab|Administered by subcutaneous injection every other week.
214868279|NCT02196701|DRUG|Methotrexate|Methotrexate was provided as 2.5 mg tablets for oral administration.
214868280|NCT03851926|RADIATION|Hypofractionated volumetric radiotherapy in 20 fractions|Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.
214868281|NCT00406744|DRUG|Intravitreal injection of Bevacizumab|
214868282|NCT00117208|DRUG|mannitol|400mg BD for 12 weeks
214868283|NCT00117208|DRUG|mannitol + pulmozyme|combination
214868284|NCT00117208|DRUG|Dornase alpha|2.5mg daily for 2 weeks
214868285|NCT02831608|BIOLOGICAL|Influenza vaccine|
214868286|NCT02831608|BIOLOGICAL|Placebo|
214868287|NCT02589314|DEVICE|Mechanical periodontal therapy|
214868288|NCT02589314|PROCEDURE|nonsurgical periodontal therapy|
214868289|NCT05418530|OTHER|with pause- without pause|start with pause expiration
214868290|NCT05418530|OTHER|without pause-with pause|start without pause expiration
214868291|NCT01439230|DRUG|Donepezil|10 mg Tablet
214868292|NCT01439230|DRUG|Aricept®|10 mg Tablet
214868293|NCT00415441|PROCEDURE|Physiotherapy program|
214868294|NCT00415441|PROCEDURE|Placebo physiotherapy treatment|
214868295|NCT03915730|OTHER|Initial periodontal therapy|Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
214868296|NCT02608138|OTHER|Iodine status among portuguese school children|
214868297|NCT04311788|DEVICE|Prophylactic self gripping mesh|Prophylactic self gripping mesh, Propgrip by Medtronic.
214868298|NCT04311788|DEVICE|Slowly absorbable continuous monofilament suture|Fascial closure by continuous slowly absorbable 4:1 suture
214868299|NCT06417736|DRUG|Megestrol Acetate 40 MG|160mg/one time/day
214868300|NCT04532359|DEVICE|Implant placement|Implant placement
214868301|NCT00000583|BIOLOGICAL|hepatitis B vaccines|
214868302|NCT00675753|GENETIC|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
214868303|NCT03607526|OTHER|Barriers|NGT sessions identifying barriers to vegetable intake.
214868304|NCT03607526|OTHER|Facilitators|NGT sessions identifying facilitators to vegetable intake.
215035169|NCT04256850|BEHAVIORAL|Self-Regulation (SR)|Teaches monitoring and reinforcement strategies designed to improve motivation and adherence to positive weight loss behavioral prescriptions.
215035170|NCT03388372|BIOLOGICAL|Nimotuzumab|Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.
214665620|NCT01805648|DRUG|rhTPO|Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10\^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10\^9/L～100×10\^9/L.
214665621|NCT00109421|BEHAVIORAL|Project ÒRÉ|Community-based adolescent social network HIV/STI intervention tailored to African American culture
214665622|NCT05068856|DRUG|HRS2543|"Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC."
214868305|NCT06053918|OTHER|additional follow-up extension at home|additional interview when leaving the sector, and the extension of follow-up of the patient at home
214665623|NCT00157300|DRUG|Epoetin beta|intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
214665624|NCT06544109|DRUG|venetoclax|patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax
214665625|NCT03580330|OTHER|mHealth intervention|Individual in the intervention group receive a weekly educational health SMS for the intervention period of 1 year. SMS content covered different health themes providing health information on lifestyle, dietary habits, body weight, smoking, medications, importance of compliance, as well as symptoms and self-management of HTN and diabetes. Community individuals who were diagnosed and were receiving necessary care previous to the investigator's intervention were sent weekly informative health SMS, as well as customized SMSs reminders to follow up on their scheduled medical appointments (eg, to check their HbA1c levels and have their annual foot or eye exams).
214868306|NCT06483841|BEHAVIORAL|Parents as Partners|The Parents as Partners program consists of 8 weekly group sessions attended by couples and was developed to strengthen the coparental relationship and promote paternal involvement. After consenting to their participation, couples will be randomly assigned to one of two conditions: intervention group or waitlist-control group. Participants will be assessed before and after the intervention on (co)parental, dyadic and work-family dimensions. Baseline (before intervention), post-test (2 months after baseline) and a follow-up assessment 6 months after the program will be performed. The intervention group will participate in the program, focusing on 5 family domains: Parents as Individuals; Parent-Child Relationships; Couple Relationship; Family of Origin Patterns; Stressors and Supports. Parents in the waitlist-control group will receive the intervention once their participation in the study is finished and if positive outcomes are found.
214868307|NCT04601610|DRUG|KN046 （PD-L1/CTLA4 BsAb）|KN046 5mg/kg Q3W
214868308|NCT04601610|DRUG|Ningetinib Tosylate（multi-target TKI）|ningtinib QD, dose will be decided by investigator
214868309|NCT05947110|OTHER|Plyometric-based hydro-kinesio therapy|The plyometric-based hydro-kinesio therapy was conducted for 45 minutes, twice weekly, for 8 successive weeks. The training was geared toward the lower body and was conducted under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
214868310|NCT05947110|OTHER|Standard exercise therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for 8 successive weeks.
214868311|NCT03856112|DRUG|Dexamethasone|Given PO
214868312|NCT03856112|DRUG|Ixazomib|Given PO
214868313|NCT03856112|DRUG|Ixazomib Citrate|Given PO
214868314|NCT03856112|DRUG|Venetoclax|Given PO
214868315|NCT02755155|DRUG|Human serum albumin infusion 4%|Continuous infusion of 15mL/kg of bodyweight over 24h/day
214868316|NCT02755155|DRUG|Human serum albumin infusion 20%|Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
214868317|NCT02424643|BEHAVIORAL|Monetary Incentive|$20 Amazon.com gift card
214868318|NCT02424643|BEHAVIORAL|Altruistic Incentive|"A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey"
214868319|NCT02424643|BEHAVIORAL|Dashboard Incentive|"A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data."
214868320|NCT02854592|DRUG|rtPA|intravenous thrombolysis with rtPa
214868321|NCT02854592|DRUG|urokinase|intravenous thrombolysis with urokinase
214868322|NCT02650479|DRUG|Exenatide|6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
214868323|NCT02650479|DRUG|Placebo|6 hour IV infusion.
214868324|NCT02650479|DRUG|Moxifloxacin|400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
214868325|NCT02650479|DRUG|Palonosetron|0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
214868326|NCT03681236|PROCEDURE|Alveolar recruitment maneuver|Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
214868327|NCT05919121|OTHER|Therapeutic exercise|"1. Stretching exercise of posterior shoulder capsule~2. Strengthening exercises: consists of 6 strengthening exercises all of which have been recommended as essential for any shoulder rehabilitation program.~3. The remaining 2 exercises are the seated press-up and the elbow push up. Both will be performed to fatigue or for a maximum of 25 repetitions. The quality of all repetitions of each exercise will continuously monitored by the investigator of the study"
214868328|NCT05919121|OTHER|hydrocortisone phonophoresis|In this study, the effective area of radiation (ERA) in the mode continuous (100 percent) is 5 cm2, in 1 MHz and 0.7 W/cm2, with four ERA treated areas. Therapy lasted five minutes (three minutes in the insertion of the supraspinatus and 37 two minutes in the infraspinatus insertion) three times weekly over 6 weeks in addition to therapeutic exercises
214868329|NCT05919121|OTHER|hydrocortisone iontophoresis|A direct current electrical stimulation unit will be used to apply iontophoresis. The unit has two electrodes; one electrode is for the negative current, and one is for the positive current. The Active (Negative) electrode will be placed on the anterolateral aspect of the shoulder joint. The passive electrode: will be placed on the upper arm region. Intensity of the current: Between the range of 3-5 mA at the point of sensation of patient was set. Treatment duration: Calculated accordingly with intensity of current. Method of application: hydrocortisone gel 10% will be administered by applying on the active rubber electrode for each session three times weekly over 6 weeks in addition to therapeutic exercises.
214868330|NCT02205983|DRUG|2 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
214868331|NCT02205983|DRUG|1000 mg Acetaminophen|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
214868332|NCT02205983|DRUG|4 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
214868333|NCT02205983|DRUG|dextrose|We are administering dextrose to healthy volunteers for our placebo group.
214868334|NCT05231538|OTHER|Neurodevelopmental therapy|NDT is a hands-on, 'problem solving approach'. It is used in the management and treatment of children who have disorders of function, movement or postural control because of damage in their central nervous system.
214868335|NCT05231538|OTHER|Routine physical therapy|stretching, passive range of motion, and active range of motion).
214868336|NCT03764761|DEVICE|AAC Technology - Standard of Care|Story Book is separate from AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and non-integrated presentation
214868337|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and but integrated presentation
214868338|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is optimal arrangement and but integrated presentation
214868339|NCT05912361|BEHAVIORAL|receiving a one hour theoretical and hands on training session before using an AI-based platform|The students at the experimental group will receive a one-hour hands-on training session before logging in to the online platform. The session will be presented by a dentist with AI experience and this session will present basic aspects of AI in radiology, deep learning (DL) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which each participant will check 11 cases of teeth with deep caries and will find the closest line between caries and pulp. their performance will be supervised by the training session presenter and the correct line will be shown them in case of making wrong line.
214868340|NCT01108211|DEVICE|Vibration Platform|The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
214868341|NCT05965453|DEVICE|the Castor single branch stent graft|Participants who received thoracic endovascular aortic repair by meant of the Castor single branch stent graft from June 2018 to June 2022 were enrolled in our study.
214868342|NCT04173624|DIAGNOSTIC_TEST|Endosonography|Endosonography (EUS) is endoscopic method for evaluated pancreatic and biliary pathology.
214868343|NCT04173624|DIAGNOSTIC_TEST|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for evaluating pancreatic and biliary pathology
214868344|NCT03275064|BIOLOGICAL|LNA043|LNA043 intra-articular injection
214868345|NCT03275064|OTHER|Placebo|Placebo intra-articular injection
214868346|NCT04159935|DEVICE|iLux® system|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
214868347|NCT02138058|DRUG|Topiramate|
214868348|NCT02138058|BEHAVIORAL|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
214868349|NCT00615654|OTHER|aquatic physical therapy|The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
214868350|NCT02340130|BIOLOGICAL|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
214868351|NCT02340130|BIOLOGICAL|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
214868352|NCT01341782|DRUG|paricalcitol|
214868353|NCT01341782|DRUG|maxacalcitol|
214868354|NCT01341782|DRUG|paricalcitol placebo|
214868355|NCT01341782|DRUG|maxacalcitol placebo|
214868356|NCT05882994|BEHAVIORAL|rom exercise|At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks. Evaluation will be done. At the end of the study, rom exercises will be applied to the patients in the control group.
214868357|NCT00685672|DRUG|adrenalin|adrenalin 2 microgram pr ml placebo
214868358|NCT00685672|DRUG|placebo|Saline instead of adrenaline in the epidural mixture
214868359|NCT00620555|DRUG|gabapentin|Orally administered gabapentin
214868360|NCT04175444|DIAGNOSTIC_TEST|VisuALL Field Analyzer|Each participant will conduct a visual field test with the visuaALL headset.
214868361|NCT04175444|DIAGNOSTIC_TEST|Humphrey Field Analyzer|Each participant will conduct a standard of care Humphrey Visual Field.
214868362|NCT00928161|DRUG|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
214665626|NCT00001325|DRUG|18 FDG|
214868363|NCT02678650|DRUG|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
214868364|NCT02678650|DRUG|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
214868365|NCT05363514|DRUG|Low Dose Naltrexone|Participant takes Low Dose Naltrexone 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
214868366|NCT05363514|DRUG|Microcrystalline cellulose|Participant takes microcrystalline cellulose 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
214868367|NCT00724048|DRUG|ACR16|ACR16 will be administered per dose and schedule specified in the arm description.
214868368|NCT00724048|OTHER|Placebo|Placebo matching to ACR16 will be administered per schedule specified in the arm description.
214868369|NCT02548130|OTHER|MELD score|introduction of MELD score
214868370|NCT06262282|BIOLOGICAL|mycobacteriophage|mycobacteriophage phage that has been found effective in killing participants NTM infection
214868371|NCT02141035|DRUG|Acetyl-l-carnitine|Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
214868372|NCT02141035|DRUG|placebo|The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
214868373|NCT00561561|BEHAVIORAL|Acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
214868374|NCT03833479|OTHER|No Further Treatment|No further treatment
214868375|NCT03833479|DRUG|TSR-042|Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
214868376|NCT02754544|PROCEDURE|Direct Electrocortical Stimulation|Undergo direct electrocortical stimulation
214868377|NCT02754544|OTHER|Electrocorticography|Undergo electrocorticography
214868378|NCT06982924|DRUG|Limertinib+bevacizumab|The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive the combination of Limertinib with bevacizuma in first-line treatment
214290854|NCT05710536|OTHER|Formulation X|This formulation containing stem cell secretome and liquorice root extract
214290855|NCT00000938|DRUG|ceftriaxone|
214868379|NCT06982924|DRUG|Limertinib|The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive Limertinib in first-line treatment
214868380|NCT01358552|OTHER|Néevo®/ NéevoDHA®|Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
214868381|NCT06990971|OTHER|No Intervention: Observational Cohort|No interventions will be performed specifically for this study. Samples will be collected from menstrual fluid naturally shed or from biopsies and/or operations that are already taking place.
214868382|NCT03131492|DIAGNOSTIC_TEST|Blood test|C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
214868383|NCT06156189|DIETARY_SUPPLEMENT|Enteral Feeding|Feeding via Nasogastric tube in intubated and ventilated patients
214868384|NCT06105827|DRUG|Control group|Give antibiotics or diclofenac sodium suppository as needed.
214868385|NCT06105827|DRUG|Ningmitai capsule|Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
214868386|NCT06105827|DRUG|Combined group (Ningmitai plus tamsulosin)|Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.
214868387|NCT06988670|DRUG|EXT608|Modified version of parathyroid hormone attached to vitamin D to extend half-life
214868388|NCT06988670|OTHER|Placebo|Placebo for injection
214868389|NCT06988995|OTHER|Information|Participants provided handouts with information on self-compassion
214868390|NCT06988995|BEHAVIORAL|Meeting|Participants meet with a psychological provider to receive information on self-compassion and training on how to utilize self-compassion
214868391|NCT06990932|DEVICE|High Intensity Laser|The therapeutic dose of laser therapy depends on power density, tissue color, and type. Darker skin may absorb the laser in the epidermal layer, but HILT can pass through without absorption. Research has improved power density and dose, with the World Association of Laser Therapy recommending a 5-7 J/cm2 dose for optimal therapeutic outcomes.
214868392|NCT06990932|OTHER|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is a popular alternative to traditional manual therapy techniques, derived from Cyriax cross-friction massage. It uses hard tools to manipulate soft tissue, varying in direction, force, and pattern, and allowing pressure to disperse to underlying tissues. Modern Instrument-assisted soft tissue mobilization instruments vary in material and design, and are used to improve musculoskeletal conditions and outcomes. Patients receive Instrument-assisted soft tissue mobilization with an M2T blade, positioned at a 45° angle, and instructed to apply an ice pack if experiencing burning sensations.
214868393|NCT06990932|OTHER|Conventional treatment|conventional physical therapy, which includes ultrasound, isometric neck exercises, chin tucks, stretching of neck muscles, and neck stabilization exercises, were used for groups A, B and C
214868394|NCT05120206|PROCEDURE|Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).|Non-surgical and surgical periodontal therapy in cigarette smokers and non-smokers
214290856|NCT00000938|DRUG|doxycycline|
214290857|NCT03534557|DIAGNOSTIC_TEST|FEV6 spirometry|During the same spirometry, to compare the relative value of FVC and FEV6
214290858|NCT00847860|DRUG|Cilostazol|Cilostazol 100 mg bid for 12 months
214868395|NCT02044549|DRUG|carbetocin|Oxycontin analogue
214868396|NCT02044549|DRUG|Syntometrine|Uterotonins
214868397|NCT06989073|PROCEDURE|Muscle Energy Technique|METs are soft tissue or joint techniques that are employed in the treatment of musculoskeletal dysfunctions.
214868398|NCT06989073|PROCEDURE|Convenional treatment|Hot pack, Range of Motion Exercises, Stretching Exercises and Strengthening exercises.
214868399|NCT06991127|DEVICE|MAIA|MAIA is an automatic microperimeter with fundus imaging capabilities that measures retinal sensitivity, fixation stability and locus of fixation, and allows the acquisition of confocal images of the retina, thanks to its confocal scanning imaging system which uses infrared and visible light.
214868400|NCT06988891|OTHER|'Evidence-based practice' training based on the flipped learning model|The evidence-based practice training, developed using the flipped learning model, was delivered once a week for four weeks. Each session was delivered as an offline training (3-24 February 2025) and a face-to-face training three days later (6-27 February 2025). The offline part of the training was delivered via the Edpuzzle platform. The training duration for each session was 75 minutes in total, 15 minutes offline and 60 minutes face-to-face.
214868401|NCT06988891|OTHER|'Evidence-based practice' training based on web-based education model|Evidence-based practice training, developed based on a web-based training model, was implemented once a week for two weeks (March 17-24, 2025). Each session was conducted offline. The first session was 20.10 minutes, and the second session was 17.44 minutes.
214868402|NCT06988891|OTHER|'Evidence-based practice' training based on traditional education model|The evidence-based practice training, developed based on the traditional/face-to-face education model, was delivered once a week for three weeks (7-21 April 2025). Each session consisted of two teaching hours (one teaching hour: 45 minutes).
214868403|NCT04222374|PROCEDURE|Intervention in the UroCCR sites|"1. Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)~2. DNA extraction:~   * For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,~  * 1 aliquot for the UroCCR biobank.~  * For patients from other UroCCR centers, only 1 aliquot will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.~3. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux."
214868404|NCT04222374|PROCEDURE|Intervention in the CRB of Bordeaux University Hospital|"1. Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.~2. Overall packing of GWAS samples for shipment to the NCI.~3. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study."
214868405|NCT04222374|PROCEDURE|Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital|Transfer of the data associated with the samples to the NCI.
214868406|NCT04222374|PROCEDURE|Subsequent intervention at the NCI (for information)|"1. Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.~2. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples."
214868407|NCT06395376|OTHER|Bikram Hot Yoga Intervention|"Active participants engage in a yoga intervention which entails participating in a minimum of 60-minutes of hot yoga (Bikram sequence), 3x per week in a heated room at 40 degrees C. The intervention will be 6-weeks of active intervention when they are participating in yoga, followed by an 6-week washout period where they will be asked to not practice yoga. Participants will be asked to give blood at 9 timepoints throughout the 12-week study, including baseline, week one, midpoint, end of Hot Yoga Intervention (Week 6) and after Washout (Week 12)"
214868408|NCT06395376|OTHER|Hot Yoga Washout|"The Washout period consists of 6-weeks occurring immediately after the Hot Yoga Intervention during which the participants do not perform any hot yoga."
214868409|NCT03923530|DRUG|Eplerenone|Eplerenone 50 mg daily
214868410|NCT00515931|RADIATION|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
214868411|NCT01955655|DRUG|Baclofen|Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
214868412|NCT01955655|OTHER|Placebo|
214868413|NCT00134173|DRUG|torcetrapib/atorvastatin|
214868414|NCT00134173|DRUG|atorvastatin|
214868415|NCT03026972|BIOLOGICAL|Placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.
214868416|NCT03026972|BIOLOGICAL|Low dose adjuvant|Population I and polulation IV are coxal muscle injection of low dose adjuvant.
214868417|NCT03026972|BIOLOGICAL|High dose adjuvant|Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.
214868418|NCT03026972|BIOLOGICAL|Low dose vaccine|Population I and population IV are coxal muscle injection of low dose vaccine.
214868419|NCT03026972|BIOLOGICAL|High dose vaccine|Population II,population III and population IV are coxal muscle injection of high dose vaccine .
214868420|NCT05426304|DRUG|Agomelatine|agomelatine 25 mg/day for 180 days
214868421|NCT05426304|DRUG|Placebo Tablets|placebo 25 mg/day for 180 days
214868422|NCT00911807|DRUG|Cerebrolysin + donepezil|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
214868423|NCT00911807|DRUG|Cerebrolysin + placebo|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks)."
214868424|NCT00911807|DRUG|Donepezil + placebo|"Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
214868425|NCT03814941|OTHER|paper-based anesthesia record|to evaluate the incidence of artifacts in the AIMS database by paper-based anesthesia record
214868426|NCT03814941|OTHER|electronic documents|to evaluate the incidence of artifacts in the AIMS database by electronic documents anesthesia record
214868427|NCT03144102|BEHAVIORAL|Virtual Reality-based therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
214868428|NCT03144102|DEVICE|Anodal transcranial direct-current stimulation (tDCS)|Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
214868429|NCT03144102|BEHAVIORAL|Occupational Therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
214868430|NCT03144102|DEVICE|Sham transcranial direct-current stimulation (tDCS)|Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
214868431|NCT00001713|DRUG|Recombinant Tissue Plasminogen Activator|
214868432|NCT00001713|DRUG|Heparin|
214868433|NCT00001713|DRUG|Warfarin|
214868434|NCT04650113|COMBINATION_PRODUCT|MTA material|Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
214868435|NCT01601366|DEVICE|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
214868436|NCT01601366|DRUG|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
214868437|NCT02944942|PROCEDURE|General anesthesia|Patients undergoing general anesthesia
214868438|NCT02612220|PROCEDURE|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
214868439|NCT02612220|OTHER|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
214868440|NCT01174082|BIOLOGICAL|KLH Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
214868441|NCT01174082|BIOLOGICAL|KLH-id Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
214868442|NCT01174082|DRUG|GM-CSF|250 mcg/m2 subcutaneously daily for 4 days after each vaccine
214868443|NCT01174082|PROCEDURE|Apheresis|Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
214868444|NCT01174082|PROCEDURE|Donor Lymphocyte Infusion (DLI)|Day 0, infusion to patient of collected donor cells.
214868445|NCT02991430|DEVICE|active neuromodulation for episodic migraine headache|Non-invasive brainstem neuromodulator. Active and placebo devices appear identical
214868446|NCT02991430|DEVICE|placebo neuromodulation for episodic migraine headache|Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
214868447|NCT01938404|BIOLOGICAL|Octaplas|Octoplas infusion solution for IV administration
214868448|NCT01938404|DRUG|Standard Plasma|Plasma given as replacement fluid
214868449|NCT02254369|DRUG|GC021109|
214868450|NCT02254369|OTHER|Placebo|
214868451|NCT01997229|BIOLOGICAL|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
214868452|NCT01997229|DRUG|Placebo|Placebo
214868453|NCT02304991|DRUG|Liquid Peanut Extract|5000mcg/ml peanut protein
214868454|NCT02304991|DRUG|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
214868455|NCT05499780|DEVICE|Sentinox|The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
214290859|NCT00847860|DRUG|Aspirin|Aspirin 100 mg qd for 12 months
214290860|NCT05245370|BEHAVIORAL|Control video|Control group 1 will see a control video consisting of basic information about the different types of psychotherapy that are covered by insurance in Germany and the process of applying for psychotherapy with the insurance. The control video is matched in duration (10 minutes), set-up and the overall topic (psychotherapy) to the intervention video testimonials.
214868456|NCT01150617|DRUG|Insulin glargine plus insulin analogues|"* Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c\<6.5% at the end of the follow-up.~* Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of \< 7.0% at the end of the follow-up."
214868457|NCT02681146|OTHER|Multimodal intervention|Educational advice + physiotherapist treatment
214868458|NCT01529918|OTHER|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
214868459|NCT03252418|DRUG|Ascorbic Acid 500 MG|ascorbic acid is vitamin that can cause gingival depigmentation
214868460|NCT03252418|DEVICE|diode laser|diode laser is soft tissue laser case photothermolysis of melanoctes
214868461|NCT03835221|DEVICE|methafilcon A toric contact lenses|Bilateral daily wear of methafilcon A toric contact lenses
214868462|NCT03835221|DEVICE|fanfilcon A toric contact lenses|Bilateral daily wear of fanfilcon A toric contact lenses
214868463|NCT06404164|PROCEDURE|Wedge resection under watershed analysis method|"* Compare the preoperative 3D reconstruction model, and use electrocautery to directionally separate and expose the target artery;~  * Auxiliary devices (unlimited) to block the target artery, but should not be severed; ③ Peripheral intravenous injection of ICG, electrocautery to mark the border of counter-staining; ④ Evaluate the actual incisal margin according to the preoperative planning, and use the cutting stapler to wedge resection of the pulmonary nodule"
214868464|NCT01258166|PROCEDURE|Surgery or immobilization|
214868465|NCT02426047|DIETARY_SUPPLEMENT|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
214868466|NCT04238988|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
214868467|NCT04238988|DRUG|Carboplatin|Chemotherapy medication
214868468|NCT04238988|DRUG|Taxol|Chemotherapy medication
214868469|NCT04350320|DRUG|Colchicine Tablets|standard therapy for COVID-19 according to the stablished hospital protocols.
214868470|NCT04350320|DRUG|Standard therapy for COVID-19 according to the stablished hospital protocols.|standard therapy for COVID-19 according to the stablished hospital protocols.
214868471|NCT02737527|PROCEDURE|24G intravenous route for Lumbar Sympathetic Block (LSB):|Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
214868472|NCT02737527|DEVICE|15-cm Chiba needle for Lumbar Sympathetic Block (LSB)|The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
215035171|NCT03388372|DRUG|Temozolomide|Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.
215035172|NCT03388372|RADIATION|Radiotherapy|Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
215035173|NCT05026164|DIETARY_SUPPLEMENT|CHI-202|Blend of cannabinoids \& other ingredients
215035174|NCT05026164|DIETARY_SUPPLEMENT|CHI-101|Placebo
215035175|NCT06032130|OTHER|Clinical measurements|Optometric measurements
215035176|NCT06032130|OTHER|Oculomotor or perceptual therapy|Oculomotor or perceptual visual learning exercices
215035177|NCT00629928|DRUG|Esomeprazole|20mg oral capsule daily
215035178|NCT00629928|DRUG|Esomeprazole|40mg oral capsule daily
215035179|NCT00629928|DRUG|Placebo|
215035180|NCT00641693|DRUG|Budesonide|16mg Nasal Spray
215035181|NCT00641693|DRUG|Budesonide|32mg Nasal Spray
215035182|NCT00641693|DRUG|Budesonide|64mg Nasal Spray
215035183|NCT00641693|DRUG|Placebo|
214290861|NCT05245370|BEHAVIORAL|Rationale video|The active control group 2 will see a short rationale and the control video. The rationale is a 2:45 minute-long animated video (designed via the visual communication platform powtoon, https://powtoon.com/) explaining some of the underlying mechanisms of depression.
214290862|NCT05245370|BEHAVIORAL|Clinician testimonial|This group will see the rationale video first, followed by testimonial of a professional clinician/psychotherapist.
215035184|NCT01179230|OTHER|SPECT imaging|Dipyridamole stress testing 0.57 mg/kg
215035185|NCT01179230|OTHER|PET imaging|Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
215035186|NCT05617261|OTHER|Conscious sedation|Conscious sedation is a combination of medications to help you relax (a sedative, for example nitrous gas) and to block out pain (commonly known as freezing, for example lidocaine).
215035187|NCT00144326|DRUG|Tiotropium Bromide|
215035188|NCT00144326|DRUG|Placebo|
215035189|NCT03889652|DIAGNOSTIC_TEST|Oct scans|Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups
215035190|NCT03901430|BEHAVIORAL|Group navigation model|In a series of peer group sessions facilitated by Guadalupe Fuentes, a CHW who designed the model, we will create a culturally-appropriate, non-stigmatizing group intervention. The group process will allow participants to explore their own MEH, better understand the ways that mental health influences well-being and everyday dynamics of their lives, and to develop empowering knowledge and action plans through the support of other women.
215035191|NCT02798887|PROCEDURE|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
215035192|NCT00995787|DRUG|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
215035193|NCT00995787|DRUG|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
215035194|NCT00003249|DRUG|carboxyamidotriazole|
215035195|NCT00003249|DRUG|chemotherapy|
215035196|NCT00003249|DRUG|ketoconazole|
215035197|NCT05552404|OTHER|conservative therapy|bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
215035198|NCT05552404|DRUG|Aminophylline|conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
215035199|NCT05552404|PROCEDURE|trans nasal sphenopalatine ganglion block|conservative therapy plus sphenopalatine ganglion block SPGB using hollow cotton swab and lidocaine 2%
215035200|NCT01518413|DRUG|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
215035201|NCT01518413|DRUG|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
215035202|NCT01871376|DRUG|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
215035203|NCT03028701|DRUG|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
215035204|NCT06164054|DEVICE|Virtual Reality Rehabilitation System|Participants of the experimental group will undergo treatment with Virtual Reality, both IVR and HB. The intervention will consist of 12 sessions lasting about 1 hour each and carried out with a frequency of three days per week within four weeks. Before starting the rehabilitation, arm illusion with the Handbox is inducted to explore the ability of the patients to perceive the virtual arm as their own. During this task, patients sit on a chair with the injured arm inside the Handbox and are invited to perform slow movements with the hand, such as moving the fingers one at a time and moving the wrist up and down. Moreover, they are invited to keep their attention to the virtual arm project on the screen that follows their natural movements. The arm illusion lasts 3 minutes, and the embodiment questionnaire is administered. Then, the treatment starts with IVR and HB sessions, which are counterbalanced to avoid the learning effect
215035205|NCT06164054|BEHAVIORAL|Traditional therapy|Participants randomly assigned to the control group will receive rehabilitation treatment as per usual clinical practice. Specifically, patients will be directed to rehabilitation facilities according to standard clinical rehabilitation pathways. They will be assigned to a physiotherapist who will administer the rehabilitation treatment for the upper limb impairment. Patients in the control group will receive the same amount of rehabilitation for the recovery of upper limb impairment as the treatment group, which means 3 physiotherapy sessions lasting 1 hour 3 times a week for 4 weeks.
215035206|NCT01681147|BEHAVIORAL|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
214868473|NCT02737527|DEVICE|Ultrasound for Lumbar Sympathetic Block (LSB)|Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
214868474|NCT02737527|DEVICE|Fluoroscope for Lumbar Sympathetic Block (LSB)|Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
214868475|NCT02737527|DRUG|10 ml of 0.25% levobupivacaine injection for LSB|After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
214868476|NCT02737527|PROCEDURE|Temperature measurement for Lumbar Sympathetic Block (LSB)|Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
214868477|NCT02737527|PROCEDURE|Postprocedure care for LSB|Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
214868478|NCT05335291|OTHER|Questionnaire study|The Turkish validity and reliability of the questionnaire will be examined.
215035207|NCT01681147|BEHAVIORAL|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
215035208|NCT00565747|DEVICE|Test culture|A standard culture medium with added GM-CSF (ready-to-use)
215035209|NCT00565747|DEVICE|Control culture|The same standard culture medium, but without any additions (ready-to-use)
215035210|NCT00183248|DRUG|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
215035211|NCT00183248|DRUG|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
215035212|NCT00183248|DRUG|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
215035213|NCT00183248|DRUG|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
214868479|NCT03375294|DRUG|Nitrous Oxide|One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
214868480|NCT03250494|DRUG|Dulox capsule (60mg)|each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
215035214|NCT00183248|PROCEDURE|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
215035215|NCT00183248|PROCEDURE|Kidney transplant|Occurs at study entry
215035216|NCT01144650|DRUG|Dapsone|Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
215035217|NCT01144650|DRUG|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
215035218|NCT03224884|PROCEDURE|Interscalene block|Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
214290863|NCT05245370|BEHAVIORAL|Patient testimonial|This group will see the rationale video first, followed by testimonial of a patient who is being treated for depression with psychotherapy.
214868481|NCT03250494|DRUG|combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI|each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
215035219|NCT03224884|PROCEDURE|Supraclavicular block|"Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus)."
215035220|NCT03309202|DRUG|PF-05221304|25 mg dose
215035221|NCT05547035|BEHAVIORAL|Patient follow-up of depression|"All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists:~* assess the depression severity by using MADRS scale~* assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures~* the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression."
215035222|NCT01697709|DRUG|Quetiapine|Quetiapine pharmacotherapy for cannabis dependence
215035223|NCT01697709|DRUG|Placebo|placebo capsules
215035224|NCT05294887|DRUG|Bisoprolol|beta-adrenergic receptor blocker
215035225|NCT05294887|DRUG|Diltiazem|calcium channel blocker
215035226|NCT05294887|DRUG|Placebo|Placebo
215035227|NCT03970031|DRUG|MSDC-0602K|MSDC-0602K tablet
215035228|NCT03970031|DRUG|Placebo|Matching tablet
215035229|NCT05228418|DRUG|Naltrexone Pill|Naltrexone oral bridge to IM naltrexone maintenance therapy
214868482|NCT03250494|DRUG|a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone|each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
214290864|NCT02848651|DRUG|Atezolizumab|Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
214290865|NCT03057431|DRUG|Placebo oral capsule|Once daily for 3 years
214868483|NCT01770392|DRUG|Nintedanib|single dose administration
214868484|NCT01770392|DRUG|Rifampicin|single dose once daily for 7 days
214868485|NCT01770392|DRUG|Nintedanib|single dose administration
214868486|NCT02362984|DRUG|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
214290866|NCT03057431|DRUG|12.5 mg hydrochlorothiazide|Once daily for 3 years
214868487|NCT02362984|DRUG|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
214868488|NCT01580813|DRUG|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
214868489|NCT01580813|DRUG|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
214868490|NCT04639713|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
214868491|NCT06881888|DRUG|Octreotide (drug)|Participants will administer the DDM-octreotide nasal spray without priming in one nostril three times a day.
214868492|NCT06881888|DRUG|Placebo|Participants will administer the placebo nasal spray without priming in one nostril three times a day.
214868493|NCT01294475|BEHAVIORAL|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
214868494|NCT04731870|OTHER|Survey research|This is not an intervention study. It involves social science research of surveys and focus groups.
214868495|NCT05652959|DEVICE|Cerviron®|Cerviron® is a medical device manufactured by PFC Pharma Manufacturing SL formulated following the provisions of the European Regulation 2017/745 on Medical Devices. Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21. Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
214868496|NCT02606175|OTHER|Taking questionnaires and tests|"At predefined timepoints:~* 2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)~* 1 test for medication adherence: BAASIS~* 1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)~* 1 test about medication knowledge"
214868497|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation|Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.
214868498|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation sham stimulation|Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.
214868499|NCT02397642|PROCEDURE|IVF/ICSI|
214868500|NCT02397642|DRUG|Human Chorionic Gonadotropin|given in different doses and timing to support the luteal phase
214868501|NCT05623943|PROCEDURE|Endovascular treatment|Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.
214868502|NCT00786279|OTHER|ethanol|15 gm ethanol daily for 6 months
214868503|NCT00786279|OTHER|Ethanol-free beverage|0 grams ethanol daily for 6 months.
214868504|NCT04271020|DEVICE|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
214868505|NCT00521027|DEVICE|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
214868506|NCT00521027|PROCEDURE|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
214868507|NCT05386082|OTHER|Modified Delphi process|The study involves a brief demographics survey and Delphi process, i.e. three rounds of information and surveys, in which participants will be asked to score/rank potential metrics.
214868508|NCT05476120|BEHAVIORAL|BATHE|The BATHE interview technique was applied 3 times, once every 3 months, for 6 months.
214868509|NCT04067427|OTHER|Mental training|App-based mental training
214290867|NCT03057431|DRUG|25.0 mg hydrochlorothiazide|Once daily for 3 years
214290868|NCT03057431|DRUG|50.0 mg hydrochlorothiazide|Once daily for 3 years
214868510|NCT06706427|BIOLOGICAL|NGGT001|Using a recombinant adeno-associated virus (AAV) vector to deliver the gene CYP4V2 via subretinal injection for the treatment of crystalline retinal degeneration.
214868511|NCT02243267|OTHER|sample collection|
214868512|NCT01622686|BEHAVIORAL|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
214868513|NCT00030992|DRUG|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m\^2/day for a total per cycle dose of 30 mg/m\^2
214868514|NCT00030992|DRUG|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
214868515|NCT00030992|DRUG|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
214868516|NCT03984292|PROCEDURE|Teaching of laparoscopic skills on a box simulator|The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
214868517|NCT05953974|OTHER|Clinical score of Granillo and al.|Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
214868518|NCT06477484|DIAGNOSTIC_TEST|Blood biomarker|Blood biomarker
214868519|NCT00523965|DRUG|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
214868520|NCT00523965|DRUG|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or \> 25 kg Miltefosine 50 mg once daily if patient weighs \<25 mg
214868521|NCT00523965|DRUG|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
214868522|NCT00523965|DRUG|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
215035230|NCT02545439|DRUG|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
215035231|NCT00415636|DRUG|IC83/LY2603618|40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2.
215035232|NCT00415636|DRUG|IC83/LY2603618|70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
214868523|NCT02901613|DEVICE|Negative-pressure wound therapy|
214868524|NCT00415766|DRUG|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
214868525|NCT00415766|DRUG|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
214868526|NCT00415766|DRUG|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
214868527|NCT04754126|BEHAVIORAL|Amazing Me|The Amazing Me Program is an evidence-based program designed to help children between the ages of 9 and 11 build self-esteem, body confidence, and eliminate weight-based bullying and teasing. This school-based curriculum satisfies national educational health requirements and provides tools for teachers to implement in 4th and 5th grade classrooms.
214868528|NCT02582866|DRUG|Lacosamide|"* Pharmaceutical Form: Oral tablets~* Concentration: 50 mg~* Route of Administration: Oral administration"
215035233|NCT00415636|DRUG|IC83/LY2603618|105 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
215035234|NCT00415636|DRUG|IC83/LY2603618|150 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
215035235|NCT00415636|DRUG|IC83/LY2603618|195 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
215035236|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
215035237|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
215035238|NCT04734210|DRUG|0.02% Betamethasone Sodium Phosphate|topical corticosteroid solution
215035239|NCT04734210|DRUG|0.04% Betamethasone Sodium Phosphate|topical corticosteroid solution
214868529|NCT01708629|DRUG|210 mg brodalumab|210 mg brodalumab administered SC
214868530|NCT01708629|DRUG|140 mg brodalumab|140 mg brodalumab administered SC
214868531|NCT01708629|DRUG|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
214868532|NCT01708629|DRUG|placebo|placebo administered SC
214868533|NCT01302613|DRUG|Capecitabine|Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
214868534|NCT01302613|DRUG|5-FU|5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
214868535|NCT01302613|DRUG|Leucovorin|Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
214868536|NCT01302613|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
214868537|NCT01302613|RADIATION|radiation|"28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a boost of 3-5 fractions of 180 cGy subsequently delivered."
215035240|NCT04734210|DRUG|Placebo|topical vehicle solution
215035241|NCT05192278|OTHER|erector spinae block|The patients will do the procedure under fluoroscopic guidance. The patients were placed in prone position. After the identification of the T4 transverse process, the targeted injection site was anesthetized with 3-4 ml of 2% lidocaine. A 25-gauge spinal needle was advanced until it contacted the transverse process at the T4 level. Next, a solution of 1mL of methylprednisolone 40mg/mL with 7 mL of 0.25% bupivacaine and 2mL of nonionic contrast in 10 ml saline 0.9% (group A) and in 20 ml saline 0.9% (group B) will injected. Then another photo will be taken with the fluoroscopy to determine the level of spread in each group. After finished, the patients will transfer to the post-operative care unit and will monitored for any complication for one hour.
214868538|NCT01302613|PROCEDURE|total mesorectal excision|Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
214868539|NCT03763552|OTHER|arthroscopic wrist arthrodesis|Cases of midcarpal wrist arthritis treated surgically with arthroscopic partial wrist fusion with cannulated screws
214868540|NCT00003179|DRUG|medroxyprogesterone|
214868541|NCT00030043|DEVICE|Penetrating auditory brainstem implant|
214868542|NCT00630097|DRUG|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
214868543|NCT04971798|BIOLOGICAL|Cell-free Stem Cell-derived Extract Formulation (CCM)|Intraarticular injection
215035242|NCT06140693|OTHER|Continuous exercise at an intensity below the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 80% of the intensity at the ventilatory threshold
215035243|NCT06140693|OTHER|Continuous exercise at an intensity at the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 100% of the intensity at the ventilatory threshold
215035244|NCT06140693|OTHER|Continuous exercise at an intensity above the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 110% of the intensity at the ventilatory threshold
215035245|NCT06140693|OTHER|Sprint interval training|22 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by four 30-s 'all-out' sprints, each with a 4-min recovery intervals at 25 W
215035246|NCT06140693|OTHER|Reduced-exertion high-intensity interval training|10 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by two 20-s 'all-out' sprints, with a 3-min and a 4-min recovery interval at 25 W after the first and second sprint respectively
215035247|NCT02940548|DRUG|Nifedipine GITS|Nifedipine GITS 30\~60mg/day for 8 weeks
215035248|NCT02940548|DRUG|Amlodipine besylate|Amlodipine besylate 5\~10mg/day for 8 weeks
215035249|NCT02684461|DRUG|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
215035250|NCT03914690|DRUG|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
215035251|NCT03914690|DRUG|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
215035252|NCT02138825|DRUG|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
215035253|NCT02138825|DRUG|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
215035254|NCT06458569|OTHER|Rehabilitation|3-weeks rehabilitation in hospital
215035255|NCT03369808|BIOLOGICAL|7.5μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
215035256|NCT03369808|BIOLOGICAL|Phosphate Buffer Solution|0.5ml phosphate buffer solution
215035257|NCT03369808|BIOLOGICAL|Aluminum Hydroxide Adjuvant|0.5ml aluminum hydroxide adjuvant
215035258|NCT03369808|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
215035259|NCT03369808|BIOLOGICAL|30μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
215035260|NCT00693758|DRUG|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
215035261|NCT00693758|OTHER|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
215035262|NCT00693758|OTHER|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
215035263|NCT00693758|DEVICE|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
214868544|NCT01159197|BEHAVIORAL|cognitive behavioral therapy|Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
214868545|NCT01666197|DRUG|diclofenac potassium 25 mg tablet|diclofenac potassium 25 mg tablet
215035264|NCT00693758|DEVICE|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
215057182|NCT01692288|BEHAVIORAL|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
215057183|NCT04317443|PROCEDURE|Super-mini percutaneous nephrolithotomy (SMP)|SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
214868546|NCT01666197|DRUG|placebo|placebo
214868547|NCT03550573|DEVICE|CardioInsight™ Noninvasive 3D Mapping System|"The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The vest wearing is coupled with a CT scan.~This exam will be performed only at baseline visit."
214868548|NCT05217719|DRUG|recombinant human thrombopoietin|The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.
214868549|NCT05217719|DRUG|normal saline|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
214868550|NCT03055702|OTHER|Mobile phone text message reminder|an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
214868551|NCT00658645|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
214868552|NCT00658645|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
214868553|NCT00658645|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
214868554|NCT02359747|GENETIC|Polymerase Chain Reaction and Whole Genome Amplification|Polymerase Chain Reaction and Whole Genome Amplification
214868555|NCT02753491|BEHAVIORAL|Motivational short interview|New designed motivational short interview model
214868556|NCT01193127|DRUG|OMS302 Solution|
214868557|NCT01193127|DRUG|OMS302 Mydriatic Solution|
214868558|NCT01193127|DRUG|OMS302 Anti-inflammatory Solution|
214868559|NCT01193127|DRUG|Balanced Salt Solution (BSS) Solution|
214868560|NCT00578669|DRUG|Fluoxetine|20mg once daily for 16 weeks
214868561|NCT00578669|DRUG|Dextrose|Once daily for 16 weeks
214868562|NCT03035344|OTHER|Metabolome study|Metabolome study in ALL patients compared to healthy controls
214868563|NCT03030820|PROCEDURE|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
214868564|NCT03033082|OTHER|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used."
214868565|NCT03246646|BEHAVIORAL|Coaching|Telephone coaching was provided in a series of telephone based sessions with CSO participants
214868566|NCT00532038|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
214868567|NCT02688426|DEVICE|Sham Low-Level Laser Therapy (Sham LLLT)|perform with the machine off
214868568|NCT02688426|DEVICE|6J Low-Level Laser Therapy (6J LLLT)|irradiation will be perform with 6J
215057184|NCT04317443|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
215057185|NCT01807169|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
215057186|NCT01391169|OTHER|seromuscular flap enforcement|seromuscular flap enforcement
214290869|NCT02435784|OTHER|The Two-Way Communication Checklist|The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
214868569|NCT03889366|DRUG|Aprepitant 125 mg|Single dose in the fasted state during treatment period 1,2 or 3
214868570|NCT01331226|BEHAVIORAL|telephone counseling 3 sessions|3 sessions of telephone counseling
214868571|NCT01331226|BEHAVIORAL|telephone counseling 1 session|1 session of telephone counseling
214868572|NCT01331226|BEHAVIORAL|written materials only|written materials only
214868573|NCT00397163|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation
214868574|NCT00397163|PROCEDURE|Placebo|Deflated cuff on upper arm and thigh for 20 min
214868575|NCT04919863|DRUG|NTP42:KVA4|Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
214868576|NCT04919863|DRUG|Placebo|Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
214868577|NCT05912439|BEHAVIORAL|SidekickHealth|Usage of mobile application called SidekickHealth.
214868578|NCT04860063|DRUG|Berberine|Participants randomly assigned to the intervention group will be provided with Berberine 500 mg administrated per os three times a day for six months
214868579|NCT04860063|DRUG|Placebo|Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months
214868580|NCT00739986|DRUG|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
214868581|NCT00739986|DRUG|Semapimod|Semapimod 60 mg IV x 3 days
214868582|NCT00739986|DRUG|Placebo|placebo IV x 3 days
214868583|NCT02569112|DEVICE|multipolar RF, varipulse|Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
214868584|NCT02569112|DEVICE|cryolipolysis|Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
214868585|NCT06309927|PROCEDURE|Operative hysteroscopy (by tissue removal device)|Surgical evacuation of the uterine cavity using the Truclear Mini-Elite hysteroscopic tissue removal device
214868586|NCT06309927|PROCEDURE|Suction curettage|Surgical evacuation of the uterine cavity with electrical vacuum suction curette
214868587|NCT02352779|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Given PO
214868588|NCT02352779|OTHER|Placebo|Given PO
214868589|NCT02352779|OTHER|Questionnaire Administration|Ancillary studies
214868590|NCT02352779|OTHER|Laboratory Biomarker Analysis|Correlative studies
214868591|NCT00306423|PROCEDURE|Other: Exercise|exercise 3 times per week for 12 weeks
214868592|NCT05695677|PROCEDURE|Capacitive-Resistive Radiofrequency therapy of the neck muscles|Capacitive-Resistive Radiofrequency therapy of the neck muscles as a non-invasive technique for treating PDPH.
214868593|NCT02185651|DRUG|Zavesca® Prescription|"Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
214868594|NCT00485420|OTHER|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
214290870|NCT02435784|OTHER|Treatment as usual|Patients will attend a psychiatric consultation as usual.
214868595|NCT04326465|DEVICE|Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage|Fractional Carbon Dioxide Laser Therapy is an ablative therapy where abnormal collagen in scarred tissue is destroyed to permit the formation of more organized collagen. Previous studies have demonstrated its efficacy in treating medical conditions (ex. hypertrophic scars) similar to Peyronies Disease. There is evidence that Fractional Carbon Dioxide Laser Therapy has the ability to target and alter the molecular pathways that are similar to the ones that lead to Peyronie's Disease.
214868596|NCT03457467|DRUG|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity
214868597|NCT03457467|RADIATION|SBRT|according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
214868598|NCT04896749|OTHER|Nerve mobilization|"Moist pack all over cervical spine for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.~Median, ulnar and radial nerve stretch with 3 sets of 10 repetitions , with 3 sec hold at final stretched position.~Following nerve mobilizations are used in experimental group/group A:~Median Nerve: Glenohumeral abduction, wrist extension, supination, glenohumeral lateral rotation, elbow extension, neck lateral bending to opposite side. Radial Nerve: Glenohumeral depression, elbow extension, whole arm internal rotation, wrist flexion Ulnar Nerve: Wrist extension, forearm pronation elbow flexion, glenohumeral lateral rotation, glenohumeral depression, shoulder abduction each with 3 sets of 10 repetitions , with 3 sec hold at final stretched position."
214868599|NCT04896749|OTHER|Conventional physical therapy|Moist pack for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.
214868600|NCT01414049|PROCEDURE|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
214868601|NCT01414049|PROCEDURE|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
214868602|NCT01398943|DRUG|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
214868603|NCT01398943|DIETARY_SUPPLEMENT|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
214868604|NCT00871741|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
214868605|NCT00871741|BIOLOGICAL|Infanrix hexa|Intramuscular, three doses
215035265|NCT01910454|BEHAVIORAL|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
215057187|NCT00812396|DRUG|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
215057188|NCT00812396|DRUG|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
214868606|NCT00871741|BIOLOGICAL|Menjugate|Intramuscular, two doses
214290871|NCT03806998|DIETARY_SUPPLEMENT|Ketoacids|Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
214290872|NCT03806998|DIETARY_SUPPLEMENT|Placebo|Provision of placebo capsules similar to active supplement
214290873|NCT01353326|DEVICE|Cormet|Cementless hip resurfacing system
214290874|NCT01353326|DEVICE|Conserve|Cemented hip resurfacing system
214290875|NCT06058676|PROCEDURE|carotid artery stenting|The procedures will be performed for patients with general or local anesthesia. Implantation of stents at the site of carotid artery stenosis for the treatment of carotid severe stenosis. A suitable balloon will be selected based on the internal carotid arterial（ICA）diameter, as shown on the digital subtraction angiography（DSA）image. The use of a balloon for predilatation or postdilatation depends on the degree of stenosis. The type of stent will be selected according to several factors, such as the length and configuration of the lesion, vascular morphology, vessel diameter, plaque characteristics, stent characteristics, and surgeon experience.
214868607|NCT02635581|DEVICE|Delta TT acetabular cup|
214868608|NCT04667260|PROCEDURE|Maxillary sinus membrane elevation|Maxillary sinus membrane elevation with blood coagulum
214868609|NCT04667260|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
214868610|NCT01565850|DRUG|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
214868611|NCT01565850|DRUG|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
214868612|NCT01565850|DRUG|COBI|COBI 150 mg tablet administered orally once daily
214868613|NCT01565850|DRUG|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
214868614|NCT01565850|DRUG|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
214868615|NCT01565850|DRUG|DRV Placebo|DRV placebo tablet administered orally once daily
214868616|NCT01565850|DRUG|COBI Placebo|COBI placebo tablet administered orally once daily
214868617|NCT01565850|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
214868618|NCT00896155|DRUG|Tamoxifen|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
215035266|NCT01910454|BEHAVIORAL|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
215035267|NCT01690273|OTHER|mobility exercise|30 minutes, twice a week
215035268|NCT01690273|OTHER|mobility and elastic resistance exercise|30 minutes, twice a week each exercises group. (total 1 hour)
214290876|NCT01217840|DRUG|Drisdol (Ergocalciferol) Vitamin D2|Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
214290877|NCT01217840|DRUG|Placebo|Placebo pill - 3 pills every 12 weeks for total of 24 weeks
214868619|NCT00896155|RADIATION|Radiotherapy|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
214868620|NCT01949961|OTHER|Ultrasound|SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for \~30 minutes, using a Bracco infusion pump.
214868621|NCT01949961|OTHER|Sham ultrasound|Mounting the ultrasound headframe but connecting this to a non-operative channel
214868622|NCT06928792|OTHER|Experimental interventional group A, (MET).|10-minute hot pack application, followed by MET on the Quadratus Lumborum (3 repetitions with a 7-second hold). Flexibility exercises include William flexion with bilateral knee-to-chest stretches (10-second hold, repeated 10 times) and static stretching of the hamstrings, gastrocnemius, and iliotibial band (5 repetitions with a 5-second hold). Strengthening exercises comprise isometric hip flexor activation (5 repetitions with a 15-second hold), side planks (3 repetitions with a 30-second hold), and static side bending (5 repetitions with a 10-second hold). The intervention will be performed once daily, consisting of 3 sets per session, continued for 4 weeks to enhance flexibility, core stability, and muscular balance, ultimately contributing to pain relief and improved functional mobility in CLBP patients
214868623|NCT06928792|OTHER|Control: group B (conventional intervention exercises)|10-minute hot pack application, followed by William flexion with bilateral knee-to-chest stretches (10-second hold, repeated 10 times). Flexibility exercises consist of static stretching for the hamstrings, gastrocnemius, and iliotibial band (5 repetitions with a 5-second hold). Strengthening exercises include isometric hip flexor activation (5 repetitions with a 15-second hold), side planks (3 repetitions with a 30-second hold), and static side bending (5 repetitions with a 10-second hold). The protocol will be performed once daily, with 3 sets per session, continued for 4 weeks to improve flexibility, core stability, and pain management in CLBP patients.
214868624|NCT00923000|DRUG|Nalbuphine|Nalbuphine 10mg with oral administration
214868625|NCT00923000|DRUG|Morphine|Morphine 10mg with oral administration
214868626|NCT00923000|DRUG|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
214868627|NCT00923000|DRUG|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
214868628|NCT00923000|DRUG|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
214868629|NCT00084448|DRUG|celecoxib|
214868630|NCT00084448|DRUG|paclitaxel|
214868631|NCT01943721|DRUG|VISION5 Product|
214868632|NCT05742347|DEVICE|DriGo Skin Protectant Textile|All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
214868633|NCT05439278|RADIATION|Hypofractionated radiotherapy|40.05 Gy in 15 fractions (daily treatment, 5 per week)
214868634|NCT05439278|RADIATION|Conventional radiotherapy|60 Gy in 30 fractions (daily treatment, 5 per week)
214868635|NCT05439278|DRUG|Temozolomide|concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
214868636|NCT06411899|DRUG|Sonelokimab|Sonelokimab
214868637|NCT06411899|DRUG|Placebo|Placebo
214868638|NCT06956430|DEVICE|Battery-powered rickshaw|A battery-powered rickshaw is a rickshaw where the wheels are turned by a small electric motors powered by a battery.
214868639|NCT06959407|DRUG|oral dexamethasone|Patients in group A will receive oral dexamethasone which will be administered at 0.6mg/kg as single dose
214868640|NCT06959407|DRUG|intramuscular dexamethasone|Patients in group B will receive intramuscular dexamethasone which will be administered in 0.6mg/kg strength as intra-gluteal injection as single dose
214868641|NCT03611543|DEVICE|Standard of Care Flat Paddle|"X-Ray Mammogram Exam.~Each screening subject will receive a 4-view 2D plus 3D combination imaging: Left Cranial Caudal (LCC), Left Medial Oblique (LMO), Right Cranial Caudal (RCC), and Right Medial Oblique (RMLO) with the current standard of care (SOC) flat paddle.~Each diagnostic subject will have her prescribed diagnostic 2D plus 3D combination imaging (CC or MLO) with the SOC flat paddle. The image view (CC or MLO) will be based on the visibility of the area of interest for which the diagnostic imaging was ordered.~The amount of compression applied in all mammograms will be to achieve tautness."
214868642|NCT03611543|DEVICE|Investigational Curved Paddle|"X-Ray Mammogram Exam.~Each screening subject will receive a CC and an MLO in one of her breasts as determined by a randomization scheme with the investigational (INV) curved paddle.~Each diagnostic subject will have her prescribed diagnostic 2D plus 3D combination imaging (CC or MLO) with the INV curved paddle. The image view (CC or MLO) will be based on the visibility of the area of interest for which the diagnostic imaging was ordered.~The amount of compression applied in all mammograms will be to achieve tautness."
215035269|NCT05201807|DEVICE|Dailies Total 1 (DT1)|TEST Lens
215057189|NCT00812396|DRUG|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
214290878|NCT03149198|OTHER|Mat Pilates exercises|The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
214290879|NCT03149198|OTHER|Aquatic aerobic exercises|"The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator."
214290880|NCT03649750|DRUG|Mucinex®|Mucinex® 600 mg ER bi-layer tablets
214290881|NCT00897104|DRUG|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
214290882|NCT00897104|DRUG|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
214290883|NCT00897104|DRUG|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
214665627|NCT06042686|DEVICE|RF Health MAC Device|Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
214665628|NCT00968734|DIETARY_SUPPLEMENT|colecalciferol|50.000UI single oral dose
214665629|NCT01122329|DIETARY_SUPPLEMENT|caprylidene|Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days
214868643|NCT06185959|BEHAVIORAL|Psychoeducation and Process Group for Asian and Asian American Psychiatric Outpatients|Participants will be individuals enrolling in a 1.5 hour weekly therapy group lasting 12 weeks and will be invited to participate in research on group processes and outcomes. The psychoeducation and process group will be a 12-session weekly closed group with 10-15 participants per group (2-3 groups total) conducted via Zoom to enhance accessibility and reduce barriers to care. Groups will be co-led by licensed clinical psychologists with experience providing both group psychotherapy and culturally responsive services. Group sessions will include brief check-ins, collaborative agenda-setting, a mini-didactic, individual reflection, and group discussion. The didactics curriculum will include topics such as intergenerational trauma, cultural differences in emotional expression, the model minority myth, family dynamics, racism, and positive connections to culture.
214868644|NCT06847633|BEHAVIORAL|Digital lifestyle intervention|The digital lifestyle intervention provides support to the patient through digital lectures, home assignments and digital group meetings as well as provides the possibility for the healthcare provider to provide personalized digital support and feedback to the patient
214868645|NCT05105490|DRUG|PerQdisc|Observational trial to collect post-market safety and efficacy information in a limited number of human patients
214868646|NCT05257213|DRUG|Heparin solution|3 ml saline solution containing 5000 IU heparin.
214868647|NCT05257213|DRUG|Anti-adhesion barrier gel|2 ml biodegradable barrier gel containing sodium hyaluronate (10 mg/ml), sodium chloride (8.5 mg/ml), disodium hydrogen phosphate (0.34mg/ml), sodium dihydrogen phosphate (0.14 mg/ml) and water for injection (QS to weight).
214868648|NCT06633419|DRUG|Opevesostat|Administered via oral tablet per dosing regimen.
214868649|NCT06633419|DRUG|Prednisone|Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.
214868650|NCT06633419|DRUG|Fludrocortisone acetate|Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.
214868651|NCT06633419|DRUG|Carbamazepine|Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).
214868652|NCT04395001|DRUG|duloxetine|All participants will receive duloxetine 30 mg once daily for one week and 60 mg once daily for 24 weeks.
214868653|NCT04395001|BEHAVIORAL|Web-based Cognitive Behavioral Therapy (CBT)|The web-based CBT program is an automated program (i.e., users learn skills with interactive, personalized training without any therapist contact) that includes 8, 35- to 45-minute training sessions, each of which provides an educational rationale and training in cognitive or behavioral pain coping skill drawn from face-to-face CBT.
214868654|NCT04395001|OTHER|Nurse-delivered Motivational Interviewing|Subjects randomized to the duloxetine and web-based Cognitive Behavioral Therapy (CBT) with nurse support will receive 6 phone calls from MI trained nurse at week 3, 6, 10, 14, 18 and 22. Telephone sessions may run for 20 minutes on the average.
214868655|NCT00946816|BEHAVIORAL|Nutritional Intervention|Nutritional Intervention
214868656|NCT01711463|DRUG|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
214868657|NCT01711463|DRUG|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
214868658|NCT06222320|OTHER|Kinesiotaping|Kinesiotaping will be applied to patients in this group in addition to painkillers. Kinesiotaping is a physical therapy technique used to treat muscle pain. It is performed with kinesiotaping tapes attached to the skin. These bands are removed after 4-5 days.
214868659|NCT06222320|DRUG|Painkillers|Patients in this group will be treated with painkillers consisting of paracetamol and dexketoprofen.
214868660|NCT00365313|DRUG|celecoxib, esomeprazole|
214868661|NCT06511648|DRUG|Erdafitinib monotherapy|Patients will receive treatment with erdafitinib alone (cohort 1)
214868662|NCT06511648|DRUG|Cetrelimab and Erdafitinib combination|Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
214868663|NCT06318780|OTHER|three-phase CT angiography|three-phase CT angiography
214868664|NCT06318780|OTHER|CEUS ultrasound|CEUS ultrasound
214868665|NCT02799095|DRUG|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
214868666|NCT02799095|DRUG|ALKS 4230 + pembrolizumab|IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
214665630|NCT01122329|DIETARY_SUPPLEMENT|Placebo|
214665631|NCT05502289|DEVICE|TEST LENS|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
215035270|NCT05539547|DEVICE|Neuromuscular Electrical Nerve Stimulation|"Application of NMES on quadriceps muscle groups bilaterally~Frequency: \>50Hz Pulse duration: 350 - 400µs Intensity: Maximal tolerance (visible quadriceps muscle contraction and/or maximally tolerated by the patient, eliciting a slight discomfort) Time: 30 minutes per session, 7 sessions per week Duty Cycle: 2s on / 18s off Duration: Until discharge to a maximum of 30 days"
214868667|NCT05644873|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
214868668|NCT05644873|DRUG|control group saline|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
214868669|NCT06340893|BEHAVIORAL|Exercise|Participants will participate in cardiovascular, agility, balance, strength and coordination training.
214868670|NCT06340893|BEHAVIORAL|Restful Play|This group will engage in restful play activities such as coloring and playing with legos.
214868671|NCT04060017|DRUG|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
214868672|NCT04060017|OTHER|Placebo|Placebo
214868673|NCT05844761|RADIATION|Triggered imaging on TrueBeam with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the TrueBeam triggered imaging motion management technique.
214868674|NCT05844761|RADIATION|Synchrony MLC tracking on fiducials with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique.
215035271|NCT05539547|OTHER|Usual Physiotherapy treatment (Chest Physiotherapy and mobility)|Daily chest physiotherapy and mobility
215035272|NCT01335607|DRUG|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
215035273|NCT01335607|DRUG|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
215035274|NCT02683902|DEVICE|Active tDCS|The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
215035275|NCT02683902|BEHAVIORAL|Hypocaloric diet|A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
215035276|NCT02683902|DEVICE|Sham tDCS|The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
215035277|NCT04028258|DIETARY_SUPPLEMENT|Mixture of fibers + Placebo|Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)
215035278|NCT04028258|DIETARY_SUPPLEMENT|Placebo + Mixture of fibers|Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)
215035279|NCT03714516|BEHAVIORAL|Psychological internet intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
215035280|NCT00004128|BIOLOGICAL|aldesleukin|
215035281|NCT00004128|BIOLOGICAL|filgrastim|
215035282|NCT00004128|DRUG|busulfan|
215035283|NCT00004128|DRUG|cyclophosphamide|
215035284|NCT00004128|DRUG|cytarabine|
215035285|NCT00004128|DRUG|daunorubicin hydrochloride|
215035286|NCT00004128|DRUG|etoposide|
215035287|NCT00004128|PROCEDURE|autologous bone marrow transplantation|
214290884|NCT02141243|PROCEDURE|Lingual Frenotomy|For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
214868675|NCT05844761|RADIATION|Synchrony MLC tracking and lung adaptive model with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique for lung cancer.
214868676|NCT03833336|OTHER|Placebo|The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.
215035288|NCT00004128|PROCEDURE|peripheral blood stem cell transplantation|
215035289|NCT00004128|RADIATION|radiation therapy|
215035290|NCT00005978|BIOLOGICAL|filgrastim|
215035291|NCT00005978|DRUG|carboplatin|
215035292|NCT00005978|DRUG|etoposide|
215035293|NCT00005978|DRUG|melphalan|
215035294|NCT00005978|PROCEDURE|autologous bone marrow transplantation|
215035295|NCT00005978|PROCEDURE|peripheral blood stem cell transplantation|
215035296|NCT00005978|RADIATION|iobenguane I 131|
215035297|NCT00005978|RADIATION|radiation therapy|
215035298|NCT04695990|DRUG|Wenyang Huoxue Decoction|Wenyang Huoxue granules
215035299|NCT04695990|DRUG|Wenyang Huoxue placebo|Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
215035300|NCT00909701|DIETARY_SUPPLEMENT|PreOP Booster|1 serving of 400 ml per study arm
214665632|NCT05502289|DEVICE|CONTROL LENS|PRECISION1™ for Astigmatism Contact Lenses (P1fA)
214665633|NCT01250821|DRUG|Menopur|"The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).~Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day."
214665634|NCT01851837|OTHER|Exercise time|Continuous training, Interval training
214665635|NCT01349348|DRUG|Tolvaptan|tablet, 15 mg, Qd, for 7 days
214665636|NCT01349348|DRUG|Tolvaptan|tablet, 7.5 mg, Qd, for 7 days
214665637|NCT01349348|DRUG|placebo|tablet, 7.5/15mg , Qd, 7days.
214665638|NCT02226666|DRUG|MRI with Multihance|Patients will have Multihance used as an IV contrast agent for their scan.
214665639|NCT02226666|DRUG|MRI with Eovist|Patients will have Eovist used as an IV contrast agent for their scan.
214665640|NCT01014884|OTHER|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
214665641|NCT01014884|OTHER|Multidisciplinary team bimonthly visits either in person or via telephone.|
214665642|NCT01014884|OTHER|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
214665643|NCT03406026|OTHER|Balance System Protocol Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. One session consists of 45 minutes of regular physiotherapy and 15 minutes in which exercises will be carried out focused on the balance systems, following the program that is detailed below.
214665644|NCT03406026|OTHER|Control Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. The control group will perform, during the 60 minutes that the session lasts, the usual physiotherapy treatment.
214665645|NCT04903860|DEVICE|total hip replacement with single use ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
214665646|NCT04903860|DEVICE|total hip replacement with conventional ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
214868677|NCT03833336|DRUG|Ferric carboxymaltose|The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo
214868678|NCT03833336|DRUG|Ferroglycine Sulfate|One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
214868679|NCT03833336|DRUG|Sucrosomial Iron|One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
214868680|NCT02839915|DRUG|Folinic Acid|Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.
214868681|NCT02839915|OTHER|Placebo|Inactive placebo comparator
214868683|NCT06540963|DRUG|Tipifarnib|Tablet
214868684|NCT06540963|DRUG|Naxitamab|IV
214868685|NCT06296901|OTHER|Perineal Wipe|use of perineal wipe
214868686|NCT04347122|DRUG|Tranexamic Acid (TXA)|Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.
214868687|NCT00901212|DEVICE|Device programming|6-month period
214868688|NCT06520592|BEHAVIORAL|With AR guided CPAP therapy|Participants will received AR training course to utilize the AR guided CPAP therapy
214868689|NCT06381973|BEHAVIORAL|ELTGOL_Physio|The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will accompany the subject by gently applying manual pressure on the chest wall and the abdomen during expiratory phases.
214868690|NCT06381973|BEHAVIORAL|ELTGOL_Auto|The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will not intervene in this arm.
214868691|NCT06381973|DEVICE|PEP|The subject will be asked to exhale through a positive expiratory pressure (PEP) device (Threshold PEP) while being in the right lateral posture.
214868692|NCT06381973|BEHAVIORAL|1L-Tidal-Breathing|The subject will be asked to breath with a fixed tidal-breathing of 1 liter per breath (monitored via a spirometer) while being in the right lateral posture.
214868693|NCT06381973|BEHAVIORAL|Spontaneous Breathing|The subject will be asked to breath spontaneously while being in the right lateral posture.
214868694|NCT06450028|DRUG|10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine|Injection of 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine.
214868695|NCT06450028|DRUG|6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine|Injection of 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine.
214868696|NCT05466461|PROCEDURE|Beautifil Flow Plus X.|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel.Single Bond TM Universal will be applied to cavity walls and margins with agitation for 20 seconds.The adhesive will be light-cured for 20 seconds. Then Beautifil Flow Plus X composite will be placed
214868697|NCT05466461|PROCEDURE|Activa bioactive restorative|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel. Bonding agent will be applied on the entire cavity and light-cured for 20 seconds then Activa bioactive restorative composite will be applied and cured for 20 seconds.
214868698|NCT05906810|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
214868699|NCT04533958|DEVICE|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
214868700|NCT06526182|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
215035301|NCT00909701|DIETARY_SUPPLEMENT|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
215035302|NCT05738538|DRUG|ziftomenib|
214665647|NCT02016807|DEVICE|ProThelial|August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
214665648|NCT01605474|OTHER|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
214665649|NCT01605474|OTHER|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
214665650|NCT03467906|OTHER|In-laboratory assessment|Participants will stay in the laboratory for two days and one night during which they will complete questionnaires, have blood drawn, and have other measurements taken.
214665651|NCT05647993|DRUG|Azithromycin Injection [Zithromax]|Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
214665652|NCT05647993|DRUG|Cefazolin|All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
214665653|NCT05647993|DRUG|Sodium Chloride 0.9% Intravenous Solution|For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
214665654|NCT04837560|DEVICE|ElastiMed's SACS 2.0|A wearable medical device that improve circulation using smart materials
214665655|NCT03845530|DIAGNOSTIC_TEST|Blood Test|Blood test taken and sent for laboratory analysis
214665656|NCT02478684|OTHER|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
214665657|NCT02478684|OTHER|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
214665658|NCT05110066|PROCEDURE|Pulmonary endarterectomy|Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
214665659|NCT05110066|PROCEDURE|Balloon pulmonary angioplasty|Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.
214665660|NCT05639764|DEVICE|Oculus Quest 2|A specific immersive virtual reality software designed to address chronic shoulder pain on the Oculus Quest 2 device.
214665661|NCT05639764|DEVICE|Oculus Quest 2|"a VRi placebo intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces."
214665662|NCT03119649|DRUG|GLPG2222 50 mg|Oral tablet(s) containing GLPG2222
214665663|NCT03119649|DRUG|GLPG2222 100 mg|Oral tablet(s) containing GLPG2222
214665664|NCT03119649|DRUG|Placebo|Matching oral tablet(s) containing placebo
214868701|NCT06526182|OTHER|Placebo|Lebrikizumab Matching placebo solution for injection administered subcutaneously.
214868702|NCT05526300|DEVICE|Intelligent Hypertension Management System|The intelligent hypertension management system is used to remotely detect the blood pressure of hypertensive patients
214868703|NCT05526300|OTHER|The standard care|The standard care
215035303|NCT01209767|DEVICE|cryolipolysis|During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
215035304|NCT01209767|PROCEDURE|Subcision|Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
214665665|NCT03119649|DRUG|GLPG2222 200 mg|Oral tablet(s) containing GLPG2222
214665666|NCT03119649|DRUG|GLPG2222 400 mg|Oral tablet(s) containing GLPG2222
214665667|NCT02375776|OTHER|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
214868704|NCT06244745|DRUG|Administration of letrozole|Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.
214868705|NCT04994483|DRUG|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
214868706|NCT04994483|DRUG|Placebo|Matching placebo given b.i.d. for 52 weeks.
215035305|NCT01209767|OTHER|Control|
215035306|NCT01702298|DRUG|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
215035307|NCT01702298|DRUG|Metformin|Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day
215035308|NCT00400686|BIOLOGICAL|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
215035309|NCT01752049|DRUG|Topical timolol maleate|"* Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient"
214868707|NCT04994015|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
214290885|NCT02141243|PROCEDURE|Labial Frenotomy|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
214868708|NCT05474846|DRUG|Melatonin|Given by PO
214868709|NCT05474846|OTHER|Placebo for Melatonin|Given by PO
214868710|NCT05474846|DRUG|Melatonin|Given by PO
214868711|NCT05474846|DRUG|Methylphenidate|Given by PO
214868712|NCT03299088|BIOLOGICAL|Pembrolizumab|Given IV
214868713|NCT03299088|DRUG|Trametinib|Given PO
214868714|NCT06170450|DEVICE|Cyclic SNM|SNM cycling: 8 hours on, 16 hours off
214868715|NCT06170450|DEVICE|Continuous SNM|Continuous SNM: on continuously, no 'off' period
214868716|NCT04809168|OTHER|Questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
214868717|NCT04809740|OTHER|Evaluate implementation of navigator-delivered Home ePRO for all cancer patients|evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes
214868718|NCT05568264|OTHER|Physical Therapy intervention|The intervention is based on five principles: active learning, caregiver engagement, environmental enrichment, strengths-based approach, and dose. The intervention will start in the NICU and continue until 12-months corrected age. Infants in the intervention group will receive up to two therapist visits per week in addition to standard of care physical therapy. Caregivers will be asked to work with their infant on activities provided by the therapist. The therapist will provide resources to support the caregiver in working on these activities with their child, and caregivers will be asked to complete the activities for as much time as possible, throughout the day. Therapists will work with caregivers to identify ways to incorporate activities into their day. Caregiver engagement and caregiver ability to complete sessions and activity recommendations will be monitored.
214868719|NCT05828745|DRUG|CB06-036|CB06-036 capsule
214868720|NCT05828745|DRUG|Placebo|Placebo capsule
214868721|NCT03672487|DRUG|Benznidazole|Benznidazole tablet
214868722|NCT03672487|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic Benznidazole
214868723|NCT03589768|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Used for active immunization of adults and children 7 years of age and older against diphtheria and tetanus.
214868724|NCT03589768|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide|A sterile isotonic suspension of tetanus and diphtheria toxoids and pertussis antigens adsorbed on Aluminum hydroxide.
214868725|NCT06530290|DRUG|Mirtazapine 15 MG|Mirtazapine (15 mg), once a day for 12 weeks
214868726|NCT06530290|DRUG|Placebo|Placebo, once a day, for 12 weeks
214868727|NCT06636240|DIETARY_SUPPLEMENT|Mulberry fruit juice|Mulberry fruit juice 200ml/day plus standard therapy for atopic dermatitis including topical Mometasone furoate cream 0.1%
214868728|NCT06636240|OTHER|Mometasone furoate 0.1% cream|Standard therapy for atopic dermatitis including Mometasone furoate cream 0.1%
214868729|NCT04911738|OTHER|Virtual Reality , immersion in a virtual titlted room|The immersion in virtual reality will be based on the HTC VIVE® device and the software developed by the Virtualis Society.
214868730|NCT06770712|OTHER|Mirror therapy|The patients were asked to sit in front of a table at an appropriate height and rest their arms on the table. A mirror was placed between both arms. The mirror was positioned so that the reflection of the healthy extremity overlapped with the paralytic extremity. In this way, the movements of the healthy upper extremity were viewed through the mirror, creating a visual movement illusion for the hemiplegic upper extremity. During the mirror therapy, exercises including forearm supination-pronation, wrist flexion-extension, finger flexion-extension, finger counting, grasping and releasing a cup, grasping and releasing a ball, and writing with a pen were performed. First, 30 minutes of bilateral TENS therapy were applied, followed by 30 minutes of mirror therapy
214868731|NCT06770712|DEVICE|Transcutaneous Electrical Nerve Stimulation|Received stimulation on the extensor muscles of the hand fingers of both the intact and paretic sides, with a frequency of 100 Hz, pulse width of 200 microseconds, and a biphasic symmetric pulse for 30 minutes. The intensity of the current was adjusted to a level that produced a visible, comfortable muscle contraction. Self-adhesive electrodes, measuring 5x5 cm, were placed on the extensor surface of the forearm, 5 cm distal to the olecranon, parallel to the long axis of the muscle. Electrical stimulation was applied using the Cefar Rehab X2 device (DJO France SAS).
214868732|NCT03060434|DRUG|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
214868733|NCT03060434|DRUG|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
214868734|NCT06185023|BEHAVIORAL|Low-intensity physical exercise|As an active control intervention, a low-intensity non-aerobic exercise program was selected that mirrors more closely the standard-of-care physical therapy currently provided to stroke patients. This control intervention will offer the same level of participant involvement and type of exercises, but without the intensity element, i.e., it will not incorporate the cardiovascular and the strengthening components.
214868735|NCT06185023|BEHAVIORAL|High-intensity physical exercise|We have developed a new exercise program specifically designed for individuals with post-stroke aphasia, Aphasia Physical EXercise (APEX), to provide a safe, stroke- and aphasia-friendly physical exercise intervention to achieve optimal physical fitness and cognitive/language gains. This intervention, based on published research and clinical practice recommendations, is a high-intensity interval training full-body workout optimized to accommodate the range of motor abilities and general deconditioning observed in stroke survivors.
215035310|NCT01752049|DRUG|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
215035311|NCT05511948|DRUG|DBI-102|Topical application on dorsal hand and upper volar arm
215035312|NCT05511948|DRUG|Vehicle gel|Inactive comparator
215035313|NCT05511948|DRUG|Hydroquinone Cream|4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
215035314|NCT00220090|DRUG|dexloxiglumide|
214868736|NCT06551441|BEHAVIORAL|High Intensity Interval Training (HIIT)|"The HIIT intervention consist of 4 intervals with each lasting 4 minutes (4x4min). If a participant reports discomfort related to the length of the intervals or start to feel unmotivated by performing the same exercise, we will use another HIIT protocol: 10x1min.~The 4x4min HIIT consists of a warm-up period of 10 minutes with a target heart rate at 60-70% of HRmax, followed by 4 HIIT intervals with a target HR ≥85%. The intervals are separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following this, a cool down period of three minutes at warm up intensity is performed.~The 10x1min HIIT consists of a 10-minute warm-up period.The warm-up is followed by 10 intervals, each lasting 1 min at 100% of maximal workload, separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following the intervals, a cool down period of three minutes at warm up intensity is performed."
214868737|NCT04190069|BEHAVIORAL|Behavioral interventions/modifications|UPMC Prescription for Wellness is an innovative physician/provider prescribed coaching and feedback program that improves patient engagement and outcomes in healthy behaviors; self-care of chronic disease and condition management; and shared decision-making. The resources available through this program are offered via a telephonic health coach, online or through a digital intervention based on the participant's convenience.
214868738|NCT04186923|OTHER|F-SPOKE|This project includes communicative, emotional, and also organizational support with outreach across different sectors and phases (F-SPOKE - family-centered, cross-sector and cross-phase organizational, communicative, and emotional support).
214868739|NCT02185716|DRUG|Levobupivacaine 0.25 %|
214868740|NCT02185716|DRUG|Levobupivacaine 0.5%|
215035315|NCT01141530|OTHER|No intervention|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
215035316|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled|Each patient will receive 12µg/kg of levosimendan by inhalation over 10 min. During 10h following inhaled dose, plasma concentrations will be measured.
215035317|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous|Each patient will receive 12µg/kg of levosimendan by intravenous (IV) administration over 10 min and at the same timepoints plasma samples will be measured
215035318|NCT01779960|OTHER|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
215035319|NCT01779960|OTHER|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
215035320|NCT05809388|BEHAVIORAL|Parent training|"Parent Training program according to Ten steps of Barkley's program plus two additional follow-up sessions. This will be conducted by a trained psychologist; each session will last approximately 60 minutes and will includes exercises, discussions and role-playing."
215035321|NCT05809388|BEHAVIORAL|Virtual Reality-assisted PT sessions|"The experimental group will follow the same program of CG sample. Parent Training sessions will be conducted by a trained psychologist; each session will last approximately 60 minutes that include:~* 40 minutes of as usual PT session, with exercises, discussions and role-playing.~* 20 minutes of VR screen with which the parents may interact; VR screen will provides instructive, stimulating, interactive, and direct feedbacks exercises to enhance parenting strategies."
215035322|NCT04574336|PROCEDURE|Surgical treatment|We anticipate that surgical treatment will include plate osteosynthesis (MIPO and ORIF), intramedullary nailing (antegrade and retrograde) and external fixation. Plate and nail types, screw configuration and surgical approaches will be decided by the surgeon. The procedure will be conducted or supervised by a senior consultant.
215035323|NCT04574336|DEVICE|Non-surgical treatment|Non-surgical treatment will include sugar tong, splint, plaster splints, hanging casts, or functional bracing as the Sarmiento brace and will be worn until a surgeon removes it. If the surgeon deems it appropriate, participants will be offered to undergo early secondary surgery with a surgical procedure of their choice. The participants will be recorded and the reason will be noted. We anticipate the surgical procedures will be similar to the previous mentioned and perhaps with the addition of bone graft.
215035324|NCT00151021|BEHAVIORAL|Tailored web-based walking program|
215035325|NCT04219410|PROCEDURE|Fully minimally invasive esophagectomy|Esophagectomy using a novel fully minimally invasive approach
214290886|NCT02141243|PROCEDURE|Sham Procedure|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
214290887|NCT05776199|DIAGNOSTIC_TEST|Sonoelastography, tensiomyography and mechanosensitivity|To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.
214868741|NCT03537716|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
214868742|NCT04428216|OTHER|Group RIB|In group RIB, RIB block will be performed. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
214868743|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 90 days)|90 days
214868744|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 180 days)|180 days
214868745|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 270 days)|270 days
214868746|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 90 days)|90 days
214868747|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 180 days)|180 days
214665668|NCT05822856|OTHER|Blood sampling and others interventions|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
214665669|NCT03529487|DRUG|Oxymetazoline|Oxymetazoline gel applied intra-analy
214665672|NCT02219230|DEVICE|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
214665673|NCT02219230|DEVICE|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
214665674|NCT02219230|DEVICE|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
214665675|NCT05485103|DRUG|Polyethylene Glycols|Take asol as total enteral nutrition, and take polyethylene glycols and glycerin enema as bowel preparations
214665676|NCT03862456|OTHER|Azithromycin|azithromycin (500 mg/24h/3 days)
214868748|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 270 days)|270 days
214868749|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 90 days)|90 days
214868750|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 180 days)|180 days
214868751|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 270 days)|270 days
214868752|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 90 days)|90 days
214868753|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 180 days)|180 days
215035326|NCT02769793|DRUG|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
215035327|NCT02769793|DRUG|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
214665677|NCT03862456|OTHER|Metronidazole|metronidazole (500 mg/8h/7 days)
214665678|NCT01113528|OTHER|Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
214665679|NCT01113528|DRUG|Sugar pill|3 times daily
214665680|NCT05356793|DRUG|SCH-1|Novel anti-infective eyedrop
214665681|NCT05356793|DRUG|Placebo|SCH-1 vehicle minus active components eyedrop
214665682|NCT05002309|BEHAVIORAL|Cognitive-Behavioural Therapy|"20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly homework will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials."
214665683|NCT05002309|DRUG|Antidepressant medication|The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
214868754|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 270 days)|270 days
214868755|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 90 days)|90 days
214868756|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 180 days)|180 days
214868757|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 270 days)|270 days
214868758|NCT03450174|DIETARY_SUPPLEMENT|Placebo|In control group, participants will receive only a placebo product
214868759|NCT03450174|BEHAVIORAL|Formative messgaes|In this group, participants will only receive daily formative messages
214868760|NCT03450174|DIETARY_SUPPLEMENT|Fortified product|In this group, participants will receive fortified product on alternate day up till 8 months
214868761|NCT03450174|COMBINATION_PRODUCT|Fortified product plus|In this group participants will receive fortified product on alternate day and formative messages up till 8 months
214868762|NCT04061031|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.
214868763|NCT04061031|BEHAVIORAL|Child-Centered Therapy with Parent Education|A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
214868764|NCT03283319|BIOLOGICAL|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
214868765|NCT03283319|BIOLOGICAL|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
214868766|NCT03283319|BIOLOGICAL|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
214868767|NCT03283319|BIOLOGICAL|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
214868768|NCT03283319|BIOLOGICAL|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
214868769|NCT05261295|DIAGNOSTIC_TEST|PEEP|PEEP of 7 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
214868770|NCT05261295|DIAGNOSTIC_TEST|ZEEP|PEEP of 0 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
215035328|NCT01010464|PROCEDURE|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
215035329|NCT04925141|DRUG|Dasatinib Tablets|Tyrosine Kinase Inhibitor (TKI)
214868771|NCT05210478|DEVICE|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
214868772|NCT03958565|BIOLOGICAL|Tyrosine Kinase Inhibitor|Targeted therapy given as standard of care.
214868773|NCT03958565|DRUG|Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]|Given Q4 weeks as standard of care
214868774|NCT03958565|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Given Q12 weeks for bone disease as standard of care
214868775|NCT06370130|DRUG|Esketamine 0.2mg/kg|"Patients received 0.2 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
214868776|NCT06370130|DRUG|Esketamine 0.3mg/kg|"Patients received 0.3 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
214868777|NCT04505748|DEVICE|Self-transfusion device|The Transfusion filter set for salvaged blood (Summit Medical Ltd, Gloucestershire, UK) has been randomly used in 20 patients postoperatively. Patients, who received autologous blood, transfused with the collected amount of blood, only once, 6h postoperatively
214868778|NCT01025544|BIOLOGICAL|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
214868779|NCT01025544|BIOLOGICAL|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
214868780|NCT03887494|DEVICE|Implantation|Implantation of Y-Strut + cementoplasty in the femoral neck
214868781|NCT00224926|PROCEDURE|Scalp Brushing|sterile, soft-head toothbrush massaged on scalp
214868782|NCT00721630|DRUG|capecitabine, lapatinib|Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
214868783|NCT05960812|PROCEDURE|skillful neglect Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear conservative treatment which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
214868784|NCT05960812|PROCEDURE|arthroscopic repair Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear repair which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
214868785|NCT00792935|DRUG|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
214868786|NCT00792935|DRUG|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
214868787|NCT00792935|DRUG|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \[(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\], the participant should remain on the same metformin dose throughout the study.
214868788|NCT03186781|BIOLOGICAL|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.
214868789|NCT03186781|BIOLOGICAL|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
214868790|NCT04663295|DEVICE|MiniMed™ 670G system|Hybrid closed loop insulin pump with associated CGM and blood glucose meter
214868791|NCT03168581|DRUG|CN-105|Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
214868792|NCT03925350|DRUG|Niraparib|300 mg PO daily
214868793|NCT03335449|OTHER|Protective ventilation group|Application of a protective ventilation strategy in order to improve gas exchange and respiratory mechanics during Robotic surgery in deep Trendelenburg position.
214868794|NCT04125849|PROCEDURE|Thoraco-laparoscopic esophagectomy|Thoraco-laparoscopic esophagectomy surgery
214290888|NCT04834076|DIAGNOSTIC_TEST|ELISA|ELISA is is a test that detects and measures toxoplasma IgG and IgM antibodies in blood.
214868795|NCT04125849|PROCEDURE|Mediastinoscopy-assisted transhiatal esophagectomy|Mediastinoscopy-assisted transhiatal esophagectomy surgery
214290889|NCT04834076|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction (PCR) is a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.
214868796|NCT05783830|DRUG|ACD856|IV injection 100 mcg
214868797|NCT05930457|DRUG|2.5-3.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2.5-3.5mCi 64Cu-FAPI-XT117 injection.
214868798|NCT05930457|DRUG|3.5-4.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 3.5-4.5mCi 64Cu-FAPI-XT117 injection.
214868799|NCT05930457|DRUG|4.5-5.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4.5-5.5mCi 64Cu-FAPI-XT117 injection.
214868800|NCT02101593|DRUG|ADI-PEG 20|
214868801|NCT05471492|DRUG|Investigational Product|PF-06480605 150 mg
214868802|NCT05471492|DRUG|Placebo|Placebo
214868803|NCT02977312|DRUG|Imatinib|Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil
214868804|NCT04096755|DIAGNOSTIC_TEST|Procedure|serum and urine samples will be taken for analysis
214868805|NCT04914221|DRUG|JLP-2002|administration of JLP-2002
214868806|NCT04914221|DRUG|Comparator|administration of comparator
214868807|NCT04638530|OTHER|Education on breaking bad news to family members remotely|Participants will receive a combination of surveys, pre- and post-tests, lectures and didactics to increase their awareness of techniques to communicate difficult topics with patients remotely as well as skill building exercises.
214868808|NCT03112330|DEVICE|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
214868809|NCT03112330|DEVICE|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
214868810|NCT04658017|DEVICE|GARNET device|Use of new filter in conjunction with standard of care dialysis.
214868811|NCT05955196|PROCEDURE|BLOOD AND TUMOR|sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece
214868812|NCT03954834|DRUG|Tirzepatide|Administered SC
214868813|NCT03954834|DRUG|Placebo|Administered SC
214868814|NCT00006395|DRUG|St. John's Wort|
214868815|NCT04395014|DIAGNOSTIC_TEST|2D Echocardiography|In this echocardiographic imaging acquisition protocol, the pregnancy patients, are colocated in the left lateral decubitus position on a clinical bed with the left arm flex and the hand behind the head. All the echocardiographic measurements are taken by the examiner in this position.
214868816|NCT02058550|OTHER|survey administration|Receive reminder email survey
214868817|NCT02058550|OTHER|computer-assisted intervention|Receive reminder email survey
214868818|NCT02058550|BEHAVIORAL|telephone-based intervention|Receive reminder phone call
214868819|NCT01844466|PROCEDURE|Physiotherapy and speech therapy|
214868820|NCT05978908|DRUG|FC-12738|Retro enversio pentapeptide of thymopentin
214868821|NCT05978908|DRUG|Saline|placebo
214868822|NCT05055830|DRUG|The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.|The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.
214868823|NCT02969265|DRUG|Amlodipine|Amlodipine Capsules
214868824|NCT02969265|DRUG|TCV-116CCB|TCV-116CCB Tablets
214868825|NCT02969265|DRUG|Amlodipine Placebo|Amlodipine placebo-matching capsules
214868826|NCT02969265|DRUG|TCV-116CCB Placebo|TCV-116CCB 8/5 mg placebo-matching tablets
214868827|NCT03223792|OTHER|Control|Routine cow's milk-based infant formula
214868828|NCT03223792|OTHER|Investigational|Partially-hydrolyzed cow's milk protein infant formula
214868829|NCT04258462|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
214868830|NCT04258462|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214868831|NCT04258462|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
214868832|NCT04335786|DRUG|Valsartan (Diovan)|"At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d."
214868833|NCT04335786|DRUG|Placebo oral tablet|At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
214868834|NCT00670163|BEHAVIORAL|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
214868835|NCT00670163|BEHAVIORAL|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
214868836|NCT00670163|BEHAVIORAL|Standard Care|Standard care will consist of usual care for STIs.
214670034|NCT04244045|OTHER|Suboccipital muscle inhibition|"The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot"
214868837|NCT05881746|PROCEDURE|anatomical liver resection|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
214868838|NCT05881746|PROCEDURE|nonanatomical liver resection|Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
214868839|NCT05200546|DIAGNOSTIC_TEST|molecular assays to screen for eXDR|"VRE detection will be performed using VIASURE Vancomycin resistance Real Time PCR Detection Kit.~BD MAX Check-Points CPO will be used to detect carbapenemase-producing organisms."
214868840|NCT04312295|BEHAVIORAL|ACP-SCT program|The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
214868841|NCT03795038|DEVICE|Lipoprotein Apheresis MONET and DALI|Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
214868842|NCT03795038|DEVICE|Lipoprotein Apheresis DIAMED and DALI|Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
214868843|NCT05443581|BEHAVIORAL|dietary intervention|Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
214868844|NCT04051034|DIETARY_SUPPLEMENT|Omega 3|"Active: 1.25 g capsules/420 35-count bottles \[1.25 g capsule contains min. 750 mg EPA + 250 mg DHA\] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles \[1.25-gram high oleic safflower oil capsule\]"
214868845|NCT04051034|OTHER|Placebo|Active: 1.25 g capsules \[1.25-gram high oleic safflower oil capsule\] and heat therapy, increase internal body temperature 1.2 C above baseline.
214868846|NCT02068664|BEHAVIORAL|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
214868847|NCT05193643|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues.
214290890|NCT04834076|DIAGNOSTIC_TEST|Sequencing|DNA sequencing is a laboratory technique used to determine the exact sequence of bases (A, C, G, and T) in a DNA molecule. The DNA base sequence carries the information a cell needs to assemble protein and RNA molecules. DNA sequence information is important to scientists investigating the functions of genes.
214290891|NCT01635946|DRUG|Isavuconazole|oral
214868848|NCT02826538|DEVICE|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
214868849|NCT02826538|DEVICE|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
214868850|NCT02903030|DRUG|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
214868851|NCT02903030|DRUG|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
214868852|NCT01502410|DRUG|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
214290892|NCT01635946|DRUG|atorvastatin|oral
214290893|NCT04614740|DRUG|VC004|25 mg capsules,50 mg capsules,100 mg capsules.
214290894|NCT00118365|OTHER|placebo|Given orally
214290895|NCT00118365|DRUG|eflornithine|Given orally
214290896|NCT00118365|DRUG|sulindac|Given orally
214290897|NCT00118365|OTHER|laboratory biomarker analysis|Correlative studies
214868853|NCT01502410|OTHER|pharmacological study|Optional correlative studies
214868854|NCT01502410|OTHER|laboratory biomarker analysis|Optional correlative studies
214868855|NCT06299930|PROCEDURE|Neoadjuvant chemotherapy|Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy
214868856|NCT06299930|PROCEDURE|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy
214868857|NCT04362748|DRUG|AMG 256|AMG 256 administered as an intravenous (IV) infusion.
214868858|NCT05272748|OTHER|Conventional Exercise + Core Stabilization Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. In addition to the exercises in the conventional exercise group, patients will perform pelvic tilt, lateral bridge, single leg bridge, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, superman exercise. Exercises will be applied 3 times a week.
215035330|NCT05619393|DEVICE|Mobilie Bi-planar X-ray Imaging system|on the Mobilie Bi-planar X-ray Imaging system, images are acquired for three movements: walking, downhill walking, and squat
214868859|NCT05272748|OTHER|Conventional Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. Terminal knee extension, straight leg raise, heel slide, adductor isometric, bridge, mini squat, heel raise, lunge, range of motion and stretching exercises for lower extremities will be performed by the patients. Exercises will be applied 3 times a week.
214290898|NCT00959309|BEHAVIORAL|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
214290899|NCT00959309|BEHAVIORAL|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
214290900|NCT03730246|PROCEDURE|cesarean sectio|consecutive parturients due for cesarean sectio
214868860|NCT03582748|PROCEDURE|sleeve gastrectomy|removal of most of stomach as a bariatric surgical procedure
214868861|NCT03582748|PROCEDURE|No sleeve gastrectomy|Non-receipt of sleeve gastrectomy procedure
214868862|NCT00253695|DEVICE|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
214868863|NCT02080169|DRUG|midazolam|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
214868864|NCT02080169|DRUG|Dexmedetomidine|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
214868865|NCT02080169|DRUG|Fentanyl|Fentanyl is used as analgesic drug in order to obtain the VAS \<3.
214868866|NCT03715504|DRUG|TP-3654|oral PIM inhibitor
214868867|NCT05984186|DEVICE|High Velocity Therapy|FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM
214868868|NCT03358186|PROCEDURE|surgically treated periprosthetic femur fracture|patients with surgically treated periprosthetic femur fracture
214868869|NCT01404923|DRUG|anti spasmodic agents|best standard of care prescriptions
214868870|NCT01404923|DRUG|alverine citrate, simeticone|on-demand therapy
214868871|NCT04074629|DIAGNOSTIC_TEST|Diagnosis, skin volatile organic compounds (VOCs)|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\\or GC-MS analysis"
214868872|NCT04322110|OTHER|PronoKal Method|Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support
214868873|NCT04322110|OTHER|Low calorie diet|Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
214868874|NCT03295981|DRUG|Zoledronic Acid|4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
214868875|NCT01960712|DEVICE|Transpapillary plastic stent (7-10 Fr)|Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
214868876|NCT05101681|DIAGNOSTIC_TEST|Teledentistry|Teledentistry using mobile photographs
214868877|NCT00261092|DRUG|Oxaliplatin|
214868878|NCT02553759|OTHER|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
214868879|NCT05253963|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be used during the second night of polysomnography .
214868880|NCT02478203|DEVICE|Airtraq|videolaryngoscope for difficult airway
214868881|NCT02478203|DEVICE|Glidescope|videolaryngoscope for difficult airway
214868882|NCT02478203|DEVICE|direct laryngoscopy|gold standart for intubation
214868883|NCT06352918|OTHER|Palmar grasp reflex stimulation|This initiative is stimulated by applying gentle pressure to the palm of the baby's palm while he or she is awake, lying on a flat surface in a symmetrical supine position.
214868884|NCT06484842|OTHER|The combined psychological resilience and self-efficacy intervention|Based on the content of the literature analysis and the group's previous research, a joint intervention programme on psychological resilience and self-efficacy for patients undergoing surgery for oesophageal cancer has been developed. The programme consists of 6 sessions in total, including preoperative period and one month after discharge, covering the period when patients' postoperative symptoms occur most severely. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospital stay; considering the smooth implementation of the intervention after the patient will be discharged from the hospital, we will conduct the intervention in an individual, offline face-to-face format during the patient's outpatient review, and set up a WeChat group in case the patients are at home to conduct the intervention in the form of an online punch card.
214868885|NCT06484842|OTHER|The mindfulness intervention|The oesophageal cancer surgery patients in the single intervention group will receive 5 sessions of mindfulness intervention consistent with the mindfulness intervention component of the combined intervention programme. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospitalisation; we will conduct the intervention in an individual, offline face-to-face format during the patients' outpatient review, and set up a WeChat group in case the patients are at home in the form of an online punch card. Each session will include a pre-session reflection and post-session homework. The whole process will be supervised and reminded by interventionists, who will respond to patients' questions in a timely manner to ensure patients safety and the smooth implementation of the intervention. Adjustments and improvements will be made at any time according to the needs of patients undergoing oesophageal cancer surgery.
214868886|NCT01162707|DEVICE|CardioMEMS HF Pressure Measurement System|Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
214868887|NCT01697553|OTHER|home automation pack coupled to teleassistance service|
214868888|NCT01697553|OTHER|Home without automation pack coupled to teleassistance service|
214868889|NCT05160233|BEHAVIORAL|Standard implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
214868890|NCT05160233|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
214868891|NCT05160233|BEHAVIORAL|Practice Facilitation|A trained facilitator provides support for implementation by delivering the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
214868892|NCT02905747|BEHAVIORAL|Medical Exercise Therapy|physiotherapy intervention with Medical exercise therapy (MET) during 3 months
214868893|NCT03596814|OTHER|No Interventional study|Retrospective data
214868894|NCT04899544|BEHAVIORAL|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|Pivotal Response Treatment in autism center.
214868895|NCT04899544|BEHAVIORAL|Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)|Pivotal Response Treatment in home environment.
214868896|NCT05060744|DEVICE|Antacid|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
214868897|NCT05060744|OTHER|Control|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
214868898|NCT04251572|OTHER|Blood sampling|Blood sampling
214868899|NCT04251572|OTHER|questionaires|Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.
214868900|NCT00476775|BEHAVIORAL|after school ethnic dance program - ballet folklorica|
214868901|NCT00476775|BEHAVIORAL|culturally-tailored, home-based screen time reduction|
214868902|NCT00476775|BEHAVIORAL|culturally-tailored health and nutrition education|
214868903|NCT01670617|OTHER|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
214868904|NCT01284361|DEVICE|30 cm Intermittent Catheter|Randomized cross-over
215035331|NCT01241630|PROCEDURE|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
214290901|NCT04981951|DRUG|Dexmedetomidine|Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.
214290902|NCT02637453|PROCEDURE|PVI|Pulmonary vein isolation
214290903|NCT02637453|PROCEDURE|CPVI+6L|After PVI, 6 ablation lines were added with an extension from pulmonary vein ostium at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
214290904|NCT00572585|DRUG|AEB071|
214290905|NCT00572585|DRUG|Placebo|
214868905|NCT01284361|DEVICE|40 cm Intermittent Catheter|randomized cross-over
214868906|NCT00663026|DRUG|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
214868907|NCT00663026|DRUG|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
214868908|NCT00663026|DRUG|placebo|Placebo subcutaneous injection once per week for 6 months
214868909|NCT00754650|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
214868910|NCT04528030|DEVICE|WAVE device|WAVE applies a transcutaneous vibration to the soles of the foot and palms of the hand to elicit nerve signalling from pressure and other limb proprioceptor sensors to pontine, cerebellar, and medullary brain areas that coordinate limb movement and reflexively activate brain areas controlling breathing. The WAVE device is a battery-operated product to reduce the episodes of Apnoea of Prematurity by vibratory stimulation to the hand and foot.
214868911|NCT00805675|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
214868912|NCT00805675|DRUG|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
214868913|NCT00805675|DRUG|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
214868914|NCT01911897|DEVICE|MobiusHD|Implant that is placed in the carotid sinus to control hypertension.
214868915|NCT00823121|PROCEDURE|freezing embryos by vitrification|vitrification by Cryotop method
214868916|NCT00823121|PROCEDURE|fresh embryo transfers|fresh embryo transfers
214868917|NCT00823121|DRUG|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
214868918|NCT00823121|DRUG|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
214868919|NCT00823121|DRUG|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
214868920|NCT02328742|BIOLOGICAL|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study."
215035332|NCT03690778|DRUG|"Metformin and Rosuvastatin seperately"|"administration of Metformin and Rosuvastatin seperately"
215035333|NCT03690778|DRUG|JLP-1310|administration of JLP-1310
215035334|NCT01912014|BEHAVIORAL|Psychosocial support and counselling|
215035335|NCT06186609|DRUG|PD-1 inhibitor 200mg per three to four weeks, for one year|"PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction."
214868921|NCT02328742|OTHER|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study."
214868922|NCT02328742|BIOLOGICAL|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study."
214868923|NCT02328742|BIOLOGICAL|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study."
214868924|NCT00712738|DRUG|Nifedipine|
214868925|NCT00712738|PROCEDURE|Phlebotomy|
214868926|NCT00712738|PROCEDURE|Urinalysis|
214868927|NCT00712738|PROCEDURE|Echocardiogram|
214868928|NCT00712738|PROCEDURE|Electrocardiogram|
214868929|NCT06018974|DEVICE|Yetitablet gaming|Playing digital games like bowling, memory games, coordination games ect. with the Yetitablet.
214868930|NCT04708639|DRUG|Alectinib|Use of ctDNA to establish response and resistance to alectinib.
214868931|NCT00325195|OTHER|placebo|placebo by intravenous infusion every 2 weeks
214868932|NCT00325195|BIOLOGICAL|pegloticase|8 mg pegloticase by intravenous infusion
214868933|NCT01892124|BEHAVIORAL|Motivational Interviewing/Cognitive Behavioral-based Therapy|
214868934|NCT05218941|PROCEDURE|Implant surgery assisted by passive robotics|Implant surgery without flap assisted by passive robotics (X-Guide®)
214868935|NCT05218941|PROCEDURE|Conventional implant surgery|Flap implant surgery
214868936|NCT00613535|DEVICE|Mechanical debridement|Mechanical shaver will be used to remove large chondral flaps and loose fragments
214868937|NCT00613535|DEVICE|Paragon T2|Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
214868938|NCT00613535|PROCEDURE|Lavage debridement|Remove loose chondral fragments
214868939|NCT00613535|DEVICE|Mechanical Debridement|Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
214868940|NCT00613535|DEVICE|RF- based Debridement|Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
214868941|NCT01536158|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
214868942|NCT01536158|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
214868943|NCT03801889|DRUG|SP-420|Self-administered by mouth
214868944|NCT05066672|DRUG|NV-5138|NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling
214868945|NCT05066672|DRUG|matched placebo|matched placebo oral capsules
214868946|NCT01248689|OTHER|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
214290906|NCT01144923|OTHER|Gabapentin and/or Nortriptyline, Physical therapy|Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)
214290907|NCT01144923|PROCEDURE|Epidural Steroid Injections (ESI)|Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone
214670035|NCT04957498|BEHAVIORAL|Guided Self-Help for Family Based Treatment|A online website provided to parents containing information learned in Family Based Treatment and up to 12 coaching sessions with a therapist.
214868947|NCT01248689|OTHER|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
214868948|NCT01248689|OTHER|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
214868949|NCT05989113|OTHER|Administration of the IPAQ-SF questionnaire|Administration of the IPAQ-SF questionnaire at the patient's consultation and upon return home
214868950|NCT02029573|DRUG|Atorvastatin|80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
214868951|NCT02029573|DRUG|Temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
214868952|NCT02029573|RADIATION|Radiotherapy|60 Gy in 30 fractions
214868953|NCT05808192|DRUG|Immunosuppressive|compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
214868954|NCT00329472|DRUG|gemcitabine, cisplatin|
214868955|NCT01751763|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator.
214868956|NCT03407235|DEVICE|Computerized Laparoscopic Trainer|Gold standard laparoscopic trainer using simulated computerized equipment.
214868957|NCT03407235|DEVICE|Box trainer with eye patch|Simple, cost effective box trainer, with loss of dept perception achieved with use of eye patch
214868958|NCT03543241|DIAGNOSTIC_TEST|MyoStrain|Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.
214868959|NCT01090921|DRUG|Bortezomib|"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."
214868960|NCT06223243|OTHER|Stingless bee honey mouthrinse|Three bottles of 90ml of stingless bee honey of 20% concentration was given to each subject. This mouthrinse preparation was instructed for subjects to be taken 30ml each, thrice daily for three days.
214868961|NCT06223243|OTHER|normal saline mouthrinse|Subjects were instructed to rinse with 30ml of normal saline (0.9% concentration) thrice daily for three days.
214868962|NCT06223243|OTHER|chlorhexidine mouthrinse|Subjects were instructed to rinse with 30ml of chlorhexidine mouthrinse thrice daily for three days.
214868963|NCT06116084|OTHER|Ericksonian Hypnosis|An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.
214290908|NCT01144923|OTHER|Combination treatment|Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
214290909|NCT00636142|BIOLOGICAL|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
214290910|NCT01059799|DRUG|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
214290911|NCT01059799|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
214670036|NCT04957498|BEHAVIORAL|Family Based Treatment|Standard Family Based Treatment provided for up to 15 sessions.
214670037|NCT03069768|DEVICE|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
214868964|NCT06116084|OTHER|Hypnosis|A hypnosis session given to patients during a scintigraphic or PET examination, in a remote manner, i.e. the hypnotherapist (MERM) is in the control room at the time of the session and communicates with the patient via a microphone and the patient has headphones.
214868965|NCT05000879|BEHAVIORAL|MMB for Moms|12-week program that emphasizes mindfulness and cognitive behavioral skills
214868966|NCT01561508|DRUG|gamma-amino-butyric acid|gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
214868967|NCT01561508|DIETARY_SUPPLEMENT|Xylitol|The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
214868968|NCT01752543|DRUG|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
214868969|NCT01752543|DRUG|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
214868970|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 1|Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
214868971|NCT00686075|OTHER|Placebo, Cohort 1|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
214868972|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 2|Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
214868973|NCT00686075|OTHER|Placebo, Cohort 2|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
214868974|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
214868975|NCT00686075|OTHER|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
214868976|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
214868977|NCT00686075|OTHER|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
214868978|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
214868979|NCT00686075|OTHER|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
214868980|NCT05164887|PROCEDURE|Laparoscopic colorectal resection|the patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics
214868981|NCT02928718|PROCEDURE|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
214868982|NCT03052218|DEVICE|Pupillometry|Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
214868983|NCT04715932|DRUG|Hesperidin|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
214868984|NCT04715932|DRUG|Placebo|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
214868985|NCT02828306|OTHER|Patient Specific Implant|Implantation of Patient Specific Implant
214868986|NCT00051987|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
214868987|NCT00002149|DRUG|Clavulanate potassium|
214868988|NCT00002149|DRUG|Pseudoephedrine hydrochloride|
214868989|NCT00002149|DRUG|Amoxicillin trihydrate|
214868990|NCT00367549|DIETARY_SUPPLEMENT|Energy-containing soft drink|Commercial energy/sports drink
214868991|NCT00993837|PROCEDURE|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
214868992|NCT02740699|DRUG|Rosuvastatin|Participants will receive 20-40 mg once daily
214868993|NCT02740699|DRUG|Atorvastatin|Participants will receive 40-80 mg once daily.
214868994|NCT02740699|RADIATION|Cardiac Computed Tomography (CT)|Cardiac CT angiography (CCTA) provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Performed at baseline, 12 months 24 months, and 36 months.
214868995|NCT02740699|RADIATION|Cardiac Magnetic Resonance Image (MRI)|Provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Cardiac MRI may be performed at baseline, and 24 months (optional).
214868996|NCT00175188|DEVICE|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
215035336|NCT05749471|DIAGNOSTIC_TEST|ASEX (Arizona Sexual Experience) administration|ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of \> 19, any one item with a score of \> 5, or any three items with a score of \> 4 would have sexual dysfunction.
215035337|NCT05439733|OTHER|Questionnaire completion|Women will be asked to complete questionnaires 6 weeks after delivery
215035338|NCT02755961|BEHAVIORAL|Dietary education|
215035339|NCT02755961|BEHAVIORAL|Education on phosphate binder use|
215035340|NCT01775527|OTHER|blood test|
215035341|NCT01029535|DEVICE|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
215035342|NCT02969070|DIETARY_SUPPLEMENT|LopiGLIK™ therapy|4 weeks of LopiGLIK™ therapy 1 capsule/day
215035343|NCT02969070|DIETARY_SUPPLEMENT|Armolipid Plus® therapy|4 weeks of Armolipid Plus® therapy 1 capsule/day
215035344|NCT05168761|PROCEDURE|partial nephrectomy|
215035345|NCT06004622|OTHER|Calgary Family Intervention Model|under two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasted about 20 minutes and was conducted by a single researcher to maintain consistency. The scheduling of these sessions took into consideration the physiological and emotional stability of the participants. If any issues or difficulties arose during the course of the sessions, they could be paused. The confidentiality and privacy of the discussion content were ensured. The intervention took place in a dedicated room within the intensive care unit, providing sufficient space and privacy.
215035346|NCT01527565|DRUG|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
215035347|NCT06235502|OTHER|Home-based cycle-exercise for COPD patients|Patients will cycle in their own home using a pedal exerciser connected to the 4M-video app
215035348|NCT06235502|OTHER|Standard of Care|Exercise at Fitness Center, home based exercise according to a programme
215035349|NCT02749747|DRUG|Sulpiride use|50mg sulpiride once a day use for 60 days
215035350|NCT02749747|DRUG|Placebo|50mg placebo once a day use for 60 days
215035351|NCT02646410|OTHER|FPD+NDOT|
215035352|NCT02646410|OTHER|FPD+DOT|
215035353|NCT02646410|OTHER|DDD+NDOT|Door to door delivery + non directly observed treatment
215035354|NCT02646410|OTHER|DDD+DOT|Door to door delivery + directly observed treatment
215035355|NCT00895921|DRUG|Olanzapine|Single intramuscular 10-mg dose
215035356|NCT00895921|DRUG|Aripiprazole|Single intramuscular 9.75-mg dose
215035357|NCT06211699|PROCEDURE|Omentopexy with Laparoscopic Sleeve Gastrectomy|Patients with omentum sewed to the remnant gastric staple line during laparoscopic sleeve gastrectomy.
215035358|NCT06211699|PROCEDURE|Clips with Laparoscopic Sleeve Gastrectomy|Patients performed clips to the remnant gastric staple line during laparoscopic sleeve gastrectomy
215035359|NCT01336348|DRUG|Prasugrel|60 mg loading dose given orally at presentation
215035360|NCT01336348|DRUG|Tirofiban|Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
215035361|NCT04223271|DIAGNOSTIC_TEST|Indicor|Handheld device with attached PPG sensor that is paired with a tablet to estimate left ventricular end diastolic pressure. Subjects will blow into the device in order to perform a standardized Valsalva maneuver for 10 seconds. The index finger will be resting in the PPG sensor during the test. Each test requires three efforts, with 45 seconds rest between efforts.
215035362|NCT00687076|DRUG|Ezetimibe|Daily dose of 10 mg of Ezetimibe
215035363|NCT00687076|DRUG|Niaspan|Daily dose of 1500 mg of Niaspan
215035364|NCT00687076|DRUG|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
215035365|NCT00687076|BEHAVIORAL|Standard care|Standard of medical care for PAD
215035366|NCT00687076|DRUG|Aspirin|Daily dose of 325 mg of aspirin
215035367|NCT00687076|DRUG|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
215035368|NCT00687076|DRUG|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
215035369|NCT00687076|DRUG|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
215035370|NCT00687076|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
215035371|NCT05375422|OTHER|SARAH|Set of exercises with components of muscle strengthening, range of motion gain and home exercises.
215035372|NCT05375422|OTHER|Educational intervention|Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
214290912|NCT03839745|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
214290913|NCT00003596|DRUG|cisplatin|
214290914|NCT00003596|DRUG|fluorouracil|
214290915|NCT00003596|DRUG|mitomycin C|
215035373|NCT05821946|OTHER|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|Before discharge, individuals will be given a user name and password to enter the website by the researcher. The first access to the website will be made via the researcher's computer, and the website will be introduced. Individuals will be shown how to access the compatible website on Android and IOS phones and tablets by the researcher. Web-based multi-source training for individuals to prevent urinary tract infections will begin. The researcher will check the use of educational materials by individuals from the administrator's menu. To increase the effectiveness of the training, reminder, motivating, and supportive messages will be sent to the patients twice a week.
215035374|NCT01203345|DRUG|IVIG|The infants received their first dose of study drug within 24 hours of randomization.
215035375|NCT01203345|DRUG|Placebo|An equal volume of 5 percent albumin solution
215035376|NCT05313581|BEHAVIORAL|START NOW WebApp|"The WebApp is based on the existing manualized START NOW skills training. START NOW aims to improve emotion- and stress regulation, social competence, effective management of encountered problems/crises, subjective well-being and resilience through improving an individual's level of psychological flexibility. It primarily employs a cognitive behaviourally oriented group skills training with integrated components from Dialectical Behavioural Therapy (DBT), Acceptance and Commitment Therapy (ACT), trauma-informed care and Motivational Interview (MI) techniques.~During the training, participants will encounter different exercises to help them train their skills. There are several mindfulness exercises in the form of audio tracks, containing, e.g., instructions on a breathing exercise. The skills training phase takes place over a period of 9 weeks (sessions 1+2, 9+10 and 11+12 are double session)."
214868997|NCT03881956|BEHAVIORAL|Health-promoting lifestyle education program|The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
214868998|NCT02649985|DRUG|[F-18]PBR06|PET radiopharmaceutical
214868999|NCT02649985|DRUG|[C-11]PBR28|PET radiopharmaceutical
214869000|NCT03046407|BIOLOGICAL|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
214869001|NCT05961865|DIAGNOSTIC_TEST|Markers of inflammation and fibrosis|"Will be analyzed the following inflammation markers:~Interleukin 6, N-terminal propeptide of type 1 procollagen (P1NP), chitinase-3-like protein 1 (YKL-40), tumor necrosis factor (TNF-alpha), GlycA, proprotein convertase subtilisin/kexin type 9 and omega-3 fatty acids."
214869002|NCT01467414|DRUG|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
214869003|NCT04302558|BEHAVIORAL|Exercise Blood Flow Restriction training|While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow
214869004|NCT04302558|BEHAVIORAL|SHAM Exercise Blood Flow Restriction training|While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
214869005|NCT00944619|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
214869006|NCT00944619|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
214869007|NCT05199519|DRUG|IBI345|IBI345 CAR-T cell injection by intravenous infusion
214869008|NCT01050608|DEVICE|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
214869009|NCT01050608|DRUG|62% ethanol based hand cleanser|"CDC based guidelines with regard to utilization in the health care environment the nest"
214869010|NCT01050608|BEHAVIORAL|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
214869011|NCT01050608|BEHAVIORAL|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
214869012|NCT05819723|OTHER|CAM score|"The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present."
214869013|NCT01616108|DRUG|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
214869014|NCT06160570|RADIATION|Intensive Modulated Radiation Therapy|Radiotherapy technique: IMRT
214869015|NCT06160570|RADIATION|3-Dimension Conformal Radiation Therapy|Radiotherapy technique: 3DCRT
214869016|NCT01545661|PROCEDURE|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
214869017|NCT01545661|PROCEDURE|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
214869018|NCT04431583|PROCEDURE|Bariatric surgery- single surgeon service|
214869019|NCT04431583|PROCEDURE|Bariatric surgery- multiple surgeon + multidisciplinary team approach|
214869020|NCT04431583|PROCEDURE|Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach|
214869021|NCT03544424|OTHER|No intervention|No intervention
214869022|NCT03627520|DRUG|[14C]Sulfatinib|300 mg Sulfatinib with 100 µCi \[14C\]
214869023|NCT02316665|DEVICE|continuous positive airway pressure|continuous positive airway pressure treatment during three months with adherence recording
214869024|NCT02316665|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
214869025|NCT04915482|DRUG|Combined use of TPO-RAs with low-dose anti-CD20 antibody|Experimental: Combined use of TPO-RAs with low-dose anti-CD20 antibody The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
214869026|NCT04915482|DRUG|The best available therapy|The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
214869027|NCT01303757|BEHAVIORAL|Dietary counselling|
214869028|NCT06273930|DRUG|5% CALCIUM SODIUM PHOSPHOSILICATE|Calcium sodium phosphosilicate is a particulate, bioactive glass material that degrades in the aqueous oral environment to release calcium and phosphate ions, leading to formation of hydroxycarbonate apatite on the dentine surface result in reduction in dentine hypersenstivity
214869029|NCT06273930|DRUG|8% Arginine|Arginine contributes to Whole Mouth Health. It also plays a role with respect to dental caries, helping to maintain a pH-neutral environment, and is proven to rapidly help relieve dentin sensitivity. Arginine is truly a remarkable ingredient now being used in oral care products.
215035377|NCT00647647|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
215035378|NCT00647647|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fasting
215035379|NCT05665283|DRUG|Ensartinib Hydrochloride|oral ALK inhibitor
215035380|NCT04154722|DRUG|Meropenem Injection|inj meropenum for 10 days
215035381|NCT04154722|DRUG|Azithromycin Powder|syp azithromycin for10days
215035382|NCT04624984|DRUG|PD-1 inhibitor|PD-1 Inhibitor, intravenous drip, d1.
215035383|NCT04624984|DRUG|PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome|PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;
215035384|NCT06489002|OTHER|Implementation Support|Health centers receiving the intervention will have access to implementation support strategies designed to support adoption of social needs screenings and referrals to community organizations for patients with unmet social needs receiving care management. Implementation support will be provided by an OCHIN trainer, practice facilitators, workflow engineer, and analysts.
215035385|NCT03839914|DRUG|Vancomycin powder|For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
215035386|NCT00735150|BEHAVIORAL|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
215035387|NCT06227949|DRUG|Luveris|Patients will self-administer a subcutaneous injection of Luveris in addition to Gonal-F (FSH) daily until a pre-set criteria to trigger ovulation is reached.
215035388|NCT06157034|OTHER|Placebo|Inert Material
215035389|NCT06157034|DIETARY_SUPPLEMENT|Zingier officinale powder|The raw form of Zingiber officinale will be grounded in powder by manual grinding and will be encapsulated.
215035390|NCT06157034|DIETARY_SUPPLEMENT|Carum carvi, L powder|The raw form of Carum carvi, L will be grounded in powder by manual grinding and will be encapsulated.
215035391|NCT06157034|DIETARY_SUPPLEMENT|Mentha spicata oil|Mentha spicata L will be extracted in the form of oil and will be encapsulated.
215035392|NCT03181191|OTHER|Oral glucose tolerance test|Oral glucose tolerance test and biopsies
215035393|NCT05109741|BEHAVIORAL|Internet-based Psychodynamic Therapy|Internet-based Psychodynamic Therapy based on the SUBGAP model developed by Farrell Silverberg
215035394|NCT05109741|BEHAVIORAL|Internet-based Behavioral Activation|Internet-based Behavioral Activation based on the BATD-R model developed by Carl Lejuez and others.
215035395|NCT02862093|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
214290916|NCT00003596|RADIATION|radiation therapy|
215035396|NCT01113684|DEVICE|Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.
215035397|NCT01508364|DRUG|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
215035398|NCT01018602|DRUG|vildagliptin|100 mg per day over 24 months
215035399|NCT01018602|DRUG|inactive pill|1 pill per day over 24 months
215035400|NCT00583219|DRUG|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
215035401|NCT00583219|DRUG|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
215035402|NCT05533840|DIAGNOSTIC_TEST|ultra-high-resolution computed tomography exams|Participants in the age groups undergo ultra-high-resolution computed tomography exam
215035403|NCT00173719|DEVICE|Standard cane|
215035404|NCT06250829|OTHER|Observational|Observational study of body composition, cytokine profile, immune status, ctDNA, serial radiology.
215035405|NCT01220661|DRUG|Cefotetan|preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
215035406|NCT05490225|DEVICE|VenaSure|The device will be surgically implanted at the access site in subjects undergoing routine hemodialysis. The device is expected to provide a target to aid in long-term cannulation success.
215035407|NCT05438927|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
215035408|NCT05438927|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
215035409|NCT05438927|BEHAVIORAL|Fact G Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
215035410|NCT05438927|BEHAVIORAL|General Anxiety Disorder (GAD)-7|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
214290917|NCT00547092|DRUG|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
214869030|NCT00684892|DEVICE|Chartis System|Assessment of airway flow and pressure
214869031|NCT06133283|BEHAVIORAL|High intensity endurance exercise|High intensity interval exercise on a recumbent stepper for 30 minutes, 3 days per week.
214869032|NCT06133283|BEHAVIORAL|Stretching exercise|Stretches of face, neck, upper extremity, trunk and lower extremity muscles including whole body stretches for 30 minutes, 3 days per week.
214869033|NCT06133283|BEHAVIORAL|Virtual reality (VR)-based gaming|VR games will involve games that challenge balance such as reaching different targets during activities such as sit to stand, dodging obstacles etc. Participants will play approximately 6 games for 30 minutes, 3 days a week.
214290918|NCT00547092|DRUG|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
214869034|NCT03783039|DEVICE|SURGICEL Powder|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Powder, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
214869035|NCT03783039|DEVICE|SURGICEL Original|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Original, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
214869036|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
214869037|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
214869038|NCT01682863|DRUG|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
214869039|NCT01682863|DRUG|Placebo|To mimic QAB149
214869040|NCT01381250|BEHAVIORAL|cognitive behavior therapy|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur \& Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
214869041|NCT00737750|DEVICE|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
214290919|NCT04480437|DEVICE|mp-BUS data collection|Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.
214869042|NCT00737750|DEVICE|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
214869043|NCT00737750|BEHAVIORAL|Control|Voluntary quadriceps muscle contractions.
214869044|NCT04269538|DRUG|PF-06480605|PF-06480605 150 mg and 450 mg SC dosing
214869045|NCT04269538|DRUG|Placebo|Placebo SC dosing
214869046|NCT01673438|DRUG|aldoxorubicin|
214869047|NCT02037035|DRUG|Ketamine|
214869048|NCT02003521|DEVICE|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
214869049|NCT00918138|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
214869050|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
214869051|NCT00918138|DRUG|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
214869052|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
214869053|NCT00918138|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
214869054|NCT03568279|PROCEDURE|Two-handed jaw thrust|The assistant applied two-handed jaw thrust for intubation.
214869055|NCT03568279|PROCEDURE|Control|The intubation was done without two-handed jaw thrust.
214869056|NCT03653117|DEVICE|Transperineal laser ablation|Minimal invasive coagulation of prostatic tissue by laser
214869057|NCT00457899|DRUG|Quetiapine IR (Immediate Release)|oral
214869058|NCT05500118|OTHER|Patients Decision Aids|Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.
214869059|NCT02592083|DRUG|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
214869060|NCT02592083|DRUG|Palbociclib|
214869061|NCT05033093|DRUG|Root Canal Sealants|it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
214869062|NCT05494645|DRUG|Exparel|Liposomal bupivicaine
214869063|NCT05494645|DRUG|Peripheral Nerve Block|Peripheral nerve block without Exparel
214869064|NCT00054574|BIOLOGICAL|panitumumab|
214869065|NCT02043587|DRUG|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
214869066|NCT02043587|DRUG|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages \>50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
214869067|NCT02043587|DRUG|PEG-asp|2,000 IU/m2 IV for ages \</= 50, age \> 50, 1000 IU/m2 IV Day 16, Courses 1A \& 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
214869068|NCT02043587|DRUG|CTX|750 mg/m2 IV, days 1 \&15 for subjects \<40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 \& 16 for subjects \< 40 years of age if day 14 bone marrow M2 or M3; Courses 1A \& 2A
214869069|NCT02043587|DRUG|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A \& 2A; Maintenance: Monthly, days 1-5
214869070|NCT02043587|DRUG|Liposomal AraC|25 mg intrathecal (IT), on days 1 \& 15 during Courses 1A \& 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
214665684|NCT06056284|BEHAVIORAL|Progressive relaxation exercises and sleep hygiene training|Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients. After seven weeks, an appointment will be given for the post-test. In the second week, those in the experimental group will be taught progressive relaxation exercise using a compact disc (CD) prepared by the Turkish Psychological Association in the hospital and after the sleep hygiene training, progressive relaxation exercise brochure and sleep hygiene training brochure will be distributed. Starting from the second week, the individuals in the experimental group will be expected to apply the trainings given in the hospital accompanied by the researcher two days a week for six weeks and to apply the trainings given to the individuals at home on the other days of the week.
215035411|NCT05438927|BEHAVIORAL|Patient Health Questionnaire (PHQ)-9|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
214869071|NCT02043587|DRUG|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B \& 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
214869072|NCT02043587|DRUG|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B \& 2B
214869073|NCT02043587|DRUG|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C \& 2C
214869074|NCT02043587|DRUG|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C \& 2C
214869075|NCT02043587|DRUG|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
214869076|NCT02043587|DRUG|Rituximab|375 mg/m2 IV once daily on days 1 \& 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C \& 2A
214869077|NCT02043587|DRUG|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
214869078|NCT05396378|DIETARY_SUPPLEMENT|Oral glucose in liquid form|A glucose containing drink that has a fixed dose of 25 g of glucose per can.
214869079|NCT05715983|PROCEDURE|Bascom II procedure|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide was injected in all orifices to visualize all tracts and sinuses. The proposal area of incision is marked nearby sinus tract openings and the skin with lateralization on one side of the cleft. A vertical-orientated incision of the skin and subcutaneous fat around the primary and secondary orifices is made using a scalpel or a monopolar electrocautery. The sinus tract is excised in en-block till unchanged subcutaneous tissue. The wound is irrigated with antiseptic solution. If postoperative wound is larger than 5 cm then a silicone draining tube is placed through the contraperature in the upper corner. The wound is closed by interrupted sutures Vicryl/Polysorb 2/0 3/0 layer by layer. Aseptic dressing is applied to the closed wound.
214869080|NCT05715983|PROCEDURE|SiLaC|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide is injected in all orifices to visualize all tracts and sinuses. All visible orifices are excised with a scalpel or dermo punch. After that hairs are removed from the sinus by Volkmann curette. A metallic stylet is used to determine the length and direction of the different tracts. Then laser destruction of the sinus is performed with FiberLase VT laser, wavelength 1460 or 1520 nm, the laser energy 10-12 Watts. The fiber delivers energy homogeneously in a continuous way. Hemostasis by electrocautery. The wound is washed with povidone-iodine solution. Aseptic dressing is applied.
214869081|NCT05250466|PROCEDURE|Radiofrequency technology|The vulva and vagina were routinely disinfected with iodophor, the negative plate was placed on the patient's waist and abdomen, and the vulva module was selected for treatment for 10 minutes per side, for a total of 20 minutes. Parameters: power 10-20W, temperature 38-42C°, once every 10 days, 5 times in total
215035412|NCT06067854|PROCEDURE|the standard procedure - without regional anaesthesia|the standard procedure - without regional anaesthesia
215035413|NCT06067854|PROCEDURE|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
215035414|NCT05448950|DEVICE|VIG Continued Access Study|Small skin incisions will be made for tunneling the graft under the skin in a standard manner. The VIG device is provided pre-loaded within a customized catheter-based delivery system for over-the-wire delivery. The VIG is inserted through an introducer sheath placed in the target vein so that the 'vessel end' of the VIG is deployed within the vein, and the 'graft end' extends out of the vein for connection to the graft. Delivery and deployment will be performed under fluoroscopic guidance. The VIG will be deployed first, connected to the AVG, then the graft and VIG will be flushed and clamped. The arterial anastomosis will then be created using a standard suturing method.
215035415|NCT06640738|DRUG|arm 2|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
214290920|NCT02697812|PROCEDURE|slow sternal retraction|the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
214290921|NCT01168531|DRUG|Pregabalin|pregabalin: 300 mg/day, po, from operative day until third postoperative day.
214869082|NCT05250466|PROCEDURE|Electrical stimulation|Routine vulvovaginal disinfection with iodophor, vaginal probes are placed in channel A, electrode pads are placed in channels B\\C\\D respectively, the frequency of electrical stimulation (the most comfortable amount) is adjusted, 10 times is a course of treatment, and mild lesions are treated for 1-2 courses of treatment , 2 to 3 courses of treatment for moderate to severe lesions.
214869083|NCT00541216|DRUG|Ephedrine|
214869084|NCT02226757|DRUG|Paclitaxel-trastzumab|"Trastuzumab~* Dose:~  * First dose: 4 mg/kg IV~ * Subsequent doses: 2 mg/kg every week IV.~* The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.~Paclitaxel~\- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab"
214869085|NCT06113926|OTHER|Bystander Acknowledgment|"The experimenter said That is so messed up that they excluded you in the task. And honestly, I would say it was racist… acknowledgment of the participants experience, …this shouldn't have happened, and I'm really sorry it did… an apology, and …I'm going to talk to the primary investigators of the study to figure out how we can make sure that this won't happen to other people a plan of action."
214869086|NCT00886223|PROCEDURE|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
214869087|NCT01955837|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
214869088|NCT01955837|DRUG|Placebo|Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
214869089|NCT06263712|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The Attempted Suicide Short Intervention Program (ASSIP) is a specific therapy for patients with a suicide attempt in their biography. The brief therapy ASSIP consists of three to four sessions of approximately 50 minutes each.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her\*his personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
214869090|NCT06263712|BEHAVIORAL|Standard of care plus resource interview group (STAR)|The standard of care plus resource interview group (STAR) will be offered a clinical interview, a risk assessment, and a non-specific resource focused intervention over three face-to-face sessions. In this resource focused intervention, the patient is asked to name her\*his resources, describe them, and give examples.
214869091|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
214869092|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
214869093|NCT06423443|BEHAVIORAL|Digital Cognitive Behavioral Therapy|digital cognitive behavioral therapy app
214869094|NCT06423443|BEHAVIORAL|Health Education|traditional on-line health education app
214869095|NCT06423443|DRUG|TAU|treatment as usual
214869096|NCT04851938|DEVICE|transcutaneous electrical nerve stimulation device|The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.
214869097|NCT03322735|DRUG|Fludarabine|25-30mg/m2/day IV for 3 days
214869098|NCT03322735|DRUG|Cyclophosphamide|cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
214869099|NCT03322735|BIOLOGICAL|BCMA CAR-T|BCMA CAR-T cells will be administered after completion of the chemotherapy.
214869100|NCT04500418|DRUG|Cenicriviroc (CVC)|Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).
214869101|NCT04500418|DRUG|Placebo|Optically identical pills without CVC.
214869102|NCT02702661|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|Fascia Iliaca Compartment Block
214869103|NCT02702661|PROCEDURE|Local Anaesthetic Infiltration (LAI)|Local Anaesthetic Infiltration (LAI) of the portal tracts
214869104|NCT02702661|DRUG|Levobupivacaine|Levobupivacaine 0.125% - 40ml
214869105|NCT04668911|OTHER|Swab|PCR test for SARS-CoV2, oral and nasal swab
214869106|NCT06021535|OTHER|No intervention|No intervention
214869107|NCT02089035|DIETARY_SUPPLEMENT|MUFA-rich dairy products (UHT milk, cheese and butter)|
214869108|NCT02089035|DIETARY_SUPPLEMENT|Conventional dairy products (UHT milk, cheese, butter)|
214869109|NCT01716715|DRUG|Cabozantinib S-malate|Given PO
214869110|NCT01716715|OTHER|Laboratory Biomarker Analysis|Correlative studies
214869111|NCT01716715|DRUG|Paclitaxel|Given IV
214869112|NCT03343444|DRUG|12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks
214869113|NCT03343444|DRUG|8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
214869114|NCT05371860|OTHER|Omit breast radiation|Omit breast radiation for 3 years after surgery
214869115|NCT04228783|BIOLOGICAL|Ad26.ZEBOV|Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).
214869116|NCT04228783|BIOLOGICAL|MVA-BN-Filo|Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.
214869117|NCT04228783|BIOLOGICAL|Placebo|Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
214869118|NCT00704574|DRUG|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
214869119|NCT00626392|DRUG|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
214869120|NCT00626392|DRUG|aspirin (ASA)|325 mg tablets administered once daily
214869121|NCT00626392|DRUG|aspirin placebo (ASA Pbo)|Tablets administered once daily
214869122|NCT00635063|DRUG|AD 923|
214869123|NCT02123810|OTHER|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
214869124|NCT03062423|DRUG|Sofodelevier|1 tablet contains 400 mg sofosbuvir
214869125|NCT03062423|DRUG|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
214869126|NCT03062423|DRUG|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
214869127|NCT02866006|DRUG|BVAC-C|Autologous B cells and monocytes transfected with E6E7 gene of HPV
214869128|NCT02866006|DRUG|Topotecan|
214869129|NCT03002571|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
215035416|NCT06640738|DRUG|arm 1|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
215035417|NCT02836249|DRUG|TAF|TAF 25 mg tablet administered orally once daily
215035418|NCT02836249|DRUG|TDF|TDF 300 mg tablet administered orally once daily
215035419|NCT02836249|DRUG|TAF Placebo|TAF placebo tablet administered orally once daily
214869130|NCT03002571|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
214869131|NCT03151811|DRUG|Melflufen|Intravenous infusion
215035420|NCT02836249|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
214290922|NCT01168531|DRUG|dexamethasone|Dexamethasone 16 mg, intravenous, before induction of anesthesia
214869132|NCT03151811|DRUG|Pomalidomide|Oral capsules
214290923|NCT01168531|DRUG|placebo|vitamin B complex formula
214290924|NCT03081065|DIETARY_SUPPLEMENT|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
214665685|NCT01954823|DEVICE|e-diary|"The e-diary can collect data on:~* Medical data: information on diseases, treatments and attending physicians~* Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data~* Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails~* Reports: textual and graphical reports of the data in the diary can be created"
214869133|NCT03151811|DRUG|Dexamethasone|Oral tablets
214869134|NCT05935111|BEHAVIORAL|Physical Activity Self-efficacy (PAS) intervention|The PAS intervention will be a web-based intervention to address the unique barriers to physical activity in adults with obesity, based on self-efficacy theory and effective behavioral change techniques. Self-efficacy is specified as a mediating psychological variable in the conceptual model for the promotion of physical activity. Self-efficacy refers to domain-specific beliefs (e.g., job-, transport-, domestic-, leisure-related physical activity) about their ability to execute differing levels of performance given situational demands. There is a rich literature on the importance of targeting self-efficacy as a modifiable mediating variable in PA-promoting interventions. Also, the PAS intervention will consist of effective behavioral change techniques (e.g., action planning, teach to use prompts/cues, goal setting, etc.).
214869135|NCT02676583|PROCEDURE|Tonsillectomy|Closure or not closure of tonsil fossa
214869136|NCT01801631|OTHER|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
214869137|NCT01801631|OTHER|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
214665686|NCT02333227|DIETARY_SUPPLEMENT|Xylitol gum|This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
214665687|NCT03436264|OTHER|MRI|fMRI
214869138|NCT04717765|DEVICE|Preventive, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
214869139|NCT04717765|DEVICE|Curative, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
214869140|NCT04717765|DEVICE|Preventive, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
214869141|NCT04717765|DEVICE|Curative, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
214869142|NCT00405444|DRUG|Fentanyl|The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
214869143|NCT00405444|DRUG|Sterile water|The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
214869144|NCT04447950|PROCEDURE|Type 2/posterior Quadratus Lumborum block|Injection of local anaesthetic into posterior boundry of Quadratus Lumborum muscle.
214869145|NCT04447950|PROCEDURE|Placebo block with Saline|Injection of saline into posterior boundary of Quadratus Lumborum muscle.
214869146|NCT00498901|DRUG|goserelin|
214869147|NCT00498901|DRUG|letrozole|
214869148|NCT00498901|DRUG|leuprolide acetate|
214869149|NCT00498901|PROCEDURE|conventional surgery|
214869150|NCT02066948|OTHER|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
214869151|NCT02066948|OTHER|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
214869152|NCT02066948|OTHER|meal pattern|skew or even
214869153|NCT02066948|DIETARY_SUPPLEMENT|even|even amount of protein distributed between each meal
214869154|NCT02066948|DIETARY_SUPPLEMENT|skew|a skewed amount of protein is distributed between each meal
214869155|NCT06232330|DEVICE|Group A|This group will receive TOA which include Weight transfers from a standing position and stepping in various star-type directions, Sit-ups from different heights with the hemiplegic lower limb behind the normal lower limb, From a kneeling position alternately projecting the lower limb forward, From a standing position with a limited base of support turning head and trunk right to left, Continuous walking on a treadmill for 10 minutes, Ascending and descending of stairs, Crossing 4 obstacles with continuous walking, Walking while simultaneously pushing a stroller, Walking while holding an object, Walking on different surfaces and slopes, The intervention took place for 5 days a week for 6 week for 20 minutes. Pre measurement was taken before the intervention and after 6 weeks post measurement was taken.
215035421|NCT01786122|OTHER|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
214869156|NCT06232330|DEVICE|Group B|This group will receive PNF techniques for trunk control. Rhythmic initiation and Rhythmic stabilization for a span of 20 minutes on both sides. In rhythmic initiation patient will move passively from trunk flexion into extension and then back to the flexed position When the patient is relaxed and moving easily, ask for active assisted motion Then begin resisting the motion then patient will perform independently in rhythmic stabilization Resist an isometric contraction of the patient's trunk flexor muscles patient will match the resistance in front and then in back
214290925|NCT00750204|DEVICE|APRV|"APRV Protocol~* Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~* Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~* Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~* P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~* Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~* If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV."
214869157|NCT02005263|PROCEDURE|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
214869158|NCT01054235|BEHAVIORAL|training|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
214869159|NCT03666650|DRUG|Edoxaban 60 MG|Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
214869160|NCT04842838|DEVICE|paclitaxel DCB|Drug-coated balloon is a new kind of coronary interventional device. The balloon coated with anti-cell proliferation drugs (paclitaxel, etc.) is sent to the stenosis site. The balloon is closely adhered to the vascular wall during the expansion, and the drug is rapidly and evenly coated on the disaffected vessels.In recent years, DCB has gradually become an alternative for the treatment of in-stent restenosis (ISR), small vessel disease (SVD) and bifurcation disease.
214869161|NCT04842838|DEVICE|DES|Provisional T technique is the preferred method for the treatment of bifurcation lesions with the existing stent.According to the 2018 European Guidelines on revascularization and the consensus group of the European Bifurcation Club (EBC), Provisional T technique is still the first choice for the treatment of Bifurcation, despite the problems related to side branches.
214869162|NCT04187417|DRUG|topical tetracaine hydrochloride 1%|topical ophthalmologic anesthestic
214290926|NCT00750204|DEVICE|Conventional MV|Low tidal-volume mechanical ventilation
214290927|NCT04305483|PROCEDURE|Laser Bleaching|Content; There are 35% hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative. The way of application; Gingival protection is applied. The gel is applied to the labial surfaces of the teeth with a thickness of 1-2 mm. The use of laser increases the effectiveness of the gel. Operator and patient use protective glasses during laser application. The gel shows its effectiveness in about eight minutes. Then the gel is removed with the help of saliva absorber. The procedure is repeated until the desired degree of whitening is achieved. Then it is checked with a color scale.
214869163|NCT04187417|DRUG|Placebo|Placebo
214869164|NCT01085734|DRUG|Avastin|1.25mg intravitreally
214869165|NCT01085734|DRUG|Osurdex|0.7mg intravitreally
214869166|NCT01085734|DRUG|Avastin|1.25mg intravitreally
214869167|NCT00715936|BEHAVIORAL|Control|
214869168|NCT00715936|BEHAVIORAL|ECD|
214869169|NCT00715936|BEHAVIORAL|Enhanced Nutrition|
214869170|NCT04032236|OTHER|caffeine|At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group
214869171|NCT02135835|DRUG|Shenfu Zhusheye|
214869172|NCT02135835|DRUG|5% glucose injection|
214869173|NCT05999058|PROCEDURE|Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation|The dacryoendoscopy was inserted into the lacrimal duct through the upper or lower lacrimal punctum. When the dacryoendoscopy reached the postsaccal obstruction, laser dacryoplasty (FOX diode laser, A.R.C. Laser, Nürnberg, Germany) was performed by widening the stenotic or obstructed section. After removing the dacryoendoscopy, a silicone tube inserted into lacrimal passage. Double bicanalicular silicone intubation was performed as previously described.
214869174|NCT02169700|PROCEDURE|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
214665688|NCT01151072|DRUG|insulin degludec|Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
214869175|NCT05178433|COMBINATION_PRODUCT|Use baby moisturizers by NeoChine|During continuous phototherapy, use skin basic care and protection in combination with baby moisturizing products, use the whole body twice a day, and the amount of each time is not less than 5 grams.
214869176|NCT03216070|DRUG|Dasatinib 50 MG|50mg of dasatinib orally daily
214869177|NCT05984875|OTHER|Collection of tumor samples, blood and vaginal and rectal swabs|The following biological samples will be collected at different time points, according to the specified cohort and after signing the inform consent form: tumor tissue (fresh and archival) or normal tissue (cohort E), ascites (when present), peripheral blood, rectal swab, vaginal swab.
214869178|NCT01759732|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -4
214869179|NCT01759732|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
214869180|NCT01759732|BIOLOGICAL|anti-thymocyte globulin|
214869181|NCT01759732|BIOLOGICAL|filgrastim|
214290928|NCT04305483|PROCEDURE|Chemical Bleaching|"Total Blanc Office Teeth Whitening System (H35) will be used as chemical whitening agent. Content; There are 35% hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water. Method of Application; Gingival protection is applied. A 1 mm thick layer of gel is applied to all of the labial surfaces of the tooth. The whitening agent remains on the tooth surface for 20 minutes. At the end of this period, the gel is removed with saliva absorber and the surface is cleaned with a moist gauze."
214869182|NCT01759732|RADIATION|Total body irradiation|200 cGy per day on D-5 \& -4
214869183|NCT01759732|PROCEDURE|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
214869184|NCT01269333|DRUG|omeprazole|omeprazole 20mg for 7 days
214869185|NCT01269333|DRUG|fluvoxamine|fluvoxamine 50mg for 7 days
214869186|NCT01269333|DRUG|placebo|placebo for 7 days
214869187|NCT03090607|DEVICE|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
214869188|NCT03090607|DRUG|Saline|Endoscopic injection of saline
214869189|NCT06148415|BEHAVIORAL|Fetal Heartbeat Monitoring Group|Fetal Heartbeat Monitoring Group
214869190|NCT02076373|DRUG|recombinant human Erythropoietin|i.v. administration
214869191|NCT02076373|DRUG|Placebo|i.v. administration
214869192|NCT04229173|DIAGNOSTIC_TEST|MRI acquisition|MRI acquisition
214869193|NCT04229173|DIAGNOSTIC_TEST|DAT-SPECT|Imaging with DAT SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography)
214290929|NCT01922128|DRUG|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
214290930|NCT02701439|DEVICE|Small membrane filtration|"Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~* Abbreviated demographic and clinical evaluation~* TB history and evaluation~* Obtain three sputum samples - one early morning sample and two spot samples~* HIV testing (and CD4 if positive)~* Chest radiograph~* Small membrane filtration intervention will be administered to both arms"
214290931|NCT05156853|DIETARY_SUPPLEMENT|Insect menus|The insect menus will consist of 6 different products: flatbread, spice-mix, paste, minced meat, sausage and falafels. The products are based on either crickets, mealworms or buffaloworm larvae.
214869194|NCT04229173|DIAGNOSTIC_TEST|blood sample, cerebrospinal fluid (optional)|blood sample, cerebrospinal fluid
214869195|NCT04229173|BEHAVIORAL|Evaluations about motor abilities, depression, cognition and lifestyle|Evaluations about motor abilities (UMSAR scale), depression (BDI scale), cognition (MoCA scale) and lifestyle (MSA- QoL)
214869196|NCT04229173|BEHAVIORAL|Evaluation about depression cognition|Evaluations about depression (BDI scale), cognition (MoCA scale)
214869197|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
214869198|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
214869199|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
214869200|NCT01739348|DRUG|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
214869201|NCT01739348|DRUG|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
214869202|NCT02804022|DEVICE|VPIA analgesia|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line with an anti-reflux valve to ensure precise drug administration and no backflow.
214869203|NCT02804022|DRUG|Morphine|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line.
214869204|NCT05180916|DEVICE|TVNS|Cerbomed NEMOS
214869205|NCT01963143|BIOLOGICAL|Gammaplex (5%)|
214869206|NCT01963143|BIOLOGICAL|Gammaplex 10|
214869207|NCT02531750|OTHER|Immobilization due to an Achilles tendon rupture|
214869208|NCT02326441|DRUG|KX2-361|
214869209|NCT04290975|OTHER|Task-shifting of follow-up care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be shifted to be performed primarily by Community Health Workers (CHWs) with specialized epilepsy training
214869210|NCT04290975|OTHER|Enhanced usual care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be performed primarily by physicians, with CHWs serving to collect standardized data regarding outcomes
214869211|NCT03107312|PROCEDURE|Single blood sample collection|Collection of single blood sample of 10 ml volume by venepuncture
214869212|NCT00482183|DRUG|Pioglitazone|
214869213|NCT02387515|OTHER|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
214869214|NCT01447420|DRUG|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
214869215|NCT01447420|DRUG|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
214869216|NCT02822495|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
214869217|NCT00097903|DRUG|Karenitecin (BNP1350)|Phase 1 study,dose-escalation design
214869218|NCT04562155|DRUG|BAY1817080|Study drug BAY1817080 will be administered orally as tablet.
214869219|NCT04562155|DRUG|Placebo|Matching Placebo for BAY1817080 will be administered orally as tablet.
214869220|NCT02398630|RADIATION|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
214869221|NCT02398630|OTHER|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
214869222|NCT02398630|OTHER|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
214869223|NCT02398630|OTHER|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
214869224|NCT00459901|DRUG|Erlotinib and capecitabine|
215035422|NCT01786122|BEHAVIORAL|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
214869225|NCT02405884|OTHER|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
215035423|NCT05477953|DRUG|Nifurtimox (BAYA2502)|At least 1 dose of nifurtimox
215035424|NCT03465774|DRUG|Doxycycline|Receive via IPC
215035425|NCT03465774|DEVICE|Indwelling Catheter|Receive IPC
215035426|NCT03465774|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214869226|NCT04986384|DRUG|Atoderm SOS spray Aerosol 200ml|A bottle of 200ml topical spray was used on the eczematous skin lesions for itch relief.
214869227|NCT04385121|OTHER|Questionnary|Family member's will answer the questionnaires by phone
215035427|NCT03465774|OTHER|Questionnaire Administration|Ancillary studies
215035428|NCT03465774|OTHER|Survey Administration|Ancillary studies
215035429|NCT05743842|DEVICE|TriSalus™ TriNav™Infusion System|Given by Infusion
215035430|NCT05743842|DIAGNOSTIC_TEST|Angiogram|X-ray photograph
215035431|NCT05743842|PROCEDURE|Y90-radioembolization procedure|procedure
215035432|NCT05610163|DRUG|Capecitabine|Given PO
215035433|NCT05610163|DRUG|5-fluorouracil|Given IV
215035434|NCT05610163|DRUG|Leucovorin calcium|Given IV
215035435|NCT05610163|DRUG|Irinotecan|Given IV
215035436|NCT05610163|DRUG|Oxaliplatin|Given IV
215035437|NCT05610163|RADIATION|Long Course Chemoradiotherapy|Receive LCRT
215035438|NCT05610163|PROCEDURE|Computed Tomography|undergo CT
215035439|NCT05610163|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
215035440|NCT05610163|PROCEDURE|Sigmoidoscopy|undergo sigmoidoscopy
215035441|NCT05610163|PROCEDURE|biopsy|undergo biopsy
215035442|NCT06412120|DRUG|Niraparib|Niraparib will be administered orally (PO) daily as tablets at one of three possible dose levels, 100mg/day, 200mg/day or 300mg/day, based upon participant weight, platelet count, and certain drug combinations and conditions assessed at baseline.
215035443|NCT02661750|DRUG|Bowel Preparation|"Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy."
214290932|NCT05156853|DIETARY_SUPPLEMENT|Plant menus|The plant menus will be based on products which can be purchased in normal supermarkets and chosen to be as equal to the insect-based products as possible.
214290933|NCT00003170|DIETARY_SUPPLEMENT|glutamine|
214290934|NCT00003170|OTHER|placebo|
215035444|NCT05132972|BIOLOGICAL|Normoxic Allogenic UCMSC|Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10\^6 cells MSC/kg body weight. The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6)
215035445|NCT05132972|OTHER|Normal saline solution|Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)
215035446|NCT04264000|DRUG|platelet-rich plasma|Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
215035447|NCT04264000|DRUG|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
215035448|NCT02259595|DRUG|HPN-07|500-1,500 mg oral capsules administered in a single dose
215035449|NCT02259595|DRUG|NAC|1,200mg NAC administered via oral capsule in single dose
215035450|NCT02259595|DRUG|Placebo|placebo oral capsule
215035451|NCT04928378|OTHER|Descriptive retrospective study|characterization of the diagnosis, management and outcome of patients with osteoarticular infection due to MDR M. tuberculosis in France (MDR IOATB).
215035452|NCT00831883|BEHAVIORAL|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
215035453|NCT00831883|BEHAVIORAL|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
215035454|NCT00925574|DRUG|CNTO 1959; Placebo|
215035455|NCT03624075|OTHER|application of kinesio taping|application of kinesio taping in the rectus femoris muscle and in the medial and lateral region of the knee
215035456|NCT00918619|DEVICE|Sangustop|Application of Sangustop haemostatic agent on resection area
215035457|NCT00918619|DRUG|Tachosil|Application of Tachosil fibrin sealant on resection area
215035458|NCT00179686|DRUG|CC-5013|
215035459|NCT03464825|OTHER|Specific and progressive balance training|Specific and progressive balance training for the intervention group
215035460|NCT06560892|DRUG|Bupivacaine injection|patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.
214290935|NCT01432353|DRUG|DFRF4539A|multiple ascending doses
215035461|NCT06560892|DRUG|Dexmedetomidine injection|Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml.
215057190|NCT04328545|DEVICE|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
214869228|NCT03516110|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.
214869229|NCT05010616|DEVICE|Fixed orthodontic appliances|"Visual presentation of patient's predicted teeth alignment at the end of orthodontic treatment:~Presenting predicted teeth alignment after orthodontic treatment to patients before treatment starts, by using photos and videos of dental digital set-up.~Predicted teeth alignment can be described as: well-leveled and aligned patient's dental arches, well engaged posterior teeth and normal frontal teeth relationships."
214869230|NCT00384644|DEVICE|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
214869231|NCT03247192|DIETARY_SUPPLEMENT|Whey protein-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
214869232|NCT03247192|DIETARY_SUPPLEMENT|Placebo-whey protein|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
214869233|NCT03247192|DIETARY_SUPPLEMENT|Placebo-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
214869234|NCT05773248|PROCEDURE|ERAS protocol|The main concepts of the ERAS protocol compared to standard care included the following aspects: preoperative counselling with a specially trained nurse, restrictive use of preoperative sedation, intraoperative fluid and opioid administration and drain placement, strict antiemetic prophylaxis, early mobilisation, bowel stimulation and removal of any catheters as well as early food intake. Additionally, the ERAS protocol included a 30-day telephone follow-up.
214869235|NCT05969249|DEVICE|Upper limb in vibration training|"The stroke subjects were all involved in the training,wear upper and lower extremity vibrators,the posture for intervention is hemiplegic upper limbs with shoulder joints slightly bent and abducted at 45 degrees, with elbows bent at 90 degrees and wrists centered. The elbow angle of this posture is set by the elbow joint rotation axis of the upper limb vibrator.~The set angle is the movable angle range of 80-110 degrees of elbow bending. The vibration rehabilitation password accepted by all subjects is Try to keep the elbow joint bent at 90 degrees during the vibration process, Resist the force of the vibration and try not to move."
214869236|NCT03819894|DIAGNOSTIC_TEST|Introduction of a lower female hs-cTn threshold|The new female hs-cTn threshold will be baed on current recommendations for each of the assays used (hs-cTn T and I). The hospitals are the unit of randomization. At 5-month intervals, randomly selected hospitals will be advised that they are to transition to the intervention phase. For all men, the standard of care, overall population threshold will be used throughout the entire study.
214869237|NCT04260555|DRUG|DW1601|Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
214869238|NCT04260555|DRUG|DW16011|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
214869239|NCT04260555|DRUG|DW16012|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
214869240|NCT01667328|PROCEDURE|Massage therapy|Presurgical 15 minute massage performed by a licensed massage therapist
214869241|NCT01667328|PROCEDURE|Standard of care|Control group will receive standard of care with no massage therapy
214869242|NCT05816590|OTHER|Med@HOME Mobile App|Meds@HOME is a software application designed for use on a personal mobile device. The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly). Optional push notifications can be set so that users are alerted to an upcoming routine. Only primary caregivers can create, edit, and delete routines. All caregivers can check off on routines and receive notifications. Caregivers can also post notes related to routines or events. App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
214869243|NCT06369831|DIAGNOSTIC_TEST|68Ga-NOTA-ABSCINT-HER2 PET/CT|68Ga-ABS011, is a single domain antibody (sdAb) with the capability to bind HER2 tumor antigens very fast, while the unbound fraction is rapidly cleared from the blood. ABS011 is labeled with gallium-68, a short-lived isotope (68Ga, t1/2: 68 min). Combining rapid targeting of HER2, fast clearance and low radiation burden make 68Ga-ABS011 is suited for specific tumor marker whole body PET/CT imaging.
214869244|NCT00723723|DRUG|Statin|Statin
214290936|NCT03829150|DRUG|Dexlan|Dexlansoprazole MR 60 mg qd for 7 days
214290937|NCT03829150|DRUG|Amoxicillin|Amoxicillin (Amolin) 1 g bid. for 7 days
214869245|NCT06971367|BEHAVIORAL|Risk assessment messaging|Participants will be shown a brief video message at their baseline visit, containing information related to HIV risk assessment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the HIV risk assessment content category.
215057191|NCT04328545|DEVICE|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
214290938|NCT03829150|DRUG|Clarithromycin 500mg|clarithromycin (Klaricid) 500 mg bid for 7 days
214665689|NCT02730806|BEHAVIORAL|NLP|NLP techniques, such as VKD, visual/auditory/kinesthetic swishes, modified especially for PTSD, will be implemented one-on-one with each woman in this arm.
214665690|NCT04549012|DRUG|Tranexamic acid|comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
214869246|NCT06971367|BEHAVIORAL|U=U messaging|Participants will be shown a brief video message at their baseline visit, containing information related to U=U core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the U=U content category.
214869247|NCT06971367|BEHAVIORAL|Community benefits messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Community Benefits core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Community Benefits content category.
214665691|NCT04549012|DRUG|Oxytocin|Oxytocin
214869248|NCT06971367|BEHAVIORAL|Fresh start effect|Participants will be shown a brief video message at their baseline visit, containing information related to Fresh Start core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Fresh start effect content category.
214869249|NCT06971367|BEHAVIORAL|Education-based messaging|Participants will be shown a brief video message at their baseline visit, containing information related to HIV education core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Education-based content category.
214869250|NCT06971367|BEHAVIORAL|Default appointment messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Default Appointment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Default Appointment content category.
214869251|NCT06971367|BEHAVIORAL|Reserved for you messaging|"Participants will be shown a brief video message at their baseline visit, containing information related to the Reserved for you core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Reserved for you content category."
214869252|NCT06971367|BEHAVIORAL|Social norms (default) messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Social Norms core concepts and encouraging them to return for a repeat HIV test. The video message will be delivered by the default avatar. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Social Norms content category.
214869253|NCT06971367|BEHAVIORAL|Social norms (varied) messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Social Norms core concepts and encouraging them to return for a repeat HIV test. The video message will be delivered by an avatar that approximately matches each participant's age and sex. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Social Norms content category.
214869254|NCT06971367|BEHAVIORAL|Goal-setting messaging|Participants will be shown a brief video message at their baseline visit, containing information related to goal-setting core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the goal-setting content category.
214869255|NCT06971367|BEHAVIORAL|Incentive|Participants will be informed that they will receive a small financial incentive if they return for repeat HIV testing in 3-6 months after enrollment.
214869256|NCT05980741|PROCEDURE|high-quality nursing|High-quality nursing
214869257|NCT05980741|PROCEDURE|Clinical Care Pathway|Clinical Care Pathway
214290939|NCT03829150|DRUG|Metronidazole|Metronidazole (Flagyl) 500 mg bid daily for 7 days
214290940|NCT03221400|DRUG|PEN-866 Sodium|PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
214869258|NCT05980741|PROCEDURE|Roy Adaptation Model|Roy Adaptation Model
214869259|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.
214869260|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
214290941|NCT03221400|DRUG|fluorouracil|Fluorouracil 2400 mg/m2 IV
214290942|NCT03221400|DRUG|Folinic acid|Folinic acid 400 mg/m2 IV
214290943|NCT03221400|DRUG|Niraparib|Niraparib
214665692|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
214665693|NCT00831051|DRUG|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
214665694|NCT00831051|DRUG|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
214665695|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
214665696|NCT00831051|DRUG|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
214665697|NCT00831051|DRUG|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
214665698|NCT01044355|DEVICE|CPAP|6 weeks treatment with fixed CPAP
214665699|NCT01044355|DEVICE|APAP|6 weeks of treatment with auto-titrating positive airway pressure
214670038|NCT03069768|DRUG|Chantix|For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
214869261|NCT00643136|DRUG|Pregabalin|Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
214869262|NCT00643136|DRUG|Placebo|Matching placebo capsules twice daily for 28 days
214869263|NCT03230500|PROCEDURE|Computer guided implant placement|Implant will be placed immediately using computer aided surgical guide
214869264|NCT02160275|DEVICE|Artificial Pancreas (Inreda Diabetic BV)|Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
214869265|NCT02160275|DEVICE|Insulin pump therapy|Patients' own insulin pump with fast-acting insulin analog
214869266|NCT03401359|GENETIC|tissue biopsy, blood sample|At baseline, 100 tumor/blood samples will be banked. Only \~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.
214869267|NCT04622215|DIAGNOSTIC_TEST|ICIQ questionnaire|questionnaire
214869268|NCT06013410|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
214869269|NCT04244123|COMBINATION_PRODUCT|integrated information and nurse led telephone clinic|combining web-based information from easypod connect with nurse led telephone clinic
214869270|NCT05980195|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy for 30 times within 50 days
214869271|NCT05980195|DRUG|Standard medical treatment|"Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months"
214869272|NCT05980195|BEHAVIORAL|Risk factor management|Management of risk factors including hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise
214869273|NCT04810403|BEHAVIORAL|SOMEBODY Eating Disorder Prevention Program|Participants will receive daily activities to complete on their most frequently used social media platform for 14 consecutive days. Daily activities have been adapted from the Body Project - an intervention that has been demonstrated to reduce internalization of the thin ideal and reduce risk for eating disorders. Examples of activities to be piloted include unfollowing social media accounts the participant perceives as reinforcing the thin-ideal and posting a selfie without makeup or editing. Based on feedback from participants, the intervention may be altered to improve acceptability, feasibility, and preliminary evidence of potential efficacy.
214869274|NCT00653679|OTHER|exercise|1 hour of endurance or resistance exercise
214869275|NCT03272061|OTHER|Aerobic-based exercise program|Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
214869276|NCT03082287|DEVICE|Fecal Calprotectin Level|Measurement of calprotectin in feces
214290944|NCT01759667|OTHER|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
214290945|NCT05976750|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
214869277|NCT02823418|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
214869278|NCT02823418|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
214869279|NCT01794026|PROCEDURE|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
214869280|NCT03506906|DIAGNOSTIC_TEST|Sleep studies under noninvasive ventilation therapy|Polysomnography Transcutaneous capnography
214869281|NCT03506906|DIAGNOSTIC_TEST|Routine tests|Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
214869282|NCT06633237|OTHER|Core training program in female amateur basketball players|The intervention consists of a core training program specifically designed to improve core and trunk stability in female amateur basketball players. The program is integrated into the warm-up routine and is applied twice a week over an 8-week period. Each session lasts approximately 12-15 minutes and includes five exercises. The training program is divided into three phases of progression, gradually increasing the difficulty of the exercises over the 8 weeks by incorporating more dynamic and functional movements.
214869283|NCT02260297|DEVICE|Wrist Actigraphy(motion sensors)with light sensors-Jawbone Up 2|
214869284|NCT05041881|DEVICE|Trifocal lens AT LISA TRI, Zeiss|lens is made of hydrophilic acrylic material with square edge technology and having diffractive optic design
214869285|NCT05041881|DEVICE|Accommodating Tetraflex HD lens, Lenstec inc.|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
214869286|NCT05041881|DEVICE|Monofocal lens, Softec HD|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
214869287|NCT03254381|BEHAVIORAL|Resistance Training|Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
214869288|NCT03254381|BEHAVIORAL|Balance and Tone Training|Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
214869289|NCT01627353|PROCEDURE|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
215035462|NCT04247438|OTHER|12h and 36h Biofilm formation on PMMA (Palapress®) dentures and samples worn by participants and brushing cycles needed to remove it.|"Capturing the clinical data for biofilm formation on PMMA dentures and samples worn by participants and the number of brushing cycles required to remove this biofilm.~Development of artificial denture biofilm substitute with similar mechanical properties to real denture biofilm."
214869290|NCT01627353|PROCEDURE|Pre-emptive wound infiltration|"The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.~The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case."
214869291|NCT00077753|DRUG|enoxaparin sodium|
214869292|NCT04781192|DRUG|Durvalumab|Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])
214869293|NCT04781192|DRUG|Regorafenib|Oral once per day, Days 1 - 21 every 28 days
214869294|NCT05345743|PROCEDURE|Surgery|All types of surgery requiring general anesthesia
214869295|NCT05962203|DIAGNOSTIC_TEST|Multi-factorial geriatric assessment, monitoring & management systems|Multi-factorial geriatric assessment, monitoring \& management systems, e.g. community-based and home-based exercise programs, polypharmacy
214869296|NCT02545348|PROCEDURE|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
214869297|NCT05375526|DEVICE|Magtrace|"In the proper ovarian ligament (or its remnants), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.~If a hysterectomy has been conducted, this step can be omitted. In the infundibulopelvic ligament (suspensory ligament of the ovary), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle."
214869298|NCT00230074|DRUG|TCH346|
214869299|NCT00581087|DRUG|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
215035463|NCT02048540|BIOLOGICAL|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
215035464|NCT02048540|DRUG|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
215035465|NCT02048540|PROCEDURE|Gastrectomy|
215035466|NCT05603637|PROCEDURE|Catheter ablation using SmartTouch radiofrequency ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using radiofrequency energy with SmatTouch ablation catheter (Biosense Webster, USA)
215035467|NCT05603637|PROCEDURE|Catheter ablation using Farawave pulsed-field ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using pulsed-field energy with Farawave ablation catheter (Boston Scientific, USA)
215035468|NCT00737360|DRUG|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
215035469|NCT06493526|DRUG|Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.|Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.
215035470|NCT05321290|OTHER|Robotic Therapy Program|
215035471|NCT05213741|DEVICE|Autonomous navigation of a magnetic colonoscope|The proposed magnetic-assisted colonoscope system consists of an megnetic field nevigator, magnetic-assisted colonoscope, and image receiving decoder. All participants will receive the magnetic-assisted colonoscopic examination by using this proposed magnetic-assisted colonoscope system
215035472|NCT04490681|DRUG|Ertugliflozin|Fixed dose Ertugliflozin (5mg)
215035473|NCT04490681|DRUG|Placebo|Placebo group
215035474|NCT01965847|BEHAVIORAL|Medication therapy management|
215035475|NCT03622151|OTHER|Primer la Llar program|Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
215035476|NCT02706392|OTHER|Laboratory Biomarker Analysis|Correlative studies
215035477|NCT02706392|BIOLOGICAL|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
215035478|NCT05170971|OTHER|fecal microbiota transplantation|The fecal bacteria were transplanted once every 5 days for a total of 4 times
215035479|NCT02109276|DEVICE|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
215035480|NCT02109276|DEVICE|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
215035481|NCT05073588|OTHER|Indo Mediterranean diet|Mediterranean diet has been shown to be effective in NAFLD adult patients. In India, it is very difficult to follow Mediterranean diet, so one group will be given Indianized version of mediterranean diet.
214869300|NCT00581087|DRUG|Placebo|Treatment : 200 mg/day hard gelatine capsule
214869301|NCT05913089|DRUG|TQB2450 injection + Chemotherapy|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells."
214869302|NCT05913089|DRUG|TQB2450 injection + Anlotinib Hydrochloride Capsule|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
214869303|NCT01268501|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
214869304|NCT02069483|BEHAVIORAL|Motivational Interviewing|Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
215035482|NCT05073588|OTHER|Calorie restricted diet|One group will be given diet restricted in calories, which most of the patients follow to lose weight
215035483|NCT05452473|OTHER|CDSS-assisted upper GI endoscopy|Expert endoscopists perform screening upper gastrointestinal endoscopy while looking at the monitor (CDSS system: automatic detection or lesion classification function) and listening to the sound of the monitor next to the original endoscopy monitor system.
215035484|NCT05452473|OTHER|no intervention|Expert endoscopists perform routine screening upper gastrointestinal endoscopy without CDSS's help.
215035485|NCT03290027|DRUG|DFD-03|DFD-03 Lotion
215035486|NCT03290027|OTHER|Placebo Comparator|Vehicle (tazarotene 0%) Lotion
215035487|NCT01891955|BEHAVIORAL|Healthy diet A|"Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called healthy diet with grains and dairy). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
215035488|NCT01891955|BEHAVIORAL|Healthy diet B|"Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called healthy diet without grains and dairy). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
215035489|NCT04570371|BEHAVIORAL|Conversation Guide + Clinical Support|The intervention is a bundled intervention (conversation guide + clinician decision support tools) which promotes the solicitation and use of patient preferences for post-surgical, non-pharmacological pain management strategies.
215035490|NCT00619866|DRUG|Elagolix|Elagolix tablets administered orally
215035491|NCT00619866|DRUG|placebo|Placebo tablet administered orally
215035492|NCT05840913|DRUG|Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge|Local anesthetic injection for intra- operative pain control
215035493|NCT01283984|DRUG|AZD2115|Single dose, oral inhalation (nebuliser solution)
215035494|NCT01283984|DRUG|Placebo|Single dose, oral inhalation (nebuliser solution)
215035495|NCT01194596|BEHAVIORAL|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine), will be given in both arms.
215035496|NCT01194596|BEHAVIORAL|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
215035497|NCT03282266|PROCEDURE|PADN|PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
215035498|NCT03282266|PROCEDURE|Sham operation|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
215035499|NCT00963872|DRUG|cyclophosphamide|50 mg/kg intravenously (IV) over 2 hours on Day -6.
215035500|NCT00963872|DRUG|fludarabine phosphate|40 mg/m\^2 over 1 hour on Days -6 through -2.
215035501|NCT00963872|RADIATION|Total body irradiation|200 cGy on Day -1
215035502|NCT00963872|BIOLOGICAL|Umbilical cord blood unit with C3a fragment|On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
215035503|NCT00963872|BIOLOGICAL|Unmanipulated UCB Unit|On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
215035504|NCT00399087|DRUG|Perifosine|Perifosine oral administration
215035505|NCT00399087|DRUG|Docetaxel|IV administration
215035506|NCT00399087|DRUG|Prednisone|Oral administration
215035507|NCT01098422|DEVICE|Yttrium-90 Radioactive Resin Microspheres|An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
215035508|NCT01135966|BEHAVIORAL|Conventional resistance training program|Conventional resistance training program is followed.
215035509|NCT01135966|BEHAVIORAL|Whole body vibration resistance training program|WBV training on FITVIBE
215035510|NCT01968980|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
215035511|NCT01968980|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
215035512|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel|
215035513|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
215035514|NCT00567554|DRUG|paclitaxel|
215035515|NCT00567554|DRUG|paclitaxel + everolimus (RAD001)|
214290946|NCT05976750|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
214290947|NCT04945551|BEHAVIORAL|Aerobic exercise training|12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.
215035516|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
215035517|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + lapatinib|
215035518|NCT00283192|DRUG|Sertraline|
215035519|NCT03212729|RADIATION|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
215057192|NCT04328545|DEVICE|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
214869305|NCT02069483|BEHAVIORAL|Tailored Feedback|Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
214869306|NCT00355810|DIETARY_SUPPLEMENT|placebo followed by Lactobacillus plantarum MF 1298|placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
214869307|NCT00355810|DIETARY_SUPPLEMENT|Lactobacillus plantarum MF1298 followed by placebo|Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
214869308|NCT00718913|DRUG|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
214869309|NCT00718913|DRUG|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
214869310|NCT00718913|DRUG|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
214869311|NCT00718913|RADIATION|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
214869312|NCT00718913|DRUG|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
214869313|NCT06227026|BIOLOGICAL|Anti-CD19 CAR-T cells|Anti-CD19 CAR-T cells are autologous T cells, engineered to express an extracellular single chain variable fragment (scFv) derived from a murine anti-human CD19 hybridoma clone FMC63 linked in frame to hinge region derived from human CD8, transmembrane domain derived from Tumor Necrosis Factor Receptor Super Family 19 (TNFRSF19) the transactivation costimulatory domain 4-1BB, and CD3 zeta signaling domain (Miltenyi Biotec Inc). Anti-CD19 CAR-T cells will be cryopreserved in infusible cryomedia for a later infusion. Anti-CD19 CAR-T cells will be administered in 1 to 3 bags. Bag aliquoting, cell content and cryomedia composition will be done according to specifications in the CMC.
214869314|NCT05513846|DEVICE|DREEM EEG Device|The DREEM EEG device will be used to measure brain age.
214869315|NCT05513846|DEVICE|SleepImage Ring|The SleepImage ring uses plethysmography to analyze sleep architecture and cardiopulmonary coupling.
214869316|NCT04522947|OTHER|Milkshake fMRI|While in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
214869317|NCT05293639|DEVICE|Pulse Field Ablation|PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
214869318|NCT04969510|DRUG|10 mg PRAX-114|Once daily oral treatment
214869319|NCT04969510|DRUG|20 mg PRAX-114|Once daily oral treatment
214869320|NCT04969510|DRUG|40 mg PRAX-114|Once daily oral treatment
214869321|NCT04969510|DRUG|60 mg PRAX-114|Once daily oral treatment
214869322|NCT04969510|DRUG|Placebo|Once daily oral treatment
214869323|NCT05054413|OTHER|Questionnaire Administration|Complete questionnaires
214869324|NCT01404832|DRUG|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
214869325|NCT00827632|DRUG|Low dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."
214869326|NCT00827632|DRUG|High dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."
214869327|NCT04265430|OTHER|Contrast Agent|Given IV
214869328|NCT04265430|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214869329|NCT04265430|OTHER|Quality-of-Life Assessment|Ancillary studies
214869330|NCT04265430|OTHER|Questionnaire Administration|Ancillary studies
214869331|NCT02102516|DRUG|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing \>=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
214869332|NCT01910389|DRUG|Tadalafil|
214869333|NCT01910389|DRUG|Placebo for tadalafil|
214869334|NCT00511095|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
214869335|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
214869336|NCT02415569|DRUG|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
214869337|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
214869338|NCT01324674|OTHER|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
214869339|NCT01324674|OTHER|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
214869340|NCT03048188|OTHER|wound dressing|Manuka honey wound dressing
214869341|NCT00294463|DRUG|Tibolone|
214869342|NCT00294463|DRUG|Estradiol|
214869343|NCT00294463|DRUG|Estradiol + Medroxy Progesterone Acetate|
214869344|NCT06824350|DEVICE|chlorination for water disinfection and surface disinfection|"* Installation of inline chlorine doser(s) for automated water disinfection.~* Provision of chlorine solution for water and surface disinfection (half of treatment facilities randomized to receive electrochlorinator, half receive bulk chlorine solution deliveries).~* Provision of mop(s), bucket(s), and spray bottles for surface cleaning."
214869345|NCT06824350|BEHAVIORAL|infection prevention and control messaging|Infection prevention and control guidance and messaging
214869346|NCT06984523|RADIATION|Varian Eclipse|Varian TrueBeam linear accelerator with photon beam Volumetric Modulated Arc Therapy (VMAT) capability. Subjects will receive 3000 centigray (cGy) in 10 fractions at 300 cGy per fraction.
214869347|NCT05217706|DRUG|Ketamine|The treatment group will receive Ketamine 0.2mg/kg IV once
214869348|NCT05217706|DRUG|normal Saline|The placebo group will receive normal saline IV in a matched syringe
214869349|NCT06990243|OTHER|Evaluation Group|An evaluation form will record the participants' socio-demographic characteristics and information about their disease/treatment. Consciousness and cognitive tests will be performed. Then, pain will be assessed with the Visual Analog Scale, 4-Question Neuropathic Pain Questionnaire,, and the Spinal Cord Injury Pain Instrument (SCIPI).
214869350|NCT06989996|DEVICE|Images Acquisition|Acquisition of useable video images
214869351|NCT02951442|BIOLOGICAL|Biological sample|
214869352|NCT02951442|PROCEDURE|Non invasive Arterial investigations|
214869353|NCT02951442|PROCEDURE|Abdominal tomodensitometry|
214869354|NCT00407758|DRUG|enzastaurin hydrochloride|
214869355|NCT05189938|DIAGNOSTIC_TEST|HBA1c data and glucose levels|All subjects will wear the professional FreeStyle Libre Pro for glucose data and HbA1c data will be collected at different time points over the participation period.
214869356|NCT04455178|DRUG|Spironolactone|spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit
214869357|NCT04455178|DRUG|Indapamide|indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
214869358|NCT03757975|PROCEDURE|urethral length measure|measure of urethral length, distribution of questionnaires before and after operation
214869359|NCT05034276|OTHER|MORE-VR|Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
214869360|NCT05011630|OTHER|Pancreaticoduodenectomy|The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA
214869361|NCT02468492|BIOLOGICAL|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
214869362|NCT02468492|OTHER|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
214869363|NCT01594450|BIOLOGICAL|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
214869364|NCT01594450|PROCEDURE|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
214869365|NCT03465917|COMBINATION_PRODUCT|Renal Denervation|Bilateral denervation of the renal arteries using extravascular administration of neurolytic alcohol
214869366|NCT02119117|DIETARY_SUPPLEMENT|CoQ10|This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
214869367|NCT02119117|DIETARY_SUPPLEMENT|Placebo|This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
214869368|NCT00069186|DRUG|Creatine Monohydrate|
214869369|NCT00228241|DEVICE|AAI vs. DDD vs. BIV pacing in different patients groups|
214869370|NCT01458106|DRUG|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
214869371|NCT01458106|DRUG|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
214869372|NCT00073021|DRUG|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
214869373|NCT00073021|DRUG|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
214869374|NCT04003584|PROCEDURE|Coronary bypass surgery|Reviewed postoperative coronary bypass patients and compared postoperative pain levels
214869375|NCT06989918|DRUG|MHB018A|MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
214869376|NCT06989918|DRUG|MHB018A placebo|6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)
214869377|NCT01644136|PROCEDURE|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
214869378|NCT01644136|PROCEDURE|regional lymph node dissection|Undergo pelvic lymph node dissection
214869379|NCT01644136|DEVICE|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
214869380|NCT04470336|OTHER|Collagen Supplement|Three capsules post-breakfast Three capsules post-dinner
214670039|NCT02726867|DRUG|levetiracetam|Treatment will consist of LEV 4000 mg i.v. over 10 minutes.
214670040|NCT02726867|DRUG|lacosamide|Treatment will consist of LCM 600 mg i.v. over 10 minutes
214869381|NCT04470336|OTHER|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
214869382|NCT04470336|OTHER|Placebo|Three capsules post-breakfast Three capsules post-dinner
214869383|NCT00362921|DRUG|Gliadel wafers in combination with O6-benzylguanine|
214869384|NCT00855803|RADIATION|radiation|Given in 1 or 5 fractions
214869385|NCT02839421|DRUG|Scaling and Root Planing combined with moxifloxacin|Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
214869386|NCT00166270|DEVICE|ExAblate 2000|
214869387|NCT06131827|OTHER|Neural mobilization|Neural mobilization will be performed with twenty oscillations per minute being repeated three sets of one minute respecting one minute interval of rest between each set for 4 days weekly for six week
214869388|NCT06131827|OTHER|Task based activities|Task based activities consisted of different types task which will be performed with the dosage of 45 minute session 5 days weekly for six week.
214665700|NCT05435521|BEHAVIORAL|Personalized multicomponent exercise program (strength, resistance, balance, and flexibility) (PMEP)|"Physical activity expert will design for each participant a personalized exercise program according to baseline situation and previous physical activity. Both will be measured prior to initiation of activity program. Each participant is free to perform physical activity program at his house, outdoor or in a gym as long as it fulfills the prespecified requirements. Exercise programs will be acquired a more personalized shape during the course of the study.~In order to motivate participants, personal motivational messages will be sent each week through mail contact or using WhatsApp Social Media.~Physical activity will be registered in an activity wristband delivered to each participant at baseline evaluation."
214869389|NCT05200962|DEVICE|transcranial direct current stimulation|In tDCS, direct electrical currents are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
214665701|NCT05435521|OTHER|Body composition|Analyze the effects of PMEP on body composition in each evaluation using an impedance threshold device
214665702|NCT05435521|OTHER|Musculoskeletal and visceral Ultrasound|Quadriceps muscle ultrasound (US) of the rectus femoris measured in each evaluation in order to analyze the effects of PMEP Visceral fat will be analyzed in each visit
214670041|NCT02726867|DRUG|Ketamine|Treatment will consist of KET 2.5 mg/kg over 10 minutes
214670042|NCT02726867|DRUG|Phenobarbital|Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
214869390|NCT04048343|DRUG|Biological: Experimental: Tezepelumab|Tezepelumab subcutaneous injection every 4 weeks
214869391|NCT02384694|OTHER|Zumba dance|Twelve weeks, 3 times weekly 1 hour training
214869392|NCT04393766|DRUG|Normal Saline|normal saline(crystalloids)
214869393|NCT03780231|OTHER|non-ischemic scar|"non-ischemic LGE with no underlying labelled cardiomyopathy is detected on CMR"
214869394|NCT05187702|OTHER|Functional exersize|Participants will be given balance and strengthening exercises covering the balance exercise protocol.
214869395|NCT05187702|OTHER|Aerobic exersize|60% of the maximum heart rate is given 3 walking eccentricity per week
214869396|NCT02310282|DEVICE|Telemedicine|In-hospital telemedicine
214869397|NCT01333280|BEHAVIORAL|Double Trouble in Recovery|DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness
214869398|NCT01333280|BEHAVIORAL|Treatment as usual|Receive usual treatment at the programs
214869399|NCT02881060|DIETARY_SUPPLEMENT|Alcohol|
214869400|NCT02881060|DIETARY_SUPPLEMENT|Placebo|
214869401|NCT02098096|OTHER|Negative Work|"Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:~1. Familiarization~2. Acclimatization~3. Progression~Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.~All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer."
214869402|NCT02098096|OTHER|Stretching|Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
214869403|NCT01170910|PROCEDURE|Static incubation|"Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.~."
214869404|NCT01170910|PROCEDURE|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
214869405|NCT00361114|DRUG|sulphadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
214869406|NCT00361114|DRUG|Chlorproguanil/dapsone|Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
214869407|NCT00361114|DRUG|Sulfadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
214869408|NCT01383798|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
214869409|NCT01383798|DIETARY_SUPPLEMENT|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
214869410|NCT01745705|OTHER|Cervical Spine Manipulation|
214869411|NCT01745705|OTHER|Manual Contact|
214869412|NCT02171676|DRUG|Docetaxel|
214869413|NCT02171676|DRUG|BIBW 2992|
214869414|NCT01698827|OTHER|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
214869415|NCT04431882|PROCEDURE|optic nerve sheath fenestration|A standard medial transconjunctival orbitotomy was performed in all cases under general anesthesia. The medial rectus muscle was disinserted and reflected nasally with 6-0 synthetic polyester suture in typical fashion for eye muscle surgery. A traction suture was then placed through the insertion stump of the medial rectus in a baseball stitch fashion to facilitate abduction of the globe. The pupil was monitored at all times. A custom- made cupped orbital retractor was inserted along the medial scleral wall and used to retract the orbital fat and allow visualization of the optic nerve sheath. Retraction and globe abduction were relaxed if any changes in pupil size were noted. When adequate visualization was achieved, multiple dural sheath fenestrations approximately 3 mm in length. Expulsion of cerebrospinal fluid was invariably observed with the initial incision into the dural sheath.
214869416|NCT03276780|BEHAVIORAL|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
214869417|NCT03276780|DRUG|combination NRT|Both groups will receive combination NRT to help with smoking cessation
214869418|NCT02178280|OTHER|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
215035520|NCT03212729|PROCEDURE|Conventional endodontic treatment|After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
215035521|NCT03464773|OTHER|PIUO Pathway|See arm descriptions
214869419|NCT01884662|BEHAVIORAL|Virtual walking|"As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking."
214869420|NCT01884662|BEHAVIORAL|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
214869421|NCT03050060|DRUG|Atezolizumab|Given IV
214869422|NCT03050060|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214869423|NCT03050060|OTHER|Laboratory Biomarker Analysis|Correlative studies
215035522|NCT03018873|OTHER|remote ischemic preconditioning （RIPC）|once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
215035523|NCT00314457|DRUG|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
215035524|NCT03124186|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
215035525|NCT05626660|OTHER|Coronary angiography and percutaneous coronary intervention|Coronary angiography and percutaneous coronary intervention via radial approach
215035526|NCT05074914|PROCEDURE|oesophagectomy|removal of oesophagus
215035527|NCT03306550|DRUG|salvianolate injection|The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
215035528|NCT03306550|DRUG|Aspirin Tablet|Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
215035529|NCT02665377|DRUG|ANP|
215035530|NCT02665377|DRUG|Placebo|
215035531|NCT05636839|RADIATION|UVB treatment|UVB treatment 3 times per week for 10 weeks
215035532|NCT02128035|PROCEDURE|With Lead Shield|"A pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
215035533|NCT03075228|DEVICE|IntelliCap|Sampling of the small intestine using a samling capsule.
214290948|NCT02632474|DRUG|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
214869424|NCT03050060|DRUG|Nelfinavir Mesylate|Given PO
214869425|NCT03050060|BIOLOGICAL|Nivolumab|Given IV
214869426|NCT03050060|BIOLOGICAL|Pembrolizumab|Given IV
214869427|NCT03245957|OTHER|Ischemic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
214869428|NCT03245957|OTHER|Haemorrhagic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
214869429|NCT00003592|DRUG|methotrexate|
215035534|NCT01527032|DRUG|melphalan, thalidomide and dexamethasone|
214869430|NCT00003592|DRUG|paclitaxel|
214869431|NCT05841446|DRUG|test apixaban tablets|specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China
214869432|NCT05841446|DRUG|reference apixaban tablets|specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA
214869433|NCT04231734|OTHER|Ketogenic Diet|Prepared ketogenic meals, 3 per day for up to 12 weeks (Day 1 through Day 84)
214869434|NCT02304458|BIOLOGICAL|Ipilimumab|Given IV
214869435|NCT02304458|OTHER|Laboratory Biomarker Analysis|Correlative studies
214869436|NCT02304458|BIOLOGICAL|Nivolumab|Given IV
214869437|NCT02304458|OTHER|Pharmacological Study|Correlative studies
214869438|NCT01109563|BEHAVIORAL|Marijuana Check-Ins|The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
215035535|NCT01474109|DRUG|macitentan 3mg|macitentan 3mg tablet once daily
215035536|NCT01474109|DRUG|macitentan 10mg|macitentan 10mg tablet once daily
214290949|NCT00271050|OTHER|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
214290950|NCT01656785|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
214869439|NCT03516214|DRUG|EGF816|Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
214869440|NCT03516214|DRUG|Trametinib|Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
214869441|NCT05504590|DEVICE|Tuohy needle group|Ultrasound-guided caudal epidural block with Touhy needle
214869442|NCT05504590|DEVICE|Quincke needle group|Ultrasound-guided caudal epidural block with Quincke needle
214869443|NCT03401450|DRUG|ACB within true AC with bupivacaine 0.5% 20cc|The adductor canal block (ACB) is more commonly being used to provide post-operative analgesia since it provides a sensory block with minimal motor block.
214869444|NCT03401450|DRUG|ACB proximal to true AC with bupivacaine 0.5% 20cc|Patients will receive ultra-sound guided single femoral triangle block injection with 20 mL of 0.5% bupivicaine
214869445|NCT03143608|DEVICE|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
214869446|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.
214869447|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|"After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days."
214869448|NCT02823652|OTHER|standard genetic education|Undergo usual care
214869449|NCT02823652|OTHER|Genetic Counseling|Complete remote counseling
214869450|NCT02823652|OTHER|Genetic Testing|Undergo germline testing
214869451|NCT02823652|OTHER|Internet-Based Intervention|Complete on-line genetic education
214869452|NCT02823652|OTHER|Survey Administration|Ancillary studies
214869453|NCT03261765|OTHER|Assessment of adhesions|Modified Nair scoring system
214869454|NCT01367652|DRUG|Letrozole|2.5 mg tablet
214869455|NCT01367652|DRUG|Letrozole|2.5 mg Tablet
214869456|NCT02784353|BEHAVIORAL|Perioperative rehabilitation program|"Perioperative rehabilitation program~* preoperative rehabilitation : 2 weeks prior to operation~* postoperative rehabilitation : 3 months after operation"
214869457|NCT02784353|BEHAVIORAL|Conventional|conventional perioperative management without rehabilitation program
214869458|NCT00813527|DRUG|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
214869459|NCT00813527|DRUG|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
214869460|NCT00681512|DIETARY_SUPPLEMENT|berry powder|"All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.~The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.~All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks."
214869461|NCT03584984|PROCEDURE|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio
214869462|NCT03584984|PROCEDURE|Anorganic Bovine Bone (ABB)|Filling the socket with Anorganic bovine bone graft material only
214869463|NCT03584984|PROCEDURE|Absorbable gelatin sponge|Filling the socket with an absorbable gelatin sponge foam pack
214869464|NCT00398255|BEHAVIORAL|self-management program|
214869465|NCT06955091|OTHER|contrast strength training|For eight weeks players performed Contrast strength training included bench press, pull-over, half squat, and forward lunge. Each session began with a 10-minute warm-up (jogging, dynamic stretching, and basic weightlifting exercises) and ended with a 5-minute cool-down. Training was performed twice a week for 8 weeks on non-consecutive days (Tuesday and Thursday). Exercises were done using free weights at 40-80% of 1-repetition maximum, in 3-4 sets of 2-4 repetitions
214869466|NCT05933343|PROCEDURE|Ethibond suture|An Ethibond™ 1 suture will be placed as a drainage seton for complex anal fistula
214869467|NCT05933343|PROCEDURE|Vessel loop|A vessel loop will be placed as a drainage seton for complex anal fistula
214869468|NCT04004156|DEVICE|PerQdisc® Nucleus Replacement Device.|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
214869469|NCT05675306|BEHAVIORAL|Dynamic Temporal and Tactile Cueing Treatment|"DTTC is a dynamic, motor-based treatment approach designed for children with severe CAS. This approach is based on Integral Stimulation (Edeal \& Gildersleeve-Neumann, 2011; Maas \& Farinella, 2012; Maas et al., 2019; Strand \& Debertine, 2000; Strand \& Skinder, 1999), in which the clinician instructs the child to listen to me, watch me, and do what I do and systematically taxes and supports the speech motor system to facilitate system-wide change in speech output (Strand, 2020)."
214869470|NCT05102721|DRUG|Avelumab and Pepinemab|IV Infusions every two weeks.
214869471|NCT05999396|DRUG|Administration of CC-3|Accelerated titration phase, Standard 3+3 titration phase, expansion phase
215035537|NCT01474109|DRUG|placebo|matching placebo once daily
215035538|NCT00101348|DRUG|erlotinib hydrochloride|Given orally
215035539|NCT00101348|BIOLOGICAL|cetuximab|Given IV
215035540|NCT00101348|BIOLOGICAL|bevacizumab|Given IV
214869472|NCT06795997|BEHAVIORAL|Tax Conditions|Participants will make hypothetical purchases of tobacco products to use throughout the next 7 days. Participants will complete a total of 21 purchasing trials each for 7 days' worth of products. They will be exposed to 4 conditions with 5 trials each, where products will increase in price: Tobacco Parity, Nicotine-Content, Harm- Reduction, and Modified Risk Tobacco Product-related taxes.
214869473|NCT06795997|BEHAVIORAL|Control Condition|Participants will make hypothetical purchases of tobacco products to use throughout the next 7 days. Participants will complete a total of 21 purchasing trials each for 7 days' worth of products. They will be exposed to a control trial.
214869474|NCT06848010|DEVICE|Automated endotracheal cuff controller|The automated endotracheal tube cuff pressure controller will continously assess and maintain the endotracheal tube cuff pressure at pre-specifed pressure level of 25 cmH20.
214869475|NCT06844305|OTHER|Prosthetic foot|The most- and least-preferred prosthetic foot
214869476|NCT06844305|OTHER|Physical therapy|Personalized physical therapy
214869477|NCT04682964|DRUG|Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.|Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
214869478|NCT06580925|DEVICE|sham tape|sham
214869479|NCT06580925|DEVICE|kinesio tape|Kinesio taping will be applied to correct shoulder posture and facilitate shoulder external rotators
214869480|NCT06580925|DEVICE|dynamic tape|Dynamic tape will be applied to correct shoulder alignment and assist concentric contraction and eccentric control of external rotators
214869481|NCT03673007|BEHAVIORAL|Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred between August 18, 2018, and March 3, 2019.
214869482|NCT03673007|BEHAVIORAL|Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after March 3, 2019.
214869483|NCT04740476|DRUG|STK-001|STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.
214869484|NCT04163432|DRUG|Durvalumab|Durvalumab is administered at a dose of 1500mg for patients who weigh \>30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized
214869485|NCT04163432|DRUG|Pemetrexed|Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is \< 45 mL/min, pemetrexed is dosed at 400 mg/m2.
214869486|NCT04163432|DRUG|Carboplatin|Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.
214869487|NCT05192876|RADIATION|Radiotherapy|Outcomes and adverse events using radiation therapy
214869488|NCT04616430|DRUG|Topical endoxifen|topical solution
214869489|NCT04616430|DRUG|Placebo|topical
214869490|NCT04220255|DEVICE|Liberty677MY Multifocal IOL|multifocal intraocular lens (IOL)
214869491|NCT00536692|DRUG|mecamylamine|topical ocular drops
214869492|NCT00633243|PROCEDURE|Modified Directly Observed Therapy (mDOT)|
214869493|NCT00633243|PROCEDURE|Self-Administered Therapy (SAT)|
214869494|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
214869495|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
214869496|NCT02022748|DRUG|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
214869497|NCT02991690|OTHER|Hypothermia|To deliver intravascular hypothermia, an Alsius Icy CoolGuard® catheter (US Food and Drug Administration approved, Premarket Notification \[510(k), K030421\]; Alsius Corporation, Irvine, California) will be inserted through the femoral vein using a sterile technique. Patients will be cooled at a maximum rate (2-2.5 ºC/hr.) until they reach the target temperature (T 33 ºC), which will be maintained for 48 hours, and then re-warmed at 0.1 ºC/hr. until normothermia (T 37ºC) is achieved.
214869498|NCT05024916|DIETARY_SUPPLEMENT|Intervention|26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.
214869499|NCT05024916|DIETARY_SUPPLEMENT|Control|26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
214869500|NCT03077399|DEVICE|SCALA|All items of SCALA are applied
214869501|NCT06582602|BIOLOGICAL|MK-2060|Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
214869502|NCT06582602|BIOLOGICAL|Placebo|Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.
215035541|NCT00101348|OTHER|laboratory biomarker analysis|Correlative studies
215035542|NCT05164471|GENETIC|verbrinacogene setparvovec|FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
214869503|NCT06638450|PROCEDURE|Dense Cranial Electroacupuncture Stimulation plus Body Acupuncture (DCEAS+BA)|"DCEAS+BA will be conducted for 2 sessions per week for 8 weeks.~For DCEAS, 6 pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). For body acupuncture, the following acupoints are used: Shenmen (HT7). Neiguan (PC6), Zhongwan (CV12), Guanyuan (CV4), Zusanli (ST36), Sanyinjiao (SP6), and Taichong (LV3).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is conducted to evoke a needling sensation. After that, electrical stimulation is delivered on DCEAS, with continuous waves at 2 Hz through an electrical acupuncture stimulation instrument (Hwarto, SDZ-II). The stimulation lasts 30 minutes."
214869504|NCT06638450|PROCEDURE|Minimal Acupuncture Stimulation (MAS)|"MAS will be conducted for 2 sessions per week for 8 weeks.~The following 6 acupoints are used: bilateral Tongtian (BL07), bilateral Shousanli (LI10) and bilateral Fuyang (BL59).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. After that, electrical stimulation is performed on bilateral Tongtian (BL07), with continuous waves at 2 Hz through an electrical acupuncture stimulation instrument (Hwarto, SDZ-II). The stimulation lasts 30 minutes."
214869505|NCT03103789|DIAGNOSTIC_TEST|single catheter mucosal impedance testing|
214869506|NCT03103789|DIAGNOSTIC_TEST|balloon assembly mucosal impedance testing|
214869507|NCT04713475|BIOLOGICAL|PBGM01|AAVhu68 viral vector
214869508|NCT02290301|DRUG|gemigliptin|
215035543|NCT05512624|BEHAVIORAL|Common Elements Treatment Approach|"For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion."
215035544|NCT02589938|OTHER|Standard Oral Hygiene|Oral hygiene care provided per individual institutions standard of care.
215035545|NCT02589938|OTHER|Standard Oral Hygiene + True Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
215035546|NCT02589938|OTHER|Standard Oral Hygiene + Sham Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
215035547|NCT00778427|DRUG|metformin hydrochloride 1000 mg tablets|
215035548|NCT02890875|OTHER|Ethanol lock|
215035549|NCT02890875|OTHER|Heparin lock|
215035550|NCT00129857|DRUG|Dexanabinol|
215035551|NCT05997329|OTHER|App for diet record (MyFood)|Patients in the intervention group will record their food intake, tube feeding, nutrition-related symptoms and body weight in the MyFood app in at least three consecutive days in advance of follow-up.The patients will thus be able to keep track of their nutrition status. They will also have access to nutrition tips for how to reach requirements if they struggle to eat sufficiently or relief symptoms that can affect food intake.Healthcare staff at the hospital and outpatient clinics will use MyFood to monitor the patient's nutrition and document this information in the electronic patient record. They will also receive decision support tailored to each individual patient, e.g. recommendations for how to use oral nutrition supplements if the patient's intake of energy or protein is too low. Patients who struggle to fulfill their requirements will receive an additional referral to a registered dietitian for nutrition treatment between week 5 and 11.
215035552|NCT01814982|DRUG|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
215035553|NCT04005300|DIETARY_SUPPLEMENT|standard enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
215035554|NCT04005300|DIETARY_SUPPLEMENT|restricted enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
215035555|NCT05056766|BEHAVIORAL|questionnaires: Epworth Sleepiness Scale; Pichot fatigue questionnaire.|"Each patient will undergo 3 to 7 polygraphy recordings according usual practice of titration At the same time, Self-questionnaires will be conducted by the patient in order to evaluate Oral appliance efficacy.~Optimal titration of oral appliance will be done according subjectives parameters. (sleepeness Reduction and fatigue Reduction).~Neither the investigator nor the patient will know the polygraphy results (apnea-hypopnea index)"
214290951|NCT01057654|DRUG|Pravastatin|Pravastatin 40 mg
214869509|NCT04111055|DEVICE|Closed-loop system|the CLV system will correct hypotension by automated adjustment of norepinephrine.
215035556|NCT02532101|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
214290952|NCT01057654|DRUG|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
214869510|NCT03665441|DRUG|eryaspase|L-asparaginase encapsulated in erythrocytes (red blood cells)
214869511|NCT03665441|DRUG|Gemcitabine plus Abraxane|gemcitabine, Abraxane
214869512|NCT03665441|DRUG|Irinotecan plus 5-FU plus leucovorin|irinotecan, 5-FU, leucovorin
214869513|NCT03996135|DEVICE|Cannulation with AccuVein AV400|Cannulation using AccuVein AV400 device
214869514|NCT01600690|OTHER|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
214869515|NCT04953936|DIETARY_SUPPLEMENT|HMB-enriched Nutritional Supplements|The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.
214869516|NCT04953936|DIETARY_SUPPLEMENT|Placebo|Placebo (maltodextrin 65 g once daily) with the same package as the intervention.
214869517|NCT04953936|BEHAVIORAL|Caloric Restrition Diet|Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies
214869518|NCT06634342|DIAGNOSTIC_TEST|HCV RNA Rapid testing|Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
214869519|NCT02051400|DEVICE|the McGrath® MAC video laryngoscope|
214869520|NCT02051400|DEVICE|the GlidesScope® Ranger video laryngoscope|
214869521|NCT02051400|DEVICE|the Macintosh laryngoscope|
214869522|NCT01746459|OTHER|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
214869523|NCT01746459|OTHER|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
215035557|NCT04857060|BEHAVIORAL|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
215035558|NCT02184533|DRUG|sodium selenite|Given PO
215035559|NCT02184533|RADIATION|radiation therapy|Undergo radiation therapy
215035560|NCT02184533|OTHER|laboratory biomarker analysis|Correlative studies
215035561|NCT02184533|OTHER|pharmacological study|Correlative studies
215035562|NCT02184533|OTHER|questionnaire administration|Ancillary studies
215035563|NCT04335968|DRUG|Melatonin 4 mg|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery.
215035564|NCT04335968|DRUG|Placebo oral tablet|placebo of this drug with the same schedule, during the same period of time.
215035565|NCT03050190|GENETIC|Therapeutic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
215035566|NCT05235204|PROCEDURE|Removal of Foley Catheter 2 to 3 days post Colovesical Fistula (CVF) repair surgery|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
215035567|NCT02521285|DRUG|Aspirin|Given PO
215035568|NCT02521285|OTHER|Laboratory Biomarker Analysis|Correlative studies
215035569|NCT02521285|OTHER|Placebo Administration|Given PO
214869524|NCT03659292|OTHER|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
214869525|NCT03659292|OTHER|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.
214869526|NCT03659292|OTHER|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
214869527|NCT03659292|OTHER|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
214869528|NCT06633081|DEVICE|handheld dynamometer|handheld dynamometer is a device that measure muscle strength
215035570|NCT02521285|OTHER|Questionnaire Administration|Ancillary studies
215035571|NCT04369105|OTHER|Prone position|The patients will be put in prone position while receiving invasive mechanical ventilation and the investigators will monitor changes in mechanical power applied to the respiratory system and compare with supine position
215035572|NCT04548648|DRUG|Acalabrutinib|Acalabrutinib at 100 mg is taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
215035573|NCT01684904|RADIATION|Proton radiation|
215035574|NCT00787150|DRUG|Apixaban|Apixaban 5 mg tablet BID for 12 weeks
215035575|NCT00787150|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 12 weeks
215035576|NCT00787150|DRUG|Warfarin sodium|At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
215035577|NCT01772654|DEVICE|Arterial Spin Labeled (ASL) MRI sequence|"The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence."
215035578|NCT02268656|DRUG|propofol concentration|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
215035579|NCT04537650|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VFSS)|A standardized dynamic radiographic examination of oropharyngeal swallowing
215035580|NCT01849276|DRUG|metformin hydrochloride|Given orally
215035581|NCT01849276|DRUG|cytarabine|Given IV
215035582|NCT01849276|OTHER|laboratory biomarker analysis|Correlative studies
215035583|NCT04695665|OTHER|Cervical pain|Exercise program for cervical spine according to McGill's approach.
215035584|NCT04695665|OTHER|Thoracic pain|Exercise program for thoracic spine according to McGill's approach.
215035585|NCT04695665|OTHER|Lumbar pain|Exercise program for lumbar spine according to McGill's approach.
215035586|NCT04998942|BEHAVIORAL|virtual cardiac wellness program|Participants assigned to this arm will participate in the experimental intervention.
215035587|NCT04998942|BEHAVIORAL|Placebo comparator|Participants assigned to this arm will participate in a placebo intervention.
215035588|NCT04269954|DRUG|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin
215035589|NCT02699307|BEHAVIORAL|Counseling|OT led counseling
215035590|NCT03477812|DEVICE|Polysomnography (Full sleep registration)|For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
215057193|NCT01325051|DRUG|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
214869529|NCT04878848|OTHER|Proprioceptive Neuromuscular Facilitation Exercises|Within the scope of proprioceptive neuromuscular facilitation exercises, rhythmic initiation, repeated stretch and hold-relax techniques in the upper extremity flexion-abduction-external rotation pattern and scapular patterns of anterior elevation, posterior depression, anterior depression and posterior elevation will be applied to the participants. In addition to these exercises, functional activities in the flexion-abduction-external rotation pattern such as hair combing, turning over from side lying, wearing a jacket, reaching on the shelf will be performed.
214869530|NCT04878848|OTHER|Conventional Rehabilitation Group|Active assisted / active range of motion exercises and Wand exercises will be applied to the participants in the conventional rehabilitation group for flexion, abduction and external rotation movements. Exercises will be applied as 5 repetitions in the first 2 weeks and 10 repetitions in the last 2 weeks. Strengthening exercises will be performed with an elastic band and free weights. Strengthening exercises will be started as 2 sets of 5 repetitions and at the end of the second week, it will be applied as 2 sets of 10 repetitions. In addition to these exercises, glenohumeral distraction, glenohumeral posterior and caudal glide will be applied for joint mobilization and it will show progression at the end of the second week.
214869531|NCT04354116|DEVICE|Rapid maxillary expansion|Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
214869532|NCT04354116|DEVICE|Maxillary Protraction|Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
214869533|NCT04782674|DIAGNOSTIC_TEST|Saliva Testing|Saliva EBV-DNA Detection comparing with PBMC and plasma EBV-DNA
214869534|NCT00000130|DRUG|Intravitreal Antibiotics|
214869535|NCT00000130|PROCEDURE|Initial Pars Plana Vitrectomy|
214869536|NCT05267743|DRUG|Tegoprazan 50mg QD|Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
214869537|NCT05267743|DRUG|Lansoprazole 30mg QD|Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
214869538|NCT05076695|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles)
214869539|NCT05076695|DRUG|trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks for a total of 6 administrations.
214869540|NCT05076695|DRUG|pyrotinib|Pyrotinib 400mg, PO daily, continuously
214869541|NCT05076695|DRUG|fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intramuscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose.
214869542|NCT04345601|BIOLOGICAL|Mesenchymal Stromal Cells|Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10\^8 MSCs.
214869543|NCT04345601|OTHER|Supportive Care|Patients will receive supportive care per their treating physician
214869544|NCT01917981|DEVICE|Personal Heart Rhythm Monitor|
214869545|NCT06032650|OTHER|Calisthenics exercise and High intensity interval training|"1. The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~2. High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax"
214869546|NCT04776538|BIOLOGICAL|Stem cells|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
214869547|NCT04776538|BIOLOGICAL|Placebo|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
214869548|NCT06324110|OTHER|Electronic Health Record Review|Ancillary studies
214869549|NCT06324110|OTHER|Interview|Ancillary studies
214869550|NCT06324110|BEHAVIORAL|Patient Navigation|Receive lung cancer screening care coordination services
214869551|NCT03957070|DEVICE|Liver Incyte|Ultrasound elasticity imaging
214869552|NCT04202003|DRUG|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
214869553|NCT05373004|DRUG|Empagliflozin 25 MG|It is the experimental drug in this trial. this drug has an approved efficacy in delaying kidney deterioration based on the results of (the EMPA-REG OUTCOME) trial. it is also recommended based on the ADA/EASD 2019 consensus, as the SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD. However, the previous trials where always add it to a patient already on an ACE inhibitor (in most cases). In this trial, it will be compared head to head with the gold standard treatment of CKD which is Enalapril 20 mg (ACE inhibitor).
214869554|NCT05373004|DRUG|Enalapril Maleate 20 mg|It is an ACE inhibitor, the active comparator in this trial, and is considered the gold standard for the treatment of diabetic kidney disease.
214869555|NCT04077190|DEVICE|Adipose-derived stem cells|5cc adipose derived stem cells.
214869556|NCT04077190|DEVICE|cortisone injection|cortisone injection
214869557|NCT06633809|OTHER|Immediate endovascular therapy|The best medical therapy includes intravenous fibrinolysis, anticoagulants or antiplatelet, but NOT any immediate endovascular therapies.
214869558|NCT06172244|OTHER|Applying with whole body vibration device|A total of 5 sets of vibration will be given at 30 Hz, 2 mm amplitude, 1 minute of application and 1 minute of rest.
214869559|NCT05707754|DRUG|Bupivacaine|Topically applied to sphenopalatine ganglion
214869560|NCT05707754|DEVICE|angiocatheter|Introduced into nose to reach sphenopalatine ganglion nerve
214869561|NCT03443830|DRUG|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
214869562|NCT00306930|DEVICE|Acetabular cup|Acetabular cup replacement
214869563|NCT03700385|DEVICE|IOWA Approach Endocardial Ablation System|Endocardial ablation using the IOWA Approach Endocardial Ablation System
214869564|NCT05726903|DRUG|Depo-subQ Provera Injectable Product|SC Injection at Home
214869565|NCT00658515|DRUG|Dalcetrapib (RO4607381)|600mg po daily
214869566|NCT00658515|DRUG|Evidence-based medical care for Acute Coronary Syndrome|As prescribed
214869567|NCT00658515|DRUG|Placebo|po daily
214869568|NCT03070587|BEHAVIORAL|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
214869569|NCT00372411|DEVICE|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
214869570|NCT00372411|OTHER|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
214869571|NCT00372411|OTHER|Usual Care|The usual chronic stroke care as delivered at each participating medical center
215035591|NCT01262105|DEVICE|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
215035592|NCT00879398|DRUG|Toviaz treatment|4 mg starting then can be followed by 8 mg
215035593|NCT06501313|DEVICE|Photobiomodulation|Soft laser therapy
215035594|NCT01716000|OTHER|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
215035595|NCT01716000|BEHAVIORAL|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
215035596|NCT04743648|BEHAVIORAL|Innovative Thinking Development Program (ITDP)|With the implementation of the program, nursing students are expected to develop innovative thinking skills.
215035597|NCT02609594|OTHER|Weekly application of Amnioband|Weekly application of Amnioband.
215035598|NCT02609594|OTHER|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
215035599|NCT02609594|OTHER|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
215035600|NCT04252079|PROCEDURE|Endovascular Repair of Juxtarenal Aortic Aneurysm|"1. History taking and clinical examination.~2. Preoperative Imaging~   CTA is the cross-sectional imaging modality of choice.~3. Preoperative evaluation~   a-Renal evaluation~   b\_ cardiac evaluation C-Pulmonary evaluation~4. Surgical techniques~   1. Anesthesia The use of general anesthesia due to the duration of the procedures and the necessity to control patient breathing to allow precise imaging and accurate device deployment.~  2. Intra operative imaging A hybrid operating room with high-quality fixed imaging is needed for the performance of FEVAR.~C-Device delivery and deployment all FEVAR procedures begin with access of the femoral arteries by either open or percutaneous technique."
215035601|NCT06038175|DEVICE|Video Head Impulse Testing|During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. (Interacoustics EyeSeeCam vHIT 3rd Generation Tests: VOR of lateral, RALP, \& LARP canals. SW: 3rd generation VE525 software. HW: laptop PC, lightweight monocular video goggles). Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side (10-20° angle, duration 150-200 ms, peak velocity of \>150°/s) in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is \<0.8 in the presence of refixation saccades .
214869572|NCT03083652|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
214869573|NCT03083652|OTHER|Sham|Conventional physiotherapy with NMES device NOT activated
214869574|NCT05159167|OTHER|Baduanjin, a type of Qigong|Baduanjin is very popular in China. There is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders.
214869575|NCT05001217|DRUG|Conventional medication|Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
214869576|NCT05001217|DRUG|Chinese herbal medicine treatment|"1. Huanglian Wendan Decoction~2. Jin Gui Shen Qi Pill~3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~4. Bu Yang Huan Wu Decoction"
214869577|NCT01028924|DRUG|Teduglutide|subcutaneous (SC), single dose
214869578|NCT01915758|DRUG|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
214869579|NCT01915758|DRUG|vehicle gel|vehicle gel
214869580|NCT01589289|DEVICE|Immunochromatographic HAT tests (DSD)|Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
214869581|NCT01589289|DEVICE|Card Agglutination Trypanosoma Test|Card Agglutination Trypanosoma Test on whole blood and as dilution
214869582|NCT01589289|DEVICE|TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|"TB POC Nucleic Acid Amplification Test: microPCR handheld device (Molbio Diagnostics PVT ltd, India)"
214869583|NCT01589289|DEVICE|TB 3-marker RDT (Tulip diagnostics)|TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
214869584|NCT01589289|DEVICE|Cryptococcal Antigen Lateral Flow Assay (Immy)|Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
214869585|NCT00052299|DRUG|cytarabine|
214869586|NCT00052299|DRUG|etoposide|
214869587|NCT00052299|DRUG|gemtuzumab ozogamicin|
214869588|NCT00052299|DRUG|idarubicin|
214869589|NCT00052299|DRUG|mitoxantrone hydrochloride|
214869590|NCT05134857|DRUG|Zonisamide|The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
214869591|NCT05134857|DRUG|Placebo|The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
214869592|NCT04127630|PROCEDURE|mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
214869593|NCT03916029|BEHAVIORAL|facilitator|Training and employment of community members to assist the diagnosis and management of otitis media
214869594|NCT04647565|OTHER|interviews|interviews (human and social sciences)
214869595|NCT04539327|DRUG|Rucaparib|Participating local sites (GEICO-associated hospitals with expertise in gynecological cancer management) will enter clinical data of those patients who have previously participated in the rucaparib access program (RAP) in Spain and have given their consent.
214869596|NCT04792762|OTHER|GIP(1-30)NH2|Intravenous administration of the peptide hormone GIP(1-30)NH2 during a stepwise glucose clamp
214869597|NCT04792762|OTHER|GIP(1-42)|Intravenous administration of the peptide hormone GIP(1-42) during a stepwise glucose clamp
214869598|NCT04792762|OTHER|Saline|Intravenous administration of saline during a stepwise glucose clamp
214869599|NCT06028880|BEHAVIORAL|Free2Be|Free2Be is a manualized 13-week face-to-face group intervention for SM individuals with one pre-session and plus 12 intervention sessions. The themes of each session are: Human nature \& Relation with suffering (S1), Emotional regulation \& Multiple selves (S2), Creative hopelessness \& Values (S3), Compassionate attention (S4), Compassionate acceptance (S5), Self-criticism; Compassion \& Flows of compassion (S6), Compassionate imagination; Compassionate self (S7), Early experiences; Stigma and shame; \& Compassionate cognitive desfusion (S8), Compassionate thinking (S9), Difficult emotions: Shame \& Anger (S10), Coming out \& Compassionate behaviour (assertiveness) (S11), Positive emotions \& Preparing for the future (S2).
214869600|NCT00631657|DRUG|Esmirtazapine|One esmirtazapine 4.5 mg tablet once a day
214869601|NCT00631657|DRUG|Placebo|One placebo tablet once a day
214869602|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
214869603|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
214869604|NCT03360955|PROCEDURE|Anesthesia|Different anesthesia technique will be compared to find out which one offers better outcome to perform ultrafast track extubation
214869605|NCT03407469|BEHAVIORAL|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
214869606|NCT04549714|PROCEDURE|High AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
214869607|NCT04549714|PROCEDURE|Middle AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
214869608|NCT04549714|PROCEDURE|Low AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
214869609|NCT00810316|DRUG|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
214869610|NCT00810316|DRUG|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
214869611|NCT00810316|DRUG|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
214869612|NCT06048432|OTHER|Conventional Physiotherapy + telephysiotherapty|Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
214869613|NCT01235832|OTHER|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (\~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
214869614|NCT01235832|OTHER|Lower-Fat Diet|The Lower-Fat diet will provide \~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
214869615|NCT01235832|OTHER|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
214869616|NCT05117983|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Real-time MRI-guided neuronavigation with a Visor neuronavigation system (ANT Neuro, Enschede, Netherlands) will be used for coil positioning. Left dorsolateral prefrontal cortex target is located in each participant.
214869617|NCT00599378|BEHAVIORAL|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
214869618|NCT00699374|DRUG|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
214869619|NCT00699374|DRUG|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
214869620|NCT05973266|BEHAVIORAL|Mobile Application-Based Bowel Preparation Training|The contents of the training in the mobile application where the patients receive bowel preparation training before the procedure are; short videos, images and slides about colonoscopy, bowel preparation drugs, liquid-clear diet and foods recommendations.A mobile application-based training will be provided to guide patients, where user (patient) usage activities are monitored by the researcher, sending notifications or reminders to the patient in accordance with the colonoscopy procedure date.
214869621|NCT00196625|DRUG|Amprenavir (drug)|
214869622|NCT00196625|DRUG|ABT-378/r (drug)|
214869623|NCT00196625|DRUG|Ritonavir (drug)|
214869624|NCT05358470|OTHER|Exercise therapy and adapted physical activity-based program|Exercise therapy and adapted physical activity program based on racket sports
214869625|NCT01853930|BEHAVIORAL|Platform for Administering Eye-movement Control Training|The Platform for Administering Eye-movement Control Training (PAECT) meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
214869626|NCT00899990|OTHER|Laboratory Biomarker Analysis|Correlative studies
214869627|NCT03322618|BIOLOGICAL|blood samples|7 tubes of 6 ml (42 ml of blood )
214869628|NCT00154271|DRUG|Valsartan, Valsartan HCT|
214869629|NCT01996449|DRUG|Eplerenone|The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
214869630|NCT01996449|DRUG|Amlodipine|The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
214869631|NCT01996449|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
214869632|NCT01996449|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
214869633|NCT01996449|PROCEDURE|Sustained hand grip|Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
214869634|NCT01996449|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
214869635|NCT01996449|PROCEDURE|Arm cycling exercise|Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
214869636|NCT01996449|PROCEDURE|Cold Pressor test|Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
214869637|NCT05275803|DIETARY_SUPPLEMENT|Probiotics|The participant would receive non-surgical periodontal treatment, after which the participant uses probiotics (BioGaia Prodentis, L. reuteri DSM 17938+L. reuteri ATCC 5289, 0.8g, qn) for another 30 days.
214869638|NCT05275803|DIETARY_SUPPLEMENT|Control|The participant does not use probiotics after non-surgical periodontal treatment.
214869639|NCT04540406|DRUG|NBT-NM108|Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
214869640|NCT04540406|OTHER|Usual Care Only|Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.
214869641|NCT05484037|OTHER|CANATEXTS|Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.
214869642|NCT00553306|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
215035602|NCT06038175|OTHER|Standard of care neurologic evaluation|A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
214869643|NCT00553306|BIOLOGICAL|aldesleukin|Given subcutaneously
215035603|NCT00375713|DRUG|Levocetirizine|1 Levocetirizine 5mg tablet per day before bedtime for 14 days
214290953|NCT01138033|DRUG|GSK2256098|GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
214869644|NCT00553306|DRUG|cyclophosphamide|Given IV
214869645|NCT00553306|PROCEDURE|biopsy|Optional correlative studies
214869646|NCT00553306|OTHER|immunohistochemistry staining method|Optional correlative studies
214869647|NCT00553306|OTHER|flow cytometry|Correlative studies
214869648|NCT00553306|GENETIC|polymerase chain reaction|Correlative studies
214869649|NCT02887456|DRUG|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
214869650|NCT02887456|DRUG|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
214869651|NCT02480868|DEVICE|ARTEBONE|4,3 g Bone Void Filler
214869652|NCT00042536|DRUG|Naltrexone HCL/ Yohimbine HCL|
214869653|NCT05915975|BEHAVIORAL|Behavioral Care Coordinated with Medical Care Intervention|Participants will be meeting with a behavioral health provider during their clinic visit. Subsequent visits can be held either via telehealth or in-person. Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months. Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.
214869654|NCT05915975|BEHAVIORAL|Behavioral Care Not Coordinated with Medical Care Intervention|Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance. The participants will be responsible for calling the clinics to set up their appointments. Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
214869655|NCT04859543|DEVICE|FoundationOneHeme|Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
214869656|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement with probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.
214869657|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement without probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.
214869658|NCT03924089|OTHER|Dietary recommendations|Dietary recommendations
214869659|NCT02879734|OTHER|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
214869660|NCT03219619|DEVICE|Cap-EGD|Undergoing cap-assisted endoscopy
214869661|NCT03219619|DEVICE|Duo|Undergoing side-viewing duodenoscope
214869662|NCT06351436|BEHAVIORAL|Mindfulness|The mindfulness-based intervention will last for three months, with 6-8 weekly sessions lasting 1.5 hours each. Participants will attend the sessions in a group format, and the sessions will be administered by registered social worker who are specialized in counseling. The intervention is delivered using an immersive virtual reality cave system. The intervention content is designed by a registered clinical psychologist accredited for delivering mindfulness-based intervention and nurses who are experienced in mindfulness training. To ensure protocol adherence, the social workers administering the intervention will receive close supervision from the clinical psychologist. Weekly meetings will be held to discuss and resolve any difficulties or challenges encountered by the social workers.
214869663|NCT02730117|DEVICE|Dialysis with continuous renal replacement therapy|Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
214869664|NCT02730117|DEVICE|Mechanical ventilator|Invasive or noninvasive form of respiratory support
214869665|NCT02730117|DRUG|Anti-Bacterial Agents|Antibacterial agents deemed appropriate by physicians in the ICU
215035604|NCT00375713|DRUG|Cetirizine|1 Cetirizine 10mg tablet per day before bedtime for 14 days.
215035605|NCT00375713|DRUG|Placebo-Levocetirizine|1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
215035606|NCT00375713|DRUG|Placebo-Cetirizine|1 Placebo-Cetirizine tablet per day before bedtime for 14 days
215035607|NCT00375713|DRUG|Standard topical steroid (1% hydrocortisone) ointment|1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
214869666|NCT02730117|DRUG|Vasopressors|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
214290954|NCT03724955|DRUG|Estradiol 2 mg|Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
214869667|NCT01310270|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega, 4.4gm/day x 1 month
214869668|NCT01310270|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|4.4 gm/day for 1 month
214869669|NCT04023162|BEHAVIORAL|Graded Activity|Active participation of participants, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.
215035608|NCT02756052|DEVICE|Anodal Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
214869670|NCT04023162|BEHAVIORAL|Group-based Therapy Exercise|Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise
214869671|NCT04023162|BEHAVIORAL|Back School|Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
214869672|NCT04475835|DRUG|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
214869673|NCT04475835|DRUG|Heparin|Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
214869674|NCT05837013|PROCEDURE|Spinal anesthesia (with nerve block)|Spinal Anesthesia and Nerve Block: No premedication will be applied. Spinal anesthesia will be administered to the patients in this group in the sitting position with a 27G Quincke needle (15 mg hyperbaric 0.5% bupivacaine) to be entered through the L2-L3 or L3-L4 interval. If hypotension develops, it will be corrected with a crystalloid infusion and ephedrine. These patients will be administered intravenous sedation with increasing doses of midazolam to provide adequate sedation. According to Hadzic, II and IH nerve block will be performed by applying 10 mL of 0.75% ropivacaine 2 cm above and 2 cm medial to the anterior superior iliac spine.
215035609|NCT02756052|DEVICE|Sham Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
215035610|NCT05726968|DRUG|Pilocaine 2% (1.5 ml) and 25 ug fentany|"Patients will be randomly allocated into the study groups according to the list of random numbers. The study groups will be as follows:~* Group P1 (N 15): patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).~* Group P2 (N 15): patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).~* Group P3 (N 15): patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)."
215035611|NCT03755427|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
215035612|NCT03755427|BIOLOGICAL|Aluminum Hydroxide Adjuvant|The seasonal influenza vaccine was a inactivated, split virion preparation of the influenza virus, propagated in embryonated chicken eggs. The aluminum hydroxide adjuvant was 0.5ml aluminum hydroxide adjuvant.
215035613|NCT04598425|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
215035614|NCT05759767|DRUG|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
215035615|NCT05759767|DRUG|Placebo|Children in this group will receive placebo once daily for 3 weeks after ESWL session.
215035616|NCT01342315|DRUG|33525|Daily dosing
215035617|NCT01342315|DRUG|Placebo|Daily dosing
215035618|NCT06291779|DEVICE|Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio|"* Collect urine from the patient to measure urinary hypoxia, xanthine concentration.~* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).~* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.~* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample."
214869675|NCT05837013|PROCEDURE|General anesthesia (GA)|General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
215035619|NCT04005833|DIAGNOSTIC_TEST|spirometry|The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
215035620|NCT06098573|BEHAVIORAL|High Alert|Participants assigned to the 'High Alert' condition will complete four interactive modules using their smartphones. These modules are hosted online via the Computerized Intervention Authoring Software, version 3.0 (https://www.cias.app \[CIAS\]). CIAS is a non- commercial, easily modifiable, web-based intervention platform used widely in the digital substance use literature. No identifiable information is requested or stored in CIAS. This program is only intended to deliver the content interactively. None of the questions asked in CIAS will be treated as research data. We will only report on the proportion of questions answered by participants (as a measure of adherence). Individual responses to questions will not be analyzed nor reported on. The purpose of the questions is for participants to engage with the content interactively
215035621|NCT06098573|BEHAVIORAL|Information condition|Participants in the DUIC Information condition will receive a Qualtrics link with six infographics created to educate about DUIC. Four infographics were retrieved from government websites, one was provided by a non-profit (i.e., Arrive Alive Drive Sober), and the research team created the final one. After reviewing each infographic, participants will respond to a few questions about the infographic. Questions asked to the DUIC Info Control will obtain data related to: seeing the infographic before, perceptions on the infographic content, aspects they liked/disliked, and likelihood to share with their peers. All items will be treated as research data.
215035622|NCT06098573|BEHAVIORAL|No contact|Participants in the passive control will receive no contact until the three and six-month follow-ups.
214290955|NCT03724955|OTHER|Placebo|The placebo group will receive placebo oral daily for 6 months
215035623|NCT00867152|DRUG|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
214290956|NCT02159014|BEHAVIORAL|Facilitated group-based aerobic dance|Physical activity facilitated by instructor
214290957|NCT02159014|BEHAVIORAL|Online, video prompted, individual aerobic dance|Supported online activity intervention
214290958|NCT02159014|BEHAVIORAL|Facilitated group-based nutritional intervention|Education, skill training, access and use of NHS Change4Life Eat Well web resource
214869676|NCT05645159|OTHER|Blended learning in heart disease|The intervention included face-to-face classes and online resources (Moodle, online syllabus, videos, websites, podcasts, activities, apps, forums, emails, tutoring).
214869677|NCT04091659|OTHER|Virtual Reality Education|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
214869678|NCT04091659|OTHER|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
214869679|NCT02419144|BEHAVIORAL|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
214869680|NCT02483208|DRUG|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
214869681|NCT02483208|DRUG|Advate|Advate infusion to analyze pharmacokinetics.
214869682|NCT00054808|DRUG|gallium nitrate|
214869683|NCT01211938|RADIATION|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
214869684|NCT01211938|RADIATION|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
214869685|NCT02164474|BEHAVIORAL|High-Intensity Interval Training|Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at \~85-90% peak oxygen uptake \[VO2peak\] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at \~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
214869686|NCT04181073|DEVICE|Jet Nebuliser|Jet Nebuliser
214869687|NCT04181073|DEVICE|Vibrating Mesh Nebuliser|Aerogen Device
214869688|NCT02926482|BEHAVIORAL|Prescriber Recruitment Bundle (PRB)|The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
214869689|NCT01069276|OTHER|No intervention in this study|No intervention in this study
214869690|NCT00054665|DRUG|PS-341|1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
214869691|NCT00054665|DRUG|Etoposide|50 mg/m\^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
214869692|NCT00054665|DRUG|Doxorubicin|10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
214869693|NCT00054665|DRUG|Vincristine|0.4 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
214869694|NCT00054665|DRUG|Cyclophosphamide|750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
214869695|NCT00054665|DRUG|Prednisone|60 mg/m\^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
214869696|NCT00054665|DRUG|Filgrastim|300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm\^3. Repeat cycle every 21 days.
214869697|NCT01284946|DRUG|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
214869698|NCT02712060|OTHER|No intervention|
214869699|NCT06574360|DRUG|S1RA plus NMDAE|Use of an S1R agonist plus an NMDA enhancer for the treatment of treatment-resistant schizophrenia.
214869700|NCT06574360|DRUG|S1RA plus Placebo Cap|Use of an S1R agonist plus placebo as a comparator
214869701|NCT05485701|DIAGNOSTIC_TEST|Screening tools for common mental disorders|A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.
214869702|NCT01243112|DRUG|1% Lidocaine with Epinephrine (1:100,000)|0.2ml Intradermal injection once.
214869703|NCT01243112|DRUG|0.25% Bupivacaine with Epinephrine (1:200,000)|0.2ml Intradermal injection once.
214869704|NCT01243112|DRUG|0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)|0.2ml Intradermal injection once.
214869705|NCT01243112|DRUG|1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)|0.2ml Intradermal injection once.
214869706|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
214869707|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
214869708|NCT01507363|DRUG|Placebo|Placebo tablets for 7 days, starting on the day of surgery
214869709|NCT04892225|BEHAVIORAL|Technology-supported behavioral intervention (text message)|A simple text message regarding the salt and fluid restriction in order to reduce the inter-dialytic weight gain will be send on daily basis to all the individuals in the intervention group.
214869710|NCT00236366|DRUG|fentanyl|
214869711|NCT04330716|BEHAVIORAL|Standard Genetic Counseling|Standard of care genetic counseling
215035624|NCT00867152|DRUG|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
214869712|NCT04330716|BEHAVIORAL|Educational Video|Video tutorial about genetic testing
214869713|NCT03824496|DIAGNOSTIC_TEST|Cranial Accelerometry Measurement|Measuring the HeadPulse using cranial accelerometry
215035625|NCT00867152|DRUG|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
214869714|NCT04451681|OTHER|Cardiopulmonary exercise test|Data such as oxygen consumption, cardiac parameters and speed of the patient are analyzed numerically on the treadmill in the KPET; Objective performance values such as maximum oxygen use (VO2max), maximum heart rate, respiratory capacity, and maximum rate will be obtained.
215035626|NCT00867152|DRUG|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
214869715|NCT00002825|BIOLOGICAL|filgrastim|
214869716|NCT00002825|DRUG|docetaxel|
215035627|NCT00867152|DRUG|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
215035628|NCT01722669|DRUG|isoquercetin or quercetin|Single dose PK/PD study
215035629|NCT04716725|DRUG|68Ga-PSMA-11|Given IV
215035630|NCT04716725|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET
214869717|NCT01081834|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
214869718|NCT01081834|DRUG|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
214869719|NCT01081834|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
215035631|NCT03888027|BEHAVIORAL|WalkMORE group|Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
215035632|NCT03592017|DEVICE|Long-wavelength autofluorescence imaging|Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
215035633|NCT04429919|DRUG|AP-325|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
215035634|NCT04429919|DRUG|Placebo|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
215035635|NCT06122948|DRUG|The midazolam group|The midazolam group will receive intranasal midazolam (0.1 mg/kg)
215035636|NCT06122948|DRUG|The midazolam ketamine group|the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
215035637|NCT03732794|DEVICE|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
215035638|NCT03030755|OTHER|Optical coherence tomography|
214290959|NCT02159014|BEHAVIORAL|Self-paced online aerobic dance activity|Self paced physical activity
214290960|NCT02159014|BEHAVIORAL|Individual self-paced nutritional intervention|Individual use of online nutritional advice resources.
214290961|NCT02482623|BEHAVIORAL|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
214290962|NCT00296894|DRUG|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
214290963|NCT00296894|DRUG|Placebo|Placebo
214290964|NCT05647954|DRUG|HX008 + TACE|HX008 Subjects receive HX008 200 mg intravenous (IV) ,day1,every 3 weeks (Q3W) Procedure: TACE cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions).
214869720|NCT02040506|DRUG|IGN523|Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
214869721|NCT02031718|BEHAVIORAL|Virtual Counseling|
214869722|NCT00562237|BIOLOGICAL|S205 placebo|2 i.m. injections per subject (0.5 mL each)
214869723|NCT00562237|BIOLOGICAL|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
214869724|NCT00562237|BIOLOGICAL|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
214869725|NCT00562237|BIOLOGICAL|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
214869726|NCT00562237|BIOLOGICAL|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
214869727|NCT00562237|BIOLOGICAL|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
214869728|NCT00562237|BIOLOGICAL|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
214869729|NCT06158256|OTHER|Voluntary apnoea|Series of static apneas at low lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds until completing the 6 minutes.
214869730|NCT04641585|DIAGNOSTIC_TEST|Patients affected by Brugada Syndrome 1|ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
214290965|NCT05647954|DRUG|Temozolomide + TACE|"Temozolomide Subjects receive Temozolomide 200 mg/sqm intravenous (IV),day1-5, every 3 weeks (Q3W)~Procedure: TACE :~cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions)."
214869731|NCT02875015|DRUG|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
214869732|NCT02875015|DRUG|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
214869733|NCT02875015|PROCEDURE|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
214869734|NCT03201432|DEVICE|Drug eluting stent (DES)|Polymer-free paclitaxel eluting stents
214869735|NCT03201432|DEVICE|Bare metal stent (BES)|Bare metal stent
214869736|NCT05665829|PROCEDURE|Awake transnasal laser-assisted surgery (TNLS)|The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.
214869737|NCT05665829|PROCEDURE|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
214869738|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
214869739|NCT01103830|DRUG|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
214869740|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning."
215035639|NCT03559556|OTHER|CT angiography|CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
215035640|NCT06621589|BEHAVIORAL|Nutritional Counseling|The intervention involves nutritional counseling aimed at improving dietary habits and overall health to participants. During the 2-month period, participants will receive guidance on nutrition, diet planning, and lifestyle changes tailored to their needs. Assessments of knowledge, attitudes, and health metrics will be conducted before and after the counseling sessions to measure the effectiveness of the intervention
215035641|NCT05498090|DRUG|Fenofibrate 145 mg|Fenofibrate 145 mg PO daily for 4 weeks
215035642|NCT03366259|DRUG|Misoprostol 200Mcg Tab|administration of 200 Mcg of misoprotol rectal
215035643|NCT03366259|PROCEDURE|elective cesarean section|elective cesarean section for full term patients
215035644|NCT04464538|BEHAVIORAL|WALC-R|Initial group education session and individualized coaching (remote)
215035645|NCT04464538|OTHER|Information leaflet|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
215035646|NCT03506360|DRUG|Dexamethasone|Given PO
215035647|NCT03506360|DRUG|Ixazomib Citrate|Given PO
215035648|NCT03506360|OTHER|Laboratory Biomarker Analysis|Correlative studies
215035649|NCT03506360|BIOLOGICAL|Pembrolizumab|Given IV
215035650|NCT02927964|DRUG|Ibrutinib|Given PO
214869741|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
214869742|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
215035651|NCT02927964|RADIATION|Radiation Therapy|Undergo radiation therapy
215035652|NCT02927964|DRUG|TLR9 Agonist SD-101|Given IT
215035653|NCT02898038|DIETARY_SUPPLEMENT|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
215035654|NCT02422108|DRUG|Denosumab|
215035655|NCT05565118|PROCEDURE|Standard Surgical Treatment|During this surgery, participants will also undergo a tissue biopsy at recording sites for correlation to neural recording data.
215035656|NCT05565118|PROCEDURE|Intraoperative Electrocorticography|Each participant will undergo intraoperative electrocorticography (ECOG) through subdural grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording technology.
215035657|NCT06271915|OTHER|SNAGs - eccentric exercise|intervention done 2 times per week, 45 minutes each session for 4 weeks
215035658|NCT06644326|DRUG|100mg IkT-148009 Wet|100mg wet tablet formulation
215035659|NCT06644326|DRUG|200 mg Itraconazole|2 100mg capsules
215035660|NCT06644326|DRUG|100mg IkT-148009 Dry|100mg dry tablet formulation
215035661|NCT06644326|DRUG|50mg IkT-148009 Wet|50mg wet tablet formulation
215035662|NCT03140969|DRUG|QR-110|RNA antisense oligonucleotide for intravitreal injection
215035663|NCT05360888|BEHAVIORAL|Tools for Life|Tools for Life focuses on empowering youth to learn more about their culture and their identity.
215035664|NCT05360888|BEHAVIORAL|Tools for Life + MISN|Tools for Life focuses on empowering youth to learn more about their culture and their identity. MISN focuses on helping youth get support from their community and social networks.
215035665|NCT05301127|DEVICE|spinal-epidural device|received combined spinal-epidural-general anesthesia.
215035666|NCT06420063|BIOLOGICAL|CD123/CD33 CART|"The intervention in this clinical trial involves a novel approach using CD22/123-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD33/123-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD33/123-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD33/123 CAR-T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
215035667|NCT02684162|BIOLOGICAL|Donor Lymphocytes|Given IV
215035668|NCT02684162|DRUG|Guadecitabine|Given SC
215035669|NCT02684162|OTHER|Laboratory Biomarker Analysis|Correlative studies
215035670|NCT03340116|PROCEDURE|Burn surgery|Burn surgery including wound debridement, skin grafting
215035671|NCT03340116|DIAGNOSTIC_TEST|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
215035672|NCT03012880|BIOLOGICAL|Daratumumab|Given IV
215035673|NCT03012880|DRUG|Dexamethasone|Given PO
215035674|NCT03012880|DRUG|Ixazomib Citrate|Given PO
215035675|NCT03012880|OTHER|Laboratory Biomarker Analysis|Correlative studies
215035676|NCT03012880|DRUG|Lenalidomide|Given PO
215035677|NCT03012880|OTHER|Questionnaire Administration|Ancillary studies
215035678|NCT05702450|BIOLOGICAL|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
214869743|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning."
214869744|NCT05495672|PROCEDURE|Local treatment|"Radical surgical resection, local radiotherapy, radiofrequency ablation (RFA) or interventional therapy (absolute alcohol or cryotherapy).~The equipment used for RFA of lung lesions consisted of the radiofrequency generator (CelonLab POWER), cold circulation pump (Celon Aquaflow Ⅲ), radiofrequency needle electrode (Celon proSurge: T20, T30 and T40 is an electrode length of 20, 30 and 40 mm respectively, and maximum output power of 20, 30 and 40 W; Olympus Surgical Technologies Europe, Hamburg, Germany)."
214869745|NCT00001705|DRUG|GP100 peptide|
214869746|NCT00001705|DRUG|IL-2|
214869747|NCT00422552|DRUG|Indacaterol (QAB149)|
214869748|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
214869749|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
214869750|NCT02701270|DIETARY_SUPPLEMENT|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
214869751|NCT02701270|DIETARY_SUPPLEMENT|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
214869752|NCT00727870|DEVICE|Shapes by PolyMem dressing|Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
214869753|NCT00727870|DEVICE|Shapes by PolyMem Silver Dressing|Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
214869754|NCT00727870|DEVICE|Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site|Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
215035679|NCT01587196|DRUG|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
215035680|NCT05329831|BEHAVIORAL|Structured training using telehealth|The intervention is based on self-care activities. Self-care states that people have an innate ability to take care of themselves.
215035681|NCT04614714|DRUG|Nicotinamide riboside chloride|Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)
215035682|NCT04614714|DRUG|Placebo|Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)
214290966|NCT05647954|DRUG|Pembrolizumab|Subjects receive Pembrolizumab 2 mg/kg intravenous (IV),day1, every 3 weeks (Q3W)
214290967|NCT00662363|DRUG|Lubiprostone|24 µg po BID given with meals for 6 days
214290968|NCT00662363|DRUG|Senna|2 tabs daily for 6 days
214869755|NCT01475097|DRUG|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
214869756|NCT01475097|DRUG|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
214869757|NCT03149445|DRUG|Tesofensine/Metoprolol|Study medication will be administered for 91 days.
215035683|NCT01933152|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
215035684|NCT01075672|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
215035685|NCT03161262|BEHAVIORAL|SMS-based reminders|The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
214869758|NCT03149445|DRUG|Placebos|Study medication will be administered for 91 days.
214869759|NCT05110482|DRUG|Syntocinon|uterotonic drugs
215035686|NCT02430714|DRUG|Lenvatinib|24mg once daily oral dosing to Unresectable thyroid cancer patients
215035687|NCT02769481|DRUG|Bexagliflozin|20 mg, tablet
215035688|NCT02769481|DRUG|Placebo for Bexagliflozin|inactive tablet to match active comparator bexagliflozin
215035689|NCT02769481|DRUG|Glimepiride|2, 4 or 6 mg, capsule
215035690|NCT02769481|DRUG|Placebo for Glimepiride|inactive capsules to match active comparator glimepiride
215035691|NCT01046994|PROCEDURE|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
215035692|NCT01046994|DRUG|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
215035693|NCT06265818|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
215035694|NCT06265818|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
215035695|NCT06548438|PROCEDURE|Transurethral resection of the bladder performed with PDD tecnique and Hexvix|For the execution of PDD cystoscopy in blue light, it is necessary to use the study drug (Hexvix) which, after intravesical instillation, causes an accumulation of porphyrins in the lesions of the bladder wall at the intracellular level. The intracellular porphyrins are photoactive fluorescent compounds that emit red light when excited with blue light. Consequently, the preneoplastic and neoplastic lesions will emit a red luminescence against a blue background, allowing for better visualisation and subsequent resection.
215035696|NCT01629888|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
215035697|NCT01629888|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
215035698|NCT03510715|DRUG|Alirocumab SAR236553 (REGN727)|"Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)"
215035699|NCT03510715|DRUG|Atorvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
214869760|NCT05110482|DRUG|Carbetocin|uterotonic drug
214869761|NCT05594264|BEHAVIORAL|HBPStories|The objective of this arm was to pilot test the web-based storytelling program to determine the preliminary impact on blood pressure and medication adherence, and if the web-based approach was an engaging approach for individuals managing hypertension.
215035700|NCT03510715|DRUG|Simvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
215035701|NCT03510715|DRUG|Fluvastatin|"Pharmaceutical form: capsule,~Route of administration: oral"
215035702|NCT03510715|DRUG|Pravastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
215035703|NCT03510715|DRUG|Lovastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
215035704|NCT03510715|DRUG|Rosuvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
215035705|NCT03510715|DRUG|Ezetimibe|"Pharmaceutical form: tablet,~Route of administration: oral"
215035706|NCT03510715|DRUG|Cholestyramine|"Pharmaceutical form: oral suspension,~Route of administration: oral"
215035707|NCT03510715|DRUG|Nicotinic acid|"Pharmaceutical form: tablet,~Route of administration: oral"
214869762|NCT01085201|DRUG|Lexiscan|Given as an infusion
214869763|NCT03173326|PROCEDURE|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
214869764|NCT03173326|PROCEDURE|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
215035708|NCT03510715|DRUG|Fenofibrate|"Pharmaceutical form: tablet,~Route of administration: oral"
215035709|NCT03510715|DRUG|Omega-3 fatty acids|"Pharmaceutical form: capsule,~Route of administration: oral"
215035710|NCT04527744|PROCEDURE|the injection of onabotulinumtoxinA at different point|For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
215035711|NCT02184286|DRUG|Nevirapine|200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
215035712|NCT02184286|DRUG|Saquinavir-sgc|1600 mg b.i.d. from pre trial to day 28
215035713|NCT03826472|OTHER|Almond Butter|Natural almond butter
215035714|NCT04310657|DIAGNOSTIC_TEST|mNGS|Metagenomics second generation sequencing technology
215035715|NCT04604431|OTHER|iREACH CDS Tool|Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
215035716|NCT00552136|PROCEDURE|Ankle Arthroplasty|
215035717|NCT00552136|PROCEDURE|Ankle Arthrodesis|Ankle fusion surgery
215035718|NCT02888340|OTHER|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
215035719|NCT00285194|DRUG|Allogeneic Islets of Langerhans|
215035720|NCT00285194|DRUG|hOKT3γ1 (Ala-Ala)|
215035721|NCT04603560|BEHAVIORAL|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
215035722|NCT04603560|BEHAVIORAL|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
215035723|NCT04994613|OTHER|Sensory adaptive environment|A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
215035724|NCT00643279|DEVICE|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
215035725|NCT00643279|OTHER|Standard of Care|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
215035726|NCT05614882|BEHAVIORAL|Written Stroke Education|The written education will be provided in the stroke folder currently in use by the Yale New Haven Health system. This written information is presented in a stroke folder and includes how to respond to the signs of stroke, dialing 9-1-1, following up with a health care provider after hospitalization due to a stroke and the importance of medication management as well as stroke risk factors, healthy eating habits, exercise habits, common changes following a stroke, stroke recurrence and stroke types. After being given two days to review the materials, patients will be asked to complete the stroke knowledge test (SKT). All participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
215035727|NCT05614882|BEHAVIORAL|Verbal Stroke Education|Participants in the verbal education group will be provided with education over two days from therapists including occupational therapy, physical therapy, speech therapy as well as a physician or nurse. The disciplines will present general stroke information including causes, risk factors, prevention, nutrition and exercise recommendations, importance of managing chronic conditions and the significance of medication compliance. After the verbal education topics are presented, the participants will be tested with the stroke knowledge test (SKT) to measure learning. All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
215035728|NCT03940248|RADIATION|Proton Accelerated Partial Breast Irradiation|38.5 Cobalt Gray Equivalent (CGE) given over 10 fractions
215035729|NCT03257501|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
215035730|NCT00301860|BIOLOGICAL|anti-thymocyte globulin|
215035731|NCT00301860|BIOLOGICAL|filgrastim|
214869765|NCT03143426|PROCEDURE|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
214869766|NCT04810026|BEHAVIORAL|Education|Healthy-lifestyle and diabetes-related virtual education (text and videos)
214869767|NCT04810026|BEHAVIORAL|Meal delivery|breakfast, lunch, and dinner adhering to the longevity diet macro-nutrient profiles
215035732|NCT00301860|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215035733|NCT00301860|DRUG|cyclosporine|
215035734|NCT00301860|DRUG|fludarabine phosphate|
215035735|NCT00301860|DRUG|melphalan|
215035736|NCT00301860|DRUG|methotrexate|
215035737|NCT00301860|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
215035738|NCT00301860|PROCEDURE|peripheral blood stem cell transplantation|
215035739|NCT02225535|OTHER|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
215035740|NCT02225535|OTHER|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
214869768|NCT04810026|BEHAVIORAL|Lifestyle coaching|calls with coach and/or nutritionist, access to Facebook community support group
214869769|NCT02074917|PROCEDURE|Anatomical ACL reconstruction|Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
215035741|NCT02225535|OTHER|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
215035742|NCT02334657|OTHER|SF-36|postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
215035743|NCT03639402|BEHAVIORAL|Health education classes|Community empowerment through involvement of local mothers (peer mothers) for dissemination of education regarding health diet and physical activity to others eligible mothers in the community (fellow mothers).
215035744|NCT01766687|DIETARY_SUPPLEMENT|Hydration|
215035745|NCT06652490|PROCEDURE|Short-axis/out-of-plane approach versus oblique- axis approach for ultrasound-guided internal jugular venous catheter.|"In the group A, The US probe will be placed perpendicular to the venous anatomy in the SAX approach.~In the group B, The US probe will be aligned at 45° angulation with the venous anatomy, and combined with an in plane needle insertion technique. The needle will be advanced from lateral to medial."
214869770|NCT02699060|PROCEDURE|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.
214869771|NCT02699060|PROCEDURE|Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring|we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was \<4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.
215035746|NCT04471311|PROCEDURE|Sub-lay mesh supported closure|A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above the arcuate line, posterior layer is reinforced suturing the peritoneum and the posterior rectus sheath; below the arcuate line, the posterior layer is reinforced suturing the peritoneum and the trasversalis fascia. Anterior layer is re-established suturing the anterior rectus sheath. A 3 cm BIO-A Mesh strip is sutureless placed between the posterior rectus sheath and the rectus muscle with an overlap of 1,5 cm at each side. In laparotomies \>20 cm two stripes of 15 cm each is designed. The midline anterior rectus sheath is closed using a running slowly absorbable suture , covering the mesh.
215035747|NCT04471311|DEVICE|BIO-A (GORE) mesh|3 cm BIO-A Mesh strip
214869772|NCT03101644|DRUG|Darunavir|The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
214869773|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
215035748|NCT04573504|DRUG|Augmentin/Flagyl or Augmentin/Clindamycin|Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
215035749|NCT04573504|DRUG|Placebo|Placebo
215035750|NCT04701554|OTHER|Qigong program|The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.
215035751|NCT04701554|OTHER|Information on healthy lifestyles, physical exercise and dietary recommendations.|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
215035752|NCT01942109|DRUG|Furosemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
215035753|NCT01942109|DRUG|Torasemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
215035754|NCT03183947|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
215035755|NCT03183947|BEHAVIORAL|Neurofeedback|Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 \& 4; controls: Days 2 \& 3)
215035756|NCT03183947|OTHER|PANAS|to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
215035757|NCT03183947|OTHER|BDI-II|to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
215035758|NCT03183947|OTHER|ERQ|To assess emotion regulation strategies before and after neurofeedback training (patients: day 3\&4; controls: day 2\&3) and after 4 weeks during a telephone interview
215035759|NCT03643237|BEHAVIORAL|Video game-based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, \& Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework
215035760|NCT03643237|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
215035761|NCT05715827|DEVICE|RAS prostatectomy and RAS cholecystectomy|"There are two types of interventions in the study.~Patients indicated for Robotic Assisted Surgery (RAS) for a prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system.~Patients indicated for Robotic Assisted Surgery (RAS) for a cholecystectomy will have the RAS surgery using the Medtronic Hugo RAS system."
215035762|NCT06159309|OTHER|Hyperbaric oxygen therapy|HBOT per local protocol, i.e. 40 sessions 2.4 ATA, at the discretion of the hyperbaric physician
215035763|NCT06985927|BEHAVIORAL|psychotherapeutic sessions|Analysis of effect of psychotherapeutic sessions based on self-concept and autobiographical memory on alcohol addiction
215035764|NCT06640764|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty with SMS Femoral Stem (Medacta)
214869774|NCT01548118|BIOLOGICAL|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
215035765|NCT05481697|DIAGNOSTIC_TEST|GRAIL Galleri|A blood test that aims to detect cancers earlier by looking for abnormal DNA shed from cancer cells into the blood.
215035766|NCT06660420|DRUG|Cyclophosphamide|Given by IV
215035767|NCT06660420|DRUG|Fludarabine|Given by IV
215035768|NCT06305429|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 6 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. They will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
215035769|NCT05576337|OTHER|16 weeks of strength training protocol|16 weeks of strength training protocol
215035770|NCT06602011|COMBINATION_PRODUCT|TACE, Lenvatinib, combined with Tislelizumab group|TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Tislelizumab (200mg administered intravenous injection on Day 1 of each 21-day cycle). After the triple therapy, surgical resection is an option if assessed by the investigator to be feasible, or continued until disease progression or intolerable if not.
215035771|NCT06601179|DEVICE|HIFU|high-intensity focused ultrasound treatment of benign prostatic hyperplasia
214869775|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
214869776|NCT01548118|BIOLOGICAL|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
214290969|NCT01379547|BEHAVIORAL|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
214290970|NCT01379547|BEHAVIORAL|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
214290971|NCT05495256|DEVICE|Respimetrix|The Respimetrix device has a low resistance airflow sensor with an inhaler to measure patients inspiratory airflow and volume. This device will thereby provide quantifiable measures of lung function and bronchodilator delivery.
214869777|NCT04916444|DEVICE|rTMS|repetitive transcranial magnetic stimulation is a painless, noninvasive form of neurostimulation. This study uses an accelerated protocol in which the neurostimulation pulses are delivered in 4 sessions per day over 4 consecutive days (16 total sessions). Active or sham rTMS will be provided at 9 weeks following botox injections.
214869778|NCT06187558|PROCEDURE|Pelvic and abdominal organ suspension technique|The intervention involves a unique organ suspension technique tailored for minimally invasive gynecologic surgeries. A fragment of a Foley catheter (2 cm of a 1 Fr/Ch) is tied at the end of an absorbable 2-0 Polyglactin suture with a straight needle to create the suspension device. This suture is introduced into the pelvic cavity via an ancillary port. It's designed to penetrate organs such as the ovary, posterior peritoneum, vesico-uterine peritoneum, or bowel. Once the suture is retrieved by passing it through the abdominal wall and pulled so that the Foley segment faces the organ's surface, it's secured using a Kelly clamp. This setup eliminates the need for a knot and offers the surgeon the flexibility to adjust the suspension tension as required.
214869779|NCT00734396|PROCEDURE|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
214869780|NCT03670693|DIAGNOSTIC_TEST|Muscle strength and fatigue assessment|Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
214869781|NCT03670693|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DEXA scan)|Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
214869782|NCT03670693|DIAGNOSTIC_TEST|Supine cardiorespiratory fitness assessment|VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)
214869783|NCT03670693|DIAGNOSTIC_TEST|fMRI Exercise assessment|Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
214869784|NCT03670693|DIAGNOSTIC_TEST|Muscle deconditioning assessment|Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
214869785|NCT03710993|DEVICE|oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding transfer standard and reference devices to assess oximeter calibration and accuracy.
214869786|NCT01118897|RADIATION|Tomotherapy|"Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)~Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.~Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy."
214869787|NCT01016327|DRUG|NMS-1116354|Oral daily administration for 7 consecutive days every 14 days
214869788|NCT04482673|DRUG|Daily Vitamin D3|6000 IU vitamin D3 daily
214869789|NCT04482673|DRUG|Daily placebo|Placebo daily
214869790|NCT04482673|DRUG|Bolus vitamin D3|Bolus 20,000 IU vitamin D3 daily for 3 days
214869791|NCT04482673|DRUG|Bolus placebo|Bolus placebo daily for 3 days
214869792|NCT04389892|DIAGNOSTIC_TEST|Contrast enhanced harmonic endoscopic ultrasound|"During the echoendoscopy the image was fixed on the region of interest (pancreatic cyst) and the extended pure harmonic detection mode was selected. 2,4ml contrast enhancement (Sonovue-Bracco Italy) was injected in the right antecubital vein of the participants followed by a flush of 5ml 0.9% saline solution to ensure that the entire quantity of the agent goes in to the blood flow.~After the administration the pancreatic cyst was observed for at least 120 seconds.We followed the enhancing behavior of the cyst wall, the septa and the solid components. Arterial enhancement (contrast uptake) was considered the first 25-30 seconds after injection and the venous phase (wah-out) 30-45 seconds after injection.~EUS-FNA was performed in all patients without contraindications"
214869793|NCT06229678|DRUG|Empagliflozin 25 MG Oral Tablet|Empagliflozin 25MG will be administered orally once per day for 3 months
214290972|NCT03273374|DEVICE|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
214290973|NCT02496650|DRUG|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
214290974|NCT01737151|RADIATION|stereotactic body radiation therapy|Undergo SBRT
214290975|NCT01737151|RADIATION|four fraction split-course SBRT|four fraction split-course SBRT
214290976|NCT00298545|DRUG|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
214290977|NCT00298545|DRUG|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
214290978|NCT02178202|BEHAVIORAL|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
214290979|NCT02178202|DEVICE|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
214869794|NCT06229678|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
214869795|NCT06229678|DRUG|Acipimox 250 Mg Oral Capsule|subjects will be started on acipimox 250mg every 6 hours for 8 days while on continued empagliflozin/placebo therapy. This will be added at the end of 3 months after they finished baseline studies
214869796|NCT02955758|BIOLOGICAL|Pembrolizumab|Given IV, 200mg fixed dose, every 3 weeks
214869797|NCT04881019|DEVICE|Continuous glucose monitoring|Continuous monitoring of blood sugar over a 10-day period.
214869798|NCT02182635|DRUG|Ba253BINEB|
214869799|NCT00867503|DRUG|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
214869800|NCT06363903|DIAGNOSTIC_TEST|mesh allergy test|a 5 mm\^2 part of polypropylene mesh will be dissolved in 1 mL Methyl ethyl ketone (MEK), 25 microliters of this solution will be topically applied in a Finn chamber, and a reaction to the topical applicant will be assessed within 48 hours after application.
214869801|NCT06363903|DIAGNOSTIC_TEST|blood tests|Blood tests for diagnosis of autoimmune diseases will be performed
214869802|NCT06363903|PROCEDURE|Mesh removal|If wish for mesh removal persists, this procedure can be performed after separate informed consent (within the study), as standard practice of care.
214869803|NCT05847803|OTHER|No intervention, questionnaire survey|No intervention, questionnaire survey
214869804|NCT02951975|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
214869805|NCT03183336|PROCEDURE|ridge split interpositional block graft|
214869806|NCT03183336|PROCEDURE|decortication Onlay block graft|
214869807|NCT01001988|OTHER|Blood sample|Blood sample for immunogenicity assessment
214869808|NCT01001988|BIOLOGICAL|JE-CV administered in Study JEC02|Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
214869809|NCT00519688|DRUG|Thalidomide|100 mg, BID
214869810|NCT00519688|DRUG|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
214869811|NCT02598856|DRUG|Intranasal (IN) naloxone 1x|Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
214869812|NCT02598856|DRUG|Intranasal (IN) naloxone 2|Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
214869813|NCT02598856|DRUG|Intravenous (IV) naloxone|Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
214869814|NCT02598856|DRUG|Intramuscular (IM) naloxone|Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
214290980|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
214290981|NCT01536847|OTHER|Dietary Intervention|300 mL of liquid food product
214290982|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
214290983|NCT01428453|DRUG|250mg rilapladib|Experimental Drug
214290984|NCT01428453|DRUG|placebo|Placebo comparator
214290985|NCT02412423|DRUG|post-transplantation cyclophosphamide|
214869815|NCT03340207|DEVICE|Pneumaglide|The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
214869816|NCT03908515|DEVICE|Foldable Capsular Vitreous Body (FCVB)|FCVB can be regarded as an artificial vitreous and consists of a thin vitreous-shaped capsule, a drain tube, and a valve. After foldable implantation into the eye, then silicone oil is injected into the capsule which inflated to support the retina. The capsular material of FCVB is silicone rubber. The capsule was fabricated a computer simulation of the human and rabbit vitreous cavities. The control of the intraocular pressure is achieved with adjusting the amount of injected medium through the tube-valve system. After the medium was injected into the capsule through the tube-valve system, the valve was subsequently fixed onto the sclera surface similar to the glaucoma valve.
214869817|NCT01442688|DRUG|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
214869818|NCT01442688|DRUG|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
214869819|NCT05369728|OTHER|Coronary CT in 1st line compared to the strategy with functional test in 1st line in patient at Intermediate Risk of Developing Stable Coronary Disease:|Coronary CT in 1st line compared to the strategy with functional test in 1st line in Patients at Intermediate Risk of Developing Stable Coronary Disease:
214869820|NCT05691088|DEVICE|Paracetamol injection|"Patients were randomized to receive either paracetamol during mechanical ventilation. When patients were randomized to receive paracetamol (40 mg/kg per day in 4 doses), a placebo infusion of normal saline was administered continuously at the same rate as an equivalent infusion. Placebos could not be distinguished from the active study drug in color, odor, or viscosity.~In both study groups, IMV was maintained with sufentanil (0-0.2 mcg/kg/h), propofol (0-4 mg/kg/h), and dexmedetomidine (0-1 mcg/kg/h). Assessment of sedation levels by the bedside nurse using the FLACC pain scale to determine if the child is adequately comfortable or in need of more or less medication to maintain adequate ventilation. Assessment of sedation levels by the bedside nurse using the FLACC pain scale (every 6 hours as a minimum time interval)."
214869821|NCT02481362|OTHER|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
214869822|NCT02481362|OTHER|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
215035772|NCT04327817|DEVICE|Multifidus stimulator|"Patient eligible for the study and have provided consent will have a baseline PET scan. Multifidus ReActiv8 Stimulator will be inserted using standard treatment for lumbar pain at Barts Health NHS Hospitals.~All patients who receive the Reactiv8 system will continue to receive multifidus stimulation 20Hz for the next 6 months as per standard of care of multifidus stimulation; at the end of this period, the patients will undergo PET scanning and questionnaires. Thereafter, stimulation will continue and 3rd PET scan will be performed at 1year post implant."
215035773|NCT03632044|DRUG|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia
215035774|NCT03632044|OTHER|Sham Comparator|The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
215035775|NCT04950439|OTHER|Collect blood sample|A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
215035776|NCT00281385|BEHAVIORAL|traditional vs. lifestyle exercise|
215035777|NCT05618925|DRUG|N803|nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\])
214869823|NCT01939574|OTHER|Chemoradiation Therapy|"* Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~* Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight."
215035778|NCT05618925|BIOLOGICAL|CD19t-haNK suspension|Derived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).
215035779|NCT05618925|DRUG|Cyclophosphamide|Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate and has the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1.
215035780|NCT05618925|DRUG|Fludarabine|Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. The chemical name for fludarabine phosphate is 9H-Purin-6-amine, 2-fluoro-9-(5-0-phosphono β-D-arabino-furanosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate is C10H13FN5O7P and it has a molecular weight of 365.2.
215035781|NCT05618925|DRUG|Rituximab|Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM.
215035782|NCT03814044|DEVICE|PEEK Suture Anchors|"Subjects who have undergone hip joint repair using PEEK Suture Anchors:~BIORAPTOR™ Knotless Suture Anchor and SpeedLock Hip Suture Anchor"
215035783|NCT06268249|DRUG|Ulinastatin|Ulinastatin was pumped continuously during the operation
215035784|NCT05929326|DIAGNOSTIC_TEST|complete blood count, PT, aPTT, fibrinogen tests|Pregnant women who are eligible for the study will have their blood collected to run complete blood count, PT, aPTT, fibrinogen tests
215035785|NCT06615219|OTHER|Intergroup contact training|The intervention program uses direct contact and four types of indirect contact as the intervention strategy and general framework, and is divided into three main steps, assessing and reflecting on aging stereotypes, carrying out indirect and direct contact, and evaluating the effectiveness of the intervention. The time period is 12 weeks, with the interventionists comprising the researcher and nursing students. The forms of the intervention include holding mini-lectures, organizing participation in voluntary activities, and nostalgia interviews.
215035786|NCT06615219|OTHER|Regular course training only|The specific process is to sign in the classroom, review the knowledge of the previous class by asking questions, introduce the content of the new class, the teacher explains the knowledge points according to the teaching objectives and teaching content, and finally assigns the post-class homework of the course content. At the end of the experiment, the control group was given compensatory intervention.
215035787|NCT06670417|DEVICE|Low level laser therapy watch: The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light|"Low level laser therapy watch:~The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light. It provides 18 individual laser beams used for extravascular blood irradiation (transcutaneous) through radial and ulnar vessels at the wrist site."
215035788|NCT06670417|OTHER|Buerger Allen exercise|Procedure-Keep the Buerger Allen exercise board on the cot. Elevate the lower extremities to an angle of 45 to 90 degree with the help of exercise board. Provided support to the lower extremities to maintain the position. Make the subject to maintain the same position in the same manner until the skin blanches (appears dead white). Lower the feet and the legs below the level of the rest of the body until redness appears (care should be taken that there is no pressure against the back of the knees). Place the legs flat on the bed for a few minutes. Ask the subjects to sit in a relaxed position while each foot is flexed and extended then inverted and everted for 3 minutes till the feet turns entirely pink. Ask the subject to rotate the feet in all the direction. Make the subject to lie quietly for 5 minutes, keeping legs warm with a blanket
215035789|NCT06670417|OTHER|Regular wound care|Regular wound care and dressing to the wound and ulcer
215035790|NCT06669702|BEHAVIORAL|12-week home based exercise|"Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an rating of perceived exertion in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.~Participants can break down the exercise time in a way that suits their time, i.e., they can do 3 × 10 minutes, 2 × 15 minutes, etc."
215035791|NCT06669702|BEHAVIORAL|Routine care|Participants in this group will continue with their current routine care and will be given a diary of exercises that they can do, which are usually given to them as part of their health care routine by physiotherapists or consultants. The diary has information about yoga-like stretching practices.
215035792|NCT06996314|DEVICE|TVNS + Slow-Paced Breathing (TVNS+SDB)|Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
215035793|NCT06996314|DEVICE|TVNS without Breathing Training (TVNS+NB)|Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
215035794|NCT06996314|DEVICE|Sham TVNS + SDB|Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
215035795|NCT06996314|DEVICE|Sham TVNS + NB|Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
214869824|NCT01939574|OTHER|Adjuvant Therapy|"* Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events\> grade 2 are noted.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight."
214869825|NCT00274820|DIETARY_SUPPLEMENT|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
214869826|NCT00274820|DRUG|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
214869827|NCT00274820|DRUG|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
214869828|NCT00274820|DRUG|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience \< grade 1 thalidomide-attributed toxicity using CTC criteria.
214869829|NCT00927394|DRUG|Aliskiren|Aliskiren 150 mg tablet
214869830|NCT00927394|DRUG|Valsartan|Valsartan 160 mg capsules
214869831|NCT00927394|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
214869832|NCT00927394|DRUG|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
214869833|NCT00630929|DRUG|Ibuprofen|800 mg oral tablet 3 times daily with meals for 6 weeks
214290986|NCT04028843|BEHAVIORAL|Healthy Beginnings|The program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the smartphone application, personalized feedback from counselors and, evidence-based behavioral intervention delivered throughout pregnancy.
214869834|NCT00630929|DRUG|Placebo|Matched placebo orally for 6 weeks
214869835|NCT00630929|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
214869836|NCT01808820|BIOLOGICAL|Dendritic Cell Vaccine|Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.
214869837|NCT01808820|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
214869838|NCT01808820|DRUG|Imiquimod|5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
214869839|NCT01808820|PROCEDURE|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
214869840|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
214869841|NCT02465294|BEHAVIORAL|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
214869842|NCT02465294|OTHER|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
214869843|NCT02465294|OTHER|Blood Test|All subjects will have blood tests performed.
214869844|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
214869845|NCT01221363|BEHAVIORAL|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
214869846|NCT01345916|DRUG|CHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 NEXT DPI® 2 months
214869847|NCT01345916|DRUG|CHF 1535 100/6 pMDI 2 months|CHF 1535 100/6 pMDI 2 months
214869848|NCT01345916|DRUG|BDP DPI 2 months|BDP DPI 2 months
214869849|NCT00150761|DRUG|Levocetirizine (drug)|
214869850|NCT02430831|DIETARY_SUPPLEMENT|Nidina|
214869851|NCT02430831|DIETARY_SUPPLEMENT|Placebo|
214869852|NCT02186626|BIOLOGICAL|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10\^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
214869853|NCT02186626|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
214869854|NCT03351465|BEHAVIORAL|Coordinated Anxiety Learning and Management|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living42 that directly incorporates our previously optional modules for depression into the main program. The computerized internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed.
214869855|NCT04604886|DIAGNOSTIC_TEST|Passive Leg Raising|Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.
214869856|NCT04604886|DIAGNOSTIC_TEST|Dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
214869857|NCT04538625|DRUG|Crofelemer 125 MG [Mytesi]|Randomized, Double-blind, Placebo-controlled, two arm trial
214869858|NCT04538625|DRUG|Placebo|Matching placebo tablets
214869859|NCT02397187|BEHAVIORAL|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
214869860|NCT01336452|RADIATION|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
214869861|NCT04245241|OTHER|High-flow nasal cannula (HFNC)|24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).
214869862|NCT03587324|DRUG|Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).|"To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)"
214869863|NCT02390128|OTHER|observational only|
214869864|NCT01683292|DRUG|Inhaled VR040|
214869865|NCT01683292|DRUG|Placebo for VR040|Placebo arm
214869866|NCT04876365|OTHER|Non-Interventional|This is a Non-Interventional Study.
214869867|NCT00916760|BIOLOGICAL|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
214869868|NCT00916760|BIOLOGICAL|Placebo|Subcutaneous monthly treatment
214869869|NCT01339338|PROCEDURE|warming the contrast media|warm the contrast media with 37℃ water-bathing
214869870|NCT05205343|OTHER|Standard of Care|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
214869871|NCT05205343|OTHER|Control Group|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
214869872|NCT00115830|DRUG|Atorvastatin|
214869873|NCT00115830|DRUG|Rosuvastatin|
214869874|NCT05705037|OTHER|CPP-ACPF|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
214869875|NCT05705037|OTHER|PBMT|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
214869876|NCT05705037|OTHER|CPP-ACPF+PBMT|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2.
214869877|NCT02865460|DRUG|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
214869878|NCT02865460|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
214869879|NCT05817682|OTHER|Interprofessional education|"The study will be conducted among students of the Krakow Academy. The experimental group will consist of 35 students participating in the Interdisciplinary Circle of Medical Simulation from the following faculties: medicine, nursing and medical rescue.~Students will be divided into 7 interprofessional teams, in which they will take classes planned for small groups."
214869880|NCT05786716|DRUG|Trastuzumab|An initial loading dose of 8 mg/kg body weight, followed thereafter by a maintenance dose of 6 mg/kg body weight administered intravenously every 21 days. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
215035796|NCT06221449|PROCEDURE|Positive end expiratory pressure|"The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O."
215035797|NCT02625428|DRUG|Optison|
215035798|NCT02625428|DIAGNOSTIC_TEST|Ultrasound (US)|A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.
215035799|NCT02625428|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.
215035800|NCT05766280|BEHAVIORAL|iCareer Soft Skills Training for Employment|The telehealth iCareer intervention will be delivered during regular educational or vocational services (i.e., services from the Office of Disability Services (ODS) and/or from the school or college counseling center). Six modules of Soft Skills Training (SST), four group sessions for each module with 60 to 90 min for each session (depending on group size) will be delivered by trained project staff (graduate counseling student assistant or graduate counseling intern) via HIPAA-compliant Zoom videoconferencing. If participants are unable to join by Zoom videoconferencing, telephone (a format widely used in Cognitive Behavior Therapy (CBT) for Post Traumatic Stress Disorder (PTSD) treatment delivery and in CBT for depression) will be utilized. Ethical guidelines for providing telehealth over videoconferencing or phone will be followed.
215035801|NCT04093453|OTHER|Placebo (Sodium Chloride)|Participant receive Placebo (Sodium Chloride)
215035802|NCT04093453|OTHER|Exercise|1 hour exercise
215035803|NCT04093453|DIETARY_SUPPLEMENT|Sodium Propionate|Participant receive Sodium Propionate
215035804|NCT06668220|DRUG|Dexmedetomidine|Dexmedetomidine has become more popular as a caudal adjuvant in children; it is a highly selective α2 agonist with sedative and analgesic properties. Dexmedetomidine possesses anxiolytic, sedative, sympatholytic, and analgesic properties without respiratory depressant effects In addition; dexmedetomidine has the ability to reduce both the anesthetic and opioid analgesic requirements during the perioperative period.
215035805|NCT06668220|DRUG|Bupivacain|Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
215035806|NCT06520553|DRUG|BI 1569912 (C-14)|unlabelled BI 1569912 mixed with \[14C\]- labelled BI 1569912
215035807|NCT06520553|DRUG|BI 1569912 (C-13)|\[13C\]- labelled BI 1569912
215035808|NCT06673823|DEVICE|Mirror therapy|Mirror Therapy (MT) is a non-invasive treatment method aimed at addressing unilateral conditions impacting either the upper or lower limbs. This technique involves placing a mirror along the patient's sagittal plane, allowing the reflection of the unaffected limb to visually overlay the affected limb.
215035809|NCT06673823|OTHER|conventional therapy|conventional therapy
215035810|NCT06674746|BEHAVIORAL|SOLUTION FOCUSED APPROACH|The interviews with the control group were planned as eight sessions. There will be defined time intervals between sessions. It is estimated to take 6 months.
215035811|NCT06675292|OTHER|Survey-based study|The demographic information of individuals with tension-type headaches, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test-6, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
214869881|NCT05786716|DRUG|Pertuzumab|An initial loading dose of 640 mg, followed thereafter by a maintenance dose of 420 mg administered intravenously every 21 days. Paediatric patients will receive an initial loading dose of 14 mg/kg (maximum 840 mg), followed thereafter by a maintenance dose of 7 mg/kg (maximum 420 mg) administered intravenously every 21 days. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
214290987|NCT02607033|OTHER|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
214290988|NCT02607033|OTHER|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
214290989|NCT04500002|DRUG|Isonicotinic Acid Hydrazide|total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
214869882|NCT04501133|DEVICE|Peripheral electrical stimulation|Electrical stimulation will be delivered to forearm muscles with an electrical stimulator (Digitimer Ltd., Hertfordshire, UK) so that they generate forces opposed to those arising from the tremorgenic input.
214869883|NCT04501133|DEVICE|Single pulse TMS|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
214869884|NCT02578030|DRUG|SHP465 12.5mg|
214869885|NCT02578030|DRUG|SHP465 25mg|
214869886|NCT06152406|PROCEDURE|Ablation and Pacemaker Implantation|All patients will be implanted with a pacemaker device with one lead positioned in right ventricle (control arm only) and an additional lead will be positioned on the distal (ventricular) HIS bundle if in intervention arm. All patients will undergo ablation.
214869887|NCT02737748|DRUG|TWB-103 Group|Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
214869888|NCT02737748|DRUG|Placebo Group|Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
214869889|NCT05811377|DRUG|Ferumoxytol|After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.
214869890|NCT05811377|DRUG|Gadobutrol|After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
214869891|NCT05418504|DRUG|Dental anesthesia|Dental anesthesia, used to do any dental procedure
214869892|NCT04480710|DRUG|CRV431 75mg|1 x 75mg softgel capsule
214869893|NCT04480710|DRUG|Placebo (1 softgel)|1 x placebo softgel capsule
214869894|NCT04480710|DRUG|CRV431 225mg|3 x 75mg softgel capsule
214869895|NCT04480710|DRUG|Placebo (3 softgels)|3 x placebo softgel capsule
214869896|NCT04480021|BEHAVIORAL|MITHRA|A mobile based application (app) in CBOs to screen, track and treat mild to moderate depression among low income women using Healthy Activity Program (HAP),a WHO-recommended evidence-based intervention.
214869897|NCT04480021|BEHAVIORAL|EUC|Group education on depression by community health workers
214869898|NCT03761264|DRUG|Odontopaste®|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
214869899|NCT03761264|DRUG|Pulpdent|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Pulpdent paste will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
215035812|NCT06675656|OTHER|DNA extraction from urine, stool and biopsy. Isolation of serum and PBMC from peripheral blood.|DNA extraction from urine, stool and biopsy for microbiome analysis. Isolation of peripheral blood mononuclear cells from peripheral blood for immunophenotypic analysis, and isolation of serum for analysis of cytokines and bacterial metabolites.
215035813|NCT07000331|OTHER|Thoracic expansion exercises|Individuals placed their hands on their lower ribs and then took 3 deep breaths under their hands in a row. After this cycle, individuals rested by taking 3-4 calm breaths. The cycle was repeated 10 times. The individual did this session 4 times a day.
215035814|NCT07000331|OTHER|Physical activity counseling|Individuals were given weekly group phone calls and meetings. Individuals were gradually accustomed to regular walking to increase their daily step count. In the first week, individuals were asked to walk a total of 30-45 minutes per day, at least 4-5 days per week, and to increase the number of steps measured at the beginning by approximately 1000-2000 steps per day to reach at least 6500 steps. In the second week, the expected goal was at least 7500 steps. In the third and fourth weeks, they were asked to reach at least 10000 steps.
215035815|NCT07004335|DRUG|Iparomlimab and Tuvonralimab Injection plus Bevacizumab|The experimental group will receive intravenous infusion of anti PD-1/CTLA-4 (Iparomlimab/Tuvonralimab) Injection (5 mg/kg) and Bevacizumab (dose 7.5mg/kg) once every 3 weeks up to 35 cycles (105 weeks).
214290990|NCT04500002|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
214869900|NCT03761264|DRUG|Amoxicillin|Teeth with abscess will be opened from the crown to allow cleaning of the canals . A sterile cotton pellet will be placed in the pulp chamber and cavity sealed with capsulated Glass ionomer cement. The patient will be prescribed oral amoxicillin at 15mg/kg body weight tds for 5 days
214869901|NCT04823975|BEHAVIORAL|Health Insurance Education Program (HIEP)|\[See arm/group description\]
214869902|NCT06154200|DRUG|Testosterone gel 4.5%|Testosterone gel applied to eyelids twice per day
214869903|NCT06154200|DRUG|Vehicle gel|Vehicle gel applied to eyelids twice per day
214869904|NCT05990478|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography|Participants will have pre- and post-treatment CEM of the affected breast
214869905|NCT05990478|DIAGNOSTIC_TEST|Breast MRI|Pre- and post-NAT breast MRI will be performed for all participants
214869906|NCT04232683|DRUG|Tamsulosin 0.4Mg Capsule|Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased
214869907|NCT04232683|DRUG|Placebo oral tablet|Placebo pill given preoperatively
214869908|NCT04375722|DEVICE|tACS|Active or Sham tACS will be applied.
214869909|NCT06039371|PROCEDURE|Biopsy Procedure|Undergo a biopsy
214869910|NCT06039371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214869911|NCT06039371|PROCEDURE|Bone Scan|Undergo bone scan
214869912|NCT06039371|DRUG|Carboplatin|Given IV
214869913|NCT06039371|PROCEDURE|Computed Tomography|Undergo CT
214869914|NCT06039371|DRUG|Etoposide|Given PO
214869915|NCT06039371|OTHER|Quality-of-Life Assessment|Ancillary studies
214869916|NCT06039371|OTHER|Questionnaire Administration|Ancillary studies
214869917|NCT06039371|DRUG|Testosterone Cypionate|Given IM
214869918|NCT06039371|OTHER|Radioconjugate|Given LuPSMA IV
214869919|NCT06039371|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA
214869920|NCT06039371|OTHER|Gallium Ga 68-PSMA-617|Given gallium 68Ga-PSMA-617
214869921|NCT06039371|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA PET
214869922|NCT06039371|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
215035816|NCT06998277|OTHER|Dietary therapy|"Participants with quiescent UC will undergo a 10-day observational period followed by 15-days of the UC-TREAT dietary intervention. Disease activity, quality of life, and gastrointestinal symptoms will be assessed throughout"
215035817|NCT06998277|OTHER|Dietary therapy|"Healthy participants will undergo a 10-day observational period, followed by 15-days of the UC-TREAT dietary intervention. Gastrointestinal symptoms will be assessed throughout."
214869923|NCT06263842|PROCEDURE|modified Elamrousy approach for socket shield technique|the jumping gap will be filled with AWTG
214869924|NCT06263842|PROCEDURE|conventional socket shield|the jumping gap will be left ungrafted
214869925|NCT06263842|PROCEDURE|combined socket shild with xenograft|the jumping gap will be filled with xenograft
214869926|NCT06975943|DRUG|Progesterone 200 mg vaginal capsules|Participants in this group will receive daily vaginal micronized progesterone (Microgest®) of dose 200 mg for a duration of two weeks following arrested preterm labor. This micronized progesterone will be administered to assess its impact on pregnancy prolongation and changes of cervical length following arrested preterm labor.
214869927|NCT06273475|OTHER|Robot-assisted Training|Gait training and functional strength training facilitated by body weight unloading robotic technology yielding a dynamic unloading force applied to the body centre of mass. Gait training will be conducted both on treadmill and overground. Functional strength training exercises include sit-to-stand, stair-walking, step-ups etc. The goal is to gradually reduce body weight unloading as participants progress through the intervention period.
214869928|NCT06273475|OTHER|Standard Training|Gait training and functional strength training facilitated without the use of body weight unloading robotic technology, thereby only allowing manual assistance from physiotherapists. The goal of training is the same as in the intervention group, however no body weight unloading device will be implemented in the active control group.
214869929|NCT06125951|DRUG|Xanamem|Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
215035818|NCT07003464|DRUG|Zanubrutinib|160 mg (2 tablets) BID. Each 4-week period constitutes one treatment cycle.
215035819|NCT07003464|DRUG|Obinutuzumab|1000 mg IV (Days 1, 8, 15 of Cycle 1; Day 1 thereafter).Each 4-week period constitutes one treatment cycle.
215035820|NCT07003464|DRUG|Bendamustine|70 mg/m² (Days 1-2 per cycle) for induction only (Cycles 1-4).Each 4-week period constitutes one treatment cycle.
215035821|NCT07015905|DRUG|REGN7508|Administered per the protocol
215035822|NCT07015905|DRUG|Apixaban|Administered per the protocol
215035823|NCT07015905|DRUG|Enoxaparin|Administered per the protocol
215035824|NCT07015905|DRUG|Placebo|Administered per the protocol
215035825|NCT06689423|DEVICE|Credo POCT Device|Testing Credo's POCT device for respiratory viruses detection.
215035826|NCT07003698|PROCEDURE|The group without the rectointercostal nerve block|Patients in this group will be administered dexketoprofen 50 mg and tramadol 100 mg intravenously in the intraoperative period. These patients will not receive the rectointercostal nerve block.
215035827|NCT07003698|PROCEDURE|The rectointercostal plane block|The rectointercostal plane block is performed under ultrasound guidance before the surgical procedure and anesthesia induction, with the patient in the supine position. Additionally, patients in this group will be administered dexketoprofen 50 mg and tramadol 100 mg intravenously in the intraoperative period.
215035828|NCT06729866|PROCEDURE|electrogram guided pulse field ablation|In persistent atrial fibrillation patients, traget electrogram was mapped firstly , pulse field ablation of pulmonary veins, posterior wall of left atrium and target electrogram was ablated, until the atrial fibrillation converted to sinus rythm or stable atrial tachycardia. The mapping and ablation procedure was repeated until AF terminated or no target electrogram was found.
215035829|NCT03557502|OTHER|Heat Therapy Group|30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session
215035830|NCT03557502|OTHER|Aerobic Exercise Group|30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak
215035831|NCT05972850|BEHAVIORAL|Vivo Heart|Vivo is an online, live, small group fitness program developed for older adults that uses individually tailored dual-tasked (i.e., cognitive-motor) exercises to improve strength, endurance, balance, and cognition and incorporates social engagement. Certified trainers deliver instruction and coaching through an interactive session for 45 min, 2-3 times/week.
215035832|NCT04070846|DRUG|[14C] LC350189|Carbon-14 labelded LC350189
215035833|NCT01822379|PROCEDURE|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
215035834|NCT00174629|DRUG|Docetaxel/DDP|
215035835|NCT00174629|DRUG|docetaxel/gemcitabine|
215035836|NCT05715762|BEHAVIORAL|prone postion|ventilation at prone positioning
215035837|NCT05715762|DRUG|NO inhalation|NO inhalation at 20 ppm
214665703|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice|"The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and talking points designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence."
214869930|NCT06125951|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.
214869931|NCT05818241|PROCEDURE|Treatment of fracture by forearm cast|Patient that are not surgically treated for DRF
214869932|NCT05818241|PROCEDURE|Surgical treatment of fracture|Patients that are surgically treated for DRF
214869933|NCT03384654|DRUG|Daratumumab|Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
215035838|NCT01516476|DRUG|Placebo|Placebo for 12 weeks
215035839|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
215035840|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
215035841|NCT01516476|DRUG|liraglutide|liraglutide for 12 weeks
215035842|NCT00270387|DRUG|Natrecor (nesiritide)|
215035843|NCT01447537|OTHER|Exercise + relaxation|Exercise + relaxation
215035844|NCT01447537|OTHER|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
214869934|NCT03384654|DRUG|Vincristine|Participant will receive vincristine 1.5 milligram per meter square (mg/m\^2) in cohort 1 and cohort 2.
214869935|NCT03384654|DRUG|Prednisone|Participant will receive prednisone 40 mg/m\^2 in cohort 1 and cohort 2.
214869936|NCT03384654|DRUG|Doxorubicin|Participant will receive doxorubicin 60 mg/m\^2 in cohort 2.
214869937|NCT03384654|BIOLOGICAL|Peg-asparaginase|Participant will receive peg-asparaginase 2500 units per meter square (U/m\^2) in cohort 2.
214869938|NCT03384654|DRUG|Cyclophosphamide|Participant will receive cyclophosphamide 1 gram per meter square (g/m\^2) once in cohort 2.
214869939|NCT03384654|DRUG|Cytarabine|Participant will receive cytarabine 75 mg/m\^2 in cohort 2.
214869940|NCT03384654|DRUG|6-mercaptopurine|Participant will receive 6-mercaptopurine 60 mg/m\^2 orally daily in cohort 2.
214869941|NCT03384654|DRUG|Methotrexate|Participant will receive methotrexate 5 g/m\^2 intravenously (IV) in cohort 2.
214869942|NCT03867955|OTHER|Collection of datas|Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
214869943|NCT05114837|DRUG|allogeneic CAR19 regulatory T cells (CAR19-tTreg)|A single dose administration of CAR19-tTreg
214869944|NCT05114837|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)
214869945|NCT05114837|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
214869946|NCT01443936|BIOLOGICAL|Ad4-H5-VTN vaccination-tonsillar route|
214665704|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice Plus|The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
214869947|NCT01443936|BIOLOGICAL|Ad4-H5-vaccination-oral route|
215035845|NCT07136038|BEHAVIORAL|Low Energy Availability Screening and Nutrition Support|Athletes will receive screening for low energy availability, strength and body composition assessments and receive nutrition support from a sports dietitian over the competitive season.
214869948|NCT01062737|DRUG|ASU|
214869949|NCT02180126|OTHER|Follow-up|Follow-up of of patients with borderline positive ANCA test results
214869950|NCT06270212|DEVICE|STAIRWAY|Evaluation of STAIRWAY (new airway device) during sedation.
214869951|NCT06270212|DEVICE|NO DEVICE|Evaluation of NO DEVICE during sedation
214869952|NCT06141161|DRUG|corticosteroids|inhailed or oral corticosteroids
214869953|NCT02922881|OTHER|Ulcerative Colitis Diet (UCD)|The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
214869954|NCT02373748|DEVICE|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
214869955|NCT00423319|DRUG|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
215035846|NCT07146555|OTHER|No Interventions|
215035847|NCT07145905|DEVICE|TCRM|N=128
215035848|NCT02333799|DRUG|Bedaquiline|100mg tablets
214869956|NCT00423319|DRUG|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
214869957|NCT00423319|DRUG|Enoxaparin-matching placebo|Administered as injection
214869958|NCT00423319|DRUG|Apixaban-matching placebo|Administered as oral tablets
214869959|NCT01584843|DRUG|GSK1358820|IM injection of Botulinum Toxin Type A
214869960|NCT03666559|DRUG|Azacitidine|Chemotherapy
214869961|NCT00009009|DRUG|immunosuppressive regimen designed to complement HAART|
214869962|NCT01157806|RADIATION|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
214869963|NCT01254266|BEHAVIORAL|inpatient hospitalization and follow up|An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
214869964|NCT01254266|BEHAVIORAL|inpatient treatment and follow up|one month inpatient treatment followed by a year-long follow up on the inpatient unit.
214869965|NCT01254266|PROCEDURE|bariatric surgery|bariatric surgery.
214869966|NCT01254266|BEHAVIORAL|inpatient treatment with follow up|1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
214869967|NCT01962480|PROCEDURE|The hernia gap is sutured intracorporally|The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson \& Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
214869968|NCT01877226|DRUG|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
214869969|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
214869970|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
214869971|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
214869972|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
215035849|NCT02333799|DRUG|PA-824|200mg tablets
215035850|NCT02333799|DRUG|Linezolid|Scored 600mg tablets
215035851|NCT06834321|DRUG|Homoharringtonine combined with androgen deprivation therapy|Homoharringtonine 1mg intravenous infusion +5% glucose injection 250ml intravenous infusion, once a day for two consecutive days, repeated administration after three weeks of intermittent treatment, lasting two cycles + continuous androgen deprivation therapy.
215035852|NCT06834321|DRUG|Placebo combined with androgen deprivation treatment group|Placebo 1mg intravenous infusion +5% glucose injection 250ml intravenous infusion, once a day for two consecutive days, and repeated administration after a break of three weeks for two cycles + continuous androgen deprivation therapy,placebo is 5% glucose injection.
215035853|NCT06834321|PROCEDURE|radical prostatectomy|Radical prostatectomy was performed 3 weeks (±7 days) after the treatment cycle.
215035854|NCT05411718|DRUG|Naproxen|Given by PO
215035855|NCT05411718|DRUG|Aspirin|Given by PO
215035856|NCT05684965|DRUG|XTX301|XTX301 monotherapy
215035857|NCT04565509|BEHAVIORAL|General Communication Message|A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.
215035858|NCT04565509|BEHAVIORAL|Focused/Targeted Message|A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.
214869973|NCT02724930|BEHAVIORAL|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
214869974|NCT00311402|DRUG|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
214869975|NCT00311402|OTHER|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
214869976|NCT05713851|DRUG|Dapagliflozin|dapagliflozin is given for 21 days vs standard of care
214869977|NCT00073619|BEHAVIORAL|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
214869978|NCT02445274|PROCEDURE|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
214869979|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
214869980|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
215035859|NCT04565509|BEHAVIORAL|Best Message Alone|The best message will be either the general or focused/targeted message described above.
215035860|NCT04565509|BEHAVIORAL|Best Message + Augmented Message or Implementation Strategy|The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
215035861|NCT00710944|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
214665705|NCT06468371|DRUG|Dopamine Agonist (Ropinirole)|Ropinirole administration will start at 0.25 mg orally once daily, two hours before bedtime. The dose will be adjusted weekly based on symptoms, increasing by 0.5 mg increments, up to a maximum of 2.0 mg, which will be maintained for the remaining 12 weeks.
214665706|NCT06468371|OTHER|Excercise training|Exercise sessions will involve using a pedal bicycle twice a week for 12 weeks, integrated into the patients' hemodialysis schedule. Each session will last 20 minutes, scheduled between the second and third hours of dialysis. The first 5 minutes will be for warm-up with slow pedaling, followed by 10 minutes of intense pedaling, and concluding with a 5-minute cool-down period of slow pedaling to gradually reduce the heart rate.
214869981|NCT01600430|DIETARY_SUPPLEMENT|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
214869982|NCT02640053|PROCEDURE|Cryotherapy|Applied topically
214869983|NCT02640053|DRUG|Paclitaxel|Given IV
214869984|NCT02640053|OTHER|Quality-of-Life Assessment|Ancillary studies
214869985|NCT02640053|OTHER|Questionnaire Administration|Ancillary studies
214869986|NCT05241028|DRUG|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
214869987|NCT04502823|PROCEDURE|Management based on sFlt-1/PlGF values|"In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~* Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~* Fetuses with sFlt-1/PlGF \<38 weekly follow up will be recommended and delivery at ≥40 weeks."
214869988|NCT03283761|DRUG|Nab-paclitaxel 150 mg/m^2|Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
214869989|NCT03283761|DRUG|Oxaliplatin 85 mg/m^2|Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
214869990|NCT03283761|DRUG|5-FU 1200 mg/m^2 x 2 D|Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
214869991|NCT03283761|DRUG|Leucovorin 400 mg/m^2|Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
214869992|NCT00148642|DEVICE|silver salts coated endotracheal tube|intubation with silver coated tube
214869993|NCT00148642|DEVICE|uncoated endotracheal tube|intubation
214869994|NCT05783544|DIAGNOSTIC_TEST|Interleukin-1B|Level of serum interleukin-1B will be detected
214869995|NCT05783544|DIAGNOSTIC_TEST|Interleukin-4|Level of serum interleukin-4 will be detected
214869996|NCT05783544|DIAGNOSTIC_TEST|Interleukin-6|Level of serum interleukin-4 will be detected
214869997|NCT05783544|DIAGNOSTIC_TEST|tumor necrosis factor - a|Level of serum tumor necrosis factor - a will be detected
214869998|NCT05783544|DIAGNOSTIC_TEST|interferon- gamma|Level of serum interferon- gamma will be detected
214869999|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
214665707|NCT05095389|DEVICE|ADRCs|Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer
214870000|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
214870001|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
214870002|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
214870003|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
214870004|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
214870005|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
214870006|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
214870007|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
214870008|NCT02036775|DRUG|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
214870009|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
214870010|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
214870011|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
214870012|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
214870013|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
214870014|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
214870015|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
214870016|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
214870017|NCT05590832|BEHAVIORAL|Activity of Whatsapp messages|Informative messages will be sent to the initiative group on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks.
214870018|NCT00769990|DIETARY_SUPPLEMENT|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
214870019|NCT00769990|RADIATION|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
214870020|NCT02131961|DRUG|Collagenase ointment|250 collagenase units/g
214870021|NCT02131961|DEVICE|Modified Contact Cast System|1 Unit
214870022|NCT05495828|DRUG|Orelabrutinib|Orelabrutinib, 150mg, po, qd
214870023|NCT06209567|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET Scans|Participants will be injected intravenously with 68Ga-PSMA-11 via intravenous catheter. PET scans will first be interpreted without information on the results of other imaging modalities. Following the blinded read of the 68Ga-PSMA-11 PET scans, all recorded findings will be correlated with the results of CE CT and MR studies and 18F-FDG PET/CT or PET/MR performed as part of standard clinical care.
214870024|NCT02959424|OTHER|Spanish Northwestern Esophageal Quality of Life questionnaire|
214870025|NCT00678886|BIOLOGICAL|otelixizumab infusion plus physician determined standard of care|infusion
214870026|NCT00678886|BIOLOGICAL|placebo infusion plus physician determined standard of care|infusion
214870027|NCT03680066|OTHER|Oral food challenge to foods with traces|"Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~* cookies, max 30 g;~* chocolate, max 30 g;~* breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end."
214870028|NCT00206323|DRUG|Topiramate (drug)|Topiramate 25 mg titrated to 200 mg
214870029|NCT00206323|DRUG|placebo/sugar pill|placebo
214870030|NCT04151901|OTHER|Resistance Exercise Rehabilitation|Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.
214870031|NCT04151901|OTHER|Walking-based rehabilitation|Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
214870032|NCT02329847|DRUG|Ibrutinib|Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
214870033|NCT02329847|DRUG|Nivolumab|Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
214870034|NCT06474715|BEHAVIORAL|Arms|The intervention includes a task-based interaction (volunteer activities) where cognitive demand is low and interactional roles are clear. The focus is on the task, rather than developing relationships, reducing the pressure of interaction. As the volunteer activities continue, they also offer the opportunity for group members to enhance empathy, another salient component of cross-group relational development. Mediated interaction supports new relational development through a disinhibiting effect, lowering inhibitions and increasing comfort and disclosure
214870035|NCT05580653|OTHER|Controlled feeding study of beef and/or pinto beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.
214870036|NCT05580653|OTHER|Controlled feeding study of eggs and/or black beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.
214870037|NCT06323525|BIOLOGICAL|TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)|Phase 1 dose escalation (3+3): dose 1 (1 × 10\^6 cells/kg), dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2: dose of RP2D.
214870038|NCT06323525|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
214870039|NCT06323525|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
214870040|NCT01943994|DRUG|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
214870041|NCT01943994|DRUG|Nicotine Replacement Therapy (NRT)|
214870042|NCT05400408|DIAGNOSTIC_TEST|VOX|Breath Biopsy Analysis
214870043|NCT06981338|COMBINATION_PRODUCT|Allogeneic Wharton's jelly mesenchymal stem cells (WJ-MSCs)|This experimental treatment combines intrathecal administration of allogeneic Wharton's jelly mesenchymal stem cells (WJ-MSCs) with transcutaneous spinal cord stimulation (tSCS) and neurorehabilitation. Participants will receive three doses of cryopreserved WJ-MSCs (30×10⁶±30% viable cells per dose) derived from umbilical cord tissue, delivered via lumbar puncture at 6-week intervals in a saline-albumin solution. The intervention includes concurrent tSCS, a non-invasive electrical stimulation technique, paired with standardised neurorehabilitation. As the first clinical study evaluating this specific combined therapy for chronic spinal cord injury (AIS A-C grades), safety monitoring incorporates regular cerebrospinal fluid analysis to assess potential immune responses.
214870044|NCT06982196|DRUG|Sulodexide|Sulodexide group：Starting after the last injection of secukinumab, oral treatment with sulodexide soft capsule (Alpha Weissmann Pharmaceuticals, Italy, approval number H20140119, specification 250 LSU) was given as 1 tab bid for 120 days or discontinued after judged to be a relapse.
214870045|NCT06982196|DRUG|Placebo|Control group: Oral treatment with placebo capsule, 1 tab bid starting after the last injection of secukinumab, discontinued after 120 days of continuous oral administration or judged to be discontinued for relapse.
214870046|NCT01736748|BEHAVIORAL|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
214870047|NCT01736748|BEHAVIORAL|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
214870048|NCT05974917|DEVICE|Serious Game (SG)|"SG which was conceived as a running game, in which an Avatar runs through the forest and overcomes obstacles through the player's performance of physical exercises.~Children will play while watching an imaginary Avatar, who shows the right movements to perform in order to collect rewards. SG will be projected with a 4K projector and controlled by the child's movements, which will be tracked in markerless mode using Azure's Kinect sensor. SG will include an adaptive tool to enable the experience based on the child's specific motor skills.~The dynamics of SG will be adapted by considering real motor and physiological data acquired during each SG session via a wristband. These data are necessary to keep the child in the aerobic zone (60-80% of maximum heart rate). The movements are:~1. Side bending: Moving an obstacle to open a passage.~2. High jump: Overcoming a low, frontal obstacle.~3. Side lunge: Avoiding a side obstacle.~4. Squat: Passing under a low, frontal obstacle."
214870049|NCT04314414|OTHER|PRC brief motivational interview intervention|The intervention will involve the following elements: establishing rapport, asking permission to discuss drugs, discussing the pros and cons associated with drug use, uncovering the gaps between current and desired quality of life and determining readiness to change. The intervention will last approximately 20 minutes and take place at the time of the clinical visit while participants are waiting to be seen by a clinician or are awaiting laboratory testing.
214870050|NCT04314414|OTHER|Phone contact|The PRC will remain in at least weekly contact by phone with each participant.
215035862|NCT06471712|DRUG|18F-LNC1007 Injection|Healthy volunteers will receive 1 MBq/kg and cancer patients will receive 3.7 MBq/kg. The injection will be carried out on the scan bed via an IV indwelling catheter. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
215035863|NCT05612230|OTHER|Data analysis|Data analysis is based on a single database from the National Health Medical Data (North Center).
215035864|NCT05613556|DEVICE|Orpyx SI® Sensory Insole System|Orpyx SI Sensory Insole System consists of Orpyx Custom Insoles and Orpyx Sensory Technology. The Orpyx Custom Insoles are precisely fabricated for an individual's feet. The Orpyx Sensory Technology, a powered limb overload warning technology, is compatible with the Orpyx Custom Insoles. It is intended for monitoring physiological parameters, such as plantar pressure, motion and temperature, and providing real-time cues for pressure offloading as the patient goes about their daily activities
215035865|NCT00314613|DRUG|Antipsychotic/Risperidone Consta|
215035866|NCT03048370|PROCEDURE|Left body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
215035867|NCT03048370|PROCEDURE|Right body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
215035868|NCT03048370|PROCEDURE|Left warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
215035869|NCT03048370|PROCEDURE|Right warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
215035870|NCT03048370|PROCEDURE|Left cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
214665708|NCT05095389|OTHER|standard care|standard care
214665709|NCT05095389|OTHER|Placebo|placebo
214870051|NCT04331561|BEHAVIORAL|sensory re-weighting|Participants will be supported in quiet standing by a safety harness and crisscrossing strap system. A cervical collar will be used to maintain consistent alignment between the head and trunk. A virtual reality headset is used to create a virtual environment in which visual stimuli will be presented. Three different body positions will be used during training: earth-vertical and clockwise and counterclockwise tilted 16º in the frontal plane. Sensory re-weighting will be driven by priming upregulation of somatosensory cues. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity.
214870052|NCT03178032|BIOLOGICAL|DNX-2401|Brain infusion of the virus through the cerebellar peduncle
214870053|NCT00420459|DRUG|Aripiprazole|All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
214870054|NCT00589329|DRUG|erythromycin and metronidazole (antibiotics)|"Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days"
214870055|NCT00589329|DRUG|placebo|IV and pill placebo
214870056|NCT00872638|PROCEDURE|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
214870057|NCT00872638|PROCEDURE|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
214870058|NCT06552143|OTHER|Stone needle therapy follows the Belt channel|Stone needle therapy follows the Belt channel involves the use of stones by the intervener to follow the path of the Belt channel by pushing and rubbing the abdomen of patients with postpartum diastasis rectus abdominis.
214870059|NCT06606626|BEHAVIORAL|Sleep deprivation|Partial (4h) or total (0h) sleep deprivation
214870060|NCT06606626|BEHAVIORAL|Sleep place|8h sleep at home or in the laboratory
214870061|NCT06982742|OTHER|Mobile Health App for Neuropathic Pain Management in MS|This intervention is a self-management mobile health application specifically designed for patients with Multiple Sclerosis who experience neuropathic pain. Unlike general symptom tracking apps, this application provides structured educational content on anti-inflammatory nutrition, physical activity, sleep hygiene, stress management, and smoking cessation. It includes goal-setting features, personalized reminders, symptom tracking tools, and feedback mechanisms to promote behavior change and self-efficacy. The intervention is designed based on Social Cognitive Theory, aiming to empower patients to actively manage their pain and improve their quality of life. T
214870062|NCT06990022|OTHER|Carbohydrate|CHO solution was a maltodextrin-based mixture containing 6.4% maltodextrin (Protein Ocean, Türkiye). An CHOMR was performed prior to SSGs. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The CHO solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before SSGs and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz
214870063|NCT06990022|OTHER|Placebo|The PLA solution consisted of purified water. Both solutions were made indistinguishable by adding 50 mg of non-calorific artificial sweetener and 50 mg of sucralose (Fibrelle, Turkey). A 25 ml bolus of 6.4% maltodextrin solution was used in a pre-weighed plastic container and sucralose water was tested as PLA for each rinse solution.
214870064|NCT06989008|OTHER|Observational Study: Relationships Among Glucose, Physical Activity and Environmental Influences|This is a single group observational study with no interventions.
214870065|NCT06990685|DRUG|Salidroside|In the salidroside group, oral administration of rhodiola capsules (Xizang Gaoyuan 'an Biotechnology Development Co., LTD.) was started on the day of entering the COS cycle, once a day, 2 pills at a time, and the drug was stopped on the trigger day.
214870066|NCT06990477|DEVICE|EIT-guided PEEP|PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to 6 every 2min.
215035871|NCT03048370|PROCEDURE|Right cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
215035872|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 4 weeks
215035873|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 24 weeks
215035874|NCT06218459|OTHER|Oldpain2go®|OldPain2Go® is a non-medical intervention for the treatment of chronic pain conditions including, but not limited to Chronic Low Back Pain. The underlying premise is rooted in the biopsychosocial model of pain, where the cause of ongoing pain and the development of chronicity, is believed to lie beyond simple tissue damage, injury or malfunction. The intervention draws upon subconscious communication as a means to help patients to re-frame their pain as less threatening and remove old, out of date, pain messages that no longer serve a purpose.
215035875|NCT06218459|OTHER|Jacobson's progressive relaxation|Jacobson's progressive relaxation is a technique commonly used for eliciting the relaxation response and relieving muscular tension. It involves sequentially relaxing various muscle groups, often starting at the head and moving down the body to the feet.
214290991|NCT02421315|BEHAVIORAL|CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment|CBT treatment consisted of 12-16 hour-long sessions. For exceptional cases not showing clinical improvement after six CBT treatment sessions, complementary pharmacological treatment (SSRI) was offered as part of our treatment protocol. CBT for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
214290992|NCT05090007|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
214870067|NCT06990945|DEVICE|Hi-Bond Universal Adhesive|"A bioactive glass adhesive containing mesoporous bioactive glass designed to promote dentin remineralization, manufactured by Mediclus, Korea. It releases calcium and phosphate ions to enhance dentin sealing and reduce hypersensitivity~The adhesive will be applied after selective caries removal following a standardized protocol:~Selective enamel etching with 37% phosphoric acid for 15 seconds.~Application of HI Bond Universal adhesive with agitation for 20 seconds.~Light curing for 20 seconds using a LED curing device.~Incremental application of a nano-hybrid composite (Optishade Universal Kerr Dental, USA).~Occlusal adjustment, finishing, and polishing."
214870068|NCT06990945|DEVICE|OptiBond Universal Adhesive|"conventional universal adhesive designed for bonding composite restorations to enamel and dentin.~The adhesive will be applied after selective caries removal following a standardized protocol:~Selective enamel etching with 37% phosphoric acid for 15 seconds.~Application of OptiBond Universal adhesive with agitation for 20 seconds.~Light curing for 20 seconds using a LED curing device.~Incremental application of a nano-hybrid composite (Optishade Universal Kerr Dental, USA).~Occlusal adjustment, finishing, and polishing."
214870069|NCT06989034|OTHER|Child Sensory Profile 2 (SP2) for Sensory processing abilities|Sensory processing abilities are evaluated using the Child Sensory Profile 2 (SP2), an 86-item caregiver questionnaire assessing six sensory systems (auditory, visual, touch, movement, body position, and oral) and three behavioral domains (conduct, social-emotional, and attentional).
214870070|NCT06989034|OTHER|HUMAC Balance System for Postural stability evaluation|"Postural stability is assessed using the HUMAC Balance System, incorporating tests such as:~* The Modified Clinical Test of Sensory Integration of Balance (mCTSIB)~* Limits of Stability (LOS) at difficulty levels 4 and 6~* Center of Pressure (COP) metrics"
214870071|NCT06989034|OTHER|Selective Motor Control Evaluation for the upper and lower extremities|"Selective voluntary motor control is evaluated using the following tools:~* Test of Arm Selective Control (TASC) for the upper extremities~* Selective Control Assessment of the Lower Extremity (SCALE) for the lower extremities"
214870072|NCT06991036|OTHER|Gastric emptying test|"After the radiolabeled breakfast meal is ingested, the participant is positioned upright between the two detectors of the Brightview system (Phillips Medical Systems, Cleveland, OH). Detector height is adjusted to include esophageal uptake, the stomach, and the small bowel. Anterior and posterior static images are acquired at 2 minutes per image using a 256 x 256 word mode matrix. Anterior and posterior images are again acquired at 1 and 2 hours post-ingestion of the radiolabeled breakfast meal.~The participant is then given the designated 'push' meal after completion of the 2-hour images. At 4 hours post-ingestion, images are acquired in the same manner as at previous time points."
214870073|NCT06990061|RADIATION|Radiation therapy|Radiation therapy will be given in 20 fractions of 2.75 Gy (total dose of 55 Gy) covering the whole bladder over 4 weeks in combination.
214870074|NCT06990217|DRUG|Oxytocin Grindeks 10 IU/ml- solution for injection|our study is aims to compare two oxytocin regimens - low VS high dose among obese women who need induction or augmentation of labor
214870075|NCT06989931|DEVICE|Intracranial Distal Access Catheter|Patients with mechanical thrombectomy for acute ischemic stroke, treatment of intracranial aneurysms and other ischemic and hemorrhagic diseases, requiring the use of Intracranial Distal Access Catheter(X-Track) to complete the procedure
214870076|NCT06990191|BEHAVIORAL|Partnered Prolonged Exposure (PPE)|The PPE condition adapts the PE protocol with strategies from Integrative Behavioral Couples Therapy (an evidence-based couple therapy. PPE involves twice-weekly 60-minute sessions, with some sessions completed by both the Veteran and their partner while others are with the Veteran only.
214870077|NCT06990191|BEHAVIORAL|Prolonged Exposure (PE)|The PE condition will follow the standardized PE manual and involve weekly 90-minute sessions and a 30-minute check-in attended only by the Veteran and the therapist.
214870078|NCT06990165|DEVICE|Photobiomodulation|Photobiomodulation applications will be performed within 1 hour after the radiotherapy session, covering the entire irradiated area, three times per week, starting from the first day of radiotherapy. The procedure will be conducted using the Antares/IBRAMED® device, with a cluster applicator featuring a 20 cm² contact area and two distinct wavelengths: four infrared laser diodes (808 nm), each with a power of 180 mW, and three red light diodes (630 nm), each with a power of 150 mW. Each diode will deliver 3 J of energy, with the wavelengths applied separately and sequentially.
214870079|NCT06990165|OTHER|Sham Control|Group B will have the device in contact with the irradiated area, following the same protocol as Group A, but with the device turned off, receiving no therapeutic light and, therefore, experiencing no biological effects from the light.
214870080|NCT06989892|DEVICE|Super High-flux dialyzer (Elisio 19HDx)|Dialysis with Super High-flux dialyzer for intervention group
214870081|NCT06989892|DEVICE|High-flux dialyzer (Elisio 19H)|Dialysis with High-flux dialyzer for control group
214870082|NCT06990048|DEVICE|AFX2 System|"The AFX2 System comprises of the following:~AFX2 Bifurcated Endograft System and delivery system AFX Vela Proxmal Endograft System and delivery system AFX Stand Alone Endograft System and delivery system"
214870083|NCT00942695|OTHER|1.5PD|average American diet plus 1.5 oz per day pistachios
214870084|NCT00942695|OTHER|3.0PD|average American diet plus 3.0 oz per day pistachios
214870085|NCT00942695|OTHER|control|average American diet without pistachios
214870086|NCT02608151|OTHER|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
214870087|NCT02608151|OTHER|massage without oil|
214870088|NCT02953951|OTHER|blood transfusion|blood transfusion different sources
214870089|NCT05761925|BEHAVIORAL|COMA-F|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc.) to the comatose patient's caregiver. These sessions will take place in person or on Zoom, depending on the participant's preference.
214870090|NCT00004421|DEVICE|implanted pulse generator|
214870091|NCT06676306|OTHER|Non-Interventional Study|Non-Interventional Study
214870092|NCT03718052|PROCEDURE|Early valve surgery (EVS)|Early valve surgery (EVS) within 72 hours of randomization
215035876|NCT02840630|OTHER|Tinned mackerel fish|Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
214290993|NCT05090007|OTHER|gut microbiota|gut microbiota
214870093|NCT03718052|PROCEDURE|Conventional Care|Conventional care according to the 2015 European guidelines.
214870094|NCT06990100|DEVICE|ACL surgery|ligamentoplasty surgery - ACL reconstruction surgery
214870095|NCT06988852|COMBINATION_PRODUCT|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|The procedures of FOLFOX-HAIC were as follows: 1) a 5 French sheath was inserted into the femoral artery by Seldinger technique, then a 3.5 French catheter entered the coeliac trunk and superior mesenteric artery to assess the feeding arteries of tumors and identify any extra-collateral vessels which may cause drug leakage. These vessels would be embolized with gelatin sponge particles or metallic coils if necessary. A 2.7 French microcatheter was selectively inserted into the left/right/proper hepatic artery then patients were transferred to inpatient ward to start chemotherapy drug infusion. The FOLFOX regimen involving oxaliplatin (130mg/m2, day 1, 0-2h), leucovorin (400 mg/m2, day 1, 2-3h), 5-Fu (400mg/m2, day 1, bolus at 3h, then 2400 mg/m2, day 1-3, 3-49h), was administered via the microcatheter. The microcatheter and sheath were removed after HAIC finished. We didn't implanted port catheter system and repeated percutaneous femoral artery puncture and catheterization once every 3
214870096|NCT06988852|PROCEDURE|hepatic arterial infusion chemotherapy (HAIC)|The procedures of FOLFOX-HAIC were as follows: 1) a 5 French sheath was inserted into the femoral artery by Seldinger technique, then a 3.5 French catheter entered the coeliac trunk and superior mesenteric artery to assess the feeding arteries of tumors and identify any extra-collateral vessels which may cause drug leakage. These vessels would be embolized with gelatin sponge particles or metallic coils if necessary. A 2.7 French microcatheter was selectively inserted into the left/right/proper hepatic artery then patients were transferred to inpatient ward to start chemotherapy drug infusion.
214870097|NCT06988852|DRUG|Bevacizumab|We would inject bevacizumab at the dose of 7.5mg/kg once every 3 weeks if the primary tumors located from right-side to splenic flexure colon or the genotype of RAS or RAF was mutational.
214870098|NCT06988852|DRUG|Cetuximab (Erbitux)|We would inject cetuximab at an initial dose of 400mg/m2 and maintained a dose of 250mg/m2 once every week if we didn't choose bevacizumab.
214870099|NCT06988852|PROCEDURE|liver resection|If patients reached potential resectable state, we would perform liver resection.
214870100|NCT01923194|DRUG|Highly Purified Urofollitropin|for Injection
214870101|NCT01923194|DRUG|Recombinant Human Follitropin Alfa|for Injection
215035877|NCT00674921|DRUG|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
215035878|NCT00674921|DRUG|Placebo|starch, magnesium stearate, sodium lauryl sulphate
214665710|NCT03343964|DIAGNOSTIC_TEST|Amplitude-integrated electroencephalography|Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
214665711|NCT03206502|DEVICE|Embrace + Alert App|Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.
214870102|NCT04658836|DRUG|Triamcinolone Acetonide 40mg/mL|Intratympanic application of triamcinolone acetonide
214870103|NCT05387538|PROCEDURE|One-layer Duct-to-mucosa Pancreaticojejunostomy|To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used
214870104|NCT05387538|PROCEDURE|Two-layer Duct-to-mucosa Pancreaticojejunostomy|The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
214870105|NCT04375683|DRUG|Flumatinib|Flumatinib 600mg per day, taken on empty stomach
215035879|NCT01657370|DRUG|MK-1602|"Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
215035880|NCT01657370|DRUG|Placebo|"Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
215035881|NCT01657370|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded."
215035882|NCT02648581|DRUG|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
214665712|NCT05888116|DEVICE|Hidrante HA|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
214665713|NCT05888116|DEVICE|Cumlaude Hidrante Interno®|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
214870106|NCT04669691|BIOLOGICAL|H5N1 antigen combined with MF59 adjuvant|Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
214870107|NCT04841252|DEVICE|FDA approved GE LOGIQ E9 (LE9) ultrasound|Ultrasound
214870108|NCT04841252|DEVICE|Alpinion clinical ultrasound machine|Ultrasound
214870109|NCT00599898|DRUG|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
214870110|NCT00599898|DRUG|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
214870111|NCT01222390|DEVICE|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
215035883|NCT05973903|DRUG|Lenvatinib|Oral Lenvatinib 20 mg once daily
215035884|NCT05973903|DRUG|Pembrolizumab|intravenous pembrolizumab 200 mg every three weeks
214870112|NCT01822275|DRUG|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
215035885|NCT05973903|DEVICE|Tumor Treating Fields (TTFields)|TTF extra-dermal scalp electrodes
215035886|NCT06788132|COMBINATION_PRODUCT|Cranberry products|One capsule of cranberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU per day for 10 days
215035887|NCT06788132|OTHER|Placebo|Starch one capsule per day for 10 days
215035888|NCT05751434|BEHAVIORAL|Exercise Therapy|The intervention will consist of exercise therapy, individualized, walking delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule, up to 5 individual treatment sessions/week to achieve a cumulative total duration of 225 to 300 mins/wk until the participant's next standard of care prostate biopsy (about 6-12 months).
215035889|NCT06316947|RADIATION|CHW-delivered intervention|WellShare CHWs will then deliver the brief, approximately 15-minute intervention to the participating parent. The new intervention components will build off existing tobacco education outreach using verbal instruction and images developed by WellShare CHWs and layer in home smoke-free rules, potential biomarker feedback about smoke exposure, and other educational intervention components that align. Additionally there will be pre and post-intervention surveys and urine samples collection for cotinine levels.
215035890|NCT06569758|DRUG|GenSci098|subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.
215035891|NCT06569758|DRUG|GenSci098 Placebo|In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, multiple doses of GenSci098 and GenSci098 Placebo will be given.
215035892|NCT03042143|BIOLOGICAL|Human umbilical cord derived CD362 enriched MSCs|Infusion of Human umbilical cord derived CD362 enriched MSCs
215035893|NCT03042143|BIOLOGICAL|Placebo (Plasma-Lyte 148)|Infusion of placebo
215035894|NCT06088043|DRUG|TAK-279|Specified drug on specified days.
215035895|NCT06088043|DRUG|Placebo|Specified drug on specified days.
214665714|NCT04751500|PROCEDURE|Outpatient hysteroscopy|Direct visualisation and careful extraction of retained pregnancy tissue using a specific hysteroscopic technology known as a hysteroscopic tissue retrieval system.
214665715|NCT04751500|BEHAVIORAL|Expectant management|Leaving the retained pregnancy tissue alone to pass by itself
214665716|NCT04751500|DRUG|Medical management|Giving medications to contract the womb to pass the retained pregnancy tissue
214870113|NCT01822275|RADIATION|Radiation therapy|
214870114|NCT04321798|BEHAVIORAL|Physical Activity|Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
214870115|NCT00703573|DRUG|S-777469 400 mg|S-777469 400 mg BID
214870116|NCT00703573|DRUG|S-777469 800 mg|S-777469 800 mg BID
214870117|NCT00703573|DRUG|Placebo|Placebo BID
215035896|NCT06088043|DRUG|Apremilast|Specified drug on specified days.
215035897|NCT06406842|OTHER|Cerebral oxygenation index guided hemodynamics management|In the autoregulation group, anesthesiologist will maintain that the cerebral oxygen index value below 0.3. If cerebral oxygen index exceeds the threshold, norepinephrine or phenylephrine will be infused continuously, or arterial partial pressure of oxygen or arterial partial pressure of carbon dioxide will be adjusted to increase regional cerebral oxygen saturation.
215035898|NCT05288751|BEHAVIORAL|Contingency Management|Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
215035899|NCT05965310|BEHAVIORAL|Virtual Psychological Intervention: Cognitive Behavioral Therapy|An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
215035900|NCT04985630|DIETARY_SUPPLEMENT|Mitopure|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
215035901|NCT04985630|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice
215035902|NCT04333537|PROCEDURE|Chest Radiography|Undergo chest x-ray
215035903|NCT04333537|PROCEDURE|Computed Tomography|Undergo SPECT/CT scan and FDG PET/CT or CT
214870118|NCT03610568|BEHAVIORAL|Growing up GREAT! Intervention|The Growing up GREAT! intervention is built around the socio-ecological model. For young adolescents, a suite of materials provides information and prompts discussion about puberty, gender equality, healthy relationships, violence, and other related themes during weekly club sessions. For parents, group sessions featuring six testimonial videos foster discussion around non-violent parenting, equal sharing of household tasks, and girls' education. Other materials for teachers, health workers, and community members complement the core toolkit materials.
214870119|NCT05541991|DIETARY_SUPPLEMENT|single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a single dose of standardised rhubarb extract
214870120|NCT05541991|DIETARY_SUPPLEMENT|placebo coated tablet|coated tablet without active principle
214870121|NCT05541991|DIETARY_SUPPLEMENT|double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a double dose of standardised rhubarb extract
214870122|NCT01918826|DEVICE|TENS|
214870123|NCT00990587|DRUG|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
214870124|NCT00825136|BEHAVIORAL|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
214870125|NCT00825136|BEHAVIORAL|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
214870126|NCT01703936|OTHER|Agricultural and life skills training program|
215035904|NCT04333537|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
215035905|NCT04333537|DRUG|Imaging Agent|Receive imaging agent via injection
214290994|NCT05343351|OTHER|Technique of injection method|"In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel."
214290995|NCT02694510|OTHER|Light-protection of TPN solutions|TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
214870127|NCT04481178|OTHER|Laser (QS, Picosecond laser)|QS-Nd Yag Laser, Picosecond laser
214870128|NCT01044654|GENETIC|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
214870129|NCT02132754|BIOLOGICAL|MK-4166|
214870130|NCT02132754|BIOLOGICAL|Pembrolizumab|
214870131|NCT04801953|DRUG|NiMODipine Injectable Solution|nimodipine solution is applied to cranial nerves during resection of vestibular schwannoma
214870132|NCT04801953|OTHER|Placebo|Sodium chloride solution is applied to cranial nerves during surgery
214870133|NCT06709807|DRUG|CKD-378 25/1000mg|QD, PO
214870134|NCT03039179|DEVICE|polyurethane foam dress|Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
214870135|NCT01303705|DRUG|Anti-OX40|Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
214870136|NCT01303705|RADIATION|Radiation|8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
214870137|NCT01303705|DRUG|Cyclophosphamide|CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.
214870138|NCT01796158|BEHAVIORAL|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
214870139|NCT01796158|BEHAVIORAL|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
215035906|NCT04333537|PROCEDURE|Neck Dissection|Undergo standard elective neck dissection
215035907|NCT04333537|PROCEDURE|Planar Imaging|Undergo planar imaging
215035908|NCT04333537|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
215035909|NCT04333537|OTHER|Questionnaire Administration|Ancillary studies
215035910|NCT04333537|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
215035911|NCT04333537|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT scan
215035912|NCT03021486|DRUG|Chlorpromazine|Given IV
215035913|NCT03021486|DRUG|Haloperidol|Given IV
215035914|NCT03021486|OTHER|Quality-of-Life Assessment|Ancillary studies
214870140|NCT03353623|DEVICE|Serious Game|"Serious Game (SG) refers to the use of immersive virtual environments and wearable haptic devices during the treatment. Two SG were specifically developed to allow a playful training of different, targeted Upper Limb (UL) movement based on typical rehabilitation exercises (reach-to-grasp, linear path tracking, hand orientation). The child interacts directly with a virtual environment through haptic feedback provided to his/her fingertips. In particular, moneybox game focused on pincer grasp and reaching tasks with pronation/supination od the hand while marble labyrinth game focused on pointing and tracking movements requiring both eye-hand and upper limb inter-joint coordination."
214870141|NCT03353623|OTHER|Conventional Therapy|Conventional therapy (CONV) refers to the neurocognitive rehabilitation approach, with the purpose of improving pointing, tracking, reaching and grasping, and pronation/supination of the forearm. The therapeutic sessions were performed with the exception of the visual channel to ensure that the child focused his/her attention on tactile/kinesthetic information to complete the task. In particular, five different tasks have been proposed during the sessions: 1) recognize trajectories; 2) arm proprioception; 3) object manipulation; 4) recognize surfaces; 5) forearm orientation.
214870142|NCT00675064|DRUG|GSK369796|Anti-malarial
214870143|NCT00675064|DRUG|Placebo|Placebo matching GSK369796
214870144|NCT06198036|OTHER|Hold-Relax Technique|Participants in this group will be treated with hold-relax PNF Technique
215035915|NCT03021486|OTHER|Questionnaire Administration|Ancillary studies
215035916|NCT04795531|DRUG|Insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
215035917|NCT04795531|DRUG|Placebo insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
215035918|NCT04795531|DRUG|Insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
215035919|NCT04795531|DRUG|Placebo insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
215035920|NCT05984849|BEHAVIORAL|vaccination game|A health game to promote HPV vaccination among youth
215035921|NCT06183723|OTHER|Combination of social-behavior model and eHealth|"The study examines how an intervention combining the social-behavior model and eHealth can improve medication adherence among individuals who struggle to follow their medical regimens. The platform offers multiple features including health education, medication reminders, online consultations, chat rooms, news, and Q\&A services.~The intervention and follow-up are based on a 28-day month. The first intervention period runs from the first to the third month post-enrollment, with the introduction of the main features and sharing of health education videos and monthly short films. A follow-up assessment and questionnaire are completed after the third month.~The second intervention period is between the fourth and sixth months and includes similar features, and face-to-face counseling. New health education videos and monthly short films are shared as well. After the sixth month, another assessment is conducted to evaluate the post-intervention effects."
215035922|NCT04887831|DRUG|Trilaciclib|Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
215035923|NCT04887831|DRUG|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
214665717|NCT04751500|DRUG|Antibiotic|Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
215035924|NCT04887831|DRUG|Cisplatin|Cisplatin administered IV on Day 1 of each 21-day cycle
215035925|NCT04887831|DRUG|Carboplatin|Carboplatin administered IV on Day 1 of each 21-day cycle
215035926|NCT04887831|DRUG|Avelumab|Avelumab administered IV on Day 1 of each 14-day maintenance cycle
215035927|NCT05917002|DEVICE|Real TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system).
215035928|NCT05917002|DEVICE|Sham TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system). The Magventure MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
215035929|NCT06628908|DRUG|Suzetrigine|Tablets for oral administration.
215035930|NCT06628908|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
215035931|NCT06628908|DRUG|Pregabalin|Capsules for oral administration.
215035932|NCT06628908|DRUG|Placebo (matched to Pregabalin)|Placebo matched to Pregabalin for oral administration.
214665718|NCT04751500|PROCEDURE|Surgical management|Passing a small cannula/catheter/currette into the womb and mechanically scraping the womb lining to remove the retained pregnancy tissue
215035933|NCT04760873|DEVICE|cryotherapy|cryotherapy is a freeze spray that will be applied to GAVE for bleeding
215035934|NCT02931097|DEVICE|Deep brain stimulation|Stimulating deep brain electrodes and pulse generator
215035935|NCT02931097|DEVICE|Sham stimulation|
215035936|NCT04017767|PROCEDURE|Induced Acute Intermittent Hypoxia (AIH)|AIH will be administered on days 1-3. Each day entails 15 and 90 second hypoxic intervals (Fraction of Inspired Oxygen (FIO2) = 0.09) alternating with 60-second normoxic intervals (FIO2 = 0.21).
215035937|NCT04017767|DEVICE|AIH mask|Induced Intermitted hypoxia will be delivered via the AIH mask. The mask has two one-way valves restricting inspiration to the top valve and expiration to the bottom valve. Hypoxic and normoxic gas mixtures will be delivered through the top valve.
214870145|NCT06198036|OTHER|Muscle Energy Technique|Participants in this group will be treated with Muscle Energy Technique via Reciprocal Inhibition Mechanism
214665719|NCT04382508|OTHER|Questionnaire|A weekly questionnaire will be filled in
214870146|NCT03792087|DRUG|SmofKabiven Peripheral|Total Parenteral Nutrition
215035938|NCT05264974|BIOLOGICAL|Autologous total tumor mRNA loaded DOTAP liposome vaccine|"All participants will receive three doses of RNA-NP vaccine (1 dose every 2 weeks) intravenously.~The vaccine dose given will be determined by a 3 + 3 design. Participants will be given one of the following vaccine doses:~Dose level 0 (starting dose level): 0.00125 mg/kg mRNA in 0.01875 mg/kg LP; Dose level 1: 0.0025 mg/kg mRNA in 0.0375 mg/kg LP; Dose level 2: 0.005 mg/kg mRNA in 0.075 mg/kg LP; or Dose level 3: 0.01 mg/kg mRNA in 0.15 mg/kg LP~If 3 or more of the initial 6 subjects experience a dose-limiting toxicity, then the initial starting dose will be reduced (dose de-escalation) to 0.000625 mg/kg mRNA encapsulated in 0.009375mg/kg LPs (Dose level -1)."
215035939|NCT03519269|DEVICE|Navio™ Robotics-assisted Surgical System|Intervention will evaluate the utility of robotic-assistance in patients undergoing total knee arthroplasty
214870147|NCT03792087|DRUG|Hospital compounded emulsion|Total Parenteral Nutrition
214870148|NCT06444932|PROCEDURE|Joint Mobilization|Patellofemoral and tibiofemoral joint mobilization
214870149|NCT06444932|PROCEDURE|Resistance Exercise Training|Lower limb resistance exercise training
214870150|NCT06444932|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|Transcutaneous Electric Nerve Stimulation (TENS)
214870151|NCT06444932|DEVICE|Heating Pad|Heating pad for heat therapy
215035940|NCT06546787|OTHER|PSYCHOTHERAPY|IPT, was prepared by the researcher who completed the interpersonal relations psychotherapy training.The first interview will be conducted face-to-face in the offices of Koç University Faculty of Nursing. Subsequent sessions will be conducted via Zoom according to the availability of the patients included in the study. The day and time of the interviews will be planned according to the availability of the patients before the interviews. A total of 12 interviews are planned to be conducted with a patient for 40-60 minutes each. Interview intervals will be organized as once a week.
215035941|NCT02496208|PROCEDURE|Biopsy Procedure|Undergo biopsies
215035942|NCT02496208|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215035943|NCT02496208|DRUG|Cabozantinib S-malate|Given PO
215035944|NCT02496208|PROCEDURE|Computed Tomography|Undergo CT scan
214870152|NCT05769933|DEVICE|Simultaneous EEG-fMRI at 7 Tesla|Scalp electroencephalography (EEG) and functional magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
214870153|NCT05769933|DEVICE|Structural MRI at 7 Tesla|Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
214870154|NCT03121378|OTHER|Blood sample 1|Blood taken before prosthesis implantation
214870155|NCT03121378|OTHER|Blood sample 2|Blood taken after prosthesis implantation
215035945|NCT02496208|PROCEDURE|Echocardiography Test|Undergo echocardiography
215035946|NCT02496208|BIOLOGICAL|Ipilimumab|Given IV
215035947|NCT02496208|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215035948|NCT02496208|BIOLOGICAL|Nivolumab|Given IV
215035949|NCT05267587|RADIATION|Hypofractionated Stereotactic Radiosurgery|Participants will be given hypofractionated stereotactic radiosurgery (fSRS) in 9 Gray Units (Gy) per fraction x 3 consecutive daily fractions (27 Gy total) to the index metastasis that will be resected.
215035950|NCT03977207|DRUG|Levothyroxine Sodium|Thyroid hormone supplement
215035951|NCT03977207|DRUG|Placebos|Placebo oral capsule
215035952|NCT05150470|OTHER|prevention|dental digital fingerprinting
215035953|NCT02970565|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
215035954|NCT02970565|BEHAVIORAL|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
215035955|NCT00893802|OTHER|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
215035956|NCT01511302|DRUG|RNS60|RNS60, 2ml, nebulized twice daily.
215035957|NCT01511302|DRUG|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
215035958|NCT01511302|DRUG|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
215035959|NCT03014635|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
215035960|NCT03014635|BIOLOGICAL|Placebos|Intramuscular injection
215035961|NCT04507204|DRUG|Adhansia XR|Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
215035962|NCT04507204|DRUG|Concerta|An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
215035963|NCT02769104|DRUG|Letrozole (Aromatase Inhibitors)|Letrozole (Aromatase Inhibitors) for 5 years
215035964|NCT02769104|DRUG|AC*4-T*4|CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
215035965|NCT01744015|BEHAVIORAL|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
214290996|NCT01569711|PROCEDURE|Deep brain stimulation of nucleus accumbens|"* Day0 : surgical placement of electrodes~* M1 : stimulation of nucleus accumbens~* M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
214290997|NCT01554384|PROCEDURE|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
214290998|NCT01554384|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
214290999|NCT05573607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin tablet
215035966|NCT01744015|OTHER|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
214870156|NCT05276882|OTHER|Hypnosis|"It will be an individualized hypnosis session of Ericksonian type. It consists in going through 3 phases: induction, dissociation, suggestion.~The principle is to focus the patient's attention by talking to her or by surprising her, or by making her do an incongruous gesture which will make her focus on a restricted idea. She will reduce her field of consciousness and concentrate. This is where her work will begin, allowing her unconscious to function in order to find her solutions. At this moment, she is particularly receptive to suggestions and the hypnotherapist accompanies and guides her thoughts and her associations of ideas on therapeutic paths. He provokes a unique personal work which aims to promote healing."
214870157|NCT05276882|OTHER|pre-surgery consultation|"Dialogue with the patient to clarify her expectations.~* Answers to the patient's questions~* Precision on the organization of the hospitalization if necessary~* Information on the postoperative period with postural advice to facilitate the first getting up with less discomfort, and postures promoting rest in the postoperative period~* Information on relaxation techniques and their interest (abdominal breathing)"
215035967|NCT04781491|BEHAVIORAL|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna
215035968|NCT04015388|DEVICE|iPro Continuous Glucose Monitoring|iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
214870158|NCT01058720|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU orally once daily for 12 weeks
214870159|NCT02288182|DEVICE|Straumann VivOss|Patients will receive Straumann VivOss for sinus augmentation.
214870160|NCT02288182|DEVICE|Geistlich Bio-Oss|Patients will receive Geistlich Bio-Oss for sinus augmentation.
214870161|NCT01647672|DRUG|Abraxane|Abraxane for neoadjuvant chemotherapy
215035969|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by DPI|Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg
215035970|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by MDI|Budiair 200 mcg or Atimos 12 mcg
215035971|NCT05093621|DRUG|Furosemide|Standard of care diuretic
215035972|NCT05093621|DRUG|Torsemide|Standard of care diuretic
215035973|NCT05253040|OTHER|KEEP Intervention|Educational intervention
215035974|NCT05253040|OTHER|control|booklet from Parkinson's UK
214870162|NCT03106649|DEVICE|Echocardiography|Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
215035975|NCT01941602|DRUG|prophylactic enoxaparin|enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
215035976|NCT01941602|PROCEDURE|non-prophylactic|no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
215035977|NCT01206517|DRUG|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
215035978|NCT01206517|DRUG|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
215035979|NCT01206517|DRUG|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
215035980|NCT03060837|DIAGNOSTIC_TEST|Preoperative Parameters|Preoperative Hmg and serum creatinine levels
215035981|NCT03060837|OTHER|Peroperative Parameters|Scope duration, perforation, hemorrhage, etc. complications
215035982|NCT03060837|OTHER|Postoperative Parameters|Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
215035983|NCT03060837|OTHER|Movement of kidney|Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
215035984|NCT03060837|PROCEDURE|single lung ventilation|Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
215035985|NCT03060837|PROCEDURE|standard ventilation|Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
215035986|NCT00865748|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
215035987|NCT00865748|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
215035988|NCT04426747|OTHER|No intervention|No intervention
215035989|NCT01846026|DRUG|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
215035990|NCT01846026|DRUG|placebo|
215035991|NCT00577369|OTHER|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
214870163|NCT03106649|DEVICE|Treatment of spinal hypotension|For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
215035992|NCT02229617|DRUG|Subcutaneous testosterone|
215035993|NCT00781547|DRUG|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
215035994|NCT03493958|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|The SHUTi program is an automated, interactive, internet-based intervention based on well-established face-to-face cognitive behavioral therapy for insomnia (CBT-I) components including sleep restriction, stimulus control, sleep hygiene, cognition
215035995|NCT05656157|DEVICE|Medical device|Clinical decision support system
215035996|NCT01041261|DIETARY_SUPPLEMENT|BariatrX Essentials 360 Treatment|Medical food
215035997|NCT04968483|OTHER|Data collection|The general data, data of postoperative complications, data of nutritional assessment and nutritional support will be collected.
215035998|NCT01854684|DRUG|Temoporfin|Given IV
215035999|NCT01854684|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
215036000|NCT01854684|DRUG|Photodynamic Therapy|Undergo intraoperative PDT
215036001|NCT01854684|OTHER|Laboratory Biomarker Analysis|Correlative studies
215036002|NCT01854684|OTHER|Pharmacological Study|Correlative studies
215036003|NCT06255353|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
215036004|NCT06255353|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
215036005|NCT06255353|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
215036006|NCT04047446|DRUG|Exparel 133 MG Per 10 ML Injection|10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
215036007|NCT04047446|DRUG|Dexamethasone|15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected
215036008|NCT05788445|DEVICE|nrTMS treatment|Using the nrTMS treatment coli to stimulation with high frequency
215036009|NCT05788445|DEVICE|nrTMS sham|Using the nrTMS sham coli to stimulation with high frequency
215036010|NCT02367456|DRUG|PF-04449913 (Glasdegib)|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
215036011|NCT02367456|DRUG|Azacitidine|75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
215036012|NCT04089410|DEVICE|Hyperthermic Fitness Treatment (HFT)|The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.
215036013|NCT04089410|DEVICE|Placebo Hyperthermic Fitness Treatment|Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.
215036014|NCT04089410|OTHER|Physical Examination|"Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand."
215036015|NCT04089410|OTHER|Assessment of Cardiorespiratory Fitness|An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
215036016|NCT04089410|OTHER|Autonomic Balance, Orthostatic and Hypoxic tolerance|"1. Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~2. Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~3. The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT."
214870164|NCT04787874|BEHAVIORAL|Prehabilitation Program|"Nutrition component: Participants will receive information on how to follow a healthy diet (Mediterranean-style diet) with emphasis on whole foods, plants, lean protein, olive oil; restriction of red meats, processed meats, processed foods, added sugar)~Exercise component: Participants will receive an activity tracker to use during the study period (3+ weeks before surgery, and 30 days after surgery). Participants will be assigned strength exercises to work on core strength and proximal muscle strength (biceps/triceps, quads, hamstrings, calves).The exercises will mainly be focused on strengthening the abdominal wall. Exercises will be tailored to patients' individual capabilities. They will also be assigned cardio exercises - either low-intensity steady state cardio vs High Intensity Interval training. Level of cardio exercise will be tailored based on patient's Duke Activity score and baseline activity."
214870165|NCT04384744|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
214870166|NCT06708364|OTHER|Virtual Reality Training|"Virtual reality training (X-BOX). Table tennis~* Frequency: 3 day per week~* Intensity: Mild to moderate as per Game. Exer-game ( River Rush)~* Time: total 30 minute of training with 5 min warm and 5 min cool down.~* Type: aerobic exercise"
214870167|NCT06708364|OTHER|Cycle Ergometer|"* Frequency: 3 days per week.~* Intensity: 40-60% of HRR~* Time: total 30 minutes with 5 min warm up and 5 min cool down~* Type: aerobic exercise"
214870168|NCT01088802|RADIATION|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
214870169|NCT01088802|DRUG|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
214870170|NCT01088802|DRUG|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
214870171|NCT05177172|OTHER|High beta glucans|higher dose betaglucans
215036017|NCT04089410|OTHER|Psychological Testing|"1. Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~2. Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~3. Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~4. Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment."
215036018|NCT04089410|OTHER|Measurement of Blood Markers|Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.
215036019|NCT03230214|DIAGNOSTIC_TEST|PCR for bacterial translocation|samples taken from the blood and ascites of patients to search for bacterial DNA
215036020|NCT02458235|DRUG|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
215036021|NCT02458235|BIOLOGICAL|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
215036022|NCT00845702|DRUG|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
215036023|NCT00845702|OTHER|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
214665720|NCT01254344|DRUG|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
214665721|NCT01254344|DRUG|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
214665722|NCT01254344|DRUG|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
214870172|NCT05177172|OTHER|Low beta glucans|lower dose beta glucans
214870173|NCT05177172|OTHER|Low beta glucans + low polar lipids|low dose betaglucans in a combination with low dose of polar lipids
214870174|NCT05177172|OTHER|Polar lipids|low dose polar lipids
214665723|NCT01254344|DRUG|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
214665724|NCT00789126|DRUG|VX-509|
214665725|NCT05004675|BIOLOGICAL|lerodalcibep|300 mg
214870175|NCT05177172|OTHER|Control|No beta glucans or polar lipids
214665726|NCT05004675|DRUG|Inclisiran|284 mg
214665727|NCT01416129|DEVICE|Standard of care socket|Amputees' preferred socket.
215036024|NCT00548886|DRUG|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
215036025|NCT05950321|PROCEDURE|Paramedian cervical epidural steroid injection|For paramedian cervical epidural steroid injection, the cervical 7 (C7) - thoracic 1 (T1) interval is determined by taking an appropriate angle with C-arm fluoroscopy to determine the interlaminar space from the posterior cervical region. The epidural space is recognized by the negative pressure reflected on the resistance syringe.
214870176|NCT06352229|BEHAVIORAL|Playful Learning in Infancy Program|Research-based knowledge on play with babies delivered to the parents systematically by public health visitors based on a manual, activity cards, and video clips at four time points from 0 to 12 months postpartum.
214870177|NCT06352229|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
214870178|NCT06002737|DEVICE|Occlusion of blood vessels with a diameter greater than 5mm and less than or equal to 7mm using harmonic scalpel|Screening of lung or esophageal surgery patients who meet the inclusion criteria but do not meet the exclusion criteria, and evaluating the effectiveness and safety of ultrasound scalpel in the process of coagulation of blood vessels with a diameter greater than 5mm but not equal to 7mm.
214870179|NCT03567382|DRUG|Tenofovir Disoproxil Fumarate|300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.
214870180|NCT03567382|BIOLOGICAL|Monovalent HBV vaccine|Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
214870181|NCT01099527|DRUG|Everolimus (RAD001)|dose escalation of capecitabine, everolimus
214870182|NCT01099527|DRUG|Capecitabine|dose escalation of capecitabine, everolimus
215036026|NCT05950321|PROCEDURE|Selective nerve root pulsed radiofrequency|For selective nerve root PRF, an 8-12 Hz linear ultrasound probe is first placed posterolateral to the neck. The level of the cervical nerve roots is determined according to the morphology of the anterior and posterior vertebral tubercles. The corresponding nerve root is visualized hypoechoically between the tubercles. The radiofrequency cannula is inserted in the same plane as the ultrasound probe (in plane) and the relevant nerve root is approached. Pulsed radiofrequency current, which has therapeutic properties in chronic pain, is applied to the relevant nerve root for 240 seconds.
215036027|NCT04542928|BEHAVIORAL|nurse facilitated face care group|The experimental group is required to receive a nurse leading 50- minute face care group every two week
214665728|NCT01416129|DEVICE|Prosthetic brimless socket|Study socket
215036028|NCT03379974|DRUG|DDAVP Inhalant Product|For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
215036029|NCT03379974|BEHAVIORAL|Exercise Intervention|For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
215036030|NCT01489904|BIOLOGICAL|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
215036031|NCT00842621|PROCEDURE|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
215036032|NCT00842621|OTHER|Laboratory Studies|"Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
215036033|NCT01427491|DEVICE|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
215036034|NCT01427491|DEVICE|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
215057194|NCT04615234|DEVICE|Pharmacogenomics test (PGx)|"The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)"
215036035|NCT02418091|BEHAVIORAL|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
215036036|NCT04817150|PROCEDURE|Laparoscopic ventral mesh rectopexy|Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore
215036037|NCT06034626|PROCEDURE|Intense pulsed light|Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
215036038|NCT06034626|DRUG|0.3% hyaluronic acid eye drops|0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
215036039|NCT01164826|DRUG|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
215036040|NCT01164826|DRUG|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
214870183|NCT01385982|OTHER|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
214870184|NCT02671227|DRUG|intrathecal Mg sulfate.|intrathecal Mg sulfate 50 mg.
214870185|NCT02671227|DRUG|intrathecal bupivacaine 15 mg.|intrathecal bupivacaine 15 mg.
214870186|NCT02175576|DEVICE|Vanguard XP Bicruciate Knee System|The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
214870187|NCT02175576|DEVICE|Vanguard CR Knee System|The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
214870188|NCT00039962|DRUG|thymalfasin (thymosin alpha 1)|
214870189|NCT00039962|DRUG|PEGinterferon alfa-2a|
214870190|NCT03183492|BIOLOGICAL|Havrix®|One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
214870191|NCT05215717|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
214870192|NCT05215717|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
215036041|NCT05119816|OTHER|music therapy intervention|Received a customize playlists prepared by a certified music therapist to listening to during KB
215036042|NCT04987372|DRUG|Dexmedetomidine|The use of multimodal painkillers pre, per and postoperative
215036043|NCT02661152|DRUG|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
215036044|NCT01198587|DRUG|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
215036045|NCT01198587|DRUG|Placebo oral capsule|Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
215036046|NCT06467682|OTHER|tele-exercise|The 12-week tele-exercise program will be performed and supported via the USTEP digital platform, with each patient taking part in 3 training sessions per week with a 60-min duration period per training session. There will be personalized training sessions: i) warm-up and warm-down, ii) aerobic exercise, and iii) strength exercises. All tele-exercise program participants, will use wearable-based tracking to assessment the cardio-oxygenation.
214870193|NCT05919316|DEVICE|Rhinophototherapy|Intranasal rhinophotometer to be used at home for 4.5 minutes three times daily for 14 days
214870194|NCT05919316|DRUG|Nasonex Nasal Spray|50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
214870195|NCT04060316|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
214870196|NCT04060316|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
214870197|NCT06047392|DIAGNOSTIC_TEST|CT coronary angiography|Patients will undergo a CTCA according to local, standard protocol.
214870198|NCT00131872|DEVICE|Expedial Vascular Access Graft|
214870199|NCT02972918|DRUG|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
214870200|NCT03601650|BEHAVIORAL|Mindful eating|Attending to the sensory properties of food as it is eaten
215036047|NCT01263327|BIOLOGICAL|HPV 16/18|Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
215057195|NCT03150550|BEHAVIORAL|Mindfulness practice|Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
214870201|NCT03601650|BEHAVIORAL|Eating without distractions|Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
214870202|NCT00211120|DRUG|Epoetin Alfa|
214870203|NCT06248541|DEVICE|treatment with low-level laser therapy|low-level laser therapy (wavelength of 620 - 640nm)
214870204|NCT06248541|DEVICE|treatment with conventional light diodes|conventional light diodes
214870205|NCT01974336|DRUG|ursodeoxycholic acid|
214870206|NCT00620659|DRUG|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
214870207|NCT00620659|DRUG|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
214870208|NCT00620659|DRUG|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
214870209|NCT06297954|DRUG|Metoclopramide|Patients will receive metoclopramide 20 mg IV in a single dose prior to randomization.
214870210|NCT06297954|DRUG|Placebo|Patients will receive placebo 10 ml IV in a single dose prior to randomization.
215036048|NCT03425916|OTHER|Physical therapy intervention|Primiparous women start a physical therapy intervention in week 6 after normal one-child delivery, based on abdominal and pelvic floor exercises, education and behavior advices. Abdominal muscle condition and activation are measured by transabdominal ultrasound and surface electromiography. This group is going to be examined after treatment and 6 and 12 months after treatment.
215036049|NCT06006104|DRUG|HRS-4357 injection|HRS-4357 injection
215036050|NCT02234193|DEVICE|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
215036051|NCT02234193|PROCEDURE|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
215036052|NCT00930124|PROCEDURE|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
215036053|NCT00930124|PROCEDURE|Distraction osteogenesis|
215036054|NCT00844506|DRUG|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
215036055|NCT00844506|DRUG|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
215036056|NCT01758029|DRUG|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
215036057|NCT05420571|PROCEDURE|digital impression|3D printed models after digital impressions
215036058|NCT05420571|PROCEDURE|alginate impression|Alginate impressions after plaster model infusion to make models
214291000|NCT05573607|DIETARY_SUPPLEMENT|Chromium|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
214291001|NCT03954756|DRUG|Apatinib and PD1|"1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks."
214291002|NCT01073553|DRUG|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
214291003|NCT01073553|DRUG|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
214870211|NCT04366427|COMBINATION_PRODUCT|L-HBO|as previously described.
214870212|NCT04366427|COMBINATION_PRODUCT|HBO|as previously described.
214870213|NCT04366427|COMBINATION_PRODUCT|30% O2|as previously described
214870214|NCT04366427|COMBINATION_PRODUCT|50% O2|as previously described
214870215|NCT06390644|DIAGNOSTIC_TEST|Periorbital Massage Therapy|Participants in this arm will receive periorbital massage therapy administered by a trained practitioner. The massage technique will involve gentle circular motions around the eye sockets and brow bone area, aiming to improve eyelid and tear gland function.
215036059|NCT02822664|BEHAVIORAL|Pedophiles patients|cerebral MRI and/or cerebral PET imaging
215036060|NCT02822664|BEHAVIORAL|Healthy subjects|cerebral MRI and/or cerebral PET imaging
215036061|NCT02822664|DEVICE|PET/MRI|
215036062|NCT01727934|DRUG|Miravirsen sodium|Subcutaneous injection
215036063|NCT01603654|DRUG|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
215036064|NCT01603654|DRUG|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
215036065|NCT04556253|DRUG|AK104|Subjects will receive AK104 by intravenous administration.
215036066|NCT04252014|BEHAVIORAL|Hookah tobacco messages|Messages communicating the risks of hookah tobacco use in 4 thematic areas: health harms, addictiveness, social use, flavorings.
215036067|NCT04009980|OTHER|OMK2 group|topical administration of OMk2 ophthalmic solution for 36 months three times/day
215036068|NCT04009980|OTHER|Placebo group|topical administration of ophthalmic placebo solution for 36 months three times/day
215036069|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.
214291004|NCT06434259|DEVICE|Digi-physical support system|A support system named Evira will be used to provide behavioral treatment.
214870216|NCT06390644|OTHER|Control Group (Standard Care)|"Participants in this arm will receive standard care for dry eye disease, which include artificial tears. They will not receive periorbital massage therapy."
214870217|NCT00698880|PROCEDURE|Right hepatic vein embolization|Embolization of the right hepatic vein
214870218|NCT00004089|BIOLOGICAL|filgrastim|
214870219|NCT00004089|DRUG|fluorouracil|
214870220|NCT00004089|DRUG|hydroxyurea|
214870221|NCT00004089|DRUG|paclitaxel|
214870222|NCT00004089|PROCEDURE|conventional surgery|
214870223|NCT00004089|RADIATION|radiation therapy|
214870224|NCT02777112|OTHER|e-mental health program|This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.
214870225|NCT02777112|OTHER|e-mental health program and job coaching|This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.
214870226|NCT02777112|OTHER|No intervention|Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
214870227|NCT04993014|DRUG|Pertuzumab|Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)
214870228|NCT04993014|DRUG|Trastuzumab|Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts
214870229|NCT04993014|OTHER|Circulating tumor cells|Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.
214870230|NCT00804713|DRUG|BST|0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
215036070|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Saline|This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.
215036071|NCT00151840|DRUG|IVIG-L|
215036072|NCT04798677|DIETARY_SUPPLEMENT|ABBC1 Immunoessential|Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor
215036073|NCT04798677|DIETARY_SUPPLEMENT|Placebo|Powder for dissolution in water, excipents. Lemon flavor
215036074|NCT04422496|DRUG|HEC96719|"single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study."
215036075|NCT02697357|BEHAVIORAL|Psychosocial Instruments|
215036076|NCT02697357|BEHAVIORAL|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|
214291005|NCT01160978|DRUG|Simvastatin 80mg|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
214291006|NCT01160978|DRUG|Control Rx|The transplant recipients who have received an organ from non-treated donors.
214291007|NCT02952781|DEVICE|EKG Patch monitors (Zio and Carnation)|Each patient will be provided with both a Zio-XT Patch monitoring system and the CAM system and will be instructed to wear both simultaneously for 7 days.
214291008|NCT04768595|DIETARY_SUPPLEMENT|Placebo|Two, 1g capsules taken daily with food
215036077|NCT01952977|DIETARY_SUPPLEMENT|Test breakfast|
215036078|NCT04076033|OTHER|functional compressive bandage|"The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers."
215036079|NCT02095106|DEVICE|Waterproof Cast|
215036080|NCT02095106|DEVICE|Traditional cast|
214291009|NCT04768595|DIETARY_SUPPLEMENT|Ceto 10|Two, 1g capsules daily with food
214870231|NCT00804713|DRUG|TST|Administer TB Skin test (TST)
214870232|NCT00804713|OTHER|QFT|Perform QFT TB test
214870233|NCT00804713|OTHER|T-spot|Perform T-Spot TB test
214870234|NCT01240213|DIETARY_SUPPLEMENT|Vitamin D|2000 IU per day of Vitamin D
214870235|NCT01240213|DIETARY_SUPPLEMENT|Placebo|1 Placebo per day
214870236|NCT06399809|DRUG|Fisetin|Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, fisetin has the best safety profile.
214870237|NCT06399809|DRUG|Placebo|The placebo will be matched to the Fisetin intervention
214870238|NCT01214915|DRUG|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
214870239|NCT02935205|DRUG|Enzalutamide|Given PO
214870240|NCT02935205|DRUG|Indomethacin|Given PO
214870241|NCT04784754|DRUG|Melatonin|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
214870242|NCT04784754|DRUG|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
214870243|NCT04346420|OTHER|Standard interface|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
214870244|NCT04346420|DEVICE|Double-Trunk Mask|The standard nasal cannula interface accompanied with the DTM is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
214870245|NCT02056392|DRUG|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
214870246|NCT02056392|DRUG|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
214870247|NCT02056392|DRUG|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
215036081|NCT04992130|BEHAVIORAL|Pre-season supplementary neurologic training program|A two-month standardized, pre-season, supplementary multi-modal training program will be prescribed to 200 athletes (intervention cohort) by a team of experienced sport science and medicine professionals targeting the specific intrinsic risk factors of interest identified in the current concussion and ACL prevention literature.
214291010|NCT04768595|DIETARY_SUPPLEMENT|Fish oil|Two, 1g capsules daily with food
215036082|NCT03373435|DRUG|exendin 9-39|Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
214291011|NCT01306591|DRUG|Bevacizumab 1|Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
214870248|NCT05255874|OTHER|Aromatherapy|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
214870249|NCT06506162|OTHER|Flavor|The study will compare sweet vs. cool flavors
214870250|NCT06506162|OTHER|Nicotine concentration|The study will compare low vs. high strength Oral Nicotine Products
214870251|NCT03039660|BEHAVIORAL|RefreshMD|Online Sleep Improvement Course
214870252|NCT03039660|BEHAVIORAL|Bond Between Us|Online Educational Course
214870253|NCT02280668|OTHER|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
214870254|NCT02280668|OTHER|the eccentric muscle damage exercise|
214870255|NCT04142892|DRUG|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
214870256|NCT05323331|OTHER|Circuit Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
214870257|NCT05323331|OTHER|Aerobic Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
215036083|NCT03373435|OTHER|Placebo|Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
215036084|NCT00553254|DRUG|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
214291012|NCT01306591|DRUG|Bevacizumab|Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
214870258|NCT04771663|OTHER|Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger|The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.
214870259|NCT00529282|DRUG|Ceftobiprole Medocaril|500 mg every 8 hours
214870260|NCT00529282|DRUG|Cefepime with or without vancomycin|120-minute infusion \[250 mL\]
214870261|NCT01846013|BEHAVIORAL|Stand|Stand at least half of the workday at work.
214870262|NCT01846013|BEHAVIORAL|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
214870263|NCT01846013|BEHAVIORAL|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
214870264|NCT03598868|DRUG|Vortioxetine|Augmentation : Vortioxetine 10 mg p.o. for week 1, Vortioxetine 5-20 mg p.o. for week 2,4,6.
214870265|NCT03598868|DRUG|Placebo|Augmentation : Placebo for week 1,2,4,6
214870266|NCT03467880|OTHER|Clinical Observation|No treatment given but observation with IOS
215057196|NCT03150550|BEHAVIORAL|Relapse prevention|It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
215057197|NCT03197610|PROCEDURE|enamel matrix derivatives|enamel matrix derivatives and subepithelial connective tissue grafts
214291013|NCT01302093|DRUG|Racecadotril Film-Coated Tablet (FCT)|A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
214291014|NCT01302093|DRUG|Racecadotril Capsule|A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
214291015|NCT04219943|PROCEDURE|Surgical Treatment for Impacted Femoral Neck Fracture|Surgical Treatment for Impacted Femoral Neck Fracture
214291016|NCT02299297|DRUG|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
214291017|NCT03951844|DEVICE|BRIDGE/EMPATIA exoskeleton|The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
214291018|NCT00000350|PROCEDURE|radioactive substance|
214291019|NCT03529851|OTHER|Weekly questionnaires|In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
214291020|NCT03789318|DRUG|CA-008 5 mg|5 mg CA-008 reconstituted in saline.
214291021|NCT03789318|DRUG|Placebo|Each cohort will use placebo reconstituted in saline.
214870267|NCT05220189|DIAGNOSTIC_TEST|EarlyTect® Bladder Cancer test|A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.
214870268|NCT04555720|BEHAVIORAL|Interdisciplinary Visit|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
214870269|NCT02249312|DRUG|BIIL 284 BS|
214870270|NCT02249312|DRUG|Placebo|
214870271|NCT00521469|DEVICE|Pro Adjuster|
214870272|NCT01899443|OTHER|Observation|This is an observational study observing relationship between routine care and outcomes after total hip or knee arthroplasty.
214870273|NCT04418843|PROCEDURE|Standard Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
214870274|NCT04418843|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
214870275|NCT01043835|PROCEDURE|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
214870276|NCT01043835|PROCEDURE|Open gastrectomy|Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
214870277|NCT00968799|PROCEDURE|Hyperthermic intraoperative intraperitoneal chemotherapy|Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
214870278|NCT00968799|PROCEDURE|Cytoreduction|"Surgical removal of tumor nodules~including resection of organs infested with tumor"
214870279|NCT00968799|DRUG|Cisplatin|Cisplatin is applied as chemotherapy during surgery
215036085|NCT00189137|DRUG|ifosfamide and doxorubicin vs gemcitabine and docetaxel|"Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection."
215036086|NCT00140686|BIOLOGICAL|Rotavirus (vaccine)|
215036087|NCT05437991|DIAGNOSTIC_TEST|Independent morphological quantifications by echo-doppler using ECST method|The physician who is usually in charge of patient follow-up performs a first evaluation of carotid stenosis percentage by echo-doppler using ECST method. Then a second physician immediately performs a second evaluation using the same echo-doppler device without knowing first evaluation conclusions.
215036088|NCT02008617|DRUG|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
215036089|NCT02008617|DRUG|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
214291022|NCT03789318|DRUG|Bupivacaine Hydrochloride|0.25% administered pre-surgery
214291023|NCT03789318|DRUG|Hydromorphone|0.02 mg/kg IV administered intraoperatively
214870280|NCT04642651|DRUG|Dexmedetomidine|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
214870281|NCT04642651|DRUG|Placebo|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
214870282|NCT05940753|OTHER|Survey about travel willingness regarding cancer treatment and follow-up|No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
214870283|NCT03173144|OTHER|Primary exposure variable|"1. Upper tertile (33.3% of the total sample) based on the ratio: fibre/meat intake is associated with better treatment outcome~2. Low intake of red and processed meat (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of dietary fibres (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with better treatment outcome, and their synergy (interaction between the factors meat and fibres) gives the best treatment outcome"
215036090|NCT02134184|BIOLOGICAL|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
215036091|NCT03569189|OTHER|High Fat Diet|"Participants will consume a high fat diet for 7 days with 65% of energy from fat. The diet will also provide an energy excess at 150% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
215036092|NCT00073125|DRUG|ABT-510/Thrombospondin-1 mimetic|
215036093|NCT03344484|OTHER|Surgical approach|Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
215057198|NCT04719221|DRUG|Evolocumab|The maximum dose of combined cholesterol therapy (Statin + Ezetimibe) is prescribed for 2 months, and a cholesterol test is performed in an outpatient clinic to ensure that LDL-Cholesterol \<70mg/dL is met. Patients who do not meet the criteria are randomized to maintain current treatment or receive additional Evolocumab according to randomization.
215057199|NCT04719221|DEVICE|NIRS IVUS|near-infrared spectroscopy
214870284|NCT03173144|OTHER|Other (exploratory) exposure variables|"* Lifestyle factors independently or combined (red and processed meat, vegetable, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/ fat, protein/ fat from red and processed meat, glucemic index)~* Pretreatment lifestyle-associated biomarkers~* Combinations of lifestyle factors and lifestyle-associated biomarkers~* Gene-environment interaction analyses~* Pretreatment levels of inflammatory molecules"
214870285|NCT03382730|OTHER|Chlorhexidine Mouth Rinse|Oral chlorhexidine gluconate oral rinse
214870286|NCT03382730|OTHER|Chlorhexidine Mouth Rinse De-Adoption|Multifaceted education and audit/feedback.
214870287|NCT00719849|BIOLOGICAL|anti-thymocyte globulin|30mg/Kg Days -6 to -4
214870288|NCT00719849|DRUG|cyclophosphamide|50 mg/Kg Day -6
214870289|NCT00719849|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
214870290|NCT00719849|DRUG|fludarabine phosphate|40mg/m2 Days -6 to -2
214870291|NCT00719849|DRUG|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
214870292|NCT00719849|PROCEDURE|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
214870293|NCT00719849|RADIATION|total body irradiation|200 cGy Day -1
214870294|NCT01323049|PROCEDURE|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
214870295|NCT01323049|PROCEDURE|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
214870296|NCT03048253|BIOLOGICAL|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
214870297|NCT06895902|DEVICE|Polypropylene Suture Eyelid Spring for Paralytic Lagophthalmos|The polypropylene loop eyelid suture spring will be centrally placed without fixation to the bone unlike a metal lid spring.
214870298|NCT03867097|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
214870299|NCT03867097|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
215036094|NCT04046640|DEVICE|Infrared thermal imaging|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a NEC InfRec R450 infrared thermal imaging camera~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
215057200|NCT06000592|DEVICE|Digitimer|transcutaneous spinal cord stimulation for blood pressure control following spinal cord injury.
215057201|NCT01179984|DEVICE|Bard® LifeStent® Vascular Stent System|Stent Implantation
214291024|NCT03789318|DRUG|Fentanyl|100 mcg IV administered intraoperatively
214291025|NCT03789318|DRUG|Acetaminophen|1000 mg IV administered intraoperatively
214291026|NCT03789318|DRUG|Oxycodone|5-10 mg PO administered post-surgery
214291027|NCT03789318|DRUG|CA-008 10 mg|10 mg CA-008 reconstituted in saline.
214870300|NCT01372774|RADIATION|stereotactic radiosurgery|Undergo RT
214870301|NCT01372774|RADIATION|whole-brain radiation therapy|Undergo radiotherapy (RT)
214870302|NCT04328857|DEVICE|pseudoelastic orthosis|The subject will be given specific physiotherapy including activities oriented to multimodal exploration and refinement of gross and fine motor skills, customized according to the functional status of the individual patient.
214870303|NCT01723579|DRUG|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
214870304|NCT01723579|DRUG|Estradiol (E2)|Daily release of 1.5 mg
214870305|NCT05551819|DIETARY_SUPPLEMENT|MDF then RUTF/RUSF|Children randomized to feeding order 1: children will be provided MDF for the first two weeks then crossover to consume RUTF/RUSF for a second two weeks.
214870306|NCT05551819|DIETARY_SUPPLEMENT|RUTF/RUSF then MDF|Children randomized to feeding order 2: children will be provided RUTF/RUSF for the first two weeks then crossover to consume MDF for a second two weeks.
214870307|NCT02828059|DRUG|Ropivacaine|Surgical wound Infiltration over 48 hours
214870308|NCT03481218|OTHER|The World Health Organization Quality of Life (WHOQOL) -BREF|The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
214870309|NCT03481218|OTHER|The Satisfaction With Life Scale - SWLS|The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.
214870310|NCT03481218|OTHER|Big Five Inventory - BFI; John in Srivastava, 1999|The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.
214870311|NCT02201290|DRUG|Eltrombopag Tablets|Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
215057202|NCT02414516|DRUG|OBP-801|OBP-801 will be administered IV
214291028|NCT03789318|DRUG|CA-008 15 mg|15 mg CA-008 reconstituted in saline.
214870312|NCT02201290|DRUG|Eltrombopag PfOS|Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
214870313|NCT00094081|DRUG|tirapazamine (SR259075)|
214870314|NCT00094081|DRUG|cisplatin|
214291029|NCT00213798|PROCEDURE|Biopsy samples|
214291030|NCT02480114|OTHER|Educational Intervention|Undergo oral care and pain management education session
214870315|NCT00094081|PROCEDURE|Radiation Therapy|
214870316|NCT05909189|OTHER|LEADing Dementia End-of-Life Planning Conversations|The LEAD Intervention is self-administered and delivered through an interactive, web-based platform designed according to recommended functionalities and user-designed principles. Through three distinct modules, the LEAD Intervention will facilitate the advance care planning processes of 1) defining care recipients' values and preferences for care, 2) developing advance care planning congruence within the pair, or a shared understanding of the care recipient's values and preferences, through conversation(s), and 3) encouraging ongoing advance care planning conversation and documentation that can be shared beyond the pair. All modules will include video tutorials to introduce the goals and tasks as well as provide interactive resources to provide support and education relevant to the content of each module. The three modules are intended to be followed in a sequential pattern.
214870317|NCT00661011|PROCEDURE|Lobectomy followed by concomitant mediastinal chemoradiotherapy|Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
214870318|NCT05224934|RADIATION|ultra-hypofractionated radiotherapy|stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively
214870319|NCT04149795|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
214870320|NCT04313049|DEVICE|JACO2|Performing tasks using joystick control
214870321|NCT04313049|DEVICE|VOCAL CONTROL|Performing tasks using vocal control
214291031|NCT02480114|DRUG|Gabapentin|Given PO
214291032|NCT02480114|OTHER|Pain Therapy|Receive usual oral health care
214870322|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 .|
214870323|NCT01632761|DRUG|omega-3 fatty acids (fish oil)|
214870324|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
214870325|NCT01632761|DIETARY_SUPPLEMENT|Fish oil placebo|
214870326|NCT01177059|GENETIC|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
214870327|NCT06955429|DEVICE|Dental restorative or endodontic treatment requiring Biodentine XP use|In this observational and prospective study, the patients are included since this intervention is schedulded as part of their routine care.
214870328|NCT06989944|BEHAVIORAL|Physical Activity (PA) program|"Participants assigned to the PA-arm will participate in at least three weekly 30-minute sessions of PA for a total of 12 weeks.~The PA program will be tailored to individuals' characteristics, skills and preferences, based on information collected in connection with the baseline assessment and physical examination. A PA program could preview some forms of aerobic/relaxation/anaerobic exercises"
214870329|NCT06990113|OTHER|three dimensional lumbar myofascial release|Three-dimensional (3D) MFR is a novel approach toward reducing fascial restrictions. It recognizes that fascia exists not only in a linear plane but also in complex multidirectional networks throughout the body.
214870330|NCT06990113|OTHER|conventional treatment.|conventional treatment, including selected physical therapy, flexibility exercise for the back, static back and abdomen exercises, and electrotherapy
214870331|NCT06554873|DRUG|Nicoderm|Depending on responder status and group assignment the maximum amount of time nicotine patches will be used is 24 weeks. The final four weeks of nicotine patch treatment will comprise 2 weeks of 14 mg patches and two weeks of 7 mg patches.
214870332|NCT06554873|DRUG|Nicorette 4Mg Chewing Gum|4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 24 weeks.
214870333|NCT06554873|DRUG|Nicorette Lozenge Product|4mg Nicorette mint lozenge; as needed maximum usage 24 weeks.
214870334|NCT06554873|OTHER|NJOY e-cigarette|Each NJOY Classic Tobacco and Menthol pod is pre-filled with 1.9 mL of e-liquid with 5% nicotine (by weight); as needed maximum usage 24 weeks.
214870335|NCT06554873|OTHER|on!|4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 24 weeks.
214870336|NCT02616432|DEVICE|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
214870337|NCT05458882|BEHAVIORAL|"living with food allergy educational booklet"|An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
214870338|NCT03762044|OTHER|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|"* Health education / patient empowerment.~* Neurodynamic activities oriented to ADL.~* Proprioceptive neuromuscular facilitation exercises oriented to ADL.~* Self-adherent self-adhesive antiedema of low compression."
214870339|NCT03762044|OTHER|Complete Decongestive Therapy (CDT)|"* Skin care.~* Kinesitherapy~* Manual lymphatic drainage (MLD)~* Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments."
214870340|NCT04660240|DEVICE|Abluminus Sirolimus Eluting Stent System (ASES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the ASES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
214870341|NCT04660240|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the OSES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
214870342|NCT06123455|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 1.0 gram of taurine powder. Dosage: 2.0 gram/day. Frequency: 2 time/day.
214870343|NCT06123455|BIOLOGICAL|Sintilimab|Sintilimab
214291033|NCT02480114|OTHER|Quality-of-Life Assessment|Ancillary studies
214291034|NCT02480114|OTHER|Questionnaire Administration|Ancillary studies
214870344|NCT06123455|DRUG|XELOX regimen|Oxaliplatin + capecitabine
215057203|NCT01465386|DRUG|bortezomib|Given SC
214870345|NCT06123455|DRUG|SOX regimen|Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium)
214870346|NCT06123455|DRUG|FOLFOX regimen|Oxaliplatin + leucovorin + fluorouracil
214291035|NCT02480114|DRUG|Oxycodone/Acetaminophen|Analgesia
214291036|NCT02480114|DRUG|Hydrocodone/Acetaminophen|Analgesia
214291037|NCT02480114|DRUG|Fentanyl|Transdermal Analgesia
214291038|NCT02480114|DRUG|Ibuprofen|NSAID Analgesia
214291039|NCT02480114|DRUG|Magic Mouthwash|Oral Solution to treat mucositis
214870347|NCT00792961|DEVICE|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
214870348|NCT05830344|DEVICE|Placebo Multi Radiance Medical® Super Pulsed Laser|Placebo, without therapeutic dose.
214870349|NCT05830344|DEVICE|Active Multi Radiance Medical® Super Pulsed Laser|Active with a dose of 8.02 J per site.
214870350|NCT04905940|DRUG|Turmeric mouthwash|Turmeric mouthwash evaluation in controlling halitosis
214870351|NCT06202729|OTHER|Questionnaire|GAD-7, VAS-A, NRS
214870352|NCT05279911|RADIATION|low-level laser therapy (LLLT)|low-level laser therapy (LLLT) with dental implants has been suggested to improve bone quality during osseointegration. Low-level laser (Gallium Aluminum Arsenide Diode \[Ga-Al-As\]) (wavelength: 808 nm, average power density: 50 mW, circular spot diameter:0.71 cm, spot area: 0.4cm2) in continuous mode was applied in six points in contact with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before and immediately after suturing. The application points were divided into two points in the labial region where the implant would be placed (apical and cervical); two points in the lingual region (apical and cervical); and two points in the occlusal direction. After suturing the laser protocol was repeated in the same points following the same protocol, resulting in a total dose of 66 J for each application moment (before and after implant placement).
214870353|NCT05907239|DEVICE|Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.
214870354|NCT05907239|DEVICE|Placebo Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.
214870355|NCT06550739|OTHER|Randomization|Randomly divide the data into a training set and a validation set in a 7:3 ratio
214870356|NCT04003896|DRUG|Abemaciclib|"Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc."
214870357|NCT01843738|RADIATION|Radiation therapy|Per standard of care
214870358|NCT01843738|DRUG|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
214870359|NCT05092152|DRUG|Esketamine hydrochloride|2 mg per kilogram of body weight
214870360|NCT05092152|DRUG|Propofol|1.5 mg per kilogram of body weight
214870361|NCT02274506|DRUG|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
214870362|NCT02274506|DRUG|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
214870363|NCT02274506|PROCEDURE|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
214870364|NCT03104478|PROCEDURE|Biological samples collection|In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
214870365|NCT02026687|DRUG|Epidural|
214870366|NCT02026687|DRUG|Intrathecal|
214870367|NCT05861297|DRUG|Dexamethasone|Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months
214870368|NCT05861297|DRUG|Prednisolone and Azathioprine|the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.
214870369|NCT05861297|DRUG|Rituximab|The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month
214870370|NCT05861297|DRUG|Eltrombopag|The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months
214870371|NCT05861297|DRUG|Romiplostim|The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months
214870372|NCT01957397|DEVICE|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
214870373|NCT01957397|DEVICE|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
214870374|NCT01957397|DEVICE|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
214870375|NCT01857141|DRUG|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
215036095|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Exercise and Nutrition|During radiation, participants will attend in-person supervised resistance training sessions once a week for 7 weeks, followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks, after radiation. Sessions will last approximately 30 minutes. During radiation, participants will be provided 15 meals each week for 7 weeks, 105 meals total. Participants will be asked to participate in 1 weekly dietary coaching session (in-person during radiation and video conference following radiation), create weekly SMART goals, follow an alternative Mediterranean diet pattern, and log all meals, snacks, and supplements consumed for the 12-week intervention.
214870376|NCT01857141|DRUG|normal saline|patients in the control groups received the equivalent volume of normal saline.
214870377|NCT03043404|DEVICE|Transcatheter aortic valve replacement|TAVR with Lotus Valve Flex System
214870378|NCT00324649|DRUG|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
214870379|NCT00324649|DRUG|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
214870380|NCT00459121|DRUG|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
214870381|NCT00459121|DRUG|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
214870382|NCT00459121|DRUG|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
214870383|NCT00459121|PROCEDURE|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
215036096|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Nutrition Only|During chemoradiotherapy, participants will be provided 15 meals each week for 7 weeks (105 meals total) that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals (approximately 30 min). Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Trainers will monitor participants' Fitbit active minutes in real time throughout the intervention period and provide aerobic exercise encouragement accordingly.
215036097|NCT06642012|OTHER|Cash only|Households received 1 mobile cash transfer per month for 6 months.
215036098|NCT06642012|OTHER|Cash + Social Behavior Change Communication|Households received 1 mobile cash transfer per month for 6 months but mothers also received an SBCC package that included interpersonal communication (1:1 consultations for mothers), bi-monthly group sessions on key health and nutrition topics, and cooking demonstrations.
215036099|NCT06642012|OTHER|Cash + top-up cash|Households received 1 mobile cash transfer per month for 6 months, receiving the base cash amount plus an additional cash top-up amount.
215036100|NCT00754572|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
215036101|NCT00754572|DRUG|methotrexate|10-25mg oral or parenteral weekly.
215036102|NCT01864434|DEVICE|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
215036103|NCT01864434|DEVICE|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
215036104|NCT02071615|DRUG|Methylphenidate 20 mg tablet given once by mouth|3-arm, single-drug dosage comparison study
214291040|NCT02127879|DEVICE|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
214870384|NCT06031233|DRUG|Nivolumab|Gradual shortening of infusion times
214870385|NCT06031233|DRUG|Pembrolizumab|Gradual shortening of infusion times
214870386|NCT06031233|DRUG|Ipilimumab|Gradual shortening of infusion times
214870387|NCT06031233|DRUG|Durvalumab|Gradual shortening of infusion times
214870388|NCT06031233|DRUG|Atezolizumab|Gradual shortening of infusion times
214870389|NCT06031233|DRUG|Bevacizumab|Gradual shortening of infusion times
214870390|NCT06031233|DRUG|Trastuzumab|Gradual shortening of infusion times
214870391|NCT02315196|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
214870392|NCT02315196|DRUG|epirubicin hydrochloride|Given IV
214870393|NCT02315196|DRUG|carboplatin|Given IV
214870394|NCT02315196|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
214870395|NCT02315196|DRUG|paclitaxel|Given IV
214870396|NCT02315196|OTHER|laboratory biomarker analysis|Correlative studies
214870397|NCT02315196|OTHER|quality-of-life assessment|Ancillary studies
214870398|NCT04365777|OTHER|OAA/S=5|Prior to anesthesia induciton, EEG signatures will be recorded at Observer's Assessment of Alertness/Sedation (OAA/S) score of 5 (awake, eye-close state) for few minutes.
214870399|NCT04365777|OTHER|OAA/S=3|Given sedative anesthetics (propofol, midazolam or dexmetomidine), EEG signatures will be recorded after reaching steady state of OAA/S=3 (responds only after name called loudly and/or repeatedly) for few minutes.
214870400|NCT04365777|OTHER|OAA/S=1|Increasing drug concentration, EEG signatures will be recorded after reaching steady state of OAA/S=1 (does not respond to noxious stimuli) for few minutes.
214870401|NCT03058094|DRUG|Pemetrexed|Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.
214870402|NCT03058094|DRUG|Cisplatin 75mg/m2|Cisplatin will be administered as an intravenous infusion.
214870403|NCT03058094|DRUG|AC0010|300mg, orally, BID
214870404|NCT00470067|DRUG|carboplatin|IV
215036105|NCT02071615|DRUG|modafinil 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
214870405|NCT00470067|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
214870406|NCT04770467|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
214870407|NCT04770467|DRUG|Placebo|Placebo given by intravenous administration
214870408|NCT04164225|BEHAVIORAL|Qigong Exercise|"Participants with chronic low back pain will follow the free 5 elements Qigong healing class (estimate of 6 hours) at the Spring Forest Qigong center and then practice the 5 elements healing Qigong at home 3 times a week for 40 minutes with a freely available online video, for 12 weeks. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed."
214870409|NCT04164225|BEHAVIORAL|P.Volve Exercises|P.Volve exercise focuses on low impact core strengthening, core stabilization, and stretching. The program is similar in delivery as Qigong (i.e., online videos). An introductory class (estimate of 2.5h) will be given by the P.Volve team, the principal investigator, and a physical therapist who has experience with P.Volve exercises. Participants will access online videos for individual home practice in 40min/session, 3x/week for 12 weeks. Participants will receive a P.ball for some exercises, while other exercises are done with no equipment. Tailored videos will be available for those with cLBP. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.
214870410|NCT05974436|OTHER|Blood and dialysate sampling|"Blood is sampled from the inlet and outlet dialyzer bloodline at 5min after dialysis start.~Spent dialysate is sampled from the outlet dialysate line at 5, 30, 90 and 240min after dialysis start.~Blood and dialysate samples are analysed for different uremic toxins. Dialysis efficiency is calculated from the analysed toxin concentrations."
214870411|NCT00246142|BIOLOGICAL|Botulinum toxin type A|
214870412|NCT03924206|DEVICE|Smoke evacuation system|The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated
214870413|NCT00005983|RADIATION|radiation therapy|
214870414|NCT00005983|PROCEDURE|surgery|surgery
214870415|NCT04260971|DEVICE|Abbott St Jude Medical Infinity 7 neurostimulator|The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study
215036106|NCT02071615|DRUG|caffein 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
215036107|NCT02071615|DRUG|placebo|
215036108|NCT00998010|DRUG|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
214665729|NCT05947019|DEVICE|Myopic amblyopia comprehensive treatment instrument|Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.
214870416|NCT04764136|DEVICE|Scoliometer (scolioscope)|Individuals with scoliosis will participate in this study. The device will be used to determine spinal rotation on the transverse plane. Repeated measures will be taken.
215036109|NCT00982384|OTHER|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
215036110|NCT00982384|OTHER|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
215036111|NCT03758807|OTHER|Manual Therapy with Traditional Biomechanical Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..
215036112|NCT03758807|OTHER|Manual Therapy with Neuroplastiicity Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
215036113|NCT05751759|DRUG|Mitiperstat|Participants receive mitiperstat orally.
215036114|NCT05835154|BEHAVIORAL|Assessment|Complete checklist
215036115|NCT05835154|OTHER|Questionnaire Administration|Complete questionnaires
215036116|NCT05835154|OTHER|Interview|Undergo semi-structured feedback interview
215036117|NCT05835154|OTHER|Electronic Health Record Review|Review of medical records
215036118|NCT03683251|DRUG|PDS Implant with Ranibizumab 100 mg/mL|Will be administered as per the schedule described in individual arm
214665730|NCT05947019|DEVICE|Glasses|Optometry with glasses as a routine treatment
214870417|NCT04558268|DRUG|Prednisone|"Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders."
215036119|NCT04484818|DRUG|Darolutamide|Given PO
214665731|NCT05771922|DIAGNOSTIC_TEST|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
214870418|NCT04558268|DRUG|Progesterone|"Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy."
215036120|NCT04484818|DRUG|Goserelin Acetate|Given via injection
215036121|NCT04484818|DRUG|Leuprolide Acetate|Given IV
215036122|NCT04484818|DRUG|Placebo Administration|Given PO
215036123|NCT04484818|OTHER|Quality-of-Life Assessment|Ancillary studies
215036124|NCT04484818|DRUG|Triptorelin|Given via injection
215036125|NCT04799275|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215036126|NCT04799275|DRUG|Cyclophosphamide|Given IV
215036127|NCT04799275|DRUG|Doxorubicin Hydrochloride|Given IV
215036128|NCT04799275|DRUG|Oral Azacitidine|Given PO
215036129|NCT04799275|DRUG|Prednisone|Given PO
215036130|NCT04799275|OTHER|Questionnaire Administration|Ancillary studies
215036131|NCT04799275|BIOLOGICAL|Rituximab|Given IV or SC
215036132|NCT04799275|DRUG|Vincristine Sulfate|Given IV
215036133|NCT06388564|DRUG|Axatilimab|Axatilimab will be administered at protocol defined dose.
214870419|NCT04558268|DIETARY_SUPPLEMENT|vit D|Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
214870420|NCT04558268|DIETARY_SUPPLEMENT|Iron Supplement|Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
214870421|NCT04558268|DIETARY_SUPPLEMENT|Folic Acid|"Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer."
214870422|NCT04098289|PROCEDURE|Hysteroscopic septum resection|Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.
214870423|NCT04098289|PROCEDURE|In vitro fertilization|Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
214870424|NCT04917289|DRUG|Chemotherapy|Started chemotherapy or change the current adjuvant therapy
214870425|NCT01290562|RADIATION|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
214870426|NCT01584557|DRUG|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
214870427|NCT01584557|DRUG|placebo or sugar pill|sugar pill
214870428|NCT05539430|BIOLOGICAL|LB1908|Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells
214870429|NCT00326560|PROCEDURE|Pterygium excision and conjunctival autograft|
214870430|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
214870431|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
214870432|NCT01366430|PROCEDURE|Gufoni|For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
214870433|NCT01366430|PROCEDURE|Sham|The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
214870434|NCT01366430|PROCEDURE|Barbecue|For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
214870435|NCT01397643|OTHER|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
215036134|NCT06388564|DRUG|Ruxolitinib|Ruxolitinib will be administered at protocol defined dose.
215036135|NCT06388564|DRUG|Corticosteroids|Corticosteroids will be administered at protocol defined dose.
215036136|NCT05700643|DIETARY_SUPPLEMENT|Montmorency cherry supplement|Montmorency cherry supplement
214870436|NCT01397643|OTHER|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
214870437|NCT04197050|DRUG|Sacubitril / Valsartan Oral Tablet|After recruiting participants and collecting the baseline information, sacubitril/valsartan group will receive sacubitril/valsartan and optimal pharmaceutical treatment (OPT). The control group will receive valsartan and OPT. A CMR scan and a post-processed imaging procedure will later be carried on in order to detect the cardiac impairment.
214870438|NCT01045538|DRUG|Vorinostat, capecitabine, and cisplatin|Vorinostat 200\~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
214870439|NCT03717025|PROCEDURE|SUCTION BLISTER EPIDERMAL GRAFTING|"1. Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~2. Blister formation is induced by using suction apparatus.~3. Recipient site is surgically prepared by doing dermabrasion.~4. After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~5. The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~6. The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~7. Donor area is dressed with dry sterile pads.~8. The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days)."
215036137|NCT05700643|DIETARY_SUPPLEMENT|Control|Placebo
214291041|NCT02127879|DEVICE|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
214665732|NCT04848805|PROCEDURE|liver transplantation|total hepatectomy material was examined by pathology laboratory
215036138|NCT04710264|OTHER|AURORA-Rec|Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.
215036139|NCT05948540|DRUG|Intervention C Daridorexant|Daridorexant will be administered 50 mg once daily at least 2 hours after the last meal and within 30 minutes of going to bed.
215036140|NCT05948540|DRUG|Intervention C Placebo|A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
215036141|NCT04914845|DRUG|KPT-9274|KPT-9274 is a first-in-class orally bioavailable, non-competitive, small molecule, dual modulator of p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase /PBEF/visfatin (NAMPT). NAMPT is the rate-limiting enzyme in the metabolic scavenging pathway that utilizes nicotinamide to replenish nicotinamide adenine dinucleotide (NAD), an essential metabolic cofactor and second messenger. Recent investigations have shown that in in vitro and in vivo models, NAMPT is uniquely essential for relapsed or refractory AML stem cells. Targeting relapsed AML stem cells, through targeting of NAMPT, may allow for a promising therapeutic opportunity for patients with relapsed or refractory AML.
215036142|NCT06245863|DEVICE|Negative pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 milliwatts (mW) per laser. Vacuum therapy: 60 mm suction cup, pulsed mode (MP9, 50 pulsations per minute) and pressure of -150 at -350 mbar. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
215036143|NCT06245863|DEVICE|Positive Pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Positive Pressure: Massage with rollers. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
215036144|NCT06245863|DEVICE|Ultrasound and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Ultrasound: 1 megahertz (MHz), continuous mode and 1 milliwatts per square centimeter (mW/cm2). The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
215036145|NCT06245863|DEVICE|Laser|Infrared Laser (808 nm), continuous mode, 100 mW. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
215036146|NCT06245863|DEVICE|Placebo Laser|Laser: off mode. The placebo treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
215036147|NCT03681145|BEHAVIORAL|Counselor delivered telehealth intervention|This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
215036148|NCT03890094|DRUG|Sufentanil|Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
215036149|NCT00750399|DRUG|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
215036150|NCT00750399|DRUG|ranibizumab|intravitreal ranibizumab 0.5 mg
215036151|NCT05134649|DRUG|OnabotulinumtoxinA|Intramuscular Injection
215036152|NCT05443828|OTHER|Breakfast Control Meal|The participants consumed extruded puff with added vitacel (cellulose) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
215036153|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed bread with added arabynoxylans (AX) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
214291042|NCT00664391|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
215036154|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed extruded puff with added wheat bran as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
215036155|NCT06295809|BIOLOGICAL|Pembrolizumab|IV Infusion
215036156|NCT06295809|BIOLOGICAL|Intismeran autogene|IM injection
215036157|NCT06295809|PROCEDURE|Surgery|Local resection of cancerous lesions of the skin
215036158|NCT04157335|BIOLOGICAL|Benralizumab 30 mg|"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).~For OLE, Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses and every 8 weeks for the rest 5 doses. For the patients on Benralizumab treatment during double blind period, placebo will be dosed at the second dose during OLE."
214291043|NCT01627522|PROCEDURE|TURP|Transurthral resection of prostate
214291044|NCT01535053|BIOLOGICAL|Dactinomycin|Given IV
214291045|NCT01535053|DRUG|Leucovorin Calcium|Given PO
214291046|NCT01535053|DRUG|Methotrexate|Given IV and IM
214291047|NCT01535053|OTHER|Quality-of-Life Assessment|Ancillary studies
214291048|NCT02303301|DIETARY_SUPPLEMENT|Probiotics|Cultures from the oropharynx
214291049|NCT02303301|DIETARY_SUPPLEMENT|Placebo|Cultures from the oropharynx
214291050|NCT06087107|OTHER|High Intensity Spinal Decompression Exercises|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes with 8-10 repetitions of each exercise.
214291051|NCT06087107|OTHER|Eldoa|The duration of the intervention will be 4 weeks, 3 sessions a week, and a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes.
214291052|NCT04671550|DIAGNOSTIC_TEST|questionnaire|"Questionnaire on Driving performances and Visual Field"
214665733|NCT03022461|OTHER|Long term follow-up|
214665734|NCT01639183|DEVICE|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
214665735|NCT01639183|OTHER|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
214870440|NCT03717025|PROCEDURE|MINI PUNCH GRAFTING|"1. Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~2. The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~3. The donor area is either upper lateral portion of thigh or gluteal region.~4. Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~5. Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~6. For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~7. For the donor area only surgipad and micropore are used.~8. Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days)."
214870441|NCT03717025|PROCEDURE|NON CULTURED EPIDERMAL CELL SUSPENSION|"1. About one-tenth the size of recipient area is selected as the donor site.~2. Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~3. The area is dressed with Bactigras gauze.~4. Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~5. Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~6. Epidermal cell suspension is carefully transferred to a tuberculin syringe.~7. With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~8. This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~9. The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal."
214870442|NCT05362838|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
214870443|NCT05362838|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
214870444|NCT00196924|BIOLOGICAL|HPV-16/18 L1/AS04|
214870445|NCT05408234|OTHER|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
214870446|NCT03156335|DEVICE|Focused Ultrasound|MR-guided Focused Ultrasound (MRgFUS) offers the possibility of lesioning deep brain targets, while obviating the need for open surgical approaches. There is no radiation, incision, or burr hole, and lesions are generated in real-time under MR image guidance. Intracranial FUS for other applications, essential tremor most notably, has been shown to be safe and effective, recently receiving Health Canada approval for this indication. The technology, methods and procedures used in this study are identical to those in essential tremor.
214870447|NCT03552835|PROCEDURE|no caries removal|occlusal caries were treated with no caries removal and placement of stainless steel crown
214870448|NCT03552835|PROCEDURE|partial caries removal upto soft dentin|occlusal caries were treated by partial caries removal upto soft dentin followed by Glass Ionomer Cement placement as a base and composite restoration
214870449|NCT03552835|PROCEDURE|partial caries removal upto firm dentin|occlusal caries were treated by partial caries removal upto firm dentin followed by Glass Ionomer Cement placement as a base and composite restoration
214870450|NCT05763108|DIAGNOSTIC_TEST|genetic test|COL1A1 or COL5A1 genetic test
214870451|NCT05763108|OTHER|Beighton joint laxity test|Based on Beighton scale.
214870452|NCT03555006|OTHER|"Dual ultrasound reading local vs remote"|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.
214870453|NCT03555006|OTHER|"Dual ultrasound reading local vs local"|The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
214870454|NCT04758975|DRUG|Venetoclax|VENETOCLAX: Ramp-up than 400 mg QD
214870455|NCT04758975|DRUG|Rituximab|RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
214870456|NCT04758975|DRUG|Ibrutinib|IBRUTINIB 420 mg QD
214870457|NCT02469259|DRUG|Oxytocin|
214665736|NCT02341612|OTHER|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
214665737|NCT02341612|OTHER|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
214665738|NCT02341612|OTHER|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
214870458|NCT02469259|OTHER|Placebo|
214870459|NCT02984085|DRUG|Genetically corrected cultured epidermal autograft (ATMP)|"Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.~By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery."
214870460|NCT02535871|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
215036159|NCT04157335|BIOLOGICAL|Matched placebo|"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
215036160|NCT05723640|DRUG|177Lu-LNC1004 Injection group 1 radionuclide therapy|The treatment regimen will consist of a single dose 30mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
215036161|NCT05723640|DRUG|177Lu-LNC1004 Injection group 2 radionuclide therapy|The treatment regimen will consist of a single dose 60mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
215036162|NCT05723640|DRUG|177Lu-LNC1004 Injection group 3 radionuclide therapy|The treatment regimen will consist of a single dose 80mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
215036163|NCT05723640|DRUG|177Lu-LNC1004 Injection group 4 radionuclide therapy|The treatment regimen will consist of a single dose 100mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
215036164|NCT03162536|DRUG|Nemtabrutinib|Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
215036165|NCT05050162|DRUG|Cisplatin|Given cisplatin IV every 3 weeks
215036166|NCT05050162|DRUG|Cisplatin|Given cisplatin IV weekly
215036167|NCT05050162|PROCEDURE|Computed Tomography|Undergo CT scan
215036168|NCT05050162|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215036169|NCT05050162|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214870461|NCT02535871|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
215036170|NCT05050162|OTHER|Quality-of-Life Assessment|Ancillary studies
215036171|NCT05050162|OTHER|Questionnaire Administration|Ancillary studies
214870462|NCT00446537|PROCEDURE|Methylphenidate|
214870463|NCT04918498|BEHAVIORAL|early physiotherapy programs|establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy
215036172|NCT05050162|RADIATION|Radiation Therapy|Undergo radiation therapy
215036173|NCT05348876|DRUG|Darolutamide (Nubeqa, BAY1841788)|600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
215036174|NCT06103838|DRUG|18F-fluciclovine injection|370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.
215036175|NCT06103838|PROCEDURE|18F-FDG PET/CT|All participants will undergo 18F-FDG PET/CT within 30 days of the 18F-fluciclovine PET/CT scan
215036176|NCT05867251|DRUG|AVZO-021|AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)
214870464|NCT04918498|BEHAVIORAL|routine treatment|provide routine nursing and rehabilitation program
214870465|NCT00883909|DRUG|dutasteride|A follow-up study in adult male subjects who have received investigational product
215036177|NCT05867251|DRUG|Palbociclib|Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor
215036178|NCT05867251|DRUG|Fulvestrant|Antineoplastic agent, estrogen receptor antagonist
215036179|NCT05867251|DRUG|Letrozole|Antineoplastic agent, aromatase inhibitor
215036180|NCT05867251|DRUG|Ribociclib|Antineoplastic CDK4/6 inhibitor
215036181|NCT05867251|DRUG|Abemaciclib|Antineoplastic CDK4/6 inhibitor
215036182|NCT05867251|DRUG|Carboplatin|Alkylating agent
215036183|NCT05867251|DRUG|Sacituzumab Govitecan-hziy|Trop-2 antibody and topoisomerase inhibitor
214870466|NCT02485171|DEVICE|SAFEWALKER|Medical device walking aids.
214870467|NCT04930419|DEVICE|Videolaryngoscopy group|Tracheal intubation will be performed using Videolaryngoscope in first intention and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
215036184|NCT04628494|BIOLOGICAL|Epcoritamab|Following mandatory pre-medication, participants will be administered epcoritamab as a subcutaneous injection.
215036185|NCT04628494|DRUG|Investigator's Choice Chemotherapy|Following mandatory pre-medication, participants will be administered intravenously either BR or R-GemOx.
215036186|NCT05623722|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.
215036187|NCT03728478|DRUG|Etanercept|Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
215036188|NCT03728478|DRUG|Methotrexate|Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
215036189|NCT03728478|DRUG|Intra-articular corticosteroid injections|Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
215036190|NCT05862285|DRUG|Ipatasertib|Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
214870468|NCT04930419|DEVICE|Direct laryngoscopy group|Tracheal intubation will be performed using Direct laryngoscopy with Macintosh blades in first intention. and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
214870469|NCT02212613|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
214870470|NCT00095316|DRUG|Caspofungin|Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
215036191|NCT05862285|DRUG|Tiragolumab|Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
215036192|NCT05862285|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.
215036193|NCT05862285|DRUG|Tiragolumab and Atezolizumab|Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
215036194|NCT05862285|DRUG|Bevacizumab|Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
215036195|NCT05862285|DRUG|Entrectinib|Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
215036196|NCT05862285|DRUG|Inavolisib|Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
215036197|NCT03308474|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
215036198|NCT04543591|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
215036199|NCT04543591|OTHER|Placebo|Matching placebo
215036200|NCT04543591|OTHER|Best supportive care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
215036201|NCT01385826|DRUG|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
215036202|NCT01385826|DRUG|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
215036203|NCT06100172|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS). Use of tAN for pain relief is an attractive alternative to pharmacologic and opioid-based approaches because it is safe and effective and presents no addiction liability.
215036204|NCT06100172|DEVICE|Sham Control Device|This device looks like the active device, but no stimulation will be delivered.
215036205|NCT04983394|OTHER|Virtual Realty Exercises|motion-controlled video game
215036206|NCT04983394|OTHER|conventional exercises|aerobic, strength, stretching, and neuromuscular exercises
215036207|NCT03270982|DEVICE|Comprehensive SRS Replacement|This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
215036208|NCT01559935|DRUG|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
215036209|NCT01559935|DRUG|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
214665739|NCT02341612|OTHER|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
214665740|NCT02341612|OTHER|passive recovery|The control group was exposed to treatment after the EIMD protocol.
214665741|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
214665742|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
214870471|NCT00095316|OTHER|Placebo|Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
215036210|NCT01559935|DRUG|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
215036211|NCT01559935|DRUG|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
215036212|NCT01559935|DRUG|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
215036213|NCT01559935|DRUG|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
215057204|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 15 opioid tablets for post-operative pain
215057205|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 25 opioid tablets for post-operative pain
215057206|NCT04278703|DRUG|oxycodone|Patients will be given a prescription for 35 opioid tablets for post-operative pain
215036214|NCT05562947|DEVICE|PDS With Ranibizumab (100 mg/mL)|Participants randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 microliters (μL) of the 100-mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for participants randomized to the IVT arm. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed 24-week intervals.
214870472|NCT03839823|COMBINATION_PRODUCT|Docetaxel / Capecitabine|"Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)"
214870473|NCT03839823|COMBINATION_PRODUCT|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day \[oral\] or (25 to 30 mg/m2 \[IV infusion\]"
214870474|NCT03839823|COMBINATION_PRODUCT|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)"
214870475|NCT03839823|DRUG|Ribociclib|Dose: 600 mg (200 mg \* 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
215036215|NCT05562947|DRUG|Ranibizumab (10 mg/mL)|Participants in the IVT arm will receive their first IVT injection of 50 μL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, participants will receive IVT ranibizumab injections of 50 μL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44.
215036216|NCT06329635|DRUG|Intrathecal Nicardipine|First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.
215036217|NCT06329635|OTHER|No intervention|"A simulated intrathecal administration operation is performed by a dedicated physician who is unblinded to the group assignment, the EVD or LD tube is not opened, and no drug is given. The simulated administration process needs to be out of the patient's view (if awake patient) and out of the presence of study team personnel."
215036218|NCT04873362|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.
215036219|NCT04873362|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
215036220|NCT04873362|DRUG|Placebo|Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
215036221|NCT04873362|DRUG|Trastuzumab|Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
215036222|NCT01916018|OTHER|Clinical and radiologic exams and blood samples|
215036223|NCT06493318|PROCEDURE|Dorsal ligamentoplasty reinforced with an internal brace|After a longitudinal dorsal incision of the wrist, an ECRB (extensor carpi radialis brevis) or palmaris longus hemi-tendon is harvested. The scapholunate positioning is adjusted using joystick pins. A 2.5 mm blind tunnel is made in the lunate and two 2.5 mm blind tunnels are made in the proximal and distal poles of the scaphoid. The tendon graft is threaded using a fiberloop and reinforced with suture tape. The graft is fixed in the proximal pole of the scaphoid with a swive-lock anchor (Arthrex®), then in the lunate, and finally fixed in the distal pole of the scaphoid by the same method. An anti-rotation scapho-capitate pin is then placed. This is maintained for 6 weeks during post-operative immobilization with a wrist orthosis. Rehabilitation begins after the pin is removed.
215036224|NCT01431430|DRUG|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
215036225|NCT01431430|DRUG|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
215036226|NCT04416724|PROCEDURE|Phacoemulsification|Lens removal by Phacoemulsification
215036227|NCT04416724|DEVICE|Selective Laser Trabeculoplasty|Laser application in trabecular meshwork
215036228|NCT05379153|DEVICE|Laser Therapy|Undergo vaginal fractional CO2 laser therapy
215036229|NCT05379153|DEVICE|Sham Intervention|Undergo placebo procedure
215036230|NCT05379153|OTHER|Questionnaire Administration|Ancillary studies
215036231|NCT05379153|OTHER|Quality of Life Assessment|Ancillary studies
215036232|NCT03186898|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215036233|NCT03186898|PROCEDURE|Computed Tomography|Undergo CT scan
215036234|NCT03186898|OTHER|Laboratory Biomarker Analysis|Correlative studies
215036235|NCT03186898|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215036236|NCT03186898|OTHER|Quality-of-Life Assessment|Ancillary studies
215036237|NCT03186898|RADIATION|Radiation Therapy|Undergo proton therapy
215036238|NCT03186898|RADIATION|Radiation Therapy|Undergo photon therapy
215036239|NCT05335031|DRUG|Ozanimod|As per product label
215036240|NCT05255900|DRUG|Metyrapone Capsules|Exposure to 24 weeks of treatment with metyrapone
214665743|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
214665744|NCT05124275|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
214665745|NCT05829057|BIOLOGICAL|Intravenous injection of P-IL-2|Ia :Single dose intravenous injection of P-IL-2；
215036241|NCT02958865|DRUG|PF-06651600 or Placebo|Delivered orally for 8 weeks.
215036242|NCT02958865|DRUG|PF-06700841 or Placebo|Delivered orally for 8 weeks.
215036243|NCT02958865|DRUG|PF-06700841|Delivered orally for 24 weeks.
215036244|NCT02958865|DRUG|PF-06651600|Delivered orally for 24 weeks.
215057207|NCT05741892|DEVICE|Fracture reposition with 3D printed patient specific repositions guides|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
215036245|NCT00694590|DRUG|plerixafor|"Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.~Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses."
214870476|NCT03839823|DRUG|Letrozole OR Anastrozole|"Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician."
214870477|NCT03839823|DRUG|Goserelin|"Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant"
214870478|NCT05144490|OTHER|Exercise|A single session of bodyweight exercise
215036246|NCT01929603|PROCEDURE|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
215036247|NCT01929603|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
215036248|NCT01929603|DRUG|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
215036249|NCT01596270|DRUG|SAR245409|Pharmaceutical form: tablet Route of administration: oral
215036250|NCT06343623|PROCEDURE|myomucosal resection and direct closure|myomucosal resection and direct closure
214291053|NCT04692571|DEVICE|PSICON Measurement Apparatus|Test apparatus acquires 16 sEMG channels, measure four DoFs of force/moment at the hand-wrist \[hand open-close (Opn-Cls); wrist extension-flexion (Ext-Flx), radial-ulnar deviation (Rad-Uln) and pronation-supination (Pro-Sup)\]. sEMG system used 16 custom encased bipolar electrodes. A commercial LTI EMG amplifier (BE328) conditioned each EMG signal before A/D conversion on a PC. A thermoplastic hand cuff secured the wrist to a six-axis load cell (AMTI, model MC3A-100) for force/moment measurement. A separate hand-grasp one-axis load cell (Omega Engineering Inc., model LCR-150) was Velcro-secured between the fingers and the thumb, to measure power grip forces. The PC acquired and stored the sEMG and load cell data, and commanded a triangular screen target. The subject controlled a second triangular cursor. Left-right movement of the cursor was controlled by wrist Ext-Flx, up-down movement by Rad-Uln deviation, cursor rotation by Pro-Sup and cursor size by hand Opn-Cls forces.
214291054|NCT00512707|DRUG|Sildenafil citrate (open label)|On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
214665746|NCT05829057|BIOLOGICAL|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
214870479|NCT00527553|DIETARY_SUPPLEMENT|not enriched egg|daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
214870480|NCT00527553|DIETARY_SUPPLEMENT|lutein|daily lutein enriched egg
214665747|NCT01978561|BIOLOGICAL|Post dosing with NT100|
214665748|NCT01978561|OTHER|Post dosing with Placebo|
214870481|NCT00527553|DIETARY_SUPPLEMENT|zeaxanthin|daily zeaxanthin enriched egg
214870482|NCT00527553|DIETARY_SUPPLEMENT|egg product from enriched eggs|daily egg product from lutein enriched eggs
214870483|NCT03849287|DRUG|CKD-333, formula I|Test drug
215036251|NCT06343623|PROCEDURE|superiorly based flap|superiorly based pharyngeal flap
214870484|NCT03849287|DRUG|CKD-333, formula II|Test drug
215036252|NCT03591159|OTHER|Membran Sweeping|Cervical Membrane Sweeping by digital examination
215036253|NCT02969577|BEHAVIORAL|Exercise Program|Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.
215036254|NCT02969577|BEHAVIORAL|Diet and Nutrition Coaching|Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.
215036255|NCT02969577|OTHER|Usual Care with Attention|Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
215036256|NCT01017900|PROCEDURE|local excision|surgical excision by orthopaedic surgeon under local anesthesia
215057208|NCT02945124|OTHER|K tape|Applying K tape to children to the lower limb muscles during motor activities.
214870485|NCT03849287|DRUG|CKD-330, D090|Reference Drug
214870486|NCT04436887|PROCEDURE|positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia|Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies \>20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
214870487|NCT05727371|COMBINATION_PRODUCT|Regen Matrix-PRP-XLHA|Single intra-articular injection at Day 0
215057209|NCT00219596|DRUG|Xalacom|
215057210|NCT00219596|DRUG|unfixed Latanoprost and Timolol|
215057211|NCT04452123|PROCEDURE|Laparoscopic argon plasma treatment of endometrioma|Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
215036257|NCT03812848|OTHER|Anticoagulation Stewardship Program|"A clinical-pharmacist led anticoagulation stewardship program that includes:~1. Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients."
215036258|NCT04198012|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
215036259|NCT04869397|BIOLOGICAL|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|"The product is provided cryopreserved by NextCell Pharma. The cells are frozen in cryobags at a concentration of 2 × 107 cells/ml in 5% Human Serum Albumin (HSA) and 10% dimethylsulfoxide (DMSO). One cryobag contains one dose. The bags are frozen in a controlled rate freezer and directly transferred to -190 ºC for storage until the time of infusion.~Cryobags are thawed at bedside and diluted in 100 ml of saline prior to administration. Cells will be delivered at a rate of 5 million cells per minute over a total of 20 minutes."
214870488|NCT05727371|DEVICE|Hylan G-F 20|Single intra-articular injection at Day 0
214870489|NCT05727371|DRUG|Placebo|Single intra-articular injection at Day 0
214870490|NCT02107365|DRUG|Asunaprevir|Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
214870491|NCT02107365|DRUG|Daclatasvir|Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
215036260|NCT04869397|OTHER|Placebo|Sodium chloride buffer supplemented with 5% HSA and 10% DMSO same volume and mode of administration as treatment group
215057212|NCT04452123|PROCEDURE|Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary|Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
214870492|NCT02107365|DRUG|Ribavirin|Ribavirin tablets or capsules 200 mg, weight-based daily dose ( \<75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
214870493|NCT02107365|DRUG|Pegylated Interferon alpha-2a|Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
214870494|NCT03453801|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
214870495|NCT03453801|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
214870496|NCT01348412|DRUG|oxaliplatin|130 mg/m²Every 21 days
214870497|NCT01348412|DRUG|raltitrexed|3 mg/m² with a maximum of 6 mg every 21 days
214665749|NCT04396587|DRUG|Sufentanil|Sufentanil(0.1μg/kg) was administered before anesthesia induction.
214870498|NCT01348412|DRUG|other intravenous chemotherapy drugs|
214870499|NCT02976324|DEVICE|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
214870500|NCT00010621|PROCEDURE|Acupuncture|
214870501|NCT00010621|PROCEDURE|chiropractic therapy|
214870502|NCT00010621|PROCEDURE|bodywork therapy|
214870503|NCT02459535|OTHER|oral stimulation glucose|oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
214870504|NCT02459535|OTHER|oral stimulation saccharin|
214870505|NCT02459535|OTHER|oral stimulation aspartame|
214870506|NCT02459535|OTHER|oral stimulation sucralose|
214870507|NCT04675619|DRUG|Oral pirfenidone|Treatment
214870508|NCT04675619|DRUG|Standard care|Treatment
214870509|NCT03908879|PROCEDURE|Standard intraosseous (IO) catheter confirmation procedure|The physician will evaluate the ability or inability of the intraosseous (IO) catheter to stand upright unassisted, the ability or inability to aspirate blood or bone marrow from the IO catheter, and whether or not there is visible or palpable extravasation of infusate from the IO catheter insertion site or surrounding subcutaneous tissue during IO catheter use.
214870510|NCT03908879|PROCEDURE|Color flow Doppler intraosseous (IO) catheter confirmation procedure|The high frequency probe of a portable ultrasound with color flow Doppler is placed adjacent to the intraosseous (IO) catheter, visualizing the IO space in long or short axis. Color flow Doppler signal will be turned on during IO use and the physician will determine if the Doppler signal is in the intraosseous space or the extraosseous space. Saved data of the ultrasound image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
214870511|NCT03908879|PROCEDURE|Pressure transduction intraosseous (IO) catheter confirmation procedure|The intraosseous (IO) catheter will be attached to a pressure transducer to demonstrate a waveform on the telemetry monitor. Physicians will evaluate for the presence of a pulsatile waveform with objective measurements of a systolic pressure, diastolic pressure and mean pressure. Saved data of the waveform image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
214870512|NCT01410500|DRUG|Carfilzomib|Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
214870513|NCT00735306|DRUG|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
215036261|NCT05227157|OTHER|swab with iron sulfate solution|measurement of the intensity of perception of metallic taste by affixing a swab iron sulfate solution 10g/l at 4 places on the tongue depending on the glossopharyngeal nerve: tip of the tongue (right and left); base of the tongue (right and left). Visual analogic Scale (0 to 5)
214870514|NCT00735306|DRUG|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
214870515|NCT00735306|RADIATION|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
214870516|NCT00304837|GENETIC|pVGI.1 (VEGF-2)|
214870517|NCT05228028|PROCEDURE|fascia iliaca compartement block|Ultrasound-guided suprainguinal FICB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
214870518|NCT05228028|PROCEDURE|quadratus lumborum block|Ultrasound-guided anterior QLB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
214870519|NCT04169542|OTHER|Questionnaire Administration|Complete questionnaires
214870520|NCT01517373|DRUG|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
214870521|NCT01517373|DRUG|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
214870522|NCT01517373|DRUG|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
214870523|NCT01517373|DRUG|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
214870524|NCT01517373|DRUG|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
214870525|NCT06621004|DRUG|Patients will receive propranolol 1-2 mg.|Patients will receive propranolol 1-2 mg. prepared in a 10 ml syringe (100 ug/ml).
214870526|NCT06621004|DRUG|Patient receives magnesium sulphate|Magnesium sulphate 10%: 1g ampoule (10ml), will be prepared in a syringe pump to be given at a rate of 40 ml/hr . Another syringe of 10 ml 0.9% sodium chloride will be prepared to be given in group (P).
214870527|NCT00759850|DEVICE|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
214870528|NCT02444117|OTHER|functional rehabilitation of social communication|
215036262|NCT06035731|OTHER|SOCIO-AESTHETICS care|SOCIO-AESTHETICS well being care performed by qualify person
214870529|NCT01001624|OTHER|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
215036263|NCT06314347|DIAGNOSTIC_TEST|Figure of 8 walk test|clinical measurement
215036264|NCT05657847|DEVICE|Photon-counting detector-CT|CT scan
215057213|NCT02018029|OTHER|cardiac resynchronisation therapy|
214870530|NCT01001624|OTHER|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
214291055|NCT00512707|DRUG|Testosterone gel|Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
214291056|NCT00512707|OTHER|Placebo gel|3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
214291057|NCT02642328|OTHER|HIIT Training|Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
214291058|NCT02642328|OTHER|Control|Continuous aerobic exercise at 65% of VO2Max
214870531|NCT05487534|OTHER|Observational|The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.
214870532|NCT04297319|PROCEDURE|Laser diiodo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.
214870533|NCT04297319|PROCEDURE|Laser Placebo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.
214870534|NCT02651259|DRUG|Rifapentine (RPT)|900 mg of RPT
214870535|NCT02651259|DRUG|Isoniazid (INH)|900 mg of INH
214870536|NCT02651259|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
214870537|NCT03756506|DEVICE|Novel Microbicidal Liquid Polymer|The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
214291059|NCT02044705|BEHAVIORAL|Active and Healthy Families|Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
214665750|NCT04396587|DRUG|Hydromorphone|Hydromorphone(20μg/kg)was administered before anesthesia induction.
214870538|NCT04470687|DEVICE|contrast enhanced ultrafast ultrasound imaging|"Ultrasound contrast medium: SonoVue 8µL/mL (Bracco International BV) Ultrasound scanner: Aixplorer® device marketed by SuperSonic Imagine©, CE Doppler UltraFast™Doppler, contrast ultrasound (CEUS), color Doppler and ultra-sensitive energy Doppler, high-performance directional energy Doppler, Elastography ShearWave™ UF-Doppler (UltraFast-Doppler) and microbubble injection (SonoVue) Apparatus for performing the UF Doppler sequence: Aixplorer, manufacturer : Supersonic Imagine, Aix-en-Provence, France, CE Marking.~3D RCA dedicated vascular probe with dedicated Doppler sequences"
214870539|NCT03293407|DRUG|Iloprost (Ventavis, BAYQ6256)|Using Breelib device
215036265|NCT06510374|DRUG|Nadofaragene Firadenovec|Vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification.
215036266|NCT00318617|DRUG|GW510516X|
214870540|NCT03293407|DEVICE|Breelib nebulizer|Used for inhalation of Ventavis
214870541|NCT03678285|OTHER|HIFRT Workout|A single high intensity functional resistance training (HIFRT) exercise bout.
214870542|NCT06426615|DEVICE|Intracranial electrodes|Placement of intracranial electrodes in the cortico-subcortical system
214870543|NCT00534807|DRUG|Vinflunine|
214870544|NCT00534807|DRUG|Rifampin|
214870545|NCT01345487|OTHER|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
214870546|NCT01345487|OTHER|Animal protein|Protein in the form of minced pork/beef
214870547|NCT05744180|OTHER|Interventional|The FitScore is a machine learning algorithm embedded within the electronic health record that identifies patients most likely to benefit from remote patient monitoring.
214870548|NCT04359511|DRUG|Prednisone|prednisone 0.7 mg/kg/d (PO)
215036267|NCT01417767|DRUG|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
215036268|NCT01417767|DRUG|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
215036269|NCT01245608|DRUG|Polypill|Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
214291060|NCT02454998|OTHER|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
214291061|NCT00477971|BIOLOGICAL|filgrastim|No administration information given
214291062|NCT00477971|DRUG|dexamethasone|Given orally
214291063|NCT00477971|DRUG|melphalan|Given IV or orally
214291064|NCT00477971|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
214291065|NCT00054145|DRUG|perifosine|
214291066|NCT01369797|OTHER|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
214291067|NCT01414907|BEHAVIORAL|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
214870549|NCT04359511|DRUG|Hydrocortisone|hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
214870550|NCT00616629|DRUG|AZD1305|Intravenous infusion
214870551|NCT06498440|DRUG|Ketorolac 0.5% Eye Drops|Participants in this arm will receive ketorolac 0.5% eye drops, administered twice daily for one week following Selective Laser Trabeculoplasty (SLT). Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX) enzymes, which play a key role in the inflammatory process. This intervention aims to reduce postoperative inflammation and pain, promoting patient comfort and potentially improving outcomes following SLT.
214870552|NCT06498440|DRUG|Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops|Participants in this arm will receive a combination of ketorolac 0.5% eye drops and fluorometholone 0.1% eye drops. Ketorolac will be administered twice daily and fluorometholone four times daily for one week following SLT. Fluorometholone is a corticosteroid that reduces inflammation by stabilizing capillary permeability and inhibiting inflammatory cell activation. The combination aims to maximize anti-inflammatory effects and enhance patient comfort, potentially leading to better postoperative outcomes compared to ketorolac alone or no treatment.
214870553|NCT04232280|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
214870554|NCT04232280|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
214870555|NCT03157648|OTHER|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
214870556|NCT05927948|DEVICE|Laight therapy, NICE V3.1 device|Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.
214870557|NCT06633172|PROCEDURE|laparoscopic ventral mesh rectopexy|performing ventral mesh rectopexy via laparoscopic surgery to correct the anterior rectocele.
214870558|NCT06633172|PROCEDURE|Trans vaginal repair|performing repair of the rectocele through the recto vaginal septum repair.
215036270|NCT05162846|OTHER|Publicly available genetic testing resources|Participants may view the publicly available Michigan Department of Health and Human Services (MDHHS) website as they wish.
215036271|NCT05162846|BEHAVIORAL|Virtual genetics navigator|A mobile-optimized website/online genetic tool developed by investigators from the University of Michigan's Center for Health Communications Research (CHCR).
215036272|NCT05162846|BEHAVIORAL|Motivational interviewing (MI)|At least 2 phone calls delivered by trained genetic health coaches using motivational interviewing and providing genetic testing information.
215036273|NCT01189721|DRUG|propofol, sevoflurane|"Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively."
215036274|NCT05534867|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 1 month, 2 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
215036275|NCT05112640|DEVICE|INSORB: subcuticular stapling device|Under the skin stapling device that delivers absorbable staples
215036276|NCT05112640|DEVICE|Subcuticular monocryl suture manufactured by Ethicon|Under the skin suture placed by hand
215036277|NCT06412666|DRUG|Aficamten|Oral Tablet
215036278|NCT06412666|DRUG|Placebo|Oral Tablet
215036279|NCT05068583|OTHER|Blood Draw|Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
215036280|NCT06335212|DEVICE|Single vision and multifocal contact lenses|Cycloplegic central autorefraction was conducted with both Grand Seiko WAM-5500 open-field auto-refractor (Grand Seiko Co Ltd) and OPD OPD-Scan III Wavefront Aberrometer (Marco) on the subjects in the following conditions: (1) no CLs, (2) SVCLs, (3) MFCLs (+2.00D Add), and (4) MFCLs (+4.00D Add). Relative peripheral power profiles were measured using the OPD under the same 4 conditions after cycloplegia.
215036281|NCT06199479|PROCEDURE|MRI Scan|Performed by MRI Scan
215036282|NCT06199479|PROCEDURE|CT Scan|Performed by CT Scan
215036283|NCT06199479|PROCEDURE|Biopsy|Standard of Care Biopsy
215036284|NCT02825667|OTHER|Physiotherapy sessions|Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
215036285|NCT02527512|DRUG|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
214870559|NCT05255848|DRUG|Unfractionated heparin|Patients will be given the same standard of care treatment plus nebulized heparin 5000IU every 8 hours started 24 hours after randomization, using a compressed air nebulizer, and will be continued for one week. In case of any complication, if the attending physician feels it necessary intervention treatment will be stopped
215036286|NCT02527512|OTHER|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
215036287|NCT01461460|DRUG|TR-701 FA 1200 mg|6 tablet of T-701 FA
215036288|NCT01461460|DRUG|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
215036289|NCT01461460|DRUG|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
215036290|NCT01461460|DRUG|Placebo|6 placebo tablets
215036291|NCT01140204|DEVICE|Implantation of a bare metal stent|Bare Metal Stent
215036292|NCT04635852|DRUG|Fentanyl|
215036293|NCT04635852|DRUG|Immediate release morphine|
215036294|NCT06448013|DRUG|Venetoclax|Given by PO
215036295|NCT06448013|DRUG|Gemtuzumab|Given by IV
215036296|NCT06448013|DRUG|Ziftomenib|Given by PO
214291068|NCT01378078|DEVICE|eldith DC-stimulator (neuroconn, Ilmenau, Germany)|daily tDCS treatment over left DLPFC, 20 min, 2 mA
214291069|NCT01378078|DEVICE|eldith DC-stimulator (Neuroconn, Ilmenau, Germany)|same as sham stimulation
214870560|NCT03560648|DEVICE|High definition surface electromyography combined with accelerometer|HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.
214870561|NCT00235196|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
215036297|NCT05189665|PROCEDURE|Extraperitoneal high sacral ligament suspension surgery|The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .
215036298|NCT05189665|PROCEDURE|Sacrospinous ligament fixation|The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.
215036299|NCT02340195|DRUG|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
215036300|NCT02553733|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
215036301|NCT02553733|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
215036302|NCT03057704|DRUG|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
215036303|NCT03057704|DRUG|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
215036304|NCT01014871|DRUG|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
215036305|NCT01014871|DRUG|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
215036306|NCT05005533|OTHER|Observational|Chronic Obstructive Pulmonary Disease Severity of Individuals by Chronic Obstructive Pulmonary Disease Assessment Test, shortness of breath Modified Medical Research Council scale, cough related quality of life Leicester Cough Questionnaire, respiratory muscle strength with Maximum Inspiratory and Expiratory Pressure, Posture with Spinal Mouse device, pain with Visual Analog Scale, severity of fatigue Fatigue Physical performance of the lower extremities will be evaluated with the Short Physical Performance Test, functional mobility will be evaluated with the Time Up and Go Test, and balance will be evaluated with the Biodex Balance System
215036307|NCT04012450|PROCEDURE|Epidural anesthesia|Performing an epidural anesthesia
215036308|NCT04012450|PROCEDURE|spina-epidural anesthesia|Performing a spina-epidural anesthesia
215036309|NCT06206590|OTHER|Whole-proteomic assay|Whole-proteomic analysis was performed on all the blood samples
215036310|NCT01542892|OTHER|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
215036311|NCT01542892|DIETARY_SUPPLEMENT|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
215036312|NCT04856280|BEHAVIORAL|Kinesiological taping|In KT Group, 6 sessions of KT were applied, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended.
215036313|NCT04856280|BEHAVIORAL|Aerobic exercise|In the AE group, walking and climbing stairs were given during the menstrual cycle, 3 days a week, 45 minutes.
215036314|NCT06042946|PROCEDURE|Microsurgical resection of ISCM|Microsurgical resection of ISCM defines the surgical removal of cancerous tumors that have spread to the spinal cord, using advanced microsurgical techniques and equipment like ultrasound, neuromonitoring, ultrasonic aspirator to prevent damage to the spinal cord.
215036315|NCT03788044|OTHER|Education|Education + Medication adherence monitoring + Feedback when low adherence
215036316|NCT05842551|COMBINATION_PRODUCT|Prismatic adaptation and electric stimulation|Combinatory effect of tEs and prismatic lenses in the experimental group and of sham stimulation and prismatic lenses in control group
214870562|NCT05811806|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
214870563|NCT04519034|OTHER|no intervention|There will be no intervention
214870564|NCT06124495|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
215036317|NCT02602652|BIOLOGICAL|a live attenuated chimeric JE vaccine|"The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity."
215036318|NCT04047485|DIAGNOSTIC_TEST|Visual Acuity|During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
215036319|NCT04047485|DIAGNOSTIC_TEST|CAM (Confusion Assesment Method)|"During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated."
215036320|NCT04047485|DIAGNOSTIC_TEST|CATQUEST 9-SF|The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
215036321|NCT04047485|DIAGNOSTIC_TEST|OCT|Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
215036322|NCT04047485|DIAGNOSTIC_TEST|6CIT|This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
215036323|NCT04047485|DIAGNOSTIC_TEST|Barthel Index|To evaluate the everyday independence of the subject and it's trend durin the follow-up
215036324|NCT04047485|DIAGNOSTIC_TEST|Endothelial Microscopy - Cornea|Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
215036325|NCT00244985|BIOLOGICAL|rituximab|IV
214291070|NCT00321945|PROCEDURE|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
214291071|NCT03700671|OTHER|High intensity interval training|Participants performed HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration
214291072|NCT03700671|OTHER|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated
215036326|NCT00244985|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
215036327|NCT02329587|OTHER|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
214291073|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Metallic)|Calcaneus Displacement Osteotomy using two metallic screws
214870565|NCT02594670|OTHER|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
215036328|NCT02329587|OTHER|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
215036329|NCT00455702|DRUG|d-cycloserine|50mg dose d-cycloserine v placebo
215036330|NCT03005002|BIOLOGICAL|Durvalumab|Given IV
215036331|NCT03005002|OTHER|Laboratory Biomarker Analysis|Correlative studies
214870566|NCT02594670|OTHER|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
214870567|NCT02594670|OTHER|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
214870568|NCT02973230|OTHER|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
215036332|NCT03005002|BIOLOGICAL|Tremelimumab|Given IV
215036333|NCT04378868|DRUG|Antibiotics, cefuroxime and metronidazole|Patient receives antibiotics while waiting appendectomy
215036334|NCT04378868|DRUG|No antibiotics|No antibiotics are given while waiting surgery.
215036335|NCT04378868|OTHER|urgent schedule|Patients can wait up to 8 hours for surgery.
215036336|NCT04378868|OTHER|less urgent schedule|Patients can wait up to 24 hours for surgery.
215036337|NCT06449118|BEHAVIORAL|Mindfulness Stress Reduction Program|Mindfulness based-Stress Reduction Program an 8-week program
215036338|NCT00062257|DRUG|irofulven|
214870569|NCT05384639|DEVICE|Dual-task Group|Participant will cycle and perform cognitive training simultaneously.
214870570|NCT05384639|DEVICE|Cycling Group|Participant will cycle only.
214870571|NCT05384639|DEVICE|Cognitive Group|Participant will perform cognitive training only.
214870572|NCT04292665|BEHAVIORAL|Classical Massage|During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.
214870573|NCT04292665|BEHAVIORAL|Benson Relaxation Exercise|During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.
214870574|NCT04292665|OTHER|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
214870575|NCT01777620|BIOLOGICAL|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
214870576|NCT01777620|DRUG|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
214870577|NCT02988024|DRUG|LY03005|LY03005
214870578|NCT02988024|DRUG|Pristiq|
215036339|NCT02908217|DRUG|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
215036340|NCT02908217|DRUG|Placebo|6 Intravenous infusions of placebo every 4 weeks.
215036341|NCT00288145|BEHAVIORAL|WOW, Working On Wellness weight management|Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
215036342|NCT03261804|BEHAVIORAL|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
215036343|NCT02010268|OTHER|Collection of stool samples|A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
215036344|NCT01038323|OTHER|CBT and milnacipran|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
215036345|NCT01038323|BEHAVIORAL|CBT with a placebo|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week starter pack. Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
215036346|NCT01038323|DRUG|Educational with milnacipran|"Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
215036347|NCT04164927|OTHER|Manual Lymphatic Drainage|"1. Lymphatic correction method was used via the KinesioTaping® to patients group.~2. Standardized 30-minute Manuel Lymphatic Drainage treatment was applied to the MLD group.~3. Control group received only physiotherapy treatment."
214291074|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Bio-integrative)|Calcaneus Displacement Osteotomy using two bio-integrative screws
214870579|NCT01740726|BEHAVIORAL|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
214665751|NCT04396587|DRUG|Oxycodone|Oxycodone(60μg/kg) was administered before anesthesia induction.
214665752|NCT04396587|DRUG|normal Saline|normal saline 10ml
214665753|NCT00444184|DRUG|Travoprost/timolol fixed combination, travoprost|
214870580|NCT01740726|DRUG|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
214870581|NCT05151666|OTHER|Sunny Health & Fitness Magnetic Mini Exercise Pedal Cycle - SF-B020026 Gray|The intervention will be that the patient cycles in a sitting position within the first 2 hours of hemodialysis treatment for 15-60 minutes/as tolerated, either intermittent/continuous duration. - Graded duration will increase every 2 weeks. This will be supervised by a dialysis nurse as per the schedule of study assessments.
214870582|NCT01434082|BEHAVIORAL|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
214870583|NCT04557020|DRUG|PD-1 antibody|neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy
214870584|NCT04557020|DRUG|Gemcitabine|neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles
215036348|NCT04164927|OTHER|Kinesio Taping|Depending on the size of the leg two or three fan cut tapes were applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Kinesio taping was applied by certified Kinesio Tape practitioner once a week to Kinesiotaping group.
215036349|NCT04164927|OTHER|Control|Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.
215036350|NCT01143402|DRUG|Dacarbazine|Given IV
215036351|NCT01143402|OTHER|Laboratory Biomarker Analysis|Correlative studies
215036352|NCT01143402|OTHER|Quality-of-Life Assessment|Ancillary studies
214665754|NCT01624194|DRUG|Oxytocin nasal spray|24IU BID (3 x 0.1 mL \[4IU\] sprays per nostril twice daily for 4-weeks.
214870585|NCT04557020|DRUG|Cisplatin|neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
215036353|NCT01143402|DRUG|Selumetinib|Given PO
214870586|NCT04557020|RADIATION|IMRT|70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
214870587|NCT00482651|RADIATION|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
214870588|NCT00482651|PROCEDURE|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
214870589|NCT00482651|PROCEDURE|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
215036354|NCT01143402|DRUG|Temozolomide|Given PO
215036355|NCT04369326|OTHER|Community-Based TPT Initiation|Community-based care delivery model for pediatric tuberculosis evaluation and initiation of preventive therapy
215036356|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
215036357|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
215036358|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
214870590|NCT00482651|PROCEDURE|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
214870591|NCT05094492|COMBINATION_PRODUCT|Curodont Repair Fluoride Plus|P11-4 self assembling peptide combined with fluoride
215036359|NCT00441025|DRUG|Alemtuzumab|
215036360|NCT02686944|BIOLOGICAL|Intuvax (ilixadencel)|Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection
214665755|NCT01624194|DRUG|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
214870592|NCT05094492|OTHER|Bifluorid 10 fluoride varnish|5% Sodium Fluoride varnish (equal to 22,600 ppm fluoride)
214870593|NCT00790335|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
214870594|NCT03929341|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography (CCTA)|Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
214870595|NCT03929341|OTHER|Cardiac Link|Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
214870596|NCT02789618|OTHER|A01|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period
215036361|NCT02842385|OTHER|Implant|One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
215036362|NCT00384943|BEHAVIORAL|Moderate-intensity Exercise|
215036363|NCT05903534|OTHER|Pediatric Endurance and Limb Strengthening Program (PEDALS) and Lower Limb Strength Training|Pediatric Endurance and Limb Strengthening Program (PEDALS) Group This will receive stationary cycling
215036364|NCT05903534|OTHER|Lower Limb Strength Training Group|Lower Limb Strength Training Group
215036365|NCT02526290|DEVICE|Intranasal Lacrimal Neurostimulator (Oculeve)|Neurostimulation device
215036366|NCT02895217|OTHER|ergocycle|
215036367|NCT05515341|DEVICE|Commercially Approved Interventional Medical Device/Therapy for Chronic Pain|Commercially Approved Interventional Medical Device/Therapy
214665756|NCT02981290|DRUG|Renodapt|Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
214665757|NCT02981290|DRUG|Mycept|Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
214665758|NCT02981290|DRUG|Cellmune|Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
214665759|NCT02981290|DRUG|CellCept|CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
214665760|NCT00274430|DRUG|dexamethasone 8 mg bid|
214665761|NCT00274430|DRUG|tadalafil 10mg bid|
214665762|NCT00000889|DRUG|Aldesleukin|
214665763|NCT03310125|DRUG|Colchicine|Over-encapsulated 0.5mg tablet twice daily
214665764|NCT03310125|DRUG|Placebo|Matching placebo capsule twice daily
215036368|NCT03860987|DRUG|goserelin|Goserelin will be administered SC at 10.8 mg every 12 weeks
215036369|NCT03860987|DRUG|Enzalutamide|Enzalutamide will be given orally at 160mg once daily
215036370|NCT03860987|DRUG|Abiraterone|Abiraterone will be taken orally at 1000 mg once daily
215036371|NCT03860987|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
215036372|NCT03860987|DRUG|Prednisone|Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
215036373|NCT03860987|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
215036374|NCT02897336|PROCEDURE|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
215036375|NCT02897336|PROCEDURE|interlaminar|interlaminar epidural corticosteroid injection
215036376|NCT01447784|BIOLOGICAL|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
214870597|NCT02789618|OTHER|B99|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.
214870598|NCT02789618|OTHER|M89|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
215036377|NCT01447784|BIOLOGICAL|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
214870599|NCT05158036|OTHER|Classic massage group|Classic massage application will be given to the Classic massage group
214870600|NCT05158036|OTHER|Connective tissue masage|Connective tissue masage application will be given to the Connective tissue masage group
214870601|NCT04709770|DRUG|2-liters polyethylene glycol with citrate and simethicone|Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
214870602|NCT04709770|DRUG|4-liters polyethylene glycol with simethicone|High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
214870603|NCT04709770|DIETARY_SUPPLEMENT|Low-residue diet|Diet before colonoscopy.
214870604|NCT02784873|OTHER|High intensity interval training|High intensity interval training within a standard cardiac rehabilitation programme
214870605|NCT02194348|DRUG|BIBN 4096 BS - in single rising doses|
214870606|NCT02194348|DRUG|Placebo|
215036378|NCT00238394|DRUG|cediranib maleate|Given orally
214870607|NCT02759601|DRUG|Tefinostat|Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
214870608|NCT04516759|DRUG|AZD1656|50mg film-coated tablets (at daily dose of 100mg BID)
215036379|NCT00238394|OTHER|laboratory biomarker analysis|Correlative studies
215036380|NCT05940428|BIOLOGICAL|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
215036381|NCT03558217|DEVICE|Collared Femoral Implant|Corail collared femoral implant for total hip arthroplasty
215036382|NCT03558217|DEVICE|Collarless Femoral Implant|Corail collarless femoral implant for total hip arthroplasty
215036383|NCT04473560|DEVICE|Catheter-directed thrombectomy|Using common femoral venous access the pigtail diagnostic catheter will be placed into the main pulmonary artery and an initial pulmonary angiogram will be performed to demonstrate the location and extent of thrombi in pulmonary arteries. Then pulmonary arterial pressures will be measured. Subsequently an Indigo catheter (Penumbra, Alameda, California) will be placed and a direct-aspiration first-pass technique will be performed purposefully to attach a large thrombus to the catheter tip by suction and then pull it out through the sheath. The decision to terminate the intervention will be at operator's discretion after careful evaluation of hemodynamic parameters (restoration of the systolic blood pressure≥100 mmHg, heart rate \<100/min), improvement of arterial blood saturation≥ 92%, practicable clot burden reduction and total amount of aspirated blood (no more than 300 ml).
215036384|NCT01923376|DRUG|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
214870609|NCT04516759|OTHER|Placebo|Matched placebo tablets
215036385|NCT01923376|DRUG|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
215036386|NCT00317122|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
215036387|NCT05677048|BEHAVIORAL|Free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing
215036388|NCT05677048|BEHAVIORAL|IGNITE-TX Group|Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator
214870610|NCT02634359|DEVICE|EarlySense home device|Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
214870611|NCT02634359|PROCEDURE|Vaginal ultrasound|Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
214870612|NCT02634359|PROCEDURE|Blood Test|Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
214870613|NCT04308707|OTHER|Breaking bad news skills|Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
214870614|NCT00752648|DRUG|TMC435350|
215036389|NCT05677048|BEHAVIORAL|IGNITE-TX and free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
215036390|NCT06555419|DRUG|Nusinersen|Administered as specified in the treatment arm.
215036391|NCT06555419|DEVICE|ThecaFlex DRx System|Implanted as specified in the treatment arm.
215036392|NCT02688959|BEHAVIORAL|Tai Chi|
215036393|NCT02688959|BEHAVIORAL|Exercise|
214870615|NCT04639804|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
214870616|NCT04639804|DRUG|Naproxen|Naproxen 500 mg tablet
214870617|NCT04639804|DRUG|Aceclofenac|Aceclofenac 100 mg tablet
214870618|NCT04639804|DRUG|Celecoxib|Celecoxib 200 mg capsule
214870619|NCT04005352|BIOLOGICAL|Brolucizumab 6 mg|Intra-vitreal injection
214870620|NCT04005352|BIOLOGICAL|Aflibercept 2 mg|Intra-vitreal injection
214870621|NCT02965040|DRUG|Roxadustat|Oral
214870622|NCT06017479|DRUG|Fosfomycin 3000 MG|Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
214870623|NCT06017479|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
214870624|NCT04058067|DRUG|Brolucizumab|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
214870625|NCT04058067|DRUG|Aflibercept|5 x every 4 weeks loading then every 8 weeks maintenance
214870626|NCT02702570|BEHAVIORAL|CASA|Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
214870627|NCT00417170|DRUG|Aliskiren|Aliskiren 300 mg tablets taken orally once daily
214870628|NCT00417170|DRUG|Amlodipine|Amlodipine 5 mg capsule taken orally once daily
214870629|NCT00417170|DRUG|Placebo Aliskiren|Placebo Aliskiren taken orally once daily.
214870630|NCT00417170|DRUG|Placebo Amlodipine|Placebo Amlodipine taken orally once daily
214870631|NCT04728009|DIETARY_SUPPLEMENT|Longan and lingzhi mushroom syrup|Fresh fruit pulps of longan were stewed in hot water until they softened. No sugar and additives were added. The pulps were removed by filtration in order to obtain concentrated longan juice. After that, spray-dried powder of lingzhi mushroom extract was dissolved in water in the ratio of 1:2. To make the finished product, 99 g of longan juice was mixed with 1 g of the lingzhi extract in water. The sugar content of the syrup was 77 degrees Brix.
214870632|NCT05180201|DIETARY_SUPPLEMENT|Synbiotic|Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide
214870633|NCT05180201|DIETARY_SUPPLEMENT|Probiotic|Lactiplantibacillus plantarum ATCC 202195
214870634|NCT05180201|OTHER|Placebo|Maltodextrin
214870635|NCT02201212|DRUG|Everolimus|
214870636|NCT01085123|DRUG|Rapimelt|oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
214870637|NCT01085123|DRUG|[11C]AZ10419369|solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
214870638|NCT05005312|DRUG|PF-07321332|Tablet
214870639|NCT05005312|DRUG|Ritonavir|PK Boosting agent
214870640|NCT01932723|BEHAVIORAL|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
214870641|NCT06550258|OTHER|Equine-assisted therapy|Hippotherapy is a therapeutic intervention applied by physiotherapists that aims to improve impaired body functions. Hippotherapy is a therapy in which the rider receives stimuli from the horse that stimulate the sensory, neuromotor and cognitive systems during riding and exercise on the back of a horse. Hippotherapy is effective on posture control, balance, gross motor functions and functional performance in children with cerebral palsy.
214870642|NCT06550258|OTHER|Traditional Pediatric Physiotherapy|In traditional pediatric physiotherapy, cushions of appropriate hardness were used for proprioceptive input. Stools of different heights were used for sitting, squatting, standing up by holding on and standing, Bobath balls and balance boards were used for balance reactions. Triangular and roll cushions of different hardness were used for weight transfer. Surfaces with different patterns were used for sensory input. The child's wishes and interests were taken into consideration in the selection of materials. The treatment was planned according to the activities that were difficult in daily life and the aim was to transfer the knowledge learned to daily life.
214870643|NCT01890135|DRUG|Zibotentan (ZD4054)|10 mg
214870644|NCT01890135|DRUG|placebo|randomized double blind
214870645|NCT06633939|BEHAVIORAL|Behavioral Treatment|The theoretical framework for the Move \&amp; Eat 2 Live intervention is guided by the health belief model (HBM), socioecological model (SEM) and motivational interviewing (MI) approach. Tailoring to the target community will include a standard cultural adaptation that will replace curriculum content and examples with Native American relevant foods, physical activities, and representation in materials. For this study, the intervention will be piloted in the target population and will include the first 5 sessions of the original 12-session program.
214870646|NCT04182724|DRUG|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
214870647|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cemented Fixation|
214870648|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cementless Fixation|
214870649|NCT01283035|DRUG|Akt Inhibitor MK2206|Given PO
214870650|NCT01283035|OTHER|Laboratory Biomarker Analysis|Correlative studies
214870651|NCT02083718|BIOLOGICAL|PBSC|
214870652|NCT02083718|BIOLOGICAL|MSCs|
214870653|NCT04530435|DEVICE|PEP flute|Participants are advised to use a PEP flute at least three times daily at an appropriate resistance. Ideally, each session consists of 15 breaths (for approximately 1 minute) repeated twice at an upright position.
214870654|NCT02621749|DEVICE|Renal replacement therapy|Patients receive renal replacement therapy according to institutional standards
214870655|NCT01680003|DRUG|Hepar-P|
214870656|NCT01680003|DRUG|Placebo for Hepar-P|
214870657|NCT02704403|DRUG|Elafibranor|
214870658|NCT02704403|DRUG|Placebo|
214870659|NCT05682859|DRUG|Roflumilast 500 Mcg Oral Tablet|Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.
214870660|NCT05682859|DRUG|Placebo|Placebo tablets
214870661|NCT03292159|DEVICE|Active RAVANS concurrent with arm motor training|Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
214870662|NCT03292159|DEVICE|Inactive RAVANS concurrent with arm motor training|Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
214870663|NCT03259659|OTHER|ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index|In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
214870664|NCT04888559|OTHER|Breakfast product: Whole grain|This intervention is a whole grain-based breakfast product containing oats and barley.
214870665|NCT04888559|OTHER|Breakfast product: Reference|This intervention is a rice-based breakfast product.
214870666|NCT01734200|DIETARY_SUPPLEMENT|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
214870667|NCT01734200|DIETARY_SUPPLEMENT|Placebo|Placebo (1.5g/day)
214870668|NCT04077918|DIETARY_SUPPLEMENT|protein diet|100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
214870669|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
215036394|NCT03655782|BEHAVIORAL|PATH + DigitMemory (DM) neurotraining|Improve visual timing and sensitivity in the dorsal stream. The mTBI subject will sit 57 cm in front of a computer monitor. During the presentation, the bars in the 'fish-shaped' window in the center of the screen formed by a sinusoidal grating, move left or right very briefly. When the screen goes blank, the subject reports which way the center pattern moved by pushing the left or right arrow key. A brief tone is presented after incorrect responses. The program adaptively changes the contrast of the test pattern so that the subject detects motion at lowest contrast possible. A sequence of patterns in each training cycle that are designed to optimally activate magnocellular neurons are shown to the subject. There are two programs, the first measures the contrast needed to see one direction of movement, and the second program measures the contrast needed to see two directions of movement, requiring memory. Both are followed by digit memory exercises.
215036395|NCT04425239|DRUG|Panitumumab|Continuous administation
214870670|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
214870671|NCT00851318|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
214870672|NCT00851318|DRUG|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
214870673|NCT03063918|OTHER|Informational Intervention|Receive a workbook
215036396|NCT04425239|DRUG|Panitumumab|Intermittent administation
214870674|NCT03063918|OTHER|Quality-of-Life Assessment|Ancillary studies
214870675|NCT03063918|OTHER|Questionnaire Administration|Ancillary studies
214870676|NCT03063918|OTHER|Survey Administration|Ancillary studies
214870677|NCT03063918|BEHAVIORAL|Telephone-Based Intervention|Receive personalized dietary intervention
214870678|NCT01839318|DEVICE|Nelfilcon A contact lenses|
214870679|NCT01839318|DEVICE|Omafilcon A contact lenses|
215036397|NCT05432973|PROCEDURE|Percutaneous Electrical Nerve Stimulation|In the PENS treatment, a biphasic continuous waveform current with a frequency of 2 Hz, a pulse width of 50 microseconds and an intensity that produces visible motor responses of the innervated muscles was used, below the patient's pain threshold. The NT6021 Percutaneous Neuromodulation equipment of the Nutek® brand distributed by Fisiolab Ibérica® was used. This equipment has the CE marking, which denotes compliance with the requirements of the legislation of Royal Decree 414/1996 of March 1, which regulates medical devices. B.O.E. of April 24, 1996
215036398|NCT05432973|PROCEDURE|Neurodynamic and manual therapy|"The manual therapy consisted of passive-assisted mobilization and massage therapy of the muscular and fascial tissue, beginning with the cervical area, kneading while asking the patient to rotate the neck and then in the same way along the muscles and soft tissues innervated by the target nerve.~Neurodynamic was performed in a passive-assisted manner, combining the patient's cervical mobilizations with the mobility of the upper limbs adapted to each case."
215036399|NCT05151640|DRUG|Nintedanib|Nintedanib
215036400|NCT03315377|PROCEDURE|Lunate-Capitate Fusion (LCF)|Operation with lunate-capitate-fusion (LCF)
214665765|NCT05821543|DRUG|metformin+sibutramine|1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)
214870680|NCT01839318|DEVICE|Etafilcon A contact lenses|
214870681|NCT04400032|BIOLOGICAL|Mesenchymal Stromal Cells|The Mesenchymal Stromal Cells will be administered intravenously
214870682|NCT00644852|OTHER|Retrospective chart review study|Retrospective study chart review long acting risperidone
214870683|NCT04495036|OTHER|data collection (21-items-patient descriptive survey)|"Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:~* Demographic data of telemedicine users and non-users~* Subjective disease perception of the dermatology patients~* Use of internet, telemedicine and telemedicine insurance model~* Patients´ willingness for additional features of telemedicine~* Advantages and disadvantages telemedicine and face-to-face consultation~* Suitable fields of dermatology for telemedicine from the patient's perspective~* Recommended structure of telemedical services by users and non-users"
215036401|NCT03315377|PROCEDURE|Four Corner Fusion (4CF)|Operation with four-corner-fusion (4CF)
215036402|NCT00748605|DRUG|S-2367 Placebo|Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
215036403|NCT00748605|DRUG|S-2367 1600 mg q.d. 54 Weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks
215036404|NCT00748605|DRUG|S-2367 1600 mg q.d. 60 weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks
215036405|NCT00748605|OTHER|LCD (low calorie diet)|A low calorie diet was utilized during the first 6 weeks of the study
214870684|NCT04495036|OTHER|data collection (23-items-physician descriptive survey)|"To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:~* Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)~* Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective"
214870685|NCT01844856|DRUG|Eravacycline|
214870686|NCT01844856|DRUG|Ertapenem|
214870687|NCT01844856|DRUG|Placebo|Administered IV to maintain the blind.
214870688|NCT03906578|DIETARY_SUPPLEMENT|Vivomixx®|Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus
214870689|NCT03906578|OTHER|Placebo|Placebo with similar appearance to probiotic
214870690|NCT05508841|OTHER|tDCS and Cognitive Training|Participants will receive mild stimulation or no stimulation along with cognitive training
214870691|NCT01420471|DRUG|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
215036406|NCT00748605|OTHER|RCD (reduced calorie diet)|A reduced calorie diet was used during the last 54 weeks for the study
215036407|NCT06548724|OTHER|assessment of quality of life before and after anal surgery|"Preoperatively, the state of continence will be assessed using Wexner Incontinence Score (WIS) . Also, the basal state of quality of life (QoL) will be assessed using a validated disease-specific tool known as Quality of Life in patients with Anal Fistula Questionnaire (QoLAFQ) (Ferrer-Márquez et al., , faecal incontinence quality of life (FIQL)~Surgical Techniques:~The selection of surgical technique depends on the type of fistula , patient choice and commitment to guidelines . Follow-up Patients will be followed-up in the outpatient clinic weekly in the first month, then every two weeks in the second month, then at 3, and 6 months postoperatively. The continence state and QoL change will be assessed using QoLAF-Q and GIQLI 3 months and6 months postoperatively."
215036408|NCT04806152|OTHER|High intensity exercise|Supervised high-intensity combined-modality exercise was administered to participants in the exercise arm for 3 times per week for 6 months. A post-exercise recovery protein drink (31g whey-based) was given within 15 minutes after each supervised exercise session.
214870692|NCT01420471|OTHER|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
214870693|NCT04261907|DRUG|ASC09/ritonavir group|ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment
215036409|NCT04806152|OTHER|Usual care home exercise|Walking 30 minutes, chair rises and flexibility exercises for trunk and upper extremities 5 days per week
215036410|NCT06548048|DIETARY_SUPPLEMENT|Dietary supplement containing plant derived phenolics|Dietary supplement containing plant derived phenolics
215036411|NCT06548048|DIETARY_SUPPLEMENT|Microcrystaline cellulose|Microcrystaline cellulose (MCC)
215036412|NCT02347410|DEVICE|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
215036413|NCT06201845|OTHER|Exercise awareness training|Group exercise training will consist of aerobic exercises including warm-up and cool-down exercises accompanied by music, and trunk strengthening training consisting of core exercises.
215036414|NCT06201845|OTHER|physical activity awareness training|In the physical activity awareness training, the benefits of exercises on systemic, psychological effects and general body health will be explained and they will be informed about different exercise practice.
215036415|NCT02382146|DRUG|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
215036416|NCT02382146|DRUG|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
215036417|NCT02824679|DRUG|hyoscine butylbromide|20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
215036418|NCT02824679|DRUG|saline|0.9%normal saline
215036419|NCT05231980|DIETARY_SUPPLEMENT|Alpha lipoic acid (ALA)|ALA is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect.
215036420|NCT05231980|DRUG|Pentoxifylline (PTX)|Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
215036421|NCT05231980|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
215036422|NCT02758821|OTHER|No CRP will be measured onsite|No CRP will be measured onsite
215036423|NCT02758821|OTHER|CRP cut-off of 20mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 20mg/L.
215036424|NCT02758821|OTHER|CRP cut-off of 40mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 40mg/L.
215036425|NCT04772794|OTHER|fraction of inspired oxygen|after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
215036426|NCT01435343|DRUG|fludarabine|30 mg/m2/day intravenously on days 1 to 4
214870694|NCT04261907|DRUG|lopinavir/ritonavir group|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment
214870695|NCT00002393|DRUG|Indinavir sulfate|
215036427|NCT01435343|DRUG|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
215036428|NCT01435343|DRUG|cytarabine|2 g/m2/day intravenously on days 1 to 4
215036429|NCT01435343|DRUG|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
215036430|NCT01435343|DRUG|plerixafor|intravenously from days 1 to 4
215036431|NCT00249626|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
215036432|NCT06422455|OTHER|Best Practice|Receive provider-based genetic counseling
215036433|NCT06422455|OTHER|Educational Intervention|Receive genetics education
215036434|NCT06422455|OTHER|Electronic Health Record Review|Ancillary studies
215036435|NCT06422455|OTHER|Genetic Counseling|Receive provider-based genetic counseling
214870696|NCT00002393|DRUG|Efavirenz|
214870697|NCT00525447|DRUG|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
214870698|NCT00525447|DRUG|lenalidomide|Up to 25 mg daily of a 21-day cycle.
214870699|NCT00525447|DRUG|dexamethasone|40 mg administered weekly.
215036436|NCT06422455|OTHER|Interview|Ancillary studies
215036437|NCT06422455|OTHER|Survey Administration|Ancillary studies
215036438|NCT00319761|DRUG|Calcitriol|
215036439|NCT03611712|DRUG|Astragalus Polysaccharides 500 mg|PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)
215036440|NCT06032182|BEHAVIORAL|CRESTR Intervention|15 1-hour sessions of CRT + SRT
215036441|NCT06032182|BEHAVIORAL|CRESTR Control|15 1-hour sessions of SRT alone
214870700|NCT04618783|BIOLOGICAL|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
214870701|NCT04618783|BIOLOGICAL|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
214870702|NCT04618783|BIOLOGICAL|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
214870703|NCT04618783|BIOLOGICAL|Three doses of control wIPV, vaccinated within one-month interval between doses|Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
214870704|NCT04618783|BIOLOGICAL|Three doses of control sIPV, vaccinated within one-month interval between doses|Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
214870705|NCT02665845|DRUG|5-ASA|5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
214870706|NCT02665845|DRUG|Corticosteroids|Corticosteroids will be given to all patients.
215036442|NCT01207037|PROCEDURE|blood samples and scintigraphy|at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
215036443|NCT04959331|DRUG|Fosfomycin Trometamol Salt|Fosfomycin 3 g 2 sachets, taken orally, once daily for two days
215036444|NCT04959331|DRUG|Nitrofurantoin|Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days
215036445|NCT04959331|DRUG|Pivmecillinam|Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days
215036446|NCT04959331|DRUG|Fosfomycin Trometamol Salt|Fosfomycin 3 g one sachet, taken orally, for one day
215036447|NCT05662670|DRUG|WJ13404 tablets|"Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied."
215036448|NCT05573308|DEVICE|Clear Aligners with Dental Monitoring|Dental Monitoring™ (DM ™). This digital technology software allows orthodontists to monitor patients remotely through continuous analytics using control vision technology, metaheuristics, and artificial intelligence.31 This app utilizes a patented artificial intelligence machine learning algorithm to calculate 3-dimensional (3D) tooth movements from intraoral photos and videos that patients capture using their smartphone cameras.
215036449|NCT05573308|DEVICE|Clear Aligners|Removabale orthodontics appliances
215036450|NCT03526172|PROCEDURE|High tibial osteotomy|Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.
215036451|NCT03526172|DEVICE|Allograft wedge|Insertion of allograft wedge into the osteotomy gap during the HTO procedure
214870708|NCT04204291|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
214870709|NCT01565057|OTHER|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
214870710|NCT04201691|OTHER|classic rehabilitation|The intervention is conventional rehabilitation that included streching, balance and coordination training. The intervention is applied to participants, manually.
214870711|NCT04201691|OTHER|classic rehabilitation+mobilization|Another intervention is manuel therapy that included gliding technics, rotational technics at cervical region. (in addition to classic rehabilitation). The intervention is applied to participants, manually.
214870712|NCT02425163|DEVICE|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
214870713|NCT02425163|PROCEDURE|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
214870714|NCT04951986|DRUG|Rifampin|Rifampicin up to 35 mg/kg/day for 14 days
215036452|NCT03526172|DEVICE|Accelerometer|ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery
215036453|NCT03526172|OTHER|Questionnaire|Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery
215036454|NCT06445907|DRUG|Azacitidine|Given by IV
215036455|NCT06445907|DRUG|Venetoclax|Given by PO
214665766|NCT05821543|DRUG|sibutramine+ microcrystalline cellulose|1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
214870715|NCT04951986|DRUG|Levofloxacin|Levofloxacin 750mg daily (for weight \<50kg) or 1 g daily (for weight \>50 kg) daily for 14 days
214870716|NCT04951986|DRUG|Rifampicin, Pyrazinamide, Ethambutol and Isoniazid|Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm
214870717|NCT04951986|DRUG|Prednisone|Prednisone 1.5mg/kg/day for 14 days
214870718|NCT04951986|DRUG|Placebo|Placebo identical to Prednisone
214870719|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 1
214870720|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 2
215036456|NCT06445907|DRUG|Q702|Given by PO
215036457|NCT01380080|DRUG|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
215036458|NCT01380080|DRUG|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
214870721|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 3
214870722|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 4
214870723|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 5
214870724|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 6
214870725|NCT04187339|OTHER|Placebo|Placebo
214870726|NCT03902886|DIAGNOSTIC_TEST|gait analysis|gait analysis using an optoelectronic system and a surface EMG
215036459|NCT01380080|DRUG|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
215036460|NCT01380080|DRUG|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
215036461|NCT01380080|DRUG|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
215036462|NCT01380080|DRUG|Isoniazid|INH 300 mg orally once daily
215036463|NCT06414902|DRUG|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV
215036464|NCT06270056|DRUG|Misoprostol|Self-administered misoprostol by clients obtaining medication abortion via telemedicine
215036465|NCT06225817|DIETARY_SUPPLEMENT|Open-label placebo pills|The placebo pills in this study are empty capsules without any ingredients inside. The capsules are made of microcrystalline cellulose.
215036466|NCT05194436|DEVICE|AeviceMD|The AeviceMD will be placed on the patient to detect wheeze and perform auscultation.
215036467|NCT05204485|PROCEDURE|Fibular intramedullary nail|The standard manufacturers approved technique will be performed including the use of 2 distal interlocking screws and the use of a minimum of 1 fibula pro tibia fixation screw depending on the patients' anatomical characteristics.
215036468|NCT05204485|PROCEDURE|Open reduction and internal fixation|An open approach (direct lateral or posterolateral incision) will be carried out. The reduction will be performed using standard techniques of clamping and traction. Fixation will be performed after reduction of the fracture with a plate and screw construct. The surgeon will then proceed to perform surgical fixation of other associated fractures or ligament injuries as indicated. This will most often include open reduction and internal fixation of the medial malleolus with screws through a separate medial incision.
215036469|NCT05845749|DRUG|Vosoritide Injection [Voxzogo]|Vosoritide will be given via a once daily subcutaneous injection at a dose of 15 ug/kg/day, at approximately the same time each day when feasible. Vosoritide will be supplied to the subject as 0.4 mg vial, 0.56 mg vial or 1.2 mg vials to be reconstituted with sterile water up to 0.8 mg/mL or 2 mg/mL concentrations for injection. The volume to be administered (injection volume) will be based on the subject's body weight and the concentration of vosoritide. All supplies will be provided to the subject for home based administration after training at the study site.
215036470|NCT05459402|DRUG|Methadone (100% dose)|Methadone for the treatment of opioid use disorder
215036471|NCT05459402|DRUG|Methadone (50% dose)|Methadone for the treatment of opioid use disorder
215036472|NCT05634538|DEVICE|Robotic-assisted PCI with Corpath GRX® System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).
215036473|NCT05634538|PROCEDURE|Standard PCI|Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.
214665767|NCT06367322|DRUG|Statin|"The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP.~Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy."
214665768|NCT00561353|DRUG|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
214870727|NCT00176423|DRUG|galantamine|see arm/group description
214870728|NCT05502081|DRUG|Casirivimab and Imdevimab Drug Combination|antiviral Monoclonal Antibodies
214870729|NCT05502081|DRUG|Remdesivir|antiviral drug
214870730|NCT05502081|DRUG|Favipiravir|antiviral drug
214870731|NCT05452122|OTHER|Auditory and Electrical Stimulation|Electrical and auditory stimulation will be applied during sleep.
215036474|NCT04619797|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
214870732|NCT02556463|DRUG|MEDI9197|Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
214870733|NCT02556463|BIOLOGICAL|durvalumab|Subjects will receive durvalumab every 4 weeks
214870734|NCT02529644|BEHAVIORAL|Taking It to the Pews (Comparison)|Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
215036475|NCT04619797|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
215036476|NCT04619797|DRUG|Pemetrexed|Pemetrexed 500 milligrams per square meter (mg/m\^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
215036477|NCT04619797|DRUG|Carboplatin|Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
215036478|NCT04619797|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
215036479|NCT04619797|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
215036480|NCT04619797|DRUG|Pembrolizumab|Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.
214870735|NCT02529644|BEHAVIORAL|Taking It to the Pews (Experimental)|Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
214870736|NCT04492644|OTHER|No intervention|No intervention
214870737|NCT05523024|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will receive one capsule of the probiotic mixture (dose:1x109 colony forming units (CFU) per day in one dose (before breakfast). The PRO preparation will contain the following bacterial strains: 50% Lactococcus lactis Rosell® - 1058, 25% Lactobacillus casei Rosell® - 215, 12,5% Lactobacillus helveticus Rosell® - 52, 12,5% Bifidobacterium bifidum Rosell® - 71). Probiotics will be administered orally.
214870738|NCT05523024|DIETARY_SUPPLEMENT|Berberine|The berberine group will receive 1500 mg of Berberine (Berberine hydrochloride 97% extract of Berberis aristata) per day in 3 doses. Berberine will be administered orally, before breakfast, dinner, and before supper.
215036481|NCT05962775|PROCEDURE|Ethanol Sclerotherapy for Endometrioma|2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
215036482|NCT06378008|DRUG|CSPS toothpaste|Toothpaste containing 5.0% weight/weight (w/w) CSPS.
215036483|NCT06378008|DRUG|Regular fluoride toothpaste (Crest Cavity Protection)|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
215036484|NCT04047576|DRUG|Sirolimus|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
215036485|NCT04047576|DRUG|Corticosteroid|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
215036486|NCT06028412|PROCEDURE|Sublobar|"The minimize unit is the subsegment, the subloar group includes wedge resection, subsegmentectomy, segmentectomy.~It is recommended to perform intraoperative lymph node pathology (not mandatory). If lymph node metastasis is positive, we must switch to lobectomy+system lymph node dissection. lymph node sampling, selective lymph node dissection or systematic lymph node dissection are allowed in this group."
215036487|NCT06028412|PROCEDURE|Lobectomy|lobectomy+system lymph node dissection
215036488|NCT05219318|DRUG|Combination PD-1/PD-L1 ICI + VEGFR-TKI|The study will enroll patients achieving an objective response beween the end of the 11th month and the end of the 13th month of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
214870739|NCT05523024|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive a placebo. Placebo will contain only the excipients and will be administered orally for 24 weeks. Placebo in no way: color, taste, smell, form of taking, the dosage will not differ from the preparations tested. However, it will not contain probiotcs or berberine. Placebo will be orally administered three times a day: before breakfast, dinner, and supper (6.00-7.00 p.m.). To meet the GCP conditions, subjects from all groups will receive the same number of capsules (six) per day.
215036489|NCT05219318|OTHER|Treatment pause|Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression
215036490|NCT06637124|DEVICE|Blood Flow Restriction Therapy Device|"Blood Flow Restriction (BFR) therapy involves units use standardized cuffs of varying widths and lengths which are physically attached to the devices and provide the capability of precisely controlling the amount of pressure applied to each limb during exercise or at rest.~We will be using Smart Cuffs® 4.0 which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it will calculate and set the optimal pressure for each participant's limb. There is no need for an external doppler probe or hand pump. Made in the USA, SmartCuffs® are registered with the FDA as a Class 1 Medical Device.~Blood flow restriction therapy is commonly paired with resistive training, so this study will explore the effect of blood flow restriction at rest for patients with osteoarthritis at different restriction levels (50% for first group and 70% for second group)."
215036491|NCT06637124|DEVICE|45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.|Patients assigned to group will receive strengthening of the lower limb musculature through moderate intensity resistance training (60% of 1RM) using a 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.
215057214|NCT01279044|BEHAVIORAL|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
215057215|NCT01279044|BEHAVIORAL|Standard HIV testing with information only|Standard HIV testing with information only
214665769|NCT00561353|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
214665770|NCT00561353|DRUG|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
214870740|NCT05523024|DIETARY_SUPPLEMENT|Probiotc and Berberine|Probiotics and Berberine groupwill receive both: a probiotics mixture (as in PRO group: 1x109 CFU/day; in one dose) and 1500 mg/day of Berberine (Berberine hydrochloride 97% extract of Berberis aristata; in 3 doses). Probiotcs and berberine will be administered orally before breakfast, before dinner, and before supper.
214870741|NCT05952518|DEVICE|Sprint PNS system|Temporary electrical stimulation of the medial nerve with implanted wires and wearable stimulator
214870742|NCT05952518|PROCEDURE|Radiofrequency Ablation|Thermal ablation of the medial nerve
215036492|NCT06638346|OTHER|Shortened FIFA 11+ warm-up exercise program|"The shortened FIFA11+ incorporates 5 exercises from the original FIFA11+ part 2 and 3: Sideways bench, single-leg stance, squats, jumping and plant and cut (refer to FIFA 11+ manual). All exercises, except plant and cut, have three levels of difficulty. Difficulty progression will follow FIFA11+ guideline option C where all players progress to the next level of all exercises after 3 or 4 weeks. This program is done on artificial turf.~Coaches will be trained on FIFA guidelines by the primary investigator and provided with explanatory placards and the FIFA 11+ manual. The primary investigator will conduct checks twice a week with the coaches to address any questions and review the program. Only the shortened FIFA11+ group will receive verbal feedback as per FIFA11+ guidelines."
215036493|NCT06638346|OTHER|Brazilian warm-up exercise program|"The control group engages in a Brazilian warm-up. The warm-up consists of exercises performed in standing and while running including the following:~* Performed in standing: Circular Arms (20-30 sec total), Opening and closing of the hips (20-30 sec total).~* Performed while running back and forth on the field: Jogging (2 times), high kicks (2 times), glute kicks (2 times)~* Performed while running forward (exercise), then small jog back without performing the exercise: hand-to-heel touches (2 times), knee and heel touches (2 times each side), side leg swings (2 times) and progressive sprint 80-90% speed (2 times).~Coaches will supervise the session but will not be allowed to give verbal feedback. This program is done on artificial turf."
215036494|NCT06638905|DRUG|Babor Ultimate ECM Repair Serum|The BABOR® Ultimate ECM Repair Serum contains Biogen plant extract, cotton thistle flower, and wakame extract. Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
215036495|NCT06638905|DRUG|Babor Cure Cream|Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
215036496|NCT06641609|DRUG|Dose-Escalation (Phase Ia) CFT8919 capsule|Phase 1a，enrolled, eligible patients receive CFT8919 150-900mg twice daily.
215036497|NCT06641609|DRUG|Dose-Expansion (Phase Ib) CFT8919 capsule|Phase 1b，enrolled, eligible patients receive CFT8919 RP2D twice daily.
215036498|NCT06641609|DRUG|Cohort-Expansion (Phase Ic) CFT8919 capsule|Phase 1c，enrolled, eligible patients receive CFT8919 RP2D twice daily.
215036499|NCT04106778|DRUG|DMT310|Topical Powder
215036500|NCT04106778|DRUG|Placebo|Placebo Topical Powder
215036501|NCT06642909|DRUG|Zuberitamab 600mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
215036502|NCT06642909|DRUG|Zuberitamab 1000mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
215036503|NCT06642909|DRUG|cyclosporine|Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)
215036504|NCT06643923|OTHER|Exercise|"F (Frequency): 3 days per week, with a total of 24 sessions. I (Intensity): Low to moderate intensity exercises with progression, ensuring no fatigue is induced.~T (Time): Each session will last 30 minutes, over a total period of 8 weeks.~T (Type):~Warm-up exercises Core stabilization exercises: Aimed at improving core stability. Cool-down exercises E (Enjoyment): Gamified exercises, with sessions conducted to music. A (Adherence): A follow-up system will be implemented, including reminder notes and regular sending of session links to ensure compliance."
215036505|NCT06643923|BEHAVIORAL|Urotherapy|The urotherapy education program was developed by an expert physiotherapist and was piloted with the families of children with DMD (16 parents) prior to the study. Pre-test and post-test assessments demonstrated that the knowledge level of DMD families increased after the training. Additionally, results from the satisfaction survey indicated a high level of satisfaction among the families regarding the urotherapy education (Mean satisfaction score: 33.875/35.000, Minimum=28, Maximum=35). Therefore, it was deemed appropriate to deliver the same urotherapy presentation to the DMD families within the scope of this study. The training lasts approximately 1 hour and will be delivered to families via an online method. Each family will receive the education individually, and no group sessions will be conducted.
215036506|NCT04548999|DRUG|Ocrelizumab|"The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W.~During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)"
215036507|NCT04548999|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg, IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
215036508|NCT04548999|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
215036509|NCT04548999|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
214870743|NCT00462124|DEVICE|Absorbable perirectal spacer|biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
214870744|NCT01329549|DRUG|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
214870745|NCT01329549|DRUG|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
214870746|NCT01329549|DRUG|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
214870747|NCT03337243|PROCEDURE|HAM and HUMCWJ Injections|SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.
214870748|NCT06549283|DEVICE|Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation|Researchers applied NIPPV treatment using binasal cannulas through a mechanical ventilator during intubation.
214870749|NCT05054478|DRUG|Daratumumab|Daratumumab added to induction, first consolidation and second consolidation
214870750|NCT00788320|DRUG|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
214870751|NCT00788320|DRUG|Placebo|Placebo three times a week for 8 weeks
214870752|NCT06625567|OTHER|Animated video|Patients will watch an educational video describing the procedure before hysteroscopy without anesthesia
214870753|NCT06252220|DRUG|DA-1726|Active
215036510|NCT00210132|DRUG|Ropivacaine|"ropivacaine at 7.5 mg/ml: 4 ml + 4 ml of saline solution to obtain 8 ml of a ropivacaine solution at 3.75 mg/ml injected into the intrapleural catheter every 6 hours.~Treatment administration = every 6 hours for 48 hours."
215036511|NCT00210132|DRUG|Reference|8 ml of saline solution will be injected into the intrapleural catheter. Treatment administration = every 6 hours for 48 hours.
215036512|NCT06206265|DRUG|TRYP-0082|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
215036513|NCT06206265|BEHAVIORAL|Psychotherapy|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
215036514|NCT03809351|DRUG|[F-18]AV-1451-PET|All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
215036515|NCT06094803|BEHAVIORAL|Mindfulness-based Zentangle Program|"Session 1 focuses on Self-awareness and Self-kindness through the Zentangle method. It covers the introduction, basic techniques, and eight steps of Zentangle. Participants practice mindfulness and learn grid and round patterns. Drawing mindfully and interactive sharing are encouraged for engagement and reflection.~Session 2 emphasizes Acceptance and Non-judgmental Attitude. It builds on the previous session, exploring advanced techniques in the Zentangle method. Participants practice mindfulness, learn organic and texturing patterns, create their own artwork, and engage in interactive sharing for reflection."
215036516|NCT04028999|DEVICE|Evaluate the effects of the EO31 shoulder sling in adults post-stoke|Investigator want to evaluate the efficient of the EO31 shoulder sling in adults post-stroke. The EO31 shoulder sling is made-to-measure shoulder pads for upper limb after cerebrovascular accident
215036517|NCT05934123|BEHAVIORAL|EMNODN NEC Care Bundle|A care bundle created by the East Midlands Neonatal Operational Delivery Network to guide neonatal services in the region to implement practices that support own mother's milk feeding and other interventions that may reduce the risk of NEC in babies born \<32 weeks' gestational age.
215036518|NCT06484166|OTHER|Fullerene cream|Patients are instructed to apply a thin layer of the Fullerene cream third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
215036519|NCT06484166|DRUG|Trolamine (Biafine)|Patients are instructed to apply a thin layer of the Trolamine (Biafine) third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
215036520|NCT03737292|DRUG|Exparel|The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.
214870754|NCT06252220|DRUG|Placebo to DA-1726|Placebo
214870755|NCT02264912|DRUG|antiplatelet drugs - P2Y12 antagonists|
214870756|NCT02208739|PROCEDURE|Nonsurgical periodontal therapy|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
214870757|NCT02208739|PROCEDURE|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
214870758|NCT03271723|OTHER|Observational study|No intervention
214665771|NCT00561353|DRUG|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
214665772|NCT02511210|BEHAVIORAL|regional anesthesia|preoperative anxiety
214870759|NCT05174195|DRUG|Desogestrel 0.075 milligram|Inserted after 3 months use of DESOGESTREL
214870760|NCT05174195|DRUG|Implanon NXT® subdermal implant|Inserted immediately
214870761|NCT04890912|RADIATION|Conventional Fractionation|Dose prescribed is 45 Gy in 25 fractions (1.8 Gy per fraction) delivered daily over 5 weeks.
215036521|NCT03737292|DRUG|Bupivacaine|The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
215036522|NCT05207670|DRUG|Mosunetuzumab (Cohorts A-C)|Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
215036523|NCT05207670|DRUG|Mosunetuzumab (Cohorts D-E)|Participants will receive SC mosunetuzumab for up to 34 cycles
215036524|NCT05207670|DRUG|Tocilizumab|Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
215036525|NCT04317105|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
215036526|NCT04317105|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215036527|NCT04317105|PROCEDURE|Computed Tomography|Undergo a CT scan
215036528|NCT04317105|DRUG|Copanlisib Hydrochloride|Given IV
215036529|NCT04317105|PROCEDURE|Echocardiography Test|Undergo ECHO
215036530|NCT04317105|BIOLOGICAL|Ipilimumab|Given IV
215036531|NCT04317105|BIOLOGICAL|Nivolumab|Given IV
215036532|NCT04317105|PROCEDURE|X-Ray Imaging|Undergo an x-ray
215036533|NCT06303310|OTHER|Gaze Stability Exercises|Group A ( Gaze Stability Exercise+ Routine Physical Therapy) Group A will receive gaze stability exercises consist of 5 structured components for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.(16)
215036534|NCT06303310|OTHER|Optokinetic Exercises|Group B (Optokinetic Exercises+Routine Physical Therapy) Group B will receive optokinetic exercises for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks
215036535|NCT06303310|OTHER|Routine Physical Therapy|Routine Physical Therapy
215036536|NCT05524012|DIAGNOSTIC_TEST|Blood sample|longitudinal blood samples for CTC monitoring
215036537|NCT05524012|DEVICE|MRI scan|longitudinal MRI scans (non-contrast enhanced)
214870762|NCT04890912|RADIATION|Hypofractionation|Dose prescribed is 30 Gy in 5 fractions (6 Gy per fraction) delivered every other day over 11 days. There will be a minimum of 36 hours and maximum of 96 hours between fractions. The entire course of treatment should be completed within no less than 10 days.
214870763|NCT05546008|DEVICE|Multislice CT|all patient will be subjected to echocardigraphy and multislice ct and compare thier results
214870764|NCT02904824|BIOLOGICAL|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
215036538|NCT05844527|DRUG|MRG-001|MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.
215036539|NCT05844527|DRUG|Saline|Sterile saline will serve as placebo treatment.
214870765|NCT02904824|BIOLOGICAL|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
214870766|NCT05019599|OTHER|low protein diet|Low protein diet (\<0.8g/kg/BW/day)
214870767|NCT04371094|DEVICE|a device to facilitate endotracheal intubation|a device to facilitate endotracheal intubation
215036540|NCT04331249|PROCEDURE|surgery or catheter based cardiac procedure (catheter ablation)|patients with implanted CIED (pacemaker, ICD or CRT) that undergo any surgery or any catheter based cardiac procedure (e.g. radiofrequency ablation)
215036541|NCT04436731|OTHER|Hypoxia Exposure|Systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
215036542|NCT04436731|DRUG|Phenylephrine|Phenylephrine (0.0625 mcg/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
215036543|NCT04436731|DRUG|Dexmedetomidine|Dexmedetomidine (12.5 ng/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
215036544|NCT04436731|DRUG|Phentolamine|Phentolamine will be locally infused via brachial artery catheter for 10 min before baseline measurement (12 mcg/dL/min) and the infusion will continue at a maintenance rate (5 mcg/dL/min) during acute normoxia and hypoxia.
215036545|NCT04436731|DRUG|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
215036546|NCT03925246|DRUG|Nivolumab|"Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity."
214665773|NCT02511210|BEHAVIORAL|general anesthesia|preoperative anxiety
214665774|NCT03728673|DRUG|Escitalopram Oral Capsules|Active capsules will contain 10 mg escitalopram oxalate.
214665775|NCT02601144|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
214665776|NCT03431948|DRUG|Nivolumab|Nivolumab 240 mg given by intravenous infusion every 2 weeks
214665777|NCT03431948|DRUG|Cabiralizumab|Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
214665778|NCT03431948|DRUG|Urelumab|Urelumab 8 mg given by intravenous infusion every 4 weeks
215036547|NCT00432965|DEVICE|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
215036548|NCT00432965|DEVICE|VAC Therapy|VAC Therapy
214665779|NCT03431948|RADIATION|Stereotactic Body Radiation Therapy|Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
214665780|NCT06244927|PROCEDURE|Replantation surgery|Surgery
214665781|NCT05817201|DRUG|Toripalimab|Toripalimab 240mg day7 and day 28，every 3 weeks 1month after radiotherapy，until progression or 1 years or intolerant.
214665782|NCT05817201|DRUG|Tegafur|Tegafur 70mg/m2/day day 1 to day 14，and day 29 to day42.
214665783|NCT05817201|RADIATION|IMRT|PGTV 54Gy/2.16Gy/25F/5W, PTV 45Gy/1.8Gy/25F/5W
214665784|NCT05498298|DEVICE|Biopotentials measurement with gtec device|A measurement of 40 minutes is performed with the gtec g.Hlamp to collect biopotential signals. 32 electrodes are attached to the body (abdomen, thorax and back).
214665785|NCT04255134|DRUG|Abatacept Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
214665786|NCT04255134|DRUG|Adalimumab Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
214665787|NCT01663441|DRUG|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
214665788|NCT01663441|DRUG|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
214870768|NCT06175988|OTHER|Visceral adiposity|Visceral adiposity assess by the visceral adiposity index
214870769|NCT02609074|PROCEDURE|Minimally invasive internal fixation surgeries|
214870770|NCT02609074|DEVICE|CPC/rhBMP-2 micro-scaffolds|
214870771|NCT02609074|DEVICE|CPC paste|
214870772|NCT05580965|OTHER|20 N pressure for 1 minute|After blood collection, 20 N pressure applied for 1 minute
214870773|NCT05580965|OTHER|20 N pressure for 3 minute|After blood collection, 20 N pressure applied for 3 minute
214870774|NCT05580965|OTHER|20 N pressure for 5 minute|After blood collection, 20 N pressure applied for 5 minute
214870775|NCT05324410|DRUG|VX-840|Solution for oral administration.
214870776|NCT05324410|DRUG|Placebo|Placebo matched to VX-840 for oral administration.
214870777|NCT04163510|BEHAVIORAL|Behavioral: Parent/Child Reading Program|A 9-week parent/child reading program will help parents to identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading. Three large-group sessions will be held in a central location, to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. Intervention sessions will be held once per week for 60-90 minute sessions.
215036549|NCT02381587|OTHER|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
215036550|NCT05804045|DRUG|Pimicotinib(ABSK021)|capsule
215036551|NCT05804045|DRUG|Placebo|capsule
214665789|NCT01663441|DRUG|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
214665790|NCT01663441|DRUG|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
214665791|NCT04813510|DEVICE|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi, electroacupuncture stimulation apparatus(HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
214665792|NCT04813510|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints).. Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
214665793|NCT03180762|DRUG|JNJ-64140284 0.1 mg|0.1 mg of JNJ-64140284 will be administered as an oral solution.
214665794|NCT03180762|DRUG|JNJ-64140284 0.5 mg|0.5 mg of JNJ-64140284 will be administered as an oral solution.
214665795|NCT03180762|DRUG|JNJ-64140284 2.5 mg|2.5 mg of JNJ-64140284 will be administered as an oral solution.
214665796|NCT03180762|DRUG|JNJ-64140284 10 mg|10 mg of JNJ-64140284 will be administered as an oral solution.
214665797|NCT03180762|DRUG|JNJ-64140284 50 mg|50 mg of JNJ-64140284 will be administered as an oral solution.
214665798|NCT03180762|DRUG|JNJ-64140284 150 mg|150 mg of JNJ-64140284 will be administered as an oral solution.
214665799|NCT03180762|DRUG|JNJ-64140284 (dose to be determined [TBD])|JNJ-64140284 (dose to be determined) will be administered as an oral solution.
214665800|NCT03180762|DRUG|Placebo|Matching placebo will be administered.
214665801|NCT00789204|OTHER|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
214665802|NCT00789204|OTHER|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
215036552|NCT05168293|OTHER|Detection of HBV-DNA in Peripheral Blood Mononuclear cells|Detection of HBV-DNA level in Peripheral Blood mononuclear cells
215057216|NCT01416740|PROCEDURE|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
214870778|NCT03928210|DRUG|Digoxin|Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
214870779|NCT05782881|BEHAVIORAL|phone calls and encouraging patients' lifestyle change and medication adherence|Use some methods to strictly intervene blood glucose , blood pressure and blood lipids for protocol treatment group people.
214870780|NCT05782881|DRUG|Statin|Treatment and management according to the guidelines
214870781|NCT02421224|BEHAVIORAL|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
214870782|NCT02421224|BEHAVIORAL|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
214870783|NCT02421224|BEHAVIORAL|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
214870784|NCT02421224|BEHAVIORAL|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
214870785|NCT02421224|BEHAVIORAL|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
214870786|NCT02421224|BEHAVIORAL|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
214870787|NCT03016819|DRUG|AL3818|Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
214870788|NCT03016819|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
214870789|NCT03016819|DRUG|AL3818 or placebo|AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
214870790|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^7 pfu /2mL administered in each deltoid
214870791|NCT00083603|BIOLOGICAL|rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)|Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
214870792|NCT00083603|BIOLOGICAL|Empty TBC-FPV|Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
214870793|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^8 pfu /2mL administered in each deltoid
214870794|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^9 pfu /2mL administered in each deltoid
215036553|NCT04046237|OTHER|Periodontal treatment|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
215036554|NCT05680818|DRUG|Encaleret|Administered as film-coated tablet for oral use
215036555|NCT05680818|DIETARY_SUPPLEMENT|Standard of Care|Calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
215036556|NCT03180268|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215036557|NCT03180268|OTHER|Clinical Observation|Undergo observation
214870795|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^7 pfu/2mL administered into each deltoid
214870796|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^8 pfu/2mL administered into each deltoid
214870797|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^9 pfu/2mL administered into each deltoid
214870798|NCT03451552|BEHAVIORAL|Patient Navigator|Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
214870799|NCT01114100|DRUG|sertraline|starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
214870800|NCT01114100|DRUG|placebo|patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
214870801|NCT02695537|DRUG|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
215036558|NCT03180268|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214870802|NCT06223087|OTHER|winter swimming|Intervention involves bathing/swimming in cold water during the winter months in open waters
214870803|NCT02032797|DRUG|Progesterone|
215036559|NCT03180268|OTHER|Laboratory Biomarker Analysis|Correlative studies
215036560|NCT03180268|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215036561|NCT03180268|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
215036562|NCT03180268|OTHER|Quality-of-Life Assessment|Ancillary studies
215036563|NCT06963021|DRUG|NBI-1065845|NBI-1065845 tablets
215036564|NCT06963021|DRUG|Placebo|Matching placebo tablets
215036565|NCT04595201|DEVICE|NIPT|Non-invasive pregnancy testing
215036566|NCT03255473|DRUG|Dexamethasone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
214665803|NCT06159855|OTHER|Intervention group: nurse-led education for bowel preparation of colonoscopy|"1. PRE-TEST~   a) Patients will be evaluated using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~2. INTERVENTION~   1. Patients will be given face-to-face training in the clinic training room of the unit.~  2. After face-to-face training is given, an educational brochure will be given to the patient.~  3. If the patient is constipated, the bowel preparation diet is requested to be started 5 days in advance. If the patient is not constipated, the bowel preparation diet is started 3 days in advance.~  4. After the intervention group is given bowel preparation training, reminders about colonoscopy will be made via instant messaging 3 to 5 days before the day of the colonoscopy.~3. LAST TEST~   1. Data will be collected again using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~  2. The cleanliness of the intestines will be evaluated by the physician using the Ottawa Bowel Preparation Scale."
214665804|NCT05651971|BEHAVIORAL|measurement group|Measurement of the distance between the origin of LCA (left colonic artery，LCA) and IMA (inferior mesenteric artery，IMA) root and the distance between IMA and IMV (inferior mesenteric vein，IMV) at the origin of LCA in rectal cancer patients
214870804|NCT04538183|OTHER|WO 5000|WO 5000
215036567|NCT03255473|DRUG|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
215036568|NCT01732185|GENETIC|Patient|Blood and histological samples will be done at day of the inclusion.
215036569|NCT06057532|DIETARY_SUPPLEMENT|UCAN SuperStarch|Intervention patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the intervention study drink and record information about how they feel before and after consumption.
215036570|NCT06057532|DIETARY_SUPPLEMENT|Gatorade|Active control patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the active control study drink and record information about how they feel before and after consumption.
215036571|NCT05246566|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
215036572|NCT06803030|DRUG|Tamsulosin Hydrochloride 0.4 mg|placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily
215036573|NCT06803030|DRUG|Solifenacin Succinate 5 mg|placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily
215036574|NCT06803030|DRUG|Mirabegron 25 mg|placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily
215036575|NCT05462262|DRUG|Intensive lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
215036576|NCT05462262|DRUG|Moderate-intensity lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
215036577|NCT00537797|OTHER|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
215036578|NCT06558578|DIAGNOSTIC_TEST|Helicobacter pylori antigen in stool|"H pylori antigen in stool: for all patients suffering from migraine and control group.~Upper GIT endoscopy: for children with positive H Pylori antigen in stool."
215036579|NCT06503913|BEHAVIORAL|Cognitive Muscular Therapy|Psychologically informed physiotherapy which integrates training to reduce overactivity of postural muscles which can interfere with the mechanics of breathing.
215036580|NCT06503913|BEHAVIORAL|Breathing visualisation|Breathing visualisation; Data from two 3D camera are combined and used to calculate respiratory volumes. These volumes are then used to drive an animation of breathing so that the patient can understand how their breathing pattern compares to an optimal pattern. Note this is not a medical device as data from this system is only used for education and not for diagnostic or treatment decisions.
215036581|NCT06563375|DRUG|NP-101|Given by mouth
214870805|NCT04538183|OTHER|WO 5001|WO 5001
214870806|NCT03680989|DEVICE|Bright Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver \~10,000 lux at 22."
214870807|NCT03680989|DEVICE|Natural Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver \~500 lux at 22."
214870808|NCT03597529|DRUG|Melatonin|melatonin
214870809|NCT00381160|BEHAVIORAL|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
214870810|NCT06194760|PROCEDURE|Vitrectomy with ILM peeling|Vitrectomy with traditional internal limiting membrane (ILM) peeling technique is regarded as the gold standard treatment for MH; it works by completely relieving of the traction of the macula and increasing the flexibility of the retina
214870811|NCT03769714|DRUG|Saline Solution for Injection|Injection of 20mL of 0.9%Normal Saline
214870812|NCT03769714|DRUG|Exparel|Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
214870813|NCT05412238|DIETARY_SUPPLEMENT|micro-and macro-nutrients fortified sachets|Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months
214870814|NCT04263324|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care.
214870815|NCT01140399|DRUG|Furosemide or Furosemide and Dopamine|"Patients randomized to pharmacological treatment receive~* either intravenous diuretics at escalating doses up to 20 mg/h~* or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m."
214665805|NCT07030153|GENETIC|Oral swab DNA analyzed for myopia-related gene variants|Beyond detecting links between gene variants and myopia development, the testing analyzes how these variants influence treatment effectiveness. The aim is to enable early risk prediction and personalized treatment guidance for children through oral DNA testing.
214870816|NCT01140399|DEVICE|Ultrafiltration|"All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight~* less than 3 kg 200 ml/h~* more than 3 kg and less than 5 kg 300 mlh~* more than 5 kg 500 mlh~Criteria for achievement of target UF goals are removal of \> 50% and \<70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited"
214870817|NCT04191850|PROCEDURE|Single Port Video-Assisted Thoracoscopic Surgery|Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
214870818|NCT02538380|PROCEDURE|EUS-B-FNA followed by EUS-FNA for LAG analysis|
214870819|NCT00401609|DRUG|gemcitabine|
214870820|NCT00401609|DRUG|vinorelbine|
214870821|NCT00401609|DRUG|cisplatin|
214870822|NCT00401609|DRUG|etoposide|
214870823|NCT00401609|DRUG|carboplatin|
214870824|NCT06453369|PROCEDURE|Y shaped Tunnel with Connective tissue graft|Sulcular incision followed by Micro-periosteal elevator will be used to elevate vertical full thickness tunnel starting coronally from the gingival sulcus and directed apically. CTG will be prepared and inserted into the coronal tunnel aperture using blunt instrument to facilitate intrusion of graft into tunnel. CTG insurted into the tunnel up to the apical level leaving a coronal part to completely cover the recession defect. Finally single interrupted suture will be used to secure the coronal exposed part of the CTG followed by sling suture fixation of the gingival flap with that of CTG. The donor CTG will be stabilized to the underlying connective tissue interproximally using 5.0 sutures.
215036582|NCT05580042|DRUG|AC-1101|For each patient, once daily (QD)
215036583|NCT05548283|DRUG|Beta-lactam antibiotic|Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
215036584|NCT05548283|DRUG|Aminoglycoside|Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
215036585|NCT01648868|DEVICE|Transcranial Magnetic Stimulation (rTMS)|Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
215036586|NCT01648868|DEVICE|Transcranial Magnetic Stimulation (rTMS)|Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
215036587|NCT03615638|OTHER|Fall prevention program|12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
215036588|NCT01292031|DRUG|Colistin|Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion
214665806|NCT06781294|DEVICE|Extracorporeal Cytokine hemadsorption therapy|Extracorporeal blood purification with oXiris set connected to cardiopulmonary bypass during all CPB time. Ultrafiltration was permitted.
214665807|NCT06456554|DEVICE|Acellular Dermal Matrix (Cortiva Tissue Matrix)|non-crosslinked dermis
215036589|NCT01292031|DRUG|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
215036590|NCT03344887|OTHER|RBC Transfusion from male donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
215036591|NCT03344887|OTHER|RBC Transfusion from female donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
215036592|NCT06506747|DEVICE|Navigated Photogrammetry|Navigated Photogrammetry shall be performed following implant surgery, rather than standard stereophotogrammetry. The patient will then receive a provisional that was manufactured using the data from FastMap Navigated Photogrammetry.
215036593|NCT06506747|DEVICE|Standard Photogrammetry|The patient will receive the existing patient care protocol that includes anatomy information for the manufacturing of the provisional. Specifically, the patient will receive a preoperative IntraOral Scan (IOS) anatomy scan with IOS-compatible fiducials. Following implant surgery, the patient will receive a scan with a standard stereophotogrammetry device. Additionally, they will receive a post-op alignment IOS with IOS-compatible anatomy fiducials and IOS-compatible implant scan bodies. The patient will then receive a provisional that was manufactured using the data from the standard stereophotogrammetry device.
215036594|NCT02484274|BIOLOGICAL|Blood samples|1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
215036595|NCT03925480|DRUG|Azithromycin 500 mg Oral Tablet x 4|A single prophylactic dose of antibiotic given during labour
215036596|NCT03925480|DRUG|Matching Placebo|Matching Placebo
214870825|NCT01755767|DRUG|Tivantinib|Tivantinib tablets
214870826|NCT01755767|DRUG|Placebo|Matching placebo tablets
214870827|NCT04665466|DEVICE|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
214870828|NCT02211196|BEHAVIORAL|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
214870829|NCT02211196|OTHER|survey administration|Ancillary studies
214870830|NCT02211196|OTHER|questionnaire administration|Ancillary studies
215036597|NCT04565665|OTHER|Best Practice|Receive standard of care
215036598|NCT04565665|BIOLOGICAL|Mesenchymal Stem Cell|Given IV
214870831|NCT06277232|OTHER|Nutrition care|Nutrition care is designed to include nutrition assessment (e.g., malnutrition screening, monitoring weight changes, etc.), optimization of individual dietary patterns, and evaluation. Through the Diet4painrelief platform, a dietician will follow up the progress of each participant in different timepoints and also plan meetings with other professionals in IPRP. A dietitian together with a physician in rehabilitation are responsible for the administration of the procedure.
214870832|NCT06277232|BEHAVIORAL|Dialogue and education (part of Interdisciplinary Pain Rehabilitation Program)|Dialogue and education consists of patient education, training in wellness and healthy living habits, meetings with families, video feedback, and couples therapy and self-training (e.g., home lessons, activity diary, physical self-training, reflection time, and self-analysis. . In addition, lectures in basic pain science and pain management are offered for both patients as well as for relatives, friends, and colleagues.
214870833|NCT06277232|BEHAVIORAL|activity training (part of Interdisciplinary Pain Rehabilitation Program)|Activity training includes graded activity training, and exposure training, which are delivered by an interdisciplinary team (i.e., a physiotherapist, an occupational therapist, and a psychologist).
214870834|NCT06277232|BEHAVIORAL|meetings (part of Interdisciplinary Pain Rehabilitation Program)|The meetings consist of conferences with patients, rehabilitation team, vocational guidance, rehabilitation coordinator, goal-setting meetings, and meetings to check goal achievement.
214870835|NCT06277232|BEHAVIORAL|Cognitive behavioral therapy (part of Interdisciplinary Pain Rehabilitation Program)|Acceptance and Commitment Therapy (ACT, e.g., goal compass, training in ACT principles, and mindfulness) is mainly delivered by psychologist in a group-treatment (e.g., training in coping strategies). The cognitive behavioral principles are also used in physiotherapy, ergonomics, and education in pain management.
214870836|NCT06277232|BEHAVIORAL|Relaxation techniques (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist and psychologist in an interdisciplinary team.
214870837|NCT06277232|BEHAVIORAL|Physical exercise (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist in an interdisciplinary team.
214870838|NCT03464630|BEHAVIORAL|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
214870839|NCT03464630|BEHAVIORAL|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
214870840|NCT04774744|OTHER|Educational Intervention|Receive digital health coaching program
214870841|NCT04774744|OTHER|Questionnaire Administration|Ancillary studies
215036599|NCT05662202|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT):~Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
215036600|NCT05662202|COMBINATION_PRODUCT|Vehicle and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT):~Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
215036601|NCT05949099|DRUG|Nirogacestat|Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.
215036602|NCT05949099|PROCEDURE|Cryoablation|Cryoablation procedure (single session) of one tumor mass between Cycles 3 and 4 of nirogacestat treatment
215036603|NCT02464748|OTHER|TiM telehealth arm|
215036604|NCT05677347|DRUG|GSK3923868|GSK3923868 will be administered
215036605|NCT05677347|DRUG|Placebo|Placebo will be administered
215036606|NCT04615013|DRUG|Capecitabine|Not applicable to this study
215036607|NCT04615013|DRUG|Carboplatin|Not applicable to this study
215036608|NCT04615013|DRUG|Docetaxel|Not applicable to this study
215036609|NCT04615013|DRUG|Fluorouracil|Not applicable to this study
215036610|NCT04615013|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or IN
215036611|NCT04615013|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215036612|NCT04615013|DRUG|Leucovorin|Not applicable to this study
215036613|NCT04615013|DRUG|Oxaliplatin|Not applicable to this study
215036614|NCT04615013|DRUG|Paclitaxel|Not applicable to this study
214870842|NCT04774744|OTHER|Supportive Care|Receive standard of care support services
214870843|NCT00191165|DRUG|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
214870844|NCT00191165|DRUG|Somatropin|In-label dosage
214870845|NCT03152734|PROCEDURE|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
214870846|NCT05554081|DEVICE|Peezy urine collection device|use peezy collection to obtain urine sample
214870847|NCT02033538|DRUG|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
214870848|NCT03007238|BIOLOGICAL|Aldesleukin|Given SC
214870849|NCT03007238|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
215036615|NCT04728113|OTHER|Supportive care visit with questionnaires|5 Questionnaires (SCNS, QLQ-C30, HADS, PTPQ, GSE) will be filled by the patient with introduction of supportive care visit
215036616|NCT04728113|OTHER|Oncological standard visit|Oncological standard visit
214870850|NCT03007238|OTHER|Laboratory Biomarker Analysis|Correlative studies
214870851|NCT03007238|OTHER|Quality-of-Life Assessment|Ancillary studies
214870852|NCT03196635|DEVICE|Patient-Assisted (PA) Breast Compression|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC \& MLO.
214870853|NCT03196635|DEVICE|Technologist-Controlled (TC) Breast Compression|TC compression will be conducted per standard of care practices at the site.
214870854|NCT01273896|DRUG|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
214870855|NCT05690490|PROCEDURE|Endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion with an offset of 2-5 mm. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
214870856|NCT05690490|PROCEDURE|Endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision is made around the lesion. Then dissection will be performed in the submucosal layer.
214870857|NCT05340829|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia
214870858|NCT01023048|OTHER|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
214870859|NCT00670202|DRUG|Fasudil Hydrochloride|Fasudil 40 mg three times a day x 14 days
214870860|NCT00670202|DRUG|Placebo Oral Tablet|Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
214870861|NCT03997279|DRUG|Saccharomyces boulardii|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
214870862|NCT03997279|DRUG|Placebo|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
214870863|NCT05801718|DIAGNOSTIC_TEST|Growth parameters & body mass index|measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.
214870864|NCT00400699|OTHER|counseling intervention|
214870865|NCT00400699|OTHER|study of socioeconomic and demographic variables|
214870866|NCT00400699|PROCEDURE|psychosocial assessment and care|
214870867|NCT01316315|DRUG|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
214870868|NCT01316315|DRUG|Placebo|Same as active
214291075|NCT01317160|DEVICE|Intermittent pneumatic compression (IPC)|6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
214870869|NCT00998309|DRUG|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
214870870|NCT03769207|DEVICE|Ambulatory ECG|Eligible participants are asked to wear the ambulatory ECG monitor
214870871|NCT01680107|DRUG|d-cycloserine|
214870872|NCT01680107|DRUG|placebo|
214870873|NCT01680107|BEHAVIORAL|cognitive-behaviour therapy|
214870874|NCT01425411|DRUG|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
214870875|NCT06453252|OTHER|we are aiming to develop a Scoring system based on certain variables derived from both groups|We are aiming to develop a Scoring system based on certain variables derived from both group
214870876|NCT05566184|DEVICE|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure, and the data will be collected. In the application of vascular access to children, a) before the procedure (20 minutes before), b) just before the procedure (20. minutes), c) during the procedure (between 20.-40. minutes), and d) 20 minutes after the procedure (40. minutes). Physiological variables that will be evaluated four times, once for each application, will be observed on the monitor, the FLACC Pain Assessment Scale will be recorded by the researcher and salivary cortisol level will be measured.
214870877|NCT05543343|DRUG|High dose or normal dose staphylococcus albicans|8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
214291076|NCT03601689|PROCEDURE|rectal resection|total mesorectal excision
214870878|NCT05543343|DRUG|Placebo|8 placebo tablets 3 times daily
214870879|NCT05233852|OTHER|"Do not do recommendation"|A drug prescription or procedure included in 'do not do' recommendations
214870880|NCT01667237|BEHAVIORAL|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
215036617|NCT06530615|PROCEDURE|Bronchoalveolar Lavage (BAL) during Bronchoscopy|Bronchoalveolar Lavage (BAL) is a standard diagnostic tool for the evaluation of lower respiratory tract pathology including respiratory infections and unexplained radiographic pulmonary lesions including lung neoplasia. It is a minimally invasive procedure that involves introduction of the bronchoscope, installation of sterile normal saline into a subsegment of the lung, and suction and collection of the recovered saline for diagnostic evaluation.
215036618|NCT04179981|DEVICE|Positive airway pressure|Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.
215036619|NCT04179981|OTHER|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
215036620|NCT03649503|OTHER|No intervention|
215036621|NCT01890330|OTHER|Canola Oil 25 g/d|Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
214670043|NCT03822403|DEVICE|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
214870881|NCT04643561|OTHER|Travelan OTC|5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
214870882|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^9 CFU/day)|
214870883|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^8 CFU/day)|
214870884|NCT02032056|OTHER|Placebo|
214870885|NCT00380744|DRUG|LY2189102|
214870886|NCT00380744|DRUG|placebo|
214870887|NCT03936595|OTHER|Core exercises protocol|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
214870888|NCT03936595|OTHER|Structural exercises protocol|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
214870889|NCT03936595|OTHER|Accentuated eccentric load exercises protocol|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Hip thrusts, 4 sets of 5 repetitions at 30% BM"
214870890|NCT03936595|OTHER|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
214870891|NCT06500793|DRUG|PF614 capsule|PF614 capsules (25-100 mg)
214870892|NCT06500793|DRUG|Nafamostat Mesylate|Nafamostat IR/ER solution/beads (total 1-10 mg)
214870893|NCT06287138|DRUG|ciprofol|Ciprofol will be infused at 0.3，0.4，0.5，0.6，0.7，0.8 mg/kg/h in sequence for 30 minutes at each dose.
215036622|NCT01890330|OTHER|Non-Canola Oil Mixture 25 g/d|Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
215036623|NCT05400564|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
215036624|NCT06326060|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
215036625|NCT06326060|DRUG|Placebo|Placebo will be administered subcutaneously.
215036626|NCT06326060|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
215036627|NCT06569797|DIETARY_SUPPLEMENT|oligosaccharides and multiple nutrients|The effect of adding milk oligosaccharides and optimizing multiple nutrients to infant formula on the growth and development of infants aged 0-1 years
215036628|NCT06569797|DIETARY_SUPPLEMENT|no oligosaccharides and optimizing multiple nutrients|The effect of traditional infant formula milk powder optimized without adding milk oligosaccharides and multiple nutrients on the growth and development of infants aged 0-1 years old.
215036629|NCT06569797|DIETARY_SUPPLEMENT|breastfeeding|The impact of breastfeeding on the growth and development of infants aged 0-1 years old.
215036630|NCT01803633|OTHER|Cheddar cheese|Tillamook medium cheddar cheese brand
215036631|NCT01803633|OTHER|Vegan cheese|Daiya brand vegan cheese
215036632|NCT06053892|DIAGNOSTIC_TEST|Puncture|Shoulder puncture with the newly designed technique using AR to overlie the US image to the imaged anatomical structures in comparision to standard US and flurosopic-guidance.
215036633|NCT06515106|BEHAVIORAL|Remote cognitive rehabilitation program|Behavioral: Remote cognitive rehabilitation program Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
214870894|NCT02005835|OTHER|Community based peer support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment"
214870895|NCT02005835|OTHER|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment"
214870896|NCT01497808|DRUG|Ipilimumab|
214870897|NCT01497808|RADIATION|Stereotactic Body Radiation Therapy|
214870898|NCT02816008|BEHAVIORAL|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
215036634|NCT06082453|DIAGNOSTIC_TEST|Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum|A quantitative polymerase chain reaction (qPCR) assay detects and quantifies DNA in a sample, and the qPCR assay used in this study targets the polA gene of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. qPCR data will only be used to determine testing performance and will not be used in clinical management of study participants.
215036635|NCT06082453|DIAGNOSTIC_TEST|Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum|The Aptima transcription-mediated amplification (TMA) assay used in this study will target RNA of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. TMA data will only be used to determine testing performance and will not be used in clinical management of study participants.
215036636|NCT06082453|OTHER|Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis|Using the Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines, new born syphilis infection is categorized by clinical providers at birth as follows: confirmed proven/highly probably, possible congenital syphilis (CS), CS less likely, or CS unlikely. These CS categories are determined using neonatal nontreponemal test results, physical exam of the infant, placental pathology, and maternal serologies and treatment history, and comparison of maternal and neonatal nontreponemal tiers. These data will be collected as part of standard clinical care.
215036637|NCT06151197|BIOLOGICAL|EN3835|Biologic: EN3835 injection
215036638|NCT06151197|OTHER|Placebo|Placebo injection
215036639|NCT06395935|OTHER|Wecare (website)|support feedback of qutionaire \& supply educational contents
215036640|NCT01715870|BEHAVIORAL|Life style and food habits questionnaire|
215036641|NCT04031508|COMBINATION_PRODUCT|lipid injectable emulsion with Fish oil|TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.
215036642|NCT06149442|OTHER|Dose of five-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (five incisions).
215036643|NCT06149442|OTHER|Dose of ten-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (ten incisions).
215036644|NCT06149442|OTHER|Dose of fifteen-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (fifteen incisions).
215036645|NCT06647589|BEHAVIORAL|Acceptance and Commitment Therapy|participants will then receive ACT-based individual therapy weekly for twelve weeks.
215036646|NCT05510908|OTHER|Non-Interventional|Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
215036647|NCT05510908|OTHER|Non-Interventional Follow-up|Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
215036648|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 1|Investigational RSV vaccine 1 administered intramuscularly on Day 1 and Day 30.
215036649|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 2|Investigational RSV vaccine 2 administered intramuscularly on Day 1 and Day 30.
215036650|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 3|Investigational RSV vaccine 3 administered intramuscularly on Day 1 and Day 30.
215036651|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 4|Investigational RSV vaccine 4 administered intramuscularly on Day 1 and Day 30.
215036652|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 5|Investigational RSV vaccine 5 administered intramuscularly on Day 1 and Day 30.
215036653|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 6|Investigational RSV vaccine 6 administered intramuscularly on Day 1.
215036654|NCT06573281|DRUG|Placebo|Placebo administered intramuscularly on Day 1 and Day 30 and for RSV\_Group F placebo administered only on Day 30.
215036655|NCT06088667|OTHER|Fascial mobilization group|In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments for 4 weeks.
215036656|NCT03636022|OTHER|VR System|Use of virtual reality to deliver exposure therapy
215036657|NCT03636022|OTHER|Control|Use of conventional delivery of exposure therapy
215036658|NCT04950153|BEHAVIORAL|Peer navigation|Peer navigators will navigate youth with HIV to provide assistance and support to optimize adherence to antiretroviral treatment (ART)
215036659|NCT04950153|BEHAVIORAL|SMS Text messaging|Short Message System (SMS) text messages to remind and encourage youth to adhere to their ART
215036660|NCT04950153|BEHAVIORAL|Social Media Engagement|HIV testing outreach using social media platforms to promote HIV testing.
215036661|NCT04950153|BEHAVIORAL|Testing Peer Navigation|Peer navigators will conduct HIV testing outreach and linkage to care to at-risk youth
215036662|NCT03762018|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
215036663|NCT03762018|DRUG|Pemetrexed|Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
214291077|NCT03898050|PROCEDURE|transcutaneous cardiac pacing|transcutaneous cardiac pacing
214291078|NCT01774968|DRUG|Human Regular U-500 Insulin|
214291079|NCT04984798|DRUG|Vitamin E|Twice daily oral supplementation with Vitamin E for 6-9 weeks.
214291080|NCT02044393|DRUG|itraconazole|multiple doses of itraconazole given as capsules
214870899|NCT02816008|BEHAVIORAL|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
214476547|NCT06769802|BEHAVIORAL|Experimental|"The children in this group and their mothers will be informed about the research and their written consent will be obtained. The scale will be filled in before the application. Before the application, Nebul will introduce the teddy bear to the mother and child. The teddy bear cannot be washed because it contains an electronic device. Therefore, it will be disinfected with a solution containing 60-70% alcohol before and after use. The recorded voice will then be played to the child and mother. Then, routine nebulizer treatment will be applied and the second audio recording will be played at the end of the treatment. The researcher will be with the child.~At the end of the nebulizer treatment, after the mask is removed, the Child Fear Scale and the Child Anxiety Scale-State Scale will be filled out. The Child Fear Scale will be filled in by both the mother and the nurse and the average will be taken."
214870900|NCT01015937|DRUG|Turmeric extract|turmeric 500 mg TID for 45 days
214870901|NCT01015937|DRUG|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
214870902|NCT00555152|OTHER|Laboratory Biomarker Analysis|Correlative studies
214870903|NCT00555152|DRUG|Lapatinib Ditosylate|Given PO
214870904|NCT00555152|OTHER|Placebo|Given PO
214870905|NCT01971437|PROCEDURE|Cystodistension & Cystoscopy|Women with refractory OAB receiving Cystoscopy and cystodistension
214870906|NCT03983915|DRUG|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
214870907|NCT03983915|DRUG|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
214870908|NCT03983915|DEVICE|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
214870909|NCT04150770|DRUG|infliximab|
214870910|NCT02467478|DRUG|Linagliptin|5 mg tablet once daily for 12 weeks
214870911|NCT02467478|DRUG|Placebo|1 tablet daily for 12 weeks
214870912|NCT06692400|PROCEDURE|endotracheal tube suctioning|Endotracheal tube suctioning occurs as part of normal care for intubated patients. This procedure will serve as the painful procedure to assess CPOT and biomarkers of hypoxia and oxidative stress.
214870913|NCT03490344|DRUG|Daratumumab|"* Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~* Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)"
214870914|NCT03490344|DRUG|Lenalidomide|Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
214870915|NCT01340326|DRUG|high dose of valsartan|comparison of different dosages of drug
214870916|NCT01340326|DRUG|usual dose of valsartan|comparison of different dosages of drug
214870917|NCT04997226|DEVICE|tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 1 and 3.
214870918|NCT04997226|DEVICE|Sham tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 2 and 4.
214870919|NCT02877459|DEVICE|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
214870920|NCT00276861|DRUG|gemcitabine hydrochloride|
214870921|NCT00276861|DRUG|oxaliplatin|
214870922|NCT02337296|BEHAVIORAL|ADHERE|"ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence."
214870923|NCT03065218|DRUG|99mTc sestamibi|The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.
214870924|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
214870925|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
214870926|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.
214870927|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.
215036664|NCT03762018|DRUG|Bevacizumab|Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
214870928|NCT01781741|COMBINATION_PRODUCT|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
214870929|NCT01781741|OTHER|quality-of-life assessment|Ancillary studies
214870930|NCT05302830|BEHAVIORAL|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
214870931|NCT05302830|BEHAVIORAL|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
214870932|NCT04521582|DRUG|Amlodipine|The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times \[including baseline and end of the study\] in the active municipality and 3 times \[including baseline and end of the study\] in the control municipality).
214870933|NCT04521582|BEHAVIORAL|Lifestyle counselling|Female Community Health Volunteer will provide lifestyle counseling at the participant's home
214870934|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Ropivacaine|
214870935|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Saline|
214870936|NCT04361149|DRUG|Capsaicin Topical Cream (0.075%)|Capsaicin cream will be administered as a topical skin cream
214870937|NCT04361149|DEVICE|Delsys Trigno Galileo System|A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.
214870938|NCT04361149|DEVICE|Excaliber, Natus Medical|Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.
214870939|NCT04361149|OTHER|Placebo Cream|Placebo cream will be administered as a topical skin cream
214870940|NCT02052050|OTHER|core stability|
215036665|NCT03762018|DRUG|Atezolizumab|Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
215036666|NCT03834363|DRUG|Fentanyl|Fentanylpatch 12 mcg/hr, change patch every three days.
215036667|NCT03834363|DRUG|Morphine Retard|Morphine retard capsules 10 mg bid.
215036668|NCT03834363|DRUG|Placebo patch|Placebo patch, change patch every three days.
215036669|NCT03834363|DRUG|Placebo oral capsule|Placebo oral capsule bid
214870941|NCT02497651|DIETARY_SUPPLEMENT|Liquid mixed meal|The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
214870942|NCT02497651|OTHER|Skin Biopsy|All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
214870943|NCT02348723|DRUG|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0
214870944|NCT02348723|DRUG|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
214870945|NCT03915028|OTHER|Spa therapy|"The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~* Cure of Drink (in addition to 4 daily cares)~* Bath in running water: Bath~* Bath in running water: Pool at 32 ° C~* Bath with aerobain~* Immersion shower bath~* Shower of high pressure under immersion in swimming pool~* General penetrating shower~* General jet shower~* Local jet shower~* Local mud bath at the feet~* Single poultice~* Multiple poultice~* Compress~* Mobilization pool~* Massages under water"
214870946|NCT01064050|DEVICE|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
214870947|NCT01337258|DRUG|Dutasteride|dutasteride 0.5mg daily.
214870948|NCT01337258|DRUG|Placebo|Men taking placebo daily
215036670|NCT02748798|DRUG|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
215036671|NCT02748798|DRUG|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
215036672|NCT02748798|DRUG|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
215036673|NCT02748798|DRUG|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
214870949|NCT00541879|BEHAVIORAL|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
214870950|NCT00541879|OTHER|comparison|
214870951|NCT06595303|DRUG|Nitrous oxide for labour analgesia|Any woman may choose to have nitrous oxide inhalation as a standard protocol for labour analgesia
214870952|NCT03460314|DRUG|Buprenorphine|Patients are tested for their normal prescription buprenorphine medication
215036674|NCT02748798|DEVICE|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
215036675|NCT02748798|DEVICE|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
214291081|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
214291082|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
214291083|NCT05965505|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
214291084|NCT00115687|DRUG|placebo|
214291085|NCT00115687|DRUG|2 mg nicotine polacrilex|
214291086|NCT04676282|OTHER|Hypothetical Scenario|Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
214291087|NCT07002255|DRUG|Azvudine tablets(FNC) and Rifampicin Capsules (RIF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC 3mg (1 tablet)+RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days; RIF: 600 mg (4 capsules) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days."
214870953|NCT04171206|OTHER|Free From Abuse|Participants in the treatment arm will watch a 15-minute talk given by an adult female survivor of IPV who tells the story of her abusive relationship. After watching the video, participants will read information on 10 signs of an unhealthy relationship. The intervention will take approximately 25 minutes to complete.
215036676|NCT02748798|DEVICE|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
214870954|NCT04171206|OTHER|Technology and crime|Participants in the placebo control arm will watch a 19-minute talk on technology development and crime. After watching the video, participants will read 10 facts about cyber security. The intervention will take approximately 25 minutes to complete.
214870955|NCT06983626|PROCEDURE|micro-dissection testicular sperm extraction|dissection of the seminefrous tubules under microscope to extract sperms
214870956|NCT06984315|OTHER|The effects of the groups on perioperative inflammation changes were compared.|Between January 2020 and April 2025, data from 849 patients who underwent total knee arthroplasty were retrospectively reviewed. Preoperative hemogram values were obtained during routine anesthesia clinic evaluation, typically one day prior to surgery. Postoperative hemogram samples were collected on the day of surgery (postoperative day 0), within 4 to 12 hours after the procedure. Blood parameters included neutrophil, lymphocyte, monocyte, and platelet counts. Based on these values, inflammatory indices such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammatory response index (SIRI) were calculated.
214870957|NCT06977620|OTHER|Closed kinetic chain exercises|Closed kinetic chain (CKC) exercises emphasize weight-bearing movements where the distal segment of the extremity is fixed, and motion occurs as the proximal segment moves over the stabilized distal segment.
214870958|NCT06977620|OTHER|Weight shifting exercises|Weight-shifting is a crucial aspect of dynamic postural control, which refers to the ability to maintain one's bodyweight within the base of support. Lateral weight-shifting, in particular, is essential for maintaining posture under dynamic conditions and is commonly performed in various activities of daily living
214870959|NCT06977620|OTHER|Complete Decongestive Therapy|CDT includes (skin care, manual lymphatic drainage, compression bandages, compression garments and exercises).
214870960|NCT01004094|BEHAVIORAL|simple goal setting|This group will set goals only
214870961|NCT01004094|BEHAVIORAL|goal setting plus action intentions|This group will set goals and form action intentions (plans)
214870962|NCT01004094|BEHAVIORAL|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
214870963|NCT01004094|BEHAVIORAL|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
214870964|NCT02365558|DRUG|Evacetrapib|Administered orally
214870965|NCT02365558|DRUG|Omeprazole|Administered orally
214870966|NCT06659965|DRUG|Intravenous Methocarbamol|At least 500 mg of intravenous methocarbamol administered within 2 hours after the end of elective spine surgery for acute postoperative pain management
215036677|NCT04532749|DRUG|Seltorexant|Participants will receive Seltorexant tablets.
214870967|NCT01330420|BEHAVIORAL|Relaxation Response Resiliency Program for Depression|"The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~* Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~* Examination and reversal of negative thought patterns.~* Physical movement, including stretching and yoga.~* Healthy eating and other positive lifestyle behaviors.~* Goal setting."
214870968|NCT02819050|DEVICE|NCPAP|Nasal Continuous Positive Airway Pressure
214870969|NCT02828241|DRUG|DFD-04 Ointment|
214870970|NCT02828241|OTHER|Placebo Ointment|
214870971|NCT06016491|BEHAVIORAL|acupressure|Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each woman, and then the person were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks.
214870972|NCT06016491|BEHAVIORAL|Sham acupressure|Compression was applied on the bone region where the meridians did not pass, parallel to the KD1 and SP6 points (approximately 1-1.5 cm away). Similar to the acupressure group, the sham group was treated with symmetrical extremities and for similar durati
214870973|NCT02838121|DRUG|Aclasta|Aclasta once annually for 2 years
214870974|NCT02838121|DRUG|Placebo|No IV aclasta
215036678|NCT04532749|DRUG|Placebo|Participants will receive matching placebo tablets.
214476548|NCT06769802|BEHAVIORAL|Control|The children in this group and their parents will be informed about the research and their written consent will be obtained. Scales will be filled in before application. Children in this group will receive routine nebulizer treatment and routine application will be performed. At the end of the treatment, the scales will be filled in again.
214476549|NCT06767761|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
214476550|NCT06767761|DRUG|Insulin Glargine U100 group|Insulin Glargine U100 s.c.,once-daily，treat-to-target dose
215036679|NCT02496312|BEHAVIORAL|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
215036680|NCT01838733|OTHER|Observational study|
215036681|NCT00121966|DRUG|Insulin Aspart|
215036682|NCT00121966|DRUG|Insulin NPH|
214476551|NCT06676891|DRUG|RZ-001|Participants will receive a single intracerebral injection of RZ-001, Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
215036683|NCT00121966|DRUG|Metformin|
215036684|NCT00121966|DRUG|Rosiglitazone|
215036685|NCT01653314|DRUG|Megavec|
215036686|NCT01653314|DRUG|Glivec|
214476552|NCT05224869|DEVICE|Medical Device Usage and Evaluation|Undergo hydrogel rectal spacer placement
215036687|NCT00642759|DRUG|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
215036688|NCT00642759|DRUG|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
215036689|NCT00642759|DRUG|Bevacizumab|IV infusion
215036690|NCT04614337|DRUG|LUM-201|Administered orally once daily
214870975|NCT03148106|DEVICE|Somatosensory Electrical Stimulation|The investigators will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
215036691|NCT04614337|DRUG|rhGH Norditropin® pen (34 µg/kg)|Administered subcutaneously (s.c., under the skin) once daily.
214665808|NCT07108231|DEVICE|Inspiratory muscle trainning|"The IMT protocol will involve the use of the Power Breath® linear resistor device, classic light model (Anvisa Registration: 81001390001). The IMT group will perform the protocol with a load ranging from 30% to 50% of maximal inspiratory pressure (MIP). Two daily sessions of 30 repetitions each will be conducted, starting with a minimum load of 30%, with a 10-minute interval between sessions, and a proposed weekly load increase based on patient tolerance.~For training load progression, patient effort will be taken into account, aiming to maintain a perceived exertion level between light and moderate fatigue (BORG scale less than 4).~Patients will remain seated at a 90° angle, using a nasal clip, and will be encouraged to perform consecutive inspirations with their mouth on the device's mouthpiece. Vital signs-including blood pressure (BP), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2), respiratory rate (RR), heart rate (HR)-and dyspnea sensat"
214870976|NCT06374862|OTHER|mobilization|specific mobilization on neuromuscular functioning, thanks to surface EMG, before and after a specific mobilization of the spine
214870977|NCT06374862|OTHER|no effect|"a mobilization identified as no effect could modulate neuromuscular activity by a placebo effect."
214870978|NCT06988930|DIAGNOSTIC_TEST|Control group|The non-operation group was treated with rehabilitation therapy for 6 weeks, and the operation group was treated with arthroscopic surgery and the pathological tissue of cartilage and subchondral bone was taken. Assessment was performed at three months, one year, and two years after treatment and recorded in the database.
214870979|NCT06990763|DRUG|Remimazolam|Remimazolam, sufentanil and rocuronium were used during induction, and remimazolam and refentanil were used during maintenance
214870980|NCT06990763|DRUG|propofol|Propofol, sufentanil and rocuronium were used during induction, and propofol and remifentanil were used during maintenance
214870981|NCT06990035|BEHAVIORAL|Mediterranean diet lessons program|Participants will attend five one-hour lessons delivered by qualified professionals to learn about foods that have a positive impact on cognitive function and how to incorporate them into their dietary regimen.
214870982|NCT06990035|BEHAVIORAL|Physical activity|Participants will undergo a 12-week physical exercise program guided by specified personal trainers.
215036692|NCT01092650|DRUG|Deuterated phenanthrene|Deuterated phenanthrene 10 micrograms
215036693|NCT05405608|DRUG|Ondansetron|hemodynamic stability in orthopedic surgeries
215036694|NCT04632173|OTHER|non interventional study|There is no intervention
215036695|NCT00385112|PROCEDURE|Echocardiogram|2D echocardiogram with Doppler flow
214291088|NCT07002255|DRUG|Azvudine tablets(FNC) and Rifampicin Capsules (RIF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3mg (1 tablet) +RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days; RIF: 600 mg (4 capsules) each time, 1 time a day, orally, for 7 consecutive days."
214870983|NCT06988982|DRUG|Intravenous Lipid Emulsion 20%|patients will receive 1.5 ml/kg bolus of intravenous lipid emulsion 20 % followed by 0.25 ml/kg/hr infusion over 30 minutes at the end of surgery
214870984|NCT06988982|DRUG|Control (placebo) group|patients will receive equal volume of normal saline at the end of surgery
215036696|NCT03720808|OTHER|Balloon Blowing|The parents of the children in this group were asked whether their children had the latex allergy or not and the children without the allergy were included in the group. The children's skills of blowing balloon were observed before the procedure. Before starting the venous blood sampling procedure, the children were asked to choose a balloon in the color they preferred and to start blowing the balloon at least 20 seconds before the procedure. Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
215036697|NCT03720808|OTHER|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
215036698|NCT03720808|OTHER|Coughing|The children included in this group were asked to cough after taking a deep breath during the venous blood sampling procedure. Before the procedure, the researcher showed the children how they should cough and asked them to imitate. The venous blood sampling was not performed until the child successfully completed coughing. The child was directed by the researcher during the procedure. Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
215036699|NCT03720808|OTHER|Control|No intervention was performed to reduce pain and fear in the control group.
215036700|NCT01230411|OTHER|saline placebo|250 cc of placebo administered IV
215036701|NCT01230411|DRUG|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
215036702|NCT02096107|DRUG|Everolimus|Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
215036703|NCT02096107|OTHER|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
215036704|NCT05023109|DRUG|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
214291089|NCT07002255|DRUG|Azvudine tablets(FNC) and Rifampicin Capsules (RIF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~RIF: 600 mg (4 capsules), 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3mg (1 tablet)+RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days."
214291090|NCT04449575|OTHER|eSwabs|from skin
214291091|NCT01083368|DRUG|temsirolimus|Given IV
215036705|NCT03612570|DEVICE|Nano-Pulse Stimulation Device|NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
214870985|NCT06989372|PROCEDURE|serratus posterior superior block|patients were placed in the lateral decubitus position for SPSIPB. The blocks were performed under the guidance of ultrasonography (USG), a high-frequency linear probe (SonoSite HFL50x, 15-6 MHz, 55-mm broadband linear array, USA) transducer was placed at the level of the spine scapula in the transverse plane, and the upper medial border of the scapula, trapezius muscle, serratus posterior superior muscle (SPSM), 2nd and 3rd ribs were visualized. The ultrasound probe is rotated 90 degrees in a parasagittal orientation to identify the first rib. After its identification, the second and third ribs are confirmed. An 80 mm sono visible needle (type) was inserted in the caudocranial direction just medial to the scapula with the in-plane technique and driven between the 2nd and 3rd ribs targeting the inferior part of the SPSM. The target was confirmed by injecting the test dose with saline. Thirty ml of 0.25% bupivacaine was subsequently injected
215036706|NCT06416475|DIETARY_SUPPLEMENT|Mankai supplementation|The overall dose of the three Mankai duckweed beverages/day contains \~10 grams of dry matter.
214870986|NCT06989372|PROCEDURE|erector spinae block|US-guided ESPB, a commonly performed interfascial plane block, was first defined by Forero et al. (21). In this technique, LA is injected in the plane between the erector spinae muscles and the thoracic transverse processes. Thus, multiple thoracic levels are anesthetized by the LA spreading in a craniocaudal direction. The transducer was then placed approximately 3 cm lateral to the midline parasagittally. The T5 transverse process and the erector spinae, rhomboid major, trapezius muscles were viewed (i.e., from deep to superficial). The block needle was advanced in a craniocaudal direction using an in-plane approach through the trapezius, rhomboid major, and erector spinae muscles. After establishing contact with the hyperechoic transverse process, 30 mL of 0.25% bupivacaine was injected in small aliquots after hydrodissection (2-3 mL, 0.9% NaCl) and checking for negative blood aspiration after every 5 mL of injection.
215036707|NCT06416475|OTHER|Water consumption|Water consumption
215036708|NCT01811420|PROCEDURE|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
215036709|NCT01811420|PROCEDURE|Conventional method|Dental caries removal using rotatory instrument
215036710|NCT01844596|BEHAVIORAL|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
215036711|NCT01844596|BEHAVIORAL|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
215036712|NCT05748769|BEHAVIORAL|Practice (UL)|Subjects performed RMs toward the units that were activated in the same order as the tested sequence 1-4-3-5-4-2, and with an activation duration and delay of 1 s. The practice included 16 blocks, each consisting of 30 RM with a 30 s pause after each block
215036713|NCT05748769|BEHAVIORAL|Observation (SO)|Subjects observed the illuminating switches while avoiding moving. The subjects observed RMs toward the units that were activated in the same order as the practiced sequence 1-4-3-5-4-2, also with an activation duration and delay of 1 s and 30 s pause after each block.
215036714|NCT05748769|BEHAVIORAL|Nature Observation (NO)|The video-clip consisted of a 16 min nature movie in cycles of one-minute observation and pausing 30 s, equivalent to the timing of RMs performed by groups UL and SO
215036715|NCT01498861|DRUG|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
215036716|NCT01498861|DRUG|Dolutegravir|Dolutegravir is an experimental HIV drug
215036717|NCT01498861|DRUG|Placebo|Placebo is a tablet with no drug in it
215036718|NCT06671210|DEVICE|Urine and vaginal swab self-control|Each participant provided urine and vaginal swabs for HPV testing.
215036719|NCT06058793|DRUG|Brigimadlin|Brigimadlin
215036720|NCT07004647|DRUG|Fludarabine|D-10 to D-2: Fludarabine (25 mg/m2/day) will be administered intravenously for 3 days;D-10 to D-2: Cyclophosphamide (250 mg/m2/day) will be administered intravenously for 3 days.
214291092|NCT01083368|BIOLOGICAL|bevacizumab|Given IV
214291093|NCT01083368|GENETIC|polymorphism analysis|Correlative studies
215036721|NCT07004153|DEVICE|Smart Coaching Insulin Pen|Subjects randomized to the intervention group will use the DIA:CONN P8 smart insulin pen with full functionality, including Setup Wizard, CGM-based insulin injection coaching, and a bolus calculator. During the 12-week application period, including the baseline visit, participants will visit the hospital up to 5 times. At the start of the period, initial basal and bolus doses will be determined using the Setup Wizard and reviewed by investigators. Throughout the study, subjects will receive real-time insulin dose recommendations and coaching via the DIA:CONN app based on CGM data, carbohydrate input, and insulin dosing history.
215036722|NCT07002723|DRUG|Esketamine combined with dexmedetomidine|After successful neuraxial anesthesia, 0.125mg/kg esketamine and 0.3ug/kg dexmedetomidine are diluted into 30ml of normal saline and continuously pumped for 20 minutes, then connected to a micropump: 15ug/kg/h esketamine 0.02ug/kg/h dexmedetomidine to 96ml saline, continuous amount: 2ml/h, continuous pumping for 48h.
214291094|NCT01083368|OTHER|laboratory biomarker analysis|Correlative studies
214291095|NCT04315909|DRUG|PRP-Fibrin Glue|Platelet-Rich Plasma-Fibrin Glue
214291096|NCT04315909|DIETARY_SUPPLEMENT|Vitamin E and C|Vitamin E and vitamin C
214291097|NCT04315909|OTHER|Placebo|Placebo
214291098|NCT05767645|DEVICE|Mistral Procedure|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
214291099|NCT07035457|DRUG|Vicadrostat|Vicadrostat
214291100|NCT07035457|DRUG|Jardiance®|Jardiance®
214291101|NCT07048756|BEHAVIORAL|Imagery Rescripting|Imagery Rescripting (Regular)
214291102|NCT07048756|BEHAVIORAL|Imagery Exposure|Imagery Exposure
214291103|NCT07048756|BEHAVIORAL|Imagery Rescripting with Disruption of Reconsolidation|Imagery Rescripting with Disruption of Reconsolidation
214665809|NCT07108231|DEVICE|Sham (No Treatment)|The control group (IMTsham) will perform two daily sessions of 30 repetitions each without any load, using the same resistor device.
214665810|NCT07106086|OTHER|Scapulothoracic mobilization|"Scapulothoracic Mobilization and Buteyko Breathing Technique:~Subjects lay supine with arms crossed, hands on opposite scapulae. The interventionist stabilized elbows and applied pressure to shoulders, with one hand on the spine using a loose fist to mobilize vertebrae. Various spinal motions-rotation, flexion, lateral flexion, and translation-were assessed. In a lateral position, the subject bent both knees and placed the upper arm on a cushion. The interventionist stood close, placing fingers under the scapula's medial border."
214665811|NCT07106086|OTHER|Buteyko breathing|Buteyko Breathing: Subjects sat upright, relaxed respiratory muscles, and breathed gently through the nose. The sequence included calm nasal inhalation and exhalation using the diaphragm, followed by shallow inhalation and slow exhalation. A brief post-exhalation breath hold was added. The cycle was repeated for several minutes.
214870987|NCT06989801|BEHAVIORAL|Urban Walk|"For each session, participants will take a 30-minute walk in an urban environment along a designated looped route. They will walk at a comfortable pace and follow the assigned path. During the walk, participants will be instructed to experience their surroundings as naturally as possible. No specific activities beyond walking are required.~To fully immerse in the experience, participants will be asked to avoid using their phones unless necessary (e.g., in case of an emergency). They should keep the GPS app recording throughout the walk without interacting with it-just allow it to run in the background.~Once the loop is completed, participants will stop the GPS recording and return to the starting point, where a research team member will be waiting. They will then be guided indoors to complete a brief post-walk survey and participate in a short interview to share their experience."
214870988|NCT06989801|BEHAVIORAL|Nature Walk|"For each session, participants will take a 30-minute walk in a natural environment along a designated looped route. They will walk at a comfortable pace and follow the assigned path. During the walk, participants will be instructed to experience their surroundings as naturally as possible. No specific activities beyond walking are required.~To fully immerse in the experience, participants will be asked to avoid using their phones unless necessary (e.g., in case of an emergency). They should keep the Gaia GPS app recording throughout the walk without interacting with it-just allow it to run in the background.~Once the loop is completed, participants will stop the GPS recording and return to the starting point, where a research team member will be waiting. They will then be guided indoors to complete a brief post-walk survey and participate in a short interview to share their experience."
214870989|NCT06989801|BEHAVIORAL|Active Nature Walk|"For each session, participants will take a 30-minute walk in a natural area, following a designated looped route. Unlike a regular walk, participants will be encouraged to engage with nature (e.g., listening to natural sounds, looking for birds, and touching flowers).~To make the most of the walk, participants will be asked to avoid using their phones unless necessary (e.g., in case of an emergency). They should keep the Gaia GPS app recording throughout the walk without interacting with it-just letting it run in the background.~Once the loop is completed, participants will stop the GPS recording and return to the starting point, where a research team member will be waiting. They will then be guided indoors to complete a brief post-walk survey and participate in a short interview to share their experience."
214870990|NCT06988839|PROCEDURE|Microneedling followed by coronally advanced flap|Microneedling will be performed using a 30 gauge lancet needles, inserted until hard tissue is felt. It will be performed in 4 sessions at 10 day intervals, followed by coronally advanced flap procedure, 2 months post microneedling.
214870991|NCT06988839|PROCEDURE|Coronally advanced flap with connective tissue graft|Coronally advanced flap operation will be performed with connective tissue graft harvested from palate after phase 1 therapy.
214870992|NCT06990568|DRUG|Lacidofil|1 capsule twice daily.
214870993|NCT06990568|DRUG|Placebo|1 capsule twice daily.
214870994|NCT06988787|BEHAVIORAL|webSTAIR|"Ten web-based modules that are completed independently by participants (\~2 modules per week) and receive therapist support via video-telehealth after the completion of every 2 skill modules (1x per week for a total of 5 meetings).~The first five modules review emotional awareness, emotion management, and distress tolerance while the final five modules raise awareness about relationship patterns and provide interpersonal skills training regarding effective assertiveness, interpersonal flexibility, and compassion for self and others."
215036723|NCT07002723|DRUG|Normal saline|After successful neuraxial anesthesia, 30ml of normal saline was continuously pumped for 20 minutes, followed by a micropump: 96ml of saline, continuous amount: 2ml/h for 48h.
214291104|NCT07048756|BEHAVIORAL|Compassion-Focused Therapy Imagery Rescripting|Imagery Rescripting in Compassion-Focused Therapy
214665812|NCT07105891|OTHER|Thawing protocol|Standard thwaing
215036724|NCT06680479|BIOLOGICAL|CH505 TF chTrimer|Stabilized CH505 TF chTrimer, 300 mcg
215036725|NCT06680479|BIOLOGICAL|3M-052-AF|3 mcg
215036726|NCT06680479|BIOLOGICAL|Aluminum Hydroxide Suspension|500 mcg
214291105|NCT06736418|DRUG|225Ac-ABD147|A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225
214291106|NCT06897696|DRUG|Dexmedetomidine+propofol+remifentanyl group|The dexmedetomidine+TIVA group will receive a bolus of 0.8-1 µg/kg dexmedetomidine for 10 minutes followed by continuous dexmedetomidine infusion at a rate of 0.3-0.5 µg/kg/hour.
214291107|NCT06897696|DRUG|propofol+remifentanyl group|propofol 5-8 mg/kg/h and remifentanil 5-10 µg/kg/h will be administered to all patients
214665813|NCT07105891|OTHER|thawing protocol|Fast thawing
214665814|NCT07105891|OTHER|thawing protocol|Ultrafast thawing
214665815|NCT07106528|DRUG|Organoid Drug Sensitivity Testing-Guided Therapy|Personalized drug selection (chemotherapy/targeted therapy/immunotherapy) based on ex vivo organoid drug response testing
214665816|NCT07106528|DRUG|Topotecan|Intravenous topotecan 1.25 mg/m² daily on days 1-5 of each 21-day cycle
214665817|NCT07107321|BEHAVIORAL|WISE Words|WISE Words is a co-designed, multicomponent deimplementation strategy package including 6 discrete strategies. Of these, three are delivered in a standard fashion: (1) dynamic training driven by improvisation methods, (2) a peer learning collaborative, and (3) external facilitation. The additional three are tailored to each educator's preferences and goals: (4) reminders, (5) educational materials, and (6) audit and feedback. Educators are supported to set and achieve goals for one feeding practice they want to stop and one they want to start.
214870995|NCT06988787|BEHAVIORAL|ExpoTx|A real-time, present-focused, intervention that does not require participants to relive or focus on past trauma(s), but rather on current social functioning; ie, how they are doing in day-to-day life, and current cognitive and psychological functioning. Therapist will meet individually with the participant for 5 sessions, 60 minutes each conducted virtually. During the 5 sessions, participants will be guided to use in vivo or in the moment ExpoTx to identified fear-based triggers. In each consecutive session, the therapist will engage the Veteran to explore cognitions that interfered with, reinforced, or diminished fear responses. Participants will be asked about their use of coping skills during exposure practice. Intentional participation in exposure for one target at least 30 minutes per day, or until SUDs lower by half. At the end of ExpoTx, the therapist will engage the Veteran in self-determining future goals and offer referrals in the community or at VA for additional support.
214870996|NCT06988787|OTHER|PsychoEd|Psycho-education (PsychEd) orientation that provides an overview of PsychEd as a process for learning about mental health symptoms and disease management related to trauma. During PsychEd sessions, therapists will focus on the following 5 areas: 1) Defining trauma and PTSD. 2) Brain Basics and Brain Injury. 3) Understanding the Role of Stress and Its impact on trauma symptoms. 4) The Role of Nutrition and Exercise in Disease Management. 5) Information on other Programs.
214870997|NCT06989333|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor)|Bronchoscopy under general anesthesia or sedation; The predetermined dose of recombinant GM-CSF was dissolved in normal saline. The diseased lung segments were located through bronchoscopy and the liquid medicine was sprayed.
214870998|NCT06990230|DEVICE|Radiofrequency Transseptal Puncture System and Auxiliary Device|"The intervention in this study stands out due to its specific focus on evaluating the safety and efficacy of a radiofrequency transseptal puncture system designed exclusively for use in the atrial septum, with the purpose of establishing a passage from the right atrium to the left atrium. This system incorporates an auxiliary radiofrequency puncture device, which serves as a crucial supportive component, enhancing the overall functionality and precision of the primary transseptal puncture system.~What further distinguishes this intervention from others is its utilization of radiofrequency energy to facilitate the transseptal puncture. Unlike traditional mechanical puncture methods, which can have a steep learning curve, potentially cause serious complications such as pericardial tamponade and cardiac rupture, and may be time-consuming and imprecise in predicting the puncture site, the radiofrequency puncture device provides a more controlled and predictable approach. The radiofrequenc"
214870999|NCT06988631|OTHER|Sensory treatment|Participants were asked to practice the foot sole sensory training program at home every day for 2 weeks.
214871000|NCT06988631|OTHER|foot care booklet|Participants were given a booklet about healthy feet and were informed.
214871001|NCT06990750|PROCEDURE|15 mmHg|Insufflation pressure was set to 15 mm Hg at the time of single port robotic sacrocolpopexy.
214871002|NCT06990750|PROCEDURE|12 mmHg|Insufflation pressure was set to 12 mm Hg at the time of single port robotic sacrocolpopexy.
214871003|NCT06989411|OTHER|Clinical pilates exercises +Interferential current therapy (real current)|All treatments were given three times a week for 8 weeks. The current intensity was determined as the mA CC level that the patient felt at the maximum but did not feel any discomfort.
214871004|NCT06989411|OTHER|Clinical pilates exercises+ Interferential current therapy (Placebo current)|All treatments were given three times a week for 8 weeks. The current intensity was set to 0.1 mA CC (necessary for the machine to work)
214871005|NCT06989697|DRUG|Cilostazol / Ginko Leaf Dried Ext.|Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.
214871006|NCT06989697|DRUG|Placebo|Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.
214871007|NCT06989125|BEHAVIORAL|Internet-based cognitive behavioral therapy|"The internet-based CBT treatment arm is delivered via the online treatment platform SpilleFri and consists of nine internet-delivered modules delivered over 10-12 weeks. Modules contain written assignments and multiple-choice lists, combined with psychoeducation delivered in text, illustrations, and videos. The treatment is assisted by a therapist. The therapist contact is primarily written and takes place in an embedded secured message system on the platform. Participants can use the written message function whenever they want, and the therapist will respond on a specific day each week. Further, participants are offered up to three sessions of face-to-face or video-based therapist support during the treatment, depending on their preference.~Treatment is regarded as completed if the participant has worked actively (logged in to the module and filled in at least one interactive exercise) in the first 6 modules of the treatment program."
214871008|NCT06989125|BEHAVIORAL|Synchronous cognitive behavioral therapy|In the sCBT condition, participants receive 9 individual sessions spread over 14-20 weeks, in a 1 to 1 format with a therapist, delivered either face-to-face or via video connection, depending on the participant's preference (there may be a mix). Treatment sessions take place weekly at the start of the course. After week 4, the aim is to have sessions at least every other week to maintain continuity in treatment. Further, participants are offered up to three additional sessions that can be included on request of participant or when therapists deem it necessary. Treatment is regarded as completed if the participant has attended 6 sessions of the treatment program.
214871009|NCT06990334|GENETIC|Whole genome sequencing analysis|RNAseq
215036727|NCT06680479|OTHER|Sodium Chloride for Injection|Sodium chloride for injection, 0.9% USP volume-matched placebo injection.
215036728|NCT07005687|OTHER|Stem Cells|MSCs Derived
215036729|NCT07002905|DRUG|ASC30 tablets or ASC30 tablets A1 or placebo|Drug: ASC30 tablets or ASC30 tablets A1 administered orally daily Drug: Placebo administered orally daily
215036730|NCT07004595|OTHER|Evaluation of patient frailty|Quality of Life questionnaire
214476553|NCT05224869|PROCEDURE|CT simulation|CT simulation of radiation treatment planning 2-7 days after hydrogel placement
214476554|NCT05224869|PROCEDURE|Stereotactic body radiation therapy|SBRT in 5 fractions over 1 week, 7 days after CT simulation
214476555|NCT05224869|RADIATION|Brachytherapy|one month after completing SBRT
214476556|NCT05224869|PROCEDURE|Post-implant dosimetry scan|one month after brachytherapy
215036731|NCT06624345|PROCEDURE|Inspiratory muscle training|Patients in the IMT group received the intervention using a threshold loading device set at a pressure range of 5-39 cmH₂O. They were instructed to perform six sets of five breaths, totaling 30 breaths, twice daily for six weeks. Additionally, the aerobic exercise regimen included upper limb exercises (raising arms without resistance), a lower limb stepping warm-up, and a walking routine consisting of 5 minutes of slow walking, 2 minutes of brisk walking, and another 5 minutes of slow walking, for a total of 30 minutes per day.
215036732|NCT06624345|PROCEDURE|Control Group|Subjects received routine care.
214665818|NCT05768789|DIETARY_SUPPLEMENT|Buoy Electrolyte|Each subject consumed Beverage 1 (Buoy Hydration Drops) at a dose containing 600 mg/L of Na+ over 4 hours while measuring urine output over 6 hours.
214871010|NCT06988696|OTHER|The Effect of Warm Sock Application on Hypothermia After admission to the urology ward, patients who meet the sample selection criteria will be identified one day prior to the surgical intervention.|"The Effect of Warm Sock Application on Hypothermia After admission to the urology ward, patients who meet the sample selection criteria will be identified one day prior to the surgical intervention. Eligible patients will be informed about the study by reading the voluntary informed consent form, which includes information about the purpose, content, and methodology of the research. Both verbal and written consent will be obtained from patients who agree to voluntarily participate in the study.~Initially, the Descriptive Characteristics Form will be administered to the patients. One group will be given heated socks, one group will be given regular socks, and one group will not receive any intervention. The effect of these interventions on hypothermia will be examined."
214871011|NCT06990516|DRUG|SHR-A1811|"Dose: 3.2 mg/kg, 4 mg/kg, or 4.8 mg/kg, administered intravenously (IV) every 3 weeks (Q3W).~Infusion Duration:~First infusion: 90 ± 10 minutes. Subsequent infusions: May be shortened to approximately 30 minutes (minimum 20 minutes, maximum 60 minutes, including flush phase) if no infusion-related reactions occur after the first dose."
214871012|NCT06990516|DRUG|Carboplatin|"Dose: Area Under the Curve (AUC) 5 mg/mL/min, administered IV Q3W.~Infusion Duration:~Should be completed within 30-60 minutes (including flush phase).~Treatment Schedule:~Up to 6 treatment cycles, with each cycle lasting 3 weeks."
214871013|NCT06990516|DRUG|Oxaliplatin|"Dose: 85 mg/m², administered IV Q3W.~Infusion Duration:~Should be infused over \>120 minutes (including flush phase).~Treatment Schedule:~Up to 6 treatment cycles, with each cycle lasting 3 weeks."
214871014|NCT06990516|DRUG|Bevacizumab|"Dose: 15 mg/kg, administered IV Q3W.~Infusion Duration:~First dose: 90 minutes. Second dose: If the first infusion is well-tolerated, may be shortened to 60 minutes.~Subsequent doses: If the 60-minute infusion is well-tolerated, all following infusions may be administered over 30 minutes (including flush phase)."
214871015|NCT06991062|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS is a non-invasive procedure in which a coil is placed over the scalp, and focused magnetic pulses are applied to parts of the brain through the coil.
214871016|NCT06990126|DRUG|bronchoscope|We will perform bronchoscopy and collect bronchoalveolar lavage fluid(BALF)
214871017|NCT03347006|DIETARY_SUPPLEMENT|SPM Active|"Supplement or placebo will be administered orally between 9 am to 9:30 am.~* Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval."
214871018|NCT03045471|DRUG|R-EPOCH|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
214871019|NCT03045471|DRUG|R-CHOP|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
215036733|NCT02411851|DRUG|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
215036734|NCT02411851|OTHER|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
215036735|NCT03683082|DRUG|Oxygen supplementation|40% FiO2 via Venturi mask
215036736|NCT03683082|DRUG|Sham O2 (medical air)|Medical air supplementation via Venturi mask
215036737|NCT02337556|OTHER|Peptamen Bariatric|Commercially available enteral diet
215036738|NCT02337556|OTHER|Replete|Commercially available enteral diet
214291108|NCT06848140|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim 20 or 32. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
214476557|NCT06677398|OTHER|Debriefing Method 1|The researchers used a debriefing method that they chose after a virtual simulation
214476558|NCT06677398|OTHER|Debriefing Method VP|The researchers used the debriefing method that virtual patient simulator presents
214476559|NCT06677398|OTHER|Debriefing Method 2|The researchers used a debriefing method that they chose after a virtual simulation
214476560|NCT06677541|OTHER|Instructional handout|A handout on how to improve sexual dysfunction/function will be provided
215036739|NCT07142083|DEVICE|Bioelectrical Impedance Analysis (BCM)|The Body Composition Monitor (BCM) device will be used to perform daily bioelectrical impedance measurements to guide fluid resuscitation in critically ill patients after major surgery. Measurements include extracellular water, intracellular water, total body water, and phase angle. The results will be used to tailor fluid therapy.
215036740|NCT07142083|PROCEDURE|Conventional Fluid Management|Patients in this group will receive fluid therapy based on standard clinical parameters including blood pressure, heart rate, urine output, laboratory values, and physical examination. No bioelectrical impedance measurement will be performed.
215036741|NCT07161323|OTHER|Sustained Natural Apophyseal Glide (SNAG)|In this intervention, participants will initially receive the SNAG technique targeting the L5-S1 lumbar segment. Participants will be seated on a treatment table with feet flat and knees at 90°. The therapist will position a specialized Mulligan belt around the L5-S1 segment and anchor it around their pelvis to generate a gentle traction force via controlled hip movement. While this force is applied, participants will perform active trunk flexion, holding the end-range position for 30 seconds. This movement will be repeated six times, constituting a 3-minute set. A total of 4 sets will be administered, with 2-minute rest periods between sets.
215036742|NCT07161323|OTHER|Sciatic Nerve Mobilization Exercises (SNME)|Participants will sit with hips and knees at 90° flexion, feet flat on the floor. The involved leg will be fully extended at the knee. In this position, the participant will be asked to perform ankle dorsiflexion and neck extension simultaneously (applying tension to the distal part of the sciatic nerve while relaxing the proximal part) and hold for 3 seconds. Next, the participant will plantarflex the ankle and flex the neck (tensioning the proximal end while relaxing the distal), again holding for 3 seconds. This 6-second sequence will be repeated 10 times per set. The exercise will be performed in 3 sets per leg, with 3-minute rests between sets.
215036743|NCT07159737|PROCEDURE|Two-stent strategy|DES from LMCA to LAD and DES to LCx using a recognised bifurcation technique such as double kissing crush (DK crush), Culotte, T-stenting or T and small protrusion (TAP).
215036744|NCT07159737|PROCEDURE|Hybrid Strategy|DES from LMCA to LAD and DCB to LCx. No LCx DES unless bail-out needed.
215036745|NCT07158775|BIOLOGICAL|BS01|a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP)
214871020|NCT05966220|DEVICE|Hip surgery with FH Ortho devices|"This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons."
214871021|NCT03504280|DRUG|Cholecalciferol|
214871022|NCT03918109|DRUG|OTO-313|single intratympanic injection of gacyclidine
214871023|NCT03918109|DRUG|Placebo|single intratympanic injection of placebo
214871024|NCT06150456|PROCEDURE|extraction|extraction: in all groups, extraction will be performed
215036746|NCT07158775|OTHER|Sham procedure control|Sham procedure without needle
215036747|NCT07158645|OTHER|Medical Food Tri-betahydroxybutyrin|Medical Food Containing Tri-betahydroxybutyrin
215036748|NCT07159009|DRUG|Biological: GB261|GB261 will be dosed according to the protocol
215036749|NCT07159646|OTHER|exercise interventions|athletic/physical protocol
215036750|NCT07161570|DEVICE|Virtual Reality (VR) Intervention|10-min VR intervention, once a day, everyday for 14 days.
214871025|NCT06150456|RADIATION|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
215036751|NCT07161570|DEVICE|Light Box (LB) intervention|30-min LB intervention once a day, everyday for 14 days.
215036752|NCT07161518|DEVICE|Low-intensity transcranial ultrasound|Active (focused) ultrasound
215036753|NCT07161518|DEVICE|Low-intensity transcranial ultrasound|Sham (unfocused) ultrasound
215036754|NCT07161518|DRUG|Propofol|Intravenous propofol administration
215036755|NCT07161193|BIOLOGICAL|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
215036756|NCT07160855|DRUG|Misoprostol (given vaginally)|800 micrograms of a single dose of vaginal misoprostol will be given
215036757|NCT07160855|DRUG|Letrozole 5 mg|10 mg oral letrozole for 3 days will be given
215036758|NCT07160855|DRUG|Placebo|oral placebo for three days will be given
215036759|NCT07159711|DIAGNOSTIC_TEST|Seismofit|"Seismofit® is a 3 x 5 x 1.5 cm Class I medical device manufactured by Ventriject, which utilizes SCG principles and machine learning to estimate an individual's fitness. It is afixed to a patient's sternum with an adhesive patch. It measures the amplitude and timing of vibrations on the chest using accelerometers. The device then averages the data collected over 45 seconds to create the SCG. From the SCG, several maxima and minima (fiducial points) are identified, which correlate to the opening and closing of the mitral and aortic valves. Features of the SCG, including the timing, frequency, amplitude, and variability of these points, are then incorporated into an algorithm that also considers patient height, weight, age, and sex to calculate the VO2 peak.~Data is transmitted via Bluetooth to an allocated smartphone app."
215036760|NCT00221858|PROCEDURE|Ultrasound guided blocks|
214476561|NCT06677541|DEVICE|Vibrator|An FDA approved vibrator device to improve sexual function will be provided
214871026|NCT06150456|BIOLOGICAL|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
214871027|NCT00438477|DRUG|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
214871028|NCT00438477|PROCEDURE|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
214871029|NCT00438477|RADIATION|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection."
215036761|NCT07160595|OTHER|Early management of postoperative pain at 3 months detected using sms|During this period, patients with persistent post-operative pain, identified through SMS screening, will receive early treatment starting at 3 months.
215036762|NCT07158697|BEHAVIORAL|HcELP_CMM|The intervention consists of two phases. Phase 1 is an initial individualized, face-to-face meeting to collaboratively set goals and develop action plan (week 1) and Phase 2 is an ongoing, personalized online support delivered by WeChat platform utilizing the official account, chat function, and synchronized online videos to integrate and sustain healthy lifestyle (weekly, week 2-12). Phase 1 covers 4 core steps: 1) assess symptom burden and lifestyle behaviors; 2) generate and analysis symptom burden and lifestyle report; 3) empowerment-based therapeutic person-centered health communication; and 4) behavior commitment. Phase 2 covers two modules: 1) integrate healthy behaviors to long-term lifestyle, and 2) sustain healthy lifestyle behaviors.
214871030|NCT01678053|DRUG|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
214871031|NCT01678053|DRUG|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
214871032|NCT04499365|DRUG|68Ga-DOTA/NOTA-FAPI-04|Each patient receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT scan within specified time.
214871033|NCT04499365|DIAGNOSTIC_TEST|PET/CT scan|PET/CT scan
214871034|NCT05993117|DEVICE|G114R VNS system|All patients treated with Rechargeable Implantable Vagus Nerve Stimulation System (G114R)
214871035|NCT04161014|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg twice daily for 3 years
214871036|NCT02983136|BEHAVIORAL|Dialogue and inter-professional learning|"The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~* Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~* The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice."
215036763|NCT07158697|BEHAVIORAL|Usual care-maintain daily lifestyle|"Participants in this group will continue with their normal daily lifestyle. WeChat-based follow-up will be performed weekly in the first 4 weeks and bi-weekly in the next 8 weeks. Each follow-up will last for 20 minutes. Follow-up communications will include: (1) general well-being assessments using brief, non-intrusive inquiries (e.g., How have participants felt overall in the past week/two weeks?); (2) disease management monitoring through standardized question tracking significant changes in their underlying diseases, intentionally avoiding exploration of intervention-targeted lifestyle behaviors (e.g., Have participants experienced notable changes in their health status or disease management approach since last contact?); and (3) addressing disease-related inquiries. For any questions inquired by participants in the control group, general advice will be given for ethical consideration."
215036764|NCT07160517|BEHAVIORAL|Visual Pedagogy and Manual Toothbrushing|Participants in this arm will use a manual toothbrush with caregiver support. Visual pedagogy resources will include printed PECS cards illustrating each step of toothbrushing and tactile sensory panels simulating toothbrush bristles, toothpaste texture, and dental floss. Caregivers will be instructed to use these materials daily at home for 3 weeks to improve comprehension, adherence, and cooperation in children with ASD.
215036765|NCT07159932|BEHAVIORAL|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug education to the patient before discharge, as well as written drug information
215036766|NCT07159802|PROCEDURE|Papillary reconstruction|"This study will be conducted to compare the effectiveness of three papillary reconstruction techniques: modified Beagle's technique, injection of albumin PRF, and injection of Hyaluronic Acid filler.~Primary outcome: volumetric assessment of papilla regeneration. Secondary outcome: improvement of pink esthetic score."
214871037|NCT01463436|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
214871038|NCT01463436|DIETARY_SUPPLEMENT|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
214871039|NCT00200759|DRUG|Cranberry juice and capsules|
214871040|NCT01882075|DRUG|Open loop|
214871041|NCT01882075|DEVICE|Closed-loop|
214871042|NCT00861198|OTHER|ERCP as per medical indication|ERCP as per medical indication
214871043|NCT03332927|OTHER|Egg based breakfast foods|Two eggs/day, 6 days per week provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet.
214871044|NCT03332927|OTHER|Non-egg based breakfast foods|Non-egg based control foods provided as breakfast foods 6 days per week such as waffles, ready-to-eat cereal, fruits and cheeses.
214291109|NCT06848140|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim 20 or 32. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
214871045|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily
214871046|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
214871047|NCT01197755|DRUG|placebo|Placebo twice daily
214871048|NCT00888823|RADIATION|Stereotactic Radiotherapy|Stereotactic Radiotherapy
214871049|NCT03040323|DRUG|Lumason 60.7Mg Powder for Injection|Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
214871050|NCT03040323|DRUG|Placebos|Placebos injected prior to ultrasound-guided biopsy
214871051|NCT00796679|DRUG|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH \>=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
214291110|NCT04405037|DRUG|Alvimopan|Alvimopan will be given to patients who are diagnosed with postoperative ileus after surgery
215036767|NCT06215118|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
215036768|NCT06215118|DRUG|Iberdomide|cereblon-modulating agent
214871052|NCT05027243|PROCEDURE|bilateral temporomandibular joint arthroscopy|The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.
214871053|NCT05027243|DRUG|Xeomin® (Merz)|For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
214871054|NCT00499174|PROCEDURE|conventional surgery|Radical prostatectomy
214871055|NCT00499174|RADIATION|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
214871056|NCT00499174|RADIATION|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
214871057|NCT00499174|PROCEDURE|Biopsies|Periodic repeat biopsies
215036769|NCT04972838|BEHAVIORAL|Remaking Recess (RR)|Remaking Recess is a flexible, school-based social engagement intervention for students with autism and their peers. The research team will work with school personnel to deliver RR during recess. RR is tailored based on the needs of schools, students, and staff.
214871058|NCT00370357|DRUG|3% w/w SPL7013 Gel (VivaGel™)|
214871059|NCT02788682|GENETIC|WT+ Diplotype|3 or 4 vitamin D binding protein major alleles
214871060|NCT03131674|OTHER|Cervical physical therapy|Patients receive a multimodal cervical physical therapy treatment
214871061|NCT03891966|PROCEDURE|Rigid Splint|50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
215036770|NCT05272384|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215036771|NCT05272384|PROCEDURE|Computed Tomography|Undergo PET/CT
215036772|NCT05272384|DRUG|Decitabine and Cedazuridine|Given PO
215036773|NCT05272384|BIOLOGICAL|Nivolumab|Given IV
215036774|NCT05272384|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215036775|NCT06399536|PROCEDURE|Individualized ANH|Participants will undergo individualized ANH based on the West China Liu's Score after anesthetic induction. The decision of autologous blood transfusion or allogeneic red cell transfusion will be made according to the West China Liu's Score.
214871062|NCT03891966|PROCEDURE|Soft Dressing|50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
214871063|NCT03761680|DIETARY_SUPPLEMENT|MEDPass mode of administration|Allocation of 50 ml of ONS four times per day distributed with the medication rounds
214871064|NCT03761680|DIETARY_SUPPLEMENT|Control Intervention|Patients receive ONS between meals or at their request as usual
214871065|NCT01133886|DRUG|Decitabine|Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
214871066|NCT02269163|BIOLOGICAL|Immune Globulin Intravenous|Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product
214871067|NCT02269163|BIOLOGICAL|Prometic's Immune Globulin Intravenous 10%|Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
214871068|NCT03296384|OTHER|Clinical and environmental evaluation|For schizophrenic's patients, specific assessment will be perform
214871069|NCT05433727|DIAGNOSTIC_TEST|videodermoscopy, lesional capillaroscopy|videodermoscopy and lesional capillaroscopy will be performed under different magnification levels to the skin lesions and data will be recorded.
214871070|NCT01026155|OTHER|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
214871071|NCT01523223|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
214871072|NCT01072955|BIOLOGICAL|Bovine Heparin|5.000UI/mL bottle with 5mL
214871073|NCT01072955|BIOLOGICAL|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
214871074|NCT03253523|PROCEDURE|Occipital neurolysis|Surgical occipital nerve decompression
214871075|NCT03802955|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
215036776|NCT05772546|DRUG|Avatrombopag|Thrombopoietin receptor agonist, tablet taken orally.
215036777|NCT05772546|DRUG|Matching Placebo|Lactose monohydrate, tablet taken orally.
215036778|NCT03283007|DRUG|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
215036779|NCT03283007|DRUG|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
215036780|NCT05938699|DRUG|NCX 470|NCX 470 0.1% vs Placebo
215036781|NCT05938699|DRUG|Placebo|NCX 0.1% vs Placebo
215036782|NCT06127199|DEVICE|Ovaprene|Non-hormonal intravaginal ring
215036783|NCT02255435|DRUG|Omaveloxolone Capsules, 2.5 mg|
215036784|NCT02255435|DRUG|Omaveloxolone Capsules, 5 mg|
215036785|NCT02255435|DRUG|Omaveloxolone Capsules, 10 mg|
215036786|NCT02255435|DRUG|Placebo|
215036787|NCT02255435|DRUG|Omaveloxolone Capsules, 20 mg|
215036788|NCT02255435|DRUG|Omaveloxolone Capsules, 40 mg|
215036789|NCT02255435|DRUG|Omaveloxolone Capsules, 80 mg|
215036790|NCT02255435|DRUG|Omaveloxolone Capsules, 160 mg|
215036791|NCT02255435|DRUG|Omaveloxolone Capsules, 300 mg|
215036792|NCT02255435|DRUG|Omaveloxolone Capsules, 150 mg|
215036793|NCT02466919|DRUG|Pantoprazole|H. pylori eradication therapy
215036794|NCT02466919|DRUG|Amoxicillin|H. pylori eradication therapy
215036795|NCT02466919|DRUG|Metronidazole|H. pylori eradication therapy
215036796|NCT02466919|DRUG|Levofloxacin|H. pylori eradication therapy
215036797|NCT02466919|DRUG|Clarithromycin|H. pylori eradication therapy
215036798|NCT05666518|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
215036799|NCT05666518|DRUG|Standard of care|Dosage at the discretion of the treating physician
215036800|NCT06483802|GENETIC|ASP2016|Intravenous (IV) infusion
215036801|NCT06483802|DRUG|Prednisolone|Oral
215036802|NCT04606914|DRUG|mirvetuximab soravtansine (MIRV; IMGN853)|Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
215036803|NCT05916040|DEVICE|Radiotherapy with MRIdian with simultaneous integrated boost|radiotherapy during 5 days given in 5 weekdays with simultaneous integrated boost
215036804|NCT05916040|OTHER|Questionnaires before, during and after radiotherapy|"Questionnaires consisting of 3 quality of life scales and 1 mental state scale:~* EORTC QLQ-C30~* EORTC QLQ-CR29~* Low Anterior Resection Syndrome Score (LARS) questionnaire~* Hospital Anxiety and Depression Scale (HADS) questionnaire"
215036805|NCT03737136|DRUG|Bortezomib|one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)
215036806|NCT05553249|BEHAVIORAL|Written Exposure Therapy|Virtual, group-based Written Exposure Therapy
215036807|NCT03467243|BEHAVIORAL|Cognitive Behavioral Social Skills Training|CBSST is a more recovery-oriented psychosocial rehabilitation intervention that helps Veterans with SMI set goals, correct errors in thinking, and build communication skills to improve social functioning
215036808|NCT03467243|BEHAVIORAL|Social Skills Training|SST is an evidence-based, manualized, goal setting curricula that teaches social skills, for example: communication skills and listening skills for Veterans with Serious mental Illness.
215036809|NCT03467243|BEHAVIORAL|Treatment as usual|TAU is when Veterans continue to receive their usual care.
214871076|NCT01413516|BEHAVIORAL|Smoking cessation counseling|Counseling sessions provided by a trained smoking counselor
215036810|NCT06011187|PROCEDURE|Routine care|Fluid administration will be given per routine care MAP between 65 - 70 mmHg
215036811|NCT06011187|DEVICE|AFM|AFM will recommand fluid bolus administration and MAP will be maintained between 65 and 70 mmHg
215036812|NCT00542373|OTHER|Cytology Specimen Collection Procedure|Undergo oral tissue collection
215036813|NCT00542373|PROCEDURE|Diagnostic Microscopy|Mouth tissue examined microscopically for cytologic features
214871077|NCT01413516|DRUG|Placebo|Sugar pill without any active medication
214871078|NCT01413516|DRUG|Varenicline|Varenicline (an approved medication for smoking cessation)
214871079|NCT05277623|DRUG|Mannitol|During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg
215036814|NCT00542373|PROCEDURE|Diagnostic Procedure|Undergo standard white light headlamp oral examination
215036815|NCT00542373|PROCEDURE|Fluorescence Imaging|Undergo widefield fluorescent and reflectance imaging
215036816|NCT00542373|PROCEDURE|Fluorescence Spectroscopy|Undergo point fluorescent spectroscopy
214291111|NCT07063576|DRUG|Baclofen 10mg|Tablet baclofen 10mg three times daily along with conventional treatment
214291112|NCT07063576|DRUG|Placebo|Tablet placebo three times daily along with conventional treatment
214291113|NCT01331447|DRUG|exemestane|25 mg tablet
214291114|NCT07133074|DIAGNOSTIC_TEST|RENEW-IN Algorithm for assessment of a beta-lactam intervention|The RENEW-IN intervention includes a detailed assessment of the participant's beta-lactam allergy history and determination of a risk-level for allergy-delabeling.
214291115|NCT07133074|OTHER|EMR Review|Electronic medical record review for comparative analysis
214291116|NCT02759471|DEVICE|comfilcon A sphere lens (control)|contact lens
214291117|NCT02759471|DEVICE|comfilcon A asphere lens (test)|contact lens
214871080|NCT05277623|OTHER|0.9% normal saline|the same amount of 0.9% normal saline
214871081|NCT03542955|DEVICE|ActiPatch|A Pulsed Shortwave Therapy Device
214871082|NCT03542955|DRUG|Etoricoxib 60 mg|nonsteroidal anti-inflammatory drug used as standard therapy
215036817|NCT05041985|DRUG|Diazepam Tablets|Diazepam 5 mg tablet once per day (bedtime) for 7 days
215036818|NCT05272878|DRUG|IRBESARTAN, tablet, 150 mg|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
215036819|NCT05272878|DRUG|Placebo, tablet, 150 mg|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
215036820|NCT05728502|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
215036821|NCT05728502|DRUG|Standard of Care (SoC)|Dosage at the discretion of the treating physician.
214291118|NCT00707707|DRUG|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
214291119|NCT00707707|DRUG|Paclitaxel|Intravenous infusion over 1 hour
214291120|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
214291121|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
214291122|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
214291123|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
214291124|NCT02879305|DRUG|Daprodustat|Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
214871083|NCT05295238|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
214871084|NCT01414595|GENETIC|DNA analysis|
214871085|NCT01414595|GENETIC|DNA methylation analysis|
214871086|NCT01414595|GENETIC|RNA analysis|
214871087|NCT01414595|GENETIC|gene expression analysis|
214871088|NCT01414595|GENETIC|polymorphism analysis|
214871089|NCT01414595|OTHER|laboratory biomarker analysis|
214871090|NCT01414595|OTHER|medical chart review|
214871091|NCT00630019|DRUG|1.5% levofloxacin ophthalmic solution|Topical application
214871092|NCT00630019|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
215036831|NCT00280202|PROCEDURE|Biopsy of the major carinal area|Biopsy performed intraoperatively
215036832|NCT00280202|PROCEDURE|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
215036833|NCT00280202|PROCEDURE|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
215036834|NCT00280202|PROCEDURE|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
215036835|NCT00280202|PROCEDURE|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
215036836|NCT00280202|PROCEDURE|Analysis of lymph nodes|Tissues banked for future analysis
215036837|NCT06334497|DRUG|Letermovir|"480mg (2X240mg- tablets) of Letermovir given orally once a day until the treatment success or the treatment failure, up to 12 weeks. In case of co-administration with cyclosporine A, the dosage of Letermovir will be reduced."
214871093|NCT04856150|DRUG|Q-1802|Q-1802 will be administered intravenously.
214871094|NCT04284995|DRUG|RUC-4 Compound|All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.
214871095|NCT02632513|DEVICE|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
214871096|NCT02821052|DRUG|insulin degludec/insulin aspart|Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
215036838|NCT06334497|DRUG|Valganciclovir|"Valganciclovir 900 mg (2X450 mg-tablets) twice a day until the treatment success or the treatment failure, up to 12 weeks. In case of impaired renal function, the dosage of valganciclovir will be reduced."
215036839|NCT06334497|DRUG|Letermovir placebo|"480mg (2X240mg- tablets) of Letermovir placebo given orally once a day until the treatment success or the treatment failure, up to 12 weeks"
215036840|NCT03604978|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215036841|NCT03604978|PROCEDURE|Echocardiography Test|Undergo ECHO
215036842|NCT03604978|BIOLOGICAL|Ipilimumab|Given IV
215036843|NCT03604978|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
215036844|NCT03604978|BIOLOGICAL|Nivolumab|Given IV
215036845|NCT03604978|RADIATION|Stereotactic Radiosurgery|Undergo multi-fraction stereotactic radiosurgery
215036846|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenate|200 µg selenium as selenate
215036847|NCT00271245|DIETARY_SUPPLEMENT|400 µg selenium as selenate|400 µg selenium as selenate
215036848|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
214871097|NCT04822233|DEVICE|Hall Technique (HT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swap and dispensed in a transport medium for microbial analyses.The preformed metal crown (PMC) will placed without local anesthetic and without crimping or trimming. When the contact points are tight, an orthodontic elastic separator will be placed for 2 hours prior to PMC placement. The PMCs will be cemented with glass ionomer Ketac cem.
215036849|NCT00271245|DIETARY_SUPPLEMENT|Placebo|Placebo
215036850|NCT05842031|BEHAVIORAL|Quality of Life Questionnaires|Identify what interventions may be helpful in improving quality of life.
215036851|NCT05842031|BEHAVIORAL|Patient Educational Needs|Identify what interventions may be helpful in improving patient educational needs
215036852|NCT05842031|BEHAVIORAL|Symptom Management|Identify what interventions may be helpful in improving symptom management Improve symptom management
215036853|NCT05568862|DIAGNOSTIC_TEST|Doppler ultrasound, Urodynamic assessment.|The patients included in the study group were given 600 cc of water in the morning and the Doppler ultrasound was performed 30 minutes later
215036854|NCT05568862|DIAGNOSTIC_TEST|Urodynamic assessment.|A transurethral double lumen catheter was used to measure intravesical pressure in the urodynamic unit for the patients in the study group immediately after the use of the Doppler USG
215036855|NCT02398331|OTHER|Standardised information and education on sexuality in women with spinal cord injury|"Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~* Educational footage~* Clinical neurological examination with educational aim~* Structured consultation providing information on the physiology of sexual response in women with spinal cord injury"
215036856|NCT00867607|DRUG|MRX-6|b.i.d treatment for 21 days
215036857|NCT00867607|DRUG|Steroid|b.i.d. 21 days
215036858|NCT06835036|OTHER|Exercise Treatment|In this study, a functional exercise programme will be performed 3 days a week for 8 weeks in three cycles as previously recommended. This programme consisted of a 5-minute warm-up and a 45-minute exercise phase.
214871098|NCT04822233|DEVICE|Modified Hall Technique (MHT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses.This group will in addition to all the procedures for the Hall will have the Caries lesions treated with 30% Silver Diamine Fluoride (SDF) before cementation of the stainless-steel crowns.
214871099|NCT04822233|DEVICE|Conventional Technique (CT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses. Conventional occlusal, proximal slicing and when necessary buccal and lingual surfaces will be carried out under local anesthesia and dental dam isolation local anesthesia.The PMC will be trimmed and crimped at the gingival margin to improve the fit, and cemented with Ketac cem.
214871100|NCT02287207|DEVICE|transcranial direct current stimulation (tDCS)|
214871101|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
214871102|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
214871103|NCT02938754|BEHAVIORAL|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
214871104|NCT02938754|BEHAVIORAL|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
214871105|NCT01208220|DEVICE|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
214871106|NCT01208220|BIOLOGICAL|Collagenase Ointment|Apply TIW
214871107|NCT02565173|DRUG|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
214871108|NCT02565173|DRUG|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
214871109|NCT02565173|DRUG|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
214871110|NCT02565173|DRUG|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
214871111|NCT02565173|DRUG|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
214871112|NCT00943267|DRUG|Drotrecogin alpha|Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
214871113|NCT00943267|DRUG|Saline (NaCl 0.9%)|Normal saline is given intrabronchially by bronchoscopy at t=0
214871114|NCT00943267|DRUG|Endotoxin|Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
214871115|NCT00943267|PROCEDURE|Bronchoscopy|Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
214871116|NCT00943267|PROCEDURE|Blood sampling|Blood sampling is done by venapuncture at t=0 and t=6
214871117|NCT03463382|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block will be administered under general anesthesia before the surgery
214871118|NCT03463382|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block will be administered under general anesthesia before the surgery
214871119|NCT03463382|DRUG|Bupivacaine (Block Drug)|0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
214871120|NCT00362479|DRUG|DR-1021|1 tablet daily
214871121|NCT06349252|PROCEDURE|Radical resection|Patients should undergo radical resection.
214291125|NCT02879305|DRUG|rhEPO|The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
214291126|NCT02879305|DRUG|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
215036859|NCT02390895|PROCEDURE|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
214291127|NCT02879305|DRUG|Iron therapy|Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
214871122|NCT02799368|DRUG|CJ Plasma Solution A Injection|Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
214871123|NCT02799368|DRUG|CJ 0.9% Normal Saline Injection|Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
214871124|NCT04275882|DIAGNOSTIC_TEST|Electrocardiogram|There will be no new intervention performed for the patients.
214871125|NCT02320760|BEHAVIORAL|Physical activity on prescription|
214871126|NCT02733926|OTHER|Adding of vegetation into the backyards of kindergarten|Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
214871127|NCT00378404|DRUG|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
214871128|NCT00378404|RADIATION|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
214871129|NCT03473769|OTHER|Vital Signs at 2 Hours|Patients vital signs assessed at 2 hours of arrival at ICU
214871130|NCT03473769|OTHER|Confusion Assessment method for the ICU (CAM-ICU)|patient must have altered mental status/fluctuating course and inattention, and either disorganized thinking or altered level of consciousness to be CAM positive; these features are determined by observing the patient during bedside cognitive testing.
214871131|NCT02448264|DRUG|BCX7353|
214871132|NCT02448264|DRUG|Placebo to match BCX7353|
215036860|NCT04019002|DRUG|Hyperpolarized 13C Pyruvate|Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
215036861|NCT06958237|DEVICE|salicylic acid wart patches|"The wart patches contain the auxiliary therapeutic substance salicylic acid at a concentration of 40%, which causes chemical exfoliation, removing the exfoliated skin. Salicylic acid softens the keratinised skin, making it easier to remove. The remedial process leads to the removal of the wart by exfoliation. The wart should disappear after about 7 days of using the patch. The treatment can be prolonged up to 21 days.~The wart patch is intended for the treatment of common warts and plantar warts. The mechanism of action of the product is the barrier and protective action of the patch, reducing the possibility of spreading viral infection and, as an auxiliary, to exfoliate keratinised epidermis, accelerating the skin renewal process."
214871133|NCT05525793|OTHER|Transitional care model|The patients who were assigned to this group with the transitional care model, 6 weeks of counseling and intervention training provided continuity of care and a safe transition, and patients were encouraged about symptom management and a healthy lifestyle.
214871134|NCT03220347|DRUG|CC-90010|CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
214871135|NCT06009627|DRUG|Dalcelli、Exemestane、Gosserine|"Dalcelli: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks~Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication~Fasting for 1 hour before and after.~Exemestane: 25mg, oral, once a day, continuous administration.~Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration"
214871136|NCT06009627|DRUG|Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection|"Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time~Calculate, otherwise terminate treatment.~5\. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction~And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise~Stop treatment.~6\. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and~Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat"
214871137|NCT02078427|BIOLOGICAL|ADVATE|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
214871138|NCT02078427|BIOLOGICAL|ADYNOVI|Antihemophilic Factor (Recombinant) Pegylated
214871139|NCT03677076|OTHER|Ancillary/Correlative|Collection of research blood and urine
214871140|NCT04651894|DEVICE|reactive hyperaemia index measurement|"reactive hyperaemia index with EndoPAT®~Pulse wave velocity measurement with Sphygmocor®"
215036862|NCT06796101|DEVICE|Vagus Nerve Stimulation|In the study, CE certified vagus nerve stimulation device Vagustim will be used. Transcutaneous auricular vagus nerve stimulation will be applied bilaterally. The stimulation pulse width is 300 microseconds, frequency is 10 Hz and will be applied biphasically for 20 minutes.
215036863|NCT06796101|OTHER|Controlled breathing exercises|"A controlled breathing exercise group will continue for a total of 2 weeks and will receive 10 sessions of 20 minutes per day.~The thoracic expansion exercise will be performed in 10 repetitions. In each intervention session, 2 sets of nadi shodhana pranayama consisting of 8 respiratory cycles will be applied to the patients, with a 2-minute rest period between the sets. Kapalabhati will be practised for 3 minutes, with 15 quick breaths in 10 seconds followed by a 20-second break (a total of 30 breaths per minute). In each session, 2 sets of bhramari pranayama consisting of 10 breathing cycles will be performed at a low respiratory rate, with a 1-minute rest period between sets. The physiological sigh exercise involves the first inspiration phase being 1 second, the second phase 0.25 seconds, and the exhalation 2 seconds for 3 minutes."
215036864|NCT00442702|DRUG|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
215036865|NCT00442702|DRUG|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
215036866|NCT01746524|DEVICE|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
215036867|NCT05068349|DRUG|Butylphthalide|Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
215036868|NCT06628570|DIAGNOSTIC_TEST|HRA + Biopsy|High-Resolution Anoscopy, or HRA, is a standard of care procedure for screening and detection of premalignant lesions of the anus. Using a small, thin round tube called an anoscope, the anal canal is examined with a high-resolution magnifying instrument called a colposcope. The application of a mildly acidic liquid on the anal canal facilitates the evaluation of abnormal tissue such as anal dysplasia. Biopsies for histological confirmation of disease will be taken. Biopsies' reporting will follow the terminology, criteria, and recommendations of the Lower Anogenital Squamous Terminology (LAST) project. Histology results will be reported as benign, condyloma acuminatum, AIN grades 1-3, or cancer. For the proposed project, aHSIL+ will be defined as AIN2 (p16 block-positive), AIN3, and cancer at the HRA encounter. All other cases will be classified as \<aHSIL, including benign, condyloma acuminatum, and AIN1
214871141|NCT03945669|PROCEDURE|Intramedullary Nailing|fracture fixation of the tibial shaft fracture with an intramedullary nail.
214871142|NCT03945669|PROCEDURE|External Ring fixation|fracture fixation of the tibial shaft fracture with an external ring fixator.
214871143|NCT01980966|DRUG|MHAA549A|IV dose
214871144|NCT01980966|DRUG|Placebo|IV dose
214871145|NCT01980966|DRUG|oseltamivir [Tamiflu]|Orally b.i.d, 5 days
214871146|NCT00229983|BEHAVIORAL|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
214871147|NCT00638027|DRUG|placebo|matched tablets bid
214871148|NCT00638027|DRUG|memantine|10 mg bid
214871149|NCT00593047|DRUG|KB2115|tablet formulation given once daily for 12 weeks
215036869|NCT06628570|DIAGNOSTIC_TEST|Anal Cytology|Anal cytology collection (swab samples) will be performed as part of the standard of care during this study. The collected cells, suspended in the SurePath liquid-based medium, will be placed on a slide and microscopically examined by a board-certified pathologist. The sample will then be interpreted using the Bethesda System: negative for intraepithelial lesion or malignancy (NILM), ASCUS, LSIL, ASC-H, or HSIL. Pathologists interpreting the anal cytology will be blinded from hrHPV testing and biopsy histology.
215036870|NCT06628570|DIAGNOSTIC_TEST|Genotyping of anal hrHPV infection|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. To identify the infecting HPV genotype, DNA will be extracted from swab samples collected with the MagNA Pure LC DNA Isolation Kit III and an LC MagNA Pure system (Roche Diagnostics GmbH, Mannheim, Germany), followed by HPV typing using the TypeSeq assay, a laboratory prepared high-throughput next-generation sequencing assay developed by NCI will be performed as described. The assay uses three sequential PCR steps resulting in barcoded L1 amplicons sequenced and submitted to a bioinformatics pipeline for typing. This TypeSeq assay qualitatively detects and identifies 51 HPV genotypes (HPV types 3, 6, 11, 13, 16, 18, 26, 28, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 97, and 114), including 14 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)
215036871|NCT06628570|DIAGNOSTIC_TEST|CINtec®PLUS|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. Dual immunostaining with p16/Ki-67 will be performed on the residual cytologic specimen by Roche MTM Laboratories (Heidelberg, Germany), using the CINtec®PLUS Kit according to the manufacturer's instructions. The anal cytology material will be stained with a mouse monoclonal antibody directed against human p16INKa (p16) protein (clone E6H4) and recombinant rabbit monoclonal antibody directed against human Ki-67 protein (clone 274-11AC3V1), using the BenchMark ULTRA instrument (Ventana Roche). Samples with insufficient cellularity will be excluded from the evaluation. A trained cytotechnologist will review all cases for cells staining positively with both markers. A slide will be considered positive if 1 or more squamous epithelial cell(s) stained positive for both p16 and Ki-67 and dual stain-positive cells will be semi-quantitatively assessed (0, 1, 2-5, 6-50, \>50).
215036872|NCT02194387|DIETARY_SUPPLEMENT|Dietary Intervention|Record dietary intake 4-7 days per week
215036873|NCT02194387|DIETARY_SUPPLEMENT|Dietary Intervention|Record dietary intake 1 day per week
214871150|NCT00371397|BEHAVIORAL|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
214871151|NCT00371397|BEHAVIORAL|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
214871152|NCT03139227|PROCEDURE|Bio specimen Collection|Patients undergo collection of blood and urine
214871153|NCT03139227|DIETARY_SUPPLEMENT|Dietary Intervention|Consume celery-banana bread
214871154|NCT03139227|OTHER|Laboratory Biomarker Analysis|Correlative studies
214871155|NCT03463473|DRUG|3 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 3 mg/kg (Q3W)
215036874|NCT02194387|OTHER|Internet-Based Intervention|Receive email coaching
215036875|NCT02194387|OTHER|Internet-Based Intervention|Participate in social networking
215036876|NCT02194387|OTHER|Laboratory Biomarker Analysis|Correlative studies
215036877|NCT02194387|OTHER|Questionnaire Administration|Ancillary studies
214871156|NCT03463473|DRUG|10 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q3W)
214871157|NCT03463473|DRUG|20 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 20 mg/kg (Q3W)
214871158|NCT03463473|DRUG|10 mg/kg Q2W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q2W)
214871159|NCT04592835|DRUG|DWRX2003|"Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites"
215036878|NCT02194387|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching
215036879|NCT02194387|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
215036880|NCT06775860|DRUG|ICP-332 Tablets|ICP-332 will be administered as tablet
215036881|NCT06775860|DRUG|ICP-332 Placebo Tablets|ICP-332 Placebo will be administered as tablet
214291128|NCT00711854|DRUG|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
214291129|NCT00711854|DRUG|Linezolid|Linezolid (600 mg IV or PO twice daily)
214871160|NCT03261986|RADIATION|Radiostereometric Analysis|RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
214871161|NCT03261986|PROCEDURE|total hip arthroplasty with RSA bead implantation|Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
214871162|NCT01284621|DRUG|BI 10773|medium dose, oral administration
214871163|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
214871164|NCT01284621|DRUG|BI 10773|medium dose oral administration
214871165|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
214871166|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
214871167|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
214871168|NCT02802631|DRUG|Minocin (minocycline) for Injection|Intravenous formulation of minocycline, a derivative of tetracycline
214871169|NCT02802631|OTHER|Placebo|Placebo - Normal Saline
214871170|NCT04579016|OTHER|PAIGE2 lifestyle intervention|Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
215036882|NCT05850416|OTHER|mGlide-Care|Mhealth mediated model of HTN care with self-monitoring and medication management
215036883|NCT05850416|OTHER|Usual Care +|Usual Care with self-monitoring support
215036884|NCT06843408|DRUG|INCA034176|IV infusion
215036885|NCT06847854|DRUG|RO7497372|RO7497372 will be administered as IVT injection as per the schedule specified in the arms.
215036886|NCT06579664|DEVICE|iTBS|Participants in active group will receive iTBS stimulation in 50-Hz triplets at 5 Hz for 600 seconds per session (2 seconds on and 8 seconds off) at 90% of their resting motor threshold to the left dorsolateral prefrontal cortex (DLPFC).Each intervention day includes 4 sessions (1800 pulses/session) of stimulation delivering a total of 7200 active pulses. This treatment protocol will be conducted 15 consecutive days.
215036887|NCT06579664|DEVICE|sham iTBS|Participants in the sham group will receive sham iTBS stimulation, which will use the same stimulation parameters, dosage, and duration as the active group, but will employ a sham coil. The sham coil is identical in appearance to the real stimulus coil and simulate the sound of a real stimulus, but do not produce a real stimulus.
214871171|NCT04579016|OTHER|Standard care|Care routinely provided to all pregnant women diagnosed with GDM
214871172|NCT01377376|DRUG|ARQ 197 and Erlotinib|Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
215036888|NCT04939090|DRUG|Olanzapine|Given PO
215036889|NCT04939090|DRUG|Megestrol Acetate|Given PO
215036890|NCT04939090|OTHER|Questionnaire Administration|Ancillary studies
215036891|NCT05581485|DRUG|Dexmetedomedine infusion|Patients received a loading dose of dexmedetomidine at 1 µg/kg over 10 minutes, followed by a continuous infusion at 1 µg/kg/h throughout the procedure. This regimen was combined with TIVA (propofol) and THRIVE to support spontaneous breathing during endoscopic laryngeal surgery.
215036892|NCT05581485|PROCEDURE|Ultrasound-Guided Superior Laryngeal Nerve Block (SLNB)|Following anesthesia induction, patients received bilateral ultrasound-guided superior laryngeal nerve blocks using 5 mL of 1% lidocaine per side. This intervention was combined with total intravenous anesthesia (TIVA) using propofol and high-flow nasal oxygenation (THRIVE) to maintain spontaneous respiration during endoscopic laryngeal surgery.
215036893|NCT06490718|DRUG|USG ESPB|"After obtaining the appropriate sonographic window, under strict aseptic precautions, the block needle is inserted in the plane of the US beam in a caudad to cranial direction until the tip is in contact with the transverse process (TP) at its lateral aspect. A test bolus of 0.9% saline (1-2 ml) is injected and sonographic evidence of erector spinae muscle displacement (posterior) from the underlying TP is sought to ensure that the tip of the block needle is indeed at the erector spinae muscle plane. The study drug from the 25 ml syringe with the label 'study drug for ESPB' (containing either 25 ml of 0.5% ropivacaine with 1:200,000 adrenaline or 0.9% saline depending on the group allocation) is injected in small aliquots over a minute. The anaesthesiologist performing the block and the patient is blinded to the group allocation.~Successful injection reveals a clearly delineated posterior displacement of the erector spinae muscle."
215036894|NCT06490718|DRUG|Intravenous Infusion|"Following ultrasound-guided erector spinae plane block (USG ESPB), patients will be transferred to the operating room. General anesthesia (GA) will be administered according to a standardized protocol.~Study Drug Infusion:~Immediately after securing the airway, an intravenous infusion from a 50 ml syringe labeled study drug for IVI will commence. The study drug contains either 30 ml of 2% lidocaine or 0.9% saline, depending on group allocation. The infusion begins with a bolus rate of 0.1 ml/kg over 10 minutes and continues at 0.1 ml/kg/hr until surgical wound closure."
215036895|NCT06304857|DRUG|Dapagliflozin|10 mg tablet q.d
215036896|NCT06304857|DRUG|Placebo|tablet matching dapagliflozin 10 mg q.d
215036897|NCT03558126|DEVICE|silicone tube|
215036898|NCT06466395|DRUG|Venetoclax|Given by PO
214871173|NCT01377376|DRUG|Placebo and Erlotinib|Oral twice daily administration of placebo and oral once daily administration of erlotinib
215036899|NCT06466395|DRUG|Hyper-CVAD|Given by IV
215036900|NCT05494086|PROCEDURE|DPLDG|Dual-port laparoscopic distal gastrectomy
215036901|NCT05494086|PROCEDURE|LDG|Laparoscopic distal gastrectomy
215036902|NCT06021600|DRUG|Cladribine|Given by PO and Given by IV (vein)
215036903|NCT00660803|DRUG|Fulvestrant|
215036904|NCT01478425|DEVICE|Lipidic Microemulsion|Topical nasal, twice a day
215036905|NCT01478425|DEVICE|Saline|Topical Nasal, twice a day
215036906|NCT00000720|DRUG|Globulin, Immune|
215036907|NCT00000720|DRUG|Zidovudine|
215036908|NCT02589821|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
215036909|NCT02589821|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
215036910|NCT00221767|DEVICE|Brindley technique (bladder system)|Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
214291130|NCT00711854|DRUG|Rifampicin|Rifampicin (600 mg IV or PO once daily)
214291131|NCT05644522|DEVICE|Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)|The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
214871174|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
214871175|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
214871176|NCT05596565|OTHER|Supervised Exercise by a physiotherapist via face to face|"Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference"
215036911|NCT03484104|DIAGNOSTIC_TEST|Measurement of tissue oxygenation index (TOI)|TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest
214665819|NCT05768789|OTHER|Water only|Each subjected ingested 1 L of Kirkland® bottled water at a rate of 6.25% of the total amount of water every 15 minutes for four hours
214665820|NCT05768789|DIETARY_SUPPLEMENT|Nuun Electrolyte|Each subject consumed 1 L of water with two dissolved Nuun® Sport Hydration tabs (Nuun, Seattle, WA), containing 600 mg of sodium, over 30 minutes (2 equal volumes every 15 minutes) while measuring urine output over 6 hours (
214665821|NCT04420793|OTHER|Questionnaire|3 voice recording tasks and 1 text entry task will be performed.
214665822|NCT06489678|DIAGNOSTIC_TEST|Robotic Assisted Bronchoscopy|Cone-beam computed tomography (CBCT) technology and robotic-assisted bronchoscopy (RAB) present promising methods to enhance biopsy accuracy and procedural safety through 3-dimensional reconstructions and increased bronchoscope tip flexibility. Additionally, the transfer of navigational data between CBCT and RAB may further improve diagnostic yield. Given their distinct approaches to enhancing diagnostic outcomes, two separate study arms are warranted for CBCT and RAB.
214871177|NCT02418663|DRUG|Fluid challenge (250 ml Lactated Ringer's solution)|"When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above"
214871178|NCT02254161|DRUG|Matching placebo|Tablet
214871179|NCT02254161|DRUG|BI 1181181 healthy elderly|Tablet
214871180|NCT02254161|DRUG|BI 1181181 Healthy young|Tablet
214871181|NCT02968849|BIOLOGICAL|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose \> 10\^6 cell culture infectious dose 50% (CCIDv50) and \< 1 × 10\^8 CCIDv50 (nominal dose of 10\^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM
214871182|NCT02968849|BIOLOGICAL|Bivalent Subtype C gp120/MF59|Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM
214871183|NCT02968849|BIOLOGICAL|Placebo|Sodium Chloride for injection, 0.9% delivered IM
214871184|NCT01090830|DRUG|Belinostat, carboplatin, paclitaxel and bevacizumab|"Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles."
215036912|NCT05971095|DEVICE|Percutaneous neuromodulation using the EPTE® Bipolar System device|"The two stimulation protocols will be applied consecutively. Firstly, the high-frequency protocol (HFS) will be applied in order to produce potentiation of the non-nociceptive pathway, using the pulsed square waveform and 5 bursts of stimulation lasting 5 seconds at a frequency of 100 Hz separated by 55 s interval between bursts. Adjustments to amplitude and pulse width are made until the patient experiences paresthesias at a perceptible but not painful intensity, and the intensity will be set 200 μA above the detection threshold for each subject.~In order to depress the nociceptive pathway, the low-frequency protocol (LFS) with stimulation at 2 Hz for 16 min with an intensity of 1000μA will subsequently be switched to. To ensure the recruitment of higher threshold type C nociceptive fibers, the intensity level will be programmed at the pain threshold for each subject."
215036913|NCT03790189|BIOLOGICAL|Subchondral and intra-articular injection of BMC|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
214665823|NCT01084252|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214665824|NCT01084252|DRUG|Dexamethasone|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214665825|NCT01084252|DRUG|Dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
214665826|NCT05964738|DRUG|Diuretics withdrawal|Diuretics that not have been demonstrated improve survival in chronic HFrEF are withdrawn
214871185|NCT03510780|PROCEDURE|Periodontal surgery with Enamel Matrix Derivative|Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft
214871186|NCT03510780|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
214291132|NCT03722537|PROCEDURE|Osteochondral Allograft|The arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface.
214665827|NCT05964738|DRUG|Diuretics maintenance|Any diuretic could be used
214665828|NCT04980703|DEVICE|Grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the patient feels burning or a little pain, put out moxa with gauze and keep for 10 seconds, so as to ensure enough heat to be penetrated into the acupoint. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
214670044|NCT03822403|DEVICE|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
214670045|NCT00909285|DEVICE|TMS stimulation|TMS stimulation and cognitive training
214670046|NCT00909285|DEVICE|Sham comparator|Sham comparator
215036914|NCT01895192|OTHER|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
214871187|NCT04719260|BEHAVIORAL|Nutrition Thinking®|In the first session, the nutritionist will carry out the anamnesis through the Empathy Map and assessment of the nutritional status to define the Nutrition Briefing. The steps described by Design Thinking as understanding, observation, and point of view comprise the first phase of this session. The ideation process will proceed from the definition of the Nutrition Challenge. Prototyping is the final stage of the first session, where an initial prototype of the diet will be co-created based on visual thinking tools and the description underlying the creation of diets. Within 24 hours the individual will receive a summary of the material developed by email. The period between sessions will comprise the testing phase and the follow-up sessions the iteration phase where the experience and previous steps are revisited in order to create new insights, anthropometric measurements will be seen as reflections of the experience and not as primary outcomes of the intervention.
215036915|NCT02385071|DRUG|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
215036916|NCT02385071|DRUG|Treatment B|Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
215036917|NCT02385071|DRUG|Treatment C|Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).
215036918|NCT02385071|DRUG|Treatment D|\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fed conditions.
215036919|NCT02385071|DRUG|Treatment E|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
215036920|NCT02385071|DRUG|Treatment F|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3\*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
215036921|NCT03101800|DRUG|Azathioprine and Allopurinol|Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
215036922|NCT03101800|DRUG|Azathioprine|Standard weight based azathioprine dosage
215036923|NCT02328495|DRUG|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
215036924|NCT02328495|OTHER|Bladder Filling|"Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used."
215036925|NCT01179373|DEVICE|TMS, H coil|TMS, H Coil, High/ Low Frequency
215036926|NCT01162759|BEHAVIORAL|Home Blood Pressure Monitoring|Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
215036927|NCT06295419|OTHER|dual task|cerebral palsy and healthy controls will be evaluated dual task conditions
215036928|NCT06295419|OTHER|single task|cerebral palsy and healthy controls will be evaluated single task conditions
215036929|NCT02285881|BEHAVIORAL|Shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
215036930|NCT01151267|OTHER|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation \>97% and end tidal CO2 at 35-45mmHg.
215036931|NCT01151267|DEVICE|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
215036932|NCT03301584|OTHER|Enhanced collaboration to promote patient participation|"Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
215036933|NCT03301584|OTHER|Usual Care treatment|The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
215036934|NCT04902040|BIOLOGICAL|Atezolizumab|Given IV
215036935|NCT04902040|DRUG|Avelumab|Given IV
214871188|NCT04719260|BEHAVIORAL|Standard Nutritional Approach|In the first session the nutritionist will carry out the food and nutritional anamnesis and assessment of the nutritional status. From this information, the nutritionist will generate the diagnostic hypothesis and determine the specific nutritional needs. The professional will be responsible for generating the dietary prescription defining the characteristics of the diet that will be delivered printed to the individual after a period of 15 days, in the second session of the protocol. The follow-up session will be based on adherence to the established conduct and monitoring of anthropometric variations.
214871189|NCT06988904|OTHER|Energy2MOB|"Intervention: The Energy2MOB programme will take place at three primary healthcare centres in Berguedà:~Baix Berguedà (Puig-Reig CAP) Berga Centre (Berga CAP) Alt Berguedà (Guardiola de Berguedà CAP)~The programme will include:~One pre-intervention visit 8 weekly group sessions One post-intervention visit One-month telephone follow-up In-person follow-ups at three and six months~The control group will continue with standard care at their usual primary healthcare centre and will only attend pre-intervention, post-intervention, and six-month follow-up visits. They will not receive group sessions or telephone follow-ups. If the Energy2MOB programme proves effective, control group participants will be invited to participate in the intervention sessions."
214871190|NCT01910974|PROCEDURE|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
214871191|NCT06897644|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
214871192|NCT06897644|DRUG|Irinotecan (CPT-11)|150 mg/sqm iv over 60 minutes day 1
214871193|NCT06897644|DRUG|Leucovorin|Leucovorin 400 mg/sqm (racemic) or l-Leucovorin 200 mg/sqm over 2 hours day 1
214871194|NCT06897644|DRUG|5-FU (5-fluorouracil)|2400 mg/sqm 46-hours infusion
214871195|NCT06897644|DRUG|gemcitabine|1000 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
214871196|NCT06897644|DRUG|Nab-paclitaxel|125 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
214871197|NCT02551666|OTHER|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
214871198|NCT02551666|OTHER|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
214871199|NCT00600808|DRUG|BPLG-003|
214871200|NCT06945926|DRUG|oxytocin nasal spray|Cases were included according to the inclusion and exclusion criteria, and induction, maintenance and resuscitation were performed according to the standard protocol for general anesthesia.Before the end of anesthesia, the experimenter administered oxytocin nasal spray (Oxytocin) that was 3 sprays in each nostril (4 IU each) for a total of 24 IU. Beginning 1 day postoperatively, administer 24 IU of oxytocin nasal spray 2 times/day in the morning and 24 IU in the evening.Until 7 days after surgery or discharge.
215036936|NCT04902040|BIOLOGICAL|Durvalumab|Given IV
215036937|NCT04902040|BIOLOGICAL|Nivolumab|Given IV
215036938|NCT04902040|BIOLOGICAL|Pembrolizumab|Given IV
215036939|NCT04902040|DRUG|Plinabulin|Given IV
215036940|NCT04902040|RADIATION|Radiation Therapy|Undergo radiation therapy
215036941|NCT03580044|COMBINATION_PRODUCT|ATM-AVI|ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
215036942|NCT03580044|DRUG|BAT|The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
215036943|NCT01365754|PROCEDURE|standard|fusion
215036944|NCT01365754|PROCEDURE|new|dynamic stabilization
215036945|NCT00251433|DRUG|lapatinib, docetaxel, trastuzumab|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
215036946|NCT00481936|DRUG|VB6-845|Intravenous infusion once weekly for 4 weeks
215036947|NCT02672995|RADIATION|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5\~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5\~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
215036948|NCT02672995|DRUG|bevacizumab|"Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
215036949|NCT06446570|DRUG|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
215036950|NCT01664624|DRUG|Roflumilast|Roflumilast tablets
214871201|NCT00229320|BEHAVIORAL|Group therapy|
214871202|NCT03664518|DRUG|Eltrombopag|subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50\~150×109/L，the eltrombopag dose Maintain. platelet count between 150\~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
214871203|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (After the Alteration)|Recombinant human interferon α-2b gel (after the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
215036951|NCT01664624|DRUG|Alogliptin|Alogliptin tablets
214476562|NCT03591003|DIAGNOSTIC_TEST|Yellow fever neutralizing antibodies measure|Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
214871204|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (Before the Alteration)|Recombinant human interferon α-2b gel (before the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
214871205|NCT03395405|DRUG|Nitazoxanide|One 500 mg tablet twice daily with food for 56 consecutive doses
214871206|NCT03395405|OTHER|Placebo|One tablet twice daily with food for 56 consecutive doses
215036952|NCT01664624|DRUG|Exenatide|Exenatide solution
215036953|NCT01664624|DRUG|Placebo to roflumilast|Placebo-matching roflumilast tablets
215036954|NCT01664624|DRUG|Placebo to alogliptin|Placebo-matching alogliptin tablets
215036955|NCT03448211|DRUG|Para-toluenesulfonamide Injection (PTS)|Intratumoral injection
215036956|NCT00127439|PROCEDURE|Manually Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
215036957|NCT00127439|OTHER|Robotic Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
215036958|NCT00104702|PROCEDURE|adjuvant therapy|
215036959|NCT00104702|PROCEDURE|conventional surgery|
215036960|NCT00104702|RADIATION|radiation therapy|
215036961|NCT04782921|DEVICE|Xenogenic bone graft material|After access to the periodontal defect via straight incision in vestibulum, at the mucogingival border or short releasing incision on adjacent tooth, Gel 40 (a mixture of collagen gel and xenogenic bone particles) or Gen-Os (pure xenogenic bone particles) will be inserted.
215036962|NCT03364504|OTHER|urine collection|3 urine collections during 24 hours
215036963|NCT02456129|DRUG|Vilaprisan (BAY1002670)|single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
215036964|NCT02456129|DRUG|[14C] Vilaprisan|an intravenous microtracer dose of \[14C\]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
215036965|NCT02456129|OTHER|Itraconazole(ITZ)|Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
215036966|NCT00751478|DRUG|ALO-01|ALO-01 capsules
215036967|NCT00751478|DRUG|MSIR|immediate release morphine sulfate
215036968|NCT00751478|DRUG|Placebo|Placebo
215036969|NCT04252209|OTHER|natural herbs of coconut, aloe vera, and pepperint|mixture of herbal oils of coconut, peppermint, aloe vera
215036970|NCT04252209|OTHER|carboxy methyl cellulose|a moisturizing gel contained 3%carboxy methyl cellulose, 3% peppermint essential oil, 10% propylene glycol, 0.1% potassium sorbate, and water up to 100%.
215036971|NCT01500317|DRUG|Tapentadol|Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
215036972|NCT01500317|DRUG|Oxycodone|Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
215036973|NCT01500317|DRUG|Placebo|Subjects received placebo three times per day (tid) for 48 hours.
214871207|NCT06570044|DIAGNOSTIC_TEST|PerioMonitor|Collection of oral rinse specimen and perform the PerioMonitor test as per the method described in the instructions for use
214871208|NCT05499286|OTHER|Mindfulness Program|Mindful Awareness and Resilience Skills for Adolescents (MARS-A) Curriculum
214871209|NCT04946396|DRUG|dexmedetomidine intravenous infusion|Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy
214871210|NCT04946396|DRUG|0.9%sodium chloride|0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy
215036974|NCT01641575|DRUG|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
215036975|NCT00335829|BIOLOGICAL|bevacizumab|
215036976|NCT00335829|DRUG|chemotherapy|
215036977|NCT00335829|DRUG|embolization therapy|
215036978|NCT00335829|PROCEDURE|hepatic artery infusion|
215036979|NCT03483948|DRUG|HMPL-523|HMPL-523 tablet
215036980|NCT03483948|DRUG|Azacitidine|Azacitidine Injection
214665829|NCT04980703|DEVICE|Sham grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the moxa burns to half （the patient hasn't feel hot or feel a little hot）, take the moxa away with tweezers. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
214665830|NCT04980703|OTHER|Standard care|Participants in the wait-list control with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.). And after waiting for 12 weeks, these patients will be treated with the same grain moxibustion as the grain moxibustion group.
214670047|NCT00909285|BEHAVIORAL|Cognitive training|TMS stimulation and cognitive training
214871211|NCT03574350|BEHAVIORAL|KS in Kangaroo Position|KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
214871212|NCT03574350|BEHAVIORAL|KS in incubator|The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
214871213|NCT02647801|BEHAVIORAL|Mindfulness intervention|"Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation)."
214871214|NCT02713919|BEHAVIORAL|Adapted German PRO-SELF© Plus Pain Control Program|Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
214871215|NCT06376851|DIAGNOSTIC_TEST|AI-enabled quantitative coronary plaque analysis (AI-QCPA)|The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.
214871216|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
214871217|NCT01638598|DRUG|Test drug|BI 1021958
214871218|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
215036981|NCT02398214|BEHAVIORAL|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to \< 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
215036982|NCT02146157|DIETARY_SUPPLEMENT|herb and mineral combination product|herb and mineral product containing cinnamon, turmeric and holy basil
215036983|NCT02146157|DIETARY_SUPPLEMENT|Placebo|Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
215036984|NCT02264314|BEHAVIORAL|Active Communication Education Program|A behavioral intervention aimed to improve the adherence to the hearing aid in older adults with hearing loss
215036985|NCT02264314|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
214670048|NCT00336193|BEHAVIORAL|Home visitation|Home visitation to improve maternal health and well-being and parenting practices
214670049|NCT03922399|PROCEDURE|Laser and Surgery|Laser and Surgery in patients with major burn scars Evaluating after three years treatment
214871219|NCT01638598|DRUG|Test drug|BI 1021958
215036986|NCT00619775|DEVICE|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
215036987|NCT00888147|DIETARY_SUPPLEMENT|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
215036988|NCT03326908|DEVICE|Spectral Domain Optical Coherence Tomography|Five SD-OCTs will be performed with various conditions of enlightenment.
215036989|NCT04259593|OTHER|exercise training|
215036990|NCT02927444|BIOLOGICAL|NBP606|A single intramuscular injection into the thigh
215036991|NCT02927444|BIOLOGICAL|Prevnar13|A single intramuscular injection into the thigh
215036992|NCT04340570|BEHAVIORAL|Medication management via televisit to home|Pharmacist led home based televisit for medication management
215036993|NCT04513925|DRUG|Atezolizumab|Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.
214476563|NCT06838221|OTHER|A Before and After study|interactive oral health educational program for children with intellectual disability and their care givers
214871220|NCT01638598|DRUG|Test drug|BI 1021958
214871221|NCT01638598|DRUG|Test drug|BI 1021958
214871222|NCT01638598|DRUG|Test drug|BI 1021958
214871223|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
214871224|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
214871225|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
214871226|NCT04876105|OTHER|Assesment of treatment preference|Multiple-choice survey questions were created by the researchers based on the studies in the literature regarding the pain and treatment preferences of the participants
214871227|NCT06277089|OTHER|Casts|According to level of scoliosis cast done and recast in a serial manner
214871228|NCT04853095|PROCEDURE|Peritoneal fixation (PerFix)|PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
214871229|NCT04853095|PROCEDURE|Standard of care|ePLND without peritoneal flap fixation
214871230|NCT03851029|OTHER|Tai chi|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
214871231|NCT03851029|OTHER|Aerobic Training|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
214871232|NCT00461253|DEVICE|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
214871233|NCT00461253|DEVICE|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
214871234|NCT02051712|BEHAVIORAL|exercise training|individualized exercise training
214871235|NCT02051712|BEHAVIORAL|Adherence measures|Measures to increase adherence to exercise training
214871236|NCT06633653|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
214871237|NCT03510598|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting machine will be used to perform the treatments.
214871238|NCT03510598|DRUG|Kybella 20 MG in 2 ML Injection|Injectable drug called KYBELLA® (deoxycholic acid)
214871239|NCT06325397|OTHER|High Intraocular Pressure (IOP)|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with Intraocular Pressure (IOP) ≤ 24 millimeters of mercury (mmHg) (low IOP) in one eye and with IOP ≥ 65 millimeters of mercury (mmHg) (high IOP) in the other eye.
214871240|NCT06325397|OTHER|Low Intraocular Pressure (IOP)|Low Intraocular Pressure (IOP) Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 24 millimeters of mercury (mmHg) (low IOP) in one eye and with IOP ≥ 65 millimeters of mercury (mmHg) (high IOP) in the other eye
214871241|NCT06316583|OTHER|TrP-DN and Acupuncture|Treatment is conducted by pain specialists and acupuncturists, each having over 5 years of relevant work experience. The treatment occurs within the three weeks leading up to menstruation, administered once a week for a total of three sessions. Additionally, participants are to engage in abdominal stretching exercises starting from the treatment day. These exercises are to be done 3-5 times daily, with each session lasting approximately 2 minutes, and this regimen is to continue for one month. If participants experience significant pain during menstruation, they may take NSAIDs orally for symptomatic relief.
214871242|NCT05915325|PROCEDURE|Physical training|"1. Supervised Physical Training in SeniorGym for 12 weeks: 1) Aerobic exercise: Patient-tailored intensity-modulated ergometer training for the limbs; 2) Resistance exercise: Patient-tailored resistance exercise by Theraband for the limbs~2. Nutrition intervention for 24 weeks: Dietitian consultation, education and intervention for 24 weeks"
214871243|NCT04240392|BEHAVIORAL|Collaborative Care (CC)|"The sites randomized to CC will have 4-6 on-site support visits at the outset of the study. These visits will occur during the first 3 months of the project. During these visits, study staff will again review buprenorphine induction procedures (heretofore referred to as initiation rather than induction) and dosing of buprenorphine as well as therapeutic behavioral treatments. The investigators will provide the center with forms and educational materials as well as an app that can be run to help dosing during initiation procedures. At the same time, the investigators will teach obstetricians, nurses and support staff the principles of motivational interviewing. The investigators will set up visits for the CM to meet with a recovery coach trainer provided by the investigators' community partner."
214871244|NCT04240392|BEHAVIORAL|Extension for Community Healthcare Outcomes (ECHO)|The Weitzman Institute (WI), a community partner and provider for the ECHO condition, is a research and innovation center focused on improving care for medically underserved and special populations. Since 2013, CHCI/WI has provided education and technical assistance through an established video conference and online learning platforms to over 800 primary care providers and over 200 care team members who treat patients with chronic pain and opioid addiction. WI partners with national experts in pain care, substance abuse disorder, and MAT to create and deliver a robust training program for clinicians across the country through Project ECHO ®. The WI will work with the study team to develop and staff the sessions.
214871245|NCT05093777|OTHER|Program Intensified Habilitation|The program is based on a holistic and family-centered concept, which acknowledges parents as experts on their child's abilities and needs. The program involves both parents and local professionals, and includes goal setting and goal-directed treatment targeted to the needs of the individual child. The program lasts for about one year and contains three in-patient group sessions over 2 weeks. In between the children are receiving individualized home training programs at home and in pre-school/kindergarten. The children train on a daily basis, both during the inpatient sessions and in the home setting.
214871246|NCT05093777|OTHER|Habilitation as usual|"When the participants are not joining the study year containing the intervention program, they will be offered habilitation services as usual administered by the primary health care services in the local community."
214871247|NCT02066103|DRUG|Paclitaxel|
214871248|NCT01364181|DRUG|Udenafil|Udenafil 50mg qd po
214871249|NCT05994001|DRUG|cardonilizumab|cardonilizumab:PD1 and CTLA-4 bispecific antibody
214871250|NCT05994001|DRUG|LM-302|LM-302 :ClAUDIN 18.2-ADC
214871251|NCT01038440|DIETARY_SUPPLEMENT|Safflower Oil|One softgel consumed daily with food
214871252|NCT01038440|DIETARY_SUPPLEMENT|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
214871253|NCT01038440|DIETARY_SUPPLEMENT|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
215036994|NCT04513925|DRUG|Tiragolumab|Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.
215036995|NCT04513925|DRUG|Durvalumab|Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight \>/= 30 kg) on Day 1 of each 28-day cycle.
215036996|NCT04943848|BIOLOGICAL|rHSC-DIPGVax|Off-the-shelf, neoantigen heat shock protein vaccine
215036997|NCT04943848|DRUG|Balstilimab|BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)
215036998|NCT04943848|DRUG|Zalifrelimab|ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
215036999|NCT06197243|OTHER|Acupuncture|Patients will receive acupuncture for 12 weeks.
215037000|NCT06197243|OTHER|Yoga|Patients will receive yoga therapy with one of three yoga instructors. Patients will remain with singular yoga instructor for duration of study. It is anticipated that patients will participate in yoga therapy for 12 weeks at home and in-clinic.
215037001|NCT06197243|OTHER|Deprescribing|Deprescribing of patients' benzodiazepine use will be monitored by psychiatric nurse. Tapering method will be followed for medication deprescription.
215037002|NCT05141383|OTHER|Urine sampling|A blood sample and a urine sample after prostate massage will be carried out at baseline
215037003|NCT04565457|DEVICE|Research CBCT|Each study participant will receive one additional CBCT scan, with 2D antiscatter grid in place. This is the only intervention in the study, referred as research CBCT scan, and it will be performed on one of the days during the participant's radiation treatment course. This additional research CBCT scan will be used strictly for the objectives of this study. It will not be used as part of the standard clinical care, such as imaging guidance of participant's radiation treatment or diagnostic purposes. To deliver participant's radiation treatment under CBCT guidance, a standard clinical CBCT scan will be acquired, as in standard clinical care protocols.
215037004|NCT06467240|PROCEDURE|hybrid rapid maxillary expander assisted with Micro-osteo perforation (MOPs)|patients with constricted maxillary will applied for hybrid expansion and group of them will assisted by Micro-osteo perforation (MOPs)
214476564|NCT06838221|OTHER|before and after study|To evaluate the oral health of a group of children with disability and determine the effectiveness of the interactive oral health education program on oral health of children and care givers' oral health knowledge.
214871254|NCT05475886|DRUG|Hydroxyethyl starch 130/0.4|An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
214871255|NCT05307510|DEVICE|Prefabricated splint|Subjects will be provided either a prefabricated splint
214871256|NCT05307510|DEVICE|Custom Orthosis|Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
214871257|NCT05969613|PROCEDURE|Regional block|regional block with 0.25% Bupivacaine at a dose of 2ml/kg with adrenaline
214871258|NCT05969613|PROCEDURE|Wound infiltration|Infiltration of surgical site with 0.25% Bupivacaine at 0.5ml/kg dose
214871259|NCT05969613|PROCEDURE|Caudal block|Infiltration of caudal epidural space with 0.25% Bupivacaine at 1ml/kg dose
214871260|NCT04020289|BEHAVIORAL|"Psychoeducational Program BalancingMySwing"|"Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy"
214871261|NCT00521534|DEVICE|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
214871262|NCT05478512|DRUG|VenObi+Ven or VenObi+VenZan|"Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~* if uMRD = Venetoclax 400 mg/d orally until cycle 13.~* if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~* if uMRD = stop treatment~* if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression"
214871263|NCT02358135|OTHER|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
214871264|NCT02358135|OTHER|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
214871265|NCT00403507|BEHAVIORAL|Participation in a monitored exercise program|No contact with control group during 20 weeks.
215037005|NCT05600777|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
215037006|NCT05600777|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
215037007|NCT04567303|DRUG|Zifibancimig|"Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant."
215037008|NCT04567303|DRUG|Ranibizumab|Participants will receive ranibizumab 100 mg/mL through the PD implant
215037009|NCT04567303|DEVICE|Port Delivery Platform|Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
214871266|NCT00403507|BEHAVIORAL|Personalized aerobic and strength training.|Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
214871267|NCT03330054|DEVICE|fundoscope|Fundoscope for eye examination
215037010|NCT01916057|DEVICE|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
214871268|NCT04608123|OTHER|none (observational study)|DBS
215037011|NCT06848413|OTHER|Arabic education video intervention based on the Positive Education about Aging and Contact Experiences (PEACE)|This video is designed based on the Positive Education about Aging and Contact Experiences (PEACE), which is suitable for professional medical that is Arabic speaker only.
215037012|NCT06308978|DRUG|FT819|FT819 will be administered as intravenous (IV) infusion at planned dose levels.
215037013|NCT06308978|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at planned dose levels.
215037014|NCT06308978|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at planned dose levels.
215037015|NCT06308978|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at planned dose levels.
215037016|NCT06847542|DEVICE|Susvimo PDS Implant|Ranizumab will be administered via a PDS implant per the schedule described in the arm.
215037017|NCT06847542|DRUG|Ranibizumab|"Participants will receive ranibizumab delivered through the PDS implant.~Participants will receive ranibizumab, 0.5 mg IVT injections as a supplemental treatment."
215037018|NCT06434636|DRUG|Transamine 10% IV/IM Solution for Injection|10 mg/kg tranexamic acid (Transamine 10% IV/IM Injectable Solution) will be placed into 100 cc physiological saline through the appropriate vascular access and injected within 15 minutes.
215037019|NCT06434636|DRUG|%0.9 Saline|100 cc %0.9 Normal Saline will be injected through the appropriate vascular access within 15 minutes
215037020|NCT05985954|DRUG|Cetuximab|Given by IV (vein)
215037021|NCT05985954|DRUG|Ulixertinib|Given by PO
215037022|NCT05985954|DRUG|Encorafenib|Given by PO
214871269|NCT05360485|BEHAVIORAL|MOV'D (Move Often eVery Day)|The MOV'D intervention is a remotely-delivered, peer-supported intervention that delivers exercise snack (2-5 minutes of moderate to vigorous activity) and behavior change technique (BCT) videos to a private social media support group with the goal of interrupting prolonged sitting at work with MVPA minutes.
214871270|NCT05360485|BEHAVIORAL|Fitbit Self-Monitoring|All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.
214871271|NCT01555671|DRUG|Meperidine|0.5 ml meperidine injection intravenously injected in randomly selected patients
214871272|NCT01555671|DRUG|Saline|0.5 ml saline solution injection intravenously injected in randomly selected patients
214871273|NCT04932161|PROCEDURE|Titanium Granules|After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.
214871274|NCT04932161|PROCEDURE|Hydroxyapatite|After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
214871275|NCT03038841|DEVICE|Mobile Health|Patients discharged from hospital will be equipped with a tracking bracelet and a smart phone
215037023|NCT06262321|RADIATION|Prophylactic Palliative Radiotherapy|Prophylactic Palliative Radiotherapy
215037024|NCT04373369|DRUG|Vorolanib|Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.
215037025|NCT04373369|DRUG|Atezolizumab|Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
215037026|NCT04961957|DEVICE|Waterproof padding|Apply waterproof padding to allow for normal bathing and water activities
215037027|NCT04961957|DEVICE|Non-waterproof padding|Apply standard padding that does not allow for normal bathing and water activities
215037028|NCT06044740|DRUG|Sevoflurane|After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.
215037029|NCT06044740|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
215037030|NCT04067011|DRUG|Ciprofloxacin 500Mg Tablet|Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
215037031|NCT04067011|DRUG|Doxycycline 100Mg Tablet|Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
215037032|NCT04067011|BIOLOGICAL|AV7909|0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
215037033|NCT03746015|BIOLOGICAL|TDV|TDV subcutaneous injection comprised of 1 molecularly characterized, attenuated dengue virus strain, and 3 chimeric dengue virus strains with potencies of not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) per dose of TDV-1, TDV-2, TDV-3, and TDV-4, respectively.
214476565|NCT05769608|DRUG|Placebo|Placebo once daily for 12 weeks
214871276|NCT00602368|OTHER|histological technique|
214871277|NCT00602368|OTHER|laboratory biomarker analysis|
214871278|NCT00602368|PROCEDURE|colposcopic biopsy|
214871279|NCT00602368|PROCEDURE|colposcopy|
214871280|NCT00602368|PROCEDURE|light-scattering spectroscopy|
214871281|NCT00602368|PROCEDURE|loop electrosurgical excision procedure|
215037034|NCT05664191|DRUG|Levosimendan|Infusion at 0.1 µg/kg/min at day 1 and day 8
215037035|NCT05664191|OTHER|Placebo|Glucose 5%, solution for injection ECOFLAC at day 1 and day 8
215037036|NCT06100562|BEHAVIORAL|Adapted Dance Program|"* Participants will attend a 2x/weekly adaptive dance session for 10 weeks. If participants miss a class due to illness or an unexpected event (loss of transportation, family emergency/need) they will receive a video of the content missed and can complete the session at home.~* Each class will start with a 10 min warm-up that will include stretching and motor games.~* Learn a section of choreography every session using action-based intervention for 30 minutes.~* Break for 5 min.~* Improvisation part of class for 10 min.~* Cool-down for 5 min."
215037037|NCT04115631|DRUG|Acalabrutinib|Given PO
215037038|NCT04115631|DRUG|Bendamustine|Given IV
215037039|NCT04115631|DRUG|Bendamustine Hydrochloride|Given IV
215037040|NCT04115631|DRUG|Cytarabine|Given IV
215037041|NCT04115631|BIOLOGICAL|Rituximab|Given IV
215037042|NCT05763121|DRUG|Dexpramipexole Dihydrochloride|oral administration of dexpramipexole tablet
215037043|NCT05763121|DRUG|Placebo|oral administration of placebo tablet
214871282|NCT04011605|PROCEDURE|Biological Sample of Carious Dentin|Dental patient volunteers will have either areas of decayed tooth structure or recurrent caries defective fillings removed using conventional, routine procedures, which will include: local anesthesia; tooth isolation using rubber dam; removal of superficial decay, weakened tooth structure or defective filling materials with rotary tooth cutting instruments; and then removal of softened dentin using sterile sharp spoon excavators, by hand. The limit of dentin removal will be determined by the clinician's estimate of tooth hardness, that is, using present conventional and ethical practice.
215037044|NCT06352151|OTHER|Routine Physiotherapy Group|Children with Down syndrome who receive routine physical therapy treatment in special education centers will undergo evaluation after eight weeks of treatment, followed by a control evaluation after 12 weeks.
215037045|NCT06352151|OTHER|Orofacial Treatment Group|"The orofacial treatment group receives therapeutic orofacial treatment in addition to routine physiotherapy treatment. Each week, one or two target exercises will be taught to the child with Down syndrome, and the exercises will gradually increase throughout the process. Parental involvement will be encouraged during the treatment to ensure active participation in therapy.~The goals of the therapy are as follows:~First Goal: Nasal hygiene and Sleep hygiene education~Second Goal: Nasal Breathing Exercise Training~Third Goal: Creating Awareness of Tongue Resting Position~Fourth Goal: Creating Lip Position Awareness - Lip Exercises~Goal Five: Chewing Muscle Exercises~Sixth Goal: Strengthening the Soft Palate~Seventh Goal: Reshaping Correct Swallowing"
214291133|NCT03722537|PROCEDURE|Ligament Reconstruction Tendon Interposition|During the LRTI, the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
214871283|NCT03047330|DRUG|Estradiol withdrawal|one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
214871284|NCT03047330|OTHER|Fragmented sleep|Fragmented sleep will be experimentally induced.
214871285|NCT04590040|OTHER|Placebo|0% nano-HAP toothpaste
214871286|NCT04590040|DEVICE|15% nano-HAP toothpaste|Toothpaste with identical base formulation as the placebo containing 15% nano-HAP
214871287|NCT04590040|DEVICE|5% KNO3 toothpaste|Toothpaste with identical base formulation as the placebo containing 5% KNO3
214871288|NCT03047629|DRUG|ENT-01|Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
214871289|NCT03047629|OTHER|Placebo|Daily dosing with a placebo
214871290|NCT00000378|DRUG|Sertraline|12 week trial dose up to 200mgs
215037046|NCT06352151|OTHER|Therapeutic Yoga Group|The therapeutic yoga group receives therapeutic yoga treatment and routine physiotherapy treatment. Children with Down syndrome will be given yoga exercises suitable for their age.
215037047|NCT04153292|DEVICE|SAPIEN M3 valve and dock|During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.
214291134|NCT06470373|DRUG|RBS-001 Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
214291135|NCT06470373|DRUG|Eylea® Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
214291136|NCT04487639|DIAGNOSTIC_TEST|SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics|a nasopharyngeal swab for SARS-CoV-2 research by RT- qPCR will be performed on the day of semen collection. On the same day, serological tests will be carried out, and 30 to 50 days after, according to HAS specifications with methods validated by the National Reference Center
214476566|NCT05769608|DRUG|lorundrostat Dose 1|lorundrostat Dose 1 once daily for 12 weeks
214871291|NCT00000378|DRUG|Nortriptyline|12 week trial dose adjusted to therapeutic level
214871292|NCT05158088|DEVICE|Borescope|Endotracheal intubation using borescope
214871293|NCT05158088|DEVICE|Video laryngoscope|Endotracheal intubation using video laryngoscope
214871294|NCT06344585|OTHER|Drop out patients who had their first access in 2021 were additionally asked to answer to a phone -call questionnaire to assess their motivation of discontinuation|"A prospective comprehensive analysis of the data contained within patient charts, encompassing personal histories and demographic details, was extracted from the internal database of the Humanitas Fertility Center. This analysis aimed at elucidating the individual reasons for treatment discontinuation after the initial clinical visit throughout the year 2021. Additionally a tailored questionnaire was administered to patients via telephone by a member of Humanitas Fertility Center staff in July 2023.~The questionnaire was submitted to the patients via a phone call. The questionnaire comprised nine questions with response limited to 'Yes' and 'No' options for all queries."
214871295|NCT02056912|GENETIC|Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene|
214871296|NCT02056912|BIOLOGICAL|Perform blood cells and fibroblasts biochemical and immuno-labeled investigations|Performed only in the two index patients enrolled in the sub-study
214871297|NCT01331629|OTHER|ART-THERAPIE|8 sessions of art therapy during radiotherapy
214871298|NCT05016609|DEVICE|OraQuick HCV Antibody test (OraSure Technologies, Inc)|The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.
215037048|NCT05209386|BEHAVIORAL|Dimension-Based Statistical Learning|"Each participant will complete self-paced blocks of stimuli that will first establish a baseline for neural activity and behavioral responses with clear speech, and will then record responses for experimentally manipulated blocks to introduce 1) speech-in-noise and 2) a Canonical-Reverse block to model an accent. Auditory stimuli will be adjusted to a comfortable level for each participant as determined by a calibration process completed by the participant. Each block involves listening to sound via earphones and making a categorical decision between initial consonants (/b/ or /p/) by tapping a button to indicate the word heard by the participant."
215037049|NCT05837676|BEHAVIORAL|Problem Solving Training for Concussion|PST-Concussion is a combined treatment consisting of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
215037050|NCT05837676|OTHER|Treatment as usual|Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
215037051|NCT06053749|DRUG|Avonex (IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
215037052|NCT06053749|DRUG|Rebif (IFNβ-1-a, Merck Europe B.V.)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
215037053|NCT06053749|DRUG|Extavia (IFNβ-1-b, Novartis Europharm Limited)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
215037054|NCT06053749|DRUG|Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
215037055|NCT06053749|DRUG|Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
215037056|NCT06053749|DRUG|MS disease modifying drugs (MSDMDs)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
215037057|NCT04732260|DRUG|Letermovir|"Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg."
215037058|NCT05456139|BEHAVIORAL|Treatment as Usual|"Families in the Treatment as Usual (TAU) condition will receive usual care and EI services in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course."
215037059|NCT05456139|BEHAVIORAL|Early Social Interaction Mobile Coaching (ESI-MC)|The ESI-MC coach will offer 24 weekly sessions for the 6-month ESI-MC condition. The parent will be the focus of training. Each session includes: setting the stage to develop that session's agenda; intervention implementation with these coaching steps: a) review the target, b) use guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to support caregiver reflection and independence in the activity, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and summarize plans for deliberate practice between sessions. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided online course and companion to the online group education meetings to engage families in the content of the online course and provide support through interaction with other families. Families will also participate in TAU usual care and EI services in their community.
215037060|NCT02254863|BIOLOGICAL|DUOC-01|Intrathecal administration of DUOC-01
215037061|NCT06050122|DRUG|Patidegib Topical Gel|Patidegib Gel 2% is a smooth, clear, colorless-to-yellow, viscous, hydro-alcoholic gel for topical administration.
215037062|NCT06050122|DRUG|Patidegib Topical Gel with no active patidegib|Vehicle Gel consists of the excipients of Patidegib Gel with no active patidegib. It is a smooth viscous gel for topical administration.
215037063|NCT06143189|OTHER|Hosting conditions|"Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments."
215037064|NCT06143189|OTHER|Hospital Clowns|"The HCs Palhaços D'Opital (PdO) have a program aiming to bring joy, affection and good mood to adults and elders in hospital environment. They work in pairs, dressed in colorful costumes and they prepared sketches in advance. Their performances recreate day-to-day situations (e.g., clowns trying to install a new TV screen; planning a wedding between the clowns and asking the public for their ideas), ending with specific closure, in order to indicate to the audience that the session had finished and to promote a positive environment after their departure. Each intervention lasted around 15 minutes."
215037065|NCT02105129|DRUG|HMPL-523|HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
214871299|NCT05016609|DEVICE|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.
215037066|NCT02105129|DRUG|Placebo|Oral administration
215037067|NCT02143882|DRUG|Fluenz|Live attenuated influenza vaccine
214291137|NCT00998660|DEVICE|Activa RC|Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
214665831|NCT06060938|OTHER|Risk stratified arm|"* Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every 1-4 years according to the risk-group)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)~* Provide a blood sample for analysis of 313 common genetic variants associated with risk of breast cancer (baseline)~* Receive a screening schedule recommendation."
214871300|NCT05016609|DRUG|Sofosbuvir/Velpatasvir (Gilead)|Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.
215037068|NCT04462471|DIAGNOSTIC_TEST|I-124 PET/CT lesion dosimetry|I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)
214670050|NCT03526432|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
214665832|NCT06060938|OTHER|Control arm|"* Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every second year)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)"
214871301|NCT01404286|BEHAVIORAL|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
214871302|NCT04545320|BEHAVIORAL|Usual care control group|Health education
214871303|NCT04545320|BEHAVIORAL|HIIT group|Once-a-week HIIT
214871304|NCT04545320|BEHAVIORAL|MICT group|Once-a-week MICT
214871305|NCT05659212|DRUG|Dexmedetomidine|Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
214871306|NCT05659212|DRUG|Magnesium sulphate|Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
214871307|NCT05659212|DRUG|Lidocaine|Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
214871308|NCT00381914|DRUG|Vitamin D|400 IU vitamin D / day
214871309|NCT00381914|DRUG|Vitamin D|800 IU vitamin D / day
214871310|NCT00381914|DRUG|Vitamin D|1200 IU vitamin D / day
214871311|NCT06490185|OTHER|Clinical data collection|Clinical significance of peri-appendiceal abscess and phlegmon in acute complicated appendicitis patients undergoing emergency appendectomy
214871312|NCT03376061|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
214871313|NCT02333656|OTHER|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
214871314|NCT04952818|DIAGNOSTIC_TEST|RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)|Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
214871315|NCT02289443|OTHER|complete denture|Comparison of different procedures
214871316|NCT06159244|OTHER|stool withdrawal|stool withdrawal at day 0 and day 7
214871317|NCT00540293|DRUG|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
214871318|NCT01574690|DEVICE|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
214871319|NCT01574690|PROCEDURE|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
214871320|NCT01574690|PROCEDURE|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
214871321|NCT00511641|BEHAVIORAL|Questionnaire|Questionnaires lasting up to 30 minutes.
214871322|NCT04684238|DRUG|Midazolam|Solution for Injection/Infusion
214871323|NCT04684238|DRUG|Isoflurane|Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
214871324|NCT01377818|PROCEDURE|ventilation|"positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.~Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night)."
214665833|NCT05111210|OTHER|Blood sample|Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed
214871325|NCT01377818|PROCEDURE|excecise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~* 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~* Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
214871326|NCT01377818|PROCEDURE|Both|both types of intervention
214871327|NCT01560741|DEVICE|Telemonitoring tools|Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
214871328|NCT01560741|DEVICE|Usual Care|The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
214871329|NCT01185197|DRUG|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
214871330|NCT01185197|DRUG|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
214871331|NCT05721287|DRUG|SBS-1000|SBS-1000 administered as a single continuous IV infusion over 60 minutes
214871332|NCT05721287|DRUG|Placebo|Normal saline (0.9% sodium chloride \[NaCl\]) administered as a single dose IV infusion over 60 minutes
214871333|NCT06298019|BIOLOGICAL|KYV-101|The investigational product, KYV-101, is an autologous CD19-targeted CAR T-cell immunotherapy.
214871334|NCT01006798|OTHER|Placebo|enteric coated capsule containing no vaccine virus
214871335|NCT01006798|BIOLOGICAL|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
214871336|NCT01006798|BIOLOGICAL|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
214871337|NCT01988129|OTHER|Sleep disorders education and screening|Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
215037069|NCT04462471|DRUG|Vemurafenib|Dose level 1 \& 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid
214871338|NCT01047514|BEHAVIORAL|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
215037070|NCT04462471|DRUG|Copanlisib|Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
215037071|NCT00724763|DEVICE|acupuncture|to Liv 3 and PE 9.
215037072|NCT00724763|DEVICE|sham needle treatment|needle not in meridian area
214871339|NCT04848922|OTHER|Hot shower intervention|Intervention group took a shower in a standing position at a water temperature of 37-41°C for 10-20 minutes between 6 and 12 hours after vaginally birth.
215037073|NCT04921982|DRUG|Propranolol|Oral administration of Propranolol, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse once a week for six consecutive weeks.
215037074|NCT04921982|DRUG|Placebo|Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.
214665834|NCT05111210|OTHER|Data collection|collection of socio-demographic, clinical and biological data.
214871340|NCT05552079|OTHER|No intervention|Patients will be asked to show their consultation slip to confirm they attend to clinic on the day. The will also be asked to show their HKID card to comfirm they are aged 40 or above. The purpose of the study will be explained. If patient agrees to proceed, he/she will be given a self-administered questionniare. An interviewer-administered questionnaire will be provided for subjects who have poor sightedness or are illiterate. Since only anonymous data and no identifiable information will be collected, participants cannot be identified from the questionnaire. Therefore, inform consent will not be obtained.
214871341|NCT05968599|DRUG|Enzalutamide|As provided in real-world setting
214871342|NCT05968599|DRUG|Abiraterone acetate|As provided in real-world setting
214871343|NCT05239546|DRUG|Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 6 cycles followed by 1000 mg every 6 weeks for 8 cycles until 1.5 years
214871344|NCT00309725|DRUG|galantamine|
215037075|NCT01734525|DRUG|Anidulafungin|Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
215037076|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from day 0 to (maximum) day 6
215037077|NCT00665834|DRUG|placebo|placebo 20 mg from day 0 to (maximum) day 6
215037078|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from discharge until the end of the study
215037079|NCT00665834|DRUG|atorvastatin|atorvastatin 80 mg from discharge until the end of the study
215037080|NCT05584098|OTHER|qSOFA, MEWS and physiological parameters combination|qSOFA ,MEWS and physiological parameters combination used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
215037081|NCT05666830|DEVICE|Lando® artificial dermal regeneration matrix|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
215037082|NCT00538850|DRUG|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
215037083|NCT00538850|DRUG|Placebo|Matching placebo to fentanyl sublingual spray.
215037084|NCT04379570|OTHER|Educational Intervention|Receive online educational information about ET medication
215037085|NCT04379570|OTHER|Text Message-based Navigation Intervention|Receive text messages
215037086|NCT04379570|BEHAVIORAL|Motivational Interviewing|Receive motivational interviewing counseling sessions
215037087|NCT04379570|OTHER|Best Practice|Attend usual care clinic visits
215037088|NCT04379570|OTHER|Questionnaire Administration|Ancillary studies
215037089|NCT04379570|OTHER|Quality-of-Life Assessment|Ancillary studies
215037090|NCT05408845|PROCEDURE|Biopsy Procedure|Undergo a biopsy
215037091|NCT05408845|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215037092|NCT05408845|PROCEDURE|Computed Tomography|Undergo a CT scan
215037093|NCT05408845|DRUG|Docetaxel|Given IV
215037094|NCT05408845|PROCEDURE|Echocardiography Test|Undergo ECHO
215037095|NCT05408845|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215037096|NCT05408845|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215037097|NCT05408845|OTHER|Questionnaire Administration|Ancillary studies
215037098|NCT05408845|BIOLOGICAL|Trastuzumab|Given IV
215037099|NCT05408845|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
215037100|NCT05408845|BIOLOGICAL|Trastuzumab Emtansine|Given IV
215037101|NCT05229744|DEVICE|sequence MRI 3D FLAIR|"Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®):~\- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product"
215037102|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered during skin closure (end of operation).
215037103|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)
215037104|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered 6 hours after the first administration.
215037105|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.
215037106|NCT03949517|DRUG|68-Ga RM2|Radioactive agent
214871345|NCT00775905|DRUG|amlodipine 10 mg tablet|
215037107|NCT03949517|DRUG|68-Ga PSMA11|Radioactive agent
215037108|NCT03949517|DEVICE|Investigational software and coils in PET/MR Scan|Investigational software and coils in PET/MR Scan by General Electric Healthcare
215037109|NCT03949517|PROCEDURE|PET/MRI|Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan
214871346|NCT04779515|PROCEDURE|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
215037110|NCT03078452|DEVICE|Power drill|Undergo bone marrow biopsy using power drill
215037111|NCT03078452|DEVICE|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
215037112|NCT04502082|BIOLOGICAL|ET140203 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
215037113|NCT01424553|OTHER|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
215037114|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with propofol|Incremental administration of propofol up to a cummulative full therapeutic dose (2mg/kg) in POH patients investigated for propofol. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.02mg/kg-0.2 mg/kg -0.6 mg/kg -1.2mg/kg).
215037115|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with ketamine|Incremental administration of ketamine up to a cummulative full therapeutic dose (1mg/kg) in POH patients investigated for ketamine. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.01 mg/kg -0.1 mg/kg -0.3 mg/kg -0.6mg/kg).
215037116|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with etomidate|Incremental administration of etomidate up to a cummulative full therapeutic dose (0.2mg/kg) in POH patients investigated for etomidate. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.002 mg/kg -0.02 mg/kg -0.06 mg/kg -1.2mg/kg).
215037117|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with midazolam|Incremental administration of midazolam up to a cummulative full therapeutic dose (0.05mg/kg) in POH patients investigated for midazolam. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.0005 mg/kg -0.005 mg/kg -0.015 mg/kg -0.03mg/kg).
215037118|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with fentanyl|Incremental administration of fentanyl up to a cummulative full therapeutic dose (1mcg/kg) in POH patients investigated for fentanyl. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.01 mcg/kg -0.1 mcg/kg -0.3 mcg/kg -0.6mcg/kg).
215037119|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with sufentanyl|Incremental administration of sufentanyl up to a cummulative full therapeutic dose (0.1mcg/kg) in POH patients investigated for sufentanyl. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.001 mcg/kg -0.01 mcg/kg -0.03 mcg/kg -0.06µg/kg).
215037120|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with alfentanil|Incremental administration of alfentanil up to a cummulative full therapeutic dose (10mcg/kg) in POH patients investigated for alfentanil. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.1 mcg/kg -1 mcg/kg -3 mcg/kg -6µg/kg).
215037121|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with remifentanil|Incremental administration of remifentanil up to a cummulative full therapeutic dose (0.5mcg/kg) in POH patients investigated for remifentanil. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.005 mcg/kg -0.05 mcg/kg -0.15 mcg/kg -0.3µg/kg).
214665835|NCT05111210|OTHER|skin biopsies|skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds
214670051|NCT03526432|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
214670052|NCT00210561|DRUG|tramadol hydrochloride , acetaminophen|
214871347|NCT04779515|PROCEDURE|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
214871348|NCT00027248|DRUG|MBI 226|
214871349|NCT04901169|DRUG|Angiotensin II|Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
214871350|NCT04901169|DRUG|Saline|Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
214871351|NCT03522610|BEHAVIORAL|ADAPT|Two hour, once a week in-person parenting program for 14 weeks plus use web-enhanced supplemental ADAPT materials
214871352|NCT02241421|DRUG|Amoxicillin|
214871353|NCT02241421|DRUG|Vancomycin|
214871354|NCT02241421|OTHER|Placebo|
214871355|NCT00000718|DRUG|Zidovudine|
214871356|NCT00000718|DRUG|Zalcitabine|
214871357|NCT03889067|BIOLOGICAL|Salmonella Typhi challenge|The challenge agents will be delivered in 30 ml of sodium bicarbonate solution, preceded by 120 ml of solution of sodium bicarbonate to neutralise gastric acid.
214871358|NCT02585934|DRUG|RVT-101|once daily, oral, 35 mg tablets
214871359|NCT02585934|DRUG|Placebo|once daily, oral, pill manufactured to match RVT-101 35 mg tablet
214871360|NCT04713553|BIOLOGICAL|BNT162b2|Intramuscular injection
214871361|NCT04713553|BIOLOGICAL|BNT162b2.B.1.351|Intramuscular injection
214871362|NCT04060030|DRUG|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
214871363|NCT04060030|OTHER|Placebo|Placebo
214871364|NCT00782574|DRUG|AZD2281|Tablets Oral BID
214871365|NCT00782574|DRUG|Cisplatin|IV every 3 weeks
215037122|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with rocuronium|Incremental administration of rocuronium up to a cummulative full therapeutic dose (0.6mg/kg) in POH patients investigated for rocuronium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.006 mg/kg -0.06 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.18 mg/kg -0.42mg/kg) are administerd under general anesthesia.
215037123|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with atracurium|Incremental administration of atracurium up to a cummulative full therapeutic dose (0.5mg/kg) in POH patients investigated for atracurium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.005 mg/kg -0.05 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.15 mg/kg -0.35mg/kg) are administered under general anesthesia .
215037124|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with cisatracurium|Incremental administration of cisatracurium up to a cummulative full therapeutic dose (0.15mg/kg) in POH patients investigated for cisatracurium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.0015 mg/kg -0.015 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.045 mg/kg -0.105mg/kg) are administered under general anesthesia .
214476567|NCT05769608|DRUG|lorundrostat Dose 2|lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria
214476568|NCT05193019|OTHER|Parenteral antiplatelet agents|Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice
214476569|NCT06465108|DRUG|MBX 2109|Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL
214871366|NCT02448706|DEVICE|Hearing Aid Fitting A|
214871367|NCT02448706|DEVICE|Hearing Aid Fitting B|
214871368|NCT01476618|OTHER|No Intervention|No Intervention
214871369|NCT03967171|OTHER|before uterine incision oxytocin|blood loss during elective cesarean section
214871370|NCT03967171|OTHER|after clamping the umbilical cord oxytocin|blood loss during elective cesarean section
214871371|NCT01344278|BEHAVIORAL|Lifestyle Counseling|A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
214476570|NCT06465108|OTHER|Placebo|Supplied in 1.4 mL water for injection
214476571|NCT06804317|OTHER|telerehabilitation|"Exercise-based interventions were conducted twice weekly for three months via videoconferencing on Microsoft Teams. The program included various components:~Aerobic and strength training, Flexibility, Balance and coordination"
214476572|NCT06805448|DRUG|MSC|Allogeneic adipose-derived mesenchymal stromal / stem cells in 10% DMSO
214871372|NCT00020371|DRUG|BMS-247550|
214871373|NCT00020371|DRUG|filgrastim|
214871374|NCT03860662|DIAGNOSTIC_TEST|Nociceptor flexor reflex|The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
214871375|NCT03860662|DRUG|Botox|botox
214871376|NCT03860662|DRUG|Baclofen|baclofen
214871377|NCT01458730|DRUG|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
214871378|NCT02067468|DEVICE|HPV test|QIAGEN - The Digene HPV test®
214871379|NCT02067468|PROCEDURE|COLPOSCOPY|Colposcopy routine health services
214871380|NCT02067468|DEVICE|cytology|Cytology routine health services
214871381|NCT01359969|DRUG|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
214871382|NCT02174419|DRUG|nalbuphine HCl ER tablets 90 mg BID|nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
214871383|NCT02174419|DRUG|nalbuphine HCl ER tablets 180 mg BID|nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
214871384|NCT02174419|DRUG|Placebo tablets BID|Placebo tablets BID administered for 10 weeks
214871385|NCT03972163|BEHAVIORAL|NIA Medication Management - Active Comparator|"As the attention control, we will refer staff in control offices to the National Institution on Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
214871386|NCT03972163|BEHAVIORAL|STOPPFrail (Screening Tool of Older Persons Prescriptions)|A screening tool used by clinicians with frail older adults with life-limiting illness to review medications
214871387|NCT03972163|BEHAVIORAL|"Discontinuing Medication Appropriately and Understanding the Art of Communication about Deprescribing"|Education resoruce used by clinicians to simplify and align medications with goals of care
214871388|NCT03972163|BEHAVIORAL|"Key Approaches to Support Informal Family Caregivers in Managing Medications"|Education resource used by clinicians to support Family Care Givers (FCGs)
214871389|NCT01260519|DRUG|Heparin|unfractionated heparin 2000 unites
215037125|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with succinylcholine|Incremental administration of succinylcholine up to a cummulative full therapeutic dose (1mg/kg) in POH patients investigated for succinylcholine. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.01 mg/kg -0.1 mg/kg). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.3 mg/kg -0.7mg/kg) are administered under general anesthesia.
215037126|NCT06430346|BEHAVIORAL|Exercise|Physical activity and resistance training
215037127|NCT05273268|OTHER|Personalized nutrition|Personalized nutrition based on individual traits delivered through mobile device app.
214871390|NCT03174262|BEHAVIORAL|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
214291138|NCT00973739|DRUG|Lapatinib|"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (\<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (\>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response."
214291139|NCT00991666|PROCEDURE|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
214476573|NCT06805448|DRUG|Saline Water (Control)|Isotonic sterile saline water
214476574|NCT06805123|OTHER|Early feeding|Begin drinking water 2 hours after the procedure. If no complications occur 2 hours after starting water intake, progress to a liquid diet. If no abnormalities are observed after the liquid diet, transition to a soft diet for the next meal.
214871391|NCT04062474|PROCEDURE|Epidural Intervention with TNF-α inhibitor|Epidural administration with TNF-α inhibitor
214871392|NCT00995280|DEVICE|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
214871393|NCT00995280|DEVICE|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
214871394|NCT05939635|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
214871395|NCT05939635|PROCEDURE|Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block|"Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
214871396|NCT05939635|DRUG|IV morphine patient-controlled analgesia (PCA)|Morphine will be administered via PCA device for the first 24 hours after surgery
214871397|NCT05876663|OTHER|Kinesio Taping|Kinesio Taping will be applied for 6 weeks and it will be changed with new one after every two days
214871398|NCT05876663|OTHER|Conventional physiotherapy protocol|"Stretching exercise for pectoralis minor and major:10 sets and 2 sessions per day for 6 weeks.~Strengthening of Rhomboids and Trapezius muscle: 10 sets and 2 sessions per day for 6 weeks.~Deep Breathing: 10 rep and 2 sessions per day for 6 weeks."
214871399|NCT03126617|BIOLOGICAL|Elotuzumab|Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
214871400|NCT00110136|DRUG|St. John's Wort|St. John's Wort 300mg tablet three times per day
214871401|NCT01059539|DRUG|Cariprazine|Cariprazine was supplied in capsules.
214871402|NCT00941148|DRUG|Insulin Glargin|
214871403|NCT00941148|DRUG|NPH insulin|
214871404|NCT00941148|DRUG|Insulin detemir|
214871405|NCT00941148|DRUG|metformin|metformin (2000 mg/day)
214871406|NCT03122925|DEVICE|MR|MR
214871407|NCT00537303|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
214871408|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
214871409|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
214871410|NCT02085135|DRUG|ALKS 5461|Sublingual tablet taken once daily
214871411|NCT05394649|DEVICE|Intravascular Lithotripsy|"A new device has been designed by Shockwave Medical Inc. for the treatment of calcified vascular lesions to support stent delivery: the C2 Shockwave Medical® (IVL), Inc. coronary lithotripsy system. The system is based on lithotripsy to induce microfractures in the calcified plaque before low-pressure balloon dilation. The C2 Shockwave Medical® coronary lithotripsy (IVL) system consists of an IVL Catheter with two lithotripsy emitters enclosed within an integrated balloon, an IVL Generator, and an IVL Connector Cable."
214871412|NCT05394649|DEVICE|Rotational Atherectomy|Rotational Atherectomy is a technique of calcic coronary plaque preparation based on the debulking of superficial calcium by a high-speed burr in order to improve vessel compliance and immediate vessel lumen gain before stenting.
214871413|NCT05328336|DRUG|Tislelizumab Nab paclitaxel|"Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will"
214871414|NCT05251519|OTHER|Kinesio Taping|Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
214871415|NCT05251519|OTHER|Conventional Rehabilitation|Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
214871416|NCT05235945|BEHAVIORAL|Online exercise intervention|Described in arm descriptions
214871417|NCT04720118|OTHER|No Intervention|There is no intervention for this study.
214871418|NCT04144478|OTHER|Web based education|Web based education
214871419|NCT06627491|BEHAVIORAL|Imagined muscle contractions|The intervention involved imagining, with no physical movement, of muscle contractions.
214871420|NCT03775759|PROCEDURE|Tricuspid valve repair or replacement|Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.
214871421|NCT03775759|OTHER|Medical management of tricuspid regurgitation|The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
215037128|NCT05273268|OTHER|Generalized nutrition|General nutrition guidelines currently used by USDA.
215037129|NCT02321501|DRUG|Ceritinib|Given PO
215037130|NCT02321501|DRUG|Everolimus|Given PO
215037131|NCT02321501|OTHER|Laboratory Biomarker Analysis|Correlative studies
215037132|NCT02321501|OTHER|Pharmacological Study|Correlative studies
214871422|NCT05532124|BIOLOGICAL|LAENNEC (Human Placenta Hydrolysate)|Intravenous Injection
214871423|NCT05532124|OTHER|normal saline|Intravenous Injection
214871424|NCT00772421|DEVICE|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
214871425|NCT04701086|DEVICE|Cationorm Pro|Eye Drops
214871426|NCT04701086|DEVICE|Vismed|Eye Drops
215037133|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (monoacylglycerol form)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
215037134|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (ethyl ester)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
215037135|NCT02781363|OTHER|Thoracic ultrasound|
215037136|NCT02781363|OTHER|CXR|
215037137|NCT01846312|OTHER|No treatment given|The participants will not receive any treatment.
215037138|NCT02343185|OTHER|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
215037139|NCT02343185|OTHER|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
215037140|NCT00922857|PROCEDURE|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
215037141|NCT00895505|DRUG|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
215037142|NCT00895505|DRUG|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
214476575|NCT06805123|OTHER|Late feeding|Maintain fasting on the day of the procedure. Begin a liquid diet 24 hours after the procedure. If no complications occur after starting the liquid diet, transition to a soft diet at the next meal.
214476576|NCT04678856|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214476577|NCT04678856|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214871427|NCT00093873|DRUG|Anti-angiogenesis|Anti-angiogenesis
214871428|NCT00093873|DRUG|AMG 706|Anti-angiogenesis
214871429|NCT01944176|DRUG|simvastatin, placebo|
214871430|NCT05119348|OTHER|STOPCOV|Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
214871431|NCT05658458|DRUG|Vericiguat (Verquvo, BAY1021189)|The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.
214871432|NCT02336724|DRUG|Famitinib|
214871433|NCT00554606|DRUG|Canakinumab|Canakinumab
214871434|NCT00823108|DRUG|GIK|12 hour infusion of GIK solution
214871435|NCT02202070|DRUG|onabotulinumtoxinA|
214871436|NCT00952211|DEVICE|CPAP|CPAP at therapeutic pressure during nighttime
214871437|NCT00952211|DEVICE|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
214871438|NCT03083080|PROCEDURE|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
214871439|NCT03083080|DRUG|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
214871440|NCT03083080|DRUG|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
214871441|NCT04005235|DEVICE|Thorasys Tremoflo C-100 Airwave Oscillometry System (FOT)|Ultrasonography will be used to confirm hemidiaphragm dysfunction after brachial plexus nerve block. In subjects with U/S confirmed hemidiaphragm dysfunction, FOT measurements will be taken before and after nerve block and post-operatively after upper extremity surgery.
214871442|NCT06353568|DEVICE|Photobiomodulation|The PBM Group will use a boot with 1344 LEDs, including 504 LEDs of 660 nm located on the sides of the boot (28.5 mW, 10 J per LED); 504 LEDs of 850 nm also located on the sides of the boot (23 mW, 8 J per LED); 168 LEDs of 660 nm located at the base of the boot (28.5 mW, 10 J per LED); and 168 LEDs of 850 nm also located at the base of the boot (23 mW, 8 J per LED) once daily for 6 minutes, over 60 days.
214476578|NCT06809075|PROCEDURE|hematopoietic precursor transplantation (TPHa)|An apheresis is performed on the patients and a selection of CD34 hematopoietic progenitors is performed. Subsequently, conditioning is performed with cyclophosphamide, thymoglobulin, corticosteroids and rituximab to subsequently infuse the hematopoietic precursors.
214476579|NCT06954181|DRUG|Voltaren® Schmerzgel forte; 2.32% (Test Product)|Voltaren® Schmerzgel forte; 2.32% containing 2.32% Diclofenac-N-Ethylethanamin.
214871443|NCT06353568|DEVICE|Simulation of Photobiomodulation|The Control Group will use a non-therapeutic LED boot (sham procedure) for 6 minutes once daily for 60 days. The boot used is identical to the active boot, but there is no light emission.
214871444|NCT06353568|BEHAVIORAL|Therapeutic education|Participants will receive therapeutic education regarding nutrition, foot examination, self-care, and guidance on physical activity.
214871445|NCT04505956|DEVICE|Holmium laser lithotripsy with Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned on.
214871446|NCT04505956|DEVICE|Holmium laser lithotripsy without Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.
214871447|NCT04314648|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|Embedding of a collaborative care team, called the Substance Use Treatment and Recovery Team (START), for inpatients with OAUDs within an existing hospital consultation liaison psychiatry service.
214871448|NCT03803930|DEVICE|Using 22G FNB, the first pass is SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
214871449|NCT03803930|DEVICE|Using 22G FNB, the first pass is MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
214871450|NCT03803930|DEVICE|Using 20G FNB, the first pass is SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
214871451|NCT03803930|DEVICE|Using 20G FNB, the first pass is MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.
214871452|NCT01392625|BIOLOGICAL|Autologous hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
214871453|NCT01392625|BIOLOGICAL|Allogeneic hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
214871454|NCT00849186|DRUG|sunitinib malate|oral
214871455|NCT00849186|PROCEDURE|neoadjuvant therapy|IV
214871456|NCT00849186|PROCEDURE|therapeutic conventional surgery|Surgery
214871457|NCT00492024|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
214871458|NCT00492024|DRUG|Placebo|Placebo - 380 mg Microcrystalline Cellulose
214871459|NCT03782909|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of;~1. Feedback via an app based food diary~2. Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it"
214871460|NCT02530658|OTHER|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
214871461|NCT02530658|OTHER|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
214871462|NCT02530658|OTHER|Informed Consent Follow-Up Visit|At or after enrollment but before the release of the gerline results, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
214871463|NCT02530658|OTHER|Return of Results Conversation|Participants will complete the assessment questionnaires.
214871464|NCT02530658|OTHER|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 28 ± 4 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
214871465|NCT02530658|PROCEDURE|Blood Sample|For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
214871466|NCT02530658|PROCEDURE|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
214871467|NCT06453135|DRUG|Eculizumab|On the Day 0, participants received a single dose of eculizumab before the transplant surgery: 900 mg (blood type antibody titer ≥ 1:64 and/or body weight ≥ 60 kg) or 600 mg (blood type antibody titer \< 1:64 and body weight \< 60 kg). Plasmapheresis was not planned. When participants developed AMR, they may receive additional dose of eculizumab.
214871468|NCT03167268|DRUG|Lycopene|
214871469|NCT03167268|OTHER|Placebo|
214871470|NCT01837524|BEHAVIORAL|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
214871471|NCT01837524|BEHAVIORAL|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
215037143|NCT04862312|BEHAVIORAL|VideoDine|Participants will VideoDine with a dining partner at least six times during an eight week period. VideoDining involves sharing a meal with someone not physically present using video chat technology. Dining partners will be recruited, trained and paired with participants. Participants will be provided Amazon Echo Show devices for video chat.
214871472|NCT05900258|DRUG|Tirbanibulin|Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
214871473|NCT02623283|OTHER|No intervention given|Participants will have a full dental examination but no operative intervention
214871474|NCT06019598|OTHER|Licorice|Ecologic sweet licorice pastilles made from Glycyrrhiza glabra grown in Calabria, Italy, with a GA content of 29.9 ±2.0 mg/g.
214871475|NCT00936897|DRUG|Ibandronate|Ibandronate 150mg PO QM (tablet)
215037144|NCT06500455|PROCEDURE|Computed Tomography|Undergo CT
215037145|NCT06500455|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FSRS
215037146|NCT06500455|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215037147|NCT06500455|RADIATION|Stereotactic Radiosurgery|Undergo SRS
215037148|NCT05438147|OTHER|CT-100 DiNaMo|Active Treatment (Study App)
215037149|NCT05438147|OTHER|Care-as-Usual|Care-As-Usual control
215037150|NCT02065284|OTHER|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
215037151|NCT04940169|PROCEDURE|anterior cruciate ligament recontruction|Firstly graft is harvested with help of arthroscopy femoral and tibial tunnels created then graft placed into tunnels
215037152|NCT03489694|PROCEDURE|Skin test endpoint titration|An allergen that is suitable to cause skin reactions when introduced to the forearm through pricking will be administered in doubling concentrations.
215037153|NCT06104644|DRUG|Deucravacitinib|Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics
215037154|NCT01121757|DRUG|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
215037155|NCT01121757|DRUG|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
215037156|NCT01466088|DRUG|Donepezil|Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
215037157|NCT01466088|DRUG|AZD3480|Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
215037158|NCT00224549|DRUG|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
215037159|NCT06352346|BEHAVIORAL|Compensatory brain game supporting Goal Management Training intervention|o The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently outside the therapy session. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
215037160|NCT05869253|BEHAVIORAL|The efficacy of Equine Assisted Occupational Therapy, for children with Attention Deficit Hyperactivity Disorder (ADHD) on cognitive-emotional aspects, daily function and participation|: A prospective cohort study with Interrupted Time-Series design will be conducted. Forty participants and their parents who were referred to EAOT will be recruited from the waiting list of Harey Yehuda stables. Assessments will take place at four time points. Time 1: baseline-when referred for EAOT. Time 2: pre-test, before first treatment session, end of 12 week waiting period. Time 3: post-test after 12 weeks of intervention and time 4: post intervention assessment, three months follow up. The intervention will be administered by a licensed EAOT, and assessments will be done by a blinded licensed occupational therapist (OT). Standardized assessment measures will be used to measure EFs, cognitive-emotional and sensory-motor aspects as well as participation at each time point.
215037161|NCT02239237|DRUG|Compound Kuh-seng Injection|Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
215037162|NCT02935764|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
215037163|NCT02935764|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
215037164|NCT02935764|DRUG|Leucovorin|400mg/m2 iv gtt,d1
214871476|NCT00936897|DRUG|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
214871477|NCT02351271|DEVICE|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
214871478|NCT02351271|DEVICE|Manual capsulorhexis&lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
214871479|NCT06349551|BIOLOGICAL|Patients of intensive care unit|Patients of intensive care unit having an arterial catheter undergoing arterial blood sampling
215037165|NCT06120790|OTHER|3 Oz water screen|Patient will consume 3 oz of water continuously without stopping and then will be monitored for one minute post completion. Patient will complete this twice in the same session.
215037166|NCT02461186|DRUG|Arterolane maleate-piperaquine phosphate (Synriam)|
215037167|NCT02461186|DRUG|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
214871480|NCT05831371|DIAGNOSTIC_TEST|TEP FDG|FDG TEP peformed in clinical routine
214871481|NCT01711892|BEHAVIORAL|Soccer training|
214871482|NCT05908630|OTHER|Hypothermia|"Accidental hypothermia is defined as: an involuntary drop in core body temperature \<35C"
215037168|NCT04834921|DEVICE|Ultraflux® EMiC®2|Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
215037169|NCT04876911|BEHAVIORAL|Simulated Presence Therapy|A video recording of a loved one is played (via an iPad) prior to or during periods where a participant is presenting with stressed/distressed behaviours.
215037170|NCT05657158|OTHER|Brolucizumab|Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included
215037171|NCT04637529|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuvix®
215037172|NCT04637529|DRUG|Ibuvix® - ibuprofen|Ibuvix® + placebo of S(+) - Ibuprofen
215037173|NCT04644952|OTHER|Electronic Health Record Review|Review of medical records
215037174|NCT03588299|DRUG|BAY2599023 (DTX201)|Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
215037175|NCT03558789|BIOLOGICAL|bovine lactoferrin|mouthwash
215037176|NCT04168931|DRUG|Trastuzumab|The first-line standard treatment for gastric cancer is based on fluoropyrimidine and platinum-containing chemotherapy (FOLFOX). When the tumor expresses HER2 3+ on IHC or 2+ and is confirmed by FISH, trastuzumab at the standard dose of 8 mg / kg in D1 of the first cycle is added, followed by 6 mg / kg every 2 weeks for the remaining cycles until disease progression, unacceptable toxicity. (3) We will use the same doses of trastuzumab, but HER2 positivity is determined by immunocytochemical expression and FISH in CTCs for patients with negative expression in tissue biopsy.
215037177|NCT06118866|DRUG|placebo-Q2W|placebo, 0mg，SC，Q2W，12 cycles
215037178|NCT06118866|DRUG|HMI-115-120mg-Q4W|HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
215037179|NCT06118866|DRUG|HMI-115-240mg-Q4W|HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
215037180|NCT06118866|DRUG|HMI-115, 240mg-Q2W|HMI-115, 240mg，SC，Q2W，12 cycles
215037181|NCT01193452|DRUG|S-1, Leucovorin|"S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week."
215037182|NCT01193452|DRUG|leucovorin, 5-fluorouracil|"leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks"
215037183|NCT04358237|DRUG|Lurbinectedin|"Lurbinectedin will be presented as a lyophilized powder for concentrate for solution for infusion in 4-mg vials. Before use, the 4-mg vial will be reconstituted with 8 mL of sterile water for injection, to give a solution containing 0.5 mg/mL of PM01183. For administration to patients as IV infusion, reconstituted vials will be diluted with glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) solution for infusion.~PM01183 will be administered as a 1 hour IV infusion Q3W, in a minimum volume of 100 mL of solution for infusion (either 5% glucose or 0.9% sodium chloride), or a minimum volume of 250 mL if through a peripheral line, always at a fixed rate and through a pump device."
215037184|NCT04358237|DRUG|Pembrolizumab|Pembrolizumab will be supplied as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
215037185|NCT05794646|OTHER|Hybrid effectiveness-implementation study type 2|Diagnosis of hepatitis C; Assessment of hepatic fibrosis; Treatment of hepatitis C; Assessment of psychological disorders and treatment or referral.
215037186|NCT06325514|DIAGNOSTIC_TEST|Artificial intelligence based program|the AI based program is based on image analysis
215037187|NCT05852938|DRUG|BION-1301|BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
215037188|NCT05852938|DRUG|Placebo|Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
215037189|NCT05712187|DRUG|ALTO-100|ALTO-100 tablet BID
215037190|NCT05712187|DRUG|Placebo|Placebo tablet BID
215037191|NCT05053152|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
215037192|NCT05053152|PROCEDURE|Bone Scan|Undergo bone scan
215037193|NCT05053152|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
215037194|NCT05053152|OTHER|Fluciclovine F18|Given fluciclovine F18
215037195|NCT05053152|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI and/or PET/MRI
215037196|NCT05053152|DRUG|Placebo Administration|Given PO
215037197|NCT05053152|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and/or PET/MRI
215037198|NCT05053152|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT or PET/MRI
215037199|NCT05053152|DRUG|Relugolix|Given PO
215037200|NCT05053152|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
215037201|NCT06226376|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes."
215037202|NCT06140017|BEHAVIORAL|Msingi Bora responsive parenting and family wellbeing program|Msingi Bora's structured curriculum of 16 biweekly sessions and monthly boosters thereafter are organized around five key messages: love and respect within the family, responsive talk, responsive play, hygiene, and nutrition.
214476580|NCT06962995|PROCEDURE|Blood Draw|Up to 60 mL (about 4-5 Tbsp) of blood will be collected for an initial blood draw and up to 30 mL (about 2-3 Tbsp) may be collected for a second blood draw, 25-45 days after first blood draw. The research blood will be collected at the time of a clinical blood draw, if possible.
214476581|NCT06962995|OTHER|Surveys|Participants will complete surveys related to attitudes and beliefs around Multi-Cancer Detection testing.
214871483|NCT04063423|PROCEDURE|blood sample|Blood sample at start and at the end of the dialysis session; membrane scoring after dialysis; total cell volume measurement of dialyzer after dialysis; micro-CT of dialyzer after dialysis.
214871484|NCT04126590|BIOLOGICAL|KN044|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg."
214871485|NCT04132700|DEVICE|Q-NRG Metobolic Cart Device|ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
214871486|NCT02287818|DRUG|Placebo|Placebo twice daily from Day 1 to Week 12
214871487|NCT02287818|DRUG|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
214871488|NCT02287818|DRUG|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL
214871489|NCT02720874|BEHAVIORAL|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
214871490|NCT02720874|BEHAVIORAL|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
214871491|NCT02720874|BEHAVIORAL|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
215037203|NCT04980326|BEHAVIORAL|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, will be adapted for use on a smartphone or other device with internet access during Phase 1 of RESPOND. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
215037204|NCT04980326|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
215037205|NCT04980326|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress
215037206|NCT04584008|DRUG|FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.|According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.
215037207|NCT04584008|DRUG|Other Therapy|Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
215037208|NCT02523014|DRUG|Vismodegib|Given PO
215037209|NCT02523014|DRUG|FAK Inhibitor GSK2256098|Given PO
215037210|NCT02523014|DRUG|Capivasertib|Given PO
215037211|NCT02523014|DRUG|Abemaciclib|Given PO
215037212|NCT05214573|DRUG|Glucagon like peptide 1 receptor agonist|Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication
215037213|NCT05214573|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor
215037214|NCT05214573|DRUG|Dipeptidyl Peptidase 4 Inhibitor|Patients in the data who filled a dipeptidyl peptidase-4 inhibitor
215037215|NCT05214573|DRUG|Sulfonylurea|Patients in the data who filled a sulfonylurea
215037216|NCT04251533|DRUG|alpelisib|300 mg orally, once per day (QD), tablets
214871492|NCT02720874|BEHAVIORAL|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
214871493|NCT02720874|BEHAVIORAL|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
214871494|NCT00002960|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
214871495|NCT04708574|BEHAVIORAL|Lifestyle intervention|
214871496|NCT04708574|OTHER|Placebo - Control|
214871497|NCT04444674|BIOLOGICAL|ChAdOx1 nCoV-19|Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19
214871498|NCT04444674|BIOLOGICAL|Normal saline 0.9%|Normal saline 0.9% as placebo
214871499|NCT04241926|DIAGNOSTIC_TEST|transpolmonary thermodilution|Thermodilution was attempted via PICC and via CICC in the same patient
214871500|NCT00111826|DEVICE|Celacade™ system|
214871501|NCT03257865|DRUG|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
214871502|NCT03257865|DRUG|Placebo|Administered orally daily for 3 weeks.
214871503|NCT01616030|OTHER|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
214871504|NCT01121848|DRUG|Leucovorin|"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:"
215037217|NCT04251533|DRUG|placebo|300 mg orally, once per day (QD), tablets
215037218|NCT04251533|DRUG|nab-paclitaxel|100 mg/m\^2 IV infusion, once per day (QD)
215037219|NCT05383482|DRUG|Afuresertib|Afuresertib 125 mg PO on days 1-5, 8-12, 15-19 or Afuresertib 125 mg QD
214665836|NCT06288594|BEHAVIORAL|Application Plus Online Therapist Support Group|Participants in the therapist-supported group will receive weekly 20-30 minute online sessions for five weeks, with content based on a semi-structured manual. After 80% completion of the psychoeducation module, the coping module becomes available, and similarly, the exposure module follows. These sessions will be conducted in adherence to a structured manual, with the therapist introducing the module of the week, guiding through exercises, assigning homework, and reviewing the previous assignments. Sessions include module introductions, exercises, homework assignments, and application use review. Feedback and PCL-5 scores guide post-session recommendations. A random 40% of sessions will undergo fidelity checks by doctoral-level psychologists.
214871505|NCT01121848|DRUG|OXALIPLATIN|"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:"
215037220|NCT05383482|DRUG|Nab paclitaxel|Nab-paclitaxel 80 mg/M2 IV D1,8, Q3W or 100 mg/M2 IV D1,8, Q3W
215037221|NCT05383482|DRUG|Docetaxel|Docetaxel 50 mg/M2 IV D1 Q3W or Docetaxel 60 mg/M2 IV D1 Q3W
215037222|NCT05383482|DRUG|Sintilimab|Sintilimab 200 mg Q3W
215037223|NCT05901636|BIOLOGICAL|INFLUENZA G1 mHA|INFLUENZA G1 mHA will be administered intramuscularly.
215037224|NCT05901636|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly.
215037225|NCT05901636|BIOLOGICAL|Al(OH)3|Al(OH)3 will be administered intramuscularly.
214670053|NCT03474003|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2002 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; RCT conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
214871506|NCT01121848|DRUG|5-Fluorouracil|"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:"
214871507|NCT05405348|BEHAVIORAL|Intervention|The patients did not eat anything during hemodialysis.
215037226|NCT06077994|BEHAVIORAL|digital Remote Patient Monitoring+BEPR+ (dRPM+)|In addition to the BEPR+ program as described, patients will use the Cloud Dx Connect Health System to take daily physiological readings (Blood pressure, heart rate, oximetry, body temperature and body weight). These data will be transmitted to a secured server supported by the provincial health care system. Participants and therapists will interact with these data in their respective dashboards and in conjunction with participants' determined medical action plan, engage in or make changes to participants current self-management regimens.
215037227|NCT06077994|BEHAVIORAL|Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)|Patients will attend the BEPR+ program 3 days per week for 6 weeks or 2 days per week for 8 weeks (total of 16 sessions). Patients will receive 90 minutes of personalized and supervised exercise training (aerobic and resistance) and 60 minutes of education designed to promote self-management. Patients will also received one-on-one sessions with a therapist to review their medical action plan for exacerbation management, program and lifestyle goals (including physical activity), determine referral needs for other health services (i.e. smoking cessation, weight management, and psychological support). Patients will use an activity monitor for feedback and motivation for physical activity.
215037228|NCT06425120|DRUG|Xuesaitong Soft Capsule|Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.
215037229|NCT06425120|DRUG|Placebo|Each participant in the placebo group will take matching placebo.
214476582|NCT06953440|DRUG|Dexamethasone Sodium Phosphate Injection|Patients will receive 4 milligrams of dexamethasone submucosal injection next to the extraction site.
214871508|NCT03574948|DRUG|5-HTP|8 weeks active substance 5-HTP (2 x 100mg per day)
214871509|NCT03574948|DRUG|Placebo oral capsule|8 weeks placebo (2 x 1 caps per day)
214871510|NCT02677714|RADIATION|99mTc-rhAnnexin V-128|Kit for the preparation of 99mTc-rhAnnexin V-128
214871511|NCT04675814|OTHER|Adapted Physical Activity (APA)|Adapted Physical Activity (APA)
214871512|NCT04223557|DEVICE|focused power ultrasound treatment|Patients will be placed in the lateral decubitus position and receive treatment with sequential bilateral PRF ablation. Before the treatment, a professional sonographer will be responsible for the length, thickness, and width of PRF sac measurement and localisation, and utilise the ultrasonic diagnostic transducer to delineate the targeted region. The treatment will launch layer-by-layer. After confirming accurate localization of the treatment, layer-by-layer PRF ablation will be performed on the patients. The device generates and delivers a pattern of conic-shaped ultrasound energy to the PRF sac noninvasively. The treatment of FPU-mediated PRF ablation will be implemented once.
214871513|NCT04223557|DEVICE|Sham treatment|Participants will receive the same procedure as those in the FPU treatment including PRF ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the PRF.
214871514|NCT05998512|OTHER|Observational register|This is a non-interventional observational registry on patients
214871515|NCT00335114|DRUG|cyclosporine ophthalmic emulsion|
214871516|NCT03429010|PROCEDURE|"New guideline anesthesia strategy team"|"New guideline anesthesia strategy team"
214871517|NCT03486691|OTHER|Routine measurement of left lobe|Routine preoperative measurement of left lobe
214871518|NCT03486691|OTHER|control group|no routine preoperative measurement of left lobe
214871519|NCT01655576|PROCEDURE|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
215037230|NCT06529692|BEHAVIORAL|Placebo Split-Belt Training|Walking on a split-belt treadmill in which the belt under the ACL leg will move at a speed that is minimally slower than the other belt.
215037231|NCT06529692|BEHAVIORAL|Split-Belt Training|Walking on a split-belt treadmill in which the treadmill belt under the ACL leg will move at a speed faster or slower than the belt under the Non-ACL leg.
214871520|NCT05798026|DRUG|EU103|EU103 will be administered via intravenous infusion.
214871521|NCT05742763|COMBINATION_PRODUCT|Ibuprofen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
214871522|NCT05742763|COMBINATION_PRODUCT|Acetaminophen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
214871523|NCT05742763|COMBINATION_PRODUCT|Placebo and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
214871524|NCT05319210|PROCEDURE|Venous catheter application|To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.
214871525|NCT02875652|BIOLOGICAL|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
214871526|NCT04182282|BEHAVIORAL|CARES Dementia-Friendly Hospitals Online Training and Certification Program|The CARES Dementia-Friendly Hospitals Online Training program is a 4-course, 16-module, video-based training program for hospital staff members. The CARES Dementia-Friendly Hospitals Online Certification Program is a 100-point certification exam evaluating knowledge from the online training protocol.
214871527|NCT06452667|PROCEDURE|platelet-rich fibin|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich fibin therapy on one side of the face. The other side of the face was treated with platelet-rich palsma.
214871528|NCT06452667|PROCEDURE|platelet-rich palsma|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich palsma therapy on one side of the face. The other side of the face was treated with platelet-rich fibin.
214871529|NCT06332989|OTHER|stroke-APP|Ambulane paramedics will use an online application to fill in several observations on scen
214871530|NCT03741712|DRUG|SHR3680|Tablet. Specifications of 80mg
214871531|NCT03741712|DRUG|SHR2554|Tablet. Specifications of 50mg and 200mg
214871532|NCT06515236|BEHAVIORAL|Strategic Treatment Assessment for Youth (STAY)|Culturally tailored measurement based care
215037232|NCT06364072|DRUG|CT001|Intranasal
215037233|NCT06390579|OTHER|Deep learning algorithm applied on retrospectively collected color fundus photographs|Deep learning algorithm applied on retrospectively collected color fundus photographs
215037234|NCT03032029|DEVICE|Adaptive Servo-Ventilation|Adaptive Bi-Level positive airway pressure with a targeted minute ventilation and auto-adjusting expiratory pressure level.
215037235|NCT06641804|PROCEDURE|Pessary care, change of pessary|Insertion of a new pessary by gynaecologist if not contraindicated, silicon or polyvinyl chloride pessary of same size, blinded to patient
215037236|NCT04385290|DRUG|MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO|"Midostaurin (IMP) induction: 25 mg or 50 mg peroral BID, days 8 to 21 depending on assigned dose level~GO (IMP) induction: 3 mg/m\^2 i.v. max 4.5 mg, on day1, or on days 1, 4, or days 1, 4, 7 depending on assigned dose level~Daunorubicin (DNR, non-IMP) induction: 60 mg/m\^2/day i.v., days 1 to 3~Cytarabine (AraC, non-IMP) induction: 200 mg/m\^2/day cont. infusion, days 1 to 7"
215057217|NCT01416740|DRUG|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
215057218|NCT01582009|DRUG|panobinostat|Given orally
215057219|NCT01582009|DRUG|everolimus|Given orally
215057220|NCT01582009|OTHER|laboratory biomarker analysis|Correlative studies
214476583|NCT06953440|OTHER|Normal Saline (Placebo)|Patients will receive 4 milligrams of normal saline solution next to the extraction site.
214670054|NCT02021968|BIOLOGICAL|TetraVax-DV-TV003|TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10\^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
214670055|NCT02021968|BIOLOGICAL|rDEN2∆30-7169|The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
214871533|NCT06515236|BEHAVIORAL|Measurement Based Care As Usual|Measurement based care as usual
214871534|NCT00991419|DRUG|[18F]AZD4694|\[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
214871535|NCT04821700|BIOLOGICAL|Carotid Stenosis|To investigate if the concurrent presence of carotid stenosis has any effect on future outcomes of patients with ischemic stroke and atrial fibrillation
214871536|NCT02792699|DRUG|ABP 798|Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
214871537|NCT02792699|DRUG|Rituximab (US)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
214871538|NCT02792699|DRUG|Rituximab (EU)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
214871539|NCT06338761|BEHAVIORAL|Smoking cessation|Stop smoking
214871540|NCT06338761|BEHAVIORAL|Switching to E-cigarette|Switching to E-cigarette
214871541|NCT02257697|DRUG|Mizoribine (MZR)|
214871542|NCT02257697|DRUG|Cyclophosphamide (CTX)|
215037237|NCT04385290|DRUG|MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2 i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
214476584|NCT06888765|OTHER|Optical Coherence Tomography (OCT) and Body Composition Analysis|"This observational study included non-invasive diagnostic assessments to evaluate retinal, choroidal, ocular, and body composition parameters. Optical Coherence Tomography (OCT) measured macular and peripapillary retinal parameters, including retinal volume and cup/disc ratio. Enhanced Depth Imaging OCT (EDI-OCT) assessed choroidal thickness and vascularity, while Optical Coherence Tomography Angiography (OCTA) analyzed vessel density and foveal avascular zone (FAZ) metrics.~Optical biometry measured axial length, anterior chamber depth, lens thickness, K1, K2, and central corneal thickness. Autorefractometry and tonometry were part of the routine ophthalmologic examination, including slit-lamp biomicroscopy. Bioelectrical impedance analysis (BIA) assessed body composition, including BMI, fat percentage, muscle mass, and metabolic age. These assessments were for research purposes only, without therapeutic intervention."
214665837|NCT06288594|BEHAVIORAL|Application Only Group|"Participants allocated to this group will have access to the TraumaRelief mobile application over a five-week period, with the exception of the online module component. The application's deployment strategy ensures a structured progression through its features: participants will gain access to the subsequent modules only after completing 80% of the preceding module. Initially, they will engage with the psychoeducation module; upon completion of at least 80% of this module, the coping with symptoms module will become available. Similarly, successful engagement with 80% of the coping module will unlock the imaginary exposure module. This sequential module access is designed to reinforce the acquisition of knowledge and skills in a stepwise manner, paralleling the structure provided to the TraumaRelief Mobile Application with Therapist Support group, yet without the additional therapist interaction."
214670056|NCT02021968|BIOLOGICAL|Placebo|The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
214871543|NCT00154869|DRUG|Peginterferon Alfa-2a plus Ribavirin|
214871544|NCT02538965|DRUG|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
214871545|NCT05555823|DRUG|ATR-002|300 mg tablets for oral intake
214871546|NCT05555823|DRUG|Placebo|matching tablets for oral intake
214871547|NCT05555823|DRUG|Repaglinide|0,5 mg tablets for oral intake
214871548|NCT05555823|DRUG|Celecoxib|100 mg capsules for oral intake
214871549|NCT06359639|BEHAVIORAL|Cognitive restructuring|Five 50-60-minute videoconferencing sessions of cognitive restructuring based on Mind Over Mood: Second Edition (MOM2) (Greenberger \& Padesky, 2016) and The Clinician's Guide to CBT Using MOM2 (Padesky \& Greenberger, 2019) as guides. The sessions will consist of understanding the cognitive model, filling in Thought Records, and complementary coping strategies of looking for evidence, action planning, and acceptance.
214871550|NCT06359639|BEHAVIORAL|Supportive counselling|Five 50-60-minute videoconferencing sessions of supportive counselling consisting of psychoeducation on breakup effects, validation of breakup experiences and emotions, introduction to deep breathing and progressive muscle relaxation, and identification of existing coping strategies.
214871551|NCT05856006|OTHER|upper trapezius stretching plus neck isometrics|upper trapezius stretching plus neck isometrics
214871552|NCT05856006|OTHER|upper trapezius stretching with mid-lower trapezius strengthening exercises plus neck isometrics|"Mid-Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
214871553|NCT00551018|DRUG|Vicriviroc|one 30 mg tablet QD
214871554|NCT00551018|DRUG|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
214871555|NCT00875797|DIETARY_SUPPLEMENT|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
214871556|NCT00875797|DIETARY_SUPPLEMENT|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
214871557|NCT05437315|BIOLOGICAL|bi-4SCAR GD2/PSMA T cells|Infusion of bi-4SCAR GD2/PSMA T cells at 10\^6 cells/kg body weight via IV
214871558|NCT06402760|OTHER|TCM comprehensive treatment|"1. Taodan Granules (TCM formulation for promoting blood circulation and removing blood stasis): The granules consist of the following herbal components: milkvetch, licorice, angelica, rhizoma chuanxiong, peach seed, Salvia miltiorrhiza, Curcuma zedoaria, Achyranthes bidentata, and sarsaparilla. Patients will take it orally in two divided doses after breakfast and dinner.~2. Fish Oil: Patients will take 1g of fish oil orally twice daily. Patients will be instructed to purchase fish oil under the guidance of the researchers.~3. Exercise Plan: Researchers will design an exercise plan for patients, who will be required to engage in at least 150 minutes of moderate-intensity aerobic exercise per week.~Patients will undergo a 16-week treatment period followed by a 24-week follow-up period. During the follow-up, patients will continue taking fish oil and adhering to the exercise regimen, while other treatment modalities will be unrestricted."
214871559|NCT06402760|DRUG|Western medicine|The treatment methods prescribed in the guidelines.
214871560|NCT04928092|PROCEDURE|Standard of care Ultra Low Contrast PCI|PCI using low amounts of contrast media which is standard of care at VCU Medical Center
214871561|NCT02006225|DRUG|Plerixafor|
215057221|NCT01582009|OTHER|pharmacological study|Correlative studies
215057222|NCT01582009|OTHER|liquid chromatography|Correlative studies
215057223|NCT01582009|OTHER|mass spectrometry|Correlative studies
215057224|NCT01582009|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214871562|NCT05213039|OTHER|assessments|All of the children with cerebral palsy will be assessed by two different physiotherapist observers. The timed 360° turn test, Expanded and revised Gross Motor Function Classification System (GMFCS-E\&R) for functional motor levels of the subjects, lower extremity muscle tone will be measured with the Modified Ashworth Scale (MASH) at the beginning of the one-time study and recorded. Pediatric Berg Balance Scale, Timed Up and Go Test, Pediatric Functional Reaching test and Modified Four Square Stepping Test, 3m walking back test (3MGYT) will be performed.Evaluations will be made by two separate physiotherapists with at least 5 years of experience in this field. The time it took for individuals to complete activities during the tests with a stopwatch will be recorded.
214871563|NCT02583958|DEVICE|Urgo 3103166|URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
214871564|NCT02583958|DEVICE|Aquacel Extra|Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
214871565|NCT00203710|DEVICE|Concentric Retriever Device|
214871566|NCT00073710|DRUG|Zemplar|
214871567|NCT00073710|PROCEDURE|42 Ca carbonate absorption via single tracer method|
214871568|NCT00073710|DRUG|Calcijex|
214871569|NCT00735618|OTHER|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
214871570|NCT02525237|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
214871571|NCT02525237|DRUG|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
214871572|NCT03364543|OTHER|Access to the Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs.
214871573|NCT03364543|OTHER|Access to social worker and a community worker|Access to social worker and a community worker, but no systematic process for addressing health-harming legal needs.
214871574|NCT06136000|OTHER|Sacral erectör spinae plane block|Group S will be placed on their side. Asepsis is fifth in the transverse plane under antisepsis standards. high-frequency linear USG probe into the spinous process . The USG probe will be shifted caudally to visualize the first and second median sacral crest. The USG probe is then placed on the second medial It will be placed 3-4 cm lateral to the sacral apex and the mid-sacral apex will be imaged. On the USG screen, from top to bottom, erector spinae muscle, multifidus muscle and sacral intermediate The crest will be displayed. 0.25% bupivacaine will be administered in a total volume of 0.5ml/kg (maximum 20 cc ) by applying negative aspiration with the in-plane technique with a 50 mm Stimuplex A needle.
214871575|NCT06136000|OTHER|Ring Block|The patient is under general anesthesia. Before the surgical procedure begins, the pediatric surgeon administers 0.5ml/kg (maximum 20cc) 0.25% bupivacaine to the base of the root of the penis with a 25-gauge needle at 3, 6, 9, and 12 o'clock.
214871576|NCT01040598|BIOLOGICAL|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
214871577|NCT03412799|DRUG|SBP-101|Administered as subcutaneous (SC) injection, escalating dose cohorts
214871578|NCT03412799|DRUG|nab-paclitaxel|Administered as intravenous (IV) infusion
214871579|NCT03412799|DRUG|Gemcitabine Injection|Administered as intravenous (IV) infusion
214871580|NCT06104943|OTHER|Heredity for cardiovascular disease|First degree relatives with a diagnosis of Cardiovascular disease.
214871581|NCT06104943|OTHER|Heredity for pancreatitis|First degree relatives with a diagnosis of pancreatitis.
214871582|NCT06104943|OTHER|Heredity for type 2 diabetes|First degree relatives with a diagnosis of type 2 diabetes.
215037238|NCT04385290|DRUG|MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO|"GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg on days 1, 4, 7; 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
215037239|NCT04385290|DRUG|MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21, induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycles 1-2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
215057225|NCT01582009|OTHER|immunohistochemistry staining method|Correlative studies
215057226|NCT05415969|OTHER|CKD-aP|Identification of CKD-aP prevalence and severity among patients on dialysis.
215057227|NCT01558284|DRUG|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
215057228|NCT01558284|DRUG|Placebo|Placebo
214871583|NCT06104943|OTHER|Heredity for hypertriglyceridemia|First degree relatives with hypertriglyceridemia
214871584|NCT04558918|DRUG|LNP023|Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
214871585|NCT04558918|DRUG|Eculizumab|"Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
214871586|NCT04558918|DRUG|Ravulizumab|"Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
214871587|NCT04553016|BIOLOGICAL|Vaccine|IM vaccination with ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4
214871588|NCT04553016|BIOLOGICAL|Placebo|IM administration of 0.9% sterile sodium chloride solution
214871589|NCT05784532|DEVICE|STERN FIX|Sternotomy closure with STERN FIX and supplemented with wires
215037240|NCT04385290|DRUG|MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
215037241|NCT00158587|DRUG|primaquine|
215037242|NCT06645223|DRUG|No Interventions|no interventions
215037243|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
214871590|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
214871591|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
214871592|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
214871593|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
214871594|NCT01338870|DRUG|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
215037244|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
215037245|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
215037246|NCT04583618|BIOLOGICAL|Pneumococcal 13 - valent conjugate vaccine-Prevnar 13|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
215037247|NCT04583618|BIOLOGICAL|Pneumococcal Vaccine Polyvalent-Pneumovax 23|Pharmaceutical form:Solution for injection Route of administration: intramuscular
215037248|NCT05968989|BIOLOGICAL|VRC-FLUMOS0116-00-VP( FLUMos-v2)|"The vaccine, FLUMos-v2, is composed of engineered pentamer yeast C. albican lumazine synthase assembled with 20 HA ectodomain trimers from the following 6 influenza strains:~Influenza A:~H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020~Influenza B:~B/Victoria lineage: B/Colorado/06/2017; B/Yamagata lineage: B/Phuket/3073/2013"
215037249|NCT02711202|DRUG|MabCampath,|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
215037250|NCT02711202|DRUG|Remicade|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
214291140|NCT02007876|BEHAVIORAL|Mobility and Activity Training|"Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.~Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2."
214291141|NCT03712319|BEHAVIORAL|REM Volver a casa|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
214670057|NCT03911674|OTHER|Oral manual stimulation of feeding in preterm infants|Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
214871595|NCT01338870|DRUG|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
214871596|NCT01338870|DRUG|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
214871597|NCT01338870|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
214871598|NCT01338870|DRUG|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
214871599|NCT01338870|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
214871600|NCT01115478|DIETARY_SUPPLEMENT|Vitamin A|Daily oral dose of 2500 IU from enrollment until delivery
214871601|NCT01115478|DIETARY_SUPPLEMENT|Zinc|Daily oral dose of 25 mg from enrollment until delivery
214871602|NCT01115478|OTHER|Placebo|Daily oral dose from enrollment until delivery
214871603|NCT00709488|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
214871604|NCT00709488|PROCEDURE|Placement of device in prostate urethra|Placement of device in prostate urethra
214871605|NCT00709488|DEVICE|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
214871606|NCT03986411|OTHER|Phase 1: Qualitative interviews: Health care professionals|Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community
214871607|NCT03986411|OTHER|Phase 2: Physiotherapy for urinary incontinence|Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence
214871608|NCT03986411|OTHER|Phase 3: Qualitative Interviews: Participants|Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
214871609|NCT01869985|DRUG|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
214871610|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
214871611|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
214871612|NCT00258128|DRUG|Salsalate|Active
214871613|NCT00258128|DRUG|Placebo|Placebo for salslate, used only in the third trial
214871614|NCT04409483|DRUG|Lopinavir-Ritonavir Drug Combination|400mg/100mg taken orally twice daily for 14 days.
214871615|NCT04409483|COMBINATION_PRODUCT|Standard Care|Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
214871616|NCT06583473|BEHAVIORAL|Interactive digital health application|The study program will provide an integrated interactive digital health application (LINE app on smartphones, incorporating information about biodata recording, health education, questionnaires, and online Q\&A)
214871617|NCT01722201|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
214871618|NCT01722201|DRUG|Risperidone|1 mg tablet once a day
214871619|NCT03977714|DEVICE|Zirconia implants with G3-coated abutments (test implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
214871620|NCT03977714|DEVICE|Zirconia implants with control abutments (test implants, negative control abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
215037251|NCT02711202|DRUG|Sirolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
215037252|NCT02711202|DRUG|Tacrolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
215037253|NCT05812170|BEHAVIORAL|Educational online session about PF|The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
215037254|NCT00159016|DRUG|Glivec|
215037255|NCT03798210|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Study group split in two arms for experimental treatment with Lactobacillus reuteri or placebo.
215037256|NCT03798210|DIETARY_SUPPLEMENT|Placebo|Placebo
215037257|NCT05624996|DRUG|Carboplatin|Given IV
215037258|NCT05624996|DRUG|Cisplatin|Given IV
214665838|NCT02558946|BEHAVIORAL|Pelvic Floor Muscle Physical Therapy|The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.
215037259|NCT05624996|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
215037260|NCT05624996|BIOLOGICAL|Durvalumab|Given IV
215037261|NCT05624996|DRUG|Etoposide|Given IV
215037262|NCT05624996|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
215037263|NCT05624996|DRUG|Nab-paclitaxel|Given IV
215037264|NCT05624996|DRUG|Paclitaxel|Given IV
215037265|NCT05624996|DRUG|Pemetrexed|Given IV
215037266|NCT05624996|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215037267|NCT05624996|OTHER|Questionnaire Administration|Ancillary studies
215037268|NCT05624996|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214871621|NCT03977714|DEVICE|Titanium implants with G3-coated abutments (control implants, test abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
215037269|NCT06498479|DRUG|HS-20093|HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.
215037270|NCT06498479|DRUG|Topotecan|Topotecan will be administered per drug label.
215037271|NCT06305234|DRUG|Pegvaliase|Must be enrolled in the 165-501 PALace study. Subjects currently receiving or who plan to receive pegvaliase treatment within 30 days after the date of enrollment in the 165-501 study, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation
215037272|NCT04653012|DEVICE|Intracranial macro-microelectrode recording|Additionnally to clinical macroelectrodes, Benkhe-Fried depth macro-microelectrodes will be implanted and recorded during the pre-surgical investigation of epileptic patients
215037273|NCT05847621|BEHAVIORAL|Peer recovery coaching with linkage to recovery resources|Peer recovery coach (PRC) assessment of the participant's state of change, engage in motivational interviewing techniques, and link the participant to community-based recovery resources according to the needs of the participant. They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.
215037274|NCT05847621|BEHAVIORAL|Usual Care|Participants will be provided with a list of community recovery resources.
215037275|NCT05064358|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
215037276|NCT01965249|DEVICE|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HR48 mm
215037277|NCT01965249|DEVICE|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
215037278|NCT05834881|BEHAVIORAL|Contingency Management (CM) combined with vocational/educational coaching|Two evidence based practices, CM and vocational/educational coaching, will be combined and delivered by paraprofessional coaches in an intervention named PEERS (Peers Education Empowering Recovery Supports). CM uses positive reinforcement (e.g., chances to win prizes) for clients who abstain from substance use. A standardized and well-validated CM protocol will be used in the proposed study. Vocational/educational coaching assists individuals in completing educational and vocational goals. A workbook developed specifically for vocational/educational coaching in emerging adults will be used in the study.
215037279|NCT06969807|DRUG|Amimestrocel|In the first month (day 1, 14, 28): 1×10E6 cells per kilogram. From the 8th to the 24th week (week 8, 12, 16, 20, 24): 1.5×10E6 cells per kilogram.
215037280|NCT06967987|DRUG|Bemarituzumab + Flot regimen|"Bemarituzumab (IV administration) over 30 min (+/- 10min) at C1D1 to C8D1 + 15 mg/kg of bodyweight + single additional dose of 7,5 mg/kg at C1D8~\+ FLOT regimen~* Fluorouracil for solution for infusion (IV administration) as a continuous IV infusion approximately 24 hours 2600 mg/m²~* Leucovorin (folinic acid) solution for infusion (IV administration) over 120 min on the first day, 200 mg/m²~* Oxaliplatin concentrate for solution for infusion (IV administration) over 120 min on the first day, 85 mg/m²~* Docetaxel concentrated for solution for infusion (IV administration) over 60 min on the first day, 50 mg/m²"
215037281|NCT06971796|DEVICE|Inspire UAS System|Participants will be implanted with the Inspire UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
215037282|NCT04902807|BIOLOGICAL|Collection of samples|Blood, Urine and Stool samples will be collected from the participants.
215037283|NCT00611663|BIOLOGICAL|Prevenar® and Pneumo23®|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE)at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)versus2)
215037284|NCT00611663|BIOLOGICAL|Placebo, Pneumo23®|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
215037285|NCT04085172|DRUG|Guanfacine hydrochloride (TAK-503)|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 18 weeks in Part A or 52 weeks in Part B.
215037286|NCT04085172|DRUG|Atomoxetine hydrochloride|Participants will receive Atomoxetine hydrochloride oral capsule once daily for 18 weeks in Part A.
215037287|NCT04085172|OTHER|Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks in Part A.
215037288|NCT06157801|BEHAVIORAL|Interview Study|"All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure."
215037289|NCT06157801|BEHAVIORAL|Survey Study|"All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure."
215037290|NCT06161831|BEHAVIORAL|Text Message/automated phone reminder|Receipt of text message or automated phone reminders notifying when the next HPV vaccine dose is due (either first or second)
215037291|NCT06364540|DRUG|Ketamine|Nebulized ketamine administered at 0.75 mg/kg via BAN
214871622|NCT03977714|DEVICE|Titanium implants with control abutments (negative control implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
215037292|NCT06364540|DRUG|Fentanyl|Nebulized fentanyl administered at 3 mcg/kg via BAN
215037293|NCT05990543|DRUG|Nelmastobart and Capecitabine|"Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle.~Capecitabine is administered orally for two weeks followed by a one-week rest period"
215037294|NCT06136208|DRUG|s.c 25 mg estradiol pellet|Subcutaneous insertion of 25 mg estradiol pellet.
215037295|NCT06279377|OTHER|Stabilization Exercises|"* Stabilizer Pressure Biofeedback device will be used in deep neck flexors training. Once the starting level is determined, training will be carried out with 2 mmHg pressure increases until the target value is 30 mmHg.~* During the exercises performed with the elastic resistance band, the patient will be asked to move the band with his hands (neck extension, right-left lateral flexion).~* During the exercises with the elastic ball, you will be asked to press your head on the ball at 90 degree angles (in 4 positions).~* Exercises will be performed in 10 repetitions by maintaining muscle contraction for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the color of the elastic resistance band or the level of the exercise will be changed and continued."
215037296|NCT06279377|OTHER|Standard Exercises|"* Cervical flexion, extension, lateral flexion and rotation movements will be performed within the scope of the warm-up and cool-down program. Cervical movements will be limited to approximately 30 degrees in the early period.~* As posture exercises, you will be asked to do scapular retraction and turning your shoulders forward and backward. In addition to these movements, pectoral stretching, anterior and posterior capsule stretching exercises will be performed.~* Elastic resistance bands will be used during neck exercises. Patients will be asked to perform cervical flexion, extension and right-left lateral flexion movements against the fixed band.~* Patients will be asked to continue each exercise for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the elastic resistance band color will be changed and the exercise will progress."
215037297|NCT00340054|OTHER|questionnaire administration|
215037298|NCT00340054|PROCEDURE|study of high risk factors|
215037299|NCT06159543|BEHAVIORAL|Mango|1.5 cups/day of mango for 12 weeks
215037300|NCT06973720|DRUG|MET097|For subcutaneous administration.
215037301|NCT06973720|DRUG|Placebo|Sterile 0.9% (w/v) saline for subcutaneous administration.
215037302|NCT06110910|DRUG|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
215037303|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 1|Two doses of the non-adjuvanted HSV formulation 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
215037304|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 2|Two doses of the non-adjuvanted HSV formulation 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
215037305|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 3|Two doses of the non-adjuvanted HSV formulation 3 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
215037306|NCT05298254|BIOLOGICAL|HSV formulation 1 with adjuvant 1|Two doses of the HSV formulation 1 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
214871623|NCT03977714|DEVICE|Zirconia implants and titanium implants, for histological and histomorphometric evaluation.|"6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary."
215037307|NCT05298254|BIOLOGICAL|HSV formulation 2 with adjuvant 1|Two doses of the HSV formulation 2 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
215037308|NCT05298254|BIOLOGICAL|HSV formulation 3 with adjuvant 1|Two doses of the HSV formulation 3 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
215037309|NCT05298254|BIOLOGICAL|HSV formulation 1 with adjuvant 2|Two doses of the HSV formulation 1 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
215037310|NCT05298254|BIOLOGICAL|HSV formulation 2 with adjuvant 2|Two doses of the HSV formulation 2 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
215037311|NCT05298254|BIOLOGICAL|HSV formulation 3 with adjuvant 2|Two doses of the HSV formulation 3 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
215037312|NCT05298254|DRUG|Placebo|Two doses of Placebo administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I and Part II of the study.
214871624|NCT04982302|PROCEDURE|Non-surgical periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets
214871625|NCT02940808|DIETARY_SUPPLEMENT|Caffeine (200mg)|Oral consumption of capsule containing 200mg caffeine.
214871626|NCT02940808|OTHER|Placebo|Oral consumption of capsule containing a placebo substance.
214871627|NCT02348255|PROCEDURE|Electric Field Therapy|Undergo NovoTTF-100A
214871628|NCT02348255|BIOLOGICAL|Bevacizumab|Given IV
214871629|NCT02348255|DRUG|Carmustine|Given IV
214871630|NCT02348255|OTHER|Quality-of-Life Assessment|Ancillary studies
214871631|NCT03147625|BEHAVIORAL|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
214871632|NCT04621019|DEVICE|BTL-785F|Treatment with study device.
214871633|NCT05076019|DRUG|Atorvastatin 80mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
215037313|NCT05298254|BIOLOGICAL|HSVTI_F1|Two doses of the formulation of the HSVTI\_F1 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.
215037314|NCT05298254|BIOLOGICAL|HSVTI_F2|Two doses of the formulation of the HSVTI\_F2 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.
215037315|NCT01561469|DRUG|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
215037316|NCT01561469|DRUG|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
215037317|NCT05002959|DEVICE|Anatomic TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.
215037318|NCT05002959|DEVICE|Reverse TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.
215037319|NCT02274675|DEVICE|Robot-assisted therapy for wrist and forearm|Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.
215037320|NCT02274675|OTHER|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
215037321|NCT02796911|DRUG|Xenograft|group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
215037322|NCT02796911|DRUG|Bioactive glass|group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
215057229|NCT03805061|OTHER|'aerobic exercise'|The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed a period of; 8 weeks, 3 days a week, 30-45 minutes each patient.
215057230|NCT03805061|DEVICE|'isokinetic exercise'|Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low exercise and exercise was applied for 5-10 minutes to cool down at the end of the study. were included in a rehabilitation program that they would apply for 3 days per week for 8 weeks.The measuring of isokinetic muscle strength, CSMI Humac Norm isokinetic dynamometer's commonly used angular velocities of 60 ° and 180 ° / sec was used.
215057231|NCT00358033|BEHAVIORAL|Counseling|
214670058|NCT02175563|DEVICE|Audiovisual feedback from smartphone based app|
214670059|NCT04844671|DEVICE|da Vinci Surgical Systems|The da Vinci Surgical Systems enable surgeons to perform delicate and complex operations through a few small incisions with robotic assisted surgery.
214871634|NCT05076019|DRUG|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
214871635|NCT03844256|COMBINATION_PRODUCT|nivolumab 480mg|Immuno-chemoradiotherapy
214871636|NCT03844256|COMBINATION_PRODUCT|nivolumab 3mg/kg, ipilimumab 1mg/kg|Immuno-chemoradiotherapy
214871637|NCT03844256|COMBINATION_PRODUCT|nivolumab 1mg/kg, ipilimumab 3mg/kg|Immuno-chemoradiotherapy
214871638|NCT05578183|DEVICE|theta burst stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
214871639|NCT05578183|DEVICE|sham stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
214871640|NCT02304497|OTHER|Platelet Rich Fibrin|Procedure: Platelet Rich Fibrin obtained
214871641|NCT05939583|OTHER|Shock Wave Therapy|Receiving Shock wave therapy + US, TENS, IR and exercises.
214871642|NCT05939583|OTHER|US, TENS, IR and exercises.|Receiving US, TENS, IR and exercises only.
214871643|NCT04731792|OTHER|Virtual Reality|a bronchial fibroscopy with a virtual reality helmet
214871644|NCT01272492|OTHER|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
214871645|NCT05986227|DRUG|toripalimab FOLFOX|Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
214871646|NCT02871492|DRUG|Pritelivir 5% w/w ointment|
214871647|NCT02871492|DRUG|Pritelivir ointment matching placebo|
214871648|NCT02871492|DRUG|Zovirax® cream|
214871649|NCT04546724|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
214871650|NCT04546724|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
215037323|NCT05825716|OTHER|Ifaa Basic|"* PSNP Systems: (1) Provision of food aid commodities (wheat, oil, and pulse) per the PSNP transfer schedule for 3-6 months; 2) Food System Taskforce (FSTF) capacity building, and 3) private sector engagement~* Health and Nutrition: 1) Government of Ethiopia (GoE) basic health extension program; 2) GoE supportive supervision coaching; 3) GoE-led community social behavior change (SBC) sessions; and 4) Community Management of Acute Malnutrition (CMAM) Programming.~* Water and Sanitation: 1) Water infrastructure development; 2) improved governance via water, sanitation and hygiene (WASH) committees; and 3) water source monitoring.~* Natural Resource Management: 1) Public works projects; 2) community training in planning and sustaining community assets; 3) Implementation of the environment and social management framework; 4) enhance participation of watershed committees"
215037324|NCT05825716|BEHAVIORAL|Ifaa Enhanced|"* PSNP Systems: 1) establishment and training of Community Technical Coordinating Forum; 2) Case management capacity building; and 3) private sector construction of infrastructure~* Health and Nutrition:1) the Care Group Model approach; 2) home garden promotion; 3) the nutrition budget calculator; and 4) labor and time-saving technologies.~* Community-level interventions are 1) adolescent nutrition school clubs; 2) religious leader mobilization and training vulnerable groups; 3) audio toolkit against harmful traditional practice; 4) enhanced SBC tools for health/nutrition promotion; 5) additional health extension programs~* Water and Sanitation: 1) Community Led Total Sanitation and Hygiene; 2) WASH systems assessments and strengthening; 3) Ensuring water quality and safety via routine monitoring; 4) Private sector engagement of WASH-related businesses;"
215037325|NCT05825716|OTHER|Ifaa Enhanced + Livelihoods|"* Additional resources provided to the groups, including 1) Engagement of Private Service Providers to enable access to sustainable credit and larger loans; 2) Financial Education using an expanded 'Smart Skills' curriculum focusing on savings, smart borrowing and effective financial management; and 3) Life Skills Training for Youth.~* Additional supports include: 1) Seven Steps of Marketing Training; 2) Climate Smart Agriculture to reduce water needs and increase soil health and vegetation coverage; 3) Producers Groups and linkages to markets/suppliers/buyers; Selected financial institutions will be provided with a credit guarantee fund and capacity-building support to help facilitate loans. Private sector value chain assessment and financing. Additional private sector engagement and linkage facilitation."
214871651|NCT02256436|BIOLOGICAL|pembrolizumab|IV infusion
214871652|NCT02256436|DRUG|paclitaxel|IV infusion
214871653|NCT02256436|DRUG|vinflunine|IV infusion
214871654|NCT02256436|DRUG|docetaxel|IV infusion
214871655|NCT05585021|DIETARY_SUPPLEMENT|Wonderlab Kids instant probiotics|"During study intervention, subjects are required to take the randomly assigned product based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period."
215037326|NCT02065986|DRUG|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
215037327|NCT06535373|OTHER|Blood flow restriction|Both groups will undergo a 6-week training intervention with training 2x a week, after which grip strength and other relevant outcomes will be measured and compared. Exercise sessions will be at least 48 hours apart. Participants will be allowed to continue with their normal exercise routine outside of the study.
215037328|NCT06576648|BEHAVIORAL|Mobile Healthy Choices (mHC)|mHC is a four-session, 20-minute, motivational interviewing-based intervention, which will be delivered on the CIAS platform. It will be tailored to participants' responses given during the interaction in the intervention. In the first two sessions, the (virtual) counselor will motivate participants to overcome stigma and utilize HIV prevention services by using tailored motivational interviewing strategies, develop an individualized change goal based on their readiness, and provide cognitive behavioral strategies. In the last two sessions, the counselor will review the change plan, monitor progress, and provide support for sustained behavioral change. The sessions will occur within three months after baseline.
215037329|NCT06576648|BEHAVIORAL|Finding Respect and Ending Stigma around HIV (FRESH)|FRESH content includes six 10-15 minute sessions with interactive, culturally sensitive multimedia modules, which will be delivered on the CIAS platform. The content will aim to improve self-efficacy, reduce intersectional stigmas and promote HIV preventative behaviors. The sessions will occur within three months after baseline.
215037330|NCT06576648|BEHAVIORAL|Standard PrEP Counseling|All participants will receive one-on-one, face to face counseling from focusing on sexual and behavioral risk assessment for HIV/STIs, risk reduction, and HIV prevention. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP, and facilitators and barriers to PrEP access. For those on PrEP, the sessions will focus on adherence. The counseling will be provided at baseline, 3 months, and 6 months.
215037331|NCT05871437|DRUG|Huaier granule|On the basis of routine clinical treatment/follow-up, take Huaier Granules orally, 10g each time, three times a day, for one year continuously or until disease progression, intolerable toxicity, withdrawal from the study for any reason or death occurs, whichever occurs first.
215037332|NCT05991427|BIOLOGICAL|Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
215037333|NCT05991427|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted (Shingrix)|2 doses of Shingrix vaccine on Day 0 and Month 4
215037334|NCT05991427|BIOLOGICAL|ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
215037335|NCT05991427|BIOLOGICAL|Shingrix|2 doses of Shingrix vaccine on Day 0 and Month 4
215037336|NCT05991427|BIOLOGICAL|IH ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
215037337|NCT05991427|BIOLOGICAL|IH saline|2 doses of saline on Day 0 and Month 4
214871656|NCT05585021|DIETARY_SUPPLEMENT|Instant probiotic placebo|"Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.~1 bottle a day. Lasting for 24 weeks intervention period."
214871657|NCT01831102|OTHER|none- observational study|
214871658|NCT03101865|DEVICE|FlorenceM|The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
214871659|NCT02004015|DRUG|injection of placebo|0.5 mg/kg milligram(s)/kilogram
214871660|NCT02004015|DRUG|injection of NMBA|
214871661|NCT04113785|DEVICE|Klassic Knee System|At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
214871662|NCT01314937|DRUG|Mebendazole|Single-dose 500 mg mebendazole tablet
214871663|NCT01314937|OTHER|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
214871664|NCT05893069|DRUG|Oxandrolone|oral oxandrolone for 12 weeks
215037338|NCT05624528|DRUG|Tolcapone|catechol-O-methyl transferase inhibitor
215037339|NCT05624528|DRUG|Placebo|Pill that contains no medicine
214871665|NCT05893069|DRUG|Placebo|oral placebo for 12 weeks
214871666|NCT04998357|OTHER|Endovascular autologous mitochondrial transplantation|During standard-of-care endovascular reperfusion procedure, subjects will have autologous mitochondria infused via microcatheter into ischemic brain.
214871667|NCT06349577|OTHER|Non-pulsatile blood flow|Non-pulsatile blood flow generated by constant centrifugal pump flow rate during cardiopulmonary bypass
214871668|NCT06349577|OTHER|Pulsatile blood flow|Pulsatile blood flow generated by variable centrifugal pump flow rate during cardiopulmonary bypass
214871669|NCT04987489|DRUG|Etavopivat tablets|Etavopivat 400 mg once daily
215037340|NCT06643871|OTHER|Adapted physical activity program involving connected bikes|The treatment being studied involves a program (DYNAMO-PSY) of adapted physical activity with an enriched environment (connected bike, visualized and experienced routes in virtual reality) and is supervised, comprising (on average) two sessions per week, a total of 20 sessions to be completed over a maximum of 15 weeks. Each session will last 60 minutes and will be supervised by a case manager. They will be composed of a warm up, session on the bike (around 30 minutes of bicycling) and stretching. They will take place in an adequate room in the clinical research department of Saint Anne Hospital. The usual hygienic-dietetic care is not modified by the study and consists of the care proposed to patients of the GHU Paris Psychiatry and Neuroscience who have had a first psychotic episode and are treated primarily with medication: clinical and biological monitoring, dietary consultations, therapeutic education group concerning diet and lifestyle.
215037341|NCT06367855|DRUG|Dexamethasone|long-acting corticosteroid IV route
215037342|NCT06367855|DRUG|Normal saline|normal saline
215037343|NCT04918407|DRUG|Empagliflozin 25 MG|25 mg
215037344|NCT04918407|DRUG|Insulin|Insulin
215037345|NCT03189719|BIOLOGICAL|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
215037346|NCT03189719|DRUG|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
214665839|NCT02558946|BEHAVIORAL|Control Group|At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
214665840|NCT05188235|DEVICE|Acoustical Resonance Device|"Infants will be studied for 15 min using an electronic tuning fork to transmit sound through the hip from a point on the skin while transmitted sounds FDA-approved stethoscope"
214871670|NCT01441947|DRUG|Cabozantinib|Given orally daily with a starting dose of 40 mg
214871671|NCT01441947|DRUG|Fulvestrant|Given intramuscularly 500 mg on Days 1 and 15 of the first 28 day cycle, then on Day 1 only each cycle after
214871672|NCT05865418|OTHER|Loaded high intensity training|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions. From the week 3rd of the intervention, the participants will perform the exercises with an adjustable weight vest with 5% of their body weight. In the middle intervention (post week 6 of the intervention which will be week 9 of the study), adolescents will be reevaluated for all the measures tested at the baseline. Weight vest will increase to 10% of their body weight for the last 4 weeks of the intervention.
214871673|NCT05865418|OTHER|High intensity circuit training (HICT)|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions.
214871674|NCT04977986|DRUG|ZYN002 - transdermal gel|Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
215037347|NCT03189719|DRUG|Cisplatin|80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
215037348|NCT03189719|DRUG|5-FU|800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
215037349|NCT05310435|DEVICE|Single volume measurement with ESD|Single volume measurement with Edema Stocking device
215037350|NCT05310435|DEVICE|Single volume measurement with WDV|Single volume measurement with water displacement volumetry method
215037351|NCT05310435|DEVICE|Single circumference measurement with tape measure|Single circumference measurement with tape measure
215037352|NCT05310435|DEVICE|Continuous volume measurement with ESD|Continuous volume measurement with Edema Stocking device
215037353|NCT05023018|DRUG|NEO100|NEO100 is a purified form of perillyl alcohol.
215037354|NCT06488846|OTHER|INVITE-Home|Curriculum to train Treatment Buddies, selected by the people with HIV, to administer LAI-ART at home with supervision of a Study Nurse.
215037355|NCT06488846|OTHER|Clinic-Administered LAI-ART|People with HIV who continue to receive LAI-ART in clinic
215037356|NCT06488846|OTHER|Oral ART|Oral ART
215057232|NCT00358033|BEHAVIORAL|Interactive Education|
215057233|NCT00358033|BEHAVIORAL|Group Support|
214871675|NCT04977986|DRUG|Placebo|"Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)~Other Names:~Placebo Comparator Matching Placebo"
214871676|NCT02174432|DRUG|nalbuphine HCl ER|nalbuphine HCl ER BID for up to 50 weeks
214871677|NCT06968208|DRUG|Puerarin|75 mg of puerarin injection, dissolved in 0.9% sodium chloride solution. The puerarin injection is manufactured under Good Manufacturing Practice (GMP) conditions by \[Harbin Medisan Pharmaceutical Co., Ltd.\], with identical appearance, size, and packaging to the blank 0.9% sodium chloride solution to ensure blinding. Stability testing confirms integrity under standard storage conditions (25°C, 60% RH).
214871678|NCT06968208|DRUG|Placebo|0.9% sodium chloride solution formulated to match the appearance, size, and taste of the active puerarin solution, with no other active pharmaceutical ingredients. 0.9% sodium chloride solution is manufactured under identical Good Manufacturing Practiceconditions by \[Shijiazhuang No.4 Pharmaceutical Co., Ltd.\] and changed to the same batch processes and packaging as the intervention group. Stability testing confirms equivalent integrity under standard storage conditions (25°C, 60% RH). Blinding is ensured through indistinguishable outer packing characteristics and labeling.
214871679|NCT06578442|OTHER|Magnetic Field Treatment|Magnetic Field Treatment was applied to the participants for 30 minutes a day, twice a week for 8 weeks, using an electromagnetic field therapy device, in a supine position, by placing circular magnetotherapy electrodes in the abdominal area, at 25 Hz and 30 Gauss power.
214871680|NCT06578442|OTHER|Constipation Coping Training|"The control group was given constipation coping training and asked to perform the taught methods every day for 8 weeks. Whether the individuals applied the methods was checked every day via telerehabilitation."
214871681|NCT03066739|DRUG|Remifentanil|0.1 micrograms/kg/mL
214871682|NCT03066739|DRUG|Remifentanil+ Placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
214871683|NCT03066739|DRUG|Remifentanil +ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
214871684|NCT05775211|BIOLOGICAL|Intrauterine administration of PBMC immunomodulated with IFNt|Standard density gradient centrifugation will be performed to obtain autologous PBMC from patients' peripheral blood (9 ml). Isolated cells will be suspended in RPMI 1640 supplemented with 10% HSA (human serum albumin) and incubated in the presence of 500 IU/ml IFNt for 24 h at 37˚C. The cultured cell suspension will be introduced into the uterine cavity via a catheter.
214871685|NCT06853197|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health
215037357|NCT03448393|BIOLOGICAL|CD19/CD22 CAR T-Cells|Cluster of differentiation 19 (CD19)/cluster of differentiation 22 (CD22) chimeric antigen receptor (CAR) T-cells will be infused on Day 0 after lymphodepleting chemotherapy regimen.
215037358|NCT03448393|DRUG|Fludarabine|Fludarabine is administered as an intravenous (IV) infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on body surface area (BSA) (25-30 mg/m\^2/dose) on Days -4, -3, -2 or Days -5, -4, -3, -2.
215037359|NCT03448393|DRUG|Cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the body surface area (BSA), at 900 mg/m\^2/dose after fludarabine infusion on Day -2 or 600 mg/m\^2/dose on Days -3 \& -2.
215037360|NCT03448393|PROCEDURE|Apheresis|According to institutional standards.
215037361|NCT03448393|OTHER|Anti-emetic|Prophylaxis and treatment.
215037362|NCT03448393|DRUG|Diphenhydramine|Pre-medication: 0.5-1 mg/kg/dose (maximum 50 mg/dose) by mouth or intravenous over 10-15 minutes.
214871686|NCT05728047|PROCEDURE|Evaluation of sublingual microcirculation with side-stream dark field imaging (cytocam)|The 'Cytocam' is a hand held computer-controlled device, a third generation video-microscope, which enables real time visualisation of the in vivo microcirculation, based upon the principle of incident dark field (IDF) illumination.
214665841|NCT04909463|DEVICE|Chest Splint|Those receiving intervention will be given the Duracore chest splint for use throughout the trial.
214871687|NCT04636164|DIAGNOSTIC_TEST|Model Dermatology (deep neural networks; Build 2020)|Physicians in the DNN group take pictures of the skin lesion and use the algorithm by uploading pictures.
214871688|NCT01018589|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application."
214871689|NCT00077857|DRUG|capecitabine (Xeloda®)|825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
214871690|NCT00077857|DRUG|docetaxel (Taxotere®)|75 mg/m\^2 intravenous on day 1 of each 3 week cycle
214871691|NCT00235404|OTHER|Multicomponent treatment|Specialized care in preparing recharge to home
214871692|NCT00235404|OTHER|usual care|Usual recharge directly from hospital to home
214871693|NCT03243058|BIOLOGICAL|ILT-101 (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin-2 (ILT-101) for two years
215037363|NCT03448393|DRUG|Acetaminophen|Pre-medication: 15 mg/kg/dose (maximum 650 mg/dose by mouth).
215037364|NCT03448393|DIAGNOSTIC_TEST|ECG|Pre-cell infusion.
215037365|NCT03448393|DIAGNOSTIC_TEST|ECHO|Pre-cell infusion.
215037366|NCT03448393|DIAGNOSTIC_TEST|MRI Brain|Pre-cell infusion.
215037367|NCT03448393|PROCEDURE|Bone marrow biopsy|Pre-cell infusion.
215037368|NCT03448393|DIAGNOSTIC_TEST|Cardiac MRI|Screening
215037369|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days, (except Cycle 1 for high-dose cohorts = 35 days).
215037370|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 21 days and 28 days.
215037371|NCT04623541|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|R-CHOP will be administered intravenously (prednisone may be administered orally) in cycles of 21 days.
215037372|NCT04623541|DRUG|Venetoclax|Venetoclax tablets will be administered orally once daily during the 5-week ramp up period in cycles of 28 or 35 days each.
215037373|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
215037374|NCT04623541|DRUG|Lenalidomide|Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days.
215037375|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
214871694|NCT03243058|OTHER|Treatment-Placebo Arm|Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.
215037376|NCT04623541|DRUG|Pirtobrutinib|Pirtobrutinib tablets will be administered in cycles of 28 days.
215037377|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
215037380|NCT03816891|DRUG|Vixarelimab|solution for injection
215037381|NCT03816891|DRUG|Placebo|solution for injection
215037382|NCT05262426|BEHAVIORAL|Behavioral: Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
215037383|NCT05262426|BEHAVIORAL|Enhanced YaCool|Enhanced YaCool is mobile application developed to support transgender women self-management of their gender and sexual health, including PrEP use. YaCool is a passcode-protected app that allows users to personalized text messaged reminders to take PrEP and/or clinic appointments, record PrEP adherence and sexual activity, and track lab tests. The application is set up to provide personalized recommendations for PrEP regimen, confirmed by clinic healthcare staff. Participants will be asked to download Enhanced YaCool to support PrEP use and gender/sexual health self-management between MES-PrEP sessions for 30 days, and thereafter until the end of Month 12 (if desired).
215037384|NCT05262426|BEHAVIORAL|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3, 6, 9 and 12. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
215037385|NCT05860673|PROCEDURE|mini invasive scoliosis surgery|"The minimally invasive technique, involves two small median skin incisions that allow the deep structures to be exposed. The muscle fibers are separated from the bony insertion by the process of subperiosteal skeletonization. The Investigators then proceed with the arthrectomy of the levels to be instrumented and the infiltration of pedicle screw pairs of the appropriate caliber according to the free-hand technique. After amplioscopic control of proper screw placement, osteotomies of the posterior elements are performed to facilitate correction of the metameres."
215037386|NCT05860673|PROCEDURE|posterior spinal fusion technique|"The standard open technique involves a longitudinal incision along the midline extended along the entire thoracolumbar spine, the paravertebral muscles are incised and spread apart to expose the posterior vertebral structures, in a stretch extending more than 30 cm. The series of facetectomies are performed first, and then pairs of pedicle screws are infixed freehand.~After performing the osteotomies necessary to mobilize the vertebral metameres at the apex of the deformity, correction by derotation maneuvers is continued, and the obtained correction is fixed with pre-shaped bars that are then connected to the screws and tightened to the nuts by dynamometric technique. Almost all vertebral levels of the thoracolumbar tract are included in the arthrodesis"
215037387|NCT04695080|DRUG|Cladribine (MAVENCLAD®)|"Cladribine (MAVENCLAD®) 3.5mg/kg, administered as weight-adjusted 10mg tablets in two treatment courses (12 months apart) lasting 8- 10 days each.~Cladribine (MAVENCLAD®) 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
215037388|NCT04695080|DRUG|Placebo|"Placebo administered as weight adjusted tablets in two treatment courses (12 months apart) lasting 8-10 days each.~Placebo 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
215037389|NCT05815134|BIOLOGICAL|blood sample|10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
215037390|NCT02077621|DRUG|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
214871695|NCT03243058|OTHER|Placebo Arm|Participants in this group will receive a placebo injection for two years.
214871696|NCT01152619|DRUG|Placebo|Subcutaneous repeated dose
215037391|NCT02077621|DRUG|Placebo|500 mL normal saline
215037392|NCT05713565|DEVICE|A digital care solution for patients with Coronary Artery Disease|A digital care solution that provides remote patient monitoring and a patient support program specifically developed for CAD patients. The digital care solution empowers self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
215057234|NCT00358033|PROCEDURE|Pharmacologic case management|Provided by clinical pharmacists
215057235|NCT02248766|DEVICE|somofilcon A|somofilcon A lens
214871697|NCT01152619|DRUG|RO4989991|Subcutaneous repeated dose
214871698|NCT00662623|BEHAVIORAL|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
214871699|NCT00662623|BEHAVIORAL|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
214871700|NCT00351884|DRUG|Vildagliptin AM|
214871701|NCT00351884|DRUG|vildagliptin pm|
214871702|NCT00351884|DRUG|placebo|
214871703|NCT05655221|DRUG|B1344|multi-site abdominal s.c. injections (maximum 2 mL at each site)
214871704|NCT05655221|OTHER|Placebo|multi-site abdominal s.c. injections (maximum 2 mL at each site)
214871705|NCT04686552|DIETARY_SUPPLEMENT|cinnamon|6 g of ground cinnamon
214871706|NCT05229003|DRUG|Anlotinib|Anlotinib 8mg or 10mg, d1-9，q2w
215037393|NCT05713565|OTHER|Standard of care for patients with Coronary Artery Disease|Follow-up and continuous care as usual in outpatient care (i.e., Standard of Care). The participants in the Standard of Care - control group will also receive an information leaflet about relevant lifestyle modifications for CAD.
215037394|NCT00780299|DEVICE|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
215037395|NCT00780299|PROCEDURE|CVVH|hemofiltration intermittent dialysis
215037396|NCT03330847|DRUG|Olaparib Continuous (28-Day cycle) 300 mg BD.|Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
215037397|NCT03330847|DRUG|Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).|Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
215037398|NCT03330847|DRUG|Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).|Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
215037399|NCT06232044|DRUG|Iberdomide|Receive PO
215037400|NCT06232044|BIOLOGICAL|Belantamab Mafodotin|Receive IV
215037401|NCT06232044|DRUG|Dexamethasone|Receive PO
215037402|NCT06232044|PROCEDURE|Echocardiography|Undergo ECHO
215037403|NCT06232044|PROCEDURE|Computed Tomography|Undergo CT
214871707|NCT05229003|DRUG|Penpulimab|Penpulimab 200mg, d6, q2w
214871708|NCT05229003|DRUG|Irinotecan|Irinotecan 180mg/m2, d6, q2w
214871709|NCT01292226|DRUG|mycophenolate mofetil|1 g PO BID for 24 weeks
214871710|NCT01292226|DRUG|antibody induction|According to manufacturer recommendation
214871711|NCT01292226|DRUG|Cyclosporine|According to manufacturer recommendation
214871712|NCT01292226|DRUG|corticosteroid|According to manufacturer recommendation
214871713|NCT05468424|OTHER|tablet (iPad or android) based role-playing game|The intervention is a tablet (iPad or android) based role-playing game called FarmVille. In FarmVille the player assumes the role of a farmer tasked with tending to crops and farm animals and using what is produced to craft goods which can be sold to expand the farm. The participant is required to play FarmVille for 5 or more hours a week for 8 weeks.
215037404|NCT06232044|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215037405|NCT06232044|PROCEDURE|Positron Emission Tomography|Undergo PET
215037406|NCT06232044|PROCEDURE|Bone Marrow Biopsy|Undergo Bone Marrow Biopsy
215037407|NCT06232044|PROCEDURE|Bone Marrow Aspiration|Undergo Bone Marrow Aspirate
215037408|NCT06232044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215037409|NCT06646679|OTHER|Ultrasonic imaging|Ultrasonic imaging
215037410|NCT01589640|OTHER|Blink Tears lubricating Eye Drops|2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
215037411|NCT01589640|OTHER|Blink Gel Tears Lubricating Eye Drops|2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
215037412|NCT01589640|OTHER|Systane Balance Lubricant Eye Drop|2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
215037413|NCT01355627|PROCEDURE|TachoSil®|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
215037414|NCT01355627|PROCEDURE|Current Practice|"Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.~In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®."
215037415|NCT03532256|BEHAVIORAL|Observation|Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.
215037416|NCT03532256|BEHAVIORAL|Text to online survey|Subset of surgical patients will receive an automated text message with a link to a secure online survey with questions that assess pain, functional status, and opioid consumption.
215037417|NCT03532256|BEHAVIORAL|Bi-directional text script|Subset of surgical patients will receive an automated bi-directional text message script with questions that assess pain, functional status, and opioid consumption.
215057236|NCT03047811|OTHER|TCR - T cell therapy|Low dose group: 1 x 10 \^8 /kg T cell total reinfusion. High dose groups: 10 x 10 \^ 8 / kgT cell total reinfusion.
214871714|NCT05468424|OTHER|tablet (iPad or android) based word puzzles and image puzzles|"This intervention is a selection of tablet (iPad or android) word puzzles and image puzzles. One word puzzle involves word making (i.e., making words from a set of random letters), and the other word searching (i.e., finding words on a grid of letters). One image puzzle is Flow Free, a game that requires the player to connect pairs of same coloured dots positioned on a grid ranging from 5x5 to 9x9. The other image puzzle is a jigsaw. The participant is required to play these games for 5 or more hours a week for 8 weeks."
214871715|NCT06970262|OTHER|Fecal suspension (provided by SShanghai Chengge Pharmaceutical Technology Co., Ltd.)|Prepare 300 ml of intestinal flora suspension from 100-150 g of feces. Administer vancomycin 500 mg via nasogastric tube every 12 hours for 48-72 hours before FMT. Clean the intestines with 2000 ml of polyethylene glycol 24 hours before FMT (except for patients with diarrhea). Subjects can eat and drink freely during preparation but must fast for at least 2 hours before FMT (water allowed). No food or water is permitted within 2 hours after FMT. Stop all antibiotics (intravenous, oral, nebulized) at least 24 hours before FMT.
214871716|NCT06823804|DRUG|10ml of 10% saline is injected centrally|"The first phase of the study is an observational study that does not alter the clinical treatment plan.~The experimental group（Sample size of 48 cases） in the second phase of the study needs to receive a central venous injection of 10ml of 10% saline to demonstrate pulmonary blood flow, while the control group （Sample size of 48 cases）requires no intervention.~The experimental group select the optimal pulmonary blood flow PEEP By Electrical impedance tomography.Change in ventilation-perfusion ratio measured by EIT during PEEP trials from baseline to 30 minutes at each PEEP level (5, 10, 15 cmH2O).~The control group was selected Best PEEP according to the PEEP table ."
214871717|NCT06283862|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
214871718|NCT06682546|DRUG|ET-26HCl 0.6mg/kg group|The initial dose is 0.6 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.
214871719|NCT06682546|DRUG|ET-26HCl 0.8mg/kg group|The initial dose is 0.8 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.
214871720|NCT06682546|DRUG|Etomidate Injectable Product 0.3mg/kg group|The initial dose is 0.3 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion).Infusion time was 1minute ± 5second.
214871721|NCT01844505|BIOLOGICAL|Nivolumab|
214871722|NCT01844505|BIOLOGICAL|Ipilimumab|
214871723|NCT01844505|BIOLOGICAL|Placebo for Nivolumab|
214871724|NCT01844505|BIOLOGICAL|Placebo for Ipilimumab|
214871725|NCT06666309|BEHAVIORAL|SBCM-PrEP + Text Messaging|Two sessions Strengths-Based Case Management intervention adapted for HIV PrEP related educational content delivered to individual clients in the syringe service program setting
214871726|NCT06666309|BEHAVIORAL|CDC-PrEP + Text Messaging|1 session PrEP education based on CDC guidelines delivered to individual clients in syringe service program settings
214871727|NCT06666309|BEHAVIORAL|T-SBCM|Up to two post-linkage sessions of SBCM delivered by a peer support specialist in a format of the participants' choice (onsite, virtual/phone) in study month 2
214871728|NCT06666309|BEHAVIORAL|Mobile Outreach|Up to two in-person field session visits will be conducted by a peer support specialist for the purpose of offering direct support to arrange joint activities for overcoming identified barriers (e.g., transportation) to PrEP care initiation in study month 2.
214871729|NCT05838430|DRUG|Solriamfetol 75 MG|Solriamfetol (trade name Sunosi), is a norepinephrine-dopamine reuptake inhibitor available in 75mg and 150mg tablets for oral administration during the day. Solriamfetol's primary indication is to treat excessive daytime sleepiness (EDS) in patients diagnosed with obstructive sleep apnea or Narcolepsy. It binds to the dopamine and the norepinephrine transporters with affinities (Ki) of 14.2 μM and 3.7 μM, respectively),does not undergo significant metabolism in humans, and has a Tmax of \~2 hours (range 1.25-3.0 hours) and a T1/2 of \~7.1 hours.
214871730|NCT05838430|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Treatment will be conducted via a HIPAA compliant video link (Zoom). Sessions 1-8 will follow our published protocol (published in 2005 by Springer).~Each session will be conducted individually and have a singular focus per session.~All sessions following the delivery of sleep restriction therapy \& stimulus control instructions (post Session 2) will include, as needed, management of non-adherence and/or time-in-bed titration."
215037418|NCT05654207|BEHAVIORAL|WeCare|WeCare combines two evidence-based strategies -- universal screening using the Computerized Adaptive Screen for Suicidal Youth and an adapted version of the SAFETY-ACUTE, which incorporates PI Lindsey's extensive work with Black youth, their families, and community stakeholders to develop culturally tailored strategies for addressing treatment barriers.
215037419|NCT02293551|DRUG|Lispro|Administered SC
215037420|NCT05967299|OTHER|Placebo Cohort 1 (1.5 mg/kg/dose) only|30mg/ml Sucrose
215037421|NCT05967299|DRUG|ZMA001 (BC-NKA-20008)|ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).
215037422|NCT02992210|GENETIC|4SCAR-GD2|GD2-specific 4th Generation CART
215037423|NCT02439463|PROCEDURE|Below-knee amputation|Patients with traumatic below-knee amputation.
215037424|NCT03742726|DEVICE|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
215037425|NCT02834741|DRUG|NYX-2925|NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
215037426|NCT01505985|DIETARY_SUPPLEMENT|Oral nutritional Supplement|Specialized nutritional supplement for seniors
215037427|NCT01505985|DIETARY_SUPPLEMENT|Placebo|placebo product with no specific nutrients
214665842|NCT02047955|DEVICE|Shoulder Arthroplasty|"Data will be collected for commercially available Sponsor devices. These systems treat both the humeral and glenoid side of the shoulder joint. The following products will be included in the study in the geographies where they are commercially available.~* Aequalis Ascend Flex Convertible Shoulder System~* Pyrocarbon Humeral Head (used with Aequalis Ascend Flex)~* Simpliciti Shoulder Prosthesis~* Aequalis Reversed Fracture Prosthesis~* Aequalis PerFORM Glenoid~* Aequalis PerFORM+ Glenoid~* Aequalis PerFORM Reversed Glenoid~Devices previously included, but discontinued under clinical investigation plan (CIP) version 4.0:~* Aequalis Resurfacing Head~* Aequalis Ascend Anatomic Shoulder System~* Aequalis IM Humeral Nail - Short and Long~* ORTHOLOC™ SPS (Shoulder Plating System)~* Aequalis Reversed II Shoulder System~* Aequalis Adjustable Reversed Prosthesis~* Aequalis Flex Revive Shoulder System"
214665843|NCT04294368|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid|The control group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF.
215037428|NCT01613651|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
215037429|NCT01613651|OTHER|questionnaire administration|Ancillary studies
215037430|NCT01613651|OTHER|intraoperative complication management/prevention|Undergo placement of pelvic drain
215037431|NCT00032812|DRUG|Raclopride|
215037432|NCT01931410|DRUG|Misoprostol|
215037433|NCT00726583|DRUG|PX-866|Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
215037434|NCT06806033|DRUG|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab 7 days prior to the first dose of glofitamab.
215037435|NCT06806033|DRUG|Glofitamab|Participants will receive IV glofitamab, both in combination with gemcitabine and oxaliplatin and as monotherapy, for up to 12 cycles (cycle length = 21 days).
215037436|NCT06806033|DRUG|Gemcitabine|Participants will receive IV gemcitabine in combination with glofitamab and oxaliplatin for up to 8 cycles (cycles length = 21 days).
215037437|NCT06806033|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin in combination with glofitamab and gemcitabine for up to 8 cycles (cycle length = 21 days).
215037438|NCT00427830|BIOLOGICAL|MVA85A|
214871731|NCT05838430|OTHER|Monitoring|No CBT-I will be administered, however, the tracking system used for CBT-I will be used for all subject conditions. This includes a sleep disorder symptoms screener, the administration of several questionnaires on a weekly basis, and the administration of daily sleep diaries online or via iPhone. Note: it is a common effect that regular monitoring of this type produces perceived clinical benefit.
214871732|NCT05838430|OTHER|Placebo|Placebo, identical in appearance to the active drug.
214871733|NCT06971016|OTHER|Mulligan Mobilization technique|"i. Mulligan Mobilization for Medial Glide: During the treatment, the patient will be positioned in a prone (face-down) posture. To execute a medial glide, the therapist will position themselves on the side opposite to the target knee. They will place a belt around the patient's waist and lower leg, aligning the upper edge of the belt with the margin of the tibial joint. Using one hand to stabilize the thigh above the knee and the other hand to support the lower leg, the therapist will apply a medial force to the knee using the belt. The therapist will then instruct the patient to flex their knee while maintaining the glide.~ii. Mulligan Mobilization for Lateral Glide: To administer a lateral glide to the knee, the therapist will position themselves next to the affected knee. They will employ the belt to facilitate the glide by applying force from the opposite side."
215037439|NCT01587560|DEVICE|PyroTITAN, Ascension Orthopedics, Inc.|All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
215037440|NCT01587560|DEVICE|TITAN, Ascension Orthopedics, Inc.|
214665844|NCT04294368|DIETARY_SUPPLEMENT|Similac Liquid Protein Fortifier|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
215037441|NCT05470686|BIOLOGICAL|blood gas via arterial catheter|Patients will have a blood sample plus a lung ultrasound before and after the physical therapy session combined with non invasive ventilation the morning after the heart surgery
215037442|NCT01146197|DRUG|TREATMENT|Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
215037443|NCT06526234|DEVICE|MRI|MR enterography
215037444|NCT02124408|BEHAVIORAL|Personalized Behavioral Intervention|
215037445|NCT01508767|OTHER|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
215037446|NCT07104513|DEVICE|Red Light|use red light twice per day, both eyes. use red light for one year in The RLRL-1year Group. use red light for two year in The RLRL-2years Group. red light for three years in The RLRL-3years Group.red light for more than three years in The RLRL- more than 3years Group.
215037447|NCT02893891|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
214665845|NCT04294368|DIETARY_SUPPLEMENT|Nestle Microlipid|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
214665846|NCT04294368|DIETARY_SUPPLEMENT|Medica Nutrition SolCarb|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU.
214665847|NCT04294368|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)|The experimental group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF. For participants in the experimental group, the investigators will continue to add fortification. Two packets of HMF per day will be added until goal fortification is reached.
214665848|NCT04294368|DIETARY_SUPPLEMENT|Similac Liquid Protein Fortifier (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base protein content in the donor breast milk for each particular batch of donor breast milk.
215037448|NCT02893891|PROCEDURE|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
215037449|NCT02893891|PROCEDURE|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
215037450|NCT02893891|DEVICE|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
215037451|NCT03923335|OTHER|DNA methylation detection|detecting the methylation status of colorectal cancer specimen
215037452|NCT03167060|DEVICE|Active RhinoChill|"Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
215037453|NCT03167060|DEVICE|Control Rhinochill|"Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
215037454|NCT03226041|DEVICE|transcutaneous monitor (TCM-4 monitor)|TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
214871734|NCT06971016|OTHER|Proprioceptive Exercises|"i. One leg balance- It requires flexing the opposite leg at the knee, hip, and ankle while standing on the affected foot. This position will be hold for one minute (60 seconds), followed by rest for 10 to 20 seconds, then continue this process twice more. Three repetitions of the same exercise will be performed with the unaffected leg after a brief break.~ii. Blind advanced one leg balance- The task will resemble one-legged balance, but the participant will be required to close their eyes while executing the routine, and then repeat it two more times.~iii. Toe walking- In this activity, the participant will be instructed to walk a 20-meter distance while balancing on their toes with their toes pointing straight ahead. They will then be asked to walk the same distance again, but this time with their toes pointing outward. After a brief rest, the entire procedure will be repeated once more."
214871735|NCT06971016|OTHER|Traditional Physical therapy|"• Stretching of the Gastrocnemius and Soleus Muscles~* Frequency: 3-5 times per week.~* Intensity: Stretch to the point of mild discomfort, not pain.~* Time: Hold each stretch for 30 seconds and repeat 3 times on each leg.~* Type: Static stretching. Gastrocnemius Stretch: Stand facing a wall with one foot forward (slightly bent) and the other foot back (straight). Press the back heel into the floor and lean forward to feel the stretch in the calf.~Soleus Stretch: From the same position, slightly bend the back knee while keeping the heel on the ground to target the lower calf (soleus muscle).~• Stretching of the Hamstrings~* Frequency: 3-5 times per week.~* Intensity: Stretch to a tolerable point of tension without causing pain.~* Time: Hold each stretch for 30 seconds and repeat 3 times on each leg.~* Type: Static stretching. Seated Hamstring Stretch: Sit on the floor with one leg straight and the other bent."
214871736|NCT04097158|OTHER|Sample Collection|The investigators will be collecting blood, urine, and spinal fluid samples.
214871737|NCT06499805|DEVICE|Audiologist-based fitting|Description hearing aids will be fitted by audiologists using established procedures.
215037455|NCT03144401|DRUG|Misoprostol|mesotac
215037456|NCT03144401|OTHER|Placebo|Placebo tablet identical to the misoprostol tablet but without the active ingredient
215037457|NCT07115667|DRUG|BCMA/CD3 bispecific antibody (CM336)|Patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration will receive radiation combined with a BCMA/CD3 bispecific antibody (CM336)
215037458|NCT02087852|OTHER|salvia for germline DNA|
215037459|NCT02087852|BEHAVIORAL|the Kidney Cancer Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
215037460|NCT02087852|BEHAVIORAL|Family History Questionnaire (when applicable)|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
215037461|NCT02087852|OTHER|Blood draw|
215037462|NCT02087852|BEHAVIORAL|Epidemiologic Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
215037463|NCT05739448|OTHER|nutritional intervention|The nutritional intervention will be based on the following 4 elements: nutritional follow-up by a dietician, fortified meals, tender and juicy meat dishes and fish dishes
215037464|NCT05739448|OTHER|physical activity|The physical activity intervention will be based on the following 2 elements: Follow-up with a trainer for adapted exercise and physical exercise instruction sheets
214665849|NCT04294368|DIETARY_SUPPLEMENT|Nestle Microlipid (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base fat content in the donor breast milk for each particular batch of donor breast milk
215037472|NCT05128747|OTHER|DASH diet|it will be face to face about the role of nutritional program to control dyslipidemia
215037473|NCT02645864|DRUG|Apatinib|250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
215037474|NCT02645864|DRUG|Irinotecan|150mg/m\^2 i.v. q2w
215037475|NCT02039830|BEHAVIORAL|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
215037476|NCT02039830|BEHAVIORAL|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
215037477|NCT07125742|OTHER|Chewing gum|The chewing gum group was asked to chew sugar-free gum for 15 minutes at each time point.
215037478|NCT07125742|OTHER|Fennel Tea|Fennel Tea: The fennel tea group received 2 g of fennel steeped in 150 ml boiling water for 10 minutes.
215037479|NCT07125742|OTHER|Ginger Tea|Ginger Tea: The ginger tea group received 2 g of fresh ginger steeped in 150 ml boiling water for 10 minutes.
215037480|NCT04756531|DRUG|PF-07321332 Dose 1|PF-07321332 Dose 1 or Placebo
215037481|NCT04756531|DRUG|PF-07321332 Dose 2|PF-07321332 Dose 2 or Placebo
215037482|NCT04756531|DRUG|PF-07321332 Dose 3|PF-07321332 Dose 3 or Placebo
214871738|NCT06499805|DEVICE|Over-the-counter fitting|In this group, over-the-counter hearing aids will be used by subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
214871739|NCT06552572|DRUG|Glofitamab|Glofitamab is administered to patients who have residual disease after CD19 CAR T-cell therapy for their relapsed or refractory diffuse large B-cell lymphoma
214871740|NCT06173947|DEVICE|FibroScan® Expert 630|The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.
214871741|NCT06338956|DRUG|LDL reduction therapy|LDL reduction therapy
214871742|NCT06509893|DRUG|aspirin 80 mg and clopidogrel 75 mg daily|post PCI patients received these two drugs as dual antiplatelet regimen
214871743|NCT06509893|DRUG|Ticagrelor 90 MG|Post PCI patients receive Ticagrelor 90 mg two times daily as single potent antiplatelet
214871744|NCT05642130|OTHER|exersice program (Muscle energy technique)|Post isometric relaxation for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks, In addition to the program designed for control group
214871745|NCT05642130|OTHER|exersice program (stretching and strengthening exercises ) In addition to postural advices|static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices
214871746|NCT06968533|DIAGNOSTIC_TEST|AI-ECG guided diagnosis|Participants undergo screening using the AI-ECG system. Participants identified as medium- to high-risk for LV dysfunction (LVEF \<50%) are recommended for echocardiography to confirm the diagnosis and guide subsequent management.
214871747|NCT00468650|DRUG|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
215037483|NCT04756531|DRUG|PF-07321332 Dose 4|PF-07321332 Dose 4 or Placebo
215037484|NCT04756531|DRUG|PF-07321332 Dose 5|PF-07321332 Dose 5 or Placebo
215037485|NCT04756531|DRUG|PF-07321332 Dose 4 or Placebo (Fed)|PF-07321332 Dose 5 or Placebo with high fat meal
215037486|NCT02375828|DRUG|Glibenclamide|Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
215037487|NCT06512883|DRUG|Benralizumab|Benralizumab will be administered as SC injection on Q4W.
215037488|NCT04221529|DRUG|Atezolizumab|1200 mg i.v. on day 1 of each cycle
215037489|NCT05643495|DRUG|VX-864|Tablets for oral administration.
215037490|NCT00791635|OTHER|Quality-of-Life Assessment|Ancillary studies
215037491|NCT00791635|OTHER|Questionnaire Administration|Complete questionnaires
215037492|NCT02257528|OTHER|Laboratory Biomarker Analysis|Correlative studies
215037493|NCT02257528|BIOLOGICAL|Nivolumab|Given IV
215037494|NCT06854016|DEVICE|Sham Laser therapy|sham laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week, for the first 2 weeks, and then a minimum of 2 sessions per week for the following 2 weeks.
215037495|NCT06854016|DEVICE|Laser therapy|laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week, for the first 2 weeks, and then a minimum of 2 sessions per week for the following 2 weeks.
215037496|NCT06854016|OTHER|RICE and physiotherapy/exercise protocol|RICE plus physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes: for the first 2 weeks RICE protocol performed daily at home by the patient, for the following 4 weeks a physiotherapy/exercise protocol will be performed at site with 2 sessions per week.
215037497|NCT06813261|OTHER|GLYLO|"commercially available combination of glycation-lowering compounds that are GRAS (generally recognized as safe) by the FDA.~GLYLO Ingredients Benfotiamine (fat-soluble Vitamin B1 derivative)-100mg Vitamin B6 (Pyridoxine Hydrochloride)-50mg Nicotinamide-200mg Alpha Lipoic Acid-150mg Piperine-10mg~For the first week, one GLYLO capsule daily, 5 minutes after the first meal. From week 2 onwards, two capsules of GLYLO daily, one capsule after the first meal and a second capsule after the last meal."
215037498|NCT06813261|OTHER|Placebo|"Visually matched capsule with microcrystalline cellulose as an inert ingredient.~For the first week, one placebo capsule daily, 5 minutes after the first meal. From week 2 onwards, two capsules of the placebo daily, one capsule after the first meal and a second capsule after the last meal."
215037499|NCT06272383|DRUG|0.15 mg/kg dexamethasone|25% less than the standard practice of dexamethasone at 0.6mg/kg
215037500|NCT06589999|DIAGNOSTIC_TEST|MP2RAGE sequence|Addition of MRI sequence MP2RAGE
214871748|NCT04056286|DIETARY_SUPPLEMENT|Whey|45 g whey protein + 20 g maltodextrin
214871749|NCT04056286|DIETARY_SUPPLEMENT|3-OHB/whey|50 g 3-OHB + 45 g whey protein + 20 g maltodextrin
214871750|NCT06438809|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|MSC suspension single does injection.
215037501|NCT05994248|DEVICE|Enform Mesh|Use of absorbable mesh in umbilical hernia repair
215037502|NCT05994248|DEVICE|Marlex|Use of non-absorbable mesh in umbilical hernia repair
215037503|NCT02831634|PROCEDURE|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
215037504|NCT06656442|DRUG|Trimetazidine|an anti-ischemic medication.
215037505|NCT06204484|OTHER|CAPEOX adjuvant therapy|In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
215057237|NCT03075852|DEVICE|Heads- Up Display Surgery|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
215037506|NCT06204484|OTHER|deferred CAPEOX adjuvant therapy|In MRD-negative deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
215037507|NCT06204484|OTHER|mFOLFOXIRI intensive adjuvant therapy|In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month mFOLFOXIRI intensive therapy, instead of the CAPEOX standard adjuvant therapy.
215037508|NCT01573117|DEVICE|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
214871751|NCT04081766|BEHAVIORAL|SUGAR Handshake|"An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~1. Signs and symptoms of hypoglycemia.~2. Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~3. Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~4. Acknowledgement by the patient~5. Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit."
214871752|NCT02539862|OTHER|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
214871753|NCT02539862|OTHER|psychoeducation|the psychoeducation is delivered by a doctor
215037509|NCT01573117|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
215037510|NCT04885530|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
215037511|NCT04885530|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
215037512|NCT04885530|DRUG|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
215037513|NCT04885530|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
215037514|NCT04885530|DRUG|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
215037515|NCT04885530|DRUG|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
215037516|NCT04788693|OTHER|Physical rehabilitation of gait with motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. In this intervention, in addition to physical exercise to correct gait, mental exercises will be included in which the patient visualizes himself performing the exercises that he will then develop with the body.
215037517|NCT04788693|OTHER|Physical rehabilitation of gait without motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. Motor imagery exercises are not included in this program.
215037518|NCT06981975|DEVICE|single plastic stent|Endoscopic biliary stenting was performed using standard techniques. The maximum bile duct diameter and length of stricture were measured after visualization on x-ray films by retrograde cholangiography. If necessary, sphincterotomy or dilation of the stricture was performed before insertion of the stent. Endoscopic stenting comprised the placement of a single plastic stent. Stents were exchanged at regular intervals or when signs of stent dysfunction were present. If imaging evaluation demonstrated spontaneous passage of the stent with resolution of the stricture, ERCP for stent retrieval was no longer necessary.
215037519|NCT06981975|DEVICE|Multiple plastic stents|Endoscopic biliary stenting was performed using standard techniques. The maximum bile duct diameter and length of stricture were measured after visualization on x-ray films by retrograde cholangiography. If necessary, sphincterotomy or dilation of the stricture was performed before insertion of the stent. Endoscopic stenting comprised the placement of multiple plastic stents. Stents were exchanged at regular intervals or when signs of stent dysfunction were present. If imaging evaluation demonstrated spontaneous passage of the stent with resolution of the stricture, ERCP for stent retrieval was no longer necessary.
215057238|NCT03504293|PROCEDURE|Combinatory EUS and ERCP|EUS performed as a supplementary procedure in addition to ERCP
215057239|NCT04054206|DRUG|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
214871754|NCT02528513|DRUG|midazolam|Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
214871755|NCT02528513|DRUG|Fentanyl|Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
214871756|NCT02528513|DRUG|propofol|After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
214871757|NCT02528513|DRUG|Dexmedetomidine|After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
214871758|NCT02528513|PROCEDURE|Procedure:sedation assessment|The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
214871759|NCT02528513|PROCEDURE|Procedure:Weaning|the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
214871760|NCT02528513|DRUG|midazolam(used for passing the SBT safety screen)|After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
214871761|NCT05783518|DRUG|desflurane|Intraoperative anesthesia maintenance
214871762|NCT05783518|DRUG|propofol|Intraoperative anesthesia maintenance
214871763|NCT00093561|DIETARY_SUPPLEMENT|lycopene|
214871764|NCT05145686|DIAGNOSTIC_TEST|Matris metalloproteinase -2, -8, -9 expressions|. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.
214871765|NCT05109338|DEVICE|Ben-Guard Garment|Wearable device designed to secure CVCs and gastrointestinal feeding tubes. The Ben-Guard Catheter Securement Device was designed specifically to better secure and conceal CVC tubing, protecting the patient by keeping tubing closer to the body.
215037520|NCT06981975|DEVICE|Fully covered self-expanding metal stents|Endoscopic biliary stenting was performed using standard techniques. The maximum bile duct diameter and length of stricture were measured after visualization on x-ray films by retrograde cholangiography. If necessary, sphincterotomy or dilation of the stricture was performed before insertion of the stent. Endoscopic stenting comprised the placement of fully covered self-expanding metal stents (fcSEMS) . Stents were exchanged at regular intervals or when signs of stent dysfunction were present. If imaging evaluation demonstrated spontaneous passage of the stent with resolution of the stricture, ERCP for stent retrieval was no longer necessary.
215037521|NCT06588101|OTHER|Written informed consent with infographic|Potential participants are provided a visual infographic depicting the key elements of the written consent form in addition to the standard written consent form.
214871766|NCT02299115|DRUG|Prednisolone|Corticosteroid
214871767|NCT02299115|DRUG|Vigabatrin|Antiepileptic
214871768|NCT04571151|DRUG|LEXETTE 0.05% Topical Foam|Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
214871769|NCT04571151|DRUG|Sorilux 0.005 % Topical Foam|Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
214871770|NCT04571151|OTHER|Vehicle Foam|Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
214871771|NCT03953989|DRUG|Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die|Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
214871772|NCT03891030|OTHER|Checklist Based Box system intervention|The intervention has both behavioural change and service utilization drop out tracing mechanism. Special type of boxes designed to schedule health educations and continued service utilization monitoring boxes will be placed at health posts and health centers respectively. Community level survey will be conducted to identify suspected pregnant mothers using stanback et al, 1999 checklist, and mothers are linked to health centers. Then, they will be followed for their subsequent attendance of consecutive maternal health services (ANC 2nd-third PNC). Mothers who fail to utilize the service will be traced; will get person-centered health education to continue the service.
214871773|NCT00899041|PROCEDURE|Total Knee Arthroplasty (TKA)|28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
214871774|NCT04874155|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode.
214871775|NCT04874155|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode.
214871776|NCT04874155|DEVICE|NTX100 Neuromodulation System - Open-Label|Noninvasive peripheral nerve stimulation device programmed to active mode.
214871777|NCT03735316|DRUG|Hydroxocobalamin|5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
214871778|NCT03735316|PROCEDURE|Cardiopulmonary Bypass|Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.
214871779|NCT03735316|DRUG|Placebos|Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
214871780|NCT04733703|OTHER|questionnaire|assessment of postoperative quality of recovery with the QoR-15
214871781|NCT04972110|DRUG|RP-3500 (camonsertib)|RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)
214871782|NCT03467139|OTHER|Abdominal breathing exercise|Deep Breathing Exercise
214871783|NCT00210990|DRUG|doripenem|
214871784|NCT06050889|OTHER|Positive Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention known to be effective for some people with shoulder pain. We expect this will make you less sensitive to the pressure applied to your shoulder and thigh and you will require more pressure than what was previously necessary to experience pain."
214871785|NCT06050889|OTHER|Negative Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention which is not effective for some people with shoulder pain. We expect this will make you more sensitive to the pressure applied to your shoulder and thigh and you will require less pressure than what was previously necessary to experience pain."
214871786|NCT03541980|DRUG|Acetaminophen|Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
214871787|NCT03541980|DRUG|Normal saline|Normal saline volume equivalent
215037522|NCT06588101|OTHER|Compensation|Potential participants are provided an e-gift card to Amazon or Second Cup as a reward for completing the enrollment questionnaire.
214871788|NCT04766164|BEHAVIORAL|Survey|Data will be obtained via self-report from participants via a one-time Qualtrics survey.
214871789|NCT03477903|DRUG|TAK-954|TAK-954 infusion
214871790|NCT03477903|DRUG|Metoclopramide|Metoclopramide infusion
214871791|NCT03477903|DRUG|Normal Saline|0.9% sodium chloride for injection
214871792|NCT04378738|BEHAVIORAL|survey|all people in the cohort
214871793|NCT05976126|OTHER|Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements|Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
214871794|NCT03833401|PROCEDURE|Autologous tissue transplantation|Root canal disinfection and revascularization with patient's own minced pulp tissues
215037523|NCT00253422|DRUG|Anastrozole|This may be Anastrazole OR a placebo
215037524|NCT00253422|DRUG|Exemestane|
215037525|NCT00253422|DRUG|Fulvestrant|
215037526|NCT06654232|OTHER|quality of life questionnaires|"All patients will receive a combination of quality of life questionnaires aimed at collecting a complete overview of different aspects of quality of life, including:~* Florida patient acceptance score (FPAS)~* Short Form Health Survey (SF-12)~* Kansas City Cardiomyopathy Questionnaire (KCCQ-12)~* Hospital Anxiety and Depression Scale (HADS)~* Florida Shock Acceptance score (FSAS)~* Steinke Sexual Concerns Inventory~* the Good Death questionnaire"
215037527|NCT06662760|DRUG|TQB3002 Tablets|TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth.
215037528|NCT02900404|OTHER|XAPPORT|A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
215037529|NCT02900404|OTHER|"Expert Panel (gold standard)"|A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
215037530|NCT06446518|DEVICE|Virtual reality exposure|Assessing immersive virtual reality as a distraction tool in anxiolysis and pain modulation.
215037531|NCT02918942|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure.
215037532|NCT04504071|DRUG|Dacomitinib|Patients will receive continuous oral therapy with the study drugs (dacomitinib 45 mg) until disease progression or unacceptable toxicity.
214871795|NCT03833401|PROCEDURE|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation
214871796|NCT03961490|OTHER|No interventional study|No interventional study
214871797|NCT00683579|DRUG|Early Treatment with HAART|HAART with possibility of de-intensification
215037533|NCT06590116|OTHER|Physical therapy|Patients with low back pain will receive a combination of education, spinal manipulative therapy, and exercise as prescribed by their physical therapist
215037534|NCT06590116|OTHER|Physical therapist provider|Physical therapists will provide a combination of education, spinal manipulative therapy, and exercise to their patients with low back pain participating in the study
215037535|NCT06987656|DRUG|Standard Pharmacologic Treatment|Standard pharmacologic management including nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants (e.g., thiocolchicoside), and analgesics (e.g., paracetamol, tramadol) for acute lumbar spasm.
215037536|NCT06987656|OTHER|Physiotherapy Intervention|Physiotherapy interventions included spinal mobilization (Maitland techniques), myofascial release, transcutaneous electrical nerve stimulation (TENS), and personalized exercise programs, as documented in patient medical records.
215057240|NCT04015570|BIOLOGICAL|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
215057241|NCT04015570|OTHER|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
215057242|NCT03320837|DIETARY_SUPPLEMENT|Infant formula|Breast milk substitute containing synbiotics
215057243|NCT03320837|OTHER|Breast milk|Breast milk
214871798|NCT00683579|OTHER|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
214871799|NCT00683579|DRUG|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA \>100,000 copies/ml
214871800|NCT03201965|DRUG|Cyclophosphamide|Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.
214871801|NCT03201965|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.
214871802|NCT03201965|DRUG|Dexamethasone, 40 mg|Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
214665850|NCT04294368|DIETARY_SUPPLEMENT|Medica Nutrition SolCarb (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base carbohydrate content in the donor breast milk for each particular batch of donor breast milk
214665851|NCT04294368|OTHER|Analysis with Miris (AB) Human Milk Analyzer|For participants in both the control and the experimental arms, each batch of donor milk will be analyzed using the Miris Human Milk Analyzer. Manufacturer recommendations for milk analysis will be strictly followed.
214871803|NCT03201965|DRUG|Daratumumab|Participants will receive 1800 mg of daratumumab subcutaneously.
214871804|NCT03813810|OTHER|Non|There would be no interventions. Only measurements will be performed.
214871805|NCT05067621|DRUG|Semaglutide Pen Injector|Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
214871806|NCT05067621|DRUG|Placebo|Injection pen contains excipients.
214871807|NCT05066334|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal cells
214871808|NCT05066334|PROCEDURE|Sham|local anaesthesia, no disc injection, no placebo injection
214871809|NCT05694780|BEHAVIORAL|Sleep intervention|Standard obstetric care plus the sleep intervention which is a 8-week program based on sleep hygiene education and cognitive-behavioral training.
214871810|NCT05039866|BIOLOGICAL|ST-920|No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
214871811|NCT04646941|OTHER|regular treatment|The patients with or without OSA received regular hypoglycemic drugs.
214871812|NCT02264470|OTHER|Not relevant|Not relevant
214871813|NCT04084600|OTHER|Kinesiotherapy Protocol|Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
214871814|NCT04084600|OTHER|Manual Therapy Protocol|Manual therapy protocol: is a manual treatment intended to the release of fascias and soft tissues.
214871815|NCT04084600|OTHER|Traditional Massage|Traditional Massage is a gentle and superficial massage.
214871816|NCT01308905|DEVICE|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
214871817|NCT06979635|DEVICE|Tandem Mobi Hybrid Closed Loop (HCL) pump|Tandem Mobi Hybrid Closed Loop (HCL) pump with an integrated Control-IQ algorithm (CIQ), the Dexcom G7 continuous glucose monitoring sensor (CGM ) and Tandem Mobi Mobile App
214871818|NCT06983314|OTHER|Observation|Observation of pharmacological prescriptions in patients with ABI
214871819|NCT06983795|PROCEDURE|PFO closure using approved PFO closure devices, Surgical PFO closure|PFO closure using approved PFO closure devices, Surgical PFO closure
214871820|NCT06983795|DRUG|Medical management|"Antiplatelet therapy~* ASA, also called acetylsalicylic acid (Aspirin, Asaphen, Entrophen, Novasen)~* clopidogrel (Plavix)~* ticagrelor (Brilinta)~* dipyridamole (Persantine)~* cilostazol~Anticoagulation therapy~* apixaban (Eliquis)~* dabigatran (Pradaxa)~* edoxaban (Lixiana)~* rivaroxaban (Xarelto)~* warfarin (Coumadin)"
214871821|NCT06983977|OTHER|Measurement of physical activity|Measurement of physical activity by accelerometer
214871822|NCT06983977|OTHER|Digital nudging|Digital feedback and nudging to participants (patients) and staff, based on participants' physical activity measurements, aiming to increase patients' physical activity and reduce sedentary time
214871823|NCT06683573|BEHAVIORAL|3D Kidney model|Brief provider led counseling and education on Chronic Kidney Disease (CKD) and hypertension guided by use of 3D kidney model visual aid
214871824|NCT06683573|BEHAVIORAL|Standard medical treatment|Standard provider led counseling and education on CKD and hypertension
214871825|NCT03469505|BEHAVIORAL|COPES|Cooperative Pain Education and Self-Management for chronic pain therapy.
214871826|NCT03469505|BEHAVIORAL|CBT-CP|Cognitive Behavioral Therapy for Chronic Pain
214871827|NCT06185608|DRUG|0.25% ropivacaine|A total of 15 ml of 0.25% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
214871828|NCT06185608|DRUG|0.5% ropivacaine|A total of 15 ml of 0.5% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
214871829|NCT06185608|DRUG|1% ropivacaine|A total of 15 ml of 1% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
214871830|NCT06983912|BEHAVIORAL|Preoperative Rehabilitation Training|"Initiate preoperative Physical Rehabilitation Training (PRT) starting from the preoperative period, with training five days a week up until the day before surgery. This includes:~Muscle Strength Training: Isometric contractions of the quadriceps, straight leg raises, etc., for 15-20 minutes per session, twice daily.~Joint Mobility Training: Flexion and extension exercises of the knee joint, ankle pump exercises, etc., for 10-15 minutes per session, twice daily.~Balance Training: One-legged standing, center of gravity shifting exercises, etc., for 10-15 minutes per session, twice daily.~Activities of Daily Living Training: Transfer training from sitting to standing, walking exercises, etc., for 10-15 minutes per session, twice daily."
214871831|NCT06454396|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
215057244|NCT02440204|PROCEDURE|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
215057245|NCT02440204|DRUG|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
215057246|NCT02440204|DRUG|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
215037537|NCT06862622|BEHAVIORAL|Computer-based visuomotor sequence learning and interference|The behavioral sequence learning and interference paradigm allows the experimental manipulation of sequence memory after long-term consolidation achieved through individualized longitudinal practice and serves the extraction of the primary behavioral outcome. The learning task requires participants to respond with keypresses on a standard computer keyboard of visual targets. Participants will implicitly (without being made aware) learn sequential regularities provided through the recurring order of cued keys contrasted with random keys. Participants will practice the learning task remotely over consecutive days until a stable performance plateau is reached. During this phase, data will be collected online, and behavioral change will be monitored in real time. Then participants will undergo the behavioral interference intervention, in which the initially learned sequence memory will be perturbed through (implicit) exposure to new sequential information (i.e., interference).
215037538|NCT05593380|DEVICE|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
214871832|NCT06983483|BEHAVIORAL|Community education and awareness, and personal lifestyle and cooling behavior modification|This component of the HAB will be achieved through community mobilization, which will encompass awareness and motivational activities throughout the intervention duration. Community groups (CGs) will be formed in each of the 11 clusters. Both male and female CGs will be formed separately and will be responsible for community mobilization activities, surveillance for primary outcome. Each CG will comprise of 6-8 members and will be a diverse group of people with varying qualifications, including local government members, local elders/elites, religious leaders, and prominent male and female members of the community. they could also name their respective CGs to enhance association, identity, and affiliation. These CGs will facilitate culturally tailored workshops, dissemination of early warnings regarding heat waves, awareness sessions, and door-to-door outreach focused on heat-health fundamentals. CGs will also maintain simple logbooks to track any incidence of heat related illness.
214871833|NCT06983483|OTHER|Participatory local structural and environmental heat mitigation solutions|"Participatory local structural and environmental heat mitigation solutions will be delivered through community participatory approach where the community and project will share the cost of intervention to improve ownership. This contribution can be monetary or non-monetary, for example, provision of labor or supplies. The modifications include:~1. Paints (Solar Reflective Paints, Lime Paints)~2. Shading (Façade, Roof)~3. Energy Sufficiency (Solar Panels with complete accessories)~4. Community Shading (Plantation, Street Shading, Field Shading space)~5. Ventilation (Windows, Wind catchers)~6. External Renders"
214871834|NCT06659679|DRUG|New use of oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
214871835|NCT06659679|DRUG|New initiation of sitagliptin|New use of sitagliptin dispensing claim is used as the reference.
215037539|NCT05593380|OTHER|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
215037540|NCT06659692|DRUG|Gonadotropins Subcutaneous|Gonadotropins s.c. multiple dose
215037541|NCT07004621|OTHER|measurment of intubation time in seconds|determine whether modern technologies such as videolaryngoscopy shorten intubation time.
215037542|NCT07003802|BEHAVIORAL|Resistance exercise|An acute bout of a 3 minute resistance exercise will be performed using a lumbar extension exercise machine
215037543|NCT07004842|OTHER|48 hr Respite Service|Caregivers will be provided with 48 hours of respite service within 6 months. Trained alternative caregivers will provide elderly-sitting service at their home, allowing the caregivers to have their personal time.
215037544|NCT07004400|DEVICE|RefluxStop™ implantation|Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use
215037545|NCT07004400|PROCEDURE|Nissen fundoplication|Standard surgical technique for Nissen fundoplication
215037546|NCT07003815|DRUG|Envafolimab + Gemcitabine + Cisplatin + Simvastatin|"Envafolimab (generic name):~Dose: 300 mg, intravenous (IV) infusion. Schedule: Day 1 of each 21-day cycle (induction phase); every 28 days (maintenance phase).~Role: PD-L1 inhibitor immunotherapy.~Gemcitabine (generic name):~Dose: 1,000 mg/m², IV infusion. Schedule: Days 1 and 8 of each 21-day cycle (induction phase only).~Cisplatin (generic name):~Dose: 25 mg/m², IV infusion. Schedule: Days 1 and 8 of each 21-day cycle (induction phase only).~Simvastatin (generic name):~Dose: 40 mg, oral tablet. Schedule: Daily (continuously through induction and maintenance phases). Investigational Role: Potential immunomodulator and chemosensitizer in biliary tract cancer.~Treatment Phases:~Induction Phase (Cycles 1-8, 21-day cycles): All four drugs administered. Maintenance Phase (Post-Cycle 8): Envafolimab + Simvastatin only (28-day cycles)."
215037547|NCT07002788|DRUG|Bupivacaine|Used for regional anesthesia during VATS procedure (e.g., paravertebral or serratus anterior plane block)
215037548|NCT07002788|DRUG|Morphine|Used for postoperative pain control via PCA device.
215037549|NCT07002788|DRUG|Paracetamol|Used as part of postoperative multimodal analgesia
215037550|NCT07002788|DRUG|Diklofenak Sodyum|Administered for postoperative pain management
215037551|NCT06616610|BEHAVIORAL|Intervention with the Mobility Platform|The experimental arm receives the Intervention with Mobility Platform that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities.
215037552|NCT06616610|BEHAVIORAL|Intervention with Traditional Therapy|The traditional cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.
215037553|NCT04810091|DRUG|Placebo Administration|Given PO
215037554|NCT04810091|OTHER|Questionnaire Administration|Ancillary studies
215037555|NCT04810091|DRUG|Telotristat Ethyl|Given PO
215037556|NCT06920238|DEVICE|Therabot-CALM|Therabot is a generative-AI-driven mobile app designed to provide mental health treatment. The feasibility of Therabot-CALM, an adapted Therabot application, is being tested for the future use of treating co-occurring substance use disorders and anxiety and/or depression. The primary purpose of this study is application feasibility.
215037557|NCT06921707|DEVICE|Clinical Decision Support Tool|WounDx is a clinical decision support tool that will help augment the clinicians' judgment regarding the wounds readiness to close.
215037558|NCT06921707|PROCEDURE|Standard of Care (SOC)|The standard of care consists of serial wound irrigation, negative pressure wound therapy, and surgical debridement
215037559|NCT04840186|PROCEDURE|Liver-resection or ablation|Liver-resection of colorectal liver metastasis. Ablation can be used as adjunct to surgery.
214871836|NCT06506214|OTHER|Questionnaires|"Responses to questionnaires:~* Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)~* Medical Adherence Self-Report Inventory (MASRI)~* Morisky Medication Adherence Scale (MMAS4)~* Visual analog scale (VAS) on the perception of disease control~* Belief on Medicine Questionnaire (BMQ)~* Care patient Feedback measure~* Hospital Anxiety and Depression Scale (HAD)~* Dermatology Life Quality Index (DLQI)"
214871837|NCT00426712|BIOLOGICAL|1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
214871838|NCT00426712|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
214871839|NCT00000717|DRUG|Primaquine|
214871840|NCT00000717|DRUG|Clindamycin|
214871841|NCT00369317|DRUG|asparaginase|Given IM
214871842|NCT00369317|DRUG|daunorubicin hydrochloride|Given IV
214871843|NCT00369317|DRUG|cytarabine|Given IV or IT
214871844|NCT00369317|DRUG|thioguanine|Given orally
214871845|NCT00369317|DRUG|etoposide|Given IV
214871846|NCT00369317|OTHER|laboratory biomarker analysis|Correlative studies
215037560|NCT04840186|DRUG|2nd line chemotherapy|2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist
215037561|NCT02229630|RADIATION|Pregnant women with intra-uterine growth restricted Foetuses|Diffusion-weighted cerebral MRI before 32 weeks of gestation
215037562|NCT06680583|OTHER|physical indicators such as shock index relatives|shock index relatives indicators used in the prediction of cirrhosis with gastrointestinal bleeding
214871847|NCT03322930|DIAGNOSTIC_TEST|Rod sensitivity|diagnostic test for rod loss in central retina
214871848|NCT01687244|DRUG|INSTILADRIN|The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
214871849|NCT02373189|DEVICE|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
214871850|NCT01449448|DRUG|Ketorolac|Subacromial injection
214871851|NCT01449448|DRUG|Triamcinolone|Subacromial Injection
214871852|NCT06634251|OTHER|No intervention|This study is purely observational and does not involve any direct intervention. It utilizes retrospective analysis of computed tomography (CT) scans to simulate the fluoroscopic visualization and screw placement technique in the anterior column fixation corridor (ACFC) of the acetabulum. The objective is to define the optimal antegrade entry point and assess anatomical parameters without performing any physical intervention on the participants.
214871853|NCT02977897|DRUG|Octreotide Acetate|Octreotide 100mcg SC q12h for 5 days
214871854|NCT06200324|OTHER|Ready-to-Use Parenteral Nutrition|"In newborns weighing less than 1000 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum volume of 128 ml/kg/day, with a provision of 4 grams/kg/day of protein and a metabolic rate of 12 mg/kg/minute.~For newborns weighing between 1001-1500 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum of 110 ml/kg/day.~When enteral intake exceeds 70 ml/kg/day, a gradual decrease in the volume of parenteral nutrition is initiated. We discontinue parenteral nutrition in newborns weighing less than 1000 grams with enteral volume of 120 ml/kg/day, and for those between 1000 grams and 1500 grams, enteral nutrition volume of 100 ml/kg/day."
215037563|NCT07000084|BIOLOGICAL|BCG Solution|Given intravesically
215037564|NCT07000084|PROCEDURE|Biopsy of Bladder|Undergo bladder biopsy
215037565|NCT07000084|PROCEDURE|Cystoscopy|Undergo cystoscopy
215037566|NCT07000084|PROCEDURE|Computed Tomography|Undergo CT Scan
215037567|NCT07000084|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215037568|NCT07000084|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215037569|NCT07000084|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
215037570|NCT07000084|DRUG|Gemcitabine|Given intravesically
215037571|NCT07004231|OTHER|GOUT Buddy, an AI chatbot|"AI Chatbot (GOUT Buddy) offers personalized gout education and awareness tailored to individual needs"
215037572|NCT07002853|OTHER|Nature-based Intervention|Combination of activities in nature such as walking, exercises (strengthening, mobility, balance), mindfulness, guided meditation, forest bathing or Shinrin-Yoku, interpretation of nature, gardening and pain education.
215037573|NCT03081390|OTHER|Mixed meal tolerance testing|An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
215037574|NCT03081390|OTHER|Skin conductance & cold pressor test|Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
214871855|NCT02990780|RADIATION|Conventionally fractionated concurrent chemo-radiotherapy|5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.
214871856|NCT02990780|RADIATION|Accelerated hypofractionated concurrent chemo-radiotherapy|5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
214871857|NCT02542553|PROCEDURE|Bilateral BAL|
214871858|NCT01177475|OTHER|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
215037575|NCT03081390|OTHER|Flow-mediated dilation testing|At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
214871859|NCT01177475|OTHER|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
214871860|NCT02917070|OTHER|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
214871861|NCT04614415|DEVICE|Autocrosslinked Hyaluronic aid|IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
214871862|NCT04614415|OTHER|placebo|The placebo consists in an isotonic saline solution (NaCl 0.9%)
214871863|NCT04504305|OTHER|NeuropAWAY|2 capsules thrice daily to be taken half an hour prior to meal.
214871864|NCT04504305|OTHER|Microcystalline cellulose|2 capsules thrice daily to be taken half an hour prior to meal.
214871865|NCT03344861|DRUG|Porfimer Sodium|Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
214871866|NCT03344861|DEVICE|Fiber optic|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
214871867|NCT06456905|BEHAVIORAL|Contingency Management|Participants in the contingent group will be rewarded on an incrementally increasing scale for submitting consecutive breathalyzer samples that are 0.00%. For every day this target is met, the participant will receive an increase in reward until a daily cap is reached. If a day contains at least one sample where the target is not met, the participant will not be paid for that day, and the amount will reset. The participant will have the opportunity to earn on this scale throughout the duration of the study.
215037576|NCT03766672|DIAGNOSTIC_TEST|Intervention Arm|The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
215037577|NCT06684769|DEVICE|Emdogain® FL|Enamel Matrix Derivatives
215037578|NCT06684769|DEVICE|Labrida BioClean®|Oscillating Chitosan Brush
215037579|NCT06682234|DRUG|obeldesivir|Tablets administered orally
214871868|NCT00185445|DRUG|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
215037580|NCT04569084|DRUG|MT-1186|Oral edaravone
215037581|NCT04569084|DRUG|Placebo|Oral
215037582|NCT06690151|BEHAVIORAL|Neurodevelopmental assessment (Bayley-IV)|Assessment of developmental delays through administration of the Bayley-4 test by a neuropsychologist
215037583|NCT06690151|OTHER|Biological sampling|"The samples to be collected at delivery will include:~* A 4 ml maternal blood sample in an EDTA tube for lipidomic and metabolomic analyses at delivery~* A 6 ml maternal blood sample in an EDTA tube (2 tubes of 3 ml) for genetic analysis~* A 4 ml venous cord blood sample in an EDTA tube for transcriptomic and epigenetic analysis; and a 2 ml EDTA tube for metabolomic/lipidomic analysis~* Samples from fresh placenta for transcriptomic, epigenetic, metabolomic, and lipidomic analyses~* A meconium sample collected as soon as possible after birth in a dry tube for microbiome analysis~During hospitalization for the cardiac surgery:~* Genome analysis samples will be collected from the father and the infant. These samples will be taken in two EDTA tubes of 3 ml each.~* Perioperative neurobiomarker samples will be collected (one EDTA tube of 500 μL preoperatively and postoperatively on Day 1 and 2).~At 1 month, a stool sample will be collected from the infants for microbiome analysis."
215037584|NCT06690151|BEHAVIORAL|ELFE dietary questionnaire|Questionnaire on diet and lifestyle during pregnancy (only for the mother)
215037585|NCT06690151|BEHAVIORAL|Post-Traumatic Stress Questionnaire IES-R (Impact of Event Scale - Revised)|The IES-R is a 22-item self-report measure (for DSM-IV) that assesses subjective distress caused by traumatic events.
215037586|NCT06690151|OTHER|Data collection for the study (Cardiovascular, developemental, fetal, pregnancy, MRI)|"* Cardiovascular follow-up data collection~* Developmental follow-up data collection~* Collection of postoperative brain MRI data, scheduled between Day 5 post-surgery and the end of the hospital stay~* Collection of data on pregnancy exposure, obstetric events, and delivery data.~* Collection of fetal ultrasound data (T2 and T3).~* Collection of fetal echocardiography data (T2 and T3)."
215037587|NCT00978458|DRUG|temozolomide|Given orally
215037588|NCT00978458|RADIATION|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
214670060|NCT03445039|DEVICE|traditional TSFE|The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.
215037589|NCT00978458|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
215037590|NCT07020429|DRUG|Huanjingjian decoction|Participants will receive the traditional Chinese herbal formulation Huanjingjian decoction, administered at a dose of one vial (10 ml) twice daily, taken 30 minutes after breakfast and dinner. The intervention will commence immediately following the cessation of menstruation and will continue until the onset of the subsequent menstrual period. Upon the completion of each menstrual cycle, the treatment will be resumed. Each treatment course spans 28 days, with a total of three consecutive cycles administered.
214871869|NCT02505087|DRUG|N-Acetylcysteine followed by Placebo|"Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout."
214871870|NCT02505087|DRUG|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
214871871|NCT02151877|DRUG|Inhaled Nitric Oxide|delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
214871872|NCT02151877|DRUG|placebo|inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
214871873|NCT00224471|BIOLOGICAL|GSK208141 vaccine|3 IM doses
214871874|NCT01117493|BEHAVIORAL|Expert Patient Programme|Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
214871875|NCT01117493|BEHAVIORAL|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
214871876|NCT00217555|DRUG|gemcitabine hydrochloride|
214871877|NCT00217555|DRUG|topotecan hydrochloride|
214871878|NCT06982586|DEVICE|Repetitive transcranial magentic stimulation|Low frequencey repetitive transcranial magentic stimulation
214871879|NCT06989827|DRUG|Preservative free artificial tear|After diagnosing patients with dry eye disease we prescribed them preservative free artificial tears and scheduled them for a follow-up keratometry.
214871880|NCT06990672|OTHER|Standard care|Receiving standard dietary and regular recommendations such as education profile and counseling to achieve a fluid intake ≥ 2500 ml, providing verbal health education counseling regarding urological calculi prevention during the hospitalization, and adequate fluid intake in person on the day of discharge. Prepare a fixed-capacity water bottle. Phone calls will be given at each follow-up phase to collect primary and secondary data via the questionnaires.
215037591|NCT07020429|DRUG|Hormone replacement therapy|Participants will begin oral administration of Utrogestan (estradiol valerate) on the 5th day of menstruation at a dose of 1 mg daily for 21 consecutive days. Starting from day 17 of treatment, medroxyprogesterone acetate will be added at a dose of 10 mg per day.
215037592|NCT07020429|DRUG|Placebo|Participants will take the placebo oral solution at a dose of 10 mL twice daily (30 minutes after breakfast and dinner). The placebo intervention will commence immediately after the cessation of menstruation and will continue until the onset of the subsequent menstrual period. At the completion of each menstrual cycle, the treatment will be resumed. Each treatment course will last for 28 days, with a total of three consecutive cycles administered.
215037593|NCT02438761|DRUG|PF-05212384|"PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression."
215037594|NCT07013409|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
215037595|NCT07013409|DIETARY_SUPPLEMENT|Maltodextrin|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
215037596|NCT06689072|OTHER|rTMS|To evaluate the role of repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing pain, decreasing craving, alleviating withdrawal symptoms, lowering relapse rates, reducing impulsivity, and improving cognitive function in patients with Opioid Use Disorder
215037597|NCT06689072|BEHAVIORAL|Psychotherapy|Using psychotherapy in opioid use disorder.
215037598|NCT06870916|OTHER|Multi-cancer Early Detection|Participants will participate in a focus group discussion asking about your knowledge, preferences, and concerns for MCEDs. During the focus group discussion, investigators will specifically talk about what the tests are and how to decide to get the test as well as their risks and benefits.
215037599|NCT06874296|DEVICE|Quality Assessment with Normothermic Machine Perfusion (NMP)|"Quality assessment using NMP in the experimental arm is performed according to previously published viability criteria for initially declined liver grafts, which are mandatory for all participating study centers, with minor device-specific modifications. These criteria are based on the Birmingham criteria used in the VITTAL trial for viability assessment of DBD and DCD grafts with the OrganOx Metra device and are comparable to the Groningen criteria previously established with the LiverAssist device, with the exception of biliary viabilit~These criteria are: Lactate clearance \< 2.5 mmol/L, And two or more of the following: Evidence of bile production, maintenance of a perfusate pH \>7.30 (without correction for at least one hour), glucose metabolism (falling perfusate glucose value with consistent downward trend), maintenance of stable arterial and portal venous flows (OrganOx Metra: 150 and 500 mL/min respectively), homogeneous perfusion with soft consistency of the parenchyma."
215037600|NCT06922851|PROCEDURE|Immunoadsorption|Immunoadsorption (IA) therapy using a protein A column for four consecutive days, plus immunoglobulin supplementation after IA
215037601|NCT06693908|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified.
214871881|NCT06990672|OTHER|Experimental|Receive the same standard dietary counseling and education handout but also the WeChat applet intervention. A WeChat-based applet will be developed for fluid intake adherence improvement and self-monitoring to prevent urinary calculi, including fluid intake reminders, fluid value recording, urine value and coluor recording, and health education, an interactive platform for communication among post-operative patients with urinary stones. The applet will tailor the daily notification to participants of fluid intake to increase their fluid consumption to more than 2,500 ml. Extra education information regarding the benefits of adherence will be provided to the experimental group only via the applet. Phone calls will be given at each follow-up phase to collect primary and secondary data via the questionnaires.
214871882|NCT06990958|PROCEDURE|Erector Spinae Plane Block (ESPB) group|ultrasound guided erector spinae plane block (at lumbar level) in lateral position .
214871883|NCT06990958|PROCEDURE|Fascia iliaca compartment block (FICB)|ultrasound guided suprainguinal approach in supine position
214871884|NCT06990178|RADIATION|Neoadjuvant concurrent chemoradiotherapy|Non-cCR group will continue with neoadjuvant concurrent chemoradiotherapy (2Gy\*20f) followed by radical surgery
214871885|NCT06989294|OTHER|Lean Leadership|Lean leadership was doing the right things to increase revenues, satisfying customers and reducing costs by eliminating all activities that do not add value to the product or service. It has five dimensions, namely: continuous improvement, self-development, qualification development, Gemba walk and Hoshin Kanri.
214871886|NCT06990308|PROCEDURE|Inflated Cuff Extubation|The adjustable pressure limiting valve will be set to 20 centimeters water pressure. To blind the Anesthesiologist Associate Investigator from the patient's group allocation, sham deflation of the endotracheal tube cuff pilot balloon will be performed with a 10 milliliter syringe. The endotracheal tube will be withdrawn into an opaque blue towel while the reservoir bag is simultaneously compressed to generate at least 20 centimeters water pressure positive airway pressure. In the rare event significant resistance is met with attempted extubation, the principal investigator will deflate the cuff in one milliliter increments until extubation is possible. This process does not unblind the Anesthesiologist Associate Investigator.
214871887|NCT06990308|PROCEDURE|Deflated Cuff Extubation|The adjustable pressure-limiting valve will be set to 20 centimeters water pressure. All air will be removed from the endotracheal tube cuff pilot balloon with a 10 milliliter syringe. The endotracheal tube will be withdrawn into an opaque blue towel, to prevent the Anesthesiologist Associate Investigator from identifying the patient's allocation, while the reservoir bag is simultaneously compressed to generate at least 20 centimeters water pressure positive airway pressure.
214871888|NCT01781520|BIOLOGICAL|DC-CIK Treatment|The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
214871889|NCT01781520|DRUG|S1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and \>1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
214871890|NCT01781520|OTHER|Best supportive care|Best supportive care
214871891|NCT00140660|DRUG|rituximab|375 mg/m2 on D1
214871892|NCT01833091|OTHER|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand \& arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
214871893|NCT00260169|BEHAVIORAL|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
215037602|NCT03552445|BIOLOGICAL|Tetanus-diphtheria (Td) and PCV13|154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0
215037603|NCT03552445|BIOLOGICAL|PCV13 alone|154 PCV13 recipients: one vaccine injection administered on Day 0
215037604|NCT03552445|BIOLOGICAL|Td alone|437 Td recipients: one vaccine injection administered on Day 0
215037605|NCT06770634|OTHER|Pain-Pressure Threshold Measurement With an Algometer|"The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral thigh, pretibial region and left forearm as remote site and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~Bilateral thigh: Mid-thigh anterior surface Bilateral pretibial region: Anterior proximal 1/3 of the pretibial area Bilateral forearm volar side center as control point"
215037606|NCT06770634|OTHER|Central Sensitization Inventory|The central sensitization scale was developed primarily to detect central sensitization findings in patients with chronic pain and consists of two parts, A and B. In part A, 25 somatic and psychosocial symptoms frequently found in patients with central sensitization.
215037607|NCT06770634|OTHER|Numeric Rating Scale|Leg pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
215037608|NCT06770634|OTHER|Lower Extremity Functional Scale|The lower extremity functional scale is a valid patient-rated outcome measure for the measurement of lower extremity function. The scale consist of 4 groups with 20 questions. The questions in these group focus on activities with increasing physical demands like questions from walking between rooms to running on uneven ground. The scoring of this scale varies from 0 (extreme difficulty/unable to perform activity) to 4 (no difficulty). The total score can be obtained by summing the scores of the individual items. The maximum score of 80 indicates no functional limitations and the minimum score of 0 indicates extreme limitations.
215057247|NCT02805465|DEVICE|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
214871894|NCT00260169|BEHAVIORAL|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
214871895|NCT04617054|DRUG|AB-106|600mg QD for each subjects.
214871896|NCT06299852|DRUG|Trastuzumab emtansine|SRT for metastatic foci
214871897|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
214871898|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
214871899|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
214871900|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
214871901|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
214871902|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
214871903|NCT02512926|DRUG|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
214871904|NCT02512926|DRUG|Cyclophosphamide|
214871905|NCT02512926|DRUG|Etoposide|
214871906|NCT00039520|DRUG|docetaxel|
214871907|NCT00039520|DRUG|sulindac|
214871908|NCT06719011|DRUG|NNC0174-1213 A|"Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts."
214871909|NCT06719011|DRUG|Cagrilintide B|"Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts."
214871910|NCT06719011|DRUG|Placebo A (NNC0174 1213 A)|"Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts."
214871911|NCT03550105|DEVICE|Gentle Jogger|Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study
214871912|NCT02426853|BEHAVIORAL|Questionnaires|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
214871913|NCT02426853|OTHER|Photos|At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
214871914|NCT02426853|BEHAVIORAL|Pamphlets|At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
214871915|NCT00758680|DRUG|MK-1006|MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
214871916|NCT00758680|DRUG|Comparator: Placebo comparator|Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
215037609|NCT06770634|OTHER|Short form 12|The Short form 12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.The scoring yields two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).Utilize the norm-based scoring system to interpret PCS and MCS scores, with a mean of 50 and a standard deviation of 10 in the general population.Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.
215037610|NCT06770634|OTHER|lower extremity volumetric measurement|It is calculated by converting the circumference measurements taken at 4 cm intervals from the ankle to the proximal thigh into lower extremity volume with Excel.
215037611|NCT06770634|OTHER|lower extremity circumference measurement|bilateral tuberosity tibia, 20 cm proximal tuberosity tibia, tuberosity tibia 10 cm distal and ankle level
215037612|NCT06770634|OTHER|Bioelectrical Impedance Analysis|With Bioelectrical Impedance Analysis, fat, muscle and water ratio and lean mass are calculated in addition to the patient's body weight.
215037613|NCT06770634|DIAGNOSTIC_TEST|Ultrasound|Measurement of subcutaneous fat tissue thickness from mid-thigh, pretibial, lateral leg and supramalleolar regions with ultrasound.The average of two measurements taken from the same area will be recorded.According to these measurements; 12-15 mm = mild lipedema or lipohyperplasia, 15-20 mm = moderate lipedema, \>20 mm = significant lipedema, \>30 mm = severe lipedema.
215037614|NCT05638113|PROCEDURE|Pleural injection of autologous blood|120 ml autologous blood will be drawn from simple venous puncture and immediately injected through the drain into the pleural cavity followed by flushing with 50ml of saline.
215037615|NCT04210960|RADIATION|Magentic resonanace imaging|The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) \_ 9583 sec, echo time (TE) \_ 25 sec, inversion time (TI) \_ 3400 sec, IR delay \_ 325 sec, echo train length (ETL) \_ 17, 50 contiguous axial slices, thickness \_ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.
215037616|NCT04210960|RADIATION|Magentic resonanace spectroscopy|Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.
215037617|NCT01346176|OTHER|Advance Directive Forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
215037618|NCT01994876|DEVICE|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
215037619|NCT01994876|DEVICE|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
215037620|NCT04194242|DRUG|HEC96719 tablets|0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1
215037621|NCT04194242|DRUG|Placebo tablet|0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
215037622|NCT00536289|DEVICE|Blunt needle|Blunt tipped suture needle
215037623|NCT06564623|DRUG|mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]|Patients will receive treatment on Day 1, 8, 15 and 22 of cycle 1 and on day 1 of remaining cycles (C2-C4) in Prime Phase. In the Boost Phase - every 2 cycles (8 weeks) beginning from C6D1.
215037624|NCT06564623|DRUG|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV every 4 weeks in both the Prime and Boost Phase.
214871917|NCT04174976|PROCEDURE|wall hernia repair|Wall hernia repair with mesh
214871918|NCT00761865|DEVICE|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
214871919|NCT03158974|DRUG|East Indian Sandalwood Oil Cream|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
214871920|NCT00574912|DRUG|Placebo|single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
214871921|NCT00574912|DRUG|Insulin Glargine 0.5 u/kg body wt SC|8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
214871922|NCT00574912|DRUG|Insulin Glargine 1.0 u/kg body wt SC|
214871923|NCT00574912|DRUG|Insulin Glargine 1.5 u/kg body wt SC|
214871924|NCT00574912|DRUG|Insulin Glargine 2.0 u/kg body wt SC|
214871925|NCT01080664|DRUG|AS703569|"Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops"
215037625|NCT06564623|DRUG|Tremelimumab|Patients will receive treatment on C1D1. Tremelimumab (300 mg) will be administered IV as a single dose on Day 1 of Cycle 1.
214871926|NCT01080664|DRUG|AS703569|"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
214871927|NCT04681066|DRUG|CM-4620 Injectable Emulsion or CM-4620-IE|Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
214871928|NCT04681066|OTHER|Placebo|Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
214871929|NCT04748523|DRUG|Mirtazapine|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
214871930|NCT04748523|DRUG|Placebo Oral Tablet|arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
214871931|NCT02958423|DEVICE|Transcranial DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers
215037626|NCT06851585|DEVICE|CathIRU Cohort|All adult patients requiring a CVP in an emergency department can participate in the study
215037627|NCT06758869|OTHER|Control|Participants will consume the Base DGA diet with a standardized non-pulse product snack.
215037628|NCT06758869|OTHER|Whole Chickpeas|Participants will consume an adjusted DGA diet with a standardized whole chickpea snack.
215037629|NCT06758869|OTHER|Puréed Chickpeas|Participants will consume an adjusted DGA diet with a standardized puréed chickpea snack.
215037630|NCT06758869|OTHER|100% Chickpea Flour Product|Participants will consume an adjusted DGA diet with a standardized 100% chickpea flour product snack.
215037631|NCT06819306|DEVICE|Hedia Diabetes Assistant|Hedia Diabetes Assistant is an insulin bolus calculator app designed to calculate an insulin bolus dose recommendation for people with type 1 or type 2 diabetes on rapid-acting insulin treatment.
214871932|NCT02958423|DEVICE|Transspinal DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers
214871933|NCT02958423|DEVICE|Transcranial DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients
214871934|NCT02958423|DEVICE|Transspinal DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
214871935|NCT06137690|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
215037632|NCT06903065|DRUG|RO7790121|Participants will be administered RO7790121 via IV infusion on Day 1, and Weeks 2, 6 and 10. Participants will then be administered RO7790121 SC injections every four weeks (Q4W) from week 14 up to and including Week 50.
215037633|NCT06898996|OTHER|Fecal immunochemical test|Detects blood in stool
215037634|NCT06903000|DEVICE|a percussion massage gun|Participants in this group will receive percussion-based vibration therapy applied using a percussion massage device (Compex Fix 2.0) with a soft head attachment. Therapy will target trapezius, levator scapula, and cervical paravertebral muscles along their origin-insertion lines for 3 minutes per muscle group.
215037635|NCT06903000|DEVICE|specially designed stainless-steel instruments|Participants will receive instrument-assisted soft tissue mobilization applied using specially designed stainless-steel instruments. Techniques (Sweep, Fan, Brush) will be applied to cervical and upper-back musculature (splenius, suboccipital, upper-middle-lower trapezius) and related fascia between C1-T1 vertebrae, parallel to muscle fibers for approximately 6 minutes per session. Each technique will consist of 8-10 repetitions.
215037636|NCT06903000|OTHER|Conventional Exercise Group (Control)|Participants in this control group will receive conventional physiotherapy treatment alone. The treatment includes heat therapy applied to the cervical region for 20 minutes, TENS application at a frequency of 100 Hz to painful areas, ROM exercises performed in all cervical directions (2 sets of 10 repetitions, 2-second holds at end-range), and isometric strengthening exercises in cervical flexion, extension, and lateral flexion directions (2 sets of 10 repetitions, 6-second holds per repetition). Sessions will take place 4 days per week for 3 weeks.
215037637|NCT05019079|OTHER|electroacupuncture|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
215057248|NCT02805465|DEVICE|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
215057249|NCT01545297|DRUG|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
214871936|NCT03866902|BEHAVIORAL|Nutrition and Physical Activity Intervention|"Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play."
214871937|NCT03866902|OTHER|English for Second Language Intervention|"Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons."
214871938|NCT04943484|PROCEDURE|imaging fluorescence NIR/ICG|"Preoperative upper GI endoscopy (UGE) UGE with submucosal injection of 2ml of ICG 0.125mg/ml solution to four peritumoral sites 15-20 hours before surgery Surgery D2 Distal gastrectomy with dissection of 1, 3, 4sb, 4sd, 5, 6, 7, 8a, 9, 11p, 12a lymph node stations (LNS) D2 Total gastrectomy with dissection of 1, 2, 3, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d, 12a LNS Intraoperative NIR/ICG technology, change of surgical conduct (CSC) A visualization of the operative field (OF) with NIR/ICG technology is performed at the beginning of surgery and before to dissect each LNS. Subsequently, surgery is performed with the naked eye.~At the end, a visualization of the OF is performed using NIR/ICG technology to verify whether residual lymph nodes in each D2 nodal station exist. CSC is defined as the occurring of the following situation: in case of persistence of nodal fluorescence in D2 nodal stations, the completion of the dissection of the residual nodal fluorescent structures."
214871939|NCT01501864|BEHAVIORAL|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
214871940|NCT06283576|DIAGNOSTIC_TEST|Liquid biopsy|"Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth"
214871941|NCT00839592|OTHER|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
215037638|NCT06924138|OTHER|Exercise|The patients included in the study will be randomly divided into two groups as the study and control groups. Randomization will be provided by a computer-aided program. The patients in the study and control groups will be evaluated at the beginning and after six weeks. Functional Respiratory Muscle Training will be given to the study group with the Powerbreathe Respironics® (UK) device. The initial training intensity will be set at 50% (threshold loading) of the MIP value measured in the patient's first evaluation. The patient will be re-evaluated and the new MIP value will be measured, increasing by 10% every 2 weeks, and the training intensity will be adjusted by calculating the measured MIP value. Patients will be asked to work four days a week until the exercise sets are completed.
215037639|NCT06924138|OTHER|Standart therapy|In the control group, the same balance exercises will be performed and will not be changed for six weeks.
215037640|NCT06900439|OTHER|Dietary Intervention|To carry out a dietary intervention using a standardized test meal where the participant's postprandial glucose to the meal is measured with a continuous glucose monitor and compared to the participant's postprandial glucose from the same standardized test meal 4 months prior.
215037641|NCT05961709|DRUG|Cemiplimab|Given by IV (vein)
215037642|NCT06747468|DRUG|Avexitide|Avexitide (also known as exendin 9-39), a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is a 31-amino acid peptide with a free amino group at the N-terminus and an amidated C-terminus. By binding to the GLP-1 receptor, avexitide inhibits GLP-1 receptor signaling, thereby reducing GLP-1 receptor-mediated insulin secretion
215037643|NCT06747468|OTHER|Placebo|Matching placebo comparator
215037644|NCT06777121|OTHER|Shoulder exercises + Thoracic extension exercise|Shoulder exercises and thoracic extension exercises were performed 5 days a week for 3 weeks.
215037645|NCT06777121|OTHER|Shoulder exercises + Thoracic kinesio taping|In addition to shoulder exercises, thoracic kinesio taping was applied. Shoulder exercises were performed 5 days a week for 3 weeks. TKT was applied once a week and remained in place for 5 days.
215037646|NCT06777121|OTHER|Shoulder exercises|Shoulder exercises were performed. They were performed 5 days a week for 3 weeks.
215037647|NCT06906926|RADIATION|Certain imaging assessments can be non-Standard of Care|Pre-Implant CT, Chest X-Ray at discharge and any related assessments during the following up visit, can be non-standard of care depending on site's / countries.
215037648|NCT01087294|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cell transplant
215037649|NCT01087294|BIOLOGICAL|Anti-CD19-chimeric-antigen-receptor-transduced T cells|"Patients receive T cells genetically engineered to express an anti-CD19 CAR. The cells are cultured in media containing IL-21, IL-7, and TWS119.~TWS119 is a glycogen synthase 3 inhibitor"
215037650|NCT01087294|PROCEDURE|Leukapheresis|Donors will undergo leukapheresis
215037651|NCT06828406|BEHAVIORAL|TeamBirth|TeamBirth
215037652|NCT07103304|OTHER|Search for activating somatic genetic mutations|"This research aims to evaluate the genetic mutations identified by liquid biopsies on the drainage vein of AVMs, and the prevalence of each mutation.~These liquid biopsies will be performed during the embolisation procedure by sampling the drainage vein of the malformation and peripheral venous blood (no additional procedures compared to standard care)."
215037653|NCT06914479|GENETIC|Ad-hCMV-Flt3L|Given via injection
215037654|NCT06914479|GENETIC|Ad-hCMV-TK|Given via injection
215037655|NCT06914479|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215037656|NCT06914479|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215037657|NCT06914479|OTHER|Survey Administration|Ancillary studies
215037658|NCT06914479|PROCEDURE|Tumor Resection|Undergo standard of care tumor resection
215037659|NCT06914479|DRUG|Valacyclovir|Given PO
215037660|NCT01400412|DRUG|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
215037661|NCT01400412|DRUG|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
215037662|NCT01400412|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
215037663|NCT01400412|DRUG|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
215037664|NCT01400412|DRUG|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
214871942|NCT04063436|DEVICE|New nasal pillows mask with PAP therapy|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
214871943|NCT04549753|DEVICE|Transcranial direct current simulation|Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
214871944|NCT01023191|PROCEDURE|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
214871945|NCT01023191|PROCEDURE|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
214871946|NCT02771886|BEHAVIORAL|Surf the Urge|"The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors."
214871947|NCT05004584|OTHER|Wheat home-based appetite assessment|Home-based appetite assessment with diet based on wheat cereal products.
214871948|NCT05004584|OTHER|Rye home-based appetite assessment|Home-based appetite assessment with diet based on rye cereal products.
214871949|NCT05004584|OTHER|Wheat clinic-based appetite assessment|Clinic-based appetite assessment with diet based on wheat cereal products.
214871950|NCT05004584|OTHER|Rye clinic-based appetite assessment|Clinic-based appetite assessment with diet based on rye cereal products.
214871951|NCT05004584|OTHER|Rye/Wheat clinic-based appetite assessment with blood sampling|Clinic-based appetite assessment with diet based on rye or wheat cereal products and continuous blood sampling.
214871952|NCT00003638|BIOLOGICAL|Detox-B adjuvant|
214871953|NCT00003638|BIOLOGICAL|THERATOPE STn-KLH vaccine|
214871954|NCT00003638|BIOLOGICAL|keyhole limpet hemocyanin|
214871955|NCT00003638|DRUG|cyclophosphamide|
214871956|NCT05060354|OTHER|Blood draw|Approximately 120 mL whole blood will be collected from each subject at each timepoint
214871957|NCT03346486|OTHER|Control diet|Regular diet
214871958|NCT03346486|OTHER|Intervention diet|Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
214871959|NCT04422782|OTHER|For each routine sample, an additional tube will be collected to measure the osmotic pressure in the blood and urine|Interventional research protocol involving the human person category 2 at risk and minimal constraints
214871960|NCT00370812|PROCEDURE|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
214871961|NCT04008654|BEHAVIORAL|ERAS Protocol|"Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
214871962|NCT04008654|BEHAVIORAL|Conventional care|This group of patients will not receive the specific ERAS protocol but will receive conventional care.
214871963|NCT03014180|DEVICE|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
214871964|NCT02416414|DEVICE|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
214871965|NCT02416414|DEVICE|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
214871966|NCT03630250|BIOLOGICAL|N. lactamica|Genetically modified N. lactamica
214871967|NCT02392351|DEVICE|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
214871968|NCT02392351|DEVICE|Renal Angiography|Percutaneous renal angiography
214871969|NCT05226546|DRUG|Platelet rich plasma (PRP)|PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
214871970|NCT05226546|OTHER|olfactory training|"The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training."
215037665|NCT01400412|DRUG|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
215037666|NCT01400412|DRUG|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
214871971|NCT03478527|DIETARY_SUPPLEMENT|Vivomixx® powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
214871972|NCT03478527|OTHER|Placebo powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
214871973|NCT02377427|DRUG|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
214871974|NCT00977886|DRUG|Placebo|Oral, 10 days
214871975|NCT00977886|DRUG|ELB353|Oral, 10 days
215037667|NCT06821542|DRUG|INCA034176|IV infusion
214871976|NCT02804711|BIOLOGICAL|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)|
214871977|NCT02804711|BIOLOGICAL|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)|
214871978|NCT02804711|BIOLOGICAL|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)|
214871979|NCT02804711|BIOLOGICAL|Placebo|
214871980|NCT02318238|OTHER|6 minutes walking test|
214871981|NCT02318238|OTHER|6 minutes step test|
214871982|NCT02318238|OTHER|4 meters gait speed|
214871983|NCT00810576|DRUG|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
215037668|NCT06821542|DRUG|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
215037669|NCT06758505|BEHAVIORAL|Strategy Training Only|Participants will receive ten 45-60-minute sessions (two times per week) in person in their residence to address real-world performance with an emphasis on START strategy, task-specific practice, and guided discovery to perform social participation activities. In session 1, participants will be guided to select 3 to 5 meaningful social activities and prioritize them. In sessions 2 - 9, participants will use structured START strategy worksheet to try the selected activity; assess execution (e.g., what went well, what did not); reflect on a plan with specific strategies and to address identified challenges; and try social participation activities again. The interventionist will use guided discovery to support START strategy application and to elicit problem solving skills. This process will be repeated iteratively across sessions. In session 10, participants will summarize lessons learned and generate an action plan for after the intervention.
215037670|NCT06758505|BEHAVIORAL|Strategy Training embedded with Acceptance and Commitment Therapy Principles|"Participants will receive ten 45-60-minute sessions (two times per week) in person in their residence to address real-world performance with task-specific practice and an emphasis on psychological processes using ACT principles. In session 1, participants will clarify value-consistent social participation goals for engaging in 3-5 meaningful activities (Do What Matters). In sessions 2-9, participants will be guided applying ACT principles to cope with negative experiences and separate self from thoughts and feelings (Open Up) and practice mindfulness, stimulate awareness, recognize same person with different experiences, and build self-compassion (Be Present). This process (i.e., try an activity that aligns with values and committed actions; assess performance; and reflect on a plan) will be repeated iteratively. In session 10, participants reflect on lessons learned and generate an action plan for after the intervention."
214871984|NCT00810576|DRUG|Bortezomib|Dose of 1.3 mg/m\^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
214871985|NCT02832180|DRUG|OC containing EE and NET|
214871986|NCT02832180|DRUG|BMS-986142|
214871987|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
214871988|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
215037671|NCT07139626|OTHER|This is an observational Study.|This is an observational study with no study-assigned interventions.Only observational measurements (blood collection for biomarker analysis) will be performed without modifying existing treatments.
215037672|NCT07141134|DEVICE|TAPAM|Device: Turn-Assist Alternating Pressure Air Mattress (TAPAM) Automated lateral turning with pressure redistribution.
215037673|NCT07141134|DEVICE|HSFM|Device: High-Specification Foam Mattress (HSFM) Standard ICU care support surface.
215037674|NCT07141134|OTHER|Manual Turning (with pillows, per protocol)|Nurse-performed scheduled manual turning (target every 2 hours, with pillows).
215037675|NCT07141134|OTHER|Positioning Pillows|Supplemental pillows used to support and maintain patient position.
215037676|NCT07119281|PROCEDURE|Group A: Cordless paste with astringent (EXP): Expasyl (Acteon PVT LTD)|Chemical gingival retraction method
215037677|NCT07119281|PROCEDURE|Group B: Cordless paste without astringent (MF): Magic FoamCord (Coltene Whaledent AG)|Chemical gingival retraction method
215037678|NCT07119281|PROCEDURE|Group C: Laser troughing (LT): Diode laser (iLase; Biolase Inc.)|Gingival retraction will be performed by using only laser. Cord will not be used.
215037679|NCT07119281|PROCEDURE|Group D: Retraction cord with astringent (RCA; Control group): Knitted cord impregnated with aluminum chloride (Ultrapak + Viscostat Clear; Ultradent Inc.)|Mechanical and chemical gingival retraction method will be used.
215057250|NCT01545297|DRUG|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
214670061|NCT03445039|PROCEDURE|bone grafting materials|The bone substitute is placed into the siuns under the membrane before the implant placement
214871989|NCT00506584|DIETARY_SUPPLEMENT|Human milk fortifier (bovine-based), pre-term formula|Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
214871990|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
214871991|NCT00506584|DIETARY_SUPPLEMENT|Pre-term/term formula|Bovine milk-derived nutrition formulated for very low birth weight infants
214871992|NCT04274231|GENETIC|different effection|Analysis of the reasons for treatment
214871993|NCT02819700|BEHAVIORAL|prevalence of behavioural dysexecutive syndrome|Behavioural Dysexecutive Syndrome Inventory (ISDC)
214871994|NCT05233930|PROCEDURE|TKR with augmented reality-based navigation system|Surgery
214871995|NCT05233930|PROCEDURE|TKR with traditional mechanically aligned technique|As per local practice and standard guidelines.
214871996|NCT06841822|OTHER|SCTL superficial plane block|The purpose of this study was to evaluate whether thoracic paravertebral nerve block performed on superficial SCTL (puncture needle did not break SCTL) was more beneficial to maintaining hemodynamic stability during the induction period of thoracoscopic lobectomy compared with SCTL deep plane (puncture needle break SCTL). We performed an ultrasound-guided paravertebral nerve block while keeping the puncture needle did nit to break through the SCTL. In 20 patients who required CT (3D) imaging to observe drug diffusion 30min after nerve block, cold stimulation was used 30min after the procedure to assess the degree of sensory loss, including the anterior chest wall (midclavian line), lateral chest wall (posterior axillary line), and posterior chest wall (paravertebral area).
214871997|NCT06841822|OTHER|SCTL deep plane block group|Ultrasound-guided thoracic paravertebral nerve block was routinely performed. SCTL was broken by a puncture needle during the ultrasound-guided thoracic paravertebral block. In 20 patients who required CT (3D) imaging to observe drug diffusion 30min after nerve block, cold stimulation was used 30min after the procedure to assess the degree of sensory loss, including the anterior chest wall (midclavian line), lateral chest wall (posterior axillary line), and posterior chest wall (paravertebral area).
214871998|NCT00596037|DRUG|Growth hormone - LB03002|
214665852|NCT06469970|DRUG|Glucose 30% Intravenous Solution|"Measurement of IDVG on admission, at 4 hours (H+4), and at 8, 16, 24, 48, 72 and 96 hours (H+8, H+16, H+24, H+48, H+72 and H+96) post-burn. The principle of this measurement consists of taking a reference blood glucose level measured on an arterial blood sample (arterial catheter) using a blood glucose meter. A bolus of 5g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection.~The intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW) are measured using the PiCCO device as part of the usual management of burn patients."
214871999|NCT06830044|DRUG|Milsaperidone|Oral milsaperidone
215037680|NCT07119762|OTHER|Pilates sections|This intervention combines Pilates with dual-task training over 20 weeks, featuring twice-weekly 60-minute sessions at moderate to vigorous intensity. It is uniquely grounded in methods from the Polestar and PhysicalMind schools and adapted for older adults (≥65 years), utilizing chairs, elastic bands, and minimal equipment. Unlike typical exercise programs, this protocol integrates cognitive tasks within Pilates exercises to simultaneously challenge physical and executive functions. Exercise intensity is individualized using heart rate monitors and the Borg scale. Assessments include trunk strength (Biodex System 4), balance (Biodex SD), and cognitive function (MoCA, Stroop, WAIS-III, TMT), making it one of the few trials to rigorously evaluate physical, cognitive, and dual-task performance outcomes in older adults. This approach is low-cost, scalable, and focused on fall prevention and autonomy maintenance.
214872000|NCT06830044|DRUG|Placebo|Oral placebo
214872001|NCT00704730|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
215037681|NCT06940141|COMBINATION_PRODUCT|Rademikibart in prefilled syringe|Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
215037682|NCT06940141|DRUG|Matching placebo in prefilled syringe|Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
215037683|NCT07143396|BEHAVIORAL|Mind-body mobile application and guided movement|Self-directed: The study team recommends daily use of the mobile app for 6 weeks, with a minimum of 4 times per week, and engagement with the somatic education program at least 3 times per week for 6 weeks. Frequency of app usage and somatic education engagement will be monitored via weekly surveys.
215037684|NCT06942689|DRUG|Perform adductor canal block with liposomal bupivacaine.|"Patient Positioning: Supine with the surgical limb slightly flexed and externally rotated.~Operator Setup: The operator stands on the surgical side, with the ultrasound machine positioned contralaterally. The anterior thigh is sterilized and draped.~Ultrasound Technique: A high-frequency (5-12 MHz) linear ultrasound probe (Sonosite M-Turbo), protected by a 3M Tegaderm dressing, is placed perpendicular to the skin at the midpoint between the femoral trochanter and the superior patellar margin. The probe is maneuvered to visualize the adductor canal structures.~Needle Insertion: After local anesthesia at the insertion site, a 22G 80 mm needle is advanced using an in-plane technique until the tip reaches the triangular hypoechoic area lateral to the femoral artery. Following negative aspiration for blood, 1.33% liposomal bupivacaine is injected around the target site."
215037685|NCT06952010|BIOLOGICAL|XB628|Intravenous infusion(s)
215037686|NCT07149597|RADIATION|Mobile CBCT Three-Dimensional Scanning|Mobile CBCT Three-Dimensional Scanning
215037687|NCT07161531|DIAGNOSTIC_TEST|Surface Electromyography|The primary lower limb muscles to be monitored include the gluteus medius, rectus femoris, vastus lateralis (quadriceps ), biceps femoris (hamstrings), tibialis anterior, and gastrocnemius medialis (calves). This setup fully utilizes a 16-channel sEMG system by monitoring each muscle group bilaterally to capture comprehensive data on muscle activity and fatigue.
215037688|NCT07159217|DRUG|Disitamab Vedotin|2.0 mg/kg administered intravenously every three weeks
215037689|NCT07159217|DRUG|Lenvatinib|≥60 kg: 12 mg once daily, or \<60 kg: 8 mg once daily
215037690|NCT07159217|DRUG|Pembrolizumab|200 mg intravenously every three weeks
215037691|NCT07159217|DRUG|Toripalimab|240 mg intravenously every three weeks
215037692|NCT07159217|DRUG|Camrelizumab|200 mg intravenously every three weeks
214872002|NCT00704730|DRUG|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
215037693|NCT07160283|DRUG|Bile duct cancer cohort|"Trilaciclib: 240 mg/m², administered via intravenous infusion over 30 minutes, completed within 4 hours prior to chemotherapy on the same day.~Chemotherapy Agents: Investigators will select chemotherapy regimens based on individual patient status. Regimens must be single-day protocols (including but not limited to gemcitabine, nab-paclitaxel, etc.), with dosing and administration per prescribing information.~Subjects receiving concomitant immunotherapy or targeted therapy in addition to chemotherapy are eligible for enrollment."
215037694|NCT07160283|DRUG|Pancreatic cancer cohort|"rilaciclib: 240 mg/m², administered via intravenous infusion over 30 minutes, completed within 4 hours prior to chemotherapy on the same day.~Chemotherapy Agents: Investigators will select chemotherapy regimens based on individual patient status. Regimens must be single-day protocols (including but not limited to gemcitabine, nab-paclitaxel, etc.), with dosing and administration per prescribing information.~Subjects receiving concomitant immunotherapy or targeted therapy in addition to chemotherapy are eligible for enrollment."
215037695|NCT07160751|OTHER|Self-questionnaire|FACT-Cog, HADS, FA12, EPICES, socio-professional and socio-demographic questionnaire
214872003|NCT06913153|BEHAVIORAL|Diet|
214872004|NCT05345613|DRUG|Tranexamic acid|Submucosal injection of standard solution including TXA during EMR procedure
214872005|NCT05345613|DRUG|Standard|Injection of standard solution
214872006|NCT06937294|DRUG|Metformin|Participants are administered metformin with an initial dose of 500 mg/day, which was incrementally increased by 500 mg/day each week until the maximum tolerated dose. The maximum dose of metformin is set at 2000 mg/day.
214872007|NCT06937294|DRUG|Placebo|Participants are administered a placebo, starting with one tablet per day, followed by an incremental increase of one tablet per week. In the absence of adverse reactions, the dosage is escalated up to a maximum of four tablets per day.
214872008|NCT06943196|OTHER|Structured physical activity break|"The structured physical activity breaks in classroom will include 5-30 minutes physical activities sequenced as: Week 1,4,7: 5-mintue stretch break, 5-minute marching in place, 30-sec jumping an invisible rope, 30-sec Flap arms like a bird, 5-minute mirror each other's actions and guess, 5-minute hop on one foot/ jump on both feet, draw on board, guess the color, make a circle and play a game of throw a ball in class. Week 2,5,8: 5-minute stretch break, 2-3 laps throughout the classroom, jumping in and out a circle on command, rock-paper-scissors-jump, paint or sketch on book, guess the animal, up-down-stop-go opposites, make a circle and play a game of throw a ball and clap in class.~Week 3,6: 5-minute stretch break, 30-sec balance on one foot, 30-sec hopping, 5-jumping jacks, 5-claps turn around and guess the shape, play a game on board or notebook, make a circle and play a game of throw a ball and jump in class."
214872009|NCT03173638|PROCEDURE|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
214872010|NCT04401865|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
214872011|NCT06955065|OTHER|battle rope training|Battle rope training is a dynamic, high-intensity exercise involving heavy ropes to improve strength, endurance, and coordination. It primarily targets the upper body, including the shoulders, arms, and core, through rhythmic, wave-like movements. This training is adaptable and effective for enhancing functional fitness in both general and adaptive athletes.
215037696|NCT07160751|OTHER|Cognitive tests|Hopkins Verbal Learning Test (HVLT). Trail Making Test (TMT). Verbal fluency test. Digit memory WAIS-IV.
215037697|NCT07160751|OTHER|Assessment of the impact of social vulnerability on patient complaints|EPICES at month 12
214872012|NCT06955065|OTHER|Bocce Throwing|Participants in the control group will engage in regular bocce training sessions as per their usual routine. These sessions will focus on standard bocce drills and techniques without additional battle rope exercise. A warm- up activity used in every training session and a proper warm-up should include Aerobic activity and Dynamic stretching . 15 to 20 repetitions of each exercise.
215037698|NCT07159152|DIETARY_SUPPLEMENT|Coffee|Participants will consume 3 cups of Arabica coffee (Guatemalan origin), providing a total of 400 mg of caffeine. Each cup is prepared with 6% coffee grounds per 100 mL of water, brewed at 90°C for 6 minutes using an electric drip coffee maker, yielding 100.8 mg caffeine per 100 mL. Immediately following coffee consumption, participants will engage in uninterrupted sitting for 3 hours. Blood pressure, heart rate, and other study questionnaires will be measured at baseline (before coffee), 1 hour after coffee intake, and hourly during the 3-hour sitting period.
214665853|NCT05067777|PROCEDURE|Massage Therapy|Receive SMT
214872013|NCT01447277|PROCEDURE|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
215037699|NCT07159152|DIETARY_SUPPLEMENT|Hibiscus drink|Participants will consume 3 servings of hibiscus leaves tea per day, each serving containing 1.25 g of dried hibiscus leaves, totaling 3.75 g per session. The tea will be prepared by steeping the leaves in 240 mL of boiling water (100°C) for 10 minutes. Immediately after consuming the hibiscus tea, participants will engage in uninterrupted sitting for 3 hours. Blood pressure, heart rate, and other study questionnaires will be measured at baseline (before tea), 1 hour after tea intake, and hourly during the 3-hour sitting.
215037700|NCT07160920|OTHER|Collect clinical data of pregnant women|Collect clinical data of pregnant women
215037701|NCT07159906|DRUG|Homoharringtonine|A cephalotaxine alkaloid and protein synthesis inhibitor that downregulates Myeloid Cell Leukemia 1 (MCL-1), administered intravenously in 21-day cycles. Dose escalation in Phase Ib will determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase II dose (RP2D).
215037702|NCT07159906|DRUG|BCL-2 inhibitor|An oral selective BCL2 inhibitor administered once daily D1-7. Combined with homoharringtonine, rituximab, and prednisone in 21-day cycles.
215037703|NCT07159906|DRUG|CD20 Antibody|An anti-CD20 monoclonal antibody administered intravenously, used in combination with chemotherapy or targeted regimens for B-cell malignancies.
215037704|NCT07159906|DRUG|Glucocorticoid (GC)|glucocorticoid , given as part of the combination regimen to enhance anti-lymphoma effect.
215037705|NCT07160803|OTHER|Intervention Program for Social Network Use Based on Activity Theory|The intervention program is structured around a three - phase framework for migrant elderly's social network use: ① triggering motivation and building basic capabilities; ② reinforcing motivation and enhancing advanced capabilities; ③ sustaining motivation and maintaining usage habits. The process involves assessing baseline status (via scales like ASNSUS, eHEALS), implementing phased interventions (teaching WeChat skills, facilitating social connections), and evaluating effectiveness (process and outcome evaluations). The 12 - week program is executed by a team including researchers, community workers, and elderly volunteers.
215037706|NCT07160803|OTHER|Routine community activities only|After receiving regular community services and management, and understanding the overall situation and needs of the intervention targets, researchers and community managers will conduct a weekly health lecture, an offline social activity involving local elderly people (such as fitness, cultural and entertainment activities, etc.), or a lecture on policies and welfare related to migrant elderly people, etc., and regularly distribute relevant paper materials.
214665854|NCT05067777|OTHER|Questionnaire Administration|Ancillary studies
214665855|NCT05067777|PROCEDURE|Sham Intervention|Receive light touch control procedure
215057251|NCT01545297|DRUG|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
214670062|NCT03445039|DEVICE|TSFE by DASK drills|The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.
214872014|NCT01447277|PROCEDURE|Femoral Block only|Performing a preoperative sciatic nerve block only
214872015|NCT02297399|DRUG|PEG-ascorbate 2L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
214872016|NCT02297399|DRUG|PEG 4L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
214872017|NCT01523457|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
214872018|NCT01143766|DRUG|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
215037707|NCT07161492|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Individualized dual-target rTMS delivered using MRI-guided neuronavigation (Dolphin Robotics). Stimulation parameters:~* Targets: Left IPL and right dPFC connectivity hotspots~* Protocol: 100 pulse-pairs/session at 0.2Hz~* Intensities: Conditioning stimulus 90% RMT, test stimulus 120% RMT~* Duration: 8.3 min/session, 5 sessions/week × 4 weeks"
215037708|NCT07161492|BEHAVIORAL|Computerized Cognitive Remediation Therapy|Structured computer-based training targeting cognitive flexibility, consisting of 4-6 exercises per session. Each exercise includes 8-24 progressively challenging tasks. Administered for 45-60 minutes per session, 5 sessions/week over 4 weeks. Delivered via specialized software on desktop computers.
215037709|NCT07161492|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|"Inactive stimulation using identical equipment with:~* Coil tilted at 90° to scalp~* Magnetic shielding insert~* Matched acoustic artifact All other parameters identical to active rTMS arm."
215037710|NCT07161492|DRUG|Selective Serotonin Reuptake Inhibitors or Serotonin-Norepinephrine Reuptake Inhibitors|"Background antidepressant therapy maintained at stable doses throughout the study. Minimum dose requirements:~* SSRIs: Paroxetine ≥20mg/day, Sertraline ≥50mg/day~* SNRIs: Venlafaxine ≥75mg/day, Duloxetine ≥60mg/day Dosage adjustments prohibited during trial participation."
215037711|NCT07159334|DRUG|Lignocaine Ointment|Applied to the anal wound three time daily after hemorrhoidectomy.
215037712|NCT07159334|DRUG|Glyceryl Trinitrate Ointment 0.2%|Applied to the anal wound three time daily after hemorrhoidectomy.
215037713|NCT07160465|OTHER|emma application|"1. Emma will allow the patient to spontaneously contact the VigilanS tele-clinician team via a simple and quick access (when the patient presses an ergonomic button with the VigilanS logo). He can also contact the National Service for Suicide Prevention (3114) or the French national emergency medical assistance service 24/7 (Samu).~2. Experts of the field have defined response thresholds for targeted questions on suicide risk and emotional tension. If the patient's answers to these questions reach these thresholds, emma will automatically send a message to the nearest VigilanS center. In this case, a message will appear indicating to the patient that the nearest center will contact him as soon as possible, encourage him to review his strategies and resources available on the app's Home and direct him to the breathing space.~3. Emma offers a Safety Plan module that will allow the patient to help him/her to put into practice what he/she will develop with the VigilanS team on a daily bas"
215037714|NCT07160504|DRUG|Vaginal estradiol tablets|Vaginal estrogen tablets 10 µg at least 3 times a week (on indication, prescribed at the outpatient clinic).
215037715|NCT07160634|DRUG|SGT-003|Adeno-associated virus (AAV)-based gene therapy that delivers a codon-optimized and CpG island-minimized human 5-repeat microdystrophin (h-μD5)
215037716|NCT07160634|DRUG|Placebo|IV infusion
215037717|NCT07159633|BEHAVIORAL|Online Couple Intervention|The OurRelationship program is approximately 8-10 hours of online content and will delivered over the course of 5-8 weeks. For the current study, we have tailored the general OurRelationship content for couples in recovery from substance misuse. For example, all users receive informational material on the nature of addition and recovery. All of the videos in the adapted program depict couples struggling with recovery-related issues. Additionally, the assessments and feedback content has been tailored. In addition to the online content, couples receive up to 100 minutes of scheduled coach Zoom calls (up to five 20-minute calls).
215037718|NCT07158853|DEVICE|Transcranial Direct Current Stimulation (tDCS)|We will deliver 2-mA tDCS current intensity during a 30 minute stimulation period (including a 30-second ramp-up and 30-second ramp-down period) to the dorsolateral prefrontal cortex. Electrodes will be fixed on marked locations based on the 10-20 EEG system. Anodal stimulating electrode will be over the left DLPFC (F3) and cathodal electrode over the right DLPFC (F4).
215037719|NCT07158853|DEVICE|Sham Stimulation|electrodes will have the same montage as active tDCS (F3/F4), but current will be ramped down after the initial 30 seconds ramp-up period. Thus, participants will feel the initial sensation associated with tDCS but will receive no active current for the rest of the stimulation period.
215037720|NCT07159620|DRUG|VEN (Venetoclax)|Orally
215037721|NCT07159620|DRUG|Azacitidine (AZA)|Subcutaneous injection
215037722|NCT07159620|DRUG|Chidamide|Orally
214872019|NCT01143766|OTHER|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
214872020|NCT01499459|GENETIC|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
215037723|NCT07159620|DRUG|vindesine|intravenous infusion
215037724|NCT07159620|DRUG|Dexamethasone|intravenous infusion or orally
215057252|NCT03051295|OTHER|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
215057253|NCT03851627|DRUG|Testosterone Undecanoate|1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter
214670063|NCT03445039|PROCEDURE|without bone grafting materials|The bone substitute will not be placed into the sinus before the implant placement.
215057254|NCT03851627|DRUG|Placebo|Placebo Arm
214872021|NCT01291394|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
214872022|NCT01886196|DRUG|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
214872023|NCT01886196|OTHER|placebo|placebo designed to mimic experimental drug (ibuprofen)
214872024|NCT01886196|BEHAVIORAL|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
214872025|NCT01886196|BEHAVIORAL|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
214872026|NCT05443568|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214872027|NCT00357253|DRUG|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
214872028|NCT00357253|RADIATION|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
214872029|NCT02897245|OTHER|No intervention|
214872030|NCT03251339|DRUG|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
214872031|NCT03251339|DRUG|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
214872032|NCT00315887|DRUG|Buprenorphine transdermal delivery system|
214872033|NCT00004137|BIOLOGICAL|filgrastim|
214872034|NCT00004137|DRUG|carboplatin|
214872035|NCT00004137|DRUG|paclitaxel|
214872036|NCT00004137|DRUG|topotecan hydrochloride|
214872037|NCT01345578|DRUG|human hepatocyte transplantation|"Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.~The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.~If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation."
214872038|NCT01345578|RADIATION|Preparative Radiation Therapy|Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
214872039|NCT05746598|DRUG|Cisplatin injection|Cisplatin 75mg/m2
214872040|NCT04556071|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight\<77 kg and/or basal platelet count \<150,000/μL will take 200 mg daily.
214872041|NCT04556071|DRUG|Bevacizumab|The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
214872042|NCT00009815|DRUG|etoposide|
214872043|NCT00009815|DRUG|leucovorin calcium|
214872044|NCT00009815|DRUG|tegafur-uracil|
214872045|NCT03980574|DIETARY_SUPPLEMENT|R Drink|R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.
214872046|NCT04123626|DRUG|QR-1123|unilateral IVT injection
214872047|NCT04123626|OTHER|Sham procedure|Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
214872048|NCT01129687|PROCEDURE|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
214872049|NCT01129687|PROCEDURE|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
214872050|NCT03035929|DRUG|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
214872051|NCT02886624|DRUG|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
214872052|NCT04949360|BEHAVIORAL|Online Cognitive-Behavioral Therapy for Insomnia and complementary therapies|The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.
214872053|NCT04949360|BEHAVIORAL|Regular Cognitive Behavioural Therapy for Insomnia|This is the gold standard behavioral treatment for insomnia and will be performed by independent board-certified sleep psychologists. The treatments will last eight weeks and the appointments will be made by video-calls.
214872054|NCT04949360|BEHAVIORAL|Sleep hygiene - minimal intervention|It is composed by educational material about normal sleep pattern and sleep hygiene. It will be delivered by SleepUp app.
215037725|NCT07159100|DEVICE|Active tDCS + elbow flexion exercise|"Participants will receive anodal tDCS targeting motor-related cortical areas using either traditional sponge-based or high-definition (HD)-tDCS configurations. The intervention is delivered at 1.5-2.0 mA for 20-30 minutes, either before or during a sustained submaximal isometric contraction task designed to induce fatigue.~tDCS will be administered in a counterbalanced crossover design, where each participant completes both active stimulation and sham stimulation conditions in separate sessions spaced at least one week apart. Sham stimulation mimics the sensory effects of active tDCS (30-second ramp-up and down) without delivering sustained current.~The intervention is unique as the target population is cancer survivors with persistent fatigue \>6 months post-treatment. Also, the tDCS is combined with neurophysiological assessments, including EMG, TMS, EEG, and MRI, to provide neurophysiological evidence of acute effects."
215037726|NCT07159100|DRUG|Sham tDCS + elbow flexion exercise|"Participants will receive anodal tDCS targeting motor-related cortical areas using either traditional sponge-based or high-definition (HD)-tDCS configurations. The intervention is delivered at 1.5-2.0 mA for 30 seconds to mimic the sensation of active tDCS (20 minutes long), either before or during a sustained submaximal isometric contraction task designed to induce fatigue.~tDCS will be administered in a counterbalanced crossover design, where each participant completes both active stimulation and sham stimulation conditions in separate sessions spaced at least one week apart. Sham stimulation mimics the sensory effects of active tDCS (30-second ramp-up and down) without delivering sustained current."
215037727|NCT07159724|DEVICE|back up, mollii-suit, compex, tens|"In order to be included in this study, individuals must have undergone at least one session of treatment with a biomedical device.~In the validity and reliability study of the Turkish version of the questionnaire, permission was first obtained from the questionnaire's author via e-mail. The Usefulness, Satisfaction and Ease of Use Questionnaire (USE) was translated from English into Turkish by two independent translators: one was a physiotherapist with a doctoral degree, and the other a faculty member at Hacettepe University School of Foreign Languages. Both translators were native Turkish speakers, fluent in English, and had no personal or professional interaction with each other. They evaluated the original questionnaire in terms of meaning and grammar to produce the Turkish version of the Usefulness, Satisfaction and Ease of Use Questionnaire (USE).~The independently translated Turkish versions of the questionnaire were then reviewed by an expert panel to reach consensus. This exp"
215037728|NCT07160790|DRUG|JP-1366 + placebo|taking JP-1366 + placebo
215037729|NCT07160790|DRUG|Placebo + Placebo|taking placebo + placebo
215037730|NCT07161154|DEVICE|Transcutaneous bone conduction hearing system|The Sentio system is an active transcutaneous bone conduction hearing system (single armed study)
215037731|NCT07160114|DEVICE|Electrical Stimulation Glove with Task-Oriented Training|Participants perform structured task-oriented training while wearing an electrical stimulation glove. The glove is embedded with electrodes that deliver low-intensity electrical impulses to the wrist and finger muscles during functional tasks. Training includes warm-up range of motion and stretching, 40 minutes of functional activities such as pegboard tasks, object manipulation, writing, and daily living tasks, followed by cool-down exercises. The intervention is delivered in 60-minute sessions, three times per week, for 8 weeks.
215037732|NCT07160114|BEHAVIORAL|Task-Oriented Training Only|Participants receive task-oriented training without the electrical stimulation glove. Training includes warm-up range of motion and stretching, 40 minutes of functional activities such as pegboard placement, grasp-and-release, writing or drawing, and simulated daily living tasks, followed by cool-down exercises. The intervention is delivered in 60-minute sessions, three times per week, for 8 weeks.
215037733|NCT07160049|DEVICE|Cold Pressor Task - Upper Limb|"This study uses a three-session cold pressor paradigm to evaluate feasibility of a wearable focused ultrasound (FUS) device for peripheral nerve stimulation.~Session 1 (Baseline): After consent, participants immerse the dominant hand in 0-1 °C water (\~10 cm depth) in an insulated bucket. Time to first pain is recorded, with 5 min rests between immersions (12 total; max single immersion 6 min). Water temperature is digitally monitored, with ice added as needed.~Session 2 (Sham): The median/ulnar/radial nerve in the dominant forearm is located by ultrasound. The FUS device is applied with hydrogel but set to sham (no output). The cold pressor protocol is repeated.~Session 3 (Active FUS): After nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The cold pressor test is repeated to record pain tolerance as an exploratory physiological response during feasibility testing."
214872055|NCT05496244|DEVICE|Laparoscopy|Laparoscopic surgery
214872056|NCT05496244|DEVICE|Robotic-assisted surgery|Robotic-assisted surgery
214872057|NCT05326282|DIAGNOSTIC_TEST|Multi-parametric ultrasound|Diagnostic ultrasound parameters used to evaluate the prostate. Transrectal scans will be performed
214872058|NCT01704274|OTHER|Low Dose GTN 0.0285 mg/hr|Low Dose GTN
214872059|NCT01704274|OTHER|High Dose GTN 0.057 mg/hr|High Dose GTN
214872060|NCT01704274|OTHER|Placebo|Placebo
214872061|NCT01386255|DRUG|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
214872062|NCT01386255|DRUG|placebo|placebo. No other names
214872063|NCT01235481|DEVICE|Exercise DVD|Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation
214872064|NCT01235481|BEHAVIORAL|Usual Care|Usual care during maintenance phase post pulmonary rehabilitation
214670064|NCT03626467|BIOLOGICAL|HPV9v|Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24
214872065|NCT02466841|PROCEDURE|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
214670065|NCT04763382|OTHER|experimental group: Training of caregivers|Pre-test, post-test, retention test, education, guide booklet delivery, android application installation and urinalysis
214670066|NCT04763382|OTHER|Control gruop|Pre-test, post-test and urinalysis
214670067|NCT00053612|DRUG|Vitamin A|
214670068|NCT04681664|OTHER|High fat diet|50 % fat
214872066|NCT00438061|BEHAVIORAL|Weight loss by dietary restriction|
214872067|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase I|"Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
214872068|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase I|"Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
215037734|NCT07160049|DEVICE|Algometry Pain Tests in the Upper Limb|"This session records pressure pain thresholds in the dominant hand with a wearable FUS device and a pressure algometer during feasibility testing.~Session 1 (Baseline): After consent and briefing, the median, ulnar, and radial nerves at three points on the dominant hand (wrist, palm, finger) are located via ultrasound and marked. A pressure algometer is applied to each site, with pressure gradually increased until pain is first reported. Thresholds are recorded, with each location tested three times with short breaks.~Session 2 (Sham): The same nerve sites are identified and marked. The wearable FUS device is applied with hydrogel but set to sham (no active output). The baseline algometry protocol is repeated.~Session 3 (Active FUS): Following nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The algometry test is repeated to record pressure pain thresholds as exploratory physiological responses during feasibility testing."
215037735|NCT07160049|DEVICE|Algometry Pain Tests in the Lower Limb|"This session records pressure pain thresholds in the dominant foot with a wearable FUS device and a pressure algometer during feasibility testing.~Session 1 (Baseline): After consent and briefing, the tibial, saphenous, and peroneal nerves at three standardized points on the dominant foot are located via ultrasound and marked. A pressure algometer is applied to each site, and pressure is gradually increased until pain is first reported. Thresholds are recorded, with repeated trials and short breaks between tests.~Session 2 (Sham): The same nerve sites are identified and marked. The wearable FUS device is applied with hydrogel but set to sham (no active output). The baseline algometry protocol is repeated.~Session 3 (Active FUS): Following nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The algometry test is then repeated to record pressure pain thresholds as exploratory physiological responses during feasibility testing."
215037736|NCT07161128|PROCEDURE|arthroscopic microfracture and biological scaffold implementation for osteochondral defects of talus|"All enrolled patients will undergo a standardized single-stage arthroscopic procedure under spinal or general anesthesia with the patient supine and the ankle placed in appropriated position. Standard anteromedial and anterolateral portals are established. The talar osteochondral defect is inspected, measured, and any unstable cartilage is sharply débrided to create stable vertical walls, exposing healthy subchondral bone. Using a 1.0- to 1.2-mm awl, multiple perforations are made perpendicular to the lesion base, 3-4 mm apart and \~2-4 mm deep, until uniform marrow fat-bleeding is observed-mobilizing mesenchymal stem cells .A sterile, resorbable, type-I/III collagen bilayer scaffold is trimmed to the exact defect footprint using a template fashioned intra-operatively."
215037737|NCT07161206|BEHAVIORAL|Digital Mindfulness Nudge Intervention|Participants will be guided through 28 Days of Mindfulness Exercises via a Telegram Channel (In a digital and nudge-based format)
215037738|NCT07158606|DRUG|efanesoctacog alpha|Efanesoctacog alpha will be administered at a dose of 50 IU/kg two times weekly during the ITI Treatment Period. The site investigator will determine the dose of efanesoctacog alpha once the subjects reaches the Follow Up Period.
215037739|NCT07158606|DRUG|Emicizumab|Emicizumab will be prescribed as standard of care bleed prevention.
214872069|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase II|Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
214872070|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase II|"Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent"
214872071|NCT06626464|DRUG|[14C]MK-8189|Oral administration
214872072|NCT06490679|PROCEDURE|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥7 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
214872073|NCT06490679|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"(a) Disclosure of biofilm with erythrosine, (b) Removal of supragingival and subgingival (up to 10 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS-Dental, Nyon Switzerland).~(c) Supra- and sub-gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
214872074|NCT03168230|PROCEDURE|Portal vein embolization (PVE)|"Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx"
214872075|NCT00362466|DRUG|Dasatinib|Tablets, Oral, Once daily, 5-7 years
214872076|NCT00362466|DRUG|Imatinib|Tablets, Oral, Once daily, 5-7 years
214872077|NCT04604340|PROCEDURE|transradial access for neuroangiography|The choice of right vs left radial artery approach would be determined by the vessels that require the highest quality of imaging (e.g. if the left vertebral artery is key to diagnosis, a left radial approach would be chosen, otherwise a right radial approach would be likely most appropriate) - this decision is at the discretion of the interventionist.
214872078|NCT04604340|PROCEDURE|transfemoral access for neuroangiography|By convention, femoral access will be obtained on the right side, unless there is overlying disease or vessel abnormality detected by ultrasound/Doppler, as is usual clinical practice.
214665856|NCT05634512|DRUG|Laronidase therapy and a stem cell transplant|To identify key differences leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH. There will be 12 samples per patient (6 pre-transplant and 6-post-transplant). Laronidase will be administered IV per protocol using standard dosing (0.58 mg/kg intravenously on a weekly basis), and six (n=6) blood samples will be collected over 24 hours for the determination of mononuclear cell lysates and plasma laronidase concentrations for a total of 18mL. The second PK monitoring will be obtained using the same PK design but following complete or near-completedonor derived myeloid engraftment which is evaluated at different time pointspost-HCT (day 30, day 42, day 60). The standard is to continue ERT through 8 weeks post-transplant.
214872079|NCT06151769|OTHER|topical pomegranate seed oil|Intervention groups: In addition to the routine care of the patients, Pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days. The patient follow-up form will be completed by the researcher every day at 12:00 noon. Again, on the 6th day of the application, evaluation surveys with the Braden risk assessment scale will be conducted by the researcher.
214872080|NCT06151769|OTHER|Sesame oil|Sesame oil
214872081|NCT00757211|GENETIC|polymorphism analysis|
214872082|NCT00757211|OTHER|laboratory biomarker analysis|
214665857|NCT05614219|OTHER|Biochemistry interpretive comment on elevated LDL-C levels|The interpretive comment on LDL-C will encourage for excluding secondary dyslipidemia (measuring Hba1C, TSH and checking current drugs and talk about diet). If secondary dyslipidemia ca be excluded we encourage to referral to lipid clinic. Familial hypercholesterolemia should be suspected if LDL-C \> 4 mmol/L in persons under the age of 40, or LDL-C \> 5 mmol/L in persons over the age of 40. The biochemistry interpretive comment will thus be released to the referring physician if the blood sample meet the criteria above. We advice that in pregnant women to control elevated LDL-C after childbirth.
214872083|NCT00757211|OTHER|questionnaire administration|
214872084|NCT06633705|DRUG|Vaginal Cream with Applicator|Vaginal Cream that contains estriol (1mg estriol in 1 g cream)
214872085|NCT00336076|OTHER|Collection of blood and bone marrow|5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
214872086|NCT06178003|BIOLOGICAL|Tpdelansbsalbac|Tpdelansbsalbac,which is Knockdown of ansB, a gene that expresses L-mentholase secreted into the extracellular region, on the basis of the genetic background of bacterium VNP20009, and construction of an ansB gene-deficient mutant strain, ΔansB.
214872087|NCT03335826|PROCEDURE|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia.
215037740|NCT07161505|DEVICE|TBS-EEG|Theta-burst stimulation (TBS) over the left dorsolateral prefrontal cortex (DLPFC) synchronized with the ongoing electroencephalographic (EEG) oscillations in the theta (3-7 Hz) range at a suprathreshold pulse intensity (up to 120% rMT).
215037741|NCT07161505|DEVICE|TBS-EEG / Spatial Control|Theta-burst stimulation (TBS) over the postcentral gyrus, synchronized with the ongoing electroencephalographic (EEG) oscillations in the theta (3-7 Hz) range at a suprathreshold pulse intensity (up to 120% rMT).
215037742|NCT07161505|DEVICE|TBS / Temporal Control|Theta-burst stimulation (TBS) over the left dorsolateral prefrontal cortex (DLPFC) at a suprathreshold pulse intensity (up to 120% rMT).
215037743|NCT07161505|DEVICE|TBS-EEG / Dose Control|"Theta-burst stimulation (TBS) similar to the TBS-EEG condition but at a subthreshold pulse intensity (up to 80% rMT)."
215037744|NCT07160959|BEHAVIORAL|Exercise|Patients will undergo a home-based low-intensity interval multi component exercise program including aerobic and strengthening exercise
214291142|NCT03712319|BEHAVIORAL|Mindfulness-Based Stress Reduction program|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
214291143|NCT06173921|PROCEDURE|robotic system|Implant placement will be navigated by robotic system based on a digital plan
214291144|NCT06173921|PROCEDURE|Static navigation system|Implant placement will be navigated by static navigation system based on a digital plan
214291145|NCT01955733|DRUG|BI 695500|
214291146|NCT03232047|DEVICE|Combined executive function and memory training|Computerized combined executive function and memory training
214665858|NCT05955027|DRUG|ZX-7101A|a drug to treat influenza, oral
214665859|NCT05955027|DRUG|Placebo|placebo control, oral
214665860|NCT06964802|OTHER|Cold salt water foot bath|The application of 175 grams of salt to cold water at a constant 22 degrees
214665861|NCT06964802|OTHER|Cold water foot bath|Constant 22 degree cold water application
214665862|NCT06964828|DEVICE|Flat-knitted compression garment|Flat knitted compression garments
214665863|NCT06157242|DRUG|Xeruborbactam Oral Prodrug|Experimental
214872088|NCT03335826|PROCEDURE|General anesthesia|General anesthesia and postoperative intravenous analgesia.
214872089|NCT04847518|DRUG|Kan Jang capsules|"One capsule contains a fixed combination of proprietary~* Andrographis paniculata Nees. herb, native extract, DER native 4,5-8,0 :1 260 mg (Diterpene lactones andrographolide and 14-deoxy, 11,12- didehydroadnrograholide) 15-20 mg~* Eleutherococcus senticosus (Rupr. et Maxim) Harms, root, native extract DER native 17-30:1 : 11.4 mg and other inactive excipients (Polycristalline cellulose, Magnesium stearate)."
214872090|NCT04847518|OTHER|Placebo capsules|Inactive excipients
215037745|NCT07160959|OTHER|Control (Standard treatment)|Patients will be treated with standard therapy based on their CKD stage
215037746|NCT07159815|OTHER|Digital follow-up|See the arm/group description.
215037747|NCT07159815|OTHER|On-site follow-up|See the arm/group description.
215037748|NCT07159815|BEHAVIORAL|Resistance exercise|See the arm/group description.
214872091|NCT02171871|OTHER|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
214872092|NCT03875859|DRUG|Remetinostat|Topical 1% remetinostat gel
214872093|NCT00460135|BEHAVIORAL|resistance training|2 times a week resistance training
214872094|NCT03400943|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily up to 2 x 12 weeks
214872095|NCT03400943|DRUG|Placebo|Matching placebo was administered to group B1 and B2.
214872096|NCT02563106|DRUG|SYN-004|
214872097|NCT02563106|DRUG|Placebo|
214872098|NCT04863599|OTHER|Questionnaire|Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
214872099|NCT01515930|BEHAVIORAL|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding monitoring diabetes care.
214872100|NCT01515930|BEHAVIORAL|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding diabetes care.
214872101|NCT01515930|BEHAVIORAL|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
214872102|NCT04729309|DRUG|[12C] RO7049389|Participants will receive oral \[12C\] RO7049389.
214872103|NCT04729309|DRUG|[13C] RO7049389|Participants will receive IV \[13C\] RO7049389.
214872104|NCT04729309|DRUG|[14C] RO7049389|Participants will receive an oral suspension of \[14C\] RO7049389.
214665864|NCT06157242|DRUG|Ceftibuten|Experimental
214872105|NCT03914911|DEVICE|Smart Biopsy Device|The radiologist will perform a routine ultrasonic guided biopsy procedure using the smart biopsy system, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
214872106|NCT00799448|DRUG|repaglinide|
214872107|NCT00799448|DRUG|biphasic human insulin 30|
214872108|NCT00799448|DRUG|insulin NPH|
214872109|NCT02784444|DRUG|MSDC-0602K|MSDC-0602K capsules
214872110|NCT02784444|DRUG|Placebo|Placebo capsules
214872111|NCT01110135|DRUG|bendamustine hydrochloride|Given IV
214872112|NCT01110135|DRUG|dexamethasone|Given PO
214872113|NCT01110135|BIOLOGICAL|filgrastim|Given SC
214872114|NCT01110135|PROCEDURE|leukapheresis|Given IV
214872115|NCT01110135|OTHER|laboratory biomarker analysis|Correlative studies
214872116|NCT01110135|OTHER|flow cytometry|Correlative studies
214872117|NCT01110135|DRUG|etoposide|Given IV
214872118|NCT04851652|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
214872119|NCT05305482|DEVICE|Drug-coated stent|The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
214872120|NCT05305482|DEVICE|Drug-eluting stent|The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
214872121|NCT01119183|BEHAVIORAL|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
214872122|NCT01119183|BEHAVIORAL|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
214872123|NCT01406483|OTHER|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
214872124|NCT01830894|DEVICE|MRI|3 MRI on different times during the study for each arm.
214872125|NCT03177174|DRUG|Cisplatin|radiotherapy combined with Chemotherapy Drugs, Cancer
214872126|NCT03177174|DRUG|Docetaxel|Docetaxel
214872127|NCT04689867|BEHAVIORAL|Cognitive Behavioral Suicide Prevention for psychosis CBSPp)|Cognitive and behavioral approach to suicide prevention among individuals with psychosis
214872128|NCT01838668|DRUG|Placebo|Two placebo capsules orally BID
214872129|NCT01838668|DRUG|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
214872130|NCT05043844|DEVICE|abdominal binder|Wearing an abdominal binder postoperatively
214872131|NCT03151291|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate (HMB)|daily intake of 3 g HMB
214872132|NCT03151291|DIETARY_SUPPLEMENT|L-carnitine (LC)|daily intake of 4 g LC
214872133|NCT03151291|DIETARY_SUPPLEMENT|Eicosapentaenoic acid (EPA)|daily intake of 2.2 g EPA
214872134|NCT03151291|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
214872135|NCT05788614|DEVICE|Reverse shoulder arthroplasty|Reverse shoulder arthroplasty
214872136|NCT06209541|BEHAVIORAL|Internet-based cognitive behavioral therapy (ICBT)|All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.
214872137|NCT06361979|DRUG|SHR-A1811|SHR-A1811: intravenous
214872138|NCT06361979|DRUG|Bevacizumab|Bevacizumab:intravenous
215037749|NCT07160647|DRUG|Ipalolimab and Tovorilimab|1.Active Ingredients: Ipalolimab and Tovorilimab (a dual-functional combination antibody consisting of Ipalolimab, a recombinant humanized monoclonal antibody targeting programmed death receptor-1 \[PD-1\], and Tovorilimab, a recombinant humanized monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein-4 \[CTLA-4\]). 2.Specification: 50 mg (2 mL) per vial. 3.Dosage and Administration: Administer via intravenous infusion at a recommended dose of 5 mg/kg every 3 weeks.
214665865|NCT06623981|BEHAVIORAL|Enhanced Brief Interpersonal Psychotherapy|Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.
214872139|NCT00205244|BEHAVIORAL|Healing images, relaxation and distraction materials|
214872140|NCT01173081|DRUG|Teriparatide|20mcg once daily for 16 weeks or until study endpoint is achieved.
214872141|NCT01173081|DRUG|Placebo|matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
214872142|NCT04934410|DRUG|Etomidate|Use of etomidate during induction as decided by attending anesthesiologist
214872143|NCT04934410|DRUG|Midazolam|Use of midazolam during induction as decided by attending anesthesiologist
214872144|NCT04934410|DRUG|Sevoflurane|Use of sevoflurane during induction as decided by attending anesthesiologist
214872145|NCT05670535|OTHER|Visual analogue scale (VAS) for dyspareunia|Dyspareunia scores between 0 to 10 points
214872146|NCT05670535|OTHER|Visual analogue scale (VAS) for vaginal dryness|Vaginal dryness scores between 0 to 10 points
214872147|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)|Sjögren's Syndrome Disease Activity Index scores between 0 to 3 points
214872148|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)|Sjögren's Syndrome Patient Reported Index scores between 0 to 10 points
214872149|NCT04177784|OTHER|Online Educational Videos|The videos were developed by the researchers based on a prior study to test if specific information about obesity and weight control influence weight bias.
214872150|NCT00513279|DRUG|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
214872151|NCT00513279|DRUG|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
214872152|NCT05430984|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|"Isolation of preperitoneal space will be accomplished to guarantee the mesh flattening with the medial border at the pubic symphysis, the lateral border at the psoas major and anterior superior iliac spine, superior border at least 3 cm above the conjoined tendon, medial inferior border 3 cm below the pectineal ligament, and lateral inferior border to permit perietalization of the spermatic cord (6-8 cm isolation of the hernia sac and spermatic cord).~For the mesh fixation group, the mesh will be fixed to the abdominal wall using suture, spiral tacks, whereas for the non-fixation group it will be left as it is and the operation will be concluded. A mesh measuring 15x10cm is placed in the preperitoneal space and fixed using limited numbers of tacks or suture. In some cases, based on body habitus, a slightly smaller mesh could be used. The peritoneum will be closed over the mesh."
214872153|NCT03285100|DIAGNOSTIC_TEST|Venipuncture|"* Approximately 6 months after discontinuation of VKAs one additional venipuncture will be performed for determination of dp-ucMGP and desmosine.~* At baseline two additional blood collection tubes will be drawn for determination of dp-ucMGP, desmosine and VKORC1 polymorphisms. Since this is during one of the last regular International Normalized Ratio (INR) testing at the anticoagulation clinic, no additional venipuncture has to be performed at this moment."
214872154|NCT03848637|DRUG|CKD-375|Test drug
214872155|NCT03848637|DRUG|D387|Reference drug
214872156|NCT06632470|DRUG|Secretome injection|Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months
214872157|NCT06632470|DRUG|Vitamin B12 Injection|Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months
214872158|NCT06007911|DRUG|Navitoclax Dose Level -1|25 mg by mouth on days 1-7.
214872159|NCT06007911|DRUG|Navitoclax Dose Level 0|50 mg by mouth on days 1-10.
214872160|NCT06007911|DRUG|Navitoclax Dose Level 1|75 mg by mouth on days 1-10.
214872161|NCT06007911|DRUG|Navitoclax Dose Level 2|100 mg by mouth on days 1-10.
214872162|NCT06007911|DRUG|Venetoclax Dose Level -1|400 mg by mouth on days 1-7.
214872163|NCT06007911|DRUG|Venetoclax Dose Levels 0 to 2|400 mg by mouth on days 1-14.
214872164|NCT06007911|DRUG|Cladribine|5 mg/m\^2 intravenously days 1-5.
214872165|NCT06007911|DRUG|Cytarabine (Cladribine Low Dose Cytarabine Backbone)|20 mg/m\^2 subcutaneous days 1-10.
214872166|NCT06007911|DRUG|Cytarabine (CLAG-M Backbone)|1.5 g/m\^2 intravenously days 1-5.
214872167|NCT06007911|DRUG|Mitoxantrone|10 mg/m\^2 intravenously days 1-3.
214872168|NCT06007911|DRUG|Granulocyte Colony-Stimulating Factor|300 mcg subcutaneously days 1-5.
214872169|NCT03173430|DRUG|Blinatumomab|Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
214872170|NCT01664130|RADIATION|stereotactic body radiation therapy|Undergo SBRT
214872171|NCT01664130|PROCEDURE|quality-of-life assessment|Ancillary studies
214872172|NCT01664130|OTHER|laboratory biomarker analysis|Correlative studies
214872173|NCT00010426|DRUG|cysteamine hydrochloride|
214872174|NCT03590912|DRUG|Mometasone 50 Mcg/Inh Nasal Spray|One spray in each nostril once daily for one month
214872175|NCT03590912|DRUG|Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)|Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks
215037750|NCT07160777|DEVICE|cross-linked hyaluronic acid|Semical Dermal Filler Fine Semical Dermal Filler Plus Semical Dermal Filler Ultra
215037751|NCT07160777|DEVICE|Mesolifter|Stabilized hyaluronic acid with NONASEM Technology. Application with Multi-Aesthetic Point Technique (MAPs)
215037752|NCT07158684|OTHER|Semi-structured interview|A qualitative semi-structured interview of the patient's anxiety before and one month after surgery.
215037753|NCT07161050|BEHAVIORAL|Nicotine Content|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
215037754|NCT07161050|BEHAVIORAL|Illegal cigarette price|At each level of nicotine content, we will manipulate the price of illegal cigarettes (1xMP, 1.5x MP, 2x MP). MP is market price.
214665866|NCT06623981|BEHAVIORAL|Supplemented Usual Care|Usual care for caregivers with PHQ-9 scores 10-27 involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.
214665867|NCT06511050|DIETARY_SUPPLEMENT|Lumbrokinase|Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.
214872176|NCT03590912|DRUG|Steroid Drug (prednisolone)|This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.
215037755|NCT07161050|BEHAVIORAL|E-cigarette price|At each level of nicotine content and illegal cigarette price, we will manipulate the price of e-cigarettes (1xMP, 1.5x MP, 2x MP). MP is the market price.
215037756|NCT07160582|BEHAVIORAL|Novel CogXergaming Training|In each session, participants will play 6 games in the same order (Fruit catch, Math, Tracking, Candy match, Letter Number Sequencing - LNS, Stroop), each of which contains 10-20 trials and will last for around 10 minutes (total = 60 minutes. The CXT program employs a progressive method to ensure the intensity of CXT remains challenging without overload. If a participant demonstrates ≥80% accuracy in 3 continuous trials for one game, then the exercises for this game will be progressed to the next level (levels: 1-9 in Table 3). Each session of CXT will last approximately 1 hour. At least one day of rest will be required between weekly training sessions.
215037757|NCT07160582|BEHAVIORAL|Exercise and Education Training Program|EEP consists of a conventional exercise program and fall-prevention education. The conventional exercise program comprises 50 minutes of supervised exercises for stretching and strengthening. A fall-prevention education program will also be provided to Group B, for about 10 minutes after each session of the exercise program. Each session of EEP will last approximately 1 hour. At least one day of rest will be required between weekly training sessions.
215037758|NCT07158918|DRUG|ABL103|IV infusion
215037759|NCT07158918|DRUG|KEYTRUDA® (pembrolizumab)|IV infusion
215037760|NCT07158918|DRUG|Taxane|IV infusion
215037761|NCT07158957|OTHER|knowledge|"-knowledge on pain in general and specifically pelvic girdle pain Pregnant women who in addition to usual care get our model WOMENinMOTION on a digital platform with self-directed content areas modules and linked tasks to promote physical activity and function by reducing concerns, pain, and building confidence for physical activity and realistic expectations.~When women consider the digital platform insufficient, they are referred to physiotherapy at clinic for physiotherapeutically individually coached content of WIM"
215037762|NCT07158957|BEHAVIORAL|motivation for behavioral change|motivation to be physically active
215037763|NCT02619565|OTHER|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
215037764|NCT06233448|DEVICE|Indirect cardiometry|Measurements of thorathic fluid content
214872177|NCT03133338|DEVICE|pelvic binder|The requirement of angioembolization can be predicted by the presence of intravenous contrast extravasation (ICE) on computed tomography (CT)
214872178|NCT04749238|DEVICE|NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm
214872179|NCT03357835|OTHER|Trauma Decision System|At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
214872180|NCT03844217|DRUG|Macimorelin 0.5mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin
215037765|NCT06275516|DEVICE|multi-sensory stimulation immersive VR+ treadmill training|Treadmill training with multi-sensory stimulation immersive VR in VR+treadmill training group
215037766|NCT06275516|DEVICE|treadmill training|Only treadmill training in treadmill training group
215037767|NCT04119037|PROCEDURE|Cordotomy|Undergo cordotomy
215037768|NCT04119037|DRUG|Morphine|Given via injection
215037769|NCT04119037|OTHER|Questionnaire Administration|Ancillary studies
215037770|NCT04119037|PROCEDURE|Sham Intervention|Undergo fake cordotomy
215037771|NCT05763563|BEHAVIORAL|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo CART-T therapy. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously.
215037772|NCT05763563|BEHAVIORAL|Aerobic Exercise|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
215037773|NCT05763563|BEHAVIORAL|Optional Aerobic Exercise Procedure|"Participants will be encouraged to complete 3 tele-supervised aerobic training sessions per week, each lasting 30 minutes. Participants will be encouraged to achieve moderate exercise intensity based on heart rate visualized on PM5 monitors. Participants will report their heart rates every 3-5 minutes during an exercise session and be encouraged to adjust pedaling cadence or flywheel resistance accordingly to achieve moderate intensity.~Exercise trainers will access logged heart rate ranges (64-76% of age-predicted maximum heart rate) to provide individualized and appropriate guidance during sessions.~Participants who are untrained or otherwise uncomfortable maintaining moderate aerobic intensity for 30 minutes will be encouraged to gradually increase the duration and intensity of their sessions until they are meeting these guidelines."
215037774|NCT05763563|RADIATION|Optional In-Person Exercise Sessions|Participants who prefer to complete RT and/or aerobic exercise sessions in-person will be allowed to do so. These sessions will be conducted in the Moffitt Promotes Resilience in Oncology Via Exercise (MPROVE) Laboratory using the same equipment participants would use for Zoom sessions, with guidance and supervision from certified exercise trainers.
214872181|NCT03844217|DRUG|Macimorelin 0.75mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
214872182|NCT03634475|DRUG|PP-001|Drug - no placebo
214872183|NCT05782959|BIOLOGICAL|BCD-245|BCD-245 is administered as prolonged intravenous infusions during each cycle
215037775|NCT06117930|OTHER|Non-Interventional Study|Non-interventional study
215037776|NCT06035042|PROCEDURE|Scheduled surgery|All subjects will be exposed to surgery
215037777|NCT02286609|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
215037778|NCT01131897|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
214665868|NCT05589493|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by dental implants following the All-on-4 Concept arrangement.
215037779|NCT06786572|OTHER|Mindfulness training|Brief mindfulness training focused on management of unwanted internal sensations
215037780|NCT06786572|BEHAVIORAL|Interoceptive exposure|Cognitive behavioral therapy focused in interoceptive exposure to unwanted internal sensations
215037781|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
215037782|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
214872184|NCT02276950|PROCEDURE|Coronary artery bypass surgery|Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass
215037783|NCT02107885|DRUG|DS-1971|6 subjects in each group will receive DS-1971.
215037784|NCT02107885|DRUG|placebo|2 subjects in each group will receive placebo.
215037785|NCT06101173|BIOLOGICAL|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
215037786|NCT06101173|BIOLOGICAL|Inactivated poliomyelitis vaccine (IPOL)|1 dose of IPOL vaccine (0.5ml) on Visit 1
215037787|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
215037788|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
215037789|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
215037790|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
215037791|NCT01227785|DEVICE|INCEPTA ICD or CRT-D|
215037792|NCT05046626|OTHER|Nutritional counseling|Intervention based on nutritional counseling under Cognitive Behavioral Theory and the used of strategies like self-monitoring, goals, cognitive restructuring and social support.
215037793|NCT00569933|BEHAVIORAL|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
215037794|NCT02147821|PROCEDURE|No Pleural Chest Tube|
215037795|NCT06633536|DRUG|Ravulizumab|open-label arm with ravulizumab administrated within the scope of routine clinical practice
215037796|NCT05456828|BIOLOGICAL|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
214665869|NCT06044285|OTHER|Low UP (meals provided)|"This study incorporates within- and between-subject comparisons. All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Food is provided by the study team for 7 days in accordance with a low UP diet.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
214872185|NCT02276950|PROCEDURE|Heart valve surgery|Heart valve surgery, aortic valve replacement or other heart valve procedures
214872186|NCT01161407|DIETARY_SUPPLEMENT|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
214872187|NCT01161407|DIETARY_SUPPLEMENT|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
214872188|NCT03910387|DRUG|Gemcitabine|Given gemcitabine/nab-paclitaxel combination therapy
214872189|NCT03910387|DRUG|Nab-paclitaxel|Given gemcitabine/nab-paclitaxel combination therapy
214872190|NCT03910387|DRUG|Telotristat Ethyl|Given PO
214872191|NCT00537420|DRUG|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
214872192|NCT00537420|DRUG|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
214872193|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
214872194|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
214872195|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
214872196|NCT00537420|DRUG|Sibutramine|Sibutramine will be taken once daily with or without food
214872197|NCT06389695|DRUG|68Ga-NYM032 injection|The radiation dose is about 3-6 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM032 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
214872198|NCT05377892|OTHER|Dietary protein|High protein followed by reduced protein diet
214872199|NCT04914455|DIAGNOSTIC_TEST|Echocardiography and transhepatic inferior vena cava assessment using ultrasound.|"For all participant :~* Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~* Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~* Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;"
214872200|NCT06396767|DIAGNOSTIC_TEST|DIA measured via Ultrasonography|Ultrasound will be used to measure Diaphragmatic Inspiratory Amplitude (DIA) of patients before and after elective cardiac surgery to determine if there is a correlation between changes in DIA and postoperative pulmonary complications.
214872201|NCT02727881|DRUG|Squalamine lactate ophthalmic solution, 0.2%|Squalamine lactate ophthalmic solution, 0.2%
214872202|NCT02727881|DRUG|Placebo Ophthalmic solution|Placebo Ophthalmic solution
214872203|NCT02727881|DRUG|ranibizumab|ranibizumab
214872204|NCT03012984|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
214872205|NCT03012984|DRUG|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
214665870|NCT06044285|OTHER|Low UP (self-guided)|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat a low UP diet according to study provided nutritional guidance.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
214665871|NCT06044285|OTHER|Active Control|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat as they normally do.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
214872206|NCT06634121|DEVICE|Transcatheter mitral valve edge-to-edge repair (M-TEER)|M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.
214872207|NCT03837002|OTHER|foot care protocol|foot assesment, foot care, foot care education
214872208|NCT00096603|DRUG|Raptiva (efalizumab)|
214872209|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
214872210|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
214665872|NCT03913910|PROCEDURE|Lipogems|Autologous micro-fragmented adipose tissue is injected in the internal orifice, mucosal, submucosal and muscular layer, then in the fistula tract and external orifice in addition to anal flap.
214872211|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
214872212|NCT04987385|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive a box with 7 sealable of 90-gram protein containers that will be dissolved in maximal 1L liquid (i.e., water or milk) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake. A wash-out period of minimum 7 days between Protein supplementation and Oral urea will be performed.
214872213|NCT04987385|DIETARY_SUPPLEMENT|Oral urea|Patients will receive a box with 7 30-grams urea sealable containers. The total daily oral urea dosage of 30 grams that will be dissolved in maximal 1L of a liquid of choice (water, milk, juice, …) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake.
214872214|NCT01226771|DRUG|"Ribavirin loading dose given"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
214476585|NCT05278234|BEHAVIORAL|STEPS|Participants will initially meet with a community health worker (CHW) for a 1-hour orientation at the participant's home, a Henry Ford Health System site or the University of Michigan Detroit Center, or virtual. The CHW will show participants how to use the web modules. Participants will be given (or mailed) a wearable activity tracker to use throughout the course of the 7-week program. Each week participants will watch a brief video on the STEPS website; they may also be asked to complete handouts in the workbook. They will have a weekly 30-minute telephone session with the CHW. CHWs will review the weekly topic, help participants practice new skills, and set a related goal. CHWs will screen for social needs and make appropriate community referrals. Participants will set walking goals each week, using step-count data from the physical activity tracker. Participants will track daily step counts.
214476586|NCT03475212|BIOLOGICAL|Virus Specific T-cell (VST) infusion|Patients will receive partially HLA-matched VSTs as a single infusion. Patients who have a partial response (\>1 log decrease in viral load without clearance) or no response and do not have treatment-related dose-limiting toxicities are eligible to receive up to 3 additional doses from day 30 after the initial infusion and at 2 weekly intervals thereafter. The viral load of the virus (or viruses) that patients are initially treated for are monitored by viral PCR.
214872215|NCT01226771|DRUG|"Priming dose of ribavirin given"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
214872216|NCT01226771|DRUG|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
214872217|NCT00552851|DRUG|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
214872218|NCT03893097|DRUG|Praziquantel|40 mg/kg at baseline
214872219|NCT03893097|DRUG|Artesunate + Mefloquine|4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12
214872220|NCT03594058|DRUG|Solabegron modified release tablets, low dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
214872221|NCT03594058|DRUG|Solabegron modified release tablets, high dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
214872222|NCT03594058|DRUG|Matching Placebo|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
214872223|NCT03881423|DRUG|Rocuronium Bromide|DEEP block to PTC 1-3
215037797|NCT05243030|BEHAVIORAL|Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
214872224|NCT02935621|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
214872225|NCT02935621|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
214872226|NCT00872794|DEVICE|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
214872227|NCT00674349|PROCEDURE|surgery|staging surgery
214872228|NCT04117919|DRUG|paper mulberry leaf|Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
214872229|NCT04117919|DRUG|Triamcinolone (Encort-A) 0.1%15g/Tube|only Topical steroids
214872230|NCT04918485|OTHER|preoperative psychological intervention|including closing the relationship between nurse and patient , knowledge education,
214872233|NCT05860205|BEHAVIORAL|Multiple Component Mobile-Aid Pain Reduction Intervention|1.Posture training through the wearable device, UPRIGHT GO. The participant wears the device on their neck. The device provides biofeedback to poor posture with vibrations and tracks posture. 2. A daily core muscle training and stretching exercise program including trunk rotation, lumbar rotation, hip flexor stretch, side plank, glute bridge, suitcase carry, and palloff press. 3. Participants will practice stress reduction through breath focus which will help them to concentrate on deep breathing to help them ignore distracting thoughts and sensations. 4. Strategies to improve daily level of activity including wearing a Garmin device that tracks their daily physical activity and reminds them to walk and the use of the communication principle to assist participants in overcoming barriers to physical activity.
214872234|NCT05860205|OTHER|Osteopathic Manipulation Treatment|Osteopathic Manipulation Treatment (OMT) will be conducted by putting pressure on certain muscles in the back and performing OMT exercises on the patient. The physician will treat participants with OMT twice during month 1 and once during month 2 and 3.
215037798|NCT05243030|BEHAVIORAL|Motivational Interactive Text Messaging (MTM)|"Participants will receive automated motivational text messages to promote PrEP initiation and adherence. These contents will be customized based on their readiness to change in regards to PrEP. The message content is individualized based on participant response to baseline survey. Those participants who indicate that they are ready to set the goal to take PrEP will receive text messages reminding them to take PrEP. Those who indicate that they are less than ready to take their PrEP can choose from a range of alternatives, such as taking on-demand PrEP or just think about taking PrEP. For those who are not ready to take PrEP, the content will be individualized based on the participant's choice, i.e., a daily message encouraging them to work toward their chosen goal. Participants who are currently not on PrEP will receive daily text messages regarding PrEP effectiveness, HIV risk and where to access PrEP."
215037799|NCT05243030|BEHAVIORAL|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3 and 6. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
214872235|NCT05860205|OTHER|Sham Osteopathic Manipulation|The sham osteopathic manipulation treatment (OMT) will be performed by the medical team. Hands will be placed on the patient as if the OMT is being performed. The physician will treat participants with sham OMT twice during month 1 and once during month 2 and 3.
214872236|NCT04632511|DEVICE|MetaSAMP|Rectal Sampler
214872237|NCT02730026|DRUG|Ketoprofen|Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.
214872238|NCT02730026|DRUG|Ketoprofen and Omeprazole|Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
214872239|NCT01804348|DEVICE|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
214872240|NCT01708148|DIETARY_SUPPLEMENT|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
214872241|NCT01708148|OTHER|Placebo|control group would receive a oral lactose placebo
214872242|NCT05180357|OTHER|FASENRA(benralizumab)|This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
214872243|NCT06247397|DEVICE|Added high-flow oxygen therapy|Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.
214872244|NCT06247397|OTHER|Standard care|Standard care with low-flow oxygen therapy in accordance with clinical routine.
214872245|NCT02784041|DRUG|single adductor-canal-block|Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
215037800|NCT05395936|OTHER|Myocardial Probe Temperature Screen|The myocardial probe is a needle that measures temperatures. The skin site for introducing the myocardial probe will be small enough that participants will not notice that temperatures have been collected. If participants have multiple operations, temperatures may be collected at each operation.
215037801|NCT05395936|OTHER|Data Collection|Study team members will collect medical history and other information to potentially understand the safety and success of breast surgery better to allow investigators to identify variables, or changes to help understand investigators roles in potential complications in breast surgery.
215037802|NCT04630808|DRUG|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1%
215037803|NCT04630808|DRUG|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005%
215037804|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws.
215037805|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE+collagen membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws and covered with a Collagen membrane subsequently.
215037806|NCT05722327|DRUG|MRTX849|Given by PO (mouth)
215037807|NCT05722327|DRUG|Irinotecan|Given by IV (vein)
214872246|NCT02784041|DRUG|periarticular infiltration|The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
215037808|NCT05722327|DRUG|Cetuximab|Given by IV (vein)
215037809|NCT03697850|DRUG|Atezolizumab|Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
215037810|NCT06549153|OTHER|Education Content|Participants will be offered group based education sessions expected to last 90 minutes
215037811|NCT06549153|OTHER|Focus Group|Participants will attend via Zoom
214476587|NCT06562790|BIOLOGICAL|Gamma PN3|500, 1000 or 1500 µg by IM injection on Days 1 and 29
214872247|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 1: 50 ug
214872248|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
214872249|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
214872250|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
214872251|NCT01415102|DRUG|Placebo|Inhaled
214872252|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
214872253|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
214872254|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
214872255|NCT01415102|DRUG|Placebo|Inhaled
214872256|NCT03518801|BEHAVIORAL|Prolonged Exposure|psychotherapy
214872257|NCT03518801|DRUG|Cannabidiol|active medication
214872258|NCT03518801|DRUG|placebo|non-active medication
214872259|NCT01919021|OTHER|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
214872260|NCT01919021|OTHER|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
214872261|NCT01919021|PROCEDURE|Assessment of Gastric motor and sensory function|
215037812|NCT04043286|DEVICE|Definitive abutment|With two height options available, On1 Base are selected depending on the thickness of the soft tissue. It remains in position from implant placement to finalization, which leaves the soft tissue undisturbed for optimized healing, moved the restorative platform of Nobel Biocare conical connection implants from bone level to tissue level, thereby simplifying the restorative procedures
215037813|NCT02724202|DRUG|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
215037814|NCT02724202|DRUG|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
215037815|NCT01323192|DRUG|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
214872262|NCT01926574|BEHAVIORAL|long rehabilitation program|
214872263|NCT01926574|BEHAVIORAL|short rehabilitation program|
214872264|NCT01926574|BEHAVIORAL|Acceptance and commitment therapy (ACT)|
214476588|NCT06562790|BIOLOGICAL|Prevnar|1 dose on Day 1 and saline placebo on Day 29
214872265|NCT04447339|PROCEDURE|Nipple Sparing Mastectomy|Prophylactic open NSM procedures
214872266|NCT05396521|OTHER|Blood Flow Restriction|Group 2 (experimental) will receive standard of care physical therapy to be done with blood flow restriction therapy (BFR). This method includes standard of care physical therapy while occluding blood flow.
214872267|NCT05396521|OTHER|Standard of Care Physical Therapy|Group 1 (Control) will receive standard of care physical therapy.
214872268|NCT05446012|DIAGNOSTIC_TEST|thyroid function tests|blood sample for thyroid function tests (TSH,T3,T3,Anti peroxidase antibody, anti thyroglobulin antibody)
214872269|NCT03067597|DRUG|Dinoprostone|The DVI contains 10 mg dinoprostone
214872270|NCT01786889|BIOLOGICAL|blood and urine|Blood collection and urine collection after consent of the patient
215037816|NCT01323192|DRUG|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
215037817|NCT01019265|DRUG|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
215037818|NCT05558644|OTHER|single arm for all patients|"* tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery."
215037819|NCT06225115|DRUG|KYN-5356|KYN-5356, oral tablet
215037820|NCT06225115|DRUG|placebo|placebo, oral tablet
214872271|NCT01786889|BEHAVIORAL|Questionnaire|The patient complete the questionnaire alone at home
214872272|NCT01786889|BEHAVIORAL|Telephone interview|The patient will be contacted by the CRA for a telephone interview of around one hour
214872273|NCT00198250|DRUG|venlafaxine|Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks
214872274|NCT01563835|DRUG|bupivacaine, fentanyl|10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
214872275|NCT01563835|DRUG|fentanyl|fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
214872276|NCT03960203|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for severe sepsis detection and prediction
214872277|NCT02021357|BEHAVIORAL|hyperbolid combined with tongue exercises on the palate|
214872278|NCT02021357|OTHER|hyperbolid|
214872279|NCT02991326|OTHER|Osteopathic Manipulative Treatment|"The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~* Compression of the fourth ventricle;~* inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~* inhibition of the inferior head of the lateral pterygoid muscle;~* intra-oral inhibition of the masseter muscle;~* Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~* BLT of the accessory ligaments - pterygomandibular raphe;~* sphenopalatine ganglion technique;~* Craniosacral rebalancing;"
214872280|NCT02991326|OTHER|Sham intervention|The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
214872281|NCT00400816|DRUG|temozolomide|Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\]
214872282|NCT04380766|PROCEDURE|Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer|Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
214872283|NCT03792295|DRUG|acetominophen, ibuprofen, oxycodone|Multimodal pain treatment group
214872284|NCT03792295|DRUG|Oxycodone|Classic opiod pain treatment group
215037821|NCT02296476|DRUG|Birabresib|Administered orally in a fasted state once daily.
215037822|NCT05785624|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
214872285|NCT01366950|BEHAVIORAL|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
214872286|NCT02455037|OTHER|Neck Strengthening|Targeted neck strengthening exercises
214872287|NCT01303770|BEHAVIORAL|Self-management cognitive rehabilitation group intervention|8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
214872288|NCT01303770|BEHAVIORAL|Control intervention|8-week group program that is not specifically directed to management of cognitive impairments.
214872289|NCT02076490|OTHER|Physical/Occupational therapy|At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
214872290|NCT02558348|DRUG|AL3818|Administered orally
214872291|NCT03781037|BEHAVIORAL|GIVE Module|The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
214872292|NCT01496300|PROCEDURE|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
214872293|NCT01496300|PROCEDURE|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
214872294|NCT06079346|DRUG|OT-101|OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene
214872295|NCT06079346|DRUG|mFOLFIRINOX|Folinic acid, 5-FU, Irinotecan, Oxaliplatin
214872296|NCT03337958|DEVICE|Ventilatory re-education|The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
214872297|NCT05267730|BEHAVIORAL|Conectar Jugando Game Program|Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
214872298|NCT04746794|BEHAVIORAL|Population-level screening|"The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified."
214872299|NCT04040192|DRUG|Crisaborole 2%|Crisaborole ointment 2%
214872300|NCT04040192|DRUG|Vehicle|Vehicle ointment
214872301|NCT03200912|DRUG|Ingenol Mebutate (Picato®)|Brand product
214872302|NCT03200912|DRUG|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
215037823|NCT05785624|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arms.
215037824|NCT05604261|DRUG|Anaprazole sodium 40 mg|Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
214476589|NCT06839859|BEHAVIORAL|Family Acceptance Project - Online|a 9-week long online group program for LGBTQ+ youth of color and their parents / caregivers
214872303|NCT03200912|DRUG|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
214872304|NCT03847298|OTHER|Physical activity and physical fitness assessment|Physical fitness was assessed using Munich Physical Fitness Test (MFT). The SenseWear Armband metabolic holter device was used to record the physical activity level for consecutive 7 days. The functional exercise capacity of the individuals was assessed by the six-minute walking test (6MWT) and cardiorespiratory capacity was assessed by maximal exercise test on the treadmill.
214872305|NCT00961402|BEHAVIORAL|Wellness Control|6-month wellness control
214476590|NCT04600544|OTHER|Non-interventional|Translational, observational study
214872306|NCT00961402|BEHAVIORAL|Exercise Intervention|6 month exercise intervention
214872307|NCT05775198|BIOLOGICAL|PBMC immunomodulated with IFNt|Autologous peripheral blood mononuclear cells (PBMC) isolated using a standard protocol will be cultured in the presence of interferon tau (IFNt) for 24 hours at 37 ˚C and administered in the uterine cavity of patients 1 day prior to embryo transfer.
214872308|NCT02882308|DRUG|Olaparib|50/25 mg BD split x 5 days
214872309|NCT02882308|DRUG|Cisplatin|60 mg/m\^2 d1-d5
214872310|NCT02882308|DRUG|Olaparib|300 mg BD x 21-28 days.
214872311|NCT02882308|DRUG|Durvalumab|1500 mg d1
214872312|NCT01955083|DEVICE|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
215037825|NCT05604261|DRUG|Anaprazole sodium 60 mg|Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
215037826|NCT05604261|DRUG|Rabeprazole sodium 20 mg|Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
215037827|NCT04257019|OTHER|Lavender oil|Inhalation of Lavender oil
215037828|NCT04257019|OTHER|Almond oil|Inhalation of Almond oil
215037829|NCT04257019|OTHER|Water|Inhalation of water
215037830|NCT00313560|DRUG|erlotinib hydrochloride|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
214872313|NCT01955083|DEVICE|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
214872314|NCT06010186|OTHER|Ultrasound measurement of the diaphragm and intercostals|"The specific research procedures correspond to the addition of :~* Two additional ultrasound examinations, i.e. at discharge from intensive care and 3 months after hospital discharge: non-invasive examination (duration 20 minutes). Ultrasound is a risk-free, painless procedure involving the placement of an ultrasound probe on the body part under investigation, without the need for a radius or puncture.~* Questionnaires to assess quality of life (SF-36) and functional impact (LCADL) of dyspnea, carried out at discharge from hospital and at 3 months (duration 15 minutes)."
214872315|NCT06571513|BEHAVIORAL|Written Exposure Therapy|During session one of the written exposure therapy intervention, the therapist will provide psychoeducation about PTSD and the rationale for the proposed intervention. Psychoeducation and treatment rationale are scripted to ensure consistency. The therapist will provide the participant with instructions for writing about the same trauma memory (their recent sexual assault) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
214872316|NCT06571513|BEHAVIORAL|Unemotional Writing|During the unemotional writing sessions, the therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did the day before the session from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. The participant will self report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
214872317|NCT05190692|DEVICE|Use simulators in Obstetrics vaginal examination|"Two simulators will be used in the study:~(1st ) : PROMPT Flex Birthing Simulator Advanced - Light (PRODUCT NO. 80106).UK, 2020 .~2nd): PROMPT Flex Cervical Dilatation \& Effacement Module -Light (PRODUCT NO. 80102),Uk,2020.~Both will be used to perform obstetric vaginal examination before examination of patients"
215037831|NCT01248325|DRUG|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
215037832|NCT01248325|DRUG|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
215037833|NCT05505461|DRUG|neoadjuvant Radiation plus SOX and PD-1 antibody|"Patients will be given the perioperative treatment as below once recruited:~First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.~The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.~SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery."
215037834|NCT04073056|DRUG|Bupivacaine|Bupivacaine Hcl 0.25% Inj
215037835|NCT05728658|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
215037836|NCT05728658|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as specified in the treatment arm.
215037837|NCT05728658|DRUG|ICP-248+Orelabrutinib|Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
215037838|NCT05728658|DRUG|ICP-248+Orelabrutinib|Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
215037839|NCT05728658|DRUG|ICP-248 +Rituximab|Eligible patients will receive ICP-248 and Rituximab as specified in the treatment arm.
215037840|NCT05728658|DRUG|ICP-248+Orelabrutinib|Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
215037841|NCT05728658|DRUG|ICP-248+Orelabrutinib+Rituximab|Eligible patients will receive ICP-248 and Orelabrutinib and Rituximab as specified in the treatment arm.
215037842|NCT03887455|DRUG|Lecanemab|10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.
215037843|NCT03887455|DRUG|Placebo|Biweekly (once every 2 weeks) administered as i.v. infusion.
215037844|NCT03887455|DRUG|Lecanemab|Dose 1 administered as a subcutaneous injection.
215037845|NCT03887455|DRUG|Lecanemab|Dose 3 administered as a subcutaneous injection.
215037846|NCT03887455|DRUG|Lecanemab|Dose 2 administered as a subcutaneous injection.
215037847|NCT03887455|DRUG|Lecanemab|10 mg/kg once every 4 weeks administered as intravenous infusion.
215037848|NCT03887455|DRUG|Drug: Lecanemab|Dose 4 administered as a subcutaneous injection.
215037849|NCT06523504|DEVICE|DIMS|wear DIMS ,and use placebo,once nightly, both eye
215037850|NCT06523504|DRUG|The 0.02% ATP Group|wear SP, and use 0.02%ATP eye drops, once nightly, both eye
214476591|NCT05476900|DRUG|HR19042 Capsules|HR19042 Capsules
214476592|NCT06280378|DRUG|KL003 Cell Injection Drug Product|Administered by intravenous infusion after myeloablative conditioning with busulfan.
214476593|NCT03654131|DEVICE|MWA|Patients are allocated to one of the two arms in a 1:1 randomization
214476594|NCT03654131|RADIATION|SBRT|Patients are allocated to one of the two arms in a 1:1 randomization
214872318|NCT05173857|DEVICE|Advance PTX|PTA in Dysfunctional Haemodialysis Access
214872319|NCT05173857|DEVICE|Advance LP (Low Profile)|Plain Old Balloon Angioplasty (POBA)
214872320|NCT05173857|DRUG|Paclitaxel (PTX)|Paclitaxel (PTX)
214872321|NCT02849938|DEVICE|TytoCare Device|Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
214872322|NCT05015283|PROCEDURE|The laparoscopic One-anastomosis gastric bypass will consist of:|gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
214872323|NCT05015283|PROCEDURE|The laparoscopic Roux-en-Y gastric bypass will consist of:|the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
214872324|NCT06173141|OTHER|low- to moderate-continuous intensity cycling exercises:|"aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
214872325|NCT06173141|OTHER|moderate- to high-interval intensity cycling exercises|"aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
214872326|NCT06173141|OTHER|hemodialysis sessions only|hemodialysis sessions only
214872327|NCT03583086|DRUG|Vorolanib|Given by mouth
214872328|NCT03583086|BIOLOGICAL|Nivolumab|Given by IV
214872329|NCT02213653|DRUG|ARM A : IV iron + epoietin zeta|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~* Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~  * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
214872330|NCT02213653|DRUG|ARM B: IV iron + epoietin zeta sequence|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~* carboxymaltose ferric (Ferinject ®) at week 1~  * Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~ * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
214872331|NCT02213653|DRUG|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
214872332|NCT00238758|DRUG|Omega-3 Polyunsaturated Fatty Acids|
214872333|NCT03555383|DIAGNOSTIC_TEST|Coagulation factor levels|The minimal functional hemostasis reserve capacity are defined by triggers as hematocrit: 27%, platelets: 30 G/l, Fibrinogen (FI): 1g/l, FII-FV-FVII-FX: 30%, Antithrombin III: 40%, FXIII: 60% levels. The estimate blood volume methodology is used for to determine the amount of allowable blood loss in volume (ml) that does not require replacement based on current and trigger levels. The individualized pyramid of intervention defined as hemostasis reserve capacity are followed at every studied patient. All measurements and calculations are performed before liver transplantation (T1), at arrival on Intensive Care Unit (T2) and 12-24-48 hours after liver transplantation (T3-4-5).
214872334|NCT01912378|DRUG|Oxytocin|
215037851|NCT06523504|DRUG|The 0.04% ATP Group|wear SP, and use 0.04%ATP eye drops, once nightly, both eye
214872335|NCT01912378|DRUG|Placebo nasal spray|
214872336|NCT06446258|OTHER|Manual therapy (myofascial release, soft tissue mobilization)|Soft tissue mobilization will be performed by a team of experienced manual therapists.
214872337|NCT04238260|BEHAVIORAL|Enhancing Physical Therapy Usual Care|The protocol is focused on the completion of a minimum of 30 minutes of weight-bearing, walking-related activities that progressively increase in intensity informed by heart rate and step counters over 4 weeks.
214872338|NCT04238260|BEHAVIORAL|Physical Therapy Usual Care|Usual physical therapy
214872339|NCT04996914|PROCEDURE|TACE|1-2 session TACE before SBRT according to the preference of the interventional radiologist. Goal of TACE is the complete emnbolization of the HCC-nodules. It is allowed to use both conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) according to the interventional radiologist preference.
214872340|NCT04996914|RADIATION|SBRT|"SBRT should be 1 month after last TACE. This can be extended till 2 months if indicated. However, prolongation of the gap between TACE and SBRT is not encouraged.~Treatment center should choose one of fractionation schedule mentioned allowed in the study, in order to achieve a balance between dose applied for tumor control and constraints for OAR PTV Dose in 5 / 8 fractions (Gy) EQD2 (α/β 10Gy) 5x 8-6 Gy @ 83% isodose = 40-30 Gy (60-40 Gy) 8 x 6-4.5 Gy @ 83% isodose = 48-36 Gy (64-43.5 Gy)"
214872341|NCT02143973|DRUG|nalbuphine HCl ER|nalbuphine HCl ER
214872342|NCT06416787|DRUG|placebo|IBI355 7.5mg/kg Q4W
214872343|NCT06416787|DRUG|IBI355|IBI355 1mg/kg Q4W
214872344|NCT04808479|BEHAVIORAL|imFREE mCBT|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
215037852|NCT06523504|COMBINATION_PRODUCT|0.02%ATP+DIMS|wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
215037853|NCT06523504|COMBINATION_PRODUCT|0.04%ATP+DIMS|wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
215037854|NCT02964377|DRUG|(+)- Epicatechin|
215037855|NCT03184753|BIOLOGICAL|OC-IgT cells|Autologous human OC-IgT cells.
215037856|NCT06477003|DEVICE|Multispectral Optoacoustic Tomography|The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
215037857|NCT06477003|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
214872345|NCT04808479|BEHAVIORAL|mHealth ED|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
215037858|NCT04534075|BIOLOGICAL|Capsules containing either dietary fiber or placebo|The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.
215037859|NCT05169346|BEHAVIORAL|Active Closed Loop Real Time fMRI Neurofeedback|Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
215037860|NCT05169346|BEHAVIORAL|Sham Closed Loop Real Time fMRI Neurofeedback|Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
215037861|NCT05548647|BEHAVIORAL|Behavioral Treatment|All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh \< 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.
215037862|NCT05548647|DRUG|Placebo|An inactive saline solution administered via subcutaneous injection
215037863|NCT05548647|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|Semaglutide 2.4 mg is a once weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist that has been FDA approved for weight loss
215037864|NCT03371719|DRUG|Apalutamide|Given PO
215037865|NCT03371719|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
215037866|NCT03371719|OTHER|Placebo Administration|Given PO
215037867|NCT01813383|OTHER|There is not any intervention|
215037868|NCT06523803|DRUG|ZW171|Administered per protocol requirements
214872346|NCT03221348|BIOLOGICAL|CHO-H01|Glyco-engineered anti-CD20 antibody
214872347|NCT02543619|OTHER|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
214872348|NCT00128830|DRUG|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
214872349|NCT00128830|DRUG|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
214872350|NCT00128830|DRUG|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
214872351|NCT00128830|DRUG|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
214872352|NCT03058653|PROCEDURE|Small fluid boluses of 50 ml|Participants will receive small 50ml boluses of fluid up to 250ml in total. The remainder will be given as infusion pump method at a rate of 1000ml/hour which will complete in 15 minutes. In total, the 500ml will be given over 25 minutes.
214872353|NCT03058653|DEVICE|LIDCORapid Monitor|Addition of the LIDCORapid Monitor to measure stroke volume
215037869|NCT01644591|OTHER|Quality-of-Life Assessment|Ancillary studies
215037870|NCT01644591|OTHER|Questionnaire Administration|Ancillary studies
215037871|NCT01644591|RADIATION|Stereotactic Radiosurgery|Undergo SRS
215037872|NCT04746898|OTHER|Virtual Reality Training|Students received their basic life support application training through virtual reality glasses with special software.
214872354|NCT03470168|DEVICE|Hyperbaric Oxygenation Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
214872355|NCT03470168|DEVICE|Normobaric Oxygenation therapy|Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
215037873|NCT04746898|OTHER|High Fidelity Simulation Training|Students received their basic life support application training through high fidelity simulator mannequins.
215037874|NCT04746898|OTHER|Low Fidelity Simulation Training|Students received their basic life support application training through low fidelity simulator mannequins.
215037875|NCT03772535|DIAGNOSTIC_TEST|Pharmacogenomics Testing|The doctor will use genetic test results to prescribe medications that are a most effective for subject.
215037876|NCT05473065|DEVICE|Multiaxial Prosthetic Foot Emulator|Participants will walk in the laboratory with the multiaxial Prosthetic Foot Emulator (PFE) in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.
215037877|NCT05473065|DEVICE|Commercially available prosthetic feet|"Participants will walk in the laboratory with the commercial prosthetic study feet in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.~Additionally, participants will be fit with one of the commercial prosthetic study feet and wear it at home and in the community for approximately one week. Participants will return to the laboratory to follow-up testing, and will complete the community trial with each of the three commercial prosthetic study feet."
215037878|NCT04134260|DRUG|Apalutamide|Given PO
215037879|NCT04134260|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215037880|NCT04134260|PROCEDURE|Bone Scan|Undergo bone scan
215037881|NCT04134260|PROCEDURE|Computed Tomography|Undergo CT
215037882|NCT04134260|DRUG|Hormone Therapy|Receive hormone therapy
214872356|NCT05234372|BEHAVIORAL|mivacunaLA|Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (\<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites \& resources.
214872357|NCT01333774|DRUG|Glucobay (Acarbose, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
215037883|NCT04134260|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215037884|NCT04134260|PROCEDURE|Positron Emission Tomography|Undergo PET
215037885|NCT04134260|OTHER|Quality-of-Life Assessment|Ancillary studies
215037886|NCT04134260|OTHER|Questionnaire Administration|Ancillary studies
215037887|NCT04134260|RADIATION|Radiation Therapy|Undergo pelvis and prostate bed radiation therapy
215037888|NCT05470478|DEVICE|Mobile neural decoding platform (mobile iBCI)|An embedded neural signal processor device will be evaluated for its ability to provide accurate and reliable closed-loop control in a home-based brain-computer interface.
215037889|NCT03122184|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
215037890|NCT03122184|BEHAVIORAL|Motivational Interviewing Health Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
214872358|NCT03728855|BEHAVIORAL|Self-administration of medication (SAM)|Patients use medication from their own stock, self-administered.
214872359|NCT04058249|DEVICE|Accelerated intermittent theta-burst stimulation over right DLPFC|"All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator."
214872360|NCT02927366|DRUG|QCC374|0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID
215037891|NCT05248594|DRUG|HEMLIBRA|Emicizumab (Hemlibra, also known as ACE910 and RO5534262) is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.
215037892|NCT00830531|DRUG|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
215037893|NCT00830531|DRUG|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
215037894|NCT01300026|DRUG|AMG 319|AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
215037895|NCT03232788|PROCEDURE|Bone regeneration|Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
214872361|NCT02927366|DRUG|Placebo Matching|"Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID"
214872362|NCT06000943|OTHER|Low vs Intermediate vs High surgical risk stratified according with SAPT/DAPT/OAC and OAC+SAPT|"All patients undergoing TAVR will be stratified according with surgical risk level and all combination of antithrombotic therapy at discharge~Low risk (SAPT vs DAPT and OAC vs OAC+SAPT) Intermediate risk (SAPT vs DAPT and OAC vs OAC+SAPT) High risk (SAPT vs DAPT and OAC vs OAC+SAPT)"
215037896|NCT03232788|DEVICE|Collagen membrane|A collagen membrane will be used to cover the autogenous bone.
215037897|NCT03232788|DEVICE|Scaffold|A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
215037898|NCT04697849|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Therapy|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
215037899|NCT04697849|BEHAVIORAL|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
215037900|NCT00846157|BIOLOGICAL|NKM injection|NKCell about 100mg IV for 6times in each chemotherapy period.
215037901|NCT00435448|DRUG|Lonidamine|
215037902|NCT02835690|BIOLOGICAL|Pembrolizumab|IV infusion
215037903|NCT03674281|DEVICE|SAP|Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).
215037904|NCT03674281|DEVICE|CLC|The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
215037905|NCT05761821|DEVICE|Leadless pacemaker|All enrolled patients were implanted with leadless pacemaker.
215037906|NCT06551220|DRUG|Trastuzumab Deruxtecan|The patients received Trastuzumab Deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable adverse effects occurred.
215037907|NCT00710593|BIOLOGICAL|HPV vaccine for strains -6, -11, -16, and -18|All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
215037908|NCT04490278|OTHER|Medical Record Review - Inpatient Treatment|Patient characteristics, medical history, and information regarding their inpatient treatment from the electronic medical record
215037909|NCT04490278|OTHER|Online Questionnaires|Patients will complete online questionnaires related to their physical, cognitive and mental health function and inquire about current treatments. The multiprofessional CoV-PICS clinic practitioners will evaluate their responses and, combined with information obtained during their virtual visits, formulate a suggested treatment plan and needed referrals.
214665873|NCT05824208|BEHAVIORAL|PRENAYOGA - prenatal yoga|The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
214665874|NCT02257606|OTHER|I-TRAVLE training|
214665875|NCT03020186|OTHER|Physical activity|
214665876|NCT03020186|OTHER|Physical activity+ MED diet|
214665877|NCT03020186|OTHER|Physical activity+green MED diet|\*\*\*\*Sub-study from all 3 main arms: Autologous fecal microbiota supplement intervention derived from the time of maximal weight loss: At the 6-month time period, the time of anticipated greatest weight reduction, participants's feces samples will be processed to capsulized inocula. Samples will be frozen within 2 hours and will be kept at -80c pending analysis. Participants will be randomized to receive either research capsules or identical placebo capsules between 8 and 14 months time period. Placebo capsules will consist of a combination of powdered cocoa and vegetable gelatin in normal saline/glycerol and will be identical in appearance to research capsules.
214665878|NCT05076422|DRUG|BI 3006337|BI 3006337
214665879|NCT05076422|DRUG|Placebo|Placebo
214872363|NCT02472223|DRUG|Betadine 5%|"One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
214872364|NCT02472223|DRUG|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
214872365|NCT06402617|PROCEDURE|Pulmonary vein isolation|Standard clinical radio-frequency ablation isolation of pulmonary veins
214872366|NCT06402617|DIAGNOSTIC_TEST|RETRO-Mapping without adjunctive ablation|RETRO-Mapping performed using research equipment and software, but without any adjunctive ablation
214872367|NCT06402617|PROCEDURE|Adjunctive ablation guided by RETRO-Mapping|Radio-frequency ablation using a European conformity (CE)-marked ablation catheter of sites of focal activation identified by RETRO-Mapping
214872368|NCT03179215|DIAGNOSTIC_TEST|fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge
214872369|NCT04251520|DIAGNOSTIC_TEST|Pharmacogenomics testing|Participants will undergo pharmacogenomics testing and will be asked to provide a one-time buccal scraping. These results will be utilized for clinical treatment decisions.
214872370|NCT04251520|OTHER|Pharmacist review|Participants will have their medical information, including patient demographics, problem list, medication list, allergies, and relevant lab work reviewed by a One Point pharmacist. The pharmacist will work with the Palliative Medicine team to make medication related recommendations to improve individual patient care. The pharmacist will call the patient roughly 48 hours following their outpatient consultation or hospital discharge to review the medication list and address any medication-related questions. The pharmacy will send refill reminders to the patients.
214872371|NCT03620968|OTHER|cognitive training|15 minutes day of brain training by an APP
214872372|NCT06476951|BEHAVIORAL|Parent-Child Physical Activity Program|The program includes online education, parent-child games, parent-child dancing, and other parent-child physical activity activities.
214872373|NCT03573778|BEHAVIORAL|iHEAL|Women work with a Registered Nurse in 10-18 visits (over 6 months) that focus on 6 inter-related 6 components (areas): Safeguarding, Managing Symptoms, Getting Basics, Cautiously Connecting, Regenerating Family, Renewing Self. Using a standard 3 phase process, and guided by 5 principles, the nurse discusses each of these components with the woman in order to identify the woman's needs, experiences and priorities. The nurse then provides personalized support to assist the woman in address the concerns that she sees as most important for her health and well-being; this support includes linking women to existing services if she chooses.
214872374|NCT03573778|BEHAVIORAL|Information about Community Services|Women are provided with information about community services appropriate for women experiencing intimate partner violence and consistent with what service providers might recommend (usual care). Women are encouraged to use this information as they see fit.
215037910|NCT03279653|PROCEDURE|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
214665880|NCT03008551|DRUG|Empagliflozin|Each participant will receive empagliflozin 25mg daily for 3 months.
214665881|NCT03008551|DRUG|Metformin|Each participant will receive metformin 1500mg daily for 3 months.
214665882|NCT00920309|DRUG|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
214665883|NCT00920309|OTHER|Standard of Care-Placebo|
214872375|NCT02475330|DIETARY_SUPPLEMENT|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
214872376|NCT06061068|PROCEDURE|Hernia belt compression|Use the hernia belt to compress the inguinal region
214872377|NCT06170905|DIETARY_SUPPLEMENT|Whey protein-preload OGTT|Intake of 25 g whey protein diluted in water 30 minutes prior to the start of a regular 75 g oral glucose tolerance test
214872378|NCT02776137|DRUG|Docetaxel|Docetaxel: 20mg/m2/w for 6 weeks
214872379|NCT02776137|RADIATION|Intensity-modulated radiotherapy|a total dose of 60Gy in 30 fractions over 6 weeks
214872380|NCT02143648|DRUG|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
214872381|NCT02143648|DRUG|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
214872382|NCT02143648|DRUG|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
214872383|NCT06105801|PROCEDURE|Endobronchial ultrasound with transbronchial needle aspiration|Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration
214872384|NCT06105801|PROCEDURE|Bronchoscopy|Participants will undergo Bronchoscopy
214872385|NCT06105801|PROCEDURE|Cryobiopsy|Participants will undergo Cryobiopsy
214872386|NCT03172663|DEVICE|pure tone audiometry|for estimate the type and degree of hearing loss
214872387|NCT05002777|DRUG|rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
214872388|NCT06062043|BEHAVIORAL|Brief ACT with CPP Education Treatment|The Brief ACT with CPP Education treatment provides women veterans with new ways of responding to difficult thoughts and emotions related to pain while also encouraging them to engage in meaningful life activities. The CPP educational component includes information about pathology, risk factors, health outcomes, and treatment that are specific to women's biological and reproductive functioning. Treatment content has been further tailored to reflect the cultural experiences of women veterans (including discussions on the interplay between military culture, perceived social norms, and gender role expectations).
214872389|NCT03051932|DRUG|Ofiramev® (IV Acetaminophen)|Post -op pain medication
214872390|NCT03051932|DRUG|Placebo IV administration|Post -op pain
215037911|NCT00525421|DRUG|Curcuminoids|Curcuminoids tablets 2000mg three times per day for 12 days
215037912|NCT00525421|DRUG|Placebo|
215037913|NCT01695603|DEVICE|Intellivent|
215037914|NCT00822302|DRUG|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
215037915|NCT00822302|DRUG|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
215037916|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
215037917|NCT02829996|DRUG|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
215037918|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
215037919|NCT02829996|DRUG|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
214476595|NCT05709145|OTHER|Written recommendation|"Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within1 year.~The colonoscopy report will included that an adequate intestinal cleansing has not been achieved and therefore it is an invalid exploration. Additionally, a written recommendation indicating that the colonoscopy should be repeated within1 year will be included in the colonoscopy report. This recommendation is addressed both to the clinician who requested the colonoscopy and to the patient himself."
214872391|NCT06657456|DIETARY_SUPPLEMENT|Phytosterol-rich extract|Experimental product: extract rich in phytosterols
214872392|NCT06657456|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
214872393|NCT06581055|DRUG|Luspatercept|As per COMMANDS Trial (NCT03682536) study protocol
214872394|NCT06581055|DRUG|Epoetin Alfa|As per COMMANDS Trial (NCT03682536) study protocol
214872395|NCT06978140|BEHAVIORAL|Personalized feedback|Material includes feedback on alcohol-related consequences with elements from Acceptance Commitment Therapy, Relapse Prevention, Cognitive Behavioral Therapy, and Behavioral Activation. Focus of the intervention is learning about personal environmental cues.
214872396|NCT06979206|OTHER|Application of Binarual Beat|The binaural beat audio file consists of pure tones at 431 Hz in the left ear and 432 Hz in the right ear, delivered via earphones continuously until the end of anesthesia.
214872397|NCT06978556|DIAGNOSTIC_TEST|No intervention is subject of the study. Only standard pre- and postoperative data will be evaluated.|No intervention is subject of the study. Only standard pre- and postoperative data will be evaluated. Including data from testing refraction, visual acuity, biometry, tomography, and OCT.
214872398|NCT06983548|BIOLOGICAL|semen, blood and urine tests|Patients will undergo several tests, including semen analysis, spermocytogram, blood and urine tests, serology, and RT-PCR. These tests will be conducted on days 7±2, 15±2, 30±3, 60±5, 90±5, and 180±15. (Patients will only undergo the V6 if the sperm PCR result comes back positive on D90).
215037920|NCT02829996|DRUG|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
215037921|NCT03690908|OTHER|no intervention (descriptive study)|no intervention (descriptive study)
214476596|NCT06404905|DRUG|BT02 monoclonal antibody injection|It is expected to include 10-30 patients assigned to dose escalation cohorts.
214476597|NCT05107219|PROCEDURE|Biopsy|Undergo biopsy
214872399|NCT06982872|DIAGNOSTIC_TEST|artificial intelligence|Different AI assisted diagnostic systems are used to diagnose lesions.
215037922|NCT01923883|PROCEDURE|EUS-FNA|EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
215037923|NCT01923883|DEVICE|Echoendoscope Olympus GF-UCT240|
215037924|NCT05201131|PROCEDURE|Rezum|Rezum
215037925|NCT02684968|PROCEDURE|Colorectal surgery|
215037926|NCT05314660|DRUG|38 % silver diamine fluoride|Application of 38% SDF on carious dentine lesions.
215037927|NCT05314660|PROCEDURE|Atraumatic restorative technique|Hand excavation of carious dentine followed by application of Glass ionomer
215037928|NCT05314660|PROCEDURE|Ultra conservative dentistry|Removal of soft dentine and enlarging of cavity to control bio film
214665884|NCT06298097|DEVICE|Connectivity measures|Electroencephalography connectivity measures will be collected and compared in both stroke patients and healthy participants. Connectivity measures will be extracted using these devices: high-density electroencephalography (using either a 128-channel or a 256-channel system) and magnetic resonance imaging.
214665885|NCT01673880|DRUG|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
214665886|NCT00942201|DRUG|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
214665887|NCT00942201|DRUG|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
214665888|NCT05004467|OTHER|Mobilization With Movement Technique|The researcher explains cervical movements to the patient to be done while the technique is performed. This movements will be the painful and limited movements detected in goniometric intervention before the treatment and movements done actively and in all range of motion.
214665889|NCT05379322|DRUG|Anti-TNF|Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.
214665890|NCT05379322|DRUG|JAK inhibitor|Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.
214665891|NCT04907604|DEVICE|A multi-modal and integrative e-health platform aimed at promoting health and reducing the negative impact of mental problems in the workplace|It addresses six main domains: improving awareness of mental health problems and reducing stigma; reducing psychosocial risk factors in the workplace; improving wellbeing and reducing psychological symptoms; ensuring early detection of mental disorders; promoting healthy behaviours and lifestyles; and facilitating early return to work.
214665892|NCT02725255|DIETARY_SUPPLEMENT|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
214665893|NCT02725255|DRUG|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
214665894|NCT02725255|DIETARY_SUPPLEMENT|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
214872400|NCT06982560|DEVICE|electrical cardiometry|use of cardiometry parameters as cardiac output, thoracic fluid content, systemic vascular resistance
214872401|NCT06982560|OTHER|traditonal methods|clinical examination, lung ultrasound, inferior vena cava
214872402|NCT06982729|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
214872403|NCT06981767|DIETARY_SUPPLEMENT|Topical Bromelain|A natural enzyme-based formulation derived from pineapple, bromelain in orabase is being investigated for its anti-inflammatory and wound-healing properties. As a non-steroidal alternative, it offers a potentially safer treatment option with minimal side effects.
214872404|NCT06981767|DRUG|0.1% topical triamcinolone acetonide|A corticosteroid-based standard treatment for OLP, triamcinolone acetonide in orabase is used for its strong anti-inflammatory and immunosuppressive effects. It serves as the conventional treatment versus novel therapy in this study
214872405|NCT06981767|COMBINATION_PRODUCT|Combination of Topical Bromelain and Triamcinolone Acetonide in Orabase|This novel formulation combines the enzymatic, healing properties of bromelain with the anti-inflammatory property of triamcinolone. It is designed to provide enhanced therapeutic effects through synergistic action, potentially reducing the required corticosteroid dose while improving clinical outcomes.
214872406|NCT06981676|DIETARY_SUPPLEMENT|DHA and EPA|Women will receive daily supplementation of LCPUFAs (DHA and EPA) from first trimester until delivery
214872407|NCT06983431|BEHAVIORAL|technology driven self coaching|subject will be provided with the technology driven lifestyle coaching based on the real time data from the wearables
214872408|NCT06983431|BEHAVIORAL|Health coaching|participants will be provided with the health coach (expert) driven lifestyle coaching based on the real-time data from the wearables
214872409|NCT06983431|BEHAVIORAL|Peer coaching|participants will be provided with the peer coach (expert) driven lifestyle coaching based on the real-time data from the wearables
214872410|NCT06983431|BEHAVIORAL|Active Control|participants will be provided with the wearable, but not exposed to any of the coaching strategies. Real-time data provided by the wearable will be available to them.
214872411|NCT06982313|DRUG|Tamoxifen (Nolvadex)|5 mg per day for 3 years during TAM-01 phase III trial
214872412|NCT06982313|DRUG|Tamoxifen (Nolvadex) placebo|Tamoxifen (Nolvadex) placebo per day for 3 years during TAM-01 phase III trial.
214872413|NCT06983119|OTHER|Case-finding for Neurocognitive Disorders|The intervention targets individuals reporting cognitive concerns without a prior diagnosis of MCI or dementia, with participants accessing three different settings for evaluation. The first setting involves General Practitioner (GP) offices, where GPs, trained in dementia risk factors and cognitive assessment tools (such as GPcog), will identify at-risk patients and refer them for further evaluation at a Center for Cognitive Disorders and Dementia (CCDD). The second setting is the Dementia Operations Center (COD) Information Desk, a public service where neuropsychologists assess citizens who independently report cognitive disturbances. The third setting includes Open Days, public events aimed at detecting early signs of cognitive decline, where neuropsychologists will assess participants using the Addenbrooke's Cognitive Examination-III (ACE-III) and the LIBRA Index. Individuals identified as at-risk in any of the three settings will be referred for further evaluation at a CCDD.
214665895|NCT00005592|BIOLOGICAL|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
214291147|NCT03323931|BEHAVIORAL|(2) robot--enhanced intervention|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by the robotic agent (Softbank Robotics Nao robot). All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
214872414|NCT06983600|OTHER|alternative therapy:sujok therapy|As of the first day of the menstrual period for a total of 10 days, the researcher will provide sensitization of the points and painful point detection with the ring and in-hand spiral in the hand macro insect and mini system. Then, moxa will be applied to the uterus and ovary reflection point between 2 minutes and 5 minutes. Moxa is a method that burns wormwood and treats it with the heat emitted to the skin by the smoke with perforated apparatus. It is one of the oldest treatment methods based on heat and plant healing. After the Moxa application, the black pepper seed will be fixed to the painful spot with the help of an air-tight plaster. The black pepper seed will be kept for at least 4 hours and maximum 8-10 hours.
214872415|NCT06981728|PROCEDURE|Mid point transverse to pleura block|"TPVB and MTPB was performed at a spinal level midway between the uppermost and the lowest fractured rib, with the patient in a sitting position, and under complete aseptic conditions, a linear ultrasound probe (GE Healthcare-Logiq F6) will be placed oblique parasagittally 3 cm lateral to spinous process used to identify the transverse process, pleura, superior costotransverse ligament, and the paravertebral space at the target vertebral level.~After skin and subcutaneous tissue infiltration with 2-3 mL of 2% lignocaine, an 18-gauge Touhy needle was inserted under ultrasound guidance until the needle tip reaches :~* the midpoint between the transverse process and the pleura (group M).~* the paravertebral space (group P). A bolus dose (0.3mL/kg) of plain bupivacaine 0.5% plus 8 mg of dexamethasone was injected after negative aspiration to blood and air."
214872416|NCT06983756|DRUG|Erythropoietin|EPO resistance
214872417|NCT06981845|DRUG|Immunosuppressive therapy|prednisone + sirolimus
214872418|NCT06981845|DRUG|Placebo|Placebo
214872419|NCT06982053|DIAGNOSTIC_TEST|Received 68Ga-NOTA-GZP PET scanning|Received twice 68Ga-NOTA-GZP PET scanning before neoadjuvant therapy and radical surgery.
214872420|NCT06982651|DRUG|MI078|"Dosage Form: Capsule Specification: 25 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day~Dosage Form: Capsule Specification: 50 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day~Dosage Form: Capsule Specification: 200 mg~Administration and Dosage: Oral. Options include:~* 1 capsule per dose, once daily;~* 2 capsules per dose, once daily;~* 3 capsules per dose, once daily;~* 4 capsules per dose, once daily; Duration of Treatment: 1 day .~Dosage Form: Capsule Specification: 200 mg~Administration and Dosage: Oral. Options include:~* 1 capsule per dose, twice daily;~* 2 capsules per dose, twice daily; Duration of Treatment: 7 days .~Dosage Form: Capsule Specification: 50mg~Administration and Dosage: Oral. Options include:~\- 5 capsule per dose, Three times a day Duration of Treatment: 3 days ."
214872421|NCT06982651|DRUG|Placebo|Placebo of MI078 Capsule
214872422|NCT06983145|OTHER|Olive Leaf tea|Individuals will consume 2-3 pieces of biscuits with caramel coloring (total 120 g) and a glass (250 mL) of tea (natural mineral water with 1.25 g. dried olive leaves)
214872423|NCT06982547|BIOLOGICAL|UTAA91 injection|After signing the informed consent form, eligible subjects will receive an infusion of UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, and safety.
214872424|NCT06983054|DRUG|ertugliflozine|SGLT2i versus placebo
214872425|NCT06983054|BEHAVIORAL|low salt diet|comparing low salt versus high salt diet
214872426|NCT06983054|DRUG|placebo|placebo tablet
214872427|NCT06983054|BEHAVIORAL|high salt diet|high salt diet
214872428|NCT06982833|OTHER|Trunk restraint|Participants were seated in a chair with a standard sitting height of 26 centimeters. After completing the 9-Hole Peg Test with their trunks free on a table of appropriate height so that their trunks would not flexion, they were secured to the chair crosswise in front of their chest with the help of a non-elastic but firm enough belt that would not cause discomfort to the person. Participants completed the 9-DPT with their trunks constrained.
214872429|NCT06438263|DRUG|Rocatinlimab|Vial supplied as a single-use preservative free solution for SC injection.
214872430|NCT06438263|DRUG|Rocatinlimab|Autoinjector for SC injection.
214872431|NCT06982014|BEHAVIORAL|cilinical simulation|he experimental group will interact with standardized patients (using moulage techniques) who exhibit signs of physical violence. This approach provides a realistic environment for students to assess the physical manifestations of violence and practice their recognition skills in a controlled, yet lifelike, setting.
214872432|NCT06982014|OTHER|Educational Video Viewing|"The control group will watch a film titled Gözlerimde Al (translated as Take My Eyes), which addresses the issue of gender-based violence. The film aims to provide insights into the emotional and physical effects of violence against women and encourages reflection on how to recognize such violence in real-life scenarios."
214872433|NCT06983873|BEHAVIORAL|adapted Canadian C-Spine rules|The CCRa are decision rules for pre-hospital cervical spine collar immobilization. They include three high-risk criteria indicating imaging, 5 low-risk criteria allowing assessment of cervical spine rotation, and finally the ability of patients to achieve limited active rotation. They have been designed and validated to avoid immobilization during transport to the emergency department without any significant cervical injury being missed.
214872434|NCT06982976|PROCEDURE|ALA-PDT|use ALA\_PDT to treat the disease
215037929|NCT01116284|PROCEDURE|Revision of gastric bypass|A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
215037930|NCT01310972|OTHER|Registry|Registry
215037931|NCT00158678|PROCEDURE|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
215037932|NCT00158678|PROCEDURE|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
215037933|NCT00158678|DRUG|concomitant cisplatin|100 mg/m2 D1, D22, D43
215037934|NCT02665910|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
215037935|NCT02665910|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
215037936|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1 hour. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
215037937|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
215037938|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3 hours. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
215037939|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
215037940|NCT01441960|DRUG|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
215037941|NCT01441960|DRUG|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
215037942|NCT05775445|PROCEDURE|Blood draw|2 6ml blood tubes will be collected from patient
215037943|NCT02408744|DRUG|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
215037944|NCT04578626|DEVICE|dry needling|The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
215037945|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Workshop|2 day workshop
215037946|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Online|Online curriculum
215037947|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Group|3 in person group sessions
215037948|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Individual|3 sessions in person one on one
215037949|NCT04841408|OTHER|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
215037950|NCT00089492|DRUG|Optimized Background ARVs|As prescribed
215037951|NCT00089492|DRUG|enfuvirtide [Fuzeon]|180mg sc once daily for 48 weeks
215037952|NCT00089492|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 48 weeks
215037953|NCT02004158|BEHAVIORAL|Positive psychology intervention|
215037954|NCT03766984|DRUG|Diclofenac sodium 25 mg|Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
215037955|NCT03766984|DRUG|Tramadol hydrochloride 25 mg|Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
215037956|NCT03766984|DRUG|Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg|Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
215037957|NCT02986074|DEVICE|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
215037958|NCT02986074|DEVICE|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
214476598|NCT05107219|PROCEDURE|Biospecimen Collection|Undergo collection of luminal fluid
215037959|NCT03842735|OTHER|exercise and rehabilitation counselling|The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).
214872435|NCT06983964|GENETIC|CD19 CART|"Dose group dosage unit (CAR+T cells/kg) Acceptable dose range Expected sample size (± 30%, CAR+T cells/kg)~1. 0.5 × 106 0.4 × 106\~0.6 × 106 3-6 cases~2. 1.0 × 106 0.7 × 106\~1.3 × 106 3-6 cases~3. 2.0 × 106 1.4 × 106\~2.6 × 106 3-6 cases Dose escalation rule The enrollment starts from dose group 1, and if no DLT occurs in the 3 subjects included, they will be transferred to the next dose group. If one of the three subjects in a certain dose group develops DLT, three additional subjects will be added to the group for cell infusion at the same dose. If there is ≥ 1 case of DLT in the 3 additional cases, it will be reduced to the previous dose group. If there are only 3 subjects in the previous dose group at this time, an additional 3 subjects need to be added for the trial; If there are already 6 subjects in the previous dose group, the trial ends and this dose is the maximum tolerated dose (MTD)."
215037960|NCT03842735|BEHAVIORAL|rehabilitation counselling|RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
215037961|NCT05511402|OTHER|Exercise training|People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.
215037962|NCT03680807|DIAGNOSTIC_TEST|Muscle function test|Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests
215037963|NCT02481414|BIOLOGICAL|PepCan|50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities
215037964|NCT02481414|BIOLOGICAL|Candin®|0.3 mL Candin® per dose administered intradermally in the extremities
215037965|NCT00360945|DRUG|cisplatin|
215037966|NCT00360945|DRUG|temozolomide|
215037967|NCT00360945|GENETIC|fluorescence in situ hybridization|
215037968|NCT00360945|GENETIC|loss of heterozygosity analysis|
215037969|NCT00360945|OTHER|immunohistochemistry staining method|
215037970|NCT00360945|OTHER|laboratory biomarker analysis|
215037971|NCT00360945|RADIATION|radiation therapy|
214476599|NCT05107219|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
215037972|NCT00216333|DRUG|combined fixed dose combination|
215037973|NCT00071955|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
215037974|NCT00071955|BIOLOGICAL|sargramostim|
215037975|NCT02004626|DRUG|Collagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
215037976|NCT02004626|DRUG|Kollagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
215037977|NCT02457026|DRUG|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
215037978|NCT02457026|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
215037979|NCT02457026|DRUG|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
215037980|NCT01006161|DRUG|SCH 527123|Low dose
215037981|NCT01006161|DRUG|SCH 527123|Medium dose
215037982|NCT01006161|DRUG|SCH 527123|High dose
214476600|NCT05107219|DRUG|Linaclotide|Given PO
214476601|NCT05107219|DRUG|Plecanatide|Given PO
215037983|NCT01006161|DRUG|SCH 527123|Placebo to match SCH 527123
215037984|NCT01444911|DEVICE|Vaginal Renewal Program|The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.
215037985|NCT01444911|DEVICE|Vaginal Dilator|Still vaginal dilator with lubricant.
215037986|NCT03581175|PROCEDURE|Colonoscopy|
215037987|NCT03581175|DRUG|Bowel cleansing regimen|
215037988|NCT04270643|DIETARY_SUPPLEMENT|Vitamin D3|ATC code A11CC05 (cholecalciferol)
215037989|NCT04270643|DIETARY_SUPPLEMENT|Placebo|Ethyl oleate
215037990|NCT02194790|BEHAVIORAL|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
215037991|NCT05804929|OTHER|Observation without intervention|Observation of food intake, body composition, microbiota, genetics, metabolic rate, metabolomics.
215037992|NCT01968343|BEHAVIORAL|Cognitive-behavioral therapy.|Subjects receive 22 sessions of cognitive-behavioral therapy.
214476602|NCT04282980|DRUG|DCC-2618|Oral kinase inhibitor
214476603|NCT05660629|OTHER|Mulligan Mobilization|Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
215037993|NCT01968343|OTHER|Supportive therapy.|Subjects receive 22 sessions of supportive therapy.
214665896|NCT00005592|BIOLOGICAL|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
214665897|NCT00005592|RADIATION|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
214665898|NCT06035497|DRUG|BMS-986369|Specified dose on specified days
214872436|NCT06982664|PROCEDURE|High Tie of Inferior Mesenteric Artery|IMA was ligated approximately 1 cm from its origin after dissection of the surrounding tissue to ensure clear visualization of the IMA root. Using this technique, the LCA and the inferior mesenteric vein were ligated near the lower border of the pancreas
214872437|NCT06982664|PROCEDURE|Low Tie of Inferior Mesenteric Artery|During this procedure, the LCA was identified and preserved, and the superior rectal artery was ligated. Before colonic transection or anastomosis, the preserved LCA underwent temporary, controlled occlusion. After assessing perfusion changes using LSCI, the occlusion was released to restore blood flow.
214872438|NCT06983197|DIAGNOSTIC_TEST|blood test|Blood samples are drawn every 3-5 days in the RRT group but only once in the control group
214872439|NCT06593054|DRUG|Ceftibuten|Ceftibuten dihydrate, formulated in capsules
214872440|NCT06593054|DRUG|Avibactam prodrug|Avibactam prodrug, formulated in capsules
214872441|NCT06593054|DRUG|CTB-AVP in Tablet|ceftibuten and avibactam prodrug, in Tablet formulation
214872442|NCT06981624|OTHER|No heparin|Hemostasis achieved using a dual-artery compression device without administration of heparin after trans-radial diagnostic catheterization
214872443|NCT06980233|BEHAVIORAL|reentry assistance mobile health app|R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session MISSION-CJ self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) SDOH resource finder; and 4) a dashboard to track R-Assist engagement.
214872444|NCT02032095|DRUG|GB-0998|
214872445|NCT03996642|BEHAVIORAL|Avatar Life Review|VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
214872446|NCT02768714|DRUG|Eurofarma's pegfilgrastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
214872447|NCT02768714|DRUG|Neulastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
214872448|NCT01688570|DRUG|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
215037994|NCT01424800|DEVICE|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
215037995|NCT02398812|OTHER|Medication assessment and treatment plan based on it|"Intervention~* Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.~* Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician."
214665899|NCT04277572|PROCEDURE|Aortic valve replacement|Aortic valve surgery
214665900|NCT06267482|PROCEDURE|ROSA PSA Parapatellar Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be the same as the standard of care (medial parapatellar approach).
214665901|NCT06267482|PROCEDURE|ROSA PSA Subvastus Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be an alternative, quad-sparring, subvastus approach.
214665902|NCT06431542|PROCEDURE|physician-applied Triamcinolone Acetonide Econazole Cream|The doctor applies the Triamcinolone Acetonide Econazole Cream onto a thin cotton swab and gently inserts it deep into the ear canal, evenly spreading the cream around the sides of the ear canal and on the surface of the eardrum.
214665903|NCT06431542|PROCEDURE|patient-applied Triamcinolone Acetonide Econazole Cream|The patient applies Triamcinolone Acetonide Econazole Cream in the external auditory canal at home using a cotton swab.
214665904|NCT02983058|RADIATION|PET/SPECT Scan|PET scan will be performed on a mCT scanner
214665905|NCT02983058|DEVICE|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
215037996|NCT00078221|DEVICE|Rheopheresis blood filtration|
215037997|NCT05090618|GENETIC|DNA analysis|GWAS
215037998|NCT02117011|OTHER|Physical Activity|Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
215037999|NCT04750421|DEVICE|Transillumination Venolux®|Transillumination Venolux® method was used on the other half of the face before injections to visualize veins.
214872449|NCT01688570|DRUG|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
214872450|NCT01688570|DRUG|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
215038000|NCT03186768|BEHAVIORAL|Soap on a rope hall pass intervention|School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
215038001|NCT06351618|OTHER|No intervention will be conducted.|No intervention will be conducted.
215038002|NCT03461718|DRUG|Ketamine|Experimental arm for sedation.
215038003|NCT03461718|DRUG|Midazolam injection|Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
215038004|NCT03461718|DRUG|Fentanyl|Part of standard sedation regimen
215038005|NCT00069641|BIOLOGICAL|Iduronate-2-sulfatase enzyme replacement therapy|Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
215038006|NCT00069641|BIOLOGICAL|iduronate-2-sulfatase enzyme replacement therapy|Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
215038007|NCT00069641|BIOLOGICAL|Placebo|Patients will receive weekly infusions of placebo.
214872451|NCT03077555|DRUG|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
215038008|NCT06102395|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, on day1 of Q3W, 2 cycle
215038009|NCT06102395|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, IV, day 1 of Q3W
215038010|NCT06102395|DRUG|Carboplatin|Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W
215038011|NCT06102395|DRUG|Nedaplatin|Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W
215038012|NCT06102395|DRUG|Nab paclitaxel|Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W
215038013|NCT06102395|DRUG|Docetaxel|Docetaxel 75 mg/m\^2, IV, day 1 of Q3W
215038014|NCT06102395|DRUG|Liposomal paclitaxel|Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W
215038015|NCT06102395|DRUG|Fluorouracil|Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
215038016|NCT05101720|PROCEDURE|Ultrasound Guided Axillary Venous Access|Direct visualization of axillary vein will be obtained with ultrasound sterile linear probe.
215038017|NCT05101720|PROCEDURE|Fluoroscopy-Guided Axillary Venous Access|Fluoroscopic landmarks will be used and axillary venous puncture will be performed without ultrasound
215038018|NCT00002529|DRUG|cyclophosphamide|cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
215038019|NCT00002529|DRUG|doxorubicin hydrochloride|doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
215038020|NCT00002529|DRUG|epirubicin hydrochloride|epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
215038021|NCT00002529|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily.
215038022|NCT00002529|DRUG|toremifene|Toremifene 60 mg daily.
215038023|NCT05058326|DIAGNOSTIC_TEST|Portable endoanal manometry|Endoanal manometry values will be obtained using de Anopress® device. Fecal incontinence severity questionaries will be filled and collected.
214872452|NCT03077555|DRUG|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
214872453|NCT01943110|DEVICE|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
214872454|NCT01943110|DEVICE|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
214872455|NCT03240237|DEVICE|Optimizer SMART|Cardiac Contractility Modulation
214872456|NCT03441932|PROCEDURE|Fiberoptic endoscopic evaluation of swallowing (FEES)|"Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree."
214872457|NCT02362555|OTHER|no intervention was used in this observational study|
214872458|NCT00637650|PROCEDURE|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
214872459|NCT00637650|PROCEDURE|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
214872460|NCT04053920|BEHAVIORAL|Low Load Resistance exercise|leg extension, leg press, leg curl and calf press
214872461|NCT04053920|BEHAVIORAL|High Load Resistance exercise|leg extension, leg press, leg curl and calf press
215038024|NCT05058326|DIAGNOSTIC_TEST|Endoanal ultrasound|To assess the integrity of the anal canal.
215038025|NCT05058326|OTHER|Incontinence severity scale questionaires|Wexner and St. Mark's scales.
215038026|NCT00948350|PROCEDURE|awake intubation|two anesthesia techniques
215038027|NCT03766061|PROCEDURE|Onlay mesh Hernioplasty|Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath
215038028|NCT03766061|PROCEDURE|Sublay Mesh Hernioplasty|Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
215038029|NCT03186638|DRUG|Ibuprofen|Given PO
215038030|NCT03186638|OTHER|Placebo|Given PO
215038031|NCT03186638|OTHER|Questionnaire Administration|Ancillary studies
215038032|NCT01055145|DRUG|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
215038033|NCT05178186|PROCEDURE|Thyroidectomy|Surgery for thyroid carcinoma
215038034|NCT00006163|BEHAVIORAL|Personalized Self-management|
215038035|NCT00006163|BEHAVIORAL|Community Resources|
215038036|NCT02902614|PROCEDURE|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
215038037|NCT02902614|PROCEDURE|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
215038038|NCT03787654|DEVICE|electroacupuncture|"BL33 and BL35 are inserted by needles of 0.30×75mm size till a depth of 60\~70mm. SP6 is inserted by needle of 0.30×40mm size till a depth of 25-30mm. After manipulation and deqi sensation generation, the electrodes will be attached to the acupoints transversely with 20Hz continuous wave and an electricity current of 2mA-6.5mA at BL33 and BL35, and 1-3.5mA at SP6. The current is adjusted from zero to the degree where patients can tolerate.~Subjects receive 3 sessions per week（every other day ideally) for 12 weeks, 36 sessions in total."
215038039|NCT03787654|DEVICE|sham electroacupuncture|"In sham electroacupuncture group, sham acupoints 1 cun(≈15mm） horizontally outwardly lateral to BL33 and BL35, and 0.5 cun (≈10mm) horizontally behind SP6 are stimulated by needles of 0.30×40mm size. The needles are inserted to a depth of 2-3mm to stand still, without any manipulation and sensation of deqi. The electrodes will also be attached to needles with an electricity current of 0.1-0.3mA.~The sessions will be the same as the electroacupuncture group."
215038040|NCT03787654|DRUG|Solifenacin|Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
215038041|NCT01263119|DRUG|Warfarin|10-mg warfarin oral dose
215038042|NCT01263119|DRUG|LY2216684|18-mg LY2216684 oral dose
215038043|NCT04653792|DRUG|Pregabalin 75mg|75 mg capsule
215038044|NCT04653792|DEVICE|Placebo|75 mg
214291148|NCT03323931|BEHAVIORAL|(1) discrete trial training / cognitive-behavior therapy|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by an interaction partner (human), under the supervision of the therapist. All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
214872462|NCT00867997|OTHER|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
214872463|NCT00867997|OTHER|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
214872464|NCT00867997|OTHER|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
214872465|NCT03603379|DRUG|C225-ILs-dox|C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
214872466|NCT03045991|BEHAVIORAL|aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
214872467|NCT03045991|BEHAVIORAL|control training|The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.
214872468|NCT03045991|BEHAVIORAL|cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
214872469|NCT05648461|RADIATION|Five fraction of post operative radiotherapy|Target volume will include tumor bed \& ipsilateral level I-III levels.
214872470|NCT00426361|BIOLOGICAL|Boostrix ® Polio|One dose of vaccine administered intramuscularly
214872471|NCT00426361|BIOLOGICAL|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
215038045|NCT02857972|DEVICE|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
215038046|NCT03135860|DRUG|Inhaled Nitric Oxide 30mcg/kg IBW/hr|Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
215038047|NCT03481439|OTHER|Collection of a Pharmaceutical intervention|collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort
215038048|NCT06310382|DRUG|GH55|GH55 capsule is a novel small molecule, highly selective dual-mechanism ERK1/2 inhibitor developed by Suzhou Genhouse Bio. Co., Ltd. This product can be used to treat cancers caused by abnormal activation of the MAPK pathway (mutational activation of RAS/RAF/MEK) by targeted inhibition of ERK1/2.
214291149|NCT04829903|DRUG|Dulaglutide|Dulaglutide injections
214291150|NCT04829903|DRUG|Liraglutide|Liraglutide injections
214291151|NCT02498860|DRUG|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
214291152|NCT02498860|DRUG|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
214665906|NCT02357277|DRUG|Budesonide|inhaled glucocorticoid budesonide as dry powder inhaler
214872472|NCT03596892|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
214872473|NCT03596892|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
214872474|NCT03596892|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
214872475|NCT06123923|OTHER|no intervention|no intervention, just retrospective observation
214872476|NCT02549235|OTHER|Ultrasound|Routine 2D/3D ultrasound assessment
214872477|NCT06396065|DRUG|AK112 Injection|Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
214872478|NCT06396065|DRUG|Placebo Injection|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
214872479|NCT00525551|DRUG|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
214872480|NCT00525551|DRUG|Placebo (NaCl)|300 mL 0.9% NaCl
214872481|NCT03603548|DRUG|Envarsus|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
214872482|NCT03603548|DRUG|Advagraf|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
214872483|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~* Respiratory rate, respiratory signs, stridor : first and second visit~* 24h holter-ECG : first and second visit~* 24h impedance pH-metry : first visit~* Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~* 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~* succimetry procedure : at first visit only between birth and 2 months"
214872484|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~* Respiratory rate, respiratory signs, stridor~* 24h holter-ECG~* 24h impedance pH-metry~* Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~* 24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index~* Succimetry procedure : at first visit only between birth and 2 months"
214872485|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
214872486|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets|"These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
214872487|NCT05607641|DRUG|Neospastil, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).~Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day."
214872488|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Pre-TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
214872489|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Post TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
214872490|NCT00269243|DRUG|Quinapril|
214872491|NCT00006019|DRUG|azacitidine|
214872492|NCT00006019|DRUG|sodium phenylbutyrate|
214872493|NCT03849183|DRUG|Nitroglycerin|Subcutaneous nitroglycerin injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
214872494|NCT03849183|DRUG|Normal saline|Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
214872495|NCT03821181|DEVICE|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
214872496|NCT03821181|DEVICE|Sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
214872497|NCT01758588|DRUG|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
214872498|NCT06633575|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
214872499|NCT04642365|DRUG|RO7296682|RO7296682 will be administered as per the schedules specified in the respective arms.
214872500|NCT04642365|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
215038049|NCT01370876|DRUG|Oxaliplatin|Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
215038050|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
215038051|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
215038052|NCT00678704|DRUG|Placebo|Placebo tablet prior to intercourse on demand
215038053|NCT01195974|DRUG|YASMIN|YASMIN for 21 days
214665907|NCT02357277|OTHER|Placebo Inhaler|inhaled placebo
215038054|NCT01195974|DRUG|GSK2248761|200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
214291153|NCT01080352|DRUG|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
214872501|NCT06665204|OTHER|Clinical Practice Guideline-adherent Care|Clinical examination procedures will be used to identify all appropriate impairment subcategories (Overuse/Overload without Other Impairment, PFP with Movement Coordination Deficits, PFP with Muscle Performance Deficits, PFP with Mobility Impairments) and create a subcategory-specific or multimodal (for patients classified to \>1 subcategory) plan of care. Research physical therapists will target all applicable impairment subcategories using the corresponding CPG-recommended interventions, all of which are recommended for use as part of standard-of-care physical therapy practice. The duration and length of care will not be prespecified or standardized across participants to allow flexibility pending participant's care needs and schedule (e.g., vacation, short-term TDY status); however, research PTs will be trained to target providing no more than 10-12 visits over no more than 6-8 weeks to promote generalizability of the CPG-adherent intervention.
214872502|NCT06665204|OTHER|Usual Care|Usual physical therapy care will be provided by a licensed outpatient staff physical therapist who is not associated with the research team. The outpatient physical therapists will not treat participants in the CPG-adherent group and will be free to treat their participants based on their current personal and organizational clinical practice standards. The research team will neither influence nor restrict the evaluations conducted or interventions provided.
214291154|NCT02762266|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214872503|NCT06985368|DRUG|SIBP-A18|"SIBP-A18 formulation for injection, Claudin18.2-ADC. Strength: 1.0, 2.0, 3.2, 4.0, 4.8, 5.6, 6.4 and 8.0 mg/kg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle. The dose escalation stage, 1mg/kg and 2mg/ kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one participant. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored. The third stage will use RP2D for further exploration."
214872504|NCT06983574|OTHER|MIA|"Through a collaborative co-creation process, MIA, a mHealth app was developed and refined over multiple iterations with the goal of promoting physical activity and fostering a lifestyle centred around an active and healthy approach. Content and design were derived from both the co-creative workshops and based on the theoretical framework of the intervention functions of the BCW. The final mHealth app is composed by five major features:~* Tailor-made tips~* Literacy aiming to improve awareness about PA and an active healthy lifestyle~* Exercise workouts~* Community calendar aiming to enhance social connections~* A diary consisting of daily activities (MIA workouts and self-registration) To customize the user experience, a brief personal description was created as the start screen, which prompts older adults to answer questions related to their baseline physical activity level, motivation, and medical history."
214872505|NCT06606639|DIETARY_SUPPLEMENT|Caffeine|acute caffeine intake (3 mg/kg)
214872506|NCT06606639|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
214872507|NCT04661891|OTHER|Isometric contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of applying joint torque to reach a pre-defined torque level based on the subject's maximal voluntary contraction (i.e., 25%, 60%, 70%, 80%, 90%). The participant will control torque intensity by responding to a biofeedback displayed on a screen. The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
214872508|NCT04661891|OTHER|Isokinetic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of moving a joint to completing a set of contractions (10-20 contractions) at various velocities (i.e., 10 degrees per second, 30 degrees per second, 60 degrees per second). The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
215038055|NCT01195974|OTHER|Placebo|Placebo taken on Days 1 - 10 or Days 12 - 21
215038056|NCT03759496|BIOLOGICAL|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
215038057|NCT05821855|DEVICE|XEN45 Glaucoma Treatment System|Ab interno implantation
215038058|NCT05821855|PROCEDURE|Trabeculectomy|Surgical Intervention
215038059|NCT01662206|DIETARY_SUPPLEMENT|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
215038060|NCT01662206|DIETARY_SUPPLEMENT|Placebo|2 capsules daily containing 348.25 mg of potato starch
215038061|NCT03274778|DRUG|Ruxolitinib 20 MG|tablets
214291155|NCT02762266|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
214291156|NCT02762266|DRUG|embolic agent|". Acceptable embolic agents include:~* Gelatin sponge (gelfoam)~* Polyvinyl alcohol (PVA) particles~* Microspheres / Embolic beads"
214291157|NCT02762266|DRUG|lipiodol|
214291158|NCT00950547|DEVICE|CARDIOPAT|Cell Saver System at bedside for ICU stay
214291159|NCT00950547|DEVICE|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
214291160|NCT05371028|OTHER|Non-interventional Study|This is non-interventional study.
214291161|NCT05542927|DIAGNOSTIC_TEST|urine chloride|Serum chloride, urinary chloride \& serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride \& urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI \& mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours
214291162|NCT00195182|BEHAVIORAL|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
214872509|NCT04661891|DEVICE|Dynamic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Multi-joint tasks (i.e. walking, squatting, cycling) will be performed at a given frequency. A motion capture system will be used to record the joint angles and ground reaction forces simultaneously.
214872510|NCT04661891|DEVICE|Isometric contraction with muscle fatigue|"An identical experiment will be performed as stated in Isometric contraction with the addition of induced muscle fatigue by repeatedly maintaining 40% of muscle torque until failure to maintain a contraction for 5 seconds."
215038062|NCT05623020|DRUG|Elranatamab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
214872511|NCT04661891|DEVICE|Multi-joint functional activities while wearing exoskeleton|Participants will be measured and fitted with the bilateral exoskeleton, and sufficient range of motion to used exoskeleton will be confirmed. HD-EMG grids will be applied to the lower limb muscles of interest. The participant will perform single-joint movements to calibrate the decoder parameters. The participant will then perform multi-joint activities (e.g., standing, squatting, walking overground or on a treadmill, cycling, or stair climbing) in a movement analysis laboratory
215038063|NCT05623020|DRUG|Daratumumab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
215038064|NCT05623020|DRUG|Lenalidomide|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
215038065|NCT05623020|DRUG|Dexamethasone|Randomized
215038066|NCT01593540|DEVICE|metal-free interdental brush|one time per day
215038067|NCT01593540|DEVICE|metal-core interdental brush|one time per day
215038068|NCT06416813|PROCEDURE|GDMT+DCB|Preventive Intervention on Eligible Vulnerable Plaques Using DCB
215038069|NCT06418958|DEVICE|Red Light|Light Curing with Red Light
215038070|NCT06418958|DEVICE|Blue Light|Light Curing with Blue Light
215038071|NCT04573972|BEHAVIORAL|Social Incentive|Receiving half the monetary incentive conditional on meeting a step goal and half the monetary incentive conditional on walking together
215038072|NCT04573972|BEHAVIORAL|Standard Incentive|Receiving the full monetary incentive conditional on meeting a step goal and not conditional on walking together
215038073|NCT03186547|DRUG|Botulinum Toxin A Injection|adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
215038074|NCT03186547|PROCEDURE|Modified Lip Repositioning Surgery|the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
215038075|NCT06216977|OTHER|Clear Liquids|Participants will not take anything by mouth after midnight the day before surgery but will be given 12 ounce clear liquid (Sugar-free Gatorade) at bedside at the pre-operative holding area
215038076|NCT06216977|OTHER|Standard of Care|Participants will not take anything my mouth after midnight day before surgery
215038077|NCT01627041|DRUG|Cytarabine|Given IV
215038078|NCT01627041|DRUG|Daunorubicin Hydrochloride|Given IV
215038079|NCT01627041|DRUG|Decitabine|Given IV
215038080|NCT01627041|OTHER|Laboratory Biomarker Analysis|Correlative studies
215038081|NCT01627041|OTHER|Pharmacological Study|Correlative studies
215038082|NCT05067335|DRUG|Romosozumab|Subjects will receive romosozumab in a specified sequence during the treatment Period.
215038083|NCT05067335|DRUG|Placebo|Subjects will receive Placebo in a specified sequence during the treatment Period.
215038084|NCT01071460|DEVICE|FlexStent Femoropopliteal Self-Expanding Stent System|"Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy~Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:~* Contralateral retrograde common femoral cross-over access or antegrade access~* Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion~* Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis~* Deployment of an appropriately sized FlexStent® to cover target lesion~* Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter~* Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications"
215038085|NCT05948553|DRUG|Intervention A Fluoxetine Hydrochloride (HCl)|Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
215038086|NCT05948553|DRUG|Intervention A Placebo|A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
214291163|NCT01438424|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily
214291164|NCT01438424|DRUG|Lamivudine|Oral, 100 mg, daily
214291165|NCT05508581|PROCEDURE|microwaves ablation of varicose veins|"Microwave ablation is an endovenous treatment. This is a similar treatment approach as laser ablation and radiofrequency ablation. Endovenous means that the treatment device is inside the vein during treatment."
214291166|NCT00118963|DRUG|Metformin|Tablets of 500 mg; 1000 mg two times daily.
214291167|NCT00118963|DRUG|Insulin BIAsp30 (Novolog 70/30)|Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
214291168|NCT00118963|DRUG|Repaglinide|Tablets of 1 mg; Dosage: 2 mg three times daily.
214291169|NCT00118963|DRUG|Placebo-Metformin|Tablets corresponding to 500 mg; two tablets two times daily.
214291170|NCT00118963|DRUG|Placebo-Repaglinide|Tablet corresponding to 1 mg; two tablets three times daily.
214291171|NCT03192254|BEHAVIORAL|self-monitoring|recording fruit and vegetable consumption
214291172|NCT03192254|BEHAVIORAL|daily monetary incentives|daily payments for consuming fruits and vegetables
214291173|NCT03192254|BEHAVIORAL|delayed lump sum monetary incentives|lump sum payments for consuming fruits and vegetables
214291174|NCT00022308|DRUG|cisplatin|
214291175|NCT00022308|DRUG|irinotecan hydrochloride|
214291176|NCT00022308|RADIATION|radiation therapy|
215038087|NCT06427096|BEHAVIORAL|Multifaceted intervention|"The multifaceted interventions is comprised of the following components:~1. To establish a BP management team led by family health instructor. The team members also include family leaders and village doctors.~2. To conduct multifaceted intervention, which includes education for a healthy lifestyle, free provision of sodium substitute, weight management, physical exercise, BP monitoring, and appropriate antihypertensive treatment for individuals with hypertension."
215038088|NCT00261833|BIOLOGICAL|Alpha1-proteinase inhibitor|60 mg/kg body weight/week intravenous
215038089|NCT00261833|OTHER|Placebo|Lyophilized preparation: 60 mg/kg body weight/week intravenous
215038090|NCT00622726|DRUG|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
215038091|NCT00622726|PROCEDURE|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
215038092|NCT03330158|DEVICE|ASTS|Implantation of a motorized spinal distraction rod
215038093|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
215038094|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
215038095|NCT00402987|DRUG|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
215038096|NCT00402987|DRUG|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
215038097|NCT05738226|DEVICE|EpiCare@Home, wearable multimodal seizure monitoring system|"Two wearable devices (Byteflies Sensor Dots) will be used. One Sensor Dot will be placed in the neck with a skin adhesive and will be connected to EEG electrodes placed behind each ear. The second Sensor Dot will be placed on the chest with an adhesive ECG electrode (i.e., a cardiac patch)."
215038098|NCT05528770|DEVICE|FCL+BPS|The automated insulin delivery system includes the Bolus Priming System, a software automatically analyzing past continuous glucose monitoring values to trigger priming insulin bolus delivery isn the suspected presence of meal like glycemic disturbances
215038099|NCT05528770|DEVICE|FCL|The automated insulin delivery system does not include the Bolus Priming System, and therefore does not automatically command priming boluses.
215038100|NCT04281667|DRUG|Oral Antibiotics|Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
215038101|NCT04281667|DRUG|Placebo|Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
215038102|NCT04281667|DRUG|Mechanical Bowel Preparation|Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
215038103|NCT03931551|DRUG|Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]|Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
215038104|NCT00398814|DRUG|Perifosine|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
215038105|NCT00398814|DRUG|Sorafenib|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
215038106|NCT05941286|DEVICE|CGM system with both glucose predictive alerts and threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with both glucose predictive alerts and threshold alerts on
215038107|NCT05941286|DEVICE|CGM system with only glucose threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with only glucose threshold alerts on
215038108|NCT05941286|DEVICE|CGM system with glucose alerts off|the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts off
215038109|NCT02151240|DRUG|Foscarnet Sodium|
215038110|NCT02151240|DRUG|Acyclovir|
215038111|NCT06451588|DRUG|FMT|Active FMT
215038112|NCT06451588|DRUG|Placebo|The placebo treatment will be prepared based on the patients' fecal samples (autologous).
215038113|NCT05542953|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
215038114|NCT00056823|DRUG|rhuFab V2 (ranibizumab)|
215038115|NCT06793397|DRUG|CYB003|CYB003 is a deuterated psilocin analog.
215038116|NCT06793397|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitator.
215038117|NCT03130569|BEHAVIORAL|Web-based Module Group|
215038118|NCT05466305|DEVICE|Gold plated chrome cobalt alloy|Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
215038119|NCT01841996|DRUG|ME1111 solution|Once a day for 28 days
215038120|NCT01841996|DRUG|Vehicle Solution|Once a day for 28 days
215038121|NCT03942081|DEVICE|Ulcer Measurement Software|Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
214291177|NCT01709591|BEHAVIORAL|Prenatal education|
214291178|NCT00572702|PROCEDURE|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
214291179|NCT00572702|PROCEDURE|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
214291180|NCT06106516|DEVICE|novel vital sign monitor|Devices that are to be introduced into the clinic but where data from clinical relevant conditions such as complications are lacking to assess the validity under clinical conditions
214291181|NCT03284827|DRUG|NOAC|edoxaban (60 mg once daily \[OD\]) for at least 6 months
215038122|NCT00364169|PROCEDURE|Degree of constipation|
215038123|NCT03245918|DRUG|Aprepitant Capsule 125 MG|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
215038124|NCT03245918|DRUG|Aprepitant oral suspension 20 mg/mL|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
215038125|NCT05992272|BIOLOGICAL|fMRI imaging (BOLD)|Will be used to investigate neural correlates of PIT effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
215038126|NCT05992272|BIOLOGICAL|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
215038127|NCT05992272|BEHAVIORAL|Trier Social Stress Test|Will be used to assess the effect of acute stress induction on behavioral and neural PIT effects. The induced stress is generated in a social context, where the participants are asked to prepare a job interview for their dream job and to present it in front of a three-member jury.
215038128|NCT05992272|BEHAVIORAL|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
215038129|NCT05992272|BEHAVIORAL|Counting Stroop task|Will be used to assess interference at stimulus level. Here either one, two, three or four identical digits from 1 to 4 are shown. Number and denotation of digits are either congruent (1, 22, 333, 4444; 88 trials) or incongruent (111, 2222, 3, 4444; 88 trials). Subjects have to indicate how many digits were shown
215038130|NCT05992272|BEHAVIORAL|No-go Simon task|Will be used to measure interference at the response level and response inhibition. We will show arrows either pointing to the left or right. The arrow can either be shown on the left or the right side of the display. In congruent trials, direction and position are the same, whereas they differ in incongruent trials. Participants have to indicate the direction of the arrow and ignore the position.
215038131|NCT05992272|DIAGNOSTIC_TEST|Stop Signal Task|"Will be used to examine inhibitory control. The participants tap the left and right side of the screen to smash two falling fruits. When the fruits pass two circles, subjects are required to tap both sides of the screen. In stop trials one of the fruits turns brown (rotten), indicating the corresponding side of the screen should not be tapped."
215038132|NCT05992272|DIAGNOSTIC_TEST|blood samples|for genetic and epigenetic testing, especially for exploratory outcome prediction using polygenic risk scores.
215038133|NCT05992272|DIAGNOSTIC_TEST|questionnaires for chronic stress|"* Perceived Stress Scale~* Social Readjustment Rating Scale~* Trier Inventory for the Assessment of Chronic"
215038134|NCT05992272|DIAGNOSTIC_TEST|hair samples|Hair cortisol measurement (3 cm hair segments) will be used to assess chronic stress.
215038135|NCT05992272|DIAGNOSTIC_TEST|saliva samples|Assessing acute stress effects in AUD.
215038136|NCT05992272|DIAGNOSTIC_TEST|EMA assessment|We will use smartphones with additional mobile sensors (wearables), which will be used to measure physical activity, data on location (GPS), geolocation-based triggering of e-Diaries, self-reported stress reactivity, cue exposure (encounters with drug-related stimuli in real life), drug craving, impulsivity and drug consumption (priming doses, binges and continuous use of all drugs of abuse).
215038137|NCT05992272|DIAGNOSTIC_TEST|clinical diagnostic|SKID-I Interview neurocognitive and psychopathological testing
215038138|NCT05643404|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
215038139|NCT05643404|DIAGNOSTIC_TEST|Echocardioghaphy|Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography
215038140|NCT06641011|DEVICE|Immediate restoration (resin- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by resin-based fissure sealant
215038141|NCT06641011|DEVICE|Immediate restoration (GI- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by glass ionomer-based fissure sealant
215038142|NCT06641011|DEVICE|Immediate restoration (Resin based) after rinsing silver fluoride application|Rinsing silver fluoride off followed by resin-based fissure sealant
215038143|NCT06641011|DEVICE|Immediate restoration (GIC) after rinsing silver fluoride application|Rinsing silver fluoride off and blot-drying of fissures followed by glass ionomer-based fissure sealant
215038144|NCT06641011|DEVICE|Resin based fissure sealant restoration one week after silver fluoride (AgF) application|Resin based fissure sealant restoration one week after silver fluoride (AgF) application
215038145|NCT06641011|DEVICE|GI- based fissure sealant restoration one week after silver fluoride (AgF) application|GI- based fissure sealant restoration one week after silver fluoride (AgF) application
215038146|NCT06563518|DRUG|Meridol|toothpaste
215038147|NCT06563518|DRUG|Colgate Cavity Protection|toothpaste
215038148|NCT03685942|DEVICE|active light therapy (LUMINETTE®)|light therapy on a portable light visor device
215038149|NCT03685942|DEVICE|placebo light therapy|placebo portable light visor device
215038150|NCT06198400|DIAGNOSTIC_TEST|Perioperative assessment of the perfusion of post-resection pancreatic remnant using indocyanine green-VerDye|The adequacy of the vascular supply of the post resection pancreatic remnant after pancreatic neck division will be evaluated using ICG detector. Indocyanine green fluorescence product -Verdye™ will be intravenously applied. The application of the substance will be performed according to the current consensus statement and recommendation
215038151|NCT04846179|DIETARY_SUPPLEMENT|Ginkgo biloba extract|Patients recruited to Ginkgo Biloba Extract (GBE) group will be advised to take Webber Natural Ginkgo Biloba 120 mg soft gel, 1 tablet twice a day for 4 months.
215038152|NCT04609982|DEVICE|ear plugs|giving half of the patients ear plugs
215038153|NCT05458739|DEVICE|ClearCoast MR System|The removed specimen is scanned using the ClearCoast MR System.
215038154|NCT05819359|DRUG|BIA 28-6156 10 mg|BIA 28-6156 10 mg, once daily, oral administration.
215038155|NCT05819359|DRUG|BIA 28-6156 60 mg|BIA 28-6156 60 mg, once daily, oral administration.
214665908|NCT03199911|DRUG|Topical Antibiotic Product|Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
214872512|NCT04661891|OTHER|Clinical Assessments|Subjects may complete a 10 meter walk test (10MWT) overground or over a pressure-sensitive walkway, 6 minute walk test (6MWT), Berg Balance scale (BBS), and/or Functional Gait Assessment (FGA). They may also complete step ups or squats.
214872513|NCT06990646|BEHAVIORAL|VR-ACT|8 MODULES OF 3D VIRTUAL REALITY Modules 1 \& 2: Awareness Regulation Skills Modules 3, 4 \& 5: Acceptance of Pain and Internal Experiences Modules 6, 7 \& 8: Behavior Change and Valued Action
214872514|NCT06990646|BEHAVIORAL|Sham-VR|8 2D non-immersive distracting video-animations delivered through a VR headset.
214872515|NCT06988878|OTHER|Evidence-based practice competence training based on the flipped learning model|This training was carried out for six weeks (11 September 2024 - 16 October 2024). Once a week, participants first watched the videos uploaded by the researcher to the Edpuzzle application and participated in the offline training. Participants who had watched the videos then attended the face-to-face/traditional training. The nurse information form, the evidence-based practice knowledge test and the evidence-based practice evaluation competence questionnaire were administered to the participants before the training (4 September 2024), at the end of the training (16 October 2024) and two months after the training (18 December 2024).
214872516|NCT06988709|OTHER|Real-time Visual Feedback|Runners will visualize their real-time ground contact time (GCT) measured by the RunScribe on a TV screen. They will be instructed to run with a goal of matching their target GCT. Their target GCT will be 5% less than their baseline.
214872517|NCT06988709|OTHER|Real-time Auditory Feedback|Runners will be instructed to match their step rate to a target step rate, 10% above their baseline step rate. A metronome will be played over a speaker to provide real-time auditory feedback of the target step rate.
214872518|NCT06988709|OTHER|Real-time Verbal Feedback|"The clinician will provide real-time verbal feedback to runner to pull your foot off the ground as quickly as you can, every 15 seconds during the retraining condition."
214872519|NCT06990607|PROCEDURE|Pars plana Vitrectomy|Pars plana Vitrectomy using 23 Gauge
214872520|NCT06990607|PROCEDURE|Silicone Oil|Silicone Oil injection after PPV
214872521|NCT06990893|DRUG|Oliceridine|a loading dose of 1.5 mg of oliceridine was intravenously injected. Ten minutes later, an intravenous analgesic pump of 0.01 mg.kg-1.h-1 oliceridine was connected with normal saline to 100 ml at a rate of 2 ml per hour
214872522|NCT06990893|DRUG|Morphine|a loading dose of 4 mg of morphine was intravenously injected. Ten minutes later, an intravenous analgesic pump of 0.03 mg.kg-1.h-1 morphine was connected with normal saline to 100 ml at a rate of 2 ml per hour
214872523|NCT06990893|DRUG|Sufentanil|A 4 ug loading dose of sufentanil was intravenously injected. Ten minutes later, an intravenous analgesic pump of 0.03 ug.kg-1 h-1 was connected. sufentanil was mixed with normal saline to 100 ml at a rate of 2 ml per hour
214872524|NCT06989398|BEHAVIORAL|Advancing Supervisors' Capacity for Mental Health at Work (ASCEND)|"The intervention will consist of a training that incorporates evidence-based content and interactive exercises. Advancing Supervisors' Capacity for Mental Health at Work (ASCEND) covers five core topics designed to equip supervisors with the knowledge and practical skills needed to effectively support the mental health of their employees. The full training is delivered over approximately 8 hours in an in-person group setting. Trainings are facilitated by a trained professional.~To support learning and skill application, participants will also receive a Manager Reference Booklet during the training. This booklet consolidates key information from the ASCEND training, serving both as a learning aid during the sessions and a practical, quick-reference tool afterward. It includes summaries of key concepts, tips, and exercises, along with space for participants to record notes."
214872525|NCT06989151|BEHAVIORAL|Cognitive Remediation Therapy|8 session psychological intervention.
214872526|NCT06989554|DEVICE|mechanical feedback insole|A 3-mm rubber insole containing four 15-mm spring-steel snap buttons aligned along the heel-mid-foot axis. Each insole is statically calibrated on a hydraulic press so that the buttons collapse at 20 % ± 1 % of the individual's body weight, producing an unmistakable plantar cue when the load limit is exceeded. The device is purely mechanical, requires no batteries, and is fitted on postoperative day 1. Participants wear the insole during every supervised walking session until discharge (≈ 14 days).
215038156|NCT05819359|DRUG|Placebo|Placebo, once daily, oral administration.
215038157|NCT06276647|BEHAVIORAL|HOME|The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum patients. The patient navigator will explain this pamphlet at postpartum discharge, then will follow-up with the patients up to 30 days in the postpartum period.
214476604|NCT04801381|PROCEDURE|Aquablation therapy|Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA
214476605|NCT04801381|PROCEDURE|Transurethral laser enucleation|Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).
214665909|NCT03199911|DRUG|Topical Non-Antibiotic Ointment|Mineral oil/petrolatum-based artificial tear ointment.
215038158|NCT05815602|DRUG|Ebastine|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
215038159|NCT05815602|DRUG|Duspatalin|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
214665910|NCT04311905|DEVICE|Diode laser|Diode laser activated irrigation
214665911|NCT04311905|OTHER|Placebo|mock Laser activated irrigation
214665912|NCT00003881|BIOLOGICAL|trastuzumab|
215038160|NCT03849209|DEVICE|Stylet slow-pull technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
215038161|NCT03849209|DEVICE|Standard suction technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe.
214872527|NCT06989554|PROCEDURE|Standard physiotherapy without feedback device|Routine inpatient physiotherapy consisting of verbal instruction to limit loading to 20 % body weight, initial bathroom-scale training, and assisted ambulation with walker or crutches. No tactile, visual, or electronic feedback device is provided. Session frequency, walking aids, analgesia, and discharge criteria are identical to the intervention arm; duration ≈ 14 days.
214872528|NCT06990074|DEVICE|cataract surgery|Robot-assisted cataract surgery
214872529|NCT06990074|DEVICE|cataract surgery|Robot-assisted cataract surgery, designed to provide superior precision and increase the safety profile of the current standard of care.
214872530|NCT06990438|DRUG|TDF (Tenofovir)|ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION
214872531|NCT06989723|DRUG|Pioglitazone 15 MG [Actos]|Participants will receive pioglitazone 15 mg, administered orally once daily. The tablet may be taken with or without food.
214872532|NCT06989723|DRUG|Empagliflozin 10 MG [Jardiance]|Participants will receive empagliflozin 10 mg, administered orally once daily. The tablet may be taken with or without food.
215038162|NCT03624725|PROCEDURE|modified BII+Braun|modified BII+Braun digestive tract reconstruction
215038163|NCT01502735|BIOLOGICAL|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
215038164|NCT01502735|BIOLOGICAL|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
215038165|NCT03775993|DRUG|Human growth hormone|Administration of growth hormone
215038166|NCT03775993|OTHER|Placebo|Administration of placebo
215038167|NCT01820000|PROCEDURE|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
215038168|NCT04497714|DIAGNOSTIC_TEST|Ultrasonic image collection|Ultrasonic image collection,consist of three static images and one dynamic image
215038169|NCT05619237|DEVICE|NanoSALV Catalytic|NanoSALV Catalytic Antimicrobial Wound Dressing Gel is a Health Canada approved medical device for the management of Chronic Wounds.
215038170|NCT01297855|DRUG|Colistin|Colistimethate Sodium dose 2.5-5mg/kg/day
215038171|NCT01297855|DRUG|Colistin plus Rifampicin|Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
215038172|NCT02219152|DRUG|tranexamic acid|
214291182|NCT03284827|DRUG|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
214291183|NCT04508244|DRUG|Placebo|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
214291184|NCT04508244|DRUG|Propranolol|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
214291185|NCT04557397|DRUG|Fruquintinib|oral VEGFR inhibitor
214291186|NCT04557397|DRUG|Itraconazole|a synthetic triazole antifungal agent
214665913|NCT00003881|DRUG|carboplatin|
214291187|NCT04557397|DRUG|Rifampin|a semisynthetic antibiotic derivative of rifamycin SV
214291188|NCT06501066|BIOLOGICAL|umbilical cord mesenchymal stem cells|Patients assigned to UC-MSC administration groups will receive one administrations
214291189|NCT06245330|DRUG|AST-001|liquid formulation for Intravenous infusion
214665914|NCT00003881|DRUG|paclitaxel|
214665915|NCT06040177|DRUG|Cadonilimab|Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
214872533|NCT06989723|DRUG|Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]|Participants will receive one tablet of pioglitazone 15 mg and one tablet of empagliflozin 10 mg, administered orally once daily. Both tablets may be taken with or without food.
214872534|NCT06990802|BEHAVIORAL|Learning Through Play plus Culturally adapted Cognitive Behaviour Therapy (LTP+CaCBT)|LTP+CaCBT has two components. LTP is underpinned by Piaget's theory of cognitive development and Bowlby's theory of attachment. The CBT component uses active listening techniques, changing negative thinking, and guided discovery (i.e., Socratic questioning style to gently probe for cultural beliefs on mental health and stimulate alternative positive thinking). This includes a culturally adapted pictorial calendar devised for women, depicting successive stages of child well-being from 0-3 years, with illustrations of mother-child play and other culturally relevant activities that promote healthy parenting and mother-child attachment.
215038173|NCT02219152|DRUG|saline|
215038174|NCT02906111|DRUG|estriol|"Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse"
215038175|NCT02906111|PROCEDURE|vaginal surgery|Control Group
215038176|NCT01874392|DRUG|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
215038177|NCT01874392|DEVICE|Artificial Pancreas (AP) device (APS©)|"Device includes:~* OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~* Dexcom® G4® CGM System (CGM) from Dexcom® Corp~* Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)"
215038178|NCT05069519|BEHAVIORAL|Personalized Smartwatch|"Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies."
215038179|NCT05069519|BEHAVIORAL|Facebook Health Education|Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support
215038180|NCT01073969|OTHER|wheat bran extract|Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
215038181|NCT01073969|OTHER|control wheat bran extract|Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
215038182|NCT00540631|BIOLOGICAL|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"
215038183|NCT03014466|BEHAVIORAL|Use of Video Projector|Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia
215038184|NCT03014466|BEHAVIORAL|Use of Video Tablet|7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
215038185|NCT01394159|PROCEDURE|22G ProCore biopsy needle|Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.
215038186|NCT01394159|PROCEDURE|22G standard FNA needle|Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
215038187|NCT02951507|OTHER|O T unilateral attachment|O T unilateral attachment system
215038188|NCT02951507|OTHER|New design of extracoronal attachment system|O T unilateral attachment
215038189|NCT03229538|DRUG|Methylprednisolone|IV Steroid pre-operative and intra-operative
215038190|NCT03229538|DRUG|Isotonic saline|Isotonic saline pre-operative and intra-operative
215038191|NCT02073474|DRUG|Sativex®|Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
214872535|NCT06990802|DRUG|Treatment as Usual (TAU)|TAU is the routine care currently available for the treatment of postnatal depression at the health care sites of intervention (e.g. diagnosis, management, antidepressant prescription and/or other forms of mental health care).
214872536|NCT06990503|DRUG|SHR-A1811|"Injection SHR - A1811 (hereinafter referred to as SHR - A1811) is an antibody - drug conjugate (ADC) targeting the HER2 protein, independently developed by Suzhou Shengdeya Biopharmaceutical Co., Ltd. (hereinafter referred to as the sponsor). It is composed of a recombinant humanized anti - HER2 IgG1 monoclonal antibody (SHR - 1805) conjugated with a small molecule component, SHR169106."
215038192|NCT01798602|DRUG|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
215038193|NCT01798602|DRUG|Placebo|Identical placebo for rosuvastatin
215038194|NCT03121521|DRUG|Melatonin 10 mg|melatonin 10mg daily p.o.
215038195|NCT03121521|DRUG|Placebo|Placebo 10mg daily p.o.
215038196|NCT02466828|DRUG|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
215038197|NCT05149820|OTHER|Electronic Point of Care Randomisation tool|Two designs of electronic point of care randomisation tool will be evaluated.
215038198|NCT05149820|DRUG|Magnesium|Liberal Strategy: magnesium supplementation at serum level \< 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level \< 1.0 mmol/L
215038199|NCT01471184|DEVICE|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
215038200|NCT01471184|DEVICE|Placebo|Placebo Eye Drops/Nasal Spray
215038201|NCT01416025|DRUG|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
215038202|NCT01352884|DRUG|AMP-224|Escalating doses of AMP-224
215038203|NCT01352884|DRUG|AMP-224|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
215038204|NCT02767076|PROCEDURE|conventional paramedian spinal anesthesia|land mark guided paramedian spinal anesthesia
215038205|NCT02767076|DEVICE|ultrasound guided paramedian spinal anesthesia|real time ultrasound guided paramedian spinal anesthesia
215038206|NCT02950337|RADIATION|Group 1: Peripherally Located Tumors|Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
215038207|NCT02950337|RADIATION|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
214872537|NCT06990503|DRUG|Chemotherapy|"The treatment regimens for the control group are as follows:~Liposomal doxorubicin: Administered intravenously on Day 1 of each 4 - week treatment cycle at a dose of 40 mg/m².~Paclitaxel: Given intravenously on Days 1, 8, 15, and 22 of each 4 - week treatment cycle at a dose of 80 mg/m² per administration.~Topotecan: Intravenously infused on Days 1, 8, and 15 of each 4 - week treatment cycle at a daily dose of 4 mg/m².~Gemcitabine: Infused intravenously on Days 1 and 8 of each 3 - week treatment cycle at a daily dose of 1000 mg/m²."
215038208|NCT02950337|RADIATION|Group 3: Centrally Located Tumors|Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
215038209|NCT04076267|OTHER|Tool assessing symptoms validation|Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
215038210|NCT03185468|GENETIC|4SCAR-PSMA|PSMA-specific 4th Generation CART
215038211|NCT03185468|GENETIC|4SCAR-FRa|FRa-specific 4th Generation CART
215038212|NCT06431347|BEHAVIORAL|Social Determinants of Health Questionnaire|Participants will also complete a questionnaire about financial barriers to care within the past year, including income bracket and difficulty affording cost-of-living or medical expenses.
215038213|NCT06078852|OTHER|Diaphragmatic ultrasound|Ultrasound evaluation of diaphragm thickness, contractility, and excursion in semi-supine and sitting positions.
215038214|NCT06078852|OTHER|Pulmonary function test|Routine spirometry, body plethysmography (FRC, TLC), maximal inspiratory/expiratory pressures (MIP, MEP), and nocturnal oximetry.
215038215|NCT04713085|DEVICE|Invasive Sacral Neuromodulation|Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)
215038216|NCT04713085|DEVICE|Non-invasive Sacral Neuromodulation|External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).
215038217|NCT06402838|DRUG|RO7269162|Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.
215038218|NCT06402838|DRUG|Placebo|Participants will receive daily doses of placebo for up to 72 weeks.
215038219|NCT06459791|PROCEDURE|Biopsy|The recommandation done based on informative tumorogram is up to study investigator
215038220|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services. Patients will receive 2 hours of MISSION-CJ services per week during and after their stay in the mental health residential rehabilitation program (total of 6-months). Services are delivered using a Critical Time Intervention stepdown approach.
215038221|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking Peer Support|The MISSION Peer Support Curriculum is rolling entry, and includes 24, one-hour exercises focused on co-occurring substance use and mental health disorders, recovery, and community integration.
214291190|NCT05253170|RADIATION|Hypofractionation|Radiation regimen of 2.5-3.0Gy x 13-17 fractions +/- sequential boost 0-7 fractions
214872538|NCT06990659|OTHER|Ambulatory care|Patients with Hepato cellular carcinoma (HCC) treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an outpatient basis: hospitalization in an outpatient unit, followed by systematic telephone and on-demand nursing follow-up for 48 hours for REH and 72 hours for CEH. A dedicated re-hospitalization circuit has also been set up in the event of complications.
214872539|NCT06990659|OTHER|Conventional inpatient care|Patients with Hepato cellular carcinoma (HCC) treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an inpatient basis: conventional hospitalization.
214872540|NCT06981949|DRUG|Dexmedetomidine|"Dexmedetomidine added to ropivacaine in the bilateral single-shot Ultrasound-guided erector spinae plane block that will be applied to each side (bilateral):~20ml/side of 0.375% ropivacaine+0.5 μg/kg/side of dexmedetomidine (lean body weight if BMI \>30)"
214291191|NCT05253170|RADIATION|Conventional Fractionation|Radiation regimen of 1.8-2.0Gy x 23-28 fractions +/- sequential boost 0-5 fractions
214872541|NCT06981949|DRUG|Ropivacaine|"Ropivacaine only in the Bilateral single-shot Ultrasound-guided Erector Spinae Plane Block:~20ml/side of 0.375% ropivacaine"
214872542|NCT04769687|BIOLOGICAL|probiotic Vivomixx®|Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
214872543|NCT04769687|BIOLOGICAL|prebiotic Orafti®Synergy1|Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
215038222|NCT06409065|BEHAVIORAL|Meditation Program|Meditation and discussion sessions will be audio recorded
215038223|NCT04512235|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
214291192|NCT06240975|OTHER|Theragun Technique|Use the Theragun for a designated duration per session, such as 5-10 minutes for one session per week for 6 weeks
214665916|NCT06040177|RADIATION|Stereotactic radiotherapy|Radiation therapy: Stereotactic radiotherapy (5-8Gy\*5F) for portal vein thrombus within 21 days after entry
214872544|NCT04769687|OTHER|Placebo|Placebo
214291193|NCT06240975|OTHER|Dry Needling Technique|Dry needle deep (20 mm) TrP acupuncture of myofascial duration per session, such as 5-10 minutes for one session per week for 6 weeks
214872545|NCT05521659|OTHER|Standardized oral care protocol|Standardized oral care protocol (3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate)
214872546|NCT06988501|BEHAVIORAL|Goal setting with mobile-based self-management tool|In addition to the nutrition education provided to both groups, the participants of the intervention group will work with the dietitian to make behavior-change goals based on SMART goal setting strategy. They will also have access to diet tracking function and weekly report on smart phone application. The dietitian will also meet with the participants virtually to track their progress and provide suggestions.
214872547|NCT06988501|OTHER|Nutrition education|The control group will receive nutrition education about blood pressure management by the dietitian
214872548|NCT06990282|OTHER|microneedling|gingival microneedling (small holes in gingiva)
214872549|NCT06990282|OTHER|scaling|scaling (plaque removal)
214872550|NCT06990282|BIOLOGICAL|Ozonated olive oil|ozonated olive oil after microneedling
214872551|NCT06989736|DIAGNOSTIC_TEST|Taste Test|Participants received nine solutions (tasteless, sweet, salty, sour, and bitter; each in two concentrations) before treatment and six weeks later.
214872552|NCT06989047|PROCEDURE|Pericapsular Nerve Group (PENG) Block|"Assigned Interventions:~Procedure/Surgery: Pericapsular Nerve Group (PENG) Block An ultrasound-guided nerve block targeting articular branches of the femoral, obturator, and accessory obturator nerves. Performed under aseptic technique using a curved low-frequency ultrasound probe to visualize the iliopsoas plane and pubic ramus.~Drug: Bupivacaine (0.25%, 30 ml) Local anesthetic used to provide analgesia in nerve block. Drug: Magnesium sulfate (10%, 5 ml = 500 mg) Adjunct used to enhance analgesic efficacy of the block."
214872553|NCT06989047|PROCEDURE|Femoral Nerve Block (FNB)|An ultrasound-guided nerve block targeting the femoral nerve to provide analgesia before spinal anesthesia in proximal femur fracture surgery. Administered using 30 ml of 0.25% bupivacaine and 5 ml of 10% magnesium sulfate (500 mg). The block is performed with an in-plane ultrasound approach, identifying the femoral nerve lateral to the femoral artery under sterile conditions.
214872554|NCT06990347|DRUG|Inetetamab and Pyrotinib Combined with Chemotherapy|Inetetamab and Pyrotinib Combined with Chemotherapy
215038224|NCT04512235|OTHER|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
215038225|NCT04512235|DRUG|cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen|According to institutional standard of care.
215038226|NCT05200845|OTHER|Conditioned Stimulus + (CS+): Flavored beverage solution with 75 calories of sucrose|Participants will consume flavored beverage solutions containing 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
215038227|NCT05200845|OTHER|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose|Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
215038228|NCT05200845|OTHER|High-Fat Test Meal Inside a Metabolic Chamber|A high-fat test meal (60% fat, 20% carbohydrate) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
215038229|NCT05200845|OTHER|High-Carbohydrate Test Meal Inside a Metabolic Chamber|A high-carbohydrate test meal (60% carbohydrate, 20% fat) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
215038230|NCT05200845|OTHER|fMRI Scan|A subset of participants with BMI \> 25 will be invited to complete an functional magnetic resonance imaging (fMRI) scan as a feasibility measure. fMRI scans will be performed while beverages (without calories) used during the intervention are delivered through a custom manifold fitted to a head coil and connected to a pump system that allows precisely timed and measured delivery of liquids. Because this is feasibility-based measure, the outcome is a count of participants who completed this task.
215038231|NCT02303262|DRUG|Mocetinostat|Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.
214872555|NCT06914154|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
215038232|NCT02303262|DRUG|Gemcitabine|Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.
214291194|NCT05937191|DRUG|Leflunomide|Leflunomide+Glucocorticoids treatment Group
214291195|NCT05937191|DRUG|Steroid Drug|Steroid Treatment
214872556|NCT06914154|DRUG|Placebo|New use of sitagliptin dispensing claim is used as the reference (active-comparator proxy for placebo).
214872557|NCT06981988|DRUG|Linperlisib ； Rituximab|Linperlisib ； Rituximab
214872558|NCT06981637|DRUG|Pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg / m2 every 4 weeks for a maximum of 12 cycles.
214872559|NCT06990620|COMBINATION_PRODUCT|TACE+AK112|TACE+AK112 (PD-1/VEGF bi-antibody, 20mg/kg, ivgtt, Q3W)
214872560|NCT06989632|DEVICE|We want to know the work and sport activities that our patients are able to undertake after a total lumbar disc replacement|
214872561|NCT06990906|DEVICE|BAIBYS Sperm selection|Software based decision support device for sperm selction based on morphology and motility
214872562|NCT06990906|PROCEDURE|Intra cytoplasmatic sperm injection|Sperm injection into oocytes for ferilization
214872563|NCT06990906|PROCEDURE|Conventional manual sperm selection|selection beased on motility at low magnification
214872564|NCT06498739|DRUG|Erector spinae plane block(15 ml bupivacaine 0.5%)|Patients will preoperatively receive high concentration-low volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% }, for each patient).
215038233|NCT00003888|DRUG|cisplatin|
214872565|NCT06498739|DRUG|Erector spinae plane block (15 ml bupivacaine 0.5% and 15ml normal saline)|Patients will preoperatively receive low concentration-high volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline}, for each patient.
214872566|NCT05775952|BIOLOGICAL|HRV-39|We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.
214872567|NCT00987753|DRUG|L-377202|For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
214872568|NCT04837755|DIAGNOSTIC_TEST|Cytokine measurements|The serum concentrations of multiple cytokines are measured.
214872569|NCT01438528|DEVICE|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
214872570|NCT02889055|DEVICE|patient requiring the MIRUS (mechanical ventilation)|
214872571|NCT05854823|RADIATION|dose-reduced radiotherapy|Patients receive 50Gy/25F, 2Gy/F QD, five days a week for 5 weeks
214872572|NCT06624709|DRUG|Iron Supplement|The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week
214872573|NCT03061682|DEVICE|"Scharioth macula lens A45sml/A45smy"|Implantation of an add on intraocular lens to low vision patients
215038234|NCT00003888|DRUG|docetaxel|
215038235|NCT00003888|DRUG|fluorouracil|
215038236|NCT00003888|RADIATION|radiation therapy|
215038237|NCT04758507|BIOLOGICAL|donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
215038238|NCT04758507|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
215038239|NCT05664373|PROCEDURE|Coronally advanced flap and deepithelized free gingival graft|Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.
215038240|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 3|One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
215038241|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 2|One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
215038242|NCT04138056|BIOLOGICAL|Boostrix-ex-US|One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
215038243|NCT04138056|BIOLOGICAL|Boostrix-US|One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
215038244|NCT04138056|DRUG|Placebo|One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
215038245|NCT06005402|BIOLOGICAL|CSX-1004|Recombinant human immunoglobulin G (IgG) 1λ monoclonal antibody specific for fentanyl and structurally related fentanyl analogs
215038246|NCT06005402|BIOLOGICAL|Placebo|Sterile saline for injection
215038247|NCT00220662|BEHAVIORAL|Readiness and Motivation Therapy|
215038248|NCT01215851|DRUG|PA-824|200 mg tablet, once daily for 14 days
215038249|NCT01215851|DRUG|Pyrazinamide|Dosed by Weight
215038250|NCT01215851|DRUG|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
214291196|NCT03401424|PROCEDURE|improved Warren-type style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision plus modified Warren cholangiobiliary reconstruction.
214872574|NCT00902031|DRUG|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
214872575|NCT00902031|DRUG|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
214872576|NCT00000734|DRUG|Sulfamethoxazole-Trimethoprim|
214872577|NCT00000734|DRUG|Zidovudine|
214872578|NCT06048627|DRUG|Amine/zinc lactate/fluoride system|Amine/zinc lactate/fluoride system (250 ppm F), meridol®, Colgate-Palmolive
214872579|NCT06048627|DRUG|negative control|Sodium fluoride mouthwash 250 ppm
214872580|NCT04546893|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
214872581|NCT00168597|DRUG|Vitamin A|
215038251|NCT01215851|DRUG|Rifafour|Rifafour e-275
215038252|NCT01215851|DRUG|Moxifloxacin|moxifloxacin 400 mg
215038253|NCT05672914|BEHAVIORAL|Tablet-based sustained care|A tablet-based motivational-interviewing intervention, tailored specifically to smokers with psychiatric disorders, to motivate the use of evidence-based tobacco treatment and cessation in cigarette smokers upon discharge from an inpatient psychiatric hospitalization. In addition, participants will receive standard hospital tobacco care (see Usual Care Arm).
215038254|NCT05340413|DRUG|Olaparib|300mg twice daily
215038255|NCT01606150|DRUG|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
215038256|NCT01606150|DRUG|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
215038257|NCT05544318|OTHER|Diatary advices|Advice regarding energy, protein and nutrient intake during cancer treatment
215038258|NCT01082939|DRUG|Fludarabine|25 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
215038259|NCT01082939|DRUG|Cyclophosphamide|250 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
215038260|NCT01082939|DRUG|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
215038261|NCT01082939|DRUG|Rituximab|"Cycle 1 (Week 1): 375 mg/m\^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m\^2/day IV on Day 2 over 4- 6 hours"
214872582|NCT06085768|BEHAVIORAL|VRE intervention|Virtual reality exposure therapy is a new treatment technology developed in recent years. This technology combines virtual reality technology with traditional exposure therapy, and uses virtual reality technology to present the exposure scenes required for exposure therapy. Therefore, it can break through the limitations of time and space and more intuitively display some things that are difficult to simulate in the treatment room. Scenes do not require the client to undergo treatment through imaginary exposure, thereby increasing the immersion and reality of the treatment. Over the past two decades, numerous studies have explored and proven the effectiveness of virtual exposure therapy.
215038262|NCT00862940|DRUG|Memantine|10 mg tablets twice daily
215038263|NCT00862940|DRUG|Placebo|Tablets twice daily
214872583|NCT02446327|OTHER|Blood sampling for biomarker assessment|
214872584|NCT02478320|DRUG|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
215038264|NCT05799118|GENETIC|GWAS|The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.
215038265|NCT02023437|DEVICE|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
215038266|NCT02023437|DEVICE|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
215038267|NCT03588702|DEVICE|RF and PEMF treatment|Treatment with Venus Legacy LB2 body applicator
215038268|NCT05226494|DRUG|fb-PMT|Daily dosing based on patient weight
215038269|NCT04546789|DRUG|M2951 (BTK inhibitor)|Participants will receive a single oral dose of M2951 (BTK inhibitor).
215038270|NCT05552859|DRUG|Insulin glargine 300 U/mL|Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
214291197|NCT03401424|PROCEDURE|Roux-en-Y style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision Roux-en-Y cholangiobiliary reconstruction.
214291198|NCT03780283|DRUG|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
214291199|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
214872585|NCT03483168|BEHAVIORAL|Culturally sensitive pain education|The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.
214872586|NCT03483168|BEHAVIORAL|Standard pain education program|"For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators."
215038271|NCT05552859|DRUG|Insulin degludec 100 U/mL|Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
215038272|NCT04722822|BEHAVIORAL|(Intervention) Recommending HPV vaccine for patients 9-10 years of age|Practices are randomized to receive training on how to recommend HPV vaccine, including both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.
215038273|NCT04722822|BEHAVIORAL|(Control) Recommending HPV vaccine for patients 11-12 years of age|Control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).
215038274|NCT06364410|DRUG|Azenosertib|Given PO
215038275|NCT06364410|PROCEDURE|Biopsy Procedure|Undergo biopsy
215038276|NCT06364410|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215038277|NCT06364410|PROCEDURE|Computed Tomography|Undergo CT
215038278|NCT06364410|PROCEDURE|Echocardiography Test|Undergo ECHO
215038279|NCT06364410|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215038280|NCT06364410|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215038281|NCT06364410|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
215038282|NCT02266667|DEVICE|2 NEMOST rods : bilateral vertebral-pelvic implantation|Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)
214291200|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
214872587|NCT04208074|OTHER|Exercise Intervention|Participants will exercise under the supervision of expert personal trainers and follow an optimized exercise program tailored to the strength and fitness level of each participant. Participants will exercise for 16 weeks; 2 days a week at the gym for an hour and 2 days of the week at home for 45 minutes.
214872588|NCT03673319|PROCEDURE|Dry needling with positives expectation|"DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
215038283|NCT02266667|DEVICE|1 NEMOST rod :unilateral vertebral-pelvic implantation|Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
215038284|NCT06425029|OTHER|Experimental Intervention (Music A)|Participants will be asked to listen to Music A on their personal device daily, at a time most convenient for them.
214665917|NCT06040177|DRUG|Renvatinib|Renvatinib: 8mg (weight \<60kg) or 12mg (weight 60kg) once a day until disease progression, intolerable toxicity
214665918|NCT04630314|DEVICE|Percutaneus Coronary Intervention|Covered Stent
214665919|NCT05574972|DEVICE|Timing Carotid Stent|all the participants in this group will be performed with Timing Carotid Stent
214665920|NCT05574972|DEVICE|Carotid Wallstent|all the participants in this group will be performed with Carotid Wallstent
214665921|NCT05347732|DIAGNOSTIC_TEST|Successfull thrombolysis|Biomarker levels will be compared between patients with successful and failed thrombolysis.
214665922|NCT05442892|PROCEDURE|Multicomponent exercise training programme|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individuals functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 30-60% of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L. Torrejón de Arroz, Madrid, Spain) combined with balance and gait retraining exercises that progressed in difficulty and functional exercises such as rises from a chair.
214665923|NCT05741697|DRUG|bi-level ventillation|non-invasive mechanical ventilation
214665924|NCT06097741|DEVICE|MRI sequences|Ultra short / zero TE sequence on MRI being tested on healthy patients and improved by manually fine tuning the sequence
214872589|NCT03673319|PROCEDURE|Dry needling with neutral expectation|"DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
214872590|NCT06205329|DRUG|WPV01 Dose 1-4|WPV01 Dose 1-4 or Placebo on day 1
214872591|NCT06205329|DRUG|WPV01 Dose 5-8 and Ritonavir|WPV01 Dose 5-8 and Ritonavir or Placebo on day 1
214872592|NCT06205329|DRUG|WPV01 Dose 9-12|WPV01 Dose 9-12 or Placebo from day 1 to day 6
214872593|NCT06205329|DRUG|WPV01 Dose 13-15 and Ritonavir|WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6
214872594|NCT06205329|DRUG|WPV01 Dose 16|Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)
214872595|NCT01664221|DRUG|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
214872596|NCT04473521|DEVICE|Investigational denture adhesive cream|The denture adhesive application will be controlled by weight (1.00g +/-0.05g) applied to the maxillary denture only.
214872597|NCT04473521|DEVICE|Super Poligrip Free|The denture adhesive application will be controlled by weight (1.00g +/- 0.05g) applied to the maxillary denture only.
214872598|NCT04461366|DEVICE|Monopolar radiofrequency|The RF electrode was moved randomly for 30 seconds over each scar. The total duration of the treatment session is only 5 minutes for each cheek. It takes 15 minutes if the forehead and 2 cheeks are affected.
214872599|NCT04461366|DEVICE|Pulsed dye laser|PDL was applied for the affected areas with no pre-treatment regimens or topical anaesthetics. There was no requirement for skin cooling.
214872600|NCT02365259|DEVICE|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
214872601|NCT04128475|OTHER|N/A - observational study.|N/A - observational study.
214872602|NCT02610387|DEVICE|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
214872603|NCT02610387|DEVICE|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
214872604|NCT03786133|DIAGNOSTIC_TEST|Analysis of microbiological tests|Collection and comparison of microbiological data
214872605|NCT00500175|DEVICE|TempTouchRM|
214872606|NCT00500175|DEVICE|Offloading|
214872607|NCT02121275|DEVICE|Ultrasound of the lungs|Ultrasound examination of the lungs
214872608|NCT02121275|DEVICE|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
214872609|NCT03457649|BIOLOGICAL|ARGX-113|
214872610|NCT03457649|BIOLOGICAL|Placebo|
214872611|NCT01467206|BEHAVIORAL|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
214872612|NCT01467206|BEHAVIORAL|Standard care|Standard care as it is given to all stoke patients after stroke
214872613|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
214872614|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
214872615|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
214872616|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
214872617|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
214872618|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
214872619|NCT00943462|RADIATION|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2-Gy fractions, for a total of 30 fractions
214872620|NCT00943462|DRUG|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
215038285|NCT06425029|OTHER|Active Comparator Intervention (Music B)|Participants will be asked to listen to music B on their personal device daily, at a time most convenient for them.
215038286|NCT06425029|OTHER|Active Comparator Intervention (Music C)|Participants will be asked to listen to music C on their personal device daily, at a time most convenient for them.
214665925|NCT00698516|DRUG|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
215038287|NCT05438667|BIOLOGICAL|TCR-T therapy|"1.Preprocessing strategy：~1. Cyclophosphamide: 300-450mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes, and 0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide,4days and 5 days before TCR-T cell infusion.~2. Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes before 3 to 5days before TCR-T cell infusion.~2.Within 3-5 days after pretreatment, subjects will receive a single TCR-T reinfusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.~3.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection) will be injected intravenously for 5 days (10 times in total).~4.After 3 months of treatment, If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed."
215038288|NCT05537584|DRUG|Sertraline|Subjects will receive 8 weeks of sertraline while monitored by the study physician
215038289|NCT05537584|DRUG|Bupropion|Subjects will receive 8 weeks of bupropion while monitored by the study physician
214665926|NCT06554990|OTHER|physical therapy excersies|1- selected physical therapy exercises
215038290|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 1 - Gluteal|Dose level 1
215038291|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 2 - Gluteal|Dose level 2
215038292|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 3 - Gluteal|Dose level 3
215038293|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 3 - Deltoids|Dose level 3
214872621|NCT05865080|DRUG|Ketamine|0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution before spinal anesthesia
214872622|NCT05865080|DRUG|Placebo|Normal saline
215038294|NCT01863550|DRUG|Bortezomib|Given SC or IV
215038295|NCT01863550|DRUG|Carfilzomib|Given IV
214872623|NCT03729076|OTHER|Crystalloid|Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
214872624|NCT03729076|OTHER|Colloid|Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
215038296|NCT01863550|DRUG|Dexamethasone|Given PO
215038297|NCT01863550|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
215038298|NCT01863550|DRUG|Lenalidomide|Given PO
215038299|NCT01863550|OTHER|Quality-of-Life Assessment|Ancillary studies
214872625|NCT01689662|DRUG|Tc 99m EC20|
214872626|NCT00000569|DRUG|triamcinolone|1200 micrograms of triamcinolone in daily divided doses
215038300|NCT03123458|BIOLOGICAL|clonal fetal MSCs|clonal fetal MSCs
215038301|NCT02616991|PROCEDURE|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
215038302|NCT06285916|DRUG|NORA520 Dose 1|Oral NORA520 tablets Dose 1 for 3 days
215038303|NCT06285916|DRUG|NORA520 Dose 2|Oral NORA520 tablets Dose 2 for 3 days
214665927|NCT06554990|OTHER|sensory perceptual motor exercises|selected sensory perceptual motor exercises
214665928|NCT05671094|BEHAVIORAL|Prehabilitation|Physical, mental, stress reducing and dietary prehabilitation programme, 4 to 2 weeks before surgery
214665929|NCT03549520|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
214665930|NCT05949125|OTHER|Cyclophosphamide (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
214665931|NCT05949125|OTHER|Fludarabine (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
214665932|NCT05949125|DRUG|R-TM123|Intravenous infusion over 20 days
214665933|NCT05949125|DRUG|Allo-RevCAR01-T|Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1.
214872627|NCT00000569|OTHER|Placebo|Placebo
215038304|NCT06285916|DRUG|Placebo|Oral Placebo tablets for 3 days
215038305|NCT06383338|DRUG|Omeprazole|Sub-therapeutic probe drug administration to measure phenoconversion.
215038306|NCT06383338|DRUG|Dextromethorphan|Sub-therapeutic probe drug administration to measure phenoconversion.
215038307|NCT05846776|DEVICE|DigiPrehab system|Using an Artificial Intelligence-Machine Learning (AI-ML) DSS platform, which analyzes a large collection of data (screening and local data) from different sources, the DigiPrehab system will allow to predict the risk of falling in the elderly subjects. Once the screening will be completed, to carry out the prevention of falls, the system will assign to the participants a personalised exercise program that the patient will carry out at home for 12 weeks. The exercises will be chosen from the following: squat at door, squat on chair, squat with knee-lift, squat with heel-raise, stand-no support, toe-raise with support, toe-raise, one leg balance, weight-shift with support, weight-shift without support, lunge with support, lunge, step on book, step over book, step onto box or stair, step forward-sideways, step forward-sideways-backwards, knee to elbow, timed up and go.
215038308|NCT03994796|DRUG|Abemaciclib|Given PO
215038309|NCT03994796|DRUG|PI3K Inhibitor paxalisib|Given PO
215038310|NCT03994796|DRUG|Entrectinib|Given PO
215038311|NCT03994796|DRUG|Adagrasib|Given PO
215038312|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
215038313|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
215038314|NCT02010502|DIETARY_SUPPLEMENT|Beetroot juice|
215038315|NCT02010502|DIETARY_SUPPLEMENT|Beetroot powder|
215038316|NCT02010502|DIETARY_SUPPLEMENT|Placebo|
215038317|NCT01435590|PROCEDURE|Curette v/s endocervical brush|
214872628|NCT01775436|BEHAVIORAL|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
215038318|NCT05311046|DIAGNOSTIC_TEST|Pediatric sepsis screening tool (either algorithmic or manual)|All participating institutions employ either an algorithmic, manual, or combined algorithmic/manual pediatric sepsis screening protocol for patients that present with fever and/or a concern for infection. While the specific parameters tested in screening tools differ, they generally consist of tests for a systemic inflammatory response (e.g. SIRS) and/or organ dysfunction (e.g. SOFA) and/or high susceptibility (e.g. immunocompromised) factors.
215038319|NCT05817942|DRUG|Filgotinib|Jyseleca
215038320|NCT02390752|DRUG|TURALIO(R)|take oral drug daily for a 28 day cycle
215038321|NCT06452277|DRUG|BAY2927088|Tablet, oral
215038322|NCT06452277|DRUG|Pembrolizumab|Intravenous (IV) infusion
215038323|NCT06452277|DRUG|Cisplatin|IV infusion
215038324|NCT06452277|DRUG|Carboplatin|IV infusion
215038325|NCT06452277|DRUG|Pemetrexed|IV infusion
215038326|NCT05946213|PROCEDURE|Computed Tomography|Undergo CT
215038327|NCT05946213|RADIATION|External Beam Radiation Therapy|Undergo EBRT
215038328|NCT05946213|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215038329|NCT05946213|OTHER|Quality-of-Life Assessment|Ancillary studies
215038330|NCT05946213|OTHER|Questionnaire Administration|Ancillary studies
215038331|NCT05946213|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215038332|NCT05363527|BIOLOGICAL|Endotoxin|Endotoxin
215038333|NCT05363527|BIOLOGICAL|Placebo|Placebo
215038334|NCT06650631|DEVICE|Knee Heatwraps|To treat the painful knee joint in patients with osteoarthritis without acute flares or inflammation. The investigational device will be used in accordance with the Instructions for Use.
215038335|NCT05172726|DRUG|tapinarof cream, 1%|applied topically once daily
215038336|NCT05115630|DRUG|Cyclophosphamide|Given by IV
215038337|NCT05115630|DRUG|Mesna|Given by IV
215038338|NCT05115630|DRUG|Filgrastim|Given by IV
215038339|NCT05115630|DRUG|Melphalan|Given by IV
214872629|NCT01775436|BEHAVIORAL|Healthy Living Control|"Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
215038340|NCT05115630|DRUG|Fludarabine phosphate|Given by IV
215038341|NCT05115630|DRUG|Tacrolimus|Given by IV
215038342|NCT05115630|DRUG|Mycophenolate mofetil|Given by IV
215038343|NCT05115630|DRUG|Total Body Irradiation One Dose|Given by IV
215038344|NCT05835986|DRUG|RO7507062|RO7507062 solution for injection will be administered SC as specified in each treatment part (arm).
215038345|NCT05835986|DRUG|Tocilizumab|When applicable, tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
215038346|NCT02554565|PROCEDURE|Tumor biopsy|Tumor biopsy before treatment
215038347|NCT02554565|PROCEDURE|Blood sampling|Blood sample before, during and after treatment
215038348|NCT05853718|DRUG|Tenofovir Alafenamide Tablets|Take 25mg TAF daily from week 28-32 of gestation until delivery
215038349|NCT02876172|DRUG|MDMA|Two sessions of MDMA-assisted therapy, one with an initial dose of 75 mg midomafetamine HCl (and optional supplemental dose of 37.5 mg) and the second with 75 or 100 mg midomafetamine HCl (with optional supplemental dose of either 37.5 mg or 50 mg respectively) given to the participant with PTSD and their significant other.
215038350|NCT02876172|BEHAVIORAL|CBCT|A three-phase, 15-session, manualized treatment from the CBCT manual
215038351|NCT02876172|BEHAVIORAL|Therapy|Manualized MDMA-assisted therapy
215038352|NCT04242095|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, and stool samples
215038353|NCT04242095|OTHER|Medical Chart Review|Review of medical records
215038354|NCT00238329|BIOLOGICAL|PEG-interferon alfa-2b|
215038355|NCT00238329|DRUG|thalidomide|
215038356|NCT01415947|DEVICE|V Chordal|"V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae off-pump . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords."
215038357|NCT05391776|DRUG|TST002 Injection|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
215038358|NCT05391776|DRUG|placebo|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
215038359|NCT04765397|PROCEDURE|Effect of different resectoscope fluids on optic nerve diameter measured by ultrasound|During the operation Blood pressure, pulse minute the number of irrigation solutions used, and intravenous serum amounts, operation time will be saved. If there is an abnormal parameters or increased optic nerve sheath surgical team will be informed.
215038360|NCT03756961|DRUG|Dexmedetomidine|The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
215038361|NCT03756961|BEHAVIORAL|Person-centred care (PCC)|The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2
215038362|NCT03756961|DRUG|Esketamine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
215038363|NCT03756961|DRUG|Lidocaine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.
215038364|NCT03756961|DEVICE|Transcutaneous Nerve Stimulation (TENS)|The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.
214665934|NCT04260607|DRUG|Ketamine Hydrochloride|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~3. Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect."
214872630|NCT03185013|BIOLOGICAL|VGX-3100|1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
215038365|NCT03756961|DRUG|Remifentanil|The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
214872631|NCT03185013|BIOLOGICAL|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
215038366|NCT03756961|DRUG|Desflurane|The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
215038367|NCT03756961|DRUG|Propofol|The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
215038368|NCT03756961|DRUG|Oxycodone|The control group receives Oxycodone as the routine pain management drug post-operative.
214872632|NCT03185013|DEVICE|Electroporation (EP)|Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
214872633|NCT04842136|OTHER|Scales and indexes|Patients with TMD regardless of diagnosis with sleep bruxism were assessed with the Jaw Function Limitations Scale (JFLS), Neck Disability Index (NDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and Headache Impact Test-6 (HIT-6) scales.
214872634|NCT06233084|DRUG|Desogestrel-Test product|Desogestrel Tablets 0.075 mg Manufactured by: POND'S CHEMICAL THAILAND R.O.P., Thailand
214872635|NCT06233084|DRUG|Desogestrel-Reference product|Desogestrel Tablets 0.075 mg Manufactured by: N.V. Organon, The Netherlands
214872636|NCT03343613|DRUG|LY3381916|IDO-1 inhibitor administered orally
214872637|NCT03343613|DRUG|LY3300054|PD-L1 inhibitor administered IV
214872638|NCT05072197|DEVICE|Mobile device as a support tool for the treatment of women with breast cancer undergoing chemotherapy|This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers.
214872639|NCT03248453|OTHER|CoPS|The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
214872640|NCT06713382|COMBINATION_PRODUCT|Pleural Saline Irrigation|This intervention, Pleural Saline Irrigation, involves the administration of up to 250 mL of sterile saline solution into the pleural cavity through a chest tube immediately following each intrapleural tPA/DNase (IPFT) therapy session. The saline irrigation is intended to aid in clearing infected pleural fluid and reducing pleural effusion volume. This maneuver is repeated based on the treating physician's criteria, differentiating it from standard care, which includes only antibiotics, chest tube placement, and IPFT without saline irrigation. The irrigation is expected to enhance infection resolution and may impact chest tube duration and the frequency of pleural interventions.
215038369|NCT06655181|DEVICE|Respiratory Muscle Training|Expiratory muscle training will be performed with POWERbreathe EX1 Medic (POWERbreathe®) device and inspiratory muscle training will be performed with POWERbreathe Medic Classic device.
215038370|NCT06667427|PROCEDURE|Nerve transfer techniques|Participants will undergo facial nerve reconstruction using nerve transfer techniques
214872641|NCT00570882|DRUG|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
215038371|NCT06985147|DRUG|DISC-3405|DISC-3405 is administered subcutaneously.
215038372|NCT06037811|DRUG|Adalimumab|Participants will be randomized 1:1 (non-blinded) to receive either adalimumab (40 mg subcutaneous every 2 weeks for 12 weeks) and prednisone vs prednisone alone. Addition of methotrexate (MTX) and/or hydroxychloroquine (HCQ) is permitted, as needed, at the discretion of the treating rheumatologist. No additional conventional synthetic, targeted synthetic or biologic DMARDs are permitted during the trial.
214872642|NCT00570882|DRUG|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
215038373|NCT06037811|DRUG|Prednisone|Prednisone as per standard of care.
215038374|NCT06601335|DRUG|AK117 in combination with AK112|Following a predefined dose and date.
215038375|NCT06601335|DRUG|Placebo in combination with Pembrolizumab|Following a predefined dose and date.
215038376|NCT06987487|BEHAVIORAL|Job Rotation Program|Nurses assigned to the intervention group will participate in a structured job rotation program across multiple cardiovascular units (e.g., intensive care, medical, surgical, rehabilitation) every two months for a period of 12 months. Each rotation cycle involves temporary reassignment to a different unit, followed by a return to the original unit. Each nurse will undergo orientation and receive support from a dedicated tutor in the host unit.
215038377|NCT06987487|BEHAVIORAL|No Job Rotation (Standard Care)|Nurses in the control group will continue their usual duties in their respective units without participating in the job rotation program. They will be exposed to the same data collection tools as the intervention group, but without any planned rotation or inter-unit movement.
215038378|NCT06856577|GENETIC|Ixo-vec|Ixo-vec will be administered intravitreally.
215038379|NCT06856577|DRUG|Aflibercept|Aflibercept will be administered intravitreally.
215038380|NCT06668896|DRUG|Progesterone|Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period.
215038381|NCT05782855|OTHER|Active Robot assisted physical training during acute hospitalisation|"Active training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the exercise movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform extension of hip and knee. The patient must use their muscular power to stretch the leg while ROBERT® provides resistance.~Training is defined as a minimum of three sessions before discharge."
215038382|NCT05782855|OTHER|Passive Robot assisted physical training during acute hospitalisation|"Passive training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform passive extension of hip and knee. ROBERT® moves the leg independently without the patient using any muscle power.~Training is defined as a minimum of three sessions before discharge."
215038383|NCT06991140|OTHER|Thorocal Mobilization Exercises|Thoracic mobilisation exercises were performed 3 days a week for a total of 6 weeks under the supervision of a physiotherapist. Thoracic mobilisation programme consisted of active self-mobilisation techniques, mobilisation exercises with foam rollers, stretching exercises including thoracic rotation and extension movements and dynamic postural exercises. Especially 'thread the needle' exercise in sitting or quadruped position, 'thoracic extension press-up' in prone position and 'extension on foam rollers' were preferred to increase the mobility of thoracic vertebral segments. The exercises were gradually made more difficult according to the tolerance of the individuals. Each exercise was performed as 10-15 repetitions and 2-3 sets. Exercise safety was ensured by informing the patients about the correct posture and movement patterns before all applications.
215038384|NCT06991140|OTHER|Core Stabilization Exercises|Core stabilization exercises were structured to target activation of deep muscle groups supporting cervical and thoracic spine stability. The exercise programme was performed 3 days a week for a total of 6 weeks under the supervision of a physiotherapist. The programme included exercises to improve head and neck control (chin tuck, head lift in supine position), exercises to improve scapular stability (scapular retraction, wall slide, serratus anterior activation) and exercises to improve trunk control in neutral spine position (arm and leg extension in four-point position, plank variations). The exercises were gradually made more difficult according to the tolerance of the individuals and each session lasted approximately 40-45 minutes. By ensuring that the exercises were performed in the correct form and in a controlled manner, overloading of the musculoskeletal system was prevented.
214872643|NCT05211076|OTHER|Music Group|"The Introductory Information Form will be filled in by researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.On the 1st day of the post-op,mothers will be able to listen to Classical Turkish Music works in the forms of Saz Semaisi,Peşrev,Medhal in Rast,Uşşak,Kürdi,Muhayyer makams for 30 minutes via their phone at 11:00am.~While the mother continues to listen to the music,at the 16th minute,the researcher will manually milk the mother for at least 15 minutes until milk comes out.At the end of the milking process,the milk accumulated in the container will be measured by the researcher with injector,recorded in the Breast Milk Follow-up Form.At the end of the music session,it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~The same procedure will be applied to the mother atb05:00pm.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
214872644|NCT05211076|OTHER|Marmet Technique Group|"Consent will be obtained from those who agree to participate in the study. The Introductory Information Form will be filled by the researcher using face-to-face interview technique.~It will be ensured that the mother fills the State Anxiety Scale with her own statement.~The Marmet Technique will be applied to the mothers at 11:00am for 20-30 minutes by the researcher.~At the end of the milking process performed in accordance with the technique, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~At 05:00pm, the same procedure will be applied to the mother. At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
215038385|NCT01983345|PROCEDURE|prenatal surgical repair of fetal myelomeningocele|open surgical repair of myelomeningocele before 26 weeks gestational age
215038386|NCT06616155|PROCEDURE|Biopsy|Undergo tissue biopsy
214872645|NCT05211076|OTHER|Control group|"The Introductory Information Form will be filled by the researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.The mothers will milk the mother manually by the researcher at 11:00am for at least 15 minutes until the milk does not come.~At the end of the milking process, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form in ml.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement. At 05:00pm, the same procedure will be applied to the mother.~At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
214872646|NCT04599127|OTHER|Mobilization with movement|The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation
214872647|NCT04599127|OTHER|Conventional physical therapy|The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
214872648|NCT02575976|BEHAVIORAL|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
214872649|NCT02575976|OTHER|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
214872650|NCT02575976|OTHER|wait list control|No cardiac rehabilitation.
214872651|NCT03530176|RADIATION|18Fluoride-Sodium Fluoride radio-isotope|The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
214872652|NCT00510289|DRUG|Sorafenib|400 mg twice a day until progression or unacceptable toxicity develops.
214872653|NCT00658931|DRUG|Drug treatment with Cymbalta|Drug treatment with Cymbalta
214872654|NCT03077035|OTHER|glass ionomer sealants|
214872655|NCT03077035|OTHER|resin-based sealant|
214872656|NCT03602963|DEVICE|Dexcom G5 Mobile CGM system|The accuracy and usability ot the Dexcom G5 mobile CGM system will be evaluated
214872657|NCT04039386|DEVICE|Cell Phone Based Cognitive Based Therapy (Pacifica App)|Cell phone application that provides support for individuals with psychosocial conditions.
214872658|NCT04039386|OTHER|Control|Subjects in the control group will receive standard care.
214872659|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|2000 IU per day
214872660|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|400 IU per os once daily
214872661|NCT02158286|OTHER|Measuring emptying rate from the gastric tube|
214872662|NCT00725114|BIOLOGICAL|Tetrodotoxin|30 µg twice daily for 4 days
214872663|NCT00725114|BIOLOGICAL|Placebo|2 mL subcutaneous injection twice daily for 4 days
214872664|NCT05534308|PROCEDURE|Transoperative taping|The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, on intraoperative period associated with compression with elastic stockings.
214872665|NCT05534308|OTHER|No trasoperative taping|Patients will received only compression stockings after surgery
214872666|NCT03150823|PROCEDURE|Upward Direct Current (Ascending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.
214872667|NCT03150823|PROCEDURE|Downward Direct Current (Descending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
214872668|NCT03150823|PROCEDURE|Sham Direct Current|Installation of electrotherapy equipment off (Sham tratment).
215038387|NCT06616155|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215038388|NCT06616155|PROCEDURE|Bone Scan|Undergo bone scan
215038389|NCT06616155|PROCEDURE|Computed Tomography|Undergo CT
215038390|NCT06616155|DRUG|Enzalutamide|Given PO
215038391|NCT06616155|DRUG|Ruxolitinib|Given PO
215038392|NCT05828030|PROCEDURE|high flow nasal cannula|the patient receives HFNC after randomization. All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
214872669|NCT04834843|OTHER|Observational study, no intervention|Observational study, no intervention
214872670|NCT04158700|DRUG|LY3200882|LY3200882 administered orally
214872671|NCT04158700|DRUG|Pembrolizumab|Pembrolizumab administered IV
214872672|NCT03222752|DEVICE|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
214872673|NCT03222752|DEVICE|Sham Cranial Electrotherapy Stimulation|The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
214872674|NCT06163599|BEHAVIORAL|Transdiagnostic Telenovela Intervention|The intervention constitutes nine videos depicting the main character, Esperanza, who is struggling with anxiety and depression, undergoing therapy involving the a trandiagnostic treatment, and completing worksheets relating to the weekly therapy sessions.
214872675|NCT02257294|DRUG|Alteplase|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
214872676|NCT02257294|OTHER|Placebo|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
214872677|NCT01684163|DRUG|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
214872678|NCT01684163|DRUG|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
214872679|NCT01684163|DRUG|Placebo|Intravenous administration of normal saline into arm.
214872680|NCT01881113|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
214872681|NCT01881113|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
214872682|NCT01458821|BEHAVIORAL|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
214872683|NCT00673387|DRUG|pramlintide acetate|subcutaneous injection, twice a day
214872684|NCT00673387|DRUG|metreleptin|subcutaneous injection, twice a day
214872685|NCT00673387|DRUG|placebo-P|subcutaneous injection, twice a day
215038393|NCT05828030|PROCEDURE|Oxygen mask|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
214872686|NCT00673387|DRUG|placebo-M|subcutaneous injection, twice a day
215038394|NCT00955578|PROCEDURE|Punch Biopsy|5-6 punch biopsies of affected areas
215038395|NCT04866719|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
215038396|NCT06990880|DRUG|GSK5458514|GSK5458514 will be administered.
215038397|NCT06592872|BEHAVIORAL|Bullying prevention|The intervention utilizes a serious (educational) videogame and teacher-led, interactive class sessions. Students exposed to the intervention will learn to respond to in-person and online bullying from the perspectives of perpetrator, victim, and bystander. The intervention enhances personal self-management skills, social skills, refusal skills, and other life skills needed to successfully navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
215038398|NCT06861413|DRUG|VX-828|Tablets for Oral Administration.
215038399|NCT06861413|DRUG|VX-828|Suspension for Oral Administration.
214872687|NCT06877819|OTHER|Motor Imaginary Technique alongwith task-oriented training|Motor imaginary technique followed by task oriented trunk control training alongwith conventional physiotherapy.Frequency: 10- 15 reps 4 times/week for 8 consecutive weeks. Time for each session will be 60 mins. First of all task based exercises will be assumed by patient. To make imaginations more strong an audio demonstration of each exercise will be recorded by therapist and will be administered to patients hearing via headphones. This will make it easy for patients to assume as they are performing theses exercises in their head. Motor imagination will be followed by practical performance of same tasks. The experimental group will receive motor imagery technique for 15 minutes followed by task-specific training for 45minutes along with conventional physiotherapy to improve postural control and balance in stroke patients. .
214872688|NCT06877819|OTHER|Task Oriented Training|Control group will receive task oriented trunk control training exercises followed by conventional physiotherapy. .Frequency: 10- 15 reps 4 times/week for 8 consecutive weeks. Time for each session will be 60 mins.
214872689|NCT01436799|DRUG|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.
214872690|NCT01436799|DRUG|Desflurane|anaesthesia was maintained by desflurane 4-7vol%
214872691|NCT01436799|DRUG|alfentanil|administration of alfentanil 10 μg kg-1 for anesthetic induction
214872692|NCT01436799|DRUG|Rocuronium|administration of rocuronium 0.6 mg kg-1 for anesthetic induction
214872693|NCT05553899|RADIATION|PET-MRI|magnetic resonance imaging with positron emission tomography scanning using the tracer 18F-FDG
215038400|NCT06207422|OTHER|Moderate intensity training program|A 10-week intervention program performed at 60-70% of the heart rate reserve. Heart rate reserve will be calculated using the Karvonen formula (target heart rate = \[(predicted maximum heart rate (= 220 - age) - resting heart rate) x %intensity\] + resting heart rate). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
215038401|NCT06207422|OTHER|High intensity training program|A 10-week intervention program performed at ≥80% of the predicted maximum heart rate (target heart rate = predicted maximum heart rate (= 220 - age) x %intensity). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
215038402|NCT07004062|OTHER|Structured Risk Assessment-Based Targeted Nursing Intervention|"Comprehensive Risk Assessment: Evaluation of lifestyle factors (diet, exercise, sleep), psychosocial stressors, medical history, and endocrine-specific biomarkers~Personalized Care Plan: Tailored interventions addressing identified risk factors~Psychological Component: Cognitive-behavioral techniques and stress management~Lifestyle Modification: Guided nutrition (low-glycemic, high-fiber diet) and physical activity plans~Reproductive Health Support: Menstrual cycle monitoring and fertility-related counseling"
215038403|NCT07003022|DRUG|cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib.|Cadonilimab: 10mg/kg Q3W; Bevacizumab: 7.5mg/kg Q3W; Regorafenib: 80mg QD; Fruquintinib: 3mg QD.
215038404|NCT07003347|DEVICE|oral spray of MgCl2|Magnesium Salt Oral Spray Device
215038405|NCT07003347|DEVICE|Saline|oral saline aerosol
215038406|NCT07004491|OTHER|Conventional therapy|Ultrasound, Transcutaneous Electrical Nerve Stimulation (TENS) and hot pack application
215038407|NCT07004491|OTHER|Conventional therapy+ Mulligan mobilization|Conventional therapy+ Mulligan mobilization
215038408|NCT07004491|OTHER|Conventional therapy+ Graston|Conventional therapy+ Graston application
215038409|NCT07002801|COMBINATION_PRODUCT|remimazolam-remifentanil|For elderly patients scheduled for elective painless gastro-intestinal endoscopy, remimazolam 0.2mg/kg and remifentanil 0.2ug/kg are used for anesthesia induction. During the operation, the doses are adjusted according to the depth of sedation of the patients.
215038410|NCT07002801|COMBINATION_PRODUCT|remimazolam-esketamine|For elderly patients scheduled for painless gastroenterological endoscopy, remimazolam 0.2mg/kg and esketamine 0.15mg/kg are used for anesthesia induction. During the operation, the dosage is adjusted according to the patient's level of sedation.
215038411|NCT07004413|DRUG|FOLFIRI+cetuximab|Cetuximab 500 mg/m², 90 min IV infusion on d1; Irinotecan: 180 mg/m², 90-120 min IV infusion on d1; Folinic acid: 400mg/m², 1-2h IV Infusion on d1; 5-FU: 2400 mg/m², 46 h IV infusion on d1. Cycles are repeated on day 15.
215038412|NCT07004413|DIAGNOSTIC_TEST|Guardant360 ctDNA assay|Determination of circulating tumor DNA (ctDNA) in the peripheral blood, part 1: retrospective threshold determination to predict radiological disease progression in Arm 2; part 2: prospective validation of the in part 1 identified ctDNA threshold to guide the scheduled treatment breaks and treatment in Arm 2
215038413|NCT07003178|DRUG|STR-P004|An in vivo CART drug administered intravenously
215038414|NCT06866145|PROCEDURE|functional endoscopic sinus surgery|sinus surgery
215038415|NCT06866145|DRUG|Dexmedetomidine|precedex
215038416|NCT07003269|DRUG|Hetrombopag|In allogeneic hematopoietic stem cell transplantation, hetrombopag is initiated at 3 µg/kg subcutaneously on day +6 post-transplant. The dose is increased by 2 µg/kg weekly up to a maximum of 10 µg/kg. Treatment is discontinued when platelet counts rise to 100×10⁹/L. If platelet counts remain ≤20×10⁹/L on day +20, hetrombopag is combined with eltrombopag 25 mg orally once daily. Fresh apheresis platelet suspensions (1 therapeutic dose, containing \>2.5×10¹¹ platelets) are administered when platelet counts are ≤20×10⁹/L or when counts are between 21-50×10⁹/L with active bleeding. If engraftment has not occurred by day +28 post-transplant, re-transplantation is required, and hetrombopag is considered ineffective.
214872694|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 1)|
214872695|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 2)|
214872696|NCT00406042|DRUG|prednisolone acetate 1%|
214872697|NCT00960115|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram \[mcg\]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
215038417|NCT04070183|BEHAVIORAL|POST Facilitation|Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
215038418|NCT04070183|BEHAVIORAL|Home Safety Evaluation|Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
215038419|NCT07004075|DRUG|Luvometinib|Luvometinib oral tablet
215038420|NCT07004075|BIOLOGICAL|Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide|Investigator's choice of chemotherapy administered IV or orally
215038421|NCT07003360|PROCEDURE|application of beautiful blukfill II shofu composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, beautiful bluk fill II composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed.
215038422|NCT07003360|PROCEDURE|application of Ivoclar vivadent bulkfill composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, Ivoclar vivadent bulkfill composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed.
215038423|NCT07003360|PROCEDURE|application of Predicta bulk fill composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, Predicta bulk fill composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed
215038424|NCT07003360|PROCEDURE|application of Stela self-cure bulk fill composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, Stela self-cure bulk fill composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed.
215038425|NCT07003776|OTHER|Biological: Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against Pan- cytokeratin by immunohistochemical procedures.
215038426|NCT07003711|OTHER|aerobic exercise and relaxation trainig|Aerobic exercise and progressive muscle relaxation training will be given to the exercise group.
215038427|NCT07003711|OTHER|aerobic exercise|Aerobic exercise will be applied to the control group.
215038428|NCT07005011|OTHER|oral irrigator|oral irrigator
215038429|NCT07003438|DRUG|Fecal microbiota transplantation (FMT)|FMT was slowly administered to the patient's small intestine with fecal suspension under anesthesia and patients received a second transplant through oral administration freeze-dried capsules containing the fecal matter.
215038430|NCT07002983|OTHER|motor control retraining exercises|"The motor control retraining package was targeted at correcting movement impairments of the scapula by re-educating muscle recruitment. There were two components to the package:~1. Motor control exercises to correct alignment and coordination, which involve a) learning optimal scapular orientation at rest and then controlling optimal orientation during active arm movements; b) muscle specific exercises for trapezius and serratus anterior~2. Manual therapy techniques commonly used in clinical practice to manage symptoms, as trigger point therapy and pectoralis minor supine manual stretch will be performed as necessary."
215038431|NCT07002983|OTHER|traditional physical therapy for shoulder dysfunction|shoulder joint mobilization, posterior capsule stretching and shoulder range of motion exercise (ROM) (Codman's pendulum exercises)
214665935|NCT04260607|DRUG|Normal saline|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~3. Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post Normal Saline re-evaluation of outcome measure at one-week post infusion."
215038432|NCT06673901|DEVICE|Measurments|Each angle was measured three times, and the mean was calculated to represent the data used for statistical analysis. The assessment position for all measurements was relaxed, comfortable standing position and wearing loose clothing, bare feet, and one foot apart between two feet on a level floor in the same room of the same building, at the same time of day. There was a fixed point in the wall, and the woman was instructed to look at it during the assessment; this point adjusts at the level of her eyes. No specific instructions were provided to the females regarding posture so that measurements during a normal standing position. Data was recorded in a data-collecting sheet.
214872698|NCT00960115|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg/m\^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
214872699|NCT00960115|BIOLOGICAL|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
215038433|NCT06868485|DRUG|WSD0922-FU Tablets, Dose level A|Oral, 21 days in each cycle
215038434|NCT06868485|DRUG|WSD0922-FU Tablets, Dose level B|Oral, 21 days in each cycle
215038435|NCT06089070|DEVICE|FreeStyle Libre Continuous Glucose Monitor System|Continuous Glucose Monitor System for people with Type 2 Diabetes
215038436|NCT06679881|DRUG|Deucrictibant|Deucrictibant extended-release tablet for once daily oral use
214872700|NCT00960115|OTHER|Saline|A single dose of saline (sodium chloride, 9 grams per liter \[g/L\]) will be administered intravenously, 3 days prior to the start of placebo.
214872701|NCT01516307|BIOLOGICAL|OPT-822/OPT-821(30 μg/100 μg)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
214872702|NCT01516307|BIOLOGICAL|Phosphate Buffer Saline (PBS)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
214872703|NCT01516307|DRUG|Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
214872704|NCT04298645|OTHER|Glycaemic response to high GI carbohydrates consumed at morning versus evening meals.|Controlled nutrition trial on the glycaemic response to morning and evening meals with high glycemic index carbohydrates among students with early and late chronotypes.
215038437|NCT06629064|BEHAVIORAL|Working Memory Training|Computer-administered working memory training program. WMT is a modified working memory capacity task designed to train working memory functioning. WMT is designed to contain high interference across trials and is adaptive to performance. As participants improve working memory, the task becomes more difficult.
215038438|NCT06629064|OTHER|Sham Training|The Sham condition requires participants to complete a similar computer task for the same length of time. The Sham Training is a modified working memory capacity task designed to place less demands on working memory.
215038439|NCT06875141|BIOLOGICAL|DM199|DM199 is a synthetic form of rhKLK1
215038440|NCT05666609|PROCEDURE|placement of non-cutting seton (silicone)|Treatment of Fistula in ano is conducted according to the institution's treatment guidelines. Silicon seton placement is conducted under general anesthesia. Identification of the FIA is secured by the insertion of a bulb-headed lacrimal probe, on which a silicon vessel loop is attached and pulled through the entire fistulous tract. In case of a perianal abscess, drainage and sphincter-sparing debridement is performed followed by secondary wound healing. The loop is ligated loosely outside the anus without any additional tension to the skin. Duration of placed seton is depending on group assignment and is set to either 4 or 12 weeks.
214476606|NCT06804720|BEHAVIORAL|Mindfulness based Self compassion|All participants in the test group completed the 8-week MBCL (Mindfulness-Based Compassionate Living) training, consisting of 2-hour sessions per week, in accordance with the MBCL training protocol. Training was conducted by one expert periodontist who is also an internationally certified MBCL instructor
215038441|NCT06716021|DRUG|Placebo|The formulation of placebo will consist of water, sodium acetate, disodium EDTA, and sulfuric acid to reproduce the same pH as the etripamil formulation.
215038442|NCT06716021|DRUG|Etripamil|The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist.
215038443|NCT07039058|BEHAVIORAL|Brief Dialectical Behavior Therapy-Skills Training|"The intervention is administered in a single session, lasting approximately 60 minutes and conducted in person. It is important to note that there are no ongoing sessions.~In the intervention, participants are provided with 5 basic skills of Dialectical Behavior Therapy: 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing body chemistry. These strategies are grouped under 3 categories: 1) Mindfulness, 2) Emotion regulation (mindfulness of current emotions, opposite-to-emotion action), 3) Tolerating distress (distraction, changing body chemistry). These skills are not designed to treat or solve the crisis. The main aim is to provide effective coping mechanisms that can be implemented quickly before the crisis escelates, to help overcome the intense emotional pain and keep the person alive."
215038444|NCT07039058|BEHAVIORAL|Relaxation|The control group will be subjected to a relaxation exercise, with the objective of managing participant expectations, researcher attention/interest, and time spent, as well as providing a coping strategy for stress.
215038445|NCT04187404|BIOLOGICAL|EO2401|Multiple dose of EO2401
215038446|NCT04187404|BIOLOGICAL|Nivolumab|Multiple dose of nivolumab
214872705|NCT03137927|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
214872706|NCT03137927|OTHER|Placebo|Placebo
214476607|NCT06242834|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214476608|NCT06242834|PROCEDURE|Computed Tomography|Undergo CT scan
214872707|NCT00537927|PROCEDURE|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
214872708|NCT05940155|DIAGNOSTIC_TEST|RT PCR test of COVID 19|diagnostic test by naso-pharyngel swab to confirm the diagnosis of covid-19 at moderate and severe cases.
214476609|NCT06242834|PROCEDURE|Echocardiography|Undergo echocardiography
214476610|NCT06242834|BIOLOGICAL|Pembrolizumab|Given IV
214872709|NCT05795738|BEHAVIORAL|Chinese character-based visuomotor training program|this program includes visual-perceptual-motor play, paper-pencil activities, and ipad games using Chinese character as activity materials
214872710|NCT05795738|BEHAVIORAL|traditional visuomotor training program|this program includes play and paper-and-pencil activities, ipad games using commercial or self-designed stuffs as activity materials
214872711|NCT04428333|DRUG|Feladilimab|Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
214872712|NCT04428333|DRUG|Pembrolizumab|Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
214872713|NCT04428333|DRUG|Placebo|Sterile normal saline
215038447|NCT07039084|DEVICE|Speech-generating device|The device is an iPad loaded with a grid-based and speech-generating communication application - a suitable application for the participant is determined at the beginning of the trial. This device is used in all 12 therapy sessions and implemented by a qualified speech pathologist in a natural, play-based setting.
215038448|NCT07039084|OTHER|Control|Participants will continue their current model of care. This means that if participants are receiving speech therapy locally, they may continue to do so given that no speech-generating device is introduced or used during this time. Participants will check in with the researching clinician at least once a week via telehealth or phone call - the aim is to stay in contact with families and reduce loss to follow-up. The clinician will also monitor treatment integrity and document any differences that may be present during this phase.
215038449|NCT06724978|DRUG|S-740792 Suspension|Participants will receive S-740792 as an oral suspension.
214872714|NCT04428333|DRUG|Platinum based chemotherapy|Cisplatin/carboplatin
214872715|NCT04428333|DRUG|Fluorouracil (5FU)|5-fluorouracil
215038450|NCT06724978|DRUG|Midazolam|Participants will receive midazolam as a syrup.
215038451|NCT06724978|DRUG|Placebo|Participants will receive placebo as an oral suspension.
215038452|NCT06724978|DRUG|S-740792 Tablet|Participants will receive S-740792 as an oral tablet.
215038453|NCT06724159|DRUG|darolutamide|Darolutamide in combination with androgen deprivation therapy and docetaxel. Following the posology and administration details of its marketing authorization and standard clinical practice
215038454|NCT06724159|DRUG|Nivolumab monotherapy|Adjuvant nivolumab following after surgical removal of urothelial carcinoma. Following the posology and administration details of its marketing authorization and standard clinical practice
214872716|NCT05364060|OTHER|Questionnaires|Different questionnaires detailed in the objectives part
214872717|NCT03370809|RADIATION|Brain PET/CT step|a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
214872718|NCT00472862|BEHAVIORAL|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
214872719|NCT02351960|DRUG|Dexlansoprazole|Dexlansoprazole capsules
215038455|NCT06724159|DRUG|enfortumab vedotin|Following the posology and administration details of its marketing authorization and standard clinical practice
215038456|NCT06725706|DIAGNOSTIC_TEST|18F-92/AV45, 11C-PIB|Each subject receive a single intravenous injection of 18F-92/AV45, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.
215038458|NCT06884670|DRUG|Interleukin-2|Tislelizumab 200mg ivd D1+Interleukin 2 100IU HD, d1-d14+ CapeOX (Capecitabine: 825mg/m2 bid po, d1-d14；Oxaliplatin 200 mg/m² ivd, d1)
215038459|NCT06884670|RADIATION|Radiotherapy|Radiotherapy 1.8Gy per time\*28
215038460|NCT06884670|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
215038461|NCT06884670|DRUG|Oxaliplatin|Oxaliplatin 200 mg/m² ivd, d1
215038462|NCT06884670|DRUG|Capecitabine|Capecitabine: 825mg/m2 bid po, d1-d14
215038463|NCT07040644|DRUG|Sacituzumab Govitecan (SG)|Sacituzumab govitecan will be administered at 10 mg/kg via intravenous infusion on Days 1 and 8 of each 21-day cycle. The treatment continues until disease progression, unacceptable toxicity, or patient withdrawal.
215038464|NCT07040644|DRUG|Toripalimab|Toripalimab will be administered at a fixed dose of 240 mg via intravenous infusion on Day 1 of each 21-day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal.
215038465|NCT07040644|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 125 mg/m² via intravenous infusion on Days 1 and 8 of each 21-day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal.
215038466|NCT06725095|OTHER|Placebo gel|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo gel
215038467|NCT06725095|OTHER|Enamel Matrix Proteins Derivative|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of non-surgical treatment plus Enamel Matrix Proteins Derivative
215038468|NCT06732999|BEHAVIORAL|Gaze-Contingent Music Reward Therapy (GC-MRT|Gaze-Contingent Music Reward Therapy (GC-MRT) is a treatment method for adults with social anxiety disorder found to be effective in reducing social anxiety in various RCTs. This method includes a computerized cognitive training to redirect threat-related attention patterns.
214872720|NCT00319982|DRUG|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
214872721|NCT00319982|DRUG|Placebo|Placebo comparator (double-blind allocation of study medication)
214872722|NCT03337165|BIOLOGICAL|tolerogenic dendritic cells|dose-escalation
214476611|NCT06242834|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214872723|NCT02517086|OTHER|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
214872724|NCT02517086|OTHER|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
214872725|NCT02517086|OTHER|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
214872726|NCT02702479|OTHER|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
214476612|NCT06242834|DRUG|Tazemetostat|Given PO
215038469|NCT06926595|DRUG|Cyclophosphamide (primary intervention for GVHD prophylaxis)|This study evaluates the use of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) following allogeneic stem cell transplantation. The intervention involves administering PTCy on days +3 and +4 post-transplant, in combination with tacrolimus and mycophenolate mofetil (MMF) for GVHD prevention. The goal is to assess the safety and efficacy of this regimen in patients undergoing reduced-intensity or non-myeloablative conditioning using peripheral blood stem cells from matched sibling, matched unrelated, and haploidentical donors
215038470|NCT07049575|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
215038471|NCT06689475|OTHER|Psychoacoustic approach|The psychoacoustic approach group will listen to normal heart sounds (S1, S2), abnormal heart sounds (S3, S4) and murmur sounds from the audio file uploaded to their mobile phones in the laboratory environment through headphones for 500 repetitions each.
214872727|NCT02702479|OTHER|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
215038472|NCT06689475|OTHER|Simulation|The simulation group will practice auscultation of heart sounds in a one-to-one and repetitive manner, working with a high reality simulator. Trainers will act as facilitators during the cardiac auscultation practice of the students in the intervention groups.
215038473|NCT06888726|DEVICE|High-intensity transcranial alternating current stimulation (Hi-tACS)|The equipment used is the transcranial microcurrent stimulator (Nexalin ADI), operated by trained therapists following standardized instructions. Three Nexalin conductive electrodes are placed on the patient's head. A 4.45×9.53 cm electrode is placed on the forehead, corresponding to the Fpz region of the 10/20 international standard electrode placement system. Two 3.18×3.81 cm electrodes are placed on the bilateral dorsolateral prefrontal cortex, corresponding to the F3 and F4 regions of the international standard electrode placement system. The stimulation frequency is 77.5 Hz, and the current intensity is 15 mA.
215038474|NCT06888726|DEVICE|Sham High-intensity transcranial alternating current stimulation (Sham-Hi-tACS)|A sham device looks exactly the same as Nexalin ADI is used.
215038475|NCT06739291|DRUG|SIGX1094R|Single drug treatment by SIGX1094R, orally administered once daily.
215038476|NCT06894160|DEVICE|Adults EXPLORER|Two sessions with the robotic gait device in patients with neuromuscular diseases.
215038477|NCT06893783|DRUG|Tarlatamab|1 mg step dose on cycle 1 day 1 10 mg target dose starting cycle 1 day 8, cycle 1 day 15, and every 2weeks thereafter
215038478|NCT06740812|DRUG|Fosaprepitant for Injection|Fosaprepitant 150mg IV administered over 15 minutes
215038479|NCT06740812|DRUG|Metoclopramide Injection|Metoclopramide 10mg IV administered over 15 minutes
215038480|NCT06659705|DRUG|68Ga-FAPI-46 for PET / CT scan and 177Lu-EB-FAPI for therapy|Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.
215038481|NCT07056712|DIETARY_SUPPLEMENT|Fenugreek seed|Fenugreek seed: 1500 mg per day for 12 weeks
215038482|NCT07056712|OTHER|Placebo|Placebo: Calcined magnesia 1500 mg per day for 12 weeks
214476613|NCT06804512|DEVICE|Visual Occlusion Goggles|The visual occlusion goggles alternate between sight and visual occlusion in a regular and programmable pattern. Based on the electrical properties of the goggles, they are also able to have the tint adjusted instead of blacking out entirely for the occlusion times during the programmed timings.
214476614|NCT06804512|BEHAVIORAL|Balance Beam Walking|Participants will walk on a treadmill mounted balance beam to assess their balance
214476615|NCT05794139|DRUG|NMD670|Tablets
214872728|NCT03506984|DEVICE|Threshold Inspiration Muscle Training Device|Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.
214872729|NCT03506984|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
215038483|NCT06664788|DEVICE|ETHIZIA|ETHIZIA patch will be applied to bleeding site intraoperatively.
215038484|NCT06664788|DEVICE|SURGICEL Original|SURGICEL Original will be applied to bleeding site intraoperatively.
215038485|NCT06748989|DIETARY_SUPPLEMENT|Cortexium food supplement|Cortexium (a specially formulated dietary supplement with pyrroloquinoline quinone, γ-aminobutyric acid and B vitamins).
215038486|NCT06748989|DIETARY_SUPPLEMENT|Placebo food supplement|Placebo food supplement is completely identical weight and outlook capsule to Cortexium, with 50% microcrystalline cellulose and 50% starch.
215038487|NCT06747611|DRUG|Vancomycin, Neomycin and MTT capsules|patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.
215038488|NCT06747611|DRUG|Placebo capsules|patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.
215038489|NCT06738017|DRUG|BMN 349|250mg oral tablet
215038490|NCT06738017|DRUG|Placebo|250mg oral tablet
214476616|NCT05794139|DRUG|Placebo|Tablets
214476617|NCT06805266|DRUG|Vortioxetine (tablet)|Vortioxetine will be used with the aim of treating freezing of gait in subjects with Parkinson Disease and depressive symptoms
215038491|NCT07058298|DRUG|GC012F injection|"Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment,the infusion doses will be (CAR-T cell count) 3 × 10\^5/kg.~Note: for subjects weighing ≤70 kg: number of infused CAR-T cells = 3 (±20%) × 10\^5 × body weight(kg); for subjects weighing \>70 kg: number of infused CART cells (fixed doses of GC012F Injection) = 3 (±20%) × 10\^5 × 70 kg."
215038492|NCT07060820|PROCEDURE|Radial Artery Puncture at 0-20 mm|Radial artery puncture performed 0-20 mm proximal to the radial styloid process during transradial coronary angiography to evaluate its impact on the incidence of radial artery spasm (RAS).
214872730|NCT05480163|OTHER|Measurement records|Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
215038493|NCT07060820|PROCEDURE|Radial Artery Puncture at >21 mm|Radial artery puncture performed at a distance greater than 21 mm proximal to the radial styloid process during transradial coronary angiography to evaluate its impact on the incidence of radial artery spasm (RAS).
215038494|NCT07060898|DIETARY_SUPPLEMENT|Active Product|Novel Nutritional Product targeting Cognition
214872731|NCT00386763|DRUG|Artemether-lumefantrine|
214872732|NCT01094886|DRUG|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
214872733|NCT03480386|BEHAVIORAL|Home Based Pulmonary Rehabilitation|Twice daily exercise routine six days a week of 3 minutes of personal breathing, 5 exercises with 10 reps each, and 6 minutes of walking with weekly health coach calls.
215038495|NCT07060898|DIETARY_SUPPLEMENT|Placebo Product|Identical placebo product
215038496|NCT06899061|DRUG|Saruparib|"Module 1:~Period 2: participants will receive saruparib orally once daily from Day 1 to Day 9. On Day 5 saruparib will be administered orally in combination with the cocktail of substrates.~Period 3: participants will receive saruparib orally once daily for up to 3 cycles of 28 days each.~Module 2:~Period 1 and Period 2: participants will receive a single oral dose of DC or RC saruparib.~Period 3: participants will receive an oral dose of rabeprazole twice daily from Day 1 to 3, and a single oral dose of rabeprazole prior to DC saruparib on Day 4.~Period 4: participants will receive an oral dose of RC saruparib daily for 3 cycles."
215038497|NCT06899061|DRUG|Digoxin|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
215038498|NCT06899061|DRUG|Furosemide|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
215038499|NCT06899061|DRUG|Metformin Hydrochloride|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
215038500|NCT06899061|DRUG|Rosuvastatin|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
214872734|NCT03806712|OTHER|multi method questionary (developped by De Rosa, in 1995 and 2014)|questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
214872735|NCT06207214|OTHER|Self-help book for university students.|"The intervention being tested, is a self-help book for university students based on Acceptance and Commitment Therapy. The book was published in 2021 and is called The Unbreakable Student: 6 Rules for Staying Sane at University. The book is by Dr Nic Hooper.~The self-help book will be posted in paper form to all participants. There are 8 chapters in the book and participants will be given eight weeks to read the book at home (with a suggestion of reading one chapter per week)."
215038501|NCT06899061|DRUG|Rabeprazole|Period 3: Participants will receive two doses of rabeprazole per day from Day 1 to 3. On Day 4, participants will receive a dose of rabeprazole followed by DC saruparib.
215038502|NCT05605093|DRUG|Shionogi Protease Inhibitor (S-217622)|S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
215038503|NCT05605093|DRUG|placebo|Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
214476618|NCT06804564|OTHER|Cold Water Immersion (CWI)|Standard immersion baths with temperature monitoring and ice supplementation. Lower limbs immersed up to the hip. Water temperature maintained at 10-12°C. Duration: 15 minutes per session. Participants perform active ankle flexion/extension to promote circulation.
214476619|NCT06804564|OTHER|Hot Water Immersion (HWI)|Controlled immersion baths. Lower limbs immersed up to the hip. Water temperature maintained at 40°C. Duration: 15 minutes per session.
214872736|NCT02955381|DEVICE|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
215038504|NCT02220985|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
215038505|NCT02220985|DRUG|Cyclophosphamide|Given IV
215038506|NCT02220985|DRUG|Fludarabine Phosphate|Given IV
215038507|NCT02220985|OTHER|Laboratory Biomarker Analysis|Correlative studies
215038508|NCT02220985|DRUG|Methotrexate|Given IV
215038509|NCT02220985|DRUG|Mycophenolate Mofetil|Given IV and PO
215038510|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
214476620|NCT06804564|OTHER|Simulated Laser Therapy|Deactivated low-level laser therapy (LLLT) device. Applicator positioned over quadriceps muscle belly. Duration: 15 minutes, with no active laser output to simulate treatment conditions.
214872737|NCT02955381|DEVICE|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
215038511|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with CD45RA-depleted cells
215038512|NCT02220985|DRUG|Tacrolimus|Given IV or PO
215038513|NCT02220985|DRUG|Thiotepa|Given IV
215038514|NCT02220985|RADIATION|Total-Body Irradiation|Undergo TBI
214872738|NCT00049582|DRUG|decitabine|Given IV
215038515|NCT06857487|DRUG|Qingre Huatan Formula|Qingre Huatan Formula, granules, 1 bag each time, twice a day, orally, continue for 10 days.
215038516|NCT06857487|DRUG|Qingre Huatan Formula placebo|Qingre Huatan Formula placebo, granules, 1 bag each time, twice a day, orally, continue for 10 days.
215038517|NCT06857487|OTHER|Guidelines-based standard care|Guidelines-based standard care for acute ischemic stroke
214872739|NCT00049582|OTHER|laboratory biomarker analysis|Correlative studies
214872740|NCT00049582|OTHER|pharmacological study|Correlative studies
214872741|NCT01789827|OTHER|Laboratory Biomarker Analysis|Correlative studies
214872742|NCT01789827|PROCEDURE|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
214872743|NCT01789827|BIOLOGICAL|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
214872744|NCT01069991|BEHAVIORAL|Patient education group|Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
214872745|NCT01069991|BEHAVIORAL|Wait list control group|No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
214872746|NCT04180163|DRUG|Lanadelumab|Lanadelumab solution, SC
215038518|NCT06866236|DRUG|QRX-3|capsule
215038519|NCT02796716|DEVICE|Testing on new technology called Accelerate ID/AST system|
215038520|NCT07131644|DRUG|Sirolimus|Comparison of different sirolimus discontinuation strategies.
215038521|NCT04533646|DRUG|Insulin|Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.
215038522|NCT04533646|DEVICE|Continuous glucose monitor (CGM)|Participants will be required to wear a CGM to measure glucose trends
214872747|NCT05392335|OTHER|Myofascial stretch|Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.
214872748|NCT05392335|OTHER|Functional massage along with myofacial stretch|In this group during the first 20 minutes, ten minutes FM will be applied to each lower extremity of the subject. The muscle groups to which FM would be applied were hip adductors, hamstrings and calf muscles. During the remaining period traditional physiotherapy involving myofascial strecth will be given. 2-3 session will be performed in a week for 8 weeks.
215038523|NCT05627674|BEHAVIORAL|Usual Care|Usual care incorporates guideline awareness and brief advice.
215038524|NCT05627674|BEHAVIORAL|RiskProfile-Clin|RiskProfile-Clin incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors.
214291201|NCT06326567|OTHER|C4 Program|C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services.
214291202|NCT00677612|BIOLOGICAL|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
214291203|NCT00763477|BIOLOGICAL|ghrelin|subcutaneous injection
214872749|NCT02235038|BEHAVIORAL|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
214872750|NCT02235038|BEHAVIORAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
214872751|NCT02235038|BEHAVIORAL|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
214872752|NCT04730349|BIOLOGICAL|Nivolumab|Specified dose on specified days
214872753|NCT04730349|BIOLOGICAL|NKTR-214|Specified dose on specified days
214872754|NCT02433054|DEVICE|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
214872755|NCT04352387|BEHAVIORAL|Montessori Method for Dementia|The Montessori Method highlights the importance of considering the past experiences, identifying interests and maximizing spared capacity and abilities of each individual.
215038525|NCT05627674|BEHAVIORAL|RiskProfile-Gen|RiskProfile-Gen incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors and genetic factors.
215038526|NCT07085117|DRUG|Teprotumumab|Participants received teprotumumab as an intravenous (IV) infusion.
215038527|NCT06735859|BEHAVIORAL|Comparison of eating windows intervention|Participants will be randomized into two groups to follow either eating window for 12 months, with normocaloric meal plans based on the Mediterranean diet adapted to Brazilian culture. After 12 months, a 3-month washout period will follow, during which participants return to their usual eating patterns. The groups will then be swapped to follow the opposite eating window for another 12 months. Finally, a new data collection will be conducted 3 months post-intervention to analyze the stability of behavior.
215038528|NCT07083154|DRUG|Mazdutide|Mazdutide injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week. The starting dose is 2.0 mg administered once weekly (QW). Based on individual patient tolerance, the dose should be gradually increased to the target therapeutic dose of 4.0 mg QW over a period of 4 to 12 weeks. The protocol permits adaptive dose escalation up to 6.0 mg weekly when clinically indicated. For participants unable to tolerate dose increases, treatment continue at their maximum tolerated dose. The total intervention duration is 76 weeks.
214872756|NCT04352387|BEHAVIORAL|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
214872757|NCT02629354|DRUG|Ibuprofen|
215038529|NCT07083154|DRUG|Placebo|Placebo injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week. The starting dose is 2.0 mg administered once weekly (QW). Based on individual patient tolerance, the dose should be gradually increased to the target therapeutic dose of 4.0 mg QW over a period of 4 to 12 weeks. The protocol permits adaptive dose escalation up to 6.0 mg weekly when clinically indicated. For participants unable to tolerate dose increases, treatment continue at their maximum tolerated dose. The total intervention duration is 76 weeks.
215038530|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
215038531|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
215038532|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 10 g/ day for 14 days
215038533|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 20 g/ day for 7 days
215038534|NCT07086703|OTHER|Induced hypothermia at 33°C|"Cooling and maintenance phase :~The aim is to achieve the target temperature of 33±0.5°C within 60 minutes after randomization. The target temperature of 33±0.5°C and device setting of 33°C will be maintained until 28 hours after randomization.~\- Rewarming: Normothermia will be restored by gradual rewarming at a rate of 0.2°C/h.~\- After rewarming: After 40 hours, in those participants who are still comatose or sedated, normothermia (36.5-37.7°C) will be maintained until 72 hours after randomization, and active warming will be avoided."
215038535|NCT07086703|OTHER|Control normothermia|"Participants whose initial temperature is below 33°C may be actively rewarmed to 36.5°-37.7°C, at which point active rewarming will be stopped and passive rewarming performed according to the latest guidelines. Participants whose initial temperature is above 33°C will not be actively rewarmed to normothermia. The goal will be to maintain temperature no higher than 37.8°C.~After 40 hours, in those participants who are still comatose or sedated, normothermia (36.5-37.7°C) will be maintained until 72 hours after randomization, and active warming will be avoided."
215038536|NCT06904027|DRUG|Glycerol phenylbutyrate Oral Liquid|"Administration and dosage: The recommended total daily dose of glycerol phenylbutyrate is calculated based on the patient's body surface area, ranging from 4.5 mL/m2/d to 11.2 mL/m2/d:~1. Recommended initial dose in phenylbutyrate-naïve patients~   * Patients with body surface area (BSA) \< 1.3 m2: 8.5 mL/m2/day~  * Patients with body surface area (BSA) ≥ 1.3 m2: 7 mL/m2/day~2. Initial dose for patients switching from sodium phenylbutyrate to glycerol phenylbutyrate: Total daily dose of glycerol phenylbutyrate (ml) = total daily dose of sodium phenylbutyrate granules (g) ×0.81 Medication Schedule: The daily total dose should be divided into equal amounts and administered with each meal or feeding (such as three to six times daily)."
215038537|NCT04163757|DIETARY_SUPPLEMENT|crocin|2 tablets crocin per day
215038538|NCT04163757|DIETARY_SUPPLEMENT|placebo|2 tablets placebo per day
215038539|NCT04630769|DRUG|IP FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation
215038540|NCT04630769|DRUG|Enoblituzumab|Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy
215038541|NCT04630769|DRUG|IL-2|IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
215038542|NCT05714072|DRUG|Ruxolitinib|10mg BID or 15mg BID
215038543|NCT05714072|DRUG|Abemaciclib|50, 100 and 150 mg
215038544|NCT05472675|PROCEDURE|Botulinum toxin and bupivacain|Botulinum toxin A AND bupivacain( local anesthetic)
215038545|NCT07091123|DEVICE|Pain pump|Spinal catheter place under local anesthesia.
214476621|NCT06805487|BIOLOGICAL|TetraVax-DV-TV003 (TV003)|0.5 ml of TV003 delivered via subcutaneous injection. TV003 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31- 7164 and 10\^3.3 PFU/mL of rDEN4Δ30
215038546|NCT07091123|DRUG|Bupivacain 0.625%/Fentanyl 2mcg/ml|A solution containing fentanyl 2 mcg/mL and bupivacaine 0.625 mg/mL at an infusion rate of 0.5 ml/hr.
215038547|NCT07091123|DEVICE|Spinal Cord Stimulator (SCS)|"Two spinal cord stimulation leads will then be advanced under fluoroscopy to the target area, typically around T7-T9 in the posterior epidural space.~Currently, there are six manufacturers of spinal cord stimulation devices with implanted programmable generators or receivers."
215038548|NCT04106505|BEHAVIORAL|Biofeedback training via app on smartphone|Biofeedback training as described in biofeedback arm.
215038549|NCT04106505|BEHAVIORAL|Sham-biofeedback training via app on smartphone|Sham-biofeedback training as described in sham-biofeedback arm.
215038550|NCT06743308|OTHER|Best Practice|Other Best Practice best practice, standard of care, standard of care, standard of care, standard therapy Undergo standard of care oncology follow-up visits
215038551|NCT06743308|OTHER|Questionnaire Administration|Ancillary studies
215038552|NCT06764121|OTHER|Haskap Berry Powder|The participants will consume four packets (16g) of haskap berry powder. The powder can be consumed with other food products.
215038553|NCT06764121|OTHER|Placebo Powder|The participants will consume four packets (24g) of placebo powder. The powder can be consumed with other food products.
215038554|NCT05743075|DRUG|Ensifentrine|A dual PDE3/PDE 4 inhibitor
215038555|NCT05743075|DRUG|Placebo|Placebo solution
214476622|NCT06805487|BIOLOGICAL|Plasmalyte|0.5 mL of PlasmaLyte delivered via subcutaneous injection
214476623|NCT06805487|BIOLOGICAL|Challenge virus ZIKV-SJRP/2016-184|0.5 ml of ZIKV-SJRP/2016-184 delivered via subcutaneous injection. ZIKV-SJRP/2016-184 contains a dose of 10\^2 plaque-forming units (PFU).
214872758|NCT02629354|DRUG|Caffeine|
214872759|NCT02629354|DRUG|Ibuprofen|
214872760|NCT02302547|DRUG|triple therapy|Dosage treatment and usual prescription
214872761|NCT02302547|DRUG|dual therapy|1 tablet (200mg/245mg) daily for 48 weeks
215038556|NCT06912646|DEVICE|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
215038557|NCT06829550|DIAGNOSTIC_TEST|indirect- 3D digital scanning|examination for dental caries, erosive tooth wear and dental fluorosis using direct assessment (visual) and indirect assessment (digital scanning)
215038558|NCT05732961|DRUG|Luspatercept|Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
215038559|NCT05405595|DRUG|ADG126|ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
215038560|NCT05405595|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab (KEYTRUDA®) is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).
215038561|NCT05405595|DRUG|Standard of Care (Trifluridine/Tipiracil-Bevacizumab)|The standard of care therapies will include Trifluridine/Tipiracil-Bevacizumab, approved for treating metastatic colorectal cancer (CRC)and various solid tumors.
214872762|NCT03613727|DRUG|Intravenous (IV) and oral Vitamin C|"Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180"
214872763|NCT04778553|DIAGNOSTIC_TEST|iMOST X-1 Hematology Analyzer|The X-1 is a point of care automated hematology analyzer
214872764|NCT00704847|DRUG|Oral Salmon Calcitonin|0.8mg SMC021, twice daily
215038562|NCT05405595|DRUG|Standard of care (Fruquintinib)|The standard of care therapy, Fruquintinib, is approved for treating metastatic colorectal cancer (CRC) and various solid tumors.
215038563|NCT07116486|DIAGNOSTIC_TEST|Radiopharmaceutical 18F-FSPG|Given by injection
215038564|NCT06474013|DEVICE|ExAblate 4000 Type 2.1|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.1 system, and this will be performed 3 times every 2 months.
215038565|NCT06921148|DEVICE|Sylk Wound Dressing|Patients will have Silk bioprotein post-surgical dressing on one side of chest wall, and will have Dermabond/Prineo on the other side of chest wall. All patients will act as their own controls for this study. This means that all patients are both in the control group as well as the intervention group, given that these surgeries are bilateral in nature and one side of their chest will receive the interventional dressing and the other will receive the control dressing.
215038566|NCT06921148|DEVICE|Dermabond/Prineo Dressing|Patients will have Silk bioprotein post-surgical dressing on one side of chest wall, and will have Dermabond/Prineo on the other side of chest wall. All patients will act as their own controls for this study. This means that all patients are both in the control group as well as the intervention group, given that these surgeries are bilateral in nature and one side of their chest will receive the interventional dressing and the other will receive the control dressing.
214872765|NCT00704847|DRUG|Oral Salmon Calcitonin (Placebo)|0.8mg Placebo, twice daily
214872766|NCT02125162|DRUG|BCX4161|Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
215038567|NCT07118215|DRUG|KarXT|Specified dose on specified days
215038568|NCT07118215|DRUG|Midazolam|Specified dose on specified days
215038569|NCT07118215|DRUG|Fexofenadine|Specified dose on specified days
215038570|NCT07118215|DRUG|Digoxin|Specified dose on specified days
215038571|NCT02581930|DRUG|Ibrutinib|Given PO
215038572|NCT02581930|OTHER|Laboratory Biomarker Analysis|Correlative studies
215038573|NCT02581930|OTHER|Pharmacogenomic Study|Correlative studies
215038574|NCT02581930|OTHER|Pharmacological Study|Correlative studies
215038575|NCT04547075|OTHER|Turkish validity and reliability|"1. Contact with developers and formation of steering committee~2. Translation from English to Turkish~3. Back translation from Turkish to English~4. Comparison of translation~5. Review of translated versions.~6. Reaching consensus and development of pilot version~7. Testing in clinical setting~8. Revision of pilot version~9. Testing of final version"
215038576|NCT07124923|OTHER|Continuity-of-Care intervention|"The intervention is a structured, multidisciplinary training and feedback program led by the Endocrinology Service at HTVC in collaboration with primary care centers in Terres de l'Ebre.~Four endocrinologists and four nurses (three educators and one diabetic foot referent) will provide onsite training to primary care physicians and nurses. Training includes six modules with theoretical and practical components, covering T2DM management, cardiovascular risk reduction, and diabetic foot care. Sessions will be held biweekly and delivered by doctor-nurse teams rotating through the participating primary care centers from July 2025 to July 2026, with each center receiving a total of 15 sessions per year.~The program also includes regular feedback to professionals on clinical performance and patient outcomes, adapting content to each center's needs. A qualitative component, involving focus groups before and after the intervention, will gather feedback and inform future implementation."
214872767|NCT02075177|DRUG|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
214872768|NCT02075177|DRUG|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
214872769|NCT02529891|OTHER|Measurement of VOC in exhaled air|Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer
214872770|NCT02013674|BIOLOGICAL|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
214872771|NCT06232473|BEHAVIORAL|Patient Education|Please see arm desciption
214872772|NCT06232473|DRUG|Duloxetine|Please see arm description
214872773|NCT06232473|DRUG|Benztropine Mesylate 0.5 MG and passive placebo RAP|Please see arm description
215038578|NCT07139301|DRUG|Early anticoagulation|Early initiation of direct oral anticoagulants will be started within four days after symptom onset.
215038579|NCT07139301|DRUG|Delayed anticoagulation|Delayed initiation of direct oral anticoagulants will be started between 5-14 days after symptom onset.
214872774|NCT06232473|BEHAVIORAL|Enhanced usual care|Please see arm description
214872775|NCT04037774|DRUG|Dexmedetomidine|comparision of different doses of dexmedetomidine used intrathecally
215038580|NCT07140237|DRUG|Oxytocin lower does (24IU)|Oxytocin (24IU) will be administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue)
215038581|NCT07140237|DRUG|Oxytocin higher does (48IU)|Oxytocin (48IU) will be administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on and under the tongue)
215038582|NCT07140237|DRUG|Atosiban|150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue)
215038583|NCT07140237|DRUG|Placebo|Placebo administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue). Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and the atosiban interventions.
215038584|NCT05185583|DRUG|Methylphenidate Hydrochloride|Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.
215038585|NCT05185583|DRUG|Placebo|Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.
215038586|NCT05891158|DRUG|Fazirsiran|Fazirsiran SC injection
214872776|NCT04037774|OTHER|placebo|addition of placebo with local anesthetic to create a control group
214872777|NCT01181362|PROCEDURE|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
214872778|NCT01462773|DRUG|Bortezomib|VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
215038587|NCT05438940|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
215038588|NCT05438940|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth
215038589|NCT05438940|BEHAVIORAL|Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
215038590|NCT06929533|DIAGNOSTIC_TEST|Pharmacogenetic Testing|Participants will donate a 1ml (one-fifth of a teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the patient's current and future care.
215038591|NCT04697823|OTHER|use of hyaluronan-enriched transfer medium|In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium
215038592|NCT05760404|PROCEDURE|Surgery for colorectal cancer|Patients undergoing upfront surgery or surgery after neoadjuvant therapy for colorectal cancer with curative intention
215038593|NCT05760404|OTHER|in vitro study|on tissues from colorectal resections
215038594|NCT06941480|DIAGNOSTIC_TEST|PET/CT|Participants will undergo 89Zr-DFO-SC16.56 Ab PET/CT
215038595|NCT06941480|BIOLOGICAL|177Lu-DTPA-SC16.56|177Lu-DTPA-SC16.56, to be administered within 2 weeks of the PET/CT
215038596|NCT07139483|DEVICE|Trans Direct-Cranial Stimulation (tDCS)|The tDCS electrodes will be inserted into 5×7 cm (35 cm2) sponges soaked with saline (0.9 M) and placed as follows: anode over the M1 contralateral to the amputated limb (adjusted based on lower/upper amputation), and cathode over the forehead, contralateral to the anode (ipsilateral to amputated limb). Total stimulation duration will be 20 min, with a rise and decline time of 30 sec and stimulus intensity of 1.5 mA for the real tDCS real. The intensity of 1.5 mA is in the midrange of recommended intensities (1-2 mA) and supports successful blinding. The sham tDCS will be identical to the real tDCS, except no current will be applied. However, as recommended, during the first and last 30 sec, the current will be ramped up to 1.5 mA and immediately back to 0 to induce scalp sensations similar to those in real tDCS, further supporting blinding. The Mini-CT tDCS Stimulator device has been developed for home use and allows double-blind administration.
215038597|NCT07139483|BEHAVIORAL|Mirror therapy|Participants will be seated with a portable mirror between their limbs so that the unaffected limb is reflected in the mirror. The participants will focus their attention on the reflection in the mirror and perform the following movements: plantarflexion and dorsiflexion and inversion and eversion of the foot, flexion and extension of the wrist and ulnar and radial deviation, for lower and upper limp amputates, respectively. The participants will continue performing the 2 sets of movements for 20 minutes (with short intermissions if needed)
215038598|NCT07146243|BEHAVIORAL|Swedish Shoulder Control Programme|An evidence-based warm-up and strengthening routine developed for handball players to reduce the risk of shoulder injuries. The physiotherapy component includes exercises for scapular control, rotator cuff strength, and shoulder mobility. The throwing block is excluded in this trial, as it is designed for the off-season and the programme is implemented during the competitive season. Exercises are performed twice per week before training sessions, last about 15 minutes, and are supervised by two physiotherapists.
215038599|NCT07146243|BEHAVIORAL|Norwegian OSTRC Shoulder Injury Prevention Programme|An evidence-based warm-up and strengthening routine developed for handball players to reduce the risk of shoulder injuries. The programme focuses on exercises for scapular control, rotator cuff strength, and functional shoulder stability. Exercises are performed twice per week before training sessions, last about 15 minutes, and are supervised by two physiotherapists.
215038600|NCT06051357|DRUG|HRS-5965 tablets|HRS-5965 tablets for 12 weeks
215038601|NCT02586194|DRUG|ASP015K|Oral
215038602|NCT02556047|DEVICE|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N\&S
215038603|NCT07160335|DRUG|HLX17|Subjects will receive HLX17 (200 mg) on Day 1 of each 3-week cycle
215038604|NCT07160335|DRUG|US-sourced Keytruda®|Subjects will receive US-sourced Keytruda® (200 mg) on Day 1 of each 3-week cycle
215038605|NCT07159750|DRUG|CGRP antibody or gepant|Patients will start anti-CGRP or its receptor antibody or gepants
215038606|NCT07159490|DEVICE|Standard-of-care prosthetic foot|Widely prescribed prosthetic foot of stiffness category appropriate to the participant's body weight and activity level.
215038607|NCT07159490|DEVICE|Standard-of-care prosthetic foot with heel-stiffening wedge|Widely prescribed prosthetic foot with a wedge inserted between the heel and foot keels intended to stiffen the behavior of the heel.
215038608|NCT07159490|DEVICE|Standard-of-care prosthetic foot of one category greater stiffness|Widely prescribed prosthetic foot of one stiffness category greater than usually prescribed based on the participant's body weight and activity level.
215038609|NCT07159490|DEVICE|Dual keel prosthetic foot|A prosthetic foot with two forefoot keels intended for load carriage applications.
215038610|NCT07159490|DEVICE|Powered ankle-foot|A powered prosthetic ankle-foot.
215038611|NCT07159555|OTHER|Blood sampling for neurofilament analysis|An additional blood sample (maximum 1 mL) is collected during routine clinically indicated blood draws in late preterm infants (34-37 weeks of gestation). Samples are obtained at birth, day 2, and weekly until 37 weeks of gestation if blood draws are already planned. No separate venipuncture is performed. Samples are processed and stored for subsequent neurofilament concentration analysis.
215038612|NCT07160907|BEHAVIORAL|Ageing Simulation Experience Program|Ageing Simulation Experience Program is a structured training that includes a multimedia lecture, a hands-on aging simulation using the PengZu Suit, and a peer discussion. It aims to enhance care workers' aging knowledge, empathy, attitudes, and communication skills through experiential learning.
215038613|NCT07159984|BEHAVIORAL|Education on Changes During Pregnancy|In the first session of the researcher-prepared training presentation, women will be informed about the structure and functions of their internal and external reproductive organs, as well as changes in physical, hormonal, social, and lifestyle activities. After the first session, there will be a 15-minute break before the second session, which will include evidence-based training on the effects of pregnancy-related changes on stress, couple harmony, and quality of life. Methods for coping with stress and pregnancy-related complaints, process management that positively impacts couple harmony, and healthy lifestyle behaviors that enhance quality of life will be discussed.
215038614|NCT07161583|DEVICE|Advanta VXT Vascular Graft|The Advanta VXT graft is a two (2)-layer graft employing a single layer ePTFE graft, which is then wrapped with an additional layer of ePTFE for increased support. Some Advanta VXT configurations include Helix, which is a monofilament bead wrapped circumferentially around a portion or the entire length of the graft (such a graft is also called a Ringed Graft). The helix rings are bonded to the exterior surface of the graft. Advanta VXT Tapers are formed by changing the graft diameter, expanding from a small Inner Diameter (ID) to a larger ID (with the result that one end is larger).
215038615|NCT07161583|DEVICE|Flixene Vascular Graft|The Flixene vascular graft is a three (3)-layered graft comprised of ePTFE. The Flixene graft was designed with an additional layer of ePTFE. As a result of its design, ring support is not necessary
215038616|NCT07160348|OTHER|Questionnaire and Physical Exam|Translation and validation of the existing HPES-Symptom and HPES-Impact Questionnaires in the Greek population
215038617|NCT07160699|DRUG|Botulinum Neurotoxin Type A|The effectiveness of the combination of BoNT with treatment goal specific non-pharmacological interventions will be evaluated.
215038618|NCT07160699|OTHER|Non-pharmacological therapies|Depending on the treatment goal different non-pharmacological therapies as a standard of care will be provided
215038619|NCT07160309|DEVICE|Densah Bur|Implant site preparation will be performed using the Densah bur system to achieve osseodensification in narrow alveolar ridges prior to implant placement.
215038620|NCT07160309|DEVICE|Magnetic Mallet|Implant site preparation will be performed using the Magnetic Mallet device to achieve osseodensification in narrow alveolar ridges prior to implant placement.
215038621|NCT07158723|OTHER|Higher protein dietary pattern|Follow energy-restricted (10% calorie reduction), higher protein dietary pattern (1.6 g protein/kg body weight)
215038622|NCT07158723|OTHER|Calorie restriction|Follow energy-restricted (10% calorie reduction) dietary pattern for 16 weeks. No restrictions on macronutrient content.
215038623|NCT07158983|OTHER|Registry review|The study is set within a project to evaluate a program for identification of family violence. The study uses mixed methods including registry review of parents to evaluate the effect of the program.
215038624|NCT07158983|OTHER|Interviews|The study is set within a project to evaluate a program for identification of family violence. The study uses mixed methods including interviews with nurses to evaluate the effect of the program.
215038625|NCT07160868|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure - device to be used at night in the treatment of sleep apnoea
215038626|NCT07158814|DRUG|Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody|ACIP Recommended Preventive Monoclonal Antibody
214872779|NCT01462773|DRUG|Interferon Alfa-2b|I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
214872780|NCT06632431|OTHER|Endometrial cancer (EC)|"Endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) Histopathological slides for these cases will be reexamined and staged according to both the Federation of Gynecology and Obestetrics (FIGO) 2009 and updated Federation of Gynecology and Obestetrics (FIGO) 2023 endometrial staging systems. Upstaging refers to reclassification to a higher stage in the FIGO 2023 system compared to Federation of Gynecology and Obestetrics (FIGO)2009, while downstaging is the opposite.~All patients underwent lymph node dissection except those with Stage IA-Grades I and II endometrioid endometrial cancer and tumor size \<2 cm."
214872781|NCT02334592|RADIATION|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
214872782|NCT00902317|PROCEDURE|Cryoplasty (PolarCath peripheral balloon catheter)|Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
214872783|NCT00902317|PROCEDURE|Laser Angioplasty (Spectranetics)|The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
214872784|NCT00902317|PROCEDURE|SilverHawk Atherectomy|Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
214872785|NCT00902317|DEVICE|Viabahn Endograft|The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
214872786|NCT00902317|PROCEDURE|"Angioplasty/Stent (Guidant Absolute stent)"|A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
214872787|NCT05367050|BEHAVIORAL|Lucid Lane Therapy Program|This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.
214872788|NCT05367050|BEHAVIORAL|Surgical Preparedness Course|This intervention is designed to help the participant prepare for their upcoming surgery. Classes will include discussions around managing chronic pain before surgery, building mental resilience, dealing with the uncertainty of a new diagnosis or treatment plan, questions to ask their anesthesiologist before and on the day of surgery, what to expect during their potential stay at the hospital, and how to optimize their recovery after surgery. Sessions will often include expert doctors who focus on surgery and medical management around it.
214872789|NCT00960635|DRUG|1,25-dihydroxy-vitamin D3 (calcitriol)|
214872790|NCT00960635|DRUG|placebo|pill without agent
214872791|NCT00416884|DRUG|Campath|30 mg on day -8 over 5-6 hours
214872792|NCT00416884|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 on day -4 through day -2
214872793|NCT00416884|RADIATION|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
214872794|NCT00416884|OTHER|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
214872795|NCT03123432|DIETARY_SUPPLEMENT|immunomodulating nutrients enriched diet|
214872796|NCT03123432|DIETARY_SUPPLEMENT|standard diet|
214872797|NCT06219278|DEVICE|Profound Matrix|The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks
214872798|NCT06812611|DEVICE|High Energy Laser Group|"The multimodal high energy laser therapy treatment with thermal control (THEAL) will be delivered with an Ixyon XP device (Mectronic, Bergamo, Italy) which allows the delivery of 4 wavelengths (650 nm, 810 nm, 980 nm and 1064 nm), with continuous and pulsed mode, average power up to 30 W, administering 10 sessions every other day.~The patients will simultaneously carry out the rehabilitation treatment exercises, as was expected in the control group."
214872799|NCT06812611|OTHER|Exercise|Daily exercise
214872800|NCT00802594|DRUG|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
214872801|NCT06908876|BIOLOGICAL|IBI302|4 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by Pro re nata (PRN) regimen.
214872802|NCT06908876|BIOLOGICAL|IBI302|8 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by PRN regimen.
214872803|NCT06908876|DRUG|Faricimab|6 mg faricimab will be administered by intravitreal injection into the study eye once every 4 weeks for 4 consecutive months, followed by PRN regimen.
214872804|NCT05940623|DEVICE|Standard care and home IOP telemonitoring with smart phone-based intervention|We expect that (1) GAT measurements over 30 months of follow-up for patients randomized to Management Paradigm I to be smaller compared with those randomized to Management Paradigm II; and that (2) the rates of RNFL/GCIPL thinning would be slower for those randomized to Management Paradigm I compared with those randomized to Management Paradigm II
214872805|NCT00278252|DRUG|etoposide|
214872806|NCT00278252|PROCEDURE|conventional surgery|
214872807|NCT06912152|BIOLOGICAL|MT027 CAR-T cells|"Prior to MT027 cell infusion, lymphodepleting chemotherapy with fludarabine and cyclophosphamide was administered.~Dose Group 1: 1×10⁷ cells per administration; Dose Group 1: 3×10⁷ cells per administration; Dose Group 1: 6×10⁷ cells per administration; Based on the data obtained, adjustments to the specific number of cells in the established dosage groups and/or the addition of dosage groups may be made after discussion between the collaborators and researchers. A dose reduction titration may also be conducted based on the completed dosage groups."
214872808|NCT06208189|BEHAVIORAL|High-effort session|Participants will perform 3 sets per exercise (total of 21 sets) with as many repetitions they can each set. We anticipate participants will perform \~10 repetitions per set in this session, with a total tempo of \~2.5 seconds per rep, averaging \~25 seconds per set. Resting period between exercises and sets will be 120 seconds. This will lead to a total session time of \~50 min. Their glycemic control will be evaluated during the following \~48 hours.
214872809|NCT06208189|BEHAVIORAL|Low-effort session|Participants will perform 6 sets per exercise (total of 42 sets) but perform half of the anticipated number of repetitions of the HIGH session (i.e., 5 reps). Repetition tempo at \~2.5 seconds will result in \~12.5 seconds per set. Resting period between exercises and sets will be 60 seconds. This prescription will also lead to a total session time of \~50 min. Thus, both the HIGH and LOW session will have similar total volume-load and session density, but differ in perceived effort after each set. Their glycemic control will be evaluated during the following \~48 hours.
215038627|NCT07159880|DRUG|Letrozole (aromatase inhibitor)|"Participants will be randomized into two groups:~Extended therapy group: 5 mg/day of letrozole for 10 days (cycle days 2-12). Standard therapy group: 5 mg/day of letrozole for 5 days (cycle days 2-6)."
215038628|NCT07160738|DRUG|PF-07220060|Tablet given orally
215038629|NCT07160738|DRUG|Itraconazole|Capsule given orally
215038630|NCT07160738|DRUG|Probenecid|Tablet given orally
215038631|NCT05986929|OTHER|focus group|Two semi-structured group interviews, lasting 30-60 minutes, on facilitators and barriers to poster use by staff members (N=6-8).
215038632|NCT05986929|OTHER|electronic survey|An electronic survey of 15 closed questions on the acceptability of the magnetic posters (N=100).
215038633|NCT05639881|BEHAVIORAL|Enhancing Your Immune Health|In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.
215038634|NCT02203643|DRUG|Carfilzomib|
215038635|NCT02203643|DRUG|Cyclophosphamide|
215038636|NCT02203643|DRUG|Lenalidomide|
215038637|NCT02203643|DRUG|Dexamethasone|
215038638|NCT05341310|BEHAVIORAL|ADHDCoach|ADHDCoach is an individually-tailored intervention to reduce parents' of children diagnosed with ADHD distress.
215038639|NCT05341310|OTHER|Treatment as usual|Treatment as usual in the outpatient clinic
215038640|NCT03561311|DEVICE|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
215038641|NCT03561311|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
214665936|NCT06264726|OTHER|HealtheRx|CRx-CVD intervention provides participants with a HealtheRx, a tool developed by researchers with personalized listings of community resources with information about housing, food assistance, utility support, transportation and crisis support for patients. A HealtheRx may can be given directly, texted or emailed to patients and caregivers. All patients enrolled in this group will receive the HealtheRx either via text and/or email based on participant preference. Participants will receive contact information for a Community Resource Navigator who can provide support with using the HealtheRx, provide additional resources upon request, and answer any questions the participant may have. Participants will also receive a 2 reminder text messages over 2 months following their initial receipt of the HealtheRx. The SMS messages offer reminders about the HealtheRx and ongoing community resource navigation support.
214872810|NCT06208189|BEHAVIORAL|Control|The control session all procedures will be identical to the HIGH session, with the exception of performing the resistance exercises. However, to simulate all other procedures participants will follow all instructions, be positioned on the equipment for the same amount of time as the HIGH session, but will not perform any repetition. Interval between fake sets and exercises will be 120 seconds. Their glycemic control will be evaluated during the following \~48 hours.
215038642|NCT04681144|DRUG|Radium-223-dichloride (Xofigo, BAY88-8223)|Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
215038643|NCT06032611|DIAGNOSTIC_TEST|COGNUM_ALZVR|"Participants will complete a battery of tests/quizzes:~* cognitive tests~* medical questionnaire~* lifestyle/fragility questionnaire~* digital clock test~* fine motor skills tests They will also wear a connected watch for 7 days."
215038644|NCT01270529|OTHER|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
215038645|NCT05165472|OTHER|Quadri-pulse theta burst stimulation|High frequency transcranial quadri-pulse theta burst stimulation prior to hand motor function training
215038646|NCT01301677|DRUG|Hydrocortisone|Hydrocortisone liquid formulation
215038647|NCT01301677|DRUG|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
215038648|NCT01301677|DRUG|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
215038649|NCT03949023|PROCEDURE|Standard of Care Cerebral Angiogram Group|"Subjects will undergo the standard of care cerebral angiogram and any intervention(s) (when applicable) that were discussed with their provider, following the standard procedural protocol for the procedure at WFBMC. There are no additional interventions or changes to the planned intervention(s) that will take place by agreeing to participate in the study.~The data collected from this procedure, following the standard of care protocol, will include the following: force of injection of contrast material for each angiographic run (peak pressure associated with injection, duration of peak, and area under pressure curve), volume of contrast utilized, images from the procedure, measurements of vessel diameter at defined distances from the catheter tip utilizing the images, catheter type, any additional device(s) (when applicable) utilized during the procedure, and if spasmolytic agents are utilized (including dose and time of administration)."
215038650|NCT02180789|DRUG|Tamsulosin OCAS|oral
215038651|NCT02266303|OTHER|Insulin Start-up Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
214665937|NCT03215914|DEVICE|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
214665938|NCT00638872|DRUG|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
214665939|NCT00638872|OTHER|0.9% NaCl|same as PDRN
214872811|NCT06914102|DRUG|Semaglutide|New use of semaglutide dispensing claim is used as the exposure.
214872812|NCT06914102|DRUG|Placebo|New use of sitagliptin dispensing claim is used as the reference (active-comparator proxy for placebo).
214872813|NCT06917326|DEVICE|Monitoring|Lung monitoring with the Neola device
215038652|NCT01015521|DRUG|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
215038653|NCT06484582|OTHER|workers|This study will be conducted as a face-to-face survey. Surveys will be created with Google Forms and will be filled out by the physiotherapist according to the participant's response.
215038654|NCT04400435|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
215038655|NCT00017043|DRUG|ixabepilone|
215038656|NCT05125003|BEHAVIORAL|FITBI|parents learn to identify high probability cues in the environment that can elicit RRBI symptoms and teach their child to inhibit repetitive behaviors and instead replace them with alternative and flexible play behaviors; and (b) teach parents how to embed this FITBI approach into their child's everyday routines
215038657|NCT05125003|BEHAVIORAL|Parental Education|Sessions will cover relevant information on young children with ASD, including understanding the ASD diagnosis, developmental changes in ASD, educational planning, advocacy, and treatment options.
215038658|NCT05086861|DEVICE|Oesophageal pacing after left atrial posterior wall isolation|Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
215038659|NCT03237806|DRUG|Deep sedated|Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
215038660|NCT03237806|DRUG|Light sedated|Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
214476624|NCT05860114|DRUG|Givinostat|"Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension~On days 1 and 13 givinostat was administered in the morning, following an overnight fasting of at least 8 hours and subjects remained fasted until at least 4 hours post-dose. Moreover the subjects were in a semi-recumbent position and remained semi-recumbent until at least 4 hours post-dose.No fluids were allowed from 1 hour before dosing until 2 hours post-dose. Water was provided ad libitum at all other times.~From Day 5 to Day 12, subjects received givinostat 50 mg as oral suspension, twice a day, in the morning and in the evening."
214665940|NCT06488196|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) is a person-centered, goal-oriented psychotherapeutic intervention designed to enhance the recipient's motivation for and commitment to a target behavior or behavior change. MI's core action mechanisms include strengthening the recipient's change talk (e.g., assertions about desire and commitment toward the target behavior) and softening the recipient's sustain talk (e.g., statements about barriers). MI clinicians achieve these goals using specific micro-skills (e.g., reflective listening) that reflect MI's fundamental spirits (i.e. collaboration, acceptance, compassion, evocation.
214665941|NCT06488196|OTHER|Treatment As Usual|TAU included the opportunity for mothers to meet with a NICU psychologist or psychology trainee at least once-per-week for supportive care.
214665942|NCT04297644|OTHER|There is no intervention|There is no intervention
214665943|NCT02988648|RADIATION|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
214665944|NCT01733355|RADIATION|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
214665945|NCT00003248|BIOLOGICAL|rituximab|
214872814|NCT04511962|OTHER|Tele-Pulmonary rehabilitation|The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.
214872815|NCT01767961|PROCEDURE|diagnostic imaging|Undergo MBS
214872816|NCT01767961|OTHER|questionnaire administration|Correlative studies
214872817|NCT01767961|PROCEDURE|quality-of-life assessment|Correlative studies
214872818|NCT04007289|DRUG|Apixaban|Administration of Apixaban ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography, Biological samples collections to identify predictors of thrombosis and liver related events
215038661|NCT04363346|DRUG|FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
215038662|NCT05251649|DEVICE|tACS combined with 40 Hz sound stimulation|"The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).~Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). Sound stimulation was turned on simultaneously at the beginning of tACS. The duration of sound stimulation was set to 5 min stimulation, 5 min rest, 5 min stimulation, 1 min rest, and continued stimulation until the end of electrical stimulation while sound stimulation was turned off."
214872819|NCT04007289|DRUG|Placebo|Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
214872820|NCT06912711|DRUG|Toripalimab|Triplizumab (240mg, Q3W, 2 cycles, induction)and (240mg, Q3W, 15 cycles, adjuvant)
214872821|NCT06912711|DRUG|Nimotuzumab|Triplizumab (200mg, Q3W, 2 cycles, induction) and (200mg, Q3W, 15 cycles, adjuvant)
214872822|NCT06912711|PROCEDURE|surgery|The complete resection of the nasopharyngeal tumor and its adequate safety boundary must be performed under general anesthesia and under the guidance of nasal endoscopy through bilateral nasal passages. The anterior incisal margin should reach 1-2cm in front of the posterior column of the nasal septum, and the upper incisal margin should reach about 0.5-1cm in front of the upper margin of the posterior nostril. The lateral incisal margin and the lower incisal margin should be individually designed according to the size and location of the tumor. A safe incisal margin of 0.5-1.0cm was obtained, and then the tumor tissue and normal tissue of the incisal margin were ablated layer by layer from the upper incisal margin to the lower incisal margin until no obvious tumor remained under the naked eye.
214476625|NCT06551519|OTHER|ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
214476626|NCT06551519|OTHER|DMT category 1|This is an observational study. There is no treatment allocation. The decision to continue their current DMT will be based solely on clinical judgement.
214665946|NCT00003248|DRUG|fludarabine phosphate|
214665947|NCT04943536|DRUG|bicalutamide|localized anti-androgen therapy
214665948|NCT04943536|RADIATION|Stereotactic body radiation therapy|localized radiation therapy
214665949|NCT02362607|BEHAVIORAL|Integrated Diabetes Management Protocol|
214872823|NCT06285994|PROCEDURE|High frequency jet ventilation|Use of high frequency jet ventilation during bronchoscopy
214872824|NCT01777360|DEVICE|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
214665950|NCT02362607|BEHAVIORAL|Standard Diabetes Management Protocol|
214665951|NCT00565500|DRUG|celecoxib|celecoxib capsules 200 mg bid for 1 week
214665952|NCT00565500|DRUG|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
214665953|NCT00565500|DRUG|placebo|placebo capsules tid for 1 week
214665954|NCT02758795|DIETARY_SUPPLEMENT|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
214872825|NCT05103189|OTHER|4D-flow sequence|all patients will be referred for a complete cardiac MRI exam with the addition of a 4D Flow sequence (does not require supplementary injection of a contrast agent and does not extend the duration of the examination) followed promptly (within the same hour) by a Doppler-echocardiography.
214872826|NCT02969174|OTHER|zimin Lu,Guo Sa|chengzhong Liu
214872827|NCT04232111|DEVICE|Heat|Heat applied to hand
214872828|NCT04232111|DEVICE|Vacuum|vacuum applied to hand
214872829|NCT04232111|DEVICE|sham|neither heat nor vacuum
214872830|NCT04051619|DRUG|intranasal oxytocin, 40 IU, twice a day for 7 days|Adjunct therapy
214872831|NCT06189638|DRUG|Antimicrobial Peptide PL-5 Topical Spray and Placebo|Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
214872832|NCT05651607|DRUG|Cannabidiol|Oral solution, taken 3 times a day (morning, noon and evening), 5 mg/kg/day from day D0 to day D4. If not effective and well tolerated, dose increase : 10 mg/kg/day from day D5 to day D9, then 20 mg/kg/day from day D10 to day D29, maximum 800 mg/day
214872833|NCT05005897|BIOLOGICAL|Cyanocobalamin|Intramuscular injection of 400 µg cobalamin to children with elevated thcy at enrollment
214872834|NCT06634433|BEHAVIORAL|Health Personnel Attitude|The intervention consists of a two-phase Training of Trainers Program (TTP) designed for health professionals aimed at enhancing interprofessional education (IPE) skills. Phase 1 includes three days of online theoretical training, focusing on topics such as interprofessional collaboration, communication, and conflict resolution. Phase 2 involves two days of face-to-face practical sessions, where participants engage in scenario-based learning and small group discussions to apply IPE concepts. The effectiveness of the program is assessed through pre-test and post-test evaluations, measuring changes in participants\&#39; knowledge, attitudes, and competencies in interprofessional education.
214872835|NCT00839553|PROCEDURE|Intrapleural Minocycline application|
214872836|NCT04060446|DEVICE|Medical Device|Smoke cigarettes with CReSSMicro topography measurement device and BioRadio device
214872837|NCT04060446|OTHER|Questionnaire Administration|Ancillary studies
214872838|NCT04060446|BEHAVIORAL|Tobacco Smoking|Smoke cigarettes
214872839|NCT01442324|PROCEDURE|Irreversible electroporation (IRE)|Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
214872840|NCT02293980|DRUG|MK-3795|Oral administration
214872841|NCT02293980|DRUG|Nivolumab|IV infusion
214872842|NCT02293980|DRUG|Cabozantinib|Oral administration
214872843|NCT02293980|DRUG|Bezlutifan|Oral administration
214872844|NCT02354404|BIOLOGICAL|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
214872845|NCT02354404|BIOLOGICAL|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].
214872846|NCT02354404|BIOLOGICAL|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
214872847|NCT03831204|DEVICE|biopac|"Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus."
214665955|NCT02758795|DIETARY_SUPPLEMENT|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
214665956|NCT06145919|BEHAVIORAL|Episodic Future Thinking (EFT)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
215038663|NCT05251649|DEVICE|Transcranial alternating current stimulation|The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).
214872848|NCT03831204|DIAGNOSTIC_TEST|prognostic scores|Effect and GWTGHF were calculated for every patient
214872849|NCT02903706|OTHER|Measure of Plasmodium prevalence (PCR)|
214872850|NCT00993486|BIOLOGICAL|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
214872851|NCT04308226|BEHAVIORAL|Patient Navigation|The navigator's principal role is to guide participants through the lung cancer screening (LCS) process. The navigator will work within the existing Boston Health Care for the Homeless (BHCHP) clinical structure and collaborate with participants' primary care providers (PCPs) to facilitate LCS low-dose computed tomography (LDCT) referral, completion, and timely follow-up by addressing participants' barriers to LCS completion and enhancing participants' self-efficacy. The navigator's secondary role is to offer brief tobacco counseling for participants who currently smoke.
214872852|NCT01626443|DIETARY_SUPPLEMENT|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
214872853|NCT01626443|DIETARY_SUPPLEMENT|Folic acid|Folic acid (200 mcg); 2 x die
214872854|NCT06598878|PROCEDURE|AR gait training|Participants will walk on a pathway projected in augmented reality (AR), following the instructions provided on the pathway Each session will last for 60 minutes, conducted three times per week, over a period of six weeks.
214872855|NCT00935610|DIETARY_SUPPLEMENT|Immunocal|20 grams per day of Immunocal for 135 days.
214872856|NCT00935610|DIETARY_SUPPLEMENT|Casein|20 grams per day for 135 days
214872857|NCT05231330|DRUG|silvernanoparticles|silvernanoparticles in fluoride varnish
214872858|NCT05231330|DRUG|SDF|silver diamine fluoride
214872859|NCT04321330|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
214872860|NCT06370286|BEHAVIORAL|concurrent exercise (CE)|Participants in the concurrent exercise group engaged in 12-minutes of aerobic exercise (40%-59% of heart rate reserve \[HRR\]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
214872861|NCT06370286|BEHAVIORAL|aerobic exercise (AE)|Participants in the aerobic exercise (AE) group participated in 25 minutes of AE (40%-59% of heart rate reserve \[HRR\]). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
214872862|NCT03610516|DRUG|CFZ533|Multiple doses of 10 mg/kg CFZ533 intravenous (IV) infusion. CFZ533 was administered every 4 weeks (Q4W; from Day 1 to Day 141), plus an additional dose of 10 mg/kg IV at Day 15, resulting in a Q2W loading regimen up to the third dose on Day 29.
214872863|NCT03610516|DRUG|Placebo|multiple doses of placebo intravenous infusion
214872864|NCT00293943|PROCEDURE|Pulmonary vein ablation|
214872865|NCT03914794|DRUG|Pemigatinib|Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.
214872866|NCT01653301|DRUG|XELAC RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
214872867|NCT01653301|DRUG|XELOX RT|"* Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
214872868|NCT06197269|OTHER|Short duration antibiotics|antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
215038664|NCT05251649|DEVICE|40 Hz sound stimulation|Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). The duration of the sound stimulation was set to stimulate for 5 min, rest for 5 min, stimulate for 5 min, rest for 1 min, and last for a total of 20 min. 15 sessions of 20 min were performed over a period of 3 weeks (21 days).
215038665|NCT01385579|OTHER|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
215038666|NCT06173089|DEVICE|Remote monitoring|Remote monitoring for patients with an ICD/CRT device
214476627|NCT02572141|DRUG|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
214872869|NCT06197269|OTHER|Standard duration antibiotics|Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
214872870|NCT01328379|DRUG|Dalfampridine-ER 5mg|5mg, twice daily
214872871|NCT01328379|DRUG|Dalfampridine-ER 10mg|10mg, twice daily
214872872|NCT01328379|OTHER|Placebo|placebo, twice daily
214872873|NCT01820234|OTHER|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
214872874|NCT01820234|OTHER|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
215038667|NCT02482311|DRUG|AZD 1775|"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food."
214872875|NCT03523078|PROCEDURE|Breast reconstructive surgery|All sorts of breast reconstructive surgery are allowed in this study in terms of timing, autologous/prosthetic and so forth.
214872876|NCT00318877|BEHAVIORAL|After school team sports program|
214872877|NCT00318877|BEHAVIORAL|After school health education program|
214872878|NCT04351633|OTHER|questionnaire assesment|questionnaire assesment
214872879|NCT06416956|DRUG|Caffeine|We will record infant\&#39;s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.
214872880|NCT00237640|DRUG|Cinnamon or placebo 500 mg capsule twice daily|Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
214872881|NCT03973307|DIAGNOSTIC_TEST|UroX bladder cancer biomarker test|Urine test using novel UroX biomarker test for bladder malignancy
214872882|NCT02218801|OTHER|Evaluation of treatment for liver metastasis|
215038668|NCT02748447|DEVICE|Automated FiO2 adjustment|AVEA ventilator according to SpO2 target range delivers an automated FiO2
215038669|NCT03944850|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions. A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body. Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal. Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
215038670|NCT05008848|BEHAVIORAL|Smoking Cessation Intervention|Participate in schedule gradual reduction program
214476628|NCT02572141|DRUG|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
214872883|NCT00660907|DRUG|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
215038671|NCT05008848|OTHER|Health Promotion and Education|Receive cessation support messages
215038672|NCT05008848|OTHER|Informational Intervention|Receive NCI's Clearing the Air booklet
215038673|NCT05008848|OTHER|Questionnaire Administration|Ancillary studies
214476629|NCT06168019|OTHER|Exposures|COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn
214872884|NCT00660907|DRUG|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
214872885|NCT00660907|DRUG|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
214872886|NCT02813265|DRUG|KPI-121 0.25% Ophthalmic Suspension|
214872887|NCT02813265|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
214872888|NCT01815476|RADIATION|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
214872889|NCT05264129|DRUG|Atogepant|Oral Tablet
214872890|NCT05264129|DRUG|Ubrogepant|Oral Tablet
214872891|NCT02053337|DEVICE|Self adhesive foam dressing|Self adhesive foam dressing
214872892|NCT00618332|DRUG|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
214872893|NCT00618332|DRUG|placebo|2 puffs in each nostril once a day for 2 weeks
214872894|NCT02692144|OTHER|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
214872895|NCT00644930|DEVICE|the application of NPPV|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
214872896|NCT00644930|DEVICE|invasive ventilation|Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist-control or synchronized intermittent mandatory ventilation (SIMV) mode.
214872897|NCT00245687|DEVICE|Tiger Tube|
214872898|NCT05395286|BEHAVIORAL|Innovation Lab|An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
214872899|NCT04208958|BIOLOGICAL|VE800|VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.
214872900|NCT04208958|DRUG|Nivolumab|Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
214872901|NCT04208958|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection.
215038674|NCT04390282|BEHAVIORAL|Application-based support system|All participants (experimental and control group) will be invited to a separate appointment at the vascular open clinic at baseline and after three months and measured regarding weight, blood pressure, Ankle Brachial Pressure Index, six minutes walking test and pain. To calculate the estimate 10-year risk of manifesting clinical cardiovascular disease, the Framingham Risk Score will be used. Further, a questionnaire will be answered at baseline and after three months containing the instruments, VascuQoL-6, Health Education Impact Questionnaire and Medication Adherence Report Scale-5.
215038675|NCT02018211|OTHER|control|passive recovery following exercise test
215038676|NCT02018211|DEVICE|graduated compression socks|graduated compression socks worn after test exercise
215038677|NCT02018211|DEVICE|neuromuscular electrical stimulation device|neuromuscular electrical stimulation device worn after test exercise
215038678|NCT05557396|OTHER|Internal Tube Length Measurement Procedures for Nazogastric Tube|Different Internal Tube Length Measurement Procedures will used for the correct placement of nasogastric tube.
215038679|NCT01020357|DRUG|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
215038680|NCT01020357|DRUG|placebo|normal saline
215038681|NCT00642044|PROCEDURE|Corneal Collagen Crosslinking|UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
215038682|NCT00360139|DEVICE|Sculptra Injection|
215038683|NCT03218865|DEVICE|VIE high flux dialyzer|Asssesment of the therapeutic effect of the vitamin E coating
215038684|NCT03218865|DEVICE|Leoceed H high flux dialyzer|Use of the Leoceed H dialyzer during one year per patient enrolled in the control group
214872902|NCT00948324|DRUG|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
214872903|NCT05773794|DIETARY_SUPPLEMENT|Soymilk, green tea, or blueberry|One dose of soymilk, green tea, or blueberry blends (460mL) with breakfast.
215038685|NCT04506684|DEVICE|Investigational RAMware downloaded onto Reveal LINQ device|The study is utilizing an investigational RAMware, either LINQ HF or ALLEVIATE-HF, that will be downloaded onto the subject's market-released Medtronic Reveal LINQ ICM. The investigational RAMware enables the hardware to record and store additional sensor data from which a respiratory rate will be derived.
215038686|NCT04975620|DEVICE|Fine needle biopsy|Taking biopsy from solid pancreatobiliary mass lesions with 8 back and forth movement of the needle within the lesion with slow withdrawal of the stylet
215038687|NCT03386773|BEHAVIORAL|16-week program|16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
215038688|NCT03386773|BEHAVIORAL|Patient generated health data|Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
214665957|NCT06145919|BEHAVIORAL|Episodic Recent Thinking (ERT)|In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
214665958|NCT02991651|DRUG|IRX4204|RXR agonist
214665959|NCT02991651|DRUG|erlotinib|inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor
214665960|NCT02163330|DRUG|Acetazolamide|
214665961|NCT02163330|DRUG|sugar pill|
214872904|NCT05773794|DIETARY_SUPPLEMENT|Control group|Breakfast with milk or water, without soymilk, green tea, or blueberry blends.
215038689|NCT03639610|DRUG|Melflufen|Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.
215038690|NCT03639610|DRUG|Dexamethasone|Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.
215038691|NCT03868501|BEHAVIORAL|n-back task|All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.
215038692|NCT03136055|DRUG|Pembrolizumab|Given Intravenously (IV)
215038693|NCT03136055|DRUG|Irinotecan|Given IV
215038694|NCT03136055|DRUG|Paclitaxel|Given IV
215038695|NCT01115504|DRUG|Thiamine|300 mg daily for 30 days
215038696|NCT03618537|DRUG|Ixazomib|Ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle.
215038697|NCT03618537|DRUG|Dexamethasone|Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue.
215038698|NCT06512532|OTHER|fireworks eye injury|patients presented with eye injury during festivals due to fireworks
215038699|NCT02410772|DRUG|rifapentine|Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
215038700|NCT02410772|DRUG|rifapentine and moxifloxacin|Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
215038701|NCT02410772|DRUG|control|standard six-month treatment
215038702|NCT02369536|DIETARY_SUPPLEMENT|nutraceutical mixture|Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
215038703|NCT02369536|DIETARY_SUPPLEMENT|placebo|Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
215038704|NCT00002237|DRUG|Peldesine|
214872905|NCT03669185|DRUG|Pentalong|Pentalong, 2 x daily 1 tablet, intake max. 133 days
214872906|NCT03669185|DRUG|Placebos|Placebos, 2 x daily 1 tablet, intake max. 133 days
215038705|NCT03005392|OTHER|exercise|"An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention)."
215038706|NCT05322278|OTHER|Data collection|No interventions
214872907|NCT04993066|DEVICE|GentleMax Pro Plus|The GentleMax Pro Plus laser system to be used in this study received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) under K201111 on May 26, 2020
214872908|NCT06551714|PROCEDURE|Phase 1 cardiac rehabilitation|"Day 1:Patients were informed about the surgery, positioning and mobilization.Range of motion (ROM), respiratory control, diaphragmatic breathing, pursed lip breathing, thoracal expansion exercises, assisted coughing,forced expiration techniques, which are the components of active breathing techniques cycle (ABTC), were taught.The use of incentive spirometry (IS) was demonstrated.Patients were performed 10 repetitions of IS exercises, and 5 repetitions ABTC and were asked to repeat them every hour.The patient was made to sit for 10 minutes and was walked 60 meters twice a day.~2:ROM, IS and diaphragmatic breathing exercises were applied 10 times each.ABTC was repeated in 5 sets. 120 meters was walked 5 times during the day.~3:Sitting time was increased to 30 minutes and walking distance was increased to 240 meters.5 steps were climbed.~4:Walking distance was increased to 360 meters.One flight of stairs was climbed.Discharge training was given."
214872909|NCT06551714|PROCEDURE|Neurophysiological facilitation techniques|"In addition to the phase 1 cardiac rehabilitation program for the group receiving neurophysiological facilitation (NPF) techniques:~NPF techniques such as perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, moderate manual pressure and abdominal co-contraction were applied for ten times for ten seconds.~Diaphragm facilitation exercise was performed by inhaling against resistance and holding the breath against resistance for 5 seconds.~Unilateral and bilateral upper extremity proprioceptive neuromuscular facilitation (PNF) movements combined with breathing were performed.~NPF techniques were performed 10 times each day throughout the treatment, while other applications (diaphragm facilitation, combined breathing exercise with upper extremity PNF technique and respiratory facilitation) were performed 5 times on the first day and 10 times on the other three days."
214872910|NCT01027195|DEVICE|Bipolar Radiofrequency (Aquamantys 6.0)|
215038707|NCT00046072|DRUG|E5564|
215038708|NCT01517984|DRUG|Tacrolimus (CNI) Withdrawal|"Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal."
215038709|NCT01517984|DRUG|Standard Immunosuppressive Therapy|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
215038710|NCT05188989|DRUG|TPN171H 2.5mg group|TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
215038711|NCT05188989|DRUG|TPN171H 5mg group|TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
215038712|NCT05188989|DRUG|TPN171H 10mg group|TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
215038713|NCT05188989|DRUG|Placebo group|Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
215038714|NCT01842659|GENETIC|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
215038715|NCT00926614|DRUG|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
215038716|NCT00926614|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
214665962|NCT03085069|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
214665963|NCT06148610|DEVICE|NewSpringForMe digital solution|Follow-up of transplanted patients for hematological diseases using the NewSpringForMe device as support of quality of life
214665964|NCT03445676|BEHAVIORAL|ABHR directly on gloves|HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
214872911|NCT01027195|DEVICE|Standard Bovie Electrocautery|
214872912|NCT05274555|OTHER|Assessment|"The Upper Limb Short Questionnaire was administered by the researcher in face-to-face sessions with the children and their caregivers.~The lower extremity functions and ambulation levels of the children were evaluated by the researcher using the Vignos Scale.~The Brooke Upper Extremity Functional Rating Scale and ABILHAND-Kids were used to evaluate children's upper extremity functions."
214291204|NCT04048031|DIETARY_SUPPLEMENT|Nutrafol Supplement Capsules|NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
214665965|NCT02007239|DRUG|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
214665966|NCT04596657|DIETARY_SUPPLEMENT|Vitamin D supplementation|Daily vitamin D3 supplementation (5000 IU)
214665967|NCT02586207|DRUG|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
214665968|NCT02586207|DRUG|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
214665969|NCT02586207|RADIATION|Radiation|70 Gy fractionated over 35 days
214665970|NCT03453060|DRUG|E-WE Thrombin- Dose 1|Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
214665971|NCT03453060|DRUG|E-WE Thrombin- Dose 2|Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
214665972|NCT03453060|DRUG|E-WE Thrombin- Dose 3|Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
214872913|NCT00661895|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
214872914|NCT00661895|DRUG|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
214872915|NCT00661895|DRUG|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
214872916|NCT00661895|DRUG|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
214872917|NCT00661895|DRUG|Metoprolol tartrate|50 mg tablets \& 100 mg tablets
214872918|NCT00661895|DRUG|Atenolol|50 mg tablet
214872919|NCT00661895|DRUG|Valsartan|80 mg tablets \& 160 mg tablet
214872920|NCT00661895|DRUG|Doxazosin|4 mg tablets
214872921|NCT00661895|DRUG|Clonidine|0.2 mg tablets
214872922|NCT00661895|DRUG|Hydralazine|50 mg tablets
214872923|NCT00661895|DRUG|Metoprolol succinate|50 mg tablet \& 100 mg tablet
214872924|NCT00661895|DRUG|Amlodipine|5 mg tablets \& 10 mg tablets
214872925|NCT06501716|PROCEDURE|Indocyanine Green|"Tumor resection, direct visualization of the chiasm and both optic nerves and ICG administration will be provided as it is recommended by the standard of care. ICG will be administered by an injection of 5 mg of ICG diluted in a 10 mL syringe performed in the line closest to the heart followed by a 10-mL saline bolus. Using near-infrared lighting, the investigators will determine the time between anterior cerebral arteries (ACA) peak luminescence to the peak luminescence of the superior hypophyseal arteries enveloping the optic chiasm (ACA to chiasm time). Because luminescence of large vessels precedes small arterial penetration, signal from the ACAs was considered as time 0 to account for possible differences in the arm-brain time between patients. In addition, the investigators will analyze the proportion of superior hypophyseal branches on the chiasm that luminesced from ICG."
214872926|NCT04371107|OTHER|consultation|Patients are followed up by teleconsultation or remote follow-up until the end of symptoms and for a maximum of 2 months
214872927|NCT04371107|DRUG|Azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
214872928|NCT02387411|OTHER|High-intensity interval exercise training|High-intensity interval exercise training \[4 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\]
214872929|NCT02387411|OTHER|Combined exercise training|High intensity \[2 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
214872930|NCT05108402|DIAGNOSTIC_TEST|Phenotyping|"After inclusion in the study, between V1 and V4, patients will be phenotyped among: NaCl sensitive patients and non-NaCl sensitive patients. they will have a low sodium diet for 2 weeks. The first week without salt supplementation and the second with salt supplementation. At the end of V4, if patient is NaCl sensitive he will continue into treatment period and go through randomization, and for patient non-NaCl sensitive they will drop out of study."
214872931|NCT05108402|DIETARY_SUPPLEMENT|Drug intake|"After being phenotyped, NaCl sensitive patients will continue the study in one of the 2 treatments arms : royal water (bottle) or salt sachet."
214872932|NCT05990985|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection (18 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
214872933|NCT05990985|DRUG|RiTUXimab Injection|RiTUXimab Injection (375 mg/m\^2) will be administered by intravenous infusion on day 0 in a 3-week treatment cycle.
214872934|NCT05990985|DRUG|Cyclophosphamid|Cyclophosphamid (750 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
214872935|NCT05990985|DRUG|Vincristine|Vincristine (1.4 mg/m\^2，maximum dose 2mg ) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
214872936|NCT05990985|DRUG|Prednisolone|Prednisolone (100mg/d) will be administered by intravenous infusion on day 1-5 in a 3-week treatment cycle.
214872937|NCT01733810|OTHER|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
214872938|NCT04247100|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Active Transcutaneous Auricular Microstimulation delivered by TENS device
214872939|NCT04247100|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation|Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered
214872940|NCT02198183|DEVICE|Casmed Fore-Sight Elite|
214872941|NCT02198183|DEVICE|Non-invasive Cardiac Output Monitor (NICOM)|
214872942|NCT05954221|PROCEDURE|Red cell lysis buffer (RCLB) application|The tissue is lysed with 50% concentration of RCLB for 15 min on a shaking device. If the lysis is judged to be insufficient, it can be repeated one more time. Finally, the treated tissue will be fixed with 10% formalin.
214872943|NCT05954221|PROCEDURE|Conventional processing|The tissue is fixed with 10% formalin.
214872944|NCT00337337|BEHAVIORAL|Multiple grain|
214872945|NCT00337337|BEHAVIORAL|Ordinary Asian- rice|
214872946|NCT06583161|BEHAVIORAL|Moderate drinking|Drink up to 16 grams of alcohol daily or almost daily \[repeated assessment center visit\] or 8-16 grams of alcohol 4 or more times per week \[web-based mental health questionnaire\]
214872947|NCT06583161|BEHAVIORAL|Quitting|No alcohol consumption
214872948|NCT06583161|BEHAVIORAL|Social drinking|Drink up to 16 grams of alcohol 1-2 days per week or drink 1-3 times per month or only on special occasions \[repeated assessment center visit\], or drink 8-16 grams of alcohol 2-3 times per week or drink 4 times per month or less \[web-based mental health questionnaire\]
214872949|NCT06583161|BEHAVIORAL|Heavy/binge drinking|Drink more than 16 grams of alcohol daily or almost daily or more than 40 grams of alcohol 1-2 days per week \[repeated assessment center visit\], or 24 grams of alcohol or more 4 or more times per week or 40 grams of alcohol or more 2-3 times per week \[web-based mental health questionnaire\]
214872950|NCT04403828|OTHER|Survey|a cross-sectional, online survey-based study administered to Dentist in Egypt. A 20-item questionnaire developed and distributed using Google Forms.
214872951|NCT04984343|RADIATION|Radiation Therapy|"Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have \>72 hours between beginning of each fraction."
214872952|NCT04575064|OTHER|Standard of Care (SoC)|Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
214872953|NCT04575064|DRUG|Remdesivir|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first
214872954|NCT02932306|DRUG|IDP-121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
214872955|NCT02932306|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
214872956|NCT03202979|DRUG|Trazodone 20 mg|"Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.~After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions."
214872957|NCT03202979|DRUG|Trazodone 10 mg|"Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.~In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
214872958|NCT03202979|DRUG|Placebo|"Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
214872959|NCT05595148|PROCEDURE|Immediate WBAT|Men or women over 18 years who present with a fracture of the acetabulum, pelvis, distal femur, proximal tibia, distal tibia, who will undergo fracture fixation within 7 days of their injury and consent to the research study.
214872960|NCT05595148|OTHER|No Intervention: Delayed WBAT|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
214872961|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
214872962|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
214872963|NCT01877746|OTHER|No intervention|No intervention, only standard medical therapy
214872964|NCT05776862|DRUG|Ursolic Acid|Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
214665973|NCT03453060|DRUG|E-WE Thrombin- Dose 4|Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
214291205|NCT04048031|OTHER|Placebo Capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
214291206|NCT00360789|BEHAVIORAL|Conventional UK physical therapy|
214665974|NCT03453060|OTHER|Placebo|Participants received a single intravenous dose of placebo.
214665975|NCT00292123|DRUG|Methadone|
214291207|NCT00360789|BEHAVIORAL|Increased intensity of UK conventional physical therapy (PT)|
214291208|NCT00360789|BEHAVIORAL|UK conventional PT plus functional strength training|
214291209|NCT02213016|DEVICE|Transcranial Magnetic Stimulation|
214665976|NCT00292123|BEHAVIORAL|Contingency Management|
214872965|NCT05776862|OTHER|Strength Training|Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session. Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets. The arm selected for exercise will be randomized.
214872966|NCT00084032|BEHAVIORAL|Structured treatment interruption|Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2
214872967|NCT00084032|DRUG|Antiretroviral regimen|Participants will take any combination of FDA-approved ARV medications prescribed by their physician
214872968|NCT02014207|OTHER|dietary treatment|
214872969|NCT01421173|DRUG|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
214872970|NCT01421173|DRUG|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
214872971|NCT01421173|DRUG|Busulfan|"AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.~Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5."
214872972|NCT01421173|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
214872973|NCT01421173|PROCEDURE|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
214872974|NCT01421173|DRUG|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
214872975|NCT01421173|DRUG|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
214872976|NCT01421173|DRUG|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
214872977|NCT01421173|DRUG|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
214872978|NCT00003324|PROCEDURE|conventional surgery|
214872979|NCT00003324|RADIATION|radiation therapy|
214872980|NCT02619435|DRUG|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
214872981|NCT06387602|PROCEDURE|Cryotherapy|Take an icepack and wrap it in a moisture-absorbing towel. The temperature of the icepack should be between 1˚ to 10˚. Any temperature below 0˚ can damage the skin. The icepack will be on strained adductors for 5-7 minutes. Patients will be advised to do cryotherapy at home for 24-42 hours after every 2 hours.
214872982|NCT06387602|PROCEDURE|Strengthening of adductors|"Both groups will perform the following strengthening of adductors which includes adductor isometrics, Side-lying adductor strengthening, and Adductor resistance with a stepper and will be done 10 repetitions, 3 times a week.~After the performance of the Adductor strengthening protocol, Group A will be given the Active release technique while Group B will be given post-isometric relaxation by the therapist."
214872983|NCT06387602|PROCEDURE|Active release technique|"Step 1: Place the body in a position (Dorsiflex ankle, flex the knee, extend the hip, flex the spine) so that the nerve is moved proximally. In this position, the nerve is relaxed on the distal side of the entrapment site and the nerve is tractioned on the proximal side.~Step 2: Place contact between the distal Gracilis and the Sartorius and push the muscle proximally. The contact should not compress the nerve.~Step 3: Move each joint so that the nerve moves distally past the muscle. The new position (Plantarflex and evert the ankle, extend the knee, flex the hip, extend the spine) will be achieved.~Step 4: Move the contact to the proximal side of the muscles and push the muscle distally.~Step 5: Move the nerve proximally again by pushing the muscle distally. This brings the position of the patient back to Step 1.~Contact will be held for a short time 5-20 seconds with repetitions 3-5 times to the injury site and 2 sessions per week."
214872984|NCT06387602|PROCEDURE|Post-Isometric Relaxation|"Step 1: Position the patient's limb at a point with the highest resistance felt during abduction.~Step 2: The patient is asked to bring the leg back into adduction using only 20% of strength against firm resistance given by the therapist.~Step 3: The patient will contract the agonist (the muscle that needs to be released) while holding an inhaled breath. Contraction should be held between 7-10 seconds without any jerking, bouncing, or wobbling.~Step 4: The patient is asked to release their effort slowly and completely. As the patient relaxes, the limb is guided into a new resistance barrier where a bind is felt again.~Step 5: After PIR, a 10-20-second latency period exists and the muscle can be stretched more easily.~Contract adductor muscle for 7-10 seconds and relax the same for 7-10 seconds with repetitions 7 times and 2 sessions per week."
214872985|NCT02065700|DRUG|Filgotinib|Administered as Oral Tablets
215038717|NCT05871931|OTHER|Tidal Model-based psychiatric nursing approach|"The intervention group will receive an eight-session Tidal Model-based psychiatric nursing approach. The sessions will take place once a week over an 8-week period. All sessions will be conducted face-to-face.~The content of the interview plan, consisting of a total of 8 interviews, is as follows:~The first interview was 'Meeting and Pretesting', the second interview was 'Creating a Personal Safety Plan, Making a Holistic Assessment', the third interview was 'Recognizing Emotions, Emotion Management and Communication Skills', the fourth interview was 'Coping Skills', and the fifth interview was 'Self Perception', The sixth interview consisted of 'Strengthening Socialisation', the seventh interview consisted of 'Planning for the Future' and the eighth interview consisted of 'Defining the achievements that will accompany him/her in the next voyages of exploration, ending the relationship between the captain and the lifeguard and making a process evaluation'."
215038718|NCT01645176|DRUG|Hydroxychloroquine/Atorvastatin|Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
215038719|NCT03308357|DIAGNOSTIC_TEST|Drug assays to measure infliximab|See protocol
215038720|NCT05472493|BIOLOGICAL|[18-F]CETO|PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, \~3 mm). CETO (\~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from \~0-90 minutes.
215038721|NCT00830050|DRUG|Naproxen|500 mg BID 7 days
215038722|NCT00830050|DRUG|Placebo|BID 7 days
215038723|NCT03981276|OTHER|Clinical rating scale to measure disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
215038724|NCT03981276|DIAGNOSTIC_TEST|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
214291210|NCT02213016|DEVICE|Sham Transcranial Magnetic Stimulation|
214665977|NCT04524975|DRUG|CD-008-0045|CD-008-0045 20 mg capsules
214665978|NCT04524975|DRUG|Placebo|Placebo capsules
214872986|NCT04864470|BEHAVIORAL|Stroke Odysseys|"The participants will take part in a twelve-week performance programme that takes place online/in a community halls/arts centre. Sessions run for three hours and during these sessions, participants devise a dance and music performance work from their own stories. The culmination of the programme will be a public facing performance to an audience of carers, health care practitioners, friends, family and the wider community, done online through Zoom.~After the performance is completed, participants will be invited to a training programme where they learn to act as advocates for life after stroke - termed 'stroke ambassadors'. The training will be a four-day programme. The programme will take place once weekly and is led by a team of artists supported by a leadership coach, on Zoom.~Following training, ambassadors will support artists in recruitment, befriend the newly discharged stroke survivors and take part in small scale performance tours to challenge the perception of disability."
214872987|NCT02782793|PROCEDURE|Endoscopic Mucosal Resection|
214872988|NCT02281292|BIOLOGICAL|LKA651 ophthalmic solution|
214872989|NCT02281292|BIOLOGICAL|Ranibizumab ophthalmic solution|
214872990|NCT02281292|BIOLOGICAL|Sham injection|Mock injection administered as an empty hub without needle
214872991|NCT03612557|DRUG|penicillin G benzathine|2.4 million units (IM) of benzathine benzylpenicillin
214872992|NCT05824416|DEVICE|Experimental: ALBA|"Device: Improve Upper Limb Mobility~The patients will undergo treatment with the conventional therapy, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise. In addition to training with the ALBA® device, Shoulder flexion, abduction, and external rotation, elbow flexion and extension."
214872993|NCT05824416|BEHAVIORAL|Conventional Therapy|The conventionl therapy will receive conventional treatment, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise
214872994|NCT03842813|DEVICE|DES-CRE8|Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.
214872995|NCT04181749|DRUG|aspirin and atorvastatin|Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
214872996|NCT05214703|OTHER|cold therapy application|cold therapy
214872997|NCT00000259|DRUG|15 % Nitrous oxide|
214872998|NCT00000259|DRUG|0.3 % Sevoflurane|
214872999|NCT00000259|DRUG|30% Nitrous oxide|
214873000|NCT00000259|DRUG|0.6% Sevoflurane|
214873001|NCT00000259|OTHER|Placebo|
214873002|NCT06394700|BEHAVIORAL|written exposure therapy|Written Exposure Therapy (WET) is a manualized exposure-based therapy involving five sequential weekly individual sessions. Each session lasts approximately 40 minutes except the first, which is one hour. In the initial session, the therapist explains the treatment rationale and guides the participant to write about their traumatic experience uninterrupted for 30 minutes. Subsequent sessions start with a brief discussion about the previous session's writing, followed by another 30-minute writing session, concluding with a short check-in. There is no homework between sessions.
214873003|NCT06394700|BEHAVIORAL|Written Exposure Therapy plus Mindfulness-Based App (WET + MBA)|"WET + MBA combines the standard WET protocol with the addition of a mindfulness practice facilitated through a mobile app called Now Meditation. This app is among the most downloaded mindfulness apps in China, used to help manage symptoms of insomnia commonly comorbid with PTSD. Participants are instructed to engage in daily mindfulness exercises according to the app's 7-Day Basic Meditation program and continue practicing mindfulness throughout the duration of the therapy. This is intended to supplement the therapeutic effects of WET by providing tools to manage insomnia and potentially enhancing the therapeutic process by fostering greater mindfulness and relaxation."
214873004|NCT06394700|BEHAVIORAL|Minimal Contact Control (MCC)|MCC contains weekly phone calls from a study therapist to monitor their status and provide support as needed, without introducing any specific therapeutic interventions. These calls are brief, generally lasting between 10 to 15 minutes, and are strictly for the purpose of engagement and safety monitoring rather than therapeutic intervention.
214873005|NCT02509299|OTHER|Physiotherapy program 1|The standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises.
214476630|NCT05929859|BEHAVIORAL|Speech Motor Chaining|Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.
214476631|NCT05492448|DIETARY_SUPPLEMENT|Placebo|Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.
214476632|NCT05492448|DIETARY_SUPPLEMENT|L. salivarius AP-32 and L. reuteri GL-104|Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.
214476633|NCT05492448|DIETARY_SUPPLEMENT|L. reuteri GL-104|Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.
214476634|NCT04290663|DRUG|Systematic RAI-treatment|Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
214476635|NCT04290663|OTHER|Decision of RAI-treatment guided by a post-operative assessment|"The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:~* No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy~* 1.1 GBq after rhTSH if Tg/LT4\>1 ng/mL or rhTSH-sTg\>10 ng/mL and normal diagnostic RAI-scintigraphy.~* 3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis~* 3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition"
214476636|NCT06375655|BEHAVIORAL|Team2BF|Team2BF includes 3-4 breastfeeding-supportive messages per time interval, sent weekly from 28 weeks gestation through delivery, daily through 2 weeks postpartum, weekly from 2 to 10 weeks, and then monthly to one year. Other maternal health topics are not addressed.
214476637|NCT06375655|BEHAVIORAL|Bright By Text|Bright By Text sends 2-4 messages per week from the first trimester through and beyond one year postpartum about a wide range of maternal and child health topics as outlined on their website; 8 messages are specifically about breastfeeding.
214476638|NCT03571386|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
214476639|NCT03571386|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|Standardized 8-week patient-centered educational approach which uses relatively intensive training in core meditation practices that teaches people how to take better care of themselves using mindfulness skills and live healthier and more adaptive lives.
214476640|NCT05361408|DRUG|Zoledronic acid, once|Intravenous infusion of 5mg zoledronic acid, once
214476641|NCT05361408|DRUG|Zoledronic acid, twice|Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
214873006|NCT02509299|OTHER|Physiotherapy program 2|COPD patients included in this group will receive the standard medical treatment and additionally, they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included neuromuscular stimulation therapy on quadriceps accompanied by lower limbs exercises
214873007|NCT02509299|DRUG|Standard medical treatment|"The standard medical treatment consists on:~* Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~* Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~\- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
214873008|NCT00422578|DRUG|tadalafil|
214873009|NCT05149677|BEHAVIORAL|Music therapy|Music therapy intervention + Standard of Care for labor pain
214873010|NCT04673682|DRUG|D309|D309(Testosterone) 1 vial, Once, IM injection
214873011|NCT04673682|DRUG|CKD-845|CKD-845(Testosterone) 1 vial, Once, IM injection
214873012|NCT06344663|OTHER|motivational interview|Before starting the interview, mothers will be informed about the interview intervals, duration, how many times it will be held, and that, unlike other interviews, the topic will be determined and the mother's opinions on this subject will be obtained. Each meeting will last approximately 15-30 minutes
214873013|NCT00019864|BIOLOGICAL|filgrastim|
214873014|NCT00019864|DRUG|cisplatin|
214873015|NCT00019864|DRUG|dexrazoxane hydrochloride|
214873016|NCT00019864|DRUG|doxorubicin hydrochloride|
214873017|NCT00019864|DRUG|leucovorin calcium|
214873018|NCT00019864|DRUG|methotrexate|
214873019|NCT00019864|PROCEDURE|adjuvant therapy|
214873020|NCT00019864|PROCEDURE|conventional surgery|
214873021|NCT00019864|PROCEDURE|neoadjuvant therapy|
214873022|NCT02763371|OTHER|Dietary: high GI lunch|High GI: High-GI rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
214873023|NCT02763371|OTHER|Dietary: low GI lunch|Low-GI: Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
214873024|NCT01902368|OTHER|gluten free diet|
214873025|NCT00956800|OTHER|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
214873026|NCT00956800|OTHER|Normal care|Control group will receive 5 routine office visits in one year
214873027|NCT04990700|PROCEDURE|Partial rib resection|1 cm partial rib resection during thoracotomy opening
214873028|NCT04293796|PROCEDURE|Vacuum-assisted biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, after neoadjuvant systemic treatment on patients with clinical complete response on primary breast cancer management we recommend to take at least 12 biopsies with 7-10G needle sizes with sentinel lymph node biopsy.
214873029|NCT05379907|OTHER|SIGNATERA™ ctDNA testing|Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.
214873030|NCT00372151|DIETARY_SUPPLEMENT|L-Theanine|400 mg/day, caps.
214873031|NCT00372151|OTHER|Placebo|caps.
214873032|NCT04416165|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
214873033|NCT03214029|DIAGNOSTIC_TEST|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
215038725|NCT02234362|DRUG|vortioxetine|Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
215038726|NCT03913351|BEHAVIORAL|Lifestyle modification|The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
215038727|NCT05338138|DEVICE|ultrasound guided central venous catheter insertion|Prospective comparative randomized controlled clinical study.
215038728|NCT03126487|PROCEDURE|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
215038729|NCT00560417|DRUG|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
215038730|NCT00560417|DRUG|Insulin Glargine|Administered subcutaneously once a day at bedtime
214665979|NCT00337636|PROCEDURE|Surgery to implant human CNS stem cells (HuCNS-SC)|single dose
215038731|NCT03807089|DEVICE|Conventional Pediatric Colonoscope|
215038732|NCT03807089|DEVICE|Short-Turn Radius Colonoscope|
215038733|NCT02164864|DRUG|Dabigatran Etexilate 110mg|Active treatment
214873034|NCT04933448|OTHER|Ketogenic Diet|The ketogenic diet (KD) is an alternative feeding regimen that has been in use since 1921. It is a high-fat, low carbohydrate, and moderate protein diet. There are various forms of the KD. The classic KD consists of long-chain triglycerides with a fat-to-combined-protein-and-carbohydrate ratio that can vary. At the investigating institution, it is standard of care to initiate a ketogenic diet at a ratio of 2:1, and to increase the ratio to 3:1 or 4:1 as needed to achieve ketosis.
214873035|NCT04249869|DRUG|VGH-AD1|VGH-AD1 includes Yi-gan-san 3.0g, Huan-shao-dan 1.0g, Danshen(Radix et Rhizoma Salviae Miltiorrhizae) 0.75g, Tian-ma(Rhizoma Gastrodiae) 0.75g, Gou-teng(Ramulus Uncariae Cum Uneis) 0.375g, and Ba-ji-tian(Radix Morindae Officinalis) 0.375g, two times per day, each serving a small packet of 7.5 grams of concentrated granules.
214873036|NCT06450795|BEHAVIORAL|Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.|HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.
214665980|NCT00337636|DRUG|Medication to suppress the immune system|Immunosuppression for 12 months post transplant
214873037|NCT03086759|PROCEDURE|platelet rich plasm|intra-articular infiltration with platelet rich plasm
214873038|NCT03086759|DRUG|Triamcinolone Hexacetonide|intra-articular infiltration withTriamcinolone Hexacetonide
214873039|NCT03086759|PROCEDURE|Isotonic Saline Solution|intra-articular infiltration with Isotonic Saline Solution
214873040|NCT00294775|DRUG|Candesartan|
215038734|NCT02164864|DRUG|Warfarin 3mg|Active comparator
215038735|NCT02164864|DRUG|Aspirin|Active comparator
215038736|NCT02164864|DRUG|Dabigatran Etexilate 150mg|Active treatment
215038737|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
215038738|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
215038739|NCT02164864|DRUG|Warfarin 5mg|Active comparator
215038740|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
215038741|NCT02164864|DRUG|Warfarin 1mg|Active comparator
214665981|NCT01095484|DRUG|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
214665982|NCT00722059|PROCEDURE|Breast Tomosynthesis|3D breast imaging
214665983|NCT01142323|DRUG|fenofibrate|160 mg po daily
214665984|NCT01959204|DRUG|Oxycodone|Pain
214665985|NCT04374903|DRUG|HCQ & AZ vs HCQ+SIR|Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus
214665986|NCT00089180|DRUG|liposomal T4N5 lotion|Given topically
214665987|NCT00089180|OTHER|placebo|Given topically
214665988|NCT00089180|OTHER|laboratory biomarker analysis|Correlative studies
215038742|NCT03257891|DRUG|Cabazitaxel|Cabazitaxel will be administered every 21 days
215038743|NCT04668833|PROCEDURE|Autologous lymphocyte infusion (ALI)|On the day after completing the last dose of radiation therapy, the patient will have an appointment scheduled in the Apheresis Unit for the infusion of unmunipulated cryopreserved cells. Patients will be pre medicated with acetaminophen (325-650 mg PO) and diphenhydramine (12.5-25 mg PO or IV) prior to infusion. Cells will be infused without a leukoreduction filter at a rate determined by cell volume.
215038744|NCT02569853|DRUG|DFN-11|
215038745|NCT02569853|OTHER|Placebo|
215038746|NCT01135472|DRUG|Esomeprazole Magnesium|NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
215038747|NCT03243461|DRUG|Temozolomide + Valproic Acid|Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
215038748|NCT04142489|OTHER|solar irradiation and biopsies|the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
215038749|NCT04358406|DRUG|Recombinant human plasma gelsolin (Rhu-pGSN)|Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
215038750|NCT04358406|OTHER|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
215038751|NCT04607343|DEVICE|Rehabilitation device based on electrical stimulation|Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
215038752|NCT05482061|OTHER|visual analog scale (VAS).|The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
214873041|NCT04591223|BEHAVIORAL|Competency-based physical training (CbM)|The intervention to be added to online social work treatment as usual (OSW) is a well-designed, one-on-one structural physical workout module which will be offered by a licensed senior physical trainer in public sports ground or gymnasium. The aim is to strengthen participants' sense of competence, improve their physical fitness, self-confidence and self-image through an outcome-driven Circuit training. One of the chief advantages of Circuit training is its adaptability. Circuit training can be performed with gym equipment and/or bodyweight exercises which is deemed to be suitable for beginner and easy to practice at home on oneself. Participants can continue to replicate the exercise with or without any equipment. The program will be delivered in six one-hour sessions, including face-to-face and online mode, over one month.
214873042|NCT03858543|DRUG|Poly-L Lactic Acid|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
214873043|NCT03858543|DEVICE|Fractional laser treatment|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
214873044|NCT02857751|BEHAVIORAL|Surf therapy|The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
214873045|NCT01056042|DRUG|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
214873046|NCT01056042|DRUG|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
214873047|NCT01386983|DRUG|5ARI|Dutasteride or Finasteride
215038753|NCT05447403|OTHER|Chewing gum combined with WeChat enhanced instructions|Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
215038754|NCT04475666|OTHER|Replenish protein group|For patients with Body mass index(BMI) \<30, use pre-ICU actual body weight(BW) for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
215038755|NCT04475666|OTHER|Standard protein group|For patients with BMI \<30, use pre-ICU actual BW for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
214665989|NCT00446394|BEHAVIORAL|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
214665990|NCT00446394|BEHAVIORAL|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
214873048|NCT01386983|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
215038756|NCT05504122|PROCEDURE|inguinal hernia repair|Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
215038757|NCT00633685|DRUG|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
215038758|NCT00633685|DRUG|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
215038759|NCT00906763|DIETARY_SUPPLEMENT|Chocolate|A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
215038760|NCT06528691|DRUG|Entrectinib|Given orally (PO) or enterally
215038761|NCT06528691|DRUG|Cyclophosphamide|Given intravenous (IV)
215038762|NCT06528691|DRUG|Etoposide|Given IV
215038763|NCT06528691|DRUG|Carboplatin|Given IV
215038764|NCT06528691|BIOLOGICAL|G-CSF|Given subcutaneous (SQ) or IV
215038765|NCT06528691|BIOLOGICAL|Pegfilgrastim|Given SQ as part of recommended Bridging Therapy instead of G-CSF.
215038766|NCT06528691|PROCEDURE|Surgery|A gross total resection or significant debulking may become possible if a response to entrectinib is seen.
214873049|NCT00465465|BIOLOGICAL|MVA 85A|i.d. injection
214873050|NCT03972735|OTHER|Psychiatric interview|PANSS, MADRS, PSP, YMRS
214873051|NCT03972735|OTHER|Clinical, diagnostic and functional evaluation|ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS
214873052|NCT03972735|OTHER|neuropsychological assessment|WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS
215038767|NCT04398576|BEHAVIORAL|Training and support|GP's receive the tools to make early identification of harmful and hazardous alcohol use possible. They are given guidelines to apply a brief intervention. At the start of the study, the T\&S-group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months.
215038768|NCT04398576|BEHAVIORAL|Community actions|There will be embedded community-based actions within a local strategy.
215038769|NCT02102009|DIETARY_SUPPLEMENT|Complete enteral formula|"Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).~Time of intervention: 3 months."
215038770|NCT02102009|OTHER|Dietary Advise|Patients will receive the usual dietary advise in these patients according hospital clinical practice .
215038771|NCT03190122|PROCEDURE|surgical excision of the tumor|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. \[NCT ID not yet assigned\]
214665991|NCT05946252|OTHER|Motor imagery|"Motor imagery will be performed according to the PETTLEP (Physical,Environment,Task,Time,Learn,Emotion,Perspective) model for 15 minutes.~1. To imagine walking activity in different environments (seaside, beach, walking path).~2. The rest activity will be imagined by sitting on a bench.~3. Upper extremity strengthening exercises with dumbbells, lower extremity strengthening exercises with elastic band and trunk-oriented bridging, posterior pelvic tilt and table top stabilization exercises will be visualized.~4. The rest activity will be imagined by sitting on a bench.~5. Imagination will end with homecoming and domestic activities."
214665992|NCT05946252|OTHER|Diaphragmatic breathing|Diaphragmatic breathing will be shown to pregnant women in the supine position, eyes closed, with one hand on the chest and the other hand on the abdomen. This practice will last for five minutes.
214873053|NCT03972735|OTHER|NECT PROGRAM|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.
215038772|NCT05820503|PROCEDURE|Ultrasound-guided lower abdominis rectus sheath block|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally
215038773|NCT05820503|PROCEDURE|Local anesthesia infiltration|Local anesthesia drugs were injected into the peri-umbilicus cord
215038774|NCT01862003|DRUG|AZD8931|160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
215038775|NCT01862003|DRUG|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
215038776|NCT01862003|DRUG|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
215038777|NCT01862003|DRUG|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
215038778|NCT01862003|DRUG|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
215038779|NCT03156829|OTHER|Splint|Custom made splint
215038780|NCT03156829|DRUG|Betamethasone|Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml
215038781|NCT03156829|COMBINATION_PRODUCT|Splint + Cortico-steroid injection|Splint + Cortico-steroid injection given in combination
215038782|NCT05367947|BEHAVIORAL|In-phase Bilateral Exercises of the upper limbs|"The intervention protocol consists of in-phase bilateral exercises for the upper limbs, which are adapted to different sport activities and to fitness functional exercises, organized in a circuit training. Specifically, each session will consist of 1-3 sets, consisting of 10-15 repetitions of 9 different exercises targeting large muscle groups of the upper limbs.~The specific exercises will include sports activities of basic technical skills of basketball (e.g., different types of passing, catching and throwing the ball) and volleyball (e.g., different types of passing and receiving the ball), whereas the fitness exercises will include shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, using resistance elastic bands, as well as exercises with the patients' own body weight (e.g., pushups, TRX).~The intervention phase for each participant will consist of 12 consecutive weeks, for 3 times per week, 30-60 minutes each session."
215038783|NCT04966325|DRUG|LC350189 200mg|Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
215038784|NCT04966325|DRUG|Placebo|Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
215038785|NCT04966325|DRUG|Moxifloxacin 400mg|Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
215038786|NCT04966325|DRUG|LC350189 600mg|Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
215038787|NCT04745091|PROCEDURE|total mesorectal excision|excision of the rectum with complete excision of the mesorectum
214665993|NCT01506791|DRUG|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
214873054|NCT01885026|BEHAVIORAL|eScreen|Access to the eScreen platform offering assessment of alcohol and drug use, with automated feedback on problematic or non-problematic use. Follow-up over time based on user needs.
214873055|NCT01885026|BEHAVIORAL|Assessment only of alcohol and drug use.|Assessment of alcohol and drug use at baseline and follow-up.
214873056|NCT01885026|BEHAVIORAL|Internet-based treatment for depression or anxiety|Internet-based treatment for primary diagnoses of depression, panic anxiety or social phobia.
215038788|NCT04600284|DRUG|AD-2101|AD-2101 16/5mg
215038789|NCT04600284|DRUG|AD-2102|AD-2102 25mg
215038790|NCT04600284|DRUG|AD-2101 + AD-2102|AD-2101 16/5mg + AD-2102 25mg
215038791|NCT06217263|DEVICE|Vibration device|Vibracool vibration device from Pain Care Labs will be used.
215038792|NCT06217263|OTHER|Vibration device&Cold application pack|Pain Care Labs' Vibracool vibration device and cold gel pack will be used.
214873057|NCT01305044|BEHAVIORAL|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
214873058|NCT01305044|BEHAVIORAL|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
214873059|NCT04532801|DRUG|Kisspeptin-10|kisspeptin-10 IV infusion
215038793|NCT02434081|DRUG|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
214873060|NCT04532801|OTHER|mixed meal tolerance test|mixed meal tolerance test
214873061|NCT04939220|PROCEDURE|TEE with SGA|SGA Placement and maintenance with inhalational anesthetic or propofol
215038794|NCT01668004|BIOLOGICAL|Golimumab|GLM 50 mg subcutaneously once monthly.
214873062|NCT04939220|PROCEDURE|TEE with Deep Sedation|Deep sedation with propofol and natural airway
214873063|NCT00833001|DEVICE|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
215038795|NCT00419744|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|
215038796|NCT00419744|DRUG|Formoterol Turbuhaler|
215038797|NCT05543317|DIAGNOSTIC_TEST|18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
215038798|NCT03462745|DEVICE|AccuVein AV 300|Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
214873064|NCT00071292|BEHAVIORAL|stress reduction program|
215038799|NCT01101126|OTHER|Pulmonary disease management|Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations
215038800|NCT01101126|OTHER|Usual care|Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
215038801|NCT04838652|DRUG|Pembrolizumab plus Chemotherapy (ICE or DHAP)|Pembrolizumab (200mg) alone or in combination with ICE (or DHAP in case of PET positive findings after P-ICE) will be admistered. 6 additional courses of pembrolizumab will be administered after the completion P-ICE or P-DHAP
215038802|NCT04473001|OTHER|Continuous vital signs and glucose monitoring|"The patients will have the following parameters and vital signs continuously monitored using wireless equipment:~* Glucose measurements (quasi-continuous, every 5 minutes)~* Heart rate~* Heart rhythm (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Signs of cardiac ischemia (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Respiration rate~* Oxygen saturation of arterial hemoglobin (%SpO2)~* Perfusion index (ratio of the pulsatile blood flow to the non-pulsatile or static blood in peripheral tissue)~* Blood pressure (quasi-continuous; every 30-60 minutes)~* Skin temperature~* Electrodermal activity~* Ambulatory activity (accelerometry)"
215038803|NCT04902612|DEVICE|HM242-Solution|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
215038804|NCT04902612|DEVICE|Saline|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
215038805|NCT00499044|OTHER|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
215038806|NCT00499044|OTHER|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
215038807|NCT00182650|BIOLOGICAL|aldesleukin|
215038808|NCT00182650|BIOLOGICAL|rituximab|
214873065|NCT00071292|BEHAVIORAL|meditation|
214873066|NCT02279134|RADIATION|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
215038809|NCT00182650|BIOLOGICAL|therapeutic autologous lymphocytes|
214873067|NCT02279134|RADIATION|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
214873068|NCT02279134|DRUG|Paclitaxel|135-150mg/m2 (D1 and D29)
215038810|NCT00182650|DRUG|fludarabine phosphate|
215038811|NCT00444314|DRUG|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
215038812|NCT00444314|DRUG|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
215038813|NCT00601341|OTHER|lumbosacral joint manipulation|lumbosacral joint manipulation
215038814|NCT00601341|OTHER|lumbar passive range of motion|lumbar passive range of motion
215038815|NCT00601341|OTHER|No active intervention|Lie on exam table for 3 minutes
215038816|NCT02850588|PROCEDURE|Transcarotid artery revascularization|Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
214873069|NCT02279134|DRUG|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
214873070|NCT03303196|DEVICE|Bihormonal Bionic Pancreas|A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
214873071|NCT05738317|DRUG|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|Adebrelimab is recommended to be administered with an infusion pump. The infusion pipeline is equipped with a 0.22-micron online filter membrane. Intravenous injection or bolus injection is not allowed. At the end of infusion, flush the infusion tube with sufficient 5% glucose or physiological saline, and do not share the same infusion tube with other drugs. In each treatment cycle, Adebrelimab should be given intravenously first.
214873072|NCT04774016|OTHER|Test formula A without added pre- and pro-biotic|An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.
214873073|NCT04774016|OTHER|Test formula B with synbiotic|Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
214873074|NCT04774016|OTHER|Test formula C with HMOs|Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
214873075|NCT04267029|DIAGNOSTIC_TEST|TADPOL battery (deep clinicolaboratory profile)|"profile dimensions:~* hemolytic~* allergic~* cardiorenal~* inflammatory~* leukoagglutinating~* exploratory bioarchive"
215038817|NCT02850588|PROCEDURE|Carotid endarterectomy|Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
215038818|NCT05634486|BEHAVIORAL|Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)|Patients randomly allocated to this arm of intervention will receive an ambulatory therapy regime of twelve 60-minute physiotherapy sessions plus four 60-minute psychotherapy sessions throughout one month of treatment
215038819|NCT05634486|OTHER|Psychoeducation (Sham intervention)|Patients randomly allocated to this arm of intervention will receive an ambulatory regime of four 60-minute non-organized psychoeducational sessions throughout one month of treatment.
215038820|NCT03573492|OTHER|Education|Type of teaching being assigned to student arms
215038821|NCT02196922|DEVICE|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
215038822|NCT02196922|OTHER|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
215038823|NCT04937192|OTHER|No intervention|No intervention
215038824|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) study capsule|The Study mHDx capsule has a mechanism that allows the mHDx to remain resident in the stomach for no more than six (6) hours. After this residency period, the Study mHDx will disassemble and pass safely through the subject's gastrointestinal system.
215038825|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) control capsule|The Control mHDX capsule does not have a functional residency mechanism so it will disassemble once safely through the esophagus (within 10 minutes) and will then pass safely through the subject's gastrointestinal system.
215038826|NCT06142864|OTHER|Data collection|Data collection
215038827|NCT02448381|DRUG|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
214873076|NCT01058772|OTHER|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score \< 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
215038828|NCT02448381|DRUG|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
215038829|NCT03700229|DRUG|Bortezomib|Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses
214873077|NCT01903135|PROCEDURE|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
214873078|NCT01903135|PROCEDURE|Pneumologist consult to establish the diagnosis of OHS|"complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.~Medical history, previous treatments."
214873079|NCT04730648|DRUG|PCSK9 inhibitor|For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
214873080|NCT02315430|DRUG|Cabozantinib S-malate|Given PO
214873081|NCT02315430|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
215038830|NCT03700229|DRUG|Rituximab|rituximab intravenously 500 mg for one dose
215038831|NCT04778150|DEVICE|VO 100 medical device from Mespere LifeSciences|The investigators want to show a positive relationship between SjvO2 and SvO2 in order to possibly use in the future SjvO2 measured by VO 100 as a noninvasive surrogate of SvO2 in patients undergoing liver transplantation surgery.
215038832|NCT01344148|DRUG|INH RIF Rifb PZA EMB AZT 3TC D4T EFV|The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
214873082|NCT02041065|DEVICE|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
214873083|NCT02041065|DEVICE|CUSA induced dissection|Ultrasound based destruction of the liver
214873084|NCT06634186|DIETARY_SUPPLEMENT|Dietary intervention|The aim of the dietary intervention is the implementation of a fiber-enriched diet. Therefore, patients receive dietary counseling, supplemented with propionate, that functions as fiber-surrogate.
214873085|NCT03242200|OTHER|Mobile Health App|Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
215038833|NCT05638074|PROCEDURE|Interlaminar Epidural Steroid Injection|"The patient will be placed in the prone position and cutaneous anesthesia is performed with 3 mL of 2% prilocaine using the sterile technique. After imaging the C7-T1 space with fluoroscopy, it will be entered from the right/left paramedian part of the C7-T1 space with an 18G Touhy needle, and the C-arm will be set in the contralateral oblique position for depth determination.~Under intermittent fluoroscopic imaging, the needle will be advanced, and access to the epidural space wiil be confirmed by the loss of resistance technique. Afterwards, the epidural spread will be controlled with a contrast agent, and a mixture of 10 mg dexamethasone, 1 mL 2% lidocaine hydrochloride, and 1 mL 0.9% saline will be applied to the epidural space. The patient will be discharged with recommendations after being kept under observation for 2 hours post-procedure. All injections will be performed by the same pain medicine specialist who has at least 5 years of experience."
215038834|NCT01652313|DRUG|Rasagiline|1 mg/day, tablets for 7 days, orally
215038835|NCT06400784|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.
215038836|NCT03748914|OTHER|Intervention Group|After delivery of the neonate via caesarean section the umbilical cord will be clamped within 30 seconds and cut long at least 30 cm by the obstetrician. The neonate is then placed under an overhead heater by the midwife. There, the umbilical cord must be untwisted and held in a vertical position. It is milked once by the neonatologist towards the baby at a speed of approximately 10 cm/s and then clamped 3 cm from the umbilicus by one member of the clinical team.
215038837|NCT03748914|OTHER|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
215038838|NCT01624753|DEVICE|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
215038839|NCT04541524|DEVICE|Santen Preserflo Microshunt|The PMS is 8.5 mm long has an outer diameter of 350 μm and a lumen diameter of 70 μm. It has a fin sized 1.1 mm located 4.5 mm distally from the internal tip of the device and it consists of poly(styrene-b-isobutylene-b-styrene) SIBS. The device was implanted 1 year prior to the present study via an ab externo approach. At the beginning of the surgery, the conjunctiva was opened. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. PMS guides aqueous humor from the anterior chamber to the subconjunctival space. The forming filtering bleb absorbs aqueous humor which leads to IOP reduction.
215038840|NCT04362735|DRUG|Vedolizumab|Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.
215038841|NCT06564883|DEVICE|0.20% sodium hyaluronate gel|Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
215038842|NCT01575574|DRUG|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
215038843|NCT02006927|DEVICE|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
215038844|NCT04435158|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous injection
215038845|NCT04435158|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous injection
215038846|NCT01501357|BEHAVIORAL|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
215038847|NCT01501357|BEHAVIORAL|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
215038848|NCT02212860|RADIATION|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
215038849|NCT02735200|DRUG|Application of topical vitamin d3 (Top-D)|Topical Vitamin D3 will be applied on the skin, externally, 1 gram daily for 120 days
215038850|NCT02735200|OTHER|Application of Aloe vera gel|"aloe vera gel will be applied~Dosage: 1 gram Duration: 120 days Frequency: Daily"
215038851|NCT02009566|RADIATION|Abdominal radiographs with microfabricated tags|Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
214873086|NCT04028193|DIETARY_SUPPLEMENT|Calogen|Polyunsaturated liquid fat supplement
214873087|NCT04028193|DIETARY_SUPPLEMENT|Resource Energy|Carbohydrate Supplement
215038852|NCT00673920|DRUG|Methotrexate|Oral or parenteral repeating dose
214873088|NCT01167101|DRUG|Rebamipide|Rebamipide 100mg Tid for 28days
214873089|NCT01167101|DRUG|pantoprazole|pantoprazole 40mg qd for 28days
214873090|NCT03288701|DEVICE|Seca medical Body Composition Analyser 515|Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
214873091|NCT04319016|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
214873092|NCT02278055|DRUG|Radium-223|
214873093|NCT00000108|BEHAVIORAL|Exercise|
214873094|NCT06270186|DIAGNOSTIC_TEST|Type 1 myotonic dystrophy|"To compare classical neuropsychological test and on Good Diag NMD software in Type 1 myotonic dystrophy patients"
214873095|NCT02329938|PROCEDURE|Lichtenstein tension free reair|a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
214873096|NCT02329938|PROCEDURE|Desarda's repair|the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
214873097|NCT04322565|DRUG|Colchicine|Cochicine 1mg/day
214873098|NCT03207243|DRUG|GSK3772847|GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
214873099|NCT03207243|DRUG|Placebo|Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
214873100|NCT03207243|DRUG|Fluticasone propionate/salmeterol|FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
214873101|NCT03207243|DRUG|Fluticasone propionate|FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
214873102|NCT06290908|PROCEDURE|RPE-P/TLIF|patients with lumbar spinal stenosis and instability who met the inclusion and exclusion criteria were treated with RPE-P/TLIF
214873103|NCT03747510|DEVICE|CarpX Device|Transverse carpal ligament release with CarpX Device
214873104|NCT03183596|DRUG|Bupivacaine|20-60cc of 0.25% Bupivacaine
214873105|NCT03183596|DRUG|Dexamethasone|2-4mg of Dexamethasone
214873106|NCT02079779|OTHER|Robotic-assisted therapy|The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
214873107|NCT02079779|OTHER|Classical therapy|Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
214873108|NCT03777618|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two differents well-known flaps for gluteal augmentation
214873109|NCT03551288|DRUG|SUVN-911|Tablet
214873110|NCT04015908|DRUG|Celecoxib|Celecoxib 100mg
214873111|NCT04015908|DRUG|Acetaminophen|Acetaminophen 325mg
214873112|NCT04015908|DRUG|Pregabalin|Pregabalin 50 mg
214873113|NCT04015908|DRUG|Oxycodone|oxycodone 5-10 mg
214873114|NCT04015908|DRUG|Percocet|Percocet (oxycodone 5mg/acetaminophen 325 mg)
214873115|NCT05801952|DEVICE|Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System|The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika\* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).
214873116|NCT02268968|DRUG|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
214873117|NCT04623086|DRUG|Insulin Degludec|Insulin Degludec injection
214873118|NCT04623086|DRUG|Insulin Glargine|Insulin Glargine injection
214873119|NCT04623086|DRUG|Placebo|9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
214873120|NCT05798910|OTHER|ALS VR (VR based serious gaming module for advanced life support training)|Using VR based serious gaming module for advanced life support training instead of taking part in a classical lecture about advanced life support.
214873121|NCT05798910|OTHER|Lecture based training for advanced life support|Taking part in a classical lecture about advanced life support.
214873122|NCT03531138|OTHER|Pulmonary Rehabilitation|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week and fill out the exercise follow-up form. Supervised exercise sessions consist of aerobic(treadmill walking, bicycle training, arm ergometer training) and strengthening training(free weights). A 6-min walk test, a 10-meter walking speed test and a 5 times sit to stand test will be performed to determine the exercise capacity of the patient. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed sequentially by the same physiotherapist, giving 20 minute rest periods within the same day.
214873123|NCT01635816|BIOLOGICAL|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
214873124|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
214873125|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
214873126|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
214873127|NCT04131738|DRUG|Baricitinib|Baricitinib may be taken without regard to food. It should be taken at the same time every day.
214873128|NCT02638025|DEVICE|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
214873129|NCT05171608|PROCEDURE|Ultrasound-based protocol based fluid therapy|"Protocol of the interventional group according to the ultrasonographic findings:~Ultrasound scan 2 hours before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate intravenous (IV) fluid therapy: 8 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.~A 2nd ultrasound scan at 30 minutes before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate further IV fluid therapy: 5 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy."
214873130|NCT01820975|DIETARY_SUPPLEMENT|High protein intake|
214873131|NCT01820975|OTHER|Placebo comparator|No protein intake
214873132|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
214873133|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
214873134|NCT04283604|DRUG|MPH|The treatment will include taking the patient's own medication by the patient himself in the treatment session 60-180 minutes before the beginning of the tests, according to their prescription given by their own physician. Participants must have consumed this medication at least 3 months before the first session as their regular treatment for ADHD. Note, we are not planning on giving the medication to the participant, rather he/she will consume their own prescribed MPH by them self.
214873135|NCT00715624|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
215038853|NCT00673920|DRUG|Ocrelizumab|"Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate."
215038854|NCT00673920|DRUG|Placebo|Intravenous repeating dose
215038855|NCT04552002|DIETARY_SUPPLEMENT|Synbiotic group|Probiotics and prebiotics
215038856|NCT06164158|OTHER|Procedural Videos|A randomized controlled trial was conducted at Pakistan Institute of Medical Sciences (PIMS) Islamabad between September 1, 2023 to November 30, 2023 under ethical approval from the Institutional ethical review board.
215038857|NCT06164158|OTHER|No procedural videos|No procedural videos
215038858|NCT01164007|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
215038859|NCT01164007|DRUG|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle.
215038860|NCT03448328|DIETARY_SUPPLEMENT|NUTRALYS pea protein supplement|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
215038861|NCT03448328|DIETARY_SUPPLEMENT|Whey Protein|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
215038862|NCT03448328|DIETARY_SUPPLEMENT|Apple juice|1.2 calories per kilogram body weight before and after eccentric exercise, and each of 4 mornings of recovery
215038863|NCT01656577|DRUG|Pexacerfont|
215038864|NCT00005852|BIOLOGICAL|anti-thymocyte globulin|
215038865|NCT00005852|BIOLOGICAL|filgrastim|
214873136|NCT00715624|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214873137|NCT00715624|DRUG|Basal Insulin|Dose to be kept stable.
214873138|NCT00715624|DRUG|Metformin|Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.
214873139|NCT00715624|DEVICE|Pen auto-injector|
214873140|NCT02264860|DIETARY_SUPPLEMENT|Zinc and SAMe|The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
214873141|NCT03960125|DEVICE|Photodynamic Therapy|Blue Light Therapy Exposure
215038866|NCT00005852|BIOLOGICAL|muromonab-CD3|
215038867|NCT00005852|DRUG|cyclophosphamide|
215038868|NCT00005852|DRUG|cyclosporine|
214873142|NCT03960125|DRUG|4% Imipramine|A tricyclic antidepressant (TCA) medication. Though it is usually taken orally, topical preparations (4%) has use in topical anesthetics and anti-pain medicaments.
214873143|NCT03960125|DRUG|Base Cream|Control to 4% Imipramine
214873144|NCT00229723|DRUG|gefitinib (Iressa)|250 mg oral tablet
214873145|NCT00229723|DRUG|cisplatin|intravenous infusion
214873146|NCT00229723|RADIATION|radiotherapy|radiation therapy
214873147|NCT00229723|DRUG|Gefitinib (Iressa)|500 mg oral tablet
214873148|NCT02572414|BEHAVIORAL|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
215038869|NCT00005852|DRUG|methylprednisolone|
215038870|NCT00005852|PROCEDURE|allogeneic bone marrow transplantation|
215038871|NCT04856527|BEHAVIORAL|Physical therapist support|Participants will receive physical therapist support to reduce postural sway variability while completing an upper limb precision aiming task in virtual reality.
215038872|NCT01816295|DRUG|Testosterone Solution|Administered topically to axillae.
215038873|NCT01816295|DRUG|Placebo Solution|Administered topically to axillae.
215038874|NCT02055846|PROCEDURE|Realisation of blood sample, urinary sample and tumor biopsy|
215038875|NCT04165824|DRUG|MT-1186|"* An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period~* Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks."
215038876|NCT04708782|DRUG|Placebo|Placebo administered QID
215038877|NCT04708782|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
215038878|NCT04708782|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
215038879|NCT05476991|DRUG|Colchicine 0.5 MG|Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
215038880|NCT05476991|DRUG|Ticagrelor 90mg|Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.
215038881|NCT05476991|DRUG|Aspirin 75-300mg|Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
215038882|NCT06559709|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
215038883|NCT06559709|OTHER|Dietary Intervention|Receive 3 meals per day and snacks
215038884|NCT06559709|OTHER|Dietary Intervention|Meet with dietitian
215038885|NCT06559709|OTHER|Medical Chart Review|Ancillary studies
215038886|NCT06559709|OTHER|Questionnaire Administration|Ancillary studies
214873149|NCT02572414|BEHAVIORAL|Health Awareness Control Intervention|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
215038887|NCT05884333|DRUG|Conditioning Chemotherapy|Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
215038888|NCT05884333|BIOLOGICAL|Cord blood graft|The double-unit CB graft will be infused on day 0 per standard practice.
215038889|NCT05867953|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Adjunct Real-time Imaging
215038890|NCT06100276|DRUG|AMT-162|AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.
215038891|NCT06963190|OTHER|Constant Resistance (CR)|Will perform inspiratory muscle training at 30% of MIP. Two daily sessions of 30 breaths or 10 minutes.
215038892|NCT06963190|OTHER|Intermittent Variable Resistance (IVR)|Will perform inspiratory muscle training at 30% of MIP. This will consist of two daily sessions of 30 breaths or 10 minutes. Additionally, the participant will complete 8 sets of 3 repetitions at 60% of the MIP, distributed throughout the day, with a one-minute rest between each repetition.
215038893|NCT05184556|BEHAVIORAL|Family-based treatment (FBT)|FBT is a structured behavioral treatment focused on empowering caregivers to take charge of the adolescent's eating behavior and return him/her to a normative weight and developmental trajectory. FBT involves three consecutive phases: 1) caregivers are fully in control of the adolescent's eating; 2) control of eating is gradually returned to the adolescent; and 3) developmental issues are explored. In the current study, FBT is adapted for delivery in the home setting in the following ways: intensified dose of treatment (2-6 hours of therapy per week over 10 - 32 weeks); use of clinician as an additional support to the family; multiple family meals in the home and community; sociocultural tailoring; and inclusion of supplemental individual work with the adolescent to improve emotion regulation/distress tolerance.
215038894|NCT05184556|BEHAVIORAL|Integrative family therapy|The integrated family therapy approach includes psychoeducation, supportive family therapy, and elements of cognitive-behavioral interventions. Families may be referred for additional nutritional counseling and prescribed a meal plan as indicated. Typical strategies include educating families on the presentation and prognosis of adolescent AN; identifying dysfunctional family structures/alliances and communication patterns; using reflective listening to engage and validate family members; challenging maladaptive beliefs about eating and weight; and supporting families in developing strategies for management of both general and eating disorder-specific distress. Treatment is generally non-directive.
215038895|NCT02041767|DRUG|Ertapenem|One single injection of 1g of ertapenem before surgery
215038896|NCT05746559|DRUG|Placebo|Participants will receive a single weight-based dose of placebo via intravenous infusion.
215038897|NCT05746559|DRUG|Ravulizumab|Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.
215038898|NCT01486888|DRUG|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
215038899|NCT05746988|OTHER|Mouthwash gargling|15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.
215038900|NCT03522402|DRUG|Sevoflurane|38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
215038901|NCT01302002|DRUG|Metformin Pre-Surgery|500 mg tablet, taken twice a day for 3 weeks
215038902|NCT01763762|BEHAVIORAL|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
215038903|NCT01763762|BEHAVIORAL|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
215038904|NCT01763762|BEHAVIORAL|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
215038905|NCT06155357|BEHAVIORAL|Multicomponent lifestyle intervention program|The multicomponent lifestyle intervention program is targeted at risk factor management, increased exercise capacity, and weight loss. The program will commence upon order/referral for ablation. Ablation would occur during the lifestyle program and the program will be continued after the ablation to complete 12 weeks or up to 36 exercise sessions.
215038906|NCT02065219|DRUG|Bupivacaine|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
215038907|NCT02065219|DRUG|Placebo|10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
215038908|NCT01749488|OTHER|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
215038909|NCT01823289|DRUG|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
215038910|NCT01276626|DIETARY_SUPPLEMENT|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
215038911|NCT01276626|OTHER|Maltodextrin|Powder containing only maltodextrin
215038912|NCT05707260|BEHAVIORAL|CKD SMS|The intervention begins with a face-to-face or digitally assisted session, entry into improving the knowledge and self-management of CKD through, using the four sources of manipulation of self-efficacy (achievement of performance, indirect experience, verbal persuasion, and self-evaluation). In this session, participants will be asked to identify their problems related to CKD and establish, based on these two goals, that they are real and achievable according to their priorities. These goals will be recorded in the monitoring format and will be monitored in the telephone or WhatsApp follow-ups. This using the performance achievement manipulation source, said session lasts 60 minutes, as does the final session at week 16.
215038913|NCT02814656|DRUG|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
215038914|NCT02814656|DRUG|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
214873150|NCT03645239|PROCEDURE|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
214873151|NCT03645239|OTHER|Preoperative pain assessment|"Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?)."
214476642|NCT05339477|OTHER|Accelerometer measurement|Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
214476643|NCT04734730|DRUG|Abiraterone Acetate|Given PO
214476644|NCT04734730|DRUG|Bicalutamide|Given PO
214476645|NCT04734730|DRUG|Degarelix|Given SC
214873152|NCT03645239|OTHER|Questionnaires|Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.
214873153|NCT03645239|OTHER|Headspace|The mindfulness exercise mobile application, Headspace, will be downloaded into the patients' mobile devices. Patients will be asked to experience a mindfulness exercise for 10-30 minutes before delivery. HADS and pain score will be asked after the intervention.
215038915|NCT00272181|DRUG|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
215038916|NCT02052973|OTHER|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
215038917|NCT05616442|DRUG|Ketotifen|Mast cell stabilizer
215038918|NCT05616442|DRUG|Vitamin E|Dietary supplement
215038919|NCT00153660|DRUG|Celecoxib(drug)|Celecoxib 100 mg bd
215038920|NCT00153660|DRUG|Naproxen(drug)|Naproxen 500 mg bd
215038921|NCT05018364|DIAGNOSTIC_TEST|Serum erythropoietin level|Evaluate serum erythropoietin level in neonates exposed to hypoxia compared to control group
215038922|NCT03255616|OTHER|mechanical stimulation|mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients
215038923|NCT03255616|OTHER|vibrotactile stimulation|non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
215038924|NCT01259011|BEHAVIORAL|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
215038925|NCT06561139|BEHAVIORAL|Mindfulness|Weekly group sessions of mindfulness, for eight weeks
214476646|NCT04734730|DRUG|Goserelin Acetate|Given SC
214476647|NCT04734730|DRUG|Leuprolide Acetate|Given IM
214476648|NCT04734730|DRUG|Prednisone|Given PO
214873154|NCT03931525|DEVICE|Fractitional Radiofrecuency with Drug Delivery|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects and which will be complemented with a skin drug
214873155|NCT03931525|DEVICE|Fractitional Radiofrecuency|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects
214873156|NCT04408235|DRUG|Enoxaparin|Low-Dose LMWH: enoxaparin 4000 IU daily; High dose LMWH: 70 IU/kg twice daily
214873157|NCT02399319|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
214873158|NCT02399319|PROCEDURE|Symphyseal Plate|A plate that spans across the symphysis to maintain reduction and stability.
215038926|NCT06172140|DRUG|Ciprofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of ciprofol, followed by intravenous injection of ciprofol (0.4mg/kg). When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
215038927|NCT06172140|DRUG|Propofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of propofol, followed by intravenous injection of propofol (2 mg/kg) for 30 seconds. When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
215038928|NCT02157428|DRUG|Flumazenil|
215038929|NCT02157428|DRUG|saline|
215038930|NCT05010473|BEHAVIORAL|Speech and non-speech sound stimulation|Listening to repetitive and extended sound presentation induces specific neural and physiological activity that we will measure via electroencephalography and pupillometry
215038931|NCT02464982|PROCEDURE|Tattoo|tattoo device with EC standards, and sterile single-use only needle
215038932|NCT01923922|RADIATION|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
214873159|NCT03526159|DRUG|Gentamicin Sulfate|Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
214873160|NCT06633159|DEVICE|MitraClip|surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets
215038933|NCT06033534|DEVICE|STIMULAN|"Procedures:~Surgical repair of the open fracture, as per standard-of-care guidelines. Insertion of the STIMULAN device at the site of the fracture. Standard post-operative care, including monitoring of inflammatory markers and clinical signs of infection."
215038934|NCT02740465|BEHAVIORAL|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
215038935|NCT02740465|BEHAVIORAL|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
215038936|NCT05583955|DRUG|NOE-105|Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
215038937|NCT05583955|DRUG|Placebo|Escalating dose levels of matching Placebo will be given
215038938|NCT01960491|DEVICE|Device Closure of Atrial Septal Defect|"Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder"
215038939|NCT04395547|DIETARY_SUPPLEMENT|JointAlive™|Combination herbal extract
215038940|NCT04395547|DIETARY_SUPPLEMENT|Placebo|Combination placebo product
215038941|NCT02643485|PROCEDURE|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
215038942|NCT03849261|DRUG|CKD-387|Test drug
215038943|NCT03849261|DRUG|D635|Reference drug
215038944|NCT00305396|DRUG|Sirolimus|
215038945|NCT05895994|DRUG|RD13-02 cell infusion|CAR-T cells
214476649|NCT04734730|OTHER|Questionnaire Administration|Ancillary studies
214476650|NCT04734730|DRUG|Talazoparib|Given PO
214476651|NCT06479096|OTHER|Brush / Espresso Mild Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
214476652|NCT06479096|OTHER|Brush / Espresso Intense Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
215038946|NCT00048984|OTHER|laboratory biomarker analysis|Correlative studies
214476653|NCT06479096|OTHER|Brush / Fresh Breath Oral Rinse|Subjects will brush and rinse with their assigned mouthwash twice daily.
215038947|NCT02135484|DRUG|Alpharadin|50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
215038948|NCT01656161|DRUG|Triptorelin embonate 22.5 mg|
215038949|NCT00226005|DRUG|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
215038950|NCT00002193|DRUG|Amprenavir|
215038951|NCT05288192|DRUG|Suprachoroidal triamcinolone acetonide (SCTA) injection|Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.
215038952|NCT00922129|DRUG|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
214873161|NCT00819637|DRUG|arformoterol (RR formoterol)|"Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.~Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses."
214873162|NCT00819637|DRUG|placebo|Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
215038953|NCT00922129|DRUG|Cyclosporin (Neoral) or Tacrolimus (Prograf)|"Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months"
215038954|NCT03510273|DEVICE|Liger Medical Thermocoagulator|"Thermocoagulation treatment by Liger Medical device (US FDA 510K clearance received)"
215038955|NCT00196040|DEVICE|PFX Closure System|
215038956|NCT01276106|DRUG|AC-201, 25mg|Capsule, 25mg BID
215038957|NCT01276106|DRUG|AC-201, 50mg|Capsule, 50mg BID
215038958|NCT01276106|DRUG|AC-201, 75mg|Capsule, 75mg BID
215038959|NCT01276106|DRUG|Placebo|Placebo BID
215038960|NCT00050804|DRUG|sertraline|
215038961|NCT03495401|DIETARY_SUPPLEMENT|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
215038962|NCT03495401|DIETARY_SUPPLEMENT|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
215038963|NCT01777477|DRUG|Chloroquine|Addition of Chloroquine to Gemcitabine
215038964|NCT01777477|DRUG|Gemcitabine|
215038965|NCT02351089|DIETARY_SUPPLEMENT|Capsules placebo|Capsules
214291211|NCT04066673|DIAGNOSTIC_TEST|Stanford-Binet Intelligence Scale, 5th Edition|The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores
214291212|NCT03381846|PROCEDURE|MOHS micrographic surgery|Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.
214291213|NCT03381846|PROCEDURE|Wide local excision|A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
214291214|NCT05000177|OTHER|30-minute computer typing task|The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.
214291215|NCT05000177|OTHER|30-minute rest|Rest for 30 minutes
214476654|NCT06479096|OTHER|Brush / Hydroalcohol|Subjects will brush and rinse with their assigned mouthwash twice daily.
215038966|NCT02351089|DIETARY_SUPPLEMENT|Capsules probiotic powder and corn starch|
215038967|NCT02258490|BIOLOGICAL|G-CSF mobilized CD34+ selected cells for transplantation|After screening and enrollment, donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using standard National Marrow Donor Program guidelines. CD34+ cell selection will be performed according to procedures given in CliniMACS Operating Manual and institutional Standard Operating Procedures. If storage after CD34+ selection is necessary, product will be kept in a monitored refrigerator. During storage, leukocyte concentration should not exceed 2 x 108 cells/ml using platelet poor plasma to adjust cell concentration. If donor's plasma is not available, CliniMACS buffer will be used. Cell processing will be performed by personnel trained by Miltenyi on CliniMACS system prior to initiation of clinical product selection. After tests are performed and product passes release criteria, patient will receive final product. No conditioning regimen will be administered prior to cell infusion.
215038968|NCT03199079|OTHER|Measurement|Measurement of cervix elasticity and length measurements is not an intervention
215038969|NCT04079738|DRUG|TAK-659|TAK-659
215038970|NCT04079738|DRUG|Ixazomib|Ixazomib
215038971|NCT06497478|DIAGNOSTIC_TEST|Ultrasonographic examination|"Ultrasonographic examination will be performed using a high-resolution (Epiq Elite Philips Medical Systems, Monza, Italia) and a linear 12-9 MHz transducer.~The patients will be placed in a supine position. Starting with the probe at the base of the neck, the common carotid artery will be explored on the transverse plane and then on the sagittal one, continuing in a cranial sense up to the carotid bifurcation. The medium-intimal thickness will be measured, defined as distance from the first hyperechoic line to the second hyperechoic line.~The femoropopliteal and run-off segments will be continuously scanned from the subinguinal region to the paramalleolar region with axial and sagittal scans. All segments will be examined for the presence of vessel wall calcifications and/or atherosclerotic plaques. In addition, flow velocity measurements will be obtained using spectral Doppler imaging and color Doppler imaging."
214291216|NCT02906059|DRUG|AZD1775|
214291217|NCT02906059|DRUG|Irinotecan|
214291218|NCT06530225|OTHER|Education and Mentoring for Prescribing Pharmacists|Pharmacists enrolled in the PrEP prescribing cohort will receive implicit bias, health disparity and health equity training for HIV prevention. In addition, the pharmacists will receive mentorship and receive an implementation toolkit on best practices for PrEP prescribing.
214291219|NCT00327678|DRUG|Rituximab|
214291220|NCT00327678|DRUG|Imatinib Mesylate|
214291221|NCT03421119|DRUG|Liraglutide 6 MG/ML Pen Injector|Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
214476655|NCT04787848|DRUG|Relistor Injectable Product|Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
214873163|NCT00819637|DRUG|levalbuterol|Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.
215038972|NCT04890184|DIETARY_SUPPLEMENT|grape juice|grape juice
215038973|NCT04890184|OTHER|control|no intervention
215038974|NCT00574015|DRUG|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
214476656|NCT06551012|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Participants will consume 2 x 70 ml bottles of nitrate-rich beetroot juice for a 7 day period prior to exercise testing
215038975|NCT00574015|DRUG|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
214873164|NCT03207737|BEHAVIORAL|MENTOR + Telehealth|Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
214873165|NCT03207737|BEHAVIORAL|Telehealth Only|Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
214873166|NCT06448806|OTHER|mobile health lifestyle intervention|You will be asked to record all dietary and physical activity log for 12 months on an application. Mobile sms reminders will be sent to you on regular basis. At day 0, at 6th and 12 months you will be asked to provide 3 ml of blood for the methylation and advance glycation level testing and your weight and body fat percentage will be measured. During this period you will have to follow the lifestyle and diet chart provided to you by the researchers.
214873167|NCT03150407|DEVICE|VR101 Device (Efficacy)|Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days
214873168|NCT03150407|OTHER|Sham Control Ring|Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days
214873169|NCT03150407|DEVICE|VR101 Device (Safety)|Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.
214873170|NCT02186288|OTHER|High-flow nasal cannula oxygen|
214873171|NCT05810688|OTHER|eating rehabilitation training|The experimental group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education.
214873172|NCT02975778|DEVICE|Pain Monitor™|Pain measured by Pain Monitor™
214873173|NCT05950178|DIAGNOSTIC_TEST|Apnea test under high-flow oxygenation|Apnea test under high-flow oxygenation in patients with a confirmed clinical brain death by a standard apnea test (under standard oxygen therapy)
214873174|NCT01165528|PROCEDURE|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
214873175|NCT05373628|DIAGNOSTIC_TEST|Gradient and pulse imaging|A novel diffusion-based magnetic resonance imaging method
214873176|NCT00423371|DEVICE|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
214873177|NCT00423371|DEVICE|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
214873178|NCT03108378|PROCEDURE|Surgery|hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
214873179|NCT03369197|DEVICE|Nasal Mask|Nasal anesthesia mask which covers the nose and attaches to the anesthesia circuit, allowing for variable positive pressure by setting the pop-off valve
215038976|NCT03478605|DRUG|Olanzapine|Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)
214873180|NCT03369197|DEVICE|Control: Nasal Cannula|Nasal cannula as per usual care
214873181|NCT03421730|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System|The VR647 Inhalation System consists of the VR647 Inhalation System 1 control unit, a VR647 nebulizer handset, a mouthpiece and VR647 Smart Cards designed specifically for this trial.
214873182|NCT03421730|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.
215038977|NCT03478605|DRUG|Aprepitant Pill|Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
215038978|NCT03478605|DRUG|Ondansetron|Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
215038979|NCT03478605|DRUG|Dexamethasone|Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
215038980|NCT03101748|DRUG|Cyclophosphamide|Given IV
215038981|NCT03101748|DRUG|Doxorubicin|Given IV
214291222|NCT03421119|DRUG|Metformin|Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
214291223|NCT03421119|DRUG|Sulfonylurea/non-sulfonylurea insulin secretagogues|Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
214476657|NCT06551012|DIETARY_SUPPLEMENT|Beetroot juice with nitrate extracted|Participants will consume 2 x 70 ml bottles of beetroot juice with nitrate extracted for a 7 day period prior to exercise testing
214873183|NCT02404766|OTHER|C0-C1 dorsal glide manual mobilization|
214873184|NCT02404766|OTHER|C7-T1 ventral cranial glide manual mobilization|
215038982|NCT03101748|OTHER|Laboratory Biomarker Analysis|Correlative studies
215038983|NCT03101748|DRUG|Neratinib|Given PO
215038984|NCT03101748|DRUG|Paclitaxel|Given IV
215038985|NCT03101748|BIOLOGICAL|Pertuzumab|Given IV
215038986|NCT03101748|BIOLOGICAL|Trastuzumab|Given IV
215038987|NCT05196776|DEVICE|Portable, handheld point-of-care ultrasound device|The patient will have an ultrasound performed using a handheld, portable device.
215038988|NCT05196776|DEVICE|Cart-based point-of-care ultrasound device|The patient will have an ultrasound performed using a traditional cart-based model.
215038989|NCT00867035|DRUG|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
215038990|NCT00867035|DRUG|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
215038991|NCT06564116|BIOLOGICAL|Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of thiomersal-free hepatitis E vaccine intramuscularly at month 0, 1 and 6.
215038992|NCT06564116|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of licensed hepatitis E vaccine intramuscularly at month 0, 1 and 6
215038993|NCT05023161|BIOLOGICAL|Blood samples|Performed a 10 ml blood sample in each of the 200 patients included.
214873185|NCT05998148|OTHER|virtual phone appointment visits|Patient will have post-operative appointments that place with telemedicine. The visits will will be virtual phone appointments scheduled at approximately 6 weeks, 12 weeks, and 6 months after surgery.
215038994|NCT02850341|DEVICE|Pedometer|Patients receive a pedometer with instructions how to raise their number of daily steps
214873186|NCT02737904|OTHER|APT|APT for 30 minutes per day on 5 days per week for 4 weeks: 2 minute warm up consisting of passive cycling, where the legs of the participant are moved passively by the APT at 10 revolutions per min (rpm). Next, the participant will cycle for up to 26 minutes, at 60rpm. In this phase, the participant is required to actively cycle and to maintain a symmetrical pattern of movement using the feedback on the display. If the participant is unable to actively cycle at any point during the 26 minute exercise period, or if they have a spasm, the MOTOmed APT will revert to the passive mode. The final phase is a cool down where participants again will have 2 minutes of passive cycling at 10rpm.
214873187|NCT02737904|OTHER|Usual care|Personalised in-patient rehabilitation programme
214873188|NCT01054404|DRUG|Furosemide|Furosemide 0.3 mg/kg
214873189|NCT01054404|DRUG|Placebo|Placebo (up to 5mL)
214873190|NCT00880789|BIOLOGICAL|CMV/AdV specific T cells|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
214873191|NCT02518672|DIETARY_SUPPLEMENT|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
214873192|NCT02518672|DIETARY_SUPPLEMENT|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
214873193|NCT02876757|DRUG|5ARI|Exposure to finasteride/dutasteride
214873194|NCT00118534|BEHAVIORAL|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
214873195|NCT00118534|BEHAVIORAL|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
214873196|NCT00311324|BEHAVIORAL|Special Intervention|
215038995|NCT02107612|DEVICE|Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture|
215038996|NCT02107612|OTHER|Denture|
214873197|NCT00311324|BEHAVIORAL|Delayed Intervention|
214873198|NCT02630979|BEHAVIORAL|Measuring satisfaction, knowledge and bias|Questionnaire based assessment.
214873199|NCT03016975|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System
214873200|NCT03016975|DRUG|Guideline Directed Medical Therapy|GDMT Only
214873201|NCT00002737|BIOLOGICAL|recombinant interferon alfa|
214873202|NCT00002737|DRUG|chemotherapy|
214873203|NCT00002737|DRUG|isotretinoin|
214873204|NCT01590797|DRUG|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks
215038997|NCT04600973|BEHAVIORAL|Technical assistance or team-based coaching|Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.
214476658|NCT06040801|BEHAVIORAL|Frailty intervention measures|"Providing management and recommendations based on the specific impairment domain.~Assessment domain:~* Functional status~* Nutrition~* Comorbidity~* Mobility/Falls~* Mood~* Cognition~* Polypharmacy~* Social support."
214873205|NCT01590797|DRUG|Placebo|Matching placebo once daily for 24 weeks
214873206|NCT01590797|BIOLOGICAL|Insulin|Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
214873207|NCT01590797|DRUG|Metformin|At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
214873208|NCT05456230|DRUG|Midazolam|Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
215038998|NCT06529484|OTHER|Warm Water Foot Bath Intervention|Participants will take a warm water foot bath at 38-40ºC for 20 minutes nightly for 7 days.
215038999|NCT06281457|OTHER|Stimulus properties: task-defining feature|The feature used to determine which stimulus feature to attend to will be varied across trials using a letter cue (M = motion-attend, C = color-attend, F = fixation-attend)
215039000|NCT06149585|OTHER|Microbial Sampling|Pool microbial sampling will be performed and changes in the microbiome will be evaluated and compared for differences
215039001|NCT05452668|DEVICE|Laser Therapy|\- Laser will be applied with the specified wave length using a diode laser device over 4 consecutive days.
215039002|NCT05452668|DEVICE|Sham procedure|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current Protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
215039003|NCT04866563|DRUG|AX-8, Part 1 of the study|orally disintegrating tablets, BID
215039004|NCT04866563|DRUG|Placebo, Part 1 of the study|orally disintegrating tablets, BID
214873209|NCT02901548|DRUG|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
215039005|NCT04866563|DRUG|AX-8, Part 2 of the study|orally disintegrating tablets, TID
215039006|NCT04866563|DRUG|Placebo, Part 2 of the study|orally disintegrating tablets, TID
215039007|NCT02035657|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
215039008|NCT04863404|OTHER|Face mask with hybrid-hyrax|Face mask with hybrid-hyrax
215039009|NCT04863404|OTHER|Face mask with conventional bonded RME|Face mask with conventional bonded RME
215039010|NCT04717401|PROCEDURE|Strain-Counterstrain|Strain-counterstrain will be applied to four muscle which are . Tender point of each muscle will be identified then the muscle will be positioned passively in the most relaxed position which will be held for 90 sec. This procedure will repeated 3 times for each muscle
215039011|NCT04717401|PROCEDURE|Muscle Energy Technique|Muscle energy technique will be applied to four muscles which are quadratus Lumborum, iliacus, piriform and erector spinae. Each muscle will be positioned passively in stretched position the patient asked to push against the therapist isometrically while holding breath for 5-10sec. After exhalation, the muscle will be moved into a new barrier. This procedure will repeated 3 times for each muscle
215039012|NCT00002487|DRUG|dipyridamole|
215039013|NCT00002487|DRUG|methotrexate|
215039014|NCT02996929|DEVICE|LC System|Subjects will undergo CIED lead extraction with the LC system
215039015|NCT02357303|DRUG|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
215039016|NCT02357303|DRUG|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
215039017|NCT02357303|OTHER|Placebo|100mL of water
215039018|NCT05613231|BEHAVIORAL|Aerobic plus muscle-strengthening physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting both aerobic and muscle-strengthening physical activity for Latina women.
215039019|NCT05613231|BEHAVIORAL|Original physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting aerobic physical activity for Latina women.
215039020|NCT02327377|BEHAVIORAL|Online Cognitive Behavior Therapy|
215039021|NCT02327377|BEHAVIORAL|Online Education|
215039022|NCT05478317|PROCEDURE|ECL- mPZ|"Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin."
215039023|NCT05478317|PROCEDURE|ECL-OF|"Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured."
215039024|NCT06545032|PROCEDURE|lumbar fusion|Minimal Invasive Transforaminal Lumbar Interbody Fusion
215039025|NCT06650410|OTHER|Virtual Intervention for Vertebral Fractures (VIVA)|VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. An exercise professional leads 1:1 once-weekly sessions (in person or virtual) over eight weeks. Sessions start with brief education on a topic, followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. The exercise professional prescribes resources using an app or that can be emailed or mailed. Exercises are tailored to the participant's abilities, and target balance, muscle strength, and endurance of back extensor muscles and scapular stabilizers.
214873210|NCT02901548|PROCEDURE|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
214873211|NCT01900561|BEHAVIORAL|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
215039026|NCT03666390|DRUG|Ketamine|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
215039027|NCT03666390|DRUG|Midazolam|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
215039028|NCT04273269|GENETIC|LYS-GM101|LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection
215039029|NCT00294749|DRUG|Ciprofloxacine|
215039031|NCT07127250|OTHER|Walking sticks|Walking with walking sticks and pedometer Daily walking activity recorded in a logbook
215039032|NCT03440801|DEVICE|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
215039033|NCT03440801|DEVICE|Xience|Durable-polymer everolimus-eluting stent Xience
215039034|NCT06708949|DRUG|Drugs Nivolumab|Given by IV Infusion
215039035|NCT06708949|DRUG|Ipilimumab|Given by IV Infusion
215039036|NCT06708949|DRUG|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV Infusion
215039037|NCT05876754|DRUG|Ivosidenib Oral Tablet|Ivosidenib 500 mg
215039038|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
215039039|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
215039040|NCT03151564|DIAGNOSTIC_TEST|Deep Learning Image Reconstruction (DLIR)|Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
215039041|NCT05464823|OTHER|Molecular Functional Portrait|Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
215039042|NCT00055185|DRUG|CD4-IgG2 (PRO 542)|
215039043|NCT05283720|DRUG|Epcoritamab|Subcutaneous Injection (SC)
215039044|NCT05283720|DRUG|Lenalidomide|Oral; Capsule
215039045|NCT05283720|DRUG|Ibrutinib|Oral; Capsule
215039046|NCT05283720|DRUG|Rituximab|Intravenous (IV); Injection
215039047|NCT05283720|DRUG|Cyclophosphamide|IV; Injection
214873212|NCT01900561|BEHAVIORAL|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
214873213|NCT01596309|DIETARY_SUPPLEMENT|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
214873214|NCT02942030|OTHER|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
214873215|NCT01006018|DRUG|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
214873216|NCT01006018|DRUG|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
215039048|NCT05283720|DRUG|Doxorubicin Hydrochloride [HCl]|IV; Injection
215039049|NCT05283720|DRUG|Prednisone|Oral; Tablet
214873217|NCT01006018|DRUG|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
214873218|NCT02113618|BEHAVIORAL|Cogmed training|Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
215039050|NCT05283720|DRUG|Polatuzumab Vedotin|IV; Injection
215039051|NCT05283720|DRUG|Venetoclax|Oral; Tablet
215039052|NCT05283720|DRUG|CC-99282|Oral; Capsule
215039053|NCT05283720|DRUG|Pirtobrutinib|Oral; Tablet
215039054|NCT06586619|BEHAVIORAL|Tai chi/qigong intervention group|The intervention is a tai chi/qigong intervention for older people living with HIV. This behavioral group-based intervention will be delivered through Zoom twice a week for 12 weeks. Each class lasts 45-60 minutes. Tai chi/qigong is a slow low impact meditative movement.
215039055|NCT06586619|BEHAVIORAL|Health Education group|Participants will be assigned to a health and wellness education group for older people living with HIV. This group will be delivered through Zoom twice a week for 12 weeks, and each class will last 45-60 minutes. Each group will learn about and discuss a health and wellness topic.
215039056|NCT06978439|DRUG|Rivaroxaban (Xarelto)|Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model-informed dose optimization study
214873219|NCT02113618|BEHAVIORAL|Standard Training|Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
215039057|NCT00789555|DRUG|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
215039058|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
215039059|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
215039060|NCT00404248|DRUG|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
215039061|NCT00404248|OTHER|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
215039063|NCT04649645|OTHER|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
215039064|NCT04649645|OTHER|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
215039065|NCT04649645|OTHER|NOT SMOKING|Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
215039066|NCT06857513|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|Patients will be interviewed about the current suffering of post-intensive care symptoms
214476659|NCT04311632|BIOLOGICAL|TCD601|Investigational Product
214873220|NCT01860352|DIETARY_SUPPLEMENT|Fish OIl|
214873221|NCT04590352|PROCEDURE|nasopharyngeal and throat swab|diagnostic specimens via nasopharyngeal swab and throat swab were collected following the current standard operating procedures.
214873222|NCT04590352|PROCEDURE|collection of mucosal lining fluid|MLF will be collected via nasal absorption at the inclusion visit by study staff and four more time points by the parents or by the children themselves. Nasal absorption is performed by maneuvering a strip of synthetic absorptive matrices (SAM) into the lumen of the nostril, avoiding rubbing against the nasal mucosa. The outside of the nose is then pressed with a finger to cause apposition of the SAM against the mucosa.
215039067|NCT06857513|DIAGNOSTIC_TEST|EuroQol 5-Dimension 3-Level|to assess health-related quality of life, focusing on the assessment of five key dimensions: mobility, self-care, daily activities, pain/discomfort and anxiety/depression.
215039068|NCT06857513|DIAGNOSTIC_TEST|EuroQol Visual Analogue Scale (EQ-VAS)|"records the patient's self-rated health on a vertical visual analogue scale where endpoints are labelled: 0 best imaginable health - 100 worst imaginable health"
214873223|NCT04590352|PROCEDURE|blood collection via fingerprick|Participants will be asked to wash their hands with soap and warm water. The procedure involves cleaning the ball of the fingertip with an alcohol swab, then using a sterile disposable lancet to pierce the skin (BD Microtainer Lancet or similar). The lancet is placed in a spring-loaded device, which propels the lancet a fixed distance (a few mm) into the skin when the trigger is pressed. Approximately 10-20 drops of blood (0.3 ml) will then be collected with a sterile capillary tube. The participant is given a cotton wool pad to mop up any extra blood, and an elastoplast-type bandage is placed over the finger if necessary. Fingerprick blood samples will only be collected from participants older than 6 months at 28-32 days after the first home visit (d0). Lancet length will be adjusted for age (2.0 mm for participants 8 years and older, 1.5 mm for participants older than 6 months and younger than 8 years).
214873224|NCT01791270|DEVICE|Continuous positive airway pressure (CPAP) therapy|"Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~1. \- Respiratory Polygraphy~2. \- Ambulatory Blood Pressure Monitoring~3. \- Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~4. \- ß1en subunit expression in peripheral blood leukocytes."
214873225|NCT02976285|PROCEDURE|arthroscopic rotator cuff repair with a polyester patch|Patients were operated under general anesthesia and a supraclavicular nerve block, in a beach-chair position with 80° forward shoulder flexion and traction between 3-5 kg. After washing and draping a standard viewing portal was placed at the dorsal softspot. Further portals included, a lateral, a dorso-lateral, an antero-lateral and an anterior portal. If additional pathologies were present, they were treated simultaneously and mostly involved the long head of the biceps tendon, treated with tenodesis or tenotomy respectively. After a thorough bursectomy, the rupture was fully visualized and thereafter its size was estimated. Following debridement of the footprint, we used a triple row repair and implanted the patch.
214873226|NCT03897985|DEVICE|Narcotrend TM|Measurement of anesthesia depth
215039069|NCT06857461|BEHAVIORAL|Uriclarity Program|"The Uriclarity Program is a behavioral lactation support intervention designed to reduce the perception of insufficient milk supply (PIM) in postpartum women. The program consists of a two-hour hands-on training session delivered within the first 24-48 hours postpartum and a WhatsApp-based follow-up support system.~During the in-person training, participants learn essential breastfeeding techniques, how to recognize normal lactation patterns, and how to use the Uriescala Ashiyama, a self-monitoring tool that evaluates neonatal urine color to assess milk transfer. Right after hospital discharge, participants receive virtual support including educational videos.~This intervention differs from standard lactation counseling by integrating self-monitoring strategies, community-based digital support, and a non-technology-dependent educational approach, making it a scalable and sustainable strategy for breastfeeding promotion."
215039070|NCT04646005|DRUG|Cemiplimab|Administered intravenously (IV) every three weeks (Q3W)
215039071|NCT04646005|BIOLOGICAL|ISA101b|Administered by subcutaneous (SC) injection on day 1, day 29, and day 50
214291224|NCT05595356|DEVICE|transcranial direct current stimulation|"Session description: An electric current of 2mA will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
214476660|NCT04311632|DRUG|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
215039072|NCT04410900|BIOLOGICAL|Wistar Rabies Virus Strain PM-1503-3M Vaccine|Given IM
214476661|NCT04311632|DRUG|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
214476662|NCT04311632|DRUG|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
214476663|NCT04311632|DRUG|ATG|Standard of Care induction therapy in solid organ transplantation
215039073|NCT04410900|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214476664|NCT06370585|DRUG|PRO-229|\- Dexpanthenol 2% and sodium hyaluronate 0.15% ophthalmic solution.
214476665|NCT06370585|DRUG|Lagricel® Ofteno PF|\- Sodium hyaluronate 0.4%. Ophthalmic solution.
214476666|NCT01736059|DRUG|CD34+ bone marrow stem cells intravitreal|
214476667|NCT06752278|DRUG|Pilocarpine|Pilocarpine is a muscarinic agonist
214476668|NCT06752278|DRUG|artificial tears|artificial tears used for the treatment of Dry eye
214476669|NCT06753578|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT); Quality of Life (QOL); Mild Cognitive Impairment (MCI); cognitive function; elderly; psychological flexibility.
215039074|NCT06313619|COMBINATION_PRODUCT|SmartAMR|"SmartAMR is a digital system including a mobile app that helps keeping record of medicine sales, sending auto-generated messages to the consumers to remind them about medicine taking time and completing doses. It also poses a symptom checker driven by artificial intelligence and a telemedicine service."
215039075|NCT06665165|DRUG|AMX0114|Antisense oligonucleotides (ASOs) are a type of medicine that treats diseases by intercepting the mRNA messages sent within the cell, resulting in fewer specific proteins being made. AMX0114 is an ASO that targets the mRNA messenger that instructs the body to create a protein called calpain-2. Calpain-2 has been linked to the degeneration and death of neurons in many neurological diseases, including people living with sporadic ALS. AMX0114 is designed to reduce the levels of calpain-2, with the goal of slowing down the process that leads to neuron injury and death.
215039076|NCT06665165|OTHER|Placebo|Placebo
215039077|NCT06524414|BIOLOGICAL|PG4|Multivalent pneumococcal conjugate vaccine
215039078|NCT06524414|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine
215039079|NCT06524414|BIOLOGICAL|15-valent pneumococcal conjugate vaccine (PCV15)|15-valent pneumococcal conjugate vaccine
215039080|NCT06816433|DRUG|Intervention D SLS-002|SLS-002 will be administered via intranasal administration (one spray per nostril, per device) at 78 mg two times per week for the first eight weeks and then once a week for the last four weeks.
215039081|NCT06816433|DRUG|Intervention D Placebo|A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.
214873227|NCT00693043|DRUG|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
214873228|NCT01233739|DRUG|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
214873229|NCT01233739|DRUG|Placebo|Administration of 2 capsules of placebo orally.
214873230|NCT05404334|DIAGNOSTIC_TEST|Androgen receptor status and BRCA mutation|Androgen receptor status by IHC and germ line BRCA mutation
214873231|NCT01708018|PROCEDURE|WATSU|"WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.~The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.~During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4)."
214873232|NCT01696279|DRUG|Lanthanum Carbonate|Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
214873233|NCT01696279|DRUG|Calcium Carbonate|Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
214873234|NCT04521387|PROCEDURE|injection therapy|The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.
214873235|NCT04521387|DRUG|Platelet Rich Plasma|Platelet rich plasma injection in the painful area of humeral epicondyle.
214873236|NCT04521387|DRUG|Corticosteroid Injection|Corticosteroid injection in the painful area of humeral epicondyle.
214873237|NCT04521387|DRUG|Hyaluronic Acid Injection|Hyaluronic acid injection in the painful area of humeral epicondyle.
214873238|NCT04521387|OTHER|Placebo Injection|Saline injection in the painful area of humeral epicondyle.
214873239|NCT04308057|PROCEDURE|Aquatic exercise|Participants belonging to Group D (sedentary group) will be randomised 1-to-1 between remaining sedentary (n=20) and following a self-managed, 8-week, aquatic-based exercise programme (n=20). The latter group will be offered an 8-week access to pool facilities. For Group D participants, all baseline assessments will be repeated at 8 weeks.
214873240|NCT06350916|BEHAVIORAL|SeamlessMD® Mobile Application|Mobile cloud-based applications (apps), such as SeamlessMD®, are readily accessible on smart phones and offer an innovative strategy to encourage and track patient adherence to recommended ERAS components pre- and postoperatively.
214476670|NCT06753578|BEHAVIORAL|standard care|standard care
214873241|NCT05378555|DRUG|Ketamine Hydrochloride|All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.
214873242|NCT02781038|BEHAVIORAL|Teaching intervention|Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
214476671|NCT04605159|BIOLOGICAL|RSV MAT|One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.
214873243|NCT02781038|BEHAVIORAL|Control|Subjects in this group will not receive the pamphlet
215039082|NCT06594770|PROCEDURE|Atraumatic Restorative Treatment|"A sharp excavator will be used to remove soft demineralized carious tissue from the patient\&#39;s primary molar 2-The molar will then be restored with capsulated Glass Ionomer in accordance to ART procedure.~3-Each capsule will be mixed for ten seconds and used for restoring teeth isolated by cotton rolls.~4-After the cement is cured, excess material will be removed with an excavator and a carver.~5-The occlusion will be tested for interferences with carbon paper. A layer of varnish coat will be applied to the surface and light-cured for 20 seconds ."
214665994|NCT01269567|PROCEDURE|Laying and management of the drain (strictly randomized arm with drainage)|At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit \< 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.
214665995|NCT01269567|PROCEDURE|No pelvic drainage|no aspiration drain at the end of intervention
214665996|NCT00622934|DRUG|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
214665997|NCT00622934|DRUG|placebo|placebo
214873244|NCT00695058|DEVICE|Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.~In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.~In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw."
214873245|NCT01881984|DRUG|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
214873246|NCT06421298|DRUG|Tafolecimab|450mg Q4W ≤6cycle
214873247|NCT06421298|DRUG|Sintilimab|200mg Q3W ≤2years
214873248|NCT06421298|DRUG|Nab paclitaxel|130mg/m² Q3W 4-6cycles
214873249|NCT06421298|DRUG|Docetaxel|75mg/m² Q3W 4-6cycles
214873250|NCT06421298|DRUG|Gemcitabine|1250mg/m² Q3W 4-6cycles
214873251|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field therapy (PEMF)|PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
214873252|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field Sham therapy|PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
214873253|NCT04366323|DRUG|ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS|Two doses of 80 million adipose-tissue derived mesenchymal stem cells
214873254|NCT04515381|OTHER|Therapeutic Touch|Therapeutic Touch
214873255|NCT04515381|OTHER|Control group|Making measurements at the beginning of the research and 4 weeks
214873256|NCT04515381|OTHER|Sham Therapeutic Touch|Sham Therapeutic Touch
214873257|NCT06079320|DRUG|Sisunatovir|Participants will receive tablets from Day 1 to Day 5
214873258|NCT06079320|DRUG|Placebo|Participants will receive matching placebo tablets from Day 1 to Day 5
214873259|NCT06851442|DRUG|TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules|Protein kinase B(AKT) inhibitors+Cyclin-dependent kinase 4/6(CDK4/6) Inhibitor+Estrogen receptor antagonists.
214873260|NCT03679676|DRUG|Omalizumab|Omalizumab is injected every 2 to 4 weeks
214873261|NCT03679676|DRUG|Dupilumab|"Dupilumab is injected every 2 weeks~combination, or placebo."
214873262|NCT03679676|OTHER|Placebo|Placebo is injected every 2 to 4 weeks
214873263|NCT04331119|DRUG|Duvelisib|SecuraBio will supply duvelisib
214873264|NCT04331119|PROCEDURE|Peripheral blood draw|-Prior to transplant, cycle 1 day 1 of duvelisib, and at the time of all imaging studies
214873265|NCT05646043|BEHAVIORAL|Physical training|Physical training consists of endurance walking and strength training. The basis for determining the number of steps per day is the baseline value of each patient. This will increase by 10-15% every week until the surgery date. The assumption of a total load increase is 120-180% compared to the baseline.
214873266|NCT05646043|BEHAVIORAL|Muscle strength training|Muscle strength training will take place using exercises to strengthen the upper and lower limbs and to strengthen the trunk. There will be a set of 5 exercises in two difficulty variants. The study subjects will perform this set 7 days a week, and will repeat the assembly a total of two times. The total time of strength training is 10 min.
214873267|NCT03239743|DEVICE|Virtual Reality|Child will wear and interact with virtual reality headset while waiting for surgery.
214873268|NCT03239743|DRUG|Midazolam|Child will receive Midazolam to help with pre-operative anxiety prior to surgery
214873269|NCT05656872|PROCEDURE|Transverse Abdominis Plane Block|Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.
214476672|NCT04605159|DRUG|Placebo|One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
214665998|NCT00501319|BEHAVIORAL|Interactive Voice Response (IVR)|Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
214665999|NCT00501319|BEHAVIORAL|Questionnaire|Questionnaires taking 20 minutes to complete.
214666000|NCT00190463|DRUG|Amphotericin B|
214666001|NCT02580734|DIETARY_SUPPLEMENT|melatonin|Cross-over randomized clinical trials
215039083|NCT06594770|PROCEDURE|Hall technique|"The procedure involves assessing the occlusion, contact points, and tooth shape. If contact points are present, orthodontic separators will be placed between the primary molars to create space for crown fitting, with the child seated upright to maintain airway safety. After 3 to 5 days, the separators will be removed, and loose plaque and debris will be cleared.~The correct crown size will be selected, ensuring it doesn't impinge on adjacent teeth, and will be filled with glass ionomer cement. The child will be instructed to bite down for two minutes to ensure proper seating. Excess cement will be removed, and contacts will be flossed. Any initial occlusal discrepancies are expected to resolve within weeks."
215039084|NCT06600971|OTHER|acupressure application|The patients in the experimental group received acupressure application for a total of 8 sessions, 2 sessions per week.
215039085|NCT03011528|DRUG|VDC-IE x2|"Week 1, 5, 9 and week 13:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
215039086|NCT03011528|DRUG|VDC-IE|"Week 1 and week 5:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
215039087|NCT03011528|DRUG|TEMIRI|"Week 9, 12, 15 and week 18:~* Temozolomide, PO, D1 to D5, 150mg/m²/d~* Irinotecan, IV, D1 to D5, 50mg/m²/d"
215039088|NCT03011528|DRUG|Consolidation BuMel|"After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~\- PBSC infusion, D0, at least 3.10\^6 CD34/kg"
215039089|NCT03011528|DRUG|Maintenance|"\* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously"
215039090|NCT03011528|PROCEDURE|Local treatment by surgery|Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added
215039091|NCT03011528|RADIATION|Local treatment by radiotherapy|Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy
215039092|NCT04726592|DRUG|Clorazepate Dipotassium|Clorazepate Dipotassium : 20 mg intravenous injection
215039093|NCT04726592|DRUG|Placebo|Placebo IV
215039094|NCT04726592|DRUG|Ketoprofen|Ketoprofen 100 mg IV
215039095|NCT04726592|DRUG|Metoclopramide|Metoclopramide 10 mg IV
215039096|NCT06858735|DRUG|Durvalumab|Given by IV
215039097|NCT06858735|DRUG|Gemcitabine|Given by IV
215039098|NCT06858735|DRUG|Cisplatin|Given by IV
215039099|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 1|Pharmaceutical form:liquid Route of administration: intramuscular
215039100|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 2|Pharmaceutical form:liquid Route of administration: intramuscular
215039101|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 3|Pharmaceutical form:liquid Route of administration: intramuscular
215039102|NCT04398706|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
215039103|NCT04398706|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
215039104|NCT04398706|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Pharmaceutical form:liquid Route of administration: intramuscular
215039105|NCT04398706|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)|Pharmaceutical form:liquid Route of administration: intramuscular
215039106|NCT04398706|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:liquid Route of administration: oral
215039107|NCT04398706|BIOLOGICAL|Hepatitis B Vaccine* [Recombinant] *as applicable|Pharmaceutical form:liquid Route of administration: intramuscular
215039108|NCT02611037|DRUG|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
215039109|NCT02611037|DRUG|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\^2).
214476673|NCT06053190|BEHAVIORAL|Sentence stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
215039110|NCT02611037|DRUG|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
215039111|NCT02611037|OTHER|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
215039112|NCT04792216|OTHER|Wild Salmon|Wild salmon fillets
215039113|NCT04792216|OTHER|Farmed Salmon|Farm salmon fillets
215039114|NCT06989580|DEVICE|BIOMONITOR IV with study software|Participants are inserted with a BIOMONITOR IV which is then turned into the investigational device by replacing the firmware with the study software.
215039115|NCT07000669|OTHER|Bilateral peribulbar block|Patients undergoing bilateral peribulbar anesthesia for cataract surgery.
215039116|NCT06995378|BEHAVIORAL|Lab Result Communication Tool|A behavioral intervention delivered through a personalized EHR-integrated lab result communication tool designed to improve emotional and cognitive responses to lab results among adults aged 65+. The tool applies behavioral science principles such as risk personalization, simplified messaging, and visual framing to reduce patient anxiety, enhance understanding, and support informed decision-making.
215039117|NCT07004257|DIETARY_SUPPLEMENT|tributyrin|tributyrin (875 mg, BID)
215039118|NCT07004348|OTHER|Animation group will receive 4 sessions of animation as education media as intervention.|Wait list group will receive the conventional session of education
215039119|NCT07003191|DRUG|Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)|First-time treatment with Metformin Hydrochloride and Empagliflozin Tablets (metformin 500mg and empagliflozin 5mg per table) for at least 6 months
215039120|NCT07003204|PROCEDURE|medical thoracoscopy|pleural fluid aspiration and cellular analysis
215039121|NCT07003854|DEVICE|Mandibular advancement device|Custom made titrable bi-bloc MADs worn during sleep to stabilize airway and treat obstructive sleep apnea
215039122|NCT07004829|BEHAVIORAL|Exercise counselling via instant messaging|The 12 weeks of messages will be sent by a trained counsellor. At baseline, participants will select their desired IM application (WhatsApp/WeChat), timing of messages (morning/noon/afternoon), message format (audio/text), and language style (spoken/written). The message library, established in the HMRF-funded study, consists of messages in text and pre-recorded voice message formats, images, videos, and stickers. Each week starts with messages on factual information and ends with a question to initiate conversations to clear any queries; counsellor will provide real-time replies. The 12-week messages are structured based on the M-PAC framework.
215039123|NCT07003659|OTHER|Tele-Yoga|This program consisted of diaphragmatic breathing, pranayama techniques consisting of nadi sodhana and ujjai, yoga poses consisting of sukhasana, bharadvajasana, marjaryasana - bitilasana, bhujaganasana, salabhasana, kapotasana, hasta uttanasana, virabhadrasana, adho mukha svanasana, bhujangasana. The exercises were carried out in a way that they would be followed up with an exercise diary in which they would take notes on continuing these exercises throughout the tele-yoga practice period, and reminder messages for the exercises were sent by the researchers to the WhatsApp group opened with the participants who participated in the study and were included in the exercise group.
215039124|NCT06543862|OTHER|CADx (AI) system|The CADx system will be used to predict the histopathology of the polyp detected.
215039125|NCT07003945|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation|With the real-time guidance of TTE, a radiofrequency electrode needle was percutaneously inserted via the transapical intramyocardial approach into the hypertrophied septum for thermal ablation. Intraoperative TTE and 12-lead electrocardiographic monitoring were employed to assess the ablation extent and prevent vascular and cardiac conduction bundle injury. The success of ablation was confirmed by evaluating contrast medium perfusion defects in the ablated areas and comparing them with the preprocedural hypertrophied septum.
215039126|NCT07003633|PROCEDURE|PENG block with 0.25% bupivacaine guided by ultrasound.|PENG (Pericapsular nerve block) is a peripheral nerve block which is performed for patients with hip fractures aimed to prevent preoperative and postoperative pain. It is performed under sterile conditions under ultrasound guideance.
215039127|NCT06151483|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
215039128|NCT06151483|OTHER|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
215039129|NCT07005050|DEVICE|RPD|Renal Pelvic Denervation
215039130|NCT07005050|DRUG|Active hypertension medical therapy|Prespecified two medication regimen for control of hypertension
215039131|NCT07002879|PROCEDURE|dry needle|"An 18-gauge needle was first used to fenestrate the common extensor tendon and lateral periosteum. Once adequate anesthesia was confirmed, an 18-gauge needle was inserted along the tendon's longitudinal axis (without exiting the skin) and advanced in a peppering motion 40 to 50 passes from superficial to deep layers over approximately two minutes"
214873270|NCT05656872|PROCEDURE|Ilioinguinal-iliohypogastric block|Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
214873271|NCT00873457|DRUG|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
214873272|NCT05046964|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Radical-7 Pulse CO-Oximeter uses photospectroscopy to non-invasively measure the total hemoglobin (SpHb) in a patient's blood throughout their C-section.
214873273|NCT01625832|PROCEDURE|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
214873274|NCT02176785|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
214873275|NCT01269541|DRUG|Mupirocin|Topical in the nose 3 times daily for 5 days
214873276|NCT01269541|DRUG|Rifampin+Clindamycine or Trimehoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
214873277|NCT02687217|DRUG|oxygen|"Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.~Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery."
215039132|NCT07002879|PROCEDURE|Platelet Rich Plasma|A 15 mL peripheral blood sample was drawn and centrifuged at 3 000 rpm for 3 minutes. Approximately 2 mL of PRP was aspirated directly from the buffy coat and injected into the epicondylar region under ultrasound guidance.
215039133|NCT05509127|DRUG|Modified universal adhesive|Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
215039134|NCT05509127|DRUG|Conventional universal adhesive|Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
215039135|NCT06873724|DRUG|SPY003-207|Experimental
215039136|NCT06873724|OTHER|Placebo|Placebo
214873278|NCT04106661|OTHER|Tai Chi|Physical activity requiring slow, controlled whole body movement and weight shifting.
215039137|NCT05968963|BEHAVIORAL|Mindfulness-based Music Therapy (MBMT)|Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment.
215039138|NCT05968963|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually.
215039139|NCT04264260|DRUG|Colchicine Tablets|three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
214873279|NCT04514432|OTHER|Music|If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
214873280|NCT04084457|DIETARY_SUPPLEMENT|Wild Blueberry powder|Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
214873281|NCT04084457|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment matched for fibre and vitamin C
214873282|NCT00074828|DRUG|LY517717|
214873283|NCT00074828|DRUG|enoxaparin|
214873284|NCT06816758|OTHER|Routine Care for Corrosive Esophagitis|This is an observational study, so participants are not assigned interventions. However, the study investigates the outcomes of patients diagnosed with corrosive esophagitis who received routine clinical care. The exposure of interest includes diagnostic and treatment procedures such as endoscopic evaluation (Zargar classification), proton pump inhibitors, corticosteroid therapy, and surgical interventions for complications like strictures. The outcomes and clinical data collected reflect routine care practices over 26 years.
214873285|NCT03503864|DRUG|Arsenic Trioxide|Arsenic trioxide（ATO） is administered 0.16mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10. Nine cycles at most of ATO-combined chemotherapy were applied in the whole scheme.
214873286|NCT06965738|PROCEDURE|Buccal fat reconstruction|Ipsilateral buccal fat rotation flap for reconstruction of lateral oropharyngectomy defect
214873287|NCT06965738|PROCEDURE|No buccal fat reconstruction|No reconstruction of lateral oropharyngectomy defect
214873288|NCT06972030|BEHAVIORAL|Motivational interviewing|After the pre-test, motivational interviewing-based training consisting of six sessions, once a week, will be applied to the students in the experimental group. A pre-test, post-test (after 6 weeks) and control test will be applied to both groups. At the end of the training, training materials will be shared with the students.
214873289|NCT06970782|DRUG|Vebreltinib|Subjects will receive Vebreltinib Enteric-coated Capsule orally twice per day (BID).
214873290|NCT06970782|DRUG|PLB1004|Subjects will receive PLB1004 80mg orally once per day (QD).
214873291|NCT06970782|DRUG|Pemetrexed plus Carboplatin or Cisplatin|Subjects randomized to the control group received pemetrexed 500 mg/m² + platinum-based chemotherapy (carboplatin AUC 5 or cisplatin 75 mg/m²) via intravenous infusion for 4-6 cycles (determined by the investigator) as initial therapy, followed by pemetrexed maintenance therapy (500 mg/m²) until disease progression, intolerable toxicity, initiation of new antitumor therapy, death, loss to follow-up, or other treatment-terminating conditions (whichever occurred first).
214873292|NCT03504163|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.
214873293|NCT03504163|DRUG|Bacillus Calmette-Guérin (BCG)|Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
214873294|NCT05550532|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
214873295|NCT05550532|OTHER|Placebo|Placebo tablet will be administered orally.
214873296|NCT06243601|BIOLOGICAL|Aloe vera Gel|A fresh aloe vera (Aloe Barbadensis) leaf will be plucked from the plant. The leaf will be washed with normal saline, peeled with scalpel and the inner gel will be blended in a blender to convert it into a watery consistency. The solution will be stored in an autoclaved flask.
214873297|NCT03898908|DRUG|encorafenib|"Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death."
214873298|NCT03898908|DRUG|binimetinib|Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
214873299|NCT03898908|RADIATION|Whole brain radiation therapy|"The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.~Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks."
215039140|NCT06879210|DEVICE|Mobile device.(phone)|Develop a mobile device \[Disease Assistance Consultation\] to help patients promptly understand their disease and how to care for it. After a 4-week trial period, conduct interviews with participants to determine whether using the mobile device can increase participants' knowledge and improve the quality of healthcare.
215039141|NCT07032636|BEHAVIORAL|Crisis Intervention - The First Line Leaders (FLL) program will utilize templated guides developed with stakeholders from the Idaho Army National Guard (ARNG), known as the Total Health Action Plan (T|The Investigators are developing training programs for soldiers and leaders to enhance their communication skills, problem-solving abilities, and approachability. They will be randomized to one of three different groups.
215039142|NCT07033195|DEVICE|Skills-based Virtual Reality Therapy|"1. A 34-minute education video session on the science behind chronic pain and the scientific principles of the therapy.~2. VR skills-based therapy: a virtual reality therapy consisting of different psychological training exercises"
214666002|NCT01576081|DEVICE|HEPHAISTOS|HEPHAISTOS unloading orthotic
214666003|NCT00445783|GENETIC|gene expression analysis|
214666004|NCT00445783|GENETIC|mutation analysis|
214666005|NCT00445783|OTHER|immunohistochemistry staining method|
214666006|NCT00445783|OTHER|laboratory biomarker analysis|
214666007|NCT00445783|PROCEDURE|examination|
214666008|NCT00445783|PROCEDURE|mutation carrier screening|
214873300|NCT03898908|RADIATION|Radiosurgery/stereotactic radiosurgery|"Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.~Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.~For GTV \> 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week."
215039143|NCT07033195|DEVICE|Distraction-based Virtual Reality Therapy|1\. A 7-minute education video session on the science behind pain-focused attention and distraction. 2. VR distraction-based therapy: a virtual reality therapy that encourages passive attention and minimizes external cognitive demands.
215039144|NCT07135869|DIAGNOSTIC_TEST|One minute sit-to-stand test|The one minute sit-to-stand test will be used as acute fatigue protocol to generate fatigue.
215039145|NCT05422612|DRUG|Intervention A Fluoxetine Hydrochloride (HCl)|Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
215039146|NCT05422612|DRUG|Intervention A Placebo|A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
215039147|NCT05422612|DRUG|Intervention B Vilazodone Hydrochloride (HCl)|Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
215039148|NCT05422612|DRUG|Intervention B Placebo|A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
215039149|NCT05422612|DRUG|Intervention C Daridorexant|Daridorexant will be administered 50 mg once daily.
215039150|NCT05422612|DRUG|Intervention C Placebo|A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
215039151|NCT05422612|DRUG|Intervention D SLS-002|• SLS-002 will be administered via intranasal administration (one spray per nostril, per device) at 78 mg two times per week for the first eight weeks and then once a week for the last four weeks.
215039152|NCT05422612|DRUG|Intervention D Placebo|A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.
214476674|NCT06053190|BEHAVIORAL|Speaking style|The sentences will be presented either in A. conversational speaking style, or B. hyper-articulated clear speech style. Clear and conversational speech samples will be elicited from a single male talker. In the conversational speech condition, which will be recorded first, the talker will be instructed to read the sentences as they would in everyday conversation. In the clear speech condition, the talker will be instructed to produce the sentences as if they would if they were talking to a person with hearing loss.
214476675|NCT05387525|DRUG|Tirbanibulin (Klisyri®) 10 mg/g ointment|Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm\^2 of the face or scalp with Actinic Keratosis (AK).
214476676|NCT05387525|DRUG|Diclofenac Sodium 3% Gel|Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
214476677|NCT04565834|GENETIC|SNP (single nucleotide polymorphism) genotyping|"We use TaqMan technique to perform SNP genotyping. The PCR reactions are carried out using the Roche Light Cycler 480 thermal cycler following the protocol recommended by Thermo Fisher Scientific. Then, replication of 10% of the samples is carried out."
214476678|NCT06514482|DIAGNOSTIC_TEST|Diagnosis|Diagnosis
214666009|NCT00445783|PROCEDURE|study of high risk factors|
215039153|NCT06878144|BEHAVIORAL|Mucormycosis|Tell the study team about any symptoms or side effects you have, follow study directions, and come to all study appointments (or contact the study team to reschedule).
215039154|NCT06893419|OTHER|Geriatric telemanagement|The geriatrician will coordinate, through a telemedicine consultation, a team consisting of the general practitioner and the nursing home staff. The geriatrician will review the diagnoses, treatments, and results of the comprehensive geriatric assessment performed by the nursing home staff. Subsequently, the entire team will conduct a multidisciplinary conference.
215039155|NCT04558229|OTHER|Additional Standardized Counseling|Research staff will follow a script designed to give unbiased, medically accurate information regarding bleeding changes that may occur with use of a contraceptive ENG implant.
215039156|NCT06762002|OTHER|blood sample|After signature of consent form,blood samples will be collected for full blood cell count;classical autoimmune investigations, immunophenotyping;auto-Abs against type IIFNs, other cytokines, or other target proteins ,Genetic explorations by whole-exome or whole-genome sequencing;Biobanking
215039157|NCT07065617|DRUG|[14C]BI 1819479|\[14C\]BI 1819479
215039158|NCT07065617|DRUG|BI 1819479|BI 1819479
215039159|NCT07065617|DRUG|BI 1819479 (C-14)|BI 1819479 mixed with \[14C\]BI 1819479
215039160|NCT04577404|DRUG|MT-1186|Treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period up to 96 weeks of treatment or until the drug is commercially available in that country.
215039161|NCT00775671|DRUG|placebo|Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
215039162|NCT00775671|DRUG|Nebivolol|Nebivolol 5 mg by mouth daily for 12 weeks.
215039163|NCT00775671|DRUG|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
215039164|NCT04066829|BEHAVIORAL|Default setting intervention|The new default settings will be implemented only for patients in the experimental arm.
214476679|NCT01982890|OTHER|Control|No intervention as this group is simply followed prospectively.
214873301|NCT06975085|BEHAVIORAL|Presentation of a personal breast cancer risk estimate|Participants answer questions that are used to calculate their personal breast cancer risk using the Gail Model. This risk estimate is presented to participants using written text and an icon array.
214873302|NCT06396858|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
214873303|NCT06396858|DRUG|Colchicine 0.5 MG|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
214873304|NCT06396858|DRUG|Placebo Rivaroxaban|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
215039165|NCT05690841|DRUG|Focal Mass Drug Administration (fMDA)|"Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by regular intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for \>= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for \>= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing)."
214291225|NCT05595356|DEVICE|sham transcranial direct current stimulation|"Session description: Three ramps of 30 seconds of current will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
214666010|NCT04648371|OTHER|Cognitive Remediation and Transcranial Direct Current Stimulation|"Cognitive Remediation (CR) is a well-established psychosocial group intervention that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.~Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation method that can be safely administered to awake outpatients. It does not require general anesthesia or surgical implantation. It utilizes low intensity electrical current (e.g., 2 mA) either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode."
214873305|NCT06396858|DRUG|Placebo Colchicine|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
214873306|NCT05436028|DEVICE|Transcatheter Tricuspid Valve Intervention|"Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb).~Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement."
214873307|NCT06574347|DRUG|Vebreltinib|Subjects will receive Vebreltinib orally twice per day (BID).
214873308|NCT06574347|DRUG|Osimertinib|Subjects will receive Osimertinib 80mg orally once per day (QD).
214873309|NCT06574347|DRUG|PLB1004|Subjects will receive PLB1004 80mg orally once per day (QD).
215039166|NCT07065968|DRUG|Teriflunomide|Teriflunomide 14 mg orally once daily for 24 weeks.
215039167|NCT07065968|DRUG|Dexamethasone|Dexamethasone 40 mg orally once daily for four consecutive days.
215039168|NCT06194799|DRUG|ACP-204|ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
215039169|NCT06566079|DRUG|ISM6331|"Dosage form: Capsule for oral administration.~Frequency of administration: Once daily overall of treatment."
215039170|NCT06456541|OTHER|Experimental Extensively Hydrolyzed Formula|Experimental powder formula
215039171|NCT06456541|OTHER|Placebo Extensively Hydrolyzed Formula|Placebo powder formula
215039172|NCT05423717|DRUG|Daridorexant 10 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
215039173|NCT05423717|DRUG|Daridorexant 25 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
215039174|NCT05423717|DRUG|Daridorexant 50 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
214666011|NCT05027269|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
214873310|NCT04512365|DRUG|Placebo oral capsule|A capsule that contains only dextrose filler administered during the first or second laboratory visit.
214873311|NCT04512365|DRUG|THC|A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
214873312|NCT06213233|DRUG|Placebo|Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
214873313|NCT06213233|DRUG|Cannabidiol|Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
214873314|NCT05830838|PROCEDURE|Computed Tomography|Undergo PET/CT
214873315|NCT05830838|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo daily adaptive online replanning for SBRT
214873316|NCT05830838|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214873317|NCT05830838|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214873318|NCT05830838|OTHER|Questionnaire Administration|Ancillary studies
215039175|NCT05423717|DRUG|Placebo|Placebo will be taken orally, once daily in the evening during the treatment period.
214873319|NCT05830838|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215039176|NCT06654323|BEHAVIORAL|Intensive Behavioral Lifestyle Modification|Participants in all arms will receive visits with their child's primary care provider (4 visits, 1 hour total), on-demand web-based learning modules that focus on building skills and knowledge in health behaviors (7 hours), and community resource counseling sessions delivered by a social worker or similar healthcare professional (4 sessions, 2 hours total). The difference between arms will be in the frequency and duration of personalized nutrition counseling delivered by a registered dietitian or similar healthcare professional: 16 sessions (60 minutes per session), 12 sessions (60 minutes per session), 9 sessions (60 minutes per session), 8 sessions (45 minutes per session), or 6 sessions (30 minutes per session).
214873320|NCT06509477|DEVICE|Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
214873321|NCT06509477|DEVICE|Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
214873322|NCT02639052|DRUG|Botox|10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
214873323|NCT02639052|DRUG|Saline|10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.
214873324|NCT04926948|OTHER|Immunotherapy|Immunotherapy
214873325|NCT04926948|OTHER|Quality-of-Life Assessment|Ancillary studies
214873326|NCT04926948|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215039177|NCT03499743|DRUG|hyoscine butyl bromide|intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion
215039178|NCT03499743|DRUG|Celecoxib 200mg|Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
215039179|NCT03499743|DRUG|Placebo Oral Tablet|a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
215039180|NCT03370315|OTHER|Dance Program|The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.
215039181|NCT03370315|OTHER|Walking Program|The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
215039182|NCT02719509|PROCEDURE|Cardiac Ultrasound|
215039183|NCT04237584|DRUG|Enzalutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in ARB (enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
215039184|NCT04237584|DRUG|Lead-in Enzalutamide followed by Radium-223/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
215039185|NCT04237584|DRUG|Lead-in Enzalutamide followed by Placebo/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
215039186|NCT04237584|DRUG|Darolutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in darolutamide that will continue after double-blind randomization to radium-223 or placebo.
215039187|NCT04237584|DRUG|Lead-in Darolutamide followed by Radium-223/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
215039188|NCT04237584|DRUG|Lead-in Darolutamide followed by Placebo/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
215039189|NCT06831422|DEVICE|Povidone-Iodine|Following electrocautery opening of the dermal layer, patients in the povidine-iodine group (Group B) will receive application of 10% sterile povidone-iodine along the entire dermis using a soaked surgical sponge. Approximately 120 seconds after application of betadine, a culture of the dermis will then be taken by dragging the culture swab along the length of the exposed dermis (dermis culture).
215039190|NCT06831422|DEVICE|Hydrogen Peroxide|Following electrocautery opening of the dermal layer, patients in the hydrogen peroxide group (Group A) will receive application of 3% sterile-filtered hydrogen peroxide along the entire dermis using a soaked surgical sponge. Approximately 120 seconds after application of hydrogen peroxide a culture of the dermis will then be taken by dragging the culture swab along the length of the exposed dermis (dermis culture).
215039191|NCT06831422|DEVICE|Xperience Antimicrobial Wash|Following electrocautery opening of the dermal layer, patients in the patients in the Xperience group (Group C) will receive application of the Xperience antimicrobial wash (NextScience, Jacksonville, FL) (32.5 g/L citric acid, 31.3 g/L sodium citrate, and 1.00 g/L sodium lauryl sulfate in sterile water) along the entire dermis using a soaked surgical sponge. Approximately 120 seconds after application of Xperience, a culture of the dermis will then be taken by dragging the culture swab along the length of the exposed dermis (dermis culture).
214873327|NCT00399256|DRUG|Acetylcysteine|
214873328|NCT00399256|DRUG|Zinc|
214873329|NCT04975893|BIOLOGICAL|mRNA-1647|No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.
214873330|NCT04975893|OTHER|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
214873331|NCT05107141|PROCEDURE|Ridge preservation|Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane
214873332|NCT05107141|DEVICE|bone graft plus a collagen membrane|
214873333|NCT00979914|OTHER|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
214873334|NCT02676362|OTHER|Gingival crevicular fluid collection with filter paper|Gingival Crevicular Fluid Dynamics
215039192|NCT06831422|DIAGNOSTIC_TEST|Bacterial Cultures|Four C. Acnes cultures will be obtained for every patient. Once the skin has dried, a culture swab will be applied along the planned incision for all patients (skin culture). Approximately 120 seconds after application of Xperience, hydrogen peroxide or betadine, or after initial incision in the case of the control group, a culture of the dermis will then taken by dragging the culture swab along the length of the exposed dermis (dermis culture). Once the glenohumeral joint is exposed, the surgeon will apply new surgical gloves, and a culture swab will be placed into the joint and along the humeral head (glenohumeral joint culture). An additional culture will then be taken from the air in the operative suite (air culture)
215039193|NCT06831422|PROCEDURE|Shoulder Arthroplasty|All patients will undergo hemiarthroplasty, anatomic total shoulder arthroplasty, or reverse total shoulder arthroplasty in accordance with the appropriate indications and enrollment in this study.
215039194|NCT06815575|DRUG|RC220|Administered by intravenous infusion over 60 minutes.
215039195|NCT06815575|DRUG|Doxorubicin (Adriamycin)|60 mg/m2 administered by intravenous infusion over 10 minutes following adminstration of intravenous RC220 on Day 1 of the combination cycles.
215039196|NCT01092221|DRUG|Allopurinol|Allopurinol 1 capsule 300 mg, BID
215039197|NCT01092221|DRUG|Placebo|Placebo 1 capsule, 300 mg, BID
215039198|NCT03586973|DRUG|Cabozantinib|Cabozantinib tablet
215039199|NCT06262542|OTHER|moxibustion and Chinese herbal medicine group|"Apply 15g of Chinese herbal powder (a mixture of scientific Chinese herbs: Jiseng Shenqi Pill, Xuanfu Daizheshi Tang, and Wendi Tang mixed in a 1:1:1 ratio, mixed with water to form a paste) to the Shénquè acupoint. Then, use 3g of 80:1 moxa wool placed in a moxibustion box for moxibustion on the lower abdomen (between the Guānyuán, Zhōngjí, and Shénquè acupoints) for 1 hour, once a day, six times a week, for a total of 12 sessions.~sham moxibustion and placebo herbal medicine group): Same acupoint frequency, but use 15g of flour instead of herbal paste and replace moxibustion with a heated nightlight for sham moxibustion."
215039200|NCT06811584|DEVICE|Peanut ball|"Participants will be provided with a mani ball, which will be covered by a cover provided by the investigator. This cover will be changed for each patient. The ball will be placed between the participant's knees, and she will be allowed to use it at least every two hours for a period of 30 minutes. Participants will also have the option to use the balloon more frequently if they wish. Balloon use will be discontinued when the cervical os reaches 10 cm dilation or when the participant is ready to begin the pushing process.~* The positions to be performed with the peanut ball will be:~* Side lying~* Bent position~* Semi-sitting position~* Taylor position."
215039201|NCT06672822|DRUG|Sodium Thiosulfate (STS)|Depending on the size of the calcinosis lesion, 1-5ml of STS (250mg/ml) will be used for injection under ultrasound guidance.
214666012|NCT05027269|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
214666013|NCT03940105|BEHAVIORAL|Packout|Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
215039202|NCT07073781|DIETARY_SUPPLEMENT|Lab4p Probiotic Consortium|"The investigational product in this study is Lab4P, a patented multi-strain probiotic consortium formulated as a food supplement and supplied in capsule form. Each daily dose contains a total of 5 × 10¹⁰ CFU of live bacteria, comprising five strains: Lactobacillus acidophilus CUL60 and CUL21, Lactobacillus plantarum CUL66, Bifidobacterium bifidum CUL20, and Bifidobacterium animalis subsp. lactis CUL34. In addition to probiotics, each capsule also contains three micronutrients at 100-200% of the recommended daily intake: Vitamin D (10 µg; 200%), Vitamin C (80 mg; 100%), and Zinc (10 mg; 100%).~Lab4P is a marketed, human-approved product manufactured by Cultech Ltd. (Port Talbot, UK) and is classified as a food supplement, available for purchase without prescription. Both the active product and placebo will be identically packaged to maintain blinding."
215039203|NCT07073781|OTHER|Placebo|Placebo capsules are composed of microcrystalline cellulose, and are identical in appearance to the test product.
215039204|NCT00122889|DRUG|Garlic powder with high allicin content|
215039205|NCT00122889|DRUG|Garlic powder with low allicin content|
215039206|NCT00122889|DRUG|Garlic oil|
215039207|NCT00122889|DRUG|Aged garlic|
215039208|NCT05647122|DRUG|AZD9592|Varying doses of AZD9592
215039209|NCT05647122|DRUG|Osimertinib|tablets administered orally
215039210|NCT05647122|DRUG|5-Fluorouracil (5-FU)|IV infusion
215039211|NCT05647122|DRUG|Leucovorin|IV infusion
215039212|NCT05647122|DRUG|Bevacizumab|IV infusion
215039213|NCT06696768|BIOLOGICAL|Bevacizumab|Given IV
215039214|NCT06696768|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
215039215|NCT06696768|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214666014|NCT06498908|DRUG|Nitrous oxide|Nitrous oxide, commonly known as laughing gas, is a colorless, non-flammable gas with a slightly sweet odor, used for its analgesic and anesthetic properties in medical and dental procedures to provide pain relief and sedation.
214666015|NCT06498908|DRUG|Oxygen|Oxygen is a colorless, odorless gas essential for human respiration and used medically to treat conditions resulting from low oxygen levels in the blood. In this trial Oxygen is being used as a placebo.
214873335|NCT04672486|BEHAVIORAL|POD Adventures|"Participants in the intervention arm will receive information about local services/national helplines and a brief problem-solving intervention that is delivered through a smartphone app with telephone guidance from a lay counsellor. The intervention is grounded in stress-coping theory, with a technical focus on practical problem solving. The emphasis on problem solving reflects the primacy of psychosocial stressors in adolescent help-seeking. Moreover, problem-solving is among the most commonly used practice elements in evidence-based psychological interventions for children and adolescents globally.~The content of the app comprises two sections: 'Adventures' which teaches problem-solving concepts and methods through contextually-appropriate games; and 'My POD' which scaffolds the student through the application of step-by-step problem-solving procedures to their own prioritized problems."
214666016|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10\^5 CAR-20/19-T cells/kg (starting dose level)"
214666017|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10\^5 CAR-20/19-T cells/kg"
214666018|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10\^6 cells/kg (single infusion)"
214666019|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.
214666020|NCT04036760|BEHAVIORAL|Research transitional care coordination|Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
214666021|NCT02642861|DRUG|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
214666022|NCT02642861|DRUG|Calcium Carbonate|Calcium carbonate for 2 weeks
214666023|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
214873336|NCT03379389|DRUG|Methenamine + Methylthioninium|Methenamine + Methylthioninium
214873337|NCT03379389|DRUG|Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Methenamine + Methylthioninium + Acriflavine + Atropa belladona
214873338|NCT03379389|DRUG|Antibiotics|Antibiotics based on individual subjects urine culture / antibiogram
214873339|NCT01455363|PROCEDURE|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
214873340|NCT01455363|OTHER|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
214873341|NCT01455363|OTHER|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
214873342|NCT04791423|BIOLOGICAL|GRAd-COV2|GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues
214873343|NCT04791423|OTHER|Placebo|Saline solution
214873344|NCT03938714|PROCEDURE|Hemorrhoidectomy|Excision of third and fourth degree hemorrhoids
214873345|NCT02834650|OTHER|Cardiac MRI with contrast|Cardiac MRI
214873346|NCT02834650|OTHER|Cardiac MRI without contrast|Cardiac MRI
214873347|NCT02834650|OTHER|Blood Test|Hematocrit, Creatinine, Troponin, BNP
214873348|NCT02834650|OTHER|Heart Rate|Holter Monitor
214873349|NCT02834650|OTHER|Pulmonary Function Test|Pulmonary Function Test
214873350|NCT02834650|OTHER|Genetic Testing|Genetic Testing
214873351|NCT02834650|OTHER|Repeat MRI scan|Repeat MRI scan
214873352|NCT00732550|PROCEDURE|Single trocar cholecystectomy|Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
214873353|NCT00732550|PROCEDURE|Standard laparoscopic cholecystectomy|Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
214873354|NCT04838548|DRUG|MRG003|Administered intravenously
214873355|NCT02730351|DRUG|Fluticasone furoate/ Vilanterol 100 mcg/25 mcg|FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening
214873356|NCT02730351|DRUG|Fluticasone propionate 250 mcg|FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening
214873357|NCT02730351|DRUG|Placebo via ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler once daily in the evening
214873358|NCT02730351|DRUG|Placebo via DISKUS / ACCUHALER|Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
214873359|NCT05532371|OTHER|Aerobic exercise training combined with lower limb strengthening|The participants performed aerobic exercise training and lower limb strengthening during this intervention.
214873360|NCT05532371|OTHER|Dual-task training combined with lower limb strengthening group (DG)|The participants performed dual-task training combined with lower limb strengthening during this intervention.
214873361|NCT05532371|OTHER|Aerobic exercise training combined with dual-task training and lower limb strengthening|The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
214873362|NCT05532371|OTHER|Only lower limb strengthening group (CG)|The participants performed only lower limb strengthening group during this intervention.
214873363|NCT05739552|OTHER|Telerehabilitation program|Application of customised respiratory and/or motor rehabilitation exercises to be carried out directly at the patients' home after hospital discharge in order to evaluate its effects.
214873364|NCT02686645|BIOLOGICAL|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
214873365|NCT02686645|DRUG|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
214873366|NCT02686645|DRUG|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
214873367|NCT02686645|DRUG|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
214873368|NCT04955535|PROCEDURE|Arthroscopic synovectomy|Arthroscopic synovectomy
214873369|NCT03822065|DRUG|LY03005|80 mg oral tablet single dose
214873370|NCT00063219|DRUG|MAC-321|
215039216|NCT06696768|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
215039217|NCT06696768|BIOLOGICAL|Emavusertib|Given PO
214873371|NCT02496936|OTHER|SFA|High saturated fatty acid/SFA oil source
215039218|NCT06696768|DRUG|Fluorouracil|Given IV
215039219|NCT06696768|DRUG|Leucovorin Calcium|Given IV
215039220|NCT06696768|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215039221|NCT06696768|DRUG|Oxaliplatin|Given IV
215039222|NCT06696768|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215039223|NCT04885621|DIETARY_SUPPLEMENT|nutrisystem-D|Nutrisystem meal replacements and Glytec glucomander-outpatient algorithm for insulin management decisions
215039224|NCT06752551|BEHAVIORAL|Apprehension-based training|"This intervention is comprised of the 3 phases:~Static phase - Isometric (static) exercises performed in progressively greater shoulder apprehension (instability) provoking conditions Dynamic phase: Isotonic (dynamic) exercises using shoulder apprehension-provoking movement patterns at a gradually increasing pace of movement.~Neurocognitive phase: Dynamic phase exercises are continued at a high pace with the addition of cognitive tasks (distractions).~The intervention is guided by a physical therapist and includes up to 8 individual (one on one) sessions. In each session the physical therapist assesses exercise performance quality and when appropriate progresses exercise intensity and/or phase. Patients are expected to perform home exercises according to their phase of the program on a daily basis in between physical therapy sessions."
215039225|NCT06752551|BEHAVIORAL|Standard physical therapy|Standard physical will be provided based on the assessment and judgment of the physical therapist. Intervention may include active exercises for increased shoulder mobility, muscle strength and neuromuscular control. Intervention may also include manual therapies such as massage, soft-tissue and joint mobilizations, dry needling, and electrophysiological modalities. No more than 8 individual sessions with a physical therapist will be provided over the course of treatment with some form of a home exercise program in between.
215039226|NCT00152438|DRUG|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
215039227|NCT00152438|OTHER|Placebo|3 identical placebo pills daily, no active ingredient.
214873372|NCT02496936|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
214873373|NCT02496936|OTHER|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
214873374|NCT02496936|OTHER|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
215039228|NCT06792799|BIOLOGICAL|anti-CD19/BCMA CAR NK cells (KN5601)|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5601) will infused in each group using the 3 + 3 dose-escalation strategy."
215039229|NCT05475366|OTHER|Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC|Formalin-Fixed Paraffin-Embedded (FFPE) samples will be centralized in which nucleic acids extraction (DNA+RNA) and FFPE-compatible RNA-sequencing will be performed in real-time (≤28 days). RNAseq reads will be processed and all 5 transcriptomic signatures will be applied for prediction of response to 5FU, oxaliplatin, irinotecan, gemcitabine and taxane. In addition, biomarkers status will be obtained for all patients as part of good clinical practice.
215039230|NCT05475366|OTHER|Biomarkers of tumor signatures (translational studies)|Blood (serum and plasma) will be drawn at baseline, week 8, and tumor progression in order to look for surrogate biomarkers of tumor signatures in liquid biopsy
215039231|NCT06523231|BIOLOGICAL|Shigella4V2|Adjuvanted Shigella4V2 administrated at 2 different doses: low and high.
215039232|NCT06523231|BIOLOGICAL|MenACWY|Control vaccine
215039233|NCT05466383|BEHAVIORAL|Exercise|Exercise rehabilitation with Schroth method
215039234|NCT05466383|DEVICE|Brace|Wear an orthopedic brace
215039235|NCT06846359|BEHAVIORAL|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
215039236|NCT06846359|BEHAVIORAL|Educational module|self-guided online module reviewing chronic GI conditions, pathophysiology, and alternative treatment options.
214873375|NCT02496936|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
215039237|NCT05821972|DRUG|Nebulization of dexmedetomidine and ketamine|Pre-operative nebulization of dexmedetomidine and ketamine
214291226|NCT05595356|DEVICE|run-in sham transcranial direct current stimulation|In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.
215039238|NCT05821972|DRUG|Nebulization of dexmedetomidine|Pre-operative nebulization of dexmedetomidine
215039239|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
214291227|NCT05595356|BEHAVIORAL|Psychoeducation video|Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.
214291228|NCT05595356|BEHAVIORAL|Tutorial video|Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
214291229|NCT00543556|DRUG|MK0767|
214873376|NCT00838435|DRUG|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
214873377|NCT01922804|DIETARY_SUPPLEMENT|K2 vitamin|K2 vitamin tablet
214873378|NCT01922804|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
214873379|NCT02747550|PROCEDURE|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
214873380|NCT02747550|PROCEDURE|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
215039240|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
214873381|NCT04731753|DEVICE|mechanical debridement|The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
215039241|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
215039242|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
215039243|NCT07094997|OTHER|Guidline-basaed massage therapy|Massage protocol based on guidelines from the Polish Society of Physiotherapy, the Polish Society of Family Medicine, the College of Family Physicians in Poland, and the European Rural and Isolated Practitioners
215039244|NCT07094997|OTHER|Swedish massage|A classical form of therapeutic massage that uses a combination of long, flowing strokes, kneading, friction, tapping, and gentle stretching to promote relaxation, improve circulation, and reduce muscle tension. It is typically performed using oil or lotion to reduce friction on the skin. Techniques are applied with light to moderate pressure and are designed to enhance general well-being and support recovery from muscular discomfort or stress
215039245|NCT07096453|DRUG|Cytogam|Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduces CMV in blood.
215039246|NCT03423979|DEVICE|Optilume™ BPH Prostatic DCB Dilation Catheter|BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
215039247|NCT03423979|DRUG|Paclitaxel|paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
214291230|NCT00656344|OTHER|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
215039248|NCT06908577|DRUG|Tozorakimab|Tozorakimab will be administered as a single SC dose using an AI or APFS device on Day 1.
215039249|NCT06908577|DEVICE|Autoinjector (AI) Device|AI device will be used to administer single SC dose of tozorakimab on Day 1.
215039250|NCT06908577|DEVICE|Accessorised Prefilled Syringe (APFS) Device|APFS device will be used to administer single SC dose of tozorakimab on Day 1.
215039251|NCT02760342|DRUG|peficitinib|Oral
215039252|NCT02760342|DRUG|Metformin|Oral
215039253|NCT06909253|DRUG|Ravulizumab|Ravulizumab, concentrate for solution for infusion
215039254|NCT07089511|OTHER|CB3P-ED + 0.1% cyclosporine eye drops|Combination of CB3P-ED + 0.1% cyclosporine eye drops
214291231|NCT05667545|DRUG|Peptide|it is about synthetic protein acting on tooth structure help information apatite crystals
214873382|NCT06513156|BEHAVIORAL|Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)|Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.
215039255|NCT07089511|OTHER|0.15% hyaluronic acid + 0.1% cyclosporine eye drops|Combination of 0.15% hyaluronic acid + 0.1% cyclosporine eye drops
215039256|NCT07088796|DEVICE|Toric IOL implantation|All surgeries were performed by the same surgeon (J.Y.) using a standardized surgical technique (phacoemulsification for cataract extraction+ IOL implantation + anterior vitrectomy) under general anesthesia. Scleral tunnel incision was created firstly. Thereafter, 5.0-5.2mm anterior capsule capsulorrhexis, and cataract aspiration were performed. A single-piece hydrophobic acrylic IOL (SN6AT3-T9) was implanted into the capsular bag. After the corneal incision was closed with 10-0 sutures, a posterior capsulectomy of 3-4 mm and anterior vitrectomy were performed through the pars plana using 25-gauge instrumentation with high cutting frequency (3,000 to 4,000 cuts per minute) and low aspiration pressure (300 to 350 mm Hg) in all eyes. A 3.5-4.0 mm posterior capsule capsulorrhexis and anterior vitrectomy were performed in patients.
215039257|NCT07088796|DEVICE|Non-toric IOL implantation|All surgeries were performed by the same surgeon (J.Y.) using a standardized surgical technique (phacoemulsification for cataract extraction+ IOL implantation + anterior vitrectomy) under general anesthesia. Scleral tunnel incision was created firstly. Thereafter, 5.0-5.2mm anterior capsule capsulorrhexis, and cataract aspiration were performed. A single-piece hydrophobic acrylic IOL (SN60WF) was implanted into the capsular bag. After the corneal incision was closed with 10-0 sutures, a posterior capsulectomy of 3-4 mm and anterior vitrectomy were performed through the pars plana using 25-gauge instrumentation with high cutting frequency (3,000 to 4,000 cuts per minute) and low aspiration pressure (300 to 350 mm Hg) in all eyes. A 3.5-4.0 mm posterior capsule capsulorrhexis and anterior vitrectomy were performed in patients.
215039258|NCT07099352|DEVICE|Acupuncture Laser Therapy|Participants will receive low-level laser therapy sessions during dialysis , applied three times per week for 4 weeks to selected treatment areas.
215039259|NCT06148935|DRUG|Vericiguat (Verquvo, BAY1021189)|Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol
215039260|NCT06889701|DRUG|TNP-2092 for injection|TNP-2092 for injection, 100 mg/vial, Intra-articular administration (IA), 10ml (50 mg) once daily for 14 days. TNP-2092 dose volume, dose, frequency, and duration can be adjusted according to the sentinel group synovial fluid TNP-2092 concentration, PK characteristics, and safety results at the EA visit.
215039261|NCT06889701|DRUG|Vancomycin Hydrochloride for Injection (IA)|Vancomycin Hydrochloride for Injection, 0.5 g/vial, Intra-articular administration, 10 mL (0.5 g) once daily for 14 days.
215039262|NCT06889701|DRUG|Vancomycin Hydrochloride for Injection (IV)|Vancomycin Hydrochloride for Injection, 0.5 g/vial, Intravenous infusion, 250 mL (1 g) q12h ± 1h per day, for 14 days.
214873383|NCT02361294|OTHER|Blood samples|
214873384|NCT05716386|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet less than 2 gram per day
214873385|NCT01135186|DRUG|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
214873386|NCT05749250|DEVICE|Acoustic cavitation of ultrasound enhancing agents|Cavitation therapy
214873387|NCT06178432|GENETIC|CRG003 injection|The dose of CRG003 will be calculated according to the participant's weight with single intravenous infusion.
214873388|NCT04755933|BEHAVIORAL|Raising Confident Children Course|An online learning tool consisting of 8 different modular components, designed to reduce the transmission of anxiety from parents to children. The modular components include: a core starter about anxiety, the role of avoidance, using play to develop childrens confidence, using Emotion Coaching with children, managing difficult behaviour, the role of sleep, exercise and diet, reducing overprotection, modelling confident behaviour and managing difficult behaviour.
214873389|NCT03878667|DIETARY_SUPPLEMENT|Curves Calcium|Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).
214873390|NCT03878667|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium (providing 950 mg/d as carbonate)
214873391|NCT03878667|DIETARY_SUPPLEMENT|Placebo|Dextrose placebo
214873392|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsolateral Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
215039263|NCT06889701|DRUG|Oral antibiotics|"Rifampicin capsules: 0.15 g/capsule. 0.45 g (3 capsules) orally once daily within 1 h before breakfast for 8 weeks (56 days).~Levofloxacin Tablets: 0.5 g/tablet. 0.5 g (1 tablet) orally once daily within 1 hour before breakfast for 8 weeks (56 days).~If susceptibility testing results show resistance to rifampicin and/or levofloxacin, or intolerance by the patient 's participant, treatment with oral minocycline hydrochloride capsules will be substituted as follows:Minocycline hydrochloride capsules: 100 mg/capsule. Administered orally q12h ± 1h daily, doubling the first dose, 200 mg (2 capsules) orally, then 100 mg (1 capsule) each time for 8 weeks (56 days).~The total duration of oral treatment during the oral administration period was 8 weeks (56 days) regardless of whether oral medication will be changed (eg, intolerance)."
214873393|NCT03840369|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|The sham TMS coil will make a similar sound to the real rTMS coil, but will not deliver a magnetic pulse. This is a no-treatment device.
215039264|NCT06889701|DRUG|Background Treatment|Background treatment will be determined by the investigator.
214873394|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsomedial Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
214873395|NCT03796039|BEHAVIORAL|Standing|Standing for an additional 100 minutes per week; 20 minutes Monday-Friday
215039265|NCT06872359|DEVICE|KIO017-1|Subcutaneous and/or supraperiostal injections in chin and/or mid-face and/or jawline. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
215039266|NCT06872359|DEVICE|KIO017-2|Subcutaneous injections in temples and/or nasolabial folds and/or marionette lines and/or mid-face. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
215039267|NCT06872359|DEVICE|KIO017-3|Injections in or around labial mucosa for lip volume and contour and/or intradermal injections in perioral lines. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
215039268|NCT06761196|OTHER|Questionnaire|The quality of life measured with different scales (BREAST-Q, EORTC QLQ C30 and BR42)
215039269|NCT07095361|DRUG|Fibrinolytic once daily|tissue plasminogen activator (tPA) 10mg will be administered once a day as part of intrapleural enzyme therapy (IET) for 3 consecutive days.
215039270|NCT07095361|DRUG|Fibrinolytic twice daily|tissue plasminogen activator (tPA) 10mg will be administered twice a day as intrapleural enzyme therapy for 3 consecutive days.
215039271|NCT07095361|DRUG|DNA degradation once daily|Deoxyribonuclease (DNase) 5mg will be administered once a day as intrapleural enzyme therapy (IET) for 3 consecutive days.
215039272|NCT07095361|DRUG|DNA degradation twice daily|Deoxyribonuclease (DNase) 5mg will be administered twice a day as intrapleural enzyme therapy for 3 consecutive days.
215039273|NCT07097909|OTHER|LLM-based CBT|An intelligent mobile application that delivers CBT for tinnitus, powered by a LLM. The app provides daily interactive sessions (≥20 minutes per day) over 4 weeks, incorporating cognitive restructuring, relaxation training, attention-shifting, and sleep hygiene guidance. The content dynamically adapts to user input to enhance engagement and personalization.
215039274|NCT07099846|DEVICE|regeneration of post extraction socket with biomaterials|after tooth extraction, in the test group we will place a demineralised bovine bone graft mixed with a gel containing hyaluronic acid and polynucleotide and we will cover the entrance of the socket with a collagen matrix
215039275|NCT06909162|DRUG|INCB123667|single dose administered orally
215039276|NCT07098988|BIOLOGICAL|Visugromab|Participants receive Visugromab (recommended dose) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
214873396|NCT05396261|DEVICE|Film forming silicone gel (7-0940)|Anecdotal evidence suggests that genital conditions in women associated with vaginal atrophy improve with the use of film-forming silicone dressings.
214873397|NCT04008628|DRUG|Nitrous Oxide|Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
214873398|NCT01679639|DRUG|aleglitazar|Single dose of aleglitazar in Periods 1, 2, 3
214873399|NCT01679639|DRUG|rifampicin|Single dose in Periods 1 and 2; multiple doses in Period 3
214873400|NCT00785460|DRUG|Benfotiamine|
214873401|NCT05387850|OTHER|no intervention|no intervention
214873402|NCT04702438|BEHAVIORAL|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
214873403|NCT00855179|DRUG|Red vine leaf extract (AS 195)|Antistax film-coated tablet 360 mg
214873404|NCT00855179|DRUG|Placebo|Placebo tablets identical to those containing Anstistax 360 mg
214873405|NCT05023837|DRUG|Pembrolizumab 100 MG Injection|Pembrolizumab iv 200mg q21d
214873406|NCT05161247|OTHER|Zona pellucida sperm selection|Sperm selection for ICSI based on the spermatozoa ability to adhere to immobilized zona pellucida proteins.
214873407|NCT05161247|OTHER|Conventional sperm selection|Sperm selection for ICSI based on the sperm morphology.
215039277|NCT07098988|DRUG|Matching placebo for visugromab|Participants receive Matching Placebo intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
215039278|NCT07098988|BIOLOGICAL|Pembrolizumab 200 mg Q3W|Participants receive Pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments after visugromab infusion.
215039279|NCT07098988|DRUG|Pemetrexed 500 mg/m^2|Participants receive Pemetrexed 500 mg/m\^2 IV on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
215039280|NCT07098988|DRUG|Carboplatin AUC 5|Participants receive Carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) on Day 1 of each 21-day cycle for four cycles.
215039281|NCT06522386|DRUG|Pirtobrutinib|Given by mouth
215039282|NCT06522386|DRUG|Rituximab|Given by vein (IV)
215039283|NCT06522386|DRUG|Venetoclax|Given by mouth
214873408|NCT05161247|OTHER|Intracytoplasmic Sperm Injection (ICSI)|Normal ICSI procedure.
214873409|NCT02913092|BEHAVIORAL|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
214873410|NCT05567146|BEHAVIORAL|Experimental group|"It is planned to use the social media platform WhatsApp application to carry out the study. technique of gamification will have content in the form of points, ranking, penalties and rewards, which are the basic principles of gamification.~Studies have shown that these contents are effective techniques to increase the interest, encouragement, motivation and purpose of the participants."
215039284|NCT06857903|BEHAVIORAL|Recruitment nudges|Participants who in the intervention condition will receive recruitment materials that contain behavioral nudges
215039285|NCT07101835|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Patients scheduled for LSG will receive a Bilateral ultrasound guided external oblique intercostal block (EOIB) preoperatively, and sensory block status will be evaluated after 30 minutes.
215039286|NCT07101835|DRUG|ıv morphine PCA|ıV PCA of 0,5mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
215039287|NCT07102966|GENETIC|Rapid whole genome sequencing|All consented patients will receive a virtual genetic evaluation and rapid whole genome sequencing
214873411|NCT00530218|DRUG|Ganciclovir|Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
215039288|NCT06147089|BEHAVIORAL|Sleep Intervention|Participants in the sleep intervention receive advice on: sleep hygiene/environment, sleep timing, naps, and exposure to light. These advices will be tailored to the personal situation of the participant, as measured during the run-in period.
215039289|NCT06147089|BEHAVIORAL|Nutritional intervention|Participants in the nutritional intervention receive personalised advice on the distribution of calories and nutrients over 24 hrs, and on specific food products based on the outcomes of the continuous glucose measurements (CGM) during the run-in period. The guidelines will include room for personal dietary preferences.
215039292|NCT07107412|OTHER|Translating the Questionnaire into Turkish and Related Processes|"The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.~Other: Validity The scale will be applied"
215039293|NCT06827262|DEVICE|Intracept™ Intraosseous Nerve Ablation|Intracept™ Intraosseous Nerve Ablation for treatment of patients diagnosed with vertebrogenic pain
215039294|NCT06162572|DRUG|S095018|Via IV infusion on Day 1 of each 21-day cycle
215039295|NCT06162572|DRUG|S095024|Via IV infusion on Day 1 of each 21-day cycle
215039296|NCT06162572|DRUG|S095029|Via IV infusion on Day 1 of each 21-day cycle
215039297|NCT06162572|DRUG|S095018 Recommended Dose Expansion (RDE)|Via IV infusion on Day 1 of each 21-day cycle
215039298|NCT06162572|DRUG|S095024 RDE|Via IV infusion on Day 1 of each 21-day cycle
215039299|NCT06162572|DRUG|S095029 RDE|Via IV infusion on Day 1 of each 21-day cycle
215039300|NCT06162572|DRUG|Cemiplimab|350 mg via IV infusion on Day 1 of each 21-day cycle
215039301|NCT04603807|DRUG|Entrectinib|Entrectinib will be self-administered orally at a dose of 600 mg (three 200 mg capsules per day) once daily with or without food.
215039302|NCT04603807|DRUG|Crizotinib|Crizotinib will be self-administered orally at a dose of 250 mg twice daily with or without food.
215039303|NCT05871814|DEVICE|Colon preparation guided by an artificial intelligence device|Regular oral and written information will be provided to this group. In addition, participants will take a picture of the last rectal effluent with the smart phone that have to upload to a server. A convolutional neural network will assess whether the bowel preparation is correct or not (clean or not). The system will issue specific recommendations based on the quality of cleansing
215039304|NCT05385978|DRUG|APHD-012|Distal jejunal-release dextrose beads (Aphaia technology, AT)
215039305|NCT05385978|DRUG|APHD-012P|Distal jejunal-release placebo beads
214873412|NCT05864963|PROCEDURE|Medial tab-type fasciocutaneous flap|"The flap can be taken in different ways depending on the defect. Once the base of the flap is identified, the posterior edge of the tibia is taken as reference; marking of the tab is performed considering that the posterior incision is located 5 cm from the posterior edge of the tibia, and the anterior incision is located longitudinally of the medial region of the tibial diaphysis, the length of the incision depends on the base of the flap and the defect's size.~The posterior incision is made first in the skin, subcutaneous cellular tissue until the fascia is identified; the subfascial flap is dissected to avoid injuring perforators, dissection is completed up to the anterior edge of the flap, if needed direct cutaneous perforators are ligated; once the subfascial plane has been identified and dissected, the tab is completed in its proximal or distal part according to the previous surgical planning. Later, the tab is rotated to the anterior region of the tibia to cover the defect."
215039306|NCT06920160|DEVICE|software Caaring (remote monitoring app)|Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/ questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to Heart Faillure.
214873413|NCT01031030|DRUG|cyclophosphamide|
214873414|NCT01031030|DRUG|epirubicin hydrochloride|
214873415|NCT01031030|DRUG|fluorouracil|
214873416|NCT01031030|DRUG|methotrexate|
214873417|NCT01031030|OTHER|laboratory biomarker analysis|
214873418|NCT01031030|PROCEDURE|adjuvant therapy|
214873419|NCT05018546|PROCEDURE|Irrigation force|RIRS with different irrigation force
214873420|NCT05090488|BEHAVIORAL|Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
214873421|NCT03750292|DEVICE|HEPAirX air filter|It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.
215039307|NCT06919939|DRUG|Epcoritamab|"Epcoritamab will be administered via subcutaneous injection at the following dose levels and schedule over a total of twelve cycles:~* Cycle 1 Day 1: Step-up dose of 0.16 mg~* Cycle 1 Day 8: Step-up dose of 0.80 mg~* Cycle 1 Day 15: First full dose of 48 mg.~* Cycles 2 through 4 Days 1, 8 and 15: 48 mg~* Cycles 5 through 12 Days 1 and 15: 48 mg"
215039308|NCT06919939|DRUG|Loncastuximab Tesirine|"Loncastuximab will be administered intravenously (IV) at the following dose level and schedule over a total of four cycles:~* Cycles 1 and 2 Day 1: 120 mcg/kg~* Cycles 3 and 4 Day 1: 75 mcg/kg~* Cycle 4 Day 22: 75 mcg/kg"
215039309|NCT05239221|DRUG|AZP-3601|Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
214291232|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
214291233|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
214291234|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
214873422|NCT03750292|DEVICE|control air filter|A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.
214873423|NCT06173856|OTHER|LED phototherapy|LED phototherapy (430-470nm) alone will be applied.
214873424|NCT02774642|BEHAVIORAL|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
214873425|NCT02774642|BEHAVIORAL|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
214873426|NCT03845803|OTHER|Reducing sedentary behaviour|Implementing sit/stand workstations at work
214873427|NCT00616070|DRUG|Difluprednate|Difluprednate
214873428|NCT00616070|OTHER|Placebo|Vehicle
214873429|NCT02588495|OTHER|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
214873430|NCT06983951|GENETIC|BCMA CART|"The cell product used in this study is a targeted BCMA autologous CART cell injection.~Research drug name: Targeted BCMA Autologous CART Cell Injection Drug code: BJBR-BCMA-006 Administration method: single intravenous injection"
215039310|NCT05239221|DRUG|Placebo|Saline solution visually matching active medication
215039311|NCT07114341|OTHER|Cranberry Intervention|30 grams of lyophilized cranberry containing 1187 mg/100 g anthocyanins were given for 7 days.
215039312|NCT02661672|DEVICE|Apollo Device|The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
215039313|NCT02661672|DEVICE|Artemis Device|The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
214873431|NCT03462979|DEVICE|Immunochromatographic lateral flow test|The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
214873432|NCT01144715|DEVICE|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
215039314|NCT07126977|BEHAVIORAL|Urotherapy training|Standard urotherapy consists of five main components aimed at regulating lower urinary tract (LUT) function in children: education about LUT function and dysfunction, establishing healthy voiding habits and behavioral modifications, lifestyle recommendations such as balanced fluid intake and nutrition, monitoring of symptoms and voiding habits, and consistent caregiver support. In contrast, specific urotherapy focuses on treating particular LUT dysfunctions and includes interventions such as alarm therapy, pelvic floor training, biofeedback, neuromodulation, and clean intermittent catheterization. All children and their caregivers participating in our study will receive urotherapy training prior to the pelvic floor rehabilitation interventions. Each urotherapy session will last approximately 60 minutes.
214873433|NCT01144715|DEVICE|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
214873434|NCT06982079|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg will be added in addition to standard of care
214873435|NCT06982755|PROCEDURE|acupuncture|acupuncture at Zusanli (ST36); sample size: 44
214873436|NCT06982755|DRUG|compound diclofenac sodium|intramuscular injection of compound diclofenac sodium injection; sample size: 44
214873437|NCT06982755|COMBINATION_PRODUCT|acupuncture combined with compound diclofenac sodium|acupuncture at Zusanli (ST36) and intramuscular injection of compound diclofenac sodium injection; sample size: 44
215039315|NCT07126977|OTHER|Diaphragmatic Breathing Exercise|The exercise will be performed under the supervision of a physiotherapist, twice a week for 8 weeks. After the correct position is established, participants will be instructed to slowly inhale through their nose and focus on feeling the breath move from top to bottom (cranial to caudal). They will be asked to hold their breath for a few seconds, then exhale slowly through pursed lips. Additionally, they will be reminded not to push only their abdomen upward while inhaling, but to feel the intra-abdominal pressure expanding evenly in all directions (360 degrees). This exercise will be performed in 3 sets of 10 repetitions.
215039316|NCT07126977|OTHER|Biofeedback-Assisted Pelvic Floor Muscle Exercises|"No invasive procedures will be performed. The physiotherapist will begin with external palpation of the perineal area to teach correct pelvic floor contractions without using accessory muscles. Once the patient masters this, animation-supported biofeedback exercises will start. If relaxation is insufficient, biofeedback will first target muscle relaxation.~Using the NeuroTrac Myoplus Pro4 device, surface electrodes will be placed at 2 and 7 o'clock on the perineum, and the reference electrode on the right thigh. Exercises will start in a lying position and progress to sitting and standing as control improves. Each session will last about 20 min, with 2-5 s contractions followed by 5-10 s relaxations."
215039317|NCT07126977|OTHER|Video Game-Based Balance Exercise Training|"In our study, in addition to the standard protocol, virtual reality-supported video game-based balance exercises will be performed twice a week for 8 weeks. Each session will include a 5-minute warm-up, 20 minutes of balance exercises, and a 5-minute cool-down period. All sessions will follow the same protocol, with identical game order and duration. Each game will be played for approximately 5 minutes, and the number of repetitions for each game will vary depending on the participant's performance level.~As a therapeutic tool, the Wii console, Wii Fit Plus game disc, and Wii Balance Board will be used. The selected exercise games will include Hula Hoop Plus, Penguin Slide, Soccer Heading, Table Tilt, Tightrope Walk, Ski Jump, and Step Up."
215039318|NCT07126977|OTHER|Functional Exercise Training|Our study will include exercises aimed at improving core stabilization, dynamic neuromuscular control, and pelvic mobility. Exercise selection will be tailored to individual needs, and the number of repetitions and duration will be adjusted based on the participant's progress. Preferred exercises will include movements such as bridge, dead bug, bilateral arm and leg lift, bear position, cat-camel, and pelvic clock.
215039319|NCT07143695|DEVICE|Parasternal intercostal thickening fraction|Parasternal intercostal thickening fraction less than 6.5%
215039320|NCT07143695|DEVICE|Sham parasternal intercostal thickening|Ultrasound assessment only for purpose of blinding
215039321|NCT07138586|RADIATION|low level laser therapy group|patients received low level laser therapy using diode laser 980 nm with a low power
215039322|NCT07138586|DRUG|Lidocaine gel group|patients was instructed to use Lidocaine gel (Oracure gel) 4 times daily.
215039323|NCT07138586|DRUG|Chlorhexidine mouthwash group (positive control group).|patients was instructed to use Chlorhexidine mouthwash (Orovex) 4 times daily (control group).
215039324|NCT07146308|OTHER|Lifestyle Management|Participants will undergo dietary and exercise interventions. The dietary intervention includes breakfast, lunch, and dinner, while the exercise intervention consists of both aerobic and resistance training.
215039325|NCT06947291|DRUG|Glumetinib Tablets|glumetinib once daily once daily under fasting conditions in each 21-day treatment cycle.
215039326|NCT06947291|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous injection in each 21-day treatment cycle.
214873438|NCT06982755|COMBINATION_PRODUCT|placebo|superficial acupuncture at Zusanli (ST36) and intramuscular injection of normal saline; sample size: 44
214873439|NCT06988865|OTHER|Clinical evaluation|treatment methods, associated symptoms, evolution and clinical presentation
214291235|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
214291236|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
214291237|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
214291238|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
214873440|NCT06989619|BEHAVIORAL|Sleep health and mindfulness intervention|This educational, healthy lifestyle intervention will include several modules detailing sleep health and mindfulness strategies. In addition, opinion leaders will be identified in the population to help diffuse messages through each housing facility.
214873441|NCT06988956|DRUG|Nimotuzumab|Nimotuzumab 400mg
214873442|NCT06988956|DRUG|Tegafur|S-1 60mg/m2
214873443|NCT06988956|RADIATION|radiotherapy|PTV 50Gy/2Gy
214873444|NCT06989684|PROCEDURE|Osseodensification|Osseodensification uses specially designed burs to densify osteotomy site
214873445|NCT06989684|PROCEDURE|Underdrilling|In underdrilling the osteotomy is smaller than implant diameter to be placed
214873446|NCT06991075|DEVICE|High frequency transcutaneous electrical nerve stimulation|TENS 7000 digital TENS unit will be used.
214873447|NCT06612957|PROCEDURE|Repair of uterine cicatricial diverticulum|Cut off the uterine cicatricial diverticular tissue in the lower portion of the uterus, and restore normal uterine muscle tissue.
214873448|NCT04129671|GENETIC|No intervention was applied|No intervention was administered
214873449|NCT00004025|BIOLOGICAL|aldesleukin|
214873450|NCT00004025|BIOLOGICAL|dendritic cell-gp100-MART-1 antigen vaccine|
214873451|NCT06429579|PROCEDURE|Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy|Potts-shunt procedure is the surgery that connect the descending aorta and the left/main pulmonary artery by direct anastomosis, a Gore-tex tube or a Gore-tex tube with flap.
214873452|NCT06429579|DRUG|Only conventional drug therapy|Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
214873453|NCT04290195|DRUG|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Intravitreal injection of 1.25 mg of ziv aflibercept in patients
214873454|NCT06988917|BEHAVIORAL|the regular rehabilitation program|Each training session consists of a 10-minute warm-up (including power cycling, full-body stretching, etc.) At the same time, use the foam axis to relax the lateral oblique femoris and iliotibial band to relieve the pressure on the lateral side of the patella), 40 minutes of formal training (including wall squats with a ball, straight leg raising resistance training, terminal resistance knee extension training, bench kick ball clamping training, and balance training), and 10 minutes of relaxation (using a foam roller, foam axis and other combined techniques to relax the muscles Especially for the lower limb muscles such as the lateral femoris, iliotibial band, and tibialis anterior muscle.
214873455|NCT06988917|DEVICE|The blood flow limiting pressure band|The experimental group (LL-BFRT group) wore a flow-limiting pressure band for exercise during routine rehabilitation training. The blood flow limiting pressure band used in this study mainly consists of a 109\*10cm leg pressure band, a barometric display dial with a pressure range of 0-300mmHg, and a pressure pump. In the experiment, we fixed the blood flow restriction pressure band in the area for measuring the circumference and adjusted the blood flow restriction pressure according to the thigh circumference of the subjects to maintain it within the range of 40%-60% arterial occlusion pressure. The way to limit blood flow is intermittent inflation, that is, during the intervals of muscle strength training, the cuff deflation operation is carried out simultaneously.
214873456|NCT06989476|OTHER|CARELOOP Intervention|"CARELOOP Intervention (Clinics cAtch needs, REfer, Link to services, and close the lOOp using an equitable family-centered Process).~CARELOOP is a way of enhancing psychosocial screenings through PSM methodology and Implementation Science, and grounded in the Clinical-Community Relationships Evaluation framework"
214873457|NCT06990633|DIAGNOSTIC_TEST|diagnostic test|"Group 1: MMR-Proficient Group Label: MMR-Proficient~Description: Patients with normal expression of MMR proteins on IHC analysis. No indication for further genetic testing.~Type: Observational Group~Group 2: dMMR Group Label: dMMR~Description: Patients with loss of MMR protein expression (MLH1, PMS2, MSH2, or MSH6) on IHC. These patients will undergo further molecular or genetic analysis to evaluate for Lynch syndrome.~Type: Observational Group"
214873458|NCT06988826|DRUG|G-CSF|G-CSF \& Antibiotic therapy in combination
214873459|NCT06988826|DRUG|Antibiotics only|Antibiotics alone
214873460|NCT06983509|DRUG|Regiocit|"Regiocit can be used as a replacement fluid for CRRT with RCA. It will be used in pre-dilution mode only.~At least 200 mL of post-replacement solution is recommended to minimize clotting in the de-aeration chamber. A replacement/dialysate solution with 22 to 26 mEq/L bicarbonate buffer is advised as the first choice. A higher concentration of bicarbonate may be required in severe cases of acidosis. The use of a non-calcium-containing dialysate or replacement fluid is advised. The rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Regiocit will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 to 4 mmol/L. A BFR between 100 to 180 mL/min will be advised; a lower BFR can minimize patient citrate exposure, particularly in patients with lower body weight."
214873461|NCT06983509|DRUG|Biphozyl|"Biphozyl is used as a replacement fluid during CRRT. It is injected into the extracorporeal circuit before (pre-dilution) or after (post-dilution) the filter. After the initiation of RRT, Biphozyl is used for late treatment of the acute condition when pH, potassium, and phosphate concentrations return to normal. Biphozyl can also be used if any other buffer is in use or during RCA.~The volume and rate of administration of Biphozyl depend on the blood concentration of phosphate and other electrolytes, acid-base balance, body fluid balance, and overall clinical condition of the patient. The volume of replacement fluid given also depends on the expected intensity (dosage) of treatment."
214873462|NCT06983509|DRUG|Prismasol 2|"Prismasol 2 is used as a replacement fluid during CRRT. It is injected into the extracorporeal circuit before (pre-dilution) or after (post-dilution) the filter.~The volume and rate of administration of Prismasol 2 depend on the blood concentration of electrolytes, acid-base balance, fluid balance, and overall clinical condition of the patient. The volume of replacement fluid administered also depends on the required intensity (dosage) of the treatment."
215039327|NCT07148336|OTHER|Symptom-based scoring system|The patients will be asked to complete the self-evaluation of symptoms and signs of neuropathy using a Neuropathy Tracker that questions symptoms quality, severity and distribution and guide the user through a systematic evaluation of pin-prick from a needle and vibration from the mobile on successive levels from the toes to the knee on both legs. Finally, the extension force or both great toes will be self-assessed by the participant. The self-examination is based on the structure of the Utah Early Neuropathy Score.
215039328|NCT07146776|PROCEDURE|open flap debridement with I-prf and xenogeneic graft|During the surgical phase of treatment, patients will undergo open flap debridement surgery. Infiltrative local anesthesia will first be administered to the involved teeth. The gingiva will be incised within the gingival sulcus using a scalpel, and a full-thickness flap will be carefully elevated with a periosteal elevator. Granulation tissue and dental calculus will be completely removed using Gracey curettes (American Eagle, USA) and an ultrasonic scaler. Subsequently, a xenogeneic bone graft mixed with injectable platelet-rich fibrin (i-PRF) will be applied. The flap will then be sutured using 4-0 polypropylene sutures.
215039329|NCT07146776|PROCEDURE|open flap debridement with saline and xenogenic graft|During the surgical phase of treatment, patients will undergo open flap debridement surgery. Infiltrative local anesthesia will first be administered to the involved teeth. The gingiva will be incised within the gingival sulcus using a scalpel, and a full-thickness flap will be carefully elevated with a periosteal elevator. Granulation tissue and dental calculus will be thoroughly removed using Gracey curettes (American Eagle, USA) and an ultrasonic scaler. A xenogeneic bone graft mixed with physiological saline will then be applied. Finally, the flap will be sutured using 4-0 polypropylene sutures.
215039330|NCT06952790|BEHAVIORAL|EveryDose Mobile Application|Participants will use this application every day for up to 10 minutes, for up to 12 weeks. The purpose of the application is to improve medication adherence. Participants will receive an alert to the mobile device while at home to ensure medication was taken, and to serve as a medication log.
215039331|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
215039332|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
215039333|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally
214666024|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow-Sham|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
214666025|NCT01691729|DEVICE|Ostomy accessory|Wearing each of the devices for 10 days each
214666026|NCT03499054|OTHER|Breathing exercises|During hemodialysis, the participants in the exercise group are asked to keep ttheir muscles relaxed, breathe normally through the nose at a rate of 3-8 times per minute with each breath held over 5 seconds in length. At the same time, the particpants are asked to also perform lower leg lifts for about 8 seconds per lift. The exercise is performed for 15-20 minutes, and after resting, blood pressure, oxygen saturation and HRV are measured.
214666027|NCT00236561|DRUG|topiramate, propranolol|
214666028|NCT00180115|DRUG|Cytarabine Dosage|
214666029|NCT05733481|DEVICE|CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries|The CapBuster System is a medical device intended to facilitate the intraluminal placement of conventional guidewires beyond chronic total occlusions prior to the utilization of interventional devices. The device system, manufactured by Praxis Medical, comprises the CapBuster support catheter and CapBuster penetrating wire which are mated together with a screw thread.
214666030|NCT02094469|DRUG|Cilostazol|Oral, Bid, 24 weeks
214666031|NCT04336150|OTHER|Hypopressive exercises|See information included in arm/group descriptions.
215039334|NCT06950645|BIOLOGICAL|Placebo|Placebo of experimental vaccine for infants three doses administered orally
215039335|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
215039336|NCT06950645|BIOLOGICAL|Placebo|Placebo of experimental vaccine for infants three doses administered orally
214666032|NCT04336150|OTHER|Hypopressive maneuver|See information included in arm/group descriptions.
214666033|NCT04336150|OTHER|Hypopressive exercises plus pelvic floor muscle contraction|See information included in arm/group descriptions.
214666034|NCT04336150|OTHER|Hypopressive maneuver plus pelvic floor muscle contraction|See information included in arm/group descriptions.
214666035|NCT06209697|DIETARY_SUPPLEMENT|red clover|Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
214666036|NCT03356847|DEVICE|Fitting of ocular implant|Removal of natural lens and replacement with a SISA monofocal intraocular implant
214666037|NCT01744899|OTHER|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
215039337|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR22|4SCAR19 and 4SCAR22
215039338|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR38|4SCAR19 and 4SCAR38
215039339|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR20|4SCAR19 and 4SCAR20
215039340|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR123|4SCAR19 and 4SCAR123
214666038|NCT02322307|OTHER|HealthPROMISE users|"Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.~Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings."
215039341|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR70|4SCAR19 and 4SCAR70
215039342|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR30|4SCAR19 and 4SCAR30
215039343|NCT06948292|DRUG|QRX-3|phase 2B CKD study
215039344|NCT06954740|DRUG|Amimestrocel|Amimestrocel will be administered at a target dose of 1×10E6 MSCs/kg body weight on day 1, 4, 8, 15.
215039345|NCT07159399|BEHAVIORAL|Pharmacist-led patient education|Trained pharnacists will provide information on: (1) the indication and the reason of DOAC prescription, (2) the name and the appearance of the DOAC agent, (3) the dose, frequency, time of administration, (4) the mechanism of action, (5) management of missed doses, (6) potential side effects and self-monitoring, and (7) perioperative management. An education leaflet about DOACs will also be provided to improve patients' understanding about the use of DOACs.
215039346|NCT07159399|OTHER|Usual Care|Patients in the usual care group will receive only usual care, without pharmacists providing additional DOAC education materials.
214666039|NCT02322307|OTHER|Control Group|In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
214666040|NCT06330753|OTHER|Trauma-informed Care Plan-|Per our IRB protocol patient participates will be consented for this study. A member of the healthcare team ( licensed nurse, social worker or doctor) will conduct the TICP with the patient. The TICP will be placed in the electronic medical record right below the patients name. The workflow is such is that if any plan of care placed on the Storyboard (under the patient's name) should be read first before engaging with a patient.
214666041|NCT01380756|DRUG|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
214666042|NCT01380756|DRUG|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
215039347|NCT07161609|DEVICE|Particle counter|The collection of air samples will begin with the surgical incision and will continue for 10 minute
214666043|NCT06094179|DRUG|Monoclonal antibody BAT6026|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
214666044|NCT06094179|DRUG|sodium chloride injection|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
215039348|NCT07159776|DEVICE|monitoring of wearable data, shopping data, biomarkers and patient reported outcomes|"1. All participants will receive a wearable device type Corsano Health Cardio watch 287-2 which is provided by the sponsor via Inovigate. Participants will be encouraged to wear the device 24h per day and need to wear the wearable device at least 12 hours per day, preferential during daytime.~2. All participants will receive a loyalty card (Xtra card Colruyt group) which is provided by the sponsor via Inovigate for food data capturing. The patient is requested to execute all grocery shopping at one of the Colruyt Group stores. He/she will always need to offer the loyalty card to the cashier prior to payment. The purchase receipt will then be automatically sent to the central food data repository at the sponsor set up for this study. Non-food or non-food related data will neither be captured nor stored during the trial.~3. biomarkers in blood and feaces will be monitored according to standard of care~4. patient reported outcomes will be monitored according to standard of care"
215039349|NCT07159529|PROCEDURE|flapless technique|taking a punch of tissue to place dental implant through surgical guide
215039350|NCT07159529|PROCEDURE|flap technique|conventional flap elevation and drilling to place dental implant
215039351|NCT07159529|PROCEDURE|tissue punching|just a punch of tissue taken to place dental implant
215039352|NCT07158931|OTHER|nordic walking|Before the NW program, participants completed a one-week familiarization phase to practice pole use. Training was held three times: 15 minutes on days 1 and 2, and 20 minutes on day 3, at 40-60% heart rate reserve (measured with a pulse oximeter). Warm-up included a 1-minute slow walk, toe raises, seated dorsiflexion, mini squats, scapular adduction, and shoulder/wrist stretches. Each session ended with a cool-down of a 2-minute slow walk and 20-second stretches for major muscle groups (quadriceps, hamstrings, lumbar extensors, gastrocnemius, shoulders, wrists).The walking poles used in this study were the Evolite Ultralite Titanium Antishock Trekking Pole, which has a titanium alloy body and a three-piece telescopic structure, adjustable to the desired length between 68 and 135 cm.
215039353|NCT07158931|OTHER|General walking|The program was performed on concrete or compacted soil surfaces, under the same physiotherapist's supervision. Walking speed was adjusted to remain below 60% of maximal heart rate and to allow participants to converse comfortably during exercise.
215039354|NCT07161466|BEHAVIORAL|lung recruitment maneuvre; PEEP|"After the patient enters the operating room, routine monitoring of ECG, non-invasive blood pressure, and SpO₂ is performed. Local anesthesia is used for radial artery puncture and catheterization to monitor invasive blood pressure.~After 3 minutes of pre-oxygenation, tracheal intubation is performed with the following ventilation parameters: VT 6-8 ml/kg, FiO₂ 60%, RR 15 breaths/min, I/E 1:2, and PEEP 4 cmH₂O. Ten minutes after the establishment of pneumoperitoneum during surgery, baseline levels of respiratory mechanical parameters and hemodynamic variables are recorded. Subsequently, alveolar recruitment is performed at a pressure of 30 cmH₂O for 30 seconds. Immediately after recruitment, the PEEP level is adjusted according to the group. The changes in respiratory mechanics parameters and hemodynamic variables after recruitment are recorded. After the outcome indicators recover to the new baseline level, the PEEP is readjusted to 4 cmH₂O."
214666045|NCT03741543|OTHER|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
214666046|NCT05006807|DEVICE|Mechanomyograph Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
214666047|NCT05006807|DEVICE|Stimpod Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
214666048|NCT05006807|DEVICE|TetraGraph Twitch Monitor|Measurement of train-of-four count and ratio and post titanic count
214666049|NCT05006807|DEVICE|TwitchView Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
214666050|NCT05006807|DEVICE|Nihon Kohden Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
214666051|NCT05006807|OTHER|Palpation of twitch count|The train-of-four count is determined by manual palpation of the evoked twitch response
214666052|NCT05563532|BEHAVIORAL|dental anxiety and oral hygiene|Evaluation of the effect of mothers' dental anxiety and oral hygiene on children's dental anxiety and periodontal status.
214666053|NCT05511389|OTHER|Anterolateral electrode position|As described previously
214666054|NCT05511389|OTHER|Anteroposterior electrode position|As described previously
214666055|NCT05511389|OTHER|Manual pressure|Manual pressure applied to the anterior electrode
214873463|NCT02442583|OTHER|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
214873464|NCT04638075|DEVICE|Supplemental Nursing System|The SNS is a device designed to deliver supplemental milk by suckling at the mother's nipple. A specially designed bottle attaches to the mother's breast and serves as the reservoir for milk. Attached to the bottle is a small tube which runs down to and is placed on the tip of the mother's nipple. With an adequate latch the neonate obtains supplementation by suckling. Additionally, this suckling stimulates milk production (Lawrence \& Lawrence, 2016).
214873465|NCT06718790|OTHER|Using menstrual cup|"In the prospective, randomized controlled study, two groups (Case = Menstrual cup, Control = Menstrual pad) will be randomly formed from individuals who volunteer to participate in the study and meet the inclusion criteria. All participants will be asked to answer the questions in the first interview questionnaire.~Women who will use menstrual cups will be trained on the use of the product and a menstrual cup will be provided for them to use. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd and 6th menstrual cycles and asked to answer questions about their menstrual cup use by sharing an online form."
215039355|NCT07161245|OTHER|Multimodal prehabilitation|"The multimodal prehabilitation program will consist of:~1. twice-weekly supervised exercise training at the hospital gym for approximately 8 weeks (induction phase), followed by 16 weeks of telematic, supervised, home-based exercise (maintenance phase);~2. nutritional consultation, including diet optimization and supplementation if needed;~3. individual or group-based psychological support."
215039356|NCT07161245|OTHER|standard of care|Participants in the control group will follow the standard of care provided by the hospital and will receive general recommendations on physical activity, nutrition, and stress/anxiety management.
215039357|NCT07160543|BEHAVIORAL|Imagination Exposure|Participants were guided to close their eyes and imagine discarding their personal object. The experimenter provided standardized verbal instructions to help participants visualize moving the item from their own space into a trash bin.
214666056|NCT02266550|DRUG|[14C] BILL 284 BS|
214666057|NCT02494141|DRUG|Curcumin|Dietary Supplement
214666058|NCT02494141|OTHER|Placebo|
214666059|NCT05418049|DRUG|Baclofen|30mg - Supplied as 10mg and 20mg tablets
214666060|NCT05418049|DRUG|Memantine|two 10 mg tablets
214666061|NCT05418049|DRUG|Roflumilast|250 mcg capsule
214666062|NCT05418049|DRUG|Placebo|Placebo pill
214666063|NCT06190314|DIAGNOSTIC_TEST|Measure serum vitamin b12 levels|Measure the vitamin b-12 levels in patients that are admitted for stroke of any kind
214666064|NCT00345605|DRUG|Sodium Phenylbutyrate|None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
214666065|NCT00345605|DRUG|Arginine|Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
214666066|NCT01335971|DRUG|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
214873466|NCT06718790|OTHER|Using menstrual pads|In the prospective, randomized controlled study, two groups (Case = Menstrual cup, Control = Menstrual pad) will be randomly formed from individuals who volunteer to participate in the study and meet the inclusion criteria. All participants will be asked to answer the questions in the first interview questionnaire. For women in the group who will use menstrual pads, the average number of pads they have used in their previous menstrual cycles will be asked and an appropriate number of menstrual pads will be provided. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd, and 6th menstrual cycles and asked to answer questions about their menstrual pad use by sharing an online form.
214873467|NCT00485680|DRUG|Olanzapine Hydrochloride|
214873468|NCT00485680|DRUG|Lithium Carbonate|
214873469|NCT01469702|DRUG|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
214873470|NCT01469702|DRUG|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
214873471|NCT01469702|DRUG|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
214873472|NCT01513382|PROCEDURE|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
214873473|NCT05318274|RADIATION|Hypofractionated radiotherapy|Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
214873474|NCT01236586|DRUG|RO4929097|
214873475|NCT01236586|DRUG|Dexamethasone|
214873476|NCT02011386|DRUG|Treatment|
214873477|NCT03255655|DEVICE|Intense Therapeutic Ultrasound Treatment - ITU|
214873478|NCT04588714|BEHAVIORAL|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
215039358|NCT07160543|DEVICE|Non-immersive Virtual Reality Exposure|Participants used a desktop computer to interact with a virtual household environment. Their personal object, photographed beforehand, was digitally embedded in the scene. Using keyboard and mouse, participants navigated to the virtual garage and dragged the object into a virtual trash bin. The experimenter remained present to provide support.
215039359|NCT07158710|DRUG|HSK42360|Oral administration, QD/BID
215039360|NCT07159919|DIETARY_SUPPLEMENT|protein supplement|Cricket protein incorporated into a whole-food source (dough balls) to be consumed once after an acute bout of resistance exercise and then consumed daily for 12 weeks alongside regular resistance training.
215039361|NCT07159919|DIETARY_SUPPLEMENT|protein supplement|Whey protein incorporated into a whole-food source (dough balls) to be consumed once after an acute bout of resistance exercise and then consumed daily for 12 weeks alongside regular resistance training.
215039362|NCT07158827|DRUG|Tavapadon|Oral: Tablet
215039363|NCT07158736|PROCEDURE|Genicular nerve block with bupivacaine and corticosteroids|genicular nerve block with ideal body-weight dosing of bupivacaine 0.5% with 4 mg dexamethasone
214666067|NCT01335971|DIETARY_SUPPLEMENT|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
214873479|NCT03365011|DRUG|Nitrous oxide gas for inhalation|Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
214873480|NCT03365011|DRUG|Placebo gas for inhalation|Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
215039364|NCT07158736|OTHER|Standard of Care|This involves standard of care pain relief for patients who do not receive the genicular nerve block for knee pain, such as acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and opioids.
215039365|NCT07160140|OTHER|Participants will receive an 8-week pedal technique training protocol in addition to their regular cycling training.|Pedal Technique Training Protocol This training is designed as a technical training to observe pedaling data, analyze right and left leg power ratios, and determine how they change when pedaling at various intensities and cadences
215039366|NCT07158840|DRUG|AK112|AK112 Monotherapy
214873481|NCT04853992|DRUG|LEO 152020|LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
214873482|NCT04853992|DRUG|LEO 152020 placebo|LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.
214873483|NCT03582826|BEHAVIORAL|Nutritional counselling|Behavioral nutritional counselling delivered via the Internet.
214873484|NCT03582826|BEHAVIORAL|Stress-reduction counseling|The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
215039367|NCT07158762|OTHER|White bread|Two slices of white bread consumption along with 150 ml of pure orange juice and 10 g of butter
215039368|NCT07158762|OTHER|Wholemeal bread|Two slices of wholemeal bread consumption along with 150 ml of pure orange juice and 10 g of butter
215039369|NCT07158567|DEVICE|intermittent theta burst stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulatory treatment. TMS has been FDA cleared since 2008 for treatment resistant depression. It is now FDA cleared for a few other indications including migraine. Magnetic pulses are delivered through a coil placed on the scalp and when the magnetic field reaches brain cells, it changes to an electric current that can increase or decrease excitability depending on the treatment parameters. Intermittent theta burst stimulation (iTBS) is a type of patterned, excitatory TMS. iTBS only takes 3 minutes to deliver and is theorized to induce a window of neuroplasticity that lasts at least 1 hour. The Magventure with Magoption x100 Stimulator and associated coil the investigators are using can be set to deliver active (real) or sham (fake or inactive) TMS. The sham device is designed to look, sound and feel like real TMS.
214873485|NCT02866526|OTHER|Patient questionnaire|quantitative and qualitative data collection will be proposed.
214873486|NCT01806818|DRUG|Epirisone 50mg or placebo TID|3 times a day after meals for 1 week
214873487|NCT00532818|DRUG|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
214666068|NCT01335971|OTHER|Placebo|Microcrystalline cellulose once daily by mouth
214873488|NCT00532818|DRUG|Placebo|Cisplatin + Topotecan plus placebo
215039370|NCT07158567|BEHAVIORAL|LoveYourBrain Yoga Program|This yoga program is evidence-based, standardized and manualized. It is developed by the LoveYourBrain Foundation (www.loveyourbrain.com). Each yoga session includes 10 min of breathing exercises, 45 min of gentle yoga or stretching exercises, 15 min of guided meditation, and 20 min of facilitated discussion with psychoeducation, detailed in a manual to ensure standardization of program content across time and instructors.
214666069|NCT00384956|DRUG|Azacitidine|
214873489|NCT00164151|DRUG|HalfLytely|
214873490|NCT00164151|DRUG|Visicol|
214873491|NCT03456154|DRUG|Botox Injectable Product|60u will be used at 3 sites of masseter muscle, on each side of the face
214873492|NCT03456154|DEVICE|Occlusal splint|In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
214873493|NCT01008982|DRUG|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
214873494|NCT02116426|BIOLOGICAL|Blood work in the ambulance|Blood sample for copeptin and troponin HS testing is taken during ambulance care.
214873495|NCT02116426|BIOLOGICAL|Blood work upon arrival in the emergency room|Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
214873496|NCT02116426|BIOLOGICAL|Blood work at 3 hours post-arrival in the emergency room|Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
214873497|NCT00210873|DRUG|topiramate|
214873498|NCT00106340|DRUG|vildagliptin|
214873499|NCT00106340|DRUG|glimepiride|
214873500|NCT00106340|DRUG|Metformin|
214873501|NCT00106340|DRUG|Vildagliptin matching placebo|
214873502|NCT00106340|DRUG|Glimepiride matching placebo|
214873503|NCT02519738|DRUG|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
214873504|NCT02519738|DRUG|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
215039371|NCT07158671|OTHER|Intervention Group|"Participants in the intervention group will:~Use the survivorship programme through mHealth every day for 3 months; Be called by the healthcare provider every 2 weeks for consultation"
215039372|NCT07160296|BEHAVIORAL|20-Week Lifestyle Program|"Nutrition counseling: Weekly group sessions with an oncology dietitian, including individualized calorie and protein goals.~Exercise: Home-based resistance and mobility exercises twice per week using online videos, and daily walking with self-tracking.~Wellness education: Weekly group sessions focused on stress management, sleep, fatigue, and mindset, facilitated by a health and wellness coach. Five of the 20 sessions will include a Speech, Voice, Swallowing, and Airway Care in Head \& Neck Cancer training series led by a speech pathologist."
214666070|NCT03095092|DRUG|BIA 6-512 400 mg|4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
214873505|NCT02519738|OTHER|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
214666071|NCT01249170|BEHAVIORAL|First year program|Information on group that underwent new educational program
214666072|NCT01249170|OTHER|Control comparison|Information from group that did not undergo new first year program
214873506|NCT02854111|OTHER|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
214873507|NCT02854111|OTHER|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
214873508|NCT06633471|DRUG|Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).|Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
214873509|NCT02149329|DRUG|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
214873510|NCT00275938|DRUG|interferon alpha 2b plus ribavirin|
214873511|NCT00275938|DRUG|interferon alpha 2b plus placebo|
214873512|NCT03688438|DEVICE|Closed-Incision Negative-Pressure Therapy|A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.
214873513|NCT05641090|OTHER|Nordic walking in water|Nordic walking in water will be based on nordic walking in water at temperature 34◦C. Nordic walking in water will be conducted at moderate intensity (40-60% heart rate reserve). The program was exercised 60 minutes include warm-up and cool down. At first 6 weeks, The exercise intensity was 40-50% heart rate reserve and it will be increased 50-60% heart rate reserve. The training program will be performed 3 times per week for 12 weeks.
214873514|NCT05641090|OTHER|No exercise intervention|This group wasn't receive intervention program. The participants in this group will do following a physician who treat them. They can exercise according to the physician recommend.
215039373|NCT07159685|PROCEDURE|Atrial fibrillation ablation|Atrial fibrillation ablation with RF, guided by navigation system
215039374|NCT07161596|BEHAVIORAL|oral health educational program|oral health educational program to the hemophilic children guided by the oral and dental care instructions provided by the AAPD and World federation of hemophilia oral care instructions
215039375|NCT07159841|DRUG|Atumelnant|Atumelnant, tablets, once daily by mouth, weight-based dosing
215039376|NCT07159841|DRUG|Placebo|Placebo, tablets, once daily by mouth, weight-based dosing
215039377|NCT07160946|OTHER|AI folow-up system|In AI follow-up group, patients will be followed up by an AI system.
214873515|NCT03169712|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
214873516|NCT03169712|BEHAVIORAL|Imagery Rehearsal Therapy|IRT protocol published by Nappi and collaborators (2010)
214873517|NCT03433898|DRUG|BI 754091|Solution for infusion
214873518|NCT03433898|DRUG|BI 754111|Solution for infusion
214873519|NCT04695145|BEHAVIORAL|Aerobic exercise in group|"Progression~The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~* Week 1-6: 12-18 reps x 2 set per exercise and muscle 30 s rest between exercises~* Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises~Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~* Week 1-6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises~* Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises~Mixed sessions~* Week 1-6: 35 s work time per exercise 25 s rest between exercises x 2 rounds~* Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
214873520|NCT04695145|BEHAVIORAL|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
214873521|NCT04494880|DRUG|Bupivacaine Injection|Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.
214873522|NCT03547076|DIAGNOSTIC_TEST|Focused ultrasound diagnostics|"Patients first be examined by nurses using a pocket-sized imaging device. Secondly, by a General Practitioner using the pocket-sized imaging device. Thirdly, reference echocardiography will be performed by cardiologist using a high-end echocardiographic scanner. Only tools (ultrasound equipment and dedicated software) approved for clinical practice will be used.~The focused ultrasound examination includes three standard apical views (4-chamber, 2-chamber and long axis) with and without color Doppler, in addition to recordings from both pleural cavities and the inferior vena cava. The reference imaging includes the same recordings, but in addition all other chambers and valves are assessed (grey scale, color Doppler, pulsed wave and continuous wave Doppler and tissue Doppler)."
214873523|NCT00517127|DRUG|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
214666073|NCT06234904|BIOLOGICAL|IBR733 Cell Injection|The minimum initial dose is 5.0×10\^9 cells and then escalate to 7.5×10\^9 cells and 10.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
214873524|NCT00517127|DRUG|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
214873525|NCT04720131|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks.
214873526|NCT04720131|DRUG|apatinib|"Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage."
214873527|NCT04720131|DRUG|Capecitabine|Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
214873528|NCT00664131|OTHER|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
214873529|NCT02292173|DRUG|Trametinib|"Dose Escalation:~Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
214873530|NCT02292173|DRUG|Sorafenib|"Dose Escalation:~Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
214873531|NCT02837614|DRUG|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
214873532|NCT02837614|DRUG|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
214873533|NCT02837614|PROCEDURE|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
214873534|NCT02837614|DRUG|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
214873535|NCT00107510|BIOLOGICAL|pegfilgrastim|
214873536|NCT00107510|DRUG|carboplatin|
214873537|NCT00107510|DRUG|docetaxel|
214873538|NCT00107510|PROCEDURE|conventional surgery|
215039378|NCT07159451|DRUG|Elacestrant|Patients will receive elacestrant 345 mg/daily administered orally for 4 weeks.
215039379|NCT07159451|DRUG|Leuprorelin|Patients randomized in arm B will recieve Leuprorelin at Day 1 and Day 29
214873539|NCT03777423|DEVICE|PEEK framework partial dentures|Polymer-based framework recently introduced made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
214873540|NCT03777423|DEVICE|Cobalt- chromium framework partial dentures|It's a bio-compatible metal used in thin sections so less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and resistance to corrosion.Drawbacks of metal frameworks can include hypersensitivity, aesthetics because of metal metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production
214873541|NCT05204836|DRUG|Zoledronic Acid Injection|5 mg / 100 mL intravenous infusion
214873542|NCT05204836|DRUG|Placebo|100 mL intravenous infusion
214873543|NCT03619681|DRUG|KN026|Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
215039380|NCT07158658|OTHER|NeoThelium FT (HCT/P 361)|NeoThelium FT (HCT/P 361) is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
215039381|NCT07160088|OTHER|Observational|This is an observational study without study-related intervention. All the treatments will be depended on the attending doctors and according to the related guidelines.
215039382|NCT07160426|BIOLOGICAL|Fresh Frozen Plasma (blood product)|Fresh Frozen Plasma
215039383|NCT07160426|DRUG|MVI and lactated ringers|placebo
215039384|NCT07158580|DEVICE|Gait Tracker|Opti Gait is a wearable gait tracker
215039385|NCT07160530|BEHAVIORAL|EAT Family Style|Rural family childcare home providers receive 7 online modules on responsive feeding practices over 16 weeks, plus 7 individual coaching sessions via Zoom with Extension agents. Providers record mealtime videos for personalized feedback, engage in goal-setting and action planning, and receive printed materials and conversation cards.
215039386|NCT07160530|BEHAVIORAL|Better Kid Care|Rural family childcare home providers receive 10 online modules about general childcare topics unrelated to nutrition, including child development, block play, oral health, supervising children, and managing a family childcare home through the Better Kid Care platform.
215039387|NCT07158892|BEHAVIORAL|Diagnostic Advance Care Planning Discussion|The intervention consists of a structured, values-based conversation modeled after Advance Care Planning (ACP) principles, adapted for diagnostic decision-making. Participants will receive a hypothetical clinical vignette involving a musculoskeletal diagnostic test (e.g., MRI, X-ray, CT, or ultrasound), followed by a simulated discussion facilitated by a trained researcher. The conversation is guided by branching scripted prompts designed to elicit the participant's values, goals, expectations, and understanding of the potential benefits and harms of testing. Responses are transcribed using verbal-to-text technology. Unlike standard decision aids or educational materials, this intervention emphasizes patient reflection and shared decision-making by prompting participants to consider what matters most to them before making a decision about the test. The discussion does not involve actual test ordering or clinical decisions but is intended to simulate a real-world ACP discussion process.
215039388|NCT07158892|BEHAVIORAL|Informational Statement Only|Participants will be presented with a brief, standardized informational statement describing what the test involves, what it may show, and general risks or limitations. No individualized values-based discussion or simulated conversation will occur.
215039389|NCT07159126|DRUG|DS3610a|Participants will receive DS3610a at the target dose. Treatment will continue until radiographic disease progression, as determined by the investigator, or until another reason for discontinuation of trial intervention occurs.
215039390|NCT07159477|BEHAVIORAL|Skin to Skin contact|Fathers are briefed on skin-to-skin: what it is/isn't, why it matters, how to do it, and benefits for father, mother, and baby. Keep the room quiet; close windows to avoid drafts. Do not perform if the father is sleeping. Smokers must not perform while smoking and should do it before smoking when possible. After mother-infant skin-to-skin and breastfeeding, start father-infant contact within four hours of birth. If clothing is unsuitable, provide a surgical gown. Place the diapered infant upright on the father's bare chest. The father supports shoulders and back, maintains eye contact, speaks softly, and touches the baby. Cover both with a blanket; only mother, father, and infant remain, with the researcher silent. Continue at least 15 minutes; end if the father requests care or the infant needs care (diapering, dressing, breastfeeding). Repeat once for the early-contact group and at least daily until discharge for the frequent-contact group; on discharge, remind daily home practice.
214873544|NCT02099682|DRUG|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
215039391|NCT07160218|DEVICE|tDCS|A 30-minute tDCS session with the cathode placed over the left dorsolateral prefrontal cortex (DLPFC), delivered in 10 sessions over 2 weeks. This protocol targets cognitive improvement in MS patients
214873545|NCT05141331|DEVICE|piezoelectric|Comparing Piezoelectric split-crest technique versus expansion using Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
214873546|NCT06731101|DRUG|Bupivacaine + Lidocaine +dexamethasone|Sonar guided block of Stellate Ganglion By Bupivacaine + Lidocaine
214873547|NCT06731101|DRUG|Tryptizole + Librax|Tryptizole + Librax
214873548|NCT00699062|DRUG|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
214873549|NCT00699062|DRUG|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
214873550|NCT04810130|OTHER|Soccer Kicking|Subjects assigned to the soccer kicking arm will complete 10 soccer kicks in 10 minutes.
215039392|NCT07160218|DEVICE|Cognitive Rehabilitation|computer-based cognitive rehabilitation exercises. Conducted in 10 sessions over 2 weeks to enhance attention, memory, and neuroplasticity in MS patients.
215039393|NCT07160218|DEVICE|Sham tDCS|Sham stimulation applied over the left DLPFC for 30 minutes, mimicking the sensation of tDCS without delivering active current, over 10 sessions, used as control to blind participants to the intervention
215039394|NCT07160179|DRUG|ABBV-6628|Intravitreal injection
215039395|NCT07160179|DRUG|SYFOVRE|Intravitreal injection
215039396|NCT07159308|BEHAVIORAL|Intrinsic Motivation Treatment|The Intrinsic Motivation treatment utilizes principles of Motivational Interviewing to help autistic young adults increase their desire and completion of daily living skills. This is a five-session intervention. Each clinical session is 60 minutes long. The goals of the treatment are to enhance motivation and behavior change.
215039397|NCT07159308|BEHAVIORAL|Extrinsic Motivation Treatment|The Extrinsic Motivation treatment utilizes behavioral principles to help autistic adolescents and young adults create reward schedules and behavioral tracking sheets to enhance desire and completion of daily living skills. This is a five-session intervention. Each clinical session is 60 minutes long. The goals of the treatment are to enhance motivation and behavior change.
215039398|NCT07159308|BEHAVIORAL|Combined Intrinsic and Extrinsic Motivation Treatment|The Combined Intrinsic and Extrinsic Motivation treatment combines elements of both intrinsic and extrinsic motivation treatments to enhance desire and completion of daily living skills. This is a five-session intervention. Each clinical session is 60-90 minutes long. The goals of the treatment are to enhance motivation and behavior change.
215039399|NCT07161024|DEVICE|Augmented reality|Augmented reality markers of different designs are tested to evaluate how they affect trainee performance.
215039400|NCT05287373|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
215039401|NCT05287373|OTHER|conventional medical management|Conventional medical management
215039402|NCT07158866|BEHAVIORAL|Ballroom Dance|"The intervention will involve twice-weekly dance sessions, lasting 45 minutes each, for 6 months. Each session will include:~1. Rhythmic warm-up with music.~2. Combination of aerobic, resistance, and coordination exercises.~3. Technical development and learning of dance routines.~4. Cool down with free-body movements to slow music."
215039403|NCT07158866|BEHAVIORAL|Multicomponent Exercise|"The Multicomponent Exercise intervention will target several physical fitness components simultaneously, including strength, balance, and aerobic fitness. The program will consist of twice-weekly sessions, each lasting 45 minutes, for 6 months. Each session will include:~1. Warm-up with light stretching and joint mobility exercises.~2. Balance exercises~3. Strength training exercises~4. Aerobic exercises~5. Cool down with flexibility and relaxation exercises."
215039404|NCT07159139|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
215039405|NCT07160569|DIAGNOSTIC_TEST|Whole Genome Sequencing (WGS), Sequence Type Analysis (ST)|Whole Genome Sequencing (WGS), Sequence Type Analysis (ST), resistome, viruloma, and phenotypic resistance of CRE
215039406|NCT07159035|PROCEDURE|Flexible ureteroscopy with FANS|The FANS with negative-pressure suction, enhancing intrarenal pressure control and fragment evacuation during flexible ureteroscopy.
215039407|NCT07159035|PROCEDURE|Mini-percutaneous nephrolithotomy (mini-PCNL)|Mini-PCNL is performed under general anesthesia with less than 20 Fr access tract, using rigid nephroscopy and stone fragmentation under direct visualization. Postoperative drainage is provided via nephrostomy or ureteral stent as per protocol.
215039408|NCT07161401|OTHER|Observational assessment|Evaluation of sleep quality using the Children's Sleep Habits Questionnaire (CSHQ) and cephalometric analysis of mandibular position (SNB), vertical dimensions (SNGoGn, FMA), and upper airway measurements. No active intervention was performed.
215039409|NCT07161076|DEVICE|3d Printed space maintainer|using Next dent permanent crown resin, a digitally designed space maintainer will be 3d printed to maintain space after extraction
215039410|NCT07161076|DEVICE|stainless steel band and loop|lab fabricated metal band and loop
215039411|NCT07159568|OTHER|Pet dog visit|Pet dog visit will take place during dedicated time slots, following prior verification of the dog's hygiene criteria. The dog may stay in the patient's room for a maximum of 15 minutes. After the visit, an evaluation questionnaire will be completed by the healthcare staff and by the relative who accompanied the dog. The patient's evaluation questionnaire will be completed at ICU discharge if patient is able to respond, or at most 28 days after inclusion if the patient remains in the ICU.
215039412|NCT07161284|OTHER|Exposition to trained peer-support registrars for a year|Exposition to trained peer-support registrars for a year
215039413|NCT07159594|OTHER|Energy restriction|Diet with LED and energy restricted diet with gradually inclusion of meals
215039414|NCT07159438|OTHER|AI-Generated Video Radiology Report Explanation|Participants receive a personalized video explanation of their own radiology imaging results, generated using artificial intelligence technology. The AI converts the participant's existing written radiology report into an easy-to-understand video format featuring an avatar narrator. Each video is approximately 1-5 minutes long and explains the participant's specific imaging findings in plain language. All AI-generated videos are reviewed by qualified medical personnel before delivery to ensure accuracy and prevent misleading information. Participants watch their personalized video and then complete survey to evaluate how well the video helped them understand their radiology results compared to the original written report.
214666074|NCT00917384|BIOLOGICAL|ramucirumab|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
215039415|NCT07160894|OTHER|Saliva and Serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 5 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.
214666075|NCT00917384|DRUG|Placebo|Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
214666076|NCT00917384|OTHER|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
214666077|NCT02591992|OTHER|Cardiac CT as the first diagnostic modality in suspected CAD|Performation of non-invasive cardiac CT angiogram
215039416|NCT07160894|OTHER|Saliva and Serum sampling|ELISA method will be used to measure IL-10 and IL-6 values in collected saliva and serum samples. For ELISA analysis, a commercial kit (Sunred Bio, Shanghai, China) pre-coated with human selected antibodies will be used.
215039417|NCT07158905|BIOLOGICAL|AV-1980R 20 µg|MultiTEP-based investigational tau vaccine formulated with the adjuvant. The vaccine is designed to elicit anti-tau antibodies in participants with preclinical Alzheimer's disease.
215039418|NCT07158905|BIOLOGICAL|AV-1980R 60 µg|MultiTEP-based tau vaccine formulated with the adjuvant, 60 µg per dose; intramuscular injections at Weeks 0, 4, 12, and 36; secondary-prevention immunotherapy in preclinical AD.
214666078|NCT02591992|OTHER|Invasive coronary angiography as indicated by the guidelines|Patient undergoes invasive coronary angiography
214873551|NCT04810130|OTHER|Soccer Heading (Frontal)|Subjects assigned to the soccer heading (frontal) arm will complete 10 frontal soccer headers (ball headed directly back to launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
214666079|NCT02636309|BEHAVIORAL|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
214666080|NCT01095861|DEVICE|FlexTip ETT (Parker FlexTip/GlideScope FlexTip)|FlexTip ETT used for endotracheal intubation
214666081|NCT01095861|DEVICE|Control - standard flexible ETT (Mallinckrodt)|"Control - standard flexible ETT~Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134"
214873552|NCT04810130|OTHER|Soccer Heading (Oblique)|Subjects assigned to the soccer heading (oblique) arm will complete 10 oblique soccer headers (ball headed 90° to the right from ball launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
214873553|NCT02929186|BEHAVIORAL|Opt-In Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
214873554|NCT02929186|BEHAVIORAL|Opt-Out Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
214873555|NCT02342639|DRUG|Rifaximin|550mg pills
214873556|NCT02342639|DRUG|Placebo|Placebo pill
214873557|NCT02212379|DRUG|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
214873558|NCT01129843|DRUG|Directly observed home based daily iron therapy|Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
214873559|NCT01274676|DEVICE|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
214873560|NCT01274676|DEVICE|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
214873561|NCT02105974|DRUG|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
214873562|NCT02105974|DRUG|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
214873563|NCT03384082|PROCEDURE|hysteroscopic treatment|treatment
214873564|NCT04632160|DEVICE|IASD System II|The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
214666082|NCT00658229|BEHAVIORAL|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
214666083|NCT00149214|DRUG|pemetrexed|500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
214666084|NCT00149214|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
214666085|NCT00149214|DRUG|doxorubicin|60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
214666086|NCT00149214|DRUG|docetaxel|100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)
214666087|NCT05877677|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
214666088|NCT05877677|DIETARY_SUPPLEMENT|Polygonatum kingianum extract drink|consume 1 bottle per day
214873565|NCT03515590|OTHER|Emulsion with solid droplets|This will be a 500 mL beverage emulsion in which the droplets are crystalline. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
214873566|NCT03515590|OTHER|Emulsion with liquid droplets|This will be a 500 mL beverage emulsion in which the droplets are liquid. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
214873567|NCT03155945|DRUG|Olorinab|Olorinab active treatment for 8 weeks.
214873568|NCT04186351|BEHAVIORAL|Encounter notification service|The caring support and services provided by SCHSA will consist of multiple components, including standard call \& care center support, medical appointment reminder, assistance to reschedule appointment, follow-up calls with either nurse or health workers to monitor health situation of service recipients, assessing needs of service recipient for elderly home care and/or rehabilitation services, providing elderly home care and/or rehabilitation services based on assessment, assessing needs of service recipient for emotional and community support, providing additional emotional support via either social calls by volunteers or counseling by social workers, and making referrals for community support services.
214666089|NCT00308815|DEVICE|Automatic CPR machine|
214873569|NCT03877991|DRUG|CBD-sesame oil capsule|A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
214873570|NCT03877991|DRUG|CBD-LNL capsule|A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
214873571|NCT03877991|DRUG|CBD powder form capsule|Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
214873572|NCT00801580|DRUG|doxorubicin liposomal|"* Cyclophosphamide~* Mesna~* Methotrexate~* Doxorubicin liposomal~* Vincristine~* Dexamethasone~* Rituximab~* Cytarabine"
214666090|NCT05952830|OTHER|ESWT group|subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii (17). Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
214873573|NCT01909830|DRUG|Arm A : Gemcitabine + Pemetrexed|"Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
214873574|NCT04941118|DRUG|Injection of dextrose, local anesthetic and saline to the myofascial trigger point|An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.
214873575|NCT04941118|DRUG|Local anesthetic and saline injection to the myofascial trigger point|A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.
214873576|NCT04332965|PROCEDURE|Non-Surgical Periodontal Treatment|Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.
214873577|NCT06884514|DRUG|Psilocybin|A moderate dose of 20 mg psilocybin will be administered.
214873578|NCT06884514|DRUG|3,4-Methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
215039419|NCT07158905|BIOLOGICAL|AV-1980R 180 µg|MultiTEP-based tau vaccine formulated with the adjuvant, 180 µg per dose; intramuscular injections at Weeks 0, 4, 12, and 36; secondary-prevention immunotherapy in preclinical AD.
215039420|NCT07158905|OTHER|Placebo|10 mM phosphate buffer formulated with the adjuvant; intramuscular injections at Weeks 0, 4, 12, and 36; no active antigen.
215039421|NCT07161661|PROCEDURE|Usual VA Care|The usual treatment provided by PM\&R clinicians for CLBP
215039422|NCT07161661|PROCEDURE|Osteopathic manipulative treatment|Between your first visit (baseline) and 12 weeks, participants will receive up to 4 usual care visits plus OMT.
215039423|NCT07159854|DEVICE|RICORDO-DTx system|Participants with will undergo a cognitive enhancement program using the Astir RICORDO-DTx system (http://www.ricordo-dtx.com), which allows for the personalization of rehabilitative content based on the needs of the target population and can be delivered remotely.
215039424|NCT07159854|DEVICE|HOMING system|Participants will also undergo motor rehabilitation sessions focused on improving balance, gait, and muscular endurance using the HOMING system (https://www.tecnobody.com/homing).
215039425|NCT07159854|DEVICE|Home-based training program|Subjects will view videos on Tablet. The treatment will be provided via a digital medicine platform on a mobile device (tablet).
215039426|NCT07159230|DIAGNOSTIC_TEST|point-of-care multiplex PCR test|community health care center in intervention group were provided with point-of-care multiplex PCR test (POCT) plus routine test. POCT testing was recommended for all enrolled patients presenting with acute respiratory infections who meet the predefined inclusion criteria. The therapeutic interventions were determined by health-care workers on the basis of POCT result, clinical assessment and guideline.
214873579|NCT06884514|DRUG|Psilocybin placebo|Mannitol capsules instead of capsules containing psilocybin.
214873580|NCT06884514|DRUG|3,4-Methylenedioxymethamphetamine placebo|Mannitol capsules instead of capsules containing MDMA.
215039427|NCT07159997|DIAGNOSTIC_TEST|Accuracy of rail sign by ultrasound st diagnosis placent previa|Accuracy of rail sign by ultrasound at derection of PAS
215039428|NCT07159893|DRUG|Inebilizumab + Rapid Steroid Tapering group|"Drug 1: Inebilizumab Generic Name: Inebilizumab Formulation: Injection (Intravenous) Dose: 300 mg Frequency:Day 6 (Week 0): First dose ；Day 20 (Week 2): Second dose ；Week 24: Third dose Route: Intravenous infusion Drug 2: Prednisone Generic Name: Prednisone Formulation: Tablet (Oral) Dose \& Tapering:Day 6-19: 60 mg daily；Day 20: 60 mg every other day (EOD)~；Day 34: 30 mg EOD → Day 48: 15 mg EOD → Day 62: 10 mg EOD → Day 76: 5 mg EOD → Day 90: Discontinue Route: Oral"
214291239|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
214873581|NCT06882811|BIOLOGICAL|CD83-positive MSC|90 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
214873582|NCT06882811|BIOLOGICAL|regulatory MSC|45 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
214873583|NCT06882811|OTHER|control solution|45 patients are infused with equal volume of control solution and receive regulatory treatment
214873584|NCT02203331|DRUG|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
214873585|NCT02203331|DRUG|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
214873586|NCT02203331|DRUG|Anastrozole|Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
214291240|NCT04563923|DRUG|Avdoralimab (IPH5401)|Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
214666091|NCT05952830|OTHER|DN group|Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
214666092|NCT03623750|DRUG|EGFR-TK Inhibitor|Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
215039429|NCT07159893|DRUG|Inebilizumab + Standard Steroid Tapering group|Drug 1: Inebilizumab Generic Name: Inebilizumab Formulation: Injection (Intravenous) Dose: 300 mg Frequency:Day 6 (Week 0): First dose ；Day 20 (Week 2): Second dose ；Week 24: Third dose Route: Intravenous infusion Drug 2: Prednisone Generic Name: Prednisone Formulation: Tablet (Oral) Dose \& Tapering:Day 6-34: 60 mg daily;Day 34: 60 mg EOD → Day 62: 30 mg EOD → Day 90: 15 mg EOD → Day 118: 10 mg EOD → Day 146: 5 mg EOD → Day 174:Discontinue; Route: Oral
214666093|NCT03623750|BIOLOGICAL|EGF-PTI|"The first day of dosing with EGF-PTI will be designated Day 1. Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92. After the 5~th vaccination, patients will enter a maintenance phase during which reduced dose vaccinations will be performed every 2 or 3 months in conjunction with the interval between detailed check-up of the patient. As this interval can vary between patients, the interval for maintenance vaccination can also vary between 2 and 3 months."
215039430|NCT07160166|OTHER|Prototype 1|Subjects will brush and rinse with their assigned mouthwash twice daily.
215039431|NCT07160166|OTHER|Prototype 2|Subjects will brush and rinse with their assigned mouthwash twice daily.
215039432|NCT07160166|OTHER|Marketed Comparator|Subjects will brush and rinse with their assigned mouthwash twice daily.
215039433|NCT07159074|DRUG|Tc 99m tilmanocept|150 mcg containing 10 mCi of Tc 99m tilmanocept will be administered through an IV route of injection. SPECT-CT imaging will then be performed.
215039434|NCT07160725|DRUG|BMS-986517|Specified dose on specified days
215039435|NCT07160374|PROCEDURE|Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE)|Transarterial chemoembolization performed through the radial artery using HepaSphere drug-eluting microspheres in patients with hepatocellular carcinoma.
215039436|NCT07159243|DRUG|HL-1186|HL-1186 tablet for oral administration.
215039437|NCT07159243|DRUG|HL-1186|HL-1186 tablet for oral administration.
215039438|NCT07159243|DRUG|HL-1186 placebo|HL-1186 placebo tablet for oral administration.
215039439|NCT07161414|DRUG|IV Rilvegostomig|Rilvegostomig administered IV.
215039440|NCT07161414|DRUG|Recombinant Human Hyaluronidase (rHu)|rHu administered subcutaneously.
215039441|NCT07161414|DRUG|SC Rilvegostomig|Rilvegostomig administered subcutaneously.
214666094|NCT03623750|DRUG|Cyclophosphamide|Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
215039442|NCT07161414|DRUG|SC rilvegostomig + rHu|SC rilvegostomig + rHu administered subcutaneously.
214291241|NCT04563923|OTHER|Control|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion"
214291242|NCT00435292|DRUG|Naproxen|nonsteroidal anti-inflammatory drug
215039443|NCT07159360|DEVICE|CLINICAL EXPLORER|8 sessions of use of the device in the rehabilitation center
215039444|NCT07159386|OTHER|EHR alert|Diagnoses of MASLD (based on ICD 9/10 code) in a patient's EHR history, visit, or problem list, will cue a non-interruptive alert to appear and prompt clinicians to use the integrated EPIC© FIB-4 calculation SmartPhrase. The tool displays the FIB-4 risk score, the advanced fibrosis risk, and the clinical guidance. LSM by ultrasound with elastography will be recommended for patients with FIB-4 \>1.3 (FIB-4 \>2.0 if age \>65) and the decision support will urge clinicians to order US with elastography through the SmartSet. LSM results will be documented in the EHR and categorized as low-risk MASLD (LSM \<8 kPa) or advanced fibrosis (LSM \>8 kPa). Results will be disseminated to the ordering PCPs and the patients. PCPs will receive information on patient counseling for MASLD, and the expanding roles of weight loss, reduced alcohol use, and exercise on disease management. PCPs will be encouraged to refer patients with advanced fibrosis to a hepatology specialist, in accordance with guidelines.
215039445|NCT07160075|BEHAVIORAL|Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs|Simultaneous administration of OAT and oral PrEP (direct observed therapy or home supply) at existing pharmacy-based programs
215039446|NCT07159373|DRUG|MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole|"Mass drug administration with moxidectin co-administered with DEC and albendazole (MoxDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged ≥ 2 years but \< 4 years - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"
215039447|NCT07159373|DRUG|IDA - Ivermectin + DEC + albendazole|"Mass drug administration with ivermectin co-administered with DEC and albendazole (IDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged \< 2 years or weight \< 15 kg - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"
215039448|NCT07161635|DEVICE|Clareon PanOptix Pro/Pro Toric Trifocal IOL|Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.
215039449|NCT07161635|PROCEDURE|Phacoemulsification|Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for IOL implantation.
215039450|NCT07160881|BEHAVIORAL|Pillow maniquin training|In this initiative, participants will be trained with a low-cost mannequin in addition to standard training.
214291243|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 250 mg|flavonoid mixture
214666095|NCT05164328|OTHER|No intervention|No intervention
215039451|NCT07160686|DRUG|Apixaban|apixaban 2.5mg twice a day for 6 months
215039452|NCT07160686|OTHER|Placebo|Placebo twice a day for 6 months
214666096|NCT04691258|BEHAVIORAL|Experimental: Complete Group|"The participants performed the squat and Stiff exercises with the maximum range of motion. In the squats, the knees were completely flirted, even if the participant could not perform the movement with neutral vertebral posture. The heels were also not supported to the ground in some participants due to lack of flexibility. It was instructed that the participants tried to perform the Squats and Stiff keeping the lumbar lordosis neutral, with the best posture they could in all training sessions, but all should perform the exercise with as much range of motion as possible.~The positioning of the feet was also carefully controlled, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the upper iliac spines (EIAS). The direction of the knees was oriented pointing in the direction of the tip of the feet parallel throughout the cycle of the movement."
214873587|NCT02203331|DRUG|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
214873588|NCT02091466|DEVICE|pre-warming|warming patients 30 minutes prior to anesthesia
214291244|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 500 mg|flavonoid mixture
214873589|NCT00124761|PROCEDURE|Surgery + WBRT|Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
214873590|NCT00124761|RADIATION|Radiosurgery + WBRT|Radiosurgery - Marginal dose based on maximum tumour diameter
214873591|NCT06341829|OTHER|Prismatic adaptation|Participants will fit with prismatic goggles that deviate their visual field by 13° either leftward or rightward. They will seat in front of a white horizontal board on which three target dots (5 mm diameter) were positioned at 0, -10 and +10° from their body midline at a distance of 57 cm from their eyes. They will perform a total of 150 verbally instructed pointing movements with their right index finger towards the right (+10°) and left (-10°) targets in a pseudorandom order.
214873592|NCT03560180|DIAGNOSTIC_TEST|Dutch score|leakage score (DUtch LeaKage, DULK), that consider several items (fever, heart rate, respiratory rate, urinary production, mental status, clinical conditions, signs of ileus, gastric retention, fascial dehiscence, abdominal pain, wound pain, leukocytosis, CRP, increase of urea or creatinine and nutrition status), to give a score
214873593|NCT03560180|DIAGNOSTIC_TEST|Serum C-reactive Protein|see study protocol
214873594|NCT03560180|DIAGNOSTIC_TEST|serum Procalcitonin|see study protocol
214873595|NCT03209557|OTHER|SmartWatch SmokeBeat Application|The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
214873596|NCT05258448|OTHER|Chemoradiotherapy|Cardiac Magnetic Resonance scan and ECG
214873597|NCT01919788|DRUG|Insulin (Insuman Rapid)|
214873598|NCT01919788|DRUG|Glucose|
214873599|NCT01919788|OTHER|Saline|
214873600|NCT03558061|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
214873601|NCT03749083|OTHER|The Functional Assessment of Cancer Therapy- Colorectal|The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.
214873602|NCT06733142|DIETARY_SUPPLEMENT|Test Product: Yoghurt|High protein spoonable yoghurt
214873603|NCT06733142|DIETARY_SUPPLEMENT|Micellar casein drink|Micellar casein drink made from water, casein powder and fruit syrup
214873604|NCT06733142|DIETARY_SUPPLEMENT|Placebo|Placebo sugar free jelly
214873605|NCT00497913|DRUG|NaCl 0.9%|
214873606|NCT00497913|DRUG|Botulinum Toxin A|
214873607|NCT03134118|DRUG|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
214873608|NCT04335318|DEVICE|AI-assisted colonoscopy|Colonoscopies performed with assistance of an AI tool that highlights the areas that are susceptible to be a polyp.
214873609|NCT05260580|OTHER|No Intervention: Routine care|
214873610|NCT03483363|DRUG|topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)|Fractures will be irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.
214873611|NCT03483363|DRUG|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure.
214873612|NCT03483363|DRUG|intravenous (IV) prophylactic antibiotic|All arms with receive standard parenteral (IV) prophylactic antibiotic.
214873613|NCT01987310|DRUG|atorvastatin|atorvastatin 20 mg per day for 6 months
214873614|NCT01987310|BEHAVIORAL|lifestyle counseling|lifestyle modification by dietician counseling and follow up
214873615|NCT06658535|DRUG|dodecafluoropentane (0.025 mL/kg)|dodecafluoropentane (0.025 mL/kg)
214873616|NCT06658535|DRUG|dodecafluoropentane (0.032 mL/kg)|dodecafluoropentane (0.032 mL/kg)
214291245|NCT05989789|DEVICE|Radioactive Seed Implantation|In patients where initially the tumour lesion could not be identified, a radioactive seed was implanted and intraoperatively detected with a geiger counter sonde.
214873617|NCT06658535|DRUG|dodecafluoropentane (0.050 mL/kg)|dodecafluoropentane (0.050 mL/kg)
214873618|NCT04726176|BIOLOGICAL|Exposure to COVID-19|To study the exposure of COVID-19 on the brain and executive functioning
214873619|NCT02613702|PROCEDURE|Free Gingival Graft|Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
214873620|NCT02613702|PROCEDURE|Original Free Gingival Graft technique|Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
215039453|NCT06152107|PROCEDURE|BTVA treatment plus optimal medical therapy (GOLD guidelines)|"Patients in experimental group will be treated with the InterVapor System in at least 2 subsegments of different segments(unless the two most severe subsegments are located in the same segment). Patients in control group will be treated with the InterVapor System in at least 1 segment.~A sequential procedure allows for at least 6 weeks and no longer than 6 months after the first procedure. Patients in both groups will receive ipsilateral hemithorax treatment per procedure, with a treatment volume (air + tissue) of ≤1700 mL per procedure and ≥1000 mL cumulatively across two procedures. All patients will continue to receive optimal medical therapy (GOLD guidelines) for the duration of the study.~Follow-up visits will be scheduled at 1, 3, 6 and 12 months following the second procedure with examination of pulmonary function tests, HRCT, 6-minute walk test, SGRQ-C, mMRC, CAT questionnaires. All adverse events during the study will be recorded."
215039454|NCT06160427|BIOLOGICAL|CTM Boost|Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.
215039455|NCT06160427|BIOLOGICAL|PRP|"PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing.~At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon."
215039456|NCT03094143|PROCEDURE|Aortic valve intervention|The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.
215039457|NCT03419234|DRUG|Abiraterone Acetate|Given PO
214873621|NCT02613702|PROCEDURE|Modified Free Gingival Graft technique|Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
214873622|NCT06144164|PROCEDURE|Immediate Lymphatic Reconstruction|Immediate Lymphatic Reconstruction will happen at the time of Axillary Lymph Node Dissection
214873623|NCT06144164|DIAGNOSTIC_TEST|Volumetric arm measurements|Volumetric arm measurements will occur at each in-person postoperative visit time points.
214873624|NCT06144164|OTHER|Lymphatic massage|Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
214873625|NCT06144164|OTHER|Range of motion exercises|Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
214873626|NCT06144164|OTHER|Compression garment use|Participants will use compression garments 24 to 48 h after surgery and will continue daily use for at least 8 h a day for 3 months or until 3 months after any adjuvant treatments are completed
215039458|NCT03419234|DRUG|Antiandrogen Therapy|Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
215039459|NCT03419234|DRUG|Cabazitaxel|Given IV
215039460|NCT03419234|OTHER|Laboratory Biomarker Analysis|Correlative studies
214873627|NCT05653284|DRUG|AK130|IV infusion, specified dose on specified days.
214873628|NCT06739993|BEHAVIORAL|Resonance frequency breathing with heart rate variability biofeedback training|During training, a ball that expands (breathe in) and shrinks (breathe out) on the screen specified the breathing frequency goal to a value of six cycles per minute (five seconds inspiration, five seconds expiration). The HRV was visualized by new symbols varying in color depending on the respectively measured values, which appeared every ten seconds. When the participants achieved the specified breathing frequency, resulting in an increased sinus arrhythmia, the symbols appearing on the smartphone display were green. When the participants did not achieve the specified breathing frequency, the symbols appeared in yellow (non-significant deviation), orange (significant deviation), or red (very significant deviation). The participants were instructed to adjust their breathing frequency to reach emergence of as many green symbols as possible for the entire training session.
215039461|NCT03419234|PROCEDURE|Orchiectomy|Undergo standard of care surgical castration with bilateral orchiectomy
215039462|NCT03419234|OTHER|Pharmacological Study|Correlative studies
215039463|NCT03419234|DRUG|Prednisone|Given PO
215039464|NCT05948566|BIOLOGICAL|TS23|Monoclonal antibody
215039465|NCT05691647|BEHAVIORAL|Chronotherapy|Chronotherapy involves three different interventions. Sleep deprivation/wake therapy will be conducted for 34 hours. To assist wake and to ensure that the participants adhere to the sleep deprivation, outpatients will be admitted to a one-night stay at the inpatient ward that is connected to the outpatient clinic at Nidaros DPS. Patients already admitted to inpatient treatment will be temporary transferred to the ward selected to oversee the sleep deprivation. Upon discharge, participants are encouraged to adhere to the sleep schedule which presents the sleep-wake phase advancement and later stabilization of the sleep-wake phase. Light therapy is provided for half an hour every day from day four in the study. In addition to the chronotherapeutic interventions, the participants will receive treatment as usual (TAU) with their assigned therapist.
215039466|NCT05691647|BEHAVIORAL|Treatment as usual|Participants allocated to receive TAU alone, will receive standard treatment for a depressive episode in the outpatient or the inpatient clinic. This study will not give restrictions or guidelines on how this treatment should be performed. The TAU-group will receive the treatment the responsible therapist considers and evaluate best fitting in the situation. Typical interventions administered in therapy for a depressive episode includes medication, cognitive behavioral therapy, and other psychotherapies.
215039467|NCT06414668|BEHAVIORAL|Cycling Intervention Group|A eight-weeks school-based cycling program. The school-based cycling intervention consists of 2 Bikeability sessions of 60 min at Physical Education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training. In addition, participants will receive encouragement strategies, one for each week of the intervention, for cycling to and from school during eight weeks.
214873629|NCT06739993|BEHAVIORAL|Anti-Stress program|The mobile system eSense Pulse from Mindfield Biosystems is used for the digital anti-stress program. To do this, the participants put on a chest strap with a sensor and can start training via the eSense app. The anti-stress program is carried out using a procedure generated for the study. During the anti-stress program units, the participants receive application-related information and tips to better understand the topic of stress, identify stressors in their own lives and reduce stress. The active control intervention of the anti-stress program was selected to investigate the effect of a specific stress level reduction without the direct modulation of physiological mechanisms of action as with HRV-BF-RFA.
214873630|NCT06754176|BEHAVIORAL|Alcohol Consumption Randomized Instructions|"Alcohol Avoidance: In this intervention assignment, participants will be instructed to avoid drinking alcohol for this day.~Alcohol Non-Avoidance: In this intervention assignment, participants will be allowed to drink alcohol for this day."
214873631|NCT04815889|BEHAVIORAL|PRIMUS parent training Group|"The parents offered a PRIMUS Group-based parent support program for 5 half days. This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The teachers will be offered a teacher group for half a day together with the parents.~For those families who need more intervention the PLUSS toddler team (from the specialist Healthcare) is established.~The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~* Support in the child's everyday environment home / preschool~* Targeted Parent Groups: toilet, sleep, food, everyday structure, handle behavioural problems~* Web courses"
214873632|NCT06901336|DRUG|[14C]-STX-478|oral administration
214873633|NCT05587569|DEVICE|Treatment of metatarsus adductus and hallux valgus with the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure|Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated study duration will be 5 years post index procedure.
214873634|NCT06677554|DRUG|Addition of ultrasound with contrast injection (SonoVue®)|Addition of contrast evaluation with SonoVue® injection (5 min including 1 min of acquisition) within the diagnostic strategy
214873635|NCT06677554|OTHER|Standard Care (in control arm)|No addition of ultrasound with contrast
214873636|NCT06895577|DRUG|neoadjuvant SCRT followed by Sintilimab plus CAPOX|SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.
214873637|NCT06891677|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy (CBT) with ACT and COPD Education|Participants receive an internet-based cognitive behavioral therapy (CBT) intervention combined with education specifically developed for COPD. The CBT program includes Acceptance and Commitment Therapy (ACT) components. The intervention lasts 8-10 weeks and consists of several online modules. Modules cover topics such as coping strategies, mindfulness techniques, disease knowledge, and symptom management. Participants complete the modules at home via a secure online platform, with regular support and feedback from trained healthcare professionals. The program aims to improve mental health, reduce anxiety and depression, enhance COPD knowledge, and help participants manage symptoms and daily life more effectively.
214873638|NCT06234202|DEVICE|Bioactive Sleeve|Pitchers will wear a bioactive sleeve immediately post-game through overnight.
214873639|NCT06234202|DEVICE|Control Sleeve|Pitchers will wear a non-bioactive sleeve immediately post-game through overnight.
215039468|NCT04095234|PROCEDURE|Acupuncture|Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation. If the patient has an electronically charged device, they will not receive TENS stimulation.
215039469|NCT04095234|PROCEDURE|Massage|Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.
215039470|NCT04861584|DRUG|Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin|4 cycle neoadjuvant therapy and radical cystectomy
215039471|NCT05823896|DRUG|Nirmatrelvir/ritonavir|300/100 mg tablet twice daily (q12h) administered orally for 15 days
215039472|NCT05823896|DRUG|Placebo/ritonavir|100mg tablet twice daily (q12h) administered orally for 15 days
215039473|NCT02979574|PROCEDURE|Electro-Acupuncture (EA)|Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.
215039474|NCT02979574|PROCEDURE|Battle Field Acupuncture (BFA)|Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.
215039475|NCT02979574|DEVICE|Wait List Control (WLC)|After the waiting period (12 weeks from randomization), participants in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
215039476|NCT04696146|DRUG|Berinert|Intrarenal dose of 500 U of Berinert
215039477|NCT04696146|DRUG|Placebo|Normal Saline placebo
215039478|NCT05849597|DRUG|Dexmedetomidine|Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous dexmedetomidine infusion in doses 0.2-0.7 mcg/kg/h.
214291246|NCT02341053|OTHER|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
214873640|NCT06902350|DRUG|CS231295|oral tablet. Only one dose on C0D1 in single-dose period. Once daily from C1D1 until disease progression, death, intolerable toxicity, loss to follow-up, withdrawal of informed consent, or the end of the trial, whichever occurs first, in multiple-dose period in both escalation and cohort expansion phases.
214873641|NCT00604136|BIOLOGICAL|tumor infiltrating lymphocytes|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro. Tumor infiltrating lymphocytes from these cultures will be assessed for tumor reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x2 days IV)and fludarabine (25 mg/mE2/day IV x5days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV every 8 hours for up to 15 doses).
215039479|NCT05849597|DRUG|Propofol|Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous propofol infusion in doses 1-2 mg/kg/h.
215039480|NCT04376593|DRUG|18F-αvβ6-BP|Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).
214873642|NCT04578444|DRUG|Zanidatamab|Administered intravenously
215039481|NCT02172794|DRUG|Tiotropium|
215039482|NCT02172794|DRUG|Placebo to tiotropium|
215039483|NCT02172794|DRUG|Salmeterol|
215039484|NCT02172794|DRUG|Placebo to salmeterol|
215039485|NCT00285779|DRUG|Etanercept|etanercept 50 mg twice weekly for 12 weeks
215039486|NCT00285779|DRUG|Placebo|
215039487|NCT04164277|BEHAVIORAL|Caregiver Component.|Facebook-based program including four new habit-formation tasks/week. Three face-to-face or virtual caregiver meetings: Meeting 1: Study orientation and healthy cooking education will be offered, and each family will receive a small bag of groceries to facilitate preparation of a recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: Study interveners will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: Study interveners will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource booklet.
215039488|NCT04164277|BEHAVIORAL|Caregiver-Preschooler Learning.|Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger on two weekdays. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
215039489|NCT04164277|BEHAVIORAL|Center-based Preschooler Component.|"Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat \& Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity."
215039490|NCT02485015|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
215039491|NCT02485015|DRUG|Apatinib|Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
215039492|NCT00307957|DEVICE|Pillar Palatal Implants|
215039493|NCT00529633|DRUG|Thalidomide|Thalidomide by mouth at night for a total of 24 weeks
214873643|NCT06649240|DRUG|Statins and/or Ezetimibe|Statin ± Ezetimibe to achieve target LDL-cholesterol level
214873644|NCT06649240|DRUG|PCSK9 inhibitor|The use of PCSK9 inhibitors is permitted to achieve target LDL-cholesterol levels in participants who did not reach the target with statins ± ezetimibe.
214873645|NCT04006210|COMBINATION_PRODUCT|ND0612 Solution for SC infusion|Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
214873646|NCT04006210|COMBINATION_PRODUCT|Placebo for SC infusion|Placebo solution administered SC via infusion pump
214873647|NCT04006210|DRUG|Oral IR-LD/CD|Encapsulated LD/CD 100mg/25mg
214873648|NCT04006210|DRUG|Placebo for Oral IR-LD/CD|Encapsulated Placebo for LD/CD 100mg/25mg
214873649|NCT06907342|DRUG|FOLFOX or FOLFIRI|Treatment allocation from tumouroid readout
214873650|NCT06911398|OTHER|Articulate Medical Intelligence Explorer (AMIE)|AMIE is an AI system for having clinical conversations with patients
214873651|NCT04874675|DRUG|diclofenac / acetaminophen /codeine|routine pain medication used post extraction of third molars
215039494|NCT00529633|OTHER|Sugar pill|Placebo by mouth at night for a total of 24 weeks
215039495|NCT06715748|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-4 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
215039496|NCT06715748|DIETARY_SUPPLEMENT|Placebo|Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
215039497|NCT04572334|OTHER|Auto and Subjective Refraction|All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
215039498|NCT04796584|OTHER|Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus|mRNA vaccination for SARS-CoV-2 is not provided by the study
215039499|NCT05615402|OTHER|Bone-specific strength training|Muscular strength and rate of force development (RFD) will be assessed in the key exercises of the intervention protocol
215039500|NCT05615402|DIETARY_SUPPLEMENT|Nutrition optimalisation|Dietary supplement of protein, vitamin D and Calcium 3x/w Dietary counselling based on individual dietary records
214873652|NCT04874675|DRUG|ibuprofen/acetaminophen/codeine|routine pain medication used post extraction of third molars
214873653|NCT05065567|DRUG|Droperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
214873654|NCT05065567|DRUG|Haloperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
214873655|NCT05065567|DRUG|Ondansetron 8mg|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
214873656|NCT06546774|DIETARY_SUPPLEMENT|Melatonin|In the study group, patients will receive melatonin supplementation for at least two months prior to IVF cycles
214873657|NCT02248038|PROCEDURE|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
214873658|NCT02248038|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
214873659|NCT03679052|DRUG|Mirtazapine|Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
214873660|NCT03679052|DRUG|Clonidine|Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
214873661|NCT03679052|DRUG|Placebo|Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
214873662|NCT06954727|OTHER|No intervention; Observational study|No intervention; observational study
214873663|NCT02339662|DRUG|Gabapentin|muscles pain treatment
214873664|NCT02339662|DRUG|Amitriptyline|muscles pain treatment
214873665|NCT05628649|BEHAVIORAL|Teaching Kitchen Collaborative Curriculum|"Participants in the intervention arm will first attend 16 weeks of intensive 2-hour classes covering hands-on cooking skills, dietary recommendations (as described within the Harvard Healthy Eating Plate), mindfulness and stress reduction skills, activity and movement techniques, and tools for behavior change. Next, they will attend monthly booster classes for 8 months, with a final assessment for the sustainability of outcomes at 18 months. Sessions will be taught by a combination of a chef educator, dietitian, health coach, or medical doctor.~The study will consist of 2 cohorts of individuals from 4 teaching kitchen program institutions. Each institution will run one-two cycles of the program with each cycle including both a treatment and control group. Each individual cohort will consist of a maximum of 80 individuals; with 40 block-randomized to the intervention and 40 in the control group receiving normal standard of care (followed by their PCP)."
214873666|NCT01630967|DRUG|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
214873667|NCT00625625|DRUG|isosulfan blue|
214873668|NCT00625625|GENETIC|polymerase chain reaction|
214873669|NCT00625625|OTHER|diagnostic laboratory biomarker analysis|
214873670|NCT00625625|OTHER|immunohistochemistry staining method|
214873671|NCT00625625|PROCEDURE|diagnostic lymphadenectomy|
215039501|NCT00736983|DRUG|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
215039502|NCT00736983|DRUG|ciprofloxacin|12 weeks; daily 2 x 500mg
214873672|NCT00625625|PROCEDURE|therapeutic conventional surgery|
214873673|NCT00625625|PROCEDURE|therapeutic lymphadenectomy|
214873674|NCT06404658|PROCEDURE|Genicular nerve block|patients who receive Genicular nerve block with spinal anathesia .
214873675|NCT05169450|DRUG|Diterpene ginkgolides meglumine injection|Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.
214873676|NCT05169450|DRUG|Ginaton|Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
214873677|NCT04385303|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle
214873678|NCT04385303|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
214873679|NCT03706937|OTHER|Semi directive interview|Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
214873680|NCT04778085|BEHAVIORAL|Illness management and recovery|Treatment given in groups, weekly for 10-12 months.
214873681|NCT04778085|OTHER|Semi-structured interviews|Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
214873682|NCT00588588|PROCEDURE|Bronchoscopy|Bronchoscopy procedure
214873683|NCT00588588|PROCEDURE|Clinical pulmonary infection score (CPIS)|Calculate CPIS
214873684|NCT05326048|OTHER|cytof analysis|cytof analysis of biological samples of CIS patients. Genomic analysis
214873685|NCT00668694|BEHAVIORAL|Stimulation|Stimulation given to the child by mother
214873686|NCT04975191|BEHAVIORAL|Resources|Participants will be provided a list of resources available at VCU that are intended to support student success
214873687|NCT04975191|BEHAVIORAL|Personalized Feedback Program (PFP)|Participants will complete an interactive online program that explores their personality-related traits to provide personalized recommendations for success
214873688|NCT04975191|BEHAVIORAL|Substance Use Feedback Program (BMI)|Participants will complete an online program based on brief motivational intervention (BMI) content/principles that explores their current substance use patterns to make personalized recommendations for success
215039503|NCT02951637|DRUG|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
214873689|NCT06176729|DRUG|Polatuzumab Vedotin, Rituximab, Lenalidomide|polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
214873690|NCT02645903|DRUG|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
214873691|NCT02645903|DRUG|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
214873692|NCT02028741|OTHER|Transverse vertebral pressures|Graded transverse mobilization directed to the thoracic spine
214873693|NCT01194063|DRUG|Omega-3 fish oil lipid emulsion|daily intravenous administration of Omegaven fish oil emulsion
214873694|NCT00506701|DRUG|Tadalafil|40 mg tablet
214873695|NCT01119781|DRUG|BIIB017(peginterferon beta-1a)|peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
214873696|NCT05065710|DRUG|ZL-1211|Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort
214873697|NCT06231095|DEVICE|continuous theta burst stimulation - cTBS|Continuous theta burst stimulation (cTBS) is a quicker and potentially more effective technique to reduce cortical hyperactivity than repetitive transcranial magnetic stimulation (rTMS). The study involves a cycle of 35 cTBS stimulations in the supplementary motor area (SMA) over 5 working days, with 7 stimulation sessions each day lasting 40 seconds. A 1-hour break between sessions will be observed, and each session will comprise 600 pulses at 90% of the motor threshold intensity.
214873698|NCT06273501|DRUG|Magtrace|Patients will receive superficial and interstitial injection with a 23 G needle with of a total volume of 0.1 - 1 ml Magtrace at four sites in or near the tumor in vulva, the same localization as the injections of Technetium99m and Patent blue for tracing SLNs performed at the surgery. The injection is performed by one of the gynecologic cancer surgeons participating in this study.The time of migration of SPIO to the groin nodes is not known for vulvar cancer. Transportation by dynamic MRI, with selective sequences repeated during a time span of 1- 60 minutes after the injection.
214873699|NCT00609180|BEHAVIORAL|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
214873700|NCT00609180|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
214873701|NCT00609180|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
214873702|NCT00609180|DIETARY_SUPPLEMENT|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
214873703|NCT03082144|DRUG|MTX|MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
214873704|NCT03082144|DRUG|Ara-C|Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
214873705|NCT03082144|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
214873706|NCT00315289|PROCEDURE|Nasolacrimal balloon catheter duct dilation|
214873707|NCT00315289|PROCEDURE|Nasolacrimal intubation|
214873708|NCT00315289|PROCEDURE|Simple Nasolacrimal duct probing|
214873709|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
214873710|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
214873711|NCT01056289|DRUG|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
214873712|NCT00098358|DRUG|Zileuton|
214873713|NCT01917916|DRUG|Placebo|Solution for subcutaneous (s.c.) injection.
214873714|NCT01917916|DRUG|BI 655064|Solution for subcutaneous (s.c.) injection.
214873715|NCT02918812|DRUG|Intracervical lidocaine|Intracervical lidocaine injected at four different points
214873716|NCT02918812|DRUG|Intramuscular Diclofenac|Intramuscular Diclofenac 30 mins before HSG
214873717|NCT02487303|DRUG|Acetaminophen Intravenous|IV 1 gram f3 doses over 24 hours
214873718|NCT02487303|DRUG|Acetaminophen Oral|Oral 1 gram 3 doses over 24 hours
214873719|NCT00216138|DRUG|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
214873720|NCT00216138|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
214873721|NCT00216138|DRUG|Premedication|Dexamethasone and antiemetic premedication
214873722|NCT00583388|DIETARY_SUPPLEMENT|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
214873723|NCT00583388|DEVICE|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
215039504|NCT02951637|DRUG|Gefitinib|Gefitinib (250mg daily)
215039505|NCT04240340|OTHER|semi-structured interview|Semi-structured, face-to-face interviews will be carried out with participants.
215039506|NCT04460781|BIOLOGICAL|Flublok Quadrivalent influenza vaccine RIV4|Route of administration: Intramuscular
214291247|NCT04236011|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
214873724|NCT04412278|OTHER|Online Survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
214873725|NCT01741168|OTHER|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
215039507|NCT04460781|BIOLOGICAL|Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4|Route of administration: Intramuscular
215039508|NCT03521700|DRUG|Rosuvastatin|For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L.
215039509|NCT05916300|OTHER|Diagnostic ultrasonography-guided physiotherapy group|"All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination."
214873726|NCT01741168|OTHER|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
214873727|NCT01708668|PROCEDURE|Epidural analgesia|
215039510|NCT01576783|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
215039511|NCT01576783|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
214291248|NCT00004482|DRUG|Cyclosporine|
214291249|NCT00004482|DRUG|methylprednisolone|
214291250|NCT00004482|DRUG|Muromonab-CD3|
214291251|NCT00004482|DRUG|prednisone|
214873728|NCT01708668|PROCEDURE|Combined spinal-epidural analgesia|
214873729|NCT01708668|PROCEDURE|Continuous epidural infusion|
214873730|NCT01708668|PROCEDURE|Intermittent epidural bolus|
214873731|NCT05568667|BEHAVIORAL|Low risk|"* remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* logbook"
214873732|NCT05568667|BEHAVIORAL|Moderate risk|"* remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* logbook"
214873733|NCT05568667|BEHAVIORAL|High risk|"* remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* 3 individual sessions of motivational coaching~* connected watch~* logbook"
215039512|NCT04096417|DRUG|Pemigatinib|Given PO
215039513|NCT04096417|OTHER|Quality-of-Life Assessment|Ancillary studies
215039514|NCT02228538|DEVICE|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system \& off-the-shelf standard knee implant system from various manufacturers
215039515|NCT01897493|DRUG|Evacetrapib|Administered orally
215039516|NCT01897493|DRUG|Digoxin|Administered orally
215039517|NCT04161534|DEVICE|KT Tape|in addition to an arm sling, KT Tape will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
215039518|NCT04161534|DEVICE|Arm Sling|An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
215039519|NCT02298725|OTHER|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
215039520|NCT02298725|OTHER|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report."
215039521|NCT04015258|DIETARY_SUPPLEMENT|Blueberries|fresh spanish blueberries
214291252|NCT03198949|DRUG|Afinitor (everolimus)|"Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)"
214291253|NCT00000633|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
214291254|NCT00000633|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
214291255|NCT06507449|DEVICE|Lithotripsy|Calcified lesion preparation using lithotripsy before implantation of a drug-eluting stent
214291256|NCT06507449|DEVICE|Orbital atherectomy|Calcified lesion preparation using orbital atherectomy before implantation of a drug-eluting stent
214873734|NCT00102947|DRUG|daptomycin (up to 14 days)|
214873735|NCT04192461|PROCEDURE|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the multi-radicular mandibular molars to be extracted as a reference and as an aid to engage the inter-radicular septum
214873736|NCT01806571|DRUG|Cytarabine|Given IV
214873737|NCT01806571|DRUG|Daunorubicin Hydrochloride|Given IV
214873738|NCT01806571|OTHER|Laboratory Biomarker Analysis|Correlative studies
214873739|NCT01806571|DRUG|Nilotinib|Given PO
214873740|NCT01806571|OTHER|Pharmacological Study|Correlative studies
215039522|NCT04015258|DIETARY_SUPPLEMENT|Blueberry powder|freeze-dried blueberry powder
215039523|NCT04015258|DIETARY_SUPPLEMENT|Blueberry components capsules|encapsulated blueberry components (microcrystalline cellulose powder in actual)
215039524|NCT01067430|DRUG|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
215039525|NCT01067430|DRUG|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
215039526|NCT05489328|OTHER|Candidate-1|Biological
215039527|NCT05489328|OTHER|Candidate-2|Biological
215039528|NCT05489328|OTHER|Candidate-3|Biological
215039529|NCT05489328|OTHER|Candidate-4|Biological
215039530|NCT05489328|OTHER|Candidate-5|Biological
215039531|NCT05489328|OTHER|Candidate-6|Biological
214873741|NCT04587999|OTHER|bladder stimulation|"The bladder stimulation technique requires the presence of 2 people:~* The child must be held by an adult (caregiver or parent) under the armpits, legs dangling.~* the first person (the investigator), performs the stimulation technique consisting of: rapid tapping (frequency of about 100 / min), over the pubic area, at the level of the bladder, alternated with external rotational movements of the pits lumbar, in the kidneys. Alternate these 2 maneuvers every 30 seconds.~* The second person starts the stopwatch at the start of the stimulation, and is about to collect the urine, 2nd jet in a sterile pot~* The maneuver ends as soon as urine is obtained, and will be stopped after 5 minutes in case of failure."
214873742|NCT04587999|OTHER|Quick wee|"The Quick wee technique requires the presence of only one person:~Stimulation of the suprapubic area by circular movements, with a cold and wet compress held by sterile forceps.~Collection of urine in a sterile container."
215039532|NCT05489328|OTHER|Candidate Control|Biological
215039533|NCT05489328|BIOLOGICAL|13vPnC|13-valent pneumococcal conjugate vaccine
215039534|NCT05489328|BIOLOGICAL|PCV15|15-valent pneumococcal conjugate vaccine
215039535|NCT04326452|DEVICE|bidirectional oxygenation mouthpiece|Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
215039536|NCT01083602|DRUG|panobinostat|PAN 20 mg PO given TIW, weeks 1\&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1\&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1\&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
215039537|NCT01083602|DRUG|bortezomib|
215039538|NCT01083602|DRUG|dexamethasone|
215039539|NCT05745155|DEVICE|Senti Wear device system with Senti-AI subsystem|"This device is a smart garment, with a similar form to a T-Shirt, jacket or tabard, embedded with ten sensor modules (nine acoustic sensors, one kinetic sensor - all able to detect signals from the chest wall and underlying structures, including the lungs) encased in silicone; the device is charged via a charging port in the garment. The device has two modes of operation: recording mode and charging mode. The device is internally (battery) powered during recording mode and mains-powered during charging mode. The device is accompanied by cloud-based software to listen to both contemporaneous and historically recorded breath sounds, for each Senti patient. To use the device, the user puts the garment on (overhead, like a T-Shirt, before joining the back piece to the front like a tabard).~Additionally, Senti-AI adds an anomaly burden score and an alert flag for review against each acoustic record for each patient."
215039540|NCT02543775|PROCEDURE|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
215039541|NCT05420948|DRUG|Pembrolizumab|A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.
215039542|NCT05420948|DRUG|Carboplatin|A chemotherapy drug used to treat cancer.
215039543|NCT05420948|DRUG|Paclitaxel|A chemotherapy drug used to treat cancer.
215039544|NCT06520397|DRUG|Ustekinumab and Upadacitinib|Participants in this group will maintain the original Ustekinumab regimen, receiving 90 mg administered subcutaneously every 8 weeks. In addition, they will receive Upadacitinib administered orally at a dosage of 45 mg daily for 12 weeks. After the 12-week period, the dosage of Upadacitinib will be adjusted based on patient condition and clinical judgment, continuing until the evaluation at week 16. Clinical efficacy of the dual-target therapy will be evaluated at week 16.
215039545|NCT06520397|DRUG|Ustekinumab|Participants will receive an additional induction dose of Ustekinumab administered intravenously at 6 mg/kg at baseline. This will be followed by subcutaneous maintenance therapy of 90 mg every 4 weeks. Clinical efficacy will be evaluated at week 16.
215039546|NCT00054522|DIETARY_SUPPLEMENT|calcitriol|
215039547|NCT00054522|DRUG|dexamethasone|
215039548|NCT02182518|DRUG|Epinastine|
215039549|NCT02182518|DRUG|Pseudoephedrine|
215039550|NCT02182518|DRUG|Placebo|Placebo during run-in period
215039551|NCT01887405|DRUG|Adrenaline auto-injector|"Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water"
215039552|NCT04232852|DIETARY_SUPPLEMENT|Probiotic mix|The probiotic mix will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule.
214291257|NCT06507449|DEVICE|High-pressure non-compliant balloon|Calcified lesion preparation using high-pressure non-compliant balloon before implantation of a drug-eluting stent
214873743|NCT04659759|OTHER|COVID-19 exposure|COVID-19 exposure during pregnancy
214291258|NCT06507449|DEVICE|Optical coherence tomography|Optical coherence tomography assessment of coronary arteries.
214873744|NCT04659759|BIOLOGICAL|COVID-19 vaccine|Receipt of any COVID-19 vaccine
215039553|NCT04232852|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive an identical capsule of maltodextrin.
215039554|NCT01674790|BEHAVIORAL|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
215039555|NCT01674790|BEHAVIORAL|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
215039556|NCT01674790|BEHAVIORAL|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
215039557|NCT01674790|BEHAVIORAL|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
215039558|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
214666097|NCT04691258|BEHAVIORAL|Active Comparator: Restricted Group|"The conventional movement technique of the squat exercise was used, in which the participants performed with the range of motion restricted to the neutral vertebral posture, approximately 90º of movement of the knee joint. may increase the range of motion if the lumbar posture did not rectify.~The positioning of the feet in this group was carefully controlled, the participants performed the exercise with the joints of the hips abducted and rotated laterally. Having markings on the ground as a reference, the feet went rotated at 21º and the lateral edge of the heels were moved away from each other, approximately with the biacromial distance. The direction of the knees was oriented pointing in the direction of the tip of the feet throughout the cycle of the movement, aligned to the lateral rotation of the hip. In the first training session, with the aid of a goniometer and metric tape, adhesive marks were placed on the floor to ensure this positioning of the support base."
214666098|NCT00257127|BIOLOGICAL|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
215039559|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
215039560|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
215039561|NCT03698279|BIOLOGICAL|Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
215039562|NCT03698279|BIOLOGICAL|FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
215039563|NCT04128709|DEVICE|Urodynamics Testing|The non-invasive device connects to the end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device the patient presses a single button in order to obtain a pressure measurement which is recorded and stored in the device along with the time and date. The measurement(s) can later be transmitted wirelessly to a smart phone that contains an app for the device.
215039564|NCT06632626|OTHER|Task oriented training exercises|Task oriented training is a type of exercises in form of tasks using papers, pens, scissors, clips, coins, screws and clay
215039565|NCT06632626|OTHER|Traditional physical therapy|Traditional physical therapy inform of mobilization, strengthening exercises of hand and streching exercises.
215039566|NCT05481736|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
215039567|NCT03767868|OTHER|color change in nail polish|The determination of color change in nail polish will be based on differences in skin temperature before and after the block.
215039568|NCT00491478|DRUG|sertraline|
215039569|NCT04275804|DEVICE|Low Magnitude High Frequence Vibration Platform|with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement \<0.1mm)
215039570|NCT04275804|OTHER|Conventional Dressing|Alternate Day Dressing
215039571|NCT04972253|DRUG|Infigratinib|Oral, dosage per protocol
215039572|NCT02180828|DRUG|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
214291259|NCT06507449|DEVICE|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.
214666099|NCT00257127|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
215039573|NCT02180828|DRUG|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
215039574|NCT01617473|PROCEDURE|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
215039575|NCT00871026|PROCEDURE|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
214666100|NCT00257127|BIOLOGICAL|Hepatitis B vaccine|0.5 mL administered intramuscularly
215039576|NCT00871026|PROCEDURE|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
215039577|NCT05662657|DIAGNOSTIC_TEST|Diagnostic Test: PCL-S Questionnaire|PCL-S and HADS questionnaires
215039578|NCT01276704|DRUG|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
215039579|NCT01276704|DRUG|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
215039580|NCT00654108|DRUG|Ciprofloxacin|500 milligrams(mg) will be administered orally twice daily for 5 days.
215039581|NCT00654108|BIOLOGICAL|Peru-15-pCTB|Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.
215039582|NCT00654108|OTHER|Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer|Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
215039583|NCT02276040|DRUG|periarticular bupivicaine and liposomal bupivicaine|Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
215039584|NCT02411409|BEHAVIORAL|HealtheRx|The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
215039585|NCT02196350|BEHAVIORAL|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
215039586|NCT02196350|BEHAVIORAL|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
215039587|NCT02196350|BEHAVIORAL|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
215039588|NCT06327438|OTHER|Complex decongestive therapy|"1. Manual lymphatic drainage (MLD).~2. Compression bandage.~3. Exercises to enhance lymphatic drainage.~4. Skin care."
214666101|NCT00257127|BIOLOGICAL|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
214666102|NCT01538615|BEHAVIORAL|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
214666103|NCT05565924|OTHER|Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
214666104|NCT05565924|OTHER|Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
215039589|NCT06327438|DEVICE|Cryotherapy|It is a mature and safe-to-use system that cools the air to -32°C. Steps of application included: 1) Apply oil or cream to moisture the skin before cryotherapy application; 2) Initialize the mini cryo-air equipment at level 6.
215039590|NCT06327438|OTHER|Kinesio taping|It is a new choice in the field of physical therapy. The material used for the KT and the original concept of the taping technique were introduced by Dr Kenso Kase in 1973.
215039591|NCT05160389|DRUG|PBI-200|Single dose of PBI-200
215039592|NCT02995590|DRUG|Hyperpolarized He3|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
215039593|NCT02239926|DRUG|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
215039594|NCT02239926|DRUG|Placebo|
215039595|NCT05213806|OTHER|Withholding feeds around transfusion|Withholding enteral feeds for preterm infants (\<30 weeks) around the time of blood transfusions to determine if any impact on the development and/or severity of Necrotizing Enterocolitis.
215039596|NCT05213806|OTHER|Continued feeds around transfusion|Continued enteral feeds
215039597|NCT01332214|DRUG|AZD2820|Subcutaneous Injection in abdomen or Thigh
215039598|NCT01332214|DRUG|Placebo|Subcutaneous Injection in abdomen or Thigh
215039599|NCT01434004|BEHAVIORAL|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
215039600|NCT00224393|DRUG|Enbrel|
214291260|NCT01396707|DRUG|Herceptin+XELOX|"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~* Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~* Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Oxaliplatin 130 mg/m2 i.v. on day 1"
215039601|NCT03187509|DRUG|Torsemide|These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
215039602|NCT03187509|OTHER|Standard Outpatient Heart Failure Management|Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
215039603|NCT02121093|PROCEDURE|vibration|
214666105|NCT05565924|OTHER|Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
214666106|NCT05565924|OTHER|Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
215039604|NCT03719807|OTHER|Rehabilitation protocol|A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
215039605|NCT03719807|OTHER|Usual Care|No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
215039606|NCT00097630|PROCEDURE|SAT: Spontaneous Awakening Trial|
215039607|NCT00097630|PROCEDURE|SBT: Spontaneous Breathing Trial|
215039608|NCT06372795|OTHER|pure effortful swallowing|"The investigator instructed the patient to swallow forcefully while squeezing the tongue upward and backward in the direction of the soft palate based on the sounds of an electronic timer."
215039609|NCT06372795|OTHER|progressive resistance swallowing training|Patients in the test group, resistance swallowing exercise was performed by providing external resistance through Iowa Oral Performance Instrument (IOPI), and all other protocols were performed the same as those in the control group.
215039610|NCT03801525|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion"
215039611|NCT03801525|DRUG|Umbralisib|"* inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form"
215039612|NCT03801525|DRUG|Venetoclax|"* B-cell lymphoma 2 (BCL-2) inhibitor~* Tablet form"
214873745|NCT01947998|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
214873746|NCT01947998|DRUG|Warfarin|For VTE prevention, DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, warfarin.
214873747|NCT01947998|DRUG|Antiplatelet drugs|For the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor
214873748|NCT01570114|DEVICE|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
214873749|NCT02618759|DRUG|DSXS|active treatment
215039613|NCT04573855|BIOLOGICAL|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
215039614|NCT00022178|DRUG|cisplatin|
215039615|NCT00022178|DRUG|cyclophosphamide|
215039616|NCT00022178|DRUG|doxorubicin hydrochloride|
215039617|NCT00022178|DRUG|epirubicin hydrochloride|
215039618|NCT00022178|DRUG|fluorouracil|
215039619|NCT00022178|DRUG|vincristine sulfate|
215039620|NCT05586373|DRUG|medication 1|Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days
214666107|NCT05565924|OTHER|Group- E; Control group|"Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study."
214666108|NCT03127020|DRUG|PQR309|taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
214666109|NCT01982110|BEHAVIORAL|Mindfulness based smoking cessation|Mindfulness based interventions are provided via a mobile phone application.
214666110|NCT01982110|BEHAVIORAL|Behavioral Smoking Cessation intervention|Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
214666111|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
214666112|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
214873750|NCT02618759|DRUG|Placebo|placebo treatment
214873751|NCT02446756|OTHER|acupuncture|
214873752|NCT02446756|OTHER|physiotherapy|
215039621|NCT05586373|DRUG|medication 2|Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days
215039622|NCT02542618|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|
214666113|NCT06497647|DRUG|Sulbutiamine|"sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group B and combined with imipramine in group C"
214666114|NCT06497647|DRUG|Imipramine|"imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group A and combined with sulbutiamine in group C"
214873753|NCT00269230|DEVICE|Pacing Lead|Left ventricular pacing lead
214873754|NCT03074344|DEVICE|XLHA+CoQ10|XLHA+CoQ10 for four times a day for 12 weeks.
214873755|NCT03074344|DEVICE|Hyaluronic acid (HA)|Hyaluronic acid (HA) for four times a day for 12 weeks.
214873756|NCT01823497|DRUG|Morphine|Morphine will be used to control pain post-surgery.
214873757|NCT05884944|PROCEDURE|Sham- Light touch, not reaching restrictive barrier|Sham- Light touch, not reaching restrictive barrier For the control group, the subjects hip, knee, and ankle joints will be moved bilaterally 3 times into each plane to mimic the OMM muscle energy treatment. The joint will be moved in each plane of motion without reaching the joint barrier. The hip joint will be moved into adduction, extension, and flexion, the knee joint will be moved into extension and flexion, and the ankle will be moved into plantarflexion and dorsiflexion 3 times in each direction without reaching the barrier passively.
215039623|NCT02542618|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
215039624|NCT02673944|DEVICE|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
215039625|NCT01889992|RADIATION|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short \& long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 \>/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
215039626|NCT01889992|PROCEDURE|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
215039627|NCT01889992|OTHER|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
214666115|NCT01025778|DRUG|Clofarabine for remission induction|
214873758|NCT05884944|PROCEDURE|Experimental: Interventional Group- OMM- Muscle energy|The interventional group will received Osteopathic Manipulative Medicine, specifically Muscle energy treatment. An osteopathic manipulative treatment protocol will be applied to the lower extremity joints bilaterally. Muscle energy technique (MET) will be applied to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated. Muscle energy is a direct active treatment asking the subject to move their joint in a direction against a counterforce by the treatment provider for 3 times for 3 seconds and repeating the procedure 3 times and afterwards a passive stretch to the joint is applied by the provider.
214873759|NCT02856555|DRUG|Firsocostat|Capsules orally once daily.
215039628|NCT01889992|DRUG|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels."
215039629|NCT01889992|PROCEDURE|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
215039630|NCT01889992|GENETIC|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
214666116|NCT01025778|DRUG|Etoposide for remission induction|
214666117|NCT01025778|DRUG|Cyclophosphamide for remission induction|
214666118|NCT01025778|DRUG|Clofarabine in conditioning before transplantation|
214666119|NCT01025778|DRUG|Thiotepa in conditioning before transplantation|
214666120|NCT01025778|DRUG|Melfalan in conditioning before transplantation|
214666121|NCT01025778|PROCEDURE|Haploidentical transplantation of T-cell depleted graft|
214873760|NCT02856555|DRUG|Placebo|Placebo matched to firsocostat orally once daily.
214873761|NCT03333941|DEVICE|ReCell® Autologous Cell Harvesting Device|RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.
214873762|NCT03955458|DRUG|EXPAREL|FICB with EXPAREL + Bupivacaine HCL (single dose)
215039631|NCT01889992|OTHER|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
215039632|NCT05077969|DRUG|Famotidine|80 mg tablet, QID for 14 days
215039633|NCT05077969|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
215039634|NCT05077969|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
215039635|NCT00352300|PROCEDURE|Adjuvant Therapy|
214666122|NCT01025778|PROCEDURE|Donor lymphocyte infusion|
214666123|NCT06961071|BIOLOGICAL|Parathyroid Allotransplant|Parathyroid Allotransplant
214666124|NCT06091423|DRUG|XELOX combined with Fruquintinib and Sintilimab|XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w
214666125|NCT05485012|DRUG|Marijuana|Double-blind administration of marijuana
214666126|NCT05485012|DRUG|Opioid|Double-blind administration of an opioid agonist
214666127|NCT03567577|DRUG|Solnatide 25 mg powder for reconstitution for solution for inhalation|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
214666128|NCT03567577|DRUG|0.9% Saline Solution|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
214666129|NCT05357690|PROCEDURE|Stellate ganglion block|Ultrasound guided injection into the stellate ganglion performed in the right side of the neck in a sterile fashion.
214666130|NCT05357690|DRUG|Bupivacaine|10 mL of 0.5% without epinephrine injected in the plane of the right stellate ganglion
214666131|NCT05357690|DRUG|Placebo|10 mL of saline injected in the plane of the right stellate ganglion
214873763|NCT03955458|DRUG|Ropivacaine|FICB with continuous infusion of ropivacaine
214873764|NCT03955458|DRUG|Bupivacaine Hydrochloride|FICB with EXPAREL + Bupivacaine HCL (Single dose)
214873765|NCT01342601|DEVICE|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
214873766|NCT01342601|DEVICE|Placebo products|Nasal Spray and Eye drops without Ectoin
214873767|NCT03155321|OTHER|It's an observational study - no intervention is planned|No intervention is planned
214873768|NCT03163524|OTHER|e-Coupon Text Modification and Reminders|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
214873769|NCT03163524|OTHER|e-Coupon standard text|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
215039636|NCT00352300|DRUG|Carboplatin|Given IV
215039637|NCT00352300|DRUG|Paclitaxel|Given IV
215039638|NCT00352300|BIOLOGICAL|Pegfilgrastim|Given IV
215039639|NCT04388826|DRUG|Veru-111|Respiratory Distress Syndrome, Adult
215039640|NCT00098800|DRUG|fenretinide|
215039641|NCT05832892|DRUG|surufatinib|"In phase Ib, surufatinib will be orally administrated 200 mg once a day (QD) or 250 mg QD per cohort escalation assignment on a 21-day cycle.~In phase II, surufatinib will be orally administrated at RP2D as determined in phase Ib."
215039642|NCT05832892|DRUG|KN046|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
215039643|NCT05832892|DRUG|gemcitabine|Gemcitabine will be administrated at 1000 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
215039644|NCT05832892|DRUG|Nab paclitaxel|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
215039645|NCT05393700|BEHAVIORAL|Action Observation Therapy|Action Observation Therapy implies the observation of video-clips representing motor tasks alone or followed by imagination and/or imitation of observed tasks.
215039646|NCT00025415|DRUG|imatinib mesylate|Given orally
215039647|NCT00025415|OTHER|pharmacological study|Correlative studies
214291261|NCT03935009|BEHAVIORAL|Manual toothbrush Curaprox 5460 ultra soft|Soft manual toothbrush (Curaprox 5460 ultra soft) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chumswill will be used to brush teeth.
214291262|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°1|Electric toothbrush (Play Smart Brush N°1) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App will be used to brush teeth.
214291263|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°2|Electric toothbrush (Play Smart Brush N°2) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia will be used to brush teeth.
214291264|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
214291265|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
214666132|NCT06533384|DRUG|As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.|As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
214666133|NCT06533384|DRUG|9 cycles of Camrelizumab as adjuvant therapy.|9 cycles of Camrelizumab as adjuvant therapy.
214666134|NCT00644592|DRUG|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
214666135|NCT00644592|DRUG|Fenofibrate|160 mg/day orally for 4 weeks
214666136|NCT04452643|BIOLOGICAL|BACMUNE (MV130)|BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
214666137|NCT04452643|OTHER|Placebo|Placebo is a solution on sodium chloride at 0.9%
214873770|NCT05462431|BEHAVIORAL|Deep relaxation exercises intervention|Deep relaxation exercises intervention: breathing exercise, suitable positions for rest, and relaxation exercise instructions.
214873771|NCT04326114|DEVICE|Inspiratory training device|Inspiratory training by a Power-breath device
214666138|NCT02549950|PROCEDURE|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
214666139|NCT02549950|PROCEDURE|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
214666140|NCT01621932|PROCEDURE|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
214873772|NCT04326114|DEVICE|Expiratory training device|Expiratory training a Winner-flow device
214666141|NCT01621932|PROCEDURE|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
214666142|NCT03947541|OTHER|Thoracolumbosacral (TLSO) brace|Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.
214666143|NCT03947541|OTHER|No Bracing|Participants will not wear a brace in the study.
214666144|NCT03094130|OTHER|News items with spin|Interpretation of news items with spin
214666145|NCT03094130|OTHER|News items without spin|Interpretation of news items without spin
214666146|NCT01859403|GENETIC|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
214666147|NCT01859403|GENETIC|Usual Care|Patients receive the same dietary recommendation regardless of their genetic information
214666148|NCT01120639|DRUG|Temozolomide|75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
214666149|NCT01120639|PROCEDURE|Stereotactic Radiosurgery (SRS)|Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)
214873773|NCT02627248|DRUG|Huaier Granule|20g tid, orally
214873774|NCT02627248|DRUG|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
214873775|NCT02627248|DRUG|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
214873776|NCT02627248|DRUG|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
214873777|NCT05637346|PROCEDURE|Intra-operative ultrasound measurement|A patient-specific 3D model will be created using an available pre-operative CT scan. Anatomical target points are selected on this virtual model before the start of the surgery. Prior to surgery, a patient-reference electromagnetic (EM) sensor will be placed between the patient and the matrass on the operating table to account for patient movement during acquisition. Intra-operatively, an initial point registration of the 3D model with the electromagnetic tracking system (EMTS) will be performed based on ultrasound (US) imaging of the arterial bifurcations by the surgeon. Then, the surgeon will acquire multiple US sweeps of the pelvic arteries (abdominal aorta and left and right iliac arteries). For validation purposes, the pre-operatively defined anatomical target points will be visualized on US imaging and by pinpointing the EM tracked pointer. All tracking and US data will be recorded and stored for post-operative analysis.
215039648|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
215039649|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
215039650|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
215039651|NCT02862574|DRUG|Andecaliximab|Administered via subcutaneous injection once weekly
215039652|NCT02862574|DRUG|Placebo|Administered via subcutaneous injection once weekly
215039653|NCT02862574|DRUG|Methotrexate|Administered orally weekly as part of the participant's current treatment regimen
215039654|NCT02862574|DRUG|TNF Inhibitor|An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
214476680|NCT06256640|DEVICE|Mandibular advancement Device|Intra oral appliances and more specifically Mandibular Advance Devices (MAD) are one of the established alternatives to treat OSA. Oral appliances and MAD are often used interchangeably but we prefer to call them MAD as it is more descriptive of its mechanism of action. MAD are placed in the mouth to temporarily advance and stabilize the lower jaw forward in order to keep the airway open during sleep.
214476681|NCT06765031|DIAGNOSTIC_TEST|Furosemide|Furosemide will be administered intravenously in the form of a push at a dose of 1 mg/kg to furosemide-naïve patients who meet the inclusion criteria and at a dose of 1.5 mg/kg to patients exposed to furosemide.
215039655|NCT03985202|OTHER|Structured exercise programme|9 week structured exercise programme. 3 sessions per week. (Intervention).The patient will be invited to the hospital for a 45-minute exercise counselling session, incorporating behaviour modification techniques. These behaviour modification techniques will be reinforced during the supervised exercise sessions. Participants will be offered 3 sessions of supervised aerobic interval exercise sessions per week on a cycle ergometer for 9 weeks.Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
214476682|NCT03928236|OTHER|Limited Intraoperative Benzodiazepine|policy for limited use of intraoperative benzodiazepine
214476683|NCT03928236|OTHER|Liberal Intraoperative Benzodiazepine|policy for liberal use of intraoperative benzodiazepine
214476684|NCT06768346|DEVICE|Hyperthermia will be delivered in combination with each instillation using the Combat BRS system|The Combat BRS system is a temperature controlled fluid recirculation system for the delivery of hyperthermic intravesical chemotherapy. The chemotherapy fluid is circulated in a closed system and warmed by an external isolated dry system using a novel innovative laminated aluminium foil heat exchanger with a small priming volume.
214476685|NCT04968366|BIOLOGICAL|Autologous dendritic cells pulsed with multiple neoantigen peptides.|Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides. DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation. After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections. For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response. According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness
214873778|NCT01730066|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|"Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups"
214873779|NCT02518516|DRUG|Rosuvastatin (≥10 mg)|"Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed \>120 days of the index date (i.e. no exposure within 120 days of the index date)."
215039656|NCT02150161|DRUG|Lidocaine/ ketamine|
214873780|NCT02518516|DRUG|Atorvastatin (≥20 mg)|"Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
214873781|NCT02518516|DRUG|Simvastatin (≥40 mg)|"Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
214873782|NCT02518516|DRUG|Fluvastatin|"Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
215039657|NCT02150161|DRUG|Fentanyl|
215039658|NCT04487444|DRUG|Thymalfasin|Synthetic 28 amino acid peptide identical to naturally circulating compound
215039659|NCT01937065|OTHER|No treatment|
215039660|NCT03276182|DEVICE|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
215039661|NCT03271866|DRUG|metformin|metformin 1500mg per day
215039662|NCT04313465|OTHER|Immediate discharge|Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
215039663|NCT05159674|DEVICE|Dexmedetomidine+electroacupuncture compound anesthesia|Dexmedetomidine and acupuncture were given together to induce anesthesia
215039664|NCT02068144|DIETARY_SUPPLEMENT|Cranberry Extract|Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
215039665|NCT02068144|OTHER|Placebo|Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
214476686|NCT04968366|DRUG|Temozolomide adjuvant chemotherapy|Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
214476687|NCT05083754|DRUG|Retifanlimab|Anti-PD-1 Therapy
214476688|NCT05083754|DRUG|Temozolomide|Anti-PD-1 Therapy
214476689|NCT05083754|RADIATION|Radiation Therapy|Standard of Care
214476690|NCT06347380|DEVICE|FemPulse System|Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.
214873783|NCT02518516|DRUG|Pravastatin|"Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
214873784|NCT02518516|DRUG|Lovastatin|"Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
214873785|NCT02518516|DRUG|Atorvastatin (<20mg)|"Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
214873786|NCT02518516|DRUG|Simvastatin (<40 mg)|"Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
214873787|NCT02188914|RADIATION|Positron emission tomography scan|
214873788|NCT02188914|OTHER|Magnetic resonance imaging|
214873789|NCT00822796|DEVICE|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
214873790|NCT00822796|DEVICE|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
214873791|NCT03937336|BEHAVIORAL|Bike Intervention Group|A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
214873792|NCT04981496|OTHER|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs
214873793|NCT06355999|BEHAVIORAL|Color Feedback|Feedback is given about the correctness of the response on the color dimension
214873794|NCT06355999|BEHAVIORAL|Shape Feedback|Feedback is given about the correctness of the response on the shape dimension
214873795|NCT00191971|DRUG|Gemcitabine|
214873796|NCT05657392|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment. Last few decades, it has been revealed that rTMS accelerates motor recovery and may reduce stroke-related symptoms.
214873797|NCT05657392|OTHER|32 electrode electroencephalography (EEG)|32-electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting
214873798|NCT02760992|DRUG|IV Baclofen|Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC
214873799|NCT02760992|DRUG|Oral Baclofen|10 mg tablet
214873800|NCT03275116|DRUG|Tiotropium 'Respimat' 5 mcg|Once daily single bronchodilation
214873801|NCT03275116|DRUG|Aclidinium Bromide/Formoterol Fumarate 340/12 mcg|Twice daily dual bronchodilation
214873802|NCT01037296|PROCEDURE|catheter ablation|ablation procedure performed with Hansen robotic navigation system
214873803|NCT01037296|PROCEDURE|catheter ablation|Ablation will be performed as normal treatment
214873804|NCT01551108|BEHAVIORAL|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
214873805|NCT01551108|BEHAVIORAL|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
214873806|NCT00307918|DEVICE|acupuncture|
215039666|NCT02001168|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
214873807|NCT04176406|DEVICE|rTMS|excitatory 5Hz rTMS will be used
214873808|NCT04176406|DEVICE|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
215039667|NCT02001168|DRUG|Docetaxel|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
215039668|NCT02001168|DRUG|rh-Endostatin|rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
215039669|NCT02001168|DRUG|Cis-platinum|Cis-platinum 60mg/m2, d1, 21 d as a cycle.
215039670|NCT04328389|BEHAVIORAL|electric toothbrush|Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque
215039671|NCT04328389|PROCEDURE|Professional oral hygiene|Professional oral hygiene using ultrosound scaling and root planing
215039672|NCT04115462|DRUG|Morphine|A 20 mg tablet of morphine
215039673|NCT04115462|DRUG|Placebo oral tablet|Matching tablet of placebo
215039674|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
214873809|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
214873810|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
214873811|NCT02036359|DRUG|erlotinib|150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
214873812|NCT02036359|DRUG|docetaxel|receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
214873813|NCT03323437|DRUG|Risperidone|Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
214873814|NCT00800007|DRUG|ANZ-521|3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
214873815|NCT00800007|DRUG|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
215039675|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
215039676|NCT04115462|DRUG|isotonic saline|A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
214873816|NCT06632899|BEHAVIORAL|combined physical and cognitive training and 1 hour of risk factor prevention and healthy lifestyle development|"Dosage: a 2-hour session once a week for 12 weeks. Each multidomain intervention session includes 1 hour of combined physical (balance, strength and aerobic exercises) and cognitive (attention, memory, calculation, visual-spatial ability, processing speed and executive function) training and 1 hour of risk factor prevention (nutrition, chronic disease management, oral health, fall prevention and transportation safety, psychosocial factors and sleep) and healthy lifestyle development (Discussion and sharing on topics such as self-health management, goal setting, and the health journal.)"
214873817|NCT00746876|DEVICE|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
214873818|NCT00746876|DEVICE|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
214873819|NCT05991648|PROCEDURE|Kangaroo Care (skin-to-skin contact)|Skin-to-skin contact between the mother and the child. The naked newborn, wearing only a diaper and a hat, is placed in a vertical position in direct contact between the mother's breasts. An elastic fabric support (made of cotton or synthetic elastic fiber) will be used to facilitate the position.
214873820|NCT04842786|OTHER|Coconut oil|Coconut oil, Parachute oil composition: 92% lauric (C12) fatty acid, 6% oleic fatty acid, 2% linoleic fatty acid
214666150|NCT03917121|DEVICE|Jet injector|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using Madajet XL injector as per the manufacturer's instructions.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
214873821|NCT04293328|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
215039677|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
215039678|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
215039679|NCT00822094|DRUG|CPX-351|
215039680|NCT00822094|DRUG|Intensive Salvage Therapy|
215039681|NCT02455869|DRUG|SRP and Placebo gel|After SRP, placebo gel was delivered subgingivally into the pocket
215039682|NCT02455869|DRUG|SRP and Atorvastatin|After SRP, Atorvastatin gel was delivered subgingivally into the pocket
215039683|NCT02455869|DRUG|SRP and Alendronate|After SRP, Alendronate gel was delivered subgingivally into the pocket
215039684|NCT01269684|DRUG|Everolimus|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
215039685|NCT04648020|DRUG|Clonidine HCl Mucoadhesive Buccal Tablet|100 μg of clonidine per tablet
215039686|NCT04648020|DRUG|Placebo Mucoadhesive Buccal Tablet|Placebo
215039687|NCT01534559|OTHER|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
215039688|NCT01621646|OTHER|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
215039689|NCT05878574|DRUG|Low molecular weight heparin|Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
215039690|NCT00163644|PROCEDURE|aereobic plus resisted exercise|
214873822|NCT04293328|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
214873823|NCT02119923|BEHAVIORAL|Working memory training|The WM consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.
214873824|NCT02119923|BEHAVIORAL|Placebo training|Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
215039691|NCT00163644|PROCEDURE|aerobic plus active exercise|
215039692|NCT00163644|OTHER|No formal exercise plus phone calls|
215039693|NCT05024513|DRUG|oxaliplatin and 5-fluorouracil|Intra-arterial chemotherapy consisted of Oxaliplatin (40mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for22 hours) on days 1-3 every 4 weeks.
215039694|NCT05024513|PROCEDURE|Biliary Drainage|External biliary drainage, or biliary stent placement; Biliary stent placement plus Iodine-125 seed strands is allowed
215039695|NCT05024513|OTHER|Best Supportive Care|Nutrition support, symptomatic treatment, and other supportive treatments
215039696|NCT05024513|PROCEDURE|External biliary drainage|External biliary drainage
215039697|NCT02030626|DEVICE|active or placebo rTMS or active or placebo tDCS|
215039698|NCT00022438|BIOLOGICAL|aldesleukin|
215039699|NCT00022438|BIOLOGICAL|incomplete Freund's adjuvant|
215039700|NCT00022438|BIOLOGICAL|recombinant tyrosinase-related protein-2|
215039701|NCT02428426|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
215039702|NCT01510093|DRUG|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
215039703|NCT01440764|DRUG|Furosemide|
215039704|NCT01440764|DRUG|Saline|
215039705|NCT00668629|DRUG|Lactic acid (Dermacid)|
215039706|NCT03542617|DRUG|Dexamethasone|
215039707|NCT03542617|DRUG|Normal Saline Solution|
215039708|NCT00070304|BIOLOGICAL|filgrastim|Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
215039709|NCT00070304|DRUG|gemcitabine hydrochloride|Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
215039710|NCT00070304|DRUG|vinorelbine tartrate|Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
215039711|NCT05951426|PROCEDURE|1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage|"1. removal of the uterus with both ovaries and fallopian tubes and pelvic lymph nodes~2. exploration of the uterine cavity and removal of the endometrium"
215039712|NCT00284128|DRUG|AVE7688|oral administration (capsules)
215039713|NCT00284128|DRUG|Losartan-potassium|oral administration (capsules)
215039714|NCT02815163|OTHER|Empowerment education|"1. admission (1 hour)~   ▪partnership~2. 2 ds after THR (30-45min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~3. 2 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~4. 6 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~5. 10 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback"
215039715|NCT00906061|DRUG|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
215039716|NCT00320606|DRUG|Immunosuppression Withdrawal|Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
215039717|NCT03984825|DRUG|GSK3640254|GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
215039718|NCT03984825|DRUG|Portia|Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.
215039719|NCT03044795|DRUG|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
215039720|NCT05090787|DEVICE|Investigational mDCB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
215039721|NCT05090787|DEVICE|Control DCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes
215039722|NCT04754464|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8-Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in water
215039723|NCT04754464|DIETARY_SUPPLEMENT|microcrystalline cellulose|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in water
215039724|NCT06157021|PROCEDURE|Rotary pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using (Fanta AF baby\* rotary files and Endo Radar\* rotary device).
215039725|NCT06157021|PROCEDURE|Manual pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using Manual H files, Mani\*)
214873825|NCT02771535|BEHAVIORAL|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
214873826|NCT02771535|BEHAVIORAL|Health Training|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
215039726|NCT04109300|GENETIC|HLADQA1*05A>G screening|DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1\*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
215039727|NCT04109300|OTHER|Standard of Care|The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
215039728|NCT02892370|DRUG|SHR0302|SHR0302 tablets (10 mg)
215039729|NCT01817387|BEHAVIORAL|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
215039730|NCT01817387|BEHAVIORAL|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
214873827|NCT00421395|BIOLOGICAL|90Y-hLL2|weekly dosing for either 2 or 3 weeks
214873828|NCT03870867|OTHER|No intervention|No intervention
214873829|NCT00140218|DRUG|R(+) pramipexole dihydrochloride monohydrate|10 mg tid oral
214873830|NCT04008849|OTHER|Safety and efficacy assessments|Long term safety and clinical outcomes
214873831|NCT06633484|OTHER|functional magnetic resonance imaging|non-diagnostic, non-invasive, passive measurement of the brain\&#39;s structure and function
214873832|NCT03568097|DRUG|Avelumab|10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
214873833|NCT01025453|DRUG|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
214873834|NCT00049530|BIOLOGICAL|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
214873835|NCT02383810|DRUG|Elsiglutide|
214873836|NCT02383810|DRUG|Placebo|
214873837|NCT01046786|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
214873838|NCT01046786|DRUG|Methylprednisolone|30 mg/kg methylprednisolone
214873839|NCT01046786|DRUG|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
215039731|NCT04906694|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
215039732|NCT04906694|DRUG|Placebo|Diluent solution
215039733|NCT00095550|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
215039734|NCT00095550|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
215039735|NCT00095550|DRUG|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
215039736|NCT05155111|DIAGNOSTIC_TEST|Telemedicine consult|A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
215039737|NCT03220009|PROCEDURE|Conventional Surgery|Undergo surgery
215039738|NCT03220009|BIOLOGICAL|Ipilimumab|Given IV
214873840|NCT04691726|DRUG|lidocaine 10mg/ml|bolus i.v. + continuous i.v. infusion
214873841|NCT04691726|DRUG|Placebo|bolus i.v. + continuous i.v. infusion
214873842|NCT04691726|DRUG|Metamizole|2,5 g i.v. BD
214873843|NCT04691726|DRUG|Morphine|continuous i.v. infusion adjusted to VAS scale score
214873844|NCT03167463|PROCEDURE|flap|Repair choanal atresia with using flap during surgery
214873845|NCT04707781|DIAGNOSTIC_TEST|chest CT|assessment of interstitial lung disease using chest CT
215039739|NCT03220009|OTHER|Laboratory Biomarker Analysis|Correlative studies
215039740|NCT03220009|BIOLOGICAL|Nivolumab|Given IV
215039741|NCT03220009|OTHER|Patient Observation|Undergo active surveillance
215039742|NCT03220009|RADIATION|Radiation Therapy|Undergo RT
215039743|NCT01483170|DRUG|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
215039744|NCT01483170|DRUG|Placebo|Placebo fexinidazole
215039745|NCT02656056|OTHER|Food: (Q-Can Plus fermented soybean beverage)|Fermented soybean beverage. Dose is 8 oz, twice daily.
215039746|NCT01190527|RADIATION|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
215039747|NCT00556114|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography
215039748|NCT01117779|DEVICE|Cryoablation|Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
215039749|NCT00399035|DRUG|Cediranib|oral tablet
215039750|NCT00399035|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
214873846|NCT02105558|DRUG|Epidural anesthesia|"￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered."
214873847|NCT02105558|DRUG|Combined spinal and epidural anesthesia|"A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr."
214873848|NCT00226174|DRUG|Curcuminoids|
214873849|NCT04100720|DEVICE|Cardiovalve Transfemoral Tricuspid Valve|The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
215039751|NCT00399035|DRUG|XELOX (Capecitabine and Oxaliplatin)|intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
215039752|NCT00399035|DRUG|Cediranib Placebo|oral tablet
215039753|NCT04899765|BIOLOGICAL|BCG vaccine|It is an attenuated live bacterial vaccine. This vaccine is a freeze-dried product that must be reconstituted.
214476691|NCT06515691|PROCEDURE|M-TAPA block|After the wound closure is completed and the patient is still under genaral anesthesia the M-TAPA block ill be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied on each side. The total volume will be 60 ml.
214873850|NCT04122144|BEHAVIORAL|ENHANCED -SPS intervention|a) Enhanced VL counseling: Explanation of VL \& Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
214873851|NCT01194986|OTHER|[11C]AZ12807110|Radioligand
214873852|NCT01194986|DRUG|AZD5213|
214873853|NCT01911286|PROCEDURE|Apnea test - Standard|
214873854|NCT01911286|PROCEDURE|Apnea test - CPAP|
214873855|NCT02549586|DRUG|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
214873856|NCT01782235|DRUG|Tocilizumab|
214873857|NCT01782235|DRUG|Placebo|
214873858|NCT01635283|BIOLOGICAL|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
214873859|NCT01635283|OTHER|laboratory biomarker analysis|Correlative studies
214873860|NCT01433549|DEVICE|Lotrafilcon B|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
214873861|NCT01433549|DEVICE|Senofilcon A|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
215039754|NCT04899765|BIOLOGICAL|Measles vaccine|It is an attenuated live virus vaccine. This vaccine is a freeze-dried product that must be reconstituted.
215039755|NCT04899765|OTHER|Placebo|Saline
215039756|NCT00716001|DRUG|N-acetylcysteine|
215039757|NCT03768037|DRUG|Anlotinib plus Pemetrexed|"Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.~Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects"
215039758|NCT03768037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
215039759|NCT03152448|BEHAVIORAL|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
215039760|NCT04586933|DIETARY_SUPPLEMENT|Omega-3|It will be investigated whether diet optimization and supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used.
215039761|NCT04586933|DIETARY_SUPPLEMENT|Placebo (soya)|Placebo (soya)
215039762|NCT04586933|BEHAVIORAL|Dietary guidance|Dietary guidance
215039763|NCT05931731|OTHER|Mechanical interference|The patients will receive mechanical interference treatment in the form of five techniques, including wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, the release of palmar hand fascia, gliding of the finger flexor tendons (using the oscillatory flexion-extension movement of the metacarpophalangeal joint) and release of the upper forearm muscle and fascia were applied. Manual techniques were performed total of 15 minutes in each session each technique included 3 sets for 3 minutes and conventional treatment
215039764|NCT05931731|OTHER|Neural mobilization|the patients will receive neurodynamic mobilizations, including sliding techniques and tensioning techniques which are thought to enhance ulnar nerve gliding and restore neural tissue mobility and conventional treatment
214873862|NCT01890447|OTHER|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
214873863|NCT01639196|OTHER|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
214873864|NCT01639196|OTHER|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
214873865|NCT04840537|PROCEDURE|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage
214873866|NCT00479778|DRUG|Bazedoxifene/conjugated estrogens|
214873867|NCT06460207|OTHER|fMRI neurofeedback|fMRI neurofeedback is a technique that allows individuals to observe real-time feedback of their brain activity as measured by fMRI scans. During a session, the participant lies inside an MRI scanner while their whole brain is scanned. This data is processed in real-time by a computer and then presented to the participant in the form of visual feedback. This feedback might be presented as a graph, a color-coded representation, or some other easily interpretable format. The participant is instructed to modulate their brain activity based on the feedback they receive. This can involve various mental strategies, such as focusing attention on specific thoughts, images, or sensations. Over repeated sessions, participants learn to consciously influence their brain activity based on the feedback they receive. Through trial and error, they discover which mental strategies are most effective for achieving their desired changes in brain activity.
214873868|NCT04496115|BEHAVIORAL|Mindfulness|Mindfulness training
214873869|NCT01631071|BIOLOGICAL|Virosomal influenza vaccine|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
214873870|NCT05631197|OTHER|Biorepair Total Protection Plus + desensitizing enamel-repair shock treatment|Domiciliary use twice a day
214873871|NCT05631197|OTHER|Sensodyne Repair & Protect|Domiciliary use twice a day
214873872|NCT05156905|DRUG|Cirmtuzumab|Cirmtuzumab will be given in combination with docetaxel.
214873873|NCT03831165|COMBINATION_PRODUCT|Melatonin 3 mg|melatonin and placebo
214873874|NCT03831165|DRUG|Acyclovir|Only acyclovir 200 mg twice a day
214873875|NCT05022589|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.
214873876|NCT02378792|DEVICE|Vagus Nerve Stimulation|Vagus Nerve Stimulator
214873877|NCT01181960|DRUG|Risperidone long acting injectable - New Starts|Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
214873878|NCT01181960|DRUG|Risperidone long acting injectable - Continuous Users|Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
215039765|NCT05931731|OTHER|conventional treatment|the patients will receive therapeutic ultrasound (frequency of 1 MHz, intensity of 1 W/cm2, for 5 minutes), transcutaneous electrical nerve stimulation (TENS) (frequency of 80 Hz, pulse duration of 60 μs, at the level of comfortable tingling sensation, for 20 minutes) and therapeutic exercises.
215039766|NCT01959685|DRUG|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
214873879|NCT01181960|DRUG|Paliperidone Palmitate -New and Continuous Users|Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
214873880|NCT01181960|DRUG|Other Antipsychotics - New Starts|Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
214873881|NCT06633848|PROCEDURE|spinal surgery|spinal surgery
214873882|NCT01687426|DRUG|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
214873883|NCT01687426|DRUG|Vehicle|1 drop in each eye daily four times a day for 14 days
214873884|NCT00581126|DRUG|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
214873885|NCT04226950|DRUG|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers;
214873886|NCT04226950|DRUG|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area \< 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
214873887|NCT03511326|DRUG|Methyl Aminolaevulinate 16% Cream|Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
214873888|NCT04043130|BEHAVIORAL|Pulse|The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
214873889|NCT02750748|DRUG|Naltrexone|
214873890|NCT02750748|OTHER|Intravail|
215039767|NCT01959685|DRUG|Placebo|Placebo, single dose
215039768|NCT04055974|BEHAVIORAL|Be a Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention targeting postpartum women. It consists of 5 weekly modules, each targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
215039769|NCT02183584|DRUG|Rifampicin|
215039770|NCT02183584|DRUG|Linagliptin|
214873891|NCT03729726|BEHAVIORAL|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model uses a placed-based collective impact framework to provide a comprehensive intervention model, including: academic support and college and career readiness services, evidence-based social emotional learning instruction to strengthen protective factors and promote healthy transitions to adulthood, and trauma-informed, medically accurate, and age appropriate sexual health education. Moreover, the 2.0 PREIS program model features a unique student advocacy component designed to ensure that youth and their families receive the wraparound supports necessary for their students to remain on track for school success.
215039771|NCT05464602|OTHER|Intervention group Lavender|This group received inhalation aromatherapy 2 drops of lavender oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
215039772|NCT05464602|OTHER|Intervention group Geranium|This group received inhalation aromatherapy 2 drops of geranium oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
215039773|NCT05427292|OTHER|serratus anterior block and PECs II block combination|The pre-surgery block will be applied. Sensorial block will be evaluated at the surgical incision site with the pinpirick test at 30 minutes after the block, and if the block is successful, surgery will begin.
215039774|NCT05406973|DEVICE|SBK microkeratome versus femtosecond laser in flap creation|prospective comparative non randomized interventional clinical study
215039775|NCT00208130|DRUG|Topiramate|
215039776|NCT02621892|DRUG|Tenapanor|
215039777|NCT02621892|DRUG|Placebo|
215039778|NCT03178409|PROCEDURE|Hepatectomy|Removal of a part of the liver
215039779|NCT01358162|OTHER|Placebo|Placebo given orally, daily for 14 consecutive days
215039780|NCT01358162|DRUG|SQ109|A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
215039781|NCT02920320|OTHER|Internet-based self-help program|
214873892|NCT06241469|DRUG|Sintilimab,nab-paclitaxel and tegio|Immunotherapy combined with chemotherapy
214873893|NCT04061525|PROCEDURE|Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration|Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
214873894|NCT00292058|DEVICE|Videoconference equipment (telepsychiatry)|
214873895|NCT04177446|DIETARY_SUPPLEMENT|a production consist of various oligopeptides and the whey protein|patients will be given extra protein intake except the basic energy intake
214873896|NCT04177446|DIETARY_SUPPLEMENT|basic energy intake|supplement as basic energy intake
214873897|NCT04177446|DIETARY_SUPPLEMENT|maltodextrin|used as placebo in the control group
214873898|NCT01667835|BEHAVIORAL|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
214873899|NCT01794897|DRUG|Experimental: Valacyclovir treatment|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
214873900|NCT01794897|DRUG|Placebo comparator|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
215039782|NCT06351514|DEVICE|Accelerated iTBS|Patients will be assigned to receive iTBS over the left dorsolateral prefrontal cortex or Frontal Medea with 5 sessions a day, every weekday for 1 week and total of 25 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 100%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions. All TBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.
215039783|NCT00151177|DEVICE|non-invasive continuous positive airway pressure ventilation|
215039784|NCT00151177|DEVICE|CPAP-treatment|night time CPAP-mask ventilation
215039785|NCT04764526|OTHER|Protein-enriched ice cream|Offering two protein-enriched ice creams
215039786|NCT01255280|BEHAVIORAL|Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
215039787|NCT01255280|BEHAVIORAL|Information, Motivation, Behavioral skills change approach to sexual risk reduction|The comparison condition will only receive the two IMB risk reduction sessions.
215039788|NCT04883268|OTHER|Expand Your Horizon|Expand Your Horizon is an online programme, comprising three 15min writing exercises delivered over the course of 1 week. In each writing exercise, participants are asked to describe the functions of their body, and why those are personally meaningful to them.
215039789|NCT04044963|BEHAVIORAL|Exercise and Prehabilitation|"All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey."
215039790|NCT03099122|BIOLOGICAL|Rabbit Anti-thymocyte Immunoglobulin|"Pharmaceutical form: creamy-white powder~Route of administration: intravenous"
215039791|NCT03099122|DRUG|Tacrolimus|"Pharmaceutical form: tablet~Route of administration: oral"
214873901|NCT01594255|DRUG|sotrastaurin|
215039792|NCT03099122|DRUG|Methylprednisolone|"Pharmaceutical form: powder~Route of administration: intravenous"
214476692|NCT06515691|PROCEDURE|Postoperative pain management|ibuprofen 400mg (Ibuprofen-PF®) intravenous (IV), and tramadol (Contramal®) 100 mg IV will be administered to all patients 20 minutes before wound closure. After surgery, Ibuprofen 400 mg will be given three times a day. A patient-controlled analgesia (PCA) system containing 10 mcg/ml fentanyl will be provided to all patients without continuous infusion. Patients can administer boluses of 0.35 mcg/kg with a 15-minute lockout period and a maximum dose of 100 mcg per hour. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV tramadol (Contramal®) 100 mg will be given as a rescue analgesic.
214476693|NCT06809478|PROCEDURE|Pulpotomy using Chitosan liquid|"1. After complete hemostasis, a cotton pellet damp with chitosan liquid will be applied and gently placed over the pulp stumps for 5 minutes and removed. Then, a thick mix of zinc oxide and eugenol will be placed and gently condensed into the pulp chamber by a moistened cotton pellet.~2. Tooth will be restored with stainless steel crown."
214476694|NCT06809478|PROCEDURE|Pulpotomy using Formocresol|"1. After complete hemostasis, a cotton pellet damp with formocresol will be applied and gently placed over the pulp stumps for 5 minutes and removed. Then, a thick mix of zinc oxide and eugenol will be placed and gently condensed into the pulp chamber by a moistened cotton pellet.~2. Tooth will be restored with stainless steel crown."
214476695|NCT05392283|DEVICE|AERO vacuum cupping device|The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
214476696|NCT04158739|DRUG|Cytarabine|Given IT
214476697|NCT04158739|BIOLOGICAL|Flotetuzumab|Given IV
214476698|NCT06310161|DEVICE|Bright light|Bright light treatment will consist of using the Re-timer device 3 times per week during dialysis sessions for 4 weeks. The Re-timer is worn like a pair of glasses and contains light emitting diodes mounted on the lower portion of the frame. The Re-timer emits blue-green 500 nm light with an intensity of \~500 lux lm/m2. Participants will be instructed to use the device for 60 minutes at the beginning of each dialysis session.
214476699|NCT06310161|DEVICE|Dim Light|Dim light treatment will use non-light emitting glasses that look identical to Re-Timer for 4 weeks at each dialysis session following baseline assessments. Participants will use the device for 60 minutes at the beginning of their dialysis session.
214476700|NCT04539392|OTHER|Questionnaires on sexuality|Panel of questionnaires assessing sexuality, relationship satisfaction, and body image
214476701|NCT03026816|DEVICE|Epidural Spinal Cord Stimulation|epidural spinal cord stimulator
214873902|NCT01594255|DRUG|sotrastaurin|
214476702|NCT05981573|DIAGNOSTIC_TEST|Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo|Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Aptamer based Assay
214476703|NCT05981573|DRUG|Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo|Measurement of Methadone and its metabolites in ISF with LC-MS and RMM
214873903|NCT01594255|DRUG|placebo to sotrastaurin|
214476704|NCT05981573|DEVICE|ISF Extraction Device 2|Up to 15 minute periods of continuous ISF collection for analysis
214476705|NCT04778410|DRUG|Magrolimab|Administered intravenously
214476706|NCT04778410|DRUG|Azacitidine|Administered either subcutaneously or IV, 75 mg/milligram per square (m\^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
214476707|NCT04778410|DRUG|Venetoclax|Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
214476708|NCT04778410|DRUG|Mitoxantrone|Administered intravenously, 8 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
214476709|NCT04778410|DRUG|Etoposide|Administered intravenously, 100 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
214476710|NCT04778410|DRUG|Cytarabine|Administered intravenously, 1000 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
214873904|NCT01594255|DRUG|Avelox|
214873905|NCT03722667|BEHAVIORAL|Technology-based Component|This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.
214873906|NCT03722667|BEHAVIORAL|TechSupport|"The TechSupport intervention is the combination of both an behavioral and emotional intervention.~Technology-based Components: This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.~Positive Psychological Training (PPT): This intervention will include a structured online training and skill building for PPT accessible by smartphone on techniques to promote optimism, resilience, well-being, and self-confidence."
214873907|NCT04105140|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
214873908|NCT04105140|DRUG|Placebo|intranasal administration of placebo (24 IU)
214873909|NCT03653910|DEVICE|Airtraq|Airtraq is a kind of videolaryngoscope for intubation
214873910|NCT03653910|DEVICE|Macintosh|Macintosh is a traditional laryngoscope for intubation
214873911|NCT03868150|DRUG|Amiodarone Injection|Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
215039793|NCT03099122|DRUG|Mycophenolate mofetil|"Pharmaceutical form: capsule~Route of administration: oral"
215039794|NCT03099122|DRUG|Mycophenolate Na|"Pharmaceutical form: capsule~Route of administration: oral"
215039795|NCT03099122|DRUG|prednisone|"Pharmaceutical form: tablet~Route of administration: oral"
214476711|NCT04778410|DRUG|CC-486|Administered orally, 300 mg on Days 1-14 during each cycle
215039796|NCT03976297|OTHER|Control Tower|A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
215039797|NCT05978934|BEHAVIORAL|Static Lighting Condition (L1)|This indoor lighting condition keeps a constant brightness and correlated color temperature.
215039798|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L2)|This indoor lighting condition has increased brightness and more blue correlated color temperature in the morning hours followed by decreased brightness and less blue correlated color temperature in the afternoon and evening hours.
215039799|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L3)|This exploratory indoor lighting condition matches the same pattern as L2 except the brightness in the morning hours is increased.
215039800|NCT04256655|DRUG|cohort 1 0.225g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
215039801|NCT04256655|DRUG|Cohort 2 0.75g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
215039802|NCT04256655|DRUG|Cohort 3 2.25 g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
215039803|NCT04336189|DRUG|Sulfadoxine-pyrimethamine (SP)|SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda. SP will be given as a single dose consisting of 3 full strength tablets.
215039804|NCT04336189|DRUG|Dihydroartemisinin-piperaquine (DP)|DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China. DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
215039805|NCT03652155|PROCEDURE|Orthognathic surgery|Patient's pre and post operative hard and soft tissues will be evaluated retrospectively through the use of con-beam computed tomography imaging for hard tissue evaluation and 3DMd three dimensional photography for soft tissue imaging.
215039806|NCT06565273|DRUG|FBL-MTX|Patients will be administered an initial dose of FBL-MTX by subcutaneous route. Subsequent doses will be titrated according to clinical response. Maximum dosage will be 2.5 mg, every 2 weeks.
215039807|NCT02239003|DRUG|DAOIB|
214476712|NCT06604208|DEVICE|Binaural Beats|"The binaural beat device is a health product that is not classified as a medical device. It functions similarly to a music box, providing different frequencies through physiological and psychological induction. This process offers binaural beat information to the Reticular Activating System (RAS) for potential changes in consciousness. The binaural beat frequencies are designed to match the brainwave frequency of light sleep, specifically 3.4 Hz (θ waves), with a base frequency of 440 Hz. The device uses three types of background music-piano music, light music, and string music-as experimental materials.~The binaural beat device offers three modes, allowing users to select different modes based on their comfort and listening preferences. This study requires that the binaural beats be listened to for at least 30 minutes. The device has a built-in app for continuous playback, so users can connect the power and listen throughout the night."
214476713|NCT06604208|DEVICE|Placebo|Placebo
214476714|NCT03770416|DRUG|Ibrutinib|Given PO
214476715|NCT03770416|BIOLOGICAL|Nivolumab|Given IV
215039808|NCT02239003|DRUG|Placebo|
215039809|NCT03781479|DRUG|Amifampridine Phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
215039810|NCT03781479|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
215039811|NCT02921256|DRUG|Capecitabine|Given PO
215039812|NCT02921256|DRUG|Fluorouracil|Given IV
215039813|NCT02921256|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
215039814|NCT02921256|DRUG|Leucovorin|Given IV
215039815|NCT02921256|DRUG|Oxaliplatin|Given IV
214476716|NCT06854679|RADIATION|Radiotherapy dose escalation|All patients will receive 45Gy in 25# to mesorectum and elective nodal volumes, and 52.5Gy in 25# as standard to primary gross tumour volume which includes primary tumour, visible nodal disease and extramural vascular invasion if present. Boost dose escalation to a maximum of 60Gy will be delivered to patients with ongoing visible disease from week 2 of treatment onwards.
214476717|NCT06855108|DRUG|Caffeine citrate oral solution|Caffeine citrate oral solution will be used and administered by enteral route (oral or by gavage tube). The loading dose (20 mg/kg) will be administered once followed by daily doses of 10 mg per kg body weight every 24 hours for two doses. The study Standard Operating Procedures (SOPs) includes details regarding caffeine preparation based on the participant's body weight.
214476718|NCT06855108|DRUG|Oral placebo solution|Identical placebo oral solution
214476719|NCT06855316|DEVICE|electromagnetic stimulation|After performing a high-intensity eccentric exercise session, participants will undergo a daily session of transcranial and/or peripheral magnetic stimulation for three days. The objective is to enhance nerve conduction, which, according to the latest theories on DOMS, may be the cause of decreased athletic performance
215039816|NCT02921256|BIOLOGICAL|Pembrolizumab|Given IV
215039817|NCT02921256|DRUG|Veliparib|Given PO
215039818|NCT00001055|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
215039819|NCT00001055|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
215039820|NCT00001055|BIOLOGICAL|rgp120/HIV-1 SF-2|
215039821|NCT05210816|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
214666151|NCT03917121|DEVICE|Needle attached dental syringe|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using standard needle-attached syringe in a classical local infiltration.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
214666152|NCT01839474|DEVICE|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
214666153|NCT02852226|OTHER|Pre Exposure Prophylaxis|Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.
215039822|NCT03152201|DIAGNOSTIC_TEST|electrophysiological signal|trasmit the electrophysiological signals to the neurosurgeon through the hardware
215039823|NCT05092750|DEVICE|FerroTraceTM|A magnetic
214666154|NCT02852226|BEHAVIORAL|Characteristics of women who enroll|The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
214873912|NCT03868150|DEVICE|Intraoperative Rapid Atrial Pacing|Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
215039824|NCT05092750|DRUG|indocyanine green (ICG)|Given by SC injection
215039825|NCT05459662|DIETARY_SUPPLEMENT|oat based porridge|Consume one preparation per day, orally
215039826|NCT05459662|DIETARY_SUPPLEMENT|plant based preparation|Consume one preparation per day, orally
215039827|NCT05316844|OTHER|There will be no interventions.|Measurements and performance tests were conducted to investigate predictors of work-related performance
215039828|NCT02630641|DRUG|Gonadotropin-releasing Hormone (GnRH) agonist therapy|This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
215039829|NCT02865174|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
215039830|NCT02865174|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
214873913|NCT04790708|RADIATION|Lutetium-177 (177Lu)-DOTATOC|5 cycles of 3,7 e 5,55 gigabequerel (GBq) of 177Lu-DOTATOC every 8-10 weeks. Cumulative activity: 18,5 e 27,75 GBq
214873914|NCT04790708|RADIATION|Yttrium-90 (90Y)-DOTATOC|5 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks. Cumulative activity: 9,25 e 13,875 GBq
215039831|NCT02865174|DRUG|Enoxaparin|Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
215039832|NCT03956160|OTHER|A co-design phase aims to ensure the feasibility and relevance of the proposed intervention and evaluation.|"4 participatory co-design workshops lasting 4 hours each that will follow a user-centered design approach: identification of end-user needs, prototyping/development of the intervention (case-management procedures and platform), iterative improvement, end-user testing.~Based on the cognitive social theory underpinning the intervention, scientific literature, an overview of existing organizations and the results of the Stroke 69 and Arthur Tybra studies (patient needs following the acute phase), the advisory committee will:~* Define the case-manager's profile, and required knowledge and skills~* Identify the resources and tools to be proposed on the Internet platform~* Test the tools and content~* Refine the program evaluation criteria~* Test and validate the study procedures."
215039833|NCT06146816|DEVICE|photobiomodulation treatment in the infrared (IR) range.|The baseline treatment included 10 weekly 30 minutes long sessions of fIR treatment.
215039834|NCT04026802|OTHER|In-Bed Resistance Training Device|Physical Therapy using the in bed training device
215039835|NCT04026802|OTHER|Standard of Care|Does not include early implementation of physical therapy
215039836|NCT02248571|DRUG|Bevacizumab|administered as combined therapy with Capecitabine
215039837|NCT02248571|DRUG|Capecitabine|administered as combined therapy with Bevacizumab
215039838|NCT02248571|DRUG|Everolimus|administered as combined therapy with Exemestane
215039839|NCT02248571|DRUG|Exemestane|administered as combined therapy with Everolimus
214873915|NCT04790708|RADIATION|177Lu-DOTATOC + 90Y-DOTATOC|"3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC alternated with 2 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks.~Cumulative activity: 18,5 e 27,75 GBq of 177Lu-DOTATOC and 9,25 e 13,875 GBq of 90Y-DOTATOC"
215039840|NCT02248571|OTHER|Patient questionaires|Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
214476720|NCT06854796|DEVICE|Recombinant collagen gel|The test device uses a recombinant collagen gel developed by Shaanxi Juzi Biotechnology Co., Ltd., which is different from other designs. The main components of recombinant collagen gel are recombinant collagen, disodium hydrogen phosphate, potassium dihydrogen phosphate, sodium chloride, water for injection, after the injection, collagen can occupy a place at the injection site to improve the visual aging caused by soft tissue loss, wrinkles and depressions, and the special manufacturing process can ensure that the gel has smoothness and ductility, which helps to achieve a smooth and natural appearance, effectively and gradually improve wrinkles and plump cheeks.
214476721|NCT06854796|DEVICE|collagen implant agent|1\. After the product is injected into the skin, the collagen implant forms a soft mesh structure through condensation, which can make up for skin defects. 2. After implantation of this product, the connective tissue cells around the implantation site will grow into the collagen network structure and gradually form a bionic structure similar to normal tissue. 3. This product is absorbable and degradable. The collagen implant will be gradually decomposed by protease in the body, and the pressure, elongation and hierarchy of the implant site tissue will affect the final degradation and duration.
214476722|NCT06855303|OTHER|Muscle Energy Teqnique using post isometric relaxation (PIR) principle|The contralateral leg may be either flexed or may lie straight on the plinth. The affected leg will be flexed at both the hip and knee joints, and then slowly straightened by the therapist until the restriction barrier is identified. The limb will be moved a little away from the restriction barrier and the isometric contraction against resistance is introduced. The patients will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb. On exhalation, the knee joint will be straightened (extended) towards its new barrier, and through that barrier a stretch will be applied and maintained for 30 seconds. 3 repetitions
214476723|NCT06855303|OTHER|Muscle Energy Teqnique using receprocal inhibition (RI) principle|The supine patient will ask to fully flex the hip and knee on the affected side. The affected leg will then be slowly straightened by the therapist until the restriction barrier is identified. The calf of the affected leg will then be placed on the practitioner's shoulder that stands facing the head of the table on the side of the affected leg. Then the patient will be asked to attempt to straighten the lower leg utilizing the antagonists to hamstrings, employing approximately 20 percent of the strength of the quadriceps. This will be resisted by the practitioner for 5 to 7 seconds. Appropriate breathing instructions will be given. On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch will be applied and maintained for 30 seconds. 3 repetitions)four repetition
215039841|NCT04658485|DEVICE|Active tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1) with the cathode located over the right primary somatosensory cortex (S1).
214666155|NCT02852226|BEHAVIORAL|referral sources of women who enroll|Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
214666156|NCT03014648|DRUG|Atezolizumab|Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
214666157|NCT02113657|DRUG|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
214666158|NCT00147927|BEHAVIORAL|Sequential emails and web support|
214666159|NCT05698186|DRUG|Thero2-01S22|Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
214666160|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
214873916|NCT04790708|RADIATION|Re-treatment 177Lu-DOTATOC|3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC every 8-10weeks. Cumulative activity: 11,1 e 16,65 GBq of 177Lu-DOTATOC
214873917|NCT04790708|RADIATION|Re-treatment 90Y-DOTATOC|3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC
214873918|NCT05987319|DEVICE|RadioFrequency Microneedling Device|RadioFrequency device will be used for the treatment of dermatologic conditions.
214873919|NCT04500093|PROCEDURE|Capsulotomy with Repair|Capsulotomy with Repair
214873920|NCT04500093|PROCEDURE|Capsuloectomy|Capsuloectomy
215039842|NCT04658485|DEVICE|Sham tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide a sham stimulation with the anode place over the primary motor cortex (M1) and cathode located over the right primary somatosensory cortex (S1). The sham stimulation consists of 30 seconds of stimulation ramping up to a maximum of 2 mA, then 19 minutes of the device providing no stimulation and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This configuration is designed to mimic the sensory experience of active tDCS.
215039843|NCT00003562|DRUG|carboplatin|
215039844|NCT00003562|DRUG|docetaxel|
215039845|NCT00158106|PROCEDURE|Speech and Language therapy for dysarthria and/or aphasia|
215039846|NCT06296680|OTHER|Reiki|The patients in the intervention group received Reiki to the seven chakra regions and additional areas with pain for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
214476724|NCT06855303|OTHER|Conventional Treatment group|This group will receive a 10 minutes application of high-frequency TENS. Hot moist pack: The patient will be made to lay in a supine position with the affected knee in slight flexion A hot moist pack will be applied around the knee for 15 minutes. Ankle pumps, Heel slides, Open chain knee flexion and extension exercises, Straight leg raise, Quad isometrics and Calf stretch. All these exercises were given 10 repetitions x1 set, three days/week
214476725|NCT06811792|PROCEDURE|Intrathecal Therapy|Patients who underwent at least one lumbar puncture and spinal canal administration of glucocorticoids during hospitalisation were classified as receiving intrathecal (IT) therapy. Dexamethasone was the glucocorticoid administered intrathecally at a dose of 5 mg per administration. All patients also received oral or intravenous anti-TB regimens, which included at least isoniazid and rifampicin for drug-sensitive TBM cases. Patients diagnosed with or suspected of having drug-resistant TBM who required second-line anti-TB drugs were excluded from the study.
214476726|NCT06813144|OTHER|inspiratory muscle exercise|Inspiratory muscle training will be given with or without smart adaptor.
214476727|NCT06811662|PROCEDURE|mitral valve replacement|complete versus partial preservation of subvavular apparatus during mitral valve replacement
214476728|NCT06812364|PROCEDURE|one level ESPB|Ultrasound will be sagittal placed against the target vertebral level T7 vertebrae in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process. The Erector Spinae muscle and transverse process will be then identified, and a blunted tip ,100mm, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in caudal -to- cephalad direction, through the inter fascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 3 ml normal saline to confirm the correct needle tip position. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the T7 vertebrae
214666161|NCT05698186|DRUG|Thero2-01S22|Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
214873921|NCT04628793|DRUG|PF-07258669|PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
214873922|NCT04628793|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
214873923|NCT03302026|BEHAVIORAL|Realtime biofeedback using fMRI|Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
214873924|NCT03039426|DRUG|Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
214873925|NCT03039426|DRUG|Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
214873926|NCT03741426|DRUG|Olaparib|Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
214873927|NCT03741426|DRUG|Cediranib|Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
214873928|NCT03741426|DRUG|Durvalumab|Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
214873929|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 11)|lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
214873930|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 21)|lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
214873931|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 31)|lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
214873932|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 41)|lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8
214873933|NCT04712981|BEHAVIORAL|HOPE|Peer leaders/role models will be trained in HOPE intervention fundamentals and assigned to online community groups with participants.
214873934|NCT00400595|DRUG|Mupirocin ointment|topical ointment (already in widespread clinical use)
214873935|NCT00400595|DRUG|Polysporin Triple|
214873936|NCT01696058|DRUG|Tiotropium|marketed product
214873937|NCT01696058|DRUG|Placebo matching Olodaterol|one dose
214873938|NCT01696058|DRUG|Tiotropium|marketed product
214873939|NCT01696058|DRUG|Olodaterol|one dose
214873940|NCT05284487|DEVICE|Jalosome® soothing gel|Jalosome® Soothing gel is a phospholipid based vesicular system based on hyaluronic acid (HA). HA supports the process of formation of extracellular matrix and collagen synthesis by fibroblasts, favoring the formation of a well-vascularized granulation tissue and thus accelerating the healing process. Jalosome® Soothing gel contains other active ingredients: Acetyl-L-carnitine which plays an important role as shuttle for energy production and is involved in cellular metabolism. It is an effective cytoprotective, anti-inflammatory, neuroprotective, metal chelator, anti-apoptotic and anti-oxidant agent. Allantoin is a key constituent of comfrey (Symphytum officinale L), it has moisturizing and keratolytic effect, increasing the water content of the extracellular matrix and enhancing desquamation of upper layers of dead skin cells. Hydrogenated phosphatidylcholine is a permeation enhancers, which increases the solubilization of active ingredients, improving their skin permeation ability.
214873941|NCT05284487|DEVICE|Placebo|The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
214873942|NCT01773837|DRUG|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
214873943|NCT01773837|DRUG|placebo|placebo (pill) p.o.
214666162|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
214666163|NCT00800072|DEVICE|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
214873944|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the hippocampus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
214873945|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the Precuneus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
214873946|NCT05805215|COMBINATION_PRODUCT|High-frequency stimulation (placebo) with Face-name association training task|High-frequency (\>1 kHz) stimulation; Standardly used as a carrier frequency; Effects are expected to he high-pass filtered by neurons
214873947|NCT05287256|DRUG|Oral Delta-8-THC Cannabis|Delta-8-THC cannabis will be orally self-administered by study participants
214873948|NCT05287256|DRUG|Oral Delta-9-THC Cannabis|Delta-9-THC cannabis will be orally self-administered by study participants
214873949|NCT05287256|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants
214873950|NCT05287256|DRUG|Vaporized Delta-8-THC Cannabis|Delta-8-THC cannabis will be self-administered by study participants using a vaporizer
214873951|NCT05287256|DRUG|Vaporized Delta-9-THC Cannabis|Delta-9-THC cannabis will be self-administered by study participants using a vaporizer
214873952|NCT05287256|DRUG|Vaporized Placebo|Placebo will be self-administered by study participants using a vaporizer
214873953|NCT01934335|DRUG|Vandetanib|
214873954|NCT01934335|OTHER|Placebo|
214873955|NCT02360176|PROCEDURE|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
215039847|NCT06296680|OTHER|Sham Reiki|The patients in the placebo group received Sham Reiki to the seven chakra regions for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
215039848|NCT06296680|OTHER|Progressive Relaxation Exercise|PRE group patients received PRE for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
214666164|NCT00749606|BEHAVIORAL|Individual telephone intervention|"Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
214873956|NCT02360176|PROCEDURE|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
215039849|NCT03822611|BEHAVIORAL|Targeted Subsidy|Voucher
214873957|NCT05384171|BEHAVIORAL|Measurement-Based Transition Assistance (MBTA)|Measurement-Based Transition Assistance (MBTA) asks Veterans about their well-being and then provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
215039850|NCT02943473|DRUG|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
214873958|NCT01371812|DRUG|GSK2239633|Drug will be orally administered at the doses and time points detailed in the 'arms' section.
214873959|NCT01371812|DRUG|Placebo|Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
214873960|NCT06130423|DRUG|Music intervention|Music therapy carried out with Music Care
214873961|NCT06130423|DRUG|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
214873962|NCT06338124|DIAGNOSTIC_TEST|Triglyceride glucose index|To evaluate the role of various laboratory biomarkers ( TyG , RAR , CAR, N\\L ratio, CRP, Serum lactate )in prediction of sepsis outcome.
214873963|NCT06343064|DRUG|Vebreltinib|Phase Ib is a dose escalation study, the initial dose of Vebreltinib is 100mg/150mg/200mg,according to the result of Phase Ib, will confirm the RP2D.
214476729|NCT06812364|PROCEDURE|two level ESPB|"The target vertebral levels are T5 transverse process (at the level of Sternal Angle, above T7 by tow vertebra)(19) and T10 transverse process (at the level of Xiphisternal Junction, below T7 by 3 vertebrae).~The block will be performed bilaterally by injecting 60mL of 0.25% bupivacaine (15mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process) in the same technique."
214476730|NCT06806202|DRUG|conventional 2% lignocaine at room temperature|This study aims to compare the effectiveness of warm 2% lignocaine (lidocaine) versus conventional room temperature 2% lignocaine for achieving successful inferior alveolar nerve blocks (IANB) in mandibular permanent molars
214476731|NCT06806202|DRUG|pre-warmed 2% lignocaine at 42°C|This study aims to compare the effectiveness of warm 2% lignocaine (lidocaine) versus conventional room temperature 2% lignocaine for achieving successful inferior alveolar nerve blocks (IANB) in mandibular permanent molars
214476732|NCT06853106|OTHER|Waitlist control group|The participants in the waitlist control group will be informed that they are on a waiting list during the intervention period, serving as a no-treatment control. They will receive the sleep intervention (i.e., the digital-based sleep management program) four weeks after the intervention period is completed.
214873964|NCT06343064|DRUG|PLB1004|Phase Ib is a dose escalation study, the initial dose of PLB1004 is 80mg/160mg,according to the result of Phase Ib, will confirm the RP2D.
214873965|NCT02669030|DRUG|suvorexant|an FDA-approved sleep aid
214873966|NCT02669030|DRUG|Placebo|control group
214873967|NCT04939376|PROCEDURE|IVF|In vitro fertilization
214873968|NCT00106964|BIOLOGICAL|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
214873969|NCT00106964|BIOLOGICAL|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
214873970|NCT00106964|BIOLOGICAL|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle."
214873971|NCT02654119|DRUG|Cyclophosphamide|Given IV
214873972|NCT02654119|OTHER|Laboratory Biomarker Analysis|Correlative studies
214873973|NCT02654119|DRUG|Paclitaxel|Given IV
214873974|NCT02654119|BIOLOGICAL|Trastuzumab|Given IV
214873975|NCT02492659|PROCEDURE|femtosecond laser-assisted cataract surgery|the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
214873976|NCT02492659|PROCEDURE|conventional phacoemulsification|continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
214873977|NCT05390593|DEVICE|iTBS-1800|Participants in the 1800-pulse intermittent TBS (iTBS-1800) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
214873978|NCT05390593|DEVICE|iTBS-1200|Participants in the 1200-pulse intermittent TBS (iTBS-1200) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
214873979|NCT03827720|DEVICE|SENSE Device|Non-invasive radiofrequency (RF) sensor
214873980|NCT04868994|DIAGNOSTIC_TEST|Whole Body MRI and ENMG|Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
214873981|NCT01261091|PROCEDURE|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
214873982|NCT01261091|PROCEDURE|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
214873983|NCT00245830|PROCEDURE|Ischemic Preconditioning|Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
214873984|NCT01679717|OTHER|Early mobilisation after CMC1-surgery|Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
214873985|NCT06158555|DRUG|250 ML NaCl 4.5 MG/ML Injection|Bolus 250 ml crystalloid. Usually 0.9% saline or compound sodium lactate solution at discretion of attending clinician
214873986|NCT03196219|DRUG|C16G2|C16G2
214873987|NCT03196219|DRUG|Placebo|Varnish Placebo
214873988|NCT01422187|DRUG|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
214873989|NCT06187090|DIETARY_SUPPLEMENT|Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form|Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
214873990|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
214873991|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
214873992|NCT00168818|DRUG|enoxaparin|40 mg once daily
214873993|NCT05408585|OTHER|Regional Anesthesia Techniques|Fascial Plane Blocks
214873994|NCT04439617|BIOLOGICAL|blood examination|use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
214873995|NCT05249452|OTHER|Preconditioning with azathiprine and hydroxyurea (3 months)|Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.
214873996|NCT00221377|DEVICE|Intubation using tracheal tubes with or without cuff|
214873997|NCT02227446|DRUG|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
214873998|NCT01866046|BEHAVIORAL|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
214873999|NCT01693796|OTHER|blood and urine samples ; Echography|
215039851|NCT05392816|OTHER|Single meal non-heme iron absorption|Two study groups, each designed as cross-over single-blinded iron isotope trials in apparent healthy Swedish women of the ages 18-45 years. Each participant serves as their own control. Meals are tagged with radiolabeled non-heme iron 55Fe and 59Fe.
215039852|NCT02103465|DRUG|Rotigotine|transdermal patch
215039853|NCT02103465|DRUG|Placebo|transdermal patch
215039854|NCT01891279|OTHER|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
215039855|NCT01891279|OTHER|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
215039856|NCT06547606|OTHER|Usual Care|Participants in the control group will recieve usual care.
215039857|NCT03157947|BEHAVIORAL|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
215039858|NCT03157947|BEHAVIORAL|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
215039859|NCT03157947|BEHAVIORAL|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
215039860|NCT03534492|DRUG|Durvalumab|Infusion
214476733|NCT06853106|BEHAVIORAL|digital-based multimodal sleep management program|The digital-based multimodal sleep management program consists of (1) sleep hygiene education, (2) sleep restriction, and (3) mindfulness breathing exercises. The program is internet-integrated and delivered via Google Meet, with 45-minute weekly sessions over four weeks. To increase participants' adherence to the sleep management program , the course instructor will request the participants to record their daily sleep diaries (time to bed, time to sleep, wake time during sleep and wake time) and sleep journals(practices of sleep hygiene, sleep restriction and mindfulness breathing exercise) in the mobile app for at least five consecutive days each week.
214666165|NCT00749606|BEHAVIORAL|Group telephone intervention|"Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
215039861|NCT03534492|DRUG|Olaparib|P.O.
215039862|NCT03747055|BEHAVIORAL|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
215039863|NCT03747055|BEHAVIORAL|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
215039864|NCT06058091|DRUG|RY_SW01 cell injection|Administer basic treatment with an injection of RY\_SW01 cell solution
215039865|NCT06058091|DRUG|Basic treatment|Basic treatment for SSc
214666166|NCT00783640|DRUG|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
214666167|NCT04917874|BIOLOGICAL|Open Label Topical Beremagene Geperpavec (B-VEC)|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
215039866|NCT00047034|DRUG|eribulin mesylate|Given IV
215039867|NCT00047034|OTHER|pharmacological study|Correlative studies
215039868|NCT00047034|OTHER|laboratory biomarker analysis|Correlative studies
215039869|NCT05892341|DEVICE|AQUACEL® Ag+ Extra™|Wound treatment with AQUACEL® Ag+ Extra™ dressing
215039870|NCT05892341|DEVICE|Cutimed® Sorbact®|Wound treatment with Cutimed® Sorbact® dressing
215039871|NCT05678426|BEHAVIORAL|Smoking cessation|Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
215039872|NCT05678426|BEHAVIORAL|Intermittent fasting|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
215039873|NCT05678426|BEHAVIORAL|Intermittent fasting with ketogenic supplement|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive a ketogenic supplement, medium-chain triglyceride fiber, to use daily. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
215039874|NCT00897026|DRUG|cyclophosphamide|
215039875|NCT00897026|DRUG|doxorubicin hydrochloride|
215039876|NCT00897026|DRUG|paclitaxel|
215039877|NCT00897026|GENETIC|fluorescence in situ hybridization|
215039878|NCT00897026|OTHER|immunohistochemistry staining method|
215039879|NCT05130073|PROCEDURE|Computed Tomography|Undergo PET/CT
215039880|NCT05130073|OTHER|Electronic Health Record Review|Review of medical records
215039881|NCT05130073|PROCEDURE|Follow-Up|Undergo follow-up
215039882|NCT05130073|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215039883|NCT00660218|DRUG|paclitaxel poliglumex|Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
215039884|NCT00660218|BIOLOGICAL|cetuximab|400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
215039885|NCT00660218|RADIATION|radiation therapy (IMRT or 3D-CRT)|radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
215039886|NCT04211363|DRUG|Roflumilast 0.3% cream|Roflumilast 0.3% cream for topical application.
215039887|NCT04211363|DRUG|Vehicle Cream|Vehicle cream for topical application.
215039888|NCT03035630|DRUG|Avelumab|Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle
215039889|NCT03035630|DRUG|Sunitinib|Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
214476734|NCT06854848|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
215039890|NCT03097289|DEVICE|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
215039891|NCT02007941|DRUG|CKD-501|From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
214476735|NCT06854848|BIOLOGICAL|urine sample|10 ml
214666168|NCT04996693|DIAGNOSTIC_TEST|Imaging on Scanner with Spectral Imaging Capabilities|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.
215039892|NCT04505488|BEHAVIORAL|ASD Screening Parent ENgagement Intervention Program (ASPEN)|The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
215039893|NCT02835469|DRUG|Menotrophin|
215039894|NCT02160821|PROCEDURE|Caudal Epidural|Ultrasound Guided Caudal Block
215039895|NCT02160821|PROCEDURE|Transversus Abdominis Plane Block|Ultrasound Guided Transversus Abdominis Plane Block
215039896|NCT05957627|PROCEDURE|Saleem's protocol|It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia
215039897|NCT01428791|BEHAVIORAL|Generations older adult membership program|"Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:~• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops."
215039898|NCT01428791|BEHAVIORAL|BRIGHTEN Heart Virtual Team intervention|"BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health \& health behavior change for 6 - 12 months, including:~• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows."
215039899|NCT03057756|COMBINATION_PRODUCT|Km+ Mfx+ Pto + H + Cfz +E+Z|Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
214874000|NCT06421883|DIETARY_SUPPLEMENT|Lactobacillus containing probiotic|"Patients will be randomized into two groups each group includes 40 patients:~Control group: 40 patients will receive their standard therapy only. Intervention group (probiotic group): 40 patients will receive probiotic 5 billion unit per day with their standard therapy for 3 months."
214874001|NCT00408083|DRUG|MultiHance|0.5 mmol/kg as a single dose administration
214874002|NCT00408083|DRUG|Magnevist|0.5 mmol/kg as a single dose administration
214874003|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal|Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken
214874004|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state|Selected dosing of Part One treatments in fasted and/or fed states
214874005|NCT03270878|DRUG|Glasdegib Oral Tablet|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
215039900|NCT05748821|DEVICE|Delfi Personal Tourniquet Systems|Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
215039901|NCT01736917|DRUG|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
215039902|NCT01736917|DRUG|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
215039903|NCT01736917|DRUG|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
214476736|NCT06808815|DRUG|DC-806|administered orally.
214476737|NCT06808815|OTHER|Placebo|administered orally.
214476738|NCT06808737|PROCEDURE|Transversus Abdominis Plane Blockage|Patient monitoring will be conducted, followed by the preparation of the skin with 10% povidone-iodine and ensuring appropriate draping. A high-frequency linear transducer will be placed transversely between the right iliac crest and subcostal margin along the midaxillary line. Structures visualized on ultrasound from superficial to deep include: skin, subcutaneous fat, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum. The TAP block will be performed in the transversus abdominis plane (TAP) between the internal oblique and transversus abdominis muscles. A 23-gauge, 60 mm blunt-tipped needle will be directed toward the TAP, and negative aspiration will be confirmed upon entry into the fascial layer. An injection of 20 mL of 0.25% bupivacaine, prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline, will be performed, followed by the visualization of the oval spread of bupivacaine in the TAP.
214476739|NCT06809452|BEHAVIORAL|Transdiagnostic Oncologic Program|"The Transdiagnostic Oncology Program (TOP) is a 12-month interdisciplinary aftercare program aimed at improving cancer survivors' quality of life by addressing common clinical issues.~In the first three months, participants attended two weekly 1-hour exercise sessions led by physiotherapists. Once a week, this was followed by 1-hour mind-body therapy for stress reduction. A dietitian provided an initial group session on nutrition and advised at least two personal consultations.~Between months 3-6, exercise was reduced to once weekly, with encouragement to continue independent exercise and relaxation. A second informational session on stress and sleep hygiene was given.~After six months, participants continued independently, meeting the family doctor quarterly to evaluate progress.~For the participants who experienced some psychological problems, sessions with a psychologist at an institute specialized for psycho-oncology, were available."
214476740|NCT06654960|DRUG|HRS9531 injection|HRS9531 injection single dose.
214476741|NCT06654960|DRUG|Metformin Hydrochloride tablets|Metformin Hydrochloride tablets 500mg.
214666169|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)|Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
214874006|NCT03270878|DRUG|Glasdegib IV infusion|Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
214874007|NCT01291771|PROCEDURE|Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire|The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
214874008|NCT04836897|DEVICE|PrizValve® valve and transapical delivery system|Transcatheter aortic valve replacement system
214874009|NCT04362553|DEVICE|wearable vital signs sensor|vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
214874010|NCT00641615|BIOLOGICAL|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
215039904|NCT01392157|DEVICE|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
215039905|NCT01392157|DEVICE|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
214666170|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)|Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
214666171|NCT00187083|DRUG|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
214874011|NCT00637767|DRUG|melphalan|
214874012|NCT00637767|PROCEDURE|autologous hematopoietic stem cell transplantation|
214874013|NCT00637767|RADIATION|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
214874014|NCT02006329|DEVICE|acupuncture|
214874015|NCT00308880|DRUG|Transamin|
214874016|NCT03544944|DRUG|TJP-008-1|Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
214874017|NCT03544944|DRUG|TJP-008-2|Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
214874018|NCT03544944|DRUG|Coolprep powder|Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
214874019|NCT00354692|DRUG|Sodium Ferric Gluconate and Iron sucrose|
214874020|NCT01238380|OTHER|patient care pathway|"Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 \& IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change."
214874021|NCT02497638|DRUG|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
214874022|NCT02497638|DRUG|Atorvastatin|Atorvastatin 20 mg once daily until progression.
214874023|NCT02497638|DRUG|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
214874024|NCT02497638|DRUG|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
214874025|NCT02390024|DEVICE|Invasive Mechanical Ventilation|"Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:~Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840"
214874026|NCT01960049|PROCEDURE|ropivacaine + iv PCA|
214874027|NCT01960049|PROCEDURE|saline and IV PCA|
214874028|NCT03510390|DRUG|Metformin|850 mg, oral, twice daily, 9-14 days
214874029|NCT03316274|DRUG|Nivolumab|Given via intralesional injection
215039906|NCT01392157|DEVICE|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
215039907|NCT01392157|DEVICE|LNG-IUS|100 women will receive an LNG-IUS
215039908|NCT03377660|OTHER|Clinical treatment|Patients undergo clinical treatment as indicated, they are studied before and after.
215039909|NCT01911260|DIETARY_SUPPLEMENT|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
215039910|NCT01911260|OTHER|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
214874030|NCT02341391|BIOLOGICAL|TissueGene-C(Low dose)|3.0 x 10\^6 cells
215039911|NCT01669512|BIOLOGICAL|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
215039912|NCT01669512|BIOLOGICAL|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
215039913|NCT01669512|BIOLOGICAL|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
215039914|NCT04748887|OTHER|oxidative stess markers|markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
215039915|NCT03493646|DRUG|Azacitidine|75mg/m2 per day for 7 days of each 28 day cycle. Cycles 1-6
214874031|NCT02341391|BIOLOGICAL|TissueGene-C(Medium dose)|1.0 x 10\^7 cells
214874032|NCT02341391|BIOLOGICAL|TissueGene-C(High dose)|3.0 x 10\^7 cells
215039916|NCT03493646|DRUG|CC-486|100 mg BID for the first 21 days of each 28-day treatment cycle (cycles 7-8). The dose should be increased from cycle 9 onwards to 150mg BID for the first 21 days of each 28-day treatment cycle (cycles 9-12) in the absence of Grade 3 or 4 AE. If 2 or more cycles are tolerated at this dose, further increments are permitted for patients with Stable Disease or if clinically indicated in consultation with the coordinating investigator as per the study dose modification schedule.
215039917|NCT00002217|DRUG|Lamivudine/Zidovudine|
215039918|NCT00002217|DRUG|Abacavir sulfate|
215039919|NCT00002217|DRUG|Amprenavir|
215039920|NCT02807701|PROCEDURE|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy~1. dissection~2. reconstruction"
215039921|NCT02807701|PROCEDURE|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
215039922|NCT01675947|DRUG|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
215039923|NCT01675947|DRUG|Lidocaine|Lidocaine 2%
215039924|NCT02645799|DRUG|LABR-312|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
214874033|NCT05800067|DRUG|axi-cel|Axicabtagene ciloleucel (Axi-cel) is an autologous anti-CD-19 chimeric antigen receptor(CAR) T-cell therapy approved by FDA in 2017 for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Now, it is the standard treatment for these patients recommended by NCCN and other guidelines. Axi-cel was approved for R/R LBCL patients who had received 2 or more prior lines of therapy on 2021 June in China.
214874034|NCT01380548|DIETARY_SUPPLEMENT|Placebo|Placebo; once/day; for 12 weeks
214874035|NCT01380548|DIETARY_SUPPLEMENT|Iron alone|Iron (3 mg); once/day; for 12 weeks
214874036|NCT01380548|DIETARY_SUPPLEMENT|Low-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
214874037|NCT01380548|DIETARY_SUPPLEMENT|Medium-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
214874038|NCT01380548|DIETARY_SUPPLEMENT|High-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
215039925|NCT02645799|DRUG|Saline (placebo)|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
215039926|NCT03140618|OTHER|The light and environment project in psychiatric inpatient care|"Complete rebuilding of a hospital ward.~The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built."
215039927|NCT06479356|BIOLOGICAL|Relma-cel|Relma-cel will be administered at one dose level:1×10\^8 CAR+T cells
215039928|NCT05923723|OTHER|FIBNUTRITION|"The dietary product selected for the study is commercially known as FIBNUTRITION, marketed in Colombia by Bio-Nutrition S.A.S with sanitary registration number NSA-001942-2016.~Ingredients of the product:~Flaxseed, Chia seeds, Psyllium, Polydextrose, Oat flour, Apple, Orange, Artificial flavor (Orange), Pineapple, Nopal, Xanthan gum (thickener), Silicon dioxide, Stevia (Natural sweetener), Lactobacillus Acidophilus Bifidus Casei (Prebiotics), Sodium Benzoate (Preservative), and Turmeric (Natural colorant)."
215039929|NCT05923723|OTHER|Placebo|The placebo is a dietary product composed of maltodextrin, cornstarch, orange flavoring, and stevia.
215039930|NCT01772940|DRUG|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
215039931|NCT01772940|DRUG|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
215039932|NCT01772940|DRUG|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
215039933|NCT01772940|DRUG|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
214874039|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
214874040|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
214874041|NCT03904264|DEVICE|Receiver in the canal (RIC) hearing aids|The RIC hearing aids fitted to subjects in arm 1 of the study will be manufactured by Widex.
214874042|NCT00735397|DRUG|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
214874043|NCT04767191|DRUG|artemether lumefantrine|The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
214874044|NCT04767191|DRUG|dihydroartemisinin piperaquine|Antimalarial Combinations
214874045|NCT02338804|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
214874046|NCT02338804|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
214874047|NCT03769961|OTHER|No intervention|No interventions - Observational study
214874048|NCT04833530|DIAGNOSTIC_TEST|Gastric Ultrasound|"In the operating room, a gastric ultrasound will be performed in the supine position and the antral cross sectional area will be measured. Anesthesia will be induced in standard procedure and positive pressure will be instituted according to the standard protocol accepted in our hospital.~At the end of the procedure, the gastric ultrasound circumference will be measured again."
214874049|NCT02369302|DRUG|DWC20141|Tablet
214874050|NCT02369302|DRUG|DWC20142|Tablet
214874051|NCT02369302|DRUG|DWC20141, DWC20142|Tablet
214874052|NCT04574440|DEVICE|multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap that will be positioned on the patient's head according to international operational guidelines and will be secured to the temporal region of the patient's forehead. The NIRS cap is entirely non-invasive and does not pose any additional risk to the patient. Monitoring will be commenced prior to the induction of anesthesia. Subsequent surgical and medical care will not be affected.
214874053|NCT06021691|BEHAVIORAL|Acquired nurturing environment|Superimposed effects of intrauterine high-sugar environment exposure and postnatal nurturing environment exposure
214874054|NCT05523791|DIETARY_SUPPLEMENT|Fortiral|Twice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
214874055|NCT05523791|DIETARY_SUPPLEMENT|Mg++|Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water
214874056|NCT06452901|OTHER|Progression and structured surgical training.|Participants will be exposed to different amounts of open vascular surgical training, but only group I will receive the complete structured and progressive training program. This ensures that all participants have access to the potential benefits derived from the intervention. Current evidence supports this approach, which supports the benefits of medical simulation in the training process of surgical residents.
214874057|NCT02763826|DEVICE|transcranial direct current stimulation|brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
214874058|NCT05055583|DRUG|Toripalimab in Combination With Platinum-based Chemotherapy|Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.
214874059|NCT05055583|PROCEDURE|Surgical treatment stage|After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.
214874060|NCT05055583|DRUG|Adjuvant treatment stage|Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
214874061|NCT04588493|DIAGNOSTIC_TEST|Lower extremity Lymphoscintigraphy|Study of lymphoscintigraphy (LCG) abnormalities in a group of patients with history of infiltration of modeling substances in buttocks and hips and complain about lower extremities edema. LCG was performed and evaluated by a single nuclear medicine specialist through injection of the sulfur nanocolloid Technetium 99m, injected intradermal and interdigital in bilateral toes. Dynamic studies were requested for all patients. Standardized acquisition times at 15, 30, 60 and 120 minutes after injection were taken. The following parameters were considered to obtain the transport index in each pelvic limb: transport kinematics, distribution pattern, index time for the appearance of regional lymph nodes, number and collection of colloids in lymph nodes and presence and quality of the colloid uptake by the lymphatic vessels. Summation of these five components resulted in the transport index, which could range from 0 to 45 points
214874062|NCT01772797|DRUG|LDK378|LDK378 is a capsule to be taken daily by mouth.
214874063|NCT01772797|DRUG|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
214874064|NCT00073697|DRUG|Escitalopram|Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
214874065|NCT00073697|BEHAVIORAL|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
214874066|NCT00073697|OTHER|Escitalopram plus IPT|Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
215039934|NCT05181488|RADIATION|intraoperative radiotherapy, IORT|A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
215039935|NCT01951391|OTHER|Control Hand Soap|Commercially available soap will be used to wash the subject's forearms
215039936|NCT01951391|OTHER|Benzalkonium Chloride Soap|Commercially available soap containing benzalkonium chloride will be used to wash the subject's forearms
215039937|NCT01951391|OTHER|Triclocarban Soap|Commercially available soap containing triclocarban will be used to wash the subject's forearms
215039938|NCT06557304|DRUG|BTK inhibitor|patients with treatment naive or R/R CLL who treatment with BTK inhibitor
215039939|NCT01938729|PROCEDURE|Liver resection and placement of hepatic artery infusion pump|
214874067|NCT03687411|PROCEDURE|Neuraxial ultrasonography|Ultrasound gel is applied to lower back lumbar spine of patient and placed with an ultrasound probe around the sacral region. The graphical interface of the software integrated with ultrasound machine will help identify the sacrum. The probe is moved in until the L3/4 interspinous space is identified for skin surface marking. Once the longitudinal scan is completed, the investigator will turn the probe 90° clockwise for transverse scan to identify ligamentum flavum.
214874068|NCT00901576|DRUG|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
215039940|NCT01938729|DRUG|FLOXURIDINE|
215039941|NCT01938729|DRUG|DEXAMETHASONE|
215039942|NCT01938729|DRUG|GEMCITABINE|
215039943|NCT06490692|OTHER|Blood Flow Restriction Training|The affected limb will have a cuff placed proximally and inflated to occlude the blood flow by 40% attested using a golden standard vascular doppler after which the individuals will perform the strengthening program set forth by the physical therapist. This is preceded by other tennis elbow interventions such as ultrasound, stretching, and deep friction massage at the extensor origin.
215039944|NCT06490692|OTHER|Conventional Strength Training|The individuals in this group will undergo the same conventional physical therapy program as the other group including ultrasound, stretching, and deep friction massage. In addition, they will undergo the same strengthening program set forth by the physical therapist however with no blood flow restriction of any kind.
215039945|NCT02481557|DEVICE|Oxalate Salt Solution|Applied by dentist
215039946|NCT05267782|DEVICE|Masimo's O3 Regional Oximetry|Correlation between new O3 regional oximetry monitoring, electroencephalography and somatosensory evoked potential in carotid endarterectomy and data collection during different stages of anaesthesia and correlation with new O3 regional oximetry
215039947|NCT01966146|DEVICE|Echography GE Healthcare Vivid E9|Echography GE Healthcare Vivid E9
215039948|NCT03416894|DEVICE|Deep Brain Stimulation|DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
215039949|NCT01734902|DRUG|Hyoscine butylbromide|sugar coated tablets for oral administration
215039950|NCT01734902|DRUG|Hyoscine butylbromide|drops for oral administration
215039951|NCT02647684|BEHAVIORAL|Self-Directed Triple P|10 Week Triple P Self directed workbook
215039952|NCT01959932|OTHER|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
214476742|NCT06654089|DIETARY_SUPPLEMENT|Emergen-C Core Super Orange Powder|A dietary supplement powder containing vitamin C, zinc, vitamin B6, vitamin B12, folate, and manganese.
214874069|NCT00901576|DRUG|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
214874070|NCT00901576|DRUG|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
214874071|NCT01559389|DRUG|Solifenacin|Women presenting with UUI symptoms receive 5 to 10 milligrams (mg) of daily solifenacin for up to 16 weeks
214874072|NCT05980689|DRUG|AK104|During neo-CRT: 2 cycles of AK104, 10mg/kg d1 q3w. After neo-CRT: 3 cycles of AK104, 10mg/kg d1 q3w.
214874073|NCT05980689|DRUG|Capecitabine|During neo-CRT: 825mg/m2 bid Monday-Friday per week
215039953|NCT01959932|OTHER|Smoking abstinence (SA)|SA for 5 days in confinement
215039954|NCT01959932|OTHER|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
215039955|NCT01239550|DRUG|Detemir|"Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.~Insulin injections will be given subcutaneously preferably in the thigh or abdomen."
215039956|NCT04838067|DEVICE|Cefaly|Transcutaneous trigeminal nerve electrical neuromodulation
215039957|NCT04271293|DRUG|Edoxaban|Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.
215039958|NCT04462575|PROCEDURE|Onlay bone block covered using collagen membrane|The ratio is 40% of xenogenic bone particles (low resorption rate) to 60% of autogenous bone particles (contains viable cells) to be placed in recipient decorticated site and covered by onlay bone block..
215039959|NCT04462575|PROCEDURE|Onlay bone block without collagen membrane|Onlay bone block without collagen membrane
215039960|NCT00758563|DRUG|Fluoride|Brush twice daily
215039961|NCT00758563|DRUG|Triclosan/Fluoride|Brush twice daily
215039962|NCT00202579|DRUG|Ivabradine|
214476743|NCT06654089|DIETARY_SUPPLEMENT|Placebo|A study product identical to the test product without active ingredients.
214666172|NCT00187083|DRUG|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
214874074|NCT05980689|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
214874075|NCT04302636|DIETARY_SUPPLEMENT|Low glycemic index diet|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
215039963|NCT00060944|DRUG|Yondelis|1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
215039964|NCT00060944|DRUG|Yondelis|0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
215039965|NCT00060944|DRUG|Dexamethasone|Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
214874076|NCT05242718|DIETARY_SUPPLEMENT|N-Acetyl-L-cysteine (NAC)|Health Canada Natural Product Number (NPN) 80056946
214874077|NCT05242718|DIETARY_SUPPLEMENT|Echinacea purpurea|Health Canada Natural Product Number (NPN) 80093896
214874078|NCT05242718|DIETARY_SUPPLEMENT|Curcumin|Health Canada Natural Product Number (NPN) 80043455
214874079|NCT05242718|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Health Canada Natural Product Number (NPN) 80097472
214874080|NCT06292117|OTHER|CYP2C19 Genotype|qPCR-based genotyping assay interrogating all Association for Molecular Pathology (AMP) recommended Tier 1 and Tier 2 single nucleotide polymorphisms (SNPs) for CYP2C19 (\*2, \*3, \*4, \*5, \*6, \*7, \*8, \*9, \*10, \*17, \*35)
214874081|NCT01564264|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
214874082|NCT05775133|DEVICE|ICG|"Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting."
214874083|NCT03258203|OTHER|Preventing Overweight Using Novel Dietary Strategies|The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
214874084|NCT04941079|OTHER|no intervention|no intervention
214874085|NCT06339697|DRUG|different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate)|Bowel preparation with different types of laxatives (compounded polyethylene glycol electrolytes and compounded sodium picosulfate)
214476744|NCT06812182|BEHAVIORAL|nurse guided clinical pathway|"Educational training sessions were provided to care providers for one week. Pre-operative; counseling and education of patient for chest physiotherapy, using spirometry, bowel preparation, early mobilization and how to predict common complications with learning to cooperate with nurses. Emphasis on patients to co-operate postoperatively was strongly stressed in spite of the pain and weakness.~Intra-operative: Optimal fluid management, short acting anesthetics, regional analgesia, opioids-sparing anesthesia, small incisions, avoiding drains, maintaining normothermia, venous thrombo-embolism \[VTE\] prophylaxis and antibiotic prophylaxis were routinely done.~Post-operative: Early oral nutrition, optimal fluid management, multimodal non-opioid analgesia, postoperative nausea and vomiting PONV prophylaxis, stimulation of gut motility, early removal of catheters and drains, early mobilization, chest physiotherapy and using spirometry effectively."
214476745|NCT06812234|OTHER|DAX Copilot|"* Enrolled in DAX Copilot program.~* Epic Haiku verified and adapted to record visits for DAX.~* Virtual training to add Patient List column to schedule for DAX Note Status, add appropriate smartlinks to note templates (AI-generated history of present illness, physical exam, and assessment and plan).~* In person at-the-elbow support from Children's Epic Support on Site team at initiation and up to 2 additional sessions."
215039966|NCT00060944|DRUG|Dexamethasone|Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
215039967|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)|Applied to the entire face twice daily for 10 weeks
214476746|NCT06812923|DEVICE|transcranial Alternating Current Stimulation (tACS)|tACS, parameters: 15mA、77.5Hz tACS, 20 times (5 times a week, four weeks totally)
214874086|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
214874087|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
214874088|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
214874089|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
214874090|NCT01461915|DRUG|Nab paclitaxel|Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
214874091|NCT01461915|DRUG|Gemcitabine|Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
214874092|NCT01461915|DRUG|Dociparstat|Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
214874093|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES randomized vouchers for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred from March 4, 2019, forward.
214874094|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES randomized vouchers for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after November 4, 2019.
214874095|NCT05724563|DRUG|Zimberelimab|Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
214874096|NCT05724563|DRUG|Domvanalimab|Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
215039968|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)|Applied to the entire face twice daily for 10 weeks
215039969|NCT01138514|DRUG|Placebo|Placebo
214476747|NCT06812923|DEVICE|Sham stimulation|Sham stimulation, matched with real tACS, except for providing electrical stimulation
214476748|NCT06108479|DRUG|DF6215|Immunotherapy (cytokine) targeting effector cells.
214476749|NCT06108479|DRUG|pembrolizumab|Anti-PD-1 immunotherapy agent
214476750|NCT06108479|DRUG|KEYTRUDA®|Anti-PD-1 immunotherapy agent
214476751|NCT03495128|OTHER|Bed Rest|3 days of head down tilt (-6 degrees) bed rest
214874097|NCT06417086|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
214874098|NCT06417086|OTHER|Sham Acupuncture|The Streitberger placebo needle will be used to simulate an acupuncture procedure without penetrating the skin. The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
214874099|NCT06417086|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks.
214874100|NCT02586246|DRUG|CDP870|Self-injection
214874101|NCT01832779|OTHER|Achalasia subjects|Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
214874102|NCT03299946|DRUG|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
214874103|NCT03299946|DRUG|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
214874104|NCT03218124|OTHER|Remifentanil Effect site concentration|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
214874105|NCT00259233|DRUG|peripheral Peptide YY administration|
214874106|NCT06287528|BIOLOGICAL|19-28z/IL-18 CAR T cells|19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL
214874107|NCT04521413|DRUG|CFI-402411|CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
214874108|NCT04521413|DRUG|Pembrolizumab|Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
214476752|NCT03495128|OTHER|Reconditioning|daily resistance training (for 3 days) on one leg
214874109|NCT06971783|OTHER|CT- control group|will receive the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
214874110|NCT06971783|OTHER|NP- Potassium nitrate gel|The gels will be applied to the sensitive lesions according to the experimental group and will be rubbed for 20 seconds using a microbrush, remaining on the lesions for 10 minutes.
214874111|NCT06971783|OTHER|AO - Acmella Oleracea Extract Gel|The Acmella oleracea gel will be applied to sensitive lesions and rubbed for 20 seconds with the aid of a microbrush, remaining on the lesions for 10 minutes.
214874112|NCT06971783|OTHER|AF - Gel of Acmella Oleracea extract associated with Fluoride.|The Acmella oleracea gel associated with fluoride will be applied to sensitive lesions and rubbed for 20 seconds with the aid of a microbrush, remaining on the lesions for 10 minutes.
214476753|NCT02215265|DRUG|Cisplatin|Chemotherapy
214874113|NCT06007066|DRUG|HSK16149 capsule|Subjects will be given 40mg or 60mg of HSK16149 orally.
214874114|NCT06007066|DRUG|Placebo|Subjects will be given HSK16149 placebo orally.
214874115|NCT02422589|DRUG|ceritinib|
214874116|NCT02422589|DRUG|warfarin|
214874117|NCT02422589|DRUG|midazolam|
214476754|NCT02215265|RADIATION|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
214476755|NCT05335122|DRUG|OTX-TIC low dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
214476756|NCT05335122|DRUG|OTX-TIC high dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
214476757|NCT05335122|DRUG|Durysta, Bimatoprost Intracameral Implant 10 µg|Durysta is injected into the anterior chamber of the eye.
214666173|NCT00187083|DRUG|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
214874118|NCT05670574|PROCEDURE|Surgery with extended (D3) mesenterectomy for small bowel tumors|
214874119|NCT01648660|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
214874120|NCT03093389|DRUG|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
214874121|NCT03093389|DRUG|Placebo|Matching placebo capsules
214874122|NCT02969681|DRUG|ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
214874123|NCT02969681|DRUG|Chemotherapy|"* mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
214874124|NCT02373033|OTHER|Natural food folate|Consumed folate-rich foods (providing additional 250 μg/d folate).
214874125|NCT02373033|OTHER|Folic acid|Received a folic acid supplement (providing additional 500 μg/d folic acid).
214874126|NCT02373033|OTHER|Apple juice|Received apple juice containing no folate or folic acid.
215039970|NCT04268238|PROCEDURE|Hygiene Guidance|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate).
215039971|NCT04268238|PROCEDURE|Sealant Application|Permaseal (Ultradent) is an unloaded resin based on methacrylate and photopolymerizable. The teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal for 5 seconds to the tooth surface and light curing for 20 seconds. After that, it is necessary to evaluate occlusion.
215039972|NCT04268238|RADIATION|Low Level Laser Application|Volunteers will receive irradiation with AsGaAl laser, wavelength of 780nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, density of energy of 35 J/cm2 (considering a spot size of 0.028cm2 of this equipment), the dose will be 1 J per point. Irradiation will be performed at a cervical, an apical point, and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
215039973|NCT02375074|BEHAVIORAL|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
215039974|NCT02375074|BEHAVIORAL|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
215039975|NCT00499525|DRUG|paclitaxel|given IV
215039976|NCT00499525|DRUG|sorafenib tosylate|given orallly
215039977|NCT00499525|OTHER|placebo|given orally
215039978|NCT00776230|BIOLOGICAL|IC51|6 mcg im. at day 0 and day 28
215039979|NCT03791879|DRUG|Caudal dexamedatomidine analgesia|"Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg."
215039980|NCT03969173|PROCEDURE|applying PEEP3|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
214476758|NCT06754852|DRUG|HMB-002 (Part A)|HMB-002 will be administered subcutaneously. Part A will utilize sentinel dosing. The planned duration of study participants in Part A is approximately 12 weeks.
214874127|NCT04699851|BEHAVIORAL|Tailored recommendations|Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
214874128|NCT04699851|BEHAVIORAL|General recommendation|The control group will receive general recommendations by email about health prevention in a pandemic.
214874129|NCT05569551|DEVICE|Adhesive pouch|Is a barrier dressing categorized under class C medical device. It is used to seal up the umbilical stump to prevent contamination until its cord detachment. It has an adhesive film that sticks to skin with a centrally located non-adhesive pouch ensuring that zero pressure is applied on the umbilicus. It is made of polyurethane, the same material as transparent intravenous cannula dressings making it hypoallergenic waterproof and breathable.
214874130|NCT06199063|OTHER|Self-Streching Exercises|The participants in the SSE group; received 1 session SSE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
214874131|NCT06199063|OTHER|Post-Isometric Relaxation Exercises|The participants in the PIRE group; received 1 session PIRE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
214874132|NCT06199063|OTHER|Reciprocal-Inhibiton Exercises|The participants in the RIE group; received 1 session RIE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
214874133|NCT01675843|PROCEDURE|Intrauterine insemination (IUI)|The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
214874134|NCT01676415|DRUG|Prednisone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days~Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study"
214874135|NCT01676415|DRUG|Topical mometasone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study."
214874136|NCT05578456|DRUG|Prednisone and Aspirin|prednisone 10 mg and aspirin 75-100mg per day per os
214874137|NCT05578456|DRUG|Placebo|placebo 2 starch tablets per day per os
214874138|NCT04869215|OTHER|EverVita Pro|EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.
214874139|NCT04869215|OTHER|Control bread|Bread baked with normal Bakers flour
214874140|NCT00587990|BIOLOGICAL|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10\^7 cells. The injections will be administered following completion of CABG surgery.
214874141|NCT00587990|GENETIC|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
215039981|NCT03969173|PROCEDURE|applying PEEP6|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
215039982|NCT03969173|PROCEDURE|applying PEEP9|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
215039983|NCT03381989|DEVICE|ASHI_INTECC Astato XS 20 0.014 guidewire|A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
214476759|NCT06754852|DRUG|HMB-002 (Part B)|HMB-002 will be administered subcutaneously. Part B dosing intervals will be determined following evaluation of Part A results. The planned duration of study participants in Part B will be approximately 21 weeks.
214874142|NCT00587990|BIOLOGICAL|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10\^8 cells. The injections will be administered following completion of CABG surgery.
214874143|NCT01205984|DRUG|methylprednisolone|Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
214874144|NCT01381315|PROCEDURE|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur \<3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
215039984|NCT00458549|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
215039985|NCT00458549|PROCEDURE|biopsy|
215039986|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg twice daily
215039987|NCT01242514|DRUG|Fostamatinib|Fostamatinib 150mg once daily
215039988|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg once daily
215039989|NCT05230277|OTHER|the active osteopathic treatment (AOT)|The AOT will first consist of the application of a visceral technique. The patient will lie on their stomach and the osteopath will touch the patient's abdomen with a wide two-handed grip. The action will consist of following the abdominal tissues in directions where tissue mobility is allowed and occurs without restriction, from the surface to the depth of the abdomen. A change in the elasticity of the colon will then be perceived when the mobility restrictions of the tissues are dissipated. The osteopath will then use a technique on the sacrum according toik-g the procedure described by Attali et al. \[8\] which consists in mobilizing the sacrum between the iliac bones.
215039990|NCT05230277|OTHER|the sham osteopathic treatment|For SOT, the patient will lie on their stomach and the osteopath will use a wide two-handed grip on the patient's abdomen to deliberately mobilize it in an imprecise manner. Next, a technique with no apparent therapeutic effects, the light touch, first described by Licciardone et al. \[13\] and proposed by others to perform simulated bone manipulations \[14\], will be applied to the sacrum
215039991|NCT03746210|DIAGNOSTIC_TEST|Standard diagnostic procedures|B-Mode ultrasound, Duplex sonography, contrast-enhanced ultrasound, elastography, CT, MRI, anthropometrics
215039992|NCT06074432|OTHER|Emergency Colorectal Resection|Patients underwent resection due to colorectal carcinoma in emergency surgery
215039993|NCT06459440|BEHAVIORAL|Group Task oriented Training|Group Task-Oriented Training for individuals with Down syndrome is an approach that focuses on improving specific skills and promoting social interaction through collaborative activities. This training method involves organizing individuals with Down syndrome into small groups to work on tasks that target various developmental areas, such as motor skills, communication, and socialization. The tasks are designed to be meaningful, engaging, and relevant to the participants' daily lives.
215039994|NCT06459440|OTHER|Routine Treatment|"1.Week 1-2 : Foundation building (4 sessions per week) Gentle stretching exercises (20 minutes). Basic strengthening exercises (20 minutes) (26). Weeks 3-4: Balance and coordination (4 sessions per week ) Balance exercises and core stability (20 minutes). Coordination drills (20 minutes) (26). Weeks 5-6: Functional activities (4 sessions per week )~Incorporate functional activities into therapy (e.g., walking, reaching) (20 minutes)"
215039995|NCT02985723|DEVICE|AT LISA tri toric 939MP|
214476760|NCT06220162|DRUG|chidamide in combination with venetoclax and azacitidine (VAC)|Enrolled patients were given chidamide 10 mg every day on days 1-14, azacitidine 75mg/m2 every day on days 1-7, and oral venetoclax began at 100mg on day 1 and increased stepwise over 3 days to reach the target dose of 400mg (100mg, 200mg, and 400mg) on days 1-28. Dose adjustments for concomitant venetoclax with CYP3A4 inhibitors were made according to the literature.
214476761|NCT05655520|DRUG|SAGE-718|Oral softgel lipid capsules
214476762|NCT03686748|BEHAVIORAL|Two-point discrimination training|Patients will undergo multiple sessions of two-point discrimination training.
214476763|NCT03686748|BEHAVIORAL|One-point discrimination training|Patients will undergo multiple sessions of one-point discrimination training.
214476764|NCT02944968|DEVICE|THERMOCOOL SMARTTOUCH® SF-5D catheter|
214476765|NCT04663204|DRUG|Sparsentan|Target dose of 400 mg daily
214874145|NCT01381315|PROCEDURE|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative-that the lymphedema rate is \<0.13 for subjects undergoing ALND-if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
214874146|NCT02754856|BIOLOGICAL|Durvalumab|Given IV
215039996|NCT05541848|OTHER|Cervical supervised exercises with laser-guided feedback (ELGF)|"Cervical supervised exercises with laser-guided feedback (ELGF) is defined as a procedure of proprioceptive training based on a type of therapeutic exercise that provides external feedback to exercise, achieving an improvement in range of motion and postural control in subjects with spinal pain. For the performance of the exercise program, Motion Guidance Clinician Kit (Motion Guidance LLC, Denver, CO, USA.) was used. The program consisted of 4 exercises, which progressed in difficulty according to the tolerance achieved over the course of the sessions: a) Maintaining the head position (cervical stabilisation); b) Cervical flexion-extension; c) Right-left rotations; d) Right-left lateral-flexions. Each exercise consisted of 4 series of 8 repetitions, except the first one, in which the head position is maintained by pointing the laser at the centre of the panel for 30 seconds (4 series). The average time to complete the entire program did not exceed 14 minutes."
215039997|NCT05541848|OTHER|Interferential current electro massage (ICE)|Interferential current electro-massage (ICE) is defined as a technique which combines simultaneously manual therapy (massage) and ICT. We used a current bipolar mode, using a carrier frequency of 4000 Hz at constant voltage and an amplitude-modulated frequency of 100 Hz (Sonopuls 692®; Enraf-Nonius BV, Rotterdam, The Netherlands), was administered. The intensity was set to provide a strong and comfortable tingling, without evoking muscle twitches even though a slight vibration (fasciculation) was allowed. The sequence combined (A) superficial stroke over the neck-shoulder for 30-45 seconds; (B) deep sliding movements, alone or (C) combined with shoulder drop, for 4-5 minutes; (D) bilateral kneading of the upper trapezius (4-5 minutes); (E) slight stretching of cervical muscles (upper trapezius, sternocleidomastoid, and levator scapulae); and repetition of step (A). The electro-massage protocol lasted 15 minutes.
215039998|NCT01485848|DRUG|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
215039999|NCT01485848|DRUG|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
215040000|NCT03112902|DEVICE|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
215040001|NCT03861338|DRUG|Sublocade|The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
214291266|NCT05654753|DRUG|active FMT|MaaT033®, a lyophilized full-ecosystem intestinal microbiota delayed release oral capsule containing native, donor-derived (pooled from 4-6 donors) microbiome product manufactured by MaaT Pharma® will be delivered orally. Patients will receive 20 Maat033 capsules, each containing approximatively 0.42 g of microbiome product at once at day 0, then 3 capsules/day from day 1 through day 20.
214291267|NCT05654753|DRUG|Placebo|Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
214291268|NCT00878085|DEVICE|Robot Therapy Device|3x a week for 4 weeks
214291269|NCT00878085|BEHAVIORAL|Occupational Therapy|3x a week for 4 weeks
214874147|NCT02754856|OTHER|Laboratory Biomarker Analysis|Correlative studies
214291270|NCT03114813|DRUG|Carvedilol|Non-selective beta-blocker as per routine clinical care
214291271|NCT03114813|OTHER|MRI scan|One hour non-invasive MRI scan
214874148|NCT02754856|PROCEDURE|Therapeutic Conventional Surgery|Undergo liver surgery
214874149|NCT02754856|BIOLOGICAL|Tremelimumab|Given IV
214874150|NCT06118606|OTHER|Case-manager led multidisciplinary follow-up after intensive care|Early in-hospital follow-up in survivors of intensive care with an increased risk of psychological/physical sequelae. The follow-up is led by a case-manager reassessing the patient after ICU discharge for psychological/physical rehabilitation needs. The CM will discuss patient needs with concerned specialists in a multidisciplinary team, leading to the establishment of a personal rehabilitation plan, communicated to the patient and next-of-kin. The CM will keep track of the patient during hospital stay and ensure primary care rehabilitation (if needed) is established once the patient is discharged from the hospital. The CM will contact the patient weekly to follow up on well-being and primary care activities until 12 weeks after discharge.
214874151|NCT01342900|DEVICE|connected to the InSpectra Monitor|
214874152|NCT03103139|PROCEDURE|Transpapillary Stent|ERCP with placement of short stent
214874153|NCT03103139|PROCEDURE|Stent across bile leak|ERCP with long stent
214874154|NCT00390559|DRUG|nicotine transdermal system|21 mg nicotine transdermal system
214874155|NCT00390559|DRUG|Nicotine transdermal system|Placebo nicotine patch
214291272|NCT03114813|PROCEDURE|Hepatic Venous Pressure Gradient (HVPG)|Second HVPG to evaluate treatment response
214291273|NCT05295043|DRUG|(CDK)4/6 inhibitor|CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
214874156|NCT00390559|OTHER|Nicotine containing cigarette|Nicotine containing cigarette
214291274|NCT05158933|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214291275|NCT05016973|DRUG|RC48-ADC|2.0mg/kg, Intravenous drip on days 1 every 21 days
214291276|NCT05016973|DRUG|Triplizumab|240mg, Intravenous drip on days 1 every 21 days
214291277|NCT06221540|BEHAVIORAL|"Myth busting information leaflet"|A written patient information leaflet displaying ten food allergy myths with the myth-busting evidence-based information clearly stated, focusing on themes pertinent to the myth-busting information
214476766|NCT06604468|DIAGNOSTIC_TEST|Thoracic bioimpedance tomography|Data collection using a thoracic bioimpedance tomography device
214874157|NCT00390559|OTHER|Placebo cigarette|Non nicotine containing cigarette
215040002|NCT02274571|DRUG|TSEC (Tissue-selective estrogen complexes)|Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
214476767|NCT06430918|OTHER|physical examination, questionnaires and inventories|Questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
214476768|NCT05875506|DRUG|Ozone gel|(Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
214476769|NCT05875506|DRUG|doxycycline hyclate saturated chitosan dressing|doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
214874158|NCT01527812|PROCEDURE|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
214874159|NCT04851535|DRUG|Jaktinib Hydrochloride Tablets|Jaktinib 100mg Bid
214874160|NCT01798316|DRUG|IV Acetaminophen|Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
214874161|NCT01798316|DRUG|Standard of Care|Standard of care pain management regimen, no IV Acetaminophen,
214874162|NCT05850806|DEVICE|The KmAsthma self-management smart phone app intervention|KmAsthma is a free app which enables users to track their symptoms, access their action plan, learn about asthma and set goals to make change
215040003|NCT02274571|OTHER|Placebo|non active
215040004|NCT02847897|DEVICE|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
214874163|NCT01147107|DRUG|Raltegravir|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
214874164|NCT01147107|DRUG|Efavirenz|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
214874165|NCT01269931|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
214874166|NCT01233895|DRUG|AVE1642|For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
214874167|NCT01233895|DRUG|Velcade|For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
214874168|NCT05070026|OTHER|uni-portal VATS group|patients received pulmonary lobectomy under general anesthesia by using uni-portal VATS method
215040005|NCT03829111|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
215040006|NCT03829111|BIOLOGICAL|Ipilimumab|Given IV
215040007|NCT03829111|BIOLOGICAL|Nivolumab|Given IV
215040008|NCT06449560|OTHER|Practice Group|Participants in this group engage in the traditional core course (1-hour lecture on upper limb soft tissue differential diagnosis and assessment techniques. They have the opportunity to observe teacher demonstrations, and the course content and instructional demonstrations are consistent and delivered by the same therapist), followed by a 20-minute practical session where they pair up for mutual hands-on practice. The assessment of upper limb soft tissue operations takes approximately 4 minutes per session, allowing for approximately 5 practice sessions.
215040009|NCT06449560|OTHER|Video Feedback Group|Participants receive the traditional core course (as the same in the practice group) along with a 20-minute video feedback session. Initially, a therapist records students' assessment techniques in action, capturing the dynamic process on video. The recorded video is then played on a screen for both the course teacher and students to watch together. Participants can annotate specific actions during the viewing, and the course teacher facilitates a reflective discussion where participants observe and identify any issues or correct actions as expected. The teacher provides feedback on areas of improvement in the action process for further practice. The self-viewing of the recorded video serves as a valuable tool for enhancing the skill performance of physical therapy interns.
214476770|NCT05111834|BEHAVIORAL|Supervised resistance training plus nutritional endorsement|resistance training 2x per week, nutritional endorsement/therapy based on individual needs
214476771|NCT05111834|BEHAVIORAL|Nutritional endorsement|nutritional endorsement/therapy based on individual needs
215040010|NCT02647671|DRUG|Aquamin®|90 days of Aquamin
215040011|NCT02647671|DRUG|Calcium Carbonate|90 days of Calcium Carbonate
215040012|NCT02647671|DRUG|Placebo|90 days of placebo
215040013|NCT04416958|DEVICE|cardiac implantable electronic device (CIED) implantation|CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony
215040014|NCT04951193|BEHAVIORAL|Behavioral Activation Therapy app|Goal2QuitVaping focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
214666174|NCT00187083|DRUG|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
214874169|NCT05070026|OTHER|three port VATS group|patients received pulmonary lobectomy under under general anesthesia by using three port VATS method
214874170|NCT03259412|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil Capsule
214874171|NCT03259412|DIETARY_SUPPLEMENT|Placebo|Olive Oil capsule manufactured to mimic fish oil capsule
214874172|NCT03510026|DEVICE|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
215040015|NCT04951193|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about quitting vaping nicotine with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
214874173|NCT04693416|OTHER|Intrapersonal Stigma Reduction|Brief intervention for stigma reduction
214874174|NCT04693416|OTHER|Interpersonal Stigma Reduction|Brief intervention for support persons of intrapersonal intervention participants.
214874175|NCT00625053|PROCEDURE|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
214874176|NCT00625053|PROCEDURE|Open midline incisional hernia repair|"* Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~* Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
214874177|NCT05232266|DRUG|Caralluma Fimbriata|Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
214874178|NCT05232266|DRUG|Placebo comparator - Microcrystalline cellulose|Placebo comparator in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
214874179|NCT00474266|BIOLOGICAL|Meningococcal vaccine GSK134612 (Nimenrix)|Single dose intramuscular injection
214874180|NCT00474266|BIOLOGICAL|Priorix-Tetra|2-dose subcutaneous injection
214874181|NCT00474266|BIOLOGICAL|Meningitec|Single dose intramuscular injection
214874182|NCT03357718|DRUG|Precedex|2 µg/kg oral
214874183|NCT03357718|DRUG|Midazolam|0.5 mg/kg
214874184|NCT04110379|BEHAVIORAL|Virtual Reality (VR)|All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
214874185|NCT04110379|BEHAVIORAL|Conventional Behavior Management Techniques|Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
215040016|NCT05791513|OTHER|Using the MAP-Knee Tool|Using the MAP-Knee Tool
215040017|NCT05791513|OTHER|Usual practice|The consultation between clinician and adolescent is conducted as per usual practice.
215040018|NCT06212817|OTHER|Dietary intervention|Increase dietary fiber intake
215040019|NCT01841242|DRUG|alcoholic povidone iodine|
214874186|NCT04880603|DEVICE|Restrata Graft|Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.
214874187|NCT04880603|PROCEDURE|Standard of Care Skin Graft|Standard of Care Skin Graft
214874188|NCT00045864|DRUG|Recombinant Human Interleukin-2 and Rituximab|
214874189|NCT03886415|DRUG|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
214874190|NCT02633748|BEHAVIORAL|Mindfulness-Based Cancer Survivorship|Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
214874191|NCT00776087|DEVICE|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
214874192|NCT00776087|DEVICE|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
215040020|NCT01841242|DRUG|alcoholic chlorhexidine|
215040021|NCT05507242|BIOLOGICAL|Tezepelumab|Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously
215040022|NCT05507242|OTHER|Placebo|Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)
215040023|NCT00811837|DRUG|Midazolam|Intravenous infusion
215040024|NCT00811837|DRUG|Remifentanil|Intravenous infusion
215040025|NCT01706185|OTHER|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
215040026|NCT01784302|DIETARY_SUPPLEMENT|Multivitamins|
215040027|NCT01784302|DIETARY_SUPPLEMENT|Sodium bicarbonate|
215040028|NCT01784302|DRUG|Maalox Plus extra|
215040029|NCT01784302|DRUG|Raltegravir 400 mg|
215040030|NCT00004264|DRUG|amifostine trihydrate|
215040031|NCT00004264|DRUG|cisplatin|
215040032|NCT00004264|DRUG|docetaxel|
215040033|NCT06767956|DRUG|GOLCADOMIDE|Golcadomide (GOLCA, CC-99282) is an oral cereblon E3 ligase modulator (CELMoD®) agent with immunomodulatory and tumor cell-autonomous activities. It is a modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities.
214291278|NCT06214104|BEHAVIORAL|Acupressur|Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
214291279|NCT01051024|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
214874193|NCT03947944|PROCEDURE|SMILE using manifest refraction planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
214874194|NCT03947944|PROCEDURE|SMILE using vector planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
214874195|NCT01529710|DRUG|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
214874196|NCT00376038|DRUG|GSK189075 oral tablets|
214874197|NCT00376038|DRUG|metformin tablets|
215040034|NCT06767956|DRUG|Nivolumab|Nivolumab is an immune checkpoint inhibitor targeted therapy drug that blocks the PD-1 (programmed death receptor-1) pathway to help prevent cancer cells from hiding from the immune system, boosting the immune system's response.
215040035|NCT06532188|PROCEDURE|Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points according to the National Acupuncture Detoxification Association (NADA) protocol, needle retention after 7 days standardized medical hypnosis:~* Induction of a trance~* suggestions for calm and good sleep"
215040036|NCT06532188|PROCEDURE|Sham Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points inserted at non-specific points on the backside of the outer ear, needle retention after 7 days standardized sham hypnosis~\- story without trance induction and suggestions"
215040037|NCT04621877|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
215040038|NCT04621877|BEHAVIORAL|Master's level clinician-delivered Behavioral Activation|Behavioral Activation as delivered by trained master's level clinicians
214291280|NCT01051024|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
214291281|NCT05715593|OTHER|health education intervention|health education intervention
214291282|NCT02577731|OTHER|Bone marrow collection|Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
215040039|NCT05667532|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|Screening Modality
215040040|NCT05880810|DEVICE|Continuous Glucose Monitor Dexcom G6 PRO|Connected to a smart phone that transmits continuous glucose monitoring data in real time to Advanced Care at Home Command Center for monitoring.
215040041|NCT06445777|BEHAVIORAL|Mental Health Prevention and Promotion|The Inner Lion Programme is made up of 12 interactive workshops which are based on four key pillars: building confidence by identifying strengths and personal qualities; improving emotional intelligence and self-awareness; establishing adaptive coping strategies and channels of support; and boosting resilience. Professionally created by Child Psychologist Stijn de Leeuw together with an advisory team of psychologists from the Netherlands and South Africa, the programme follows a carefully structured and curated prevention and promotion mental health curriculum with games, crafting activities, psycho-educational stories, dance, movement, and breathing exercises. Workshops are led by local role models (a male-female duo) with lived experience trained to be mental health coaches.
215040042|NCT03110562|DRUG|Selinexor|oral 100 mg dose
214291283|NCT02577731|OTHER|Blood collection|Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
214291284|NCT02577731|OTHER|Clinical data collection|Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
214291285|NCT00505843|DRUG|MK0657|7mg MK0657 capsules
214291286|NCT00505843|DRUG|Comparator: Placebo (unspecified)|7mg MK0657 Pbo capsules
214291287|NCT00505843|DRUG|Comparator: levodopa|levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
214291288|NCT00505843|DRUG|Comparator: carbidopa|carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
215040043|NCT03110562|DRUG|Bortezomib|subcutaneous dose of 1.3 mg/m2
215040044|NCT03110562|DRUG|Dexamethasone|oral dose of 20mg
215040045|NCT03409770|OTHER|Therapeutic hypothermia|Whole body cooling using a servo controlled device
214874198|NCT06551415|DRUG|Dabigatran Etexilate 150mg|100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
214874199|NCT06551415|DRUG|Apixaban 5MG|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
214874200|NCT02199886|DRUG|BIBH 1|labeled with eight to ten millicurie of 131I
214874201|NCT02308566|PROCEDURE|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
214874202|NCT02308566|PROCEDURE|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
214874203|NCT04445597|OTHER|Sampling of tissue|In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed
214874204|NCT02003950|OTHER|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
214874205|NCT03389815|DRUG|WX-0593 Tablets|tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
214874206|NCT06550466|OTHER|Breakfast only|Participants will attend a breakfast-only arm without the exercise protocol.
214874207|NCT06550466|OTHER|FAST|Participants will be exercised for 90 minutes following a 12-hour overnight fast
214874208|NCT06550466|OTHER|FED|Participants will be exercised 90 minutes after a breakfast
215040046|NCT05198570|OTHER|Pharmacokinetic analysis|Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring
215040047|NCT06640439|DEVICE|photobiomodulation|830 nm LED was used to irradiate the post-extraction area
215040048|NCT06640439|DRUG|Antibiotic|ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
215040049|NCT06645184|DIETARY_SUPPLEMENT|Oral nutritional supplement|During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.
215040050|NCT06535009|DRUG|ONO-7914|Specified dose on specified days
215040051|NCT06535009|DRUG|ONO-4538|Specified dose on specified days
215040052|NCT05343988|DEVICE|Percutaneous Electrical Nerve Field Stimulation (PENFS) device application|PENFS device will be used to treat children with paroxysmal sympathetic hyperactivity (PSH) due to acute severe brain injury.
214291289|NCT04056676|PROCEDURE|Thoracic paravertebral block under ultrasound guidance|Ultrasound-guided thoracic paravertebral blocks in T2, T4 level
214874209|NCT04711616|BEHAVIORAL|physical therapy intervention|physical therapy interventions include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
215040053|NCT03314805|DRUG|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
215040054|NCT03314805|DRUG|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
215040055|NCT03314805|PROCEDURE|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
214291290|NCT04056676|PROCEDURE|Intraoperative modified PEC block|Pectoral nerve block by surgeon under direct vision after total mastectomy
214291291|NCT04056676|PROCEDURE|GA with ETT|General anesthesia with endotracheal intubation
214291292|NCT01770548|GENETIC|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
214291293|NCT01770548|GENETIC|DNA collection|DNA collection
214291294|NCT01770548|OTHER|Auditory evoked potentials|auditory evoked potentials
214874210|NCT01695863|DRUG|comparing 2 drugs on their effect on the bowel preparation for colonoscopy|the effects of the drug on the colon preparation for colonoscopy
215040056|NCT06176547|DIAGNOSTIC_TEST|HbA1c|Blood glucose in last 3 months
215040057|NCT01321580|DEVICE|Masimo Pronto 7|non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
215040058|NCT03435952|DRUG|Pembrolizumab|200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.
215040059|NCT03435952|BIOLOGICAL|Clostridium Novyi-NT|"Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8.~Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10\^4 spores followed by dose escalation."
215040060|NCT03435952|DRUG|Doxycycline|Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
215040061|NCT03344705|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.
214874211|NCT00813800|DRUG|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
214874212|NCT03456453|BEHAVIORAL|NIDA Standard for HIV Prevention|The NIDA Standard is a manualized, HIV prevention education intervention focused on reducing risky sexual and drug use practices. It will be adapted for Facebook in this pilot trial.
215040062|NCT03344705|DRUG|Fludarabine|Two days before cell infusion,all patients will be treated with fludarabine for 3 days
215040063|NCT03344705|DRUG|Cyclophosphamide|Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
215040064|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose of 1 mg with each subsequent cohort increased starting dose level until MTD is reached.
215040065|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.
215040066|NCT05806190|DEVICE|Continuous Glucose Monitoring|Continuous Glucose Monitoring using a Dexcom G6 Continuous Glucose Monitoring Device
215040067|NCT06245655|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS 7000 digital TENS unit, a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
215040068|NCT04139408|DEVICE|Disposable Pulmonary Surgical Marker|The subjects will undergo Marker placement procedure, within 24h before VATS.
214291295|NCT05599568|OTHER|Exercise|Either concentric or excentric exercise
214874213|NCT03930251|BEHAVIORAL|Clinic-Based Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.
214874214|NCT03930251|BEHAVIORAL|Partial-Remote Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
215040069|NCT04980157|BEHAVIORAL|CARES-HCV|CARES-HCV is an educational intervention to promote both hepatitis c screening and colorectal cancer screening among diverse baby boomers in the area.
215040070|NCT06080204|DRUG|Octreotide LAR|Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
215040071|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Verum Tablets"|The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
215040072|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Placebo Tablets"|The placebo will be a matched control.
215040073|NCT02458118|DRUG|Secretin|Secretin 1 IU/kg over 3 min
215040074|NCT00058747|DRUG|Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.|
215040075|NCT02720458|OTHER|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
214291296|NCT01080521|PROCEDURE|Cognitive Assessment|Ancillary studies
214874215|NCT06975631|DEVICE|TrHCROSS®|Single injection of 4.4 ml of viscoelastic sodium hyaluronate solution crosslinked.
215040076|NCT02720458|BEHAVIORAL|Short-term simple self-help program|"The short-term simple self-help program consists in:~* Restriction of time in bed~* Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
215040077|NCT02339051|BEHAVIORAL|Jumping on one leg|
215040078|NCT05857748|DRUG|lifitegrast|patient newly started on medication will be followed for 6 months
215040079|NCT07003126|BEHAVIORAL|Circadian Rhythm Intervention Combined with Bladder Training|Participants diagnosed with primary nocturnal enuresis will be screened at Shanghai Children's Medical Center, and eligible patients will be enrolled. Participants will be randomly assigned to the Bladder Training Combined with Circadian Rhythm Intervention Group, which will receive a 6-month integrated protocol encompassing bladder training and circadian rhythm intervention. The bladder training component includes fluid intake restriction, micturition desire-relaxation training, and sphincter control training. Circadian rhythm interventions involve sleep hygiene education, chronotype-guided bedtime scheduling, and morning bright light therapy.
215040080|NCT07003126|BEHAVIORAL|Bladder Training (basic treatment for enuresis)|Participants diagnosed with primary nocturnal enuresis will be screened at Shanghai Children's Medical Center, and those meeting eligibility criteria will be enrolled. Participants will be randomized to the Bladder Training Only Group, which will receive a 6-month intervention comprising fluid intake restriction, micturition desire-relaxation training, and sphincter control training.
214291297|NCT01080521|OTHER|Quality-of-Life Assessment|Ancillary studies
214291298|NCT03821298|OTHER|Standard of Care Hand Therapy|8 sessions 2 times a week for 4 weeks
214291299|NCT04334291|COMBINATION_PRODUCT|Observational (registry)|Observational study.
214874216|NCT06975631|DEVICE|Hyalone®|Single injection of 4.4 ml of viscoelastic sodium hyaluronate solution crosslinked
214666175|NCT00187083|DRUG|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
214874217|NCT06267859|COMBINATION_PRODUCT|The use of a combination of microelements and vitamins against the background of physiotherapy|If necessary, necessary microelements and vitamins will be added to the treatment process. At the same time, physiotherapeutic procedures will be added at the rehabilitation stage.
214874218|NCT06852755|OTHER|Blood Sample Collection|Collection of peripheral blood samples for mitochondrial analysis, including the extraction of mononuclear cells and plasma for further assessment of mitochondrial quality and quantity.
214874219|NCT06978010|OTHER|Platelet-Rich Plasma (PRP) intraoperatively|Patients receive platelet-rich plasma (PRP) intraoperatively during cesarean section (5 ml before hysterography, 5 ml subcutaneously before skin closure).
214874220|NCT06041217|DRUG|Semaglutide|Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.
214874221|NCT06041217|DRUG|Placebo|Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
214874222|NCT06982248|DRUG|NSP and chitosan nanoparticles gel loaded by quercetin|NSP and chitosan nanoparticles gel loaded by quercetin
214874223|NCT06982248|DRUG|NSP and chitosan nanoparticles gel|NSP and chitosan nanoparticles gel
214874224|NCT06982248|PROCEDURE|scaling and root planning|NSPT
214874225|NCT06982443|BEHAVIORAL|Mindfulness based relapse prevention|"Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness."
215040081|NCT07002957|OTHER|Spiritual Music Therapy|In the first session of the spiritual music therapy application, information was given about music, music therapy and its history, and information was given about the Turkish Music makam structure and makam differences and the traces these makams leave on the person's body and soul. In addition, the technique of receiving and giving sound was taught. In the next five sessions, Rast, Uşşak, Segâh, Hüseyni and Hicaz makams were listened to, accompanied by the sound of kanun and water. Information was given about the musical and therapeutic status of the makams, 3 works related to the relevant makam were taught, performed and information was given about the spiritual messages of the piece, its composer and lyricist. At the same time, rhythm studies were done with the bendir to accompany the relevant makam. At the end of each session, the makam of the day was listened to, accompanied by the sound of kanun and water.
215040082|NCT07004140|OTHER|3T MRI research scan|Baseline MRI scan
215040083|NCT07004140|OTHER|Field-Cycling Imaging research scan|Baseline FCI scan
215040084|NCT07004140|OTHER|Follow up 3T MRI research scan|Day 30 3T MRI scan
215040085|NCT07004140|OTHER|Follow up Field-Cycling Imaging research scan|Day 30 FCI scan
215040086|NCT07004140|OTHER|Blood samples for clotting experiments in vitro|Thrombi from whole blood from ischaemic stroke patients will be formed and examined using bench top nuclear magnetic resonance (NMR) assays. At baseline and 30 days after stroke onset.
215040087|NCT07004166|OTHER|Z-track method|Z-track method, the skin will be pulled laterally by 2.5-3.5 cm before needle insertion at a 90-degree angle. After aspiration and injection, the needle will be withdrawn and the skin released immediately.
214291300|NCT02723032|DEVICE|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
214291301|NCT04690543|PROCEDURE|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
214291302|NCT04690543|PROCEDURE|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
214291303|NCT04841902|OTHER|Life Style Intervention Manual (With Exercise Under Supervision)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.
214291304|NCT04841902|OTHER|General Advice|General advice to stay healthy and active
214666176|NCT00187083|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
214874226|NCT06982950|OTHER|Manipulation of Sleep Duration|After a baseline assessment of sleep, participants will undergo either 2 nights of restricted sleep (4 hour time in bed) followed by a recovery sleep, OR 3 nights of an extended sleep opportunity (10 hour time in bed)
215040088|NCT07004166|OTHER|TPR method|TPR method, while the needle is inserted at a 90-degree angle, deep pressure will be applied to the muscle, then rapidly released to create a snapping motion that facilitates the injection. This technique relies on rapid muscle relaxation rather than needle movement by the dominant hand.
214666177|NCT04748263|OTHER|No intervention. Only survey and normal use of eye-tracking|"The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE."
214666178|NCT00892437|DRUG|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
215040089|NCT07002866|BEHAVIORAL|HIV Risk Reduction (HIVRR)|This is an intervention comprised of 5 sessions of an evidence-based, HIV/STI risk reduction with PrEP to strengthen HIV prevention knowledge and behavioral skills intervention. Session content cover harm reduction, social support networks, HIV knowledge, transmission risks and testing procedures for HIV/STIs, build enthusiasm for condom use, alternatives to unsafe sex, importance of safer sex negotiations, strategies to negotiate safer sex, setting appropriate risk reduction goals, introduction to PrEP, PrEP screening and eligibility; monitoring and managing PrEP side effects and stigma, recognizing and understanding consequences of abusive behavior by any sexual partners or others; build safety plan skills; review and identify ways to increase social support; build skill in communication with health care professionals.
215040090|NCT07002866|BEHAVIORAL|PrEP Peer Supporters (PS)|PrEP peer supporter are women currently on PrEP willing to share their lived experiences. Women will meet with peer supporters in a group at least 8 times during the intervention period (every 2-3 months). Sessions with peers will involve unstructured, in-depth discussions that integrate peers' own lived experiences and emerging PrEP-related issues as raised by participants. These may include, how to mitigate PrEP stigma and disclosure, creating PrEP adherence strategies, navigating family and intimate relationship issues, and navigating provider attitudes. At each stage of the facility visit (waiting space, consultation, and pharmacy), peer supporters will explain facility protocols, and strategies women can use to overcome facility-level barriers to care.
215040091|NCT07002866|BEHAVIORAL|Matched Savings Accounts + Financial Literacy (FL)|A matched savings account (MSA) is a savings account held at a local bank whereby deposits made by the participants are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce participants to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each participant will receive an account held in her own name, and will be allowed to save an equivalent of US$10 a month or US$200 for the 20-months intervention period. During the intervention period, participants will have direct access to both their personal savings deposited in the accounts and the match provided by the study. In addition, participants will also receive six 1-2-hour financial literacy (FL) workshop sessions that cover components on saving, and financial management.
215040092|NCT07003958|OTHER|application of deproteinization agents|Since there is no in vivo study in the literature evaluating the clinical success of the use of hypochlorous acid for deproteinization in fissure sealants, our planned study is the first in this regard.
215040093|NCT07005024|DRUG|Apixaban 2.5 mg twice daily|Apixaban, a direct oral anticoagulant (DOAC), will be administered at a prophylactic dose of 2.5 mg by mouth twice daily for 6 months. This dose is guideline-recommended for VTE prevention in high-risk ambulatory cancer patients. Participants will continue their cancer-directed therapy during this time. No study-mandated visits or labs are required beyond standard care.
214666179|NCT00892437|DRUG|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
215040094|NCT07005024|DRUG|Apixaban 5 mg once daily|Apixaban will be administered at 5 mg by mouth once daily for 6 months. This alternative prophylactic schedule is being studied to assess its effectiveness and adherence in patients with a Khorana Risk Score of 2. Participants will continue their usual cancer treatment. This arm evaluates a simplified dosing strategy in a real-world, pragmatic design.
215040095|NCT07005024|DRUG|No anticoagulation|Participants randomized to this arm will not receive apixaban or any other anticoagulant for VTE prevention. This reflects current standard care for many cancer outpatients with moderate risk (Khorana Score = 2). Outcomes will be monitored through routine care and medical record abstraction.
215040096|NCT07004933|DRUG|bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)|Rapid antiretroviral treatment initiation with BIC/FTC/TAF
215040097|NCT07002840|OTHER|Cross- legged sitting position|CLS in which the legs were crossed with hip and knee joints flexed
215040098|NCT07002840|OTHER|Physical Therapy Rehabilitation Program|Strengthening Exercises Stretching Exercises Range of Motion Exercises
215040099|NCT07002944|OTHER|Brachial plexus pulsed radiofrequency|Patients will receive pulsed radiofrequency of brachial plexus with steroids injection.
215040100|NCT07002944|OTHER|Sholder individual nerves pulsed radiofrequency|Patients will receive shoulder individual nerves pulsed radiofrequency with steroids injection.
215040101|NCT07002944|OTHER|Control|Patients will receive conservative treatment (paracetamol 1000 tid and pregabalin 75 mg bid; can be increased to 150 mg bid , oxycodone 10 mg oral every 12 hrs .
215040102|NCT07004101|OTHER|virtual reality|virtual reality and biodex training
215040103|NCT07004101|OTHER|biodex training|biodex training
215040104|NCT07004101|OTHER|conventional balance exercises|conventional balance exercises
215040105|NCT07003646|PROCEDURE|Catheter directed intervention, any device|Catheter directed intervention for treatment of pulmonary embolism
215040106|NCT07003646|DRUG|Alteplase|Systemic thrombolysis
215040107|NCT07003568|DRUG|Dual-targeting BCMA-GPRC5D CAR-T cell infusion|Approximately 3-5 days prior to BCMA-GPRC5D CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
215040108|NCT07003880|DRUG|Methoxyflurane anesthesia|A single Penthrox (3mL) self-inhaler will be administered 5-minutes prior to the onset of the procedure, before local anesthesia. Patients will undergo the procedure, have post-procedural vital signs, and remain in clinic for observation for 30 minutes post-procedure per our usual post-procedure monitoring.
215040109|NCT07003867|OTHER|Ventilator inspiratory trigger sensitivity adjustment , threshold device training|Ventilator inspiratory trigger sensitivity adjustment threshold device training
215040110|NCT07003113|DEVICE|Ischemic Preconditioning|The intervention arm will include full blood flow occlusion in one thigh for 5 minutes followed by 5 minutes of reperfusion for a cycle of 50 minutes.
214666180|NCT00892437|DRUG|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
214666181|NCT00892437|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
214666182|NCT00892437|DRUG|COBI placebo|Placebo to match COBI administered orally once daily
214666183|NCT00892437|DRUG|RTV placebo|Placebo to match RTV administered orally once daily
214666184|NCT01961531|DEVICE|Accuboost APBI|28Gy delivered in 5 daily fractions
214666185|NCT01606462|DRUG|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
215040111|NCT07003113|DEVICE|Sham Intervention|This intervention includes 25mmHg of pressure, which is not sufficient for blodo flow occlusion.
215040112|NCT07002736|OTHER|The Biodex training|Participants will undergo balance training using the Biodex Balance System plus Traditional balance training
215040113|NCT07002736|OTHER|Traditional balance training|Traditional balance training only
214291305|NCT04841902|OTHER|Life Style Intervention Manual (Home Based)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.
214476772|NCT06595719|DIETARY_SUPPLEMENT|Multi-Strain Probiotics|Each sachet of the multi-strain probiotics contain 30 billion CFU of 6 strains which includes Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC®02120
215040114|NCT07004855|OTHER|30 hr Respite Service|Caregivers will be provided with 30 hours of respite service within 6 months. Trained substitute caregivers will provide in-home elderly-sitting service.
215040115|NCT07004855|OTHER|Case follow-up|Case follow-up service provided by social workers. Social workers will call the caregiver regularly to see if situation changes.
215040116|NCT07004855|OTHER|Crisis management|Crisis management and councelling provided by social workers and professionals.
214874227|NCT06983860|PROCEDURE|Application and demonstration of endoscope-assisted low-temperature plasma radiofrequency ablation resection of tonsils|Low temperature plasma radiofofency ablation of tonsil under 70° nasal endoscope can directly view the lesion area on the monitor, clearly enlarge the operating field, and has the advantages of small surgical trauma, good hemostatic effect, light postoperative pain, low probability of postoperative bleeding and quick postoperative recovery of patients, etc. It is a good surgical mode integrating surgery and teaching, and has brought great benefits to patients, and is worth promoting and applying.
214874228|NCT06981910|BEHAVIORAL|Psychoeducation program|Each psychoeducation session included informational components, a preliminary group discussion of the topic, structured education on the discussed topic, awareness-raising activities within the group, opportunities for sharing, and emotional support. When participants' attention waned during sessions, breathing exercises were introduced. Depending on the group's preference, sessions concluded with a 2-3-minute poetry listening session and/or breathing exercises. At the end of each session, educational booklets prepared specifically for that session were distributed to the participants.
214874229|NCT06982989|DEVICE|use LED to treat pelvic pain|Use led to treat pelvic pain
215040117|NCT07004855|OTHER|Phone Check-in|Regular phone check-in and on-demand services (e.g., escort to hospital) provided by volunteers.
215040118|NCT07004114|OTHER|Neurocognitive training group|Neurocognitive training is a rehabilitation approach that, unlike traditional treatment methods which primarily focus on improving physical performance, emphasizes cognitive functions and psychometric skills. It is a program developed by integrating motor learning strategies and cognitive challenges into neuromuscular training. These cognitive challenges include tasks requiring quick reactions, motor-motor or cognitive-motor tasks (dual-task), congruent and incongruent tasks, exercises involving mathematical calculations (working memory), and response inhibition tasks.
215040119|NCT07002775|DEVICE|Transesophageal ultrasound|Transesophageal ultrasound with built-in ultrasound software (Philips QLAB 3D quantification advance, Philips Healthcare, USA, speckle tracking echocardiography (STE,Speckle tracking echocardiography) to evaluate stroke volume and cardiac output in different position with the same person
215040120|NCT07004738|OTHER|Pelvic floor exercises|The bladder should be emptied before the exercise. In order to correctly identify the pelvic floor muscles, it is necessary to initially try to hold urine while emptying the bladder. If the result is successful, it means that the correct muscles have contracted. During the learning phase, the exercise can be done in a supine position with the legs bent at the knees or in a sitting position. Initially, the pelvic floor muscles should be contracted for 5 seconds by pulling them inward as if stopping the passage of urine or gas, and then rested for 5 seconds.
215040121|NCT07004738|OTHER|Control group|Women in this group who have been diagnosed with pelvic floor dysfunction will not be given any exercises. Women will continue their routine lives and their evaluations will be made.
215040122|NCT07003152|DIAGNOSTIC_TEST|diagnosis of endolymphatic hydrops in hydrocephalus patients|the hydrocephalus could be associated with endolymphatic hydrops, this study designed to show the relationship between both of these diseases by special tests for diagnosis
215040123|NCT07004959|PROCEDURE|Vaginal ultrasound-guided ethanol sclerotherapy|Use of an endovaginal ultrasound probe combined with a puncture guide. The technique involves locating the endometriosis cyst, echo-guided drainage via the endovaginal route, sclerotherapy (replacement of 60% of the punctured volume with 95% ethanol left in place for 10 minutes) and then reaspiration of the ethanol.
214291306|NCT03010254|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
214476773|NCT06595719|DIETARY_SUPPLEMENT|Placebo|Replicate for multi-strain probiotics without any active ingredients
214666186|NCT05936086|DRUG|Cytoxan|Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);
214666187|NCT05936086|DRUG|Etoposide|etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.
214666188|NCT05936086|DRUG|Dexamethasone|Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
214666189|NCT05936086|DRUG|Cyclosporine (CSA)|Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
214291307|NCT03010254|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
214291308|NCT03010254|PROCEDURE|Cataract surgery|IOL bilateral implantation
214291309|NCT03556007|DRUG|LY3471851|LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
214291310|NCT03556007|DRUG|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
214291311|NCT06095427|BIOLOGICAL|LY06006 (Denosumab Biosimilar)|single dose of 60 mg LY006006 s.c.
214291312|NCT06095427|BIOLOGICAL|US-Prolia (Denosumab)|single dose of 60 mg US-Prolia s.c.
214291313|NCT06095427|BIOLOGICAL|EU-Prolia|single dose of 60 mg EU-Prolia s.c.
214874230|NCT06983652|DEVICE|THz scanning using THz Imaging system.|The THz scanning system is non-invasive and non-contact. It is a prototype developed by Institute of Materials Research and Engineering (IMRE), A\*STAR, Singapore and is performed for the purpose of research. THz scanning will provide safety data in human and the measurement of cornea hydration status. Each THz scan will take approximately 1 second. Real-time data will be generated when participants are positioned in front of the device.
214874231|NCT06804876|DEVICE|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
215040124|NCT07004959|PROCEDURE|Laparoscopic cystectomy|Conventional laparoscopy, with the laparoscope introduced through a 10mm incision at the umbilicus, and the laparoscopic instruments used through two or three 5mm incisions (suprapubic and right and left fossa iliaca). The surgical technique may vary according to the patient and the surgeon's preferences or habits, but must necessarily include a cystectomy (cyst wall sent for anatomopathology).
214291314|NCT01404325|DRUG|standard therapy|centre specific CNI-based triple drug immunosuppression
214874232|NCT06982534|BIOLOGICAL|UTAA91 injection|CAR-modified gamma delta T cells
214874233|NCT06982391|BEHAVIORAL|Resilience-Focused Acceptance and Commitment Therapy (ReACT) Program|The Resilience-Focused Acceptance and Commitment Therapy (ReACT) program is a structured, group-based psychological intervention specifically designed for women who have undergone mastectomy following breast cancer. The program consists of three weekly 90-minute sessions integrating core ACT processes, including acceptance, defusion, mindfulness, values clarification, and committed action, with an emphasis on building psychological resilience, self-compassion, and enhancing perceived social support. The program uniquely combines evidence-based ACT techniques with group exercises focused on post-cancer psychosocial adjustment.
214874234|NCT06982391|OTHER|No intervention|Standard Care
214874235|NCT06982612|OTHER|Hot environment|Participants exercising in a 36 degrees celsius environment
214874236|NCT06982612|OTHER|Temperate condition|Participants exercising in a 18 degrees celsius environment
214874237|NCT00006043|DRUG|temozolomide|
214874238|NCT02635113|DEVICE|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
214874239|NCT06190418|OTHER|Loaded sit to stand strengthening exercise|This Group will be given with the wieghted vest equal to that of 1RM for each child and Sit-to-Stand Strengthening Excerise will be given 3 times per week for 6 weeks
214874240|NCT06190418|OTHER|Unloaded sit to stand strengthening exercise|This Group will be given with the Sit-to-Stand Strengthening Excerise without any external load for 3 times per week for 6 weeks
215040125|NCT07004387|DRUG|Amino acid solution|Adult patients scheduled for orthotopic liver transplant to receive an intravenous infusion of a mixture of amino acids including L arginine, at a dose of 2 g per kg of ideal body weight up to a maximum of 100 g per day, from their admission to the operating room until three days after surgery; the infusion will begin in the operating room prior to the start of the surgery, will be administered through an exclusive lumen of a central venous catheter (CVC) immediately after the CVC is in place; the infusion will continue when the patient is in the intensive care unit (ICU); as soon as the patient begins enteral nutrition, the infusion will be reduced to meet the dose of 2 g per kg of protein intake per day up to a maximum of 100 g daily, until completing 72 H of infusion. The Control Group consists of previously transplanted patients at this institution who did not receive this type of therapy.
214476774|NCT06813820|DEVICE|Revivent System|BioVentrix has developed the Revivent System to mirror SVR. The Revivent System is used to place permanent cardiac implants to the epicardial surface for the purpose of reconfiguring abnormal cardiac geometry that is contributing to the dysfunction.
214874241|NCT01802450|DRUG|Dasatinib|
214874242|NCT00700297|DRUG|Colchicine|100 mg Colchicine per day for 4 months
214874243|NCT00700297|DRUG|Placebo|One tablet placebo per day for 4 months
214874244|NCT03095638|DRUG|Conventional dolutegravir 10 mg tablet|Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
214874245|NCT03095638|DRUG|Conventional dolutegravir 50 mg tablet|Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
214291315|NCT01404325|DRUG|Everolimus|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
214291316|NCT02144233|PROCEDURE|Occlusal adjustment|"The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)"
214666190|NCT01183494|DRUG|FOLFIRI, Avastin, Irinotecan|Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1\*1/\*1 and UGT1A1\*1/\*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
214874246|NCT03095638|DRUG|Dispersible dolutegravir 5 mg tablet|Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
214291317|NCT02144233|PROCEDURE|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
214476775|NCT06813729|BIOLOGICAL|Shotblocker|The infant was first placed on the examination table. To calm the infant, the mother was asked to hold the infants' hands and talk to him/her. Before the injection, while one nurse held the infants' leg for the injection, Shotblocker® was applied to the skin by the experienced nurse ensuring that the points were in direct contact. Then, the nurse administered the pneumococcal conjugate vaccine (0.5 ml, IM, Vastus Lateralis Site) through the central hole. After each use, the Shotblocker® was disinfected with 70% alcohol before being used on another infant.
214874247|NCT03095638|DRUG|Conventional dolutegravir 25 mg tablet|Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
214874248|NCT05358080|DRUG|Entelon Tab. 50mg|twice daily for 24months
214874249|NCT05358080|DRUG|Placebo|twice daily for 24months
214874250|NCT06608550|OTHER|short video film|Children will be trained with a short movie to prepare for the endoscopy procedure. The content of the short movie video training will include; introduction of the outpatient clinic, things to be considered before the procedure, preparation for the procedure, introduction of the endoscopy room, introduction of the service to come after endoscopy, issues to be considered after the procedure. The short movie training is expected to last approximately 5 minutes.
214874251|NCT06983704|PROCEDURE|AGV plate|AGV plate using a 27-gauge needle
214874252|NCT06983704|PROCEDURE|bevacizumab injection|subconjunctival injection of bevacizumab
214874253|NCT06983002|BEHAVIORAL|Experimental group: AC-group therapy intervention.|"The aim is to increase Affect consciousness and Affect integration with 15 two hour group session interventions. Interview for 4 central affect categories to become familiar with the questions/techniques is used pre and post group. Group meeting 1 presents the AC affect theory, 13 affect categories and the group program related to each individual group meeting. Group meetings 2-14 lectures on the current affect category, bodily attentional signals and inner mood/mental content, exploration of impact, handling and the signal function of emotions and non-verbal body language and verbal descriptions related to the desire and ability to express oneself. Group meeting 15 is evaluation, clarification, repetition and closure of the group. On arrival focus on disturbances (internal and external) for each participant and performance of four body awareness exercises is used. Therapeutic writings and listening to a piece of music shared by the participants in rotation are methods i"
214874254|NCT06983002|BEHAVIORAL|Control group 1: Body Awareness Group.|The aim is to connect with and become more confident about the body experiences, needs and feelings, to gain an increased understanding of oneself. The Group consists of 15 group sessions. Group meeting 1 Introduces Body Awareness Therapy, group structure and content and focus on experiences and expectations. The practice of slow, simple movements for the whole body in a standing position, introduction of The Autonomous Compass model, giving an opportunity to figure out where to place themselves in the compass in the moment, exercise stimulating the feet and a relaxation exercise. Group meetings 2-14 focuses on a topic as grounding, balance, breathe, play, posture due to habitual positions, body language and emotions, self-compassion and boundaries, explored through experience by using various physical exercises, sharing body experiences and psychoeducation. Session 15 contains summary, evaluation and repetition.Reflection on the previous session and sharing homework is included.
215040126|NCT07004387|DRUG|Amino Acid infusion|adult patients scheduled for orthotopic liver transplant to receive an intravenous infusion of a mixture of amino acids including L arginine, at a dose of 2 g per kg of ideal body weight up to a maximum of 100 g per day, from their admission to the operating room until three days after surgery; the infusion will begin in the operating room prior to the start of the surgery, will be administered through an exclusive lumen of a central venous catheter (CVC) immediately after the CVC is in place; the infusion will continue when the patient is in the intensive care unit (ICU); as soon as the patient begins enteral nutrition, the infusion will be reduced to meet the dose of 2 g per kg of protein intake per day up to a maximum of 100 g daily, until completing 72 H of infusion. The Control Group consists of previously transplanted patients at this institution who did not receive this type of therapy.
215040127|NCT07004985|BEHAVIORAL|Kahoot Reinforcement|"Students in this group will complete four interactive reinforcement sessions using the Kahoot platform, following the theoretical content of the Normal Birth and Postpartum Period course. Each session includes 25 multiple-choice questions delivered in a gamified format, with real-time feedback and scoring. The intervention aims to increase motivation, focus, and retention of knowledge."
215040128|NCT07004985|BEHAVIORAL|Google Forms Reinforcement|Students in this group will complete four structured reinforcement sessions using Google Forms, after participating in the same theoretical course content. Each session consists of 25 multiple-choice questions, delivered in a self-paced online format. The intervention supports repetition and reflection, aiming to improve academic performance and motivation.
215040129|NCT07003009|DIAGNOSTIC_TEST|Malign Lymph Node Washout|During routine axillary lymph node sampling, which is performed as part of standard staging using imaging methods, a washout sample (which is not not routinely applied ) will be obtained by injecting 1 cc of 0.9% saline into axillary lymph nodes suspected to be metastatic. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 1.
215040130|NCT07003009|DIAGNOSTIC_TEST|Benign Lymph Node Washout|Description: During the biopsy performed to histopathologically confirm the benign nature of a radiologically presumed benign axillary lymph node, a washout sampling will also be conducted by injecting 1 cc of 0.9% saline into benign lymph node. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 2.
215040131|NCT07003737|DRUG|Blinatumomab|"Blinatumomab is administered starting approximately one month before allogeneic hematopoietic stem cell transplantation (allo-HSCT).~For participants weighing ≥45 kg: 9 μg/day is administered on Days 1-3, followed by 28 μg/day on Days 4-14.~For participants weighing \<45 kg: 5 μg/m²/day (based on body surface area) is administered on Days 1-3, followed by 15 μg/m²/day on Days 4-14. The total dose must not exceed the dosage used for participants ≥45 kg."
215040132|NCT07003737|OTHER|Consolidation Chemotherapy or Direct Allogeneic HSCT|Participants in the Non-BiTE group will either proceed directly to allogeneic hematopoietic stem cell transplantation (allo-HSCT) or receive one additional cycle of consolidation chemotherapy prior to
214666191|NCT02750410|DRUG|Dulaglutide|Administered subcutaneously (SC)
214666192|NCT02750410|DRUG|Placebo|Administered SC
214666193|NCT01886664|DRUG|sevoflurane|
214666194|NCT01886664|DRUG|Desflurane|
215040133|NCT07003607|BEHAVIORAL|Control group (placebo)|Children in the control group received routine health education, which included cancer-related treatment, care, and general health education (e.g., treatment-related, diet, and exercise) without systematic PA health education. Every four weeks, knowledge related to sports activities, the harms of insufficient physical activity, and the benefits of increasing physical activity were pushed through the WeChat platform. During the hospitalization of the child patient, they can voluntarily participate in the activities organized by social workers.
215040134|NCT07003607|BEHAVIORAL|In-Hospital Program|"Researchers will conduct a comprehensive evaluation for each pediatric patient, including:~* Disease status and clinical characteristics~* Patient and family knowledge regarding physical activity (PA)~* Availability of social support systems"
214291318|NCT03160534|OTHER|preoperative exercise|Each intervention session contains a stretching part and aerobic training
214874255|NCT06983002|BEHAVIORAL|Control group 2: Art Psychotherapy group.|"The aim is to keep an open non-directive psychodynamic and analytical approach to explore, discover and feel ownership of creativity as a form of expression. The group consists of 15 group sessions, where session 1-4 is setting the framework by presenting art mediums to be used collectively, creating security, a sense of community and solidarity sharing common challenges. Each individual is free to choose the motive and form of expression, with a high level of sharing and learning. Creative experiences made together on the use of art materials to convey the inner world, become the starting point for further creative exploration on a individual level with their inner selves in a self-developing therapeutic process. Session 1: Introduction to projection and how to read oneself into an object by using figures and sandplay. Sessions 2 - 4: How one can transfer, animate, or create personal expressions using collage, acrylic painting and clay.Groups 5-15 allows freedom to choo"
214874256|NCT06982092|DRUG|sugammadex|: patients will receive the reversal drug according to the group to which they had been randomised. in the Sugammadex Group will receive 2 mg/kg sugammadex.
214874257|NCT06982092|DRUG|Neostigmine|Patients in the NEO Group will receive 50 mic/kg neostigmine and .01-.02 mg/kg atropine
214874258|NCT06991023|DIETARY_SUPPLEMENT|Prebiotic (Bimuno®)|The prebiotic supplement (Bimuno®) is a galactooligosaccharide (GOS) supplement derived from lactose which is publicly available and sold in the UK. Subjects will consume a daily dose of 2.75g GOS (3.65g total powder) which will be administered in sachets and consumed with breakfast by mixing into water, tea or coffee, or sprinkling on top of/mixing into food.
214874259|NCT06991023|DIETARY_SUPPLEMENT|Placebo|A matched placebo for the prebiotic intervention, containing 3.65g of maltodextrin. Consumed in the same manner as the prebiotics.
214874260|NCT06989281|BEHAVIORAL|FLOW Lifestyle Medicine Clinic|The FLOW Lifestyle Medicine Clinic is a 12-month multidisciplinary program for improving obesity and obesity-related chronic conditions. FLOW is an evidence-based program that aligns with USPSTF recommendations for intensive behavioral counseling for obesity and cardiovascular disease risk reduction. There are at least 12 clinician/patient encounters in the FLOW clinic over 12 months including 6 with a registered dietitian and 6 with a FLOW physician. Behavioral Health assessments and visits are also offered as part of FLOW but are optional.
214874261|NCT06990451|OTHER|time pressure|a set of alternative cognitive strategies that allow patients in real-life tasks to compensate for their mental slowness
214874262|NCT06990451|OTHER|step square exercise|is a form of highly specific balance training for falls prevention which directly addresses stepping capacity-a commonly executed protective strategy for maintaining balance in the everyday environment
214874263|NCT06990451|OTHER|functional care training|Intensive functional endurance, strength, and balance exercises, and selected physical therapy interventions for balance
214874264|NCT06989450|DEVICE|Sidekick digital patient support program for patients with breast cancer|A digital health program delivered through an app that provides holistic lifestyle intervention and medication adherence support.
214874265|NCT06989450|OTHER|Standard of care for breast cancer patients|Standard of care includes adjuvant breast cancer treatment and optional cancer rehabilitation
214874266|NCT06989775|DEVICE|Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System|Box lesion ablation with the Isolator Synergy EnCompass Clamp System and LAAE using the AtriClip LAA Exclusion System at the time of planned cardiac surgery
214874267|NCT01878487|DEVICE|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|"There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~1. At baseline~2. After thrombus aspiration with a thrombus extraction catheter~3. After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such."
214874268|NCT03429400|DRUG|Morphine Sulfate|Morphine every 4 hours as needed for up to a maximum of 5 days
214874269|NCT03565679|DEVICE|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
214874270|NCT03565679|DEVICE|CO-OXIMETRY SENSORS|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
214874271|NCT01064154|DRUG|Carvedilol|Carvedilol Tablets 25 mg
214874272|NCT00635232|DRUG|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
214874273|NCT00635232|DRUG|placebo|placebo capsules once daily for 12 weeks
214874274|NCT00635232|DRUG|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
214874275|NCT00635232|DRUG|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
214874276|NCT00635232|DRUG|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
214874277|NCT02330315|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
215040135|NCT07003607|BEHAVIORAL|In-Hospital Program|"Based on assessment findings, two structured educational sessions (20-30 minutes each) will be delivered, covering:~* Disease-specific knowledge and PA guidelines~* Practical strategies for safe exercise (e.g., intensity adjustment, injury prevention)~* Interactive demonstrations of age-appropriate movement techniques"
214666195|NCT03392129|OTHER|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week 40 minutes each session) of treatment with the Ai Chi Method, and educational intervention in relation to asthma.
214874278|NCT02330315|DEVICE|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
214874279|NCT06989749|OTHER|Anodal tDCS|Transcranial direct current stimulation (tDCS) is an experimental manipulation of brain circuitry using electrical current applied to the scalp. The equipment is commercially available (StarStim8, Neuroelectrics, Spain) and marketed for experimental research on brain function. Current is applied at 2 mA for 20 minutes. Electrodes are placed on the C3 and FP2 regions. There is a 30-second ramp-up and 30-second ramp-down of stimulation for each tDCS condition to minimize any discomfort during stimulation. In the anodal condition, real tDCS stimulation enters from the C3 electrode, and exits at the FP2 electrode.
214874280|NCT06989749|OTHER|Cathodal tDCS|Transcranial direct current stimulation (tDCS) is an experimental manipulation of brain circuitry using electrical current applied to the scalp. The equipment is commercially available (StarStim8, Neuroelectrics, Spain) and marketed for experimental research on brain function. Current is applied at 2 mA for 20 minutes. Electrodes are placed on the C3 and FP2 regions. There is a 30-second ramp-up and 30-second ramp-down of stimulation for each tDCS condition to minimize any discomfort during stimulation. In the cathodal condition, real tDCS stimulation enters from the FP2 electrode, and exits at the C3 electrode.
214874281|NCT06989749|OTHER|Sham tDCS|This is the sham (or placebo) tDCS intervention. The tDCS device is applied for one minute, for a 30-second ramp-up and 30-second ramp-down of stimulation.
214874282|NCT06988800|DEVICE|Paced breathing wellness breathing sessions|The paced breathing condition used timed auditory and visual cues to guide participants through breathing cycles at a rate of five breaths per minute (Murtezani, 2018), designed to stimulate the parasympathetic nervous system and promote relaxation. The audiovisual cues included spoken instructions, music, and breath-like sounds (as described in Marentakis, Borthakur, Batchelor et al., 2021). The tonal audio cues rose in pitch during inhalation and fell during exhalation, creating a clear auditory signal for breath pacing. The same harmonic drone used in the mindfulness intervention provided a calming background, though here it was combined with the rhythmic pacing. Visually, the pacing was synchronized with the image of a lotus flower opening during inhalation and closing during exhalation, reinforcing the breathing rhythm.
214874283|NCT06988800|DEVICE|Mindfulness video sessions|The audio component of the mindfulness intervention featured a female narrator guiding participants through mindfulness exercises, focusing on breath awareness and cultivating non-judgmental attention to thoughts and feelings (Sibinga, 2016). Ambient tonal sounds, including a harmonic drone with slow timbral changes, played softly in the background to support relaxation. Importantly, no rhythmic audio cues were included to avoid inducing breathing entrainment. This setup emphasized passive, mindful observation rather than active breath control, encouraging participants to observe their bodily sensations and thoughts without judgment.
214874284|NCT06534528|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
214874285|NCT05300828|DRUG|Genexl PM|Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
214874286|NCT06411379|DRUG|Sonelokimab|Sonelokimab
214874287|NCT06411379|DRUG|Placebo|Placebo
215040136|NCT07003607|BEHAVIORAL|In-Hospital Program|"Patients will co-develop personalized PA plans using the six-step self-regulation framework from the ITHBC (Integrative Theory of Health Behavior Change), including:~* Short/long-term goal formulation~* Progress monitoring tools~* Barrier problem-solving protocols"
215040137|NCT07003607|BEHAVIORAL|Post-Discharge Program|Patients will perform PA 3-5 times weekly (20-30 minutes/session) aligned with individualized goals, adhering to oncology-specific safety guidelines
215040138|NCT07003607|BEHAVIORAL|Post-Discharge Program|"Mondays: Curated PA educational content (e.g., home-based exercise videos, fatigue management tips) will be disseminated via the WeChat platform.~Sundays: Scheduled telehealth check-ins with patients and caregivers to:~* Review PA adherence and experiential feedback~* Address knowledge gaps through tailored coaching~* Reinforce behavior change techniques (e.g., self-monitoring logs)"
215040139|NCT07003607|BEHAVIORAL|Post-Discharge Program|Regular monitoring and evaluation will be conducted to assess PA outcomes: comprehensive evaluations will identify barriers (e.g., treatment-related fatigue) and guide real-time adjustments to the exercise plan based on the patient's physical condition and performance. To enhance adherence, families will collaboratively set alarm reminders for PA sessions, and caregivers will be invited to supervise daily activities.
215040140|NCT07003555|DRUG|Dual-targeting BCMA-CD19 CAR-T cell infusion|Approximately 3-5 days prior to BCMA-CD19 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
214666196|NCT03392129|OTHER|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
214874288|NCT06678854|OTHER|Training about Aphasia|Training will include direct teaching, aphasia simulations, scenario-based training and a panel with persons with aphasia with the goal of increasing confidence for law enforcement officers and first responders providing services to and communicating with persons with aphasia.
215040141|NCT07004803|OTHER|Virtual reality video watching|The children in the VR experimental group of the study will be subjected to the clinic's routine venipuncture procedure and the video-watching intervention with virtual reality headset. Routine care includes informing the child and parents about the procedure and questions that strengthen communication and distract attention. For example, it consists of questions such as 'How old are you?', 'Do you go to school?', 'Can you tell me the name of your favorite friend?'. Virtual reality headset will be introduced to the child before the procedure and information about how to use them will be given. After the measurements, intravenous access will be started. During the procedure, children will be shown a roller coaster video on virtual reality headset. The video-viewing process will be started 2 minutes before the venipuncture procedure. The video viewing time is planned to last an average of 4 minutes. Measurements were made during and after the procedure
215040142|NCT07004803|OTHER|Tablet video watching|The children in the experimental group of the study will be subjected to the clinic's routine venipuncture procedure and the video-watching intervention with Tablet. Routine care includes informing the child and parents about the procedure and questions that strengthen communication and distract attention. For example, it consists of questions such as 'How old are you?', 'Do you go to school?', 'Can you tell me the name of your favorite friend?'. Tablet will be introduced to the child before the procedure and information about how to use them will be given. After the measurements, intravenous access will be started. During the procedure, children will be shown a roller coaster video on tablet. The video-viewing process will be started 2 minutes before the venipuncture procedure. The video viewing time is planned to last an average of 4 minutes. Measurements were made during and after the procedure.
215040143|NCT07004569|DEVICE|Percutaneous coronary intervention (PCI)|Patients is under Percutaneous coronary intervention (PCI) by using contemporary drug eluting stent (DES). Angiolite is a thin-strut cobalt-chromium durable fluoroacrylate polymer-based, sirolimus-eluting stent that is CE marked and commercially available. Stent sizes 2.0mm to 4.5mm in 9mm to 49mm lengths will be used.
215040144|NCT07004725|DRUG|niacin sustained release capsules|The first stage: the niacin group was given niacin sustained-release capsules for 3 months, and the control group was given placebo for 3 months. The second stage: Both groups were given niacin sustained-release capsules for 3 months. Dosage of niacin sustained-release capsules and placebo: 500mg once a day for week 1-4; The dose is 1000mg once a day for 5 to 12 weeks
215040145|NCT07004725|DRUG|Placebo|The group was given oral placebo for 3 months in the first stage and niacin sustained-release capsules for 3 months in the second stage. Dosage of niacin sustained-release capsules and placebo: 500mg once a day for week 1-4; The dose is 1000mg once a day for 5 to 12 weeks.
215040146|NCT07002827|DRUG|Darbepoetin|Darbepoetin will be given s/c at dose of 40 mcg once a week (total 4 doses) for 1 month
215040147|NCT07002827|DRUG|G-CSF|G-CSF will be given at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30
214874289|NCT05278650|OTHER|Senior PharmAssist^TM Program Implementation|"Representatives from three diverse communities will participate in co-design workshops to refine the Senior PharmAssistTM (SPA) implementation toolkit, which will then be delivered to agency staff from these partnering communities through a series of learning collaborative sessions to facilitate implementation of SPA core components in each community.~Community champions will be trained to deliver a community-based program to deliver the core components of SPA:~1. Medication Therapy Management (MTM);~2. Medication co-payment assistance;~3. Tailored community referrals; and~4. Medicare insurance counseling"
214874290|NCT04469816|BEHAVIORAL|Family Check-Up 4 Health|A parent-training intervention to improve child health, school readiness and manage obesity.
214874291|NCT04469816|OTHER|Services as Usual|Services/Treatment as usual.
214874292|NCT06595277|DIAGNOSTIC_TEST|Neuromuscular blockade|Neuromuscular blockade will be measured in all patients using a quantitative measurement (TOFScan, IdMed, Marseille, France) during surgery and after surgery until either full neuromuscular recovery or time of scheduled extubation.
215040148|NCT07002827|DRUG|Lactulose|Standard Medical Tretament part
215040149|NCT07002827|BIOLOGICAL|Albumin|Standard Medical Tretament part
215040150|NCT06675591|OTHER|Rapid sodium correction|"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \&lt; 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."
214291319|NCT02389088|DRUG|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
214291320|NCT03025867|DRUG|Niraparib|
214874293|NCT02369458|DRUG|Mitomycin-C|
214874294|NCT02369458|DRUG|Pegfilgrastim|
214874295|NCT02909283|PROCEDURE|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
214874296|NCT00121134|DRUG|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
214874297|NCT00121134|DRUG|Cyclophosphamide|Once a day for 6 months
214874298|NCT00121134|DRUG|Methotrexate|Twice daily for the first two days of every week for 6 months
214874299|NCT00121134|DRUG|Capecitabine|"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"
215040151|NCT06675591|OTHER|Slow sodium correction|"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \&lt; 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."
214874300|NCT04080544|DRUG|[18F]AV-1451|The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.
214874301|NCT04080544|PROCEDURE|Positron Emission Tomography|Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
214874302|NCT06694753|BIOLOGICAL|mRNA-1645-eODGT8|eOD-GT8 60mer is a self-assembling nanoparticle composed of 60 subunits of the engineered HIV-1 gp120 outer domain germline targeting version 8 (eOD-GT8) fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 15-amino acid Glycine-Serine linker. eOD-GT8 60mer will be delivered using an mRNA lipid nanoparticle (LNP) platform. To be administered by intramuscular (IM) injection at doses of 10 or 30 mcg.
214874303|NCT06694753|BIOLOGICAL|mRNA-1645-CoreG28v2|core-g28v2 60mer is a nanoparticle composed of 60 protein subunits of an engineered core-gp120 fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 21-amino acid Glycine-Serine linker. Core-g28v2 60mer will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.
214874304|NCT06694753|BIOLOGICAL|mRNA-1645-N332GT5|"N332-GT5 gp151 is an HIV envelope glycoprotein gp151 trimer based on BG505 SOSIP MD39 (clade A) trimer with germline-targeting mutations added that confer the ability to bind germline precursors of BG18 class B cells. N332-GT5 gp151 will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg."
214874305|NCT06694753|BIOLOGICAL|Placebo|Saline
214874306|NCT04967508|DRUG|Stelara® (Ustekinumab)|Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.
214874307|NCT04967508|DRUG|SB17 (Proposed Ustekinumab Biosimilar)|"Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection."
214874308|NCT03011190|BEHAVIORAL|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
214874309|NCT03338842|DEVICE|Distractor and Lower limb VR|In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
214874310|NCT00002241|DRUG|Indinavir sulfate|
214874311|NCT00002241|DRUG|Ritonavir|
214874312|NCT00002241|DRUG|Lamivudine|
214874313|NCT00002241|DRUG|Stavudine|
214874314|NCT05464849|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
214874315|NCT06876454|PROCEDURE|Gastrostomy Tube|Feeding gastrostomy tube insertion
214874316|NCT06876454|DEVICE|Self Expanding Metal esophageal Stent|Fully covered SEMS in the esophagus
214874317|NCT02954926|DRUG|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
214874318|NCT03273491|BEHAVIORAL|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
214874319|NCT03273491|BEHAVIORAL|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
214874320|NCT06695598|DRUG|CKD-383|QD, PO
214874321|NCT00118131|DRUG|cisplatin|
214874322|NCT00118131|DRUG|docetaxel|
214874323|NCT00534014|DIETARY_SUPPLEMENT|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
214874324|NCT02803229|DRUG|Adderall-XR|
214874325|NCT02803229|DRUG|Matched placebo|matched placebo provided for placebo arm
214874326|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
214874327|NCT01024686|BIOLOGICAL|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
214874328|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
214874329|NCT04819035|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
214874330|NCT00857584|DRUG|Extended release quetiapine (quetiapine XR)|"Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.~Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study."
214874331|NCT00857584|DRUG|Sertraline|"Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study."
214874332|NCT00857584|DRUG|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
214874333|NCT00696579|DRUG|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
214874334|NCT00696579|DRUG|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
214874335|NCT03967587|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
214874336|NCT04677296|OTHER|VS002A|Amino acid based ORS/Medical food
214666197|NCT01860170|DRUG|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
214874337|NCT04677296|OTHER|WHO-ORS|WHO Oral rehydration solution, which is glucose based
214874338|NCT00259272|DRUG|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
214874339|NCT04051112|DRUG|SCB-313|10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
214874340|NCT04172116|DEVICE|Continuous glucose monitoring|see arm/group descriptions
214874341|NCT03336177|OTHER|Semi-structured face to face interviews.|Patients will be interviewed by open-ended questions face to face concerning their past experiences. The recorded interview will be transcribed and analyzed by psychodynamic and semio-pragmatic approach.
215040152|NCT07004920|OTHER|IPOS-ICU|This is a prospective observational study. Health care providers will be asked to will out the IPOS-ICU for patients in the intensive care unit.
215040153|NCT07002749|DRUG|Tranexamic Acid (TXA)|I would like to see the effect of prophylactic tranexamic acid in women undergoing ELLSCS in preventing PPH in my setup.
215040154|NCT07002749|DEVICE|Placebo|one group will get placebo
215040155|NCT07003750|OTHER|Surgical wound infection prevention bundle|utilization of locally customized surgical wound infection bundle to prevent and or control of infection in patients undergoing CABG surgery
215040156|NCT07004530|PROCEDURE|Magnetically Controlled Capsule Endoscopy (MCCE)|. The MCCE used in this study is the magnetically controlled capsule endoscopy (MCE, AnPx USA) which is a capsule measuring 28x12mm, and contains a permanent magnet inside its dome. Images are captured and recorded at 2 frames/s
215040157|NCT07004530|PROCEDURE|Esophageal-gastro-Duodenoscopy (EGD)|Esophageal-gastro-Duodenoscopy (EGD) is commonly performed to look for source of bleeding in patients with anaemia. However, from our own analysis and from retrospective studies of EGD in patients with ACS, EGD finding was normal or non-significant in 20-80% patients14-16. Moreover, EGD was associated with non-negligible periprocedural risks in patients with ACS, including death directly attributed to EGD (9.1%; 95% CI 7.6-10.9%), hypotension (24.1%; 95% CI 17.0-32.9%), arrhythmias (8.3%; 95% CI 4.5-15.1%) and recurrent ACS (6.5%; 95% CI 3.2-12.8%)
215040158|NCT05788991|DRUG|Dequalinium Chloride|Fluomizin vaginal tablets (10 mg dequalinium chloride) used once a day for 6 days
214291321|NCT03472027|BIOLOGICAL|BCD-145|Anti-CTLA-4 monoclonal antibody, IV infusion
214291322|NCT03134989|DEVICE|Cochlear implant|Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
214874342|NCT02838654|PROCEDURE|cervical epidural injection|sensitivity, specificity, positive predictive value, negative predictive value
214874343|NCT05653024|DRUG|Salbutamol|8 puffs of 100 mcg inhaled salbutamol administered with spacer
214874344|NCT05653024|DRUG|Placebo|8 puffs of placebo inhaler administered with spacer
214874345|NCT04465773|PROCEDURE|general anesthesia for scheduled gynecological surgery|
214874346|NCT04465773|DRUG|Propofol|continuous infusion, target concentration adjusted to maintain bispectral index between 45 and 55
215040159|NCT05788991|DRUG|Metronidazole Oral|Metronidazole oral tablets (500 mg) taken twice a day for 7 days
215040160|NCT05270863|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
215040161|NCT05270863|DRUG|Carbachol PF|A single drop in each eye at a visit.
215040162|NCT05270863|DRUG|Brimonidine tartrate|A single drop in each eye at a visit.
215040163|NCT04464473|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
214291323|NCT03451344|OTHER|Integrated rehabilitation group|Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
214291324|NCT03451344|OTHER|Community-based rehabilitation group|Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
214874347|NCT04465773|DRUG|Remifentanil, Ultiva®|continuous infusion, target concentration 1 ng/ml
214874348|NCT04465773|PROCEDURE|tetanic stimulations|10-20-30-40-50-60 milliamps, 5 seconds, 100 Hertz 2 minutes between stimulations delivered via the standard neuromuscular blocking agents monitor
214874349|NCT04465773|DEVICE|VideoAlgesiGraph|non invasive infrared camera placed in front of the left eye of the patients during the study period, connected to a laptop. No part of the device touches the eye.
214874350|NCT00005727|BEHAVIORAL|Intervention|Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
214874351|NCT00501501|PROCEDURE|Cesarean section|
214874352|NCT00501501|PROCEDURE|Vaginal delivery|
214874353|NCT00309894|BIOLOGICAL|sargramostim|
214874354|NCT00309894|DRUG|ketoconazole|
214874355|NCT00309894|DRUG|therapeutic hydrocortisone|
214874356|NCT03008876|DRUG|Acetaminophen|infants receive acetaminophen for treatment of their PDA
214874357|NCT03008876|DRUG|Ibuprofen|infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
214874358|NCT04220931|DRUG|botulinum toxin injection|injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
214874359|NCT02001831|DIETARY_SUPPLEMENT|Supplement|
214874360|NCT02001831|DIETARY_SUPPLEMENT|Placebo|
214874361|NCT00813631|OTHER|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
214874362|NCT03654469|OTHER|questionnaires and electronic mini-spirometry|prospective screening study based on questionnaires and electronic mini-spirometry (Néo-6(®)) that includes a representative sample of dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany
214874363|NCT02490267|OTHER|Quality of Life questionnaire|
214291325|NCT00569296|BIOLOGICAL|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
214874364|NCT02368574|PROCEDURE|Class II hysterectomy|Class II hysterectomy
214874365|NCT04682769|OTHER|Other|Patients with Coronary Heart Disease and Depressive Disorder are receiving routine treatment by their physician.
214291326|NCT00569296|BIOLOGICAL|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
214291327|NCT00569296|BIOLOGICAL|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
214666198|NCT01860170|DRUG|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
214666199|NCT01860170|DRUG|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
214666200|NCT02832089|DRUG|oral carvedilol|oral carvedilol in escalating doses for reducing ventricular rate in AF patients
214666201|NCT03823729|DEVICE|Elosan Cabin|The Elosan Cabin is a closed, electrically insulated, biocompatible cabin for the short-term application of electrostatic high voltage. Patients assigned to the Group A will have 8 sessions in the Elosan cabin, with an interval of 3 to 4 days between sessions.
214666202|NCT03390829|OTHER|semi-directed interviews|semi-directed interviews
214666203|NCT02284724|PROCEDURE|Dry Needling|
214666204|NCT02284724|PROCEDURE|Sham Needling|
214666205|NCT01531725|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
214666206|NCT02844790|DRUG|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
214666207|NCT03467178|DRUG|Decitabine|Nucleic Acid Synthesis Inhibitor
214874366|NCT02636192|DRUG|No Intervention|This is an observational study and participants did not receive any intervention in this study.
214666208|NCT03467178|DRUG|Carboplatin|Chemotherapy medication
214874367|NCT02884401|DEVICE|Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)|A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
214874368|NCT00238706|DEVICE|Radiofrequency ablation|
214874369|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
214874370|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
214874371|NCT02086903|DRUG|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
214874372|NCT02086903|DRUG|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
214874373|NCT00375349|PROCEDURE|Ultrasound to demonstrate existence of fatty liver|
214874374|NCT03715075|PROCEDURE|Caesarean Section|Caesarean Section
214476776|NCT06813729|BIOLOGICAL|Manuel Pressure|The infant was first placed on the examination table. To calm the infant, the mother was asked to hold the infants' hands and talk to him/her. Next, while one nurse held the infants' leg for the injection, 10-second manual pressure was applied on the vaccine injection site by the experienced nurse. Then pneumococcal conjugate vaccine was administered in accordance with the standard injection technique (0.5 ml, IM, Vastus Lateralis Site).
214666209|NCT03467178|DRUG|Pegylated Liposomal Doxorubicin|Chemotherapy medication
215040164|NCT06630156|BIOLOGICAL|Revascularization of Immature Young Permenant Teeth|"An access cavity was prepared under rubber dam, isolation, root canal system disinfection was done without mechanical instrumentation. Subsequently, triple antibiotic paste was placed into the apical portion of the canal and filled to just below the CEJ. The access cavity was temporarily restored with glass ionomer.~4 weeks later, after reopening of the access, the antibiotic paste was gently flushed out of the canal with sterile normal saline. The root canal system was irrigated. A sterile #35 K-file will be introduced into the canal beyond the apical foramen using a push and pull motion to provoke bleeding from the periapical tissue. After bleeding control and formation of fresh blood clot, 3 mm of Bio (MTA) will be placed in Group A, 3 mm of Total Fill biocearmic root repair material will be placed in Group B after a moist cotton pellet was placed over the capping material and the access cavity will be sealed with G C"
215040165|NCT05919563|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
214666210|NCT03467178|DRUG|Gemcitabine|Chemotherapy medication
214666211|NCT03467178|DRUG|Paclitaxel|Chemotherapy medication
214874375|NCT01264536|DIETARY_SUPPLEMENT|lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
214874376|NCT01264536|DIETARY_SUPPLEMENT|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
215040166|NCT06696209|OTHER|Analysis of the withdrawal time of the Upper Gastrointestinal Endoscopy|Time of last esophageal image - time of first image of the second portion of the duodenum.
214874377|NCT00469911|PROCEDURE|Magnetic Resonance Spectroscopy|Magnetic Resonance Spectroscopy is a noninvasive procedure that provides detailed body images on any plane.
214874378|NCT00469911|PROCEDURE|Ex vivo heart biopsy|Heart transplant patients will have their normal clinical routine heart biopsy
214874379|NCT03681327|OTHER|Sensory stimulation during sleep|Sensory stimulation during sleep
214874380|NCT05892692|BEHAVIORAL|Ecological Momentary Intervention|Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.
214874381|NCT00527865|DRUG|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
214874382|NCT00527865|DRUG|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
214874383|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
214874384|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
214874385|NCT01659086|BIOLOGICAL|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
214874386|NCT04445363|DRUG|Jaktinib hydrochloride cream|Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks
214874387|NCT04445363|DRUG|Placebo|Dose extension: Placebo
214874388|NCT02954263|DRUG|TD-1439|
214874389|NCT02954263|DRUG|Placebo|
214874390|NCT01199679|PROCEDURE|Mucosectomy|Endoscopic mucosal resection in the upper GI tract.
214874391|NCT01199679|PROCEDURE|Rubber Band Ligation|Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
215040167|NCT06696209|OTHER|Analysis of the total time of the Upper Gastrointestinal Endoscopy|Time of last esophageal image - time of first esophageal image
214874392|NCT02573090|PROCEDURE|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
214874393|NCT02573090|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
214874394|NCT05944380|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the PENG block
214874395|NCT05944380|DRUG|0,9% normal saline|20 mL 0.9% normal saline will be injected for the PENG block
214874396|NCT05009680|DRUG|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
214874397|NCT05009680|DRUG|Placebo|Placebo is administered orally twice a day
214874398|NCT04719962|PROCEDURE|Targeted proteomics in skin +/- cerebrospinal or synovial fluid to diagnose disseminated Lyme disease|"Following a 2-days course of local daily clobetasol propionate 0,05% cream application, a skin biopsy (3 mm punch-biopsy ) of healthy-looking skin of the upper part of the thigh will be performed in all patients,.~Arthrocentesis (in patients with Lyme arthritis only) and lumbar puncture to collect cerebrospinal fluid (in patients with neuroborreliosis only) will be performed in the usual care setting as appropriated.~All biological samples will be subject to Borrelia culture, PCR and SRM-MS proteomics."
215040168|NCT06696209|OTHER|Upper gastrointestinal endoscopy: Common Practices|"Execution of UGE using high-resolution endoscopes, with the option of virtual chromoendoscopy, according with the physician's preference. Possible optimization of visualization with washing and/or the use of simethicone or similar, as pre-medication or during the examination, according with the physician's preference. Patients will be randomised to one of the following measurements-total time versus withdrawal time-in a parallel 1:1 scheme.~The allocation of the randomisation group will be computer-generated. The endoscopist must record the time at which the following three anatomical structures are reached (either by noting during the procedure or based on the information in the photographic documentation), before any biopsies or therapeutic interventions, in the format xxh:xxmin:xxsec:~1. First esophageal image;~2. First image of the second portion of the duodenum;~3. Last esophageal image."
215040169|NCT03246906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
215040170|NCT03246906|DRUG|Cyclophosphamide|Given IV
215040171|NCT03246906|DRUG|Cyclosporine|Given PO
215040172|NCT03246906|DRUG|Mycophenolate Mofetil|Given PO
215040173|NCT03246906|DRUG|Sirolimus|Given PO
215040174|NCT01681641|OTHER|A psycho-social intervention|
215040175|NCT06868459|OTHER|Data Collection|Subjects with planned PED-TAE delivered via TriNav will receive their treatment following routine standard of care procedures. Post-procedural data obtained by a patient chart review will be collected in a study database. No additional study-specific interventions or visits outside of the routine clinical treatment will be performed.
215040176|NCT07029971|BIOLOGICAL|BB-TL1A-VIAL-HLE|Anti-TL1A monoclonal antibody
215040177|NCT04824092|DRUG|Tafasitamab|Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
215040178|NCT04824092|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
215040179|NCT04824092|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
215040180|NCT04824092|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
215040181|NCT04824092|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
215040182|NCT04824092|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
215040183|NCT04824092|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
215040184|NCT04824092|DRUG|Tafasitamab placebo|0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
214874399|NCT01841476|DRUG|POL6326|
214874400|NCT00086827|DRUG|romidepsin|Given IV
214874401|NCT00086827|OTHER|laboratory biomarker analysis|Correlative studies
214874402|NCT01912027|PROCEDURE|Open Latarjet technique|
214874403|NCT01912027|PROCEDURE|Arthroscopic Latarjet techniques|
215040185|NCT04824092|DRUG|Lenalidomide placebo|Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
215040186|NCT06612970|DRUG|HB0056|HB0056 Injection
215040187|NCT06612970|DRUG|Placebo|Placebo
215040188|NCT07032376|BEHAVIORAL|Survey|All participants will complete a baseline survey and have medical information collected.
215040189|NCT07032376|BEHAVIORAL|Rectal Expulsion Device use|"During the participant's clinic visit for constipation, the Rectal Expulsion Device will be available for the gastroenterology care provider to use if the decision is made to use this during the clinic visit.~In addition, the care provider will have access to the RED brochure and the Michigan Chart (MICHART) Our Practice Advisory (OPA) - a decision support tool in MiChart to support care navigation using RED."
215040190|NCT07117838|OTHER|virtual reality|Virtual reality application were applied to patients during coronary angiography.
215040191|NCT07117838|OTHER|music|Patients will listen to music during coronary angiography.
215040192|NCT06712927|DRUG|Ipilimumab|1 mg/kg of Ipilimumab will be administered via IV every 8 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur
215040193|NCT06712927|DRUG|Nivolumab + Relatlimab FDC|Relatlimab 160mg + Nivo 480mg will be administered via IV every 4 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur
215040194|NCT05198557|DRUG|Inebilizumab|Participants will receive IV inebilizumab.
215040195|NCT05198557|DRUG|Placebo|Participants will receive IV placebo matched to inebilizumab.
215040196|NCT06721884|DIETARY_SUPPLEMENT|Artemisia Annua Leaf|"The intervention is Artecinua™ which is an organic Artemisia annua dried leaf powder in a vegan / kosher/ halal capsule. Artemisia annua L is classified as a 'generally regarded as safe' (GRAS) herb. Participants will be instructed to wean up to a full 5g dose by the following schedule.~1. gram (3 caps) 1st day,~2. grams (6 caps) 3/am, 3/pm, for the 3rd day,~3. grams (9 caps) 3/am 3/noon 3/pm for the 5th day,~4. grams (12 caps) 4/am, 4/noon, 4/pm for the 7th day,~5. grams (15 caps) 5/am, 5/noon, 5/pm for rest of intervention period (4 weeks)~Containers of ArtecinuaTM will be kept in a secured cabinet before being administered, under climate-controlled conditions, and checked weekly to ensure consistent ambient temperature.~The justification of the 5g a day dosing is based on empiric experience and is in line with recommended dosages by the pharmacopeia of the People's Republic of China and has been previously used in clinical trials"
215040197|NCT06721884|OTHER|placebo|We have chosen dried-leaf alfalfa of equal weight and dosing to the interventional product (5 grams, 15 caps, 5/am, 5/noon, 5/pm for the 4 weeks of the intervention period plus an additional 1 week dose escalation period to match the dosing of the Artemisia product). We have chosen this as a comparator in consultation with SIBO and herbal medicine content experts as alfalfa matches the texture and color of Artemisia annua and, in the doses used, will provide no meaningful amounts of FODMAPs or antimicrobial phytochemicals. The alfalfa will be sourced from Bulk Apotherapy, LCC, and encapsulated at the same facility as the Artemisia capsules. Containers of placebo capsules will be kept in a secured cabinet before being administered, under climate-controlled conditions, and checked weekly to ensure consistent ambient temperature.
215040198|NCT06884618|DRUG|RO7673396|RO7673396 will be administered as per the schedule specified in the protocol.
214874404|NCT00611273|DEVICE|GFX|The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
214874405|NCT04358289|OTHER|Basic antimicrobial stewardship education|Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines
214874406|NCT04358289|OTHER|Participatory action research group in commune health center and community|"* Establish a participatory action research group~* Engagement with the group through participatory action research involving problem identification, planning change strategies, implementing strategies, and evaluation"
215040199|NCT06240260|DEVICE|TENS (transcutaneous electrical nerve stimulation) unit|"Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of a mild electrical current.~A TENS machine is a small, battery-operated device that has leads connected to sticky pads called electrodes."
215040200|NCT06240260|OTHER|Standard care|Paracervical block only or participant declines analgesia for IUD insertion
215040201|NCT06892093|DIETARY_SUPPLEMENT|Probiotics|Participants in this group will receive a daily dose of probiotics as an adjunct to standard Neratinib therapy. The probiotics will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks (two treatment cycles). Loperamide will be administered prophylactically according to the FDA-recommended schedule to prevent Neratinib-associated diarrhea. The aim is to assess the efficacy of probiotics in reducing Neratinib-induced diarrhea and improving quality of life.
215040202|NCT06892093|DIETARY_SUPPLEMENT|Placebo|Participants in this group will receive a daily dose of a placebo that is identical in appearance, taste, and administration method to the probiotic granules, in addition to standard Neratinib therapy. The placebo will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks. Loperamide will also be administered prophylactically to all participants in accordance with FDA recommendations. This group will serve as a control to evaluate the true effect of probiotics on Neratinib-induced diarrhea.
214666212|NCT03851601|OTHER|blood samples|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
214666213|NCT05343195|OTHER|Task-oriented exercise|Task-oriented exercise program for patients after total hip replacement.
214874407|NCT04358289|OTHER|Antimicrobial stewardship program in hospitals|"The intervention activities in hospitals will include: training a health-worker in each of the participating hospitals to act as a facilitator or activator; forming an antibiotic stewardship group; meeting regularly and following an action-research cycle that includes problem identification, planning change strategies, implementing strategies, and evaluating strategies"
214874408|NCT04358289|OTHER|Community education|Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels
214874409|NCT00021580|PROCEDURE|human cadaveric islet cell transplantation|
214874410|NCT04211727|DIAGNOSTIC_TEST|Capillary finger prick blood sample|Patients will have a blood finger prick sample
214874411|NCT04684004|OTHER|To report number of HF events and deaths|In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
214874412|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
214874413|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 90 µg/kg (IV)
214874414|NCT01104467|OTHER|Placebo|1 bolus injection of placebo IV
214874415|NCT00561704|DRUG|losartan|losartan, 100mg daily,
214874416|NCT05009914|PROCEDURE|cardiac denervation|Excision of Marshall ligament and Waterstone fat pad during CABG.
214874417|NCT04888598|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) Angiography|Measurement of retinal vessel density and distribution in the macula using new generation OCT device
214874418|NCT00678197|OTHER|Access Intervention|
214874419|NCT00678197|OTHER|Bonus/Pay-for-Performance Intervention|
214874420|NCT04102280|DEVICE|Dialyser|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
214874421|NCT00683631|OTHER|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
214874422|NCT05933980|DRUG|Rego+Tori+Cele|combination of Toripalimab,regorafenib and celecoxib
214874423|NCT05182320|DEVICE|OrthoPath|unilateral TKA and THA patients using the BPMpathway rehabilitation sensor system
214874424|NCT05182320|DEVICE|Control|unilateral TKA and THA patients not using the BPMpathway rehabilitation sensor system
214874425|NCT02511821|OTHER|Computer-Assisted Intervention|Complete online surveys
214874426|NCT02511821|DEVICE|Vivofit watch|Wear Vivofit watch
214874427|NCT02511821|OTHER|Quality-of-Life Assessment|Ancillary studies
214874428|NCT02511821|OTHER|Questionnaire Administration|Ancillary studies
214666214|NCT05343195|OTHER|Control|Control intervention: conventional physiotherapy after hip replacement
214666215|NCT00481481|DRUG|tacrolimus|immunosuppression
214874429|NCT04049110|DRUG|Forxiga 10mg|Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
214874430|NCT04049110|DRUG|Placebo|Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
215040203|NCT06892093|DRUG|Loperamide|All participants will receive prophylactic loperamide to reduce the risk of Neratinib-induced diarrhea. Loperamide will be administered according to the FDA-recommended schedule: 4 mg TID for the first 14 days of treatment, then 4 mg BID from Day 15 to Day 42. This intervention is implemented as a standard supportive therapy and not as a randomized variable.
215040204|NCT06574529|DEVICE|Video-observed therapy (vDOT)|All participants are required to send 5 times per week a short video showing they are actually taking their treatment for tuberculosis via a dedicated application on their cellphone
215040205|NCT06885957|DRUG|Mab Therapy|Whether receive mab therapy or not.
214666216|NCT05352685|DRUG|Propofol Injection|1% propofol is used for target-controlled infusion, and gradually increase the effect concentration at 0.2ug/ml. Make the subject's sedation depth reach light sedation and deep sedation respectively. EEG data were collected during wakefulness, light sedation, deep sedation, and recovery.
214666217|NCT04386889|OTHER|Vasculitis In SLE|20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
214666218|NCT01238120|DRUG|Ibuprofen|200 mg BID and 8 hours apart
214666219|NCT01238120|BEHAVIORAL|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
214666220|NCT01238120|DRUG|Placebo|200mg BID and 8 hours apart
214666221|NCT01661257|DRUG|Infliximab|
214666222|NCT04558697|DRUG|Shepherd's Purse extractum oleosum vagitories|Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days
214666223|NCT04558697|DRUG|Tea tree oil vagitories|Tea tree oil vagitories will be administered once daily for 5 days
214666224|NCT04558697|DRUG|Hyperici extractum oleosum vagitories|Hyperici extractum oleosum vagitories will be administered once daily for 5 days
214666225|NCT04558697|DRUG|Vagitories - Probiotic|Vagitories - Probiotic will be administered once daily for 5 days
214666226|NCT05212025|DRUG|Adavosertib|Taken Orally
214666227|NCT05212025|DRUG|Gemcitabine|Intravenous Infusion
214666228|NCT04696744|BIOLOGICAL|CTC detection|"The collection and analysis of CTCs will be carried out in the following 6 steps: A blood sample will be taken: a maximum volume of 30 ml on 3 x 10 ml BD Vacutainer® EDTA tubes is required for the study.~CTCs will be enumerated and characterized by immunofluorescence after immunostaining with the following antibodies: anticytokeratin, anti-CD44, anti-N-cadherin and anti-PD-L1.~• - Secondary criterion(s) : Different tumor and clinical parameters will be analysed to find a correlation with CTC detection Gene expression profiles will be analyzed using the RNAseq single-cell at different times: before treatment, at interim times, and in case of relapse in order to establish correlations between patients at high risk of relapse and their molecular profiles"
214666229|NCT02167477|DEVICE|Macintosh laryngoscopy|Tracheal intubation
214666230|NCT02167477|DEVICE|Storz C-MAC, standard blade|Tracheal intubation
214666231|NCT02167477|DEVICE|Storz C-MAC, D-BLADE|Tracheal intubation
214666232|NCT02048514|DEVICE|The Nellix® EndoVascular Aneurysm Sealing System|
214666233|NCT06075940|DEVICE|MAGNITUDE BRS|Treatment with the MAGNITUDE Scaffold
214666234|NCT00864734|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
214666235|NCT00864734|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
214666236|NCT02888626|DEVICE|Microlens Array|Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
214666237|NCT02152969|DRUG|Telmisartan|
214666238|NCT02152969|DRUG|Amlodipine|
214666239|NCT02152969|DRUG|Chlorthalidone|
214666240|NCT03596164|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
214666241|NCT03596164|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.
214666242|NCT03596164|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
214666243|NCT03596164|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
214666244|NCT01457248|DEVICE|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
214666245|NCT01457248|DEVICE|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
214666246|NCT04112914|BEHAVIORAL|Post-concussion education for families|An educational intervention for families will be developed based on the CDC guidelines for returning to daily activities, school, and sports, adapted with stakeholder feedback to meet the learning needs of low health literacy parents.
214666247|NCT04457921|OTHER|deep tissue massage|DTM was applied to participants in the experimental group twice (at the 10th and 22nd h) after cesarean
214666248|NCT04896177|DEVICE|Sirolimus drug-eluting coronary balloon catheter|Patients in experimental group will undergo PCI, using sirolimus drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
214666249|NCT04896177|DEVICE|Paclitaxel drug-eluting coronary balloon catheter|Patients in control group will undergo PCI, using paclitaxel drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
214666250|NCT03669705|PROCEDURE|Omitting axillary surgery in early breast cancer|Before the Sentinel Node era all invasive breast cancer was recommended to have axillary dissection but after the introduction of national breast cancer screening this guideline statement was challenged by this national Swedish cohort.
214666251|NCT03679221|OTHER|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
215040206|NCT03995472|DRUG|SHR-1501|Administered subcutaneously
215040207|NCT03995472|DRUG|SHR-1316|Administered intravenously
214476777|NCT06813482|BEHAVIORAL|Digitally enabled cardiac rehabilitation|"The intervention consists of an 8-week remotely delivered cardiac rehabilitation program. It includes an initial assessment during week 1, six weeks of participation in a digitally enabled cardiac rehabilitation (DeCR) program (weeks 2-7), and a final assessment in week 8. Participants will utilize a digital mobile application and receive weekly telehealth consultations with a cardiac nurse. The program is designed to facilitate behavior change and improve outcomes through the following modalities:~1. Telehealth - individualized coaching delivered via telephone by a cardiac nurse, to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~2. Mobile application (called SmartCR) and nurse web portal - for remote monitoring and personalized care planning. The app monitors health and physical activity, has prompted tasks and delivers education via video, audio and written articles."
214476778|NCT06813482|BEHAVIORAL|F2F-CR|Traditional Face-to-face cardiac rehabilitation
215040208|NCT06839261|DIAGNOSTIC_TEST|Intubation Difficulty Scale|The Intubation Difficulty Scale (IDS) is an objective way to classify easy and difficult intubation. A score ≤ 5 indicates an easy or mildly difficult intubation, while IDS \> 5 suggests difficult intubation, requiring additional techniques or attempts.
215040209|NCT06839261|OTHER|Artificial Intelligence|The program made with Python 3 programming language using open source libraries. It will be developed to predict difficult intubation with 6 different photo data of patients, this process will be taught with a learning process and then tested.
215040210|NCT04667962|OTHER|Online questionnaire|Participants will have to complete 3 online self-questionnaires: the first one at enrollment, the second one 1 month after enrollment (M1) and the third one 3 months after enrollment (M3). Each questionnaire will take an estimated 20 minutes to complete.
215040211|NCT06899165|DRUG|Psilocybin|Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists
215040212|NCT06899165|BEHAVIORAL|Integration sessions|weekly integration sessions (therapy) for 6 weeks
215040213|NCT06763081|OTHER|Not applicable- observational study|It's an observational study. Participants are not assigned an intervention as part of the study.
215040214|NCT06399484|OTHER|Manual mobilizations of the median nerve|"Slippage of the median nerve in the wrist: the subject's starting position (P0) will be recumbent supine with the cervical spine in a neutral position, the shoulder girdle in neutral position, 30º of glenohumeral abduction in neutral rotation, 90º of elbow flexion, prone-supination of the neutral forearm, wrist and fingers in neutral position. From this position the movements will be 1) Glenohumeral abduction up to 90º; 2) Glenohumeral external rotation to the frontal plane; 3) Supination of the forearm; 4) Extension of the wrist and fingers; 5) Elbow extension. This position is will combine with an ipsilateral cervical inclination (distal sliding). The proximal slide is carried out bringing the fingers of the hand towards the flexion while performing a contralateral cervical tilt.~Median nerve tension: the starting position and movements are the same described above but this time it will be done with contralateral cervical tilt."
215040215|NCT06399484|OTHER|Wrist movements|Movements of the wrist joint will be performed as a placebo treatment
215040216|NCT05547867|PROCEDURE|Radial head prosthesis|Radial head arthroplasty in comminuted radial head fractures.
215040217|NCT05424705|DIAGNOSTIC_TEST|OCT, NIRS|
215040218|NCT01613885|OTHER|No Intervention|This study does not involve any intervention other than obtaining blood, nasal/cheek/throat/skin swabs, saliva, sputum, urine, and stool samples, breathing and skin tests.
215040219|NCT03186820|OTHER|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
214476779|NCT06813482|BEHAVIORAL|Usual Care Group|Usual Care - eligible for cardiac rehabilitation and who unlikely participated in any formal cardiac rehabilitation program
214666252|NCT02931448|DEVICE|Dosage of the blood HbCO thanks to the carboxymeter MASIMO RAD 57|
214666253|NCT00699790|DRUG|CCR2 Antagonist|Tablets, Oral, 50 mg, once daily, 12 weeks
214666254|NCT00699790|DRUG|Placebo|Tablets, Oral, 0mg, once daily, 12 weeks
214666255|NCT03427073|DRUG|ALM201|Drug: ALM201 administered subcutaneously
214666256|NCT01358383|DRUG|naproxen|250mg, oral dose
214666257|NCT01358383|DRUG|esomeprazole|20mg, oral dose
214666258|NCT00508729|DRUG|Qingyi granules|
214666259|NCT01776125|OTHER|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
214666260|NCT02955329|DRUG|Nicotine|Participants will vape tobacco leaves with nicotine out of the PAX device.
214666261|NCT02955329|DRUG|Cannabis|Participants will vape marijuana leaves with nicotine out of the PAX device.
214666262|NCT02955329|DEVICE|PAX Loose Leaf Vaporizer|In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
214666263|NCT01564979|DRUG|preseptal injection of botulinum toxin type A|botulinum toxin type A (Botox)2.5 units, 5 points
214666264|NCT01564979|DRUG|pretarsal injection of Botulinum toxin type A|Botulinum toxin type A 2,5 units, 5 points
214666265|NCT04273984|DRUG|Misoprostol|Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.
214666266|NCT00332787|DRUG|Fluoxetine|
214666267|NCT00759603|DRUG|Lenalidomide|Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
214666268|NCT00759603|DRUG|Rituximab|Dose of 375 mg/m\^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
214666269|NCT01870544|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
215040220|NCT03676387|OTHER|ultrasound guided|"Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation \[ETT OD=0.55\*(subglottic diameter)+1.16\] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes."
215040221|NCT06581848|DRUG|Elranatamab|According to the approved label, the recommended doses are step-up doses of 12 mg on day 1 and 32 mg on day 4, followed by a full treatment dose of 76 mg weekly from week 2 to week 24. For patients who have received at least 24 weeks of treatment and have achieved a response, the dosing interval should transition to an every two week schedule.
215040222|NCT05243459|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention away from threat face stimuli.
215040223|NCT05243459|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
215040224|NCT05243459|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose while viewing the face matrices. The music is played throughout and is not contingent upon gaze behavior.
215040225|NCT06669754|DRUG|Deucrictibant|Deucrictibant 40mg extended-release tablet for once daily oral use
215040226|NCT06669754|DRUG|Placebo|Placebo
215040227|NCT05442736|DRUG|Ciprofloxacin|studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
215040228|NCT06802055|DRUG|Sirolimus (Rapamune®)|Sirolimus 1-3 mg once daily orally, with a target trough blood concentration of 4-12 ng/ml.
215040229|NCT06802055|DRUG|Cyclosporin A (CsA)|Cyclosporine A 25-150 mg orally every 12 hours, with the dose adjusted based on renal function and trough concentration. For patients with normal renal function, the target trough concentration is approximately 150 ng/ml. For patients with impaired renal function, the cyclosporine A dose is reduced to 25-50 mg every 12 hours, aiming for recovery or stabilization of renal function.
215040230|NCT05063786|BIOLOGICAL|Trastuzumab|"6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks.~\* If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
215040231|NCT05063786|DRUG|Alpelisib|300 mg oral once daily.
215040232|NCT05063786|DRUG|Fulvestrant|500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.
215040233|NCT05063786|DRUG|Vinorelbine|Oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.
215040234|NCT05063786|DRUG|Capecitabine|1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.
215040235|NCT05063786|DRUG|Eribulin|1.23 mg/m2 IV on days 1 and 8, every 3 weeks.
214666270|NCT01870544|DIETARY_SUPPLEMENT|Placebo|placebo will be administered daily for 44 days
214666271|NCT02835495|BEHAVIORAL|HELP Vets Intervention|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
214666272|NCT02835495|BEHAVIORAL|Individual Education Program|Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
214666273|NCT04551443|BIOLOGICAL|Intravenous infusion placebo|Intravenous infusion placebo or WJMSCs in patients with AMI
214666274|NCT04551443|BIOLOGICAL|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with AMI
214666275|NCT00669773|DRUG|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
214666276|NCT00669773|DRUG|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
214666277|NCT04733820|DRUG|Adjuvant chemotherapy|Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
214666278|NCT04242030|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
214666279|NCT04242030|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.
214666280|NCT03219125|DEVICE|Dixon Magnetic Resonance Imaging|MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
214666281|NCT03219125|DEVICE|dual-energy X-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
214874431|NCT02293369|PROCEDURE|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
215040236|NCT05050084|DRUG|Bicalutamide|Drug
214476780|NCT06814457|PROCEDURE|a nursing care bundle on oral intake|a nursing care bundle on oral intake will be started the day after their successful extubation and extend for 14th days. Additionally, the participants will be provided with a brief education on safe swallowing.
214874432|NCT02293369|PROCEDURE|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
215040237|NCT05050084|DRUG|Buserelin|Drug
215040238|NCT05050084|DRUG|Darolutamide|Given PO
215040239|NCT05050084|DRUG|Degarelix|Drug
215040240|NCT05050084|DRUG|Flutamide|Drug
215040241|NCT05050084|DRUG|Goserelin|Drug
215040242|NCT05050084|DRUG|Histrelin|Drug
215040243|NCT05050084|DRUG|Leuprolide|Drug
215040244|NCT05050084|RADIATION|Radiation Therapy|Undergo RT
215040245|NCT05050084|DRUG|Relugolix|Drug
215040246|NCT05050084|DRUG|Triptorelin|Drug
215040247|NCT01920243|BEHAVIORAL|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
215040248|NCT01005290|DRUG|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
215040249|NCT01005290|DRUG|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
215040250|NCT06934473|OTHER|GIP(3-30)NH2 / study tool|Selective antagonist of the GIPR, GIP(3-30)NH2
214476781|NCT06814522|DRUG|Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate|25 mg, single dose of synthetic psilocybin
214476782|NCT06841900|DEVICE|Cochlear Implantation|Standard cochlear implantation
214476783|NCT06808867|DIETARY_SUPPLEMENT|Placebo|Eligible subjects will receive Placebo to take daily for six weeks
214476784|NCT06808867|DIETARY_SUPPLEMENT|Dietary Supplement with Active Ingredient Blend|Eligible subjects will receive Active supplement to take daily for six weeks
214476785|NCT06808841|DRUG|Sufentanil injection|Different concentrations of sufentanil were administered to three different subgroups of patients in the same way
214476786|NCT06808841|DRUG|Placebo|Placebo
214666282|NCT06023108|DEVICE|Orthokeratology|OK lenses will be used to evaluate the condition that causes dry eye in the treatment of myopia.
214874433|NCT02553031|DEVICE|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
214874434|NCT03874286|DIAGNOSTIC_TEST|Liver Transplant|Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsies are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.
214874435|NCT00906386|DRUG|Varenicline|oral, 1 mg twice daily, 12 weeks
214874436|NCT00906386|DRUG|placebo|oral, 1 mg twice daily, 12 weeks
214874437|NCT02817945|DRUG|68Ga-NOTA-3P-TATE-RGD|68Ga-NOTA-3P-TATE-RGD were injected into the patients before the PET/CT scans
215040251|NCT06934473|OTHER|Saline (NaCl 0,9 %) (placebo)|Placebo (NaCl 0,9%)
215040252|NCT06934473|OTHER|GIP(1-42)|Agonist of the GIPR, GIP(1-42)
215040253|NCT07145333|DRUG|Topotecan - usual|Topotecan Capsule
215040254|NCT07145333|DRUG|Topotecan - study|China Import Topotecan Capsule
215040255|NCT07140913|DRUG|Xanomeline/Trospium Chloride|Specified dose on specified days
215040256|NCT07140913|DRUG|Lithium|Specified dose on specified days
215040257|NCT07140913|DRUG|Valproate|Specified dose on specified days
215040258|NCT07140913|DRUG|Lamotrigine|Specified dose on specified days
215040259|NCT07140913|DRUG|Placebo|Specified dose on specified days
215040260|NCT07140172|PROCEDURE|Axillary lymph node dissection (ALND)|Surgical removal of lymphatic tissue within the anatomical boundaries of the axilla (standard of care in the upfront surgery setting in patients with cN+ BC)
215040261|NCT07140172|PROCEDURE|Axillary radiotherapy (ART)|Axillary irradiation
215040262|NCT06949553|OTHER|No study intervention|No visits or examinations, laboratory tests or procedures are mandated or required for this study. Patients will be recruited through a registry if patients who had participated in previous OASIS trials. After this referral, the study is conducted entirely electronically.
215040263|NCT07141082|OTHER|Art therapy combined with Exercise|The intervention program consists of one hour of expressive art intervention followed by one hour of exercise training. Art therapy sessions will be conducted in small groups of eight participants, facilitated by a part-time registered expressive art therapist. Each session begins with a 5-minute introduction and check-in, welcoming participants and encouraging them to share their current status. This is followed by a 10-minute mindfulness exercise designed to center participants and promote relaxation, preparing them for the creative activities ahead. The core of each session features a 20-minute art-making process focused on specific themes that guide participants in exploring their pain and personal narratives.
215040264|NCT07141082|OTHER|Exercise|each one-hour session in the exercise control group will involve progressive back and general reconditioning exercises, along with back care education to support self-management of LBP.
215040265|NCT07147855|BEHAVIORAL|Take your sexuality back|A 12 weeks group program.
214874438|NCT04001127|OTHER|High Intensity Functional Training|"The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing)."
215040266|NCT07148115|OTHER|Collect data on all pregnancies before and after diagnosis of SLE.|"For participants who are still alive, data are collected from interviews with patients using a prepared questionnaire that asks about all pregnancies and obstetrical events prior to and following the diagnosis of SLE.~For deceased patients, data are taken from the medical records of obstetrical events.~Data will be collected on anthropometric, biological, immunological, and histological features before and after the diagnosis of SLE, if available.~The activity and severity of the disease after diagnosis will be assessed using the recommended tools."
215040267|NCT07148076|BEHAVIORAL|Education Program|This intervention consists of a structured educational program specifically designed for educational staff in primary schools and kindergartens, focusing on the care of children with type 1 diabetes. The program includes interactive lectures, practical workshops, and case studies covering diabetes management, symptom recognition, emergency procedures, and day-to-day support for children with type 1 diabetes in educational settings. Unlike standard informational sessions or general health education, this intervention is tailored to address the unique challenges and responsibilities faced by school and kindergarten staff. The program is delivered in-person by certified diabetes educators and includes pre- and post-training assessments to measure changes in knowledge, perceptions, and attitudes. Participants are tracked using unique codes to allow for longitudinal comparison of results before, immediately after, and three months following the intervention.
214291328|NCT04951245|PROCEDURE|UC group: ultrasound-assisted CNSs guided|1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast. The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla. During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used. Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle . A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters. Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region. Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
214291329|NCT04951245|PROCEDURE|GC group: CNSs plus ICG dual-tracer-guided|The preparation of CNSs mapping was identical to that of the UC group. 1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast. A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs. All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed. The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
214874439|NCT05132036|OTHER|lung ultrasound|"Subjects are enrolled during their usual session in the hemodialysis unit of the Amiens University Hospital. Before starting the hemodialysis, lung ultrasound according to the 8 sites score and a measure of bioimpedance will be performed in dorsal decubitus. In a 2nd time, an echocardiography is realized. During haemodialysis session, biological analysis and clinical score will be assessed"
215040268|NCT07148583|DIETARY_SUPPLEMENT|BioAmicus Complete|Oral liquid probiotic (multistrain) administered by caregivers per protocol/label for 42 days to infants with functional GI symptoms. Given as drops by mouth; dosing and administration instructions per protocol. No other probiotic products allowed during the study. Concomitant medications and routine management may be used as clinically indicated. Adherence is recorded; lot/batch number captured.
215040269|NCT07148583|OTHER|Usual Care (No Probiotic)|Standard clinical management for infant functional gastrointestinal symptoms per local practice. No probiotic supplementation is provided during the study period. Participants follow the same visit and assessment schedule as the intervention arm. Concomitant medications and supportive care may be used as clinically indicated.
215040270|NCT07147868|BEHAVIORAL|Structured Education Program for Caregivers of Chemotherapy Patients|A structured educational intervention designed for caregivers of cancer patients undergoing chemotherapy, delivered in 30-45 minute sessions to groups of 4-5 participants. The program includes modules on self-efficacy, stress management, healthy lifestyle behaviors, interpersonal relationships, and nutrition based on the Mediterranean diet. Content covers evidence-based strategies for improving family health, psychological well-being, and dietary adherence. Sessions are conducted by a certified practitioner with 480 hours of family counseling training in a university hospital's medical oncology unit seminar room. The intervention aims to reduce caregiver burden, enhance psychological well-being, improve adherence to the Mediterranean diet, and promote family health, as assessed by the Family Health Scale (ASÖ), Mediterranean Diet Adherence Scale (MEDAS), and Psychological Well-Being Scale (PİO) at baseline (t0), post-intervention (t1), and 6 weeks follow-up (t2).
215040271|NCT07150338|DRUG|QRX-3|Compounded new drug regime
215040272|NCT07150338|DRUG|Eseronate|Neukidney innovative drug
215040273|NCT07148895|PROCEDURE|Post-surgical drain|During surgery, at the completion of the Sistrunk procedure, participants in the drain cohort will have a suction drain placed, which will be removed based on standard criteria prior to discharge from the hospital. Wound care following drain removal will be standardized, with instructions for patients to allow the area to heal naturally and to follow a regimen of cleaning and applying topical antibiotic ointment for several days.
215040274|NCT07148895|PROCEDURE|No post-surgical drain|Patients will be recovered in SOC manner from Sistrunk surgery without drain placement
214874440|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
215040275|NCT07150663|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nanocrystalline Megestrol Acetate Oral Suspension Nanocrystalline Megestrol Acetate Oral Suspension (125 mg/mL) was administered to the study group at 5 mL orally once daily (equivalent to 625 mg/day) until disease progression or completion of 8 weeks (maximum treatment duration: 8 weeks), whichever occurred first.
214874441|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
214874442|NCT06935162|DRUG|Teclistamab (Tec)|Teclistamab will be administered via a subcutaneous injection
214874443|NCT06936878|BEHAVIORAL|BOLSTER Program|This supportive care program includes six telehealth sessions led by a trained nurse to help patients with advanced gynecological or gastrointestinal cancers and their care partners build skills, manage symptoms, and cope with challenges. Two additional sessions will be help support care partners. Participants will also get access to the BOLSTER website, which offers personalized educational materials to support their well-being
214874444|NCT05999812|DRUG|all trans Retinoic Acid|ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days
214874445|NCT05999812|DRUG|Atezolizumab|Atezolizumab IV D1, 840 mg every 14 days
214874446|NCT05999812|DRUG|Bevacizumab|Bevacizumab IV D1, 10 mg/kg every 14 days
214874447|NCT06941181|OTHER|neurocognitive tasks|"1. risk-processing: Participants choose between two choices across 72 trials of a forced choice decision-making neurocognitive task (Holt and Laury, 2002). Each trial included a high and low monetary outcome with an associated probability of occurring. Each choice option is shown as a pie with ten slices represented probabilities, in which each piece corresponded to ten percent.~2. cognitive control: A multi-source interference task (MSIT; Bush et al., 2003) is used in which participants are presented with three digits and asked to identify the digit different from the others. In the neutral condition, the target's identity is congruent with its relative position. In the interference condition, the target's identity does not match its relative position. There are a total of 96 neutral trials and 96 interference trials."
214874448|NCT06537388|PROCEDURE|Ventilation type|Type of ventilation used during the EBUS procedure, either HFJV or IPPV
214874449|NCT06940310|BEHAVIORAL|Daily load-velocity-based training intensity adjustment.|At the beginning of the training session, the one-repetition maximum (1RM) will be estimated based on the individual's load-velocity relationship, using the general velocity associated with the 1RM for the exercises included in the session. Additionally, during the training sessions, intensity will be monitored, and load will be adjusted in real time by movement velocity.
214874450|NCT06940310|BEHAVIORAL|Training intensity prescription based on an initial 1RM estimation using load-velocity relationship|In the first training session, the one-repetition maximum (1RM) will be estimated based on the individual's load-velocity relationship, using the general velocity associated with the 1RM for the exercises included in the session. This 1RM will be used to prescribe exercise intensity throughout the intervention.
214874451|NCT06940310|BEHAVIORAL|Traditional training with intensity prescription based on 1RM testing.|The traditional training group will follow a training program using the traditionally employed methodology for assessing and prescribing training intensity in breast cancer survivors. This methodology is based on an initial 1RM estimation conducted through a 1RM test, which will be used to prescribe the training load throughout the intervention.
214874452|NCT02658838|DRUG|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
214874453|NCT02658838|DRUG|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
214874454|NCT02658838|DRUG|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
214874455|NCT02658838|DRUG|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
214874456|NCT06948968|OTHER|Social Role Participation Questionnaire|Validity and Reliability of the Turkish Version of the Adapted Social Role Participation Questionnaire in Ankylosing Spondylitis
214874457|NCT06955117|OTHER|Physical Therapy Exercises|"Experimental - McKenzie Technique (Group A) Intervention Type: Other: Physical Therapy Exercises~Other Names:~Intervention for low back pain~Description:~Soft Tissue Mobilization: Manual massage to release muscle tension (5-10 mins)~Lumbar Mobilization Techniques:~PA Mobilization (Posteroanterior glide) on the lumbar spine (Grade I-IV, 3-5 min per segment)~Side-lying Rotational Mobilization (3 sets × 10 reps)~Muscle Energy Techniques (METs):~Pelvic Tilts (3 sets × 10 reps)~Hip Flexor Stretch with Isometric Hold (3 sets × 10 sec per side)~Core Stabilization Exercises:~Bridge Exercise (3 sets × 10-15 reps)~Dead Bug Exercise (3 sets × 10 reps per side)~Modalities:~Hot Pack (15-20 mins) for relaxation before therapy~TENS (10 mins) for pain relief before mobilization"
214874458|NCT06955117|OTHER|Group B|"Manual Therapy (Group B)~Description:~Soft Tissue Mobilization: Manual massage to release muscle tension (5-10 mins)~Lumbar Mobilization Techniques:~PA Mobilization (Posteroanterior glide) on the lumbar spine (Grade I-IV, 3-5 min per segment)~Side-lying Rotational Mobilization (3 sets × 10 reps)~Muscle Energy Techniques (METs):~Pelvic Tilts (3 sets × 10 reps)~Hip Flexor Stretch with Isometric Hold (3 sets × 10 sec per side)~Core Stabilization Exercises:~Bridge Exercise (3 sets × 10-15 reps)~Dead Bug Exercise (3 sets × 10 reps per side)~Modalities:~Hot Pack (15-20 mins) for relaxation before therapy~TENS (10 mins) for pain relief before mobilization"
214874459|NCT06322784|DIETARY_SUPPLEMENT|Oat bran (dietary fiber)|"Dietary fiber, known as the seventh type of nutrients, refers to carbohydrate polymers that have health benefits for the human body, mainly derived from plant cell walls such as grains, fruits, and vegetables.Mediterranean cuisine is a dietary pattern"
214874460|NCT01707056|OTHER|Black Coffee|Taking Synthroid with 12 ounces of black coffee for 6 weeks.
214874461|NCT01707056|OTHER|Coffee with Milk|Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
214874462|NCT01707056|OTHER|Black Tea|Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
214874463|NCT01707056|OTHER|Water|Taking Synthroid with water for a period of 6 weeks.
215040276|NCT07150663|OTHER|Standard Therapy|Standard Therapy
215040277|NCT07149753|DRUG|MILTEFOSINE gel|Each patient will receive a 30 g tube of G-MTF with instructions and recommendations for use. The first dose will be in the FOSCAL clinical studies unit; subsequent doses will be applied at the patient's site of origin based on their autonomy, once a day (morning or night). Instructions include washing hands thoroughly, cleaning the lesion, applying a thin layer of gel, leaving it uncovered for at least 15 minutes, avoiding contact with water until the next dose, and storing the gel properly during treatment.
215040278|NCT07150442|PROCEDURE|POP surgery and PRP injection|Patient who undergo POP surgery will receive PRP injection
215040279|NCT07150442|PROCEDURE|POP surgery and placebo injection|patient who receive POP surgery and placebo injection
215040280|NCT07149714|DEVICE|iVAC 2L|The goal of this study is to investigate the safety and clinical efficacy of temporary mechanical support system with the iVAC 2L transaortic device in high-risk percutaneous coronary intervention (PCI) in Russia and Belarus. The POTOK trial will include patients with indications for elective, urgent and emergency PCI.
214874464|NCT00805467|DRUG|Fostamatinib Disodium (R935788)|50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
215040281|NCT07150273|DEVICE|UNIVELO Sub-Q 2mL|Test device
215040282|NCT07150273|DEVICE|Restylane Sub-Q 2mL|Comparator Device
215040283|NCT07148349|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
215040284|NCT07150117|BEHAVIORAL|Exercise|A supervised 12-week cycling-based aerobic exercise intervention performed twice per week.
215040285|NCT07150910|BEHAVIORAL|Interdental brush|In accordance with the manufacturer's recommendations, the IDBs were stated to be suitable for multiple uses. Participants were advised to replace the IDB once the bristles lost their shape or if the metal wire became damaged.
215040286|NCT07150910|BEHAVIORAL|Rubber bristles interdental cleaner|Two sizes were selected for the study: XS/S - Orange, designed for narrow and very narrow interdental spaces, and M/L - Turquoise, suitable for medium to large spaces. Since the tested RBICs were designed by the manufacturer for single use, participants were instructed to use a new RBIC at each application.
215040287|NCT07156071|OTHER|Serum 1|Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 1 group.
215040288|NCT07156071|OTHER|Serum 2|Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 2 group.
215040289|NCT07149974|DEVICE|EEG and fNIRS|For EEG and fNIRS, EEG signals will be recorded using the ANT Neuro eego rt 8 amplifier device (ANT Neuro, Hengelo, The Netherlands), with electrodes placed at C3, C4, F3, F4, Fpz, M1, M2, and GND (ground). fNIRS signals will be recorded using the Artinis Brite Lite fNIRS device(Artinis Medical Systems, The Netherlands). The overall channel configuration consists of eight sources and four detectors. Among these, four sources (T2a-d) and four detectors (R1-4) form four short-separation channels, while the remaining four sources and four detectors constitute six long-separation channels (T1-R1, T3-R1, T3-R2, T4-R3, T5-R3, T5-R4). The overall configuration is approximately arranged in two L-shaped layouts surrounding the F3 and F4 regions.
215040290|NCT07149974|DEVICE|EEG|EEG signals will be recorded using the ANT Neuro eego rt 8 amplifier device (ANT Neuro, Hengelo, The Netherlands), with electrodes placed at C3, C4, F3, F4, Fpz, M1, M2, and GND (ground).
214874465|NCT03283267|DRUG|Sodium Zirconium Cyclosilicate (ZS)|Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
215040291|NCT07149974|DEVICE|fNIRS|fNIRS signals will be recorded using the Artinis Brite Lite fNIRS device(Artinis Medical Systems, The Netherlands). The overall channel configuration consists of eight sources and four detectors. Among these, four sources (T2a-d) and four detectors (R1-4) form four short-separation channels, while the remaining four sources and four detectors constitute six long-separation channels (T1-R1, T3-R1, T3-R2, T4-R3, T5-R3, T5-R4). The overall configuration is approximately arranged in two L-shaped layouts surrounding the F3 and F4 regions.
215040292|NCT07150403|DRUG|Oxaliplatin intravenous|85 mg/m² IV over 2 hours ; 1 cycle each 15 days
215040293|NCT07150403|DRUG|5 FU bolus|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous)
215040294|NCT07150403|DRUG|Folinic acid|400 mg/m² in intravenous
215040295|NCT07150403|DRUG|5 FU continuous|2400 mg/m² intravenously over 46 hours
215040296|NCT07150403|DRUG|Irinotecan|180 mg/m² IV over 1h30
215040297|NCT07150403|DRUG|FRUQUINTINIB|5 mg capsule, taken orally, once daily for 3 weeks, followed by a 7-day break, then resumed (Day 1= Day 29).
215040298|NCT07150403|DRUG|BEVACIZUMAB|5 mg/kg over 90 minutes for the 1st course and in case of good tolerance the 2nd course should be administered over 60 minutes. The next courses should be administered in 30 minutes in case of good tolerance during the 2nd course
215040299|NCT07149610|DEVICE|M-health solution classified as Class I Medical Devices, equipped with a CE certificate. The m-health solution will be integrated with the EPR currently used by the CADs of the Marche region|"The m-health solution used in the study includes the following interfaces:~1. for the HCPs of the CADs:~   * a section of the EPR currently used (Metaclinic), to set the mobile application and to collect clinical data recorded by the patients;~  * a software to develop and monitor personalised diets (MetaDieta);~2. for the patients: two mobile applications, one for the monitoring of the clinical data and life style (DiaWatch Meteda) and one for the monitoring of the diet (MyDiet), with the latter accessible from a 'button' included in the first one.~The HCPs of the CADs, already having access to the EPR Metaclinic, will access a dedicated section for the setting of the target values and goals (e.g., glycaemia, physical activity, etc.) and for the activation of the app DiaWatch Meteda. After the connection of the app with Metaclinic, the data registered in the apps by the patients will be visible by the HCPs in the EPR dashboard."
214291330|NCT00945139|DRUG|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
214291331|NCT00945139|DRUG|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
214291332|NCT03370354|BEHAVIORAL|Observational|Ask patients about sleep quality and identify reasons of troubled sleeping patterns in the units.
214291333|NCT01797003|OTHER|High tibial osteotomy|
214874466|NCT04697836|PROCEDURE|ST|"After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients."
214874467|NCT05353010|DRUG|Tacrolimus|Tacrolimus 5mg (1 mg \* 5 capsules)
214874468|NCT05353010|DRUG|IN-A001(Tegoprazan)|IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)
215040300|NCT07158073|DEVICE|FiO₂ titration, under the guidance of ORI|In Group R, FiO₂ was titrated between 30% and 50% under the guidance of ORI and SpO₂ values. Accordingly, if SpO₂ was ≥ 98%, FiO₂ was reduced in 5% increments to a minimum of 30%, aiming to achieve an ORI value of 0 or as close to 0 as possible.
215040301|NCT07158073|DEVICE|Conventional oxygen administration|In Group C, FiO₂ was maintained at 50% throughout the surgery, provided that SpO₂ remained ≥ 98%.
215040302|NCT07155161|OTHER|Assesment|assessment
215040303|NCT07160933|OTHER|No Intervention: Observational Cohort|This study phase is a qualitative exploration of participants' preferences and recommendations for a psychosocial intervention.
215040304|NCT07159048|DEVICE|Multimodal Tumor Thermal Therapy System|All subjects were treated with a multi-modal thermal therapy system (Shanghai MAaGI Medical Technology Co., Ltd.) following a temperature-controlled tumor ablation protocol. Complete ablation of intrahepatic lesions was achieved, resulting in no evidence of disease (NED) within the liver. For lesions that could not be fully ablated in a single session, two treatment sessions were performed to attain intrahepatic NED status.
215040305|NCT07159048|DEVICE|Radiofrequency Ablation System or Microwave Ablation System|All subjects were treated with a radiofrequency ablation system or microwave ablation System. Complete ablation of intrahepatic lesions was achieved, resulting in no evidence of disease (NED) within the liver. For lesions that could not be fully ablated in a single session, two treatment sessions were performed to attain intrahepatic NED status.
215040306|NCT07159763|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
215040307|NCT07159763|COMBINATION_PRODUCT|Placebo|Placebo to match
215040308|NCT07161453|DRUG|SOX plus PD-1 inhibitor|SOX or XELOX plus PD-1 inhibitor
215040309|NCT07161453|DRUG|PD-1 / PD-L1 monoclonal antibody|PD-1/PD-L1 monoclonal antibody
215040310|NCT07161453|DRUG|SOX Chemotherapy|SOX or XELOX
215040311|NCT07161453|DRUG|Tegafur-Ugotex or Capecitabine|Tegafur-Ugotex or Capecitabine
215040312|NCT07159321|OTHER|Comprehensive geriatric assessment|Functional status will be evaluated using Activities of Daily Living (ADL) (assessing bathing, dressing, toileting, transferring, eating, and continence; Katz, 1970) and Instrumental ADL (IADL) (assessing shopping, cooking, medication management, phone use, housework, laundry, transportation, and finances; Lawton \& Brody, 1969). Nutritional status will be measured via the Mini-Nutritional Assessment-Short Form (MNA-SF) (Arabic version; Abd-Al-Atty et al., 2012), a 6-item tool (appetite, weight loss, mobility, illness, neuropsychological issues, BMI) scored 0-14, classifying patients as well-nourished (≥12), at risk (8-11), or malnourished (0-7; Rubenstein et al., 2001). Cognition will be assessed using the Saint Louis University Mental Status (SLUMS) exam (Arabic version; Abdelrahamn et al., 2014), a 30-point test evaluating calculation, orientation, memory, fluency, and visuospatial function, with dementia thresholds at \<20 (\<12 years education) or \<21 (≥12 years; Tariq et al., 2006).
215040313|NCT07159321|OTHER|European Organization for Research and Treatment-Quality of life questionnaire|"Quality of life assessment by European Organization for Research and Treatment-Quality of life questionnaire and breast cancer-specific module (EORTC QLQ-C30)and QLQ-BR23)~EORTC QLQ-C30 is a validated tool designed to measure cancer patients' physical, psychological and social functions. It consists of 30 items measuring Global Health status (2 items), Functional scales (15 items) and Symptoms scales/items (13 items). Items were measured using a 4-point Likert Scale ranging from Not at all (1) to Very much (4).~EORTC-BR23 consists of 23 items which measure two main scales Functional Scale (8 items) and Symptoms scales (15 items). Items measured using 4-point Likert Scale ranging from Not at all (1) to Very much (4)."
215040314|NCT07159321|OTHER|Clinical Frailty Scale|Frailty will be assessed using the Clinical Frailty Scale (CFS), a validated and widely used tool developed by (Rockwood et al., 2005). The CFS is a 9-point ordinal scale that categorizes older adults based on their level of physical fitness, functional independence, and comorbidities, ranging from 1 indicate very fit to 9 indicate terminally ill. Participants were evaluated by trained clinicians based on their clinical judgment, incorporating information from patient interviews. The scale provides a practical and reliable measure of frailty in geriatric populations and has demonstrated strong predictive validity for adverse health outcomes including hospitalization, institutionalization, and mortality.
215040315|NCT07159659|DIETARY_SUPPLEMENT|MCT Diet|MCT diet for patients following lung resection
215040316|NCT07159087|DEVICE|Sirolimus Coated PTCA Balloon Catheter(Genoss® SCB)|Drug Coated Balloon
215040317|NCT07159087|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)|Drug Coated Balloon
215040318|NCT07159542|BEHAVIORAL|listening intervention|Music or podcast listening intervention
215040319|NCT07159542|BEHAVIORAL|Neuropsychology assessment|Neuropsychology assessment
215040320|NCT07159542|OTHER|brain imaging examination|EEG: recording of neural dynamic
215040321|NCT07159165|PROCEDURE|Minimally invasive surgical treatment for benign prostatic obstruction|"Surgical management of BPO using contemporary minimally invasive procedures, including but not limited to: Transurethral resection of the prostate (TURP), Holmium laser enucleation of the prostate (HoLEP), Thulium laser enucleation of the prostate (ThuLEP), Rezum® water vapor thermal therapy.~Procedures are performed according to standard clinical practice at each participating center, with perioperative and follow-up data prospectively recorded in the MIUS registry."
214874469|NCT05353010|DRUG|IN-A001(Tegoprazan) + Tacrolimus|IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)
214874470|NCT01761370|PROCEDURE|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
215040322|NCT07159672|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving) performed as part of standard clinical care for patients with periampullary malignant neoplasms. This procedure is not assigned by the study protocol, but is the exposure of interest. The study observes nutritional, metabolic, molecular, and imaging outcomes at baseline (preoperative), and at 3 and 6 months after hospital discharge.
215040323|NCT07160010|DIAGNOSTIC_TEST|Sophia Herditary Cancer Solution|To compare the performance of MGI's DNBSEQ-G400 sequencing instrument with the gold standard Illumina instruments (MiSeq and NextSeq 550) using the same capture DNA libraries constructed with Sophia Genetics assays.
215040324|NCT07161232|BEHAVIORAL|Standardized Postoperative Rehabilitation Protocol|"This intervention is a standardized, progressive rehabilitation protocol for patients after lumbar disc herniation surgery, delivered under the guidance of a senior physical therapist. The protocol aims to improve pain, restore function, and prevent complications through core stability exercises and neurodynamic techniques. The exercises are performed once daily and progressed based on patient tolerance. The protocol consists of two phases:~Initial Phase ( commencing postoperatively): Includes: 1) Transverse abdominis activation; 2) Sit-to-stand training with abdominal bracing; 3) Four-point kneeling rockbacks for spinal mobility; 4) Neural mobilization techniques (performed in sitting); 5) Neural sliding techniques (performed in sitting).~Progressive Phase: Builds upon the initial exercises by increasing the range of motion, adding isometric hold times, and integrating cervical movement with neural techniques to increase difficulty and intensity."
215040325|NCT07160556|OTHER|Observational|no intervention was required for this cross sectional study
215040326|NCT07158619|DIETARY_SUPPLEMENT|OIT with cashew nut protein|After 8 months of continued oral immunotherapy (OIT) with cashew nuts, patients will undergo hospital-based assessments, including skin prick testing, laboratory evaluations, and an open Oral Food Challenge (OFC) to assess desensitization. Patients who had a negative OFC after 3 months in the initial phase-confirming desensitization-will skip the pre-break OFC and proceed directly to the next stage. Following a 4-week interruption in OIT, patients will return for a final hospital visit, during which a concluding OFC will be conducted to evaluate sustained unresponsiveness. Additional laboratory tests and skin prick testing will also be performed during this visit.
215040327|NCT07159191|DRUG|Envafolimab Injection, Axitinib Tablets|"Envafolimab + Axitinib~* Envafolimab 400 mg, subcutaneous injection, day 1, every 3 weeks;~* Axitinib 5 mg, orally, twice daily"
215040328|NCT07159022|PROCEDURE|High Flow Nasal Cannula Oxygenation|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
215040329|NCT07159022|PROCEDURE|Face Mask Oxygenation|conventional oxygen therapy will be administered through common mask with a flow up to 6 Liters per minute
215040330|NCT07160842|BEHAVIORAL|Hand hygiene intervention|The educational intervention consisted of a two-part training session: (i) a thirty-minute didactic session introducing the 7-step alcohol-based hand rub (ABHR) technique (14), the importance of proper hand hygiene for infection prevention; and (ii) a practical component on hand hygiene with real-time feedback.
215040331|NCT07161375|DEVICE|Infrared Thermography|Infrared thermography will be used to predict the success of an erector spinae block by measuring the temperature difference between the blocked and unblocked sides.
215040332|NCT07160816|DRUG|Insulin icodec|Participants with T1D will be treated with commercially available insulin icodec.
215040333|NCT07159412|DRUG|Vonoprazan-amoxicillin combined with Huazhi Rougan Granule|Vonoprazan-amoxicillin dual therapy combined with Huazhi Rougan Granule
215040334|NCT07159412|DRUG|Vonoprazan-amoxicillin combined with Huazhi Rougan Granule placebo|Vonoprazan-amoxicillin dual therapy combined with Huazhi Rougan Granule placebo
215040335|NCT07159464|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
215040336|NCT07158996|DRUG|Biological: cizutamig|Cizutamig will be dosed according to the protocol.
215040337|NCT07159282|OTHER|XWRAP|Application of XWRAP + standard of care for up to 12 weeks.
214476787|NCT06842862|DEVICE|GGED|This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
214476788|NCT06841068|BIOLOGICAL|Amniotic fluid or placental CD117 stem cells|CD117 (c-Kit) positive stem cells, extracted from ethical fetal sources such as amniotic fluid and placental tissue.
214476789|NCT06841965|DRUG|Intravenous thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
214476790|NCT06596018|RADIATION|SBRT|Target the primary tumor region with a single dose of 8Gy using 6MV-X rays, administered once a day for three consecutive days.
214476791|NCT06596018|DRUG|Chemotherapy|Continue to follow the original chemotherapy regimen（anthracycline and/or taxane based regimens）
214476792|NCT06841237|OTHER|Xiang Lei Ointment plus Clinical standard treatment protocols|A therapy for chronic wound healing
214874471|NCT01761370|PROCEDURE|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
214874472|NCT02656888|DRUG|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
214874473|NCT02656888|DRUG|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
214874474|NCT04513288|DIETARY_SUPPLEMENT|Experimental treatment L-citrulline (Protéocit®)|Enteral administration of citrulline for 5 days.
214874475|NCT04513288|OTHER|Placebo treatment|Enteral administration of iso-nitrogenous placebo for 5 days.
215040338|NCT07159204|DRUG|Paclitaxel polymer micelle immunocombination|Paclitaxel polymer micelle immunocombination
214476793|NCT06841237|OTHER|Clinical standard treatment protocols|A therapy for chronic wound healing
214476794|NCT06777576|DEVICE|Hands-free exoskeleton|"A device trainer specialist from the investigation site will deliver training sessions with the exoskeleton to pair of participants (a pair corresponds to an individual with SCI and his/her companion). The device trainer will follow the progression of the pair through the training program and ensure they learn all the device basic skills. Each training session lasts an average of 1.5 hours, variations according to the user's learning pace and tolerance. During the sessions with the exoskeleton, the participants will engage in mobility activities on different surfaces and perform Activities of Daily Living in simulated environments such as kitchen, bathroom, elevators and outdoor spaces."
214476795|NCT02905331|DRUG|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
214476796|NCT02905331|DRUG|Placebo|Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
214476797|NCT01385202|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
214476798|NCT06594497|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
214476799|NCT06594497|OTHER|Conventional Physiotherapy + Kinesthetic motor imagery training|Conventional Physiotherapy + Kinesthetic motor imagery training
215040339|NCT07161544|BIOLOGICAL|AAVB-039|Single subretinal administration
215040340|NCT07159971|DEVICE|School B|Nutritional therapy supported by a mobile application.
214476800|NCT03681262|DEVICE|High frequency spinal cord stimulation|We will use Senza® (Nevro Corp., Palo Alto, CA) trial and implant systems to deliver high frequency spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. High frequency waveform will be delivered with following parameters: frequency of 10,000 hertz, pulse width of 20 microseconds, and amplitude of 0-15 milliamperes.
214476801|NCT03681262|DEVICE|Burst spinal cord stimulation|We will use BusrtDRTM (Abbott Saint Jude Medical, St. Paul, MN) trial and implant systems to deliver burst spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. The parameters of the stimulation are as below: each burst includes 5 pulses of electrical stimulation at intra-burst frequency of 500 hertz without time for discharge in between pulses. These bursts will be repeated at inter-burst frequency of 40-60 hertz. The amplitude will range between 0 and 15 milliamperes.
214476802|NCT04305366|OTHER|Tissue collection|Blood draw, Fine Needle Aspiration, Saliva Swab, Tumor/tissue sample
214476803|NCT03368729|DRUG|Niraparib|Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
214666283|NCT06023108|DEVICE|Spectacles|Spectacles will be used to evaluate the condition that causes dry eye in the treatment of myopia.
214666284|NCT02631161|OTHER|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
214666285|NCT02631161|OTHER|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
214666286|NCT05038761|DEVICE|CGM System|"Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days."
214476804|NCT03368729|DRUG|Trastuzumab|Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
214476805|NCT04860765|DEVICE|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
214476806|NCT06751862|DIETARY_SUPPLEMENT|150g of fat with glucose|The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of glucose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
214666287|NCT05038761|PROCEDURE|Standard Venous Blood Glucose Test|Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
214666288|NCT05421754|DEVICE|ANNE Sleep|ANNE Sleep system for 1 night with HST followed by 3 nights of ANNE Sleep system alone.
214666289|NCT01449825|DRUG|Pazopanib use|Treatment with pazopanib
214666290|NCT01449825|DRUG|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
214666291|NCT05741203|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound
215040341|NCT07159971|OTHER|Control|Conventional nutritional treatment.
215040342|NCT07159516|DIAGNOSTIC_TEST|Diagnostic interview|SCID-5 Clinician Version (SCID-5-CV) was used as gold standard method for determining if diagnostic criteria of PTSD was met or not (First, 2023). SCID-5-CV has been validated for use via telephone with good results for PTSD (Osorio et al., 2019). Only the PTSD-chapter was used, and exclusively birth-related traumatic experiences were considered. This was done achieved by adding a question to the interview guide, addressing potentially traumatic experiences associated with healthcare during a physical examination, operation, intensive care or childbirth.
215040343|NCT07161297|DRUG|Intravenous remimazolam (5 mg initially, with optional 2.5 mg boluses) plus fentanyl (100 mcg) for procedural sedation.|\- Remimazolam + Fentanyl IV fentanyl 100 mcg is given first, followed after 1 minute by IV remimazolam 5 mg over 1 minute. Additional 2.5 mg boluses may be given every 2 minutes as needed. Colonoscopy starts 1 minute after sedation. Vital signs are monitored throughout.
215040344|NCT07161297|DRUG|Intravenous midazolam (3 mg initially, with optional 3 mg boluses) plus fentanyl (100 mcg) for procedural sedation.|\- Midazolam + Fentanyl (≤1000 caratteri) IV fentanyl 100 mcg is given first, followed after 1 minute by IV midazolam 3 mg over 1 minute. Additional midazolam may be administered based on clinical judgment. Colonoscopy starts 1 minute after sedation. Vital signs are monitored throughout.
215040345|NCT04817189|DRUG|NEPA (300mg netupitant/0.5mg palonosetron)|Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
215040346|NCT04817189|DRUG|Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)|Standard of care will be administered on Day 1 of each cycle.
214476807|NCT06751862|DIETARY_SUPPLEMENT|150g of fat with fructose|Description: The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of fructose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
214476808|NCT06751862|DIETARY_SUPPLEMENT|150g of fat with sucrose|The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of sucrose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
214476809|NCT06751862|DIETARY_SUPPLEMENT|Short-term (7 days) fructose restriction|Subjects will receive a package of glucose and selected foods without fructose to supplement their diet. For seven days they then will adhere to the diet without fructose and keep the detailed dietary record.
214666292|NCT01330290|DRUG|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
214874476|NCT01908907|DIETARY_SUPPLEMENT|DHA oil|Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
214874477|NCT01908907|DIETARY_SUPPLEMENT|(MCT) Control oil|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
214874478|NCT00761657|DRUG|Roxadustat|Capsule
214874479|NCT00761657|DRUG|Placebo|Capsule
214874480|NCT02989324|DRUG|MisoprostoL|Vaginal MisoprostoL
214874481|NCT02989324|DEVICE|Foley Catheter|Misoprostol Plus Foley Catheter
214874482|NCT03593538|DRUG|Metformin|Metformin capsule
214874483|NCT03593538|DRUG|Placebo|Sucrose filler in gel capsules
215040347|NCT04817189|DRUG|Dexamethasone, 8 mg (oral) or equivalent IV dose|Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
214874484|NCT05329324|OTHER|Questionnaire for study group|Demographic features, Stage and Type, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
214874485|NCT05329324|OTHER|Questionnaire for control group|Demographic features, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
215040348|NCT05056896|DRUG|Aspirin|Capsule taken orally
215040349|NCT05056896|OTHER|Placebo|Capsule taken orally
214874486|NCT01393886|PROCEDURE|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
214874487|NCT02173314|OTHER|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
214874488|NCT00999323|DEVICE|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
215040350|NCT06270407|DRUG|Tranexamic Acid 100 MG/ML|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
215040351|NCT06270407|DRUG|0.9%sodium chloride|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
215040352|NCT06433700|OTHER|BAS|NOMESCO (Nordic Medico-Statistical Committee) Classification of Surgical Procedures (KJDF10 \& KJDF11 \[gastric bypass\]; KJDF20 \& KJDF21 \[gastric banding\]; KJDF40, KJDF41, KJDF96 \& KJDF97 \[gastric sleeve\]).
215040353|NCT06433700|OTHER|Non-BAS|Patients without BAS codes
215040354|NCT00561990|DRUG|Nimotuzumab|
215040355|NCT06224023|DIAGNOSTIC_TEST|Determination of presepsin levels in ascites|A diagnostic paracentesis will be performed and presepsin level will be determined in ascites.
215040356|NCT00492453|PROCEDURE|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
215040357|NCT05157061|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a prebiotic supplement is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
214476810|NCT06753747|DRUG|Palbociclib|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle.
214476811|NCT06753747|DRUG|Afatinib(30mg)|Afatinib will be administered orally at a dose of 30 mg once daily (QD) in each 4-week cycle.
214666293|NCT04687124|DIETARY_SUPPLEMENT|Fish oil|Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
214666294|NCT04687124|OTHER|standard care|No specified intervention
214666295|NCT02095561|OTHER|HPV self testing|Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
215040358|NCT05157061|DIETARY_SUPPLEMENT|Maltodextrine|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a placebo is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
215040359|NCT01334918|DRUG|regadenoson|Administered by intravenous bolus.
215040360|NCT01334918|RADIATION|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Administered by intravenous infusion
215040361|NCT01334918|RADIATION|Contrast|Administered by intravenous infusion.
215040362|NCT01334918|PROCEDURE|Single Photon Emission Computed Tomography|Procedure/Surgery
215040363|NCT01334918|PROCEDURE|Multidetector Computed Tomography|Procedure/Surgery
215040364|NCT03172143|PROCEDURE|Mesenteric Sparing Ileocolic Resection|In this resection, the mesentery will be spared, or left in situ during resection.
214874489|NCT05435937|BEHAVIORAL|Partnering for change (P4C-Swe)|"P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation."
214874490|NCT05435937|BEHAVIORAL|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
214874491|NCT01793948|DRUG|metformin hydrochloride|Given PO
214874492|NCT01793948|OTHER|placebo|Given PO
214874493|NCT01793948|OTHER|laboratory biomarker analysis|Correlative studies
214874494|NCT03601130|DEVICE|HydroxyColl Bone Graft Substitute|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
214874495|NCT03601130|DEVICE|DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
214874496|NCT05968118|DRUG|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
214874497|NCT05968118|DRUG|Placebo|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo
214874498|NCT04060095|PROCEDURE|standardized noxious stimulus under general anesthesia.|"50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient."
214874499|NCT01707264|DRUG|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
214874500|NCT06223386|BEHAVIORAL|Designed on-line course A with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided at the beginning of the 3-month intervention. Participants can consult with the dietitian via the APP on their mobile phones during the intervention period. These materials will encompass dietary and physical activity guidelines by the government in Taiwan.
214874501|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education.
215040365|NCT03172143|PROCEDURE|High Ligation Ileocolic Resection|"In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen."
215040366|NCT00414375|PROCEDURE|Operation on Admission|Laparoscopic appendectomy on admission
215040367|NCT00414375|PROCEDURE|Drainage and Interval Appendectomy|drainage with interval appendectomy
215040368|NCT02273089|DEVICE|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
215040369|NCT02842593|BEHAVIORAL|Lower-repetition, heavier-load|8-12 reps/set at \~80% 1 repetition maximum
214476812|NCT06753747|DRUG|Afatinib(40mg)|Afatinib will be administered orally at a dose of 40 mg once daily (QD) in each 4-week cycle.
214666296|NCT06448156|DIAGNOSTIC_TEST|"cardiac arrest and sudden death"|"Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated"
215040370|NCT02842593|BEHAVIORAL|Higher-repetition, lighter-load|20-25 reps/set at \~30% 1 repetition maximum
215040371|NCT02200601|DEVICE|Seipher Wellness|
215040372|NCT06718738|BIOLOGICAL|IM96 CAR-T Cells|IM96 CAR-T Cells, 12×10\^8 CAR-T cells, 20×10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
215040373|NCT01583673|OTHER|Amino Acid Formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
215040374|NCT01583673|OTHER|Amino Acid formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
215040375|NCT05807568|OTHER|NCAEM EM-SART Pre-Screen|Participants will be verbally asked the 3 participant questions on the NCAEM EM-SART Pre-Screen either directly or with support of hospital approved telephonic interpreters. Answers will be documented by the investigator digitally. Participants will be interviewed one time for a duration of approximately 15 minutes. No further action will be taken on study participants with negative elder mistreatment screens, unless findings concerning for emotional distress are identified by the investigator. If emotional distress is identified, these observations will be communicated to Geriatric Medicine team in person or via secure/encrypted email, with recommendations to follow-up with the participant about the results and take appropriate care actions. Study participants with positive elder mistreatment will have results shared with the study participant directly and with the Geriatric Medicine primary team via secure/encrypted email.
214874502|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 3 months.
214874503|NCT06223386|BEHAVIORAL|Designed on-line course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 6-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 6 months.
214874504|NCT01188512|BIOLOGICAL|BPZE1|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
214874505|NCT01188512|BIOLOGICAL|Placebo|Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
214874506|NCT02420912|DRUG|Ibrutinib|Given PO
214874507|NCT02420912|OTHER|Laboratory Biomarker Analysis|Correlative studies
214874508|NCT02420912|BIOLOGICAL|Nivolumab|Given IV
214874509|NCT00610610|DRUG|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
214874510|NCT00610610|DRUG|Placebo|Same shape Placebo
214874511|NCT02673814|BIOLOGICAL|durvalumab|
214874512|NCT02673814|BIOLOGICAL|bavituximab|
214874513|NCT04533997|DRUG|Hypertonic saline solution plus intravenous furosemide|"Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide \> 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%"
214874514|NCT04533997|DRUG|Intravenous furosemide|"Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide \> 160 mg"
214874515|NCT02218554|GENETIC|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
214874516|NCT05188677|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
214874517|NCT05188677|BIOLOGICAL|Comirnaty Vaccine|intramuscular injection
214874518|NCT05188677|BIOLOGICAL|Vaxzevria Vaccine|intramuscular injection
214874519|NCT05188677|BIOLOGICAL|CoronaVac Vaccine|intramuscular injection
214874520|NCT04394039|OTHER|Public space exposure|landscapes with nature and/or classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to noncontemplative ones.
214874521|NCT03900455|DEVICE|Hydrocellular polyurethane foam multilayer dressing|Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
214874522|NCT03900455|PROCEDURE|Standard preventive care|Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
214874523|NCT00270855|PROCEDURE|Arm Crank Ergometry|Use of an upper body cycle to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
214874524|NCT00270855|PROCEDURE|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
214874525|NCT05424679|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention is a brief intervention that directly targets suicide risk with demonstrated efficacy and is a recommended best practice for suicide prevention. The intervention aims to provide participants with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when under particular stress. It also includes a series of brief telephone calls to revise the safety plan and facilitate connections to care. The study team will adapt the intervention to target a larger range of mental health distress.
214874526|NCT05424679|BEHAVIORAL|Caring Contacts|Caring contacts is a cost and time effective suicide prevention intervention. It traditionally utilizes letters and postcards that are sent to an individual to remind them that they are cared about and that they matter. Research suggests that this intervention significantly reduces the likelihood of dying by suicide and suicide attempt over a person's lifetime. This intervention has the potential to reach more individuals at risk in the community. In this study, the research team will allow participants to receive these messages by postcard/MMS and will adapt the intervention to align with cultural values.
215040376|NCT01317303|PROCEDURE|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
215040377|NCT01317303|PROCEDURE|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
215040378|NCT01317303|PROCEDURE|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
215040379|NCT01317303|PROCEDURE|iTBS|190 seconds of intermittent theta-burst stimulation
215040380|NCT05981326|PROCEDURE|Biopsy|biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment
215040381|NCT05981326|PROCEDURE|Blood samples|Centralized blood samples will be performed at inclusion + evaluation visits
215040382|NCT05981326|BEHAVIORAL|Questionnaires|Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion
215040383|NCT00765219|BEHAVIORAL|CBT|10-12 weekly sessions of CBT in person or over the telephone.
215040384|NCT00765219|OTHER|Usual Care|Treatment as usual provided by participants' physician(s)
215040385|NCT05188638|DRUG|SoftOx Inhaled Solution (SIS)|SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
215040386|NCT05188638|DRUG|Placebo|Sterile isotonic saline
215040387|NCT02275507|DEVICE|Masimo Rainbow Sensor|Non-Invasive Hemoglobin Measurement
215040388|NCT01619917|DEVICE|Fractional Vascular Laser|laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
215040389|NCT02025998|DRUG|Ibudilast|Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
214291334|NCT03564847|BEHAVIORAL|LTP Plus|"LTP+Dads is a 12 - session group integrated parenting intervention: i.e LTP (Learning through Play) which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment. In each stage, there are five areas of child development: sense of self, physical, relationships, understanding, and communication. All areas are written in simple, low-literacy language.~Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~Third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
215040390|NCT02025998|OTHER|Matched placebo|A matched placebo (suggar pill) will be administered as a control condition.
215040391|NCT03362268|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
215040392|NCT03362268|DRUG|omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
215040393|NCT00286299|OTHER|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
215040394|NCT00286299|OTHER|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
214291335|NCT01014520|DRUG|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
214291336|NCT01554423|OTHER|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
214291337|NCT01554423|BEHAVIORAL|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
215040395|NCT00286299|OTHER|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
215040396|NCT05949879|OTHER|Pecan LOW|Participants are provided with a quantity of pecans that delivers 6% of the participant's estimated energy needs for 28 days.
215040397|NCT05949879|OTHER|Pecan MID|Participants are provided with a quantity of pecans that delivers 13% of the participant's estimated energy needs for 28 days.
215040398|NCT05949879|OTHER|Pecan HIGH|Participants are provided with a quantity of pecans that delivers 20% of the participant's estimated energy needs for 28 days.
215040399|NCT05949879|OTHER|CONTROL|Participants are asked to maintain their current habitual diet and to avoid any tree nut/peanut consumption for the entire 28-day intervention period.
215040400|NCT06403449|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R (G-WET) is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete.The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
214476813|NCT06753747|DRUG|Afatinib(RP2D)|In the Phase 2 study, the recommended Phase 2 dose (RP2D) of Afatinib, determined during the Phase 1b portion, will be utilized.
214476814|NCT06594055|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitoring is a wearable device that continuously collects glucose data from interstitial fluid.
214476815|NCT06594055|DEVICE|Self-monitoring blood glucose|The control group used self-monitoring blood glucose (SMBG) for two weeks with a manual food diary, followed by diet education. They then repeated SMBG with a food diary three months later, with a final follow-up at the 6-month mark.
214476816|NCT06594055|DEVICE|AI food camera|The AI food camera automatically detects the contents and nutritional information of foods.
215040401|NCT06403449|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
215040402|NCT06261255|PROCEDURE|ATT + EMD|All surgical treatments will be performed by the same experienced periodontist (IP) after the administration of local anesthesia. Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the remaining fragments will be extracted as minimally invasively as possible. A tooth-supported surgical guide will be used to prepare the recipient site following the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the CARP model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if osteotomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, EMD will be applied to the root surface of the donor tooth
215040403|NCT04372485|BEHAVIORAL|mHealth Intervention|Adolescents will receive text messages to facilitate treatment adherence
215040404|NCT03381599|DRUG|Filgrastim Injection|Filgrastim of 10 ug/kg/day will be given for four serial days.
215040405|NCT03292237|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
215040406|NCT01295489|OTHER|Laboratory Biomarker Analysis|Correlative studies
215040407|NCT05918848|DEVICE|Filme Gyno-V® Vaginal Ovules|Administration of tocopherol (Filme Gyno-V® Vaginal Ovules) for 14 days
215040408|NCT04368208|OTHER|Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery|The Edinburgh questionnaire is a self questionnaire validated for postnatal depression between 4 and 6 weeks postnatal
215040409|NCT01068184|DRUG|AZD6553|Single or multiple oral dose
215040410|NCT01068184|DRUG|Placebo|single or multiple oral dose
215040411|NCT01051245|BEHAVIORAL|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
214476817|NCT06594055|DEVICE|Food diary|A food diary is a record in which the user manually writes down the consumed foods and their amounts.
214476818|NCT05774665|DRUG|Omega 3|Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)
214476819|NCT05774665|OTHER|Placebo|Placebo consisting of soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)).
214476820|NCT05599724|OTHER|Biocollection|"For the FERTITHEQUE, will be collected:~* Clinical characteristics~* Biological characteristics measured as part of the usual follow-up~* consultation n°2 : DNA~* consultation n°2 : plasma~* consultation n°2 : serum~* consultation n°2 : vaginal microbiota~* consultation n°3 : follicular fluid (puncture fluid)~* consultation n°4 : plasma~* consultation n°4 : vaginal microbiota."
214476821|NCT06592989|DRUG|sorafenib, gefitinib|Sofantinib: 250mg, QD, oral; Gefitinib: 250mg, QD, oral.
214476822|NCT04370834|BIOLOGICAL|Tocilizumab|Given IV
214666297|NCT03880812|OTHER|Societal cost|Annual societal cost information to the US for carpal tunnel release surgery was displayed.
214476823|NCT06355986|BEHAVIORAL|Alert-based computerized decision support|An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the provider that his or her patient is at risk for stroke due to AF, and that there is no order for anticoagulation. Clinicians who receive the computer alert will have three options: 1) access an order template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence-based clinical practice guidelines to learn more about stroke prevention in AF, or 3) continue with order entry after providing an explanation for why anticoagulation was not prescribed.
214666298|NCT02580058|BIOLOGICAL|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
214666299|NCT02580058|DRUG|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
214666300|NCT03593694|BEHAVIORAL|TECH DM-BAT|Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
214666301|NCT03593694|BEHAVIORAL|TECH DMBAT Active Comparator|Technology delivered diabetes education and home tele monitoring
214666302|NCT03593694|BEHAVIORAL|TECH DMBAT Other|Technology delivered diabetes education
214666303|NCT05125653|PROCEDURE|Indocyanine Green Fluorescent Laparoscopic Cholangiography|Indocyanine Green Fluorescent Cholangiography
214666304|NCT05125653|PROCEDURE|White Light|Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
214666305|NCT04837911|DEVICE|Spirobank Smart|Patients using the Spirobank Smart
214666306|NCT05382481|DIAGNOSTIC_TEST|Peak value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the peak level of anti-Xa after 4 to 6 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the peak value of anti Xa.
214476824|NCT05032066|DRUG|HZN-825|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
215040412|NCT01051245|OTHER|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
214666307|NCT05382481|DIAGNOSTIC_TEST|Trough value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.
214666308|NCT05382481|DIAGNOSTIC_TEST|Control Group|This group will receive fixed dose of low molecular weight heparins (LMWH) 40mg, once a day. And will not detect the level of anti-Xa
214666309|NCT04210570|DEVICE|Memsorb|Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit
214666310|NCT04210570|DRUG|Chemical granulate absorber|Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
214874527|NCT04292041|OTHER|Fasting mimicking diet|"3 cycles of programmed nutrition using a fasting mimicking diet (Chemolieve (R)), each cycle consisting of 4 days. Pre and post nutritional cycles, clinical and metabolic assessments are taken, as per protocol. Allowing for a 3 month washout time, the 'post' assessment is planned approximately 6 months from the initial (pre) assessment."
214874528|NCT04934059|DRUG|Yuxuebi tablet|0.5g/ tablet
214874529|NCT04934059|DRUG|Placebo tablet|0.5g/ tablet
214874530|NCT00142389|BIOLOGICAL|pneumococcal polysaccharide and protein conjugate vaccines|
214874531|NCT03365557|PROCEDURE|Airway peak pressure|Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
214874532|NCT02152605|DRUG|UMEC/VI|Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
214874533|NCT02152605|DRUG|Placebo|Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
214874534|NCT05366140|OTHER|Prospective follow-up of patients who have received instrumented lumbar arthrodesis supplemented the Implanet Jazz System(TM)|To assess the clinical outcomes of patients receiving standard of care Implanet Jazz System(TM) at the time of their instrumented lumbar arthrodesis.
214874535|NCT02271347|DRUG|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
214874536|NCT04524208|DRUG|Cabozantinib|Cabozantinib is administered orally at the dose of 60 mg per day..
214874537|NCT00132860|DRUG|azithromycin|
214874538|NCT00646334|DEVICE|Mesh Implantation|An elective incisional Hernia repair is performed by using Optilene® Mesh Elastic, a lightweight and large pore mesh, knitted from monofilament polypropylene. Due to the multidirectional elasticity the mesh is able to adapt to all movements taking place in the abdominal wall.
214874539|NCT00646334|DEVICE|Mesh Implantation|Ultrapro® Mesh is a knitted, partly absorbable, lightweight mesh, consisting of equal parts of nonabsorbable polypropylene and absorbable polyglecaprone (Monocryl®). Polyglecaprone is fully absorbed in the body by hydrolysis. The addition of polyglecapron filament is only intended to reinforce the mesh to allow a convenient intraoperative handling and mesh placement, without additional function. Ultrapro® is an elastic mesh having enlarged elasticity cross to the blue strips.
214874540|NCT03413293|DIAGNOSTIC_TEST|Diagnosis of bacterial infections|Cultures
214874541|NCT03151408|DRUG|Pracinostat|60 mg capsule
214874542|NCT03151408|DRUG|Placebos|capsule
214874543|NCT03151408|DRUG|Azacitidine|SC or IV injection
214874544|NCT04149106|DRUG|Sulfadoxine pyrimethamine + Amodiaquin|Monthly dose of SPAQ over three days for SMC
214874545|NCT04149106|DRUG|Dihydroartemisinin piperaquin|Monthly dose of DHAPQ for SMC
214874546|NCT00837473|DEVICE|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
214874547|NCT01489631|DRUG|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
214874548|NCT01489631|DRUG|marcaine|bupivacaine 0,125%
214874549|NCT01489631|DRUG|sufentanil|sufentanil 1mcg/ml
214874550|NCT01489631|DRUG|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
214874551|NCT05030558|BEHAVIORAL|Web-assisted patient education intervention designed according to the common-sense model|Implementation of patient education with the website created about fibromyalgia disease in 4 weeks according to the disease perception themes reached as a result of the qualitative research.
214874552|NCT05030558|BEHAVIORAL|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
214874553|NCT05782127|DRUG|Onureg + Venetoclax|Combination of Onureg and Venetoclax
214874554|NCT04674865|OTHER|Standardized Physical therapy protocol|Standardized Phase 1 protocol without for 7 days without ANB sessions.
214874555|NCT04674865|OTHER|Alternate nostrils breathing|Alternate nostrils breathing 2 sessions per day
214874556|NCT01952210|BEHAVIORAL|nutritional consultation and exercise program|The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
214874557|NCT01952210|BEHAVIORAL|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
214874558|NCT01724489|DRUG|Growth hormone|
214874559|NCT01724489|DRUG|Placebo|
214874560|NCT04576923|DIAGNOSTIC_TEST|Velacur by Sonic Incytes|liver stiffness measurement
214874561|NCT00128271|DRUG|Bavituximab|
214874562|NCT04732624|DRUG|Oral Rehydration Solution|Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
214874563|NCT04732624|DRUG|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
214874564|NCT00620100|DRUG|Docetaxel|
214476825|NCT05032066|DRUG|Placebo|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
214476826|NCT06408038|OTHER|For each patient included, the samples described below will be collected:|"* A single blood sample will be taken before initiation of the metastatic treatment line. The volume of total blood sampled is 34mL.~* A tumour sample (FFPE block already archived) from a metastasis (other than bone) if available or, failing this, from the primary breast tumour, will be sent to the sponsor in order to meet the objectives of the study.~Once the blood sample has been taken, patients will have completed their participation in the study."
214874565|NCT04485832|DEVICE|Telehealth care|Patients in the intervention group daily answer 6 questions, which are focused on the recognition of AECOPD, using the electronic healthcare platform Evita by Swisscom, which has been and continuously is developed by the study team and Swisscom. The study team daily analyses all patients online and reacts according to a pre-specified action plan.
215040413|NCT03185221|DEVICE|Cordimax|One rapamycin eluting stent for treating the adapted coronary patients
215040414|NCT03185221|DEVICE|XIENCE V|One everolimus eluting stent for treating the adapted coronary patients
214666311|NCT02137044|BEHAVIORAL|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
214666312|NCT01917331|DRUG|Beclometasone/Formoterol/Glycopyrrolate|Active drug tested
214666313|NCT01917331|DRUG|Beclometasone/Formoterol|Active comparator
214666314|NCT02032953|DIETARY_SUPPLEMENT|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
214666315|NCT02032953|DRUG|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg\*min. Ten minuts after starting the insulin, and when the the blood glucose is\<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
214666316|NCT03486314|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
214874566|NCT04485832|DIAGNOSTIC_TEST|Weekly CAT measurement|
215040415|NCT00805389|BIOLOGICAL|Engerix-B™|2 doses intramuscular injections
215040416|NCT00805389|BIOLOGICAL|Fendrix™|2 doses intramuscular injections
215040417|NCT00805389|BIOLOGICAL|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
215040418|NCT00805389|BIOLOGICAL|HBsAg (Booster injection)|Single dose intramuscular injection
215040419|NCT02036346|DIETARY_SUPPLEMENT|Oral Ηydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
215040420|NCT02036346|OTHER|Advise on calculated oral fluid requirements|
215040421|NCT02036346|OTHER|No nutritional advice will be given|
215040422|NCT05962944|DEVICE|Olympus Cellsens software|Olympus cellsens software will be used to visualise the cells and MS teams screen share will be used to send the live images in real time.
215040423|NCT02670902|BEHAVIORAL|Critical Time Intervention-Residential (CTI-R)|CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
215040424|NCT02670902|BEHAVIORAL|Enhanced Usual Discharge Services-Residential|The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.
215040425|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
215040426|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
215040427|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
215040428|NCT05324241|DIETARY_SUPPLEMENT|Fat Microcapsules|Consumption of a drink that contains microencapsulated fat that will be released either in the stomach or in the distal small intestines.
214476827|NCT04093921|BEHAVIORAL|MET-based therapy|see previous
214476828|NCT04093921|BEHAVIORAL|Standard Care|To include all recommended outpatient treatments
214476829|NCT06585839|BEHAVIORAL|Digital coaching solution to improve childbirth experience|Intervention provides coaching to improve the childbirth experience and offers comprehensive perinatal mental health support to pregnant and postpartum women. It features emotion tracking and exercise customization functionality, along with an avatar-based platform. The app includes digital psychotherapy exercises and psychoeducation. These core elements are complemented by exercises in mindfulness, relaxation, and self-soothing.
214874567|NCT02940132|DRUG|SC10914|SC10914 will be administered orally.
214874568|NCT04865393|DRUG|SPR206|SPR206 100 mg single-dose IV infused over 1 hour
214476830|NCT06585839|OTHER|Application for the control group|Application for the control group including surveys.
214476831|NCT04102111|DRUG|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily.
214666317|NCT03486314|DRUG|Rifampin|Rifampin capsules.
214874569|NCT05082792|DIAGNOSTIC_TEST|doppler ultrasound|"Doppler ultrasound evaluation of AVF:~* pre-operative evaluation: venous system (patency of central veins and deep venous system, patency of superficial veins, the latter diameter, depth form skin surface, distance from nearby artery, any sizable adjacent tributaries), and arterial system including morphological evaluation (course, diameter, wall alterations, any stenoocclusive disorders) and functional evaluation (flow volume and ability to dilate)~* post-operative evaluation: anastomotic site (type of anastomosis, patency, diameter, PSV and any other morphologic alterations), inflow afferent artery (diameter, PSV and flow volume), outflow efferent vein (patency, diameter, color flow, spectral waveform)~* the first post-operative sonographic evaluation will be done after removal of stiches from the wound and periodic monitoring every one week up until completion of 6 weeks"
214874570|NCT00923273|DRUG|FDG-PET|PET CT will be performed at baseline and after two cycles of treatment.
215040429|NCT03721250|OTHER|epidural|thoracic epidural analgesia
215040430|NCT02550145|DRUG|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
215040431|NCT02550145|OTHER|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
215040432|NCT03054714|DEVICE|catheter replacement|catheter removal and delayed replacement, versus exchange over a guidewire
215040433|NCT04209556|DRUG|PF-06826647 100 mg QD|Investigational Product
215040434|NCT04209556|DRUG|PF-06826647 300 mg QD|Investigational Product
215040435|NCT04209556|DRUG|PF-06826647 600 mg QD|Investigational Product
215040436|NCT04209556|DRUG|Placebo|Matched Placebo
215040437|NCT04209556|DRUG|PF-6826647 400 mg QD|Investigational Product
215040438|NCT02605902|BEHAVIORAL|(i)Comprehensive Behavioral Intervention for Tics|
215040439|NCT02605902|BEHAVIORAL|internet-delivered psychoeducation and relaxation training|
215040440|NCT06131658|OTHER|Functional motor control excercise|This include functional motor control thrice a week for six weeks
215040441|NCT06131658|OTHER|convectional excercise|This include convectional exercise thrice a week for six weeks
215040442|NCT01409096|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
215040443|NCT01409096|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
214476832|NCT04102111|DRUG|Placebo|Participants will receive oral tablets of matching placebo twice daily.
214476833|NCT06590441|DEVICE|Myopia control spectacles|Myopia control spectacles fitted with temperature sensors
214666318|NCT03486314|DRUG|Docetaxel|Docetaxel intravenous infusion.
214666319|NCT03486314|DRUG|Carboplatin|Carboplatin intravenous infusion.
214666320|NCT03486314|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
214666321|NCT01047410|OTHER|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
215040444|NCT05050903|OTHER|Rhinovirus infection|Inoculation with rhinovirus-16
215040445|NCT04726995|OTHER|CHOP and BFM regiments|used CHOP and BFM regiments
215040446|NCT03348124|BEHAVIORAL|"Children - what does it involve?"|"Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling."
214874571|NCT00923273|DRUG|Pemetrexed|
214874572|NCT00923273|DRUG|Sirolimus|
214874573|NCT00923273|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed
214874574|NCT00923273|DIETARY_SUPPLEMENT|Folic acid tablets|1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
214874575|NCT00923273|DRUG|Dexamethasone tablets|4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
215040447|NCT00099255|DRUG|SGN-30|
215040448|NCT01180283|DRUG|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
215040449|NCT06026150|OTHER|Ultrasound scanning of inguinal area for femoral nerve and artery|ultrasound scanning of inguinal region is done in femoral fracture patient to identify femoral artery and nerve
215040450|NCT01599884|DRUG|N-acetylcysteine|1800 mg twice daily for 8 weeks
215040451|NCT01599884|DRUG|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
215040452|NCT00093366|BIOLOGICAL|etanercept|
215040453|NCT00093366|DRUG|arsenic trioxide|
215040454|NCT02282228|DEVICE|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
215040455|NCT05091411|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
215040456|NCT02270658|DEVICE|CPAP|
215040457|NCT04375436|DRUG|NTRX-07-SDD|NTRX-07-SDD for oral administration
215040458|NCT04003298|DEVICE|Electric toothbrush|Electric toothbrush and power interdental device
215040459|NCT04003298|DEVICE|Control|Oscillating-rotating
214874576|NCT05584592|OTHER|Intergrate early palliatuve care + Conventional chemotherapy|Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
214874577|NCT05584592|OTHER|Conventional chemotherapy|patients to receive routine palliative care when they want it or when it is needed by health care providers. In other words, if a patient assigned to the control group desires palliative care, they can receive conventional palliative care.
214874578|NCT02744118|OTHER|5A's Model|"The adapted 5A's model will include the following elements:~1. Ask the patient about their marijuana use~2. Advise every patient to quit/reduce marijuana use using clear, specific personalized advice~3. Assess factors affecting choice of behavior and behavior change~4. Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient~5. Arrange follow-up for ongoing assistance and support, and to adjust treatment plans"
214874579|NCT02744118|OTHER|Healthy Internet Use Model|"The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:~1. Balance~2. Boundaries~3. Communication"
214874580|NCT00224419|BEHAVIORAL|Motivational interviewing for smoking cessation|All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
214874581|NCT00224419|BEHAVIORAL|Cognitive behaviors therapy|6 counseling sessions delivered over the phone or in person
214874582|NCT00224419|DRUG|CBT + NRT|Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
214874583|NCT04540679|OTHER|VIP4SCI|Technology-enabled self-management \& rehabilitation solution
214874584|NCT06359106|DRUG|80% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 80%, and the total gas flow rate will be set at 2L/minute.
214874585|NCT06359106|DRUG|40% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 40%, and the total gas flow rate will be set at 2L/minute.
214874586|NCT03730818|OTHER|Water-based Exercise Group|The intervention consist will of a water-based exercise protocol
214874587|NCT03730818|OTHER|Land-based Exercise Group|The intervention will consist of a land-based exercise protocol
214874588|NCT03578575|DRUG|Danggui Buxue Tang|Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.
214874589|NCT03578575|DRUG|Placebo|Placebo is a very low dose Danggui Buxue Tang powder.
214874590|NCT01723618|DRUG|CRD007|
214874591|NCT06231056|DIETARY_SUPPLEMENT|Probiotic iNatal®|iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215)
214874592|NCT05551871|DRUG|Simvastatin|the patient will receive Simvastatin for 7 days
214874593|NCT05551871|DRUG|Placebo drug|the patient will receive Placebo drug for 7 days
214874594|NCT04084093|DEVICE|Surfactant Gel|This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.
214874595|NCT00359593|BEHAVIORAL|Knowledge translation intervention package|
214874596|NCT00493415|DRUG|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
214874597|NCT00493415|DRUG|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
214874598|NCT05496660|OTHER|NHE+KT|the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
214874599|NCT05496660|OTHER|NHE|the Nodic hamstring exercise plus the kinesio taping without tension during 4-week consisting 12 sessions
214874600|NCT02346266|OTHER|SMART Education|
214874601|NCT02235090|OTHER|Direct current stimulation of cervical spinal cord|10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
214874602|NCT01478165|DRUG|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
214874603|NCT01478165|DRUG|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
214874604|NCT03206463|DRUG|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
214874605|NCT03206463|DRUG|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
214874606|NCT03206463|DRUG|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
214874607|NCT03718312|PROCEDURE|clamping with pre-conditioning (PCl)|"PCI procedure: clamping of the supracellular thoracic aorta for 5 minutes followed by a 5-minutes de-clamping period.~PCI procedure is repeated twice."
214874608|NCT02009514|OTHER|Glucose-containing compared to glucose-free hemodialysate|Comparison of effects on glucose variation
214874609|NCT01235195|DRUG|sertraline hydrochloride|50 mg capsule, single-dose
214874610|NCT01235195|DRUG|sertraline hydrochloride|50 mg tablet, single-dose
214874611|NCT02936414|DRUG|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
215040460|NCT06316726|COMBINATION_PRODUCT|full bed silicone mattress plus other measures|full bed silicone mattress plus put silicone pads on the head and shoulders, cotton rolls wraps bony prominence (elbows and heels), petrissage every two hours on shoulders to fingers and lower legs to heels, change location of ankle pads, use round gel full of air sit pad, a pillow on the knees
215040461|NCT00498992|DIETARY_SUPPLEMENT|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
215040462|NCT03578250|OTHER|Robotic Training|Upper extremity training on a robotic device with or without error augmentation force field.
214476835|NCT06807060|BEHAVIORAL|'Light, activity and sleep in my daily life' intervention|"The intervention is complex in that it considers multiple factors (e.g., light-related behaviour, physical activity and sleep behaviour) and multiple components (e.g., cognitive goal setting and implementation).~The intervention is delivered as a web-based course on a digital learning platform. Course material is placed in nine modules covering electric lighting, daylight, physical activity outdoors and sleep. Besides online material, the course includes a test kit containing light bulbs, a sleep mask, a checklist for the room inventory, a cap, a notebook, and a sleep diary. The purpose of the test kit is to encourage experimentation and provide handouts and printed copies to facilitate the completion of assignments."
214476836|NCT02782676|DEVICE|Investigational Healon5 OVD|ophthalmic viscosurgical device
214476837|NCT02782676|DEVICE|Healon5 OVD|ophthalmic viscosurgical device
214666322|NCT01047410|OTHER|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
214874612|NCT02936414|DRUG|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
214874613|NCT01473524|DRUG|Obeticholic Acid (OCA)|OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.
214874614|NCT01473524|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
214874615|NCT05519319|PROCEDURE|RFA|RFA will be performed
214874616|NCT05519319|PROCEDURE|PDT|PDT will be performed
214874617|NCT05519319|PROCEDURE|RFA combined with PDT|RFA and PDT will be performed
215040463|NCT03680885|DRUG|Lidocaine gel|Lidocaine gel 5%, PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
215040464|NCT03680885|DRUG|Placebo|PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
215040465|NCT03680885|DRUG|Injected lidocaine|Standard FDA-approved dental injectable lidocaine
215040466|NCT01188941|BEHAVIORAL|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
215040467|NCT02863393|OTHER|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
215040468|NCT03908203|PROCEDURE|Minimally invasive one-level lumbar deformity correction|The study treatment represents modified technique of MIS TLIF: one level screws fixation using Wiltse approach at one side, the other side - percutaneously, one level decompression, correction of segmental deformity by performing vertebrotomy and then intervertebral fusion.
215040469|NCT01798888|PROCEDURE|Implantation of Deep Brain Stimulation|
215040470|NCT00212836|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
214874618|NCT04287335|DIAGNOSTIC_TEST|Multitarget stool FIT-DNA test - ColoClear|Multitarget stool FIT-DNA test
214874619|NCT04287335|DIAGNOSTIC_TEST|FIT|fecal immunochemical test
214874620|NCT04287335|PROCEDURE|Colonoscopy|diagnostic colonoscopy
214874621|NCT01544179|DRUG|Gefitinib|Investigational Drug
215040471|NCT00212836|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
214476838|NCT04258566|DEVICE|Optical Molecular Imaging|Tracks and localizes intrahepatic lesions
214476839|NCT04258566|RADIATION|Indocyanine Green|Fluorescent dye used for visualization of cells and tissue
214874622|NCT01544179|DRUG|Placebo|Matching placebo as comparator
214874623|NCT01544179|DRUG|Pemetrexed|Chemotherapy (concomitant therapy)
214874624|NCT01544179|DRUG|Cisplatin|Chemotherapy (concomitant therapy)
214874625|NCT00006216|BIOLOGICAL|PA-1-STK ovarian carcinoma vaccine|
214874626|NCT00006216|DRUG|ganciclovir|
214874627|NCT06447311|OTHER|Hyaluronic acid gel|Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.
214874628|NCT06633328|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with severe aplastic anemia
214874629|NCT06633328|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with severe aplastic anemia
214874630|NCT02410980|DRUG|Tretinoin cream 0.1%|Assessment of the skin change
214874631|NCT03466268|DRUG|Gumarontinib Tablets|Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
215040472|NCT05975658|DEVICE|Gabi SmartCare Pediarity System [Gabi Band, Gabi Monitor App, Gabi Analytics]|Gabi SmartCare has created a monitoring system named Pediarity System that obtains pediatric vitals data through non-invasive means through a Gabi band. When paired with a proprietary algorithm and software - Gabi Analytics - the cloud-based platform measures blood oxygen levels, pulse rate (and variability), respiratory rate, actigraphy, inter-beat interval, and tracking for the time the device is worn (or not worn by the child). Three LEDs on the monitor are used for capturing this information. Peak wavelengths for the red, infrared, and green LEDs operate at 660nm, 950nm, and 526nm respectively. The Gabi band features an optical front end coupled with an analog front end using 24 bits. Bluetooth data transmission is utilized on a mobile phone application with a tablet-based system in a CSV format for the purpose of offline data processing.
214874633|NCT05794360|BEHAVIORAL|ACtive Children Enhance LEaRning and AttenTION (ACCELERATION)|A diverse group of key informants (i.e., PE teachers, school athletic department director) and community stakeholders (i.e., professional soccer coaches, Houston Dynamo Academy director) were engaged to help the research team design, modify, and implement the ACCELERATION curriculum to ensure program relevance and appeal. There are several components that described below make our program design both comprehensive and highly adaptable for optimal reach and effectiveness. These include staff development training, parent workshops, on-site and virtual developmental programs, delivery and implementation support from community stakeholders, online resources, family engagement events, equipment donations to improve activity, and on-going support and mentoring services for parents and school-based educators.
214874634|NCT01327508|DEVICE|TRIGEN SURESHOT Distal Targeting Instrumentation.|image-guided localization system
214874635|NCT01327508|OTHER|Free-hand technique|Free-hand technique utilizes x-rays to find screw holes.
214874636|NCT00282919|DRUG|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
214874637|NCT01279083|DRUG|DE-112|Topical ocular solution
214874638|NCT01279083|DRUG|DE-112|Topical ocular solution
214874639|NCT01279083|DRUG|DE-112|Topical ocular solution
214874640|NCT01279083|DRUG|DE-112|Topical ocular solution
214874641|NCT01279083|DRUG|DE-112 Vehicle Solution|Topical ocular solution
214874642|NCT01279083|DRUG|Timolol Maleate Solution|Topical ocular solution
214874643|NCT01438996|BIOLOGICAL|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
214874644|NCT01413607|DEVICE|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
214874645|NCT01413607|DEVICE|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
214874646|NCT02398383|OTHER|Oral Glucose Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Patients will drink 1.75 gm/kg glucose (Glucola) to a maximum of 75 gm. Venous samples for glucose and c-peptide will be drawn from the IV at 0, 30, 60, 90 and 120 minutes. Subjects will be instructed to eat at least 75 gm carbohydrates daily in the week prior to this test.
215040473|NCT06345768|OTHER|Stress Ball|It is a ball 5-6 cm in size and not too hard. It will be given to both hands of the patients and they will be asked to count from 1 to 5. This application will be repeated for 15 minutes.
215040474|NCT05000983|DRUG|PluroGel|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
215040475|NCT05000983|DRUG|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
215040476|NCT04504955|OTHER|Observational Non-Interventional Registry|Observational Non-Interventional Registry
214666323|NCT06411184|DRUG|Regulator T Cells|Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs
214874647|NCT02398383|OTHER|Mixed Meal Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Subjects will consume 6 kcal/kg (6 ml/kg) Boost High Protein Nutritional Energy Drink (Mead-Johnson) over five minutes to a maximum of 360 ml. Venous samples for glucose, glucagon, GLP-1, GIP, and c-peptide will be drawn at -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes.
214874648|NCT02398383|OTHER|Hypoglycemic Clamp|All subjects with CF and adult (but not pediatric) controls will undergo one-step hypoglycemic clamp. Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling and a second IV for infusion of insulin and dextrose.
214874649|NCT00000978|DRUG|Zidovudine|
214874650|NCT00000978|DRUG|Zalcitabine|
214874651|NCT06324851|DRUG|Drospirenone / Estetrol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Drospirenone/Estetrol at any time of the menstrual cycle
215040477|NCT06090344|OTHER|Traditional video format|6 x 3 minute videos designed in the same format as traditionally found on the internet
215040478|NCT06090344|OTHER|Evidence-informed video format|6 x 3 minute videos designed in the format recommended by advice in the literature
215040479|NCT06389058|OTHER|Recommendation for the diagnoses and treatment of Severe Asthma|No intervention planned in this phase for the patients. Recommendations to be developed for healthcare and condition.
214666324|NCT05510986|DRUG|Fentanyl group|Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
214874652|NCT06324851|DRUG|Nomegestrol Acetate / Estradiol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol at any time of the menstrual cycle
214874653|NCT06324851|DRUG|Ethinylestradiol / Dienogest|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest at any time of the menstrual cycle
214874654|NCT06048965|OTHER|No intervention to be performed|No intervention to be performed. Anonymous survey only.
214874655|NCT01004653|BIOLOGICAL|H1N1 influenza A Vaccine (Split virion), Inactivated|100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
215040480|NCT06070662|DIAGNOSTIC_TEST|Coronary microvascular disease testing during coronary angiography|During invasive coronary angiography, in addition to coronary angiography performed as per routine clinical care, participants will have angiographic testing for coronary microvascular disease using routine clinical procedures. This will consist of fractional flow reserve (FFR), coronary flow reserve, index of microvascular resistance and vasospasm provocation testing with acetylcholine (Ach).
215040481|NCT06070662|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan including exercise|Participants will undergo a cardiac magnetic resonance scan compromising 1) T1 mapping, 2) oxygenation-sensitive MRI and 3) perfusion imaging. All will be obtained at rest and during exercise using a step ergometer.
215040482|NCT06070662|DIAGNOSTIC_TEST|Additional analysis of already acquired CT scan|Previously acquired CTCA images from the main research study will be transferred to Heartflow for computation of coronary blood volume.
215040483|NCT04083417|DRUG|Phenoxymethylpenicillin|tablet PcV 1000 mg x 3 for 10 days
215040484|NCT04083417|OTHER|No antibiotic treatment|No prescription of antibiotics
215040485|NCT05484128|DIETARY_SUPPLEMENT|Gastrus|"Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475.~Gastrus will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus."
215040486|NCT05484128|OTHER|Placebo|placebo has an identical preparation to Gastrus
215040487|NCT06068504|OTHER|Arm-cranking exercise|Arm-cranking exercise
215040488|NCT06068504|OTHER|Heating|Immersion of the foot in warm water
215040489|NCT02549066|PROCEDURE|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
215040490|NCT02549066|DRUG|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) \< 12 %."
215040491|NCT00624845|DRUG|OMS103HP|Maximum 6 bags of OMS103HP irrigation solution
215040492|NCT00624845|DRUG|Vehicle|Maximum of 6 bags of vehicle irrigation solution
215040493|NCT05871957|DRUG|Vitamin D Drops|Supplement 2000IU of vitamin D, no matter the brand or manufacturer for 1 month.
215040494|NCT03323957|DIAGNOSTIC_TEST|nutritional screening tool|screening of disease associated malnutrition in sick infants
215040495|NCT03763578|OTHER|Licorice|Natural herbal product
215040496|NCT02168556|BEHAVIORAL|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
215040497|NCT02168556|BEHAVIORAL|Video|Subject watches an informational video prior to undergoing urodynamic testing.
215040498|NCT02168556|OTHER|Standard of care|Standard of care
215040499|NCT03387956|DRUG|Intrathecal atropine|100ug intrathecal atropine will be injected with spinal anesthesia
215040500|NCT03387956|DRUG|dexamethasone|intravenous 8 mg dexamethasone (2ml).
215040501|NCT04682665|DRUG|Icosapent Ethyl Oral Capsule|Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
215040502|NCT04682665|OTHER|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
215040503|NCT02235324|BIOLOGICAL|ziv-aflibercept|Given IV
215040504|NCT02235324|DRUG|leucovorin calcium|Given IV
214666325|NCT05510986|DRUG|Oxycodone Hydrochloride group|"Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes."
214874656|NCT03479567|OTHER|Gait accelerometry|accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)
214874657|NCT03479567|OTHER|balance accelerometry|accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
214874658|NCT03479567|OTHER|Fine motor skill test|assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
214874659|NCT03479567|DIAGNOSTIC_TEST|Paratonia Assessment Instrument (PAI)|diagnosis of paratonia based on passive movement of the four limbs
214874660|NCT03479567|OTHER|myotonometric measurement of muscle tone|MyotonPRO measurement of muscle tone
214874661|NCT01967914|OTHER|PVI|Measurement of PVI (plethysmography variability index)
214874662|NCT02573844|DRUG|Proklama|
214874663|NCT02573844|DRUG|Placebo|
215040505|NCT02235324|DRUG|fluorouracil|Given IV
215040506|NCT02235324|OTHER|laboratory biomarker analysis|Correlative studies
215040507|NCT02136992|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
215040508|NCT02136992|DRUG|placebo|placebo will be taken two tablets 3 times a day during the whole study process
215040509|NCT02063451|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
215040510|NCT00240851|DRUG|acetaminophen extended release|
215040511|NCT02704208|BEHAVIORAL|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
215040512|NCT02704208|BEHAVIORAL|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
214666326|NCT00488527|DRUG|Insulin glargine|Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (\<6.0 mmol/L), and the active treatment is to be continued for three more months.
215040513|NCT00527228|DRUG|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
214291338|NCT01554423|BEHAVIORAL|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
214666327|NCT02729961|DRUG|Brentuximab Vedotin|Given IV
214874664|NCT04395144|PROCEDURE|Awake Prone Positioning|Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h
214874665|NCT04395144|PROCEDURE|Standard care|Patients will not receive any special instructions with regards to proning.
215040514|NCT00527228|DRUG|placebo|
215040515|NCT05428644|BEHAVIORAL|massage therapy|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage and placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
215040516|NCT00565565|DRUG|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
215040517|NCT00506623|DRUG|Capecitabine, Irinotecan|
215040518|NCT04347421|DIETARY_SUPPLEMENT|Krill oil group|This group takes 500 mg/day Krill oil for 12 weeks.
215040519|NCT04347421|DIETARY_SUPPLEMENT|Placebo group|This group takes 500 mg/day Placebo for 12 weeks.
215040520|NCT02315092|DEVICE|Fluorescence Imaging|Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
215040521|NCT01069913|DRUG|BG00012|"Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation."
215040522|NCT00284180|DRUG|Vinflunine|Novel second generation vinca alkaloid
215040523|NCT00284180|DRUG|Trastuzumab|Anti-HER2 monoclonal antibody
215040524|NCT05140356|DEVICE|Applied high amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week
215040525|NCT05140356|DEVICE|Applied low amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
214291339|NCT00128947|DRUG|Mycophenolic Acid|
214291340|NCT00128947|DRUG|Mycophenolate 7-O-Phenolic Glucuronide|
214666328|NCT02729961|DRUG|Ceritinib|Given PO
214666329|NCT02729961|OTHER|Laboratory Biomarker Analysis|Correlative studies
214666330|NCT02729961|OTHER|Pharmacological Study|Correlative studies
214666331|NCT00954785|DEVICE|Ankle brace|Sports Stirrup ankle brace (Aircast)
214666332|NCT00954785|DRUG|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
214666333|NCT00954785|DRUG|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
214666334|NCT04392986|OTHER|Sunlight exposure|The weather was sunny and found suitable for outside activity and sunlight exposure program, with a mean temperature of 27.0-28.5 °C, the humidity of 64-80%, and global solar exposure of 1.28 to 2.99 MJ/m2 during treatment.\[15\] Participants were asked to lie on the beach for 45 minutes per day between 2 to 3 pm to avoid extreme skin irritation and sunburn from direct sunlight exposure.
214666335|NCT02028949|DRUG|Zavedos®|
214666336|NCT02028949|OTHER|Blood samples|
214874666|NCT01750489|DEVICE|non-invasive ventilation (NIV)|
214874667|NCT03278392|BEHAVIORAL|Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
215040526|NCT01899547|PROCEDURE|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
215040527|NCT01899547|PROCEDURE|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
215040528|NCT03421184|OTHER|blood sample|25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
215040529|NCT03421184|OTHER|urine sample|10 ml
215040530|NCT03421184|OTHER|food questionnaire|dietary habit enquiry and a 48h dietary
215040531|NCT03421184|OTHER|hair|lock of hair
214291341|NCT02123355|DRUG|Induction of anesthesia|Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
215040532|NCT04585308|DEVICE|transShield Embolic Protection System|Used for embolic protection during TAVR.
215040533|NCT02005744|DRUG|CKD-501|CKD-501 0.5mg, PO(per oral), once
215040534|NCT02724839|BEHAVIORAL|Group nutrition sessions|The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).
215040535|NCT02724839|DEVICE|Fitbit|Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.
215040536|NCT01081392|BIOLOGICAL|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
215040537|NCT02143284|DEVICE|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
215040538|NCT03070678|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
214874668|NCT03278392|BEHAVIORAL|Placebo Non-stress task|Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
214874669|NCT05800158|DIAGNOSTIC_TEST|Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit|A reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2.
214874670|NCT01399567|BEHAVIORAL|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
214874671|NCT02456935|DRUG|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
214874672|NCT02456935|DRUG|Esomeprazole 40 mg QD|Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
214874673|NCT02861014|BIOLOGICAL|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
215040539|NCT03070678|DRUG|Mefenamic acid|"Pharmaceutical form: capsule~Route of administration: oral"
215040540|NCT05878067|DRUG|ABBV-444|Lubricant Eye drops
215040541|NCT00433485|DRUG|sirolimus|
215040542|NCT00433485|GENETIC|comparative genomic hybridization|
215040543|NCT00433485|GENETIC|gene expression analysis|
215040544|NCT00433485|GENETIC|microarray analysis|
215040545|NCT00433485|GENETIC|protein expression analysis|
215040546|NCT00433485|GENETIC|proteomic profiling|
215040547|NCT00433485|OTHER|laboratory biomarker analysis|
215040548|NCT00433485|OTHER|mass spectrometry|
215040549|NCT00433485|PROCEDURE|biopsy|
215040550|NCT00949533|DRUG|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
214874674|NCT00236912|DRUG|levofloxacin; metronidazole|
214874675|NCT04321681|OTHER|no intervention|no intervention
215040551|NCT03896191|PROCEDURE|Revision TKR surgery|This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.
215040552|NCT03896191|OTHER|No intervention.|This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
215040553|NCT01597817|OTHER|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
215040554|NCT01597817|OTHER|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
215040555|NCT05964569|OTHER|model-guided optimization of treatment plan|original treatmant plans are optimized based on model-based NTCP
215040556|NCT05964569|OTHER|standard treatment plan, no optimization|original treatment plans are not optimized
215040557|NCT03082924|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
215040558|NCT03082924|DEVICE|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
215040559|NCT03082924|DEVICE|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
214874676|NCT00219817|DRUG|RC-1291 HCl|
214874677|NCT02432053|DRUG|Advagraf|
214874678|NCT00256113|DRUG|Saredutant succinate (SR48968C)|
214874679|NCT03551821|DRUG|ATI-50002|Topical Solution
214874680|NCT01819870|DRUG|Dilatrend SR capsule 32mg|"* 1 capsule, oral, once daily, 7days~* over the period I\&II(crossover)"
214874681|NCT01819870|DRUG|Dilatrend IR tablet 25mg|"* 1 tablet, oral, once daily, 7days~* over the period I\&II(crossover)"
214874682|NCT02023294|PROCEDURE|Convetional laparoscopic Sleeve Gastrectomy|Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
215040560|NCT03082924|DEVICE|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
215040561|NCT00406861|DRUG|montelukast in treatment of ENL reaction|
215040562|NCT00618761|OTHER|hyperglycemic clamp test|hyperglycemic clamp test
215040563|NCT00557193|DRUG|Asparaginase|Given IV, IM, or PO
215040564|NCT00557193|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215040565|NCT00557193|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215040566|NCT00557193|DRUG|Cyclophosphamide|Given IV
215040567|NCT00557193|DRUG|Cytarabine|Given IV or IT
215040568|NCT00557193|DRUG|Daunorubicin Hydrochloride|Given IV
215040569|NCT00557193|DRUG|Dexamethasone|Given IV or PO
215040570|NCT00557193|PROCEDURE|Echocardiography|Undergo ECHO
215040571|NCT00557193|DRUG|Etoposide|Given IV
215040572|NCT00557193|BIOLOGICAL|Filgrastim|Given IV or SC
215040573|NCT00557193|OTHER|Laboratory Biomarker Analysis|Correlative studies
214874683|NCT02023294|PROCEDURE|SILS Sleeve gastrectomy|Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
214874684|NCT04522817|BIOLOGICAL|CLBS119|Peripheral blood derived autologous CD34+ cells
214874685|NCT03857750|DRUG|Rocuronium|0.6 mg/kg
214874686|NCT02546466|PROCEDURE|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
214874687|NCT02546466|PROCEDURE|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
214874688|NCT02546466|BEHAVIORAL|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
214874689|NCT02826772|DRUG|GT0918|anti-tumor activity
214874690|NCT03482258|DIETARY_SUPPLEMENT|Prebiotic|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).
214874691|NCT03482258|DIETARY_SUPPLEMENT|Maltodextrin|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
215040574|NCT00557193|DRUG|Lestaurtinib|Given PO
215040575|NCT00557193|DRUG|Leucovorin Calcium|Given IV
215040576|NCT00557193|DRUG|Mercaptopurine|Given PO
215040577|NCT00557193|DRUG|Methotrexate|Given IV, IT, or PO
215040578|NCT00557193|DRUG|Methylprednisolone|Given IV
215040579|NCT00557193|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215040580|NCT00557193|DRUG|Pegaspargase|Given IM
215040581|NCT00557193|OTHER|Pharmacological Study|Correlative studies
215040582|NCT00557193|DRUG|Prednisone|Given PO
215040583|NCT00557193|DRUG|Therapeutic Hydrocortisone|Given IT
215040584|NCT00557193|DRUG|Vincristine Sulfate|Given IV
215040585|NCT02332811|DRUG|sevelamer carbonate 800mg|"Pharmaceutical form:tablet~Route of administration: oral"
215040586|NCT02332811|DRUG|sevelamer carbonate 2.4 g|"Pharmaceutical form:powder~Route of administration: oral"
215040587|NCT02975960|BIOLOGICAL|injection of autologous stromal vascular fraction|"1. Acquiring autologous stromal vascular fraction (SVF) from liposuction~2. purifying SVF from lipoaspirates and making syringe filled with SVF~3. SVF injection - Inject SVF on fingers subcutaneously."
215040588|NCT03769688|DRUG|Cervicovaginal secretions|Same as arm descriptions
215040589|NCT03769688|DRUG|Metronidazole gel|5 day course of vaginal MetroGel will be used prior to VMT intervention.
214874692|NCT03815734|PROCEDURE|motor imagery|motor imagery during the postoperative immobilization period
214874693|NCT01707771|PROCEDURE|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
214874694|NCT01707771|BEHAVIORAL|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
215040590|NCT03769688|DIAGNOSTIC_TEST|Screening tests|Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.
215040591|NCT03769688|BEHAVIORAL|Activities restriction|Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
215040592|NCT03769688|OTHER|Sterile Saline placebo|This will be administered as a placebo in place of cervicovaginal secretions
215040593|NCT00976456|DRUG|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
215040594|NCT00976456|DRUG|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
215040595|NCT06087380|PROCEDURE|auricular acupressure|Auricular pressure The experimental group commenced auricular acupressure intervention post-surgery. Questionnaire assessments and heart rate variability measurements were conducted in the experimental group on the first, second, third, and fourth days before discharge.
215040596|NCT06087380|OTHER|standard ward care|standard ward care
215040597|NCT01631968|PROCEDURE|Cement without antibiotic.|
215040598|NCT01631968|PROCEDURE|Cement with erytromycin and colistin.|
215040599|NCT02474810|DRUG|Alteplase|Alteplase for CVC dysfunction.
215040600|NCT02037529|DRUG|Eribulin Mesylate|Given IV
215040601|NCT02037529|OTHER|Laboratory Biomarker Analysis|Correlative studies
215040602|NCT02037529|DRUG|Paclitaxel|Given IV
215040603|NCT02037529|OTHER|Quality-of-Life Assessment|Ancillary studies
215040604|NCT05523908|RADIATION|High-dose hypofraction Arm|Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f
215040605|NCT05523908|RADIATION|Low-dose hypofraction Arm (Standard BED)|Patients in this arm would receive low-dose fractionated radiotherapy with 48Gy/12f
215040606|NCT02131766|DEVICE|DiAs|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
214874695|NCT03223844|DRUG|Dextroamphetamine Sulfate|Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
215040607|NCT02131766|OTHER|Sensor Augmented Pump Therapy|Insulin pump plus CGM.
215040608|NCT02474121|DEVICE|Bone marrow concentration device|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
215040609|NCT00718315|DRUG|erlotinib [Tarceva]|150mg po daily
215040610|NCT00718315|DRUG|fusidic acid [Verutex]|topical, daily for 30 days.
215040611|NCT00718315|DRUG|erythromycin [Eritex]|topical, daily for 30 days.
215040612|NCT00718315|DRUG|Fisiogel|topical, daily for 30 days
215040613|NCT05177250|DEVICE|HPLC|taking urine samples from participants and analyze these samples to detect bisphenol A and paraben
215040614|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 35mg TID
215040615|NCT00034814|DRUG|Placebo|Enzyme-inducing placebo TID
215040616|NCT00034814|DRUG|Talampanel|Enzyme-inducing Talampanel 35 mg TID
215040617|NCT00034814|DRUG|Talampanel|Enzyme-inducing TLP 50mg TID
215040618|NCT00034814|DRUG|Placebo|Non-enzyme-inducing placebo TID
215040619|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 25mg TID
215040620|NCT03527784|DEVICE|Parietene Macro|Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.
215040621|NCT03527784|DEVICE|Parietex Parastomal|Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.
215040622|NCT03527784|DEVICE|Dynamesh IPST|Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
214666337|NCT00659438|DRUG|ZD6474 (Vandetanib)|300mg orally, once daily
215040623|NCT00365950|DRUG|Duration of anticoagulation|
215040624|NCT00365950|DRUG|Warfarin duration|
215040625|NCT06461780|OTHER|Line-based questionnaire follow-up|The participant will use LINE group to report irAE severity, distress, financial toxicity and change trajectory of quality of life in one-year follow-up. If the severity grade of irAE reach the threshold and require referral, an alarm will appear to notify the research team to conduct and transfer to a clinical specialitst, or refer to the emergency room for treatment. Additionally, the Line group will also provide clinical relevant immunotherapy health education information currently and routinely used in study site. Patients can view it according to their interests, but the APP will not actively promote it.
215040626|NCT00003561|BIOLOGICAL|recombinant interferon alfa|
215040627|NCT00003561|BIOLOGICAL|sargramostim|
215040628|NCT00637910|DRUG|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
214666338|NCT00659438|DRUG|Bicalutamide|150mg orally, once daily
214666339|NCT00659438|DRUG|Placebo|orally, once daily
214874696|NCT06633341|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion
214874697|NCT04992208|BIOLOGICAL|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
214874698|NCT02870010|BIOLOGICAL|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
214874699|NCT02870010|RADIATION|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
214874700|NCT01090752|DRUG|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
215040629|NCT00637910|DRUG|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). \_Until disease progression or unacceptable toxicity develops
215040630|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
215040631|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
215040632|NCT01170663|BIOLOGICAL|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
215040633|NCT01170663|DRUG|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
214874701|NCT01090752|DRUG|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
214874702|NCT01756079|DRUG|boceprevir|
214874703|NCT01756079|BIOLOGICAL|PegIFN-2b|
215040634|NCT01170663|DRUG|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
215040635|NCT00529295|DRUG|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
215040636|NCT01927913|DRUG|SPD602|32, 50 or 75 mg/kg/day BID, capsule
215040637|NCT01927913|DRUG|Deferasirox|Per approved country specific label
215040638|NCT06163339|OTHER|Cultural Formulation Interview|Usual Care is enhanced with the Cultural Formulation Interview (CFI) aimed at strengthening assessment and treatment adherence
215040639|NCT00427037|DRUG|Cholecalciferol|50,000 IU weekly by mouth
215040640|NCT00427037|DRUG|Placebo|identical placebo pill orally by mouth
215040641|NCT06513208|DRUG|Ketorolac Tromethamine|IV Ketorolac 15mg every 6 hours, x 4 doses
215040642|NCT06513208|DRUG|Placebo|IV saline as placebo
215040643|NCT02172014|DRUG|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
214874704|NCT01756079|DRUG|RBV|
214874705|NCT03263975|OTHER|Gatorade or Enterade|Commercially available oral rehydration therapies
214874706|NCT02581397|DRUG|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
215040644|NCT02172014|DRUG|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
215040645|NCT00799565|GENETIC|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
215040646|NCT00765414|BIOLOGICAL|Myozyme|30 mg/kg qow f and 40 mg/kg qow
215040647|NCT01217034|DRUG|TACE with sorafenib|Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
215040648|NCT01217034|PROCEDURE|TACE alone|TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
215040649|NCT05239078|DRUG|local anaesthetic injection|Inferior alveolar nerve block
215040650|NCT04065321|PROCEDURE|PET-CT examination|All patients in the control group will undergo PET-CT examination after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years.
215040651|NCT04065321|PROCEDURE|Peripheral blood detection|All patients in the trial group will be followed up after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years. Peripheral blood will be collected for detection of circulating tumor cells at each follow-up. If circulating tumor cells are abnormal (number of circulating tumor cells ≥ 2 or CD133 ≥ 1), PET-CT will be performed immediately.
215040652|NCT02746809|DEVICE|CoreValve Evolut 34R TAVR system|"The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~1. Evolut 34R Transcatheter Aortic Valve (TAV)~2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~3. EnVeo R Loading System (LS)"
214291342|NCT02123355|PROCEDURE|Intubation|After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35\~40 mmHg，pulse oxygen saturation is more than 95%.
214291343|NCT02123355|DRUG|Sevoflurane, remifentanil ,vecuronium|Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
214291344|NCT02123355|DRUG|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
214291345|NCT02123355|DRUG|Placebo|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
214874707|NCT02581397|DRUG|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
214874708|NCT02581397|DRUG|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
214874709|NCT01620294|PROCEDURE|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
214874710|NCT01620294|PROCEDURE|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
214874711|NCT05853744|DRUG|lavender essential oil inhaled using cotton balls|cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
214874712|NCT05853744|DRUG|lavender essential oil inhaled using face mask|These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer throughout a face mask. A cotton ball soaked with water was put 10 cm next to the patient.
215040653|NCT01621100|DRUG|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
215040654|NCT00374647|DRUG|mycophenolate mofetil|
215040655|NCT00374647|DRUG|sirolimus|
215040656|NCT01071161|DRUG|azithromycin|azithromycin, tablets, during 12 weeks, three times a week, 250mg
215040657|NCT01071161|DRUG|placebo|placebo
215040658|NCT05217173|OTHER|telerehabilitation|It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks
215040659|NCT04931381|OTHER|Chemotherapy guided by organoid drug sensitivity test|Chemotherapy guided by organoid will be given to advanced pancreatic cancer patients.
215040660|NCT02791243|DRUG|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
215040661|NCT02791243|DRUG|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
214291346|NCT06486090|BEHAVIORAL|#Utviklingsklar|The intervention consists of 1) an e-learning course, 2) a workshop to create plans and practices for injury-prevention, 3) a mid-season meeting
214291347|NCT02141282|DRUG|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.
214874713|NCT05853744|DRUG|Distilled water|inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
214874714|NCT00103220|DRUG|SJG-136|Given IV
214874715|NCT02907255|DEVICE|Oximetry monitor|Wireless respiratory monitoring system
214874716|NCT05418114|DRUG|Magnesium sulfate|. One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
214874717|NCT02620436|OTHER|Core Mother Shelter Model|"1. Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.~2. Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.~3. Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility."
214874718|NCT05635032|OTHER|Comprehensive clinical assessment and biological samples collection|To establish the first Portuguese registry and biobank of PF-ILDs, comprising both extensive patient-level data, and systematic biological sampling (DNA, RNA, plasma, serum, bronchoalveolar lavage, lung tissue) at baseline and repeated biological sampling of blood and pharyngeal swabs performed at 6, 12 and 18 months, or whenever progression criteria are met or an acute exacerbation occurs. Participants will have regular visits at maximum intervals of 6 months, when their clinical condition and lung function tests are reassessed. A high resolution computed tomography (HRCT) scan of the lung will be performed every 12 months. Progressive fibrosis will be diagnosed based on meeting at least two of the following three criteria, occurring within the last year: (i) worsening of symptoms; (ii) absolute decline in FVC ≥5% predicted or absolute decline in DLCO (corrected for Hb) ≥10% predicted; (iii) increased extent of fibrotic changes on HRCT.
214874719|NCT00159237|PROCEDURE|blood test|
214874720|NCT04854044|DRUG|Akt/ERK Inhibitor ONC201|Given orally
214874721|NCT04854044|RADIATION|Radiation Therapy|Undergo radiation therapy
214874722|NCT04854044|PROCEDURE|Resection|Undergo surgical resection
214874723|NCT02000765|DRUG|GSK2140944 for Injection|GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing \[14C\] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
214874724|NCT02000765|DRUG|GSK2140944 Capsule|GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing \[14C\] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
214874725|NCT02794246|BIOLOGICAL|CART-19 cells|
214874726|NCT00186940|DRUG|Rasburicase|Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
214874727|NCT04467450|DRUG|botulinum toxin type A|ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
214874728|NCT04467450|DRUG|Methyl Prednisolonate|ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
214874729|NCT01722422|DRUG|oxygen and saline|
214874730|NCT05494476|PROCEDURE|implant insertion|after flap detachment, implant bed will be prepared with twist-drill, implant will be inserted according to randomization (1 or 2 mm under bone)
214874731|NCT01994291|DRUG|Ranibizumab|"Intravitreal Injection supplied as:~* 10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~* 6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~* Adminstered once a month for 12 weeks"
214874732|NCT01994291|DRUG|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks"
214874733|NCT01994291|DRUG|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
214874734|NCT01994291|DRUG|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
215040662|NCT02791243|DRUG|Negative Control|0.9% aqueous NaCl
215040663|NCT03044444|DIETARY_SUPPLEMENT|citrus extract|Participants will receive either a low or high dose citrus extract
215040664|NCT03044444|OTHER|placebo|participants will receive 500mg of maltodextrin
215040665|NCT01478984|PROCEDURE|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
215040666|NCT01478984|PROCEDURE|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
215040667|NCT02055508|BEHAVIORAL|Exercise Intervention|
215040668|NCT02055508|OTHER|Care-Management-Phone-Calls|
215040669|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Lantus solution for injection~Route of administration: subcutaneous"
215040670|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: New insulin glargine formulation solution for injection~Route of administration: subcutaneous"
215040671|NCT02196753|OTHER|PET CT|"All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient's weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV\> 40% of the background."
215040672|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 130 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
215040673|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 145 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
215040674|NCT00281970|DRUG|cisplatin|
215040675|NCT00281970|DRUG|docetaxel|
215040676|NCT00281970|PROCEDURE|adjuvant therapy|
215040677|NCT02230345|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
214291348|NCT02323230|BIOLOGICAL|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
215040678|NCT02230345|DIETARY_SUPPLEMENT|Acidified milk|Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
215040679|NCT02279927|DEVICE|Ureteroscopy|Ureteroscopy with laser stone fragmentation
215040680|NCT00205127|PROCEDURE|Cardiac PET imaging- rest and pharmacological stress|
215040681|NCT05740514|BEHAVIORAL|Exercise|Exercise training.
215040682|NCT05740514|BEHAVIORAL|De-training|Exercise de-training via unilateral knee immobilization.
215040683|NCT01924780|DEVICE|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
215040684|NCT01924780|DEVICE|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
215040685|NCT01924780|DEVICE|NEMOS Device sham stimulation 10 minutes|
215040686|NCT04518137|DRUG|ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle|48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
215040687|NCT00734552|DIETARY_SUPPLEMENT|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d."
215040688|NCT00734552|DIETARY_SUPPLEMENT|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
215040689|NCT03070626|DIETARY_SUPPLEMENT|PreOp®|No preoperative drink.
215040690|NCT02523950|PROCEDURE|Staged phacoemulsification and DMEK|"Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.~Stage 2. DMEK is performed secondarily according to the corneal status of patients."
215040691|NCT02523950|PROCEDURE|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
214476840|NCT05378620|BEHAVIORAL|Project Dulce + Dulce Digital|Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.
215040692|NCT02523950|DEVICE|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
215040693|NCT01151657|DIETARY_SUPPLEMENT|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
215040694|NCT01151657|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing maltodextrin
215040695|NCT05453214|DRUG|Fludrocortisone Acetate 0.1 MG|Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
215040696|NCT00894387|DRUG|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
215040697|NCT00894387|DRUG|Placebo|Placebo
215040698|NCT01128569|DRUG|Fluticasone Furoate|FF
215040699|NCT01128569|DRUG|FF/Vilanterol (VI; GW642444M)|FF/VI
215040700|NCT01128569|DRUG|Placebo|Placebo Inhaler
215040701|NCT02236676|BEHAVIORAL|Nap after rehearsal trials|Behavioral
215040702|NCT02805140|BEHAVIORAL|Virtual exercise|Using videoconferencing, mothers assigned to intervention arm will participate in daily (weekdays) virtual exercise sessions for 6 weeks with other mothers.
215040703|NCT02805140|BEHAVIORAL|Mobile apps|During virtual exercise sessions, mothers assigned to intervention arm will follow exercise routines using mobile exercise apps that are recommended by study staff.
215040704|NCT02805140|BEHAVIORAL|Exercise resources and information|For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.
215040705|NCT02768207|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
215040706|NCT02768207|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg tablets (four 240 mg tablet) orally BID from Day 1 to Day 28 of each 28-day cycle of the treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
215040707|NCT06341894|DRUG|Dalpiciclib|CDK4/6 inhibitor dalpiciclib, 100mg orally qd
215040708|NCT06341894|DRUG|Endocrine therapy|Fulvestrant/AI
215040709|NCT03830580|OTHER|Positive stimulation (singing)|A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
215040710|NCT00563732|DRUG|Lecozotan|
215040711|NCT02519842|DRUG|Fosaprepitant|
215040712|NCT02519842|DRUG|Placebo for fosaprepitant|
215040713|NCT02519842|DRUG|Ondansetron|
215040714|NCT02519842|DRUG|Dexamethasone|
215040715|NCT02519842|DRUG|5-HT3 antagonist|
215040716|NCT04767711|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri with cholecalciferol compared to cholecalciferol only.
215040717|NCT04767711|DRUG|Prednisolone|Oral glucocorticoid 25 mg daily for 7 days.
215040718|NCT05053061|BEHAVIORAL|Application program for pulmonary rehabilitation|Exercise videos for pulmonary rehabilitation
215040719|NCT00133627|DRUG|Ketotifen|
215040720|NCT03928925|OTHER|Bougie|disposable tracheal tube introducer of approximately 70 cm in length
215040721|NCT03928925|OTHER|Endotracheal Tube with Stylet|endotracheal tube preloaded with a removable, malleable stylet
215040722|NCT04907071|DEVICE|Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)|The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
215040723|NCT03737552|OTHER|Polysomnography|Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).
215040724|NCT02234349|PROCEDURE|pancreas kidney transplantation|
215040725|NCT02234349|PROCEDURE|kidney transplantation|
214666340|NCT02388776|DEVICE|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
214666341|NCT03826914|DIETARY_SUPPLEMENT|CardioFlex Q10|CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
215040726|NCT03912870|OTHER|Value of Flow Cytometry in Infectious Point of Care|"To validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures. The results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity.~This study is the preliminary study, necessary to determine the detection characteristics of these biomarkers."
215040727|NCT04435314|DRUG|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days
214291349|NCT02323230|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
214666342|NCT03826914|DIETARY_SUPPLEMENT|Placebo|Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
214666343|NCT05174715|OTHER|BIA|nutritional status was evaluated using BIA
214666344|NCT04334148|DRUG|Hydroxychloroquine|oral self administered tablet
214666345|NCT04334148|DRUG|Placebo oral tablet|oral self administered tablet
215040728|NCT04435314|DRUG|Placebo|Subjects will receive placebo TID for 7 days.
215040729|NCT02468830|DRUG|mirabegron|Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
215040730|NCT00008086|DIETARY_SUPPLEMENT|calcitriol|
215040731|NCT00008086|DRUG|carboplatin|
214291350|NCT05973383|BEHAVIORAL|LongLife Active- Basic|"The digital service LongLife Active with three core subjects:~1\) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars."
214291351|NCT05973383|BEHAVIORAL|LongLife Active- Standard|"The digital service LongLife Active with three core subjects:~1\) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Standard are also offered a community with social support."
214666346|NCT05218629|DRUG|Anlotinib, PD-1 inhibitor|Anlotinib, 8-12 mg/day, orally, day 1-14; PD-1 inhibitor 200 mg iv, every 21 days one cycle
215040732|NCT05786287|BIOLOGICAL|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
215040733|NCT05786287|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
215040734|NCT02268643|OTHER|ultrasound plus clinical breast examination|all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
215040735|NCT04904835|DIAGNOSTIC_TEST|Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|All samples will be tested with both CE-marked HBV serological predicate assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) and Access HBV serological assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) according to respective Instructions For Use to determine non-reactive (NR), initially reactive (IR), repeatedly reactive (RR), or confirmed or not confirmed Positive.
215040736|NCT01295710|BIOLOGICAL|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
215040737|NCT01295710|BIOLOGICAL|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
215040738|NCT00413348|DRUG|Lactobacillus acidophilus NCFM|
215057551|NCT04816981|DEVICE|EBUS-Elastography|Patients undergoing LN staging for lung cancer with EBUS-TBNA will have digital images and biopsy of every LN obtained in accordance with standards of care. Prior to the lymph node biopsy by EBUS-TBNA, elastography will be performed. The relative strain of tissues in the scanned area of the LNs will be displayed as a colour map, with stiffer areas in blue and softer tissue in red. Elastography and B-mode images will be displayed side by side and images recorded and saved onto an external drive for analysis. Elastography images will be fed to the NeuralSeg algorithm which has a network architecture similar to the standard U-Net for image segmentation. The automatically identified regions of interest will be overlaid onto the EBUS Elastography images to extract the LN stiffness measurements. After overlaying, NeuralSeg will determine the proportion of the LN area within 9 previously defined stiffness thresholds.
215040739|NCT05589987|DEVICE|power mobility|"Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded."
215040740|NCT04147273|DEVICE|Determination of postprandial glucose response by continuous glucose measurement after consuming different carbohydrate containing foods|"One day prior to the study beginning, participants were equipped with a CGM system (FreeStyle Libre®, Abbott Diabetes Care, Alameda, CA, USA). This CGM system provides glucose recordings every 15 min over a period of 14 days. The glucose data were downloaded manually by a scan with a handheld device.~On the second day of the study, participants consumed portions of these three test products containing 50 g of available carbohydrate on 3 separate days without a washout period. The products were tested in random order at the same time of the morning after a 10 h overnight fast. Venous blood samples were collected at 0, 15, 30, 45, 60, 75, 90, 105 and 120 min postprandial by inserting an intravenous cannula into a forearm vein. Capillary blood samples were obtained through finger pricking. Blood glucose levels in these samples were measured with a high quality SMBG system (ContourXT/Contour next, Ascensia Diabetes Care, Leverkusen, Deutschland, Germany)."
215040741|NCT00713011|DRUG|Adalat XL|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
214874735|NCT06362694|DRUG|Dabrafenib + Trametinib|Dabrafenib is an inhibitor of some mutated forms of BRAF kinases. Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib 623 and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumors.
214874736|NCT04762849|PROCEDURE|Laparoscopic one anastomosis gastric bypass|Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.
215040742|NCT00713011|DRUG|Tiazac XC|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
215040743|NCT02999607|OTHER|transcranial direct current stimulation|0.5 mA, 1mA, 2mA for 10 minutes each
215040744|NCT05098314|OTHER|Personalized interventions regarding the Cicat-Occitanie network|"First of all, healthcare professionals from EHPAD in the intervention arm were invited by email to answer a closed questionnaire. It was built by the authors, on Google forms, and consisted of 11 questions divided into 2 sections.~Section 1 collected data about the participants. In section 2, they were asked to score from 0 to 4 (ranging from not at all to a lot ) the various obstacles to teleconsultations reported by the literature."
215040745|NCT02785328|OTHER|memory evaluation at V1 and V2 (with treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
215040746|NCT02785328|OTHER|memory evaluation at V1 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
215040747|NCT02785328|OTHER|memory evaluation at V1 and V2 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
215040748|NCT00512564|OTHER|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
215040749|NCT01493414|DRUG|INC424|All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
215040750|NCT00051077|DRUG|Adefovir dipivoxil|
215040751|NCT00051077|DRUG|Peginterferon-alfa-2A|
215040752|NCT00051077|DRUG|Ribavirin|
215040753|NCT00051077|PROCEDURE|Liver Biopsy|
214666347|NCT02164565|DRUG|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
214666348|NCT02164565|DRUG|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
214666349|NCT00288210|PROCEDURE|Primary angioplasty in acute myocardial infarction|
214666350|NCT05689060|OTHER|mulling Straight leg raising technique|Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.
214666351|NCT05689060|OTHER|post facilitation stretch|Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
215057552|NCT00343499|DRUG|valsartan|
214476841|NCT06050720|DEVICE|Apne-Scan DC1 device|The primary objective of this exploratory study is to assess Apnea-Tech's UKCA Class I Apne-Scan DC1 sleep apnoea screening device in assisting a clinical diagnosis of sleep apnoea in comparison to standard sleep apnoea test devices (ResMed NOX T3 and Phillips Alice Night One).
214666352|NCT05068804|PROCEDURE|Cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
214666353|NCT05068804|OTHER|control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
214666354|NCT00542828|BIOLOGICAL|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
214666355|NCT00947102|OTHER|Observation|
214666356|NCT02558023|DRUG|Urapidil|"Urapidil (Eupressyl\*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
214666357|NCT02558023|DRUG|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
214666358|NCT03759652|BEHAVIORAL|before-after study|The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
214874737|NCT04762849|DEVICE|A shape-memory ring for adjustable gastric banding|A shape-memory ring (SMR) use for adjustable gastric banding. SMR is placed around the gastric pouch above the gastro-entero-anastomosis.
214874738|NCT04379791|OTHER|Data collection from routine medical records|Data collection from routine medical records for criteria for fracture related infections (FRI) and for wound complications. Data collection from routine medical records for risk factors.
214874739|NCT03289273|DRUG|Regorafenib (Stivarga, BAY73-4506)|As per the treating physicians discretion
214874740|NCT05916274|BIOLOGICAL|Blood and fecal samples|Blood and fecal samples will be performed
214874741|NCT05916274|PROCEDURE|Coolonic biopsies|colonic biopsies will be analysed
214874742|NCT03775044|DEVICE|Medherent Device|The Medherent Medication Management Device (MMD) is intended to enable patients to self-manage their medication at home when it may otherwise require assistance.
214874743|NCT05708989|PROCEDURE|Caudal Block|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
214874744|NCT05708989|PROCEDURE|Ultrasound-guided Pudendal Block|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
214874745|NCT05708989|DRUG|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
214874746|NCT05708989|DRUG|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
214874747|NCT05209165|DRUG|Semaglutide|weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program
214874748|NCT05209165|DRUG|Placebo|Matching placebo and intake visit for VA MOVE
214874749|NCT03585634|BEHAVIORAL|Dads in Gear Program|
214874750|NCT04608435|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
214874751|NCT06413043|DRUG|Selenium|Add on Selenium (100mcg once daily) with Vitamin B Complex and Standard Treatment for Grave's Disease
214874752|NCT01017796|DRUG|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
214874753|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|Starting dose 1.0 mg/kg/week given subcutaneously
214874754|NCT00085384|DRUG|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.25 mg/kg/week given subcutaneously"
214874755|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.5 mg/kg/week given subcutaneously~EG-Intron"
214874756|NCT05629975|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|"Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum\& bifidobacterium (500 mg) every day for 7 days."
214874757|NCT00856375|DRUG|NKTR-102|IV every 3 weeks
214874758|NCT00856375|DRUG|irinotecan|IV every 3 weeks
214874759|NCT06091670|OTHER|No intervention|There is no intervention. The research is cross-sectional-descriptive type.
214874760|NCT04380597|DRUG|Calcipotriene and betamethasone dipropionate aerosol foam|Prescribed according to clinical practice and following Product Data Sheet instructions
214874761|NCT02794597|BEHAVIORAL|SHINE intervention group|Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
214874762|NCT06174597|PROCEDURE|UCA-PSCs/bFGF or bFGF Intramuscular injection|After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
214874763|NCT04020783|OTHER|NO Intervention|NO Intervention
214874764|NCT01807247|PROCEDURE|Intensive lower limbs muscles strengthening|
214874765|NCT02943135|DRUG|lidocaine in-situ gel|lidocaine in-situ gel
214874766|NCT02943135|DRUG|placebo in-situ gel|placebo in-situ gel
214874767|NCT05885984|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) plus health education|Session 1: Reviewing experiences on struggles with CRF, realising consequence of controlling, introducing acceptance as an alternative, adopting virtual mindfulness. Education (patient): epidemiologic features of advanced lung cancer. Session 2: Separate thoughts/feelings related to CRF. Education (patient): treatments and symptoms of advanced lung cancer. Session 3: Reviewing caregiver's experiences of struggling with caregiving burden,introducing acceptance as an alternative. Education (caregiver): epidemiologic features of advanced lung cancer. Session 4: Separate caregivers' thoughts/feelings related to caregiving burden. Education (caregiver): treatments and symptoms of advanced lung cancer. Session 5:Understand the importance of values and clarifying personal values for dyads. Education (dyads): eating suggestions. Session 6: Emphasise ongoing value-based goals and commitment to actions for a meaningful cancer life for dyads. Education (dyads): exercising suggestions.
214874768|NCT05885984|OTHER|Health education|Session 1: health education on the epidemiologic features of advanced lung cancer will be taught to patients. Session 2: health education on treatments and related symptoms of advanced lung cancer will be taught to patients. Session 3: health education on the epidemiologic features of advanced lung cancer will be taught to caregivers. Session 4: health education on treatments and related symptoms of advanced lung cancer will be taught to caregivers. Session 5: health education on eating suggestions for advanced lung cancer patients and caregivers will be taught. Session 6: health education on exercising suggestions for advanced lung cancer patients and caregivers will be taught.
214874769|NCT01014377|DEVICE|VascuActive|
214874770|NCT01179711|DEVICE|Glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
214874771|NCT02922738|OTHER|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
214874772|NCT01010113|OTHER|Standard infant formula with prebiotics|From 0-6 months of age. As per standard requirement
214874773|NCT01010113|OTHER|Infant formula with synbiotics|From 0-6 months of age as per standard requirement
215040754|NCT04926116|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
215040755|NCT04926116|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
215040756|NCT03443635|BEHAVIORAL|Treatment|The intervention educates subjects through the hands-on cooking and nutrition education classes how to buy, cook, store, and consume healthy foods as an adjunct to healthy activity levels and avoidance of such health risks factors as smoking, excessive alcohol intake, and drug use.
215040757|NCT01072526|DRUG|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
215040758|NCT01072526|DRUG|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
215040759|NCT05589454|DRUG|Atorvastatin Calcium tablets 80mg|Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
215040760|NCT05589454|DRUG|Atorvastatin Calcium tablets 20mg|Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
215040761|NCT04402710|BEHAVIORAL|Self-compassion|Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes
215040762|NCT04402710|BEHAVIORAL|Control Group|Six week behavioural change program aimed to increase physical activity plus information on general health topics.
215040763|NCT02336061|BEHAVIORAL|Evaluation of gender differences on the psychosocial and economic impact.|
215040764|NCT03859037|OTHER|Umbilical cord milking|100 babies will have squeezing of blood from umbilical cord towards baby
215040765|NCT00414570|DRUG|[18]F-FLT PET scan|Injection of \[18\]F-FLT radiopharmaceutical followed by PET imaging.
215040766|NCT01977365|BEHAVIORAL|Growth promotion based on child centered approach|"\- Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.~Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.~Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.~\- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers."
215040767|NCT03612024|BEHAVIORAL|questionnaire|a standardized questionnaire was sent to all participants
215040768|NCT01977222|DEVICE|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
215057553|NCT06496308|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
214874774|NCT00576108|DRUG|KD7040 Topical Gel|KD7040 topical gel
214874775|NCT00576108|DRUG|Placebo gel|Placebo gel
214874776|NCT00385008|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
214874777|NCT00385008|DRUG|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
215040769|NCT01713439|BIOLOGICAL|Injection of allogeneic neuroblastoma cells|Patients will receive a fixed dose of IL-2 gene modified tumor cells (10\^7/kg, 10\^8 max) already shown to be safe from a previous protocol, and an escalating dose of Lptn transduced tumor cells, beginning at 10\^4/kg and rising to 10\^7/kg (10\^8 max). Patients will be assigned to an appropriate dose level for injection # 1. Injection #2 will contain 10 times more Lptn transduced cells than injection #1, until the max dose (10\^8) has been reached in the first injection. The dose of injections 3 through 8 will be the same as the dose of injection #2. Initial injection volumes will be \<1ml and should be injected in a single site. Only if these first patients show no undue local toxicity (including tumor cell growth) will multiple injection sites be used for subsequent high cell-dose studies.
214874778|NCT05537350|DIETARY_SUPPLEMENT|Lumenato|Supplementation of 12 weeks
214874779|NCT02953977|BEHAVIORAL|Diabetes Prevention Program|An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
214874780|NCT02210845|BEHAVIORAL|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
215040770|NCT02146443|OTHER|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
215040771|NCT02146443|OTHER|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
215040772|NCT02146443|DEVICE|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
215040773|NCT04124627|PROCEDURE|Ultrasound guidance in addition to radiographic guidance|Patients that will be operated will receive ultrasound guidance in addition to radiographic guidance, that is gold standard
215040774|NCT02514343|DRUG|Magnesium Sulfate|1ml of 10% magnesium sulfate with 1.5 ml of sterile water
215040775|NCT02514343|DRUG|Bupivacaine|1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
215040776|NCT04330976|BEHAVIORAL|Nutrition and physical activity intervention|Messages sent on nutrition and physical activity in pregnancy
215040777|NCT04330976|BEHAVIORAL|Control|Messages sent on general health during pregnancy
215040778|NCT05378412|BEHAVIORAL|3Cs|The 3Cs program is an educational strategy aimed at fostering resilience and compassion in people. It is based on improving the mental well-being of the participants by transforming their attitudes and behaviors through increased consciousness.
215040779|NCT00680628|DRUG|Tenecteplase + Enoxaparin|"Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.~Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: \<60Kg=30mg; ≥60Kg to \<70Kg=35mg; ≥70Kg to \<80Kg=40mg; ≥80Kg to \<90Kg=45mg; ≥90Kg=50mg"
215040780|NCT00680628|DRUG|0.9% Saline + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
215040781|NCT05922618|DEVICE|I-One|"I-ONE® is a medical device certified by the Ministry of Health as a Medical Device (risk class II A) for the treatment of inflammatory and degenerative tissue pathologies. The device consists of a signal generator and an applicator, called a solenoid. The solenoid will be placed on the joint, not necessarily in direct contact with the skin. The device works with a rechargeable battery and is equipped with an hour counter to assess patient compliance.~Treatment with I-ONE® therapy will start within 3-7 days of recruitment, will last 6 hours a day and will be maintained for 60 days. The treatment will be carried out at home and the device will be delivered directly to the patient's home by courier."
215040782|NCT06084351|DRUG|Convalescent Plasma|"Class: Blood product Physical Description: Opaque yellow fluid within a container labelled with the statement Caution: New Drug - Limited by Federal (or United States) law to investigational use). Container will also be labelled with the International Society of Blood Transfusion format for Blood Components. Label will contain the expiration date and the donor identification number. Label will also contain information pertaining to the ABO typing of the plasma. A copy of the IBST identifier will be placed with the patient chart.~Manufacture: Plasma will be collected via apheresis via collaboration with American Blood Bank Corporation, a FDA-registered blood establishment. The donors will be screened in accordance with the FDA guidance for donor eligibility for COVID-19:"
215040783|NCT06084351|OTHER|Standard of Care|Standard of care treatment for hospitalized COVID-19 patients
215040784|NCT05321329|DRUG|Capecitabine|Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
215040785|NCT03027674|DRUG|10% nifedipine cream|Topical treatment for Raynaud
215040786|NCT03027674|DRUG|5% sildenafil cream|Topical treatment for Raynaud
214874781|NCT02210845|BEHAVIORAL|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
214874782|NCT02210845|OTHER|Standard Care at BCDiabetes|usual care dictated by GCP at BCDiabetes.ca
214874783|NCT05231005|BIOLOGICAL|BNT162b2 vaccine|fourth dose of the BNT162b2 vaccine (30 microgram) adminstered IM
214874784|NCT02234219|PROCEDURE|Heart-shape anastomosis|a new operation approach for Hirschsprung disease
214874785|NCT02234219|PROCEDURE|Soave anastomosis|traditional approach for Hirschsprung disease
214874786|NCT03420586|DRUG|Nitrous Oxide|The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
214874787|NCT01153295|PROCEDURE|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
214874788|NCT01153295|PROCEDURE|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
214874789|NCT04582084|DRUG|Etanercept|Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
214874790|NCT02695784|DIETARY_SUPPLEMENT|Probiotic Continuation|This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
214874791|NCT04839484|DEVICE|Study Product|up to 2cc per injection of filler placed into nasolabial fold.
214874792|NCT04839484|DEVICE|Active Control|up to 2cc per injection of filler placed into nasolabial fold.
215040787|NCT06303427|OTHER|Modified constraint-induced movement therapy|"The unaffected arm will be restricted by using an upper extremity sling that will strap to the child's trunk with a distal end fastened to prevent the movement of the unaffected limb.~The modified constraint-induced movement therapy will include these exercises.~1. Playing with ball.~2. Playing with modeling clay.~3. Playing with LEGOS (building towers or different shapes from the toy bricks).~4. Tearing a paper towel from a roll.~5. Holding and eating biscuits.~6. Eating with a spoon.~7. Drinking from a glass.~8. Combing hair.~9. Brushing teeth.~10. Making bubbles using a bubble blower.~11. Pulling a toy.~12. Placing a hat or piece of cloth on the head.~13. Applying lotion to the trained caregiver."
214874793|NCT00003302|PROCEDURE|biopsy|
214874794|NCT00003302|DIAGNOSTIC_TEST|magnetic resonance imaging|
214874795|NCT00003302|DIAGNOSTIC_TEST|mammography|
214874796|NCT03201445|DRUG|Filgotinib|200 mg tablet administered orally once daily
214874797|NCT03201445|DRUG|Placebo|Placebo to match filgotinib tablet administered orally once daily
214874798|NCT03201445|DRUG|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
214874799|NCT04873973|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
214874800|NCT01228019|DRUG|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
214874801|NCT05179330|DEVICE|OMEGO®|Lower limb rehabilitation with and without visual feedback
214874802|NCT03892499|DRUG|Olinciguat|Oral Tablet
214874803|NCT03892499|DRUG|Itraconazole|Oral Capsule
214874804|NCT06301906|DRUG|LipoCol Forte Capsule 600mg bid|LipoCol Forte Capsule 600mg bid for 12 months
214874805|NCT03191591|BEHAVIORAL|First 1,000 Days Program Site|Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
214874806|NCT01577550|DRUG|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
214874807|NCT01577550|DRUG|Placebo, i.v.|Single i.v. administration of placebo
214874808|NCT01577550|DRUG|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
214874809|NCT01577550|DRUG|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
214874810|NCT01577550|DRUG|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
214874811|NCT01577550|DRUG|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
214874812|NCT01577550|DRUG|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
214874813|NCT01577550|DRUG|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
214874814|NCT01577550|DRUG|Placebo, s.c.|Single s.c. administration of placebo
214874815|NCT01577550|DRUG|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
214874816|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3 + bracket|
214874817|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3|
214874818|NCT02132806|PROCEDURE|Piezosurgery|
214874819|NCT06297915|DRUG|Ketamine|Ketamine infusion was administered at 1 mg/kg (in 1 hour)
214874820|NCT06297915|DRUG|Lidocain|Lidocaine infusion was administered at 3 mg/kg (in 1 hour)
214874821|NCT02914210|DEVICE|Virtual physical therapy rehabilitation program|Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
214874822|NCT02914210|OTHER|No intervention|Traditional physical therapy delivered in clinic or via home-health visits
214874823|NCT01241110|DRUG|Ofloxacin group A, Azitromycin group B|Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
214874824|NCT01241110|DRUG|azitromycin|azitromicin vs ofluxacin
214874825|NCT00144157|DRUG|Nevirapine|
214874826|NCT00144157|DRUG|Zidovudine|
214874827|NCT00144157|DRUG|3TC|
214874828|NCT03153033|BEHAVIORAL|Fatigue protocol|The figure 8 protocol (fatigue intervention) requires the participants to propel three times as many laps as possible for four minutes each with their wheelchair. The protocol has been developed and used previously. Every bout of four minutes is separated by 90 seconds of rest. Each lap consists of a right and left turn and two complete stops after half a lap. Measurements during the protocol include the Rate of Perceived Exertion (RPE) scale, heart rate, and propulsion kinetics.
214874829|NCT00534456|DRUG|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
214874830|NCT00534456|DRUG|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
214874831|NCT05577195|DEVICE|Impella|To provide active left ventricular unloading in the experimental arm
214874832|NCT05577195|DEVICE|VA-ECMO|To provide circulatory support in both arms
214874833|NCT03354260|OTHER|Personalized adapted oral diet and nutritional education|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
214874834|NCT01774708|DEVICE|Pressure sensitive pad|"The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.~This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient."
214874835|NCT06975501|BEHAVIORAL|Exercise Intervention|Participants will receive twice-weekly aerobic and balance training sessions, with medication compliance education.
214874836|NCT06975501|BEHAVIORAL|Cognitive Intervention|Participants will participate in twice-weekly structured cognitive training sessions, with medication compliance education.
214874837|NCT01963286|DEVICE|ICD with enhanced SVT discriminators|ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
214874838|NCT03663634|OTHER|Cytochalasin B use in ICSI handling medium|A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate
214874839|NCT04091711|DEVICE|ReX-C system|Oral oncolytic medications are dispensed to patients via ReX-C system
214874840|NCT04278950|DRUG|Povidone-Iodine|For the PVP-I group, the final concentration of available iodine in the solution will be 0.01%, (from diluting 10% PVP-I solution), as previously demonstrated to be below ciliotoxic levels of 1.25% and greater than 0.01% which is the lower limit of active potency.
214874841|NCT04278950|DRUG|Placebos|The placebo will be 2.5mL of saline with brown food coloring.
214874842|NCT02581722|DEVICE|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
214874843|NCT06182761|DRUG|Sunvozertinib combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.
214874844|NCT04810949|DIETARY_SUPPLEMENT|Vitamine D3 supplementation|1\. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
214874845|NCT04810949|DIETARY_SUPPLEMENT|Diet and sun exposure|"2\. Hygienic-dietary recommendations will consist of 2 steps~1. Sun exposure at least 10 minutes a day from 10: 00-6: 00 pm~2. Consumption of foods rich in vitamin D: milk, fish, almonds, mushrooms"
214874846|NCT06484725|GENETIC|Oncotype DX assay|Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with ER-positive and human epidermal growth factor 2 (HER2)- negative breast cancer (BC); nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. According to Oncotype DX Recurrent Score (RS)® a high RS shows a worse prognosis and predicts chemotherapy benefit in patients with ER-positive HER2-negative BC.
214874847|NCT06407986|DIAGNOSTIC_TEST|pulmonary function test|Whether the estimated value of FEV1 and FVC is greater than 80%.
214874848|NCT05509816|DRUG|Midazolam|Administered orally.
214874849|NCT05509816|DRUG|Imlunestrant|Administered orally.
214874850|NCT02087189|DEVICE|First ICD/CRT-D implantation or upgrade from pacemaker|
215040788|NCT06303427|OTHER|Electrical stimulation|The participants in this group will first receive a 20-minute session of electrical stimulation (on time of 10 s, off time of 30 s, pulse rate of 35 Hz, the pulse width of 300 µs).
215040789|NCT03630146|BEHAVIORAL|iPeer2Peer program|In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
215040790|NCT03630146|OTHER|Waitlist control|The control group will receive standard care but without the iPeer2Peer Program.
214874851|NCT04570462|OTHER|Hypothermia Via Cooling Machine- Arctic Sun 5000|"Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.~Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming.~The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject."
214874852|NCT05375877|DEVICE|iATROS|"The digital eHealth platform of iATROS in combination with a wearable will be used independently by the subjects of the study. In particular, the reminder function is used to remind patients to record their ECGs, take medication and perform other tasks they may have created themselves, or to use other iATROS functions, such as teleconsultation or remote medical data reporting. Furthermore, the designed training program for atrial fibrillation patients teaches them how to deal with their own disease.~If unhealthy or dangerous vital signs are detected during the use of these medical devices over a longer period of time, the patient receives feedback through the application for medical presentation. This includes the detection of atrial fibrillation recurrences."
214874853|NCT03203564|DRUG|Modufolin (arfolitixorin)|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
214874854|NCT02377050|OTHER|Higher Volume Feeding Goal|feeding volume goal of 180-200 ml/kg/day
214874855|NCT04429438|BIOLOGICAL|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after conventional chemotherapy will be treated with multiple 4SCAR gene-engineered T cells
214874856|NCT00500136|PROCEDURE|mortality salience|
214874857|NCT05129007|DEVICE|Oura ring|Photopletysmography based noninvasive device
214874858|NCT05434429|OTHER|mobile application|Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
214874859|NCT05865730|OTHER|Live Bacterial Product - Akkermansia muciniphila|Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
214874860|NCT01189487|DRUG|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
214874861|NCT04386486|OTHER|Bathe anamnesis method|BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.
214874862|NCT04386486|OTHER|standart anamnesis|standart anamnesis is applied to second group and preoperative examinations are completed.
214874863|NCT01879748|DRUG|Rasagiline|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
214874864|NCT01879748|DRUG|Placebo|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
214874865|NCT04630158|OTHER|SAF312 Placebo|Topical ocular, suspension eye drops
214874866|NCT04630158|DRUG|SAF312|Topical ocular, suspension eye drops
214874867|NCT03363386|PROCEDURE|Proprioceptive Exercises|Patients trained for proprioceptive exercises
214874868|NCT03363386|PROCEDURE|Resistive Exercises|Patients trained for resistive exercises
214874869|NCT03363386|PROCEDURE|Aerobic Exercise|Patients were educated with treadmill walking for 30 minutes of each exercise session
214874870|NCT05162014|DRUG|empagliflozin|empagliflozin
214874871|NCT05162014|DRUG|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
215040791|NCT03109405|DEVICE|Stimulation-assisted venous access|Stimulation-assisted venous access
215040792|NCT03109405|OTHER|20 guage cannula for IV, tourniquet optional|Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
215040793|NCT03243773|OTHER|Lung ultrasound|Point-of-care ultrasound exam of both lungs in 4 predefined zones.
214874872|NCT00120679|DRUG|darbepoetin alfa|
214874873|NCT00120679|DRUG|recombinant human erythropoietin (rHuEPO)|
214874874|NCT04594317|DEVICE|low level laser therapy|buccal application of diode laser on non-contact mode
215040794|NCT05626712|BIOLOGICAL|CELZ-201 Administration|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10\^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.
215040795|NCT05626712|OTHER|Control Group|Enhanced standard of care for Type 1 Diabetes treatment only.
215040796|NCT00808392|BIOLOGICAL|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
214874875|NCT02074618|OTHER|Physical exercise.|Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
214874876|NCT00912925|BIOLOGICAL|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
214874877|NCT00912925|BIOLOGICAL|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
214874878|NCT03136965|BIOLOGICAL|PRP|Injection of autologous platelet rich plasma (PRP)
214874879|NCT03136965|PROCEDURE|Dry Needling|This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
215040797|NCT00808392|BIOLOGICAL|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
215040798|NCT02976181|DEVICE|IPG|Patient might require IPG device to be implanted under standard of care
215040799|NCT00641264|DRUG|Omeprazole|
215040800|NCT00641264|BEHAVIORAL|Quality of Life questionnaire|
215040801|NCT05849766|DRUG|Dapagliflozin Farxiga®|Dapagliflozin 10 mg once daily
215040802|NCT05849766|DRUG|Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®|Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily
214874880|NCT03136965|PROCEDURE|Dry Needling - Sham|This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
214874881|NCT04152187|OTHER|Inspiratory muscle training|The treatment group will receive inspiratory muscle training.
214874882|NCT03485365|DRUG|GSK3858279 IV|GSK3858279 will be available as solution for injection to be administered via IV route.
214874883|NCT03485365|DRUG|GSK3858279 SC|GSK3858279 will be available as solution for injection to be administered via SC route.
214874884|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC or IV)|Placebo will be available as sodium chloride solution to be administered via SC or IV route.
214874885|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC)|Placebo will be available as sodium chloride solution to be administered via SC route.
214874886|NCT04868968|DRUG|DFV890|100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.
215040803|NCT02923154|DRUG|MT-3995|
215040804|NCT02923154|DRUG|Placebo|
215040805|NCT06463184|DRUG|Xevinapant|Xevinapant is an investigational medication, taken orally, that promotes cancer cell death via apoptosis.
215040806|NCT04773665|BIOLOGICAL|VBI-2902a|VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
215040807|NCT04773665|BIOLOGICAL|Placebo|0.9% sodium chloride
215040808|NCT04773665|BIOLOGICAL|VBI-2905a|VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
215040809|NCT03383042|DRUG|Cohort 1 (JP-1366 A mg)|Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
215040810|NCT03383042|DRUG|Cohort 2 (JP-1366 B mg)|Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
215040811|NCT03383042|DRUG|Cohort 3 (JP-1366 C mg)|Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
215040812|NCT03383042|DRUG|Cohort 4 (JP-1366 D mg)|Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
215040813|NCT03383042|DRUG|Cohort 5 (JP-1366 E mg)|Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
214874887|NCT00767624|DRUG|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
214874888|NCT00767624|BEHAVIORAL|Desensitization Therapy for Insomnia|
214874889|NCT00767624|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|
214874890|NCT01410643|OTHER|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
214874891|NCT04159870|DRUG|Rifaximin|Rifaximin pills 400 mg x 3/day
214874892|NCT04159870|DRUG|Norfloxacin|Norlfloxacin 400 mg 1 pill/day
214874893|NCT01349777|DRUG|Pregrel®|Pregrel® 75mg daily for 12 months
214874894|NCT01349777|DRUG|Plavix®|Plavix® 75mg daily for 12 months
214874895|NCT02563392|PROCEDURE|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
214874896|NCT02563392|PROCEDURE|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
215040814|NCT03383042|DRUG|Cohort 6 (JP-1366 F mg)|Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
215040815|NCT03383042|DRUG|Cohort 7 (JP-1366 G mg)|Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
215040816|NCT03383042|DRUG|Cohort 8 (JP-1366 H mg)|Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
215040817|NCT03383042|DRUG|Cohort 9 (JP-1366 I mg)|Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
215040818|NCT02192567|DRUG|DS-5573a|"Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1."
215040819|NCT04946695|OTHER|Telefisio India|Implement telephysiotherapy programmes in low-resource areas.
215040820|NCT03215043|DIETARY_SUPPLEMENT|Eriocitrin|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
215040821|NCT03215043|OTHER|Placebo|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
215040822|NCT03574961|BEHAVIORAL|e-Support group|Online (remote), web-based support group via private video link.
215040823|NCT03574961|BEHAVIORAL|e-Journaling placebo|Online journaling activity.
215040824|NCT05884125|DEVICE|Checkpoint BEST System|Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair
215040825|NCT05880147|DEVICE|Consent App|Family will receive their study information and consent form in an app on a tablet
215040826|NCT05880147|OTHER|Traditional paper-based consent|Patient/family will receive their study information and consent on a traditional paper form
215040827|NCT06105866|DIAGNOSTIC_TEST|Tricuspid Annular Plane Systolic Excursion|Transthoracic echocardiography will be performed on patients during hospitalization and preoperatively to investigate the relationship between preoperative fasting and right ventricular functions. This will be examined by looking at TAPSE
215040828|NCT01605669|OTHER|Tranthoracic Echocardiogram|standard measurement
215040829|NCT01605669|DEVICE|Cardiac Ascultation Recordings with Electronic stethoscope|3M device
215057554|NCT06496308|DRUG|Bendamustine|Bendamustine IV will be administered as per the schedule specified in the respective arm.
215057555|NCT06496308|DRUG|Rituximab|Rituximab IV will be administered as per the schedule specified in the respective arm.
215040830|NCT04389073|DRUG|Vinorelbine 40mg|Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
215040831|NCT04389073|BIOLOGICAL|Toripalimab 240mg|Toripalimab 240 MG IV infusion every 3 weeks. Toripalimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
215040832|NCT04389073|BIOLOGICAL|Bevacizumab 5 mg/kg|Bevacizumab 5 mg/kg IV infusion every 3 weeks. Bevacizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
215040833|NCT04389073|DRUG|Cyclophosphamide 50 mg|50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
214874897|NCT04269681|DEVICE|High Flow Nasal Cannula|"Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher \& Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature.~The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea.~The HFNC should be offered to the patient in ARF as follows:~* Initial parameters: Flow 45 ml / L, FiO2 50%, AIRVO 37oC temperature;~* Titrate the flow up to 60ml / L or up to the maximum tolerated;~* Titrate FiO2 to maintain SatO2 between 92% to 98%, starting with 50%;~* Keep the AIRVO temperature at 37oC, if not possible, acceptable down to 34oC."
215040834|NCT04389073|DRUG|Capecitabine 500Mg Oral Tablet|500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
215040835|NCT04389073|DRUG|Cisplatin|Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
215040836|NCT06476678|DEVICE|Speedboat™ Ultraslim|Use of Speedboat™ Ultraslim for performing endoscopic submucosal dissection of esophageal lesions.
215040837|NCT06510036|OTHER|The post-processing generated after scanning is converted into energy spectrum image data (SBI)|It will not open special sequences for patients, will not increase the cost of diagnosis and treatment, will not increase radiation exposure during enhanced CT scanning, and will not affect the normal diagnosis and treatment process of patients throughout the process.
215040838|NCT06402162|OTHER|exercise|The study will include 40 tennis players diagnosed with rotator cuff lesions who meet the inclusion criteria. The 1st group will be randomly divided into 2 groups as control (n=20) and 2nd group as core exercise (n=20). Unlike the control group, core exercises will be added to the routine exercise program of tennis players once a day, 3 days a week for 8 weeks.
215040839|NCT00945659|DEVICE|Continuous Glucose Sensor|Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
215040840|NCT00945659|OTHER|Standard Care|Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
215040841|NCT00945659|BEHAVIORAL|CGS + Behavior Therapy|Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
215040842|NCT06568419|BEHAVIORAL|Transdiagnostic, work-focused Cognitive Behavioural Therapy|Transdiagnostic, work-focused Cognitive Behavioural Therapy focuses on core mechanisms that creates and maintain illness in depression and anxiety. Namely reducing avoidance and/or suppression of unwanted thoughts, avoidance of meaningful activity and increase cognitive flexibility while under psychological stress.
215040843|NCT06186232|PROCEDURE|guided bone regeneration (GBR).|guided bone regeneration (GBR) using polymethylmethacrylate (PMMA) polymer as membrane.
215040844|NCT06492928|OTHER|Psychomotor Vigilance Task|T0 - at the start of the shift: completion of the 1st PVT / socio-demographic and workstation questionnaire T1 - at the end of the shift: completion of the second PVT and questionnaire on the course of the shift that has just taken place T2 - 1 week after the end of the shift: additional questionnaire sent with scales to assess work-related fatigue (MBI), anxiety (PSS), sleep quality (PSQI) and chronotype (MEQ).
215040845|NCT03325504|BIOLOGICAL|Cultured Mesenchymal Stem Cells|Cultured Mesenchymal Stem Cells obtained from expanded bone marrow
215040846|NCT03325504|PROCEDURE|Autologous iliac crest graft|Autologous iliac crest grafting
215040847|NCT05514288|PROCEDURE|Endobariatric procedure|Endoscopic sleeve gastroplasty or transoral outlet reduction
215040848|NCT03108196|PROCEDURE|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
215057556|NCT06496308|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
215057557|NCT00367562|DRUG|ENALAPRIL VALSARTAN METHYLPREDNISONE|
215057558|NCT03179852|BEHAVIORAL|nutrition education|nutrition education
214291352|NCT05973383|BEHAVIORAL|LongLife Active- Premium|"The digital service LongLife Active with three core subjects:~1\) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Premium are also offered a community with social support plus private on-line health consultations. The number of private health consultations is 3 for a 3 months subscription, 4 for a 6 months subscription, and 6 for a 12 months subscription."
214291353|NCT04284618|DIAGNOSTIC_TEST|assessment of standardized and off axis view radiographs|Radiographic assessment of hallux valgus interphalangeus angles is performed on preoperative standing anteroposterior and on off axis view radiographs. These radiographs are taken by equalizing the hyperpronation of the greater toe.
214874898|NCT04269681|OTHER|Standard respiratory support|The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea. For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team. NIPPV will be performed with the patient in a supine position at 45 degrees. The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage. A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort. The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
214874899|NCT04292652|PROCEDURE|AAA surgery|EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
214874900|NCT02345837|DEVICE|endometrial sampling|injury to the endometrium
214874901|NCT02345837|DRUG|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
214874902|NCT00403637|DRUG|indacaterol maleate|
214874903|NCT03885752|DRUG|chewed mint gum|In the preoperative waiting area before transferring to the operating room, patients in group G chewed mint gum for 2 minutes and then spit it out.
214874904|NCT03885752|OTHER|swallow twice|asked to swallow twice without any additional treatment.
214874905|NCT01865942|PROCEDURE|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
214874906|NCT01865942|PROCEDURE|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
214874907|NCT06462560|OTHER|Vivo Online Exercise Program|Virtual online exercise programs conducted by the Vivo team consisting of multiple time a week group live programs
214874908|NCT06462560|OTHER|Medbridge Home program|At home exercise program accessed through exercise descriptions and short vidoes
214874909|NCT06532851|OTHER|Progressive Resistance Exercise (PRE)|A structured exercise regimen focusing on increasing muscular strength and endurance through progressive resistance.
214874910|NCT06532851|OTHER|Aerobic Exercise|An exercise program focusing on cardiovascular conditioning using a stationary bike.
214874911|NCT06532851|OTHER|Control|A set of general strength and balance exercises that do not target the specific therapeutic goals of the other interventions.
214874912|NCT01871571|BIOLOGICAL|bevacizumab|Given IV
215040849|NCT03108196|PROCEDURE|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
214874913|NCT01871571|DRUG|oxaliplatin|Given IV
214874914|NCT01871571|DRUG|leucovorin calcium|Given IV
214874915|NCT01871571|DRUG|fluorouracil|Given IV
214874916|NCT01871571|OTHER|laboratory biomarker analysis|Correlative studies
214874917|NCT00865371|DRUG|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
214874918|NCT00865371|DRUG|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
214874919|NCT00763061|DRUG|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo \& 9 PM
214874920|NCT00763061|DRUG|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM \& 9 PM
214874921|NCT03661697|DEVICE|Laser Therapy|"Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face."
214874922|NCT03661697|OTHER|Basic Skin Care Regimen|Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
214874923|NCT03661697|OTHER|Lytera|cosmeceutical serum applied to face daily for 12 weeks
214874924|NCT01789723|DRUG|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
214874925|NCT01789723|DRUG|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
214874926|NCT02910063|DRUG|Blinatumomab|Blinatumomab monotherapy
214874927|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour infusion, every 3 weeks
214874928|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-min infusion, every 3 weeks
214874929|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour infusion, every 3 weeks
214874930|NCT05949411|OTHER|Screening visit|Subjects will be invited to perform the screening visit to sign the informed consent and then to ensure that they are able to participate in this study.
214874931|NCT05949411|OTHER|Lactulose test|Fasted subjects (at least 10 hours) will receive on oral load of 10 g of lactulose. Then, exhaled H2 will be measured every 30 minutes during 4 hours.
214874932|NCT05949411|OTHER|Administration of standardized meals with characterized dietary fiber content|Subjects will receive standardized breakfasts and lunches characterized in terms of dietary fiber content. Urine, saliva, feces samples will be collected. Breath test and gastrointestinal symptoms will be followed during maximum 8h. Subjects will also complete SF36 questionnaire, food diary and stool/transit questionnaire.
214874933|NCT05233111|BEHAVIORAL|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.
214874934|NCT05233111|BEHAVIORAL|Treatment as Usual|This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
214874935|NCT05540028|BIOLOGICAL|IVT PCV-25|25 valent pneumococcal conjugate vaccine
215040850|NCT06746428|BEHAVIORAL|Exercise Coaching|An exercise coaching program tailored for women with Stage I-IVA endometrial cancer who have undergone total or modified radical hysterectomy with surgical staging. The intervention targets a total of 8 participants who are planned to complete pelvic external beam radiation therapy as part of their adjuvant treatment.
215040851|NCT03352765|DRUG|rituximab|rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
215040852|NCT03352765|DRUG|bendamustine|bendamustine 160 mg/m2 intravenously on days -3 and -2
215040853|NCT03352765|DRUG|melphalan|melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
215040854|NCT03352765|PROCEDURE|Autologous Stem Cell Transplantation (ASCT)|reinfusion of autologous stem cells on day 0.
215040855|NCT04401462|PROCEDURE|Tension band wiring or plate fixation|Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name
215040856|NCT04401462|BEHAVIORAL|Sling or a long-arm plaster|Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
215040857|NCT06638476|OTHER|Perturbation Induced Step training|A sudden lateral displacement of the treadmill.
215040858|NCT06638476|OTHER|Voluntary step training|Voluntary steps emphasizing speed, movement of center of mass and taking larger steps.
215040859|NCT06642727|BEHAVIORAL|laughter yoga|Laughter yoga reduces stress levels through sessions lasting approximately 40 minutes without any invasive or pharmacological interventions. It regulates breathing, relaxes muscles, stimulates circulation, increases pain thresholds, strengthens immunity, lightens the mind, enhances social relationships, promotes mental balance, and boosts self-esteem, hope, energy, and quality of life. The content of a session includes deep breathing exercises, warm-up exercises, childlike games, and laughter exercises.
215040860|NCT04299984|PROCEDURE|Open Conversion after EVAR|"See Open Conversions group description."
214874936|NCT05540028|BIOLOGICAL|PCV 20|20 valent pneumococcal conjugate vaccine
215040861|NCT04299984|PROCEDURE|SemiConversion after EVAR|"See SemiConversions group description."
215040862|NCT06644820|DIAGNOSTIC_TEST|radiology|"Chest x ray posteroanterior view and lateral view.~CT. chest without contrast:~To assess the underlying lung pathology e.g. multiple bullae, interstitial lung disease (ILD) , cavitating lesions or nodules."
215040863|NCT05140239|OTHER|No Intervention|Non Interventional
215040864|NCT03232918|DRUG|Half dose Oxytocin|Patients randomized to the half dose oxytocin group will have the oxytocin infusion reduced to 50 % prior to placement of combined spinal epidural for labor analgesia
214874937|NCT04590638|OTHER|tumescent with adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.
214874938|NCT04590638|OTHER|tumescent without adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
215040865|NCT00216190|DRUG|Dexmedetomidine HCL Injection|
215040866|NCT00216190|DRUG|Midazolam Injection|
215040867|NCT02026167|BEHAVIORAL|Collaborative Care|Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
215040868|NCT05601128|DRUG|CAB + RPV|At Day 1 all participants will initiate oral CAB 30 mg + RPV 25 mg once daily for at least 28 days during the Oral Phase. Participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections at month 1 visit followed by CAB LA 400 mg + RPV LA 600 mg IM injections monthly at M2, M3, M4 and M5 visits. Then, starting at month 6 visit, participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections every 2 months at M6, M8, M10 and M12.
215040869|NCT06572072|DEVICE|Negative Pressure Ventilation|Substitution of positive pressure ventilation by negative pressure ventilation
215040870|NCT05905172|DRUG|Hydronidone capsules|After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.
215040871|NCT05905172|DRUG|The placebo capsules|After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
215040872|NCT04562116|DRUG|Nemolizumab|Nemolizumab 30 mg will be administered as SC injections.
215040873|NCT04562116|DRUG|CYP 450 Substrates|CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially available prescribing information.
215040874|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
215040875|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
215040876|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
215040877|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
215040878|NCT04258748|BEHAVIORAL|Motivational Interviewing (MI)|In each of the four MI counseling sessions that were delivered, the researcher approached mothers in small groups of 5 via three phases, in 15-30 minutes, to establish rapport/ alliance in the first phase, to identify health needs in the second phase and finally to reinforce dental needs in the third phase.
214874939|NCT05179538|BEHAVIORAL|Cued picture-naming therapy|The proposed study will administer Cued Picture-Naming Treatment (CPNT) four days per week for four weeks (i.e. 16 sessions). During therapy, participants will attempt to name eight consecutive presentations of the same black and white picture, for each of the 20 pictures, with cueing from the administrator. Trials will include (1) independent naming, (2) orthographic cueing (i.e. the written word beneath the picture.), (3) repeating, (4) naming after a short delay (i.e. approximately three seconds), (5)semantic cueing (i.e. three cues providing semantic information about the target will be spoken to the participant by the clinician), (6) phonological cueing (i.e. the first sound and letter will be spoken by the clinician), (7) repeating, and (8) naming after a short delay. The administrator will provide the correct response for each incorrect participant response and will ask the participant to repeat it.
214874940|NCT02752087|DRUG|LY900014|Administered SC
214874941|NCT00343356|DRUG|Trement|
214874942|NCT02474875|OTHER|Educational program|Patients in experimental groups will receive different educational sessions (contents and duration)
214874943|NCT04204473|DRUG|TY-9591(10mg,40mg) qd. po|Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
214874944|NCT03975231|DRUG|Dabrafenib|Given PO
214874945|NCT03975231|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214874946|NCT03975231|DRUG|Trametinib|Given PO
214874947|NCT03460392|DRUG|Antibiotic therapy|To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
214874948|NCT06633055|DRUG|JH013 injection|JH013 injection is a BAFF-R inhibitor monoclonal antibody
214874949|NCT06633055|DRUG|Placebo|JH013 injections placebo
214874950|NCT00843635|DRUG|Tadalafil|Given orally
214874951|NCT00843635|OTHER|Placebo|Given orally
214874952|NCT03408535|OTHER|Eriksholm Guide to Better Hearing|Online rehabilitation program.
214874953|NCT01547130|DRUG|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
214874954|NCT01547130|DRUG|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
214874955|NCT01324505|DRUG|semaglutide|Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
214874956|NCT01324505|DRUG|placebo|Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
214874957|NCT01324505|DRUG|Microgyn®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
214291354|NCT05847231|BEHAVIORAL|Perceived Stress, Mandala application|Mandala
214291355|NCT05670392|DEVICE|laser and High intensity Tesla magnetic stimulation|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals followed by Eight (8) HITS therapies) Patients will receive two (2) HITS treatments per week for four (4) weeks(.
214874958|NCT06310304|DRUG|Ruxolitinib IR|Tablet
214874959|NCT06310304|DRUG|Ruxolitinib XR|Tablet
214874960|NCT00776750|BIOLOGICAL|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
214874961|NCT00140348|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
214874962|NCT04523935|OTHER|Placebo|Fructose powder identical with the drugs was used
214874963|NCT04523935|DRUG|Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.|Drugs were used either singly or in combination guided by clinical findings and investigations.
214291356|NCT05670392|DEVICE|laser (without HITS treatment)|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals as described above.
214874964|NCT02457663|PROCEDURE|Blood Draw|Blood is to be collected at admission, prior to the 1st operating procedure, once daily for the following 7 consecutive days, at day 15, and at discharge (11 blood draws total). Blood will be taken from IV catheter or routine venipuncture if the catheter is not in place. The blood draw will occur prior to the induction of anesthesia or operating surgical procedure.
214874965|NCT02803424|OTHER|Volume controlled ventilation|During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.
214874966|NCT02803424|OTHER|Autoflow-volume controlled ventilation|After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
214874967|NCT03496610|DRUG|Liposomal Bupivicaine|Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
214874968|NCT03496610|PROCEDURE|QL Block|Patient will receive ultrasound guided QL Block
214874969|NCT02143921|BEHAVIORAL|Training intervention|Intervention group service providers received intervention training
214874970|NCT03013855|DEVICE|FIT-SOC|Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
214874971|NCT03013855|DEVICE|FIT-DRE|Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
214874972|NCT04435184|DRUG|Crizanlizumab|Crizanlizumab 5.0 mg/kg in 100 ml IV once.
214874973|NCT04435184|OTHER|0.9% saline|0.9% saline 100 ml IV once.
214874974|NCT02714426|BEHAVIORAL|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
214874975|NCT02714426|OTHER|Brain health|Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
214874976|NCT03360084|PROCEDURE|Percutaneous lung biopsy under CT guidance|Percutaneous lung biopsy under CT guidance
214874977|NCT05046743|OTHER|Colonic gas load|Colonic infusion of gas via an anal cannula
215040879|NCT04258748|BEHAVIORAL|Gaming and MI|In each of the four MI counseling sessions, the researcher approached mothers via three phases, in 15-30 minutes, to establish rapport/ alliance, to identify and finally reinforce dental needs in the same pattern as MI group. In addition, the children were engaged in 'Happy Teeth, Healthy Kids' which is an android tablet game that was included in the MI session scheduled for the mothers. Children were told to follow correct steps of brushing in order to obtain happy bright teeth. This helped the children realize that brushing teeth will give them a bright smile.
215040880|NCT04258748|BEHAVIORAL|Conventional dental health education|It was delivered through a 15-minutes oral health session given to mothers of preschoolers. Mothers were given brief information about causes of dental caries and role of plaque, toothbrush size, diet / frequency of sweet snacks, brushing technique, toothpaste and fluoride use as well as regular dental visits. Participants were then shown a short educational video about prevention of dental caries among children coupled with oral hygiene instructions. At the end of the session, participants were given a leaflet reinforcing the information to take home.
215040881|NCT03525847|DIAGNOSTIC_TEST|Endosonography|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control. Passage in the same pancreatic mass of first using standard FNA method then contrast enhanced FNA method or vice versa according to the randomization
215040882|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the modified approach|The modified approach includes the ipsilateral calf venous access and the contralateral femoral venous access. Through contralateral femoral venous access, a hydrophilic guide wire and a catheter will be crossover through the thrombus side to the distal calf vein. The ipsilateral calf venous access will be punctured under the guidance of ascending venography. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
215040883|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the traditional approach|The traditional approach will be punctured from the ipsilateral popliteal vein under ultrasound guidance. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
215040884|NCT02898948|BIOLOGICAL|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
215040885|NCT00534001|DRUG|bupropion hydrochloride|Given orally
215040886|NCT00534001|OTHER|placebo|Given orally
215040887|NCT05964686|COMBINATION_PRODUCT|Conventional group (NaOCl/EDTA)|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
215040888|NCT05964686|COMBINATION_PRODUCT|Dual laser group (Er,Cr:YSGG/Diode):|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
215040889|NCT05964686|COMBINATION_PRODUCT|Combined group (EDTA/Diode):|17% EDTA was used to remove smear layer followed by diode laser for disinfection
215040890|NCT01136369|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
215040891|NCT05831943|DIAGNOSTIC_TEST|Contrast enhanced Kidney CT|"* Test group : Patient undergoing CT scan with 80kVP protocol and using low concentration intravascular contrast media ( Iobrix 270 mgl/MI , Taejoon pharm, Seoul, South Korea)~* Control group : Patient undergoing CT scan with 120kVP protocol and using high concentration intravascular contrast media ( Iobrix 320 mgl/MI , Taejoon pharm, Seoul, South Korea)"
215040892|NCT03501628|DIETARY_SUPPLEMENT|Placebo|Supplementation twice daily (1 serving dose per consumption) of maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
214874978|NCT05046743|OTHER|Sham load|Sham infusion of gas via an anal cannula
214874979|NCT01727726|DRUG|Brexpiprazole|tablet/capsule
214874980|NCT01727726|DRUG|Seroquel XR|tablet/capsule
214874981|NCT01727726|DRUG|Placebo|tablet/capsule
214874982|NCT03939715|BIOLOGICAL|DermaPure®|Surgical intervention using DermaPure®
214874983|NCT03939715|PROCEDURE|native tissue|Surgical intervention using native tissue
214874984|NCT04333030|OTHER|questionnaire|Tobacco Use and Risk Questionnaire
215040893|NCT03501628|DIETARY_SUPPLEMENT|L-leucine + maltodextrin|Supplementation twice daily (1 serving dose per consumption) of L-leucine + maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
215040894|NCT03501628|DIETARY_SUPPLEMENT|Whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
215040895|NCT03501628|DIETARY_SUPPLEMENT|Hydrolyzed whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of hydrolyzed whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
215040896|NCT03501628|DIETARY_SUPPLEMENT|Soy protein concentrate|Supplementation twice daily (1 serving dose per consumption) of soy protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
215040897|NCT05439980|OTHER|Knowledge questionnaire|Completion of a questionnaire at baseline
215040898|NCT05439980|OTHER|Focus groups|structured interviews
215040899|NCT00317837|PROCEDURE|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
215040900|NCT00317837|PROCEDURE|bipolar hemiarthroplasty|bipolar hemiarthroplasty
215040901|NCT01503320|DIETARY_SUPPLEMENT|Enteral glutamine|Dosage of glutamine: 0.57g/kg, \~ 30g/day= 3sachets
215040902|NCT01503320|DIETARY_SUPPLEMENT|Placebo|Similar appearing nutritional supplement without glutamine.
215040903|NCT02412670|DRUG|Methotrexate|Given IV
215040904|NCT02412670|DRUG|Vinblastine|Given IV
215040905|NCT02412670|DRUG|Doxorubicin|Given IV
215040906|NCT02412670|DRUG|Cisplatin|Given IV
215040907|NCT02412670|DRUG|Gemcitabine|Given IV
215040908|NCT02412670|DRUG|Carboplatin|Given IV
215040909|NCT02412670|DRUG|Pegfilgrastim|Administered subcutaneously
214291357|NCT05503641|OTHER|Cognitive and psychomotor stimulation|"Each cognitive stimulation session aimed to maintain and/or improve cognition through memory, language, executive functions, attention, concentration, and perception activities. All the people in the two groups performed the same cognitive stimulation activities adapted to their cognitive and sensory abilities.~The psychomotricity sessions were aimed at maintaining and/or improving the motor, cognitive, social and affective functioning of the person through activities that work on postural tone, body scheme, laterality, fine and gross motor skills, balance, flexibility, among others, adding a cognitive component. All the psychomotricity activities were adapted to the motor and cognitive abilities of the users."
214291358|NCT04273646|BIOLOGICAL|UC-MSCs|4 times of UC-MSCs(0.5\*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).
214874985|NCT05318430|DEVICE|Subcutaneous closed-suction drainage device|This subcutaneous closed-suction drainage device was designed to be placed subcutaneously when surgeons have completed all intra-abdominal operations and are about to suture subcutaneous layer and skin
214874986|NCT02985216|DRUG|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO"
214874987|NCT02985216|DRUG|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
214874988|NCT01131468|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
214874989|NCT00258700|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
214874990|NCT04760496|DRUG|Oxytocin 4 mIU/mL|Oxytocin at 4 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
214874991|NCT04760496|DRUG|Oxytocin 2 mIU/mL|Oxytocin at 2 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
215040910|NCT02412670|PROCEDURE|Nephroureterectomy|Undergo nephroureterectomy and lymph node dissection
215040911|NCT02341066|DEVICE|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
215040912|NCT01593371|DRUG|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
215040913|NCT01593371|DRUG|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
215040914|NCT04306328|DEVICE|Neurostimulation|Implantation of 2 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
215040915|NCT01946334|DEVICE|anorectal manometry and high-resolution three-dimensional|
215040916|NCT00508456|DRUG|Temodar (Temozolomide)|150 mg/m\^2 orally once a day for 7 consecutive days (days 8 through 15).
215040917|NCT00508456|DIETARY_SUPPLEMENT|Hominex-2|"Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only shakes containing Hominex-2®."
215040918|NCT02363166|OTHER|Acute Abscess Group|Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
215040919|NCT05414799|OTHER|figure eight vision exercise|figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.
215040920|NCT05414799|OTHER|chin nodding|chin nodding performed in sitting for keeping head placed straight over spine, place finger on chin and tuck-in the chin while head straight back until a stretch is felt at base of head.
215040921|NCT05414799|OTHER|neck stretching|"trapezius : neck flexion with opposite side bending and same side rotation for both sides.~sternocleidomastoid : neck extension with opposite side bending and same side rotation for both sides."
215040922|NCT03549325|BIOLOGICAL|Neisseria lactamica|Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.
215040923|NCT01836757|DRUG|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
215040924|NCT01836757|DRUG|Placebo|
215040925|NCT00227253|PROCEDURE|Determination of growth hormone status|Growth hormone stimulating testing using Arginine and Clonidine, Corticotrophin releasing hormone stimulation test
215040926|NCT00227253|PROCEDURE|Measurement of growth, thyroid and sex hormone levels|Gonadotrophin releasing hormone stimulation test Thyroid testing - T4, TSH, T3 uptake, and anti-thyroidal antibodies baseline sample - no medication administered
215040927|NCT00227253|PROCEDURE|Behavior and neuropsychometric evaluations|evaluation by neuropsychologist, standardized testing geared to study participant's age, abilities and past medical history
215040928|NCT00227253|PROCEDURE|Audiological and ear, nose and throat examination|neurotological exam, behavioral audiometry, immittance audiometry, assessment of the function of the inner ear using otoacoustic emissions, Auditory brain responses
215040929|NCT00227253|PROCEDURE|Magnetic resonance imaging of the brain|MRI of the brain - standard clinical procedure
215040930|NCT00227253|PROCEDURE|Dysmorphology evaluation|Genetic evaluation with picture and measurements, physical exam
215040931|NCT00227253|PROCEDURE|Neurology examination|physical examination including observation of balance, coordination and reflexes.
215040932|NCT00227253|PROCEDURE|Dental evaluation|Visual detal inspection with panorex X-ray of the entire mouth
215040933|NCT00227253|PROCEDURE|Speech pathology evaluation|Standardized speech \& language tests and naturalistic assessment procedures.
215040934|NCT00227253|PROCEDURE|Psychiatric evaluation|Psychiatric interview about history of psychiatric and medical illnesses, family psychiatric and medical history, demographic info also obtained
214874992|NCT04627987|DIAGNOSTIC_TEST|Cardiac MRI scan|Cardiac MRI scan pre- and post- aortic valve replacement to assess degree of left ventricular remodelling, fibrosis and myocardial blood flow.
214874993|NCT04627987|DIAGNOSTIC_TEST|Serum biomarkers (High sensitivity troponin, NT-proBNP|Blood tests looking evidence of cardiac structural remodelling and function.
215040935|NCT00227253|PROCEDURE|Orthopedic evaluation|Physical exam by orthopedic surgeon and a dysplasia series of radiographs including AP and lateral radiographics of the feet, APs of the knees, pelvis, thoracic lumbar spine and chest, laterals of thoracic lumbar and cervical spine, lateral of the skull, AP and lateral of the forearm, bone age evaluation with radiograph of left hand
215040936|NCT00227253|PROCEDURE|Ophthalmologic evaluation|exam will determine visual acuity using one of the following: Snellen chart, Allen acuity, target acuity, optokinetic nystagmus (OKN), or Teller acuity depending on study participants ability level. Motility/alignment will also be determined using cover/uncover test. Pupils examined using slit lamp. Dilated fundus exam and cycloplegic refraction which will require dilating drops in both eyes. Cyclogen 1% and NeuSynephrine 2.5% are using. In children less than 6 months old, less potent mydriatrics and cycloplegics are used Cyclogel 0.5% or Tropicamide 1%. Intraocular pressure will be measured in adults and cooperative teens using applanation tonometry. A topical anesthetic will be used to perform this measurement.
215040937|NCT00227253|PROCEDURE|Gastrointestinal evaluation|physical exam and medical history by board certified gastroenterologist.
215040938|NCT05385822|BEHAVIORAL|Pelvic Floor Muscle Training|"* Isolated, quite light tension in the pelvic floor 10 times, where the tension is released immediately~* Constant tension for 30 seconds twice, with a 30-second pause~* Total relaxation for 1 minute They must perform these exercises once a day during the trial period of 3 months"
215040939|NCT05951907|PROCEDURE|Maxillary extraction without palatal injection|Extraction of maxillary premolars by only buccal injection without palatal by using articaine 4% HCL with epinephrine (1:100,000)
215040940|NCT05951907|PROCEDURE|Maxillary extraction with buccal and palatal injection|Extraction of maxillary premolars by only buccal and palatal injection by using lidocaine 2 % HCL with epinephrine (1:80,000)
215040941|NCT04770207|DRUG|Injection of drug-eluting microspheres with multiple drugs into solid tumors|Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
215040942|NCT00934921|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
215040943|NCT00934921|DRUG|Zofran®|1 x 8 mg ODT
215040944|NCT04349969|DRUG|AK117|All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
215040945|NCT04349969|DRUG|AK117+AK104|All Subjects will receive 3 weekly infusions of AK117 (Days 1, 8, and 15) and 1 infusion of AK104 (on Day 1) as combination therapy in each 21-day treatment cycle until unacceptable toxicity, documentation of confirmed PD, or subject withdrawal.
215040946|NCT04361279|DRUG|SIBP-02|Injection，100mg/10ml
215040947|NCT04361279|DRUG|Rituximab|Injection，100mg/10ml
215040948|NCT03917615|OTHER|pelvic floor contraction|Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
215040949|NCT06375681|BEHAVIORAL|Visual and / or Auditory Cognitive Tasks (1)|"Seven sessions (\~45-75 minutes) of cognitive tasks in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements."
215040950|NCT06375681|BEHAVIORAL|Visual and / or Auditory Cognitive Tasks (2)|"Two sets of 10 sessions (\~20 minutes) of cognitive tasks either at home or in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements."
215040951|NCT01495013|DRUG|1mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
215040952|NCT01495013|DRUG|2mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
214874994|NCT04627987|PROCEDURE|Implantable Loop Recorder|Determine post-AVR arrhythmia burden
214874995|NCT04627987|DIAGNOSTIC_TEST|6 minute walk test|Validated assessment of functional capacity - distance walked over 6 minute time frame.
215040953|NCT01495013|DRUG|3mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
215040954|NCT01495013|DRUG|4mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
214874996|NCT04627987|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound assessment of heart structure and function. Standard of care in valve surgery pathway.
214874997|NCT01476332|DRUG|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
214874998|NCT01476332|DRUG|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
215040955|NCT01495013|DRUG|1mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
215040956|NCT01495013|DRUG|2mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
215040957|NCT01495013|DRUG|3mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
215040958|NCT01495013|DRUG|4mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
215040959|NCT01495013|DRUG|1mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
215040960|NCT01495013|DRUG|2mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
215040961|NCT01495013|DRUG|3mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
215040962|NCT01495013|DRUG|4mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
214874999|NCT01476332|DRUG|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
215040963|NCT01495013|DRUG|10mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
215040964|NCT01495013|DRUG|20mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
215040965|NCT05121350|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.
215040966|NCT05121350|DRUG|Epirubicin|Epirubicin can inhibit the synthesis of DNA and RNA.
215040967|NCT05121350|DRUG|Arotinib hydrochloride capsule placebo|Placebo of Anlotinib hydrochloride capsule
214875000|NCT03306446|DRUG|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
215040968|NCT05932498|PROCEDURE|Hip surgery|"Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively."
215040969|NCT05547672|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
215040970|NCT00969020|PROCEDURE|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
215040971|NCT00593619|DRUG|Iron dextran|300mg in 250cc normal saline given over 2 hours
215040972|NCT00593619|DRUG|Iron sucrose|300mg in 250cc normal saline given over 2 hours
214875001|NCT03810326|DEVICE|CTR device (tradename named Xtend)|Non invasive active splint
214875002|NCT01405014|BEHAVIORAL|Hold Me Tight|Relationship enhancement group
214875003|NCT05769257|DRUG|IS-001|Intravenous injection of IS-001 investigational drug
215040973|NCT03261830|DRUG|Cefazolin|Primary intervention
215040974|NCT03261830|DRUG|Clindamycin|For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
215040975|NCT03261830|DRUG|Saline|Placebo Intervention
215040976|NCT02635295|BEHAVIORAL|Mobile cooperation during the clinical practicum|"The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT."
215040977|NCT00654732|DRUG|Bleomycin|Given IV
215040978|NCT00654732|DRUG|Dacarbazine|Given IV
215040979|NCT00654732|DRUG|Doxorubicin Hydrochloride|Given IV
215040980|NCT00654732|BIOLOGICAL|Rituximab|Given IV
215040981|NCT00654732|DRUG|Vinblastine|Given IV
215040982|NCT01958086|DEVICE|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
215040983|NCT04165837|DRUG|FB-101|Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
215040984|NCT04165837|DRUG|Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
215040985|NCT04951349|DRUG|GX-03|Same dosage used in Bactroban Nasal studies.
214875004|NCT00770081|DRUG|vildagliptin|50mg qd
214875005|NCT00770081|DRUG|sitagliptin|25mg qd
214875006|NCT01882972|BEHAVIORAL|Exercise|
214875007|NCT01882972|BEHAVIORAL|Meditation|
215040986|NCT04951349|DRUG|Petrolatum ointment|Viscous ointment similar in form to study drug.
214875008|NCT00006348|DRUG|ondansetron|
214875009|NCT00006348|OTHER|placebo|
214875010|NCT00010530|PROCEDURE|Meditation|
214875011|NCT00323466|PROCEDURE|IMRT versus conventional radiotherapy|Comparing MRT versus conventional radiotherapy
214875012|NCT03813953|PROCEDURE|Liver resection|Resection of diseased liver
214875013|NCT04496284|OTHER|Vitrification via slush nitrogen|blastocyst stage embryos will be vitrified via slush nitrogen
214875014|NCT06015763|PROCEDURE|Endoscopy|Endoscopic biopsy
215040987|NCT01228214|DRUG|Placebo|Placebo 5mg/daily for 12 months
215040988|NCT01228214|DRUG|amiloride|5mg/daily for 12 months
215040989|NCT01742884|OTHER|Thealoz|Instillation of 1 drop of Thealoz
215040990|NCT01742884|OTHER|Vehicle|1 drop of the vehicle will be instillated in the eye
215040991|NCT00404807|DEVICE|CPAP(Continuous Positive Airway Pressure)|
215040992|NCT02575144|DRUG|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle
214875015|NCT01019668|DRUG|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
214875016|NCT01019668|DRUG|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
215040993|NCT02575144|DRUG|Lenalidomide|25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of \>60 cc/min
215040994|NCT02575144|DRUG|Dexamethasone|40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
215040995|NCT03573050|DRUG|RIV-TDS 13.3 mg/24 h|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
215040996|NCT03573050|DRUG|Exelon® 13.3 mg/24 hours transdermal patch|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
215040997|NCT05455892|OTHER|Clinical data collection during hospitalization in short geriatric units.|Retrospective clinical data collection, at time of infection and 10 days later. Correlation between mortality and gravity. Identification of predictive mortality factors such as frailty, preexisting comorbidities, complications and treatments. Description of medical prescription evolutions.
215040998|NCT05748002|OTHER|Pentacam and Corvis ST|morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST
215040999|NCT06030518|DIAGNOSTIC_TEST|Magnet Assisted Capsule Endoscopy|Procedures will be performed in the morning after an overnight fast. Patients wear a belt containing sensors and a data recorder. The patient will be asked to drink 500-1000ml (containing 80mg simethicone; volume depending on tolerance) immediately before swallowing the capsule. Gastric examination will proceed as previously described for a robot-controlled magnetic assisted capsule endoscopy. The whole procedure is anticipated to take 30-60 minutes. The patient will be discharged from hospital on completion of gastric examination but if clinically indicated will wear the belt for small bowel capsule study for eight hours to allow small bowel examination before detaching the equipment and returning it the following day. On completion of examination, the patient will be asked to complete a questionnaire about their capsule endoscopy experience. The full study (upper GI tract and small bowel) will then be downloaded onto the computer for formal reading and reporting.
215041000|NCT01879007|DRUG|Factive® Tab / Factive IV|
215041001|NCT03342560|DEVICE|Sonographic SWE measurements with 4 different ultrasound systems|Sonographic Shear wave elastography will be performed to quantify liver fibrosis
214875017|NCT05011045|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215041002|NCT02872038|DRUG|Cefepime|Cefepime intraperitoneal continuous dosing
215041003|NCT02872038|DRUG|Cefazolin plus Ceftazidime|
215041004|NCT05032586|DEVICE|wearing virtual reality headsets|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
215041005|NCT03213509|OTHER|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
215041006|NCT01229124|GENETIC|RNA analysis|
214875018|NCT05011045|OTHER|Neurocognitive Assessment|Undergo neurocognitive function assessment
214875019|NCT05011045|OTHER|Quality-of-Life Assessment|Complete questionnaires
214875020|NCT05011045|OTHER|Questionnaire Administration|Complete questionnaires
214875021|NCT04546880|OTHER|Breathing exercises|"Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing."
214875022|NCT04546880|OTHER|Stabilization exercises|"Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability."
214875023|NCT00720252|DEVICE|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
214875024|NCT04762277|DRUG|Spesolimab - solution for infusion|Solution for infusion
215041007|NCT01229124|GENETIC|nucleic acid sequencing|
215041008|NCT01229124|GENETIC|reverse transcriptase-polymerase chain reaction|
215041009|NCT01229124|OTHER|laboratory biomarker analysis|
215041010|NCT00725088|BEHAVIORAL|Exercise training|Exercise training
215041011|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
215041012|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
215041013|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
215041014|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
214875025|NCT04762277|DRUG|Placebo matching spesolimab - solution for infusion|Solution for infusion
214875026|NCT04762277|DRUG|Spesolimab- solution for injection|Solution for injection
214875027|NCT04762277|DRUG|Placebo matching to spesolimab- solution for injection|Solution for injection
214875028|NCT01860677|DEVICE|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
214875029|NCT06979427|DIAGNOSTIC_TEST|NIFFR|Fractional flow reserve derived from CT angiography from lesion between 50-70%
214875030|NCT06983691|BEHAVIORAL|Patient Navigation Program|The patient navigation program will integrate 1) education to enhance understanding of the treatment regimen, follow-up care, and the importance of adherence, 2) symptom management and adherence strategies, and 3) skills and resources to enhance women's symptom coping and self-management abilities.
214875031|NCT06983106|OTHER|body composition calculate|The goal of this observational study is to learn about the value of body composition as predictors of pathological grading and prognosis in patients with gastroenteropancreatic neuroendocrine neoplasms. The volume of abdominal skeletal muscle and fat tissue is calculated based on CT scans at diagnosis.
214875032|NCT06982638|DEVICE|TMS+ Gait training|"Participants in this single-arm study will receive a personalized, accelerated course of continuous theta burst stimulation (cTBS) over a functionally defined subregion of the supplementary motor area (SMA), which is individually targeted using resting-state functional MRI. The stimulation will be delivered using a MagPro Cool-B65 A/P figure-of-eight coil at 110% of resting motor threshold.~Each participant will undergo 6 treatment visits over 2 weeks , receiving 8 rTMS sessions per day (600 pulses/session), totaling 28,800 pulses across the study. TMS sessions will be interleaved with dual-task gait training involving cognitive walking exercises. Gait training will be conducted for 30 minutes per visit, immediately following stimulation blocks. Safety, tolerability, adherence, gait performance, and neuroplasticity will be evaluated pre- and post-intervention using clinical scales, motor evoked potentials (MEPs), and functional MRI."
214875033|NCT06982703|DIETARY_SUPPLEMENT|Food Supplement DBZ (acronym for: DIBUZIN) containing calcium butyrate, vitamin D and zinc,|In this prospective pilot study, we plan to evaluate the effects of a Food Supplement DBZ (acronym for: DIBUZIN) containing calcium butyrate, vitamin D and zinc, on the variation of intestinal microbiota and prevention of antibiotic-induced diarrhea, in individuals who have been prescribed antibiotic therapy.
214875034|NCT06982703|DIETARY_SUPPLEMENT|Placebo|The intervention with Placebo involves the intake of a product free of bityrate, zinc and vitD
214875035|NCT06983717|PROCEDURE|lacrimal deroofing|After infiltration anesthesia, patient underwent proximal lacrimal deroofing. Proper punctal dilatation is done, followed by combined 1 snip punctoplasty with a lateral canaliculotomy/ Punctotomy and posterior canaliculotomy of the lateral third. En-bloc expulsion of the concretion was done in case of canaliculitis.
215041015|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
215041016|NCT04554004|DIAGNOSTIC_TEST|CCTA, CT-MPI, DSA, FFR|The patients who enrolled the study will undergo coronary CT angiography(CCTA), dynamic CT-MPI, invasive coronary angiography and invasive computation of fractional flow reserve (FFR)
215041017|NCT04756453|DEVICE|clip-traction|A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
215041018|NCT01370551|DRUG|Estriol 0.03 mg, lyophylized lactobacillus|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
214875036|NCT06977490|DRUG|Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)|Single intravenous administration of 3.0 mg/kg in each period.
214875037|NCT06977490|DRUG|Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)|Single intravenous administration of 3.0 mg/kg in each period.
214875038|NCT06982339|OTHER|Air Conditioner|Air conditioners will be window-mounted units powered by 110v AC.
214875039|NCT06982339|OTHER|Electricity subsidy|Electricity subsidies will consist of a single block subsidy of USD 100, intended to provide support for the electricity costs associated with operating an air conditioning unit.
214875040|NCT06982040|DRUG|NTQ5082 capsules 100 mg|NTQ5082 capsules 100 mg
214875041|NCT06982040|DRUG|NTQ5082 capsules 200 mg|NTQ5082 capsules 200 mg
214875042|NCT06982040|DRUG|NTQ5082 capsules 300 mg|NTQ5082 capsules 300 mg
214875043|NCT06982040|DRUG|Placebo|Placebo
214875044|NCT06983834|BEHAVIORAL|Psychoeducation|Mindfulness Based Psychoeducation
214875045|NCT06983132|DIAGNOSTIC_TEST|Cerebral imaging (MRI) according to a dedicated protocol with central MRI reading|Cerebral MRI according to dedicated protocol, central MRI reading.
214875046|NCT06983132|DIAGNOSTIC_TEST|Determination of circulating biomarkers|High-throughput molecular analysis will be performed on plasma samples collected assessing a selected panel of biomarkers, associated with endothelial cell profiles using automated and high-throughput ELISA. The interactions between mutation profile, protein biomarkers, and clinical variables will be correlated with patients' outcomes.
214875047|NCT06981858|DRUG|Enlonstobart Injection|Sequential Enlonstobart Injection with concurrent chemoradiotherapy
214875048|NCT06982326|OTHER|MF+|During the MF+ session, before each physical testing phase, participants completed a 30-min Colour Word Stroop task (CST) to trigger MF. The paper-based version of the CST was completed in quiet rooms following the same protocol as in previous studies. This prolonged cognitive task was reported to require sustained attention and automatic response inhibition and effectively induced MF through cognitive manipulation. ThyIt had ben Four colour words (red, blue, green and yellow) were randomly printed and participants were asked to verbalise the colour of each word.
214875049|NCT06982326|OTHER|MF-|During the control session, before each physical testing phase, participants watched emotionally neutral documentaries for 30 min.
215041019|NCT00833521|DRUG|Zolpidem 10 mg tablets|1 x 10 mg
215041020|NCT00833521|DRUG|AMBIEN® 10 mg tablets|1 x 10 mg
215041021|NCT04466358|PROCEDURE|Modified CLOSE protocol|Modified CLOSE protocol guided isolation of pulmonary veins.
215041022|NCT04466358|PROCEDURE|High density mapping guided pulmonary vein isolation|Modified CLOSE protocol guided isolation of pulmonary veins with additional ablations at sites of gaps or dormant conduction as evidenced by high density mapping of pulmonary vein antra.
215041023|NCT03832985|GENETIC|Receive an adult-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
214875050|NCT06983236|BEHAVIORAL|AI-enabled patient education material|Students in the intervention group will be asked to prepare patient education material for a patient using an artificial intelligence (AI) tool on 'infection care'. First, the intervention group will receive 2 hours of training on artificial intelligence. This training will take place in a classroom environment with internet access. All students in the intervention group will be trained at the same time and their questions will be answered. The students will not receive any additional counselling after the training. It will be explained to the students in the intervention group that they will first have to prepare the educational material using the AI tool and that they can use support tools such as books, magazines and websites while preparing the educational material. Students will be given five days and will be asked to submit their patient education materials at the end of the five days and will be asked to complete the patient education information form.
214875051|NCT06983236|BEHAVIORAL|Traditional patient education material|"Students in the control group will be interviewed and asked to prepare a patient education material about infection care for a patient. Students will be informed that they can use additional tools such as books, magazines, and websites to prepare educational materials. Students will be given five days and at the end of the five days, they will be asked to submit their patient education materials and fill out the Patient Education Information Form. Students will be asked to write down the references they used in detail and include direct links to the websites of the Internet resources."
214875052|NCT06982378|DRUG|GLP-1 receptor agonist|on and not on treatment
214875053|NCT06981897|BEHAVIORAL|early cognitive therapy program in addition to selected physical therapy program (positioning, chest care exercise).|"A.Positioning for head injury patients~B.Chest clearance intervention~C.Procedure for cognitive therapy All these exercises are given to patients even when they are on ventilator support of around 20-30 minutes six days /week .~1. coma stimulation incorporated with cognition training such as : i. Multimodal Sensory stimulation, including :~   1. Visual~  2. Auditory~  3. Olfactory~  4. Gustatory~  5. Tactile- Administered by rubbing different textures like satin, silk, fur, smooth metal, sandpaper, or cool or warm items over the patient's body surfaces.~   ii. Calling out their names, using patient's relatives help for transferring were used for improving the cognition and conscious levels.~2. Kinesthetic Stimulation~   1. Passive movements~  2. Joint approximation Each movement two times, allowing 1 minute to respond. This will be performed either in bed or in the wheelchair, one extremity at a time."
214875054|NCT06981897|BEHAVIORAL|selected physical therapy program (Chest care exercise, passive movement of the four limbs) in addition to early cognitive therapy program|"The patient was placed in a comfortable position with a head-up position Passive range of movement for all four limbs \& positioning for head injury patients,. Joint approximation and Chest clearance intervention and Procedure for cognitive therapy~Multimodal Sensory stimulation, including :~Visual Auditory- Olfactory-. Gustatory- Tactile- Calling out their names, using patients relative help for transferring were used for improving the cognition and conscious levels."
214875055|NCT06981897|BEHAVIORAL|Control group|The patient was placed in a comfortable position with a head-up position , Passive range of movement for all four limbs and positioning for head injury patients,. Joint approximation and Chest clearance intervention
214875056|NCT00866190|DRUG|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
215041024|NCT03832985|GENETIC|Receive a pediatric-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
215041025|NCT03832985|GENETIC|Control - No Result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have not received an adult-onset genomic result.
215041026|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Low Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 2 consecutive minutes for each side, only once for the experiment duration.
215041027|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Intermediate Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 3 sessions of 2 minutes, with 2 minutes of rest for each side. stimulation will be provided only once for the experiment duration.
215041028|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (High Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 8 consecutive minutes for each side, only once for the experiment duration.
214875057|NCT00866190|DRUG|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
214875058|NCT01163630|DRUG|esomeprazole/ASA Fixed Dose Combination (FDC)|esomeprazole 20 mg/ASA 81 mg oral capsule
214875059|NCT00491140|GENETIC|Gene mutations analysis and FISH|FISH and mutation analysis of multiple genes
214875060|NCT04249544|DRUG|Pramipexole|1mg of pramipexole
214875061|NCT04249544|DRUG|Placebo|1mg equivalent of placebo
214875062|NCT06284447|OTHER|Non-Interventional Study|Non interventional study
214875063|NCT02898753|DRUG|VAL-1221|VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
214875064|NCT02898753|DRUG|RhGAA|Active comparator
215041029|NCT06541808|OTHER|Sham mechanical Vagus Nerve Stimulation|Participants will be treated with a fake vagus stimulation by letting the operator hold the neck of the participant in one hand and placing the other hand on the abdomen without any stretch on the vagus nerve
215041030|NCT06643091|DRUG|Nintedanib|Nintedanib150 mg twice a day for 6 months Or Nintedanib 100mg twice a day in case of dose adjustment Oral route (during meals)
215041031|NCT04493671|DRUG|TBAJ-876 suspension|TBAJ-876 oral suspension, orally administered
215041032|NCT04493671|DRUG|Placebo suspension|Placebo for TBAJ-876 oral Suspension; orally administered
215041033|NCT04493671|DRUG|TBAJ-876 100 mg tablet|TBAJ-876 100 mg tablets, orally administered
214291359|NCT04273646|DRUG|Placebo|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
214291360|NCT01743131|DRUG|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
215041034|NCT04493671|DRUG|TBAJ-876 25 mg tablet|TBAJ-876 25 mg tablets, orally administered
215041035|NCT03524599|OTHER|Intervention municipality|In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
215041036|NCT06320197|OTHER|In situ simulation assessment|Unannounced in situ simulation assessment during working hours
215041037|NCT03602508|DRUG|mirabegron|oral
215041038|NCT03602508|DRUG|solifenacin|oral
215041039|NCT03602508|DRUG|darifenacin|oral
215041040|NCT03602508|DRUG|imidafenacin|oral
215041041|NCT03602508|DRUG|tolterodine|oral
215041042|NCT03602508|DRUG|oxybutynin|oral
215041043|NCT03602508|DRUG|trospium|oral
215041044|NCT03602508|DRUG|fesoterodine|oral
214291361|NCT01743131|DRUG|placebo|
214291362|NCT03695679|BEHAVIORAL|Interactive computer-based intervention|"There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~1. Perceived Susceptibility and Perceived Severity~2. Perceived Benefits and Perceived Barriers~3. Cue to Action~4. Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information."
214291363|NCT04840238|DRUG|Cholecalciferol|30,000IU cholecalciferol
214291364|NCT04840238|DRUG|Placebo|Placebo tablets
214875065|NCT03734315|DEVICE|Ostenil®|Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
214875066|NCT06662227|BIOLOGICAL|Single dose injection of certain dose of UWD-19|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-19 cells
214875067|NCT00642278|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
214875068|NCT00642278|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
214875069|NCT00642278|DRUG|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
214875070|NCT00090363|DRUG|ZD4054 15 mg|15 mg oral tablet once daily
214875071|NCT00090363|DRUG|Placebo|
214875072|NCT00090363|DRUG|ZD4054 10 mg|10mg oral tablet once daily
214875073|NCT03713619|DRUG|secukinumab|Secukinumab 300mg every 2 or every 4 weeks
214875074|NCT03713619|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
214875075|NCT03484143|DEVICE|Active Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
215041045|NCT03602508|DRUG|propiverine|oral
215041046|NCT06293781|DEVICE|Web-based ACT|ACT program delivered online
215041047|NCT06293781|BEHAVIORAL|Treatment as usual|Treatment as usual for major depressive disorder
215041048|NCT00718432|BEHAVIORAL|Exercise and nutritional integrated care|Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
215041049|NCT00718432|BEHAVIORAL|Usual care with education|The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
215041050|NCT00718432|BEHAVIORAL|Problem solving therapy (PST) integrated care|Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
215041051|NCT02362685|DEVICE|functional test|subjects perform a metabolic exercise testing
215041052|NCT02362685|GENETIC|matching genotype with phenotype|
214875076|NCT03484143|DEVICE|Sham Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
214875077|NCT05068154|DIAGNOSTIC_TEST|Myovista® WavECG™|The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired 12-lead ECG signal which is then analysed using artificial intelligence to provide information relating to left ventricular relaxation abnormalities
214875078|NCT05912270|BEHAVIORAL|Orchestra in Class|See arm/group descriptions
214875079|NCT00557089|DRUG|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
214875080|NCT00557089|OTHER|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
215041053|NCT06545006|OTHER|isometric contractions|Participants will perform 20 minutes of isometric contractions in different positions, with contraction durations of 10 seconds and a number of repetitions between 4 and 10, depending on their progress in the training program.
215041054|NCT06545006|OTHER|stroboscopic glasses|"This training involves performing skill exercises with a rugby ball while wearing stroboscopic glasses. The glasses have alternating opaque and clear sections, causing multiple and/or fragmented vision.~The goal is to improve the processing of visual information at the level of higher functions. This aids in decision-making. It does not involve the same structures and functions implicated in reflexive muscle recruitment strategies as the Quick Release, so it should not be a confounding factor. However, it provides a beneficial, stimulating, and enjoyable training session, increasing subject adherence as they work on a skill useful in their sport."
215041055|NCT06545006|OTHER|Quick Release|"The distance (in mm) of the anterior head translation will be measured using a linear displacement sensor. The subject will be instructed to recruit their extensor muscles as quickly and as strongly as possible to minimise the head displacement distance. They will be aware of their score after each repetition (real-time feedback).~Subjects must react to a rapid forward displacement of the cervical spine, without impact. To generate this forward displacement without impact, subjects are positioned with support in front of the forehead, holding their head and neck. The subject must exert an isometric flexion effort against this frontal support (energy storage), with the intensity set by the examiner based on the Maximum Isometric Force measured during a prior maximal isometric test. The frontal resistance will suddenly release, and the head displacement in the sagittal plane will be measured until the recruitment of the cervical spine extensor muscles stops this displacement"
215041056|NCT00646230|DRUG|fenretinide|
215041057|NCT00646230|OTHER|high performance liquid chromatography|
215041058|NCT00646230|OTHER|pharmacological study|
215041059|NCT01280942|BEHAVIORAL|EWS Nursing Alerts|An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.
214875081|NCT06060067|BIOLOGICAL|TDV|TDV SC injection on Day 1 and Day 90 of the study
214875082|NCT06060067|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
214875083|NCT06982690|PROCEDURE|Spinal Anesthesia|A total of 10-12 mg of 0.5% bupivacaine will be administered into the cerebrospinal fluid of the subarachnoid space using a 25-gauge Quincke spinal needle via an 18-gauge introducer (adjusted by body height). Midazolam (2-5 mg) may be used to decrease anxiety.
215041060|NCT01280942|DEVICE|Wireless Remote Sensor|A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
214291365|NCT06475482|OTHER|Lip hydrant|lip hydrant containing peppermint oil, perilla frutescens, and Emblica fruit extract or petroleum gel.
214291366|NCT06475482|OTHER|Petroleum gel|Vaseline
214291367|NCT00224055|DRUG|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
214291368|NCT00224055|DRUG|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
214291369|NCT02068443|DRUG|Alogliptin|Alogliptin tablets
214291370|NCT02068443|DRUG|Metformin hydrochloride|Metformin hydrochloride tablets
214291371|NCT02068443|DRUG|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
214291372|NCT02983331|PROCEDURE|complications during procedure|patients may have anesthesia related complications during procedure
214291373|NCT02391740|OTHER|Questionnaire|
214291374|NCT03407378|DRUG|IPT803|Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
214291375|NCT03407378|GENETIC|Optional pharmacogenetic assessment|Blood sample of 3 milliliters for genotyping assessment (according to patient consent).
214291376|NCT03407378|OTHER|Questionnaires|Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)
214291377|NCT03407378|OTHER|Optional Blood-Oxygen-level Dependent functionalMRI|BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)
214291378|NCT03407378|OTHER|Motor Assessments before taking regular PD treatment|Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.
214875084|NCT06982690|PROCEDURE|General Anesthesia|Induction will be performed with propofol (0.5-1.5 mg/kg) and fentanyl (1-2 µg/kg), and anesthesia will be maintained with sevoflurane (1-3 vol %) via a laryngeal mask or endotracheal intubation. Rocuronium (0.5-0.6 mg/kg) will be used for induction, maintenance and occurrence of obturator jerk.
214875085|NCT06595264|PROCEDURE|embolization therapy|Embolization in the neuroradiological department is the Golden Standard for the treatment of vein of Galen malformations.
214875086|NCT06281171|OTHER|SkillTalk for Autistic Young Adults|A Microskills video training library on communication skills for autistic young adults.
214875087|NCT06281171|OTHER|Flyer Library|A collection of existing online resources on relationship skills
214875088|NCT06102291|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
214875089|NCT06102291|OTHER|Acupuncture|The main acupoints are Ashi points, Shenshu (BL23), Guanyuanshu (BL26). There are three sessions per week with each session lasting for 20 min. There will be 4 weeks of treatment for each participant in total.
214875090|NCT06988722|DEVICE|650 nm Diode Laser PBM|A 650 nm red diode laser applied at three points (buccal, palatal, and crestal) around the implant site using 100 mW power for 60 seconds per point (total dose 18 J). Applied immediately post-op and repeated within 48 hours. Used for photobiomodulation to reduce pain and improve healing.
215041061|NCT05283889|PROCEDURE|Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
215041062|NCT05283889|PROCEDURE|Sham Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
215041063|NCT02498366|OTHER|physical tests|"each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3."
215041064|NCT04549454|BEHAVIORAL|FITSTART+ PBI|Personalized normative feedback on other parents behaviors + alcohol-specific parenting advice + general parenting advice
215041065|NCT04549454|BEHAVIORAL|General Parenting Advice|General parenting advice
215041066|NCT06455904|PROCEDURE|Training sessions|The training program will be performed during 15 weeks, with one session per week.
215041067|NCT06278051|DRUG|Rivaroxaban granules for oral suspension|Treatment dose and period decided by its prescription
215041068|NCT06278051|DRUG|Warfarin|Treatment dose and period decided by its prescription
215041069|NCT04336826|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
215041070|NCT04332783|BEHAVIORAL|psychophysics of sequential biases (no drug or patient work)|Psychophysical experiment on sequential effects in medical image perception. Observers, including clinicians, perform psychophysical continuous report match-to-sample and forced-choice discrimination judgments of medical images, including radiographs and photographs. Observer discrimination accuracy is measured on a trial-wise basis and sequential effects in those judgments are measured. Images can be presented with different interstimulus intervals and in different spatial locations and in different orders. Accuracy, and other signal detection metrics are computed as a function of these factors.
215041071|NCT02446002|DRUG|Lofexidine + Naltrexone|Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
215041072|NCT03158831|DRUG|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
215041073|NCT02419495|DRUG|Capecitabine|Given PO
215041074|NCT02419495|DRUG|Carboplatin|Given IV
214875091|NCT06988722|DEVICE|810 nm Diode Laser PBM|A 810 nm red diode laser applied at three points (buccal, palatal, and crestal) around the implant site using 100 mW power for 60 seconds per point (total dose 18 J). Applied immediately post-op and repeated within 48 hours. Used for photobiomodulation to reduce pain and improve healing.
214875092|NCT06988722|DEVICE|Sham Laser PBM|Identical laser handpiece applied at the same locations and durations as the active PBM groups, but without laser emission. Used to maintain blinding and simulate treatment without therapeutic effect.
214875093|NCT06989268|DRUG|Linaclotide 290 micrograms|290 μg linaclotide once daily oral administration with 125mL of water
214875094|NCT06989268|DRUG|Placebo|Placebo, empty capsule, once daily oral administration with 125mL of water
214875095|NCT06990412|DEVICE|NEO|a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO
215041075|NCT02419495|DRUG|Cyclophosphamide|Given IV
215041076|NCT02419495|DRUG|Doxorubicin|Given IV
215041077|NCT02419495|DRUG|Eribulin|Given IV
215041078|NCT02419495|DRUG|Fluorouracil|Given IV
215041079|NCT02419495|BIOLOGICAL|Ipilimumab|Given IV
215041080|NCT02419495|DRUG|Irinotecan Hydrochloride|Given IV
215041081|NCT02419495|DRUG|Leucovorin Calcium|Given IV
215041082|NCT02419495|BIOLOGICAL|Nivolumab|Given IV
215041083|NCT02419495|DRUG|Olaparib|Given PO
215041084|NCT02419495|DRUG|Oxaliplatin|Given IV
215041085|NCT02419495|DRUG|Paclitaxel|Given IV
215041086|NCT02419495|BIOLOGICAL|Pembrolizumab|Given IV
214875096|NCT06989502|BEHAVIORAL|Co-creation (2016 to 2019) + Co-design (2023 to 2024)|"It includes interventions implemented in a sequential way: a) The co-creation intervention (between 2016 and 2019), and b) the co-design intervention (between 2023 and 2024).~In this group of sequential interventions, relevant stakeholders have already been engaged in the project and they would be familiar with the intervention components. Their participation this time will enable updating and refining the previous co-creation intervention through the co-design process.~The intervention will encompass activities with the health service users and healthcare workers, in Peru, Nepal, and Mozambique"
214666359|NCT05098288|BEHAVIORAL|Multicentre Pain Monitor + Unified Protocol|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMA. In terms of monitoring, the Multicentre Pain Monitor is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
214875097|NCT06989502|BEHAVIORAL|Co-design only (2023 to 2024)|"The same intervention activities of the first group (between 2023 and 2024), but without having them involved in the previous co-creation process. In consequence, relevant stakeholders in the corresponding sites are not expected to be as engaged in the project (in contrast to the intervention that includes co-creation), and they would not be very familiar with the intervention components of COHESION-I.~As in the first group, the intervention will encompass activities with the health service users and healthcare workers, in Peru, Nepal, and Mozambique"
214875098|NCT02552212|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
214875099|NCT02552212|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"
214875100|NCT00654290|DRUG|Amiodarone + Propranolol|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
214875101|NCT00654290|DRUG|Amiodarone|Amiodarone treated 7 days pre-operation to 5 days post CABG
215041087|NCT02419495|DRUG|Pemetrexed|Given IV
215041088|NCT02419495|DRUG|Selinexor|Given PO
215041089|NCT02419495|DRUG|Topotecan|Given IV
215041090|NCT06421350|DEVICE|Spinal Cord Stimulation Device|The closed-loop spinal cord stimulation mechanism uses dynamic adjusting stimulation parameters based on real-time physiologic response and is uniquely positioned to mitigate the aberrant inflammatory and neurosensory processing and autonomic dysfunction driving CRPS and its progression between phases.
215041091|NCT06461533|DRUG|Susoctocog Alfa (Genetical Recombination)|Susoctocog Alfa (Genetical Recombination), Intravenous injection
215041092|NCT00016354|DRUG|benzoylphenylurea|
215041093|NCT05261711|DRUG|AB1|This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
214875102|NCT00654290|DRUG|Propranolol|Propranolol from 7 days pre-operation to 5 days post CABG
214875103|NCT02489253|OTHER|CT coronary angiogram and carotid ultrasound|Scans in addition to routine clinical care
214875104|NCT03020589|DRUG|Tacrolimus|See description in arm/group sections
214875105|NCT06330272|PROCEDURE|Application of dental mousse based on CPP-ACPF|"Treatment will begin with pumice prophylaxis of incisors with IMH lesions. After this step, the teeth will be dried before applying dental foam based on CPP-ACPF (Tooth Mousse PlusTM, GC Corporation, Tokyo, Japan).~The application of Tooth Mousse PlusTM to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush. The cream will remain on the surface for 1 minute, which will be timed. The application will be carried out once a week, for four consecutive weeks."
214875106|NCT06989385|OTHER|This is an observational study. Interventions are standard of care and include: High-flow nasal oxygen (HFNO) Non-invasive ventilation (NIV) Pnose monitoring|No experimental interventions are administered as part of the study.
214875107|NCT02093130|DIETARY_SUPPLEMENT|Pomegranate Juice|
214875108|NCT02093130|DIETARY_SUPPLEMENT|Placebo|
214875109|NCT02302053|DIETARY_SUPPLEMENT|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
214875110|NCT02302053|DIETARY_SUPPLEMENT|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
214875111|NCT00946686|DRUG|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
215041094|NCT06422247|DRUG|Systemic therapy|Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician
215041095|NCT02160808|DRUG|Secretin|Drug to stimulate pancreatic secretion
215041096|NCT02160808|DRUG|Placebo|
215041097|NCT05273567|DRUG|guanfacine-ER|guanfacine-er dispensed daily, starting at 1mg and increasing to 4mg/day or the maximum tolerated dose.
215041098|NCT05273567|OTHER|Placebo|placebo will be dispensed similar to the active arm.
215041099|NCT05965700|DRUG|NVG-291|A once daily injection
215041100|NCT05605249|DEVICE|Cue X|The Cue X movement training module includes several games that can be performed in someone's home environment. The games are designed based on known physiotherapy guidelines and evidence for improving motor symptoms for people with PD and delivered in AR. Some of the games also have integrated cueing to allow people with more severe mobility impairments to participate. Feedback of performance can be given using the movement data of the AR headsets.
214666360|NCT06382753|OTHER|Gingival inflammation|Patients were scored for their status of gingival inflammation using Gingival Index and Bleeding on Probing Scores
214666361|NCT06266637|OTHER|Conventional Physical Therapy Program|"Conventional Physical Therapy program:~trunk muscles strengthening exercises, trunk muscles endurance exercises, trunk proprioception exercises . postural correction exercises. Core exercise Spinal mobility exercises"
214875112|NCT00946686|DRUG|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
214875113|NCT06428526|DEVICE|Continuous stimulation strategy|Participants will be administered stimulation with a constant frequency stimulation.
214875114|NCT06428526|DEVICE|Closed-loop stimulation strategy|Participants will be administered with an activity-dependent stimulation.
214875115|NCT06990204|DRUG|Azilsartan medoxomil 80 mg tablet|1 tablet of 80 mg of azilsartan medoxomil
214875116|NCT06990204|DRUG|Edarbi® 80 mg tablets|1 tablet of 80 mg of azilsartan medoxomil.
214875117|NCT02436967|OTHER|Carotid endarterectomy in clinical healthcare.|For the this study itself there is no intervention caused by the extra CT or MRI. The patients are scheduled for surgery as the routine intervention to reduce the risk of a new stroke in clinical practice. The performed extra diagnostic CT and MRI in this study before surgery will compare the vessel wall images with histology regardless of the patients status or medication.
214875118|NCT06681935|PROCEDURE|Oral Cavity Reconstruction|This procedure includes a planned surgical connection from the oral cavity to the neck soft tissues which is repaired through free or pedicled flap reconstruction.
214875119|NCT06082674|DEVICE|Vayu bCPAP|The Vayu bCPAP uses a constant flow of dry oxygen from the source with an adjustable flow meter. Oxygen is blended by Venturi blender with ambient air to create a source of oxygen-enriched air of adjustable concentration.
214875120|NCT06082674|DEVICE|Mechanical Ventilator Driven CPAP|Mechanical Ventilator Driven CPAP
214875121|NCT00290160|BEHAVIORAL|Protein supplementation|
214875122|NCT05491876|OTHER|Chest physiotherapy with breathing exercises and ACBT|Group A got chest physiotherapy with breathing exercises and ACBT
215041101|NCT06975800|BEHAVIORAL|Low social feedback|Social information is provided to participants signaling that the upcoming trial will be low in negative affect and cognitive effort.
215041102|NCT06975800|BEHAVIORAL|High social feedback|Social information is provided to participants signaling that the upcoming trial will be high in negative affect and cognitive effort.
215041103|NCT03874559|DIAGNOSTIC_TEST|Blood Draw|Serum samples will be obtained from each patient enrolled
215041104|NCT04267445|PROCEDURE|Embolization of prostatic artery under ultrasound guidance|Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
215041105|NCT00860600|DRUG|PG2|500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time
215041106|NCT06220318|DRUG|C019199|The C019199 will be taken orally, once a day
215041107|NCT06220318|DRUG|Sintilimab|Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.
214875123|NCT05491876|OTHER|Chest physiotherapy with breathing exercises|Group B got chest physiotherapy with breathing exercises.
214875124|NCT04572893|DRUG|danicamtiv|Myosin activator
214875125|NCT03784053|OTHER|Immersive virtual reality|At the start of every session, the participants' top five occupational problems will be reviewed, and a list of apps corresponding to the desired occupational problem will be offered through the immersive virtual reality device (Oculus Go). There will be eight 30-minute virtual reality sessions.
214875126|NCT04410237|DEVICE|Med-Jet|"One half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
214875127|NCT04410237|OTHER|Traditional Syringe|"One half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
214875128|NCT00376194|DRUG|DMSA|
214875129|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
214875130|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
214875131|NCT03589235|PROCEDURE|A free gingival graft|A free gingival graft will be used for the treatment of gingival recession
214875132|NCT03589235|DEVICE|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be applied in both donor and receiving sites after the free gingival graft.
214875133|NCT03589235|DEVICE|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be applied in both donor and receiving sites after the free gingival graft.
214875134|NCT04254939|DRUG|CS3007 (BLU-285)|"A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days."
214875135|NCT00197496|PROCEDURE|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
214875136|NCT02606214|DRUG|TBA-354|
214875137|NCT02606214|DRUG|TBA-354 Placebo|
214875138|NCT02995876|PROCEDURE|Glaze layer|A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
214875139|NCT02995876|PROCEDURE|E-max Press layer|A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
214875140|NCT01519986|DIETARY_SUPPLEMENT|Vitamin D3|Supplement of vitamin D3
214875141|NCT01519986|DIETARY_SUPPLEMENT|Placebo|Placebo
214875142|NCT00418821|BIOLOGICAL|Laronidase|dose of 0.58mg/kg body weight intravenously (IV) every week
214875143|NCT00674557|DRUG|SOD1 inhibitor ATN-224|
214875144|NCT00674557|DRUG|exemestane|
214875145|NCT00674557|GENETIC|protein expression analysis|
215041108|NCT05721079|DEVICE|ECP (Extracorporeal Photopheresis System)|Patients who are assigned to the ECP group receive treatments by means of the THERAKOS ® CELLEX ® Photopheresis System (Mallinckrodt Pharmaceuticals Inc.) with either double- or single-needle access. During the leukapheretic processing, 1500 ml of whole blood is processed, and peripheral blood mononuclear cells (MCNs) are separated by centrifugation and collected in the buffy coat. 8-methoxypsoralen (Uvadex®, Mallinckrodt Pharmaceuticals Inc.) at a dose of 20 μg/ml is added to the MNC collection bag and cells are irradiated with ultraviolet A light (1.5 J/cm2) in a 1-mm-thick film through a photoactivation plate. After exposure of the cells to the ultraviolet light, the buffy coat is reinfused into the patient.
215041109|NCT02625779|DRUG|Valproate and Placebo|
215041110|NCT02625779|DRUG|Valproate and Cytidine-containing Drug|
215041111|NCT02625779|DRUG|Valproate and Creatine-containing Drug|
214875146|NCT00674557|GENETIC|proteomic profiling|
215041112|NCT06376825|BEHAVIORAL|MyLife: An internet-based self-help program to reduce burnout|MyLife is a internet-based and Acceptance and Commitment Therapy oriented self-help program to reduce burnout. In this study a tailored to teachers version of the program will be used.
215041113|NCT02565459|BIOLOGICAL|Mesenchymal Stromal Cells|
215041114|NCT06565143|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak alternating currents.
215041115|NCT06565143|DEVICE|Sham transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
215041116|NCT02993263|DEVICE|VectraplexECG System with CEB®|The device will be used after noncardiac surgery
214666362|NCT06266637|OTHER|Physiotherapeutic Scoliosis-Specific Exercise (Schroth)|It uses exercises customized for each patient to return the curved spine to a more natural position. The spine is addressed in all three anatomical planes - sagittal, frontal and transverse. The purpose of the method is to create spinal balance and stability by improving body mechanics and spinal stabilization to prevent further curve progression
214875147|NCT00674557|OTHER|laboratory biomarker analysis|
215041117|NCT01364831|BEHAVIORAL|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
215041118|NCT04035031|DRUG|Forxiga 10mg|Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)
215041119|NCT04035031|DRUG|Placebo|Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
215041120|NCT01221116|DRUG|levosimendan|levosimendan 0.1 microgram/kg/min) for 24 hours
215041121|NCT01616147|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
215041122|NCT01616147|BEHAVIORAL|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
215041123|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
215041124|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
215041125|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
215041126|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
215041127|NCT04321655|OTHER|High Intensity LASER Therapy (HILT)|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ (millijoule)/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J"
215041128|NCT04321655|OTHER|Ibuprofen Gel Phonophoresis (IGP)|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. (8 min/ one session each day for 3 days/week for 8 weeks).
215041129|NCT04321655|OTHER|Transcranial Direct Current Stimulation (tDCS)|Anode electrode -C3/C4 (contralateral side of the most affected knee), Cathode electrode- contralateral supraorbital area. (2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
215041130|NCT04321655|OTHER|Conventional Physiotherapy (CPT)|"1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
215041131|NCT05221892|DRUG|Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin|Tablets to be taken 30 minutes before each of 4 trips.
215041132|NCT05221892|DRUG|Ginger|Tablets to be taken 30 minutes before each of 4 trips.
214666363|NCT04950231|OTHER|The questionnaire survey|Questionnaires were issued and collected by 6 competent nurses with strict training, data entry by 2 researchers, statistical analysis by 1 researcher, and quality control by the other 2 researchers throughout the process.
214666364|NCT01773395|BIOLOGICAL|GVAX|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the GVAX arm will receive GVAX vaccine.
214875148|NCT00674557|OTHER|pharmacological study|
214875149|NCT03862066|OTHER|Blood collection|5 milliliters (mL) of blood will be collected at the time of surgery
214875150|NCT03862066|OTHER|Tissue collection|Left over tissue will be collected at the time of surgery
214875151|NCT01212354|RADIATION|Radiotherapy|7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
214875152|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
214875153|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
214875154|NCT00727766|DRUG|Clofarabine|
214875155|NCT03349008|DRUG|Entecavir|Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
214291379|NCT03407378|OTHER|Motor Assessments on regular PD treatment|Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
214875156|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate|Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
214666365|NCT01773395|BIOLOGICAL|Placebo Vaccine|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the placebo arm will receive placebo vaccine.
214875157|NCT03349008|DRUG|Diammonium Glycyrrhizinate|Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
214875158|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate Placebo|Magnesium Isoglycyrrhizinate Injection Placebo
214875159|NCT03349008|DRUG|Diammonium Glycyrrhizinate Placebo|Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
215041133|NCT03732469|DRUG|Acetaminophen|Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
215041134|NCT03732469|DRUG|Fentanyl|Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
215041135|NCT03732469|DRUG|Propofol|Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
215041136|NCT02434861|DRUG|Rolapitant|
215041137|NCT02434861|DRUG|Digoxin|P-gp substrate
214666366|NCT01773395|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant|Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor. This is given as a transfusion through a central intravenous line (IV usually placed in the chest or arm).
214875160|NCT00416702|DRUG|QAB149|
214875161|NCT01866059|DEVICE|Calcium silicate cement|Calcium silicate cement
214875162|NCT01866059|DEVICE|Glass Ionomer Cement|Glass Ionomer Cement
214875163|NCT01866059|DEVICE|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
214875164|NCT01123837|OTHER|Intravenous fluid|"The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery."
214875165|NCT01123837|OTHER|D5LR or lactated ringers|"The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction."
215041138|NCT02434861|DRUG|Sulfasalazine|BCRP substrate
215041139|NCT02434861|DRUG|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
215041140|NCT00743470|DRUG|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
215041141|NCT00743470|DRUG|rifabutin|rifabutin capsule; see arms for intervention description
215041142|NCT05695105|DEVICE|Electric Toothbrush-Generated Vibration|Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth
215041143|NCT05695105|DEVICE|Mini-Implant-Assisted Orthodontic Treatment|Testing mini-implant-assisted heavy force application to treat ankylosis of teeth
215041144|NCT04594993|DEVICE|INFINITY™ with ADAPTIS™ Technology Total Ankle System|Total Ankle Replacement
215041145|NCT02990702|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
215041146|NCT02990702|OTHER|Ultrasound guided coracoid infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
215041147|NCT02990702|DRUG|Bupivacaine|
215041148|NCT02990702|DEVICE|Ultrasound|
214291380|NCT06186531|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM, a formulated dietary supplement, will be an ovalized tablet measuring 8.51 mm x 15.49 mm. Each pill will contain a white PEG coating and an equal mixture of, daidzein, genistein, and S-equol.
214291381|NCT06186531|DRUG|Placebo|Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
214291382|NCT02699528|DRUG|methylphenidate|The drug will be prescribed as indicated for attention deficit disorder
214875166|NCT04121754|DEVICE|MR-001|Participants will walk using the investigational device (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 3 times a week for 5 weeks.
214875167|NCT04121754|OTHER|Active Walking|Participants will walk for thirty (30) minutes at a time, 3 times a week for 5 weeks. No mobile devices, music players or headphones will be allowed. They will wear foot sensors during their active walking sessions to measure gait biomechanics.
214875168|NCT05352347|DRUG|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
214875169|NCT05352347|DRUG|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
215041149|NCT05311423|DIAGNOSTIC_TEST|QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra|Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
214291383|NCT05178966|BEHAVIORAL|Bp OneDay psychoeducation program|"The BP One-Day Psychoeducation program is based on a single day of psychoeducation . This program was carried out by members of the bipolar expert center network in various hospitals of the network and included :~* Representation of BD~* Definition, diagnosis and awareness of the disorder~* Depressive, hypo / manic symptoms~* Vulnerability to BD causes of BD, risk factors for relapses~* Drug treatments, drug compliance and non-drug treatments~* Early detection of prodromal signs~* Communication techniques~Each BP One-Day psychoeducation session welcomes an average of ten participants (5 patients / 5 caregivers). At the end of the day, participants receive a booklet containing the main information of the day.~BP One-Day program is delivered by a nurse and a psychologist specialized in both BD and therapy group facilitation. A specialized psychiatrist intervenes in the section Medication treatments and medication adherence for a period of approximately one hour."
214666367|NCT01773395|DRUG|Busulfan|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
214666368|NCT01773395|DRUG|Fludarabine|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
215041150|NCT00572559|DRUG|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
215041151|NCT00572559|DRUG|Linezolid|600 mg every 12 hours (intravenously \[IV\] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
215041152|NCT06644092|OTHER|Investigation of the Effectiveness of Physiotherapy and Rehabilitation After Osteochondral Allograft Transplantation Operation|The treatment protocol to be applied to the patients after surgery was determined. The protocol includes; cold application, game ready device application, CPM device application, patellar mobilization, soft tissue mobilization application, TENS, conventional TENS and NMES application, ultrasound application, stretching exercises, strengthening exercises, mobilization exercises, balance and proprioception exercises, walking training and kinesio taping.
215041153|NCT00741078|DRUG|statin, amlodipine|
214291384|NCT06161220|DRUG|Carbidopa capsule|Dose: 4x 100 mg
215041154|NCT05983705|BEHAVIORAL|AFFEKT - a manual based brief parent program for parents of children (aged 6-12 years) with externalizing behaviors.|The AFFEKT program includes five group sessions, two hours each, provided on a weekly basis. The program is delivered by therapist trained in Cognitive and Behavioral Therapy (CBT) and AFFEKT. The participants also receive a participation material, covering the same themes that are addressed in the program and working sheets for the home-assignments that are provided in-between sessions.
215041155|NCT01729039|BEHAVIORAL|standard balance rehabilitation|All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
214291385|NCT06161220|DRUG|Moxifloxacin Tablets, USP|Dose: 400 mg
214291386|NCT06161220|DRUG|Placebo|Placebo capsules matching the carbidopa capsules
214875170|NCT05352347|DRUG|Placebo|Normal saline (NS) 100mL bid
214875171|NCT02304627|DRUG|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
214875172|NCT01558180|BEHAVIORAL|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
214875173|NCT01558180|BEHAVIORAL|Usual Care|educational handouts on pediatric insomnia
214875174|NCT03258073|OTHER|Medical simulation using scenario execution|Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
214291387|NCT01986855|DRUG|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
214875175|NCT01196676|DRUG|AZD4451|1 mg capsules, 5 mg capsules, and 25 mg capsules
214666369|NCT01773395|DRUG|Tacrolimus|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
214875176|NCT01196676|DRUG|Placebo|1 mg capsules, 5 mg capsules, and 25 mg capsules
214875177|NCT01550627|OTHER|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
214875178|NCT01550627|OTHER|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
214875179|NCT05896930|DRUG|Meropenem 6g IV over 6 hours|Meropenem 6g intravenously over 6 hours once daily on days 1-14.
214875180|NCT05896930|DRUG|Ertapenem 1g IM|Ertapenem 1g intramuscularly once daily on days 1-14.
214875181|NCT05896930|DRUG|Meropenem 3g IV|Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
214875182|NCT05896930|DRUG|Ertapenem 1g IV|Ertapenem 1g intravenously once daily on days 1-14.
214875183|NCT05896930|DRUG|Amoxicillin/CA twice daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
214875184|NCT05896930|DRUG|Rifampicin 35 mg/kg|Rifampicin 35 mg/kg once daily on days 1-14.
214875185|NCT05896930|DRUG|Meropenem 6g IV over 60 minutes|Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
215041156|NCT01729039|BEHAVIORAL|gaze stability|Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
215041157|NCT01729039|BEHAVIORAL|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
215041158|NCT06592079|PROCEDURE|Immediate implant and connective tissue graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
215041159|NCT06592079|PROCEDURE|Immediate implant with connective tissue graft and bone graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Xenograft will placed to fill the jumping gap.Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
215041160|NCT06074263|DRUG|Dexamethasone 8mg|Dexamethasone 8mg will be taken orally just prior to surgery.
215041161|NCT06074263|OTHER|Placebo|Placebo capsule which looks identical to dexamethasone capsule
214875186|NCT05896930|DRUG|Rifafour e-275|Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
214875187|NCT05896930|DRUG|Meropenem 4g IV|Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
214875188|NCT05896930|DRUG|Amoxicillin/CA once daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
214875189|NCT05600790|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
214875190|NCT03330210|PROCEDURE|3D printing|Manufacturing and use of a model printed in 3D
214875191|NCT06632314|DIETARY_SUPPLEMENT|Enteral feeding|Enteral feeding will be withheld or continued in very low birthweight neonates during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.
214291388|NCT01986855|DRUG|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
214291389|NCT01986855|DRUG|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
214291390|NCT01986855|DRUG|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
214875192|NCT01062867|DRUG|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
214875193|NCT00085475|DRUG|imatinib mesylate|
214875194|NCT00085475|PROCEDURE|conventional surgery|
214875195|NCT01696851|OTHER|tests and questionnaires|lung test, depression and self-efficacy questionnaires and Functional testing.
214291391|NCT01940679|DIETARY_SUPPLEMENT|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
214291392|NCT00664742|DRUG|Fluvastatin XL®|Fluvastatin extended release 80 mg
215041162|NCT06982105|DRUG|Trimethoprim Sulfamethoxazole|"* For osteoarticular infections- 4-5 mg/kg/dose (based on TMP) PO every 8 hours (max dose 320mg/dose)~* For head and neck infections- 5-6 mg/kg/dose (based on TMP PO every 12 hours (max dose 320mg/dose)~Duration will be at the discretion of the treating provider"
215041163|NCT01772251|DRUG|Oshadi Icp|
215041164|NCT03624556|DIETARY_SUPPLEMENT|EGCG FontUp|Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.
215041165|NCT03624556|OTHER|Placebo FontUp|Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
214666370|NCT01773395|DRUG|Methotrexate|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
214666371|NCT03228186|DRUG|Pevonedistat|25mg/m2 days 1, 3, 5
214666372|NCT03228186|DRUG|Docetaxel|75mg/m2 day 1
214875196|NCT03958253|OTHER|Toolbox for Lung Cancer Screening|"-Toolbox of evidence-based elements that a primary care or referral site could implement to address known barriers to screening and referral, as well as required elements for screening. These elements will be designed to be adaptable to the unique needs and screening processes of the participating practices.~* Patient education materials~* Primary care practice educational materials~* Pack-years/eligibility calculator~* Local referral process guide~* Smoking cessation materials and support~* Shared decision-making guide~* LDCT best practice guidelines"
215041166|NCT06650384|DRUG|Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin|Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day
215041167|NCT06650384|DRUG|Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin|Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day
215041168|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
214291393|NCT04317066|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on day 1 of each 3-week cycle.
214666373|NCT06295926|DRUG|Serplulimab|Undergo 4 cycles of synchronous radiotherapy and chemotherapy combined with Sintilimab immunotherapy, followed by Sintilimab monotherapy for maintenance treatment until disease progression or up to 1 year.
214666374|NCT04312997|DRUG|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
214875197|NCT05068453|DRUG|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|OH2：less than 8mL/time，Q2W，i.t.；
214875198|NCT05068453|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody for injection|HX-008：200mg/time，Q3W，i.v.；
214875199|NCT05068453|RADIATION|RT|3 times radiation，totally 24-30 Gy for each lession.
214875200|NCT02472327|BEHAVIORAL|Pre-operative support|
214875201|NCT01325727|OTHER|Brief computerized feedback|Brief computerized feedback
214875202|NCT01325727|OTHER|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
214875203|NCT03483727|DEVICE|SIMMAXMARCHERYAN|Digital cognitive aid during the management of simulated combat wounded.
214875204|NCT05148260|BEHAVIORAL|Learning Through Play plus (LTP+)|Group-1: Experimental (n=40 participants) will receive the LTP+ which consist of a total of 12-group integrated treatment sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother/child pair per sub-group.
214875205|NCT05148260|BEHAVIORAL|Psychoeducation|Group-2: Controlled (n=40 participants) will receive 'psychoeducation' which consist of a total of 12-group sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother-child pair per sub-group.
214875206|NCT01333891|DRUG|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
214875207|NCT01333891|DRUG|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
214875208|NCT01333891|DEVICE|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
214875209|NCT01333891|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
214666375|NCT04312997|DRUG|Placebo|Sterile saline for inhalation
214666376|NCT01548664|OTHER|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
215041169|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|
215041170|NCT06569810|DEVICE|Repeated Low-Level Red Light (RLRL) therapy|In our study, we do not implement any interventions; rather, we collect follow-up information from patients who, due to insufficient response to traditional myopia control therapies, have transitioned to Repeated Low-Level Red Light (RLRL) therapy. The data gathered will reflect treatment patterns as per the approved indications for RLRL therapy, where subjects may have undergone treatment sessions twice daily, each lasting for 3 minutes with a minimum interval of 4 hours between sessions. Our analysis will focus on the real-world outcomes, specifically evaluating the proportion of participants who have achieved effective myopia control (defined as AL elongation of less than 0.1mm per year or SER progression of less than 0.25 diopter per year) after 12 months of documented RLRL therapy use among the collected data from eligible subjects.
215041171|NCT05934526|DRUG|Placebo|Matching capsule containing placebo
215041172|NCT05934526|DRUG|Seralutinib|Capsule containing seralutinib
215041173|NCT05934526|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib or placebo delivery
214291394|NCT01907503|PROCEDURE|Evaluation of the balance of force platform|
214666377|NCT01548664|OTHER|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
215041174|NCT03490565|BEHAVIORAL|Exercise training|Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
215041175|NCT01348893|BEHAVIORAL|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
215041176|NCT00698841|DRUG|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m\^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m\^2 over 60 minutes.
215041177|NCT06984510|OTHER|Observational|Observational
215041178|NCT06605209|DEVICE|Peripheral Balloon-Expandable Covered Stent System|The intervention in this clinical trial involves the Peripheral Balloon-Expandable Covered Stent System. This stent system is specifically designed for the treatment of stenosis and/or occlusion in the common and external iliac arteries.
214291395|NCT03072628|OTHER|e-cig with nicotine|use an e-cig with nicotine for 30 minutes
214291396|NCT03072628|OTHER|e-cig without nicotine|use an e-cig without nicotine for 30 minutes
214291397|NCT03072628|OTHER|nicotine inhaler|use a nicotine inhaler for 30 minutes
214291398|NCT03072628|OTHER|sham control|use an empty e-cigarette for 30 minutes
214291399|NCT01864447|BEHAVIORAL|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
215041179|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - fast|Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions
214291400|NCT06052007|BEHAVIORAL|LC-Based Debriefing|LC-based debriefing encourages reflection by allowing learners to identify and explore topics of particular interest. The model is defined as a structured post-event LC, which is useful for improving competence, professional development, and clinical judgment among intensive care unit and trauma nurses. The model is useful not only for one recipient by allowing reflection on positive and negative experiences but also for the whole group by allowing them to make connections to their own practice that day or to previous experiences, supporting teamwork. It also helps them understand what good practice is by doing their own self-assessment with peers' benchmarking.
215041180|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - slow|Continuous passive motion device (CPM) of ankle 0.25HZ (15rpm) for 10 repetitions
215041181|NCT06817603|DEVICE|Procedural Oxygen Mask|Procedural Oxygen Mask will be used
215041182|NCT06817603|DEVICE|High-Flow Nasal Cannula|High-Flow Nasal Cannula (HFNC) will be used.
214291401|NCT06052007|BEHAVIORAL|3D Model-Based Debriefing|The model has three parts: defusing, discovering, and deepening. The experiential learning theory on which this model is based facilitates learning goals. This model allows its participants to create new mental models for future practice, develop critical thinking skills, and identify knowledge gaps. In the model, a debriefing session starts with preliminary information and ends with a summary of what has been learned. Participants' gaps in understanding and learning are identified, and how they can apply their learnings to practice is discussed.
214666378|NCT03784430|PROCEDURE|Immediate dental implant placement|Tooth will be extracted and a dental implant will be positioned at the same time.
215041183|NCT06817642|OTHER|Data recovery from language and cognitive assessment|Data recovery from language assessment: Core Assessment of LAnaguage Processing, and from neuropsychological assessment : Montreal Cognitive Assessment, Trail Making Test, Batterie Rapide d'Efficience Frontale (BREF), animal fluency, 5 words of Dubois, Ne
214291402|NCT02434731|DEVICE|Buzzy® device|Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
214291403|NCT02152579|DRUG|Isosorbide-5-mononitrate|Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
214666379|NCT03784430|PROCEDURE|Immediate dental implant placement with CTG|Tooth will be extracted and a dental implant will be positioned at the same time with a connective tissue graft.
214666380|NCT03671083|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
214666381|NCT00181077|DRUG|2% buffered hypertonic saline administration|
214666382|NCT04246047|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
214666383|NCT04246047|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
214666384|NCT04246047|DRUG|Bortezomib|Proteasome Inhibitor
214666385|NCT04246047|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
214666386|NCT02481505|DRUG|Chloroprocaine HCl 1%|Intrathecal Route
214666387|NCT04768582|DIAGNOSTIC_TEST|P2Y12-reaction-units (PRU) by VerifyNow-P2Y12 assay|The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).
214666388|NCT05888896|OTHER|methyldopa tablets 250mg|patients will be taken methyldopa tablets 250mg in the morning orally with a lot of water after breakfast daily and this medication continues for 8 weeks
214666389|NCT05888896|OTHER|methyldopa tablets 250mg + foot reflexology|patients will receive methyldopa tablets 250mg in oral way once daily per 8 weeks and patients will receive foot reflexology two sessions per week, every session will last for 30 minutes and sessions will last for 8 weeks.
214666390|NCT05139030|DRUG|bupivacaine liposome injectable suspension|Adductor canal block with EXPAREL
215041184|NCT06662279|DEVICE|Removable Rapid Palatal Expander|Removable palatal expander where expanders are changed to obtain up to .25mm expansion per expander
215041185|NCT06662279|DEVICE|Banded Palatal Expander|Palatal expander cemented into mouth where a screw is turned to obtain .25mm expansion per turn
214666391|NCT05139030|DRUG|Bupivacaine Hydrochloride|Adductor Canal Block with bupivacaine HCl
215041186|NCT06655740|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
215041187|NCT06453772|PROCEDURE|Liposuction|Primary or secondary liposuction is performed by the surgical staff. The study analyzed variables including weight, height, BMI, preoperative hemoglobin, and aspirated volume. Additionally, preoperative hemoglobin (Hb), hematocrit (Hto), platelets, prothrombin time (Tp), partial prothrombin time (TpT), and International Normalized Ratio (INR) were evaluated. Hb and Hto levels were reassessed 24 hours post-surgery to monitor changes.
215041188|NCT06603493|OTHER|Assessment of sleep disorders|: Sleep disturbances will be assessed with the Pittsburgh Sleep Quality Index
215041189|NCT06603493|OTHER|Assessment of Central Sensitization|Central sensitization will be assessed with the Central Sensitization Inventory
215041190|NCT06603493|OTHER|Assessment of depression, anxiety and stress levels|Depression, anxiety and stress levels will be assessed using the Depression, Anxiety, Stress Scale (DASS-21)
215041191|NCT00697385|DRUG|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
215041192|NCT05751577|PROCEDURE|TAVI WITHOUT ON-SITE SURGERY|After randomization, study TAVI operators of the participating center will schedule the patient for TAVI in their hospital without on-site surgery
215041193|NCT05751577|PROCEDURE|TAVI WITH ON-SITE SURGERY|After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
215041194|NCT00650507|PROCEDURE|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
215041195|NCT00650507|PROCEDURE|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
215041196|NCT05574881|DRUG|Dalpiciclib|150 mg qd
215041197|NCT05574881|DRUG|Fulvestrant|500mg d1, 15, 29, and then q4w
215041198|NCT05574881|DRUG|Pertuzumab|840mg q3w, and then 420 mg q3w
215041199|NCT05574881|DRUG|Trastuzumab|8 mg/kg q3w, and then 6 mg/kg q3w
215057559|NCT06138353|DRUG|Shuxuening injection or placebo|Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
214666392|NCT01472484|OTHER|586/8x87 white|2 x 50 g
214666393|NCT01472484|OTHER|586/8x87 brown|2 x 50 g
214291404|NCT02930421|OTHER|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
214666394|NCT01472484|OTHER|BAT 881|2 x 50 g
214666395|NCT01472484|OTHER|586/8|2 x 50 g
214666396|NCT04216173|OTHER|Acupuncture|Acupuncture weekly for 12 consecutive weeks. Acupuncture protocol consists of both scalp and body acupuncture points.
214666397|NCT05585749|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
214666398|NCT01136239|DRUG|N-acetycysteine (600mg twice daily)|N-acetycysteine (600mg twice daily) for one year
214666399|NCT01136239|DRUG|Placebo|Placebo (600mg twice daily)
214666400|NCT01982630|DRUG|MK-8521|
214666401|NCT01982630|DRUG|Liraglutide|
214666402|NCT01982630|DRUG|Placebo|
214666403|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
214666404|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
214666405|NCT05290220|DRUG|HLX07|1500 mg
214666406|NCT05290220|DRUG|HLX10|300 mg
214666407|NCT05290220|DRUG|HLX04|15mg/kg
214666408|NCT05290220|DRUG|lenvatinib|12 mg (BW≥60 kg) or 8 mg (BW \<60 kg)
214666409|NCT01059149|DEVICE|repetitive transcranial magnetic stimulation|MagPro x100 (MagVenture A/S, DANEMARK)
214666410|NCT06085157|OTHER|electronic diary|a smartphone application for self-documentation of drinking pattern
214666411|NCT02812511|PROCEDURE|Biopsy|Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.
214666412|NCT02070432|DRUG|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
214666413|NCT05221190|PROCEDURE|Single buccal infiltration|injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.
214666414|NCT05221190|PROCEDURE|Inferior alveolar nerve block|Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
214666415|NCT01629849|DRUG|Placebo to BI 1021958 qd|tablet
214666416|NCT01629849|DRUG|BI 1021958 bid|tablets
214666417|NCT01629849|DRUG|Placebo to BI 1021958 bid|tablets
214666418|NCT01629849|DRUG|BI 1021958 qd|tablet
214666419|NCT04439786|DRUG|placebo|the control group will be given the same volume of saline.
214666420|NCT04439786|DRUG|lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
215041200|NCT06992024|COMBINATION_PRODUCT|Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody|Electroacupuncture (EA) Combined With Paclitaxel Protein-bound (Chemo) and PD-1 Antibody (IO) for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer. Electroacupuncture stimulates specific acupoints（dense-sparse wave，30min）d0, d1, d7, d8 + Paclitaxel Protein-bound (125mg/m2) d1, d8 + PD-1 Antibody (not limited to specific drugs，dosages should be calculated according to corresponding drug instructions) d1, Q3W. If the diseases are well controlled after 6 cycles, maintenance treatment, namely Electroacupuncture stimulates specific acupoints（dense-sparse wave，30min）d0, d1 + PD-1 Antibody (not limited to specific drugs，dosages should be calculated according to corresponding drug instructions) d1, Q3W, will be continually conducted until the diseases progress.
214875210|NCT01333891|DEVICE|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
214875211|NCT01470768|OTHER|Amino Acid-based Formula with high DHA and ARA|
215041201|NCT06988735|PROCEDURE|Nonrobotic TCRAT|Nonrobotic TCRAT for CABG
215041202|NCT06988735|PROCEDURE|Robotic TCRAT|Robotic TCRAT for CABG
215041203|NCT02976805|DRUG|4L PegLyte + 15 mg bisacodyl|Randomized
215041204|NCT02976805|DRUG|6L PegLyte + 15 mg bisacodyl|Randomized
215041205|NCT07003243|DRUG|Local melatonin powder|A single topical dose of 3 mg of pure melatonin powder was mixed with particulate bone graft and normal saline, then packed into the jumping gap around immediately placed dental implants. The intervention was performed at the time of surgery following atraumatic tooth extraction. The aim was to enhance osseointegration and minimize crestal bone loss over a 6-month healing period.
214666421|NCT04990076|PROCEDURE|Hysterectomy|Surgery includes different types of hysterectomy: vaginal hysterectomy, total abdominal hysterectomy and laparoscopic or Robotic hysterectomy. The type of hysterectomy does not influence histological outcome, as long as the uterus is removed in one part (no power morcellation). Indications for surgery and the type of surgery are according to the departments' protocols. If the patient is deemed to be inoperable due to the extent of the disease, a representive biopsy (e.g. trucut biopsy) will be accepted if sufficiently motivated by the oncology team.
214666422|NCT03165396|DRUG|Propofol|Propofol is the most common clinical anesthetics.
214666423|NCT03165396|DRUG|Sevoflurane|Sevoflurane is the most common clinical anesthetics.
214666424|NCT02673281|OTHER|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
214875212|NCT01470768|OTHER|Amino Acid-based Formula with lower DHA and ARA|
214875213|NCT03664492|OTHER|Educational whiteboard video|Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
214875214|NCT01246063|DRUG|carfilzomib|
214875215|NCT01246063|DRUG|pegylated liposomal doxorubicin (PLD)|
214875216|NCT01246063|DRUG|Dexamethasone|
214875217|NCT03805711|DEVICE|HLT® Transcatheter System|Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
215041206|NCT07004088|BEHAVIORAL|Mandala coloring|"Female patients undergoing dialysis treatment in the dialysis unit were informed about the study. After women are informed about the effects of mandala application on health and how to paint mandala; voluntary consent form, personal information form, Dialysis Symptom Index Scale, Self-Care Power Scale for Chronic Dialysis Patients were filled. One hour after the start of each dialysis session, the patients were given mandalas for 20-30 minutes and asked to paint. The women's own paints and mandalas were preserved for the next session. After the sixth dialysis session , the patients were asked to refill the scales with one-on-one interviews, and the verbal opinions and feedback of the patients about the application were taken."
215041207|NCT01325233|DRUG|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
215041208|NCT01325233|DRUG|Placebo|500 ml normal saline, tiw, 2 weeks
215041209|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose A|Dose A, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
215041210|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose B|Dose B, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
215041211|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose C|Dose C, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
215041212|NCT06194656|OTHER|HER3 Monoclonal antibodies-Dose D|The optimal recommended dosage (RP2D) of SIBP-03intravenous, infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
215041213|NCT06194656|OTHER|Placebo|SIBP-03 solvent without HER3 antibody, intravenous infusion (IV), once every one weeks, 21 days as a cycle.
215041214|NCT06194656|COMBINATION_PRODUCT|Cetuximab injection|Medications used for combination therapy, intravenous infusion (IV). Administer once a week.
215041215|NCT05493657|DRUG|Aspirin single antiplatelet therapy|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
215041216|NCT05493657|DRUG|Clopidogrel single antiplatelet therapy|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
214666425|NCT02673281|OTHER|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
214666426|NCT00070447|BIOLOGICAL|rituximab|
214666427|NCT00070447|DRUG|cyclophosphamide|
214666428|NCT00070447|DRUG|doxorubicin hydrochloride|
214666429|NCT00070447|DRUG|prednisone|
214666430|NCT00070447|DRUG|vincristine sulfate|
214666431|NCT00070447|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214291405|NCT01593488|DRUG|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
214291406|NCT02771990|DEVICE|Sham transcranial direct current stimulation|sham stimulation
214875218|NCT00483483|BEHAVIORAL|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
214875219|NCT00483483|BEHAVIORAL|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
214875220|NCT03125980|DRUG|capecitabine plus oxaliplatin before and after surgery|"Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Repeat every 3 weeks (Q3W)"
214875221|NCT03125980|DRUG|capecitabine plus oxaliplatin after surgery|"Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Q3W"
214875222|NCT05050110|OTHER|Fruits and Vegetable increase|Increase fruits and vegetable consumption in chronic Kidney Patients to maintain Normokalemia
214291407|NCT02771990|DEVICE|transcranial direct current stimulation|2 milliamp (mA) 20 minutes
214291408|NCT02691299|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
214875223|NCT04676659|DRUG|TNK-tPA|Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
214875224|NCT05404945|DRUG|Pembrolizumab|Pembrolizumab 400 mg IV
214875225|NCT05404945|DRUG|Doxorubicin|Doxorubicin 25mg/m2 IV
214875226|NCT05404945|DRUG|Vinblastine|Vinblastine 6mg/m2 IV
214875227|NCT05404945|DRUG|Dacarbazine|Dacarbazine 375mg/m2 IV
215041217|NCT06941857|DRUG|Oxaliplatin|65mg/m2 will be administered as a 120 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
215041218|NCT06941857|DRUG|Irinotecan|150 mg/m2 will be administered as a 90 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
215041219|NCT06941857|DRUG|Folinic Acid|50 mg will be administered as a 15 minute IV infusion (-5/+20 min) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. Folinic acid can be given concurrent with irinotecan. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
214291409|NCT02691299|DRUG|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
215041220|NCT06941857|DRUG|5-Fluorouracil (5-FU)|2400 mgm2 will be administered as a continuous IV Infusion (-120/+ 120 minutes) over approximately 46 hours on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
214291410|NCT00002007|DRUG|Zidovudine|
214291411|NCT00002007|DRUG|Sargramostim|
214291412|NCT03807869|PROCEDURE|combined glaucoma surgery|phacoemulsification of cataract and I-stent by-pass implantation
214291413|NCT00848081|DRUG|Tadalafil|5 mg taken by mouth once daily for 12 weeks
214875228|NCT05404945|DRUG|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg IV
215041221|NCT06941857|DRUG|NC410|100 mg will be administered as a 60 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
215041222|NCT06941857|DRUG|Nivolumab|400 mg will be administered as a 30 minute IV Infusion (-5/+20 minutes) once on Cycle 1 Day 1. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
215041223|NCT06941857|DRUG|Ipilimumab|50 mg will be administered as a 30 minute IV Infusion (-5/+20 minutes) once on Cycle 1 Day 1. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
215041224|NCT07143617|BIOLOGICAL|STR-P004|STR-P004 Intravenous infusion
214291414|NCT00848081|DRUG|Placebo|By mouth once daily for 12 weeks
215041225|NCT07149506|OTHER|Epicatechin|A comparison will be made between oral catechin (epicatechin) from two approaches: a preventive approach and a therapeutic approach.
214291415|NCT03032731|BEHAVIORAL|Website and pedometer intervention|Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
214291416|NCT03032731|OTHER|Control|Standard, publicly available NHS resources for healthy lifestyles.
214291417|NCT02355353|OTHER|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
214291418|NCT03590587|DRUG|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
214291419|NCT03590587|DEVICE|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
214291420|NCT01739478|OTHER|Packing of abscess cavity|
214291421|NCT01739478|OTHER|External dressing|Application of external dressing whilst abscess cavity heals
214875229|NCT04328961|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
214875230|NCT04328961|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
214875231|NCT03132779|DRUG|Intralipid|Adose of intralipid given and rechecking NKcells activity
214875232|NCT01178528|DRUG|ivabradine|7.5 mg bd
214875233|NCT01178528|DRUG|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
214875234|NCT01178528|DRUG|Carvedilol|25 mg bd
214875235|NCT04157127|BIOLOGICAL|Autologous DC Therapy|Autologous DC Therapy
214875236|NCT06906081|DRUG|Kerendia (Finerenone, BAY94-8862)|"Titration of finerenone will be based on baseline eGFR. Participants with eGFR \> 60 mL/min/1.73m² will start on a 20mg dosage. Medication dosage will be increased to 40 mg after one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level.~Participants with eGFR \< 60 and \>25 Participants with eGFR \< 60 mL/min/1.73m² (and eGFR \< 25 mL/min/1.73m²) will start on a 10mg dosage. Medication dosage will be increased to 20 mg after one month if serum potassium \< 4.8 mmol/l. Subsequently, Medication dosage will be increased to 40 mg after an additional one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level.~Finerenone is administered orally as immediate release tablets."
215041226|NCT07149506|OTHER|Epigallocatechin Gallate (EGCG)|A comparison will be made between topical catechin (EGCG) from two approaches: a preventive approach and a therapeutic approach.
215041227|NCT07149506|OTHER|Microcrystalline Cellulose NF (placebo)|A comparison will be made between oral placebo (microcrystalline cellulose) from two approaches: a preventive approach and a therapeutic approach.
215041228|NCT07149506|OTHER|Saline (0.9% NaCl)|A comparison will be made between topical placebo (0.9% saline solution) from two approaches: a preventive approach and a therapeutic approach.
215041229|NCT05530733|PROCEDURE|Pacifier|Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.
215041230|NCT05530733|PROCEDURE|Breast milk|For babies assigned to the pacifier with breast milk group, their own breast milk will be applied by dripping 1 ml into the pacifier.
215041231|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
215041232|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
215041233|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
214666432|NCT02237027|BIOLOGICAL|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
214875237|NCT06906081|DRUG|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
214875238|NCT06135051|DEVICE|Diadem prototype|The device delivers low-intensity ultrasonic waves into specific brain targets.
214875239|NCT06399432|BEHAVIORAL|Mediterranean Diet|"In the Mediterranean Diet, all foods are included. Red meat will be limited to 1/week, poultry to ≤3 times/week and fish to 2-3 times/week. Supplementation with extra-virgin olive oil and nuts, providing 1 liter of olive oil per week and 30 gr a day of nuts.~The dietician will personalize the dietary advice by adapting it to the patient's condition, preferences and beliefs, will encourage adherence, and transmit a sense of empowerment. A change in diet with specific, attainable goals will be negotiated between the dietician and the participant.~Dieticians will conduct a phone call once in every 2-week period to assess dietary compliance using a 24-hour food recall, the Mediterranean Diet Adherence Form. MD patients will keep a diet diary for 3 days every two weeks, which they will discuss with the dietician during their scheduled dietician assessment. The Baseline Visit with the dietician can occur either in-person or via video communication software."
215041234|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
215041235|NCT01082848|DRUG|aripiprazole|10 mg QD during 26 weeks
215041236|NCT01082848|DRUG|placebo|QD during 26 weeks
215041237|NCT05498584|BEHAVIORAL|exercise based cardiac rehabilitation|The types of exercise are treadmill walking/walking-jogging/jogging, ergometer cycling, stair climbing, or elliptical machine training. The training intensity is gradually increased fortnightly to reach the targeted Borg's rate of perceived exertion (RPE) of 12-14. The training duration is 40 minutes, which included 5-10 minutes of warm-up and cool-down exercises. The training frequency is three sessions per week, with 36 sessions concluding a complete course.
215041238|NCT03088787|DEVICE|Nexfin measuremtents|There will be only observational recordings, no interevntion
215041239|NCT02146924|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given IV
215041240|NCT02146924|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
215041241|NCT02146924|OTHER|Laboratory Biomarker Analysis|Correlative studies
215041242|NCT04104347|OTHER|Metacognitive training (MCT)|Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz \& Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
215041243|NCT04104347|OTHER|Support group|Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
215041244|NCT05198258|OTHER|Implementation strategy - experimental group|On-line theoretical education and three hours of practical training by the project leaders. Contact with the project team via e-mail, phone and on-line repetition of the education for remaining of the clinical examination, neck-specific program and the progression of exercises.
214666433|NCT02237027|BIOLOGICAL|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
214666434|NCT03451448|DIAGNOSTIC_TEST|PET/MRI|PET/MRI with USPIO contrast
214666435|NCT03451448|DIAGNOSTIC_TEST|MRI|MRI with USPIO contrast
214875240|NCT03441282|DRUG|Fentanyl|"After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia."
214875241|NCT06659718|DRUG|Oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
214875242|NCT06659718|DRUG|Sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
214875243|NCT06865131|DEVICE|StrataXRT|StrataXRT being a silicone-based cream forming a film, it is very flexible and can be applied easily to the prone position and to the contours of the large breast unlike some other barrier film skin interventions
214875244|NCT03739645|BEHAVIORAL|Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety|After fear conditioning the cue induces autonomic responses like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after cueing or conditioning. Activity across blocks in the conditioning stage shows that the skin conductance can be described by levels, and slopes which might be related to state anxiety and trait anxiety (Spielberger trait and state anxiety inventory or questionnaire). These skin conductance measures may be concrete metrics for psychological processes in healthy subjects. We will carry out a partial correlation analysis of levels, state anxiety and trait anxiety, and then a similar analysis of slopes, state anxiety and trait anxiety. These results may show that concrete skin conductance levels and slopes are related to metrics of subjective self report measures of state and trait anxiety.
214875245|NCT04666805|DRUG|Tamoxifen|20 mg/d, oral administration
214875246|NCT04666805|DRUG|Toremifene|60 mg/d, oral administration
214875247|NCT04666805|DRUG|Anastrozole|1 tablet (1 mg) per day, oral administration
214875248|NCT04666805|DRUG|Letrozole|Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.
214875249|NCT04666805|DRUG|Exemestane|The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
214875250|NCT04042376|DRUG|Ibrutinib|Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg\*3 capsules taken together at one time).
214875251|NCT06927700|BEHAVIORAL|Modified Risk Claim Type - None|Participants will view smokeless tobacco ads with no modified risk claim (control)
214875252|NCT06927700|BEHAVIORAL|Product Brand - General Snus|Participants will views ads for the smokeless tobacco brand General Snus
214875253|NCT06927700|BEHAVIORAL|Product Brand - Copenhagen|Participants will views ads for the smokeless tobacco brand Copenhagen
214875254|NCT06927700|BEHAVIORAL|Modified Risk Claim Type - Multiple Diseases|Participants will view smokeless tobacco ads with a claim about lower risks for multiple diseases
214875255|NCT06927700|BEHAVIORAL|Modified Risk Claim Type - Lung Cancer|Participants will either view smokeless tobacco ads with a modified risk claim about lower risks for lung cancer only
214875256|NCT06938867|BIOLOGICAL|SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli|SNIPR001 is a live biotherapeutic product
214875257|NCT06938867|OTHER|Placebo 10 mL|Placebo 10 mL matching to SNIPR001 will be administered.
214875258|NCT06229262|DIETARY_SUPPLEMENT|Mango group|Participants will consume 1.5 cups of mangos per day for 12 weeks.
214875259|NCT04759105|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells
214875260|NCT04759105|OTHER|Sham Procedure|anaesthesia, no disc injection, no placebo injection
214291422|NCT02753101|DRUG|[18F]-FTC-146|10 mCi± 1 mCi of \[18F\]FTC-146 intravenously
214875261|NCT00549575|DRUG|L ARG|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
214875262|NCT00549575|DRUG|Placebo|After double blind randomization, patients received a placebo.
214875263|NCT04343157|RADIATION|Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)|In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.
214875264|NCT05779852|OTHER|self-hypnosis and dressing|self-hypnosis during dressing
214875265|NCT05779852|OTHER|dressing|dressing without self-hypnosis
214875266|NCT03928730|PROCEDURE|resection and removal|Surgical resection or removal for histopathological examination
214666436|NCT03459040|DRUG|Alpha 1-Antitrypsin|AAT will be given either in the hospital or the outpatient clinic two times per week.
214666437|NCT04205552|DRUG|Nivolumab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
214666438|NCT04205552|DRUG|Relatlimab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
214666439|NCT03142100|DEVICE|cochlear implants and hearing aids|speech perception tests and bimodal fitting
214666440|NCT06372977|DIAGNOSTIC_TEST|kappa index|CSF albumin /serum albumin ratio (Qalb) k-index = (CSF kFLC/serum kFLC)/Qalb
214666441|NCT04930939|OTHER|Aerobic training cardiac rehabilitation program|Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
214875267|NCT00213135|DRUG|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
214875268|NCT00213135|DRUG|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
215041245|NCT05198258|OTHER|Implementation - control group|Physiotherapists in the control group will receive the same theoretical and practical training as the experimental group but without repetition of the education or support from the research team.
214875269|NCT00213135|OTHER|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
214875270|NCT01208987|OTHER|Medication History was printed|
214875271|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
215041246|NCT04446403|PROCEDURE|Suprascapular Nerve Block|The patient will be put in sitting down position with upper limbs pending beside the body then a high-frequency linear ultrasound probe will be positioned transversely above the spine of the scapula. The suprascapular nerve often appears as hypereccoic structure at the suprascapular notch. A 20-gauge spinal needle will be advanced in-plane from medial to lateral 10mL of bupivacaine 0.25% into the suprascapular notch deep to the superior transverse scapular ligament (STSL) and adjacent to the suprascapular artery (SSA) .
215041247|NCT04446403|PROCEDURE|Axillary Nerve Block|Patient will be put in sitting position, with the shoulder in full adduction. linear transducer (8-14 MHz) will be positioned in the short axis orientation at the neck of humerous to identify the axillary artery about 1 to 3 cm from the skin surface.The artery is the most reliable landmark, then a 21-gauge 90 mm needle will be advanced in-plane and 10 mL of bupivacaine 0.25% will be injected adjacent to the artery.
215041248|NCT04446403|PROCEDURE|posterior cord block|Patient will be put in supine position with head turned away from side that will be blocked with the arm abducted 90 and flexed at the elbow then linear transducer (8-14 MHz) will be positioned in short-axis just medial to coracoid process.Once the artery will be identified, an attempt will be made to identify the hyperechoic cords of the brachial plexus and their corresponding positions relative to the artery, although these may not always be identifiable. The needle will be inserted in plane from the cephalad end of the probe. 10 mL bupivacaine 0.25% will be injected at the posterior cord.
215041249|NCT04446403|PROCEDURE|General anesthesia|General anaesthesia will be induced after giving nerve block in a standardized way with propofol 1.5-2.5mg/kg, fentanyl 2-3 µ/kg and atracurium 0.5mg/kg. maintenance of anaesthesia with isoflurane and atracurium 0.1mg/kg/20min.
215041250|NCT00331032|DRUG|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
215041251|NCT00331032|DRUG|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
215041252|NCT06289465|OTHER|Observation|Seasonal workers will be assessed in the assessment area established in the hazelnut field and healthy controls will be assessed in their homes.
215041253|NCT04055753|DRUG|Doxil|Doxil 50 mg/m2, as per institutional standard
215041254|NCT04055753|DRUG|Doxorubicin|Doxorubicin 75 mg/m2, IV over 5-15 min OR Continuous infusion over 48-72 hours
215041255|NCT05544721|DRUG|Ropivacaine|0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
215041256|NCT04948112|DEVICE|real time continuous glucose monitor|CGM sensor will read blood glucose every 10 minutes
215041257|NCT04948112|DEVICE|blinded continuous glucose monitor|CGM that records blood glucose but not visible to patient
215041258|NCT04122378|OTHER|acupuncture|The acupuncture will be provided by the licensed acupuncturist using standard methods.
215041259|NCT03838744|DRUG|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy
214666442|NCT03732924|DIAGNOSTIC_TEST|Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement|To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
214875272|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
214875273|NCT01239108|DRUG|SGI-1776|SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.
214875274|NCT00373633|PROCEDURE|Thoracic Epidural|Gold standard for post thoracotomy pain
215041260|NCT03838744|DRUG|Experimental arm: Trabectedin + Olaparib|Trabectedin given in combination to olaparib
215041261|NCT06102655|DRUG|Jiajian Guishen Formulation|Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment.
215041262|NCT05906771|DIETARY_SUPPLEMENT|Metabolaid(R)|"The participating subjects will have to follow the intake of the nutraceutical for 3 months, as well as attend the stipulated visits. Participants will be given a register to control their daily intake of the nutraceutical. They should not change their daily habits.~The nutraceutical has been elaborated by Monteloeder, S.L. It is a combination of Hibiscus sabdariffa flowers and Lippia citriodora leaves. The dose that the participants of the experimental group will receive will be 300mg plus 20mg of microcrystalline cellulose. The product is presented in an unflavored capsule, it is a reddish-brown powder with a characteristic odor and a slightly bitter taste. The manufacturing date of the product was 01/12/2022 and the expiration date was 30/11/2024."
214875275|NCT00373633|PROCEDURE|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
214875276|NCT02291640|DEVICE|MIL|direct laryngoscopy
214875277|NCT02291640|DEVICE|CoPilot|video laryngoscopy
214875278|NCT01635348|BEHAVIORAL|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
214875279|NCT01635348|BEHAVIORAL|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
214875280|NCT04063085|DEVICE|PROTAHERE Absorbable Adhesion Barrier|40 mg/ml (4%) cross-linked hyaluronan
214875281|NCT04063085|DEVICE|Hyalobarrier Gel|Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan
214875282|NCT04063085|OTHER|No treatment|No anti-adhesion agent applied
214875283|NCT04063085|DEVICE|Seprafilm Adhesion Barrier|a hyaluronate carboxymethylcellulose-based bioresorbable membrane
214875284|NCT04063085|DEVICE|Gynecare Interceed (TC7) Absorbable Adhesion Barrier|an oxidized regenerated cellulose absorbable membrane
215041263|NCT05906771|DIETARY_SUPPLEMENT|Nutraceutical placebo|"The participating subjects will have to follow the intake of the nutraceutical for 3 months, as well as attend the stipulated visits. Participants will be given a register to control their daily intake of the nutraceutical. They should not change their daily habits.~Nutraceutical placebo contains microcystalline cellulose (185mg) and maltodextrin (185mg)."
215041264|NCT05578066|OTHER|Developing teams of Local Leaders|A team of local leaders, consisting of 3-5 PHC providers and 1-2 users at each CESFAM will be developed in months 1-3 of the intervention.The teams will comprise some individuals who have provided critical support and input, including participating in the exploratory research phase and the Community-Based Participatory Research (CBPR) adaptation of the intervention framework for the Chilean context developed previously. The teams will assist with the data collection process throughout the study by encouraging colleagues to complete questionnaires and recruit users, as well as oversee and implement the intervention at their respective CESFAM. They will receive training to develop their skills as leaders and support the implementation process at their respective CESFAM.
215041265|NCT05578066|OTHER|Analysis of Internal Policies, Procedures and Protocols|This component involves evaluating CESFAM policies, procedures, and protocols using an anti-stigma/pro-recovery approach to identify strengths and areas for improvement in service delivery for individuals affected by MISUI. This will be completed using a policy analysis tool based on existing frameworks, such as the Health Equity Impact Assessment Tool (PHO \& OMHLTC, 2012) and the QualityRights Toolkit (WHO, 2012). At least 5 policies, procedures, or protocols to be analyzed will be selected by the local leaders at intervention CESFAM during months 3-6 of the intervention. Recommendations concerning health equity, prevention of stigma, and promotion of recoveryoriented practices for individuals with MISUI will be developed and shared following analysis. Each intervention CESFAM will be expected to implement at least one recommendation and make the necessary efforts to educate PHC providers about the policy change in months 7-18 of the intervention.
215041266|NCT05578066|OTHER|Raising Awareness|Various forms of media will be used to raise awareness about stigma related to MISUI among PHC providers and users. Local leaders at intervention CESFAM will determine the type of media they would like to use; this may include images, film, music, or a combination of media. The research team will work with local leaders to develop messaging to include in the media and assist with showcasing these pieces within each intervention CESFAM. This component will be implemented throughout the intervention (intervention months 1-18). Depending on the type of media, instances of use will be tracked accordingly. For example with posters, data on the number of posters posted at a CESFAM over what time period and an estimation of the number of PHC providers and users who have viewed the posters will be collected.
215057560|NCT03674970|DRUG|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
214666443|NCT03425383|DIAGNOSTIC_TEST|FMD and c-IMT|"The diameter of the target artery (right brachial artery) will be measured from two- dimensional ultrasound images, with a 70 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA).~c-IMT will be assessed by M-mode ultrasonography via a vivid 7 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA) with participants in the supine position."
214875285|NCT03451357|DIAGNOSTIC_TEST|Dependence degree already certificated by Dependence Law.|The European Council defines dependence as the state in which people, due to causes linked to the lack or loss of physical, psychological, or intellectual autonomy, are in need of assistance and/or significant help to carry out common activities of daily life. In primary care, the nurses in charge are trained of data collection. This situation needs of formal care provided by health or/and social workers, private or public.
214875286|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
214875287|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
214875288|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
214666444|NCT05954039|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex|The study foresees the intake of 2 capsules per day during 84 days
214666445|NCT05954039|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
215041267|NCT05578066|OTHER|Innovative Contact-Based Education|Educational workshops will include anti-stigma and recovery principles, along with specific MISUI topics relevant to PHC providers. This will be determined by findings from the exploratory phase, current research, best practices, and the perspectives of local leaders. It may include (1) supporting CESFAM PHC providers in preventing stigma and promoting recovery in their practice and (2) enhancing the competencies of CESFAM PHC providers for discussing MISUI with their users, identifying MISUI signs and symptoms, and referring users to psychosocial centres for treatment. The key feature of these workshops is the contact-based educational element, where people with lived experience participate in developing and delivering the curriculum to CESFAM PHC providers. Four three-hour workshops will be held at each intervention CESFAM and will be facilitated by two academic/clinical trainers with expertise in stigma research and practice, and one person with lived experience.
215041268|NCT05578066|OTHER|Recovery-Based Arts|Local leaders at CESFAM will select one PHC provider member and recruit one artist to develop an arts curriculum and facilitate the art sessions. The facilitators will select an art form to use throughout the sessions, and in collaboration with local leaders they will determine themes related to MISUI to cover in each session (planning process will be completed in intervention months 7-8). Arts workshops will be held for 10 weeks, with each session lasting up to three hours (during intervention months 9-12). Ten users affected by MISUI and at least three CESFAM PHC providers will participate in the workshops each week. At the end of the 10-week program, each CESFAM will host an exhibition to showcase the artwork that has been produced (during intervention months 13-18). All PHC providers and users, as well as community members, will be invited to attend the exhibition. PHC providers and users will be invited to speak about their experiences learning and working together to create art.
215041269|NCT06032884|PROCEDURE|continuous renal replacement therapy (CRRT)|renal replacement therapy (RRT).
215041270|NCT06032884|PROCEDURE|Intermittent hemodialysis (IHD)|renal replacement therapy (RRT).
215041271|NCT01626742|OTHER|Ready to Drink Flavored Beverage|2 servings a day
214875289|NCT02879903|PROCEDURE|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
215041272|NCT01626742|OTHER|Ready to drink flavored beverage w/ AN 777|2 servings a day
215041273|NCT04533945|DEVICE|FreeStyle Libre|The Freestyle Libre is a device worn on the back of the arm to measure glucose levels in the interstitial fluid. The device is applied by the patient and can be worn for 14 days, at which time it is replaced with a new device. The device does not require calibration with blood glucose testing. A scan with the receiver or a cell phone can be used to obtain glucose levels. The device does not alarm, so scanning is the only way for a patient to know if they are hypo or hyperglycemic. Studies have shown that the use of this technology can improve glycemic control as measured by Hemoglobin A1c and glucose variability in some patients. In addition, use of this technology in the outpatient setting has been associated with both improved patient satisfaction and increased glucose monitoring
215041274|NCT01585025|DRUG|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
215041275|NCT00890760|BIOLOGICAL|AdCh63 ME-TRAP|5 x 10\*10 vp IM
215041276|NCT00890760|BIOLOGICAL|MVA ME-TRAP|2 x 10\*8 pfu ID
215041277|NCT00890760|OTHER|Sporozoite challenge|Infected mosquito bite
215041278|NCT00890760|BIOLOGICAL|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10\*10 vp MVA ME-TRAP 2 x 10\*8 pfu
215041279|NCT04801576|OTHER|Flouride in mouthrinses|Custom made toothpastes and mouthrinses that do or do not contain flouride as sodium fluoride in different concentrations.
215041280|NCT04801576|OTHER|Placebo mouthrinse|Mouthrinses without flouride
215041281|NCT02202564|PROCEDURE|LT|Orthotopic LT
215041282|NCT02202564|DRUG|ADV-TK|
215041283|NCT02202564|DRUG|ganciclovir|
215041284|NCT02612246|DRUG|GLPG1972 single ascending doses|single dose, oral solution
215041285|NCT02612246|DRUG|Placebo single dose|single dose, oral solution, matching placebo
215041286|NCT02612246|DRUG|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
215041287|NCT02612246|DRUG|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
215041288|NCT03893526|DRUG|Entresto|Single dose administration of entresto
215041289|NCT03893526|DRUG|Sitagliptin|Single dose administration of sitagliptin
215041290|NCT03893526|DRUG|Valsartan|single doses administration of valsartan
215041291|NCT03893526|DRUG|Placebo|placebo day
215041292|NCT06413732|OTHER|Conventional physiotherapy|Conventional physiotherapy was applied for approximately 1 hour, 5 days a week.
215041293|NCT02475421|BIOLOGICAL|Glucagon|One hour glucagon-clamp followed by one hour of blood sampling
215041294|NCT00692887|DEVICE|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
215041295|NCT02466724|DEVICE|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
215041296|NCT05061030|BIOLOGICAL|the ATMP Protrans|Protrans consists of Wharton's jelly derived mesenchymal stromal cells
215041297|NCT05889325|PROCEDURE|DEB-TACE plus HAIC|the patients received HepaSphere DEB-TACE plus HAIC
215041298|NCT01792167|BEHAVIORAL|Second Step Curriculum|social emotional learning program for 6th-8th graders. 15 50 minutes lessons in 6th grade, 13 50 minute lessons in 7th and 8th grade. covers empathy, perspective taking, anger management, impulse control, problem-solving, alcohol and drug prevention, sexual harassment, prejudice, bully prevention, bystander intervention
214666446|NCT02974244|DRUG|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
214875290|NCT02879903|PROCEDURE|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
214875291|NCT02879903|PROCEDURE|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
214875292|NCT04153903|OTHER|OCT, coronary angiography, FFR|Coronary images by OCT and angiography and FFR values will be registered.
214875293|NCT00292890|DEVICE|insulin needle|
214875294|NCT02027532|DRUG|Cefazolin|
214875295|NCT02027532|DRUG|Vancomycin|
214875296|NCT03838900|DEVICE|Loop|The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
214875297|NCT03758716|DRUG|FB825, FB825-15D11, Anti-CemX|Pharmaceutical form: 20mg/ml solution Route of administration: IV
214875298|NCT00004126|DRUG|oxaliplatin|
214875299|NCT00004126|DRUG|paclitaxel|
215041299|NCT04108650|OTHER|Fit & Strong! group|Consistent with the original format of F\&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
215041300|NCT00626080|DRUG|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
215041301|NCT00626080|DRUG|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
215041302|NCT00582907|DRUG|Rilonacept|2.2 mg/kg/wk by subcutaneous injection, for 3 months
215041303|NCT00582907|DRUG|Placebo|placebo by subcutaneous injection weekly for 3 months
215041304|NCT01701882|DRUG|tenofovir/emtricitabine/rilpivirine|
215041305|NCT06078826|OTHER|passive music therapy|30 minutes before tracheal aspiration to intubated patients connected to mechanical ventilator treated in the 3rd step intensive care unit. and music between 60-74 dB will be played via headphones and MP3 player during aspiration (Şahin, 2018). This music is a 30-minute Hüseyni makam mp3 music recording . Hüseyni makam is effective in the morning and at dawn, and its effect is high between morning and noon. For this reason, passive music therapy practice in the research will be done by the researcher in the morning and afternoon. This maqam has beauty, benevolence, silence, comfort, a sense of peace and a refreshing feature. It has positive effects on the liver, heart, internal organs and spirit and unites with nature.
215041306|NCT06078826|OTHER|foot massage|Massage will be applied by the researcher in the research. Towel, sponge, etc. under the foot to be worked on. The foot will be held at a 45 degree angle While applying, 1-2 drops of liquid Vaseline will be used to moisten the hand. A total of 30 minutes of foot massage will be made for each individual, 15 minutes per foot. Foot massage will start 30 minutes before the start of aspiration and massage will continue throughout the aspiration period. Since the speed of the massage movements and the number of repetitions should be at the normal frequency, the massage will be done at a speed that does not disturb the individual, has a non-stimulating and calming effect and does not tire the practitioner. In the massage, efflorescence (stroking), petrissage and friction (circular rubbing) movements that support circulation and relax the tissues will be used. Evaluations will be made before the foot massage, at the end of the foot massage and 30 minutes after the foot massage.
215041307|NCT04707092|DRUG|Antibiotic|Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week
214875300|NCT01396512|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous
214875301|NCT01396512|BIOLOGICAL|Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)|0.5 mL, Subcutaneous
214291423|NCT02136186|DEVICE|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
214875302|NCT03830372|DEVICE|VR Tier One|"10 sessions of 20 minutes virtual terapeutic game~Thanks to using VR googles and the phenomenon of total immersion VR Tier One terapy game allows to completely separate the patient from the hospital environment and provides an intense visual, auditory and kinesthetic stimulation. Depending on the stage of therapy it can have a calming and mood-improving effect or it can motivate and cognitively activate the patient. The additional aim of the game is to help the patients regain their emotional balance, let them recognize their resources in order to bring them to power in the rehabilitation process and trigger the natural recovery mechanisms."
214875303|NCT03830372|OTHER|Control|10 sessions of 20 minutes of Schultz Autogenic Training
214875304|NCT00154752|PROCEDURE|CCRT, Pelvic lymphadenoectomy.|
214875305|NCT06064578|BEHAVIORAL|Project SOLVE|Project SOLVE is a \~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
214875306|NCT04175288|OTHER|Ultrasound, manual therapy and exercise|The experimental group will receive ultrasound (US) for 3 sessions a week for 4 weeks, with continuous US (1.8 w/cm2, 1 Mega Hz 8 minutes). Manual therapy will include posterior glides to talocrural joint, subtalar lateral glide, a 1st tarsometatarsal joint dorsal glide and extension mobilization to the 1st metatarsophalangeal joint. All participants in each group will be given specific exercises by the investgators targeting intrinsic and extrinsic muscles of the foot and ankle. Specific stretches for the plantar fascia and Achilles tendon, will be performed. Home exercises will be recorded using a log.
214875307|NCT02323828|DIETARY_SUPPLEMENT|High RS cookies|High RS cookies ingestion in healthy young adults
214875308|NCT02323828|DIETARY_SUPPLEMENT|Placebo|Placebo cookies ingestion in healthy young adults
214875309|NCT02625597|DEVICE|Cotton Pellet|
214875310|NCT02625597|DEVICE|Polytetrafluoroethylene Tape|
214875311|NCT02625597|DEVICE|Synthetic Foam|
214875312|NCT02625597|DEVICE|Polyvinylsiloxane|
214875313|NCT06435689|OTHER|Sampling|Blood and surgical specimen sampling the day of surgery
215041308|NCT03825627|DEVICE|Transcranial Direct Current Stimulation|"Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp at F3 (active electrode, 4.4×4.4cm) and on the contralateral supraorbital area (reference electrode, 5.1×10.2cm).~Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton, Alberta, Canada). For each stimulation, the direct current is initially increased in a ramp-like fashion over 10 s until reaching 2 milliampere (mA) and will be similarly decreased at the end of stimulation.~In the active tDCS condition, stimulation will be maintained for 20 min; in the sham condition, it will be turned off after 15 s of stimulation, with a ramp-up/down of 10 s (i.e., 35 s total)."
215041309|NCT04971928|DRUG|GSK3228836|GSK3228836 will be administered
214875314|NCT01739049|DRUG|Liraglutide|liraglutide
214875315|NCT01739049|BEHAVIORAL|Diet and Exercise|diet and exercise
214875316|NCT01822106|OTHER|Placebo|
214875317|NCT02690987|DRUG|Exenatide|"Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.~The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of \~130-190 pg/mL."
214875318|NCT02690987|BIOLOGICAL|Desacyl ghrelin|"Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. Good Manufacturing Practice (GMP)-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).~The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of \~13-19 ng/mL."
214875319|NCT02690987|BIOLOGICAL|Saline|The placebo visit will involve an intravenous infusion of normal saline.
214875320|NCT00470392|DRUG|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
214875321|NCT00470392|DRUG|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
214875322|NCT06020144|DRUG|TLL-018|Oral tablets administered 2pieces BID for 52 weeks.
214875323|NCT06020144|DRUG|Tofacitinib|Oral tablets administered 1pieces BID for 52 weeks.
214875324|NCT02474277|OTHER|30 sec chair stand test|diagnostic test for functional impairment
214875325|NCT04786847|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)
214875326|NCT04419753|BEHAVIORAL|attention focus walking training|Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.
215041310|NCT00193024|DRUG|Docetaxel|
215041311|NCT00193024|DRUG|Epirubicin|
215041312|NCT01853709|BEHAVIORAL|Education|
215041313|NCT01853709|OTHER|Fiber free diet|
215041314|NCT01853709|DIETARY_SUPPLEMENT|Adjuvants|
215041315|NCT01853709|DRUG|Polyethylene glycol (PEG)|
215041316|NCT01853709|DRUG|Bisacodyl|
214875327|NCT04458285|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
214875328|NCT04458285|DRUG|Valsartan 80mg Tablet|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
215041317|NCT04627129|DRUG|SHR2554 and Itraconazole|Single dose of oral administration of SHR2554 and Multiple dose of oral of Itraconazole Capsules
215041318|NCT04032821|DRUG|Alkotinib（300mg)|1\. First empty stomach, after the meal.2. After eating first, after fasting.
215041319|NCT04601129|PROCEDURE|enhanced recovery after surgery program|practice of an enhanced recovery after surgery program, according to the international reviews of literature and national recommendation
215041320|NCT04937725|DIAGNOSTIC_TEST|eye tracking|Eye tracker will be used to evaluate study parameters
215041321|NCT00905229|DRUG|Phytonadione|2.5 mg po
215041322|NCT00905229|DRUG|Phytonadione|0.5 mg IV
215041323|NCT00456573|PROCEDURE|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
215041324|NCT03070093|DRUG|gilteritinib|oral
215041325|NCT00057161|BEHAVIORAL|Coordinated Representative Payeeship with Case Management|
215041326|NCT04670861|PROCEDURE|Upper extremity Biodex balance training|"The person assumes the prone plank posture with both hands poisoned in the area assigned for foot placement on the tilting balance platform. Using the four keypads, the person's left hand, left wrist, right hand and right wrist positions are entered into the system using the midline of the hand and the platform grid as reference points. The dot that appears on the position patient screen represents the person's segmental center of gravity.~During each trial test, the person should shift his weight to move the cursor from the center along a target path and back as quickly and with a little deviation as possible. The same process is repeated for each of the targets. Target paths activate in a random order."
214666447|NCT02974244|DRUG|basal insulin|basal insulin treatment in the customary clinical care in USA
214666448|NCT01273818|DRUG|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
214291424|NCT01199523|DRUG|Placebo|oral
214666449|NCT01273818|DRUG|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
215041327|NCT01126073|DRUG|Niacin/laropiprant|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
215041328|NCT01126073|DRUG|Placebo|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
215041329|NCT05834049|BEHAVIORAL|Virtual Parental Presence on Induction of Anesthesia|Apple Inc's FaceTime™ video application will be used when the child is taken to the operating room
214875329|NCT03647085|DEVICE|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
214875330|NCT02500043|DRUG|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
214875331|NCT02500043|DRUG|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
214875332|NCT05099250|DRUG|Bupivacain|local anesthetic agent
214875333|NCT05099250|DRUG|magnesium sulfate|In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines
215041330|NCT05834049|BEHAVIORAL|Midazolam|Preoperative midazolam (0.5 mg/kg of oral midazolam with a maximum dose of 20mg) will be given unless medically contraindicated.
215041331|NCT00686673|BEHAVIORAL|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
214875334|NCT05099250|OTHER|saline|medical solution
214875335|NCT00590616|PROCEDURE|transthoracic examination|observational transthoracic examination
214875336|NCT05602324|DIETARY_SUPPLEMENT|Lauric Acid and Berberine|intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
215041332|NCT00686673|BEHAVIORAL|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
215041333|NCT06117007|DIETARY_SUPPLEMENT|Betalains|"Betalains extracted from red beetroot (Beta vulgaris) encapsulated in edible capsules.~(25 mg betalains per capsule)"
215041334|NCT06117007|OTHER|Placebo|Placebo capsules containing rice hulls. (0 mg betalains per capsule)
215041335|NCT01453166|OTHER|Brazilian heart-prevent meal|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
215041336|NCT01453166|OTHER|Heart prevent control meal weekly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
215041337|NCT01453166|OTHER|Heart prevent control Meal monthly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
215041338|NCT02429817|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|99mTc-DTPA solution placed on the nebulizer reservoir
215041339|NCT02429817|DEVICE|Aeroneb Solo|
215041340|NCT02429817|DEVICE|Jet Nebulizer|
215041341|NCT02429817|OTHER|Single photon emission computed tomography|Imaging technique to investigate lung aerosol distribution
215041342|NCT02429817|OTHER|Spirometry|FEV1, FVC assessment
215041343|NCT03004885|DEVICE|PrismaLung|Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
214291425|NCT01199523|DRUG|mirabegron|oral
214875337|NCT01782014|PROCEDURE|colonoscopy|colonoscopy using different methods of insufflation
214875338|NCT02094417|DRUG|AMG531|Subcutaneous, weekly injection
214875339|NCT02692443|DEVICE|Magnetic Resonance Imaging|Brain MRI without Contrast
214875340|NCT02692443|BEHAVIORAL|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
214875341|NCT03063411|OTHER|Executive Function Intervention|In the executive function training group, children will complete computerised tasks requiring working memory and inhibitory control over four weekly sessions lasting 15-20 minutes. The aim is to improve their executive function skills. In the active control group, children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
214875342|NCT03063411|OTHER|Active Control Group|This is the active control condition. Children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
214875343|NCT00411411|DRUG|Januvia|200 mg t.i.d
214875344|NCT00411411|DRUG|Placebo|Placebo
214875345|NCT00748761|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
214875346|NCT00748761|BEHAVIORAL|Waitlist|Contact waitlist weekly for 12 weeks
214875347|NCT03301649|DRUG|Generic Ivermectin Lotion 0.5%|Topical lotion, generic formulation of the brand product.
214875348|NCT03301649|DRUG|Sklice® (Ivermectin) Lotion 0.5%|Topical lotion, brand product.
214875349|NCT03301649|DRUG|Vehicle Lotion|Topical lotion, placebo. Has no active ingredient.
214875350|NCT00762918|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol 5000 IU capsule by mouth daily for 3 months
214875351|NCT02159313|DRUG|Riociguat(Adempas,BAY63-2521)|Single dose of a whole 2.5 mg riociguat tablet
214875352|NCT02816606|PROCEDURE|Flexible reamers|These reamers allow creation of the femoral tunnel to be made in reduced knee flexion and potentially maximise tunnel length
214875353|NCT02816606|PROCEDURE|70-degree arthroscope|Using this arthroscope (rather than the more traditional 30-degree) gives improved visualisation of the femoral and tibial footprints. This may translate into better positioning of the tunnel within these regions
214875354|NCT01564537|DRUG|Ixazomib|Ixazomib capsules
214875355|NCT01564537|DRUG|Lenalidomide|Lenalidomide capsules
215041344|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
215041345|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids.|Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
215041346|NCT05007964|DEVICE|Spatz4 Adjustable Balloon System|The Spatz4 Adjustable Balloon System is designed to assist weight loss by partially filling the stomach and inducing satiety. The intragastrical balloon is implanted endoscopically for up to 12 months.
215041347|NCT06244589|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy: Cholecystectomy that performed with laparoscopic method
215041348|NCT06244589|PROCEDURE|Open-conversion cholecystectomy|Open-conversion cholecystectomy: Cases in which laparotomy (Generally right subcostal incision) was performed based on intraoperative findings.
215041349|NCT03144167|OTHER|Analysis of spectroscopic biomarkers of proliferation for six-month survival|Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
215041350|NCT04149665|DEVICE|simple blind observation|Device that measures continuously the angle of bed by mechanical Ventilation to assess the time the bed is above 35°.
215041351|NCT01161771|PROCEDURE|Cataract Surgery and Limbal relaxing incision|Cataract extraction and limbal-relaxing incisions
215041352|NCT06460376|OTHER|Wurn Technique|"Treatment:~Site-specific pressures for 30 seconds across the restrictive bands of adhered tissues and structures, working progressively deeper from the most superficial tissues Traction: focusing on these adhered areas, engage the uterine fundus and sidewalls and traction them to the left.~To assist and improve the mobility of the soft tissues, release the traction tension either suddenly or gradually, depending on the desired effect to decrease spasms and adhesions between the uterus and the bladder. The baseline treatment was moist heat.~Each therapy session was 30 minutes for 6 weeks and 2 sessions per week. 10 minutes for baseline treatment."
215041353|NCT06460376|OTHER|Mercier Therapy|"Treatment:~The patient lay face up on a massage or exam table. Feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles.~Manual poking, pressing, and massage actions do three things:~Reveals visceral adhesions. Find tender spots. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that make up fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Abdominal massage with pressing, deep strokes, and friction. The baseline treatment was moist heat. Each therapy session was 25 minutes for 6 weeks and 1 session per week. 10 minutes for baseline treatment"
215041354|NCT04934267|OTHER|Eccentric Exercise for subjects with JHS|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
215041355|NCT04934267|OTHER|Eccentric Exercise for Controls|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
215041356|NCT04949009|DRUG|Avatrombopag|Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
214875356|NCT01564537|DRUG|Dexamethasone|Dexamethasone tablets
214875357|NCT01564537|DRUG|Placebo|Ixazomib placebo-matching capsules
214875358|NCT04405843|DRUG|Ivermectin Oral Product|Ivermectin oral suspension, 6 mg/mL
214875359|NCT04405843|DRUG|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
214875360|NCT01286935|DRUG|Safinamide|
214875361|NCT01286935|DRUG|Safinamide|
214875362|NCT01286935|DRUG|Placebo|
214875363|NCT01635218|DRUG|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
215041357|NCT03516721|OTHER|the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET|
214875364|NCT01635218|DRUG|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
214875365|NCT01635218|DRUG|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
214875366|NCT03559400|DRUG|local gentamicin injection|Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
215041358|NCT00998257|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Patients under daily life treatment with YAZ according to local drug information.
215041359|NCT03564886|DRUG|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
215041360|NCT03564886|DRUG|Normal saline|Lactate Ringer's (LR, 273mOsm/L)
215041361|NCT01658046|OTHER|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
215041362|NCT01658046|OTHER|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
215041363|NCT01658046|OTHER|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
215041364|NCT01741961|PROCEDURE|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
215041365|NCT03007771|DEVICE|Magnetic Resonance-guided High-Intensity Focused Ultrasound|-Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
215041366|NCT00785720|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
215041367|NCT03610048|DRUG|ALKS 5461|samidorphan + buprenorphine administered sublingually
215041368|NCT03773809|OTHER|Vitamin D capsule|The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape \& appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3
215041369|NCT03773809|OTHER|placebo|oral administration of placebo
215041370|NCT00992550|DRUG|Cigarette|
215041371|NCT00992550|DRUG|Hookah|
215041372|NCT02900430|OTHER|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
215041373|NCT02900430|DRUG|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
215041374|NCT00085748|DRUG|paliperidone ER|
215041375|NCT03526263|PROCEDURE|Gastric mucosal devitalization|During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
215041376|NCT00006384|BIOLOGICAL|recombinant interferon alfa|
215041377|NCT00006384|DRUG|semaxanib|
215041378|NCT01155050|DEVICE|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
215041379|NCT01155050|BEHAVIORAL|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
215041380|NCT01155050|DEVICE|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
215041381|NCT01636284|BIOLOGICAL|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
215041382|NCT03577899|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
214666450|NCT01273818|DRUG|Gentamicin|80 mg gentamicin application intraoperatively
214875367|NCT03559400|DRUG|placebo saline injection|Treatment includes debridement and administration of the local antibiotic which will consist of 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
214875368|NCT04285593|OTHER|Bulgarian squats|The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
214291426|NCT01199523|DRUG|moxifloxacin|oral
214875369|NCT04707976|DEVICE|Navina Smart|CE-marked NavinaTM Smart including Navina Smart App.
214875370|NCT04707976|OTHER|Standard Bowel Care|Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
214875371|NCT03262038|DRUG|Ondansetron|This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
214875372|NCT03262038|DRUG|Placebo Comparator|This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
214875373|NCT04327739|OTHER|Intervention 1 Exercise|• Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles
214875374|NCT04327739|OTHER|Intervention 2 Exercise and INIT|"* Exercise programme same as Intervention Group 1 and~* Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique"
214875375|NCT04327739|OTHER|Intervention 3 Exercise and SMT|"* Exercise programme same as Intervention Group 1 and~* Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant."
214875376|NCT04327739|OTHER|Control|Participants allocated to this group received general consulting istructions and a home based general exercise sheet
214875377|NCT03751618|PROCEDURE|Hip arthroscopy|"Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure."
214875378|NCT02679235|DRUG|POST Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
215041383|NCT03577899|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
215041384|NCT03577899|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
215041385|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
215041386|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP
215041387|NCT04510207|BIOLOGICAL|Placebo|The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
215041388|NCT01340456|DRUG|Rifampicin treatment|induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
215041389|NCT05456048|DRUG|VAH regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
215041390|NCT05456048|DRUG|VEN+HMA regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
215041391|NCT01146613|DRUG|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
215041392|NCT01146613|DRUG|Placebo|identical matched placebo x 2, 2xday, 13 weeks
215041393|NCT04120207|BEHAVIORAL|Home-based Pilates|The Home-based Pilates group will complete two Pilates classes at home, twice weekly, for a period of eight weeks.
215041394|NCT04120207|OTHER|Delayed-start Pilates|The Delayed-start group will maintain their regular daily activities, and be provided with a copy of the Pilates DVD following the intervention, for their own use.
215041395|NCT02854163|DRUG|Secukinumab|All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
215041396|NCT02232360|DRUG|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
215041397|NCT02232360|DRUG|Rosuvastatin alone|Rosuvastatin 10mg per day
215041398|NCT00729950|BIOLOGICAL|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
215041399|NCT04862754|OTHER|interval training exercise|interval training exercise
215041400|NCT00241150|DRUG|VALSARTAN|
215041401|NCT04612426|DEVICE|Brain-computer Interface-Pedaling Training System|The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.
215041402|NCT04612426|DEVICE|Traditional Pedaling Training System|The patient will wear the same EEG equipment that will only collect data, but not guide training.
215041403|NCT00506467|PROCEDURE|Vibration Response Imaging|Lung function test performed using the VRI system immediately before or after the standard lung function test.
215041404|NCT01186757|DRUG|PF-03715455|PF-03715455 1.6 mg BID
215041405|NCT01186757|DRUG|PF-03715455|PF-03715455 4mg BID
215041406|NCT01186757|DRUG|PF-03715455|PF-03715455 10 mg BID
215041407|NCT01186757|DRUG|Placebo|Placebo
215041408|NCT01920490|DEVICE|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
215041409|NCT01920490|DEVICE|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
215041410|NCT02113319|DRUG|dasatinib|dasatinib 50 mg and 20 mg During one year
215041411|NCT03792516|DRUG|artesunate ointment 40%|artesunate formulated as an ointment to be applied topically to the vulva
214875379|NCT04559737|OTHER|Case Management|"Population management platforms capable of automatically risk stratifying patients (eg, automatically identifying poor users) may be another cost-effective technology-based tool by enabling a management by exception (MBE) follow-up intervention. This intervention concentrates provider effort on patients most at need by allowing providers to passively observe successful users and actively intervene only in CPAP strugglers. Therefore, in addition to Usual Care we will implement this population management process by identifying CPAP strugglers only and further follow-up encounters will be triggered for these select patients for troubleshooting. Additionally, throughout the 1-year period, Q1 window of \<70% nights \>4 hours will trigger a phone call and at the discretion of the sleep provider convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year."
214875380|NCT05574608|BIOLOGICAL|CD123-CAR-NK cells|CD123-CAR-NK is an allogenic CD123-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
214875381|NCT03040700|OTHER|Myocardial Perfusion Scan|Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)
214875382|NCT03040700|OTHER|Coronary CTA|Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX-Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
214875383|NCT00094861|DRUG|Palifermin|
214875384|NCT00094861|DRUG|Placebo|
214875385|NCT00094861|RADIATION|Radiotherapy|
214875386|NCT00094861|DRUG|Paclitaxel|
214875387|NCT00094861|DRUG|Carboplatin|
214875388|NCT03795766|PROCEDURE|Surgeries for gynecologic disease|All patients accept surgeries for gynecologic disease.
214875389|NCT01995305|GENETIC|human whole exome|he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
214875390|NCT01995305|GENETIC|whole genomic|This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.
214875391|NCT03275714|DEVICE|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
215041412|NCT06280248|PROCEDURE|Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst|"The technical success rates, clinical success rates, and potential complications of the different endoscopic ultrasound-guided techniques for the best drainage of pancreatic fluid collections (PFCs) as regard type, caliber, and number of plastic stents and the ideal timing for stent removal will be assessed.~Also compare early vs. late intervention for complete endoscopic necrosectomy of walled off pancreatic necrosis (WOPN ) as regard to technical success rates, clinical success rates, potential complications, and the number of sessions needed will be done.~In order to evaluate total resolution or a reduction in cyst diameters with clinically significant improvement in symptoms, patients will be monitored for one month and six months following the insertion of the stent."
215041413|NCT03183310|DRUG|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
215041414|NCT03183310|DEVICE|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
215041415|NCT03183310|DRUG|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
215041416|NCT01959529|DRUG|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
214291427|NCT00310128|DRUG|cisplatin|
215041417|NCT01959529|DRUG|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
214291428|NCT00310128|DRUG|cytarabine|
214291429|NCT00310128|DRUG|etoposide|
214291430|NCT00310128|DRUG|methylprednisolone|
214291431|NCT00310128|DRUG|rituximab|
214291432|NCT00310128|DRUG|yttrium Y 90 ibritumomab tiuxetan|
214291433|NCT00310128|PROCEDURE|antibody therapy|
214291434|NCT00310128|PROCEDURE|biological therapy|
215041418|NCT02892240|OTHER|No intervention. Observational study|
214875392|NCT03269318|DRUG|Montelukast or Salmeterol or Theophylline or Steroid|Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
214875393|NCT06028321|DRUG|Part 1 Group 1 Regime A (ACM-001.1)|"Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B."
214875394|NCT06028321|DRUG|Part 1 Group 2 Regimen C (Pindolol)|Drug: Pindolol tablets for oral use.
214875395|NCT06028321|DRUG|Part 2 Group D (Pindolol)|Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
214875396|NCT06028321|DRUG|Part 2 Group E (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
215041419|NCT05900752|DIETARY_SUPPLEMENT|QiMeiYan Probiotics|consume one sachet of the assigned product, once a day after meals.
215041420|NCT05900752|DIETARY_SUPPLEMENT|Placebo product|consume one sachet of the assigned product, once a day after meals.
215041421|NCT05804721|DRUG|Apipe (Aripiprazole10 mg)|Test drug
215041422|NCT05804721|DRUG|Abilify (Aripiprazole10 mg)|Reference drug
215041423|NCT02283034|DEVICE|The CPRmeter|Feedback device - 1
215041424|NCT02283034|DEVICE|The PocketCPR|Feedback device - 2
215041425|NCT02283034|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
215041426|NCT02283034|DEVICE|The CPREazy|Feedback device - 3
215041427|NCT02283034|DEVICE|The CPR PRO APP|Feedback device - 4
215041428|NCT02283034|DEVICE|The CardioPump|Feedback devices - 5
215041429|NCT02283034|DEVICE|Standard BLS|Chest compressions without CPR feedback device (manual resuscitation)
215041430|NCT05839925|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II|The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).
215041431|NCT00652834|PROCEDURE|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
215041432|NCT00652834|DRUG|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
215041433|NCT02983409|RADIATION|Pstone|A adult patients who were diagnosed as urinary stone by the urinary CT
215041434|NCT00633841|BIOLOGICAL|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
215041435|NCT02818517|OTHER|ACE inhibitors|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
215041436|NCT02818517|OTHER|beta blockers|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
215041437|NCT02668666|DRUG|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
215041438|NCT02668666|DRUG|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
215041439|NCT05630456|OTHER|Receving feedback|Receving regular feedback from a health provider
215041440|NCT05630456|OTHER|No regular feedback|No regular feedback from a health provider
215041441|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|50 mg twice-daily (BID)
215041442|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|150 mg quaque die (QD)
215041443|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|200 mg quaque die (QD)
215041444|NCT01848093|OTHER|sputum collection|collecting of spontaneous sputum from the patient
215041445|NCT00827957|DEVICE|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
215041446|NCT00827957|DEVICE|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
215041447|NCT01987414|BEHAVIORAL|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
214291435|NCT00310128|PROCEDURE|chemotherapy|
215041448|NCT01987414|DEVICE|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
215041449|NCT01987414|OTHER|No treatment|Participants will maintain their daily routines during the no treatment period.
215041450|NCT02054637|DRUG|Lanreotide|
215041451|NCT00503490|DRUG|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
215041452|NCT00503490|DRUG|placebo|BID
215041453|NCT06179979|DIAGNOSTIC_TEST|PET/CT with 11C-PiB|Subjects considered suitable will undergo a clinical and neuropsychological evaluation and a PET/CT study with intravenous administration of 11C-PIB.
215041454|NCT01999192|DRUG|Tregalizumab|humanized anti-CD4 mAb
215041455|NCT01999192|DRUG|Placebo|identical end formulation buffer
215041456|NCT06441279|PROCEDURE|intra-articular injection with Platelet lysate (PL).|2 ml of Platelet lysate will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly
215041457|NCT06441279|PROCEDURE|intra-articular injection with Hyaluronic Acid.|2 ml of Hyaluronic Acid will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly.
215041458|NCT00827229|DEVICE|Labor Monitor|
215041459|NCT02169648|DRUG|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
215041460|NCT00854360|DRUG|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
215041461|NCT00854360|DRUG|Placebo|HFA Vehicle Aerosol
215041462|NCT05309525|DRUG|Collagenase Clostridium Histolyticum-Aaes|subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
215041463|NCT05309525|DRUG|Lysteda 650 MG Oral Tablet|Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
215041464|NCT03894085|DRUG|Paroxetine|Paroxetine treatment for 4 weeks usage:20-80mg Qd
215041465|NCT06639789|DIETARY_SUPPLEMENT|Vitamin B12 (B12)|The new formulation of vitamin B12 will be ingested 3 days before and on the day of testing (3 hours before).
215041466|NCT06639789|DIETARY_SUPPLEMENT|PLACEBO (PLA)|The placebo will be ingested 3 days before and the same day of the tests (3 hours before).
215041467|NCT06564805|DRUG|Candida Albicans Antigen Injection|subcutaneous administration of Candida albicans antigen
215041468|NCT03410654|DRUG|Tacrolimus, Extended Release, (Envarsus Xr)|After conversion of tacrolimus immediate release to tacrolimus extended release.
214875397|NCT06028321|DRUG|Part 2 Group F (ACM-001.1 )|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
214875398|NCT06028321|DRUG|Part 2 Group G (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
215041469|NCT05961098|DRUG|RBD1016|RBD1016 with NAs background treatment will be explored.
215041470|NCT05957042|DRUG|Lumason|Up to 4.8mL administered intravenously
215041471|NCT06564233|BEHAVIORAL|care.coach Avatar™|"care.coach Avatar™ (avatar) is a conversational relational agent that serves as a virtual companion and appears on a tablet device as an animated pet avatar. Each avatar is supervised by a 24x7 remote team of trained human staff whose abilities are augmented by artificial intelligence (AI) and software-driven health coaching and clinical protocols for consistency, automation, and scale. This unique human-in-the-loop design enables safe, empathic, natural conversations that form the basis for trusting relations and lasting behavior change. In addition to being a companion, the avatar educates patients about their condition, helps manage symptoms, and reinforces other healthy habits. Independent studies have demonstrated improved outcomes at a reduced cost of care. A pilot study demonstrated the feasibility of care.coach Avatar™ as a psychosocial support and health coach in hospitalized HCT patients. More research is needed to assess efficacy and applications in other HCT settings."
215041472|NCT06563843|PROCEDURE|Robotic-assisted TKA|Robotic-assisted Total Knee Arthroplasty or total knee replacement is a surgical procedure using a robot to resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
214875399|NCT06028321|DRUG|Part 1 Group 1 Regimen B (Pindolol)|Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
215041473|NCT06563843|PROCEDURE|Conventional TKA|Conventional Total Knee Arthroplasty or total knee replacement is a surgical procedure to manually resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
215041474|NCT06400082|DRUG|Insulin|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
215041475|NCT06400082|DRUG|Povidone-Iodine|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
215041476|NCT05298930|OTHER|Physical activity program|"The supervised sessions will be offered 4 times a week in the participants' rooms by the APA teachers and will include moderate intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient will also be able to perform unsupervised sessions (on their own), following the advice given by the APA teacher. These unsupervised sessions can be done independently on the bike.~In order to encourage patients to perform these unsupervised sessions, patients and their relatives will be given a connected device and will have access to a mobile application developed by the Kiplin company, which offers connected physical activity games to be performed in teams (from 2 to 4 participants). These games, lasting from 1 to 3 weeks, use the participants' daily PA level as a unit of animation and are punctuated by challenges."
215041477|NCT06565130|OTHER|Attention skills training|Attention skills program planned with occupational therapy principles
215041478|NCT03297658|DEVICE|electro-acupuncture (EA)|stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health
215041479|NCT03297658|DEVICE|sham|Micro electrodes will be placed but there will be no stimulation
215041480|NCT03192436|DEVICE|Ultrasound|Low-intensity (Ispta \< 720 mW/cm2, Isppa \< 190 W/cm2) transcranial focused ultrasound
215041481|NCT05694247|DEVICE|CorNeat KPro|The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.
215041482|NCT03952845|OTHER|Capsaicinoid|This is a tolerability study on doses lower than previously published for the use of intranasal capsaicinoid in the treatment of rhinitis
215041483|NCT06560333|DRUG|N0892|1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg
215041484|NCT06560333|DRUG|Januvia® + Glifage XR® + Placebo|1 tablet of Januvia® 100mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Forxiga ®10mg
214291436|NCT00310128|PROCEDURE|monoclonal antibody therapy|
214291437|NCT00310128|PROCEDURE|radiation therapy|
215041485|NCT06560333|DRUG|Forxiga® + Glifage XR® + Placebo|1 tablet of Forxiga ®10mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Januvia ® 100mg
215041486|NCT05081830|BEHAVIORAL|Transdiagnostic online intervention|Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.
214875400|NCT06028321|OTHER|Part 1 Group 1 Regimen A (Placebo)|Placebo for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
214875401|NCT06028321|OTHER|Part 2 Group E (Placebo)|"Placebo for oral use. Subjects were dosed over a four day treatment period twice daily.~Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D."
214875402|NCT06028321|OTHER|Part 2 Group F (Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
214875403|NCT06028321|OTHER|Part 2 Group G ( Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
214875404|NCT03850548|OTHER|Prosthetic joint infection with Cutibacterium acnes|patients having a prosthesis infection with C.acnes identified by specific PCR
214875405|NCT04541316|DEVICE|ProFlor inguinal hernia device|Inguinal hernia repair
214875406|NCT06255158|BEHAVIORAL|INSIGHT Program|"INSIGHT Program:~the program targets the reduction of EMSs' interference in social information processing, which may otherwise lead to the use of deviant behavior to fulfill emotional and sexual needs. Furthermore, the program has specific goals: (1) developing insight about the offense cycle; (2) fostering empathy for victims; (3) enhancing intimate and social/ interpersonal skills; (4) increasing emotional regulation skills."
214875407|NCT06255158|OTHER|Treatment As Usual (TAU)|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
214875408|NCT05160857|DRUG|Herombopag Olamine|The initial dose of hetropapa is recommended to be 7.5mg, once a day, oral on an empty stomach, and can only be eaten after oral administration for 2 hours, so as to avoid taking it with meals.
214875409|NCT02249130|DRUG|Tipranavir (TPV)|
214875410|NCT02249130|DRUG|Ritonavir (RTV)|
214875411|NCT02249130|DRUG|Delavirdine (DLV)|
215041487|NCT05081830|BEHAVIORAL|TCC online intervention|This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
214875412|NCT02249130|DRUG|Zidovudine (ZDV)|
214875413|NCT02249130|DRUG|Lamivudine (3TC)|
214875414|NCT02249130|DRUG|Stavudine (d4T)|
214875415|NCT05682651|PROCEDURE|tracheal stenosis follow-up file|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
215041488|NCT01889914|DRUG|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
215041489|NCT05390788|OTHER|Application Of Neuromuscular Bands; Kinesio Taping|"Kinesio tape is a specialized elastic and adherent adhesive tape that mimics the elasticity of skeletal muscle, in that it can be extended up to 140% of its original length, before application to the skin, without allowing restrictions in the range of motion. of structures. Subsequently, it provides a tensile (shear) force on the skin, consisting of a fabric with special characteristics, such as air permeability and water resistance, and can be used for repeated days. Kinesio will be applied from a point 10 cm below the anterior superior iliac spine and divided in a Y shape above the patella, ending at the tibial tuberosity; from the upper third of the medial thigh to the medial border of the patella; from the greater trochanter of the femur, ending at the lateral margin of the patella."
214875416|NCT04437459|OTHER|High-fat shake|Participant consumes a high-fat test shake. Blood is drawn before and 4 hours after this shake to measure triglycerides.
214875417|NCT04437459|OTHER|Pure glucose solution|Participant consumes 75 grams of pure glucose. Blood is drawn before and 2 hours after this drink to measure glucose.
214875418|NCT01551030|DRUG|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
214875419|NCT01458691|PROCEDURE|Steroid injection into the glenohumeral joint|"* Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
214875420|NCT01458691|PROCEDURE|Allogeneic PRP injection into the glenohumeral joint|"* Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
214875421|NCT03914092|DRUG|triamcinolone acetonide injection|,1 mm percutaneous intralesional injection
214875422|NCT03914092|BEHAVIORAL|Smith Accent method of voice therapy|regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
214875423|NCT05810233|DIETARY_SUPPLEMENT|Ascorbic acid 1000mg|Health supplement
214875424|NCT05810233|OTHER|Placebo|Glucose chewable tablet without any ascorbic acid
214875425|NCT04918589|DRUG|Tranexamic acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
214875426|NCT04918589|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
215041490|NCT05119010|DIETARY_SUPPLEMENT|Continuous ketogenic diet|ARM A : continuous ketogenic diet
215041491|NCT05119010|DIETARY_SUPPLEMENT|Discontinuous ketogenic diet|ARM B : discontinuous ketogenic diet
215041492|NCT05119010|DIETARY_SUPPLEMENT|beta-hydroxybutyrate (BHB) supplementation|ARM C : BHB supplementation
215041493|NCT01651468|DIETARY_SUPPLEMENT|HEMOFIX|unique complex herbal mixture
215041494|NCT04049500|OTHER|Digital Diabetes Prevention Program (dDPP)|dDPP tool suite to integrate with the EHR and clinical workflows
215041495|NCT02441218|DRUG|Ivabradine|2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
215041496|NCT02441218|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
215041497|NCT04754490|DIAGNOSTIC_TEST|Speech Recognition|Speech Recognition
215041498|NCT04454515|DRUG|Dexmedetomidine|Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.
215041499|NCT04454515|DRUG|placebo|normal saline infusion
215041500|NCT01541371|DRUG|Paliperidone ER|Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
215041501|NCT03781674|DRUG|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age
215041502|NCT03781674|DRUG|progesterone 200mg|Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
214291438|NCT00310128|PROCEDURE|radioimmunotherapy|
214291439|NCT00310128|PROCEDURE|radioisotope therapy|
215041503|NCT03781674|DRUG|placebo to progesterone 200mg|Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
215041504|NCT03781674|DRUG|placebo to progesterone 400mg|Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age
215041505|NCT03248323|RADIATION|dyna-pbv|
215041506|NCT06453031|PROCEDURE|Gastric Ischemic Preconditioning Before Esophagectomy|Does embolization of the left gastric artery prior oesophagectomy reduce postoperative complications, particularly anastomotic leaks and ischemia of the gastric conduit?
215041507|NCT03290352|OTHER|Questionnaire|Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
215041508|NCT04747301|DEVICE|Double-balloon catheter (UTAH CVX-RIPE) for cervical ripening|"Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA). The catheter will be inserted manually until the proximal balloon is in the cervical canal, the distal balloon should be intrauterine and in the extra-amniotic space. The intrauterine balloon is inflated with 40mL saline and retracted so that it rests against the internal oz. The proximal balloon should now be outside the external oz and is inflated with 20mL saline. If the balloons are correctly situated on both ends of the cervix, they can be inflated with up to 80mL saline each.~Cardiotocograph will be performed 30min, 2 hours after insertion and every 6 hours. The balloon is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another balloon is placed for a maximum of another 24 hours.~The patients will be examined in case of extremely painful or membranes ruptured."
214291440|NCT03114228|DRUG|Midostaurin|Midostaurin 50 mg (two 25 mg capsules) twice a day on days 8-21
214291441|NCT05264077|DRUG|Dexmedetomidine Hydrochloride|Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
214291442|NCT03415191|DRUG|Ketamine|A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision
214666451|NCT03815175|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
214875427|NCT03332810|BEHAVIORAL|SME family based physical activity|"* One train-the-trainer workshop: to train the service providers from 8-15 NGO service units on the concept of SME, ways of conducting mental well-being activities and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder).~* Two SME family-based physical activities held by each NGO service unit: to organize enjoyable activities according to the needs of individual district as well as to promote positive psychology under the theme of SME. All these activities are organized by the NGO service providers in collaboration with District Healthy City Committee."
214875428|NCT03332810|BEHAVIORAL|Gathering activity|\- Gathering activities will be held for control groups. However, SME concept or techniques will not be introduced during the activity. Physical activity will not be used as the intervention method.
214875429|NCT02256423|DRUG|REFERENCE 1: Nurofen® 200 mg tablet|
214875430|NCT02256423|DRUG|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|
214875431|NCT02256423|DRUG|ibuprofen 200 mg soft gel capsule|
214875432|NCT06280521|OTHER|fGQ-ASC|French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC)
214875433|NCT01649401|DEVICE|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
214875434|NCT01649401|DEVICE|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
214875435|NCT05871723|OTHER|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|o measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
214875436|NCT05871723|OTHER|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56. The Berg Balance Scale is commonly used in clinical and research settings to assess balance impairment and monitor changes in balance over time, particularly in individuals with neurological conditions such as stroke. The test has good reliability and validity and is considered a gold standard for assessing balance in these populations.
215041509|NCT04747301|DRUG|Dinoprostone 10mg (Propess)|"Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured."
215041510|NCT06325787|PROCEDURE|thyroid lobectomy|thyroid lobectomy
215041511|NCT06325787|PROCEDURE|image-guided thermal ablation|radiofrequency ablation or microwave ablation or laser ablation
215041512|NCT04946604|BEHAVIORAL|Ashtangayoga|This is an active and intense type of yoga, focused on physical activity and breath control
215041513|NCT01131052|DRUG|Insulin Glargine|glargine once a day
215041514|NCT01131052|DRUG|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
215041515|NCT01131052|DRUG|Insulin glulisine|glulisine given as needed before meals
215041516|NCT02404714|DEVICE|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
215041517|NCT01426802|DRUG|vildagliptin|Drug 50mg vildagliptin bid
215041518|NCT03609424|DRUG|PDR001, Imatinib|"-Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~* Recommended dose defined in phase Ib part will be tested"
215041519|NCT02497105|OTHER|Ketogenic Diet|Dietary
215041520|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Sevoflurane|Sevoflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
215041521|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Desflurane|Desflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
215041522|NCT01127919|BEHAVIORAL|Aerobic Exercise Training|40 minutes, 3 times a week for 35 weeks.
215041523|NCT01127919|OTHER|Cognitive Component|Provide general information about health and fitness
215041524|NCT06250764|DIAGNOSTIC_TEST|Clinical periodontal measuremenets|The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G
215041525|NCT06250764|DIAGNOSTIC_TEST|ELISA test from gingival crevicular fluid (GCF)|GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively
215041526|NCT00969423|DEVICE|5mm videoscope|use of 5mm videoscope
215041527|NCT00969423|DEVICE|10mm videoscope|use of 10mm videoscope
215041528|NCT02867137|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
215041529|NCT00470015|BIOLOGICAL|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
215041530|NCT00470015|BIOLOGICAL|IL-2|0.5x10\^6/m\^2
215041531|NCT00470015|BIOLOGICAL|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
215041532|NCT00470015|BIOLOGICAL|GM-CSF|300mcg
215041533|NCT00470015|BIOLOGICAL|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
215041534|NCT00744744|OTHER|informational intervention|Patient educational information
215041535|NCT00744744|OTHER|questionnaire administration|Survey
214291443|NCT03415191|DRUG|Normal Saline|A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
214291444|NCT00660998|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
214291445|NCT00660998|DRUG|Placebo|Matching placebo
214291446|NCT02534870|DRUG|ABT-450/r/ABT-267|Tablet
215041536|NCT00744744|PROCEDURE|management of therapy complications|Survey
215041537|NCT00744744|PROCEDURE|psychosocial assessment and care|Survey
215041538|NCT00744744|PROCEDURE|quality-of-life assessment|Survey
215041539|NCT00146744|BIOLOGICAL|Mtb72F/AS02A|
215041540|NCT05015231|DIAGNOSTIC_TEST|Echocardiography and MRI|Echocardiography and renal MRI before and after fistula closure
215041541|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
215041542|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
215041543|NCT01528592|DRUG|Carbidopa-Levodopa|Equivalent amount of carbidopa-levodopa will be provide to you
215041544|NCT01334255|DRUG|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
215041545|NCT03825705|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
215041546|NCT03825705|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
214875437|NCT04511260|DEVICE|NuEra Tight VRF Handpiece|"The VRF is a Model that belongs to the NuEra Tight RF Family, specific for the treatment of small areas.~The NuEra is FDA cleared (K151296) for a wide range of indications including but not limited to, selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The NuEra Tight VRF with the small area handpiece is CE marked in Europe and currently under review by the FDA. The system and its accessories, are intended to be use for a wide range of indications including, but not limited to:~· Provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation of soft tissue."
214875438|NCT05630417|OTHER|Feet and Back Massage|"Foot massage: Feet are the most neglected organs of people and therefore cause many complaints. Foot massage is a massage applied to the back of the foot, toes, soles of the feet, the muscles between the thumb and little fingers, and the heel, where the muscles between the metatarsal bones are located.~Back massage: Back massage is a non-invasive nursing intervention that can be easily applied by nurses. In back massage application; A 10-minute back massage program applied by Çınar and Eşer (2012) will be applied."
214875439|NCT04762472|DRUG|Montelukast Oral Tablet|i) Montelukast 10mg daily (tablet) orally x 26 weeks
214875440|NCT04762472|DRUG|Montelukast Placebo Oral Tablet|i) Placebo (Montelukast identical) tablet 1 daily orally x 26weeks
214875441|NCT00578266|DRUG|Cyclophosphamide,Campath IH and TBI|"DAY 5 TREATMENT~* 6 5 CYTOXAN 50 mg/kg WITH MESNA~* 5 CYTOXAN 50 mg/kg WITH MESNA;~* 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~* 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~* 2 TBI; CAMPATH; TACROLIMUS~* 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)"
215041547|NCT04116255|OTHER|Mandibular oral occlusal splint|The panoramic open-mouth and close-mouth radiographs of the first group(splint group) were taken, and intraoral and extraoral examinations were performed by an experienced dentist that also examined the radiographs. The upper jaw of the patients was measured with an alginate impression material, to obtain a hard plaster model. Then, using these models, a vacuum plate machine made a customized mandibular oral occlusal splint suitable for each patient's teeth. The suitability of the splints was checked and confirmed by the dentist on the first and seventh days of use. The patients were asked to use these splints at night (for at least six hours) throughout the study.
214291447|NCT02534870|DRUG|ABT-333|Tablet
214291448|NCT01817998|OTHER|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
214291449|NCT06295770|DRUG|Obinutuzumab|Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.
214291450|NCT06066554|DEVICE|Puva (psoralin and uva )|Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque
214291451|NCT05237154|OTHER|Intervention with intermittent fasting.|Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).
214291452|NCT05237154|OTHER|Intervention with high-intensity interval training.|Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
214291453|NCT06409572|DIAGNOSTIC_TEST|GeneXpert MTB/RIF|Rapid and accurate method for detection of tuberculosis.
214291454|NCT00002904|DRUG|trabectedin|
214291455|NCT03331419|BEHAVIORAL|Exercise test|30 sec of knee squats followed by a six minute walk test repeated on consecutive days.
214291456|NCT02064868|DRUG|Serelaxin|30 µg/kg/day IV infusion
214291457|NCT02064868|DRUG|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
214291458|NCT00020475|DRUG|gp100 antigen|
214291459|NCT00020475|DRUG|interleukin-2|
214291460|NCT00020475|DRUG|MART-1 antigen|
214875442|NCT04777149|OTHER|transcranial Random Noise Stimulation (tRNS)|Two electrodes will be placed over the targeted areas on participant's head. A current of random frequency and intensity will be delivered. TRNS will be applied during the first 20 min of functional task practice.
215041548|NCT04116255|OTHER|Temporomandibular joint Exercises|This program was created by combining patient training and a home exercise program. The exercise program consisted of slow passive and active mouth opening and closing exercises, isometric masseter exercises, mouth stretching exercises, and resistant mouth opening and closing exercises. Each exercise set was administered twice a day, and each movement was undertaken for 10 seconds and repeated 15 times. The training was given by an experienced physical medicine and rehabilitation expert over approximately 45 minutes. The exercise program was demonstrated for the patients in front of a mirror, and each exercise was performed by a set of patients under the supervision of a doctor. A training document including the written exercise program was to the patients in the exercises group.
215041549|NCT05303883|OTHER|Pediatric Constrained Induced Movement Therapy|Constraint of the child's less-impaired upper extremity for first 17 days of treatment. Children wear a removable, lightweight constraint for the first 17 of 20 therapy sessions.
214291461|NCT00020475|DRUG|Montanide ISA-51|
214291462|NCT00711711|OTHER|Manual lymphatic drainage|Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
214875443|NCT04777149|OTHER|transcranial Direct Current Stimulation (tDCS)|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered. TDCS will be applied during the first 20 min of functional task practice.
214875444|NCT04777149|OTHER|sham-stimulation|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered for 1- 2 min.
214875445|NCT00290550|DRUG|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
214875446|NCT03558386|BEHAVIORAL|ePRO survey|An electronic patient reported outcomes survey will be completed by the patient.
214875447|NCT03426163|DEVICE|Virtual reality|Application of knee MRI transformed virtual reality system
215041550|NCT01088685|DEVICE|Experimental Blister Patch|Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals
215041551|NCT01088685|DEVICE|Marketed Pflaster|Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
215041552|NCT01935388|OTHER|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
215041553|NCT02487511|OTHER|Duration of HP therapy|the comparison of HP eradication rate between 7 days and 14 days
215041554|NCT00338637|DEVICE|APOS shoe kit|
215041555|NCT00966108|DEVICE|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
215041556|NCT02271880|OTHER|Medication as usual|Physicians will prescribe medication as usual to the adolescent.
215041557|NCT02271880|OTHER|STAR|Adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.
215041558|NCT01914588|PROCEDURE|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
214291463|NCT00711711|OTHER|relaxation|Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
215041559|NCT01914588|OTHER|Standard care|"* Detailed instruction about medical therapy and lifestyle counseling~* Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~* Follow-up visits"
215041560|NCT05245903|DEVICE|Emerald Device Monitoring|The study participants will have the Emerald device deployed in their home for up to 12 weeks as they participate in the parent study (ClinicalTrials.gov identifier NCT04430517). The device will be deployed in the bedroom of each subject to capture behavior continuously. The Emerald device is a radio-wave sensor that will use signal processing and machine learning algorithms to track the gait, movement, respiration, and sleep of these subjects via low-powered radio signals. Reflections of the radio signals are processed using algorithms to convert them into movement data, sleep stages, and key sleep parameters. These data will supplement bioenergetic, imaging, and biochemical data with digital biomarkers and phenotyping using this device.
215041561|NCT00806585|DRUG|MK-0736|
215041562|NCT00806585|DRUG|Comparator: Placebo|
214291464|NCT03025503|OTHER|nipple stimulation|
215041563|NCT00806585|DRUG|Comparator: HCTZ|
215041564|NCT04345055|OTHER|Treatment of the lumbar fasciae|Treat the lumbar facial with a manual technique
215041565|NCT04345055|OTHER|Placebo intervention|Introduce in a machine off
215041566|NCT03985735|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
215041567|NCT04863742|DRUG|Dextenza 0.4Mg Ophthalmic Insert|sustained released dexamethasone, 0.4mg
215041568|NCT04863742|DRUG|Prednisolone Acetate|Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
215041569|NCT03423511|DEVICE|MiStent II coronary artery stent|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
214291465|NCT00823394|BEHAVIORAL|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
214291466|NCT00823394|OTHER|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
214875448|NCT05018312|BEHAVIORAL|Modified Collaborative Assessment (MCA)|The Modified Collaborative Assessment (MCA) will be assessment of the patients that Is more thoroughly-done, and which will be inspired by the school of Therapeutic Assessment and Collaborative Assessment. It will include the EASE, SCID-interview, PSE, ADOS and SCIP-interviews.
214875449|NCT05018312|BEHAVIORAL|Assessment as Usual (AAU)|Assessment as usual is the standard assessment the patients will receive in the clinic. It includes one or more interviews with a mental health professional in the clinic.
214875450|NCT02400853|DEVICE|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
214875451|NCT02400853|PROCEDURE|Cord blood analysis|Cord blood will be collected during deliverance and analysed
214875452|NCT02549027|DRUG|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
214875453|NCT02549027|DRUG|MK-6096|Oral MK-6096 tablets (5 mg strength)
214875454|NCT02549027|DRUG|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
214875455|NCT05651789|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.
214875456|NCT05651789|DRUG|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
214875457|NCT03450044|BIOLOGICAL|Dendritic cells|Adoptive transfer of autologous DCs
215041570|NCT03423511|DEVICE|Xience or Promus coronary artery stents|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
215041571|NCT00474903|DRUG|acetylsalicylic acid|Given orally
215041572|NCT00474903|DRUG|esomeprazole magnesium|Given orally
214875458|NCT03589040|DRUG|Etonogestrel 68Mg Implant|Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
214875459|NCT03589040|DRUG|rilpivirine|Oral rilpvirine 25mg
214875460|NCT03589040|DRUG|darunavir|Oral darunavir+ritonavir 600/100mg
214875461|NCT00740012|OTHER|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
214875462|NCT00740012|OTHER|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
214875463|NCT00740012|OTHER|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
214875464|NCT00740012|OTHER|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
214875465|NCT00740012|OTHER|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
214875466|NCT00740012|OTHER|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
214875467|NCT03850314|DIETARY_SUPPLEMENT|Glycine|Glycine powder to be dissolved in water.
214875468|NCT01323712|DIETARY_SUPPLEMENT|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
214875469|NCT03240835|DRUG|cisplatin and docetaxel|"NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles."
214875470|NCT03240835|RADIATION|IMRT|intensity modulation radiation therapy
214875471|NCT01000558|OTHER|biologic sample preservation procedure|
214875472|NCT01504958|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS."
214875473|NCT01504958|BEHAVIORAL|NICE Cognitive Training|"12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group."
214291467|NCT00823394|BEHAVIORAL|Self-help Materials|Information on how to lower risk for developing cancer.
214291468|NCT01899690|DRUG|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
214291469|NCT01938378|BIOLOGICAL|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
214291470|NCT02240160|DRUG|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
214875474|NCT03115216|PROCEDURE|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
214875475|NCT03115216|PROCEDURE|CEIOL|Manual cataract extraction and intraocular lens placement
214875476|NCT01343316|DEVICE|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
214875477|NCT00127218|DRUG|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
214875478|NCT00127218|DRUG|niacin|long-acting niacin daily for 18 months
214875479|NCT00127218|DRUG|Placebo|matching placebo pill daily for 18 months
214875480|NCT00405808|DRUG|Rimonabant|Once daily in the morning
214875481|NCT00405808|DRUG|Placebo|Once daily in the morning
214291471|NCT00754624|DRUG|Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler|Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
214875482|NCT02810379|PROCEDURE|written informed consent|
214875483|NCT02810379|PROCEDURE|video+written informed consent|
214875484|NCT00099879|DRUG|BMS-275183|
215041573|NCT00474903|OTHER|placebo|Given orally
215041574|NCT02847403|DRUG|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
214875485|NCT03897803|DIAGNOSTIC_TEST|strain elastography|strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.
214875486|NCT02974179|BIOLOGICAL|Subjects from Study AG-CLI-0206 who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
214875487|NCT05850585|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
214875488|NCT05850585|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
214875489|NCT01421511|DRUG|TR-701 FA|"* TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~* TR-701 FA Tablets, 200 mg, orally once daily"
215041575|NCT02847403|OTHER|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
214875490|NCT01421511|DRUG|Linezolid|"* Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~* Linezolid Tablets, 600 mg, orally every 12 hours"
214875491|NCT00163488|DRUG|Ciclesonide|
214875492|NCT01505153|BIOLOGICAL|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
215041576|NCT02599116|OTHER|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
214875493|NCT05260060|BEHAVIORAL|Treatment as usual: Control|Treatment usually delivered in service that may include but is not limited to cognitive behaviour therapy, exposure, eye movement desensitisation and reprocessing , behaviour therapy, family therapy.
214875494|NCT05260060|BEHAVIORAL|Group Metacognitive Therapy (Group-MCT): Experimental|Group metacognitive therapy (Group-MCT) focuses on developing adaptive control of worry, repetitive negative thinking and attention and modifies beliefs that maintain unhelpful thinking patterns. Treatment is 6 to 8 weekly sessions delivered by two trained mental health professionals, guided by a treatment manual, lasting approximately 90 minutes each session.
214875495|NCT04581369|OTHER|Care Coordinator Intervention for Direct Intervention Group|"The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers.~The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes.~The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians."
215041577|NCT02599116|OTHER|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
215041578|NCT04843280|PROCEDURE|FORCE therapeutics (physical therapy)|6 weeks of internet based physical therapy following arthroscopic knee surgery
215041579|NCT04843280|PROCEDURE|Traditional Outpatient Physical Therapy|6 weeks of outpatient physical therapy following arthroscopic knee surgery
215041580|NCT04457024|OTHER|classification statistics|Without any intervention
215041581|NCT01936831|DRUG|Isoniazid|INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.
215041582|NCT01936831|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.
215041583|NCT03435380|BEHAVIORAL|Patient activation|Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
215041584|NCT03435380|BEHAVIORAL|Primary care physician activation|Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.
215041585|NCT03435380|BEHAVIORAL|Control|Mailed educational materials.
215041586|NCT01103414|DRUG|Mitoglitazone|50 mg capsules, once daily for 84 days
215041587|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 100 mg capsules, once daily for 84 days
215041588|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 150 mg capsules, once daily for 84 days
215041589|NCT01103414|DRUG|Pioglitazone|Pioglitazone 45 mg, once daily for 84 days
215041590|NCT01103414|DRUG|Placebo|Placebo, once daily for 84 days
215041591|NCT02526914|DRUG|Intranasal Oxytocin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
214291472|NCT00418314|DEVICE|Control|Empiric programming or one-time optimization using a non-IEGM method.
215041592|NCT02526914|DRUG|Intranasal vasopressin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
214291473|NCT00418314|DEVICE|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
215041593|NCT02526914|DRUG|Intranasal placebo|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
215041594|NCT00788112|DRUG|vorinostat|
215041595|NCT00788112|GENETIC|protein expression analysis|
215041596|NCT00788112|OTHER|immunohistochemistry staining method|
215041597|NCT00788112|OTHER|laboratory biomarker analysis|
215041598|NCT00788112|PROCEDURE|neoadjuvant therapy|
215041599|NCT00788112|PROCEDURE|therapeutic conventional surgery|
215057561|NCT06110949|DEVICE|Triaxial accelerometry|A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction, in order to collect raw data regarding patient mobility (duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity) during the admission (from the admission day to discharge).
214291474|NCT05001386|BIOLOGICAL|Blood collection for the evaluation of the anti-drugs sensitivity|The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.
214291475|NCT05947370|DRUG|Berberine Chloride|Traditional Chinese medicine
214291476|NCT05947370|DRUG|Placebo|Placebo control
214875496|NCT04581369|OTHER|Care Coordinator Intervention for Standard of Care Group|For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge. Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months. This is the extent of interventions received for participants in this arm.
214875497|NCT04581369|OTHER|Caregiver Intervention|Caregivers of the participants will be assessed for caregiver burden at 3 time points.
214875498|NCT01360463|BEHAVIORAL|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
214875499|NCT01360463|BEHAVIORAL|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
214875500|NCT04460508|DRUG|Pegylated rhG-CSF|Pegylated rhG-CSF:6mg
214875501|NCT04460508|DRUG|rhG-CSF|rhG-CSF:5ug/kg/d
214875502|NCT00780910|DRUG|MP-424|750 mg every 8 hours for 12 weeks
214875503|NCT00780910|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
215041600|NCT06249464|BEHAVIORAL|comprehensive rehabilitation|"All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
215041601|NCT06249464|DRUG|Lidocaine hydrochloride|the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
215041602|NCT02188966|DEVICE|Geographic Information System|"GIS data is delivered by SimaTech Enterprise System communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform"
215041603|NCT04494789|DRUG|Fludrocortisone Acetate|50mcg
215041604|NCT04494789|DRUG|Fludrocortisone Acetate|100mcg
215041605|NCT04494789|DRUG|Fludrocortisone Acetate|200mcg
215041606|NCT04494789|OTHER|Standard Therapy|NO Fludrocortisone
215041607|NCT04562415|DEVICE|Active Repetitive Transcranial Magnetic Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and inhibitor rTMS was applied with a frequency of 1 Hz consisting of 1200 pulses for 20 minutes. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
215041608|NCT04562415|DEVICE|Active Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
215041609|NCT04562415|DEVICE|Sham Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and sham cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
214875504|NCT00780910|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
214875505|NCT06360055|DRUG|Dabigatran Etexilate|Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.
214875506|NCT06360055|DIETARY_SUPPLEMENT|D-mannose|Subjects will take 3g (1g\*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions).
214875507|NCT06382610|DIETARY_SUPPLEMENT|Melatonin|Melatonin will be administered in three different forms
214875508|NCT03879434|DEVICE|Ostenil® Mini|Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
214875509|NCT04680858|OTHER|DECT|Use of a digital enhanced telecommunication headset for team communication
214875510|NCT04962386|DRUG|Hormone replacement therapy|HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.
214875511|NCT00299286|DRUG|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
214875512|NCT00299286|DRUG|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
214875513|NCT03880786|DEVICE|pudendal PNE test lead|All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
215041610|NCT00711373|PROCEDURE|Allogeneic hand transplantation|Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
214875514|NCT01111825|DRUG|Temsirolimus|"28 day treatment cycle Phase 1~* Weekly intravenously (IV) on days 1, 8, 15, and 22~* Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~* Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~* HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22"
214875515|NCT01111825|DRUG|Neratinib|"28 day treatment cycle~• 240 mg orally daily"
215041611|NCT04088903|DRUG|Daratumumab|\>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
215041612|NCT06486402|OTHER|participation rate|participation rate
215041613|NCT05140343|DIAGNOSTIC_TEST|KARDIA Mobile ECG Monitoring (KMCM)|The KMCM will be introduced to the patient of the KMCM arm in the outpatient clinic. The activation and configuration will be done together with the physician in the outpatient clinic (installation of the ECG app, enabling heart rate rhythm notification). Patients are requested to acquired ECGs twice weekly plus additional ECGs if symptomatic. In case of symptoms the patient is asked to generate an ECG and communicate the event timely to the investigator and to the treating physician by sending a report through the ECG app. An e-mail account created for the study will be checked at least once a day. The arrhythmia diagnosis will be performed by the clinician based on the ECG information, independently of the arrhythmia classification automatically performed by the device. In case of stronger symptoms of any kind at any time the patient is asked to request medical help regardless of the KMCM notifications. Change of management will be collected.
215041614|NCT00004157|BIOLOGICAL|filgrastim|
215041615|NCT00004157|BIOLOGICAL|recombinant interleukin-11|
215041616|NCT04859998|BEHAVIORAL|dog-assisted therapy|It will consist of 20 sessions conducted twice a week in the facilities of the association. It will involve different activities and physical exercises facilitated by the dogs. The program will be conducted in two associations (12 participants in each one, 6 belonging to the experimental and 6 belonging to the control group in each association) and in groups of three participants.
215041617|NCT05206903|OTHER|Questionnaires|Questionnaires about pandemia process
215041618|NCT05162248|DIAGNOSTIC_TEST|Microsatellite instability analysis|Molecular analysis for Microsatellite Instability (MSI) status was performed using immunohistochemistry (IHC). IHC now recognized as an approved method to highly precision predict MSI in colorectal cancer.
215041619|NCT05790694|DRUG|HBM9378 (SKB378) Injection|Strength: 225 mg (1.5 mL)/vial
215041620|NCT05790694|DRUG|Placebo|Strength: 225 mg (1.5 mL)/vial
215041621|NCT03859076|BEHAVIORAL|MB-BP|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions \& a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, \& specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, \& stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
215041622|NCT03859076|OTHER|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
215041623|NCT03534882|OTHER|Discontinuation of topical prostaglandin analogue therapy|Participants are asked to discontinue their prostaglandin analogue eye drops for the designated time period (42 days)
215041624|NCT04792385|DRUG|E4/DRSP 15/3 mg combined tablet|One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
215041625|NCT03641196|DEVICE|Fixed appliance|Use of a cemented modified palatal Nance appliance presenting a bite-plane
215041626|NCT03641196|PROCEDURE|Composite bite plane|treatment with a composite build up in the palatal aspect of the upper central incisors.
215041627|NCT06399055|DRUG|CKD-387|1 Tablet
215041628|NCT06399055|DRUG|D484|1 Tablet
215057562|NCT02020434|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
215057563|NCT02277574|BIOLOGICAL|AMP-110|2, 5, or 10 mg/kg
214291477|NCT06508073|OTHER|Neural Therapy|The injection was prepared using a solution of lidocaine 2% and saline 0.9%. A 0.4% lidocaine solution was prepared by diluting 1 cc of lidocaine with 4 cc of saline.
214291478|NCT06391164|DRUG|XC243 25 mg|Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days
215041629|NCT05940350|BEHAVIORAL|Telerehabilitation Stroke Coaching of Program (TeleSCoP) group|"The sampling criteria will be assigned to the intervention (TeleSCoP) and control groups by stratified randomization (1:1) in patients with acute ischemic stroke. A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10. The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months."
214875516|NCT00089024|DRUG|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 \& 2; Repeat one 3-week cycle starting day 22
214875517|NCT00089024|DRUG|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 \& 2; Repeat one 3-week cycle starting day 22
214875518|NCT00089024|DRUG|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
214875519|NCT00089024|DRUG|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
214875520|NCT00089024|PROCEDURE|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
214875521|NCT00089024|PROCEDURE|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 \[negative margins\] or R1 \[positive microscopic margins\]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
214875522|NCT00089024|PROCEDURE|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
214875523|NCT00089024|RADIATION|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
214875524|NCT01539018|DRUG|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
214875525|NCT01539018|DRUG|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
214476842|NCT02394626|PROCEDURE|Surgery followed by adjuvant second-line therapy|"Surgery:~Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.~Adjuvant second-line therapy:~Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol."
214476843|NCT02394626|PROCEDURE|Second-line therapy alone|Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
214476844|NCT03404791|DRUG|TAR-200|TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
214476845|NCT05340348|OTHER|Blood samples (36 mL) + fecal samples + hair sample|Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
214875526|NCT01329783|OTHER|maraviroc|No intervention is distributed during this trial.
214875527|NCT04472676|DRUG|LY3473329|Administered orally.
214875528|NCT04472676|DRUG|Placebo|Administered orally.
215041630|NCT00409955|PROCEDURE|Lamellar transplant with lyophilized corneas|
215041631|NCT00085527|DRUG|depsipeptide|
215057564|NCT02277574|OTHER|Placebo|Placebo
214875529|NCT05204082|DEVICE|Single Use Vein Entry Indicator Device|Electronic pressure sensing device, integrated to a conventional needle catheter, and which indicates continuously during intravenous cannulation whether the tip of the needle is inside or outside of a vein, to assist a clinician in intravenous cannulation.
214875530|NCT06265194|BEHAVIORAL|EMDR|The fibromyalgia protocol applied to the patients in the study was developed specifically for fibromyalgia by Konuk, and colleagues (Konuk et al.). In addition to the article, the details of the protocol and the study sheet are presented supplementary. After a short introduction, the participants were informed about the protocol, their -consent was obtained for registration, and a visual, tactile and audio bilateral stimulus that will be used in the application was introduced.
214666452|NCT03815175|DRUG|DAPT (aspirin and/or P2Y12 receptor inhibitor)|"1-month clear subjects (pooled from Xience 28 USA study and Xience 28 Global study) will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up."
214875531|NCT06265194|BEHAVIORAL|TAU|Treatment as Usual (TAU): Routine fibromyalgia treatments, referred to as Treatment as Usual (TAU) in this study, were initiated in the outpatient clinic conditions. TAU are treatments designed by rheumatologists in accordance with current rheumatology guidelines.
214875532|NCT02691143|OTHER|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
214875533|NCT04937114|PROCEDURE|Barbed suture|Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries
214875534|NCT06422910|OTHER|Telerehabilitation|"Home exercises will be delivered through a video mobile application. In this application, exercises for knee osteoarthritis will be presented according to their types (stretching, strengthening, etc.). Videos deemed appropriate by the physiotherapist will be added to the exercise prescription and sent to the patients via message. Patients will have the opportunity to remotely access their own exercise prescription with visual, auditory and written commands.~Translated with DeepL.com (free version)"
214291479|NCT06391164|DRUG|XC243 50 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
214666453|NCT05833880|BEHAVIORAL|Self-administered questionnaire|Self-administered questionnaire regarding complementary and alternative medicine use
214666454|NCT06316427|DRUG|Autologous CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.
214875535|NCT02485119|DRUG|BAY94-9343|Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
214875536|NCT04074616|DEVICE|High Dose|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
214875537|NCT04074616|DEVICE|Low dose|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
214875538|NCT02552303|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
214875539|NCT02552303|DRUG|Armodafinil|Active medication
214875540|NCT02552303|DRUG|Placebo|Placebo for Nuvigil (armodafinil)
214875541|NCT01377987|DRUG|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
214875542|NCT01377987|DRUG|Placebo|4 mg/kg, once daily before bed, for 7 days
214875543|NCT06149806|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
214875544|NCT05113433|OTHER|conventional physical therapy|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session."
214875545|NCT05113433|OTHER|standing frame.|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty ."
214875546|NCT01401556|OTHER|case management|
214291480|NCT06391164|DRUG|XC243 75 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
214291481|NCT06391164|DRUG|Placebo|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
214291482|NCT00003204|DRUG|cyclophosphamide|Given IV
214291483|NCT00003204|DRUG|fludarabine phosphate|Given IV
214291484|NCT00003204|DRUG|vincristine sulfate|Given IV
214666455|NCT06316427|DRUG|Prior-HSCT donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.
214666456|NCT06316427|DRUG|New donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
214666457|NCT02032628|BEHAVIORAL|Exercise|The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
214666458|NCT01636037|DRUG|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
214291485|NCT00003204|DRUG|prednisone|Given PO
214291486|NCT00003204|BIOLOGICAL|rituximab|Given IV
214291487|NCT00003204|OTHER|laboratory biomarker analysis|Correlative studies
214291488|NCT04416503|OTHER|Foot reflexology|Foot reflexology was performed for 12 week in the study group,whereas the control group continued their routine treatment and follow-up.
214291489|NCT06363968|DEVICE|RETeval|as previous
214291490|NCT00002222|DRUG|Valganciclovir|
214666459|NCT05124938|DIAGNOSTIC_TEST|Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.|a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
214875547|NCT01401556|OTHER|Multifaceted quality improvement intervention|
214875548|NCT02529215|BEHAVIORAL|Just-in-time training (JITT)|The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
215057565|NCT00033423|BIOLOGICAL|rituximab|
215057566|NCT00033423|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214875549|NCT06427707|DRUG|Intravenous Infusion of propofol, lidocaine, Magnesium sulfate|intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. the effect of either Propofol injection, or ketamine injection or dexmeditomidine injection on intraoperative bleeding
214875550|NCT06427707|DRUG|Intravenous infusion of ketamine, lidocaine, Magnesium sulfate|Patients will receive intravenous infusion of Ketamine 0.1-0.2 mg.kg-1.h-1 (intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. dose of 1 mg.kg-1), lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1.
214875551|NCT06427707|DRUG|Intravenous infusion of dexmedetomidine, lidocaine, Magnesium sulfate|Dexmeditomidine (Precedex® 200 mcg.2ml-1) with a rate of 0.2-0.6 mcg.Kg-1.h-1. lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1
214875552|NCT01247883|DRUG|PF-04634817|single dose, 20mg, tablet
214875553|NCT01247883|DRUG|PF-04634817|single dose, 20mg, solution
215041632|NCT01093014|BEHAVIORAL|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
214666460|NCT05207462|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
214875554|NCT02482961|DRUG|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
214875555|NCT04471129|OTHER|HFO/O2C/NIV|High-flow oxygen therapy + O2C + Non invasive ventilation
214875556|NCT04471129|OTHER|NIV/O2C/HFO|Non invasive ventilation + O2C + High-flow oxygen therapy
214875557|NCT06629844|OTHER|The VR dementia education group|The intervention group will receive the VR dementia education program, which will be conducted once for each participant, and each session will accommodate a maximum of 20 participants. The VR dementia education program will follow the flow below, integrating video dramatizations, VR experiences, lectures, and discussions. The program is designed to simulate real-life dementia care situations, encourage reflection, and enhance nursing students' understanding of dementia management. The following are the steps for intervention: Introduction (3 minutes), Pre-Program Questionnaire (10 minutes), Lecture Introduction (2 minutes), Bad Drama (Unfriendly Communication) (10 minutes), Bad VR (10 minutes), Discussion (5 minutes), Lecture 1: What is Dementia? (10 minutes), Good VR (10 minutes), Good Drama (10 minutes), Lecture 2: What Can We Do to Support PLWD? (5 minutes), N-impro (10 minutes), Post-Program Questionnaire (10 minutes), Conclusion (5 minutes).
214875558|NCT06629844|OTHER|The control group|The intervention begins with an introduction to the VR dementia program, outlining its objectives and setting participant expectations. A pre-program questionnaire follows to assess baseline knowledge, attitudes, and intention to assist people with dementia. A brief lecture introduces a dramatization showing ineffective communication with a PLWD, followed by a VR scenario highlighting poor care practices. After discussing these observations, participants attend a lecture explaining dementia's symptoms and progression, with culturally adapted video content for Indonesian audiences. Next, a positive VR scenario demonstrates best practices in dementia care, followed by a video on supportive communication. A second lecture offers practical strategies for caregiving and communication, complemented by an N-impro session to deepen understanding. The session concludes with a post-program questionnaire and final reflection to encourage real-world application of the learned skills.
214875559|NCT02937389|DIAGNOSTIC_TEST|Patients after esophagectomy|Endoscopic examinations are performed at 1 and 8 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
214875560|NCT05128760|DIAGNOSTIC_TEST|characterization of aPL|characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)
214875561|NCT06455540|PROCEDURE|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the superior hypogastric plexus block will be performed on all the patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
214666461|NCT00866437|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
214875562|NCT01775189|DRUG|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
214875563|NCT01775189|DRUG|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
214875564|NCT01775189|DRUG|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
214875565|NCT01775189|DRUG|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
214875566|NCT02600689|BEHAVIORAL|Physical exercise training|
214875567|NCT02600689|BEHAVIORAL|Cognitive exercise training|
214875568|NCT02996292|DEVICE|Traditional brackets|Treating of crowding using traditional brackets
214875569|NCT02996292|DEVICE|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
215041633|NCT01093014|BEHAVIORAL|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
215057567|NCT01656005|DRUG|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
214291491|NCT00710710|DRUG|BI 2536|Intravenous Infusion
214291492|NCT01477606|DRUG|Midostaurin|"Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year."
215041634|NCT01093014|BEHAVIORAL|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
215041635|NCT01649193|OTHER|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
214875570|NCT02996292|DEVICE|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
214875571|NCT04603157|BEHAVIORAL|Hybrid Exercise Training|Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
214875572|NCT04799938|BEHAVIORAL|Exercise|180 minutes of moderate-intensity exercise per week
214875573|NCT01016470|DIETARY_SUPPLEMENT|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
214875574|NCT01016470|DIETARY_SUPPLEMENT|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
215041636|NCT04225858|PROCEDURE|Omission of sentinel lymph node biopsy|No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
215041637|NCT04753775|DRUG|Aloe vera gel|
214875575|NCT02506283|DEVICE|Zamar Therapy CT clinic|Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
214875576|NCT01455298|OTHER|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
215041638|NCT02383316|OTHER|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
215041639|NCT03563547|BEHAVIORAL|Dietary counseling (fat modifed diet)|Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
215041640|NCT03563547|BEHAVIORAL|Dietary Counseling (fat modified + soy enriched diet)|"Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
215041641|NCT03745950|DRUG|Olaparib Oral Capsule|\- Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
214875577|NCT05913505|BEHAVIORAL|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
214875578|NCT05913505|BEHAVIORAL|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
214875579|NCT03372291|OTHER|Usual Care|Usual leukemia care with all the supportive care measures instituted by the leukemia team
214875580|NCT03372291|OTHER|Psychological intervention|Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
215041642|NCT03745950|DRUG|Placebo oral capsule|\- Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
215041643|NCT01362101|BEHAVIORAL|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~* Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~* Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
215057568|NCT01656005|DRUG|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
214875581|NCT05248165|DEVICE|PCI|Percutaneous coronary intervention
214875582|NCT04141930|DRUG|Baloxavir Marboxil|Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset
214875583|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
214875584|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
214875585|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
215041644|NCT00700206|DRUG|Ezatiostat Hydrochloride|"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
215041645|NCT02922946|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
215041646|NCT02319486|DRUG|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
215041647|NCT02319486|DRUG|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
215041648|NCT02220634|DRUG|Regadenoson|Injection for intravenous administration
215041649|NCT04794933|OTHER|Conventional therapy|
215041650|NCT04794933|OTHER|CT+ PNF in extremity pattern|
215041651|NCT04794933|OTHER|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|
215041652|NCT04089514|DRUG|Adalimumab|Administered as specified in the treatment arm
215041653|NCT00671086|DRUG|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
215041654|NCT00671086|DRUG|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
215041655|NCT00003616|DRUG|irinotecan hydrochloride|
215041656|NCT00794092|DRUG|Sinerem administration|Single dose
215041657|NCT02115321|DRUG|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
215041658|NCT02115321|DRUG|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
214476846|NCT06553131|DEVICE|Neuromuscular Transmission Monitoring|A neuromuscular transmission module connected to electrodes applied to the skin and positioned to provide stimulation of a single nerve and monitor the muscular response to nerve stimulation
214666462|NCT00866437|DRUG|Skin test panel|"Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
214875586|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
215041659|NCT02115321|DRUG|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
215041660|NCT05407701|DIETARY_SUPPLEMENT|Cranberry Juice|100% cranberry juice
215041661|NCT05407701|DIETARY_SUPPLEMENT|Placebo|Placebo juice
215041662|NCT00551083|OTHER|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR\*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
215041663|NCT00551083|OTHER|Usual Care (UC)|"Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would."
215041664|NCT00248924|BEHAVIORAL|Social Services|
215041665|NCT04501432|OTHER|No intervention|This study does not include an intervention
215041666|NCT02493764|DRUG|Imipenem|Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
215041667|NCT02493764|DRUG|Relebactam|Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
215041668|NCT02493764|DRUG|Cilastatin|Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
215041669|NCT02493764|DRUG|Piperacillin|Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
215041670|NCT02493764|DRUG|Tazobactam|Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
215041671|NCT02493764|DRUG|Linezolid|Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
215041672|NCT00859833|DRUG|Adenosine|Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
215041673|NCT00859833|DRUG|Regadenoson|Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
215041674|NCT04929964|PROCEDURE|MRM , Toilet Mastectomy , BCS|MRM , modified radical mastectomy : removing breast and axilla toilet mastectomy : palliative removal of tumor load BCS ,Breast conservative surgery
215041675|NCT04528589|OTHER|prenatal psychotherapy|Prenatal psychotherapy to break intergenerational risk of adverse childhood events
215041676|NCT00863161|DRUG|AZD3355|capsule, oral, single dose
215041677|NCT03218917|DRUG|Brensocatib 10 mg|Administered once per day for 24 weeks
215041678|NCT03218917|DRUG|Brensocatib 25 mg|Administered once per day for 24 weeks
215041679|NCT03218917|DRUG|Placebo|Administered once per day for 24 weeks
215041680|NCT01307449|BIOLOGICAL|PNEUMOVAX|1 dose of PNEUMOVAX
215041681|NCT01307449|BIOLOGICAL|Prevnar|1 dose of Prevnar
215041682|NCT01561976|DRUG|Metformin hydrochloride prolonged release|1000mg in fasting state
215041683|NCT01561976|DRUG|metformin hydrochloride prolonged release|1000mg in fed state
215041684|NCT01561976|DRUG|Metformin hydrochloride sustained release/Glimepiride|1000/2mg in fed state
215041685|NCT02468583|DRUG|FX006 32 mg|Experimental
215041686|NCT02468583|DRUG|TCA IR 40 mg|Comparator
214875587|NCT02121392|DEVICE|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
214875588|NCT02121392|DEVICE|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
214875589|NCT02121392|DRUG|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
215041687|NCT01507701|DRUG|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
214875590|NCT05719792|PROCEDURE|Transforaminal Epidural Steroid Injection|In the TFESI group, all patients were positioned prone. The injection site was cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) was applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle was inserted just below the pedicle. It was advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position was confirmed through a lateral view. Using lateral views, the needle was placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized. Once the epidural distribution of the contrast agent was confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 2 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride was injected.
215041688|NCT00427193|BEHAVIORAL|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
215041689|NCT00427193|BEHAVIORAL|Control|Participants continue their current diet for 24 months
215041690|NCT05508828|PROCEDURE|Percutaneous Continuous Irrigation assisted Vacuum Drainage Combined With Transgastric Necrosectomy|All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.
215041691|NCT01463527|DEVICE|Nellcor NPB-70 Capnograph|Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
215041692|NCT05136170|DRUG|Cenegermin|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.
215041693|NCT05136170|OTHER|Vehicle|Vehicle was instilled with the same scheme of the test product
215041694|NCT06544915|DIETARY_SUPPLEMENT|Synbiotic, Probiotic, Placebo|Use of dietary supplements to improve gut microbiome and cardiometabolic health
215041695|NCT03420365|BEHAVIORAL|Aerobic exercise|30 minutes of either aerobic, or balance and coordination, or reading magazines
215041696|NCT05194150|DEVICE|non-diffractive monofocal IOL|Rayone EMV
215041697|NCT05194150|DEVICE|standard EDOF IOL|Acrysof IQ Vivity
215041698|NCT00748631|DEVICE|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
215041699|NCT00337038|DRUG|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
214476847|NCT04245956|PROCEDURE|Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire|The intervention consists of measuring a series of hemodynamic indices in a stenosed coronary using a pressure wire, immediately before and after transcatheter mitral valve repair using the percutaneous edge-to-edge MitraClip system in patients with severe mitral insufficiency and concomitant intermediate coronary artery stenosis.
215041700|NCT06021808|PROCEDURE|Thoracoscopic LAA clipping|The surgeons measured the length of the base of the LAA, an appropriately sized LAA clip is then inserted with the aid of a thoracoscope and placed parallel to the base of the LAA.
215041701|NCT06021808|DRUG|Novel oral anticoagulant|For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
215041702|NCT00005590|DRUG|levofloxacin|
215041703|NCT03167138|BIOLOGICAL|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
215041704|NCT03167138|DEVICE|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
215041705|NCT02129712|BEHAVIORAL|Cognitive training|
215041706|NCT03593174|DEVICE|Ossur Rigid Dressing|Removable Rigid Dressing
214875591|NCT05719792|PROCEDURE|Erector Spina Plane Block|Patients are placed in the prone position to determine the vertebrae in the middle of the involved area. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a high-frequency (8 MHz) linear ultrasound (USG) probe. The transverse process is, then, visualized approximately at the 3 cm lateral from the midline and the erector spinae muscle is visualized on it. The 22-gauge 50 mm block needle is advanced towards the in-plane section craniocaudally and the transverse process is touched. Then the needle is then withdrawn minimally to confirm that it is between the erector spinae muscle and the transverse process through hydrodissection. Following that, 5 mL from 0.5% bupivacaine hydrochloride, 8 mg dexamethasone and 3 ml saline is administered and local anesthetic spread is confirmed by USG.
214875592|NCT03763357|DEVICE|Heat Therapy (HT)|Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.
214875593|NCT00741286|DRUG|Aspirin|Asprin (100mg) plus placebo
214875594|NCT00741286|DRUG|cilostazol|Aspirin (100mg) plus cilostazol (200mg)
214875595|NCT05689957|DRUG|Deep neuromuscular block using intravenous rocuronium induction at 1.2mg/kg and maintainance of 8-12mcg/kg/min for deep neuromuscular block|both arm are using low pressure pneumoperitoneum in laparoscopic surgery, moderate and deep neuromuscular block are monitor with neuromuscular monitoring. if surgical condition is inadequate, surgeon are allowed to increase intraabdominal pressure as per standard care
214875596|NCT00391963|DEVICE|Bispectral index, Entropy|
214875597|NCT01352416|DRUG|Ranolazine|Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
214875598|NCT01352416|DRUG|Placebo|Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
214875599|NCT06467110|DEVICE|transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)|The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.
215041707|NCT03593174|DEVICE|Elastic Bandage|Usual modality: Elastic bandage
215041708|NCT01119287|DRUG|Dexamethasone 0.1% ophthalmic suspension|Maxidex
215041709|NCT01119287|DRUG|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
215041710|NCT01119287|OTHER|Inactive ingredients, used as placebo|Tears Naturale II
215041711|NCT00689806|DRUG|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not \> 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
215041712|NCT00689806|DRUG|Placebo|Placebo by mouth once daily for weeks 1-4.
215041713|NCT04086355|OTHER|oromotor exercises and neuromuscular electrical stimulations|treatment study group with occupational exercises and electrical stimulation
215041714|NCT05203380|DRUG|dupilumab|Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)
215041715|NCT04851574|DRUG|Sugammadex Injection|Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.
215041716|NCT00041028|DRUG|EF5|
215041717|NCT00041028|OTHER|flow cytometry|
215041718|NCT00041028|OTHER|immunohistochemistry staining method|
215041719|NCT00383071|BIOLOGICAL|H5N1 vaccine|Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
215041720|NCT00383071|PROCEDURE|Apheresis|Once subjects achieved a high antibody titer (\>1:160), they could begin apheresis to collect plasma.
215041721|NCT04795375|BEHAVIORAL|Physical Activity counseling|"The Physical activity counseling techniques will be based on the Self Determination Theory and Five A's (Assess, Advise, Agree, Assist, Arrange). Guidelines for physical activity will include combined aerobic and resistance exercises.~Each participant in the intervention group will receive personal exercise prescriptions in accordance the post-surgical statues and exercise recommendations after bariatric surgery. Participants will receive long term follow-up and accompaniment during the first six months after the surgery, through Personal meetings with a certified nurse, Phone-calls, motivational massages, and Exercise Videos."
214476848|NCT03589547|DRUG|Durvalumab|Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)
214476849|NCT03589547|RADIATION|SBRT|"SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.~The dose will consist of 20Gy (2 fractions of 10Gy)~\*3 fractions are allowed for centrally located tumors"
214875600|NCT01831258|DEVICE|SensAwake On|
214875601|NCT01831258|DEVICE|SensAwake Off|
214875602|NCT00807716|OTHER|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
215041722|NCT03240107|PROCEDURE|levator resection|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene."
215041723|NCT03240107|PROCEDURE|levator tucking|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene."
214875603|NCT00807716|OTHER|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
215057569|NCT01656005|DRUG|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
215057570|NCT01656005|DRUG|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
215041724|NCT04403919|DEVICE|Conventional Closure: Knee|Traditional closure will consist of arthrotomy (deep layer) closed with figure of eight number 1 vicryl plus followed by closure of the intermediate layer with 0 Vicryl plus. The intermediate layer will be performed at surgeon's discretion especially in thin patients. Subdermal layer with 2-0 vicryl suture followed by subcuticular 3-0 monofilament suture (monocryl PLUS, Ethicon; Johnson \& Johnson) and Dermabond advanced.
215041725|NCT04403919|DEVICE|Barbed suture closure: Knee|The barbed suture closure will consist of number 2 Stratafix symmetric PDS PLUS for the arthrotomy, intermediate layer will be performed at surgeon's discretion in thin patients, if performed will entail stratafix spiral, subdermal 2-0 stratafix spiral monocryl plus. Followed by subcuticular 3-0 stratafix spiral monocryl plus suture and Dermabond advance.
215041726|NCT04403919|DEVICE|Conventional Closure: Hip|"1. The capsule will be closed with Vicryl Plus number 1~2. Deep fascia with figure of eight interrupted number 1 braided absorbable suture (Vicryl plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal fat layer simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl plus)~4. Subcuticular 3-0 monofilament suture (monocryl plus , Ethicon; Johnson \& Johnson)~5. followed by the use of skin adhesive (Dermabond Advanced, Ethicon; Johnson \&Johnson)."
215041727|NCT04403919|DEVICE|Barbed suture closure: Hip|"1. The capsule will be closed with stratafix symmetric PDS Plus~2. Deep fascia will be closed with Stratafix Symmetric PDS Plus (Stratafix symmetric PDS plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal layer with running number 2-0 barbed suture (stratafix spiral monocryl plus, Ethicon; Johnson \& Johnson, Somerville, NJ)~4. Subcuticular suture with stratafix spiral monocryl plus, Ethicon~5. followed by the use of skin adhesive (Dermabond advanced, Ethicon; Johnson \&Johnson)."
214875604|NCT02896790|OTHER|Interviews with 2 oncologists and 10 patients|
214875605|NCT02896790|OTHER|Interviews with 15 patients|
214875606|NCT05115487|DIAGNOSTIC_TEST|digital dynamometer|Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
214875607|NCT02597127|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
214875608|NCT02597127|DRUG|Normal Saline|Saline (sterile, normal, 0.9%) solution given as SC injections
214875609|NCT03231566|BEHAVIORAL|Pain Neuroscience Education|See arm/group description
214875610|NCT03097848|PROCEDURE|RFA|for eligible cases, radiofrequency ablation will be given only.
214875611|NCT03097848|DRUG|Sorafenib|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
214875612|NCT00823810|OTHER|PET/CT|18F-FDG PET/CT
215041728|NCT00000389|DRUG|Fluvoxamine|
215041729|NCT00579644|DRUG|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
215041730|NCT00579644|DRUG|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
215041731|NCT01612676|DRUG|FE 202158|
215041732|NCT02743741|DRUG|Lutetium-177 Octreotate|Radiopharmaceutical
214666463|NCT05033210|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a WHO developed support strategy that involves humane, supportive and practical help for individuals living in a serious humanitarian crisis. PFA does not necessarily involve a discussion of the event(s) that cause the distress but aims particularly at five basic elements that are crucial to promote in the aftermath of crises, i.e. a sense of safety, calm, self- and community efficacy, connectedness, and hope (Hobfoll et al., 2007). It consists of a conversation (approximately 30-45 minutes) that a helper has with a participant which can be provided remotely (e.g. videoconferencing or telephone). It has various themes; the helper provides non-intruding practical care and support, listen to needs and concerns, helps people to address basic needs (e.g. information), listens to people without pressuring them to talk, comforts people and helps them to feel calm, helps people to connect to information, services, and social support, and protects people from further harm (WHO, 2011).
215041733|NCT03923868|DRUG|D-0120|D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
215057571|NCT01656005|DRUG|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
214875613|NCT03938623|OTHER|Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
214875614|NCT00645632|DRUG|cisplatin|
214875615|NCT00645632|DRUG|doxorubicin hydrochloride|
214875616|NCT00645632|DRUG|ifosfamide|
214875617|NCT00645632|DRUG|methotrexate|
214875618|NCT00645632|PROCEDURE|adjuvant therapy|
214875619|NCT00645632|PROCEDURE|neoadjuvant therapy|
214875620|NCT00645632|PROCEDURE|therapeutic conventional surgery|
214875621|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One stick pack containing 500 mg acetylsalicylic acid dry powder
214875622|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One tablet containing 500 mg acetylsalicylic acid
214875623|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One effervescent tablet containing 500 mg acetylsalicylic acid
214875624|NCT00658047|DRUG|CH-1504|Comparison of different doses of CH-1504
214875625|NCT00658047|DRUG|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
214875626|NCT02679638|OTHER|Factors and perceptions questionnaire|A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
215041734|NCT04319809|DEVICE|Object recognition subsystem|The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
215041735|NCT01156844|DRUG|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
215041736|NCT01156844|DRUG|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
215041737|NCT04831671|OTHER|Surgical Approach - Infra-patella nailing|The intra-medullary nail will be introduced via an infra-patella incision.
214666464|NCT05033210|BEHAVIORAL|Care as Usual (CAU)|In addition to PFA, both arms will be allowed to receive any usual care (CAU). CAU ranges from community care to specialised psychological treatments.
214666465|NCT05033210|BEHAVIORAL|Doing What Matters in Times of Stress (DWM)|DWM is based on the acceptance and commitment therapy (ACT), a form of cognitive-behavioural therapy, with distinct features (Hayes, Levin, Plumb-Vilardaga, Villatte \& Pistorello, 2013). ACT is based on the concept that ongoing attempts to suppress unwanted thoughts and feelings can make these problems worse, so instead it emphasises on learning new ways to accommodate these thoughts and feelings without letting them dominate. ACT has been shown to be useful for a range of mental health issues (Tjak et al., 2015) and has been used successfully in a guided self-help format (Hayes et al., 2013). DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, will be adapted for use on a smartphone or other device with internet access.
214875627|NCT02679638|OTHER|Qualitative interview|Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
215041738|NCT04831671|OTHER|Surgical Approach - Supra-patella nailing|The intra-medullary nail will be introduced via a supra-patella incision.
215041739|NCT05064722|DEVICE|Self Forming Magnets (SFM)|To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
215041740|NCT06446583|OTHER|Chewing sugar-free gum|Upon arrival at the preoperative preparation room, patients begin chewing sugar-free gum provided by the preoperative nurse. They continue chewing until they enter the operating room (for at least 15 minutes). Before entering the operating room, it is confirmed that the gum has been discarded.
215041741|NCT03264144|BEHAVIORAL|Social norms campaign|Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
215041742|NCT03679104|PROCEDURE|Closure of mucosotomy using endoscopic clips|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
215041743|NCT03679104|PROCEDURE|Closure of mucosotomy using OverStitch™ suturing device|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
215041744|NCT03147183|DRUG|Thymoglobulin|This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
215041745|NCT05214352|OTHER|co-design in the intervention manual elaboration to increase the participation in the community|"It will co-design an intervention manual between all participants (families, young people with cerebral palsy and therapists) and researchers, using the involvement matrix to increase the participation of young people in the community.~Different focus grous will be created to work together and various online meetings, masterclass, workshops to increase the knowlodge in all groups."
215041746|NCT03231553|OTHER|MiQuit text message support programme|MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
215041747|NCT05859113|DEVICE|Ziacom Galaxy dental implant with internal connical prosthetic connection|Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection
215041748|NCT05859113|DEVICE|Ziacom Zinic dental implant with internal hexagonal prosthetic connection|Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
215041749|NCT00024934|DRUG|B-Lymphocyte Stimulator (BLyS)|
215041750|NCT01726764|OTHER|St John's Wort|
215041751|NCT01726764|DRUG|Metformin|
215041752|NCT05124730|DRUG|Metformin 500mg prolonged release tablets (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
214875628|NCT05062213|OTHER|Moisturizer Body Lotion|Moisturizer Body Lotion
214875629|NCT03829787|DEVICE|Eye tracking|Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
214875630|NCT00994578|BEHAVIORAL|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
215041753|NCT05124730|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of Reference (R) Product was administered orally with 240 mL of water.
215041754|NCT04824833|PROCEDURE|Serratus anterior plane block|local anesthetic application between serratus anterior muscle and 5th rib
214476850|NCT06814912|OTHER|Survey using a questionnaire|virtual reality headset is added during treatment administration. Patient must complete a survey at the end of treatment administration and virtual headset use.
214476851|NCT06808919|OTHER|Whole Body Vibration Exercise|The participants underwent a prescribed exercise protocol involving both static and dynamic exercises on the designated platform. Specifically, static squats at a 30º angle, dynamic deep squats ranging from 30 to 60º, toe raises, weight transfer maneuvers during squats, as well as static and dynamic squat exercises performed unilaterally were implemented as part of the program
214476852|NCT06808919|OTHER|Aerobic Exercise|The participants assigned to the aerobic exercise group were directed to engage in running activity on a conventional treadmill. The participants engaged in aerobic exercise, specifically moderate-to-high-intensity running at 65-80% of their maximal heart rate, for durations of 30-45 minutes per session, three times weekly. Heart rate was monitored with a portable pulse oximetry device.
214476853|NCT06808919|OTHER|Strengthening Exercise|Strengthening group, participants engaged in various lower extremity strengthening activities such as straight leg raises, abduction and adduction movements, knee flexion-extension, ankle plantar-dorsiflexion exercises. These exercises were performed both on a bed and in standing positions, utilizing resistance exercise bands.
214476854|NCT06810830|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy (iCBT)|A structured 7-week program focusing on cognitive restructuring, stress management, and emotional regulation.
214875631|NCT00994578|BEHAVIORAL|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
214875632|NCT00994578|BEHAVIORAL|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
214875633|NCT00220831|DRUG|Natural source Vitamin E 400IU/day|
214875634|NCT02008435|BEHAVIORAL|Enriched GLB|Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
215041755|NCT05697718|BIOLOGICAL|MSC|a single injection dose i.v.
215041756|NCT02249078|DRUG|E6011|E6011 solution for injection
215041757|NCT02249078|DRUG|Placebo|Placebo 2-mL vial solution for injection
215041758|NCT01204788|PROCEDURE|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
215041759|NCT01204788|PROCEDURE|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
215041760|NCT05525962|BEHAVIORAL|questionnaries, scales, cognitive tests|"A first interview is planned with a psycholgist in the weeks following the minor arrival in the structure (M0)~* M0: cognitive test, psychiatric classification and psychologic assessments~* M12 and M24: psychiatric classification and psychologic assessments"
215041761|NCT03892317|BEHAVIORAL|Pharmacist led medication adherence interventions|Medication adherence interventions which will be tailored to individual patient need
215041762|NCT05460182|OTHER|CAF+CTG|Coronally Advanced Flap + Connective Tissue Graft
215041763|NCT05460182|OTHER|CAF|Coronally Advanced Flap
215041764|NCT04675827|DRUG|Pertuzumab and tratuzumab fixed dose combination|Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles
215041765|NCT04675827|DRUG|Trastuzumab emtansine|Treatment administration: adjuvant T-DM1 for 14 cycles.
215041766|NCT01554098|PROCEDURE|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
215041767|NCT01554098|PROCEDURE|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
215041768|NCT04589897|DEVICE|Manuka honey sinus rinse|Will follow a modified NHS nasal rinse protocol with the addition of manuka honey
215041769|NCT04589897|DEVICE|Standard sinus rinse|will follow the standard NHS nasal rinse protocol
215041770|NCT00107276|DRUG|capecitabine|
215041771|NCT00107276|DRUG|cyclophosphamide|
214476855|NCT06810830|BEHAVIORAL|Internet-Based EMDR Flash Technique (iEMDR-FT)|A 3-session protocol adapted to minimize re-exposure to distressing cancer-related memories through rapid bilateral stimulation and positive imagery.
214875635|NCT02008435|BEHAVIORAL|Standard GLB|This arm is the standard Group Lifestyle Balance program
214875636|NCT05914688|DRUG|LY3209590 (Formulation 1)|Administered SC.
214875637|NCT05914688|DRUG|LY3209590 (Formulation 2)|Administered SC.
215041772|NCT04846231|DIETARY_SUPPLEMENT|Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
215041773|NCT04846231|DRUG|Rosuvastatin|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
215041774|NCT04846231|OTHER|Placebo|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
215041775|NCT02980107|OTHER|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
214476856|NCT06809023|BEHAVIORAL|Sleep restriction|Participants will be asked to sleep 4h/night
214291493|NCT01477606|DRUG|Cytarabine|"Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (\>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2)."
214670069|NCT04468958|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
214875638|NCT04045483|OTHER|Virtual reality based cognitive training|The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
214875639|NCT00811928|DRUG|Posaconazole|"40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
214875640|NCT00811928|DRUG|Fluconazole|"50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
214875641|NCT06548997|DRUG|GZR18|5 μg/kg-maximum tolerated dose (MTD), single dose or two doses
214875642|NCT06548997|OTHER|Placebo|administered the same volume as GZR18
214875643|NCT03353883|DRUG|Triptorelin SR|GnRH agonist depot( Decapeptyl) will be taken in the previous mid luteal cycle in group A and the first day in group B
214875644|NCT00641069|DEVICE|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
214875645|NCT03431545|BEHAVIORAL|PALS and|"Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call."
214875646|NCT03431545|BEHAVIORAL|BEECH|"Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration."
215041776|NCT02980107|OTHER|PLS|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
215041777|NCT06353815|OTHER|4% articaine infiltration|Two injections using short needle and dental syringe will be given , the first injection is 1.5 ml out of 1.8 ml of 4% articaine with 1:100,000 epinephrine (ARTINIBSA 4% 1:100,000) in the mucobuccal fold adjacent to the mandibular first Molar, the second injection is 0.3 ml in the lingual side for lingual soft and hard tissues .
215041778|NCT00082121|DRUG|TP10|
215041779|NCT04626102|BEHAVIORAL|Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)|"The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session."
215041780|NCT04626102|BEHAVIORAL|Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)|"This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below."
215057572|NCT00050557|BEHAVIORAL|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
214291494|NCT01477606|DRUG|Daunorubicin|"Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)"
214291495|NCT05885789|PROCEDURE|Intubation in Bed-Up-Head-Elevated (BUHE) position|Comparing laryngoscopic view in paediatric patients during sniffing position and BUHE position
214670070|NCT04468958|OTHER|Normal saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
214875647|NCT03431545|BEHAVIORAL|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
214875648|NCT00171951|DRUG|Pasireotide|Pasireotide 600 μg or 900 μg was administered as an SC injection.
214875649|NCT05593419|DEVICE|TIIC signature|Collect tumor tissue of 300 gastric cancer patients at treatment baseline, samples will be transferred to central lab to detect the density and spatial proximity of certain immune cells infiltrated in tumor by multi complex immunohistochemistry, and evaluate patients' TIIC signature.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastaticorgan ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
214875650|NCT00396812|DRUG|Rituximab|"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
214875651|NCT04327323|DEVICE|CCM device implantation|CCM implantation involves the introduction of two active fixation stimulation leads, fixed on the interventricular septum, and connected to the CCM generator (Optimizer Smart IV, Impulse Dynamic, and any subsequent versions of the same device) inserted in the subcutaneous or submuscular pocket. The implantation is ususally performed using vascular access via right or left cephalic or subclavian vein. The CCM signal consists of 2-3 biphasic pulses lasting 10 msec (total duration of about 20 ms) with an amplitude between 4.0 and 7.5 V, delivered during the absolute refractory period of the ventricle, at a distance of 40 msec from ventricular sensing. The CCM device is compatible with other pacing and defibrillation devices already implanted in the patient; at the time of the implantation, the devices are checked in order to confirm the absence of interference between the devices. The patient is instructed to charge the device battery weekly.
215041781|NCT03064828|RADIATION|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
215041782|NCT03064828|RADIATION|CT colonoscopy (low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
215041783|NCT02049411|DRUG|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
215041784|NCT02049411|DRUG|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
215041785|NCT05361174|BIOLOGICAL|IOV-4001|A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
215041786|NCT06163287|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing molecular hydrogen
215041787|NCT06163287|DIETARY_SUPPLEMENT|Placebo|Inert substance
215041788|NCT04972851|BEHAVIORAL|Self-Determined Learning Model of Instruction (SDLMI)|"SDLMI is a teaching model that enables providers to teach students to:~* make choices and decisions about setting a goal~* develop action plans for academic or other goals~* self-monitor and self-evaluate progress toward goal attainment~* adjust the goal or plan"
214291496|NCT01365325|OTHER|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
214291497|NCT01365325|OTHER|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
214291498|NCT01030939|DRUG|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
214291499|NCT02228551|OTHER|Augmented renal clearance Point prevalence study|An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
214291500|NCT04537767|DRUG|Esmolol|The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
214291501|NCT04537767|DRUG|Placebo|Placebo
214291502|NCT02034279|DRUG|Albumin|Intravenous infusion of 20% albumin
214291503|NCT04876625|DEVICE|myTAP oral appliance plus mouth shield|myTAP anti-snoring oral appliance worn with mouth shield for all 8-weeks; the mouth shield is a comfort accessory that fits over the oral appliance itself and extends into the oral vestibule.
214291504|NCT04876625|DEVICE|myTAP oral appliance alone for first 4 weeks|myTAP anti-snoring oral appliance worn alone for first 4 weeks followed by wearing it for 4 weeks with the mouth shield
214670071|NCT01232972|PROCEDURE|vitrification of oocytes|eggs will be preserved via vitrification the day they are retrieved from the participant
214670072|NCT04583865|OTHER|teleconsultation|In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
215041789|NCT06010680|DRUG|[14C]SHR2554|Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.
215041790|NCT02117102|OTHER|Bladder and lumbar stimulation technic|
215041791|NCT02832570|DRUG|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
215041792|NCT02832570|DRUG|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
215041793|NCT06165991|DRUG|Liposomal bupivacaine, Bupivacaine|"1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA"
215041794|NCT04750161|OTHER|No intervention|No intervention will be given to participants. It is purely observational.
215057573|NCT00050557|BEHAVIORAL|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
214291505|NCT04762797|OTHER|Non|This is a retrospective study, without intervention.
215041795|NCT04152239|PROCEDURE|Motorized spiral enteroscopy (MSE)|Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
214875652|NCT02108093|PROCEDURE|retrograde autologous priming|Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
214875653|NCT03096158|OTHER|Ventilatory Muscle Training (TREMVEN)|"Early cardiac rehabilitation after coronary artery bypass graft:~The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit."
214875654|NCT03096158|OTHER|Aerobic Training (AERO)|"Early cardiac rehabilitation after coronary artery bypass graft:~It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit."
214875655|NCT03096158|OTHER|Isometric Handgrip Training (ISO)|"Early cardiac rehabilitation after coronary artery bypass graft:~Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit."
214875656|NCT03008317|DEVICE|PEEK|a metallic denture base
214875657|NCT05309018|OTHER|Interviews|Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
214875658|NCT03783325|BEHAVIORAL|UV Counseling|This is a sub-study that involves a behavioral intervention. Participants will wear a UV dosimetry for 3 weeks, return the device and receive feedback. After the feedback, they will re-wear the device for an additional 3 weeks.
214875659|NCT03783325|OTHER|UV Photo|Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
214875660|NCT03783325|OTHER|Biological Sample|Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
214875661|NCT04601571|DEVICE|CORTRAK Stylet|The stylet is a component of the CORTRAK feeding tube system used to confirm the correct placement of the feeding tube
214875662|NCT03998397|BIOLOGICAL|blood alcohol concentration withdrawal|The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
214875663|NCT05567510|DRUG|BMS-986369|Specified dose on specified days
214875664|NCT05178342|DRUG|CA-4948|"Patients will be treated orally with CA-4948 at 300 mg BID (2x200mg) over 4 cycles. One cycle consists of 28 days, 21 of which are treatment days, followed by 7 days off.~Patients with erythroid response (HI-E) after 4 cycles who tolerate CA-4948 may continue to receive CA-4948 until loss of HI-E response."
214875665|NCT00131599|DRUG|5FU/LV|5FU/LV
214875666|NCT01515917|DRUG|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
214875667|NCT01515917|DRUG|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
214875668|NCT01515917|OTHER|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
214875669|NCT01515917|OTHER|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
214875670|NCT02015065|DRUG|Vandetanib|Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
215041796|NCT06256055|BIOLOGICAL|UCMYM802 Injection|1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.
214291506|NCT04682067|BEHAVIORAL|Contingency Management|Escalating financial incentives contingent upon biochemical evidence of abstinence
214875671|NCT00014352|DRUG|docetaxel|
214875672|NCT00014352|DRUG|doxorubicin hydrochloride|
214875673|NCT00014352|DRUG|estramustine phosphate sodium|
214875674|NCT00014352|DRUG|ketoconazole|
214875675|NCT00014352|DRUG|warfarin|
214875676|NCT04590105|DEVICE|"Smartphone App SB Colonoscopy Prep"|We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.
214291507|NCT04682067|BEHAVIORAL|Usual Care smoking cessation|Usual care smoking cessation support
214291508|NCT00045500|DRUG|7-hydroxystaurosporine|
214291509|NCT00045500|DRUG|prednisone|
214291510|NCT00731289|DRUG|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
214291511|NCT00731289|DRUG|triamcinolone|"one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention"
214875677|NCT04590105|OTHER|Written Instruction|Written Instruction
215041797|NCT05321563|BEHAVIORAL|iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)|iDECIDE is a 4 session curriculum that addresses topics such as the neurobiology of substance use, adolescent brain development, industry tactics, motivations for using substances, risk and protective factors, triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. Facilitators are selected by schools and community agencies to receive free trainings conducted by the iDECIDE team, which includes personnel from the Massachusetts Department of Public Health, Massachusetts General Hospital (MGH) Center for Addiction Medicine, and the Institute for Health and Recovery.
215041798|NCT06241300|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program is an evidence-based group parenting intervention designed to reduce disruptive behavior in young children (2-8 years old).
214875678|NCT06968468|BEHAVIORAL|Resilient Together ALS|This intervention will teach resiliency and coping skills (mindfulness, meaning making, etc) to dyads soon after ALS diagnosis in order to manage distress associated with an ALS diagnosis. These sessions will take place over Zoom with both the person diagnosed with ALS and their primary informal caregiver.
215041799|NCT00476645|DRUG|Fulvestrant|Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
215041800|NCT05944692|DEVICE|Tripolar electroencephalography|We will record physiological signals with the tripolar electroencephalography
215041801|NCT06563908|PROCEDURE|Lipiodol® uterine treatment prior to IVF/ICSI|Lipiodol®, treatment will be performed by a HSG technique with X-ray screening on day 3 or day 5 after oocyte retrieval. The contrast medium will be Lipiodol Ultra Fluide® (Guerbet, France), an iodized poppy seed oil obtained by substitution of ethyl esters for the glyceryl esters of Lipiodol®. One millilitre of Lipiodol Ultra Fluide® contains 0.48g iodine. Women will lie in the left lateral or supine position. Radiologists will use a 'no touch' technique after applying antiseptic solution to the cervix. Uterine cannulation using the Cook HSG catheter will be applied to conduct Lipiodol® treatment. Prewarmed (37oC) Lipiodol® will be slowly instilled, with intermittent fluoroscopic X-ray guidance. Up to 10 ml of Lipiodol® will be slowly injected into the uterus and directly monitored by fluoroscopy. If intravasation was observed on X-ray (contrast apparent in the venous system), instillation will be stopped immediately.
215041802|NCT01448616|DRUG|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
215041803|NCT01448616|DRUG|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints."
215041804|NCT01448616|DRUG|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
215041805|NCT01448616|DRUG|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
215041806|NCT01852981|BEHAVIORAL|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
215041807|NCT01852981|BEHAVIORAL|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
215041808|NCT03164161|DEVICE|Cold pressor test|Described before.
215041809|NCT03164161|OTHER|β-endorphins evaluation in saliva|Described before.
215041810|NCT03164161|OTHER|β-endorphins evaluation in blood plasma|Described before.
215041811|NCT05486767|DIAGNOSTIC_TEST|Transient elastography|Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
215041812|NCT06120322|OTHER|Environmental factor monitoring; collection of blood, feces and urine. For UC: collection of 8 additional biopsies|During the routine surveillance according to the normal clinical practice, blood samples, feces and urines will be collected from UC patients and T1D patients (0, 6, and 12 months). Moreover, for UC patients during the surveillance sigmoidoscopy according to the normal clinical practice (or colonoscopy if the patient has more than 8 years; at the enrollment and after 12 months), colonic biopsies will be collected
215041813|NCT00987350|DEVICE|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
215041814|NCT00987350|DEVICE|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
215041815|NCT00987350|BIOLOGICAL|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
215041816|NCT03808571|OTHER|cord blood specimen during the delivery|The cord blood will be taken during the delivery of baby.
215041817|NCT00628381|DIETARY_SUPPLEMENT|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
215041818|NCT00628381|DIETARY_SUPPLEMENT|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
215041819|NCT01991860|DRUG|APD421- Amisulpride for IV injection|APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
215041820|NCT01991860|DRUG|Placebo|Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
215041821|NCT01775540|DRUG|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
215041822|NCT01775540|DRUG|Saline solution|Saline solution,1 drop used QID for 4 weeks
215041823|NCT01775540|DRUG|Maxidex|Eyedrop-1 drop QID for 4 weeks
215041824|NCT03281213|OTHER|Thoracotomy|
215041825|NCT05334940|OTHER|not applicable, observational study|Patients do not receive intervention
214875679|NCT01120704|DRUG|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes \>10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
215041826|NCT05049863|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil is commercially available.
215041827|NCT05049863|DRUG|Allopurinol|Allopurinol is commercially available.
215041828|NCT05049863|DRUG|Irinotecan|Irinotecan is commercially available.
215041829|NCT00143884|PROCEDURE|Reduced intensity conditioning|
215041830|NCT00143884|PROCEDURE|Prophylactic donor leukocyte infusions|
215041831|NCT00172367|DRUG|Lycopene|
215041832|NCT04847882|BEHAVIORAL|Questionnaire|Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
215041833|NCT02900014|PROCEDURE|sampling mesenchymal stem cells|nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
215041834|NCT00397540|PROCEDURE|PEIT|Percutaneous Ethanol Injection Therapy
215041835|NCT00397540|PROCEDURE|RFTA|Radiofrequency Thermal Ablation
215041836|NCT00116571|DRUG|Lemuteporfin for injection|
215041837|NCT00116571|DEVICE|Transurethral drug delivery system|
215041838|NCT00116571|DEVICE|Transurethral light delivery system|
215041839|NCT04651530|PROCEDURE|Phaco|phacoemulsification of cataract only
215041840|NCT04651530|PROCEDURE|Phaco+ECP|Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
215041841|NCT05600413|DIETARY_SUPPLEMENT|L-Citrulline|4 weeks of L-Citrulline supplementation (6 grams/day)
215041842|NCT05600413|DIETARY_SUPPLEMENT|Placebo|4 weeks of Placebo (crystalline cellulose)
215041843|NCT01129206|DRUG|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
215041844|NCT01129206|DRUG|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
215041845|NCT01129206|RADIATION|fludeoxyglucose F 18|Correlative studies
215041846|NCT01129206|PROCEDURE|positron emission tomography|Correlative studies
214670073|NCT01266148|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
215041847|NCT05244161|BEHAVIORAL|RMV-ECD|Combined radio messaging, video job aids (primarily for CHWs), Care for Childhood Development package
215041848|NCT06033625|PROCEDURE|CEMENTLESS TOTAL KNEE REPLACEMENT|CEMENTLESS CRUCIATE RETAINING BICOMPARTMENTAL TOTAL KNEE REPLACEMENT
215041849|NCT00090506|BEHAVIORAL|Yoga|
215041850|NCT01119638|DRUG|Escitalopram|Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
215041851|NCT01119638|DRUG|Risperidone|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
215041852|NCT02373904|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
215041853|NCT01800786|DEVICE|CPAP|
215041854|NCT00242606|DRUG|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
215041855|NCT00242606|DRUG|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
215041856|NCT00485173|DEVICE|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
215041857|NCT03006055|DEVICE|Circulating tumor cells|
215041858|NCT00746811|DRUG|P-OM3|4 grams/day - 4 one gram capsules
215041859|NCT00746811|DRUG|Placebo|4 grams/day - 4 one gram capsules
215041860|NCT04941885|DRUG|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab plus cyclophosphamide metronomic chemotherapy plus AI.
215041861|NCT06068192|OTHER|no intervention|no intervention
215041862|NCT05150626|DRUG|DBPR108 tablets|Drug: DBPR108, tablets, oral
215041863|NCT06530459|DRUG|Menopausal hormone therapy|Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily Ingest Micronized Progesterone 200mg daily for 12 days each month
215041864|NCT06530459|BEHAVIORAL|Exercise training|Exercises would focus on upper and lower body strength generally. It is anticipated that the participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week.
215057574|NCT03363191|DRUG|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol will be supplied as inhalation powder in ELLIPTA DPI. It will contain 2 strips with 30 blisters per strip. First strip will contain fluticasone furoate 100 mcg dry white powder blended with lactose. Second strip will contain vilanterol 25 mcg dry white powder blended with lactose and magnesium stearate.
214476857|NCT06808958|BEHAVIORAL|Experimental (Bathtub Bath) Group|The newborn's eyes will be covered with a phototherapy eye patch and placed in the baby's jeans and the treatment will be started. The position (face down and back down) is changed every two hours. And phototherapy is paused every three hours for feeding. Therefore, the bath will be given half an hour after the phototherapy application is completed before the two phototherapy sessions. The physiological parameters of the newborns will be evaluated 0 minutes before the bath. Then the bathtub bath application will be started. The bath application will be completed in a time not exceeding 5 minutes. Physiological parameters, stress and comfort will be assessed 15 minutes after bathing. Then, 15 minutes after starting the phototherapy session and 15 minutes before ending the phototherapy session, physiological parameters, stress and comfort will be assessed. The measured physiological parameters (respiratory rate, heart rate, oxygen saturation and body temperature), stress and comfort scor
214875680|NCT01120704|DRUG|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes \>10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
214875681|NCT01120704|BEHAVIORAL|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 \& 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
214875682|NCT01120704|BEHAVIORAL|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
215041865|NCT06530459|COMBINATION_PRODUCT|Menopausal hormone therapy + exercise training|"1. Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily and Ingest Micronized Progesterone 200mg daily for 12 days each month~2. Exercises would focus on upper and lower body strength generally. It is anticipated that patients ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week."
215041866|NCT03713801|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.
215041867|NCT03713801|DRUG|Placebo|Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
215041868|NCT01296165|BEHAVIORAL|Analysing the behaviours of travellers while visiting India|For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value \<0.05 will be deemed to represent statistical significance.
215041869|NCT05913674|DRUG|Modified early post-operative intraperitoneal chemotherapy (mEPIC)|"On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2."
215041870|NCT03202173|DIAGNOSTIC_TEST|10% fluorescein|The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
215041871|NCT06109727|DEVICE|cerebellar transcranial electrical stimulation|Cerebellar transcranial electrical stimulation - 20 mA - 20 min
215041872|NCT05137158|DEVICE|Intermittent theta burst stimulation|Intermittent theta burst stimulation(iTBS) on the left DLPFC, the left DLPFC will be targeted utilizing the localite neuronavigation system. The stimulation intensity is set at 80% of resting motor threshold(RMT), and the other parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 600 pulses per session, total duration of 3 minutes and 20 seconds.
214291512|NCT00715078|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
214291513|NCT00402766|DRUG|Cisplatin|Starting Dose: 60 mg/m\^2 by vein, Over 2 Hours
214291514|NCT00402766|DRUG|Imatinib Mesylate|Starting Dose: 300 mg PO Daily
214291515|NCT00402766|DRUG|Pemetrexed|Starting Dose: 500 mg/m\^2 by vein, Over 40 Minutes
214291516|NCT00402766|DRUG|Dexamethasone|20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
214476858|NCT06814314|DIAGNOSTIC_TEST|Transcriptomic investigation|Transcriptomic investigation followed by ontology classification
214875683|NCT01120704|BEHAVIORAL|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
214875684|NCT01120704|BEHAVIORAL|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 \& 23."
214875685|NCT05810584|DEVICE|Revision LR femoral stem|Revision LR is a modular femoral stem used for hip replacement
214875686|NCT01061268|DRUG|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
214875687|NCT01061268|DRUG|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
215041873|NCT05137158|DEVICE|Sham stimulation|The same procedure will be performed in sham group including the RMT assessment and the neuronavigation system for target localization, but the sham coil will vertical to the brain surface and deliver a very slight magnetic field, which have the same appearance and sound, and provide the same tactile sensations as the active coils.
215041874|NCT03906084|PROCEDURE|Corticotomy and low laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
215041875|NCT03906084|PROCEDURE|Corticotomy facilitated Orthodontics|Corticotomy is carried out under local anesthesia in right side.
215041876|NCT05516121|DRUG|VLT-015|100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days
215041877|NCT02076711|DRUG|Metoprololsuccinate|
215041878|NCT02076711|DRUG|Placebo|Placebo
215041879|NCT02149966|DRUG|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
215041880|NCT02149966|DRUG|Placebo|Placebo will be administered by mouth (orally) each day for a period of 14 days.
215041881|NCT05540483|DRUG|Disitamab Vedotin combined with Zimberelizumab|Treatment regimen: Disitamab Vedotin , 2.5mg/kg, intravenously D1, once every 14 days (Q2W), combined with Zimberelizumab, 240mg, intravenously D1, once every 14 days (Q2W).
215041882|NCT01480778|DRUG|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
215041883|NCT01480778|DRUG|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
215041884|NCT04082130|PROCEDURE|(XCM)+(CAF)|The description of this intervention has been already given before.
215041885|NCT04082130|PROCEDURE|(SCTG)+(CAF)|The description of this intervention has been already given before.
214670074|NCT01266148|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
215041886|NCT06645418|DIAGNOSTIC_TEST|relative Hand grip strength|To perform this study the relative handgrip strength (rHGS) index was used. The rHGSi is defined as the sum of the handgrip strength of both hands divided by body mass index (BMI), and it is considered a better prognostic tool than handgrip strength. rHGS was measured by Jamar hand dynamometer. The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
215041887|NCT06645418|DIAGNOSTIC_TEST|senior fitness test|The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
215041888|NCT03181984|DRUG|Hemoporfin|Hemoporfin mediated photodynamic therapy
215041889|NCT01356147|DRUG|Dornase alfa|2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
215041890|NCT01356147|DRUG|Placebo|No therapy will be given to placebo arm
215041891|NCT04171895|OTHER|Questionnaires|Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.
215041892|NCT04171895|OTHER|Communication training Part 1 (no longer recruiting)|1.5 hour Communication Training will be delivered through videoconferencing using the WebEx or Zoom platforms. The Training consists of a 30-minute lecture watched independently, and two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) completed as part of a virtual meeting. The lecture will be pre-recorded by Drs. Applebaum and Parker and will be sent via REDCap to ICs prior to the training to watch idependently. REDCap will log when ICs watch the lecture so that study staff know the participant has completed this aspect of the training. For the second part of the training ICs will participate in a virtual meeting for approximately 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs.
215041893|NCT04171895|OTHER|Enhanced usual care|"Participant will complete a survey on distress and receive feedback about distress and given a resource packet with support information and targeted referrals based on needs. The participant will also receive a physical or electronic copy of a book entitled Cancer Caregiving A to Z published by the American Cancer Society. At the conclusion of their participation in the study, EUC participants will be given access to the pre-training video and Advanced Care Planning forms sent to Communication Training participants."
215057575|NCT03363191|DRUG|Fluticasone Furoate|Fluticasone furoate will be supplied as inhalation powder in ELLIPTA DPI. It will contain a single strip with 30 blisters, containing fluticasone furoate 100 mcg dry white powder blended with lactose.
214670075|NCT01266148|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
215041894|NCT04171895|OTHER|Communication training Part II|Part II The communication training developed in Part 1 will have two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) and consist of a 20-30 minute lecture and 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs. Realistic scenarios were created and tailored according to ICs' reported concerns. After training, ICs will be coached through setting a SMART goal related to conducting ACP conversations, which emphasize Specific, Measurable, Attainable, Relevant and Time-bound steps that motivate and direct behavior change. Two weeks post training, a booster phone call will be made to ICs to check progress toward their SMART goal, address barriers with problem-solving and review skills as indicated.
214670076|NCT01266148|DRUG|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
214875688|NCT02675569|PROCEDURE|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
214875689|NCT02675569|PROCEDURE|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
214875690|NCT00755443|DEVICE|Drug eluting stent|Drug eluting stent implantation
214875691|NCT00755443|DEVICE|Bare metal stent|
214875692|NCT00109408|DRUG|Methotrexate|7.5-20mg po weekly
214875693|NCT00109408|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
214875694|NCT00233402|DRUG|Hexvix|Single Instillation, Transurethral Resection of the Bladder
214875695|NCT00233402|PROCEDURE|Standard white light cystoscopy|
214875696|NCT04034563|PROCEDURE|1) Risk of metachronous advanced neoplasia at 3-year, beyond 3 years surveillance colonoscopy|"3-year group: High-risk subjects who have baseline colonoscopy done in 2014, 2015 and 2016 and will be eligible for 3-year surveillance colonoscopy in 2017-2019.~Beyond 3 years group: High-risk subjects who had screening colonoscopy prior 3 years, but not received or scheduled for a surveillance colonoscopy- either due to non-adherence or limited access to surveillance colonoscopy will be eligible for surveillance colonoscopy in 2017-2019.~For the surveillance interval beyond 3 years group, recruitment will be prioritizing to subjects who had the screening colonoscopy at the earliest date. This will in part ensure that subjects in this group will consist those with the longest surveillance interval, leading to an applicable estimation of the risk of metachronous advanced neoplasia beyond 3 years surveillance interval."
214875697|NCT04016220|DRUG|Budesonide|first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
214875698|NCT04016220|DRUG|normal saline|first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
214875699|NCT06012461|OTHER|Closed-loop DBS stimulation for 24 hours|Continuous closed-loop modulation for 24 hours
214875700|NCT06012461|OTHER|Open-loop DBS stimulation for 24 hours|Continuous open-loop modulation for 24 hours
214875701|NCT06012461|OTHER|Closed-loop DBS stimulation for 72 hours|Continuous closed-loop modulation for 72 hours
214875702|NCT06012461|OTHER|Open-loop DBS stimulation for 72 hours|Continuous open-loop modulation for 72 hours
214875703|NCT04032249|BEHAVIORAL|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food
214875704|NCT04032249|BEHAVIORAL|Intervention Group (IG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food, but also, they will have monitored the self-control of the weight in order to compare the impact of self-weighing versus not doing it
214875705|NCT04181723|DRUG|Trofinetide|Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
214875706|NCT04181723|OTHER|Placebo|Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
214875707|NCT04810637|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
214875708|NCT05886387|OTHER|High PEEP + Recruitment maneuvers|The use of a High PEEP (positive end-expiratory pressure) level after recruiting collapsed alveoli can protect from mechanical ventilation associated lung injury
214875709|NCT05886387|OTHER|Standard PEEP. Low positive end-expriatory pressure|Mechanical ventilation is managed with a low standard PEEP without recruitment manneuvers
214875710|NCT06112392|DIAGNOSTIC_TEST|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
214875711|NCT06112392|DIAGNOSTIC_TEST|Treatment （Oral standard anti-Parkinson's drugs）|Treatment （Oral standard anti-Parkinson's drugs）
215057576|NCT03363191|DRUG|Salbutamol/Albuterol|Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.
215057577|NCT01078194|DEVICE|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
215057578|NCT03299244|DRUG|Etelcalcetide|Administered intravenously three times per week.
215057579|NCT03299244|DRUG|Cinacalcet|Cinacalcet administered orally once a day.
214670077|NCT01266148|DRUG|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
214875712|NCT05269979|BEHAVIORAL|Prevention of hip fractures|Physical exercise and lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
214875713|NCT00486941|BEHAVIORAL|Exercise and diet - based on DPS and DPP|
214291517|NCT03598192|PROCEDURE|TAP|The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%
214291518|NCT03598192|PROCEDURE|PVB|The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
214291519|NCT03598192|DRUG|Ropivacaine|Ropivacaine has been treated the both group
214875714|NCT02361242|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
214875715|NCT00339092|BEHAVIORAL|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
215041895|NCT03741270|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).
215041896|NCT06596642|DRUG|Luspatercept|As per product label
215041897|NCT05218161|DRUG|Dexmedetomidine alone|All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
215041898|NCT01659502|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
215041899|NCT06994416|DEVICE|novel fluorescent localization marker needle|novel fluorescent localization needle, which features a controllable shedding quantum dot chiral nanofluorescent coating
215041900|NCT06994416|DEVICE|conventional localization marker needle|conventional localization marker needle, without any coating
215041901|NCT00829998|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg, single-dose fasting
215041902|NCT00829998|DRUG|Sonata® 10 mg Capsules|1 x 10 mg, single-dose fasting
215041903|NCT03159988|DRUG|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
215041904|NCT03159988|BEHAVIORAL|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
215041905|NCT06459804|PROCEDURE|Electro Dry Needling|"Standard Physiotherapy:~It will include Hot pack (10 min), Stretching of levator scapulae (3 times with 30 seconds hold), Scapular stabilization exercises (10 times with 5 seconds hold).~Scapular Stabilization exercises will be comprised of four exercise programs. The participants will sit on the knees in 90° flexion position, and a Swiss ball will be propped up between the stomach and chest."
215041906|NCT06459804|PROCEDURE|Dry Needling|Dry Needling
214291520|NCT03598192|DRUG|Sufentanil|Sufentanil has been included in Arm/Group Descriptions
214291521|NCT06369194|PROCEDURE|Colorectal Surgery|Postoperative Audit
214291522|NCT04090840|BEHAVIORAL|Intermittent Fasting|Time restricted eating for 8 hours per day, with 16 hour fast. During the daily fast, patients are encouraged to drink water, black coffee, or green tea without sugar, cream, milk, or sweeteners.
214291523|NCT04464512|DRUG|Sufentanil|IV buprenorphine plus IV sufentanil treatment group.
214875716|NCT00339092|BEHAVIORAL|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
214875717|NCT06043687|DRUG|Dentifrice Paste|Scaling and Root planing followed by dentifrice usage
215041907|NCT00933478|DEVICE|Clay|Small dime sized piece of clay.
215041908|NCT05132296|BEHAVIORAL|Behavioral Intervention|Undergo behavioral counseling
214291524|NCT00840554|OTHER|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
214291525|NCT00840554|OTHER|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
214291526|NCT04719507|PROCEDURE|erector spinae block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.
214291527|NCT04719507|PROCEDURE|thoracic paravertebral block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.
214291528|NCT04719507|DRUG|Pethidine Only Product in Parenteral Dose Form|pethidine (1 mg/kg ) once
214291529|NCT01503281|OTHER|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
214291530|NCT01516320|PROCEDURE|Roux-en-Y Gastric Bypass|A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
214875718|NCT06060379|OTHER|GiochiAMO a 626|The subjects of the intervention group will play three different games: a role-playing game, a card game and a board game.
214875719|NCT00499421|PROCEDURE|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
214875720|NCT02612259|DIETARY_SUPPLEMENT|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
215041909|NCT05132296|OTHER|Best Practice|Receive usual care supportive services
215041910|NCT05132296|DEVICE|FitBit|Receive FitBit
215041911|NCT05132296|BEHAVIORAL|Nutrition Education|Receive nutrition education
215041912|NCT05132296|OTHER|Physical Activity|Undergo physical activity
215041913|NCT05132296|OTHER|Questionnaire Administration|Ancillary studies
215041914|NCT06996808|DEVICE|Bakri Baloon|Bakri Balloon Standard insertion and inflation as per hospital protocol following delivery.
215041915|NCT06996808|DEVICE|Celox gauze|Celox gauze will be placed intrauterine according to manufacturer instructions, post-vaginal or cesarean delivery. Duration and removal will follow standardized clinical guidelines
215041916|NCT06674902|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
214875721|NCT02612259|OTHER|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
214875722|NCT04962152|DRUG|Nalbuphine Sebacate or Sesame oil (placebo)|ultrasound-guided intramuscular injection after the induction of anesthesia immediately
215041917|NCT06675721|OTHER|Study Questionnaire|A survey questionnaire to assess factors related to vaccination adherence, including factors such as vaccine novelty, cost, and prior knowledge among vulnerable populations.
215041918|NCT06675201|BIOLOGICAL|neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)|"Experimental Group: Neoantigen Vaccine Combined with Immune Checkpoint Inhibitors (ICIs) Neoantigen Vaccine: Administered via subcutaneous injections at multiple sites, including bilateral axillary and bilateral inguinal regions. The initial phase consists of 5 injections during the first cycle, given at weeks 1, 2, 4, 6, and 8. Thereafter, the vaccine is administered once every 4 weeks, continuing for 1 year, or until disease progression, intolerable adverse events, or death from any cause.~ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.~Control Group: ICIs ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause."
215041919|NCT06998485|BEHAVIORAL|Arm Basis Training|This program is a systematic training regimen specifically designed to improve proximal motor control for patients with severe upper extremity hemiparesis. The core principles of the Arm Basis Training Program focus on rebuilding the fundamental capacity for specific and selective motor control before progressing to more complex motor patterns.
215041920|NCT06998615|OTHER|shoulder impingement group|"the Patients with shoulder impingement syndrome in this group had at least 3 out of the following 6 criteria 1) positive Neer's sign; 2) positive Hawkins' sign; 3) pain on active shoulder elevation in the scapular plane, 4) pain on the C5-C6 dermatome; 5) pain on palpation of the rotator cuff tendons and 6) pain with resisted isometric abduction."
214291531|NCT01516320|PROCEDURE|Laparoscopic adjustable gastric banding|A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
214291532|NCT01516320|PROCEDURE|Vertical Sleeve Gastrectomy|A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
214291533|NCT05390957|BEHAVIORAL|Acceptance Based Behavioural Therapy - Revised|The study intervention is a revised, updated version of a previously studied eight-module (8-week) online, acceptance-based behavioural therapy (ABBT) for chronic pain that was tailored specifically to a military, RCMP, and veteran population. The online treatment material is administered via the WebCAPSI Therapy program.
214291534|NCT04867850|OTHER|Usual Care|Individual clinicians will receive an automated weekly email detailing a weekly roster of their upcoming repeat-patient visits (Index Visit) with patients at high risk of 6-month mortality as determined by a validated machine learning prognostic algorithm. Clinicians will receive a HIPAA compliant text message on the morning of the appointment reminding them to consider a serious illness conversation with patients on the list.
214291535|NCT04867850|OTHER|Clinician Nudge|Clinicians will receive the usual care weekly email and text message described above under Usual Care. In addition, embedded in the weekly email, clinicians will receive performance feedback information detailing their documented SICs relative to those documented by peers.
214291536|NCT04867850|OTHER|Patient Nudge|Ahead of the Index Visit, high risk patients as identified by the prognostic algorithm will receive a nudge via personal text message and email consisting of a normalizing message prompting patients with a personalized link to a short electronic questionnaire on SIC topics.
214291537|NCT00714454|OTHER|APS Topical Lotion|
214291538|NCT00714454|OTHER|Placebo|
214291539|NCT00066950|DRUG|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
214875723|NCT03357653|DRUG|Losartan group|Losartan 50 mg daily
214875724|NCT03357653|DRUG|Placebo group|Placebo 1 pill daily
214291540|NCT00066950|DEVICE|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
214291541|NCT00369993|DRUG|fluticasone propionate/salmeterol|
214291542|NCT01411696|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
214291543|NCT05738161|DRUG|Magrolimab|Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
214291544|NCT05738161|DRUG|Cisplatin|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
214291545|NCT05738161|DRUG|Gemcitabine|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
214291546|NCT03864211|PROCEDURE|Thermal ablation|Radiofrequency ablation or microwave ablation is performed under CT or ultrasound guidance for one to five target lesions.
214291547|NCT03864211|DRUG|Toripalimab|"Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation."
214875725|NCT05147324|BEHAVIORAL|"MyPlan - Individualized Planned Eating Pattern"|Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating pattern adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal at least three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of the eating pattern is based on adherence according to logs and youth/guardian acceptability.
214875726|NCT03638414|OTHER|ePainQ questionnaire|This is a questionnaire which will be given to the intervention group about their perceptions of treatment. It will be online.
214875727|NCT01740050|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
215041921|NCT06998615|OTHER|normal subjects|the subjects in this group had no pain or disability in shoulder
215041922|NCT05946018|OTHER|Educational video on ergonomics|A 6-8 minute education video that includes information on why ergonomics is important and recommendations for how to arrange the operating room to reduce the risk of injury.
215041923|NCT05946018|OTHER|Verbal physical therapy coaching sessions|Physical therapy coaching sessions include a standard assessment with individualized instruction on range of motion, strength, endurance, and flexibility.
215041924|NCT06245434|BEHAVIORAL|Repeated behavioural assessment|"One CRS-R per visit~* 4 SECONDs~* Eye tracking during every clinical assessment~* Recording every 2-4h of the Glasgow Coma Score~* Recording every 2h of the temperature and pupillometer reactivity to light"
215041925|NCT06245434|BEHAVIORAL|Act-Pass paradigm|Before and after sedation withdrawal Assessment of infra-clinical response to an active paradigm (attention focalisation or diversion).
215041926|NCT06245434|BEHAVIORAL|Biological measures of circadian and monoamines biomarkers|Systematic urinary sampling every 2 hours for melatonin, cortisol and monoamines metabolites
215041927|NCT06245434|BEHAVIORAL|Transcriptomic and genomic analysis|Definition of the peripheral cellular clock by 2 transcriptomic measures Constitution of a genomic biobank to analyse the cofounding factors for circadian disruption and differential clinical recovery
215041928|NCT06245434|BEHAVIORAL|Polysomnography with concomitant environment recording|"One 48h polysomnography for the first visit~\+ 3\* 24h polysomnography for each visit Synchronised recordings of light, sound, activity in patients' rooms"
215041929|NCT06245434|BEHAVIORAL|Actimetry|Continuous recording of movements at the wrist during 7 days after sedation withdrawal
215041930|NCT06245434|BEHAVIORAL|Morphological MRI|Precise description of brain lesion by a 3T MRI within the 1st week after sedation withdrawal
215041931|NCT06245434|BEHAVIORAL|Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.|Video recording of spontaneous patients' movements in the bed and synchronized during 2h with high-density EEG.
215041932|NCT07003048|BEHAVIORAL|Singing, dancing in small groups and active listening to live music at the Berlin Philharmony building|"Pregnant women are invited from 12 gestational weeks onwards to participate in active and passive interventions following a protocol derived from our feasibility study. The following interventions take place:~LIVE GROUP~1. concerts customized for pregnant women by professionals. They talk before and in between the concerts about the meaning of the music with the study attendants. The sessions take around one hour.~2. workshops in singing led by professional coaches performed in small groups within the Philharmonic building involving pregnant women to actively learn melodies of songs which they can repeat at home on a daily basis.~3. workshops in dancing led by professional coaches performed in small groups within the Philharmonic building involving pregnant women to actively learn to move with music which they can repeat at home on a daily basis.~DIGITAL GROUP The described interventions are all digitalized with interviews encouraging the second group to participate from home."
215041933|NCT07002892|DRUG|Ozon treatment|Each patient will receive 2 ml 10 μg/ml ozon perineural injection into the median nerve under US guidance, for 1 session.
215041934|NCT07002892|DRUG|Steroid treatment|Each patient will receive 2 ml:(1 ml betamethasone dipropionate+1ml saline) perineural injection into the median nerve under US guidance, for 1 session.
215041935|NCT07002892|DRUG|Dextrose 5%|Each patient will receive 2 ml %5 dextrose perineural injection into the median nerve under US guidance, for 1 session.
215041936|NCT07004517|DIAGNOSTIC_TEST|peri-implant probing before and after crown removal|"Before removal of the prosthetic reconstruction:~* Measurement of PPD-1: The PPDs at 6 site were measured as the distance from the mucosal margin to the base of the peri-implant pocket.~* Measurement of BOP-1：Bleeding sites after gentle probing within 15s were recorded as BOP scores. A positive score (1 point) was recorded if bleeding was observed during either of probing assessment by two researchers.~After removal of the prosthetic reconstruction, PPD-2 and BOP-2 were recorded following the same protocol."
215041937|NCT07002970|OTHER|aerobic exercise program|All study group patients performed aerobic exercise on a treadmill. approved by the American College of Sports Medicine.
215041938|NCT07002970|OTHER|Mediterranean diet|received a Mediterranean diet for 12 weeks tailored according to patients caloric needs
215041939|NCT07003087|OTHER|Shoe's sole modification|Shoe's sole modification by insertion of supporting materials
215057580|NCT04431843|DIETARY_SUPPLEMENT|Spirulina maxima extract|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week
214291548|NCT03867929|OTHER|25-Hydroxy vitamin D|27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
214875728|NCT01740050|PROCEDURE|RYGB|
214875729|NCT01740050|PROCEDURE|LAGB|
214875730|NCT06050343|DRUG|Humulin® Regular|subcutaneous injection at a dose of 0.3 IU / kg
214875731|NCT06050343|DRUG|Rinsulin® R|subcutaneous injection at a dose of 0.3 IU / kg
215057581|NCT04431843|DIETARY_SUPPLEMENT|Placebo|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week
215057582|NCT03679949|DRUG|Oxycodone|Oxycodone, 2.5 mg
214875732|NCT01869855|PROCEDURE|Subdural Drainage|
214875733|NCT01869855|PROCEDURE|Subperiosteal Drainage|
214875734|NCT02965586|DRUG|intrathecal|intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
214875735|NCT05369312|DRUG|BPI-442096|Subjects will receive BPI-442096 until disease progression
214875736|NCT05924607|OTHER|Standard clamshells method|The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position
214875737|NCT05924607|OTHER|Targeted VMO strengthening|Targeted VMO strengthening The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
214875738|NCT00048737|DRUG|Zevalin Radioimmunotherapy|Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
214875739|NCT00048737|DRUG|Rituximab|250 mg/m\^2 on day 1 and day 8
214875740|NCT00048737|DRUG|Fludarabine|30 mg/m\^2/day for 3 days
214875741|NCT00048737|DRUG|Cyclophosphamide|750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
214875742|NCT00048737|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation 2 days after chemotherapy
214875743|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
214875744|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
214875745|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
214875746|NCT05738044|OTHER|No intervention|No intervention
214875747|NCT03486366|OTHER|non interventional trial|other
214875748|NCT02508129|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.
214875749|NCT02508129|BEHAVIORAL|Sleep Healthy Using the Internet|"SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure."
214875750|NCT02508129|BEHAVIORAL|Enhanced Usual Care|Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
214875751|NCT03190902|BEHAVIORAL|Attention Processing Training program (APT)|
214875752|NCT03190902|BEHAVIORAL|nonspecific computer training (n-ST)|
214875753|NCT02018575|DIETARY_SUPPLEMENT|Crystalline Lysine Amino Acid Mix|Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
214875754|NCT02018575|DIETARY_SUPPLEMENT|White corn meal porridge|A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
214875755|NCT06126341|OTHER|Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM|Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.
214875756|NCT06126341|BEHAVIORAL|Hospital Anxiety and Depression Scale|Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire
214875757|NCT06126341|BEHAVIORAL|Duke-UNC Functional Social Support Questionnaire|A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.
214875758|NCT06126341|BEHAVIORAL|Distress Thermometer|The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress
214875759|NCT06126341|BEHAVIORAL|FACT-BMT|The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains
214875760|NCT06126341|BEHAVIORAL|Psychosocial Assessments of Candidates for Transplantation|The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation
215041940|NCT07003971|BEHAVIORAL|counselling|After the participants in the experimental group signed the 'Informed Consent Form', the Instagram addresses actively used by the pregnant women participating in the study will be taken, the Instagram account created by the researcher will be shared with the pregnant women in the experimental group, the participants will be ensured to follow the Instagram address created by the researcher and join the Instagram DM group. After the participation to the platform is completed, the visibility of the participants in the account will be checked. After the visibility of all participants is ensured, pre-tests created in Google Forms and uploaded to WhatsApp and Instagram DM group will be applied.
214875761|NCT06974357|DIAGNOSTIC_TEST|Genetic testing|blood draws for genetic testing
214875762|NCT05360940|DIAGNOSTIC_TEST|H.pylori stool antigen rapid test and stool parasitological examination|200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done
214875763|NCT04384653|DRUG|Furosemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution for subcutaneous administration (80 mg)
214875764|NCT04384653|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration
214875765|NCT04384653|DEVICE|Medfusion 3500 (v6) precision infusion pump|Furosemide Injection Solution for subcutaneous administration (80 mg)
215057583|NCT03679949|DRUG|Cannabis (THC:CBD = ~ 1:0)|Cannabis with high THC concentration and negligible CBD concentrations
215057584|NCT03679949|DRUG|Cannabis (THC:CBD = ~ 0:1)|Cannabis with high CBD concentration and negligible THC concentrations
214875766|NCT06977867|DEVICE|Stress Ball|All hemodialysis patients who meet the inclusion criteria will be asked to squeeze a stress ball during their dialysis sessions (3 times a week for 1 month, totaling 12 sessions). Anxiety, comfort, and patient satisfaction levels will be assessed using three measurements: a pre-test before the intervention, a mid-test at the end of the 6th session (2nd week), and a post-test after the 12th session. Patients will be instructed to use the stress ball throughout their dialysis session. They will be asked to squeeze the ball for at least 10-15 minutes during each session.
214875767|NCT06977867|OTHER|standard care|The hemodialysis patients in the control group will not use the stress ball and will receive standard care throughout the study period. Similar to the intervention group, levels of anxiety, comfort, and patient satisfaction will be assessed at three time points: prior to the intervention (pre-test), at the end of the second week (after the 6th session), and at the end of the fourth week (post-test, after the 12th session).
214875768|NCT06654687|DEVICE|Transthoracic Echocardiography|Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output.
214875769|NCT06654687|DRUG|Ringer lactate 1000 ml|Patients will receive 1000 mL of Ringer's lactate solution over 15 minutes.
214875770|NCT06654687|DRUG|Albumin|Patients will receive 250 mL of human albumin 5% over 10 minutes
214875771|NCT06654687|DRUG|Ringer lactate 750 ml|Patients will receive 750 mL of Ringer's lactate solution over 15 minutes.
214875772|NCT06983444|PROCEDURE|TURP|Using bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH.
214875773|NCT06983444|PROCEDURE|TUEP|Using bipolar enucleation loop diathermy via cystoscopy, to anatomically enucleate prostate.
214875774|NCT06983457|COMBINATION_PRODUCT|Therapeutic ultrasound|Participants in Group A will receive therapeutic ultrasound (TUS) as the primary intervention for managing chronic heel spur pain. The TUS treatment will be administered using a frequency of 1 MHz, which is effective for targeting deeper tissues. The intensity will range from 0.8 to 2.0 W/cm², depending on patient tolerance, and will be applied in a continuous mode to maximize thermal effects. Each treatment session will last for 4 minutes, and Treatment sessions will be conducted daily Monday through Friday for a period of 2 weeks in a series of ten treatments. The TUS application will focus on the medial calcaneal tubercle and the surrounding inflamed soft tissues to reduce pain and promote tissue healing.
214875775|NCT06983457|COMBINATION_PRODUCT|Shockwave Therapy|Group B (Shockwave therapy) Participants in Group B will receive extracorporeal shockwave therapy to perform the shock wave treatments, an apparatus generating a shock wave in a pneumatic manner was used, i.e., BTL-5000 SWT POWER + HIGH INTENSITY LASER 12 - to perform the shock wave treatments, an apparatus generating a shock wave in a pneumatic manner was used. Before starting the procedure, each patient was informed about the principles of the shock wave action and the possibility of side effects. Each of the project participants underwent a series of 5 treatments at 7-day intervals.
214875776|NCT06982781|DEVICE|Flow Re-Direction Endoluminal Device System(FRED)|Flow Diverter (FD) devices are developed based on reconstructing the parent artery's lumen. FDs are designed with a denser mesh compared to conventional intracranial stents. By covering the aneurysm neck, these stents redirect blood flow away from the aneurysm, promoting intra-aneurysmal flow stagnation and subsequent thrombosis formation. Currently, FDs are primarily used for the treatment of wide-neck aneurysms.
214875777|NCT05604456|PROCEDURE|secondary ear reconstruction based on Nagata method|Secondary auricular reconstructions based on Nagata method were conducted on patients who sought for secondary revision.
214875778|NCT00896480|BIOLOGICAL|Immunotherapeutic GSK2132231A|Administration by intramuscular injection
214875779|NCT04492826|PROCEDURE|Postoperative infections rate|Assess the postoperative infection rate after otolaryngology bone flap surgery.
214875780|NCT03457935|OTHER|blood samples|Blood samples
214875781|NCT03580486|OTHER|The squares test|The squares test (ST) originally used in handedness is modified. The ST is a reliable, not time-consuming and easy to administer test for evaluated hand function.
214291549|NCT06147310|PROCEDURE|Study Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Alveolar ridge preservation with blood platelet concentrate: heat-treated albumin (Alb-PRF) and advanced platelet-rich fibrin. The experimental site will be filled with A-PRF plugs/membranes until level flushed with the level of bone. An additional Alb-PRF membrane will be tucked and inserted below the buccal and oral flap. Surgical flaps will not be raised. Soft tissue will be tunnelled and undermined for insertion of the Alb-PRF membrane. The extraction site and membranes will be stabilized by cross-mattress sutures and allowed for secondary intention healing.
214291550|NCT06147310|PROCEDURE|Control Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Cross mattress suture will be applied and site allowed to heal naturally.
214291551|NCT02890706|DEVICE|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
214291552|NCT03263442|DRUG|Thiamine|200 mg IV three times daily for seven days
214875782|NCT01478386|OTHER|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
214875783|NCT01478386|DEVICE|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
214875784|NCT01478386|DEVICE|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
214875785|NCT04220424|DIAGNOSTIC_TEST|MR and Histopathology images based prediction of molecular pathology and patient survival|MR and Histopathology images based prediction of molecular pathology and patient survival in gliomas by leverage artificial intelligence algorithms
214875786|NCT05183386|PROCEDURE|dental socket regeneration|after a dental extraction the fresh socket is filled with graft materials and compared with the spontaneous healing (control)
214875787|NCT03887312|BEHAVIORAL|t-CETA|Cognitive Behavioural Therapy (CBT) based approach delivered over the telephone. Components are available for common problems, including anxiety, depression, PTSD, conduct problems, substance abuse, and safety issues (including self-harm or suicidal ideation), and a tailored treatment package is produced for each child based on the presenting problem(s) and response to treatment. There are components for use with both child and caregiver.
215057585|NCT03679949|DRUG|Cannabis (THC:CBD = ~ 1:1)|Cannabis with equivalent CBD and THC concentrations
214291553|NCT03263442|DRUG|Normal saline|Normal saline IV three times daily for seven days
214291554|NCT04384666|DRUG|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)|LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
214875788|NCT03887312|BEHAVIORAL|Médecins du Monde treatment as usual|Case manager-led care, with referral to a psychotherapist or psychiatrist as necessary. Médecins du Monde's approach is based on a joint collaboration between mental health trained case managers (who undergo extensive training by experts in the field on topics including Psychological First Aid, Child Protection, Gender Based Violence, etc.) and psychotherapists from different schools (providing Eye Movement Desensitization and Reprocessing \[EMDR\] for trauma, Interpersonal Therapy \[IPT\] for depression, Cognitive Behavioural Therapy \[CBT\], motivational counselling, familial or systemic therapy, and integrative approaches). Thus the number and content of sessions, and the person delivering treatment (case manager, psychotherapist, psychiatrist) vary.
214875789|NCT01069874|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
214875790|NCT01069874|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
214875791|NCT06164093|OTHER|RNA sequencing is performed on the remaining LPCs|RNA sequencing is performed on the remaining LPCs previously transplanted back into the patients. And the results are analysed combined with the data from the previous clinical trial. (Please note that patients will not receive cell transplantation again as they have already received the treatment in the previous trial \[NCT03655808\])
214875792|NCT06164093|OTHER|Immunofluorescence staining is performed in the surgically resected lung tissue sections|The aim of this intervention is to detect Krt5 protein expression by staining the surgically resected lung tissue sections. This is done to confirm the presence of a small number of LPCs in the lung tissue of patients with bronchiectasis and to investigate their distribution.
214875793|NCT02012348|OTHER|Antibacterial soap with triclocarban|
215041941|NCT07003971|OTHER|Control|After the 'Informed Consent Form' is signed by the pregnant women in the control group, the telephone numbers of the participants will be taken and recorded in the directory. Participants will also be asked to save the researcher's phone number. After being registered in the phone book, questionnaires and scales will be shared via WhatsApp and asked to answer the pre-tests prepared in Google Forms. Pregnant women who answer will be asked to return with a WhatsApp message in the form of 'I answered' or 'I sent'. The control group will not be trained on Instagram, but will be provided with standardised medical care established by the Turkish Ministry of Health during the follow-up period.
215041942|NCT07004478|OTHER|Translating the Generic Functional Index into Turkish and Related Processes|The translation process will follow a specific protocol in accordance with the guidelines. It will include two independent forward translations and one back-translation, conducted after obtaining written permission from the original authors. Discrepancies between translations will be reviewed by an expert committee to resolve terminological and cultural differences. The process will ensure conceptual and cultural equivalence between the original English version and the Turkish version. The final version of the questionnaire will be adapted to the target population and finalized in consultation with the original authors.
215041943|NCT07004478|OTHER|Validity|Content validity will be calculated with the Content Validity Index, which is a result of expert opinions in terms of clarity, difficulty, and suitability of the Turkish version of the Generic Functional Index.
215041944|NCT07004478|OTHER|Internal consistency and Reliability|The internal consistency of the items will be tested with Cronbach alpha. Test-retest reliability will be tested with intraclass correlation coefficient.
215041945|NCT00834197|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose non-fasting
215041946|NCT00834197|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose non-fasting
215041947|NCT00840333|DRUG|MP-376 (Levofloxacin solution for Inhalation)|DOSE BASED ON PATIENTS WEIGHT
215041948|NCT06997107|OTHER|Health promotional messages generated by Artificial Intelligence|Short (850 characters) and long (1 page) messages will be generated by a Generative Artificial Intelligence (ChatGPT 4.0) on different health-related topics
215041949|NCT06997107|OTHER|Health promotional messages generated by humans|Short (850 characters) and long (1 page) messages will be generated by a primary care and/or public health human expert on different health-related topics
215041950|NCT06545617|DRUG|BAT8006 for Injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.
215041951|NCT05889507|PROCEDURE|Whole body hypothermia|Whole-body hypothermia (33.5±0.5°C) initiated within 6 hours of birth and continued for 72 hours. The rectal temperature will be maintained at 33.5±0.5°C using a servo-controlled cooling machine.
215041952|NCT05889507|PROCEDURE|Targeted normothermia|The axillary temperature will be maintained at 37±0.5°C for the first 80 hours and any hyperthermia will be treated with a standardised protocol.
215041953|NCT05889507|OTHER|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
215057586|NCT03679949|DRUG|Placebo|Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
215057587|NCT00000333|DRUG|Benztropine|
215057588|NCT05561647|OTHER|No Intervention|This is non-interventional study.
214875794|NCT02012348|OTHER|Antibacterial soap + benzalkonium chloride|
214875795|NCT02012348|OTHER|Control soap|
214875796|NCT05639075|OTHER|Peripheral vision|A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
214875797|NCT00818987|OTHER|Open reduction internal fixation; reduction and immobilization|
214875798|NCT03915509|DEVICE|Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis|Lasak Impladent Implants (sandblasted)
214291555|NCT04384666|OTHER|Neupro 4 mg / 24 Hr. Transdermal Patch|Neupro 4 mg /24 Hr. Transdermal Patch
214291556|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
214291557|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237 mL
214291558|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
214875799|NCT02760745|OTHER|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
214875800|NCT06983301|OTHER|Brief Cognitive Behavioural Therapy (CBT) for OCD|A brief 5-session CBT face-to-face intervention (therapist supported, involving workbooks) for adolescent Obsessive Compulsive Disorder (OCD). The brief CBT consists of 5 sessions of 60 to 90-minutes, with the option of 2 additional booster sessions (also 60 to 90 minutes), spanning a total of 24 weeks. The intervention includes home tasks, completion of regular routine outcome measures and participants listening to audio-recordings of the therapy sessions. The intervention sessions are delivered by routine child and adolescent mental health services (CAMHS) practitioners and take place in NHS and NHS-commissioned child and adolescent mental health services.
214875801|NCT06982001|BEHAVIORAL|Brachial line guided hemodynamic management|Anesthesiologists in charge of the patients will guide their hemodynamic management based on the monitoring of brachial/humeral arterial line, instead of the most frequently used radial line.
215041954|NCT05889507|DIAGNOSTIC_TEST|Follow up assessment at 2 years of age|The assessment will be carried out using the Bayley Scales of Infant and Toddler Development IV. In addition, all infants will have a detailed neurological examination, including Gross Motor Function Classification System (GMFCS) for cerebral palsy, vision, and hearing assessment. Babies who die or who cannot be assessed with the Bayley-IV due to severe disability will be allocated a Cognitive Scale Composite score one point below the basal test score. PARCA-R will be completed by the parents immediately.
214291559|NCT04387175|DEVICE|Carriere Motion 3D Class III Appliance|The device made of stainless steel consists of a flexible bar with two pads at the end which are bonded bilaterally with composite resin to the lower second deciduous molar or the lower first permanent molar at the rear and the lower deciduous canine at the front. The base on the lower deciduous canine has a hook to which bilaterally elastic latex bands are connected with the vestibular tubes of the cemented bands on the upper deciduous second molars (Force 2 elastics ) or on the first permanent upper molars (Force 1 elastics), on whose palatine surface the a rapid maxillary expander is welded.
214875802|NCT06982001|BEHAVIORAL|Radial line guided hemodynamic management|The anesthesiologist will guide their hemodynamic management on the classically used radial arterial line.
214875803|NCT06982001|DEVICE|Radial line catheterization|An arterial line will be inserted in the radial artery of the patient.
214875804|NCT06982001|DEVICE|Brachial line catheterization|An arterial line will be inserted in the brachial artery of the patient.
215041955|NCT05622942|BIOLOGICAL|PBPV|Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
215041956|NCT05622942|BIOLOGICAL|PPV23|Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
214291560|NCT04387175|DEVICE|Facial mask|The facial mask consists of a chin pad and frontal pad connected by a central steel bar. On the central bar there is a horizontal steel bar to which latex elastic bands are attached which develop 14 ounces of force. The elastics are connected to the rapid maxillary expander by means of two hooks welded on the bands of the second upper deciduous molars or the first upper permanent molars.
214875805|NCT06983067|DEVICE|Cornerstone C1000 Robotic Surgery System|Minimally invasive surgical instruments are controlled by the physician using a master-slave operating system for urologic laparoscopic surgical operations.
214875806|NCT06587217|DRUG|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
214875807|NCT06587217|DRUG|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
214875808|NCT05734014|BEHAVIORAL|Connectedness Activities|Indigenous Connectedness: Promoting respect, listening to elders, understanding Crow cultural values.
214875809|NCT06982170|DEVICE|A physical activity and reminiscence therapy|There were two parts in this study, one was co-design (participants co-designed the device) and the other was a pilot intervention. The two parts were iterative. In the interventional part, participants were asked to cycling the co-design rehabilitation bike and also did reminiscence or any cognitive therapy at the same time. The intervention session lasted at least 15 minutes, twice a week for 12 weeks.
214875810|NCT00860392|DRUG|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
214875811|NCT03553576|DRUG|Low volume bolus|Administration of a low-volume bolus (6.25 mL) of greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
214875812|NCT03553576|DRUG|High volume bolus|Administration of a high-volume bolus (10 mL) of lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
214875813|NCT06981871|OTHER|Evaluation of the gingival phenotype of the incisors in the upper and lower jaws|Assessment of gingival thickness (Kan et al 2015) and keratinised tissue height of the incisors with UNC-15 peridontal probe (Hu-Freidy, USA) and clinical photography.
214875814|NCT06982209|DEVICE|Analgesia/Nociception Index (ANI)|ANI was monitored using the ANI monitor (MetroDoloris, France) in both groups, but only guided adjustments in the ANI group
215041957|NCT06863753|OTHER|Kangoroo mother care|Kangaroo mother care will be practiced once, when the service, mother and baby are available, and then the training will be given. For skin-to-skin contact, the newborn will be laid naked on the mother's bare chest in the prone position, the newborn's abdomen and chest will be in contact with the mother's skin. Subsequently, the newborn's head will be turned to the side so that the airway remains open. The newborn will stay in this position for at least 45 minutes.
215041958|NCT06673498|DRUG|Lusutrombopag combined with recombinant human thrombopoietin|After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days
215041959|NCT06674174|OTHER|lower limb strength training|Experimental group will receive lower limb strength training treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
215041960|NCT06674174|OTHER|endurance training|Control group will receive endurance training, treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
214875815|NCT06989138|OTHER|Stabilitation Exercise|Patients will be included with the guidance of a physician specialized in the relevant field. After randomization, the patients included in the groups will be given 1 session of training before the start of treatment. In this training, soft orthosis use and home exercise programs will be explained to the patients in the intervention group. Soft orthoses; It will be explained that they should use for 10-12hours during the day for 4-6weeks, take them off during rest, sleep and exercise, and use them during active hours. Home exercise program; as in the classical approach, stretching and strengthening exercises will first be explained to the patient practically by the physiotherapist and then the patient will be asked to practice. Participants will be accompanied by a physiotherapist in the clinical environment 2 days a week for 10 weeks according to the groups they are divided into. Patients will be asked to practice the home exercise program taught in the training session 6 days a week.
214875816|NCT06989138|OTHER|Conventional Exercise|Patients will be included with the guidance of a physician specialized in the relevant field. After randomization, the patients included in the groups will be given 1 session of training before the start of treatment. In this training, soft orthosis use and home exercise programs will be explained to the patients in the intervention group. Soft orthoses; It will be explained that they should use for 10-12hours during the day for 4-6weeks, take them off during rest, sleep and exercise, and use them during active hours. Home exercise program; as in the classical approach, stretching and strengthening exercises will first be explained to the patient practically by the physiotherapist and then the patient will be asked to practice. Participants will be accompanied by a physiotherapist in the clinical environment 2 days a week for 10 weeks according to the groups they are divided into. Patients will be asked to practice the home exercise program taught in the training session 6 days a week.
214875817|NCT06989138|OTHER|Orthosis|Patients will be included with the guidance of a physician specialized in the relevant field. After randomization, the patients included in the groups will be given 1 session of training before the start of treatment. In this training, soft orthosis use and home exercise programs will be explained to the patients in the intervention group. Soft orthoses; It will be explained that they should use for 10-12hours during the day for 4-6weeks, take them off during rest, sleep and exercise, and use them during active hours.
214875818|NCT01413490|DRUG|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
214875819|NCT00771459|DRUG|Ropivacaine 0.5 %|Local infiltration analgesia
214875820|NCT00771459|DRUG|Isotonic NaCl|Local infiltration analgesia
214875821|NCT03263897|DEVICE|insufflation|mobile interface driven insufflation of the ear canal
215041961|NCT05790356|DRUG|Fecal Microbial transplant|Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.
215041962|NCT05790356|OTHER|Placebo capsules|The placebo capsules will not contain FMT but will have the same appearance.
215041963|NCT07004543|PROCEDURE|Standard Silicone Toe Separator Application|Participants will be instructed to wear standard, commercially available silicone toe separators during a single evaluation session. The intervention consists of applying the separators between the toes while the participant is barefoot, both in static standing and while walking on a treadmill equipped with a Zebris pressure analysis system. Measurements will be taken immediately before and after the application, including plantar pressure distribution, intermetatarsal spacing (via imaging), digital circulation (via thermography and visual assessment), foot posture (using the Foot Posture Index - FPI-6), and subjective comfort levels (via Visual Analog Scale). The toe separators are not customized and reflect common consumer-grade devices marketed for podiatric or wellness purposes.
215041964|NCT06681272|OTHER|Questionnaire|sleep quality assessment using the PROMIS (Patient-Reported Outcomes Measurement Information System) item Bank score
215041965|NCT06681272|OTHER|Questionnaire|assessment of emotional state using the Neuropathic Pain Symptom Inventory score (NPSI)
215041966|NCT06681272|OTHER|Questionnaire|To assess whether pain measured by a Numercial rating scale (NRS) predicts chronic postoperative pain.
215041967|NCT06623201|DRUG|aminolevulinic acid HCL (ALA)|Prior to ALA application, the areas will be cleaned with alcohol and debrided gently with prep tape. ALA will then be applied to each of the study lesions and allowed to incubate for 3 hours with occlusion prior to the PDT.
215041968|NCT06623201|DEVICE|BLU-U device model 4170E|Participants will be subjected to dose illumination with blue light (BLU-U Model 4170E) at a power fluence of 20 mW/cm2 for a total time of 16 minutes and 40 seconds (1,000 seconds). This will result in a total light delivery dose of 20 J/cm2.
215041969|NCT07004816|OTHER|Uncover mutation profiles|Uncover mutation profiles
215041970|NCT07003230|DIETARY_SUPPLEMENT|vegan and omnivorous diet|Participants underwent a 2-week omnivorous diet intervention, followed by a 2-week vegan diet intervention
215041971|NCT07003477|DIAGNOSTIC_TEST|Detection of peripheral blood biomarkers|Peripheral blood samples were collected from patients suffering from acute stroke. The concentration of the biomarker glial fibrillary acidic protein (GFAP) was then detected. This was aimed at differentiating between hemorrhagic stroke and non - hemorrhagic stroke. Time - concentration curves were constructed, thereby offering a novel potential approach for the rapid identification of stroke types within ambulances.
215041972|NCT07003828|DIAGNOSTIC_TEST|CEUS examinations|CEUS examinations were performed at three predetermined time points during each HD session: immediately before, 3 hours after HD initiation, and 15 minutes post-dialysis.
215041973|NCT06370208|DIETARY_SUPPLEMENT|Probiotic Bactoblis® EVOL (Streptococcus salivarius eK12)|Bactoblis® EVOL: containing one billion CFU of probiotic Streptococcus salivarius eK12
214670078|NCT02735317|DRUG|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
214875822|NCT03263897|DEVICE|placebo insufflation|mobile interface driven placebo insufflation of the ear canal
214875823|NCT00205803|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
214875824|NCT00205803|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
215041974|NCT03830398|DRUG|Paracetamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
215041975|NCT03830398|DRUG|Deksketoprofen trometamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
214875825|NCT00401986|DEVICE|Bronchial thermoplasty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
214875826|NCT06613347|OTHER|whitening maintenance|whitening maintenance regimen
214875827|NCT06613347|OTHER|whitening maintenance MW|maintenance MW
214875828|NCT06613347|OTHER|negative control|negative control
214875829|NCT05686473|BEHAVIORAL|Program of psychoeducation of parents and professionals|"The program consists of a standardized manual-based treatment package as an easily accessible treatment tool for use by professionals in the specialist health services, who have treatment responsibilities for children diagnosed with FASD in Norway.~The intervention program will last for about 2 months and includes eight sessions, including six digitally based, interactive psychoeducational sessions.~Topics will be:~1. General information about FASD~2. Intervention strategies in kindergartens/schools for children with FASD~3. Families living with FASD - activities of daily living~4. Self-regulatory deficits - how to cope~5. Executive functions in daily life~6. Social development in children with FASD~7. Guidance in social settings~8. Challenging behavior - what can be done"
214875830|NCT06616064|BEHAVIORAL|personalised feedback and brief motivational|personalised feedback and brief motivational
214875831|NCT06616064|OTHER|routine lifestyle advice|routine lifestyle advice
214875832|NCT06616064|OTHER|questionnaire CliniCAP|questionnaire CliniCAP
214875833|NCT06617169|DRUG|MNPR-101-PCTA-177Lu|MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.
214875834|NCT05656001|OTHER|Real-time functional magnetic resonance imaging Neurofeedback and Real-time Biofeedback|Participants will take part in three runs of real-time functional magnetic resonance imaging feedback (rt-fMRI-NF) training with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive biofeedback will take part in three runs of biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
215041976|NCT03830398|DRUG|Placebo|The investigators apply placebo during a week in preoperative room 45 min before ECT
215041977|NCT06675760|DEVICE|The intervention group|The intervention group received training through a mobile augmented reality application in the laboratory.
215041978|NCT07003308|PROCEDURE|Anterior White Line Advancement Surgery|This technique involves a skin incision at the eyelid crease, dissection through the orbicularis muscle to expose the tarsus, and proximal dissection in the pre-Müller-conjunctival plane to visualize the white line. A double-armed 5-0 absorbable suture is used to advance the white line to the anterior tarsal surface. Eyelid height and contour are assessed before final fixation. Skin closure is completed with a non-absorbable suture.
214875835|NCT05656001|OTHER|Sham functional magnetic resonance imaging neurofeedback and sham biofeedback|Participants will take part in three runs of sham neurofeedback with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive sham biofeedback will take part in three runs of sham biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
214875836|NCT06870968|BEHAVIORAL|Exercise Training|The Exercise Training will follow a progressive interval-based training program designed for youth with MS. Participants will engage in three weekly exercise sessions. Participants will be given access to links to live virtual structured exercise sessions. The sessions will be scheduled weekly in partnership with a coach. A trained fitness instructor will lead the participants in a 10-minute warm-up, followed by 30 minutes of interval training, and a 10-minute stretching and cool down activity. Intervals will progress in intensity over the course of the 20-week program and progression will be based on individualized target heart rate zones. The session will be delivered via a live feed in order to foster social support from the participants peers enrolled in the program. Participants will have the option of completing the class in real-time and make up classes will also be available through a repository of sessions accessible through links to the repository cloud.
215041979|NCT07003308|PROCEDURE|Posterior White Line Advancement Surgery|This conjunctival technique uses a traction suture and eyelid eversion to access the posterior surface of the eyelid. A conjunctival incision is made above the superior tarsal border, followed by dissection to expose the white line. A double-armed 5-0 absorbable suture is passed through the anterior tarsus and the white line, and tied after confirming adequate eyelid position. The conjunctiva is not sutured.
215041980|NCT07003373|DRUG|hormone replacement therapy (HRT) group|Estradiol valerate is initiated at 4 mg/day on day 2 of the menstrual cycle and is adjusted to 8 mg/day based on endometrial thickness. Once the endometrial thickness reaches ≥8 mm, progesterone supplementation is started (400 mg vaginal suppositories twice daily and 50 mg intramuscular injections daily) for 5 days before blastocyst transfer.
215041981|NCT07002931|PROCEDURE|khoury block graft|Bone blocks will be harvested from the retromolar area after measuring of the size required and measuring of the donor site anatomy. Piezoelectric device will be used to perform the graft osteotomy. The osteotomy lines will be connected and the graft will be mobilized using a bibeveled chisel and mallet. Sharp bony edges will be smoothened and the donor defect was packed with gelatin sponges. The bone block margins will be smoothened and separated into two thinner bone shells using titanium disk with copious saline irrigation. The blocks will be fixed into the recipient site buccally using at least two microscrews leaving a gap to be filled with bone graft. Particulate xenogenic bone graft will be mixed with the autogenous bone chips (50% Xenograft: 50% Autogenous graft) to fill the gap.
215057589|NCT02747147|DEVICE|TIVA blood collection device|the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
215041982|NCT07002931|PROCEDURE|urban sausage technique|: A resorbable pericardium membrane will be fixed with titanium pins on the lingual bone plate (2-3mm from the bone crest) and on the buccal bone plate allowing for packing of particulate mix of bone graft (50% Xenograft: 50% Autogenous graft). Overfilling of the graft will be respected to compensate for future resorption. The membrane will be stretched over the graft ensuring maximum immobilization of the graft.
215041983|NCT07002931|PROCEDURE|non resorbable membrane|A non-resorbable polytetrafluoroethylene (PTFE) membrane (Permamem membrane, Botiss Biomaterials, Germany) will be fixed with titanium tacks on the lingual bone plate (2-3mm from the bone crest) and on the buccal bone plate allowing for packing of particulate mix of bone graft (50% Xenograft: 50% Autogenous graft). Overfilling of the graft will be respected to compensate for future resorption.
214875837|NCT06870968|BEHAVIORAL|Mobility and Flexibility Training|The Mobility and Flexibility Training will be focused on improving mobility and flexibility through three times a week stretching and mobility program. A 5-minute warm up will be followed by a series of stretches and mobility patterns that will be repeated as a circuit four times. Each session will focus on a specific muscle group - upper body, lower body or core. The classes will be led by a fitness instructor in the same manner as the exercise intervention arm with a virtual link sent to the participants.
215041984|NCT07004582|PROCEDURE|HDR brachytherapy|High dose rate (HDR) brachytherapy for the treatment of high-risk or recurrent prostate cancer
214875838|NCT05697016|DRUG|Sivelestat Sodium for Injection|Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-\[2-\[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl\]amino-acetate tetrahydrate\]
214875839|NCT05697016|DRUG|The Placebo|Excipients used for the sivelestat sodium
214875840|NCT06680414|OTHER|Supportive Vaccine Communication Using Motivational Interviewing|Supportive Vaccine Communication using Motivational Interviewing will be administered to the pregnant mothers in the experimental group by the researcher. The training will take place in 3-part and 6-sessions, one week apart, and each session will last approximately 40 minutes. The training will be carried out as group training with 3-5 people. Data collection forms will be applied before and after the program.
214875841|NCT05038800|BIOLOGICAL|MK-0482|IV infusion
214875842|NCT06695572|DRUG|CKD-383|QD, PO
214875843|NCT06464432|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR); Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD) consisting of 4 therapeutic modules: 1. Emotion Regulation, 2, Self-concept, 3. Relationship Patterns, 4. Prolonged Exposure.
215041985|NCT07004582|DIAGNOSTIC_TEST|Diagnostic biopsy|Transperineal prostate biopsies guided with transrectal ultrasound for the diagnosis of (recurrent) prostate cancer
215041986|NCT06225206|BEHAVIORAL|donor-derived cell free DNA in liver|Determine the difference in age, gender, LFTs, IS regimen (tacrolimus/sirolimus/cyclosporin with mycophenolate mofetil (MMF) and /or prednisone) between patients who underwent liver transplant \<1 year PTX and \>1 year PTX
215041987|NCT06625372|DIETARY_SUPPLEMENT|SMOF lipid|The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.
215041988|NCT06625372|DIETARY_SUPPLEMENT|INTRALIPIDS|The Intralipid will be given to the patient as fat component of total parenteral nutrition.
215041989|NCT04701242|DRUG|Ezetimibe 10mg|comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
215041990|NCT00861549|DRUG|Phencynonate hydrochloride|2mg/tablet
215041991|NCT04712669|DRUG|rodatristat ethyl 300 mg tablet BID|rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care
215041992|NCT04712669|DRUG|rodatristat ethyl 600 mg BID|2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care
215041993|NCT04712669|DRUG|Placebo|2 matching placebo tablets on top of standard of care
215041994|NCT06623019|DIAGNOSTIC_TEST|Validation and reliability|As this is a cross-sectional validation study, there is no intervention.
215041995|NCT06698640|BEHAVIORAL|Automated SMS|Participants will receive automated SMS messages reminding them of their Well-Child Visits. These messages will be standardized and sent at intervals designed to prompt appointment attendance.
215041996|NCT06698640|BEHAVIORAL|Automated SMS + Scheduling Assistance|Participants will receive the same automated SMS messages as in Arm 2, but with the added component of proactive appointment scheduling assistance. This may include options for scheduling directly through the SMS platform or follow-up messages encouraging appointment setting.
215041997|NCT05578209|DEVICE|intermittent theta burst stimulation|stimulatory protocol
215041998|NCT02798003|OTHER|Functional magnetic resonance imaging (fMRI)|The food-cue elicited response in the reward-circuitry of the brain will be assessed by using fMRI. This technique is based on different magnetic properties of oxygenated and deoxygenated blood. Increased neuronal activity causes an increase in blood flow. Thereby, neuronal activity is indirectly reflected by changes in blood oxygenation level-dependent (BOLD) contrast.
215041999|NCT01821755|BEHAVIORAL|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
215042000|NCT04826237|DRUG|Statin|Oral dose to be taken with methylprednisolone
215042001|NCT04826237|DRUG|methylprednisolone|oral dose, standard of care
214875844|NCT02927977|OTHER|control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
214875845|NCT02927977|OTHER|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
215042002|NCT04826237|DRUG|dexamethasone|Drug for intratympanic administration
215042003|NCT04826237|DRUG|Placebo|Capsule the same as for statins but without statin
215042004|NCT02622035|BEHAVIORAL|Provision of information|Information about fruit and vegetable feeding for children framed in gain vs. loss manner
215042005|NCT02622035|BEHAVIORAL|Emotion induction|Film clip designed to induce anger or fear
215042006|NCT02622035|BEHAVIORAL|visual perceptual load|visual and interactivity-based load of virtual reality buffet environment
214875846|NCT04995692|BEHAVIORAL|Telehealth Education for Asthma Connecting Hospital and Home|TEACHH aims to provide educational support to families managing childhood asthma throughout the transition from hospital to home, and includes several core components: 1) Health literacy-informed inpatient teaching for child and caregiver including pictorial materials, hands-on demonstration, and use of teach-back/show-back techniques; 2) Facilitated identification of rescue and controller medications using color- and shape-coded medication labels and a pictorial asthma action plan; and 3) A pair of virtual follow-up visits after discharge to reinforce inpatient teaching and support families during the shift from acute exacerbation to preventive care management. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices, 2-4 days after discharge (first visit) and 3 weeks after discharge (second visit). All intervention activities will be completed within 1 month of discharge.
214875847|NCT04995692|BEHAVIORAL|Standard Care (SC) Comparison Group|Patients in the SC group will receive standard impatient management, including pre-recorded asthma education videos shown prior to discharge and the hospital action plan. PCP follow-up with be scheduled within a week of discharge. All SC measures will also be provided to subjects randomized to TEACHH.
214875848|NCT00017823|PROCEDURE|Acupressure|
214875849|NCT05185401|OTHER|Observational study|Retrospective data-analysis
214875850|NCT00612430|DRUG|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG \& 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data \& order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
214875851|NCT01104792|DRUG|Cariprazine|Cariprazine was supplied in capsules.
214875852|NCT01102374|DRUG|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
214875853|NCT01102374|DRUG|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
214875854|NCT01102374|DRUG|Placebo|Placebo monthly
214875855|NCT01102374|DIETARY_SUPPLEMENT|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
214875856|NCT02071849|DEVICE|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
214875857|NCT04703582|DIAGNOSTIC_TEST|Activated clotting time|Relationship between elongated baseline activated clotting time and comorbidity
214875858|NCT00937482|DRUG|cediranib maleate|Given orally
214875859|NCT00937482|RADIATION|whole-brain radiation therapy|Undergo whole-brain radiotherapy
214875860|NCT04619992|DEVICE|Currently marketed Hydrophillic Intermittent Catheter|Currently marketed Hollister standard with tip hydrophilic intermittent catheter
215042007|NCT01566240|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 (capped at 162mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 \& 36.
215042008|NCT01566240|DRUG|Carboplatin|Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, \& 36.
215042009|NCT01566240|RADIATION|Radiotherapy|Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
215042010|NCT01566240|DRUG|Cisplatin|Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
215042011|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine pattern diagnosis.
215042012|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine tongue diagnosis.
215042013|NCT04747288|DIAGNOSTIC_TEST|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
215042014|NCT04747288|DIAGNOSTIC_TEST|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
215042015|NCT04747288|DIAGNOSTIC_TEST|Ocular Surface Diseast Index (OSDI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).
215042016|NCT04747288|DIAGNOSTIC_TEST|EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
214875861|NCT04619992|DEVICE|Test Hydrophilic Intermittent Catheter|Hollister standard with tip hydrophilic intermittent catheter with design enhancements
214875862|NCT05710939|OTHER|exercises|
214875863|NCT03866720|OTHER|Carbohydrate rich breakfast|A porridge breakfast meal fed at a carbohydrate delivery rate of 7.3 mg/kJ of each participants resting metabolic rate.
214875864|NCT03866720|DIETARY_SUPPLEMENT|Whey protein enriched breakfast|A porridge breakfast meal in which 15 grams of whey protein is substituted in place of carbohydrate and a small portion of fat.
214875865|NCT02116959|DRUG|Melphalan|
214875866|NCT02116959|DRUG|Carboplatin|
214875867|NCT02116959|DRUG|Etoposide|
214875868|NCT02116959|DRUG|Vincristine|
214875869|NCT02148289|DIETARY_SUPPLEMENT|Nitrate rich beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
215042017|NCT04747288|DIAGNOSTIC_TEST|36-Item Short Form Survey (SF-36)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).
215057590|NCT01628068|DEVICE|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
214875870|NCT02148289|DIETARY_SUPPLEMENT|Nitrate free beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
214875871|NCT01190943|OTHER|Laboratory Biomarker Analysis|Correlative studies
214875872|NCT03559166|DRUG|BLD-2660|Randomized to active product or placebo
214875873|NCT01175031|OTHER|Manipulation of Positive Airway Pressure (PAP)|Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
214875874|NCT03852173|BEHAVIORAL|Wasserschulen|"Schools receive following materials and trainings:~* one training sessions for teachers (at the beginning of the intervention)~* refillable water bottles for each school student~* drying rack for water bottles for each classroom~* educational material for each class and for school events~* informational material for parents"
214875875|NCT06240520|DRUG|Panobinostat 20 MG Oral Capsule|Panobinostat 20mg will be administered once orally
214875876|NCT06240520|DRUG|Pyrimethamine 200mg Oral Tablet|Pyrimethamine 200mg will be administered once orally
214875877|NCT06240520|DRUG|Lenalidomide 25 MG Oral Capsule|Lenalidomide 25mg will be administered once orally
214875878|NCT06884215|OTHER|Mitopure Topical Formula 3|Topical skin cream containing Mitopure
214875879|NCT06884215|OTHER|Mitopure Topical Formula 4|Topical skin cream containing Mitopure
214875880|NCT03457155|OTHER|VS-I dosing in plasma samples|"VS-I dosing in plasma samples using ELISA protocol :~* At intensive care admission time~* 24h after admission time~* In case of FA occurrence~* In case of sinusal rhythm recovery (in patients with new onset FA)"
215042018|NCT03693495|DIAGNOSTIC_TEST|ellume·lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.
215042019|NCT03693495|DIAGNOSTIC_TEST|Bacterial Culture|Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.
215042020|NCT03693495|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR)|Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
214291561|NCT04445324|BEHAVIORAL|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
214875881|NCT03911518|PROCEDURE|Loop drainage|Loop drainage will occur via 2 small incisions, approximately 2 cm, with the cuff from the base of a sterile glove pulled through and then tied off.
214875882|NCT03911518|PROCEDURE|Incision and drainage|The wound will be incised with a #11 blade scalpel along the point of maximal fluctuance, approximately 2-3 cm, and then all loculations bluntly dissected with a set of Kelly clamps. After drainage of pus, the wound will be loosely packed with gauze.
214875883|NCT00555360|BEHAVIORAL|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
214875884|NCT00555360|BEHAVIORAL|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
214875885|NCT06367491|OTHER|Registration in a database|All patients with bone metastasis enrolled at the centre will be entered into the database and followed until death or interruption of follow-up for any another cause
214875886|NCT00792363|DRUG|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
214875887|NCT00792363|DRUG|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
214875888|NCT04164914|DIETARY_SUPPLEMENT|Prebiotic|Soluble prebiotic fiber (resistant dextrin 14 g/d x 4 weeks)
214875889|NCT03301623|OTHER|Clinical Decision Support|The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.
214875890|NCT03301623|OTHER|Patient Education and Activation Tools|"The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication)."
214875891|NCT00658021|DRUG|Placebo|Subcutaneous injection, twice a day
214875892|NCT00658021|DRUG|Exenatide|Subcutaneous injection, 5 µg, twice a day
214875893|NCT00658021|DRUG|Exenatide|Subcutaneous injection,10 µg, twice a day
214875894|NCT04544501|BEHAVIORAL|Culturally-Targeted Video|"Culturally targeted narrative video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. With R03 funding (R03CA191543) we developed a culturally targeted narrative video for at-risk Latinas. A multidisciplinary team of researchers collaborated with filmmakers to develop the script and video. The script was informed by health behavior conceptual models, evidence-based risk communication strategies, and formative research (40 interviews with providers and at-risk Latinas). The script addressed identified knowledge gaps (e.g., incorrect belief that pap smears screen for ovarian cancer), facilitators (e.g., inform family cancer risk), barriers (e.g., emotional concerns), and cultural factors (e.g., respect). The 18-minute video illustrates the GCRA process with the story of Rosa, a Latina cancer survivor at increased risk of HBOC. Rosa learns about HBOC risk factors, overcomes barriers, and attends genetic counseling."
215042021|NCT03929003|BEHAVIORAL|Inspired|The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
214875895|NCT04544501|OTHER|FORCE Fact Sheet|A publically available Spanish-language fact sheet about HBOC and GCRA developed by FORCE.
214875896|NCT00003920|BIOLOGICAL|filgrastim|
214875897|NCT00003920|DRUG|cyclosporine|
214875898|NCT00003920|PROCEDURE|peripheral blood stem cell transplantation|
214875899|NCT00003920|RADIATION|indium In 111 monoclonal antibody m170|
214875900|NCT00003920|RADIATION|yttrium Y 90 monoclonal antibody m170|
214875901|NCT01058460|PROCEDURE|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
214875902|NCT04197427|DEVICE|Experimental Oral Rinse|Experimental Oral Rinse is a proprietary formulation of GRAS ingredients
214875903|NCT04197427|DEVICE|Placebo|Placebo formulation without the active ingredients
214875904|NCT03449927|OTHER|Specialized menu|-Specialized menu that will guide participant food choices if the participant experiences nausea or diarrhea
214875905|NCT03449927|OTHER|Standard of care menu|-Standard registered dietitian support
214875906|NCT03449927|OTHER|Self report dietary intake worksheet|-Self report nausea and diarrhea
214875907|NCT03449927|OTHER|Post study questionnaire|-Completed upon count recovery and prior to discharge
215042022|NCT01819272|DRUG|Met DR|metformin delayed-release tablets
214670079|NCT02735317|DRUG|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
214670080|NCT05523726|BEHAVIORAL|pCBT-I|Telehealth coaching
214875908|NCT00393965|DRUG|MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
214875909|NCT03756467|BEHAVIORAL|Girl Empower Program|Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
214875910|NCT06490614|DRUG|Dexmedetomidine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
214875911|NCT06490614|DRUG|Nalbuphine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, 10 mg of Nalbuphine (nalufin 20mg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
215042023|NCT01819272|DRUG|Met XR|metformin extended-release tablets
215042024|NCT01819272|DRUG|Placebo|placebo delayed-release tablets
215042025|NCT06028828|DRUG|Fludarabine|Given Day-5, Day-4, Day-3, Day-2
215042026|NCT06028828|DRUG|Melphalan|Given Day-5
215042027|NCT06028828|RADIATION|Total Body Irradiation|Given Day-1
215042028|NCT02868424|DRUG|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
215042029|NCT03291132|OTHER|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
215042030|NCT02207543|OTHER|Medical telephone contact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
215042031|NCT02225652|DRUG|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
215042032|NCT05731271|DRUG|TST003|IV humanized anti-GREM1 monoclonal antibody
215042033|NCT03801512|OTHER|Steroid|Triamcinolone 1pc + lidocaine 1% 1cc inject at neuritis nerve roots
215042034|NCT03801512|OTHER|Acupuncture|1.5 inch acupuncture needles insert at acupoints BL23, BL24, BL25 and BL26
215042035|NCT03801512|OTHER|Platelet Rich Plasma|Inject investigators Platelet Rich Plasma at neuritis nerve roots
215042036|NCT06563960|OTHER|carbonated water|Participants will drink carbonated water during videofluoroscopy.
215042037|NCT00503984|DRUG|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
215042038|NCT00503984|DRUG|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
215042039|NCT00503984|DRUG|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
214875912|NCT06303479|OTHER|Non-Instrumental breathing exercise group|Before starting the exercises, participants will be told about diaphragmatic breathing exercises, maximum inspiratory holding technique and thoracic expansion exercises through the Zoom program by telerehabilitation method, and people will be checked by the physiotherapist who manages the program during the practice. The program will last for 8 weeks and will be planned to be implemented 5 days a week in total, including 2 days of telerehabilitation, 3 days of home program. The participant will be asked to start the exercises in a reclining position with his back to the chair. He will be asked to place his right hand on his upper abdomen and his left hand on the upper side of his chest. In each session, the exercises will be performed with 1 set of 10 repetitions for each of the diaphragmatic breathing and thoracic expansion exercises and will progress with progression.
214875913|NCT06303479|OTHER|Instrumental breathing exercise group|The volume-oriented spirometer works with pressure and its indicator changes during breathing. When the participants breathe, the pressure in the tube decreases and the piston of the spirometer rises. The inhaled breath volume is seen at the top of the piston. In our study, participants will be told about the exercises through the Zoom program using the telerehabilitation method, and people will be checked by the responsible physiotherapist who manages the program during the application. The program will last for 8 weeks, 2 days of telerehabilitation, 3 days of home program will be planned to be implemented 5 days a week in total. Participants will be instructed to breathe up to their total lung capacity and maintain continuous inspiration for at least 3 seconds. The exercises will start with 1 set of 15 repetitions and the program will progress with progression.
214875914|NCT04808466|DRUG|Paclitaxel|Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
214875915|NCT04808466|DRUG|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
214875916|NCT04885465|BEHAVIORAL|web-based psychoeducational support|Caregivers in the experimental group will have access to psycho-educational support through a web-based plattform during 3 months.
215042040|NCT00503984|GENETIC|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
215042041|NCT00503984|DRUG|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
215042042|NCT00503984|DRUG|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
215042043|NCT02282748|OTHER|No intervention|
215042044|NCT00754884|DRUG|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
215042045|NCT00754884|DRUG|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
215042046|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
215042047|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
215042048|NCT01246960|BIOLOGICAL|Ramucirumab|Administered intravenously
215042049|NCT01246960|DRUG|Placebo|Administered intravenously
215042050|NCT01246960|DRUG|Oxaliplatin|Administered intravenously
215042051|NCT01246960|DRUG|Leucovorin|Administered intravenously
215042052|NCT01246960|DRUG|5-Fluorouracil|Administered intravenously
215042053|NCT05809947|OTHER|Neuromuscular electrical stimulation|One bout of neuromuscular electrical stimulation in conjunction with forced lengthening contractions on one leg
215042054|NCT00716820|DRUG|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
215042055|NCT04324281|OTHER|Investigation|cadaveric dissection
215042056|NCT00886730|BEHAVIORAL|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
215042057|NCT00886730|BEHAVIORAL|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
215042058|NCT00886730|BEHAVIORAL|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
215042059|NCT02267434|BIOLOGICAL|Low dose AFFITOPE® PD03A + Adjuvant|s.c. injection
215042060|NCT02267434|BIOLOGICAL|High dose AFFITOPE® PD03A + Adjuvant|s.c. injection
215042061|NCT02267434|BIOLOGICAL|Adjuvant without active component|s.c. injection
215042062|NCT02022709|DRUG|Fluoxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
214670081|NCT04050501|DEVICE|non-invasive Vagus Nerve Stimulator|Two stimulations of two minutes each will be applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The stimulation side in the neck will be the radiological side of the stroke.
214875917|NCT06405282|OTHER|Manual Lymphatic Drainage|MLD is a gentle manual technique used to decongest swollen areas and redirect lymphatic flow to non-congested areas
214875918|NCT06405282|DEVICE|Near infrared spectroscopy|Oxygen saturation measurement
214875919|NCT06405282|DEVICE|Temperature|Thermal imaging
215042063|NCT02022709|DRUG|Sertraline|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
215042064|NCT02022709|DRUG|Paroxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
215042065|NCT02022709|DRUG|Citalopram|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
215042066|NCT02022709|DRUG|Fluvoxamine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
215042067|NCT02022709|BEHAVIORAL|Exposure and Response Prevention|8 exposure and response prevention (ERP) sessions,once a week
215042068|NCT00445094|DRUG|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
215042069|NCT00445094|DRUG|Comparator: amikacin / Duration of Treatment: 3 Days|
215042070|NCT00445094|DRUG|Comparator: tazocin / Duration of Treatment: 3 Days|
215042071|NCT00445094|DRUG|Comparator: vancomycin / Duration of Treatment: 3 Days|
215042072|NCT03789981|GENETIC|Immunogenic profile|RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling
215042073|NCT00003873|DRUG|fluorouracil|Given IV or orally
215042074|NCT00003873|DRUG|eniluracil|Given orally
214875920|NCT06405282|DEVICE|Tissue Dialectic Constant|TDC captured by lymphatic fluid scanning device
214875921|NCT06311162|BEHAVIORAL|Life-Style app|The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
215042075|NCT03583229|DRUG|Aspirin 75mg|7 days treatment with 75 mg aspirin daily.
215042076|NCT03583229|OTHER|Extracorporeal photopheresis|4 x ECP treatments in 60 days.
215042077|NCT06405386|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
215042078|NCT06405386|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
214875922|NCT06311162|OTHER|Sham Comparator|The parents get a flyer with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.
214875923|NCT02015429|DIETARY_SUPPLEMENT|Pasta meal with added fractions or control with no fractions|
214875924|NCT06050473|PROCEDURE|Nerve-sacrificing procedure|Surgical fixation of the clavicle fracture will be performed through a horizontal incision over the clavicle. During the incision and soft tissue dissection, the surgeon will not attempt to identify the supraclavicular nerve branches. Instead, the surgeon will cut the nerve branches during the dissection.
214875925|NCT06050473|PROCEDURE|Nerve preserving procedure|Surgical fixation of the clavicle fracture will be performed through the same horizontal incision over the clavicle. The surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
215042079|NCT00693550|OTHER|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
215042080|NCT06564662|DEVICE|Rapid Response EEG|The Ceribell(R) Rapid Response EEG is a relatively new device that is becoming standard of care in the adult critical care. In this pediatric study the device will be placed by trained ICU physicians
215042081|NCT04779099|BEHAVIORAL|Brief 4-session intervention for borderline personality disorder|Intervention consists of weekly 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support. This intervention is detailed in a published manual.
215042082|NCT04779099|BEHAVIORAL|Treatment as usual|TAU comprises access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
215042083|NCT05345483|DEVICE|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter
214875926|NCT06884852|DRUG|Erector spinae plane block (ESPB)|"Erector spinae plane block (ESPB) using multilevel injections of bupivacaine 0.25%.~We will inject 15ml at the level of T2 and 15ml at the level of T5."
214875927|NCT06884852|DRUG|Thoracic epidural block|Thoracic epidural block at level of T5 -T6 using 10 ml of bupivacaine 0.25% as a bolus followed by 5 ml bupivacaine 0.25% every 1-2 hours depending on the duration of surgery and the response of the patient.
214875928|NCT03577548|OTHER|Auto- questionnaires|10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).
214875929|NCT01205386|DEVICE|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
214875930|NCT01498731|BEHAVIORAL|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
214875931|NCT01830491|DRUG|Clopidogrel|
214875932|NCT01830491|DRUG|aspirin 100mg|
214875933|NCT02067273|DEVICE|Transcranial Magnetic Stimulation (TMS)|
214875934|NCT02092467|DRUG|tofacitinib|Oral tablet, 5 mg BID
214875935|NCT02092467|DRUG|tofacitinib|Oral tablet, 10 mg BID
214875936|NCT02092467|BIOLOGICAL|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
214875937|NCT02092467|BIOLOGICAL|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
214875938|NCT00151112|PROCEDURE|Positioning and plexus anesthesia|positioning during plexus anesthesia
214875939|NCT01595386|DRUG|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
214875940|NCT01595386|DRUG|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
214875941|NCT03321838|BEHAVIORAL|accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
214875942|NCT05778487|DIETARY_SUPPLEMENT|Gatorade Thirst Quencher|Gatorade Thirst Quencher, 710ml (45g of carbohydrates, 6.3% carbohydrates, 25.4kcal/100ml)
214875943|NCT01831401|PROCEDURE|Operating table position 0° head down (Horizontal)|
214875944|NCT01831401|PROCEDURE|Operating table position 7° head down.|
214476859|NCT06815133|DRUG|Zilbrysq|Zilbrysq is a medicine used to treat generalized myasthenia gravis anti-AChR (a disease that leads to muscle weakness and tiredness) in adults whose immune system produces antibodies against a protein called the acetylcholine receptor. It is given as a subcutaneous injection (under the skin) once daily in a prefilled syringe that can be self-injected, and the dose depends on the patient's body weight. There are 3 available doses: 16.6 mg/0.416 mL for patients weighing less than 56 kg (123 lbs); 23 mg/0.574 mL for patients between 56 kg and less than 77 kg (123-170 lbs); and 32.4 mg/0.81 mL for patients weighing 77 kg and above (\>170 lbs). This can be injected into the abdomen, front of the thighs, and back of the upper arms (only if administered by a caregiver),
214875945|NCT01831401|PROCEDURE|Operating table position Y° head down|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
214875946|NCT01831401|DEVICE|Standard straight acetabular component introducer without alignment guide.|
214875947|NCT01831401|DEVICE|Modified 35° acetabular component introducer.|
214875948|NCT01831401|DEVICE|Inclinometer-assisted acetabular component introducer.|
214875949|NCT03579927|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
214875950|NCT03579927|DRUG|Carmustine|Given IV
214875951|NCT03579927|DRUG|Cytarabine|Given IV
214875952|NCT03579927|DRUG|Etoposide|Given IV
214875953|NCT03579927|BIOLOGICAL|Filgrastim|Given SC
214875954|NCT03579927|DRUG|Melphalan|Given IV
214875955|NCT03579927|BIOLOGICAL|Rituximab|Given IV
214875956|NCT03579927|BIOLOGICAL|Umbilical Cord Blood-derived Natural Killer Cells|Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
214875957|NCT01119794|DRUG|Ofatumumab and Bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
214875958|NCT05458180|DRUG|Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)|"Drug: Liposomal mitoxantrone hydrochloride (15 mg/m2, 18 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.~Drug: Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3 of each 21-day cycle.~Drug: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle."
214875959|NCT04180631|DIAGNOSTIC_TEST|Quantitative ultrasound imaging parameter (QUS)|Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
214875960|NCT02167373|OTHER|Cogito Companion Intervention|
214875961|NCT02167373|DEVICE|mobile phone application|
214875962|NCT05527574|OTHER|Resistance Exercise|Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months
214875963|NCT01147263|OTHER|Evaluation of autonomic parameters|Physical examination, ECG, Loop recorder, Heart rate variability evaluation
214875964|NCT04175535|PROCEDURE|Percutaneous Posterior Endoscopic Cervical Discectomy|The most common alternative in the case of soft cervical disc herniations.
214875965|NCT04175535|PROCEDURE|Anterior cervical decompression and fusion|The standard procedure for operation of cervical disc herniations.
214875966|NCT03869086|OTHER|Freeze dried blueberry powder|36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
215042084|NCT03326245|DRUG|Methylphenidate Pill|Oral methylphenidate (60 mg) given 30 minutes prior to bolus \[11C\]raclopride
215042085|NCT03326245|DRUG|Oral Placebo|Oral PL will be given 30 minutes prior to bolus \[11C\]raclopride injection
215042086|NCT03326245|DRUG|Intravenous Placebo|Intravenous Placebo given 30 minutes post bolus injection of \[11C\]raclopride.
215042087|NCT03326245|DRUG|Intravenous methylphenidate|Intravenous methylphenidate 0.25 mg/kg in 3ml sterile saline given 30 minutes post bolus injection of \[11C\]raclopride.
215042088|NCT01144000|DRUG|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
215042089|NCT05716945|DRUG|Fluorometholone 0.1% Oph Susp|"Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily."
214875967|NCT03869086|OTHER|Anthocyanin free, sugar-matched placebo|36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
214875968|NCT05259995|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
214875969|NCT05201196|OTHER|Conventional physical therapy|Targeted muscle stretching and Strengthening (flexors, Extensors, abductors, internal and external rotators, of Shoulder, Elbow, forearm (supination \& pronation) and hand 10 repetitions×1 set, 4 days/ week. Transcutaneous Electrical nerve Stimulation for 10-20 min, 4 days/ week. Total of 16 sessions were given each consisting of 45 mins.
214875970|NCT05201196|OTHER|Task Oriented Training|"Experimental group was given Task oriented protocol including activities such as Table-top polishing, Arm cradling, Reach forward and pick-up or touch an object, Reached sideway to pick-up an object and transferring it to a table in front, Pouring~½ cup of water from a measuring pot into wide mouth glass held in opposite hand, Picking up pen from thumb and first two fingers, lifting a basket and placing it on the table 10 repetitions×1 set for each activity, 4-5days/week. Total of 16 sessions were given each consisting of 45 mins"
214875971|NCT04689555|PROCEDURE|Novel method without manual compression|Novel method for femoral artery hemostasis without manual compression. After sheath removal, four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
214875972|NCT04689555|PROCEDURE|Standard method with manual compression.|Standard method for femoral artery hemostasis with manual compression.After sheath removal, manual compression was continued for at least 10 minutes or until hemostasis. After that four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
214875973|NCT04013984|OTHER|Accupuncture|In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons
214875974|NCT00005614|DRUG|Gemcitabine hydrochloride|Gemcitabine via IV
214875975|NCT00000535|BEHAVIORAL|diet, reducing|
214875976|NCT00000535|BEHAVIORAL|diet, sodium-restricted|
214875977|NCT02906566|DRUG|Retinol|Retinol in the form of vitamin A lotion
215042090|NCT05716945|DRUG|Dexamethasone 0.1% ophthalmic suspension|Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
215042091|NCT05716945|OTHER|Stop steroids|Half the patients in each study arm will discontinue steroids.
215042092|NCT00772759|DRUG|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
214875978|NCT02906566|DRUG|Placebo|Placebo of Retinol
214875979|NCT04320121|DIETARY_SUPPLEMENT|Nelutri™|Nelutri™ 2,000 mg/day for 12 weeks
214875980|NCT04320121|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
214476860|NCT05830201|BEHAVIORAL|No Dog Present|Dog is not present during pin removal
214875981|NCT04320654|OTHER|exercise|The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
214875982|NCT01835054|OTHER|Blood biomarkers|Observational Study using Imaging and Biomarkers
214875983|NCT01835054|GENETIC|DNA collection|Observational Study using Imaging and Biomarkers
215042093|NCT00772759|DRUG|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
215042094|NCT06426979|DRUG|Methotrexate|Methotrexate 25 mg/ml was given as single-dose of intramuscular (IM) injection in a dose of 50 mg/m2.
215042095|NCT06426979|DRUG|Letrozole|FEMARA 2.5 mg tablets two tablets daily
215042096|NCT00140140|DRUG|ABI-007|Weekly intravenous infusions over 30 minutes.
215042097|NCT00140140|DRUG|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
215042098|NCT00140140|DRUG|Trastuzumab|"Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor."
215057591|NCT03160456|DEVICE|Transcutaneous electrical stimulation|The device needs to be started by pressing the 'on' button. Once the device is turned on the current intensity can be increased by pushing the '+' button and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the 'off' button.
214476861|NCT05830201|BEHAVIORAL|Dog is Present|Dog is present during pin removal
215042099|NCT00140140|BIOLOGICAL|G-CSF|"During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was \>20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor."
214875984|NCT01835054|OTHER|Echocardiography|Observational Study using Imaging and Biomarkers
214875985|NCT01835054|OTHER|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
214875986|NCT01835054|OTHER|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
214875987|NCT01835054|OTHER|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
214875988|NCT01835054|OTHER|Holter ECG|Observational Study using Imaging and Biomarkers
214875989|NCT02761005|DRUG|Eradication of H. pylori|For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
215042100|NCT01761578|DEVICE|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
215042101|NCT03376516|DRUG|Wilate|von Willebrand factor / Factor VIII (plasma derived)
215042102|NCT01216488|DRUG|Xylocaine|40 ml or 25 ml of Xylocaine injection
215042103|NCT01359956|DRUG|Dacarbazine|900 mg / m2 every 3 weeks
215042104|NCT01359956|DRUG|Fotemustine|100 mg / m2 every 3 weeks
215042105|NCT01359956|DRUG|Interferon Alfa-2b|5 M units every 3 weeks
215042106|NCT03968874|DEVICE|Light box therapy|The intervention is sitting in front of a lightbox for 1 hour in the morning upon waking up.
215042107|NCT03968874|DEVICE|Negative Ion Generator|The intervention is sitting in front of a modified negative ion generator for 1 hour in the morning upon waking up.
215042108|NCT05123326|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM/ Sonoclot tests will be done in all patients at enrolment and after initiating anticoagulation in those who are eligible for the same.
215042109|NCT05123326|DIAGNOSTIC_TEST|Genetic tests for Thrombophilia|Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.
215042110|NCT05123326|DIAGNOSTIC_TEST|ELISA tests/ Functional assays|Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays
215042111|NCT06544044|BEHAVIORAL|Brief Mindfulness' Self compassion|session includes mindfulness exercises like breath awareness and body scans, self-compassion practices like self-kindness meditations, and emotional regulation strategies such as cognitive reappraisal and response modulation. Discussions focus on applying mindfulness and self-compassion to manage difficult emotions, improve interpersonal interactions, and reduce aggression. Home practice assignments encourage students to integrate mindfulness and self-compassion into their daily lives. The program curriculum is based on existing evidence-based interventions, including mindfulness-based stress reduction for teens.
215042112|NCT04236999|BEHAVIORAL|Yo Sé Lo Que Quiero (YSLQQ)|"This program is organized in 12 sessions around three themes:~* Knowledge and attitudes (sessions 1, 3, 5 and 9): Students reflect on their knowledge of legal and illegal drugs, using critical thinking to obtain an objective assessment of this knowledge.~* Intrapersonal skills (sessions 4, 6, 8, 10. 11. and 12): Activities are carried out where students can put themselves in everyday situations and develop skills such as assertiveness, problem solving, among others.~* Interpersonal skills (sessions 2 and 7): Students are instructed to practice refusal skills, assertiveness, and analyze coping strategies."
215042113|NCT05544253|PROCEDURE|mitomycin C-based hyperthermic intraperitoneal chemotherapy|The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
215042114|NCT04551300|DRUG|VS-505|4 dosages of experimental drug
214875990|NCT02952898|DRUG|GDC 695|GDC 695 is a topical gel.
215042115|NCT04551300|DRUG|Sevelamer Carbonate|Active Comparator
214875991|NCT02952898|DRUG|Diclofenac Sodium Gel, 3%|Diclofenac sodium gel, 3% is an FDA-approved drug.
214875992|NCT02952898|DRUG|Vehicle gel|Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
214875993|NCT02868645|BIOLOGICAL|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
214875994|NCT02297698|BIOLOGICAL|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
214875995|NCT02297698|DRUG|Trastuzumab|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
215042116|NCT01784029|DRUG|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
214476862|NCT06807827|BEHAVIORAL|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
214875996|NCT02297698|DRUG|GM-CSF|For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
214875997|NCT00000212|DRUG|Desipramine|
214875998|NCT03252912|BIOLOGICAL|blood samples|Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
214875999|NCT02864810|DRUG|[18F]GP1|\[18F\]GP1 PET/CT imaging for detecting thromboembolism
214876000|NCT00255710|BIOLOGICAL|filgrastim|
214876001|NCT00255710|DRUG|cyclophosphamide|
214876002|NCT00255710|DRUG|fludarabine phosphate|
214876003|NCT00255710|DRUG|mycophenolate mofetil|
214876004|NCT00255710|DRUG|tacrolimus|
214876005|NCT00255710|PROCEDURE|allogeneic bone marrow transplantation|
214876006|NCT00255710|PROCEDURE|peripheral blood stem cell transplantation|
214876007|NCT00255710|RADIATION|radiation therapy|
214876008|NCT00399880|BEHAVIORAL|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
214876009|NCT00007527|DRUG|naloxone|
214876010|NCT00007527|DRUG|buprenorphine|
214876011|NCT04129073|OTHER|Intensive care treatment|Intensive care treatment; Utilization of neuroprognostication tools
214876012|NCT05423795|OTHER|Telemedicine-based intervention|Telemedicine-based intervention Multifaceted intervention including daily videoconferences with audit and feedback, educational interventions, and dissemination of published works
214876013|NCT05423795|OTHER|Standard of care arm|Classic expertise (as routinely performed in the participating ICU)
214876014|NCT01399879|OTHER|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
214876015|NCT00159627|DRUG|KW-3902IV|
214876016|NCT04400682|DRUG|FAVIRA 200 MG Film Tablet|FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.
214876017|NCT04400682|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
214876018|NCT03812744|DRUG|Whole coffee cherry extract (WCCE)|100mg WCCE
214876019|NCT03812744|DRUG|Placebo Oral Capsule [CEBOCAP]|Silica Oxide
214876020|NCT05083130|BEHAVIORAL|a wake prone positioning|The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position for at least 8 hours per day. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers.
214876021|NCT03393663|OTHER|CKD-related outcomes|the study is observational
214876022|NCT04493086|DIAGNOSTIC_TEST|FFRCT-angio|According to invasive coronary angiography (CAG) images, image databases of critical lesions, diffuse lesions, left main trunk lesions, ostium lesions and bifurcation lesions were established. In order to ensure that the position of the pressure guide wire sensor is consistent with that of FFRCT-angio, a professional with unknown FFR results is used to mark the position of the pressure wire sensor on the CAG image. The clinical information and characteristics of coronary artery lesions were collected, and the baseline data of patients were completed. The accuracy and diagnostic performance of FFRCT-angio in the diagnosis of functional stenosis (FFR \< 0.8) were evaluated with FFR value measured by pressure guide wire as reference standard.
214876023|NCT06167863|DIAGNOSTIC_TEST|radiomics|extracted image features from CT or MRI
214876024|NCT02293863|DRUG|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
214876025|NCT02293863|DRUG|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
214876026|NCT02293863|DRUG|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
214876027|NCT00566566|OTHER|sample without DNA|family history, anthropometric measurements and blood sampling
214876028|NCT03694600|DIAGNOSTIC_TEST|Multi-analyte blood Test|intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
214876029|NCT02646852|DRUG|PLX038|
214876030|NCT02332954|DRUG|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
214876031|NCT03086382|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
214876032|NCT03086382|DRUG|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
214876033|NCT03993782|OTHER|A19010-R|A snus product
214876034|NCT03993782|OTHER|B19010-O|A snus product
214876035|NCT00927797|DRUG|Cyclophosphamide, Pentostatin, Rituximab|
215042117|NCT03344341|DRUG|Dapagliflozin|Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
215042118|NCT03344341|DRUG|Acarbose|Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
215042119|NCT01317992|DRUG|Ibudilast|Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
214476863|NCT06807827|OTHER|Basic Education|Basic Education about lifestyle Modification(Provide guidance on how to maintain a healthy lifestyle, including balanced diet, exercise and regular sleep patterns). General Knowledge advancement. General knowledge about disease and medicine. Pill planner will be provided to keep them adherent to their medication. General Medication counselling.
214666466|NCT05033210|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011). The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. In these 90-minute sessions participants may talk to trained non-professional helpers (who are supervised by registered (clinical) psychologists). PM+ has four core features: it is brief (five sessions); delivered by non-specialist helpers; transdiagnostic thereby addressing depression, anxiety, PTSD, stress and problems as defined by people themselves; and originally designed for people in low-income country communities but easily adaptable to different (vulnerable) populations, cultures and languages.
214876036|NCT01975727|DRUG|Placebo|Injection of placebo (saline 0.9%)
214876037|NCT01975727|DRUG|Dexamethasone 3 mg|10 ml Seringue with Dexamethasone
214876038|NCT01975727|DRUG|Dexamethasone 6 mg|10 ml Seringue with Dexamethasone
214876039|NCT01975727|DRUG|Dexamethasone 12 mg|10 ml Seringue with Dexamethasone
214876040|NCT00901992|BEHAVIORAL|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
214876041|NCT00901992|BEHAVIORAL|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
214876042|NCT03364868|DRUG|Oral Insulin|treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
214876043|NCT03364868|OTHER|Placebo|treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
214876044|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of parenchymal lung change cause|Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.
214876045|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of recurrence and non-recurrence|Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment
214876046|NCT02097680|DRUG|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
215042120|NCT01317992|DRUG|Placebo|Placebo 4 capsules, orally, twice daily for 8 weeks.
214876047|NCT02097680|DRUG|Placebo|One placebo capsule every two days during four months
214876048|NCT01485744|DRUG|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
215042121|NCT02024412|DRUG|monosialotetrahexosylganglioside Sodium|it is a component extract from pig's brain,shenjie is the brand name
215042122|NCT02024412|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
215042123|NCT01737866|DRUG|AMG 423|omecamtiv mecarbil
215042124|NCT04129307|BEHAVIORAL|Motor imagery|This group will perform motor imagery training in combination with physical practice on motor learning of different motor tasks.
215042125|NCT04129307|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group in combination with physical practice on motor learning of various motor tasks.
215042126|NCT04129307|BEHAVIORAL|Action observation|This group will perform action observation training in combination with physical practice on motor learning of various motor tasks.
215042127|NCT03324789|OTHER|Single Implant Partial Over-denture|Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
215042128|NCT03324789|OTHER|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
215042129|NCT01149746|DRUG|Tamsulosin|Test 0.4 mg Capsule
215042130|NCT01149746|DRUG|Tamsulosin|Reference Listed 0.4 mg Capsule
215042131|NCT00639457|DRUG|Pioglitazone|Oral 30mg/day for 16 weeks
214876049|NCT02388360|DRUG|topical prostaglandin analogs|
215042132|NCT00639457|BEHAVIORAL|Exercise training|Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
215042133|NCT05287750|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
215042134|NCT01150292|DIETARY_SUPPLEMENT|First period DHA|400 mg DHA supplementation by day for 2 weeks during the first study period
215042135|NCT01150292|DIETARY_SUPPLEMENT|Second period DHA|400 mg DHA supplementation by day for 2 weeks during the second study period
215042136|NCT04628130|OTHER|Yoga Therapy|Yoga based self managed practices personalised to chronic pain patients
215042137|NCT01482858|DIETARY_SUPPLEMENT|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
215042138|NCT01482858|OTHER|Placebo|Gelatin capsules, each containing 500 mg \[comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose\] for oral use as placebo
215042139|NCT03089060|DEVICE|Silicone Finger cap|Treatment with silicone finger cap
215042140|NCT03089060|DEVICE|Film Dressing|Treatment with conventional film dressing
215042141|NCT00370292|DRUG|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
215057592|NCT03160456|DEVICE|Continuous positive airway pressure|CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
214666467|NCT00820040|DEVICE|acellular porcine dermal collagen mesh|porcine mesh for hernia repair/ abdominal wall reconstruction
214876050|NCT05154461|OTHER|Alginate|BHB covered in alginate will be realised in stomach-duodenum
214876051|NCT05154461|OTHER|Pea-protein|BHB covered in pea-protein will be released in ileum-colon
214666468|NCT02058381|DRUG|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
214666469|NCT02058381|DRUG|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
214876052|NCT03854682|PROCEDURE|Radiofrequency microtenotomy|A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
215042142|NCT00370292|DRUG|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
215042143|NCT00003614|DRUG|estramustine phosphate sodium|
215042144|NCT00003614|DRUG|paclitaxel|
215042145|NCT05412992|DRUG|DMTS Patch|DMTS applied before surgery and worn for 96 hours
215042146|NCT05412992|DRUG|Placebo Patch|Matching patches that have no active drug applied before surgery and worn for 96 hours
215042147|NCT01843530|DRUG|Berinert|
215042148|NCT01843530|DRUG|Clemastin|
215042149|NCT01843530|DRUG|Cortisone acetate|
215042150|NCT01843530|DRUG|NaCl|
215042151|NCT01518790|DRUG|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
215042152|NCT05361460|OTHER|Cognitive decline|This is an observation study with the aim of explore patients' experiences of their early and late postoperative cognition after major orthopaedic surgery in relation to postoperative cognitive function assessed with validated neuropsychological tests, inflammatory signalling molecules and quality of postoperative recovery as well as to describe the relative's view of early postoperative cognition.
215042153|NCT06049914|BEHAVIORAL|Experimental group|"1. Exercise interventions~   * Measuring blood pressure and weight: before starting exercise~  * Flexibility exercises: 5-10 minutes of stretching~  * Strength exercises: Consists of 4 upper body exercises (Biceps Curl, Dips, Front raise, Chest press) and 5 lower body exercises (Leg lateral rotation, Leg extension, Hip abduction, Squat, Heel raise). The intensity of the band starts according to the subject's muscle strength.~  * Aerobic exercise: 5 times a week, home-based, 30 minutes or more each time~2. Nutritional interventions~   * Well nourished: Overall diet check and correction~  * at risk: Correction of diet and intake of up to 2 packs of supplemental protein products per day~  * Malnourished: Correction of diet and intake of up to 3 packs of supplemental protein products per day~  * Nutrition counseling is provided at the beginning of the intervention and high-protein diet composition education is provided~  * Confirm compliance and provide feedback once every 2 weeks"
215042154|NCT04714593|BIOLOGICAL|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
215042155|NCT00276419|DRUG|Diclofenac|Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
215042156|NCT00276419|DRUG|Placebo|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
215042157|NCT01706484|DRUG|BNO 1016|comparison of different dosages of drug and placebo
214876053|NCT03854682|BEHAVIORAL|Strength training|Non-surgical treatment consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
214876054|NCT06732895|DRUG|Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
214876055|NCT06732895|DRUG|Placebo for navepegritide|Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
215042158|NCT05162690|DRUG|Dapagliflozin 10 milligram|10mg per day of Dapagliflozin will be given to the patients
215042159|NCT05162690|OTHER|Placebo|Metformin DPP4 inhibitors
215042160|NCT02483364|OTHER|HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)|A single application in the context of a single surgical intervention.
215042161|NCT06073522|OTHER|Artificial Intelligence for combining multi-domain data acquisition|Artificial Intelligence and machine learning techniques to combine data coming from multidomains data collection (such as clinical multiaxial assessments and questionnaires, Neuroimaging, Upper limb movement analysis during clinical assessment and daily life )
215042162|NCT02208219|BEHAVIORAL|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
215057593|NCT00360178|DRUG|Valsartan plus Hydrochlorothiazide|
215057594|NCT00360178|DRUG|Candesartan plus Hydrochlorothiazide|
215057595|NCT00360178|DRUG|Amlodipine|
215042163|NCT02208219|BEHAVIORAL|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
215042164|NCT02208219|BEHAVIORAL|Conventional treatment|"This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~* Passive mobilization: controlled manipulation of movements to release a joint.~* Stretch and progressive resistance training.~* Task-specific training: reaching and manipulation of different objects.~* Intense physical training: repetition of sequence of movements."
215042165|NCT00639951|BIOLOGICAL|A|20 vials up front in a Single Dose of Antivipmyn
215042166|NCT00639951|BIOLOGICAL|Antivipmyn ®|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
214291562|NCT04445324|OTHER|Control Group (pharmacotherapy and/or psychotherapy, n=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
214876056|NCT06871722|BEHAVIORAL|Plant based diet|"The plant-based diet in this study is defined as a predominantly vegetarian dietary pattern, consisting of two vegetarian meals per day and one meal that includes animal-derived protein. The diet is based on whole foods while avoiding ultra-processed foods.~Macronutrient Composition Caloric Intake: 30-35 kcal per kilogram of body weight per day Protein Intake: 0.8-1 g per kilogram of body weight per day Fat Sources Animal-derived fats are to be avoided. Plant-based oils are recommended as the primary source of dietary fats. Protein Sources Emphasis is placed on plant-based protein sources, including nuts, beans, edamame, tofu, and tempeh.~Dairy consumption is permitted, but cow's milk is discouraged. Instead, plant-based alternatives such as almond milk and soy-based milk (e.g., tofu milk) are recommended.~Egg consumption is allowed but limited to no more than one egg per day"
214876057|NCT06821633|PROCEDURE|Targeted laser photocoagulation guided by OCTA (Optical Coherence Tomography Angiography)|The patient's eyes were first scanned using the Topcon OCTA (five-field montage) with a 24×20mm and a 6×6mm scan range. After enrollment, the patient underwent treatment on the same day in the retinal laser room. The laser treatment was performed by the same ophthalmologist. After obtaining baseline fundus images, the treating ophthalmologist overlaid the OCTA images onto the fundus images using retinal vessel alignment to guide targeted photocoagulation of the retinal non-perfusion (NP) areas under OCTA guidance. The specific photocoagulation method involved applying a grid pattern of spot laser (3×3) to the NP area once, with the treatment area extending beyond the NP boundary by one laser spot diameter. The total procedure duration was 10-20 minutes.
214876058|NCT06347705|BIOLOGICAL|2141-V11 Antibody|2141-V11 Antibody: Intratumor injection
214876059|NCT06831552|BEHAVIORAL|RISE Intervention|Income-poverty targeted, supportive care intervention that includes direct cash transfers delivered by the Fund for Guaranteed Income, a non-profit organization, along with benefits counseling to discuss the risk of means-tested benefits loss or reduction. Funds will be dispersed to families via debit card or through personal banking, PayPal, or Venmo on a twice monthly basis for a total of twelve disbursements (6-months). Meetings with a benefits counselor will be conducted by the HIPAA-compliant video conference platform, Zoom.
214876060|NCT06115044|PROCEDURE|Intermittent diurnal nutrition|Calculated daily nutritional requirement given as three equal bolus feeds in daytime with prolonged overnight fast
214876061|NCT06115044|PROCEDURE|Continuous|Calculated daily nutritional requirement given over 24 hours
214291563|NCT03917108|DEVICE|retraction cord|retraction cord ( Ultra dent sizes #0, #00, #000 ) is placed in the gingival sulcus using blunt instrument and using cotton roll isolation.
214291564|NCT03917108|DEVICE|subgingival clamp|subgingival clamp (KSK clamps W8A, #44, #42, #43) or (Brinker clamps B5, B6) is placed to retract the gingiva with rubber dam isolation
214876062|NCT00187382|DRUG|Multiple vs. single courses of antenatalcorticosteroids|
215042167|NCT01042314|DRUG|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
215042168|NCT01042314|DRUG|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
215042169|NCT01819740|OTHER|"determine the levels of the HEM substance in seminal plasma"|
215042170|NCT00508521|DEVICE|Functional Electrical Stimulation|commercially available surface electrical stimulator
215042171|NCT00508521|OTHER|Standard Care|Standard care as ordered by their physician and covered by their insurance company.
214876063|NCT03462459|DRUG|Vancomycin|Vancomycin capsule, 125 mg
215042172|NCT05365100|DRUG|BN102|oral tablets: BN102, BID
215042173|NCT05790447|DRUG|Thymalfasin|loading dose with thymalfasin based on the amounts of T lymphocyte
215042174|NCT05790447|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
215042175|NCT05790447|DRUG|PD-1/PD-L1 inhibitor|The PD-1/PD-L1 inhibitors are used within one week after radiotherapy
215042176|NCT05790447|DRUG|GM-CSF|subcutaneous injection daily for 7 consecutive days
215042177|NCT02764411|DRUG|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
215042178|NCT05874089|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® 450 billions/sachets
215042179|NCT05874089|DIETARY_SUPPLEMENT|Placebo|Placebo sachets with maltose, cornstarch and dioxide
215042180|NCT03528317|OTHER|Alternate day fasting|Alternate day fasting with a high protein diet
214876064|NCT03462459|DRUG|Placebo|Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
215042181|NCT01265485|DRUG|coated suppository|Dose escalating study
214876065|NCT06758661|DRUG|D352|1 tablet
214876066|NCT06758661|DRUG|D794|4 capsule
214876067|NCT06907537|DIETARY_SUPPLEMENT|Food containing plasmalogen|Take four capsules per day in the morning.
215042182|NCT05247203|BIOLOGICAL|Telitacicept|subcutaneous injection
215042183|NCT05247203|DRUG|standard therapy|A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
215042184|NCT04946058|PROCEDURE|hyebrid Mathieu Urethroplasty|incision of the urethral plate during the procedure
215042185|NCT01622296|DRUG|Sodium bicarbonate|8.4% neutralizing solution
215042186|NCT01622296|DRUG|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
214291565|NCT01550380|DRUG|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
214291566|NCT03899142|BIOLOGICAL|a human hepatitis B immunoglobulin solution for injection for intramuscular administration|intramuscular administration
214291567|NCT01463878|DIETARY_SUPPLEMENT|Glycerna|Diabetes specific formula
214291568|NCT01463878|DIETARY_SUPPLEMENT|Jevity - Control Diet|Control Diet
214291569|NCT00052208|DRUG|gefitinib|Given PO
214291570|NCT00052208|RADIATION|radiation therapy|Undergo radiation therapy
214291571|NCT00052208|OTHER|laboratory biomarker analysis|Correlative studies
214291572|NCT01262950|OTHER|portable motion detector|
214291573|NCT03804879|DRUG|Nidufexor|50 mg (two 25 mg) LMB763 capsules for oral administration
214876068|NCT06907537|DIETARY_SUPPLEMENT|Food without plasmalogen|Take four capsules per day in the morning.
214876069|NCT04465552|OTHER|Patients received standard of care treatment during hospitalization|All patients admitted with covid-19 will be enrolled and followed for the duration of their hospitalization as well as during outpatient follow for up to 6 months, in those recovered, to assess clinical outcomes.
214876070|NCT04215991|DRUG|Cefiderocol|Administered intravenously over 3 hours
214876071|NCT04215991|DRUG|Standard of Care|Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
214876072|NCT06934889|DRUG|ERAS-801|will be administered orally at the assigned dose once daily starting on Cycle 1 Day 1.
214876073|NCT06934889|DRUG|ABBV-637|will be administered intravenously over one hour (+/- 10 min) once every 28 days on the first day of the new cycle.
214876074|NCT06934889|DRUG|ABBV-155|will be administered intravenously over at least 30 minutes once every 21 days on the first day of the new cycle.
214876075|NCT06934889|DRUG|Temozolomide|Temozolomide will be continued for 6 cycles after radiation.
214876076|NCT06934889|RADIATION|Radiotherapy|will be given as per standard of care radiation for GBM
214876077|NCT05978141|OTHER|Optional Blood Sample and Nail Sample|Participants may provide optional research blood and nail samples for biobanking and future use
214291574|NCT03804879|OTHER|Placebo|Placebo capsules for oral administration
214291575|NCT03804879|DRUG|Standard of Care (SoC)|Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
214291576|NCT00221754|DRUG|Pravastatin (drug)|
214876078|NCT06236139|BIOLOGICAL|Anti-STEAP1 CAR T-cells|Given IV
214876079|NCT06236139|PROCEDURE|Biopsy|Undergo tumor biopsy
214876080|NCT06236139|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214876081|NCT06236139|PROCEDURE|Bone Scan|Undergo NM bone scan
214876082|NCT06236139|PROCEDURE|Computed Tomography|Undergo CT scan
214876083|NCT06236139|DRUG|Cyclophosphamide|Given IV
214876084|NCT06236139|PROCEDURE|Echocardiography|Undergo ECHO
214876085|NCT06236139|DRUG|Enzalutamide|Given PO
214876086|NCT06236139|DRUG|Fludarabine|Given IV
214876087|NCT06236139|PROCEDURE|Leukapheresis|Undergo leukapheresis
214876088|NCT06236139|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214876089|NCT06236139|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214876090|NCT06236139|PROCEDURE|Positron Emission Tomography|Undergo PET scan
215042187|NCT01731795|DRUG|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
215042188|NCT01652781|DRUG|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
215042189|NCT05003193|DEVICE|pedometer|2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
214476864|NCT06502782|DIAGNOSTIC_TEST|digital assesment|Gingival recession sites were scanned with an intraoral optical surface scanner, and STL images were recorded. The images were imported into image analysis software. The depth, width and area of gingival recession were calculated using Autocat program.
214876091|NCT05219474|DIAGNOSTIC_TEST|Cochlear implant Computer Model Implementation|"The computer model will use standard Cochlear Implant settings to evaluate psychophysical and speech understanding abilities and sound quality with standard CI settings and then use these measures to build subject-specific models and determine experimental active electrode conditions to be tested: model-optimized, and two best-electrodes settings (2 types); 3) evaluate speech understanding and sound quality measures after using experimental settings regularly for 1.5 months; and 4) compare performance across experimental and clinical conditions.~The analysis will include four levels of repeated measures with active CI electrode conditions. These levels include the clinical baseline condition (all available electrodes active) and three experimental conditions (model-optimized, best-electrodes, and restricted best-electrodes)."
214876092|NCT00586534|BEHAVIORAL|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
214476865|NCT06656052|OTHER|1. working memory task.|Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants will be asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher.
214876093|NCT00586534|BEHAVIORAL|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
214876094|NCT02302989|DRUG|Ranibizumab 0.5mg|
214876095|NCT02929056|BIOLOGICAL|AmnioExCel dressing and compression therapy|Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
214876096|NCT02929056|PROCEDURE|SOC alginate dressing and compression therapy|Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
214876097|NCT02647385|DRUG|Block with lidocaine for SAM and PEC I block|"Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption."
214876098|NCT05860855|PROCEDURE|Augmentative craniotomy|Expansion of the skull
214876099|NCT05860855|PROCEDURE|Decompressive craniotomy|Standard hemicraniectomy
214876100|NCT03132155|DRUG|AMG 337|6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
214876101|NCT04584762|DEVICE|Automated Variable Pressure Insufflation|Acute migraine treatment
214666470|NCT06217991|PROCEDURE|PTST(parachute-tunnel-style technique)for esophagogastrostomy|Suture the gastric remnant at the mark on the back wall of the esophagus.(Don't tighten the suture); Pull the esophageal stump out of the tunnel meanwhile tighten the suture and the gastric stump to close the back wall of the esophagus and the gastric stump together;Cut the back esophageal wall close to the esophageal stump,cut the front gastric wall along line B. Suture the back esophageal wall and the upper edge of the front gastric wall incision from right to left;Remove residual esophageal nail, and suture the back esophageal wall and the lower edge of the gastric incision from right to left. Suture the anterior wall of the stomach at the lower edge of the tunnel with the serosa layer at the lower edge of the front wall of the esophagus stomach anastomosis;Suture the upper edge of the tunnel with the front wall of the esophagus and the left and right lateral walls at the gastric stump suture of the original posterior wall of the esophagus. (all use 3-0 barbed suture continuously)
214876102|NCT01654016|DRUG|Detralex|Detralex 500 mg twice daily for three month prior to surgery
214876103|NCT00538369|OTHER|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
214876104|NCT00538369|DEVICE|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
214876105|NCT04638101|BEHAVIORAL|Mindfulness-based intervention|Mindfulness-based intervention: The proposed MBI was designed based on well-known MBI programs including Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy and adapted to adolescents' needs and language. The program consisted of 8 weekly sessions in groups of up to 8 participants, lasting 1h30. Two MBI groups were offered per week (Wednesdays and Fridays) and participants had the possibility to choose the most convenient day for them. Two instructors were present for each group throughout the intervention.For each session one theme was addressed, such as attention and the stabilisation of the focus of attention, bodily sensations, breath, emotions, thoughts, compassion, stress, stress reactivity and coping strategies.
214876106|NCT05089669|OTHER|Interactive e-book|The nasogastric tube feeding interactive e-book has a lot of elements such as text content, videos, pictures, links, and other interactive content with which the students can interact. The participants can use the interactive e-book to learn nasogastric tube feeding.
214876107|NCT05089669|OTHER|paper textbook|The paper textbook has text content and pictures. The participants can use the paper textbook to learn nasogastric tube feeding.
214876108|NCT05790603|DEVICE|Intervention group with PHD-Band|The initial compression pressure was systolic blood pressure plus 10mmHg. Pressure will be released by 20mmHg and 40mmHg 1 hour and 2 hours respectively after the surgery and then the band will be removed after 3 hours if no bleeding occurs. The compression will continue if bleeding occurs.
214876109|NCT05790603|DEVICE|Control group with TR-Band|TR-Band will be inflated with 15 mL of air The band will be deflated with 1 mL of air hourly for the following 2 hours after the procedure. After 3 hours, the band will be removed if no bleeding occurs. If rebleeding occurs, the band will be inflated with appropriate volume of air until bleeding stops .
214876110|NCT01650584|DRUG|ISTA Tears|sterile ophthalmic solution
214876111|NCT01650584|DRUG|Systane|Sterile ophthalmic solution
214876112|NCT03763305|DRUG|Propofol continuous infusion|Propofol intravenous continuous infusion for anesthetic induction and maintenance
214876113|NCT03763305|DRUG|Remifentanil|Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
214876114|NCT03763305|DRUG|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol 1.5\~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
214876115|NCT03763305|DRUG|Desflurane|1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
214666471|NCT00749632|DRUG|oxybutynin|low dose oxybutynin administered daily
214876116|NCT03763305|DRUG|Propofol bolus injection|Propofol intravenous injection for anesthetic induction
214666472|NCT00749632|DRUG|oxybutynin|middle dose oxybutynin administered daily
214876117|NCT03763305|DRUG|Fentanyl|Fentanyl intravenous injection for anesthetic induction
214876118|NCT03655314|OTHER|NEWT|The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
214876119|NCT03655314|OTHER|Usual care|The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
214876120|NCT06226181|PROCEDURE|Dacryocystorhinostomy and amniotic membrane|Dacryocystorhinostomy surgery with amniotic membrane placement on the osteotomy site.
214876121|NCT06226181|PROCEDURE|Conventional dacryocystorhinostomy|Conventional dacryocystorhinostomy surgery without adding amniotic membrane
215042190|NCT05351528|OTHER|Questionnaire|Caregiver burden and healthy lifestyle behaviors were evaluated.
215042191|NCT00372957|DRUG|GW823093 15mg|White opaque capsule containing 15mg of GW823093 as free base
215042192|NCT00372957|DRUG|GW823093 placebo capsule|Matching placebo of GW823093 capsule or 15mg capsule
215042193|NCT00372957|DRUG|GW823093 30mg|White opaque capsule containing 15mg of GW823093 as free base
215042194|NCT04778592|DRUG|ETX-018810|Study Drug
214666473|NCT00749632|DRUG|oxybutynin|high dose oxybutynin administered daily
215042195|NCT04778592|DRUG|Placebo|Placebo
214666474|NCT01666132|OTHER|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
214876122|NCT04320823|DEVICE|Updated Plasma Collection Feature|Plasma collection using a novel, patented system that supports a more individualized collection approach.
215042196|NCT03568747|DEVICE|noninvasive ventilation|dual-limb circuit NIV were given on maquet servo i apparatus
215042197|NCT03568747|DEVICE|oxygen therapy|oxygen therapy were introduced to the side port of the facemask
215042198|NCT01192126|DEVICE|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
214291577|NCT01738763|DIETARY_SUPPLEMENT|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
214666475|NCT01666132|OTHER|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
215042199|NCT01192126|DEVICE|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
215042200|NCT04513782|DIAGNOSTIC_TEST|Audiological Assessments|Participants will all undergo routine audiological assessments. The results from these assessments will be evaluated in order to advance understanding of central hearing loss.
214876123|NCT04320823|DEVICE|Current Plasma Collection Approach|Plasma collection using the current collection approach.
214876124|NCT04365192|DEVICE|I-gel|"The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary."
214876125|NCT04365192|DEVICE|Self-pressurized air-Q|The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
214876126|NCT02521272|OTHER|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
214876127|NCT02521272|DEVICE|air pocket|Zero air pocket or one-liter air pocket in the snow.
214876128|NCT03685812|DIAGNOSTIC_TEST|Autocad software|The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
214876129|NCT00251511|DRUG|Arsenic Trioxide|
214876130|NCT02925403|BIOLOGICAL|R21/Matrix-M1|
214876131|NCT02925403|OTHER|Saline|
214876132|NCT02488954|OTHER|Probiotics in the form of cheese portion|
215042201|NCT05952050|DRUG|Dexmedetomidine|Different Administration Routes of Dexmedetomidine
215042202|NCT04556344|BEHAVIORAL|Emotional skills|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
214666476|NCT01666132|OTHER|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
214666477|NCT00772395|DRUG|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
214666478|NCT00772395|DRUG|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
215042203|NCT04556344|BEHAVIORAL|Short free talk and relaxation|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
215042204|NCT01115907|DEVICE|Freedom SOLO Stentless Heart Valve|Freedom SOLO Stentless Heart Valve
215042205|NCT00818090|DRUG|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
215042206|NCT00537043|DRUG|SK&F-105517 (COREG CR FDC)|
214876133|NCT00199147|DRUG|Cytarabine|
214876134|NCT00199147|DRUG|Etoposide|
214876135|NCT00199147|DRUG|Idarubicin|
214876136|NCT00199147|DRUG|G-CSF|
214876137|NCT00199147|DRUG|Fludarabine|
214876138|NCT00199147|PROCEDURE|Stem cell apheresis|
214876139|NCT00199147|PROCEDURE|Stem cell transplantation|
215042207|NCT04156139|DEVICE|HFNC|The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
215042208|NCT04156139|DEVICE|NPPV|The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
215042209|NCT06414083|DEVICE|Diathermy|Diathermy will be used to ablate the randomized sample.
215042210|NCT06414083|DEVICE|CO2 Laser|CO2 Laser will be used to ablate the randomized sample.
215042211|NCT06414083|DEVICE|Argon Beam Coagulator|Argon Beam Coagulator will be used to ablate the randomized sample.
215042212|NCT00638729|DRUG|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
215042213|NCT00638729|DRUG|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
215042214|NCT00638729|DRUG|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
215042215|NCT05444738|DRUG|oral lollipop with oxytocin (24IU)|Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.
214876140|NCT06505798|PROCEDURE|Catheter Ablation|Participants randomised to the catheter ablation arm will undergo Pulmonary Vein Isolation (PVI) which is the essential ablation intervention. The technique used will be at the discretion of the treating physician but may include Cryoballoon (Medtronic/Boston Scientific), Radiofrequency: CARTO (Biosense), pulsed field radiofrequency ablation, or Precision (Abbott Medical) electro-anatomical mapping systems. Additional ablation lesions may be delivered as preferred by the operator and will be documented. Electro-anatomical voltage maps will be collected (in SR/AF) and stored for later analysis.
214876141|NCT04173325|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
214876142|NCT04173325|DRUG|Irinotecan Injection [Camptosar]|Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
214876143|NCT05625074|PROCEDURE|Conventional surgery for great saphenous vein insufficiency|Arch ligation and stripping of great saphenous vein. Prophilatic anticoagulation - Low molecular weight heparin vs DOACs Antibiotics Non-steoridal anti-inflamatory drugs
214876144|NCT01184443|DRUG|Olanzapine|Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
214876145|NCT00459043|DRUG|ZD6474|Taken orally once every morning
214876146|NCT00459043|DRUG|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
214876147|NCT02499484|DRUG|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
214876148|NCT02499484|OTHER|Placebo ointment|Topical placebo ointment will be used in combination with a eccentric home exercise program
214876149|NCT02499484|OTHER|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
214876150|NCT00167284|BEHAVIORAL|physician and patient education; physician practice redesign|
214876151|NCT05982002|DEVICE|shock wave|ESWT (Chattanooga, Intelect RPW, USA) continues mode, hand piece transmitter R SW D20 /20mm, with the following Parameter: Shock pressure of 3-4 bars, wave frequency of 12 Hz.
214876152|NCT05982002|OTHER|Moderate intensity aerobic exercise|Treadmail training exercise 60%-75% of Maximum heart rate MHR 2 times/ week
214876153|NCT05982002|OTHER|Energy-restricted diet|energy intake was 500K calorie below daily requirements on average three meals at the same time of the day
214876154|NCT01547702|BEHAVIORAL|Teacher Help for ADHD|"Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~* Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~* Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~* Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~* Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~* Session 5: Help to use instructional interventions for ADHD~* Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours"
214876155|NCT01842997|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
214876156|NCT02521805|OTHER|Animal protein|
214876157|NCT02521805|OTHER|Vegetable protein|
214876158|NCT02521805|OTHER|Dietary fiber (cereal food matrice)|
214876159|NCT02521805|OTHER|Dietary fiber (meat food matrice)|
214876160|NCT02521805|OTHER|Dietary fiber (vegetable food matrice)|
214876161|NCT00839397|DRUG|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI"
214876162|NCT03127111|GENETIC|Gene mutations analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
214876163|NCT03127111|GENETIC|Gene methylation analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for specific gene methylation or CIMP status analysis by MethyLight or bisulfite sequencing. Whole-genome bisulfite sequencing will be used to identify novel candidate set of predictive markers.
214876164|NCT03127111|GENETIC|Gene expression analysis|RNA extracted from paired fresh-frozen tumor and normal tissues or serum is used for specific gene expression analysis by real-time reverse-transcription PCR (RT-qPCR). RNA-seq will be used to identify novel candidate set of predictive markers.
214876165|NCT03127111|GENETIC|SNP analysis|Genomic DNA extracted from serum is used for specific SNP analysis by using sequencing. GWAS with SNPs array will be used to identify novel candidate set of predictive markers.
214876166|NCT03127111|GENETIC|Protein expression analysis|Tissue microarray made from formalin-fixed paraffin-embedded (FFPE) paired tumor and normal tissues is used for specific protein expression analysis by immunohistochemistry staining.
214291578|NCT01585428|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
214876167|NCT00004186|DRUG|carboplatin|
214291579|NCT01585428|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
214876168|NCT00004186|DRUG|etoposide|
214876169|NCT00004186|DRUG|ifosfamide|
214876170|NCT00004186|DRUG|topotecan hydrochloride|
214876171|NCT00004186|RADIATION|radiation therapy|
214876172|NCT06387524|PROCEDURE|McConnell Taping|Begin with the patient in supine lying with the knee slightly bent. The knee should be completely relaxed and a foam roller or rolled up towel under the knee. Start the tape in line with the middle of the knee cap at the outer aspect of the knee. Using your thumb on top of the sports tape, gently push the patella towards the inner aspect of the knee whilst simultaneously using your fingers to pull the skin at the inner aspect of the knee towards the patella. Finish this taping technique at the inner aspect of the knee ensuring you have created some wrinkling of the skin at the inner aspect of the knee.
214876173|NCT06387524|PROCEDURE|ECCENTRIC EXERCISES:|"Performed for 6 weeks, in 3 sets of 10-12 repetitions each day. Detailed protocol is as under:~Warm up phase (5 minutes) It will comprise of following components 5 minutes warm up exercise protocol: Marching in place while swinging your arm, rotating toe touching, walking jacks, leg swings, arm circles, shoulder shrugs Eccentric exercises: Each of the following exercise will be performed for 30 seconds, repetitions and hold time will increase with increasing weeks according to patient's stamina.~Straight leg raise, side lying hip abduction, single leg bridging, supported double leg squatting, hip hikes,supported single leg squatting Following is the detailed description of Cool down phase: Hip stretch, cat cow stretch, oblique stretch, lower back stretch, calf stretch, cross body shoulder stretch"
214876174|NCT04683224|BIOLOGICAL|UB-612|100 µg \[microgram\] of an experimental study vaccine
214876175|NCT04683224|OTHER|Placebo|Placebo is a 0.9% sodium chloride (normal saline) injection
214876176|NCT01477723|OTHER|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
214876177|NCT02618525|OTHER|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
214876178|NCT02618525|OTHER|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
214876179|NCT01860625|DRUG|Donepezil patch|
214876180|NCT01860625|DRUG|placebo|
214876181|NCT04190758|OTHER|Care as usual|No intervention will be given. The study will follow the effects of care as usual.
214876182|NCT03414216|PROCEDURE|Group 1 early offloading surgery|As above.
214876183|NCT03414216|PROCEDURE|Group 2 - off-loading in fiberglass cast|As above.
214876184|NCT06334224|DEVICE|Low load resistance training with blood flow restriction|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
214876185|NCT06334224|OTHER|Low load resistance training|Leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
214876186|NCT00330317|DRUG|letrozole|2.5mg letrozole once-daily
214876187|NCT01794455|DRUG|Sertraline|50mg - 200mg daily
214876188|NCT01794455|DRUG|Candesartan|4mg - 32mg daily
214876189|NCT03794050|OTHER|Resistance training exercise|randomized complete crossover for acute resistance training exercise session
214876190|NCT03794050|OTHER|Aerobic training exercise|randomized complete crossover for acute aerobic exercise training exercise session
214876191|NCT03523455|DIETARY_SUPPLEMENT|Iron Aid IPS (Iron Protein Succinylate)|Taken orally in capsule form
214876192|NCT03523455|OTHER|Sugar Pill|Taken orally in capsule form
214291580|NCT01585428|BIOLOGICAL|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
214291581|NCT01585428|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
214876193|NCT02899195|DRUG|Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration. Maintenance: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
214876194|NCT05531110|DEVICE|Cataract surgery with insertion of Eyhance ICB00|Cataract surgery with insertion of Eyhance ICB00
214876195|NCT05531110|DEVICE|Cataract surgery with insertion of Alcon SN60WF|Cataract surgery with insertion of Alcon SN60WF
214876196|NCT00010764|PROCEDURE|Acupuncture|
214876197|NCT00351403|DRUG|Ribavirin|Rebetol 200 mg: applied as hard capsule
214876198|NCT00351403|DRUG|Peginterferon alfa 2b|PegIntron (50/80/100/120/150 microgram): applied by injection
214876199|NCT00192803|DRUG|candesartan|
214876200|NCT00719875|DRUG|Vorinostat|BID days -7, 1-7 and 15-21, 200 mg
214876201|NCT04561271|OTHER|foot reflexology|Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.
214876202|NCT04561271|OTHER|toucher massage|one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
214876203|NCT02206360|PROCEDURE|Endoscopic Ultrasound|
214876204|NCT02206360|PROCEDURE|Magnetic Resonance Imaging (MRI)|
214876205|NCT06582030|BEHAVIORAL|Assessment|Ancillary studies
214876206|NCT06582030|OTHER|Educational Activity|View the chronically relapsing brain disease vignette
214876207|NCT06582030|OTHER|Educational Activity|View the brain disease vignette
214876208|NCT06582030|OTHER|Educational Activity|View the disease vignette
214876209|NCT06582030|OTHER|Educational Activity|View the illness vignette
214876210|NCT06582030|OTHER|Educational Activity|View the disorder vignette
214876211|NCT06582030|OTHER|Educational Activity|View the problem vignette
214876212|NCT06582030|OTHER|Training|Attend a SAS workshop
214876213|NCT03156504|DRUG|Ketamine Hydrochloride|Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
214876214|NCT01998763|DIETARY_SUPPLEMENT|Placebo|placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
214876215|NCT01998763|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU per day
215042216|NCT05444738|DRUG|oral lollipop with placebo|Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
215042217|NCT01750853|DRUG|LY3045697|Administered orally
215042218|NCT01750853|DRUG|Placebo|Administered orally
215042219|NCT02660229|DRUG|Oxycodone Hydrochloride|Oxycodone injection
215042220|NCT02660229|DRUG|Morphine Sulphate|Morphine sulphate injection
215042221|NCT04636996|OTHER|artificial intelligence assisted follow-up|We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
215042222|NCT01110057|DRUG|Placebo|Placebo to match GW856553
215042223|NCT01110057|DRUG|GS856553|GW586553 7.5mg bid
215042224|NCT00938262|DRUG|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
215042225|NCT04944771|DRUG|Capivasertib|Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
215042226|NCT04944771|DRUG|Rabeprazole|Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
215042227|NCT02640300|DRUG|Clozapine|Switching to clozapine with immediate or gradual antipsychotic discontinuation
215042228|NCT02128087|BEHAVIORAL|Two-way SMS intervention|"Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours."
215042229|NCT02128087|BEHAVIORAL|One-way SMS intervention group|Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
215042230|NCT03690245|PROCEDURE|Initiation of Resuscitation While Attached to the Cord|Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
215042231|NCT03838835|BEHAVIORAL|Augmented equine-facilitated CBT group program|Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
215042232|NCT03838835|BEHAVIORAL|TAU is equine-facilitated group therapy|TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
214876216|NCT04520126|DIETARY_SUPPLEMENT|Olivomed (capsules containing hydroxytyrosol)|patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.
215042233|NCT03838835|OTHER|WLC|WLC consists of youth who are not yet receiving any services at Gallop NYC.
215042234|NCT05165706|BEHAVIORAL|Dietary Intervention Mediterranean Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
215042235|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
215042236|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Fat Diet|Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
215042237|NCT00399529|BIOLOGICAL|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
214291582|NCT01084174|DRUG|Peanut powder|Delivered orally
214291583|NCT01084174|DRUG|Peanut extract|Delivered sublingually
214291584|NCT01084174|DRUG|Placebo extract|Delivered sublingually
214291585|NCT01084174|DRUG|Placebo powder|Delivered orally
214291586|NCT00479661|DRUG|Dexmedetomidine|Continuous infusion
214291587|NCT00479661|DRUG|Propofol|Continuous infusion
214876217|NCT04520126|DIETARY_SUPPLEMENT|OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).|patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.
214876218|NCT01423123|DRUG|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
214876219|NCT01423123|BIOLOGICAL|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
214876220|NCT01423123|DRUG|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
214876221|NCT04677101|DIAGNOSTIC_TEST|Liver Biopsy|Fine-needle liver biopsy
214876222|NCT06582823|OTHER|Health belief model-based community educational program|"The 5-week intervention includes two weekly 60-minute face-to-face sessions for 8-10 participants, two weekly telephone follow-ups, and a booster session.~Week 1: Focuses on increasing knowledge about atrial fibrillation (AF), its risks, complications, and treatment benefits. The principal investigator (PI) provides education using interactive methods and colored visuals.~Week 2: Emphasizes skill building for pulse palpation to detect irregular pulses. Participants learn through demonstrations and practice using a simulated arm.~Weeks 3-4:Telephone follow-ups monitor adherence to pulse checking and address barriers. Support and advice are provided by the PI.~Week 5: A booster session reinforces knowledge and skills with scenario-based practice and use of a simulated arm."
214876223|NCT06582823|OTHER|Control|The control group will receive an information leaflet presenting information about AF, health risks and complications associated with AF, common methods to screen for AF, and follow-up actions if positive screening results are suspected.
214876224|NCT04862910|OTHER|Kinect Based Virtual Reality Training|The participant will receive the game instructions from the examiner.Protocol will be implemented 3 steps Warm Up phase Activity phase and cool down phase. The games will be played under the supervision and guidance of the therapist.Games are selected from Kinect games Kinect Sports Kinect Adventures and Your Shape Fitness Evolved. Three treatment sessions per week will be given to each participant. Total duration of each treatment session will be 45 Minutes.Participants will be instructed to walk outdoors for 30 Minutes daily. Routine Medication and routine diet will be continued.
214876225|NCT04862910|OTHER|Control Group|"* They will be instructed to walk outdoors daily for 30 Minutes.~* They will continue their daily activities with a routine diet and routine Medication"
214876226|NCT00450801|DRUG|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
214876227|NCT00450801|DRUG|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
214876228|NCT00450801|DRUG|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
214876229|NCT00450801|DRUG|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
214876230|NCT00450801|DRUG|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
214876231|NCT00450801|DRUG|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
214876232|NCT00450801|DRUG|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
214876233|NCT00450801|DRUG|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
214876234|NCT00450801|DRUG|Thalidomide|Maintenance therapy.
214876235|NCT00450801|DRUG|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
214876236|NCT00450801|DRUG|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
214876237|NCT00450801|DRUG|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
214876238|NCT00450801|DRUG|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
214876239|NCT00450801|DRUG|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
214876240|NCT05963815|OTHER|Spine surgery|Patients operated with laminectomy, microscopic discectomy, percutaneous transforaminal endoscopic discectomy, and spondylodesis.
214876241|NCT03452137|DRUG|Atezolizumab|Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
214876242|NCT03452137|DRUG|Placebo|Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
214876243|NCT05186649|OTHER|WARFARIN|5 mg of daily dosage
214876244|NCT02372279|OTHER|Embryo observation|In EO group, conventional observations will be made.
214876245|NCT06582394|COMBINATION_PRODUCT|Exp Group|Balance and coordination were targeted through virtual stepping tasks, where participants practiced stepping in various directions to improve postural control and lower limb function. Additionally, they performed virtual balance exercises by standing on simulated platforms of varying stability. For gait and mobility, participants practiced walking in a virtual environment with real-time feedback to correct gait abnormalities. They also encountered virtual obstacles, which required them to adapt their walking patterns and improve mobility. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.
214876246|NCT06582394|OTHER|Control group|For gait training, participants practiced walking on flat surfaces, sometimes with the assistance of parallel bars or walking aids, to improve their walking speed, step length, and rhythm. They also performed sit-to-stand exercises to strengthen the lower limbs and improve mobility for daily activities. Additionally, manual therapy techniques, such as joint mobilizations and stretching, were applied to reduce spasticity and increase range of motion in the affected limbs. Both treatment groups progressed based on individual capabilities, with therapists adjusting exercises accordingly throughout the study. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.
214876247|NCT05081986|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
214876248|NCT05081986|DRUG|Cycloserine|Cycloserine 100mg
214876249|NCT05081986|DRUG|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
214876250|NCT04653025|DEVICE|Implant placement|After tooth extraction implants were placed either immediate or delayed approach
214876251|NCT04283019|DRUG|CBD|CBD will be orally ingested
214876252|NCT04283019|DRUG|THC|THC will be orally ingested
214291588|NCT02843932|OTHER|functional brain MRI|functional imagery during motor-perception tasks
214876253|NCT00261443|DRUG|Lithium or Valproate with placebo (PBO)|"Tablets, Oral, once daily~lithium 250-2100 mg/day~valproate 250-2500mg/day~Placebo once daily"
214876254|NCT00261443|DRUG|Lithium or Valproate with Aripiprazole|"Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)~lithium 250-2100 mg/day~valproate 250-2500mg/day~aripiprazole 15-30 mg/day"
214876255|NCT04205058|DIETARY_SUPPLEMENT|Standard coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
214876256|NCT04205058|DIETARY_SUPPLEMENT|Caffeine-free coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
214876257|NCT04205058|DIETARY_SUPPLEMENT|Drinking water|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
214876258|NCT03536741|PROCEDURE|TAP block and RS block + General Intravenous Anesthestic|transversus abdominis plane block and rectus sheath block
214876259|NCT03536741|DRUG|General Intravenous Anesthetic|General Intravenous Anesthetic
214876260|NCT04747145|DEVICE|Radiation|60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
214876261|NCT04747145|DRUG|Concurrent Chemotherapy (Temozolomide)|75mg/m\^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
214876262|NCT04747145|DRUG|Adjuvant Chemotherapy (Temozolomide)|Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m\^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
214876263|NCT02373449|OTHER|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
214876264|NCT02373449|DRUG|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
214876265|NCT02755649|DRUG|Dupilumab|
214876266|NCT02755649|DRUG|Matching Placebo|
214876267|NCT01772875|PROCEDURE|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
214876268|NCT01049178|DRUG|Oral Silymarin|Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
214876269|NCT01049178|DRUG|Oral Silymarin, maintenance dose|The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
214876270|NCT01049178|DRUG|Placebo|
214876271|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.
214876272|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.
215042238|NCT00399529|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
214666479|NCT04898452|OTHER|A new model of interaction across health services with use of welfare technology and telemedicine|Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
214876273|NCT03420911|DRUG|dexketoprofen trometamol|
215042239|NCT00399529|DRUG|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
214291589|NCT01879501|BEHAVIORAL|Low Vision Self-Management Program|The program has been describe above.
214291590|NCT06413342|DRUG|Sintilimab|Patients should receive their first dose of sintilimab within 42 days after completing the final radiotherapy session and continue treatment until disease progression, occurrence of intolerable toxicity, loss to follow-up, death, or as determined by the investigator, whichever comes first. The maximum duration of sintilimab treatment is 12 months (from the initiation of therapy). No other anti-tumor therapies are permitted during the treatment period.
214291591|NCT02536196|DEVICE|Embolic Protection Device|Embolic protection
214291592|NCT02536196|PROCEDURE|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
214291593|NCT00673465|DRUG|SCH 497079|SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
214291594|NCT00673465|DRUG|Placebo|Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
214666480|NCT03460418|OTHER|Phone contact|Assessment of the different outcomes by means of a phone contact
214666481|NCT01420185|GENETIC|RNA analysis|
214876274|NCT03420911|DRUG|Midazolam|
214876275|NCT03541928|DRUG|HSV-Tk|"Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells."
214876276|NCT03541928|DRUG|Valacyclovir|The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.
214876277|NCT03541928|DRUG|Bicalutamide|"The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain."
214876278|NCT03541928|DRUG|Leuprolide Acetate|Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
214876279|NCT03541928|RADIATION|Brachytherapy, External beam radiotherapy|On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.
214876280|NCT03541928|PROCEDURE|Radical prostatectomy|approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.
214876281|NCT01286753|DRUG|Vemurafenib|Vemurafenib 960 mg orally twice daily.
214876282|NCT06323447|DIAGNOSTIC_TEST|PointCheck|Binary classification of severe neutropenia
214876283|NCT05012189|DRUG|Oseltamivir|Nursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza.
215042240|NCT02133573|DRUG|Progesterone|Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.
215042241|NCT02133573|DRUG|Vaginal lubricant|Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
215042242|NCT02825108|DRUG|Intra uterine injection of tissue culture medium containing HCG+ET|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
215042243|NCT02825108|DRUG|Intra uterine injection of tissue culture medium +ET|) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
215042244|NCT02825108|PROCEDURE|ET|the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
215042245|NCT03687281|OTHER|Survey|"The questionnaire consists of three parts:~* knowledge assessment;~* socio-demographic, medical and lifestyle data;~* use of Chemsex."
215042246|NCT04041193|BEHAVIORAL|SIDERA^B|The group will receive a kit home-based (a tablet home, access to a daily individualized training program). Five sessions for a week (3 components: monitoring, motor rehabilitation acitivities, motivational support)
215042247|NCT04041193|BEHAVIORAL|Usual Care Program|Usual Care program activities (paper and pencil at home)
215042248|NCT01402310|OTHER|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
215042249|NCT06048458|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance with stress perfusion|Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
215042250|NCT06048458|DIAGNOSTIC_TEST|CT coronary angiography|CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease
215042251|NCT06048458|DIAGNOSTIC_TEST|Retinal OCT angiography|Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
215042252|NCT06048458|DIAGNOSTIC_TEST|Sublingual microscopy (GlycoCheck)|To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
214876284|NCT05012189|DRUG|Baloxavir|Nursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza.
214876285|NCT02657928|OTHER|Laboratory Biomarker Analysis|Correlative studies
214876286|NCT02657928|DRUG|Letrozole|Given PO
214876287|NCT02657928|DRUG|Ribociclib|Given PO
214876288|NCT01644383|BEHAVIORAL|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
215042253|NCT06048458|DIAGNOSTIC_TEST|Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)|Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
215042254|NCT02345239|DRUG|Pantoprazole|proton pump inhibitor
215042255|NCT03423407|DEVICE|Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|FDA approved scanner
214876289|NCT02753361|PROCEDURE|Ultrasound guidance|In the second arm, ultrasound will be used to guide the regional block
215042256|NCT06547736|DRUG|SHR-A2102 or/and HRS-4642|"Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
215042257|NCT06547736|DRUG|SHR-A1904 or/and HRS-4642|"Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
215042258|NCT06547736|DRUG|SHR-A1811 or/and HRS-4642|"Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
214876290|NCT02881697|OTHER|Adipose tissue sampling|
214876291|NCT03946852|DEVICE|Abdominal Regional Perfusion|Abdominal Regional Perfusion
214876292|NCT04050215|PROCEDURE|Computed Tomography|Undergo PET/CT
214876293|NCT04050215|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
214876294|NCT04050215|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214876295|NCT04050215|OTHER|Questionnaire Administration|Ancillary studies
214876296|NCT00005884|DRUG|eflornithine|
214876297|NCT05646459|DRUG|cannabidiol|This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
214876298|NCT05646459|DEVICE|floss|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
214876299|NCT05646459|DEVICE|proxabrush|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
214291595|NCT00673465|DRUG|Metformin|Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
214876300|NCT06552039|OTHER|Polyherbal Hair Oil|Apply oil with the help of fingertips on your scalp and massage it gently enabling it to penetrate into the roots (follicle) of your hair. Don't apply with your palms and never rub it vigorously as it may uproot weak hair. Let the oil gradually seep into follicle of your hair \& nourish them for the whole night. The oil may be removed in the morning by washing of hair with Ayurvedic Shampoo. Dosage form: liquid frequency: Three times a week Route of Administration: Topical
214876301|NCT06552039|OTHER|Minoxidil Herbal Hair Oil + Minoxidil 5 (%) Hair Serum|"First, apply the herbal hair oil generously to your scalp and hair, ensuring thorough coverage. Gently massage it in with your fingertips to promote circulation and absorption. After the oil application, follow the instructions provided for the application of the minoxidil hair serum. Apply the serum to the areas of your scalp where you desire hair growth, using the dropper provided or as directed. Massage it gently into your scalp to ensure even distribution and absorption. Leave the serum on without rinsing.~Dosage form: liquid Frequency : For Minoxidil - Daily Night Application For Herbal Hair Oil- Thrice a week.~Route of Administration: Topical"
214876302|NCT06552039|OTHER|Minoxidil Hair Serum|Apply the amount prescribed to the area of the scalp being treated, beginning in the center of the area. Dosage form: liquid Frequency : Daily night Application of Minoxidil Route of Administration: Topical
214876303|NCT04852523|DRUG|18F-fluciclovine|18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.
214876304|NCT03324295|DIAGNOSTIC_TEST|cortical cataract|Blood urea
214876305|NCT05269095|PROCEDURE|Spinal anesthesia only|Patients will receive spinal anesthesia with 2-3 ml 0.5% (10-15 mg) hyperbaric bupivacaine plus 25 ug fentanyl at the L3/4 interspaces.
214291596|NCT03578159|OTHER|Chhatralaya|Chhatralaya, home for children provide living resources along with spiritual practices.
214476866|NCT06656052|OTHER|2. Visual and Verbal Fluency Task|Stroop colour word test (modified Stroop test): participants will be asked to name the colour of ink that each word is printed in. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
214666482|NCT01420185|GENETIC|gene expression analysis|
214876306|NCT05269095|BIOLOGICAL|Spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.
214876307|NCT05269095|BIOLOGICAL|Ultrasound-guided Adductor Canal block (ACB) technique with infiltration of the interspace between popliteal artery and the capsule of posterior knee block ('PACK)|Adductor Canal block (ACB) technique will be performed using 16 ml bupivacaine 0025% As regarding the Popliteal artery and the capsule of posterior knee block ('PACK), it will be performed Using 16 ml bupivacaine 0.25%
214876308|NCT04012788|DIETARY_SUPPLEMENT|Synbiotic mixture|A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)
214876309|NCT04012788|OTHER|Placebo comparator|Placebo powder
214876310|NCT00725257|OTHER|Mediterranean diet|The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
214876311|NCT00725257|OTHER|Low-fat diet|The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
214876312|NCT00269139|BEHAVIORAL|Crisis resolution|
214876313|NCT05088850|OTHER|no intervention|no intervention
214876314|NCT05175703|DEVICE|Passeo-18 Lux Paclitaxel releasing Balloon Catheter|collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
214876315|NCT05858918|DRUG|Clopidogrel|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
214476867|NCT06656052|OTHER|3. Motor Task|Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
214876316|NCT05858918|DRUG|Ticagrelor|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
214876317|NCT05314803|BEHAVIORAL|Yoga|Participants receive the yoga program, which is delivered by a trained yoga instructor (completed at least a 200-hour yoga teacher training, Yoga Thrive Teacher Training Certification (or similar), and/or practical experience working with individuals affected by cancer). The first class of the week is comprised of 45 minutes of gentle, progressive, hatha-based yoga sequencing and postures with the last 15 minutes focused on guided behaviour change and mindfulness techniques that varies week-to-week, based on the participants in the class. The second class of the week is 60 minutes of gentle, yin-based yoga sequencing and postures with an element of opening and relaxing.
215042259|NCT00516282|DRUG|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
215042260|NCT00516282|DRUG|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
215042261|NCT03085680|DRUG|Curcumin|Participants will be given curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
215042262|NCT03085680|DRUG|microcrystalline cellulose|Participants will be instructed to consume two capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
215042263|NCT00738296|DRUG|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
215042264|NCT00738296|DRUG|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
215042265|NCT00738296|DRUG|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
215042266|NCT02431325|DRUG|Teduglutide|
215042267|NCT02431325|DRUG|Placebo|
215042268|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
215042269|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
215042270|NCT05157087|DRUG|Omalizumab|"Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab."
215042271|NCT01603017|DEVICE|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
215042272|NCT01603017|DEVICE|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
215042273|NCT04931238|DRUG|JS016|Single Intravenous Injection of JS016 with a dose of 50mg/kg
215042274|NCT02901886|BEHAVIORAL|Intensive smoking cessation intervention|The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
215042275|NCT02185300|DRUG|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
215042276|NCT02185300|DRUG|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
214476868|NCT05559866|DEVICE|Apollo ESG with ERBE HAPC|Utilizing two approved devices in combination to assess durability of suturing.
214476869|NCT05559866|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label.
214666483|NCT01420185|GENETIC|microarray analysis|
214666484|NCT01420185|GENETIC|reverse transcriptase-polymerase chain reaction|
214666485|NCT01420185|OTHER|laboratory biomarker analysis|
214876318|NCT02291575|OTHER|Training|(please see Arm Description)
214876319|NCT02291575|OTHER|Control|This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
214876320|NCT01531660|BEHAVIORAL|step-up jogging program|
214876321|NCT05780060|BEHAVIORAL|Standard of care, RPM and digital feedback|Standard stroke follow up, RPM and a patient facing smartphone application containing real time BP feedback, educational models, treatment adherence push notification reminders, digital education and digital incentives (n=30). Outcomes will include recruitment, retention and follow up metrics, self-reported adherence to medication regimens and life-style recommendations, patient engagement with RPM data and patient-facing application, cost-effectiveness of the interventions and changes in blood pressure as well as biomarkers like LDL and Hemoglobin A1C.
215042277|NCT06041321|DEVICE|Reparel Sleeve|For the purpose of this study, the Reparel Sleeve will be evaluated against a placebo sleeve of similar feel, texture, and look. The indication is that due to its technology, the Reparel sleeve will allow for the ability to reflect energy using a blend of semi-conductors grounded to nanoparticles interwoven between fibers of the sleeve. Thermal energy is then absorbed from the patient thus activating electrons on the nanoparticles and releasing photonic energy directed at tissues within the surrounding area7. This photostimulation is expected to alleviate pain and inflammation while promoting wound healing as well as tissue regeneration.
215042278|NCT06041321|DEVICE|Placebo Sleeve|Generic sleeve used as a placebo. This placebo will have a similar feel, texture, and look with no additional technology.
215042279|NCT01641484|PROCEDURE|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
215042280|NCT03857776|OTHER|Open dialogue about complementary alternative medicine|1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
215042281|NCT03857776|OTHER|Standard care|Standard care including referral to a homepage about CAM
215042282|NCT02045602|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
214876322|NCT05780060|BEHAVIORAL|Standard of care and RPM only|Standard stroke clinic follow up and remote blood pressure monitoring (n=30). Outcomes will include qualitative patient and provider experiences with the TBIs including barriers and facilitators to the use of RPM and patient-facing application in the study population
214876323|NCT04913558|OTHER|Aerobic exercise|"The exercise will be performed by using the treadmill as the following:~\- The first stage (warming up): It consists of 5 minutes warming up with the treadmill speed set at 1.0 mile per hour.~\- The second stage (active stage): It consists of 20 minutes with the treadmill speed set at 3.0 miles per hour.~\- Third stage (cooling down): It consists of 5 minutes of cooling down with the treadmill speed set at 1.0 miles per hour."
215042283|NCT02045602|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
215042284|NCT02045602|DRUG|Abraxane®|125 mg/m2 intravenous administration
215042285|NCT01818687|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
215042286|NCT00049361|DRUG|temozolomide|
215042287|NCT00049361|DRUG|thalidomide|
215042288|NCT00049361|RADIATION|radiation therapy|
215042289|NCT05524831|OTHER|KINESIOTAPE|kinesiotape will be applied on orbicularis oris muscle
215042290|NCT05524831|OTHER|oromotor training|selected oromotor training: Perioral sensory stimulation ,Tapping,Tongue pressure,Jaw exercises andIntraoral stimulation
215042291|NCT05185076|DEVICE|CureSight|watch CureSight treatment for 90 minutes per day, 5 days a week for 16 weeks
215042292|NCT01885988|DRUG|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
214291597|NCT04383405|OTHER|Aquatic Training|Aquatic Training training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises follow a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e. catching a ball thrown by the therapist). Subjects performed three sessions a week for four weeks and each session lasting 45 minutes. The training was carried out by a physiotherapist who had at least 5 years of experience in aquatic neurorehabilitation.
214666486|NCT04432428|DRUG|Sufentanil Sublingual Tablet|"all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil"
215042293|NCT01885988|DRUG|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
215042294|NCT02353962|OTHER|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. The intervention duration is three weeks. During this week the patients play daily a half hour on workdays. The treatening therapist will adjust the intensity according to the progress of the patient.
215042295|NCT00744861|DEVICE|Exospine sham|Inactive Exospine LIPUS device (dual transducers)
215042296|NCT00744861|DEVICE|Exospine|Active Exospine LIPUS device (dual transducers)
215042297|NCT00744861|DEVICE|Exogen 4000+|Active Exogen LIPUS device (single transducer)
215042298|NCT00744861|DEVICE|Exogen 4000+ sham|Inactive Exogen 4000+ LIPUS device (single transducer)
215042299|NCT05746858|OTHER|no intervention (observational study)|No intervention (observational study)
215042300|NCT02507986|DEVICE|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
215042301|NCT02507986|DEVICE|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
215042302|NCT00401076|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
215042303|NCT05584579|PROCEDURE|laparoscopic surgery|laparoscopic surgery
215042304|NCT01252615|BEHAVIORAL|patient only|education, behavioral strategies, psychological interventions
215042305|NCT01252615|BEHAVIORAL|patient and partner intervention|education, psychological support, behavioral strategies
215042306|NCT03212352|DRUG|Mifepristone|Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.
215042307|NCT03212352|DRUG|Misoprostol|Regular treatment with Misoprostol 800 mcg.
215042308|NCT05201651|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.
214876324|NCT04913558|OTHER|Traditional Treatment|"1. General advice for reducing fatigue and stress~2. Fluid and diet advice~3. Carrying the Baby~4. While Breastfeeding in a sitting position~5. Selecting Clothing"
214876325|NCT02382042|BEHAVIORAL|Intensive Referral Intervention|
214876326|NCT00880178|DRUG|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
214876327|NCT00880178|DRUG|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
214876328|NCT05173181|DEVICE|Flexible intramedullary nail|Fixation of distal ulna fracture with flexible intramedullary nail
214876329|NCT01909856|DRUG|Palonosetron|Palonosetron 0.25mg d1,d3
214876330|NCT01909856|DRUG|Granisetron|Granisetron 3mg d1-3
214876331|NCT01909856|DRUG|Dexamethasone|Dexamethasone 10mg d1-3
214876332|NCT01909856|DRUG|Cisplatin|3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3
214876333|NCT03402061|DIETARY_SUPPLEMENT|nutrient enhanced recipes|normal ingredients will be substituted to promote nutrient density of products
215042309|NCT05201651|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
215042310|NCT01385592|DRUG|AFQ056|
215042311|NCT01385592|DRUG|Placebo|
215042312|NCT06263036|OTHER|Men|Laryngeal cartilages
215042313|NCT06263036|OTHER|Women|Laryngeal cartilages
215042314|NCT02746302|DRUG|HS-20004|
215042315|NCT02746302|DRUG|Placebo|
215042316|NCT00795028|OTHER|Standard Care for people after hip fracture|
215042317|NCT00795028|OTHER|Standard Care + exercise intervention|
215042318|NCT05739266|BEHAVIORAL|3 minutes step test|3 minutes step test- Stair hight:20 cm, Pace: 96 steps per minute
215042319|NCT03103854|BEHAVIORAL|BURST physical activity|BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.
215042320|NCT03103854|BEHAVIORAL|Text Message Reminders|Patients were sent daily text message reminders to remind them to exercise.
215042321|NCT03103854|BEHAVIORAL|Moderate Intensity Continuous Training|This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
214666487|NCT02252978|DRUG|ciprofloxacin|Given PO
214876334|NCT03401125|OTHER|Medical file data collection|The information described in the 'outcome measures' section will be collected from the medical files of the patients.
214876335|NCT04933968|BIOLOGICAL|ALVR106|Infusion, visually identical to placebo
214876336|NCT04933968|BIOLOGICAL|Placebo|Infusion, visually identical to ALVR106
214876337|NCT03621501|DEVICE|Percutaneous coronary intervention|At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
214876338|NCT06369597|PROCEDURE|Robotic telesurgery|Telesurgery by domestic surgical robot
214876339|NCT06369597|PROCEDURE|Laparoscopic surgery|Local laparoscopic surgery
214876340|NCT03318731|OTHER|Sugar Pill|Taken orally in capsule form
215042322|NCT06211712|DRUG|Experimental: Human Urinary Kallidinogenase|Before the first day of endovascular therapy (non-bridging), dissolve Human Urinary Kallidinogenase in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
215042323|NCT06211712|DRUG|Placebo Comparator: Placebo|Before the first day of endovascular therapy (non-bridging), dissolve placebo in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
215042324|NCT05357040|DRUG|Nitrous oxide gas for inhalation|"60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
215042325|NCT05357040|DRUG|Placebo|"60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
215042326|NCT06012851|BEHAVIORAL|Mobile behavioral parent training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
215042327|NCT06012851|BEHAVIORAL|In the moment feedback|In-the-moment feedback will include parenting feedback.
214666488|NCT02252978|OTHER|placebo|Given PO
214666489|NCT02252978|OTHER|quality-of-life assessment|Ancillary studies
214666490|NCT02252978|OTHER|laboratory biomarker analysis|Correlative studies
215042328|NCT06012851|BEHAVIORAL|In the moment suggestions|In-the-moment feedback will include suggestions for parenting strategies.
215042329|NCT03407768|BEHAVIORAL|Individualized interventions|"A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques."
215042330|NCT05162586|DRUG|Enpatoran low dose|Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
215042331|NCT05162586|DRUG|Enpatoran medium dose|Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
215042332|NCT05162586|DRUG|Enpatoran high dose|Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
215042333|NCT05162586|DRUG|Placebo|Participants will receive placebo matched to Enpatoran up to 24 weeks.
215042334|NCT02304159|DRUG|daclatasvir|
215042335|NCT02304159|DRUG|Sofosbuvir, Sovaldi|
215042336|NCT02304159|DRUG|Ribavirin|
214876341|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, Low Dose|Taken orally in capsule form
214876342|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, High Dose|Taken orally in capsule form
214876343|NCT01567475|DRUG|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
215042337|NCT05683366|DEVICE|No Intervention|There is no intervention in this study
215042338|NCT03398330|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fed state
215042339|NCT03398330|DRUG|OxyContin®|Orally taking OXYCONTIN® 40mg in fed state
215042340|NCT02347605|DRUG|Nicotine lozenge 4 mg|
215042341|NCT02347605|DRUG|Placebo lozenge|
215042342|NCT05732038|BEHAVIORAL|Healthy Minds Program (HMP)|Participants assigned to the HMP group will be asked to complete a minimum of 10 minutes per day of meditation for 12 weeks. For the first four weeks, participants will listen to prescribed meditations that will teach them the foundations of mindfulness. During weeks 5-12, participants will have full access to the HMP meditation library.
215042343|NCT05732038|BEHAVIORAL|Wellness App (WA)|"Participants in the WA group will listen to a minimum of 10 minutes per day of a caregiver specific educational podcast (including topics such as Caring for the Caregiver or Folate and Preventing Alzheimer's) delivered via a mobile app for the 12 weeks. The app contains one podcast per day for twelve weeks."
215042344|NCT02083978|OTHER|MRI scanning|
215042345|NCT02876731|DEVICE|PET-CT|NaF PET-CT
215042346|NCT02876731|DEVICE|MRI|DWMRI
215042347|NCT00317811|DIETARY_SUPPLEMENT|ascorbic acid|
215042348|NCT00317811|DRUG|bortezomib|
215042349|NCT00317811|DRUG|melphalan|
214291598|NCT04383405|OTHER|Conventional Training|Conventional land-based therapy consists of customized exercises focused on static and dynamic postural stability improvement. The exercises included the active-assisted mobilization, the muscle stretching the postural transition, the balance and the gait training. The control approach was carried out three times a week for four weeks and each session lasted 45 minutes.
214876344|NCT03729817|DEVICE|Submaximal balloon angioplasty|An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.
214876345|NCT01229709|BEHAVIORAL|Mindfulness Based Tinnitus Reduction|The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
214876346|NCT03214393|DIAGNOSTIC_TEST|Doppler|Doppler will be done to pregnant women with Pre-Eclampsia
214876347|NCT03214393|DIAGNOSTIC_TEST|serum antibodies|serum antibodies will be measured for pregnant women with Pre-Eclampsia
215042350|NCT05515744|PROCEDURE|Childbirth|Induction or planned cesarean
215042351|NCT02759133|DEVICE|Metal wire|Localization technique for breast surgery using metal wire
215042352|NCT02759133|DEVICE|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
215042353|NCT00805584|DRUG|desloratadine|Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
215042354|NCT02256995|DEVICE|uChek|The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
215042355|NCT02051192|BEHAVIORAL|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
215042356|NCT02051192|OTHER|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
215042357|NCT01567722|GENETIC|DNA analysis|This sample will be used for germline DNA analysis.
215042358|NCT01567722|GENETIC|RNA analysis|RNA will be sheared, reverse transcribed, and sequenced to assess transcribed sequences.
215042359|NCT01567722|GENETIC|gene expression analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
215042360|NCT01567722|GENETIC|polymorphism analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
215042361|NCT01567722|OTHER|biologic sample preservation procedure|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
214876348|NCT03339167|DIETARY_SUPPLEMENT|Metabolic availability of lysine in millet|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from millet and 1 level from millet with lentils.
215042362|NCT01567722|OTHER|flow cytometry|Information will include HIV RNA load at time of malignancy diagnosis) and imaging tests, results of the diagnostic tumor biopsy and bone marrow biopsy, and results of flow cytometry, cytogenetics, and molecular studies.
215042363|NCT01567722|OTHER|medical chart review|Participants will be followed prospectively to record the types of treatment given, and treatment outcome and toxicity.
215042364|NCT03961126|DRUG|Injection of autologous fatty tissue associated with autologous platelet-rich plasma.|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
215042365|NCT03961126|DRUG|Corticosteroids (clobetasol 0.05%)|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
215042366|NCT03179878|DRUG|Placebo|Placebo
215042367|NCT03179878|DRUG|SYNB1020|Investigational Product
215042368|NCT00344981|DRUG|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
215042369|NCT00344981|DRUG|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches \>400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
215042370|NCT04162834|DRUG|Papaverine|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
215042371|NCT04162834|DRUG|Normal saline|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
214876349|NCT03679182|DRUG|Olanzapine|Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
215042372|NCT03234634|PROCEDURE|endovascular thrombectomy|"Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~1. Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~2. Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well."
214876350|NCT03902730|OTHER|Traditional Back Squat|Participants will complete traditional back squat in this four treatment crossover design.
214876351|NCT03902730|OTHER|Barefoot Back Squat|Participants will complete barefoot back squat in this four treatment crossover design.
215042373|NCT06362109|BEHAVIORAL|Routine rehabilitation|"Routine rehabilitation consists of:~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
215042374|NCT06362109|DEVICE|Intermittent Oro-esophageal Tube Feeding|The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
215042375|NCT00382174|DRUG|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
215042376|NCT00382174|DRUG|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
214876352|NCT03902730|OTHER|Box Squat|Participants will complete box squat in this four treatment crossover design.
214876353|NCT03902730|OTHER|Traditional Back Squat with Chains|Participants will complete traditional back squat with chains in this four treatment crossover design.
214876354|NCT05856630|DRUG|Goserelin Acetate Sustained-Release Microspheres for Injection|10.8mg, Single dose, subcutaneously（SC）
214876355|NCT05856630|DRUG|Zoladex 10.8 MG Drug Implant|10.8mg, Single dose, subcutaneously（SC）
214876356|NCT01865240|DEVICE|Renal Denervation|Renal Denervation Catheter
214291599|NCT01829191|DEVICE|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
214291600|NCT01829191|DEVICE|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
214291601|NCT03516591|DRUG|AMV564 14-Day CIV|A 14-Day Continuous Intravenous Infusion regimen
214291602|NCT03707327|OTHER|Game Ready|the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
214876357|NCT06224465|OTHER|aerobic exercises|"Antiaging diet instruction :Be aware of the amount of calories, Reduce overall fat and sugar intake, Drink at least 10 glasses of water every day in order to remain healthy.~d. Eat a variety of complex carbohydrates and vegetables instead of bread, rice, and corn."
214876358|NCT02252991|OTHER|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
214876359|NCT01250886|DRUG|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
214876360|NCT01250886|DRUG|Normal saline solution|Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
215042377|NCT02108288|DRUG|OPC-1085EL ophthalmic solution|
214291603|NCT03707327|OTHER|Ice pack|the participants remained for 20 minutes with cryotherapy with ice pack
214876361|NCT01250886|DRUG|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
214876362|NCT03936426|DRUG|Cu-64 SARTATE and Cu-67 SARTATE|Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
214876363|NCT06380881|DRUG|SHR-2017|SHR-2017
214876364|NCT03253055|RADIATION|DEXA|Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are \~8uSv and \~4uSv respectively.
215042378|NCT02108288|DRUG|Carteolol long-acting ophthalmic solution|
215042379|NCT02108288|DRUG|Latanoprost ophthalmic solution|
215042380|NCT03868358|DEVICE|transcranial magnetic stimulation|"The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks"
215042381|NCT02160288|DRUG|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
215042382|NCT02160288|DRUG|Normal Saline|Dispensed in a 5 cc syringe
215042383|NCT02566863|DRUG|Dexmedetomidine|1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
214876365|NCT03253055|RADIATION|pQCT|A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
214876366|NCT03253055|OTHER|Lifestyle Questionnaire|Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
214876367|NCT03253055|OTHER|Aerobic Fitness|Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
215042384|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
214291604|NCT02103764|DRUG|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
214876368|NCT03253055|OTHER|Muscular Strength|Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
214876369|NCT03253055|BIOLOGICAL|Blood draw and finger prick test|15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count
214876370|NCT03253055|OTHER|Muscular Power|Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
214876371|NCT01120509|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
214876372|NCT02172235|DRUG|Pioglitazone|
214876373|NCT02172235|DRUG|Pioglitazone - low dose|
214876374|NCT02172235|DRUG|BI 10773 - low dose|
215042385|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
215042386|NCT02450825|DEVICE|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
215042387|NCT02690142|DRUG|Placebo|Single dose i.v.
215042388|NCT02690142|DRUG|ABY-035 i.v.|Single dose i.v.
215042389|NCT02690142|DRUG|ABY-035 s.c.|Single dose s.c.
215042390|NCT02170064|DRUG|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
215042391|NCT04683705|DIAGNOSTIC_TEST|Ultrasound|"1. High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~2. High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~3. Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI)."
215042392|NCT03195569|DRUG|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
215042393|NCT03195569|DRUG|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
215042394|NCT03195569|DRUG|Paclitaxel|175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
215042395|NCT03195569|DRUG|Carboplatin|AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
214291605|NCT02103764|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
214876375|NCT02172235|DRUG|BI 10773 - medium dose|
214876376|NCT02172235|DRUG|BI 10773 - high dose|
215042396|NCT03323164|DRUG|Timolol Maleate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
215042397|NCT03323164|DRUG|Brimonidine Tartrate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
215042398|NCT00164281|DRUG|Isoniazid|Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
215042399|NCT06071676|OTHER|conventional impression group|Silicon impression material loaded on plastic tray and inserted inside the patient mouth
214876377|NCT06403124|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation by reconstruction plate and screws
214876378|NCT04270318|OTHER|CH Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
214876379|NCT04270318|OTHER|CH pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
214876380|NCT04270318|OTHER|MTA Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
215042400|NCT06071676|OTHER|digital impression group|direct scanning was done using intraoral scanner to the female housing of the attachments on position
215042401|NCT02144467|DEVICE|MRI|fMRI, sMRI, ASL and DTI
215042402|NCT04756830|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
215042403|NCT01732614|PROCEDURE|Topcon Endpoint Management laser|
215042404|NCT05408780|DRUG|AC-OLE-01-VA|formulation of tricaprilin or matching placebo
215042405|NCT05791214|OTHER|score|Creation and validation of new nurse' score in ICU
215042406|NCT03794973|BIOLOGICAL|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
215042407|NCT03794973|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
215042408|NCT01337570|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
215042409|NCT01337570|OTHER|Placebo|Vaginal Ring containing no drug substance
215042410|NCT01337570|DRUG|Dapivirine|
215042411|NCT05945888|DRUG|BI 3000202|BI 3000202
215042412|NCT05945888|DRUG|Placebo matching BI 3000202|Placebo matching BI 3000202
215042413|NCT02638909|DRUG|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
215042414|NCT03434834|DEVICE|optical coherence tomography|OCT measurements of 5 locations in the esophagus
215042415|NCT04753489|DRUG|Rivaroxaban film-coated tablet 10 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.
214291606|NCT02608710|DRUG|RDEA3170 4.5 mg|
214876381|NCT04270318|OTHER|MTA pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
215042416|NCT04753489|DRUG|Xarelto® film-coated tablet 10 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.
215042417|NCT04397380|DEVICE|Thermography|Measure Temperature using Thermal Camera
215042418|NCT04397380|DEVICE|Tympanic Temperature|Measure Temperature using Tympanic Temperature
215042419|NCT01082302|DRUG|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
215042420|NCT01082302|OTHER|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
215042421|NCT03848780|DRUG|Desflurane|
214291607|NCT02608710|DRUG|RDEA3170 6 mg|
214291608|NCT02608710|DRUG|RDEA3170 12 mg|
214291609|NCT04612556|DRUG|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
214876382|NCT02119819|DRUG|LY2944876|Administered SC
214876383|NCT02119819|DRUG|Exenatide extended-release|Administered SC
214876384|NCT02119819|DRUG|Placebo|Administered SC
214876385|NCT02119819|DRUG|Metformin|Oral
214876386|NCT02132858|OTHER|cytology specimen collection procedure|Correlative studies
214876387|NCT02132858|OTHER|laboratory biomarker analysis|Correlative studies
214876388|NCT02699684|DEVICE|Lotrafilcon B contact lenses with EOBO-41|Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
214876389|NCT02699684|DEVICE|Lotrafilcon B contact lenses|Lotrafilcon B contact lenses packaged with copolymer 845
214876390|NCT02699684|DEVICE|Hydrogen peroxide-based lens care solution|Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
214876391|NCT02699684|DEVICE|Saline solution for rinsing contact lenses|Commercially-available saline solution used as needed
214876392|NCT02699684|DEVICE|Saline solution for rinsing contact lens case|Commercially-available solution used as needed
214876393|NCT01160003|DRUG|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
214876394|NCT01160003|DRUG|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
214876395|NCT03256279|DEVICE|".014 NiTi heat-activated archwire"|".014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment"
215042422|NCT01126957|DRUG|Ketamine|Ketamine was given as a 0.5mg / Kg bolus.
215042423|NCT01126957|DRUG|Placebo|Placebo given as an bolus to control group.
215042424|NCT01126957|DRUG|Fentanyl|Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
215042425|NCT01126957|DRUG|Propofol|Propofol given to both arms to maintain sedation throughout procedure.
215042426|NCT05298475|DRUG|Statin|Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
215042427|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor once a month SC
215042428|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor twice a month SC
215042429|NCT03347630|DIAGNOSTIC_TEST|MRI|Thoraco-abominal MRI
215042430|NCT02092181|DRUG|Mirabegron|25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
215042431|NCT02092181|DRUG|Placebo|Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
215042432|NCT04405817|DEVICE|ECMO|ECMO for circulatory and/or respiratory support
215042433|NCT00105664|PROCEDURE|Collaborative care model|
215042434|NCT00105664|PROCEDURE|Group interventions|
215042435|NCT00105664|PROCEDURE|Facilitated consultation|
214876396|NCT03256279|DEVICE|".014 NiTi Superelastic archwire"|".014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment"
214666491|NCT04934735|PROCEDURE|Rehabilitation program group|"The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~1. Intake by a case manager~2. Referral to an occupational physician was within one week of the intake.~3. Charting an occupational rehabilitation program and timing the RTW date~4. Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~5. Provision of a guidance booklet for employers on the RTW of cardiac patients.~6. The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~7. Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned."
214876397|NCT02897583|PROCEDURE|YAG vitreolysis|
214876398|NCT02662283|DRUG|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
214876399|NCT02662283|DRUG|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
214876400|NCT05262998|PROCEDURE|Plate fixation|"Procedure: plate fixation~Plate fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. A standard surgical protocol was used, the approach was moved inferiorly, the fracture was reduced, sometimes with osteosutur and fixed with an antero-superior anatomical plate. 3.5mm Locked and cortical screws were used on both sides of the fracture. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
215042436|NCT02343315|DEVICE|TENS|"Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.~* Equipment- TENS (CEFAR Basic TENS Machine)~* Electrodes- Four channel electrode to cover the site of pain~* Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.~* Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.~* Frequency- 5 Hertz~* Duration- 30 minutes"
214291610|NCT02237950|DRUG|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
214666492|NCT02493751|DRUG|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
214291611|NCT02237950|DRUG|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
214666493|NCT02493751|DRUG|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
214666494|NCT02183454|DEVICE|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
214666495|NCT03195140|DEVICE|Predictive Low Glucose Suspend|Application of Predictive Low Glucose Suspend
214666496|NCT06017323|DRUG|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15every 28 days (1 cycle)
214666497|NCT06017323|DRUG|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15every 28 days (1 cycle)
214666498|NCT06017323|DRUG|Proglumide Dose level 1|Daily dose of 1200 mg orally given as400 mg orally (PO), three times a day(TID) (dose level 1)
214666499|NCT06017323|DRUG|Proglumide Dose level 2|Daily dose of 1600 mg orally given as800 mg orally (PO) twice a day (BID)(dose level 2).
214666500|NCT03968510|PROCEDURE|parathyroidectomy|routine parathyroidectomy will be done for the treatment of adenoma
214666501|NCT01824602|DRUG|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
214666502|NCT01824602|DRUG|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
214666503|NCT01824602|DRUG|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
214666504|NCT01824602|DRUG|Placebo|Placebo sugar pills
214666505|NCT04396457|DRUG|Pembrolizumab|Human PD-1 Monoclonal antibody
214666506|NCT04396457|DRUG|Pemetrexed|Antineoplastic antimetabolite
214666507|NCT05313230|OTHER|CITRASATE SLED|Applying of CITRASATE SLED
214666508|NCT02077322|DEVICE|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
214666509|NCT02077322|DEVICE|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
214666510|NCT02713750|OTHER|reversible contraceptive methods|"1. Consistent male condom use only~2. Consistent female condom use only~3. Hormonal contraception, combined oral contraceptive pills and male/female condom~4. Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~5. Hormonal contraception , progestin only hormonal implant and male/female condom~6. Intrauterine device and male/female condom"
214666511|NCT04853797|DRUG|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
214666512|NCT04853797|DRUG|Ivabradine|15 mg oral Ivabradine.
214666513|NCT04853797|DRUG|Placebo|Oral placebo (calcium supplements).
214666514|NCT00248950|BEHAVIORAL|Positive affect induction and /or self affirmation induction|
214666515|NCT03420677|DEVICE|Application of tones|During NREM sleep, tones (max. 60 dB) will be played using a portable, safe, in-home device. This device records biosignals (e.g. brain activity) and precisely times the tones during NREM sleep. It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
215042437|NCT02343315|OTHER|SMCE|"Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.~Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities."
214666516|NCT03420677|DEVICE|No application of tones|This is the sham-control intervention; The device will only record biosignals but will not play tones.
214666517|NCT04374994|DRUG|Avanafil 50 MG|Oral phosphodiesterase type 5 inhibitors
214666518|NCT04374994|DRUG|Placebo oral tablet|lactose and maize starch, Egypt
214666519|NCT04299269|OTHER|Questionnaire|Questionnaire including questions about Quality of life, symptoms and general informations
214666520|NCT02513446|DRUG|BI 1026706|Single dose of BI 1026706 on Day 1
214666521|NCT02513446|DRUG|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
214666522|NCT00204386|DRUG|Topiramate|
214666523|NCT06449625|DRUG|Semaglutide Pen Injector [Ozempic]|Semaglutide active drug
214666524|NCT06449625|DRUG|Placebo|semaglutide placebo
214666525|NCT03141437|OTHER|Best Practice|Receive standard of care
214666526|NCT03141437|OTHER|Educational Intervention|Receive educational materials
214666527|NCT03141437|OTHER|Internet-Based Intervention|Use decision-making website
214666528|NCT03141437|OTHER|Questionnaire Administration|Ancillary studies
214666529|NCT01310530|RADIATION|Proton Beam Radiotherapy|Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
214666530|NCT02485717|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
214666531|NCT02485717|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
214666532|NCT02024256|OTHER|Cold pads soaked in Magnesium sulfate solution|
214666533|NCT02024256|OTHER|Cold pads soaked in water|
214666534|NCT03987750|DRUG|Safinamide Methanesulfonate 150mg|150 mg (free base)
214666535|NCT03987750|DRUG|Safinamide Methanesulfonate 100mg|100 mg (free base)
214666536|NCT03987750|DRUG|Safinamide Methanesulfonate matching placebo|placebo
214666537|NCT03767010|OTHER|Control (no PLM)|Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
214666538|NCT03767010|OTHER|PLM|PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
214666539|NCT05452070|DEVICE|HArmonyCa Lidocaine Injectable Gel|Subdermal or deep dermal injection
214666540|NCT05903781|DIAGNOSTIC_TEST|Prostate MRI|MRI of the prostate
214666541|NCT05036785|OTHER|Timing of suture removal|Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery
214666542|NCT02568904|OTHER|Alcohol|every participant will drink vodka at a dose of 2ml/kg bodyweight
214666543|NCT02568904|OTHER|Glucose|oral Glucose tolerance test
214666544|NCT02568904|OTHER|Fructose|oral fructose tolerance test
214666545|NCT02568904|OTHER|vehicle|control (water)
214666546|NCT00448461|DRUG|heparin|comparison between heparin and bivalirudin
214666547|NCT00448461|DRUG|bivalirudin|comparison between heparin and bivalirudin
214666548|NCT03822468|DRUG|Ribociclib|Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib was supplied as 200 mg tablets as individual patient supply packaged bottles.
214666549|NCT03822468|DRUG|Anastrozole|Anastrozole 1 mg tablets for oral use QD continuously
214666550|NCT03822468|DRUG|Letrozole|Letrozole 2.5 mg tablets for oral use QD continuously
214666551|NCT03822468|DRUG|Goserelin|Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
214666552|NCT04215679|OTHER|Three-dimensional immersive virtual reality application|In this group, individuals will be included in a game program that will last for 3 days a week for a total of 6 weeks and 45 minutes a day. Individuals will use the IVR to rehabilitate functions that are frequently used in daily life through task-oriented games. The IVR device will be placed on the head of the individual by closing the eyes of the individual and the Leap Motion device will be used to enable individuals to see their own hands in a virtual reality environment. In order to ensure the safety of individuals, practices shall be carried out with the individual sitting in the chair and leaning against the back. A total of 3 different games will be used for upper extremity function, each game will be 15 minutes and the total session time will be 45 minutes.
214666553|NCT04215679|OTHER|Motor imagery|Motor imagery will be performed with the eyes closed. In addition, for the safety of the individual, the individual will sit comfortably in a chair in a quiet environment and sit back. In the motor imagery group, individuals will be shown videos of the 3 games for 2 times in the IVR group and will be asked to imagine that they perform the same functions in the IVR games. The motor imagery will be 3 days a week for a total of 6 weeks and 45 minutes per day (including rest periods).
214666554|NCT04215679|OTHER|Conventional physiotherapy|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
214876401|NCT05262998|PROCEDURE|Intramedullary Screw|"Procedure: Intramedullary screw fixation~Intramedullary screw fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. Intramedullary screw fixation was performed by using a 1.6 or 2.8 mm-diameter threaded guide pin and a 85-100 mm long, 4.5 or 6.5 mm-diameter cannulated screw tapped in along the guide pin. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin.~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
214876402|NCT06415877|OTHER|Episio Training|episio repair training
214876403|NCT04987697|BEHAVIORAL|counseling|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
214876404|NCT04839692|DRUG|Hyaluronic acid filler|Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.
214876405|NCT04924257|DRUG|Esketamine nasal spray|Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS \<10).
214876406|NCT04924257|PROCEDURE|Electroconvulsive therapy|Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS \<10).
214876407|NCT04798612|DRUG|Pegasys|45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between
214876408|NCT04798612|DRUG|Saline|0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between
215042438|NCT02343315|OTHER|UHEP|"All the participants will receive the following treatments:~1. Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.~2. Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.~3. Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen)."
215042439|NCT03339596|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
215042440|NCT03339596|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
215042441|NCT03576235|DRUG|PG102P|Daily dose of 1.5g
215042442|NCT03576235|DRUG|Placebo|Daily dose of placebo
214876409|NCT01158092|DEVICE|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
214876410|NCT01158092|OTHER|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
214876411|NCT03146962|DRUG|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
214876412|NCT04135326|OTHER|Quality-of-Life Assessment|Ancillary studies
215042443|NCT02522039|DRUG|Latanoprost|1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
215042444|NCT02522039|DRUG|Timolol|1 drop of timolol was given to study eye after washout period of 1 week between drugs
215042445|NCT02522039|DRUG|Dorzolamide|1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
215042446|NCT05119530|DIAGNOSTIC_TEST|AcuVid COVID-19 Rapid Antigen Saliva Test|The AcuVid COVID-19 Rapid Antigen Saliva Test is a lateral flow immunoassay to detect SARS-CoV-2 nucleocapsid antigens in human saliva specimens
215042447|NCT00790673|DRUG|CF 102|Oral capsules
214876413|NCT04135326|OTHER|Questionnaire Administration|Ancillary studies
214876414|NCT04135326|PROCEDURE|Transcranial Direct Current Stimulation|Undergo tDCS
214876415|NCT05438914|DEVICE|Repair of the subscapularis|"The subscapularis will be repaired using the suture through bone and prosthesis holes surgical technique."
214876416|NCT03899441|OTHER|Video|Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
214291612|NCT02237950|DRUG|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
214291613|NCT02818322|DEVICE|telemedical monitoring ( T)|
214291614|NCT02818322|DEVICE|classic monitoring|
214876417|NCT00087620|DRUG|XELODA [capecitabine]|
214876418|NCT00955526|DRUG|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
214876419|NCT00955526|DRUG|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
214876420|NCT00955526|DRUG|Placebo|Two placebo tablets once daily for 12 weeks
214876421|NCT04236323|DRUG|Not used remifentanil infusion|Remifentanil is not used during operation
215042448|NCT00790673|DRUG|Placebo|Matching placebo capsules
215042449|NCT05811325|OTHER|kinesiotaping without craniosacral therapy|The first treatment group will receive kinesio taping for 6 weeks atleast 4 times per week
215042450|NCT05811325|OTHER|kinesiotaping with craniosacral therapy|The second treatment group will receive kinesio taping with craniosacral therapy for 6 weeks atleast 4 times per week with each session lasting for 60 minutes
215042451|NCT06050980|DRUG|HSK40118|Oral administration, QD
215057596|NCT06269510|BEHAVIORAL|ENGAGE-ALD Application (APP)|"Participants randomized to this will complete the app at the time of enrollment.~If in-person, will complete the app on a research laptop or iPad. The ENGAGE-ALD app consists of two modules developed based on preliminary data: 1) a misconception correction module and 2) a treatment matching module designed to match patients to participant's preferred form of alcohol treatment based on preferences for 19 different dimensions of alcohol treatment. The intervention will consist of administering a single session of the ENGAGE-ALD app."
214876422|NCT03460639|RADIATION|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
214876423|NCT03460639|RADIATION|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
214876424|NCT03460639|DIAGNOSTIC_TEST|Control group|In this group, we will only induce fatigue.
214876425|NCT02283008|BEHAVIORAL|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
214876426|NCT04007653|OTHER|Observation|No intervention
214876427|NCT03239223|DRUG|ABI-1968|Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
214876428|NCT04855578|OTHER|In-Hopsital Patient Educational Brochure|The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.
215042452|NCT05812326|DRUG|AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells|AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
215042453|NCT03508050|DEVICE|Clamping the Double Lumen Tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
215042454|NCT02625181|PROCEDURE|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
215042455|NCT02625181|PROCEDURE|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
215042456|NCT02625181|PROCEDURE|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
215042457|NCT02625181|PROCEDURE|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
215042458|NCT02625181|DEVICE|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
215042459|NCT02625181|DEVICE|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
215042460|NCT02625181|PROCEDURE|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
215042461|NCT02625181|PROCEDURE|Elective surgery|Surgical procedures that are scheduled and not an emergency.
215042462|NCT02625181|DRUG|Propofol|Anesthetic drug used to maintain general anesthesia
215042463|NCT02625181|DRUG|Sevoflurane|Anesthetic drug used to maintain general anesthesia
215042464|NCT02625181|DRUG|Isoflurane|Anesthetic drug used to maintain general anesthesia
215042465|NCT02625181|DRUG|Desflurane|Anesthetic drug used to maintain general anesthesia
215042466|NCT02625181|DRUG|Scopolamine|Prophylactic antiemetic
215042467|NCT02625181|DRUG|Droperidol|Prophylactic antiemetic \& rescue antiemetic
215042468|NCT02625181|DRUG|Haloperidol|Prophylactic antiemetic \& rescue antiemetic
215042469|NCT02625181|DRUG|Dexamethasone|Prophylactic antiemetic \& rescue antiemetic
215042470|NCT02625181|DRUG|Promethazine|Prophylactic antiemetic \& rescue antiemetic
215042471|NCT02625181|DRUG|Meclizine|Prophylactic antiemetic \& rescue antiemetic
215042472|NCT02625181|DRUG|Aprepitant|Prophylactic antiemetic \& rescue antiemetic
215042473|NCT02625181|DRUG|Metoclopramide|Rescue antiemetic
215042474|NCT02625181|DRUG|Fentanyl|Analgesic drug / Opioid
215042475|NCT02625181|DRUG|Sufentanil|Analgesic drug / Opioid
215042476|NCT02625181|DRUG|Alfentanil|Analgesic drug / Opioid
215042477|NCT02625181|DRUG|Remifentanil|Analgesic drug / Opioid
215042478|NCT02625181|DRUG|Morphine|Analgesic drug / Opioid
215042479|NCT02625181|DRUG|Meperidine|Analgesic drug / Opioid
215042480|NCT02625181|DRUG|Hydromorphone|Analgesic drug / Opioid
215042481|NCT02625181|DRUG|Methadone|Analgesic drug / Opioid
215042482|NCT02625181|DRUG|Oxycodone|Analgesic drug / Opioid
215042483|NCT02625181|DRUG|Oxymorphone|Analgesic drug / Opioid
214291615|NCT03530904|OTHER|mobilization|Early mobilization after CIED implantation
215042484|NCT02625181|DRUG|Hydrocodone|Analgesic drug / Opioid
215042485|NCT02625181|DRUG|Ketamine|Analgetic / Analgesic drug
215042486|NCT02625181|DRUG|Ondansetron|Prophylactic antiemetic \& rescue antiemetic
215042487|NCT02625181|DRUG|Granisetron|Prophylactic antiemetic \& rescue antiemetic
214876429|NCT04855578|OTHER|Physician Education about Gabapentinoid Prescription|An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
214876430|NCT02935153|BIOLOGICAL|Anti-CD22-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
214876431|NCT06353542|DIAGNOSTIC_TEST|Software analysis|The tested AI software analyzes the optic disc retinography to determine if the patient is healthy, a glaucoma suspect, or a glaucoma case
214876432|NCT06353542|DIAGNOSTIC_TEST|Ophthalmologist examination|The ophthalmologist (a glaucoma specialist) will analyze the tests and will examine the patient to determine if the patient is healthy, a glaucoma suspect or a glaucoma case
214876433|NCT03608865|DRUG|Durvalumab with Tremelimumab|Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis. Durvalumab 1500mg + tremelimumab 750 mg will be administered as a 60 minute each one IV infusion every 4 weeks. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site.
214876434|NCT02376400|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29 or 57.
214876435|NCT02376400|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29 or 57.
214876436|NCT02376400|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
214876437|NCT00581165|DRUG|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
214876438|NCT06362863|DIETARY_SUPPLEMENT|enteral nutrition biscuits|Addition of enteral nutritional biscuits to existing pharmacological treatment.
214876439|NCT01917214|OTHER|Sutent: Observational Study|Sutent oral therapy
214876440|NCT00002780|BIOLOGICAL|aldesleukin|
214876441|NCT00002780|BIOLOGICAL|cytokine therapy|
214876442|NCT00002780|BIOLOGICAL|sargramostim|
214876443|NCT00002780|DRUG|carboplatin|
214876444|NCT00002780|DRUG|cyclophosphamide|
214876445|NCT00002780|DRUG|thiotepa|
215042488|NCT02625181|DRUG|Dolasetron mesylate|Prophylactic antiemetic \& rescue antiemetic
215042489|NCT02625181|DRUG|Palonosetron|Prophylactic antiemetic \& rescue antiemetic
215042490|NCT02625181|DRUG|Tropisetron|Prophylactic antiemetic \& rescue antiemetic
215042491|NCT02625181|DRUG|Ramosetron|Prophylactic antiemetic \& rescue antiemetic
214876446|NCT00002780|PROCEDURE|peripheral blood stem cell transplantation|
214876447|NCT00926783|PROCEDURE|CFAE ablation|CFAE ablation (targeted vs. generalized)
215042492|NCT01542970|DIETARY_SUPPLEMENT|Placebo|Olive oil
215042493|NCT01542970|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
214291616|NCT01996982|DEVICE|CCS Device|Core Cooling System Device
214876448|NCT05577221|DEVICE|High Flow Nasal Air|Administration of air at high flow by using a high flow nasal oxygenation (FiO2 21%) device
214876449|NCT00070551|BIOLOGICAL|GTI-2040|Given IV
214876450|NCT00070551|DRUG|cytarabine|Given IV
214876451|NCT00070551|OTHER|pharmacological study|Optional correlative studies
214876452|NCT00070551|OTHER|laboratory biomarker analysis|Optional correlative studies
214876453|NCT03600987|BEHAVIORAL|Simultaneous music and reading lyrics|listening to music with singing of the lyrics simultaneously with reading the written lyrics.
214876454|NCT03600987|BEHAVIORAL|Priming with music|priming by listening to music and singing of the lyrics followed by reading the written lyrics.
214876455|NCT03600987|BEHAVIORAL|Control|control condition using reading materials without music.
214876456|NCT05177718|DRUG|Natalizumab 300 MG in 15 ML Injection|Disease modifying agent
214876457|NCT04737096|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
214876458|NCT04737096|DRUG|Placebo|placebo
214876459|NCT04737096|DEVICE|tDCS|tDCS
214876460|NCT00117910|DRUG|pegfilgrastim|
214876461|NCT01326650|DRUG|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
214876462|NCT01326650|DRUG|placebo|daily oral placebo supplement for three years
214876463|NCT06112496|DEVICE|EMG|Neuro-EMG-Micro, Neurosoft, Ivanovo, Russia, will be used for the assessment of muscle activity for muscles.
214876464|NCT00235209|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
215042494|NCT01542970|DIETARY_SUPPLEMENT|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
215042495|NCT01542970|DIETARY_SUPPLEMENT|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
215042496|NCT03710889|DRUG|Abaloparatide|Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH\[1-34\] and 76% homology to human PTHrP\[1-34\].
214876465|NCT06240195|OTHER|data collection|Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability
214876466|NCT05630690|DEVICE|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
214876467|NCT05187130|OTHER|Mindfulness|60 patients in the mindfulness-based breathing and music therapy group were divided into subgroups of 5 participants each. Each 6-person group started by having participants complete the pretest State Anxiety Inventory, Beck Depression Inventory, and Psychological Well-Being Scale via Survey Monkey. Mindfulness-based breathing and music therapy was applied to each patient group in approximately 45-minute sessions per day. At the end of the session, participants re-filled the posttest State Anxiety Inventory, Work-Related Tension Scale, and Psychological Well-Being Scale. A total of 3 sessions were completed with an interval of two days.
214876468|NCT00613886|DEVICE|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
214876469|NCT00613886|BEHAVIORAL|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
214876470|NCT05346926|DEVICE|3D-printed cast|The 3D-printed casts are produced using 3D print technology based on software by Belgian software company: The patient's forearm is scanned with a tablet (duration: approx. 5 min), whereupon the cast is printed overnight according to the scan (duration: approx. 4h) and adjusted to the patient during the next appointment.
214876471|NCT05346926|DEVICE|Conventional cast|A conventional plaster cast is applied for treatment of the distal radius fracture.
214876472|NCT06414226|DIETARY_SUPPLEMENT|Krill and Fish Oil vs. Placebo|Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.
214876473|NCT00753857|OTHER|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
214876474|NCT00753857|OTHER|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
214876475|NCT05127512|OTHER|Education Video|A 6.47-minute education video was created by the research group based on American Urogynecology Society (AUGS) and International Urogynecologic Association (IUGA) patient education pamphlets. Participants in the intervention group will be asked to watch this video after completing a baseline knowledge questionnaire of pelvic floor disorders.
214876476|NCT04855149|OTHER|Patient satisfaction|Patient satisfaction evaluated with EVAN LR questionnaire
214876477|NCT02065856|BIOLOGICAL|AVANZ Salsola|AVANZ Salsola
214876478|NCT03301571|OTHER|Change in preload and afterload|Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated
214876479|NCT03301571|OTHER|Inspired oxygen|Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively
214876480|NCT03301571|OTHER|Pacemaker mode|Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
214876481|NCT03021889|BEHAVIORAL|Nutritional therapy|The nutritional therapy intervention group received monthly nutritional guidelines for 12 weeks focusing on the diet for dyslipidemia, based on the recommendation of the type I diet of the Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection in children and adolescents. In addition, participants in the intervention group received weekly phone calls for nutritional counseling.
214876482|NCT03021889|BEHAVIORAL|Control group|The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
214876483|NCT03684967|DRUG|Fruquintinib|Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
214876484|NCT05026996|DRUG|Pelacarsen|Single subcutaneous injection of pelacarsen
214876485|NCT04569669|DIAGNOSTIC_TEST|FFR and FFRCT|All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
214876486|NCT06246214|DEVICE|Blue Light Therapy|The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue).
214876487|NCT06246214|DEVICE|ControlLT|The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED.
214876488|NCT06097455|GENETIC|ARI0003|Treatment with ARI0003 cells
214876489|NCT03927014|OTHER|thiol/disulfide levels|Venous blood will sample from the antecubital veins for measuring the serum concentration of thiol/disulfide levels. The serum thiol/disulfide levels will measure using commercially available reagent kits, which is produced to detect human thiol/disulfide levels (Rel Assay Diagnostics Gaziantep, Turkey). The thiol/disulfide levels measurements were performed in accordance with the company's protocol.
214876490|NCT02186834|DRUG|Selinexor|Selinexor orally as outlined in the study treatment arm.
214876491|NCT02186834|DRUG|Liposomal doxorubicin|Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
214876492|NCT02186834|DRUG|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
214876493|NCT04228835|DIAGNOSTIC_TEST|Fluorescence Cholangiography|Administration of ICG for fluorescence cholangiography
214876494|NCT05744141|PROCEDURE|Relaxation Exercises|"Relaxation exercises consist of voluntary, rhythmic and regular stretching and relaxation of large and small muscle groups until the whole body relaxes. For this exercise application, the Relaxation Exercises CD prepared by the Turkish Psychological Association will be used. The CD consists of 30 minutes and relaxation exercises are explained with the sound of a stream accompanied by verbal instructions. This exercise includes rhythmic breathing, muscle relaxation exercises and music (stream sound)."
214876495|NCT05011747|PROCEDURE|single-site rigid probe viscotrabeculotomy (VT)|single-site VT by the rigid probe trabeculotome is performed through a superonasal triangular scleral flap.
214876496|NCT05011747|PROCEDURE|two-site rigid probe viscotrabeculotomy (VT)|Two-site VT by the rigid probe trabeculotome is performed through a superonasal and an inferotemporal triangular scleral flap.
214876497|NCT03636997|PROCEDURE|Draining seton|Number 1 silk suture was passed through the fistula track and tied as loose seton
214876498|NCT03636997|PROCEDURE|Rerouting of track|The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
214876499|NCT01236911|OTHER|Calcium Measurement|after moderate-severe TBI (less as 24 hrs)
214876500|NCT00749892|DRUG|Erlotinib Hydrochloride|Given PO
214876501|NCT01799369|BEHAVIORAL|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
214876502|NCT01053000|DRUG|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
214876503|NCT00126282|BEHAVIORAL|behavior therapy|
214876504|NCT00126282|DRUG|D-Cycloserine|
214876505|NCT00714896|BEHAVIORAL|Stepped-Care|"* stage-based expert system written intervention at baseline and 3 months~* in-person stage appropriate counseling at baseline and 3 months~* telephone counseling sessions at weeks 2,4 and 8,~* as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~* optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
214876506|NCT00714896|BEHAVIORAL|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
214876507|NCT03924518|DRUG|Granisetron Hydrochloride|Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
214876508|NCT03924518|DRUG|Placebo（Normal saline）|therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
214876509|NCT03107221|BEHAVIORAL|"Smart Eating internet-based self-help programme"|An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
214876510|NCT02191761|DRUG|SM04755|Escalating Doses
214876511|NCT03887793|OTHER|VACs|The VACs (Vaccinate Adolescents against Cancer) model for HPV vaccine quality improvement is a strategy developed by the American Cancer Society to improve HPV vaccination coverage in large integrated health care delivery systems. It includes the development of a quality improvement (QI) action plan, the formation of a QI team of health care providers, education for the QI team about HPV-related disease burden and vaccine efficacy, HPV vaccine coverage assessments at several time points that are shared with individual clinics within the health are system, and the adoption of specific QI strategies by participating clinics in the health care system.
214876512|NCT02572245|DEVICE|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
214876513|NCT02572245|DEVICE|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
214876514|NCT01422629|DEVICE|Ultrasonic ablation device|High Intensity focused ultrasound treatment
214876515|NCT04462211|PROCEDURE|Implementation of management pharmacological protocol of constipation|"first 48 hours:~* polyethylene glycol 3350 (about 17 grams) 1 every 8 hours enterally.~* Patients who have vomiting and / or gastric residue greater than 500 mL (in a timely measurement every 6 hours) will also be given domperidone 10 mg every 8 hours intravenously.~* Patients who have excessive abdominal distension will be administered in addition, levosulpiride 25 mg every 8 hours intravenously.~  48 hour evaluation:~* Patients who do not have bowel movements will be administered lactulose or sodium phosphate enema.~* For patients who do not have a bowel movement, administration of neostigmine intravenously or of naloxone enterally will be evaluated.~* Every patient who uses one or more prokinetics will have an electrocardiogram.~* Any patient who has bowel movements during management, doses of polyethylene glycol 3350 will be adjusted according to the daily goal of bowel movements, the days of treatment of the prokinetics will be adjusted, for a maximum of 5 consecutive days."
214876516|NCT04462211|PROCEDURE|Implementation of bundle of prevention and non-pharmacological management|"Bundle of prevention:~* Start early enteral nutrition.~* Optimize and / or decrease opioid doses.~* Start early mobilization.~Non-pharmacological management bundle~* Select laxative and/or prokinetic/s to manage constipation.~* Optimize and / or decrease doses of opioids and sedatives.~* Start early mobilization.~* Pharmacological reconciliation."
214876517|NCT01191944|DRUG|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
214876518|NCT01191944|DRUG|pramipexole extended release tablet|0.375mg-4.5mg, once a day
214876519|NCT01404130|DRUG|Isotretinoin|0.5-1mg/kg daily for 4-6 months
214876520|NCT03513055|OTHER|nurse inject premixed insulin|nurse inject premixed insulin，coaching in the injection technique
214876521|NCT00358410|DRUG|GW679769 oral tablets|2x GW679769 60mg tablets
214876522|NCT00358410|DRUG|Placebo|Placebo oral tablets to match experimental intervention
214876523|NCT00905710|PROCEDURE|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
214876524|NCT02055664|DRUG|Ropivacaine 0.2%|
214876525|NCT02055664|DRUG|Chlorure de sodium 0.9%|
214876526|NCT02814890|PROCEDURE|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
214876527|NCT02814890|PROCEDURE|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
214876528|NCT04093375|PROCEDURE|Radical Prostatectomy|Radical prostatectomy with or without androgen deprivation therapy
214666555|NCT06338891|OTHER|Main questionnaire|Main questionnaire will evaluate the demographic and genetic characteristics, clinical manifestations, and self-perception of sensitivity to wheat or other food and the possible relationship between the intake of wheat or other foods and the flare-ups of the disease in FMF patients
214876529|NCT04093375|OTHER|Radical Radiotherapy|Radical Radiotherapy with adjuvant androgen deprivation therapy
214876530|NCT05853042|DIAGNOSTIC_TEST|high-sensitivity cardiac troponin testing|Lithium heparin plasma samples will be measured with Mindray Bio-Medical CL-1200i Chemiluminescence Immunoassay Analyzer.
214876531|NCT01056315|DRUG|GRT3938Y|Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
214876532|NCT01056315|DRUG|Placebo|Overencapsulated tablets of placebo, 16 weeks treatment.
214876533|NCT05416788|OTHER|cervical manipulation|high-velocity, low-amplitude cervical manipulation
214876534|NCT05416788|OTHER|Sham intervention|lateral flexion and cervical rotation without manipulation
214876535|NCT02733380|DRUG|Chidamide|30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
214876536|NCT02733380|DRUG|Vinorelbine|20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
214876537|NCT02733380|DRUG|Liposomal Doxorubicin or mitoxantrone|20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
214876538|NCT02733380|DRUG|Dexamethasone|10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
214876539|NCT02733380|DRUG|Thalidomide|100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
214876540|NCT00469144|DRUG|Busulfan|"Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
214876541|NCT00469144|DRUG|Fludarabine|40 mg/m\^2 IV Daily Over 1 Hour x 4 Days
214876542|NCT00601562|DRUG|Zidovudine|
214876543|NCT04602546|DEVICE|BIS Complete Monitoring System|The BIS™ EEG complete monitoring system is intended for use under the direct supervision of a licensed healthcare practitioner or by personnel trained in its proper use. The system and its associated parameters are intended for use on adult patients within a hospital or medical facility, providing patient care to monitor the state of the brain by data acquisition of EEG signals.
214876544|NCT04185623|PROCEDURE|denudation time lag|The time between ovum pickup and denudation of oocyte
214876545|NCT04130750|COMBINATION_PRODUCT|treatment of drug screening|Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
214876546|NCT03951025|DIETARY_SUPPLEMENT|Melatonin oral administration|One tablet with1 mg of melatonin and 82 mg of excipients
214876547|NCT03951025|DIETARY_SUPPLEMENT|Melatonin sublingual administration|One tablet with 1 mg of melatonin and 82 mg of excipients
214876548|NCT03905720|PROCEDURE|Acupuncture|A licensed acupuncturist will assess participants' symptoms and administer acupuncture needles in accordance with traditional Chinese medicine principles and the study protocol. Treatments will provided daily for up to four hospital days.
214876549|NCT03905720|BEHAVIORAL|Pain Counseling|Participants will receive sessions with a counselor trained in pain management. The pain counselor will explain, review, and discuss the contents of a Pain Control booklet. Sessions will include pain assessment, pain education, and coping skills, provided daily for up to four hospital days.
215057597|NCT06269510|BEHAVIORAL|Treatment Facilitation bundle|Participants will complete a survey. The module includes motivational interviewing-informed content tailored to address and assist in overcoming barriers. After taking the survey, participants will receive a virtual coaching session (either via phone or online virtual platform). Sessions will focus on identifying participant goals with respect to alcohol use and liver health, providing education on risks of alcohol use to liver health and risks of relapse, reviewing participants individually identified barriers to alcohol treatment, exploring benefits of and these barriers to alcohol treatment, and performing collaborative goal-setting, among other topics.
214876550|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using Polypropylene mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
214876551|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using OviTex 1S permanent mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
214876552|NCT01577589|DRUG|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
214876553|NCT01577589|DRUG|Placebo in 50 ml infusion volume|IV infusion
214876554|NCT01577589|DRUG|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
214876555|NCT01577589|DRUG|Placebo in 250 ml infusion volume|IV infusion
214876556|NCT01577589|DRUG|600 mg ceftaroline in 100 ml infusion volume|IV infusion
214876557|NCT01577589|DRUG|Placebo in 100 ml infusion volume|IV infusion
214876558|NCT00461201|PROCEDURE|Nurse practitioner care of patients|
214876559|NCT02046486|DRUG|Ticagrelor 180mg whole tablets|
214876560|NCT02046486|DRUG|Ticagrelor 180mg crushed and dispersed|
214876561|NCT03624309|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
214876562|NCT03624309|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
214876563|NCT05529446|DEVICE|Combination therapy (CT)|Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US \& TENS where this approach was effective in pain modulation
214876564|NCT06050304|BEHAVIORAL|Observation of behavior and search of biomarkers with 3 blood tests.3 weeks wearing an actimeter|In the form of a small watch, which collects the level of motor activity throughout the day and night. Patients will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. We want to know if certain uses lead to more behavioral problems (especially after periods of cessation).
214876565|NCT06050304|BIOLOGICAL|3 blood tests|We will try to identify biomarkers of BS: blood proteins, genetic markers passed on by your parents, or the expression of proteins in particular situations
214876566|NCT05742035|PROCEDURE|Venipuncture|Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
214876567|NCT04573114|PROCEDURE|Verticalization|Progressive levels of verticalization
214876568|NCT04837924|PROCEDURE|fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml)|Land mark technique will be used to perform FICB on the side of the hip fracture. The injection site is one centimetre caudal from the junction between medial 2/3 and lateral 1/3 in the imaginary line between anterior superior iliac spine and ipsilateral pubic tubercle. The goal is to administer local anesthetic in the fascia iliaca compartment.
214876569|NCT04837924|DRUG|paracetamol 1 gram IV|paracetamol 1 gram IV every six hours, 4 times in 24 hours
214876570|NCT04837924|DRUG|Rescue analgesic tramadol 100 mg IV if needed|Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours
214876571|NCT04837924|PROCEDURE|Sham injection|Sting with blunt needle, (without piercing the skin), same site as fascia iliaca compartment block
214876572|NCT05616637|DIAGNOSTIC_TEST|Navicular Drop Test|While participants in sitting position, the navicular tuberosity (NT) will be palpated.The most distal protruding portion of the medial NT will be marked. Participants will be asked to stand with equal weight on both feet. The new distance will be measured. The navicular drop test (NDT) results will then be obtained by comparing the measured values between the sitting and standing positions. Each measurement will be repeated three times and the average of the 3 measurements will be calculated. The expression in mm of the distance between the two marks will be considered the amount of ND. The amount of navicular fall of 10 mm or more will be interpreted as pes planus. Measurements will be made on both extremities. As a result of the measurements, if pes planus is present in a single extremity, that extremity, if it is present in both extremities, the extremity with higher NDT or if it is equal on both sides, the dominant extremity will be tested.
214876573|NCT05616637|OTHER|Lower Extremity Length Measurement|Lower extremity length will be recorded to normalize dynamic balance test data. The person will lie in the supine position. The distance between the umbilicus and the anterior superior of the spina iliaca will be measured in cm with the help of a tape measure. If there is no asymmetry, it will be assumed that there is no rotation in the pelvis, and it will be started to measure the length of the lower extremity. If pelvic asymmetry is detected, the pelvic position will be corrected manually. Then, the most inferior point of the spina iliaca anterior superior and the most distal point of the medial malleolus will be marked and measured and recorded. Lower extremity length and data in 3 different directions will be used in cm. The purpose of using formulas is to easily provide comparisons with other studies using the same type of data. The data obtained from the formula is expressed as a percentage of the length of the limb.
215042497|NCT02648945|OTHER|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
215042498|NCT00133445|BIOLOGICAL|DTaP-Hep B-IPV Vaccine|U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
215042499|NCT00133445|BIOLOGICAL|Monovalent Hep B Vaccine|U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
215042500|NCT00133445|DRUG|Placebo|Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
215042501|NCT03700177|DRUG|Dexamethasone|modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.
215042502|NCT03700177|DRUG|Placebo|modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
215042503|NCT03700177|DRUG|Ropivacaine Injection [Naropin]|30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
215042504|NCT01159093|BEHAVIORAL|Family Decision Support|Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
215042505|NCT01159093|BEHAVIORAL|Clinician Decision Support|Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
215042506|NCT01159093|OTHER|Family Decision Support and Clinician Decision Support|This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
215042507|NCT01159093|OTHER|Control|Usual care
215042508|NCT05725122|PROCEDURE|Extracorporeal shock wave lithotripsy|Extracorporeal shock wave lithotripsy will given to the patients
215042509|NCT05725122|PROCEDURE|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy.|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy will be given to the patients
215057598|NCT06269510|BEHAVIORAL|Enhanced Usual Care|This group will receive standard hepatology care, and an educational pamphlet defining alcohol treatment resources available within Michigan Medicine and giving information on how participants can access these resources. This information will be given directly to participants that enroll in person or e-mailed to participants or sent via postal mail for those that enroll remotely.
214666556|NCT06338891|OTHER|Secondary questionnaire|Secondary questionnaire will investigate the possible appearance of gastrointestinal and extraintestinal symptoms linked to the ingestion of gluten/wheat, which are not identifiable, by the patient, as FMF flare-ups, but might be compatible with a NCGS/NCWS diagnosis
214666557|NCT06511908|DRUG|(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)|Arm 1 and 2 Experimental Intervention
214666558|NCT06511908|DRUG|Placebo|Arm 1 and 2 Control Intervention
214666559|NCT05300087|DRUG|Albuterol Sulfate Inhalation Aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
214666560|NCT05300087|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation|MDI, 2 puffs, single dose, fasting
214666561|NCT01390545|DRUG|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
214666562|NCT02725502|DRUG|Linagliptin|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
214666563|NCT02725502|DRUG|Placebo|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
214666564|NCT02810990|DRUG|Bosutinib|"Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 \> 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
214666565|NCT03992313|OTHER|Community-based HCV rapid test|HCV rapid tests will be done in the village
214666566|NCT03992313|OTHER|Facility-based HCV rapid test|HCV rapid tests will be done in the health center
214666567|NCT03992313|OTHER|Plasmatic HCV viral load|HCV viral load will be done in provincial hospital on plasma using GenXpert
214666568|NCT03992313|OTHER|DBS HCV viral load|HCV viral load will be done in Phnom Penh by DBS using Omunis kit
214666569|NCT06971458|PROCEDURE|Sclerotherapy|ultrasound (US)-guided sclerotherapy for the treatment of ovarian endometrioma
214666570|NCT05662514|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis BLa80|"Test product contain 3 × 109 colony-forming units \[CFU\] Bifidobacterium animalis subsp. lactis BLa80 strains, for each packet.~Subjects ingested one packet (3 g/packet) of Test product per day (2 hours after taking antibiotics in the evening), for 14 days."
214666571|NCT05662514|OTHER|Placebo|To maintain the blinding, patients in the control group received placebo included in identical packets. Control product per day (2 hours after taking antibiotics), for 14 days.
214666572|NCT03050164|DRUG|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
214666573|NCT03050164|DRUG|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
214666574|NCT00867750|DEVICE|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
214666575|NCT00867750|DRUG|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
214666576|NCT03822910|DIAGNOSTIC_TEST|Pattern Separation Paradigm|Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
214666577|NCT03822910|DIAGNOSTIC_TEST|Sequential Associative Mismatch Paradigm|used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
214666578|NCT03822910|DIAGNOSTIC_TEST|Encoding Plasticity Paradigm|Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
214666579|NCT05422300|BEHAVIORAL|Fed|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine.
214666580|NCT05422300|BEHAVIORAL|Ex-Fed|"Participants will be subjected to a full-body resistance exercise protocol, consisting of an upper and lower body circuit. The upper body circuit will be a chest press and dumbbell row superset, whereas the lower body circuit will be leg press and leg extension (4 sets of 10 repetitions @ 75% of their 1 repetition max, respectively). The inter-set rest period will be 90 seconds.~Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine."
214666581|NCT00377650|DEVICE|Percutaneous thrombectomy|
214666582|NCT03248128|DRUG|FF/VI via ELLIPTA DPI|ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
215042510|NCT04098705|OTHER|Introduction of the World Health Organization Triage Scale|"The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol."
214666583|NCT03248128|DRUG|FF via ELLIPTA DPI|ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
214666584|NCT06107829|DRUG|Valbenazine Oral Capsule|Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
214666585|NCT01914679|DEVICE|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
214666586|NCT04026789|OTHER|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
214666587|NCT04026789|OTHER|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
214666588|NCT01158612|DRUG|Growth Hormone|infusion of Growth hormone in the patella tendon.
214666589|NCT00215254|DRUG|quetiapine|
214666590|NCT02051101|OTHER|Biopsy sample from Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
214666591|NCT01363050|DRUG|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
214666592|NCT03180463|DRUG|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2\*10\^7 cells,
214666593|NCT03180463|PROCEDURE|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
214666594|NCT05024994|DRUG|E7820|100mg of E7820 QD
214666595|NCT00002850|DRUG|ciprofloxacin|Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
214666596|NCT00002850|DRUG|ofloxacin|Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
214666597|NCT00002850|DRUG|160 mg trimethoprim and 800 mg sulfamethoxazole|Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet \[TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole\] every 12 hours for two months..
214666598|NCT02848547|BEHAVIORAL|Text Messaging via Short Message Service|
214666599|NCT00049764|DRUG|Drotrecogin alfa (activated)|
214666600|NCT00049764|DRUG|Placebo|
214666601|NCT02001740|DRUG|Triamcinalone (steroid) and lidocaine|receive once
214666602|NCT02001740|OTHER|Lidocaine|receive once
214666603|NCT06418542|DEVICE|use of florescein|Fluorescein, an organic contrast agent, is used in FFA to detect retinal pathologies.
214666604|NCT04630054|DEVICE|Face mask|Intervention individuals will be given cloth or surgical face masks.
214666605|NCT04630054|BEHAVIORAL|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
214666606|NCT03200951|DRUG|Bolus group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
214666607|NCT03200951|DRUG|Infusion group for epidural block|Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
214666608|NCT04820192|OTHER|Craniosacral Therapy|The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.
214666609|NCT01729689|OTHER|counseling intervention|Undergo cognitive behavioral therapy
214666610|NCT01729689|OTHER|questionnaire administration|Ancillary studies
214666611|NCT01729689|PROCEDURE|quality-of-life assessment|Ancillary studies
214666612|NCT01253733|BEHAVIORAL|MD2ME|The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
214666613|NCT05347654|OTHER|Local treatment with silver sulphadiazine only|Local treatment with silver sulphadiazine and tulle from day 0 to day 8 (included). From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
214666614|NCT05347654|OTHER|Local treatment with silver sulphadiazine followed by URGOCLEAN® dressing|Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
214666615|NCT02297789|DEVICE|Investigative Full Face Mask with Headgear|
214666616|NCT05599958|DIAGNOSTIC_TEST|sweat chloride test|assessing chloride (Cl-) concentration in sweat of the patient
215042511|NCT04034888|BEHAVIORAL|HEX|HEX is a customized exercise program with components including: 1) controlled flexibility movements; 2) progressive ADL training focusing on bed mobility, bed to chair transfers, and indoor walking; 3) task-specific seated resistance training to improve ability to get out of bed and; 4) and balance exercises. Participants will be expected to perform their HEX program at least 2 times/week in their home and all individualized exercise sessions will be supervised by an Exercise Physiologist. Each exercise has four levels of difficulty, which will be progressed as tolerated throughout the 12-weeks. Seated resistance exercises were designed to target all the major muscle groups and will include the following: arm curls, shoulder raises (lateral/front), overhead arm raise, wrist curls, leg extensions, hip flexion, hip ab/adduction, sit-to-stands, torso rotation, and marching.
215042512|NCT05758324|DIETARY_SUPPLEMENT|Nutri PNEA|4 sequences of 10 tablets (one intake)
215042513|NCT05758324|DIETARY_SUPPLEMENT|Placebo|4 sequences of 10 tablets (one intake)
215042514|NCT03643081|DEVICE|"Use of the camera Fluobeam"|"Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy."
215042515|NCT03425955|DEVICE|SUNEKOS ® 200|"4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
214666617|NCT05599958|GENETIC|genetic testing|detection of CFTR mutation
214666618|NCT01321489|DRUG|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
214666619|NCT01321489|DRUG|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
214666620|NCT05772364|OTHER|Loading of low-calcium water first, then high-calcium water|All cohort subjects are asked to consume water with less than 5 mg/L of calcium first, then are asked to consume water with at least 400 mg/L of calcium
214666621|NCT01974791|BEHAVIORAL|GET Living|GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
214666622|NCT01058603|OTHER|- Conventional culture medium for IVF|Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
214666623|NCT01058603|OTHER|- Endocell®|Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
214666624|NCT00590161|DRUG|pentoxifylline (PTX)|400 mg PO tid
214666625|NCT00590161|DRUG|placebo|placebo tid
214666626|NCT01360125|GENETIC|proteomic profiling|
214666627|NCT01360125|OTHER|flow cytometry|
214666628|NCT01360125|OTHER|laboratory biomarker analysis|
214666629|NCT03791632|OTHER|classical lecture style presentation|classical lecture style presentation
214666630|NCT03791632|OTHER|an intervention in the form of fun workshops|an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
214666631|NCT03791632|OTHER|digital media intervention|digital media intervention
214666632|NCT04054310|DIAGNOSTIC_TEST|Liver Multi Scan|MRI to create cT1, T2\* and PDFF images of patients liver.
214666633|NCT03260647|OTHER|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
214666634|NCT00787436|DRUG|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
214666635|NCT03751384|DIETARY_SUPPLEMENT|Möllers Omega-3 Ekstra Sterk|
214666636|NCT03751384|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|
214666637|NCT04150458|DRUG|18F-fluorocholine PET/CT.|18F-fluorocholine positron emission tomography / computed tomography
214666638|NCT05115084|OTHER|no intervention|no intervention
214666639|NCT04152759|DRUG|Drug: BAT2506 injection Other Names: Simponi(EU-licensed)|"Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)"
214666640|NCT06602336|DEVICE|Continuous Lactate Monitoring Device|Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device.
214666641|NCT06600906|DRUG|Hyperpolarized 13C-Pyruvate|Given intravenously (IV)
214666642|NCT06600906|PROCEDURE|Computed tomography (CT)|Undergo CT imaging
214666643|NCT06600906|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
214666644|NCT00735332|DRUG|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
214666645|NCT06444438|DIAGNOSTIC_TEST|subarachnoid hemorrhage|CT presented subarachnoid hemorrhage
214666646|NCT03528525|OTHER||observation
214666647|NCT03153852|DRUG|Modified Jessner's solution|Modified Jessner's solution will be applied on the right side until frosting
214666648|NCT03153852|DRUG|Glycolic acid|Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
214666649|NCT03153852|DRUG|Trichloroacetic acid|Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
214666650|NCT06657014|OTHER|mind-mindedness|The Mind-Mindedness Training Intervention is a structured program designed specifically for primary caregivers of preschool-aged children (ages 4 to 7) who exhibit signs of social anxiety. This intervention is unique because it focuses on enhancing caregivers' understanding and responsiveness to their children's emotional and mental states through the concept of mind-mindedness.
214876574|NCT05616637|OTHER|Y Balance Test|While the individual tries to balance on one bare foot at the midpoint of the assembly, the individual will also be asked to reach as far as possible with the other foot in the anterior, posteromedial and posterolateral directions, touch the tip of the toe, and then immediately return to the starting position without disturbing the balance. The test will be evaluated for 3 repetitions. Situations where the participant will be requested to repeat the test: the foot on the ground passes the reference point or the heel lifts off the ground, perturbations caused by the environment, contact of the foot with the ground, and loss of balance when returning to the starting position. 10 seconds between 3 repetitions during testing will be given. Each participant will be given the right to try 6 times before starting the test in order to eliminate the possible learning parameter. The test will be repeated 3 times in each direction and the closest distance in cm will be recorded.
214876575|NCT03846583|DRUG|Tucatinib|Tucatinib is a drug that inhibits human epidermal growth factor receptor 2 (HER-2) protein, which is a protein expressed in the cancer cells. By inhibiting this protein, tucatinib may help stop or reduce the growth of the tumor
214876576|NCT03846583|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
214876577|NCT03846583|DRUG|Trastuzumab|"• Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When Trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system."
214876578|NCT03846583|DRUG|Aromatase Inhibitor|These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
214876579|NCT00442871|DRUG|eltrombopag|eltrombopag 50 mg oral
214876580|NCT04149093|DIAGNOSTIC_TEST|Calretinin staining|"A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.~Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining."
214876581|NCT04194294|DRUG|Lidocaine|Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.
215042516|NCT03425955|DEVICE|"SUNEKOS® 1200 and SUNEKOS® 200"|"5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
215042517|NCT03076684|OTHER|low-fructose diet|Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to \<5% of energy and keeping their weight stable.
215042518|NCT03076684|DRUG|Allopurinol|Subjects in the drug arm will take the drug allopurinol daily.
215042519|NCT03254784|DRUG|BMS-986165 Capsule|Oral capsule
215042520|NCT03254784|DRUG|BMS-986165 Tablet|Oral tablet
214291617|NCT03551860|PROCEDURE|TQL|"For the intervention of TQL peripheral nerve block the needle tip will be advanced by in-plane technique and local anaesthetic will be deposited between psoas major and quadratus lumborum muscles. 20 ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
214876582|NCT04194294|OTHER|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
214876583|NCT04718948|DEVICE|Urinary Multimodal Fiber Optic Spectroscopy|"Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.~It will be administered through a appositely designed device"
214876584|NCT04718948|DIAGNOSTIC_TEST|Urine Cytology|An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine
214876585|NCT04718948|PROCEDURE|Surgery|It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)
214876586|NCT02156167|DEVICE|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
214876587|NCT04585230|DRUG|CBD|CBD oil Roll-On Stick
214876588|NCT04585230|DRUG|Mineral Oil|Mineral Oil- Roll on Stick
214876589|NCT04585230|DRUG|Placebo|Roll- On stick with no CBD and no Mineral Oil
214876590|NCT03021863|BEHAVIORAL|Group A Reminder|Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
214876591|NCT03021863|BEHAVIORAL|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
214876592|NCT03021863|BEHAVIORAL|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
214876593|NCT03021863|BEHAVIORAL|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
214876594|NCT03021863|BEHAVIORAL|Group E Reminder|Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
214876595|NCT03021863|BEHAVIORAL|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
214876596|NCT03021863|BEHAVIORAL|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
214876597|NCT03021863|BEHAVIORAL|Group H Reminder|Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
214876598|NCT03021863|BEHAVIORAL|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
215042521|NCT00180284|DEVICE|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
215042522|NCT00570713|DRUG|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
215042523|NCT00570713|DRUG|Placebo|As per package insert.
214666651|NCT06656156|OTHER|Proprioceptive neuromuscular facilitation technique|"Experimental group was given proprioceptive neuromuscular facilitation technique (PNF) along with conventional treatment.~PNF will be applied on iliopsoas and hamstring muscles, 3 repetitions/session with a break of 2 minutes/repetition (10 second isometric Contraction then 10 second stretch)~Treatment contains total 12 sessions (3 times/week for 4 consecutive weeks)"
214666652|NCT06656156|OTHER|Conventional treatment|"Conventional treatment contains tens and hotpack.~Tens Will be applied for 20 minutes and hotpack for 10 minutes~Total 12 sessions (3 times/week for 4 consecutive weeks)"
214666653|NCT06657209|PROCEDURE|Insulin resistance testing|Steady state Plasma Glucose test
214666654|NCT06657209|PROCEDURE|OGTT|Will collect 5 blood draws during the test to measure insulin secretion
214666655|NCT06657209|PROCEDURE|Fat biopsy|Needle biopsy to gather a sample of abdominal subcutaneous fat
214666656|NCT06657209|RADIATION|DXA scan|Whole body DXA scan
214666657|NCT06657209|PROCEDURE|MRI|Abdominal MRI
214666658|NCT06657209|PROCEDURE|1H-MRS|Spectroscopy of the abdominal region
214666659|NCT06657209|DRUG|Tirzepatide|16 weeks started at 2.5mg/week and increased to 5mg/week dose
214666660|NCT06657209|DRUG|Pioglitazone|16 weeks at a 45mg/day dose
214666661|NCT06657625|OTHER|Sepsis Performance Improvement Program|Training/awareness for medical and paramedical staff; creation of informational posters; development of an institutional pathway in the emergency department; creation of a protocol ; establishment of a sepsis team with a dedicated contact number.
214666662|NCT06656533|OTHER|Repeated Transcranial magnetic stimulation (rTMS)|Transcranial Magnetic Stimulation (TMS) involves a procedure where parts of the participants brain will be non-invasively (i.e. indirectly) stimulated by magnetic pulses. These magnetic pulses induce very brief activity in brain areas underlying the TMS coil. TMS will be performed by giving repetitive pulses (rTMS). rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder. The goal of this study is to optimize the impact of rTMS therapy on sleep outcomes for patients with insomnia disorder.
214666663|NCT02053805|OTHER|PSA|PSA. Serum \& plasma will be stored for future investigations
214876599|NCT04150263|PROCEDURE|Intraocular lens (IOL) ab externo scleral suture fixation|traditional IOL scleral suture fixation
214876600|NCT04150263|PROCEDURE|Modified IOL ab externo scleral suture fixation|Modified IOL scleral suture fixation
214666664|NCT02053805|OTHER|IPSS questionnaire|the validated International Prostate Symptom Score
214666665|NCT02053805|OTHER|DRE (Digital Rectal Examination )|physical examination for the prostate gland
214666666|NCT02053805|OTHER|urine flow and residual|The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
214666667|NCT02053805|PROCEDURE|a multiparametric prostate MRI|The MRI will be reported on a 5 point Likert Scale
214666668|NCT02053805|PROCEDURE|trans-rectal ultra-sound guided prostate biopsy|12 core Trans-rectal prostatic biopsy for diagnostic purposes
214666669|NCT03999970|OTHER|Sand fly bite|Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
214666670|NCT02452359|DEVICE|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
214666671|NCT00584350|OTHER|Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
214666672|NCT00584350|OTHER|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
214666673|NCT00584350|OTHER|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
214666674|NCT02985801|DRUG|Pancrelipase|Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units
214666675|NCT02985801|DRUG|Placebo Oral Capsule|Placebo Oral Capsule
214666676|NCT07106450|BEHAVIORAL|Acute Resistance Exercise|Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).
214666677|NCT07107971|DEVICE|Paclitaxel-eluting balloon|Participants in the intervention group will receive local treatment of non-obstructive, lipid-rich coronary plaques using a paclitaxel-coated drug-eluting balloon (DCB) in addition to guideline-directed medical therapy (GDMT). The DCB will be applied to plaques identified as high-risk based on near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) imaging, defined by a maxLCBI4mm ≥325. The balloon catheter diameter will be sized 1:1 according to the true lumen diameter as derived from IVUS. Balloon length will be sized to the LRP length as measured with IVUS including a 5 mm margin on each side. The balloon will be inflated at nominal pressure (6-8 ATM) during a period of at least 60 seconds, but preferably for 90 seconds if tolerated. A 5 mm margin is taken into account to differentiate between single or multiple LRPs within the same coronary artery.
214876601|NCT06552013|OTHER|MERV 13 filter|This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.
214876602|NCT06552013|OTHER|Sham filter|This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.
214876603|NCT03138590|DEVICE|Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS|Transcranial Direct Current Stimulation targeting the trigeminal nerve
214876604|NCT04981327|DRUG|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|Apixaban 5 MG BID versus Apixaban 2.5 MG BID
214876605|NCT02237391|OTHER|CIPAP Program|The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
214876606|NCT02237391|OTHER|Treatment as Usual (TAU)|Control group
214876607|NCT06034782|DIAGNOSTIC_TEST|Fine Needle Aspiration|Fine Needle Aspiration of a salivary gland tumor
214876608|NCT06034782|PROCEDURE|Histologic Examination|Histologic examination of resected salivary tumor
214876609|NCT00436865|BEHAVIORAL|Weight loss|
214876610|NCT03803982|PROCEDURE|Deep Neuromuscular Blockade|The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
214876611|NCT03803982|DRUG|Sugammadex|Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
214876612|NCT05110820|DIAGNOSTIC_TEST|Automated quantitative pupillometer|Quantitative measurement of pupillary variables was performed at the time of arrival at the ED (0 h), and at the 6-, 12-, and 24-h time points on hospital day (HD) 1. The worst value among those recorded within 24 h and during the total measurement period was selected as the 24-h and total lowest values. If a patient was discharged before HD 3, measurements were taken only until discharge. The initial value was measured within 1 h after arrival at the ED because of the requisite time for obtaining informed consent before enrollment. At each time point, the lowest values for the NPi and qPLR of each eye were retained for analysis. The sPLR (standard PLR) was serially measured in the ED and after admission by emergency physicians using a manual penlight. We classified the reactivity of the sPLR as reactive, sluggish, or non-reactive. Non-reactive sPLR was defined when pupillary reactivity was not identified bilaterally.
214876613|NCT04363957|OTHER|Brachytherapy video|Patients will watch a video that contains information about brachytherapy
214876614|NCT04363957|OTHER|Standard Brachytherapy Consent Process|Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
214876615|NCT00253448|RADIATION|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
214876616|NCT00253448|RADIATION|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
214876617|NCT02564887|DEVICE|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
214876618|NCT00043628|PROCEDURE|Stem Cell Mobilization|
214876619|NCT00000620|DRUG|Anti-hyperglycemic Agents|Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
214876620|NCT00000620|DRUG|Anti-hypertensive Agents|Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
214876621|NCT00000620|DRUG|Blinded fenofibrate or placebo plus simvastatin|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
214876622|NCT02850731|DEVICE|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
214876623|NCT04626648|BEHAVIORAL|Pause with a sugar containing drink|Three-minute long intraoperative pause, including a sugar-containing drink
214876624|NCT00348504|DRUG|levosimendan|
214876625|NCT00348504|DRUG|dobutamine|
214876626|NCT03267901|OTHER|food|45 g of walnut / iso-caloric white bread
214876627|NCT04683016|OTHER|Questionnaires|"Patients will be asked two sets of questions:~* questionnaire about their perception of periodontal disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire.~All these two sets of questions will be asked before and after non surgical periodontal therapy"
214876628|NCT06003296|PROCEDURE|Calcaneocuboid arthrodesis|Calcaneocuboid arthrodesis in triple arthrodesis
214876629|NCT01199016|PROCEDURE|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
214876630|NCT01199016|PROCEDURE|Nose/throat swab|To be performed at every study visit
214876631|NCT01199016|BIOLOGICAL|Observational|Observational Study Only
215042524|NCT00570713|DRUG|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
215042525|NCT04982952|BEHAVIORAL|Contingency Management - Increasing|Increasing incentive payment for abstinent participant
215042526|NCT04982952|BEHAVIORAL|Fixed payments|Fixed payments for attending study visits
214876632|NCT02318303|DRUG|GSP 301-1 NS (QD)|GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril
214876633|NCT02318303|DRUG|GSP 301-2 NS (BID)|GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril
214876634|NCT02318303|DRUG|GSP 301 Placebo NS|GSP 301 placebo NS administered as 2 sprays/nostril
214876635|NCT02318303|DRUG|Olopatadine HCl-1 NS (QD)|Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril
214876636|NCT02318303|DRUG|Olopatadine HCl-2 NS (BID)|Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril
214876637|NCT02318303|DRUG|Mometasone Furoate-1 NS (QD)|Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril
214876638|NCT02318303|DRUG|Mometasone Furoate-2 NS (BID)|Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
214876639|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
214876640|NCT01090518|DRUG|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
214876641|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
214876642|NCT00309803|DEVICE|FiberNet Embolic Protection Device|
214876643|NCT01616342|DEVICE|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
214876644|NCT06551376|OTHER|Ovarian Stimulation Start|To compare ovarian response accordin to ovarian stimualtion start
214876645|NCT04628897|BEHAVIORAL|Exposures|"1. Total area of available floor space inside the home (m2)~2. Frequency that child plays outdoors~3. Total number of physical hazards in the home (presence of open stairwells, stove height)~4. Total number of fine-motor activity items available to the child~5. Presence of gross-motor activity items available to the child across each category (e.g., fixed, portable: ball equipment, push/pull equipment, riding equipment, rocking and twisting equipment)~6. Hemoglobin concentration (g/L)."
214876646|NCT00986050|DRUG|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
214876647|NCT00986050|DEVICE|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
214876648|NCT00986050|DEVICE|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
214876649|NCT03140371|DIETARY_SUPPLEMENT|High energy high protein peptide feed study|"Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
214876650|NCT06256107|DEVICE|Virtual Reality Headset|Virtual Reality Headset
214876651|NCT01638585|DRUG|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
214876652|NCT02265926|DEVICE|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
214876653|NCT04001946|DEVICE|Button Huggie|low profile, external securement device for G-buttons
214876654|NCT06626295|OTHER|exercise-snack group|Adolescents in the exercise-snacks group will perform 4 \&amp;amp;amp;#34;exercise-snacks\&amp;amp;amp;#34; sessions per day during 3 weeks in addition to multidimensional care program. These sessions will consist of 1-min various intense supervised exercises . They will also receive information about their attitudes to physical activity.
214876655|NCT05461196|BEHAVIORAL|CPMRx|Patients use a mobile application to track pain medication usage and pain scores.
214876656|NCT01320384|OTHER|O2 conventional|standard low flow therapy
214876657|NCT01320384|DEVICE|O2-HFN : high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
214876658|NCT01320384|DEVICE|O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
214876659|NCT02248883|DRUG|TPV low|
214876660|NCT02248883|DRUG|Placebo|
214876661|NCT02248883|DRUG|Moxifloxacin|
214876662|NCT02248883|DRUG|TPV high|
214876663|NCT02248883|DRUG|RTV|
214876664|NCT05972330|DIETARY_SUPPLEMENT|VRx MyBiotics Oral Lozenges|VRx MyBiotics Oral Lozenges are composed of prebiotics, probiotics, and postbiotics.
214876665|NCT04218734|DRUG|DBPR108|DBPR108: 100 mg, once daily for 24 weeks.
214876666|NCT04218734|DRUG|metformin hydrochloride|metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
214876667|NCT04218734|DRUG|placepo|placebo:100 mg, once daily for 24 weeks.
214876668|NCT00100308|DRUG|Unfractioned heparin|Low-dose continuous-infusion, 500 units/hour per seven days
214876669|NCT00100308|DRUG|saline|Saline placebo
214876670|NCT01192607|DEVICE|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
214876671|NCT01228578|DIETARY_SUPPLEMENT|Multivitamin supplements B,C and E|One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
214876672|NCT01150812|DRUG|AZD8165|Oral suspension, 2 mg/mL and 20 mg/mL, single doses
214876673|NCT00717379|DRUG|Tacrolimus|oral
214876674|NCT00717379|DRUG|Mycophenolate Mofetil|oral
214876675|NCT00717379|DRUG|Methylprednisolone or equivalent|oral
214876676|NCT00717379|DRUG|Prednisone|oral
214876677|NCT03742947|DIAGNOSTIC_TEST|peripartum haemostasis|Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
214876678|NCT04032717|DRUG|Q-Griffithsin (Q-GRFT) enema|Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
214876679|NCT04032717|OTHER|Placebo enema|Approximately 125mL of 0.9% sodium chloride solution
215042527|NCT02431156|OTHER|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
215042528|NCT01649713|DRUG|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
215042529|NCT00776360|DRUG|oxytocin|80mIE/min as continuous infusion for 70 minutes
214666678|NCT07107867|BEHAVIORAL|breastfeding counseling|Pregnant women assigned to the intervention group then participated in a breastfeeding counseling training program held at the gynecology and obstetrics unit of an university training and research hospital. The training sessions lasted 60 to 90 minutes and included small groups of 5 to 6 participants, based on recommendations from the literature. The training was delivered through a slide presentation, and participants received a printed training booklet beforehand. Visual aids, including a baby model and breast model, were also used to enhance understanding. The training content was developed in line with infant feeding guidelines from UNICEF, the Turkish Ministry of Health, and relevant literature.
215042530|NCT00776360|DRUG|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
215042531|NCT06154603|PROCEDURE|Surgical treatment type|This observational design will study the clinical outcome for each type of upper gastrointestinal perforation in relation to surgical or non-surgery treatment and in relation to treatment centre.
215042532|NCT04179422|OTHER|anthropometric measurement|weight, height, BMI
215042533|NCT04179422|OTHER|nutritional questionnaire|24hs food recall, presence of feeding disorders
215042534|NCT03498573|OTHER|tunneling surgical technique|sticky bone prepared by centrifuge patient blood and mixing with xinograft
214291618|NCT03551860|PROCEDURE|FIB|"The needle tip will be advanced by in-plane technique and local anaesthetic will be deposited deep to the fascia iliaca. 20ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
214291619|NCT05493527|DEVICE|noninvasive high frequency oscillatory ventilation|"A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~1. a frequency of 10 Hertz ( range, 8-12 Hz);~2. an inspiratory time of 50% (1:1)~3. an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~4. Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~5. fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
214291620|NCT05493527|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~1. Peep ranging from 5 to 10 cmH2O,~2. Peak inspiratory pressure range 15-25 cmH2O~3. Rate range 40-50 breath/minute~4. FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
214291621|NCT01574326|DRUG|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
214291622|NCT01574326|DRUG|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
214291623|NCT01294293|DRUG|TLR8 Agonist VTX-2337|Given SC
214291624|NCT01294293|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214291625|NCT01294293|OTHER|Pharmacological Study|Correlative studies
214291626|NCT01294293|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214291627|NCT01294293|DRUG|Paclitaxel|Given IV
214291628|NCT01330589|DRUG|Placebo|Non-active placebo for 7 days: PO/TID
214291629|NCT01330589|DRUG|St. Johns Wort|For 7 days: 300mg PO/TID
214291630|NCT02278250|DRUG|M4344 10 mg BIW|Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214291631|NCT02278250|DRUG|M4344 20 mg BIW|Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214666679|NCT07107711|PROCEDURE|One-Stop Hybrid Surgery|With the patient under moderate hypothermia (approx. 28°C) and cardiopulmonary bypass, surgeons perform a total arch replacement using a standard 4-branched graft. After the open repair is complete, a separate, distinct covered stent graft is deployed antegradely into the descending aorta through the open distal end of the arch graft. Completion angiography confirms correct placement.
214666680|NCT07107711|PROCEDURE|Conventional Total Arch Replacement with Frozen Elephant Trunk|With the patient under deep hypothermic circulatory arrest (23°C-25°C) and cardiopulmonary bypass, surgeons perform a total arch replacement using an integrated hybrid prosthesis (Frozen Elephant Trunk), which consists of a vascular graft sutured to a covered stent graft. This single device is deployed antegradely into the descending aorta, and the arch vessels are then reattached to the branches of the prosthetic graft.
214666681|NCT05715190|OTHER|Education|Visiting the medical psoriasis outpatient clinic. Receiving a medical consultation, phototherapy and methotrexate treatment. Psoriasis plaque measurement, psoriasis care and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a multidisciplinary nurse-led educational program
214666682|NCT05635838|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214666683|NCT05635838|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
215042535|NCT05207384|PROCEDURE|Ozone (O2-O3) injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
215042536|NCT05207384|PROCEDURE|Corticosteroid injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
215042537|NCT06168396|DEVICE|Somatosensation Device|The somatosensation device will be worn on the lower limb (either the residual limb for an amputee, or limb with decreased sensation for a participant with diabetic neuropathy) while performing outcome measures.
214666684|NCT06383520|DRUG|68Ga-aGPC3-scFv/Fab|"For pharmacokinetics, healthy volunteer underwent PET imaging targeting GPC3. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~For Cancer patients, subjects should have targeting GPC3 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (AFP, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
214876680|NCT02685683|DRUG|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of \>50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI \<7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
214876681|NCT00314951|DRUG|Fidaxomicin|200 mg oral capsules two times daily (q12h regimen)
214876682|NCT00314951|DRUG|Vancomycin|125 mg capsules q6hr (4 times a day)
214876683|NCT00314951|DRUG|Matching Placebo to Fidaxomicin|Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
214876684|NCT05961917|OTHER|5 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 5 cmH2O
214876685|NCT05961917|OTHER|10 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 10 cmH2O
214876686|NCT05063032|OTHER|Radiofrecuency ablation|Radiofrequency ablation to treat left atrial flutter, guided by high-density mapping versus linear ablation.
215042538|NCT06168396|OTHER|Baseline|Participants will perform outcome measures without wearing the somatosensation device.
215042539|NCT06220084|BEHAVIORAL|Dance for PD®|The intervention consists of 16 60-min adapted to Greek culture DfPD® classes, which will be performed twice weekly for 8 weeks and instructed by a single researcher, who has the approval to use it for research reasons. The intervention will be delivered both live and online in separate periods for each participant.
215042540|NCT04881760|DRUG|LY3437943|Administered SC
215042541|NCT04881760|DRUG|Placebo|Administered SC
215042542|NCT06513533|OTHER|Placebo|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
215042543|NCT06513533|DRUG|Dimethyl fumarate|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
215042544|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
215042545|NCT04769869|DRUG|Placebo for AZD4604 for inhalation via DPI|"Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10."
215042546|NCT04769869|DRUG|AZD4604 for IV administration|Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
215042547|NCT04769869|DRUG|AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
215042548|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
215042549|NCT00135083|DRUG|insulin glulisine|"* Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below."
215042550|NCT05873088|DIAGNOSTIC_TEST|Isometric|Effects of Isometric Exercise in Female Patients With Osteoarthritis
215042551|NCT05873088|DIAGNOSTIC_TEST|Isotonic Exercise|Effects of Isotonic Exercise in Female Patients With Osteoarthritis
215042552|NCT00867139|DRUG|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
215042553|NCT00867139|DRUG|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
215042554|NCT00867139|OTHER|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
215042555|NCT00240266|DRUG|Rosuvastatin|
215042556|NCT01203397|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G|APLIED 4 TIMES/DAY AT LESION
214876687|NCT03495921|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
214876688|NCT03495921|DRUG|Irinotecan|Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.
214876689|NCT03495921|DRUG|Temozolomide|Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
214876690|NCT04935684|DRUG|Fecal Microbiota Transplantation|"Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes."
214876691|NCT02072603|OTHER|HITSystem|"Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action alerts for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants."
214876692|NCT02072603|OTHER|Standard of Care|current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
214876693|NCT04010552|DRUG|NALRINOX combination|NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
215042557|NCT03272555|OTHER|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
215042558|NCT05495581|DRUG|pudexacianinium chloride|Intravenous
215042559|NCT02133079|BIOLOGICAL|autologous gp96 vaccination|vaccination of autologous gp96 derived from tumor tissue + basal treatment
215042560|NCT05993741|DEVICE|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
215042561|NCT06327711|OTHER|Control: CHO Blend|2 servings as a snack or between meals morning and evening
215042562|NCT06327711|OTHER|Experimental: CHO Blend plus AN100|2 servings as a snack or between meals morning and evening
215042563|NCT05994352|OTHER|virtual reality simulation|The effect of virtual reality simulation on therapeutic communication skill levels
215042564|NCT01538199|DEVICE|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
215042565|NCT01538199|DEVICE|Sham device|The sham device does not emit near-infrared radiation.
215042566|NCT05965219|DRUG|Emraclidine|Emraclidine tablets.
215042567|NCT05965219|DRUG|Itraconazole|Itraconazole oral solution.
215042568|NCT05965219|DRUG|Carbamazepine|Carbamazepine tablets.
214876694|NCT01382537|DEVICE|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
214876695|NCT01382537|DEVICE|InterX 5000|Placebo treatment
214876696|NCT04387942|DRUG|IL-2|For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
214876697|NCT05320887|OTHER|Normal Nicotine Content Vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
215042569|NCT05965219|DRUG|Metformin|Metformin tablets.
215042570|NCT02081586|BEHAVIORAL|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
215042571|NCT02081586|DEVICE|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
215042572|NCT02081586|OTHER|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
215042573|NCT02951260|DRUG|Metformin|17 days treatment with metformin
215042574|NCT02951260|OTHER|Placebo|17 days treatment with placebo
215042575|NCT02118155|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
215042576|NCT04017234|OTHER|frequency following response, eye exercise, and transcutaneous|frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
215042577|NCT04844333|OTHER|Extubation under deep anesthesia|When the patient in sedation or anesthesia state, no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 \< 45mmhg, regular waveform, stable circulation, the patient is in deep anesthesia state, and the endotracheal tube is removed.
215042578|NCT02460276|DRUG|Lenalidomide|
215042579|NCT02460276|DRUG|Ibrutinib|
215042580|NCT02460276|DRUG|Rituximab|
215042581|NCT04845256|DEVICE|SOMAVAC 100 Sustained Vacuum System|Evaluate performance of sustained vacuum system compared to manual suction bulbs
215042582|NCT04221893|RADIATION|Radiation Therapy (RT)|Undergo radiation therapy
215042583|NCT00571883|OTHER|questionnaire administration|
214666685|NCT04677114|DRUG|Buprenorphine and Outpatient Parenteral Antibiotic Therapy|Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.
214876698|NCT05320887|OTHER|Normal nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
214876699|NCT05320887|OTHER|Low nicotine content vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
214876700|NCT05320887|OTHER|Low nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
214876701|NCT06457893|OTHER|The health belief model-based exercise training program and health belief model-based education|The health belief model-based exercise training program and education program will implement with the students in the experimental group for 5 weeks and follow-ups will be made at the 3rd and 6th months.
214876702|NCT01577771|BIOLOGICAL|Prevnar13 (manufactured by Pfizer)|Prevnar13 administered IM in the antero-lateral thigh
214876703|NCT04936165|PROCEDURE|Low-Level Laser Therapy|Use 810-nm-photosource to irradiate the participants' brain and forearm for 10 minutes with a water-cooling radiator to keep it at 25 ± 0.5 ℃.
214876704|NCT00435760|DRUG|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
215042584|NCT00571883|PROCEDURE|psychosocial assessment and care|
215042585|NCT00571883|PROCEDURE|quality-of-life assessment|
215042586|NCT00571883|PROCEDURE|regional lymph node dissection|
214876705|NCT00435760|DRUG|Placebo Tiotropium|1 puff once daily, 1 day treatment
214876706|NCT00435760|DRUG|Tiotropium|1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
214876707|NCT00435760|DRUG|Placebo LAS34273|1 puff, 1 dat treatment
215042587|NCT00571883|PROCEDURE|therapeutic conventional surgery|
215042588|NCT05290532|OTHER|Individualized exercise training|The intervention will consist of a multicomponent exercise training program, which will composed of supervised progressive resistance exercise training, aerobic and anaerobic exercises. This training period consist on 2 training sessions of 40 minutes (Warm up 5´+ aerobic exercise 15´+ anaerobic exercise 15´+ stretching 5´)per week during 4 weeks after one week of discharge
215042589|NCT05513963|BEHAVIORAL|Clairity|Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.
215042590|NCT03904160|BEHAVIORAL|Weight management|Please see the arm descriptions.
215042591|NCT03393104|BEHAVIORAL|Motor Control Exercise|Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.
215042592|NCT03393104|BEHAVIORAL|Patient Education|Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
215042593|NCT03722810|OTHER|Intervention|"The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher."
215042594|NCT03722810|OTHER|Sham comparator|In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
215042595|NCT05064228|BEHAVIORAL|Mobile Rewarding Activity Centered Treatment (m-ReACT)|Participants will utilize m-ReACT for 12-weeks, reporting daily on substance-free activity engagement and enjoyment (EMA). m-ReACT will utilize these EMA reports to generate brief, automated, and personalized feedback about enjoyed categories of substance-free activities as well as make suggestions for increasing engagement in those rewarding, goal-oriented substance-free activities, and provide personalized suggestions of activities of interest.
215042596|NCT03601299|OTHER|Traditional food|Increasing traditional food consumption through Head start programs in Alaska
214876708|NCT06125730|OTHER|DIME Beauty Eyelash Boost Serum|The test product contains Water, Glycerin, Amino Acids (Sodium PCA, Sodium Lactate, Arginine, Aspartic Acid, PCA, Glycine, Alanine, Serine, Valine, Proline, Threonine, Isoleucine, Histidine, Phenylalanine), Hyaluronic Acid, Panthenol, Aloe Leaf Extract, Niacinamide, Purslane, Chebulic Fruit Extract, Apple Fruit Extract, Tocopherol, Phenoxyethanol, Hexanediol, Ethylhexylglycerin, Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-4.
214876709|NCT02490644|PROCEDURE|Blood sampling|Blood sampling 5ml
214876710|NCT06381557|DRUG|Zhengyuan Capsules|Zhengyuan capsules, 4 capsules at a time, 3 times per day;
214876711|NCT06381557|DRUG|Placebo contains 5%-10% Zhengyuan Capsule total mixed powder|Zhengyuan capsules simulator（Placebo contains 5%-10% Zhengyuan Capsule total mixed powder）, 4 capsules at a time, 3 times per day;
214876712|NCT02590965|DRUG|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
215042597|NCT05802901|PROCEDURE|Spinal manipulation|Spinal manipulation of the lumbar spine only to be performed in the spinal manipulation arm/group.
215042598|NCT05802901|PROCEDURE|Dry needling|Dry needling of the lumbar erector spinae, multifidus, and gluteus medius on the symptomatic side performed in the dry needling arm/group.
214876713|NCT02590965|DRUG|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
214876714|NCT05717465|OTHER|Anatomy diagrams|"The visual aids used included:~* An anatomical diagram illustrating how a lumbar puncture is carried out~* Paling palette, diagram illustrating the number of individuals affected by a particular condition~* Paling perspective scale, diagram comparing the risk of an event occurring in comparison to other 'everyday' risks"
214876715|NCT05717465|OTHER|Standard informed consent|Audio narration of a video containing text information relating to the lumbar puncture procedure (including risks) and an image of a consent form
214876716|NCT00904657|DRUG|sunitinib (Sutent)|50 mg capsule Sutent, one application a day for five days
214876717|NCT02106234|OTHER|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
214876718|NCT03446807|DRUG|Droxidopa|Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.
214876719|NCT03446807|DRUG|Placebo Oral Tablet|Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
214876720|NCT03915405|DRUG|KHK2455|orally, once daily.
215042599|NCT05802901|PROCEDURE|Spinal manipulation and dry needling|The spinal manipulation and dry needling arm/group receive both spinal manipulation and dry needling as outlined in the other groups.
215042600|NCT04146155|DRUG|Liraglutide+standard-of-care treatment|"Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.~Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies in accordance with local clinical practice guidelines."
215042601|NCT04146155|OTHER|standard-of-care treatment|Standard-of-care treatment including: metformin should be given as the first line therapy as long as it is tolerated and not contraindicated; other agents, including sulfonylureas or glucosidase inhibitor or insulin, should be added to metformin .Glycemic control will be managed by the investigators in accordance with local clinical practice guidelines by the adjustment of concomitant glucose-lowering agents or the addition of new antidiabetic medications with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
215042602|NCT05671250|COMBINATION_PRODUCT|PRP gel and SOC-treatment|Platelet-lysate loaded sustained release thermo-gelling formulation
215042603|NCT05671250|COMBINATION_PRODUCT|EPO/ISDN/UFH cryogel dressing|Erythropoietin/Isosorbide dinitrate loaded cryogel scaffold
215042604|NCT05671250|PROCEDURE|Standard of Care|Sharp debridement, saline washing and regular saline dressing
215042605|NCT00951392|DRUG|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests"
215042606|NCT00951392|PROCEDURE|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :~* Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~* Global transcriptome analysis by DNA Chip"
215042607|NCT00951392|DEVICE|indirect calorimetry|energy expenditure measurement
214666686|NCT04677114|DRUG|Buprenorphine and standard of care antibiotic treatment|All participants will receive treatment of OUD and the infection per usual clinical care.
214876721|NCT03915405|DRUG|Avelumab|IV Administration
215042608|NCT04613388|OTHER|Assesment of Effectiveness and side effects|Case Report forms, Quality of life questionaire
215042609|NCT04033692|DEVICE|JuggerKnot Mini Soft Anchor|Patient who have been implanted with one or more JuggerKnot Mini Soft Anchor(s) who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc.
215042610|NCT05390684|OTHER|audit of complications, prospective data collection|Prospective colecction of data will be performed to create a predictive model of leak and major complication
215042611|NCT05296161|DRUG|Ocrelizumab|Personalized B cell tailored ocrelizumab treatment
215042612|NCT02382354|DRUG|remifentanil|The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
215042613|NCT02382354|DEVICE|i-gel|I-gel insertion was inserted 5 min after anesthesia induction
215042614|NCT02382354|DEVICE|laryngeal mask airway|laryngeal mask airway insertion was inserted 5 min after anesthesia induction
215042615|NCT02382354|DRUG|propofol|Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
215042616|NCT01677988|DRUG|Neo-adjuvant Chemotherapy|"1. Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~2. Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~   1. Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~  2. Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
215042617|NCT01677988|RADIATION|Chemoradiation|"1. Chemoradiation may be administered at selected approved CTN sites.~2. Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~   1. Unresectable → Off study. Subsequent treatment per patient's primary MD.~  2. Resectable → Continue to Registration #3 for Surgical Resection"
215042618|NCT01677988|PROCEDURE|Surgical Resection|"1. Meets criteria for resectable\* →pancreaticoduodenectomy (POD)~2. At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
214876722|NCT00055367|DRUG|natalizumab|
214876723|NCT04284059|DRUG|Placebos|Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
214876724|NCT04284059|DIETARY_SUPPLEMENT|vitamin AD|A vitamin AD capsule contains vitamin A 2000 IU and vitamin D 700 IU. The patients need to administrate 3 capsules once a day for 8 weeks.
214876725|NCT04284059|DIETARY_SUPPLEMENT|vitamin D|A vitamin D capsule contains vitamin D 400 IU. The patients need to asministrate 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks.
214876726|NCT03247179|OTHER|PTSD Coach mobile application|The PTSD Coach app is publicly available for free, and draws on cognitive behavioral therapy components to help participants learn, manage, and cope with their PTSD symptoms in real time.
214876727|NCT03281759|DEVICE|Transcranial LED Therapy (Active coil helmet)|The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
214876728|NCT03281759|DEVICE|Transcranial LED Therapy (Inactive coil helmet)|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
214291632|NCT02278250|DRUG|M4344 40 mg BIW|Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214291633|NCT02278250|DRUG|M4344 80 mg BIW|Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214876729|NCT02569918|DEVICE|Surface electrical stimulation|"Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject."
214876730|NCT00599053|DRUG|Azithromycin|10 mg/kg IV per dose given for 10 days
214876731|NCT03168334|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
214876732|NCT03168334|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
214876733|NCT00979641|DRUG|Docetaxel|
214876734|NCT00381433|DRUG|AVI-4065 Injection|
214876735|NCT02734407|PROCEDURE|Assigned Intervention|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
214876736|NCT02734407|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
214876737|NCT05291611|BEHAVIORAL|Online-based Cognitive-behavioral Therapy for OCD|26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
214876738|NCT05341830|BEHAVIORAL|Recovery housing|Recovery housing provides housing and other services to individuals who are recovering from substance-use disorders. They provide a substance-free living environment, as well as services to assist residents with life in recovery. These services include connections to employment and educational opportunities, help obtaining documentation such as a driver's license, connection to mutual aid, and assistance building life skills.
214876739|NCT00271401|OTHER|Angioplasty|
214876740|NCT00271401|OTHER|Intracoronary Stent|
214876741|NCT00271401|DRUG|Abxicimab|
214291634|NCT02278250|DRUG|M4344 160 mg BIW|Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214666687|NCT04933812|BEHAVIORAL|Facebook discussions and Virtual group meetings|Participants must join a study-specific private Facebook group and engage in discussion. Once the discussion is complete, participants have the opportunity to join virtual group sessions via Zoom
214876742|NCT00271401|DRUG|Heparin|
214876743|NCT00271401|DRUG|Placebo|
214876744|NCT01525017|BIOLOGICAL|Combig-DC (allogeneic dendritic cells) Cancer Vaccine|Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
214876745|NCT02929888|DRUG|Lysine Acetilsalicilate|
214876746|NCT02929888|DRUG|Aspirin|
214876747|NCT05141617|PROCEDURE|Endoscopic treatment|Patients in the endoscopic treatment receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices
214876748|NCT05141617|PROCEDURE|TIPS|Patients in the TIPS group receive Transjugular Intrahepatic Portosystemic Shunt
214876749|NCT06983093|OTHER|Rain Stick|The rain stick to be used in the study is a toy made of wood, ranging in length from 20 to 120 cm. It is also a very entertaining musical instrument that imitates the sound of real rain. It is suitable for use by children aged 4 to 6. It has spiral shapes and colorful beads inside. When the rain stick is turned up and down, it produces a perfect rain sound that drizzles and patters. It is also known as a rain sound stick. The visual and auditory nature of the rain stick can distract the child during the blood collection process.
214876750|NCT06983093|OTHER|Musical Egg|The musical egg to be used in the study is a toy made of wood, approximately 6.5-7 cm in size. These wooden shaker eggs are a fun and interesting musical instrument. It is suitable for use by children aged 4-6. It is filled with iron sand and when shaken, it makes a clear sound and adds a unique rhythm to the music. This egg imitates the sound of maracas when shaken. Maracas are a musical instrument that makes a sound when shaken thanks to the parts in its hollow body. It is also known as musical eggs, egg shakers, musical egg maracas, Easter egg percussion instruments. The visual and auditory nature of the musical egg can distract the child during the blood collection process.
214876751|NCT03799328|OTHER|multi-OIT|low dose OIT to multiple foods
214876752|NCT05498779|PROCEDURE|Ablation therapy|Radiofrequency or microwave ablation
214876753|NCT01671332|DRUG|Docetaxel|IV over 60 minutes, 75 mg/m2
214876754|NCT01671332|DRUG|Suramin|IV over 30 minutes
214876755|NCT01671332|DRUG|Docetaxel|IV over 60 minutes. 56 mg/m2
214876756|NCT02728843|DRUG|Deferiprone|600 mg tablets
214876757|NCT02728843|DRUG|Placebo|Tablets that match the deferiprone tablets in appearance
214876758|NCT02985190|DRUG|Azacitidine|Azacitidine at 75mg/m²/j for 7 days.
214876759|NCT03535389|DIAGNOSTIC_TEST|Knee 4DCT|Dynamic knee 4DCT
214876760|NCT02379572|DEVICE|iMRI-guided surgery|For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
214876761|NCT02379572|DRUG|5-ALA-guided surgery|For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
214876762|NCT00345657|DRUG|Niacin Extended Release/Lovastatin|
214876763|NCT03741699|DRUG|Pre-treatment with rLH (Luveris 75 IU),|Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
214876764|NCT06616844|DEVICE|InnovaMatrix® AC|SOC plus weekly application of the study device
214876765|NCT05419609|PROCEDURE|Limited facelift|A limited procedure under local anesthesia that addresses signs of aging in the lower face and neck
214291635|NCT02278250|DRUG|M4344 300 mg BIW|Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214876766|NCT05419609|PROCEDURE|Full facelift|A full face and neck lift that addresses signs of aging in the face and neck
214876767|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction With Lower Face and Jawline"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction With Lower Face and Jawline is a 5-item questionnaire. Each item is rated 1-4, with 1 being Very Dissatisfied and 4 being Very Satisfied. Lower scores suggest the person may be less pleased with the appearance of their lower face and jawline."
214876768|NCT05419609|OTHER|"FACE-Q | Aesthetics - Recovery Early Symptoms"|"Completed by patients. The FACE-Q \| Aesthetics - Recovery Early Symptoms is a 17-item questionnaire. Each item is rated 1-4, with 1 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms early in their recovery following an aesthetic facial procedure."
215042619|NCT00928772|DEVICE|CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
215042620|NCT00928772|DRUG|MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
215042621|NCT00928772|OTHER|NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED|NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
215042622|NCT00544206|OTHER|standard enteral feeding product|16 hrs daily x 5 days
215042623|NCT00544206|OTHER|Diabetes specific feeding product|16 hrs daily for 5 days
215042624|NCT01332656|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
214876769|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction with Outcome"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction with Outcome is a 6-item questionnaire. Each item is rated 1-4, with 1 being Definitely disagree and 4 being Definitely agree. Lower scores suggest the person may be less pleased with their final appearance following surgery and the decision to have an aesthetic facial procedure."
214876770|NCT05419609|OTHER|"FACE-Q | Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck"|"Completed by patients. The FACE-Q \| Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck is a 15-item questionnaire. Each item is rated 1-3, with 1 being Not at all and 3 being A lot. Lower scores suggest the person may be experiencing fewer chronic symptoms following an aesthetic facial procedure."
215042625|NCT01332656|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
215042626|NCT01332656|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
215042627|NCT01332656|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
215042628|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
215042629|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
215042630|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
215042631|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
215042632|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
215042633|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
215042634|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
215042635|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
215042636|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
215042637|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
215042638|NCT00499837|DRUG|Aerosolized, human, plasma-derived Alpha-1 Antitrypsin|
215042639|NCT04955184|DEVICE|non-invasive monitoring|non-invasive measurements of cardiac output
215042640|NCT05687370|PROCEDURE|Modified dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using modified dynamic short-axis view.
215042641|NCT05687370|PROCEDURE|Long-axis technique|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
215042642|NCT03888560|DEVICE|Micro-osteoperforations|MOPs will be performed using SIA Excalibur Mini-Implant with dimension 1.6 mm in width and length of 6 mm, screw 3 mm depth into buccal bone of intervention sites
215042643|NCT02361892|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
214291636|NCT02278250|DRUG|M4344 450 mg BIW|Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214291637|NCT02278250|DRUG|M4344 700 mg BIW|Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214876771|NCT02623985|DEVICE|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
215042644|NCT05364450|BEHAVIORAL|Enhanced Usual Care|"Interventionists will provide a brief explanation of the intervention and coaching to the group on how to utilize the resources provided. Prior to the single session group, EUC participants will have received a workbook with the National Cancer Institute's Facing Forward: Life After Cancer Treatment booklet on maximizing quality of life during cancer survivorship and the American Society of Clinical Oncology's Guide to Cancer Survivorship."
215042645|NCT05364450|BEHAVIORAL|Acceptance Commitment Therapy|Interventionists will support participants in adopting a psychologically flexible posture toward FCR through six interdependent processes of change - acceptance, cognitive defusion, mindfulness, perspective taking, values, and committed action. During ACT sessions, participants will learn to respond adaptively to FCR by being more fully aware of thoughts, feelings, and bodily sensations without judging or attempting to control or avoid them. Participants will also clarify their deeply-held values and set action goals in alignment with their values.
215042646|NCT05364450|BEHAVIORAL|Cognitive Behavioral Therapy|Interventionists will provide psycho-education on the cognitive behavioral model of FCR and assist participants in changing unhelpful thinking patterns and maladaptive behaviors linked to FCR. Session topics will include FCR triggers, behavioral experiments to reduce FCR-perpetuating safety behaviors, and pleasant events scheduling. Interventionists will also provide evidence-based information on behaviors that may reduce recurrence risk (e.g., achieving a healthy weight, physical activity, cancer surveillance).
215042647|NCT03634956|DRUG|Group B. Sugammadex sodium-IONM|Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
215042648|NCT05663684|DRUG|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
215042649|NCT05663684|DRUG|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
215042650|NCT05754866|PROCEDURE|Transbronchial lung cryobiopsy|Lung tissue was obtained by transbronchial lung cryobiopsy for subsequent pathology and clinical diagnosis.
215042651|NCT05754866|PROCEDURE|Transbronchial lung biopsy|Lung tissue was obtained by transbronchial lung biopsy for subsequent pathology and clinical diagnosis.
215042652|NCT00271544|DEVICE|Pacing Lead|implant and follow-up of study device
215042653|NCT06564064|DEVICE|abdominal binder|study group will be abdominal binders and control group will be control group , 12 hrs and one week later VAS and QOR 40 will assess patient,s wellbeing
215042654|NCT05700409|BEHAVIORAL|Intensive lifestyle consultations|detailed above
215042655|NCT03358030|DRUG|ISIS 416858|Subcutaneous injection
215042656|NCT03358030|DRUG|Placebo|Subcutaneous injection
215042657|NCT05595109|DRUG|Silymarin|"Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice."
215042658|NCT05595109|DRUG|Placebo|which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
214291638|NCT02278250|DRUG|M4344 1050 mg BIW|Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214291639|NCT02278250|DRUG|M4344 1200 mg BIW|Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214291640|NCT02278250|DRUG|M4344 100 mg BID|Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214291641|NCT02278250|DRUG|M4344 150 mg QD|Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214876772|NCT02623985|DEVICE|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
214876773|NCT02623985|DEVICE|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
214876774|NCT01867983|BEHAVIORAL|Weight gain prevention and smoking cessation|"The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls."
214876775|NCT01867983|BEHAVIORAL|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
214876776|NCT01432379|BIOLOGICAL|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
214876777|NCT02831647|DIETARY_SUPPLEMENT|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
214876778|NCT01176708|DRUG|dipeptidyl peptidase 4 (DPP4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
214876779|NCT01176708|OTHER|oral glucose|50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
214876780|NCT01176708|OTHER|intravenous glucose|1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
214876781|NCT01806506|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
214876782|NCT01806506|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
214666688|NCT06219863|BEHAVIORAL|Body weight supported harness|A body weight supported harness will be provided to families for one month to set up in their home. Caregivers will be asked to use the harness for their infants for 30 min per day, 5 days a week. Caregivers will complete a daily log describing harness use. At the end of the month, they will complete feasibility and acceptability questionnaires.
214876783|NCT04141475|DIETARY_SUPPLEMENT|Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
214876784|NCT04141475|DIETARY_SUPPLEMENT|Placebo - Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
214876785|NCT05922475|DIETARY_SUPPLEMENT|Protein|"Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep."
215042659|NCT02445209|OTHER|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
215042660|NCT02445209|OTHER|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
215042661|NCT04887532|DRUG|HR19042 capsule|phase 1 :8mg; phase 2:12mg; phase 3:16mg
215042662|NCT05215002|OTHER|Telephone Call|Patient will be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
215042663|NCT05215002|OTHER|No telephone call|Patient will not be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
215042664|NCT03445312|BEHAVIORAL|not processing urine cultures|microbiology lab will not process culture unless called
215042665|NCT05730842|DRUG|EDG-5506 Tablet|Single Oral Dose - Tablet
215042666|NCT05730842|DRUG|Radiolabeled EDG-5506 Suspension|Single Oral Dose
215042667|NCT05730842|DRUG|Radiolabeled EDG-5506 Intravenous|Single Intravenous Dose
215042668|NCT02433938|PROCEDURE|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
215042669|NCT02433938|PROCEDURE|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
215042670|NCT04894682|BIOLOGICAL|Vaccine inoculation against SARS-CoV-2|Inoculation with any type of approved vaccines according to the standard or recommended dose
214666689|NCT04296630|OTHER|Social media message #1|Social media message promoting colorectal cancer screening
214666690|NCT04296630|OTHER|Social media message #2|A different social media message promoting colorectal cancer screening
214876786|NCT05922475|OTHER|Placebo|Resistance exercise training only group did not consume supplemental protein.
214876787|NCT01771471|BIOLOGICAL|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
215042671|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
215042672|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
214291642|NCT02278250|DRUG|M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214876788|NCT01771471|OTHER|Placebo|0.9% w/v Sodium Chloride for Injection, USP
214876789|NCT01305174|DEVICE|PROTEGE GPS stent vs. VISI-PRO stent|Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
215042673|NCT06324032|PROCEDURE|EUS Elastography (EUS-E)|All procedures will be performed with Olympus echoendoscopes (Olympus Europa SE \& CO. KG, Hamburg, Germany) or Pentax echoendoscopes in combination with dedicated elastography software
215042674|NCT00652171|DRUG|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
215042675|NCT00652171|DIETARY_SUPPLEMENT|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
215042676|NCT04487509|OTHER|THROMBOLYSE|the treatment delivered to the emergency room, in particular the nature of the treatment for obstruction (primary angioplasty or thrombolysis)
215042677|NCT03361878|DRUG|Metformin Hydrochloride|Single dose of 500mg oral metformin
215042678|NCT04314622|DRUG|Supaglutide|Administered SC
215042679|NCT04314622|DRUG|Placebo|Administered SC
215042680|NCT00158093|DRUG|Nebivolol|
215042681|NCT00158093|DRUG|Atenolol|
215042682|NCT00158093|DRUG|Moxifloxacin|
215042683|NCT03973957|DEVICE|Indwelling pleural catheter placement|Indwelling pleural catheter placement by interventional pulmonologist
215042684|NCT03973957|DRUG|Fentanyl Citrate|Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
215042685|NCT03973957|DRUG|Talc Slurry|Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
215042686|NCT03973957|DEVICE|Drainage collection bag|Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
215042687|NCT02623244|PROCEDURE|Laparoscopic oophorocystectomy or oophorectomy|
215042688|NCT02009579|DRUG|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
214876790|NCT01293838|DRUG|Cipralex®|"Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~* 10 mg tablets: 28~* 20 mg tablets: 84~Total for 30 participants:~* 10 mg tablets: 840~* 20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~\*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~\*20 mg tablets: 1512"
214876791|NCT05608980|DRUG|0.01% hypochlorous acid|once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
215042689|NCT02009579|DRUG|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
215042690|NCT04069442|OTHER|This is a non-interventional study|This is a non-interventional study
215042691|NCT02727608|DRUG|Eculizumab|Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.
215042692|NCT01472731|OTHER|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
215042693|NCT01472731|DRUG|GC1008|5 mg/kg intravenous use
215042694|NCT00755170|DRUG|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
215042695|NCT00755170|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
215042696|NCT01298336|DRUG|Clarithromycin|500 mg twice a day seven days a week
215042697|NCT01298336|DRUG|Moxifloxacin|400 mg per day seven days a week
215042698|NCT04597749|DIAGNOSTIC_TEST|PSG|In-lab sleep polysomnography test
215042699|NCT04597749|DIAGNOSTIC_TEST|Home Sleep Apnea Test with FDA cleared devices|In-lab HST test
215042700|NCT04597749|OTHER|Non-Contact Screening App|Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.
215042701|NCT05415488|OTHER|Online dietary group treatment|Dietary advice will be given during one 90 minute online group session
215042702|NCT02604511|DRUG|Ibrutinib|
215042703|NCT04400825|OTHER|Dry needling|Dry needling of the active MTrPs following the technique described by Hong et al (1994,1995)
215042704|NCT03770286|DEVICE|5% Fluoride Varnish|Topical varnish
214476870|NCT04614948|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
214476871|NCT04614948|OTHER|Placebo|Placebo will be administered as IM injection on Day 1 and Day 57.
214666691|NCT04296630|OTHER|Social media message #3|A different social media message promoting colorectal cancer screening
214666692|NCT04296630|OTHER|Social Media Message #4|A different social media message promoting colorectal cancer screening.
214666693|NCT04296630|OTHER|Tailored Social Media Message|Tailored social media messages promoting colorectal cancer screening.
214876792|NCT05608980|DRUG|Placebo|once daily eyelid wipes for 2 weeks
214876793|NCT00088621|DRUG|Lurasidone 80mg tablet|
214876794|NCT00373698|BEHAVIORAL|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
215042705|NCT03770286|DEVICE|38% Silver diamine fluoride|Topical varnish
215042706|NCT03770286|DEVICE|Super Floss|Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
215042707|NCT06305208|DEVICE|Endoscopic gastric suturing|Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
215042708|NCT06305208|DEVICE|Endoscopic gastric plication|Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
215042709|NCT06305208|DEVICE|Revisional gastroplasty|Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
215042710|NCT06305208|DEVICE|Transoral outlet reduction endoscopy (TORe)|Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
215042711|NCT06305208|DEVICE|Duodenal mucosal resurfacing (DMR)|Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
215042712|NCT06305208|DEVICE|Intragastric balloon(s)|The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.
215042713|NCT02505425|BEHAVIORAL|Behavioral Support|"ENABLE CHF-PC includes:~1. In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~2. Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
215042714|NCT02505425|BEHAVIORAL|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
215042715|NCT03571490|DRUG|Ropivacaine|Single shot of ropivacaine 0.325%
215042716|NCT03571490|DRUG|Saline|Single shot of saline 0.9%
215042717|NCT02406222|DRUG|Pomalidomide|Chemotherapy
215042718|NCT02406222|DRUG|Dexamethasone|Chemotherapy
215042719|NCT02406222|DRUG|Cyclophosphamide|Chemotherapy
215042720|NCT02297412|DRUG|Minocycline Hydrochloride|Given PO
215042721|NCT02297412|OTHER|Placebo|Given PO
215042722|NCT02297412|OTHER|Quality-of-Life Assessment|Ancillary studies
215042723|NCT02297412|OTHER|Questionnaire Administration|Ancillary studies
214666694|NCT05640908|DEVICE|iFuse Bedrock Granite Implant System|Surgical procedure of the spine with pelvic fixation/fusion using iFuse Bedrock Granite
214876795|NCT06494345|BIOLOGICAL|Genolair, solution for subcutaneous administration, 150 mg|Genolair (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
214876796|NCT06494345|BIOLOGICAL|Genolair, lyophilisate for the preparation of solution for subcutaneous administration|Genolair (omalizumab), lyophilisate for the preparation of solution for subcutaneous administration, 150 mg for single subcutaneous administration
214876797|NCT06494345|BIOLOGICAL|Xolair®, solution for subcutaneous administration, 150 mg|Xolair® (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
214876798|NCT05819216|DEVICE|Treadmill|Gait training on treadmill training
214876799|NCT02841163|DRUG|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
215042724|NCT01596114|OTHER|Stopping treatment with TKI|stopping until loss of MMR
214476874|NCT06551142|BIOLOGICAL|GSK5764227|GSK5764227 will be administered
214476875|NCT06551142|DRUG|Cisplatin|Cisplatin will be administered
214476876|NCT06551142|DRUG|Carboplatin|Carboplatin will be administered
214476877|NCT06551142|BIOLOGICAL|Atezolizumab|Atezolizumab will be administered
214476878|NCT06551142|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered
214876800|NCT02841163|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
214876801|NCT02841163|PROCEDURE|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214876802|NCT02841163|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214876803|NCT02841163|PROCEDURE|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
214876804|NCT00892996|DRUG|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
214876805|NCT00892996|DRUG|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
214876806|NCT00227110|DRUG|Pioglitazone|30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
214876807|NCT00227110|DRUG|Placebo|Placebo is given to match pioglitazone.
214876808|NCT02418481|BIOLOGICAL|DC-CIK|DC-CIK cells will be used against tumor cells.
214876809|NCT02418481|BIOLOGICAL|γδ T Cell|γδ T cells will be used against breast tumor.
214876810|NCT02418481|BIOLOGICAL|Combination|γδ T/DC-CIK cells will be used against breast tumor.
214876811|NCT03862755|DRUG|Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)|Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
214876812|NCT00006458|RADIATION|indium In 111 monoclonal antibody MN-14|
214876813|NCT00006458|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
214876814|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes|In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.
214876815|NCT04844762|BEHAVIORAL|Usual brand menthol cigarettes and substitutes|In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.
214876816|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes and menthol cigarettes|In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.
215042725|NCT04068805|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
215042726|NCT02031302|DEVICE|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] of \<1.0 cm2 or index of \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
215042727|NCT05479370|BIOLOGICAL|Flublok Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
215042728|NCT05479370|BIOLOGICAL|Fluarix Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
215042729|NCT05479370|BIOLOGICAL|Flucelvax Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214476879|NCT06551142|BIOLOGICAL|Durvalumab|Durvalumab will be administered
214876817|NCT02188173|DRUG|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
214291643|NCT02278250|DRUG|M4344 350 mg QD|Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214476880|NCT06551142|BIOLOGICAL|Cetuximab|Cetuximab will be administered
214876818|NCT04067986|DRUG|Camrelizumab|"Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w~One course will last 28 days. Oral administration at a dose of 250 mg/d"
214876819|NCT04067986|DRUG|Apatinib|Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd
214876820|NCT02829151|DRUG|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
214876821|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
214876822|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
214876823|NCT04257045|OTHER|Interview|Participate in semi-structure, in-depth qualitative interviews
214876824|NCT04257045|OTHER|Questionnaire Administration|Complete questionnaires
214476881|NCT06551142|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered
214476882|NCT05564637|DRUG|Treprostinil|30mcg (5 breaths) of inhaled treprostinil will be administered during the RHC procedure and patients will be initiated on outpatient inhaled treprostinil therapy for 3-months with gradual up titration to target dose as per standard clinical practice.
214876825|NCT04257045|OTHER|Survey Administration|Complete survey
214876826|NCT04128020|DRUG|Nivolumab|Nivolumab
214876827|NCT04128020|DRUG|Azacitidine|Azacitidine
214876828|NCT04824157|OTHER|Non|Follow up
214476883|NCT05564637|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC) while exercising|A procedure to measure how well or poorly your heart is pumping and to measure the pressures in the heart and lungs. A catheter will be inserted into a vein and artery in order to take the measurements and this will be conducted while exercising on a supine cycle ergometer. Various measurements will be taken during periods of rest and exercise.
214876829|NCT02865421|DRUG|stem cells|adipose tissue derived stromal vascular fraction
215042730|NCT03050710|DEVICE|Princess® VOLUME Lidocaine|Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
215042731|NCT03374306|DRUG|Atropine (0.01%)|tropical application
214476884|NCT05564637|DIAGNOSTIC_TEST|Optional Muscle Biopsy|A sample of muscle tissue will be collected and analyzed for the ability of the cells to utilize oxygen.
215042732|NCT03374306|DRUG|Artificial tear|tropical application
214666695|NCT04644900|OTHER|chewed mint gum|In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.
215042733|NCT06642077|DRUG|LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml|A total of 2 ampoules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml were injected into the sternotomy incision site and around the chest tubes of 30 patients in the experimental group. The total number and dose of opioids, the total number and dose of analgesics used to relieve the pain of the patients in the 24 hours after the injection of 2 ampules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml, and the total number and dose of analgesics were recorded, and the patients were interviewed face-to-face 24 hours later, and PoRI was recorded. No intervention was performed on 30 patients in the control group, and standard treatment and care continued to be applied to these patients.
215042734|NCT06644443|BIOLOGICAL|BCMA-GPRC5D CAR-T cells|patient was subjected to 2-5×10\^6 BCMA-GPRC5D CAR-T cells/kg
214876830|NCT02865421|DRUG|platelet rich plasma|platelet rich plasma transplanted in bald area at a distance
214876831|NCT06017076|OTHER|Oral energy drinks|Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.
214291644|NCT02278250|DRUG|M4344 400 mg|Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214291645|NCT02278250|DRUG|M4344 500 mg|Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214876832|NCT06017076|DEVICE|Warming matress|From the end of anesthesia, warming matriss at 40 ℃ was used to keep warm until the end of surgery.
214876833|NCT00361062|BEHAVIORAL|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
214876834|NCT03761563|DEVICE|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
214876835|NCT03165838|BEHAVIORAL|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
214876836|NCT03165838|BEHAVIORAL|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
214876837|NCT04277143|DRUG|Daptomycin|"Adult patients are given the recommended dose of daptomycin for injection. Patients with creatinine clearance (CLCR) ≥ 30 mL / min: 6 mg / kg every 24 hours.~Patients with creatinine clearance (CLCR) \<30mL / min (including hemodialysis or peritoneal dialysis): 6mg / kg every 48 hours. Dissolve 6mg / kg of this drug in 0.9% sodium chloride injection and instill it over a 30-minute time course once every 24 or 48 hours."
214876838|NCT00477633|DRUG|Norethindrone/ethinyl estradiol|1 tablet per day
214876839|NCT02553447|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
214876840|NCT02553447|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214876841|NCT03323047|DRUG|Acetaminophen|Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
214876842|NCT03323047|DRUG|Low-dose Dexamethasone|Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
214876843|NCT03323047|DRUG|Placebo Oral Tablet|Oral placebo 1 hr pre-operatively
214876844|NCT03323047|DRUG|High-Dose Dexamethasone|Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
214876845|NCT03583684|BEHAVIORAL|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
214876846|NCT00963560|DEVICE|ReSTOR +3|Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
214876847|NCT00963560|DEVICE|Crystalens HD|Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
214876848|NCT00963560|DEVICE|Crystalens AO|Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
214876849|NCT05888194|DEVICE|Mucogyne® gel|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
214876850|NCT03509805|DIAGNOSTIC_TEST|polysomnography|
214876851|NCT00095797|DRUG|R(+)XK469|Given IV
214876852|NCT00095797|OTHER|pharmacological study|Correlative studies
214876853|NCT00095797|OTHER|laboratory biomarker analysis|Optional correlative studies
215042735|NCT05085132|BEHAVIORAL|MindFi app: Standard content|Digital wellness training in this study will be delivered via the MindFi app, designed by Jaedye Labs. Content includes learning, assesesment, and practice tracks A core component of the exercises in this app is mindfulness training; however, the app also incorporates other exercises drawn from positive psychology such as journaling and diaphragmatic breathing. The app goes beyond traditional guided meditation through content that reinforces the principles and attitudes taught during in-person training, and also seeks to maximize user experience by using interactive tasks and progress charts.
214666696|NCT04644900|OTHER|Mouthwash|Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
214876854|NCT04494984|DRUG|INM005|The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
214876855|NCT04494984|DRUG|Placebo|Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
214876856|NCT00815360|DRUG|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
214876857|NCT00815360|PROCEDURE|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
214876858|NCT00815360|DRUG|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
214876859|NCT00815360|PROCEDURE|macular laser|macular laser to areas of retinal thickening or leakage
214876860|NCT02996214|DRUG|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
214876861|NCT02996214|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.
214876862|NCT02996214|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
214876863|NCT02340052|DRUG|Pain treatment|Registration af actual analgesic treatment and outcomes
214876864|NCT02242032|DRUG|P-321 Ophthalmic Solution|
214876865|NCT02242032|DRUG|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
214876866|NCT01852500|OTHER|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
214876867|NCT01852500|OTHER|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
214876868|NCT04123561|DRUG|TLC599|TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
214876869|NCT04123561|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
214876870|NCT04123561|OTHER|Normal Saline|0.9% normal saline
214876871|NCT00522561|OTHER|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
214876872|NCT05236283|DIAGNOSTIC_TEST|Blood Culture|Blood Culture
214876873|NCT02454127|BEHAVIORAL|Atkins Diet|Dietary counseling for 1 year
214876874|NCT02454127|BEHAVIORAL|Zone Diet|Dietary counseling for 1 year
214876875|NCT02454127|BEHAVIORAL|Weight Watchers Diet|Dietary counseling for 1 year
214876876|NCT02454127|BEHAVIORAL|Ornish Diet|Dietary counseling for 1 year
214876877|NCT02777073|DRUG|Victoza|Single dose of Liraglutide
214876878|NCT02777073|DRUG|Placebo|Single dose of generic placebo
214876879|NCT02777073|DRUG|Dapagliflozin 10mg Tab|single dose of 10 mg dapagliflozin
214876880|NCT01296282|DEVICE|Medronics CRT Optivol Impedance Measurement|Pacemaker
214876881|NCT01296282|DEVICE|External Thoracic Impedance Measurement|
214876882|NCT02792608|BEHAVIORAL|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
214876883|NCT05614427|DIAGNOSTIC_TEST|Innova Lateral Flow Test|Lateral flow test performed on anterior nasal or buccal swabs
214876884|NCT00769873|DRUG|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance \< 30) for 21 days
214876885|NCT04229927|DRUG|BPDO-1603|"Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug"
214876886|NCT05622240|DRUG|99mTc-MIRC213|99mTc-MIRC213 were intravenous injected into the patients before the wholebody and SPECT/CT scans
214876887|NCT05734612|DRUG|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
214876888|NCT05734612|DRUG|Placebo (lactose)|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
214876889|NCT04286451|BEHAVIORAL|Sleep Restriction|Women will be undergo 4 nights of sleep restriction.
214876890|NCT04286451|BEHAVIORAL|Habitual Sleep|Women will be undergo 4 nights of habitual sleep.
215042736|NCT05085132|BEHAVIORAL|Mindfi app: Standard content without practice|In this condition, participants will receive a version of the MindFi app that does NOT contain the practice tracks, only the learning and assessment tracks.
215042737|NCT06645197|DRUG|SNUG01|Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette
215042738|NCT04476992|DRUG|Nitric Oxide-Sessions|Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).
215042739|NCT04476992|DRUG|Nitric Oxide-Continuous and Sessions|"Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm."
215042740|NCT06395558|BEHAVIORAL|Lifestyle intervention|Multimodal web-based intervention programme on anxiety, depression and cognitive impairment consisting of knowledge development sessions and practical/gaming sessions focused on different domains: cognitive competence, socio-relational competence and emotions/affectivity, and physical activity-nutrition
215042741|NCT02383784|DIETARY_SUPPLEMENT|Low GI index diet|Low glycemic index diet
215042742|NCT02383784|DIETARY_SUPPLEMENT|High GI diet|High glycemic index diet
215042743|NCT04708522|BEHAVIORAL|Breath Control - Equal Breathing Technique|The equal breathing (EB) exercise also known as square or box breathing will follow the four-part breathing cycle of inhalation, hold, exhalation, hold, repeat. Each part of the cycle will be a 4 second count repeated for 20 minutes.
215042744|NCT04708522|BEHAVIORAL|Guided Mindfulness Exercise|The guided seated mindfulness (GSM) exercise will lead the participant through a 20 minute mindfulness meditation exercise using an audio recording.
215042745|NCT04708522|BEHAVIORAL|Control|The control intervention will utilize a sham exercise. The participant will be asked to rest in a comfortable seated position for the duration of the 20 minute session.
215042746|NCT03950856|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
215042747|NCT03950856|DRUG|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
214291646|NCT02278250|DRUG|Carboplatin|Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
214291647|NCT00192842|DRUG|curcumin (+ gemcitabine)|
215042748|NCT01533545|DRUG|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
215042749|NCT01533545|DRUG|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
215042750|NCT01389687|BIOLOGICAL|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
215042751|NCT00000621|DRUG|all trans retinoic acid|
215042752|NCT00000621|DRUG|13 cis retinoic acid|
214291648|NCT02532790|DRUG|Prednisone|1.5mg/kg/d
214291649|NCT02532790|DRUG|ACEI|0.2-0.3mg/kg/d
214291650|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
214291651|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
214291652|NCT02379806|DRUG|Enoxaparin|
214291653|NCT02379806|DRUG|Placebo|
214291654|NCT05276544|BEHAVIORAL|Dietary intervention|Dietary intervention: Preparation and follow-up of diet program.
214291655|NCT03134027|PROCEDURE|Bone marrow biopsy|Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.
214291656|NCT03134027|PROCEDURE|Tumor biopsy|Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX.
214291657|NCT00523003|DIETARY_SUPPLEMENT|high protein|2.2 g protein/kg of LBM per day
214291658|NCT00523003|DIETARY_SUPPLEMENT|standard protein|1.1 g protein/kg LBM/day standard protein diet
215042753|NCT00000621|DRUG|placebo|
215042754|NCT03150264|DEVICE|PCV-VG, PEEP5cmH₂O|This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.
215042755|NCT03150264|DEVICE|PCV, PEEP5cmH₂O|This is a traditional ventilation mode used in obese patients in the past.
215042756|NCT00753532|DIETARY_SUPPLEMENT|200mg of Palm vitamin E (tocotrienols) or placebo|Individuals randomized in the (MRI+ve) and (MRI -ve) cohort respectively. In the MRI(+ve) cohort, 62 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 59 were assigned to placebo, taken orally twice a day for a study period of two years. In the MRI(-ve) cohort, 63 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 57 consumed placebo, taken twice a day for a follow up period of 1 year.
215042757|NCT00678522|DRUG|Atorvastatin|80 mg atorvastatin daily on two following days
215042758|NCT06157073|DEVICE|Closed-loop ventilator|Fully automated closed-loop ventilator using the INTELLIVENT software
215042759|NCT06157073|DEVICE|Open-loop ventilator|Conventional closed-loop ventilator with manual adjustments by the physician in charge
215042760|NCT05958602|BEHAVIORAL|Technology|See previous response.
215042761|NCT05958602|BEHAVIORAL|Standard DSMES Only|See previous response.
215042762|NCT05958602|BEHAVIORAL|Traditional Recruitment Methods|See previous response.
215042763|NCT05958602|BEHAVIORAL|CHW-Led Recruitment Methods|See previous response.
215042764|NCT05899829|DRUG|Camlipixant|Camlipixant will be administered
215042765|NCT05899829|DRUG|Rabeprazole|Rabeprazole will be administered
214876891|NCT03962283|DRUG|Rifaximin|Rifaximin 200mcg four times daily
214876892|NCT03962283|DRUG|Placebo oral tablet|Placebo Rifaximin four times daily
214876893|NCT05756283|BEHAVIORAL|Multimodal Prehabilitation|"EXERCISE~* Supervised exercise~  * High intensity interval training~ * Strength exercise~* Home-based exercise / promotion of physical activity~  * Low-moderate intensity aerobic training~ * Inspiratory muscle training~ * Low-moderate intensity strength training~NUTRITION: nutrition education and optimization. Intake of 0.4g/kg of whey isolate after every supervised training.~PSYCHOSOCIAL: mindfulness, cognitive reframing and coping strategies."
215042766|NCT05899829|DRUG|Rifampin|Rifampin will be administered.
215042767|NCT04174352|DRUG|Tamoxifen|estrogen modulator
215042768|NCT04174352|DIAGNOSTIC_TEST|FES PET/CT|Radiolabeled estrogen \[18F\]-fluoroestradiol (FES) in combination with Positron Emission Tomography / Computed Tomography is a molecular imaging technique for measuring pharmacodynamic effects of endocrine therapy. The injected dose of 18F-FES will be 6 mCi (185 MBq) ± 20% with a specific activity greater than 170 Ci/mmol at the time of injection for an activity dose of 6 mCi. Participant will receive baseline imaging and repeat imaging after 3-4 weeks to evaluate for FES blockade as assigned dose level.
215042769|NCT00188214|PROCEDURE|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
215042770|NCT03479983|DIETARY_SUPPLEMENT|AMX160|500 mg Phyllanthus emblica L. fresh fruit extract capsules
215042771|NCT03479983|DIETARY_SUPPLEMENT|Placebo|500 mg roasted rice powder in visually identical capsules
215042772|NCT01578161|DRUG|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
215042773|NCT01578161|DRUG|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
215042774|NCT01855893|OTHER|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
215042775|NCT01855893|OTHER|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
215042776|NCT04487405|DEVICE|OVAnex|OVAnex is a multivarite index assay assessing ovarian cancer risk
215042777|NCT03062943|DRUG|Nintedanib|
215042778|NCT01520181|DRUG|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
215042779|NCT04811690|BEHAVIORAL|front-of-package modification|testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks
215042780|NCT05432609|DIAGNOSTIC_TEST|Weight bearing CT|Weight bearing CT in loaded and unloaded positions
215042781|NCT04482127|OTHER|SubEpithelial connective graft|Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
214291659|NCT00135720|DRUG|Enbrel (Etanercept)|
214876894|NCT05150847|OTHER|Oxygenation|Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
214876895|NCT05097794|DRUG|BR1015-1|\- Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.
214291660|NCT02338284|OTHER|ultrasound of globe|"* A high resolution 7.5 -10 MHz linear array ultrasound transducer probe will be used. A large amount of standard water-soluble ultrasound transmission gel will be applied to the patient's closed eyelid. The globe will be scanned in the transverse plane.• The ONSD will be measured at a predefined point 3 mm posterior to the globe in both eyes. • Measurement of the ONSD for both eyes will be done and the average the two measurements will be taken.~* A value \> 58mm (from reference 1) will be considered as indicative of increased ICP and the primary ICU team will be informed for rapid measures to decrease ICP or urgent imaging of the CNS."
214876896|NCT05097794|DRUG|BR1015-2|\- Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.
214876897|NCT05097794|DRUG|BR1015-1 + BR1015-2|\- Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
214876898|NCT01374269|OTHER|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
215042782|NCT04329767|DEVICE|IRIS 1.0|Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
215042783|NCT05175014|BIOLOGICAL|PCV10 full dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a full dose.
215042784|NCT05175014|BIOLOGICAL|PCV10 fractional dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a fractional dose.
215042785|NCT05470166|DRUG|Lidocaine IV|lidocaine infusion as bolus 1.5mg/kg then 2mg/kg/hr
215042786|NCT05470166|OTHER|saline IV|saline infusion same volume as lidocaine
215042787|NCT06152848|OTHER|Data and samples collection|Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples
215042788|NCT06272890|BEHAVIORAL|motivational interviewing|motivational interviewing
215042789|NCT05348967|DIETARY_SUPPLEMENT|TECADRIOL|Food supplement with D-chiro-inositol and alpha-lactalbumin
215042790|NCT05465655|OTHER|ECG monitoring for Conduction Disturbances|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
215042791|NCT04337151|DEVICE|MAGEC Spine Rod|Magnetically controlled growing spine rod used for the surgical treatment of scoliosis.
215042792|NCT04337151|DIAGNOSTIC_TEST|Titanium blood test|A blood test captured to measure the level of titanium
215042793|NCT03699865|OTHER|Nicotine content|Study-supplied cigarettes will contain either intermediate or very low nicotine content
214876899|NCT01374269|DRUG|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
214876900|NCT03961659|DRUG|Liraglutid|Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
214876901|NCT03961659|DRUG|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
214876902|NCT03961659|DRUG|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
214876903|NCT04553874|OTHER||observational study without intervention
214876904|NCT02602444|DRUG|ticagrelor|180 mg loading dose
214876905|NCT04228016|DEVICE|Device: nastent™|Patients with Nasal obstruction at night, will be used intrasal stent during 15 nights. These are flexible silicone tubes that are lubricated and easy to insert into the nasal cavities, which would restore the permeability of the nasal cavities.
214876906|NCT05602883|BEHAVIORAL|music therapy|Music is played for 30 minutes to the pregnant woman who is hospitalized due to the threat of premature birth.
214876907|NCT05439083|BIOLOGICAL|9-valent HPV vaccine|All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
214876908|NCT02944305|PROCEDURE|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
214876909|NCT06129305|OTHER|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography
214876910|NCT05017597|OTHER|Rehabilitation|Exercises completed, and rate of perceived exertion (RPE) will be reviewed during \& after each exercise session. Exercises will be modified by either increasing or decreasing the intensity. Decisions will be made based RPE, physical symptoms \& any identified barriers or supports. Weeks 1, 3, 5, \& 7, Cancer-related fatigue (CRF) education will be assigned. During weeks 2, 4, 6, \& 8, CRF education will be reviewed and a plan for how to apply the information will be developed. Participant will be guided through 6 steps of problem solving to address one occupational performance problem identified by participant within Canadian Occupational Performance Measure. Goal \& action plan for the week will be shared with the participant electronically. At the beginning of each session, participant will describe progress on previous week action plan. Based on participant's response, either a new goal will be developed or the current one modified..
214876911|NCT05607654|DEVICE|active iTBS|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
214876912|NCT05607654|DEVICE|sham rTMS|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214876913|NCT04669847|OTHER|Trunk-oriented exercise program|The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.
215042794|NCT05154734|DRUG|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
215042795|NCT05036135|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
215042796|NCT05036135|DRUG|Placebo|Placebo administered via dry powder inhalation
215042797|NCT05456087|DRUG|incobotulinumtoxin A|Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
215042798|NCT05869747|BEHAVIORAL|Blood Donation|Participants asked to donate whole blood at a donation facility from a list provided by the study.
215042799|NCT05869747|BEHAVIORAL|Plasma Donation|Participants asked to donate plasma at a donation facility from a list provided by the study.
215042800|NCT05869747|BEHAVIORAL|Zone 2 Training|Participants asked to work out in their custom Zone 2 heart range 4 times a week for 45 to 60 minutes.
215042801|NCT05869747|BEHAVIORAL|Intermittent Fasting|Participants asked to engage in an intermittent fasting routine of a 16 hour fast followed by an 8 hour eating period at least 4 times a week.
215042802|NCT05869747|BEHAVIORAL|Surveys|Participants were asked to complete surveys throughout the study to monitor intervention progress and to collect baseline and end-of-study data.
215042803|NCT04411992|DEVICE|Vibrating Device|The device used for the vibration application was produced to control pain and distract attention by providing vibration of 150 at 183 Hz (9000-11,000/min). The device is used again by being cleaned with 70% alcohol. The device was placed put 3 cm above the injection site. It should be ensured to completely contact with skin. Vibration was applied on the site for 3 minutes before injection
214291661|NCT02848183|DRUG|Cytarabine|
214291662|NCT02848183|DRUG|Idarubicin|
214291663|NCT02848183|DRUG|Mitoxantrone|
215042804|NCT04173169|DRUG|Elagolix 200 MG|Elagolix tablet
215042805|NCT04173169|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
215042806|NCT01442987|DRUG|Irbesartan/Atorvastatin A|once daily, P.O. 8week
215042807|NCT01442987|DRUG|Irbesartan|once daily, P.O. 8week
215042808|NCT01442987|DRUG|Atorvastatin A|once daily, P.O. 8week
215042809|NCT01442987|DRUG|Placebo|once daily, P.O. 8week
215042810|NCT01442987|DRUG|Irbesartan/Atorvastatin B|once daily, P.O. 8week
215042811|NCT01442987|DRUG|Atorvastatin B|once daily, P.O. 8week
214291664|NCT02848183|DRUG|Etoposide|
214291665|NCT02848183|PROCEDURE|Hematopoietic stem cell transplantation|
215042812|NCT06429787|DRUG|Balfaxar|BALFAXAR (prothrombin complex concentrate, human-lans) is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure
215042813|NCT06429787|DRUG|Kcentra|"KCENTRA, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with:~* acute major bleeding or~* need for an urgent surgery/invasive procedure"
215042814|NCT04194554|DRUG|Niraparib|given PO per dose escalation schedule
215042815|NCT04194554|DRUG|Leuprolide|22.5 mg q3 month
215042816|NCT04194554|DRUG|Abiraterone Acetate|1000 mg daily
215042817|NCT04194554|RADIATION|Stereotactic body radiotherapy (SBRT)|5-6 fraction SBRT (total dose: 37.5-40 Gy)
215042818|NCT06490367|BEHAVIORAL|Time-Restricted Eating Diet|Participants engage in a time-restricted eating diet, specifically maintaining a 6-8-hour eating window every day for 12 weeks. Participants are allowed to self-select the timing of the eating window, but once selected, they are asked to maintain that schedule daily. Outside of that window, for the remaining 16-18 hours of day/night, participants are asked not to consume calorie-containing food or drink. Beverages without calories are allowed.
215042819|NCT00949039|DRUG|Isolated pelvis perfusion|injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
215042820|NCT00949039|RADIATION|radiotherapy|chemotherapy and/or radiotherapy and/or surgery
215042821|NCT00949039|PROCEDURE|Surgery|
215042822|NCT03517358|OTHER|Service of care|Subjects will be receiving care from case management or clinical pharmacy.
215042823|NCT05438121|DEVICE|SeQuent Please Neo|DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
215042824|NCT06569823|BIOLOGICAL|Z-1018|Formulation for injection
215042825|NCT06569823|BIOLOGICAL|Shingrix|Formulation for injection
214876914|NCT04669847|OTHER|Conventional exercise program|Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
214876915|NCT03705130|DEVICE|Single Vision Contact Lens|Spherical Contact Lens worn on non-dispensing basis
214876916|NCT03705130|DEVICE|Multifocal Contact Lens 1|Multifocal Contact Lens worn on non-dispensing basis
214876917|NCT03705130|DEVICE|Multifocal Contact Lens 2|Multifocal Contact Lens worn on non-dispensing basis
215042826|NCT06570252|DEVICE|activated Light Source (aPDT)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~Activation of SW4000 Light Source (Class 1 Laser Device) that generates red light consisting of 2 channels of 700 mW, 664 nm light (continuous wave) used to activate the disinfecting formulation.~Duration of illumination 2 minutes"
215042827|NCT06570252|DEVICE|non activated Light Source (Control)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~No activation of SW4000 Light Source~Waiting for 2 minutes"
214876918|NCT00278889|DRUG|AZD2171|oral tablet
214876919|NCT00278889|DRUG|5-fluorouracil|intravenous infusion
214876920|NCT00278889|DRUG|Leucovorin|intravenous infusion
214876921|NCT00278889|DRUG|Oxaliplatin|intravenous infusion
214876922|NCT00278889|DRUG|Bevacizumab|intravenous infusion
214876923|NCT01987479|DRUG|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
214876924|NCT01987479|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
214876925|NCT01987479|DRUG|Methotrexate|Methotrexate will be administered per investigator's discretion.
215042828|NCT00561379|DRUG|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
215042829|NCT00561379|DRUG|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
215042830|NCT05007158|OTHER|procalcitonin blood test|blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
215042831|NCT06570200|PROCEDURE|PMPR+iPRF|locally applied iPRF in the periodontal pocket
215042832|NCT06570200|DRUG|PMPR+iPRF+Vit.D|locally applied iPRF plus vitamin D in the periodontal pocket
215042833|NCT06570200|PROCEDURE|PMPR only|scaling and root planing only will be done for the periodontal pocket for the control group
215042834|NCT02781558|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
215042835|NCT02781558|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
215042836|NCT01356368|DRUG|Cisplatin, Gemzar, Docetaxel, Alimta|Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
215042837|NCT01064726|DRUG|Ibuprofen|800 mg oral
215042838|NCT01064726|DRUG|Fluticasone propionate|200 mcg intra-nasal
215042839|NCT01064726|DRUG|Placebo|Placebo
215042840|NCT00380146|DRUG|sulfadoxine-pyrimethamine|
215042841|NCT03240328|BIOLOGICAL|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
215042842|NCT06539481|DRUG|fluocinolone acetonide 190 micrograms|ILUVIEN®, is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye. ILUVIEN® delivers corticosteroid directly to the intended site of action for up to 36 months.
215042843|NCT00545779|DRUG|Ibandronate|150 mg orally once monthly for 6 months
215042844|NCT07004907|DEVICE|Treatment with the pedriatic mode of the APD cycler|Patients weighing less than 20 kg will be treated for 4 weeks with APD using the PAED mode of the Silencia PD cycler
214876926|NCT03276065|DEVICE|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
215042845|NCT04612140|PROCEDURE|Radiosurgery|The study subjects randomized in this study arm will undergo a radiosurgery procedure.
215042846|NCT04612140|PROCEDURE|Repeated catheter ablation|The study subjects randomized in this study arm will undergo repeated catheter ablation.
214876927|NCT03276065|OTHER|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
214876928|NCT05006391|OTHER|Tele-Coaching (Online) Community-Based Exercise|"PHASE 1-Intervention Phase (6 months): Participants will engage in an individual tailored home-based exercise program involving aerobic, resistance, balance and flexibility training \~60min, 3 times per week for 24 weeks. Intervention will include: Component 1) biweekly 60 min personal online coaching with a certified trainer from the YMCA (13 sessions) who will monitor and progress exercise intensity; Component 2) weekly online group-based exercise classes \~60 min each led by a trainer at YMCA; Component 3) monthly online evidence-based self-management education sessions focused on topics related to self-management and health, and physical activity living with HIV; and Component 4) a wireless physical activity monitor (WPAM) to self-monitor steps, distance, calories burned, and active minutes.~PHASE 2: Post-Intervention (6 months): Participants will be encouraged to continue with unsupervised home / outdoor-based exercise 3 times per week and to continue using their WPAM throughout."
214876929|NCT01449097|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
214876930|NCT01449097|PROCEDURE|The femoral nerve block|US-guided femoral nerve block with ropivacaine
215042847|NCT06621277|OTHER|No intervention|No intervention
215042848|NCT06621277|OTHER|Tailored counseling programs (Phase 2)|Optimized care services and tailored counseling programs for young patients with GI tumors at the Heidelberg University Hospital (Phase 2)
215042849|NCT03802396|DRUG|CN-105|"Three doses of CN-105 will be used in three successive cohorts of 50 patients each.~0.1 mg/kg (cohort 1), 0.5 mg/kg (cohort 2), 1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses."
215042850|NCT03802396|DRUG|Placebo|Patients will receive placebo intravenously every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
215042851|NCT06629961|PROCEDURE|abutment placement|Placement of a subcrestal implant at more than 35 N and placement of a trans-epithelial abutment at 30 N
215042852|NCT06629961|PROCEDURE|Ti-base placement|Placement of a subcrestal implant at more than 35 N and placement of a Tibase placement at 30 N
215042853|NCT06719089|DEVICE|Biodegradable double loop ureteral stent|This ureteral stent is based on natural polymers and degrades inside the human body without causing obstruction, avoiding the need of a second surgery for stent removal and minimizing complications related to encrustation and bacterial infections.
215042854|NCT06719089|DEVICE|PolyUrethane Double Loop Ureteral Stent|This ureteral stent is a double J made of 100% polyurethan, heat-sensitive and radiopaque for excellent patient tolerance and high incrustation resistance.
215042855|NCT04955041|OTHER|MRI|T2\* MRI
215042856|NCT00163293|DRUG|Ciclesonide|Ciclesonide metered-dose inhaler
215042857|NCT00163293|DRUG|Placebo|Ciclesonide placebo-matching metered-dose inhaler
214291666|NCT03775057|OTHER|MyDoseCoach app|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
214876931|NCT01449097|PROCEDURE|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
214876932|NCT06498869|DRUG|Ketamine Hcl 50Mg/Ml Inj|This group will be administered ketamine (0.25-0.50 mg/kg)
215042858|NCT02561962|DRUG|AMG 224|Administered as an IV infusion.
215042859|NCT05729087|BEHAVIORAL|Blended intervention group|"Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session."
215042860|NCT01580787|DEVICE|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
215042861|NCT01580787|OTHER|Physical Therapy|Patients of the control group was trained with balance exercises.
215042862|NCT01484249|DEVICE|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
215042863|NCT00004682|DRUG|immune globulin|
215042864|NCT00244192|DRUG|infliximab (Remicade)|
215042865|NCT00373542|DRUG|ropinirole CR-RLS|
215042866|NCT01150357|DRUG|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
215042867|NCT01150357|DRUG|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
214876933|NCT03623178|OTHER|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
214876934|NCT00254852|PROCEDURE|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
214876935|NCT00254852|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
214876936|NCT00254852|PROCEDURE|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
214876937|NCT00254852|PROCEDURE|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
214876938|NCT00254852|PROCEDURE|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
214876939|NCT06915857|DEVICE|Topical Betamethasone|Betamethasone a TC, reduces RD by promoting the synthesis of anti-inflammatory proteins while also preventing other inflammatory proteins from being synthesized
214876940|NCT06943222|OTHER|Traditional Play|"The intervention for the traditional play group included activities such as Shtapu and skipping rope. Both traditional play activities were scheduled 3 times per week (3 Session/week) over the 6-month period.~Both activities took place outdoors and in the institutional gymnasium, depending on the prevailing weather conditions. Each session lasted 35 minutes and took place in the morning hours (8-11 a.m.). Prior to each type of activity, a specific warm-up was conducted, following methodological guidelines for preschoolers' physical education."
215042868|NCT01150357|DRUG|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
215042869|NCT05042206|BIOLOGICAL|Cellgram-CKD|Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
215042870|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose|Intravitreally (IVT) injection.
215042871|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg|Intravitreally (IVT) injection.
215042872|NCT05850520|DRUG|Sham|Sham procedure will be given on visits when an active injection is not planned.
214876941|NCT06952361|PROCEDURE|Red blood cell transfusion|Standard red blood cell transfusion performed as part of routine clinical care. All participants received one or more units of RBCs based on a restrictive hemoglobin threshold. The transfusion protocol was not altered for the purpose of the study.
214876942|NCT06954532|BEHAVIORAL|Interoceptive training|There will be 6 interoceptive training sessions. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy, relative to their objective accuracy.
214876943|NCT06282601|OTHER|Audiogram|Tonal and vocal free-field without lip-reading
214876944|NCT06282601|OTHER|Musical priming for the syntax test|Listening to music with a regular or irregular rhythm, then judging the grammaticality of 2x6 blocks of French sentences interrupted by a pause, each block presenting 4 sentences including 2 grammatically correct sentences and 2 grammatically incorrect sentences. The sentences are pronounced by a French female voice at a natural rhythm and comfortable volume.
214876945|NCT06282601|OTHER|Test MMSE|test to assess a person's cognitive functions and memory capacity.
214876946|NCT06282601|OTHER|Barcelona Music Reward Questionnaire|"20 questions exploring 5 main facets of the musical reward experience, with 4 items for each of the 5 facets, for which participants indicate the level of agreement using a 5-level scale, ranging from strongly disagree to strongly agree."
215042873|NCT05850520|DIAGNOSTIC_TEST|Fluorescein|Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
215042874|NCT03252093|DRUG|Angiotensin-(1-7)|Subcutaneous injection of 200 mcg/kg/day
215042875|NCT03252093|DRUG|Placebo for Angiotensin-(1-7)|Subcutaneous injection of Placebo
215042876|NCT04312945|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
215042877|NCT04312945|OTHER|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
215042878|NCT06116175|PROCEDURE|60 degree thermal radiofequency of tennis elbow|under strict aseptic technique ultrasound guided TRF of lateral epicondylitis advanced for 5 mm active tip canula
215042879|NCT05714514|DRUG|Imlifidase administered in the ConfIdeS study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
215042880|NCT05714514|OTHER|Best available treatment administered in the ConfIdeS study|Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
215057599|NCT05895097|DEVICE|Left bundle branch pacemaker|Left bundle branch pacing (LBBP) will be the pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Final lead position will be confirmed according to ECG parameters. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory.
215057600|NCT05895097|DEVICE|Conventional pacing|Right ventricular pacing in patients with LVEF ≥ 40% and cardiac resynchronization therapy in patients with LVEF \< 40 %
215042881|NCT05017558|DIAGNOSTIC_TEST|point of care|"HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~1. Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~   * High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~  * Low risk (maternal VL \<1000 cp/ml): NVP for 6 weeks.~2. virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~3. In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~4. support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support"
215042882|NCT05471986|DEVICE|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Subjects will have underwent Fundus Photography using FDA approved non-mydriatic fundus cameras compatible with EyeCheckup which are either TOPCON NW400, CANNON CR2, CANNON CR2 Plus or OPTOMED AURORA IQ
215042883|NCT06932835|DRUG|Transversus Abdominis Plane (TAP) Block|Transversus Abdominis Plane (TAP) Block is performed under ultrasound guidance before the surgical procedure and anesthesia induction, with the patient in the supine position.
215042884|NCT06932835|DRUG|Modified Thoracoabdominal Nerve Block (M-TAPA)|Modified Thoracoabdominal Nerve Block (M-TAPA) is performed under ultrasound guidance before the surgical procedure and anesthesia induction, with the patient in the supine position.
214666697|NCT01674764|PROCEDURE|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
215042885|NCT04838704|DRUG|Ruxolitinib+Calcineurin inhibitor+Methotrexate|low-dose ruxolitinib combine with calcineurin inhibitor and short course of methotrexate.
215042886|NCT04838704|DRUG|Calcineurin Inhibitor+Methotrexate+Mycophenolate mofetil|calcineurin inhibitor and short course of methotrexate and mycophenolate mofetil
215042887|NCT01589614|DRUG|PH-797804|Tablet, 6mg, single
215042888|NCT01589614|DRUG|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
215042889|NCT06932276|BEHAVIORAL|"Some things a re better outside"|"Some Things Are Better Outside interventionis designed to encourage participants to voluntarily create a smoke-free home by accepting a norm of never smoking at home, whether indoors or outdoors, such as on balconies. The intervention is delivered over six weeks and consists of four components: an initial mailing of printed materials, a coaching call, and two additional mailings. It is based on five steps to adopting a smoke-free home: 1) deciding on the reasons for creating one, 2) discussing it with family members, 3) choosing a date to go smoke-free, 4) making the home a smoke-free environment, and 5) maintaining it as smoke-free."
215042890|NCT06937307|DRUG|Droxidopa capsules|Droxidopa is an oral synthetic amino acid that is directly metabolized to norepinephrine by dopa-decarboxylase. It will be administered at an initial dose of 100 mg three times daily, titrated in 100 mg increments every 24 hours based on blood pressure response, up to a maximum of 300 mg three times daily. Doses will be given approximately 4 hours apart during daytime hours, at least 3 hours apart, with a maximum total daily dose of 900 mg. The treatment duration is 28 days. The drug will be over-encapsulated using opaque capsules to maintain the double-blind design.
215042891|NCT06937307|OTHER|Placebo|Matching placebo capsules containing microcrystalline cellulose (from Millipore Sigma) will be over-encapsulated using identical opaque capsules to maintain blinding. Placebo will be administered following the same schedule as the active treatment: three times daily with the same titration protocol based on blood pressure response, for a treatment duration of 28 days. The Columbia University Research Pharmacy will perform over-encapsulation of both active drug and placebo to ensure they are identical in appearance.
215042892|NCT06944639|DEVICE|Membrane Jason MB GmbH Non-cross-linked (NCL)|The membrane will be stabilized in the oral mucosa using sutures and flowable composite.
215042893|NCT06944639|DEVICE|Membrane BioMend Extend Glutaraldehyde cross-linked|The membrane will be stabilized in the oral mucosa using sutures and flowable composite.
215042894|NCT06944639|DEVICE|Membrane OSSIX Agile Ribose cross-linked (RCL)|The membrane will be stabilized in the oral mucosa using sutures and flowable composite.
215042895|NCT04175184|OTHER|Mobilisation with Movement|"MWM is a pain-free manual therapy procedure that aims to restore full active pain-free range of motion. It consists of an accessory movement performed by the therapist followed by an active movement executed by the patient. The accessory glide might be produced by the therapist´s hands or by a belt. Minor changes in the amount of force or direction of the glide are common to produce better results.~The MWM procedures will be used pragmatically in this study. Therefore, several attempts might be needed to produce the outcome desired. In the case of the shoulder, they can be applied to the glenohumeral joint, scapulothoracic joint, acromioclavicular joint, cervical and thoracic spines and the rib cage. The decision making process in this study will be based on the outcome observed. The procedure that produced the greatest improvement in active pain-free range of motion will be the one used on that occasion."
215057601|NCT04576910|BIOLOGICAL|vaccinated with Sabin IPV|the 4th dose of polio vaccination
214291667|NCT06362811|PROCEDURE|Sacral Erector Spinae Plane Block|Ultrasound-guided bilateral injection of 1ml/kg 0.25% bupivacaine into the plane underneath the erector spinae muscles over sacral crests. The needle is inserted with in-plane technique from cranial to caudal direction over S3-4.
214291668|NCT01005420|DIETARY_SUPPLEMENT|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
214666698|NCT01674764|PROCEDURE|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
214666699|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 40mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
214666700|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 20mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
214666701|NCT03166800|DRUG|Placebo|This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
214876947|NCT05927363|OTHER|Therapeutic educational consolidation program in Phase 3 of cardiac rehabilitation associating a patient & caregiver partnership|"In the experimental group, patients benefit from the usual management as part of the phase 2 post-CR follow-up, with the provision of an information booklet on the benefits of physical activity, and a telephone contact in the event of any questions. In addition, they benefit from the Consolidation therapeutic education program in phase 3 of CR associating a patient \& caregiver partnership, which consists of two teleconsultation sessions at 2 and 4 months, followed by a remote group education workshop co-facilitated by the patient and caregiver partnership at 5 months.~Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions."
214876948|NCT05927363|OTHER|Teleconsultation at 2 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
214876949|NCT05927363|OTHER|Teleconsultation at 4 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
214876950|NCT05927363|OTHER|Remote group education workshop|This remote workshop will be co-facilitated by the patient and caregiver partnership at 5 months
214876951|NCT05927363|OTHER|Administration of self-questionnaires: IPAQ, EMAPS, the Exercise Confidence Survey, EQ-5D-5L and the Mediterranean diet adherence score.|Patients are then randomly assigned to either the control group (usual management) or the experimental group (management with Patient and Caregiver partnership).
215042896|NCT04175184|OTHER|Sham Mobilisation with Movement|Sham MWM is a comparator procedure used in this research to control for placebo related mechanisms of action. This procedure has already been used in previous research (Delgado-Gil et al 2015). Briefly, the therapist will stand opposite to the affected shoulder, he/she will place the thenar eminence of the anterior hand on the skin in front of the humeral head, while the posterior hand will rest on the scapula. Both hands will just lightly rest on the skin, no accessory glide will be performed to the humeral head. Then, the participant will move his/her shoulder in the direction previously selected. Shall the procedure elicit pain-free full range of motion, the participant will move their shoulder ten times. Otherwise, the movement should be performed up to the onset of symptoms.
215042897|NCT06305390|DIAGNOSTIC_TEST|PET/MRI|18F-PSMA PET/MRI
215042898|NCT05985239|PROCEDURE|VI|Laparoscopic or robotic surgery with virtual ileostomy
215042899|NCT05985239|PROCEDURE|DI|Laparoscopic or robotic surgery with virtual ileostomy
215042900|NCT03243864|DRUG|Ceftazidime-avibactam|Patients will be started on 2.5 gm IV every 8 hours
215042901|NCT06715228|BEHAVIORAL|shitali pranayama respiratory rehabilitation training|in this group, patients (n=20) with obstructive sleep apnea will participate and will administer six cycles of 5-min shitali respiratory pranayama exercise rehabilitation training (the rehabilitation will be repeated or applied at morning, afternoon, and also at evening) for 12 week as a daily performance
215042902|NCT05812352|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application
215042903|NCT05812352|BEHAVIORAL|Instructional flashcard|Single page (instructional flashcard) with pictures corresponding to each of the 6 steps of tourniquet application
215042904|NCT05812352|BEHAVIORAL|In-person training|Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt
215042905|NCT02562781|DRUG|Oxygen|Oxygen in sufficient quantity to maintain SpO2 \> 98%
215042906|NCT02562781|OTHER|Air|Supplemental Oxygen in sufficient quantity to maintain SpO2 \> 90%
215042907|NCT01658059|OTHER|Homeopathic remedy|drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
215042908|NCT01658059|OTHER|Placebo|drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
215042909|NCT01597739|DRUG|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
215042910|NCT01597739|DRUG|Placebo|Form=capsule; route=oral use; twice daily.
215042911|NCT02916264|PROCEDURE|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
215042912|NCT03198871|DRUG|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
215042913|NCT03198871|DRUG|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
215042914|NCT00332618|DEVICE|OXYGENATED GLYCEROL TRIESTERS|
215042915|NCT03886467|OTHER|Community-based nutrition education|Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
215042916|NCT02982629|BEHAVIORAL|Reminder letter Intervention|Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
215042917|NCT00626535|DRUG|Esomeprazole|20mg Oral Once Daily
215042918|NCT00626535|DRUG|Matching placebo|Oral Once Daily
215042919|NCT03117647|PROCEDURE|Mansoura-VV compression suture|two compression suture both are v shaped apex of each suture placed 2 cm below suture line of C.S and 3 cm from the lateral border of the uterus on the right and left side
215042920|NCT05529407|DEVICE|Simple Vaginal Tampon|Use of single use vaginal tampons
215042921|NCT05529407|DEVICE|Glass Vaginal Trainer|Use of glass vaginal trainers
215042922|NCT05745610|DRUG|Shen Hai Long Capsule|3 times/day (9 capsules/day) for 12 weeks
215042923|NCT05745610|DRUG|Sheng Jing Capsule|3 times/day (12 capsules/day) for 12 weeks
215042924|NCT04691388|DRUG|sintilimab combined with anlotinib|All patients will receive sintilimab combined with anlotinib every 3 weeks
215057602|NCT04576910|BIOLOGICAL|vaccinated with bOPV|the 4th dose of polio vaccination
214876952|NCT05927363|DIAGNOSTIC_TEST|6-minute walk test and administers the modified Borg scale at its conclusion.|What is a modified Borg scale? The Modified Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered following a six-minute walking test, one of the most common and frequently used measures to assess disease severity in patients with pulmonary arterial hypertension. Upon conclusion of the 6-minute walking test, the modified Borg scale will be recorded.
214876953|NCT05927363|DIAGNOSTIC_TEST|Biological check-up|This check-up includes total cholesterol, LDL, HDL, triglycerides, HbA1c.
214876954|NCT05927363|DEVICE|Accelerometer|"An accelerometer is given to the patient, with instructions to wear it for 7 days following the visit (it will then be returned by post).Pre-stamped bubble envelopes are given to the patient to return their accelerometer to the measurement points specified in the follow-up."
214876955|NCT05927363|OTHER|Administration of a logbook|The patient is given a logbook for daily monitoring of non-measurable physical activities, treatments and medical procedures carried out, as well as any intercurrent events.
215042925|NCT05192915|DEVICE|Modular customized AFO|Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
215042926|NCT05812885|DEVICE|TENS|Active TENS
215042927|NCT06477627|OTHER|change of environment|The participants will change from inland to coastal environment to see the effect. We will take VAMS blood samples and nose swabs from the participant to measure this effect.
215042928|NCT06477627|OTHER|no intervention|reference groups, stay in their coastal or inland environment
215042929|NCT01732536|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
215042930|NCT01732536|PROCEDURE|Sham procedure|In-office bilateral sham procedure
215042931|NCT01732536|DRUG|Mometasone furoate nasal spray|Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
215042932|NCT02212665|BEHAVIORAL|High intense interval training|
214291669|NCT01005420|DIETARY_SUPPLEMENT|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
214291670|NCT00728780|DRUG|ABT-143|once
214291671|NCT00728780|DRUG|ABT-335 and rosuvastatin|once
215042933|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer|
214291672|NCT00237601|OTHER|obstetric care|
214291673|NCT04208620|DRUG|Placebo|Placebo administered subcutaneously
214291674|NCT04208620|DRUG|Cotadutide|Cotadutide administered subcutaneously
214876956|NCT06953973|OTHER|Tecar Therapy|Tecar Therapy will be applied by a specialist physiotherapist with WINTECARE T-PLUS-Switzerland. Participants in the experimental group included in the Tecar therapy application will be applied to the muscle groups in the neck region at a fixed frequency of 0.448 Mhz for 10 minutes.
214291675|NCT03930576|OTHER|Receipt of termination services outside of legal setting|This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
214291676|NCT06332651|OTHER|Black beans|Black beans cooked and mashed and amino acid mixture as liquid drink to make methionine the limiting amino acid in the food consumed
214291677|NCT06332651|OTHER|Milk|Skimmed milk as liquid drink and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
214876957|NCT06953973|OTHER|Sham Tecar Therapy|Tecar Therapy will be applied by a specialist physiotherapist with WINTECARE T-PLUS-Switzerland. The patient will be positioned as in the Tecar group, but the heating feature of the device will not be activated.
215042934|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+HIIT|
215042935|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+group intervention|
215042936|NCT03753048|PROCEDURE|Y-Graft|Y-Graft Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, the left internal thoracic artery is cut off distally and the right internal thoracic artery is cut off proximally and distally. Then they anastomose the following way. Left internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, distal part of the right internal thoracic artery should be anastomosed to the obtuse marginal artery. Finally, proximal part of the right internal thoracic artery is anastomosed to the left internal thoracic artery as Y-graft in the end to side fashion. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
215042937|NCT03753048|PROCEDURE|In-Situ|In-Situ Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, both internal thoracic arteries are cut off distally. Then they anastomose the following way. Right internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, left internal thoracic artery should be anastomosed to the obtuse marginal artery. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
215042938|NCT00165828|DRUG|Zonegran|Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
215042939|NCT03345277|OTHER|Continuous Temperature monitoring|Residents in a long term care facility will wear a thermometer continuously for 3 months, measuring their body temperature
215042940|NCT02359006|DRUG|Minocycline|Minocycline will be compared with placebo
215042941|NCT02359006|DRUG|Placebo|Placebo will be compared with minocycline
215042942|NCT05323890|DRUG|Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy|Patients received tislelizumab at a fixed dose of 200 mg every three weeks (q3w, 21 days) for 2 cycles.
215042943|NCT02845986|PROCEDURE|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
215042944|NCT02845986|DRUG|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
215042945|NCT06049147|DRUG|MBF-015 4 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
214291678|NCT06332651|OTHER|Sorghum|Sorghum cooked and mashed and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
214291679|NCT04962633|OTHER|Probiotic Pasta|Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
214291680|NCT04962633|OTHER|Control Pasta|Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
214666702|NCT06076746|BEHAVIORAL|NIC Psychotherapeutic Intervention(s) for İneffective Coping|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
214876958|NCT06953973|OTHER|Standard Physiotherapy Program|This study will include routinely applied conventional physiotherapy, heat modalities, electrotherapy (transcutaneous electrical nerve stimulation (TENS) and ultrasound therapy), and exercises. In this study, hot pack will be used to induce vasodilation and reduce muscle spasm. Hot pack will be used for 15 minutes to relax muscle spasms and increase soft tissue flexibility. TENS is a simple noninvasive modality and is widely used in both acute and chronic neck pain. In our study, 50 Hz conventional TENS with a pulse duration of \<150 microseconds will be used. TENS will be applied to the painful area of the neck for 20 minutes. Ultrasound therapy used to warm deep tissues is one of the most frequently used physical therapy methods. An ultrasound device (Chattanooga, USA) will be used in the study. Ultrasound gel will be applied circularly with a thickness of 2-3 mm. Ultrasound will be applied with a 4 cm2 probe for 5 minutes with a frequency of 1 MHz and 1.5 Wt/cm2. Within the scope o
214876959|NCT06372496|DRUG|Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate|Participants will receive FF/UMEC/VI
214876960|NCT06372496|DRUG|Inhaled corticosteroids/long-acting beta-2 agonists|Participants will receive ICS/LABA
214876961|NCT05846230|DRUG|BI 1291583|Tablet
214876962|NCT05846230|DRUG|Placebo matching BI 1291583|Tablet
214876963|NCT01880567|DRUG|Ibrutinib|Given PO
214876964|NCT01880567|OTHER|Laboratory Biomarker Analysis|Correlative studies
214876965|NCT01880567|BIOLOGICAL|Rituximab|Given IV
214876966|NCT06832410|BIOLOGICAL|Biological/Vaccine|Infused into the hepatic portal vein.
214876967|NCT03646058|DRUG|Buprenorphine|Buprenorphine, 0.4mg pills, sublingual
215042946|NCT06049147|DRUG|MBF-015 16 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
215042947|NCT06049147|DRUG|Placebo|Hard gelatin capsules filled with cellulose microcrystalline
215042948|NCT05373485|BIOLOGICAL|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
215042949|NCT05373485|BIOLOGICAL|Placebo|2 doses of placebo on Day 0 and Day 21
215042950|NCT06088173|OTHER|exercises|Patients in both group will use Kleinert splint. Sessions will start with ice application if there is edema and continue with scar tissue massage. After general hand massage, passive flexion, active extension exercises; tenodesis exercise and passive punch will be performed for the postoperative (postop) first two weeks. In postop 3-4 weeks, four finger sliding exercises, active half fist and NMES (Neuromuscular electrical stimulation) will be performed. In postop 5-6 weeks, blocking exercises, full punch, grappling hooks and small on-digits holding and releasing exercises will be performed additionally.
215042951|NCT06088173|OTHER|Exercises and Education|In addition to the same treatment as the patients in the first group, in the first postoperative (postop) two weeks, the gmi will be explained to the patients and lateralization will be started. lateralization refers to right-left discrimination and the patients will be presented with visuals with the help of the noi recognise app and they will have to decide whether the visual is right or left hand. In the postop 3-4th weeks, the motor imagery stage will be started and imagery will be practiced with the help of the same app. In postop 5-6 weeks, mirror therapy will be practiced with the help of a mirror box.
214291681|NCT03676933|DRUG|DS107E|
214876968|NCT03646058|DRUG|Placebo|Placebo pills, sublingual, specifically made to mimick buprenorphine pills
214876969|NCT04876092|DRUG|JNJ-67856633|Participants will receive JNJ-67856633 orally.
214876970|NCT04876092|DRUG|Ibrutinib|Participants will receive Ibrutinib orally.
214876971|NCT05307731|DRUG|Fingolimod|0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
214876972|NCT05307731|DRUG|guideline-based treatment for DM|guideline-based treatment for DM
214876973|NCT06195072|DRUG|Amlitelimab|"IP will be administered subcutaneously by the Investigator or designee as follows:~* Amlitelimab or~* Matching placebo"
214876974|NCT06195072|DRUG|BI 1015550 (Nerandomilast)|Study participants will take the active investigational product BI 1015550 (Nerandomilast) or matching placebo provided as film-coated tablets, administered orally BID.
215042952|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
215042953|NCT01581684|DRUG|Placebo|Solution for oral administration
215042954|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
215042955|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
215042956|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
215042957|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
215042958|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
215042959|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
215042960|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
215042961|NCT06095895|OTHER|venipuncture|An additional measurement of exposure of mycophenolic acid and/or tacrolimus will be performed
215042962|NCT03728933|DRUG|Rotigotine 1 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).
215042963|NCT03728933|DRUG|Rotigotine 2 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).
215042964|NCT03728933|DRUG|Placebo|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
215042965|NCT02838641|DEVICE|GeneXpert|Real time integrated and automated nucleic acid amplification test for detection of TB
215042966|NCT03496116|OTHER|ECIG Session|Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
215042967|NCT01155557|DEVICE|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
214876975|NCT06195072|DRUG|Placebo|see Experimental Arm intervention description
214876976|NCT05291260|PROCEDURE|Cast immobilization|A cast to immobilize the MCP, in 10-30 degrees (slight) flexion (neutral position), and the CMC joint, in 30-40 degrees palmar abduction, is applied (IP joint is free).
214876977|NCT05291260|PROCEDURE|Surgical treatment|"In general, two surgical techniques are described in literature and used in daily clinical practice:~* If the UCL is ruptured in the middle of the ligament, sutures are used to reattach the ligament remnants together.~* When no viable UCL ligaments are present, the UCL is reattached directly to the bone using suture anchors."
214876978|NCT06529757|OTHER|Whole body cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to whole body skin wetting. Skin wetting will be performed by spraying water onto the whole body throughout the exercise bout.
215042968|NCT01155557|BEHAVIORAL|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
215042969|NCT02403544|RADIATION|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
215042970|NCT02403544|DRUG|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
215042971|NCT02403544|DRUG|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
215042972|NCT03235050|DRUG|MEDI0382 low dose|Pharmaceutical form: solution Route of administration: subcutaneous
215042973|NCT03235050|DRUG|MEDI0382 mid dose|Pharmaceutical form: solution Route of administration: subcutaneous
215042974|NCT03235050|DRUG|MEDI0382 high dose|Pharmaceutical form: solution Route of administration: subcutaneous
215042975|NCT03235050|DRUG|Placebo|Pharmaceutical form: solution Route of administration: subcutaneous
214291682|NCT03676933|DRUG|Vehicle|
214291683|NCT03676933|DRUG|Hydrocortisone Butyrate 0.1% Cream|Steroid taken topically once a day
214476885|NCT06594796|BEHAVIORAL|Combined lifestyle intervention and LBP care (physiotherapy, exercise therapy)|One of five recognized combined lifestyle interventions (BeweegKuur, CooL, SSIB, SLIMMER, X-Fittt) integrated with LBP care.
214876979|NCT06529757|OTHER|Non-cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modalities.
214876980|NCT06809114|DRUG|AT03-65|Treatment will continue until disease progression, unacceptable toxicity, subject withdrawal of consent or death.
214876981|NCT03464721|DEVICE|issued with SMART ANGEL device|patients will use the technology at home to record and transmit data for blood pressure and oxygen saturation
214876982|NCT04944979|BIOLOGICAL|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
214876983|NCT05897645|OTHER|Registration|collect clinical date, assess the morphologic characteristics of plaque
214876984|NCT05983250|DRUG|TNX-103|oral levosimendan 1 mg
214876985|NCT05983250|DRUG|Placebo|Placebo
214876986|NCT02168192|BEHAVIORAL|Simulation-Debrief|Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
214876987|NCT02168192|BEHAVIORAL|Traditional lecture|Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
214876988|NCT02145715|DRUG|Velcade|
214876989|NCT02145715|DRUG|Thalidomide|
214876990|NCT02145715|DRUG|Dexamethasone|
214876991|NCT02145715|DRUG|Panobinostat|
214876992|NCT02267044|DRUG|Ropivacaine|The drug used for the interscalene blocks
214876993|NCT06235489|OTHER|Palfique Bulk Flow|removal of caries in primary molars and placement of restorative materials
215042976|NCT03235050|DRUG|Liraglutide|Pharmaceutical form: solution Route of administration: subcutaneous
215042977|NCT02823002|PROCEDURE|Slow, Room Temperature Injection|The room temperature local anesthetic agent will be administered by slow infiltration.
215042978|NCT02823002|PROCEDURE|Rapid, Room Temperature Injection|The room temperature local anesthetic agent will be administered by rapid infiltration.
215042979|NCT02823002|PROCEDURE|Slow, Warm Temperature Injection|The warmed local anesthetic agent will be administered by slow infiltration.
215042980|NCT02823002|PROCEDURE|Rapid, Warm Temperature Injection|The warmed local anesthetic agent will be administered by rapid infiltration.
215042981|NCT02823002|PROCEDURE|Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
215042982|NCT02823002|PROCEDURE|Non-Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
215042983|NCT02823002|DRUG|Lidocaine|Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
215042984|NCT02823002|DRUG|Buffer|Sodium Bicarbonate
215042985|NCT03852030|BEHAVIORAL|Text or email message|Text or email messages sent to research participants
215042986|NCT03995160|PROCEDURE|Use of closed suction drainage following total knee arthroplasty|Use of closed suction drainage following total knee arthroplasty
215042987|NCT03995160|PROCEDURE|Abstain of using a closed suction drainage|Abstain of using a closed suction drainage following total knee arthroplasty
214876994|NCT04488315|DRUG|Dexamethasone lipid microsphere plus ropivacaine|Local scalp infiltration solution will consist of 30ml miscible liquids containing 8 mg dexamethasone lipid microsphere, 150mg ropivacaine and normal saline.
214876995|NCT04488315|DRUG|Ropivacaine alone|Local scalp infiltration solution will consist of 30ml miscible liquids containing 150mg ropivacaine and normal saline
214876996|NCT06582459|DEVICE|HFNC treatment|HFNC treatment HFNC therapy. The initial flow rate of 50-60 L/min was subsequently adjusted to maintain an oxygen saturation (SpO2) ≥92%. The FiO2 was titrated to maintain the PaO2 between 60 and 80 mmHg.
214876997|NCT06582459|DEVICE|NIV treatment|NIV treatment A Mindray SV300 ventilator (Mindray Medical International Limited, Shenzhen, China) was used to deliver NIV via an oronasal mask. The initial inspiratory positive airway pressure (IPAP) was 12-15 cmH2O and adjusted later to achieve a tidal volume of 6-8 mL/kg of predicted body weight and a respiratory rate of \&amp;lt;30 breaths/min. The expiratory positive airway pressure (EPAP) was established at 5-8 cmH2O. Additional-ly, FiO2 was titrated to maintain a PaO2 between 60 and 80 mmHg.
214876998|NCT03301545|PROCEDURE|Fast-Track to Bariatric Surgery|30 participants from the urban Indigenous community who have Type 2 diabetes and are candidates for bariatric surgery at the Centre for Metabolic and Bariatric Surgery will be randomized to the fast-track to bariatric surgery group.
214876999|NCT06486870|DRUG|Gonadotropin|Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days. The aim of treatment is to achieve mono-ovulation. Monitoring of treatment is achieved by serial transvaginal ultrasound scanning every other day starting from cycle day nine. Size and number of follicles is recorded in patients follow up sheets. The dose of hMG is reviewed around stimulation day 10 and if follicular development is unsatisfactory, the dose is increased to 75 IU daily .If a good response is not achieved day16 ; the cycle is cancelled. A new cycle is commenced with a higher starting dose of hMG (75 IU per day). When one follicle reached a size of \> =18 mm a single dose of 10,000 IU human chorionic gonadotrophin (hCG, Pregnyl, Epifasi, Choriomon) is given.
214877000|NCT06486870|DRUG|Letrozole|5 mg LE oral tablets are administered on the fifth day of menses and then every day for 5 days. Treatment is repeated for up to six cycles
214877001|NCT06486870|PROCEDURE|laparoscopic ovarian drilling|"Laparoscopic ovarian drilling will be done according to the following:~Electrocautery using a mixed current in monopolar electrosurgical needle will be into introduced through the ovarian ipsilateral parts and applied up to 4 point cauterisation of the ovarian capsule, each for 4 second, at 40 W and for a diameter of 3mm and a depth of 4 mm in the antimesentric surface . (Amer et al 2003, Sawant S et al 2019) ,the procedure will be applied for one ovary .~The patient under the study will be followed up to six months of continuous marital life after the procedure"
214877002|NCT06179654|BEHAVIORAL|Preoperative pelvic floor physical therapy|Pelvic floor physical therapy to start before prostate surgery rather than after surgery.
215042988|NCT01171911|DRUG|Nicardipine , Esmolol|A loading dose of Nicardipine 10mg was at a bolus injected through vein , then continuous trans-venous titration at a speed 1ug/kg was kept. A loading dose of Esmolol 0.5mg/kg/min was at a bolus injected through vein , then continuous trans-venous titration at a speed 0.2mg/kg/min was kept.
215042989|NCT05117814|DRUG|Zanubrutinib|as long as 24 months or consolidated with ASCT or WBRT after achieving PR or CR
215042990|NCT03545672|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
215042991|NCT03015493|OTHER|Neural mobilization combined with traction|Neural mobilization techniques combined with cervical traction for the cervical nerve roots
214291684|NCT02792933|PROCEDURE|air in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
214666703|NCT06076746|BEHAVIORAL|psychotherapeutic intervention|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
214877003|NCT03914625|DRUG|Asparaginase Erwinia chrysanthemi|Given IV or IM
214877004|NCT03914625|BIOLOGICAL|Blinatumomab|Given IV
214877005|NCT03914625|DRUG|Cyclophosphamide|Given IV
214877006|NCT03914625|DRUG|Cytarabine|Given IT or IV
214877007|NCT03914625|DRUG|Dexamethasone|Given PO or IV
214877008|NCT03914625|DRUG|Doxorubicin Hydrochloride|Given IV
214877009|NCT03914625|DRUG|Leucovorin Calcium|Given PO or IV
214877010|NCT03914625|DRUG|Mercaptopurine|Given PO
214877011|NCT03914625|DRUG|Mercaptopurine Oral Suspension|Given PO
214877012|NCT03914625|DRUG|Methotrexate|Given IT or IV
214877013|NCT03914625|DRUG|Pegaspargase|Given IV or IM
214877014|NCT03914625|DRUG|Prednisolone|Given PO or IV
214877015|NCT03914625|DRUG|Prednisone|Given PO or IV
215042992|NCT03015493|OTHER|Traction|Traction techniques for the cervical spine
215042993|NCT01628913|DRUG|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
215042994|NCT01628913|DRUG|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
215042995|NCT02015247|PROCEDURE|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
215042996|NCT02315222|DIETARY_SUPPLEMENT|Regenium|
215042997|NCT02315222|DIETARY_SUPPLEMENT|Placebo|
215042998|NCT02315222|PROCEDURE|Full Mouth Disinfection|
215042999|NCT06306001|DRUG|Methylene Blue|Subjects in the intervention arm will receive a 1 mg/kg bolus of methylene blue over 30 minutes, followed by an infusion of 0.15 mg/kg/h. The infusion rate may be increased in steps of 0.15 mg/kg/h every 30 minutes until a maximum of 0.5 mg/kg/h.
215043000|NCT06306001|OTHER|Placebo|Subjects in the placebo arm will receive normal saline in the same volumetric dose as methylene blue in the intervention arm
215043001|NCT00023335|DRUG|Rifapentine|
215043002|NCT00023335|DRUG|Isoniazid|
215043003|NCT02912819|OTHER|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
215043004|NCT05017623|DRUG|YH003|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
215043005|NCT00415090|DRUG|Nevirapine|Switch one of ARV drugs to Nevirapine
215043006|NCT00712387|BEHAVIORAL|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
214877016|NCT03914625|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
215043007|NCT03567889|DRUG|Daromun|Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.
215043008|NCT03567889|PROCEDURE|Surgery|Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
215043009|NCT03567889|DRUG|Adjuvant therapy|Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
215043010|NCT01281111|DRUG|Dimethyl Fumarate (BG00012)|
215043011|NCT01281111|DRUG|Aspirin|
215043012|NCT01281111|DRUG|BG00012 matching placebo|
215043013|NCT01281111|DRUG|ASA matching placebo|
215043014|NCT05935956|DEVICE|Magnetic Peripheral Nerve Stimulation|Magnetic Peripheral Nerve Stimulation
215043015|NCT03606577|DRUG|Carfilzomib|Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)
215043016|NCT03606577|DRUG|Daratumumab|induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 \& D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
215043017|NCT03606577|DRUG|Lenalidomide|induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)
215043018|NCT03606577|DRUG|Dexamethasone|induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
215043019|NCT00090376|DRUG|GPI 1485|
215043020|NCT02415556|DRUG|Regular Human Insulin|Regular human insulin 40 IU daily over 24 weeks
214877017|NCT03914625|RADIATION|Radiation Therapy|Undergo testicular radiation therapy
214877018|NCT03914625|DRUG|Thioguanine|Given PO
214877019|NCT03914625|DRUG|Vincristine Sulfate|Given IV
215043021|NCT02415556|DRUG|Placebo|Intranasal sterile saline 40 IU daily over 24 weeks
215043022|NCT04885101|PROCEDURE|LISWT Group|The treatment consists of a weekly session and 4,000 pulses will be emitted each of the eight sessions totaling 32,000 pulses with a frequency of 18Hz and 100mJ of energy.
214877020|NCT05870579|DRUG|[68Ga]Ga-NeoB|"\[68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions, at screening, potentially at Cycle 2 Day 15 visit, and between 4 and 8 weeks after the last administered dose of \[177Lu\]Lu-NeoB.~\[68Ga\]Ga-NeoB will be administered as a single intravenous (i.v.) dose."
215043023|NCT04885101|PROCEDURE|NARFT Group|The device used will be with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. Eight radio frequency sessions will be held with an interval of seven days between them.
215043024|NCT04885101|PROCEDURE|Sham Group|In the RNA group, radiofrequency will be applied, the device used will be the Nèartek Esthetic Ibramed - Tecarterapia e Radiofrequency Apparatus, with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. The radiofrequency will be applied with the patient in the supine position on both sides of the penis with an opposite dispersion plate against the radiofrequency emitter. To perform the procedure, the therapist will use a glove. Eight radio frequency sessions will be held with an interval of seven days between them.
215043025|NCT06434558|PROCEDURE|Cryosa Procedure|The Cryosa Procedure is part of the ARCTIC-3 protocol (IRB #854182). Therefore, all patients enrolled in this study are expected to undergo the Cryosa Procedure. Undergoing the Cryosa Procedure is not a part of this protocol.
215043026|NCT04699344|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.
215043027|NCT00105534|DRUG|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
215043028|NCT00105534|OTHER|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
215043029|NCT01621178|DRUG|Dulaglutide|Administered SC
215043030|NCT01621178|DRUG|Insulin glargine|Administered SC
215043031|NCT01621178|DRUG|Insulin lispro|Administered SC
215043032|NCT02258802|BEHAVIORAL|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
215043033|NCT03005730|OTHER|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
215043034|NCT03005730|OTHER|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
214877021|NCT05870579|DRUG|[177Lu]Lu-NeoB|Study participants will receive \[177Lu\]Lu-NeoB once every cycle
215043035|NCT02781441|BEHAVIORAL|Question prompt list (QPL)|
215043036|NCT02781441|BEHAVIORAL|Education brochure of Groupe Français des Myélodysplasies|
215043037|NCT01041430|OTHER|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
214291685|NCT02792933|PROCEDURE|saline in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
214476886|NCT06290999|DIAGNOSTIC_TEST|multifrequential admittancemetry|"Every participant of the study have to complete an Ear, Nose and Throat examination included a conventional audiometry, and a multifrequential admittancemetry.~if radio-interventional venous stenting is not indicated, an multifrequential admittancemetry will also be performed 3 months after the procedure."
214476887|NCT06651658|PROCEDURE|Pleural embolisation|Administration of pleural blood patch with tandem needle technique
214877022|NCT05870579|DRUG|Ribociclib|600 mg once daily (OD) days 1 to 21 every 28 days
214877023|NCT05870579|DRUG|Fulvestrant|500 mg at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and every 28 days thereafter
214877024|NCT05870579|OTHER|Goserelin|For pre/peri-menopausal women and men only.
214877025|NCT04998851|DRUG|Ocrelizumab|Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
214877026|NCT00268385|OTHER|Laboratory Biomarker Analysis|Correlative studies
214877027|NCT00268385|OTHER|Pharmacological Study|Correlative studies
214877028|NCT00268385|DRUG|Temozolomide|Given orally
214877029|NCT00268385|DRUG|Vorinostat|Given orally
214877030|NCT06057571|DRUG|TT-00420 (tinengotinib)|TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
214877031|NCT04149223|OTHER|Evidence-based standardized Cirrhosis order set|Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
214877032|NCT02633163|DRUG|Low Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10\^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
214877033|NCT02633163|DRUG|High Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10\^6 cells/kg in Plasma-Lyte A solution.
214877034|NCT02633163|DRUG|Placebo Infusion|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
214877035|NCT05459935|DEVICE|PBM Tonsil Arm|exposure of hypertrophic tonsils to photobiomodulation
214877036|NCT05459935|DEVICE|Sham PBM Tonsil Arm|non-powered exposure of hypertrophic tonsils to photobiomodulation
214476888|NCT06815666|PROCEDURE|Bronchoscopy & Metastasectomy|Routine bronchoscopy and standard of care metastasectomy
214877037|NCT06084117|OTHER|HFNO|Respiratory support with HFNO (as opposed to NIV, as per standard of care)
214877038|NCT06084117|OTHER|NIV|Respiratory support with Non-invasive ventilation, standard of care
214877039|NCT06408298|DRUG|Hydroxychloroquine Sulfate 400Mg Tab|hydroxychloroquine sulfate tablet
214877040|NCT06408298|DRUG|Placebo|Inactive tablet
214877041|NCT03385655|DRUG|Adavosertib|250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1
214877042|NCT03385655|DRUG|Savolitinib|600mg once daily, orally.
214877043|NCT03385655|DRUG|Darolutamide|600mg twice daily, orally.
214877044|NCT03385655|DRUG|CFI-400945|Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.
214877045|NCT03385655|DRUG|Ipatasertib|400mg daily 3 weeks on, 1 week off
214877046|NCT03385655|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
214877047|NCT03385655|DRUG|Carboplatin|AUC 5 IV 60min Day 1 q 21 days
214877048|NCT05925530|DRUG|Durvalumab|Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
214877049|NCT06850753|PROCEDURE|Liver transplantation after en bloc resection of the liver and pancreas|Exenteration of the upper right part of the abdomen, including the liver and pancreas en bloc in locally advanced hilar cholangiocarcinoma, followed by liver transplantation
214877050|NCT04802564|OTHER|regular hand therapy|edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
214877051|NCT06425926|DRUG|GIM-531|GIM-531 administered orally daily
214877052|NCT06425926|DRUG|Anti-PD-1 monoclonal antibody|Continued treatment with anti-PD-1 therapy
214877053|NCT05873686|DRUG|NXP900|NXP900 is an orally administered SRC/YES1 kinase inhibitor
215043038|NCT01041430|OTHER|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
215043039|NCT05863455|DRUG|mild sedation and analgesia|Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation
215043040|NCT05863455|DRUG|control|ntravenous injection of an equivalent volume of saline before radial artery cannulation.
214877054|NCT05964387|DEVICE|SDF|38% SDF will be applied to the hypoplastic area of the enrolled first permanent molar.
214877055|NCT05964387|DEVICE|Placebo|An inert liquid will be applied to the hypoplastic area of the enrolled first permanent molar.
215043041|NCT03502564|BEHAVIORAL|CBT for ED|Cognitive behavior therapy (CBT) for eating disorders (ED) is a 16-session individual therapy protocol which will focus on maintaining improvements in eating following intensive treatment, as well as addressing overconcern with weight/shape. Interventions will be adopted from the Enhanced CBT for ED manual.
215043042|NCT03502564|BEHAVIORAL|Concurrent CBT for ED and PTSD|The concurrent ED and PTSD intervention will consist of 16 sessions of CBT for both PTSD and for ED (ED interventions described above). CBT for PTSD will be based on interventions in the Cognitive Processing Therapy (CPT) manual.
215043043|NCT01606579|DRUG|PRI-724|PRI-724
215043044|NCT01606579|DRUG|PRI-724|PRI-724 in combination with dasatinib
215043045|NCT01606579|DRUG|PRI-724|PRI-724 in combination with low dose ara-C therapy
215043046|NCT06400667|DEVICE|Upper limb Kinematic Assessment with Optoelectronic system|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks. During the data acquisition protocol, the subject perform five trial for each upper limb of a determinate functional task for each session. Every subject repeat this operations 2 times with 2 different operators.
215043047|NCT03665259|PROCEDURE|Pure oxygen group|pre-oxygenation with 100% oxygen during induction of anesthesia
215043048|NCT03665259|PROCEDURE|Lower oxygen group|Pre-oxygenation with 60% oxygen during induction of anesthesia
215043049|NCT02935192|BIOLOGICAL|Vaccine|Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection
214877056|NCT03648814|PROCEDURE|Intracameral injection|A/C injection of 1.25 mg/0.05 mL bevacizumab
214877057|NCT03648814|PROCEDURE|Intravitreal injection|Vitreous injection of 1.25 mg/0.05 mL bevacizumab
214877058|NCT06457256|BEHAVIORAL|CLS-A-FUERTE|CLS-A-FUERTE Intervention Description: The CLS-A-FUERTE program is a school clinician training and psychosocial intervention program designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). Participating school clinicians are supported by a clinical research team of trainers who co-leads weekly training/consultation meetings and observes each intervention component (i.e., 6 weekly parent and student skills groups, as well as classroom management in the form of a Daily Report Card) in-vivo via videoconferencing.
214877059|NCT05557591|DRUG|BNT116|BNT116 is administered by IV injection.
214877060|NCT05557591|DRUG|Cemiplimab|Cemiplimab is administered Q3W by IV infusion
214877061|NCT02185690|DRUG|Binimetinib|"Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.~MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule."
214877062|NCT02185690|DRUG|Pemetrexed|4-6 cycles given intravenously in combination with carboplatin as per standard therapy.
214877063|NCT02185690|DRUG|Carboplatin|4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
215043050|NCT02935192|OTHER|Placebo|Phosphate buffered saline, 0.5 mL by IM injection
215043051|NCT04464239|DRUG|TS-142|TS-142 tablets
215043052|NCT04464239|DRUG|TS-142 Placebo|TS-142 matching placebo tablets
215043053|NCT02176915|BEHAVIORAL|Group program|
215043054|NCT02176915|BEHAVIORAL|Print Materials|
215043055|NCT01160809|OTHER|Mosquito repellent|Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
215043056|NCT01528579|OTHER|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
215043057|NCT01528579|BEHAVIORAL|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
215043058|NCT01528579|OTHER|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
215043059|NCT02465931|OTHER|Paper and Pencil Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
215043060|NCT02465931|OTHER|Digital Informed Consent Tool|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
215043061|NCT01561833|DRUG|Sorafenib|Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
215043062|NCT02896257|OTHER|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
215043063|NCT02394821|DRUG|Polihexanide 2%|
215043064|NCT02394821|DRUG|Metronidazole 0.8%|
215043065|NCT02441842|DRUG|atenolol|administered 60 minutes pre procedure
215043066|NCT02441842|DRUG|lisinopril|administered 60 minutes pre procedure
215043067|NCT02441842|OTHER|glucose|administered 60 minutes pre procedure
215043068|NCT00403156|DRUG|Imatinib Mesylate /Ranibizumab|
214877064|NCT06671457|DEVICE|Active transcranial direct current stimulation|"The intervention uses transcranial direct current stimulation (tDCS). The targeted brain regions are identified by conducting simultaneous fMRI-EEG data collection and sleep staging, comparing fMRI data between wakefulness and sleep states. Brain regions that show differences are calculated as potential targets for electrical stimulation. If no differentiated regions are found in a participant, specific areas are chosen based on individualized modeling results from previous experiments, targeting areas such as the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OPFC), medial prefrontal cortex (mPFC), and posterior cingulate cortex (PCC). Two regions are selected within each brain area for parameter scanning (with each stimulation lasting 10 seconds and EEG data recorded 10 seconds before and after stimulation).~In our prior studies, we observed a decrease in EEG microstate complexity during sleep, with electrical stimulation influencing this complexity reduction to some"
214877065|NCT06671457|DEVICE|Sham transcranial direct current stimulation|In the sham stimulation group, the placement of the tDCS electrodes is identical to that of the active stimulation group. After the stimulation begins, the current gradually increases over 15 seconds. However, upon reaching the therapeutic current level, it immediately begins to decrease, lowering to 0 mA within 15 seconds and remaining at 0 mA throughout the rest of the session. During the last 15 seconds of the stimulation, there is another gradual decrease in current to 0 mA. This approach creates a similar subjective sensation to the real stimulation, making it difficult for participants to discern which type of electrical stimulation they are receiving.
214877066|NCT04201964|DRUG|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
214877067|NCT06433414|OTHER|PAUSE App|Participants receiving the intervention will receive access to the PAUSE App, a self-management tool for SDMG intended for patients to use during an acute illness. The app asks users a series of questions regarding signs and symptoms that identify a qualifying sick day illness, and screens for 'red flags' that would require emergency, or HCP or urgent care referral, and help patients identify which of their medications they should temporarily withhold or adjusted, tailored to a patients' current medication list. This aims to provide patients with interactive support for managing medication during a sick day event. As part of the intervention, patients will also receive a SDMG patient handout. The intervention addresses the previously identified challenges described above via an interactive and individualized electronic application designed to facilitate provision of SDMG.
214877068|NCT02438904|BIOLOGICAL|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
214877069|NCT02438904|DEVICE|Miltenyi device|Miltenyi device is used for CD34+ cell infusions) to patients who experience poor graft function after stem cell transplantation (SCT).
214877070|NCT00072787|DRUG|S-1|
214877071|NCT00072787|DRUG|cisplatin|
214877072|NCT00478244|DRUG|busulfan|Day -9 through Day -6: 1.1 mg/kg if \< 12 kg IV every 6 hours; 0.8 mg/kg if \> 12 kg.
214877073|NCT00478244|DRUG|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
215043069|NCT00492557|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
215043070|NCT00492557|BIOLOGICAL|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
215043071|NCT05384314|DEVICE|RespiraSense|The use of continuous electronic monitoring of respiratory rate
215043072|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic CGRP|Immunoassay kit for the evaluation of CGRP in blood
215043073|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic SP|Immunoassay kit for the evaluation of SP in blood
214476889|NCT06814626|DIETARY_SUPPLEMENT|12-week nutritional intervention with Friliver dispensing|After TIPS placement patients of the treatment group receive a 12-week nutritional intervention that includes a personalized diet, Friliver dispensing (Dompé; 2 sachets 3 times a day) and a diet diary to report the quantity and quality of the foods eaten every single day.
214877074|NCT00478244|DRUG|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
214877075|NCT00478244|PROCEDURE|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
214877076|NCT05968417|OTHER|Observational study - sample collection only.|No intervention - blood and/or bone marrow sample collection only
214877077|NCT01870440|DRUG|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
214877078|NCT00154518|PROCEDURE|Orthodontic treatment|
215043074|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic enkephalins|Immunoassay kit for the evaluation of enkephalins in blood
215043075|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic VIP|Immunoassay kit for the evaluation of VIP in blood
215043076|NCT05958914|DIAGNOSTIC_TEST|Dosage of CGRP in follicolar fluid|Immunoassay kit for the evaluation of CGRP in follicolar fluid
215043077|NCT05958914|DIAGNOSTIC_TEST|Dosage of SP in follicolar fluid|Immunoassay kit for the evaluation of SP in follicolar fluid
215043078|NCT05958914|DIAGNOSTIC_TEST|Dosage of enkephalins in follicolar fluid|Immunoassay kit for the evaluation of enkephalins in follicolar fluid
214291686|NCT00290368|PROCEDURE|Skin Prick Test|
214291687|NCT00290368|PROCEDURE|Nasal allergen challenge|
214291688|NCT00290368|PROCEDURE|Nasal filter paper placement|
215043079|NCT05958914|DIAGNOSTIC_TEST|Dosage of VIP in follicolar fluid|Immunoassay kit for the evaluation of VIP in follicolar fluid
215043080|NCT01574144|DEVICE|AVIVO™ PiiX Patch Monitor System|External monitoring for 30 days post-discharge.
215043081|NCT05816824|OTHER|Symptom monitoring software via visual feedback|With PhysioAnalyst software, individuals are evaluated using clinical tools (questionnaire, scale). These evaluations provide visual feedback to individuals in the form of tables and graphs. In this way, patients can observe the changes in their clinical status.
215043082|NCT01322256|PROCEDURE|Bone scintigraphy|Bone scintigraphy of the affected area
215043083|NCT01322256|PROCEDURE|Leukoscan|Scintigraphy with labeled neutrophils
215043084|NCT01322256|PROCEDURE|PET / CT|PET / CT of the affected area
215043085|NCT01322256|PROCEDURE|Bone biopsy|A bone biopsy is performed during pre-inclusion work up.
215043086|NCT01322256|BIOLOGICAL|Bloodwork|CRP and procalcitonin are measured in the pre-inclusion work up.
214877079|NCT04618640|BIOLOGICAL|DTaP-IPV combination vaccine|Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
214666704|NCT05888259|OTHER|foot insole|The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
214877080|NCT01675466|PROCEDURE|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
214877081|NCT01675466|PROCEDURE|General anaesthesia|
214877082|NCT01675466|DEVICE|Laparoscopic instruments|
215043087|NCT04102007|DRUG|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
215043088|NCT03669796|DIETARY_SUPPLEMENT|Marine protein hydrolysate (mph)|Marine (Cod) protein hydrolysate
215043089|NCT03669796|DIETARY_SUPPLEMENT|Control|Maltodextrin/Casein
215043090|NCT03816189|DIAGNOSTIC_TEST|Blood test|Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing
215043091|NCT03816189|DIAGNOSTIC_TEST|Skin biopsies|In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
215043092|NCT04093232|DRUG|Hymovis|All subjects will receive 2 ultrasound guided Hymovis injections and the goal of the study is to correlate responsiveness to subjects unique SF biomarker panel results before the first Hymovis injection and identify potential mechanism of action of those OA patients who receive the greatest benefit.
215043093|NCT02629926|OTHER|GH Replacement (NutropinAq®)|GH Replacement continued.
215043094|NCT02629926|OTHER|No additional treatment|GH Replacement not continued.
215043095|NCT02481193|DRUG|Cisatracurium|Different doses of cisatracurium pretreatment
215043096|NCT03571932|BEHAVIORAL|Family planning and immunization service integration|The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
215043097|NCT05130593|DIETARY_SUPPLEMENT|Nutrasorb bar|250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
215043098|NCT00892008|DRUG|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
215043099|NCT04195490|PROCEDURE|feminizing genitoplasty|feminizing genitoplasty including vaginoplasty,clitroplasty, labioplasty and urethroplasty
215043100|NCT02312648|OTHER|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
215043101|NCT02312648|OTHER|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
215043102|NCT03497273|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
214666705|NCT05879263|OTHER|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
214666706|NCT05879263|OTHER|CONTINUOS ENTERAL NUTRITITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
214666707|NCT00468715|DRUG|bicalutamide|
214877083|NCT03106389|DRUG|Misoprostol|400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
214877084|NCT03106389|DEVICE|Misoprostol/Transcervical catheter|Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag
214877085|NCT01658501|DRUG|50 mg PB1023|
214877086|NCT01658501|DRUG|70 mg PB1023|
214877087|NCT01658501|DRUG|100 mg PB1023|
214877088|NCT01658501|DRUG|Placebo (0.9% Sodium Chloride)|
214877089|NCT01658501|DRUG|Victoza®|
214877090|NCT01658501|OTHER|Diet and Exercise|
214877091|NCT01658501|DRUG|Metformin|
215043103|NCT03497273|DRUG|Corticosteroid|Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
215043104|NCT04389697|DIETARY_SUPPLEMENT|Clear fluids and food up to up to 1 hour before the procedure|Clear fluids and food up to up to 1 hour before the start of the procedure
215043105|NCT00329030|DRUG|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
215043106|NCT00329030|DRUG|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
215043107|NCT06199414|DEVICE|Venous Closure|Vascular closure to achieve vascular hemostasis following femoral access with large bore sheaths in catheter ablation procedures
215043108|NCT06370390|BEHAVIORAL|swallowing function training|"The group rehabilitation program comprised daily 60-minute sessions, five times per week for a duration of 4 weeks.~The group rehabilitation program included: Rehabilitation oral and facial exercises, Game-based surface electromyographic biofeedback training, Participants experience sharing, Individual direct feeding training"
215043109|NCT06230809|BEHAVIORAL|Web-based self-help|Web-based self-help with 5 modules, lasting 5 weeks.
215043110|NCT02725333|PROCEDURE|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
215043111|NCT04224519|BIOLOGICAL|sIPV batch 1|Type I 30 DU, Type II 32 DU, Type III 45 DU
215043112|NCT04224519|BIOLOGICAL|sIPV batch 2|Type I 30 DU, Type II 32 DU, Type III 45 DU
215043113|NCT04224519|BIOLOGICAL|sIPV batch 3|Type I 30 DU, Type II 32 DU, Type III 45 DU
215043114|NCT00468091|DRUG|exendin(9-39)amide|
215043115|NCT00468091|DRUG|atropine|
215043116|NCT02320188|OTHER|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
215043117|NCT02320188|OTHER|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
215043118|NCT04955288|PROCEDURE|Aortic balloon assisted resuscitation|On the basis of the traditional resuscitation mode, the aortic balloon occlusion technology is used, that is, at the same time when the cardiopulmonary resuscitation starts, the aortic balloon catheter is quickly punctured to the distal end of the aortic zone I (septum level) through ultrasound assistance, and then Continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
214666708|NCT00468715|OTHER|diagnostic laboratory biomarker analysis|
214666709|NCT00468715|OTHER|immunohistochemistry staining method|
214666710|NCT01620996|BEHAVIORAL|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
214666711|NCT01620996|BEHAVIORAL|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
214877092|NCT01658501|DRUG|Sulfonylurea|
215043119|NCT04955288|PROCEDURE|Traditional cardiopulmonary resuscitation|"Use the traditional manual chest compression mode, that is, refer to the latest version of the CPR Guidelines.~Artificial chest compressions are performed under the monitoring of the pressure quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, the compression position is fixed, and the chest wall fully rebounds."
215043120|NCT04955288|PROCEDURE|Esophageal cooling|The new transesophageal cooling method is adopted, that is, the esophageal cooling catheter is indwelled after resuscitation in patients with cardiac arrest, and then connected to a small temperature-controlled water circulation system to continuously infuse 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature-controlled water circulation system is adjusted Maintain the target body temperature of (33±0.5)°C for 24 hours, and then rewarm to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
215043121|NCT04955288|PROCEDURE|traditional cooling|The traditional body surface ice blanket cooling method is adopted, that is, the patient with cardiac arrest lies on the temperature control blanket after resuscitation, and then uses the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃. The temperature of the circulating water is controlled by adjusting the ice blanket host to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
214666712|NCT01620996|BEHAVIORAL|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours."
215043122|NCT02449525|PROCEDURE|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
214666713|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
214666714|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
214666715|NCT04442581|DRUG|Cabozantinib S-malate|Given PO
214666716|NCT04442581|BIOLOGICAL|Pembrolizumab|Given IV
214666717|NCT00181688|DRUG|Iressa (ZD1839)|
214666718|NCT00181688|DRUG|Arimidex (Anastrozole)|
215043123|NCT01021800|BIOLOGICAL|MIS|Cell infusion
215043124|NCT01627691|DEVICE|Lotus Valve System|"* bioprosthetic bovine pericardial aortic valve~* delivery system"
215043125|NCT04653974|BEHAVIORAL|Needle-free injection|"This study was performed among children aged 4-11 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 70 patients were evaluated in accordance with the exclusion criteria and 56 children (31 girls and 25 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the Wong-Baker Pain Scale at three time points: immediately after injection (Pain 1), during treatment (Pain 2), and at the end of the treatment (Pain 3)."
215043126|NCT04130412|PROCEDURE|open release|Open release of lateral retinaculae
215043127|NCT02035514|BIOLOGICAL|Bone marrow autologous mesenchymal stem cells transplantation|
214476890|NCT06814626|OTHER|12-week nutritional intervention with personalized diet|After TIPS placement patients of the treatment group receive a 12-week nutritional intervention that includes a personalized diet, Friliver dispensing (Dompé; 2 sachets 3 times a day) and a diet diary to report the quantity and quality of the foods eaten every single day.
214666719|NCT02359123|OTHER|Cannabics capsules|Cannabis extract in an oil formulation
214666720|NCT00711451|BEHAVIORAL|Manual removal|Manual removal of placenta during cesarean delivery
215043128|NCT06454656|OTHER|MOBILE|"Intensive motor learning based intervention to target specific walking goals as identified using the Gait Outcome Assessment List.~Full Protocol outlining strategies available on request.~Three key principles underpin the intervention:~Principle 1: The type of task~Principle 2: The type of practice~Principle 3: The type of Feedback"
215043129|NCT04054362|DRUG|Paclitaxel protein bound|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
215043130|NCT04054362|DRUG|Cisplatin|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
215043131|NCT04054362|DRUG|Gemcitabine|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
215043132|NCT04054362|DRUG|Paricalcitol|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
215043133|NCT02126163|BEHAVIORAL|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
215043134|NCT03736148|OTHER|Manual Manipulation|Subject was in supine position, and the therapist applied a manual manipulation with right side bending and left rotation of the neck.
214291689|NCT00290368|PROCEDURE|Nasal lavage|
214666721|NCT00711451|PROCEDURE|Expressed removal|Surgeon will perform an expressed delivery of the placenta
214666722|NCT02062177|DRUG|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
214666723|NCT02062177|DRUG|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged \< 70, 0.03 mg/Kg if aged \> 70.
214666724|NCT04205591|PROCEDURE|split bone block technique|A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants
214666725|NCT03518840|DEVICE|SIJ Belt|Support Belts
214666726|NCT03890276|OTHER|HMS EL&C training module|No additional information
214666727|NCT03890276|OTHER|Videos used to supplement live trainer|\[Cherrie to add\]
214666728|NCT05346562|DIETARY_SUPPLEMENT|Cannabidiol|Cannabidiol tablets
214666729|NCT05346562|DIETARY_SUPPLEMENT|Placebo|Cannabidiol-matched placebo tablets
214666730|NCT02742389|OTHER|Preprocedure Telephone Call|The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
214666731|NCT05652660|DRUG|ARV-471|Experimental
214877093|NCT01658501|DRUG|Metformin and Sulfonylurea|
214877094|NCT06142318|DRUG|Pirfenidone|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
214877095|NCT06142318|DRUG|Placebo|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
215043135|NCT03736148|OTHER|Instrument-assisted Manipulation|The instrument-assisted manipulation was applied using a handheld Activator IV Adjusting Instrument. Contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. The spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of C3.
215043136|NCT03736148|OTHER|Placebo|Subject was in supine position, and the therapist placed ths subject's cervical with right side bending and left rotation but no manual manipulation was applied.
215043137|NCT04763434|DRUG|dexamethasone; dexmedetomidine; ropivacaine|Ultrasound-guided multilevelTPVB is performed at the end of lobectomy
215043138|NCT01482130|BEHAVIORAL|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
215043139|NCT01482130|BEHAVIORAL|recommendations|"The control group will be encouraged to follow a training program according to recommended exercise guidelines:~* Weight bearing activities (walking, jogging or strength training)~* 30 - 60 minutes, 3 - 5 times each week~* A total of 2 - 3 hours each week should be achieved"
215043140|NCT04524988|PROCEDURE|Laparoscopic Simulation Training|All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
215043141|NCT03847584|OTHER|Survey|The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.
215043142|NCT05551468|BEHAVIORAL|StayFine guided app-based personalised intervention modules|Participants work on guided app-based personalised intervention modules in the StayFine app over the course of three months. The modules are selected by the participant based on shared decision making and a personalized advice. The intervention is based on Preventive Cognitive Therapy (PCT) with elements of Cognitive Behavioral Therapy (CBT) and Positive Psychology. Modules are: psycho education (mandatory), cognitive restructuring (mandatory), positive affect, behavioral activation, exposure, wellness, sleep and a relapse prevention plan (mandatory).
215043143|NCT05551468|BEHAVIORAL|StayFine app-based monitoring|Monitoring six times per day for two weeks in the StayFine app.
215043144|NCT06389175|DEVICE|Transcutaneous non-invasive vagus nerve stimulation (tVNS)|"Participants receive tVNS during the neuroimaging sessions and the extended stimulation period. To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established, conventional stimulation protocol (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany). To improve blinding, the stimulations intensities will be adjusted to correspond to a mild pricking sensation for tVNS and sham.~The extended stimulation period in the experimental group involves six sessions with at least 1.5h of stimulation (stimulation in the lab or at home with home device using the same stimulation protocol as during the neuroimaging sessions; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany)."
215043145|NCT06389175|DEVICE|Sham stimulation|"The control intervention consists of a sham stimulation. In the neuroimaging session the electrode will be placed upside down to stimulate the earlobe, which is not innervated by vagal afferent fibers. To improve blinding, the same stimulation protocol as for the tVNS will be applied (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany) and stimulation intensities will be adjusted to correspond to a mild pricking sensation.~During the extended stimulation period, the electrode will be placed at the cymba conchae, but only receive a low-intensity stimulation below the perception threshold (0.1mA). To ensure blinding, participants will be instructed that the extended stimulation period will examine the effects of a low- vs. high-intensity tVNS protocol. Each repeated stimulation period will involve six sessions with at least 1.5h of low-intensity stimulation (stimulation in the lab or at home with home device; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany)."
215043146|NCT00181844|DRUG|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children \<12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
215043147|NCT05855018|DRUG|Atropine sulfate eye drops|One drop once daily
214666732|NCT05652660|DRUG|Rosuvastatin|Probe substrate
214666733|NCT04354025|BIOLOGICAL|Cytokine induced memory-like NK cells|-The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.
214877096|NCT03778684|DIAGNOSTIC_TEST|Visceral fat thickness|An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.
214877097|NCT03778684|DIAGNOSTIC_TEST|Body mass index|Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.
214877098|NCT00109226|DRUG|Avastin (Bevacizumab)|
214877099|NCT04342455|OTHER|double-low scanning|a CT angiography protocol with low radiation and contrast agent exposure
214877100|NCT01085071|DRUG|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
214877101|NCT01085071|DRUG|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
214877102|NCT00098605|DRUG|lapatinib ditosylate|Given orally
214877103|NCT00098605|OTHER|laboratory biomarker analysis|Correlative studies
214877104|NCT00098605|PROCEDURE|quality-of-life assessment|Ancillary studies
214877105|NCT00098605|OTHER|questionnaire administration|Ancillary studies
214877106|NCT01609452|BIOLOGICAL|Blisibimod|
214877107|NCT01609452|OTHER|Placebo|
214877108|NCT02089659|DRUG|Doravirine|Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
214877109|NCT01228799|PROCEDURE|trabeculectomy|trabeculectomy with mitomycin C 0.2mg/ml
214877110|NCT01228799|PROCEDURE|Canaloplasty|Canaloplasty with implant of suture
215043148|NCT04416113|PROCEDURE|photobiomodulation and photodynamic therapy|antiviral treatment
215043149|NCT03814928|BEHAVIORAL|Caregivers eCourse|Investigators will request that family/caregivers/general public watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
215043150|NCT05242601|OTHER||no intervention
215043151|NCT00678730|DRUG|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
215043152|NCT04507906|DRUG|Nivolumab Combined with Anlotinib|In combination dose finding phase, Phase 1b will begin with Dose Level 1; anlotinib 12 mg/day orally (from days 1 to 14 in a 21-day cycle) and nivolumab (360mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (anlotinib 10 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously) and Dose Level 3 (anlotinib 8 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously).If RP2D was reached in Part A, eligible patients would be enrolled and receive nivolumab (360mg q3w, intravenously) plus anlotinib (RP2D, QD from day 1 to 14 of a 21-day cycle) .
214291690|NCT00290368|PROCEDURE|Nasal scrape|
214877111|NCT00750685|DEVICE|Mentor Smooth Becker 50 Expander/Breast Implant|The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
214877112|NCT05703087|BEHAVIORAL|Positive cueing in the information video before a primary TKA|Two weeks before the surgery, in the outpatient clinic (during their preoperative appointment), the pre-surgery information video was shown to the patients. Patients were randomly allocated to either the positive cueing group (intervention) or the standard care group (control) with Castor EDC (14) using a variable block randomization model. Patients did not know whether they watched the adapted video or the standard video.
214877113|NCT05864989|PROCEDURE|Non-incised papila surgical approach only|Reconstructive periodontal surgery
214877114|NCT05864989|PROCEDURE|Non-incised papila surgical approach with connective tissue grafting|Reconstructive periodontal surgery
214877115|NCT04864028|OTHER|physical activity|15min sitting, 15min standing, 15min sitting, 15 min low intensity cycling
215043153|NCT03763734|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
215043154|NCT04513808|DRUG|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia, titrated to clinical need.
215043155|NCT04513808|DRUG|Sevoflurane intravenous anesthesia|Sevoflurane intravenous anesthesia, titrated to clinical need.
215043156|NCT04802603|RADIATION|Spine stereotactic body radiotherapy|"Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions."
214291691|NCT00290368|PROCEDURE|Nasal symptoms score|
214476891|NCT06814626|OTHER|12-week nutritional intervention with diet diary to report foods eaten.|After TIPS placement patients of the treatment group receive a 12-week nutritional intervention that includes a personalized diet, Friliver dispensing (Dompé; 2 sachets 3 times a day) and a diet diary to report the quantity and quality of the foods eaten every single day.
214476892|NCT04055012|DRUG|Metformin|500mg tabs of Metformin Extended Release
214877116|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block|
214877117|NCT03228797|PROCEDURE|multiholed catheter|gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
214877118|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block &multiholed catheter|a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
214877119|NCT03635476|OTHER|Qualitative interview study|The group in question is part of a research program aimed at developing and evaluating the LIFANA Nutrition Solution, a meal planning recommended system, which suggests meals based on the user's personal profile. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists.
214476893|NCT04055012|DRUG|Placebo|Placebo Tabs
214476894|NCT05153317|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules or tablets for oral administration.
214476895|NCT05153317|DRUG|IVA|Granules or tablets for oral administration.
214877120|NCT01868347|OTHER|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
214877121|NCT01868347|OTHER|control|PEEP after pneumoperitoneum and trendelenburg
214877122|NCT01744639|BEHAVIORAL|HCC under treatment with radioablation|The evaluation will take place over a period of 30 days.
214877123|NCT05231434|OTHER|water|hydration with mineral water in 10 equal portions, administered at regular intervals from the 15th minute of exercise until the end of the recovery period.
214877124|NCT05231434|OTHER|aerobic activity|aerobic activity
214877125|NCT03209843|PROCEDURE|Percutaneous recanalization of chronic total occlusion|Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
214877126|NCT03507088|DRUG|Fluoroestradiol (18F)|A FES-PET/(CT) will be performed twice during protocol execution. Patients will be injected with approximately 222 MBq 18F-FES each time.
214877127|NCT05469295|DEVICE|CGM MB-1701 device treatment|This is a pre-approved motorized traction device.
214877128|NCT05469295|DEVICE|CGM MB-1701 Sham device treatment|It is manufactured in the same way as the test device and the operation pattern. However, the actual effect of the massage is minimized.
214877129|NCT02928055|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
214877130|NCT03815214|BEHAVIORAL|Partial meal replacement program|Four meals consist of meal replacements made by OPTAVIA, such as shakes, soups, bars, biscuits, hot drinks, and puddings. Meal replacements will be provided to subjects without charge. For two other daily meals, subjects or their caregivers will be taught how to prepare meals consisting of 5-7 ounces (cooked) of a low-fat protein, 3 servings of non-starchy vegetables, and up to 2 servings of healthy fats.
215043157|NCT05592548|DEVICE|cold atmospheric plasma|Cold atmospheric plasma will be generated on the skin surface using an electric device
215043158|NCT05023460|DEVICE|Paresthesia-free (burst) ONS|Stimulation intensity target of 60% of paresthesia threshold.
215043159|NCT05023460|DEVICE|Placebo|ONS system deactivated
215043160|NCT05373472|BIOLOGICAL|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
215043161|NCT05373472|BIOLOGICAL|Placebo|2 doses of placebo on Day 0 and Day 21
215043162|NCT06637657|OTHER|No intervention (observational study)|No intervention, only guideline implementation (observational study)
215043163|NCT06637098|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
215043164|NCT06637098|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
215043165|NCT06637098|BEHAVIORAL|Gastrostomy feeding|Feeding begins through the gastrostomy tube. A registered dietitian will develop a tailored feeding plan, specifying the type and amount of nutrition. Healthcare providers regularly monitor the patient's tolerance to feeding, checking for any signs of complications. Adjustments to the feeding regimen may be made based on the patient's progress and nutritional needs.
215043166|NCT04661033|DRUG|Isatuximab SAR650984|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
214476896|NCT05501808|PROCEDURE|cerasmart|the patient received a crown made of cerasmart ceramic
214476897|NCT05501808|PROCEDURE|enamic|the patient received a crown made of enamic ceramic
214476898|NCT05633147|DRUG|Linaprazan glurate|"Investigational Medicinal Product: Linaprazan glurate (tablets).~Part I:~Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10.~Part II:~Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days."
214877131|NCT03815214|BEHAVIORAL|Dietary Counseling|Participants will receive one 45-minute counseling session on a healthy diet
215043167|NCT06191445|PROCEDURE|Conventional Landmark Technique|The investigator will perform spinal anesthesia using the conventional landmark technique.
215043168|NCT06191445|PROCEDURE|Ultrasound Assisted Technique|The investigator will perform spinal anesthesia using the ultrasound assisted technique.
215043169|NCT06191445|PROCEDURE|Real-Time Ultrasound Guided Technique|The investigator will perform spinal anesthesia using the real-time ultrasound-guided technique.
215043170|NCT05276674|DEVICE|ZNN Bactiguard Retrograde Femoral Nail|Femoral fracture internal fixation.
215043171|NCT06117059|RADIATION|3 fractions of prostate SBRT|Radical radiotherapy using only 3 fractions of prostate SBRT over 3 consecutive days
215043172|NCT03811470|OTHER|Standard diabetes management model in each MMC center|Standard diabetes management model in each MMC center
215043173|NCT04562311|DRUG|Chidamide|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
215043174|NCT06557759|BEHAVIORAL|Listening to Calming Music|Participants will listen to calming music, which may enhance health and wellness by reducing autonomic reactivity and improving bodily awareness, brain-body connection, and emotional wellbeing.
215043175|NCT05891899|OTHER|observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
215043176|NCT04087356|GENETIC|Blood draw|Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.
215043177|NCT02711501|PROCEDURE|Laser-assisted surgery.|laser-assisted surgery
215043178|NCT02711501|PROCEDURE|conventional surgery by blade|conventional surgery
215043179|NCT02622191|DEVICE|Spectral domain Optical Coherence Tomography|Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
215043180|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
215043181|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
215043182|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
214666734|NCT04354025|DRUG|Fludarabine|-Fludarabine (dose: 30 mg/m\^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
214666735|NCT04354025|DRUG|Ara-C|-Ara-C (dose: 2000mg/m\^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
214666736|NCT04354025|DRUG|G-CSF|-Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
215043183|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
214666737|NCT04354025|DRUG|Interleukin-2|-IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
215043184|NCT00565409|DRUG|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
215043185|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
215043186|NCT00294034|DEVICE|Pacemaker|
214666738|NCT04354025|PROCEDURE|Leukapheresis|-Donor only
214666739|NCT03425565|DRUG|Pembrolizumab|3 weekly cycles of Pembrolizumab administered by IV
214666740|NCT00875420|DRUG|RAD1901|10 mg Oral once a day for 28 days.
214666741|NCT00875420|DRUG|RAD1901|25 mg Oral once a day for 28 days
214666742|NCT00875420|DRUG|RAD1901|50 mg Oral once a day for 28 days.
214666743|NCT00875420|DRUG|RAD1901|100 mg Oral once a day for 28 days
214666744|NCT00875420|DRUG|Placebo|Placebo Oral once a day for 28 days
214666745|NCT05077189|OTHER|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale|"4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~1. Demographics Survey~2. DC/TMD Symptom Questionnaire (SQ)~3. Graded Chronic Pain Scale (GCPS)~4. Jaw Functional Limitation Scale-20 (JFLS-20)"
214666746|NCT01904461|DEVICE|Vacuum device|
214666747|NCT01904461|PROCEDURE|Conventional surgery|
214666748|NCT03068026|DEVICE|VitaBreath|The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
214666749|NCT03068026|OTHER|Pursed Lip Breathing technique|Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
214666750|NCT04512885|OTHER|Survey|Survey via questionnaire
214666751|NCT02975869|OTHER|Standard Leukemia Care|
214666752|NCT02975869|OTHER|Palliative Care|
214666753|NCT00001259|DRUG|Leuprolide|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
214666754|NCT00001259|DRUG|Estradiol Patches|Transdermal Estradiol, 100mcg/day by skin patch
214666755|NCT00001259|DRUG|Progesterone|Progesterone suppository, 200mg vaginally twice/day
214666756|NCT00001259|DRUG|Placebo patch|Placebo by skin patch
214666757|NCT00001259|DRUG|Placebo injection|Placebo given intramuscularly monthly
214666758|NCT00001259|DRUG|Placebo suppository|Placebo vaginal suppository
214666759|NCT03633578|BEHAVIORAL|walk test|"The patient will have to walk on a treadmill in four different conditions:~* without distraction at preferential speed~* with distraction at preferential speed~* without distraction at the speed of 130% of the preferential speed~* with distraction at the speed of 130% of the preferential speed"
214666760|NCT03142997|DIAGNOSTIC_TEST|Lung ultrasound|we will perform lung ultrasound for both groups to calculate lung score.
214666761|NCT04160403|OTHER|physical therapy intervention|NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
215043187|NCT05884372|DRUG|Eldecalcitol|the same as arm descriptions.
215043188|NCT05884372|DRUG|Native Vitamin D|the same as arm descriptions.
215043189|NCT05884372|DRUG|Denosumab|the same as arm descriptions.
215043190|NCT05884372|DRUG|Calcium|the same as arm descriptions.
215043191|NCT05973162|OTHER|Virtual Realty Training|"They would be receiving treatment as follow:~Virtual Reality is a technology that aims to completely immerse the user inside the computer generated world, giving the impression to the user that they have stepped inside the synthetic world. RA mobile phone , head mounted display (HMD) will be used and videos of patient's interest will be played on phone which will create a 3D world around the patient.~And while watching conventional physical therapy will be performed side by side.~Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
214666762|NCT06407362|DIAGNOSTIC_TEST|Cerebral Oxygen Saturation|We have designed this study to evaluate the accuracy of PVI, PI and rSO2 in both ventilation modes in patients undergoing septorhinoplasty operation under general anaesthesia
214877132|NCT01937078|DRUG|Famotidine|Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
214877133|NCT03886298|PROCEDURE|radiofrequency splanchnic denervation|the authors will denervate the splanchnic nerves via radiofrequency
214877134|NCT03886298|PROCEDURE|retrocrural celiac denervation|the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
215043192|NCT05973162|OTHER|Transverse friction massage (TFM)|"They would be receiving treatment as follow:~Transverse friction massage (Soft tissue mobilization technique) on the surrounding burn region for 5-10min in intervals. Frequency: 3 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 10 mins Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
215043193|NCT00654537|DRUG|Rosuvastatin|
215043194|NCT00654537|DRUG|Atorvastatin|
214666763|NCT01226667|DRUG|Pregabalin|"Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly."
214666764|NCT02935881|DEVICE|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
214877135|NCT01761383|OTHER|Nintendo Wii video console and Nintendo Wii Fit Plus games|The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
215043195|NCT00654537|DRUG|Pravastatin|
215043196|NCT00654537|DRUG|Simvastatin|
215043197|NCT01484652|DRUG|COV795|2 tablets taken every 12 hours
215043198|NCT01484652|DRUG|Placebo|2 tablets taken every 12 hours
215043199|NCT01158859|DRUG|Pregabalin|Preoperative administration of pregabalin vs placebo 1 hour before surgery
215043200|NCT03134326|DEVICE|R1-25 and R2-25 Pulse Oximeter Sensor|
214877136|NCT00108134|DRUG|PEP005|
214877137|NCT03317418|OTHER|ATR-FTIR Spectrophotometry|Spectrometry imaging
214877138|NCT03564158|DRUG|meropenem-vaborbactam|Meropenem-Vaborbactam being studied for effects on TQT
215043201|NCT03950635|DIETARY_SUPPLEMENT|Dietary Intervention|Consume whole-foods, fiber-rich diet
215043202|NCT03950635|DIETARY_SUPPLEMENT|Dietary Intervention|Consume high fat, low carbohydrate (ketogenic) diet
215043203|NCT03950635|OTHER|Questionnaire Administration|Ancillary studies
215043204|NCT04207320|DEVICE|αβ+ T-cell depletion with Miltenyi CliniMACS system|Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.
215043205|NCT06384170|DEVICE|Spinal Cord Stimulation- Closed loop|This is a percutaneously placed epidural electrode that is connected to a battery-powered impulse generator for power. The electrical delivery is monitored in real-time with the measurement of evoked compound action potentials and adjusted to provide titration of therapeutic stimulation delivery.
215043206|NCT05622578|OTHER|QST, CPM and Paisudoscan|Quantified pain tests
215043207|NCT01006395|DRUG|Zoledronic acid|yearly infusion
215043208|NCT01006395|DRUG|Placebo|yearly infusion
215043209|NCT02958345|BIOLOGICAL|Zostavax|Vaccination with one dose of Zostavax per Zostavax package insert
215043210|NCT02958345|OTHER|Placebo|Injection of 0.65 mL of sterile normal saline
214476899|NCT05633147|DRUG|Drug drug interaction (DDI) - Clarithromycin (Part I)|Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
214666765|NCT02935881|PROCEDURE|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
214666766|NCT04223167|DIETARY_SUPPLEMENT|Red Bull Energy Drink|473 ml Reb Bull Energy Drink
214666767|NCT04223167|DIETARY_SUPPLEMENT|Water|473 ml Water
215043211|NCT03350464|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
215043212|NCT02287779|DRUG|SHP626|
215043213|NCT02287779|DRUG|Placebo|
215043214|NCT01936558|OTHER|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
215043215|NCT01958749|PROCEDURE|Fat graft with Platelet Rich Plasma|
214666768|NCT04745832|DRUG|Zandelisib|Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
214666769|NCT04745832|DRUG|Rituximab|Rituximab IV 375 mg/m2 for 6 cycles
214666770|NCT04745832|DRUG|Bendamustine|Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
214666771|NCT04745832|DRUG|CHOP|Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
214666772|NCT06411795|DRUG|Bupivacaine|Given via epidural and injection
214666773|NCT06411795|DRUG|Hydromorphone|Given via epidural
214666774|NCT06411795|DRUG|Iopamidol|Given via epidural
214666775|NCT06411795|DRUG|Liposomal Bupivacaine|Given injection
214666776|NCT06411795|OTHER|Medical Chart Review|Ancillary studies
214666777|NCT06411795|OTHER|Questionnaire Administration|Ancillary studies
214666778|NCT06411795|DRUG|Thoracic Epidural Analgesia|Undergo thoracic epidural placement
214666779|NCT06411795|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
214666780|NCT06411795|PROCEDURE|X-Ray Imaging|Undergo x-ray
214666781|NCT06449599|DEVICE|ultrasound|"Local anesthesia 400 mg(20ml) prilocaine 2% to surgical field and additionally ultrasound-guided RIB with 0,25% bupivacaine 20 ml will be applied to the patients who will be inserted cardiac implantable electronic devices An additional 100 mg of prilocaine will be administered as the first-line rescue treatment if the intraoperative NRS-11 score was ≥4.If the patient has an NRS-11 score of ≥4 again during the procedure,100 mg of prilocaine will be administered again as the second rescue treatment.~In the postoperative follow-up of the patients,1 g of paracetamol will be administered IV as an infusion for 20 minutes as the first rescue treatment if the patients have an NRS-11 pain score of ≥4. Two hours after IV paracetamol,if the NRS-11 score≥4, 50 mg of tramadol HCL will be administered IV as the second rescue treatment.In addition, when the NRS score is ≥4 at follow-up, paracetamol 1 g, IV will be administered with dosing intervals not shorter than 6 hours."
214666782|NCT06449599|PROCEDURE|parenteral local anesthesia|"Only local anesthesia 400 mg(20ml) prilocaine 2% prilocaine to surgical field will be applied to the patients who will be inserted cardiac implantable electronic devices.~An additional 100 mg of prilocaine will be administered as the first-line rescue treatment if the intraoperative NRS-11 score was ≥4.If the patient has an NRS-11 score of ≥4 again during the procedure,100 mg of prilocaine will be administered again as the second rescue treatment.~In the postoperative follow-up of the patients,1 g of paracetamol will be administered IV as an infusion for 20 minutes as the first rescue treatment if the patients have an NRS-11 pain score of ≥4. Two hours after IV paracetamol,if the NRS-11 score≥4, 50 mg of tramadol HCL will be administered IV as the second rescue treatment.In addition, when the NRS score is ≥4 at follow-up, paracetamol (1 g, IV) will be administered with dosing intervals not shorter than 6 hours."
214877139|NCT03564158|DRUG|Placebo|Placebo
214877140|NCT03564158|DRUG|Moxifloxacin|Active Comparator
214877141|NCT04653649|BIOLOGICAL|HSP-CAR30|Anti-CD30 CAR T-cells
214877142|NCT05076357|BEHAVIORAL|Caloric Restriction|-30% of participants total energy requirements
214877143|NCT05076357|OTHER|Cold intervention|Sessions of 90min each every 2nd day involving cold exposure
214877144|NCT02525900|PROCEDURE|Wound Infiltration|Wound Infiltration with 0.25% Bupivacine
214877145|NCT02525900|PROCEDURE|TAP Blocks|bilateral TAP block with 0.25% Bupivacaine
214877146|NCT02525900|PROCEDURE|TAP Catheters|bilateral TAP Catheter with repeat bolus of 0.25% Bupivacaine
214877147|NCT00509366|DRUG|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
214877148|NCT00509366|DRUG|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
214877149|NCT00509366|DRUG|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
214877150|NCT00509366|DRUG|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
214877151|NCT02906358|BEHAVIORAL|Community-based pain self-management|
214877152|NCT02906358|BEHAVIORAL|Clinic-based pain self-management|
214877153|NCT01171118|DRUG|Physostigmine|Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
214877154|NCT01171118|DRUG|Oxygen|The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.
214877155|NCT01171118|DRUG|Placebo|The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
214877156|NCT01145508|DRUG|Docetaxel|Given IV
214877157|NCT01145508|OTHER|Laboratory Biomarker Analysis|Correlative studies
215043216|NCT01150032|OTHER|Bone quality complementary exams|"realisation of following exams to evaluate fracture risk in osteopenic women:~* hip and wrist Dual energy X-ray Absorptiometry (DXA)~* wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)~* hip Quantitative Computed Tomography (QCT)~* High Resolution Digital X-Ray of calcaneum using BMA(tm) system~* low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)"
215043217|NCT06266546|DRUG|Tranexamic acid|Prophylactic tranexamic acid will be instilled via endobronchial route in all patients undergoing transbronchial cryobiopsy. The medication will be administered through the bronchoscope one minute prior to the cryobiopsy. 500 mg of TXA diluted in 10 ml of saline and the procedure would be carried out as usual.
215043218|NCT04900298|DEVICE|SafeHaven Automated Hand Hygiene Device|Anesthesia providers in the intervention arm will be given a personal hand hygiene device, containing 64% ethyl alcohol, which provides actionable real-time performance feedback. The personalized device will be affixed to the provider's waist and will remain there for use throughout the perioperative period. Performance feedback is given to the anesthesia provider in real time with the number of personal hand hygiene events and an hourly hand hygiene rate, which is displayed on the device. Devices will be handed out to participating providers in the preoperative bay and retrieved in the post-anesthesia care unit upon case completion.
215043219|NCT05886478|DRUG|No intervention|As this is an observational study, no intervention will be administered.
215043220|NCT06564558|OTHER|Spinal Strengthening Exercises|Individuals in the experimental group will carry out 3 sets of 10 repetitions or what is tolerated within a Borg scale intensity of 4-5 with 70-80% of perceived exertion with appropriately picked elastic bands. The exercises include: Shoulder horizontal abduction; Shoulder elevation; Back Extensions over a plinth; Shoulder extension exercises; One arm and opposite leg lifts from quadruped; and finally bilateral arm lifts with upper thoracic extension from prone (superman exercise).
215043221|NCT06564558|OTHER|Thoracic Spine Stretching|Participants will be instructed to do two exercises: Firstly, to lay supine with and hinge the thoracic spine over a roller placed in a way that would ensure the patient is forward lying and not completely supine. The participant will be instructed to maintain hinging until a stretch or pressure feeling is felt in the midback and hold this position for 3 sets of 30 seconds. Secondly, the patient was asked to be in a seated position, clasp the hands together and behind the head while arching backward over the chair and looking up. This exercise will be done for 3 sets of 20-30 repetitions with a slight hold time at the end of the movement. All interventions will be carried out for 45 minute sessions 3 times per week.
214476900|NCT05633147|DRUG|Drug drug interaction (DDI) - Midazolam (Part 2)|Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).
214476901|NCT06595628|PROCEDURE|Lichtenstein Mesh-Based Hernioplasty|This is a tension-free hernioplasty procedure that uses a synthetic mesh to reinforce the inguinal canal floor. The mesh is fixed to the inguinal ligament and internal oblique aponeurosis, creating a barrier to prevent hernia recurrence. It is considered the gold standard for inguinal hernia repair and is widely used for its effectiveness in reducing recurrence rates and postoperative complications.
214476902|NCT06595628|PROCEDURE|Combined Modified Guarnieri-Desarda Tissue-Based Hernioplasty|This technique combines elements of the Guarnieri and Desarda tissue-based repairs. It does not involve the use of synthetic mesh, relying instead on the patient's own tissues to reinforce the inguinal canal. The Guarnieri technique reshapes the internal ring to improve the inguinal canal's shutter mechanism, while the Desarda technique reinforces the posterior wall using the external oblique aponeurosis. This approach aims to preserve natural anatomy and minimize complications associated with mesh use.
214476903|NCT00517153|DRUG|miglustat|Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
214476904|NCT03663205|DRUG|Tislelizumab|Administered intravenously
214877158|NCT01145508|DRUG|Prednisone|Given PO
214877159|NCT01145508|BIOLOGICAL|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
215043222|NCT06564558|OTHER|Thoracic Spine Mobilization|The patient will be seated with both hands clasped at shoulder level. An experienced and blinded therapist standing homolateral to the patient supports the clasped hands with one arm while placing the other hand was placed at different thoracic regions until the thoracolumbar junction. Specifically, the dorsal aspect of the index finger and pad of the thumb were used to create a fixation point at the junction. Following that, gentle extension-directed glides (postero-anterior) will be done by the therapist for 3 sets of 10 repetitions or until tolerated by the patient.
215043223|NCT06564558|OTHER|Sham Postural Correction|comprised an hour of social interaction with similar participants where a blinded therapist will provide educational tips for dealing with kyphosis along with educational reading material for each participant.
215043224|NCT06399224|DEVICE|Local Plantar vibrator|A vibrating device that applies 80 hz vibration waves applied on the sole of the foot
214877160|NCT01145508|BIOLOGICAL|Rilimogene Galvacirepvec|Given SC
214877161|NCT06633679|BEHAVIORAL|Se Cuida Intervention|The intervention consist in an internet based cognitive behavioural therapy program delivered through a online platform. Intervention consist of 8 weeks with 8 weekly modules assigned to the participants. The program has been translated and adapted to the Brazilian and is based on CBT techniques focused on managing psychological symptoms of anxiety and depression in young people. Out of a total 14 modules adaptaded, 8 will be delivered in the treatment: 5 will be available to all participants and 3 will be tailored according to the initial assessment and interviews. The intervention is self-guided with support on demand, meaning that when participants need support, they could chat directly through the platform text message channel with a psychoteraphist responsible for them. Also, once a week each participants receive feedbacks regarding their work on the program\&#39;s exercises.
214476905|NCT03663205|DRUG|Cisplatin|Administered intravenously
214476906|NCT03663205|DRUG|Carboplatin|Administered intravenously
214476907|NCT03663205|DRUG|Pemetrexed|Administered intravenously
214476908|NCT06814899|DRUG|Fosfomycin|In this retrospective study, the investigators want to analyze the medical records of all patients admitted to the Lecco ASST from 04/01/2020 to 12/31/2023 treated with IV fosfomycin in order to evaluate different clinical outcomes.
214877162|NCT02844400|DEVICE|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
215043225|NCT06399224|OTHER|Otago exercise|Warm up Front Knee strength Back knee strength Side hip strength Calf raising Toe raising Sit to stand Heel walk Toe walk One leg standing Side way walk Cool down
215043226|NCT05140421|BEHAVIORAL|Data to Suppression (D2S)|Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
214877163|NCT02844400|OTHER|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
214877164|NCT06340711|DRUG|OBP-301|2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study
214877165|NCT06340711|DRUG|Pembrolizumab|400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years
214877166|NCT05875311|DEVICE|telemonitoring|"The system consists of the following elements:~Professional website at the ambulatory centre, which allows:~To set up an individualised care plan To establish the patient's risk profile and targets for improvement. Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred Advise the patient on self-management strategies.~Mobile application software with the following functions:~Scheduled exercise sessions Medication reminder Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.) Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~Training monitor: guides the patient in the performance of their exercise. Access to certified health information for patients"
214877167|NCT05875311|OTHER|control follow-up|Patients are instructed to perform 150 minutes per week of moderate physical activity and follow healthy lifestyles
214877168|NCT00062985|BEHAVIORAL|Mail-based weight loss intervention|
215043227|NCT04064905|BIOLOGICAL|mRNA-1893|Zika vaccine
215043228|NCT04064905|OTHER|Placebo|0.9% sodium chloride
215043229|NCT04849897|DEVICE|Experimental: Virtual Reality Guided Imagery|Platform and VR Goggles
215043230|NCT04849897|OTHER|Active Comparator: Audio Only Guided Imagery|Audio Recordings of Guided Imagery via an iPAD
215043231|NCT05554679|DRUG|Metformin|Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.
215043232|NCT06505226|BEHAVIORAL|in person meditation|in person guided meditation
215043233|NCT06505226|BEHAVIORAL|in person meditation using headphones|in person meditation using headphones
215043234|NCT06505226|BEHAVIORAL|virtual meditation|virtually guided meditation via Zoom
215043235|NCT00114348|PROCEDURE|R-Blocks|
215043236|NCT00114348|PROCEDURE|Protocol II-Ida|
215043237|NCT04970914|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
215043238|NCT04970914|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
215043239|NCT02257684|DRUG|pegcrisantaspase|
214476909|NCT06813495|BEHAVIORAL|Eastern Principles Acceptance and Commitment Therapy for Nurses and Nursing Aids (EPACT NNA)|The EPACT intervention will be group-based with 5-10 participants per group. The group-based format has been shown to be an effective delivery method for NNAs (O'Brien, et al., 2019b). The EPACT protocol is comprised of two 2.5-hour sessions spaced one week apart.
214877169|NCT00062985|BEHAVIORAL|Phone-based weight loss intervention|
214877170|NCT04584385|DIAGNOSTIC_TEST|EEG|EEG monitoring
214877171|NCT02593253|OTHER|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
214877172|NCT02593253|OTHER|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
214877173|NCT02045147|BEHAVIORAL|Grp 1a Low Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation."
214877174|NCT02045147|BEHAVIORAL|Grp 2a Low Cognition, High Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations."
214877175|NCT02045147|BEHAVIORAL|Grp 3a Normal Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals."
215043240|NCT06274957|OTHER|CONTROL|Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education
215043241|NCT06274957|DEVICE|PEP DEVICE|"Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~PEP training was applied using the Acapella device.~In addition, participants were subjected to two sessions of 10 minutes each with the Acapella device. In the study, the Acapella device, capable of sustaining expiratory flow of at least 15 L/min for 3 seconds, was activated by taking a deep breath, holding the breath for 2-3 seconds, and then exhaling into the device."
215043242|NCT06274957|DEVICE|HFCWO DEVICE|"Patients were provided with conventional exercises including Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~In addition, participants will receive High-Frequency Chest Wall Oscillation (HFCWO) therapy twice a day for 10 minutes each.~HFCWO training was applıed using the WEST device"
215043243|NCT02128776|OTHER|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
215043244|NCT02128776|OTHER|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
215043245|NCT04313582|BEHAVIORAL|SmartPrompt smartphone application|The SmartPrompt is a smartphone application designed specifically for older adults with difficulties remembering to do daily tasks due to cognitive difficulties.
215043246|NCT02587910|DIETARY_SUPPLEMENT|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
215043247|NCT02587910|DIETARY_SUPPLEMENT|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
214666783|NCT03716726|BEHAVIORAL|WE CARE SDoH Screening Survey|The survey will be given at all visits by the front desk staff to all parents of SCA patients. It consists of 12 questions designed to: (1) briefly identify 6 unmet material needs (e.g., childcare, employment, food security, household heat, housing inadequate education) by self-report and (2) using a family-centered approach, determine whether parents would like assistance with each problem Parents wanting help will receive a resource referral. Clinical team members will be trained to review the WE CARE SDoH survey at visits and to provide community resource information sheets to parents with needs. Completed surveys will be scanned into the EHR
214666784|NCT03716726|BEHAVIORAL|Family Resource Book|The Family Resource book will contain one-page information sheets listing community resources (e.g., food pantries) and their contact information (i.e. telephone number) for each specific material need (e.g., food insecurity). Information sheets will be specific to each site and written at, or below, the 8th grade level. For parents with an identified need, providers will be instructed to give an information sheet. The book will contain six separate tabs, one for each unmet need, and will contain multiple copies of the information sheets. The Family Resource Book will be made available in each exam room. The investigators will work with each practice to create a Family Resource Book prior to study initiation.
214666785|NCT03716726|OTHER|Standard of care|Usual outpatient care for pediatric patients with sickle cell anemia will be provided.
214666786|NCT00159484|DRUG|EPO906, celecoxib|EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
214666787|NCT01733706|DEVICE|No nicotine electronic cigarette|"The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine."
215043248|NCT05478278|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains psilocybin (API only in a capsule).
215043249|NCT05478278|DRUG|Moxifloxacin|The positive comparator used in this study is a 400 mg moxifloxacin tablet.
215043250|NCT05478278|DRUG|Micro-Crystalline Cellulose|The placebo used in this study is encapsulated using a HPMC capsule and contains micro-crystalline cellulose.
215043251|NCT04434755|OTHER|health care professionals' exposure to bioethical issues|health care professionals were differentiated considering the work context and the type of patients cured
214666788|NCT01733706|OTHER|Standard counseling|standard counseling
214666789|NCT04680884|DRUG|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
214666790|NCT04680884|DRUG|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
214666791|NCT04680884|DRUG|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
214666792|NCT04680884|OTHER|Standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
214666793|NCT00337532|DRUG|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
214666794|NCT00337532|DRUG|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
214666795|NCT01416181|DRUG|natalizumab|Administered as specified in the treatment arm
214666796|NCT01416181|DRUG|Placebo|Matched placebo in part 1
214666797|NCT05446675|PROCEDURE|Endoscopic eTEP|Endoscopic extended view totally extraperitoneal prosthesis repair.
214666798|NCT05446675|PROCEDURE|Open Rives-Stoppa|Open Rives-Stoppa repair with retromuscular mesh placement.
215043252|NCT06133023|PROCEDURE|Plastic stent|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed."
215043253|NCT06133023|PROCEDURE|LAMS|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed."
215043254|NCT06432465|DEVICE|active tDCS|The anode will be placed over the right DLPFC (F4 on the EEG 10-20 system) and the cathode over the left DLPFC65 (F3) using 25cm2 sponges at an intensity of 2mA. Stimulation will be delivered for 20 minutes via two saline-soaked surface sponge electrodes and a battery-driven, constant current stimulator (NeuroConn DC Stimulator Plus).
215043255|NCT06432465|DEVICE|sham tDCS|Same device and procedures as active tDCS with the exception that the device includes a study mode, in which subject-specific codes are entered to deliver active or sham stimulation, keeping the administrator blinded. Sham stimulation will use a method in which stimulation will be ramped up and back down over a 30-second period at the beginning and end of sham tDCS.
215043256|NCT01570387|DRUG|Pomalidomide|Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle
215043257|NCT01570387|DRUG|Dexamethasone|10-20 mg on days 1, 8, 15, and 22
215043258|NCT02499744|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
215043259|NCT02499744|DEVICE|HHFNC|"For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
215043260|NCT04204824|OTHER|Ultrasound and exercise|"The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home"
215043261|NCT03325231|OTHER|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
214877176|NCT02045147|BEHAVIORAL|Grp 4a Normal Cognition, High Activation Intervention|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
215043262|NCT03332030|DIAGNOSTIC_TEST|Collection of Stem Cells|One time collection of a 20 ml blood sample
215043263|NCT04629742|OTHER|Seawater Pizza|A seawater pizza administered to 12 healthy subjects
214666799|NCT04878783|DIAGNOSTIC_TEST|CT scan|Patients undergoing CT scan staging for gastric and EJ junction cancer + perioperative chemotherapy (FLOT regimen) , CT scan re-staging and radical gastrectomy or esophagogastrectomy will be enrolled in the study
215043264|NCT04629742|OTHER|Standard pizza|A standard pizza administered to 12 healthy subjects
215043265|NCT05495022|BEHAVIORAL|Mindfulness-based stress reduction (MBSR) program|Mindfulness-based stress reduction (MBSR) program will be applied by the researcher to the midwives in the experimental group. Conscious Awareness-Based Stress Reduction will be applied by the researcher (S.Ö.C.) who has received training (16 hours) and has a certificate in this field. Stress reduction program based on mindfulness is planned as 2 sessions per week for 4 weeks, a total of 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individual and group sessions by determining the days when midwives are available online.
215043266|NCT01987557|BEHAVIORAL|rate group|walking with a high cadence (steps per minute)
214666800|NCT06058234|DRUG|Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease|FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
214666801|NCT01789879|DRUG|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
214666802|NCT01789879|DRUG|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
214877177|NCT02556983|RADIATION|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
214877178|NCT00549289|DRUG|cyclosporine A|
214476910|NCT06813495|BEHAVIORAL|Acceptance and Commitment Therapy for Nurses and Nursing Aids (ACT NNA)|The ACT for NNA intervention has been previously tested for NNAs. It contains only the six core processes identified above and omits the added EPACT components of acceptance of suffering, common humanity, impermanence, self- and other-compassion, and non-self-attachment. It will be delivered in a similar group-based format of 5-10 participants in two 2.5 -hour sessions.
215043267|NCT01987557|BEHAVIORAL|magnitude treadmill group|
215043268|NCT01987557|BEHAVIORAL|regular treadmill walking|
215043269|NCT05266547|DEVICE|OCT guided coronary intervention|patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group
214877179|NCT04067453|OTHER|Fatiguing contractions|10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
214877180|NCT00700830|DRUG|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
214877181|NCT00264550|DRUG|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
214877182|NCT00264550|DRUG|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
214877183|NCT00264550|DRUG|Methotrexate|Participants will receive methotrexate capsules weekly.
214877184|NCT00264550|DRUG|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
214877185|NCT00264550|DRUG|Placebo capsules|Participants will receive placebo capsules weekly
215043270|NCT00773084|DRUG|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
215043271|NCT02272127|DRUG|icotinib|
214476911|NCT06815770|DRUG|Terlipressin Injectable Product|Terlipressin Injectable Product
214476912|NCT06811337|PROCEDURE|Open Sinus Elevation|Open Sinus Elevation
214476913|NCT06811337|PROCEDURE|Closed Sinus Elevation|Closed Sinus Elevation
214476914|NCT06589726|DRUG|Placebo|Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.
214877186|NCT04261101|OTHER|Test-enhanced learning|Test-enhanced learning with short answers of questions regarding diabetes and adrenal
214877187|NCT04455321|PROCEDURE|Suture materials effect on istmocel|Effect of suture materials with different absorption times on istmocel
214877188|NCT02246114|DEVICE|piCO+ Smokerlyzer® monitor|
215043272|NCT06645795|COMBINATION_PRODUCT|Robot assisted gait training plus conventional physical therapy|Participants will complete 8 weeks of intervention of robot assisted gait training with the ATLAS 2030 exoskeleton (Marsi Bionics) owned by the school which they attend to. They will have 2 weekly sessions (16 sessions in total) for 4 weeks. Each session will last up to 1 hour (depending on the child's tolerance) although a minimum of 30 minutes per session and a minimum of 12 sessions will be set in this time. The training mode will be automatic. In addition, they will continue to carry out the rest of their usual treatments.
215043273|NCT06645795|OTHER|Conventional pjysical therapy|Participants will complete 8 weeks of conventional therapy, with 2 sessions per week (16 sessions total). During the conventional treatment period, participants will continue with the conventional physical therapy they have received thus far. The content of the usual care treatment does not specifically address gait training, but consists of elements addressing range of motion, tone reduction, balance, activities of daily living, etc. The conventional intervention may be different for each individual based on their needs (to represent usual care), however, participants will be advised not to change the intervention, type, and frequency during the study.
215043274|NCT06176209|DIAGNOSTIC_TEST|screening tool with biomarkers for prediction of chronic post traumatic neck pain|Diagnostic screening with biomarkers for prediction of chronic post traumatic neck pain
215043275|NCT00431964|DRUG|azithromycin 250 mg tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
215043276|NCT00431964|DRUG|placebo tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
215043277|NCT03991585|BEHAVIORAL|Musical Contour Regulation Facilitation (MCRF)|MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
214476915|NCT06589726|DRUG|Moxifloxacin|Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.
214476916|NCT06589726|DRUG|Enpatoran low dose|Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.
214877189|NCT02246114|OTHER|Text messages|
214877190|NCT02740114|DRUG|Bupivacaine|150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
214877191|NCT02740114|DRUG|Liposomal Bupivacaine|266 mg injected on each side of the wound at the end of surgery before wound closure.
214877192|NCT02740114|DRUG|Oxycodone|1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
214877193|NCT02740114|BEHAVIORAL|Pill Diary|Participants complete a pill diary every day for 30 days after hospital discharge.
214877194|NCT02740114|BEHAVIORAL|Symptom Questionnaire|Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
214877195|NCT00000542|DRUG|Inhibitors, ACE|
214877196|NCT00000542|DRUG|amlodipine|
215043278|NCT01918189|BEHAVIORAL|behavioral pain self-management intervention Pain EASE|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
215043279|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"Samples will be tested by comparing Access anti-HAV assay results to final anti-HAV sample status, and Access anti-HAV IgM results to final anti-HAV IgM status, according to respective instructions for use (IFU) or study guide, as applicable, to determine to determine non-reactive (NR), reactive (R), Negative, Positive or Equivocal (EQ).~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).~For evaluation of the clinical performance of Access anti-HAV IgM assay, all clinical samples, except pre- and post-vaccinated patient samples, will be tested with the reference assays Abbott - ARCHITECT® HAVAb-IgM, DiaSorin - LIAISON® Anti-HAV IgM, and SIEMENS Healthineers Atellica IM® Hepatitis A IgM (aHAVM)."
215043280|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"All samples will be tested pre- and post-vaccination by comparing Access anti-HAV assay results to final anti-HAV status, according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity.~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT)."
214877197|NCT00000542|DRUG|lisinopril|
214877198|NCT00000542|DRUG|doxazosin|
214877199|NCT00000542|DRUG|chlorthalidone|
214877200|NCT00000542|DRUG|pravastatin|
214877201|NCT00000542|BEHAVIORAL|diet, fat-restricted|
214877202|NCT00171665|DRUG|Diclofenac topical sodium gel 1%|
214877203|NCT03416829|BEHAVIORAL|Ambulatory voice biofeedback|Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
214877204|NCT06582862|OTHER|Exercise|Subjects will do aerobic and anaerobic exercise
214877205|NCT01439009|DRUG|Tolvaptan|Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
214877206|NCT01439009|DRUG|Placebo of tolvaptan|Once-daily oral administration of one placebo tablet in the morning
214877207|NCT06582992|OTHER|RRBS|Measure of genomic regions with differentially methylated profiles and differentially expressed protein
214877208|NCT02091024|DIETARY_SUPPLEMENT|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
214877209|NCT02091024|DIETARY_SUPPLEMENT|Placebo|Placebo 200mg, twice a day
215043281|NCT04915716|OTHER|Peripheral blood glucose levels were monitored|Peripheral blood glucose levels were monitored
215043282|NCT04450732|DRUG|GQ1001|anti-HER2 antibody drug conjugate
215043283|NCT00133133|DRUG|ALGRX 4975|
214877210|NCT02125864|PROCEDURE|intravitreal injection|collecting blood samples
214877211|NCT03392350|BEHAVIORAL|Physician Body Scan Consultation with Behavioral Intervention|The RENEW™ program consisted of 7 bi-monthly face-to-face web sessions over 16-18 weeks followed by an average of 15 monthly check-in sessions (maintenance) over 80 weeks.This included modules on responding to stress, enhancing effects of relaxation, nourishing theimmune system, physical activity, and social support.
214877212|NCT05516355|BEHAVIORAL|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn,1990).~During the retreat, participants will receive intensive training during 3 days (from 4:00pm to 9pm the first day and from 7 am to 10 pm including breaks, the second and third days), including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga. Training is delivered by certified instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
214877213|NCT05516355|BEHAVIORAL|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of daily formal and informal practices.~Training will be conducted during 3 days of the retreat (same schedule as the MBSR training). The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering. CCT program is delivered by certified instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
214877214|NCT06581913|OTHER|Behavioral assessment|Eating Awareness, Acceptance of Food Cravings, Healthy Life Awareness Health Perception
214877215|NCT01403220|PROCEDURE|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
214877216|NCT01403220|PROCEDURE|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
215043284|NCT01130792|DIETARY_SUPPLEMENT|Lactobacillus GG|10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
215043285|NCT01130792|DIETARY_SUPPLEMENT|Inulin|Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
215043286|NCT05539651|DRUG|RBD5044|Subcutaneously Administered RBD5044 in Healthy Subjects
215043287|NCT05539651|DRUG|Placebo|Subcutaneously Administered Placebo in Healthy Subjects
214877217|NCT06550544|PROCEDURE|Office hysteroscopy|"A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. Vaginoscopic approach will be used. A 5 F grasper will be used to grasp and extract the IUD.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
214877218|NCT06550544|PROCEDURE|Ultrasound guided|"An alligator forceps will be introduced into the uterine cavity under ultrasound sound guidance. The IUD will be grasped and extracted outside the uterus.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
214877219|NCT05015257|DIETARY_SUPPLEMENT|Standard F100|100 kcal and 3 g protein per 100 ml
214877220|NCT05015257|DIETARY_SUPPLEMENT|Standard F75 + Plumpynut|Standard F75 with ready to-use therapeutic food (Plumpynut)
214877221|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 with CMV + Plumpynut|Alternative F75 containing CMV with ready to-use therapeutic food (Plumpynut)
214877222|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 without CMV + Plumpynut|Alternative F75 with no CMV with ready to-use therapeutic food (Plumpynut)
215043288|NCT04301648|OTHER|STAR Nurse|"This intervention will consist in that the nurse who is in the hemodynamic nurse's office will do the STAR Nurse's tasks and competences.~Although the intervention will be detailed through phase 1 (integrative review) and 2 (Delphy methodology).~It is expected that the main STAR nurse's competencies and tasks in the nurse's office will be:~1. To guarantee a comprehensive evaluation and appropriate triage to candidates for an interventional procedure of structural heart disease, coordinating the request for complementary tests and previous visits.~2. Make education to the patient and family.~3. Make communication bridge with cardiologists.~4. Establish specific patient-centered care processes.~5. Promote continuity of care after discharge, follow up after discharge, and reevaluate quality of life and fragility."
215043289|NCT04301648|OTHER|Common Practice|Common practice will consist in that the nurse who is in the hemodynamic nurse's office will do her usual task that is exclusively health education.
215043290|NCT00396617|DEVICE|prothesis voice|The device may be used for patient using another type of voice prosthesis, of for patient undergoing total laryngectomy. This device is definitively placed in two parts:The first one is introduced in the puncture (TEP) through the esophagus (retrograde way). The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
215043291|NCT00396617|PROCEDURE|total laryngectomy|The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
215043292|NCT01312831|OTHER|Vitamin B12 (cyanocobalamin)|
215043293|NCT02189109|DRUG|NVX-108|0.2% emulsion administered i.v.
215043294|NCT03481348|DEVICE|Pharyngeal Electrical Stimulation|Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.
215043295|NCT03268564|BEHAVIORAL|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~1. Viewing a promotion video and a demonstration video~2. Brief motivational interviewing through telephone~3. Visiting the HIVST-online webpage~4. Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~1. Viewing a promotion video and a demonstration video~2. Visiting the HIVST-online webpage~3. Receiving a free self-testing kit and follow-up reminders"
215043296|NCT04001400|DRUG|Rabeprazole 20mg bid|Rabeprazole 20mg tablet b.i.d.
215043297|NCT04001400|DRUG|Rabeprazole 20mg qd|Rabeprazole 20mg tablet q.d.
215043298|NCT01165034|OTHER|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
215043299|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
215043300|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
215043301|NCT03144284|OTHER|Knowledge, attitude, and practice survey|A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
214476917|NCT06589726|DRUG|Enpatoran high dose|Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.
214666803|NCT01789879|DRUG|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
214877223|NCT00696787|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
214877224|NCT00696787|DRUG|Lyrica® (Pregabalin)|
214877225|NCT00696787|DRUG|Placebo|
214877226|NCT06632886|DIAGNOSTIC_TEST|AI-Assisted Non-Contrast CT for Multi-Cancer Screening|Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.
214877227|NCT04257539|BEHAVIORAL|Intervention to Reduce Sedentary Time|Chronic low back pain participants in the intervention group will be provided with a wrist-worn activity device that vibrates after prolonged sedentariness and meet with a health coach trained in motivational interviewing to discuss individual sedentary levels and provide education surrounding sitting habits and strategies for new habit development. Participants will meet with the health coach initially and at 4 weeks during the 8 week intervention period.
215043302|NCT01057979|BEHAVIORAL|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
214877228|NCT06142474|DRUG|SGLT2 inhibitor|Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group
214877229|NCT05723939|DIETARY_SUPPLEMENT|Carnosine supplementation|Intake of carnosine supplement in form of capsules or functionally enriched chicken meet for three weeks
214877230|NCT05723939|DIETARY_SUPPLEMENT|Controls|Intake of placebo capsules or regular chicken meet for three weeks
214877231|NCT01549405|OTHER|İntercostal nerve block|Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
215043303|NCT01057979|BEHAVIORAL|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
215043304|NCT05882396|OTHER|Rood's approach|Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.
215043305|NCT05882396|OTHER|Traditional physical therapy program|Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
215043306|NCT04039932|BEHAVIORAL|FLAME|The FLAME intervention trains pairs of faith leaders and community health workers and deploys them to conduct behavior change outreach in their communities.
215043307|NCT01657305|DRUG|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
215043308|NCT01657305|DEVICE|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
215043309|NCT06254066|DRUG|Adebrelimab plus Fluzoparib|Adebrelimab combined with Fluzoparib in HRD-positive HR +/HER2- advanced breast cancer
215043310|NCT00578097|BIOLOGICAL|Botulinum toxin type A|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
215043311|NCT00578097|DRUG|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
214877232|NCT02656069|DRUG|G-Pen (glucagon injection)|1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
214877233|NCT02656069|DRUG|Lilly Glucagon (glucagon injection [rDNA origin])|1 mg of Lilly glucagon reconstituted from lyophilized powder
214877234|NCT02666209|DRUG|Ulocuplumab|CXCR4 inhibitor given weekly on a 28 day cycle intravenously
214877235|NCT02666209|DRUG|Lenalidomide|immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
214877236|NCT02666209|DRUG|Bortezomib|proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
214877237|NCT02666209|DRUG|Dexamethasone|steroid given at physician discretion on a 28 day cycles
214877238|NCT04578405|PROCEDURE|Intracorporeal anastomosis|Anastomosis performed totally laparoscopically
214877239|NCT04578405|PROCEDURE|Extracorporeal anastomosis|Anastomosis performed through a minilaparotomy
214877240|NCT00129389|DRUG|Fluorouracil|Arm A: FAC Arm B: FAC-wP
214877241|NCT00129389|DRUG|Doxorubicin|Arm A: FAC Arm B: FAC-wP
214877242|NCT00129389|DRUG|Cyclophosphamide|Arm A: FAC Arm B: FAC-wP
214877243|NCT00129389|DRUG|Paclitaxel|Arm B: FAC-wP
214877244|NCT02837848|PROCEDURE|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
214877245|NCT02837848|PROCEDURE|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
214877246|NCT03215186|OTHER|observational study|
214877247|NCT01192763|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
214877248|NCT01192763|OTHER|laboratory biomarker analysis|Correlative studies
214877249|NCT01192763|OTHER|pharmacological study|Correlative studies
214877250|NCT01192763|PROCEDURE|neoadjuvant therapy|
214877251|NCT01192763|PROCEDURE|therapeutic conventional surgery|
214877252|NCT00041626|GENETIC|INGN 201|
214877253|NCT05623618|BEHAVIORAL|PACE labelling|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
215043312|NCT01249001|DRUG|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
215043313|NCT01249001|DRUG|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
215043314|NCT03841409|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
215043315|NCT05595746|PROCEDURE|dental implant placement|In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.
215043316|NCT02333448|BIOLOGICAL|Blood sample taken on the day the treatment is initiated|
215043317|NCT02333448|BIOLOGICAL|Blood sample taken on day 3 after initiation of treatment|
215043318|NCT02333448|BIOLOGICAL|Blood sample taken on day 5 after initiation of|
215043319|NCT02333448|BIOLOGICAL|Blood sample taken on day 7 after initiation of treatment|
215043320|NCT02333448|BIOLOGICAL|Blood sample taken on day 10 after initiation of treatment|
215043321|NCT04103450|DRUG|Vibegron|oral administration
215043322|NCT04786054|DIAGNOSTIC_TEST|BED Questionnaire|BED Questionnaire
214877254|NCT01602718|OTHER|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
214877255|NCT06633315|OTHER|low dos dexmedetomidine|received dexmedetomidine 2.5 μ g/kg nasal drops
214877256|NCT06633315|OTHER|high dos dexmedetomidine|received dexmedetomidine 3 μ g/kg nasal drops
214877257|NCT06633315|OTHER|dexmedetomidine and esketamine|received dexmedetomidine 2 μ g/kg nasal drops plus ketamine 0.5 mg/kg nasal drops
214877258|NCT05304247|OTHER|questionnaire and clinical examination|Prevalence and Risk Factors of Black Tooth Stains and Their Relation With Caries Experience in Primary Teeth of A Group of Preschool Children
214877259|NCT02187692|BEHAVIORAL|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
214877260|NCT02916667|OTHER|dietary guidelines|dietary guidelines will include chrono- nutrition diet plan
214877261|NCT01796418|DRUG|Beraprost sodium|
215043323|NCT06564415|PROCEDURE|Transperineal Laser Ablation of Prostate|Transperineal Laser Ablation of the Prostate is an ultra minimally-invasive procedure that consists in the insertion trough the perineum skin of laser fibers into the prostatic adenoma, under US guidance. Laser energy generates an area of coagulative necrosis that will bring to a reduction of the prostatic volume.
215043324|NCT04442893|BEHAVIORAL|Rumination-Focused Cognitive Behaviour Therapy|Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.
215043325|NCT04442893|OTHER|Health Education programme|Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
215043326|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
215043327|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
215043328|NCT00814255|DRUG|Adalimumab|Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
215043329|NCT00814255|DRUG|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
215043330|NCT00814255|DRUG|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
215043331|NCT01390623|DRUG|Ceftriaxone|"Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.~The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria."
215043332|NCT04342247|DRUG|external testosteron|external testosteron
215043333|NCT01901692|RADIATION|TACE+External beam RT|Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
214877262|NCT04809051|OTHER|Stratified Transplant Survival Metric|"Both transplant metric conditions display the number of hearts offered to each center, the number of hearts accepted by each center, and the number of transplants performed at each center (in a year), in addition to the condition-specific metrics below. The stratified condition instead features a pair of values corresponding to each center's offers/acceptances/transplant survival rates for donor hearts of optimal or adequate quality."
214877263|NCT04809051|OTHER|SRTR Information Format|The information format varies based on how the transplant hospital statistics are organized when presented to participants on the choice screen. The SRTR conditions mimic the information format present on the SRTR public reporting website.
215043334|NCT01901692|DRUG|Sorafenib|Sorafenib 800 mg/day orally
215043335|NCT06184802|BEHAVIORAL|TAU+Multisensory room|Multisensory room session included exercises in different interaction areas that allow to make up a multisensory experience where the patient can freely perform in different directions experimenting combinations of play
215043336|NCT06184802|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
215043337|NCT00487916|DRUG|AMA1-C1/ISA 720|
215043338|NCT05388578|DEVICE|Blood pressure monitor|Participants will receive the Withings BPM connect monitor and do weekly self-measurements of blood pressure.
215043339|NCT05388578|DEVICE|Weighting scale|Participants will receive the Withings Body scale and do weekly self-measurements of their body weight and BMI.
215043340|NCT05388578|DEVICE|Activity tracker|Participants will receive the Withings Move to automatically keep track of their number of steps and activity type.
215043341|NCT05388578|DEVICE|ECG device|Participants will receive the Withings Move ECG to make daily measurements of heart rhythm, an algorithm will detect abnormalities in heart rhythm such as atrial fibrillation.
215043342|NCT06055751|DEVICE|TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473)|No intervention will be done as part of this prospective registry. Implantation of Boston Scientific Loop Recorder (LUX-Dx) will be performed regardless of this research and outside this research protocol per standard of care
215043343|NCT01180127|DIETARY_SUPPLEMENT|Flavanol containing food product|12 weeks, 2X/day, 20g serving
215043344|NCT01180127|BEHAVIORAL|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
215043345|NCT01180127|DIETARY_SUPPLEMENT|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
215043346|NCT01180127|BEHAVIORAL|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
215043347|NCT01731925|DRUG|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
215043348|NCT01731925|DRUG|Placebo (for sunitinib)|
214877264|NCT03430765|BEHAVIORAL|Acceptance and Commitment Therapy|Single 2-hour individual Acceptance and Commitment Therapy coping skills session.
214877265|NCT02709291|BEHAVIORAL|behavioral parent training|Parents receive up to 6 sessions of the Family Check-Up program
214877266|NCT02709291|BEHAVIORAL|interventionist training|Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
214877267|NCT01013558|DRUG|Remifentanil|0.15 microgram/kg/min continuous infusion.
214877268|NCT01013558|DRUG|saline|continuous infusion
214877269|NCT03348735|DRUG|Lidocaine patch 5%|Application of Lidocaine 5% patch for 12 hours.
214877270|NCT03348735|DRUG|Capsaicin 8% Patch|Application of Capsaicin 8% patch for
215043349|NCT01731925|DRUG|Sunitinib|Sunitinib 37.5 mg daily
215043350|NCT03026179|BEHAVIORAL|Play Nicely|Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
215043351|NCT05152602|PROCEDURE|Bilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
215043352|NCT05152602|PROCEDURE|Unilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
215043353|NCT00879489|BIOLOGICAL|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
215043354|NCT00160953|PROCEDURE|Endorectal Coil Magnetic Resonance Images|
215043355|NCT01696643|DRUG|CB-5945|
215043356|NCT01696643|DRUG|Placebo|
215043357|NCT03663192|DEVICE|strain echocardiography|strain echocardiography during septic shock
215043358|NCT03196830|BIOLOGICAL|CAR-T|For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
215043359|NCT02526784|DRUG|degarelix|
215043360|NCT03166748|COMBINATION_PRODUCT|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
215043361|NCT05260749|PROCEDURE|real-time fMRI neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
215043362|NCT05260749|PROCEDURE|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI sham neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
215043363|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
215043364|NCT00518180|BIOLOGICAL|Tdap Vaccine|One dose of vaccine administered intramuscularly
215043365|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
215043366|NCT03662061|OTHER|Assessment of the follow-up of oncological and geriatric recommendations 4 months after the RCP|"After inclusion, patient's results are discussed at a weekly onco-geriatric multidisciplinary team meeting including surgeons, geriatrics, oncologists, radiotherapist, nurse, pharmacist. Oncological and geriatric recommendations are given.~A phone call is made to the patient to evaluate the follow-up of the oncological and geriatric recommendations defined during the RCP along with their survival, autonomy and quality of life."
215043367|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT"
215043368|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT"
215043369|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT"
215043370|NCT01564017|BIOLOGICAL|Allergovac depot|"depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT"
214877271|NCT03348735|DRUG|Pregabalin|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
214877272|NCT03219190|BEHAVIORAL|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
214877273|NCT01830790|DRUG|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
214877274|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to hemodynamic parameters|Patient who will be adjusted according to hemodynamic parameter
214877275|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to NOL monitoring|Patient who will be adjusted according to NOL monitoring
214877276|NCT00018356|PROCEDURE|exercise|
215043371|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT"
215043372|NCT01564017|BIOLOGICAL|Allergovac depot|"Sterile suspension for subcutaneous injection.~Same number of administration as the active groups"
215043373|NCT04734314|OTHER|conventional physical therapy|conventional physical therapy in the form of transcutaneous electrical stimulation (TENS) for 20 min and hot pack for 10 min Each patient received 12 sessions three session per week.
215043374|NCT04734314|OTHER|vojta therapy|"Vojta Dynamic Neuromuscular Stabilization (DNS) is a therapy used to manage neurological and musculoskeletal conditions each patient in the study group (group B) was instructed to lie prone on an examination table with the participant's shoulders abducted, elbows flexed approximately 80-90°, and the forearms hanging off the edge of the table. Pressure-like stimulation of the calcaneus and ASIS were performed in the postural position named by Vojta as reflex creeping.~Each patient received 12 sessions three session per week."
215043375|NCT02917005|DRUG|Palbociclib|CDK 4/6 inhibitor
215043376|NCT02917005|DRUG|Exemestane|Aromatase inhibitor
215043377|NCT02917005|DRUG|Goserelin|LHRH agonist
215043378|NCT03738722|DRUG|Oxygen|HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
215043379|NCT04858581|DIAGNOSTIC_TEST|Virological and serological tests|Survey, RT-PCR test and blood test
215043380|NCT00529360|DRUG|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
215043381|NCT00529360|DRUG|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
215043382|NCT03060902|BEHAVIORAL|Dialectical Behavior Therapy Skills|DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
214666804|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Patients will receive 20 sessions of active HD-tDCS for a duration of 20min. Sessions will be delivered twice-daily over 2 weeks on the 5 consecutive working days. The number of electrodes used, electrode placement on the scalp (based on EEG 10/10), and the individual currents that need to be injected from each electrode will be determined based on the brain networks identified as involved in their hallucinations during a fMRI acquisition performed at baseline, and computed using a neurotargeting software that allows determining optimal electrode montages for achieving maximal brain current flow in the targeted brain region.
214877277|NCT00018356|DRUG|testosterone|
214877278|NCT00754715|DRUG|AZD2516|Solution administered once orally
214877279|NCT00754715|DRUG|Placebo|Solution administered only once
215043383|NCT01465841|DEVICE|PC 400 coils (Penumbra )|The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.
215043384|NCT06101810|BEHAVIORAL|COMET|information already included in arm/group descriptions.
215043385|NCT06101810|BEHAVIORAL|CBT|information already included in arm/group descriptions.
215043386|NCT06098326|DRUG|cyclophosphamide, fludarabine, and antithymocyte globulin|"1. Cyclophosphamide 50 mg/kg/day i.v. daily on days -3 and -2 (for 2 days)~2. Fludarabine 30 mg/m2/day i.v. daily on days -7to -2 (for 6 days)~3. Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)"
215043387|NCT00138684|PROCEDURE|venesection|Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
215043388|NCT05905562|OTHER|core stabilization exercises|Core muscles activation exercises will be performed on patients to target the abdominals.
215043389|NCT05905562|OTHER|Spinal mobilization techniques|lumbar spine joint mobilization techniques will be performed to patient in prone lying.
214877280|NCT01226407|DRUG|CG200745|Multiple administration (IV) over the cycles untile MTD/LTD
214877281|NCT01797237|DEVICE|PFNA|
214877282|NCT01797237|DEVICE|InterTAN|
214877283|NCT00706862|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
214877284|NCT00706862|DRUG|Placebo|Oral, twice per day
214877285|NCT04735926|DRUG|Calcifediol 75mcg|Soft gelatin capsule. Oral administration once per week
214877286|NCT04735926|DRUG|Calcifediol 100mcg|Soft gelatin capsule. Oral administration once per week
214877287|NCT04735926|DRUG|Calcifediol 125mcg|Soft gelatin capsule. Oral administration once per week.
214877288|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
214877289|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
214877290|NCT03548701|DIAGNOSTIC_TEST|Thromboelastometry testing|Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities
214877291|NCT00000246|DRUG|Flumazenil|
214877292|NCT00603837|DEVICE|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
215043390|NCT04565730|OTHER|Grup I= General anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
214877293|NCT00603837|DEVICE|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
214877294|NCT03578549|DEVICE|Pulse Oximetry|Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
214877295|NCT04611529|DRUG|Ibuprofen 400 mg|Ibuprofen 400mg
214877296|NCT04611529|DRUG|Topical diclofenac|Diclofenac 1% gel 4gm
214877297|NCT04879680|PROCEDURE|sentinel node detection|Under general anesthesia 5 ml at 2.5mg/ml of Infracyanine ® (Laboratoire SERB; France) were injected circumferentially around the areola. Two ml of patent blue-V dye (Laboratoire Guerbet, Aulney-Sous-Bois, France) were injected in combination in the cohort of patients undergoing the procedure after primary chemotherapy. This was followed by a breast massage to facilitate absorption into the lymph vessels, then the surgical lights were turned off and image were obtained under near-infrared light using a first generation Near Infra Red (NIR) device \[K\]. Course of subcutaneous lymphatic drainage pathway fluorescence was followed up to where it disappeared to enter to deeper axilla and an incision was performed at that place. Lymphatic duct identification using the NIR camera allowed localization and removal of the sentinel lymph node(s).
214877298|NCT00967460|BEHAVIORAL|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
214877299|NCT06486857|DIAGNOSTIC_TEST|a novel gas detection method for dyslipidemia screening|Multidimensional Mass Spectrometry Technologies Based on Exhaled Metabolic Fingerprint Spectra for Dyslipidemia Detection
214877300|NCT02305160|DRUG|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
214877301|NCT02305160|DRUG|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
214877302|NCT04867174|BEHAVIORAL|Financial incentives|Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)
214877303|NCT04867174|BEHAVIORAL|Convenient scheduling link|In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).
214877304|NCT04867174|BEHAVIORAL|Race concordant|Randomized to a messenger who is race concordant with the participant
214877305|NCT04867174|BEHAVIORAL|Gender concordant|Randomized to a messenger who is gender concordant with the participant
214877306|NCT01776931|DIETARY_SUPPLEMENT|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
214877307|NCT02121873|DEVICE|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
214877308|NCT02121873|DEVICE|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
214877309|NCT02121873|DEVICE|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
214877310|NCT04851392|DRUG|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
214877311|NCT04851392|DRUG|Cannabis with THC without CBD|Cannabis with THC without CBD - inhaled and vaporised cannabis flower
214877312|NCT04851392|DRUG|Placebo cannabis|Placebo cannabis, without THC and without CBD - inhaled and vaporised
214877313|NCT03668392|DRUG|Asparaginase|Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
214877314|NCT03571412|DEVICE|repetitive Transcranial Magnetic Stimulation|Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
215043391|NCT04565730|OTHER|Grup II= Spinal anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
215043392|NCT00956293|DRUG|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
214877315|NCT03988686|PROCEDURE|Radical prostatectomy plus standard care|To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer
214877316|NCT03988686|DRUG|Standard of care for metastatic prostate cancer|androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
214877317|NCT02974712|DRUG|Fentanyl|
214877318|NCT02974712|DRUG|Saline|
214877319|NCT00451048|DRUG|sunitinib malate|Given orally
214877320|NCT02193334|DRUG|KP-100IT|
214877321|NCT02193334|DRUG|Placebo|
214877322|NCT03079635|DIETARY_SUPPLEMENT|Control|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
214877323|NCT03079635|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
214877324|NCT00900835|OTHER|educational intervention|
214877325|NCT00900835|OTHER|questionnaire administration|
214877326|NCT00900835|OTHER|study of socioeconomic and demographic variables|
214877327|NCT00900835|PROCEDURE|assessment of therapy complications|
214877328|NCT00900835|PROCEDURE|fatigue assessment and management|
215043393|NCT00956293|DRUG|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
214666805|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|Participants will receive 20 sessions of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS. However, stimulation will only be administered in the initial 30 seconds of the 20-minute period, with no further stimulation during the remaining duration. This approach aims to replicate the tingling sensation commonly associated with active stimulation.
214877329|NCT00900835|PROCEDURE|quality-of-life assessment|
214877330|NCT00900835|PROCEDURE|standard follow-up care|
214877331|NCT01161134|DRUG|Meloxicam|Meloxicam Tablets 15 mg
214877332|NCT02040441|DRUG|Spironolactone|
214877333|NCT02040441|DRUG|Placebo|
214877334|NCT02040441|DRUG|Standard care|Standard diabetes care
214877335|NCT04795596|PROCEDURE|secondary cytoreductive surgery|resection of isolated recurrent ovarian carcinoma in platinum resistant disease
214877336|NCT04795596|DRUG|Chemotherapy|second line chemotherapy according to investigator's choice
214877337|NCT00026299|DRUG|ZD1839|
214877338|NCT00026299|DRUG|oxaliplatin|
214877339|NCT00001605|BIOLOGICAL|Nontypeable Haemophilus influenzae|
214877340|NCT01927198|DRUG|Placebo|
214877341|NCT01927198|DRUG|RDEA3170 5 mg|
214877342|NCT01927198|DRUG|RDEA3170 10 mg|
214877343|NCT01927198|DRUG|RDEA3170 12.5 mg|
214877344|NCT04414345|DRUG|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
214877345|NCT04414345|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily"
214877346|NCT02723747|OTHER|myocardial perfusion with magnetic resonance imaging|
214877347|NCT04140162|DRUG|Daratumumab|"Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1"
214877348|NCT04140162|DRUG|Lenalidomide|"Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression"
214877349|NCT04140162|DRUG|Bortezomib|Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
214877350|NCT04140162|DRUG|Dexamethasone|Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
214877351|NCT00425373|DRUG|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
214877352|NCT00425373|DRUG|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
214877353|NCT00425373|DRUG|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
214877354|NCT00425373|DRUG|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
214877355|NCT00425373|DRUG|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
214877356|NCT00425373|DRUG|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
215043394|NCT00956293|DRUG|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
215043395|NCT00956293|DRUG|Cyclosporin A (CsA)|Dosage was based according to blood level
215043396|NCT00956293|DRUG|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
214877357|NCT00425373|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
214877358|NCT00425373|DRUG|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
214877359|NCT00425373|DRUG|Placebo|4 tablet and 2 capsule placebos taken once daily
214877360|NCT03918460|DEVICE|ANEUFIX|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
214877361|NCT03458260|DRUG|Pixantrone|6 cycles - dose = 80mg/m²
214877362|NCT03458260|OTHER|Ifosfamide|6 cycles - 1500 mg/m2
214877363|NCT03458260|OTHER|Etoposide|6 cycles - 150 mg/m2
214877364|NCT03458260|OTHER|Rituximab|6 cycles - 375 mg/m2
214877365|NCT03458260|PROCEDURE|Transplant|after 2 or 6 cycles
214877366|NCT01859910|PROCEDURE|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
214877367|NCT01859910|PROCEDURE|routine preparation for cataract|
214877368|NCT04504123|DRUG|Doxycycline Hyclate|Doxycycline Hyclate capsules, USP 50 mg
214877369|NCT04504123|DRUG|Placebo|Placebo
214877370|NCT03624907|RADIATION|Daily Stereotactic Body Radiotherapy|After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.
214877371|NCT03624907|RADIATION|Non-Daily Stereotactic Body Radiotherapy|After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.
214877372|NCT02052011|DRUG|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
214877373|NCT02052011|DRUG|Placebo|
214666806|NCT01411410|DRUG|Paclitaxel|"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~* The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~* Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."
214666807|NCT01411410|DRUG|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
214877374|NCT04234971|DRUG|Intervention group (DBM/BMP)|All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
214877375|NCT04234971|DRUG|Control group(autologous ICBG)|The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
214877376|NCT02227511|DIETARY_SUPPLEMENT|Fruits|Randomization to extra fruit or nuts as snacks
214877377|NCT02227511|DIETARY_SUPPLEMENT|Nuts|
214877378|NCT02341898|OTHER|Educational programme for all nurses|
214877379|NCT02341898|OTHER|Training and structured support for nominated key nurses|
214877380|NCT02341898|OTHER|Facultative train-the-trainer module for key nurses|
214877381|NCT02341898|OTHER|Printed study material|
214877382|NCT02341898|OTHER|Supportive material (poster, mugs etc.)|
214877383|NCT02354794|DIETARY_SUPPLEMENT|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
214877384|NCT02354794|DIETARY_SUPPLEMENT|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
214877385|NCT01851330|DRUG|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
214877386|NCT01851330|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214877387|NCT00134667|DRUG|Photodynamic Therapy (PDT) with Visudyne (verteporfin)|
214877388|NCT00134667|DRUG|Macugen (pegaptanib sodium)|
214877389|NCT02480348|DEVICE|Polymer-free DES (Drug Eluting Stent)|
214877390|NCT00551668|PROCEDURE|proximal patellar surgery|Initial proximal patellar surgery
214877391|NCT00551668|PROCEDURE|Nonoperative|Nonoperative without surgery
215043397|NCT04780139|DIAGNOSTIC_TEST|Ultrasonographic Evaluation of Internal Jugular Vein Cross Sectional Area|Measuring the internal jugular vein cross section area and relate this to the incidence of hypotension after spinal anesthesia.
215043398|NCT04243148|COMBINATION_PRODUCT|Home exercise program for 12 months.|Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.
214877392|NCT03238612|DRUG|FFA, clarithromycin, oseltamivir|2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
214877393|NCT03238612|DRUG|Oseltamivir alone|2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
214877394|NCT03529825|DRUG|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
214877395|NCT04352868|DEVICE|Intelliwave multifocal, toric, soft contact lens|This is a quarterly disposable, multifocal, toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
214877396|NCT04352868|DEVICE|Intelliwave toric, soft contact lens|This is a quarterly disposable toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
214877397|NCT01210872|OTHER|questionnaire administration|
214877398|NCT01210872|PROCEDURE|quality-of-life assessment|
214877399|NCT01210872|PROCEDURE|standard follow-up care|
214877400|NCT04819763|OTHER|Physical therapy|"Coordination training for lateral movement of the mandible (spatula exercise):~1. A wooden spatula is loosely placed between the teeth of the upper and lower jaw; the head must be aligned with the body axis; the exercise should be performed in front of a mirror.~2. The lower jaw moves to the left and back to the center with little contact to the spatula~3. The lower jaw moves to the right and back to the center under contact with the spatula~Training of the left lateral pterygoid muscle:~1. The left palm is placed on the left temple region~2. Right hand forms a fist and is placed on the tip of the right chin~3. Both arms are aligned parallel to the surface of the floor~4. The lower jaw is moved to the right against a moderate resistance of the fist = concentric muscle work~5. With measured force of the fist, the lower jaw is brought back to the center = eccentric muscle work (Right lateral pterygoid muscle training with opposite hands.)"
214877401|NCT04819763|OTHER|Appliance therapy|"Upper and lower jaw impressions are registered by using an intraoral scanner. The arbitrary hinge axis position is determined using a face bow.~The stabilization appliance with anterior canine guidance is manufactured in the Lexmann laboratory in Dresden.~The stabilization appliance is incorporated by the dentist and the static and dynamic occlusion is checked. A tension-free fit of the appliance on the lower jaw is necessary. Additionally, equal contacts in the side teeth area and incisors guidance in the case of mandibular protrusion are checked visually and by using occlusion foil. During mandibular lateral movement only the canine guidance takes place and is also registered optically and by using occlusion foil.Interference contacts should be adjusted.~The patient is instructed to wear the stabilization appliance while sleeping. The wearing rhythm is described as intermittent. (three nights - wearing the appliance, one night - not wearing the appliance)."
215043399|NCT04243148|COMBINATION_PRODUCT|Multispecies probiotic: Vivomixx®|"Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435\*, Bifidobacterium infantis DSM 24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440\*\*~\* Re-classified as B. lactis \*\* Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study."
215043400|NCT04243148|COMBINATION_PRODUCT|Branched-chain amino acids (BCAA)|Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.
215043401|NCT04243148|COMBINATION_PRODUCT|No specific intervention.|Follow up as a clinical practice
215043402|NCT02536664|DRUG|Rituximab|
215043403|NCT03383666|DEVICE|PulseRider® Aneurysm Neck Reconstruction Device|Neck Reconstruction Device
215043404|NCT00549159|DEVICE|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
215043405|NCT00549159|DEVICE|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
215043406|NCT01790373|BEHAVIORAL|Suubi+Adherence|"* Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~* Financial education and workshops on asset-building, future planning, and protection from risks~* Mentorship from a young adult/near-peer~* Family-based microenterprise development training~* Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
215043407|NCT01790373|BEHAVIORAL|Bolstered Standard of Care|"-Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
214877402|NCT03155516|OTHER|Good pain management (GPM) procedure|"In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required."
214877403|NCT03155516|OTHER|Current practice procedure|Current practice clinical procedure for pain management
214877404|NCT05412355|PROCEDURE|ERAS protocol|ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
214877405|NCT06256523|DRUG|GZR18|0.5mg-13mg
215043408|NCT04063813|BEHAVIORAL|Experimental: 40 minute up trial|
215043409|NCT04063813|BEHAVIORAL|Experimental: 40 minute down trial|
215043410|NCT04063813|BEHAVIORAL|Experimental: Two 20 minute up trials|
215043411|NCT04063813|BEHAVIORAL|Experimental: Two 20 min down trials|
215043412|NCT04063813|BEHAVIORAL|Active Comparator: Sedentary trial|
215043413|NCT03807583|DRUG|Aminoven 10%|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care."
214877406|NCT06256523|OTHER|Placebo|administered the same volume as GZR18
215043414|NCT03807583|DIETARY_SUPPLEMENT|RENORAL|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care."
215043415|NCT01873105|OTHER|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
215043416|NCT01221506|DRUG|Pazopanib|800 mg PO QD x 28 days
215043417|NCT01221506|DEVICE|DCE-MRI and Quantitative Doppler Ultrasound|Contrast-enhanced MRI
214877407|NCT01105624|DRUG|azithromycin ophthalmic solution, 1%|1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
214877408|NCT01105624|DRUG|Visine® for Contacts®|1-2 drops QID for the treatment period (29 ± 1 day)
214877409|NCT00561418|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
214877410|NCT00561418|OTHER|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
215043418|NCT03055091|OTHER|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
215043419|NCT03055091|OTHER|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
215043420|NCT00098995|DRUG|cisplatin|
215043421|NCT00098995|DRUG|tirapazamine|
215043422|NCT00098995|RADIATION|brachytherapy|
215043423|NCT00098995|RADIATION|radiation therapy|
215043424|NCT01455480|DRUG|RPh201, botanical drug product|topical
215043425|NCT02412150|DRUG|Desflurane|Anesthesia is maintained with desflurane
215043426|NCT02412150|DRUG|Remifentanil|Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
215043427|NCT02412150|PROCEDURE|Thyroidectomy|The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
215043428|NCT02412150|OTHER|Vital signs|"Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.~And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed."
214291692|NCT06384716|OTHER|rehabilitation programme based on motor control of core muscles|The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.
214666808|NCT06434740|RADIATION|Stereotactic Body Radiation Therapy，SBRT|The enrolled subjects will receive SBRT treatment for lung metastases.The dose segmentation is 10Gy/f, with a total dose of 50Gy/5f, once every other day.
214666809|NCT06434740|DRUG|Puterizumab|Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).
215043429|NCT02412150|BEHAVIORAL|Cough reflex|During recovery from anesthesia at operation room, cough reflex is measured and rated. \[Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)\]
215043430|NCT02412150|BEHAVIORAL|Ramsay Sedation Scale|"When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.~1. Awake Patient anxious and agitated or restless or both!~2. Patient cooperative, oriented and tranquil!~3. Patient responds to commands only!~4. Asleep A brisk response to a light glabellar tap or loud auditory stimulus!~5. A sluggish response to a light glabellar tap or loud auditory stimulus!~6. No response to a light glabellar tap or loud auditory stimulus"
215043431|NCT02412150|OTHER|Extubation time and Recovery time|"The time from discontinuing anesthetic gas to endotracheal extubation is measured.~And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured."
215043432|NCT02412150|BEHAVIORAL|Visual analogue scale|The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
215043433|NCT02412150|OTHER|Postoperative bleeding|The amount of postoperative bleeding which is collected in the barovac is measured.
215043434|NCT02412150|OTHER|Postoperative complications|Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
215043435|NCT02412150|OTHER|Time to remove drainage and duration of hospital staying|The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
214291693|NCT04296305|DRUG|Hydromorphone|Given IV after
214291694|NCT04296305|DRUG|Placebo Administration|Given IV after
214291695|NCT04296305|OTHER|Questionnaire Administration|Ancillary studies
214877411|NCT02960490|DRUG|E6011|subcutaneous administration
214877412|NCT02960490|DRUG|Placebo|subcutaneous administration
214877413|NCT00437359|DRUG|Toremifene citrate|Toremifene citrate: 40-mg tablets by mouth once daily.
214877414|NCT00437359|DRUG|Anastrozole|Anastrozole: 1-mg tablets by mouth once daily.
214877415|NCT00516152|DRUG|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis~* 7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 3 Fludarabine 30 mg/m(2)IV~* 2 REST Tacrolimus 0.01 mg/kg CIVI~* 1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~  * 1 Methotrexate 5mg/m(2)IV~ * 3 Methotrexate 5mg/m(2)IV~ * 6 Methotrexate 5mg/m(2)IV~ * 7 G-CSF 5mcg/kg SQ daily~ * 11 Methotrexate 5mg/m(2)IV~ * 90 Evaluate Response"
214877416|NCT01480362|DEVICE|Negative Pressure Wound Therapy|"Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations."
214877417|NCT01480362|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
214877418|NCT06357806|DRUG|Sintilimab|100mg/10ml/1bottle
214877419|NCT06357806|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
214877420|NCT06357806|DRUG|NAs|tablets
215043436|NCT02412150|DRUG|Dexmedetomidine|Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
215043437|NCT02412150|DRUG|Normal saline|Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
215043438|NCT02803905|BIOLOGICAL|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
215043439|NCT01918137|DIETARY_SUPPLEMENT|chocolate bar|
215043440|NCT01918137|DIETARY_SUPPLEMENT|Porridge|
215043441|NCT02972996|OTHER|Blueberry|22 g freeze-dried whole blueberry powder
215043442|NCT02972996|OTHER|Placebo|22 g placebo blueberry powder
215043443|NCT04265131|OTHER|art therapy|Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
215043444|NCT04655157|DRUG|encorafenib|A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.
215043445|NCT04655157|DRUG|nivolumab|A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.
215043446|NCT04655157|DRUG|ipilimumab|A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
215043447|NCT04655157|DRUG|binimetinib|A small molecule, selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
215043448|NCT02728024|OTHER|Missing items, Errors in Completion, Difficulties|
215043449|NCT04051177|BEHAVIORAL|"Interactive Communication with Openness, Passion, and Empowerment ICOPE"|"The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions."
215043450|NCT04051177|BEHAVIORAL|Nutrition Curriculum|"The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)"
215043451|NCT00335166|DRUG|Pardaprunox|12-42 mg
215043452|NCT00335166|DRUG|pramipexole|1.5-4.5 mg
215043453|NCT00335166|DRUG|Placebo Comparator|Placebo
215043454|NCT04534673|DRUG|Lambda 180 mcg S.C|Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7
214291696|NCT06126133|DEVICE|Near Infrared Spectroscopy|Two NIRS probes will be attached to the extremity to be operated on and to the other lower extremity on the opposite side, at a level approximately coinciding with the midline above the quandriceps femoris muscle.
214291697|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
214291698|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
214877421|NCT02971098|PROCEDURE|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
214877422|NCT02667067|DEVICE|Simplify Disc|Simplify Disc at one level in the cervical spine.
214877423|NCT02667067|DEVICE|Anterior Cervical Discectomy & Fusion|"This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®\|C Disc trial."
214877424|NCT00832156|BIOLOGICAL|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
214877425|NCT00843895|BIOLOGICAL|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
214877426|NCT02368314|DRUG|Sodium Enoxaparine|30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
214877427|NCT03791463|DRUG|salvianolic acid A|Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
214877428|NCT04550923|COMBINATION_PRODUCT|Z-Brace interbody fusion device|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
214877429|NCT04550923|COMBINATION_PRODUCT|PEEK interbody fusion device|Use rigid (PEEK) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
214877430|NCT01027338|OTHER|Tai chi exercise|
214877431|NCT05396235|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
214877432|NCT05396235|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
214877433|NCT05503511|DRUG|NPT 2042 (bumetanide analog) or Matching Placebo|Soft gelatin capsules
214877434|NCT02655705|DRUG|Cyclosporine A|Male 200 mg/day, Female 150 mg/day for 16 weeks
214877435|NCT02655705|DRUG|Methotrexate|Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
214877436|NCT05311579|COMBINATION_PRODUCT|Niraparib plus anlotinib|"Niraparib QD D1-21 plus Anlotinib 10mg QD D1-14 until disease progression or intolerable toxicity~21days/cycle"
214877437|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 (single treatment cycle)
214877438|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. on day 1 (single treatment cycle)
214877439|NCT01333397|DRUG|Placebo|I.M. on day 1 (single treatment cycle)
214877440|NCT03840187|DIAGNOSTIC_TEST|Digital cervicography|Colposcopist findings and digital cervicography employing Gynescope system
214877441|NCT02068703|BEHAVIORAL|Sleep Education Presentation|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
214877442|NCT02068703|BEHAVIORAL|Sleep Tool Demonstration|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
214877443|NCT03817541|DEVICE|Edmon (reg), BBraun|exhaled propofol will be compared With plasma propofol values
214877444|NCT02939625|DEVICE|muscle training|
214877445|NCT02939625|DEVICE|Continue Positive Airway Pressure|
214877446|NCT02939625|DEVICE|bilevel positive airway pressure|
214877447|NCT03957525|OTHER|Pre-Operative Preparatory Virtual Reality Program|The Influence of a Pre-Operative Preparatory Virtual Reality Program on the Self-Assessed Anxiety of Children Undergoing Elective Surgery
214877448|NCT02786225|BEHAVIORAL|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a VUMC perinatologist and a VUSN nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
214877449|NCT02786225|BEHAVIORAL|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
214877450|NCT03266939|DRUG|Lorcaserin|10 mg acute administration of lorcasein
214877451|NCT03266939|DRUG|Placebo Oral Tablet|Placebo
214877452|NCT05368116|OTHER|Video Assisted Self Management Program|"The main aim of this intervention is to educate the cancer patients receiving chemotherapy regarding the management of chemotherapy related side effects.~It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including nausea vomiting , Diarrhea , Fever , Mucositis , Skin changes , and Alopecia related distress.~The participants were given video when they comes to the Oncology day care and researcher instructs the participants to watch the video and at the same time the doubts asked by the participants were cleared by the researcher."
214877453|NCT05368116|OTHER|Standard of care|Standard of care
214877454|NCT01085357|PROCEDURE|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
214291699|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
214877455|NCT01085357|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
214877456|NCT00004757|DRUG|acyclovir|
214877457|NCT05489614|DRUG|Olpasiran|Participants will receive olpasiran by subcutaneous (SC) injection.
214877458|NCT00796055|DRUG|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
214877459|NCT03100123|DRUG|Aspirin 81 mg|Aspirin 81 mg po daily in tablet form.
214877460|NCT03100123|DRUG|Low-molecular-weight heparin|The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
214877461|NCT00435812|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24
214877462|NCT00435812|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4, and Week 24
214877463|NCT04637555|DRUG|sacubitril/valsartan|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
214877464|NCT01439412|PROCEDURE|Acupuncture and standard treatment|"This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.~In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.~The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes."
215043455|NCT06077877|DRUG|GSK4524101|GSK452101 will be administered.
214877465|NCT01439412|OTHER|Standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
215043456|NCT06077877|DRUG|Niraparib|Niraparib will be administered.
215043457|NCT01273571|DRUG|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
215043458|NCT03368066|DRUG|Cosyntropin|Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
214877466|NCT03957850|BEHAVIORAL|Cognitive Reappraisal Training|The training procedure is adapted from a study by Denny \& Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.
214877467|NCT03957850|BEHAVIORAL|Control Training|The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
214877468|NCT05301595|PROCEDURE|TAP block|Please see description of TAP block group.
214877469|NCT05301595|PROCEDURE|QL Block|Please see description of QL block group.
214877470|NCT00003643|BIOLOGICAL|bleomycin sulfate|
214877471|NCT00003643|BIOLOGICAL|filgrastim|
214877472|NCT00003643|DRUG|cisplatin|
214877473|NCT00003643|DRUG|etoposide|
214877474|NCT00003643|DRUG|paclitaxel|
214877475|NCT00378495|DRUG|Miltefosine: initially 2.5 mg/kg/day for 28 days|
215043459|NCT05407103|OTHER|Cold Acupressure|For the cold acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the cold acupressure pouches were kept in a freezer for 40 minutes.
215043460|NCT05407103|OTHER|Warm Acupressure|For the warm acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the warm acupressure pouches were heated in a microwave at 600 W for one minute.
214877476|NCT04082338|BEHAVIORAL|VPN|"The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period."
214877477|NCT04082338|BEHAVIORAL|TM|Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
214877478|NCT00034138|DRUG|oregovomab|
214877479|NCT06463522|PROCEDURE|Autologous Tumor-infiltrating Lymphocytes|Autologous Tumor-infiltrating Lymphocytes, 2.0\*10\^7/Kg, single intravenous infusion.
215043461|NCT03961308|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
215043462|NCT04561856|DRUG|Dexamethasone|Intravenous 4mg
214877480|NCT06070558|DEVICE|MRI with Real Time MRI Rapid Flash sequence|MRI examination of temporomandibular joint with Real Time MRI Rapid Flash sequence
214877481|NCT03669224|OTHER|Nano Care Gold|Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
214877482|NCT03669224|OTHER|No intervention|No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
214877483|NCT03669224|OTHER|Chlorhexidine|2 % chlorhexidine gluconate. This group will be compared with no intervention group.
214877484|NCT03776916|OTHER|Simethicone administration 20-30 min before the procedure|Patients intake simethicone 20-30 min before the procedure
214877485|NCT03776916|OTHER|Simethicone administration 31-60 min before the procedure|Patients intake simethicone administration 31-60 min before the procedure.
214877486|NCT03776916|OTHER|Simethicone administration > 60 min before the procedure|Patients intake simethicone administration \> 60 min before the procedure.
215043463|NCT04561856|DRUG|Dexamethasone|Perineural 4mg
215043464|NCT04561856|DRUG|Placebo|Normal Saline 2ml
215043465|NCT05690425|DRUG|BC3402 Injection|Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.
215043466|NCT00000857|DRUG|Interleukin-12|
215043467|NCT00894595|BEHAVIORAL|Knäkontroll, SISU Idrottsböcker©, Sweden, 2005|The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
215043468|NCT03150537|BIOLOGICAL|Fluviral influenza vaccine|Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection
215043469|NCT06008977|OTHER|Exercise Test|Supervised pedaling on an ergometer (stationary bike) at a moderate pace for a goal of 30 minutes. The exercise test will be scheduled at infusion visits 1, 6, and 12 or 1 and 3 over the treatment cycle, depending on the group assignment.
215043470|NCT03703505|DRUG|AG-348|120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled \[14C\]AG-348.
215043471|NCT03703505|DRUG|[13C6]AG-348|IV microdose of approximately 100 micrograms (mcg), single dose.
214291700|NCT01370174|OTHER|Physical Training Interventions|Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
214291701|NCT04862845|DRUG|Duloxetine and Pregabalin|will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.
214877487|NCT06469502|PROCEDURE|Stretching Exercises|Group 1 will be included in the program consisting of stretching exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of stretching exercises (3 times a week) under the supervision of a physiotherapist.
214877488|NCT06469502|PROCEDURE|Strengthening Exercises|Group 2 will be included in the program consisting of strengthening exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of strengthening exercises (3 times a week) under the supervision of a physiotherapist.
214877489|NCT00039702|DRUG|[123] 5-I-A-85380|
214877490|NCT00469664|DRUG|Guanfacine/Tenex|
215043472|NCT03872115|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
215043473|NCT04443088|DRUG|INV-1120|INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.
215043474|NCT04443088|COMBINATION_PRODUCT|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.
215043475|NCT05172297|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
215043476|NCT03659825|DIETARY_SUPPLEMENT|Ketone Ester|Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
215043477|NCT03659825|DIETARY_SUPPLEMENT|Taste Matched Placebo|Placebo that tastes similar to active intervention
214877491|NCT01044121|OTHER|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
214877492|NCT05019443|DEVICE|Wedge Scoring Balloon|Scoring balloon
214877493|NCT05019443|DEVICE|Conventional Balloon|Conventional balloon
214877494|NCT02211443|BIOLOGICAL|Recombinant full human Anti-EGFR Monoclonal Antibody|
214877495|NCT01654003|OTHER|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
215043478|NCT03659825|OTHER|Hypoxic exposure|Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
215043479|NCT00713193|DRUG|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
215043480|NCT00713193|DRUG|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
215043481|NCT01143636|DEVICE|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
215043482|NCT03131193|OTHER|Physician|Study primary health centers will be staffed with an additional physician
214877496|NCT01654003|OTHER|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
214877497|NCT02029196|OTHER|E-vapour product|Smokers of conventional cigarettes who switch to use an e-vapour product.
214877498|NCT02029196|OTHER|Conventional cigarette|Smokers of conventional cigarettes who continue smoking conventional cigarettes.
215043483|NCT03131193|OTHER|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
215043484|NCT03131193|BEHAVIORAL|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
215043485|NCT04815174|OTHER|Standard of Care|(i) advanced clinical and biological monitoring system (ii) symptomatic treatment adapted to the patient's needs, such as antibiotic therapy, oxygen therapy and blood transfusion; (iii) dialysis or mechanical ventilation.
215043486|NCT01044719|DRUG|Ceftazidime|Ceftazidime 2g TDS IV
215043487|NCT01044719|DRUG|Tobramycin|Tobramycin 7mg/kg/day OD IV
215043488|NCT01044719|DRUG|Meropenem|Meropenem 2g TDS IV
215043489|NCT02227745|DRUG|Dorzolamide hydrochloride (2%)|"Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed"
214877499|NCT05567770|DRUG|Actinium-J591|Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
214877500|NCT05567770|RADIATION|Stereotactic Body Radiation Therapy|Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
215043490|NCT02227745|DRUG|Placebo Sodium hyaluronate 4mg|"Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed."
215043491|NCT05773469|OTHER|Exercise|Ski traverse of Greenland polar Icecap
215043492|NCT05773469|OTHER|Nutrition|Maximising energy intake by consuming over the theoretical 2.4 x RMR
215043493|NCT01174563|DRUG|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
215043494|NCT00020748|DRUG|epirubicin hydrochloride|
215043495|NCT00020748|DRUG|irinotecan hydrochloride|
215043496|NCT02427932|DRUG|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
215043497|NCT02427932|DRUG|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
215043498|NCT02427932|DRUG|Gentamicin|Prescribed to non-pregnant participants
215043499|NCT01761149|DRUG|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
215043500|NCT04670484|OTHER|Wearing Mask|Participants wearing masks as per federal guidelines to prevent Coronavirus spread
215043501|NCT01395745|DRUG|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
215043502|NCT01395745|DRUG|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
215043503|NCT03402841|DRUG|Olaparib|300 mg twice daily - oral
215043504|NCT01198665|DRUG|RAD001 (Everolimus)|Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks
215043505|NCT03174067|DRUG|Buprenorphine|The participant receives buprenorphine
215043506|NCT03174067|DRUG|Clonidine|The participant receives clonidine
215043507|NCT00178009|BEHAVIORAL|self-paced instruction|Patients and caregivers review a DVD as often as they wish on how to care for routine and emergency procedures associated with their artificial heart
214291702|NCT04862845|DRUG|pregabalin|received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.
214877501|NCT05567770|DRUG|Androgen Deprivation Therapy|Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
214877502|NCT04537832|OTHER|No Intervention|No Intervention
215043508|NCT00309283|DRUG|Long-acting somatostatin|Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
215043509|NCT00309283|OTHER|Saline solution|Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
214291703|NCT04862845|DRUG|sham|received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
214877503|NCT03579342|BEHAVIORAL|App-technology and active coaching to improve lifestyles behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
214877504|NCT03579342|BEHAVIORAL|App-technology to improve lifestyle behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
214877505|NCT04223375|BEHAVIORAL|Nutrition Training|Postpartum women were educated on postpartum healthy and regular nutrition.
215043510|NCT01347060|DRUG|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
215043511|NCT01347060|DRUG|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
215043512|NCT06171061|DRUG|Yangxinshi tablet|In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
215043513|NCT06171061|OTHER|Basic medication|The control group will be given basic medication only. The treatment period is 24 weeks.
215043514|NCT02666560|DEVICE|Auditory Cueing|Auditory cueing set at different frequency rates
215043515|NCT00100425|PROCEDURE|Viceral Perception Testing|
215043516|NCT00293176|DRUG|Donepezil Hydrochloride|Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
215043517|NCT00293176|DRUG|Placebo|Subjects will receive matching placebo tablets.
215043518|NCT05358002|PROCEDURE|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
215043519|NCT01737892|DRUG|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
215043520|NCT01737892|DRUG|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
214877506|NCT02658799|DRUG|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
214877507|NCT02658799|DRUG|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
214877508|NCT00905671|DEVICE|LipiScan Coronary Imaging Catheter|Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
214877509|NCT03790371|DRUG|Misoprostol|vaginal misoprostol prior IUD insertion
214877510|NCT03790371|DRUG|Placebos|vaginal placebo tablet prior IUD insertion
215043521|NCT03732755|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
215043522|NCT00006379|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
215043523|NCT00006379|BIOLOGICAL|graft-versus-tumor induction therapy|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
215043524|NCT00006379|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
215043525|NCT00006379|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
215043526|NCT00006379|PROCEDURE|peripheral blood stem cell transplantation|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
215043527|NCT00645502|DRUG|risperidone|
215043528|NCT01542788|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
215043529|NCT01542788|DRUG|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
215043530|NCT01542788|DRUG|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
215043531|NCT01542788|DRUG|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
215043532|NCT02112084|BEHAVIORAL|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
215043533|NCT03315585|DEVICE|steep pulse device|Applying the steep pulse to treat the patients with Prostate cancer
215043534|NCT05572294|BEHAVIORAL|Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy|Sickle cell patients admitted with a vaso-occlusive pain crisis over a consecutive 12-week period will be offered participation in the study. After providing informed consent, participants will have access to 4 videos containing guided mindfulness meditation, breathing exercises, and gentle yoga therapy. The videos are 5-12 minutes long and taught by a physical therapist who is also certified in yoga therapy. Participants may turn off the video at any time. Participants will have access to the videos for the duration of their hospitalization, and they may watch the videos as many times as they desire.
215043535|NCT02972307|OTHER|wheelchair skills|the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
214877511|NCT02052193|DRUG|Dabrafenib|Measurement of toxicity related to UV exposure
214877512|NCT02052193|DRUG|Vemurafenib|Measurement of toxicity related to UV exposure
215043536|NCT05781581|OTHER|no intervention|no intervention
215043537|NCT03419182|PROCEDURE|Open Reduction internal Fixation|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture.
215043538|NCT03419182|PROCEDURE|Open Reduction Internal Fixation with Total Hip Arthroscopy|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture, and replaces the cartilage and bone of the greater trochanter with prosthetic components.
215043539|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Auditory Training|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
215043540|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Control Condition|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The control condition will be subjects watching a silent movie for 20 min during active tDCS stimulation.
214877513|NCT01679509|PROCEDURE|Single-port laparoscopic adnexal surgery|
214877514|NCT01679509|PROCEDURE|Three-port laparoscopic adnexal surgery|
214877515|NCT02289456|DRUG|nab-Paclitaxel|
214877516|NCT02289456|DRUG|Carboplatin|
214877517|NCT05511311|PROCEDURE|Resistance Training|Resistance training developed by the researcher (SCR-RSCM) for 12 weeks
214877518|NCT05511311|PROCEDURE|Standard Therapy|Standard therapy for 12 weeks
214877519|NCT00019240|DRUG|cidofovir|
214877520|NCT04682925|OTHER|skin care arm of where evidence-based practices in the implementation guide|"1. The nasal mucosa and nasal skin under the nasogastric tube will be cleaned and dried twice a day with a pH-compatible cleanser.~2. A water-based moisturizing cream will be applied to the nasal skin under the nasogastric tube twice a day, after care with a pH-compatible cleanser.~3. Spray skin barrier will be applied twice a day after applying water-based moisturizing cream to the nasal skin under the nasogastric tube.~4. The nasal mucosa and nasal skin under the nasogastric tube will be evaluated twice daily for signs of pressure-related injury. All these care interventions applied to the skin care arm will be applied together with the doctor and nurse responsible for the treatment and care of the patient."
214877521|NCT04682925|DEVICE|hydrocolloid (Convatec Granuflex-extra thin) dressing|The nasal skin of the patients and the surrounding skin will be cleaned with a pH-compatible cleaner, dried and a new hydrocolloid cover will be applied once a day. All these care interventions applied to the hydrocolloid dressing arm will be applied together with the physician and nurse responsible for the treatment and care of the patient.
214877522|NCT04682925|OTHER|control|In routine care, the skin under the nasogastric tube is evaluated once a day for redness and wound formation by the nurse responsible for the patient's care and is cleaned and dried with appropriate cleaners.
214877523|NCT06582186|DRUG|Individualization of first voriconazole maintenance doses|Individualization of first voriconazole maintenance doses
214877524|NCT03743155|BIOLOGICAL|mesenchymal cells|Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
214877525|NCT01767324|DEVICE|Injection to deltoid|Deliver 0.5 milliliters of saline intradermally
214877526|NCT01767324|DEVICE|Injection to forearm|Deliver 0.5 milliliters of saline intradermally
214877527|NCT01767324|DEVICE|Injection to thigh|Deliver 0.5 milliliters of saline intradermally
214877528|NCT04594824|OTHER|No Intervention|no intervention
214877529|NCT02796638|DEVICE|Adaptive Servo-Ventilation|A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
214877530|NCT00030225|BIOLOGICAL|ELAD|
214877531|NCT00030225|OTHER|Standard of care (Control)|
214877532|NCT02279108|DRUG|indocyanine green|One injection, 2.5 milligrams per patient, intradermal use
214877533|NCT02279108|DRUG|isotope|One injection, 20 MBq techntium99, intradermal use
214877534|NCT00920790|BIOLOGICAL|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
214877535|NCT01148615|DRUG|Aflibercept (AVE0005)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214877536|NCT01148615|DRUG|Docetaxel (XRP6976)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214877537|NCT03885115|BEHAVIORAL|Intervention|Involves 12-weeks of education related to healthy behaviors, nutrition, and exercise from certified fitness instructors.
214877538|NCT00143871|DRUG|Rituximab|
214877539|NCT03375177|OTHER|Natural history of disease|registry plan
214877540|NCT03672253|DRUG|CAR-T Re-treatment|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
214877541|NCT03637387|DRUG|BIIB074|Administered as specified in the treatment arm
214877542|NCT03637387|DRUG|Placebo|Administered as specified in the treatment arm.
214877543|NCT02567877|PROCEDURE|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
214877544|NCT02567877|DRUG|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
214877545|NCT01661062|OTHER|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
214877546|NCT01013662|PROCEDURE|glycemic control|exogenous insulin
214877547|NCT02997748|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
214877548|NCT04411914|DRUG|Clavulanic Acid|Drug will be given in 250mg capsules.
214877549|NCT04411914|OTHER|Placebo|Placebo
214877550|NCT00824343|DRUG|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
214877551|NCT04410614|PROCEDURE|Free epithelial (gingival) graft|1mm thickness epithelial layer harvested from the palate (1st molar area) is grafted and stabilised at the dental or implant area deficient of keratinized mucosa
214877552|NCT01375179|DRUG|KRP203|
214877553|NCT01375179|DRUG|Placebo matching KRP203|
214877554|NCT03028116|BIOLOGICAL|influenza vaccine|"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."
214877555|NCT03028116|BIOLOGICAL|Placebo|water for injection
214877556|NCT01581125|BEHAVIORAL|Sleep:wake 1|Sleep and Wake durations for arm 1
214877557|NCT01581125|BEHAVIORAL|Sleep:wake 2|Sleep and Wake durations for arm2
215043541|NCT03537703|COMBINATION_PRODUCT|Sham tDCS + Auditory Training|Sham tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 1 min with the current then slowly ramped down to 0 amps over the course of another minute. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
215043542|NCT02092714|OTHER|laboratory biomarker analysis|Correlative studies
215043543|NCT04069988|BEHAVIORAL|Baduanjin program|This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
215043544|NCT05772871|DRUG|Huaiqihuang granule|Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
215043545|NCT05772871|DRUG|Prednisone|Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
215043546|NCT05772871|DRUG|Levamisole placebo|Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
215043547|NCT05772871|DRUG|Levamisole|Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
214877558|NCT01778634|DRUG|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
214877559|NCT01778634|DRUG|Placebo|D5W
214877560|NCT05456958|OTHER|MRI Biofeedback|We will use state-of-the-art fMRI and neurofeedback of brain signals in order to teach patients with PTSD to self-regulate pathological brain activity that is associated with their symptoms. Indeed, feedback information is crucial for learning, where rt-fMRI-based neurofeedback makes information about brain activity accessible to our consciousness (Ros et al., 2014; Sitaram et al., 2017). It thus provides a reinforcement signal to induce personalized learning mechanisms, allowing individuals to search for appropriate cognitive strategies to voluntarily control brain activity. The feedback signal will come from activity within either the amygdala or PCC.
214877561|NCT05456958|OTHER|Sham-MRI Biofeedback|In the sham-control arm (N=20), individuals will receive fake neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
214877562|NCT02876718|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
214877563|NCT03944824|OTHER|Exercise Plan using resistance bands|Exercise under the guidance of an exercise physiologist using elastic resistance bands and weekly meeting with an exercise physiologist for 12 weeks
214877564|NCT03944824|DIAGNOSTIC_TEST|Modified Fried Frailty Scale|Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.
214877565|NCT05906524|DRUG|KD6001|KD6001 will be administered intravenously.
214877566|NCT05906524|DRUG|Tislelizumab|Tislelizumab will be administered intravenously.
214877567|NCT05906524|DRUG|Bevacizumab|Bevacizumab will be administered intravenously.
214877568|NCT00377832|DRUG|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
214877569|NCT01495078|PROCEDURE|Telemonitoring|"Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses."
214877570|NCT01504997|DEVICE|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
214877571|NCT04969731|DRUG|Immuncell-LC|IV
214877572|NCT04969731|DRUG|Gemcitabine|IV
214877573|NCT04048291|BEHAVIORAL|Brisk walking and balance training|6 months of combined brisk walking and balance training
214877574|NCT04048291|BEHAVIORAL|Upper limb exercise|6 month of hand dexterity training
214877575|NCT05198180|DRUG|Topical 30%Potassium hydroxide solution|Patients will apply the solution every day under occlusion for 3 months
214877576|NCT05198180|DRUG|Topical 45% hydrogen peroxide solution|Patients will apply the solution every day under occlusion
214877577|NCT03650530|OTHER|The Family Talk Intervention|The family meets two interventionists at six time points.
214877578|NCT06434974|OTHER|Interview|Interviewer administered questionnaire
214877579|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
214877580|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
214877581|NCT03555123|DRUG|Simdax|Levosimendan2.5mg/ml
214877582|NCT02166658|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
214877583|NCT02808416|BIOLOGICAL|Personalized cellular vaccine|"Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen mRNA pulsed cellular vaccines.~Other Names:~• Tumor antigen pulsed DC and PBMC, autologous tumor vaccine"
214877584|NCT06164262|OTHER|Individuals with CSVD|This does not entail the application of interventions.
214877585|NCT01035983|DRUG|Frovatriptan 2.5 mg|
214877586|NCT00895414|DRUG|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
214877587|NCT00895414|DRUG|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
214877588|NCT01229163|DEVICE|Automated Contingency Management (ACM) software|
214877589|NCT00252239|DRUG|tenecteplase|This study will compare 3 different doses of tenecteplase to tPA.
214877590|NCT00252239|DRUG|tissue plasminogen activator, tPA|To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
214877591|NCT06442306|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a cognitive-based education intervention that aims to change pain beliefs in patients experiencing CMP. Researchers have found PNE beneficial in assisting patients to reframe their understanding, attitudes, thoughts, and beliefs regarding their pain experience. PNE directs patients to relate chronic pain to overly sensitive nerves rather than assumed tissue damage. Further, PNE encourages patients to perform daily activities, work, and function in society, all despite pain. This facilitates behavior changes that are key in amending a patient's biopsychosocial state. Multiple sources make a strong case for the incorporation of PNE in having positive effects on reducing physical disability and modulating fear and anxiety in patients with CMP. Researchers have established a positive influence of PNE toward decreased kinesiophobia and have demonstrated a relation between increased self-efficacy and increased functional ability.
214877592|NCT06442306|OTHER|General Health Education|General Health Education included: 20 Benefits of Walking 30 Minutes a Day; Why You Should Quit: Smoking Cessation; Heat vs. Cold: How to Use it For Pain Control; Sleep Hygiene.
214877593|NCT04235361|DIAGNOSTIC_TEST|Differential RPA tests|The mobile diagnostic suitcases will be deployed at Ebola Treatment centres in DRC. Samples of patients refered for diagnostic testing will be tested by PCR by existing diagnostic teams, and will be additionally tested by the mobile suitcase laboratory using differential RPA tests for 6 parameters.
215043548|NCT05772871|DRUG|Huaiqihuang Granule placebo|Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
215043549|NCT04445948|DRUG|Esomeprazole 40 milligrams Oral Tablet|Proton Pump inhibitor
214877594|NCT00478426|DRUG|Sunitinib Malate|Given PO
214877595|NCT01216787|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
214877596|NCT01216787|OTHER|pharmacological study|
214877597|NCT01216787|PROCEDURE|therapeutic conventional surgery|
214877598|NCT01216787|OTHER|laboratory biomarker analysis|Correlative studies
214877599|NCT05572671|BEHAVIORAL|Laboratory task modeling smoking lapse behavior|Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.
214877600|NCT02288156|DRUG|Capsaicin|via nasal spray
214877601|NCT02288156|DRUG|placebo|via nasal spray
214877602|NCT03251235|BEHAVIORAL|Cognitive Behaviour Therapy|
214877603|NCT02950818|BEHAVIORAL|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
214877604|NCT05354635|OTHER|Antibiotics Dosing|Dosing concerns the main antibiotics used in the unit: b-lactams, linezolid, vancomycin and aminosides
214877605|NCT03489109|BEHAVIORAL|Intermittent fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet
214877606|NCT03489109|OTHER|Standard of Care|Subject will receive standard of care recommendations for healthy diet and lifestyle
214877607|NCT04147923|DIETARY_SUPPLEMENT|Floradapt Mature Immune Defense + Multivitamin|The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of \>1 x 10\^9 CFU. Participants will also consume a multivitamin.
214877608|NCT04147923|DIETARY_SUPPLEMENT|Placebo + Multivitamin|No active ingredients + a multivitamin supplement
214877609|NCT06201429|DEVICE|Mechanical Tissue Resuscitation (MTR™)|Mechanical Tissue Resuscitation (MTR™) to externally drain excess fluid volume from the site of surgery in patients who have undergone a surgical procedure (craniotomy/craniectomy) for which a portion of the skull has been removed resulting in exposure of the dura/brain and require drainage of fluid.
214877610|NCT06111352|DRUG|Pralidoxime|Inj. Pralidoxime 1 gm I/V will be given as first dose over 10-20 minutes. If no improvement of muscle weakness, then repeat the dose after one hour. Then 1 gram of Inj. Pralidoxime will be given at an 8-hour interval
215043550|NCT04445948|DRUG|Amoxicillin 1000 milligrams tablets|Penicillin derivative antibiotic
215043551|NCT04445948|DRUG|Clarithromycin 500 milligrams Tablets|Macrolide antibiotic
215043552|NCT04445948|DRUG|MetroNIDAZOLE 500 milligrams Oral Tablet|Antiprotozoal
215043553|NCT04445948|DRUG|Lactoferrin Bovine sachets 200 milligrams|a protein found naturally in milk from humans and cows
214877611|NCT06111352|DRUG|Atropine|Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
214877612|NCT03471000|OTHER|Short implants Treatment|Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
215043554|NCT06652295|OTHER|Complex decongestive physiotherapy (CDP)|CDP consists of patient education, manual lymph drainage, short traction bandaging, skin/nail care and exercise. The applications of all modalities of the CDP programme were performed by the physiotherapist.
214877613|NCT03471000|OTHER|Regular implants Treatment|Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
214877614|NCT02181790|DEVICE|Excimer laser|twice weekly treatments with the excimer laser for a total of 8 weeks.
214877615|NCT02181790|DRUG|Acitretin|17.5mg/d
214877616|NCT01005277|OTHER|Laboratory Biomarker Analysis|Correlative studies
214877617|NCT00927732|DRUG|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
214877618|NCT00927732|DRUG|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
214877619|NCT05255796|PROCEDURE|one-piece|Patients underwent phacoemulsification cataract surgery with one-piece IOL implantation.
214877620|NCT05255796|PROCEDURE|plate-haptic|Patients underwent phacoemulsification cataract surgery with plate-haptic IOL implantation.
214877621|NCT03107247|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
214877622|NCT03696238|DIETARY_SUPPLEMENT|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
214877623|NCT03696238|OTHER|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
214877624|NCT01323751|DRUG|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
214877625|NCT02493192|DRUG|pethidine and haloperidol injection|
214877626|NCT02493192|OTHER|birth ball|
214877627|NCT04785755|DRUG|Oral standard diuretics therapy|Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
215043555|NCT06652295|OTHER|Self-administered Complex Decongestive Physiotherapy (CDP)|The self-administered CDP programme consisted of patient education, self-manual lymph drainage, self-short traction bandage application, self-skin/nail care and exercise. Participants were given one session of patient education before the self-administered CDP programme and patients were given practical information about all applications. Additionally, each component of the self-administered CDP programme was presented to the participants with a patient booklet and a video prepared by the researchers. Patients in the self-CDP group were followed up once a week with a patient follow-up diary.
215043556|NCT02181920|DRUG|Metamizole|
214877628|NCT04785755|DRUG|Hypertonic saline solution|Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
214877629|NCT04785755|DRUG|Etilefrine|Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
214877630|NCT03047434|OTHER||
214877631|NCT01741883|BEHAVIORAL|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
214877632|NCT01741883|BEHAVIORAL|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
214877633|NCT01617252|DEVICE|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
214877634|NCT04655430|OTHER|3-second SDF application|Dosage: 3-second 38% SDF solution application
214877635|NCT04655430|OTHER|5-second SDF application|Dosage: 5-second 38% SDF solution application
215043557|NCT02181920|DRUG|Diclofenac|
215043558|NCT02181920|DRUG|Diclofenac placebo|
215043559|NCT02181920|DRUG|Metamizole placebo|
215043560|NCT04692389|DEVICE|Jalosome soothing gel|This study has not got other intervention
215043561|NCT01280968|BIOLOGICAL|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
215043562|NCT01280968|BIOLOGICAL|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
215043563|NCT00097279|DRUG|biphasic insulin aspart|
214877636|NCT04655430|OTHER|10-second SDF application|Dosage: 10-second 38% SDF solution application
214877637|NCT04655430|OTHER|15-second SDF application|Dosage: 15-second 38% SDF solution application
214877638|NCT04655430|OTHER|30-second SDF application|Dosage: 30-second 38% SDF solution application
214877639|NCT04655430|OTHER|45-second SDF application|Dosage: 45-second 38% SDF solution application
214877640|NCT04655430|OTHER|60-second SDF application|Dosage: 60-second 38% SDF solution application
214877641|NCT04655430|OTHER|120-second SDF application|Dosage: 120-second 38% SDF solution application
214877642|NCT04655430|OTHER|180-second SDF application|Dosage: 180-second 38% SDF solution application
214877643|NCT01178216|BIOLOGICAL|Rituxan|Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
214877644|NCT00025259|BIOLOGICAL|Bleomycin Sulfate|Given IV or SC
215043564|NCT00097279|DRUG|pioglitazone|
214877645|NCT00025259|DRUG|Cisplatin|Given IV
214877646|NCT00025259|DRUG|Cyclophosphamide|Given IV
214877647|NCT00025259|DRUG|Cytarabine|Given IV
214877648|NCT00025259|DRUG|Dexamethasone|Given IV
214877649|NCT00025259|DRUG|Doxorubicin Hydrochloride|Given IV
214877650|NCT00025259|DRUG|Etoposide|Given IV
215043565|NCT00097279|DRUG|metformin|
215043566|NCT03890510|OTHER|Ringer's Lactate solution|Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.
215043567|NCT03890510|PROCEDURE|Spine surgery under general Anesthesia in the prone position|The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.
215043568|NCT00557037|DRUG|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
215043569|NCT03540680|OTHER|Blood punction|"For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood."
214877651|NCT00025259|BIOLOGICAL|Filgrastim|Given SC
214877652|NCT00025259|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
214877653|NCT00025259|DRUG|Prednisone|Given orally
214877654|NCT00025259|DRUG|Vincristine Sulfate Liposome|Given IV
214877655|NCT02029157|DRUG|ARQ197|
214877656|NCT02029157|DRUG|Placebo|
214877657|NCT00863772|BIOLOGICAL|tanezumab|5 mg dose Intravenously every 8 weeks for duration of study
214877658|NCT00863772|BIOLOGICAL|tanezumab|10 mg dose Intravenously every 8 weeks for duration of study
214877659|NCT00863772|OTHER|Placebo|Placebo, Intravenously, every 8 weeks for duration of study
214877660|NCT06633770|DIAGNOSTIC_TEST|proclcitonin and presepsin|"All included patients will be subjected to:~* laboratory investigations~  * Complete Blood Count (CBC),~ * Liver Function Test(LFT) ( ALT,AST, Billirubin, total protein and albumin)~ * Kidney function test (KFT) ( Urea and creatinine)~ * Random Blood Glucose (RBG).~ * Erythrocyte Sedimentation Rate(ESR )~ * Urine analysis -A special investigations include (blood culture, C Reactive protein (CRP), proclcitonin and presepsin)."
214877661|NCT01449370|DRUG|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
214877662|NCT01883349|PROCEDURE|Kidney Transplant|Kidney Transplant Surgery
214877663|NCT01883349|OTHER|No kidney transplant|The control group was made up of subjects without ESRD and were not on the renal transplantation waitlist.
214877664|NCT03864887|PROCEDURE|Oxygen supply of high-low-high procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).
214877665|NCT03864887|PROCEDURE|Oxygen supply of low-high-low procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).
214877666|NCT03864887|DEVICE|Optical monitor for hemodynamic parameter.|Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
214877667|NCT03616717|DRUG|Modafinil|"Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil"
214877668|NCT03616717|DRUG|placebo|Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
214877669|NCT02722915|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
215043570|NCT02987738|DRUG|Dapagliflozin|two administrations in the evening and 12 hours later
215043571|NCT02987738|DRUG|Placebo Oral Tablet|two administrations in the evening and 12 hours later
215043572|NCT00001066|DRUG|Lamivudine|
215043573|NCT00001066|DRUG|Zidovudine|
215043574|NCT00001066|DRUG|Didanosine|
215043575|NCT03688971|DRUG|Omiganan|Omiganan Topical Gel
215043576|NCT03688971|DRUG|Ketoconazole|Ketoconazole Cream
214877670|NCT02722915|BEHAVIORAL|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 \& 4; controls without AVH: Days 2 \& 3)
214877671|NCT02722915|OTHER|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
214877672|NCT02722915|OTHER|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
214877673|NCT02722915|OTHER|SF36|questionnaire about life quality after 1 week during a telephone interview
214877674|NCT00769938|DEVICE|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
214877675|NCT00908310|DRUG|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
214877676|NCT02607267|OTHER|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
214877677|NCT06611280|OTHER|No Interventions|No delivered intervention.
214877678|NCT04854889|DRUG|Decitabine|Demethylating agents
214877679|NCT03423186|DRUG|SOBI003|Weekly i.v.infusion
214877680|NCT05343546|DEVICE|Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion|"Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion within seven days of giving Misoprostol Early insertion or 2-4 weeks after Misoprostol use Standard insertion"
214877681|NCT04792424|OTHER|Regional citrate anticoagulation|Starting RCA 4 mmol/L (adjust the rate by BFR)
214877682|NCT04792424|DRUG|Vasopressor|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
214877683|NCT04792424|DRUG|Antibiotic|Antibacterial agents deemed appropriate by physicians in the ICU
214877684|NCT04792424|DEVICE|Dialysis with continuous renal replacement therapy|Prismaflex
214877685|NCT00564330|DRUG|Esomeprazole|20mg bid
214877686|NCT00564330|DRUG|Placebo|Placebo bid
214877687|NCT01888510|PROCEDURE|computed tomography|Undergo conventional free breathing CT
214877688|NCT01888510|PROCEDURE|4-dimensional computed tomography|Undergo 4D CT
214877689|NCT01888510|PROCEDURE|computed tomography|Undergo ABC CT
214877690|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo ABC CBCT
214877691|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo free breathing CBCT
214877692|NCT00464789|DRUG|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
214877693|NCT01709929|DRUG|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
214877694|NCT00534404|DRUG|Nicotine patches|Participants will wear nicotine patches.
214877695|NCT00534404|BEHAVIORAL|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
214877696|NCT00534404|BEHAVIORAL|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
214877697|NCT01898273|DRUG|I-124-CLR1404|single-dose, intravenous
215043577|NCT03688971|DRUG|Placebo|Vehicle
214877698|NCT01307748|OTHER|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
214877699|NCT02180737|DRUG|Dexmeditomedine|
214877700|NCT05421364|BIOLOGICAL|Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)|Approximately 9 ml blood from each patient will be collected on the day of the LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. PBMCs (1x106cells/ml) suspended in RPMI 1640 supplemented with 10% HSA will be incubated in the presence of 10 IU/ml hHCG for 48 h. On day 2 after LH peak, fresh PBMCs (1x107 cells) will be also obtained from the same patients, these fresh PBMCs will be immediately combined with the 2-day cultured PBMC and suspended in PBS (2x107 cells/200µl). This cell suspension will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak.
214877701|NCT06982430|OTHER|phone call|"Included patients were evaluated on day 7 after discharge from the ED through a telephone call.~This evaluation aimed to identify a recurrence of RC, defined as a NRS score greater than 3 within the 7 days following inclusion and/or a return visit for the same complaint"
214877702|NCT06982404|DIAGNOSTIC_TEST|Time Zero Donor Heart Biopsy for Molecular Analysis|"This intervention involves obtaining a right ventricular myocardial biopsy from the donor heart at the time of organ procurement (Time Zero), prior to transplantation. The biopsy is divided into two parts: one for routine histopathological evaluation and the other preserved in RNAlater® for molecular analysis using microarray technology. This molecular profiling is designed to detect early tissue injury and gene expression patterns associated with graft viability and transplant outcomes. The intervention is performed only once per donor and does not alter the standard clinical care of the recipient."
214877703|NCT06983587|RADIATION|Bone densitometry scan|"Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).~In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.~The total duration of the patient's participation in this research will be approximately 2 hours."
214877704|NCT06983535|DEVICE|cervical balloon catheter|Patients will be randomized to inpatient or outpatient setting while having the cervical ripening balloon catheter
215043578|NCT01627886|DRUG|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
214877705|NCT06982898|PROCEDURE|Fixed prosthesis with bimanual CR and intraoral scan|"Tooth-supported fixed prostheses were fabricated using centric relation records obtained by two different methods:~1. Bimanual manipulation technique, with jaw relation records captured using an intraoral scanner.~2. Neuromuscular deprogramming technique, with jaw relation records obtained using a jaw movement tracking and analysis device."
214877706|NCT02785952|BIOLOGICAL|Ipilimumab|Given IV
214877707|NCT02785952|OTHER|Laboratory Biomarker Analysis|Correlative studies
214877708|NCT02785952|BIOLOGICAL|Nivolumab|Given IV
214877709|NCT02785952|OTHER|Quality-of-Life Assessment|Ancillary studies
214877710|NCT02785952|OTHER|Questionnaire Administration|Ancillary studies
214877711|NCT01226394|PROCEDURE|laparotomy plus HIPEC|Laparotomy + HIPEC
214877712|NCT01363024|DRUG|MFGR1877S|Intravenous escalating dose
214877713|NCT04688905|DIAGNOSTIC_TEST|Invasive hemodynamics of left ventricle via conductance catheter at rest, with exercise and with temporary vena cava occlusion|Invasive hemodynamics of left ventricle will be done by the conductance method. Left ventricular stiffness constant will be obtained by temporary vena cava occlusion. Right heart catherization will be done by pulmonary artery catherization and cardiac output will be estimated by thermodilution and Fick´s method.
214877714|NCT02304133|OTHER|Education|
214877715|NCT01141855|DRUG|Champix|"Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days~1mb b.d. for 70 days (full course 3 months)"
214877716|NCT01141855|BEHAVIORAL|Counselling alone|Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
214877717|NCT06633185|DRUG|phenytoin cream|application of the cream after internal anal sphincterotomy versus non application.
214877718|NCT06633185|DRUG|no phenytoin cream|Non application of the phenytoin cream
214877719|NCT02793505|DRUG|metformin|This is not an intervention but an observed exposure.
214877720|NCT02793505|DRUG|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
214877721|NCT01026311|DRUG|Coenzyme q 10|200 mg of Coenzyme q 10
215043579|NCT03507725|BEHAVIORAL|Meditation|"The brief mind-body intervention, specifically developed for this study, is a combination of mindfulness meditation with a specific cognitive component of guided imagery. Patient intervention, they will be given headphones connected to an MP4 player in the clinic area to listen to a pre-biopsy mindfulness exercise (10 minutes). They will then be brought into the biopsy procedure room and given a second set of headphones, guiding the patient through the mindfulness intervention during the biopsy procedure (10 minutes)."
215043580|NCT03507725|PROCEDURE|Prostate Biopsy|Prostate needle biopsy under local anesthesia
214877722|NCT01026311|DRUG|placebo|1 placebo q d during treatment period
214877723|NCT04917471|DIETARY_SUPPLEMENT|Beet root juice|70 ml bid
214877724|NCT04917471|DIETARY_SUPPLEMENT|Placebo juice|70 ml bid
214877725|NCT04108026|DRUG|Durvalumab|1500 mg IV every 4 weeks
214877726|NCT02520297|DRUG|TRV130|Drug
214877727|NCT05351671|DRUG|RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at 10 mg/kg every 8 hours for total of 3 doses.
214877728|NCT05351671|DRUG|RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at a loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses.
214877729|NCT05351671|DRUG|Placebo (saline dosed every 8 hours for a total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of placebo (saline) dosed every 8 hours for a total of 3 doses.
214877730|NCT02895828|OTHER|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
214877731|NCT02895828|OTHER|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
214877732|NCT00111553|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
214877733|NCT06981923|DEVICE|CMAC D-Blade|Intubation will be performed using the CMAC D-Blade
214877734|NCT06981923|DEVICE|CMAC Video Stylet|Intubation will be performed using the CMAC Video stylet
214877735|NCT06981650|BEHAVIORAL|video|use of a video
214877736|NCT06981650|BEHAVIORAL|education|standard talk and paper handout
214877737|NCT06292403|OTHER|Strength Training|training time will be 30 minutes therapy, once a day, 3 days a week for 8 weeks. were allowed to rest for 3-5 min during each training.
214877738|NCT06292403|OTHER|Mirror therapy|Participants in the (trial group) mirror and strength training group observed the reflection of the exercising arm and leg in the mirror. Participants in the (control group) strength training only group will exercise without a mirror entirely.
214877739|NCT01741051|DEVICE|HEPA Filter|
214877740|NCT05671016|PROCEDURE|MRI scans and questionnaires|Extra baseline MRI scan performed and questionnaires (EORTC validated questionnaires involving EORTC QLQ C-30, EORTC BN20 and EORTC ELD14) to assess quality of life at baseline, 4 weeks and 8 weeks after treatment
214877741|NCT05700370|DIAGNOSTIC_TEST|MyProstateScore|MyProstateScore is a urine-based biomarker test used to predict the risk of clinically significant prostate cancer
214877742|NCT00062400|PROCEDURE|psychosocial assessment and care|
214877743|NCT02566356|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
214877744|NCT02566356|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
214877745|NCT00351533|DRUG|Fish oil (eicosapentaenoic acid and docosahexanoic acid)|Liquid fish oil 7.5cc enterally every 6 hours
214877746|NCT05795647|DRUG|Pentoxifylline+Tocopherol|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
214877747|NCT01321463|DRUG|PH-797804|6 mg oral tablet once daily for 12 weeks
214877748|NCT01321463|DRUG|Placebo|Placebo oral tablet once daily for 12 weeks
215043581|NCT03507725|BEHAVIORAL|Questionnaires|Questionnaires completion will be by telephone interview or manual completion of paper or online REDCap instruments, depending on participant preference.
215043582|NCT05262569|OTHER|ileus|retrospectively allocation according to a postoperative outcome-ileus
215043583|NCT00451230|DRUG|cocaine|
215043584|NCT00451230|DRUG|hydrocortisone|
215043585|NCT05231863|DRUG|TKIs|tyrosine kinase inhibitors based therapy
215043586|NCT00087217|DRUG|tanespimycin|Given IV
215043587|NCT00087217|DRUG|paclitaxel|Given IV
215043588|NCT00087217|OTHER|laboratory biomarker analysis|Correlative studies
215043589|NCT00087217|OTHER|pharmacological study|Correlative studies
214877749|NCT03564418|PROCEDURE|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|"Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points.~Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that the needle is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
214877750|NCT03564418|PROCEDURE|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|"Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that it is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
214877751|NCT05148390|DEVICE|Cutimed® Gelling Fiber|application of dressing
214877752|NCT01656538|DRUG|Paclitaxel|
214877753|NCT01656538|DRUG|Reolysin|
214877754|NCT05644600|DRUG|Nintedanib|The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
215043590|NCT06643273|OTHER|Robotic rehabilitation|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
215043591|NCT06643273|OTHER|Conventional rehabilitation|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
215043592|NCT02247128|DRUG|Aspirin + clopidogrel|
215043593|NCT02247128|DRUG|Aspirin monotherapy|
214877755|NCT05644600|DRUG|AZD5055|The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
214877756|NCT04297033|DRUG|Lovastatin|lovastatin 40mg/d 12m
214877757|NCT04297033|DRUG|Placebo|placebo
214877758|NCT00315731|BIOLOGICAL|Follicular Lymphoma|For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
215043594|NCT02247128|DRUG|OAC + clopicogrel|
215043595|NCT02247128|DRUG|OAC monotherapy|
214877759|NCT06457165|DEVICE|Difficult Intubation|Noted for each patient.
214877760|NCT06457165|DEVICE|Not Difficult Intubation|Noted for each patient.
214877761|NCT04614246|DRUG|BAY1817080|Tablet, oral administration
214877762|NCT04614246|DRUG|Elagolix|Tablet, oral administration
214877763|NCT04614246|DRUG|Placebo|Tablet, oral administration
214877764|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): No maintenance treatment."
215043596|NCT05411497|BIOLOGICAL|Autologous MUC1-activated T-cells|Given IV
215043597|NCT05411497|DRUG|Cyclophosphamide|Given IV
215043598|NCT01202084|DRUG|Formoterol/Fluticasone|
215043599|NCT01202084|DRUG|Foraseq®|
215043600|NCT01202084|DRUG|Fluticasone|
215043601|NCT04704193|OTHER|Survey of Decision Aid|The decision aid will be evaluated by a survey administered to those who have used the tool.
215043602|NCT04667156|DRUG|SHR6390|SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
215043603|NCT05181228|BEHAVIORAL|Web-Based Education Based on Family-Centered Empowerment Model|Parents in the intervention group will receive care for ten weeks using the family-centered empowerment model (FCEM). The first step (two weeks) is to increase knowledge. For this purpose, they will receive web-based training on cancer. The second step (four weeks) is to develop parents' self-efficacy and problem-solving skills. A web-based training and group meeting will be held to share information and experiences on the evaluation and control of the side effects of the treatment and to increase their self-efficacy in care. The third step (three week) was to increase self-esteem through participation in the training. At this stage, each participant will be asked to teach one of the family members responsible for the child's care what they have learned in the last two sessions. In the fourth step (one week), all participants in the intervention group will be evaluated by asking questions about the topics discussed in the second and third sessions and the overall content taught.
215043604|NCT00542178|DRUG|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
215043605|NCT00542178|DRUG|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
214877765|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab."
214877766|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy."
214877768|NCT01851200|DRUG|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
214877769|NCT01680497|DEVICE|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
214877770|NCT06084897|DRUG|TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.|"A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin."
214877771|NCT06084897|BIOLOGICAL|PD-1 inhibitor|Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab
214877772|NCT06084897|RADIATION|Consolidation Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66Gy/19f or 40Gy/20f for organ metastasis patients. Radiation treatment is planned after chemotherapy completed.
214877773|NCT06084897|RADIATION|Salvage Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66\~49.22Gy/19f \~23f or 40\~50Gy/20\~25f for organ metastasis patients. Radiation treatment is planned after disease progression when recommended by multidisciplinary team.
214877774|NCT00725205|BIOLOGICAL|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms \[mcg\]/killogram \[kg\]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
214877775|NCT00725205|DRUG|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
214877776|NCT04468516|DEVICE|KKT|Vibroacoustic sound waves applied focally.
214877777|NCT04468516|DEVICE|sham KKT|sham KKT
214877778|NCT05911880|BEHAVIORAL|Plant-based diet for 14 days in patients with rheumatoid arthritis.|Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.
214877779|NCT04990427|DRUG|CLBS201|1 x 10\^6 to 300 x 10\^6 autologous CD34+ cells
214877780|NCT00006630|DRUG|Vaccinia Immune Globulin (Human)|
214877781|NCT02777398|PROCEDURE|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
214877782|NCT02777398|PROCEDURE|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
214877783|NCT01229579|DRUG|Zinc Sulfate|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
214877784|NCT01229579|OTHER|Placebo|2.5 ml placebo syrup daily with containing no elemental zinc from day 14 to 18 weeks of age.
214877785|NCT03904589|DIAGNOSTIC_TEST|Quality of Life assessment|Quality of life will be assessed by means of the Seattle Angina Questionnaire and the Patient Health Questionnaire.
214877786|NCT01128608|PROCEDURE|24-Hr Esohpageal pH Monitoring|There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
214877787|NCT01128608|PROCEDURE|PCO2 Acid Perfusion and 0.1N HCI Perfusion|A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
214877788|NCT00125112|BEHAVIORAL|Internet-based intervention designed to reduce binge eating and improve healthy weight regulation|
215043606|NCT00542178|DRUG|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
215043607|NCT00542178|DRUG|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
215043608|NCT00542178|DRUG|Fenofibrate|Blinded fenofibrate
215043609|NCT00542178|DRUG|Simvastatin|Simvastatin 20-40 mg/d
215043610|NCT00542178|DRUG|Placebo|Placebo
215043611|NCT02281045|DEVICE|EVODIAL dialyzer and Selectbag citrate|Evodial is a trademark of Hospal-Gambro.
214877789|NCT02125721|DRUG|Tiopronin 1g per day|500mg PO BID x 7 days
214877790|NCT02125721|DRUG|Tiopronin 2g per day|1g PO BID x 7 days
214877791|NCT02125721|DRUG|Tiopronin 3g per day|1.5g PO BID x 7 days
215043612|NCT02281045|DEVICE|Regional citrate anticoagulation|Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
215043613|NCT01099488|PROCEDURE|Blood withdrawal|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
215043614|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
215043615|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
215043616|NCT06157593|PROCEDURE|NAVA|weaning from mechanical ventilator using neurally adjusted ventilatory assist
215043617|NCT01916473|OTHER|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
215043618|NCT01916473|OTHER|Continuous wound infusion|Continuous wound infusion via catheter
214877792|NCT03197181|DEVICE|transcranial direct current stimulation|Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
214877793|NCT02551484|DEVICE|Measurements using NIRS|
214877794|NCT02551484|DEVICE|TCPO2 measurements|
214877795|NCT02551484|OTHER|2-minute walk test|
214877796|NCT05322109|DIAGNOSTIC_TEST|CMR|Clinically indicated cardiac magnetic resonance tomography executed according to international guideline recommendations.
214877797|NCT05537636|OTHER|Rehabiltiation using exercise and manual therapy|"A licensed Physical Therapist will provide manual therapy to help restore spinal and scapular mobility. In association with this patients will be prescribed home exercises using a phased approach.~Phase 1 to gain mobility of the spine and scapular motor control Phase 2 to gain shoulder mobility to strengthen scapular and spine musculature Phase 3 shoulder strengthening with long lever arms."
214877798|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
214877799|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.
214877800|NCT05997732|DRUG|Norepinephrine Bitartrate|Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
214877801|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.
214877802|NCT05997732|DRUG|Phentolamine Mesylate|Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.
214877803|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.
214877804|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.
214877805|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.
214877806|NCT00431483|BEHAVIORAL|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
214877807|NCT01062711|DIETARY_SUPPLEMENT|Whey or soy protein|Whey and casein are isolated milk proteins
214877808|NCT06632912|BIOLOGICAL|2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Two doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0 and 6 months.
214877809|NCT06632912|BIOLOGICAL|3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Three doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0, 2, and 6 months.
214877810|NCT00996892|DRUG|Cobimetinib|Repeated oral dosing.
214877811|NCT00996892|DRUG|Pictilisib|Repeated oral dosing.
214877812|NCT01653912|DRUG|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
214877813|NCT01144247|DRUG|alloreactive CTL|cellular immunotherapy with alloCTL
214877814|NCT03309527|BEHAVIORAL|e-aid Cognitive Behavior Therapy|e-aid Cognitive Behavior Therapy
214877815|NCT03309527|BEHAVIORAL|e-aid Sleep Hygiene Education|e-aid Sleep Hygiene Education
215043619|NCT03449576|OTHER|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
215043620|NCT03449576|OTHER|Exposure Therapy with Psychotherapy group|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
215043621|NCT05629871|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
214877816|NCT06052280|OTHER|Telerehabilitation exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the TrE group will continue with prescribed self-training at home through telerehabilitation, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The TrE arm will be supported by a telerehabilitation device which will be installed and tested at the patients' home immediately after the outpatient intensive program. The device will track any access and exercise duration, so that the physiotherapists will be able to remotely monitor both the actual duration of each session and their weekly frequency. One session per week will be directly and online supervised by a physiotherapist, while the other two will be recorded only."
214877817|NCT06052280|OTHER|Home self-exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the HSE group will continue with prescribed self-training at home, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The HSE arm will be given a booklet containing detailed explanations and pictures of the assigned exercises, in order to guide them in the correct execution of the requested movements. Subjects in this group will be asked to fill in a training diary to keep track of the training sessions and their duration. Once a week a physiotherapist will contact patients to discuss possible problems encountered in performing the exercises and to help in solving them."
214877818|NCT03940625|DIAGNOSTIC_TEST|Cardiac MRI and echocardiography, laboratory parameters|Cardiac MRI including cine imaging (volumetric determination of LV-EF), late gadolinium enhancement, strain analysis, T1 mapping and T2 mapping Echocardiography including 3D-EF, diastolic function and strain analysis Determination of laboratory parameters including cardiac enzymes (Troponin T and high sensitivity Troponin T) and cardiac markers (BNP and NT-pro BNP)
214877819|NCT02171494|DRUG|IVAX Warfarin|
214877820|NCT02171494|DRUG|BMS Coumadin|
215043622|NCT05629871|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
215043623|NCT05629871|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
215043624|NCT05629871|PROCEDURE|Actimetry|Measurement of actimetrics for 14 days at inclusion and at 24 months
215043625|NCT05629871|DIAGNOSTIC_TEST|Fractional diuresis|Split diuresis from 7pm-7am, 7am-12am and 12pm-19pm during polysomnography at inclusion inclusion and 24 months to measure melatonin concentration
215043626|NCT05629871|PROCEDURE|Internal temperature measurement|eCelsius capsule to measure internal temperature at inclusion and 24 months
215043627|NCT05629871|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
214877821|NCT06246968|DRUG|Pembrolizumab|Participants will receive Pembrolizumab as part of standard of care treatment.
214877822|NCT06246968|DEVICE|Cryoablation|Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection.
214877823|NCT06484621|BEHAVIORAL|Acceptance and Commitment Therapy-Based Physical Activity Intervention|Provides experiential training in values-clarification and acceptance strategies to increase autonomous motivation for achieving self-determined physical activity goal via group-based workshops, email feedback, and brief support calls.
214877824|NCT06484621|BEHAVIORAL|Physical Activity Education Control|Provides didactic instruction on physical activity and behavioral strategies for achieving prescribed physical activity goals via group-based workshops, email feedback, and brief support calls.
214877825|NCT06490939|DRUG|Efepoetin Alfa|Single-intravenous administration
214877826|NCT03955978|DRUG|TSR-042|-TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
214877827|NCT03955978|RADIATION|Brachytherapy|-This trial will include image-guided brachytherapy with three-dimensional (3-D) treatment planning and in cases where pelvic radiation is deemed appropriate by the treating radiation oncologist, external beam radiation therapy (EBRT) using intensity modulated radiation therapy (IMRT) technique.
214877828|NCT03955978|PROCEDURE|Endometrial biopsy|-Prior to the start of treatment with TSR-042. If this biopsy yields insufficient tumor tissue, an archival sample may be requested, with Fraction 1 of brachytherapy, with Fraction 4 of brachytherapy
214877829|NCT03955978|PROCEDURE|Blood draw for immune response|-Prior to the start of any treatment, at the time of brachytherapy fractions 1 and 4 (corresponding to endometrial biopsy), prior to fourth dose of TSR-042, 6 weeks after the completion of all protocol related therapy
214877830|NCT00602641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214877831|NCT00602641|DRUG|Lenalidomide|Given PO
214877832|NCT00602641|DRUG|Melphalan|Given PO
214877833|NCT00602641|DRUG|Prednisone|Given PO
214877834|NCT00602641|OTHER|Quality-of-Life Assessment|Ancillary studies
215043628|NCT03518151|OTHER|Product placement intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
214877835|NCT00602641|DRUG|Thalidomide|Given PO
214877836|NCT06496828|PROCEDURE|Biologically-oriented preparation technique|The preparation will be made according to the new principles of biologically oriented technique to receive monolithic and bi-layered all-ceramic crowns.
214877837|NCT06496828|PROCEDURE|Conventional method of preparation|Teeth prepared with shoulder margins to receive monolithic and bi-layered all-ceramic crowns
214877838|NCT02181855|PROCEDURE|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
214877839|NCT03722589|BIOLOGICAL|Flublok|0.5 mL intramuscular dose of Flublok
214877840|NCT03722589|BIOLOGICAL|Flucelvax|0.5 mL intramuscular dose of Flucelvax
214291704|NCT05545254|GENETIC|genetic testing|Two questionnaires were included in the link, one referring to the demographic information, and another one involving the health-promoting lifestyle. In the demographic information, the genetic test results were not requested to be written, but the participants need to answer whether they understand the results. The HPLP-Ⅱ is an scale instrument used to evaluate a person's health-promoting lifestyle behaviors, which contains 52 items and has been translated into Chinese in 1997. It contains 6 subscales: self-actualization, health responsibility, physical activity, nutrition, interpersonal relationships and stress management.
214666810|NCT04945993|DEVICE|Endomethasone N|Endomethasone N is a powder intended to be mixed extemporaneously with a eugenol-based liquid (i.e, Endomethasone Liquid) to obtain a permanent root canal sealer. After selection of dentists, they will screen consecutively and systematically eligible patients, will send them the Patient Information Letter and will enroll them in the clinical investigation if non opposition from the patient. Patient clinical data will be recorded in an electronic Case Report Form. Pseudonymized retro-alveolar radiographies at baseline consultation and at 5 and 10 years post-obturation consultations will be recorded in the e-CRF. These radiographies will be examined by 2 independent endodontists and the results of these examinations will be recorded in the e-CRF. Site data will be collected on a Site Questionnaire with Visual Analog Scales.
214666811|NCT00304590|DRUG|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
214877841|NCT03722589|BIOLOGICAL|Fluarix|0.5 mL intramuscular dose of Fluarix
214877842|NCT03722589|BIOLOGICAL|Fluzone|0.5 mL intramuscular dose of Fluzone
214877843|NCT03722589|BIOLOGICAL|Fluzone High-Dose|0.5 mL intramuscular dose of Fluzone
214877844|NCT00003392|BIOLOGICAL|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
214877845|NCT00003392|DRUG|carboplatin|18 AUC IV, approximately days 21, 42
214877846|NCT00003392|DRUG|cyclophosphamide|4 gm/m2 IV, day 1
214877847|NCT00003392|DRUG|melphalan|140 mg/m2 IV , approximately day 63
214877848|NCT00003392|DRUG|paclitaxel|170 mg/m2 IV day 1
214877849|NCT00003392|PROCEDURE|bone marrow ablation with stem cell support|
214877850|NCT00003392|PROCEDURE|peripheral blood stem cell transplantation|
214877851|NCT05013307|OTHER|CASE|The Clinical Assessment for Sports Exertion (CASE) addresses the physical performance of athletes by quantifying physiological and symptomatic responses to dynamic exertion. It was developed by clinicians at the Baylor Scott and White Sports Concussion Program in an effort to identify specific system impairments in athletes who were unable to successfully demonstrate readiness for return to play protocols.
214877852|NCT04659642|DRUG|Dexmedetomidine Injection [Precedex]|the drug is given 15 minutes before the estimated end of surgery
214877853|NCT04659642|DRUG|Fentanyl Citrate Injection|the drug is given 15 minutes before the estimated end of surgery
214877854|NCT04659642|COMBINATION_PRODUCT|dexmedetomidine and fentanyl|the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
214877855|NCT01738295|DRUG|Donepezil administration|
214666812|NCT01518530|DEVICE|Occiflex Robotic Intervention System|Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
214666813|NCT00467844|DRUG|GTx-024|1 mg GTx 024
214666814|NCT00467844|DRUG|GTx-024|3 mg GTx-024
214666815|NCT00467844|DRUG|Placebo|Matching Placebo
214666816|NCT00262405|DRUG|zileuton|
214877856|NCT01738295|DRUG|Placebo administration|
214877857|NCT02390947|DRUG|Famitinib|25 mg p.o. qd
214877858|NCT02390947|DRUG|Placebo|25 mg p.o. qd
214877859|NCT01541085|DRUG|Darunavir/Ritonavir (DRV/r)|Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
214877860|NCT01541085|DRUG|Efavirenz (EFV)|Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
214877861|NCT02540005|OTHER|ROTEM analysis|
214877862|NCT03408639|DRUG|CinnaPoietin®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
214877863|NCT03408639|DRUG|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
214877864|NCT03408639|DRUG|Nephrovit|Nephrovit tablet is daily administered to all the patients.
214877865|NCT03408639|DRUG|Vitamin B12 Injection|Vitamin B12 is monthly injected to all the patients.
214877866|NCT01405482|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle
214877867|NCT01405482|OTHER|Normal Saline injection|10 cc of Normal Saline will be injected under EMG guidance into the Anterior and Middle Scalenes and Pectoralis Minor muscle of individual diagnosed with Thoracic Outlet Syndrome.
214877868|NCT05113368|DRUG|Regorafenib|Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
214877869|NCT05113368|DRUG|Fulvestrant|500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
214877870|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
214877871|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
214877872|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
214877873|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
214877874|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
214877875|NCT00070499|DRUG|Dasatinib|Given PO
214877876|NCT00070499|DRUG|Imatinib Mesylate|Given PO
214877877|NCT00070499|OTHER|Laboratory Biomarker Analysis|Correlative studies
214877878|NCT06151626|OTHER|virtual-reality based rhythmic skill training|Participants wear VR headsets and Oculus Touch controllers and undergo rhythm skill training for a total of 35 minutes.
214877879|NCT06151626|OTHER|rhythmic skill training with visual feedback|The rhythm skill training activities in this group are the same as the virtual reality-based system. Participants received 35 minutes of rhythm skill training presented through a computer interface
214877880|NCT06151626|OTHER|strengthening group|Participants receive an upper limb strengthening exercise program under the supervision of a therapist to ensure that the strengthening exercises are performed correctly. This includes: proprioceptive neuromuscular facilitation, resistance training, and tendon gliding exercises.
215043629|NCT03518151|OTHER|Sham comparator|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
215043630|NCT06058416|BIOLOGICAL|Healive (hepatitis A vacine(human diploid cell), inactivated)|"The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively."
215043631|NCT04171960|DIAGNOSTIC_TEST|Blood draw|Venous whole blood collection within 12 hours and 12-24 hours following injury.
215043632|NCT04171960|OTHER|Outcome assessments|Administered at baseline.
215043633|NCT06988748|OTHER|Assigned Interventions (diet training)|"Pain and bleeding will be evaluated at 4 hours, 8 hours, 24 hours and 7 days after adenotonsillectomy by using Wong-Baker Faces Pain Rating Scale and Follow-up and Evaluation Form for Children After Adenotonsillectomy in Children."
215043634|NCT05896202|OTHER|taVNS Video|One third of the participants will see the taVNS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
215043635|NCT05896202|OTHER|Educational materials|Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.
215043636|NCT05896202|OTHER|TMS Video|One third of the participants will see the TMS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
215043637|NCT03313999|DEVICE|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
215043638|NCT06995469|PROCEDURE|Chairless Chair® 2.0 Passive Lower-Limb Exoskeleton|"Participants used a passive lower-limb exoskeleton (Chairless Chair® 2.0) during their regular work tasks involving prolonged standing. The device enables a semi-seated posture without the need for external power, aiming to reduce lower limb strain.~The intervention involved each participant performing their typical standing tasks once with the exoskeleton and once without it, in a within-subject repeated-measures design. Each participant served as their own control.~Objective data were collected using a plantar pressure platform (Podoprint S4, Namrol) to measure:~Plantar pressure distribution~Postural stability~Body sway"
215043639|NCT06995612|BEHAVIORAL|SMART-CPT|SMART-CPT T is a psychotherapy that combines Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD) and Cognitive Symptom Management and Rehabilitation Training (CogSMART) for neurobehavioral and neurocognitive symptoms to simultaneously target persistent postconcussive symptoms and PTSD
215043640|NCT06995612|BEHAVIORAL|CPT|CPT is a cognitive behavioral treatment specifically targeting PTSD and other corollary symptoms following traumatic events (Resick \& Schnicke, 1992). Based on a social cognitive theory of PTSD and trauma, CPT focuses on identifying the content of trauma-related thoughts, examining whether these thoughts are consistent or inconsistent with a patient's prior beliefs about the world, and addressing the impact these thoughts have on emotions and behaviors. Patients are taught to recognize and challenge thought patterns such as, assimilation (distorting the memory of the traumatic event to fit prior world beliefs), over-accommodation (excessively altering world beliefs to be consistent with the trauma), or the reinforcement of previously held distorted world beliefs.
215043641|NCT06669871|OTHER|Shirt-A|A dress shirt of a specific design will be provided to the participants, in which weight of the front side will be double than the back side.
215043642|NCT06669871|OTHER|Shirt-B|A dress shirt of a simple design will be provided to the participants, in which weight of the front side will be equal to the back side.
214291705|NCT06219850|OTHER|No intervention|The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.
214291706|NCT01564381|DIETARY_SUPPLEMENT|ResA|90mg of resveratrol conjugated with arginine.
214291707|NCT01564381|DIETARY_SUPPLEMENT|Resveratrol|90mg of resveratrol.
214877881|NCT06151626|OTHER|breathing and muscle relaxation exercises|5 minutes of breathing and muscle relaxation exercises
214877882|NCT05064423|BEHAVIORAL|Clinical Trials Education Program|The Community Health Educator (CHE) will provide CT education and outreach to increase clinical trial knowledge and the importance of clinical trials research and participation. The clinical trials educational activities will include the use of NCI Colorectal Cancer resources and materials, including a PowerPoint presentation, clinical trials information, and online resources. The CHE will tailor the PowerPoint slides to ensure that they are culturally tailored, visually appealing, low-literacy, language appropriate and include appropriate visuals. The CTs educational sessions will be delivered in Spanish and English and will take approximately 45 minutes to 1 hour.
214877883|NCT05133934|OTHER|Observational|A cohort study will be used to collect patient data, analyze the clinical characteristics, TCM syndromes, and treatment of knee osteoarthritis in China
214877884|NCT04648696|DRUG|Vancomycin CI|The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin
214877885|NCT04648696|DRUG|Vancomycin II|Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
214291708|NCT01564381|DIETARY_SUPPLEMENT|Placebo|Made up of cellulose.
214877886|NCT03761940|OTHER|EQ5D questionnaire and a demographic questionnaire|questionnaires
214877887|NCT06303843|OTHER|Transfer with an electric ride-on car|The children in the experimental group will be transported to the operating theatre by a electric ride-on car.
214877888|NCT06160219|DRUG|Hydroxycobalamin|prophylactic use of hydroxycobalamin in vasoplegia in high risk patients undergoing cardiac surgeries
214877889|NCT06121934|DRUG|Carica Papaya Leaf Extract|Active drug: CPLE 500mg 2 capsule t.i.d for 5 dayseive CPLE or placebo once daily for 5 days.
214877890|NCT06121934|DRUG|Placebo|Placebo: visually matched placebo 2 capsule t.i.d for 5 days
214877891|NCT03597919|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.
214877892|NCT01589718|DRUG|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
214877893|NCT01589718|DRUG|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
214877894|NCT00894829|BIOLOGICAL|heparin sodium - Eurofarma|Heparin sodium 5.000 UI - Eurofarma
214291709|NCT05193864|DEVICE|Device: JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
214291710|NCT04997161|DRUG|Sodium Zirconium Cyclosilicate (SZC)|Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
214877895|NCT00894829|BIOLOGICAL|heparin sodium - APP|Heparin sodium APP 5.000 USP
214877896|NCT05096429|BEHAVIORAL|PROVIDENT|Each of the state's 39 municipalities will be randomised to the intervention (PROVIDENT) or comparator condition. An interactive, web-based tool will be developed to visualize the PROVIDENT model predictions. Municipalities assigned to the treatment arm will receive neighborhood risk predictions from the PROVIDENT model, and state agencies and community-based organizations will direct resources to neighborhoods identified as high risk. Municipalities assigned to the control arm will continue to receive surveillance information and overdose prevention resources, but they will not receive neighborhood risk predictions from this study.
214877897|NCT05173441|BIOLOGICAL|Human COVID-19 immunoglobulin (pH4) for intravenous injection|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
214877898|NCT05173441|DRUG|Placebo|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
214877899|NCT05495698|DRUG|single-inhaler triple therapy (Trimbow)|Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
214877900|NCT05495698|DEVICE|E-health application: Curavista app & FindAir e-device|Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir
214877901|NCT05495698|DRUG|multi-inhaler triple therapy (Qvar + Bevespi)|Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.
214877902|NCT02295540|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated IMRT
214877903|NCT02295540|RADIATION|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
214877904|NCT02295540|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214877905|NCT02295540|OTHER|laboratory biomarker analysis|Correlative studies
214291711|NCT04997161|OTHER|Enhanced dietary advice|Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.
214291712|NCT04997161|OTHER|Standard dietary advice including K+ restriction.|Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.
214291713|NCT01908374|DIETARY_SUPPLEMENT|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
214291714|NCT05261256|DIAGNOSTIC_TEST|Exercise stress echocardiography|Study participants perform an exercise stress echocardiography on a semi-supine bicycle ergometer using using a continuous incremental bicycle protocol with a work rate increment every 3 minutes according to gender and weight.
214291715|NCT00680381|BEHAVIORAL|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
214291716|NCT00680381|BEHAVIORAL|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
214666817|NCT00262405|DRUG|azathioprine/prednisone|
214877906|NCT04107792|BEHAVIORAL|parental sense of competence workshop|The intervention will be a two-hour parent education workshop that provides education and teaches parent-mediated strategies for managing children's behaviours associated with SPIs.
214877907|NCT03103841|PROCEDURE|Sleep studies [Polysomnography]|Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires
214291717|NCT00680381|BEHAVIORAL|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
214291718|NCT00425360|BIOLOGICAL|sargramostim|
214877908|NCT05985772|OTHER|Non-Operative Pain Management|The non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing. This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks. Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
214291719|NCT00425360|BIOLOGICAL|telomerase peptide vaccine GV1001|
214291720|NCT00425360|DRUG|capecitabine|
214291721|NCT00425360|DRUG|gemcitabine hydrochloride|
214476920|NCT06768840|DRUG|Baricitinib|oral baricitinib 4mg for adults and 2mg for children 10-16 years for group A
214877909|NCT05985772|PROCEDURE|Operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment|The operative treatment group (ARM 2) will be treated acutely with a transtibial medial meniscus root repair and will be non-weight bearing for 6 weeks as well. For ARM 1 subjects if no subjective improvement is seen at 3 months, crossover will be allowed to a transtibial medial meniscal root repair (acute operative pathway (ARM 2)
214877910|NCT01476566|BEHAVIORAL|Educational intervention|Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
214877911|NCT06416046|DEVICE|Gemini laser|Photobiomodulation (810 + 980 nm, 15s/point, 11.8J/cm²) to evaluate healing and pain relief in recurrent aphthous stomatitis. A 0.7mm intraoral tip will be used - spot 0.38cm2 on the extent of the lesion.
214877912|NCT06416046|OTHER|Placebo|Examination and follow-up until the lesion heals spontaneously. The laser will not be activated.
214877913|NCT01861912|DEVICE|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities
214877914|NCT01861912|DRUG|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7\~14 days after TACE.
214877915|NCT01861912|DRUG|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
214877916|NCT01861912|DRUG|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
214877917|NCT02836314|OTHER|Anorganic Bovine Bone Mineral (ABBM)|In the control group, periodontal intrabony defects were treated with ABBM alone.
214877918|NCT02836314|OTHER|Anorganic Bovine Bone Mineral and Platelet Rich Fibrin (PRF)|In the test group, periodontal intrabony defects were treated with ABBM and PRF combination.
214877919|NCT00750581|DRUG|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
214877920|NCT03252561|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
214877921|NCT03252561|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
214877922|NCT01533012|PROCEDURE|Pressure difference|Peak inspiratory pressures difference between two lungs
214877923|NCT06185881|PROCEDURE|restoration of cervical carious teeth|restoration of carious cervical lesions by glass ionomer
214877924|NCT02009592|DRUG|Rifaximin|Both arms receive Rifaximin
214291722|NCT03750799|DEVICE|Whole body vibration|Whole body vibration was applied on the right lower extremity in the experimental group.
214291723|NCT03750799|DEVICE|Sham vibration|Sham vibration was applied on the right lower extremity in the Control sham group
214291724|NCT05693441|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
214291725|NCT05693441|OTHER|Reference berry-like product|Subjects should consume a reference product (isocaloric to active product, containing berry aromas and colouring but no actual berry compounds) daily during the 12 week intervention period.
214476921|NCT06768840|DRUG|oral mini pulse|pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children
214476922|NCT06768840|RADIATION|Narrow Band UVB Treatment|narrowband ultraviolet rays B phototherapy two sessions per week
214476923|NCT06769776|OTHER|No Drain i.e. Omission of abdominal drain placement|Omission of abdominal drain placement in intervention arm. The No-drain arm will be compared to drain arm
214476924|NCT06605339|BEHAVIORAL|Virtual Reality|Virtual Reality Distraction
214666818|NCT00440323|DRUG|SB-649868|SB-649868 tablets will be available with dose strength of 5 and 25 mg.
214877925|NCT03120325|DEVICE|Vagal Nerve Stimulation|Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
214877926|NCT02401997|BEHAVIORAL|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
214877927|NCT04431765|OTHER|Eye Movement Desensitization Reprocessing therapy|The Eye Movement Desensitization Reprocessing therapy uses bi-alternating (right-left) sensory stimulation through eye movements. The patient follows the therapist's fingers from right to left in front of his eyes and also by auditory stimuli. The patient wears a helmet that alternately makes him hear a sound to the right, then to the left or touch the patient holds in his hands buzzers that alternately vibrate from right to left, or alternatively the therapist taps the patient's knees or the back of his hands.
214877928|NCT04431765|BEHAVIORAL|Trauma-Centred Cognitive and Behavioural Therapy|A CBT is a short, scientifically validated therapy that focuses on the interactions between thoughts, emotions and behaviours. These therapies focus on the current problems of the person, while taking into account their historical causes. They help gradually overcome disabling symptoms and aim to strengthen adaptive behaviours. A CBT relies on different techniques that help the patient to identify the mechanisms at the origin of his difficulties, to experiment with new behaviors and thus to gradually come out of vicious circles that perpetuate and aggravate the psychic suffering.
214877929|NCT01689779|DRUG|100,000 IU cholecalciferol|active drug
214877930|NCT01689779|DRUG|Placebo|comparator drug
215043643|NCT06994715|OTHER|Acupressure|The patient will be placed in a suitable position (supine) or alternatively in a side-lying position, and the patient's privacy will be taken into account to determine the pressure points. The patient's own finger measurement will be taken into account when determining the pressure points. Acupressure points will be marked using a surgical marking pen. The pressure will be applied manually. The thumb will be used for this. Before applying direct pressure to the point, a light rubbing movement will be made for approximately 15 seconds on the point area to reduce tension and tissue sensitivity, to warm, relax and prepare. Approximately 2 minutes of pressure will be applied to each point in a circular manner. Each application will last approximately 18 minutes. The patient will be measured 9 times in total during 4 sessions.
215043644|NCT06994715|OTHER|pseudo acupressure|A pseudo acupressure will be applied to the patients in the supine or side-lying position. The researcher will perform this application by wearing gloves. Wearing gloves will reduce the therapeutic interaction with the patient. Since applying pressure or circular rubbing movements to patients may enter the area where other meridians pass and create a different effect, it will be waited for 2 minutes without applying any pressure or rubbing movements on the bone protrusions where the meridian does not pass and where there are no active pressure points. The application will be determined to be approximately 2 cm away from the acupressure points. The application will again be done manually with the thumb. Each application will take approximately 18 minutes. 4 sessions of application and a total of 9 measurements will be made to the patients.
215043645|NCT06996366|OTHER|Outreach to encourage Annual Wellness Visit completion|Mailed and telephone outreach to patient.
215043646|NCT06997276|DRUG|Mirdametinib (MEK Inhibitor)|Mirdametinib will be administered as a single, oral, 4 mg dose in the morning on Day 1 for each study participant enrolled in the study.
215043647|NCT06624800|PROCEDURE|Shoulder chuna treatment(posterior displacement, anterior displacement, or lateral displacement)|The Shoulder Chuna therapy for the shoulder joint will be performed on the affected shoulder from the second day of hospitalization until the day before discharge.
215043648|NCT06624800|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
215043649|NCT05992376|BEHAVIORAL|Food system and demand generation|The Vegetables for All program will create FitFood Zones (FFZs) in low-income estates in urban and peri-urban areas with a minimum of 1,000 households and 10 mama mbogas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will support mama mbogas to source vegetables from Good Agricultural Practices (GAP)-compliant suppliers, support the uptake of digital solutions for mama mbogas to access vegetables, create business-to-business mentorship opportunities, and support county governments to improve market infrastructure. To encourage BoP parents of children 3-11 years to buy and consume more vegetables, the program will include a demand generation component. This will be implemented through a communication campaign, including above-the-line (ATL) activities (mass media such as radio and television), below-the-line (BTL) activities (market activations and others), and FFZ branding.
215043650|NCT04586075|DIAGNOSTIC_TEST|Trio Whole Genome Sequencing and Participant-Specific Research|"The initial evaluation begins with short-read genome sequencing of DNA extracted from blood of affected individual(s) and participating family members (The most common approach will be trio whole genome sequencing, which involves the affected child + their parents).~Additional evaluation may include: functional assessments, animal modeling, reverse phenotyping (may require an interim visit), epigenetic profiling, or clinical database matching through selective sharing of coded patient data with external collaborators (e.g., via Matchmaker Exchange and Phenome Central), long read genome sequencing, de novo genome assembly, RNA sequencing, and novel bioinformatics analyses"
215043651|NCT06699251|BEHAVIORAL|Chat|Chat is a brief motivational interviewing intervention for partner clinic participants with an alcohol or cannabis use condition.
214291726|NCT02151253|DRUG|Armodafinil|Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
214666819|NCT00440323|DRUG|Zolpidem|Zolpidem capsules will be available with dose strength of 10 mg.
214666820|NCT00440323|DRUG|Placebo|Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
215043652|NCT06699251|BEHAVIORAL|Enhanced Usual Care|An informational brochure will be give to partner clinic participants with an alcohol or cannabis use condition.
215043653|NCT06006923|DRUG|Regorafenib|A multi-kinase inhibitor that targets several receptor tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), which may also have immunomodulatory affect in the tumor microenvironment.
215043654|NCT06006923|DRUG|Pembrolizumab|An anti-PD1 blockade / immune checkpoint inhibitor treatment approved for patients with high microsatellite instability (MSI-H) colorectal cancer (CRC) as first line therapy.
214877931|NCT01966250|DEVICE|electroacupuncture and usual care|"Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.~Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated."
214877932|NCT01966250|DEVICE|Usual care|Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
214877933|NCT02435732|DRUG|Placebo saline solution|saline solution
214877934|NCT02435732|DRUG|Heparin|Added to the one of the arms receiving 200U/kg dose of CINRYZE
214877935|NCT02435732|DRUG|CINRYZE|200U/kg IV dose with or without heparin, or 500U/kg IV dose
214877936|NCT00109460|BEHAVIORAL|Tobacco Use Disorder|
214877937|NCT00587860|DRUG|St. John's wort|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
214877938|NCT00587860|DRUG|Placebo|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
214877939|NCT04370678|BEHAVIORAL|Change in preference to surgery under COVID-19 pandemic.|Under the COVID-19 pandemic all arthroscopic procedures were cancelled. We wished to describe if patients experienced a change in preference to surgery under this period.
214877940|NCT02711878|BEHAVIORAL|Let's Move Program|Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
214877941|NCT02711878|BEHAVIORAL|Let's Flex Program|Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
214877942|NCT02711878|BEHAVIORAL|Group Motivational Interviewing|Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
215043655|NCT06701461|DEVICE|Electrodermal Activity signal|Determining if the electrodermal activity signals, as measured by the Embrace Plus smartwatch) can be used to measure osteoarthritic patient pain levels.
215043656|NCT06715358|BEHAVIORAL|Reintervention|"* SI! Program environment intervention from 2nd grade through all Elementary Education.~* SI! Program classroom intervention in 2nd grade.~* SI! Program classroom intervention in 5th grade."
215043657|NCT06715358|BEHAVIORAL|Late intervention|"* SI! Program environment intervention from 5th grade through all Elementary Education.~* SI! Program classroom intervention in 5th grade."
215043658|NCT06707922|DRUG|Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate|Peginterferon α-2b Injection, subcutaneous injection, once a week. Tenofovir Alafenamide Fumarate, Oral administration, once a day.
215043659|NCT06717360|DRUG|AG2304T|AG2304T, QD, PO
215043660|NCT06717360|DRUG|AG2304R|AG2304R, QD, PO
215043661|NCT04928547|DIAGNOSTIC_TEST|Test|Different test
215043662|NCT04809233|DRUG|Tipifarnib|
215043663|NCT06764615|DRUG|Zasocitinib|Zasocitinib capsules.
215043664|NCT06766968|DEVICE|Graduated Compression Stocking: 1 month using|Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
215043665|NCT06766968|DEVICE|Graduated Compression Stocking: 1 week using|Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
215043666|NCT03424733|DRUG|Plegridy|Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
215043667|NCT03424733|DRUG|Prednisone|Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
215043668|NCT03424733|DRUG|Tylenol Pill|Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
214291727|NCT02151253|DRUG|Placebo|Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
214291728|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485180-R|Intravenous injection of radioligand in the arm with PET imaging of the brain.
214666821|NCT01655511|DRUG|Tafamidis|240 mg, solution, single dose
215043669|NCT04925427|BEHAVIORAL|Case Management and Peer Recovery|A blend between a Critical Time Intervention (CTI) case management model and a peer recovery coaching approach. CORI will employ peer-based case management/recovery coaching and other transitional services (e.g., peer navigation) to provide support and service linkages to medication-assisted treatment (MAT) and harm reduction interventions to reduce subsequent opioid use and related harms.
215043670|NCT04925427|BEHAVIORAL|Naloxone-Only|Participants will be trained on naloxone administration, and upon re-entry, they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
215043671|NCT02618941|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
215043672|NCT00208338|DEVICE|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
215043673|NCT00208338|PROCEDURE|Rotator cuff repair|Standard surgical repair of torn rotator cuff
215043674|NCT04133415|RADIATION|Lattice stereotactic body radiation therapy|-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
215043675|NCT04133415|PROCEDURE|Peripheral blood|-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy
215043676|NCT04549467|DRUG|Lamivudine 300 MG|Experimental arm
214291729|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485626|Intravenous injection of radioligand in the arm with PET imaging of the brain.
214291730|NCT00748683|OTHER|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
214291731|NCT00005937|DRUG|Antithymocyte globulin|Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
214877943|NCT05083897|OTHER|hip adduction isometric contraction|addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
214877944|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
214877945|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
214877946|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
214877947|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
214877948|NCT03926949|OTHER|Parenteral Nutrition|Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
214877949|NCT03926949|OTHER|Standard Nutrition Care|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
214877950|NCT00923897|RADIATION|Palliative RT|Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
214877951|NCT01259271|DEVICE|Selective Nerve Stimulation (SNS) stimulator device|Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.
214877952|NCT02240615|DEVICE|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
214877953|NCT00311597|PROCEDURE|Radiosurgery|single fractionated radiation therapy
214877954|NCT05985629|DRUG|IPACK|Infiltration between the popliteal artery and capsules of the knee (IPACK) is a novel ultrasound-guided technique that provides additional regional analgesic relief to the posterior aspect of the knee without complications seen in a sciatic nerve block. The intention of the IPACK block is to anesthetize the terminal sensory nerves while sparing the main trucks of the common peroneal and tibial nerves.
215043677|NCT04549467|DRUG|Emtricitabine / Tenofovir Disoproxil Pill|Active Comparator
215043678|NCT00399022|DRUG|Duloxetine|
214291732|NCT00005937|DRUG|Cyclosporine|Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
214291733|NCT06507319|DEVICE|Direct bone anchored pull distal slider|distalization from the palatal side only.
214291734|NCT06507319|DEVICE|Indirect bone anchored dual force distalizer.|distalization from the palatal and buccal sides.
214877955|NCT05985629|DRUG|PLACEBO|The control group will receive the normal pre-procedure care including a pre-operative visit, surgery, and post-operative care. The control group will receive a sham block consisting of saline in the same anatomical location and manner that the intervention IPACK block is administered.
215043679|NCT02501421|BIOLOGICAL|tuberculosis vaccine|Live recombinant influenza vectored tuberculosis vaccine
215043680|NCT02501421|BIOLOGICAL|Placebo|Buffer
215043681|NCT06819475|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Non-invasive MRI will be used to measure the major muscle groups in the calf muscle mtOXPHOS in childhood survivors of Acute Lymphoblastic Leukemia (ALL) in SJLIFE cohort and healthy controls and measure how muscle mitochondria produce energy to function.
215043682|NCT06819475|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy|Non-invasive MRS will be used to measure the major muscle groups in the calf muscle mtOXPHOS in childhood survivors of Acute Lymphoblastic Leukemia (ALL) in SJLIFE cohort and healthy controls and measure how muscle mitochondria produce energy to function.
215043683|NCT06819475|OTHER|Physical function assessment|As part of the SJLIFE visit in the Human Performance Lab, the participant's physical health will be assessed by testing muscle strength, physical function, and lean muscle mass.
215043684|NCT06819475|OTHER|Peripheral blood sample|Peripheral blood sample will be used to evaluate muscle morphology, mitochondrial health and epigenetic differences in the muscles of survivors and age/sex-matched healthy controls.
215043685|NCT06819475|OTHER|Skeletal muscle biopsy|Muscle biopsy will be used to evaluate muscle morphology, mitochondrial health and epigenetic differences in muscles of survivors and age/sex-matched healthy controls.
215043686|NCT06819475|DIAGNOSTIC_TEST|Muscle Ultrasound|Bilateral quadriceps and calf muscle ultrasound will be used to measure muscle volume by calculating the cross-sectional area using the Cavalieri method.
214877956|NCT03261505|DEVICE|Acupuncture|Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
215043687|NCT00630617|BEHAVIORAL|Diet, Physical activity, Physical inactivity|Community based participatory research design
215043688|NCT02051426|OTHER|D-serine|single P.O. administration of D-serine (2.1g)
214666822|NCT01655511|DRUG|Tafamidis|480 mg, solution, single dose
214877957|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
214877958|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
214877959|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
214877960|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
214877961|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
214877962|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
214877963|NCT01371747|DRUG|losartan|losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
214877964|NCT01371747|DRUG|spironolactone|Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
214877965|NCT05825443|DRUG|Camrelizumab|Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.
214877966|NCT02522923|OTHER|Physical Therapist|The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.
214877967|NCT02522923|OTHER|Primary Care Provider|The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
214877968|NCT04678050|DRUG|Ketamine/ propofol|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
214877969|NCT04678050|DRUG|Dexmedetomidine|Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
214877970|NCT06257381|OTHER|VO2max|"Overall design 16 non-smoking individuals with COPD and 16 controls (non-smokers) matched for age and sex on a group level will be included in the study. The study consists of two study days. Separation between the study days are at least 48 hours and maximum 10 days.~Before entering the study: Informed written and oral consent.~Study day 1: Medical examination, full lung function testing (dynamic spirometry, whole-body plethysmography, diffusion capacity) followed by a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 3h).~Study day 2: Participants will undergo a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 1,5h)."
214877971|NCT03092219|DEVICE|TEOSYAL RHA Redensity|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
214877972|NCT06194617|DRUG|Direct oral anticoagulant|Patients take DOACs according to their condition, with the dosage determined by the clinical physician.
215043689|NCT02051426|OTHER|Placebo|single P.O. administration of Placebo
214666823|NCT01655511|DRUG|Tafamidis|TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.
214877973|NCT02666443|DRUG|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
214877974|NCT02666443|DRUG|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
214877975|NCT02666443|DRUG|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
214877976|NCT00373763|PROCEDURE|Fetoscopic tracheal balloon occlusion|
214877977|NCT05161910|OTHER|Biomarkers|Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).
214877978|NCT04767438|OTHER|Pregnant women|All pregnant women that present to the 12-week scan in the Obstetrics Unit
215043690|NCT00946595|DRUG|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
215043691|NCT00946595|DRUG|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
215043692|NCT06047938|RADIATION|ultrasound on carotid|CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children\[11\]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
215043693|NCT00916448|DRUG|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
215043694|NCT00916448|DRUG|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
215043695|NCT00946933|DIETARY_SUPPLEMENT|NH4Cl (ammonium chloride)|0.2 g/kg/day of NH4Cl (ammonium chloride)
215043696|NCT00946933|DIETARY_SUPPLEMENT|placebo|0.025 g/kg/day of NaCl (sodium chloride)
215043697|NCT05679063|OTHER|Physiotherapy|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group
215043698|NCT05679063|OTHER|Sham, Control|Talks about healthy habits
214877979|NCT03637010|OTHER|Breakfast in the Classroom|For all breakfasts, the students will use the 'grab and go' approach from hallway kiosks. The students will take the breakfasts back to their respective classroom and consume them there.
214877980|NCT02729571|BIOLOGICAL|MTBVAC|Live-attenuated tuberculosis vaccine
214877981|NCT02729571|BIOLOGICAL|BCG|Commercially available live-attenuated tuberculosis vaccine
214877982|NCT05187728|OTHER|No Intervention|No more intervention will be given.
214877983|NCT01443728|DRUG|Experimental: Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU \[2.5 mg\] given once a month
214877984|NCT01443728|DRUG|Active Comparator: Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU \[0.3 mg\] given once a month
214877985|NCT00293111|DRUG|SDX-101 (R-Etodolac)|
214877986|NCT00912938|DRUG|zoledronic acid|Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
214877987|NCT00125671|DRUG|Warfarin|
214877988|NCT02861924|OTHER|microcirculatory responses|"The effect of the duration and intensity of the pressure; reproducibility and correlation with ischemic hyperemia post.~measurements are made with the Imager SPECKLE imager (LSCI) give the microvascular perfusion data in arbitrary units called perfusion units (UP)."
214877989|NCT06361199|DRUG|Proximod|Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis
214877990|NCT06361199|DRUG|Placebo|Placebo controlled
214877991|NCT00229775|DRUG|artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine|
214877992|NCT05937360|OTHER|cross-sectional community based study|Participants (women between the ages of 18 and 45 years) are selected randomly throughout various regions of Trinidad. Every 10th house from the selected regions would be assessed.
214877993|NCT00269425|BEHAVIORAL|American Heart Association Step 2 diet|Low fat diet with patient education and diet analysis
214877994|NCT00269425|BEHAVIORAL|Mediterranean diet|Mediterranean style diet with patient education and diet analysis
214877995|NCT01403051|DRUG|EFV/FTC/TDF|FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
214877996|NCT01403051|DRUG|Calcium Carbonate|Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
214666824|NCT06338644|DRUG|Palbociclib|3 weeks on, 1 week off
214877997|NCT01403051|DRUG|Vitamin D3|One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
214877998|NCT01403051|DRUG|Placebo for calcium carbonate|A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
214877999|NCT01403051|DRUG|Placebo for vitamin D3|A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
214878000|NCT00862615|OTHER|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|"Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.~Isotopes are :~(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)"
214878001|NCT01092858|DRUG|Testosterone Undeconate (Nebido, BAY86-5037)|Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
214878002|NCT01092858|DRUG|Placebo|Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
214878003|NCT06509113|BEHAVIORAL|The online HIV-related stigma training|The intervention is an online HIV-related stigma training that takes 6 hours in 4 weeks to be completed.
214878004|NCT06509113|BEHAVIORAL|The online HIV epidemiology training with no specific content on stigma|Nursing students will be trained in an online HIV epidemiology training with no specific content on stigma. It will take 6 hours in 4 weeks to complete the training.
214878005|NCT00573378|DRUG|PEG-IFN-a2b|Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.
214878006|NCT05411757|COMBINATION_PRODUCT|IBR900 combined with Lenvatinib|IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Lenvatinib: body weight ≥ 60kg, 12mg/qd; body weight \< 60kg, 8mg/qd; administered continuously from D5 of the first cycle
214878007|NCT05411757|COMBINATION_PRODUCT|IBR900 combined with Bevacizumab|IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Bevacizumab:15mg/kg, D1 of each cycle.
214878008|NCT03032848|DRUG|Conjugated Estrogen|use of 1 gram per day
214878009|NCT03032848|DRUG|Promestriene|use of 1 gram per day
214878010|NCT03032848|DRUG|Estriol|use of 1 gram per day
214878011|NCT03032848|DRUG|Vaginal Moisturizer - Cream|use of 1 gram per day
215043699|NCT03238053|PROCEDURE|Vaginal laser treatment|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
215043700|NCT03238053|DEVICE|sham|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
214878012|NCT04797026|OTHER|Letters to increase social connection with goal to alleviate loneliness|Our hypothesis is that a social program connecting patients in residential care facilities with high school students through monthly letter writing would positively impact quality of life for both, reducing quantitative and qualitiative measures of loneliness
214878013|NCT02487914|DEVICE|iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)|drug delivery through interferential current.
214878014|NCT02487914|DRUG|Lidocaine 10% was sprayed at the identified region|
214878015|NCT02487914|DEVICE|interferential current|
214878016|NCT01025414|DRUG|enteral nutrition|Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines
214878017|NCT01025414|DRUG|Parenteral nutrition|Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
214878018|NCT05238610|PROCEDURE|PFO closure|PFO-closure will be performed after 3-6 month of observation and monitoring for paroxysmal atrial fibrillation
214878019|NCT02197819|DEVICE|Sling|
214878020|NCT02197819|DEVICE|External Rotation Brace|
214878021|NCT03831711|DRUG|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
214878022|NCT03831711|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214878023|NCT03831711|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
214878024|NCT03831711|DEVICE|Investigational software and coils in PET/MR scan|General Electric (GE) Healthcare non-approved PET scanner coils and software
215043701|NCT03238053|DEVICE|laser system|FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
215043702|NCT06907407|OTHER|Diaphragmatic Myofascial Release|six technique will be applied; 1-Diaphragmatic transverse plane, 2-Anteroposterior equilibrium technique, 3-Supra and infrahyoid fascial induction, 4-Psoas fascial induction,5-Diaphragm stretching technique and 6-Phrenic centre inhibition. diaphragmatic breathing, Mobilization of the ascending colon, descending colon, sigmoid colon, and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual plus medication
214291735|NCT06286904|DEVICE|Skiin Garment system|Individuals will be asked to wear a Skiin Garment system for the duration of their hospitalization (minimum one day).The system will collect accelerometer, ECG, temperature, heart rate, steps and sleep metrics data if enable. Then, they will be asked to answer a questionnaire about their experiences with the device and the study.
214291736|NCT03676595|OTHER|interactive video game-based exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
214878025|NCT05244694|DRUG|Insulin|Priming dose then a constant infusion at 40 mU•m-2•min-1
214878026|NCT01701011|BEHAVIORAL|Coping intervention|Positive reappraisal coping intervention
214878027|NCT05242315|DRUG|Envarsus Oral Product|as described in arm/group description
214878028|NCT05242315|DRUG|Prograf (SOC)|Prograf (SOC)
214878029|NCT04610879|DRUG|Carbamazepine|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
214878030|NCT04610879|DRUG|Levetiracetam|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
214878031|NCT04610879|BEHAVIORAL|Parent based sleep (PBS) intervention|The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
214878032|NCT00183560|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
214878033|NCT00183560|DRUG|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
214878034|NCT00183560|DRUG|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
214878035|NCT00071279|DRUG|SR34006 (idraparinux sodium) Injection|
215043703|NCT06907407|OTHER|visceral mobilization techniques|Mobilization of the ascending colon, descending colon, sigmoid colon, and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual plus medication
214291737|NCT03676595|OTHER|no exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
214291738|NCT00505531|DRUG|Tramadol Extended Release Oral Capsule|Tramadol ER- up to either 200 mg or 300 mg based on randomization
214878036|NCT02816411|DIETARY_SUPPLEMENT|Milk protein isolate|"Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water.~Placebo consisted of 365 ml water, 125 ml sugar-free cordial and 2g of low-calorie glucose/dextrose powder."
214878037|NCT02816411|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
214878038|NCT03112642|PROCEDURE|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered.
214878039|NCT03112642|DEVICE|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
214878040|NCT01577940|PROCEDURE|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
214878041|NCT01577940|PROCEDURE|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
214878042|NCT04497948|DRUG|Acalabrutinib|Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
214878043|NCT04348695|DRUG|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days"
214878044|NCT04348695|OTHER|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
214878045|NCT03936712|DIETARY_SUPPLEMENT|Energy Drink|Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.
214291739|NCT00505531|DRUG|Benadryl|Placebo group will take up to 25 mg of Benadryl
214291740|NCT00326989|PROCEDURE|intracoronary stem cell therapy|extracorporal shock waves prior to intracoronary cell therapy
214291741|NCT01288469|DRUG|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
214291742|NCT01288469|DRUG|Placebo (for alirocumab)|One SC injection in the abdomen only.
214291743|NCT01288469|DRUG|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
214291744|NCT01288469|DRUG|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
214291745|NCT04537507|PROCEDURE|Coronary angiography|
214878046|NCT03936712|DIETARY_SUPPLEMENT|Placebo Drink|The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
214878047|NCT01439256|BEHAVIORAL|Computer Controlled Telephone Counseling|The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
214878048|NCT01439256|OTHER|Physician information and management recommendations|Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
214878049|NCT00142025|DRUG|Oxcarbazepine|
214878050|NCT05153993|OTHER|Fascia stretch|"Stretch of the fascia plantaris during 3x30, 5x/week, 6 weeks"
214878051|NCT00247494|DRUG|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
215043704|NCT06907407|OTHER|irritable bowel syndrome medication|the patients will receive irritable bowel syndrome medication
215043705|NCT06534775|OTHER|Questionnary|"The patients were included in a previous study (PABLOS) - These patients received locoregional anesthesia (LRA) by deep parasternal intercostal block (Deep-PIP) or bilateral superficial parasternal intercostal block (Superficial-PIP), compared with standard management (general anesthesia without LRA) for chronic postoperative pain after cardiac surgery by sternotomy.~In PABLOS 2.0 study, the evaluation focuses on the presence of chronic pain between 12 and 24 months postoperatively. There is no intervention in PABLOS 2.0 study but only a questionnary."
215043706|NCT06505460|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
215043707|NCT04473833|PROCEDURE|Serial Transvaginal Ultrasonography|Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
215043708|NCT05229614|RADIATION|Carbon Ion Therapy|After confirming the disease stability and upon patient inclusion in the study, hypofractionated carbon ion boost will be administered to one site of disease previously untreated. Patient will be irradiated to a single lesion with a total dose of 24 Gy\[RBE\], 8 Gy\[RBE\]/fraction, one fraction/day, for 3 days.
215043709|NCT05229614|DRUG|Immunotherapy (Pembrolizumab)|Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
215043710|NCT06148311|DRUG|Matching placebo|One matching placebo will be given under the tongue on a thin dissolvable film.
215043711|NCT06148311|DRUG|Dexmedetomidine|Dexmedetomidine 120 mcg will be given under the tongue on a thin dissolvable film.
215043712|NCT06904313|DRUG|Piflufolastat F18|Participants will be injected with Piflufolastat F18 and imaged for up to 3 hours on a PET scanner
215043713|NCT06927674|BEHAVIORAL|Consumption of vegetables|DELIVER is designed to address challenges of low consumption of vegetables in both variety and quantity by working with smallholder farmers to increase production and promoting healthier diets through greater vegetable consumption. The project will build the capacity of smallholder farmers in vegetable production through collaborating with lead farmers to establish demonstration plots that showcase advanced agricultural techniques and technologies. These plots will serve as training hubs for other farmers in vegetable production, postharvest handling, as well as business and market planning. DELIVER aims to increase consumption among neighbors of the smallholder farmers by asking the farmers to recruit at least one neighbor family to whom they will regularly sell vegetables. The project also includes a livelihood component that will increase market connections and access to finance for smallholder farmers.
215043714|NCT06934681|BEHAVIORAL|Usual Care Group|Participants will receive the standard intervention provided by the healthcare service, which includes recommendations for physical exercise, physical activity, and healthy eating. This intervention is delivered by the Endocrinology and Nutrition Department at Hospital Universitario y Politécnico La Fe and consists of periodic individual follow-ups (at least three in-person visits per year, both pre- and post-bariatric surgery) by specialized medical staff in Endocrinology and licensed Nutrition and Dietetics professionals. Additionally, it includes five preoperative group sessions focusing on various aspects of healthy nutrition, physical exercise, and physical activity.
215043715|NCT06934681|BEHAVIORAL|Controlled exercise with telerehabilitation|Participants will receive the same standard care as the control group, including the same number of visits with the physician and nutritionist and participation in group sessions. Additionally, they will follow a structured physical exercise program, tailored to individual capabilities, combining aerobic and strength exercises, which will primarily be carried out at home with the assistance of telerehabilitation. Physical exercise will be structured in different phases: prior to surgery (prehabilitation), after surgery (rehabilitation), with maintenance periods in between.
215043716|NCT06507540|OTHER|No intervention (observational study)|Retrospective description of diagnostics and treatements of dental emergencies
215043717|NCT06943209|OTHER|Creation of a contraception education program and post on social networks for high school students|Training of peer influencers and program design.
215043718|NCT06943209|OTHER|Education program|View videos/messages created by peer influencers on social networks
215043719|NCT06943209|OTHER|Survey and questionnaires|Respond to the sexual health and contraception knowledge survey and the education program satisfaction survey
215043720|NCT06945523|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
214291746|NCT00255047|BIOLOGICAL|DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|0.5 mL, Intramuscular
214291747|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
214878052|NCT04420845|BEHAVIORAL|Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES)|SHES outlines the importance of sleep for people with type 2 diabetes mellitus and provide practical information and guidance about sleep habits. Specifically, the focus will be on: avoiding consumption of caffeine, nicotine, alcohol; avoiding use of light emitting devices before bedtime; avoiding excessive intake of fluids or heavy meals before bedtime; promoting regulation of light, noise, and temperature in the bedroom; timing of and importance of exercise; maintaining consistent sleep and wake times; establishing a pre-bedtime routine; and managing stress.
214878053|NCT00834496|PROCEDURE|Liver biopsy|percutaneous liver biopsy
214878054|NCT04651413|DIAGNOSTIC_TEST|PCR Value|Data collection and interpretation
214878055|NCT02329535|DRUG|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
214878056|NCT02242045|DRUG|Idelalisib|150 mg tablet(s) administered orally twice daily
214878057|NCT03039270|OTHER|With sonic activation (SMART Device®)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM, SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the sonic activation side, immediately after the gel's application, sonic activation(Smart Sonic Device, FGM, SC, Brazil) was performed for 1.5 minutes in total for side (30 seconds per tooth). After the time of 30 seconds in each of the three anterior teeth of the respective side, the gel was removed from teeth with cotton. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
214878058|NCT03039270|OTHER|Control (Without sonic activation)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM,SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the side allocated for application without sonic activation, gel was kept for 10 minutes, after which it was removed from the teeth. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
214878059|NCT03760185|DRUG|Brimonidine Tartrate|All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.
214878060|NCT02473523|OTHER|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
214878061|NCT02473523|OTHER|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
214878062|NCT02473523|DEVICE|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
214878063|NCT02473523|DEVICE|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
214878064|NCT02473523|OTHER|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
214878065|NCT02473523|OTHER|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
214878066|NCT02473523|OTHER|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
214878067|NCT02473523|OTHER|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
214878068|NCT00866879|DRUG|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
214878069|NCT00866879|OTHER|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
214476925|NCT06603519|DIETARY_SUPPLEMENT|Modified Plant-Based Mediterranean Diet|Two-week dietary intervention after the participants' scheduled colonoscopy consisting of vegetarian high-fiber meals. These meals are designed to provide a substantial intake of dietary fiber through a variety of plant-based foods, including whole grains, legumes, fruits, vegetables, nuts, and seeds. Meals will be delivered bi-weekly, and compliance will be monitored through regular check-ins with a study dietitian.
214878070|NCT00866879|PROCEDURE|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
214878071|NCT00866879|PROCEDURE|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
214878072|NCT00866879|PROCEDURE|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
214878073|NCT00866879|OTHER|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
214878074|NCT00866879|PROCEDURE|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
214878075|NCT04278716|OTHER|Safe return to play checklist|this objective checklist will be utilized by the physical therapy staff and surgeon to determine whether an athlete is safe to return to their sport
214878076|NCT03443271|PROCEDURE|TAP Block with Bupivicaine|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.
215043721|NCT06945523|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
214476926|NCT04741230|DEVICE|Gebauer Lenticule|The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
214476927|NCT06655636|DEVICE|Device tuned to Assistance|The device spring components will be tuned to produce an assistive supination torque on the forearm.
214878077|NCT03443271|PROCEDURE|TAP Block with Placebo drug|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
214878078|NCT03563911|BEHAVIORAL|Brief Mindfulness-Based Intervention (BMBI)|The BMBI is be based on a BMBI which demonstrated analgesic effects in a previous study. Relative to full-length interventions, we will employ a brief intervention; the 20-minute BMBI session will include education on the foundational concepts of mindfulness and its relevance to chronic pain (5 minutes) and a guided mindfulness practice involving focused attention on the breath and monitoring of thoughts, feelings, and body sensations (15 minutes). BMBI participants will be encouraged to practice the taught mindfulness technique at home at least 20 minutes/day for 1 week (a handout and link to an online guided mindfulness practice will be provided).
214878079|NCT03563911|BEHAVIORAL|Control/Nutrition Education|The Control intervention will involve nutrition education, adapted from an existing manual of cognitive-behavioral therapy for opioid-treated chronic pain. Control intervention protocol will match the BMBI in terms of time / structure to control for the non-specific, non-mindfulness effects of BMBI. The 20-minute Control session will include education on the relationship between diet and pain (10 minutes) and recommendations for a healthy diet (10 minutes). Control participants will be encouraged to prepare healthy meals at home at least 20 minutes/day for 1 week (a handout and link to online resources will be provided).
214291748|NCT00255047|BIOLOGICAL|DTaP-IPV and ActHIB®|0.5 mL, Intramuscular
214291749|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
214291750|NCT01516814|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
214291751|NCT01516814|DRUG|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
214291752|NCT01516814|DRUG|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
214878080|NCT00976911|DRUG|Bevacizumab|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
214878081|NCT00976911|DRUG|liposomal doxorubicin|40mg/m2 iv every 4 weeks
214878082|NCT00976911|DRUG|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
214878083|NCT00976911|DRUG|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
214878084|NCT02101580|DRUG|ADI-PEG 20|
214878085|NCT02954991|DRUG|Glesatinib|Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
214878086|NCT02954991|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
214878087|NCT02954991|DRUG|Mocetinostat|Mocetinostat is an HDAC inhibitor.
214878088|NCT02954991|DRUG|Nivolumab|nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
215043722|NCT06421649|RADIATION|Proton Beam Therapy|All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.
215043723|NCT04860466|DRUG|CC-96673|IV Infusion
214291753|NCT01574612|DRUG|acyclovir/hydrocortisone cream|cream applied topically to lesion five times daily for five days
214291754|NCT02395900|DIETARY_SUPPLEMENT|Flaxseed|
214291755|NCT02395900|OTHER|control|
214291756|NCT05982275|GENETIC|CARTemis-1|A dose escalation design will be applied in successive patient cohorts until identification of Dose Limiting Toxicity (maximum dose: 6x10\^6 CAR-T/kg divided over 2 days).
214878089|NCT00576316|DRUG|Symbicort Turbuhaler 160/4.5|
214878090|NCT06410235|OTHER|Thoracic manipulation and exercise program|The group received exercises and manipulation with physiotherapist follow-up for eight weeks and thoracic manipulation was performed once a week.
214878091|NCT06410235|OTHER|exercise program|The group received exercise
214878092|NCT05757973|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
214878093|NCT05576883|BEHAVIORAL|Transdiagnostic emotion regulation intervention|"The intervention under study includes 5 therapeutic approaches, namely: Positive psychology \[PP\], Mindfulness, Acceptance and Commitment Therapy \[ACT\], Breathing and relaxation, and Self-compassion \[SC\].~The intervention consists of 4 core features:~(i) monitoring through filling in EMAs assessing participants emotional states~(ii) feedback through visualization of participant emotional states upon every completion of the EMAs~(iii) exercises targeting different emotion regulation skills \[i.e., upregulation of positive affect, mindfulness, cognitive defusion, breathing and relaxation, self-compassion) and health facts (i.e., control intervention) describing health information including nutrition, exercise, sleeping habits.~(iv) psychoeducative articles describing the 5 therapeutic approaches (PP, ACT, Mindfulness, Breathing and Relaxation, SC)"
214878094|NCT01624701|OTHER|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
214878095|NCT03876262|DRUG|Moxidectin|2mg tablets, encapsulated for blinding
214878096|NCT03876262|DRUG|Ivermectin|3mg tablets, encapsulated for blinding
214291757|NCT01894165|DRUG|ALXN1101|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
214291758|NCT01894165|DRUG|Placebo|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
214878097|NCT02220062|PROCEDURE|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5\~10cc ethanol would be performed as bilateral injections at the celiac trunk.
214878098|NCT02220062|PROCEDURE|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2\~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
214878099|NCT05321641|BEHAVIORAL|Mobile phone message reminders.|Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.
214878100|NCT05467696|DRUG|CTP-543|For each period, subjects will be dosed with CTP-543 12 mg (1 x 12 mg tablet)
214878101|NCT04831359|DEVICE|Doppler ultrasound|Tissue Doppler ultrasound on pediatric patients
214878102|NCT06173271|DIETARY_SUPPLEMENT|multi-intervention program and protein foods supplementation|This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.
214878103|NCT01105871|DRUG|naloxone|4 mg naloxone in 10 ml saline given iv bolus
214878104|NCT01105871|DRUG|Placebo|10 ml of normal saline iv bolus
214878105|NCT03926520|DEVICE|Electroconvulsive Therapy (ECT)|Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.
214878106|NCT02594865|DIETARY_SUPPLEMENT|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
214878107|NCT02594865|DIETARY_SUPPLEMENT|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
214878108|NCT05184543|OTHER|Routine Exercise Program|8 weeks of routine basketball training will be done. Dynamic stretching exercises, in which large muscle groups are exercised, can be applied for 20 minutes.
214878109|NCT05184543|OTHER|Core Stability Exercise Program|In addition to the 8-week routine basketball training, 20 min core stability exercises will be given to the Core Group. Core stability exercises will be performed on the stable surface for the first 4 weeks, and core stability exercises will be performed on unstable surfaces for the next 4 weeks.
214878110|NCT05184543|OTHER|Body Weight Neuromuscular Warm-Up Program|Each 20-minute program consists of 5 different parts. The beginning of the program consists of low-speed running exercises with the ball. The running track for each exercise will include 4 basketball court areas. The second part consists of active stretching exercises. The third part consists of exercises focusing on general strength. The fourth part consists of plyometric, balance, and jump exercises. The final section consists of a sprint with sudden changes of direction and basketball movements.
214878111|NCT01014793|DRUG|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
215043724|NCT06954454|OTHER|prenatal physical exercise intervention|Multicomponent prenatal exercise program including aerobic, coordination, strength, stretching, balance, postural, and pelvic floor muscle training exercises. Delivered either in person or online by qualified exercise physiologists. Duration and frequency: two sessions of 60 minutes per week for 12 weeks. Moderate intensity: According to the Borg scale of perceived exertion, from six to 20, moderate exercise is rated between 13 and 14. Each pregnant woman will rate her exercise on the Borg perceived exertion scale from six to 20. Settings: home or healthcare, university, or fitness centers. Following international guidelines for physical activity during pregnancy (ACOG-USA, ACSM-USA, CSEP-Canada, PSOG-Poland, SEGO-Spain).
214291759|NCT06229197|PROCEDURE|Billroth II reconstruction|Billroth II reconstruction, in which a loop of jejunum is mobilized and anastomosed to the gastric remnant
214291760|NCT06229197|PROCEDURE|Braun Anastomosis|This is an additional surgical connection (anastomosis) created between two parts of the small intestine, specifically between the afferent (incoming) and efferent (outgoing) limbs of the jejunum near the gastrojejunostomy (the new connection between the stomach and small intestine created during a Billroth II procedure).
214291761|NCT03987529|OTHER|sevoflurane|volatile anesthetic
214291762|NCT03987529|OTHER|propofol|intravenous anesthetic
214878112|NCT06523660|BEHAVIORAL|CHUCK CHUCK SKILLS: CHild's Understanding of Cognitive sKills|The intervention will consist of an online EF training that will be delivered across 10 sessions (one 1 hour session per week for ten weeks). It will target core EF components including inhibitory control, attention shifting, and working memory in children with Autism Spectrum Disorder aged 5 to 7 years. It will also provide strategies (e.g., behavioral principles, compliance training) for promoting behavioral regulation and emotion regulation in these children. Accompanied parent coaching will be provided to enhance children's generalization of EF skill attainment.
214878113|NCT06523660|BEHAVIORAL|Parent Psychoeducation|Group-based parent psychoeducation, which consists of 10 sessions, 1-hour weekly program delivered via telehealth, will be provided to the control group.
214878114|NCT05257226|BEHAVIORAL|frailty|questionaire
214878115|NCT06088030|DRUG|Arsenic trioxide|Patients should be treated with the corresponding first-line chemotherapy regimen first, for example: Neuroblastoma: CAV (cyclophosphamide, pinarubicin, vincristine), PVP (cisplatin, etoposide) ,CT (cyclophosphamide, topotecan).If patients was evaluted as PD/SD after treatments, arsenic trioxide (ATO) will be administered 0.18mg/kg per day over six hours IV daily for ten days in combination with previous chemotherapy regimen on the third day of each treatment cycle. Other pediatric tumors with TP53 mutations not mentioned above will have similar treatment regimens. If the efficacy of the conventional standard chemotherapy regimen is evaluated as PD/SD, then the next course of treatment will be combined with ATO on the basis of the standard chemotherapy regimen.
214878116|NCT04588025|DEVICE|Point-of-care Portable Perfusion Phantom, P4|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
214878117|NCT01365312|DRUG|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
214878118|NCT01365312|DRUG|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
214878119|NCT00599963|DRUG|paricalcitol|paricalcitol 1 mg/day
214878120|NCT01342757|DRUG|vorinostat|Given orally
214878121|NCT01342757|DRUG|temozolomide|Given orally
214878122|NCT01342757|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MRI
214878123|NCT01342757|OTHER|survey administration|Ancillary studies
215043725|NCT05722223|COMBINATION_PRODUCT|Trimodal prehabilitation|Pancreatic cancer patients (not stage 4) will undergo trimodal prehabilitation: nutrition, psychological, and exercise support.
214291763|NCT00230568|DRUG|Aricept|
214291764|NCT00197964|BEHAVIORAL|Enhance asthma knowledge, self-efficacy, social support|
214878124|NCT06600269|PROCEDURE|Cycling Training|Cycling combined with priming strategies to enhance motor learning tasks. Each session will last for 15 minutes, conducted three times per week, over a period of two weeks.
214878125|NCT02648932|BIOLOGICAL|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
214878126|NCT02648932|PROCEDURE|Matched Unrelated Donor Transplant|
214878127|NCT04554446|PROCEDURE|T-MSAT(Motion style acupuncture treatment using traction)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
214878128|NCT04554446|PROCEDURE|Korean medicine treatment|acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
214878129|NCT04117802|OTHER|Maple syrup|Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.
214878130|NCT04117802|OTHER|Placebo|Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
214878131|NCT05840679|DRUG|Irrigation Solution|Different concentrations of NaOCl are being used as the endodontic irrigant.
214878132|NCT04963543|OTHER|FID123238|Lubricant applied to the ocular surface
214878133|NCT01596738|DRUG|Tranexamic Acid|"1. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~2. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
215043726|NCT03984188|DRUG|Theophylline ER|200 mg extended release (ER) low-dose theophylline taken orally daily
215043727|NCT03984188|DRUG|Placebo oral tablet|Manufactured methylcellulose placebo tablet taken orally daily
215043728|NCT03984188|OTHER|Standard of Care Treatment|Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment
215043729|NCT04111354|DEVICE|Pacemaker implantation|Pacemaker implantation
215043730|NCT03508674|DEVICE|Levita Magnetic Surgical System|use of surgical tool
215043731|NCT01173679|DRUG|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
215043732|NCT01173679|DRUG|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
214878134|NCT01596738|DRUG|Saline|"1. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~2. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
214878135|NCT03032679|OTHER|Non interventional study|No intervention
214878136|NCT06354452|OTHER|Person-level linkage of the database looking for relationship with sepsis survival and previous intake of certain drug families and previous dependence on health services.|"A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted to hospitals in the region will be carried out.~Both the overall data of patients admitted to hospitals in any ward and those admitted to ICU will be analysed. The survival data of patients will be compared with their previous individual drug consumption, trying to find out the relationship between chronic consumption of certain families of drugs and inhospital survival to sepsis. In addition, drug dependence and dependence on health services of sepsis survivors will be studied in comparison with their situation prior to sepsis."
214878137|NCT06171100|DRUG|Tolvaptan|"Oral ingestion of low dose Tolvaptan (7.5mg daily) for management of inpatient hyponatraemia for 1st dose Tolvaptan group.~Oral ingestion of low dose Tolvaptan (7.5mg daily) or standard dose Tolvaptan (15mg daily) for 2nd dose Tolvaptan group."
214878138|NCT05350605|BEHAVIORAL|Breastfeeding position education with lactation simulation model|pregnant women will receive training with a lactation simulation model once in the last trimester.The pregnant woman will wear the lactation simulation model during the education period and show what she has learned practically on the model.Mothers who have given birth will be supported to practice the breastfeeding position in the postpartum service.
215043733|NCT01173679|DRUG|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
215043734|NCT01031888|DRUG|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
215043735|NCT01031888|DRUG|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
215043736|NCT02552797|BEHAVIORAL|Shared Decision Making tool|
215043737|NCT06259357|OTHER|Protocolized protective mechanical ventilation in prone position|Prone Position: Study subjects randomized to the intervention group will be placed and maintained in prone position for at least 16 hours/day until the time of organ procurement or decline (typically 24-48 hours after donation consent) or the time that the lungs are declined for transplant.
215043738|NCT00848263|PROCEDURE|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
215043739|NCT00848263|PROCEDURE|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
215043740|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
215043741|NCT00984503|DRUG|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
215043742|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
215043743|NCT00984503|DRUG|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
215043744|NCT06154018|DRUG|Protamin|ACT and Clot- Pro test will be ran after initial and possible next protamine administrations
215043745|NCT05174585|BIOLOGICAL|JAB-BX102 (anti-CD73 monoclonal antibody)|Administered by intravenous infusion (IV)
215043746|NCT05174585|BIOLOGICAL|pembrolizumab (anti-PD-1 monoclonal antibody)|Administered by intravenous infusion (IV)
214878139|NCT02603991|PROCEDURE|PINS Vagus Nerve Stimulator|The stimulators are implanted in the body,with the stimulation of the IPG
214878140|NCT02603991|DRUG|Levetiracetam|The best anti-epileptic drugs to patients who participate in this study，Levetiracetam，
214878141|NCT03111771|PROCEDURE|carcinological surgery|carcinological surgery for Group K +
214878142|NCT03111771|PROCEDURE|cervical surgery|cervical surgery for Group K-
214878143|NCT03395457|DRUG|Care as usual|Application of usual pharmacological care for chronic migraine
214291765|NCT05122273|DEVICE|Stella BIO|Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
214878144|NCT03395457|OTHER|Manual Therapy|5 sessions of manual therapy over 12 weeks
214878145|NCT04079465|DEVICE|O2matic|O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
214878146|NCT03068117|OTHER|Regular Early Specialist Symptom Control Treatment (RESSCT)|"Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
214878147|NCT04516993|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
214878148|NCT04516993|DRUG|The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|Best treatment arm
214878149|NCT02678078|PROCEDURE|Analyzing biopsy samples|Analyzing biopsy samples that is preformed as part of the patient treatment.
214878150|NCT03461731|DEVICE|Control|laser beam only
214878151|NCT03461731|DEVICE|800 nm laser|800 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
214476928|NCT06655636|DEVICE|Device tuned to Sham (Slack Springs)|The device spring components will be tuned to slack springs to serve as a placebo. The user will think they are receiving forces but in reality the device will not be providing any forces.
214476929|NCT06655636|DEVICE|Device tuned to Anti-Assistance|The device spring components will be tuned to produce a resistive supination torque on the forearm.
214878152|NCT03461731|DEVICE|combination laser|800 nm and 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
214878153|NCT03461731|DEVICE|905 nm laser|905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
214878154|NCT00013091|BEHAVIORAL|Self-management therapy; Psychoeducational group therapy|
214878155|NCT05908292|PROCEDURE|Pelvic Floor Scar Tissue Self-Scar Massage|Self scar-massage intervention of healed pelvic floor scar tissue for 5 minutes, 3x/week for 6 weeks.
214878156|NCT00002926|DRUG|cytarabine|
214878157|NCT00002926|DRUG|etoposide|
214878158|NCT00002926|DRUG|idarubicin|
214878159|NCT00002926|PROCEDURE|allogeneic bone marrow transplantation|
214878160|NCT00002926|PROCEDURE|peripheral blood stem cell transplantation|
214878161|NCT01287026|PROCEDURE|Cardiac Real-time MRI RHC (Right Heart Catheterization)|
214878162|NCT01434810|DEVICE|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
214878163|NCT01434810|DEVICE|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
214878164|NCT01753557|DRUG|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
214878165|NCT01753557|DRUG|RBV|RBV: 600 - 1000 mg/day based on body weight for 24 weeks
214878166|NCT01753557|DRUG|PEG-IFN alfa-2a|PEG-IFN alfa-2a: 180mcg/week for 24 weeks
214878167|NCT01261923|DRUG|Alitretinoin|30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
214878168|NCT05042895|PROCEDURE|Group A|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
214878169|NCT05042895|PROCEDURE|Group B|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
214878170|NCT03071939|OTHER|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
214878171|NCT05388513|PROCEDURE|Surgical Resection|Surgically treated patients included
214878172|NCT04893018|BIOLOGICAL|Efineptakin alfa|Given IM
214878173|NCT06358235|OTHER|Music Therapy|30-minute music therapy session.
214476930|NCT06655220|DRUG|Metformin hydrochloride|Metformin hydrochloride
214878174|NCT06358235|OTHER|No Music therapy|The practice where patients are simply fitted with headphones and rest quietly without listening to music.
214878175|NCT02352935|DEVICE|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
214878176|NCT01886079|DRUG|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
214878177|NCT01886079|DRUG|Saline|0.4 mcg/kg/h, IV
214878178|NCT03521843|DEVICE|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
214878179|NCT03521843|DEVICE|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
214878180|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214878181|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214878182|NCT04022408|DIAGNOSTIC_TEST|Liquid based cytology|Liquid based cytology
214878183|NCT04022408|DIAGNOSTIC_TEST|Conventional cytology|Conventional cytology
214878184|NCT02381184|DRUG|clomiphene citrate|receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
214878185|NCT02381184|PROCEDURE|laparoscopic ovarian drilling (LOD)|Laparoscopy was performed under general anesthesia, using three-puncture technique
214878186|NCT05336032|OTHER|Food (rice)|Cooked rice with 75 gm carbohydrate
214878187|NCT00242632|DRUG|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
214878188|NCT01350570|OTHER|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
214878189|NCT01350570|OTHER|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
215043747|NCT02559648|DRUG|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
215043748|NCT02559648|DRUG|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
215043749|NCT01250054|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
215043750|NCT01250054|DEVICE|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
215043751|NCT04106115|DRUG|Durvalumab|1500 mg IV infusion every 4 weeks for up to 7 doses
214476931|NCT06655220|DRUG|BI 1815368|BI 1815368
214476932|NCT06655870|DRUG|mRNA-0184|SC injection
214476933|NCT06606249|BEHAVIORAL|Self-Help Plus (SH+)|"Self-Help Plus is a novel, brief, low-intensity intervention, recently developed by the World Health Organization (WHO) and intended to help people with and without mental disorders cope with distress stemming from diverse types of adversity.The key components of the program are based on acceptance and commitment therapy (ACT), a distinct form of cognitive-behavioural therapy. SH+ draws on ACT techniques of coping with stress, compassion and acceptance toward oneself and others, and living following one's values.~An online version called Doing what matters in times of stress is available as an illustrated guide and pre-recorded audio."
214878190|NCT01350570|OTHER|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
215043752|NCT04106115|BIOLOGICAL|S-488210/S-488211|S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
214878191|NCT01350570|DRUG|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
214878192|NCT05575609|OTHER|children with Diabetes Mellitus, Type 1|assessment of Relation between anthropometric measurements and balance in children with type 1 diabetes
214878193|NCT04030715|DRUG|bismuth-containing quadral therapy based on antibiotic susceptibility|the different mucosal pathology graded by New Sydney System
214878194|NCT01307111|DRUG|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
214878195|NCT01307111|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
214878196|NCT00627861|DRUG|Aliskiren|150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.
214878197|NCT00627861|DRUG|Extended-release metoprolol|50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.
214878198|NCT02645331|BEHAVIORAL|Remind-to-move|
214878199|NCT02645331|BEHAVIORAL|Modified constraint induced movement therapy|
214878200|NCT02645331|BEHAVIORAL|Conventional rehabilitation|
214878201|NCT02122029|BEHAVIORAL|Lifestyle counselling|Behavioral techniques for weight management
214878202|NCT02122029|PROCEDURE|Bariatric Surgery|Vertical Banding Gastroplasty
214878203|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
214878204|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
214878205|NCT00682357|DRUG|Placebo and Lidocaine|Placebo and lidocaine 20 mg
214878206|NCT02090166|OTHER|Blood test|a blood test will be taken from each patient
215043753|NCT04815798|COMBINATION_PRODUCT|Bacteriophage-loaded Microcapsule Spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
214878207|NCT05727826|DEVICE|Thrive MD-01 .|The experimental group received a 60 Hz vibration stimulation treatment using the SMV method three times per week for two weeks (EG).
214878208|NCT03857269|OTHER|Acupoint Massage|The operators is trained for two weeks. At 9 o'clock in the morning, the elderly are organized by Nursing home to perform acupressure.Intervention frequency will be monday to saturday per week for 6 months.
214878209|NCT03857269|OTHER|lavender essential oil|Modulated by an international aroma therapist,The cotton ball containing essential oil is replaced by the operator at 9 am.Intervention frequency will be monday to saturday per week for 6 months.
215043754|NCT04815798|COMBINATION_PRODUCT|Placebo|Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.
215043755|NCT04815798|PROCEDURE|Standard of Care|Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
215043756|NCT01978483|DRUG|Denosumab|
215043757|NCT01978483|RADIATION|UVB exposure|
215043758|NCT01978483|DRUG|Diphenylcyclopropenone|
215043759|NCT01978483|DRUG|Normal Saline|
215043760|NCT01577602|OTHER|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
215043761|NCT01577602|OTHER|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
215043762|NCT01577602|OTHER|Combined intervention|Combines the printed medication list with the open ended question
215043763|NCT05626933|PROCEDURE|Buccinator myomucosal flap with Furlow palatoplasty|Anatomical restoration concept using Buccinator myomucosal flap with Furlow palatoplasty is an effective technique for lengthening the palate and improving speech outcomes
215043764|NCT04470388|DRUG|EDP-514|Oral Capsule
215043765|NCT04470388|DRUG|Placebo|Placebo to match EDP-514
215043766|NCT02777086|BEHAVIORAL|StaySafe|StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
215043767|NCT01312519|DEVICE|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
215043768|NCT01312519|DEVICE|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
215043769|NCT06353477|DRUG|EPs® 7630|EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \&gt;12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.
215043770|NCT03372161|DRUG|SP-102|injection
214476934|NCT06606249|BEHAVIORAL|Psychological First Aid (PFA)|Psychological First Aid (PFA) is also developed by the WHO and is a general supportive intervention, aimed at listening and understanding the needs and concerns of people, providing support without pressuring them to talk.
214878210|NCT03857269|OTHER|Acupoint Massage and lavender essential oil|At the same time as the acupressure, patients began to smell the essential oil.Intervention frequency will be monday to saturday per week for 6 months.
214878211|NCT04682522|DRUG|Metronidazole Oral|250 mg Three times a day
215043771|NCT03372161|DRUG|Placebo|injection
215043772|NCT05067205|PROCEDURE|Carpal tunnel release surgery|Preoperative, 3 days, 2 weeks, 4 weeks and 24 weeks postoperatively
215043773|NCT05389748|OTHER|Placebo|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to placebo in association with standard of care
215043774|NCT05389748|BIOLOGICAL|dodecafluoropentane emulsion (DDFPe)|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to DDFPe in association with standard of care
215043775|NCT05938348|BEHAVIORAL|angiopuncture|we conducted acupuncture on perforators by using acupuncture needles.
215043776|NCT03395496|DRUG|Biodentine|Biodentine pulpotomy agent
215043777|NCT03395496|DRUG|ProRoot (Aggregate)|ProRoot MTA pulpotomy agent
215043778|NCT04054336|BEHAVIORAL|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
214878212|NCT06137625|BEHAVIORAL|With regular rhythm|All children learn one dance choreographie with regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
215043779|NCT04054336|BEHAVIORAL|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
215043780|NCT04054336|BEHAVIORAL|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
214476935|NCT06655428|DEVICE|Endobronchial Therman Liquid Ablation (ETLA)|The ETLA System is a minimally invasive bronchoscopic treatment designed to deliver heated normal saline to targeted emphysematous lung regions with hyperinflation to cause tissue ablation and subsequent volume reduction as a means for treating emphysema. The ETLA procedures will be performed under general anesthesia. Each procedure will be limited to treatment in a single lung, with either unilateral or bilateral treatment over the two procedures.
214878213|NCT06137625|BEHAVIORAL|Without regular rhythm|All children learn one dance choreographie without regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
214878214|NCT01902225|DRUG|Istodax|
214878215|NCT01902225|DRUG|Doxil|
214878216|NCT01171755|DRUG|Gemcitabine TS-1|Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA\<1.25 M2, 80 mg/day; 1.25 M2≤BSA\<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
214878217|NCT01703624|DRUG|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
214878218|NCT02565212|DRUG|Montelukast,mometazon froat|
214878219|NCT05605899|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
214878220|NCT05605899|DRUG|Cyclophosphamide|Administered intravenously
214878221|NCT05605899|DRUG|Fludarabine|Administered intravenously
214878222|NCT05605899|DRUG|Etoposide|Administered intravenously
214878223|NCT05605899|DRUG|Rituximab|Administered intravenously
214878224|NCT05605899|DRUG|Doxorubicin|Administered intravenously
215043781|NCT01294852|OTHER|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]).
215043782|NCT01133665|DRUG|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
215043783|NCT03954912|PROCEDURE|MAKO assisted unicondylar knee arthroplasty|MAKO assisted
215043784|NCT03954912|PROCEDURE|NAVIO assisted unicondylar knee arthroplasty|NAVIO assisted
215043785|NCT02916511|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
215043786|NCT02916511|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
215043787|NCT02916511|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
214291766|NCT04682015|OTHER|WeChat platform group|Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment and side effects of antihypertensive drugs. Participants will be reminded to take their blood pressure regularly and enter the blood pressure readings into the WeChat platform. If participants enter extremely high or low readings, they will be asked to seek medical help from doctors. Participants can also consult doctors online via WeChat platform by text and voice messages, or voice calls.
214291767|NCT03923855|DEVICE|BTL-899|BTL-899 therapy
214291768|NCT02452398|DEVICE|Treatment group|The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.
214291769|NCT02452398|OTHER|No intervention|Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
214291770|NCT00499876|DRUG|mefloquine|250mg weekly PO for 6 months
214291771|NCT00499876|OTHER|placebo|1 tablet weekly PO for 6 months
214666825|NCT04320095|DEVICE|Bizact tonsillectomy device|Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.
214666826|NCT03010189|DEVICE|Actigraphy|A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.
214878225|NCT05605899|DRUG|Vincristine|Administered intravenously
214878226|NCT05605899|DRUG|Prednisone|Administered orally
214878227|NCT06257095|BEHAVIORAL|Stepped-care social and mental health engagement|Each student will be matched to an older adult and the students will make one call o the older adult which lasts upto 1 hour each week for 8 weeks. Ending each call, the student will assess symptoms of depression anxiety through questionnaires. If the participant responds yes on two consecutive calls to any of these questions, they will be asked if they would like to receive a call from the University of Texas Health Science Center Trauma and Resilience Center to discuss free counseling services.
214878228|NCT06257095|BEHAVIORAL|APS Usual care|Participants will receive a phone call for data collection. Then they will be offered to receive an abbreviated version of the stepped-care social and mental health engagement intervention, lasting only 6-weeks with the option to continue calls if agreeable between the student and older adult.
214878229|NCT00588458|PROCEDURE|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
214878230|NCT03474458|DRUG|Doxycycline|Doxycycline
214878231|NCT03474458|DRUG|Standard of care therapy|Standard of care therapy
215043788|NCT03429738|DRUG|Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets|Experimental drug
215043789|NCT03429738|DRUG|RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets|Active Comparator
214878232|NCT06206135|DRUG|the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)|The initial dose of Nephoxil capsules for the subjects participating in this study shall be determined at the investigator's discretion, and subjects shall be classified into either the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) according to the initial dose. It will be conducted with 13 visits over 48 weeks.
214878233|NCT00520819|DRUG|Antioxidant-rich food items|
214878234|NCT00549679|DRUG|GSK256066|PDE4 inhibitor
214878235|NCT00549679|DRUG|Placebo|Placebo
214878236|NCT05368064|OTHER|observational|collection of phenotype data
214878237|NCT03300843|BIOLOGICAL|Peptide loaded dendritic cell vaccine|On days 0, 14 (+/- 5 days), 28 (+/- 5 days), and 42 (+/- 5 days). The vaccine will be administered as both an intravenous (IV) infusion and a subcutaneous (SQ) injection. The total dose will be divided equally between intravenous (IV) and SQ containing 1.0E7 to 8.0E7 cells per cycle depending upon the manufacturing yield.
214878238|NCT01992718|PROCEDURE|Evaluation of MRI, US for pelvic and uterine conditions|"Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).~A patient survey will be included."
214878239|NCT01992718|PROCEDURE|Patient preference between MRI and Ultrasound|"Subjects may take part in this arm because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.~Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete."
214878240|NCT05516979|DRUG|100 mg AP1189|AP1189 tablets for oral use
214878241|NCT05516979|DRUG|Placebo|Matching placebo for oral use
214878242|NCT04577664|PROCEDURE|total thyroidectomy|a total thyroidectomy (TT) in which the entire gland is removed
214878243|NCT04577664|PROCEDURE|subtotal thyroidectomy|subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.
214878244|NCT06474208|DRUG|Formulation 1|Oral suspension of Vericiguat (BAY1021189) in single dose (SD).
215043790|NCT05953298|DEVICE|Electrical impedance tomography (EIT)|Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level
215043791|NCT03283488|DRUG|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
215043792|NCT03283488|DRUG|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
215043793|NCT01464645|DEVICE|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
215043794|NCT00002395|DRUG|Topotecan|
215043795|NCT04001842|OTHER|Surgical reconstruction of the mandible using an axially vascularized bone construct|Surgically reconstructing defects of the mandible using reconstruction plate and Titanium mesh filled with an artificial bone substitute to form a bone construct. This construct will be vascularized at the same operation using a vein graft from the forearm. The vein graft will be microsurgically connected to an artery and vein within the facial/neck region to provide a vascular supply to the construct (arterio venous loop)
214291772|NCT02301494|DRUG|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
214291773|NCT02301494|DRUG|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
214291774|NCT00627003|DRUG|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
214291775|NCT00627003|OTHER|Placebo|Placebo oral tablets administered daily for 5 weeks
214291776|NCT04216017|DRUG|kenalog|Cortisone injection into shoulder
214878245|NCT06474208|DRUG|Formulation 2|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.
214291777|NCT04216017|DRUG|Lidocaine|Lidocaine injection into shoulder
214291778|NCT01957644|DRUG|Azacitidine|
214878246|NCT06474208|DRUG|Formulation 3|Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.
215043796|NCT05912621|DRUG|Tirzepatide|Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.
214291779|NCT01957644|DRUG|Volasertib|
214666827|NCT03010189|DEVICE|Heart-rate variability monitoring|A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.
214878247|NCT06474208|DRUG|Formulation 4|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose and flavor in SD.
214878248|NCT06474208|DRUG|Formulation 5 (placebo)|Matching placebo of formulation 1 in SD.
214878249|NCT03660306|PROCEDURE|opioid anesthesia|opioid anesthesia means using sufentanil during surgery
214878250|NCT03660306|PROCEDURE|opioid free anesthesia|opioid free anesthesia means giving no opioids during surgery
214878251|NCT04482387|DEVICE|DigiVis visual acuity app|Self-testing of visual acuity app on two occasions
214878252|NCT04011670|OTHER|200 mg caffeine tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
214291780|NCT05974033|COMBINATION_PRODUCT|Stenting plus medical therapy|Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.
214878253|NCT04011670|OTHER|Non-active tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
214878254|NCT06964113|DRUG|Filgotinib Maleate|Administered as oral tablets.
214878255|NCT04462887|BEHAVIORAL|Nursing intervention program|The intervention consisted of structured information (SI) provided in a booklet, nursing telephone support (NTS) and access to a nurse pager 24h/day. The SI booklet, Sudden Cardiac Arrest: A Survivor's Experience, contains 2 components: a descriptive component including individual verbatim statements about experiences of others during the first year of recovery and a management component outlining successful strategies used by others in dealing with issues in recovery. The NTS telephone calls included: check-in about current concerns, assessment of the topic for the week, review of common recovery experiences, discussion of behavioral strategies for dealing with the topic for the week, provision of positive feedback for strategies already working well, anxiety reduction statements, practice of new behaviors using role-playing and problem solving techniques, summarization, setting specific goals for the upcoming week, and collaborating on a learning assignment for the subsequent week.
215043797|NCT06064487|DIAGNOSTIC_TEST|renal cell arrest and damage biomarkers assessment|measurement of TIMP2 and IGFBP7, KIM-1
215043798|NCT04790500|OTHER|mobilization technique|Mobilization of sacroiliac joint which will increase the range of motion and reduction in pain and improvement in functional limitation.
215043799|NCT04790500|OTHER|muscle energy technique|Muscle energy technique it is known as active muscular relaxation technique. It helps in lengthening the shorten muscle and increasing range of restricted muscles
215043800|NCT02151929|DEVICE|Bioresorbable vascular scaffold|stenting of an acute thrombotic lesion in patient within STEMI
215043801|NCT02151929|DEVICE|Everolimus eluting stent|stenting of an acute thrombotic lesion in patient within STEMI
215043802|NCT03906526|DRUG|VTX-2337|Motolimod
215043803|NCT03906526|DRUG|Nivolumab|IV Nivolumab
215043804|NCT03547427|OTHER|Basal insulin alone|A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
215043805|NCT03547427|OTHER|Basal pramlintide and reduced basal insulin|A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at \~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
215043806|NCT03547427|OTHER|CGM|Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
215043807|NCT03547427|OTHER|Acetaminophen test|Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
215043808|NCT03547427|OTHER|Insulin-induced hypoglycemia|During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
215043809|NCT03547427|OTHER|Exercise-induced hypoglycemia|During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
215043810|NCT02122380|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
215043811|NCT02122380|DRUG|Placebo|1 placebo pill by mouth per day for 30 days
214291781|NCT05974033|DRUG|Medical therapy alone|Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.
214291782|NCT03970161|DEVICE|routine ophthalmic examination|Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
214291783|NCT00002245|DRUG|Abacavir sulfate|
214291784|NCT00002245|DRUG|Amprenavir|
214291785|NCT00002245|DRUG|Lamivudine|
214291786|NCT01435954|DRUG|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
214291787|NCT01435954|DRUG|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
214291788|NCT03559465|PROCEDURE|skin biopsy|"A skin biopsy will be performed in 10 patients in the form of 2 punches of 5 mm in the injured area in aseptic condition with a Rodnan score.~In this study, 10 skin biopsies are needed, and will be performed on the first 10 patients accepting this biopsy."
214291789|NCT03559465|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte
215043812|NCT00786162|OTHER|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
215043813|NCT00786162|OTHER|BP cuff at workplace|Provided BP cuff for communal use at the worksite
214291790|NCT05457673|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
214291791|NCT04941001|DEVICE|ReferID|The ReferID tool is a digital tool which can be used to facilitate a review of asthma in primary care
214291792|NCT03077750|DRUG|VBP-245 Topical Gel|Topical application BID
214291793|NCT03077750|DRUG|Vehicle|Vehicle Control With No Active Pharmaceutical Ingredients
214291794|NCT00168727|DRUG|ibritumomab tiuxetan (Zevalin®)|
214878256|NCT05096832|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|"Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).~Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily"
214878257|NCT05096832|BIOLOGICAL|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
214878258|NCT01739699|DRUG|Acetaminophen|
214878259|NCT01739699|DRUG|Placebo|
214878260|NCT06361121|PROCEDURE|mid-point transverse process to pleura (MTP) block|"the T1-T12 thoracic spinal levels will be sonographically identified using a high frequency linear US probe (HFL\_50, 15\_6MHz). Then the probe will be placed vertically and nearly 3 cm lateral to the spinous process at the thoracic level T4/T5. The paraspinal muscles (erector spinae, trapezius, rhomboid), transverse processes , superior costo-transverse ligament (SCTL) and parietal pleura will be all identified under parasagittal scanning.~In MTP block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the 2 transverse processes and advanced till it reaches the mid-point between the transverse process and pleura. After negative aspiration of blood or air, a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected superficial to the SCTL."
214878261|NCT06361121|PROCEDURE|Thoracic Paravertebral Block|In the TPV block group , the transverse process and the pleura will be identified and the needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards
214878262|NCT04625491|OTHER|Observational|Observational
214878263|NCT00273689|DRUG|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
214878264|NCT00273689|DRUG|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
214878265|NCT04566289|DEVICE|PiCSO|Percutaneous coronary intervention
214878266|NCT04322058|OTHER|The Dads' Club|The core intervention is Core 24/7 workshop attendance
214878267|NCT01517958|OTHER|Respiratory Distress Group|Diagnostic lung ultrasound.
214878268|NCT01517958|OTHER|Control Group|Lung ultrasound
214878269|NCT05652595|DRUG|GP40141|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
214878270|NCT05652595|DRUG|Nplate|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
214878271|NCT01767038|PROCEDURE|OCT Spectralis|
214878272|NCT01767038|PROCEDURE|microperimetry|
214878273|NCT00046241|DRUG|Extended-release bupropion hydrochloride|
214878274|NCT05424458|PROCEDURE|Anterior Implant Treatment|Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.
215043814|NCT04127318|BEHAVIORAL|Pedaling Group|Participants will pedal at low-moderate intensity using a stationary pedal ergometer concurrent to their immunotherapy infusion (30 minutes).
214878275|NCT01390532|DEVICE|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|"Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (\>85% PHR).~Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA)."
214878276|NCT03000478|BEHAVIORAL|Prolonged Exposure|
214878277|NCT03000478|BEHAVIORAL|Virtual Reality Exposure Therapy|
214878278|NCT03296878|OTHER|Own-Price Elasticity|The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
214878279|NCT03296878|OTHER|Cross-Price Elasticity|The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
214878280|NCT04311671|DRUG|Moxidectin|2 mg tablets, encapsulated for blinding
214878281|NCT04311671|DRUG|Ivermectin|3 mg tablets, encapsulated for blinding
214291795|NCT04245696|DEVICE|Dermal Handpiece / SubQ Handpiece|Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
214878282|NCT04311671|DRUG|Albendazole|400 mg tablets
214878283|NCT06206798|BEHAVIORAL|Resourcefulness Group|The content of the Resourcefulness intervention group includes 6 sessions such as session 1 to introduce resourcefulness skills; sessions 2-4 to discuss personal resourcefulness skills including planning daily activities, and positive self-talk; sessions 4-5 to discuss social resourcefulness skills including relying on family or friends, and seeking professional assistance.
214878284|NCT02468856|DRUG|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
215043815|NCT05160948|OTHER|Informational Report|All EcoMAPPE participants and their caregivers will be invited to complete a questionnaire to assess their understanding of air pollution and attitudes and beliefs about science and research before and after receiving their individual study air pollution monitoring results collected as part of their participation in EcoMAPPE.
215043816|NCT02710539|DRUG|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
215043817|NCT02710539|DRUG|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
215043818|NCT04016857|PROCEDURE|RIPC|4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff
215043819|NCT04016857|PROCEDURE|Control|deflated cuff placed on the left arm for 40 min
215043820|NCT02875470|DEVICE|Intensiv Perio Set|Diamond burs for root planing
214878285|NCT02468856|DRUG|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
214878286|NCT05432661|DEVICE|HİGH-FLOW NASAL OXYGEN USE (HFNO)|It is aimed to show that the use of HFNO can improve oxygenation compared to the use of nasal cannula in ERCP procedures performed under sedation in the prone position.
214878287|NCT01663883|OTHER|Isometric exercise|use of a handgrip for 3x2 minutes
214878288|NCT03349983|BIOLOGICAL|MVA-BN-Brachyury/ FPV-Brachyury|Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months
214878289|NCT05453097|DIAGNOSTIC_TEST|Selvester QRS Score with Preoperative ECG|Selvester QRS score will be calculated with the preoperative ECG of the patients.
214291796|NCT05594914|DRUG|AK104|AK104 plus TC regimen(paclitaxel liposome , carboplatin), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 plus TC regimen is combined with radiotherapy for 2 cycles.
214666828|NCT03010189|DEVICE|Pupillometry|A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
214666829|NCT03723096|DRUG|CC-4047|CC-4047 will be administered orally
214878290|NCT04664946|DRUG|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
214878291|NCT02842073|DRUG|Naltrexone|Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
214878292|NCT02842073|DRUG|Bupropion|Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
214878293|NCT05938504|OTHER|ONS_320275|Subjects will consume two packs (165ml/pack) of placebo ONS (ONS\_320275) orally daily at any time of day.
214878294|NCT05938504|OTHER|ONS_211567|Subjects will consume two packs (165ml/pack) of test ONS (ONS\_211567) orally daily at any time of day.
214878295|NCT04302038|DIETARY_SUPPLEMENT|Protein|Additional daily protein provided by potato protein.
214291797|NCT03888547|OTHER|Occupational Therapy Health & Wellness Education|The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules. One of the investigators will lead each of these weekly modules under the direct supervision of the Principal Investigator. Investigators will be trained to provide the standardized educational module for each topic area and for using outcome measures. Each module will have an identified theme and information provided in each group will be education to topic, evidence based literature on intervention strategies, lifestyle, or environmental modifications that improve performance of daily activities that will last approximately 45 minutes. After, group sharing of ideas and individual identification of weekly goals for integration of 1-3 targeted interventions will occur and last approximately 30-45 minutes).
214666830|NCT01928979|OTHER|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
214666831|NCT04590612|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|25mg-100mg tablets to be taken orally three times a day on an empty stomach
214666832|NCT04590612|DRUG|Citalopram|20 mg tablet to be taken orally once and at the same time of the day, daily.
214878296|NCT04302038|DIETARY_SUPPLEMENT|Placebo control|No additional dietary protein (outside of 0.8 g/kg/day as provided by diet)
214878297|NCT00195338|DRUG|etanercept|
214878298|NCT00022334|BIOLOGICAL|AFP|Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
214878299|NCT01366625|DEVICE|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
214878300|NCT03523338|DRUG|Apalutamide|Participants will receive apalutamide 240 mg orally once daily.
214878301|NCT03523338|DRUG|ADT (Standard of Care)|Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
214878302|NCT03031418|DIAGNOSTIC_TEST|ExoDx Prostate Intelliscore|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
215043821|NCT02875470|DEVICE|Gracey curette|
215043822|NCT06354673|PROCEDURE|Stellate ganglion block|Sympathectomy by using combination of regional nerve block and systemic drugs
215043823|NCT06354673|DRUG|Dexmedetomidine|intravenous Dexmedetomidine infusion
215043824|NCT06354673|DRUG|Ketamine|intravenous ketamine infusion
215043825|NCT06255405|BEHAVIORAL|Self-compassion|The dyadic parent-child self-compassion program is designed by the research team and validated by a panel of experts. It includes 5 weekly sessions. Each session lasts for 60 minutes. The dyads will be guided to do self-compassion practices (e.g. affectionate breathing, compassionate letters to oneself etc). Didactic topics, inquiry, and home practices are also involved.
215043826|NCT00272792|DRUG|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
215043827|NCT00272792|DRUG|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
215043828|NCT06447766|BEHAVIORAL|Feeding Families Your Way Program|Feeding Families Your Way is a video-based education program delivered by the University of Rhode Island Supplemental Nutrition Assistance Program - Education (SNAP-Ed).
215043829|NCT00530881|DRUG|PHX1149|
214666833|NCT01451515|DRUG|Prednisone|Given orally (PO).
214878303|NCT04976413|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy|Experimental arm will receive eight phase EMDR treatment using manualized standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12-14 weeks.
214878304|NCT04976413|BEHAVIORAL|Counselling as usual|Control arm will receive counseling as usual for 12-14 weeks
214878305|NCT02437435|OTHER|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
214878306|NCT02437435|OTHER|Placebo Intervention|Patient supine, legs in triple flexion, feet on table. Physical Therapist take contact with his right hand in patient's belly for 5 minutes, without any movement.
215043830|NCT00558818|DRUG|Clevudine|clevudine 30 mg qd
215043831|NCT05987124|DRUG|Defibrotide|HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
215043832|NCT01510873|OTHER|HRQOL evaluation|"Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start."
215043833|NCT00888225|PROCEDURE|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
215043834|NCT00888225|PROCEDURE|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
215043835|NCT02854995|PROCEDURE|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
215043836|NCT02854995|PROCEDURE|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.\[5\] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
215043837|NCT04927481|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
215043838|NCT00112892|DIETARY_SUPPLEMENT|selenium|
215043839|NCT00112892|DRUG|irinotecan hydrochloride|
215043840|NCT02718235|OTHER|Overall survival|Observation of overall and disease free survival
214291798|NCT05489809|PROCEDURE|Endotracheal extubation with suctioning|General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.
214291799|NCT05489809|PROCEDURE|Endotracheal extubation with positive pressure|General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
214666834|NCT01451515|DRUG|Vincristine|Given intravenously (IV).
215043841|NCT06513000|DIAGNOSTIC_TEST|Dry eye diagnostic system|"following tests:~1. Non-invasive tear film break up time (TBUT), a parameter of tear film stability.~2. Non-invasive tear meniscus height.~3. Evaluation of Meibomian glands function.~4. Lipid layer thickness.~5. Eyelid margin.~6. Analysis of conjunctival hyperemia.~7. Cornea sodium fluorescein staining.~8. Schirmer I test"
215043842|NCT02255539|DEVICE|Geelong Prototype Mask|A nasal pillows prototype mask to be trialled with a PAP therapy device for a period of 6 weeks. Participants will wear the mask in place of their current mask for the duration of the trial.
215043843|NCT01024348|DRUG|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
215043844|NCT01024348|DRUG|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
215043845|NCT04389905|BEHAVIORAL|Dental education - Motivational Interviewing|Motivational Interviewing - Focusing on oral/dental health
215043846|NCT03855566|BEHAVIORAL|Intensive behavioral therapy for obesity|Approximately 24, 20 minute sessions over 12 months focused on diet and physical activity behavior change goals to promote weight loss. Framework includes health belief model, transtheoretical model and motivational interviewing.
215043847|NCT03916809|OTHER|EMST|Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
215043848|NCT02870465|PROCEDURE|Closed Reduction Internal Fixation|K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.
215043849|NCT02921789|DRUG|Bleselumab|Intravenous infusion
214476936|NCT06654206|OTHER|Exercise|"Supervised strength exercise sessions: There will be two sessions per week, each lasting 50 minutes. Each session will consist of three distinct parts:~Warm-up: 10 minutes of global strength and aerobic exercises at 6/10 on the Rating Perceived Exertion (RPE) scale.~Strength training: 6 strength exercises targeting the major muscle groups, lasting 30 minutes. The initial load will be set at 70% of the estimated 1-RM (assessed in the first session and based on the individual patient). When the participant is able to complete 3 sets of 12 repetitions with the established weight in two consecutive sessions, the weight will be increased by 10%. The exercises will be performed in a circuit format with 30 seconds of rest between exercises and 90 seconds of rest between sets.~Cool-down/stretching: 10 minutes of a combination of breathing exercises and stretching for the major muscle groups.~Promotion of physical activity: Participants"
214476937|NCT06654206|OTHER|Home exercise|Participants will complete three weekly home training sessions that will not coincide with supervised training days. Each session will last 20 minutes, they will complete two sets of five exercises, with one minute of work and one minute of rest.
214878307|NCT06632535|OTHER|Chiropractic care|Chiropractic treatment will involve a personalized treatment plan within the context of a general care protocol administered by a chiropractor at the Osher Clinical Center for Integrative Health. The treatment plan will be customized to the patient's clinical needs following the current evidence and clinical practice guidelines.
214878308|NCT06632535|OTHER|Group medical visits|Participants will simultaneously enroll in virtual group medical visits with group discussion, practice based learning, and curricular themes pertaining to chronic pain management, healthy aging, and pillars of lifestyle medicine.
215043850|NCT02921789|DRUG|Basiliximab|Bolus injection
215043851|NCT02921789|DRUG|Mycophenolate Mofetil (MMF)|Oral Intravenous
215043852|NCT02921789|DRUG|Tacrolimus Capsules|Oral Capsule
215043853|NCT02921789|DRUG|Methylprednisone|Oral or Intravenous
215043854|NCT02921789|DRUG|Prednisone|Oral Tablet
214476938|NCT05638360|DRUG|Ru Yi Jin Huang Powder|Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
214476939|NCT05638360|DRUG|Placebo|Each patch contains 13g starch and 10c.c. water.
214666835|NCT01451515|DRUG|Daunorubicin|Given IV.
214878309|NCT03981913|BEHAVIORAL|Simon Task with high-density EEG recording|"The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected."
214878310|NCT05354921|DEVICE|Indwelling Catheter|Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (\>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
215043855|NCT04101097|OTHER||
215043856|NCT05390164|DIAGNOSTIC_TEST|skin biopsy|skin biopsy to be analyzed by ELISA
215043857|NCT02896946|RADIATION|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
215043858|NCT01808378|DRUG|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
215043859|NCT03681756|BEHAVIORAL|WALK|Walking program
215043860|NCT02028845|DEVICE|Biliary cannulation with loop guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
215043861|NCT02028845|DEVICE|Biliary cannulation with straight guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
214878311|NCT05354921|DEVICE|Intermittent Catheterization|"Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR\>400 mL, an intermittent catheter will be used. If PVR\> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.~It is expected that a small percentage of patients in either group will not have a PVR\>400 mL preoperatively.~These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR\>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR\>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time."
214878312|NCT02252406|DRUG|Ranolazine|Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
214666836|NCT01451515|DRUG|PEG-asparaginase|Given intramuscularly (IM) or IV.
214878313|NCT02252406|OTHER|Placebo|Matching placebo tablets daily for 24 weeks.
214878314|NCT04034407|PROCEDURE|Damage control surgery|"All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis."
214878315|NCT00183911|DRUG|floxuridine, 5-Fluorouracil, leucovorin|
214878316|NCT00183911|PROCEDURE|External Beam Radiotherapy|
214878317|NCT00183911|PROCEDURE|Surgery|
214666837|NCT01451515|DRUG|Erwinia asparaginase|Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
214666838|NCT01451515|DRUG|Doxorubicin|Given IV.
214878318|NCT03545893|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
214878319|NCT03545893|DRUG|OxyCODONE 5 Mg Oral Tablet|Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
214878320|NCT01117571|DEVICE|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
214878321|NCT03900897|DEVICE|MED-EL SYNCHRONY PIN Cochlear Implant|Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.
214878322|NCT03900897|OTHER|Cochlear Implant|Chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020.
214878323|NCT05538078|DRUG|Ozone gel|application of Ozone gel after scaling by ultrasonic scaler in the bottom of periodontal pocket
214878324|NCT00002678|DRUG|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
214878325|NCT00002678|DRUG|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
214878326|NCT00002678|DRUG|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
214878327|NCT03244683|DIETARY_SUPPLEMENT|Ensure Surgical|Subjects randomized to the intervention arm will consume two Ensure Surgical for 5-7 days.
214878328|NCT03244683|OTHER|Nutrition counseling|All study subjects will be provided with nutrition counseling at the time of study enrollment.
214878329|NCT03244683|OTHER|Low-intensity exercise therapy|Patients randomized to the intervention arm will also be provided with verbal and written instructions for light resistance training. The exercises will be performed at home during the preoperative study period.
214878330|NCT05549531|DRUG|ACT-1004-1239 (10 mg)|ACT-1004-1239 will be administered as 1 capsule of 10 mg strength to be taken under fed conditions.
214666839|NCT01451515|DRUG|Cyclophosphamide|Given IV.
214666840|NCT01451515|DRUG|Cytarabine|Given IV or IT.
214666841|NCT01451515|DRUG|Thioguanine|Given PO.
214666842|NCT01451515|DRUG|Clofarabine|Given IV.
214666843|NCT01451515|DRUG|Methotrexate|Given IV, IM or IT.
214666844|NCT01451515|DRUG|Mercaptopurine|Given PO.
214666845|NCT01451515|DRUG|Dexamethasone|Given PO or IV.
214666846|NCT01451515|DRUG|Hydrocortisone|Given IT.
214878331|NCT05549531|DRUG|Itraconazole (200 mg, o.d.)|Itraconazole 200 mg will be administered as capsules (2 x 100 mg capsule) to be taken under fed conditions.
214878332|NCT01970774|OTHER|MTM with PGx|Patients will attend MTM sessions and receive PGx testing
214878333|NCT05909280|OTHER|Pressure-volume loop measurements|Pressure-volume loop measurements using a conductance catheter
214878334|NCT04264676|DRUG|Metronidazole Oral Tablet|Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
214878335|NCT04264676|DRUG|Placebo oral tablet|Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
214878336|NCT00447876|BIOLOGICAL|Botulinum toxin type A|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
214666847|NCT01451515|DRUG|Etoposide|Given IV.
214666848|NCT05771571|OTHER|Functional olive oil, enhanced with orange peel extract|The functional olive oil was enriched with 10% w/w orange peel extract
214666849|NCT05771571|OTHER|Control|Refined olive oil
214878337|NCT00447876|DRUG|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
214666850|NCT05932433|BEHAVIORAL|Exercise|Each session (45 minutes aprox) is made by: mobility, endurance and final exercise to rest. The sesion is going to perform twice a week during 6 weeks.
214878338|NCT02533180|BIOLOGICAL|Immunosuppression withdrawal|"Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued."
214878339|NCT05762692|DEVICE|High-flow nasal oxygenation device|The patients included will be oxygenated by HFNO device during the operation
214878340|NCT05705076|DRUG|catheter induced thromboprophylaxis|Direct oral anticoagulation for catheter induced thromboprophylaxis
214878341|NCT05537974|PROCEDURE|Endotracheal aspiration|Clearance of endotracheal secretions via a catheter.
214878342|NCT02397876|OTHER|Partially Hydrolyzed Whey formula|Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
214878344|NCT03753191|DEVICE|transcranial direct current stimulation|Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
214878345|NCT03042091|DRUG|Polyethylene Glycol|Given orally
214878346|NCT03042091|DRUG|Neomycin|Given orally
214878347|NCT03042091|DRUG|Metronidazole Hydrochloride|Given orally
214878348|NCT03042091|PROCEDURE|Therapeutic Conventional Surgery|Undergo colorectal resection
214878349|NCT04914169|DEVICE|ICRS|The ICRS enables a stationary bike to automatically adjust the pedaling resistance (i.e. training intensity) according to the subject's heart rate. The training intensity is determined by monitoring whether the subject is able to maintain a 50-70 cycles/min cadence with 60-80% HRR. Subjects heart rate was detected by a wearable device for heart rate, synching with the stationary bike.
214666851|NCT06067113|PROCEDURE|Supraaortic and transcranial duplex|Ecographic evaluation of supraaortic and transcranial arteries, including presence of plaques, flow velocities and pulsatility index
214666852|NCT02185469|PROCEDURE|Pneumatic retinopexy|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
214878350|NCT06239857|PROCEDURE|Epidural pulsed radiofrequency|The radiofrequency treatment is applied under sterile conditions in the operating room environment. The target epidural area is reached under fluoroscopy guidance using a radiofrequency needle. After control of the needle position, radiofrequency treatment is given. Radiofrequency parameters are set as maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
214666853|NCT02185469|PROCEDURE|vitrectomy|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
214666854|NCT02185469|DRUG|sulfur hexafluoride (SF6)|
214878351|NCT02432157|DRUG|HTS 3%|3% HTS at a dose of 250 ml every 6 hours for 7 days
214878352|NCT02432157|DRUG|Standard fluid management|Routine fluid management strategy as pre-specified by our SAH management protocol.
214878353|NCT03171974|DRUG|Dexamethasone|dexamethasone will be injected intracapsular under US
214878354|NCT03171974|DEVICE|US|dexamethasone will be injected intracapsular under US
214878355|NCT05012826|OTHER|Osteopathic Manipulative Treatment in addition to Physiotherapy|Participants in this group will receive OMT in addition to the same interventions of PT group. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
215043862|NCT04304560|DRUG|Dapagliflozin 10 MG|inhibitor of sodium-glucose cotransporter 2
215043863|NCT04304560|DRUG|Placebo oral tablet|Similar Placebo oral tablet
215043864|NCT04099277|DRUG|LY3435151|Administered IV
215043865|NCT04099277|DRUG|Pembrolizumab|Administered IV
215043866|NCT04995172|PROCEDURE|Computed Tomography|Undergo mobile CT-assisted bronchoscopy
214666855|NCT02185469|DEVICE|5/8-in 25-gauge needle|
214666856|NCT02185469|DEVICE|laser|intraoperative laser retinopexy
214666857|NCT02621385|DRUG|tradipitant|test agent
214666858|NCT02621385|DRUG|Midazolam|substrate for drug-drug interaction assessment
214666859|NCT03126227|BIOLOGICAL|AR101|AR101 powder provided in capsules
214666860|NCT03126227|BIOLOGICAL|Placebo|Placebo powder provided in capsules
214666861|NCT04727216|DEVICE|Dorsal Root Ganglion Stimulation (DRG-S)|Dorsal Root Ganglion stimulation will be delivered with continuous dosing and 2 different ON/OFF periods to compare effects for each patient.
214666862|NCT00716937|PROCEDURE|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
214666863|NCT00716937|PROCEDURE|laying open|laying open the site of excision of sinus or cyst without any flap
214666864|NCT05282485|DIETARY_SUPPLEMENT|Synbiotic|Synbiotic (2'-FL HMO + B. infantis probiotics)
214666865|NCT05282485|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
214666866|NCT06042179|BEHAVIORAL|Frequent PT|Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
214666867|NCT06042179|BEHAVIORAL|Intense PT|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
214878356|NCT05012826|OTHER|Physiotherapy|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 8 weeks. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council.
214666868|NCT05509257|DRUG|Naltrexone|Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
214878357|NCT01510626|DIETARY_SUPPLEMENT|Food proteins|Food proteins
214878358|NCT01510626|DRUG|Omalizumab|Drug
214878359|NCT04475172|COMBINATION_PRODUCT|Self-Adhesive Flowable Composite|"Fusio Self-Adhesive Flowable Composite combines the benefits of adhesive and restorative technology into one product . Immediately upon application Fusio conditions, bonds, and seals without the need for an etchant or an adhesive.~It is based on the bonding technology that uses glycerophosphate dimethacrylate(GPDM)to etch enamel and dentin, and hydroxyethyl methacrylate (HEMA) to enhance wetting and penetration by resin into dentin."
214878360|NCT02964572|DRUG|Glimepiride|In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
214878361|NCT02964572|DRUG|Empagliflozin|Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
214878362|NCT01038362|OTHER|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
214666869|NCT05509257|DRUG|Placebo|Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
214666870|NCT03669133|DRUG|Vitamin E|Vitamin E 800 IU/daily
214878363|NCT01038362|OTHER|No Almonds|NCEP Step 1 diet without almonds
214878364|NCT04283968|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
214878365|NCT04283968|BIOLOGICAL|placebo fecal transplantation|placebo fecal transplantation
214878366|NCT05056662|DIAGNOSTIC_TEST|Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR|Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.
214878367|NCT01535092|DRUG|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
214878368|NCT01535092|DRUG|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
214878369|NCT02354625|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
214878370|NCT01609023|DRUG|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
214878371|NCT04478812|DIAGNOSTIC_TEST|Single Group Assignment|Tbit™ System will detect S100B and GFAP concentrations with the blood specimen collected
214666871|NCT03669133|DRUG|Placebo|Matching placebo daily
214666872|NCT01601392|PROCEDURE|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
214666873|NCT01601392|PROCEDURE|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
214878372|NCT02352012|OTHER|Autologous blood|Autologous blood was perfused to the target pulmonary segment
214878373|NCT02352012|DEVICE|Bronchial plug|Bronchial plug was placed to the target pulmonary segment
214878374|NCT00852722|OTHER|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
214878375|NCT04400422|DIETARY_SUPPLEMENT|Lipano formula|Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD
214878376|NCT00292786|BEHAVIORAL|Walking Practice with Functional Electrical Stimulation|
214878377|NCT00292786|BEHAVIORAL|Walking Practice|
214878378|NCT01584817|OTHER|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
214878379|NCT06435910|BIOLOGICAL|DC vaccines|Antigen-presenting and immune modifying DCvacs to treat MM
214878380|NCT05798455|DRUG|Sodium Pentaborate|Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
214878381|NCT03904108|DRUG|Ramucirumab|platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
214878382|NCT05158543|OTHER|conventional therapy|The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.
214878383|NCT05158543|OTHER|Task oriented training (moderate intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.
215043867|NCT04995172|OTHER|Electronic Health Record Review|Patients' medical records are reviewed
215043868|NCT04995172|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo radial probe EBUS
215043869|NCT02838667|PROCEDURE|Standard of Care plus Nephrology Care|
215043870|NCT01766102|PROCEDURE|Intra-operative Mammography|The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
215043871|NCT01766102|PROCEDURE|Standard Mammography|There is not an added device associated with this arm.
215043872|NCT04212663|PROCEDURE|The tendon release of musculi tibialis posterior|To release the tendon of musculi tibialis posterior.
215043873|NCT04212663|PROCEDURE|Anterior tibial tendon transfer(TATT)|To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.
215043874|NCT04212663|PROCEDURE|Achilles tendon lengthing|To lengthen the achilles tendon by using two incisions.
215043875|NCT04212663|PROCEDURE|Fascial release|To cut off the metatarsal fascia in the middle part.
214291800|NCT04429737|DIETARY_SUPPLEMENT|clam protein capsules|The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
214291801|NCT04429737|DIETARY_SUPPLEMENT|Clam peptide plus Chlorella capsules|The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
214291802|NCT04429737|DIETARY_SUPPLEMENT|Placebo|The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
214291803|NCT02046109|PROCEDURE|Repair|
214878384|NCT05158543|OTHER|Task oriented training (high intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
214878385|NCT04302714|PROCEDURE|Hysteroscopic injection|Hysteroscopic injection
214878386|NCT04302714|PROCEDURE|Cervical injection|Cervical injection
214878387|NCT02047734|DRUG|Ozanimod|Oral capsule, daily for 24 months
214878388|NCT02047734|DRUG|Ozanimod placebo|Oral capsule, daily for 24 months
214878389|NCT02047734|DRUG|Interferon beta-1a|Intramuscular injection, 30 µg, weekly for 24 months
214878390|NCT02047734|DRUG|Interferon beta-1a placebo|Intramuscular injection, weekly for 24 months
214878391|NCT03413579|BIOLOGICAL|Nimotuzumab ( h-R3)|Humanized monoclonal antibody
214878392|NCT03413579|OTHER|Placebo|
214878393|NCT05850364|BIOLOGICAL|Sabin Strain Inactivated Poliovirus Vaccine|Totally 1440 healthy infants of 6 weeks old (42-47 days) are planned to be enrolled, and then randomized in a 1:1:1:1 ratio into four groups, i.e., co-administration group 1 (group C1), co-administration group 2 (group C2), staggered administration group 1 (group S1) and staggered administration group 2 (group S2). Participants in group C1 and C2 will receive sIPV at 6,10, 14 weeks old, administered concomitantly with routine infant vaccine (may include DTP-HepB-Hib vaccine, PCV10 or rotavirus vaccine in accordance with the local routine vaccination schedule). Participants in group S1 will receive sIPV at 6,10,14 weeks old, and receive routine infant vaccines at 8,12,16 weeks old. Participant s in group S2 will receive routine infant vaccines at 6,10,14 weeks old, and receive sIPV at 8,12, 16 weeks old.
215043876|NCT00598650|DRUG|E2020|Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
214291804|NCT02046109|PROCEDURE|Replace|
214878394|NCT00093275|DRUG|HP184|
214878395|NCT03872518|DEVICE|Urovac|The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. There is also a removable cloth-covered platform to reduce spills.
215043877|NCT06379828|OTHER|Please note that this is an observational study; not applicable|Please note that this is an observational study; not applicable
215043878|NCT05198401|OTHER|covid-19|viral infection
215043879|NCT06361134|BEHAVIORAL|SAFE Early İntervention|As part of the intervention, sensory-based intervention was applied in an enriched environment. In the home setting, physiotherapists collaborated with the family to advance the intervention. The intervention was revised by making monthly home visits to infants with a corrected age of 42 weeks.
215043880|NCT06361134|BEHAVIORAL|NDT based therapy|Neuromotor evaluations of the babies were performed in a clinical setting. The rehabilitation program to be implemented was given to the family as a booklet. The programs of the children examined in the clinic every month were revised.
215043881|NCT01697111|DRUG|EE20/DRSP(BAY86-5300)|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
215043882|NCT01697111|DRUG|Placebo|One tablet (no active ingredient) / day and one tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day, for the first 24 weeks and the later 28 weeks, respectively
215043883|NCT01697111|DRUG|Dienogest|Dienogest 1mg twice a day (bid)
215043884|NCT04391712|DEVICE|MLS Laser|Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
215043885|NCT04391712|OTHER|Regular Inpatient Medical Care|Regular inpatient medical care
215043886|NCT02886130|DIETARY_SUPPLEMENT|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
214476940|NCT06808763|OTHER|Knee Rehabilitation Exercise Program|"Rehabilitation Program Description:~The rehabilitation program was designed to restore knee function and strength progressively in football players recovering from anterior cruciate ligament (ACL) injuries. Key elements of the program are detailed below:~Program Components:~Session Structure:~Each session lasted 60 to 90 minutes. Sessions were performed multiple times weekly, progressively adjusted throughout the program.~Session Breakdown:~Warm-Up and Jump Exercises (Part 1):~Focused on preparing the body for physical activity and improving jump dynamics.~Dynamic Exercises (Part 2):~Included drop-jumps, side-hops, and crossover-hops for dynamic knee stabilization and balance.~Strength Exercises:~Targeted muscle groups included hamstrings, quadriceps, and calves. Exercises consisted of one-legged leg press, eccentric leg press, squats, one-legged squats on a balance mat, one-legged leg curls, Nordic hamstring, one-legged toe-raises, and lunge exercises.~Resistance training was i"
214878396|NCT03639818|OTHER|individual sessions of cognitive remediation|The cognitive remediation will be led by a psychologist specialized in neuropsychology, trained and experienced in this method. Cognitive remediation will be performed at a rate of 1 to 2 sessions per week for the duration of the study. This treatment will be carried out individually for half in face-to-face session in the clinical immuno-hematology department, face-to-face with the neuropsychologist, half at home with computer-based home exercises using PRESCO software ® from HAPPYNEURON®
214878397|NCT02460406|OTHER|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching \& walking so on).
215043887|NCT02886130|DIETARY_SUPPLEMENT|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
215043888|NCT01426061|OTHER|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
215043889|NCT01426061|OTHER|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
215043890|NCT01426061|OTHER|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
215043891|NCT05810519|BEHAVIORAL|Active break with the proposed lumbar and hip extension exercises|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting. In the experimental intervention, the exercise program include exercises and will be based on patient education. The participants will also explain the importance of regular training and receive a booklet with photographed and described exercises.
215043892|NCT05810519|BEHAVIORAL|Self-care recommendations|Participants assigned to the control group will receive an educational self-care book containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. The control group will perform their regular baseline activities.
215043893|NCT03590886|OTHER|total response Group|biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
215043894|NCT04259216|BEHAVIORAL|IMPACT Intervention|Brief remote session + tailored, daily 8-week mobile application facilitated messaging secondary prevention intervention.
215043895|NCT04259216|OTHER|Control: Enhanced Online Resources (EOR)|EOR group participants will receive standardized information on cyberbullying.
215043896|NCT03239457|BIOLOGICAL|Heberprot P|75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
215043897|NCT04286178|DIETARY_SUPPLEMENT|creatine monohydrate|Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.
215043898|NCT04286178|DIETARY_SUPPLEMENT|ubiquinol|Coenzyme Q10 (CoQ10, ubiquinol) will be taken at a dose of 10mg/kg/day divided into 2 daily doses with a daily maximum of 500mg. CoQ10 will be administered orally in 50mg softgels containing 50mg of ubiquinol (Active Q®), provided by Tishcon Corporation.
215043899|NCT04286178|DIETARY_SUPPLEMENT|glucose tablet|Creatine placebo will be in the form of a glucose tablet with identical appearance and taste to the active supplement. The number of tablets/day will be determined based on the dose of creatine required for each patient.
215043900|NCT04286178|DIETARY_SUPPLEMENT|gel capsule|Ubiquinol placebo will be in the form of a gel capsule with identical appearance to the active supplement. The number of capsules/day will be determined based on the dose of ubiquinol required for each patient.
215043901|NCT04286178|BEHAVIORAL|Exercise|"Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)"
215043902|NCT04067089|PROCEDURE|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
215043903|NCT04067089|PROCEDURE|Surgical aortic valve replacement|Surgical aortic valve replacement
214476941|NCT04159012|DEVICE|Transcranial direct current stimulation|"A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4)."
214476942|NCT06756529|OTHER|hand massage|Hand massage was applied to the patients before surgery, on the morning of surgery and after surgery.
214878398|NCT02460406|OTHER|progressive functional strength training|"Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball \& heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
214878399|NCT03362606|BIOLOGICAL|OC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
214878400|NCT00005052|BIOLOGICAL|GM2-KLH vaccine|
214878401|NCT00005052|BIOLOGICAL|QS21|
214878402|NCT00005052|PROCEDURE|adjuvant therapy|
214878403|NCT01608061|DEVICE|DBS-f on|deep brain stimulation of the fornix
214878404|NCT01608061|DEVICE|DBS-f off|deep brain stimulation of the fornix turned off
214878405|NCT02933437|DRUG|Ajmaline|Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
214878406|NCT03458299|BEHAVIORAL|Motivational Interviewing|2 hours of motivational interviewing
214878407|NCT03458299|BEHAVIORAL|Psychoeducation|2 hours of DVD viewing and discussion
214878408|NCT06007833|BEHAVIORAL|Physical Therapy and Rehabilitation Modalities|In the experimental group, the subjects who were taken to the physical therapy modality in addition to conventional therapy. Total, each session was performed for 60 minutes, 8 weeks, 3 days a week, under the supervision of a physiotherapist, while the other days, the family member performed 3 times a day, each movement for 3 sets, 10-15 repetitions, for a total of 60 minutes. A rest interval of less than 2 minutes was given between each set. By making use of heat modalities before starting the exercises, the elongation ability of the warmed tense structure was increased and the risk of damage in stretching exercises was reduced. The cold application was applied to the soft tissues in the extended position for 1-2 minutes with a cold pack, as the application of cold immediately after the stretching would ensure the preservation of the range of motion. Progress in the exercise program; adjusted for strength, endurance, flexibility, balance and functionality parameters.
214878409|NCT06007833|BEHAVIORAL|Conventional Group|As a conservative treatment in the control group, post-surgical plastering followed by orthoses and positioning was applied.
214878410|NCT01936506|BEHAVIORAL|Cognitive Training A|
214476943|NCT06043531|OTHER|Experimental: EVOO|Subjects will consume 50g of cold pressed EVOO per day for 28 days.
214476944|NCT06493994|OTHER|transaxillary (TAX) transcatheter aortic valve replacement|Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).
214291805|NCT03349749|DEVICE|LiDCOplus haemodynamic monitor|Patients in study group receive intravenous fluid bolus as part of standard fluid resuscitation. Fluid responsiveness (i.e. improvement in cardiac output) is estimated using both standard clinical parameters and by LiDCOplus haemodynamic monitor (with the clinician initially blinded to the latter) before a final decision about fluid responsiveness is made.
214476945|NCT02326974|DRUG|T-DM1|Neoadjuvant treatment is for a total of 18 weeks.
214476946|NCT02326974|DRUG|Pertuzumab|Neoadjuvant treatment is for a total of 18 weeks.
214878411|NCT01936506|BEHAVIORAL|Cognitive Training B|
214878412|NCT01285297|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Injection of up to 18 mL BMAC
214878413|NCT01873183|OTHER|Goal directed fluid therapy|
214291806|NCT01839773|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
214878414|NCT03059797|DRUG|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
214878415|NCT03059797|DRUG|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
214291807|NCT01839773|DRUG|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
214291808|NCT02548247|DIETARY_SUPPLEMENT|Orafti® Inulin|Dietary fiber
214878416|NCT05696379|OTHER|Angiography derived index of micro-circulatory resistance (Angio-IMR)|Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
214878417|NCT02498041|PROCEDURE|Transnasal Endoscopy|Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
214878418|NCT02498041|DEVICE|Office-based disposable transnasal endoscopy Endosheath|Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
214878419|NCT02498041|DEVICE|Standard upper GI endoscopy|Upper GI endoscopy with standard gastroscope.
214878420|NCT02498041|PROCEDURE|Esophageal biopsies|2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
214878421|NCT02847871|BEHAVIORAL|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:~* Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.~* Perform a nutritional assessment by a dietician followed by appropriate care management.~* Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.~* At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;~* Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
214878422|NCT01109147|OTHER|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
214878423|NCT01109147|GENETIC|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
214291809|NCT02548247|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214878424|NCT00451945|PROCEDURE|biopsy|
215043904|NCT02399644|BEHAVIORAL|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
215043905|NCT02399644|OTHER|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
215043906|NCT00371371|PROCEDURE|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
215043907|NCT00371371|PROCEDURE|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
214878425|NCT00451945|DEVICE|3d-ultrasound and fusion of UL and PET/CT|
214878426|NCT03518645|DEVICE|OPN strategy|Predilatation with OPN balloon will be performed as a lesion preparation for BVS Absorb implantation.
214878427|NCT03518645|DEVICE|standard strategy|Predilatation with standard balloon will be performed as a lesion preparation for BVS Absorb implantation.
214878428|NCT02715570|DRUG|PC945 - single doses|Safety and tolerability of single doses
214878429|NCT02715570|DRUG|Placebo - single doses|Safety and tolerability of single doses
214291810|NCT04572932|DRUG|lactobacillus delbruekii|Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
214476947|NCT02326974|PROCEDURE|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
214476948|NCT04370431|DRUG|TTYP01 single ascending doses|TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)
214878430|NCT02715570|DRUG|PC945 - repeat doses|Safety and tolerability of repeat doses
214878431|NCT02715570|DRUG|Placebo - repeat doses|Safety and tolerability of repeat doses
214878432|NCT01320891|BEHAVIORAL|balanced solutions|during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.
214878433|NCT01320891|BEHAVIORAL|not balanced|during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.
214878434|NCT03585920|BEHAVIORAL|Expanded Corn Snack|A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
214878435|NCT00479960|BEHAVIORAL|commercially available omega-3 fatty acids supplementation|
214291811|NCT02193568|PROCEDURE|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
214291812|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
214291813|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Undergo craniotomy
214878436|NCT04999891|OTHER|Neurocognitive tests|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, NuDESC, 3D-CAM.
214878437|NCT05786846|DRUG|Iodinated contrast agents|Patients who use iodinated contrast agents clinically
214878438|NCT02952586|DRUG|Avelumab|Avelumab + SOC Chemoradiation
214878439|NCT02952586|OTHER|Chemoradiation|Cisplatin + Radiation Therapy
214878440|NCT00161863|BIOLOGICAL|FSME-IMMUN NEW 0.25 ml|
215043908|NCT00371371|PROCEDURE|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
215043909|NCT01720030|DRUG|Levosimendan|Verum therapy
215043910|NCT01720030|DRUG|Conventional therapy|Placebo therapy to safeguard blinding
215043911|NCT03454230|PROCEDURE|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
214291814|NCT02193568|OTHER|Arm II (intubated general anesthesia)|Ancillary studies
214291815|NCT02193568|PROCEDURE|Arm I (light sedation)|Undergo craniotomy
214291816|NCT02193568|OTHER|Arm I (light sedation)|Ancillary studies
214291817|NCT00806754|DRUG|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
214878441|NCT01121081|DRUG|Alga Dunaliella Bardawil|4 capsules per day, 2 in the morning 2 in the evening for 3 month
214878442|NCT01121081|DRUG|Placebo|"Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month"
214878443|NCT05331807|DIETARY_SUPPLEMENT|Omega-3 FA|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA)
214878444|NCT05331807|DIETARY_SUPPLEMENT|Vitamin D|one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
214878445|NCT05331807|COMBINATION_PRODUCT|Combined Omega-3 and Vitamin D Supplementation|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA) and one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
214878446|NCT02961088|OTHER|Pasta as part of a low GI/GL diet|
214878447|NCT00492778|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
214878448|NCT00492778|DRUG|Cisplatin|Given IV
214878449|NCT00492778|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214878450|NCT00492778|RADIATION|Internal Radiation Therapy|Given intracavitarily or interstitially
214291818|NCT00806754|DRUG|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
214291819|NCT01650233|BEHAVIORAL|Mindfulness-based stress reduction|
214291820|NCT01927510|BEHAVIORAL|Early mobilisation|
214878451|NCT05088811|DIAGNOSTIC_TEST|WRAP53, UCA-1|Diagnostic value of UCA-1 and WRAP53 in HCC
214878452|NCT00237393|DRUG|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
214878453|NCT00237393|DRUG|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
214878454|NCT05654311|OTHER|Nasal surgery|Nasal surgery under general anesthesia using inhalational agent (sevoflurane)
214878455|NCT02208804|DEVICE|Holmium-166-poly (L-lactic acid) microspheres|
214291821|NCT00492037|DRUG|YM087 oral|
214291822|NCT02601378|DRUG|LXS196|LXS196 as a single agent
214291823|NCT02601378|DRUG|LXS196 and HDM201|LXS196 in combination with HDM201
214291824|NCT04944953|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
214291825|NCT04944953|DRUG|Botulinum toxin type A injection [HG-102]|Single administration, Day 0, 20 units
214878456|NCT06633601|DEVICE|MR-Guided Focused Ultrasound Technology|MRI Guidance for use with High-intensity-focused ultrasound (HIFUS)
214878457|NCT06633601|DRUG|Definity Suspension for Injection|Microbubble contrast agents for ultrasound
214878458|NCT01335035|DRUG|deferasirox|
214878459|NCT00789035|DRUG|BI 10773|
214878460|NCT00789035|DRUG|placebo|
214878461|NCT00789035|DRUG|metformin|
214878462|NCT00157924|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
214291826|NCT03100032|BIOLOGICAL|NVD-001|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with NVD-001.
214291827|NCT03100032|PROCEDURE|Standard of Care|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with autologous locally cancellous bone (laminectomy)
214291828|NCT00352144|DRUG|Eszopiclone|Eszopiclone 3 mg
214291829|NCT00352144|DRUG|Placebo|Placebo tablet
214291830|NCT00927784|BIOLOGICAL|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
214291831|NCT00927784|DRUG|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
214878463|NCT00157924|DRUG|atorvastatin|atorvastatin 10mg
214878464|NCT01118975|DRUG|Vorinostat|"300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
214878465|NCT01118975|DRUG|Lapatinib|1,250 mg once daily
214878466|NCT05697523|OTHER|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
214878467|NCT04174612|DRUG|Cytarabine|100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7
214878468|NCT04174612|DRUG|Daunorubicin|60 mg/m2/die day 1-3
214878469|NCT04174612|DRUG|Midostaurin|50 mg/bid day 8-21
214878470|NCT04174612|DRUG|Cytarabine HD|100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
214878471|NCT05300750|OTHER|Oral fluids|Starting amount of oral fluid after 2 hours post C/s should be 5cm and then increase gradually to be 45-50 cm of oral fluid at 4 hours post C/s and 100 cm each hours later.
214878472|NCT05300750|OTHER|Chewing gum|Chewed free sugar gum for 15 minutes
214878473|NCT01072617|DEVICE|Transcranial magnetic stimulation via MagPro x100 device|"Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.~Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system."
214878474|NCT05440318|DEVICE|Wireless wearable digital devices|Wireless wearable digital devices (including a small patch, modified watch, and datahub smartphone with electronic Patient Reported Outcomes \[ePRO\] capability) will be provided to each participant enrolled in the study.
214878475|NCT01034956|DEVICE|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
214878476|NCT03296111|OTHER|Questionnaires on pain and quality of life|"Patients will be asked to complete several questionnaires about their pain and the impact on their quality of life.~They will complete the questionnaires in the ophthalmology consultation room or at home and return it by mail (or present it at the next consultation).~Patients will be asked to complete several questionnaires :~* Questionnaire about the characteristics of ocular neuropathic pain (7 items)~* DEQ-5 (Dry Eye Questionnaire)~* ODI (Ocular Surface Disease Index)~* BPI (Brief Pain Inventory)~* HADS (Hospital Anxiety and Depression Scale)"
214878477|NCT06063057|BIOLOGICAL|low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml
215043912|NCT06048211|OTHER|Stool color scale|observationnal trial about the use of the stool color scale by the health professionnals
215043913|NCT04467814|BEHAVIORAL|Better Together|"Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.~Caregiver participants in the intervention group will receive up to six telephone or video calls with the research assistant or Clinical Resource Therapist. Sessions will review the knowledge translation (KT) product with family members (\~15 minutes), art goals, brainstorm strategies, and discuss setbacks. The calls with the caregiver may occur 1 to 2 times in the hospital, within one week of going home, and then in Months 2 and 3."
215043914|NCT04467814|BEHAVIORAL|Usual Care|Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.
215043915|NCT02487953|DRUG|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
215043916|NCT02487953|OTHER|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
215043917|NCT02487953|OTHER|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
215043918|NCT02487953|OTHER|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
215043919|NCT05465525|PROCEDURE|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
214291832|NCT02170051|BEHAVIORAL|CBSST-CCT|
214291833|NCT02170051|BEHAVIORAL|Goal focused supportive contact|
214878478|NCT06063057|BIOLOGICAL|medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml
214878479|NCT06063057|BIOLOGICAL|high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml
214878480|NCT06063057|BIOLOGICAL|Enterovirus type EV71 vaccine (Vero cell), Inactivated|Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)
214878481|NCT01917292|PROCEDURE|One-Stage Full-Mouth Disinfection|"1. Basic oral hygiene instructions~2. Dental extractions will be performed (only in cases of teeth that could not be saved)~3. Standard cycle of supragingival ultrasonic scaling and polishing~4. Scaling and root planning after the administration of local anesthesia, four quadrants in one session~5. Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets"
214878482|NCT01917292|PROCEDURE|Periodontal care|"1. Basic oral hygiene instructions~2. Standard cycle of supragingival ultrasonic scaling and polishing"
214878483|NCT02304666|PROCEDURE|Colonoscopy for biopsies samples|
214878484|NCT03138408|DRUG|SC-004|Intravenous
214878485|NCT03138408|DRUG|ABBV-181|Intravenous
214878486|NCT00098423|DRUG|tanespimycin|Given IV
214878487|NCT00098423|DRUG|cytarabine|Given IV
214878488|NCT06500325|PROCEDURE|retrograde titanium elastic nails for fixation of proximal third tibial shaft fractures in children|Two TENs were used in all cases using the double-C construct in most cases to gain three point of fixation. The starting point for nail insertion is 1.5-2.0 cm proximal to the physis of distal tibia. Both nails are then inserted through the entry holes and advanced to pass the level of the fracture site to achieve fixation. The two incisions for nail entry are closed in a layered fashion, and the wounds are well padded with gauze.
214291834|NCT03030508|OTHER|No intervention|
214291835|NCT04912947|DIETARY_SUPPLEMENT|Immusystem|Dietary supplement containing: Piceid, Glycine, Glutamine, Acetylcysteine, Zinc and Vitamin B6
214291836|NCT04912947|OTHER|Placebo|Maltodextrin placebo capsule
214291837|NCT02353598|DRUG|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
214476949|NCT04370431|DRUG|Placebo|Placebo control for Part A of the study
214878489|NCT00693095|BIOLOGICAL|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
214878490|NCT00693095|BIOLOGICAL|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
214878491|NCT02468050|BEHAVIORAL|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
214878492|NCT02468050|BEHAVIORAL|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
214878493|NCT00711035|BIOLOGICAL|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|"Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
214878494|NCT04236934|OTHER|Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis|Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
214878495|NCT04233996|DRUG|Piperacillin-Tazobactam 4 g-0.5 g|Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h
214878496|NCT04233996|DRUG|Cefepime 2000 mg|Patients with FN who required empirical treatment with cefepime 2g/8h
214878497|NCT04233996|DRUG|Meropenem 1000 mg|Patients with FN who required empirical treatment with meropenem 1g/8h
214878498|NCT04462432|OTHER|no intervention|This is an observation study, with no intervention.
214878499|NCT05873933|OTHER|Hemptress Oil|Full ingredient list of the test product: Rubus occidentalis (Black raspberry) seed oil\*, Carica papaya (Papaya) seed oil\*, Bixa orellana (Annatto) seed oil\*, Orbignya oleifera (Babassu) seed oil\*, Borago officinalis (Bourrache) seed oil\*, Daucus carota (Carrot) seed oil\*, Hibiscus sabdariffa (Hibiscus) seed oil\*, Aronia melanocarpa (Chokeberry) seed oil\*, Vaccinium macrocarpon (Cranberry) seed oil\*, Moringa oleifera (Moringa) seed oil\*\*, Persea americana (Avocado) oil\*, Ribes nigrum (Black currant) seed oil\*, Copaifera officinalis (Copaiba) resin\*, Canabis sativa (Hemp) seed oil\*, Moringa peregrina seed oil extract \& Caprylic/Capric Triglyceride\*\* (Moringa peregrina extract), Ascorbyl tetraisopalmitate (Vitamin C), Proprietary full-spectrum blend of Cannabis sativa (Hemp) extract, Silica (Algica), Ergocalciferol (Vitamin D2), Menaquinone (Vitamin K2), Tocopherol (Vitamin E)\* Organic Ingredient\* Wild Crafted/Regenerative\*\*
214878500|NCT04669561|DRUG|Lifitegrast 5% Ophthalmic Solution|Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
214878501|NCT05468801|OTHER|Individualized Homeopathic Remedy|An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.
214878502|NCT05468801|OTHER|Placebo|Placebo plus Standard Pharmacologic Treatment
214878503|NCT03338725|OTHER|Clinical pharmacy model|Patients who are being monitored by a clinical pharmacy model
214878504|NCT00051935|DRUG|Alglucosidase alfa|20 mg/kg (qow); intravenous
214878505|NCT00626808|DRUG|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
214878506|NCT00047112|DRUG|cisplatin|
214878507|NCT00047112|DRUG|fluorouracil|
214878508|NCT00047112|PROCEDURE|conventional surgery|
214878509|NCT00047112|PROCEDURE|neoadjuvant therapy|
214878510|NCT00047112|RADIATION|radiation therapy|
214878511|NCT00643812|OTHER|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
214878512|NCT00643812|OTHER|Installation of gun locker in household|"Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline."
214878513|NCT03203122|OTHER|IPL laser|IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type
214878514|NCT03203122|OTHER|No sham treatment|The treatment is slightly painful, and noisy. Sham treatment impossible
214878515|NCT03226535|DEVICE|Ultrasound-CT Fusion|The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
214878516|NCT02208830|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
214878517|NCT02208830|OTHER|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
214878518|NCT03396003|DEVICE|GALILEI G6 Lens Professional|Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators
214878519|NCT03396003|DEVICE|Oculus Pentacam AXL|A single measurement of the eye will be taken using the Oculus Pentacam AXL
214878520|NCT03953326|BEHAVIORAL|HeartPhone app|Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
214878521|NCT03953326|DRUG|Acetylcholine|Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
214878522|NCT03953326|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
214878523|NCT03953326|DRUG|L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester|This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
214878524|NCT00621270|DRUG|BCI-540|BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
214878525|NCT00820781|PROCEDURE|Portacaval shunt|Subject taken to the operating room and undergoes portacaval shunt surgery
214878526|NCT00820781|PROCEDURE|Sclerotherapy|Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
214878527|NCT05051514|DIAGNOSTIC_TEST|Evaluation|To examine the differences in postural stability, anxiety/depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
214878528|NCT01586507|DRUG|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
214878529|NCT01586507|DRUG|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
214878530|NCT05842993|DEVICE|Hydrogen generator|Patient inhales hydrogen gas for 2 hours per day in the flow rate of 2L/min via nasal cannula by applying hydrogen generator (HZS-2700A, Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks.
214878531|NCT05842993|DEVICE|Analogue machine|Patient inhales normal air for 2 hours per day in the flow rate of 2L/min via nasal cannula with analogue machine for 12 weeks. This machine has the same appearance as the hydrogen generator.
215043920|NCT05465525|PROCEDURE|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
215043921|NCT05465525|OTHER|No Block|The patients will receive general anesthesia.
215043922|NCT04444089|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound with a curvilinear probe (DDED) is performed in all patients in a supine position on the lateral wall of the chest at approximately the level of the lower ribs using an ultrasound probe at a frequency of 4-12 MHz (AcusonX300, Siemens Korea, Seoul, South Korea). The mean number of B-lines detected on the ultrasound image and the percentage of patients who showed B-lines on their images were recorded. The mean of three measurements is used. Inter-observer variability is estimated to be 0.766 (95% confidence interval 0.675-0.847).
215043923|NCT04618029|OTHER|Home Modification|"Home Modification Intervention~Floor~Provide recommendations to:~* Fix the back of the rugs and mats with adhesive/heavy duty tape~* Buy non-slip mats~* Tie all cables with a proper cable tie~Lighting~Provide recommendations to:~* Buy a torch light~* To replace worn light bulbs~* Buy a light switch~Bathroom~Provide recommendations to:~* Buy a non-slip mat~* Install a grab rail~* Buy a commode chair for showering~Stairways~Provide recommendations to:~• Fix an adhesive tape for stair contrast"
214878532|NCT02548169|BIOLOGICAL|DC Vaccine + Standard of Care Chemotherapy|"4 doses of DC vaccine at 2 weeks interval, combined with either:~* Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~* FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~* Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL."
214878533|NCT02072343|DEVICE|No-DCCM|
214878534|NCT02072343|DEVICE|DCCM|
214878535|NCT02072343|OTHER|Water 5ml in tracheal tube|
214878536|NCT02072343|OTHER|Water 10ml in tracheal tube|
214878537|NCT04349943|OTHER|nutrition therapy|With enteral nutrition as the preferred solution, the gradual transition from slow to fast, from lean to dense, from essential to whole protein type is conducted.
214878538|NCT00055042|DRUG|Vitamin E|
214878539|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 70%|The incubator will be set to an ambient relative humidity (RH) of 70%.
215043924|NCT04618029|OTHER|Education|"Techniques Description Energy Conservation~* Take your time~* Go to the toilet more often, so you don't have to rush~* Use a nearby toilet: commode, different bathroom~* Prepare ahead (e.g., toilet paper near, other items for toileting, etc.)~* Adjust equipment before changing position~* Avoid transfers when tired~* Ask for help if you feel sick or especially tired~* Allow time for eyes to adjust to change in lighting~Task Simplification~* Plan and organise workspaces to eliminate unnecessary steps, save time, energy and reduce fatigue.~* Prioritise and plan activities, alternating between active and quiet jobs and include rest periods.~Ergonomics~* Proper positioning while doing tasks~* Safe mobility around the home"
215043925|NCT03249363|PROCEDURE|Group A - Pulsed PVP-I Irrigation|
215043926|NCT03423602|DEVICE|PerQseal®|Large hole closure system
215043927|NCT06447909|BEHAVIORAL|Treatment App|"The behavioral treatment app content consists of tasks that caregivers can assign to their children in the app (e.g., finish homework, make bed, etc.). These tasks are completed offline, and then caregivers approve the child's completion of those tasks through the app, administering a token reward (coins) in-app. In the child version of the app, children take care of a virtual pet by feeding, cleaning, buying various accessories (using in-game coins), and exploring different lands with the virtual pet. The caregiver-assigned token coins can be used to redeem items needed to raise their pet, and access virtual lands. Caregivers can also choose to have their child redeem virtual tokens for real-life rewards. Ultimately, the app combines a video game with evidence-based principles to help children practice important tasks and behaviors as administered by caregivers."
214291838|NCT02353598|DRUG|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
214291839|NCT02353598|DRUG|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
214291840|NCT02353598|DRUG|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
214878540|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 90%|The incubator will be set to an ambient relative humidity (RH) of 90%.
214878541|NCT05937828|OTHER|data collection|description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.
214878542|NCT00345943|OTHER|MRI|Magnetic Resonance Imaging scans
214878543|NCT00345943|BEHAVIORAL|Neuropsychological Testing|Neuropsychological tests
214878544|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
214878545|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
214878546|NCT03052868|OTHER|Cognitive Assessment|Cognitive testing session
214878547|NCT05228938|PROCEDURE|VNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
214878548|NCT05228938|PROCEDURE|laparoscopic|laparoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
214878549|NCT00789737|DRUG|Welchol|Welchol 625mg tablets
214878550|NCT00789737|DRUG|Placebo|placebo
214878551|NCT00891917|DIETARY_SUPPLEMENT|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
214291841|NCT03580694|DRUG|REGN4659|REGN4659 will be administered by intravenous (IV) infusion.
214291842|NCT03580694|DRUG|Cemiplimab|Cemiplimab will be administered by intravenous (IV) infusion.
214878552|NCT00891917|DIETARY_SUPPLEMENT|syrup (placebo)|syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
214878553|NCT03147755|OTHER|No intervention|No intervention
214878554|NCT02870218|DRUG|Smoking research cigarettes with e-cigarette|Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
214878555|NCT02870218|DRUG|Nicotine discrimination thresholds|Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.
214878556|NCT00384930|DRUG|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
215043928|NCT06447909|BEHAVIORAL|Sham app|As described above, the child will access a virtual pet that they can feed, clean and buy various accessories by redeeming virtual coins. They will not be able to explore different lands with that pet. Coins in the placebo version will be rewarded non-contingently. Additionally, children will not be able to redeem coins for real-life rewards as above in the treatment app. Caregivers will not need to review and approve tasks in order to redeem coins. The caregiver-version of the app will not contain the Assigned or Review tabs as assigned above, since the child will earn coins regardless of whether or not they complete tasks, so caregivers will not be able to review nor assign tasks. Instead, caregivers in this group will only have access to the guide tab which will contain helpful articles the parent can read about disruptive behavior problems in children.
215043929|NCT03423121|DRUG|Tauroursodeoxycholic Acid|Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
215043930|NCT03423121|DRUG|Placebo oral capsule|Participants will be given four capsules of the placebo twice daily.
214476950|NCT04370431|DRUG|TTYP01, 60 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
214476951|NCT04370431|DRUG|TTYP01, 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
214476952|NCT04370431|DRUG|Radicut® (ampoule), 30 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes
214878557|NCT00384930|DRUG|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
214878558|NCT00384930|DRUG|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
214878559|NCT00384930|DRUG|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
214878560|NCT00384930|DRUG|placebo|Placebo tablet taken by mouth one a day for twelve weeks
214878561|NCT00418002|DRUG|AQW051|
214878562|NCT02798432|PROCEDURE|Total knee arthroplasty|Use of an uncemented femoral component or a cemented femoral component randomly assigned.
214878563|NCT02798432|DEVICE|NEXGEN LPS total knee arthroplasty|Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).
214878564|NCT02686138|DRUG|Tenapanor|
215043931|NCT00419692|DRUG|Ropinirole|Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
214476953|NCT04370431|DRUG|Radicut® (bag) , 60 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes
214476954|NCT04370431|DRUG|TTYP01, up to 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
214878565|NCT02686138|DRUG|Placebo|
214878566|NCT01819610|DRUG|SPRIX|
214878567|NCT05039138|OTHER|NEUROMUSCULAR TRAINING EXERCISE|patients will receive neuromuscular training exercises in group II
214878568|NCT05039138|OTHER|traditional training exerises|traditional strength training exercises in group I
214878569|NCT04134338|OTHER|To evaluate the effect of wound infection on costs|the degree of costs that is required for trating wound infection
214878570|NCT04988087|DRUG|MHV370|MHV370 for 24 weeks
214878571|NCT04988087|DRUG|Placebo|Placebo for 24 weeks
214878572|NCT02845193|DEVICE|Modified Nasoalveolar molding|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
214878573|NCT02845193|DEVICE|Taping|Infants will receive a tape only on the upper lip segments to mold it to touch each other.
214878574|NCT02845193|DEVICE|CAD/NAM|computer aided design NAM
214878575|NCT00827437|OTHER|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
214878576|NCT02613182|DRUG|NEOD001|NEOD001
215043932|NCT04841954|DIAGNOSTIC_TEST|hemp prick-test|hemp seed and flower prick-test
215043933|NCT00272220|BEHAVIORAL|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
214878577|NCT00194701|BEHAVIORAL|Walking exercise|
214878578|NCT06168630|OTHER|Manual lymph drainage|It consists of patients who will receive manual lymph drainage everyday for 5 days. The subject's position will be supine with their knees bent. Every session will be of 45 minutes. Manual lymph drainage will with abdominal lymph drainage, after which central lymph stimulation will be performed. Then, by stimulating the bilateral axillary lymph nodes, the flow of fluid over the right and left breasts will be directed toward the axillary lymph nodes. While the patients in the prone position, bilateral axillary lymph nodes will be stimulated, and each manual lymph drainage will be performed from the dorsum to the axillary lymph node .
214878579|NCT06168630|OTHER|Control group|The other group will receive massage for 20 minutes every day for 5 days from first day of treatment. Massage will be done using the index and middle fingers in a spiral motion towards the nipples.
214878580|NCT03629756|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
214878581|NCT03629756|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
214878582|NCT05809167|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
214878583|NCT03968978|BIOLOGICAL|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
214878584|NCT03968978|BIOLOGICAL|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
214878585|NCT03832101|BEHAVIORAL|MATB|MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
214878586|NCT00000494|DRUG|indomethacin|
214878587|NCT00000494|PROCEDURE|surgery, cardiovascular|
214878588|NCT03471923|DIAGNOSTIC_TEST|Neurological Examination|The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.
215043934|NCT00149786|BEHAVIORAL|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
215043935|NCT00149786|BEHAVIORAL|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
215043936|NCT02474979|DEVICE|CBPM-system|The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
215043937|NCT02474979|OTHER|Control|
215043938|NCT03173014|DEVICE|EEG|EEG monitoring
214878589|NCT03471923|DIAGNOSTIC_TEST|Assessment of Non-Motor Features|All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
215043939|NCT03059784|OTHER|APP-based multifaceted management|Patients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.
215043940|NCT03917030|PROCEDURE|Open flap debridement with osteoplasty|Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the toot.
215043941|NCT03917030|PROCEDURE|Open flap debridement without osteoplasty|Treatment of furcation grade II defect with open flap debridement only.
215043942|NCT03243565|BIOLOGICAL|OM-85|OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.
215043943|NCT03243565|BIOLOGICAL|Placebo|Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
214878590|NCT02955823|DRUG|Rituximab-Dexamethasone-Lenalidomide|"1. st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~2. nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~   * if \<PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~  * if \<PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
214878591|NCT05043441|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with psychoeducation materials provided.
214878592|NCT05043441|BEHAVIORAL|Psychoeducation|The psychoeducation control group will receive care as usual with psychoeducation materials provided.
214878593|NCT06226012|DEVICE|pulsed magnetic field|Children in this group received pulsed magnetic therapy in addition to traditional exercise program
214878594|NCT06226012|DEVICE|Low level laser|Children in this group received low level laser therapy in addition to traditional exercise program
214878595|NCT01953978|DRUG|Dexamethasone|Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
214878596|NCT01953978|OTHER|Placebo|Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
214878597|NCT01953978|DRUG|Morphine|Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
214878598|NCT01953978|DRUG|Zofran|Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
214878599|NCT01953978|DRUG|Paracetamol|Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
214878600|NCT01953978|DRUG|Ibuprofen|Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
214878601|NCT00270907|DRUG|CT-2103|135 mg/m\^2 IV on Day 1.
214878602|NCT00270907|DRUG|Gemcitabine|1000 mg/m\^2 IV on Day 1 and 8.
214878603|NCT06525103|DEVICE|electromagnitic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology.~* Frequency : 50 or 60 Hz.~* Intenisty: 0-100 .Input voltage: 230 V"
214878604|NCT06525103|DEVICE|whole body vibration|"Crazy fit machine.~* Input voltage:220 V.~* Frequency : 30 Hz.~* Maximum power: 1500W.~* Intensity:1 to 50 levels."
214878605|NCT02254434|DRUG|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
214878606|NCT02335918|DRUG|Combination of varlilumab and nivolumab|"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
214878607|NCT05382585|OTHER|Next generation Sequencing|Next generation sequencing for 161 genes
214878608|NCT00351975|DRUG|Belinostat|Given IV
214878609|NCT00351975|DRUG|Azacitidine|Given SC
214878610|NCT00351975|OTHER|Laboratory Biomarker Analysis|Correlative studies
214878611|NCT01188278|DRUG|Imatinib|Drug being observed but not provided
214878612|NCT02064985|DRUG|"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
214878613|NCT03108053|PROCEDURE|Semirigid Ureteroscopy (URS) With Guide Wire|Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
214878614|NCT03108053|DEVICE|Semirigid Ureteroscopy (URS) Without Guide Wire|Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
214878615|NCT05450601|DRUG|HCP2102-1|Take once daily for 2 weeks orally
214878616|NCT05450601|DRUG|HPP2104-1|Placebo drug. Take once daily for 2 weeks orally
214878617|NCT05450601|DRUG|HCP2102-2|Take once daily for 6 weeks orally
214476955|NCT02577354|DEVICE|ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.
214878618|NCT05450601|DRUG|HPP2104-2|Placebo drug. Take once daily for 6 weeks orally
214878619|NCT05450601|DRUG|RLD2106-1|Take once daily for 2 weeks orally
214878620|NCT05450601|DRUG|HPP2103-1|Placebo drug. Take once daily for 2 weeks orally
214878621|NCT05450601|DRUG|RLD2106-2|Take once daily for 6 weeks orally
214878622|NCT05450601|DRUG|HPP2103-2|Placebo drug. Take once daily for 6 weeks orally
214878623|NCT04142112|DEVICE|Ohana IVF Sperm Preparation Kit (OHB035)|The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
214878624|NCT04142112|DEVICE|Standard IVF Preparation Kit (OHB037)|The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
214666874|NCT01601392|PROCEDURE|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
214878625|NCT05123183|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36 and CV17 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to CV17 point (single point) and ST36 point (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
214878626|NCT05123183|OTHER|back massage group|The mother sits in the chair and leans forward, placing her arms on the table at her level and resting her head on her arms. The mother's breasts are naked and freely released. The researcher massages the mother from top to bottom on both sides of the spine between the scapula bones. At this time, his fists are clenched and the thumb is open. While pressing firmly with his fists, small circular friction movements are made with his thumb. From the neck to the scapula, both sides of the spine are rubbed at the same time for 3 minutes. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
214878627|NCT05123183|OTHER|control group|No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
214878628|NCT01326923|DRUG|Cetuximab|Single arm phase II study of chemotherapy
214878629|NCT04054557|OTHER|Telemedicine|Participate in virtual visits with oncologist
214878630|NCT04054557|OTHER|Best Practice|Receive 4 in-office visits with oncologist
214878631|NCT04054557|OTHER|Questionnaire Administration|Ancillary studies
214878632|NCT04054557|OTHER|Quality-of-Life Assessment|Ancillary studies
214878633|NCT04054557|OTHER|Survey Administration|Complete electronic survey
214878634|NCT04054557|BEHAVIORAL|Behavioral Intervention|Use smart pill bottle
214878635|NCT04054557|OTHER|Educational Intervention|Receives time-specific reminders and messages
214878636|NCT05304039|BEHAVIORAL|Questionnaires|Questionnaires about asthma control and quality of life
214878637|NCT05304039|DEVICE|Spirometry|Spirometry monitoring at home
214878638|NCT05304039|DEVICE|Fractional Exhaled Nitric Oxide (FeNO)|Measuring fractional exhaled nitric oxide at home
214878639|NCT05304039|DEVICE|Corsano watch|Monitoring vital parameters at home
214878640|NCT05304039|DEVICE|e-Nose|Breathprint will be performed using e-Nose
214878641|NCT05304039|PROCEDURE|Nasopharyngeal swabs and nasal lining fluid|Nasopharyngeal swabs and nasal lining fluid will be performed
214878642|NCT05304039|DEVICE|Sputum culture|If patients produce sputum, the sputum will be analysed
214878643|NCT05304039|PROCEDURE|Blood sample|Blood sample for standard care and 10 ml extra will be taken
214878644|NCT06381596|DEVICE|OcuMet Beacon|OcuMet Beacon is a novel fundus camera the can detect, capture, and assess FPF.
214878645|NCT06137261|DIAGNOSTIC_TEST|Screening for heart failure|"• Anamnesis and Physical examination: Focus on signs of HF; will be performed by a trained employee.~• ECG: A standard 12-lead ECG will be recorded by a trained employee and will be interpreted by an experienced cardiologist.~• Echocardiography: A standard full echocardiogram will be acquired by a trained employee.~• Blood biomarkers: Venous blood samples will be taken and circulating levels of a broad range of markers related to obesity and/or heart failure will be determined. Also, an extra 10 mL blood sample will be drawn during the same venepuncture to be stored to determine additional biomarkers at a later stage.~• EQ-5D-5L questionnaire: EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which are divided into five degrees of severity, ranging from 'no problems' to 'extreme problems'."
214878646|NCT06229171|OTHER|adherence support system based on a vocal assistant|"Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken.~Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre."
214878647|NCT05497180|DEVICE|passive myofunctional appliance|passive myofunctional appliance
214878648|NCT05497180|DEVICE|standard oral appliance|standard oral appliance
214878649|NCT06002204|OTHER|Observational Study|No Treatment or Intervention Provided
214878650|NCT06780176|OTHER|Biospecimen Collection|Blood collection at baseline and time of surgery
214878651|NCT06780176|DIAGNOSTIC_TEST|Surgical Tissue Collection|Tissue collection will be attempted at time of surgery
215043944|NCT00560508|DRUG|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
215043945|NCT00560508|DRUG|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
215043946|NCT01781884|DRUG|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
215043947|NCT01781884|DRUG|Placebo|
215043948|NCT01354223|DEVICE|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
215043949|NCT01354223|DEVICE|ocufilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
215043950|NCT03323684|OTHER|Quadratus lumborum block Group (QL)|20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
215043951|NCT03323684|OTHER|Transversus abdominis plane Group (TAP)|20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
215043952|NCT03323684|OTHER|Control group (C)|No intervention will be done
215043953|NCT03323684|DRUG|Paracetamol infusion|Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
215043954|NCT03323684|DRUG|Ketorolac analgesia|In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
215043955|NCT03323684|DRUG|fentanyl|With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
215043956|NCT01035502|DRUG|Elacytarabine plus idarubicin|"Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.~Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.~It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy."
214878652|NCT06780176|BEHAVIORAL|Survey Collection|Survey collection at baseline, post-surgery, at 1, 3 and 5 year follow up visits
214878653|NCT06239077|OTHER|Non Invasive Prenatal Test via blood sample|Maternal - blood draw, Paternal - blood draw/Saliva sample
214878654|NCT01200069|DRUG|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
214878655|NCT01200069|DRUG|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
214878656|NCT01313377|DRUG|gemcitabine hydrochloride|
215043957|NCT00569322|PROCEDURE|BG Test|
215043958|NCT03150381|BEHAVIORAL|Weight Loss Only|24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
214476956|NCT02577354|DEVICE|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.
214878657|NCT01313377|DRUG|oxaliplatin|
214878658|NCT01313377|OTHER|clinical observation|
215043959|NCT03150381|BEHAVIORAL|Weight Loss Plus|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
215043960|NCT03150381|BEHAVIORAL|Control|Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
214291843|NCT01032642|DEVICE|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
214291844|NCT02239757|PROCEDURE|Left radial approach|Primary PCI performed through left radial approach.
214291845|NCT02239757|PROCEDURE|Right radial approach|Primary PCI performed through right radial approach.
214291846|NCT01867021|BIOLOGICAL|Fluvirin(TIVf)|
214291847|NCT01867021|BIOLOGICAL|Agriflu (TIV)|
215043961|NCT05794607|OTHER|Rehabilitation group|The intervention group will be given strength training to improve muscle strength and flexibility, and aerobic exercise training to improve exercise capacity with function.
215043962|NCT01490034|BEHAVIORAL|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
215043963|NCT01490034|BEHAVIORAL|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
215043964|NCT01490034|BEHAVIORAL|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
215043965|NCT01490034|BEHAVIORAL|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
215043966|NCT03246087|DEVICE|Acupunture|"acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed."
215043967|NCT03246087|OTHER|Standard of care|standard of care home exercise program
215043968|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab|Administration of Lilly Bamlanivimab to COVID positive patients
215043969|NCT04790786|BIOLOGICAL|Regeneron Casirivimab + Imdevimab|Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients
215043970|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab + Etesevimab|Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients
215043971|NCT04790786|BIOLOGICAL|Sotrovimab|Administration of Sotrovimab to COVID positive patients
215043972|NCT04790786|BIOLOGICAL|Bebtelovimab|Administration of Bebtelovimab to COVID positive patients
215043973|NCT04188132|OTHER|EEG -BCI based Feedback for rehabilitation|Subjects will undergo EEG based BCI as feedback for rehabilitation
215043974|NCT01082627|DRUG|Somatostatin|250ug/h,Continuous I.V. infusion,maximal 14 days
215043975|NCT01082627|OTHER|common daily practice|common daily practice
215043976|NCT04734457|DRUG|Levothyroxin|We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
215043977|NCT01973868|DRUG|Regorafenib (Stivarga, BAY73-4506)|
215043978|NCT01973868|DRUG|Cetuximab (ERBITUX)|
215043979|NCT00948688|RADIATION|Radiation therapy|Once per day, 5 days a week for 6 weeks
215043980|NCT00948688|DRUG|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
215043981|NCT00948688|DRUG|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
215043982|NCT03714607|DEVICE|Erbium Yttrium Aluminum Garnet (Er:YAG) laser|5 Er:YAG laser therapies vaginally administered at monthly intervals
215043983|NCT00563758|DRUG|tegaserod|
215043984|NCT02480088|DRUG|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
215043985|NCT02480088|DRUG|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
215043986|NCT01963988|PROCEDURE|Transurethral Coagulation (TUC)|
215043987|NCT01963988|PROCEDURE|Transurethral Resection(TUR)|
215043988|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
215043989|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
215043990|NCT05494268|DRUG|Carbohydrate|Preoperative Carbohydrate Loading Drink
215043991|NCT02987608|DEVICE|Power Up|Smartphone phone app
215043992|NCT03180229|DRUG|Granisetron 1 Mg/mL Intravenous Solution|1 milligram (mg) will use on group Granisetron before 5 min induction
215043993|NCT00362492|PROCEDURE|Bilateral ultrasound examination 7+/- 2 after surgery|
215043994|NCT03601390|DEVICE|PET/CT and EBV DNA|PET/CT and EBV DNA will be proformed after the IMRT treatment
215043995|NCT03407092|OTHER|ADAPT cohort|Thrombectomy with distal aspiration technique
215043996|NCT03407092|OTHER|Stentriever Cohort|Thrombectomy with stent retriever
215043997|NCT00006004|DRUG|carboplatin|
215043998|NCT00006004|DRUG|cisplatin|
215043999|NCT00006004|DRUG|gemcitabine hydrochloride|
215044000|NCT00006004|DRUG|paclitaxel|
215044001|NCT03218280|DRUG|Vitamin C|
215044002|NCT05556486|DEVICE|GlioStem|GlioStem is an oligothiophene derivative which can penetrate physiological cell membranes and selectively binds to structures inside the GSCs. GlioStem is conveniently administered ex-vivo onto the investigated tissue or cell culture by a pipette. After only a few minutes, the GSCs will emit green light from GlioStem molecules under blue illumination.
215044003|NCT04286152|DRUG|Mirabegron 50 MG|The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal
215044004|NCT04286152|DRUG|Placebo oral tablet|A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
215044005|NCT01340222|BIOLOGICAL|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
215044006|NCT01774812|DIETARY_SUPPLEMENT|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
215044007|NCT01774812|DIETARY_SUPPLEMENT|Ergocalciferol|50,000IU 1x per week for 6 weeks
215044008|NCT03280693|DIAGNOSTIC_TEST|Diagnostic test|Body balance was assessed using Berg Balance Scale (BBS), while BMD of the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA) scan.
214291848|NCT00881712|RADIATION|PET positive nodal disease measuring 15 mm or greater|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.
214291849|NCT00881712|RADIATION|PET positive nodal disease measuring less than 15 mm|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
214878659|NCT01313377|PROCEDURE|adjuvant therapy|
214878660|NCT01313377|PROCEDURE|quality-of-life assessment|
214878661|NCT02925481|BEHAVIORAL|Moderate Online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 150 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
214878662|NCT02925481|BEHAVIORAL|Stretching and toning|Phase 1: Developing 12 week prescription for online control videos Phase 2: Online streaming stretching and toning videos completed at home which consist of a warm-up, 1 balance, 2 core, 2-3 upper body and lower body exercises, 6 stretches, cool-down
214878663|NCT02925481|BEHAVIORAL|Low dose online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 60 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
214878664|NCT06795724|OTHER|PENG block|For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 20cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
214878665|NCT06795724|OTHER|Control|Standard analgesia method will be applied and analgesia will be provided with tramadol hydrochloride and paracetamol.
214878666|NCT02883049|DRUG|Clofarabine|Given IV
214878667|NCT02883049|DRUG|Cyclophosphamide|Given IV
214878668|NCT02883049|DRUG|Cytarabine|Given IT, IV, or SC
215044009|NCT01078948|DEVICE|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
215044010|NCT02343848|DEVICE|smart bracelet.|Physical activity will be evaluated using smart bracelet.
215044011|NCT01092884|DIETARY_SUPPLEMENT|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
215044012|NCT01092884|OTHER|Placebo|This placebo capsule will be taken orally three times daily
215044013|NCT05850767|OTHER|Sleep deprivation|Participants will stay fully awake for 24 hours
215044014|NCT00147992|PROCEDURE|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
215044015|NCT06377384|OTHER|FLIGHT Intervention|Personalized and multimodality intervention focusing upon modifiable lifestyle factors, environmental modifications, and transdisciplinary clinical care.
215044016|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)|The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
215044017|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training (RAS)|The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
215044018|NCT03838614|BEHAVIORAL|Muscle power training (MPT)|The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
215044019|NCT03838614|OTHER|Controls|Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
215044020|NCT03492502|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|"Consenting allo- SCT patients with acute steroid-resistant GI-related GVHD grade III-IV will receive autologous FMT by nasogastric tube. Standardized stool suspension will be given once a day for two consecutive days.In order to prevent aspiration, patients will be kept in a 45ᵒ upright position for four hours. Participants will fast the night before and be treated with proton pump inhibitors prior to each FMT.~In cases where complete response was not obtained within 7 days after autologous FMT, patients may be eligible for another trail of autologous FMT or to switch to other pharmacological interventions. Stool samples will be collected before and after the intervention for microbial analyses."
215044021|NCT02673983|PROCEDURE|Endoscopic full-thickness biopsy|
215044022|NCT03552107|DRUG|Lorcaserin|Treatment initiation with Lorcaserin
215044023|NCT06395116|OTHER|Denture base material|Denture base material constructed with different techniques for completely edentulous populations
214878669|NCT02883049|DRUG|Dasatinib|Given PO
214878670|NCT02883049|DRUG|Daunorubicin Hydrochloride|Given IV
214878671|NCT02883049|DRUG|Dexamethasone|PO or IV
214878672|NCT02883049|DRUG|Doxorubicin Hydrochloride|Given IV
215044024|NCT02665325|DRUG|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
215044025|NCT01493089|DRUG|Zegerid|20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
215044026|NCT01493089|DRUG|Losec|20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
215044027|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-discordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
215044028|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-concordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
214476957|NCT06788821|DIAGNOSTIC_TEST|Description of the trend of major thyroid ultrasound biometric parameters|Use of prenatal ultrasonography for diagnosis and prognostic guidance in suspected fetal thyroid changes.
214666875|NCT06042049|DRUG|Nirsevimab|Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.
214878673|NCT02883049|DRUG|Etoposide|Given IV
214878674|NCT02883049|DRUG|Hydrocortisone Sodium Succinate|Given IT
214666876|NCT02132390|DRUG|Goserelin|
214666877|NCT02132390|DRUG|Toremifene|
214666878|NCT05206110|DRUG|10 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 10 mg ketorolac (IV). Also, 10 mg IV ketorolac will be given 8h and 16h after the surgery
214878675|NCT02883049|OTHER|Laboratory Biomarker Analysis|Correlative studies
214878676|NCT02883049|DRUG|Leucovorin Calcium|Given PO or IV
215044029|NCT05276336|PROCEDURE|Radiofrequency turbinate reduction|Before the radiofrequency turbinate reduction procedure, local anaesthesia will be given by applying a cotton tamponade soaked in lidocaine adrenaline 1:5000 titration and added with xylocaine gel for 10 minutes in both nostrils. Then, a mixture of 1 mL of lidocaine 2% and 2 mL of sodium chloride 0,9% will be infiltrated to both nostrils using 3 mL and 1 mL needles until the inferior turbinates are pale. The radiofrequency probe (made by Sutter, both in monopolar and bipolar modes) will be inserted to the distal inferior turbinate until the black line from the probe is inside the inferior turbinate (approximately 10-12 mm). The procedure will be done for 10 seconds and the insertion of the probe can be done in 2-3 sites. After this, subjects from this group will be treated with pharmacology treatment using intranasal steroid and AH-1 according to ARIA WHO guideline 2008, similar to the pharmacology treatment received by the control group.
215044030|NCT05276336|DRUG|Pharmacology treatment|Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
215044031|NCT03202394|DRUG|BIO-11006|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
215044032|NCT03202394|DRUG|Placebo|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
215044033|NCT01555060|DIETARY_SUPPLEMENT|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
215044034|NCT03012334|DRUG|Lasmiditan|Dose is based on treatment sequence in 5-way crossover
215044035|NCT03012334|DRUG|Alprazolam|Active comparator based on treatment sequence in 5-way crossover
215044036|NCT03012334|OTHER|Placebo|Placebo comparator based on treatment sequence in 5-way crossover
215044037|NCT02347592|DEVICE|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
215044038|NCT02347592|DEVICE|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
215044039|NCT00368524|BEHAVIORAL|contingency management and behavioral day treatment|
215044040|NCT06000930|DIAGNOSTIC_TEST|Troponin fragmentation|laboratory test from blood sample
215044041|NCT03488329|DIETARY_SUPPLEMENT|Individual nutritional therapy|"Guidance from a clinical dietician.~Individual nutrition plan~A package containing foods and drinks, which will cover their nutritional needs the first day after discharge.~A goodiebag containing samples on protein-rich milk-based drinks.~Telephone follow-up after 4 and 30 days and the possibility to call the dietician in case of questions about nutrition."
215044042|NCT03946969|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for two cycles.
215044043|NCT03946969|DRUG|Liposomal Paclitaxel + Cisplatin + S-1|Liposomal Paclitaxel (135mg/m2), ivd, d1 + Cisplatin (25mg/m2), ivd, d1-3 + S-1 capsule (40mg), po, d1-14, repeated every 3 weeks for two cycles.
214666879|NCT05206110|DRUG|30 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 30 mg ketorolac (IV). Also, 30 mg ketorolac will be given 8h and 16h after the surgery
214666880|NCT01735110|PROCEDURE|transfemoral intervention (TFI)|
214878677|NCT02883049|DRUG|Mercaptopurine|Given PO
214878678|NCT02883049|DRUG|Methotrexate|Given IT and IV
214878679|NCT02883049|DRUG|Pegaspargase|Given IV
214878680|NCT02883049|DRUG|Prednisone|Given PO or IV
214878681|NCT02883049|RADIATION|Radiation Therapy|Undergo radiation therapy
214878682|NCT02883049|DRUG|Thioguanine|Given PO
214878683|NCT02883049|DRUG|Vincristine Sulfate|Given IV
214878684|NCT05877716|DEVICE|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
214878685|NCT05877716|BEHAVIORAL|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
214878686|NCT05877716|OTHER|Early Psychosis Coordinated Specialty Care|Participants will continue to engage in treatment as usual at their early psychosis coordinated specialty care clinic. These clinics may follow the NAVIGATE model, as an example.
214878687|NCT05806606|OTHER|Dyadic empowerment based heart failure management program|The 16-week De-HF Program is delivered on a dyadic basis, The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.
214878688|NCT05806606|OTHER|Dyadic education program|The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
214878689|NCT05041829|OTHER|Dietary sodium|Low sodium diet with sodium of \<2.3 g/day (\<100 mmol/day) and high sodium diet with sodium of ≥4 - \<6 g/day (≥174 - \<261 mmo/day)
214878690|NCT04769921|DEVICE|dental implants and abutments from Nobel Biocare|The implants will be inserted in an All-on-4 configuration; Abutments will be connected to the implants and serve as support for a full-arch implant-supported restoration.
214878691|NCT06647056|DRUG|Psilocybin|Administration of psilocybin 25 mg
214878692|NCT06647056|OTHER|MRI|Two standard MRI + fMRI scans before (D-3) and after (D5) treatment
214878693|NCT01887171|DRUG|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
214878694|NCT01691235|DEVICE|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
214878695|NCT03456388|DRUG|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
214878696|NCT03456388|DRUG|placebo enteric-coated tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
214878697|NCT00620685|DRUG|Placebo|Tablet, once daily for 4 weeks
214878698|NCT00620685|DRUG|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
214878699|NCT00620685|DRUG|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
214666881|NCT01735110|PROCEDURE|Transradial intervention|
214878700|NCT01810510|PROCEDURE|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
215044044|NCT02167789|DEVICE|Paradym CRT 8770|
215044045|NCT00325143|BIOLOGICAL|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
215044046|NCT00325143|BIOLOGICAL|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
215044047|NCT00314873|DRUG|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
215044048|NCT00712517|DRUG|propofol|propofol anesthesia 3-5mg/kg
215044049|NCT00712517|DRUG|sevoflurane|sevoflurane anesthesia
215044050|NCT01870869|DEVICE|Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection|Surgical implant
215044051|NCT04279743|DIETARY_SUPPLEMENT|omega-3 phospholipids|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
214291850|NCT00881712|RADIATION|Patients considered resectable|Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
214666882|NCT06428630|DRUG|dexamethasone oral rinse|"The study drug is FDA approved (NDC- 0054-3177) and will be used as it would be used in a standard of care setting. The rinse will be administered on the same therapeutic dose to OLP/OLR (0.5 mg/5ml of dexamethasone oral rinse once (rinse for 2 minutes or 5 minutes), then spit the excess into a cup.~The oral rinse dexamethasone 0.5 mg/5ml will be used only on the subjects who participated in the study."
214878701|NCT01810510|PROCEDURE|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
214878702|NCT00001526|DRUG|Daclizumab (Zenapax)|
214878703|NCT02245412|BIOLOGICAL|ALXN1007 10 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
214878704|NCT02245412|BIOLOGICAL|ALXN1007 20 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
214878705|NCT02245412|BIOLOGICAL|ALXN1007 20 mg/kg twice weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
214878706|NCT05009511|BEHAVIORAL|Learning through feedback|The goal of this investigation is to examine the influence of feedback timing on learning and brain function.
214878707|NCT03293316|DEVICE|Transcranial Random Noise Stimulation|The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
214878708|NCT02593643|DRUG|Ketamine|
214878709|NCT02593643|DRUG|Midazolam|
214878710|NCT02593643|OTHER|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
214878711|NCT03677583|OTHER|Duckweed|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
214878712|NCT03677583|OTHER|Spinach|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
214878713|NCT06013826|OTHER|Telenursing|Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated.
214878714|NCT05146843|DRUG|Mitoquinone|Mitoquinone pill, 20 mg/day
214878715|NCT05146843|OTHER|Placebo|Placebo pill, 20 mg/day
214878716|NCT04320043|PROCEDURE|Anterior cervical decompression|Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
214878717|NCT00490984|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
214878718|NCT05576766|PROCEDURE|Routine care|"1. Routine information provided before surgery.~2. No nutritional therapy.~3. No aerobic exercise.~4. No pelvic floor muscle training.~5. No psychiatrist intervention.~6. Bowel preparation with oral cathartic agent.~7. Fasting for over 8 hours; no oral carbohydrate solution (OCS) loading before surgery.~8. Hypothermia prevention not emphasized.~9. General anesthesia; regional block not emphasized.~10. Routine blood pressure management.~11. Mobilization from postoperative day 1.~12. Start oral feeding from postoperative day 1.~13. Patient-controlled analgesia with opioids.~14. Thromboembolism prophylaxis with low-molecular-weight heparin (LMWH).~15. Routine pelvic drainage tube removal (usually at postoperative day 4).~16. Routine urinary catheterization removal (usually at postoperative day 14)."
215044052|NCT04279743|DIETARY_SUPPLEMENT|omega-3 Triglycerides|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
214291851|NCT04770350|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
214291852|NCT03859349|DIAGNOSTIC_TEST|Selective Targeted Sampling|After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
214291853|NCT03859349|DIAGNOSTIC_TEST|Systematic Sampling|Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
214291854|NCT01397474|OTHER|PPTFM|Peripheral Perfusion Targeted Fluid Management
214666883|NCT06353711|BEHAVIORAL|CA-LINC Intervention|Participants received the CA-LINC intervention.
214666884|NCT06353711|BEHAVIORAL|Treatment as Usual|Participants received Treatment as Usual
214878719|NCT05576766|PROCEDURE|ERAS management pathway|"1. Patient consultation and education before surgery.~2. Nutritional intervention for patients whose BMI\<18.5 or BMI\>24 kg/m2.~3. Aerobic exercise for 2 weeks before surgery.~4. Pelvic floor muscle training for 2 weeks before surgery.~5. Psychiatrist intervention for patients with severe depression and anxiety.~6. No bowel preparation before surgery.~7. Provide oral carbohydrate solution 2 hours before surgery.~8. Hypothermia prevention.~9. General anesthesia combined with regional block.~10. Goal-directed fluid infusion and targeted blood pressure management.~11. Early mobilization.~12. Early oral feeding.~13. Multimodal analgesia, including opioids and non-steroid anti-inflammatory drugs.~14. Thromboembolism prophylaxis with low-molecular-weight heparin; rivaroxaban for high-risk patients.~15. Early pelvic drainage tube removal (at postoperative day 2) unless contraindicated.~16. Early urinary catheterization removal (at postoperative day 7) unless contraindicated."
214878720|NCT03003650|DEVICE|ACURATE TF™|ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
214878721|NCT00004492|DRUG|clotrimazole|
214878722|NCT00004492|DRUG|hydroxyurea|
214878723|NCT02713009|DIETARY_SUPPLEMENT|Pregnancy multi-vitamin (including 10μg vitamin D3)|
214878724|NCT02713009|DIETARY_SUPPLEMENT|10μg vitamin D3|
214878725|NCT02713009|DIETARY_SUPPLEMENT|0μg vitamin D (placebo)|
214878726|NCT05644197|OTHER|Multidisciplinary program|"Multidisciplinary program:~* APA interventions: 12 weeks Each week at home, cardio-respiratory endurance sessions for muscle strengthening and balance work from the Autohome interface (Neuradom) and one week supervised by an APA teacher.~* Nutrition interventions: A group nutrition workshop at the Hôpital Privé de Provence.~* Psychological intervention:~  5 sessions of 1h30 in group, the first session will take place at the Private Hospital of Provence and the others by videoconference.~An individual session the week following the last group session.~-Visit with the urologist, 5 weeks after the prostatectomy."
214878727|NCT01050465|OTHER|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
214878728|NCT01392963|DRUG|botulinum toxin type A neurotoxin complex|29-40 U injection
214878729|NCT01392963|DRUG|Placebo|29-40 U 0.9% NaCl injection
214878730|NCT00369486|PROCEDURE|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
214878731|NCT00369486|DRUG|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
214878732|NCT00369486|DRUG|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
214878733|NCT00369486|DRUG|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
214878734|NCT00369486|DRUG|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
214878735|NCT05815017|DEVICE|Yoomi Physical Therapy Software|Physical Therapy software via a computer/monitor will be set up for the patient. It will begin with a tutorial video for different exercises in the form of games and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
214878736|NCT00402116|DRUG|enzastaurin|"Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles"
215044053|NCT02286895|BIOLOGICAL|pentavalent rotavirus vaccine (PRV)|Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
215044054|NCT02286895|BIOLOGICAL|measles vaccine (MV)|A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
215044055|NCT02286895|BIOLOGICAL|yellow fever vaccine (YFV)|A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
214291855|NCT03519646|DRUG|Eliglustat|"1. This is a 3-year study and the enrollment time of this study is 24 months.~2. The participants have to receive the investigational agent, Cerdelga~3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~4. IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~5. No need for fasting before use, but can't take with grapefruit juice.~6. Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test."
214291856|NCT04510012|OTHER|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
214291857|NCT00296881|DEVICE|PERIOWAVE|
214878737|NCT00402116|DRUG|temozolomide|75 milligrams per meter squared (mg/m\^2), oral, daily, 6 weeks then 200 mg/m\^2, oral, daily, twelve 28 day cycles
214878738|NCT00402116|RADIATION|radiation therapy|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
214878739|NCT04214197|DRUG|Crisaborole 2% Top Oint|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
214878740|NCT01998945|BEHAVIORAL|Exposure-based Cognitive Behavioral Therapy|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
214878741|NCT01998945|BEHAVIORAL|Relaxation Training|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
214878742|NCT04588545|RADIATION|Radiation Therapy|Participants will receive radiation therapy (RT), either whole brain radiation therapy or focal brain/spine RT. The goal of RT is to palliate symptoms and improve the flow of Intrathecal (IT) therapy through the cerebrospinal fluid (CSF). As such, various RT schedules and targets are permitted. It is expected that the majority of patients will receive WBRT with 30 Gy in 10 fractions. However, shorter fractions of 20 Gy in 5 fractions of WBRT are permitted. In those patients who have more localized leptomeningeal disease in the spine, focal RT in up to 10 fractions may be administered with the exact dose left up to the discretion of the treating radiation oncologist.
214878743|NCT04588545|DRUG|Pertuzumab|Participants will be treated at 1 of 4 dose levels of pertuzumab, beginning at 10 mg and increasing up to 80 mg or Maximum Tolerated Dose (MTD).
214878744|NCT04588545|DRUG|Trastuzumab|Participants will be treated at a fixed dose of 80 mg trastuzumab.
214878745|NCT01822626|BEHAVIORAL|motivational counseling|A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
214878746|NCT04778904|BIOLOGICAL|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine
214878747|NCT04778904|BIOLOGICAL|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine
214878748|NCT04778904|BIOLOGICAL|Nivolumab|Human immunoglobulin G4 monoclonal antibody
214878749|NCT02896712|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT will assist cocaine patients to notice internal cravings and triggers, abandon attempts to manage these triggers via active avoidance, suppression or other control-based strategies, and to make commitments to engage in behaviors consistent with chosen values or goals. ACT encourages clients to experience thoughts and feelings from an observer perspective, and helps clients not to believe distressing thoughts and feelings as if those thoughts and feelings are literally true and in need of action. ACT treatment will be based on the ACT therapy manual developed and tested previously.
214878750|NCT02896712|BEHAVIORAL|Drug Counseling (DC)|The investigators will use the manual-guided individual DC modeled after the NIDA Collaborative Cocaine Treatment Study and used as the active control therapy in previous studies. DC approximates clinical practice as it is considered the most common type of evidence-based treatment in the community for patients actively using cocaine.
214291858|NCT04317131|DIAGNOSTIC_TEST|Research Diagnostic Criteria of Functional Disorders of the Masticatory System BKD / ZCURNŻ - Polish version|Interview and clinical examination of stomatognathic system based on standardized tool BDK/ZCURNŻ.
214291859|NCT04317131|DEVICE|Clinical examination of the stomatognathic system (structural and functional)|Examination with the use of JMA+Analyser (Jaw Motion Analyser) to analyse movement and function of the temporomandibular joints, mandibular position, condyle position (EPA), and access the muscle action potentials through bipolar skin surface electrodes EMG, assessment of occlusion by visual method according to Angle Classification.
214878751|NCT02896712|BEHAVIORAL|Contingency Management (CM)|The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.
214878752|NCT02896712|DRUG|Placebo|The placebo capsule will be filled with corn starch and riboflavin.
214878753|NCT02896712|DRUG|Modafinil|Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
214878754|NCT01437930|DIETARY_SUPPLEMENT|n-3 PUFA|"products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~1. linseed oil (20g/d)(PPM, Magdeburg)~2. echium oil (20g/d) (HARKE Nutrition)~3. microalgae powder(12g/d)(HARKE Nutrition)"
214878755|NCT06297421|PROCEDURE|Fecal Microbiota Transplantation|Oral Fecal Microbiota Transplantation Capsule
214878756|NCT06297421|PROCEDURE|Placebo|Oral Placebo Capsule
214878757|NCT03057821|OTHER|3% hydrogen peroxide|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
214878758|NCT04634279|BEHAVIORAL|Collaborative care Plus|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In this model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care. In the Collaborative Care Plus condition, the care coordinator involves family in care, teaches family about naloxone use, and provides Caring Contacts, a suicide prevention method, to patients.
214878759|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
214878760|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
214878761|NCT01810302|DRUG|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
214878762|NCT01810302|DRUG|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
214878763|NCT01193179|DRUG|OPC-262|Oral administration of tablets for 52 weeks
214878764|NCT02358902|DEVICE|tDCS|tDCS - DC stimulator, Neurocom, Germany
214878765|NCT02358902|PROCEDURE|active intervention of aerobic exercise|different types of aerobic exercise
214878766|NCT02358902|DEVICE|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
214878767|NCT02358902|PROCEDURE|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
214878768|NCT04138043|DRUG|Placebo|Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
214878769|NCT04138043|DRUG|GSK2330811|GSK2330811 will be available as SC injection 150 mg/mL.
214878770|NCT02856802|DRUG|Sumatriptan 10 mg Nasal Spray|100 μL nasal spray once
214878771|NCT02856802|OTHER|Sumatriptan Placebo Nasal Spray|100 μL nasal spray once
214878772|NCT03772717|DEVICE|Non-invasive vagus nerve stimulation (nVNS)|The nVNS study intervention will be delivered using a handheld electrical neuromuscular stimulator device (VitalStim 400). Participants will deliver nVNS twice per day for 60 minutes each time at least 5 days per week. The two electrodes for the device will be placed on the subjects left cervical (neck) region. Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters. The stimulation frequency (number of pulses) and amplitude (amount of current) will be set during the initial baseline session in the clinic at a level that prevents discomfort and does not impact cardiorespiratory parameters. The stimulator will be placed in a comfortable position, such as next to the pillow. The stimulators are battery-powered and allow configuration of the stimulation parameters to the comfort of the patient.
214878773|NCT03772717|OTHER|Standard of care treatment|Patients will be asked to continue their standard medication regimens which include in most cases will involve 3 weekly infusions of intravenous immunoglobulin (IVIG) (1 gm/kg) and rarely plasma exchange (PLEX).
214878774|NCT03584087|DRUG|Normal Saline|TG 0 (0Hr)
214878775|NCT03584087|DRUG|Terlipressin|Duration of Terlipressin after EVL
214878776|NCT05787626|OTHER|manipulation|miofascial technique in diaphragmatic region
214878777|NCT02743429|DRUG|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days."
214878778|NCT03659929|DRUG|Amphetamine Sulfate|active experimental AR19
214878779|NCT03659929|DRUG|Placebo|Matching placebo
214878780|NCT02764346|BEHAVIORAL|iCanCope app|"In addition to standard medical care, adolescents in the experimental group will receive access to the iCanCope smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component."
214878781|NCT02764346|BEHAVIORAL|iCanCope attention control app|"The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the iCanCope control app, with limited functionality."
214878782|NCT03281018|BEHAVIORAL|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session|The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
214878783|NCT06553352|DRUG|Zanubrutinib combined with Obinutuzumab|Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.
214878784|NCT05114213|RADIATION|SBRT|online adaptive MR-guided hypofractionated stereotactic radiotherapy
214878785|NCT05114213|DRUG|SOC chemotherapy|The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
215044056|NCT02286895|BIOLOGICAL|meningitis conjugate vaccine (PsA-TT-5μg)|A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
215044057|NCT01093313|BEHAVIORAL|Cognitive therapy|
215044058|NCT01093313|BEHAVIORAL|attention training|
215044059|NCT05302895|DEVICE|All-in-one health monitoring device|The staff will use the new monitoring device to carry out the health monitoring on every day during the 12-week period. After each round of health monitoring by the traditional and the new devices, the staff will need to fill in log sheets designed by HKU to document the time consumed for the entire process.
215044060|NCT04747262|BEHAVIORAL|SPACE|SPACE program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and OCD (Lebowitz, 2013; Lebowitz, Omer, Hermes \& Scahill, 2014)
215044061|NCT06279611|DRUG|LY007|FC and LY007 infusion
215044062|NCT02791464|BEHAVIORAL|Transcendental Meditation program|a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
215044063|NCT04167943|DRUG|Dual cured resin modified tricalcium silicate cement|A resin based, dual cured tricalcium silicate based cement
215044064|NCT01073293|BIOLOGICAL|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
215044065|NCT01073293|BIOLOGICAL|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
214291860|NCT04317131|DEVICE|3D examination of the body posture|Comprehensive, three- dimensional examination of the body posture (static and dynamic) in the area of the spine, lower limbs and feet, performed by photogrammetric method (4th Generation MORA) and non- invasive image acquisition technology with the aid of infrared (Kineod) and The CQElektronik system.
215044066|NCT01073293|BIOLOGICAL|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
215044067|NCT03036852|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
215044068|NCT03261895|BEHAVIORAL|Nurse-led Integrative health and wellness programme|Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinese medicine.
215044069|NCT03866317|DRUG|Secukinumab|All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
215044070|NCT01926132|DRUG|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
215044071|NCT01926132|DRUG|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
215044072|NCT04435743|DRUG|Lenalidomide|"Lenalidomide is given as any following dosage:~1. 25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~2. 15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~3. 25mg, PO QD, Day 1-10 in every 21 days for 1 year;~4. 25mg, PO QD, Day 1-21 in every 28 days for 1 year;~5. 25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~6. 20mg, PO QD, Day 1-21 in every 28 days for 12 cycles."
215044073|NCT00639288|OTHER|modified CPT-C|modified CPT-C
215044074|NCT03849105|RADIATION|4-L-[131I]iodo-phenylalanine (131I-IPA)|"Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy"
214878786|NCT03352739|DEVICE|DBS of the fornix, power on|"DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
214878787|NCT03352739|DEVICE|DBS of the NbM, power on|"DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
214878788|NCT03352739|DEVICE|DBS of the fornix, power off|"DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
214878789|NCT03352739|DEVICE|DBS of the NbM, power off|"DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
214878790|NCT06306248|OTHER|Total sleep deprivation|non pharmacologic treatment for depression
214878791|NCT05289869|DRUG|High-dose oxytocin|Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
214878792|NCT05289869|DRUG|Low-dose oxytocin|Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
214878793|NCT05146830|OTHER|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
214878794|NCT01867463|BIOLOGICAL|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
214878795|NCT01867463|BIOLOGICAL|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
214878796|NCT01867463|BIOLOGICAL|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
215044075|NCT00991809|DRUG|Alfentanil|15 mcg/kg IM
215044076|NCT00991809|DRUG|Diphenhydramine|25 mg IM
215044077|NCT02478151|DEVICE|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
215044078|NCT03569943|DEVICE|Robot Based Transtympanic drain placement|Placement of a transtympanic drain with a robot based device assistance called RobOtol
215044079|NCT02422329|BEHAVIORAL|Questionnaires|Participants complete questionnaires at baseline and after intervention.
215044080|NCT02422329|BEHAVIORAL|Video|Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
215044081|NCT02422329|BEHAVIORAL|Fact Sheet|Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
215044082|NCT04591119|PROCEDURE|Transversus Thoracic Muscle Plane Block|40 ml %0.375 bupivacaine divided into 4 equal doses will be injected by the surgeon between internal intercostal muscle and transversus thoracis muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space
214878797|NCT06115525|OTHER|mNUTRIC score|The mNUTRIC score is a useful means of gauging the nutritional risk of patients in intensive care. Originally designed for IC unit patients, the score is calculated even when patient cooperation is unfeasible, making it applicable for intubated patients. Information necessary for calculation can be obtained from the patient's kin. The mNUTRIC score (without IL-6) classifies patients according to predefined metrics. The following information is necessary: (1) the patient's age, (2) their APACHE II score, (3) their SOFA score, (4) their comorbidities, and (5) the number of days they were hospitalized before being admitted to ICU.
214878798|NCT06115525|OTHER|NRS-2002|The NRS-2002 score is a tool utilised to measure the nutritional risk of patients in intensive care units. This tool was specifically developed for the purpose of evaluating intensive care unit patients and can be calculated without requiring the patient's active involvement. Additionally, it can be applied to patients who have been intubated and the required information can be sourced from their family members or relatives. The Nutritional Risk Screening (NRS)-2002 assesses a patient's nutritional risk based on five variables: (1) recent unexplained weight loss, (2) appetite, (3) BMI, (4) disease-related stress factors (comorbidities), and (5) age over 70 years which is an additional risk factor.
214878799|NCT03278626|DRUG|Nivolimumab+Carboplatin/paclitaxel+Radiation|In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
214878800|NCT04107272|DEVICE|Real repetitive transcranial magnetic stimulation|"The real rTMS will be delivered over M1 (hand representation) of dual hemispheres with 10 trains of 10 Hz pulses for 10 seconds, with a total of 1,000 pulses per hemisphere. The real rTMS intensity will be set as 80% resting motor threshold and the interval between each train of pulses will be set as 50 seconds. The real rTMS will be delivered as daily session for five consecutive days, followed by two fortnightly maintenance sessions during the follow-up period after the completion of five daily sessions. The real rTMS will be delivered by designated physical therapists using figure-of-8 shaped coil."
214878801|NCT04107272|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham rTMS of this study will be delivered with the same active coil angled 90-degree way from the scalp. The intensity of sham rTMS will be set at lowest stimulator output that can generate similar noise to the real rTMS. The sham rTMS will be delivered in the same manner and duration with real rTMS.
214878802|NCT03013816|BEHAVIORAL|Organ Donation Education: Testimonial Messaging|The testimonial messaging video intervention will be shown
214878803|NCT03013816|BEHAVIORAL|Organ Donation Education: Informational Messaging|The informational messaging video intervention will be shown
214878804|NCT03013816|BEHAVIORAL|Organ Donation Education: Blended Messaging|The blended messaging video intervention will be shown
214878805|NCT05349708|DEVICE|THE-FACS|Telehealth home-monitoring tablet and blood pressure cuff
214878806|NCT00580788|DRUG|PTHrP (1-36)|IND # 49,175
214878807|NCT03232671|DIAGNOSTIC_TEST|MIF ELISA|Blood sample
214878808|NCT04971187|DRUG|Bintrafusp Alfa|Given IV
214878809|NCT04971187|DRUG|Pemetrexed|Given IV
214878810|NCT04971187|DRUG|Carboplatin|Given IV
214476958|NCT06309784|PROCEDURE|Drill Guidance System (DGS)|During a standard surgical procedure where a drill/k wire is being inserted the surgeon may choose (in advance) to supplement their drilling with use of the Drill Guidance System. This will be a supplement to normal practice. it is anticipated it will make surgery more accurate, swifter and safer. If however the surgeon is not finding the DGS useful it can be abandoned and standard drilling with X-ray guidance used
214878811|NCT04971187|DRUG|Cisplatin|Given IV
214878812|NCT00547586|DRUG|N-methylnaltrexone bromide (MOA-728)|Oral
214878813|NCT00547586|OTHER|placebo|placebo
214878814|NCT03743415|BEHAVIORAL|Handbook|see arm/group descriptions
214878815|NCT03743415|BEHAVIORAL|TIP-C plus Handbook|see arm/group descriptions
214878816|NCT03612921|DRUG|oral Amantadine sulfate|oral amantadine
214878817|NCT03612921|DRUG|i.v Amantadine Sulfate|intra venous amantadine
214878818|NCT03612921|DRUG|placebo tablet|placebo tablet
214878819|NCT04598399|BEHAVIORAL|Mindfulness Based Relapse Prevention|7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.
214878820|NCT04598399|BEHAVIORAL|Relaxation/ meditation|7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants
214878821|NCT02460367|DRUG|Docetaxel|
214878822|NCT02460367|BIOLOGICAL|Tergenpumatucel-L|
214878823|NCT02460367|DRUG|Indoximod|
214878824|NCT06521099|BEHAVIORAL|Evaluative Conditioning with positive stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social motivation (between none to high) on Likert-scales. In the conditioning phase, emotional social pictures will be selected and paired with non-social positive stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
214878825|NCT06521099|BEHAVIORAL|Conditioning with neutral stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social motivation (between none to high) on Likert-scales. In the conditioning phase, emotional social pictures will be selected and paired with with neutral non-social stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
214878826|NCT04435535|PROCEDURE|PEP|Positive expiratory pressure 10 cmH2O 15 min
214878827|NCT03385850|OTHER|enteral nutrition|early enteral nutrition group or delayed enteral nutrition group
214878828|NCT01062347|BIOLOGICAL|Zinc|
214878829|NCT04353895|DEVICE|Guidance for pedicle screw insertion (Mazor Stealth)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
214878830|NCT04353895|DEVICE|Guidance for pedicle screw insertion (O-arm Navigation)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
214878831|NCT05228431|DRUG|XELOX|Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
214878832|NCT05228431|DRUG|Capecitabine monotherapy|During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
214878833|NCT05228431|RADIATION|Radiation|The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.
214878834|NCT05009017|DRUG|Bevacizumab|Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab
214878835|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention + IVR booster calls|1\) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
214878836|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
214878837|NCT01125371|BEHAVIORAL|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
214878838|NCT03195335|OTHER|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
214878839|NCT04808336|OTHER|PRP injection.|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
214878840|NCT04808336|PROCEDURE|fixation surgical procedure|Group 2: thirty patients underwent surgery
214878841|NCT04800549|OTHER|Oral Mucositis|The data of the study were obtained by conducting six interviews with each child and the family. The first interview was conducted before starting to treatment on the first day of the treatment, the second interview was conducted on the 2nd day after the treatment and the following interviews were conducted on the 4th, 8th, 16th, and 21st days and in-mouth mucosa of the patient was evaluated by taking in-mouth pictures following interviewing with the child and the family. Oral care application was conducted four times a day with sodium bicarbonate solution and a lollipop made with black mulberry syrup (after meals and before going to the bed at night). Oral care was first conducted by the researcher, the oral care was then taught to the patient and patient's relatives and the application was evaluated. Figure 1 shows the study design.
214878842|NCT06632808|OTHER|Exercise|Deep cervical flexor muscle exercises target the deep neck muscles that play a crucial role in the stabilization of the cervical spine and the maintenance of proper posture. These muscles, particularly the longus colli and longus capitis, are responsible for the correct alignment of the head and neck. The exercises typically involve gentle flexion of the neck (bringing the chin towards the chest) with low-intensity, controlled movements. The goal is to strengthen these muscles, enhance spinal stability, and alleviate symptoms such as tension-type headaches. Additionally, these exercises support postural control and can reduce excessive strain on the neck.
214878843|NCT00170664|DRUG|Paclitaxel|
214878844|NCT00170664|DRUG|Carboplatin|
214878845|NCT05209594|BEHAVIORAL|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.
214878846|NCT05209594|BEHAVIORAL|Standard GSA Programming|Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
214878847|NCT06079567|DIAGNOSTIC_TEST|Validation of new COMs for FSHD2 patients|Monitoring of commonly used and new COMs in FSHD2 patients
214878848|NCT01823601|BEHAVIORAL|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
214878849|NCT01823601|BEHAVIORAL|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
214878850|NCT01935518|DRUG|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
214878851|NCT02548390|DRUG|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
214878852|NCT06633978|DEVICE|MediTrain|Participants will engage with a digital meditation app for 30m/day for 6wks. MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
214291861|NCT04317131|DEVICE|Functional assessment of the spine and lower limbs|Functional assessment of the spine and lower limbs mobility trough a wireless motion sensor Moover.
214878853|NCT06633978|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
214878854|NCT06633978|DEVICE|Sleep monitor|Sleep Profiler devices are FDA-cleared reduced-montage EEG recording devices that will be used in accordance with its FDA clearance. They are completely non-invasive and are designed to be comfortable enough to wear all night without interfering with normal sleep. These devices enable quality sleep recordings in the comfort of people's homes, rather than required an overnight stay at a sleep lab at UCSF.
214878855|NCT06323148|DRUG|Osimertinib|Adjuvant osimertinib for three years after radical surgery
214878856|NCT06323148|DRUG|No adjuvant therapy|No adjuvant therapy
214878857|NCT06551766|DEVICE|Photosensitive hydrogel|In the photosensitive hydrogel group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by photosensitive hydrogel.
214878858|NCT06551766|DEVICE|6-0 absorbable stitches|In the suture fixation group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by two stitches using 6-0 absorbable wire.
214878859|NCT05378594|DIAGNOSTIC_TEST|Nasal allergen challenge|graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
214291862|NCT04317131|DEVICE|Complementary tests|Anthropometric measurements (height, weight, waist and hip circumference, skin folds), foot pressure on the ground and body balance accessed by pedobarograph FreeMed, body mass components measured by the Tanita MC 980 MA (BIA method), evaluation of 7-days of physical activity by accelerometer ActiGraph GT3X-BT, blood pressure measurement by Medel Connect Cardio MB 10 monitor.
214291863|NCT02056314|OTHER|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
214291864|NCT02056314|OTHER|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
214291865|NCT00335868|DRUG|danusertib|
214291866|NCT00335868|OTHER|laboratory biomarker analysis|
214291867|NCT00335868|OTHER|pharmacological study|
214291868|NCT01877434|PROCEDURE|Reversed shoulder arthroplasty|
214878860|NCT05097365|DIETARY_SUPPLEMENT|Vitamin B12 + folic acid supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.
214878861|NCT05097365|DIETARY_SUPPLEMENT|Placebo supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.
214878862|NCT04207463|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
214878863|NCT04207463|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
214878864|NCT00124124|DRUG|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
214878865|NCT00124124|DRUG|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
214878866|NCT04974203|DEVICE|AptameX|DNA aptamer-based test using patient's saliva
214878867|NCT01266031|DRUG|vorinostat|Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.
214878868|NCT01266031|DRUG|bevacizumab|Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.
214878869|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
214878870|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
214878871|NCT04399486|OTHER|Physical Therapy|Physical Therapy is a therapeutic exercise, education and functional activities provided on a one to one basis with a licensed Physical Therapist to meet functional goals.
214878872|NCT03179423|DRUG|GNbAC1|Monthly IV repeated dose
214878873|NCT03179423|DRUG|Placebo|Monthly IV repeated dose
214878874|NCT04036838|COMBINATION_PRODUCT|PyloPlus UBT System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
214878875|NCT04036838|DIAGNOSTIC_TEST|Histology|Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
214878876|NCT04036838|DIAGNOSTIC_TEST|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
214878877|NCT04036838|DIAGNOSTIC_TEST|H.pylori Culture|Biopsy specimen obtained and sent to lab for culture analysis
214878878|NCT03718650|DRUG|Pimonidazole|Patients will take a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral pimonidazole HCI 16 to 24 hours prior to surgery.
214878879|NCT03718650|PROCEDURE|Surgical Resection|Patients will undergo Pancreaticoduodenectomy or Whipple procedure, which involves the resection of the pancreatic head, duodenum, gallbladder, and a portion of the stomach, 16 to 24 hours after consuming oral pimonidazole.
214878880|NCT00775125|DRUG|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
214878881|NCT04009707|OTHER|MoCA (Montreal Cognitive Assessment) test|the MoCA questionnaire is used to assess cognitive disorders
214878882|NCT04009707|OTHER|BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test|This questionnaire is used to assess cognitive disorders
214878883|NCT00003911|RADIATION|stereotactic radiosurgery|
214878884|NCT00275574|PROCEDURE|acupuncture|acupuncture
214878885|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice1|100% Orange Juice
214878886|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
214878887|NCT03685201|DIETARY_SUPPLEMENT|Raw Orange|Raw Orange
214878888|NCT02153463|BEHAVIORAL|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
214878889|NCT03074786|DRUG|Dapivirine|Silicone elastomer vaginal matrix ring
214878890|NCT03074786|DRUG|Truvada|Tablets to be taken orally daily
214878891|NCT06501430|OTHER|Heating Therapy|Heating Therapy will be performed on subjects along with PNF Exercises.
215044083|NCT04591119|PROCEDURE|Parasternal Intercostal Plane Block|40 ml %0.375 bupivacaine injection will be performed by ultrasound guidance after completion of surgery between pectoralis major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally by anesthesiologist.
214476959|NCT04186650|BIOLOGICAL|COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin|Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
214878892|NCT06501430|OTHER|Manual Soft tissue Release|Manual Soft tissue Release will be performed on subjects along with PNF Exercises.
214878893|NCT01644630|PROCEDURE|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~\- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
214878894|NCT01644630|PROCEDURE|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
215044084|NCT05348811|DRUG|HAIC combined with donafenib and sintilimab|"HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter \> 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times.~Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or \> 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol."
215044085|NCT05317130|OTHER|Athlete health monitoring|Observational study
215044086|NCT00002766|BIOLOGICAL|dactinomycin|
215044087|NCT00002766|BIOLOGICAL|sargramostim|
214878895|NCT04738695|DIAGNOSTIC_TEST|Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)|Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
214878896|NCT00569855|DRUG|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
214878897|NCT05232812|RADIATION|3-[11C]-OHB|The PET tracer 3-\[11C\]-OHB is used to quantify 3-hydroxybutyrate uptake
214878898|NCT02931981|PROCEDURE|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
214878899|NCT02392949|BEHAVIORAL|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
214878900|NCT02392949|OTHER|Placebo|The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
214878901|NCT06467396|DEVICE|Large Vessel Occlusion Biomarkers Test|Duplex Point of Care test to measure the concentration of blood biomarkers (FABP+NT-proBNP) associated to Large Vessel Occlusion in blood samples used in combination with an APP.
214878902|NCT03883308|BEHAVIORAL|Multi-domain cognitive training|The cognitive exercises are designed to train executive functions and memory.
214878903|NCT03883308|BEHAVIORAL|Cross-word puzzle training|The active control group will be asked to complete a variety of crossword puzzles using the same curriculum assigned to the TG group.
214878904|NCT05162508|OTHER|Nasopharyngeal swab|Nasopharyngeal swab available in Standard Of Care (SOC) will be analysed (Full-length SARS-CoV-2 RNA sequencing and Transcriptomic analyses)
214878905|NCT01146756|DRUG|AZD6244|MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
214878906|NCT05532709|OTHER|Plyometric training|m level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps
214878907|NCT05532709|OTHER|Circuit training|"The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes."
215044088|NCT00002766|DRUG|carmustine|
215044089|NCT00002766|DRUG|cyclophosphamide|
215044090|NCT00002766|DRUG|cytarabine|
215044091|NCT00002766|DRUG|daunorubicin hydrochloride|
215044092|NCT00002766|DRUG|doxorubicin hydrochloride|
215044093|NCT00002766|DRUG|etoposide|
215044094|NCT00002766|DRUG|mercaptopurine|
215044095|NCT00002766|DRUG|methotrexate|
215044096|NCT00002766|DRUG|mitoxantrone hydrochloride|
214878908|NCT03938285|OTHER|Theranova 400 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
214878909|NCT03938285|OTHER|FxCordiax 120 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
214878910|NCT05296863|COMBINATION_PRODUCT|Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|"Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
214878911|NCT05296863|COMBINATION_PRODUCT|Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.
214878912|NCT05296863|COMBINATION_PRODUCT|Placebo and 5% Minoxidil|"Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
214878913|NCT01708967|PROCEDURE|pretreatment method for transnasal endoscopy|"Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity."
214878914|NCT04417413|DEVICE|Fotona ProlapLase|Non-ablative SMOOTH mode intravaginal Er:YAG teratment for pelvic organ prolapse
214878915|NCT03731442|RADIATION|Involved field irradiation|Involved field irradiation; intensity-modulated radiation therapy
214878916|NCT03731442|RADIATION|Elective field irradiation|Elective field irradiation; intensity-modulated radiation therapy
214878917|NCT03731442|DRUG|Paclitaxel|Paclitaxel 135-150mg/m2, d1, every 3 weeks
214878918|NCT03731442|DRUG|Platinum|for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;
214878919|NCT03731442|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
215044097|NCT00002766|DRUG|pegaspargase|
215044098|NCT00002766|DRUG|prednisone|
215044099|NCT00002766|DRUG|vincristine sulfate|
215044100|NCT00002766|RADIATION|radiation therapy|
215044101|NCT01451411|DRUG|Conivaptan hydrochloride|Intravenous
215044102|NCT01451411|DRUG|Placebo|Intravenous
215044103|NCT03483389|DRUG|Alcohol, Ethyl|Randomized within-subjects design
215044104|NCT03483389|OTHER|Alcohol, Ethyl - placebo|Randomized within-subjects design
215044105|NCT00020254|BIOLOGICAL|aldesleukin|
215044106|NCT00020254|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|
215044107|NCT00020254|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
215044108|NCT00020254|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
215044109|NCT00020254|BIOLOGICAL|sargramostim|
215044110|NCT00020254|DRUG|nilutamide|
215044111|NCT00077974|DRUG|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
214878920|NCT06582940|RADIATION|MRI-guided adaptive SRT|MRI-guided online adaptive SRT (without PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. MRI will be acquired.
215044112|NCT00256126|DRUG|Saizen|Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
215044113|NCT00256126|DRUG|Saizen|Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
215044114|NCT03674983|BEHAVIORAL|Conditional Economic Incentive (CEI)|"If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes."
214878921|NCT06582940|RADIATION|Conventional SRT|Conventional SRT (with PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. CBCT will be acquired.
214878922|NCT00187993|DRUG|Growth hormone|
215044115|NCT04161664|DRUG|Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
215044116|NCT02652221|DEVICE|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
215044117|NCT00003816|BIOLOGICAL|anti-thymocyte globulin|Given IV
215044118|NCT00003816|DRUG|busulfan|Given IV
215044119|NCT00003816|DRUG|carboplatin|Given IV
215044120|NCT00003816|DRUG|cyclophosphamide|Given IV
215044121|NCT00003816|DRUG|etoposide|Given IV
215044122|NCT00003816|DRUG|fludarabine phosphate|Given IV
215044123|NCT00003816|DRUG|melphalan|Given IV
215044124|NCT00003816|DRUG|thiotepa|Given IV
215044125|NCT00003816|RADIATION|total-body irradiation|Given twice daily for 3 days
215044126|NCT01877304|DEVICE|AKITA|
215044127|NCT06068517|DEVICE|Closed incision negative pressure wound therapy|After the completion of abdominal surgery and standardised skin closure with staples, ciNPWT will be applied, using a commercially available device.
214878923|NCT04355065|BEHAVIORAL|Cognitive Traning with The Secret Trail of Moon|Patients are pharmacologically stable and receive a cognitive intervention with our videogame once a week in the hospital.
214878924|NCT04355065|BEHAVIORAL|Cognitive Traning with Therapeutic Chess|This group is pharmacologically stable. This group performs cognitive training through a therapeutic chess protocol designed by a chess psychologist. The training is done from home and we contact them weekly to correct the exercises done and to follow up.
214878925|NCT04355065|DRUG|Control Group|"These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group."
214878926|NCT00005957|RADIATION|Standard Breast Irradiation|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
214878927|NCT00005957|RADIATION|Breast Radiation plus Regional Radiation|Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
214878928|NCT05734248|PROCEDURE|Facial filler injection|Hyaluronic acid will be injected on the cheek, based on the aesthetic evaluation of the face.
214878929|NCT05107596|DRUG|64Cu-DOTA-ECL1i|Inject PET Radioisotope for imaging
214878930|NCT00616512|PROCEDURE|GF Strong Water Protocol|The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
214878931|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
214878932|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
214878933|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
214878934|NCT00053183|PROCEDURE|conventional surgery|
214878935|NCT00053183|RADIATION|brachytherapy|
214878936|NCT00053183|RADIATION|radiation therapy|
214878937|NCT05204498|BEHAVIORAL|Education plan and adherence to exercise|"Through phone calls with a motivating sense at any time of the day, twice a week.~* It will be recorded in an Excel table each time the patient is called.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 8 weeks. At the end of week 8, patients will be referred to the pulmonary rehabilitation unit to evaluate the anthropometric parameters, assess dyspnea with the modified scale of the Medical Research Council, the hospital anxiety and depression scale, the Saint George respiratory questionnaire , the pulmonary information You need the questionnaire and the 6-minute walk test again."
214878938|NCT00799825|BIOLOGICAL|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
214878939|NCT03685422|OTHER|Virtual Reality|Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Visual analog scale-anxiety (VAS-A), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.
215044128|NCT06068517|DEVICE|Standard dressing|After the completion of abdominal surgery and standardised skin closure with staples, standard dressings will be applied.
215044129|NCT00312286|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
215044130|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
215044131|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
215044132|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
215044133|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
215044134|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
215044135|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
215044136|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
215044137|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
215044138|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
215044139|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
214878940|NCT05086263|DEVICE|Pico G2 4k|"On this virtual reality headset, it will be loaded with an educational virtual reality mock MRI training titled Ready Teddy. This training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Furthermore, using audio/visual cues, when the viewer moves their head too much in a MRI like setting they are reminded to stay still. Biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure."
214878941|NCT04600258|DIETARY_SUPPLEMENT|Dark Chocolate|The patients will receive 40g per day of dark chocolate for 2 months
214878942|NCT05489666|DIETARY_SUPPLEMENT|Nature Made Vitamin D3 5,000 IU, 125mcg|Taking a 5,000 IU oral supplement of Vitamin D3, daily, for 8 weeks, may improve strength performance in women who have and are continuing a resistance trained workout regimen. After blood vitamin D levels have been raised to an optimal range, a lower dosage may be assigned as needed from 5,000 IU per day to 1,000-2,000 IU per day.
214878943|NCT05489666|DIETARY_SUPPLEMENT|Placebo|Resistance trained women may not improve their strength performance with low levels of vitamin D in the blood.
214878944|NCT06168110|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control
215044140|NCT01404247|OTHER|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
215044141|NCT01404247|PROCEDURE|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
215044142|NCT02141009|BIOLOGICAL|Prevnar 13|
214878945|NCT00582010|DRUG|inhaled nitric oxide|inhaled 80ppm for duration of surgery.
214878946|NCT00582010|DRUG|nitrogen gas|inhaled
215044143|NCT02250417|OTHER|Wave sleep surface|The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
215044144|NCT02874729|PROCEDURE|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
215044145|NCT02874729|PROCEDURE|Urine collection|Urine will be collected in appropriate sterile holders provided.
215044146|NCT02874729|PROCEDURE|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
215044147|NCT02874729|PROCEDURE|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
215044148|NCT00899912|GENETIC|microarray analysis|
215044149|NCT00899912|OTHER|diagnostic laboratory biomarker analysis|
215044150|NCT05579652|DIAGNOSTIC_TEST|Abdominal tension measurement|A tensiometer scale will be used to measure the tension needed to pull each side of the abdominal wall to midline
215044151|NCT01711528|DRUG|Bortezomib|Given SC
215044152|NCT01711528|DRUG|Dexamethasone|Given PO
215044153|NCT01711528|DRUG|Dinaciclib|Given IV
215044154|NCT01711528|OTHER|Laboratory Biomarker Analysis|Correlative studies
215044155|NCT04340154|BIOLOGICAL|chimeric antigen receptor T cell|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given twice（anti-CD19 CAR-T first, then anti-CD22 CAR-T). All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
215044156|NCT00002366|DRUG|Ritonavir|
215044157|NCT02405299|OTHER|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
214878947|NCT03596138|OTHER|Evaluate the reliability and reproductibility of the automated angular measurement by the Gazelab|Compare the results of the Gazelab to the alternate occlusion by prism bar (standard gold) examiners.
214878948|NCT00792350|DRUG|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
215044158|NCT03376932|DRUG|FF/UMEC/VI|FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
214291869|NCT02853110|RADIATION|Hypo-FLAME study|SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (\~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
214476960|NCT06819774|DRUG|Cetirizine Hydrochloride Injection|The subjects received a single dose of 1-2 ml of the injection of cetirizine hydrochloride (administered by intravenous push) and a 1 ml dose of the injection simulant of diphenhydramine hydrochloride (administered by deep intramuscular injection), both as a simulation of a single administration.
214878949|NCT03229135|DEVICE|other antibacterial agents，breathing machine|If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
214878950|NCT05603403|DRUG|Probiatop|1 sachet orally, 2 times a day, for 42 days
214878951|NCT05603403|OTHER|Placebo|1 sachet orally, 2 times a day, for 42 days
215044159|NCT03376932|DRUG|FP/SAL|FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
215044160|NCT03376932|DRUG|Tiotropium|TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.
215044161|NCT03376932|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
215044162|NCT03376932|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.
214878952|NCT05382403|DEVICE|Jada® System|This is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted. The device is made of medical grade silicone. The distal end, which is placed in the uterus, is an elliptical loop. The circular cervical seal, just outside the external cervical os, is filled with 60 - 120 mL sterile water. Low-level vacuum (80 ± 10 mm Hg) is applied and pooled blood is evacuated from the uterus as it collapses. Once there is no bleeding, the device remains in the uterus for at least 1 hour. The suction is then disconnected, the seal emptied of water, the device left in place, and the patient monitored for an additional 30 minutes. If bleeding remains controlled, the device is removed. If bleeding is uncontrolled with the Jada® System patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
214878953|NCT05382403|OTHER|Standard care|Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
214878954|NCT00601575|DRUG|Lithium|
214878955|NCT04049136|DIAGNOSTIC_TEST|NT-proBNP|Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
214878956|NCT04316793|OTHER|Dry needling|Intramuscular insertion of an OPTIMED 40mm x 0.3mm acupuncture needle in a trigger point of the infraspinatus muscle
214878957|NCT04316793|OTHER|Sham needling (SN)|Intradermal insertion of an OPTIMED 40mm x 0.3mm acupuncture needle over the infraspinatus region
214878958|NCT01159561|BIOLOGICAL|Western Equine Encephalitis Vaccine|Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
214878959|NCT00333151|DRUG|liraglutide|
214878960|NCT00333151|DRUG|rosiglitazone|
214878961|NCT00333151|DRUG|metformin|
215044163|NCT03376932|DEVICE|DISKUS DPI|The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.
214878962|NCT02439970|DRUG|Brincidofovir|
214878963|NCT02439970|DRUG|Valganciclovir|
214878964|NCT06072573|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
215044164|NCT03376932|DEVICE|RESPIMAT inhaler|The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.
215044165|NCT03376932|DEVICE|Metered Dose Inhaler|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
215044166|NCT03376932|DEVICE|Connected Inhaler System|The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.
215044167|NCT03419429|DRUG|Simvastatin|Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.
215044168|NCT03419429|OTHER|EDTA|EDTA is a demineralizing agent used for root surface conditioning.
215044169|NCT03419429|DEVICE|Occlusive membrane|Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.
215044170|NCT03419429|DEVICE|Modified perforated membrane|Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration
215044171|NCT02949011|DRUG|Baloxavir Marboxil|Tablets taken orally
214878965|NCT06072573|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
214878966|NCT03763474|COMBINATION_PRODUCT|Euglyca application|'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
214878967|NCT01492920|DIETARY_SUPPLEMENT|Acetyl-L-Carnitine Hydrochloride|Given orally
214878968|NCT01492920|OTHER|Placebo|Given orally
214878969|NCT01492920|OTHER|Questionnaire Administration|Ancillary studies
214878970|NCT01492920|OTHER|Quality-of-Life Assessment|Ancillary studies
214878971|NCT01161485|BEHAVIORAL|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
215044172|NCT02949011|DRUG|Placebo to Baloxavir Marboxil|Matching tablets taken orally
215044173|NCT02949011|DRUG|Oseltamivir|Capsules taken orally
215044174|NCT02949011|DRUG|Placebo to Oseltamivir|Matching placebo capsules taken orally
215044175|NCT06338111|DIAGNOSTIC_TEST|ELISA Sepsis Biomarkers dosage|Observational
215044176|NCT01752218|DEVICE|arcuate incision|
215044177|NCT05829876|OTHER|High Frequency ECG Mapping|A high frequency ECG map will be performed to assess the optimum left ventricular pacing site.
215044178|NCT05829876|OTHER|Q-LV Measurement|Measurement of Q wave on 12 lead ECG to LV stimulus to assess optimum left ventricular pacing site.
215044179|NCT05014152|DEVICE|Q-temp-w1|Q-temp-w1 is a contact type body temperature patch developed by Quanta Computer Co., Ltd. It is mainly used to measure the body temperature of the human body. It can be used for general body temperature measurement, home temperature measurement records and medical tracking.
215044180|NCT05014152|DEVICE|Omron thermometer(MC-171W)|Omron thermometer(MC-171W) is mainly used to measure the body temperature of the human body. The reference temperature patch used in this study is the OMRON thermometer, model: MC-171W.
214878972|NCT01161485|BEHAVIORAL|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
214878973|NCT01161485|BEHAVIORAL|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
214878974|NCT03766607|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
214878975|NCT03766607|DRUG|Ramucirumab|Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days
214878976|NCT03766607|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
214878977|NCT02806115|PROCEDURE|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
214878978|NCT02806115|DRUG|Acetic Acid|The concentration of acetic acid used in this study is 1.5%.
214878979|NCT02806115|DEVICE|endoscope|This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
214878980|NCT04218578|DIAGNOSTIC_TEST|speckle tracking analysis of transthoracic echocardiogram|analysis at workstation with 2D strain-Speckle tracking echocardiography of transthoracic cardiac echo at baseline and one-year follow up examination
215044181|NCT02523287|BIOLOGICAL|Fluad|Randomized assignment
215044182|NCT02523287|BIOLOGICAL|Saline|Randomized assignment
214476961|NCT06819774|DRUG|Diphenhydramine Hydrochloride Injection|The subjects received 1 ml of the injection of Diphenhydramine Hydrochloride (for deep intramuscular injection) and 1 ml of the injection of Simulated Cetirizine Hydrochloride (administered by rapid intravenous injection over 1 to 2 minutes), each as a single dose.
214878981|NCT01128309|BEHAVIORAL|Stress Reduction Intervention|eight week group program, plus daily homework practice
214476962|NCT06820931|DRUG|Xuandi Ziyin Mixture|Treatment is given only with the hospital preparation 'Xuandi Ziyin Mixture' with a dosage of 30ml per administration three times a day.
214878982|NCT01128309|BEHAVIORAL|Active Control intervention|weekly group meetings for eight weeks, plus daily homework practice
214476963|NCT06817317|OTHER|Model Based Training|experimental group
214878983|NCT00008307|BIOLOGICAL|anti-thymocyte globulin|
214878984|NCT00008307|DRUG|cyclosporine|
215044183|NCT02489084|OTHER|Blood sampling|
215044184|NCT00163189|DRUG|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
215044185|NCT06348095|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
215044186|NCT06348095|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
214476964|NCT06817317|OTHER|Peer and Self-Learning Group|experimental group
215044187|NCT01995097|BEHAVIORAL|Scheduled Gradual Reduction Text Messages|
214878985|NCT00008307|DRUG|fludarabine phosphate|
214878986|NCT00008307|DRUG|melphalan|
214878987|NCT00008307|DRUG|methylprednisolone|
214878988|NCT00008307|DRUG|mycophenolate mofetil|
214878989|NCT00008307|PROCEDURE|allogeneic bone marrow transplantation|
214878990|NCT00008307|PROCEDURE|peripheral blood stem cell transplantation|
215044188|NCT01995097|BEHAVIORAL|Support Text Messages|
215044189|NCT05035888|DRUG|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
215044190|NCT05035888|DRUG|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
215044191|NCT02154061|DRUG|IIV Flu Vaccine|This is an FDA approved and tested Inactivated Flu Vaccine.
215044192|NCT02154061|DRUG|Metronidazole|This is a standard antibiotic
215044193|NCT02154061|DRUG|Neomycin|This is a standard antibiotic.
215044194|NCT02154061|DRUG|Vancomycin|This is a standard antibiotic.
215044195|NCT00506142|DRUG|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
215044196|NCT00477984|DRUG|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
215044197|NCT02946203|OTHER|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
215044198|NCT02946203|OTHER|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
214878991|NCT00008307|PROCEDURE|syngeneic bone marrow transplantation|
214878992|NCT03709511|OTHER|Cardiac rehabilitation|perioperative rehabilitation consists of education, inspiratory muscle training, active cycle of breathing techniques, and early mobilization.
215044199|NCT00346723|BIOLOGICAL|Influvac® subunit influenza vaccine for i.m./deep s.c.injection|
215044200|NCT04106245|BEHAVIORAL|Behavioral Intervention|Participate in PACK Health
215044201|NCT04106245|OTHER|Survey Administration|Complete survey
215044202|NCT02862119|PROCEDURE|FFR Treatment Arm|Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
215044203|NCT02862119|OTHER|Conservative Treatment Arm|Initial Conservative management of non-culprit lesions during index hospital admission
215044204|NCT05443529|OTHER|Adaptive sports|Participation in community adaptive sports programs
215044205|NCT03319576|OTHER|Feeding at 4 hours|Patients will be fed 4 hours after their gastrostomy tube placement procedure.
215044206|NCT00454116|DRUG|Vandetanib|once daily oral tablet two doses
215044207|NCT00454116|DRUG|FOLFIRI|Intravenous infusion
215044208|NCT01399853|BIOLOGICAL|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
215044209|NCT01399853|BIOLOGICAL|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
214878993|NCT02498028|PROCEDURE|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
214878994|NCT02498028|PROCEDURE|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
214878995|NCT04521101|OTHER|VAST Course|Educational course to teach non-technical skills
214878996|NCT03717012|DRUG|Nintedanib|stable dose
215044210|NCT01399853|BIOLOGICAL|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
214878997|NCT03717012|OTHER|Pulmonary rehabilitation program|12 weeks
214878998|NCT02386124|OTHER|frailty evaluation|assessment of mental and physical frailty before discharge from cardiac departement
214878999|NCT01425658|DRUG|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
214879000|NCT01425658|DRUG|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
215044211|NCT01399853|BIOLOGICAL|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
215044212|NCT01399853|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
215044213|NCT02213250|DRUG|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
215044214|NCT06005909|OTHER|Cawthorne-Cooksey Exercises|"A- Head and Eye Movements While Lying and Sitting:~1. While keeping your head still, look up and then down again.~2. Look from side to side while keeping your head still.~3. Extend your hand at arm's length, draw your fingers towards your nose while focusing your eyes on your fingers.~4. With eyes open, slowly turn your head from side to side.~5. Turn your head from side to side quickly.~6. With eyes open, slowly move your head up and down.~7. Move your head up and down quickly.~8. Repeat items 4,5,6 and 7 with your eyes closed.~B-Head and Body Movements While Sitting:~1. Place an object on the floor in front of your feet, reach out to pick it up, then upright return to your position. Looking down while picking up the item, then Remind you to look up when trying to fix it.~2. Lean forward and move the object forward and back under your knees. C- Standing Exercises~1-Get from a sitting position to a standing position and sit down again. 2-Repeat this with your eyes closed."
215044215|NCT06005909|OTHER|Mechanical Hippotherapy Exercises|"From the patient on the mechanical hippotherapy device;~* Maintaining trunk balance while raising both hands above head,~* Maintaining trunk balance while opening the arms next to the trunk,~* Maintaining trunk balance while extending the arms back and forth with successive movements,~* Maintaining trunk balance with hands clasped behind the waist,~* The arms are open to both sides, while transferring the weight ball from one hand to the other, it is requested to maintain the body balance."
215044216|NCT03186339|PROCEDURE|TAVI|transfemoral transcatheter aortic valve implantation
215044217|NCT03186339|PROCEDURE|SAVR|isolated surgical valve replacement
215044218|NCT03186339|OTHER|MM|management of aortic stenosis by medical treatment only
214879001|NCT01425658|DRUG|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
214476965|NCT06819917|OTHER|Identification of liver fibrosis biomarkers|"Patients will be recruited in the study using 2 different approaches. The first is patients who are referred to clinical centers as part of an existing assessment where a decision to perform a liver biopsy has been made (routine biopsy). This decision can be based on standard liver function tests AST, ALT, FIB-4 (performed up to 8 months before biopsy), fibroscan (performed up to 6 months before biopsy) or other factors.~In addition, patients F0-F2 who underwent a biopsy within the last 6 months but at least 1 month ago, can be recalled to join the study. If patients agree to participate in the study, they will be recalled to the site for a blood draw and ultrasound scan."
214476966|NCT06820541|DEVICE|Double plastic pigtail stent plus fully covered self-expandable metal stent|After contrast injection, the cystic duct orifice will be detected. Using a sphincterotome, a 0.035-inch hydrophilic angled guidewire will be negotiated into the gallbladder. Dilation of the cystic duct will be performed using standard devices designed for biliary intervention, including pneumatic dilators or dilation progressive catheters. After dilation, a 7Fr plastic, double pigtail stent, length of 12 or 15 cm, will be deployed across the papilla. Finally, a fully-covered self-expandable metal stent will be placed alongside the gallbladder drainage for biliary drainage.
214879002|NCT05029219|DEVICE|Arm I (Virtual reality group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The test group receives about 60 minutes of training using a virtual reality program."
214879003|NCT05029219|DEVICE|Arm II (Self study group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The control group have provided with video materials and books provided during audiovisual education and have given time for self-study for 60 minutes. Subsequently, a second test is performed with a fluroscopy-guided lumbar transforaminal epidural block with a human-shaped phantom."
214879004|NCT06526624|DRUG|HS-20093|Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.
215044219|NCT06108570|OTHER|Cosmetic Product TOPIALYSE Baume Protect+|One or two application.s of TOPIALYSE Baume Protect+ daily on one side for 28±3 days and the Neutral Product daily on the other side for 28±3 days. The side will be decided before by randomisation.
215044220|NCT03333603|DRUG|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
215044221|NCT01917318|DRUG|Iloperidone|"Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)"
215044222|NCT01917318|DRUG|Placebo|During 8 weeks subjects will receive oral placebo
215044223|NCT02748681|DEVICE|Auto CPAP AirSense™ 10(Resmed)|AutoSet CPAP without telemedicine monitoring
215044224|NCT01760070|DEVICE|Hybrid knife|Use Hybrid knife in ESD procedure
215044225|NCT01760070|DEVICE|IT knife|Use IT knife in ESD procedure.
215044226|NCT03557866|DIAGNOSTIC_TEST|running|individuals will be asked to run for 5 km in self selected speed
214476967|NCT06820541|DEVICE|Fully covered self-expandable metal stent|After biliary cannulation, a fully covered self-expandable metal stent will be placed for biliary drainage
214476968|NCT06819241|BEHAVIORAL|AI chatbot support|Integrating the practice of self-monitoring of HBP with the use of AI chatbot responses. This arm includes reminders for patients to monitor their BP and take antihypertensive medications, and involves tracking BP readings over time and offering feedback. Moreover, this arm offers physician-endorsed guidance on modifying the dosage of antihypertensive medication and implementing lifestyle adjustments. It offers education on hypertension and the potential side effects of medication, as well as assistance with medication refills and scheduling appointments.
214476969|NCT06819241|BEHAVIORAL|telemonitoring and case management|Combining self-monitoring of HBP with telemonitoring and case management. This arm includes reminders for patients to monitor their BP and take antihypertensive medications, and involves tracking BP readings over time and offering feedback. Moreover, this arm offers physician-endorsed guidance on modifying the dosage of antihypertensive medication and implementing lifestyle adjustments. It offers education on hypertension and the potential side effects of medication, as well as assistance with medication refills and scheduling appointments.
215044227|NCT04868344|DRUG|MRG003|Administered intravenously
215044228|NCT01008618|DRUG|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
215044229|NCT01008618|DRUG|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
215044230|NCT03410069|DEVICE|IKORUS UP system|Continuous assessment of the urethral microcirculation
215044231|NCT01306747|BEHAVIORAL|The Stanford Chronic Pain Self-Management Programme|The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
215044232|NCT00151450|DRUG|Pregabalin|
215044233|NCT00151450|DRUG|Venlafaxine XR|
215044234|NCT06405126|DIAGNOSTIC_TEST|Optiek predictive model|Patient data will be extracted to run the predictive model, which will estimate the probability of group 2 pulmonary hypertension. However the results of the model will have no diagnostic or therapeutic implications in this phase of the investigation.
215044235|NCT00742625|DRUG|daunorubicin hydrochloride|Given IV
215044236|NCT00742625|DRUG|cytarabine|Given IV
215044237|NCT00742625|DRUG|bortezomib|Given IV
215044238|NCT05357833|DRUG|Ferumoxytol infusion|Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
215044239|NCT05357833|DRUG|Gadoteridol|Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
214879005|NCT05640258|DIAGNOSTIC_TEST|rotatory chair testing in a velocity step protocol.|Tc was evaluated by the rotational velocity step test using the OtoaccessTM interface (Interacoustics Nydiag 200, Middlefart, Denmark). Subjects were seated on the rotatory chair wearing videonystagmography goggles with their heads supported and tilted 30° forward, thus bringing the horizontal semicircular canals plane perpendicular to the axis of rotation. Standard videonystagmography techniques were employed to record eye-movements. Subsequent to eye movements' calibration, the chair was accelerated about the yaw axis at 30°/sec2 to a maximal velocity of 90°/sec, followed by rotation at a constant velocity. After 57 seconds of constant velocity rotation, the chair was decelerated to zero velocity at 30°/sec2. The described velocity step was conducted both clockwise and counter-clockwise, giving a total run time of 4 minutes.
214879006|NCT01932918|DRUG|Patient controlled analgesia|"1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients."
214879007|NCT06361719|OTHER|Experimental Group (EG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
214879008|NCT06361719|OTHER|Control Group (CG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
214879009|NCT02640690|BEHAVIORAL|Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)|(10) 1-hour sessions of trauma sensitive yoga
214879010|NCT02640690|BEHAVIORAL|Cognitive Processing Therapy|(12) 1.5 hour sessions of cognitive processing therapy
214879011|NCT01520870|DRUG|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
214879012|NCT04648800|DRUG|BCG-10 vaccine|"The BCG-10 anti-tuberculosis vaccine~* powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~* lyophilised BCG vaccine~* one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain."
214879013|NCT04648800|DRUG|0.9% saline|0.9% saline
214879014|NCT00176618|DRUG|sulindac|Sulindac 150 mg po BID
214879015|NCT00176618|DRUG|curcumin|Curcumin 250 mg po BID
215044240|NCT05357833|DIAGNOSTIC_TEST|MRI Brain and Cervical Spine|3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
215044241|NCT01291966|BEHAVIORAL|Motivational interview|
215044242|NCT02432430|BEHAVIORAL|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage|Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
215044243|NCT02432430|BEHAVIORAL|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage|Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
215044244|NCT04256187|OTHER|Qualitative interview|Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
215044245|NCT00891150|DRUG|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
215044246|NCT05245539|DRUG|CVL-231|CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.
215044247|NCT01084889|DEVICE|surgical mesh implantation (TiLOOP® Total 6)|The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.
215044248|NCT04429464|DEVICE|AcQBlate Force Sensing Ablation Catheter|Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias
215044249|NCT03338400|DRUG|Dexamethasone|Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.
215044250|NCT03338400|DRUG|Normal saline|Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
215044251|NCT00363571|DRUG|GTN, Diamox|
215044252|NCT00800800|DRUG|Rosuvastatin|40 mg, oral, single dose
215044253|NCT00800800|DRUG|Placebo|oral, single dose
215044254|NCT03984721|DIAGNOSTIC_TEST|Amyloidosis typing using mass spectrometry-based proteomics|Amyloidosis typing using nanoLC-MS/MS method
215044255|NCT04179110|DRUG|Pembrolizumab and Ramucirumab|Patients will receive Pembrolizumab 200 mg \& Ramucirumab 10 mg/kg every 3 weeks.
214879016|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with ligation.
214879017|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with sclerotherapy.
214879018|NCT05978752|PROCEDURE|Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated)|For patients with GOV1 esophagogastric varices, only gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will not be treated.
215044256|NCT02941614|BEHAVIORAL|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
215044257|NCT02012803|PROCEDURE|End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture|Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
215044258|NCT02012803|OTHER|Conservative treatment of achilles tendon rupture|Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
215044259|NCT03454789|DRUG|brachial plexus block for LB Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
215044260|NCT03454789|DRUG|brachial plexus block for BS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
215044261|NCT03454789|DRUG|brachial plexus block for LS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
215044262|NCT03454789|DRUG|brachial plexus block for BL Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
215044263|NCT02227303|BEHAVIORAL|lifestyle modification instructional and motivational sessions|
215044264|NCT01012284|DRUG|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
215044265|NCT00093509|DRUG|doxorubicin hydrochloride|To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
215044266|NCT00093509|DRUG|ifosfamide and mesna|2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
215044267|NCT00093509|PROCEDURE|hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator|Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90.
215044268|NCT00093509|RADIATION|radiation therapy|External beam megavoltage (≥ 4 MV) beams will be used at SSD, SAD ≥ 70 cm at a dose rate of \> 100 cGy/min. Fraction sizes of 180 cGy will be used 5 times per weeks in a continuous course. Total dose will be 45 Gy + 10%, consistent with sites being treated.
215044269|NCT06345885|BIOLOGICAL|HPV vaccine|Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months
215044270|NCT05009095|DEVICE|The Listening Program® with bone conduction headphones|The Listening Program method of Music-Based Auditory Stimulation is enhanced with the addition of bone conduction technology with the ABT Bone Conduction System. Bone Conduction combines the experience of listening to music through modified headphones adding subtle, synchronized acoustic vibration of the skin and skeletal system, engaging the whole body and brain in the listening process. This multi-sensory approach accelerates and expands the benefits of The Listening Program.
215044271|NCT05046392|BEHAVIORAL|Face-to-Face ART Adherence Intervention|All participants will receive a one hour face-to-face session with an adherence coach, based on LifeSteps. The session will cover behavioral skills that are important for maintaining adherence to ART and will explore potential barriers for managing each skill. Cognitive-behavioral therapy, problem solving, and motivational interviewing techniques are used to explore barriers and create health goals.
215044272|NCT05046392|BEHAVIORAL|Carium Mobile Health Platform|Participants assigned to the experimental condition will receive access to a mobile health app, called Carium, for 12 months. The app will be used to facilitate continued coaching from the adherence coach. The app incorporates automated medications reminders with interactive adherence coaching via a secure messaging feature. Participants will receive custom medication reminders as push notifications that will ask them to indicate if they have taken their medication or not. This will allow adherence coaches to monitor self-reported adherence in the app. Adherence coaches will use the secure messaging feature to check-in with participants and reach out to participants who appear to be struggling with adherence and offer assistance.
215044273|NCT06465784|PROCEDURE|Retrograde and Antegrade Ureteroscopic Laser Lithotripsy|Comparison Between Retrograde and Antegrade Ureteroscopic Laser Lithotripsy for Management of Medium Sized Proximal Ureteral Stones: A Randomized Prospective Study
215044274|NCT03906643|DRUG|HS-201|HS-201 will be administered intravenously as a single dose
215044275|NCT03759990|DEVICE|lean|Videolaryngoscope used in intubation
215044276|NCT03759990|DEVICE|obese|Videolaryngoscope used in intubation
215044277|NCT05962021|DRUG|Toripalimab plus Chemotherapy|Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
215044278|NCT01865487|BIOLOGICAL|H56ug/IC31nmol|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
215044279|NCT01865487|BIOLOGICAL|Placebo|Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
214879019|NCT04743687|DRUG|Zanubrutinib|Oral Zanuburutinib, 160mg twice a day
214879020|NCT03254498|DEVICE|Endocuff|It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
214879021|NCT03254498|DEVICE|cap assisted colonoscopy (CAC)|cap assisted colonoscopy (CAC)
214879022|NCT04520009|BEHAVIORAL|Activity Restriction|Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).
214879023|NCT04520009|BEHAVIORAL|Activity as Tolerated|Instructions advising activity as tolerated and return to work based on patient discretion
214879024|NCT06329609|DEVICE|Airvo 3 with respiratory rate algorithm|Airvo 3 with respiratory rate algorithm is an active humidification system used to deliver high flow respiratory gases (air and/or oxygen) and monitor respiratory rate
215044280|NCT01441388|DRUG|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
215044281|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
215044282|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
215044283|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
215044284|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
215044285|NCT01441388|DRUG|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
215044286|NCT01441388|DRUG|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
215044287|NCT02821325|OTHER|MRI|"Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.~2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2."
215044288|NCT04008914|OTHER|retrospective observation|Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
215044289|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin ER Tablet|Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
215044290|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin IR Tablet|Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
215044291|NCT03218839|DEVICE|PrePex male circumcision device|PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
215044292|NCT04945486|OTHER|Peer-mentor intervention|Peer-mentor support for up to 6 months
215044293|NCT01213082|DRUG|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
215044294|NCT01213082|DRUG|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
215044295|NCT01213082|DRUG|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
214476970|NCT06820801|OTHER|pelvic floor muscles strength and function|using pressure perineometer to evaluate pelvic floor muscles strength and using PFDI to evaluate pelvic floor muscles function
214879025|NCT03300583|BEHAVIORAL|Focus groups|Focus group discussion led by the PI and facilitated by another researcher.
214879026|NCT03300583|BEHAVIORAL|Semi-structured interviews|1:1 semi-structured interviews led by the PI
214879027|NCT02910011|DRUG|Nanodox 1% (doxycycline monohydrate hydrogel)|Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
214879028|NCT04575311|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
214879029|NCT04575311|OTHER|Placebo|Matching Placebo
214879030|NCT02463357|DIETARY_SUPPLEMENT|Quercetin|
214879031|NCT02463357|DRUG|Nifedipine extended release|
215044296|NCT00129285|DRUG|Low Dose Modafinil|modafinil 200 mg/day
215044297|NCT00129285|DRUG|High Dose Modafinil|modafinil 400 mg/day
215044298|NCT00129285|DRUG|Placebo|placebo 400 mg/day
215044299|NCT03758261|DRUG|Paravertebral nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
215044300|NCT03758261|DRUG|Erector Spinae nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
215044301|NCT01883024|OTHER|A decision support software|
215044302|NCT01883024|OTHER|Insulin Pump|
215044303|NCT01883024|OTHER|Continuous glucose monitoring|
214879032|NCT02463357|DRUG|Methazolamide|
214879033|NCT02463357|DRUG|Metformin|
214879034|NCT02463357|DRUG|Placebo|
214879035|NCT02463357|DRUG|Nitrite|
214879036|NCT06319040|OTHER|Muscle strength measurement|Muscle strength of both legs, maximal reciprocal concentric isokinetic knee extension (quadriceps) and flexion (hamstring) at 60°/s, 90°/s and 180°/s speeds were evaluated
214879037|NCT06319040|OTHER|Knee joint proprioception|Knee joint proprioception was assessed by joint position sense. Joint position sense was measured by the previously taught ability to actively find joint position (EPAB)
214879038|NCT06319040|OTHER|Balance|The patients and healthy individuals participating in our study were evaluated with the General Stability Index (GSI) for general balance ability, Anterior-Posterior Stability Index (APSI) for anterior-posterior balance ability, Medial-Lateral Stability Index (MLSI) for lateral balance ability and Fall Risk Index (DRI) and Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk. High values obtained indicate deterioration in balance and increased risk of falling.
214476971|NCT06819618|OTHER|Monitoring with Apple Watch|Patients will receive Apple Watch for Monitoring of Biosignals throughout the hospital stay
214879039|NCT06319040|OTHER|Fall risk test|Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk
214879040|NCT06319040|OTHER|Tegner Activity Level|Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
214879041|NCT06319040|OTHER|Lysholm Knee Scoring Scale|Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
214879042|NCT04844060|OTHER|Lumbar punction|Lumbar punction
214879043|NCT03742791|DRUG|TS-134|5 mg to 80 mg oral solution
214879044|NCT03742791|DRUG|Placebo|Matched Placebo oral solution
214879045|NCT03509857|DEVICE|BUZZY(tm)|"Risks associated with the BUZZY(tm) device The intervention group will receive vibration only, with application of the BUZZY device just proximal to the intravenous infusion site immediately before and during propofol infusion.~There are no known risks for the use of the BUZZY(tm) device, which is registered as an FDA class III device (therapeutic massager)."
215044304|NCT03848416|BIOLOGICAL|Ixekizumab|Administered SC
215044305|NCT00988793|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
215044306|NCT00988793|PROCEDURE|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
215044307|NCT06271824|BEHAVIORAL|Self-Compassion Based Resilient Caregiving Course|The Resilience Habits for Caregivers Course is a live, online, weekly 6 session program lasting 1.5 hours per session. The structure contains didactics, group discussions, guided exercises, and practices facilitated by a certified self-compassion instructor. Topics covered include: (1) noticing and accepting emotions (including conflicting emotions); (2) cultivating curiosity and self-compassion; (3) relating skillfully to difficult thoughts; (4) savoring and gratitude practices.
215044308|NCT02639390|DEVICE|Robotic Therapy|Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
215044309|NCT02639390|OTHER|Conventional Therapy|An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
215044310|NCT01908140|DRUG|Aclidinium Bromide / Formoterol Fumarate|
215044311|NCT01908140|DRUG|Salmeterol / Fluticasone|
214476972|NCT06820398|OTHER|Functional exercise with progressive strength and resistance load|This group will perform functional exercises with progressive strength and resistance load, adjusted based on heart rate.
214476973|NCT06820398|OTHER|Functional exercises without any load|This group will perform functional exercises, without strength or resistance load
214879046|NCT03509857|OTHER|No Intervention|No intervention
214879047|NCT01328522|DRUG|SAR153191 (REGN88)|"Pharmaceutical form:solution~Route of administration: subcutaneous"
214879048|NCT04944186|OTHER|Structured Pressure Injury Patient Education (mySPIPE)|It consists of PI education topics which include four main topics; 1) Pressure Injury: Why Me, which will be covering the basic information that patient need to know about PI; 2) Look After Your Skin, in this topics, patient will be thought about how skin checking was done and why it need to be done; 3) Preventing pressure injury, in this topic, patient will be emphasized on the suitable repositioning for them and the benefit of support surfaces and preventive wound dressing; 4) Help your PI heal, in this topic patient will be guided on what are condition that help PI healing and dietary needs to support wound healing
214879049|NCT04944186|OTHER|Standard Patient Education|No fixed content/ duration of patient education. Basically, patient repositioning emphasized verbally after wound dressing completed.
214879050|NCT01098630|OTHER|Medical Chart Review|Patients' medical record information is collected and staff complete the treatment review form
214879051|NCT01098630|OTHER|Questionnaire Administration|Ancillary studies
214879052|NCT00899522|OTHER|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
214879053|NCT00899522|PROCEDURE|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
214476974|NCT06816953|DIAGNOSTIC_TEST|HEAD-US|HEAD-US for evaluate haemophilic arthropathy in 6 joints. (Elbow, Knee, Ankle)
214879054|NCT00181558|DRUG|Atrasentan|
214879055|NCT00181558|DRUG|Zoledronic Acid (Zometa)|
214879056|NCT01619566|DRUG|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
214879057|NCT00641225|DRUG|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
214879058|NCT00851435|BIOLOGICAL|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
214879059|NCT00356655|BEHAVIORAL|Psychoeducation|
214879060|NCT01399658|PROCEDURE|Image-guided brachytherapy|MRI-guided application of brachytherapy
214879061|NCT01399658|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|Assessing tumor proliferation in Gynecologic cancer
214879062|NCT04230902|BIOLOGICAL|Microfragmented Adipose Tissue Transplant|Autologous Microfragmented Adipose Tissue derived using Lipogems® Kit
214879063|NCT04230902|DRUG|Corticosteroid injection|intra-articular knee injection of corticosteroid
214879064|NCT02890784|DRUG|dasatinib (SPRYCEL®)|Treatment optimization for patients with chronic myeloid leukemia (CML)
214879065|NCT02460679|DRUG|EPI-589|An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
214879066|NCT02620579|DRUG|Propranolol LA (60 mg)|Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
214879067|NCT02620579|DRUG|Placebo|Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
215044312|NCT05257928|BEHAVIORAL|CARE-CITE Gait|The CARE-CITE intervention content modified to address gait rehabilitation, and test 4-weeks of CARE-CITE-Gait in 15 CP/SS dyads.It will occur in the dyad's home.CP will complete 6 online CARE-CITE modules. Modules will include demonstration videos and instructive content covering the following areas:principles of functional task practice, the adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity. Examples are provided to address potential SS frustration and improve adherence.Underpinning the content is the concept of autonomy support,with examples of fostering empathy, problem-solving, instruction in the use of non-controlling language with role-playing situations and the importance of creating choice in activities. During the two home therapy sessions, the physical therapist will work with the CP and stroke survivor to collaboratively develop goals and an exercise program to improve mobility, gait and balance.
215044313|NCT05822154|OTHER|comprehensive geriatric assessment|The clinical, biological and functional characteristics will be collected in elderly subjects attending the hospitals of participating centers.
214476975|NCT06816953|DIAGNOSTIC_TEST|Urinary carboxy-terminal cross linked telopeptide of type II collagen|Cartilage biomarker represent cartilage degradation
214476976|NCT06816953|DIAGNOSTIC_TEST|Inflammatory markers|Inflammatory markers included CBC, Ferritin, ESR, CRP
214879068|NCT02620579|BEHAVIORAL|Shoulder Anatomy Education|Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
214879069|NCT02620579|BEHAVIORAL|Pain Processing Education|Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
214879070|NCT01277159|DRUG|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
214879071|NCT01277159|DRUG|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
214879072|NCT01277159|DRUG|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
214879073|NCT01277159|DRUG|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
214879074|NCT01277159|DRUG|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
214879075|NCT06551870|OTHER|Physical activity|The complexity of the games will increase as the levels of the sports games advance, which leads to faster movements with greater demands to progress in the sequence of the games, which allows reaching increases in intensity.
214879076|NCT00796107|DRUG|RG1507|R1507 was administered at a dose 16 mg/kg every 3 weeks.
214879077|NCT00796107|DRUG|Letrozole|Letrozole was administered orally at a dose 2.5 mg daily.
215044314|NCT02234726|BEHAVIORAL|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
215044315|NCT03256721|DRUG|Apatinib/docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
215044316|NCT03256721|DRUG|docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
215044317|NCT01135225|DEVICE|PROMUS(TM) Element (TM) Stent System|The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
215044318|NCT01135225|DEVICE|Evolution Stent System|The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
215044319|NCT02136043|DEVICE|PBASE system 1.1 (active treatment)|
215044320|NCT01130181|DRUG|Cholecalciferol|loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU
214291870|NCT01307397|DRUG|Vemurafenib|Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
214291871|NCT00302835|DRUG|non-phenacetin containing analgesics|
214879078|NCT03977142|DIAGNOSTIC_TEST|Radical 7 Masimo Hemoglobin pulse co-oximeter non invasive monitor|Measure hemoglobin levels non invasively by pulse co-oximeter
214879079|NCT04468451|BEHAVIORAL|A 48-hour ROC training program with a standing posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
215044321|NCT01130181|DRUG|Placebo|Matching placebo
214291872|NCT03748758|COMBINATION_PRODUCT|Drug: OP0201|Drug OP0201
214291873|NCT03748758|COMBINATION_PRODUCT|Drug: Placebo|Placebo
214291874|NCT01932112|DRUG|Adenosine arm|After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
214291875|NCT04422470|OTHER|Non-interventional study|Non-interventional study
214291876|NCT05795075|PROCEDURE|Computerized Modified Paramedian Approach Technique|Computerized Modified Paramedian Approach Technique ( CMPAT )
214291877|NCT05795075|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
214879080|NCT04468451|BEHAVIORAL|A 24-hour ROC training program with a standing posture|The 1-hour training session is composed of a 30-to-35-minute car play and a 25-minute natural play. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
214879081|NCT04468451|BEHAVIORAL|A regular therapy program without receiving any ROC training|The regular therapy group will be an active control group without receiving any additional training. The training dosage will be their own therapy, including occupational, physical and speech therapy. They will continue their regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks.
214879082|NCT06198166|OTHER|Cuevas Medek|Group A: will receive Cuevas Medek (CME) In a following procedure: supporting the patient in balance at the leg level and with slight posterior support. Then, once kept in the air for few seconds, slight up and down oscillations will make. The materials that will be used consists of three wooden boxes with the same dimensions (20cm x 40cm x 60cm), a bigger box, a wooden plate and two planks with the same dimensions (17cm x 80cm). Boxes
214879083|NCT06198166|OTHER|Standard kinetic programs|Group B: will receive standard kinetic programs consisting of stretching (2 sets 15 repetitions with 5 seconds hold) , passive mobilizations (2 sets of 20 repetitions), orthosis( for 6 hours). These techniques and orthotics devices typically focus on tight muscles, maintain proper foot alignment and to address sensory processing difficulties and promote relaxation. Stretching will focus on the hamstrings and calf muscles tightness.
214879084|NCT06346925|DRUG|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
214879085|NCT00366366|BIOLOGICAL|Infanrix-Hexa|
214879086|NCT00900822|DEVICE|Straumann Bone Ceramic|Granules applied once during surgery
214879087|NCT00900822|DEVICE|BioOss|Granules that are applied once during surgery
214879088|NCT03391414|DRUG|hypertonic bicarbonate|8.4% sodium bicarbonate inhaled
214879089|NCT03391414|DRUG|sodium chloride|7% sodium chloride inhaled
214879090|NCT01721317|DRUG|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
214879091|NCT01721317|DRUG|Placebo|Matching placebo will be available
215044322|NCT05554458|BEHAVIORAL|ChildTaks+ intervention|The ChildTalks+ Intervention ChildTalks+ is a preventive intervention originally developed in the Netherlands, targeting children up to 18 years of age. It has been implemented in Norway, Italy, and Portugal. It has a clear and well-described theoretical basis focusing on psychoeducation. Its key strategy is to provide feasible and replicable interventions to improve the quality of life of families where parents are affected by a mental disorder.
215044323|NCT01436110|DRUG|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
215044324|NCT01436110|DRUG|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
215044325|NCT01436110|DRUG|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
214879092|NCT00006509|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214879093|NCT00006509|BIOLOGICAL|gp160 MN/LAI-2|
214291878|NCT05475795|OTHER|Metapex|obturation of root canals of primary molars with Metapex
214291879|NCT05475795|OTHER|Endoflas|obturation of root canals of primary molars with Endoflas
214879094|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction by Therapeutic VR|Therapeutic VR+MBT was provided using a head-mounted display which designed to enclose eyes and block external stimuli almost entirely. Patients can see immersive natural scenes through VR devices and hear stereo sounds through headphones. We uploaded a programme, which was designed to induce recordings of guided meditations (The same as the MBT), musics for meditation and consists of meditation-videos of 40 minutes. We will guide patients to choose their favorite meditation videos, such as forest, seaside, lake, snow mountain, field and so on.
214879095|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction|39 participates randomized and allocated to this group. MBT was conducted as an 8-week group intervention. Sessions typically began with formal mindfulness meditations that include breathing exercises, prolonged expiratory relaxation, body scan, and meditation. MBT was delivered by the first author, who has specialized training in mindfulness meditation.
214879096|NCT01117649|DRUG|HES 10%|HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
214879097|NCT01117649|DRUG|HES 6%|HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
214879098|NCT01117649|DRUG|balanced electrolyte solution|plasma adapted Ringer's solution
214879099|NCT00706485|DEVICE|Yttrium-90 Plaque Applicator|Placed on the dura during surgery for 10-17 1/2 minutes
214879100|NCT03366207|DRUG|Ciprofloxacin|Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
214291880|NCT02387060|DRUG|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
214291881|NCT02387060|DRUG|Fentanyl|Intrathecal administration of fentanyl 25 mcg
214879101|NCT02587078|DRUG|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
214879102|NCT02587078|DRUG|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
214879103|NCT01651793|OTHER|Caffeinated cocoa|70 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
214879104|NCT01651793|OTHER|Cocoa|21 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
215044326|NCT01923766|DRUG|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
215044327|NCT03912610|DIAGNOSTIC_TEST|Functional magnetic resonance examination|Functional magnetic resonance examination by a Ultra high field magnetic resonance instrument named MAGNATOM 7T.
215044328|NCT04321616|DRUG|Hydroxychloroquine|Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
215044329|NCT04321616|DRUG|Remdesivir|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
215044330|NCT04321616|OTHER|(Standard of Care) SoC|The standard of care will be supplied to all patients not receiving a drug intervention.
215044331|NCT03461939|OTHER|ePRIME symptom monitoring tool|ePRIME is an online system for patients to self-report symptoms and AE during cancer treatment. ePRIME allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating notifications for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
215044332|NCT01175343|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
215044333|NCT01175343|OTHER|Laboratory Biomarker Analysis|Correlative studies
215044334|NCT03940807|DRUG|11.25mg GnRH agonist|"Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
215044335|NCT03940807|DRUG|0.1 mg GnRH agonist|"Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
215044336|NCT03940807|DRUG|25 µg transdermal oestradiol|Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
215044337|NCT01883921|OTHER|Immunoglobulin Therapy|
215044338|NCT01088503|DRUG|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
215044339|NCT02943694|DEVICE|TaTME with CS-Compact (GelPoint pathway)|Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
215044340|NCT02626169|DRUG|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
215044341|NCT02626169|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
215044342|NCT02637986|DIETARY_SUPPLEMENT|Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|2 capsules will be given per day
215044343|NCT02637986|OTHER|Placebo - capsule with no active ingredient|2 capsules will be given per day
215044344|NCT06452693|DRUG|TQA3038 injection/placebo|TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.
214291882|NCT00560859|PROCEDURE|Adenotonsillectomy (AT) - removal of adenoids and tonsils|Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
214291883|NCT00560859|OTHER|Watchful Waiting|Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
214879105|NCT01651793|OTHER|Caffeine|473 ml brewed water containing 66 mg caffeine, caramel coloring and one packet Truvia sweetener
214879106|NCT01651793|OTHER|Placebo|473 ml of brewed water, caramel coloring and one packet Truvia sweetener
214879107|NCT01737073|BEHAVIORAL|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
214879108|NCT01737073|BEHAVIORAL|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
214476977|NCT06817447|PROCEDURE|Pulmonary vein isolation plus cavo-tricuspid isthmus ablation|For those who are randomized to CTI+CPVI Arm, additional CPVI should be performed after finishing CTI ablation. CPVI could be performed using open-irrigated contact-force catheter, cryoballoon catheter or pulse-field ablation catheter. The endpoint is defined as both entrance and exit block in the pulmonary veins.
214879109|NCT01737073|OTHER|Enhanced usual care|Weekly automated wellness tip and usual clinical care
214879110|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
214879111|NCT04022876|DRUG|Carboplatin|Carboplatin administered IV on Day 1 of every 21-day cycle.
214879112|NCT04022876|DRUG|Pemetrexed|Pemetrexed administered IV on Day 1 of every 21-day cycle.
215044345|NCT06452693|DRUG|Nucleotide drugs Control group|Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
215044346|NCT03983447|BEHAVIORAL|School-based intervention to promote PA and reduce ST|"This intervention was realized with all the children (1st grade-5th grade) and involved :~1. Physical (Environmental) adaptation of playgrounds~2. Time adaptation of lunch breaks~3. Curriculum-based program for children~4. Workshops and newsletters for parents~5. Meetings for teachers"
215044347|NCT03461471|BEHAVIORAL|Exercise Intervention|Exercise intervention
214879113|NCT04022876|DRUG|Placebo|Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
214879114|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.
214879115|NCT04022876|DRUG|Topotecan|Topotecan administered IV on Days 1-5 of every 21-day cycle.
215044348|NCT02266563|DRUG|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
215044349|NCT02266563|DRUG|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
215044350|NCT00888537|OTHER|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
215044351|NCT00888537|OTHER|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
214879116|NCT03907657|DRUG|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
215044352|NCT00002907|DRUG|bryostatin 1|
214879117|NCT03907657|DRUG|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
214879118|NCT00215280|DRUG|ivermectin and albendazole|
214879119|NCT04860674|DRUG|PD-1 inhibitor +ICE|PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen
215044353|NCT05129956|DEVICE|"Covidien Emprint Ablation System with Thermosphere Technology"|The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
215044354|NCT01531998|DRUG|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
215044355|NCT01531998|DRUG|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
215044356|NCT01531998|DRUG|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
215044357|NCT01531998|DRUG|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
215044358|NCT01531998|BEHAVIORAL|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
214291884|NCT05628532|DEVICE|Use of the DBLG1 system|During the treatment period, the patient will use the DBLG1 system (consisting of a DBLG1 handset with an embedded software named loop mode, a TERUMO MEDISAFE WITH patch pump and a Dexcom continuous glucose monitoring (CGM) G6). The main function of DBLG1 System is to adjust the insulin delivery at the correct time in order to maintain the patient's blood glucose in the target range and thus minimize both hypoglycaemic events and long-term complications associated with elevated average glycemia.
214291885|NCT01716767|OTHER|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
214291886|NCT01716767|OTHER|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
214291887|NCT05419869|DRUG|ALTO-100 PO Tablet|Two tablets daily
214291888|NCT01115725|DRUG|Gonal-f® (follitropin alfa)|Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
214291889|NCT01405742|DRUG|rF.VIII|40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
215044359|NCT03037970|DRUG|RhPDGF-BB|One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
215044360|NCT03037970|OTHER|Placebo|Collagen Wound Dressing wetted with buffer.
215044361|NCT02604459|DEVICE|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
215044362|NCT02604459|DEVICE|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
215044363|NCT02604459|PROCEDURE|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
215044364|NCT02604459|PROCEDURE|General anesthesia|General anesthesia will be used in both groups
215044365|NCT02604459|DRUG|propofol|propofol per protocol
215044366|NCT02604459|DRUG|fentanyl|fentanyl per protocol
214291890|NCT04614064|OTHER|Exposure to London Underground ambient particulate matter|Exposure to particulate matter on the London Underground
214879120|NCT05523466|OTHER|Acupuncture Active|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Active acupuncture using specific Traditional Chinese Acupuncture points: E36, BP6, F3, IG4, for 20 minutes.
215044367|NCT02604459|DRUG|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
214879121|NCT05523466|OTHER|Acupuncture Sham|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Sham acupuncture using sham points (points not recognized as Acupuncture points), with the duration of 20 minutes
214879122|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining and sulfur hexafluoride (SF6) tamponade
214879123|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole."
215044368|NCT00186628|PROCEDURE|Total lymphoid irradiation|Total lymphoid irradiation (TLI) administered at 80cGy for 10 days
215044369|NCT00186628|DRUG|Rituximab|Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
215044370|NCT00186628|DRUG|Anti-thymoglobulin, rabbit (ATG, rabbit ATG)|Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
215044371|NCT00186628|DRUG|Cyclosporine|Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates \> 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
215044372|NCT00186628|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
214291891|NCT04614064|OTHER|Exposure to London air ambient particulate matter|Exposure to ambient particulate matter on the London Overground (as a proxy as a proxy for a clean air London area while maintaining other aspects of a train journey)
214291892|NCT05371691|DEVICE|Myofunctional appliance|Myifunctional appliance will be used for growing patients who have Cl.II div.1 malocclusion, two types of appliances are involved myobrace and twin=block appliance
214291893|NCT02503735|DRUG|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
214291894|NCT00718952|DRUG|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
214291895|NCT00718952|DRUG|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
215044373|NCT00186628|DRUG|Filgrastim|Filgrastim provided as needed for neutrophil support
215044374|NCT00186628|DRUG|Granisetron|Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
215044375|NCT00186628|DRUG|Solumedrol|Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
215044376|NCT00186628|DRUG|Acetaminophen|Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
215044377|NCT00186628|DRUG|Diphenhydramine|Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
215044378|NCT00186628|DRUG|Hydrocortisone|Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
214879124|NCT00751192|DEVICE|HIV-testing motivational videos|
214879125|NCT00751192|DEVICE|Standard public health text|
214879126|NCT06241625|DIAGNOSTIC_TEST|Virtual Reality (VR) Contrast Function Test|Patients perform a new Virtual Reality (VR) Contrast Function Test
214879127|NCT02130622|DRUG|Promethazine|
214879128|NCT02130622|DRUG|Sugar pill|
214879129|NCT03740581|DRUG|Insulin|Basal Bolus regimen (Participant to receive, Insulin \>= 3 times per day)
214879130|NCT02444910|DRUG|KDT501|600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
214879131|NCT04413110|DEVICE|Polysomnography|PSG was carried out for 41 patients with subjective cognitive impairment and 41 age and sex-matched controls. PSG with standard EEG montage that includes bilateral EOG and four EEG leads were used. A single attended overnight PSG study was performed at the Clinical Neurophysiology Unit of Mansoura University Hospitals. Patients were studied in a quiet, darkened room with no medications were used to induce sleep. All participants underwent one night of laboratory-based PSG.
214879132|NCT02455895|DEVICE|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
214879133|NCT05382234|DIAGNOSTIC_TEST|CBC, ESR ,CRP,Liver Function ,renal function ,ABG,Na,K,D-dimmer ,cardiac enzyme,ferritin ,blood and urine culture in negative cases|cllinical and laboratory evaluation of MIS-C,Effectivness of different therapeutic modalities,Outcome of cases (morbidity,mortality)
214879134|NCT01837134|DEVICE|telemedical (TM) group|telemedical devices (weighing machine and step counter)
214879135|NCT01837134|BEHAVIORAL|telemedical coaching (TMC) group|care calls once per week for 12 weeks
214879136|NCT03399708|DRUG|Apremilast 30mg|Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.
214879137|NCT03713632|DRUG|Secukinumab|Secukinumab 300mg every 2 or every 4 weeks
214879138|NCT03713632|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
214879139|NCT02393352|OTHER|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
214879140|NCT02393352|OTHER|Electrical Stimulation Therapy|
214879141|NCT03744299|OTHER|Questionnaire|Patients and caregivers are asked to complete a questionnaire
214879142|NCT03543215|OTHER|Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)|All patients with confirmed endometrial cancer will have received Ultrasound and MRI as part of routine standard of care. Textural features from this will be analysed to see if can predict prognosis.
214879143|NCT06578871|RADIATION|Intensity Modulated Radiotherapy (IMRT) to Mucosa at Risk|Patients in Arm 1, after the surgical procedure, will receive radiotherapy to the at-risk mucosa.
214879144|NCT06578871|PROCEDURE|Surgical Intervention|These patients will undergo Neck dissection, TORS tonsillectomy (unilateral vs bilateral tonsillectomy at the discretion of the treating physician) + ipsilateral tongue base mucosectomy.
214879145|NCT06578871|RADIATION|Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck|For Arm1, after the surgical procedure, the patients will receive radiotherapy to the ipsilateral neck. For Arm2, the patients will only receive IMRT to neck, if multiple ipsilateral nodes or single ipsilateral node \>3 cm is observed
215044379|NCT05822310|PROCEDURE|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.
215044380|NCT05822310|PROCEDURE|intraairticular steroid injection|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The femoral neck was detected under ultrasonography and the joint capsule was entered with a 22G 9 cm spinal needle. Then, 5 cc bupivacaine and 5 mg betamethasone were given and the procedure was terminated.
214291896|NCT00718952|DRUG|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
214291897|NCT00996645|OTHER|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
214291898|NCT00118001|BEHAVIORAL|Worry exposure|
214879146|NCT01059578|DRUG|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
214879147|NCT01059578|DRUG|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
214291899|NCT00118001|BEHAVIORAL|Applied relaxation|
214291900|NCT03491371|DRUG|Methylsulfonic apatinib|Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
214879148|NCT01059578|RADIATION|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
214879149|NCT01469078|DRUG|Monofer®|Single Bolus Injections
214879150|NCT02751671|PROCEDURE|POCUS|The use of Point-of-care ultrasound before urine sample procedure
214879151|NCT02751671|PROCEDURE|Standard|Urine sampling procedure without prior ultrasound
214879152|NCT02234076|BEHAVIORAL|VRET|
214879153|NCT02234076|BEHAVIORAL|TAU|Treatment as usual offered by the participating mental health care organisations
214879154|NCT05344131|OTHER|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Biopsychosocial approach
214879155|NCT05220644|PROCEDURE|Protocols for the management of end-of-life symptoms|Application of the care protocol and data collection
214879156|NCT04077944|DIAGNOSTIC_TEST|maternal serum concentration of trace elements and heavy metals levels|The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
214291901|NCT04372901|PROCEDURE|Digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
214291902|NCT04372901|PROCEDURE|Digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement.
214879157|NCT02255968|DRUG|EDP-788|EDP-788 Capsules. All interventions are given as multiple doses.
214879158|NCT02255968|DRUG|Placebo|Matching placebo capsules. All interventions are given as multiple doses
214879159|NCT02184767|DRUG|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
214879160|NCT03861624|PROCEDURE|Intramedullary nailing with standard SIGN nail|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the standard SIGN nail (SIGN Fracture Care International, Richland, WA). The number of interlocking screws is at the discretion of the treating surgeon, who also has the option to use an external fixator for damage control, and later conversion to IMN when clinically appropriate. The experimental group procedure is less common in the study setting, and thus, viewed as the experimental group.
214879161|NCT03861624|PROCEDURE|External Fixation with uniplanar Dispofix external fixator|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the uniplanar Dispofix external fixator with two Shanz screws placed proximally and two Schanz screws placed distally to fracture site with a single stainless steel bar.The active comparator group procedure is more common in the study setting, and thus, viewed as the comparator group.
214879162|NCT02806024|DRUG|Tranexamic Acid|
214879163|NCT02806024|DRUG|Placebo Drug|50 cc Normal Saline IV
215044381|NCT05822310|PROCEDURE|pericapsular nerve group (PENG) block|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The high-frequency linear ultrasonography probe was placed on the anterior superior iliacspina (ASIS). Later, the anterior inferior iliac spine (AIIS) was detected by descending caudally. Afterwards, the probe was brought to the oblique position and AIIS, iliopubikeminence, psoas muscle and tendon were seen. Using a 22G 90-mm Quinckespinal needle, the tendon of the iliopsoas muscle was entered in the lateral-medial direction in the in-plane plane and bone contact was achieved. After negative aspiration, 15 ml of 0.5% bupivacaine were administered by seeing the appropriate drug distribution.
215044382|NCT01585727|PROCEDURE|TME|Total mesorectal excision
215044383|NCT01585727|PROCEDURE|TME|Total mesorectal excision
215044384|NCT01585727|PROCEDURE|Neuromonitoring|Intraoperative neuromonitoring of pelvic autonomic nerves.
215044385|NCT01076010|DRUG|Tivozanib|Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
215044386|NCT01076010|DRUG|Sorafenib|Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
215044387|NCT03259295|DEVICE|Digiclamp (Skin tag removal initial plus follow-up)|Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
214879164|NCT02892149|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
214879165|NCT02892149|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
214879166|NCT05671536|BEHAVIORAL|motivational interview|Intervention arm will receive motivational interview by the researcher, once a month for 4 times at least 20 minutes. The researcher received education about motivational interview.
214879167|NCT03456141|PROCEDURE|third molar surgery|The patient is asked to complete the diary each post-surgery day for 14 days. Recovery is organized into three QOL domains: lifestyle, oral function, and pain.
214879168|NCT05870618|BIOLOGICAL|vaccinate with DTap|vaccinate with DTap
214879169|NCT05870618|BIOLOGICAL|vaccinate with DT|vaccinate with DT
214879170|NCT06622642|PROCEDURE|Transoral technique for mandibular angle fracture reduction|In transoral technique approach inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. A 5-hole 2mm miniplate with 2 holes anterior and 2 holes posterior to fracture line will be screwed to external oblique ridge and MMF will be removed and incision line will be closed.
214879171|NCT06622642|PROCEDURE|Transbuccal technique for mandibular angle fracture reduction|In transbuccal technique inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. extraorally a stab incision will be made with scalpel blade parallel to relaxed resting skin tension lines through which the cannula with a trocar will be inserted through facial tissue down to bone. Transbuccal instrument system will cionsist of transbuccal guide, mountable retractor, drill sleeve, drill guide, and 2mm drill bit. A 2mm titanium miniplate will be placed along buccal cortex and screwed through trocar system. MMF will be removed and incision line closed
214879172|NCT00032786|DRUG|natalizumab|
214879173|NCT02352688|PROCEDURE|Enhanced Colorectal Geriatric Care|
214879174|NCT00652561|DRUG|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
214879175|NCT04187170|OTHER|Strength physical training|progressive high-load strength training over 6 months, consisting in repeated physical exercises to increase the muscular mass and force by altering concentric and eccentric muscle contractions against high resistance.
214879176|NCT05294250|DRUG|XC8|XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods
214879177|NCT01994850|DRUG|brentuximab vedotin|Trade name: Adcetris
214879178|NCT05550506|DRUG|Duloxetine|Patients who use duloxetine for chronic pain or fibromyalgia
214879179|NCT05725551|DEVICE|ShotBlocker|"Before the procedure, the protruding surface of the vehicle was placed on the injection site in contact with the skin and used by holding it during injection. The level of pain and fear experienced by the child during and 5 minutes after the injection was evaluated with the Facial Expressions Pain Scale and Visual Comparison Scale, and the level of fear was evaluated with the Child Fear Scale by the child, the parent accompanying the child, and the observer."
214879180|NCT05725551|OTHER|Finger Puppet group|"During the interaction between the finger puppet and the child, an intramuscular injection was made. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
214879181|NCT05725551|OTHER|Balloon group|"An intramuscular injection was given when the child began to inflate the balloon. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
215044388|NCT06470516|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA.
214879182|NCT00247312|RADIATION|Pd-103|
214879183|NCT01618565|PROCEDURE|Hands-On Training|one-time, 30 minute hands-on training
214879184|NCT01618565|PROCEDURE|Demonstration|30 minutes passive training
214879185|NCT00442962|DRUG|Efavirenz|600-mg tablet taken orally daily
215044389|NCT06470516|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
215044390|NCT03939585|BIOLOGICAL|Cellular therapy product|"Cellular therapy product: Allogeneic transplant donor lymphocytes, depleted of TCR-αβ T cells and B cells; enriched for NK cells and TCRγδ T cells.~* Infused using venous catheter on post-transplant Day 28 (+ 7 days).~* Single infusion of entire lymphocyte product derived from two-blood volume leukapheresis (non-mobilized)."
215044391|NCT05669222|DIAGNOSTIC_TEST|FAST Technique|The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.
215044392|NCT05669222|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
214879186|NCT00442962|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
214879187|NCT06025240|DIAGNOSTIC_TEST|cf-DNA|In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is \>20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.
214879188|NCT06025240|DIAGNOSTIC_TEST|Immunological Events following renal transplant in older age|Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the \<60 and \>60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
214879189|NCT06025240|OTHER|Determining Predictive Models for Post-transplant HLA-specific Antibody Formation|A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
214879190|NCT00323050|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
214879191|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 1|HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)
214879192|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 2|HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)
214879193|NCT03277066|DRUG|Placebo patch|Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
214879194|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
214879195|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
214879196|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
214879197|NCT01111955|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
214879198|NCT01111955|DRUG|Metformin|Capsules, Oral, ≥ 1500 mg, once daily, 28 days
214879199|NCT05235516|DRUG|AK104|q3w iv
215044393|NCT03545048|OTHER|Internet based exercises|Exercises for knee OA (online- digital health)
215044394|NCT06043336|DRUG|Dexamethasone, granisetron & palonosetron|. Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
215044395|NCT01361659|PROCEDURE|shockwave treatment|9 treatments in 3 months
215044396|NCT06127433|DRUG|Insulin Glargine|Insulin Glargine
215044397|NCT06127433|DRUG|Metformin|Metformin
215044398|NCT06127433|DRUG|Dapagliflozin|Dapagliflozin
215044399|NCT06127433|DRUG|Insulin aspart|Insulin aspart
214879200|NCT05235516|RADIATION|EBRT|45-50.4Gy
214879201|NCT05235516|RADIATION|BT|≥80Gy
214879202|NCT05235516|DRUG|cisplatin|qw iv
214879203|NCT05235516|DRUG|Placebo|q3w iv
214879204|NCT00186524|BEHAVIORAL|Breast Cancer Support Group|
215044400|NCT03767439|DRUG|Vismodegib|150 mg PO daily
215044401|NCT03767439|DRUG|Nivolumab|480 mg IV every 4 weeks
215044402|NCT03767439|DRUG|Ipilimumab|1 mg/kg IV every 6 weeks
215044403|NCT04678258|PROCEDURE|HR electroanatomic mapping and MVG catheter ablation|High resolution CTI mapping using the mini-electrodes at the 8 mm catheter tip followed by voltage guided ablation
214879205|NCT01938495|DEVICE|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
214879206|NCT04254341|OTHER|patients with OSA|Sleep study
215044404|NCT04678258|PROCEDURE|Conventional bipolar mapping and linear catheter ablation|Bipolar mapping and conventional anatomic linear catheter ablation
215044405|NCT04815564|DEVICE|Invisalign|Invisalign clear aligner system
215044406|NCT06642415|PROCEDURE|Surgery under loupes|surgery performed under loupes
215044407|NCT06642415|PROCEDURE|surgery performed under microscope|surgery performed under microscope
215044408|NCT05943262|DEVICE|mesoscale nonlinear optical microscope|The mesoscale nonlinear optical microscope based on the principles of nonlinear optics and computed-algorithms can acquire large-area image within few minutes.
215044409|NCT03767881|DEVICE|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
215044410|NCT02789982|DRUG|β-adrenergic blocker propranolol|
215044411|NCT02789982|BEHAVIORAL|Treatment as usual|
215044412|NCT04201535|DIAGNOSTIC_TEST|Protein arrays on plasma samples|Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.
215044413|NCT00766519|OTHER|volume optimization|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~  \+ systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is \> 10%"
214291903|NCT01003912|BIOLOGICAL|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
214291904|NCT02261155|PROCEDURE|Hypnosis|hypnotic Relaxation without specific analgesic suggestion
214879207|NCT04102917|DIAGNOSTIC_TEST|QFR assessment|The quantitative flow ratio (QFR) is a novel angiography-based method for noninvasive functional assessment of intermediate coronary lesions.
214879208|NCT03893084|OTHER|Pregnancy preparation training|Pregnancy preparation education; folic acid use, physical activity, nutrition, addictions counseling issues are included.
214879209|NCT05709379|BEHAVIORAL|Sedentary behavior|Interrupting sitting with walking/jogging at either high -or low physical activity intensity.
214879210|NCT04891003|DIAGNOSTIC_TEST|Ultrasonography|The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
214879211|NCT00386984|DRUG|Somatostatin (octreotide)|
214879212|NCT02756208|BIOLOGICAL|300 ug FLSC vaccine|FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
214879213|NCT02756208|BIOLOGICAL|150 ug FLSC vaccine|FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
214879214|NCT02756208|BIOLOGICAL|75 ug FLSC vaccine|FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
215044414|NCT00766519|OTHER|standard volume administration|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV"
215044415|NCT02603757|DIETARY_SUPPLEMENT|cholecalciferol|2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
215044416|NCT05747248|DEVICE|Ultrasonography|Tracheal, diaphragmatic and lung ultrasonography
215044417|NCT02668289|OTHER|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
215044418|NCT02668289|OTHER|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
215044419|NCT02668289|OTHER|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
215044420|NCT02668289|OTHER|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
214291905|NCT02420392|DRUG|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
214291906|NCT00314912|DRUG|Tramiprosate (3APS)|
214291907|NCT03971058|BIOLOGICAL|IXIARO®- Japanese Encephalitis vaccine|Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
214291908|NCT06348602|DRUG|Cyclosporine ophthalmic solution 0.1%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of 1 drop in each eye every 12 hours, continued for a duration of 12 continuous months
214879215|NCT02756208|BIOLOGICAL|Placebo|Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
214879216|NCT03774407|DRUG|vaginal estriol|Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.
214879217|NCT02417987|OTHER|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
214291909|NCT06348602|DRUG|Tacrolimus ophthalmic ointment 0.03%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of approximately 1 cm or the necessary amount to cover the lower fornix, every 12 hours, continued for a duration of 12 continuous months
214291910|NCT04231357|DRUG|platelet rich plasma|platelet rich plasma prepared from peripheral blood using single spin centrifugation
214291911|NCT03672747|DEVICE|transcranial direct-current stimulation (tDCS)|20 minutes duration using high-definition system with center-surround configuration
214879218|NCT02417987|DRUG|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
214879219|NCT02417987|BIOLOGICAL|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
215044421|NCT02668289|OTHER|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
215044422|NCT02668289|OTHER|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
214476978|NCT06817447|PROCEDURE|Cavo-tricuspid isthmus ablation|"In periprocedural period, all antiarrhythmic drugs were discontinued for at least 5 half-lives and amiodarone for 2 months before the procedure. An electrophysiological study was performed after overnight fasting and mild sedated state with administration of intravenous midazolam and fentanyl.~CTI ablation should be performed under the CARTO or Ensite electroanatomic mapping system using an open-irrigated contact-force ablation catheter. Radiofrequency should be delivered at 30-50 W with a contact-force between 5-30 g in a point-by-point fashion until the CTI line is completed. Touch-up radiofrequency should be performed as needed. The endpoint of ablation is termination of AFL, if present, and the demonstration of bidirectional block across the CTI by using differential pacing."
214879220|NCT04841577|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
214879221|NCT04841577|BIOLOGICAL|FLU-QIV|FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
214879222|NCT06209840|OTHER|Control Group|The session is 50 minutes long and consists of 20 minutes of classical physiotherapy for gross motor functions and 30 minutes of classical physiotherapy for the upper extremity. A total of 16 sessions will be applied 2 days a week for 8 weeks.
214879223|NCT06209840|OTHER|Study (Music) Group|The session is 50 minutes long and consists of 20 minutes of classical physiotherapy for gross motor functions and 30 minutes of music therapy for the upper extremity. A total of 16 sessions will be applied 2 days a week for 8 weeks.
214879224|NCT00001725|DRUG|Dextromethorphan|
214879225|NCT01134302|PROCEDURE|Norwood management strategy|Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
214879226|NCT01134302|PROCEDURE|Hybrid Strategy|"Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.~The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies."
215044423|NCT02668289|OTHER|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
215044424|NCT02668289|PROCEDURE|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
215044425|NCT02668289|OTHER|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
215044426|NCT02249403|DRUG|Talsaclidine 6 mg|
214879227|NCT06170216|DRUG|immunochemotherapies|Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
214879228|NCT05102552|DRUG|SPN-817, Treatment B|SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
214879229|NCT05102552|DRUG|SPN-817, Treatment C|SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
215044427|NCT02249403|DRUG|Talsaclidine 12 mg|
215044428|NCT02249403|DRUG|Talsaclidine 24 mg|
214879230|NCT05102552|DRUG|BIS-001, Treatment A|BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
214879231|NCT01992185|DRUG|Photocil for Vitiligo|Photocil for Vitiligo
214879232|NCT01992185|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
214879233|NCT03617783|DRUG|Prebiotin|Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
214879234|NCT03617783|DRUG|Placebo|placebo-OEI
215044429|NCT02249403|DRUG|Talsaclidine 36 mg|
215044430|NCT02249403|DRUG|Placebo|
215044431|NCT02552576|BIOLOGICAL|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
214879235|NCT02419781|PROCEDURE|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
214879236|NCT02419781|PROCEDURE|No endovascular therapy|
214879237|NCT03222310|DRUG|Ipatasertib|Ipatasertib 100 mg tablet orally once daily.
214879238|NCT03222310|DRUG|Itraconazole|Itraconazole 100 mg capsules orally once daily.
214879239|NCT00985244|DRUG|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
214879240|NCT00985244|DRUG|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
214879241|NCT03188224|OTHER|MyTransition app|MyTransition app is designed to support youth moving from pediatric to adult healthcare.
214879242|NCT00237978|DRUG|Adapalen|
214879243|NCT00237978|RADIATION|VIS and wIRA|
214879244|NCT05630911|OTHER|Standing tasks with different task difficulty|The three different standing positions will include wide-base standing on foam (WBF) with low-level of task difficulty, narrow-base standing on foam (NBF) with moderate-level of task difficulty, and tandem standing on foam (TAF) with high-level of task difficulty.
214879245|NCT06238622|DRUG|BI 1015550|BI 1015550
214879246|NCT06467708|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS).
214879247|NCT00438217|DRUG|Triptorelin (GnRH agonists)|
214879248|NCT00438217|DRUG|Leuprolide (GnRH agonists)|
214879249|NCT02782806|DEVICE|Masimo Rad-67 Pulse Oximeter|Noninvasive pulse oximeter
214879250|NCT01420965|DRUG|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
214879251|NCT01420965|OTHER|Sipuleucel-T (Provenge)|Vaccine
215044432|NCT06246305|OTHER|conventional physical therapy training|conventional therapy rehabilitation program is divided into three phases: on-brace, off-brace, and active mobilization. The on-brace phase (post-op 0-6 weeks) mainly consists of low-intensity whole-body exercises with shoulder girdle, elbow, and hand mobilization exercises on the affected side. The off-brace phase (post-op 6-9 weeks) consists of passive shoulder ROM exercises using an exercise stick and an early scapular stabilization exercise. The active mobilization phase (post-op 9-12 weeks) consists of both active and passive shoulder ROM , strengthening exercise with progressive resistance, and scapular stabilization exercises. The intervention is done 3 times per week for 12 weeks.
215044433|NCT06246305|DEVICE|Virtual Reality (VR) training|During the on-brace phase (0-6 weeks), participants in this group will use the program as performed in the control group. During the off-brace (6-9 weeks post-op) and active mobilization phases (9-12 weeks post-op), participants will use the Virtual Reality machine. this program involves warming up and down stretching exercises and exercise training that includes bilateral shoulder elevation, boxing, bowling and tennis games accompanied by avatar. The intervention is done 3 times per week for 12 weeks.
215044434|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
215044435|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
214879252|NCT01420965|DRUG|Cyclophosphamide|Low dose- Immune Enhancer
214879253|NCT02895100|DRUG|PTG-100|Daily dosing of PTG-100 by subject for a 12 week treatment period.
214879254|NCT02895100|DRUG|Placebo|Daily dosing of Placebo capsules by subject for a 12 week treatment period.
214879255|NCT04319783|DRUG|Darolutamide|Darolutamide alone
214879256|NCT04319783|RADIATION|Radiotherapy|Darolutamide + Consolidation Radiotherapy
214879257|NCT00593151|OTHER|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
214879258|NCT00593151|BIOLOGICAL|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
214879259|NCT05119153|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo designed to mimic coffee color.
214879260|NCT05119153|DIETARY_SUPPLEMENT|Light Roasted Coffee|12 oz light roast coffee
214879261|NCT05119153|DIETARY_SUPPLEMENT|Medium Roasted Coffee|12 oz medium roast coffee
214879262|NCT05119153|DIETARY_SUPPLEMENT|Dark Roasted Coffee|12 oz dark roast coffee
215044436|NCT02915497|BEHAVIORAL|Abbreviated Early Prolonged Exposure Therapy|Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
215044437|NCT06396936|OTHER|Calisthenic exercise program|Calisthenic exercises to be applied in our study; These are exercises that are performed by creating resistance only with your body weight, without the need for any equipment or gym.
215044438|NCT01726374|DRUG|BEP(500)|"One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15"
214879263|NCT06040775|DEVICE|Theta Burst Transcranial magnetic Stimulation using real MCF-B65 coil|"Site of stimulation will be predetermined at Dorsolateral prefrontal cortex of non-dominant side using the BeamF3 method.1 burst will be - 3 pulses at 50 Hz, burst will be set at 5Hz i.e. interburst interval 200ms .~At100% of resting motor threshold of dominant side - 5 trains (each 40sec on and 20 sec off) will be given at each session with a pause of 1 minute in between 2 trains Standard therapy with Applied Behavior Analysis and sensory integration would continue"
214879264|NCT06040775|DEVICE|Sham magnetic stimulation using sham MCF-B65 coil|"Similar set parameters using a sham coil which simulates sound and tactile effect of real coil but no electromagnetic induction is produced.~Standard therapy with Applied Behavior Analysis and sensory integration would continue"
214879265|NCT01322867|DRUG|alprazolam tablet|0,25 mg oral tablets given once
214879266|NCT01322867|DRUG|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
214879267|NCT02695810|DRUG|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
214879268|NCT02695810|DRUG|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
214879269|NCT02695810|BEHAVIORAL|Exercise|Interval training, 5 times per week, 30 min per session
214879270|NCT00339144|DRUG|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
214879271|NCT00339144|DRUG|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
214879272|NCT00339144|DRUG|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
214879273|NCT02547090|PROCEDURE|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
215044439|NCT05819762|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab LS screening panel on a specified Flow Cytometry
215044440|NCT03440008|OTHER|Dynamic 3D bone motion capture|Two x-ray systems will image the subjects ankle while they walk, allowing us to calculate ankle joint angle and alignment
214879274|NCT00912613|OTHER|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
214879275|NCT05354739|DEVICE|The vibration cold device (BUZZY)|If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized
214879276|NCT06393517|DRUG|PF-06954522 IR (Formulation 1)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
214879277|NCT06393517|DRUG|PF-06954522 MR (Formulation 2)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
214879278|NCT06393517|DRUG|PF-06954522 MR (Formulation 3)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
214879279|NCT00555841|DRUG|ALC and Placebo|ALC and Placebo
215044441|NCT03440008|DEVICE|wedged insole|medial or lateral wedge (appropriate for varus or valgus misalignment) will be applied during 1 data collection session to evaluate effect of wedging on misalignment
215044442|NCT04700423|DRUG|moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
215044443|NCT04700423|DRUG|ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
215044444|NCT04700423|DRUG|ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]|Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
214879280|NCT06236841|DRUG|XH-S004 tablet|XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.
215044445|NCT04700423|DRUG|ivermectin (200 µg/kg)|Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
215044446|NCT04700423|DRUG|moxidectin (8 mg)|Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
215044447|NCT03735732|BEHAVIORAL|prime|groups be confronted with health or palatability aspects of food items
214879281|NCT06236841|DRUG|XH-S004 placebo tablet|XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
214879282|NCT06398119|OTHER|Traditional Treatment Program|Traditional Treatment Program for improving hand function
214879283|NCT06398119|OTHER|Virtual Reality Program|Virtual Reality Program for improving hand function
214879284|NCT02365116|BEHAVIORAL|Peer mentorship|Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
214879285|NCT02365116|BEHAVIORAL|Enhanced Usual Care|The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
214879286|NCT01751737|PROCEDURE|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
215044448|NCT04231448|DRUG|R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)|R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
215044449|NCT04231448|DRUG|Tucidinostat|Tucidinostat ：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of Tucidinostat on day 1, day 4, day 8, day 11 in a 21-day cycle.
214879287|NCT00766779|PROCEDURE|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
214879288|NCT00766779|DRUG|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
214879289|NCT01154361|DRUG|Icatibant (subcutaneous) and plazebo (intravenous)|
214879290|NCT01154361|DRUG|Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)|
214879291|NCT03280381|OTHER|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
214879292|NCT03280381|OTHER|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
214879293|NCT05810428|PROCEDURE|GKRS-VR training|One month after radiosurgery, GKRS-VR subjects will receive neuromodulation treatment twice a week (30' per time), for 8 consecutive weeks followed by 9 months of remote rehabilitation. GKRS-VR group will perform neuromodulation based on VR sensorimotor rehabilitation using an immersive system developed ad-hoc. Treatments will include voluntary mimic movements reinforced by VR augmented feedback, consisting in the reflection of a real-time avatar animation, multiplied when needed, associated with different targets to reach based on specific facial gestures. The execution of motion multiplier on avatar will be allowed in order to personalize treatments, emphasizing a graded exposure to pain perception. In addition, the investigators will develop a dedicated mobile-application for remote rehabilitation with the aim of prescribing VR augmented feedback home exercises and immersive VR pain neuromodulation.
215044450|NCT04231448|DRUG|Placebo|Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
215044451|NCT05450211|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.
215044452|NCT05450211|DEVICE|Patient controlled analgesia|Patient-controlled analgesia will be used for pain control after surgery in both groups.
215044453|NCT03419494|DRUG|PLD|PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
215044454|NCT03419494|DRUG|DNR|DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
215044455|NCT03132987|OTHER|Progressive strengthening program|The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
214476979|NCT06818305|DRUG|Finerenone (BAY 94-8862)|"Adjusting lifestyle and managing underlying conditions according to the Chronic Kidney Disease Early Screening, Diagnosis, and Prevention Guidelines (2022 Edition) + Finerenone (10mg/d or 20mg/d)."
214476980|NCT06818305|DRUG|Empagliflozin 10 mg|"Adjusting lifestyle and managing underlying conditions according to the Chronic Kidney Disease Early Screening, Diagnosis, and Prevention Guidelines (2022 Edition) + Empagliflozin (10mg/d)."
214476981|NCT06817551|DRUG|Dexamethasone|\*Please see description for dexamethasone + supportive care arm.
214879294|NCT05810428|PROCEDURE|Control Group|Control Group will undergo only radiosurgery with no rehabilitation and they will perform only clinical evaluation at study entry, after three months and one year.
214879295|NCT01772485|BEHAVIORAL|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
214879296|NCT01772485|BEHAVIORAL|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
214879297|NCT04538482|BEHAVIORAL|DASH Diet|Participant will receive foods following the DASH dietary pattern for 28 days.
214879298|NCT04538482|BEHAVIORAL|standard American diet|Participants will receive foods following the standard American diet for 28 days.
214879299|NCT03799432|OTHER|COAST-IS|COAST-IS has been designed to equip organizations with the knowledge, motivation, and skill needed to thoughtfully match implementation strategies to identified determinants by applying intervention mapping. The COAST-IS intervention will include four different modes of delivery: 1) dissemination of educational materials; 2) five web-based interactive education sessions on the need for tailoring implementation strategies and the application of intervention mapping; 3) site visits to discuss change objectives necessary to successfully implement trauma-focused cognitive behavioral therapy; and 4) organizational coaching related to using an intervention mapping approach.
214879300|NCT03799432|OTHER|TF-CBT Learning Collaborative|The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
214879301|NCT03651882|DRUG|Oxytocin|Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.
214879302|NCT03651882|DRUG|Carbetocin|Carbetocin is given 0.1mg intravenously as a bolus after delivery.
214879303|NCT03430388|BIOLOGICAL|Yellow Fever vaccine (17D)|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
214879304|NCT02257385|DRUG|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
215044456|NCT05338073|DIAGNOSTIC_TEST|Known 3Dx Test|Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
215044457|NCT01775384|DIETARY_SUPPLEMENT|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
215044458|NCT01775384|DIETARY_SUPPLEMENT|Placebo|
215044459|NCT04605666|BIOLOGICAL|CD19-CAR-T2 Cells|CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
215044460|NCT03360994|OTHER|WATChmAN Active Surveillance|WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.
215044461|NCT03360994|OTHER|In-person Active Surveillance|In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
215044462|NCT03498716|DRUG|Atezolizumab|"Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year"
215044463|NCT03498716|DRUG|Paclitaxel|Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.
215044464|NCT03498716|DRUG|Dose-dense Doxorubicin or dose-dense Epirubicin|"Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses"
215044465|NCT03498716|DRUG|Cyclophosphamide|Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
215044466|NCT05337566|DRUG|Azithromycin Pill + Cefuroxime|Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
215044467|NCT05337566|DRUG|Placebo + Cefuroxime|Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
215044468|NCT05613816|PROCEDURE|Senhance Surgical System|100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System
214879305|NCT02257385|DRUG|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
214879306|NCT02257385|DRUG|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
214879307|NCT02257385|DRUG|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
214879308|NCT02257385|DRUG|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
214879309|NCT02257385|DRUG|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
214476982|NCT06817551|OTHER|Supportive Care|\*Please see description for supportive care arm.
214476983|NCT06815796|PROCEDURE|Arthroscopic Loop tenodesis of long head of biceps.|Loop tenodesis of the long head of biceps tendon.
214476984|NCT06815796|PROCEDURE|Anchor Tenodesis of Long head of biceps tendon|Anchor Tenodesis of Long head of biceps tendon
214879310|NCT02257385|DRUG|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
214879311|NCT03259438|BEHAVIORAL|Qigong|Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
214879312|NCT03259438|BEHAVIORAL|Healthy Living (CHIP + Pre-Train)|The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
214879313|NCT01242722|DEVICE|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
214879314|NCT01990482|DIETARY_SUPPLEMENT|caffe|
214879315|NCT01990482|DIETARY_SUPPLEMENT|Water|
214879316|NCT03279692|DRUG|Pembrolizumab|pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
214879317|NCT00620087|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
214879318|NCT00620087|PROCEDURE|Screening Mammography|A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
214879319|NCT00575887|DRUG|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
214879320|NCT01942889|DIETARY_SUPPLEMENT|Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program|Vit E, Vit C, Selenomethionine, Zinc gluconate
214879321|NCT05151354|OTHER|Psychotherapy|Patients receive 8 weeks of inpatient psychotherapeutic treatment. Treatment consists of individual and group psychodynamic psychotherapy, as well as an individual combination of art, music, body-oriented and relaxation therapies, which are also carried out in group settings. Treatments is provided by an interdisciplinary team of psychotherapists with a medical or psychology degree, art of music therapists, social workers, physiotherapists and specialist nurses.
214879322|NCT00482807|DRUG|bicalutamide|
214879323|NCT00482807|DRUG|docetaxel|
214879324|NCT00482807|DRUG|goserelin|
214879325|NCT00482807|RADIATION|intensity-modulated radiation therapy|
214879326|NCT02458287|BIOLOGICAL|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
214879327|NCT02458287|BIOLOGICAL|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
215044469|NCT06029790|OTHER|gum chewing|For the patients in the experimental group, sugar-free xylitol gum containing 1.2-1.37 grams of xylitol per piece, available in the market, will be used. Participants in the experimental group will start chewing gum on the first postoperative day and will be allowed to chew a single piece of gum 3 times a day at 9:00, 14:00 and 19:00, respectively, for 15 minutes. The gum will be given to the participants regularly by a researcher until the first reported flatulence.
214879328|NCT02458287|BIOLOGICAL|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
214879329|NCT02458287|BIOLOGICAL|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
214879330|NCT00925366|OTHER|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
214879331|NCT00087282|DRUG|alvocidib|
214879332|NCT00087282|DRUG|irinotecan hydrochloride|
214476985|NCT06819553|DRUG|Oral Potassium Citrate|Evaluate the Effectiveness of Oral Potassium Citrate in Preventing Ureteral Stent Encrustation in Patients Undergoing Ureteroscopy for Uric Acid Kidney Stones
214476986|NCT06817148|PROCEDURE|transcatheter aortic valve replacement (TAVR)|percutaneous transcatheter aortic valve replacement
214476987|NCT06817148|PROCEDURE|surgical aortic valve replacement (SAVR)|surgical aortic valve replacement
215044470|NCT02702050|OTHER|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
214879333|NCT01686230|OTHER|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
214879334|NCT01686230|DRUG|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
214879335|NCT06550752|COMBINATION_PRODUCT|UC-MSCs and PRP|UC-MSCs are progenitor cells that can differentiate into various types of cells in the body and have the ability to regenerate and repair damaged tissue. During repair and regeneration, these cells secrete expedient and powerful bioactive paracrine factors including cytokines, chemokines, collagen, fibronectin, and growth factors promoting tissue repair, angiogenesis, and the regeneration of nerve cells as well as regulating cellular pathways including immunomodulation and inflammatory responses. Additionally, PRP contains numerous growth factors and cytokines, including vascular endothelial growth factor (VEGF), transforming growth factor beta-1 and beta-2 (TGF-β1/2), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), interleukin 8 and matrix metalloproteinases 2,9. The combined effect of these factors provided by PRP injections is proposed to have anti- inflammatory, reparative, neuroprotective and neurotrophic effects that contribute to the treatment of ED.
214879336|NCT03421795|OTHER|Let's Talk About Pain Training|See arm/group descriptions.
214879337|NCT03421795|OTHER|Family Centered Care Training|See arm/group descriptions.
214879338|NCT06629831|OTHER|group with complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
214879339|NCT06629831|OTHER|group without complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
214879340|NCT03391726|OTHER|CART-19 cells|CART-19 cells treat
214879341|NCT05189834|DIETARY_SUPPLEMENT|Gelsectan|Xyloglucan, vegetable protein and xylooligosaccharides
214879342|NCT06423807|DRUG|Ondansetron lozenge|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
214879343|NCT03149757|BEHAVIORAL|YouTHrive|"The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring."
215044471|NCT02702050|OTHER|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
215044472|NCT00212602|DRUG|ONO-7436|
214879344|NCT03149757|BEHAVIORAL|Information-only Control|Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
215044473|NCT04588142|DIETARY_SUPPLEMENT|Probiotic|Non-elite athletes receive probiotic for 6 weeks
215044474|NCT04588142|DIETARY_SUPPLEMENT|Placebo|Non-elite athletes receive placebo for 6 weeks
215044475|NCT00265850|BIOLOGICAL|bevacizumab|Given IV
215044476|NCT00265850|BIOLOGICAL|cetuximab|Given IV
215044477|NCT00265850|DRUG|FOLFOX or|Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
215044478|NCT00265850|DRUG|FOLFIRI|Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
214879345|NCT02600533|PROCEDURE|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
214879346|NCT00655343|DRUG|ATG-Fresenius S|"20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation"
214879347|NCT02800642|DRUG|Aflibercept (Eylea, BAY86-5321)|The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.
214879348|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
214879349|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
214879350|NCT02027428|DRUG|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
214879351|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
214879352|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
214879353|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
214879354|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
214879355|NCT05232188|PROCEDURE|Percutaneous nephrolithotomy|percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
214879356|NCT05191537|OTHER|Sustained Natural Apophyseal Glides|The patient sits well supported in a chair. The cervical spine and head are set in a neutral position. A painless passive posterior to anterior (PA) glide is applied in the plane of the facets on either the spinous process or the articular pillar/cervical lamina. While the glide is sustained the patient actively moves their neck in the direction that previously produced the symptoms. If symptom-free, the patient applies over-pressure further into the movement restriction. 3-6 repetitions are performed
215044479|NCT01287299|OTHER|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
215044480|NCT01287299|OTHER|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
215044481|NCT03939390|DRUG|time of administration of Corifollitropin Alfa|The treatment will be identical in both arms. The difference between the arms is the moment of the Administration of Corifollitropin Alfa: follicular phase of the menstrual cycle (control group) vs. luteal phase of the menstrual cycle (study group).
215044482|NCT04149743|DIAGNOSTIC_TEST|Standard of Care with Hemotag|Comparison of outcomes
215044483|NCT04641832|OTHER|Soccer heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
215044484|NCT02783833|DRUG|MMV390048 40mg|
215044485|NCT02783833|DRUG|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
214476988|NCT06817291|PROCEDURE|Laparoscopic endobiliary stent|During laparoscopic gallblader surgery, a quidewire is inserted in the cystic duct, via the common bile duct and advanced into the duodenum. The plastic stent is threaded over the wire and pushed in position, with a catheter. When the stent is crossing the papilla, the wire is first removed, and then the catheter. The procedure is done under x-ray guidance.
214879357|NCT05191537|OTHER|shoulder Mobilization with arm movement|The patient is seated. The therapist contacts the length of the spinous process with the medial aspect of the thumb. A transverse glide is applied by the therapist's index finger against the thumb contacting the spinous process. The direction of the glide is to the contralateral side of the pain. While the mobilisation is sustained the patient moves their arm through a pain-free abduction range. 3-5 sets of 6-10 repetitions may be performed.
215044486|NCT03616821|DRUG|Brazikumab|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
215044487|NCT03616821|DRUG|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
215044488|NCT00760552|OTHER|High Intensity Intervention|High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
214879358|NCT06283732|DIETARY_SUPPLEMENT|Greens powder|Participants are to consume one scoop (8.5 g) of the greens powder mixed in 8-10 oz of water every morning before breakfast for two weeks.
215044489|NCT00760552|OTHER|Low Intensity Intervention|Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, \& possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
215044490|NCT00760552|OTHER|All- 6 month pharmacist intervention|All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
214879359|NCT04004585|BEHAVIORAL|Get Up For Your Health|"The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting."
214879360|NCT07133802|BIOLOGICAL|Placebo Group|Each human dose: 0.2 mL
214879361|NCT07133802|BIOLOGICAL|Test Group|Each human dose is 0.2 mL
215044491|NCT01276951|DIETARY_SUPPLEMENT|Delivery and return of chocolate|At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
215044492|NCT01276951|PROCEDURE|Determination of blood pressure|Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
215044493|NCT01276951|PROCEDURE|Anthropometric Measurements|The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
215044494|NCT01276951|PROCEDURE|Food Anamnesis|With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
215044495|NCT01276951|PROCEDURE|Samples: serological tests and culture of mononuclear cells|At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
215044496|NCT01276951|PROCEDURE|Analysis of cytokine production|We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
215044497|NCT00475098|DRUG|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
215044498|NCT04883944|OTHER|Intervention group|"Mother will be involved in implementing the non-pharmacological techniques during the performance of the heel stick procedure as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding;~* exposure to maternal voice."
215044499|NCT04883944|OTHER|Standard care group|"A second nurse will perform the non-pharmacological techniques during the performance of the heel stick procedure without the maternal involvement as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding."
215044500|NCT04384614|DIAGNOSTIC_TEST|Test PCR|Viral load (COVID+) testing by PCR
214879362|NCT00517556|DRUG|CCOCP|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
214879363|NCT00517556|DRUG|Traditional OCP|(traditional OCP) (21 active days/7 inactive days) treatment regimen
214879364|NCT05857852|DEVICE|Low-Intensity Focused Ultrasound|Low-Intensity Focused Ultrasound administration to right dorsal anterior insula, in one of two sessions
214879365|NCT05857852|DEVICE|Sham LIFU device|Sham LIFU device administered in one of two sessions
214879366|NCT06824857|OTHER|Abdominal Massage Application|As part of the abdominal massage application, patient follow-up forms and checklists were prepared. Before starting the study, the abdominal massage practitioner participated in a certification program on this topic and received a competency certificate. Patients will be followed up for the first 3 days postoperatively using the prepared patient follow-up forms. Abdominal massage will be applied to each patient for 15 minutes according to a certain standard as stated in the literature
214879367|NCT03371459|DRUG|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
214879368|NCT03371459|DRUG|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
214879369|NCT05645705|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
214476989|NCT06818760|DIAGNOSTIC_TEST|Masimo Smart Wristband|Continuous wear of Masimo Smart Wristband
214879370|NCT05645705|OTHER|LISTERINE Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
214879371|NCT05645705|OTHER|Listerine Advanced Gum Alcohol|Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.
214879372|NCT05645705|OTHER|Listerine Advanced Gum Zero|Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.
214879373|NCT05645705|OTHER|LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
214879374|NCT01864395|PROCEDURE|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
214879375|NCT01864395|PROCEDURE|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
215044501|NCT04384614|GENETIC|TDR|IDR and blood sampling for testing DNA Cheque
215044502|NCT04384614|OTHER|Clinical Examination|COVID 19 symptoms and Physical Examination
215044503|NCT04293198|DEVICE|KODEX-EPD System|The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure
215044504|NCT04293198|DEVICE|Fluoroscopy with contrast dye|Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
214879376|NCT01864395|PROCEDURE|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
214879377|NCT02988635|OTHER|Early Palliative Care|Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
214879378|NCT01382654|DRUG|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
214879379|NCT01382654|DRUG|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
214879380|NCT01382654|DRUG|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
214879381|NCT01382654|DRUG|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
214879382|NCT01382654|DRUG|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
214879383|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
214879384|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
214879385|NCT01909063|DIETARY_SUPPLEMENT|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
214879386|NCT01589497|DRUG|Rifampicin|Participants with body weight \</= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight \>50kg were administered one 600 mg tablet orally once daily.
214879387|NCT01589497|DRUG|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
215044505|NCT03400423|DRUG|Caffeine|Oral administration of 1.2mg/kg of powdered caffeine with water.
215044506|NCT03400423|BEHAVIORAL|Moderate Intensity Exercise|Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)\*0.6.
215044507|NCT04350684|DRUG|Umifenovir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
215044508|NCT04350684|DRUG|Interferon-β 1a|This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
215044509|NCT04350684|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
215044510|NCT04350684|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
214879388|NCT01589497|DRUG|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
214879389|NCT01589497|DRUG|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
214879390|NCT01589497|DRUG|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
214879391|NCT05365724|BIOLOGICAL|Omicron COVID-19 Vaccine (Vero Cell), Inactivated|2 doses of vaccine according to the immunization schedule of 0, 21-28 days
214879392|NCT06230406|PROCEDURE|surgery for artherial and/or venous diseases|collection of vascular samples from surgery and blood samples
214879393|NCT02648100|OTHER|biomarker study|
214879394|NCT04771975|BEHAVIORAL|Exercise Counselling|Phase 1: See previous description for MatchQEP (Intervention) group. Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants had the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner. The 8-week program was open to all participants from Phase 1 who choose to continue in the study, regardless of initial randomization status. Behavioural and exercise counselling were offered to phase 2 participants.
214879395|NCT04771975|BEHAVIORAL|Partner Matching|"Phase 1: All participants will be matched with another participant (fellow BCS) and will facilitate / support exercise with their partner for the duration of the study.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants were rematched with different partner for this phase of the trial.~Participants will be matched based on personal and cancer-related characteristics."
214879396|NCT04771975|BEHAVIORAL|Resistance training sessions led by a QEP|Phase 2: participants were offered the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner.
215044511|NCT04350684|DRUG|Standards of Care|This Drug will be used in all arms as mandated by our governmental guidelines.
215044512|NCT00929266|BIOLOGICAL|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
215044513|NCT04723719|BEHAVIORAL|SIESTA|SIESTA is a CBT sleep training for adolescents with ADHD with a focus on sleep hygiene, motivational interviewing and planning and organization.
215044514|NCT04723719|OTHER|Treatment as usual for ADHD|Participants continue their treatment as usual for ADHD.
215044515|NCT01306292|DRUG|SonoVue|dose of 4.8 mL administered intravenously one time
215044516|NCT01306292|DRUG|Placebo|Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
215044517|NCT01326442|OTHER|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
215044518|NCT01326442|DIETARY_SUPPLEMENT|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
215044519|NCT02213029|DRUG|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or \>150mg
215044520|NCT02213029|DRUG|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
214879397|NCT00002070|DRUG|Sargramostim|
214879398|NCT00002070|DRUG|Ganciclovir|
214879399|NCT03683771|DIAGNOSTIC_TEST|Transvaginal US with Doppler study|Transvaginal Ultrasound with doppler study on endometrium will be made
214879400|NCT05645952|OTHER|Clinical follow up of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
214879401|NCT03783429|DRUG|Digoxin|Digoxin tablets will be given orally
214879402|NCT03783429|DRUG|Placebos|Placebo tablets will be given orally
214879403|NCT02906241|BEHAVIORAL|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
214879404|NCT02906241|BEHAVIORAL|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
214879405|NCT05393843|DIETARY_SUPPLEMENT|omega-3 fatty acids, anthocyanins and alpha-cyclodextrins|administration for 12 weeks
214879406|NCT05393843|BEHAVIORAL|diet|12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women
214879407|NCT05393843|OTHER|placebo|sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins; administration for 12 weeks
215044521|NCT02213029|DRUG|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
215044522|NCT02213029|DRUG|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
215044523|NCT03251521|OTHER|pain rating during injection with botulinum toxin|The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
215044524|NCT02797821|DRUG|Asfotase alfa|
215044525|NCT00353002|DRUG|Ametop (4% Amethocaine cream )|
215044526|NCT00353002|DRUG|Maxilene (4% Liposomal Lidocaine)|
215044527|NCT05291754|DEVICE|PEEK Cranioplasty|3D printed PEEK skull implant
215044528|NCT04391920|DEVICE|CytoSorb 300 mL device|CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.
214879408|NCT02368951|DRUG|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
214879409|NCT02976987|DRUG|Cidofovir|
214879410|NCT03735069|PROCEDURE|IPT (Indirect pulp treatment)|Indirect pulp treatment involves complete caries excavation from the dentin-enamel junction using a round bur. Caries near the pulp is removed with caution using spoon excavator until the remaining dentine shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material is placed, followed by resin-modified glass ionomer (RMGI) build-up material, and the final restoration; a preformed Stainless Steel Crown (SSC).
214879411|NCT03735069|PROCEDURE|Cvek/partial pulpotomy|Cvek/partial pulpotomy involves removal of inflamed pulp tissue to depth until healthy pulp tissue is reached (depth of 2-4 mm), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
214879412|NCT03735069|PROCEDURE|Cervical pulpotomy|Cervical pulpotomy involves removal of inflamed pulp tissue from all pulp chamber as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 6 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber (2-3mm) thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
214879413|NCT01170013|BEHAVIORAL|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
215044529|NCT02455739|OTHER|chewing gum|postoperative gum chewing to improve gastrointestinal function
215044530|NCT02098135|DEVICE|ArmeoSenso|Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
215044531|NCT02588885|BEHAVIORAL|Trauma-sensitive Care|"Psychological intervention~1. education~2. empowerment~3. desensitization~4. relaxation tools~Physical therapy intervention~1. techniques to address muscular tension~2. empowerment~3. comfort~4. encouragement of trauma-related coping skills"
215044532|NCT03130686|DEVICE|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
214879414|NCT01170013|BEHAVIORAL|Parent psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
214879415|NCT03033966|DEVICE|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
214879416|NCT03058432|RADIATION|Radiotherapy alone|
215044533|NCT01101607|PROCEDURE|Distal Forearm Fracture Reduction|Fracture reduction
215044534|NCT04426474|DRUG|LY3502970|Administered orally.
215044535|NCT04426474|DRUG|Placebo|Administered orally.
214879417|NCT03058432|RADIATION|Concurrent chemoradiotherapy|
214879418|NCT04688892|DEVICE|Cupping|dynamic cupping
214879419|NCT05603377|DIAGNOSTIC_TEST|functional endoscopic evaluation of swallow|functional endoscopic evaluation of swallow
215044536|NCT06009302|PROCEDURE|US guided block of mandibular nerve|Extraoral ultrasound-guided block of the mandibular nerve will be performed in the examined group using an ultrasound device, using ropivacaine (0.75%, 2.5 mL).
215044537|NCT06009302|PROCEDURE|Intraoral block of lower alveolar nerve|Block of lower alveolar nerve will be applied intraoraly using articaine+adrenaline
215044538|NCT02027792|OTHER|Cabbage leave wraps|
215044539|NCT02027792|DRUG|Diclofenac Gel|
215044540|NCT02298621|OTHER|pomegranate juice|Randomized clinical trial or RCT
215044541|NCT02298621|OTHER|placebo|Randomized clinical trial or RCT
215044542|NCT04863794|DRUG|RO7248824|A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
215044543|NCT01435161|DRUG|Nifedipine,|Nifedipine 30-60mg/day
214879420|NCT00277173|BEHAVIORAL|Adoption of Crew Resource Management approach|
214879421|NCT01197144|DRUG|adalimumab|Subcutaneous, 40 mg every other week for 4 weeks
214879422|NCT01197144|DRUG|Placebo|Subcutaneous, every other week for 4 weeks
214879423|NCT00151346|DRUG|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
215044544|NCT01435161|DRUG|Telmisartan|Telmisartan 80-160mg/day
215044545|NCT05562505|OTHER|Venovenous ECMO|ECMO therapy for patients with hypoxic respiratory failure.
215044546|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
215044547|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
215044548|NCT00363584|DRUG|capecitabine|
215044549|NCT00363584|OTHER|clinical observation|
215044550|NCT00363584|PROCEDURE|adjuvant therapy|
215044551|NCT03507127|DRUG|Varenicline|Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.
215044552|NCT03507127|DRUG|Placebo|Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
215044553|NCT03942224|DRUG|Bortezomib|Given SC
215044554|NCT03942224|BIOLOGICAL|Daratumumab|Given IV
215044555|NCT03942224|DRUG|Dexamethasone|Given IV and PO
215044556|NCT03942224|DRUG|Ixazomib|Given PO
215044557|NCT02271529|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
215044558|NCT01011114|DRUG|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
215044559|NCT01011114|DRUG|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
215044560|NCT05986266|DRUG|Carbetocin|To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
215044561|NCT02209467|OTHER|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
215044562|NCT04103021|DEVICE|Port-A-Cath|Totally implanted central venous access device
215044563|NCT03655067|BEHAVIORAL|CATCH-IT|The CATCH-IT internet program consists of 14 modules and exercises and activities based on best practices components of depression prevention. They will be instructed to complete at least 2 modules a week, over a period of 6 weeks. This would require at least 40 minutes per week (approximately 20 minutes minimum per module).
215044564|NCT05059886|OTHER|completion of a questionnaire on the practice of sports and possible injuries|completion of a questionnaire on the practice of sports and possible injuries
215044565|NCT01497756|DEVICE|CAPP use|Any abdominal pelvic pressure
215044566|NCT03224039|DRUG|Sufentanil|Intranasal for one dose (experimental)
215044567|NCT03224039|DRUG|Normal saline|Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
215044568|NCT03224039|DRUG|Morphine|intravenous push for one dose (active comparator)
215044569|NCT00079313|DRUG|Imatinib|
215044570|NCT02866812|OTHER|questionnaires assessing the state of fatigue, depression and anxiety|
215044571|NCT02588469|OTHER|Interventional group|"Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA."
215044572|NCT02588469|OTHER|Control group|Standard obesity care with physical activity program
215044573|NCT02583347|DEVICE|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
215044574|NCT02031406|OTHER|Post-discharge counseling on medication adherence & literacy|
215044575|NCT00613431|DRUG|CS8080|CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
215044576|NCT00613431|DRUG|Placebo|Some subjects will receive matching placebo instead of CS-8080.
215044577|NCT02525198|DIETARY_SUPPLEMENT|fatty acid/flavonoid blend|see arm description
215044578|NCT02525198|DIETARY_SUPPLEMENT|Placebo|see arm description
215044579|NCT05701553|DRUG|Anti-PD-1/PD-L1|Intravenous injection at indicated dose for at least 6 months
215044580|NCT05701553|DRUG|S-Adenosyl-Methionine|Taken orally at indicated dose for at least 6 months
215044581|NCT02441894|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
215044582|NCT02441894|DRUG|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
214879424|NCT00151346|DRUG|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
214879425|NCT02143076|BEHAVIORAL|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
215044583|NCT02441894|DRUG|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
215044584|NCT02441894|DRUG|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
215044585|NCT02441894|DRUG|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
214879426|NCT02143076|BEHAVIORAL|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
214879427|NCT02143076|BEHAVIORAL|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
214879428|NCT05996562|PROCEDURE|Pulmonary Artery Denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55°C for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA."
214879429|NCT04334694|DEVICE|Atrial flow regulator (Occlutech® AFR device)|Atrial septostomy followed by implantation of AFR.
214879430|NCT00115427|DRUG|Liatermin (r-metHuGDNF)|
214879431|NCT01279720|BIOLOGICAL|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
214879432|NCT00397774|BEHAVIORAL|Physical exercise|Physical exercise twice a week for 8 weeks, and best supportive care
215044586|NCT02441894|DRUG|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
215044587|NCT02441894|DRUG|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
215044588|NCT04902209|PROCEDURE|postural stability measurements|"Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment"
215044589|NCT02006108|DRUG|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
215044590|NCT02006108|OTHER|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
215044591|NCT01492426|DRUG|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
215044592|NCT01492426|DRUG|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
215044593|NCT01492426|DRUG|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
215044594|NCT01492426|DRUG|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
215044595|NCT04119752|DIETARY_SUPPLEMENT|Curcumin powder|10g of curcumin powder
215044596|NCT04119752|DIETARY_SUPPLEMENT|Placebo|1g of sucralose
215044597|NCT01283438|DEVICE|Barricaid|Annular closure device
215044598|NCT01283438|DEVICE|Standard of Care|Standard Limited discectomy
214879433|NCT00397774|OTHER|best supportive care|
214879434|NCT00000474|BEHAVIORAL|behavior therapy|
214879435|NCT05600465|BEHAVIORAL|Behavioral Activation + Occupational Therapy|In the BA-OT Approach, the PI will use an evidence-based 4-step process (Goal-Plan-Do-Check) to assist the older adults to develop strategies to plan and execute daily health self-management activities. BA-OT teaches older adults with MCC and functional limitations to 1) set achievable and meaningful activity goals, 2) engage in action planning that includes brainstorming strategies to overcome barriers, 3) evaluate the results after performing the activity, and 4) to modify the plan or choose a new goal, then generalize strategies to new problems. By assisting participants to develop daily routines and integrate safe health self-management activities into these routines, occupational therapists are providing strategies that support adaptation in the face of stressful situations.. Goal examples may include adapting and scheduling exercise plans, or exploring assistive devices and strategies for safe and healthy meal preparation.
214879436|NCT05600465|BEHAVIORAL|Enhanced Usual Care|Fitbit, 1 hour training, handout on managing chronic conditions
215044599|NCT00322049|BIOLOGICAL|Tetravalent live attenuated dengue vaccine|"DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit)."
215044600|NCT00322049|BIOLOGICAL|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
214879437|NCT00708773|DRUG|Irinotecan|"90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination."
214879438|NCT05856643|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8, 2.0×10\^8and 5.0×10\^8 cells. The infusion is given every 2 weeks.
214879439|NCT03159338|BIOLOGICAL|Platelet rich fibrin|Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
214879440|NCT03159338|BIOLOGICAL|Placebo|In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
214879441|NCT02542605|DRUG|Erenumab|Administered once on day 1 of Part B of the study by intravenous infusion.
214879442|NCT02542605|DRUG|Placebo|Administered once on day 1 of Part B of the study by intravenous infusion.
215044601|NCT01978145|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
215044602|NCT01978145|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
215044603|NCT01254448|DRUG|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
215044604|NCT01254448|DRUG|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
215044605|NCT02026011|DRUG|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
215044606|NCT02026011|DRUG|Placebo|Sugar pill, matched to the active study medication in capsule size and color
215044607|NCT01400009|DRUG|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
215044608|NCT01400009|DRUG|Placebo|Standard Placebo made of Lactose 100 mg
215044609|NCT02252315|OTHER|Educational Brochure|Participants will receive written education materials about mild traumatic brain injury.
214879443|NCT02542605|DRUG|PACAP-38 Challenge Agent|"Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack."
214879444|NCT02682927|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
214879445|NCT02682927|DRUG|Matching Placebo|Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
214879446|NCT00676780|DRUG|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
214879447|NCT04605874|OTHER|Package Quantity (cigarillos)|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack.
214879448|NCT02796794|DIETARY_SUPPLEMENT|Genistein|Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
214879449|NCT02796794|OTHER|enteral nutrition only|These are the patients receiving enteral nutrition
214879450|NCT05705765|OTHER|Suspension training|Training with suspension devices. 12 sessions of 40-45 min in four weeks.
214879451|NCT05705765|OTHER|Instability training|Training on unstable surfaces. 12 sessions of 40-45 min in four weeks.
214879452|NCT01559883|OTHER|no intervention is being made|This is a Non-Interventional Study (NIS)
214879453|NCT01562561|DRUG|repaglinide|2 mg at each main meal
214879454|NCT01562561|DRUG|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
214879455|NCT00003445|DRUG|docetaxel|
214879456|NCT04820205|DRUG|Intranasal dexmedetomidine and ketamine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
214879457|NCT04820205|DRUG|Oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
214879458|NCT06548945|DRUG|GZR18|5 mg-maximum tolerated dose (MTD), single dose
214879459|NCT06548945|OTHER|Placebo|administered the same volume as GZR18
214879460|NCT01952314|DRUG|Naftopidil 75mg|naftopidil 75mg 1T qd hs
215044610|NCT02252315|OTHER|Verbal education module|A structured in-person education module about mild traumatic brain injury.
215044611|NCT01770743|BIOLOGICAL|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
215044612|NCT01770743|BIOLOGICAL|BioThrax|
215044613|NCT00000906|DRUG|Ritonavir|
215044614|NCT00000906|DRUG|Saquinavir|
215044615|NCT00000906|DRUG|Methadone hydrochloride|
215044616|NCT00403325|DRUG|rhuFab V2 [ranibizumab] ( Lucentis )|
215044617|NCT05257382|PROCEDURE|ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy|After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)
215044618|NCT02477488|DRUG|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
214879461|NCT01952314|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
214879462|NCT01952314|DRUG|Standard treatment|Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
214879463|NCT00627510|OTHER|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
214879464|NCT00591981|BEHAVIORAL|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
214879465|NCT01613313|DRUG|Collagenase Clostridium Histolyticum|This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
214879466|NCT02766283|DRUG|iodinated contrast agents|Intravascular application
214879467|NCT00096837|DRUG|Motexafin Gadolinium Injection|
215044619|NCT00529243|DRUG|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
214879468|NCT01795911|BIOLOGICAL|Pegylated Interferon Lambda|
215044620|NCT01048398|DRUG|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
215044621|NCT01048398|DRUG|paracetamol|Control group: intravenous paracetamol 1g
214879469|NCT01795911|DRUG|Ribasphere|
214879470|NCT01795911|DRUG|Daclatasvir|
214879471|NCT06076460|OTHER|Early Total Enteral Feeding|This group will receive enteral feeding volumes at a rate of 80 ml/kg/day starting within the first two hours after birth. Volumes will increased by 20 ml/kg/day till day 4 (total 140 ml/kg/d) and then 150ml/kg/day on day 5.
214879472|NCT06076460|OTHER|Conventional Enteral Feeding|This group will receive enteral feeding volumes at a rate of 20 ml/kg/day starting within the first two hours after birth and rest of the daily requirement as Total parenteral nutrition. Volumes will be increased by 20 ml/kg/day till day 3 and thereafter by 30 ml/kg/d till 150ml/kg/day on day 6.
214879473|NCT06632548|DEVICE|telescopic overdenture|two implant retained mandibular overdenture with telescopic attachment
214879474|NCT04011163|DEVICE|VPIA pump|The pump is a specially designed and manufactured infusion syringe pump for intravenous analgesia. It incorporates the VPIA study regimen to meet the specific requirements of the clinical trial. It is intended to be used only for delivering drugs intravenously.
214879475|NCT04011163|DRUG|Morphine|Intravenous medication used is morphine diluted in normal saline to a concentration of 1mg/ml. This is a standard dilution and are routine drugs used as standard of care.
214879476|NCT05168943|DEVICE|Nylon (Polyamide) Epidural Catheter|Nylon (Polyamide) Epidural Catheter
214879477|NCT05168943|DEVICE|Polyurethane Epidural Catheter|Polyurethane Epidural Catheter
214879478|NCT04269473|PROCEDURE|Telehealth Gait Retraining|Telehealth gait retraining is a novel approach to train participants to adopt a non-rearfoot foot strike pattern during running via telecommunications. During telehealth gait retraining, video of a participant's running form are sent to clinicians over a mobile device app and running form feedback is given. This process is repeated once a week for four weeks and then every other week until week 8.
214879479|NCT04269473|PROCEDURE|Standard Physical Therapy Treatment|Participants receiving standard Physical Therapy will visit the Physical Therapy Clinic every 2 to 3 weeks to be treated by a Physical Therapist.
214879480|NCT04269473|PROCEDURE|Return to Running Protocol|The Return to Running protocol is a six-phase running volume progression to re-introduce running slowly and safely after experiencing a running-related injury.
214879481|NCT04269473|PROCEDURE|At Home Exercise Program|The At Home Exercise Program consists of 4 lower leg and foot exercises that participants can perform on their own time.
215044622|NCT06473298|OTHER|Visual Light Tracking|visual light tracking program consists of 10 tasks every task lasts for 6 minutes and may be repeated for the child especially in the first sessions to give him trials to him/her to understand the exercise.
215044623|NCT01053507|DRUG|sumatriptan/naproxen sodium|Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
214879482|NCT02414776|DRUG|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
214879483|NCT04007991|DRUG|Ecopipam|Ecopipam HCI tablets administered PO to establish 2 mg/kg/day
214879484|NCT04007991|DRUG|Placebo|Matching Placebo
214879485|NCT00203593|BEHAVIORAL|Exercise|
214879486|NCT00203593|DEVICE|Blood volume|
214879487|NCT00203593|PROCEDURE|VO2max test|
214879488|NCT00203593|PROCEDURE|Lower body negative pressure|
214879489|NCT00203593|BEHAVIORAL|Heart Rate|
214879490|NCT00203593|PROCEDURE|Blood Pressure|
214879491|NCT00203593|BEHAVIORAL|Total Peripheral Resistance|
214879492|NCT03878771|BIOLOGICAL|Platelet rich fibrin gel in Orabase|applied on oral mucositis and /or ulcer 3 times per day
214879493|NCT03878771|DRUG|Dermovate cream in Orabase|applied on oral mucositis and /or ulcer 3 times per day
214879494|NCT07134452|DIAGNOSTIC_TEST|Baseline Assessments|Evaluation of isokinetic muscle strength, grip strength, upper extremity weight-bearing capacity, proprioceptive sense, reaction time, and functional performance in both groups
214879495|NCT06904846|DEVICE|iCan o3 CGM Continuous Glucose Monitoring System|"A continuous Glucose Monitoring System (CGM System) is a real-time, continuous glucose monitoring device indicated for the management of diabetes for adult persons (age 18 and older). It is intended to replace finger prick blood glucose testing for diabetes treatment decisions. The CGM System also shows trends and tracks patterns, and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the CGM System results should be based on the glucose trends and several sequential readings over time.~The CGM System can be used in conjunction with smart devices with corresponding applications (apps) where the user manually controls actions for therapy decisions. During this study, Self-Monitoring Blood Glucose (SMBG) assessed by an iCan o3 CGM System blinded to the patient for 15 days as the baseline and unblinded observation period using an iCan o3 CGM System for 45 days occurs."
214879496|NCT05929378|PROCEDURE|Lightweight mesh fixation|Lightweight mesh fixation in 3 points
214879497|NCT04679701|DEVICE|Amparo Confidence Socket|"The Amparo Confidence Socket technology takes a different approach by starting with a prefabricated socket (https://www.amparo.world/confidence-socket-en). The socket is made from a moldable thermoplastic and has the attachment point pre-assembled. This prefabricated socket is essentially an off-the-shelf product that can be heated, then molded directly to the patient's residual limb. This removes many of the intermediate steps in traditional socket fabrication. The product's molding temperature is between 60-70 ˚C but the insulation of a silicone liner between the plastic and limb ensures safe temperatures for the patient. This process is currently used in several workshops in Europe and with approximately 50 patients currently using the product. In general, it has been shown to be safe and effective in creating below-knee prosthesis."
214879498|NCT03533023|BEHAVIORAL|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
214879499|NCT03533023|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
214879500|NCT05314816|DIAGNOSTIC_TEST|Blood culture identification panel|multiplex PCR panel to be performed on positive blood cultures
214879501|NCT05048329|OTHER|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and colorectal clinical team
214879502|NCT05048329|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
215044624|NCT01053507|DRUG|Placebo|Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
215044625|NCT02377843|BEHAVIORAL|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
214879503|NCT03524521|BEHAVIORAL|Interval Training|Interval training is prescribed 3 days per week using 5 body weight exercises in a progressive fashion.
214879504|NCT03524521|BEHAVIORAL|Standard of Care|Walking prescribed to meet current exercise guidelines; 150 minutes per week.
214879505|NCT03310749|DRUG|Gemigliptin|A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
214879506|NCT03310749|DRUG|Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day|A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
214879507|NCT03310749|DRUG|Metformin|A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
214879508|NCT03888066|DRUG|Patiromer|The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
214879509|NCT03888066|DRUG|Placebos|The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
214879510|NCT02428439|DRUG|bupropion or lamotrigine|Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
214879511|NCT01613768|DRUG|eribulin mesylate|Given IV
214879512|NCT00168935|DRUG|Fresubin protein energy Drink (CAVE! nutritional intervention)|
214879513|NCT01824381|PROCEDURE|Place amniotic membrane in large wounds|"After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.~The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.~We will place a new membrane weekly to a maximum of 6 times."
214879514|NCT01824381|PROCEDURE|Obtaining and Cryopreservation of amniotic membrane|
214879515|NCT01824381|DRUG|amniotic membrane|
215044626|NCT02377843|BEHAVIORAL|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
215044627|NCT00918606|DRUG|LIPO-102|LIPO-102
215044628|NCT03233828|BIOLOGICAL|Aldesleukin|500,000 IU in 0.1mL
215044629|NCT03233828|OTHER|Saline|0.1 mL of sterile saline solution (0.9% m/v)
215044630|NCT03925571|OTHER|musicotherapy|If the patient is randomized in the experimental group, he listens the Music-care® playlists and chose two closed to his musical tastes. The playlists are unique compositions create by Music-care® (french company), not known from the general public, categorized by theme (jazz, rock, world music…).
215044631|NCT04420858|BEHAVIORAL|Enhanced (experimental) education|See arm description.
215044632|NCT04420858|BEHAVIORAL|Standard (control) education.|See arm description.
215044633|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water|
215044634|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate|
215044635|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate + protein|
215044636|NCT02859974|BEHAVIORAL|Respiratory retraining for PVFMD|"Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.~Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.~Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase."
215044637|NCT04242706|DEVICE|ETTEvac|Endotracheal tube with evacuation lumen without noble metal coating
215044638|NCT04242706|DEVICE|BIP ETTEvac|Endotracheal tube with evacuation lumen with noble metal coating
215044639|NCT06453382|BEHAVIORAL|Behavioural change modification, Screening, NCD related knowledge practice and attitude|The investigators will provide periodic training regarding the control and prevention of NCDs to the stakeholders. The investigators will provide WHO-Package of Essential Non-Communicable Diseases (PEN) protocol training to the stakeholders involved in healthcare service delivery. The investigators will equip the government healthcare facilities with the equipment needed for the screening of NCDs. For the stakeholders who are not directly involved with healthcare service delivery, the investigators will train them about the 5 NCDs (diabetes, hypertension, chronic respiratory disease, cancer, and mental illness) and the 5 NCD risk factors (unhealthy diet, inadequate physical activity, tobacco cessation, alcohol cessation, and air pollution). The investigators will also share information, education, and communication (IEC) materials with the stakeholders, and then they will share the information with the community.
215044640|NCT02852967|DRUG|Belumosudil|
215044641|NCT02852967|DRUG|Placebo|Placebo tablets matching belumosudil
214879516|NCT05013008|DRUG|Finerenone (Kerendia, BAY94-8862)|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
214879517|NCT05013008|DRUG|Placebo|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
214879518|NCT03667638|COMBINATION_PRODUCT|Platelet-Rich Plasma|Adding PRP to wound bed during surgical debridement
214879519|NCT04530955|DEVICE|Prometra II Programmable Pump - Flowonix Medical|The valve gated Prometra II Programmable Pump will be replacing the prior peristaltic Synchromed II pump and a 20% dose decrease will be performed at the time of the replacement.
214879520|NCT04187755|DRUG|Ceftazidime Injection|Ceftazidime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 6 hourly)
214879521|NCT04187755|DRUG|Cefepime Injection|Cefepime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 8 hourly)
214879522|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
214879523|NCT02340481|DRUG|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
215044642|NCT02898922|BIOLOGICAL|hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae|20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
215044643|NCT01936233|DRUG|Aspirin|Aspirin 0.1 QD po
215044644|NCT01936233|DRUG|Lamivudine|LAminvudine 0.1 QD po
214879524|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
214879525|NCT02340481|DRUG|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
214879526|NCT00408525|DRUG|donepezil|donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
214879527|NCT02115490|DRUG|Bisphosphonates|
214879528|NCT01094015|DRUG|lidocaine-prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
214879529|NCT01094015|OTHER|gel application for the transmission of ultrasound|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
214879530|NCT04109092|DRUG|E7766|E7766, solution, intravesically.
214879531|NCT02351661|OTHER|There was no intervention|observational study, no intervention
214879532|NCT05327153|BEHAVIORAL|Acceptance and Commitment Therapy|The theoretical foundation of ACT is Relational Frame Theory (RFT) based on the functional contextualism philosophy, which suggests that the main psychological problem derived verbal and cognitive interaction with environment, leading to behaviors contrary to long-term values and psychological inflexibility. The psychopathological model of ACT includes six core parts: experiential avoidance, cognitive fusion, attachment to the conceptualized self, conceptualized past and feared future, lack of value clarity, inaction.
214879533|NCT00956423|BEHAVIORAL|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
214879534|NCT00956423|BEHAVIORAL|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
214879535|NCT06582797|OTHER|discontinuation of ART|patient will discontinue their standard of care HIV treatment with ART while being closely monitored
214879536|NCT01194167|DRUG|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
214879537|NCT04981717|DRUG|REGN1908-1909|Subcutaneous (SC) for a total of 5 administrations
214879538|NCT04981717|DRUG|Matching Placebo|SC for a total of 5 administrations
214879539|NCT00674739|DRUG|Imiquimod|daily topical application for up to 8 weeks
214879540|NCT00674739|DRUG|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
214879541|NCT00674739|DRUG|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
214879542|NCT04686955|DRUG|Xiao-Xian-Gui-Fu-Tang|The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
214879543|NCT01519310|OTHER|Antibiotic (metronidazole and ciprofloxacin)/probiotic|"Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks."
214879544|NCT05050812|DEVICE|grounding mat|Participants will sleep on an Earthing Elite sleep mat produced and sold by Earthing.com
214879545|NCT02207634|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
214879546|NCT02207634|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
214879547|NCT02207634|DRUG|Background Statin Therapy|Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
214879548|NCT03275142|DEVICE|Icare tonometer|Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
214879549|NCT00038025|DRUG|Deoxycoformycin (DCF)|Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
214879550|NCT00563329|PROCEDURE|Reduction Intervention + Adherence Intervention|
214879551|NCT00563329|BEHAVIORAL|Reduction Intervention|
214879552|NCT00563329|PROCEDURE|control|
214879553|NCT01368653|BEHAVIORAL|Standard treatment|Standard treatment includes a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help smokers quit smoking
214879554|NCT01368653|BEHAVIORAL|Standard treatment+practice quitting|This intervention includes standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling
214879555|NCT01368653|DRUG|Very low nicotine cigarettes|This intervention will be offered to a subset of smokers from both of the other study arms. To be eligible for this intervention, participants must be smoking at the follow-up interview conducted four weeks after a target quit day in the two arms listed above. Tobacco cigarettes containing very low levels of nicotine (.016-.019 mg in smoke from the cigarettes). These are to be smoked no more often than a smoker normally smokes regular cigarettes and for no longer than 6 weeks.
214879556|NCT02101125|DRUG|BMS-986020|
214879557|NCT02101125|DRUG|Rosuvastatin|
214879558|NCT03691766|OTHER|Photobiomodulation Therapy|Photobiomodulation therapy, a mix of red lights thought to improve mitochondrial function will be applied in and acute and chronic manner to test whether muscle fatigue improves in persons with MS.
214879559|NCT03691766|OTHER|Placebo|Device with sham light source
214879560|NCT03054701|OTHER|Hip specific resistance exercise|Hip specific resistance exercise
214879561|NCT03054701|OTHER|Knee specific resistance exercise|Knee specific resistance exercise
214879562|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
214879563|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
214879564|NCT00591773|DRUG|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
214879565|NCT00264173|DRUG|Valproate sodium|
214879566|NCT00825760|DRUG|Topical PPA904 gel and light|
214879567|NCT00825760|DRUG|Topical placebo gel plus light|
214879568|NCT00459355|BEHAVIORAL|Home Safety Toolkit|Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
214879569|NCT01849965|DRUG|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
214879570|NCT01849965|DRUG|placebo vehicle gel|
214879571|NCT01849965|DRUG|Standard of Care gel, Aquasite|
214879572|NCT03579108|OTHER|Retrospective Chart Review|Chart review
214879573|NCT05439681|DEVICE|Theranova 400|medium cut off (MCO) membrane
214879574|NCT05439681|DEVICE|FX 10|low-flux membrane
214879575|NCT05439681|DEVICE|FX CorDiax 800|high-flux membrane
214879576|NCT05439681|DEVICE|HDF|hemodiafiltration
214879577|NCT02998697|DRUG|Ferrous Sulfate|Ferrous sulfate 200 mg t.i.d for 90 days
214879578|NCT02998697|DRUG|Placebo Oral Capsule|Lactose 200 mg t.i.d for 90 days
214879579|NCT01068145|DRUG|SCH 527123|Very low dose SCH 527123, once daily for 7 days
214879580|NCT01068145|DRUG|SCH 527123|Low dose SCH 527123, once daily for 7 days
214879581|NCT01068145|DRUG|SCH 527123|Medium dose SCH 527123, once daily for 7 days
214879582|NCT01068145|DRUG|SCH 527123|High dose SCH 527123, once daily for 7 days
214879583|NCT01068145|DRUG|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
214879584|NCT01068145|DRUG|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
214879585|NCT01068145|DRUG|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
214879586|NCT01068145|DRUG|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
214879587|NCT01068145|DRUG|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
214879588|NCT00287586|DRUG|Testosterone Gel (Androgel)|7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
214879589|NCT00287586|DRUG|Placebo|Placebo-matching testosterone gel daily for 3 years
214879590|NCT00307398|DRUG|Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg|One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.
214879591|NCT00307398|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
214666885|NCT05379504|BEHAVIORAL|Standard Health Education|Participants randomized to the standard health education arm will receive the intervention at month 1 and then months 3, 6, 9, and 12 (coinciding with the quarterly interviews). The participant will use the tablet and telehealth platform to complete the interview and education session with research staff. The content of these sessions will be focused on helping the participant (and family member/caregiver as appropriate) understand their health data, assisting them with any technology issues and providing the participant with education on their condition(s) and any requested resources. Research staff will will also provide any additional health education if there are changes to conditions or new diagnoses after an outside provider visit.
214879592|NCT02135614|DRUG|Presatovir|Presatovir 200 mg (4 x 50 mg tablets) administered orally
214879593|NCT02135614|DRUG|Presatovir placebo|Presatovir placebo tablets administered orally
214879594|NCT01358214|BEHAVIORAL|Questionnaire on Quality of Life.|The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
214879595|NCT05768581|OTHER|Concurrent Training|Participants should perform strength training and aerobic exercises
214879596|NCT05768581|OTHER|Strength Training|Participants should perform strength exercises
214879597|NCT05768581|OTHER|Aerobic training|Participants should perform aerobic exercises
214879598|NCT03675061|OTHER|Current care|Tocolysis and a complete corticosteroid treatment.
214879599|NCT03675061|DEVICE|PartoSure Test negative|Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
214879600|NCT03675061|DEVICE|PartoSure Test positive|Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
214879601|NCT03101605|OTHER|e-learning teaching module|As described
214879602|NCT03101605|OTHER|Standard teaching method|As described
214879603|NCT01437839|DRUG|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
214879604|NCT01437839|DRUG|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
214879605|NCT06109155|DRUG|Tranexamic acid|tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
214879606|NCT05415163|PROCEDURE|vascular photobiomodulation|application of photobiomodulation with the device O Ecco ILIB (Eccofibras, São Paulo, Brazil) containing its red wavelength 660 nm ± 10 nm and power 100 mW, with an application time of 30 minutes. The device will be positioned with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
214879607|NCT05409586|PROCEDURE|segmental mastectomy|The preferred method in the treatment of some patients diagnosed with IGM
214879608|NCT02147041|DRUG|EGCG(Epigallocatechin Gallate)|500mg, three times a day, duration:12 weeks
214879609|NCT02147041|DRUG|Placebo|
214879610|NCT00033007|BEHAVIORAL|Behavior Therapy|
214879611|NCT01507311|DRUG|liraglutide|A single dose injected subcutaneously (under the skin)
214879612|NCT01507311|DRUG|placebo|A single dose injected subcutaneously (under the skin)
214879613|NCT01726829|DEVICE|MD-Logic Artificial Pancreas (MDLAP) system|
214879614|NCT01726829|PROCEDURE|sensor augmented pump therapy|
214879615|NCT02655731|DEVICE|PVI with HeartLight|Catheter ablation
214879616|NCT01542801|DRUG|Norfloxacin|Norfloxacin 400 mg per day
214879617|NCT01542801|DRUG|ciprofloxacin|Ciprofloxacin 750 mg per week
214879618|NCT02116270|BIOLOGICAL|Blood sample|3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
214879619|NCT03928483|BEHAVIORAL|Modified WW Food program|Participants will receive a structured, holistic, behavioral weight management program that encourages development of healthy habits to help individuals eat healthier, move more, and shift to a more helpful mindset.
214879620|NCT03675230|DEVICE|Tomotherapy HD|Patients with Medulloblastoma receiving Tomotherapy
214879621|NCT03675230|DEVICE|3DCRT|Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
214879622|NCT03011138|PROCEDURE|Gait velocity|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
214879623|NCT04237337|OTHER|Exposure to MS drugs|Exposure in ICSRs to MS drugs (dichotomous, exposed/not exposed), for each individual MS drug
214879624|NCT04158388|OTHER|Mediterranean-diet enriched with a higher dose of tryptophan and magnesium|That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium
214879625|NCT04158388|OTHER|Isocaloric diet|That group eaten isocaloric diet plan based on Mediterranean diet.
214879626|NCT04158388|OTHER|Manual therapy|That group received moderate pressure digital manual therapy.
214879627|NCT04158388|OTHER|Placebo therapy|That group was treated with a US (in off mode) without conductive gel.
214879628|NCT05642845|DRUG|Atorvastatin film-coated tablet 40 mg|Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.
214879629|NCT05642845|DRUG|Liprimar® film-coated tablet 40 mg|"Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin."
214879630|NCT03734939|OTHER|None intervention is planned.|None intervention is planned, just a survey.
214879631|NCT00237965|BEHAVIORAL|Mole Mapping Diagram|
214879632|NCT02366429|BEHAVIORAL|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
215044645|NCT03853044|DRUG|Chidamide|Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles
215044646|NCT03853044|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
215044647|NCT03853044|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
215044648|NCT03853044|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
214879633|NCT02366429|OTHER|TAU|Treatment as usual provided at antenatal clinics and other health care instances
214879634|NCT02462291|OTHER|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
214879635|NCT03327259|BEHAVIORAL|Activity Planning|The therapist will work with the participant to select a challenging, yet rewarding or value-driven activity that he/she can engage in 5x and monitor daily over the upcoming week.
214879636|NCT03327259|BEHAVIORAL|Therapist Guided Activity Practice|The therapist will work with the participant to plan and carry out a brief in-vivo version of their goal/target activity. The therapist will guide the participant through the activity for approximately 15 minutes.
214879637|NCT00029029|PROCEDURE|pain therapy|
214879638|NCT00029029|PROCEDURE|radiofrequency ablation|
215044649|NCT03853044|DRUG|Prednisone|Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
215044650|NCT05171153|OTHER|Densitometry with Trabecular Bone Score|"Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine."
215044651|NCT05171153|OTHER|Quantitative Ultrasound of Calcaneus|Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).
215044652|NCT05171153|OTHER|Laboratory test|Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
215044653|NCT00080574|PROCEDURE|Skin Biopsy|
215044654|NCT04313738|OTHER|Assigned Interventions|Home visit, health education
215044655|NCT05674227|PROCEDURE|Robotic surgery|Surgical treatment of operable lung cancers using robotic systems
215044656|NCT05674227|PROCEDURE|Video-assisted thoracoscopy|Surgical treatment of operable lung cancers using a video-assisted thoracoscopy approach (VAT)
214879639|NCT05938608|DRUG|Regimen 1 (Oral primaquine)|Primaquine 15 mg base orally once
214879640|NCT05938608|DRUG|Regimen 2 (IV primaquine phosphate)|Primaquine 7.5 mg base in normal saline 500 mL infused over 30 minutes intravenously
214879641|NCT05938608|DRUG|Regimen 3 (IV carboxyprimaquine)|Carboxyprimaquine 7.93 mg base in normal saline 500 mL infused over 30 minutes intravenously
214879642|NCT00316095|DRUG|telmisartan|
214879643|NCT00316095|DRUG|simvastatin|
214879644|NCT05823324|BEHAVIORAL|Therapeutic play group|The dramatization method with teddy bear, one of the TP methods, was applied during the PIVC intervention
214879645|NCT02495259|DEVICE|ZU-bend stylet|Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
214879646|NCT02495259|DEVICE|GlideScope|Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
214879647|NCT02495259|DEVICE|GlideRite stylet|Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
214879648|NCT02495259|DEVICE|Macintosh blade|Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
214879649|NCT02495259|DEVICE|Regular Double-lumen endobronchial tube (DLT) Stylet|Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
214879650|NCT01713452|PROCEDURE|Purse string closure|"1. An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~2. Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~3. Diameter of the skin defect should then be measured.~4. A postoperative photo will then be taken."
214879651|NCT01713452|PROCEDURE|Primary closure|"1. An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~2. Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (\<1.5cm). No subcutaneous drains will be placed.~3. Length of the incision should be measured in centimeters.~4. A postoperative photo will then be taken."
214879652|NCT06548178|DRUG|T-DXd|T-DXd (5.4 mg/kg Q3W on Day 1) ×6 cycles.
214879653|NCT06548178|DRUG|THP|Docetaxel (75 mg/m2 Q3W on Day 1) concurrent with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg Q3W on Day 1) and pertuzumab (840 mg loading dose followed by 420 mg Q3W on Day 1) × 6 cycles.
214879654|NCT02931929|DRUG|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
214879655|NCT03106987|DRUG|Active Comparator: Olaparib tablets|"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
214879656|NCT03106987|DRUG|Placebo|"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
214879657|NCT04368351|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
215044657|NCT05674227|PROCEDURE|Open surgery|Surgical treatment of operable lung cancers using open surgery
215044658|NCT01673776|DEVICE|PulsioFlex® Monitoring|"* goal directed therapy according to PulsioFlex® Monitoring- measurements~* femoral catheter~* extended perioperative monitoring~* nutritional supplementation, (if necessary)"
215044659|NCT05021939|OTHER|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
215044660|NCT05021939|OTHER|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
215044661|NCT01693367|DEVICE|DLS 5.0 (Dynamic locking screws)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
214879658|NCT04368351|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
214879659|NCT04368351|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
214879660|NCT06633094|OTHER|Educational videos|Internet will be used to deliver educational videos to subjects enrolled in the home management arm of the study which will be available on the Carilion Clinic Orthopaedic Education YouTube Channel. This will consist of a prerecorded video made by the three pediatric orthopaedic surgeons on this study explaining the nature of buckle fractures and treatment. Participants will be sent a link to the video over email (an example of a similar video in clinical use at Carilion Orthopaedics and the script of the video can be found in the study document attached).
214879661|NCT02114385|BIOLOGICAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
214879662|NCT02114385|BIOLOGICAL|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
214879663|NCT02268578|DEVICE|Transcranial Direct Current Stimulation|2mA tDCS
214879664|NCT02268578|PROCEDURE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
215044662|NCT01693367|DEVICE|SLS (Standard locking screw)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
214879665|NCT03566615|DEVICE|CAP-straight|This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
214879666|NCT03566615|DEVICE|CAP-daisy|This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
214879667|NCT03566615|OTHER|water|using water instead of traditional air insufflation to help insertion
214879668|NCT01325844|PROCEDURE|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
214879669|NCT00482781|BIOLOGICAL|Infanrix|
214879670|NCT00482781|BIOLOGICAL|Pediatrix|
215044663|NCT01229683|PROCEDURE|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
215044664|NCT02136914|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
214879671|NCT00789243|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
214879672|NCT02295917|DEVICE|Transvaginal sonography|Transvaginal sonography
214879673|NCT01275729|DRUG|Furosemide|dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
214879674|NCT00131495|DRUG|Testosterone (transdermal patches)|Testosterone patch (300mcg/day, changed twice a week for one year
214879675|NCT00131495|DRUG|Placebo patch|placebo patch changed twice a week for one year
215044665|NCT02136914|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
215044666|NCT04136145|DRUG|Belimumab for IV|Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.
215044667|NCT04136145|DRUG|Belimumab for SC|Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
214879676|NCT04860609|OTHER|Conventional Physiotherapy|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Bed Rest with lumbar Sacral Support~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
214879677|NCT04860609|OTHER|Lumber Spinal Decompression|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Decompression therapy session lumbar spinal decompression therapy for 30 minutes.~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
214879678|NCT05114278|DRUG|Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
214879679|NCT05114278|DRUG|oral iron|All patients will receive an oral iron supplementation (100mg/day).
214879680|NCT04813783|OTHER|Mucositis care training to be given in line with MASCC / ISOO 2019|Mucositis care training to be given in line with MASCC / ISOO 2019
214879681|NCT00040131|DRUG|IL-10|
214879682|NCT02524457|OTHER|This is an observational study. There are no interventions|
214879683|NCT00302445|DRUG|Efalizumab|
214879684|NCT00302445|DEVICE|Narrow Band Phototherapy|
214879685|NCT01915745|OTHER|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
214879686|NCT00593905|DRUG|Sitaxsentan|Sitaxsentan sodium 100 mg tablet every morning
214879687|NCT00593905|DRUG|Bosentan, Ambrisentan|Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
214879688|NCT06501677|BEHAVIORAL|WBI|"The WBI will comprise of four sessions focusing on CRAFT principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to the DP (PPR; i.e., actively listening, showing understanding, expressing interest in what their DP is thinking and feeling, and trying to see where the DPs is coming from), (3) understanding the DP's drinking reinforcers, and (4) supporting the DP if they want help and engaging in positive, healthy activities with the DP. ' partner.~Each module will take \~20-30 minutes and each session will: (1) instill optimism in CPs, (2) be solution-focused, (3) emphasize that the CP is not responsible for the DP's behaviors, and (4) use a nonjudgmental, non-confrontational, empathetic style. The WBI intervention is focused on reduced drinking in the DP and improved CP wellness."
214879689|NCT03527953|OTHER|Tetric EvoCeram Bulkfill|The preparation will be etched with 37% phosphoric acid. It will be then rinsed with an air-water spray and dried, leaving the dentin slightly moist. An etch-and-rinse adhesive, ExciTE F, will be applied and agitated on the prepared surfaces for at least 10 seconds. The adhesive will be air-thinned and light-cured for 20 seconds with an LED curing unit. The sectional matrix will be placed and fixed with wooden wedges. Then the bulk-fill resin composite, TBF, will be placed in bulk in about 4-mm thickness and then will be cured for 20 seconds.
214879690|NCT03527953|OTHER|Surefil SDR Flowable bulkfill|The preparation will be etched. A two-step etch-and-rinse adhesive, Prime\&Bond NT will be applied to all enamel/dentin surfaces, air-dried for 5 seconds, and will be light cured for 10 seconds. After the sectional matrix will be placed, the flowable bulk-fill resin composite, SureFil SDR™ flow (Dentsply Caulk, Milford, DE, USA), will be placed in a 4-mm bulk increment in the dentinal part cured for 20 seconds and will be followed by a covering layer of the nanohybrid resin composite, Ceram.X Mono that will be cured for 20 seconds.
214879691|NCT03527953|OTHER|everX fiber-reinforced resin|The enamel will be etched with 37% phosphoric acid for 10 seconds, then will be rinsed, and dried with an air/water syringe for at least 5 seconds. Self-etch adhesive, G-aenial Bond (GC Co., Tokyo, Japan), will be applied to all enamel/dentin surfaces and gently air thinned and then will be light cured for 10 seconds. After the matrix will be placed and wedged, mesial or distal walls will be built with 1-2-mm layers of G-aenial Posterior resin composite. The fiber-reinforced composite, everX Posterior, will be placed into the cavity in approximately 4-mm thickness. The last 2 mm of the cavity will be restored using the G-aenial Posterior composite as an overlay layer. Each increment will be light cured for 20 seconds using an LED unit.
214879692|NCT05547841|DEVICE|Echocardiography acquisition|Echocardiography examination of all participants using PHILIPS. Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), 6 weeks and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
214879693|NCT03486665|OTHER|Blood Sampling|Blood samples will be taken from all patients and healthy volunteers.
214879694|NCT03486665|OTHER|CSF Sampling|CSF sample will be taken from hospitalized newly diagnosed patients only.
214879695|NCT02441660|DRUG|Capsaicin 8% Patch|Applied topically for 1 hour
214879696|NCT02441660|DRUG|Low Dose Capsaicin 0.025% Well Patch|
214879697|NCT03438292|DIETARY_SUPPLEMENT|Berberine|Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
214879698|NCT03438292|DIETARY_SUPPLEMENT|TPGS emulsified berberine|Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
214879699|NCT03438292|DIETARY_SUPPLEMENT|Quillaja extract emulsified berberine|Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
214879700|NCT05518188|BIOLOGICAL|MELPIDA|MELPIDA, a recombinant serotype 9 adeno-associated virus (AAV) encoding a codon-optimized human AP4M1 transgene
214879701|NCT06251089|DRUG|CPC mouthwash|0.07% CPC mouthwash
214879702|NCT06251089|DRUG|Placebo|placebo of the CPC mouthwash
214879703|NCT03242525|DIAGNOSTIC_TEST|POCT and central laboratory blood analysis|In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
214879704|NCT02871323|BIOLOGICAL|Durvalumab|Given IV
214879705|NCT02871323|OTHER|Laboratory Biomarker Analysis|Correlative studies
214879706|NCT02681510|DRUG|Varenicline|Standard FDA approved 12 weeks of treatment with Varenicline
214879707|NCT02681510|DRUG|Nicotine Transdermal Patch|Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
214879708|NCT02681510|DRUG|Nicotine Mini|Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
214879709|NCT01516918|DRUG|VX-222|tablet, 400-mg twice daily
214879710|NCT01516918|DRUG|telaprevir|tablet, 1125-mg twice daily
215044668|NCT02915627|DEVICE|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
215044669|NCT00004466|DRUG|Atorvastatin|
215044670|NCT00004466|DRUG|Placebo|
215044671|NCT03249324|BEHAVIORAL|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
214476990|NCT06307574|BEHAVIORAL|bpMedManage|In this 16-week RCT, a total of 100 older adults with MCI will be recruited. There are two treatment arms, bpMedManage-S and bpMedManage-P with 50 participants in each arm. Participants randomized into the bpMEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on the education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.
214879711|NCT01516918|DRUG|ribavirin|tablet, 1000-mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
214879712|NCT01516918|BIOLOGICAL|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
214879713|NCT04637802|BEHAVIORAL|CBT (SurgeryPal)|The SurgeryPal intervention is a cognitive-behavioral program for youth undergoing major surgery. SurgeryPal is delivered in two 4-week phases: the pre-operative phase, and the post-operative phase. Each phase consists of 3 separate treatment modules for youth and parents, which teach cognitive and behavioral coping skills to target known psychosocial and behavioral risk factors (i.e. anxiety/distress and sleep disturbance) for poorer postsurgical outcomes, and provide training in pain self-management skills. Pre-operative modules include: 1) Preparing for surgery, 2) Coping with stress before surgery, and 3) Getting ready for the hospital. Postoperative modules include: 1) Coping at home after surgery, 2) Return to activities and school, and 3) Long-term recovery. Modules are self-guided and interactive, and focus on phases of preparation and recovery from surgery. The goal of the program is to reduce pain and enhance quality of life following surgery in youth.
214879714|NCT04637802|BEHAVIORAL|Education|The patient education website will serve as the active comparator. The purpose is to control for time, attention, and online usage. Youth and parents will be provided access to an education website containing information about pediatric surgery at the same time interval as the active intervention; however, there will be no exposure to cognitive and behavioral coping skills. Similar to the CBT condition, the presurgery period of Education will be administered for one month prior to surgery and the postsurgery period will be administered for one month after the post-discharge assessment.
214879715|NCT03872687|DEVICE|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size that will fit the interdental spaces around the implant.
214879716|NCT03872687|DEVICE|interdental brushes|Subjects in this group will only receive interdental brushes
214879717|NCT03893019|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
214879718|NCT03149796|OTHER|laboratory blood tests|Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
214879719|NCT04315506|BEHAVIORAL|#EnufSnuff.TXT Intervention|The SGR program will reduce smokeless tobacco until you reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
214879720|NCT04315506|BEHAVIORAL|Enough Snuff Intervention|Participants will be sent the Enough Snuff cessation manual. One weeks after it is sent, participants will then receive text messages from the study team twice a week for ten weeks.
214666886|NCT05379504|BEHAVIORAL|Self Management|"The self-management intervention will be delivered over the course of a year. There will be a minimum of four intervention sessions with each healthcare profession (OT, RN and SW) for 12 visits per participant. The team (OT, RN and SW) will meet twice during the first 2 months to determine a lead interventionist based on the participant's SMART goals and areas of concern. The lead interventionist will have three additional sessions with the participant and will be the point-person for sensor system alerts and messages. Goal Attainment Scaling \[83\] will be administered during the quarterly interview to assess participant progress on SMART goals. This measure is administered collectively with the participant, provides further accountability, offers opportunities to the participant for reflection on progress, and is a concrete measure of success of the self-management intervention."
214666887|NCT03031210|DRUG|Amoxicillin|(90 mg/kg/day) twice daily
214666888|NCT01464697|DRUG|Oral micronized progesterone|300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
214666889|NCT01464697|DRUG|placebo|placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
214666890|NCT04896853|BIOLOGICAL|ProTrans®|Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells
214666891|NCT03184935|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
214666892|NCT03184935|DRUG|Decitabine|Decitabine，20mg/m\^2/d
214666893|NCT05751369|BEHAVIORAL|Education plus Support|Brief behavioral support for using TECW Tracker
214666894|NCT00167479|DRUG|risperidone (Risperdal)|
214666895|NCT00900796|OTHER|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
214666896|NCT02730559|OTHER|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
214666897|NCT01926587|DRUG|oral rigosertib|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
214666898|NCT01926587|DRUG|Azacitidine|Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
214666899|NCT02939521|PROCEDURE|Surgery|
214666900|NCT04932889|OTHER|Survey|A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
214666901|NCT04932889|OTHER|Laboratory parameters|The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
214879721|NCT01491191|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
214476991|NCT06656754|OTHER|Isometric Reaching|"The intervention of Isometric Reaching is the process of restricting the participant's hand movement in place, while using the forces they apply to the robot handle to drive a reaching arm simulation"
214476992|NCT06651463|OTHER|Videorecording|Two cameras will be used to make the recordings: a classic camera placed on a stand 1 meter from your head, outside the sterile area and the color camera of the microscope used for the surgery.
214666902|NCT04932889|OTHER|chest computed tomography|Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
214666903|NCT00811226|DRUG|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
214666904|NCT01147783|OTHER|CT, MRI|
214666905|NCT04373083|DRUG|Cemiplimab|Administered in 3-week intervals
214666906|NCT04373083|RADIATION|Involved-site radiotherapy (IS-RT)|Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
214666907|NCT04988230|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
214666908|NCT04988230|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
214879722|NCT01491191|DIETARY_SUPPLEMENT|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
214879723|NCT01044108|DRUG|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
214879724|NCT01044108|DRUG|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
214879725|NCT01044108|DRUG|placebo|Placebo will be administered as a comparator at each dose level.
214879726|NCT00999817|DRUG|reference [dextromethorphan]|single 30 mg oral dose
214879727|NCT00999817|DRUG|test [PF-00299804 + dextromethorphan]|single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
214879728|NCT02203409|PROCEDURE|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
214879729|NCT00958893|DRUG|25 mg Proellex|one 25 mg capsules
214879730|NCT03594760|DIAGNOSTIC_TEST|18F-DCFPyL IV injection|Patient will receive one injection of 18F-DCFPyL and undergo PET-CT imaging
214879731|NCT03991676|BEHAVIORAL|Values-Based Behavioral Treatment|The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
214879732|NCT03005665|DRUG|Acetazolamide|
214879733|NCT03005665|DRUG|Normal Saline|
214879734|NCT06501326|DRUG|Liraglutide|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
215044672|NCT03249324|OTHER|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
215044673|NCT01148667|DIETARY_SUPPLEMENT|Casein hydrolysate added with LGG|Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
215044674|NCT01148667|DIETARY_SUPPLEMENT|Infants drink casein hydrolysate without LGG|Infants drink extensively hydrolysed casein formula without added LGG
215044675|NCT04368013|PROCEDURE|Extended sampling and procedures|The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
215044676|NCT00579423|BIOLOGICAL|QS21|"* Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~* Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~* Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
215044677|NCT02957630|DRUG|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
215044678|NCT02957630|DRUG|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
215044679|NCT02957630|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
215044680|NCT05047042|BEHAVIORAL|Advanced Cancer Support in Virtual Rehabilitation and Exercise|The study intervention will consist of an individualized 8-week program of online exercise modules, supervised interactive group class and one-to-one consultations with an exercise or rehabilitation specialist and a pain and symptom physician, delivered via secure live Zoom sessions.
215044681|NCT02099396|DRUG|Docetaxel+lobaplatin|
215044682|NCT02099396|DRUG|Gemcitabine+lobaplatin|
215044683|NCT00198471|DRUG|Vitrase|
215044684|NCT00219089|DRUG|aliskiren|
215044685|NCT00089622|DRUG|Intravenous Levodopa|
215044686|NCT00089622|DRUG|Lisuride Transdermal System|
215044687|NCT04741906|PROCEDURE|Dental implant surgery|Dental surgery in patients treated with antiresorptive medication
215044688|NCT04741906|PROCEDURE|Prosthetic treatment|Prosthetic treatment and loading of the dental implants
215044689|NCT02149459|RADIATION|Partial brain re-irradiation.|Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
215044690|NCT02149459|DRUG|Metformin|Different cohorts will receive no, low dose or higher dose metformin.
215044691|NCT02149459|BEHAVIORAL|low carbohydrate diet|Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
215044692|NCT05483959|OTHER|BIPAP mode/SIMV PC mode|BIPAP is a mode of ventilation recently used in ARDS
215044693|NCT02307630|BIOLOGICAL|124I-Humanized 3F8|
215044694|NCT05320484|OTHER|Clinical Pilates Exercises|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
215044695|NCT05320484|OTHER|Classic Posture exercise|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
215044696|NCT05993793|DEVICE|Fototherapy|The Antares brand Laser device was used for 3 sessions with an interval of 24 hours. The Visual Analogue Scale (VAS) was used before starting treatment, after the first and second sessions, and 1 week after the third session. In addition, at the end of the treatment, the closure, or not, of the lesion was verified, and the questionnaires performed prior to phototherapy were reapplied. The VAS assesses the patient's level of pain, which can be divided into mild pain (1-2), moderate pain (3-7), and severe pain (8-10). The Bristol Scale is based on the identification of the patient's consistency of stools, while types 1-2 correspond to constipation, 3-4 indicate normal intestinal rhythm, 5 indicate lack of fiber, and 6-7 correspond to diarrhea
215044697|NCT03388892|DEVICE|paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)|Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
214879735|NCT06501326|DRUG|Orlistat|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
214879736|NCT01284010|GENETIC|DNA analysis|
214879737|NCT01284010|GENETIC|fluorescence in situ hybridization|
214879738|NCT01284010|GENETIC|gene expression analysis|
214879739|NCT01284010|GENETIC|microarray analysis|
214879740|NCT01284010|GENETIC|mutation analysis|
214879741|NCT01284010|GENETIC|polymerase chain reaction|
215044698|NCT03388892|DEVICE|Plain Balloon|Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
215044699|NCT05038696|BIOLOGICAL|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.
215044700|NCT05504512|OTHER|No intervention|No intervention
215044701|NCT03950258|PROCEDURE|endovascular embolization|Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
215044702|NCT04468373|DEVICE|WA-NG (NG-IMT) Telescope Prothesis|The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
215044703|NCT02448199|DRUG|Meloxicam and Glucosamine|Experimental
215044704|NCT02448199|DRUG|Meloxicam|Active Comparator
215044705|NCT02448199|DRUG|Glucosamine|Active Comparator
215044706|NCT02831660|DRUG|idarucizumab|
215044707|NCT05016258|DEVICE|KONTACT MB|Dental implant surgery
215044708|NCT05871619|PROCEDURE|Remin Pro|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
214476993|NCT05043064|PROCEDURE|Wet lab tasks|Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model
214879742|NCT01284010|OTHER|laboratory biomarker analysis|
214879743|NCT00741338|BIOLOGICAL|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
214879744|NCT00741338|DRUG|Cyclosporine A (CsA)|Orally three times daily.
214879745|NCT00741338|DRUG|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
214879746|NCT03593395|OTHER|Peer Mentoring [PM]|Virtual Peer Mentoring
215044709|NCT05871619|PROCEDURE|X Pur Remin|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
215044710|NCT05871619|PROCEDURE|Fluoride varnish|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
215044711|NCT06146647|BEHAVIORAL|Positive body image TV show|This is a 15 minute (approximately) show that has positive body image content embedded in the storyline. It also showcases a diverse range of body sizes in the casting.
215044712|NCT06146647|BEHAVIORAL|Positive body image music video|This is a positive body image song with strong visual representation of diverse body sizes in the music video.
215044713|NCT06146647|BEHAVIORAL|Active control TV show about a visit to the dentist|14 minute tv show following a tv character as he visits the dentist.
214476994|NCT05735964|DRUG|Indocyanine green|Intravenous and endoluminal dosing
214879747|NCT03593395|OTHER|Structured Education Based Transition Program STE|Education-based program
214879748|NCT04979936|PROCEDURE|laparoscopic cholecystectomy|
214879749|NCT04979936|PROCEDURE|percutaneous cholecystostomy|
214879750|NCT01764399|BEHAVIORAL|Care4U|
214879751|NCT03802071|DRUG|Durvalumab+doxorubicin cobination|Durvalumab 1500mg IV Doxorubicin 75mg/m2 IV D1 Q3weeks (up to 8cycles)
214879752|NCT00141089|DRUG|Tegaserod|
214879753|NCT06304246|OTHER|Measurement Pain Threshold|Measurement Pain Threshold: Manual dolorimetry will be used to assess the pain threshold in the non-dominant hand of patients in the preoperative waiting room prior to spinal anesthesia. The dolorimeter head will be placed vertically on the wrist of the non-dominant hand, and pressure will be applied with increments of 1 kg/cm2/s. The pressure applied when the patient perceives pain will be recorded in kg/cm2. The measurement will be repeated three times for each patient, and the average will be recorded as the pain threshold value.
214666909|NCT03884634|DEVICE|Dabir Micropressure Overlay|"The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off."
214666910|NCT04979884|DRUG|cyclosporine|Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
214666911|NCT03088579|DEVICE|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
214666912|NCT01403129|PROCEDURE|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
214666913|NCT01403129|PROCEDURE|Optical Coherence Tomography (OCT) Exam|OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
214666914|NCT01879020|DRUG|TA-8995|Drug: TA-8995 1mg
214666915|NCT01879020|DRUG|TA-8995|Drug: TA-8995 2.5mg
214666916|NCT01879020|DRUG|TA-8995|Drug: TA-8995 5mg
214666917|NCT01879020|DRUG|TA-8995|Drug: TA-8995 10mg
214666918|NCT01879020|DRUG|TA-8995|Drug: TA-8995 25mg
214666919|NCT01879020|DRUG|Placebo|Placebo (TA-8995 1mg)
214666920|NCT01879020|DRUG|Placebo|Placebo (TA-8995 2.5mg)
214666921|NCT01879020|DRUG|Placebo|Placebo (TA-8995 5mg)
214879754|NCT06304246|OTHER|Measurement of Serum Asprosin|Measurement of Serum Asprosin: For serum asprosin measurements, blood will be drawn in the preoperative waiting room before the application of spinal anesthesia. The blood samples will be centrifuged, and the serum will be stored at -20°C to measure serum asprosin levels. After all patient blood is collected, serum asprosin will be evaluated with a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
214879755|NCT04832022|OTHER|Biological samples|Serum and plasma samples. At baseline, 3, 6 and 12 months
214879756|NCT05810103|DRUG|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
214879757|NCT00309686|DRUG|Paliperidone ER|
214879758|NCT00067743|DRUG|Lenalidomide|supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
214879759|NCT06168487|DRUG|Telmisartan|Patients will be given telmisartan alone or with standard of care chemotherapy.
214879760|NCT06168487|OTHER|Standard of Care Regimen|Standard of Care Regimen
214879761|NCT03423719|DIETARY_SUPPLEMENT|Fiit-ns®|Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.
214879762|NCT03423719|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.
215044714|NCT06146647|BEHAVIORAL|Active control music video about brushing teeth|Music video of a tv character singing about brushing teeth
214476995|NCT05489120|OTHER|Consumption of FLAVIS|Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.
214476996|NCT06476704|DRUG|Administration of L-TC|Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session
214476997|NCT06476704|RADIATION|HFRT alone|"HFRT : 30 Gy in 5 fractions of 6 Gy.~1 fraction per day, 5 days per week."
214476998|NCT05685225|DRUG|Stage 1: Naltrexone/Acetaminophen|Combination
214666922|NCT01879020|DRUG|Placebo|Placebo (TA-8995 10mg)
214666923|NCT01879020|DRUG|Placebo|Placebo (TA-8995 25mg)
214666924|NCT01121406|DRUG|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
214666925|NCT01121406|DRUG|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
214666926|NCT01121406|DRUG|Topotecan|Patients receive topotecan in 3 or 4 week schedule
214666927|NCT01121406|DRUG|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
214666928|NCT01121406|DRUG|BI 6727|Patients receive BI 6727 infusion every 3 weeks
214666929|NCT05146908|BIOLOGICAL|2 Blood samples from arterial and/or central venous catheters|5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
214666930|NCT05146908|OTHER|Echography|"In 3 steps:~* before initiation of enteral nutrition~* 4h after initiation of enteral nutrition~* After 24 hours of enteral nutrition"
214666931|NCT05146908|OTHER|Data collection|"At inclusion:~Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.~Within the first 24 hours, collection of:~* echographic parameters at H0, H4 and H24~* venous congestion parameters~* biological parameters within 24 hours Constitution of a biobank (at H0 and H24)~Within the first 7 days, collection of:~* the occurrence or not of the primary endpoint (and time to occurrence).~* symptoms of gastrointestinal dysfunction~Within 30 days, collection of:~* organ failure and replacement over the period, and mortality.~* the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study."
214666932|NCT05187169|DRUG|VS-6766|Dual RAF/MEK inhibitor
214666933|NCT03185130|DRUG|Normal Saline 5mL|Control arm subjects will receive Normal Saline 5 mL IV over 1 hour
214666934|NCT03185130|DRUG|Normal Saline 20mL/kg|Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
214879763|NCT03632018|BEHAVIORAL|HEART-PLAY|Participants assigned to the HEART-PLAY intervention will receive standard CR. Additionally, they will receive pedometers, group education, and educational materials introduced by peer Health Coaches for 12 months. Before or after their regularly scheduled CR appointments, they will meet at the clinic as a group twice per week to receive Health Tips and participate in discussions. At 8 weeks in to the 12-week CR, they will begin to discuss with their peer Health Coaches the transition from the formal CR setting into community-based exercise. As part of this transition, peer Health Coaches will slowly introduce group community walks and train participants in the proper use of resistance bands. Health Coaches will have talk with their assigned participants about relapse prevention and sustaining exercise following the termination of formal CR.
214879764|NCT03632018|BEHAVIORAL|Standard Cardiac Rehabilitation|During the 12-week intervention period, the STANDARD intervention participants will receive standard of care by attending the 36 sessions of standard CR as prescribed by his/her physician and administered by the Step Clinic.
214879765|NCT02995408|BEHAVIORAL|Relaxation Response Resiliency Program for Parents of Children with ASD|
214879766|NCT01630070|DEVICE|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
214879767|NCT03511599|DRUG|Cycloserine|Cycloserine 100mg
214879768|NCT03511599|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
214879769|NCT03511599|DRUG|Placebo Oral Tablet|Placebo tablet matched to cycloserine tab
214879770|NCT05063851|DRUG|Memantine Hydrochloride Tablets|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
214879771|NCT05063851|DRUG|Placebo|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
214879772|NCT01098474|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
214879773|NCT01098474|BIOLOGICAL|Tritanrix™ HB+Hib|Intramuscular, 3 doses
214879774|NCT01098474|BIOLOGICAL|Prevnar™|Intramuscular, 3 doses
214879775|NCT01098474|BIOLOGICAL|Polio Sabin™|Oral, 3 doses
214879776|NCT01098474|BIOLOGICAL|Menjugate™|Intramuscular, 3 doses
214879777|NCT04128189|BIOLOGICAL|Shingrix|Both arms receive standard 2 doses of Shingrix. Transplanted subjects may receive 3rd dose.
214879778|NCT05560386|BEHAVIORAL|Text messaging|text messaging content to support diabetes prevention.
214879779|NCT05560386|BEHAVIORAL|Virtual workshop|virtual workshop content to support diabetes prevention.
214879780|NCT00425763|DRUG|AQAS|AQAS dosed by body weight, on days 0, 1, 2
214879781|NCT05932043|DIAGNOSTIC_TEST|This is a non-interventional study|None (this is a non-interventional study)
214879782|NCT04736745|BIOLOGICAL|IPN59011|Powder and solvent for solution for injection
214879783|NCT04736745|BIOLOGICAL|Azzalure|Powder for solution for injection
214879784|NCT04736745|DRUG|Placebo|Powder for solution for injection
214879785|NCT00002528|DRUG|tamoxifen citrate|20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
214879786|NCT00002528|PROCEDURE|conventional surgery|Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
214879787|NCT00002528|RADIATION|radiation therapy|No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.
214879788|NCT00002528|PROCEDURE|Axillary clearance|Axillary node dissection.
214879789|NCT02451761|BIOLOGICAL|Blood sampling|
214879790|NCT01598194|DEVICE|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
215044715|NCT05792748|PROCEDURE|Pulp hemostasis with a dry cotton pellet|Application of a dry cotton pellet, then the chamber was filled with ZOE directly over the pulp
214476999|NCT05685225|DRUG|Stage 1: Naltrexone|Naltrexone alone
214477000|NCT05685225|DRUG|Stage 1: Acetaminophen|Acetaminophen alone
214477001|NCT05685225|DRUG|Stage1: Placebo|Matching placebo
214879791|NCT02910804|DRUG|68Ga-BBN-IRDye800CW|
214879792|NCT02910804|DEVICE|PET/NIRF|
215044716|NCT05792748|PROCEDURE|Pulp hemostasis with a wet cotton pellet impregnated with FS|Application of a a wet cotton pellet impregnated with FS, then the chamber was filled with ZOE directly over the pulp
215044717|NCT05792748|PROCEDURE|Stainless steel crown|Stainless steel crown placed as a final restoration
214477002|NCT05685225|DRUG|Stage 2: Naltrxone/Acetaminophen high dose|Combination high dose
214477003|NCT05685225|DRUG|Stage 2: Naltrexone/Acetaminophen medium dose|Combination medium dose
214477004|NCT05685225|DRUG|Stage 2: Naltrxone/Acetaminophen low dose|Combination low dose
214879793|NCT02910804|PROCEDURE|PET/NIR fluorescent imaging-guided surgery|
215044718|NCT03330444|PROCEDURE|Endometrial biopsy and endometrial fluid collection|On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
214879794|NCT03266601|DRUG|Recombinant Human Interferon α-2b Spray|Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).
214879795|NCT03266601|DRUG|Ribavirin|Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).
214879796|NCT05972369|OTHER|12-Week Tailored Exercise Intervention|12-week individually tailored exercise therapy program based on patient presentation. Supervised physiotherapy plus home exercise
214879797|NCT01804972|OTHER|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
214879798|NCT01804972|OTHER|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
214879799|NCT03260725|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered in the clinic.
214879800|NCT03260725|BEHAVIORAL|Internet-delivered PCIT (I-PCIT)|I-PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered to families in their own home in real-time via videoconferencing over the Internet by a remote therapist.
214879801|NCT01078870|DRUG|Lexapro|10mg/cap 1\~2# QD
214879802|NCT01078870|DRUG|Cymbalta|30mg/cap 30\~60mg/QD
214879803|NCT01078870|DRUG|Placebo|1\~2#/cap QD
214879804|NCT01654315|DEVICE|Myomo Robotic Arm|"Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion."
214879805|NCT01654315|BEHAVIORAL|RTP Standard Therapy|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
214879806|NCT04552860|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
214879807|NCT05491486|BEHAVIORAL|Mindfulness-based Group Therapy|see above
214879808|NCT03657186|DIETARY_SUPPLEMENT|ProbioSatys™|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
214879809|NCT03657186|OTHER|Placebo|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
214879810|NCT00699426|DRUG|nexium|40 mg once daily is tested together with Yoghurt
214879811|NCT00699426|DRUG|nexium|nexium and placebo are tested
214879812|NCT00699426|DIETARY_SUPPLEMENT|Yoghurt|Yoghurt
214879813|NCT00699426|DRUG|placebo+placebo|placebo and placebo are tested.
214879814|NCT05273346|BEHAVIORAL|Traditional Chinese medicinal ointment|The Group1 will be treated using the Comprehensive Conservative TCM Treatment Group protocol.The special TCM ointment will be applied to the waist, and then Tuina, in order to play the comprehensive therapeutic role of Tuina and medicine, promoting blood circulation and removing stasis, warming and dispersing cold, strengthening tendons and strengthening bones, regulating qi and blood. The method of ointment is generally used with rubbing method, rubbing method, flat pushing method and kneading method. Treatment time: 7 minutes.
214879815|NCT05273346|BEHAVIORAL|Acupotomy|It is in the special acupoints or Ashixue for cutting, stripping and other different stimulation, in order to reduce the tension of soft tissue outside the spinal canal, reduce the trend of dynamic and static spinal canal stenosis, to achieve the purpose of relieving pain and removing disease, opening points and collaterals. Acupotomy can separate the adhesive tissue, which can improve the blood circulation of the local tissue and promote the absorption of inflammation. Most acupotomy points are tenderness points or induration points, such as yaojiaji and Shenshu. Treatment time: 3 minutes.
214879816|NCT05273346|BEHAVIORAL|Cupping therapy with bamboo cup|Put the bamboo cup with the thickness of the thumb into the cup and boil it, then find the meridian and select the acupoint, Pierce the skin with a needle at the appropriate acupoint, and remove the heated bamboo cup from the cup while it is hot. When the temperature of the steam in the bamboo cup is reduced, steam will condense into water quickly, which produces strong negative pressure. Through the medicinal force, heat and the suction of the bamboo cup, the blood stasis in the affected area is smoothly discharged, so that qi and blood can be unblocked and pain can be eliminated. Treatment time: 20 minutes.
214879817|NCT05273346|OTHER|Oral Chinese medicine granules|Oral Chinese medicine granules use to nourish liver and kidney, improve qi and blood. Patients voluntarily take it when they think it is necessary.
215044719|NCT04217109|DIAGNOSTIC_TEST|Odour sampling|"Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.~Positive marking is characterized by a sitting position of the dog in front of the sample."
215044720|NCT01247064|DRUG|Nebulized 3% saline|4 mL of nebulized 3% saline once
215044721|NCT01247064|DRUG|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
215044722|NCT04470297|DRUG|Ramelteon 8mg|Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
214477005|NCT05685225|DRUG|Stage 2: Placebo|Matching Placebo
214477006|NCT06819709|OTHER|Botanical Moisturizer + Oral Supplement + Unscented Soap|"The intervention includes 3 products:~1. A botanical moisturizer~2. An oral supplement containing l-histidine (an amino acid) and antioxidants~3. An unscented bar of soap"
214477007|NCT06820437|OTHER|Low-fidelity (Visually Enhanced Mental Simulation-VEMS) simulation training|Intervention group 1: Low-fidelity (Visually Enhanced Mental Simulation-VEMS) simulation training will be conducted on active external bleeding control management skills of caregivers of elderly individuals. In this intervention poster and cards will be used.
214879818|NCT05273346|BEHAVIORAL|Epidural Steroid Injections (ESIs)|The Group2 will be treated using the Modern Medicine Conservative Treatment Program Group protocol.All Epidural Steroid Injections(ESIs) will be performed by a physician in an outpatient surgical setting(a sterile operating room),the patient will be in prone position,while monitored the vital signs. After aseptic treatment, 1mg non-granular betamethasone plus 5mL 0.9% sodium chloride solution will be injected. Patients will repeat ESIs up to four times within three months after randomization, depending on the response to the previous ESIs, when the degree of pain increases or the degree of relief is less than 50%.
214879819|NCT05273346|BEHAVIORAL|Interferential current therapy|The 30-50cm padded electrode will be properly fixed on the left and right sides of the lumbar spinal stenosis, and the two groups of current will be crossed at the lesion. Constant frequency output 90Hz, frequency conversion output 90-100Hz, the current intensity is generally suitable for patient tolerance, each treatment for 10min, a total of 20 minutes. Twice a week for 3 months.
214879820|NCT05273346|BEHAVIORAL|Thermal therapy|After the interferential current therapy, the patient will receive Bohm light for 5 minutes at the site of lumbar spinal stenosis and massage for 5 minutes at low back. Twice a week for 3 months.
214879821|NCT05273346|OTHER|Oral painkillers|NSAID drugs, if necessary.
214879822|NCT05434169|BIOLOGICAL|Arterial Blood Gas|The procedure of arterial blood collection will be conducted in a seated position for all three groups. The patient is in a supine position, with the forearm comfortably placed on a small table. The needle used for blood collection is a 25 gauge needle without local anesthetic. This method of sampling is identical to the one used in daily practice in the Emergency department of Fribourg
214879823|NCT05547217|DEVICE|Hand Therapy using the MyHand System|The MyHandTM System is a smart-mechatronic device programmed with proprietary hand function training regiments (protocols) based on deep research in neuroplasticity. It provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy. Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
215044723|NCT03767543|DRUG|INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
215044724|NCT02507154|DRUG|Cetuximab + NK cells|
214477008|NCT06820437|OTHER|High-fidelity (simulated patient/standard patient) simulation training|Intervention group 2: High-fidelity (simulated patient/standard patient) simulation training will be conducted for caregivers of elderly individuals in active external bleeding control management skills. Standardized patient who will act as elderly will be used in this intervention.
214666935|NCT03185130|DRUG|Prochlorperazine 0.15 mg/kg up to 10 mg IV|Standard Treatment Arm and Study Arm will receive prochlorperazine 0.15 mg/kg up to 10mg IV slow push
214666936|NCT03185130|DRUG|Diphenhydramine 1 mg/kg up to 50 mg IV|Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
214666937|NCT05057728|BEHAVIORAL|Social-Emotional Prevention Program enhanced version|The intervention is provided for all children for whom parental consent is obtained. The intervention includes a classroom curriculum, teacher training and parent training.
214666938|NCT01925703|DRUG|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
214666939|NCT02000843|PROCEDURE|tympanoplasty -- conchal cavum approach|Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
214666940|NCT03064282|OTHER|Placebo|observation of skin changes if any
214666941|NCT03064282|DRUG|papaverine|observation of symptoms
214666942|NCT00058370|DRUG|cisplatin|
214666943|NCT00058370|DRUG|lomustine|
214666944|NCT00058370|DRUG|vincristine sulfate|
214666945|NCT00058370|PROCEDURE|adjuvant therapy|
214666946|NCT00058370|RADIATION|iodine I 131 monoclonal antibody 3F8|
214666947|NCT00058370|RADIATION|radiation therapy|
214666948|NCT03215277|DRUG|Bimekizumab|One bimekizumab dose will be administered.
214666949|NCT03215277|DRUG|Certolizumab pegol|Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
214666950|NCT03215277|OTHER|Placebo|Placebo will be provided to maintain the blinding.
214666951|NCT05232955|DEVICE|PET/MR scanner|Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
214666952|NCT03794986|BEHAVIORAL|Trauma-informed SGM affirmative care|"All SGM male survivors who meet inclusion criteria, including significant emotional distress, will complete pre-test measures and be randomized to 6-week Motivational Interviewing (MI) delivered by peers in online groups or 6-week MI with trauma-informed, SGM affirmative care delivered by peers in online groups.~Participants will complete pre-intervention (baseline), end of the 6-week intervention, 60- and 120-days follow-up assessments via an online survey platform, to determine if there was an increase in formal treatment engagement, and any significant changes in mental health symptomology (i.e., PTSD, depression, high-risk drinking, and illicit substance use)."
214666953|NCT03794986|BEHAVIORAL|Motivational Interviewing|"Major principles and tenets of Motivational Interviewing (MI) group include: Non-confrontational nature of group; environment is one of respect, safety, and encouragement of all group members; purpose is to learn about members' personal thoughts and choices and not to push an agenda"
214666954|NCT04518371|OTHER|Reinforced composite for the fabrication of permanent, indirect restorations using a CAD/CAM grinding process.|Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments
214666955|NCT06067477|DIETARY_SUPPLEMENT|Vitamin D Supplement|Vitamin D Supplement
214666956|NCT01882725|DEVICE|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
214666957|NCT04562337|DRUG|SHR1316|Anti-PD-L1 antibody
214666958|NCT04562337|DRUG|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
214666959|NCT04562337|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
214666960|NCT04562337|RADIATION|Radiation therapy|Thoracic radiation therapy ,TRT
214666961|NCT04562337|DRUG|Cisplatin|Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
214666962|NCT04236453|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
214666963|NCT04236453|DRUG|Darunavir|Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
214666964|NCT04236453|DRUG|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
214666965|NCT04236453|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally on Day 1.
214879824|NCT06581458|DRUG|tDCS|The immediate intervention group will continue to receive five tDCS treatments per week for 6 months. The late intervention group will receive five sham treatments per week for 3 months and then begin receiving five weekly tDCS treatments for an additional 3 months.
214879825|NCT05084924|DEVICE|Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
214879826|NCT00078117|DRUG|Buprenorphine|
215044725|NCT03313830|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate (WPH)|Subjects will ingest WPH on one occasion.
214879827|NCT05387343|DIAGNOSTIC_TEST|Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test|Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.
214879828|NCT00704132|DRUG|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
214666966|NCT01854177|DRUG|Aprepitant|
214666967|NCT01854177|DRUG|Placebo|
214666968|NCT03155451|DIAGNOSTIC_TEST|methylation markers screening|ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
214666969|NCT02277886|DRUG|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
214666970|NCT02277886|DRUG|esomeprazole|40mg/tablet, one tablet once before breakfast
214666971|NCT05742945|PROCEDURE|Immediate lymphatic reconstruction|Breast cancer patients receive axillary lymph node dissection and immediate lymphatic reconstruction
214666972|NCT00269763|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
215044726|NCT03313830|DIETARY_SUPPLEMENT|Intact Whey Protein (WHEY)|Subject will ingest WHEY on another occasion.
215044727|NCT02918669|RADIATION|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point."
215044728|NCT06512506|OTHER|non-intervention|non-intervention
215044729|NCT00364247|DRUG|CG5503 IR;tapentadol|
215044730|NCT05029310|DRUG|Patiromer Oral Product|interaction study
214879829|NCT00704132|DRUG|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
214879830|NCT06582420|DRUG|Fibrinogen concentrate|Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
214879831|NCT06582420|DRUG|Standard trauma care|Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
214879832|NCT00226291|OTHER|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
214879833|NCT01144429|BIOLOGICAL|Allergoid, allergenic extract of 100% Birch|Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks
214879834|NCT02228850|DRUG|Alprostadil|
214879835|NCT02228850|OTHER|Placebo|
214879836|NCT00390208|DRUG|ranibizumab, dexamethasone and verteporfin|One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
214879837|NCT00390208|DRUG|Ranibizumab|One 0.5 mg intravitreal Ranibizumab injection
214879838|NCT03335514|DIAGNOSTIC_TEST|expression of GALNT4|Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
214879839|NCT01010243|DRUG|Lenalidomide, Pioglitazone, dexamethasone, treosulfan|"Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.~Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy"
214879840|NCT02289703|DRUG|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
214879841|NCT00943748|DRUG|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
214879842|NCT00943748|DRUG|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
214879843|NCT06198244|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS)|Defecation frequency per week, abdominal pain or discomfort, type of stool, severity of the constipation, frequency and consistency of stool, were measured before the commencement of treatment by using Romes-IV criteria, Visual Analogue Scale (VAS),Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS).After taking the measurements apply TENS on abdomen i.e. on the lower gastrointestinal tract, placed two skin electrodes of TENS on the abdomen lateral to the umbilicus and other two electrodes on back side at T9-L2 level for a month (20 minutes per session and 3 times a week) along with baseline treatment in which general movements were performed. After the completion of treatment same tools were used to re-assess the defecation frequency per week, abdominal pain or discomfort, type of stool, and severity of the constipation, frequency and consistency of stool for the measurement of final reading(Pre and post-treatment).
215044731|NCT04698304|PROCEDURE|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.
215044732|NCT05559099|DRUG|Tecovirimat Oral Capsule|"200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)"
215044733|NCT05559099|DRUG|Placebo|Capsules to match tecovirimat
215044734|NCT00577200|DRUG|Midazolam|Midazolam
215044735|NCT00577200|DRUG|Sufentanil|Sufentanil
215044736|NCT00577200|DRUG|Propofol|Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
215044737|NCT03177538|DRUG|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
215044738|NCT03177538|DRUG|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
214879844|NCT06198244|OTHER|Baseline Treatment|In control group, after the recruitment of participants according to the inclusion criteria. The baseline measurement were recorded by using Romes-IV criteria, Visual Analogue Scale (VAS), Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS). The baseline treatment is given in which general movements were performed i.e. Double knee-to-chest movement, sitting, standing, rolling as well as stretching of calf, hamstrings, adductors of both sides. Again assess the patient severity of constipation, frequency and consistency of stool, abdominal pain and functional status after the end of last session of the treatment(Pre and Post-treatment method).
214879845|NCT01130662|DRUG|combination therapy using decitabine and midostaurin|"Cohort 1:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.~Cohort 2:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.~Cohort 3:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle."
214879846|NCT00700362|PROCEDURE|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
214879847|NCT00700362|PROCEDURE|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
214879848|NCT06291194|DRUG|AJU-S56 5%|After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
214879849|NCT06291194|DRUG|Placebo Group(Vehicle)|After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
214879850|NCT04284072|DEVICE|Sensor Dot|Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).
214879851|NCT00182325|BEHAVIORAL|personalized web prenatal information|
214879852|NCT00182325|BEHAVIORAL|general web prenatal information|
214879853|NCT01972399|PROCEDURE|Laser|This is a surgery that the patient will undergo and the laser will be used to clean the surface of the implant.
214879854|NCT01972399|PROCEDURE|Mechanical debridement|This is a surgery that the patient will undergo to have the surface of the implant cleaned using hand instruments.
214879855|NCT05094661|PROCEDURE|BiPAP|The patient recives respiratory support with bilevel positive airway pressure system until treatment improves or fails (needs intubation/dies).
214879856|NCT05094661|PROCEDURE|CPAP|The patient recives respiratory support with continuous positive airway pressure system until treatment improves or fails (needs intubation/dies).
214879857|NCT03338530|BEHAVIORAL|Comprehensive School-Based Intervention|School staff administered the 5 components during the school year. Social Skills Groups were conducted 2-3x/wk. for a total of 60-90 min./wk.; each group contained 3-6 students with social impairments. The Individual Daily Note was administered across the school day to reinforce new skills and reduce problem symptoms. Students' performance on targets was linked to home rewards. Mind Reading computer instruction targeting emotion recognition skills was conducted 3x/wk. for a total of 60 min./wk. Therapeutic Activities were conducted 2x/wk. for a total of 40-60 min./wk.; these cooperative activities were designed to practice targeted skills. Parent Training was conducted 1x/month for 60-90 min./session in order to increase home-school communication and integrate the CSBI across settings.
215044739|NCT05518461|DEVICE|iThrive WI Intervention|Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
215044740|NCT04842851|DEVICE|cardiac resynchronization therapy|Cardiac resynchronization therapy in patients with systemic right ventricle
215044741|NCT05185843|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
215044742|NCT06174740|BEHAVIORAL|Music-cued audiovisual motor training|In addition to visual cues, music stimuli guide finger sequence movement both rhythmically (temporal component) and sonically (pitch-finger alignment).
215044743|NCT06174740|BEHAVIORAL|Visually-cued motor training|Visual cues guide finger sequence movement by indicating which finger to move in alignment with the position and of the visual cue.
215044744|NCT06121895|OTHER|Video Laryngeal Mask|Patients who are intubated using Video Laryngeal Mask for intubation purposes will be included.
215044745|NCT06121895|OTHER|Fastrack Laryngeal Mask|Patients who are intubated using Fastrack Laryngeal Mask for intubation purposes will be included.
215044749|NCT03179761|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine given intramuscularly
215044750|NCT03179761|OTHER|Laboratory Biomarker Analysis|Correlative studies
215044751|NCT03179761|BIOLOGICAL|Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine given intramuscularly
215044752|NCT05289752|PROCEDURE|dental implants in the mandible|placement of two interforaminal dental implants in the canine region in the mandible
215044753|NCT05289752|DEVICE|locator attachment and overdenture|placement of locator attachment and insertion of mandibular overdenture
215044754|NCT00584857|DRUG|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
215044755|NCT03278522|DRUG|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
215044756|NCT00448448|DEVICE|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
214477009|NCT06816849|OTHER|Recommended water intake|All participants received personalized consultation from a dietitian on adequate fluid intake and the selection of drinks based on dietary guidelines. They were required to follow the intervention for four months.
214666973|NCT04071665|PROCEDURE|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion
214666974|NCT03338946|DEVICE|CIED interrogation|CareLink Express interrogation
214879858|NCT02566681|BIOLOGICAL|MSC construct for Osteonecrosis|"30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.~The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures."
214879859|NCT03632213|DRUG|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
214477010|NCT06818253|DIETARY_SUPPLEMENT|The Effect of Glycerol Supplements|The main factor that distinguishes this intervention is first of all the dosage of the dietary supplement and the effects on the variables to be analyzed related to physical performance.
214879860|NCT03632213|DRUG|Placebo|Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
214879861|NCT01867892|DRUG|ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT|oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
214879862|NCT01867892|DRUG|ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT|Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
214879863|NCT03956940|DEVICE|Intplex test|Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
214879864|NCT02850692|OTHER|measure of endothelial function|Arterial tone index measured by EndoPAT®. Patient should neither eat nor drink at least 4 hours before exam and should neither smoke 3 hours before the exam.
214879865|NCT02850692|BIOLOGICAL|Blood sample|21 ml of blood to measure : hepatic workup, complete blood count (CBC), platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), C-reactive protein (CRP), lipid test, ionograms, creatinine, tissue plasminogen activator factor (tPA), plasminogen activator inhibitor-1 (PAI-1), tissue factor pathway inhibitor (TFPI), Willebrand factor, soluble thrombomodulin, blood levels of endoglin and syndecan. And level beta human chorionic gonadotropin (beta-HCG) for woman only.
214477011|NCT06817343|BIOLOGICAL|Aflibercept (2.0 mg)|PRN IVT Aflibercept
214666975|NCT04881877|DEVICE|Synthetic nitrite Condom|The condoms is composed of a synthetic nitrile rubber latex and 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and clear and colourless. It is manufactured by Karex Industries. It is currently experimental.
214666976|NCT04881877|DEVICE|Latex and graphene Condom|The condom is composed of a natural rubber latex with graphene. It is 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is greyish in colour. It is manufactured by Karex Industries. It is currently experimental.
214879866|NCT02850692|OTHER|Hepatic elastography|Hepatic elastography by Fibrocan®. Patient should neither eat nor drink at least 2 hours before exam. 10 successive measurements are made.
214879867|NCT02850692|DIAGNOSTIC_TEST|Injected abdominal CT|"Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit."
214879868|NCT04080466|RADIATION|Low-dose CT Scan|"Low dose computed tomography, also known as qCT, is sensitive to the mineral content within bone tissue, and can assess bone mineral density, a strong predictor of bone strength and stiffness, which can influence the health of the cartilage. Participants will undergo a low dose CT scan of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
215044757|NCT00448448|OTHER|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
215044758|NCT04366856|BEHAVIORAL|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
215044759|NCT04366856|BEHAVIORAL|2: No instruction regarding positioning|group with no instruction regarding positioning (control group)
215044760|NCT02916316|DRUG|R-CHOP with doxorubicin|Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
215044761|NCT03856866|DRUG|Hydroxychloroquine|Hydroxychloroquine: 4mg/kg/day, divided bid.
215044762|NCT03856866|DRUG|Placebo|Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
215044763|NCT04548206|OTHER|Pilates training|The program consisted of core-based Pilates exercises on the mat for 60 minutes.
215044764|NCT04548206|OTHER|control|The program consisted of progressive relaxation exercises at home.
215044765|NCT01425476|DRUG|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
215044766|NCT01425476|DRUG|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
215044767|NCT01425476|DRUG|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
215044768|NCT01384318|OTHER|Manometer|Measuring cuff pressure
215044769|NCT01808469|BIOLOGICAL|Monoclonal antibody|
215044770|NCT04549558|DIAGNOSTIC_TEST|Multimodal Ultrasound|Multimodal Ultrasound (Strain Ultrasound Elastography, Conventional Grey-Scale Ultrasound, Color-Doppler Ultrasound, and Ultrasound Guided Fine Needle Aspirate) on Axillary Lymph Nodes
215044771|NCT06154590|DRUG|Method(s)1 Attribution|"Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
215044772|NCT06154590|DRUG|Method(s)2 Attribution,|"Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
215044773|NCT02284191|RADIATION|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
215044774|NCT05678140|DEVICE|soft tissue mobilization|soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
215044775|NCT05678140|OTHER|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
215044776|NCT01188967|DRUG|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
215044777|NCT01188967|DRUG|Placebo|Placebo
215044778|NCT01859013|DRUG|Topiramate|Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.
215044779|NCT01859013|OTHER|Placebo|Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
215044780|NCT04826380|PROCEDURE|Trapeziectomy|Simple trapeziectomy (without LRTI)
215044781|NCT01659060|OTHER|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
215044782|NCT01659060|OTHER|Placebo Chocolate|Placebo intervention
215044783|NCT02308514|DEVICE|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
214666977|NCT04881877|DEVICE|Standard latex condom|The condoms is composed of a natural rubber latex. It is 180 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is natural in colour. It is manufactured by Karex Industries. It has World Health Organisation (WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union, South African Bureau of Standards and US FDA approval
214879869|NCT04080466|OTHER|Blood/Urine Collection|"Collection of blood and urine allows the researchers to look for a biomarker in the blood and urine that might help to predict the evolution of disease/hip osteoarthritis. Identifying a marker in the blood and urine that could be used for early detection of individuals with cam deformity that are at-risk of hip degeneration could greatly improve patient care.~Participants in the Cam Group will undergo the blood and urine collection twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo a blood and urine collection once as part of the study."
214879870|NCT04080466|OTHER|Patient Reported Questionnaires|"The purpose of the questionnaires is to assess how much trouble the participant is having with their hip and how it affects their quality of life.~Participants in the Cam Group will complete the questionnaires twice; once before surgery and once 2-years post-operative. Participants in the Control Group will complete the questionnaires once as part of the study."
214879871|NCT04080466|RADIATION|EOS Scan|"The EOS® uses a new imaging technique that allows precise measurement of the hip and pelvis geometry and structure. This innovative x-ray technique exposes participants to 2-10 times less radiation than a routine x-ray and can capture multiple images at once.~Participants in the Cam Group will undergo the EOS scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
214879872|NCT04080466|RADIATION|PET-MRI|"Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that allows physicians to examine bone and cartilage at the molecular level.~Participants in the Cam Group will undergo the scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
214879873|NCT04080466|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Participants in the Cam Group will undergo the Motion Analysis session twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the Motion Analysis session once as part of the study."
214879874|NCT04080466|RADIATION|3T MRI|"Participants will undergo a 3-Tesla (3T) Magnetic Resonance Imaging (MRI) of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
214879875|NCT02513225|BEHAVIORAL|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
214879876|NCT02513225|OTHER|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
214879877|NCT02220517|DEVICE|MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
214879878|NCT02220517|DEVICE|MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
214879879|NCT06579625|OTHER|Cancer education|Participants in the experimental group will receive cancer education.
214879880|NCT01850134|OTHER|Experimental Study Product|
214879881|NCT01850134|OTHER|Control Study Product|
215044784|NCT02308514|OTHER|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
215044785|NCT04269421|PROCEDURE|calcaneo-stop: arthrosis of the subtalar joint|arthrosis of the subtalar joint with a screw in the talus bone to stop pathological pronation of the heel
215044786|NCT01363102|PROCEDURE|SOMS|Apply a number to mobilization goal for patient
215044787|NCT04582214|DEVICE|MetaNeb® System|The intervention device use in this study is The MetaNeb® System (Hill-Rom; St. Paul, MN). It is an FDA 510k cleared device (k124032), powered by compressed gas, that delivers oscillation and lung expansion (OLE) therapy using both continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP). The device also provides supplemental oxygen when used with compressed oxygen and can deliver aerosol therapy during CPEP and/or CHFO. The therapy is indicated for mobilization of secretions, lung expansion therapy and the treatment and prevention of pulmonary atelectasis. The device also provides supplemental oxygen when used with compressed oxygen.
215044788|NCT00784121|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
214879882|NCT03583307|DRUG|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
214879883|NCT05465837|PROCEDURE|Tracheostomy|Early and Late Tracheostomy (\</= 10 days: Early and \>10 days: Late)
214477012|NCT04622644|DEVICE|Device: clinical investigation microwave device class IIa not marked CE for stroke detection|Patients with hyperacute stroke are referred to the emergency room with a 'stroke code'. Clinical collected data includes NIHSS and mRS. Patients will undergo to NCCT in order to exclude the haemorragic nature of vascular disease. In the same diagnostic session the patient undergo to CTA with tri-phase protocol to assess LVO. Before starting the CTA acquisition with iodinate contrast injection the StrokeWave will be placed on the head of the patients in the CT room passing toward the gantry of the CT avoiding any loose of time. The scanning with the StrokeWave will be performed in about 5 minutes and the system will be removed allowing the CTA acquisition.
214879884|NCT03417778|DRUG|Filgotinib|100 mg tablet administered orally
214879885|NCT00652340|DRUG|apricoxib/erlotinib|"apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert"
214879886|NCT00652340|DRUG|erlotinib/placebo|"erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day"
214879887|NCT04562610|DRUG|Intravenous Infusion group|The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
214879888|NCT04562610|DRUG|All oral administration group|Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
214879889|NCT04151680|DRUG|Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive intermittent treatment with a novel oral anticoagulant drug
214879890|NCT04151680|DRUG|Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive chronic treatment with a novel oral anticoagulant drug
214879891|NCT00578474|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
214879892|NCT00578474|DRUG|Ofloxacin otic solution|5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
214879893|NCT00578474|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
214879894|NCT04932421|BEHAVIORAL|Emotion Detectives: Unified protocol for transdiagnostic treatment of emotional disorders in children (UP-C)|"UP-C is a transdiagnostic and emotion-focused cognitive-behavioral group intervention for children aged 6-13 years old with emotions disorders (i.e., anxious and/or mood disorders) and their parents. UP-C unifies cognitive-behavioral, contextual (eg. mindfulness) and parental training techniques aiming to reduce the intensity and frequency of children's clinical symptomatology.~The intervention consists of 15 weekly group sessions (90 minutes per session; 5-8 children and parents per group) conducted by at least two clinical psychologists trained in the UP-C. The sessions start with the parents and children together (15 minutes); then, one psychologist conduct the session with the group of children while the other psychologist conduct the session with the group of parents, simultaneously (60 minutes); finally, the session ends with the group together (15 minutes). This is a structured and manualized intervention with a manual for the therapist and a workbook for the child and parents."
214879895|NCT04932421|OTHER|ABC of Emotions|"ABC of Emotions is a psychoeducational group intervention for children with anxiety and/or mood disorders, aged between 6 to 13 years. ABC of Emotions consists of 5 group psychoeducation sessions (about 90 minutes per session; 5-8 children per group). This is a structured and manualized intervention, with a manual for the therapist and a workbook for the child.~The contents of the sessions were developed by the researchers of this study and are based on classic psychoeducational cognitive-behavioral therapies (CBT) strategies. Since anxiety disorders are more frequent in childhood than mood disorders (e.g., Merikangas et al., 2009), this program is essentially based on psychoeducation materials focused on emotions such as anxiety and fear. However, the same materials are available in an attachment, adapted for use with children to whom the main emotion is not fear/anxiety, but sadness (as in mood disorders)."
214879896|NCT03682107|BIOLOGICAL|Andes virus DNA vaccine|A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg or 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.
214879897|NCT03682107|OTHER|Placebo|Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System
214666978|NCT01415960|DRUG|Leuprolide acetate 22.5 mg depot, GP-Pharm SA|Administered by im injection, twice during the study, three months apart
214666979|NCT02167061|DRUG|DA-1229_01|complex single administration
214666980|NCT02167061|DRUG|E+M|co-administration of 2 drugs
214879898|NCT03692832|PROCEDURE|LH|Laparoscopic hysterectomy following AAGL class IV E, vault closed vaginally
215044789|NCT02930148|OTHER|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
214666981|NCT02167061|DRUG|DA-1229_01 fast|
214666982|NCT02167061|DRUG|DA-1229_01 fed|
214879899|NCT03692832|PROCEDURE|VH|Vaginal hysterectomy following Heaney technique
214879900|NCT00491712|PROCEDURE|Glaucoma drainage implant with/without triamcinolone|
215044790|NCT04031729|DRUG|Aspirin 81 mg|Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
215044791|NCT04031729|DRUG|Placebo oral tablet|Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
215044792|NCT05358327|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
215044793|NCT01951053|DRUG|JNJ-40411813|Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
215044794|NCT01951053|DRUG|Placebo|Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
215044795|NCT01951053|DRUG|Citalopram|Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
215044796|NCT05430061|DIETARY_SUPPLEMENT|slowly digestible carbohydrate|carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
215044797|NCT05631444|BIOLOGICAL|Cell-based therapy|One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
215044798|NCT01832727|DRUG|Oprozomib|Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.
215044799|NCT01832727|DRUG|Dexamethasone|Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
215044800|NCT02216526|OTHER|Cetaphil® Restoraderm|
215044801|NCT02216526|OTHER|Excipial|
214666983|NCT01901744|PROCEDURE|Cataract Surgery|
214666984|NCT00234949|DRUG|cefdinir|
214666985|NCT00234949|DRUG|cephalexin|
214666986|NCT01382069|DRUG|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
214666987|NCT01382069|DRUG|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
214666988|NCT00003565|DRUG|docetaxel|
214666989|NCT04278742|OTHER|Patient education|Using a collaborative approach to engage patients in their own care, allowing patients to continue to have full control of their treatment. The clinician and patient co-creates the treatment plan.
214879901|NCT01004809|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
214879902|NCT00182546|PROCEDURE|Two diagnostic management strategies|
214879903|NCT00214383|BEHAVIORAL|CHESS Internet telehealth|CHESS Internet telehealth
214666990|NCT02498652|DRUG|RDEA3170 2.5 mg|"Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets)."
215044802|NCT05081362|OTHER|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity during ten minutes in rest and ten minutes in orthostatic position
215044803|NCT01738243|DRUG|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
214666991|NCT02498652|DRUG|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
214666992|NCT03069638|DRUG|Dexmedetomidine|Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
214666993|NCT03069638|DRUG|Sedatives/Hypnotics,Other|Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
214666994|NCT02302911|BEHAVIORAL|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
214666995|NCT02302911|BEHAVIORAL|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
214666996|NCT02302911|OTHER|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
214666997|NCT02988804|DEVICE|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
214666998|NCT02988804|DEVICE|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
214879904|NCT04898686|BIOLOGICAL|Probiotic chewables|chewables containing Lacticaseibacillus rhamnosus GG
214879905|NCT04898686|BIOLOGICAL|Placebo chewables|chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.
214879906|NCT00862732|BEHAVIORAL|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
214879907|NCT00862732|OTHER|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
214879908|NCT05757375|OTHER|Mulligan Manuel Therapy Consept|Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.
214879909|NCT03607487|DRUG|INCB054707|INCB054707 tablet administered orally once daily at the protocol-defined dose.
214879910|NCT03607487|DRUG|Placebo|Placebo tablet administered orally once daily.
214879911|NCT05853575|DRUG|Adagrasib|KRAS G12C inhibitor
214879912|NCT01816659|DRUG|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
214879913|NCT00004378|PROCEDURE|Stem Cell Transplantation|
214879914|NCT04900519|BIOLOGICAL|STI-6643|Anti-CD47 human monoclonal antibody
214879915|NCT01890434|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
214879916|NCT05011318|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
214879917|NCT05011318|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
214879918|NCT02382861|DEVICE|Neurally adjusted ventilatory assist|In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
214879919|NCT02382861|DEVICE|Noninvasive pressure support ventilation|In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
214879920|NCT03852537|DRUG|Methylprednisolone|Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.
214879921|NCT03852537|OTHER|Usual Care|Usual care as determined by the patients treatment team.
214879922|NCT03203681|DRUG|Natesto|4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.
214879923|NCT02768831|OTHER|CPAP|Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
214879924|NCT02768831|OTHER|Tidal volume|The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
214879925|NCT04149652|DIAGNOSTIC_TEST|Lung Elastosonography|Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.
214879926|NCT01141205|BIOLOGICAL|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
214666999|NCT02331264|OTHER|Exposure to metal debris|The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
214879927|NCT01141205|DRUG|Saline|1.2 ml saline intramuscularly
214879928|NCT03259386|DEVICE|Microelectrode array|Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
214879929|NCT01408602|DRUG|MRC375|MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
214879930|NCT01408602|DRUG|Matching Placebo|Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
214879931|NCT01408602|DRUG|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
214879932|NCT05085444|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
214879933|NCT04052334|DRUG|TIL|Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
214879934|NCT04052334|DRUG|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
214879935|NCT04052334|DRUG|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
214879936|NCT04052334|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
214879937|NCT04664933|DRUG|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
214879938|NCT06159491|DRUG|Pacritinib|Participants will take Pacritinib 100 mg - 200mg BID for each 28 day cycle
214879939|NCT06159491|DRUG|Azacitidine|Azacitidine 75mg/m\^2 will be administered IV or SQ QD D1-7 of each 28 day cycle
214879940|NCT06299839|DRUG|PAS-004 Capsules|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1 mg, 4mg, and 10 mg strength capsules, intended for oral administration once daily.
215044804|NCT01738243|DRUG|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
215044805|NCT06571344|DRUG|Cholecalciferol|"The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm."
215044806|NCT05918445|DRUG|PM8002|IV infusion
215044807|NCT00467441|DRUG|VSF-173|
214879941|NCT06299839|DRUG|PAS-004 Tablets|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 4mg strength tablets, intended for oral administration once daily.
214879942|NCT01898221|DRUG|Ethanol|We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a \~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
215044808|NCT05030584|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
215044809|NCT05030584|DRUG|Placebo|Matching placebo orally once daily.
215044810|NCT03083782|DRUG|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
215044811|NCT03083782|DRUG|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
215044812|NCT03083782|DRUG|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
215044813|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
214879943|NCT01898221|PROCEDURE|Ablation|The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
214879944|NCT02984163|BEHAVIORAL|Exercise|Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.
214667000|NCT04207710|DRUG|Gebauer's Pain Ease Top Aerosol Mist Spray|Topical refrigerant spray
215044814|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
215044815|NCT00749437|RADIATION|3-dimensional conformal accelerated partial breast irradiation|Accelerated partial breast irradiation following lumpectomy with placement of Acculoc fiducial markers.
215044816|NCT03230188|OTHER|functional Magnetic Resonance Imaging (research grade)|Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
215044817|NCT03230188|OTHER|Cognitive Function Testing (non-diagnostic)|Subjects will take non-diagnostic cognitive function tests
215044818|NCT03230188|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
215044819|NCT04017130|DRUG|MT-0169|MT-0169 intravenous infusion.
215044820|NCT02478489|DRUG|Oral naltrexone (PO-NTX)|oral naltrexone
215044821|NCT02478489|DRUG|Extended-release injectable naltrexone (XR-NTX)|injectable naltrexone
215044822|NCT04381247|DIAGNOSTIC_TEST|Molecular diagnostics in HAP and VAP|Airway samples will be analyzed both by standard and molecular based microbiological analysis.
215044823|NCT02455167|DRUG|Simeprivir (SMV)|Experimental Single arm study. All participants will get the same treatment.
214477013|NCT06856538|DRUG|Bupivacain|After the location will be confirmed through hydrodissection of 1 ml on the plane between the rhomboid major and the underlying intercostal muscles after confirming a negative aspiration via a a 22-gauge short bevel sonovisible needle (Spinocan, B. Braun Melsungen AG, Germany) using an in-plane technique then 10 ml of bupivacaine (concentration 0.25%) will be injected. and its spread will be manifested by the hydrodissection and widening of the plane visualized by ultrasound.
214667001|NCT04207710|DRUG|Gebauer's Ethyl Chloride|Topical refrigerant spray
214667002|NCT03660501|DEVICE|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.
214667003|NCT00465569|DRUG|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
214667004|NCT00465569|OTHER|Placebo|
214667005|NCT04706572|OTHER|Stimulation with external auditory bio-feedback|Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
214667006|NCT05387590|BEHAVIORAL|Preventiometer device with wellness coaching|Four wellness coaching sessions with a certified wellness coach to develop and implement your own personalized wellness plan will be included in this study.
214879945|NCT06648967|DIETARY_SUPPLEMENT|Supplementation with a multi-ingredient whey supplement|Malabsorption of two different fructose boluses at baseline and after 3 and 5 weeks of multi-ingredient whey supplementation.
214879946|NCT06250036|DRUG|Single agent zimberelimab|Single agent zimberelimab (PD-1 inhibitor) Q3W
214879947|NCT06250036|DRUG|Combination zimberelimab + domvanalimab|Combination zimberelimab + domvanalimab (TIGIT inhibitor) Q3W
214879948|NCT05326412|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: subcutaneous
214879949|NCT02928185|BEHAVIORAL|semi-structured interviews|
214879950|NCT06298513|OTHER|Cardiac rehabilitation|Six weeks of cardiac rehabilitation with physical training
215044824|NCT02455167|DRUG|Sofosbuvir (SOF)|Experimental Single arm study. All participants will get the same treatment.
215044825|NCT02455167|DRUG|Ribavirin (RBV)|Experimental Single arm study. All participants will get the same treatment.
215044826|NCT04436744|DRUG|Giredestrant|During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
215044827|NCT04436744|DRUG|Anastrozole|During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
215044828|NCT04436744|DRUG|Palbociclib|During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.
215044829|NCT04436744|PROCEDURE|Surgery|Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
214879951|NCT06037694|PROCEDURE|Conventional Free Gingival Graft|Implant site with insufficient dimensions of KM will be covered by a conventional free gingival graft.
214879952|NCT06037694|PROCEDURE|'Mesh Free Gingival Graft|Implant site with insufficient dimensions of KM will be covered by a expanded meshed free gingival graft.
214879953|NCT05814822|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.
214879954|NCT05814822|BEHAVIORAL|Sleep Hygiene Education (SHE-TM)|Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.
214879955|NCT06383182|PROCEDURE|endovascular treatment|all patients with anterior circulation large vessel occlusion will receive endovascular treatment.
214879956|NCT05405660|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
214879957|NCT05405660|DRUG|Matching Placebo|Subcutaneous Administration
214879958|NCT06470295|OTHER|Saline|Normal saline will be infused during insulin-induced hypoglycemia
214879959|NCT06470295|BIOLOGICAL|C-peptide|C-peptide will be infused during insulin-induced hypoglycemia
214879960|NCT06532747|BEHAVIORAL|Integrated Lifestyle Intervention (ILI)|ILI participants will receive training in empirically supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with BWL content adapted to meet the needs of EAs.
214879961|NCT06532747|BEHAVIORAL|Monitoring with digital tools|All participants will receive digital tools to facilitate self-monitoring-the initial 4-month program will consist of group sessions via Zoom (8 weekly, 4 bi-weekly) with weekly tailored e-coaching, followed by monthly boosters through 12 months.
214879962|NCT05595408|DRUG|Adjuvant chemotherapy|cisplatin/carboplatin-gemcitabine 4-6 cycles
214879963|NCT05595408|DRUG|adjuvant immunotherapy|immunotherapy for one year
214879964|NCT03236415|DEVICE|Xience Drug Eluting Stent|Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
215044830|NCT01133847|DRUG|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
215044831|NCT01133847|BEHAVIORAL|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
215044832|NCT01133847|BEHAVIORAL|Parent Training|Nine sessions on parenting a child with ADHD
215044833|NCT01133847|DRUG|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
215044834|NCT01133847|DRUG|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
215044835|NCT01133847|DRUG|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
215044836|NCT05504499|DEVICE|Interspinous Fusion|The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
214477014|NCT06856538|DEVICE|Ultrasound|A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
214879965|NCT03236415|DEVICE|ABSORB Bioresorbable Vascular Scaffold|Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
214879966|NCT04714983|BIOLOGICAL|DNX-2440|DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
214879967|NCT03652558|DEVICE|Ozone application with the Ozonytron XL device|An ozone generator (Ozonytron; Bionix, Munchen, Germany) with an KPX probe (CA Probe; Ozonytron, Bionix, Munchen, Germany) was used for OT. Topical gaseous ozone was applied into the periodontal pocket twice a week for 2 weeks based on the manufacturer's instructions. Ozone applications were at 75% power for 30 seconds (75 µg/ml). Ozone applications were performed by an experienced investigator. Ozone applications in the control side were simulated without starting the ozone generator
214879968|NCT00858481|DRUG|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
214879969|NCT00858481|DRUG|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
214879970|NCT00858481|DRUG|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
214879971|NCT00858481|DRUG|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
215044837|NCT04430998|DRUG|Zinc L-Carnosine|Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
215044838|NCT04430998|DRUG|Chlorhexidine|Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
215044839|NCT04430998|OTHER|Water|Rinse mouth with 10 ml of water, retain for 3 minutes, 3 times daily
215044840|NCT03430167|OTHER|home therapy|Patients will be given a set of instructions for completing home therapy for range of motion and strengthening
215044841|NCT03430167|OTHER|formal therapy|Patients will be sent to physical therapist for formal treatment to regain range of motion and strengthening exercises
215044842|NCT03586947|DRUG|Vitamin D3 400 UNT Oral Capsule|50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
215044843|NCT02539550|DRUG|Placebo|Placebo
215044844|NCT02539550|DRUG|PF-06266047|PF-06266047
215044845|NCT01463033|DRUG|Levetiracetam|55 mg/kg/day given in 2 divided doses 12 hours apart
215044846|NCT00335881|BIOLOGICAL|hepatitis B vaccine|
215044847|NCT00658268|DRUG|Clodronate|60 mg/ml, 10 ml, single dose mixed in bone graft at operation
215044848|NCT00658268|DRUG|Placebo|10 ml, single dose mixed in bone graft at operation
214477015|NCT06664021|DRUG|Tislelizumab combined with S-1|Tislelizumab：200mg q3w iv , lasts for one year. S-1：40mg, 50mg, or 60mg orally twice daily for 4 weeks, depending on body surface area, followed by 2 weeks of rest，lasts four cycles.
215044849|NCT03950232|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
214879972|NCT03017703|DRUG|Eplerenone|
214879973|NCT03850925|PROCEDURE|Laser therapy|4 consecutive sessions of laser therapy
214879974|NCT00818688|PROCEDURE|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
214879975|NCT05127915|DEVICE|Adient absorbable filter + best practice VTE prophylaxis|Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
214879976|NCT05127915|DEVICE|best practice VTE prophylaxis|Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
214879977|NCT06522633|DRUG|The intervention involves the discontinuation of the opioid.|Patients with dysphagia and esophageal manometry indicating opioid-induced esophageal dysfunction (OIED) will have the opioid discontinued, and esophageal manometry will be repeated.
214879978|NCT06393946|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
214879979|NCT01822366|BEHAVIORAL|Trauma-focused Cognitive Behavioral Therapy|
214879980|NCT02875964|DEVICE|electroencephalogram|Implanting electrode to measure brain activity
215044850|NCT04812925|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
215044851|NCT04222192|OTHER|Epidural block|Epidural catheter insertions
215044852|NCT03709901|OTHER|Active Allograft|Injection of viable allograft into the nucleus pulposus of the degenerated disc
215044853|NCT03709901|OTHER|Placebo|Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
215044854|NCT04284709|OTHER|cognitive-physical training|combined physical and cognitive training
215044855|NCT03361488|OTHER|Trained anesthesiogist|
215044856|NCT01858727|OTHER|forced air warming group|30 minutes before the preoperative will use forced air warming
215044857|NCT01858727|OTHER|control group|do not heating group
215044858|NCT03573674|BEHAVIORAL|CE - Cognitive Ergonomics (KERGO)|"CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
215044859|NCT03573674|BEHAVIORAL|RS - Recovery Support (KUORMA)|"RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
214667007|NCT04950738|OTHER|pess tack acupuncture|Patients enrolled will receive intervention in a form of either press tack acupuncture needles or press tack placebos. Three total intervention sessions will be taken place on day 1,3,5 from patient's enrolment. Needles/placebos skin withdrawal will be done 48 hours after treatment by an acupuncture doctor or by a trained ICU nurne. In cases when a patient will be transferred from the ICU, the 3 study interventions will be continued in the new ward.
214667008|NCT04950738|OTHER|pess tack placebo|pess tack stickers without a needle
214879981|NCT02875964|DEVICE|magnetoencephalogram|Implanting electrode to measure brain activity
214879982|NCT05199090|DRUG|MBL949|subcutaneous injections administered for 14 weeks
214879983|NCT05199090|DRUG|Placebo|Placebo Comparator to MLB949
214879984|NCT03414086|OTHER|Healthy Control|Ten healthy adult patients evaluating serum, PBMC's, and RNA.
214879985|NCT03414086|OTHER|Myositis in Remission|Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
214879986|NCT06237439|BEHAVIORAL|Move with HaRT|Move with HaRT is a group-based, manualized mind-body intervention.
214879987|NCT05833698|DIAGNOSTIC_TEST|Elevation of NLR|Blood test
214879988|NCT03276078|DRUG|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
214879989|NCT03476733|OTHER|Detection of drug related problem in inpatient|Detection of drug related problem in inpatient
215044860|NCT03053128|DEVICE|Cardiac shock wave therapy|Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
215044861|NCT03053128|OTHER|Sham cardiac shock wave (Control group)|Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
215044862|NCT00967616|DRUG|CS7017|CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
214667009|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
214879990|NCT02552732|DEVICE|NHF with or without Oxygen|NHF using myAIRVO™ 2 will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
214879991|NCT04635293|PROCEDURE|preoperative infusion of levosimendan|the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
214879992|NCT04635293|PROCEDURE|no preoperative infusion of levosimendan|the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
214879993|NCT04939194|BEHAVIORAL|Fast Track Protocol|We will apply 22 items of ERAS society
214879994|NCT06634238|OTHER|Incremental shuttle walk test|Participants were recommended to wear comfortable clothing and appropriate shoes for the test. To minimize variability, one masked and one unmasked ISWT was performed on the same participant at the same time of day, one day apart
214879995|NCT01767948|DRUG|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
214879996|NCT00387556|DRUG|Ondansetron|ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
214879997|NCT00487968|DRUG|eltrombopag|
214879998|NCT04942743|DIAGNOSTIC_TEST|MRI|MRI OF TMJ
215044863|NCT00967616|DRUG|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)|"FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)"
215044864|NCT03627052|DRUG|Itacitinib|In the double-blind period, itacitinib administered orally once or twice daily at the protocol-defined dose according to treatment group randomization. In the open-label extension, itacitinib administered at doses determined from the double-blind period.
215044865|NCT03627052|DRUG|Placebo|Placebo administered orally twice daily in the double-blind period.
215044866|NCT05833711|DRUG|Froniglutide|SC Weekly Injection
215044867|NCT05833711|DRUG|Placebo|SC Weekly Injection
215044868|NCT05489471|OTHER|Artificial intelligence review|The AI looks for ten different abnormalities on each chest X-ray and produces a heat map and percentage confidence score if it detects an abnormality.
215044869|NCT05556889|PROCEDURE|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
214667010|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
214667011|NCT01121016|DRUG|Montelukast|10mg, qn, 4 weeks
214667012|NCT01121016|OTHER|placebo to montelukast|same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
214879999|NCT06552156|DIETARY_SUPPLEMENT|Dietary Emulsifier|Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.
214880000|NCT03912545|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214880001|NCT02122692|DRUG|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
214880002|NCT02122692|DRUG|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
214880003|NCT02122692|DRUG|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
214880004|NCT00933647|DIETARY_SUPPLEMENT|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
214880005|NCT00933647|DIETARY_SUPPLEMENT|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
214880006|NCT00933647|DIETARY_SUPPLEMENT|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
214880007|NCT02290223|BEHAVIORAL|Behavioral Based Treatment Model|Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
214880008|NCT05835908|OTHER|Phone questionnaire|Patients will be contacted by the investigator to collect information regarding follow-up from the initial call to the Emergency call center until the patient is taken care of in the health care facility to which he/she has been admitted.
214880009|NCT02495623|DRUG|SYN-010 21 mg|
214880010|NCT02495623|DRUG|SYN-010 42 mg|
214880011|NCT02495623|DRUG|Placebo|
215044870|NCT05556889|PROCEDURE|Traditional auriculotemporal nerve blockade|Traditional auriculotemporal nerve blockade
215044871|NCT01368614|DEVICE|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
214880012|NCT06443723|DIAGNOSTIC_TEST|USG, blood tests, waist, hip, height and blood pressure measurements|"MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5."
214880013|NCT01616355|OTHER|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
214880014|NCT01858272|DRUG|H5.020CMV.PDGF-b and limb compression bandage|
214880015|NCT06469203|DRUG|Oxytocin|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
214880016|NCT06469203|DRUG|Sodium Chloride 0.9% Inj|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
214880017|NCT00812448|DIETARY_SUPPLEMENT|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
214880018|NCT04082156|DEVICE|electrical stimulation|electrical stimulation
214880019|NCT04082156|DEVICE|Sham|no stimulation
214880020|NCT04220970|OTHER|BIA-ALCL|Observational : no intervention
214880021|NCT04965077|DRUG|Recombinant Humanized Monoclonal Antibody MIL97 for Injection|"Dose escalation phase: The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL97 every 3 week on Day 1 of each cycle. Additional 1 or 2 dose cohorts will receive an intravenous infusion of MIL97 every 2 week on Day 1 of each cycle after last patient finishes DLT observation period.~Dose expansion phase: One or two recommended expansion doses (either Q3W or Q2W) will be selected from 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg) based on results of dose escalation phase. MIL97 will be administered via intravenous infusion for 60 to 90 minutes on Day 1 of each cycle."
214880022|NCT00747032|DRUG|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
214880023|NCT00747032|DRUG|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
214880024|NCT05509075|DIETARY_SUPPLEMENT|nutraceuticals|antioxidants
214880025|NCT01669603|DIETARY_SUPPLEMENT|Bifidobacterium lactis Bl-04|The study product will be a 2\*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
214880026|NCT01669603|DIETARY_SUPPLEMENT|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
214880027|NCT01669603|BIOLOGICAL|Rhinovirus|rhinovirus for experimental challenge
214880028|NCT00030472|DRUG|pegylated liposomal doxorubicin hydrochloride|
214880029|NCT05589506|DEVICE|Removable partial denture PEEK|A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
214880030|NCT02425566|DRUG|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
214880031|NCT02425566|DRUG|Nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
214880032|NCT03368456|BEHAVIORAL|S4E|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs and a forthcoming module on tobacco prevention and cessation.
214880033|NCT03368456|BEHAVIORAL|Usual Care|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
214880034|NCT01550029|BEHAVIORAL|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle."
214880035|NCT01550029|BEHAVIORAL|Counseling/Managing Mood|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
214880036|NCT00802932|DEVICE|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
214880037|NCT00802932|DEVICE|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
214880038|NCT06223776|PROCEDURE|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
214880039|NCT05662839|DEVICE|Cytological Brushing|All participants will undergo cytological brushing to collect cell samples for analysis
214880040|NCT04800679|DRUG|receive 4 monthly IVB injections and then rescue IVB|IVB group that receive 4 monthly IVB injections and then rescue IVB
214880041|NCT04800679|DRUG|PRP group|PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
214880042|NCT04800679|DRUG|IVB injections and a modified laser|Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
214880043|NCT07134842|BIOLOGICAL|Ipilimumab (3 mg/kg)|All participants will be treated with ipilimumab (3mg/kg) for up to 2 cycles. Each cycle will last 21 days with participants receiving ipilimumab on the 1st day of the cycle.
214880044|NCT07134283|PROCEDURE|Preoperative and Postoperative Cold Therapy with Gel Cold Pack|Cold therapy was applied using a conventional gel cold pack , pre-cooled at -17°C for at least 2 hours. In the intervention group, cold application was performed three times before surgery (20 minutes per session with 40-minute intervals), and continued postoperatively for 24 hours with the same frequency. This protocol aimed to reduce pain, swelling, bleeding, and improve functional outcomes after total knee arthroplasty.
214880045|NCT07134283|PROCEDURE|Postoperative Cold Therapy with Gel Cold Pack|Cold therapy applied only in the postoperative period, for 24 hours, using the same method as the intervention group (20-minute applications with 40-minute breaks.
214880046|NCT06653803|PROCEDURE|Rhomboid Intercostal Block (RIB)|Intraoperative Ipsilateral Ultrasound-guided RIB
214880047|NCT06653803|PROCEDURE|Retrolaminar Block (RLB)|Intraoperative Ipsilateral Ultrasound-guided RLB
214880048|NCT07133555|OTHER|Healthcare counseling service|Using peer health navigators to support linkage to HIV prevention and treatment resources among Black MSM in online spaces following mobile testing.
214880049|NCT07134595|OTHER|C-CAPD Prescription|The prescription for the M-CAPD therapy is the C-CAPD with an additional 1 to 2 short, low-volume, 15 to 30-minute dwells per exchange before instilling the computed full dwell volume.
214880050|NCT07134595|OTHER|M-CAPD Prescription|The prescription for the M-CAPD therapy is the C-CAPD with an additional 1 to 2 short, low-volume, 15 to 30-minute dwells per exchange before instilling the computed full dwell volume.
214880051|NCT07134634|DEVICE|tremor device|tremor ball on versus tremor ball off
214880052|NCT07134699|OTHER|Participants are not assigned an intervention|For observational studies, participants are not assigned an intervention as part of the study.
214880053|NCT07133659|DRUG|Avatrombopag 20 mg Oral Tablet|Description: Patients will start on avatrombopag 20 mg every other day for a week then the dose will be readjusted according to the platelet count.
214880054|NCT06983080|DRUG|Trazodone 25 mg|Trazodone 25 mg at bedtime, which can be increased to 50 mg after 14 days of treatment.
214880055|NCT06982456|OTHER|Manual Therapy on the Upper Trapezius with or without Passive Stretching|The intervention consists of manual therapy techniques applied to the upper fibers of the trapezius muscle, including superficial massage, deep massage, and pressure release technique. In one of the experimental groups, this treatment is followed by passive stretching. The control group receives no intervention. Algometric measurements (pressure pain threshold) are taken before and after the intervention, and at one-week and two-week follow-up points to assess the effectiveness and persistence of the treatment.
214880056|NCT04798131|OTHER|Active neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will continuously receive visual feedback computed from the fMRI signal analyzed with the hallucinations decoder. Patients will be trained to maintain the brain state associated with the no-hallucination state using appropriate coping strategies. A 5th fMRI scan will be performed at 1 month post-treatment.
214880057|NCT04798131|OTHER|Sham neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will receive a random feedback and a 5th run at 1 month post-treatment.
214880058|NCT05973292|OTHER|resin cement containing phosphate ester monomer 10-methacryloyloxydecyl dihydrogen phosphate|Adhesive resin cement containing an MDP agent that is added to bonding agents to enhance bonding to ceramics like Ziconia and E-max
214880059|NCT05973292|OTHER|Non MDP containg resin cement|Adhesive resin cement not containing an MDP agent
214880060|NCT05967871|BIOLOGICAL|Fecal Microbiota Transplant|Participants will receive approximately 50 grams of human stool/150mL (approximately 107 microbes/mL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.
214880061|NCT06983886|DRUG|Tranexamic Acid|A local anesthetic solution was prepared by mixing 10 ml of 1% lidocaine with adrenaline (1:100,000) and 5 ml of tranexamic acid (50 mg/ml), resulting in a total volume of 15 ml. The solution was injected at the planned mandibular osteotomy sites on both the medial and lateral aspects of the ramus of the mandible. The injection was administered after completion of general anesthesia, followed by a 5-minute waiting period to allow the anesthetic to take effect before the surgical incision was made.
214880062|NCT06983886|DRUG|Normal Saline Solution (NSS)|A local anesthetic solution was prepared by mixing 10 ml of 1% lidocaine with adrenaline (1:100,000) and 5 ml of normal saline (NSS), resulting in a total volume of 15 ml. The solution was injected at the planned mandibular osteotomy sites on both the medial and lateral aspects of the ramus of the mandible. The injection was administered after the induction of general anesthesia, followed by a 5-minute waiting period to allow the anesthetic to take effect before making the surgical incision.
214880063|NCT06983886|DRUG|Lidocaine (drug)|A local anesthetic solution was prepared by mixing 10 ml of 1% lidocaine with adrenaline (1:100,000) and 5 ml of normal saline (NSS) or 5 ml of tranexamic acid (50 mg/ml) depends on allocated group, resulting in a total volume of 15 ml. The solution was injected at the planned mandibular osteotomy sites on both the medial and lateral aspects of the ramus of the mandible. The injection was administered after the induction of general anesthesia, followed by a 5-minute waiting period to allow the anesthetic to take effect before making the surgical incision.
214880064|NCT04070235|DRUG|SH229 tablets|SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
214880065|NCT04070235|DRUG|Daclatasvir dihydrochloride|Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
214880066|NCT01004003|DRUG|Sorafenib|
214880067|NCT01004003|DRUG|BIBF 1120|Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
215044872|NCT01368614|DEVICE|Respironics OnmiLab BiPAP S mode|Currently cleared Non-Invasive Ventilation (NIV) therapy modality
214880068|NCT05104190|OTHER|Stabilization of teeth during debonding using fingure pressure and elastic wafer|To control pain during debonding in one group , teeth were stabilized with finger pressure with cotton between finger and teeth and then debonding using open mouth technique was done. In second group teeth were stabilized using a plastic wafer between maxillary and mandibular teeth and then debonding was done using closed mouth technique. In order to reduce biasness, all of the patients were debonded with same plier and with wires still ligated to brackets. With the help of VAS, pain score was measured after debonding. A single operator performed complete procedure of debonding and pain recording.
214880069|NCT01026987|DRUG|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
214880070|NCT01026987|DRUG|AMD3100|
214880071|NCT01026987|PROCEDURE|Leukapheresis|
214880072|NCT01026987|PROCEDURE|Stem Cell Infusion|
214880073|NCT02394704|OTHER|Sensory attention training|"Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks."
214880074|NCT00392912|DRUG|AndroGel (Solvay Pharmaceuticals)|Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.
214880075|NCT06216678|OTHER|Healthy Dietary Pattern with Cottonseed Oil|Cottonseed Oil
214880076|NCT06216678|OTHER|Healthy Dietary Pattern with Fatty Acid-Matched Plant Oils|Plant oil blend fatty acid matched
215044873|NCT01368614|DEVICE|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
215044874|NCT02951780|DRUG|LY3185643|Administered SC
215044875|NCT02951780|DRUG|rGlucagon|Administered SC
214291912|NCT05613595|BEHAVIORAL|Positive Psychotherapy|"Positive Psychotherapy is an effective treatment for many mental disorders and depression is primary empirical target. Its primary goal is to build positive emotion, engagement, and meaning in life that will alleviate depression and other mental health disorders. Thus PPT may offer a new way to treat and prevent mental health issues.~Interventions sessions included, Session Records Session One: Positive Introduction and Gratitude Journal Session Two: Character Strengths and Signature Strengths Session Three: Practical Wisdom , Session Four: A Better Version of Me , Session Five: Open and Closed Memories, Session Six: Forgiveness Session Seven: Maximizing versus Satisficing, Session Eight: Gratitude ,Session Nine: Hope and Optimism, Session Ten: Posttraumatic Growth, Session Eleven: Slowness and Savoring, Session Twelve: Positive Relationships, Session Thirteen: Positive Communication, Session Fourteen: Altruism , Session Fifteen: Meaning and Purpose"
214291913|NCT05613595|BEHAVIORAL|Counseling Group|Caregivers in control group only regular counseling will be provided (psychoeducation). it will be based upon the insight of cerebral palsy and training based on Adaptive skill functioning of the CP child of the caregivers
214291914|NCT00280098|DRUG|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
214880077|NCT06216678|OTHER|Healthy Dietary Pattern with PUFA:SFA Ratio-Matched Plant Oil|Plant oil with matched PUFA to SFA ratio
214880078|NCT01507766|DRUG|early enteral nutrition|The enteral nutrition was started within 48h after admission
215044876|NCT03522961|DRUG|Nitrofurantoin Prophylaxis/Placebo|Drug: Nitrofurantoin Drug: Placebo
215044877|NCT03522961|DRUG|Cranberry capsules|Drug: TheraCran® One Cranberry capsules
215044878|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
214291915|NCT00922181|DEVICE|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
214291916|NCT00922181|DEVICE|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
214291917|NCT02206334|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
214880079|NCT01507766|DRUG|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
214880080|NCT00117832|DRUG|Azelastine nasal spray|
214880081|NCT05931978|OTHER|CKD dashboard|Online dashboard that visualizes patients' individual PROM- and clinical data related to their kidney disease.
214880082|NCT02693860|DRUG|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.
215044879|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
215044880|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
215044881|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
215044882|NCT04414293|RADIATION|Lung Low Dose Radiation|The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
215044883|NCT01374425|DRUG|5-Fluorouracil|5-Fluorouracil 400 milligrams per meter-squared (mg/m\^2) by IV bolus and subsequent 2400 mg/m\^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
214880083|NCT02693860|DRUG|89Zr-J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
214880084|NCT06820190|OTHER|Multiple Mid-Transverse Process to Pleura (MTP) Block|Patients will receive multiple mid-transverse process to pleura (MTP) block after induction of anesthesia.
214880085|NCT06820190|DRUG|Morphine|Patients will receive IV-PCA. Morphine is generally administered as an initial loading dose of 0.05-0.1 mg/kg before the end of surgery, with PCA settings of a bolus dose of 0.01-0.03 mg/kg, a lockout interval of 6-10 min, and a background infusion of 0.01-0.02 mg/kg/h.
214880086|NCT06824259|PROCEDURE|Follow up if MRI is negative|Enter the follow-up cohort without systematic biopsy when prostate cancer is clinically suspected and no PIRADS v2.1 score ≥3 lesions are detected on initial examination. MR plus regional saturation biopsy was performed when MRI progressed.
214880087|NCT06824259|PROCEDURE|Systematic biopsy if MRI is negative|Systematic biopsy was performed if there was clinical suspicion of prostate cancer and no PIRADS v2.1 score ≥3 lesions were detected on initial examination. If the biopsy was negative enter the follow-up cohort.
214880088|NCT02824471|OTHER|SCD Group|No Intervention. Use of discard blood/tissue
214880089|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM)|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM) After performing PVI, electrogram mapping of the posterior left atrial wall is conducted. Subsequently, PWI and EGM ablation are performed. In this group, multipolar mapping catheters are used for EGM mapping. Target EGMs include spatially discrete potentials (STPs), localized short cycle length potentials (SCLPs), and focal activities.
215044884|NCT01374425|DRUG|Bevacizumab|Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
215044885|NCT01374425|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
215044886|NCT01374425|DRUG|Leucovorin|Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
215044887|NCT01374425|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
215044888|NCT01374425|DRUG|Capecitabine|Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
215044889|NCT04804527|OTHER|Intensified physiotherapy|Physiotherapy x2
214880090|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI)|After performing PVI, the mapping catheter will be placed on the posterior wall to assess electrical activity and guide ablation. A bottom linear ablation (25-40W) will be performed, connecting the lowest points beneath the lower PVs. A top linear ablation (25-40W) will be conducted at the top of the left atrium, connecting the highest points above the upper PVs. If posterior wall isolation is not achieved after completing the bottom and top lines, mapping and localization of the earliest activation point within the box will be performed during pacing from the coronary sinus (CS). Posterior wall isolation will be completed by identifying and ablating local potentials at the entry and exit sites.
214880091|NCT06633523|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|The distance between the ablation lines on the posterior wall after circumferential pulmonary vein isolation should be at least 2 centimeters to limit the portion of the posterior wall within the PVI ablation zone. PVI will be confirmed by verifying entrance and exit block at the PV orifices.
214880092|NCT03633201|DEVICE|Cruciate Retaining|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
215044890|NCT04804527|OTHER|Usual care physiotherapy|Physiotherapy x1
214291918|NCT06382792|PROCEDURE|proximal humeral resection for tumor and allograft prosthetic composite reconstruction|allograft prosthetic composite
215044891|NCT01245725|DRUG|Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
215044892|NCT01245725|DRUG|Placebo|"Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
215044893|NCT02359903|DRUG|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
215044894|NCT02359903|DRUG|Infliximab (Remicade)|
215044895|NCT03279926|BEHAVIORAL|PLAY|Activity trackers + curriculum information
215044896|NCT03279926|BEHAVIORAL|PLAY Parents|Enhanced parental engagement
215044897|NCT03279926|BEHAVIORAL|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
215044898|NCT05309044|BEHAVIORAL|Planetary Health Diet Group|This group includes a diet proportional to the EAT-Lancet reference diet (2500 kcal), with a caloric intake of 1200 to 1800 kcal, in addition to a behavioral change protocol during the time of the study (4 months).
215044899|NCT05309044|OTHER|Low-fat diet group|This group includes a low-fat, low-calorie diet (1200-1800 kcal), in addition to a behavioral change protocol
214291919|NCT01335984|PROCEDURE|Telemonitoring|"The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center."
214880093|NCT03633201|DEVICE|Medial Congruent|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
214880094|NCT07001319|DRUG|GS-3242|Administered orally
214880095|NCT07001319|DRUG|BVY|Administered orally
214291920|NCT01335984|PROCEDURE|Telemonitoring & Telemedicine|"The subjects who are assigned in the Telemonitoring \& Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions."
214880096|NCT07001319|DRUG|Standard of Care|Antiretroviral therapy, administered orally Non-NNRTIs, examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
214880097|NCT07134530|DEVICE|HPI-driven intraoperative hemodynamic management strategy|Hemodynamic management protocol based on information detected by Edwards HemoSphere monitor equipped with the Acumen Hypotension Prediction Index software (HPI)
214880098|NCT07134530|DEVICE|GDT strategy|Current clinical hemodynamic care
214880099|NCT04440670|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth
214880100|NCT04440670|BIOLOGICAL|normal saline|preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth
215044900|NCT05309044|OTHER|Waiting list group|This group will only receive digital information with recommendations on healthy eating. When the study has finished, this group will receive a behavioral change protocol with a low-fat, low-calorie diet.
215044901|NCT00546481|DRUG|methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]|0.6 micrograms/kg every 2 weeks
215044902|NCT00546481|DRUG|Epoetin|As prescribed, iv, 3 times weekly
215044903|NCT01227057|BEHAVIORAL|Cognitive Rehabilitation and Exposure Therapy for Compulsive Hoarding|The intervention includes cognitive remediation for deficits in executive functioning and exposure therapy for discarding/acquiring.
215044904|NCT01227057|BEHAVIORAL|Case Management|Case management
215044905|NCT05016089|OTHER|The 16-style simplified Pilates exercise programme|The 16-style simplified Pilates exercise programme was developed by a group of experienced Pilates and rehabilitation experts from our completed pilot work.
215044906|NCT03152578|OTHER|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
215044907|NCT03152578|OTHER|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
215044908|NCT03152578|OTHER|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
215044909|NCT01840033|DEVICE|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
214291921|NCT01335984|OTHER|control group|"\- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks)."
214880101|NCT06803927|DEVICE|Barrett's Esophagus Test (LDT)|Barrett's Esophagus Test (LDT) will be performed on esophageal cells collected using the EndoSign Cell Collection Device (510(k) cleared) and compared to the results of standard of care EGD plus biopsies (if applicable)
215044910|NCT01840033|DEVICE|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
214291922|NCT04542772|OTHER|Mirror Therapy|Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.
214880102|NCT01179698|PROCEDURE|Navigation surgery|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
214880103|NCT01179698|PROCEDURE|Navigation system|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
214880104|NCT04252898|BEHAVIORAL|Front-of-pack nutrition label Nutri-Score|The intervention consists of displaying the Nutri-Score on dishes and pre-packed foods.
214880105|NCT01045213|OTHER|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
214880106|NCT01914627|DRUG|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
214880107|NCT01914627|DRUG|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
214880108|NCT00313339|DRUG|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
214880109|NCT00732576|DIETARY_SUPPLEMENT|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
215044911|NCT05268757|BEHAVIORAL|Oral hygiene discontinuation|Oral hygiene discontinuation for 14 days followed by 14 days of regular oral care
215044912|NCT02752347|DEVICE|Surface EMG device|measuring the muscles activity using surface EMG device
214291923|NCT04542772|OTHER|Regular Rehabilitation|Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
215044913|NCT04549480|DRUG|Bosutinib capsule|100 mg dose of bosutinib pediatric capsule
215044914|NCT04549480|DRUG|Bosutinib tablet|100 mg dose of bosutinib tablet
215044915|NCT02982330|BEHAVIORAL|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing \<10% carbohydrate, \~75% fat, and 15% protein. Matched for calories to the active comparator arm.
215044916|NCT02982330|BEHAVIORAL|Guidelines Breakfast|A low fat breakfast containing \~55% carbohydrate, \<30% fat, and 15% protein. Matched for calories to the experimental arm.
215044917|NCT05115435|BEHAVIORAL|neuro linguistic programming|Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
215044918|NCT00300014|PROCEDURE|Intravitreal triamcinolone injection|
215044919|NCT00300014|PROCEDURE|Air-fluid exchange|
214291924|NCT00144092|PROCEDURE|stem cell source|
214667013|NCT03009695|DEVICE|High frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
214667014|NCT03009695|DEVICE|Low frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.
215044920|NCT03931226|DRUG|Drug consumption|number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
214667015|NCT03009695|DEVICE|Sham|Sham stimulation will be performed by an H-sham-coil. The H-sham-coil is designed to mimic the auditory artifacts and the scalp sensation evoked by the real coil, without stimulating the brain itself. As in the other groups, in each patient the rMT will be determined before each repetitive dTMS session. The sham stimulation will be performed either at high frequency (50% of subjects) or at low-frequency (50% of subjects), according to the previously described methodologies. All obese people in this group will be submitted at the sight of food preferred (cue).
214667016|NCT05266638|OTHER|Data collection (radiological parameters, outcome information) from electronic patient files in hospital data system|Collection of medical data and medical images (MRI, radiographs) of the lumbar spine and pelvis of patients having received TLIF with degenerative spinal diseases from the years 2015-2020 and statistical analysis of the coded data.
214667017|NCT06554496|DEVICE|CPAP Treatment|Continuous Positive Airway Pressure (CPAP) therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
214667018|NCT01038492|BEHAVIORAL|p16 Methylation and Lung Cancer Education|"* patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~* patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~* a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~* patients are called again at three months and asked about any changes in their attitudes or smoking habits."
214667019|NCT00922935|DEVICE|Cresco|Cresco components loading 10 days post surgery
214667020|NCT00922935|DEVICE|Cresco|Cresco loading at 6-8 weeks post surgery
214667021|NCT00922935|DEVICE|Straumann components|Straumann components loading 6-8 weeks post surgery
214880110|NCT00732576|DIETARY_SUPPLEMENT|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
214880111|NCT00732576|DIETARY_SUPPLEMENT|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
214880112|NCT01118286|DRUG|Nifedipine (Adalat, BAYA1040)|Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
214880113|NCT02317289|DEVICE|Detection of freezing|single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
214880114|NCT00929279|DRUG|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
214880115|NCT00929279|DRUG|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
214880116|NCT02445976|DRUG|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
214880117|NCT00563576|DRUG|Femring®|"Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months."
214880118|NCT00563576|DRUG|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
214880119|NCT00798876|DIETARY_SUPPLEMENT|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
214880120|NCT00798876|DIETARY_SUPPLEMENT|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
214880121|NCT00798876|DIETARY_SUPPLEMENT|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
214880122|NCT00798876|DIETARY_SUPPLEMENT|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
215044921|NCT02953912|PROCEDURE|Reciproc single-file|The Reciproc is a single-file nickel-titanium systems , made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue
215044922|NCT02953912|PROCEDURE|One Shape single-file|One Shape is one of the few single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue.In addition to , the electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
215044923|NCT01240863|DRUG|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
215044924|NCT01240863|DRUG|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
214291925|NCT03428360|DRUG|Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category|The subjects in this study administered DBF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically used the diazepam rectal gel or other rescue medication, without the presence of study staff.
214291926|NCT00718224|DRUG|Semuloparin sodium|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
214291927|NCT00718224|DRUG|Enoxaparin|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
214880123|NCT00798876|OTHER|Medical Examination|Subjects will have a routine medical exam.
214880124|NCT00798876|OTHER|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
214880125|NCT00798876|OTHER|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
214880126|NCT00798876|PROCEDURE|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
214880127|NCT05934240|OTHER|Manual therapy group|Manual therapy will be applied to the diaphragm and thoracic region.
215044925|NCT03017443|BEHAVIORAL|Nutrisystem Turbo 10|Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.
214880128|NCT05934240|OTHER|Sham-manual therapy|Sham-manual therapy will be applied to the diaphragm and thoracic region.
214880129|NCT00521040|DRUG|Levocetirizine dihydrochloride|
214880130|NCT01525264|BEHAVIORAL|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
214880131|NCT01525264|BEHAVIORAL|Healthy Wife Control Group|Intervention group of couples who received education about importance of Healthy diet
214291928|NCT00718224|DRUG|Placebo|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
214291929|NCT04631081|PROCEDURE|coverage of the fingertips with bipedicled palmar island flap|The initial step is wound debridement. To design the flap, a longitudinal line is drawn at the junction of the volar and dorsal parts of the finger, starting from the distal part of the proximal interphalangeal joint flexion crease. It will be harvested from distal to proximal dissecting the digital canal plane. By releasing the Cleland and Grayson ligaments, the neurovascular bundle will be dissected. On the intermediate phalange, the dorsal branch of the neurovascular bundle must be preserved to maintain blood flow to the dorsal skin. Dissection is completed at the junction between the palmo-dorsal arteries and the collateral neurovascular bundles on both sides of the finger. A triangle may be resected at the distal edge of the flap to reshape of the pulp. Bone may be resected if needed to allow tension-free closure of the distal part of the flap. No Immobilization will be necessary.
214667022|NCT03306771|DIAGNOSTIC_TEST|Ultrasound Duplex|The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
214880132|NCT06633731|OTHER|Biocellulose Mask|Immediately after treatment, a Biocellulose Mask was applied to the subjects global face for 8 to 10 minutes.
214667023|NCT01619618|GENETIC|mutation analysis|
214880133|NCT06633731|OTHER|Post Procedure Cream|Immediately after treatment and after Biocellulose Mask removal, the Post-Procedure Cream was applied to the subjects global face. Subjects were instructed to apply to the global face from days 1 - 3 post treatment.
214667024|NCT01619618|GENETIC|polymerase chain reaction|
214667025|NCT01619618|GENETIC|polymorphism analysis|
214667026|NCT01619618|OTHER|laboratory biomarker analysis|
215044926|NCT03017443|BEHAVIORAL|Nutrisystem My Way|The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (\~50% kcal from carbohydrate, \~25% from protein, \~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.
214880134|NCT06633731|OTHER|Gentle Cleanser|Subjects were instructed to wash their face with the Gentle Foaming Cleanser twice daily for 12 weeks.
214880135|NCT06633731|OTHER|Facial Moisturizer|Subjects were instructed to apply the facial moisturizer twice daily to the global face from day 3 after treatment until next study visit.
214880136|NCT06633731|OTHER|sunscreen|Subjects were instructed to apply the bland sunscreen to the global face once daily in the morning, with re-application with extended sun exposure per FDA guidelines.
214880137|NCT01945073|BEHAVIORAL|Educational Booklet (BK)|The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
214880138|NCT01945073|OTHER|Formal Counselling (CB)|The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
214880139|NCT04769063|OTHER|Kinesio Tape|Gluteus medius facilitation and knee spiral taping techniques will be applied to treat dynamic knee valgus
214880140|NCT00097396|BIOLOGICAL|rF1V vaccine|
214667027|NCT00414622|DRUG|DMXB-A|
214880141|NCT02576912|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) given intravenously.
214880142|NCT02576912|DRUG|Active Pregnenolone|A dose given sublingually.
214880143|NCT02576912|DRUG|Placebo|A placebo dose given sublingually.
214667028|NCT01607723|OTHER|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
214880144|NCT02576912|DRUG|Placebo|Placebo dose given intravenously.
214880145|NCT00147602|DRUG|atorvastatin|
214880146|NCT05819203|DEVICE|Healsea Babykids|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
214880147|NCT05819203|DEVICE|Placebo|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
214880148|NCT06010849|DIAGNOSTIC_TEST|Trunk control|Trunk control
214880149|NCT03320421|RADIATION|Radiation therapy|"Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.~Intensity modulated radiation treatment is used."
214880150|NCT00527306|DIETARY_SUPPLEMENT|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
214880151|NCT03232632|DRUG|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl ®)
214880152|NCT01064752|DRUG|Minocycline|100 mg po bid for 8 weeks
214880153|NCT02748967|DRUG|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
215044927|NCT03017443|BEHAVIORAL|Nutrisystem DASH|The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included \< 30% fat (\< 7% saturated fat), \< 150 mg/d of cholesterol, and \< 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu \[7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week\], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.
215044928|NCT03017443|BEHAVIORAL|Dieting on Your Own (DIY) - DASH|The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
215044929|NCT01419119|DRUG|Cholecalciferol high dose at Vitamin D deficiency|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
215044930|NCT01419119|DRUG|Cholecalciferol median dose at Vitamin D insufficiency|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
214291930|NCT04631081|OTHER|occlusive dressing|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing. Skin proximal to the injury will be degreased to increase adherence of the dressing. Distally, the film leaves a pocket to collect wound exudate. During treatment, the foul-smelling liquid produced by the wound and clots collected in the occlusive dressing will not be removed. A gauze covers the occlusive dressing to protect the liquid pocket and cover potential smell.
214291931|NCT00707824|DRUG|nalbuphine|nalbuphine 5 mg epidural
214291932|NCT00707824|DRUG|nalbuphine|nalbuphine 10 mg epidural
214291933|NCT00707824|OTHER|NSS|NSS
214880154|NCT02748967|DRUG|Placebo|Participant will receive single dose of Placebo on Day 1.
214880155|NCT00094406|PROCEDURE|Bronchoscopy|
214880156|NCT00094406|PROCEDURE|Bronchoalveolar lavage|
214880157|NCT00094406|DRUG|Endotoxin|
214880158|NCT00094406|DRUG|Carbon Monoxide|
214880159|NCT04475783|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA)|PTA with an drug-coated balloon catheter (DCB) in the femoropopliteal artery
214880160|NCT03993730|DEVICE|ICD|Insertion of ICD in patients with LVEF \<45% and LGE on CMR.
214880161|NCT03993730|DEVICE|ILR|Insertion of ILR in patients with LVEF \<45% and LGE on CMR.
214880162|NCT06027385|DIAGNOSTIC_TEST|molecular-based screening|Test for three mutations in the CTNS gene and one mutation in the SMA1 gene.
214880163|NCT02185053|DRUG|CPC-201|
214880164|NCT06400277|OTHER|Edentulous maxilla final impression for complete denture|Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.
214880165|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery
214880166|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
214880167|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
214880168|NCT01462812|DRUG|Sumatriptan|Sumatriptan 20mg
214880169|NCT01462812|DRUG|Placebo|Matching placebo
214880170|NCT06536959|DRUG|PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine|"For AML patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~For MDS patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 14 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~The venetoclax starting dose is 100 mg on the first day, ramping up to 200 mg on the second day and finally 400 mg once daily. The steady daily dose (after ramp-up phase) should be reduced to 100 mg (coadministered with moderate CYP3A inhibitors or P-gp inhibitors) and 70 mg (coadministered with strong CYP3A4 inhibitors)."
214880171|NCT00471952|DRUG|Maxalt 10mg MLT plus Caffeine 75mg|One migraine attack will be treated
214880172|NCT00471952|DRUG|Maxalt 10mg MLT plus Placebo|One migraine attack will be treated with Maxalt 10mg plus placebo
214880173|NCT00471952|DRUG|Placebo + Placebo|One migraine attack will be treated with double placebo
214880174|NCT00198237|DRUG|docetaxel & capecitabine|
214880175|NCT04332887|BEHAVIORAL|Multidimensional Exercise Program|Patients in the experimental group will receive a 12-week multidimensional exercise program; patients in the control group will maintain their usual life activities.
214880176|NCT02521376|DRUG|Entospletinib|Entospletinib 100 mg tablet administered orally
214880177|NCT04105127|DEVICE|orthodontic - Anterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
214880178|NCT04105127|DEVICE|orthodontic - Posterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
214880179|NCT00006460|DRUG|hyperbaric oxygen|
214880180|NCT00006460|RADIATION|radiation therapy|
214880181|NCT02391129|PROCEDURE|Operation for Periprosthetic fractures of the hip with stem loosening|
214880182|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
214880183|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
215044931|NCT01419119|DRUG|Cholecalciferol low dose at Vitamin D deficiency|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
215044932|NCT01419119|DRUG|Cholecalciferol median dose at sufficient Vitamin D level|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
215044933|NCT03783780|DEVICE|INVSENSOR00031|Noninvasive pulse oximeter sensor
215044934|NCT01440361|DRUG|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
215044935|NCT01440361|DRUG|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
214667029|NCT01607723|OTHER|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
214880184|NCT00729573|DRUG|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
214880185|NCT00729573|DRUG|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
214880186|NCT03193073|DIAGNOSTIC_TEST|detailed echocardiography|Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
214880187|NCT03193073|DIAGNOSTIC_TEST|serum fibroblast growth factor-23|serum levels of FGF-23
214880188|NCT03193073|DIAGNOSTIC_TEST|flow mediated dilatation of forearm|superficial sonar assess the diameter of brachial vessel on exposure to stress
214880189|NCT03131544|DEVICE|MRI Guided Transrectal Periuretheral Transitional Zone Ablation|Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
214880190|NCT03844386|BIOLOGICAL|MVA.tHIVconsv3|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
214880191|NCT03844386|BIOLOGICAL|MVA.tHIVconsv4|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
215044936|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 10 mg|FDC of EZ10 mg/Ator 10mg
215044937|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 20 mg|FDC of EZ10 mg/Ator 20mg
215044938|NCT03768427|DRUG|Atorvastatin|Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
215044939|NCT03768427|DRUG|Placebo for FDC EZ/Ator|A single placebo tablet administered orally QD for 84 days
215044940|NCT03768427|DRUG|Placebo for atorvastatin|Two placebo tablets matching atorvastatin administered orally QD for 84 days
215044941|NCT03358602|RADIATION|Radiotherapy|Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
215044942|NCT03358602|PROCEDURE|Selective neck dissection|Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
215044943|NCT00499668|DRUG|aprepitant|125 mg orally for 7 days
215044944|NCT00499668|DRUG|ondansetron hydrochloride|24 mg orally for 7 days
215044945|NCT03537443|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Prenatal and postpartum supplementation with vitamin D3 and/or placebo.
214667030|NCT04952727|BIOLOGICAL|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
214667031|NCT04952727|BIOLOGICAL|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
214880192|NCT03844386|OTHER|Placebo|The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
214880193|NCT03766412|OTHER|High School start time|The time that the school starts
214880194|NCT05228535|DIETARY_SUPPLEMENT|Human milk fortifier|Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
214667032|NCT04293250|PROCEDURE|Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group|Compare postoperative pain scores for the physical activity Vs non-physical activity group
214667033|NCT04493749|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings Move ECG and ECG signal for the reference 12-lead ECG
214667034|NCT00849212|DRUG|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
214667035|NCT03584802|OTHER|Therapeutic plasma exchanges|The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
214667036|NCT03584802|OTHER|Conventional treatment of AE-IPF|Conventional treatment of AE-IPF
214667037|NCT00158977|DEVICE|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT
214667038|NCT04478422|OTHER|Muscle strengthening with vascular occlusion|The muscle strengthening group with partial vascular occlusion will perform the strengthening exercises: single leg squat on 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat. The equipment for vascular occlusion will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017). If necessary, the pressure can be adjusted at intervals and after the end of the exercise, an interval of 5 minutes is suggested for blood reperfusion.
214667039|NCT04478422|OTHER|Conventional muscle strengthening|The conventional muscle strengthening group perform the same exercises as the intervention group: One-legged squat on a 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat, however, without restriction on blood flow.
214880195|NCT03597464|DRUG|Voclosporin|Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
214880196|NCT03597464|DRUG|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
214880197|NCT01796938|DRUG|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
214667040|NCT01864135|DEVICE|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
214667041|NCT01864135|DEVICE|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
214667042|NCT01108991|BEHAVIORAL|Physical activity self-management|This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
214667043|NCT01108991|OTHER|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
214667044|NCT00095303|BEHAVIORAL|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
214667045|NCT00095303|BEHAVIORAL|Treatment as Usual|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
214667046|NCT01499576|PROCEDURE|Acetic acid chromoendoscopy|Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
214667047|NCT03953560|DIAGNOSTIC_TEST|dyspnea grade ≥ II according NYHA-WHO|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated~Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~1. Pulsioximetry.~2. Electrocardiogram.~3. Blood sample with determination of NT-ProBNP.~4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~6. Right heart catheterization \& Pulmonary CT Scan are required for confirming the diagnosis"
214667048|NCT03291327|DIETARY_SUPPLEMENT|Probiotics|Lozenges for Home use
214880198|NCT04960033|BEHAVIORAL|FRAX|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
214880199|NCT02128061|DRUG|Lenalidomide|
214880200|NCT02128061|DRUG|Rituximab|
214880201|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
214880202|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
214880203|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
214880204|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
214880205|NCT05852561|OTHER|Group Superficial+Deep Serratus Anterior Plan Block|The block will be performed after induction of general anesthesia and surgical positioning. 15 ml of 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and latissimus dorsalis muscles. The same concentration of block fluid will be applied between the serratus anterior and the outer intercostal muscle.
215044946|NCT03037125|PROCEDURE|Split Crest with PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap
215044947|NCT03037125|PROCEDURE|Split Crest without PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
215044948|NCT02710877|DEVICE|Programmed Intermittent bolus|Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.
215044949|NCT02710877|OTHER|Manual epidural bolus|Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.
214291934|NCT01240447|BIOLOGICAL|racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
214291935|NCT01240447|OTHER|Best support treatment|Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
214880206|NCT05852561|OTHER|Group Deep Serratus Anterior Plan Block|30 ml 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and outer intercostal muscle.
214880207|NCT01371383|DIETARY_SUPPLEMENT|n-3 fatty acids|EPA 1680 mg/d + DHA 880 mg/d
215044950|NCT02710877|DRUG|Levobupivacaine|Levobupivacaine 0,0625% through peridural catheter
215044951|NCT02710877|DRUG|Sufentanil 4 mcg|Sufentanil 0,4 mcg/ml through peridural catheter
215044952|NCT02710877|DRUG|Sufentanil 5 mcg|Sufentanil 5 mcg through peridural catheter
215044953|NCT03160625|DEVICE|Rate Adaptive Pacing|Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
215044954|NCT03517670|OTHER|Rhythmic tolerance|Rhythmic intolerance is defined by the occurrence of arrhythmia prompting the initiation of an antiarrhythmic medication and the need to decrease or even to stop the infusion of milrinone
215044955|NCT03517670|OTHER|Hematological tolerance|Hematological tolerance will be considered good if milrinone infusion was not interrupted owing to the occurrence of thrombocytopenia
215044956|NCT03517670|OTHER|Milrinone efficiency on cerebral vasospasm|It will be assessed using ultrasound measurements of middle cerebral arteries velocities. A decrease of at least 20% of the mean velocity or of the Lindegaard index will be considered as a significant positive effect of the treatment (including milrinone).
215044957|NCT03517670|OTHER|Milrinone efficiency using the modified Rankin scale|Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to perform all usual activities, despite certain symptoms, 2= Slight disability. Able to take care of his own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderate severe disability. Unable to meet their own physical needs without help and unable to walk without help, 5 Severe disability. Needs constant care and attention, bedridden, incontinent, 6 = Death.
215044958|NCT00784862|DRUG|Anastrozole|1mg, orally, once daily
215044959|NCT00784862|DRUG|Tamoxifen|20mg, orally, once daily
215044960|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
215044961|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
215044962|NCT00776789|OTHER|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
215044963|NCT00776789|OTHER|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
215044964|NCT04607629|BIOLOGICAL|Genolar® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
214291936|NCT00159471|DRUG|capecitabine, gemcitabine, docetaxel|
214291937|NCT04570150|DRUG|Sugammadex|Subjects who are randomized to into the sugammadex arm (Arm I) will receive sugammadex for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm II (neostigmine group).
214880208|NCT01371383|DIETARY_SUPPLEMENT|placebo|Soybean oil
214880209|NCT04243083|DRUG|TLL018 tablet, placebo|Oral QD
214880210|NCT04502420|DIAGNOSTIC_TEST|Lung function before and after surgery|A diagnostic test
214880211|NCT02111928|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
214880212|NCT00005827|DIETARY_SUPPLEMENT|genistein|
214880213|NCT01566227|OTHER|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
215044965|NCT04607629|BIOLOGICAL|Xolair® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
215044966|NCT01951664|OTHER|Baseline Study Measures|Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
215044967|NCT01951664|BEHAVIORAL|Yoga Evaluation|The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
215044968|NCT01951664|BEHAVIORAL|Yoga Program|The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
215044969|NCT01951664|BEHAVIORAL|Yoga Practice Plan|To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
215044970|NCT01951664|OTHER|Study Assessments|Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
215044971|NCT02164344|DIETARY_SUPPLEMENT|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
215044972|NCT01341743|DRUG|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
215044973|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
214291938|NCT04570150|DRUG|Neostigmine|Subjects who are randomized into the neostigmine arm (Arm II) will receive neostigmine for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm I (sugammadex group).
214291939|NCT04712305|OTHER|No intervention required|No intervention required
214291940|NCT00256893|DRUG|ropinirole|
214880214|NCT04473066|PROCEDURE|Adenotonsillectomoy +/- turbinate reduction|Tonsillectomies were performed by bipolar electrocautery while adenoidectomies were done by monopolar suction diathermy. Turbinate reduction (by either submucosal bipolar diathermy or radiofrequency) would be offered if the subject had on-going history of allergic rhinitis and examination revealed at least grade II turbinate hypertrophy. (Grade I = no turbinate hypertrophy; Grade II = turbinate hypertrophy without touching the septum; Grade III = turbinate hypertrophy touching the septum).
214880215|NCT01621477|DRUG|clofarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
214880216|NCT01621477|DRUG|cytarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
214667049|NCT04548947|PROCEDURE|Cold snare polypectomy in conjunction with a submucosal injection|The cold snare polypectomy in conjunction with a submucosal injection is a procedure during which the endoscopist resects the colorectal polyps during a colonoscopy, without any electrocautery.
214880217|NCT01621477|DRUG|busulfan|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
214880218|NCT01621477|DRUG|Plerixafor|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
214880219|NCT01621477|DRUG|cyclophosphamide|Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
214880220|NCT01621477|DRUG|antithymocyte globulin (rabbit)|Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
214880221|NCT01621477|BIOLOGICAL|stem cells|Patients undergo T cell replete Hematopoietic stem cell infusion on Day 0 and Day +1. Patients undergo natural killer (NK) cell transplantation on day +6 (Day 0 is first stem cell infusion).
214880222|NCT01621477|DRUG|Tacrolimus|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
214880223|NCT01621477|DRUG|mycophenolate mofetil|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
214880224|NCT04928079|PROCEDURE|deep brain stimulation|performing deep brain stimulation if needed
214880225|NCT04928079|DRUG|Anti-Parkinsonian Drugs|Using anti-parkinsonian drugs if needed
214880226|NCT04940559|DRUG|Danicopan - Tablet|Oral tablet.
214880227|NCT04940559|DRUG|Danicopan - Softgel|Oral softgel capsule.
214880228|NCT04940559|DRUG|Danicopan - LFC|Oral LFC.
214880229|NCT00143247|DRUG|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
215044974|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
215044975|NCT06193564|OTHER|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) A constant current of 2 mA was applied to the experimental group for 20 minutes.
214880230|NCT00340678|DRUG|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
214880231|NCT00340678|DRUG|Placebo|Treatment with placebo corresponding to each dose of losartan.
214880232|NCT06764225|OTHER|low-sodium substitute salt|This study specifically customized sodium reducing substitute salts with a sodium chloride content not exceeding 62% and without the addition of potassium chloride.
214880233|NCT06828198|DEVICE|KOS® XL|Delivery of medical device as injection
214880234|NCT07134192|PROCEDURE|Fluorescent-guided Surgery|Surgical treatment of the patient group will include the administration of a fluorescent dye and intraoperatively the resection will be aided and guided by the fluorescent signal. The wound bed will be inspected, areas with fluorescent signal will be excised and obtained separately for histopathology. Patients will receive the current post-operative standard of care for sarcoma patients
214880235|NCT07133620|DEVICE|Transcutaneous electrical acupoint stimulation|"Before the operation, the patient received transcutaneous electrical acupoint stimulation (TEAS) at bilateral Zusanli (ST 36), Neiguan (PC 6), and Ciliao (BL 32) acupoints with sterilized electrode patches. The stimulation intensity and current intensity that gave the patient an effective pricking sensation (Qi arrival) were maintained for 30 minutes. The stimulation method in the post-anesthesia care unit (PACU) was consistent with that before the operation."
214880236|NCT07133620|DEVICE|Sham transcutaneous Electrical Acupoint Stimulation|Before the operation, disinfection patches with electrodes were applied to Zusanli (ST 36), Neiguan (PC 6), and Ciliao (BL 32) acupointst, but no electrical stimulation was conducted. The stimulation method in the post-anesthesia care unit (PACU) was the same as that before the operation.
214880237|NCT06901115|PROCEDURE|Nesbit technique|it is composed of development of trough at the right prostatic lobe (at 10 o'clock) from the bladder neck proximally down to a level just above the external urethral sphincter distally, then deepening the trough until the prostatic capsule, performing haemostasias then resection of lateral lobes in halves, upper right, lower right, upper left and at last lower left respectively with haemostasias in-between. Then resection of the median lobe if present. Final haemostasias then ensues before insertion of the triple way catheter with normal saline irrigation.
214667050|NCT04283461|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
214667051|NCT05227846|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
214667052|NCT02580539|BIOLOGICAL|Group A|Peptide-stimulated T cells 2 x 10\^7/m\^2
214667053|NCT02580539|BIOLOGICAL|Group B|Peptide-stimulated T cells per dose-escalation protocol
214667054|NCT02228499|OTHER|Survey|We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
214667055|NCT05669742|DRUG|Empagliflozin|sodium-glucose transport protein two inhibitor
214667056|NCT05669742|DRUG|olanzapine|antipsychotics
214667057|NCT02495779|DRUG|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
214667058|NCT02495779|BEHAVIORAL|CBT-based counseling|Brief CBT-based counseling to promote adherence
214667059|NCT04342065|DRUG|Celecoxib capsules|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
214667060|NCT04342065|DRUG|Pregabalin 150mg|received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.
214667061|NCT01558687|DRUG|Drug (including placebo)|"Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide."
214667062|NCT01558687|OTHER|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
214667063|NCT00748657|BIOLOGICAL|Bevacizumab|Given IV
214667064|NCT00748657|OTHER|Laboratory Biomarker Analysis|Correlative studies
214667065|NCT04313946|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
214667066|NCT01213056|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Cognitive Behavioral (Active treatment condition)
214880238|NCT06901115|PROCEDURE|Corkscrew technique|the Corkscrew technique was performed by resection starting at 3 o'clock and carried on in a clockwise manner till 3 o'clock again. Prostate was resected from bladder neck downwards to the verumontanum after dividing the gland, imaginary, into 3 zones or thirds, proximal, middle and distal zone. The gland was resected zone by zone in this corkscrew manner. Once the proximal third is resected and hemostasis done, the middle third resection is done in the same manner, The process is repeated for the distal third. Hemostasis was performed instantly.
214880239|NCT06840314|DEVICE|Pelvic floor therapy|Once randomized to either the vibrating pelvic floor massage arm or the traditional vaginal dilator arm, they will receive instructions on frequency of device use and will use manufacturer's instructions for specifics of device use. We will not dictate more specific instructions on use, nor is this standard of care, as every patient is unique and will need to retain autonomy in terms of how quickly they progress in the use of the product. They will then complete a survey at 4 weeks which includes measures of sexual function and pelvic pain, as well of global impressions of improvement in their symptoms.
214880240|NCT06352593|DRUG|Intraoperative Dexmedetomidine|Patients will be administered DEX 0.5 μg/kg for 10 min and then 0.4 μg/kg/h adjusted to 0.2-0.6 μg/kg/h.
214880241|NCT06352593|OTHER|Placebo|Patients will receive normal saline.
214880242|NCT04734405|DRUG|Prof-001|Prof-001 cream
214880243|NCT04734405|DRUG|Fluconazole 150 mg|Fluconazole capsule
214880244|NCT04734405|DRUG|Placebo cream|ointment base to mimic Prof-001
214880245|NCT04734405|DRUG|Placebo capsule|encapsulated lactose powder to mimic 150 mg fluconazole capsule
214880246|NCT07133581|OTHER|FEXO (Fun Exercise for Older Adults)|A 14-week supervised multicomponent playful exercise program for institutionalized older adults. It consists of 3 sessions per week (55-60 minutes), including aerobic, strength, balance, flexibility, and gait exercises in a group-based, game-like setting. The structure includes 2 weeks of familiarization followed by 3 progressive 4-week levels. The intervention aims to improve intrinsic capacity, reduce frailty, and enhance physical and cognitive function.
214880247|NCT07133672|OTHER|Exercise|Exercise sessions will begin with flexibility exercises targeting the shoulder and neck regions. This will be followed by breathing exercises utilizing fundamental respiratory techniques. Extremity exercises will include movements focused on the upper extremities and trunk, with progression applied according to a pre-established plan. Each session will conclude with cool-down exercises. Additionally, patients will be encouraged to engage in regular walking on a weekly basis.
214880248|NCT07133672|OTHER|Standard care|Patients will receive education regarding the critical aspects to consider after hospital discharge. Standard postoperative care protocols will be implemented.
214880249|NCT07134712|BIOLOGICAL|Cord Blood Nucleated cells|MiSaver will be administered via peripheral intravenous injection. Based on dosage, the experimental group will be divided into two subgroups: 0.5 × 10⁷ or 1.6 × 10⁷ nucleated cells per kilogram of patient body weight.
214880250|NCT07134062|OTHER|Bridge technique MWM|Patient in supine, head resting on a pillow, cervical spine relaxed in a neutral position, physiotherapist sitting or standing at the head of the table. Hands support both sides of the head through the thenar eminence on each side, fingers in contact with the C7, T1or T2 articular pillar bilaterally.
214880251|NCT07134062|OTHER|Dry Needling|Participants in this group received two sessions per week of D.N. treatment for the trapezius muscle.
214880252|NCT07133490|DRUG|intraperitoneal chemotherapy|Through a peritoneal access port, irinotecan will be administered at the same time as systemic (chemo)therapy
214880253|NCT07133854|DIAGNOSTIC_TEST|Imaging PET/MRI|"MRI using 1H-MRS and Dixon sequences on a 3 T clinical MRI system (Ingenia, Philips Healthcare, Best, the Netherlands) will be performed.~\[11C\]-palmitate: 1 x i.v. injection of 175 MBq followed by TEP imaging. \[18F\]-FTHA: oral administration of 75 MBq followed by TEP imaging."
214880254|NCT07133854|DIAGNOSTIC_TEST|Stable isotope infusions|"\[6,6 D2\]-glucose infusion (0.22 µmol/kg/min, preceded by a bolus of 22 µmol/kg) will start from -180 until time + 360.~\[1,1,2,3,3-2H\]-glycerol (0.05 µmol/kg/min.) and of \[7,7,8,8-2H\] palmitate (0.01 µmol/kg/min) will start from time -60 until time +360."
214880255|NCT07133854|DIAGNOSTIC_TEST|meal test|A liquid meal will be administered at time 0. The liquid meal (400 ml) energy breakdown is 50% (101g) from glucose, 33% (31g) from fat, and 17% (40g) from protein; participants will consume the 400 ml in 4 aliquots of 100 ml over 20 min, supplemented with 0.9 g of U-\[13C\]-glucose and 9 μmol/kg lean mass of \[U-13C\]-palmitate.
214880256|NCT07133854|DIAGNOSTIC_TEST|Indirect calorimetry|Indirect calorimetry (Vmax Series from Vyaire medical, licence # 22536), measured during10 minutes, every hour.
214880257|NCT07134894|BEHAVIORAL|Intensive Bimanual Therapy plus Conventional Physical Therapy|A combined rehabilitation program delivered over 8 weeks, three sessions per week. Each 60-minute session includes 30 minutes of Conventional Physical Therapy (CPT) to improve range of motion, muscle strength, balance, and gross motor function, and 30 minutes of Intensive Bimanual Therapy (IBT) to enhance bilateral hand coordination and functional independence. IBT tasks progress from basic grasping and object transfer to complex daily activities such as buttoning, puzzle assembly, water pouring, and feeding with utensils. Two sessions are supervised by a physiotherapist and one is completed at home under caregiver guidance.
214880258|NCT07134894|BEHAVIORAL|Conventional Physical Therapy|A standard physiotherapy program delivered over 8 weeks, three sessions per week, each lasting 40 minutes. Sessions focus on upper limb range of motion, strengthening, postural control, and functional mobility without targeted bimanual training. Exercises include assisted stretches, squats, heel raises, step-ups, knee lifts, yoga-based poses, animal walks, single-leg stance, and stair climbing to promote flexibility, balance, and gross motor performance. Two sessions are supervised by a physiotherapist and one is performed at home with caregiver supervision.
214880259|NCT07134036|DEVICE|Navigation system|Patients underwent total hip arthroplasty via the direct anterior approach using a computer navigation system to assist in intraoperative limb length measurement.
214880260|NCT07134036|PROCEDURE|Conventional total hip arthroplasty|Patients underwent total hip arthroplasty via the direct anterior approach conventionally.
214880261|NCT07133425|DRUG|SAR445877|Given by IV
214880262|NCT07135011|DEVICE|Primary gluteal enhancement|120 participants will undergo primary buttock enhancement procedures utilizing the Ergonomix2® Diamond®, Motiva Injector®, Motiva® Inflatable Balloon, Motiva® Reusable Channel Dissector, and Motiva® GEM Channel Separator devices.
214880263|NCT07135193|DIETARY_SUPPLEMENT|Cordyceps cicadae|Cordyceps cicadae 500mg
214880264|NCT07135193|DIETARY_SUPPLEMENT|Blank control|Blank control
214880265|NCT07133919|BEHAVIORAL|AI-Assisted Child-Friendly Communication|"AI-assisted communication tailored to the developmental stage, age, and gender of children aged 7-12 will be used. Using ChatGPT, voice recordings explaining the local anesthesia process in a child-friendly and reassuring way-avoiding anxiety-provoking terms such as pain and needle-will be prepared. Additionally, a one-minute calming and distracting story will be generated to be played during anesthesia to reduce anxiety and improve cooperation. Children will listen to the AI-generated explanation before the procedure and the story during anesthesia."
214880266|NCT07133919|BEHAVIORAL|Traditional Behavior Management Techniques|"Before local anesthesia, traditional behavior management techniques will be applied by the pediatric dentist based on clinical experience. These include a modified Tell-Show-Do approach (avoiding direct exposure to anxiety-provoking items like dental syringes), voice control, and positive reinforcement. The anesthesia procedure will be explained verbally in an age-appropriate and reassuring manner, for example by describing the use of a magic sleepy spray to numb the tooth. Following this, topical anesthesia and then local anesthesia will be administered. The total procedure will not exceed 5 minutes."
214880267|NCT07134777|DIAGNOSTIC_TEST|MRI|Functional MRI scan
214880268|NCT07133841|DIAGNOSTIC_TEST|Pre-Season Assessments|Pre-Season Assessments including performance based tests and thermal imaging.
214880269|NCT07135141|DRUG|Sleeve gastrectomy plus early mazdutide initiation|After sleeve gastrectomy is preformed, mazdutide injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week at 5th month post procedure. The treatment begins with a starting dose of 2.0 mg, followed by a titration schedule increasing by 2.0 mg every 4 weeks (2.0 mg → 4.0 mg). If well-tolerated, participants reached the target maintenance dose of 6.0 mg (4.0 mg → 6.0 mg)weekly for maintenance. The protocol permits adaptive dose downgrade to 4.0 mg weekly when clinically indicated, such as intolerance. The total intervention is maintained until 48 weeks post procedure.
214880270|NCT07135141|DRUG|Sleeve gastrectomy followed with early mazdutide placebo initation|After sleeve gastrectomy is preformed, mazdutide placebo injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week at 5th month post procedure. The treatment begins with a starting dose of 2.0 mg placebo, followed by a titration schedule increasing by 2.0 mg every 4 weeks (2.0 mg → 4.0 mg). If well-tolerated, participants reached the target maintenance dose of 6.0 mg placebo(4.0 mg → 6.0 mg) weekly for maintenance. The protocol permits adaptive dose downgrade to 4.0 mg weekly when clinically indicated, such as intolerance. The total intervention is maintained until 48 weeks post procedure.
214880271|NCT07134517|OTHER|Pilates exercise|The principles of centering, concentration, breathing, control, flow, and precision in the Pilates method will be explained to participants. Pelvic floor activity and lateral breathing will be taught and practiced, along with neutral spine alignment. The first and last 5 minutes of each session will consist of stretching exercises. Stretching exercises will begin with 3-5 repetitions, while strengthening and stabilization exercises will start with 6-8 repetitions, with the number of repetitions increasing each week based on participants' tolerance. Springs are attached according to the purpose and difficulty level of the exercises. Stretching exercises are performed with lighter resistance springs, while strengthening and stabilization exercises are performed with higher resistance springs. All movements will be demonstrated and explained to ensure the exercises are performed correctly. Verbal cues will be given for breath control and centering.
214880272|NCT06934564|BEHAVIORAL|Active de-Implementation|During active de-implementation (3 months), the local team will distribute the strategy components (i.e., clinician education, decision support, evaluation, consensus building around perioperative testing pathways, facility-specific feedback, and a pay-for-performance incentive) at the local site.
214880273|NCT01288144|OTHER|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
214880274|NCT04399044|PROCEDURE|Prophylactic muscle flap|"A muscle flap refers to taking an expendable muscle with its vascular supply and moving it to a new area. In this case, the investigators will take a muscle from the leg or abdomen that is redundant (other muscles perform the same function) and moving it to cover vascular grafts to provide healthy tissue to prevent infection."
214880275|NCT06937593|DRUG|VIS954|A humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
214880276|NCT06937593|DRUG|Placebo|VIS954 Placebo
214880277|NCT05529667|DRUG|INCB054828, Paclitaxel|"phase 1\>~\- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2\> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent."
214880278|NCT06953154|DIAGNOSTIC_TEST|monocyte distribution width|We compare the measured value with the MDW threshold value already established in the literature and its correlation with the SOFA score, qSOFA, lactate, and PVI in terms of sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV).
214291941|NCT01650623|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
214880279|NCT06514742|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
214880280|NCT06514742|OTHER|Placebo|Placebo tablet will be administered orally.
214880281|NCT03424122|DRUG|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
214880282|NCT03424122|DRUG|Rituximab|Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
214880283|NCT03424122|DRUG|Bendamustine|Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
214880284|NCT03424122|DRUG|Ibrutinib|Ibrutinib administered orally once daily.
214880285|NCT04951700|OTHER|Other|This is not an intervention study
214880286|NCT06829563|DRUG|RZ-629|Administered orally
214880287|NCT06829563|DRUG|Placebo|Administered orally
215044976|NCT06193564|OTHER|Cervical Stabilization Exercises|"Before initiating the stabilization exercises, individuals included in the study were instructed on correct postural alignment. Cervical chin tuck movement was taught during the exercise along with postural alignment and craniocervical flexion movement was requested. After teaching craniocervical flexion exercises in all positions (supine, lying on the side, prone, crawling, sitting, and standing), participants were instructed to perform the movement slowly.~The purpose of this phase was to establish the relationship between vision and motor learning using the Pressure Biofeedback Stabilizer device. The device was positioned on the neck area and inflated to 20 mmHg. The pressure level gradually increased in 2-mmHg increments from 20 to 30 mmHg. For each pressure value (22, 24, 26, 28, 30 mmHg), participants were asked to maintain craniocervical flexion for 10 seconds, and this exercise was repeated ten times."
215044977|NCT06193564|OTHER|Sham-Transcranial Direct Current Stimulation (tDCS)|tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) (Figure 2). As shown in the figure, a constant current of 2 mA was applied to the experimental group for 20 minutes. For the sham group, electrodes were placed in the same areas and a current of 0 mA was applied.
215044978|NCT02742129|DRUG|Nebulized Sodium Nitrite|Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
215044979|NCT02742129|DRUG|Placebo|Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
215044980|NCT02448966|PROCEDURE|open esophagectomy|
215044981|NCT02448966|PROCEDURE|Minimally invasive esophagectomy|
215044982|NCT02747758|DEVICE|cathodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
215044983|NCT02747758|DEVICE|sham transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.
215044984|NCT02747758|DEVICE|anodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
215044985|NCT02527395|OTHER|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
214880288|NCT06829563|OTHER|Fasted|Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout
214880289|NCT06829563|OTHER|Fed|Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout
214880290|NCT05919160|DEVICE|DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task|Devices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab)
214880291|NCT05825573|DRUG|Vitamin K antagonist|VKA study medications (Warfarin, Fluindione and Acenocoumarol) will be prescribed and supplied in the usual setting of patient care with respect of the international guidelines and recommended dose protocols and will not be specifically supplied for the trial. Anticoagulant treatment will be prescribed for 6 months. The recommended INR target will be \[2-3\] and \[2-2.5\] for patients treated with concomitant antiplatelet therapy. Biological monitoring will be performed at discretion of physicians as usual care.
214880292|NCT05825573|DRUG|Direct oral anticoagulant|DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care and will not be specifically supplied for the trial. The usual doses of DOA will be prescribed: dabigatran 150mg twice a day, apixaban 5mg twice a day and rivaroxaban 20mg once a day. The adjusted doses (dabigatran 110mg twice a day, apixaban 2.5mg twice a day and rivaroxaban 15mg once a day) will be prescribed according to clinical practice treatment guidelines.
214880293|NCT05133726|OTHER|Text4Support|Daily supportive text messages
214880294|NCT05133726|OTHER|Peer support|Meeting with peers who have lived experiences with similar diagnoses but are in recovery
214880295|NCT00588068|OTHER|Tumor and Marrow Markers|Tumor and Marrow Markers
214880296|NCT06484491|RADIATION|Dose-escalated intensity-modulated proton therapy (IMPT-74)|Heterogeneous simultaneous integrated boost of 74.0 Gy (RBE) to primary tumor \>15mm away form mediastinal envelope, and 64.0 Gy (RBE) to primary tumor =\< 15mm away from mediastinal envelope. The rest of the clinical target volume, including affected lymph nodes, receives 60.0 Gy (RBE).
214880297|NCT06484491|DRUG|Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy|"Induction course:~-Cisplatin (75 mg/m2) or carboplatin (AUC 6) + pemetrexed (500mg/m2).~Concurrent chemoradiotherapy:~* Weekly cisplatin (20mg/m2) + docetaxel (20mg/m2) on Mondays.~* Radiotherapy will be given for 5x5 days."
214291942|NCT01650623|BEHAVIORAL|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
214667067|NCT05270603|OTHER|ICARUS intraoperative adverse events calculator|"The ICARUS calculator is a web-based tool that uses answers to Boolean, yes/no questions to determine the iAE grade (appendix I). The calculator providers iAE grade outputs for the 5 iAE classification systems.~https://garnmile.com/iaecalc/~Development of the ICARUS calculator was performed as follows: Referencing the 5 classification systems, we first assembled a list of Boolean questions based on the iAE grade descriptions. This list was distilled to the minimum number of questions necessary to represent all descriptions in the combined list of iAE grades. Next, these questions were used to independently establish the conditional logic required to determine iAE grade for each classification system. The questions and logic were translated into Hypertext Preprocessor (PHP), a server-side programming language, and JavaScript, a client-side scripting language."
214667068|NCT01416311|DRUG|Eltrombopag|
214880298|NCT06484491|DRUG|Immunotherapy: adjuvant durvalumab|"Adjuvant treatment will be given starting 1-6 weeks after chemoradiotherapy if no progression, good performance (PS 0-1), no other contra-indication for immunotherapy.~Doses:~* Start durvalumab 10 mg/kg 1x/14 days.~* If possible after 2 courses switch to 1500 mg flat dose 1x/4 wk.~* Continue for 12 months in total."
214880299|NCT06170944|DEVICE|Remote ischemic preconditioning|The patients in experiment group will receive treatment with RIC (5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg) for 1 year as an adjunct to guideline-based treatment.
214880300|NCT02836522|BEHAVIORAL|Assessment of Health-Related Quality|Demographic Questionnaire, ANCHOR HRSI, FACT-G, MDASI, Patient ECOG PS, PGIC
214880301|NCT03134248|DEVICE|Dailies Aquacomfort Plus Toric|daily disposable contact lens
214880302|NCT03134248|DEVICE|1-Day Acuvue Moist for Astigmatism|daily disposable contact lens
214880303|NCT03134248|DEVICE|MyDay Toric|daily disposable contact lens
214880304|NCT05204706|OTHER|MyManis app|The women will receive a brochure outlining the app features and step guide on how to download the app which will be available in both Bahasa Melayu and English languages. A link to download the app via text message will also be sent to participants for convenience. Once the app has been downloaded, participants will be invited to set up an account. Once completed this will give them full access to the MyManis app. The key component of MyManis app content presented under six main tabs which are homepage, information, diet, exercise, wellbeing and GDM monitoring. The women will be invited to join group peer support through WhatsApp facilitated by a dietitian trained in motivational interviewing. The women will be notified via text message if an update of the app is required. If there's women who have not accessed the app for over a two-week period will be flagged and a notification will be sent via the app to motivate app engagement.
214880305|NCT01762800|DRUG|fluticasone propionate/salmeterol 50/250mcg|Active, 50/250mcg, Twice daily (morning and evening)
214880306|NCT01762800|DRUG|fluticasone propionate/salmeterol placebo|Placebo, Twice daily (morning and evening)
214880307|NCT01762800|DRUG|tiotropium bromide 18mcg|Active, 18mcg, Once daily(morning)
214880308|NCT01762800|DRUG|tiotropium bromide placebo|Placebo, Once daily(morning)
214880309|NCT01762800|DRUG|fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg|Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
214291943|NCT02281461|DEVICE|Male circumcision using a non-surgical device|Male Circumcision
214291944|NCT00261664|DEVICE|telehomecare|
214291945|NCT05585697|OTHER|None - crossectional|None - crossectional
214667069|NCT02739464|OTHER|Exercise + SOC PT/OT|
214667070|NCT02739464|OTHER|SOC PT/OT|
214667071|NCT02279511|DRUG|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
214880310|NCT03015987|OTHER|diode laser activated irrigation|diode laser became the most common and affordable type of laser used in endodontics for many uses , its disinfection effect is an important issue which not discussed in clinical trial before , So this study is assigned to study that
214880311|NCT01153100|DRUG|Glargine|Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
214880312|NCT00478062|BIOLOGICAL|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
214880313|NCT00478062|PROCEDURE|adjuvant therapy|
214880314|NCT06140446|DEVICE|FeverApp|The (self-management) FeverApp contains evidence-based information about fever and how to deal with it, tailored (phase-oriented) fever advices, and the option to monitor the health status of the child during a fever episode. All information and advices are based on the clinical expertise of paediatricians and the most recent international literature on fever, and complement the Dutch national fever guidelines. It is expected that by letting the body fight the infection on its own in a safe way, less ABs are needed, and the immune system will get stronger leading to less future infections as well.
214880315|NCT06140446|DEVICE|DMT App|The (self-care) DMT App is a decision making tool (DMT) that can be used by parents to choose a safe and effective herbal medicine (HM) product to reduce symptoms of mild, acute uncomplicated URTIs in their child. The advices that the DMT App provides, are based on a systematic review (SR) of SRs on effectiveness of HM for URTIs, a SR on working mechanisms of the most promising herbs, a prescription rates study of HM for URTIs in 6 European countries, and current EMA status of the included herbs. No prescription from a doctor is needed for these products.
215044986|NCT02527395|OTHER|Pain during 1 min. thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
215044987|NCT02527395|OTHER|Heat pain detection threshold|The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
215044988|NCT03394989|DRUG|Fluticasone propionate/salmeterol 100/50 µg|Test Arm: Dry powder inhaler
215044989|NCT03394989|OTHER|Placebo|Placebo
215044990|NCT03394989|DRUG|Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT|Comparator Arm: Dry powder inhaler
215044991|NCT04509258|DRUG|N-acetyl cysteine|a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care
215044992|NCT04509258|DIETARY_SUPPLEMENT|acetyl L-carnitine|Naturallu occuring amino acid derivative which can be taken as a dietary supplement involves in mitochondrial function and energy production and is suggested to have a role in lowering organ damage resulting from aluminium phosphide poisonong in addition to sodium bicarbonate and ondansetron as standard of care
214291946|NCT00725023|DEVICE|TDP© Lamp|TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
215044993|NCT04509258|DRUG|medicated paraffin oil|refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care
215044994|NCT04509258|DRUG|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
215044995|NCT02390492|DRUG|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study
215044996|NCT02390492|DRUG|Period 2 treatment|200-mg/100-mcCi oral \[14C\]-ipatasertib on Day 15 of study
214291947|NCT00725023|DEVICE|Dummy TDP© Lamp|The dummy TDP© heat lamp is an electrical device with the heating element removed.
214291948|NCT04061915|BEHAVIORAL|Infographic Intervention|The intervention consists of participants viewing an HIV self-testing infographic.
214291949|NCT04061915|BEHAVIORAL|Paper-based HIV self-testing information|The control arm will read paper-based HIV self-testing instructions.
214291950|NCT06434844|PROCEDURE|Auricular acupunctures|After disinfection of the external ear with 75% alcohol wipes, 018x 13 filiform needles (Mocm International Limited) will be used to perform the auricular acupunctures at the relaxation point, tranquilizer point and master cerebral point at the left and right external ears.
214291951|NCT06434844|PROCEDURE|Sham acupunctures|The auricular acupoints of finger, shoulder and tonsil will be targeted instead. These points are also located at the external ear and comparable to those in the intervention group. The external ear will be disinfected with 75% alcohol wipes. Auricular acupunctures with 018x 13 filiform needles (Mocm International Limited) will be carried out at the finger point, shoulder point and tonsil point of the left and right external ears.
214667072|NCT02279511|DRUG|PLACEBO|Infusion of 500 mL of saline solution. (IV)
214667073|NCT00397150|BEHAVIORAL|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
214667074|NCT00002365|DRUG|LXR015-1|
214667075|NCT05850377|DRUG|5-Aminolevulinic Acid (5-ALA) Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.
214667076|NCT05850377|PROCEDURE|Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)|During the surgical exploration of the glioma, the neurosurgeon will attempt to identify the mass. The location of the tumor will be assessed using the blue-light filtered microscope. A biopsy of the fluorescent region will be taken to confirm the glioma subtype. The tumor will then be maximally resected.
214667077|NCT04375878|DRUG|MS1819|MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
215044997|NCT00518050|BEHAVIORAL|Focus group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~* Screening, skin self-examination, sun protection, and other cancer preventive practices;~* Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~* Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
215044998|NCT00518050|BEHAVIORAL|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
215044999|NCT03710356|DRUG|Danazol 200 MG|DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
215045000|NCT00002372|DRUG|Indinavir sulfate|
215045001|NCT00002372|DRUG|Amprenavir|
215045002|NCT00002372|DRUG|Nelfinavir mesylate|
215045003|NCT00002372|DRUG|Saquinavir|
215045004|NCT02959788|OTHER|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
215045005|NCT04299386|DEVICE|NeoPhylaxis|NeoPhylaxis® gel is designed for the non-surgical decontamination of the implant surface and can be used for professional regular implant maintenance, with or without peri-implant mucositis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in non-sterile form.
215045006|NCT04299386|DEVICE|ImplanTreat|ImplanTreat® gel can be used for the surgical decontamination of the implant surface and can be used to decontaminate implants with peri-implantitis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in sterile form.
214880316|NCT04209283|BEHAVIORAL|Visuospatial interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
214880317|NCT02111603|DRUG|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
214880318|NCT05931653|OTHER|Multimodal Physical therapy|• Multimodal Physical therapy: Hot pack for 15 mins, TENS for 15 mins, Ultrasound at 1.5 W/cm2 intensity for 5 mins, Soft tissue release for \<5-15 mins as per need, HVLA, PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets, Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets). 03 days/week for 06 weeks.
215045007|NCT02775266|OTHER|Alpha lipoic acid|Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.
215045008|NCT02775266|PROCEDURE|Scaling and Root planing|Scaling and root planing will be done at baseline.
215045009|NCT02008643|OTHER|filling questionnary to quality of life|filling questionnary to quality of life
215045010|NCT01880190|OTHER|Ringer's Lactate|
215045011|NCT01880190|OTHER|HES 130/0.4 and Ringer's Lactate|
215045012|NCT04849273|DRUG|TPX-0131|Oral TPX-0131 tablets
215045013|NCT01604460|PROCEDURE|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
215045014|NCT01604460|PROCEDURE|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
215045015|NCT03304366|DIAGNOSTIC_TEST|Pentacam (scheimpflug imaging)|Corneal changes including thickness, elevations....etc
215045016|NCT02873078|BEHAVIORAL|Internet-delivered Cognitive behavior therapy|The treatment is delivered via an online platform and is based on interventions for adults, adolescents and children tested in previous trials. Therapists are CBT-psychologists och students in clinical psychology under supervision.
215045017|NCT03225404|OTHER|Epte group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
215045018|NCT03225404|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
214667078|NCT04375878|DRUG|Porcine PERT|Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.
214667079|NCT03659435|DRUG|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
214667080|NCT03659435|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
214667081|NCT00428363|DEVICE|Cataract surgery with implantation of an intraocular lens|
214667082|NCT04744558|OTHER|Low carb high fat ketogenic dieting|Macronutrient ratios for low carb high fat ketogenic diet were 20 %, 5 %, 75 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
215045019|NCT02803684|OTHER|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
215045020|NCT02874092|DRUG|Ticagrelor|
215045021|NCT02874092|DRUG|MTX therapy|
215045022|NCT03582579|BEHAVIORAL|Training in Virtual Reality|Action Video Game Based Training in Virtual Reality
215045023|NCT03582579|BEHAVIORAL|Training on a computer screen|Action Video Game Based Training on a computer screen
215045024|NCT06187857|BEHAVIORAL|Ecologically Oriented Neurorehabilitation of Memory (EON-Mem)|Feasibility study of a virtually-delivered adaptation of an ecologically oriented neurorehabilitation of memory (EON-Mem) in improving memory for healthy older adults
215045025|NCT02286063|DRUG|Ambulatory Oxygen|"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."
215045026|NCT03499756|BEHAVIORAL|Couple-based interpersonal psychotherapy|The contents include: (1) an overview of changes associated with the role transition of parenthood and an introduction to the coping skills relating to role transition and parenting; (2) discussing common postpartum and interpersonal difficulties, such as conflicts with partners or extended family, and teaching effective communication skills to resolve interpersonal conflicts and maintain a good interpersonal relationship; and (3) building family strengths and resources by enhancing family sense of coherence, such as reassessing the challenges of the new role, applying problem solving techniques to deal with role transition and interpersonal problems, and developing new social support.
215045027|NCT05663060|DRUG|Probiotic Formula|Probiotic Formula
214880319|NCT05931653|OTHER|Proprioceptive training along with and Multimodal Physical therapy|"* Multimodal Physical Therapy: Hot pack-5 mins, TENS-5 mins, U.S (1.5 W/cm2)-5 mins, Soft tissue release-\<5-15 mins, HVLA, PA Glides (Central and Transverse)-10 sec each 5 sets, Lumbar facet gapping-10 sec 3 sets and Lumbar rotational facet gapping-10 sec 3 sets. 3 days/week for 6 weeks.~* Proprioceptive Training:1. Trunk Balance (15 mins). In sitting, kneeling, quadruped, and supine positions for 30 seconds to 2 minutes. Progression to more challenging. Each will be performed for 2-3 mins. In case of pain exercise will be interrupted and substituted with another one.~  2\. PNF Training (10-12 mins). Each PNF training-1 set of 15 reps with 30s rest between and 60s after 15 reps. Week 1-2 alternate full isometrics of trunk flexors and extensors for 10s in sitting. Week 3-4, 5s resisted concentric, 5s eccentric and 5s isometrics contractions in forward and backward bending. Week 5-6, alternate chop and lift movement patterns of upper extremities in diagonal and spiral directions for 10s."
214880320|NCT04495335|DEVICE|photobiomodulation|Laser treatment will complete using Gallium-Aluminum-Arsenide (GaA1As) diode laser and application will complete by laser energy immediately and three times a week for just 15 days after surgery.
214880321|NCT02827695|BEHAVIORAL|SMASK|Medication adherence and BP monitoring
214880322|NCT02827695|BEHAVIORAL|EnhancedSC|Standard care without med reminder functions with healthy lifestyle texts
214880323|NCT00437918|DRUG|nateglinide|
214880324|NCT00437918|DRUG|acarbose|
214880325|NCT01867203|OTHER|Genotyping|DNA extraction from blood
214880326|NCT04272749|BEHAVIORAL|Assess opinons on the milk beverages|Questionnaires and consumption behaviors of dairy and non-dairy milks, including whole, 2% fat, 1% fat, skim, unsweetened almond, sweetened almond, unsweetened coconut, sweetened coconut, unsweetened soy, sweetened soy, unsweetened rice, and sweetened rice.....
215045028|NCT02693756|OTHER|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
215045029|NCT03780257|DRUG|QR-421a|RNA antisense oligonucleotide for intravitreal injection
215045030|NCT03780257|OTHER|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
215045031|NCT03810976|DRUG|Eribulin, gemcitabine|Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1\& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1\& Day 8 every 3 weeks
215045032|NCT01974284|DRUG|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
215045033|NCT00677794|DRUG|Clear fluids|Clear fluids only after lunch.
215045034|NCT00677794|DRUG|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
215045035|NCT00677794|DRUG|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
215045036|NCT03986957|OTHER|No interventions|No interventions - observational study
215045037|NCT02194413|PROCEDURE|therapeutic touch|receiving healing touch
215045038|NCT02194413|OTHER|quality-of-life assessment|Ancillary studies
215045039|NCT02194413|OTHER|questionnaire administration|Ancillary studies
215045040|NCT01777867|PROCEDURE|Cough Reflex Sensitivity|Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
215045041|NCT01777867|PROCEDURE|Methacholine Challenge|A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
215045042|NCT02629861|DRUG|Fremanezumab|"Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site."
215045043|NCT02629861|DRUG|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
215045044|NCT03722979|PROCEDURE|Cardiac surgery|The study will enroll patients having a planned cardiac surgery under extracorporeal circulation (CEC)
215045045|NCT00685061|DRUG|Thymoglobulin|Induction
214667083|NCT04744558|OTHER|Low carb high fat non-ketogenic dieting|Macronutrient ratios for low carb high fat non-ketogenic diet were 20 %, 15 %, 65 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
214667084|NCT04355286|DRUG|Bemotrizinol|Market-image topical sunscreen formulation containing BEMT (6%)
214880327|NCT00979199|OTHER|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
214880328|NCT04204057|DRUG|Tenalisib|Tenalisib 800 mg BID, Orally
215045046|NCT00685061|DRUG|Campath-1H|Induction
215045047|NCT00685061|DRUG|Daclizumab|Induction
215045048|NCT01090947|DEVICE|ProtoCAD|Aquiring acoustic signals from heart patients.
215045049|NCT05225909|DEVICE|Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope|ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
215045050|NCT01272427|DIETARY_SUPPLEMENT|water with glucose|0.75 g/kg body weight of glucose added to water
215045051|NCT01272427|DIETARY_SUPPLEMENT|water and whey protein|0.75 g/kg body weight of whey protein added to water
215045052|NCT01272427|DIETARY_SUPPLEMENT|water with noncaloric sweetener|0.15 g of sucralose added to water
214880329|NCT04063150|BIOLOGICAL|fIPV (0.1 mL) ID|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.
214880330|NCT04063150|BIOLOGICAL|fIPV (0.1mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
214880331|NCT04063150|BIOLOGICAL|fIPV (0.2mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
214880332|NCT04063150|BIOLOGICAL|IPV|Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
214880333|NCT05597150|DIETARY_SUPPLEMENT|Magnesium Citrate|Each participant should receive a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.
214880334|NCT02735538|PROCEDURE|osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head will undergo total hip replacement.
214880335|NCT02735538|PROCEDURE|osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement.
214880336|NCT00529139|DEVICE|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
214880337|NCT00529139|DEVICE|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. \<90 mg/dL (\<15 mmol/L)
214880338|NCT06172634|DRUG|dentritic cell infusion and immunecheckpoint inhibitor|dentritic cell infusion and immunecheckpoint inhibitor
214880339|NCT04271917|DRUG|cannabidiol|Use of cannabidiol as an alternative to standard of care treatment of acute pain.
214880340|NCT04271917|DRUG|placebo|Inactive placebo oil to imitate CBD oil
214880341|NCT04271917|DRUG|acetaminophen 500mg and ibuprofen 200mg combo|standard of care
214880342|NCT06349941|DEVICE|Movn app|Participants will have 12-week home-based exercise program delivered via a commercially available home-based cardiac rehabilitation platform called Movn. The plan includes an accelerometer, blood pressure scale, and mobile application.
214880343|NCT06349941|DEVICE|Accelerometer|Participants will receive a FitBit for monitoring of physical function.
215045053|NCT03627702|RADIATION|Irradiated VIP (Visible Incoherent Polarized)|20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
214667085|NCT02512796|DRUG|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
214880344|NCT05526755|DRUG|Osimertinib 80 mg/40 mg|Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
214880345|NCT02458209|BIOLOGICAL|bococizumab PFS:Pfizer|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
214880346|NCT02458209|BIOLOGICAL|bococizumab PFS: BIP|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
214880347|NCT02458209|BIOLOGICAL|bococizumab PFP|150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
214880348|NCT04733261|OTHER|Diaphragmatic mobility|Therapist will manually make contact with Pisiform Hypothenar region and last three fingers among the underneath the costal cartilage of the 7th in the direction of 10 ribs. For the duration of participant's inhalation, the counselor drag softly within a upward course accompany the increase motion of the ribs. For the period of expiration, the counselor will deepens make contact with in the direction of the internal costal border. Taking place consequent breathing, the counselor wanted on the way to expand traction as well as slickly make deeper the contact.
214880349|NCT04733261|OTHER|Chest Physiotherapy|Patients allocated to the control group and interventional group received pulmonary rehabilitation two times a day beginning happening the day of entrance on the way to the intensive care unit. It consists of side-lying positioning with the head of the bed horizontal for at least 20 min with the most affected lung on chest x-ray positioned uppermost is also known as postural drainage, 4 sets of 6 cycles of expiratory chest wall vibrations , and airway suctioning at least three times through the endotracheal and tracheotomy tube disperse in the course of the management
214880350|NCT01753297|DRUG|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
215045054|NCT01685684|DRUG|Oxycodone DETERx|40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
215045055|NCT01685684|DRUG|Placebo|Placebo, divided into 2 doses, q12h
214667086|NCT03677570|DIAGNOSTIC_TEST|postural stability|Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
214880351|NCT04687683|OTHER|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions. This stretching exercise will be applied in 5 repetitions for one session.
214667087|NCT03280212|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets.
214667088|NCT03550690|DEVICE|Large Volume Paracentesis|Insertion of a plastic tube into the abdomen and draining off ascitic fluid under local anaesthetic, removing the drain afterwards
215045056|NCT00907621|PROCEDURE|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
215045057|NCT00606489|DRUG|Caldolor|800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
215045058|NCT00606489|DRUG|Placebo|Placebo
214291952|NCT04855097|DIAGNOSTIC_TEST|BVA-100|The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.
214291953|NCT00531999|DRUG|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
214880352|NCT04687683|OTHER|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions for one session.
214880353|NCT04687683|OTHER|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions for one session.
214880354|NCT01346787|DRUG|CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE|Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
214880355|NCT06423092|OTHER|Music therapy songwriting|"Session 1: The goal of the first music therapy session is to know the parents musically and to provide information about song creation. This is achieved by exploring their favorite songs. Options for creating a song (original song or song parody) are presented and possibilities for creating lyrics are discussed.~Sessions 2-7: The structure of the song will be created and discussed with the parents. Parents will also be invited to include written messages from other family members in the lyrics if they wish. In each session, the developing welcome song is sung together with the parents, accompanied by the music therapist, who provides vocal or instrumental support.~The final sessions (Sessions 8-9) are dedicated to singing the final version of the song with the parents and their infant. Should the parents desire, a final recording of the song will also be made and the digital songbook will be created."
214880356|NCT00878176|PROCEDURE|First stage tined lead procedure|bilateral first stage tined lead placement
214880357|NCT00840489|DRUG|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
214880358|NCT00840489|DRUG|Colchicine|Colchicine 0.5 mg bd for 24 weeks
214880359|NCT02765763|DRUG|2-Minute Reveal Masque|
214880360|NCT02765763|DRUG|24/7 Barrier Repair Cream|
214880361|NCT02765763|DRUG|8-in-1 BioSerum|
214880362|NCT02765763|DRUG|Null Formula 2-Minute Reveal Masque|
214880363|NCT02765763|DRUG|Null Formula 24/7 Barrier Repair Cream|
214880364|NCT02765763|DRUG|Null Formula 8-in-1 BioSerum|
214880365|NCT03776149|DIETARY_SUPPLEMENT|Beetroot juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
215045059|NCT06511583|PROCEDURE|Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department|For laryngotracheal aspiration using a blind probe, the patient will be positioned in a seated or semi-seated position; if this is not possible, the aspiration will be performed in a supine position. A soft, sterile catheter connected to the suction apparatus will be inserted into one nostril while keeping the patient\&#39;s head tilted back. When the tip of the catheter reaches the back of the pharynx, the patient will need to breathe to facilitate the insertion and allow the catheter to advance into the larynx and trachea. At this point, using negative suction pressure for a maximum of 3-5 seconds, the secretions will be aspirated. The aspiration will be repeated multiple times in cycles of 3-5 seconds.
214291954|NCT00531999|DRUG|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
214291955|NCT03952104|OTHER|Strength training|Strength training
214667089|NCT03550690|DEVICE|Rocket Indwelling Pleural Catheter|A small plastic tube under the skin which is left in place so that the fluid can be drained if it builds up again
214667090|NCT03759275|OTHER|pMDT(Baseline Investigation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
214667091|NCT00194350|PROCEDURE|Test for Factor V Leiden gene mutation|
215045060|NCT06511583|PROCEDURE|Aspiration Procedure Using Fibrobronchoscopy in the Emergency Department|"Equipment Setup:~A sterile bronchoscope will be connected to the suction apparatus.~Procedure:~The bronchoscope will be gently inserted through the patient\&#39;s nostril or mouth, advancing carefully through the pharynx and larynx into the trachea and bronchi.~The physician will visually inspect the airways through the bronchoscope. Using the bronchoscope's suction channel, secretions will be aspirated from the trachea and bronchi.~Suctioning will be performed intermittently to avoid hypoxia, with each suctioning cycle lasting no more than 3-5 seconds.~The procedure may be repeated as necessary to ensure thorough aspiration of secretions."
214880366|NCT03776149|DIETARY_SUPPLEMENT|Black currant juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
214880367|NCT02897518|DEVICE|Imago V-Balde|the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
214880368|NCT02897518|DEVICE|Glidescope|the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
214880369|NCT02229474|BEHAVIORAL|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
214880370|NCT01562860|PROCEDURE|Pronator Teres Release|Surgical release of median nerve compression
214880371|NCT01562860|PROCEDURE|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
215045061|NCT05815914|OTHER|app|The app will include a nutritional education programme through the APP throughout the study. At 2, 4, 6 and 8 months data will be collected through a telematics questionnaire
215045062|NCT05815914|OTHER|control group|Routine nutritional and dietary recommendations will be given.
215045063|NCT00902330|PROCEDURE|energy-based therapy|Given once a day for 18 weeks
214880372|NCT01562860|PROCEDURE|dual compression release|both procedures will be done on the same day
214880373|NCT01562860|PROCEDURE|median nerve release only|only the carpal tunnel compression is released
214880374|NCT01045330|BEHAVIORAL|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
215045064|NCT00902330|PROCEDURE|sham intervention|Given once a day for 18 weeks
215045065|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
215045066|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
215045067|NCT01911455|DRUG|acamprosate|
215045068|NCT01911455|DRUG|Placebo|
215045069|NCT06543485|PROCEDURE|intramedullary screw fixation of metacarpal fractures|intramedullary screw fixation of metacarpal fractures through limited open approach
215045070|NCT05271747|DIETARY_SUPPLEMENT|AB-Kolicare|Probiotic multi-strain formulation containing Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 for 21 days, 5 drops/day preferably during the first intake of milk
215045071|NCT05271747|DIETARY_SUPPLEMENT|Reuteri gotas|Probiotic single-strain formulation containing Lactobacillus reuteri DSM17938 for 21 days, 5 drops/day before or after any daily meal.
214880375|NCT02315274|OTHER|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
214880376|NCT00972296|DEVICE|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
215045072|NCT03785184|DRUG|venetoclax|tablet; oral
214291956|NCT06012825|BEHAVIORAL|Physical Activity|"The program will consist of 2 consecutive rounds of 12-week programming, 2x/week for 60 minutes on a Health Insurance Portability and Accountability Act (HIPAA)-compliant Zoom account. The PA program will be structured to ensure equivalent PA doses are provided. This will be done by allocating time to a warm-up (5 min), an introduction and demonstration of the activity (5 min), the PA (30 min), cool down and stretching (5 min). Time will also be devoted for interaction to develop rapport, transition to the next activity, and to handle internet connectivity issues (15 min)."
214291957|NCT03336047|BEHAVIORAL|personal activity intelligence|"Participants randomized to the PAI intervention will receive a Mio Slice fitness bracelet and asked to install the Mio Pai 2.0 app on their smart phone. This tracks their fitness score based on the PAI algorithm where the goal is to maintain 100 PAI points a week. PAI is earned incrementally based on time spent in three different heart rate zones, low, medium and high intensity. PAI is recorded every day and added to the weekly total and the PAI earned on the same day the previous week is deleted (on Tuesday, the PAI earned the previous Tuesday will disappear).~Participants will be encouraged to maintain 100 PAI during the 8 weeks intervention by telephone messages (sms)."
214291958|NCT03336047|BEHAVIORAL|10,000 steps daily|Participants randomized to the 10,000 step intervention will receive a fit bit zip step counter and asked to obtain 10.000 steps per day. Participants will be encouraged to obtain 10.000 steps per day by telephone messages (sms).
214880377|NCT05263310|BEHAVIORAL|Prepare for Your Diabetes Care|Educational video and Action Plan handout
214880378|NCT05263310|BEHAVIORAL|Usual Care|Control arm patients will continue with usual care
214880379|NCT00261781|BEHAVIORAL|Treadmill training|Walking on a treadmill 3 times per week for 6 weeks
214880380|NCT01174043|DRUG|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
215045073|NCT03785184|DRUG|lenalidomide|capsule; oral
215045074|NCT03785184|DRUG|dexamethasone|tablet; oral
215045075|NCT06328842|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214667092|NCT06189820|DIAGNOSTIC_TEST|FAPI PET/CT|"In the department of Nuclear Medicine:~* Installation in a relax chair after weight and height control~* Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started.~* Intravenous injection of 3 MBq/kg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq/kg 68Ga-FAPI46"
214667093|NCT02441530|DIETARY_SUPPLEMENT|Vitamin D|
214880381|NCT02470845|DRUG|herbal patches of Tian Jiu group|The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo（CorydulisRhizoma）、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo（CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm\*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.
214880382|NCT02470845|DRUG|placebo patches of placebo-control group|The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm\*1cm round size.Each patch will be applied on one acupoint.
214667094|NCT02441530|DIETARY_SUPPLEMENT|Vitamin E|
214880383|NCT02049970|DRUG|dexmedetomidine|1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
214880384|NCT02049970|DRUG|bupivacaine|30 ml 0.25 % bupivacaine is applied around brachial plexus
214880385|NCT00448383|BIOLOGICAL|adalimumab|40mg every other week
214880386|NCT02646761|DEVICE|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
214880387|NCT02646761|OTHER|Standard of Care Physical Therapy|Physical therapy rehabilitation program
214880388|NCT03148665|DEVICE|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
214880389|NCT03002701|BEHAVIORAL|UNDERPIN-ICU program|UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
214880390|NCT03399825|DEVICE|OCT-A|"optical coherence tomography angiography~Imaging with optical coherence tomography angiography"
214880391|NCT04283422|DIAGNOSTIC_TEST|Biofire filmarray|"Identification of microorganisms including:~1. Isolation of microorganisms:~   The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~2. Identification of the organism by Vitek2~3. Antibiotic sensitivity test of the organism by Vitek2~4. Identification of the organism by Biofire filmarray"
214880392|NCT05579002|OTHER|Questionnaires and tests|"Application of three questionnaires:~1. Canadian Occupational Performance Measure (CORM),~2. a version of the Disabilities of the Arm Shoulder and Hand (DASH) modified for the child~3. a questionnaire developed by CEREFAM~   * Two analytical and functional tests:~1\) the Action Research Arm Test (ARAT) 2) modified 400-point assessment."
214880393|NCT03955003|BEHAVIORAL|Group Drumming|Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
214880394|NCT03955003|OTHER|Attention Control|This is intended to control for time, place, and group affect.
214880395|NCT04679493|DRUG|XC7 100 mg single|The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
214880396|NCT04679493|DRUG|XC7 200 mg single|The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
214880397|NCT04679493|DRUG|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 capsules once)
214880398|NCT04679493|DRUG|XC7 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
214880399|NCT04679493|DRUG|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
214880400|NCT00086593|DRUG|lamotrigine|
214667095|NCT02441530|DRUG|Ibuprofen|
214667096|NCT03150940|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram used to demonstrate cardiac function
214667097|NCT03150940|DIAGNOSTIC_TEST|bedside cardiac ultrasound|bedside cardiac ultrasound to see 2D images of each participants heart. Without the use of radiation.
214667098|NCT01097902|DRUG|Ibuprofen|800 mg oral one time only
214880401|NCT03903211|DRUG|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
214880402|NCT02104115|OTHER|MRI scanners|
214880403|NCT02104115|OTHER|VAS Symptom scores|
214880404|NCT05035277|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
214667099|NCT01097902|DRUG|Placebo tablet|Placebo tablet oral one time only
214667100|NCT03482661|OTHER|magnetic steering|The capsule was controlled to pass through the pylorus by magnet steering.
214667101|NCT02146846|DRUG|Imatinib|Patients with chronic myeloid leukemia who receive Imatinib as treatment
214880405|NCT05035277|DRUG|Apixaban|Standard dose apixaban will be one of the options for the patients in the experimental arm.
214880406|NCT05035277|DRUG|Rivaroxaban|Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
214880407|NCT05035277|DRUG|Edoxaban|Standard dose edoxaban will be one of the options for the patients in the experimental arm.
214880408|NCT06498167|DRUG|Upadacitinib|Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).
214880409|NCT03092973|DIAGNOSTIC_TEST|Ultrasound|
214880410|NCT00486031|DRUG|Balsalazide Disodium|
214880411|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
215045076|NCT06328842|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
215045077|NCT03544450|BEHAVIORAL|Psychosocial counselling|"Individuals with psychological distress receive psychosocial counselling and enhanced usual care. The psychosocial the counselling process consists of: (i) introduction, explanation and rapport building; (ii) assessment of and understanding of the problem (including looking for positive assets); (iii) goal setting (asking the client what outcomes are preferred); (iv) problem management (exploring and identifying solutions, brainstorming, working with existing coping strategies, using social and cultural resources, and additional techniques such as relaxation and psycho-education); (v) implementation (making a plan of action and transition); and, finally, (vi) termination of counselling (including closing and follow-up). Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support)."
214880412|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
214880413|NCT01499446|DRUG|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
214880414|NCT01499446|DRUG|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
214880415|NCT04131348|PROCEDURE|botulinum toxin type A|From to December 2016 to December 2018, a single-center prospective comparative study was performed in 80 patients with LMIH at our tertiary center.
214880416|NCT04335539|DRUG|Cefiderocol|Administered intravenously over 3 hours
215045078|NCT03544450|OTHER|Enhanced Usual Care|Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
215045079|NCT00165789|DRUG|E2007|
215045080|NCT00002414|DRUG|CPI-1189|
215045081|NCT03776084|DEVICE|Continuous Positive Airway Pressure|CPAP indication
214880417|NCT04335539|DRUG|Standard of Care|Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
214880418|NCT02609438|BEHAVIORAL|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
214880419|NCT02609438|BEHAVIORAL|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
214880420|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate DISKUS|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.
214880421|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate ROTACAP|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
214880422|NCT00515918|DIETARY_SUPPLEMENT|iron|
214880423|NCT03209817|DIETARY_SUPPLEMENT|Red cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
214880424|NCT03209817|DIETARY_SUPPLEMENT|Yellow cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
214667102|NCT02783781|PROCEDURE|Cardiac surgery (extracorporeal circulation; beating heart)|"Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.~Blood sample collection Urine sample collection"
214667103|NCT00195351|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
214667104|NCT00195351|DRUG|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
214667105|NCT03319199|DIETARY_SUPPLEMENT|"SLIM WATER"|2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
214667106|NCT03319199|OTHER|Placebo - water|for a duration of 16 weeks
214667107|NCT04512079|DRUG|Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)
214667108|NCT04512079|DRUG|Apixaban|(5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
214667109|NCT05008887|DRUG|Methotrexate|Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
214667110|NCT05008887|DRUG|5-fluorouracil|Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
214667111|NCT05008887|DEVICE|Fractional CO2 laser|Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo
214667112|NCT00540540|DEVICE|Diffuse Optical Spectroscopy|Breast properties scanning
214667113|NCT02111369|DRUG|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
214667114|NCT02111369|PROCEDURE|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
214667115|NCT01203488|DRUG|Vitamin A|5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
214667116|NCT01203488|OTHER|Sham Procedure|Control infants received a sham procedure rather than placebo injections.
214667117|NCT05641454|DIETARY_SUPPLEMENT|ElevATP supplement|ElevATP supplement containing apple and ancient peat extract
214667118|NCT05641454|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
214667119|NCT06395272|DEVICE|SURA|The motor points are the site of penetration of the motor nerve fibres and the highest concentration of motor plates in the muscle, which when stimulated produce the maximum effective muscle contraction. For 15 minutes and in a comfortable seated position at 90° hip, knee and foot, sustained pressure of 30 seconds each shall be exerted through the output plunger of the proprioceptive stimulus device.
214667120|NCT00877838|DRUG|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
214667121|NCT00877838|DRUG|Placebo|Gelatin capsules resembling the ones containing the active substance
214667122|NCT01300143|OTHER|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
214667123|NCT01300143|OTHER|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
214667124|NCT02344940|DRUG|Toremifene|patients will take toremifene 60 mg qd.
214667125|NCT02344940|DRUG|Tamoxifen|patients will take tamoxifen 10 mg bid.
214667126|NCT05911997|DRUG|MTC 01|Slurry to be administered via colonoscopy
214667127|NCT05911997|DRUG|Fecal Microbiota Transplantation (FMT)|Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
214667128|NCT05401071|OTHER|Short Regimen with Rifapentine 10mg/kg|rifapentine 10mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
214667129|NCT05401071|COMBINATION_PRODUCT|Standardized Regimen|"During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, \>71kg 750mg daily; isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, \>71kg 375mg daily; pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, \>71kg 1600mg daily; ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, \>71kg 1375mg daily; All treatment is taken orally.~During the continuation phase, rifampicin ≤50kg 450mg daily, \>50kg 600mg daily; isoniazid 300mg daily; All treatment is taken orally."
214667130|NCT05401071|OTHER|Short Regimen with Rifapentine 15mg/kg|rifapentine 15mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
214667131|NCT05401071|OTHER|Short Regimen with Rifapentine 20mg/kg|rifapentine 20mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
214667132|NCT03381040|DEVICE|Restylane Lyft|Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.
215045082|NCT03732989|DEVICE|Interactive toy prototype|The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).
214291959|NCT00671892|BIOLOGICAL|Lipopolysaccharide endotoxin|"Delivered in nebulized form expressed in activity units(endotoxin units -EU).~Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:~Challenge One first saline then 5000 EU 10,000 EU 20,000 EU~Challenge 1 and 2 must be at least 2 weeks apart.~Challenge 2 Saline 40,000 EU 80,000 EU"
214667133|NCT03381040|DEVICE|Restylane Volyme|"Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope."
214667134|NCT02715648|DRUG|Phenazopyridine|
214667135|NCT05000801|BIOLOGICAL|DC vaccine|Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
214880425|NCT01931878|DRUG|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
214880426|NCT01931878|DRUG|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
214667136|NCT04350515|OTHER|Cyberball: Other Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, one of the avatars is excluded.
214667137|NCT04350515|OTHER|Cyberball: Player Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, the subject is excluded by the avatars.
215045083|NCT03732989|DEVICE|Non-interactive toy prototype|This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
215045084|NCT02001129|BEHAVIORAL|Automated Telephone System|Participants receive automated reminder phone calls.
215045085|NCT02001129|BEHAVIORAL|Personalized Telephone Call|Participants receive reminder phone calls by study staff.
215045086|NCT02001129|BEHAVIORAL|Usual Care|Participants receive a standard reminder letter in the mail.
215045087|NCT05930080|DRUG|SKCPT|the randomly assigned subjects took the study drug for 12 weeks
215045088|NCT05930080|DRUG|Celebrex|the randomly assigned subjects took the study drug for 12 weeks
215045089|NCT01816048|DRUG|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
215045090|NCT01816048|RADIATION|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
215045091|NCT01816048|PROCEDURE|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
215045092|NCT01816048|PROCEDURE|Computed Tomography|Undergo 18F NaF PET/CT scan
215045093|NCT02663310|PROCEDURE|Surgery|Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
215045094|NCT02663310|PROCEDURE|Rehabilitation|The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
215045095|NCT03625076|DRUG|Intra-articular Lidocaine|20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
215045096|NCT03625076|DRUG|Procedural Sedation with etomidate or propofol|Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
215045097|NCT02692573|OTHER|positioning|prone positioning for the initial 5 minutes of life
215045098|NCT02692573|OTHER|positioning|supine positioning for the initial 5 minutes of life
215045099|NCT03089814|PROCEDURE|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
215045100|NCT02145936|OTHER|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
215045101|NCT00197821|BIOLOGICAL|pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
215045102|NCT02327767|DEVICE|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
215045103|NCT01645202|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
214477016|NCT06857578|PROCEDURE|Total revision of Roux-en-Y gastric bypass|"1. The entire previous gastric bypass construction is released from any adhesions and all parts of the small intestine are measured and assessed.~2. All or parts of the first part of the intestine that food reaches after the gastric pouch (so-called Roux) is resected. The reason is that parts of the intestine that are considered to be of poor quality (for example, affected by a lot of adhesions or abnormally dilated) are removed. This can be about 1.5 meters of intestine, which corresponds to 10-25% of the entire length of the small intestine.~   The gastric pouch will be small (\<30 ml).~3. A new gastric bypass construction is constructed where the intestine receiving food from the esophagus (Roux) will be 1 meter, and the small intestine part from the closed stomach at least 1.5 meters.~The remaining length of the small intestine below the jejuno-jejunal anastomosis should be minimum 3 meters."
214880427|NCT01157988|DRUG|ibritumomab tiuxetan (Zevalin)|During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count \> 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
214880428|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
214880429|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
214880430|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (350 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
214880431|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (150 mg liposomal)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
214880432|NCT06551818|OTHER|SesZen-Bio High Dose 1 (500 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
214880433|NCT06551818|OTHER|Placebo|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
214880434|NCT06579235|DIAGNOSTIC_TEST|Proteomics|All samples of cases (with LNB) and controls (without LNB) will undergo proteomic analyses.
214880435|NCT04775303|DRUG|Cyclosporine 0.1% (Ikervis®) eye drop|One drop of Cyclosporine 0.1% (Ikervis®) eye drop once daily for 12 weeks
214880436|NCT00052637|DRUG|hexaminolevulinate|
214880437|NCT00052637|PROCEDURE|biopsy|
215045104|NCT00930449|OTHER|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.~Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
214291960|NCT00821977|DRUG|Vildagliptin|
214291961|NCT00821977|DRUG|Vildagliptin|
214291962|NCT00821977|DRUG|Placebo|
214880438|NCT00052637|PROCEDURE|cystoscopy|
214880439|NCT01645787|DRUG|4-aminopyridine|10 mg/twice daily
214880440|NCT01645787|DRUG|Placebo|Crossover study involving one trial with sugar pill (placebo)
214880441|NCT02473198|DRUG|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
214880442|NCT02473198|DRUG|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
214880443|NCT02473198|DRUG|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
214880444|NCT02473198|DRUG|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
214880445|NCT05082740|OTHER|Notification of a revised breast cancer risk estimate|These women will be given the opportunity to learn of their revised breast cancer risk estimate which has been re-calculated with the inclusion of new strong independent risk factors. These women will be offered a clinical consultation to discuss their risk and will a subset will be asked to take part in a qualitative interview about their experiences.
214880446|NCT01371539|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
214880447|NCT01371539|DEVICE|Comfilcon A contact lens|Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
214291963|NCT05008497|OTHER|Questionnaire|Questionnaire
214880448|NCT01537939|BEHAVIORAL|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
214880449|NCT02006602|DRUG|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
214880450|NCT02006602|DRUG|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).
215045105|NCT00930449|OTHER|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
215045106|NCT00930449|OTHER|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
215045107|NCT00163098|DRUG|UK-369,003|
215045108|NCT01105663|OTHER|Pharmacokinetic Sampling and pharmacogenetic analysis|Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
215045109|NCT02432573|BEHAVIORAL|Delayed rounds|
215045110|NCT04575519|DRUG|Control group|placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
215045111|NCT04575519|DRUG|ASA group|Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
215045112|NCT04575519|DRUG|IBU group|Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
215045113|NCT04575519|DRUG|SoC TB|Standard of Care Tuberculosis treatment
215045114|NCT04620161|DRUG|Pradigastat Tablets 20mg|20mg, once daily, oral administration
215045115|NCT04620161|DRUG|Pradigastat Tablets 40mg|40mg, once daily, oral administration
215045116|NCT04620161|DRUG|Pradigastat Tablets 20mg matching Placebo|once daily, oral administration
215045117|NCT04620161|DRUG|Pradigastat Tablets 40mg matching Placebo|once daily, oral administration
214880451|NCT01009502|DRUG|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
214880452|NCT00294580|DRUG|Maloprim|
215045118|NCT03751397|OTHER|blood test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein, beta-2 microglobulin, uromodulin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
215045119|NCT03751397|OTHER|urine test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein beta-2 microglobulin, uromodulin, albumin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
215045120|NCT04290624|OTHER|Experimental Dentifrice: Stannous Fluoride|Participants will be instructed to dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion containing 0.454% w/w Stannous fluoride for 2 minutes twice daily (morning and evening) for 12 weeks.
215045121|NCT04290624|DEVICE|COREGA Denture Foaming Cleanser|Participant will clean their denture using 2 pumps of the denture cleansing foam and a denture cleaning brush for 90 timed seconds outside of the mouth twice daily (morning and evening) for 12 weeks.
215045122|NCT04290624|OTHER|Mouth rinse: Sodium Fluoride|Participants will take 10 ml of the mouth rinse containing 90 ppm sodium fluoride and swished around the mouth for 1 minute twice daily (morning and evening) for 12 weeks.
215045123|NCT02479191|DEVICE|Ovation Abdominal Stent Graft Platform|
215045124|NCT03041220|PROCEDURE|cesarean section|obese patients (BMI of 30 or greater) who have had a cesarean section
215045125|NCT04042805|BIOLOGICAL|Sintilimab|200mg intravenously every 3 weeks
215045126|NCT04042805|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
215045127|NCT00267930|DRUG|Vernakalant (oral)|
215045128|NCT00267930|DRUG|Placebo comparator|
214667138|NCT04350515|OTHER|Mindfulness: Emotion Regulation Task|In this task, subjects listen to an audio file containing a scripted emotion regulation exercise. This exercise is based by the authors Nissen \& Sturm (2018). It takes around 14 minutes to complete the whole task.
214880453|NCT04902014|BEHAVIORAL|Motivational Interviewing|The individuals will be scheduled for and participate in six biweekly in person SDT based MI sessions. These sessions will take place in the HPCRL at CSU. The MI sessions will be conducted by a PhD student who has been trained by a MI practitioner. Participants will be provided a log book and will be asked to log their PA, with the goal of completing at least 150 minutes of PA per week. They will set biweekly PA goals, which will be discussed in the MI sessions. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
214880454|NCT04902014|BEHAVIORAL|Education|These participants will receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting. These participants will not do any other study related activities. At the conclusion of the study, these participants will be offered the chance to participate in one MI session.
214880455|NCT04902014|BEHAVIORAL|Wearable Fitness Trackers|Individuals assigned to this experimental condition will be given a wrist-worn WFT and will be instructed to wear it for the duration of the study. They will also download the corresponding mobile application on their smartphones. They will be trained by a member of our team on how to utilize the WFT and mobile application. The intended WFT tracks daily steps, miles traveled, kcals expended, and daily activity time. This device provides these data to the wearer via a small screen. Participants will be instructed to aim to complete at least 150 minutes of PA per week. Researchers will have the capability to track participant daily PA via the WFT and associated API. These individuals will be asked to set biweekly PA goals. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
214880456|NCT04902014|BEHAVIORAL|Wearable Fitness Tracker+|These individuals will be given the wrist-worn WFT, be instructed to wear it for the duration of the study AND be scheduled for six SDT based MI sessions. These participants will also be trained by a member of our team on how to utilize the WFT and associated application. They will be instructed to aim to complete 150 minutes of PA per week. These participants will be asked to set biweekly PA goals which will be discussed in MI sessions. Researchers will have the capability to track participant daily PA via the WFT and associated API. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
215045129|NCT04077177|BEHAVIORAL|Male Athlete Body Project|Participants who meet eligibility criteria and consent to the study will be randomized to one of two conditions: intervention condition (i.e., Male Athlete Body Project) or an assessment only control condition. The intervention groups will take place at IIT. Participants who accept randomization to condition will complete baseline questionnaires after randomization (immediately prior to Session 1 in the intervention condition and after being randomized to the assessment only control condition). Questionnaires will be repeated immediately post-intervention (intervention condition)/after a 3-week interval (control). All participants will be asked to complete the questionnaires again, 4 weeks after the previous round of questionnaires. The 3, 80-minute group sessions will be separated by 1 week.
215045130|NCT03346993|DRUG|Bupivacaine Hydrochloride 5 MG/ML|Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine
215045131|NCT02579811|DRUG|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
215045132|NCT02018120|PROCEDURE|connective tissue graft|
215045133|NCT02018120|PROCEDURE|platelet rich fibrin|
215045134|NCT04052373|PROCEDURE|Implantoplasty|Implantoplasty is the mechanical smoothening of rough titanium implants as part of the surgical treatment of peri-implantitis. Treatment is thought to facilitate self-performed oral hygiene.
215045135|NCT04052373|PROCEDURE|Open flap debridement alone|Open flap debridement alone
215045136|NCT02598037|DIETARY_SUPPLEMENT|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
215045137|NCT05230498|DEVICE|anatomy-based fitting then default fitting|Cochlear implant with anatomy-based fitting then default fitting
215045138|NCT05230498|DEVICE|default fitting then anatomy-based fitting|Cochlear implant with anatomy-based fitting then default fitting
215045139|NCT05626491|DEVICE|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
215045140|NCT05626491|DEVICE|Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive sham treatment (no active stimulation) every other day via a headband.
214880457|NCT00551512|DRUG|CBP501 and Cisplatin|CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
214291964|NCT05029674|DEVICE|Whoop|Wear WHOOP Strap, complete surveys
214880458|NCT01783912|BEHAVIORAL|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
214880459|NCT01783912|BEHAVIORAL|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
214880460|NCT01783912|DRUG|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
214880461|NCT01783912|BEHAVIORAL|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
214880462|NCT00079950|DRUG|Pegamotecan|
214880463|NCT04877821|DRUG|Sintilimab|200mg on days 1 (Q3W) of the neoadjuvant and adjuvant phase of the study; IV injection.
214880464|NCT04877821|DRUG|Anlotinib|12mg on d1-14 of Cycles 1-8 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
214880465|NCT04877821|DRUG|Nab paclitaxel|100 mg/m² on day 1, 8 and 15 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
214880466|NCT04877821|DRUG|Carboplatin|AUC 5 on days 1 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
214880467|NCT04877821|DRUG|Epirubicin|90 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
214880468|NCT04877821|DRUG|Cyclophosphamide|600 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
214880469|NCT01493921|DRUG|SR-T100 gel|Patient will be instructed to self-apply approximately 0.3\~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
214880470|NCT01493921|DRUG|Vehicle gel|Patient wil be instructed to self-apply approximately 0.3\~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
214880471|NCT01545518|DRUG|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
214880472|NCT03545542|DIAGNOSTIC_TEST|Initial fecal microbiome|Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
214880473|NCT03545542|DIAGNOSTIC_TEST|Initial fecal volatile organic compounds|Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
214880474|NCT03545542|DIAGNOSTIC_TEST|Initial breath volatile organic compounds|Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
214880475|NCT03545542|DIAGNOSTIC_TEST|Microbiome under chemotherapy|Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to Société Internationale d´Onclogie Pediatrique Neuroblastoma Group (SIOPEN) guidelines
214880476|NCT03545542|DIAGNOSTIC_TEST|Fecal volatile organic compounds under chemotherapy|"Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
214880477|NCT03545542|DIAGNOSTIC_TEST|Breath volatile organic compounds under chemotherapy|"Breath sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
214880478|NCT03545542|DIAGNOSTIC_TEST|Final microbiome|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
214880479|NCT03545542|DIAGNOSTIC_TEST|Final fecal volatile organic compounds|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
214880480|NCT03545542|DIAGNOSTIC_TEST|Final breath volatile organic compounds|Breath sampling 3 weeks after completion of chemotherapy Neuroblastoma group
214880481|NCT00637494|DRUG|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
214880482|NCT00637494|DRUG|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
214880483|NCT02559180|DRUG|aflibercept|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
214880484|NCT03196245|OTHER|There is no intervention.|There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
214880485|NCT00919126|DRUG|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
214880486|NCT00919126|DRUG|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
214880487|NCT00919126|DRUG|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
214880488|NCT06550960|DEVICE|Evaluation of two biopsy systems|Each subject will have prostate biopsy taken in 6 locations in one lobe of the prostate and then biopsy in 6 locations in the other lobe of the prostate
214880489|NCT05125965|OTHER|additional time for the MRI|3 additional minutes to perform the MRI
214880490|NCT03539263|DIETARY_SUPPLEMENT|Bifihappy|"During the six weeks of treatment, the experimental group will take daily doses of 2,5 g with a concentration of 4x109 CFU/sachet of a mixture of lyophilised probiotic strains of the following species:~* Lactobacillus fermentum~* Lactobacillus rhamnosus~* Lactobacillus plantarum~* Bifidobacterium longum"
214880491|NCT03539263|OTHER|Placebo|During the six weeks of treatment, the experimental group will take daily doses of 2,5 g of maltodextrin
214880492|NCT04291625|PROCEDURE|Levator muscle resection|"Surgery was performed under general anaesthesia. Two milliliters of 2% lidocaine with 1:100 000 epinephrine is injected subcutaneously. After the upper eyelid incision at the desired crease line, the orbital septum was opened and the preaponeurotic fat was identified and dissected off the levator aponeurosis. The aponeurosis was disinserted from the tarsus, and the complex of levator aponeurosis and Muller muscle was dissected free from the conjunctiva. The desired eyelid height was determined from the proposed formula.~Satisfactory Intraoperative lagophthalmos was defined as a difference of less than 1 mm between recommended by the formula and actual intraoperative lagophthalmos.~After permanent fixation, a caliper was used for precise measurement of lagophthalmos in a supine position. Additional sutures were placed on the medial and lateral sides for satisfactory eyelid contour. The redundant levator complex was excised. Eyelid crease was made by placing three interrupted sutures"
214880493|NCT02904863|BIOLOGICAL|Extra blood draw samples|
214880494|NCT01485822|PROCEDURE|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
215045141|NCT06268899|OTHER|First mobilization protocol|The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed \>60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
215045142|NCT04445662|BEHAVIORAL|Financial incentives|Escalating financial rewards for saliva cotinine levels \<30 ng/mL, assessed 10 times over 12 weeks
215045143|NCT04445662|DRUG|Varenicline|"* Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement"
214291965|NCT05725720|OTHER|Gut microbiome analysis|Characterization of the compositional and functional modifications of gut microbiome in patients affected by lymphoma undergoing therapy with CAR-T cells from baseline until the restaging after 18 months from the CAR-T cell infusion
214291966|NCT06441344|DRUG|Toripalimab plus Anlotinib|For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used
214291967|NCT06441344|DRUG|Toripalimab|For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used
214291968|NCT00842686|DRUG|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
214291969|NCT03408756|DRUG|methotrexate|Participants will receive methotrexate through oral or subcutaneous route of administration
214880495|NCT01485822|DRUG|Travoprost 0.004% ophthalmic solution|
214880496|NCT00237523|DRUG|IoGen (molecular iodine)|
214880497|NCT06432855|OTHER|Blood collection|20 ml-blood sample
214880498|NCT06432855|OTHER|saliva collection|saliva sample
215045144|NCT04445662|BEHAVIORAL|Tobacco coaching|5 one-on-one tobacco cessation coaching sessions over 12 weeks
215045145|NCT05161871|DEVICE|Cathodal transcranial direct current stimulation|The cathodal transcranial direct current stimulation protocol will consist in five daily sessions, each lasting 20 min. The montage will provide a bilateral stimulation on occipital areas, with the reference anodal electrodes positioned on the M1 areas. The stimulation will be applied via 4 conductive-rubber square electrodes (5x5 cm) placed in sponges saturated with high conductivity gel and connected to a battery-operated stimulator system. Direct current with maximal intensity of 1.5 mA with be provided for 20 minutes.
215045146|NCT05161871|DEVICE|Sham cathodal transcranial direct current stimulation|Sham stimulation will be performed by the same protocol as active stimulation; however, the device will be switched off 30 seconds after the beginning of stimulation. This way, the patient will experience the same sensations as with active stimulation without receiving actual stimulation.
215045147|NCT02999009|DEVICE|Trident II Tritanium Acetabular Shell|A hemispherical acetabular shell indicated for cementless application.
215045148|NCT04832698|OTHER|Survey Administration|Complete survey
214880499|NCT05088135|DEVICE|Bilateral Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as bilateral Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
214291970|NCT00939328|BIOLOGICAL|rituximab|
214291971|NCT00939328|DRUG|bendamustine hydrochloride|
214291972|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
214880500|NCT05088135|DEVICE|Unilateral-Right Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-right Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
214880501|NCT05088135|DEVICE|Unilateral-Left Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-left Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
214880502|NCT00150956|PROCEDURE|Daily home hemodialysis|
214880503|NCT03035578|DRUG|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
214880504|NCT03035578|DRUG|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
214880505|NCT00852007|BIOLOGICAL|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
214880506|NCT02032680|BEHAVIORAL|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
214880507|NCT02032680|BEHAVIORAL|In-persons Multi-Family Group Psycho-Education treatment|This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.
214880508|NCT02032680|OTHER|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
214880509|NCT03619265|DIETARY_SUPPLEMENT|Prickly pear juice|3 ounces daily for 8 weeks.
214880510|NCT03619265|DIETARY_SUPPLEMENT|Pear-flavored juice|3 ounces daily for 8 weeks.
214880511|NCT02758639|BEHAVIORAL|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
214880512|NCT02404116|OTHER|Metacognitive Therapy|Participants will receive treatment which focus's on helping reduce excessive thinking about health,
214880513|NCT02404116|OTHER|Wait List|Individuals are on a waiting list
214880514|NCT02207712|DEVICE|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
214880515|NCT02207712|DRUG|Ranibizumab|Standard ranibizumab treatment only
214880516|NCT04736225|OTHER|Insulin Self-Titration Education Program|The program contents of instruction included blood glucose self-monitoring, types of insulin, insulin self-administration, insulin dose titration, hyperglycemia or hypoglycemia self-management, diet, and exercise.a 20-min one-on-one training session from a nurse on how to self-titrate the insulin dose. The participants were taught to monitor their before-breakfast and before-dinner blood glucose levels at home and adjust their insulin doses accordingly.
214291973|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
214291974|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
215045149|NCT06447545|DEVICE|Changing pressure of Pneumoperitoneum to 6-10 mmHg|Result of changing pneumoperitoneum pressure on CBD injury and pain
214291975|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
214291976|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
214291977|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
215045150|NCT06447545|DEVICE|Changing pressure of Pneumoperitoneum to 12-15 mmHg|Result of changing pneumoperitoneum pressure on CBD injury and pain
215045151|NCT00956384|PROCEDURE|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
215045152|NCT00956384|PROCEDURE|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
215045153|NCT01448642|DRUG|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
215045154|NCT01448642|DRUG|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
215045155|NCT02076945|PROCEDURE|US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)|
215045156|NCT05320978|DEVICE|Hand grip test, computed tomography|A hand grip test, abdominal computed tomography are performed before surgery.
215045157|NCT06560944|DRUG|Combined oral contraceptive pill|Ingesting their existing combined oral contraceptive pill at a specific time of day in relation to assessment of outcome measures
215045158|NCT02916485|DEVICE|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
215045159|NCT00425620|DRUG|SinuNase|Lavage
215045160|NCT02020161|DRUG|Atra|
215045161|NCT02020161|DRUG|Idarubicin|
215045162|NCT02020161|DRUG|methotrexate|
215045163|NCT05970328|DEVICE|Hexoskin Medical System|Participant wears both the Hexoskin Medical System and the Nasiff Holter Monitor at the same time to acquire ECG recordings.
215045164|NCT02998190|DRUG|Single Ascending Doses of EB8018|
215045165|NCT02998190|DRUG|Single Ascending Doses of placebo|
214880517|NCT05501535|DEVICE|ND:YAG LASER|The standard therapy for PCO is now Nd: YAG laser posterior capsulotomy, which has a success rate of more than 95%. The neodymium: yttrium-aluminum-garnet (Nd:YAG) laser, with a wavelength of 1064 nm, is a solid-state laser that may destroy ocular tissues by achieving optical breakdown with a brief, high-power pulse .Ionization or plasma production occurs in the ocular tissue as a result of optical breakdown. This plasma production subsequently generates acoustic and shock waves, which destroy tissue. Because of its cost-effectiveness, speed, and lack of invasiveness, it is the chosen treatment option in PCO
214880518|NCT04957238|OTHER|ARBORea decision-making tool|Online ARBORea decision-making tool will guide the use of physical restraints in ICU patients based on objective information on neurological status, level of equipment related to critical illness, and patient's family presence and involvement in patient's surveillance.
214880519|NCT03959111|OTHER|Stimulation at Location 1|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
214880520|NCT03959111|OTHER|Stimulation at Location 2|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
214880521|NCT01524978|DRUG|cetuximab|Escalating doses administered on Day 1 and then once weekly by intravenous infusion.
214880522|NCT01524978|DRUG|vemurafenib|Escalating doses given orally twice a day starting on Day 2
214880523|NCT01524978|DRUG|vemurafenib|960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.
214880524|NCT03536611|DRUG|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
214880525|NCT03536611|DRUG|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
214880526|NCT04808973|DRUG|Dolutegravir plus lamivudine in a FDC|All participants will receive an ART regimen composed by Lamivudine plus Dolutegravir in a single pill (FDC)
214880527|NCT00687830|DRUG|Polyethylene Glycol afternoon|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
214880528|NCT00687830|DRUG|Polyethylene Glycol morning|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
214880529|NCT00426101|DRUG|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days"
214880530|NCT00426101|DRUG|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk"
214880531|NCT00426101|DRUG|Cyclosporin|"WK 1-8:~\- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~\- Aim for around 200 microgram/L. Monitor GFR."
214880532|NCT00426101|PROCEDURE|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: \<1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, \>3 yrs 12 mg. Prednisolone: \<1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, \>3 yrs 10 mg."
214880533|NCT00426101|PROCEDURE|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
214880534|NCT03146104|DRUG|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
214880535|NCT03146104|DRUG|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
214880536|NCT05858112|DIAGNOSTIC_TEST|SuperTROPO novel assay to measure the long forms of cTnT|SuperTROPO novel assay to measure the long forms of cTnT
214880537|NCT02447601|DRUG|PEX168|200µg,injected subcutaneously,once a week.
214880538|NCT02447601|DRUG|Simvastatin|40mg,oral,two times
214880539|NCT03349346|DRUG|Idelalisib|Tablet (s) or dispersible tablets for suspension administered orally twice daily
214880540|NCT03349346|DRUG|Rituximab|375 mg/m\^2 administered intravenously
214880541|NCT03349346|DRUG|Ifosfamide|3 mg/m\^2 administered intravenously
214880542|NCT03349346|DRUG|Carboplatin|635 mg/m\^2 administered intravenously
214880543|NCT03349346|DRUG|Etoposide|100 mg/m\^2 administered intravenously
214880544|NCT04812522|BEHAVIORAL|Clean Cut program|Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis
214880545|NCT01427530|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
214880546|NCT03252730|OTHER|WO 4260 Cosmetic Product for Topical Use|Application on the hair scalp at least once a day over four weeks
215045166|NCT02998190|DRUG|Multiple Ascending Doses of EB8018|
215045167|NCT02998190|DRUG|Multiple Ascending Doses of placebo|
215045168|NCT06104345|BIOLOGICAL|Oral typhoid fever vaccine|Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.
215045169|NCT06104345|BIOLOGICAL|Oral cholera vaccine|Oral cholera vaccine (Dukoral®) on Days 0 and 7.
215045170|NCT01331590|DRUG|G-CSF|
215045171|NCT01331590|DRUG|Ifosfamide|
214291978|NCT01529346|DRUG|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
215045172|NCT01331590|DRUG|Etoposide|
215045173|NCT01331590|DRUG|Dexamethasone|
215045174|NCT01331590|DRUG|Mesna|
215045175|NCT05471375|OTHER|Database Entry|Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments
215045176|NCT02551588|PROCEDURE|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
214291979|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
214880547|NCT05383755|BEHAVIORAL|Digital intervention for pregnant adolescents living with HIV|The newly developed digital intervention will include SMS for reminder purposes and Web-based components such as virtual simulations, gamified elements, and didactic content to educate and build relevant skills (e.g., disclosure self-efficacy) to facilitate social support from caregiving family members. The intervention will (1) raise awareness about the intersecting stigmas of HIV and pregnancy; (2) highlight the effects of these stigmas on disclosure and social support; and (3) increase self-efficacy and communication skills for disclosure and enlistment of family members as social support allies. The goal of the intervention is to improve PMTCT engagement among pregnant unmarried ALHIV. Our theory-informed Web-based intervention will be use 3C Institute's Dynamic e-Learning Platform (DeLP), a customizable software platform that implements the evidence-based cognitive theory of multimedia learning (CTML) to effectively engage users.
215045177|NCT00601367|DRUG|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
215045178|NCT06032039|DRUG|Triamcinolone|Standard treatment for osteoarthritis knee pain
215045179|NCT06032039|OTHER|Platelet Rich Plasma|Alternative treatment for osteoarthritis knee pain
215045180|NCT04829513|PROCEDURE|Home Exercise|This is a home exercise programme that involves flexibility and strengthening of the waist, hip girdle and sacroiliac region. These exercises are first shown by the physiotherapist in hospital, and then they are asked to do the exercises at home using illustrated forms. Patients continue the exercises as a home programme once a day for 1 month.
215045181|NCT04829513|PROCEDURE|Ligament Correction Kinesiotaping|Ligament correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
215045182|NCT04829513|PROCEDURE|Lymphatic Correction Kinesiotaping|Lymphatic correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
215045183|NCT01445275|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
215045184|NCT01445275|OTHER|Medical Chart Review|Ancillary study
215045185|NCT01445275|OTHER|Study of Socioeconomic and Demographic Variables|Ancillary studies
215045186|NCT00656370|DRUG|recombinant human hyaluronidase|150 Units in 1mL
215045187|NCT00285571|BEHAVIORAL|Controlled Feeding Intervention|
215045188|NCT00646386|DRUG|adalimumab|40 mg eow Week 0 - Week 24
214291980|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
214291981|NCT01529346|OTHER|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
214291982|NCT00735592|OTHER|Observational|Retrospective data obtained from electronic files
214291983|NCT00386776|OTHER|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
214667139|NCT04350515|OTHER|Mindfulness: Word Recognition Task|"In this task, subjects listen to an audio file containing a scripted word recognition exercise. It contains both contrary words recognition (e.g. The opposite of loud is ...) and completion of german sayings (e.g. That's where the dog is...). It takes around 14 minutes to complete the whole task."
214667140|NCT03267355|DEVICE|Endoscopic Ultrasound|Indication of EUS
215045189|NCT00646386|DRUG|placebo for adalimumab|40 mg eow Week 0 - Week 24
215045190|NCT03953807|DRUG|Dexamethasone Intravitreal Implant|Implant 700 μg
215045191|NCT02266160|DRUG|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
215045192|NCT02266160|OTHER|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
215045193|NCT03833141|OTHER|Survey Administration|Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.
215045194|NCT01816984|DRUG|PI3K inhibitor BKM120|Given PO
215045195|NCT01816984|BIOLOGICAL|cetuximab|Given IV
215045196|NCT00281593|DRUG|Telmisartan|
215045197|NCT00281593|DRUG|Ramipril|
215045198|NCT05688969|OTHER|early versus late biopsy|early (3-6 weeks) versus late (6-8 months) biopsy
215045199|NCT04052009|OTHER|Conventional gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
215045200|NCT04052009|OTHER|End-effector based gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
214667141|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention|This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.
214880548|NCT02888730|DRUG|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
214880549|NCT02888730|DRUG|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
214880550|NCT05854524|PROCEDURE|Aerobic exercise|The intervention is exercise and there are no drugs or devices used in this trial. The exercise consists of two intensity levels of a 30-minute aerobic exercise intervention with both arms crossing over to both conditions: low intensity exercise (60-70% of estimated maximum heart rate (EMRH)) and moderate-vigorous intensity exercise (75-85% of EMHR).
214880551|NCT03697824|DRUG|GSK3377794|GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
214880552|NCT03697824|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.
214880553|NCT03697824|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
214880554|NCT03697824|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
214880555|NCT00687024|PROCEDURE|Magnetoencephalography|MEG will be performed on a whole head Omega 151-channel gradiometer system. At least 15 2-minute periods of spontaneous data are recorded. The sampling rate for data acquisition is 625Hz, with a bandpass filter of 3 to 70 Hz and a notch filter of 60Hz.
214291984|NCT03454581|PROCEDURE|Photobiomodulation|PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.
214880556|NCT00687024|PROCEDURE|MR imaging|MR imaging will be performed on a GE 1.5T system using a variety of sequences, including sagittal T1, axial T2, axial FLAIR, coronal dual echo, coronal FLAIR, axial 3D T2 frFSE and axial SPGR.
214880557|NCT00687024|PROCEDURE|Diffusion Tensor Imaging|Diffusion tensor imaging will be performed on the same scanner, using single shot diffusion-weighted echo planar imaging. Twenty-five 'xial contiguous slices are obtained aligned to the anterior commissure line to cover the whole brain, giving a total imaging time of 4min 40sec.
214880558|NCT04944524|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12months;~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
214880559|NCT04944524|DRUG|Methotrexate|"1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
214880560|NCT03046641|OTHER|Continuous training|Study group I (42 participants) received the continuous training.
214880561|NCT03046641|OTHER|The interval training|Study group II (40 participants) received the interval training.
214880562|NCT04631536|DRUG|Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|active Comparator: Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc). Treatment to be continued until 14 days or discharge/death whichever occurs first. It includes: Nebivolol 5 mg PO daily, Sigmart 10 mg PO twice daily, Atorvastatin 40 mg PO daily, Folic Acid 5 mg PO daily, L-arginine 1000 mg PO 3 times daily.
214880563|NCT04631536|DRUG|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
214880564|NCT02813941|OTHER|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
214880565|NCT02813941|OTHER|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
214880566|NCT02813941|OTHER|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
214880567|NCT02501018|BIOLOGICAL|CLBS12|Intramuscular transfusion of CLBS12.
214880568|NCT02501018|DRUG|SOC|Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
214880569|NCT02234102|DEVICE|Endoscopically guided laser ablation HeartLight system|
214880570|NCT04931121|DRUG|Viscosupplements|Synovial fluid is collected as part of a conventional injection of viscosupplement
214291985|NCT03454581|PROCEDURE|Manual Therapy (MT)|Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .
214291986|NCT02902965|DRUG|Ibrutinib|Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
214880571|NCT01065402|DIETARY_SUPPLEMENT|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
214880572|NCT01065402|DIETARY_SUPPLEMENT|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
214880573|NCT01749202|DIETARY_SUPPLEMENT|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
214880574|NCT01749202|DIETARY_SUPPLEMENT|EPA softgels|3 x 500 mg softgel capsules/day
214880575|NCT01749202|OTHER|Sunflower Oil Food|3 servings/day
215045201|NCT04052009|OTHER|combined training (conventional and end-effector-based)|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
215045202|NCT01147302|BIOLOGICAL|Placebo|
215045203|NCT01147302|BIOLOGICAL|C1 Esterase Inhibitor (Human)|
215045204|NCT00309218|DRUG|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
215045205|NCT01342094|DRUG|DE-111 ophthalmic solution|
215045206|NCT01342094|DRUG|Timolol ophthalmic solution 0.5%|
215045207|NCT01342094|DRUG|Placebo ophthalmic solution|
215045208|NCT01321814|BEHAVIORAL|Cognitive behavioural therapy|6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
215045209|NCT01170351|DRUG|Cyclosporine-A|Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
215045210|NCT03375099|BEHAVIORAL|Lethal Means Counseling|Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.
215045211|NCT03375099|BEHAVIORAL|Health and Stress Reduction|Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
214291987|NCT02902965|DRUG|Bortezomib|Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
214880576|NCT01749202|OTHER|SDA soybean Oil Food|3 servings/day
214880577|NCT01181570|DRUG|Adalimumab|Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
214880578|NCT01181570|DRUG|Placebo|Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
214880579|NCT02352870|BEHAVIORAL|Computerised Cognitive Behavioural Therapy|Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
214880580|NCT02352870|BEHAVIORAL|Telephone support|Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
214880581|NCT01730924|PROCEDURE|Pulmonary vein isolation using contact force sensing catheter|
214880582|NCT03305367|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.
214880583|NCT02708771|DRUG|Polyunsaturated fatty acids omega-3|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
214880584|NCT02708771|DRUG|Placebo|4 daily capsules of similar appearance and flavor without active ingredient
214880585|NCT01602393|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
214880586|NCT01602393|DRUG|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
214880587|NCT01602393|DRUG|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
214880588|NCT01666665|DRUG|Metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
215045212|NCT04784156|PROCEDURE|Subtalar (Talocalcaneal) Arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
215045213|NCT04784156|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
215045214|NCT02121509|DRUG|Linagliptin|1 x Linagliptin tablet
215045215|NCT02121509|DRUG|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
215045216|NCT02121509|DRUG|Metformin ER|3 x Metformin ER tablets
215045217|NCT01600287|OTHER|IAADS|"In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS error (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS error values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol."
215045218|NCT01600287|OTHER|Manual propofol administration|"In manual mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value."
215045219|NCT04713189|DRUG|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
214880589|NCT01666665|DRUG|Sugar pill|Sugar pill up to 3 times per day for 12 months
214880590|NCT02688660|OTHER|MRI Scans|
214880591|NCT02879344|OTHER|Blood draw|
214880592|NCT01139229|OTHER|hybrid everted esophagogastric anastomosis|
214880593|NCT01139229|OTHER|the conventional hand-sewn anastomosis|
214880594|NCT01139229|OTHER|a stapled anastomosis|
214880595|NCT04649944|DIAGNOSTIC_TEST|Serological test and phone interview|"Families are interviewed by telephone to gather information about the family cluster (i.e. age and number of cohabitants, their symptoms and swab results, if performed), the subject who tested positive (i.e.sex, age, course of the disease, symptoms suggestive of COVID-19) and children aged between 4 and 16 y.o. (i.e. sex, age, drug therapy and/or chronic diseases, symptoms suggestive of COVID-19).~Children, young adults and the cohabitant who previously tested positive to the swab undergo a serological test for the detection of IgG and IgM antibodies for Sars-Cov-2."
214880596|NCT00313989|PROCEDURE|Evaluation of the success rate of implants|Evaluation of the success rate of implants
214880597|NCT05847829|DEVICE|T-REEX algorithm|Phase locked transcranial stimulation.
214880598|NCT03498495|BEHAVIORAL|Self-Monitoring Activity-restriction and Relaxation Training (SMART)|SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
214880599|NCT02538822|DEVICE|dynamic imaging|In vivo study of biomechanical behavior of ATA from preoperative dynamic imaging : dynamic CT-scan and 4D-magnetic resonance imaging (MRI)
214880600|NCT02538822|DEVICE|mechanical testing|In vitro study of with mechanical inflation testing of ATA tissue harvested during surgery.
214880601|NCT03389516|OTHER|Polymem|wound care dressings
214291988|NCT02902965|DRUG|Dexamethasone|"Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects \>75 years of age.~Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter."
214291989|NCT05651633|DRUG|lidocaine hydrochloride 5mg/g|1-2 drops up to six times daily for a maximum of 7 days
214880602|NCT03389516|OTHER|Lanolin|wound care oinment
214880603|NCT06416514|OTHER|Personalized intervention|Personalized intervention means implementing multi-component non-pharmacological interventions based on different health profiles，such as art therapy, exercise therapy, cognitive therapy and other monotherapies. Usual care means care as routine.
214880604|NCT00242424|BIOLOGICAL|2005-2006 trivalent inactivated influenza vaccine|Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
214880605|NCT04450758|PROCEDURE|Bridge to Surgery (stent or stoma)|The study is an observational study and patients will not be randomized. Resection is defined as upfront surgical resection, Bridge to Surgery as a two stage procedure.
214880606|NCT02165735|BEHAVIORAL|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
214880607|NCT02165735|OTHER|Usual care|Usual HIV care
214880608|NCT03066258|GENETIC|RGX-314|RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
214880609|NCT01271218|OTHER|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
214880610|NCT01271218|OTHER|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
214880611|NCT00098618|DRUG|sorafenib tosylate|Given orally
215045220|NCT04713189|DRUG|Placebo|Participants in the stage Ⅰ were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence. I
215045221|NCT02070653|DRUG|Ticagrelor|
215045222|NCT02070653|DRUG|Placebo|
215045223|NCT01172028|DRUG|Taxotere (Docetaxel)|Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
215045224|NCT01172028|DRUG|Alimta (Pemetrexed)|ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
215045225|NCT01061528|DRUG|Transdermal Nicotine|Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
215045226|NCT02515318|OTHER|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
214880612|NCT00098618|BIOLOGICAL|recombinant interferon alfa|Given orally
214880613|NCT00098618|OTHER|laboratory biomarker analysis|Correlative studies
214880614|NCT03892018|DRUG|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
214880615|NCT02784795|DRUG|LY3039478|Administered orally
214880616|NCT02784795|DRUG|Taladegib|Administered orally
214880617|NCT02784795|DRUG|Abemaciclib|Administered orally
214880618|NCT02784795|DRUG|Cisplatin|Administered IV
214880619|NCT02784795|DRUG|Gemcitabine|Administered IV
214880620|NCT02784795|DRUG|Carboplatin|Administered IV
214880621|NCT02784795|DRUG|LY3023414|Administered orally
214880622|NCT01238107|DRUG|MT-102|BETA BLOCKER
214880623|NCT00295061|DRUG|Alpha-1 MP|alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
214880624|NCT00295061|DRUG|alpha-1 proteinase inhibitor (human)|Prolastin
214880625|NCT00595309|BIOLOGICAL|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
214880626|NCT00626561|DRUG|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
214880627|NCT00626561|DRUG|Paclitaxel|60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.
214880628|NCT00101283|DRUG|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
215045227|NCT02515318|DRUG|Medical standard treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~\- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
215045228|NCT05556434|DIAGNOSTIC_TEST|radiological evaluation|"All patients undergoing hepatectomy receive imaging evaluation and laboratory test before and after surgery to define clinical parameters.~diseases"
214291990|NCT04960150|DEVICE|Press tack needle|"Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm"
214291991|NCT04960150|DEVICE|Plesterin|Plesterin
214291992|NCT01509833|DRUG|rFSH|Administration of rFSH for ovarian stimulation.
214291993|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
214880629|NCT00101283|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
214880630|NCT00101283|DRUG|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
214880631|NCT04947917|PROCEDURE|SpotTM Tattoo Ink|Ink injection
214880632|NCT05034016|DEVICE|High Myopic Posterior Scleral Fixation System|Implant HM into the eye through posterior scleral reinforcement
214880633|NCT06124417|DRUG|Sertraline|The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication.
214880634|NCT02995863|DEVICE|Rigid Rocker Sole Footwear|
214880635|NCT02995863|DEVICE|Therapeutic Footwear|
214880636|NCT02514902|DEVICE|Lateral Flow Device|A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
214880637|NCT04812808|DRUG|Bazedoxifene 20 mg|"Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events."
214291994|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
214291995|NCT04502953|PROCEDURE|Vertical plication|Vertical plication of the rectovaginal septum was done
214291996|NCT04502953|PROCEDURE|Horizontal plication|Horizontal plication of the rectovaginal septum was done
214291997|NCT01151644|BIOLOGICAL|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
214291998|NCT00232817|DRUG|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
214880638|NCT04197778|DRUG|DDO-3055 tablet|DDO-3055 tablet, 2 single doses separated by 6 days.
214880639|NCT05224609|DRUG|Lorlatinib|Single 100mg oral dose anti-cancer agent
214880640|NCT04663971|PROCEDURE|Any surgery|Any surgical procedures performed for inflammatory bowel diseases
214880641|NCT04663971|PROCEDURE|Any medical treatment|Any treatment (including non-surgical) performed for inflammatory bowel diseases
214880642|NCT05467787|BEHAVIORAL|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
214880643|NCT05467787|BEHAVIORAL|Video-chat Psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
214880644|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate~Intra muscular"
214880645|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate~Intramuscular injection"
215045229|NCT03111030|BEHAVIORAL|ProacTive SCI|"Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:~1. An assessment of motivated the participant is to be physically active~2. A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.~   B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.~3. Progress and barriers will be reassessed and discussed."
215045230|NCT00619996|DRUG|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
215045231|NCT00619996|DRUG|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
215045232|NCT03703388|DIETARY_SUPPLEMENT|Arctigenin|Arctigenin capsule
215045233|NCT05311514|BIOLOGICAL|Allogeneic platelet lysate eye drops|Eye drops
215045234|NCT02350218|DRUG|Eglandin|Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
215045235|NCT04021290|DRUG|DTG/3TC FDC|DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
215045236|NCT04021290|DRUG|CAR|Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
215045237|NCT00636181|DEVICE|Auto AFlex|Positive pressure therapy treatment
215045238|NCT00636181|DEVICE|Auto CPAP|Positive pressure therapy treatment
215045239|NCT00636181|DEVICE|CPAP|Positive pressure therapy treatment
215045240|NCT04818905|DIETARY_SUPPLEMENT|Helichrysum italicum infusion|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
215045241|NCT04818905|OTHER|Hot water|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
215045242|NCT05477654|DIAGNOSTIC_TEST|Extensive motor-cognitive testing protocol|Screening of their functional performance while monitoring brain and muscle activity
215045243|NCT03820011|OTHER|PEM+|PEM+ is a five-step recursive process (i.e., the caregiver can repeat the five-step process to create as many intervention plans for their child as needed, relative to the number of activities in which change is desired based on the YC-PEM e-PRO, and it offers tiered support to the user during completion (tier 1: frequently asked questions available in the application, tier 2: support provided by email, tier 3: support provided by phone).
215045244|NCT04188951|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
215045245|NCT05248490|OTHER|pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization
215045246|NCT02046018|OTHER|ICCM delivered by VHT|VHT's deliver ICCM to children under five in their communities
215045247|NCT02046018|OTHER|ICCM delivered by VHT with Cell Phone|ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
214880646|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Monovalent MF59-Adjuvanted vaccine
214291999|NCT05527145|PROCEDURE|Minimally invasive surgery|Surgery with decompression. Central decompression of the stenotic segment with undercutting of the lateral recesses.
214292000|NCT05527145|PROCEDURE|Percutaneous Spacer|percutaneous image guided outpatient procedure that enables interspinous spacer insertion and fusion
214292001|NCT02197507|DEVICE|Digitized sensor|Measure of grip strength of the dominant hand
214292002|NCT04481750|DRUG|MT-1186|Solution or suspension
214292003|NCT04481750|DRUG|MT-1186-matching placebo|Solution or suspension
214880647|NCT05291338|DRUG|Doxorubicin|no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size
214880648|NCT05291338|DRUG|Lipiodol|Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.
214880649|NCT00801502|DIETARY_SUPPLEMENT|Oily fish consumption|Two portions of salmon per week from week 20 of pregnancy until giving birth
214880650|NCT00801502|OTHER|Control|No change to habitual diet from week 20 of pregnancy until giving birth
214880651|NCT02605915|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
214880652|NCT02605915|DRUG|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter\*min (mg/mL\*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
214880653|NCT02605915|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.
214880654|NCT02605915|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
214292004|NCT04316754|OTHER|music|"During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group."
214292005|NCT03344432|DIAGNOSTIC_TEST|with intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
214292006|NCT03344432|DIAGNOSTIC_TEST|without intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
214292007|NCT02178631|BEHAVIORAL|Deprexis|Online self-help
214292008|NCT02178631|OTHER|CAU|Care as usual
214292009|NCT03785665|DEVICE|MDI|Capsule MD1 (Motility dummy 1)
214292010|NCT03520231|DRUG|Denosumab|RANK Ligand Inhibitor
214292011|NCT03520231|OTHER|Denosumab Placebo|Placebo
214292012|NCT03520231|DRUG|Gemcitabine|Antineoplastic Agent
214292013|NCT03520231|DRUG|Carboplatin|Antineoplastic Agent
214292014|NCT03520231|DRUG|Cisplatin|Antineoplastic Agent
214292015|NCT03520231|DIETARY_SUPPLEMENT|Calcium|Calcium Supplement
214292016|NCT03520231|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D Supplement
214292017|NCT00301574|DRUG|galantamine|
214292018|NCT01558830|DRUG|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
214292019|NCT01558830|DRUG|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
214292020|NCT04913025|DRUG|Nivolumab|60-minute IV infusion, as a flat dose of 480mg
214292021|NCT04913025|DRUG|Pembrolizumab|60-minute IV infusion, as a flat dose of 400mg
214292022|NCT05066373|DRUG|EDP1815 capsule A|EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
214292023|NCT05066373|DRUG|EDP1815 capsule B|EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
214292024|NCT05066373|DRUG|EDP1815 tablet|EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
214292025|NCT00273442|DRUG|timolol maleate|
214292026|NCT00273442|DRUG|dorzolamide/timolol maleate fixed combination|
214292027|NCT06217289|OTHER|Observation|Observation and knowledgement on behavior of healthcare professional workers during hpreparation of oral solid pharmaceutical drug
214880655|NCT02605915|DRUG|Trastuzumab|Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
214880656|NCT02605915|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).
214880657|NCT02605915|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
214880658|NCT02605915|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
214880659|NCT05546437|DEVICE|Ion Endoluminal System|Ion Endoluminal dye marking procedure for pulmonary nodule
214880660|NCT00185588|DRUG|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
214880661|NCT00185588|DRUG|Gemcitabine|850 mg/m2
214880662|NCT02604407|DRUG|SHP465 12.5mg capsules (one capsule daily)|one capsule daily
214880663|NCT02604407|OTHER|Placebo|Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
214880664|NCT02604407|DRUG|SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)|One capsule daily
214880665|NCT03638388|PROCEDURE|Dry needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of my muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and the subject will sit in a chair without moving my arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
214880666|NCT03638388|PROCEDURE|Dry needling with intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of the muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject sits in a chair without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
214880667|NCT05980845|BEHAVIORAL|Nature sounds|Nature sounds would be played for 30 minutes in three HD sessions for one week, starting from the beginning of the session. Afterwards, the patients were informed about the usage of the Mp3 player and in-ear headphones, they were demonstrated that they could adjust the volume to the level they desired, and it was stated that they should not detach the headphones until the 30-minute recording was over.
215045248|NCT02046018|OTHER|No intervention|VHT's selected by no ICCM training given and no drugs or cell phones.
214477017|NCT06661681|BEHAVIORAL|Cognitive Functional Therapy (CFT)|"Cognitive Functional Therapy (CFT) is underpinned by a strong therapeutic alliance, active listening, and motivational interviewing style, covering the following domains:~i) Making sense of pain involves discussing the multidimensional nature of persistent pain, as well as the beliefs, emotions, and behaviors that can perpetuate the vicious cycle of pain and disability.~ii) Exposure with control involves a functional training designed to normalize maladaptive and provocative postural and movement behaviors, where individuals will learn strategies to improve their body awareness and control and modify postures and tasks commonly associated with pain.~iii) Lifestyle change aims to help patients embrace a healthy lifestyle, which will include promoting a gradual increase in physical activity, sleep hygiene counseling, stress management strategies, and social re-engagement."
214880668|NCT02335697|BEHAVIORAL|Attitude change towards female circumcision|The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
214880669|NCT02335697|OTHER|No intervention|
214880670|NCT02010645|DRUG|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
214880671|NCT02010645|DRUG|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
214880672|NCT01914692|DRUG|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
214880673|NCT03333265|DRUG|100mg Berberine hydrochloride|patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months
214880674|NCT03333265|DRUG|300mg Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months
214880675|NCT03333265|DRUG|Placebo Oral Tablet|patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
214880676|NCT00398866|DRUG|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
214880677|NCT00398866|DRUG|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
214880678|NCT00398866|DRUG|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
214880679|NCT03631316|DRUG|Generic Valganciclovir|900 mg daily during 4 days
214880680|NCT03631316|DRUG|Innovative Valganciclovir|900 mg daily during 4 days
214880681|NCT02396719|DEVICE|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
214880682|NCT05167799|DEVICE|Cardiac Contractility Modulation (CCM)|Patients will be implanted with CCM device according to indications, to improve Heart Failure symptoms and then enrolled in the Registry if they fullfil Inclusion and Exclusion Criteria (First of all if they are diagnosed with TTR Amyloidosis)
214880683|NCT00606632|DRUG|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
214880684|NCT00606632|PROCEDURE|CT|contrast enhanced CT scan
214880685|NCT03094637|DRUG|Azacitidine|Given IV
214880686|NCT03094637|BIOLOGICAL|Pembrolizumab|Given IV
214880687|NCT06316011|DEVICE|Magnetocardiography|Magnetocardiography
214880688|NCT03610230|DRUG|Iron Isomaltoside|Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
214880689|NCT03610230|DRUG|Iron sucrose|the currently most widely used intravenous iron preparation with good safety profile
214880690|NCT00191191|DRUG|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
214880691|NCT00191191|DRUG|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
214880692|NCT05445492|DEVICE|CPM Device|The CPM device and reference device are used simultaneous to validate the CPM device.
214880693|NCT05175040|PROCEDURE|Prophylactic manual rotation|Prophylactic manual rotation, performed in the experimental arm, involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation, performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.
214880694|NCT05175040|PROCEDURE|Sham rotation|Sham rotation, performed in the comparator arm, involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation. Duration of the vaginal exam for sham rotation will be consistent with that used for prophylactic manual rotation and will be performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.
214880695|NCT05973968|DRUG|Surufatinib|Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1) or death (during the treatment of the patient). The treatment and survival status of the tumor after disease progression were recorded.
214880696|NCT02289872|DEVICE|Macintosh Laryngoscope|Direct-Laryngoscopy
214880697|NCT02289872|DEVICE|TruView PCD Video laryngoscope|Video-Laryngoscopy
214880698|NCT03633825|BEHAVIORAL|Brief help-seeking barrier reduction intervention|The BRI was designed to overcome common concerns and misconceptions (i.e., barriers) related to using crisis services. It works by first asking the user about what potential barriers may keep them from using the crisis service referrals, and then, based on the user's response, by providing information intended to help the user overcome the potential barrier(s) they selected. By exploring the menu of barriers, users could read brief messages designed to dispel common misconceptions or concerns related to each barrier. For example, a common concern among Koko users was that calls to lifelines invariably result in visits by the police or other emergency services. Users who feared this possibility could tap on the associated button and learn that active rescues such as these are extremely rare, and occur in less than one percent of all cases. Whenever possible, we used language throughout the intervention to help validate the experiences of the users.
214880699|NCT03348163|DRUG|B/FTC/TAF|B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)
214880700|NCT03348163|DRUG|Current ART|Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
214880701|NCT01749423|BIOLOGICAL|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
214880702|NCT03390855|OTHER|Broccoli sprouts|
214880703|NCT05392218|BEHAVIORAL|motivational interviewing|consisted of six sessions (twice each week) up to 30 minutes of individual sessions. Each session contained a different component and topic that included substance abuse, physical activity, healthy sleep, stress management, nutrition and social support. The components in order were randomized for each participant.
214880704|NCT05392218|BEHAVIORAL|general health education|rceived the same amount of virtual session equivalent to MI form. However, the structure of the sessions consisted of brief advice to promote healthy lifestyle delivered by different therapists
214880705|NCT01657435|DEVICE|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
214880706|NCT01964079|DRUG|Amlodipine|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
214880707|NCT01964079|DRUG|Losartan|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
214880708|NCT02423421|OTHER|Faecal microbiota transplantation|Human Stool.
214880709|NCT05894837|DRUG|Serplulimab+Regorafenib|Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
214880710|NCT05894837|DRUG|Hepatic Artery Bicarbonate Infusion|hepatic artery bicarbonate infusion: once every four weeks
214880711|NCT03646994|DRUG|Crizotinib|Crizotinib Cap 250 mg po bid
214880712|NCT01102101|DRUG|Remifentanil|Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.
214880713|NCT05639582|OTHER|fractal analysis|fractal analysis is a method that numerically expresses bone changes.
214880714|NCT01267994|DRUG|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
214880715|NCT00004180|DRUG|rosiglitazone maleate|
214880716|NCT03837743|DRUG|DUR-928 Topical Solution|Topical solution containing active drug
214880717|NCT03837743|DRUG|Vehicle Topical Solution|Topical solution containing no active drug
214880718|NCT01350583|DRUG|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
214477018|NCT06661681|OTHER|Therapeutic exercises group|Each session will include stretching exercises targeting the following muscles i) Upper trapezius; ii) Pectoralis minor; iii) Posterior shoulder region, and strengthening exercises targeting the following muscles i) Lower trapezius, ii) Middle trapezius, iii) Serratus punch exercise, iv) Shoulder external rotators, and v) Shoulder internal rotators.
214880719|NCT02293889|DIETARY_SUPPLEMENT|Vitamin D3 2000IU/daily 3 months|Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (\>50nmol/L) by 3 months.
214880720|NCT02293889|BEHAVIORAL|PA intervention People with Osteoarthritis Walking Programme|The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
214667142|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention|This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
214667143|NCT01020331|DRUG|Memantine|
214667144|NCT03832231|DEVICE|Shear Wave Elastography|Ultrasound technology to assess tissue stiffness
214667145|NCT02916446|BIOLOGICAL|Viaskin Peanut 250 mcg|
214880721|NCT02293889|OTHER|Placebo capsule (Vitamin D): edible oil|Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
214880722|NCT04730037|DRUG|Edoxaban|\- Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
214880723|NCT04730037|DRUG|Warfarin Potassium|\- Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)
214880724|NCT04730037|DRUG|Warfarin Potassium placebo|\- Warfarin K 1 mg placebo tablets once daily
214880725|NCT04730037|DRUG|Edoxaban placebo|\- Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
214880726|NCT03388489|BEHAVIORAL|Mind-Body Walking|walking, breathing, and mindfulness
214880727|NCT00424918|BEHAVIORAL|Physical Activity, reduced sedentary behavior|
214880728|NCT01857843|DEVICE|Zotalolimus Eluting Stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1."
214880729|NCT01857843|DEVICE|Everolimus eluting stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1."
214880730|NCT01857843|DRUG|Ezetimibe 10mg & Simvastatin 40mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
214292028|NCT05039242|OTHER|Conventional Physical Therapy)|"Participants will receive a Hand exercise program including 8 different movements according to Flat 20 (flexion, extension, radial deviation of the fingers, dorsal flexion, palmar flexion, ulnar deviation of the fingers, and opposition and abduction of thumbs.~Repetitions include 5 times during each session, as given in the study. Balanced resistive hand exercise with use of physio hand ball squeezes including finger abduction and adduction exercises with MCP extended and gross grip.~Each contraction to be held for 3-5 seconds with a 20-second rest between contractions. Five repetitions of each resistive exercise will be done."
214880731|NCT01857843|DRUG|Pravastatin 20mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
214292029|NCT05039242|OTHER|Kinesiotaping with I shaped application|Participants will receive Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm with less than 50% stretch of the subjects on both hands, once a week for a total time period of 4 weeks with 4 KT applications in total (19). Kinesiotape will be worn by the subjects for 3 days. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs.
214880732|NCT06625632|DRUG|Antiemetic Drug|All participants in the two groups will receive antiemetic drugs (ondansetron 4 mg) every 12 hours, for 5 days.
214880733|NCT06625632|DIETARY_SUPPLEMENT|Vitamin B6|All participants in the two groups will receive vitamin B6 (50 mg), once daily, for 5 days.
214880734|NCT06625632|OTHER|Home care advice|All participants in both groups will be advised to eat small portions of food, drink plenty of liquids, and avoid fatty and fried foods. Additionally, they should steer clear of highly spiced foods, foods and beverages with strong odors, caffeine, and consume neither very hot nor very cold foods and liquids.
214880735|NCT06625632|OTHER|Kinesiotaping|It will be applied for all participants in the experimental group only for 5 days. The participant will be asked to stand in erect position, her hands beside her body then applying the kinesiotape from origin (from top to bottom where the stomach is placed on the abdominal region) to insertion (alongside the gastric curvature) with tension 25% for 5 days.
214880736|NCT01275430|DEVICE|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
214880737|NCT01275430|OTHER|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
214880738|NCT03096912|DRUG|Ribociclib|Ribociclib Oral 600 mg x 1 a day 21 days on 1 week off in 28 days cycles
214477019|NCT04408430|DEVICE|Transseptal ViMAC|Transseptal TMVR using balloon-expandable aortic transcatheter valves.
214477020|NCT06663696|DEVICE|Supraflex Cruz Sirolimus-eluting Coronary Stent System|Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent
214880739|NCT02558439|DRUG|CNTX-4975|
214880740|NCT02558439|OTHER|Placebo|
214880741|NCT04069338|PROCEDURE|Lithotripter|Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
214880742|NCT03145389|PROCEDURE|Epidural catheter placement|After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
214880743|NCT03277924|DRUG|Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
214477021|NCT06660719|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
214880744|NCT03277924|DRUG|Nivolumab 100 MG/10 ML [Opdivo]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
214880745|NCT03277924|DRUG|Epirubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
214880746|NCT03277924|DRUG|Ifosfamide|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
214880747|NCT03277924|DRUG|Doxorubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
214880748|NCT03277924|DRUG|Dacarbazine|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
214880749|NCT03277924|DRUG|Cisplatin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
214880750|NCT03277924|DRUG|Methotrexate|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
214880751|NCT02175901|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
214880752|NCT02175901|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
214880753|NCT02175901|DRUG|Amoxicillin|antibiotic of each quadruple therapy
214880754|NCT02175901|DRUG|Metronidazole|antibiotic of the amoxicillin/metronidazole-based quadruple therapy
214880755|NCT02175901|DRUG|Clarithromycin|antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
214880756|NCT03223701|COMBINATION_PRODUCT|Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion|The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
214880757|NCT04759768|DRUG|Nalmefene Hydrochloride|3mg nasal spray
214880758|NCT04759768|DRUG|Nalmefene|1mg intramuscular injection
214880759|NCT02996487|DRUG|Vancomycin|
214477022|NCT06660719|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
214477023|NCT06661083|DIETARY_SUPPLEMENT|EGCG, FA, HA, B12|EGCG + FA + HA + B12 (1 cps /die)
214667146|NCT02916446|BIOLOGICAL|Placebo|
214667147|NCT05634564|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously on Days 1 of every 3 weeks.
214880760|NCT02996487|OTHER|Placebo|
214880761|NCT04492592|BEHAVIORAL|Workshop|Workshop
214880762|NCT04492592|BEHAVIORAL|SMS/Texting|SMS/Texting
214880763|NCT04898530|OTHER|NO INTERVENTION|There is no intervention for this study.
214880764|NCT05755971|OTHER|Combination taping|Elastic and rigid tapes applied together for six weeks
214880765|NCT07134049|OTHER|sensory integration therapy|"Sensory Integration Therapy (SIT) is a client-centered rehabilitation approach aimed at improving adaptive and functional responses to sensory stimuli in changing environments. It is based on structured, individualized activities conducted in enriched sensory environments. These environments are designed to be engaging and motivating for children through the use of interactive and playful tasks that match their sensory processing profiles.~Sensory integration plays a key role in motor planning, postural control, attention, and emotional regulation. Deficits in sensory integration-particularly in vestibular, tactile, and proprioceptive systems-may result in poor muscle tone, difficulty with balance and coordination, and impaired motor planning. These issues can negatively impact the development of gross motor, fine motor, language, and academic skills. For this reason, sensory-based interventions that support neural organization and promote adaptive responses are commonly recommended i"
214880766|NCT07135128|DRUG|225Ac-FAPI-XT|Patients will receive \[225Ac\]Ac-FAPI-XT(XT117) administration at an interval of 6 weeks between each dose.
214880767|NCT07133997|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
214880768|NCT07133997|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214880769|NCT07133997|BIOLOGICAL|Blinatumomab|Given CIV
215045250|NCT06566014|OTHER|Evaluation of XAI-assisted spina bifida diagnosis|AI feedback
215045251|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|30 µg
215045252|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|300 µg
215045253|NCT04224701|BIOLOGICAL|Placebo|Tris NaCl Diluent
214667148|NCT05634564|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
214880770|NCT07133997|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214880771|NCT07133997|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214880772|NCT07133997|DRUG|Cyclophosphamide|Given cyclophosphamide
214880773|NCT07133997|PROCEDURE|Echocardiography Test|Undergo ECHO
214880774|NCT07133997|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214880775|NCT07133997|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214880776|NCT07133997|DRUG|Venetoclax|Given PO
215045254|NCT04476576|BEHAVIORAL|Aerobic exercise (experimental)|3 times per week, 30 minutes each time. Entrance in heat: 8-10 min of joint mobility and / or the aerobic exercise in the main part at light intensity (OMNI 3-4) Main part: minimum 30 minutes, maximun 60 minutes. Intensity: moderate, guided by Talk Test and effort perception scale 5-6 OMNI. Type: aerobic, cycling or walking at home using a treadmill or exercise bike and / or cycling and walking outdoors according to the patient's possibilities and preferences. Return to calm: 5 min of aerobic physical activity of main part at mild intensity (OMNI 3-4), then static stretching. Pictures with each type of exercise will be offered and detailed explained.
215045255|NCT04476576|BEHAVIORAL|Flexibility exercise (active comparator)|Entrance in heat: 10 min of joint mobility. Main part: Minimum 30 minutes. Frequency: 3 times por week Intensity: The patient should be able to slowly stretch the muscle to a position of mild discomfort. Type: Static Stretch Time: 15-30 seconds 2 repetitions of each stretch Number of exercises: 12 . Pictures with each muscle group to exercise will be offered and detailed explained.
215045256|NCT05015504|BEHAVIORAL|Time restricted feeding|In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
215045257|NCT03069716|DEVICE|Smartphone Text Messaging|A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
214292030|NCT05039242|OTHER|Kinesiotaping with Fan-shaped Application|"Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects, once a week for a total time period of 4 weeks with 4 KT applications in total.~Kinesiotape will be worn by the subjects for 3 days. Less than 50% stretch with space correction technique. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs."
214880777|NCT07133997|DRUG|Vincristine|Given vincristine
214880778|NCT07134205|DRUG|JMT101|JMT101, 6 mg/kg, administered by IV infusion once every two weeks (one treatment cycle is 4 weeks).
214880779|NCT07134205|DRUG|Irinotecan|Irinotecan, 180mg/m\^2, administered by IV infusion once every two weeks (one treatment cycle is 4 weeks).
214880780|NCT07134205|DRUG|Regorafenib|Regorafenib, 160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
214880781|NCT07133698|DEVICE|High Flow nasal Cannula|"Eligible subjects successfully passing a SBT will be extubated and immediately randomized (1:1:1) to receive one of the following post-extubation respiratory supports for ≥24 hours:~HVNI Arm: High-Velocity Nasal Insufflation (Flow: 40-60 L/min, FiO₂ titrated to SpO₂ ≥92%)."
214880782|NCT07133698|DEVICE|High velocity nasal insufflation|HFNC Arm: High-Flow Nasal Cannula (Flow: 50-60 L/min, FiO₂ titrated to SpO₂ ≥92%).
214880783|NCT07133698|DEVICE|Noninvasive ventilation|NIV Arm: Non-Invasive Ventilation (Mode: \[e.g., PSV\], IPAP: \[e.g., 8-12 cmH₂O\], EPAP: \[e.g., 4-6 cmH₂O\], FiO₂ titrated to SpO₂ ≥92%) delivered via \[e.g., oronasal mask\] for ≥16 hours/day initially, with weaning per protocol.
214880784|NCT07133945|PROCEDURE|Silicone plaster or Steristrip or Vaseline|Prophylatic treatment of the skin before breakage of the skin in dupuytrens disease
214880785|NCT07115069|DRUG|GLP-1 receptor agonist|Any FDA-approved GLP-1 receptor agonist
214880786|NCT07115069|PROCEDURE|Gastric Bypass Surgery (laparoscopic)|Patients undergo laparoscopic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
214880787|NCT07115069|PROCEDURE|Gastric Bypass Surgery (robotic)|Patients undergo robotic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
214880788|NCT07134166|OTHER|data collection|data collection
214880789|NCT07135050|GENETIC|MZ-1866|AAV-9 gene therapy delivered by intracerebroventricular injection
214880790|NCT07134647|BEHAVIORAL|video animation-supported inhaler medication training|"The training is presented not verbally but with the prepared Video Animation Support"
214880791|NCT07133750|DRUG|PM8002|IV infusion
214880792|NCT07133750|DRUG|Chemotherapy Regimen 1|IV infusion
214880793|NCT07133750|DRUG|Chemotherapy Regimen 2|Oral administration and IV infusion
214880794|NCT07133282|BEHAVIORAL|Group exercise programme|12-week group exercise programme
214880795|NCT07133334|OTHER|Selenium disulfide|1% SeS2
214880796|NCT07133334|OTHER|Piroctone olamine|0.5% piroctone olamine
214880797|NCT07134465|DRUG|HSK31858 Tablets and Itraconazole Capsules|"HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered.~Itraconazole capsules After a 10-day washout period, Take Itraconazole capsules 200mg in the morning and 200mg in the evening on D11 . A single dose of Itraconazole capsules 200 mg will be administered every morning from Day 12 to Day 14. On the morning of Day 15, take a single dose of itraconazole capsules 200mg, followed by a single dose of HSK31858 tablets 40 mg 1 hour later,"
214880798|NCT07133256|BEHAVIORAL|Resistance Exercise|Structured machine-based resistance exercise protocol performed under supervision, targeting osteogenic loading to improve bone mineral density and alter bone metabolism markers in CKD stage 3-4 patients.
214667149|NCT05634564|DRUG|Nab paclitaxel|Gemcitabine 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
214667150|NCT05634564|RADIATION|Hypofractionated radiotherapy with simultaneous integrated boost|Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions.
214880799|NCT07133256|BEHAVIORAL|Aerobic Training|"Participants in this arm performed supervised aerobic exercise (treadmill walking) three times per week for six months. Each session included:~5-minute warm-up~30-minute treadmill walking at 60%-80% of age-predicted maximum heart rate (HRmax = 220 - age)~10-minute cool-down Exercise sessions were supervised by trained exercise professionals and tailored to maintain target heart rate zones."
214880800|NCT07133815|DRUG|SHR-1918|SHR-1918
214880801|NCT07134413|DRUG|QL1706 plus bevacizumab with or without chemotherapy|"QL1706(iparomlimab and Tuvonralimab) was generated by using MabPair, a new technological platform that enables the production of two antibodies close to their natural forms from a single host cell line and is manufactured as one product. QL1706 contains a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 that were produced together in a fixed ratio. Each antibody was individually optimized to achieve desirable target coverage and antibody effector functions.~Bevacizumab is a monoclonal antibody medication used to treat various cancers and a specific eye disease. It works by blocking a protein called VEGF, which helps tumors form new blood vessels, thus starving the tumor of nutrients and oxygen.~Chemotherapy (nab-paclitaxel, pemetrexed, or docetaxel) Nab-paclitaxel, also known as nanoparticle albumin-bound paclitaxel, is a chemotherapy drug used to treat certain cancers. It's a form of paclitaxel that's bound to albumin nanoparticles, which improves its solubility and delivery to cance"
214880802|NCT07133542|BEHAVIORAL|Dynamic Matrix Management for Weight Control (DMM-WC)|Precision weight management using a two-dimensional grid model. Participants undergo bi-weekly positioning on a waist risk-body fat matrix (9 grids), receiving tiered interventions (e.g., high-intensity exercise + dietary control for high-risk grids; maintenance plans for low-risk grids). Real-time progress feedback via visual spatial migration maps promotes adherence. Comparator group receives standardized aerobic prescription without dynamic adjustments.
214880803|NCT07133542|BEHAVIORAL|Standard Aerobic Prescription|Personalized progressive aerobic exercise program. Participants receive baseline-adjusted intensity prescriptions (40-90% heart rate reserve), with adherence monitored via wearable devices. NO dynamic adjustments, tiered strategies, or visual feedback are provided throughout the 8-week intervention.
214880804|NCT06828224|DEVICE|KOS® L|Delivery of medical device as injection
214880805|NCT04521803|DRUG|high dose Rifampicin (RIF)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
214880806|NCT06655857|OTHER|Usual Care|Participants are provided care as usual. Clinicians (CKD, HD, KTx) will educate participants on the kidney transplant process. Clinician will receive the education intervention to provide participants at study end.
214880807|NCT06655857|OTHER|Community Health Worker Assistance|Community health worker will address unmet social needs and participant symptoms through evaluations and intake to clinical and community services
214880808|NCT06655857|OTHER|Intervention Providers|Intervention providers will receive education, which will include training on working with CHWs, reducing bias in clinical decision-making, and increasing affirming/reducing stigmatizing language in electronic health records (EHRs).
214880809|NCT06599216|DRUG|Adebrelimab+Dalpciclib+Standard Endocrine Therapy|Adebrelimab: 1200mg, intravenously, Q4w Dalpiciclib: 150mg once a day for 3 weeks, stop for 1 week, Q4w Standard Endocrine Therapy: Choice of endocrine therapy is according to guidelines and centre policy by investigator
214880810|NCT06983639|DIAGNOSTIC_TEST|Fecal occult blood testing|Fecal testing for blood as surveillance efter polyp removal
214880811|NCT06983639|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy after polyp removal according to guidelines
214880812|NCT00000591|PROCEDURE|lymphocyte depletion|
215045258|NCT03069716|DEVICE|Fitbit Charge HR|The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
215045259|NCT06503185|BEHAVIORAL|Prehabilitation|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
215045260|NCT05437419|DRUG|TCK-276|Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.
214292031|NCT01252017|DRUG|nilotinib|nilotinib (200mg/tab) 1 tab everyday
214667151|NCT01132014|BIOLOGICAL|OCDC|OCDC,an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with either intravenous Daclizumab, or with a combination of Daclizumab and intravenous Bevacizumab.
214667152|NCT04192604|OTHER|WMSDsQ|Work-related MusculoSkeletal Disorders Questionnaire
214667153|NCT02940964|BEHAVIORAL|Count on me Singapore (COMS) CPR|Using the song as a mental metronome to guide CPR.
214667154|NCT02940964|BEHAVIORAL|Standard CPR|"Standard CPR with one-and-two-and-three.... counting"
214667155|NCT00863668|DRUG|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
214667156|NCT00863668|DRUG|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
214667157|NCT00863668|PROCEDURE|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
214880813|NCT06981598|BEHAVIORAL|Cognitive Behavioral Coaching Training|Behavioral technicians will engage in a structured, deliberate-practice-based training program designed to enhance competence in evidence-based interventions (EBIs) over a 10-week period. The program begins with an initial seminar that provides an overview of the training framework, key research supporting deliberate practice, and specific intervention techniques. Each participant is assigned a coach-either a clinical psychologist or a licensed MSW with expertise in the EBI Toolkit-who will provide individualized guidance throughout the training. During the weekly coaching sessions, participants will review session notes, engage in structured practice exercises, and work toward mastering the skills and competencies necessary for effective intervention delivery. Weekly homework assignments will allow participants to practice each tool as though they were working with an SM client, followed by self-reflections that will be discussed in coaching sessions.
214880814|NCT06981611|BEHAVIORAL|Vulvodynia Intervention: a multimodal treatment for provoked vulvodynia|The intervention is based around physiological and psychosocial components working with goal-directed behavioral change. Includes both educational and practical elements, examples of these are vulva care, lubrication exercises, pelvic floor relaxation, work with thoughts, feelings, and behaviors related to the pain, as well as thoughts, feelings and behaviors related to sex and desire, and educational and practical elements focusing on open communication and validation. The treatment sessions are approximately 60 minutes each. There is a possibility for the participants to involve partner during two of the treatment sessions.
214880815|NCT04288479|BEHAVIORAL|Single high-intensity interval training session|10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
214880816|NCT04603547|DEVICE|Transcutaneous Carbon Dioxide Monitoring|Once an infant is identified as being eligible for TH treatment and hypothermia was initiated according to the department clinical practice guidelines, and written informed consent was obtained from one of the parents, tcPCO2 monitoring can be started. Transcutaneous CO2 will be measured by SenTec Digital Monitor (software version SW-V07.00; MPB SW-V05.00.12) with V-Sign™ Sensor (SenTec AG, Thervil, Switzerland). Also, we will use small blood samples (0.2 ml) from clinical blood draws up to 4 times following starting transcutaneous CO2 monitoring for measuring blood gas for research purposes.
214880817|NCT06856213|DRUG|Cetuximab|Cetuximab 250 mg/m2 will be administered as an intravenous infusion over 60 minutes. Cetuximab loading dose is 400 mg/m2 infusion and will be administered over 120 minutes. During maintenance, cetuximab at 500 mg/m2 will be administered as an intravenous infusion over 120 minutes.
214880818|NCT06856213|DRUG|Paclitaxel|Paclitaxel at a dose of 80 mg/m² will be administered after cetuximab as an intravenous infusion over 60 minutes weekly.
214880819|NCT04961463|BEHAVIORAL|psychoeducation|
214880820|NCT02602600|DRUG|Liraglutide|"* Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~* Weight maintenance diet for 2 weeks"
215045261|NCT05437419|DRUG|TCK-276 Placebo|Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.
215045262|NCT05076045|DEVICE|Personal sound amplification products|Participants will be tested with bilateral personal sound amplification products.
215045263|NCT03391882|DRUG|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
215045264|NCT03391882|DRUG|subcutaneous apomorphine|subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
215045265|NCT02786056|OTHER|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
215045266|NCT03014804|BIOLOGICAL|autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Given ID
215045267|NCT03014804|OTHER|Laboratory Biomarker Analysis|Correlative studies
215045268|NCT03014804|BIOLOGICAL|Nivolumab|Given IV
215045269|NCT03014804|OTHER|Quality-of-Life Assessment|Ancillary studies
215045270|NCT03014804|OTHER|Questionnaire Administration|Ancillary studies
215045271|NCT06080555|DRUG|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.
214292032|NCT05346159|DIAGNOSTIC_TEST|the correlation between level of adrenal androgen and gender-typed behavior in Girls with TS|"Laboratory assessment Serum dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) will be measured using an enzyme mediated chemiluminescence for all participants Gender-typed behavior assessment~* Parents of girls aged two to six years will evaluate their children's gender-typed behavior using the Pre school Activities Inventory~* For girls above 6 years gender characteristics and gender role behavior will be evaluated using The Children's Sex Role Inventory (Child-adapted version of the original Bem Sex Role Inventory)~* For all participants a Parent-Report Gender Identity Questionnaire for Children will be used to evaluate gender role behavior"
215045272|NCT06080555|DRUG|Ferric Carboxymaltose Injection [Ferinject]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
215045273|NCT02128022|DRUG|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
215045274|NCT02128022|DRUG|Glibenclamide|Oral Glibenclamide 5mg
215045275|NCT06322134|OTHER|Drowning incident|Patients categorized as drowning have been experiencing respiratory impairment from submersion or immersion in liquid and needing rescue by the Royal Danish Air Force's Search and Rescue (SAR) helicopters.
215045276|NCT05752656|OTHER|Clinical examinations|Clinical examinations and administration of clinical scales
215045277|NCT05230576|DIAGNOSTIC_TEST|Deep learning training cohort|train the deep learning model
215045278|NCT05230576|DIAGNOSTIC_TEST|Deep learning validation cohort|evaluate the model
214880821|NCT05245318|OTHER|Standard Clinical care|The standard care treatment comprises 12 face-to-face individual physiotherapy sessions at a ratio of 1 session a week. Every patient in the control group will be treated in a tailored manner according to their results on the baseline measurements. The multimodal treatment program will consist of exercises to increase strength, endurance and coordination of the cervical spine and shoulder stabilising muscles, exercises to increase mobility and improve posture. In case of jaw complaints stretching exercises of the masticatory muscles are added to the program. In addition, manual mobilisations and manual techniques to decrease muscle tension in neck and jaw muscles can be added to the exercise program if necessary. Patients will receive counselling to learn about their neck/jaw complaints but no tinnitus counselling. Patients will be motivated to perform the exercise program at home on a daily basis. Patients will be evaluated weekly.
214880822|NCT05245318|DEVICE|Blended physiotherapy program|The experimental group will receive a blended physiotherapy program consisting of six physiotherapy treatments over a period of 12 weeks, meaning one treatment session every two weeks. In addition, a smartphone application will offer the patients a daily exercise program, based upon the standard physiotherapy treatment, and psychological counselling. Before the start of the program, the exercises will be tailored to the area, type and degree of the patient's dysfunctions. During the six physiotherapy treatment sessions patients will (if needed), receive additional manual mobilisations to increase mobility of the neck and/or temporomandibular joints or manual techniques to decrease muscle tension in neck and jaw muscles. Additional counselling on knowledge about neck and jaw pain and advice about good posture and movement habits will also be provided by the physiotherapist during these six treatment sessions.
214880823|NCT03563651|PROCEDURE|Biopsy|Undergo biopsy
214880824|NCT03563651|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and stool
214880825|NCT03563651|OTHER|Laboratory Biomarker Analysis|Correlative studies
214880826|NCT03563651|OTHER|Questionnaire Administration|Ancillary studies
214880827|NCT00000116|DIETARY_SUPPLEMENT|Vitamin A|15000 IU/d as retinyl palmitate
214880828|NCT00000116|DIETARY_SUPPLEMENT|Docosahexaenoic acid|1200 mg/d
214880829|NCT00000116|DIETARY_SUPPLEMENT|Control fatty acid|
214880830|NCT00967655|BIOLOGICAL|panitumumab|
214667158|NCT00863668|PROCEDURE|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
214292033|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
214292034|NCT01594125|DRUG|Nintedanib low dose|twice daily oral dosing
214292035|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
214292036|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
214880831|NCT00967655|DRUG|capecitabine|
214880832|NCT00967655|DRUG|irinotecan hydrochloride|
214880833|NCT00967655|PROCEDURE|neoadjuvant therapy|
214880834|NCT00967655|PROCEDURE|therapeutic conventional surgery|
214880835|NCT00967655|RADIATION|radiation therapy|
214880836|NCT00093119|DRUG|ABI-007|
214880837|NCT04085055|DIAGNOSTIC_TEST|Solid pancreatic mass lesion biopsy|The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
214880838|NCT05079581|OTHER|Pelvic floor exercises|"The participants in the intervention group will be taught exercises involving strengthening the muscles around the pelvic floor in sitting, standing and lying positions by a physiotherapist who has been trained in women's health for 4 years and will be asked to perform them as home exercises every day for 8 weeks. The exercises are as follows:~They will be asked to tighten the muscles around the urethra, vagina and rectum as hard as possible, upwards and inwards (from the bottom up) and hold it in this way for 8-10 seconds. It will be applied in different positions as in the table."
214880839|NCT05223140|BEHAVIORAL|Birth within 7 minutes of rumping|Birth within 7 minutes of rumping (+3 station), within 5 minutes of birth of pelvis, within 3 minutes of birth of umbilicus
214880840|NCT05223140|BEHAVIORAL|Premature cord clamping|Umbilical cord clamping \<1 minute following birth
214880841|NCT00743418|DEVICE|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
214880842|NCT01716975|DRUG|EVP-6124|Arms 1, 2
214880843|NCT01716975|DRUG|Placebo|Arm 3
214880844|NCT06321679|PROCEDURE|Imaging evaluation|each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
214880845|NCT01130597|DRUG|patiromer|Active investigational drug
214880846|NCT01130597|DRUG|spironolactone|
214880847|NCT04529954|DRUG|Valproic Acid delivered to ICV|Valproic Acid delivered to ICV via an implantable pump and catheter system
214880848|NCT00822978|DRUG|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
214667159|NCT02112968|PROCEDURE|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
214880849|NCT06470178|COMBINATION_PRODUCT|corhot1: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
214880850|NCT06470178|COMBINATION_PRODUCT|corhot2: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
214880851|NCT03816943|BEHAVIORAL|Whatsapp|a WhatsApp message with encouraging words will be sent after bond up
214880852|NCT03816943|BEHAVIORAL|Call|a telephone call will be made after bond up to provide encoring words
214880853|NCT03921593|PROCEDURE|Solid Organ Pancreas Transplantation with or without Kidney Transplantation|Deceased donor pancreas transplantation
214880854|NCT04646876|DRUG|Magnesium Sulfate|Prospective , comparative , double blind study
214880855|NCT04646876|DRUG|Placebo|Prospective , comparative , double blind study
214880856|NCT05052476|DIETARY_SUPPLEMENT|Bactecal® D Liquid|The patients will be randomized into two arms, A and B, in function of the intervention dose
214880857|NCT01301729|DRUG|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
214880858|NCT01301729|DRUG|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
214880859|NCT01301729|DRUG|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
214880860|NCT03039114|DRUG|Parsaclisib|Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.
214880861|NCT03039114|DRUG|Hexal|Bendamustine 90 mg/m\^2 administered intravenously at protocol-defined timepoints.
214292037|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
214667160|NCT02112968|PROCEDURE|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
214667161|NCT02112968|PROCEDURE|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
214667162|NCT00202540|DRUG|S18986|
214667163|NCT06447792|OTHER|Loading protocol|The prosthetic restoration and functional loading of the dental implant.
214667164|NCT05233995|PROCEDURE|Damage Control Surgery|Delayed anastomosis
214880862|NCT03039114|DRUG|Gazyvaro|Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
214880863|NCT00200044|DEVICE|Gatekeeper Reflux Repair System|The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score \>15.
214880864|NCT06858007|DEVICE|KOS® M|Delivery of medical device as injection
214880865|NCT05520125|BIOLOGICAL|Mesenchymal stem cells enriched by extracellular vesicles|Mesenchymal stem cells enriched by extracellular vesicles
214880866|NCT05520125|OTHER|Standard treatment of bone defects|Standard surgical treatment of bone defects
214880867|NCT06990256|DIETARY_SUPPLEMENT|Fisetin intervention|Participants assigned to this intervention take capsules containing a fixed dose of Fisetin daily after breakfast.
214880868|NCT06990256|DIETARY_SUPPLEMENT|Placebo|Participants assigned to this intervention take a capsule containing 500 mg of corn starch daily after breakfast.
214880869|NCT06990256|DIETARY_SUPPLEMENT|Urolithin A intervention|Participants assigned to this intervention take capsules containing a fixed dose of Urolithin A daily after breakfast.
214880870|NCT01956305|DRUG|DS-7309|DS-7309 powder in bottle
214880871|NCT01956305|DRUG|placebo|placebo to match DS-7309 powder in bottle
214880872|NCT01956305|DRUG|Metformin|Metformin 500mg tablet for Cohort F
214880873|NCT04704570|OTHER|Exercise|Spinal stabilization exercise
214880874|NCT04704570|OTHER|Remotely and face to face evaluation of Functional Capacity Level|Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
214880875|NCT03870165|BEHAVIORAL|Resistance exercise|Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
214880876|NCT03870165|OTHER|Salmon|Participants will ingest salmon immediately after resistance exercise
214880877|NCT03870165|DIETARY_SUPPLEMENT|Isolated amino acids and fatty acids|Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
214880878|NCT05761665|OTHER|Evaluation|Kinesiophobia=Tampa scale Balance=Berg Balance Scale Falling=The Fall Activity Scale( Tinetti) Walking speed=Timed Get Up and Walk Test ,Two-Minute Walking Test Fragility=Frail Fragility Questionnaire, Clinical Fragility Scale
214667165|NCT03542552|DRUG|Magnesium Sulfate|Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
214667166|NCT03542552|DRUG|Nifedipine|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
214880879|NCT06446128|BIOLOGICAL|CD19/CD20/BCMA CAR T cells|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CD19/CD20/BCMA CAR T cells.~Cyclophosphamide and fludarabine will be given from day-5 to day-3 before the infusion for lymphodepletion. On day0 subjects will receive one dose treatment with CD19/CD20/BCMA CAR T cells by intravenous (IV) injection"
214880880|NCT04873934|DRUG|Inclisiran|Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
214880881|NCT02567240|OTHER|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
214880882|NCT01739660|DRUG|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
214880883|NCT05794503|DRUG|Neostigmine|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.
214880884|NCT05794503|DRUG|Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex
214880885|NCT02567630|BEHAVIORAL|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
214880886|NCT05638061|OTHER|Soy protein|Soy foods or isolated soy protein
214880887|NCT06998966|BEHAVIORAL|Algorithmic Defaulting (Indication-Based Default)|PPIs are frequently overprescribed, and the CareConnect default prescription setting of 90 days with three refills (360 pill days) exceed standard guidelines (in most cases, 60 pill days). It is unclear whether this is the most appropriate workflow. Given that deprescribing PPIs carries minimal risk for most patients, this initiative will assess whether modifying defaulted prescription lengths influences prescribing behavior while ensuring physicians retain full decision-making authority.
214880888|NCT06998966|BEHAVIORAL|Active Physician Choice|PPIs are frequently overprescribed, and the CareConnect default prescription setting of 90 days with three refills (360 pill days) exceed standard guidelines (in most cases, 60 pill days). It is unclear whether this is the most appropriate workflow. Given that deprescribing PPIs carries minimal risk for most patients, this initiative will assess whether requiring providers to actively select prescription lengths influences prescribing behavior while ensuring physicians retain full decision-making authority.
214667167|NCT01850810|OTHER|Experimental Study Product|
214667168|NCT01850810|OTHER|Control Study Product|
214667169|NCT03446924|DIETARY_SUPPLEMENT|Phosphatidic Acid|To be administered a single dose of 1.5 g phosphatidic acid in capsule form (250 mg / capsule).
214880889|NCT00497861|PROCEDURE|Activator Methods Chiropractic Technique|
214880890|NCT01051947|DRUG|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
214880891|NCT01051947|DRUG|Metoprolol|dosage prescribed prior to starting on study
214880892|NCT05758857|BEHAVIORAL|Experimental: Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
214880893|NCT05758857|BEHAVIORAL|Experimental: Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
214880894|NCT05758857|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
214880895|NCT07133789|OTHER|blood sampling of all patients and their parents|blood sampling of all patients and their parents
214880896|NCT07134803|DEVICE|Bonding of the orthodontic brackets with dental loupe with Zumax Dental loupes DFK Angled Loupe with a magnification of x3.0 and focus depth of 42cm|Bonding of the orthodontic brackets on patients' teeth with dental loupe with Zumax Dental loupes DFK Angled Loupe with a magnification of x3.0 and focus depth of 42cm. Then the scanned for STL file and be superimposed with the gold standard created for the patient individually.
214880897|NCT07133503|OTHER|radiological evaluation|Using a line drawn through the midpoints of the teeth, parallel to their long axes, the anterior crest morphology was assessed. For maxillary central, lateral, and canine teeth, alveolar crest width and height, buccal bone thickness, and tooth-crest angle were measured separately. To determine buccal bone thickness, measurements were taken from the buccal crest apex, the midpoint of the root, and the apex of the tooth. The height of the alveolar crest was defined as the length of a line drawn parallel to the crest's long axis between the nasal fossa floor and the alveolar crest. The width of the alveolar crest was calculated by averaging measurements taken from the midpoints of three equal sections of the alveolar crest. The buccal undercut was determined as the point where the crest came closest to the root in the sagittal plane. Additionally, the angle between the tooth roots and the alveolar crest was measured to determine the root position in the radial plane
214880898|NCT07133438|DRUG|Anti-VEGF drug|conventional anti-VEGF therapy (intravitreal injections of conbercept 0.5 mg initially once a month for 3 months, followed by on-demand therapy which based on recurrence criteria)
214880899|NCT07133438|DRUG|Mecobalamin 5 MG|oral mecobalamin capsules 0.5 mg three times daily for 6 months
214880900|NCT07133438|DRUG|Placebo|placebo capsule with a similar appearance and odor to the mecobalamin capsules three times daily for 6 months
214880901|NCT07133529|BEHAVIORAL|Perceived food uncertainty|Participants remain unaware of both the scheduled time and the length of the next meal.
214880902|NCT07133529|BEHAVIORAL|Perceived food certainty|Participants are aware of both the scheduled time and the length of the next meal.
214880903|NCT06866444|DRUG|Observational|In a cohort of patients treated with duloxetine for fibromyalgia, participants vitals signs (blood pressure, heart rate, oxygen saturation level, temperature) will be taken as well as height and weight. Participants will fill out a questionnaire regarding their fibromyalgia diagnosis and symptoms. Lastly, participants will complete two sets of blood samples. One blood sample will evaluate genetic variants for duloxetine metabolizing capacity. The other sample will be used to analyze the level of concentration of duloxetine.
214880904|NCT07134764|DEVICE|Virtual reality session|Patients included in the intervention group (VR group) participated in a comprehensive virtual reality program designed to reduce perioperative anxiety and pain. Prior to their surgery, they attended an introductory VR session aimed at familiarizing them with the technology and providing a calming, immersive environment to help alleviate preoperative stress. Throughout their surgical journey, these patients continued to receive the usual standard care, which included thorough preoperative consultations with healthcare providers, detailed information about the planned surgical procedure, and the provision of standard postoperative care to support recovery. Additionally, during the surgery itself, patients underwent a VR session delivered via a headset, offering real-time immersive distraction and relaxation to minimize intraoperative anxiety and pain perception.
214880905|NCT07135180|DIETARY_SUPPLEMENT|Cordyceps cicadae|Cordyceps cicadae 500mg
214880906|NCT07135180|DIETARY_SUPPLEMENT|Blank control|Blank control
214880907|NCT07003529|OTHER|Unenhanced brain MRI|Unenhanced brain MRI in five sequences: 1) T1-weighted anatomical sequences 2) Resting-state functional sequences 3) Task-based functional sequence 4) Structural sequence using Diffusion Tensor Imaging (DTI) 5) Routine magnetic resonance spectroscopy sequence
214880908|NCT07134296|RADIATION|MR-Guided Irradiation|MR-Guided Irradiation
215045279|NCT06519136|OTHER|Distance Reiki|"According to Usui, the second level Reiki application will be applied for 20 minutes a day between 19.00 and 21.00 in the evening for four consecutive days by the researcher who has completed his second level training, in accordance with the Second Level Reiki Application Protocol."
215045280|NCT06519136|OTHER|Sham Reiki|It will be stated that remote energy application will be applied to the Sham Reiki group and no application will be made.
215045281|NCT02809885|BIOLOGICAL|Hepatitis E serology|
215045282|NCT04285697|OTHER|infection prevention bundle|"The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family"
215045283|NCT01380665|DEVICE|Prevena Incisional Management System|All evaluable patients will utilize the Prevena Incisional Management System
215045284|NCT06126497|DRUG|Ropanicant|Tablet
214880909|NCT07134075|DRUG|intracochlear triamcinolone acetonide injection|intracochlear triamcinolone acetonide injection of through the round window membrane
214880910|NCT07134075|DRUG|intracochlear injection of dexamethasone through the round window membrane|intracochlear injection of dexamethasone sodium phosphate through the round window membrane
214880911|NCT07134075|DRUG|intracochlear dexamethasone injection and intratympanic dexamethasone injection|intracochlear dexamethasone sodium phosphate injection of through the round window membrane, intratympanic dexamethasone sodium phosphate injection through the tympanic membrane
214880912|NCT07134075|DRUG|intratympanic dexamethasone injection|intratympanic dexamethasone sodium phosphate injection (10mg/ml) through tympanic membrane，once every other day, for a total of 4 injections.
214880913|NCT07133893|BEHAVIORAL|Attention bias assessment and modification|Attention bias assessment and modification involve two versions of the dot-probe task. These tasks are based on the premise that repeated attention shifts can retrain attentional biases, with the expectation that reducing attentional bias toward threats will alleviate sub-clinical anxiety symptoms.
214880914|NCT07133893|DEVICE|Transcranial photobiomodulation|Participants will receive near-infrared light at 1064 nanometers to the right side of the forehead for 8 minutes. The investigators have introduced this form of transcranial photobiomodulation (tPBM) as a means of human cognitive enhancement, and as an adjunct for attention bias modification for the reduction of symptoms of depression. In the present study, the investigators wish to extend these findings to the use of attention bias modification for the reduction of sub-clinical anxiety.
214880915|NCT07134478|DRUG|HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered. Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg wi|"HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered.~Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg will be administered every morning from Day 6 to Day 14. On the morning of Day 15, rifampicin capsules 600 mg and HSK31858 tablets 40 mg will be co-administered."
214880916|NCT07133971|OTHER|skin care product（Cerave Neuroceramide Moisturizing Repair Body Lotion）|All study participants will use Cerave Neuroceramide Moisturizing Body Lotion during the trial period, applying it every night to dry skin areas. If topical medications are used, they should be applied first to dry skin areas, followed by the product.
214880917|NCT04591951|BEHAVIORAL|I2-ART|Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
214880918|NCT04591951|OTHER|Usual care|Care as usual
214880919|NCT00315237|DRUG|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
214880920|NCT00400842|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
214880921|NCT00400842|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
214880922|NCT00400842|DRUG|Placebo|Placebo
214880923|NCT06867523|OTHER|Eye Mask|Participants in this group will wear an eye mask between 11:00 PM and 07:00 AM for three consecutive nights to assess its effects on delirium and pain levels in pediatric intensive care unit patients
214880924|NCT06867523|OTHER|Earplugs|Participants in this group will use earplugs between 11:00 PM and 07:00 AM for three consecutive nights to evaluate their effects on delirium incidence and pain levels.
214880925|NCT05737784|DRUG|PRAX-222 - Initial Dose|PRAX-222
214880926|NCT05737784|DRUG|PRAX-222 - Initial Ascending Doses|Ascending doses of PRAX-222
214880927|NCT05737784|DRUG|PRAX-222 - Optional Ascending Doses|Escalation of PRAX-222 dose(s)
214880928|NCT05737784|DRUG|PRAX-222 - Fixed Doses|Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
214880929|NCT05737784|PROCEDURE|Placebo|Placebo procedure
214880930|NCT07010887|OTHER|Short Interval|A standardized and reliable soccer heading protocol will be used for the experiment. Participants perform 16 headers or kicking with 1 header per 30 seconds. The sessions (twice per week for 4 weeks) will be separated by 24 hours.
214880931|NCT07010887|OTHER|Long Interval|A standardized and reliable soccer heading protocol will be used for the experiment. Participants perform 16 headers or kicking with 1 header per 30 seconds. The sessions (twice per week for 4 weeks) will be separated by 72 hours.
214880932|NCT06874751|OTHER|No treatment given|No treatment given
214880933|NCT06874751|OTHER|No treatment given|No treatment given
214880934|NCT07021053|BEHAVIORAL|Alcohol Change Course Enhanced|The Alcohol Change Course Enhanced is an adaptation of the Alcohol Change Course, originally developed and evaluated in Switzerland. The Course is a six-lesson ICBT intervention delivered over eight weeks to individuals who self-report alcohol misuse. Due to therapist registration and availability, eligible clients residing in Saskatchewan will be offered the option of receiving therapist assistance (or not) alongside the Course, while clients from other Canadian provinces will not receive therapist support. In addition to the monitoring of weekly measures available to all clients, those receiving therapist support will receive weekly secure messaging from their assigned therapist for eight weeks. Therapists will spend approximately 15 minutes per week/per client receiving therapist support. Phone calls will be used in the event that there is a significant clinical issue requiring therapist attention that cannot be addressed over messaging (e.g., sudden increase in symptoms).
215045285|NCT02406417|DEVICE|Investigation for pituitary dysfunction by blood tests.|Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
215045286|NCT02406417|DEVICE|Dynamic function tests and pituitary imaging|Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
215045287|NCT06573008|DRUG|GP681 40mg|2 x 20mg tablets taken orally
215045288|NCT06573008|DRUG|GP681 Simulant|Placebo tablets matching GP681 40mg
214880935|NCT03431142|DRUG|Clopidogrel|Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
214880936|NCT03431142|DRUG|Clopidogrel+aspirin|Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
214880937|NCT07019922|DRUG|1mg elsunersen|24 weeks every 4 weeks intrathecally
214880938|NCT07019922|PROCEDURE|sham procedure|24 weeks of sham-procedure every 4 weeks
214880939|NCT07019922|DRUG|0.5mg elsunersen|24 weeks every 4 weeks intrathecally
214880940|NCT03946553|OTHER||No intervention
214880941|NCT02266537|DRUG|Tamsulosin|
214880942|NCT02266537|DRUG|Alfuzosin|
214880943|NCT02266537|DRUG|Doxazosin|
214880944|NCT02266537|DRUG|Placebo|
214880945|NCT03303209|OTHER|Patient-centered opioid tapering protocol|All patients who entered the study agreed to partner with their pain physician on a patient-centered opioid tapering program. The research component of the study was to observe patient response (in terms of change in MEDD and pain intensity) at month 4.
214880946|NCT05500950|OTHER|CDU and CT-DCG or CT examination|patients with space occupying lesions in the lacrimal sac area completed CDU and CT-DCG or CT examination before surgery
214880947|NCT06435156|DRUG|Sotagliflozin|Sodium-glucose Co-transporter inhibitor
214880948|NCT06435156|DRUG|Placebo|Matched placebo
214880949|NCT06697626|DIETARY_SUPPLEMENT|Inulin, B-vitamins and vitamin D|"Intervention twice daily with:~10g chicory inulin 100µg folic acid 5µg vitamin B12 5mg vitamin B6 2.5mg riboflavin 5µg vitamin D"
214880950|NCT06697626|DIETARY_SUPPLEMENT|Placebo group|A twice daily placebo drink with similar energy content but without the additional nutrient provision
214880951|NCT07133321|BEHAVIORAL|Husband Group Health education.|The community-based husband group health education will target expectant fathers with pregnant partners. It will focus on reshaping gender-related attitudes and beliefs, promoting caregiving best practices, preventing violence against women, and improving men's involvement in maternal health. The intervention will comprise group sessions with 20 participants each, conducted over three sessions lasting 2.5 hours each, with a 15-day interval between sessions. The sessions will cover key topics, including recognizing obstetric danger signs, preparing for childbirth, fostering men's engagement in maternal health, advocating nonviolence and shared responsibility, and encouraging joint decision-making.
214880952|NCT07133321|BEHAVIORAL|Helping Mothers Survive + RMC|"The Helping Mothers Survive training is designed by Jhpiego, an affiliate of Johns Hopkins University, in collaboration with global health partners, including the World Health Organization (WHO), Laerdal Global Health, and the International Confederation of Midwives (ICM) for healthcare professionals involved in childbirth care focusing on saving lives at birth in low-resource settings. This on-site training will use realistic simulations to enhance skills in identifying and managing key causes of maternal mortality, such as postpartum hemorrhage and preeclampsia, starting with essential labor care. The program employs the MamaNatalie birthing simulator, a low-tech realistic tool for hands-on practice developed by Laerdal Global Health. MamaNatalie features a model uterus with a neonate, placenta, and umbilical cord, enabling simulations of postpartum hemorrhage, breech delivery, vacuum-assisted birth, and normal labor."
214880953|NCT07134179|OTHER|Experience of pain during caesarean delivery|We wish to investigate how women experience insufficient regional anesthesia during cesarean sections, in cases where the regional anesthesia was not converted to general anesthesia. The focus is on exploring the factors that contribute positively and negatively to the woman's experience in this situation
214880954|NCT01833819|DRUG|Dexmedetomidine and lidocaine|
214880955|NCT01833819|DRUG|Remifentanil|
214880956|NCT02942641|PROCEDURE|Indwelling urethral catheterization (Foley)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received indwelling urethral catheter as the intervention."
214880957|NCT02942641|PROCEDURE|Clean intermittent catheterization (CIC)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received CIC as the intervention."
214667170|NCT03446924|DIETARY_SUPPLEMENT|Rice flour|Rice flour placebo to be administered a single dose of 1.5 g in capsule form (250 mg / capsule).
214880958|NCT02942641|DEVICE|Foley|
214880959|NCT04262180|OTHER|Base intervention-Fitbit with EHR integration|Every subject will start with a base intervention - Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal
214880960|NCT04262180|OTHER|Coaching Calls|Non-responders to base intervention will be randomized to coaching calls.
214880961|NCT04262180|OTHER|Online Gym|Non-responders to base intervention will be randomized to online gym.
214880962|NCT06619626|DEVICE|alveolar recruitment strategy applied group|the effect of alveolar recruitment strategy on the mechanical parameters of the patients
214880963|NCT06619626|DRUG|group without alveolar recruitment strategy|effect on mechanical parameters of patients without alveolar recruitment strategy
214880964|NCT04450576|DIAGNOSTIC_TEST|Glycosylated hemoglobin|Glycosylated hemoglobin levels associated with correlative measures of diastolic cardiac function
214880965|NCT03038594|DRUG|Somatropin|
214880966|NCT03038594|DRUG|0.09% Saline Solution|
214880967|NCT05157906|BEHAVIORAL|Education based|The interventional materials will be provided digitally for 12 weeks, with the monthly theme featured from the educational Grow Happy book and related tips and videos that will be released weekly.
214880968|NCT05157906|BEHAVIORAL|Control|At enrollment, subject will be provided with the Mother and Child booklet, which is the Indonesian standard of care for parenting guidance.
214880969|NCT03790150|OTHER|Evidence-based practices|Implementation of evidence-based practices
214880970|NCT03492827|DRUG|chlorhexidine acetate gargle|observe whether it can achieve the effect of preventing postoperative infection
214880971|NCT01203020|DRUG|Busulfan|Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
214880972|NCT01203020|DRUG|Fludarabine|Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
215045289|NCT03913130|DRUG|QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
214880973|NCT06550973|PROCEDURE|pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique|Rescue techniques, such as pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique, wire-guided cannulation over a pancreatic stent and transpancreatic biliary sphincterotomy, will be used at the discretion of the endoscopist \[12\]. After deep cannulation, a cholangiogram to better define the characteristics of the stenosis will be done. The stent will then be inserted over a guidewire and deployed across the stenosis. All stents will be fully covered SEMSs or partially covered SEMSs of 10 mm diameter. The length of the stent will be chosen at the discretion of the endoscopist performing the procedure. A prophylactic pancreatic stent will be placed in patients who will be thought to be at high risk of post-procedure pancreatitis at the discretion of the treating endoscopist.
214880974|NCT02312908|DRUG|Clonazepam|For experimental treatment of RBD
214880975|NCT02312908|DRUG|Placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
214880976|NCT04549103|OTHER|Baduanjin exercise program|Baduanjin (BDJ), also known as Eight-Section Brocades, is one of the forms of traditional Chinese Qigong exercises, characterized by symmetrical physical posture, movements, mindfulness, and breathing. Its primary focus is on the release of 'Qi' or internal body energy with the intent of improving health outcomes. BDJ encompasses eight simple movements involving combinations of postures, meditation, slow relaxing movements, and breathing exercises. It is a low intensity exercise, which have been found to improve range of motion, strength and general health. The simplicity and low intensity level is ideal for older adults to practice at home using instructional videos.
214880977|NCT04815655|PROCEDURE|Cartilage tympanoplasty|is the reconstruction of the tympanic membrane (TM) by using catilage
214880978|NCT02202863|DIETARY_SUPPLEMENT|Red wine grape pomace flour (WGPF)|Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
214880979|NCT00357084|DRUG|methotrexate|
214880980|NCT00357084|DRUG|methylprednisolone|
214880981|NCT00357084|DRUG|prednisone|
214880982|NCT00421980|DRUG|Etanercept|
214880983|NCT04966273|DEVICE|Microcatheter|Only to be used if Biosensor Microcatheter does not perform accordingly
214880984|NCT01464931|DRUG|Denosumab|Adminstered by subcutaneous injection
214880985|NCT05503810|BEHAVIORAL|Social support|Contact ones a week with Informal caregiver or peer support
214880986|NCT01840865|DEVICE|brain stimulation|oscillating direct current brain stimulation
214880987|NCT01840865|DEVICE|no stimulation|sham Stimulation
214667171|NCT05292677|DRUG|Steroid/Anesthesia Mixture|Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.
214667172|NCT05292677|DRUG|Placebo|2 mL of Normal Saline
214880988|NCT07047781|OTHER|Assessment|Individuals between the ages of 7 and 14 who are receiving primary education and meet the inclusion criteria will be included in this study planned to evaluate the relationship between smartphone addiction and thoracic hyperkyphosis in children with thoracic hyperkyphosis.
214880989|NCT05567263|PROCEDURE|Bulk-fill resin composite, (3M, ESPE)|Teeth will be restored with Bulk-fill resin composite, (3M, ESPE)
214880990|NCT05567263|PROCEDURE|Surefil one™ Self-Adhesive Composite Hybrid|teeth will be restored with Surefil one™ Self-Adhesive Composite Hybrid
214880991|NCT03835676|DRUG|Treprostinil|"After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~* Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~* CMR will be performed at 6 monthly intervals for 2 years.~* Peak power output at 6,12, 18 and 24 month~* Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)"
214880992|NCT05920512|DRUG|Sodium valproate extended-release tablets|Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
214880993|NCT02505308|OTHER|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
214880994|NCT01925300|DRUG|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
214880995|NCT01925300|DRUG|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
214880996|NCT01925300|DRUG|Concor 5mg 2T and Crestor 20 mg 1Tab|
214880997|NCT04364659|BEHAVIORAL|Food-Specific Inhibitory Control Training (FoodT App)|FoodTrainer (FoodT) is a simple game that aims to train individuals to 'stop' to certain unhealthy foods. Repeatedly playing this game is hypothesised to help build associations between certain foods (such as chocolate) and stopping, putting the brakes on unhelpful eating behaviour.
214880998|NCT01844232|DRUG|arbaclofen|Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
214667173|NCT02367092|BEHAVIORAL|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
214880999|NCT01754337|OTHER|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
214881000|NCT06633354|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-ALL Targeted CAR T-cells by intravenous infusion
214881001|NCT00201409|DRUG|Placebo|Placebo will be administered by slow intravenous infusion once daily for 14 days.
214881002|NCT00201409|DRUG|GM-CSF|Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
214881003|NCT02598947|OTHER|Manual therapy|Exercise, behaviour change interventions and manual therapy
214881004|NCT02655783|OTHER|5% dextrose|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
214881005|NCT02655783|OTHER|normal saline|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
214881006|NCT02094911|BEHAVIORAL|Combined lifestyle intervention|"10-month intervention period with:~* weekly group-based sports lessons supervised by a physiotherapist~* individual dietary advice by a dietician~* case management by practice nurse~* maintenance programme to guide subjects to maintain lifestyle behaviour change"
214881007|NCT02094911|OTHER|Usual care group|Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
214881008|NCT05637164|DRUG|norepinephrine bitartrate|The treatment group will receive a continuous infusion of norepinephrine at the beginning of anesthesia induction until 15 minutes after intubation. The dosage of norepinephrine was decided by the up-and-down sequential allocation method with an initial dose of 0.05 µg/kg/min and a 0.005 µg/kg/min gradient.
214881009|NCT03909269|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring five times over 17 weeks
214881010|NCT03909269|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.
214881011|NCT03909269|RADIATION|Erythrocyte life span|Erythrocyte life span measured by Crom-51 labelling over 4 weeks
214881012|NCT03909269|DEVICE|Carbon monoxide (CO)-rebreathing method|Measurement of total blood volume, plasma volume and erythrocyte volume
214881013|NCT05607979|DRUG|Lavior Diabetic Wound Gel|Daily application of hydrogel treatment for 60 days.
214667174|NCT01259466|DRUG|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
214667175|NCT03322657|DRUG|Neostigmine|Neostigmine injection
214667176|NCT03322657|DRUG|Glycopyrrolate|Glycopyrrolate injection
214667177|NCT03322657|DRUG|Sugammadex|Sugammadex injection
214667178|NCT00519623|OTHER|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
214667179|NCT02662439|DEVICE|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
214667180|NCT02596776|PROCEDURE|Fat biopsy|up to 16 biopsy samples will be taken from each subject
214881014|NCT05607979|DRUG|Smith & Nephew Solosite Gel Hydrogel Wound Dressing|Daily application of hydrogel treatment for 60 days.
214881015|NCT00338728|DRUG|Imatinib Mesylate|Given PO
214881016|NCT00338728|DRUG|Letrozole|Given PO
214881017|NCT02391480|DRUG|ABBV-075|ABBV-075 Oral tablets
214881018|NCT02391480|DRUG|Venetoclax|Venetoclax tablets, film-coated
214881019|NCT01897038|DRUG|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
214881020|NCT01897038|DRUG|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
214881021|NCT04102189|DRUG|Semaglutide|Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
214881022|NCT04102189|OTHER|Placebo|Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks
214881023|NCT05289973|DEVICE|TruNatomy Files|Newly introduced endodontic file with high flexibility.
214881024|NCT05289973|DEVICE|HyFlex EDM Files|Endodontic files
214881025|NCT03889080|DIAGNOSTIC_TEST|functional MRI|functional MRI scan of the brain
214881026|NCT01178710|DRUG|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
214881027|NCT01747746|DRUG|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
214881028|NCT01747746|DRUG|Warfarin and Enoxaparin|Historical Control
214881029|NCT05992766|OTHER|Reformer Pilates|Reformer Pilates exercises activates the lumbopelvic muscles and supports functional movement. Activated muscles support the spine and reduce the load on the spine by correcting the posture, helping the core muscles such as the abdomen and spine stay healthier by attaching them to a neutral pelvis Pilates consists of a sliding platform working with the help of a pulley system specific to the use, allowing the individual to apply certain resistances, and providing the opportunity to exercise sitting, standing, or lying down.
214881030|NCT05992766|OTHER|Hammock Yoga|Hammock Yoga is performed with a silk hammock, which is an auxiliary equipment. The most distinctive characteristic that makes Hammock Yoga different from other exercises is the spine traction provided by the upside-down posture, and the smooth and shiny silk hammock allows strengthening exercises. The Hammock Yoga aims to reduce the load on the spine by upside-down postures that defy the laws of physics.
214881031|NCT05992766|OTHER|Traditional mat exercises|The mat exercises help build core strength, stamina, and motor control of the abdominal and lumbar trunk musculature. The exercises focus on the re-education of a precise co-contraction pattern of local muscles of the spine. Also mat exercise increases the level of endorphins and the stimulation of mechanoreceptors, causing biomechanical stress to support healing in tissues.
214881032|NCT03020537|BIOLOGICAL|Fluzone|Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
214881033|NCT05706883|PROCEDURE|Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes|Patients with evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes suspected of being metastasis from lung cancer will be submitted to the biopsy from this location.
214881034|NCT05706883|PROCEDURE|Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes|Patients without evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes will be submitted to the biopsy considered less invasive and effective based on imaging data and clinical health status.
214881035|NCT05327673|OTHER|questionnaire|"* quality of life score: FACT-BMT~* decisional conflict scale~* Discreet Choice Experiment questionnaire"
214881036|NCT02933255|BIOLOGICAL|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10\^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10\^9 infectious units.
214881037|NCT02933255|DRUG|Nivolumab|Nivolumab is to be administered as a flat dose over approximately 30-minutes via intravenous (IV) infusion.
215045290|NCT04194827|DIAGNOSTIC_TEST|Adalimumab serum trough concentration|Dose reduction based on adalimumab serum trough concentration
215045291|NCT04194827|DIAGNOSTIC_TEST|Disease activity|Dose reduction based on adalimumab diseas activity
215045292|NCT04194827|DRUG|Adalimumab|Adalimumab
215045293|NCT04979598|OTHER|Home exercise program|A home exercise program is provided but this is an observational study. The effect of the exercise program is not under investigation.
215045294|NCT02558868|DRUG|Irinotecan|
215045295|NCT02558868|DRUG|Oxaliplatin|
215045296|NCT02878382|OTHER|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
215045297|NCT02878382|OTHER|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
215045298|NCT00267176|DRUG|lumiracoxib|
215045299|NCT05709847|OTHER|Coffee|24 ounces of coffee will be consumed daily
215045300|NCT03822026|OTHER|Hyperventilation test|Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
215045301|NCT02948439|OTHER|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
215045302|NCT05646082|DRUG|Dostarlimab in Combination Antiretroviral Therapy|Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
215045303|NCT05728554|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
215045304|NCT05728554|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
214881038|NCT02933255|PROCEDURE|Prostatectomy|Participants in the neoadjuvant cohort will undergo a radical prostatectomy in week 9. (If surgery is scheduled earlier than 9 weeks after initial dosing, the 6 and 8 week dosing may be skipped, and surgery may be done as early as week 5.)
214881039|NCT02933255|PROCEDURE|Biopsy|A baseline biopsy is performed for participants in the neoadjuvant cohort that do not have a previous collection of biopsy material.
214881040|NCT02933255|DRUG|Tylenol|Participants who experience aches or fever after vaccination may take Tylenol as directed.
214881041|NCT00368017|DRUG|pioglitazone|30 mg once a day for 12 weeks
214881042|NCT00368017|DRUG|placebo|1 pill once a day for 12 weeks
214881043|NCT03005912|DEVICE|Conventional acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
214881044|NCT03005912|DEVICE|Conventional bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
214881045|NCT03005912|DEVICE|VoIP acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
214881046|NCT03005912|DEVICE|VoIP bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
214881047|NCT01824043|DRUG|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
214881048|NCT00758966|DRUG|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
214881049|NCT00758966|DRUG|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
214881050|NCT00758966|DRUG|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
214881051|NCT04875936|BEHAVIORAL|Motor Imagery and Real-Time fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will use right-hand motor imagery coupled with fMRI neurofeedback to help them re-engage the left hemisphere by shifting brain activation leftward relative to the initial left-right asymmetry. Following group assignment, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. During the MRI sessions they will receive real time neurofeedback about how well they are engaging the left side of their brain compared to the right side. They will also practice the same task for 30 min a day as homework using the most effective motor imagery strategy that worked for them in the MRI scanner.
214881052|NCT04875936|BEHAVIORAL|Motor Imagery and Sham fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will practice right-hand motor imagery coupled with sham fMRI neurofeedback. As the experimental group, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. However, during the MRI sessions they will receive sham neurofeedback on the basis of another participant's brain activity. Like the experimental group, they will also practice the same task for 30 min a day as homework.
215045305|NCT05728554|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
215045306|NCT06126159|DIAGNOSTIC_TEST|multiparametric and fat-detection magnetic resonance imaging (MRI)|Differentiating of renal AMLs with minimal fat and RCCs
215045307|NCT01015950|DIETARY_SUPPLEMENT|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
215045308|NCT01015950|DIETARY_SUPPLEMENT|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
215045309|NCT01015950|DIETARY_SUPPLEMENT|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
215045310|NCT01015950|DIETARY_SUPPLEMENT|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
215045311|NCT05615064|OTHER|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players
215045312|NCT04013178|BEHAVIORAL|Accentuated eccentric loading + electromyostimulation|An innovative training intervention to optimize muscle strength and muscle mass
215045313|NCT04013178|BEHAVIORAL|Conventional resistance training|A conventional approach to resistance training
215045314|NCT00365807|BEHAVIORAL|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
215045315|NCT00365807|OTHER|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
215045316|NCT02494414|OTHER|Long-term follow-up|Vital and neurological follow-up
215045317|NCT01085214|OTHER|Laboratory Biomarker Analysis|Correlative studies
215045318|NCT01085214|DRUG|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
215045319|NCT01634152|DRUG|Placebo|2 actuations once daily in the evening
214667181|NCT02596776|DRUG|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
214881053|NCT00481403|BEHAVIORAL|Microarray analysis|Microarray analysis
214881054|NCT00481403|BEHAVIORAL|Microarray|Microarray
214881055|NCT03387566|DRUG|HB002.1M|HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
214881056|NCT00444379|DRUG|Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir|Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
215045320|NCT01634152|DRUG|Tiotropium low dose mcg|2 actuations once daily in the evening
214881057|NCT02862561|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
215045321|NCT01634152|DRUG|Tiotropium high dose|2 actuations once daily in the evening
215045322|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Capsules|Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
215045323|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
215045324|NCT03615885|DIETARY_SUPPLEMENT|Placebo|"130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
214881058|NCT02862561|BIOLOGICAL|Precision Cells|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
214881059|NCT03645707|BEHAVIORAL|CAR Training and Psychoeducational Sessions|"Participation in the CAR Training Program, a 1-day training program developed by the J\&J Human Performance Institute (HPI). The CAR Training Program uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.~Participants will attend eight weekly follow-up psychoeducational group sessions facilitated by a licensed mental health counselor that will meet for 90 minutes. The themes of these sessions will be RISE - Resilience, Insight, Self-Compassion, and Empowerment. Due to limited time and flexibility in sessions, participants will practice skills through optional homework activities to facilitate learning between sessions."
215045325|NCT01482715|DRUG|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
215045326|NCT04117633|DEVICE|Laparoscopy|Laparoscopic Procedures for Rectopexy
214881060|NCT01410656|BEHAVIORAL|Telephone Implementation Intention|Telephone implementation intention counseling
214292038|NCT02678845|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
215045327|NCT04206761|DRUG|QVM149|QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
215045328|NCT04206761|DRUG|High Dose Dual Therapy (ICS/LABA)|High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
215045329|NCT03526211|DEVICE|FES cycling|On the patient, three pairs of electrodes will be applied on tibial hamstring, quadriceps and gluteal muscles of each lower limb. Cycloergometer will be installed in passive mode. Then, optimal stimulation intensity for each muscle will be defined. During twenty minutes, neuromuscular electrical stimulation will generate a passive pedaling on cycloergometer.
214292039|NCT01404390|DRUG|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
214881061|NCT01410656|BEHAVIORAL|Self-completed implementation intention|Self-administered implementation intention intervention
214881062|NCT03513133|BEHAVIORAL|working memory training|Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
214881063|NCT03166137|DEVICE|Carbon dioxide laser|Radiation by carbon dioxide laser
215045330|NCT00251108|PROCEDURE|Cardiorespiratory fitness training|
214881064|NCT03166137|DEVICE|Cryotherapy|Device using cooling effect
214881065|NCT00683345|DRUG|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
214881066|NCT00683345|DRUG|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
215045331|NCT06039514|DEVICE|GGTCA-AD mobile app|The intervention will be done through an adaptation of the GGTCA app for teenagers: GGTCA-AD. This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in cognitive behavior therapy (CBT) in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
214881067|NCT05753878|DRUG|HH-120 nasal spray, PartA cohort 1|A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
214881068|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 2-7|A single dose of HH-120 nasal spray.
214881069|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 8-9|Two doses of HH-120 nasal spray.
214881070|NCT05753878|DRUG|HH-120 nasal spray, Part B|HH-120 nasal spray, 10 times daily for 7 consecutive days.
214881071|NCT05753878|OTHER|Placebo nasal spray, Part B|Placebo nasal spray, 10 times daily for 7 consecutive days.
214881072|NCT04244383|DIAGNOSTIC_TEST|interleukin IL-1beta and interleukin IL-18|pro-inflammatory cytokines measured in the serum
214881073|NCT01790477|PROCEDURE|Auricular Acupuncture|Application of auricular acupuncture to 5 points on the ear
214881074|NCT00015873|DRUG|asparaginase|
214881075|NCT00015873|DRUG|cytarabine|
214881076|NCT00015873|DRUG|mercaptopurine|
214881077|NCT00015873|DRUG|methotrexate|
214292040|NCT01404390|DRUG|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
214881078|NCT00015873|DRUG|prednisolone|
214881079|NCT00015873|DRUG|vincristine sulfate|
214881080|NCT03917927|DEVICE|Eztetic dental implant|narrow diameter dental implant
214881081|NCT03295682|DEVICE|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
214881082|NCT04670276|PROCEDURE|injection of emulsified adipose tissue stromal vascular fraction|Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
214881083|NCT00212680|DRUG|ONO-1101|
214881084|NCT03532373|OTHER|Preference Elicitation tool|A preference elicitation tool for carpal tunnel syndrome
214881085|NCT00467324|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
214292041|NCT02562430|DRUG|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
214292042|NCT02562430|DRUG|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
214292043|NCT03327298|PROCEDURE|pedicle screw fixation|One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
214881086|NCT00338312|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
214881087|NCT00338312|DRUG|Placebo patch|placebo patch changed twice a week for one year
214292044|NCT06495164|DRUG|Palbociclib|CDK4/6 inhibitor
214881088|NCT06434623|OTHER|patient record|using patient record to construct AI models
214881089|NCT00049179|DRUG|cytarabine|ind and consol: 200 mg/m2/d continuous IV days 1-7
214881090|NCT00049179|DRUG|gemtuzumab ozogamicin|ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
214881091|NCT01531543|DEVICE|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
214881092|NCT03925259|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a 'third wave' behaviour therapy delivered on a one to one basis.
214881093|NCT02987452|OTHER|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
214881094|NCT02987452|OTHER|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
214292045|NCT06495164|DRUG|Aromatase inhibitor|Aromatase inhibitor
214292046|NCT06495164|DRUG|Ribociclib|CDK4/6 inhibitor
214292047|NCT06495164|DRUG|Abemaciclib|CDK4/6 inhibitor
214292048|NCT03441854|DEVICE|HFNC group|Application of HFNC oxygen delivery after extubation.
214292049|NCT01484873|DRUG|Exenatide|Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
214292050|NCT03416257|OTHER|No intervention|
214292051|NCT00608231|DRUG|Dexmedetomidine Hydrochloride Infusion|Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
214881095|NCT02987452|OTHER|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
214881096|NCT06089200|PROCEDURE|Transversus Abdominal Plane Block|20 cc of bupivacaine 0.2% was given to the transversus abdominis plane
214881097|NCT06089200|PROCEDURE|Spinal Morphine|100 µg was administered intrathecally preoperatively
214881098|NCT04234659|DEVICE|Clinical placement of a temporary IMPELLA® mechanical circulatory support device.|Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.
214881099|NCT03526783|PROCEDURE|Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass (150 cm alimentary limb, 50 cm biliopancreaty limb)
214881100|NCT03526783|PROCEDURE|Mini/One anastomosis gastric bypass|Laparoscopic Mini/One anastomosis gastric bypass (200 cm biliopancreatic limb)
214881101|NCT05289297|PROCEDURE|Karydakis Flap Procedure|Pilonidal sinus surgery will be performed with the Karydakis Flap procedure.
214881102|NCT05289297|PROCEDURE|Burow's Triangle Advancement Flap Procedure|Pilonidal sinus surgery will be performed with the Burow's Triangle Advancement Flap procedure.
214881103|NCT04803305|DRUG|PF-06946860|subcutaneous injection
214881104|NCT04803305|DRUG|Placebo for PF-06946860|subcutaneous injection
214881105|NCT03629197|BEHAVIORAL|Communication skills training|Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
214881106|NCT03629197|OTHER|Attention control|Physician will review materials based on CDC opioid prescribing guidelines.
214881107|NCT00886405|DRUG|Transdermal nitroglycerin|Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
214881108|NCT06432374|BEHAVIORAL|WET|"The five weekly WET sessions were delivered online via Canvas. Five session modules were created, each containing writing instructions for the respective session and an assignment feature for participants to upload their narratives. All sessions included 30 minutes of writing. Following instructions, participants wrote about a specific work-related trauma event in detail and described the emotions and thoughts experienced during the event. While all sessions were self-paced, participants were advised to complete each subsequent session within one week. Participants had the option to self-administer sessions or participate in Zoom office hours for live writing sessions with a facilitator who had completed WET training providing the writing instructions."
214881109|NCT00753662|DEVICE|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
214881110|NCT00753662|DEVICE|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
214881111|NCT00753662|DEVICE|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
214881112|NCT05886868|DRUG|BL0020|"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."
214881113|NCT00000812|DRUG|Thalidomide|
215045332|NCT06039514|DEVICE|GGNeutra mobile app|"the control group will complete another module belonging to the GGTUDE digital platform. Specifically, this app is called GGNEUTRA, and the statements that compose it are totally independent of the target of the study. The operation is similar, sentences appear in the center of the screen, but in this case, the person must accept those sentences that are true, for example: Madrid is the capital of Spain, by dragging it to the top of the screen; and reject those that are false, for example: Tokyo is the capital of Spain, by dragging it to the bottom of the screen."
215045333|NCT00094276|BEHAVIORAL|Facilitated Asthma Communication Intervention (FACI)|A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
214292052|NCT00608231|DRUG|Normal Saline|Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
214292053|NCT02564042|DRUG|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
214292054|NCT02564042|DRUG|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
214292055|NCT02564042|DRUG|Vehicle cream|White to off-white vehicle cream base to be applied topically
214881114|NCT02963233|PROCEDURE|Closed reduction and percutaneous pinning and immobilization|
214881115|NCT02963233|PROCEDURE|Non-operative reduction and immobilization|
214881116|NCT05772247|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound score was calculated by the results of lung ultrasound examination
214881117|NCT04479644|DRUG|BRII-198|BRII-198 given intravenously
214881118|NCT04479644|DRUG|Placebo|Placebo given intravenously
215045334|NCT00094276|BEHAVIORAL|Breathmobile intervention|A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
215045335|NCT01349114|DRUG|aliskiren 300 mg once daily|aliskiren 300 mg daily
215045336|NCT01349114|DRUG|Placebo/sugar pill|Sugar pill/placebo
215045337|NCT01233544|PROCEDURE|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
215045338|NCT00882089|DEVICE|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
214292056|NCT01549392|DEVICE|DECT|DECT at tumor progression and 3 months later
214292057|NCT01549392|DEVICE|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
214292058|NCT01356966|DRUG|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
214292059|NCT01356966|DRUG|Placebo|2 placebo pills PO BID for12 weeks
214292060|NCT01356966|DIETARY_SUPPLEMENT|Folate|Folate 1 mg daily for 12 weeks
214292061|NCT06120556|DRUG|GLP-1 receptor agonist|Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
214292062|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with a patented fermented rye bran|During the treatment period, participants will be provided 2 packages of puff（fermented rye bran）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
214881119|NCT03245827|DRUG|Clomiphene|clomiphene capsule 25mg twice a week
214881120|NCT03245827|DRUG|Placebo|placebo capsule 25mg twice a week
214881121|NCT02944773|PROCEDURE|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
214881122|NCT04246827|BEHAVIORAL|Enhanced Lifestyle Weight Management|The Enhanced Lifestyle Weight Management program was a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors were integrated into a lifestyle behavioral weight loss intervention.
214881123|NCT05615831|BEHAVIORAL|Resistance Training with Blood flow restriction|Participants will perform six weeks of blood flow restriction (60% occlusion) combined with resistance training at 30% of 1RM. The intervention comprises five exercises: incline chest press, seated row, leg press, knee extension, and knee flexion. The protocol is as follows: 30 repetitions followed by three sets of 15 repetitions for a total of four sets and 75 repetitions per exercise. There will be a one-minute recovery between sets where the cuffs remain inflated and a four-minute recovery between exercises where the cuffs will be deflated.
214881124|NCT05865548|DRUG|Aspirin 150 mg|Aspirin 150 mg PO daily
215045339|NCT04470765|DEVICE|Zida|Transcutaneous Tibial Nerve Stimulation
215045340|NCT01450345|DRUG|Pregabalin|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
215045341|NCT05170685|BIOLOGICAL|Nivolumab plus Relatlimab FDC|
214881125|NCT05865548|PROCEDURE|Standard of care|Surgery with or without radiation, palliative chemo as per investigators choice
214881126|NCT06093230|DRUG|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
214667182|NCT02596776|OTHER|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
214881127|NCT05650840|PROCEDURE|Charcoal based whitening toothpaste (signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded.~Intervention drug : whitening toothpaste charcoal based whitening toothpaste compared to calcium carbonate and perlite whitening toothpaste~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush (Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination"
214881128|NCT05650840|PROCEDURE|Calcium carbonate /perlite containing whitening toothpaste (signal whitening moonlight toothpaste Unilever Mashreq - Egypt).|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using calcium carbonate /perlite containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded. The main operator will perform the tooth brushing procedures for all the patients himself twice daily.~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush(Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination Device used is atomic force microscopy to determine enamel abrasion after brushing"
214881129|NCT03928067|BEHAVIORAL|PNF + SAF|Personalized normative feedback (PNF) to correct misperceived peer drinking norms abroad + sojourner adjustment feedback (SAF) to promote cultural engagement abroad.
215045342|NCT00735657|DEVICE|needle|Peribulbar blockade with standard (25 mm) needle
215045343|NCT00735657|DEVICE|needle|Peribulbar blockade with short (12.5 mm) needle
215045344|NCT00735657|PROCEDURE|Pars Plana Vitrectomy|Peribulbar block
214667183|NCT02527304|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo adaptive staged SBRT
214667184|NCT02527304|OTHER|Quality-of-Life Assessment|Ancillary studies
214667185|NCT02527304|OTHER|Questionnaire Administration|Ancillary studies
214881130|NCT00553735|DRUG|Cyclosporine A 0.05%|Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
214881131|NCT00553735|DRUG|Arificial Tear|Artificial Tear - three times a day for 18 months.
214881132|NCT05792579|PROCEDURE|stoma closure|early closure of stoma in trauma patients
214881133|NCT03654599|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
214881134|NCT03654599|BEHAVIORAL|Digital Stories Intervention|Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
215045345|NCT00413114|DRUG|Obatoclax mesylate (GX15-070MS)|
215045346|NCT01152437|DRUG|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
215045347|NCT01152437|DRUG|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
215045348|NCT01985022|BEHAVIORAL|Group-ESI|The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.
214881135|NCT03654599|BEHAVIORAL|Information Control Intervention|Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.
214881136|NCT04084548|DRUG|Lidocaine and ketamine|Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
214881137|NCT04084548|DRUG|Lidocaine|Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
214292063|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with common refined wheat|During the treatment period, participants will be provided 2 packages of puff （common refined wheat）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
214881138|NCT04084548|DRUG|Ketamine|Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
214881139|NCT04084548|DRUG|Placebo|Perioperative placebo infusion (normal saline)
214881140|NCT06570369|DRUG|SP-624|Oral dose, once daily for 2 weeks
214292064|NCT01179945|OTHER|benzoate containing test drinks|"Subjects will consume 500ml of water with 0.5 grams of sodium benzoate, followed by a solution of 75g sugar in 500ml water with 0.5 grams sodium benzoate 3 hours later.~Each solution will be consumed over 5 minutes."
214292065|NCT01179945|OTHER|non sodium benzoate containing test drinks|"Subjects will consume 500ml of water followed by a solution of 75g sugar in 500ml water 3 hours later.~Each solution will be consumed over 5 minutes."
214667186|NCT02527304|RADIATION|Stereotactic Body Radiation Therapy|Undergo adaptive staged SBRT
214881141|NCT06570369|DRUG|Placebo|Oral dose, once daily for 2 weeks
214881142|NCT05207891|DEVICE|Intervention mattress|The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
214881143|NCT05473195|DRUG|BVL-GSK098 9mg|BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
214881144|NCT05473195|DRUG|Ethionamide 250mg|Ethionamide 250 mg po OD (Eto250)
214881145|NCT05473195|DRUG|Ethionamide 250 mg|Ethionamide 750 mg po given in a single or divided dose (Eto750)
214881146|NCT05473195|DRUG|Isoniazid 300 MG|Isoniazid 300 mg po OD (INH)
214881147|NCT06478706|DRUG|ETD001|Twice daily doses
214881148|NCT06478706|DRUG|Placebo|Twice daily doses
214881149|NCT06141018|DEVICE|Cross-linked intra-articular hyaluronic acid|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
214881150|NCT06141018|OTHER|Placebo|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
214881151|NCT02989909|DEVICE|CATS tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
214881152|NCT02989909|DEVICE|Goldmann tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
214881153|NCT03917251|DIAGNOSTIC_TEST|Coronary flow and pressure measurement in patients with ventricular pacing|Coronary flow and pressure measurement in patients with ventricular pacing
214881154|NCT02017015|DRUG|nab-paclitaxel|nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
214881155|NCT02017015|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
214292066|NCT04219332|DRUG|Subserosa injection of indocyanine green|After preoperative exploration, the indocyanine green powder (Dandong Yichuang Pharmaceutical Co) is dissolved in 0.5 mg/ml of sterile water and the prepared solution (1.5 ml for each point) is injected along the subserosal of the stomach at 6 specific points along the lesser and greater curvature of the stomach.
214881156|NCT02864576|BEHAVIORAL|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program. Patients will walk with a moderate intensity 10 minutes the first week and will increase gradually up to 30 minutes-walk with a moderate intensity. Patients will also perform 5 minutes of warm-up and stretching."
214881157|NCT02864576|BEHAVIORAL|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Health Promotion:~12 weeks of health promotion sessions. These sessions will be carried out by a specialized/trained nurse."
214881158|NCT01184495|DRUG|Epoetin Alfa-BioManguinhos|Subcutaneous administration of EPO-BioManguinhos
214667187|NCT04282577|DIAGNOSTIC_TEST|urinary nephrin and alpha one microglobulin|urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA
214881159|NCT01184495|DRUG|Epoetin Alfa-BioSimilar|Subcutaneous administration of EPO-BioSimilar
214881160|NCT02076087|PROCEDURE|Liposuction/lipectomy|Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
214881161|NCT04936737|DIETARY_SUPPLEMENT|Beta-alanine supplementation|The supplementation will be administrated in the dosage of 20mg.kg-1. On the first and the sixth (last one), one dose of beta-alanine will be taken. On the other four days of supplementation, the volunteers will take 2 doses (20mg.kg-1) of Beta-alanine.
214881162|NCT04936737|OTHER|High intensity interval exercise|The HIIE sessions will consist of 10 series of 1 min of effort, divided into two blocks of 5 series each. There will be an interval of 5 min of passive recovery; within each block, the interval between sets will be 1 min of active recovery. The exercise will be conducted in a mechanical brake cycle ergometer, with load applied by placing washers on a load plate (Biotec 2100, Cefise, Brazil).
214881163|NCT03383523|DRUG|Emodepside (BAY 44-4400)|2 tablets compared to the liquid formulation
214881164|NCT05014282|DRUG|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
214881165|NCT05014282|BEHAVIORAL|Counseling|Phone counseling with the state tobacco quitline.
214881166|NCT05014282|DRUG|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
214881167|NCT05014282|BEHAVIORAL|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
214881168|NCT06236061|DRUG|LCZ|LCZ 200 mg
214881169|NCT06236061|DRUG|LCZ/AML 200 mg/2.5 mg|LCZ/AML 200 mg/2.5 mg
214881170|NCT06236061|DRUG|LCZ/AML 200 mg/5 mg|LCZ/AML 200 mg/5 mg
214881171|NCT06236061|DRUG|LCZ/AML 200 mg/10 mg|LCZ/AML 200 mg/10 mg
214881172|NCT06236061|OTHER|Placebo|Matching placebo of Amlodipine.
214881173|NCT04687176|DRUG|Oral Arsenic Trioxide Formulation|"Patients will be recruited to oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days. Daunorubicin or idarubicin will only be used during induction in patients \<65 with presenting white blood cell count (WBC) ≥ 10 x 10\^9/L. In patients not receiving daunorubicin, hydroxyurea if WBC ≥ 5 x 10\^9/L within the first 14 days of induction. A reassessment bone marrow aspirate will be performed on day 28 of induction for assessment of morphologic remission.~Four weeks after the completion of induction phase, all patients, regardless of initial WBC, will receive two cycles of chemotherapy-free AAA consolidation (14 days every 28 days).~Four weeks after completion of consolidation, all patients will receive 12 cycles of chemotherapy-free AAA maintenance (14 days every 8 week)."
214881174|NCT03663452|BEHAVIORAL|Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS)|TACTICS begins with a mixed methods assessment (using data from medical records, staff surveys, and staff interviews) to identify barriers and facilitators of PE use in each clinic. From a menu of implementation strategies that can be matched to local conditions, an implementation plan is developed in collaboration with clinic personnel and deployed to address specific barriers and leverage strengths at each clinic site over a 5-month period.
214292067|NCT04219332|DRUG|submucosal injection of indocyanine green|One day before surgery, 1.25 mg/ml indocyanine green (Dandong Yichuang Pharmaceutical Co) was prepared in sterile water and 0.5 ml of the solution was injected into the submucosal layer at 4 quadrants around the primary tumor, amounting to 2.5 mg of indocyanine green.
214292068|NCT02743806|DRUG|Vedolizumab|Vedolizumab IV infusion
214667188|NCT02433249|BEHAVIORAL|1 Physical Activity|Fall reducing strength (5), balance (12) and flexibility (4) exercises as well as walking. Participants were also given a Fitbit One with instructions on how to use
214881175|NCT03663452|BEHAVIORAL|Prolonged exposure training|Providers will receive a 2-day workshop training in the delivery of prolonged exposure, followed by weekly phone clinical consultation.
214881176|NCT05179928|PROCEDURE|Erector Spinae Plane Block (ESPB)|Postoperative Bilateral Ultrasound-guided ESPB
214881177|NCT05179928|PROCEDURE|Rectus Sheath Block (RSB)|Postoperative Bilateral Ultrasound-guided RSB
214881178|NCT06798909|DRUG|Valganciclovir (Pre-emptive CMV Therapy)|Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
214881179|NCT06798909|DRUG|Valganciclovir CMV Prophylaxis|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 200 days post transplantation as prophylaxis.
214881180|NCT05620238|DRUG|Carfilzomib|Investigate the home administration of Carfilzomib IV reported by both patients and health care staff compared to the hospital setting.
214881181|NCT05848115|DEVICE|Bi-level Positive Airway Pressure|An appropriately sized vented BiPAP face mask with a good seal will be applied and monitored by trained respiratory therapists. Patients will be started on an inspiratory peak airway pressure (IPAP) of 10 cm of water and expiratory positive airway pressure (EPAP) of 5 cm of water per Children's Hospital Colorado (CHCO) clinical pathway. BiPAP pressures will be titrated to effect per the treating physician, using assessment of physical examination, vitals, and asthma score per institutional clinical pathway. Study participants will remain on BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the ongoing use of BiPAP or not.
214881182|NCT05848115|DEVICE|Sham Bi-level Positive Airway Pressure|The sham BiPAP will have pressure attenuated using an orifice restrictor as described in previous double blinded studies using sham non-invasive ventilation. With this set-up pressures no greater than 2 cm of water have been documented at the location of the face mask. This will ensure that the patient is not receiving positive pressure with any effectiveness or deleterious effects. Study participants will remain on sham BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the use of BiPAP or not.
214881183|NCT05656781|OTHER|Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)|Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
214881184|NCT06496542|BEHAVIORAL|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
214881185|NCT06496542|OTHER|Standard advice control|Initial nutrition consultation without subsequent counseling
214881186|NCT02580110|OTHER|Sucrose|
214881187|NCT02580110|OTHER|Stevia glycosides|
214881188|NCT02580110|OTHER|saccharin|
214881189|NCT04643977|DEVICE|mARG-01-17 (mesohyal AGRIBENONE)|Dermal Filler
214881190|NCT01478412|OTHER|Polymer based fiducial placement|Fiducial marker placement with rectal ultrasound imaging.
214881191|NCT02291510|DRUG|Met DR|metformin delayed-release tablets
214881192|NCT02291510|DRUG|Met XR|metformin extended-release tablets
215045349|NCT01985022|BEHAVIORAL|Individual-ESI|The Individual-ESI intervention consists of twice-weekly home-based individualized coaching sessions. Parents learn how to support their child's communication, social, and play skills in everyday routines, activities, and places. Individual-ESI begins with an initial home visit, followed by a month of program planning, 6 months of intervention implementation, and 2 months of generalization. During generalization, the clinician meets with the family in a variety of community settings to teach the parent how to implement strategies in new settings.
215045350|NCT01507740|DRUG|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
215045351|NCT01507740|DRUG|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
215045352|NCT01507740|DRUG|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
215045353|NCT03374020|DEVICE|Notal OCT|Imaging using Notal OCT
215045354|NCT01623063|PROCEDURE|Hysteroscopy|hysteroscopy with guided biopsies
215045355|NCT01624714|DRUG|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
215045356|NCT01624714|DRUG|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
215045357|NCT04542122|BEHAVIORAL|Choices and judgements|In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
214881193|NCT02291510|DRUG|Met IR|metformin immediate-release tablets
214881194|NCT04210219|DRUG|JNJ-64264681|JNJ-64264681 capsule will be administered orally.
214881195|NCT04657224|DRUG|JNJ-64264681|JNJ-64264681 capsules will be administered orally.
215045358|NCT02145884|DRUG|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
215045359|NCT01359124|BEHAVIORAL|Exercise Cycle|Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
214881196|NCT04657224|DRUG|JNJ-67856633|JNJ-67856633 capsules or tablets will be administered orally.
214881197|NCT05802797|OTHER|Algae Oil Fortified Soymilk|Flavored soymilk beverage fortified with 0.4% algae oil with both EPA and DHA
214881198|NCT05802797|DIETARY_SUPPLEMENT|Algae Oil Capsule|Algae oil capsules with EPA and DHA
214881199|NCT03765788|DRUG|Secukinumab 300 mg, s.c.|Secukinumab 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
214881200|NCT03765788|DRUG|Prednisolone|Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
214881201|NCT03765788|DRUG|Placebo|Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
214881202|NCT06550713|DRUG|TQB3455 tablet+Azacitidine for Injection|TQB3455 is a selective IDH2 mutant enzyme inhibitor. Azacitidine for injection is a cytosine nucleoside drug that is used for demethylation therapy.
214881203|NCT00122759|DRUG|ketamine|
214881204|NCT01940991|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
214881205|NCT01940991|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
214881206|NCT01534169|DRUG|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
214881207|NCT04269525|BIOLOGICAL|UC-MSCs|After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
214881208|NCT00610246|DRUG|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
214881209|NCT02147964|DRUG|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months \[all subjects\]
214881210|NCT02147964|DRUG|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]
214881211|NCT02147964|DRUG|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
214881212|NCT02147964|DRUG|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
215045360|NCT01359124|BEHAVIORAL|Land-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
215045361|NCT01359124|BEHAVIORAL|Water-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
215045362|NCT04544306|OTHER|Partial oral antimicrobial therapy|Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
215045363|NCT03136120|DRUG|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
215045364|NCT03136120|PROCEDURE|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
215045365|NCT05173779|PROCEDURE|Left atrial isolation by catheter ablation|Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
215045366|NCT01657357|OTHER|Routine followup|questionnaires
215045367|NCT00279214|DRUG|drotrecogin alfa (activated)|
215045368|NCT03445767|OTHER|MedSafer|An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.
215045369|NCT04662450|BEHAVIORAL|ABM affective pain stimuli|Patients undergo ABM training to shift attention away from affective pain stimuli
215045370|NCT04662450|BEHAVIORAL|ABM sensory pain stimuli|Patients undergo ABM training to shift attention away from sensory pain stimuli
214667189|NCT02433249|BEHAVIORAL|Interpersonal Motivation|Strategies used to support Interpersonal motivational targets include: a) discuss and model ways to provide and receive more support for physical activity, b) identify environmental barriers to being physically active, c) problem-solve environmental and social barriers to being physically active, d) use and create new resources that support physical activity behavior
214881213|NCT02147964|DRUG|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
214881214|NCT02147964|DRUG|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
214881215|NCT02147964|DRUG|placebo ketoconazole|placebo ketoconazole daily for 4 months
214881216|NCT01236443|DRUG|HPPH|3 mg/m2 IV
214881217|NCT05021432|OTHER|Virtual reality training group|This group will receive video based games
214881218|NCT05021432|OTHER|Circuit Training group|They will receive Task-oriented Circuit training exercise program
214881219|NCT03358706|DRUG|Ustekinumab IV Infusion|Participants will receive a single IV infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8.
214881220|NCT03358706|DRUG|Ustekinumab SC Injection|Participants will receive a Ustekinumab 90 mg SC maintenance dose on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator.
214881221|NCT03358706|DRUG|Midazolam 2 mg|Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.
214881222|NCT03358706|DRUG|Warfarin 10 mg|Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.
214881223|NCT03358706|DRUG|Vitamin K 10 mg|Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.
214881224|NCT03358706|DRUG|Omeprazole 20 mg|Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.
214881225|NCT03358706|DRUG|Dextromethorphan 30 mg|Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.
215045371|NCT04662450|BEHAVIORAL|Placebo|Patients undergo ABM training to receive affective/neutral and sensory/neutral word pairs
215045372|NCT01058850|BIOLOGICAL|Rindopepimut|250 or 500 mcg; intradermal injection
215045373|NCT03064308|OTHER|Exercise Programme|Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
214881226|NCT03358706|DRUG|Caffeine 100 mg|Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
214881227|NCT00391560|DRUG|perifosine|Identical intervention in both arms.
214881228|NCT01876225|BEHAVIORAL|Forced coughing during cervical punch biopsy|
214881229|NCT03203850|DRUG|Deferasirox FCT|Taken orally once per day (QD) as a film coated tablet (FCT)
214881230|NCT03203850|PROCEDURE|Phlebotomy|according to investigator's decision
214881231|NCT00429429|PROCEDURE|Sublingual immunotherapy|Drops of peanut protein placed and held under the tongue for a specific time before swallowed.
214881232|NCT03956394|DIAGNOSTIC_TEST|UltraFast ultrasound|The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.
214881233|NCT01659125|BEHAVIORAL|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
214881234|NCT01913886|PROCEDURE|MSCs injection|MSCs cells will be injected in two aliquots of 10 ml by catheterism
214881235|NCT04392895|PROCEDURE|Para Aortic Lymphadenectomy (PAL) by laparoscopy|Para Aortic Lymphadenectomy (PAL) by laparoscopy
214881236|NCT03251170|DRUG|Ketamine|Patients will receive :1 mg/Kg ketamine for induction of anesthesia
214881237|NCT03251170|DRUG|Fentanyl|Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
214881238|NCT03251170|DRUG|Midazolam|Patients will receive 0.05 mg/Kg midazolam
214881239|NCT02126826|DRUG|BI 1026706|Multiple Rising Doses (oral solution, tablet)
214881240|NCT02126826|DRUG|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
214881241|NCT02972190|PROCEDURE|Bilateral decompression with TLIF|Bilateral decompression of neural elements combined with TLIF
214881242|NCT02972190|PROCEDURE|laminectomy with PLIF|Decompression of neural elements using laminectomy combined with PLIF
214881243|NCT02972190|DEVICE|Pedicle screw and interbody cage|Pedicle screw and interbody cage
214881244|NCT04211116|DEVICE|Central venous line insertion|Pediatric patients indicated to central venous line insertion
214881245|NCT04622241|OTHER|Eave Tubes|The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g. bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides. No additional screening will be done. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
214881246|NCT04622241|OTHER|Eave Ribbons|"Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial).~All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
214881247|NCT04622241|OTHER|Full House Screening|"Full house screening includes screening eaves/ceilings, ventilation openings, and windows. Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials. or ceilings, if eaves are closed and ventilation openings. We are also filling in any gaps in the walls. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
214881248|NCT04622241|OTHER|Partial House Screening|Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present. In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls. No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
214881249|NCT01860235|DRUG|EMLA|% eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
214881250|NCT01860235|DRUG|Injectable anesthesia|Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
214477024|NCT04924400|BEHAVIORAL|CHIP Program|"GHP members randomized to the intervention arm will participate in the following activities:~* Attend 2 group meetings per week over 6 weeks, followed by one group meeting per week for 6 weeks (12 weeks total); each meeting will last about one hour. CHIP classes for weeks 1-4 and week 12 require in-person attendance, while week 5-11 classes can be attended either virtually or in-person.~* Receive a copy of The Optimal Diet, The Official CHIP Cookbook.~The following data will be collected at weeks 1,12 and 26:~* Biometrics: weight, BMI, waist circumference, systolic and diastolic blood pressure~* Biomarkers (blood tests): HbA1c, LDL-C~* Psychometrics: Wellbeing360 survey"
214881251|NCT01860235|DRUG|2% Benzocaine|Topical anesthetic - 200mg/g of 2% benzocaine
214881252|NCT01860235|DRUG|Placebo|Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
214881253|NCT02712723|DRUG|Letrozole|Nonsteroidal aromatase inhibitor
214881254|NCT02712723|DRUG|Ribociclib|Oral cyclin-dependent kinase (CDK) inhibitor
214881255|NCT02712723|DRUG|Placebo|Placebo for ribociclib
214881256|NCT02478229|DRUG|Sofosbuvir (SOF) and Ledipasvir (LDV)|
214881257|NCT04965805|DEVICE|cold plasmaJet kINPen Med|experimental, non-inferiority
214881258|NCT04965805|DEVICE|Best practice wound dressings|comparative,
215045374|NCT02642757|BEHAVIORAL|AUDIT brief intervention|Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
215045375|NCT02642757|OTHER|Pamphlet on alcohol use|Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
215045376|NCT04272164|OTHER|technical taekwando training|Light jogging followed by star jump, Different running styles (forward, backward and sideways), Stretching exercises (Upper and lower Limb), Pushups and sit ups, Punches (single, double, triple, nonstop punches including speed and power, punches with forward and backward stepping), Kicks (rising kick, front kick, middle kick, drop kick ( in +out+center), Stances (walk stance, punching stance, front deep stance, kicking stance), Blockings (solar block, upper block and lower block), Self -defense (neck gripping, hand gripping, locking), Sand bag drills, Balance training 10 repeatitions of 1 set each, 3 days a week for 8 weeks
215045377|NCT04272164|OTHER|weighted rope jump training|Basic bounce step with both feet 2. Bell jump with both feet 3. Skier's jump 4. Right foot skipping 5. Left foot skipping, 6. Alternate foot step 7. Boxer shuffle 8. Side straddle 9. Scissors 10. Bonus jump with both feet After the preparatory weighted rope jump training (WRJT) for 1 week, subjects in experimental group followed jumping training by repetition method 3 days in a week for 8 weeks in addition to the routine taekwondo training program. 3 sets per week with 30 seconds training duration and 30 seconds rest duration. with progressive increase in the intensity and no. of sets.
215045378|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
215045379|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
215045380|NCT01214837|BIOLOGICAL|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
215045381|NCT05650866|DEVICE|Activation of pro-erectile nerves within the pelvic plexus|The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.
215045382|NCT04748549|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
215045383|NCT04748549|OTHER|Immersive Audio Experience|A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient.
215045384|NCT04748549|OTHER|Sham Virtual Reality Experience|Subjects will wear VR headsets and headphones but will not view any content or listen to any audible content.
215045385|NCT06994130|DIAGNOSTIC_TEST|Seravue|. This study seeks to test the performance of the SeravueTM (LC-SPIK) device alone or in combination with ultrasound as a tool for HCC surveillance in diverse patient populations and clinical settings.
215045386|NCT06629389|DRUG|Cannabidiol 100 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
215045387|NCT06629389|DRUG|cannabidiol 300 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
214881259|NCT05629715|DEVICE|ROSA Knee System|The Zimmer Biomet ROSA Knee System is a commercially available, FDA approved robotic assistant for performing TKA. It uses preoperative x-rays to create a three-dimensional image of the patient's knee anatomy which is used to create a preoperative template of the implants to be used and provides intraoperative guidance for bone cuts during the TKA. The robotic system also assesses the soft tissue envelope around the knee and can assist with the soft tissue balancing of the knee arthroplasty. Alternatively, it can also be used in an imageless mode where bone cuts are performed based on intra-operative mapping using anatomic landmarks.
214881260|NCT05629715|DEVICE|KneeAlign Computer Assisted Navigation System|The OrthAlign KneeAlign computer assisted navigation system is a commercially available device that uses gyroscopic limb position sensing technology mounted to intramedullary and extramedullary jigs to measure bone resection cuts in TKA that ultimately dictate implant position.
215045388|NCT06629389|DRUG|Cannabidiol 400 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
215045389|NCT06629389|DRUG|Placebo|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
215045390|NCT06694246|OTHER|Improving technique|"A checklist was developed to ensure the important steps were followed, with tips for obtaining a more adequate sample. This checklist was put in the outpatient procedures room, and each physician performing a biopsy was asked to fill it out.~Also, a diagram containing illustrative images with the basic steps was put in the procedures room.~The topic was covered in the biweekly scientific meeting, and all factors attributed to the inadequate sample were discussed.~The department lead mentioned the topic in the OBGYN department's private messaging group.~It was finally mentioned in the morning meeting."
215045391|NCT06694246|OTHER|Using hysteroscopy in candidate patients|"Patients with focal lesions on ultrasound will undergo hysteroscopy and biopsy instead of blind endometrial sampling.~Patient with stenosed cervix or failed previous sampling might also undergo hysteroscopic guided biopsy."
215045392|NCT06694246|OTHER|Analgesia|Analgesia in the form of paracetamol or NSAIDs might be given to some patients 30- 60 minutes before the procedure to reduce the procedure-associated pain and the resultant failure to complete it and obtain an adequate sample.
215045393|NCT01049087|RADIATION|Plasma volume determination (99mTc-albumin)|The test is performed using 5MBq technetium-labeled albumin (99mTc-albumin-Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
215045394|NCT01049087|RADIATION|Plasma volume determination (125I-albumin)|The test is performed using 0.2MBq 125iodine-labeled albumin (125I-albumin) with several postinjection samples for accurate zero-time extrapolation.
215045395|NCT06696261|DRUG|Lianxiaxiaopi Granules|The participants took orally 1 sachet of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
215045396|NCT06696261|DRUG|a simulated agent of Lianxiaxiaopi Granules|The participants took orally 1 sachet of simulated agent of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
215045397|NCT06716736|BIOLOGICAL|socket preservation using dentine graft mixed with i-PRF|surgical extraction of horizontally impacted third molar , placement of dentin graft mixed with i-PRF inside the socket , suturing
215045398|NCT06716736|BIOLOGICAL|socket preservation using bone allograft|surgical extraction of horizontally impacted third molar , placement of bone allograft inside the socket , suturing
215045399|NCT06716736|BIOLOGICAL|socket preservation using collagen cone|surgical extraction of horizontally impacted third molar , placement of collagen cone inside the socket , suturing
215045400|NCT01580228|DRUG|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m\^2 on Day 1, 10 mg/m\^2 on Day 8, and 14 mg/m\^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
214881261|NCT03884361|DIAGNOSTIC_TEST|Vaginal Microbiome as result of aminocentesis|we will take a blood samples and a vaginale samples after and before the aminicentesis and check if the sample that we took after is different and contain microrganisms , if we find a different o we can say that as result of the Elective Amniocentesis
214477025|NCT04924400|BEHAVIORAL|Usual Care|"GHP members assigned to the control arm will receive the routine standard of care for GHP members. Members will receive a summary of diabetes-related benefits available to members with type 2 diabetes.~The following data will be collected at weeks 1,12 and 26:~* Biometrics: Weight, BMI, waist circumference, systolic and diastolic blood pressure~* Biomarkers (blood tests): HbA1c, LDL-C~* Psychometrics: Wellbeing360 survey"
214477026|NCT06663189|DRUG|treatment withdrawal|Patients will STOP their DMT
214881262|NCT02640482|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
214881263|NCT02640482|DRUG|Placebo for ABT-493/ABT-530|tablet
214881264|NCT01173120|DEVICE|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
214881265|NCT00517881|DRUG|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
214881266|NCT00113763|OTHER|Best supportive care|Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
214881267|NCT00113763|DRUG|Panitumumab|Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
215045401|NCT01580228|DRUG|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
215045402|NCT03758183|PROCEDURE|total knee arthroplasty|
215045403|NCT02449187|DRUG|JLP-1310, Fasted followed by fed|"In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition."
215045404|NCT02449187|DRUG|JLP-1310, Fed followed by fasted|"In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition."
215045405|NCT03410160|DIAGNOSTIC_TEST|Clinical and biochemical examination.|Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
215045406|NCT00457626|DRUG|Valsartan|Extemporaneous suspension of valsartan, orally.
215045407|NCT04729790|DRUG|PRIM-DJ2727|oral FMT capsules
215045408|NCT03730519|DEVICE|Baroreflex Activation Therapy with Barostim Neo|Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
215045409|NCT02896309|DIETARY_SUPPLEMENT|Sodium bicarbonate|
215045410|NCT02896309|DIETARY_SUPPLEMENT|Sodium chloride|
215045411|NCT03279107|OTHER|Soluble corn fiber|soluble corn fiber
215045412|NCT03279107|OTHER|maltodextrin|maltodextrin
215045413|NCT01471613|PROCEDURE|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
215045414|NCT01471613|DRUG|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
215045415|NCT01471613|BIOLOGICAL|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
215045416|NCT01471613|OTHER|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
215057255|NCT04499027|DIAGNOSTIC_TEST|Lung ultrasound scan|"12 hours postoperatively using a convex ultrasound probe LUS will be performed by an experienced radiologist according to standardized protocols. For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines will be identified. Each one will be divided into upper and lower halves, making a sum of 6 different quadrants for each side: anterior superior, anterior inferior, lateral superior, lateral inferior, posterior superior, posterior inferior.~For each quadrant a score will be assigned based on B lines which are defined as comet like artifacts indicating subpleural interstitial edema as follows:~(0) normal aeration: A lines with lung sliding or fewer than two isolated B lines; (1) moderate loss of lung aeration: well-defined, multiple B lines ; (2) severe loss of lung aeration: multiple coalescent B lines; and (3) complete loss of lung aeration or lung consolidation."
215057256|NCT06231407|BEHAVIORAL|Recovery Oriented CBTp Medication Management|The prescriber structures the medication appointment to elicit and focus on subjects long term, valued goals (aspirations). With this information the prescriber will develop a plan to increase daily activity to facilitate the aspiration's pursuit. Obstacles (psychotic symptoms, motivational problems) will be identified and a formulation developed with the individual. Psychosocial interventions will be implemented for the various obstacles alongside monitoring and implementing of medications. Across sessions, the prescriber will continue to implement and monitor psychosocial interventions.
215057257|NCT06231407|BEHAVIORAL|Treatment as Usual|Residents will conduct medication management appointments as normally conducted
215057258|NCT00000407|BEHAVIORAL|Vocational counseling intervention|
215057259|NCT00000407|BEHAVIORAL|Reading materials for control participants|
215057260|NCT00000407|BEHAVIORAL|Standard of care|No education or behavioral intervention
215057261|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 3 months|Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
215057262|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 6 months|Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
215057263|NCT05870969|BEHAVIORAL|Liver cancer surveillance annually|Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
215057264|NCT04058899|DRUG|Dexmedetomidine|sedative and might be analgesic drug
215057265|NCT04058899|DRUG|Nalbuphine|agonist antagonist narcotic
214881268|NCT04675099|BEHAVIORAL|pCARE|"Mothering from the Inside Out is an evidence-based intervention delivered in substance use treatment settings that helps mothers with substance use disorders foster parent-child attachment, cope with stressful parenting situations, and promote their child's healthy development. This 3 month counseling intervention both improves parent-child attachment and decreases rates of drug relapse among mothers. The proposed mechanism of action targeted by the intervention is a change in parental reflective functioning, defined as the capacity to recognize and make sense of mental states (especially emotional states) and understand how they influence behavior and relationships."
214881269|NCT04675099|OTHER|Standard Early Intervention services|The state of Massachusetts provides voluntary early childhood development services to substance-exposed infants through a system of Early Intervention programs. These programs offer coordinated services to all infants and toddlers with disabilities and those at risk for developmental delays in homes and child centers beginning at birth.
214881270|NCT05794893|BEHAVIORAL|Good Behavior Game|Universal school-based intervention reinforcing prosocial behaviors and discouraging disruptive behaviors in young students.
214881271|NCT01383707|DRUG|5-Fluorouracil (5-FU)|Participants will receive 5-FU 400 mg per meter-squared (mg/m\^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m\^2, continuous infusion over 46 hours up to 12 cycles.
214881272|NCT01383707|DRUG|Bevacizumab|Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).
214881273|NCT01383707|DRUG|Levofolinic acid|Participants will receive levofolinic acid 200 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
214881274|NCT01383707|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
214881275|NCT03849911|DIAGNOSTIC_TEST|Neurophysiological Prognosis|SEP and EEG evaluation for Neurological Prognosis of Cardiac Arrest
214881276|NCT03849911|DIAGNOSTIC_TEST|Multimodal Prognosis for poor early neurological outcome|Brain CT, SEP and EEG evaluation
215045417|NCT04608019|OTHER|Immediate Antibiotics|increase airway clearance/start oral antibiotics right away
214477027|NCT06663189|DRUG|Usual DMT continuation|Patients will continue their DMT during the trial as usual : Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate
214477028|NCT06663189|OTHER|MRI|Cerebral+spinal cord enhanced MRI (M0) Cerebral enhanced MRI (M6, Relapse early visit) Unenhanced cerebral MRI (M12, M18, M24, Relapse distant visit
214477029|NCT06663189|BEHAVIORAL|Quality of Life questionnaires|EQ-5D5L: EuroQol-5-Dimension 5 levels Burden of Treatment Questionnaire (BTQ self-administered questionnaires) Hospital Anxiety and Depression (HAD) questionnaire
214477030|NCT06663189|OTHER|Disability evaluation tests|EDSS: Expanded Disability Status Scale 25Foot/Walk 9-HPT:Nine Hole Peg Test
214881277|NCT02013817|DRUG|rituximab [MabThera/Rituxan]|Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
214881278|NCT02013817|DRUG|fludarabine|Every 4 weeks, 6 cycles
214881279|NCT02013817|DRUG|cyclophosphamide|Every 4 weeks, 3 cycles
214881280|NCT05211518|OTHER|Tasty&Healthy|exclude pro-inflammatory dietary components
214881281|NCT05211518|OTHER|Habitual diet|subjects will continue their habitual diet.
214881282|NCT04603872|DRUG|CD19/BCMA Targeted CAR T-cells and dasatinib|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.
214881283|NCT04603872|DRUG|CD19/BCMA Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
214881284|NCT05504837|BIOLOGICAL|KB407 (Nebulization)|Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR
214881285|NCT06057948|BIOLOGICAL|OPT-821 (QS-21)|Comprised of the immunological adjuvant OPT-821 (QS-21)
214881286|NCT06057948|DIETARY_SUPPLEMENT|oral β-glucan|Participants will be randomized to receive this agent in two different schedules
214881287|NCT04410419|DIETARY_SUPPLEMENT|Pre-operative carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
214881288|NCT06286696|DIAGNOSTIC_TEST|Optic Nerve Sheath Diameter|Point of care ultrasonography of the optic nerve sheath diameter
214881289|NCT05543408|BEHAVIORAL|EXERCISE|individualized, progressive, exercise program
215045418|NCT04608019|OTHER|Tailored Treatment|increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better
215045419|NCT03549338|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
215045420|NCT03549338|DRUG|Futuximab|Futuximab is one of two mAb components that constitute Sym004.
215045421|NCT03549338|DRUG|Modotuximab|Modotuximab is one of two mAb components that constitute Sym004.
215045422|NCT05593354|DEVICE|Micropulse Transscleral laser therapy|Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine
215045423|NCT00269113|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
215045424|NCT00269113|DRUG|Standard chemotherapy|As prescribed
215045425|NCT00652743|BIOLOGICAL|Pandemic influenza vaccine GSK1562902A|IM administration
214477031|NCT06826248|DRUG|Darqeen Capsule|Effect of Darqeen capsule on Thyroid hormones
214881290|NCT05546463|BEHAVIORAL|Digital games|"A digital game was played via iPad Air 2 32GB 9.7-inch wi-fi model tablet. The researcher created a folder with a range of selected games to appeal to different preferences. Children could choose from the following games: Word Travel, Talking Tom Candy Run, 384 Puzzles for Kids, Masha and The Bear, Subway Surfers, Head Ball 2 and Dream League Soccer."
214881291|NCT03004339|DRUG|SOR007 Ointment 2.0%|
214881292|NCT03004339|DRUG|SOR007 Ointment 1.0%|
214881293|NCT03004339|DRUG|SOR007 Ointment 0.3%|
214881294|NCT03004339|DRUG|SOR007 Ointment 0.15%|
214881295|NCT03004339|DRUG|SOR007 Ointment Placebo|
214881296|NCT03004339|DRUG|Taclonex® Ointment|
214881297|NCT01133457|DRUG|Finasteride|Finasteride tablets 1 mg
214881298|NCT02678208|DRUG|Tranexamic Acid|
214881299|NCT02678208|DRUG|5% glucose|
214881300|NCT02129608|DEVICE|LLLT|The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
214881301|NCT02129608|DRUG|Lorcaserin|10 mg pills twice daily for 12 weeks.
214881302|NCT03624920|DRUG|THN102 Dosage A|THN102 Dosages A: placebo
214881303|NCT03624920|DRUG|THN102 Dosage B|THN102 Dosage B : 200mg/2mg
214881304|NCT03624920|DRUG|THN102 Dosage C|THN102 Dosage C: 200mg/18mg
214881305|NCT05628831|PROCEDURE|vNOTES suspension with autologous tissue|Autologous tissue will be fixated on solid points in pelvis using vNOTES.
215045426|NCT04253210|OTHER|psychological|Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
215045427|NCT05309967|OTHER|GLUMA DESINSITIZER|GLUTARALDEHYDE
215045428|NCT05309967|OTHER|PLACEBO|DESTILLED WATER
215045429|NCT04832347|OTHER|Exercise|Exercise Group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
215045430|NCT04832347|OTHER|Vagus Nerve Stimulation|Vagus therapy will be applied for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
215045431|NCT01714323|BEHAVIORAL|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free \& Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
215045432|NCT01714323|BEHAVIORAL|Standard Care|Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
215045433|NCT03293303|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
215045434|NCT00755807|DRUG|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
215045435|NCT00755807|DRUG|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
215045436|NCT00157963|DRUG|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
215045437|NCT03704038|PROCEDURE|PEEP level|Patients will have variable PEEP levels and will be monitored
214881306|NCT05628831|PROCEDURE|Vaginal surgery|Vaginal hysterectomy will be done with anterior and/or posterior repair depending on the judgment of the surgeon at the time of the operation. Uterosacral and cardinal ligaments will be repositioned and attached to the vaginal vault after hysterectomy at the time of vault closure. A modified McCall culdoplasty will be done in this group to prevent enterocele and further apical prolapse
214881307|NCT00641628|PROCEDURE|mastectomy|
214881308|NCT05431894|BEHAVIORAL|Laguna Coach Intervention Group|Behavioral and mental support was delivered through personal interactions with Laguna Coaches via phone, video, or web chat. Behavioral and mental support was individualized to best match each patient's needs and strengths. Support was provided to participants through human interactions over approximately 30 days.
214881309|NCT03600389|BEHAVIORAL|Patient Priorities Care|
214881310|NCT00451204|DRUG|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
214881311|NCT00451204|DRUG|Placebo|Placebo capsule, once a day, treatment duration is 2 years
214881312|NCT00451204|DRUG|Copaxone|Injection, once a day, all subjects
214881313|NCT00282529|DEVICE|High Risk Lymphedema Education and Device Intervention|
214881314|NCT04831814|DIAGNOSTIC_TEST|Near Focus NBI|Colonoscopy with near focus narrowing band imaging technology . Optical specifications include a 2 mm near field focal depth. Optical diagnosis of polyps were according to NICE and WASP, respectively.
214881315|NCT04831814|DIAGNOSTIC_TEST|Standard Focus NBI|Colonoscopy with narrow band imaging technology.Optical diagnosis of polyps were according to NICE and WASP, respectively.
214881316|NCT00000814|DRUG|Nevirapine|
214881317|NCT00000814|DRUG|Zidovudine|
214881318|NCT00000814|DRUG|Didanosine|
214881319|NCT03055624|DEVICE|Embosphere microparticles for prostate artery embolization|Pelvic angiograms will be performed and microspheres delivered to the arteries supplying the prostate to alleviate symptoms of benign prostatic hyperplasia.
214881320|NCT02880670|DRUG|BMS-986142|
214881321|NCT03573154|OTHER|administration of the liquid 1 and then the liquid 2|The patient will received the e-liquid 1 in the first visit and the e-liquid 2 in the second
214881322|NCT03573154|OTHER|administration of the liquid 2 and then the liquid 1|The patient will received the e-liquid 2 in the first visit and the e-liquid 1 in the second
214881323|NCT05131555|DRUG|Placebo: Placebo + exercise training.|Oral placebo Exercise training: Interval-based cycling exercise
214881324|NCT05131555|DRUG|H1 blockade: H1 receptor antagonist + exercise training|H1 blockade: oral blockade Exercise training: Interval-based cycling exercise
214881325|NCT05131555|DRUG|H2 Blockade: H2 receptor antagonist + exercise training|H2 blockade: oral blockade Exercise training: Interval-based cycling exercise
214881326|NCT02352818|OTHER|no study intervention|
214881327|NCT06632223|OTHER|Sensory motor training|Each session will be composed of 10 minutes of warm-up, followed by 50-60 minutes of sensory motor exercises, followed by 5-10 minutes of cool down.
214881328|NCT06632223|OTHER|Traditional physical therapy|traditional physical therapy program in form of stretching exercises, strengthening exercises, scar management, and gait training
215045438|NCT03971175|PROCEDURE|Forceps biopsy|Endobronchial biopsy with the forceps
215045439|NCT03971175|PROCEDURE|Cryobiopsy|Endobronchial biopsy with the cryobiopsy probe
215045440|NCT03531814|BEHAVIORAL|Medication Event Monitoring System (MEMS^TM)|A computerized method of tracking the dates and times of a pill bottle being opened.
214477032|NCT06824948|DRUG|Timolol Maleate Gel|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel one time a day during Day 3-Day 12.
214477033|NCT06824948|DRUG|Placebo|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo one time a day during Day 3-Day 12.
214477034|NCT06824948|DRUG|Timolol Maleate Gel|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel 2 times a day during Day 3-Day 12.
214477035|NCT06824948|DRUG|Placebo|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo 2 times a day during Day 3-Day 12.
214477036|NCT06824948|DRUG|Timolol Maleate Gel|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel 3 times a day during Day 3-Day 12.
214881329|NCT01582152|DRUG|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
214881330|NCT01582152|DRUG|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
214881331|NCT06066294|BIOLOGICAL|Regimen 1|WHO Pre-qualified rabies vaccine (Rabivax-S), WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7
214881332|NCT06066294|BIOLOGICAL|Regimen 2|WHO Pre-qualified rabies vaccine (Rabivax-S), Government of India approved vaccination schedule, 3 visits, 0.1ml 1 site on day 0, 7 and 28
214881333|NCT01118065|DRUG|everolimus|
214881334|NCT03494101|OTHER|Blood samples|Blood samples will be collected and analyzed at different study time points
214881335|NCT03494101|OTHER|Stool samples|Stool samples will be collected and analyzed at different study time points
214881336|NCT03494101|OTHER|Clinical information|Clinical information will be collected at different study time points using questionnaires
214881337|NCT03449004|OTHER|Validation of the OPSI questionnaire|A questionnaire to measure satisfaction with online information for patients with low back pain
214881338|NCT03364946|OTHER|No intervention|No intervention, observational study
214881339|NCT02103504|DEVICE|DePuy Attune posterior stabilized fixed bearing total knee replacement|
214881340|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 24 weeks
214881341|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 48 weeks
214881342|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 24 weeks
215045441|NCT03531814|OTHER|Questionnaires|Adult and pediatric participants completed a series of questionnaires to assess medication adherence, demographics, life events, and barriers to adherence.
215045442|NCT06397859|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
215045443|NCT03875638|DRUG|Levetiracetam|Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability
215045444|NCT03875638|DRUG|Placebo oral capsule|The placebo is a capsule that is identical in appearance to the levetiracetam
215045445|NCT02495285|DRUG|Gelofusine 4%|
215045446|NCT02495285|DRUG|Gelaspan 4%|
215045447|NCT03957382|DEVICE|Accero® (heal) Stent|The Accero® (heal) Stent will only be used in line with the Instructions For Use (IFU). Patients participating in this PMCF (Post- Market Clinical Follow-up) will not be exposed to any additional risk. There are no additional treatments or investigations other than done in the clinical routine.
215045448|NCT04505761|DEVICE|Virtual Reality|Participants will use a Virtual Reality headset with a range of applications applicable for rehabilitation after COVID-19. Applications target physical, psychological, and cognitive rehabilitation. VR headset will be used for six weeks first at the physiotherapist's practice, and when possible, at home.
215045449|NCT01783210|BEHAVIORAL|Specific Therapeutic Lifestyle Changes program in pregnancy|"TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the talk test (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks."
215045450|NCT01783210|BEHAVIORAL|Dietary and behavioral counselling in pregnancy|"The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.~30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks."
215045451|NCT04937634|DRUG|Melphalan|The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m\^2/day. Infuse Melphalan over 30 minutes.
214881343|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 48 weeks
214292069|NCT03206853|PROCEDURE|Hybrid Operating Techniques|It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
214881344|NCT01331850|DRUG|RO5024048|1000 mg oral doses twice a day for 24 weeks
214881345|NCT01331850|DRUG|danoprevir|100 mg oral doses twice a day for 24 weeks
214881346|NCT01331850|DRUG|ritonavir|100 mg oral doses twice a day for 24 weeks
214881347|NCT02753920|OTHER|voiding trial|1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
214881348|NCT02753920|DEVICE|Foley catheter|If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
215045452|NCT04930315|DRUG|Apatinib Mesylate|250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery
215045453|NCT04930315|DRUG|Camrelizumab|200mg, iv, d1, q2w, both in two groups
215045454|NCT01231789|PROCEDURE|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
215045455|NCT01231789|PROCEDURE|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
215045456|NCT05367869|PROCEDURE|Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy|General anaesthesia ,supine position with hyperextension to the neck Low collar incision to the neck , incision to the skin and platysma muscle and fascia ,upper and lower flaps are developed ,separation of strap muscles and identification of the thyroid gland after freeing of investing fascia Ligation of the middle thyroid vein and ligation and separation of the superior pedicle away from the external laryngeal nerve At this point of operation and before ligation of inferior pedicle methylene blue 0.05% spraying is applied to the field the amount varies according to size of the thyroid lobe and variation in population and neck size Thyroid gland stained by bluish color , recurrent laryngeal nerve not stained or minimally stained so we can avoid injury to it parathyroid glands get red of the stain after about 3 minutes so we can avoid injury to it thyroid gland lose its stain in about 15 minutes so we can remove any residual and decrease residual tissue or recurrence
215045457|NCT05111145|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
215045458|NCT05111145|DRUG|IVA|Tablets for oral administration.
215045459|NCT01836289|DRUG|High-dose Cyclophosphamide|
215045460|NCT04587037|PROCEDURE|fascia lata allograft|underwent superior capsule reconstruction using fascia lata allograft
215045461|NCT04587037|PROCEDURE|human dermal allograft|underwent superior capsule reconstruction using human dermal allograft
215045462|NCT03201640|BEHAVIORAL|slideshow|Participants will be shown a slideshow showing a child being prepared for surgery
215045463|NCT03201640|BEHAVIORAL|virtual|Participants will be shown an immersive virtual reality preparation for surgery
215057266|NCT04058899|DEVICE|infusion pump|infusion pump for titration of fluid containing drug infusion
215057267|NCT01266889|DEVICE|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
214881349|NCT02011477|OTHER|Neural Glide|This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
214881350|NCT02011477|OTHER|Neural stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
214881351|NCT05249673|OTHER|global postural reeducation|"GPR interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
214881352|NCT05249673|OTHER|neck stabilization training|"Each exercise session will be comprised 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.~performed. The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient."
214881353|NCT00936247|DRUG|HES 130/0.42 + electrolyte solution|Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
214881354|NCT00936247|DRUG|Albumin + electrolyte solution|Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
214881355|NCT01149408|DRUG|Decitabine (Dacogen)|Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
214881356|NCT00181714|DRUG|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
214881357|NCT04352725|PROCEDURE|End-expiratory lung volume measurement and incremental PEEP titration|"* End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o~* incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
214881358|NCT03437031|DEVICE|Virtual Reality device|For those patients randomized to VR, the study staff member will explain the use of the Samsung VR goggle set, and thereafter will allow the patient to use the device freely for up to 30 minutes. Intervals of 2-5 minutes is suggested for first-time use, and patients will be to allowed to discontinue it at any time as long as they are not experiencing any discomfort or side effects (dizziness, motion sickness, etc.). The study staff member will be present at all times, and will work with hospital staff as necessary to ensure the patient is receiving appropriate clinical care throughout the duration of the intervention.
215045464|NCT05558488|OTHER|Meatless, restrictive ketogenic diet|"Each participant received a nutritional plan that was the same qualitatively but differed quantitatively - a 500 kcal reduction based on Estimated Energy Requirement (EER) was assumed. Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8gxKg-1xbody weight-1xday-1) with three meals a day. The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 gxKg-1xbody weight-1xday-1(\~25-30%), fats (\~65-70%,with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\<30gxday-1;\<10%).~The food lists encouraged the consumption of fish,raw and cooked vegetables, eggs,fruits with the lowest glycemic index (blueberry, raspberry), plant oils and fats from avocado,olives.Drinks permitted were tea, coffee without sugar and the foods and drinks to be avoided were alcohol,meat (any kind of meat),bread,pasta,rice,milk,dairy and potatoes."
215045465|NCT03549741|DRUG|Clomiphene Citrate 50mg|oral tablets
215045466|NCT03549741|DRUG|Cabergoline Oral Tablet|oral tablets
215045467|NCT03549741|DRUG|Placebo Oral Tablet|oral tablets
215045468|NCT02126046|GENETIC|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
215045469|NCT01761708|PROCEDURE|primary ventral hernia repair with mesh|
215045470|NCT00297869|PROCEDURE|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
215045471|NCT00360958|PROCEDURE|ultrafiltration|
215045472|NCT05468281|OTHER|Checklist implementation|. Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
215045473|NCT00330369|DRUG|Darusentan|Darusentan administered orally once daily
214292070|NCT05383300|DRUG|Oxytocin nasal spray|Intranasal spray containing 40 IU of oxytocin
214881359|NCT00266539|DRUG|E-TRANS Fentanyl hydrochloride; Morphine|
214292071|NCT05383300|OTHER|Placebo spray|Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin
214292072|NCT03589443|DRUG|Multiplexed heptapeptides|Heptapeptides QRH and KSP
214292073|NCT02635555|DRUG|Phenylephrine|100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
214292074|NCT01887574|OTHER|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
214292075|NCT03931421|BIOLOGICAL|CAR-T treatment|a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.
214881360|NCT02686736|BEHAVIORAL|Internet-based educational intervention|The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
214881361|NCT02794870|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
214881362|NCT02794870|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
214881363|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia preservation|Thicker abdominal flaps will be preserved during the surgery.
214881364|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia ablation|Thinner abdominal flaps will be preserved during surgery.
214881365|NCT02140385|DEVICE|Lymphoscintigraphy|Post-operative lymphatic imaging will be conducted using a common radiographic medium
214881366|NCT02140385|DEVICE|3D Imaging|Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
214881367|NCT02140385|DEVICE|Abdominal ultrasound|Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
214881368|NCT06192056|BEHAVIORAL|RNT Focused Web- Based Self-Help Program|This 10 day long intervention contains psychoeducational contents, experimental exercises, monitoring behavior and committed action strategies. Each step of the intervention aims to develop a specific psychological flexibility skill like cognitive defusion etc.
214881369|NCT04366687|BEHAVIORAL|Smart Parents - Safe and Healthy Kids|Smart Parents - Safe and Healthy Kids (SPHSK) is a module designed to be added to existing evidence-based parent education programs. Because the module builds off of the core parenting skills developed in existing parent education programs, the module can be delivered in one session. SPSHK is comprised of three key CSA-prevention components: healthy child sexual development, parent-child communication about sex and sexual behaviors, and CSA-specific safety strategies such as vetting a babysitter and monitoring one-on-one time with adults. Behaviorally based, the module presents developmentally comprehensive information to parents of children 0-13 and utilizes role-playing scenarios and activities to maximize parents' use of learned skills.
214881370|NCT04366687|BEHAVIORAL|Parents as Teachers|Parents as Teachers (PAT) is a parent-support program delivered to parents of children under five and focuses on improving parenting skills through parent-child interactions, development centered parenting, and general well-being. PAT has demonstrated positive effects on child and parent outcomes related to school readiness.
214881371|NCT03886883|OTHER|Exercise induced hypoalgesia (EIH)|An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).
214881372|NCT03886883|OTHER|Static stretch (SS)|Two bouts of 30 seconds of static stretching (SS) of the knee flexors.
214881373|NCT03886883|OTHER|Rest|The participants rested in a seated position for 10 minutes
214881374|NCT03886883|OTHER|Conditioned pain modulation (CPM)|A CPM response was induced by way of the cold pressor test.
215045474|NCT00330369|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
215045475|NCT05135598|OTHER|Partners for Life health behavior change program|A health behavior change intervention based on partner learning, utilizing low-tech media and a workbook.
215045476|NCT04973358|OTHER|buccotherm mouthwash|twice a day for 14 weeks
215045477|NCT04973358|OTHER|placebo mouthwash|twice a day for 14 weeks
215045478|NCT00553566|PROCEDURE|medical chart review|
215045479|NCT00553566|PROCEDURE|questionnaire administration|
215045480|NCT00553566|PROCEDURE|study of socioeconomic and demographic variables|
214292076|NCT05687422|PROCEDURE|100μm laser spot diameter micropulse laser|100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
214881375|NCT03336528|DRUG|Degludec|Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner blood glucose (BG) between 100 mg/dL and 180 mg/dL.
215045481|NCT02539186|BIOLOGICAL|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
215045482|NCT02539186|DEVICE|splint|
215045483|NCT00878267|BEHAVIORAL|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
215045484|NCT02336815|DRUG|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
215045485|NCT02336815|DRUG|Dexamethasone|20 mg was given with each dose of Selinexor.
215045486|NCT02002507|OTHER|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
215045487|NCT03564574|COMBINATION_PRODUCT|Lipid Emulsion|All patients in the 'Study group' received a single dose of 100 ml of 20 percent Lipid emulsion as an infusion over 1 hour along with routine treatment as per institution protocols. Atropine was administered to patients by doubling dose method, which comprised of administering atropine starting from 2mg and to double the dose and administer till complete atropinization. Following this an infusion of 10 percent of the atropinizing dose was given every hour. Patients were evaluated using a standardized clinical interview, physical examination, laboratory tests.
215045488|NCT00952705|BIOLOGICAL|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
215045489|NCT00952705|BIOLOGICAL|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
215045490|NCT00952705|BIOLOGICAL|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
215045491|NCT02944838|BEHAVIORAL|Senior Change Makers Advocacy Program|see description
214292077|NCT05687422|PROCEDURE|200μm laser spot diameter micropulse laser|200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
214477037|NCT06824948|DRUG|Placebo|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo 3 times a day during Day 3-Day 12.
215045492|NCT02944838|BEHAVIORAL|Senior Change Makers Physical Activity Program|see description
215045493|NCT05821452|DRUG|Camrelizumab|200mgQ3w
214881376|NCT03336528|DRUG|Glargine|Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dL and 180 mg/dL.
214881377|NCT03336528|DRUG|Aspart|Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
214881378|NCT03581591|BIOLOGICAL|Burosumab|recombinant human IgG1 monoclonal antibody to fibroblast growth factor 23)
214881379|NCT02842138|BIOLOGICAL|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
215045494|NCT05821452|DRUG|Paclitaxel|175mg/m2，D1，Q3w
215045495|NCT05821452|DRUG|Cisplatin|75mg/m2，D1，Q3w
215045496|NCT05821452|RADIATION|Radiotherapy|41.4Gy, 1.8Gy each time, 5 times a week
215045497|NCT06038292|RADIATION|DXA Scan|DEXA (dual x-ray absorptiometry) Scans which measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip, the spine and the bones of the hands and can easily diagnose osteoporosis.
215045498|NCT00578851|DEVICE|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
215045499|NCT04337242|BEHAVIORAL|B-DIT|Blended Dynamic Interpersonal Therapy
215045500|NCT04337242|BEHAVIORAL|B-CBT|Blended Cognitive Behavioral Therapy
215045501|NCT04337242|BEHAVIORAL|DIT|Dynamic Interpersonal Therapy
215045502|NCT04337242|BEHAVIORAL|Cognitive Behavioral Therapy|CBT
215045503|NCT01444820|RADIATION|hypofractionation|Centres using IMRT will use the dose painting technique to treat the prostate + proximal 1-cm SV to 6800 cGy in 25 fractions while the pelvic lymph nodes will receive 4500 cGy in 25 fractions. For patients with T3b, the whole SV is to be treated to 6800 cGy. Institutions using 3D-CRT will deliver the required dose to the pelvic volume (including pelvic lymph nodes and boost volume) - 4500 cGy - and a concomitant boost to the prostate and proximal 1-cm (or the whole SV if involved) SV to 6800 cGy.
215045504|NCT01444820|RADIATION|conventional|"The first phase: whole pelvis including the prostate and regional lymph nodes treated with 4400 cGy in 22 fractions.~The second phase: prostate + proximal 1-cm SV treated with 3200 cGy in 16 fractions.~For patients with T3b, the whole SV is to be treated to 7600 cGy."
215045505|NCT03702179|DRUG|Durvalumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
215045506|NCT03702179|DRUG|Tremelimumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
215045507|NCT03702179|RADIATION|Radiotherapy|Radiotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder.
215045508|NCT04633330|DRUG|AHCC®capsules|AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
214477038|NCT04424316|BIOLOGICAL|RSVpreF|RSV vaccine (RSVpreF)
214477039|NCT04424316|BIOLOGICAL|Placebo|Placebo
214881380|NCT05676814|DRUG|Pecto-intercostal Fascial Block (PIFB)|PIFB done with bupivacaine and epinephrine
214881381|NCT05676814|DRUG|PIFB with adjuvants|PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone
215045509|NCT04633330|DRUG|Simulation of AHCC®capsules|TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
215045510|NCT04401774|DRUG|Nivolumab|Nivolumab will be given every 4 weeks at 480mg flat dose intravenously for one year (total of 13 nivolumab doses).
215045511|NCT06417671|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule per day.
215045512|NCT06417671|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule per day.
215045513|NCT02502552|OTHER|blood specimen|blood specimen
214881382|NCT01960023|DRUG|Cetuximab|400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
215045514|NCT05378802|OTHER|different modes of mechanical ventilation|Four different ventilation modes were performed one by one and respiratory parameters were recorded.
215045515|NCT06632782|BEHAVIORAL|Breath Awareness using pyramid|Participants are provided 1-2 hr training for 6 weeks on bringing breath awareness to the present moment using a pyramid
215045516|NCT04615546|BEHAVIORAL|Use of Continuous Glucose Monitor (CGM)|Participants will wear CGM
215045517|NCT04615546|OTHER|"Use of Cardea Solo monitoring"|"Participants will wear a Cardea Solo patch during blinded CGM use"
214881383|NCT01960023|DRUG|Neratinib|"Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study."
214881384|NCT02856438|DRUG|Elotuzumab|Specified dose on specified days
214881385|NCT02856438|DRUG|Lenalidomide|Specified dose on specified days
214881386|NCT02856438|DRUG|Dexamethasone|Specified dose on specified days
214881387|NCT00039338|PROCEDURE|conventional surgery|Radial hysterectomy
214881388|NCT00039338|PROCEDURE|neoadjuvant chemotherapy|Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
214881389|NCT00039338|RADIATION|brachytherapy|Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
214881390|NCT00039338|RADIATION|radiation therapy|Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
214881391|NCT00039338|DRUG|cisplatin|Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
214881392|NCT00002638|BIOLOGICAL|filgrastim|
214881393|NCT00002638|BIOLOGICAL|sargramostim|
214881394|NCT00002638|DRUG|carmustine|
214881395|NCT00002638|DRUG|cyclophosphamide|
215045518|NCT04038879|DIAGNOSTIC_TEST|MRI|MRI of the heart
214881396|NCT00002638|DRUG|cytarabine|
214881397|NCT00002638|DRUG|etoposide|
214881398|NCT00002638|PROCEDURE|peripheral blood stem cell transplantation|
214881399|NCT00002638|RADIATION|radiation therapy|
214881400|NCT05545124|DRUG|Donafenib + Tislelizumab|Donafenib 100mg, BID+Tislelizumab 200mg, D1; q3w
214881401|NCT00946517|OTHER|Questionnaires|Parenting and behavioral questionnaires
215045519|NCT06180603|PROCEDURE|Gravity fluid drainage in the radiology department|Patients will be referred to the radiology department. Thoracentesis will be performed according to local guidelines.
215045520|NCT06180603|PROCEDURE|Manual drainage in the emergency department|Thoracentesis will be performed according to current guidelines in the emergency department. Fluid will manually be drained using a syringe connected to a three-way stopcock. Thoracentesis will be stopped early if:
214667190|NCT02433249|BEHAVIORAL|Intrapersonal Motivation|Strategies used to support intrapersonal motivation included a) use of the goal attainment scale, b) facilitating the formation of action plans, c) identify and problem solve personal barriers to being active, d) identify satisfying aspects of being active, e) self-evaluate physical activity patterns and progress.
214881402|NCT02437903|DEVICE|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
214881403|NCT03834142|DEVICE|NSS-2 Bridge|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
214881404|NCT02202707|DRUG|Gabapentin|Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.
214881405|NCT00230178|DRUG|Rasburicase (SR29142)|30-min IV infusion
214881406|NCT00230178|DRUG|Allopurinol|Oral administration
214881407|NCT02652611|PROCEDURE|SI Screw Removal Surgery|
214881408|NCT02652611|PROCEDURE|Non-screw removal treatment (non-operative management)|
214881409|NCT00611260|BEHAVIORAL|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
214881410|NCT00611260|OTHER|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
214881411|NCT02237092|PROCEDURE|Measurement of IAP|The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
214881412|NCT03577301|BEHAVIORAL|Clinic-based Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based intervention sessions.
214881413|NCT03577301|BEHAVIORAL|Remote Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver intervention sessions to the participant in a location remote from the clinic setting.
214881414|NCT03577301|BEHAVIORAL|Multi-modal Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based or remote intervention sessions. First MI session is in person immediately after baseline. Sessions 2-4 can be delivered in person or remotely based on youth preference.
214881415|NCT01114607|DRUG|GSK1605786 ChemoCentryx: formulation A|ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
214881416|NCT01114607|DRUG|GSK1605786 GSK: formulation B|GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
214881417|NCT01114607|DRUG|GSK1605786 GSK direct-fill: formulation C|GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
215045521|NCT01510574|DRUG|Misoprostol|3 x 200mcg tablets of oral misoprostol
215045522|NCT01510574|DRUG|placebo|3 x placebo tablets resembling misoprostol taken orally
215045523|NCT04445909|DEVICE|VA-ECMO|Deployment of extracorporeal membrane oxygenation cardiac assist device.
214477040|NCT06819124|BEHAVIORAL|Structured Communicative Interaction|"Two interlocutors, one with ALS and their caregiver will work together. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the \_\_\_\_ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success."
214881418|NCT01114607|DRUG|GSK1605786 GSK modified-process: formulation D|GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
214881419|NCT01114607|DRUG|GSK1605786 GSK tablet: formulation E|GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
214881420|NCT04774497|OTHER|Oxygen inhalation treatment group|Oxygen inhalation group: oxygen inhalation was started on the first day of chemotherapy, and the oxygen inhalation volume was 2 L / min, 8 hours / day for 3 consecutive days.
214881421|NCT04774497|OTHER|Control group|The control group was not given oxygen inhalation.
214881422|NCT05668546|DEVICE|isokinetic testing CSMI HUMAC NORM instrument|The strength (PT) of the bilateral knee flexors and extensors were tested with isokinetic test. Tests were performed under the guidance of a rehabilitation medicine specialist, and the system was calibrated prior to their commencement. The patients were seated in upright position and were fixed with pelvic and thigh belts. Concentric extension (PT\_E) and concentric flexion (PT\_F) were measured between the 0° and 90° knee ranges at angular velocities of 60°/s and 180°/s (60 PT\_E, 60 PT\_F, 180 PT\_E, and 180 PT\_F, respectively) The tests were repeated five times at each velocity, and the highest PTs were selected for statistical analysis. The participants performed repeated trials before sets, while a 20-second rest was provided between sets.
214881423|NCT00002225|DRUG|Efavirenz|
214881424|NCT00002225|DRUG|Stavudine|
214881425|NCT00002225|DRUG|Didanosine|
214881426|NCT00659958|DRUG|Zonisamide|300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
214881427|NCT00137761|DRUG|ZD 1839|Taken orally once daily
214881428|NCT00137761|DRUG|Docetaxel|Given intravenously once weekly for 2 out of 3 weeks
214881429|NCT06395805|DIAGNOSTIC_TEST|BREF, ADL, AIS.|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL) -BREF~2. scale I - ADL according to Lawton~3. the AIS questionnaire~4. the Zimet Multidimensional Scale of Perceived Social Support - the original version of the MSPSS"
214881430|NCT06582498|BEHAVIORAL|Active intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivors at randomization (2nd visit). Furthermore, they will be offered 3 individual sessions with health professionals (oncological dietitian, sports therapist, and oncological psychologist) and 3 group sessions with the same professionals. The duration of the individual visits is expected to be 45-60 minutes approximately, and group sessions will be planned for 1.5h duration approximately.
214881431|NCT06582498|BEHAVIORAL|Low-intensity intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivor at randomization (2nd visit). These recommendations are all based on information from the World Cancer Research Fund, the American Institute for Cancer Research, and the American Cancer Society.
214881432|NCT04172597|DRUG|Poziotinib Hydrochloride|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
214881433|NCT04172597|DRUG|Loperamide|Loperamide as prescribed by the physician.
215045524|NCT03659578|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
214477041|NCT06819124|BEHAVIORAL|Unstructured communicative interaction|"Two interlocutors, one with ALS and their caregiver will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set."
214667191|NCT05042245|DRUG|Ornithine aspartate granule|Ornithine aspartate granules in the experimental arm.
214667192|NCT05042245|DRUG|Silymarin capsule|Silymarin capsules in the active comparator arm.
214667193|NCT05042245|DRUG|Silymarin capsule simulant|Silymarin capsule simulant in the experimental arm.
214881434|NCT01542151|OTHER|Time of labor induction|Assigned time of labor induction - morning or evening
214881435|NCT00794339|DRUG|64Cu-ATSM|
215045525|NCT03659578|RADIATION|split-course radiotherapy|Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost
215045526|NCT03659578|DRUG|thymosin alpha 1|subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
214881436|NCT00794339|DRUG|FDG|
214881437|NCT01611857|DRUG|Tivantinib|Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
214881438|NCT01611857|DRUG|FOLFOX|The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.
214881439|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
214881440|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
215045527|NCT02031614|PROCEDURE|Phlebotomy|Withdrawal of 500 mL of whole blood.
215045528|NCT04539171|OTHER|Pain Neuroscience Education and Physical Exercise|Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
214667194|NCT05042245|DRUG|Ornithine aspartate granule simulant|Ornithine aspartate granule simulant in the active comparator arm.
214667195|NCT00291629|DRUG|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
214881441|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine bolus to be given 1 hour pre-operatively
214881442|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine infusion will be started after the bolus and be continued for 24 hours post-operatively
214881443|NCT03484650|OTHER|Placebo|Control patients will receive a placebo bolus and infusion of saline to match the experimental arm.
215045529|NCT04490798|PROCEDURE|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat the different painful syndromes. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation.
215045530|NCT06358495|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Digital CBT-I is an online, six-module, self-guided CBT-I intervention. It includes videos and read information on behavioral (e.g., stimulus control, relaxation) and cognitive (e.g., restructuring, reducing arousal, and problem-solving) techniques, as well as psychoeducation (e.g., sleep hygiene). Participants complete homework following each session and track their sleep using an online diary. Young people could choose to involve their parents, for example, through completing sessions together. However, we will add a virtual session for parents as their involvement may improve adolescent engagement with the intervention as well as outcomes for adolescent sleep problems (Gradisar et al., 2011). This module will include an overview of the program components (behavioural, cognitive, and educational), goals and homework, and addresses parents' beliefs about sleep.
215045531|NCT06358495|OTHER|Active Control|Participants are encouraged to continue any care they are already receiving and will be placed on a wait-list for digital CBT-I after their final assessment. All activities participants try for improving their own sleep problems between assessments will be recorded and coded for.
214881444|NCT01918202|DRUG|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
214667196|NCT00291629|PROCEDURE|collection of mobilized peripheral blood stem cells|
214881445|NCT01918202|DRUG|PF-02545920|"The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional."
214881446|NCT01918202|DRUG|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
215045532|NCT03399448|BIOLOGICAL|NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1|Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
214881447|NCT01384903|DRUG|KW-3357|Intravenous infusion once a day
214881448|NCT01384903|DRUG|Plasma-derived antithrombin|Intravenous infusion once a day
214881449|NCT03523299|PROCEDURE|Cryoablation|Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
214881450|NCT06632574|DRUG|paclitaxel cationic liposomes|Paclitaxel cationic liposomes is a modified new drug. In this study, administration is performed through arterial catheter infusion.
215045533|NCT03399448|DRUG|Cyclophosphamide|a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
215045534|NCT03399448|DRUG|Fludarabine|a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
214667197|NCT00291629|PROCEDURE|Intracoronary infusion of mobilized cells|
214881451|NCT00328848|BEHAVIORAL|Behavioral|Group Treatment(patient education, self management support, caregiver support)
214881452|NCT00328848|BEHAVIORAL|behavioral|patient education, self management support, caregiver support
214881453|NCT05083065|BIOLOGICAL|Covid-19 vaccine|"* First dose or complete cycle of Comirnaty (Pfizer/BioNTech) vaccine~* First dose or complete cycle of Spikevax (Moderna) vaccine~* First dose or complete cycle of AstraZeneca/Vaxzevria vaccine~* Complete cycle of vaccination using one type of vaccine for the first dose and a different type for the second dose~* Janssen (Johnson \& Johnson) vaccine (single dose)"
215045535|NCT03399448|DEVICE|NY-ESO-1 expression testing|Testing to determine if NY-ESO-1 is expressed on tumor tissue.
215045536|NCT04781582|PROCEDURE|Lung volume reduction surgery|Surgical lung volume reduction
215045537|NCT04781582|PROCEDURE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction by endobronchial valves
215045538|NCT05155982|BIOLOGICAL|COVAC-1|Intramuscular vaccine against SARS-CoV-2
215045539|NCT05155982|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
214881454|NCT01777230|PROCEDURE|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
214881455|NCT01777230|PROCEDURE|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
214667198|NCT06559618|DRUG|Phage Therapy|A 20 mL sterile solution containing one to three individual phage drug substances (TPC) with total strength (potency) 3 x 10\^8 plaque-forming units (PFU), will be administered intravesicularly twice a day (one instillation in the morning and one in the evening \[at least six hours apart\], respectively) for 7 days. The selection of individual phages to include in the TPC are personalized/customized for each participant per phage susceptibility testing to the participant's urinary E. coli (testing is conducted by TAILФR Service Center). Each dose of TPC will be followed with a 10 mL flush of sterile 0.9% saline solution.
214881456|NCT01777230|PROCEDURE|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
214881457|NCT02292095|PROCEDURE|TAPB group|transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.
214881458|NCT02292095|PROCEDURE|PCIA group|The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
214881459|NCT06488339|DIETARY_SUPPLEMENT|Protein and oil supplement|Take 1 sachet/day replaced dinner
214881460|NCT05795322|OTHER|Sound healing with tuning forks|"Over the course of a half-hour virtual session, a specially developed triple OM track created by tuning forks was played."
214881461|NCT03751007|BIOLOGICAL|AG019 - Low Dose|Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)
214881462|NCT03751007|DRUG|Teplizumab|Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).
214881463|NCT03751007|DRUG|Placebo-AG019|Formulated identically to AG019 with the active ingredient removed.
214881464|NCT03751007|DRUG|Placebo-Teplizumab|Formulated identically to teplizumab with the active ingredient removed.
214881465|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks
214881466|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 8 weeks.
214881467|NCT01392235|DRUG|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
214881468|NCT06551779|PROCEDURE|inyección perineural con solución de dextrosa tamponada|Application of perineural injection with buffered dextrose solution, adding 2.5 ml of 7.5% sodium bicarbonate to a 250 ml bottle of glucose solution at 5% concentration, applying 1cc of the solution at different points on the path of the facial nerve.
214667199|NCT06559618|OTHER|Placebo|Sterile 0.9% saline solution also 20 mL, followed with a 10 mL flush of the same solution.
214881469|NCT03647670|DRUG|PF-04965842|orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
214881470|NCT03647670|DRUG|Midazolam|substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
214881471|NCT01134432|DRUG|prednisolone + mabthera|"Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks"
214881472|NCT01134432|DRUG|Prednisolone|Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
214881473|NCT05044559|OTHER|Continuous Positive Air Way Group|CPAP between 10 and 12 cmH2O
214667200|NCT02842814|OTHER|Drug free|Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
214881474|NCT05044559|OTHER|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
214881475|NCT05620537|OTHER|observation|There are no interventions.
214881476|NCT02214537|OTHER|MACS|
215057268|NCT01825330|DEVICE|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
215057269|NCT01825330|DEVICE|sham|
215057270|NCT03634111|PROCEDURE|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
215057271|NCT03634111|DRUG|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
215057272|NCT03634111|DRUG|Ropivacaine|Ropivacaine 0.25% 20 ml each side
215057273|NCT04490525|DEVICE|Telerehabilitation|Blood pressure (iHealth Neo/BP5s), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), and tablet (iPad Air 2).
215057274|NCT04683406|DRUG|ZSP1273 600 mg|3 X 200-mg tablet taken orally
215057275|NCT04683406|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir2 X 75-mg
215057276|NCT04683406|DRUG|Oseltamivir(oral)|2 X 75-mg tablet taken orally
215057277|NCT04683406|DRUG|Placebo to ZSP1273|Placebo capsules matching ZSP1273 600 mg
215057278|NCT01947283|BEHAVIORAL|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
215057279|NCT01947283|BEHAVIORAL|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
215057280|NCT03369366|DEVICE|NobelActive|NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.
214881477|NCT05876637|OTHER|Left Nostril Breathing|The participants which will show cardiovascular hyper reactivity towards CPT will be divided into 2 groups having 30 participants in each group. Experimental group will receive Left Nostril Breathing(slow, deep breath taken through your left nostril while closing your right nostril with your right thumb. Then just as gently exhale long, slowly, and completely through the left nostril, just as gently. It will be done while sitting) for 10 minutes twice a day for the duration of 12 weeks. Follow up will be taken through administration Cold pressor test after every 4,8 and 12 weeks.
214881478|NCT05876637|OTHER|Conventional|30 participants will be recruited in conventional group which will receive simple deep breathing exercises of 3 sessions per week for the duration of 12 weeks.Follow up will be taken after every 4,8 and 12 weeks.
214881479|NCT05707793|OTHER|Evaluating sexual function, quality of life and pelvic floor muscle strength, as well as thickness and force (strength) of voluntary contractions of the core muscles|Evaluation through Vaginal Laxity Questionnaire, Female Sexual Function Index, Short-Form 36 Health Survey, modified Oxford grading scale and ultrasound imaging
214881480|NCT03011593|OTHER|Nutrition Support Product|Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
214881481|NCT05998876|DEVICE|Remote Medication Monitor (RMM) - Prototype|Inserted Microneedle Electrode Array for assaying dermal interstitial fluid.
214881482|NCT05998876|DRUG|Daily Methadone Dose|patient takes their prescribed daily dose of methadone
214881483|NCT05100160|DRUG|Gabapentin|Given by PO
214881484|NCT05100160|OTHER|Placebo|Given by PO
214881485|NCT04667286|PROCEDURE|Prone Position (PP)|Prone the patients on oxygen for at least 10 hrs a day
214881486|NCT05322122|DEVICE|Side-to-side anastomosis duodeno-ileostomy diversion procedure|Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.
214881487|NCT00524966|PROCEDURE|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
214881488|NCT06161779|OTHER|Surgical reconstruction|submental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer
214881489|NCT04317079|DIETARY_SUPPLEMENT|Hydroxytyrosol|Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
214881490|NCT04317079|OTHER|Diet|Consultation by a dietitian was offered to all participants
214881491|NCT05624398|DEVICE|Vivity IOL|Cataract surgery with implantation of the Vivity IOL along with concurrent implantation of the Hydrus Microstent
214881492|NCT03404739|DRUG|Saline Solution|These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.
214881493|NCT03404739|DRUG|Ceftazidime|These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
214881494|NCT04660279|DIAGNOSTIC_TEST|Dynamic Whole-Body parametric PET/CT|Dynamic whole-body PET/CT imaging protocol
214881495|NCT00616421|BIOLOGICAL|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
214881496|NCT00616421|BIOLOGICAL|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
214881497|NCT00616421|BIOLOGICAL|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
214881498|NCT03885687|BEHAVIORAL|Exercise with Music|The Exercise with Music intervention is recorded exercise playlist, which provide exercise instructions tailored to patients' musical choices and exercise capacity.
214881499|NCT03885687|BEHAVIORAL|Exercise|The exercise group will receive exercise brochure and will be advised to exercise at least twice daily.
214881500|NCT06037005|OTHER|Cognitive Behavioral Therapy Group|Group intervention program based on cognitive behavioral approach of ten sessions; It was completed in approximately one and a half months (May-June 2022) in the Faculty of Nursing, by dividing the experimental group into two separate groups, two days a week for each group. Each session was held for approximately one hour. The last measurement was made three months after the last therapy session (September 2022).
214881501|NCT02481869|BIOLOGICAL|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
214881502|NCT02481869|DRUG|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
214881503|NCT00953966|OTHER|Genetically modified potatoes|Starch from genetically modified potatoes
214881504|NCT00711880|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
214881505|NCT00711880|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
214881506|NCT00560820|DRUG|Deferasirox|30 mg/kg/day
214881507|NCT01883466|OTHER|Forearm venous occlusion plethysmography study|Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
214881508|NCT02779166|DRUG|Celecoxib|Received 400mg celecoxib prior to surgery
214881509|NCT02779166|DRUG|placebo|
214881510|NCT05439967|OTHER|Augmented and Virtual Reality Gait and balanceTraining|C-Mill VR+ device used for training. The training was carried out 3 days a week for 6 weeks, with each exercise session lasting approximately 1.5 hours, accompanied by a physiotherapist. Training started with conventional exercises, continued with C-Mill VR+ training, and ended with stretching and relaxation exercises. The patients in the intervention group were applied the exercises with the same principles with conventional training, except the exercises performed in standing and walking. Patients performed 10 exercises in AR and VR gait training for 4 minutes and resting the individuals by sitting for 1 minute between exercises.
214881511|NCT05439967|OTHER|Conventional Training|Conventional training was applied to the patients in the control group. Conventional training was planned taking into account the following goals: increasing mobility by improving the impaired kinesthetic sensation; improving axial rotation, coordination, flexibility of soft tissues, mobility in and out of bed; increasing body image perception by improving upright and proper posture; and improving balance and gait. The training was applied 3 days a week for 6 weeks, with each exercise session lasting 40-50 minutes, accompanied by a physiotherapist. Each of the exercises was done in 2 sets of 10 repetitions. In gait training, each exercise was performed for 4 minutes.
214881512|NCT04341324|OTHER|It is an observational study.|
214881513|NCT03778138|DRUG|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
214881514|NCT00734058|DEVICE|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
214881515|NCT06452134|DRUG|Coenzyme Q10 100 MG Oral Tablet|Coenzyme Q10 oral Tablet with dosage of 100mg daily given for a period of 30 days after surgery.
214881516|NCT06452134|DRUG|Placebo|Exactly same looking agent in the form of a tablet with same size and color to CoezymeQ10 with no active property given for a period of 30 days after surgery.
214881517|NCT01822717|BEHAVIORAL|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
214881518|NCT01822717|BEHAVIORAL|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
214881519|NCT03908437|DRUG|buprenorphine/naloxone|"A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs"
214881520|NCT05351931|DIETARY_SUPPLEMENT|Salovum and SPC-flakes or corresponding placebo|Salovum and SPC-flakes are foods approved for specific medical purposes.
214881521|NCT06106347|DEVICE|mfERG device (RETIscan; Roland Instruments, Wiesbaden, Germany)|physiological macular function
214881522|NCT04258176|OTHER|Multidisciplinary outpatient pathway|Coordinators, assigned to improve the care flow, review and align the patient's appointments and tests in agreement with the patient's wishes. Outpatient consultations are arranged to take place the same day and schedules for care providers are coordinated. The patients' attendance in outpatient clinics are planned sequentially where the delivering specialty writes a summary to the subsequent specialty. Afterwards, the involved physicians and nurses attend an interdisciplinary conference, resulting in a joint treatment plan, with feedback and notice of modifications, which is delivered to the patient and general practice.
214881523|NCT01990586|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
214881524|NCT04867343|DRUG|HR020602 injection|HR020602 injection
214881525|NCT04867343|DRUG|fentanyl injection ； remifentanil injection|fentanyl injection + remifentanil injection
214667201|NCT02842814|DRUG|HCQ|Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
214881526|NCT02370238|DRUG|paclitaxel|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
214881527|NCT02370238|DRUG|Reparixin|reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
214881528|NCT02370238|DRUG|placebo|placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
214881529|NCT02819284|DRUG|KPI-121 0.25% Ophthalmic Suspension|
214881530|NCT02819284|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
214881531|NCT04641052|OTHER|Music listening|The music type will be chosen by the patients and researchers will not have any influence on their choices.
214881532|NCT05175235|DEVICE|CURATE.AI|Efficacy and toxicity measurements at the end of each two-/three- week dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of nivolumab/pembrolizumab for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
215045540|NCT05833217|PROCEDURE|Adipose Tissue Biopsy|After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.
214881533|NCT05175235|DRUG|Nivolumab, Pembrolizumab|Treatment with the selected regimen will take up to a maximum duration of 12 months, in two-/three- week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; Maximum total cumulative dose per cycle of nNivolumab/pembrolizumab in the predetermined safety range is set at 100% of standard starting dose (i.e. , 240 mg/m2 once every 2 weeks for single agent Nivolumab and 200 mg/m2 once every 3 weeks for single agent Pembrolizumab). Minimum total cumulative dose per cycle of nivolumab/pembrolizumab in the predetermined safety range is set at 30% of the standard starting dose (i.e. 8072 mg/m2 once every 2 weeks for single agent Nivolumab and 60 mg/m2 once every 3 weeks for single agent Pembrolizumab). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
214881534|NCT00790725|OTHER|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
214881535|NCT00790725|OTHER|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
214881536|NCT00714116|DRUG|SBI-087|Single IV or SC dose of SBI-087
214881537|NCT03021681|OTHER|autologous bronchial basal cell transplantation|the investigators obtained extraction bronchial basal cells micro tissue from 3\~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
214881538|NCT04342819|DRUG|SGLT2 inhibitor|Sodium-Glucose Like Transporter 2 Inhibitor
214881539|NCT03908450|DEVICE|PTCA of coronary de novo lesion PCB|PTCA of coronary de novo lesion with drug coated balloon
214881540|NCT03908450|DEVICE|PTCA of coronary de novo lesion SCB|PTCA of coronary de novo lesion with drug coated balloon
214881541|NCT01569295|DRUG|Idelalisib|Idelalisib 150 mg administered orally twice daily
214667202|NCT02842814|DRUG|GC+HCQ|Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
214881542|NCT01569295|DRUG|Rituximab|Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions
214667203|NCT06513702|PROCEDURE|Transesophageal lung ultrasound (TELUS) guided recruitment maneuver|"1. Lung reinflation guided by transesophageal lung ultrasound (TELUS) after cardiopulmonary bypass weaning~2. TELUS guided recruitment maneuver with continuous positive pressure of 30cmh20 for 20 seconds and 40cmh20 for 20 seconds during sternal wiring"
214881543|NCT01569295|DRUG|Bendamustine|Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
214881544|NCT01569295|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
214881545|NCT03717181|DRUG|Lixivaptan|Daily dose of lixivaptan optimized using a predetermined titration protocol.
214881546|NCT05778812|BEHAVIORAL|Full Sleep|"Daily lessons about sleep and skills that can help with sleep. Participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach, for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
214881547|NCT05778812|BEHAVIORAL|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
214881548|NCT03597295|DRUG|Retifanlimab|Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
214881549|NCT02366169|DEVICE|Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure|The procedure is performed transorally under general anesthesia. The physicians staples the fundus of the stomach to the esophagus approximately 3cm superior to the Z-line in 2 or more locations. The procedural result is anatomically and functionally similar to standard anterior fundoplication (Dor-Thal operation). The staples are standard, 4.8mm titanium surgical staples. Each application of the device fires a quintuplet of staples (5) in three staggered rows. Anti-retching medications at the time of the procedure are essential.
214881550|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.M., single or multiple-dose
214881551|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.N., single or multiple-dose
214881552|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.H., single or multiple-dose
214881553|NCT05638581|BIOLOGICAL|LTOWB|Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.
214881554|NCT05638581|BIOLOGICAL|Components|Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.
214881555|NCT03749057|DRUG|Rivaroxaban|Rivaroxaban 15-20 mg daily
214881556|NCT00609999|DRUG|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.
214881557|NCT01728129|DEVICE|DANA Rapid|The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.
214881558|NCT01728129|OTHER|MACE|The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.
214881559|NCT00879411|DRUG|Micardis|
214881560|NCT03157479|DRUG|Intravenous anesthetic|Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
214881561|NCT03157479|DRUG|Crystalloid Solutions|Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician
214881562|NCT03157479|DIAGNOSTIC_TEST|Esophageal pressure measurement|A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure
214881563|NCT03157479|DIAGNOSTIC_TEST|Lung volume measurement with the nitrogen washin-washout technique|Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
214881564|NCT05786560|BEHAVIORAL|BABE (Body Appreciation and Better Eating)|The participants will be randomized into either a treatment or control group. For the treatment arm, girls will participate in the Body Project for 30 minutes, then will be given a 30-minute self-compassion-based nutrition education lesson. Nutrition topics will cover the basic biochemistry of nutrition, nutrition needs for teenage girls, and ways to find balance in eating, framed in the constructs of self-compassion. The control group will receive the same 30-minute Body Project class and the same 30-minute nutrition education class; however, there will be no incorporation of self-compassion.
214881565|NCT02244814|BEHAVIORAL|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
214881566|NCT02244814|BEHAVIORAL|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
214881567|NCT01884337|DRUG|Apixaban|
214881568|NCT02455518|DRUG|Oxycodone/acetaminophen|
214881569|NCT02455518|DRUG|Hydrocodone/acetaminophen|
214881570|NCT02455518|DRUG|Codeine/acetaminophen|
214881571|NCT02455518|DRUG|Ibuprofen/acetaminophen|
214881572|NCT00428116|DRUG|HAART|Combination first line antiretrovirals as previously described.
214881573|NCT02021513|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
214881574|NCT02021513|DIETARY_SUPPLEMENT|Olive Oil|Placebo group
214881575|NCT00737152|OTHER|RAS 130 with diet and exercise|Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
214881576|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
214881577|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
214881578|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
214881579|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
214881580|NCT05342779|PROCEDURE|stripping of great saphenous vein|"I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure."
214881581|NCT01038297|DRUG|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
214881582|NCT01038297|DRUG|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
214881583|NCT02508935|DRUG|XARTEMIS XR|XARTEMIS XR \[7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)\] Extended-Release Tablets
214881584|NCT02125877|DRUG|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
214881585|NCT02125877|DRUG|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
214881586|NCT01973595|DIETARY_SUPPLEMENT|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
214881587|NCT01973595|OTHER|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
214881588|NCT01044264|DRUG|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
214881589|NCT01044264|DRUG|Placebo|Placebo
214881590|NCT05896735|PROCEDURE|Ultrasound-guided axillary vein catheterization|All axillary vein catheterizations were performed according to standard central venous catheterization procedures, which were performed under ultrasound guidance at the bedside. Before the operation, patients were placed in a supine position with the upper limb placed in a natural position, and the ultrasound probe and wires were wrapped with a sterile protective sheath. Ultrasound pre-scanning the axillary artery and axillary vein, and pay attention to using the minimum pressure to control the ultrasound probe to avoid crushing the blood vessels. The operator holds the ultrasound probe and puncture needle to puncture the axillary vein under the guidance of ultrasound. After drawing out of the dark red blood, the guide wire was inserted and the puncture needle was withdrawn. The three-lumen CVC catheter was then inserted using the Seldinger technique.
214881591|NCT00003577|DRUG|CMF regimen|
214881592|NCT00003577|DRUG|cyclophosphamide|
214881593|NCT00003577|DRUG|epirubicin hydrochloride|
214881594|NCT00003577|DRUG|fluorouracil|
214881595|NCT00003577|DRUG|methotrexate|
214881596|NCT00003577|PROCEDURE|adjuvant therapy|
214881597|NCT00003577|RADIATION|radiation therapy|
214881598|NCT04581330|DEVICE|DEKA SmartXide C02 laser|One pass with a 1-mm spot density and a 60 micron depth will be performed followed by a 1-mm spot density and a 200 micron depth will be used
214881599|NCT02859753|OTHER|Percutaneous Radiofrequency Ablation|
214881600|NCT02859753|OTHER|Percutaneous Microwave Ablation|
214881601|NCT03901092|DRUG|flortaucipir F 18|No study drug will be administered.
214881602|NCT04871672|OTHER|Pilates Exercises|basic five pilates intermediate workout based on the principles of Pilates
214881603|NCT04871672|OTHER|Home Exercise program|home exercise
214881604|NCT00655772|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®): 0.16% sodium chlorite (NaClO2) with an efficacy of 0.1% chlorine dioxide (ClO2),Placebo mouthwash: glycerin, mint oil and distilled water, contents are almost the same as those in the experimental mouthwash except ClO2.
214881605|NCT01513278|DRUG|APN201|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
214881606|NCT01513278|DRUG|Placebo|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
214881607|NCT01776255|BEHAVIORAL|Healthy Children, Strong Families|"Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year."
214881608|NCT01776255|BEHAVIORAL|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
214881609|NCT04852029|OTHER|Low dose hCG|Patients will either maintain the current dose of have an increased dose prescribed based on randomization
214881610|NCT06254612|DRUG|SP-624|Once daily oral administration of two capsules totaling 20 mg/day
214881611|NCT06254612|DRUG|Placebo|Once daily oral administration of two matching placebo capsules
214881612|NCT05101369|DRUG|INCB086550|INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
214881613|NCT04791514|DRUG|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
214881614|NCT03052296|DEVICE|Passeo-18 Lux DCB|The endovascular procedure is conducted as per the local standard practice and device instruction for use
214881615|NCT01316302|DRUG|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
214881616|NCT01316302|DRUG|Placebo|Matching placebo, taken QD for 12 weeks.
214881617|NCT04547842|DRUG|Mirtazapine 30 MG|mirtazapine is given in arm M to prevent PONV
214881618|NCT04547842|DRUG|Dexamethasone|Dexamethasone is given in arm D to prevent PONV
214881619|NCT01210612|DEVICE|Unilateral CAI|five-toed socks usage
214881620|NCT06359288|OTHER|Group receiving QR code supported training|During the training process, QR codes were integrated into the sections related to the care of the newborn in the guide to provide mothers with the opportunity to watch the video simultaneously while reading the guide in practices requiring skills related to hygienic care of the newborn and nutrition / communication / sleep, and to allow them to watch it repeatedly as long as they feel the need. In these videos, the application steps were shown one by one. When the code is scanned with a smartphone, it automatically redirects the user to the specified URL. The QR codes in the Implementation Guide on the Care of the Newborn consist of eight videos) that allow mothers to watch the hygienic care of the newborn in practice. After the end of this phase of the training, the questionnaires were re-administered to the mothers in both groups one month after discharge.
214881621|NCT05129605|DIAGNOSTIC_TEST|Prostate cancer screening|Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
214881622|NCT00182247|PROCEDURE|venogram|
214881623|NCT05698225|OTHER|Streptococcus pneumoniae serotype 6B|A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
214881624|NCT01920022|DRUG|Mifepristone|Day one of medical abortion
214881625|NCT01920022|DRUG|etonorgestrel|
214881626|NCT03287843|PROCEDURE|Total mesorectal excision before 56 days (4-8 weeks)|Low anterior resection or abdominoperineal resection
214881627|NCT03287843|PROCEDURE|Total mesorectal excision after 56 days (8-12 weeks)|Low anterior resection or abdominoperineal resection
214881628|NCT02847988|DEVICE|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
214881629|NCT02847988|DEVICE|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
214881630|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 1|Brain training games with physical exercise component.
214881631|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 2|Cognitive training games with physical exercise component.
214881632|NCT00710866|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)|Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
214881633|NCT00086281|DRUG|Xyrem (X)|Xyrem (Sodium Oxybate) Oral Solution
214881634|NCT00086281|DRUG|Zolpidem (Z)|Zolpidem 10 mg oral tablets
214881635|NCT00086281|DRUG|Modafinil (M)|Modafinil Oral Tablets
214881636|NCT00086281|DRUG|Placebo (P)|Placebo Oral Solution
214881637|NCT04543890|RADIATION|Hyperfractionated radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
214881638|NCT04543890|RADIATION|Hypofractionated radiotherapy|Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
214881639|NCT04543890|DRUG|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
214881640|NCT04543890|DRUG|Cisplatin|Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
214881641|NCT03212248|DIAGNOSTIC_TEST|Thoracic Ultrasound (TUS)|
214881642|NCT01403857|OTHER|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
214881643|NCT01403857|OTHER|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
214881644|NCT04274712|DIAGNOSTIC_TEST|INNOGRAFT Heart Suite|Liquid biopsy to identify acute rejection
214881645|NCT02234492|DRUG|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
214881646|NCT06327152|DRUG|Caffeine|"Infants randomized to receive caffeine will continue to receive caffeine at the current weight-based dose (which is the standard of care maintenance dose of 10-15 mg/kg/day) given every 24 hours. The weight-based dose calculated using the weight at the time of enrollment will be the weight-based dose used for the duration of the study. The dose will be weight adjusted every 7 days, starting on the day of enrollment. Caffeine will be given enterally, via nasogastric tube or by mouth.~The study drug (caffeine) will be administered for a maximum of 4 weeks. The study drug will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The study drug will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
214881647|NCT06327152|OTHER|Sterile Water Placebo|"Infants randomized to the placebo group will be given sterile water at an equivalent volume to the volume if caffeine were to be given, using the previous weight-based caffeine dose. The placebo will be given every 24 hours. The dose/volume will be weight adjusted every 7 days, starting on the day of enrollment. The placebo will be given enterally, via nasogastric tube or by mouth.~The placebo will be administered for a maximum of 4 weeks. The placebo will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The placebo will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
214881648|NCT07133724|OTHER|AI-Based Smart Assessment and Rehabilitation Training|Through the integration of wireless inertial sensors and smartphone imaging, the system can monitor pelvic and lumbar movements in real time, generate a digital twin model, and deliver instant feedback to guide patients in performing correct exercises.
214881649|NCT07135167|COMBINATION_PRODUCT|Epi-ON corneal cross-linking (CXL)|"Corneal cross-linking involves the following steps:~* applying riboflavin (Vitamin B2 eye drops) to the eye, then~* exposing the eye to ultraviolet (UV-A) light for 20 minutes."
215057281|NCT03369366|DEVICE|KLS Martin Mandibular Reconstruction Implant|The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).
214881650|NCT07134088|DRUG|Blinatumomab|Blinatumomab will be administered as a SC injection for up to 5 cycles (each cycle will be 35 days).
214881651|NCT07134335|DRUG|UBT251|Subcutaneous injection once weekly
214881652|NCT07134335|DRUG|UBT251|Subcutaneous injection once weekly
214881653|NCT07134335|DRUG|UBT251|Subcutaneous injection once weekly
214881654|NCT07134218|DRUG|serplulimab、bevacizumab|short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 2 cycles of FOLFOX + serplulimab + bevacizumab → 2 cycles of FOLFOX + serplulimab.
214881655|NCT07134218|OTHER|neoadjuvant chemoradiation therapy|short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 4 cycles of FOLFOX alone.
214881656|NCT07134309|OTHER|Exercise Training|Reformer, mat pilates, and general posture exercise training were performed twice a weekly for 12 weeks. Before starting pilates training, the key elements of pilates were taught to patients for one session. In evaluation, Visual Analog Scale (VAS) was used for pain intensity, Oswestry Low Back Pain Questionnaire for disability, Short Form - 36 Questionnaire (SF-36) for quality of life, Sit-lie test for flexibility, McGill extension test for trunk extension endurance. Demographic information of individuals was recorded.
214881657|NCT04489719|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214881658|NCT04489719|OTHER|Questionnaire Administration|Ancillary studies
214881659|NCT04489719|DRUG|Radium Ra 223 Dichloride|Given IV
214881660|NCT06066957|DRUG|Letermovir 480 MG [Prevymis]|"Letermovir for CMV prophylaxis in thoracic organ transplant recipients.~Letermovir will be administered by oral administration, as per study protocol. The intended duration of therapy will be up to 365 days, depending on organ transplanted and donor and recipient CMV status. However, treatment may discontinued as discussed in Section 7.~Letermovir is dosed at 480mg daily for patients with CrCl \>10. Dose adjustment, as per package insert, is recommended in setting of co-administration of cyclosporine, with dose reduction of letermovir to 240mg daily. Missed doses of letermovir will not be made up."
214881661|NCT02881840|DRUG|14C-APD421|
214881662|NCT03071276|DRUG|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
214881663|NCT03071276|DRUG|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
214881664|NCT03071276|DRUG|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
214881665|NCT03071276|DRUG|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
214881666|NCT02376673|OTHER|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
214881667|NCT02376673|OTHER|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
214881668|NCT06689748|OTHER|Delphi procedure|The study involves generating consensus statements by experts on the training requirements for physicians involved with airway management in critically ill patients using a Delphi process.
214881669|NCT07033598|DRUG|Pacritinib|100-mg capsules
214881670|NCT07033598|DRUG|Hydroxyurea|capsules or tablets
214881671|NCT07036679|DIETARY_SUPPLEMENT|Energy Active Product|Participants will use their Energy Active Product as directed for a period of 6 weeks.
214881672|NCT07036679|DIETARY_SUPPLEMENT|Energy Placebo Control|Participants will use their Energy Placebo Control as directed for a period of 6 weeks.
214881673|NCT05890534|DRUG|Pycnogenol®|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
214881674|NCT05890534|DRUG|Placebo|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
214881675|NCT03390426|DRUG|Mepivacaine|An ultrasound guided injection of mepivacaine superomedially to the femoral artery.
214881676|NCT03390426|PROCEDURE|Perifemoral Injection of Local Anesthetic|An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
214881677|NCT03390426|DRUG|Saline|An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.
214881678|NCT02593682|DRUG|suvorexant|
214881679|NCT02593682|DRUG|placebo|
214881680|NCT01568138|DEVICE|PliCath HF System|To evaluate the safety and feasibility of the BioVentrix PliCath HF Epicardial Catheter-based Ventricular Reduction (ECVR) System for left ventricular (LV) volume reduction in heart failure (HF). The System utilizes anchors that are implanted into the scarred portion of the heart, rendering the ventricle smaller.
214881681|NCT05736627|OTHER|Online|Online research course delivered live digitally at a distance.
214881682|NCT01682616|DRUG|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
214881683|NCT01682616|DRUG|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
214881684|NCT01325181|DRUG|Verteporfin|a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
214881685|NCT01325181|DRUG|ranibizumab|Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
214881686|NCT03673527|DRUG|topical formulation of tacrolimus|Topical application of tacrolimus twice daily for 14 days (one dose on Day 14).
214881687|NCT02335736|DRUG|Gonadotropins releasing hormone antagonist|
214881688|NCT01781000|BEHAVIORAL|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
214881689|NCT01781000|BEHAVIORAL|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
214881690|NCT01781000|BEHAVIORAL|Treatment as usual|standard treatment protocol of schizophrenia ward
214881691|NCT03540771|OTHER|Palliative Care|"The intervention will comprise an approach to render palliative care, as taught to hepatologists through an on-line learning platform, and as delivered by PC providers as routine care. The elements of the intervention, which will be guided by a checklist and implemented over the course of interactions with the patient and caregivers at the initial, 1, 2, and 3 month visits, to include:~1. Patient/caregiver understanding of diagnosis, illness and prognosis~2. Symptom assessment and management~3. Psychosocial assessment and management~4. Distress screening and management~5. Discussion of goals of care~6. Advanced directives"
214881692|NCT02516553|DRUG|BI 894999|film-coated tablets
214881693|NCT01584453|DRUG|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
214881694|NCT01584453|DRUG|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
214881695|NCT02716727|DEVICE|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
214881696|NCT02716727|DEVICE|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
214881697|NCT03830827|DRUG|Vortioxetine|8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks
214881698|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program - Social Enhanced|Specific G-CBT intervention for adolescents with social anxiety disorder
214881699|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program|Generic G-CBT intervention for adolescents with anxiety disorders
214881700|NCT02924727|DRUG|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
214881701|NCT02924727|DRUG|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
214881702|NCT02924727|DRUG|Placebo of LCZ696|Matching placebo of LCZ696 tablets
214881703|NCT02924727|DRUG|Placebo of ramipril|Matching placebo of ramipril capsule
214881704|NCT02924727|DRUG|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
214881705|NCT02924727|DRUG|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
214881706|NCT02516527|DRUG|Ipilimumab|
214881707|NCT03720327|BEHAVIORAL|Get FIT|The Get FIT arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; and one 45 minute behavioral counseling session to set personal goals and provide education by a health coach.
214881708|NCT03720327|BEHAVIORAL|Get FIT+|The Get FIT+ arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; one 45 minute behavioral counseling session to set personal goals and provide education by a health coach; and personalized text messaging for 3 months by a health coach. The health coach will have access to these participants' daily food and activity data through the smartphone application, and will monitor progress and send push-only text messages to participants in this group based on the participant's goals and progress in the areas of physical activity, nutrition, and weight loss.
214881709|NCT06197373|PROCEDURE|Laparoscopic cholecystectomy|Doing laparoscopic cholecystectomy after ERCP at different intervals
214881710|NCT00682682|OTHER|Virtual Reality video distraction|"Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game."
214881711|NCT00682682|OTHER|Virtual Reality video game|"Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World"
214881712|NCT03052127|DRUG|Light-activated AU-011|Study treatment
214881713|NCT03052127|DEVICE|Laser Activation|Study treatment
214881714|NCT00707382|GENETIC|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described."
214881715|NCT00707382|OTHER|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
214881716|NCT00707382|OTHER|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
214881717|NCT02494180|DRUG|fentanyl|arm A receiving iv fentanyl
214881718|NCT02494180|DRUG|pethidine|arm B receiving iv pethidine
214881719|NCT02494180|DRUG|Diazepam|arm B receiving iv diazepam
214881720|NCT02494180|DRUG|Midazolam|arm A receiving iv midazolam
214881721|NCT06206382|PROCEDURE|Whipple operation|Whipple operation is the surgery used for pancreatic head cancer in the form of pancreaticoduodenectomy then reconstruction
214881722|NCT05451992|DIETARY_SUPPLEMENT|Placebo|The group will have to consume a jar every day (approx. 75 ml) which contain (water, malt-dextrins, 0.1% starch, 0.1% guar gum, flavorings and colorants)
214881723|NCT05451992|DIETARY_SUPPLEMENT|SuperFood|The group will have to consume a jar of superfood (vegetable smoothie) every day. The jar will be filled with approx. 75 ml which corresponds to about 75 g. The superfood formulated by the University of Bolzano on the basis of the results and evidence acquired in collaboration with the Istituto Superiore di Sanità. Composition: pomegranate, walnuts, moringa, broccoli, according to the proportions indicated in Annex 2. This mixture has been analyzed by an external laboratory and authorized for human use
214881724|NCT02636543|OTHER|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
214881725|NCT02636543|OTHER|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
214881726|NCT01396915|DIETARY_SUPPLEMENT|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
214881727|NCT01166165|DRUG|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
214881728|NCT01166165|DRUG|Placebo|3 placebo tablets daily for 20 weeks
214881729|NCT03694327|DEVICE|CT-101-M|Mobile Application
214881730|NCT03694327|DEVICE|QuitGuide|Mobile Application
214881731|NCT03354767|PROCEDURE|Aortic and aortic valve surgery|
214881732|NCT00611481|BEHAVIORAL|Tai Chi|a set of pre-designed Tai Chi Movements
214881733|NCT00611481|BEHAVIORAL|Strength training|Lower-extremity strength training exercises
214881734|NCT00611481|BEHAVIORAL|Low-Impact Exercise Control|a set of chair-based low-impact exercises
214881735|NCT01404715|DRUG|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
214881736|NCT01404715|DRUG|Imatinib|A single oral dose of 600 mg of imatinib
214881737|NCT03778827|BEHAVIORAL|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of weekly individual parent training sessions and center-based therapy for a total of 13 weekly treatment hours.
214881738|NCT01879865|OTHER|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
214881739|NCT01879865|OTHER|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
214881740|NCT02767154|DEVICE|A colloid Dextran 40 solution for extracorporeal circulation|The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
214881741|NCT02767154|DEVICE|Ringer-Acetate and Mannitol|Currently clinic standard for priming the CPB circuit.
214881742|NCT06186180|OTHER|inspiratory muscle training|They will perform 5 sets of 10 repetitions with a 1-minute rest between sets, 5 days a week, using a specific respiratory muscle training device
214881743|NCT02936180|BIOLOGICAL|HD-TIV|
214881744|NCT02936180|BIOLOGICAL|SD-QIV|
214881745|NCT01982812|DRUG|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
214881746|NCT01982812|DRUG|Standard AED|Active comparitor, Standard AED
214881747|NCT03072979|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy
214881748|NCT05535153|OTHER|functional movement screen|The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
214881749|NCT06102083|DRUG|TDI01 suspension|"Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily."
214881750|NCT02365194|BEHAVIORAL|Prehabilitation|information included in arm description
214881751|NCT02365194|BEHAVIORAL|Standard counseling|information included in arm description
214881752|NCT03865368|OTHER|Whole Body Vibration Training|Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
214881753|NCT00070200|BIOLOGICAL|filgrastim|
214881754|NCT00070200|DRUG|cisplatin|
214881755|NCT00070200|DRUG|cyclophosphamide|
214881756|NCT00070200|DRUG|doxorubicin hydrochloride|
214881757|NCT00070200|DRUG|etoposide|
214881758|NCT00070200|DRUG|isotretinoin|
214881759|NCT00070200|DRUG|melphalan|
214881760|NCT00070200|DRUG|topotecan hydrochloride|
214881761|NCT00070200|DRUG|vincristine sulfate|
214881762|NCT00070200|PROCEDURE|conventional surgery|
214881763|NCT00070200|PROCEDURE|peripheral blood stem cell transplantation|
214881764|NCT00070200|RADIATION|radiation therapy|
214881765|NCT04784533|DRUG|CTP-543|Oral dosing
214881766|NCT04784533|DRUG|Placebo|Oral dosing
214881767|NCT04339283|DIETARY_SUPPLEMENT|Standardized Hibiscus sabdariffa tea|Daily consumption of Standardized Hibiscus sabdariffa tea
214881768|NCT02632461|BEHAVIORAL|Podcasts|Participants will receive twice weekly podcasts that will cover topics related to weight loss.
214881769|NCT02632461|BEHAVIORAL|Mobile Diet Application|Participants will use a mobile application on their smartphone to track their diet.
214881770|NCT02632461|BEHAVIORAL|Bite Counter|Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
214881771|NCT05189444|DRUG|Vonoprazan|20mg bid
214881772|NCT05189444|DRUG|Amoxicillin|0.75g tid
214881773|NCT05189444|DRUG|Esomeprazole|20mg bid
214881774|NCT05189444|DRUG|Amoxicillin|1.0g bid
214881775|NCT05189444|DRUG|Clarithromycin|0.5g bid
214881776|NCT05189444|DRUG|Bismuth potassium citrate|0.22g bid
214881777|NCT03781284|DIAGNOSTIC_TEST|[18F]-FDG PET/MRI|
214881778|NCT03781284|DIAGNOSTIC_TEST|Colonoscopy|
214881779|NCT05312320|OTHER|Information film|"* Sexual activity after MI does not increase risk of recurrence or death~* Sexual activity is associated with improved outcome after MI~* Resuming sexual activity as normal is recommended and completely safe"
214667204|NCT06513702|OTHER|Manual bag lung reinflation|"After weaning of CPB, Lung will be reinflated by 5 deep manual bag infaltion until full inflation observed by the anesthetist.~During sternal wiring, Lung ultrasound will be examine - LUNG ultrasound score will be taken- no recruitment maneuver will be done in this contro group (Basically this group of patient is a routine practice in cardiac surgery"
214667205|NCT03157557|BEHAVIORAL|Lifestyle treatment|Lifestyle treatment
214667206|NCT05394844|DEVICE|Dexcom G6|Dexcom G6 CGM device
214881780|NCT03269227|RADIATION|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
214881781|NCT03122080|DEVICE|Electroacupuncture(EA)|"Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients."
214881782|NCT03122080|DEVICE|Placebo acupuncture|Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
215057282|NCT04783311|BIOLOGICAL|EuCorVac-19|Two intramuscular doses (0.5mL per dose) at 3-week interval
215057283|NCT04783311|OTHER|Normal Saline|Two intramuscular doses (0.5mL per dose) at 3-week interval
215057284|NCT02491047|DEVICE|BonyPid-1000|BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment
215057285|NCT02491047|OTHER|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
215057286|NCT00426868|OTHER|Direct injection of ADRCs into the Left Ventricle|Dose escalation
215057287|NCT00426868|OTHER|Direct injection of placebo into the Left Ventricle|
215057288|NCT03918382|OTHER|Electronic Patient-Reported Outcome|Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
215057289|NCT05811754|OTHER|Data collection|"This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum."
215057290|NCT04186325|PROCEDURE|DIAPHRAGMATIC exercising|inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
215057291|NCT03571750|BEHAVIORAL|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
215057292|NCT03571750|BEHAVIORAL|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
215057293|NCT00460655|DRUG|GSK1358820|botulinum toxin type A
215057294|NCT00460655|DRUG|Placebo|Placebo
214477042|NCT06280560|PROCEDURE|Controlled Ovarian Stimulation + Luteal Phase Support|Short COS protocol with GnRH antagonist followed by progesterone supplementation. Will be initiated after a negative vaginal ultrasonographic scans to define ovarian quiescence, on days 1 and 2 of the menstrual period. For ovarian stimulation, 150-225 UI /day of FSHrec (GONAL F) will be administered along or in combination with 75 UI/day of HMG (Menopur). From day 6 onwards, HMG/FSHrec will be administered on an individual basis according to the serum E2 levels and transvaginal ovarian ultrasound scans and GnRH antagonist (Orgalutran) 0.25 mg /day is introduced as soon as a follicle of 14 mms diameter has achieved. hCGrec (6500 IU, Ovitrelle) will be administered when 7 or 8 follicles with a maximum diameter of \>17-18 mms will observed. 400 mg of micronized vaginal progesterone will be administered (200 mg twice a day vaginal route), during 5 days. An endometrial biopsy and a blood sample will be obtained 7 days after hCG administration (hCH+7)
214667207|NCT01898546|PROCEDURE|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
214667208|NCT01898546|PROCEDURE|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
214881783|NCT03122080|OTHER|Standard care|Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
214881784|NCT04290273|DIAGNOSTIC_TEST|MED Test|Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
214881785|NCT04290273|DEVICE|Wearing device|Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.
214881786|NCT01894594|DRUG|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: \*\~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: \*\~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~\* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
214667209|NCT02296840|DRUG|Ibuprofen|Ibuprofen 10mg/kg/day every 6-8 hours
214667210|NCT02296840|DRUG|Hydrocodone-Acetaminophen|Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
214667211|NCT05707065|OTHER|core strengthening exercises|The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.
214667212|NCT05707065|OTHER|Proprioceptive Neuromuscular Facilitation|lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
214667213|NCT04641286|OTHER|Body motion categorisation|All patients will receive passive motion categorisation monitoring
214667214|NCT05555342|PROCEDURE|Irreversible electroporation (IRE) ablation|IRE will be performed using the NanoKnife or Aliya System. CT or cone-beam CT will be used to direct electrode placement.
214667215|NCT05555342|RADIATION|Radiation Therapy|Moderate-dose radiation therapy to the target tumor(s) in 1 fraction.
215057295|NCT04265248|DEVICE|Virtual Reality Headset|The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
215057296|NCT04265248|BEHAVIORAL|Exercise|The subjects will perform evidence-based exercises for the neck.
215057297|NCT03056235|DEVICE|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
215057298|NCT03056235|DEVICE|Saline|Saline control
215057299|NCT00986791|OTHER|GSP-A|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
215057300|NCT00119197|BIOLOGICAL|killed whole cell oral cholera vaccine|"Bivalent oral killed cholera vaccine: each dose of this vaccine contains:~* Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells~* Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells~* Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells~* Inactivated V.Cholerae O139 - 50.109 cells~each 1.5 mL dose given orally, two doses given 14 days apart"
215057301|NCT00119197|BIOLOGICAL|Heat Killed E. coli|"Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.~Each 1.5 mL dose given orally, two doses given 14 days apart"
214667216|NCT01812161|OTHER|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
215057302|NCT00330304|DRUG|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
215057303|NCT00330304|DRUG|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
215057304|NCT00330304|DRUG|isoniazid|Isoniazid, 10mg/kg daily for study period
215057305|NCT00330304|OTHER|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
215057306|NCT01542463|DRUG|insulin detemir|Prescribed at the discretion of the physician
214881787|NCT05962762|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|"The trial was conducted sequentially from the low dose group to the high dose group, with 3-6 subjects enrolled in each dose group. The trial was conducted on a case-by-case basis in the high dose group, with each subject in the high dose group being enrolled in subsequent subjects only after completion of at least 7 days of post-dose safety observation. Each subject received only one corresponding dose. All subjects received experimental drugs and conventional treatment during the study period.~All subjects in each test dose group will complete a 4-week (28-day) dose-limiting toxicity (DLT) After the observational evaluation period, a decision will be made by the investigator and sponsor based on a discussion of relevant safety data whether to start the next dose group."
214881788|NCT06427837|OTHER|Same 2nd course|The same snack food will be served in the second course
214881789|NCT06427837|OTHER|Different 2nd course|A different snack food will be served in the second course
214881790|NCT00307437|DRUG|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
214881791|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
214881792|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
214881793|NCT00797537|PROCEDURE|Echography|Echography
214881794|NCT01609712|PROCEDURE|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
214881795|NCT05895955|BIOLOGICAL|TetraFluvac TF vaccine|"The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus\] produced by The Government Pharmaceutical Organization (GPO), Thailand.~Each prefilled dose of TetraFluvac TF contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
214881796|NCT05895955|BIOLOGICAL|Vaxigrip vaccine|"Vaxigrip vaccine is commercially available seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like strain and A/Darwin/9/2021 (H3N2)-like strain and B/Austria/1359417/2021-like strain and B/Phuket/3073/2013-like strain, manufactured by Sanofi Pasteur, Ltd. France.~Each prefilled dose of Vaxigrip vaccine contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
214881797|NCT04104802|DEVICE|MRI|"All patients included will benefit from both methods of assessing anatomical relationships between the facial nerve and the parotid tumor:~1\) New medical imaging technique evaluated: 3 Tesla Parotidic MRI High Resolution with Specific Sequences and Gadolinium Injection 2) Standard Gold: Intraoperative Exam"
214881798|NCT01581866|DRUG|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
214881799|NCT03006302|DRUG|Epacadostat|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.
214881800|NCT03006302|DRUG|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.
214881801|NCT03006302|BIOLOGICAL|CRS-207|CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.
214881802|NCT03006302|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.
214881803|NCT03006302|BIOLOGICAL|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). GVAX will be administered on Day 2 of Cycles 1 and 2.
214881804|NCT03578666|OTHER|Massage|The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
214477043|NCT06280560|PROCEDURE|Hormonal Replacement Therapy programmed artificial cycle|6 mg of oestradiol orally administered starting the first day of the menstrual period, followed by an endometrial scan 10-days later, and when a 7 mms triple line endometrium has seen by vaginal ultrasound scan, 800 mg of micronized vaginal progesterone (400 mg twice a day vaginal route), during five days, will be added to the oestrogen therapy. An endometrial biopsy and a blood sample will be obtained on day 5 of progesterone administration (P+5)
214477044|NCT06280560|PROCEDURE|Natural Cycle (NC)|No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)
214881805|NCT03578666|OTHER|Cold water immersion|The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
214881806|NCT05200000|BIOLOGICAL|SygeLIX-Coll-T|Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.
214881807|NCT03450252|DEVICE|Active pacing|Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.
214881808|NCT03450252|DEVICE|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
214881809|NCT05238454|BIOLOGICAL|SCTV01C|intramuscular injection
214881810|NCT05238454|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
214881811|NCT05238454|BIOLOGICAL|Comirnaty|intramuscular injection
214881812|NCT00788944|PROCEDURE|blood draw|Test Article was not provided to subjects for this study.
214881813|NCT01593943|BEHAVIORAL|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
214881814|NCT00076076|DRUG|Roflumilast|
214881815|NCT00409448|BEHAVIORAL|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
214881816|NCT00409448|BEHAVIORAL|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
214881817|NCT04275986|PROCEDURE|Intensity modulated radiotherapy (IMRT)|Intensity-modulated radiation therapy (IMRT) with a total dose of 45Gy in 25 fractions
214881818|NCT04275986|DRUG|Chemotherapy|Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
214881819|NCT04293900|OTHER|24-hour dietary recall|Dietary intake assessment conducted by a Registered Dietitian Nutritionist. This assessment will occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
214881820|NCT04293900|OTHER|Hand grip strength|Measurement of grip strength using a hand dynamometer. This will test occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
214881821|NCT04293900|OTHER|International Physical Activity Questionnaire|Survey about physical activity over the previous 7 days. This survey will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
214881822|NCT04293900|OTHER|Patient-reported outcomes survey|Survey about symptoms and side effects experienced during cancer treatment. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
214881823|NCT04293900|OTHER|Pittsburgh Sleep Quality Index|Survey about sleep habits and quality over the past month. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
214881824|NCT04293900|OTHER|Functional Assessment of Cancer Treatment - Lymphoma|Survey about quality of life for people with a diagnosis of lymphoma. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
214881825|NCT04293900|OTHER|urine sample (optional)|Collect three urine samples either in the clinic or at home. This specimen collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
214881826|NCT04293900|OTHER|fecal sample (optional)|Collect a fecal sample either in the clinic or at home. This sample collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
214881827|NCT02849483|DRUG|Ramosetron|Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
214881828|NCT02849483|DRUG|Normal saline|Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
214881829|NCT00525798|DRUG|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
214881830|NCT00525798|DRUG|SMC021 Placebo|SMC021 - Placebo, once daily
214881831|NCT05812443|OTHER|Shabad Kriya Meditation|The Shabad Krya meditation technique, used in Kundalini Yoga, will be performed by the participants of this intervention group for 8 consecutive weeks, for 30 minutes, before going to sleep. This group will be trained by a Kundalini Yoga teacher with extensive experience in Shabad Krya meditation. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
214881832|NCT05812443|OTHER|Relaxing reading|Relaxing reading will be performed by the participants of this control group for 8 consecutive weeks, for 30 minutes, before going to sleep. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
214881833|NCT00482586|OTHER|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
214881834|NCT00482586|OTHER|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
214881835|NCT00482586|PROCEDURE|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
214881836|NCT05251610|DRUG|20mg oral propranolol and oxytocin|Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin
214881837|NCT05251610|DRUG|Oxytocin only|Participants will have outright augmentation or induction of labor with oxytocin
214881838|NCT06111261|DRUG|Albumin solution|200ml of 20% Human Serum Albumin
215045541|NCT05833217|DIAGNOSTIC_TEST|Steady State Plasma Glucose (SSPG) Test|An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if participants are insulin sensitive or insulin resistant. This test is approximately 5-6 hours in length. Participants will be asked to fast for 12 hours. The insulin sensitivity test is designed to measure how well your cells remove glucose from your blood in response to insulin. During this test participants will have two small catheters (tubing) placed in their veins (I.V. lines). The total amount of blood that will be drawn during this test will be 140 mL of blood (approximately 9.5 tablespoons). Insulin is a natural hormone, and octreotide (a synthetic hormone) is a drug that temporarily blocks the secretion of insulin from your pancreas. A member of the research team is present and monitoring the results along with the nursing staff.
214881839|NCT06111261|DRUG|Balanced crystalloid solution|Balanced crystalloid solution
214881840|NCT01666392|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
214881841|NCT01666392|DIETARY_SUPPLEMENT|Placebo|Placebo
214881842|NCT05449860|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes|Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
214881843|NCT01017627|OTHER|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
215045542|NCT00873925|BIOLOGICAL|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
215045543|NCT00873925|DIETARY_SUPPLEMENT|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
215045544|NCT00873925|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
215045545|NCT03997032|DIETARY_SUPPLEMENT|Ocufolin|Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
215045546|NCT01381367|BIOLOGICAL|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
215045547|NCT01381367|DRUG|Normal Saline|normal saline, 0.5ml given subcutaneously
215045548|NCT05353686|DRUG|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
215045549|NCT05353686|DRUG|XEN-D0501|Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
215045550|NCT03730584|DRUG|Ropivacaine|"Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath."
215045551|NCT03730584|BIOLOGICAL|Blood test|Blood test during the first bath with Ropivacaine for Titration of Ropivacaine
215045552|NCT00586794|DRUG|Sildenafil|3x per day 20 mg TID
214881844|NCT01017627|OTHER|No change from normal routine|Normal unit policy for labs and anemia treatment
214881845|NCT05780476|BEHAVIORAL|Psychoeducation|6 sessions of 2 hours over 6 weeks
214881846|NCT05780476|BEHAVIORAL|Psychoeducation + virtual reality|6 sessions of 2 hours over 6 weeks. Virtual reality experience will be carry out in the last 30 minutes of each meeting. Virtual reality consists of 360-degree videos depicting everyday situations and allowing the caregivers to feel the specific symptoms of dementia (e.g., disorientation, agnosia, apraxia and memory loss).
214881847|NCT05102227|DEVICE|Left bundle branch area pacing|A dual-chamber DF-1 defibrillator is implanted. Left bundle branch area pacing is performed for cardiac resynchronization therapy.
214881848|NCT00589927|DRUG|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
215045553|NCT00586794|DRUG|Placebo|3x per day, 20 mg TID
214881849|NCT00589927|DRUG|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
214881850|NCT00877162|BEHAVIORAL|Controlled crying and routines|Behavioural (teaching and support)
214881851|NCT01270191|DRUG|Exenatide|They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
215045554|NCT03759600|DRUG|Niraparib|Niraparib capsule
214881852|NCT01270191|DRUG|Humulin-N|The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
214881853|NCT01352780|BEHAVIORAL|Motivational interviewing|"Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.~Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client's perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening."
214881854|NCT00754546|DRUG|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
214881855|NCT00754546|DRUG|Placebo: Normal Saline|Normal saline was nebulized.
214881856|NCT00754546|OTHER|Treadmill Exercise|
214881857|NCT00754546|OTHER|Cycle Exercise|
214881858|NCT03183167|OTHER|No intervention|
214881859|NCT00208273|DRUG|Letrozole - Concomitant|
214881860|NCT00208273|DRUG|Letrozole - Sequential|
214881861|NCT01249573|OTHER|fascia therapy or transcutaneous fibrolysis|fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
214667217|NCT01812161|OTHER|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of \<5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
214667218|NCT00385021|DRUG|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
214667219|NCT00104871|DRUG|Bortezomib|Administered IV at the dose of 1.3 mg/m\^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
214667220|NCT00843180|OTHER|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
214667221|NCT06533553|DRUG|Dexpramipexole Dihydrochloride|Administration of dexpramipexole tablet
214667222|NCT06294028|OTHER|Adverse events collection|Collection of deaths from any cause, hospitalizations or emergency consultations for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)
214881862|NCT04948892|OTHER|Prescence of the father during cesarean section in general anesthesia|The father is now present in the OR during cesarean section category 1, instead of waiting outside
214667223|NCT06294028|OTHER|Quality of life questionnaire EQ-5D-5L|"Questionnaire on the patient's quality of life and health in 6 questions: on mobility, the person's autonomy, current activities, pain, anxiety. Answers range from no problem to unable and 5 possible answers to each question.~The last question concerns the patient's health, the patient must rate his or her health on a scale of 0 to 100"
214881863|NCT02349867|DRUG|Gemcitabine|Given IV
214881864|NCT02349867|DRUG|Sorafenib|Given PO
214881865|NCT02349867|DRUG|Vorinostat|Given PO
214881866|NCT02349867|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
214881867|NCT02349867|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215045555|NCT03317743|DRUG|NOV140101 (IDX-1197)|The dose levels will be escalated following a 3+3 dose escalation scheme.
215045556|NCT05173974|DEVICE|Super Poligrip Free|A single application of 1 gram of Super Poligrip Free will be applied topically to oral tissues via the upper denture.
215045557|NCT05173974|DEVICE|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
215045558|NCT05173974|DEVICE|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
215045559|NCT01697085|DIETARY_SUPPLEMENT|Sea buckthorn oil|
214881868|NCT02349867|OTHER|RosetteSep|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
214881869|NCT02349867|OTHER|DEPfff|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
214881870|NCT06040151|DEVICE|Digizorg mobile app (quality evaluation study)|Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care. Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions. The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.
214881871|NCT03316547|OTHER|SENSE Program|Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises \[passive range of motion (PROM), gentle stretching\]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
214881872|NCT04841005|OTHER|The Square-Step Exercise Training|The Square-Step Exercise is instructed to walk according to the step pattern shown on a 100 \* 250 cm mat, divided into 40 squares of 25 cm each. It includes forward, backward, lateral and diagonal steps, and step patterns are progressively made more complex. Each pattern consists of two to 16 steps; Individuals are asked to repeat the step pattern until they reach the end of the mat. Each step pattern is repeated 4-10 times to ensure that individuals can complete the pattern. The individuals included in the study will exercise in easy-difficulty patterns for the first 2 weeks, medium-difficulty patterns in the 3rd and 4th weeks, medium and advanced patterns in the 5th and 6th weeks, and advanced patterns in the 7th and 8th weeks. The square-step exercise group will perform 15 minutes of warm-up exercise, 30 minutes of progressive square-step exercise, and 10 minutes of cool-down exercise accompanied by a physiotherapist, 3 days a week.
214881873|NCT04841005|OTHER|Strengthening Exercise Training|Thera-Band brand elastic bands will be used to apply resistance in strengthening training. To determine the intensity of the exercise, the perceived difficulty level after 15 repetitions with the elastic band will be evaluated with the Borg scale. If the perceived difficulty level is at the level of 12-14 (slightly difficult), it will be considered as the starting difficulty level.In the strengthening exercise group will perform, shoulder abduction, shoulder press after elbow flexion, horizontal abduction, punching with an elastic band, triceps strengthening, external rotation of the shoulder, hip abduction with external rotation and sit-to-stand exercises for 8 weeks, 3 days / week , 3 sets / sessions, 8-12 repetitions. For each exercise, it will be applied as 8 repetitions in the initial workload. In the next exercise sessions, the number of repetitions will be increased until the patient can comfortably perform 12 repetitions with the same load.
214881874|NCT00355953|DRUG|Genistein|
214881875|NCT00782405|DRUG|quetiapine|XR, 150-300mg
214667224|NCT06294028|OTHER|Medical-economic evaluation|"Collection of expenses incurred by the care of patients in each arm will be collected over a period of 36 months.~Direct medical and non-medical costs as well as costs related to absences from the workplace will be included in the analysis. Healthcare consumption will be collected using the National Health Data System (SNDS)."
214881876|NCT00782405|DRUG|mirtazapine|30-45 mg
214881877|NCT04874805|OTHER|Measurement of oxygen saturation|Measurement of oxygen saturation by pulse oximetry once a day, at 6 a.m., for a minimum of 3 days, thanks to three pulse oximeters (1 measurement point per device/day), in parallel with a synchronous sampling, programmed as part of the usual care, of arterial gasometry.
214881878|NCT02939053|DEVICE|SOZO|The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.
214881879|NCT00721227|PROCEDURE|Reduction Gastroplasty|"* Subjects will undergo reduction gastroplasty by gastric plication~* Subjects are followed for 12 months to evaluate outcomes and potential complications."
214881880|NCT03857282|OTHER|Aerobic Exercises|5 to 10 min warm up exercises than 30min bicycle exercise and 5 to 10 min cool down exercises
214881881|NCT03857282|OTHER|Tai Chi Exercises|5 to 10 min warm up exercises and 30 min Tai Chi exercises and than than 5 to 10 min cool down exercises.
214881882|NCT01827865|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
214881883|NCT01827865|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
214881884|NCT03608527|BEHAVIORAL|Voluntary-based upper limb motor rehabilitation|Exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, mainly including task-oriented movements with the goal to improve activities of daily living. Both proximal and distal muscles are involved, in actions such as grasping wooden cubes of different sizes, pinching, reaching targets displayed in front of the patient, and doing patchwork or paper mandala.
214881885|NCT03608527|BEHAVIORAL|Passive upper limb mobilization|Passive mobilization delivered by a physical therapist of shoulder, elbow, wrist and fingers without detectable muscle activity.
214881886|NCT05528601|BEHAVIORAL|use of Endo App®|use of Endo App® smartphone application containing endometriosis relevant exercises and educational material
214881887|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3|50,000 IU VD3 / week for 8 weeks
214477045|NCT06280560|PROCEDURE|Endometrial receptivity reference group|Recruited among women belonging to the oocyte donation program and will follow the procedures described above for the Natural Cycle group. No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)
214881888|NCT04005612|DIETARY_SUPPLEMENT|omega-3 fatty acid|300 mg of omega 3-FA once daily for 8 weeks
214881889|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3 and omega-3 fatty acid|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
214881890|NCT04005612|OTHER|control|no intervention
214881891|NCT02759692|DEVICE|TEST Contact Lens|
214881892|NCT02759692|DEVICE|CONTROL Contact Lens|
214881893|NCT01159080|DRUG|routine dose tacrolimus and less myfortic|oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day
214881894|NCT01159080|DRUG|reduced dose tacrolimus and conventional myfortic|low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
214881895|NCT06570187|DRUG|Dexmedetomidine|Dexmedetomidine will be administered with an initial dose of 0.2 μg/kg/hour, infusion rate is to be titrated based on response for at least 24 hours.
215045560|NCT01697085|DIETARY_SUPPLEMENT|Placebo oil|
215045561|NCT06206863|OTHER|Exercise Intervention|Participate in virtual exercise classes
215045562|NCT06206863|OTHER|Questionnaire Administration|Ancillary studies
215045563|NCT06319404|OTHER||
215045564|NCT00050583|BEHAVIORAL|Cognitive Behavioral Therapy|Ten Weekly Sessions of Manualized CBT
215045565|NCT00050583|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
215045566|NCT02098304|DEVICE|Calcivis Caries Activity Imaging System|Teeth imaged with the Calcivis Caries Activity Imaging System
215045567|NCT00733486|DEVICE|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
215045568|NCT06487299|DRUG|Ferrous Lactate|The injection solution was 3 ferrous lactate (10ml:0.1g iron) mixed with 20ml saline.
215045569|NCT06487299|DRUG|Iron sucrose|The injection was 3 shots of ferrous lactate (5ml:100mg iron) mixed with 35ml saline.
215045570|NCT06487299|DRUG|0.9% NaCl solution|The same volume and color as Iron sucrose.
215045571|NCT01891929|BEHAVIORAL|RECOS (COgnitive REmediation for Schizophrenia)|"Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
215045572|NCT01891929|BEHAVIORAL|TAU (Treatment As Usual)|"The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
215045573|NCT04638751|DRUG|Immunotherapy|Checkpoint inhibitor
215045574|NCT04638751|DRUG|Chemotherapy|Any form of chemotherapy
214292078|NCT04750720|OTHER|Sampling by venipuncture (and eventually by nasopharyngeal swab)|"Biological samples :~* Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test~* PBMC (peripheral blood mononuclear cells)~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to SARS-CoV-2 infection~* Notion of hospitalization/ambulatory follow-up~Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)~* Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells"
214881896|NCT06570187|DRUG|Propofol|Propofol will be administered as the comparator sedative with the standard treatment of sepsis and septic shock.
214881897|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy|phacoemulsification with viscocanalostomy
214881898|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy and ologen|phacoemulsification with viscocanalostomy with ologen
214881899|NCT04169945|OTHER|Ultrasonic instrumentation|Full mouth root surface debridement
214881900|NCT04169945|OTHER|Air polishing with erythritol powder|Air flow PLUS
214881901|NCT05871034|PROCEDURE|phacoemulsification|cataract extraction
214881902|NCT05185765|OTHER|Bread|Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
214881903|NCT00679133|DRUG|MGCD265|Oral daily administration; 7 days on / 7 days off
214881904|NCT03763006|PROCEDURE|Eyelid cleaning|This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.
214881905|NCT00732485|DRUG|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
214881906|NCT00732485|DRUG|placebo|Placebo, sugar pill, from admission to 6 months post burn
214881907|NCT00451178|DRUG|enzastaurin|1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years
214881908|NCT00451178|DRUG|rituximab|375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
214292079|NCT00660530|DRUG|Lanthanum Carbonate Chewable Product|Lanthanum carbonate 1 g to be chewed, three times daily with meals
214292080|NCT00660530|DRUG|Lanthanum carbonate crushed powder|Lanthanum carbonate (Fosrenol) 1 g crushed into a fine powder, three times daily with meal
214292081|NCT00849381|BIOLOGICAL|GSK580299, GSK Biological's HPV vaccine|All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
214881909|NCT00451178|DRUG|cyclophosphamide|750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
214881910|NCT00451178|DRUG|doxorubicin|50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
214881911|NCT00451178|DRUG|vincristine|1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
214881912|NCT00451178|DRUG|prednisone|100 mg, oral, Days 1-5, six 21-day cycles
214881913|NCT00050245|DRUG|Rituximab|
214881914|NCT07059585|BEHAVIORAL|CGA|Participants will come once in person for the standard of care surgery. After the surgery, participants will receive delirium assessment questionnaires twice daily in the hospital for a duration of up to 7 days after surgery and, up to two sensory aids if required, one pair of eyeglasses as well as frequent orientation of physical and occupational therapy. On postoperative day 14, the subjects will be assessed for the same, whether at home or in-patient. The assessment completion could take up to an hour.
215045575|NCT04638751|PROCEDURE|CRC surgical resection|Surgical resection to remove colorectal cancer
215045576|NCT04638751|PROCEDURE|Colonoscopy|Standard-of-care colonoscopy for CRC screening
215045577|NCT00815386|DEVICE|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
215045578|NCT04691921|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19
215045579|NCT04482725|OTHER|Trial product 1|Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL
215045580|NCT04482725|OTHER|Trial product 2|Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
215045581|NCT04482725|OTHER|Trial product 3|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL
215045582|NCT04482725|OTHER|Trial product 4|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL
214881915|NCT07059585|OTHER|control|Participants will come once in person for the standard of care surgery. After the surgery, participants will receive assessment questionnaires regarding perioperative delirium, twice daily in the hospital for a duration of up to 7 days after surgery. On postoperative day 14, the subjects will be assessed for the same, whether at home or in-patient. The assessment completion could take up to an hour.
214881916|NCT07134270|PROCEDURE|MDRO Rectal Screening|Repeated rectal swab collection for screening digestive colonization with multidrug-resistant organisms (MDRO), performed at admission (or within 14 days prior), on day 7, weekly during hospitalization, and at discharge.
214881917|NCT07134270|OTHER|30-Day Telephone Follow-Up|Structured phone interview conducted 30 days post-discharge, using a standardized questionnaire assessing new infections, rehospitalizations, antibiotic use, and self-rated health status.
214881918|NCT01807286|DRUG|Pomalidomide|"Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I."
214881919|NCT01807286|DRUG|Melphalan|Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
214881920|NCT01807286|DRUG|Dexamethasone|Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
214881921|NCT01807286|BEHAVIORAL|Questionnaires|Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
214881922|NCT06389682|DRUG|68Ga-NYM005 injection|he radiation dose is about 2-7 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM005 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
214881924|NCT07134985|OTHER|No intervention|No intervention
214881925|NCT06828237|DEVICE|KOS® S|Delivery of medical device as injection
214881926|NCT00633347|DRUG|Antagonist GnRH Cetrotide|Cetrotide 0.25 mg. daily/ 7 days
214881927|NCT00633347|DRUG|Agonist GnRH Acetate Triptoreline|Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
214881928|NCT06196814|DRUG|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
214881929|NCT07113236|BEHAVIORAL|Instructions, advices|A first moment: informed conversation and exploration of myths and realities with the aim of exploring the perceptions and attitudes of participating children and adolescents towards the vaccine against HPV-associated cancers through an open and reflective dialogue; a second moment with the presentation of a testimonial video and reflection with the aim of learning from the experiences of others, finding inspiration and motivation in their stories, and feeling connected with other people; and a third moment of 360° feedback with the aim of receiving final information about HPV, HPV-associated cancers, and the importance of vaccination.
214881930|NCT07113236|OTHER|No instructions|No instructions for vaccination
214881931|NCT06919952|BEHAVIORAL|Resilience|The Resilience program focuses on drawing on resilience assets and resources, both internal and external. Participants will have access to materials (e.g., lessons, videos, webinars, coaching calls) supporting the adoption of strategies for improving well-being. Behavior change strategies used are meant to increase intervention adherence and improve well-being and resilience.
214881932|NCT06919952|BEHAVIORAL|Physical Activity|The Physical Activity program focuses on supporting physical activity health habits. Participants will have access to materials (e.g., lessons, videos, webinars, coaching calls) supporting the adoption of strategies of evidence-based strategies for physical activity goals. Behavior change strategies used are meant to help establish, improve or maintain healthy physical activity habits.
214881933|NCT07117669|DRUG|ENP-501|"* Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks~* Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose"
214881934|NCT07117669|DRUG|Placebo|"* Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks~* Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose"
214881935|NCT07121946|BIOLOGICAL|LTZ-301|LTZ-301 will be dosed IV, in initial 28 day cycles. First cycle dosing is every week. Second through fifth cycles are dosed every 2 weeks. Sixth cycle and beyond are 21 day cycles, and are dosed once every 3 weeks.
214881936|NCT07121946|BIOLOGICAL|LTZ-301|LTZ-301will be dosed IV, as above
214881937|NCT07121946|BIOLOGICAL|LTZ-301|LTZ-301will be dosed IV, as above
214881938|NCT05371041|DEVICE|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
214881939|NCT07128056|BEHAVIORAL|Mobile phone video game distraction|Children in the intervention group will play age-appropriate, non-violent mobile phone video games for approximately 20 minutes before induction of anesthesia. This is intended as a distraction technique to reduce preoperative anxiety and improve postoperative pain outcomes. Participants will also receive standard perioperative care.
214881940|NCT07128056|OTHER|Standard peri operative care|Standard preoperative and postoperative care according to institutional protocol, without mobile phone video game distraction.
214881941|NCT07134140|DIETARY_SUPPLEMENT|Omega-3|Participants will take three capsules per day (a total of 1,500 mg EPA and 750 mg DHA). They will take 1 g with each main meal (breakfast, lunch, and dinner).
214881942|NCT07134140|DIETARY_SUPPLEMENT|Placebo comparator|Participants will take 3 g of olive oil. They will take 1 g with each main meal (breakfast, lunch, and dinner).
214881943|NCT07133776|DRUG|PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases.|This study involves a four-drug combination regimen consisting of a PD-1 inhibitor, tenofovir, chidamide, and lenalidomide for the treatment of EBV Infectious diseases, aiming to inhibit viral replication and restore immune function through multiple mechanisms. The intervention includes not only pharmacological treatment but also pre-treatment assessments (such as EBV-DNA load, immune status, cardiac and renal function), efficacy monitoring during treatment (e.g., ORR, changes in EBV-DNA), and post-treatment follow-up for safety and survival outcomes (including OS, PFS, and adverse events), in order to comprehensively evaluate the clinical value and feasibility of this combination therapy.
214881944|NCT07134868|DIAGNOSTIC_TEST|Thiol- Disulfide Blood Sample Measurement|Measurement of thiol-disulfide homeostasis parameters and inflammatory markers from serum samples.
214881945|NCT07134491|BIOLOGICAL|Piece of kidney removal|removal for a piece of kidney for research purposes during biopsy or graft removal performed as part of routine care
214881946|NCT07134491|BIOLOGICAL|Stool collection|Stool collection for research purposes
214881947|NCT07134491|BIOLOGICAL|Blood collection|Additional blood volume for research purposes during a routine blood collection
214881948|NCT07134023|OTHER|Supportive Care|"Initial Educational Assessment In addition to standard care, patients will meet the coordinating nurse for an initial educational assessment to evaluate their needs and present the multidisciplinary workshop program and individual support options. The nurse will register the patient for the first session, provide program materials, schedule the first follow-up call (1 month post-inclusion), and collect study questionnaires and demographics. If needed, the assessment may be scheduled within 15 days of inclusion.~Educational Workshops Patients may attend workshops on topics like endometriosis, diet, sexuality, pain, fatigue, emotions, Pilates, non-drug symptom management, hypnoanalgesia, and fertility. At least three workshops are required, offered over two days.~Telephone Follow-up Monthly calls for 6 months, then at 9 and 12 months, will monitor symptoms and refer patients to support services as needed."
214881949|NCT07133412|DEVICE|TetraGraph|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
214881950|NCT07133269|OTHER|Care Coach-led Palliative Surgical Oncology (PSO)|"* Patients will receive the current standard of care based on their surgeon's usual clinical practice.~* Additionally, patients will receive the Care Coach-led Palliative Surgical Oncology (PSO) intervention. The PSO intervention will be delivered during all phases of an advanced cancer patient's surgical journey.~  * Pre-surgery: After pre-surgery consultations, care coaches will conduct Serious Illness Conversations (SIC) and focus on exploration of patients' hopes and worries, critical functions, social setup, and identification of a healthcare proxy.~ * The Care coach will also screen for psychological and emotional needs using the Distress Thermometer pre-surgery upon recruitment, and at 1, 3, 6, 9 \&12 months post-surgery. This will help to identify areas requiring palliative interventions such as symptom management or psychosocial support and for follow-up actions to be taken."
214881951|NCT07133269|OTHER|Rehabilitation|"• Patients will receive services from a dedicated rehabilitation service comprising of a Rehabilitation Physician, Physiotherapist, and Dietician.~* Pre-surgery: Patients will be triaged based on their frailty \[Clinical Frailty Scale (CFS)\], malnutrition risk \[Malnutrition Universal Screening Tool (MUST)\], and physical function \[5-sit-to-stand (5-STS)\] and will receive preventive rehabilitation interventions tailored to their functional needs.~* During surgical admission: The rehabilitation physician will review the progress of patients and refer them to a dietitian if needed. Patients may be followed-up by a rehabilitation physician one-month post-discharge and referred to a physiotherapist if required.~* Post-surgery: Patients will be screened by care coaches for functional needs using the CFS and 5-STS at months 3, 6, 9 \& 12 post-surgery who will make referrals to rehabilitation professionals as needed."
214881952|NCT07134907|DRUG|Silodosin|Silodosin is an α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieve the dynamic obstruction of bladder outlet, and improve the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
214881953|NCT07134907|DRUG|Tamsolusin|Tamsulosin is an α1A-adrenergic receptor blocker which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
214881954|NCT07134322|BEHAVIORAL|The aim of this research is to record how many families go to court for the breakdown of parent-child relationships and to understand how many of these families, one year after the judge's ruling, hav|"This is the first qualitative and quantitative study on conflict-ridden families who go to court and involve social and psychological support services.~Furthermore, the survey will provide precise data on the extent of the phenomenon being investigated."
215045583|NCT04482725|OTHER|Trial product 5|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL
215045584|NCT04482725|OTHER|Trial product 6|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL
215045585|NCT04482725|OTHER|Trial product 7|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL
215045586|NCT04482725|OTHER|Trial product 8|Buffering agent: Disodium hydrogen phosphate dihydrate 5.34 mg/mL Isotonic agent: NaCl 6.72 mg/mL
215045587|NCT04482725|OTHER|Trial product 9|Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL
214292082|NCT05175690|DIAGNOSTIC_TEST|Diagnostic Software as Medical Device|"AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses.~The AudibleHealth Dx is a cloud-based AI/ML (locked ML) diagnostic software as medical device (Dx SaMD) with a mobile app based graphical user interface (GUI) designed to operate with COTS Android Operating System (OS) and Apple OS based mobile devices. The AudibleHealth Dx system uses a forced cough vocalization (FCV) signal data signature (SDS) to diagnose COVID-19 illness in ambulatory adults. Results are sent to ordering physicians, State Health Departments, and participants using Health Level 7 (HL7) compliant communication protocols."
214292083|NCT05502328|DIETARY_SUPPLEMENT|Energy Study Product Usage|Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
215045588|NCT04482725|OTHER|Trial product 10|Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
215045589|NCT04482725|OTHER|Trial product 10|Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
214292084|NCT02729974|PROCEDURE|ROTEM|rapid testing of blood clot formation
214292085|NCT02729974|PROCEDURE|standard treatment|visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
214292086|NCT01548092|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
214881955|NCT07133763|DRUG|PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders.|This study investigates a novel multi-targeted regimen combining a PD-1 inhibitor, tenofovir, chidamide, and lenalidomide for relapsed/refractory EBV-associated lymphoproliferative disorders (LPDs). Unlike conventional therapies focused on antivirals or chemotherapy alone, this approach integrates antiviral suppression, epigenetic reactivation, immune modulation, and checkpoint blockade to achieve synergistic antitumor and antiviral effects. Preliminary data show effective EBV inhibition and tumor regression. This strategy offers a promising and distinct therapeutic option for EBV-driven lymphoid malignancies resistant to standard treatment.
214881956|NCT07134556|DRUG|Zimberelimab (AB122)|Patients will receive zimberelimab as an IV at a dose of 360 mg on D1 of each 21-day cycle until unacceptable toxicity, disease progression, death, discontinuation from the Study treatment for any other reason or End of Study (EoS), whichever occurs first.
214881957|NCT07134556|DRUG|Domvanalimab (DOM)|Patients will receive domvanalimab as an IV at a dose of 1200 mg on D1 of each 21-day cycle until unacceptable toxicity, disease progression, death, discontinuation from the Study treatment for any other reason or End of Study (EoS), whichever occurs first.
214881958|NCT07134556|DRUG|Sacituzumab Govitecan (SG)|Patients will receive sacituzumab govitecan as an IV at a dose of 10 mg/kg on D1 and D8 of each 21-day cycle until unacceptable toxicity, disease progression, death, discontinuation from the Study treatment for any other reason or End of Study (EoS), whichever occurs first.
214881959|NCT04159103|BIOLOGICAL|mRNA-3927|mRNA-3927 dispersion for IV infusion
214881960|NCT02834676|DRUG|Gelified Ethanol|Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
214881961|NCT05788783|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
214881962|NCT05788783|OTHER|Canine Education & Bonding|Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
214881963|NCT06935760|OTHER|Fire and forget|Evidence informed prescription of BP lowering drugs based on the average observed blood pressure (BP) reduction and risk of treatment discontinuation due to adverse effects in double-blind placebo-controlled randomised clinical trials. Clinicians will prescribe BP treatment regimen using generic, established BP lowering medications that will be expected to achieve at least 80% of future systolic BP values under 130 mmHg. Treatment will be delivered remotely through telehealth consultation. Participants will be asked to avoid routine BP measurements after treatment is commenced to avoid misleading chance fluctuations in BP before 12 weeks. Adverse events will be monitored remotely, and treatments can be adjusted according to adverse events but not according to BP measurements
215045590|NCT04482725|OTHER|Trial product 12|Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
215045591|NCT02367963|BEHAVIORAL|Training period|Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
214292087|NCT00303498|DRUG|Sitexsentin sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
214292088|NCT00303498|DRUG|Placebo|placebo identical to the study drug in description, dose and duration
214881964|NCT06935760|OTHER|Usual care with more intensive BP monitoring|"Participants will follow-up with their usual general practitioner, who will treat participants BP according to local practice guidelines. General practitioners will have access to the same BP lowering medications as the fire and forget treatment group. Participants will continue to monitor their BP throughout the 12 week period through home BP monitoring with optional 24 hour ambulatory BP monitoring. Participants will maintain a BP diary and present their BP results to their treating physician."
214881965|NCT03623347|OTHER|TMZ and BEV induction before chemoradiotherapy|New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.
214881966|NCT01243775|DRUG|Belotaxel|60 mg/m2 3 weekly (day 1)
214881967|NCT01243775|DRUG|Belloxa|70 mg/m2 3 weekly (day 2)
214881968|NCT02447744|BEHAVIORAL|Mindfulness based intervention|The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
214881969|NCT05327192|OTHER|No intervention, only sampling|No intervention
214881970|NCT03207867|DRUG|NIR178|"NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.~NIR178 was administered orally twice daily (BID) as a capsule (Part 1, Part 2 and Japanese safety run-in) and as a film-coated table (Part 3). There were up to 3 dose levels assessed: 80, 160 and 240 mg. Three alternative dosing schedules were evaluated: continuous (Part 1, Part 2, Part 3, Japanese safety run-in), 2 weeks on/2 weeks off (Part 2) and 1 week on/1 week off (Part 2).~Each cycle consisted of 28 days."
214881971|NCT03207867|DRUG|PDR001|PDR001 is a human monoclonal antibody (MAb) administered on Day 1 of each cycle. PDR001 400 mg was administered via intravenous (i.v.) infusion over 30 minutes every 4 weeks (Q4W).
214881972|NCT05422625|DEVICE|PTNS Treatment|Patients will be placed in a comfortable position, sitting or supine. The treatment leg will be propped up comfortably on a footrest but draped and out of view from the patient. A 34-gauge needle electrode will be inserted at a 60-degree angle 5 cm cephalad to the medial malleolus and slightly posterior to the tibia. A PTNS surface electrode will be placed on the ipsilateral calcaneus as well as 2 inactive sham surface electrodes, 1 under the little toe and 1 on the top of the foot. When the PTNS lead set is connected to the Urgent PC stimulator, a current level of 0.5 to 9 mA at 20 Hz is selected based on each patient's foot and plantar motor and sensory responses. Treatment lasts 30 minutes and given once weekly for 12 consecutive weeks.
214292089|NCT02461355|BEHAVIORAL|Aphasia therapy|Aphasia therapy using a computerized scripting program
214292090|NCT02461355|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
214292091|NCT02461355|DEVICE|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
214292092|NCT02220582|OTHER|MRI|Magnetic Resonance Imaging
214881973|NCT05422625|DEVICE|Sham PTNS Treatment|"Patients will be positioned similarly as PTNS patients. A Streitberger needle will be used at the tibial nerve insertion site as described above to simulate needle placement. Three electrodes will be placed on the patient's foot, two active TENS electrodes and one inactive TENS electrode. The TENS grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe. Another gel electrode will be placed on the top of the foot just above the small toe for conduction. These two electrodes will be connected to the TENS unit lead wires for sham stimulation. A third, inactive, gel electrode, will be placed near the medial aspect of the calcaneus to mimic the PTNS treatment. The TENS electrode will be connected by lead wires to the TENS unit set at 20 HZ. The TENS unit will be turned on and stimulation slowly increased to the patient's first sensory level and then turned off."
214292093|NCT05481645|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.
214881974|NCT03205527|OTHER|Overground slip perturbation training|Slips will be induced by a low-friction platform (65×30×0.6 cm, μ\<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.
214881975|NCT06010628|DRUG|Tenecteplase|intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
214881976|NCT05083416|BEHAVIORAL|Prolonged Nightly Fasting|Limiting daily period of food intake to 10 hours and nightly fasting period to 14 hours.
214881977|NCT05083416|BEHAVIORAL|Regular Eating pattern|Food intake not limited to a specific time during day/night.
214881978|NCT05792020|DEVICE|Focused Ultrasound Stimulation|This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.
214881979|NCT05541887|OTHER|Muscadine Wine Polyphenol|dealcoholized muscadine wine with alcohol content \<0.5% with addition of 50ppm of sodium metabisulfite for preservation
214292094|NCT05481645|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
214292095|NCT05481645|DRUG|Carboplatin Injection|Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.
214292096|NCT05481645|DRUG|Paclitaxel Injection|Paclitaxel is a diterpene alkaloid with anticancer activity
214881980|NCT05541887|OTHER|Placebo|this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention. 50ppm of sodium metabisulfite for preservation
214881981|NCT05904132|DEVICE|tACS device|you will receive one of four treatment conditions that include active and sham tACS. The four conditions are the following: (1) closed-loop-tACS (peak-locked), (2) closed-loop-tACS (trough-locked), (3) open-loop tACS, and (4) sham tACS. Although each subject will undergo all four treatments in four separate study visits, the order of the treatments will be randomized
214881982|NCT05291676|BIOLOGICAL|Fluzone|Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer
214881983|NCT05291676|BIOLOGICAL|Fluad|Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
214477046|NCT06265207|OTHER|Virtual reality|Before the mammography, a 20-minute relaxing video featuring nature and forest views will be watched with VR SHINECON 360 degree glasses. Since it is seen in the literature that watching a video for 20 minutes provides effective results, the video viewing time was determined as 20 minutes.
214477047|NCT06265207|OTHER|routine maintenance|routine maintenance
214667225|NCT03808311|OTHER|Treatment strategy regarding different systolic BP goals|The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (\<120 mmHg in the intensive arm and \<140 mmHg in the standard arm).
214667226|NCT05207761|DRUG|D565|Q.D. in both eye
214667227|NCT05207761|DRUG|D930|T.I.D in both eye
214667228|NCT01336101|DEVICE|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
214667229|NCT00761215|DRUG|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
214881984|NCT05921643|DEVICE|verre bioactif 45S5 GlassBONE|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
214881985|NCT05921643|DEVICE|verre bioactif S53P4 Bonalive|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
214881986|NCT06795815|OTHER|Go Wish Game|"The Go Wish Game (GWG) provides a simple tool, composed by 35 cards to identify individual priorities. GWG is welcomed as a first step in clarifying values and personal thoughts linked to the end of life. The GWG discussion will be divided into two meetings. During the first one, the physician instructs the patients and their caregivers on how the GWG works. The patient will be invited to divide the cards into three sets, labeling the content of the cards within each set as: Very important;more or less important and not important.~This will be the base for the second meeting. During the second meeting - scheduled within one week - each category of card sets will be discussed with patients and their caregivers. The identification of the most relevant wishes or priorities of each patient will be incorporated into the individual therapeutic plan and the patient will be offered the option to make a formal ACP in the following 4 weeks."
214881987|NCT06795945|DIETARY_SUPPLEMENT|TPG1|"* Thymus Nuclear Extract Dose 1 (860 mg \[2 tablets, 2x/day; total 4 tablets per day\])~* Placebo (6 tablets, 2x/day; total 12 tablets per day)"
214881988|NCT06795945|DIETARY_SUPPLEMENT|TPG2|"* Thymus Nuclear Extract Dose 2 (2150 mg \[5 tablets, 2x/day; total 10 tablets per day\])~* Placebo (3 tablets, 2x/day; total 6 tablets per day)"
214881989|NCT06795945|DIETARY_SUPPLEMENT|TPG3|Thymus Nuclear Extract Dose 3 (3440 mg \[8 tablets, 2x/day; total 16 tablets per day\])
214881990|NCT06795945|DIETARY_SUPPLEMENT|Placebo|Placebo (8 tablets, 2x/day; total 16 tablets per day)
214881991|NCT05562388|DEVICE|Somnodent Classic|The efficacy of the device will be evaluated in regards to the response of nocturia. Once patients report an average of voiding per night of less than 2 in the preceding 2 weeks of the follow up they will be classified as responders in term of nocturia and will be evaluated with a second sleep study. Efficacy of MAD will be assessed by comparing the apnea hypopnea index (AHI) values of pre and post sleep study with MAD, and they will be classified as responders if they have 50% improvement in AHI.
214881992|NCT05889624|BEHAVIORAL|CBT|"During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 booster CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes."
214881993|NCT05889624|DRUG|Amitriptyline|During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).
214881994|NCT02303795|DRUG|Rivaroxaban|Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
214881995|NCT02303795|DRUG|Warfarin|"Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.~Patients with 65 \> years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day."
214667230|NCT00761215|DRUG|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
214667231|NCT00761215|DRUG|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
214667232|NCT04373603|DRUG|Tranexamic acid|TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
214667233|NCT04373603|OTHER|Saline|sodium chloride and water for use as control
214667234|NCT04373603|DRUG|Hyaluronic acid|Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
214667235|NCT02882607|BEHAVIORAL|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
214667236|NCT02246361|PROCEDURE|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
214667237|NCT06970145|DRUG|Anlotinib|Anlotinib Hydrochloride Capsules (12mg),Chiatai Tianqing Pharma (China).
214667238|NCT06970938|OTHER|Cardiac rehabilitation program|The experimental group patients were included in the cardiac rehabilitation program. The cardiac rehabilitation program was implemented in the cardiopulmonary rehabilitation unit with bicycle ergometry devices by a team consisting of a physical medicine and rehabilitation physician, physiotherapist and nurse. The target heart rate that could be achieved during exercise was determined according to the patient's age and the medications he/she used. The exercise intensity was planned as low and moderate according to the target heart rate percentage. The program was organized as 30 sessions, 5 days a week, for 6 weeks. The sessions were implemented for half an hour while the patients were monitored from the bicycle ergometry device.
214667239|NCT06350383|BEHAVIORAL|WINGS+PM+|WINGS+PM+ is a safety, harm reduction, and brief psychological intervention combined and adapted by community members from informal settlements in Kenya (IPV survivors, health clinic staff, and CHVs) from two evidence-based interventions: Wings of Hope (WINGS) and Problem Management Plus (PM+). This intervention was designed to be facilitated by non-specialists (e.g., CHVs). It involves seven 90-minute weekly sessions. The intervention is informed by social cognitive theory.
214667240|NCT06350383|BEHAVIORAL|PM+-only|PM+: is a brief psychological intervention also designed to be facilitated by non-specialists (e.g. CHVs) and focused on problem management and evidence-based behavioral strategies to enhance one's capacity to adaptively manage psychological distress. It has been shown to be effective at reducing psychological distress among women who have experienced gender-based violence in informal settlements in Nairobi, Kenya. PM+ involves five 90-minute, weekly individual sessions.
214667241|NCT04201379|OTHER|quality of life assesment|The sociodemographic and clinical characteristics of the individuals who meet the study criteria will be recorded. Evaluations of the participants will be done only once
214881996|NCT00080145|DRUG|Risperidone|
214881997|NCT00080145|BEHAVIORAL|Behavior Therapy|
214881998|NCT01432067|OTHER|Adapted physical activity|Physical activity advices according to a program adapted to physical status of the patient.
214881999|NCT01432067|OTHER|Classic physical activities|Daily physical activities based on a standard guide
214882000|NCT03102606|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
214882001|NCT03102606|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
214882002|NCT03102606|OTHER|Saline Placebo|Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration
214882003|NCT03102606|OTHER|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
214882004|NCT05326204|OTHER|Home blood glucose monitoring|Self monitoring of capillary blood glucose
214667242|NCT01781949|OTHER|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
214667243|NCT01781949|OTHER|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS \<30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
214667244|NCT01781949|OTHER|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
214667245|NCT01561287|PROCEDURE|Dermal Autograft|Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.
214667246|NCT01561287|PROCEDURE|AlloDerm|The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
214882005|NCT03707405|BEHAVIORAL|Ride-On Cars Training with Different Postures|All programs will include 120 minutes/per session, 2 sessions/per week. All participants will continue their regular therapy during the whole study. The treatment strategy of ROC training with different postures will be based on the exploratory learning which focuses on providing opportunities to the participants to explore environmental properties with various motor patterns during the intervention.
214882006|NCT01277601|DRUG|TDF|TDF 300 mg tablets administered orally once daily
214882007|NCT01277601|DRUG|Peg-IFN|Peg-IFN 180 µg administered via subcutaneous injection once weekly
214882008|NCT03120182|DRUG|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization
214882009|NCT03120182|DRUG|Placebo Oral Tablet|Patients will receive placebo medication 100mg daily for 12 days after randomization
214882010|NCT00151931|DRUG|Lanthanum carbonate|
214882011|NCT06163235|OTHER|Obemar platform|Online platform for education and follow-up
214882012|NCT06508307|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors|The maximum number of lesions that each participant is allowed to inject at one time is two.
214882013|NCT03336736|DIAGNOSTIC_TEST|Exercise|"The study design will be a prospective cross-sectional observational project, with no intervention.~Data on a participant's physical activity levels, physical fitness and quality of life will be collected using physical testing and questionnaires."
214882014|NCT00305474|DRUG|Risperidone|Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
214882015|NCT04151043|BEHAVIORAL|Suggestions|Verbal suggestions or no suggestions about treatment outcome
214882016|NCT04151043|DEVICE|Deep brain stimulation|Regulation of deep brain stimulation intensity
214882017|NCT00963066|DEVICE|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
214882018|NCT00963066|DEVICE|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
214882019|NCT00963066|DEVICE|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
214882020|NCT04587726|BEHAVIORAL|Girl's room video|"Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~1. Appearance comparison~2. Body appreciation~3. Body talk~4. Body functionality~5. Appearance teasing \& bullying~6. Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020."
214882021|NCT04587726|OTHER|Control video - Chicken Girls|Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
214667247|NCT02302495|DRUG|Carfilzomib|"DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study."
214667248|NCT02364817|BEHAVIORAL|cognitive and psychiatric assessment|"Administered at baseline:~* Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)~* hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)~* psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)~* cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)~* impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)~* alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.~* administered at week 12: ASRS"
214667249|NCT00460928|DRUG|intravenous immune globulin (IVIG)|
214667250|NCT00604578|DRUG|Pioglitazone Hydrochloride|
214667251|NCT05057351|OTHER|Isopentenyltheophylline 0.44% + Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
214667252|NCT05057351|OTHER|Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
214667253|NCT02826057|OTHER|Targeted temperature management (33 degree Celsius)|
214667254|NCT05146622|BEHAVIORAL|Workplaces in the World|Formative research activities to better understand attitudes and behaviors of outdoor workers with respect to UV safety.
214667255|NCT00921921|DRUG|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
214667256|NCT00921921|DRUG|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
214882022|NCT00347386|DRUG|Drug: Zinc (zinc sulphate)|Dissolvable tablet 10 mg. Once daily during the illness
214882023|NCT00347386|DRUG|Placebo|Placebo tablet, once daily
214882024|NCT01711515|DRUG|Cisplatin|Given IV
214882025|NCT01711515|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
214882026|NCT01711515|RADIATION|Internal Radiation Therapy|Undergo intracavitary brachytherapy
214882027|NCT01711515|BIOLOGICAL|Ipilimumab|Given IV
214882028|NCT01711515|OTHER|Laboratory Biomarker Analysis|Correlative studies
214882029|NCT01155973|BEHAVIORAL|EDUCORE intervention|Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
214882030|NCT01155973|OTHER|Control group|SCORE oral information and counseling as standard practice care
214882031|NCT01080560|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
214882032|NCT03381170|BIOLOGICAL|Ublituximab|Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E
214882033|NCT00916643|DEVICE|HELP Secura (apheresis treatment)|Process is described in Arm (above).
214882034|NCT03632915|DRUG|Levetiracetam|Standard of care
214882035|NCT03632915|DRUG|Lacosamide|Standard of care
214882036|NCT03632915|DRUG|Phenytoin|Standard of care
214882037|NCT03632915|DRUG|Phenobarbital|Standard of care
214882038|NCT03632915|DRUG|Ketamine|Standard of care
214882039|NCT03632915|DRUG|Valproic Acid|Standard of care
214882040|NCT03196063|OTHER|Eccentric|Exercises based on eccentric contractions of the quadriceps femoris muscle, using a 15º inclined plane. A serie of 15 repetitions of the squat will be performed, with the frequency of three times a week for eight weeks. The load of the exercises will be increased weekly.
214667257|NCT03742804|BIOLOGICAL|Intratumoral G100|G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
214882041|NCT03196063|OTHER|Modified Protocol|Protocol based on the Heavy Slow resistance program, with the addition of an isometric phase at the beginning of the protocol, and with exercises using body weight without the use of mechanotherapy.
214882042|NCT01843296|DRUG|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
214882043|NCT01843296|PROCEDURE|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
214882044|NCT01843296|DRUG|Bupivacaine|
214882045|NCT01843296|DRUG|Fentanyl|
214882046|NCT00678210|DRUG|CP-690,550|tablets, 2 mg BID for 12 weeks
214882047|NCT00678210|DRUG|CP-690,550|tablets, 5 mg BID for 12 weeks
214882048|NCT00678210|DRUG|CP-690,550|tablets, 15 mg BID for 12 weeks
214882049|NCT00678210|DRUG|Placebo|tablets, BID for 12 weeks
214882050|NCT04825912|BEHAVIORAL|Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience|The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
214882051|NCT01981902|DEVICE|Non-Invasive Optical Spectroscopic|Non-Invasive Optical Spectroscopic
214882052|NCT02934399|OTHER|27 hour subcutaneous fluid sampling|"One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours)."
214882053|NCT06048952|BEHAVIORAL|Music Therapy|Huseyni maqam, Pentatonic music
214882054|NCT06230042|OTHER|Types of catheters|One type of catheters were used for patients
214882055|NCT03674736|DIETARY_SUPPLEMENT|Dietary Intakes|Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
215045592|NCT02367963|BEHAVIORAL|Peer-group|The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
215045593|NCT01774773|DRUG|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
214882056|NCT02394470|OTHER|Deuterium oxide dilution|Reference standard for total body water: deuterium oxide dilution by mass spectrometry
214882057|NCT02394470|OTHER|Bioimpedentiometry|Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance
214882058|NCT02394470|OTHER|Lung and subcutaneous ultrasound|Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)
214882059|NCT04442399|BEHAVIORAL|Family Connections|Ten intervention sessions were covered, ranging form understanding HIV and to handling stigma and discrimination.
214882060|NCT00251329|DRUG|neoadjuvant chemotherapy|
214882061|NCT02077140|DRUG|MDT-10013|
214882062|NCT02077140|DRUG|Standard of care for pain|
214882063|NCT04750889|DEVICE|RFID tags|Installation of the RFID tag device wire localization)
214882064|NCT04750889|DEVICE|Wire localization|Installation of the wire localization device
214882065|NCT03550911|OTHER|Biological Collection From Samples From The Gut Microbiota|The aim of this study is just to constitute a biological collection from samples from the Gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
214882066|NCT04756661|DRUG|Carbetocin|100 mcg of Carbetocin intravenous injection
214882067|NCT04756661|DRUG|Oxytocin|10 IU oxytocin IV drip
214882068|NCT04756661|DRUG|Misoprostol|400 mcg rectal
214882069|NCT05203783|OTHER|McKenzie Exercises|"McKenzie exercises: The McKenzie set consists of 5 exercises.~1. Prone-lying~2. Prone-extension~3. Prone press ups~4. Progressive extension with pillows~5. Standing extension"
214882070|NCT05203783|OTHER|Kinesio Tape Application|Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
214882071|NCT01469728|PROCEDURE|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
214882072|NCT01469728|PROCEDURE|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
214882073|NCT00477048|DRUG|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
214882074|NCT00974922|DRUG|Aliskiren|150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
214882075|NCT00974922|DIETARY_SUPPLEMENT|Cholecalciferol|3000 I.U. once daily for 6 weeks
214882076|NCT00974922|DIETARY_SUPPLEMENT|Placebo|Placebo for two weeks
214882077|NCT04929327|PROCEDURE|Self etch Pit and fissure sealant application (prevent seal)|Sealing deep pits and fissures
214882078|NCT04929327|PROCEDURE|Self etch Pit and fissure sealant application (prevent seal) with prior sandblasting|Sandblasting before Sealing deep pits and fissures
214882079|NCT04929327|PROCEDURE|Total etch resin based sealant ultraseal xt|Sealing deep pits and fissures
214882080|NCT03808480|DRUG|CA and Nivolumab|Cyclophosphamide 500mg/m2 IV on D1 (C1-4), 1cycle=21days) Doxorubicin 50mg/m2 IV on D1 (C1\~4, 1cycle=21days) Nivolumab 360 mg/IV C2\~4 D1 (1cycle=21days) Nivolumab 400mg/IV on D1 from Cycle 5 every 4 weeks.
215045594|NCT01774773|DRUG|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
215045595|NCT01774773|DRUG|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
215045596|NCT03289143|DRUG|Semorinemab|Participants will receive Semorinemab intravenously (IV).
215045597|NCT03289143|DRUG|Placebo|Matching placebo doses of Semorinemab given intravenously (IV).
214882081|NCT04363580|OTHER|Auditory processing disorder screening tool|"Screening tool : a questionnaire completed by the parents and the child's teacher and a mini-battery of tests composed of verbal and nonverbal assessments.~Questions for parents are grouped into four sections:~* Reference pattern and portrait of the child.~* Auditory history.~* History of speech and language development.~* School history.~The teacher questionnaire has seven sections:~* Portrait of the child.~* Reading and writing.~* Speaking.~* Mathematics.~* Music.~* Memory.~* Listening skills and understanding:~  * Concentration and organization.~ * Environment.~Mini-battery of tests:~* Dichotic Numeric Listening Test.~* Identification test of 15 patterns of frequency-varying sounds at each ear.~* Test of 10 monosyllables in noise per ear.~* Auditory memory test by measuring the range of figures (instead of words in order to reduce the contribution of language processing)."
215045598|NCT03289143|DRUG|[18F]GTP1|\[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
214667258|NCT05121103|DRUG|EZM0414|Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)
214882082|NCT01195610|BEHAVIORAL|Dietary intervention|Instruction to diet for 6 month
214882083|NCT02166255|BIOLOGICAL|siRNA-transfected peripheral blood mononuclear cells APN401|Given IV
214882084|NCT02166255|OTHER|laboratory biomarker analysis|Correlative studies
214882085|NCT03164876|DRUG|AUT00206|4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
214882086|NCT03164876|DRUG|Placebo|4 capsules of placebo, twice daily, to take orally with food for 4 weeks
214882087|NCT05473494|OTHER|training group|Trainings on diabetic foot care consisting of min 20 max 40 minutes will be given in 5 sessions for nine weeks. Training will be given face to face online.
214882088|NCT05473494|OTHER|control group|Group not to be trained.
214882089|NCT04820738|OTHER|Sensorimotor training exercises|Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking
214882090|NCT04820738|OTHER|Without Sensorimotor training exercises|Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
214882091|NCT02333058|DRUG|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA:~One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
214882092|NCT04070261|OTHER|iOS application usability test|user tasks, questionnaires, semi-structured interviews
214882093|NCT01808547|DRUG|ISV-303|0.075% bromfenac in DuraSite dosed BID
214882094|NCT01808547|OTHER|DuraSite Vehicle|DuraSite vehicle dosed BID
214882095|NCT04459039|DRUG|1000 mL 0.9% sterile saline|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
214882096|NCT04459039|DRUG|250 mL 0.9% sterile saline|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.
214882097|NCT06230445|OTHER|UHealth digital therapeutic|UHealth digital therapeutic is an application that patients can report their symptoms. If the contents that patients fill in reach the threshold, UHealth application will automatic report to doctor and the doctor will give medical advisement through UHealth digital therapeutic application.
214882098|NCT05190445|DRUG|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|HER2/4-1BB
214882099|NCT05190445|DRUG|Cinrebafusp alfa (PRS-343) in combination with tucatinib|HER2/4-1BB
214882100|NCT01009814|DRUG|BMS-663068|BMS-663068 will be administered as a tablet formulation
214882101|NCT01009814|DRUG|Ritonavir|Ritonavir will be administered as a capsule.
214882102|NCT00618371|DRUG|Raltegravir (MK-0518)|Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
214882103|NCT05823688|DEVICE|Electrical Impedance Tomography|Measure of regional ventilation by Electrical Impedance Tomography (EIT) before and during pneumoperitoneum
214882104|NCT06531278|DRUG|Irinotecan liposome|"* Patients are planned to receive irinotecan liposomal (60 mg/m2; d1) of every cycle.~* 27 days a cycle"
214882105|NCT06531278|DRUG|Adebrelimab|"* Patients are planned to receive Adebrelimab (20 mg/kg; d1) of every cycle.~* 27 days a cycle"
214882106|NCT06531278|DRUG|Oxaliplatin|"* Patients are planned to receive Oxaliplatin (85 mg/m2; d1) of every cycle.~* 27 days a cycle"
214882107|NCT06531278|DRUG|Fluorouracil|"* Patients are planned to receive fluorouracil (2400mg/m2; d1) of every cycle.~* 27 days a cycle"
215045599|NCT06110403|DRUG|TRIXEO AEROSPHERE|BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.
215045600|NCT02547103|OTHER|Chlorhexidine gluconate-soaked cloths|
214882108|NCT06531278|DRUG|Calcium folinate|"* Patients are planned to receive Calcium folinate (400mg/m2; d1) of every cycle.~* 27 days a cycle"
214882109|NCT01059461|DRUG|Cerebrolysin®|injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
214882110|NCT03080025|BEHAVIORAL|CBCT® (Cognitively Based Compassion-Training)|"The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.~The therapeutic tools are based on systemic approaches \& techniques, which contains a resource- \& solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).~Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):~a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression."
214882111|NCT00836407|DRUG|Ipilimumab|Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
215045601|NCT02547103|OTHER|Normal saline|
215045602|NCT02547103|OTHER|mupirocin ointment|
215045603|NCT03257358|DRUG|Fingolimod|Commercially available 0.5mg hard capsules, taken orally once per day
215045604|NCT00328796|PROCEDURE|acupuncture in 6 specific points|
215045605|NCT00328796|DRUG|lidocaine 10mg/ml|
215045606|NCT00730756|DRUG|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
215045607|NCT00730756|OTHER|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
215045608|NCT00305877|BIOLOGICAL|cetuximab|Given IV
215045609|NCT00305877|DRUG|gemcitabine hydrochloride|Given IV
215045610|NCT00305877|DRUG|capecitabine|Given orally
214882112|NCT00836407|BIOLOGICAL|Pancreatic Cancer Vaccine|The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
214882113|NCT00550511|RADIATION|Surgeon-performed ultrasound|After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
214882114|NCT06139822|OTHER|Experimental Group|Hamstring stretching is the main intervention which is being used along with convention protocol for plantar fasciitis.
214882115|NCT06139822|OTHER|Control Group|Control group included Cold pack for 7 to 10 mins. Followed by stretching of plantar fascia .
214882116|NCT03022084|DEVICE|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
215045611|NCT00305877|RADIATION|radiation therapy|Undergo radiation therapy
215045612|NCT00305877|BIOLOGICAL|bevacizumab|Given IV
215045613|NCT00305877|OTHER|laboratory biomarker analysis|Correlative studies
215045614|NCT05504759|OTHER|splint|Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
214882117|NCT03022084|OTHER|Cognitive Behavioral Therapy|Standard of Care
214882118|NCT05005052|DRUG|Vessel|Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
214882119|NCT05005052|DRUG|Placebo|Placebo and no compression or venopharmaceutical regimen
214882120|NCT02735759|DEVICE|Photoacoustic flow cytometry device|The device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. Anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. Patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.
215045615|NCT05504759|OTHER|steroid|Betamethasone Dipropionate + Betamethasone Sodium Phosphate-1 ml will be administered once at the beginning of the study to patients who will receive steroid injection, one of the local injection treatments. Steroid injection will be applied to the most sensitive point on the lateral epicondyle. Afterwards, patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during daytime hours for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
215057307|NCT02438033|DEVICE|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
215057308|NCT04973995|BEHAVIORAL|several physical examinations|By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
215057309|NCT00510445|DRUG|Imetelstat Sodium (GRN163L)|"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."
215057310|NCT03592771|BEHAVIORAL|THRIVE App|Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
215057311|NCT03592771|BEHAVIORAL|Tailored Feedback Messages|Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
214882121|NCT02579473|DRUG|SER-214|SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
214882122|NCT03474666|PROCEDURE|Strict Glycemic Control Group|The strict protocol adopted to conduct the study was proposed by Keegan e Cols.(2010) to be used among adult LT recipients that consist of a continuous intravenous insulin infusion. The targeted blood glucose range is 80-130 mg/dL. The procedure must be stopped when the patient can ingest at least 50% of liquid diet or receive bolus tube feedings.
214667261|NCT00297414|OTHER|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
214882123|NCT03474666|PROCEDURE|Standard Glycemic Control Group|"The targeted blood glucose range is 130-180 mg/dL~* Blood glucose reading: ≤ 180 mg/dL - subcutaneous insulin dose: 0~* Blood glucose reading: ≥181 mg/dL and ≤250 mg/dL - subcutaneous insulin dose: 5 IU~* Blood glucose reading: ≥251 mg/dL and ≤300 mg/dL - subcutaneous insulin dose: 10 IU~* Blood glucose reading: ≥301 - subcutaneous insulin dose: 15 IU"
214882124|NCT02380326|PROCEDURE|Advanced endoscopic imaging modalities|Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
214882125|NCT04933383|DRUG|AQ001S 0.125 mg/ml|administered by nebulization once daily
215045616|NCT05504759|OTHER|dry needling|The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x30 mm needles will be used for dry needling. Dry needle treatment will be applied to the painful trigger points in the forearm extensor group muscles with the stick-pull technique, 1 session per week, for a total of 2 sessions. Afterwards, the patients will be given a 2 weeks rest protocol (works that may strain the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The purpose of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. During the treatment of lateral epicondylitis, home exercises will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
214882126|NCT04933383|DRUG|Budesonide 0.125 mg/ml inhalation suspension|administered by nebulization once daily
214882127|NCT01207583|OTHER|Non-interventional observational study|Non-interventional observational study
214882128|NCT01899339|OTHER|submassive PA treatment with Ekosonic endo device|Ultra Sound energy along with tPA to treat submassive pulmonary embolism
214882129|NCT02743624|PROCEDURE|Variation of the level of pressure support during the mechanical ventilation|The pressure support of the patient was changed form the baseline to 20 cmH20 and then stepwise decreased to 2 cmH20,
214882130|NCT03827889|PROCEDURE|WMP of fluoride varnish|Application of fluoride varnish (drug of the intervention - Duraphat, Colgate) on all teeth, regardless of the lesions found
214882131|NCT03827889|PROCEDURE|TWLP of fluoride varnish|application of the fluoride varnish (drug of the intervention - Duraphat, Colgate) only on the teeth with active initial caries lesions detected through visual examination after prophylaxis
215045617|NCT00251836|PROCEDURE|Laparoscopic hand-assisted donor nephrectomy|
215045618|NCT05017870|DRUG|KSR-001|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
215045619|NCT05017870|DRUG|KSR-004|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
215045620|NCT05017870|DRUG|KSR-001-02|KSR-001-02
215045621|NCT05017870|DRUG|KSR-001-03|KSR-001-03
215045622|NCT01152307|BEHAVIORAL|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
215045623|NCT01126190|BIOLOGICAL|Neugranin|Neugranin will be administered per dose and schedule specified in the arm description.
215045624|NCT01126190|BIOLOGICAL|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
215045625|NCT01126190|DRUG|Chemotherapy|The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
215045626|NCT04817202|DRUG|hzVSF-v13 (intravenous, single dose)|Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)
215045627|NCT04817202|DRUG|hzVSF-v13 (subcutaneous, single dose)|Dosage form: 100mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
215045628|NCT04817202|DRUG|hzVSF-v13 (intravenous, multiple dose)|Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
215045629|NCT04817202|DRUG|Placebo (intravenous, single dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1 (single administration)
215045630|NCT04817202|DRUG|Placebo (subcutaneous, single dose)|Dosage form: 0.9% NaCl Solution Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
215045631|NCT04817202|DRUG|Placebo (intravenous, multiple dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
215045632|NCT00524121|DRUG|erlotinib hydrochloride|Oral
215045633|NCT00524121|OTHER|immunohistochemistry staining method|Correlative Study
215045634|NCT00524121|RADIATION|radiation therapy|Radiation Treatment
215045635|NCT03334838|DRUG|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
215045636|NCT04554303|DRUG|S-amlodipine 2.5mg|Oral administration, 1 tablet per day
214882132|NCT03827889|BEHAVIORAL|DHP (educational intervention)|The control group will receive diet and hygiene guidance (educational intervention) through verbal explanations and teeth brushing practices
214882133|NCT03309761|OTHER|Blood test|6ml blood sample taken
214882134|NCT05032781|DRUG|Intra-arterial cold saline, minocycline, and magnesium|See study design
214882135|NCT05690932|DRUG|PBI-200 Tablet|Single dose of PBI-200 tablet
214882136|NCT05690932|DRUG|PBI-200 Capsule|Single dose of PBI-200 capsule
214882137|NCT05690932|DRUG|PBI-200 Suspension|Single dose of PBI-200 suspension
215045637|NCT04554303|DRUG|Amlodipine 5mg|Oral administration, 1 tablet per day
214667262|NCT03885284|DRUG|mFOLFIRINOX|"Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~* Irinotecan 150 mg/m2 IV day 1~* Oxaliplatin 85 mg/m2 IV day 1~* Leucovorin 400 mg/m2 IV day 1~* 5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~* Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~* Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3."
214882138|NCT03194828|BEHAVIORAL|Medication reminder|Using the real-time data capture of the electronic device, an automated voice call or text message will be sent to active arm participants only when a missed dose is determined
214882139|NCT03194828|BEHAVIORAL|Medication monitoring only|Patients will use an electronic medication monitoring device to record their actual medication use
214882140|NCT05693259|DEVICE|Electrolyzed Alkaline Reduced Water (EARW) generated from electrolyzed ionizer|Patient will be allocated randomly to two groups: EARW and PW groups. For 6 weeks, patients drink water (10mL/kg body weight/day ) generated from the device installed in the house before starting intervention. Patients will be instructed to drink in empty stomach, and to drink immediately after generation of water. The total amount that the patient drank the day before will be monitored by a researcher using survey form of mobile phone everyday.
214882141|NCT02968602|DRUG|Minocycline|Minocycline capsules taken twice daily for two weeks.
214882142|NCT02968602|OTHER|Placebo|Placebo capsules taken twice daily for two weeks.
214882143|NCT02522689|PROCEDURE|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
215045638|NCT00572182|DRUG|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
215045639|NCT04758481|RADIATION|primary tumour radiotherapy|The study subjects will undergo primary tumour radiotherapy.
214292097|NCT05481645|DRUG|Doxorubicin Hydrochloride Injection|Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.
214292098|NCT05481645|DRUG|Gemcitabine Hydrochloride Injection|Gemcitabine is a cell cycle specific antimetabolic drug, which mainly acts on tumor cells at the DNA synthesis stage.
215045640|NCT04758481|RADIATION|stereotactic body radiotherapy|The study subjects will undergo stereotactic body radiotherapy.
214292099|NCT05481645|DRUG|Docetaxel injection|Docetaxel is an anti-tumor drug of paclitaxel, which plays an anti-tumor role by interfering with the microtubule network necessary for cell Mitosis and interphase cell function.
214292100|NCT02310464|DRUG|OBI-833/OBI-821|
214882144|NCT02522689|PROCEDURE|Endoscopic kidney stone surgery|Micro PCNL will be performed.
214882145|NCT00129883|BEHAVIORAL|Professional education|
214882146|NCT00129883|BEHAVIORAL|Implementation of a Critical Care Pathway|
214882147|NCT00129883|BEHAVIORAL|Professional audit and feedback|
214882148|NCT00129883|BEHAVIORAL|Process analysis and redesign|
214292101|NCT02234375|DRUG|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
214882149|NCT04447313|OTHER|Survey Administration|Ancillary studies
214882150|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive ACT telephone coaching
214882151|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive SBT telephone coaching
214882152|NCT05015426|BIOLOGICAL|Gamma Delta T-Cell Infusion|Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.
214882153|NCT06101342|DRUG|Lenacapavir Injection|Administered subcutaneously
214882154|NCT06101342|DRUG|Lenacapavir Tablet|Administered orally
215045641|NCT04758481|RADIATION|maintenance radiotherapy|The study subjects will undergo maintenance radiotherapy.
215045642|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
215045643|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
215045644|NCT04955067|DIAGNOSTIC_TEST|Diagnositic test|The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object
215045645|NCT00706147|DRUG|Arimoclomol|Drug: Arimoclomol capsules given three times per day
215045646|NCT00706147|DRUG|Placebo|Drug: Placebo capsules given three times per day
214292102|NCT03430596|DRUG|Pramipexole|The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
214292103|NCT03430596|DRUG|Trihexyphenidyl hydrochloride|he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
214292104|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
214292105|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
214882155|NCT06101342|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
214882156|NCT05151289|BIOLOGICAL|Blood test at time of inclusion for sFlt-1/PlGF ratio|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the inclusion visit.
214882157|NCT05151289|BIOLOGICAL|Follow-up blood test 2 to 4 weeks after inclusion|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the follow-up visit (about 2-4 weeks after inclusion). This second sample is not mandatory for the evaluation of the study's main endpoint.
215045647|NCT01114737|DRUG|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
215045648|NCT01114737|DRUG|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
215045649|NCT03637283|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
214292106|NCT01988103|DRUG|Placebo|Placebo tablet BID for 16 weeks
215045650|NCT03637283|PROCEDURE|fan-shaped photocoagulation|vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
215045651|NCT02722005|BEHAVIORAL|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
215045652|NCT02722005|BEHAVIORAL|Access to referral to social services|Access to referral to a host of social services.
215045653|NCT04373304|OTHER|low FODMAP diet|A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
214667263|NCT03885284|RADIATION|Proton beam radiation|Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7
214667264|NCT06358872|DRUG|Azithromycin for Oral Suspension|Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.
214667265|NCT04045210|OTHER|Psychological Support Based on Positive Suggestions|Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1 to intervention by ICU doulas or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 3 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention.
214667266|NCT04333966|BEHAVIORAL|Interactive Social Networking Site Parent Based Intervention|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
214667267|NCT04333966|BEHAVIORAL|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call to Action: A Guide for Families.
214882158|NCT05151289|DIAGNOSTIC_TEST|Placenta analysis for all included patients, even in case of normal birthweight|"After delivery, the placenta of each included patient is sent to anatomo-pathology (even in case of normal weight of the baby at birth). An anatomopathologist referent, designated for the study in each center, performs an analysis (aware of the clinic but not of the sFLT-1/PlGF ratio results), according to the benchmark criteria grid. Local analysis will classify the placenta as vascular IUGR or nonvascular IUGR."
214882159|NCT00005553|PROCEDURE|Catheter Ablation|
214882160|NCT03719651|BEHAVIORAL|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
214882161|NCT03719651|BEHAVIORAL|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
214882162|NCT03719651|BEHAVIORAL|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
214882163|NCT03719651|BEHAVIORAL|TF-CBT|TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
214882164|NCT03613233|PROCEDURE|Glaucoma surgery|phacoemulsification
214882165|NCT01860274|DEVICE|External Mesh for vein grafts|
214882166|NCT05747105|BEHAVIORAL|Sleep Extension|The 16-week protocol includes 11 total individual visits that integrate applicable elements of Cognitive Behavioral Therapy for Insomnia (CBT-I) and health behavior change theory. The first 6 weeks include weekly sessions (\~45 minutes each) focused on psychoeducation about sleep, goal-setting and self-monitoring, stimulus control, addressing cognitive and somatic arousal, sleep hygiene, and challenging negative thoughts about sleep. Sleep restriction will also be used in specific cases where sleep efficiency is low (\<85%). The remaining 10 weeks include briefer biweekly visits (5 visits, \~15-20 minutes each) to reinforce health behavior change strategies through topics such as problem-solving barriers, utilizing social support, identifying setbacks and creating an action plan, and relapse prevention. Self-reported sleep diary data and subjective sleepiness will be collected at each visit.
214882167|NCT04905628|DEVICE|Dexcom CGM System|Dexcom CGM System
214882168|NCT04233294|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
214882169|NCT04233294|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
214882170|NCT04233294|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
214882171|NCT02352467|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
214882172|NCT02654028|PROCEDURE|Autotransfusion|These group of patients will receive autotransfusion before liver resection.
214882173|NCT02654028|OTHER|Control group|These group of patients will not receive autotransfusion before liver resection.
214667268|NCT00484354|DRUG|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
214667269|NCT00484354|OTHER|Normal saline|IV Normal saline with volume given determined by patient weight
214882174|NCT05435261|PROCEDURE|BKA|"Below Knee Amputation:~* Under spinal anesthesia~* BKA~* closure in layers (terminal closure) with suction drain."
214882175|NCT05435261|PROCEDURE|Debridement with Ex_Fix (salvage)|"Debridement and External Fixation (salvage):~* Under spinal anesthesia~* wound debridement and wash.~* external fixation."
214882176|NCT03842319|OTHER|Microbiota analysis|From the feces and oral cavity samples, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
214882177|NCT03842319|OTHER|Immunological analysis|A study of immunological cell populations, inmunogenetics and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
214882178|NCT03842319|OTHER|Proteome analysis|A study of host and microbiota proteome will be carried out from samples using mass spectrometry
214882179|NCT03842319|OTHER|Metabolome analysis|A study of host and microbiota metabolome will be carried out from samples using MS-based as well as NMR-based methods
214882180|NCT03842319|OTHER|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies
214667270|NCT00484354|OTHER|Bicarbonate|IV bicarbonate, dosed by weight
214667271|NCT00484354|OTHER|Placebo|Normal saline, with volume given based on patient weight
214667272|NCT00820638|DEVICE|myomo e100|use of the myomo e100 in home
214667273|NCT02942498|DRUG|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
214667274|NCT02942498|DRUG|Placebo|Placebo
214667275|NCT01112709|BEHAVIORAL|SCT-based Resistance Training exercise program|Two supervised RT sessions per week for the first 3 months, then a self-monitored RT phase for the remainder of the study, with primarily Internet-based contact.
214667276|NCT01112709|OTHER|Standard Intervention with minimal contact|This is the control condition for comparison; the approach will be identical to the experimental condition, but without the theoretical components (skills to increase self efficacy for RT, self regulation for RT). Contact with the study staff will be reduced from that received by the experimental group.
214667277|NCT03024775|DIETARY_SUPPLEMENT|Wheat flour|Wheat flour will be administered three times per day for 15 days.
214667278|NCT03024775|DIETARY_SUPPLEMENT|Placebo|Placebo (xylose) will be administered three times per day for 15 days.
214667279|NCT01201499|DRUG|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or \~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
214667280|NCT01201499|DRUG|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
214667281|NCT01780233|DRUG|Fentanyl 400 µg sublingual spray|
214667282|NCT01780233|DRUG|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
214667283|NCT01780233|DRUG|Fentanyl citrate injection 100 µg intravenously|
214882181|NCT03842319|OTHER|Diet evaluation|Biochemical analysis and questionaries for diet adherence and exercise registration
214882182|NCT03842319|OTHER|MedDiet|The high-intensity Mediterranean diet will include the promotion of the following: a) abundant use of olive oil (\>40 g/d) for cooking and dressing dishes; b) consumption of \>2 daily servings of vegetables; c) \>2-3 daily serving of fresh fruits; d) \>3 weekly servings of legumes; e) \>3 weekly servings of fish or seafood; f) \>1 weekly serving of nuts or seeds; g) select white meats instead of red meats or processed meats; and h) cook regularly with tomato, garlic and onion adding or no other aromatic herbs, and dress vegetables, pasta, rice and other dishes with tomato, garlic and onion adding or no other aromatic herbs. Two main meals per day should be eaten (seated at a table, lasting more than 20 minutes). A recommendation to drink a glass of wine per day during meals is given. Limited consumption is advised for cured ham, red meat, chocolate, cured or fatty cheeses
214882183|NCT01257178|DRUG|LY2624803|Administered orally
214882184|NCT03054233|PROCEDURE|Crossed leg sitting position|Spinal anesthesia done in crossed leg sitting position
214882185|NCT05224128|DRUG|Imatinib 200mg|Imatinib have to be taken 200mg/day orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
214882186|NCT05224128|DRUG|Placebo|Capsules (similar appearance with imatinib) without active substance have to be taken orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
214882187|NCT04702243|DIAGNOSTIC_TEST|Genetic Testing for PCD or PID|Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.
214882188|NCT04702243|OTHER|Unaffected Family Member Genetic Testing|Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.
214882189|NCT02075307|DIETARY_SUPPLEMENT|Blueberry Powder|
214882190|NCT02075307|DIETARY_SUPPLEMENT|Placebo|
214882191|NCT05065255|DEVICE|SpeediCath® catheters|Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.
215045654|NCT03048201|DEVICE|Physica Kinematic Retaining Knee System|Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation
215045655|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
215045656|NCT03048201|DEVICE|Physica Posterior Stabilized Knee System|Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.
215045657|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System with LMC Liner|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
215045658|NCT04843631|DRUG|BFI-751|Single use vial, solution
214882192|NCT04350450|DRUG|Hydroxychloroquine|400 mg tablet
214882193|NCT01573299|OTHER|Mobilization of stroke patients|"In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset."
215045659|NCT04843631|DRUG|EU-STELARA®|Pre-filled syringe, solution
215045660|NCT04843631|DRUG|US-STELARA®|Pre-filled syringe, solution
215045661|NCT05747274|DEVICE|SRDK0921|SRDK0921 is an IVD composed of IVD kit for qPCR (SRDK0921KIT) and a cloud-based software (SRDK0921SOFT). It is a class C, rule 3k, IVD according to Regulation (EU) 2017/746.
214667284|NCT01780233|DRUG|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
214667285|NCT01814423|DRUG|Chloroquine-base 50 mg|
214667286|NCT01814423|DRUG|Chloroquine-base 70 mg|
214667287|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
214667288|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
214667289|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
214667290|NCT01916395|DRUG|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
215045662|NCT00068289|DRUG|bortezomib|
215045663|NCT00983034|DRUG|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
214882194|NCT02934191|DRUG|Celecoxib|Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
214882195|NCT02934191|OTHER|Placebo|Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.
214882196|NCT02934191|DRUG|Acetaminophen|Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
214882197|NCT02934191|DRUG|Oxycodone|Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
214882198|NCT04060186|PROCEDURE|Balloninflation|Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.
214882199|NCT03237507|DRUG|S-1|40-60mg/m\^2 bid, days 1-14, oral，every 3 weeks.
214882200|NCT03237507|DRUG|oxaliplatin|100mg/m\^2 days 1，intravenous infusion, every 3 weeks.
215045664|NCT01446874|DRUG|0.12% chlorhexidine solution|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
215045665|NCT02681367|OTHER|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
215045666|NCT06395701|RADIATION|radioteraphy and chemotherapy after RTU --trimodality therapy--|TMT ( trimodality treatment) consists of complete and maximal TURBT of the bladder tumor, followed by definitive radiotherapy combined with a radiosensitizing agent.
215045667|NCT02554994|OTHER|Multifactorial intervention|"There are six components of intervention in this study.~* For all participants:~  1. Group exercise~ 2. Nutritional supplement(commercial liquid formula will be provided every day).~* For selected participants:~  1. Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~ 2. At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~ 3. Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
215045668|NCT02554994|OTHER|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
215045669|NCT03925363|DEVICE|Physical activity mobile-application|The active group will be given the feedback app and the control group the blind app
215045670|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
215045671|NCT00457392|DRUG|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
215045672|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
215045673|NCT00457392|DRUG|placebo|Placebo daily by oral capsules in a continuous regimen
215045674|NCT05075889|DRUG|Indocyanine Green|Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment
215045675|NCT03991910|DRUG|Placebos|the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.
215045676|NCT03991910|DRUG|Ramipril 5Mg Oral Capsule|the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
214882201|NCT03237507|DEVICE|Hyperthermic Intraperitoneal|hyperthermic intraperitoneal chemoperfusion
214882202|NCT03237507|DRUG|Paclitaxel|intraperitoneal perfusion
214882203|NCT05821335|OTHER|Leap motion assisted rehabilitation|Hand Therapy via leap motion sensor
215045677|NCT00776529|OTHER|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
215045678|NCT00776529|OTHER|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
214882204|NCT05821335|OTHER|Traditional program|Hand Therapy by physiotherapist via traditional methods
214882205|NCT01402635|DEVICE|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
214882206|NCT02089607|DEVICE|Thoracoabdominal Aortic Aneurysm Arm|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches."
214882207|NCT02089607|DEVICE|Aortic Arch Aneurysm Arm|The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
214882208|NCT03533309|PROCEDURE|Computer guided surgical cutting guide|comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent
214882209|NCT03533309|PROCEDURE|Conventional alveolar ridge splitting|comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
214882210|NCT00841828|DRUG|Epirubicin|
214882211|NCT00841828|DRUG|Cyclophosphamide|
214882212|NCT00841828|DRUG|Docetaxel|
214882213|NCT00841828|DRUG|Lapatinib|
215045679|NCT02878083|DRUG|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
215045680|NCT02878083|DRUG|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
215045681|NCT01591265|PROCEDURE|Extraction of upper and lower FPM teeth|Extraction of upper and lower FPM teeth
215045682|NCT01591265|PROCEDURE|Extraction of lower FPM tooth|Extraction of lower FPM tooth only
215045683|NCT00399074|DRUG|sulfadoxine pyrimethamine|Monthly SP
215045684|NCT05886153|DEVICE|Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
215045685|NCT03218774|BEHAVIORAL|Home Exercise Group|The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.
215045686|NCT03218774|BEHAVIORAL|Fitness Center Group|The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
215045687|NCT05956847|PROCEDURE|gastroscopy|When performing gastroscopy, the endoscopist will perform a biopsy based on the condition of gastric mucosal lesions, with one specimen retained and the remaining specimens subjected to pathological examination
214292107|NCT05901675|OTHER|Lifestyle Management Program|The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.
214292108|NCT05901675|OTHER|Post-stroke Optimization of Walking using Explosive Resistance|POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
214882214|NCT00841828|DRUG|Trastuzumab|
214882215|NCT05308628|DIAGNOSTIC_TEST|Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)|Liver biopsies will be performed at 3 months, 6 months and 12 months post-transplant. Fibrosis was evaluated using the liver allograft fibrosis score (LAFSc) staging system. Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA)or (FBLN3,YKL40,LECT2 etc.)
214882216|NCT01231204|PROCEDURE|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
215045688|NCT02986633|OTHER|Echocardiography|
215045689|NCT01135992|DRUG|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
215045690|NCT01135992|DRUG|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
215045691|NCT00000413|BEHAVIORAL|Psychoeducational program|
214667291|NCT05187117|BEHAVIORAL|CAPABLE Family - Open Label Pilot|"As in CAPABLE (NA\_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations for cognitive decline will be made on a per-client basis as part of the open-label pilot. Topics of adaptations include problem areas addresses, care partner involvement, length/frequency of visits, types of assessments and questions asked, and brainstorming/action planning structure."
214667292|NCT05187117|BEHAVIORAL|CAPABLE Family - Randomized Control Trial|As in CAPABLE (NA\_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
214667293|NCT05591833|PROCEDURE|SASI|Single-Anastomosis Sleeve ileal (SASI) Bypass
214667294|NCT05591833|PROCEDURE|SAS-J|Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
214667295|NCT00083538|DRUG|Dexamethasone|
215045692|NCT01977898|DRUG|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
214292109|NCT06151158|BEHAVIORAL|Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+)|Stanley Brown Safety Planning completed in the emergency department with 3 follow-up contacts after discharge
214292110|NCT06151158|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI)|Five session crisis focused version of IPT for adolescents.
214667296|NCT00083538|DRUG|Thalidomide|
214667297|NCT00083538|DRUG|Cisplatinum|
214667298|NCT00083538|DRUG|Adriamycin|
214667299|NCT00083538|DRUG|Cyclophosphamide|
214667300|NCT00083538|DRUG|Etoposide|
214667301|NCT01597869|DEVICE|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
214667302|NCT05846633|DEVICE|C mell treadmill|C Mell treadmill provides Virtual Reality environment for rehabilitation with obstacles and motivational assistance
214667303|NCT04902287|BEHAVIORAL|Training Intervention for the Engagement of Families (TIES)|This intervention involves training service personnel in a method of communication that elicits a person's intrinsic motivation for change.
214667304|NCT00839111|DRUG|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
214667305|NCT00839111|DRUG|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
214667306|NCT00543179|DRUG|Somatuline (Lanreotide Autogel®)|
214667307|NCT01662999|DRUG|Saxagliptin|
214667308|NCT01662999|DRUG|Dapagliflozin|
214667309|NCT04632979|PROCEDURE|Backwards running on a Treadmil with a negative slope|Running backward on a treadmill with a negative slope
214667310|NCT02866344|PROCEDURE|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
214667311|NCT02866344|PROCEDURE|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
214667312|NCT05832762|PROCEDURE|Endovascular treatment (EVT) + Best medical treatment (BMT)|"Endovascular treatment (EVT) in the experimental arm can be performed with any recanalization strategy based on the operator's choice, and anatomical and radiological situation: MT using aspiration or stent retriever, with or without stenting (CE-labelled) or angioplasty. In case of acute stenting, the use of antiplatelet drugs will be based on the operator's preference, anatomical situation, and risk of hemorrhage.~Best medical treatment (BMT) : Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies."
214667313|NCT05832762|PROCEDURE|Best medical treatment (BMT)|Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies.
214667314|NCT03490487|DRUG|conventional antiepileptic drugs|will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
214667315|NCT03490487|DRUG|oral steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
214292111|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for cough|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have neurogenic cough for which superior laryngeal nerve block is recommended will undergo this procedure under ultrasound guidance. Patients without neurogenic cough will also be recruited for ultrasound assessment to establish landmarks and normal variation. Patients will be assessed for their comfort with undergoing the procedure and clinicians will be surveyed on the ease and benefit of performing the procedure under ultrasound guidance.
214882217|NCT01231204|PROCEDURE|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
214882218|NCT04705272|OTHER|Questionnaire|Pregnant women will be included in the study at the time of their first or second trimester ultrasound in the Hautepierre and CMCO ultrasound department. The period of inclusion should extend from 1 October 2020 to 31 October 2021 with a duration of participation of each subject of 9 months.
214882219|NCT05430217|DRUG|Buspirone|1 tablet (15 mg) once per day for 28 days
214882220|NCT05430217|DRUG|Placebo|1 placebo tablet once per day for 28 days
214882221|NCT04974749|BIOLOGICAL|REPLAGAL|REPLAGAL IV infusion.
214882222|NCT04414618|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
214882223|NCT04414618|DRUG|Placebo|Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
214882224|NCT02681835|DEVICE|C-MAC laryngoscope|Intubation performed using C-MAC laryngoscope
214882225|NCT02681835|DEVICE|Macintosh laryngoscope|Intubation performed using laryngoscope with Macintosh blade
214882226|NCT05159024|DIAGNOSTIC_TEST|CRP, PCT, and WBCs trajectories|the levels of CRP, PCT, and WBCs were assessed before surgery and after the onset of leak
214882227|NCT00362336|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
214882228|NCT00362336|BIOLOGICAL|CombAct-HIB®|0.5 mL, IM
214882229|NCT00362336|BIOLOGICAL|Engerix B® Pediatric|0.5 mL, IM
214882230|NCT05328219|OTHER|Chewing gums with PEG solution|"Patients undergoing colonoscopy under experimental group was advised to take 2L of PEG solution and packets of sugarless sweet mint flavored chewing gums.~The patients are advised to Chew one stick of sugarless gum for at least 10 min after taking each glass of PEG solution and discard the chewing gum before taking next glass."
214882231|NCT05328219|OTHER|Standard of care|Standard of care
214882232|NCT04290143|OTHER|Colored healing water|Patients will be treated with colored healing water for 20 minutes.
214882233|NCT04290143|OTHER|Placebo treatment (colored tap water)|Patients will be treated with colored tap water for 20 minutes.
214882234|NCT00658879|DRUG|Somavert (Pegvisomant)|"Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
214882235|NCT00360984|DRUG|insulin glargine|
214882236|NCT00360984|DEVICE|continuous subcutaneous insulin infusion|
214882237|NCT06139302|DRUG|BI 1015550|BI 1015550
214882238|NCT05935202|DRUG|Mitapivat sulfate|Subjects enrolled Maximum dose: will receive Mitapivat during 56 weeks Starting dose: 50 mg BD Maximum dose: 100 mg BD
214667316|NCT01322815|DRUG|chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
214667317|NCT01322815|DRUG|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
214882239|NCT01857479|DRUG|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
214882240|NCT01857479|DRUG|Inhaled amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\].~The first dose will be administered under direct supervision."
214882241|NCT00612664|DRUG|Anti-CD137 (4-1BB) (BMS-663513)|IV solution, IV, until PD or toxicity
214882242|NCT01727037|PROCEDURE|Bronchoscopic intrabullous autologous blood instillation|
214882243|NCT02614105|PROCEDURE|Pelvic floor muscle training|16 weeks of group-based exercise
214882244|NCT02614105|PROCEDURE|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
214882245|NCT02614105|OTHER|Control|Brief information only
214667318|NCT01665937|DRUG|STA-9090|"IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen."
214292112|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have vocal fold atrophy or vocal fold paresis/paralysis for whom injection laryngoplasty is recommended will undergo laryngeal ultrasound prior to the procedure to assess baseline anatomy as well as following the procedure (both immediately following the procedure as well as at follow-up visits) in order to assess the amount of injectate.
214667319|NCT04002167|BEHAVIORAL|Neurofeedback|The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.
214667320|NCT04002167|BEHAVIORAL|Cognitive training|The Cognitive training group will receive computerized working memory training with performance feedback.
214667321|NCT04580147|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
214667322|NCT04580147|OTHER|Sham control|Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
214667323|NCT02932267|DRUG|Adapalene 0.3% / BPO 2.5% gel|Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
214667324|NCT05609526|OTHER|Compression Therapy|6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.
214667325|NCT05609526|OTHER|Inspiratory muscle training|Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
214667326|NCT05609526|OTHER|Calf muscle exercise training|A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.
214667327|NCT04876547|PROCEDURE|appendectomy|appendectomy performance
214667328|NCT02412865|BEHAVIORAL|Quit4Baby|
214667329|NCT02412865|BEHAVIORAL|Text4Baby|
214667330|NCT02049502|BIOLOGICAL|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
214667331|NCT02049502|PROCEDURE|sigmoidoscopy|
214667332|NCT04176861|DEVICE|home-based Brainwave Entrainment Technology|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights
214667333|NCT04970667|DRUG|Flupentixol melitracen tablets|Patients were treated with Flupentixol and melitracen tablets for 12 weeks
214667334|NCT06154070|DRUG|DaxibotulinumtoxinA|"Patients enrolled who meet eligibility will receive a total of 344 units of DAXI Injections in divided doses over 19 landmarks, including the face, head and shoulders, as identified per the EEG paradigm, at visit 2.~Follow-up visits via combination of phone and in office will occur at V3, week 8 thru V9, week 24."
214667335|NCT03781557|DIETARY_SUPPLEMENT|Docosahexaenoic acid|High-concentrated DHA
215045693|NCT01977898|DRUG|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
214667336|NCT03781557|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|High-concentrated EPA
215045694|NCT01997645|PROCEDURE|LIFT|
214667337|NCT03781557|DIETARY_SUPPLEMENT|Olive oil|Olive Oil softgels
214292113|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphagia|Patients with and without swallowing complaints will be enrolled to assess their tongue, suprahyoid and infrahyoid musculature, including muscle identification, bulk and function.
214667338|NCT05636280|OTHER|schroth exercise|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
214667339|NCT05636280|OTHER|traditional scoliosis exercise|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
214667340|NCT00004829|DRUG|tobramycin|
214667341|NCT01447693|PROCEDURE|application of ointment (olive-omega 3 ointment)|
214667342|NCT02421393|OTHER|supervised exercise training|"Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity."
214667343|NCT01904487|RADIATION|[11C]flumazenil|\[11C\]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
214667344|NCT01904487|DRUG|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
214667345|NCT00003729|DRUG|cytarabine|
215045695|NCT01997645|PROCEDURE|RAF|
215045696|NCT05771714|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
215045697|NCT06320704|DEVICE|Digital occlusal adjustment using Occulosense digital device|Digital occlusal adjustment of mandibular complete denture using Occulosense digital device
214667346|NCT00003729|DRUG|fludarabine phosphate|
214882246|NCT01474200|DEVICE|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
215045698|NCT01615783|OTHER|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
215045699|NCT01615783|OTHER|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
215045700|NCT04441697|DIAGNOSTIC_TEST|Multiple sleep latency tests|The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.
215045701|NCT02306811|DRUG|Vatelizumab|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
215045702|NCT04144777|DIETARY_SUPPLEMENT|Solarplast|Subjects will take one capsule of Solarplast (100mg) daily for 45 days.
215045703|NCT00046904|BIOLOGICAL|etanercept|
215045704|NCT02184598|BEHAVIORAL|Cognitive training|12 weeks of cognitive training; 4 sessions/week; duration 30 min
214882247|NCT01474200|DRUG|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
214882248|NCT02798588|RADIATION|PET-MRI|18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)-\>8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
214882249|NCT02130115|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
214882250|NCT04573894|DIAGNOSTIC_TEST|Procalcitonin dosage|Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
215045705|NCT02184598|BEHAVIORAL|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
215045706|NCT03446898|OTHER|Chronic hypoxic environment|Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
215045707|NCT04563767|PROCEDURE|Infinitome|Added sequence of rs-fMRI.
215045708|NCT06308224|OTHER|Modified-Otago Exercises|"Walking for 15 minutes before or after the strengthening and balance exercises of Modified-Otago.~Strengthening exercises for 10 minutes: Knee extensor, Knee flexor, Hip adductor, Ankle plantar flexors (calf raises), and Ankle dorsiflexion (toe raises).~Balance exercises 20 minutes: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel-toe stand), Tandem walk (heel-toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backward, sit to stand and Stair walking."
214882251|NCT00742118|PROCEDURE|Colic biopsies|colic biopsies and analysis
214882252|NCT06200506|DEVICE|Transabdominal radiofrecuency application|"A transabdominal radiofrequency application will be performed, with a suprapubic active plate and a passive plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks.~Frequency: 3 times a week sessions will be held three times a week for three weeks"
214882253|NCT06200506|DEVICE|Intracavitary radiofrequency application|"An intracavitary vaginal radiofrequency application will be performed, with an active intracavitary head and with a fixed plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks. Frequency: 3 times a week sessions will be held three times a week for three weeks."
215045709|NCT06308224|OTHER|Tai-Chi Exercises|"Warm-up exercises for 10 minutes.~Tai Chi Qigong Exercises for 30 minutes: Commencing form and regulating breathing, Expanding your chest, Painting a rainbow, Circling arms to separate the clouds, Fixed step invert brachial, Row a boat in the middle of the lake, Shoulder the ball, Turning the body to look at the moon, Twisting waist and pushing palms, Horse step and cloud hands, Drag the sea and watch the sky, Undulating waves, Dove spreading wings, Extend arms and punch, Wild goose flying, Flywheel turning, Bounce ball while stepping, Pressing palms in calmness.~Cool-down exercises for 5 minutes."
214667347|NCT00003729|DRUG|idarubicin|
214479552|NCT06870162|BEHAVIORAL|Pain Disengagement Training|The intervention involves approximately 8 sessions. The first session will involve a psychoeducation component describing the association between negative emotions and pain and the rationale for the intervention strategies. The intervention sessions will consist of approximately 30 minutes of writing alternating between imaginal exposure writing and positive writing periods alternating back and forth (e.g., 3-5 minutes of imaginal exposure writing followed by 3-5 minutes of positive writing before returning to imaginal exposure writing, etc.). Exposure writing will involve writing about a pain-related catastrophic worry repeatedly until it becomes less anxiety-provoking. The positive writing topics will change with each prompt and will be structured by session theme (e.g., values/goals, meaningful activities). They will also complete between session practice by setting aside a time for worrying and then completing a meaningful activity.
214882254|NCT04913142|OTHER|Fecal and oral samples|oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
214882255|NCT02490280|BEHAVIORAL|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
214882256|NCT00738257|DRUG|Pamidronate|
214882257|NCT02441725|OTHER|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
214882258|NCT03798925|OTHER|None Intervention|It is observational study
214882259|NCT01207895|DEVICE|PET imaging with [18F]-FLT|Up to three \[18F\]-FLT PET scans; one before beginning treatment, one at week three of treatment, and one at week 11, after completion of treatment but prior to surgery.
214882260|NCT01207895|DRUG|[18F]-fluorodeoxythymidine|\[18F\]-fluorodeoxythymidine is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
214882261|NCT02370524|DRUG|[18F]T807|All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
214882262|NCT02661217|DRUG|LCZ696|"LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient."
214882263|NCT03417635|BEHAVIORAL|Guided focused attention|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The focused attention practice itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
214882264|NCT03417635|BEHAVIORAL|Acoustic music|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The acoustic music track itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
214882265|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein|Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
215045710|NCT04676100|OTHER|Cardiac rehabilitation|"A CR program is defined as one that offers initial assessment, structured exercise (can be supervised or unsupervised) and at least one other strategy to control risk factors. The registry pertains to phase II CR.~Quality of care and patient outcomes are benchmarked with other countries anonymously, through 2 registry dashboards (real-time). The dashboards will also show change over time in 6-month increments; Sites will be encouraged to continue to provide data on new patients until all indicators show quality as possible.~Sites will be supported in quality improvement by the ICRR user sub-committee. High-performing programs will be recognized on ICRR's website and ICCPR's social media accounts. This mechanism may be used in future to support program accreditation."
214882266|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein and Resistance Exericse|Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
214882267|NCT01960335|OTHER|Whey Protein and RISE exercise routine|Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
214882268|NCT02075515|BIOLOGICAL|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
214882269|NCT06042582|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
214882270|NCT05771948|DEVICE|CCoat|CCoat is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. CCoat is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.
214882271|NCT00378573|DRUG|docetaxel|
214882272|NCT00378573|DRUG|gemcitabine|
214882273|NCT00378573|DRUG|bevacizumab|
214882274|NCT03086486|DRUG|Pretomanid|200mg tablets
214667348|NCT00642330|DRUG|oral ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
214292114|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphonia|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have muscle tension dysphonia will undergo ultrasonography during their visit with laryngology or speech language pathology.
214667349|NCT00642330|DRUG|intravenous ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
214667350|NCT00303550|DRUG|Intravenous iclaprim|
214667351|NCT00303550|DRUG|Intravenous linezolid|
214667352|NCT02628587|DRUG|Generic clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
214667353|NCT02628587|DRUG|Patent clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
214667354|NCT01586091|DRUG|Levocetirizine Oral Tablet|
214667355|NCT01586091|DRUG|Fexofenadine 60 Mg Oral Tablet|
214667356|NCT01586091|DRUG|Placebo Oral Tablet|
214667357|NCT01561131|DIETARY_SUPPLEMENT|Whey protein|45g protein/d; Dosage 3x15g protein daily
214667358|NCT01561131|DIETARY_SUPPLEMENT|Whey protein enriched with calcium|45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily
214667359|NCT01561131|DIETARY_SUPPLEMENT|Soy protein|45g soy protein/d; dosage 15g soy protein x 3 daily
214667360|NCT01561131|DIETARY_SUPPLEMENT|Maltodextrin|48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
214667361|NCT01312194|PROCEDURE|Root canal therapy in one visit|Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
214882275|NCT03086486|DRUG|Linezolid|Scored 600mg tablets
214882276|NCT03086486|DRUG|Bedaquiline|100mg tablets
214882277|NCT03086486|DRUG|Placebo Linezolid|Scored 600 mg tablets
214882278|NCT00196326|DRUG|DR-1011|Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
214882279|NCT06004791|DRUG|Herombopag + CsA|Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
214882280|NCT06004791|DRUG|rhTPO combined with Herombopag + CsA|rhTPO (15000U, subcutaneous injection, once a day for 7 days, once a month for 3 months)，Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
214882281|NCT05435846|DRUG|Capmatinib|Given orally
214667362|NCT01312194|PROCEDURE|Root Canal Therapy in two-vist|The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
214882282|NCT05435846|DRUG|Trametinib|Given orally
214882283|NCT00808314|DRUG|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
214882284|NCT00808314|DRUG|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
214882285|NCT01190631|DEVICE|Acrysof IQ (SN60WF) IOL|Acrysof IQ (SN60WF) intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient. Unilateral (one eye only) implantation is planned.
214882286|NCT00676260|DRUG|Pioglitazone|Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks
214882287|NCT00676260|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
214667363|NCT04644718|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
214667364|NCT03730896|PROCEDURE|Dry needling|Dryneedling of the sternocleidomastoid muscles within a standard treatment approach of physical therapy
214882288|NCT03545204|OTHER|Kangaroo Mother Care Package|"The KMC package will include creation of KMC Champions from within the community, social mobilization to create awareness and its acceptance with families using powerful IEC tools such as docudrama, flip charts, pictorials in local languages; engagement of community and community leaders, capacity building of health care providers on Kangaroo mother care, essential newborn care ENC, policy dialogues with stake holders in the public and private sectors and delivery of a KMC kit  to the pregnant female by the Implementation team"
215045711|NCT05042648|DRUG|Buprenorphine patch|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest. The skin should be dry, clean, non irritated, non hairy (hair should be trimmed with scissors, not shaved), and without large scars.
215045712|NCT06259318|BEHAVIORAL|Kanasina Gulabi|Kanasina Gulabi is a theory-driven, educational-behavioral intervention designed to improve the quality of life and diabetes management among young adults living with type 2 diabetes in Mysore district, South India. In this intervention, young adults with type 2 diabetes were matched to non-specialist peer navigators -- trained young adult peers who were also managing type 2 diabetes -- and developed action plans to improve their physical and mental health outcomes. Intervention components included group education, mindfulness activities, self care activity tracking, and phone follow-ups to address knowledge gaps and misinformation about type 2 diabetes, build self-efficacy for type 2 diabetes-related self care activities, and provide emotional support for diabetes management.
215045713|NCT01178840|DEVICE|WC then FC2|4 uses of WC followed by 4 uses of FC2
215045714|NCT01178840|DEVICE|FC2 then WC|4 uses of WC followed by 4 uses of FC2
215045715|NCT04844125|DRUG|SHR-1209|SHR-1209
215045716|NCT04844125|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
215045717|NCT04946630|DEVICE|PreciseInhale|Three different settings of the medical device PreciseInhale will be used in the study; PreciseInhale Whole Lung Exposure, PreciseInhale Bronchial Bolus/Breath hold Exposure and PreciseInhale Alveolar Bolus/Breath hold Exposure.
215045718|NCT04946630|OTHER|Seretide Evohaler forte|Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.
215045719|NCT04515888|OTHER|PFDI-20 / PFIQ-7 questionnaires|PFDI-20 / PFIQ-7 questionnaires (one shot)
215045720|NCT05531552|DRUG|clinical pharmacy application|assessment clinical pharmacist in management of CAD and ICU patients.
215045721|NCT04458740|OTHER|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
215045722|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
215045723|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
215045724|NCT00041340|DRUG|imatinib mesylate|Given orally
215045725|NCT00041340|OTHER|laboratory biomarker analysis|Correlative studies
214292115|NCT03590041|BEHAVIORAL|Standardized SMA|Patients receiving the Standardized SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, delivered only by health educators. The Standardized SMA approach will be uniformly administered at each practice. Topics will be covered in a predetermined order and patients will not have a say in terms of what content they wish to cover. Patients receive the Standardized SMA approach if their practice is randomly assigned to the Standardized SMA arm. Practices are cluster-randomized to deliver a standardized or patient-driven group visit model.
214882289|NCT03545204|OTHER|Routine Standard Care|Routine Standard Care ( essential Newborn care )ENC
214882290|NCT04189601|DIAGNOSTIC_TEST|Complement measurements|Blood and urine tests to assess the complement activation state
214882291|NCT02088801|DEVICE|Airtraq, blade without channel for tracheal tube intubation|Intubation
214882292|NCT02088801|DEVICE|KingVision , blade without channel for tracheal tube intubation|
215045726|NCT01001351|DRUG|PRT-201|Applied topically during surgery.
215045727|NCT01001351|DRUG|Placebo|Applied topically during surgery
215045728|NCT01136525|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
214882293|NCT02088801|DEVICE|A.P. Advance, blade without channel for tracheal tube intubation|
214882294|NCT02088801|DEVICE|Macintosh|
214882295|NCT03394469|OTHER|collection|Blood, urinary and faecal samples
214882296|NCT01372748|OTHER|Standard CPR|30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
214882297|NCT01372748|OTHER|Continuous chest compressions|Continuous chest compressions during the first 6 minutes of the resuscitation.
214882298|NCT03744624|PROCEDURE|Laparoscopic liver resection|Laparoscopic liver resection for oncological purposes
214882299|NCT03744624|DEVICE|3D printing model|Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
215045729|NCT01466491|DRUG|Paracervical block technique with lidocaine|The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
215045730|NCT02727322|DRUG|Nitrofurantoin|Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
215045731|NCT02727322|DRUG|Placebo|Placebo
215045732|NCT05595200|DIAGNOSTIC_TEST|Level III portable sleep study|Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge
215045733|NCT05745649|OTHER|Resistance exercises|Resistance exercises
215045734|NCT05745649|OTHER|Ankle weights|Ankle weights
215045735|NCT04263844|DRUG|Intranasal dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
215045736|NCT04263844|DRUG|Intranasal Midazolam|subject will receive premedication with intranasal midazolam thirty minutes before induction
215045737|NCT04110106|OTHER|no intervention|All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H\&Y scale by a neurologist.
214667365|NCT01530139|BEHAVIORAL|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
215045738|NCT00772278|PROCEDURE|carotid artery stenting|carotid artery angiography, angioplasty and stenting
215045739|NCT00772278|PROCEDURE|carotid endarterectomy|open surgery including endarterectomy
215045740|NCT05510518|DIAGNOSTIC_TEST|oral glucose tolerance test (OGTT)|• The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.
214882300|NCT05919719|PROCEDURE|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Fluid expansion will be delayed while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard).~Our index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline, During abdominal compression, After the 10 to 20ml/kg crystalloid fluid expansion Abdominal compression : a sphygmomanometer will be inflated to a pressure of less than 10 mmHg and will be applied to the center of the patient's abdomen. Then, a gentle compression on the sphygmomanometer will be performed, calibrated at 22 - 26 mmHg according to the sphygmomanometer. The echocardiographic assessments will take place between 10 and 60 seconds after the start of the compression, which will therefore last less than a minute."
215045741|NCT05545592|OTHER|Low oestrogen dosage|From the second day of the menstrual cycle, femoston (estradiol tablets) were orally taken 2 mg q.d.. The endometrial thickness and serum oestrogen and progesterone levels were monitored on the 12th to 14th days of the menstrual cycle.
215045742|NCT03795649|DRUG|Tranexamic Acid|Imunomodulatory effect
215045743|NCT04457986|DRUG|Erector spina plane block (ESP)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
215045744|NCT04457986|DRUG|Modified thoracolumbar interfacial plane block (MTI)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
215045745|NCT04457986|DRUG|Intravenous patient controlled analgesia (IV-PCA)|Patient will receive intravenous patient controlled analgesia with tramadol
214667366|NCT01530139|BEHAVIORAL|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
214882301|NCT05991869|BEHAVIORAL|Point-of-care decision support intervention|"PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as high priority one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly."
214882302|NCT00134901|DRUG|Memantine|Memantine
214882303|NCT00134901|DRUG|placebo|placebo
214882304|NCT01666769|DRUG|Micafungin|4 mg/kg/day
214882305|NCT01666769|DRUG|Micafungin|8 mg/kg/day
214882306|NCT01666769|DRUG|Micafungin|Standard of care Dosing
214882307|NCT06651606|BEHAVIORAL|Progressive Ratio Training (PRT)|"Progressive ratio training (PRT) is used to prevent recurrence of the proxy response when extinction errors occur. PRT involves providing a reinforcer for the proxy response on a geometric progressive ratio (PR) scale. The schedule requirement will increase for the target response each time a reinforcer is delivered. For example, once a reinforcer is delivered on the PR-2 schedule, the requirement will increase to a PR-4, then to a PR-8, -16,~-32, etc."
214882308|NCT06651606|BEHAVIORAL|Differential Reinforcement of Alternative (DRA) Behavior with Extinction|In DRA with extinction, the proxy for problem behavior is placed on extinction and no longer produces reinforcement. The proxy for communication behavior produces reinforcement on a fixed-ratio 1 schedule of reinforcement.
214882309|NCT04766112|OTHER|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training
214882310|NCT04766112|OTHER|Group II|Group II will receive yang style Tai chi exercise which consist of 10 positions.
214882311|NCT03806010|PROCEDURE|Quantitative sensory testing|Quantitative sensory testing
214882312|NCT04863443|DEVICE|Ultrasound|ultrasound scanner to collect sonographic imaging data from the breast
214882313|NCT02268877|OTHER|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
214882314|NCT02268877|DEVICE|Ultrasound|An ultrasound will be performed by a radiology department technician
214882315|NCT03180281|DRUG|DPP4|sitagliptin phosphate 100mg qd
214882316|NCT03180281|DRUG|Insulin|Insulin Glargine or detemir 0.2U/kg qd
214882317|NCT03180281|DRUG|SU|Glimepiride 1-2mg qd
215045746|NCT05211349|OTHER|Dual-Task Timed Up and Go Test (cognitive)|It evaluates balance with a simultaneous cognitive and motor task. The cognitive task of the test is serial triple subtraction while the TUG test is a motor task. Balance performance will be recorded in seconds.
214667367|NCT01530139|BEHAVIORAL|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
214667368|NCT01530139|BEHAVIORAL|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
214882318|NCT03503695|DEVICE|Sterile acupuncture semi-permanent (ASP) gold needles|
214882319|NCT03296501|BIOLOGICAL|Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients|3 injections of ADRC: 1 intraspinal and 2 intrathecal
214882320|NCT04238650|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
214882321|NCT04238650|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
214882322|NCT05472246|DEVICE|Wearing a virtual reality headset|VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure
214882323|NCT02704169|OTHER|Spatially registered endoscopy|
214882324|NCT03347825|PROCEDURE|Robotic-assisted lobectomy using da Vinci Surgical System|Robotic-assisted lobectomy
214882325|NCT03347825|PROCEDURE|VATS (video assisted thoracic surgery)|VATS (video assisted thoracic surgery)
214882326|NCT03347825|PROCEDURE|Open lobectomy|Open lobectomy
214882327|NCT06581718|DEVICE|Eye Gaze Control|Eye Gaze Control - UGI and LGI endoscopy
214882328|NCT01457937|DRUG|Pegylated Interferon, Ribavirin, Boceprevir|"PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)"
214882329|NCT03188744|OTHER|Assessment of the pelvic floor function|Vaginal palpation and perineometry.
214882330|NCT03188744|OTHER|Questionnaire application|Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.
214882331|NCT03438994|DIAGNOSTIC_TEST|Play.Care|iPad based game to assess movement as the player interacts with the screen
214882332|NCT02631889|DEVICE|Transcollation technology|The use transcollation technology for dissection during lung surgery
214882333|NCT02631889|DEVICE|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
214882334|NCT04495569|BIOLOGICAL|recombinant anti-rabies human monoclonal antibody injection (SYN023)|The finished product of SYN023 is a mixture of two anti-rabies human monoclonal antibodies, CTB011 and CTB012 by equal quantity, containing 3.0 mg/mL active ingredients in both.
214882335|NCT04495569|BIOLOGICAL|Rabies Vaccine|The Chinese licensed Vero Cell Freeze-dried Rabies Vaccine was injected to Cohort B as per the vaccination precedure on Days 1, 4, 8, 15, 28 respectively.
214882336|NCT01807065|BIOLOGICAL|sipuleucel-T|Given IV
214882337|NCT01807065|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
214882338|NCT01807065|OTHER|laboratory biomarker analysis|Correlative studies
214882339|NCT00366743|PROCEDURE|Conventional LASIK|
214882340|NCT00366743|PROCEDURE|Wavefront-guided LASIK|
215045747|NCT05211349|OTHER|3-m Backward Walk Test|It is used to assess fall risk and balance. It is calculated in how many seconds an individual can walk backward a marked distance of 3 meters.
214882341|NCT04453540|DIAGNOSTIC_TEST|FilmArray PCR on respiratory samples|Molecular test performed on respiratory samples realized for microbiological routine testing as part of the care
214882342|NCT00356525|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
214882343|NCT00356525|DRUG|gemcitabine|1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
214882344|NCT00356525|DRUG|carboplatin|area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
214882345|NCT00356525|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
214882346|NCT04811937|DIAGNOSTIC_TEST|Computer-aided polypectomy decision support by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedbackwill be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp and the information to help the polypectomy.
214882347|NCT03026491|OTHER|Chewing evaluation|Each child was required to bite and chew a standardized biscuit while chewing video recording. Chewing function was scored with the Karaduman Chewing Performance Scale (KCPS).
214882348|NCT01295320|PROCEDURE|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
214882349|NCT02467140|DEVICE|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
214882350|NCT02467140|DEVICE|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
214882351|NCT00462904|DRUG|BPI|BPI will be give IV with an initial bolus given over 30 minutes and then a continuous infusion for the next 47.5 hours
214882352|NCT02325492|DRUG|Aramchol|
214882353|NCT02325492|DRUG|Placebo|
214882354|NCT02325492|DEVICE|Ultrasound|
214882355|NCT02947360|OTHER|Focused vascular ultrasound of the carotid arteries|Emergency physicians and a trained research sonographer will perform a focused vascular ultrasound of the carotids (FOVUS) in patients presenting to the emergency department with chest pain. The diagnostic test characteristics (sensitivity, sensitivity, negative predictive value, positive predictive value and likelihood ratios) for FOVUS carotid plaque height will be determined in relation to our primary outcome (30-day major adverse cardiac events)
214882356|NCT01494116|OTHER|900 mL of 0.9% Normal Saline|"The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered."
214882357|NCT01775826|OTHER|Measurement|Measured usual (day-to-day) behavior with body-worn sensors.
214882358|NCT01863914|DRUG|Rosuvastatin|Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
214882359|NCT02905058|DRUG|Ketoprofen|oral non-steroidal antiinflammatory drug
214882360|NCT02905058|DRUG|placebo|
214882361|NCT05820464|DIAGNOSTIC_TEST|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
214882362|NCT02263287|OTHER|LeSCoD scale|LeSCoD is a clinical scale
214667369|NCT01687673|DRUG|Temsirolimus|10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
214882363|NCT01101815|DRUG|Oral Naltrexone|50 mg/day-oral
214667370|NCT01687673|DRUG|Sorafenib:|200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
214882364|NCT01101815|DRUG|Naltrexone Implant|monthly-implant
214882365|NCT01101815|BEHAVIORAL|Group Drug Counseling Manual Driven|Given to both groups biweekly, weeks 2 - 48. Counseling will consist of three components: 1) giving advice, support and clinical management aimed to maintain abstinence; 2) adherence enhancement to encourage keeping appointments, taking ART medications as prescribed and getting treatment for associated problems; and 3) reviewing behaviors that are likely to spread HIV and other infectious diseases, and counseling on how to stop them.
214882366|NCT01187056|BEHAVIORAL|Training programme|2 x 2 hours of training (workshops)
214882367|NCT04307888|DEVICE|Perclose Proglide (Abbott)|Common Femoral Artery percutaneous access closure by means of Perclose Proglide device
214882368|NCT02738710|PROCEDURE|transumbilical incision|incision within umbilicus
214882369|NCT02738710|PROCEDURE|Infra umbilical incision|incision about 1 cm below umbilicus
214882370|NCT00017095|BIOLOGICAL|filgrastim|
214882371|NCT00017095|DRUG|cyclophosphamide|
214882372|NCT00017095|DRUG|docetaxel|
214882373|NCT00017095|DRUG|epirubicin hydrochloride|
214882374|NCT00017095|DRUG|fluorouracil|
214882375|NCT00017095|GENETIC|microarray analysis|
214882376|NCT00017095|OTHER|immunohistochemistry staining method|
214882377|NCT00017095|OTHER|laboratory biomarker analysis|
214882378|NCT00017095|PROCEDURE|biopsy|
214882379|NCT00017095|PROCEDURE|conventional surgery|
214882380|NCT00017095|PROCEDURE|neoadjuvant therapy|
214882381|NCT00017095|RADIATION|radiation therapy|
214882382|NCT02233439|DIETARY_SUPPLEMENT|Herbal galactagogue|
214882383|NCT02233439|DIETARY_SUPPLEMENT|Placebo|
214882384|NCT00365092|PROCEDURE|Insertion of tympanostomy tubes|
214882385|NCT04405830|PROCEDURE|Renal replacement therapy|Renal replacement therapy (RRT) refers to modalities of treatment that are used to replace the waste filtering functions of a normal kidney.
214667371|NCT02234622|BEHAVIORAL|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
214882386|NCT03510962|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.
214882387|NCT03510962|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
214882388|NCT03510962|DRUG|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
214882389|NCT03510962|OTHER|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
214882390|NCT03510962|OTHER|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention."
214882391|NCT03510962|OTHER|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
214882392|NCT05454670|PROCEDURE|Two-flap palatoplasty|Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured
214882393|NCT01900951|DRUG|Temozolomide|
214667372|NCT02234622|BEHAVIORAL|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
214882394|NCT01406444|DRUG|rhIGF-1|Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
214882395|NCT01406444|DRUG|Risedronate|Risedronate 35mg PO one time weekly
214882396|NCT01406444|DRUG|Placebo|Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
214882397|NCT01685840|OTHER|Usual Care|Usual Care
214882398|NCT01685840|DEVICE|Biomarker-guided care NT-proBNP|Device: NT-proBNP
214882399|NCT01119573|GENETIC|RNA analysis|
214882400|NCT01119573|GENETIC|microarray analysis|
214882401|NCT01119573|GENETIC|reverse transcriptase-polymerase chain reaction|
214882402|NCT01119573|OTHER|laboratory biomarker analysis|
214882403|NCT05056038|PROCEDURE|Lateral Quadratus Lumborum block|Local anesthetic may spread to the T6-L1 spinal nerves and paravertebral area by spreading through the lateral QLB to the transversus abdominis plane, and posteriorly via the anterior thoracolumbar fascia.
214882404|NCT05056038|PROCEDURE|Posterior Quadratus Lumborum Block|In posterior QLB, the local anesthetic can spread on the anterior and lateral cutaneous branches of T4-L1 spinal nerves by administration of the agent to the lateral interfascial triangle.
214882405|NCT03935438|OTHER|Cardiac rehabilitation|The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.
214882406|NCT01357148|DRUG|Sitagliptin Phosphate/Metformin HCl (JANUMET®)|Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
214882407|NCT03378752|PROCEDURE|HFJV|On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
214882408|NCT06124937|DRUG|Empagliflozin 10 MG|The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
214882409|NCT06124937|DRUG|Placebo|The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.
214882410|NCT04382287|PROCEDURE|Remin Pro® and MI Paste Plus®|Te toothastes were applied at home twice a day over the six anterior upper primary teeth
214882411|NCT03173287|PROCEDURE|Quantification of liver fibrosis|Procedure MRI and liver biopsy
214882412|NCT04210050|DEVICE|Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.|"In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time.~For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring."
214882413|NCT04210050|DIAGNOSTIC_TEST|Arterial blood gas (ABG) and serum bicarbonate level|Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
214882414|NCT04210050|DIAGNOSTIC_TEST|Overnight home oximetry and transcutaneous CO2 monitoring|will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
214882415|NCT04225910|DRUG|225Ac-PSMA|all the patients will receive 225Ac-PSMA RLT for 2 cycles. The dosage will be calculated according to 100KBq/kg body weight. The drug will be administered by vein injection.
214882416|NCT06017050|BEHAVIORAL|BullyDown|BullyDown is an 8 week, text messaging-based prevention program aimed to prevent bullying behaviors among middle school-aged youth. Message content is based upon the social-emotional learning model.
214882417|NCT06017050|BEHAVIORAL|Attention-matched control|The attention-matched control will receive the messages for the same number of days as the intervention. Content will talk about 'healthy lifestyle' topics, such as fitness and healthy social media use.
214882418|NCT05093764|DEVICE|VIV TAVR with BVF using TCEP|The insertion and retrieval of the SENTINEL device is performed at the time of the patients TAVR procedure in the same setting while they are sedated under moderate sedation or general anesthesia depending on the case. The device is inserted at the initiation of the procedure through 6F right radial artery access and the filters are positioned in the left common carotid artery and brachiocephalic artery. After deployment, the usual TAVR procedure is performed. At the conclusion of the procedure, the SENTINEL device is extracted and hemostasis is achieved at the radial access site in the usual fashion with patent hemostasis.
214882419|NCT04556786|BEHAVIORAL|Transitions of care|The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
214882420|NCT00598572|DRUG|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
215045748|NCT05211349|OTHER|Modified Four Square Step Test|It is a performance test that evaluates dynamic balance in stroke individuals with the ability to avoid obstacles and take steps in all directions. Balance performance is recorded in seconds.
214882421|NCT04928768|OTHER|Questionnaire|A validated questionnaire (five-point Likert scale) through 10 items developed by Lee et al 2018 is employed to measure the level of orthodontic treatment satisfaction in 10 items; overall satisfaction, tooth alignment, facial appearance, eating and chewing, confident smile and self-image, retention state, treatment duration, treatment costs, intention to recommend, and relief of previous concerns. Total satisfaction is calculated by averaging the Likert scores from the 10 items
214882422|NCT06179563|OTHER|On-Demand Telemonitoring|Patients assigned to the on-demand intervention group do not have to use the app at set time intervals but will be asked to use the app at their own discretion, in case of symptoms. This implies that patients have full control over their monitoring activities. Patients have the option to reach out to the hospital whenever they feel the need.
214882423|NCT03311750|DRUG|Panitumumab|6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
214882424|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 500 mg|500 mg tablet taken orally with one meal daily
214882425|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 1000 mg|1000 mg tablet taken orally with one meal daily
214882426|NCT04036110|OTHER|Placebo|1 tablet taken orally with one meal daily
214882427|NCT05056623|BEHAVIORAL|Dyadic pain management program|"Face-to-face part: The DPM will start with 20-30 minutes of physical exercise supervised by research assistant, followed by 20-minutes of pain management education. Communication skills regarding the practice of various pain management techniques by the participants and their caregivers will be taught. At the end of the session, the caregiver and research assistant will help the older adults to make portfolio entries on the activities of the day, to help them recall the various pain-relief methods learned in each class.~Home-based part: An exercise book will be given to guide them in performing exercises at home. It is recommended to perform 30 minutes of exercise, 3 times a week, at home and the more frequent the exercise time, the better.~All participants will join a WhatsApp group to receive teaching materials and videos of the physical exercises learned, for practice at home. The team will produce compact disc (CD) with the exercise video clips to the dyads for revision."
214882428|NCT05056623|OTHER|Usual care and pain management pamphlet|Usual care and pain management pamphlet
214882429|NCT05210010|DEVICE|CA-4F|"The study intervention is the CA-4F algorithm developed by Ensho Health.~The algorithm is a process for converting input parameters to a CA-4F Risk Score intended to facilitate clinical prioritization of patients suitable for follow-up investigation for ATTR-CM.~The algorithm is applied using the CA-4F Likelihood Estimator which encodes it in software and records its outputs. The CA-4F Likelihood Estimator is controlled through a graphical user interface called the CA-4F Controller.~The CA-4F Likelihood Estimator and its Controller are Class I medical devices in Canada registered under the Medical Device Establishment License of Ensho Health (license 16208)."
214882430|NCT04914234|DRUG|Atenolol Succinate Oral Tablet|Atenolol 50 mg
214882431|NCT04914234|DRUG|Metoprolol Succinate Oral Tablet|Metoprolol 100 mg
214882432|NCT00898573|DRUG|lapatinib ditosylate|
214882433|NCT00898573|GENETIC|fluorescence in situ hybridization|
214882434|NCT00898573|GENETIC|gene expression analysis|
214882435|NCT00898573|GENETIC|mutation analysis|
214882436|NCT00898573|GENETIC|polymerase chain reaction|
214882437|NCT00898573|GENETIC|reverse transcriptase-polymerase chain reaction|
214882438|NCT00898573|OTHER|cell sorting|
214882439|NCT00898573|OTHER|immunohistochemistry staining method|
214882440|NCT00898573|OTHER|laboratory biomarker analysis|
214882441|NCT01471730|DRUG|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
214882442|NCT01471730|DRUG|Saline solution|Normal saline will be administered to control patients.
214882443|NCT01471730|DRUG|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
215045749|NCT05211349|OTHER|Timed Up and Go Test|It is used to assess balance and functional mobility. The participant is asked to get up from the chair she/he is sitting in, walk the marked distance of 3 meters and return to her/his seat again. The elapsed time is recorded in seconds.
214882444|NCT03946280|PROCEDURE|conventional X-ray based Fluoroscopy|catheter tracking via conventional X-ray based Fluoroscopy
214882445|NCT03946280|PROCEDURE|low X-ray 3D navigation technique|catheter tracking via low X-ray 3D navigation technique
214882446|NCT03981692|OTHER|Consecutive dual task|8 weeks and 2 days per week, one session 45 min. Consecutive dual task creates the idea that it may provide more workable work without creating stress while doing secondary task during dual task.
214882447|NCT03981692|OTHER|Integrated dual task|8 weeks and 2 days per week, one session 45 min. Integrated dual task is a proven mode of work that has positive effects on geriatrics
214882448|NCT04252092|OTHER|Sensory training|15 session,20 minutes sensory training program
214882449|NCT04252092|OTHER|Electrical stimulation|15 session,20 minutes electrical stimulation program
214882450|NCT02925104|DRUG|INC280|
214882451|NCT00315796|DEVICE|Biophilic Nature Scene and Sound|
214882452|NCT00934687|DRUG|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
214882453|NCT00934687|OTHER|0.9% NaCl solution|0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
215045750|NCT05211349|OTHER|Berg Balance Test|It consists of 14 items and evaluates dynamic balance and functional mobility in stroke. The maximum score is 56. Higher scores indicate better balance.
215045751|NCT03886948|DRUG|LY3074828|Administered subcutaneously (SC)
215045752|NCT03886948|DEVICE|Pre-filled syringe (PFS)|PFS used to administer LY3074828
215045753|NCT03886948|DEVICE|Autoinjector (AI)|AI used to administer LY3074828
215045754|NCT01139541|BEHAVIORAL|Social walking intervention|In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
215045755|NCT00658489|BEHAVIORAL|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
215045756|NCT05703217|PROCEDURE|classical physical therapy with physiotherapy.|C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds. In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.
214882454|NCT03612349|BEHAVIORAL|Experimental Tobacco Marketplace Task|Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
214882455|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Low dose：DDO-3055 tablets for 7 days or Placebo for 7 days
214882456|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Medium dose：DDO-3055 tablets for 7 days or Placebo for 7 days
214882457|NCT04775615|DRUG|DDO-3055 tablets；Placebo|High dose：DDO-3055 tablets for 7 days or Placebo for 7 days
214882458|NCT04428450|DEVICE|Deprexis|CBT-based, integrative online self-help program
214882459|NCT01322230|OTHER|Control|Multimedia Control
215045757|NCT01123148|DEVICE|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
215045758|NCT05367193|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy for vitreoretinal disease in highly myopic eyes
214882460|NCT01322230|OTHER|WISEMD Original|Current WISEMD
215045759|NCT05367193|DEVICE|NGENUITY® 3D Visualization System (Alcon, TX, USA)|Injection of ICG to stain internal limiting membrane
215045760|NCT00355030|DRUG|somatropin|0.05 mg/kg/day
215045761|NCT00355030|DRUG|leuprorelin|11.25 mg/3 months
214882461|NCT01322230|OTHER|Social Networking|Social networking feature
214882462|NCT01322230|OTHER|Social Networking plus Emotional Design|social networking features plus user interface enhancements
214882463|NCT03239847|OTHER|EndoPhys Sheath and Radial Arterial Line|
214882464|NCT03239847|OTHER|EndoPhys Sheath|
214882465|NCT03364842|DRUG|Furosemide|Administering furosemide
214882466|NCT03437070|DRUG|Trabectedin|Administered intravenously per protocol on Day 1 for 21-day cycles.
214882467|NCT03437070|DRUG|Doxorubicin|Administered intravenously per protocol on Day 1 for 21-day cycles.
214882468|NCT03437070|DRUG|Olaratumab|Administered intravenously per protocol
214882469|NCT02195661|DIETARY_SUPPLEMENT|Melatonin|
214882470|NCT02195661|DRUG|Chloral Hydrate|
214882471|NCT03382587|DRUG|Aflibercept (Eylea, BAY86-5321)|"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"
214882472|NCT02077361|GENETIC|rAAV2.REP1 vector|No additional details needed.
214882473|NCT03190811|BIOLOGICAL|Anti-PD-1 plus DC-CIK|"Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.~DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible."
214882474|NCT03190811|BIOLOGICAL|Anti-PD-1 alone|Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
214882475|NCT04272424|PROCEDURE|laparoscopic mesh fixation|laparoscopic mesh fixation by non fixation,tacker and histoacryl
214882476|NCT02884570|OTHER|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
214882477|NCT01464632|DEVICE|EPIK™ uni-compartmental knee|This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
214882478|NCT05937737|BEHAVIORAL|Type 2 Diabetes Diet Modification|A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.
214882479|NCT03323242|DEVICE|LigaSure|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
214882480|NCT03323242|DEVICE|Harmonic Ultrasonic dissector|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
214882481|NCT00613652|DRUG|AZD4877|10 mg IV (3 weeks treatment 1 week rest)
214882482|NCT06006429|OTHER|Numerical dental impression by intraoral scanner|Intervention consists in an 3D intra oral representation of the oral cavity
214882483|NCT03637426|OTHER|Laser|GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours.
214882484|NCT03637426|OTHER|nano-hydroxyapatite|The GnHAP volunteers were submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications
214882485|NCT03637426|OTHER|Laser + nano-hydroxyapatite|GLASERnHAP first received laser application and subsequently the application of nanohydroxyapatite according to the manufacturer's recommendations.
214882486|NCT03637426|OTHER|PLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
214882487|NCT05017961|DEVICE|Autograft|An autograft bone will be harvested from proximal tibia or posterior superior iliac crest. First the bony landmarks of the posterior iliac crest or proximal tibia are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. After 1 cm skin incision and gentle dissection of subcutaneous soft tissue, the bone harvesting device inserted through the skin and subcutaneous tissues until it reaches the cortical bone. Then, manual pressure is used to position the bone harvesting device against the dense cortical bone. A battery-powered power instrument is then will be used to drill the harvesting device into the medullary cavity. After the harvesting device insertion the cancellous strips of bone will be harvested and applied to the fracture site gap.At the conclusion of autograft bone harvesting procedure, the wound will be closed with 3-0 Nylon and a sterile dressing will be applied to the harvest site.
214882488|NCT05017961|DEVICE|Allograft only|The jar containing allograft tissue and cryopreservation solution will be placed in a sterile basin containing a warm (35°C to 39°C; 95°F to 102.2°F) sterile irrigant (Normal saline or 5% Dextrose in Lactated Ringer's Solution). The jar containing the allograft will remain in this solution until the contents of the jar flows freely upon inversion. The jar will be removed from the warm solution once free-flowing. Sterile gauze or the optional strainer will be used to decant the cryopreservation solution into a waste container. 5% Dextrose in Lactated Ringer's Solution will be added to the indicated fill line to immerse the allograft tissue. The cap will be replaced and inverted twice to suspend tissue until ready for use. 5% Dextrose will be decanted in Lactated Ringer's Solution prior to use. Implant will be used within 2 hours of thawing.
214882489|NCT05017961|DEVICE|Allograft combined with BMAC|A bone marrow aspiration kit will be used for bone marrow aspiration. First the bony landmarks of the posterior iliac crest and sacroiliac joint are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. Then, the bone marrow aspiration trochar and needle are percutaneously inserted through the skin and subcutaneous tis- sues until it reaches the posterior iliac crest. The trajectory of the needle will be parallel to the iliac crest, or perpendicular to the Anterior Superior Iliac Spine (ASIS) or Posterior Superior Iliac Spine (PSIS), depending on the harvest site used. After the trochar is inserted into the posterior iliac crest but prior to aspiration, 1 mL of heparin (1,000 U/mL) will be preloaded into the syringe. Approximately 60 mL of bone marrow will be aspirated, which requires the use of two 30-mL syringes. At the conclusion of BMAC harvesting, a sterile dressing will be applied to the harvest site.
214882490|NCT00420732|BIOLOGICAL|HyperAcute-Lung Cancer Vaccine|300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
214882491|NCT02892552|RADIATION|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
214882492|NCT02892552|RADIATION|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
214882493|NCT03500380|DRUG|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
214882494|NCT03500380|DRUG|Lapatinib|Lapatinib 1250 mg orally once daily during each 21-day cycle.
214882495|NCT03500380|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 orally daily on Days 1-14 of each 21-day treatment cycle.
214882496|NCT00537511|DRUG|Pomalidomide|
214882497|NCT00537511|DRUG|Cisplatin|
214882498|NCT00537511|DRUG|Etoposide|
214882499|NCT06141343|DIETARY_SUPPLEMENT|Veillonella atypica FB0054|Veillonella contains Veillonella atypica FB0054 as the active ingredient with microcrystalline cellulose and hypromellose as excipients. The two doses are 15 billion cfu (high dose) and 7.5 billion cfu (low dose). Placebo capsules contain microcrystalline cellulose and hypromellose. Both Veillonella and placebo are encapsulated in acid-resistant capsules to improve delivery to the large intestine, which participants will take orally at home on a daily basis for four weeks.
214882500|NCT06141343|OTHER|Placebo|Placebo will be given as the non-active study control
214882501|NCT00004338|DRUG|zinc acetate|
214882502|NCT00103714|DRUG|denufosol tetrasodium (INS37217)|
214882503|NCT04196647|OTHER|Home titration|Patients have their initial dosage titration of duodopa done in their own home, supported by one visit from nursing staff, and one video consultation a day
214882504|NCT01252277|DRUG|Lovaza™|4 capsules daily for 6 months
214882505|NCT00457483|DRUG|hydrochlorothiazide|12.5 mg once-a-day
214292116|NCT03590041|BEHAVIORAL|Patient-driven SMA|Patients receiving the Patient-driven SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, but patients are in control of time spent and order of the topics. The Patient-driven SMA will be delivered by a multidisciplinary team consisting of a Health Educator, medical provider, Behavioral Health Professional, and a diabetes peer mentor. Patient-driven SMAs may be delivered differently at each practice, as patients choose the topics that are most important to spend the most time on. All topics will be covered, but the order and time spent is up to the group. Patients receive the Patient-driven SMA approach if their practice is randomly assigned to that arm. Practices are cluster-randomized to deliver a standardized or patient-driven SMA model.
214882506|NCT00457483|DRUG|valsartan, 80 mg once-a-day|80 mg once-a-day
214882507|NCT04535687|DRUG|Fluzoparib|Fluzoparib
214882508|NCT03140787|DRUG|Nasal Spray of Lidocaine HCL|This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
214882509|NCT03140787|DRUG|Infiltration injection of Lidocaine HCL|This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
214882510|NCT02771470|DRUG|Probiotics|Microbial composition using probiotic
214882511|NCT02771470|DRUG|placebo|Microbiota modulation using placebo
214882512|NCT04940637|DRUG|niraparib and dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
214882513|NCT02802904|OTHER|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
214882514|NCT02802904|OTHER|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
214882515|NCT02802904|OTHER|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
214882516|NCT03687840|DIAGNOSTIC_TEST|gait analysis|Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
214882517|NCT02447146|OTHER|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
214292117|NCT05746754|RADIATION|CSI|30 Gy in 10 fractions to CNS
214882518|NCT02447146|OTHER|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
214882519|NCT04603326|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
214882520|NCT04566055|DEVICE|AlloSure|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
214882521|NCT05902338|OTHER|Music|"L400 Over Ear Music Headset Glowing Cat Ear Headphones 7 branded headphones will be used for musical measurements (70-80 bpm music)."
214882522|NCT06277765|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
214882523|NCT06277765|OTHER|placebo|Placebo
214882524|NCT00246324|DRUG|Interferon beta 1a, oral doxycycline|Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
215045762|NCT00983866|BEHAVIORAL|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
215045763|NCT05124717|DRUG|Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
215045764|NCT05124717|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orallyn with 240 mL of water.
215045765|NCT05143333|OTHER|DANA app|The Defense Automated Neurobehavioral Assessment (DANA) is a battery of cognitive tests delivered via an electronic tablet or smartphone. The platform allows higher temporal precision and frequency of measurement than traditional neuropsychological methods while including previously standardized cognitive tests and allowing individuals to repeatedly self-administer the battery in their own homes without examiner supervision. Hence, the DANA battery bypasses several of the major limitations associated with in-person cognitive exams.
214882525|NCT06181149|BEHAVIORAL|Delaying speech initiation|This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use transcranial magnetic stimulation to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
214882526|NCT06181149|BEHAVIORAL|Auditory errors and pre-speech auditory modulation|This intervention will examine the contributions of auditory errors to pre-speech auditory modulation. Participants will receive auditory perturbations while speaking, and we will collect their brain activities throughout the study.
214882527|NCT06181149|BEHAVIORAL|Contributions of the speech premotor cortex to pre-speech auditory modulation|This intervention will examine the effects of stimulation of the left ventral premotor cortex on pre-speech auditory modulation. Participants will receive electrical stimulation while speaking.
214882528|NCT06181149|BEHAVIORAL|Delaying auditory feedback|This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use delayed auditory feedback to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
214882529|NCT05578599|DEVICE|Swiftsure CCS device|The Swiftsure CSS device will be used twice per patient in addition to standard oral health care procedures among intubated adult patients undergoing mechanical ventilation in the ICU.
214882530|NCT01284452|DRUG|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
214292118|NCT01967121|DEVICE|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
215045766|NCT00987285|BEHAVIORAL|CASM +|Computer Assisted Self Management plus Social Support
215045767|NCT00987285|BEHAVIORAL|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
215045768|NCT05446935|PROCEDURE|HITOC|Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2).
215045769|NCT00593060|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
215045770|NCT00593060|DRUG|Cetuximab|One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
214292119|NCT01967121|OTHER|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
214292120|NCT01538420|DRUG|GLPG0492|Oral solution
214292121|NCT01538420|DRUG|Placebo|Placebo oral solution
214292122|NCT02289898|DRUG|Demcizumab|administered intravenously
214292123|NCT02289898|DRUG|Abraxane®|administered intravenously
214292124|NCT02289898|DRUG|gemcitabine|administered intravenously
214292125|NCT02289898|DRUG|Placebo|
214882531|NCT01284452|DRUG|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
214292126|NCT03353493|BEHAVIORAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams \& Teasdale (2013).
214292127|NCT03353493|OTHER|TAU|Treatment as usual (TAU)
214292128|NCT03634449|DEVICE|i-gel|i-gel is a supraglottic airway devices with a gastric suction channel.
214292129|NCT03634449|DEVICE|endotracheal tube|Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
214292130|NCT00002862|DRUG|perillyl alcohol|
214882532|NCT04267432|DIETARY_SUPPLEMENT|Placebo|Blank
214882533|NCT04267432|DIETARY_SUPPLEMENT|TCI633|Probiotics
214882534|NCT04267432|DRUG|Type 2 collagen|Positive control group
214882535|NCT02547688|DEVICE|Nasal High Flow|
214882536|NCT02006732|DRUG|olodaterol|fixed dose combination
214882537|NCT02006732|DRUG|tiotropium|fixed dose combination
214882538|NCT02006732|DRUG|placebo|
214882539|NCT02505737|BEHAVIORAL|TH-CBT|Telephone-Based Cognitive Behavioral Therapy (TH-CBT). A 10-session treatment protocol that incorporates behavioral activation, thought monitoring and restructuring, relaxation training, worry control, sleep hygiene, and caregiver psychoeducation and support
214882540|NCT02505737|OTHER|Enhanced Usual Care|Community-based treatment as usual and supplemental reading material
214882541|NCT00321178|DRUG|SR4 - switch to CR4|switch to oral treatment after 4 weeks SR 'standard' therapy
214882542|NCT04936711|DEVICE|Resteck Shiatsu Neck and Back Massager|back massager device sold on the market that can readily be purchased online or in store
214882543|NCT04936711|DRUG|Marcaine|Marcaine spray at incision site after closure
214882544|NCT03899246|DRUG|Eight Percent Topical Capsaicin|See arm description
214882545|NCT02649569|DEVICE|Monitoring Device|Wear activity monitor
214882546|NCT02649569|OTHER|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
214882547|NCT00690066|DRUG|PROCHYMAL®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
214882548|NCT00690066|DRUG|Placebo|Intravenous infusion of excipients of PROCHYMAL®
214882549|NCT03732430|DRUG|IBI308|A humanized anti-PD-1 monoclonal antibody
214882550|NCT05401227|DRUG|Ketamine|Ketamine during an MRI
214882551|NCT05401227|DRUG|Ts-134|4 days of TS-134 20 mg
214882552|NCT05401227|DRUG|Placebo|4 days of placebo TS-134
214882553|NCT05794698|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
214882554|NCT02358512|OTHER|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
214882555|NCT04342195|PROCEDURE|Blood draw|Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.
214882556|NCT03893643|OTHER|no intervention|no intervention in an observational study
214882557|NCT02285088|DRUG|GBT440|GBT440 will be administered as oral capsules
214882558|NCT02285088|DRUG|Placebo|Matching placebo will be administered as oral capsules
214882559|NCT01180426|DRUG|CHR-2797|120mg once daily oral for 48 weeks
214882560|NCT05497791|DEVICE|transcranial laser stimulation associated with NMES|"The cluster was applied on the skin covering the head. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.~The NMES was started, after 5 minutes the transcranial laser stimulation (active or placebo-treatment) was started. Then, the therapies were combined. After finishing the transcranial laser stimulation (active or placebo-treatment), the NMES was continued until completing 30 minutes."
214882561|NCT05497791|OTHER|Placebo|The transcranial laser was applied identically for all groups, but the null dose was used in the placebo group. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.
214882562|NCT04604613|PROCEDURE|Bilateral Salpingectomy with Oophorectomy|Undergo standard of care bilateral salpingo-oophorectomy
214882563|NCT04604613|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214882564|NCT04604613|PROCEDURE|Hysterectomy|Undergo standard of care hysterectomy
214882565|NCT04604613|OTHER|Laboratory Biomarker Analysis|Correlative studies
214882566|NCT04604613|PROCEDURE|Lymph Node Mapping|Undergo sentinel lymph node mapping
214882567|NCT04604613|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node biopsy
214882568|NCT03448497|OTHER|Non-interventional|Non-interventional
214882569|NCT02274831|OTHER|Email Reminder of need to follow up with primary physician|
214882570|NCT03516513|BEHAVIORAL|Problem Solving Therapy as Usual|Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.
214882571|NCT03516513|BEHAVIORAL|Assisted Problem Solving Therapy|Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
214882572|NCT07134998|DRUG|HRS-6093|HRS-6093
214882573|NCT07134790|DRUG|VE818|VE818, is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women
214882574|NCT07134790|DRUG|Placebo|Enteric capsules filled with approximately 400mg of microcrystalline cellulose (bulking agent)
214882575|NCT07134790|DRUG|Oral Vancomycin|Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation
214882576|NCT06854757|BEHAVIORAL|RIVER|RIVER is a peer grief support process intervention developed by Peer Support Community Partners.
214882577|NCT06854757|BEHAVIORAL|Enhanced care as usual|The enhanced care as usual condition involves a psychoeducational booklet developed by What's Your Grief, as well as a list of local grief resources.
214882578|NCT01682395|PROCEDURE|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
214882579|NCT01682395|PROCEDURE|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
214882580|NCT01682395|PROCEDURE|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
214882581|NCT01098487|DRUG|Eltrombopag olamine|Thrombopoietin receptor agonist
214882582|NCT00345631|OTHER|Manual Compression|Manual compression
214882583|NCT00345631|DEVICE|Vascular Closure Device|Investigational vascular closure device
214882584|NCT05866185|BEHAVIORAL|Therapy|The standard of care procedures for adults with clinically elevated anxiety and/or depression from their mental health provider.
214882585|NCT05866185|BEHAVIORAL|Therapy + Adhere.ly|Participants receive therapy as usual enhanced with a simple, HIPAA-compliant, web-based application to help mental health providers implement homework during therapy for adults with elevated anxiety and/or depression. The three major components of the app help providers to (1) Practice interactive, digitized therapeutic exercises with patients in-session; (2) Remind patients to practice exercises for homework, and (3) Review homework during the next session.
214882586|NCT03294720|PROCEDURE|Bio-ACL|ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
214882587|NCT03294720|DEVICE|amnion wrap and BMAC|amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
214882588|NCT00751556|DRUG|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
215045771|NCT02877069|DEVICE|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
215045772|NCT06495957|OTHER|Electroacupuncture group|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes.
214292131|NCT02118389|DIETARY_SUPPLEMENT|Glucerna|Glucerna 52g meal replacement
214292132|NCT04788888|DEVICE|Navitor Transcatheter Aortic Valve and FlexNav Delivery System|"For traditional application, the Navitor valve is indicated for transcatheter delivery in patients with symptomatic severe native aortic stenosis who are intermediate or low surgical risk.~For the valve-in-valve application, the Navitor valve is indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve.~Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve and FlexNav Delivery system"
214882589|NCT00751556|DRUG|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
214882590|NCT06259188|DEVICE|Respiratory Muscle Training Device|In the both groups the initial pressure load will be set to the resistance level corresponding to the 40% of the MIP and MEP measurement. Participants will be asked to rest following 5 breathing cycles and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. In breathing exercise device group participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. In IMT+EMT group, patients will be able to practice different to device. As the progression progresses, the perceived exertion level will be increased by 5-10% every week, to be in the range of 4-6 according to the Modified Borg scale.
214882591|NCT06259188|DEVICE|Personalized Breathing Exercise Device|Personalized Breathing Exercise Device
214882592|NCT00567905|DIETARY_SUPPLEMENT|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
214882593|NCT01281605|BEHAVIORAL|Active titration algorithm|Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(\<110mg/dl).
214882594|NCT01281605|BEHAVIORAL|Usual titration algorithm|All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG\>=110mg/dL, and by 4 IU/day if the FPG\>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG \< 70 mg/dL.
215045773|NCT06495957|OTHER|Micro-acupuncture group|After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes. Electrical stimulation is applied briefly for the first 30 seconds.
215045774|NCT01049373|DRUG|HDC|(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
215045775|NCT01049373|DRUG|Placebo solution|10 drops, t.i.d, 15 weeks
215045776|NCT02061475|DRUG|Lidocaine Patches|
215045777|NCT01125410|DRUG|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
214292133|NCT02363517|DRUG|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
214882595|NCT07134829|BEHAVIORAL|Stroboscopic Visual Conditions|Participants will perform walking trials under three visual conditions: high-frequency stroboscopic glasses, low-frequency stroboscopic glasses, and no-glasses control. Each participant will complete three 5-meter walking trials per condition, with the order of conditions randomized. Gait parameters will be recorded using the GAITRite walkway system, and muscle activity will be measured using surface electromyography.
214882596|NCT07133477|DIETARY_SUPPLEMENT|Omega 3-9-11|Fish oil capsules containing a fish oil concentrate from North Atlantic fish species containing EPA / DHA / cetoleic acid and gondoic in controlled amounts.
214882597|NCT07133477|DIETARY_SUPPLEMENT|Placebo|Corn oil capsules
214882598|NCT04936399|BIOLOGICAL|Nivolumab|Participants will receive Nivolumab after prior chemotherapy as part of an early access to medicines scheme (EAMS) program in the United Kingdom (UK)
214882599|NCT03591497|OTHER|Virtual Reality|As described in Experimental arm description.
214882600|NCT06270303|PROCEDURE|Access flap & surgical debridement|Following surgical exposure, roots are carefully debrided.
214882601|NCT06270303|PROCEDURE|Application of bone substitute material (BioOss Collagen)|Following surgical debridement, the bone substitute material is applied to the furcation defect.
214882602|NCT00447993|COMBINATION_PRODUCT|Low Dose NT-501|Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery
214882603|NCT00447993|COMBINATION_PRODUCT|High Dose NT-501|High Dose NT-501 Implanted in study eye and fellow eye received sham surgery
214882604|NCT04302012|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and/or after administration of mydriatic agent
214882605|NCT04302012|DRUG|Mydriatic Agent|Subjects may be administered mydriatic medication to dilate their pupils.
214882606|NCT05957744|PROCEDURE|Colorectal surgery|Right hemicolectomy, left colectomy, total colectomy, anterior resection
214882607|NCT03161340|DRUG|Rapamycin|Patients will take Rapamycin 2 days before IVF until 15 days after IVF
214882608|NCT06604091|OTHER|Treatment protocol|Treatment options for ovarian stimulation include long-acting and antagonist regimens and other ovulation induction regimens. Options for frozen embryo transfer include natural protocols, mild ovarian stimulation regimens, hormone replacement therapy (HRT) regimens, and down-regulated combined HRT regimens. The treatment regimen is refined in the above protocol. The treatment of patients follows the principles of real-world clinical practice.
214882609|NCT06692686|DEVICE|Pre-fabricated (PF) ankle-foot orthosis (AFO)|These pre-manufactured orthoses are customized to fit each patient. These devices can help to distribute weight evenly along the foot, but do not offer much opportunity for adjustment to a patient's specific needs. These AFOs achieve ankle motion through material deflection and lack a single point of articulation.
214882610|NCT06692686|DEVICE|Carbon-strut (CS) ankle-foot orthosis (AFO)|These AFO designs are built from a custom mold of the patient's affected limb for a more individualized fit. It includes a solid ankle design and achieves ankle motion through material deflection and lacks a single point of articulation.
214882611|NCT06692686|DEVICE|Multifunctional articulating (MA) ankle-foot orthosis (AFO)|These AFO designs are also built from a custom mold of the patient's affected limb, but these orthoses have a true articulation at the ankle to provide controlled ankle movement in a range determined appropriate by the orthotist through gait analysis.
214882612|NCT05186675|PROCEDURE|superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
214882613|NCT01885195|DRUG|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
215045778|NCT01125410|DRUG|Clindamycin|vaginal cream, 2%, once daily for 7 days
214882614|NCT01770717|OTHER|Spatial Frequency Domain Imaging|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
214292134|NCT05554094|DRUG|Psilocybin|Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.
214292135|NCT03071770|DRUG|ivosidenib (AG-120)|A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
214882615|NCT03677154|DRUG|Mosunetuzumab Intravenous (IV)|Participants in cohorts A and B will receive IV mosunetuzumab.
214882616|NCT03677154|DRUG|Mosunetuzumab Subcutaneous (SC)|Participants in Cohort C will receive SC mosunetuzumab.
214882617|NCT03677154|DRUG|Polatuzumab Vedotin|Participants in Cohort C will receive IV polatuzumab vedotin.
214882618|NCT03677154|DRUG|Tocilizumab|Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
214882619|NCT01429116|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
215045779|NCT06300177|DRUG|D-1553 Tablet|D-1553 is a KRAS inhibitor.
215045780|NCT06300177|DRUG|Docetaxel injection|Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.
215045781|NCT05531006|OTHER|retrospective cohort study|retrospective patient file review
215045782|NCT02960633|DEVICE|Corail with collar.|
214882620|NCT05808075|OTHER|NovaProTM Fill Universal Dental Composite|NovaProTM Fill Universal ,Nanova product
214882621|NCT02836938|OTHER|Collection of exhaled breath volatile organic compounds|
215045783|NCT02960633|DEVICE|Corail without collar.|
215045784|NCT04009239|BEHAVIORAL|Time Restricted Feeding|Consuming energy during a short interval during the day
215045785|NCT00339040|BIOLOGICAL|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
214667373|NCT06970912|DRUG|Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy|"Patients receive 4 cycles of neoadjuvant dalpiciclib (125 mg orally, days 1-21 of 28-day cycles) combined with an aromatase inhibitor (letrozole/anastrozole/exemestane). Post-surgery treatment is guided by ctDNA status: （1）ctDNA-negative at baseline and post-neoadjuvant, with post-op Ki67 ≤10% :Continue dalpiciclib + endocrine therapy (ET) for 2 years； （2）ctDNA-positive → negative, or persistently ctDNA-negative with post-op Ki67 \>10% :Randomized 1:1 to:~* Arm B1: Dalpiciclib + ET for 2 years.~* Arm B2: Adjuvant chemotherapy (investigator's choice) → dalpiciclib + ET for 2 years；（3）Persistently ctDNA-positive or ctDNA-negative → positive:~Mandatory adjuvant chemotherapy → dalpiciclib + ET for 2 years. Premenopausal women undergo ovarian suppression with LHRH agonists."
214667374|NCT06970912|DRUG|Taxane-Based Neoadjuvant Chemotherapy|Patients receive 4 cycles of taxane-based neoadjuvant chemotherapy (e.g., paclitaxel 80 mg/m² weekly or docetaxel 75-100 mg/m² triweekly) before surgery. Post-surgery adjuvant chemotherapy (physician's choice) may be administered. This arm serves as the control group for comparing standard chemotherapy efficacy.
214667375|NCT00584662|DRUG|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
214667376|NCT01199341|DRUG|AZD1981|100 mg per oral, twice daily for 14 days
214667377|NCT01199341|DRUG|Warfarin|10 x 2.5 mg per oral, once daily at day 1 and day 15
214667378|NCT01199341|DRUG|AZD1981|4 x 100 mg per oral, twice daily for 14 days
214667379|NCT02453841|DRUG|Oxymetazoline|
214667380|NCT06011486|COMBINATION_PRODUCT|Lymphocyte infusion (ImmuneCellVir-I)|Infusion of donor CMV specific cells into patients eligible to the trial
214667381|NCT05012566|DEVICE|Juvederm|"* Juvederm Volbella: 15mg/ml, it is injected 1.5ml per patient per treatment (a total of 3ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Volifit: 17.5mg/ml, it is injected 3ml per patient per treatment (a total of 6ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Voluma: 20mg/ml, it is injected 5ml per patient per treatment (a total of 10ml per patient split in 2 treatment sessions at a 4 months interval)"
214667382|NCT05012566|DRUG|Vistabex|Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
214667383|NCT02291159|DEVICE|DNHS ® (Dry Needling for Hypertonia and Spasticity)|Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
214882622|NCT03692390|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
214882623|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
214882624|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
214882625|NCT02874209|OTHER|sodium MRI|
214882626|NCT06262230|BEHAVIORAL|Online Inclusive Companionship Intervention|After prior intervention, professionals will conduct a lecture for ordinary children, which includes basic knowledge of ASD and communication skills with ASD children. These ordinary children will be paired with ASD children then. The entire intervention including 12 sessions will last for 3 months. Researchers will prepare a series of themes that the ASD children could choose, and the ordinary children need to ask their paired ASD children what activities they want to choose before each session. Then, they will carry out this entertainment online together through Tencent WeMeet. A researcher will supervise online at the same time and record the communication through instant video. The Researcher will turn off the video and sound throughout the process and will not intervene in the conversation between the ASD children and ordinary children except for special circumstances.
214882627|NCT04616547|OTHER|Questionnaire Administration|Ancillary studies
214882628|NCT04616547|RADIATION|Tin Sn 117m Pentetate|Given IV
214882629|NCT03791047|OTHER|Balance Analysis|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
214882630|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction with lateral extra articular tenodesis|Anatomical single bundle ACLR with modified Lemiere technique
214882631|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction only|arthroscopic anatomical single bundle ACL Reconstruction
214882632|NCT00642681|DRUG|Technosphere Insulin|Technosphere® Insulin (TI) Inhalation Powder, prandial
215045786|NCT00339040|OTHER|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
215045787|NCT04602143|DRUG|Testosterone gel|Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
215045788|NCT05399927|OTHER|Music Intervention|The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
215045789|NCT03920501|BEHAVIORAL|Tele-Critical Care|Daily multidisciplinary rounds with a board certified physician through tele-critical care focusing on: 1) diagnosis; 2) active problems; and 3) therapeutic goals. In addition, the management of health care quality indicators will be conducted by a specially trained (Science of Improvement) board-certified intensive care physician.
215045790|NCT00003312|RADIATION|iodine I 125|
215045791|NCT02135627|DRUG|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
215045792|NCT02135627|OTHER|Current standard therapy|
214667384|NCT02291159|DEVICE|Sham Dry Needling|Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
214667385|NCT05747404|DIAGNOSTIC_TEST|Echocardiography|\- Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume
214667386|NCT01430247|OTHER|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
214882633|NCT04487951|OTHER|Pro BNP , Vitamin D|This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.
215045793|NCT05069727|PROCEDURE|Regular Protocol with advanced carbohydrate counting|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD~* Finetune ICR~* Target 100 or 110 mg/dl~* AIT: 2-3 hour~* Insulin Bolus for meal (advanced carb counting)~* The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~* Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use)."
215045794|NCT05069727|PROCEDURE|Simplified Protocol with fixed carbohydrate content|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD \>60)~* Target 100 mg/dl~* AIT: 2 hours~* Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~* The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits."
215045795|NCT06101004|DEVICE|CVA-Flow|CVA-FLOW Software Device is indicated for the detection of Stroke and LVO in patients with suspected stroke.
215045796|NCT02961270|DRUG|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
214667387|NCT01944215|DIETARY_SUPPLEMENT|Meal|effect of meal
214882634|NCT06122376|DEVICE|U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
214882635|NCT06122376|DEVICE|Soft Manual Toothbrush|Twice daily brushing for two minutes with fluoride toothpaste
214882636|NCT02653430|PROCEDURE|Sleeve gastrectomy|"After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons."
214882637|NCT00509795|BIOLOGICAL|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
214667388|NCT01944215|OTHER|Exercise|effect of exercise
214667389|NCT01944215|RADIATION|Sestamibi|reduce radiation dose
214882638|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
214882639|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
214882640|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
214882641|NCT00656266|DRUG|mycophenolate mofetil|immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept
214882642|NCT00656266|OTHER|placebo medication|medication that looks like mycophenolate mofetil
214882643|NCT05006547|OTHER|Electromyograph Biofeedback training of the peroneal muscle|The exercise will be performed with the subject sitting in front of a computer monitor, on an elevated chair, and his feet will be in the air. The examiner will ask the subject to perform a maximum contraction of the paronal muscles, in an open kinematic chain. After reference, the subject will begin a five-minute practice. The practice will be divided into rounds of: eight seconds of muscle work and 15 seconds rest.
214882644|NCT01782430|PROCEDURE|- standard oxygenation|
214882645|NCT02296931|OTHER|Saline|Standard IV Saline Fluids
214292136|NCT00430690|PROCEDURE|acoustic startle testing|acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
214882646|NCT02296931|DRUG|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
214882647|NCT04570787|PROCEDURE|Urinary bladder catheterisation|Installation of Foley catheter into the urinary bladder
214882648|NCT05258383|OTHER|3D maps of physical doses|3D maps of physical doses delivered to organs by positioning imaging will be calculated based on the patient's CT image used by the treatment planning system (dosimetric calculation performed by Monte Carlo method).
214882649|NCT02217254|PROCEDURE|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
214882650|NCT03101176|DRUG|SonoVue|The ultrasound contrast agent used for the CEUS specific ultrasound mode
214292137|NCT03369392|OTHER|Panda application|A smartphone-based postoperative pain management tool
214882651|NCT06633120|OTHER|IVM|Immature oocytes will be retrieved from small ovarian follicles and matured overnight in the laboratory prior to undergoing fertilization and embryo culture.
214882652|NCT05147012|OTHER|Data collected|"The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients."
214882653|NCT01561261|OTHER|Continuous tissue perfusion monitoring by near-infrared spectroscopy (NIRS) and intramuscular pressure (IMP)|Continuous monitoring of tissue perfusion using NIRS in all 4 leg muscle compartments and IMP via indwelling catheters in anterior and deep posterior compartments. These measures will not provided in real time to treating physicians. All clinical care, including the diagnosis of ACS, will be according to the current standard-of-care practiced at each institution, Clinicians may use the indwelling IMP monitor to obtain up to 2 discrete measures of IMP if they encounter a clinical situation in which they would normally measure IMP as an adjunct in their normal standard-of-care for the monitoring and diagnosis of compartment syndrome. Patients who undergo fasciotomy will also have NIRS and IMP values recorded from all 4 leg compartments immediately before and after fasciotomy.
214882654|NCT01428154|DRUG|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
214882655|NCT06741865|BEHAVIORAL|Lifestyle Intervention|This arm involves interventions like health coaching, dietary changes, exercise programs, and other lifestyle modifications.
214882656|NCT06741865|OTHER|Standard Health Education|Participants in the Standard of Care Arm will receive basic educational materials focused on general cognitive and physical health maintenance.
214292138|NCT03303534|DIETARY_SUPPLEMENT|ScandiShake|weight gain supplement low in protein
214292139|NCT04920370|DRUG|ALXN1720 SC|ALXN1720 will be administered via SC route.
214292140|NCT04920370|DRUG|ALXN1720 IV|ALXN1720 will be administered via IV route.
214292141|NCT04920370|DRUG|rHuPH20|rHuPH20 will be administered via SC route.
214292142|NCT04920370|DRUG|Placebo SC|Placebo will be administered via SC route.
214292143|NCT04920370|DRUG|Placebo IV|Placebo will be administered via IV route.
214292144|NCT00004196|BIOLOGICAL|recombinant interferon alfa|
214292145|NCT00004196|PROCEDURE|lymphangiography|
214292146|NCT00004196|DRUG|Observation|
214882657|NCT04244578|DEVICE|Active tDCS|Active tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
214882658|NCT04244578|DEVICE|Sham tDCS|Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
214292147|NCT02066870|DRUG|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
214667390|NCT01944215|DRUG|Caffeine Tablet|effect of caffeine
214292148|NCT02066870|DRUG|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
214292149|NCT01813578|OTHER|Exercise|Intensive aerobic and muscle endurance exercise
214667391|NCT01944215|OTHER|External Heating|Heating Pad and warm blanket robe
214667392|NCT00618956|DRUG|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily \[BID\]), oral administration.
214667393|NCT00618956|DRUG|Placebo|Placebo
214667394|NCT02388230|DEVICE|Ultrasound imaging|
214667395|NCT01658800|BIOLOGICAL|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
214667396|NCT02495363|PROCEDURE|PECS Block|"As standard departmental protocol ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
214667397|NCT02495363|DRUG|Bupivacaine 0.25-0.5%|"Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
214667398|NCT04882007|DRUG|OSE-127|mAb antagonist to CD127 receptor (or IL-7Rα)
214667399|NCT04882007|DRUG|Placebo|Normal saline
214667400|NCT03906682|BEHAVIORAL|RAP Club|RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
214667401|NCT03906682|BEHAVIORAL|Healthy Topics|Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
214667402|NCT02006576|DRUG|600 mg ibuprofen three times daily for 48 weeks|
214667403|NCT02006576|OTHER|Placebo three times daily|
214882659|NCT02762461|PROCEDURE|IVF or ICSI|
214882660|NCT02653833|DRUG|Tadalafil 20 MG|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
214292150|NCT05557604|DRUG|Decapeptyl|STAD androgen deprivation
214667404|NCT02158078|DEVICE|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
214667405|NCT00904787|DRUG|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
214667406|NCT04642235|OTHER|Nature Nook|The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.
214667407|NCT04642235|BEHAVIORAL|Nature Coach|"The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
214882661|NCT02653833|OTHER|beetroot juice extract|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
214882662|NCT01729403|DRUG|aleglitazar|150 mcg orally daily, 16 weeks
214882663|NCT01729403|DRUG|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
214882664|NCT01729403|DRUG|placebo|orally daily, 16 weeks
214882665|NCT03764618|DRUG|Fostamatinib disodium|"Fostamatinib (100mg PO bid or 150 mg PO bid)~The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed."
214882666|NCT03764618|DRUG|Placebo|Placebo
214882667|NCT06736041|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214882668|NCT06736041|BIOLOGICAL|Prevnar 20 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214882669|NCT06736041|BIOLOGICAL|M-M-R II vaccine|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
214882670|NCT06736041|BIOLOGICAL|RotaTeq|Pharmaceutical form:Solution-Route of administration:Oral
214882671|NCT06736041|BIOLOGICAL|Vaxelis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214882672|NCT06736041|BIOLOGICAL|Varivax|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
214882673|NCT06736041|BIOLOGICAL|Hexaxim Vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214882674|NCT06764160|DRUG|Eculizumab|Participants will receive Eculizumab via intravenous (IV) infusion.
214882675|NCT05528471|OTHER|Dietary intervention|To compare an iso-caloric, low fructose diet (\~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (\~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
214882676|NCT07063238|DRUG|MK-8527|Oral administration
214882677|NCT07063238|DRUG|Moxifloxacin|Oral administration
214882678|NCT07063238|DRUG|Placebo|Oral administration
215045797|NCT00988156|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
214882679|NCT07069517|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBTi)|CBTi focuses on stimulus control, eliminating maladaptive coping habits, reducing arousal, and challenging maladaptive thoughts about sleep in an effort to reduce time to fall asleep and time awake during the night.
214882680|NCT07069517|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares (CBTn)|CBTn involves writing about a distressing or frequent nightmare, rewriting the narrative of the nightmare to target trauma-related themes, and reading the rescripted nightmare narrative.
214882681|NCT07069517|BEHAVIORAL|Written Exposure Therapy (WET)|WET is a trauma-focused intervention in which individuals write about their worst traumatic experience following scripted instruction from the therapist.
214882682|NCT07069517|BEHAVIORAL|Sleep Hygiene|Involves reviewing sleep diary data, sleep education, and reviewing and discussing sleep hygiene practices.
214882683|NCT05491213|BEHAVIORAL|TELESCOPE, Remote Decision Coaching with Navigation Intervention|The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
214882684|NCT07073547|BIOLOGICAL|GC012F (AZD0120)|GC012F (AZD0120) is a BCMA/CD19 dual CAR T cell product under investigation for early-line treatment in subjects with Multiple Myeloma
214882685|NCT06769048|DRUG|Placebo-matching BI 1584862|Placebo-matching BI 1584862
214882686|NCT06769048|DRUG|BI 1584862|BI 1584862
214882687|NCT07133932|DEVICE|Transcutaneous electrical phrenic nerve stimulation|Non-invasive transcutaneous electrical phrenic nerve stimulation which can cause explicit contraction of the diaphragm, and the stimulation current may be set to 5-30mA depending on the participant's condition.
214882688|NCT07133932|DEVICE|Sham (No Treatment)|The stimulation current is set to 0.
214882689|NCT07133984|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac MRI, also known as cardiac magnetic resonance imaging, is a non-invasive imaging technique that uses strong magnetic fields and radio waves to produce detailed pictures of the heart and its surrounding structures
214882690|NCT07133347|DEVICE|Brain computer interface controlled functional electrical stimulation therapy integrated with social media|The investigators created an app interface (FlickTok) to have brain computer interface (g.tech gel 16 channel EEG headset) controlled functional electrical stimulation (NeuroTrac Electrical Stimulator) integrated with social media (Instagram reels or YouTube Shorts)
214882691|NCT07133594|OTHER|RTEQ (RadioTherapy Experience Questionnaire) in French|Complete the RTEQ questionnaire translated and adapted to the French language in patients receiving external radiotherapy. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.
214882692|NCT07133594|OTHER|EORTC PATSAT-C33 questionnaire|Complete the EORTC-PATSAT-C33 questionnaire after completing the RTEQ questionnaire. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.
214882693|NCT07134582|OTHER|Hippotherapy 1x/week|This group will perform hippotherapy once per week for 12 weeks
214882694|NCT07134582|OTHER|Hippotherapy 2x/week|This group will perform hippotherapy twice per week for 12 weeks
214882695|NCT07078630|DIETARY_SUPPLEMENT|Placebo|Participants instructed to intake the placebo capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.
214882696|NCT07078630|DIETARY_SUPPLEMENT|HydroCurc®|Participants instructed to intake the HydroCurc® capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.
214882697|NCT07078630|DIETARY_SUPPLEMENT|Ferrous sulphate 200mg oral tablet providing 65 mg of elemental iron|Participants instructed to intake the ferrous sulphate tablet along with the HydroCurc® or the placebo together, preferably and separated from food, tea or coffee, at the same time of the day.
214882698|NCT06898593|BEHAVIORAL|Collaborative care model with clinical decision support system|A new patient-level clinical decision support system (CDSS) will include enhancing the existing pre-visit questionnaire to capture patient-reported goals and concerns, and displaying pre-visit questionnaire responses and clinical information within a patient-level dashboard in the electronic health record (EHR) for use by clinicians and patients.
215045798|NCT00988156|DRUG|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
215045799|NCT02499887|DRUG|beclamethasone dipropionate|Inhaler
215045800|NCT02499887|DRUG|albuterol|Inhaler
215045801|NCT02499887|DRUG|Prednisone|Oral corticosteroid
215045802|NCT06338163|COMBINATION_PRODUCT|Polihexanide-based bundle|Pre- and intra-operative decontamination will be accomplished in the treatment (experimental) arm with Polihexanide-based products
215045803|NCT06338163|COMBINATION_PRODUCT|Standard bundle|Pre- and intra-operative decontamination will be accomplished in the control arm with normal soap/shampoo and saline solution
215045804|NCT01805284|DRUG|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
215045805|NCT05254353|PROCEDURE|Analyses of proximal and distal samples|Evaluate the difference between proximal and distal CSF samples
215045806|NCT02476604|BEHAVIORAL|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
215045807|NCT03138317|BIOLOGICAL|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
215045808|NCT03138317|BIOLOGICAL|Plasma|This group will receive a knee injection with 6 ml of plasma.
215045809|NCT03138317|BIOLOGICAL|Placebo|This group will receive a knee injection with 6 ml saline solution.
215045810|NCT00104988|DRUG|temozolomide|75 mg/m\^2/day PO daily for 6 weeks followed by a 2-week break
215045811|NCT00104988|DRUG|thalidomide|200 mg/day PO daily
215045812|NCT01720394|DEVICE|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
215045813|NCT01720394|DRUG|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
215045814|NCT00615576|DRUG|SB-656933|SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.
215045815|NCT00615576|DRUG|Placebo|A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
215045816|NCT00812955|DRUG|ABT-143|Once daily for 8 weeks
214882699|NCT06898593|BEHAVIORAL|Collaborative care model|Collaborative care model of integrated behavioral health and primary care.
214882700|NCT07081022|DRUG|JS203 in combination with gemcitabine and oxaliplatin|Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days/cycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.
215045817|NCT00812955|DRUG|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
215045818|NCT00650052|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fasting
215045819|NCT00650052|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fasting
215045820|NCT05499026|DRUG|Chenodeoxycholic Acid|Bile acid
215045821|NCT00775957|PROCEDURE|FLT-PET scan|imaging scan
215045822|NCT00775957|PROCEDURE|FDG-PET scan|imaging scan
215045823|NCT04251832|DRUG|Sodium Thiosulfate|Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
215045824|NCT06061692|DRUG|Tongxinluo Capsule|4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
215045825|NCT02536716|PROCEDURE|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
215045826|NCT02536716|PROCEDURE|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
215045827|NCT05658718|PROCEDURE|refractive surgery|refractive surgery
215045828|NCT02391311|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
215045829|NCT05156437|DRUG|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin
215045830|NCT05156437|DRUG|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
215045831|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
215045832|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
214667408|NCT04642235|OTHER|Nature Nook + Nature Coach|The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
214667409|NCT01656239|DRUG|fedovapagon 1 mg|
214667410|NCT01656239|DRUG|fedovapagon 2 mg|
214667411|NCT01656239|DRUG|fedovapagon 4 mg|
214667412|NCT01656239|DRUG|Placebo ( sugar pill)|
214667413|NCT05559814|DRUG|Intraluminal peppermint oil|Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal
214667414|NCT05559814|DRUG|Placebo|Intraluminal flushing of placebo solution through the scope during scope withdrawal
214667415|NCT02587494|PROCEDURE|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
214667416|NCT01999829|DRUG|citrate of caffeine|
214667417|NCT01999829|DRUG|placebo|
214667418|NCT03483532|DIETARY_SUPPLEMENT|Lit Control pH Up|dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A
214667419|NCT03483532|DIETARY_SUPPLEMENT|dry cocoa extract|(Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.
214667420|NCT02593370|DRUG|Lidocaine-epinephrine added gadoterate meglumine|
214667421|NCT06596304|OTHER|Low intensity-resistance training with lower limb blood flow restriction|In the LIRT-BFR, participants will perform 4 sets of 20 bilateral leg presses and knee extensions repetitions with BFR at 30% of 1-RM, with 30-second rest intervals between sets, in an estimated total of 30-minute session per participant. Cuffs will be placed in the upper thighs and inflated with a pressure that is 1.3 times the individual's ankle systolic blood pressure in the data collection day for the entirety of the training session with a commercial cuff (width×length; 11×85 cm, SC10™, Hokanson, Inc., WA, USA).
214667422|NCT06596304|OTHER|High Intensity Resistance Training|In the HIRT participants will perform bilateral leg presses and knee extension without BFR at 75% of one-repetition maximum (1-RM), for 3 sets of 10 reps, with 2-minute rest intervals, in an estimated total of 30-minute session per participant.
214667423|NCT05175170|BEHAVIORAL|Decision-aid|The decision aid consists of domains related to human reproduction, fertility, and fertility preservation. The domains address priority learning objectives in each domain to increase knowledge on the impact of gender-affirming medical interventions on fertility and fertility preservation options.
214667424|NCT04965519|DRUG|RC48-ADC|2.0mg/kg IV every 2 weeks
214882701|NCT07081022|DRUG|JS203 in combination with ifosfamide, carboplatin and etoposide|Ifosfamide, carboplatin and etoposide, 3 cycles (Q3W) and JS203, Cycle 1 QW, Cycle 2 and therafter Q3W until trasnplant, progression or unacceptable toxicity.
214882702|NCT07081022|DRUG|JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 6 cycles (Q3W) and JS203, 8 cycles (21 days/cycle), Cycle 1 QW, Cycle 2 to Cycle 8 Q3W.
214882703|NCT07081022|DRUG|JS203 combined with lenalidomide|lenalidomide,12 cycles, Cycle 1(Q3W), Cycle 2 to Cycle 12 (Q4W) and JS203, 12 cycles, Cycle 1 (21 days/cycle) QW, Cycle 2 to Cycle 12 (28 days/cycle) Q4W.
214882704|NCT07081152|OTHER|Ferrous sulfate|All participants will receive a single dose of 15 mg of iron as isotopically prepared ferrous sulfate labelled with 57Fe. The iron dose will be given with ascorbic acid to attain a molar ratio of ascorbic acid:iron of 2:1
214882705|NCT06817278|BEHAVIORAL|Adaptable IERITA|IERITA is a 12-week acceptance-based behavioral therapy. The goal is to reduce self-injury through learning and using other ways to regulate emotions. IERITA includes modules where the participants can read text, watch videos, listen to audio, and message their allocated therapists. The adolescent treatment is 11 modules, and the parent course is six. Both adolescents and parents receive separate asynchronous online therapist support. The adapted IERITA intervention is tailored to the participant and can thus entail different adaptions for different participants. Adaptions can entail changes in therapist contact, what material to focus on, and how to work with the treatment. The adapted IERITA intervention is offered between week four and 12.
214667425|NCT06657300|DRUG|PRP|A single dose of 1 ml PRP (Vacusera) was injected into the 1st CMC joint of the first group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
214667426|NCT06657300|DRUG|Corticosteroid|A single dose of 20 mg(1ml) of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
214667427|NCT06656858|OTHER|Static stretching|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds
214667428|NCT06656858|OTHER|PNF stretching|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds.
214667429|NCT06656858|OTHER|Static stretching with BFR|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
214667430|NCT06656858|OTHER|PNF stretching with BFR|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
214667431|NCT06656858|OTHER|Control|No stretching was applied to the control group. An information brochure about hamstring injuries was provided to the participants.
214667432|NCT06657469|OTHER|Attention Functions Training (AFT)|The AFT protocol included 18 group-based sessions, 75 minutes each, administered twice a week over a nine-week period. The training focused on improving sustained attention, selective-spatial attention, and executive attention through computerized tasks like the Conjunctive Continuous Performance Task and Go/No-Go tasks.
214667433|NCT06657469|OTHER|Executive Functions Training (EFT)|The EFT protocol included similar session structures with a focus on executive functions such as working memory, cognitive flexibility, and problem-solving. Tasks included computerized games such as visual puzzles.
214667434|NCT06656182|OTHER|Cervical and Thoracic SNAGs|cervical SNAGs (C3-C7) and thoracic SNAGs (T1-T12) with 6 repetitions of 1 set three times per week for 4 weeks along with scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
214667435|NCT06656182|OTHER|traditional physical therapy and scapular mobilizations|scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
214667436|NCT06657482|BEHAVIORAL|Delayed school start time|The intervention group will start school two hours later on Mondays (at 10.15 ± 15 min) and one hour later on Tuesdays (9.15 ± 15 min) and to ordinary school start time (8.15 ± 15 min) for the rest of the week
214667437|NCT06656806|DRUG|Measure concentrations of CBD in spot urine collections from subjects treated with inhaled CBD|Measure concentrations of CBD in spot urine collections from subjects with generalized anxiety disorder treated with inhaled CBD
214667438|NCT06656806|DRUG|Determine the presence and concentration of CBD in subject's plasma with inhaled CBD|Determine the presence and concentration of CBD in plasma of subjects with generalized anxiety disorder treated with inhaled CBD
214667439|NCT06656559|DRUG|Envafolimab and Surufatinib|Envafolimab: 150mg, SC, qw Surufatinib: 150mg, p.o., qd
214667440|NCT06656624|DRUG|Ribociclib combined with AI±OFS|Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
214882706|NCT06817278|BEHAVIORAL|Standard IERITA|IERITA is a 12-week acceptance-based behavioral therapy. The goal is to reduce self-injury through learning and using other ways to regulate emotions. IERITA includes modules where the participants can read text, watch videos, listen to audio, and message their allocated therapists. The adolescent treatment is 11 modules, and the parent course is six. Both adolescents and parents receive separate asynchronous online therapist support.
214882707|NCT06817278|OTHER|Treatment as usual|Participants are free to any receive regular care (i.e., psychosocial treatment, medications, or a combination of both) as needed during the trial.
214882708|NCT07082244|PROCEDURE|Dental implant placement|Participants will have a dental implant placed at a toothless site
214882709|NCT07082244|PROCEDURE|Guided bone regeneration with collagen membrane|Participants will receive guided bone regeneration at a toothless site with bone substitute and a collagen membrane.
214882710|NCT07082244|PROCEDURE|Guided bone regeneration with acellular dermal matrix.|Participants will receive guided bone regeneration at a toothless site with bone substitute and an acellular dermal matrix.
214882711|NCT07080229|DRUG|Intranasal dexmedetomidine|Intranasal dexmedetomidine (1 mcg/kg ideal body weight) will be diluted to a total volume of 1 ml and will be administered via a mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.
214882712|NCT07080229|DRUG|Intranasal normal saline|Intranasal normal saline (1 ml) will be administered via mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.
214882713|NCT07079306|BEHAVIORAL|BeFree+Bot|Text messaging program called BeFree and access to BBot, ChatGPT chatbot
214882714|NCT07079306|BEHAVIORAL|BeFree|Text messaging program called BeFree
214882715|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3|Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
214882716|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3 Pediatric Dose|Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
214882717|NCT05052047|OTHER|Brisk Walking Group|Brisk Walk: 20 min/day (The researchers found, for most people, brisk walking could be defined as moving at a pace of 2.7 miles per hour or 100 steps per minute for adults under about age 60 or guidelines define brisk walking as occurring when individuals move at a pace that increases their heart rate to about 70% of their heart rate maximum) Patient will also perform breathing exercises as given to Control group, Positioning (lean forward when needed) Percussion coughing when needed
214882718|NCT05052047|OTHER|Conventional Breathing Exercise Group|"Breathing exercises: 20 min/day~Breathing Ex includes:~• Pursed lip breathing: Sit with your back straight, inhale through your nose for 2 seconds. Purse your lips like you rae blowing on hot food and then breath out slowly, take twice as long to exhale as you took to breath in 4-5 times a day~• Diaphragmatic breathing: Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs . breathe in slowly through your nose tighten your stomach, letting them fall inward as you exhale through your pursed lips. Practice these exercises 5-10 minutes about 3-4 times a day.~Positioning (lean forward when needed) Percussion coughing when needed"
214882719|NCT02713269|PROCEDURE|Computed Tomography|Undergo CT scan
214882720|NCT02713269|OTHER|Quality-of-Life Assessment|Ancillary studies
214882721|NCT02713269|OTHER|Questionnaire Administration|Ancillary studies
214882722|NCT02713269|RADIATION|Stereotactic Radiosurgery|Undergo CT-guided SSRS
214882723|NCT02713269|PROCEDURE|Thermal Ablation Therapy|Undergo thermal ablation therapy
214882724|NCT06930755|DRUG|NMS-03305293|Route of administration: Oral
214882725|NCT06930755|DRUG|Topotecan|Route of administration: Intravenous
214882726|NCT05002998|DRUG|Teprotumumab|"Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w).~Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration"
214882727|NCT05002998|DRUG|Placebo|Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
214882728|NCT06071169|OTHER|progressive relaxation exercise|Nurses will be asked to perform relaxation exercises 3 days a week for 5 weeks, 20 minutes in each practice.
215045833|NCT05809323|OTHER|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 12 weeks all patients will return for re-assessment.
215045834|NCT05809323|OTHER|Control Group|Patients in the control group will be instructed to continue with baseline physical activities over the duration of the study and be given instructions on the use of the activity tracker. At the end of 12 weeks all patients will return for re-assessment.
215045835|NCT02649920|DEVICE|Cervical ripening balloon|
215045836|NCT02649920|DRUG|Dinoprostone|
214882729|NCT00256399|DRUG|Alfuzosin 10 mg|
214882730|NCT06902545|DRUG|zolbetuximab|Intravenous
214882731|NCT07134816|OTHER|Cognitive and behavioral therapy for auditory hallucinations|Consists of 16 one-hour individual sessions (one session per week over a 16-week period) of cognitive behavioral therapy, divided into three types of interventions (modules) that have been independently proven to be effective in the management of auditory hallucinations.
214882732|NCT07134816|OTHER|Usual treatment|Consists of an antipsychotic medication treatment (including dosage changes and molecule changes.), regular consultation with a psychiatrist (once a month on average), and if necessary, one-off psychological support or family interventions not including specific CBT for positive symptoms
214882733|NCT07134569|BEHAVIORAL|VR-based motor training|Six weeks, twice per week.
214882734|NCT04326205|DEVICE|transcranial direct current stimulation, tDCS|"The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice."
214882735|NCT04326205|DEVICE|functional electrical stimulation, FES|"The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice."
214882736|NCT04326205|OTHER|no stimulation|Both tDCS and FES will not be used in this section.
214882737|NCT02072304|BEHAVIORAL|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
214882738|NCT02072304|BEHAVIORAL|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
215045837|NCT01875081|BIOLOGICAL|Livercellgram|"Livercellgram~* Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20\~25℃~  * Injection Method: Directly inject into liver through hepatic artery"
215045838|NCT00820144|BIOLOGICAL|CTB by nasal way|
215045839|NCT00820144|BIOLOGICAL|absorption of CTB by oral way|absorption of CTB by oral way
215045840|NCT00820144|BIOLOGICAL|absorption of dukoral by oral way|absorption of dukoral by oral way
215045841|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
215045842|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
214882739|NCT07104461|OTHER|Oat porridge|"Oat flakes, 81g (equivalent to 9 g of protein), were presented to participants in the form of porridge, prepared with 500 mL coconut milk (equivalent to 0.5 g of protein) and 10 g of zero calorie sugar free syrup.~The total energy content was equivalent to 400 Kcal.~Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study."
214882740|NCT07104461|DIETARY_SUPPLEMENT|Whey protein isolate|"Whey protein isolate, 38g (equivalent to 34.2 g of protein), was presented to participants in the form of a porridge.~Other ingredients in the whey protein enriched porridge:~* Oat flakes 54 g (equivalent to 6 g of protein)~* Coconut milk 300 mL (equivalent to 0.3 g of protein)~* Water 150 mL~* Zero calorie sugar free syrup 10 g~The total energy content was equivalent to 401.74 Kcal.~Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study"
214882741|NCT07104461|DIETARY_SUPPLEMENT|Potato protein isolate|"Potato protein isolate, 38g (equivalent to 34.39 g of protein), was presented to participants in the form of a porridge.~Other ingredients in the potato protein enriched porridge:~* Oat flakes 54 g (equivalent to 6 g of protein)~* Coconut milk 300 mL (equivalent to 0.3 g of protein)~* Water 150 mL~* Zero calorie sugar free syrup 10 g~The total energy content equiv. 401.36 Kcal.~Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study."
214882742|NCT07104461|DIETARY_SUPPLEMENT|Meal replacement shake|"A meal replacement, 90 g (equivalent to 40 g of total protein), was presented to participants in the form of a shake.~Other ingredients in the meal replacement shake:~\- Water 500 mL~The total energy was equivalent to 400 Kcal~Participants were instructed to consume the entire meal replacement shake presented to them in 15 minutes on an empty stomach when attending the study."
214882743|NCT05565079|BIOLOGICAL|Regenerative tissue matrix and enamel matrix derivative|Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).
214882744|NCT05565079|BIOLOGICAL|Regenerative tissue matrix|Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
214882745|NCT03554434|BIOLOGICAL|AM0010|AM0010
214882746|NCT06085573|DRUG|Dexmedetomidine Hydrochloride|"\<Sedation of non-invasive procedures and tests without intubation in pediatrics\> For children aged 2 years or older, the usual dosage of dexmedetomidine is 12 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~For children aged 1 month to \< 2 years old, the usual dosage of dexmedetomidine is 9 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~The infusion rate should be reduced according to patient's condition."
214882747|NCT00274118|DRUG|telmisartan|
214882748|NCT00274118|DRUG|enalapril|
214882749|NCT05538910|OTHER|Placebo Nicotine Patch|Comparator
214882750|NCT05538910|DRUG|Nicotine Patch|Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
214882751|NCT05792696|BEHAVIORAL|PPI guided strategies|For targeted MAP or lower, if PPI\<1, more fluid therapy. if PPI\>3, vasoconstriction therapy. For MAP\<65mmHg and 1\<=PPI\<3, test bolus of 250 ml crystalloid fluid.
214882752|NCT05792696|BEHAVIORAL|Empirical strategies|Fluid therapy or vasoconstriction depended on experiences of anesthetic staffs.
214882753|NCT06827951|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|"Participants will undergo the standard PCIT program, which consists of two phases: Child-Directed Interaction (CDI) and Parent-Directed Interaction (PDI).~* CDI Phase: Parents will learn and practice techniques that focus on strengthening the parent-child relationship through play and positive reinforcement.~* PDI Phase: Parents will be coached in effective discipline strategies to manage their child's behavioral problems."
214882754|NCT07115394|OTHER|EEG recording|EEG will be recorded at high sampling rate
214882755|NCT07128238|BEHAVIORAL|lifestyle intervention|This study implemented lifestyle interventions including dietary and exercise interventions. Based on the assessment of the physical condition of the volunteers, a personalized training plan is formulated and a standardized diet is provided. The entire intervention process lasts for 8 weeks.
214882756|NCT07133711|DEVICE|Noninvasive ventilation|Weaning from noninvasive ventilation for patients with acute exacerbation of COPD
214882757|NCT06937788|DRUG|Upadacitinib|30 mg tablet daily
214882758|NCT06937788|BIOLOGICAL|Dupilumab|300 mg injection every other week
214882759|NCT00550030|RADIATION|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
214882760|NCT00550030|OTHER|No treatment|no UV exposure
214882761|NCT01123967|OTHER|proactive outreach (PRO)|a mailed invitation letter followed by telephone outreach
214882762|NCT01123967|OTHER|telephone counseling (TC)|free telephone counseling
214882763|NCT01123967|OTHER|Nicotine replacement therapy (NRT)|free nicotine replacement therapy (NRT)
214882764|NCT01123967|OTHER|Usual care (UC)|nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
214667441|NCT06656624|DRUG|physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS|Docetaxel: 100mg/m2 IV drip every 21 days; Paclitaxel: 175mg/m2 every 21 days, IV drip; Paclitaxel for Injection (Albumin Bound): 100\~150mg/m2 IV drip every 7 days; Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week; Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
214667442|NCT06657417|DEVICE|Video laryngoscopy|Standard video laryngoscopy before video laryngoscopy with additional larynGuide overlay
214667443|NCT06657417|DEVICE|Video larnygoscopy|Video laryngoscopy with additional larynGuide overlay before standard video laryngoscopy
214882765|NCT00912912|DRUG|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
214667444|NCT06656130|OTHER|Pranayama|Pranayama is the practice of breath regulation. It's a main component of yoga, an exercise for physical and mental wellness. The practice of pranayama involves breathing exercises and patterns. Patient purposely inhale, exhale, and hold his/her breath in a specific sequence.
214667445|NCT06656130|OTHER|Jacobson's progressive muscle relaxation technique|Jacobson's relaxation technique is a type of therapy that focuses on tightening and relaxing specific 14 muscle groups in sequence. It's also known as progressive relaxation therapy. By concentrating on specific areas and tensing and then relaxing them, patient can become more aware of his/her body and physical sensations,
214667446|NCT06656429|DRUG|Transforaminal Epidural Steroid Injections|Transforaminal Epidural Steroid Injections
214882766|NCT00306995|BIOLOGICAL|SB218352_15|Non-adjuvanted pandemic influenza A formulation 1 vaccine
214882767|NCT00306995|BIOLOGICAL|SB218352_8|Non-adjuvanted pandemic influenza A formulation 2 vaccine
214882768|NCT00306995|BIOLOGICAL|SB218352_4|Non-adjuvanted pandemic influenza A formulation 3 vaccine
214882769|NCT00306995|BIOLOGICAL|SB218352_2|Non-adjuvanted pandemic influenza A formulation 4 vaccine
214882770|NCT00306995|BIOLOGICAL|SB218352_8AL|Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
214667447|NCT00345891|BEHAVIORAL|Coping-focused counseling telephone calls|
214667448|NCT05171387|DRUG|Darolutamide 600 mg twice daily|The participants will take 2 tablets (300 mg each tablet) of study treatment (darolutamide) orally bid at about 12 hour intervals.
214667449|NCT05171387|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body.
214667450|NCT00128687|BEHAVIORAL|risk reduction|Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (\< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
214667451|NCT02001012|DRUG|Artemether-lumefantrine combination|
214667452|NCT02001012|DRUG|Chloroquine|
214882771|NCT00306995|BIOLOGICAL|SB218352_4AL|Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
214882772|NCT00306995|BIOLOGICAL|SB218352_2AL|Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
214882773|NCT06379724|DRUG|Tranexamic acid|100mg/mL 10mL vials x2 of injectable tranexamic acid will be filled into a 20 milliliter syringe with a spray tip.
214882774|NCT06379724|DRUG|Thrombin JMI|The wound base is then sprayed with a film of Thrombin-JMI
214882775|NCT06379724|PROCEDURE|skin graft|Skin is taken from uninjured part of the participant's body and used to surgically cover a wound or injured area with skin that contains the epidermis and a portion of the dermis.
214882776|NCT04188678|OTHER|Bone Marrow Transplant (BMT)|Bone marrow transplantation will be conducted according to the investigators' institution's standard of care, or else according to research protocol (if applicable).Study visits that include the performance of assessments will occur prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. All dates are +/- 7 days. The initial study visit will take place during standard of care pre-transplant evaluations, which typically span 3-4 days. The post-BMT visits will take place before or after regularly-scheduled BMT follow up.
214882777|NCT06956690|BIOLOGICAL|ENV-501|ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker.
214882778|NCT06421532|DRUG|XYWAV|Daily before bedtime for 3 months
214882779|NCT06421532|DEVICE|gammaCore Sapphire|Twice daily for 3 months
214882780|NCT03325101|PROCEDURE|Cryosurgery|Undergo cryosurgery
214882781|NCT03325101|BIOLOGICAL|Pembrolizumab|IV
214882782|NCT03325101|PROCEDURE|Pheresis|apheresis
214882783|NCT03325101|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Intra-tumoral injection
214882784|NCT05338528|BEHAVIORAL|BE-FIT exercise program|BE-FIT is an evidence-based exercise program that focuses on early mobilization and recovery by minimizing bed rest, promoting functional tasks, and encouraging self-management. The intervention ist based on the Mobilization of Vulnerable Elders (MOVE) program and consists of a bedside exercise plan, done independently by the patient without the need for additional rehabilitation or healthcare staff.
214882785|NCT02721459|DRUG|XL888|"Level 1: XL888 30 mg by mouth (PO) twice weekly (BIW). Level 2: XL888 45 mg PO BIW.~Level 3: XL888 60 mg PO BIW. Level 4: XL888 90 mg PO BIW."
214882786|NCT02721459|DRUG|Vemurafenib|Vemurafenib 720 mg by mouth twice a day (BID)
214882787|NCT02721459|DRUG|Cobimetinib|Cobimetinib 40 mg by mouth once daily (QD). Administered 3 weeks on, 1 week off.
214882788|NCT02679144|DRUG|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
214667453|NCT05059353|DEVICE|Digitally based multidomain intervention|"Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.~Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.~Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.~Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed."
214667454|NCT01650805|DRUG|ponatinib|45 mg tablet, taken orally once daily
214667455|NCT01650805|DRUG|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
215045843|NCT02435667|OTHER|Resistance Exercise Training|"1. Aerobic Exercise~   a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~2. Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~   a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~3. Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises"
215045844|NCT02435667|RADIATION|DEXA bone scan|A DEXA scan that provides bone density measures.
215045845|NCT02435667|OTHER|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
214667456|NCT06818422|OTHER|Home exercise and recommendations for nonspecific neck pain|The intervention involves neck exercises and recommendations for nonspecific neck pain. Patients will perform the exercises at home three times a day for 2 weeks and record their progress in an exercise diary. They will be monitored by a physician for pain levels and receive additional support at the 15th day, 30th day and 3rd months.
215045846|NCT02435667|OTHER|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
215045847|NCT02435667|OTHER|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
215045848|NCT02435667|OTHER|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
215045849|NCT04807166|DRUG|Drug: Anlotinib|Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle
215045850|NCT04807166|DRUG|Drug: Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1
215045851|NCT01815424|DRUG|placebo|placebo BID for 16 weeks and then re-randomized into active groups
215045852|NCT01815424|DRUG|CP-690,550|CP-690,550 5mg BID for 52 weeks
215045853|NCT01815424|DRUG|CP-690,550|CP-690,550 10mg BID for 52 weeks
215045854|NCT01350050|DRUG|articaine|"Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections."
214667457|NCT06819943|PROCEDURE|Automated Lateral Rotation Therapy|Platform-based automated lateral tilt system integrated into the Linet Multicare bed, which allows the entire bed platform to be tilted laterally up to 30 degrees along the axial axis, either manually or automatically. The system includes Continuous Low Pressure (CLP) mode, which automatically redistributes pressure to maintain low interface pressure, and Microclimate Management (MCM) to control moisture and heat at the skin interface. The intervention is designed to redistribute interface pressure as a preventive strategy against pressure injuries in critically ill patients.
215045855|NCT01350050|OTHER|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
215045856|NCT01309204|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
215045857|NCT01309204|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
214667458|NCT04905082|OTHER|Best Practice|Receive usual care
215045858|NCT01309204|DRUG|Brinzolamide 1% ophthalmic suspension|
214882789|NCT05540327|DRUG|M5049 low dose|Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 194 weeks.
214882790|NCT05540327|DRUG|M5049 medium dose|Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 194 weeks.
214882791|NCT05540327|DRUG|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 194 weeks.
214882792|NCT05540327|DRUG|Placebo|Participants will receive M5049 matching placebo orally, BID for up to 194 weeks.
214882793|NCT06206408|DRUG|Fezolinetant|oral
214882794|NCT06206408|DRUG|Placebo|oral
214882795|NCT04069884|RADIATION|regional nodal irradiation|external-beam radiotherapy (XRT)
214882796|NCT04069884|RADIATION|WBI|Whole Breast Irradiation
214667459|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics tool after genomic test results are available
214667460|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics before sequencing results are available
214882797|NCT04069884|RADIATION|chestwall XRT|chestwall irradiation
214882798|NCT06489899|BEHAVIORAL|PEGISUS|PEGISUS is an 8-session intervention for substance use and gender equitable beliefs.
214882799|NCT06424938|PROCEDURE|Patients who underwent epidural block|The researchers administered an epidural block to prevent post-operative pain to the epidural block group undergoing midline incision surgery for major gynecologic cancer.
214882800|NCT06424938|PROCEDURE|Patients who underwent erector spina plane block|Researchers applied a erector spina plane block to prevent postoperative pain to the erector spina plane block group undergoing midline incision surgery for major gynecological cancer.
214667461|NCT04905082|PROCEDURE|Genomic Profile|Receive genomics test results
214667462|NCT04905082|OTHER|Survey Administration|Ancillary studies
214882801|NCT03842982|DRUG|HIPEC|"HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours."
214882802|NCT05573763|DEVICE|F&P Toffee|Nasal pillows mask
214882803|NCT04324073|DRUG|Sarilumab|(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1
214882804|NCT06797362|DRUG|NVL-520|Oral tablet
214882805|NCT05520567|DRUG|Gilteritinib|Oral
214882806|NCT05520567|DRUG|Venetoclax|Oral
214882807|NCT05520567|DRUG|Azacitidine|Subcutaneous injection or intravenous infusion
214667463|NCT06656091|DRUG|simmitinib|simmitinib 6mg,QD ,3 weeks on 1 week off
214667464|NCT06656091|DRUG|investigator's choice of chemotherapy,include docetaxel or irinotecan.|docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks
214882808|NCT06790004|PROCEDURE|Laparotomy|Open Surgery
214882809|NCT06790004|PROCEDURE|Laparoscopy|Minimally invasive surgery
214882810|NCT05714657|RADIATION|Shortened Course Adjuvant Radiotherapy Following TORS|Shortened Course Adjuvant Radiotherapy Following TORS
214882811|NCT06958328|PROCEDURE|Biopsy Procedure|Undergo tumor tissue biopsy
214882812|NCT06958328|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214882813|NCT06958328|DRUG|Capecitabine|Given capecitabine
214882814|NCT06958328|PROCEDURE|Computed Tomography|Undergo CT
214882815|NCT06958328|RADIATION|Dose-escalated Radiation Therapy|Undergo dose-escalated radiation using intensity-modulated radiation therapy treatment planning
214882816|NCT06958328|DRUG|Fluorouracil|Given fluorouracil
214882817|NCT06958328|DRUG|Gemcitabine|Given gemcitabine
214882818|NCT06958328|DRUG|Irinotecan Hydrochloride|Given irinotecan hydrochloride
214882819|NCT06958328|DRUG|Irinotecan Sucrosofate|Given liposomal irinotecan
214882820|NCT06958328|DRUG|Leucovorin Calcium|Given leucovorin calcium
214882821|NCT06958328|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214882822|NCT06958328|DRUG|Nab-paclitaxel|Given nab-paclitaxel
214667465|NCT06656611|OTHER|HPV self sampling|Selected women will perform a vaginal self-sampling using a swab
214667466|NCT06655922|DIAGNOSTIC_TEST|FAPI Imaging|Studies have shown that imaging with radionuclide-labeled fibroblast activation protein inhibitor (FAPI) is a reliable technique for detecting myocardial fibrosis and activated CFs in arteries. Preliminary evidence suggests that FAPI imaging can assess plaque characteristics and the status of myocardial fibrosis in various cardiovascular diseases.
214882823|NCT06958328|OTHER|Observation Activity|Undergo observation
214882824|NCT06958328|DRUG|Oxaliplatin|Given oxaliplatin
214882825|NCT06958328|OTHER|Questionnaire Administration|Ancillary studies
215045859|NCT01309204|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
215045860|NCT03439046|DRUG|Ribociclib|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
215045861|NCT03439046|DRUG|Letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
215045862|NCT03439046|DRUG|Alpelisib|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
215045863|NCT03439046|DRUG|Fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
214882826|NCT06958328|RADIATION|Radiation Therapy|Undergo standard radiation therapy
214882827|NCT06795529|OTHER|"Palliative Care Intervention, TARGET-PC"|Palliative care intervention focused on eliciting patients' goals and values to facilitate discussion and documentation of health care preferences.
215045864|NCT03516175|DEVICE|High flow transnasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange
215045865|NCT03516175|DEVICE|Pre oxygenation using tight fitting facemask|100% oxygen via a tight fitting facemask
215045866|NCT04244071|DEVICE|Bair Paws Blanket 81003 and FOC device 87500|This study is a randomized, pretest - posttest controlled experimental design.
215045867|NCT04244071|OTHER|routine hospital care|routine hospital care
215045868|NCT00257946|PROCEDURE|Repair of CDH w/SIS Gold|
215045869|NCT00257946|PROCEDURE|Repair of CDH w/Alloderm|
215045870|NCT05080439|OTHER|Diacutaneous Fibrolysis|Application of diacutaneous fibrolysis in teres major
214882828|NCT06795529|OTHER|Enhanced Usual Care|Oncology clinicians will receive an electronic message to encourage them to discuss and document their patients' health care preferences.
215045871|NCT05080439|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
215045872|NCT03046446|DRUG|FX006 32 mg|Single intra-articular injection
215045873|NCT02871349|DRUG|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
215045874|NCT02871349|DRUG|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
215045875|NCT02871349|DEVICE|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
214882830|NCT06010719|DRUG|Azithromycin|oral azithromycin (20 mg/kg, single directly observed dose, oral suspension),
214882831|NCT06010719|DRUG|Amoxicillin|Standard of Care. A 7-day, twice-daily course of amoxicillin will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
214882832|NCT06010719|OTHER|Placebo|A 7-day, twice-daily course of placebo will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
214882833|NCT04329247|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
214882834|NCT05833139|DRUG|Zongertinib|Zongertinib
214882835|NCT05833139|DRUG|Itraconazole|Itraconazole
214882836|NCT00371033|DRUG|Pregabalin|Pregabalin 150 mg/d (50 mg orally 3 times daily) for 2 weeks, then 300 mg/d (100 mg orally 3 times daily) for 2 weeks, and then 600 mg/d (200 mg orally 3 times daily) for 2 weeks.
214882837|NCT00371033|DRUG|Placebo|Placebo at same frequency as pregabablin
214882838|NCT04110327|DEVICE|MicroStent|Treatment of arterial stenosis or occlusion with the MicroStent Peripheral Vascular Stent System
214882839|NCT06160973|OTHER|Feed the Household|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household
214882840|NCT06160973|OTHER|Dedicated Driver|Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
214882841|NCT06160973|OTHER|Feed the Individual|Medically tailored meals will be provided for the enrolled individual
215045876|NCT01977196|BIOLOGICAL|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
215045877|NCT03917875|BEHAVIORAL|Personalized feedback intervention|The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
215045878|NCT06281743|OTHER|Survey|A web based survey is sent out to pediatric critical care physicians
215045879|NCT00925002|DRUG|Tafamidis|20 mg oral Fx-1006A daily
215045880|NCT02808897|DEVICE|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (Fr) shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
214882842|NCT06160973|OTHER|Commercial Shipper|Meals will be delivered by a commercial shipping organization
214882843|NCT06847152|DIAGNOSTIC_TEST|spatial memory test|"The assessment of spatial memory corresponds in our study to a navigation task, i.e. learning a route through the hospital. The route encoding phase is first carried out. The participant follows the experimenter, with the instruction to pay close attention to the route in order to be able to do it again alone. For directions, it is said this way or that way and not left or right. The route includes 18 intersections.~The participant immediately does the route again alone. The number of correct answers (BR), i.e. correct directions taken at each intersection, is counted as well as the time to complete the route (TR). Direction errors are corrected. This is recall 1.~The participant is then asked to do the route a second time. The correct answers and the times to complete the route are recorded. Errors are corrected (feedback). This is recall 2.~If the participant makes a mistake on recall 1 or 2, a third attempt is made. This is recall 3.~After an interval of 1 hour, the partic"
214292151|NCT05854732|OTHER|Inclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a experimental group with fixed speed of 5.0 mph and increased inclination of 1% after every one minute. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and increased inclination of 1% after every one minute for 30 minutes ending with Cool down for 5 minutes.
214882844|NCT04819464|DRUG|Cenerimod|A single oral dose of 0.5 mg.
214882845|NCT06847399|DRUG|Tirzepatide|Tirzepatide
214882846|NCT06847399|DRUG|Lisdexamfetamine Dimesylate|Lisdexamfetamine dimesylate
214882847|NCT06847399|BEHAVIORAL|Guided self-help cognitive behavioral therapy|Guided self-help cognitive behavioral therapy
215045881|NCT02808897|DEVICE|Active Tube Clearance drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 Fr shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
215045882|NCT00613548|PROCEDURE|CABG alone|CABG alone
215045883|NCT00613548|PROCEDURE|CABG + Mitral repair|CABG + Mitral repair
215045884|NCT03765216|DRUG|2L Polyethylene Glycol (PEG)|Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
215045885|NCT03765216|DRUG|4L Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
215045886|NCT05853354|BIOLOGICAL|Denosumab|Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
215045887|NCT03757429|OTHER|RS-virus infection|The intervention consists of lower respiratory tract infection due to RS-virus
215045888|NCT04038073|DIAGNOSTIC_TEST|Antistreptolysin O Test|Test to evaluate of any histories of streptococcal infections
215045889|NCT04038073|DIAGNOSTIC_TEST|Anti-Deoxyribonuclease B|Test to evaluate of any histories of streptococcal infections
215045890|NCT04038073|DIAGNOSTIC_TEST|TLR, MyD88, IRAK-4 polymorphism|Test to evaluate of the frequency and types of genetic alterations of innate immunity
215045891|NCT04038073|DIAGNOSTIC_TEST|Anti-Basal Ganglia Antibody|Test to evaluate the autoimmune component
215045892|NCT00651222|OTHER|No intervention was required|Death records were reviewed, therefore, there was no intervention
214882848|NCT06847399|DRUG|Placebo (oral)|Placebo (oral)
214882849|NCT06847399|DRUG|Placebo (injection)|Placebo (injection)
214882850|NCT04450251|OTHER|Data Collection|Collect observational fetal electrocardiogram (ECG) readings with a novel wearable device.
214882859|NCT05621616|DRUG|mirabegron|"Participants will receive mirabegron prolonged-release microgranula-based oral suspension once daily. The initial dose of mirabegron will be based on the participant's weight.~The initial low dose will be up-titrated to a higher dose at weeks 2, 4 or 8 unless the participant is determined to be effectively treated with the low dose, based on urodynamics and the participants'e-diary."
214882860|NCT06166186|OTHER|music|A music with a standard volume will be delivered to the patients via headphones from the beginning of anesthesia induction to extubation.
214882861|NCT06166186|OTHER|no music|Headphones will be applied to the patients but no music will be played from the beginning of anesthesia induction to extubation.
214882862|NCT06087159|BEHAVIORAL|mHealth Toolkit for Wellness & Empowering Lives of School Community (mWEL)|mWEL-App is a preventive intervention tool for teachers and parents as a self-help support. It integrates three key mental health presentive service functions: i) comprehensive screen to assess mental health (anxiety, depression), stress, and related contextual risks; ii) a tailored strength and weakness profile/report with recommendations to promote self-awareness and mental health knowledge; and iii) tailored evidence-based strategies and additional support and clinical resources to improve skills in stress management, emotion regulation, and maintain mental wellness. mWEL will be designed as a self-administered tool. Participating parents and teachers can access to mWEL app after they sign up for an account. Intervention participants will have access to the App anytime within a 3-5 month study period.
214882863|NCT04255277|DRUG|Combined oral contraceptives (COC)|A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
214667467|NCT06655961|OTHER|Garden Activities Program|When we look at the studies evaluating the effect of gardening activities on hospitalized children; it is seen that mostly children's opinions about therapeutic gardens are included and studies involving active gardening activities are limited. Shao et al. (2020) gave hospitalized children a task about garden plants and made them full this task through active participation and mobile games. However, it is seen that the gardening activity applied in this study was limited to a 5-minute task. The most important difference of our study from these studies is that a standardized gardening activity program will be applied to hospitalized children during their hospitalization and the active participation of the child will be ensured.
215045893|NCT03200002|DRUG|Cyclophosphamide|Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
215045894|NCT03200002|DRUG|Mycophenolate Mofetil|Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count \<1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count \<1000/mm3.
215045895|NCT00293163|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
215045896|NCT02016391|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
215045897|NCT01017224|OTHER|18F-FAZA|PET scan
215045898|NCT00346619|DRUG|Nelfinavir|
215045899|NCT02259816|DRUG|Telmisartan|
215045900|NCT02259816|DRUG|Amlodipine|
214882864|NCT04255277|DRUG|Moxifloxacin 400mg|A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
214882865|NCT04255277|DRUG|Cenerimod 0.5 mg|This will be administered orally as a film-coated tablet in the morning.
214882866|NCT04255277|DRUG|Cenerimod 4 mg|This will be administered orally as a film-coated tablet in the morning.
215045901|NCT01496287|DEVICE|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
215045902|NCT00358319|DRUG|Karenitecin|
215045903|NCT00358319|DRUG|Valproic Acid|
215045904|NCT02834455|DEVICE|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
215045905|NCT02834455|DEVICE|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
215045906|NCT04353687|DEVICE|Robotic-assisted inguinal hernia repair|Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.
215045907|NCT03667105|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions.
215045908|NCT03667105|OTHER|MC|Xenogenous graft placed in the surgical site.
215045909|NCT03667105|OTHER|XDM|Xenogenous dermal collagen graft placed in the surgical site.
215045910|NCT04164433|DEVICE|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
215045911|NCT03064932|OTHER|Controlled feeding diet|Average American diet with different levels of spices
215045912|NCT04221633|BEHAVIORAL|Enhancing Early Engagement (E3) webinar|Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.
215045913|NCT04221633|BEHAVIORAL|Consultation for E3 training|10 consultation calls with experts in engagement, child trauma, and mental health screening to support the webinar training
215045914|NCT02538120|OTHER|Microvascular assessment|Microvascular assessment
215045915|NCT05011136|OTHER|No intervention. This is a qualitative study|US nephrologists who care for dialysis patients will be asked to complete an internet based survey evaluating the time and effort required for home dialysis patient care.
214667468|NCT06655961|OTHER|Clinical routine treatment and nursing care protocol|Within the scope of the clinic routine treatment and nursing protocol; the decision to hospitalize the child, orientation to the clinic, execution of hospitalization paperwork, room placement, invasive intervention and treatment procedures are carried out. Treatment and care hours are revised according to individual order characteristics; 08.00-20.00, 08.00-16.00-00.00, 06.00-12.00-18.00-00.00 are planned considering the time order. 13.00-15.00 are the visiting hours. The child is not allowed to leave the clinic except for any medical purpose. No intervention will be applied to the control group of this study until the discharge process takes place.
214667469|NCT06660693|DRUG|Upadacitinib Oral Product|Upadacitinib oral 45mg once daily.
214882867|NCT04255277|OTHER|Charcoal, activated|Granules for oral suspension will be used and administered open-label.
214667470|NCT02625402|BEHAVIORAL|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
214667471|NCT02625402|BEHAVIORAL|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
214667472|NCT03849326|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
214667473|NCT03849326|BIOLOGICAL|blood test|complete blood count and cytokine concentration
214667474|NCT03849326|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
214667475|NCT03849326|DEVICE|actigraphy|assessment of sleep quality
214882868|NCT04255277|DRUG|Matching Placebo|Cenerimod matching placebo tablets will be administered once daily orally in the morning.
214882869|NCT06311838|BEHAVIORAL|Motivational Interviewing/Community Reinforcement Approach (MI/CRA)|MI/CRA includes two Motivational Interviewing sessions and twelve 1-hour Community Reinforcement Approach sessions.
214882870|NCT06311838|BEHAVIORAL|Strengths-Based Outreach and Advocacy (SBOA )|The number of Strengths-Based Outreach and Advocacy sessions participants will receive are flexibly determined based upon youth needs.
214882871|NCT06311838|BEHAVIORAL|Services as Usual (SAU)|Participants assigned to this group will receive the standard services provided to all youth involved with the drop-in center.
214882872|NCT03922529|BEHAVIORAL|MACRO-I|MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format \[site transitioning to home\]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.
214882873|NCT03922529|OTHER|Usual Care|Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
214882874|NCT06572683|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
214882875|NCT06105645|DEVICE|DIXI Medical Microdeep® Micro- Macro Depth electrodes|It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.
214882876|NCT06105645|DEVICE|Standard electrodes|Standard electrodes used usually during the SEEG
214882877|NCT04294160|DRUG|Dabrafenib|Capsule for oral use
214882878|NCT04294160|DRUG|LTT462|Capsule for oral use
214882879|NCT04294160|DRUG|Trametinib|Tablet for oral use
214882880|NCT04294160|DRUG|LXH254|Tablet for oral use
214882881|NCT04294160|DRUG|TNO155|Capsule for oral use
214882882|NCT04294160|BIOLOGICAL|Spartalizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
214882883|NCT04294160|BIOLOGICAL|Tislelizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
214882884|NCT06145633|PROCEDURE|Biopsy Procedure|Undergo biopsy
214882885|NCT06145633|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214882886|NCT06145633|PROCEDURE|Bone Scan|Undergo bone scan
214882887|NCT06145633|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, SPECT/CT
214882888|NCT06145633|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
214882889|NCT06145633|OTHER|Gallium Ga 68 Gozetotide|Given IV
214667476|NCT03849326|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging (optional)"
214667477|NCT06388057|DIAGNOSTIC_TEST|Intraoperative Small Bowel Ultrasonography|An intraoperative ultrasound study will be performed on the intestinal segment identified as the resection site
214667478|NCT05750914|DEVICE|Broadband Light|Broadband Light treatment using standard protocol
214882890|NCT06145633|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given 177Lu-PSMA-617
214882891|NCT06145633|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET
214882892|NCT06145633|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214882893|NCT06145633|DRUG|Vorinostat|Given IV
214882894|NCT04158245|DRUG|18F-fluciclovine PET Scan|The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
214882895|NCT05292326|DEVICE|PacePress|an electronically-controlled compression site which, thanks to a well-selected compression force, may contribute significantly to preventing hemorrhagic complications following electrotherapy procedures, including to increasing safety of CIED implantation procedures and accelerate wound healing significantly
214882896|NCT05292326|DEVICE|standard compression band|standard used compression band/sand bag
214882897|NCT03785600|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
214882898|NCT03785600|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
214882899|NCT03842228|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214882900|NCT03842228|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214882901|NCT03842228|PROCEDURE|Computed Tomography|Undergo CT
214882902|NCT03842228|DRUG|Copanlisib Hydrochloride|Given IV
214882903|NCT03842228|BIOLOGICAL|Durvalumab|Given IV
214882904|NCT03842228|PROCEDURE|Echocardiography Test|Undergo ECHO
214882905|NCT03842228|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214882906|NCT03842228|DRUG|Olaparib|Given PO
214882907|NCT03842228|PROCEDURE|X-Ray Imaging|Undergo x-ray
214882908|NCT05193396|DRUG|Hydrocortisone|Patients are randomized to oral hydrocortisone (10 mg twice daily) or placebo for 16 weeks.
214882909|NCT05193396|DRUG|Placebo|Patients are randomized to oral hydrocortisone (10 mg twice daily) or placebo for 16 weeks.
214882910|NCT06358001|DEVICE|EchoTip AcuCore|Using endoscopic ultrasound guided needle to collect biopsies
214882911|NCT06390826|PROCEDURE|Biopsy Procedure|Undergo biopsy
214882912|NCT06390826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215045916|NCT05726149|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
215045917|NCT05726149|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
214882913|NCT06390826|PROCEDURE|Computed Tomography|Undergo CT scan
214882914|NCT06390826|PROCEDURE|Echocardiography Test|Undergo ECHO
214882915|NCT06390826|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214882916|NCT06390826|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
214882917|NCT06390826|DRUG|Sunitinib|Given PO
214882918|NCT06772623|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
214882919|NCT06772623|DRUG|Budigalimab|IV Infusion
214882920|NCT06772623|DRUG|Pembrolizumab|IV Injection
214882921|NCT06772623|DRUG|Pembrolizumab|IV Infusion
214882922|NCT06772623|DRUG|Carboplatin|IV Infusion
214882923|NCT06772623|DRUG|Pemetrexed|IV Infusion
214882924|NCT06772623|DRUG|Cisplatin|IV Infusion
214882925|NCT02196181|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214882926|NCT02196181|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214882927|NCT02196181|DRUG|Dabrafenib Mesylate|Given PO
214882928|NCT02196181|PROCEDURE|Echocardiography Test|Undergo ECHO
214882929|NCT02196181|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214882930|NCT02196181|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214882931|NCT02196181|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214882932|NCT05069558|DEVICE|Investigational PFO Closure Device|Occlutech Flex II PFO Closure Device
214882933|NCT05069558|DEVICE|Standard of Care PFO Closure Device|Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
214882934|NCT03933631|DRUG|Pilocarpine|pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
214882935|NCT03933631|DRUG|Prednisolone|Prednisolone acetate ophthalmic suspension 1%
214882936|NCT03933631|DRUG|Ofloxacin|Ofloxacin Drops
214882937|NCT04969978|BEHAVIORAL|Enhanced Academic Detailing|"* Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation~* Follow-up booster sessions~* Monthly performance audit and feedback"
214882938|NCT04969978|OTHER|Informational Intervention|Receive overview of Quitline services and use of Quitline eReferral via online materials
214882939|NCT06390839|PROCEDURE|Biopsy Procedure|Undergo biopsy
214882940|NCT06390839|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214882941|NCT06390839|PROCEDURE|Computed Tomography|Undergo CT scan
214882942|NCT06390839|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214882943|NCT06390839|DRUG|Palbociclib|Given PO
214882944|NCT05229666|OTHER|Cognitive Challenge|Cognitive challenge delivered via computer.
214882945|NCT04119739|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
214882946|NCT04119739|DRUG|Ibuprofen Arginine|Oral tablets
214882947|NCT06351371|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214882948|NCT06351371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214667479|NCT05446844|OTHER|A nurse caring behavior protocol|"Nursing interventions based on caring behaviors protocol was provided as follows:~* Caring behaviors during ICU admission and orientation processes included orienting patients to time, place, and person.~* Caring behaviors during physical care informing patients regarding the purpose and expected duration of mechanical ventilator use.~* Caring behaviors during psychological care included offering religious sound meditation.~* Caring behaviors during social interaction included maintaining eye contact during nurse-patient interaction.~* Caring behaviors during health teaching included providing health teaching for patients.~* Caring behaviors during maintaining a safe healing environment included providing patients with an explanation regarding nursing activities."
214667480|NCT05446844|OTHER|Routine nursing care|Routine nursing care was concentrated mainly on hard skills of physically demanding care such as monitoring vital signs.
214882949|NCT06351371|PROCEDURE|Computed Tomography|Undergo CT
214882950|NCT06351371|DRUG|Erdafitinib|Given orally
214882951|NCT06351371|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214882952|NCT04666311|DIAGNOSTIC_TEST|Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB|"CAD4TB version 6 and 7: Software tool for detecting lung abnormalities in computer tomogram images (pulmonary abnormalities) and frontal chest radiograph images (tuberculosis abnormalities) ; availability is guaranteed by Delft Imaging System; EC 0344 Certificate (vs.6); CE mark pending (vs.7). Will be performed by a registered and qualified radiographer in accordance with national regulations.~Afinion AS100 Analyzer and Afinion CRP: In vitro diagnostic to determine the amount of CRP in human whole blood, serum or plasma; CE-mark ; Will be performed by qualified, GCP-trained study personnel."
214882953|NCT04666311|DIAGNOSTIC_TEST|CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection|"CAD4COVID: Non-commercial product. Software tool for detecting pneumonia-related features to be expected in COVID-19 patients; availability is guaranteed by Delft Imaging System; CE certified. Will be performed by a registered and qualified radiographer/health professional in accordance with national regulations. Analysis in combination with differential white blood cell count.~SD Biosensor, STANDARDTM Q COVID-19 Ag Test (rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2)"
214882954|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
214882955|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
214882956|NCT05235126|DEVICE|Decoria intense|All subjects will receive treatment at Visit 1 with the option to receive a touch-up treatment at Visit 2. Evaluation of the nasolabial folds will be performed by PI using the Wrinkle Severity Rating Scale (WSRS).
214667481|NCT02173600|BEHAVIORAL|Group-level Intensive dietary Counselling|
214882957|NCT05216432|DRUG|RLY-2608|RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
214882958|NCT05216432|DRUG|Fulvestrant|500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
214882959|NCT05216432|DRUG|Palbociclib 125mg|125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
214882960|NCT05216432|DRUG|Ribociclib 400mg|400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
214882961|NCT05216432|DRUG|Ribociclib 600mg|600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
214882962|NCT05216432|DRUG|PF-07220060 100mg|PF-07220060 100 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
214882963|NCT05216432|DRUG|PF-07220060 300 mg|PF-07220060 300 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
214882964|NCT01503632|BEHAVIORAL|Behavioral Intervention|Receive intervention program
214882965|NCT01503632|BEHAVIORAL|Compliance Monitoring|Correlative studies
214882966|NCT01503632|OTHER|Laboratory Biomarker Analysis|Correlative studies
214882967|NCT01503632|DRUG|Mercaptopurine|Given orally
214882968|NCT01503632|OTHER|Questionnaire Administration|Ancillary studies
214882969|NCT01503632|PROCEDURE|Standard Follow-Up Care|Receive usual standard of care
214882970|NCT04334941|DRUG|Atezolizumab|Given IV
214882971|NCT04334941|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214882972|NCT04334941|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214882973|NCT04334941|PROCEDURE|Computed Tomography|Undergo CT scan
214882974|NCT04334941|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214882975|NCT04334941|DRUG|Talazoparib|Given PO
214882976|NCT06176170|DEVICE|VividWhite Glaucoma Implant (VW-51)|Subconjunctival surgical implantation of the VW-51 implant in the study eye.
214882977|NCT03683290|OTHER|Image acquisition and analysis|Oocyte image obtention and analysis prior to intracytoplasmic sperm injection
214882978|NCT01272037|DRUG|Anastrozole|Given PO
214882979|NCT01272037|DRUG|Exemestane|Given PO
214882980|NCT01272037|OTHER|Laboratory Biomarker Analysis|Correlative studies
214882981|NCT01272037|DRUG|Letrozole|Given PO
214882982|NCT01272037|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 12/1/12)
214882983|NCT01272037|DRUG|Systemic Chemotherapy|Given IV
214882984|NCT01272037|DRUG|Tamoxifen Citrate|Given PO
214882985|NCT01121562|DRUG|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
214882986|NCT04152863|BIOLOGICAL|Gebasaxturev IV|Administered as an IV infusion of 1 X 10\^9 TCID50
214882987|NCT04152863|BIOLOGICAL|Gebasaxturev ITu|Administered as an ITu injection of 3 X 10\^8 TCID50
214882988|NCT04152863|DRUG|Pembrolizumab|Administered as an IV infusion of 200 mg
214882989|NCT00195455|DRUG|Trimegestone|
214882990|NCT00195455|DRUG|17b Estradiol|
214882991|NCT05936515|OTHER|Training of nurses and nursing assistants|Training of nurses and nursing assistants, based on the model of hygiene correspondents, in order to disseminate good geriatric practices
214667482|NCT02173600|BEHAVIORAL|Individual-level Intensive Dietary Counselling|
214667483|NCT06825390|DEVICE|Cryo-auriculotherapy|The cryo-IQ device (containing compressed nitrous oxide) with a narrow-tip nozzle will be used. After disinfection of the device and both ears, 7 inter-related points in the auricular cartography will be treated with a 1-2 second application of cold gas, applied to both ears. Treatment points will be: mesoderm master, spine, reticular formation, sensory master point, thalamus, adrenocorticotropic hormone, and corpus callosum.
214882992|NCT02771288|DEVICE|Bioresorbable Vascular Scaffold|
214882993|NCT01297985|BEHAVIORAL|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a week course to an 8-week course, meeting for 2 1/2 hours once a week.
214882994|NCT06454097|DIAGNOSTIC_TEST|Assess the response glioma to radiochemotherapy using radiogenomics-based AI model|Predict the radiochemotherapy sensitivity of patients with glioma using an established radiogenomics-based artificial intellegent mode
214882995|NCT02658942|PROCEDURE|Ureteroscopy|In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
214882996|NCT02658942|PROCEDURE|Shockwave lithotripsy|In Group B patients, a Siemens Lithostar Lithotriptor
215045918|NCT05726149|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
215045919|NCT00216281|DRUG|Clozapine augmented with atomoxetine up to 40 mg or placebo|
215045920|NCT04340518|DEVICE|Scleral lens|Scleral contact lenses, manufactured in rigid gas permeable fluorosilicone acrylate polymers and treated with plasma treatment prior to use.
215045921|NCT00473018|BEHAVIORAL|standard versus enhanced risk reduction counseling|
215045922|NCT01561911|DRUG|Chi Lob 7/4 (A chimeric monoclonal antibody)|3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
215045923|NCT00416741|BEHAVIORAL|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting \[plasma flucose
215045924|NCT00305448|DRUG|Fulvestrant|250 intramuscular injection
215045925|NCT00305448|DRUG|Fulvestrant|500 mg intramuscular injection
215045926|NCT02918526|DEVICE|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
215045927|NCT03401320|DRUG|Letrozole ISM|2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
215045928|NCT04194879|DIAGNOSTIC_TEST|multi-target FIT-DNA analysis|ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
215045929|NCT00429988|GENETIC|fluorescence in situ hybridization|
215045930|NCT00429988|GENETIC|polymerase chain reaction|
215045931|NCT00429988|GENETIC|proteomic profiling|
215045932|NCT00429988|OTHER|cytology specimen collection procedure|
214882997|NCT02829476|BIOLOGICAL|Osteoblast sample|culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
214882998|NCT02436226|DRUG|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
214882999|NCT02436226|DRUG|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
215045933|NCT00429988|OTHER|immunohistochemistry staining method|
215045934|NCT00429988|PROCEDURE|breast duct lavage|
215045935|NCT00328172|DRUG|Placebo|Placebo matching BI 1356
215045936|NCT00328172|DRUG|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
215045937|NCT00328172|DRUG|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
215045938|NCT00328172|DRUG|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
215045939|NCT00328172|DRUG|Metformin|Metformin
214883000|NCT01613430|BEHAVIORAL|Coach Training (COACH)|"Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening."
214883001|NCT01613430|BEHAVIORAL|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
214883002|NCT00580892|DEVICE|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
214883003|NCT00533312|DRUG|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
214883004|NCT00533312|DRUG|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
214883005|NCT00533312|DRUG|Comparator : niacin / Duraton of Treatment: 4 Weeks|
214292152|NCT05854732|OTHER|Uninclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a active comparator with fixed speed of 5.0 mph and fixed inclination. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and fixed inclination for 30 minutes ending with Cool down for 5 minutes.
214292153|NCT01493570|DRUG|BI 409306|Film-coated tablet
214883006|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group|The regimen includes resistance training (using bands, weights, and bodyweight for major muscle groups) and core strengthening (targeting abdominal, lower back, hip, and gluteal muscles) exercises.
214883007|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group Plus Vitamin D Supplementation|Group 1 Intervention plus Vitamin D Supplementation: Daily vitamin D supplementation, with the dosage adjusted based on initial serum 25(OH)D levels to achieve and maintain optimal vitamin D
214883008|NCT06301191|DRUG|Semaglutide, 1.0 mg/mL|Semaglutide, 1.0 mg/mL
214883009|NCT06301191|DRUG|Dipeptidyl Peptidase 4 inhibitor|Dipeptidyl Peptidase 4 inhibitor
214883010|NCT05797844|OTHER|Active implementational educational strategy|4 follow-up visits (active implemantation strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days. These follow-ups included adherence to evidence-based guidelines, nurses' application of endotracheal cuff pressure measurement and solving the problems encountered during its implementation. Uncertainties associated with evidence-based guidance on endotracheal tube cuff pressure control were clarified during these sessions.
215045940|NCT02803385|OTHER|Continous Epidural Analgesia|continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.
214292154|NCT01493570|DRUG|Placebo|Film-coated tablet
214292155|NCT01149824|DRUG|Salvinorin A|
214292156|NCT01149824|DRUG|Placebo|
214292157|NCT05586529|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol is vitamin D derivative and as our population already vit D deficient so post-operative hypocalcemia can be prevented.
214292158|NCT02809456|DRUG|Nicorandil|oral intake
214667484|NCT06825390|DEVICE|Sham auriculotherapy|For the sham procedure, an empty gas canister will be used in the cryo-IQ device. This will make the same noise and temporary skin imprint on the ear, but does not deliver any cooling effect. The same 7 ear points will be sham-treated in a protocol that is imperceptibly different from the verum auriculotherapy treatment.
214667485|NCT06825390|OTHER|Experimental auricular stimulation|Three points on each ear will be repeatedly stimulated with a plastic (von Frey) filament. This will be felt, but not be painful and should not result in lasting irritation.
214292159|NCT02899910|BEHAVIORAL|Health education|Education on lifestyle changes for treatment of metabolic syndrome
214667486|NCT03697239|DRUG|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
215045941|NCT02803385|OTHER|Patient Controlled Epidural Analgesia|patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
214292160|NCT02899910|BEHAVIORAL|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
214292161|NCT02964962|DEVICE|29 mm LOTUS Edge™ Valve System|Transcatheter aortic valve replacement
214292162|NCT05870020|OTHER|Questionnaire (DBS-QoLs)|"The DBS-QoLs questionnaire will be sent to the patients for answer:~The questonnaire will be sent at :~* the inclusion~* 15 days after the inclusion~* 1 year after the inclusion"
215045942|NCT00066872|DRUG|imiquimod|
215045943|NCT00066872|PROCEDURE|conventional surgery|
215045944|NCT02782910|DEVICE|Smartphone-Based Ambulatory Assessment, Feedback via physician|Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
215045945|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at morning
215045946|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at night
215045947|NCT03293121|BEHAVIORAL|Strength and Coordination Training|Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength \& coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
215045948|NCT03293121|BEHAVIORAL|Walking|Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
214883011|NCT05797844|OTHER|Passive implementational educational strategy|Theoretical training on endotracheal tube cuff pressure management through a 4-hour presentation prepared with evidence-based guide and literature. A PowerPoint presentation including endotracheal tube cuff pressure normal values, complications related to endotracheal tube cuff pressure, management of endotracheal tube cuff pressure, endotracheal tube cuff pressure control methods, methods affecting endotracheal tube cuff pressure, how to measure endotracheal tube cuff pressure was made.
214883012|NCT05376644|DRUG|99mTc-ADAPT6|One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
214883013|NCT05376644|DRUG|99mTc-DARPinG3|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
214883014|NCT00611546|OTHER|Photo-protection|Parenteral solutions are protected from day light using aluminum covers
214883015|NCT00611546|OTHER|Photo-exposure|Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
214883016|NCT01694225|OTHER|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
214883017|NCT03786458|BEHAVIORAL|web-based decision aid|The decision aid is then developed further process of evidence synthesis and multidisciplinary external review.
214883018|NCT04237272|OTHER|Pod System E-cig|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
214883019|NCT04237272|OTHER|Customizable Tank E-cig|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week
214883020|NCT04237272|OTHER|Control|Participants will not receive any e-cigarette
214883021|NCT02540083|DEVICE|DBT and FFDM|Subjects underwent FFDM breast imaging followed by DBT breast imaging
214883022|NCT02797171|BIOLOGICAL|VRC01|Administered by intravenous (IV) infusion
214883023|NCT02797171|BIOLOGICAL|VRC01LS|Administered by intravenous (IV) infusion
214883024|NCT01527409|BEHAVIORAL|Tailored health partnership program|"When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement."
214883025|NCT01527409|BEHAVIORAL|Usual care and health education workshop|"While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group."
214883026|NCT02982291|PROCEDURE|Williams flexion protocol|The Williams flexion protocol group will participate in 15 treatment sessions.
214883027|NCT02982291|PROCEDURE|Focused spinal stenosis rehabilitation|The focused spinal stenosis rehabilitation group will participate in 5 treatment sessions.
214883028|NCT01606774|OTHER|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
214883029|NCT05237492|DRUG|Tramadol|Blood samples will be drawn from 15 patients. Tramadol will be added to all this samples in-vitro and its influence on platelets´ function will be measured.
214883030|NCT06621446|OTHER|Comprehensive intervention model|A dry eye intervention strategy: including health education, the use of eye drops, and regular review.
214667487|NCT03697239|DRUG|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
214667488|NCT03697239|DRUG|Cisplatin|25mg/m2 in 500\*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
214667489|NCT03697239|DRUG|Gemcitabine|1000mg/m2 in 500\*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
214667490|NCT04770103|BEHAVIORAL|Balance recovery|"Balance recovery by stepping ascertains the capability of the participant to recover when subjected to a loss of balance in the forward direction.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
214667491|NCT04770103|BEHAVIORAL|Postural Sway|"Postural sway is a pseudo-static measure of postural control that evaluates a participants balance recovery ability when the perturbation does not require a dynamic step recovery.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
214667492|NCT04321863|OTHER|Faecal calprotectin (FC)|FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).
214883031|NCT04592146|DEVICE|Frailty multicomponent intervention supported by POSITIVE|This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb. Furthermore, through a tablet device, other relevant information (e.g. state of mind, activities of daily living-ADLs, etc.) is collected. The same device is used to enhance communication with the clinical team and follow the tailored intervention
214667493|NCT04321863|OTHER|quantitative Faecal Immunochemical Testing (qFIT)|Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).
214883032|NCT04592146|OTHER|Frailty multicomponent intervention|This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
214883033|NCT02509169|DRUG|TAE plus P53 gene|Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
214883034|NCT02509169|OTHER|TAE|Trans-catheter embolization
214883035|NCT05726786|DRUG|Immunonutrition|"Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.~IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag"
214883036|NCT03170063|PROCEDURE|Procedure/Surgery: Biofluid samplings|Biofluid samplings (blood and cerebrospinal fluid (CSF))
214883037|NCT04110210|DRUG|Bilateral Ultrasound-Guided Erector Spinae Plane Block|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
214883038|NCT04110210|DRUG|Morphine Consumption|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
214883039|NCT02407639|OTHER|CO2|gas
214667494|NCT04321863|OTHER|Serum and faecal zinc|Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
214667495|NCT00500097|DEVICE|Digital retina image|
214667496|NCT00500097|DEVICE|direct ophthalmoscopy|
214667497|NCT00500097|PROCEDURE|comprehensive eye exam|
214883040|NCT02407639|OTHER|air|air
214883041|NCT01709539|PROCEDURE|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
214883042|NCT00199524|DEVICE|Navigator Ureteral Access Sheath|ureteral access sheath
214883043|NCT02641158|OTHER|Control Group|"After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward."
214883044|NCT02641158|BEHAVIORAL|Care Facilitation Group|"The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services."
214883045|NCT06035835|COMBINATION_PRODUCT|Lacticaseibacillus rhamnosus|Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day)
214883046|NCT06035835|COMBINATION_PRODUCT|Lactobacillus acidophilus + Bifidobacterium bifidum|Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h)
214883047|NCT03993379|DRUG|CX-072|CX-072 in combination with ipilimumab
214883048|NCT03993379|DRUG|Ipilimumab|CX-072 in combination with ipilimumab
214883049|NCT01427608|DRUG|Sertraline + Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
214883050|NCT01427608|DRUG|Sertraline + Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
214883051|NCT00325871|PROCEDURE|concurrent chemoradiation|
214883052|NCT04486365|PROCEDURE|Bifocal bone transport.|The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
214883053|NCT04486365|PROCEDURE|Trifocal bone transport|The trifocal approach is two osteotomies creating two separate transported bone segments.
214883054|NCT04742374|BIOLOGICAL|Blood sampling|Blood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis
214883055|NCT04999657|DEVICE|Non-invasive low-frequency tibial nerve stimulator (TNS-01)|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
214883056|NCT03443531|DRUG|Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
214883057|NCT03443531|DRUG|Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
214883058|NCT03443531|DRUG|Placebo Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given placebo Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
214883059|NCT03443531|DRUG|Placebo Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given placebo Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
214883060|NCT04098510|DIETARY_SUPPLEMENT|MitoQ|Subjects ingest 8x20 mg MitoQ capsules
214883061|NCT05044195|BIOLOGICAL|aQIV|Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1
215045949|NCT00030147|DRUG|Raloxifene|60 mg a day orally administered
214477048|NCT06816290|OTHER|"This research uses a qualitative method called photovoice. Participants express their experience of being a nursing student in a foreign country through visuals and share their feelings and"|"Photovoice is a participant-centered research method that allows participants to convey their experiences through visual data. This method is particularly used to understand social issues and the challenges individuals face. Participants take photos that they find meaningful related to the research topic and express their feelings, thoughts, and experiences through these images.~In this study, the Photovoice method is used to visualize the experiences of being a nursing student in a foreign country. Participants share their cultural adaptation, educational processes, personal challenges, and overall life experiences through photos taken with their smartphones. The photos are then analyzed in-depth during face-to-face interviews with the participants, where they discuss the meaning of the photo, the reason for choosing it, and their personal experiences."
214667498|NCT04926155|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
214667499|NCT02287246|DRUG|Extended-Release liposomal bupivacaine (Exparel)|20mL
214667500|NCT02287246|DRUG|Normal saline|20mL
214667501|NCT03261869|OTHER|Cold application|
214667502|NCT02514057|OTHER|Questionnaire|Form filling only
214883062|NCT05044195|BIOLOGICAL|Comparator QIV|Participants receive a 0.5-mL intramuscular dose of Comparator QIV on Day 1
214883063|NCT00659243|DRUG|rhBSSL|0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
214883064|NCT00659243|DRUG|Placebo|One week treatment
214883065|NCT03685214|DRUG|0.9% saline|we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
214883066|NCT03685214|DRUG|lactated Ringer's solution|we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
214883067|NCT04134195|DEVICE|Transcranial direct current stimulation|2mA stimulation for 20 minutes
214883068|NCT06158919|DRUG|Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine|"Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w SOX : Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1\~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1\~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1\~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1\~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable."
214883069|NCT01554319|DRUG|SB010|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL."
214883070|NCT01554319|DRUG|Placebo (phosphate-buffered saline)|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board."
214883071|NCT06223802|BEHAVIORAL|biodex training|women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
215045950|NCT00030147|DRUG|Rimostil|1000 mg twice a day administered orally
215045951|NCT00030147|DRUG|Transdermal Estradiol|100 microgram per day transdermal estradiol
215045952|NCT00030147|DRUG|Placebo skin patch and placebo tablets|matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
215045953|NCT03750019|BEHAVIORAL|Satisfying rehearsal task|Participants rehearsed satisfying aspects of the lunchtime meal they just ate.
215045954|NCT03750019|BEHAVIORAL|Dissatisfying rehearsal task|Participants rehearsed dissatisfying aspects of the lunchtime meal they just ate.
214667503|NCT01877655|BIOLOGICAL|ASP0113|Intramuscular injection
214667504|NCT01877655|DRUG|Placebo|Intramuscular injection
214667505|NCT07026435|PROCEDURE|LSTR|Lesion Sterilization and Tissue Repair (LSTR) is a minimally invasive pulp therapy using ciprofloxacin and metronidazole mixed with iodoform-calcium hydroxide, without canal instrumentation. The access cavity is sealed and restored with SSC or compomer.
214667506|NCT07026435|PROCEDURE|Pulpectomy|Pulpectomy includes mechanical canal preparation, irrigation, and obturation using iodoform-calcium hydroxide paste, followed by final restoration with stainless steel crown or compomer.
214667507|NCT07032246|DEVICE|quantitative brain MRI (icobrain mr)|"Quantitative brain MRI refers to using a specialised software to compute volumes of brain structures and of MS lesions from brain MRI scans, and to measures differences between a previous brain MRI scan and the current brain MRI scan.~The quantitative brain MRI solution being investigated in the PROCLAIM study is icobrain mr, a software solution that uses artificial intelligence (AI) to help with tracking of MS disease progression by measuring brain structures and lesions on magnetic resonance imaging (MRI)."
214883072|NCT01933477|OTHER|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
214883073|NCT02067962|BIOLOGICAL|Blood sample|Blood sample
214667508|NCT07032246|OTHER|Standard of Care (SOC)|Standard of Care practices at each participating site for management of multiple sclerosis.
214667509|NCT07030504|DRUG|SAL0133|once daily single dose or seven days multiple dose of SAL0133 tables
214883074|NCT03863548|OTHER|complication|collection of post-operative bleeding complications
214883075|NCT03135002|OTHER|Other|
214883076|NCT04816071|DRUG|Essential amino acids|Dietary Supplement
214883077|NCT04816071|DIETARY_SUPPLEMENT|Maltodextrin|Control
214883078|NCT04837144|DEVICE|Physical Rehabilitation with MAK exoskeleton|The participants will assist to 9 physical rehabilitation sessions with the MAK exoskeleton. During these sessions, different movements and therapies will be conducted using the studied device.
214883079|NCT05933044|DRUG|Durvalumab|Chemoradiotherapy plus durvalumab
215045955|NCT03750019|BEHAVIORAL|Neutral rehearsal|Participants rehearsed their journey to campus that day.
215045956|NCT00875914|PROCEDURE|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
215045957|NCT00558636|DRUG|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), \[400 mg, (2 tablets x 200 mg each) orally, twice daily\] on Study Days 2-19 and paclitaxel (175 mg/m\^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
215045958|NCT00558636|DRUG|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m\^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
215045959|NCT00374114|PROCEDURE|cervical conization|
215045960|NCT00374114|PROCEDURE|ultrasonic surgical aspiration of the cervix|
215045961|NCT01990742|BEHAVIORAL|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
215045962|NCT01868828|DRUG|PAD|Induction Therapy of PAD for 4 cycles.
215045963|NCT01868828|DRUG|VCD|Induction Therapy of VCD for 4 cycles.
214883080|NCT06263192|PROCEDURE|Intrauterine insemination|Intrauterine insemination with sperm donors
214883081|NCT06372574|DRUG|RO7617991|RO7617991 will be administered by intravenous (IV) infusion. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
214883082|NCT06372574|DRUG|Tocilizumab|Tocilizumab 8 mg/kg IV will be administered to patients when necessary to treat potential cytokine release syndrome (CRS), as described in the protocol.
215045964|NCT01868828|OTHER|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
214883083|NCT04148573|DRUG|NFX88 - 1|3 times a day
214883084|NCT04148573|DRUG|NFX88 - 2|3 times a day
214883085|NCT04148573|DRUG|NFX88 - 3|3 times a day
214883086|NCT04148573|DRUG|PLACEBO - 4|3 times a day
215045965|NCT03443687|BEHAVIORAL|Pelvic Floor Physical Therapy|Pelvic floor exercises for 3 months under instruction of physical therapist
215045966|NCT03443687|DEVICE|Home Biofeedback|Pelvic floor exercises for 3 months using biofeedback device
215045967|NCT06314009|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a functional Magnetic Resonance Imaging (fMRI) using arterial spin labeling (ASL) and other Magnetic Resonance (MR) sequences
215045968|NCT02091076|DEVICE|Silk fibroin with bioactive coating layer dressing|
215045969|NCT02091076|DEVICE|Bactigras wound dressing|
215045970|NCT06337448|DEVICE|Blue LED|The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, and he LED will be positioned in the direction of the patient's genitalia, keeping the internal and external vulvar lips open, so the LED can reach the largest possible region for therapeutic action.
215045971|NCT06563856|DRUG|TEPEZZA|Administered as a SubQ injection or IV injection.
215045972|NCT06563856|DRUG|EDP|Administered as a SubQ injection.
215045973|NCT04108273|BEHAVIORAL|Organizational Skills Training|OST targets three core organizational skills domains - Tracking Assignments, Managing Materials and Time Management - in a program consisting of sessions over 12 weeks, each training lasting about 1 hour, and corresponding 30-60 minute weekly review sessions with the parent and the child, 2-3 days following each training session.
215045974|NCT05261659|BEHAVIORAL|Exposure Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
214667510|NCT07030504|DRUG|SAL0133 placebo|once daily single dose or seven days multiple dose of SAL0133 placebo
214667511|NCT06742125|DEVICE|Drug-coated balloon (DCB)|Drug-coated balloon treatment of target lesions in patients with premature STEMI undergoing percutaneous coronary intervention.
214667512|NCT06742125|DEVICE|Drug-eluting stent (DES)|Drug-eluting stent treatment of target lesions in patients with premature STEMI undergoing percutaneous coronary intervention.
214667513|NCT06749054|DRUG|Oral Lenacapavir|Tablets administered without regard to food
214667514|NCT06749054|DRUG|Subcutaneous Lenacapavir|Administered via subcutaneous injections
214667515|NCT06749054|DRUG|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
214667516|NCT06900595|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214883087|NCT04289363|BEHAVIORAL|Clinical program implementation|Using mixed methods and triangulating multiple sources of data collected over the course of parent and ancillary studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED-initiated BUP clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness. Converging provider and patient perspectives and field notes with process measures and intervention outcomes, including proportions screened, treated, and engaged in treatment, will provide explanation to contextualize and better understand feasibility, acceptability, and factors associated with the rate with which the ED-initiated BUP innovation is adopted and how well it is sustained.
214883088|NCT06128486|DEVICE|Soft Contact Lens|Vision Correction
214883089|NCT00727012|DEVICE|mitral valve repair (SJM® Rigid Saddle Ring)|mitral valve repair due to mitral degenerative or functional disease
214883090|NCT05881434|OTHER|Emergency Department Visit Expectations Questionnaire|Patients presented with novel questionnaire designed to illicit patient's self-reported expectations across four domains (overall purpose of visit, medication intervention, imaging intervention and disposition) during check-in when arriving at the emergency department. Patients instructed to present the completed questionnaire to the treating provider.
214883091|NCT05731193|OTHER|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.|After 3 days students will take 3 tests with different levels of white noise pollution added ( signal-to-noise ratio (SNR) 20, 40 and none added)
214883092|NCT02585778|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
215045975|NCT05261659|BEHAVIORAL|Exposure Therapy|These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
215045976|NCT04357899|DRUG|thrombolysis therapy|
215045977|NCT04357899|PROCEDURE|endovascular therapy|
214667517|NCT06900595|DRUG|Cabozantinib|Given PO
214667518|NCT06900595|BIOLOGICAL|Cemiplimab|Given IV
214667519|NCT06900595|PROCEDURE|Computed Tomography|Undergo CT scan
214667520|NCT06900595|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214667521|NCT05592847|OTHER|Nurse Navigator Program|Identification of specific chronic conditions and suggestion of management care of primary care physicians and referrals to specialists via nurse navigator team members.
214667522|NCT03973268|DEVICE|Arm 1, 2, 3 device interventions|MagPro 100 TMS Therapy System
214667523|NCT03973268|OTHER|Arm 2 Interventions|Placebo
215045978|NCT04357899|PROCEDURE|decompressive surgery|
214667524|NCT03973268|DRUG|Arm 1, 2, 3 drug Interventions|Ketamine
215045979|NCT04357899|DIAGNOSTIC_TEST|multimodal imaging in acute ischemic stroke|
215045980|NCT04357899|PROCEDURE|transfer of acute stroke patients to tertiary stroke centers|
215045981|NCT04357899|DRUG|initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention|
215045982|NCT03830879|OTHER|No intervention|This cohort study have any no intervention.
215045983|NCT03929692|BEHAVIORAL|Multi-layer health promotion program|
214667525|NCT03973268|DRUG|Arm 1 and 2 Interventions|Perampanel
214667526|NCT00036790|DRUG|doxorubicin hydrochloride|
214667527|NCT00036790|DRUG|motexafin gadolinium|
214667528|NCT05881408|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
214667529|NCT05881408|GENETIC|placebo|Single IV infusion of matching placebo
214883093|NCT02585778|DRUG|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
214883094|NCT02585778|DRUG|Lipid-Modifying Therapy (LMT)|Statins at stable, maximally tolerated dose with or without other LMT as clinically indicated.
215045984|NCT03929692|OTHER|Standard health education|
215045985|NCT05173090|DRUG|Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery|Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
215045986|NCT03715790|BEHAVIORAL|EP referred group|Referred for sudden cardiac death (SCD) risk stratification and management
215045987|NCT03715790|BEHAVIORAL|Non-Referred group|Not referred for sudden cardiac death (SCD) risk stratification and management.
214667530|NCT05393739|DEVICE|Theta burst transcranial magnetic stimulation (TBS) procedure|The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
214883095|NCT02585778|DRUG|Antihyperglycemic Drug|Insulin (injectable or inhaled) alone or with other antihyperglycemic drugs as clinically indicated.
214883096|NCT00504751|DRUG|bortezomib, dexamethasone, ifosfamide|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
214883097|NCT00504751|DRUG|mesna, cisplatin, etoposide, rituximab|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
214883098|NCT01051362|DRUG|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
214883099|NCT01795950|DRUG|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
214883100|NCT02691325|DRUG|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
214883101|NCT02691325|DRUG|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose.
214883102|NCT02691325|DRUG|Activated charcoal|The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
214883103|NCT04958655|BEHAVIORAL|Tetris Task|a visual task where participants are asked to play 'tetris' i.e. attend to and manipulate shapes and positions on screen
215045988|NCT02007629|DRUG|Riociguat (Adempas, BAY63-2521)|Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
215045989|NCT04933292|DRUG|Methylprednisolone and Mycophenolate mofetil|Methylprednisolone combination of mycophenolate mofetil
215045990|NCT04933292|DRUG|Methylprednisolone and azathioprine|Methylprednisolone combination of azathioprine
215045991|NCT05639959|DRUG|Mometasone Nasal 50 Mcg/Inh Nasal Spray|Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.
215045992|NCT05639959|DEVICE|Nasal spray|device can work properly for actuation during trials
215045993|NCT04046393|DEVICE|"Taiwan Scientific noninvasive blood pressure meter TS-0411"|measure autonomic nerve
215045994|NCT04046393|DEVICE|Meridian Energy Analysis Device(MEAD)|measure meridian energy
214883104|NCT04958655|BEHAVIORAL|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate a specific future mental image to reduce cue-induced craving for alcohol
214883105|NCT05113784|DRUG|Meplazumab for Injection|humanized antibody target CD147
214883106|NCT05113784|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
215045995|NCT04046393|PROCEDURE|bacteria culture|use culture swab to culture nasal discharge
215045996|NCT04046393|PROCEDURE|nasopharyngoscopic examination|use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
215045997|NCT04046393|COMBINATION_PRODUCT|TCM nasal irrigation|Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
215045998|NCT05469919|DRUG|Ceralasertib|Ceralasertib taken orally
215045999|NCT02953184|DRUG|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
215046000|NCT02953184|DRUG|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
215046001|NCT02953184|DRUG|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
215046002|NCT02953184|DRUG|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
215046003|NCT02953184|DRUG|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
215046004|NCT02953184|DRUG|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
215046005|NCT02953184|PROCEDURE|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
215046006|NCT02953184|PROCEDURE|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
215046007|NCT02953184|PROCEDURE|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
215046008|NCT02097784|PROCEDURE|Echocardiography|
215046009|NCT02261961|BIOLOGICAL|TDAP|Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo
214883107|NCT00445432|BIOLOGICAL|adalimumab|Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
214883108|NCT00445432|OTHER|Placebo|Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
215046010|NCT02261961|OTHER|Acute Resistance Exercise|Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle
215046011|NCT02261961|OTHER|Resistance Exercise Training|Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.
215046012|NCT02261961|OTHER|Post-training Follow-up|Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.
214667531|NCT06088836|DRUG|Retrolaminar block group|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency linear ultrasound probe (6-11 MHz) was placed into a longitudinal orientation in the paraspinous line 1 cm from the midline. Lamina appeared as a continuous line interrupted by the intra laminar spaces.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done Then, an 18-gauge Tuohy needle was inserted in plane 1 cm lateral to the spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina."
214667532|NCT06088836|DRUG|Erector spinae plane block group.|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles"
214667533|NCT06938854|DEVICE|Peripheral Intravascular Lithotripsy (IVL)|For the Disrupt PAD Japan study, the Shockwave Medical Peripheral IVL System (SWM-831) is intended for lithotripsy enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the femoropopliteal arteries.
214667534|NCT05847881|BEHAVIORAL|Self-guided at home activities|After the kick-off meeting participants will complete the cultural probe kit for 3 weeks. This kit is a design research tool, to prompt participants to document, map, journal, and reflect on various aspects of daily lives. Following this, participants will attend a facilitated workshop and then complete the next at-home kits.
214883109|NCT04456088|COMBINATION_PRODUCT|150 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.
214883110|NCT04456088|COMBINATION_PRODUCT|80 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.
214883111|NCT00273988|DRUG|nevirapine|
214883112|NCT04470648|DIAGNOSTIC_TEST|blood test for SARS-COV2 serology|each person who will accept to participate will have a bood test for a SARS-COV2 serology
214883113|NCT00000846|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
214883114|NCT00000846|BIOLOGICAL|HIV-1 Peptide Immunogen, Multivalent|
214883115|NCT05866965|OTHER|PRF|centrifuge patient's blood to collect 1 block of yellowish condensed fibrin, which is platelet-rich fibrin
214883116|NCT05866965|OTHER|standard third molar surgical removal|standard third molar surgery following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
214883117|NCT01288716|DRUG|Arbaclofen|
214883118|NCT03810716|DEVICE|Interactive Platform|The participants will see the interactive platform.
214883119|NCT02054338|DRUG|Vinflunine+Gemcitabine|Vinflunine 320 mg/m² IV on day 1 and.Gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks
214883120|NCT02054338|DRUG|Paclitaxel+Gemcitabine|paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
214883121|NCT02827955|DEVICE|Gamma Knife® radiosurgery bilateral|
214883122|NCT06383455|PROCEDURE|Non-surgical periodontal therapy|An ultrasonic device (Cavitron Plus, Dentsply®, Duisburg, Germany) and periodontal hand instruments (periodontal curettes; Chicago, IL) were used for non-surgical periodontal treatment. The treatment procedure also included detailed oral hygiene instructions and full-mouth scaling and root planing. Scaling and root planing (SRP) was applied to all four quadrants under local anesthesia in a single appointment. No medication or mouthwash was prescribed to the patients.
214883123|NCT01482312|DEVICE|lotrafilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
214883124|NCT01482312|DEVICE|comfilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
214883125|NCT01482312|OTHER|Glasses|Glasses per habitual prescription
214883126|NCT01818115|DEVICE|Hydrus Implant|
214883127|NCT01818115|PROCEDURE|IOL placement|
214883128|NCT01699815|DRUG|Acetaminophen|
215046013|NCT02261961|DIETARY_SUPPLEMENT|Nutritional Supplement (Muscle Armor)|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
214883129|NCT02779244|PROCEDURE|Early Weight bearing + Cam Boot|Patients will be transitioned to weight bearing as tolerated in a cam boot.
214883130|NCT02779244|PROCEDURE|Non-Weight Bearing + Cam Boot|Subject will be transitioned to non weight bearing cam boot, standard treatment.
214883131|NCT03586089|DRUG|Phenobarbital Sodium|Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)
214883132|NCT03586089|DRUG|Inactive placebo|Single dose of inactive placebo prepared in 250 ml D5W).
214883133|NCT04168892|DRUG|150 IU of HMG in patients with age ≤ 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
214883134|NCT04168892|DRUG|225 IU of HMG in patients with age > 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
214883135|NCT03353701|BEHAVIORAL|Contingency Management (CM)|A reinforcement delivery method that involves financial incentive to participants for sustained alcohol abstinence. CM will start after the participants complete the baseline measures and last for at least 30 days and up to 90 days.
214292163|NCT02279901|BEHAVIORAL|Telemedicine Education|"Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:~1. OSA program~2. CPAP program~Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor."
214667535|NCT06953310|OTHER|Shamba Maisha|"The Shamba Maisha Intervention intervention has three key parts:~Farming Equipment and Training: The study will provide families with water pumps, seeds, and other farming tools to improve their ability to grow food. Caregivers and girls will also get training on how to use these tools.~School-based Farming: Girls will participate in practical farming activities at school, where they can learn and practice the farming skills. This also benefits the entire school because the crops grown can be used to provide food for students.~Caregiver and Adolescent Relationship Strengthening: Families will take part in special sessions where they will learn how to improve their communication, reduce stress, and talk about important topics like sexual health."
214667536|NCT00435552|PROCEDURE|Ease-It Spray|
214667537|NCT06046560|DRUG|SGLT2 inhibitor, GLP-1 RA|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
214667538|NCT06046560|BEHAVIORAL|Education-First|For the first 2-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 2 months, be invited to participate in the remote clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for therapy.
214667539|NCT04513158|BIOLOGICAL|Convalescent Plasma|Plasma obtained from individuals previously diagnosed with SARS-CoV-2 (COVID-19) is administered to hospitalized patients meeting inclusion/exclusion criteria and have provided informed consent.
214667540|NCT03439345|DRUG|Fenofibrate 145 mg|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
214667541|NCT03439345|DRUG|Placebo Oral Tablet|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
214667542|NCT04974307|DEVICE|OrCam MyEye 2|The OrCam MyEye 2 is a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs. Its advertised functions include text reading, facial recognition, and product identification.
214667543|NCT02610023|OTHER|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
214883136|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, PET/MRI|The study will use blood samples from COVID biobank at University Health Network. Samples will be collected at time of admission to ER in patients discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers. Echocardiography studies will be assessed for structural and functional abnormalities. All included patients will have prospective short-term follow-up (3-6 months) for assessment of clinical events and subclinical cardiovascular disease. 50 patients who had clinical cardiac MRI at our center within 5 years prior to COVID-19 (January 2015-January 2020) and have since tested positive for COVID-19 will be recruited for research cardiac MRI to compare changes between baseline (pre-COVID) and follow-up (post-COVID imaging). A subgroup of 50 patients will undergo cardiac PET/MRI at 1-3 months post COVID-19 diagnosis to evaluate for myocardial inflammation and other imaging markers of cardiac injury.
214883137|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, MRI|The study will involve use of blood samples from the COVID biobank at UHN (University Health Network) for measurement of blood biomarkers. Echocardiography Studies will be systematically assessed for structural and functional abnormalities. All included patients assessment of clinical events and subclinical cardiovascular disease.
215046014|NCT02261961|DIETARY_SUPPLEMENT|Placebo (Kool-Aid)|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
215046015|NCT04935255|OTHER|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).
215046016|NCT04919720|BEHAVIORAL|FRAM Model and Human Factors/Quality Improvement Intervention|The group will use semi-structured interviews and ethnographic observations to inform development of a Functional Resonance Analysis Method (FRAM) model of the process for rescue of deteriorating patients in EGS, using information from 3 hospitals. A focus group approach will be used in co-designing reform of the system for responding to post-operative deterioration, working with small groups of frontline clinical staff from relevant areas in the three Trusts involved.
215046017|NCT03112876|OTHER|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
215046018|NCT02640027|PROCEDURE|Cast removal at home using a telemedicine tool|Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
215046019|NCT02908711|DRUG|0.5% ropivacaine|Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
215046020|NCT01198626|DRUG|JNJ-32729463|150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
214667544|NCT02610023|OTHER|Laboratory Biomarker Analysis|Correlative studies
214667545|NCT02610023|DEVICE|Spectroscopy|Undergo resonance Raman spectroscopy
214667546|NCT02951598|DRUG|Florbetapir F 18 PET Scan|Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
214667547|NCT04806568|OTHER|Cognitive Training|The cognitive training treatment is a Greek adaptation of BrainHQ developed by Posit Science Corporation. The intervention will target speed, attention, working memory, and executive function through the visual and auditory domains via a set of 15 exercises. Each daily training session consists of four exercises chosen from an active set of six. Participants will be instructed to train for one hour per day, three days per week, over 12 weeks via a tablet. Each subject will receive at least 29 sessions of computerized cognitive training.
214667548|NCT04806568|DEVICE|Monitoring of daily activity|Monitoring of daily activity via Fitbit Charge 4 smartwatch.
214667549|NCT06299176|OTHER|Whole Heart Radiation Therapy|Radiation to the whole heart in one treatment with a prescribed dose of 5 Gy.
214883138|NCT02325076|DEVICE|Spirodoc|A device to detect the physical condition of the lungs
214883139|NCT01085760|DRUG|Vancomycin|Comparison of different doses of drug
214883140|NCT01085760|DRUG|Vancomycin|Comparison of different doses of drug
214883141|NCT01085760|DRUG|Metronidazole|Comparison of different doses of drug
214883142|NCT01085760|DRUG|Metronidazole|Comparison of different doses of drug
214883143|NCT01085760|DRUG|Vancomycin|Comparison of different drug doses
214883144|NCT03225001|DEVICE|Edwards SAPIEN XT transcatheter valve, Model 9300TFX|Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
214883145|NCT05463640|BIOLOGICAL|ADGRE2 CAR-T|ADGRE2 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
214883146|NCT01656057|DRUG|Acetaminophen|Acetaminophen dissolved in 50 ml of water
214883147|NCT01656057|DRUG|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
214883148|NCT01656057|DRUG|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
214883149|NCT01656057|OTHER|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
214883150|NCT01656057|OTHER|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
214883151|NCT02836925|DRUG|Ledipasvir+Sofosbuvir|"Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg~* 12 weeks in previously untreated infected patients~* 24 weeks for previously treated patients with uncertain subsequent retreatment options"
214883152|NCT02836925|DRUG|Sofosbuvir+Velpatasvir|"Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg~· 12 weeks of treatment"
214883153|NCT02281422|DRUG|BIA 2-093|
214883154|NCT05585203|BEHAVIORAL|Contingency management|"The investigators will implement a prize-based contingency management protocol in which residents will complete three pre-planned recovery-oriented activities each week for a period of up to 12 weeks. Upon verified completion of the activities each week, participants may earn prize incentives through drawing from a prize fishbowl or spinning a virtual prize wheel.~Prizes will be money added to a debit card. On the first week and individual has completed pre-planned activities, s/he can receive up to 1 draw per activity completed (3 total), and each week the number of prize draws per activity will escalate by 1. If a participant fails to complete any activities, he/she will not receive the draws for the uncompleted activities, and the prize draws would be reset to 1 in the next week. Participants can earn up to $75 in incentives in total."
214883155|NCT05585203|BEHAVIORAL|Usual Care|Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
214883156|NCT03454503|DRUG|Imatinib|Film coated tablet contains 400 mg imatinib (as mesilate)
214883157|NCT05298917|DEVICE|silicone hydrogel contact lens|silicone hydrogel contact lens
214883158|NCT00799058|DRUG|dapivirine 4789|dapivirine gel 4789, 0.05%, 2.5g applied once daily
214883159|NCT00799058|DRUG|dapivirine gel 4759|dapivirine gel 4759, 0.05%, 2.5g applied once daily
214883160|NCT00799058|DRUG|Drug placebo|HEC-based universal placebo gel, 2.5g applied once daily
214883161|NCT06333418|DEVICE|Virtual Reality Glasses Group|Before the colonoscopy procedure, 360-degree VR video scenes will be watched to patients 30 minutes using VR head device.
214883162|NCT06333418|DEVICE|Glass waterfall|Before the colonoscopy procedure, patients will watch and listen 30 minutes a portative glass waterfall
215046021|NCT01198626|DRUG|moxifloxacin|400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
215046022|NCT01198626|DRUG|JNJ-32729463 (Open-Label)|Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
215046023|NCT03817489|BEHAVIORAL|Baduanjin qigong|The intervention consists of eight sequential forms of movements which is practiced with guidance on rhythmic breathing and mindful awareness. Each cycle of the eight movements requires 10 to 15 minutes for completion. Four cycles will be practiced in each session with short breaks arranged between them.
214883163|NCT01962818|OTHER|HFOV combined with sigh breaths|"It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
214883164|NCT06128408|DRUG|risperidone, olanzapine, aripiprazole|Participants from the retrospective cohort were randomly assigned to one of the three drug groups of risperidone, olanzapine and aripiprazole for a period of 1 years of treatment.
214883165|NCT00000543|BEHAVIORAL|dietary supplements|
214292164|NCT02279901|BEHAVIORAL|IVR|"Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.~Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform."
214883166|NCT00000543|DRUG|calcium|
214883167|NCT06299787|DEVICE|intermittent theta burst stimulation|Theta-burst stimulation
214883168|NCT06299787|DEVICE|Sham stimulation|Stimulation with double-sided B70-type coil
214883169|NCT03639779|DRUG|Sodium Thiosulfate|A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
214883170|NCT03639779|OTHER|Saline Solution|A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.
214883171|NCT03766815|DIETARY_SUPPLEMENT|BCAA 200mg/kg/day|BCAA supplement based on 200mg/kg/day for 18 days.
214883172|NCT03766815|DIETARY_SUPPLEMENT|Placebo|Fiber supplement jelly for 18 days.
214883173|NCT03766815|DIETARY_SUPPLEMENT|BCAA 400mg/kg/day|BCAA supplement based on 400mg/kg/day for 18 days.
214883174|NCT03766815|BEHAVIORAL|Muscle damaging exercise|Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.
214883175|NCT06328049|DRUG|Trilaciclib Injection|Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.
214883176|NCT02088697|DRUG|Placebo|
214883177|NCT02088697|DRUG|ASC-01|
214883178|NCT02368483|OTHER|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
214883179|NCT00810511|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel contact lens
214883180|NCT00810511|DEVICE|Comfilcon A contact lens|Silicone hydrogel contact lens
214883181|NCT04258592|DRUG|(18F)MFBG|One intravenous injection of 4 MBq/kg (adults) One intravenous injection of 2 MBq/kg (minor participants)
214883182|NCT04258592|DEVICE|PET/CT|Adult patients will undergo a dynamic PET scan for the first 30 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection. Pediatric patients will undergo, depending on what is feasible for the child, at least 1 and up to 2 static whole-body PET/CTs. In patients 12 years or older, also a dynamic PET scan can be performed.
214883183|NCT04258592|OTHER|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, in patients undergoing a dynamic PET scan venous blood samples will be obtained for metabolite analysis and activity measurements at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min and 120 ± 60 min in adult participants; 5 ± 2 min, 10 ± 5 min, 30 ± 15 min, 50 ± 25 min, 90 ± 30 min in minor participants).
214883184|NCT04177082|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
214883185|NCT01221701|BEHAVIORAL|In-Home Cognitive Behavioral Psychology|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and 1 booster session provided 1 month after the 15th session.
214883186|NCT05326035|DRUG|WJ05129|WJ05129:Twice daily (except for single dose), 12 hours apart, fixed time is recommended
214883187|NCT00145951|BEHAVIORAL|motivational interviewing, brief advice in primary care|motivational interviewing, brief advice in primary care
214883188|NCT03106675|DEVICE|Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T|"Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.~Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area."
214883189|NCT03106675|DEVICE|Varian Truebeam Radiotherapy System|Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography
215046024|NCT03817489|BEHAVIORAL|Mindfulness meditation|The intervention is developed based on the core components of the established Mindfulness-Based Stress Reduction and the Mindful Self-Compassion program with adaptation for local practice. The focus of the group is to nurture mindful awareness, acceptance, and self-compassion. The group sessions are composed of a combination of mindfulness-based practice, relaxation, and yoga exercise. The basic philosophy of this intervention is the emphasis of the nurturing of self-kindness attitude, and non-attachment attitude towards inter-personal connectedness and letting go of self-criticism, need for control, and defensive separation in times of adversity. Short breaks will be arranged between each practice.
215046025|NCT02563730|PROCEDURE|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
215046026|NCT05221008|DRUG|SHR6508；Placebo|Group A:SHR6508 low dose
215046027|NCT05221008|DRUG|SHR6508；Placebo|Group B:SHR6508 medium dose
215046028|NCT05221008|DRUG|SHR6508；Placebo|Group C:SHR6508 high dose
215046029|NCT05221008|DRUG|SHR6508；Placebo|Group D:SHR6508 high dose(single dose)
215046030|NCT02897115|BIOLOGICAL|Adalimumab|Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
215046031|NCT02897115|OTHER|Non-steroidal Anti-inflammatory Drugs (NSAIDs)|ASAS recommended NSAID doses to treat axial spondyloarthritis.
215046032|NCT06467630|PROCEDURE|Preserving alveolar bone volume after tooth extraction|"* Visit 1: A periodontal or dental implant surgery is done aiming to preserve alveolar bone volume after extraction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* V2bis (1 month +/- 1 week) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
215046033|NCT06467630|PROCEDURE|Alveolar crest reconstruction|"* Visit 1: A periodontal or dental implant surgery is done aiming to alveolar crest reconstruction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
214292165|NCT04484792|OTHER|green tea mouthwash|green tea bags in 100 ml warm water for 5 min
214292166|NCT04484792|OTHER|green tea mouthwash|, in Group B its prepared by soaking tea bags in 100 ml hot water followed by ice addition.
214883190|NCT06456021|BEHAVIORAL|The Relational Playbook|The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.
214883191|NCT06456021|BEHAVIORAL|Leadership Coaching|Leadership coaching is a novel implementation strategy that enables proactive, knowledgeable, and supportive leadership behaviors. Although coaching has been embraced in the VA, through Whole Health and the VA Leadership Coaching Program, no studies have examined the impact on innovation implementation with clinical managers.
214883192|NCT03815461|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
214883193|NCT03232593|DRUG|Atezolizumab|Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
214883194|NCT05271656|DEVICE|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake of fiber pills 5 days, and contrast agent 48 hours prior to scheduled C-Scan capsule ingestion. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan Track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
214883195|NCT06511765|DRUG|Ropivacaine and dexamethasone injection solution|Injection of Ropivacaine and dexamethasone
214883196|NCT06511765|DRUG|Sodium Chloride 0.9% Injection Solution|Injection of sodium chloride 0.9%
214883197|NCT02930044|OTHER|Early administration of subcutaneous insulin glargine dose|DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units.
214883198|NCT02930044|OTHER|IV insulin infusion|All patients will receive the standard of care which is a protocol based continuous insulin infusion
214883199|NCT02930044|DRUG|IV fluid repletion|0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
214883200|NCT06583044|OTHER|Questionnaire|It includes 33 questions measuring awareness and knowledge about bruxism.
214883201|NCT04606160|BEHAVIORAL|Single Session Problem-Solving Intervention|The intervention will be a researcher led 30-45 minute session using the problem-solving module from the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Issues (MATCH-ADTC protocol.
214883202|NCT04076930|DRUG|angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)|The use of ACEI/ARB within a 90-day after the date of PD initiation (exposure ascertainment window period).
214883203|NCT03038386|OTHER|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
214883204|NCT02614924|DEVICE|Flexible fibreoptic scope|Patient intubated using fibreoptic scope
214883205|NCT02614924|DEVICE|Pentax AWS videolaryngoscope|Patient intubated using Pentax AWS videolaryngoscope
214883206|NCT03003195|DRUG|P10s-PADRE|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection for a total of 4 vaccinations.
214883207|NCT03673917|OTHER|Educational video|The educational video on skin cancer for cosmetologists
214883208|NCT03673917|OTHER|Control video|A publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer
214883209|NCT06488534|DIETARY_SUPPLEMENT|Fermentable Oligo-, Di- Monosaccharides And Polyols (FODMAPs)|A FODMAP solution of 200 mL will be infused in the colon for over 20 min. via the lumen of the solid-state catheter for high-resolution colonic manometry.
214883210|NCT01012336|DRUG|Aprepitant/Ramosetron/Dexamethasone|"Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.~Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.~Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg."
214883211|NCT02517008|OTHER|Mama kit|A low-cost non-monetary incentive (mama kit) was provided to all women who delivered at the facility between June 1, 2013 - Aug 31, 2013. Women were told about the intervention during ANC, and safe motherhood groups in the community promoted the intervention in the catchment areas of the treatment facilities.
214883212|NCT00911300|DRUG|fondaparinux|Comparison of different drugs
214883213|NCT00911300|DRUG|unfractionated heparin|Comparison of different drugs
215046034|NCT06467630|PROCEDURE|Covering bone defects during immediate implant placement.|"* Visit 1: A periodontal or dental implant surgery is done aiming to cover bone defects during immediate implant placement.~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (3 months ± 1 month) - Late post-surgery follow-up"
215046035|NCT00487981|DEVICE|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
215046036|NCT01345448|DRUG|Brimonidine|0.1% Brimonidine Lotion, dosed once.
215046037|NCT01345448|DRUG|Placebo Lotion|Placebo Lotion dosed once.
215046038|NCT02869724|OTHER|Weekly divided delivery|
214292167|NCT04484792|OTHER|placebo|Plain water
214883214|NCT00911300|DRUG|Vitamin-K-Antagonist|Comparison of different drugs
214883215|NCT00180999|DRUG|Erythropoiétine|
214883216|NCT01055756|DRUG|Loratadine + Pseudoephedrine sulfate|Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
214883217|NCT06531837|DRUG|Esketamine(Continuous infusion)|Continuous intravenous infusion of esketamine at a dose of 0.2 mg/(kg · h). Collect resting-state EEG data and NRS scores 40 minutes after administration.
214883218|NCT06531837|DRUG|Remifentanil (Target-Controlled Infusion)|The plasma drug concentrations of remifentanil were set at 0.5 ng/ml, 1 ng/ml, and 1.5 ng/ml. After each plasma drug concentration reached a steady state, the NRS scores were assessed, and resting-state EEG was recorded for at least 5 minutes.
214883219|NCT06531837|DRUG|Flurbiprofen (Single intravenous injection)|Single intravenous injection of Flurbiprofen at a dose of 100 mg. Collect resting-state EEG data and NRS scores 10 minutes after administration.
214883220|NCT06531837|DEVICE|Spinal Cord Stimulation|Collect resting-state EEG data and NRS scores with the spinal cord stimulator both turned off and on.
214883221|NCT06531837|OTHER|No intervention|Collect resting-state EEG data and NRS scores.
214883222|NCT00948272|BIOLOGICAL|Purified Vero Rabies Vaccine - Serum Free|0.5 mL, Intramuscular
214883223|NCT00948272|BIOLOGICAL|Purified inactivated rabies vaccine|0.5 mL, Intramuscular
214883224|NCT01724450|DRUG|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
215046039|NCT02869724|OTHER|Monthly divided delivery|
214883225|NCT01724450|DRUG|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
214883226|NCT04821193|DRUG|Skin antisepsis with 5% NaHCO3 water solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
214883227|NCT04821193|DRUG|Skin antisepsis with 2% Chlorhexidine Gluconate solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
214883228|NCT05298345|OTHER|Family Champions Project Primary Services|"Primary Services: participants receive 12 hours of TYRO Leadership curricula, 6 hours of Core Communication curricula.~Support Services (optional): participants choose from a menu of classes (1-3 hours) at the walk-in mini clinic to meet a variety of self-identified needs."
215046040|NCT04145076|DRUG|Placebo|Two oral doses of placebo.
215046041|NCT04145076|DRUG|Citalopram|Single oral dose of citalopram (20mg) and single oral dose of placebo.
215046042|NCT04145076|DRUG|Tianeptine|Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
215046043|NCT00392093|DRUG|Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d|
215046044|NCT03510130|OTHER|Routine leg movement|Routine leg movement to the right and left in the supine position during the second stage of labor, for 3 minutes every 20-30 minutes by the attending physician or nurse.
215046045|NCT01659450|OTHER|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
215046046|NCT01659450|OTHER|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
215046047|NCT01659450|OTHER|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
214883229|NCT02542956|DRUG|Exparel|receive Exparel by injection
214883230|NCT02542956|DRUG|Marcaine|receive Marcaine in a pain pump
214883231|NCT02542956|DRUG|Marcaine|receive Marcaine by injection
215046048|NCT05246969|OTHER|Sepsis detection|The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.
215046049|NCT01365793|DRUG|0.45% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
214883232|NCT00794508|BIOLOGICAL|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
214883233|NCT01720888|OTHER|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
215046050|NCT01365793|DRUG|0.9% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
215046051|NCT01365793|DRUG|0.45% saline intravenous fluid|0.45% saline fluid
215046052|NCT01365793|DRUG|0.9% saline Intravenous fluid|0.9% saline fluid
215046053|NCT03764111|DEVICE|Large Mobile Ultrasound System|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.
215046054|NCT03764111|DEVICE|Handheld Ultrasound Machine|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.
215046055|NCT01342731|DRUG|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
215046056|NCT01416961|RADIATION|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
214883234|NCT04167592|DRUG|Benzydamine Hydrochloride 0.15% Oral Rinse|Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
214883235|NCT04167592|DRUG|Water|Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
214883236|NCT06008275|DRUG|Neratinib Oral Tablet|240mg oral daily. Dosing will follow standard dose escalation procedures
214883237|NCT06008275|DRUG|Ruxolitinib Oral Tablet|20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
214883238|NCT05812534|DRUG|Cadonilimab|Subjects who met the study population conditions were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2. Every 3 weeks is a cycle, with a total of 4-6 cycles (the number of chemotherapy cycles is determined by the researchers). Cadonilimab 10mg/kg, bevacizumab 7.5 mg/kg and pemetrexed 500mg/m2 were then maintained until disease progression, intolerable toxicity or other causes specified in the regimen occurred. When the subject first has imaging disease progression, if the researcher judges that it is clinically beneficial and tolerant to the test drug, he will be allowed to continue treatment.
215046057|NCT01416961|DRUG|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
215046058|NCT01416961|DRUG|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
215046059|NCT02808429|DRUG|Placebo|Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
215046060|NCT02808429|DRUG|Atacicept 25 mg|Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
215046061|NCT02808429|DRUG|Atacicept 75 mg|Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
214883239|NCT04414774|DEVICE|GG-Suicide-Ideation|GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
214883240|NCT01128543|DRUG|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
214883241|NCT04642404|DRUG|Epidiolex 100 mg/mL Oral Solution|Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
214883242|NCT04642404|DRUG|Placebo|Placebo drug will be a solution with the same taste, texture and color as the drug.
214883243|NCT00785148|DRUG|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
214883244|NCT05298826|DRUG|recombinant factor VIIa|using recombinant factor VIIa
214883245|NCT03874728|OTHER|Minimal shoes|A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.
214883246|NCT03874728|OTHER|Standardised conventional shoes|The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.
214883247|NCT03874728|OTHER|Barefoot|Participants will conduct the assessments barefoot.
214883248|NCT03874728|OTHER|"Smart shoe insoles"|Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.
214883249|NCT03334461|COMBINATION_PRODUCT|Exposure to oral antiseptics or enamel remineralisation agent|
214883250|NCT04114487|OTHER|dual task balance training|The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
214883251|NCT01941498|DEVICE|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
214883252|NCT01941498|PROCEDURE|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
215046062|NCT05468502|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
215046063|NCT01794910|OTHER|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
214883253|NCT00842205|DRUG|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
215046064|NCT04095065|BEHAVIORAL|itMatters|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking.
214883254|NCT00842205|DRUG|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
214883255|NCT05667025|OTHER|Conservative rehabilitation|Joint range of motion, strengthening, balance-coordination and stretching exercises included in the conservative physiotherapy program 5 days a week for a total of 6 weeks
214883256|NCT05667025|OTHER|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation|In addition to conservative treatment, cycling FES to the affected lower extremity for 20 minutes, 3 days a week for 4 weeks. During the treatment, the patient will be seated on a chair and her feet will be fixed to the pedal with velcro tape, and the comfort during the treatment will be provided with calf supports.
214883257|NCT05088785|DRUG|FES|\[18F\]FES PET imaging.
214883258|NCT02015845|DEVICE|Accuvein|
214883259|NCT02015845|DEVICE|Routine technique|Placement of peripheral intravenous catheters using the routine technique
214883260|NCT04391504|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
214883261|NCT05783232|DIETARY_SUPPLEMENT|Placebo Control Form 1 Capsules|Participants will use their Placebo Control Form 1 Capsules as directed for a period of 4 weeks.
214883262|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.1 Capsules|Participants will use their Radicle Health Active Study Product 1.1 Capsules as directed for a period of 4 weeks.
214883263|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.2 Capsules|Participants will use their Radicle Health Active Study Product 1.2 Capsules as directed for a period of 4 weeks.
214883264|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.3 Capsules|Participants will use their Radicle Health Active Study Product 1.3 Capsules as directed for a period of 4 weeks.
214883265|NCT05532033|DEVICE|High flow nasal cannula|A device able to delivery high flow oxygen therapy
214883266|NCT05532033|DEVICE|Facial mask|standard oxygen therapy
215046065|NCT04095065|BEHAVIORAL|itMatters and itMatters Sexual Violence Prevention|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
214883267|NCT00166647|PROCEDURE|Blood Sampling|
214883268|NCT00282451|DRUG|biphasic insulin aspart|
214883269|NCT00282451|DRUG|insulin aspart|
214883270|NCT01267487|DRUG|Heparin fixed doses|"Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery."
214883271|NCT01267487|DRUG|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
214883272|NCT01267487|DRUG|Heparin and protamine titration|"Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve."
214883273|NCT03394157|OTHER|metabolic surgery|operation to cure type2 diabetes
214883274|NCT06281444|DEVICE|ESWT|"All patients in both groups will be applied with a home-based exercise program around for 30-minutes per day for four weeks. The exercises that mentioned in the research content are knee range of motion and strengthening exercises for the knee. It will be checked by phone on a weekly basis. Also, each patient in group 1 will receive shockwaves of continuous frequency and intensity (1000 shocks, 2.0 to 3.0 bar,10 Hz and 0.08-0.25mJ/mm2 energy range), while the second group of patients will receive sham-ESWT.~ESWT application will be applied to the medial part of the knee area on the side where the pain is described, or at the patellofemoral and tibiofemoral borders of the affected knee, and will be given in four sessions in total once a week."
214883275|NCT06281444|DEVICE|Sham-ESWT|Sham ESWT application will be set to 1000 pulses, 2-3 bar pressure, 10 Hz frequency and 0 mJ/mm2 energy to be sham.
214883276|NCT00396565|DRUG|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
214883277|NCT00396565|DRUG|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
214883278|NCT00396565|DRUG|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
214883279|NCT06257251|OTHER|Histological slides digitization|Histological slides of the capsule samples taken during surgery will be collected for analysis and digitized. Using the NDPview2 software, the investigators will manually count the silicone particles present in the peri-prosthetic capsule and measure the surface area of the capsule to estimate the silicone particle density.
214883280|NCT00005195|PROCEDURE|Catheter ablation|
214883281|NCT06581887|BEHAVIORAL|Classical conditioning task|To evaluate the neurophysiological and physiological response to a classical conditioning task, which is comparable to findings that have been made in the mdx dystrophic mouse (deficient in Dp427). The investigators will assess correlations between the specific DMD/BMD genotype and susceptibility to conditioning, as well as the relationship between conditioning and behavioural/emotional characteristics of the syndrome.
214883282|NCT05507736|OTHER|Acupuncture|13 Indwelling, sterile and disposable needles (SEIRIN NEW PYONEX® from 0.9 mm in length and 0.22 mm in diameter) on day 1 and 5 of the second cycle of irinotecan leaving them inserted for 4 days.
214883283|NCT05610423|OTHER|no intervention|No intervention. Observational study only
214883284|NCT02192398|DRUG|Guanfacine|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
214883285|NCT02192398|DRUG|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
214883286|NCT06581367|DRUG|Tailoring the course duration to the patient's needs.|Patients will be advised to visit the center as soon as they feel better and are afebrile for a clinical assessment including vital signs (temperature, blood pressure, respiratory rate, pulse, and oxygen saturation) and C-reactive protein rapid testing after completing two full days of antibiotic.
214883287|NCT06581367|DRUG|Complete a 7-day course|The antibiotic course must be completed (7 days at least).
214883288|NCT06285292|DEVICE|EMY|"Patients in the intervention group (rehabilitation with the EMY medical device) will undergo 2 rehabilitation sessions with a physiotherapist trained in pelviperineology between M0 and M2. The aim of these sessions will be to learn proper perineal contraction and combat the deficits identified during the physiotherapist's assessment. They will have to perform pelvic-perineal re-education exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months. Then, for a further 3 months, their program can be modified for free, on-demand use (e.g. 2 x 10 minutes per week). After the main criterion at M6, they will be free to modify their rehabilitation program in the application according to their symptoms, and follow their program until the end of the study"
214883289|NCT04317092|DRUG|Tocilizumab Injection|Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). A second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the Investigator.
214883290|NCT01632657|DRUG|Sumatriptan|Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
214883291|NCT01632657|OTHER|Placebo|Single injection saline 0.5ml subcutaneously in recovery
214883292|NCT05154838|PROCEDURE|Drainage and packing of pilonidal abscess|Patients will be treated as per standard care, their wound drained, cleaned and packed. Microbiology swab samples will be obtained.
214883293|NCT01668914|PROCEDURE|IM-SLNB|IM-SLNB is performed according to the pre-operative lymphoscintigraphy
214883294|NCT01668914|RADIATION|99mTc-SC|Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
214883295|NCT01668914|DEVICE|Histologic Examination|All IMSLNs were analyzed by histologic examination for future therapy planning.
214883296|NCT01668914|DEVICE|LSG|lymphoscintigraphy was performed 0.5\~1.0 hour before surgery
214883297|NCT01668914|DRUG|Methylthioninium|Four milliliters of methylthioninium was injected intraparenchymally around the primary tumor 10 min before surgery
214883298|NCT04324021|BIOLOGICAL|Emapalumab|I.v. infusion every third day
214883299|NCT04324021|BIOLOGICAL|Anakinra|Daily i.v. infusion
214883300|NCT02454855|DRUG|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
214883301|NCT02454855|DRUG|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
214883302|NCT03097991|BEHAVIORAL|Focused Coparenting Consultation|Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
214883303|NCT00604682|DRUG|CC10004|2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
214883304|NCT05107648|BEHAVIORAL|Gardner GOALS|12 lesson curriculum focusing on healthy eating, increased physical activity and decreased screen time
214883305|NCT00002704|BIOLOGICAL|filgrastim|
214883306|NCT00002704|DRUG|asparaginase|
214883307|NCT00002704|DRUG|cyclophosphamide|
214883308|NCT00002704|DRUG|daunorubicin hydrochloride|
214883309|NCT00002704|DRUG|dexamethasone|
214883310|NCT00002704|DRUG|etoposide|
214883311|NCT00002704|DRUG|leucovorin calcium|
214883312|NCT00002704|DRUG|liposomal cytarabine|
214883313|NCT00002704|DRUG|mercaptopurine|
214883314|NCT00002704|DRUG|mesna|
214883315|NCT00002704|DRUG|methotrexate|
214883316|NCT00002704|DRUG|therapeutic hydrocortisone|
214883317|NCT00002704|DRUG|thiotepa|
215046066|NCT04095065|BEHAVIORAL|itMatters Well-being and itMatters Sexual Violence Prevention|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
215046067|NCT04095065|BEHAVIORAL|itMatters Well-being|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
215046068|NCT01469039|DRUG|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
215046069|NCT01469039|DRUG|Placebo|Placebo for IM injection, given monthly
214883318|NCT00002704|DRUG|vincristine sulfate|
214883319|NCT00002704|RADIATION|low-LET electron therapy|
214883320|NCT00002704|RADIATION|low-LET photon therapy|
214883321|NCT06147648|DRUG|Tacrolimus Sustained-release Capsules|Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
214883322|NCT01436630|OTHER|Step Test and Six Minute Walk.|The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
214883323|NCT00299130|DRUG|Folate|A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
214883324|NCT00299130|DRUG|Methotrexate|A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
214883325|NCT00299130|DRUG|Methylprednisolone|Intravenous infusion
214883326|NCT00299130|DRUG|Placebo|Placebo to rituximab intravenous infusion
214883327|NCT00299130|DRUG|Rituximab|Intravenous infusion
214883328|NCT02211417|DRUG|Oral DS107|
214883329|NCT02211417|DRUG|Placebo|
214883330|NCT02271295|DRUG|Enoxaparine|Enoxaparine 4000UI/day during 24 months
214883331|NCT01198132|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
214883332|NCT01198132|DIETARY_SUPPLEMENT|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
214883333|NCT01198132|DRUG|Rebif|Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
214883334|NCT02930759|DRUG|BAY987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-096)
214883335|NCT05416242|DEVICE|Traditional braces|MBT 0.022 perception traditional braces will be used without any acceleration method.
214883336|NCT05416242|DEVICE|Self-ligating braces|MBT 0.022 perception Self-ligating braces will be used without any acceleration method.
214883337|NCT05416242|PROCEDURE|Self-ligating braces + piezocision|Flapless corticotomy will be applied for the upper anterior teeth.
214883338|NCT04133987|BIOLOGICAL|Tetravalent live attenuated dengue vaccine admixture TV005|The admixtures of the candidate vaccines each contain 4 live attenuated dengue viruses, each of a different serotype.
214883339|NCT04133987|BIOLOGICAL|Placebo|PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.
215046070|NCT01132703|DRUG|Glyburide for Injection|Administered as specified in the Treatment Arm.
215046071|NCT01132703|DRUG|Placebo|Administered as specified in the Treatment Arm.
215046072|NCT02700672|OTHER|Observational study|Observational study: kinematic variables, falls and executive function were analyzed
215046073|NCT00698828|DRUG|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
215046074|NCT00698828|DRUG|SUN11031 20 μg/kg|Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
214883340|NCT03166098|DIAGNOSTIC_TEST|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
214883341|NCT02495662|DRUG|PEG-liposomal prednisolone sodium phosphate|Liposomal prednisolone
214883342|NCT02495662|DRUG|Placebo|0.9% normal saline
214883343|NCT00346918|DRUG|Sirolimus|Standard plus Sirolimus
214883344|NCT00346918|OTHER|Standard|Standard
214883345|NCT01959061|DRUG|Raltitrexed|4mg, every 4 weeks,transhepatic arterial infusion
214883346|NCT01959061|DRUG|Oxaliplatin|100\~150mg, every 4 weeks, transhepatic arterial infusion
214883347|NCT01959061|DRUG|lipiodol|5-20ml, every 4 weeks, hepatic artery embolization
214883348|NCT00437697|DRUG|dalteparin|
214883349|NCT00727103|DRUG|Varenicline|Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.
214883350|NCT00727103|DRUG|Placebo|Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
214883351|NCT00257621|DRUG|GW640385|
214883352|NCT00257621|DRUG|Ritonavir|
214883353|NCT01755091|DRUG|Dronabinol|
214883354|NCT01755091|DRUG|Placebo (for Dronabinol)|
214883355|NCT03936803|BEHAVIORAL|aerobic interval training exercise .|Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with HR at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum HR. The exercise session was terminated by 5 minutes cool-down
214883356|NCT03936803|DEVICE|electro acupuncture|"electroacupuncture (EA) of (2 Hz, 4 mA) was applied at points of:liver 3 LR3,liver 14 LR 14, gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
214883357|NCT04264325|OTHER|diaphragmatic ultrasound measure|patients with lung neoplasms and malignant pleural effusions who need a diagnostic or therapeutic thoracocentesis
214883358|NCT05677035|DRUG|LINO-1713 1 tablet|LINO-1713 1 tablet is administered once. Oral administration with 200mL of water
214883359|NCT05677035|DRUG|LINO-1713 once a day for 24 days|Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.
214883360|NCT00490841|DEVICE|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
214883361|NCT05973799|OTHER|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
214883362|NCT05973799|OTHER|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
214883363|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
214883364|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
214883365|NCT06028295|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
214883366|NCT03305133|OTHER|Immunohistochemistry|The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.
214883367|NCT06134726|DIAGNOSTIC_TEST|seropositivity of rheumatoid factor|All participants were tested for seropositivity of rheumatoid factor and anticitrullinated protein antibodies
214883368|NCT02252354|DRUG|[14C]-TAK-385 Oral Solution|TAK-385 oral radiolabelled solution
214883369|NCT02252354|DRUG|TAK-385 Tablets|TAK-385 tablets 2 X 40 mg
214883370|NCT02252354|DRUG|[14C]-TAK-385 Solution for Intravenous Infusion|TAK-385 intravenous (IV) radiolabelled solution
214883371|NCT05680584|DRUG|Melatonin 3 MG|0.1 mg/ kg melatonin in 10 ml apple juice 1 hour before induction of anesthesia
214883372|NCT05680584|DRUG|Hydroxyzine Pill|1 mg/ kg hydroxyzine in 10 ml apple juice 1 hour before induction of anesthesia
214883373|NCT05680584|OTHER|Placebo|10 ml apple juice 1 hour before induction of anesthesia
214883374|NCT05142397|PROCEDURE|Focused Ultrasound|Focused ultrasound generates heat effects, mechanical effects and cavitation effects that denature the diseased tissues, facilitate necrosis and allow them to be replaced by surrounding normal healthy tissues.
214883375|NCT01119365|OTHER|Bright light|Light is administered through a custom designed mask with LED lights.
214883376|NCT04146103|DRUG|Novex|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
214883377|NCT05920837|DEVICE|MyotonPRO|Muscles' viscoelastic properties assess with myotonPRO.
214883378|NCT05920837|OTHER|Box and Block Test|Upper extremity's functionality assess with Box and Block Test.
214883379|NCT04780178|BEHAVIORAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias|A telephone-based acceptance and commitment therapy for caregivers
214883380|NCT07133373|OTHER|Turkish Coffee (unfiltered, boiled)|Standardized Turkish coffee (unfiltered and boiled) was administered once daily for 4 weeks. Each serving was approximately 75 mL, prepared using a consistent protocol without added sugar or milk. The coffee was sourced from the same batch and brewed in a traditional cezve. Compliance and adverse effects were monitored throughout the intervention.
214883381|NCT07133906|DEVICE|Continuous glucose monitoring|A blinded Abbott Freestyle Libre 3 Pro will be placed on the newborn
214883382|NCT07133906|DEVICE|Cerebral near-infrared spectroscopy|Blinded cerebral near infrared spectroscopy will be assessed
214883383|NCT06619405|DIAGNOSTIC_TEST|Streetlab VR|Streetlab VR is a virtual reality headset that is warn to simulate walking through a maze at different light levels.
214883384|NCT02350816|DRUG|HGT-1410|HGT-1410 administered according to Patient Group assignment.
214883385|NCT04700137|OTHER|Caring Contacts Plus Introductory Phone Call (CC+)|One introductory semi-structured caring phone conversation with a follow-up specialist to check-in, establish a personal connection, and provide resources at the 0-2 week time-point followed by 11 non-demanding, caring text or email messages sent over the course of 6 months.
215046075|NCT00698828|DRUG|SUN11031 40 μg/kg|Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
215046076|NCT02013609|DRUG|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
215046077|NCT00358111|DEVICE|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
215046078|NCT05983094|DRUG|Utidelone|Utidelone injection 30mg/m2, on days 1-5 of each cycle
215046079|NCT05983094|DRUG|Carboplatin|Carboplatin Area under curve(AUC)6, iv, was administered on day 1
215046080|NCT05983094|DRUG|Epirubicin|Epirubicin 75mg/m2 was administered on day 1
214883386|NCT04700137|OTHER|Caring Contacts without an introductory phone call (CC)|Eleven non-demanding, caring text or email messages sent over the course of 6 months. Participants will not know or have spoken to the follow-up specialist who sends the caring messages.
215046081|NCT05983094|DRUG|Trastuzumab|Trastuzumab 8mg/kg iv in first cycle on day 1, then 6mg/kg in the rest cycles
215046082|NCT05983094|DRUG|Pertuzumab|Pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles
215046083|NCT00856609|DRUG|Byetta (exenatide)|Exenatide is an injectable medication
215046084|NCT00856609|BEHAVIORAL|Weight loss|Because response to weight loss
215046085|NCT00856609|OTHER|Metabolic Chamber|The subject stays in the small room
215046086|NCT00856609|DRUG|Placebo|
214883387|NCT05332821|DRUG|PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
214883388|NCT05332821|PROCEDURE|TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
214883389|NCT01461564|PROCEDURE|Colonoscopy|Screening colonoscopy
214883390|NCT04735861|DRUG|Sintilimab|Sintilimab 200mg iv. q3w, up to 2 years.
214883391|NCT04735861|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
214883392|NCT00174954|PROCEDURE|MRI|Subjects underwent MRI to evaluate tophi.
214883393|NCT01324531|PROCEDURE|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
214883394|NCT01324531|PROCEDURE|Bankart repair|Bankart repair based on surgeon's preference
214883395|NCT00224380|BEHAVIORAL|Using Medications Effectively|
214883396|NCT01190553|DRUG|Amantadine|Initiation: IV amantadine 200mg/500ml \* 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
214883397|NCT02016703|OTHER|Erythritol drink|
214883398|NCT02016703|OTHER|Placebo drink|
214883399|NCT05937997|PROCEDURE|high intensity physiotherapy|high intensity exercises for 3 weeks inpatient rehabilitation
214883400|NCT05937997|PROCEDURE|moderate intensity physiotherapy|moderate intensity exercises for 3 weeks inpatient rehabilitation
214883401|NCT05937997|PROCEDURE|low intensity physiotherapy|low intensity exercises for 3 weeks inpatient rehabilitation
214883402|NCT00839254|BIOLOGICAL|Pneumococcal conjugate vaccine Synflorix (GSK1024850A)|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
215046087|NCT04037228|DEVICE|KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)|The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
215046088|NCT00533130|PROCEDURE|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
215046089|NCT00533130|PROCEDURE|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
215046090|NCT05730881|PROCEDURE|ECMO|VA-ECMO is a life support measures, we need to estimate the survival by different techniques to allocate therapeutic interventions properly
215046091|NCT03346525|DRUG|intramuscular benzathine penicillin G (BPG) prophylaxis|Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days.
215046092|NCT02731287|DRUG|Timolol|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
215046093|NCT02731287|DRUG|Placebo|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
214883403|NCT00839254|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children \< 12 months of age at the time of first study vaccination.
214883404|NCT00839254|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children \>= 12 months of age at the time of first study vaccination.
215046094|NCT00783432|DRUG|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
215046095|NCT00783432|DRUG|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
215046096|NCT00373607|DRUG|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
215046097|NCT00373607|DRUG|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
215046098|NCT00852410|DRUG|1% lidocaine with 1:100,000 adrenaline|high dose
215046099|NCT00852410|DRUG|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
214883405|NCT02765425|DEVICE|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
214883406|NCT02028494|DRUG|Capecitabine|Two dosages comparison
214883407|NCT05755776|DRUG|TMF|switch ETV to TMF
215046100|NCT02546882|BIOLOGICAL|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
214883408|NCT04460560|DRUG|Terlipressin|"For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump"
214883409|NCT02757573|PROCEDURE|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
214883410|NCT03062163|OTHER|Resveratrol lipoic Acid|Transdermal patch loaded with resveratrol and lipoic acid
214667550|NCT05207397|OTHER|Lactate infusion|The unlabeled lactate infusion cocktail (30% L(+)-lactic acid solution (Sigma) with 2N NaOH, pH4.8) and stable isotope infusions were made by a pharmacy and tested to be sterile and pyrogen free. Upon arriving to the KU Clinical and Translational Science Unit, a catheter will be placed in the subject's hand, which will be placed into a heated hand box for collection of arterialized blood. A second catheter will be placed in the opposing forearm vein for the infusion of lactate isotope solution and unlabeled lactate infusion cocktail. After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. We will then administer priming doses of 57.5 mg \[13C3\]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of \[13C3\]lactate at 10 mg/min and D2-glucose at 2 mg/min \[53\]. Along with the continuous isotope infusion we will begin infusion of the Na-lact
214883411|NCT03062163|OTHER|Placebo|Transdermal patch loaded with normal saline
214883412|NCT04835623|DRUG|Cyclosporine 0.09% Ophthalmic Solution|one drop each eye twice daily
214883413|NCT01138982|BEHAVIORAL|Youth Mentoring program|
214883414|NCT01307176|BEHAVIORAL|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
214883415|NCT02204306|GENETIC|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
214883416|NCT00463697|DRUG|GW642444H (100mcg)|H salt
214883417|NCT00463697|DRUG|placebo|placebo
214883418|NCT00463697|DRUG|GW642444M (25, 100 & 400 mcg)|M salt
214883419|NCT05151783|OTHER|conventional physiotherapy|"Control group receivewill routine physical therapy including modalities like ultrasound (3 MHz continuous type; duration 10 minutes), heat modalities (apply to the involved region of shoulder joint shoulder for 10 minutes), shoulder ROM exercises, capsular stretching, and joint mobilization 5 times per week for four weeks. Duration of session will be 40 minutes.~All Maitland mobilization will be given in supine position. After giving glenohumeral (GH) joint distraction, GH caudal glide, GH dorsal glide, and GH ventral glide were given at a rate of 2-3/second oscillations for 1-2 minutes to patients. Grade I or II rhythmic oscillations will be applied in pain free movement."
214883420|NCT05151783|OTHER|PNF technique|Group will receive scapular PNF techniques with routine physical therapy explained above For PNF techniques, patients will be lying on unaffected shoulder. In this group, 20 repetitions of diagonal scapular Pattern (Anterior Elevation and Posterior Depression and Posterior Elevation and Anterior Depression) with 20 sec rest period will be given to patients. Preparatory instructions for the desired movement will be given to patients at the start of procedure. PNF facilitation techniques of RI (Rhythmic initiation) \& repeated contractions will be used in all patterns
214883421|NCT00789997|DRUG|Prednisone|prednisone 40 mg daily for 10 days or placebo prednisone
214883422|NCT00789997|DRUG|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
214883423|NCT00789997|DRUG|levofloxacin|Levofloxacin 750 mg daily for 10 days.
215046101|NCT02546882|DRUG|saline|1 ml saline was injected for 1 cm2 area.
215046102|NCT01738061|BEHAVIORAL|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
215046103|NCT00124930|DRUG|Olanzapine|
215046104|NCT00124930|DRUG|Haldol|
215046105|NCT00537472|DRUG|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
215046106|NCT00537472|DRUG|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
214667551|NCT06834009|DRUG|SUZ|Powder for oral administration.
214667552|NCT06173752|BEHAVIORAL|Exposure therapy|Participants will complete exposure therapy for up to 12 weeks, and coached exposure session will be approximately 50 minutes.
214883424|NCT00234962|DRUG|Lopinavir/Ritonavir|
214883425|NCT01484327|DRUG|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
214883426|NCT04842292|DRUG|Heparin|Nebulized heparin 25,000 units every 6 hours
214883427|NCT04842292|DRUG|Placebo|Sodium chloride 0.9% every 6 hours
214883428|NCT02174289|DEVICE|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
214883429|NCT03859765|BEHAVIORAL|HCT Symptoms and Steps|HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
214883430|NCT05418244|OTHER|Inhaled Isopropyl Alcohol|Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares
215046107|NCT06169618|OTHER|cervical radiculopathy|this group will have patients with cervical radiculopathy
215046108|NCT06169618|OTHER|normal group|this group will have normal subjects
214883431|NCT05418244|DRUG|Oral Ondansetron|4 mg oral disintegrating ondansetron tablet once
214667553|NCT06226090|DRUG|TG103 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
214883432|NCT05418244|OTHER|Inhaled Placebo|Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares
214883433|NCT05212389|DRUG|Femicept|150 μg levonorgestrel +30 μg ethinylestradiol
214883434|NCT05212389|DRUG|Placebo|Placebo
214883435|NCT02687529|DEVICE|CST001|
214883436|NCT01467986|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
214883437|NCT01467986|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
214883438|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
214883439|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
214883440|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
214883441|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
214883442|NCT03703869|DRUG|Insulin glargine (U300)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
215046109|NCT03273907|DEVICE|CyPass Micro-Stent implanted with CyPass 241-S applier|CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
215046110|NCT03273907|PROCEDURE|Cataract surgery|Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit
215046111|NCT01074073|DRUG|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
214667554|NCT06226090|DRUG|Placebo 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
214667555|NCT06226090|DRUG|TG103 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
214667556|NCT06226090|DRUG|Placebo 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
214883443|NCT05868512|DIAGNOSTIC_TEST|Dry needling|Dry Needling Along With Routine Physical Therapy for Chronic Neck Pain
214883444|NCT05868512|DIAGNOSTIC_TEST|Therapeutic ultrasound|Therapeutic ultrasound Along With Routine Physical Therapy for Chronic Neck Pain
214883445|NCT01522612|DRUG|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
214883446|NCT01522612|DRUG|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
214883447|NCT01522612|DRUG|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
214883448|NCT03709979|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
214883449|NCT05778903|OTHER|Nerve block|Suprazygomatic maxillary nerve block
214883450|NCT02458859|DEVICE|PICO (single use portable negative pressure wound therapy)|Single use portable negative pressure wound therapy
214883451|NCT03174379|PROCEDURE|Standard of Care with no acupuncture|The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
215046112|NCT02491281|DRUG|LNA043|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
215046113|NCT02491281|DRUG|Placebo|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
215046114|NCT03019887|DRUG|reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine|
214883452|NCT03174379|PROCEDURE|Acupuncture|The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
214883453|NCT00464438|DRUG|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
214883454|NCT00464438|DRUG|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
214883455|NCT01970800|DRUG|Growth Hormone|Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
214883456|NCT02374138|BEHAVIORAL|Parental stress management|"The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches."
214883457|NCT02374138|OTHER|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
214883458|NCT04139759|OTHER|hand massage|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
214883459|NCT04139759|OTHER|foot massage|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
214883460|NCT05393479|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is a psychological treatment recommended by the World Health Organization for perinatal depression. The THP is based on the basic tenets of cognitive behavioural therapy (CBT) that aims to identify unhealthy thoughts and the vicious effects it has on the emotions and behaviour of a person and transform to healthy thinking style that ultimately impacts one's emotions and behaviour, too. The intervention aims to bring positive outcomes in three areas - a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. A randomized controlled trial (RCT) showed that the intervention was effective in reducing depressive symptoms and disability and improving functioning. Additionally, women receiving THP had higher rate of exclusive breastfeeding, and engaging more with their infants. Similarly, infants of these women were also less likely to have diarrhoeal episode and more likely to complete immunization.
214883461|NCT03536533|OTHER|Exergame|Each of the 8 exercise sessions will last at least 42 minutes, with an actual training duration of 21 minutes. The participants will be accustomed gradually to the game. On one hand this will be achieved by increasing the difficulty in subsequent levels within the exergame.
214883462|NCT06217211|DIETARY_SUPPLEMENT|Remolacha|BJ or PL will be administered 3 h before the start of the NO2- evaluation test since the peak in blood occurs 2-3 h after ingesting NO3-. Both drinks (BJ and PL) will be provided in an unlabeled 140ml maroon red plastic bottle. Participants will receive a randomly assigned bottle. containing 140 ml (\~ 12.8 mmol, \~ 808 mg NO3-) of BJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, United Kingdom) or PL.
214883463|NCT05358509|DRUG|Ferric carboxymaltose|Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
214883464|NCT05358509|DRUG|Iron isomaltoside|Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
214883465|NCT05358509|DRUG|Ferric Sulfate|Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
214883466|NCT02106897|DRUG|BIIB059 (litifilimab)|See Arm Descriptions
214883467|NCT02106897|DRUG|Placebo|See Arm Descriptions
215046115|NCT01389986|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
215046116|NCT02983240|DEVICE|Electrical Uterine Pacemaker|The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
215046117|NCT03018158|DEVICE|denture wear.|MR Imaging was collected with or without denture wear.
215046118|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
215046119|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
214883468|NCT04228497|DEVICE|gastric ultrasound|Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.
214883469|NCT04228497|OTHER|the clear fluid intake|the clear fluid intake
214883470|NCT00685776|DRUG|anacetrapib|Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
214883471|NCT00685776|DRUG|Comparator: placebo|Participants will receive one placebo tablet once daily for 76 weeks.
214883472|NCT00489827|DRUG|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
214883473|NCT00489827|OTHER|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
214883474|NCT01977274|OTHER|gynecological cancer|blood and tumor samples
214883475|NCT01689727|DRUG|Technetium Tc 99m EC20|
214667557|NCT06226090|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
214883476|NCT06516003|DEVICE|Immersive Virtual Reality Goggles|Immersive Virtual Reality goggles are a head mounted device placed over a patient's head and eyes that allows them to play in a virtual reality game.
214883477|NCT06516003|BEHAVIORAL|Standard of Care|Distraction techniques like tablet, phone, television, parent, child life specialist
214883478|NCT05405582|COMBINATION_PRODUCT|Community-based differentiated HIV prevention incl.PrEP with SRH|Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).
214883479|NCT05405582|OTHER|Primary Health Clinic based HIV prevention and care|Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.
215046120|NCT01448538|DRUG|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
215046121|NCT01421966|BIOLOGICAL|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
215046122|NCT01421966|BIOLOGICAL|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
215046123|NCT06438991|OTHER|Adjustment of spinal cord stimulation parameters for voluntary motor control|All patients will receive a spinal cord stimulator and undergo adjustment of stimulation parameters for optimal voluntary lower extremity motor control during research visits. Muscle strength will be assessed with the stimulation turned on and off.
215046124|NCT00205764|DRUG|Melphalan|
214883480|NCT02132793|BEHAVIORAL|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
215046125|NCT05282875|DRUG|management of immunosuppressive therapy|"3 groups :~* Discontinuation of immunosuppressive agents~* Reduction of immunosuppressive agents~* Maintenance of immunosuppressive agents"
215046126|NCT00987714|PROCEDURE|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
214883481|NCT02132793|BEHAVIORAL|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
214883482|NCT02237703|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
214883483|NCT00166582|DEVICE|electronic medication monitoring system|
214883484|NCT00166582|BEHAVIORAL|parent-adolescent communication and problem-solving skills|
214883485|NCT03337269|OTHER|Educational video|Approximately 7 minute video on the HPV vaccine
214883486|NCT03337269|OTHER|Educational handout|One page handout on the HPV vaccine
214883487|NCT03337269|OTHER|Control|Control
214883488|NCT02226601|DRUG|Aprepitant|3 days perioperative Aprepitant once a day
214883489|NCT02226601|DRUG|Placebo|3 days perioperative Placebot once a day
214883490|NCT06549855|DRUG|Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)|"1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day"
214883491|NCT00394563|DRUG|RN624 (PF-04383119)|10 mcg/kg
214883492|NCT00394563|DRUG|RN624 (PF-04383119)|25 mcg/kg
214883493|NCT00394563|DRUG|RN624 (PF-04383119)|50 mcg/kg
214883494|NCT00394563|DRUG|RN624 (PF-04383119)|100 mcg/kg
214883495|NCT00394563|DRUG|RN624 (PF-04383119)|200 mcg/kg
214883496|NCT00394563|DRUG|placebo|
214883497|NCT05769010|DRUG|SHR-A1811|SHR-A1811: intravenous
214883498|NCT05769010|DRUG|Pyrotinib|Pyrotinib: oral
214883499|NCT05769010|DRUG|Bevacizumab|Bevacizumab: intravenous
214883500|NCT04143243|BEHAVIORAL|ACT on Life|1 day group workshop of ACT plus ERS
214883501|NCT04143243|BEHAVIORAL|Education, Resources, and Support|1 day group workshop of Education, Resources, and Support
214883502|NCT01590277|DRUG|Active Ethanol|Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
214883503|NCT01590277|DRUG|Active Iomazenil|Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.
214883504|NCT01590277|DRUG|Placebo|Control: no alcohol, administered for a total of 90 minutes.
215046127|NCT05636202|OTHER|No intervention|There was no intervention in the retrospective study
215046128|NCT02373618|OTHER|DN and conventional PT|Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
215046129|NCT02373618|OTHER|Conventional PT|Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
215046130|NCT05394610|DEVICE|Sana Device|Audio Visual Stimulation patterns intended to produce a therapeutic benefit.
215046131|NCT05394610|DRUG|Sana Device (Control)|A control device that mimics the physcial appearance of the Sana device.
215046132|NCT04828707|DEVICE|Nerivio active device|Nerivio neurostimulator of conditional pain modulation (CPM)
215046133|NCT04828707|DEVICE|Nerivio sham device|Nerivio neurostimulator with an electrical output not intended for neurostimulation
215046134|NCT04836442|OTHER|Alcohol-PTSD-PFI (AP-PFI)|Integrated computer-based personalized feedback intervention to specifically target anxiety sensitivity in the context of hazardous drinking and PTSD symptoms. The AP-PFI will focus on feedback about alcohol behavior in the context of PTSD symptoms, AS, and coping-oriented alcohol use.
214883505|NCT01590277|DRUG|Placebo|Control: no iomazenil, administered for a total of 10 minutes
214883506|NCT06218576|OTHER|None, purely observational study|None, purely observational study
214883507|NCT04386616|DRUG|MSTT1041A|Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
214883508|NCT04386616|DRUG|MSTT1041A-matched Placebo|Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
214883509|NCT04386616|DRUG|UTTR1147A|Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
214883510|NCT04386616|DRUG|UTTR1147A-matched Placebo|Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
214883511|NCT01377012|BIOLOGICAL|Secukinumab (AIN457)|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
214883512|NCT01377012|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
214883513|NCT02159079|OTHER|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
214883514|NCT03848390|BEHAVIORAL|Conventional diet|The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.
214883515|NCT03848390|BEHAVIORAL|Modified Time-restricted Feeding|The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.
214883516|NCT03848390|BEHAVIORAL|Physical activity|At least 30 minutes of physical activity per day 5 times per week.
214883517|NCT03848390|BEHAVIORAL|Restricted consumption of sweetened beverages|Restricted consumption of juice, soda, and other sweetened beverages.
214883518|NCT01591343|BIOLOGICAL|Depigoid® (500 DPP/ml)|"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"
214883519|NCT00005000|DRUG|Nelfinavir mesylate|
214883520|NCT00005000|DRUG|Efavirenz|
214883521|NCT00005000|DRUG|Lamivudine|
214883522|NCT00005000|DRUG|Keyhole-Limpet Hemocyanin|
214883523|NCT00005000|DRUG|Stavudine|
214883524|NCT00005000|DRUG|Zidovudine|
214883525|NCT00005000|DRUG|Didanosine|
214883526|NCT04539652|DRUG|Experimental|Experimental group are treated with TenofoBell®
214883527|NCT00562783|DRUG|Vitaliver|
214883528|NCT00562783|DRUG|Placebo|
214883529|NCT00805961|RADIATION|Radiation therapy|Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
215046135|NCT04836442|OTHER|Active Comparison Condition (C-PFI)|Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
214292168|NCT03815331|DRUG|Xiaflex®|medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
215046136|NCT04548973|DRUG|Esketamine|Esketamine
215046137|NCT04548973|DRUG|Normal saline|2ml normal saline
214292169|NCT03815331|DRUG|Aveed|Aveed® is an FDA-approved medication for treatment of hypogonadism (low testosterone). It is not approved for the treatment of Peyronie's Disease. Aveed® 750 mg/3mL injection will be placed intramuscularly at the beginning of study, at four weeks, at 10 weeks thereafter.
214292170|NCT03838640|DEVICE|EPIQ 5|As described in summary Trade name of the device Philips EPIQ 5
214292171|NCT00103142|BIOLOGICAL|falimarev|Given subcutaneously and intradermally
214883530|NCT00805961|DRUG|Temozolomide|Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
214883531|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
214883532|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
214883533|NCT00805961|DRUG|Everolimus|Everolimus 10mg by mouth daily, beginning Week 11
214883534|NCT04380961|DRUG|Sirukumab|Participants will receive single dose infusion of sirukumab on Day 1.
214883535|NCT04380961|DRUG|Placebo|Participants will receive placebo IV single dose infusion on Day 1.
214883536|NCT04380961|OTHER|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
214883537|NCT05093361|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty for the treatment of hip arthritis.
214883538|NCT05093361|PROCEDURE|Physical Therapy|Self-driven training according to the training plan instructed by physical therapist.
214883539|NCT00002505|BIOLOGICAL|filgrastim|
214883540|NCT00002505|BIOLOGICAL|recombinant interferon gamma|
214883541|NCT00002505|BIOLOGICAL|tumor cell lysate vaccine therapy|
214883542|NCT06233773|PROCEDURE|Kinesio Taping|Kinesio Taping
214883543|NCT06233773|PROCEDURE|Manual Lymph Drainage|Manual Lymph Drainage Group
214883544|NCT06233773|OTHER|Control Group|Control Group
214883545|NCT05544279|BEHAVIORAL|Education|Education is given about the focused disease and its nursing care management
214883546|NCT06495112|OTHER|Soft contact lens with lathe cut technique Lathe|athe cut technique Lathe cutting involves shaping a solid block of lens material into the desired form using precision machinery. This method allows for customized lens designs but may result in a less smooth surface compared to cast molding. Cast molding, on the other hand, uses a liquid monomer that is cured in a mold to form the lens. This technique typically results in a smoother and more uniform lens surface.
214883547|NCT06495112|DIAGNOSTIC_TEST|Soft contact lens with cast molding technique|Participants in this arm would receive Cast molding soft contact lenses and would wear them according to the study protocol, also likely for a specified duration.The cast molding technique for soft contact lenses involves creating lenses by polymerizing a liquid monomer mixture within a mold that forms the desired lens shape. Here's a brief overview of the steps involved in the cast molding process
214883548|NCT01186484|DRUG|JNJ-212082|250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
214883549|NCT01862484|DIETARY_SUPPLEMENT|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
214883550|NCT01862484|DIETARY_SUPPLEMENT|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
215046138|NCT04153487|DRUG|Ascorbic Acid Injectable Product|Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
214883551|NCT04423887|OTHER|Lower Extremity Resistance Exercise Training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
214883552|NCT04423887|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
214883553|NCT04423887|DEVICE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
214883554|NCT04423887|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
215046139|NCT04153487|DRUG|Placebo|Placebo saline / 6 hours for 96 hours
215046140|NCT00601744|BEHAVIORAL|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
215046141|NCT00601744|BEHAVIORAL|Questionnaire|5-10 minute questionnaire to be completed after the interview.
215046142|NCT04616898|DEVICE|Venus Bliss|The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.
215046143|NCT01343472|BEHAVIORAL|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
215046144|NCT01343472|BEHAVIORAL|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
215046145|NCT00916227|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
215046146|NCT03869112|BEHAVIORAL|Physical activity intervention|Physical activity group will be given a charge 2 FitBit device to monitor their PA specially steps count, step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home-based intervention.
214292172|NCT00103142|BIOLOGICAL|inalimarev|Given subcutaneously and intradermally
214292173|NCT00103142|BIOLOGICAL|sargramostim|Given subcutaneously
214477049|NCT06817746|BEHAVIORAL|FIRRST|FIRRST is based on the principles of Naturalistic Developmental Behavioral Interventions (NDBIs), and more specifically on the principles of Infant Start and iBASIS. FIRRST targets ASD prodromes including diminished eye contact, diminished communicative intent, diminished social orientation, and unusual pattern of object exploration. Additionally, it also targets motor immaturity, frequent in infants at risk for ASD. FIRRST is a systemic approach, integrated within the family dynamics and culture. The program will address the five elements identified in efficacious very early intervention: 1) parent involvement, 2) frequency and length of intervention, 3) individualized, developmentally appropriate activities, 4) beginning the interventions as early as possible, and 5) increasing parental sensitivity and responsivity to infant cues. FIRRST will be delivered by experienced licensed health professionals trained by the developer of the intervention.
214883555|NCT04423887|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
214883556|NCT00364000|DRUG|Calcium acetate|Calcium acetate in 240 chronic HD patients
214883557|NCT00364000|DRUG|Sevelamer|label sevelamer (RenagelR) 800 mg tablets
214883558|NCT02908087|DRUG|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
214883559|NCT02908087|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
214292174|NCT00103142|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
214883560|NCT00553176|OTHER|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
214883561|NCT04094727|DRUG|Presumptive treatment with Artemether-lumefantrine (AL)|All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
214883562|NCT04094727|OTHER|Enhanced vector control|"The mop up indoor residual spraying (IRS) campaign will be targeted to farms and cattle posts/kraals in intervention areas in December 2019 to fill gaps from the routine spray campaign (September to November 2019) and utilize the same insecticides and protocols as the national campaign. The team will spray each unsprayed structure with the recommended solution of dichloro-diphenyl-trichloroethane (DDT) for traditional structures and/or Actellic for modern structures, tarps and tents.~Alternative vector control interventions, including LLINs (long-lasting insecticide treated bed nets), sprayed tents/tarps and topical repellents will be distributed to eligible HRPs between November and January 2020 during one round."
214883563|NCT06055829|DRUG|Insulin injection and blood glucose|The FreeStyle Libre sensor continuously measures glucose every minute and saves the glucose data. Scan the sensor at least every 8 hours for a full glycemic profile. The below data is displayed after a typical 1-second scan of the FreeStyle LibreLink app or FreeStyle Libre reader via the sensor:
214883564|NCT02506829|BEHAVIORAL|Smoking cessation counseling (Quitline)|
214883565|NCT02506829|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|
214883566|NCT02506829|BEHAVIORAL|Financial incentives|
214883567|NCT01632280|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes-anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.~In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks."
214883568|NCT05972148|OTHER|Digital scanning|Five intraoral scans, one for each arch before the insertion of scanbodies, were obtained. The implant locations were then marked, and the software trimmed a 6mm diameter circular section of the scan from the implant locations to allow the scanbodies to be added. Abutment-level polyetheretherketone (PEEK) scanbodies were hand-tightened onto each implant and not moved for the remainder of the scans. Scanbodies were scanned using a circular scan path, and scanning was finalized.
214883569|NCT05972148|OTHER|Photogrammetry|Rectangular-shaped titanium photogrammetry scanbodies were hand-tightened onto the Implants. Scanbodies were not moved before completing all scans for each arch. A total of five scans of each arch were obtained using a photogrammetry device. Measurements were successfully recorded by turning them green on the computer screen.
214883570|NCT00993421|DRUG|LY377604|Given daily, orally for 24 weeks
214883571|NCT00993421|DRUG|Sibutramine|given daily, orally for 24 weeks
214883572|NCT00993421|DRUG|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
214883573|NCT00993421|DRUG|Placebo sibutramine|given daily, orally for 24 weeks
214883574|NCT00993421|DRUG|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
214883575|NCT00993421|DRUG|Placebo LY377604|given daily, orally for 24 weeks
214883576|NCT00716794|DRUG|HE3235|HE3235 will be administered orally in 28 day cycles.
214883577|NCT04357080|PROCEDURE|Urethroplasty|Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft
214883578|NCT02687347|DRUG|oral methadone|Oral methadone is the study drug
215046147|NCT03869112|OTHER|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
215046148|NCT03139448|DEVICE|Oxygen via nasal cannula|Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.
214667558|NCT06226090|DRUG|Placebo 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
215046149|NCT03139448|DEVICE|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
215046150|NCT00713687|DRUG|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"1. Photodynamic therapy (PDT) after successful drainage:~   Photosan® 2 mg/kg i.v. 48 hrs before laser activation~2. 9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~   * Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~  * Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~  * iteration every 14 days~  * afterwards 4 weeks intermission~3. Iteration of 1. and 2. in case of good compatibility"
214292175|NCT05370222|BEHAVIORAL|Dietary weight loss intervention|Based on an energy assessment from the data collected at T0 (energy intake, physical activity level, and resting metabolism), individualized nutritional advice will be given during an interview in order to propose a dietary rebalancing and a light caloric restriction. Caloric restriction will be generated to decrease body weight by ≈ 0.5 to 1 kg per week, as advised in several publications. As for the dietary rebalancing, it will concern in particular the distribution of macronutrients and their nature (glycemic index, nature of lipids), the fibers intake, or the reduction of consumption of refined and/or energy-dense foods based on the ANSES Recommended Dietary Allowances and on the food consumption guidelines of the National Nutrition and Health Program.
214883579|NCT02687347|DRUG|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
214883580|NCT03616145|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Experimental Condition
214883581|NCT03616145|OTHER|Light Touch|Comparator Arm
214883582|NCT01296997|DIETARY_SUPPLEMENT|calcium phosphate|the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
214883583|NCT01296997|OTHER|placebo|the subjects consumed a bread without pentacalcium phosphate
214883584|NCT00286026|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
214883585|NCT03248973|DRUG|Ampicillin Injection|Ampicillin injection 2 g q4h for 3 weeks
214883586|NCT05410964|DEVICE|VIO System|To investigate the potential for the VIO System to display microscopic skin structure in people of different age, sex, race, and skin health
214883587|NCT00970827|PROCEDURE|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
214883588|NCT00334373|PROCEDURE|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
214883589|NCT01700231|PROCEDURE|Liver resection|Liver resection of patient with neoplastic hepatic tumors
214883590|NCT03736031|BEHAVIORAL|Intervention (Promotora)|If the patient is in the intervention group, the promotora will call the patient in order to invite them to a meeting. Meetings will be arranged by the promotora and the patients. A total of 2 group meetings will be required by all participants and 1 family meeting.
214883591|NCT02304029|DEVICE|MRI|
214883592|NCT03461601|PROCEDURE|HCG Uterine flushing|HCG Uterine flushing was done one day before IUI with HCG (500 IU) in 10 ml of saline.
214883593|NCT03461601|PROCEDURE|IUI|Intrauterine insemination (IUI)
214883594|NCT03461601|PROCEDURE|Vaginal flushing with 10 ml normal saline|Flushing of the vagina with 10 ml of saline
214883595|NCT00649779|DRUG|albuterol sulfate extended-release 8 mg tablets|8mg, single dose fasting
214883596|NCT00649779|DRUG|VoSpire™ ER 8 mg tablets|8mg, single dose fasting
214883597|NCT00003198|DRUG|ifosfamide|
214883598|NCT00003198|DRUG|topotecan hydrochloride|
214883599|NCT04825340|BIOLOGICAL|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine|0.2 ml/vial, 0.2ml/dose/per person
214883600|NCT06745323|DRUG|Tarlatamab|Tarlatamab will be administered by IV infusion.
214883601|NCT06282783|DRUG|Topiramate|Single dose of 400mg
214883602|NCT03997773|BEHAVIORAL|Face-it Intervention|The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
214883603|NCT02215967|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
214883604|NCT02215967|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
214883605|NCT02215967|BIOLOGICAL|Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 15.0x10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
214883606|NCT06309966|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
214883607|NCT06309966|DRUG|BHV-7000|BHV-7000 75 mg. Participants will take blinded investigational product (IP) once daily
214883608|NCT06309966|DRUG|Placebo|Matching placebo taken once daily
214883609|NCT05286866|PROCEDURE|Dental implant bed preparation|Drilling an osteotomy for placement of a dental implant
214883610|NCT05695066|PROCEDURE|Preoperative fasting instruction|Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
214883611|NCT06769412|DRUG|aflibercept 2 mg|No study-specific investigations for this descriptive observational study
214883612|NCT02254265|DRUG|OTX-101 0.05%|OTX-101 0.05% Ophthalmic Solution
214883613|NCT02254265|DRUG|OTX-101 0.09%|OTX-101 0.09% Ophthalmic Solution
214883614|NCT02254265|DRUG|Vehicle|Vehicle of OTX-101 Ophthalmic Solution
215046151|NCT02250248|BIOLOGICAL|AttraX Putty|
215046152|NCT02250248|OTHER|Iliac Crest Bone Graft (ICBG)|
215046153|NCT02442050|OTHER|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
215046154|NCT02442050|OTHER|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
214477050|NCT06817746|BEHAVIORAL|Parent Education|Families will receive written educational material focused on supporting child development and targeting ASD specific immaturities and atypicalities. Additionally, parent education families will receive counseling once per month for 6 months delivered by a licensed health professional aiming at supporting the family well being and helping the family to connect with the local public health services.
214477051|NCT06820892|OTHER|Survey|The study utilised a 16-item questionnaire to evaluate the quality of information received during antenatal diagnosis consultations and its congruence with subsequent experiences following birth and hospitalisation of the infant. The questionnaire encompassed seven questions pertaining to consultation arrangements, including duration, frequency and unit visits, six questions addressing the received information, and three questions exploring the long-term outcomes of the child.
214883615|NCT05801588|OTHER|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
214883616|NCT05801588|OTHER|Usual care|The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
215046155|NCT00523978|DEVICE|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
215046156|NCT00523978|DRUG|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
215046157|NCT00637351|PROCEDURE|Blood sample|One blood sample will be collected at the time of screening for subjects
215046158|NCT00637351|PROCEDURE|Urine sample|One urine sample will be collected at the time of screening for subjects
215046159|NCT02490189|BEHAVIORAL|Mindfulness-based Intervention|Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
215046160|NCT02490189|BEHAVIORAL|Cognitive Behavior Group Therapy|Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
215046161|NCT04145596|DRUG|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
215046162|NCT04656405|OTHER|Online real-time quality measurement and feedback video-based CPR training|"Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants."
215046163|NCT04656405|OTHER|Online real-time feedback video-based CPR training without quality measurement|"Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants."
215046164|NCT04656405|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance."
215046165|NCT03899350|OTHER|No intervention|No intervention
215046166|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
215046167|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
215046168|NCT00961038|DRUG|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
214883617|NCT01954745|DRUG|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
214883618|NCT04727047|DEVICE|neuromuscular electrical stimulation|All subjects will receive standard rehabilitation for Achilles tendon repair. In addition, neuromuscular electrical stimulation will be applied to the calf muscles of the injured leg. The stimulation volume, the electrode placement and the intensity of the stimulation will be selected based on the mechanical strength of healing Achilles tendon. The intervention will be applied for 6 weeks after repair.
214883619|NCT03672045|DRUG|Carbetocin|carbetocin administered IV, over 1 minute following delivery of the fetal head
214883620|NCT06264063|BEHAVIORAL|control group|the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
214883621|NCT06264063|BEHAVIORAL|experimental group|the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
214883622|NCT06264063|DIAGNOSTIC_TEST|EEG power in alpha band|partecipants were submitted to registration of electrical activity with EEG to study the EEG power in alpha band
214883623|NCT07135037|DRUG|Sildenafil 25 MG|Sildenafil is a vasodilator drug which improve blood supply to placenta.Therefore, it should improve idiopathic oligohydramnios.
214883624|NCT07135037|DRUG|L-Arginine, 1000 Mg Oral Tablet|Aminoacid with vasodilator property which improve blood supply to placenta.Therefore, it should improve idiopathic oligohydramnios.
214883625|NCT07134426|OTHER|D10-phenanthrene|All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].
214883626|NCT07077850|DRUG|Dexamethasone (IV)|Intravenous administration of 8 mg dexamethasone sodium phosphate given as a single dose before surgery under spinal anesthesia. This corticosteroid is being evaluated for its potential to prevent postoperative urinary retention (POUR) by reducing inflammation and other perioperative effects.
214883627|NCT07077850|DRUG|Normal Saline (0.9% NaCl)|Intravenous administration of 0.9% normal saline (placebo) given as a single dose before surgery under spinal anesthesia. This inert solution is used to compare against the active drug dexamethasone to determine its effect on postoperative urinary retention (POUR).
214883628|NCT02369198|DRUG|TargomiRs|"TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected."
214883629|NCT06930729|BEHAVIORAL|Behavioral Activation Therapy App|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures at weeks 12, 16, 20, and 24 post-randomization.
215046169|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Ultravision™ System|The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.
215046170|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Airseal® iFS|The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
215046171|NCT03551782|DRUG|Cetrelimab 480 mg|Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
214292176|NCT04261751|OTHER|Clinician Questionnaire|Nurses will take the Clinician Questionnaire electronically
214883630|NCT06930729|BEHAVIORAL|Telehealth Delivered Behavioral Activation|8 sessions of telehealth-delivered Behavioral Activation with a mental health provider over a 10-week period.
215046172|NCT03551782|DRUG|Apalutamide 240 mg|Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.
215046173|NCT01554748|PROCEDURE|Total joint arthroplasty|
214292177|NCT00628992|OTHER|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
214292178|NCT00628992|OTHER|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
214292179|NCT00628992|OTHER|Cycloergometer training|Muscular rehabilitation of the leg
214292180|NCT00628992|OTHER|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
214292181|NCT04320446|BEHAVIORAL|Test in the morning|The exercise test was performed between 8 a.m and 11 a.m
214292182|NCT04320446|BEHAVIORAL|Test in the afternoon|The exercise test was performed between 5 p.m. and 8 p.m.a
214292183|NCT05226325|DRUG|Dexmedetomidine|patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
214292184|NCT03267186|DRUG|Ibrutinib|Given PO
214883631|NCT07095582|BEHAVIORAL|Internet-delivered cognitive behavioral therapy|The Wellbeing Course was developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behavioural intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins per week/per client.
214667559|NCT05125081|DRUG|Liuwei Dihuang Pill (marketed product in China)|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
214883632|NCT07095582|BEHAVIORAL|Additional Loneliness Content|The additional Loneliness Content was developed at the Online Therapy Unit, University of Regina, Canada. Relevant sections of the resource will be included at the end of each lesson within the Wellbeing Course. The Loneliness Content provides psychoeducation and skills for loneliness using a cognitive behavioral framework. Consistent with the Wellbeing Course content, the Loneliness Content will target 1) identification of loneliness; 2) loneliness thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling for loneliness; 4) behaviours (conversation skills); and 5) relapse prevention.
214883633|NCT03252743|BEHAVIORAL|Exposure-based internet-delivered CBT|"The main target in treatment is exposure for abdominal symptoms by reducing avoidance and provoking symptoms. Participants are encouraged to gradually increase the difficulty by combining multiple challenges.~The parents are taught how to reduce the risk for reinforcement of children's symptom behavior, and to support their child to complete the treatment.~All treatment content is delivered over the internet, containing texts, videos, audio-files and examples. The modules are unlocked sequentially as participants worked their way through the treatment.~Therapist support consists primarily of encouragement of any progress made in the treatment and support to find individual exercises."
214883634|NCT02310256|OTHER|Five plus exercise training|calf raise exercise
214883635|NCT00352417|DRUG|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
214883636|NCT00352417|DRUG|Placebo|oral dosing, 1 time daily for 12 weeks
214883637|NCT06194942|OTHER|chiropractic manipulation|Chiropractic manipulation is a manual therapy technique commonly used by chiropractors. It involves the application of controlled, sudden force to a specific joint, often with the goal of improving joint function, reducing pain, and promoting overall musculoskeletal health.In the context of thoracic chiropractic manipulation, the chiropractor focuses on the vertebrae and joints in the thoracic spine.
214883638|NCT06194942|OTHER|sham manipulation|"Sham manipulation refers to a simulated or placebo form of a manual therapy intervention, often used in research studies, especially in clinical trials involving chiropractic or physical therapy. the term sham manipulation likely implies a procedure that mimics the physical aspects of a real chiropractic manipulation but does not involve the actual therapeutic forces or movements.~The chiropractic treatment group received thoracic chiropractic manipulations (HVLA) twice a week for a total of six sessions over three weeks, while the control group received sham manipulations."
214883639|NCT00002200|DRUG|Abacavir sulfate|
215046174|NCT00960089|DEVICE|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
215046175|NCT05790291|OTHER|Checklist|the experimental group will practice using the checklist
215046176|NCT01523938|BEHAVIORAL|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
215046177|NCT00696878|DRUG|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
215046178|NCT00696878|BIOLOGICAL|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
215046179|NCT00696878|BIOLOGICAL|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
215046180|NCT00696878|BIOLOGICAL|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
215046181|NCT00696878|DRUG|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
215046182|NCT01901536|BEHAVIORAL|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
215046183|NCT02712788|DRUG|Milrinone|
215046184|NCT02712788|DRUG|Placebo|
215046185|NCT04337047|OTHER|questionnaire assesment|questionnaire assesment
215046186|NCT00940602|DRUG|Deferasirox|Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
215046187|NCT00940602|DRUG|Placebo|Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
215046188|NCT01880957|DRUG|Lithium|
215046189|NCT01880957|DRUG|Lamotrigine|
215046190|NCT04856878|DRUG|Vancomycin|The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.
215046191|NCT04994223|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival
215046192|NCT02969135|BEHAVIORAL|Progressive early passive and active movement|Post-surgical physical therapy including active exercise
215046193|NCT02969135|BEHAVIORAL|Limited early passive movement|Post-surgical physical therapy including passive mobilisation
215046194|NCT01120405|DRUG|Xenon|
215046195|NCT01120405|DRUG|Sevoflurane|
215046196|NCT02107534|BEHAVIORAL|parent training (dyslexia)|The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
215046197|NCT02332473|DRUG|Ypeginterferon alfa-2b|
215046198|NCT02332473|DRUG|Granulocyte-macrophage colony stimulating factor|
215046199|NCT01459809|DRUG|GLIMEPIRIDE|"Pharmaceutical form: oral~Route of administration: oral"
215046200|NCT01459809|DRUG|METFORMIN|"Pharmaceutical form: oral~Route of administration: oral"
215046201|NCT04902989|OTHER|pollutants and pollen|Pollutants (ozone, SO3, NO3, PM2.5, diesel exhaust particles)
215046202|NCT03525509|DRUG|Methadone hydrochloride|Epidural bolus of 4mg of preservative free methadone hydrochloride (4mL of 1mg/mL solution)
215046203|NCT03525509|DRUG|Morphine Sulfate|Epidural bolus of 4mg of preservative free morphine sulfate (4mL of 1mg/mL solution)
215046204|NCT01418521|DRUG|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
215046205|NCT01418521|DRUG|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
215046206|NCT03920891|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
215046207|NCT03920891|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~3. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~4. Evaluated the procedure and radiofrequency ablation time.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
215046208|NCT01709357|OTHER|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
215046209|NCT01709357|OTHER|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
215046210|NCT01709357|OTHER|Ischemic compression technique|"The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds."
215046211|NCT01709357|OTHER|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
215046212|NCT06304155|DIAGNOSTIC_TEST|Diagnostic efficacy,SUV|"The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 18F-FAPI PET were calculated and compared to evaluate the diagnostic efficacy.~Standardized uptake value (SUV) of 18F-FDG and 18F-FAPI for each target lesion of subject or suspected primary tumor or/and metastasis."
214883640|NCT07113678|BEHAVIORAL|Body confidence podcast episode and supplementary exercises in a journal|"The 52-minute long podcast episode is hosted on the How to Fail podcast featuring a conversation between its host, Elizabeth Day, and the guest, actor and activist, Pamela Anderson (It wasn't about being pretty, it was about being brave).~The podcast episode is accompanied by supplementary exercises in a journal to reinforce the body confidence messages shared during the episode. The 8-page journal (Beauty on Your Own Terms) consists of two primary activities. The first activity (A vision for your future) involves 3 questions, a 3-minute visualisation exercise, and a prompt for written reflection all intended to facilitate accepting your body as it is, rejecting societal and media pressures that define beauty narrowly, and defining beauty on your own terms. The second activity (Beauty-on-your-own-terms challenge) involves 4 exercises intended to help women reflect on what they can change about your routine and habits to start defining beauty on your own terms."
214292185|NCT03267186|OTHER|Laboratory Biomarker Analysis|Correlative studies
214883641|NCT07113678|BEHAVIORAL|Body confidence podcast episode|"The podcast episode is hosted on the How to Fail podcast featuring a conversation between its host, Elizabeth Day, and the guest, actor and activist, Pamela Anderson (It wasn't about being pretty, it was about being brave)."
214883642|NCT07113678|BEHAVIORAL|Non-body image-related podcast episode|"A podcast episode from the same podcast series as the intervention, How to Fail, which contains no body image content and is matched on length and guest similarities. The episode features host Elizabeth Day in conversation with actor and activist Cynthia Nixon (Being brave is feeling scared and doing it anyway), which is 47 minutes in length."
214883643|NCT07133308|DRUG|Deuruxolitinib|Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg
214883644|NCT07133308|DRUG|Placebo|Deuruxolitinib matching placebo will be dosed orally as tablets
214883645|NCT07133568|OTHER|Fun Exercise for Older Adults (FEXO)|The FEXO (Fun Exercise for Older Adults) program is a 14-week, multicomponent, recreational exercise intervention designed to enhance intrinsic capacity, motivation, and adherence in community-dwelling older adults. Participants engage in three non-consecutive, supervised group sessions per week (maximum instructor-to-participant ratio 1:15), each lasting approximately 60 minutes. The program begins with a two-week familiarization phase followed by three progressive phases (4 weeks each), with exercise intensity, repetitions, and resistance levels adjusted based on functional performance assessed by the Short Physical Performance Battery (SPPB).
214883646|NCT07133568|OTHER|OTAGO|The OTAGO Exercise Program is a structured, evidence-based intervention developed to improve lower-limb strength and balance and reduce fall risk in older adults. In this study, participants in the control group will complete three non-consecutive, supervised sessions per week for a total duration of 14 weeks. Sessions will be delivered in group settings under the supervision of a licensed physiotherapist. The program includes individualized strength training for the lower extremities, progressive balance exercises, and walking routines. Although originally designed as a home-based program, in this trial it will be implemented in indoor, climate-controlled, non-slip-floor facilities provided by local institutions. The OTAGO protocol does not include recreational, cognitive, or playful components, serving instead as a standard, structured intervention against which the FEXO program will be compared.
214883647|NCT07133360|PROCEDURE|Third molar extraction|Surgical third molar extraction with conventional medication
215046213|NCT04836533|OTHER|Experimental: Computerized Cognitive Training|Participants will complete 4 weeks of executive functioning / processing speed training through the BrainHQ platform on their personal computers.
215046214|NCT04836533|DRUG|Experimental: Open-label antidepressant treatment|Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.
215046215|NCT04836533|OTHER|Active Comparator: Solitaire Training|Participants will complete 4 weeks of Solitaire training through the BrainHQ platform on their personal computers.
215046216|NCT04836533|OTHER|Placebo Comparator: Placebo-controlled antidepressant treatment|Participants will be told they have a 50/50 chance of receiving a placebo or antidepressant.
215046217|NCT03789708|DIETARY_SUPPLEMENT|Gum Arabic|Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
215046218|NCT03789708|OTHER|Placebo|Maltodextrin powder, easily soluble
215046219|NCT03260712|DRUG|Pembrolizumab|The dose of pembrolizumab in this trial is 200 mg Q3W.
215046220|NCT03260712|DRUG|Cisplatin|25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
215046221|NCT03260712|DRUG|Gemcitabine|1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
215046222|NCT02435654|DRUG|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
215046223|NCT04392973|COMBINATION_PRODUCT|Favipiravir and Hydroxychloroquine|"Route of Administration: Oral (or through Nasogastric tube)~Dose:~Favipiravir: Administer 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (total days of therapy is 10 days or till hospital discharge)~Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily."
215046224|NCT00575666|DRUG|Insulin or Placebo|intranasal, 40IU, 4 times daily
215046225|NCT00938301|DRUG|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
215046226|NCT00938301|DRUG|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
215046227|NCT00508482|OTHER|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks."
214883648|NCT07134608|PROCEDURE|Popliteal Plexus Block with 20 ml|Different position while blocking the popliteal sciatic nerve block
214883649|NCT07134933|PROCEDURE|ESP (erector spinae plane)block|The ESP block was performed unilaterally in the direction of the surgery by the same anesthetist. Blocks were performed using an Esaote ultrasound device (Esaote My Lab 6 US machine, Florence, Italy), a multifrequency convex probe (1-8 MHz), and a 22-gauge, 50 mm facet needle (B. Braun Sonoplex, Melsungen, Germany). The block needle was placed at the level of the T4 spinal process using the in-plane approach, approximately 3 cm lateral to the T4 spinous process in the parasagittal plane. After visualizing the transverse process with the in-plane approach, the 50 mm facet needle (B. Braun Sonoplex, Melsungen, Germany) was inserted through the skin, and a test dose of 1 ml of 0.9% NaCl was injected between the fascia of the trapezius, rhomboid, and erector spinae muscles and the transverse vertebral process to confirm the location. A total of 20 ml of 0.5% bupivacaine was used as a local anesthetic.
215046228|NCT00508482|DRUG|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
215046229|NCT00508482|OTHER|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
215046230|NCT03753022|OTHER|Group G5|Submitted to peep 5
215046231|NCT03753022|OTHER|Group G10|Submitted to peep 10
215046232|NCT03753022|OTHER|Group G15|Submitted to peep 15
214883650|NCT05314101|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
214883651|NCT05314101|DRUG|bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
214883652|NCT05314101|DRUG|TAS-102|Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
214883653|NCT02117739|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
214883654|NCT02117739|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
215046233|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with local anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL.
215046234|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with placebo|Block performed with bilaterally inserted q-tips with isotone NaCl
215046235|NCT06029205|BEHAVIORAL|Conscious Awareness-Based Educatıon|The effect of Conscious Awareness-Based Education on nurses
215046236|NCT06029205|BEHAVIORAL|Stress coping training|The effect of stress coping training on nurses
215046237|NCT02289469|OTHER|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
215046238|NCT00327912|PROCEDURE|Laparoscopic Biliopancreatic diversion with Duodenal switch|
215046239|NCT00327912|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
215046240|NCT01402921|DEVICE|V0322 BC|"* Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~* The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~* 3 months duration daily treatment"
214883655|NCT05921253|DEVICE|PARASYM neuromodulation device|Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
214883656|NCT05921253|DEVICE|PARASYM neuromodulation device|"Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study."
214883657|NCT01496976|DRUG|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m\^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
214883658|NCT01496976|DRUG|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
214883659|NCT01496976|DRUG|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
214883660|NCT06071702|DEVICE|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloybased stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
214883661|NCT05619263|BEHAVIORAL|Disaster PrepWise-Caregiver|The Disaster PrepWise (DPW) intervention consists of five interactive modules and two supplemental sections (special topics and resources on various types of disasters). The five modules are: (1) Complete a Personal \& Household Assessment, (2) Develop a Personal Emergency Network, (3) Develop Emergency Information \& Gather Important Documents, (4) Keep a 3-5 Day Supply of Medications \& Medical Supplies, and (5) Build an Emergency Supply Kit. Through an initial visit (IV1) and a follow-up phone conversation 4 weeks later (IV2), the interventionist will develop a personalized disaster management plan and provide it to the participant for sharing with family and friends. Eight weeks after the initial session, the interventionist will make a final follow-up call (IV3) to provide any additional assistance caregivers may need.
215046241|NCT05362994|DEVICE|Selution SLR™ sirolimus-eluting balloon|If the residual stenosis is ≤30% after initial plain old balloon angioplasty, the investigators will perform angioplasty with the Selution SLR catheter, inflated at nominal pressure for at least 120 seconds. After dilatation of the entire target-lesion, biplane angiograms and IVUS imaging will be obtained. Technical success is defined as residual diameter stenosis ≤30% and adequate distal run-off. Bail-out stenting will be performed if residual stenosis is \>30%, either after plain old balloon angioplasty or angioplasty with Selution SLR. For lesions with residual stenosis \>30% but not suitable for stenting, repeat angioplasty will be performed for at most twice.
215046242|NCT05362994|DEVICE|Plain old balloon angioplasty|The investigators routinely start with a balloon catheter with a diameter ≥0.5 mm smaller than the reference vessel and ended with a balloon catheter with the size approximately equal to the reference vessel diameter. Three minutes after balloon predilation, the investigators will obtain an angiogram. If the residual stenosis is ≤30%, no further intervention will be performed in the plain old balloon (POB) group.
215046243|NCT03026244|DIETARY_SUPPLEMENT|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
215046244|NCT03026244|DIETARY_SUPPLEMENT|Placebo product|3 periods of 3 weeks placebo product
215046245|NCT03807388|DEVICE|ReMindCare Intervention Group|Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
215046246|NCT03807388|OTHER|Treatment as Usual|Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
215046247|NCT00587041|DIETARY_SUPPLEMENT|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
215046248|NCT00587041|DIETARY_SUPPLEMENT|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
214667560|NCT05125081|DRUG|Liuwei Dihuang Pill（placebo ）|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
215046249|NCT00587041|OTHER|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
215046250|NCT04996329|OTHER|early health warning intervention|early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
215046251|NCT01769924|OTHER|Nephrectomy|Nephrectomy for the purposes of living kidney donation
215046252|NCT04298619|DIAGNOSTIC_TEST|Standard cohort: Clinical lab follow-up|
215046253|NCT04298619|DIAGNOSTIC_TEST|Imaging cohort: integrated imaging follow-up|
215046254|NCT02359656|PROCEDURE|surgical treatment|C1-C1 arthrodesis
214883662|NCT03225794|DIAGNOSTIC_TEST|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
214883663|NCT05938621|BEHAVIORAL|behavioral therapy and education|Sessions that focus on developing self-awareness and strategies to improve well-being will be the focus of the interventions.
214883664|NCT06308549|BEHAVIORAL|MyDiaMate|MyDiaMate programme
214883665|NCT03598790|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
214883666|NCT04009681|DRUG|THOR-707|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
214883667|NCT04009681|DRUG|Checkpoint inhibitor|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
214883668|NCT04009681|DRUG|anti-EGFR antibody|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
214883669|NCT02912559|DRUG|Atezolizumab|Given IV
215046255|NCT02359656|OTHER|non operative treatment for odontoid non unions|specific non operative treatment protocol
215046256|NCT05753462|DRUG|Phase 1, SQY51|SQY51 is administered by intravenous infusion.
214883670|NCT02912559|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214883671|NCT02912559|PROCEDURE|Computed Tomography|Undergo CT
215046257|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 1)|SQY51 is administered by intravenous infusion at dose 1
215046258|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 2)|SQY51 is administered by intravenous infusion at dose 2.
215046259|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 3)|SQY51 is administered by intravenous infusion at dose 3.
215046260|NCT00770302|DRUG|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
215046261|NCT00002143|DRUG|Acitretin|
214883672|NCT02912559|DRUG|Fluorouracil|Given IV
214883673|NCT02912559|DRUG|Leucovorin Calcium|Given IV
214883674|NCT02912559|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214883675|NCT02912559|DRUG|Oxaliplatin|Given IV
214883676|NCT02912559|OTHER|Quality-of-Life Assessment|Ancillary studies
214883677|NCT04092283|DRUG|Carboplatin|Given IV
214883678|NCT04092283|DRUG|Cisplatin|Given IV
214883679|NCT04092283|BIOLOGICAL|Durvalumab|Given IV
214883680|NCT04092283|DRUG|Etoposide|Given IV
214883681|NCT04092283|DRUG|Paclitaxel|Given IV
214883682|NCT04092283|DRUG|Pemetrexed Disodium|Given IV
214883683|NCT02834013|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214883684|NCT02834013|PROCEDURE|Computed Tomography|Undergo CT
215046262|NCT05249686|OTHER|Manual Therapy + Dry Needling|"Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ)."
214883685|NCT02834013|PROCEDURE|Echocardiography Test|Undergo ECHO
214883686|NCT02834013|BIOLOGICAL|Ipilimumab|Given IV
215046263|NCT05249686|OTHER|Manual Therapy|Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
215046264|NCT03115372|OTHER|Educational Intervention|Attend CRC education session
215046265|NCT03115372|OTHER|Educational Intervention|Attend healthy nutrition session
214883687|NCT02834013|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214883688|NCT02834013|BIOLOGICAL|Nivolumab|Given IV
214883689|NCT05646979|BEHAVIORAL|EFT group|EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
214883690|NCT04846829|DRUG|Placebo|saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
214883691|NCT04846829|DEVICE|intermittent theta burst stimulation|"10 sessions of treatment with cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds"
214883692|NCT04846829|DRUG|intravenous citalopram hydrochloride (CIT)|CIT will be administered intravenously using established clinical procedures. A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
214883693|NCT04846829|DEVICE|continuous theta burst stimulation|"10 sessions of treatment with iTBS to left or cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered"
214883694|NCT04164199|DRUG|Tislelizumab|Administered intravenously.
214883695|NCT04164199|DRUG|Pamiparib|Administered orally.
214883696|NCT04164199|DRUG|Temozolomide|Administered orally.
214883697|NCT04164199|DRUG|Sitravatinib|Administered orally.
214883698|NCT04164199|DRUG|Ociperlimab|Administered intravenously.
214883699|NCT04164199|DRUG|BAT1706|Administered intravenously.
214883700|NCT04164199|DRUG|Fruquintinib|Administered orally.
214883701|NCT04164199|DRUG|BGB-15025|Administered orally.
215046266|NCT03115372|OTHER|Informational Intervention|Receive CRC screening brochure
215046267|NCT03115372|OTHER|Survey Administration|Ancillary studies
215046268|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about CRC screening
215046269|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
214292186|NCT02598076|BEHAVIORAL|motivational interviewing|Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
214477052|NCT06816680|PROCEDURE|APF + FGG|In APF + FGG technique, a split- thickness flap was prepared and apically positioned using 5-0 (PDS\*II, Polydioxanone, ETHICON) or 6-0 (PROLENE, ETHICON) sutures for flap stabilization. To eliminate muscle and frenum attachment at recipient site, vestibuloplasty and a periosteal incision were performed. A 4 mm or 6 mm healing abutment was then screwed onto the implants. FGG was harvested from palate in a 7-8 mm width and trimmed to an even thickness of 1 to 1.5 mm. A resorbable hemostatic sponge (Spongostan, Ethicon, Johnson \& Johnson) was placed at donor site for wound coverage. For graft fixation, a loop suture with 6-0 (PROLENE, ETHICON) was first placed at the center of recipient site, additional sutures were added to enhance stabilization.
214883702|NCT04164199|DRUG|Zanidatamab|Administered intravenously.
214883703|NCT04164199|DRUG|BGB-A445|Administered intravenously.
214883704|NCT04164199|DRUG|Surzebiclimab|Administered intravenously.
214883705|NCT04164199|DRUG|Lenvatinib|Administered orally.
214883706|NCT04164199|DRUG|LBL-007|Administered intravenously.
214883707|NCT06781489|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb
214883708|NCT06781489|DRUG|Gabapentin 300mg|Oral gabapentin capsule
214883709|NCT06781489|DRUG|Ibuprofen Arginine|Oral ibuprofen arginine tablets
214883710|NCT04589845|DRUG|Entrectinib|Adults and pediatric participants with a BSA ≥1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 milligrams per square meter (mg/m\^2) (BSA=0.43-0.50 m\^2).
214883711|NCT04589845|DRUG|Entrectinib|Adults and pediatric participants with a BSA ≥ 1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 mg/m\^2 (BSA=≤0.50 m\^2).
214883712|NCT04589845|DRUG|Alectinib|Alectinib will be administered orally BID with food at a dosage of 600 mg (four 150-mg capsules).
214883713|NCT04589845|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged ≥18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.
214883714|NCT04589845|DRUG|Ipatasertib|For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
214883715|NCT04589845|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
214883716|NCT04589845|DRUG|Inavolisib|GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
215046270|NCT03091790|DEVICE|Synthetic Mesh|Synthetic mesh used during open ventral hernia repair
215046271|NCT03091790|DEVICE|Biologic Mesh|Biologic mesh used during open ventral hernia repair
215046272|NCT04287972|PROCEDURE|DPC|The anterior fat pad is dissected until the left crura is visible, pars flaccida is open and the right crura exposed. Phreno-oesophageal ligament is sectioned starting from the right crura. Posterior and anterior vagal nerve are recognized before the oesophageal dissection. An intra-abdominal oesophagus lengths of 2 or 3 cm is obtained in order to reduce tension. Left and right crura are sutured with 2 or 3 non absorbable 2-0 stitches; an additional anterior stitch is posed if necessary to calibrate hiatus size without oesophageal deviation.
214883717|NCT04589845|DRUG|Belvarafenib|Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
214883718|NCT04589845|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).
214292187|NCT02598076|BEHAVIORAL|standard psychotherapy|Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
214883719|NCT04589845|DRUG|Divarasib|Divarasib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric participants. A treatment cycle consists of 3 weeks (21 days).
214883720|NCT04589845|DRUG|Camonsertib|Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
214883721|NCT06778798|COMBINATION_PRODUCT|Median nerve neural mobilization and oral gabapentin|Manual therapy maneuver performed in the upper limb combined with gabapentin oral capsules.
214883722|NCT06778798|DRUG|Gabapentin 300mg|Gabapentin oral capsules
215046273|NCT04287972|PROCEDURE|LSG|After omental section close to gastric insertion, gastric stapling is realised with triple line endo stapler (normally 5 or 6 re-loads). The gastrectomy begins 5-6 cm from the pylorus; gastric fundus is totally resected keeping a distance of 5-10 mm from oesophagus. Any bleeding on staple line is controlled with surgical clips or coagulator.
214883723|NCT06778759|COMBINATION_PRODUCT|median nerve neural mobilization combined with oral ibuprofen arginine|Manual therapy maneuver performed in the upper limb combined with ibuprofen arginine oral tablets
214477053|NCT06816680|PROCEDURE|PPF group|For the PPF group, the palatal sliding flap was a modified version of modified roll technique, as described in previous cohort study. Unlike the original technique, the crestal incision was placed 5 mm palatally from the border of keratinized tissue to allow for KMW redistribution, and a partially split-thickness flap was harvested from palatal connective tissue graft (CTG). Following buccal pouch flap preparation, a slight APF was required in cases with limited vestibular depth. When the palatal pedicle CTG was rolled in buccal pouch flap, a loop suture with 6-0 (PROLENE, ETHICON) was used for flap stabilization.
214883724|NCT06778759|DRUG|Ibuprofen Arginine|Ibuprofen arginine oral tablets
214883725|NCT02555254|PROCEDURE|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
214883726|NCT02555254|PROCEDURE|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
214883727|NCT02830724|DRUG|Cyclophosphamide|"For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV"
214883728|NCT02830724|DRUG|Fludarabine|"For Phase I, Days -7 to -5:~Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB~For Phase II, Days -7 to -3:~25 mg/m(2)/day x 5 days IVPB"
214883729|NCT02830724|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
214883730|NCT02830724|BIOLOGICAL|Anti-hCD70 CAR transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).
214883731|NCT06037018|BIOLOGICAL|CC312|Doses from 0.3 to 45 µg/dose by intravenous infusion
214883732|NCT06497842|BEHAVIORAL|High-effort resistance exercise training|Six sets per exercise, 8 repetitions per set.
214883733|NCT06497842|BEHAVIORAL|Low-effort resistance exercise training|Three sets per exercise, 4 repetitions per set.
214883734|NCT02638090|DRUG|Vorinostat|Administered per treatment arm guidelines.
214883735|NCT02638090|DRUG|Pembrolizumab|Administered per treatment arm guidelines.
214883736|NCT06193057|PROCEDURE|Total ankle arthroplasty|Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
214883737|NCT06826833|PROCEDURE|Erector Spinae Plane (ESP) Block|A regional anesthesia technique in which 20 mL of 0.25% bupivacaine is injected under ultrasound guidance at the T8-T10 level to provide postoperative pain relief.
214883738|NCT06290648|BEHAVIORAL|Forging New Paths|The study intervention is Forging New Paths (FNP) a newly developed intervention for people with mental illness with criminal legal system involvement that is designed to be delivered in community mental health settings. FNP combines Cognitive Behavioral Treatment (CBT) techniques with social learning principles in a group format. The intervention is organized into a modular format to create a flexible intervention structure. It includes 5 treatment modules each consisting of two to four group sessions for a total of 14-16 sessions, which may be delivered over multiple meetings at the facilitators' discretion. The intervention is designed to be delivered to 8-12 people by two intervention facilitators. It can be delivered in person, virtually, or in a hybrid format.
214883739|NCT03575000|DRUG|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
214883740|NCT05384587|DRUG|asciminib|Supplied in 40 mg and 100 mg tablets for oral use to be taken daily. Dose may be increased at 6 and 12 months based on molecular response with BCR-ABL1 Polymerase Chain Reaction testing.
214883741|NCT06040268|DRUG|Advair HFA|6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily
215046274|NCT05522686|OTHER|Patients in the Brochure Education Group|Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
214883742|NCT06040268|DRUG|Placebo|HFA134a inhaler
214883743|NCT04319237|OTHER|Handgrip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles.
214883744|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)|"The Wechsler Test of Adult Reading (WTAR) is a neuropsychological assessment tool used to provide a measure of Intellectual function. Participants are presented with 50 irregularly spelled words and prompted to pronounce each; the irregular grapheme-to-phoneme translations (such as the gh in the word tough) in the prompts make it difficult to pronounce without having previously learned the word. A high WTAR score is correlated with higher general intelligence as measured by the Wechsler intelligence scales."
214883745|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)|The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of twelve subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory).
214883746|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Color Trails|The Color Trails test measures sustained attention and sequencing. Numbered circles are printed with vivid pink or yellow backgrounds that are perceptible to color-blind individuals. Participants rapidly connect circles numbered 1-25 in sequence and rapidly connect numbered circles in sequence, but alternates between pink and yellow. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.
214883747|NCT04319237|BEHAVIORAL|Neuropsychological Assessment -Stroop Color and Word Test|The Stroop Color and Word Test is based on the observation that individuals can read words much faster than they can identify and name colors. The test-taker reads color words or names ink colors from different pages as quickly as possible within a time limit. The test yields three scores based on the number of items completed on each of the three stimulus sheets. An Interference score is useful in determining the individual's cognitive flexibility, creativity, and reaction to cognitive pressures.
214883748|NCT04319237|BEHAVIORAL|Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire|The PROMIS-29 questionnaire assesses each of 7 domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities). A higher score equals more of the concept being measured.
214883749|NCT04319237|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-3) and the add-on EORTC QLQ Non-Hodgkin's Lymphoma (EORTC QLQ-NHL-HG29) module. All scales range from 0-100, a high scale score represents a higher response level. For example, a high functional score represents a high level of functioning.
214883750|NCT04319237|BEHAVIORAL|Quality of Life (EQ-5D-5L) Questionnaire|The EQ-5D-5L questionnaire is a self assessed quality of life questionnaire. The scale measures quality of life on a 5 component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.
215046275|NCT05522686|OTHER|Patients in the Video Education Group|Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
215046276|NCT05522686|OTHER|Patients in the Brochure-Supported Video Education Group|Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
215046277|NCT05522686|OTHER|Control Group|Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
214292188|NCT00490854|DRUG|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
215046278|NCT03085901|DEVICE|Precizon toric intraocular lens|Phacoemulsification and implantation of Precizon toric intraocular lens
215046279|NCT03085901|DEVICE|Tecnis toric intraocular lens|Phacoemulsification and implantation of Tecnis toric intraocular lens
215046280|NCT04943237|DRUG|Anti-TNF agents|Group of patients using anti-TNF for the last 5 years.
215046281|NCT04943237|DRUG|Conventional therapy users for the last 5 years|Group of patients not using anti-TNF. Group of patients using conventional therapy (non -steroid anti-inflammatory drugs and/or salazopyrin) for the last 5 years
215046282|NCT02772029|DRUG|Apatinib Mesylate Tablets|Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
214292189|NCT00490854|DRUG|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
214292190|NCT04030754|COMBINATION_PRODUCT|amniotic membrane|amniotic membrane is a biological dressing
214292191|NCT04030754|COMBINATION_PRODUCT|duoderm dressing|duoderm dressing is a synthetic dressing
214292192|NCT00198965|BEHAVIORAL|dietary education|
214292193|NCT00198965|BEHAVIORAL|dietary education and provided full fat snack foods|
214292194|NCT00198965|BEHAVIORAL|dietary education and provided fat free snack foods|
214292195|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
215046283|NCT01944020|DEVICE|CPAP|use of CPAP each night for 2 months
215046284|NCT03793621|DRUG|BI 730357|single rising oral dose
215046285|NCT03793621|DRUG|Placebo|single rising oral dose
215046286|NCT00602693|BIOLOGICAL|umbilical cord blood transplantation|Infusion of umbilical cord blood
215046287|NCT00602693|DRUG|Allopurinol|Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
214292196|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
214292197|NCT04840290|DRUG|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
214292198|NCT03109587|DIETARY_SUPPLEMENT|Vivomixx|900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
214292199|NCT03109587|DIETARY_SUPPLEMENT|Placebo|maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
214292200|NCT05248945|DRUG|Evobrutinib|Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
214292201|NCT05248945|DRUG|Carbamazepine|Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
214883751|NCT04319237|BEHAVIORAL|PROMIS Cognitive Function 4a Questionnaire|The PROMIS measures function, symptoms, behavior and feelings.
214883752|NCT04319237|BEHAVIORAL|Comprehensive Score for Financial Toxicity (COST) measure|The COST is a questionnaire made up of 11 statements around topics including costs, concerns and resources and is designed to measure financial toxicity. The user answers questions about their concern over finances numbered from 0-4, with 0 being not at all and 4 being very much.
214883753|NCT03686488|DRUG|TAS 102|TAS 102 35 mg will be administered orally twice daily every 2 weeks.
214883754|NCT03686488|DRUG|Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]|Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
215046288|NCT00602693|DRUG|fludarabine phosphate|40 mg/m\^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
214292202|NCT01137045|BIOLOGICAL|SPEEDA and TRCS SPEEDA|"For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28.~For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28.~For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI"
215046289|NCT00602693|DRUG|Cyclophosphamide|50 mg/kg intravenous over 2 hours on Day -6
215046290|NCT00602693|RADIATION|Total body irradiation|200 cGy on Day -1
215046291|NCT00602693|BIOLOGICAL|Treg infusion|Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10\^5 Treg/kg.
215046292|NCT00602693|DRUG|Sirolimus|Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
215046293|NCT06086743|OTHER|Experimental Group|This group will perform 10 minutes of same warm up exercises. After warm up participants will perform 4 resistance exercises with induced EMS. The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises. the intensity of EMS would be 100A and it would remain same throughout training session. The current administered would be galvanic current. Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
215046294|NCT06086743|OTHER|Control Group|Group B (Control group)will perform 10 minutes of same warm up exercises (Arm swings, jogging on the spot, Walks on treadmill). Group B will perform same 4 resistance exercises without EMS. These 4 exercises include Bicep curls, Triceps dips, Quadriceps chair and squats.The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises and the participants will be instructed, not to perform any kind of exercise during this period.Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
215046295|NCT01809886|DRUG|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).
215046296|NCT01809886|DRUG|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
215046297|NCT04451759|OTHER|MRI exploration|ultra high field (7T) magnetic resonance imaging
215046298|NCT00110214|DRUG|docetaxel|Given IV
214292203|NCT03264495|OTHER|Weight the food served minus the left-overs|
214477054|NCT06818175|PROCEDURE|Ultrsound Guided Hydrodissection of the Thoracolumbar Fascia|The injection of a fluid solution to separate facial or tissue layers in the body. Usually guided by ultrasound.
214883755|NCT05720806|OTHER|Weight Bearing as tolerated (WBAT) immediately following surgery.|Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.
214883756|NCT05720806|OTHER|Flat foot weight bearing (FFWB) immediately following surgery|Subject will be provided standard of care physcial therapy following surgical intervention except
214883757|NCT02917720|OTHER|TKI discontinuation|2nd or 3rd TKI stop after pre-treatment with nilotinib.
214883758|NCT02917720|DRUG|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
214883759|NCT06756932|DRUG|BGB-21447|Administered orally.
214883760|NCT06756932|DRUG|Fulvestrant|Administered via intramuscular injection.
214883761|NCT06756932|DRUG|BGB-43395|Administered orally.
214883762|NCT05410561|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will comprise one session of brief psychoeducation and referral information to alcohol use disorder (AUD) treatment.
214883763|NCT05410561|BEHAVIORAL|TeleTx intervention|TeleTx will consist of an initial session and then 8 \~counseling sessions.
214883764|NCT04371445|DRUG|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
215046299|NCT00110214|OTHER|placebo|Given IV
215046300|NCT00110214|DRUG|prednisone|Given orally
215046301|NCT00110214|BIOLOGICAL|bevacizumab|Given IV
215046302|NCT00110214|OTHER|laboratory biomarker analysis|Correlative studies
215046303|NCT05685420|DRUG|Herombopag|Thrombopoietin receptor agonist
215046304|NCT02171026|DRUG|Dabigatran etexilate|
215046305|NCT02171026|DRUG|Amiodarone|
215046306|NCT01025557|OTHER|Dietary intervention|Dietary treatments with beverages
215046307|NCT03623698|DRUG|Nebulised hypertonic saline|Nebulised hypertonic saline used for a period of at least 12 months
215046308|NCT05412264|BEHAVIORAL|Website intervention|12 week motivational emails, recording pedometer steps and waist circumference
215046309|NCT00811954|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
215046310|NCT00811954|DRUG|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
215046311|NCT00811954|DRUG|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
215046312|NCT00811954|DRUG|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
215046313|NCT00811954|DRUG|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
215046314|NCT05680493|PROCEDURE|Manual pressure release|lengthens the muscle up to the increasing resistance, then gradually applies gentle pressure on MTrp until fingers feels a definite increase in tissue resistance (first barrier). Pressure would maintain until clinician sense relief of tension
215046315|NCT05680493|PROCEDURE|Dry needling|A filiform needle is inserted at 45 degree in to trigger point and then twirl the needle up and down to release trigger point
215046316|NCT05680493|PROCEDURE|Heat therapy|Hydro collator pack will be placed on affected area for relaxation and pain relief for 15 min
215046317|NCT03710265|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
215046318|NCT06288425|OTHER|Non interventional|Non interventional. Review of clinical, biopsy (histopathological and molecular) features associated with rejection and non-rejection pathology diagnosis
215046319|NCT01658553|DRUG|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
215046320|NCT01016067|DEVICE|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
215046321|NCT01016067|PROCEDURE|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
215046322|NCT04983771|DEVICE|Annotate ultrasound scans|Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
214292204|NCT03003936|BEHAVIORAL|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
214292205|NCT04606173|OTHER|Team Education for Adopting Changes in Healthcare (TEACH)|TEACH, an educational strategy which includes evidence-based strategies to improve task-specific teamwork will occur across 4 brief (20-30 minutes) team meetings over a 12-week period.
214292206|NCT01818908|DRUG|DA-EPOCH|DA-EPOCH regimen
215046323|NCT02103127|DEVICE|755nm Alexandrite laser with lens array|
215046324|NCT01960283|DRUG|Methotrexate (Novatrex ®) + anti-H1|"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."
215046325|NCT01960283|DRUG|Placebo + anti-H1|"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."
215046326|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Original doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
214883765|NCT04371445|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
214477055|NCT06818175|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|The therapeutic application of manually guided forces by an osteopathic physician (US Usage) to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. OMT employs a variety of techniques.
214667561|NCT05562193|BEHAVIORAL|Physical activity intervention coupled with standard post-cancer directed treatment care|CCS will participate in a 16-week physical activity program. CCS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize CCS' success. CCS will receive a Fitbit at the beginning of the intervention.
214883766|NCT01839435|PROCEDURE|outpatient surgery|
214883767|NCT06957483|BEHAVIORAL|REACH-SCI (Reducing sedEntary Activities to improve Cardiovascular Health in individuals with a Spinal Cord Injury)|The REACH-SCI intervention was co-designed with key stakeholders and aims to reduce and break up sedentary behaviour in individuals with paraplegia. The intervention will last eight weeks and involve (1) a wearable activity tracker to give reminders to break up sedentary behaviour, (2) education around what sedentary behaviour is, how to reduce and break up sedentary behaviour, and the benefits of doing so, (3) a goal setting worksheet related to sedentary behaviour, (4) one-to-one motivational support sessions to help set goals, review progress and give motivation, (5) peer support using a smartphone app, and (6) activity tools to support breaking up sedentary behaviour throughout the day.
214477056|NCT06816602|BEHAVIORAL|education|Receiving structured education
214667562|NCT05562193|OTHER|Standard post-cancer directed treatment care control|CCS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations and the International Pediatric Oncology Exercise Guidelines will be offered to CCS following completion of 16-week follow-up. Moreover, CCS will receive a Fitbit following completion of 16-week follow-up
214883770|NCT06782490|DRUG|BMS-986368|Specified dose on specified days
214883771|NCT06782490|DRUG|Placebo|Specified dose on specified days
214883772|NCT03735992|BEHAVIORAL|Mind-body medicine group program|The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
214883773|NCT06031441|DRUG|RO7566802|RO7566802 solution for infusion will be administered as specified in each treatment arm.
214883774|NCT06031441|DRUG|Atezolizumab|Atezolizumab solution for infusion will be administered as specified in each treatment arm.
214883775|NCT06075277|DRUG|zongertinib|Participants received a single oral dose of 240 mg Zongertinib (4 x 60 mg tablets) in two periods: in Period 1 after an overnight fast of at least 10 hours, and in Period 2 following a high fat/high calorie meal.
214883776|NCT03885635|PROCEDURE|Hemiarch repair|Current standard of surgical repair consisting of ascending aortic replacement with open distal anastomosis at level of proximal arch under a period of hypothermic circulatory arrest . No surgical or endovascular intervention is carried out in the mid arch or descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
214883777|NCT03885635|PROCEDURE|Extended arch repair|Surgical replacement of the ascending aorta along with intervention on the arch and descending aorta. Techniques for distal aspect of extended arch technique include but are not limited to total arch replacement along with TEVAR, Frozen Elephant Trunk procedure or surgical proximal arch replacement with bare metal stents in arch and descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
214883778|NCT06543693|OTHER|ultrasound training|PoCUS training
214883779|NCT05292183|OTHER|Electrical Stimulation|We will use a computer randomized stimulation of specific areas in the amygdala while showing a computer randomized set of pictures.
214883780|NCT05075824|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight \>= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight \>= 100 kg). Dosing schedule will be as per Arm Description.
214883781|NCT05075824|DRUG|Placebo|Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
215046327|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Monkey doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush monkey doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
215046328|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Dog without velcro doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush dog doll, without velcro in palms. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
215046329|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Bear doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush smiling bear doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
214883782|NCT02919215|BEHAVIORAL|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as a support for teachers if needed. All participants can access and/or provide usual services. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
214883783|NCT03501368|DRUG|Ceritinib|Participants will take ceritinib by mouth (PO) once daily at a dose of up to 450 mg (3 capsules of 150 mg)
214883784|NCT03501368|DRUG|Trametinib|Participants will take trametinib by mouth at a dose of 2 mg daily
214883785|NCT03755804|DRUG|bendamustine|Given intravenously (IV)
214883786|NCT03755804|DRUG|Etoposide|Given intravenously (IV)
214883787|NCT03755804|DRUG|Doxorubicin|Given intravenously (IV)
214883788|NCT03755804|DRUG|Bleomycin|Given intravenously (IV)
214883789|NCT03755804|DRUG|Vincristine|Given intravenously (IV)
214883790|NCT03755804|DRUG|Vinblastine|Given intravenously (IV)
214883791|NCT03755804|DRUG|Prednisone|Given orally (PO)
214883792|NCT03755804|DRUG|Filgrastim|Given subcutaneously (SQ) or IV
214883793|NCT03755804|DRUG|Brentuximab Vedotin|Given intravenously (IV)
214883794|NCT03755804|DRUG|Cyclophosphamide|Given intravenously (IV)
214883795|NCT03755804|DRUG|DTIC|Given intravenously (IV)
214883796|NCT03755804|OTHER|Quality of Life Measurements|Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.
214883797|NCT03755804|RADIATION|Radiotherapy|Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
214883798|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Perception Training: Visual Sweeps; Mind's Eye; Hawk Eye; and Divided Attention. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
214883799|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Cognitive Control Training: Mind Bender; Divided Attention; Card Shark; and Freeze Frame. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
214883800|NCT05274243|DRUG|2-HOBA|2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
214883801|NCT05274243|OTHER|Placebo|Placebo (provided as three capsules) three times a day for 4 weeks
214883802|NCT04610229|RADIATION|Hypofractionation guioded by dose painting|1
214883803|NCT05177211|DRUG|Fedratinib Pill|Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.
214883804|NCT05414357|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging at rest and in activation with attentional task|"Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~* Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~* Biological and physiological measurements~* Spatial memory task~* Cognitive battery~* Questionnaires (sleep, quality of life)"
214883805|NCT04305145|DRUG|Infliximab|Infusion
214883806|NCT04305145|DRUG|Methylprednisolone|Infusion
214883807|NCT04305145|DRUG|Prednisone|Orally
214883808|NCT00111527|OTHER|Optimized echo-guided CRT pacing|Echo-TDI guided VV-delay optimization
214883809|NCT00111527|OTHER|normal RV pacing|PM or ICD implant according to patient indication
214883810|NCT06632496|DEVICE|BD Prevue(TM) II|Ultrasound-guided peripheral intravenous catheter placement procedure using the BD Prevue(TM) II
215046330|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Rabbit doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush rabbit doll, with a neutral expression. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
215046331|NCT02057965|DRUG|Mesenchymal Stromal Cells|Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10\^6 million MSCs per/kg body weight
215046332|NCT06016322|DIETARY_SUPPLEMENT|Dried Chicory Root|"Subjects will receive 1 sachet of 10g WholeFiberTM for the first 2 weeks (equals 8.5 g fiber), and 2 sachets of 10g WholeFiberTM per day for the last two weeks (equals 17 g fiber).~WholeFiberTM is a fiber-rich dried vegetable made from the chicory root that contains four types of prebiotic fibers (inulin, pectin, cellulose, hemi-cellulose)."
215046333|NCT03961191|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
214883811|NCT05928390|DRUG|Pasireotide Diaspartate|Injectable ampoules
214883812|NCT06634589|DRUG|BGB-16673|Administered orally
214883813|NCT06634589|DRUG|Sonrotoclax|Administered orally
214883814|NCT06634589|DRUG|Zanubrutinib|Administered orally
214883815|NCT06634589|DRUG|Mosunetuzumab|Administered subcutaneously
214883816|NCT06634589|DRUG|Glofitamab|Administered intravenously
214883817|NCT06634589|DRUG|Obinutuzumab|Administered intravenously
214883818|NCT06021704|BEHAVIORAL|Enhanced home health aide training in dementia and dementia-related behaviors|8 hours (2 instructional days) of enhanced curriculum dementia-specific instruction for home health aides
214883819|NCT05199688|DRUG|Satralizumab|Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
215046334|NCT03961191|DIAGNOSTIC_TEST|high-risk HPV|High-risk HPV testing for the cervical cytology
215046335|NCT03961191|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
214883820|NCT03975491|BEHAVIORAL|Moderate-Intensity Aerobic Exercise|The exercise intervention will consist of moderate-intensity (50-70% age-predicted maximum heart rate) treadmill walking. All exercise sessions will begin with a five-minute warm up of slow walking, 30-60 minutes of moderate-intensity walking, and a five-minute cool down of slow walking.
214883821|NCT03975491|BEHAVIORAL|Wait-List Control|Participants randomized into the wait-list control group are asked to maintain their pre-study levels of physical activity and follow the recommendations provided by their physician.
214883822|NCT03882034|DRUG|Pegvisomant|A fixed dose of pegvisomant 10-mg started on Day 1 of intervention and continued daily afterwards, will be administered subcutaneously according to manufacturer's recommendations. Adjustment of the dose will occur as per protocol.
214883823|NCT06666699|DEVICE|EUS access device|The intervention involves the use of an EUS access device to gain access to the bile duct via hepaticogastrostomy.
214883824|NCT06443021|DEVICE|PD cycler|"After a training phase and a run-in period of up to 6 weeks, depending on the PD cycler used prior to the study, the interventional phase will be initiated.~* Study phase A, variation of dwell duration: Duration of short cycles (cycle 1 and 2) 30 min, 60 min, 90 min, 120 min (and 150 min depending on the patient´s constitution and at the discretion of the treating physician)~* Study phase B, variation of dialysis fluid glucose composition: 1st cycle: 1.5% glucose concentration, 2nd cycle: 2.3% glucose concentration, 3rd cycle: 1.5% glucose concentration, 4th cycle: 2.3% glucose concentration; all following cycles to be applied as prescribed by the treating physician.~* Study phase C, variation of fill volume: 60% fill volume, 80% fill volume, 100% fill volume and 120% fill volume. (Volume of 120% will only be applied in case the patient tolerates these volumes according to the IPP."
214883825|NCT05875714|DRUG|Apremilast|Apremilast (Otezla), oral medication Day 1: 10 mg in the morning. Day 2: 10 mg in the morning and 10 mg in the evening. Day 3: 10 mg in the morning and 20 mg in the evening. Day 4: 20 mg in the morning and 20 mg in the evening. Day 5: 20 mg in the morning and 30 mg in the evening Day 6: 30 mg twice daily Maintenance dosing: 30 mg twice daily
214883826|NCT06015438|BEHAVIORAL|Home Exercise Program|Participants will perform a minimum of one exercise from each of the targeted muscle groups at a frequency of every other day, for a total of 3-4 days a week of exercise with a rest day. The entire strengthening exercise routine should take approximately 25-30 minutes to perform, including rest periods. Each muscle grouping of exercises is designed to progress from minimal muscle effort required to moderate to maximal effort. Participants will use a video to perform the exercises as well as a handout with specific instructions.
214883827|NCT06015438|BEHAVIORAL|Short Exercise Program|Participants in this group will attend one in-person visit expected to last about 60 minutes. The clinic visit will consist of standard of care procedures and tests for individuals with mild-to-severe HS .
214883828|NCT06233942|DRUG|BG-C9074|administered by intravenous infusion
214883829|NCT06233942|DRUG|Tislelizumab|administered by intravenous infusion
214883830|NCT05200208|DIETARY_SUPPLEMENT|Citicoline supplement|Participants with AD will receive a dietary citicoline supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
214883831|NCT05200208|OTHER|Placebo|Participants with AD will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
214883832|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day."
214883833|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful."
214883834|NCT02506153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214883835|NCT02506153|PROCEDURE|Computed Tomography|Undergo CT scan
214883836|NCT02506153|BIOLOGICAL|Ipilimumab|Given IV
214883837|NCT02506153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214883838|NCT02506153|BIOLOGICAL|Pembrolizumab|Given IV
214883839|NCT02506153|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214883840|NCT02506153|OTHER|Quality-of-Life Assessment|Ancillary studies
214883841|NCT02506153|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
214883842|NCT05456191|DRUG|Asciminib|Asciminib 80 mg QD administered under fasting conditions.
214883843|NCT05456191|DRUG|Nilotinib|Nilotinib 300 mg BID administered under fasting conditions.
214883844|NCT06572228|DRUG|dupilumab|Administered by subcutaneous (SC) injection
214883845|NCT06572228|DRUG|Matching Placebo|Administered by SC injection
214883846|NCT06572228|DRUG|ICS/LABA|Administered at a blinded dose
214883847|NCT02723734|OTHER|Decipher® Testing|Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.
214883848|NCT03128060|OTHER|Home-based palliative care|The HBPC model consists of home visits by an interdisciplinary primary palliative care team (a physician, nurse, social worker, and chaplain). This team provides pain and symptom management, psychosocial support, advance care planning, spiritual counseling, grief counseling, and other services to meet patient and caregiver needs. Within the first week of a patient's enrollment, team members separately visit the patient at home to assess his/her needs as well as the needs of his/her caregiver. Following the patient's initial assessment, subsequent home visits are based on the patient's and caregiver's needs. At a minimum, a core team member visits the patient at home once per week. Additionally, a 24/7 helpline provides access to nurse counseling and after-hours home visits as needed. As a patient's health declines and he/she becomes eligible for hospice care, HBPC clinicians will refer the patient to hospice.
214883849|NCT03128060|OTHER|Enhanced usual care|"Usual primary care consists of: 1) appointment-based access to primary care providers (PCPs) as requested by the patient; 2) case management services; and 3) provider support through palliative care consultation. These PCPs provide family/internal medicine services as well as access to specialist care. They also offer disease case management and pain and symptom management.~These usual care services are enhanced through training in palliative care provided to PCPs. The training addresses core elements of palliative care, specifically these 6 topics: a palliative care overview; strategies for improving patient-provider communications; instruction in ACP; instruction in managing patients' pain and symptoms; care coordination; and preventing medical crises."
215046336|NCT02625350|OTHER|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
215046337|NCT02625350|OTHER|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
215046338|NCT02625350|OTHER|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
215046339|NCT00634140|DRUG|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
215046340|NCT00634140|DRUG|Placebo|placebo for 4-6 weeks
215046341|NCT01452477|DRUG|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
215046342|NCT01452477|DRUG|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
215046343|NCT06391892|PROCEDURE|Neoadjuvant chemotherapy instead of upfront surgery|"All patients included into the study are recommended to go for upfront surgery (CT and CA19-9) by tumor board.~If preoperative ctDNA is positive, the investigators assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead.~* Apart from blood collection (within the scope of clinical routine), there is no additional diagnostic intervention performed on the patient.~* The respective neoadjuvant chemotherapeutical drug will be selected and applied by the treating medical oncologist at physicians choice (unaffected by study participation), usually mFOLFIRINOX or Gemcitabine/nabPaclitaxel at standardized dosage recommended by NCCN and local guidelines.~FOLFIRONOX: Folinic acid (also known as leucovorin), F - Fluorouracil (5-FU), IRIN - Irinotecan, OX - Oxaliplatin."
215046344|NCT06391892|PROCEDURE|Upfront surgery|Standard of care as recommended by tumor board (not affected by study conditions).
215046345|NCT03999580|DRUG|vitamin D3|"3000 or 4000 UI/ day:~Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance"
215046346|NCT03509818|OTHER|plyometric exercise|acute plyometric exercise
215046347|NCT03509818|OTHER|Aerobic exercise|acute aerobic exercise
214883850|NCT06267846|DRUG|NBI-1070770|Suspension for oral administration
214883851|NCT06267846|DRUG|Placebo|Suspension for oral administration
214883852|NCT03536312|PROCEDURE|Thoracic Aortic Surgery|Thoracic aortic surgery to treat thoracic aortic aneurysm
214667563|NCT05519696|BEHAVIORAL|Intervention|Participants receiving the intervention will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting and includes a focus on cultural topics related to collectivism. Participants receive FitBits to track their physical activity and through the FitBit mobile app are connected to their group members to encourage communication and social support.
214667564|NCT05519696|BEHAVIORAL|Comparison|Participants receiving the comparison program will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, group walking program, and individual-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting only (and no focus on collectivism). Participants receive FitBits to track their physical activity, but are not connected to their group members on the mobile app.
214883853|NCT05180773|DRUG|Bromocriptine|Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
214883854|NCT05180773|DRUG|Placebo|Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
214883855|NCT05180773|DRUG|Guideline Directed Medical Therapy for Heart Failure (GDMT)|GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
214883856|NCT05180773|DRUG|Rivaroxaban|Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
214883857|NCT05180773|DRUG|Second Placebo|Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
214883858|NCT05832177|BEHAVIORAL|Cancer CientoUno (101) program|The Spanish version of Cancer 101 consists of several modules that address cancer control and prevention, risk factors, early detection and screening guidelines, cancer diagnosis and stages, cancer treatment, cancer and genetics, cancer and chronic disease, patient and caregiver support, HPV, biobanking, and clinical trials. All modules contain a written summary with learning objectives, a PowerPoint presentation, pre- and post-module evaluations with an answer sheet, a glossary, references, and supplemental resources. This program will occur on an ongoing basis.
215046348|NCT03192098|DEVICE|Savary bougie dilation|Patients will be dilated with the use of the Savary bougienage device
215046349|NCT03421886|DEVICE|Aerodentis system|The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
215046350|NCT03421886|DEVICE|Invisalign clear aligner system|Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
215046351|NCT01138475|DRUG|Paricalcitol|1 microgram by mouth daily for 6 weeks
214667565|NCT06025136|OTHER|Using a gel pillow|Within the scope of the study, gel pillows with a cold surface were used in the patients in the study group. It is produced by combining the obtained special liquid with elastic material with NASA approved molecule exchange technology and is made of OEKO-TEX CLASS 1 certified material.Thanks to the gel material on the pillow surface, the surface temperature is reduced from 37°C to 24°C in about 10 seconds. It gives a feeling of coolness with its thermal conductivity feature.
214667566|NCT06194201|DRUG|HRS9432|Dosing frequency: intravenously once week
214667567|NCT06194201|DRUG|Caspofungin Acetate for Injection|Dosing frequency: D1 70mg，followed by 50mg intravenously once daily
215046352|NCT01138475|DRUG|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
215046353|NCT01138475|DRUG|Placebo|Inactive substance, one capsule daily for 6 weeks
214883859|NCT05832177|BEHAVIORAL|Latinos y el cáncer/Hablemos de cáncer (Translation in English: Latinos and Cancer/Let's Talk About Cancer)|This is a biennial cancer symposium focused on cancer topics important to Hispanic/Latinos. This day-long event includes a plenary session and concurrent sessions where healthcare professionals present educational information about cancer, cancer prevention, early detection methods, and other related topics.
214883860|NCT05832177|BEHAVIORAL|¡Salud! Serie de Charlas (Translation in English: Health! Talk Series)|This is an educational and community outreach effort comprised of local charlas (talks) led by Hispanic/Latino healthcare professionals (e.g., the partnership Community Health Educator \[CHE\], topic experts) who provide education and answer questions about specific cancer topics. The charlas may be conducted in multiple modalities (in person, virtual, hybrid) and may be conducted in English and/or Spanish. At least three events will be held each year in the partnership locations.
214883861|NCT05832177|BEHAVIORAL|Community/Researcher Forum: El Puente (Translation in English: The Bridge).|The main goal of the El Puente annual event is to generate dialogue between community members and researchers about cancer treatment and cancer-focused research topics. During El Puente's presentations, researchers present their projects and data results to community members, allowing community members to react to the research, make suggestions, and express concerns.
214883862|NCT05832177|BEHAVIORAL|Lunch and Learn Updated Recommendations Series.|This is a virtual podcast that will discuss cancer-related recommendations and guidelines from the United States Preventive Services Task Force (USPSTF). The podcasts are pre-recorded, 30 minute long, and will be in English and/or Spanish. This podcast will be hosted by the Outreach Core (OC) CHE, and feature experts who will explain the updated recommendations and active steps that community members and providers can take to facilitate adherence. This activity will begin according to the project timeline
214883863|NCT05832177|BEHAVIORAL|Community Engagement (CE) Training Program for U54 Partnership Investigators|This is a series of 2 1/2-day CE workshops designed and delivered up to 20 partnership researchers (including faculty and junior investigators) delivered across four sessions per year (6 to 10 researchers per year). Each session includes two hours of lectures (didactic material) and one hour of practice activities (practical application of the theoretical content). Session topics will include CE: concepts and principles, theoretical roots, levels, and ethics. The OC team will provide educational materials and additional references in each session.
214883864|NCT05832177|BEHAVIORAL|Community Advisory Panels (CAP)|These CAPs work closely with the (CHE) to oversee the identification, development, and coordination of the outreach activities; provide advice on the development and implementation of community needs and assessments; provide guidance for recruitment and retention of research participants; and assist in the recruitment for educational events and research and vetting community educational materials and the content of protocols for research projects.
214883865|NCT05832177|BEHAVIORAL|Research Corner|The goal is to provide bidirectional communication between the community and researchers to increase CE strategies into cancer disparities research through periodic meetings between community members and researchers to discuss CE strategies, research recruitment strategies, dissemination strategies, among others.
215046354|NCT02169011|PROCEDURE|Latissimus Dorsi Flap Reconstruction|Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
215046355|NCT02169011|PROCEDURE|TAP Flap Reconstruction|Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
215046356|NCT01941771|DRUG|Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
215046357|NCT01941771|DRUG|Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
215046358|NCT03413904|PROCEDURE|transanal TME|transanal approach to TME in rectal cancer
215046359|NCT03413904|PROCEDURE|laparoscopic TME|laparoscopic approach to TME in rectal cancer
215046360|NCT01033084|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
215046361|NCT01033084|DRUG|Sertraline|Patient will receive sertraline 50mg/day.
215046362|NCT01033084|OTHER|double placebo|double placebo arm (sham stimulation/placebo pill)
215046363|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
215046364|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
215046365|NCT00893841|DRUG|placebo|placebo
215046366|NCT00893841|DRUG|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
215046367|NCT00606645|BIOLOGICAL|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
215046368|NCT00605059|DRUG|[123I]AV94|Evaluation of \[123I\] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
215046369|NCT01624935|BEHAVIORAL|interpersonal psychotherapy|interpersonal psychotherapy
215046370|NCT00459940|DRUG|Pioglitazone|
215046371|NCT00883155|DRUG|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
215046372|NCT00883155|DRUG|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
215046373|NCT03968692|DIAGNOSTIC_TEST|Prostate-Specific Antigen test|Prostate-Specific Antigen (PSA) test as opportunistic screening or in the presence of symptoms
215046374|NCT01871025|OTHER|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
215046375|NCT01871025|OTHER|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
215046376|NCT02125344|DRUG|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
215046377|NCT02125344|DRUG|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
214883866|NCT05832177|BEHAVIORAL|Community-based Training Program (CBTP) for Community Leaders and Stakeholders.|The CBTP provides the opportunity to acquire knowledge to impart cancer prevention education (Cancer 101) and skills necessary to disseminate educational information (hands-on experiences through OC educational activities). This training will be provided in-person and remotely to increase participation. This activity will begin according to the project timeline.
215046378|NCT02125344|DRUG|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
215046379|NCT02125344|DRUG|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
215046380|NCT02125344|DRUG|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
215046381|NCT02125344|DRUG|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
215046382|NCT02125344|DRUG|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
215046383|NCT02125344|DRUG|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
215046384|NCT04375527|DRUG|Binimetinib|Given PO
215046385|NCT04375527|BIOLOGICAL|Nivolumab|Given IV
215046386|NCT04375527|OTHER|Questionnaire Administration|Ancillary studies
215046387|NCT05120050|DEVICE|ASP Health instrument|The instrument is an integrated device with a short processing time (measured in 2 to 3 minutes) that distributes cells from limited volume samples (measured in microliters). The process involves a novel aerosolization technique that transfers liquid sample to a glass slide via a burst of air. After the sample is deposited on the glass slide, the automated system uses an integrated heating strip to heat the specimen slide. This process is similar to using a hair dryer to dry the specimen slide in the current ROSE setting. After drying the slide, the system uses series of pumps to dispense microliters of stain reagent onto the slide to stain the cells. Currently, the system is configured to perform DiffQuik staining, which is commonly used in the ROSE process. In the future, the staining capability will be broadened to include other staining processes such as Rapid PAP, H\&E staining etc.
215046388|NCT03006588|PROCEDURE|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
215046389|NCT00547963|BEHAVIORAL|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
215046390|NCT02117778|PROCEDURE|Continuous Nerve Block|
215046391|NCT04344730|DRUG|Dexamethasone injection|Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
215046392|NCT04344730|DRUG|placebo|Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
215046393|NCT04344730|PROCEDURE|conventional oxygen|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
214477057|NCT06819384|OTHER|Movement Pattern Training|The group A Movement Pattern Training 2set each set 20 repition lasting for eight weeks.
215046394|NCT04344730|PROCEDURE|CPAP|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment.The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
214477058|NCT06819384|OTHER|propioceptive neuromuscular facilitation|The group B propioceptive neuromuscular facilitation 2set each set 20 repition lasting for eight weeks.
214477059|NCT06816407|DRUG|Prucalopride 2mg|Prucalopride 2mg taken preoperatively
214477060|NCT06816407|DRUG|Prucalopride 4mg|Prucalopride 4mg taken preoperatively
214477061|NCT06816407|OTHER|Standard Care|Standard Supportive care
214477062|NCT03752892|OTHER|intervention -1-leg cycle training|partitioned aerobic exercise training
214477063|NCT03752892|OTHER|usual care - 2-leg cycle training|conventional aerobic exercise training
214883867|NCT05832177|BEHAVIORAL|Integrate Cancer 101 into the Stakeholders Programs|This program will offer stakeholders a no-cost workshop of three credit hours to increase cancer prevention education among Hispanic/Latinos. CMEs will be provided virtually to increase participation. This activity will begin according to the project timeline.
214883868|NCT05832177|BEHAVIORAL|Community Engagement (CE) Training Program for Lay Community Members|A series of two-day CE workshops designed and delivered to 30 lay community members over a four-year period (6 to 10 participants per year). The proposed CE workshops includes: 1) CE principles, 2) cancer prevention education principles, and 3) community-based promotion strategies for cancer prevention. This activity will begin according to the project timeline.
214883869|NCT06080477|BEHAVIORAL|Enhanced Usual Care|Participants randomized to usual care will continue to receive their standard clinical care at Queen Elizabeth Central Hospital (QECH) as previously. The clinical team will be provided a summary of the results of the eligibility assessment, specifically an interpretation of the scores on the symptomatology and disability scales with any relevant clinical recommendations. These individuals will receive no home-based services.
214883870|NCT06080477|BEHAVIORAL|Adapted ENHANCE Intervention|Participants randomized to the intervention arm will receive community-based rehabilitation (CBR) delivered by the Queen Elizabeth Central Hospital (QECH) clinical team of psychiatric nurses. The ENHANCE CBR intervention will consist of nurse-delivered home visits over approximately a 12-month period with decreasing intensity, with approximately weekly visits for an initial phase of 2-4 months; biweekly visits for an intermediate phase of 4-6 months; and monthly for a final transition phase of 3-4 months. The exact schedule and duration of each phase will be individualized by the nurse to the participant based on the participant's initial presentation and their response during the intervention. The intervention team will deliver intervention content with the participant and/or family members and caregivers as appropriate to the module.
214883871|NCT06230224|DRUG|Odronextamab|Administered by intravenous (IV) infusion
214883872|NCT06230224|DRUG|Ifosfamide|Administered by IV infusion, as part of the ICE ± R salvage therapy
215046395|NCT04344730|PROCEDURE|HFNO|TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2
215046396|NCT04344730|PROCEDURE|mechanical ventilation|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
215046397|NCT01534481|BIOLOGICAL|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
215046398|NCT01534481|DIETARY_SUPPLEMENT|Preterm Formula|Preterm Formula determined by center practice.
215046399|NCT01130337|DRUG|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
215046400|NCT01130337|DRUG|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
215046401|NCT01130337|DRUG|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
215046402|NCT06515015|DEVICE|Endobronchial Silicon Spigots|The single-use endobronchial silicon spigot is injection-molded from implant-grade silicone and has a solid conical body. The endobronchial silicon spigot is used for the temporary occlusion of the target bronchus. It is delivered to the target bronchus through a bronchoscope using biopsy forceps, and the position of the blocker is adjusted to occlude the responsible bronchus leading to the pleural air leakage.
215046403|NCT01247623|BIOLOGICAL|GV1001|
215046404|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
215046405|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
215046406|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
215046407|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
215046408|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
215046409|NCT03886493|DRUG|Dupilumab|dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
214883873|NCT06230224|DRUG|Carboplatin|Administered by IV infusion, as part of the ICE ± R salvage therapy
214883874|NCT06230224|DRUG|Etoposide|Administered by IV infusion, as part of the ICE ± R salvage therapy
214883875|NCT06230224|DRUG|Rituximab|Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.
214883876|NCT06230224|DRUG|Dexamethasone|Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.
214883877|NCT06230224|DRUG|Cisplatin|Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.
214883878|NCT06230224|DRUG|Cytarabine|Administered by IV infusion, as part of the DHAP ± R salvage therapy.
214883879|NCT06230224|DRUG|Gemcitabine|Administered by IV infusion, as part of the GDP ± R salvage therapy.
214883880|NCT03418844|OTHER|Self-questionnaires of living conditions and quality of life|Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)
214883881|NCT03418844|DIAGNOSTIC_TEST|Cardiac, pulmonary, auditory and biological assessment|"Patients will perform :~* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~* Blood tests"
214883882|NCT04524000|DRUG|Alpelisib|"\[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1."
214883883|NCT04524000|DRUG|Fulvestrant|Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
214883884|NCT06400238|PROCEDURE|Biopsy Procedure|Undergo biopsy
214883885|NCT06400238|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214883886|NCT06400238|PROCEDURE|Computed Tomography|Undergo CT scan
214883887|NCT06400238|DRUG|Copanlisib|Given IV
214883888|NCT06400238|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214883889|NCT05861986|DRUG|Risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
214883890|NCT06106295|DRUG|Metyrapone|250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)
214883891|NCT04936854|DRUG|Sirolimus 1 mg Oral Tablet|2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
214883892|NCT04936854|DRUG|Methylprednisolone|500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks. Total period of treatment 12 weeks.
214883893|NCT05503264|DRUG|Satralizumab|In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments.
214883894|NCT05503264|OTHER|Placebo|Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device \[NSD\] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.
214883895|NCT04429295|BIOLOGICAL|DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214883896|NCT04429295|BIOLOGICAL|DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214883897|NCT04429295|BIOLOGICAL|Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214883898|NCT04429295|BIOLOGICAL|Poliomyelitis Vaccine bivalent types 1 and 3|Pharmaceutical form:Oral suspension Route of administration: Oral
214883899|NCT04429295|BIOLOGICAL|Human Rotavirus, live attenuated|Pharmaceutical form:Oral suspension Route of administration: Oral
214883900|NCT04429295|BIOLOGICAL|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214883901|NCT05327387|OTHER|model-based electrical brain stimulation|Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.
214883902|NCT04546009|DRUG|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
214883903|NCT04546009|DRUG|Giredestrant-matched Placebo|Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
214883904|NCT04546009|DRUG|Letrozole|Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
214883905|NCT04546009|DRUG|Letrozole-matched Placebo|Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
214883906|NCT04546009|DRUG|Palbociclib|Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
215046410|NCT00609752|DRUG|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
214883907|NCT04546009|DRUG|LHRH Agonist|Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
214883908|NCT04509934|OTHER|Connective Tissue Manipulation|The position of the patients during treatment sessions was sitting with the hips and knees at 90° flexion and feet supported, arms relaxed on the thighs, back naked and straight, allowing optimal tension of the connective tissue. The CTM procedure consisted of treating 3 sections in the back. These sections were basic (sacral and lumbar regions), lower thoracic (L1 through T7) and anterior pelvic. All sessions were ended with bilateral long strokes to the iliac crest and subcostal regions. The physiotherapist applied strokes bilaterally by her middle finger of the right or left hand to the defined zones of the mentioned sections in the back. The treatment started from the basic section, and progress to other regions was decided according to the vascular reaction of the connective tissue. Each session lasted for 5 to 20 minutes, depending on the extent of the treated area.
214883909|NCT06337513|OTHER|Rehabilitation intervention|"The intervention consists of a physiotherapist-coordinated (PT) interdisciplinary outpatient rehabilitation offer for 6-months.~The intervention encompasses 3 individual sessions with the PT, if needed individual sessions with the interdisciplinary team (PT, occupational therapist, OT, nurse, and social worker) (a maximum of 6 hours), and patient education in two group seminars."
214883910|NCT06337513|OTHER|Usual care|Both the intervention and the control group will receive usual care.
214883911|NCT05829317|DRUG|Magnesium sulfate|Intravenous Magnesium sulfate
214883912|NCT05829317|DRUG|Placebo|0.9% NaCl
214883913|NCT05998772|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Application of 82,5 g of glucose monohydrate solved in 300ml water
214883914|NCT05998772|OTHER|Placebo Oral Glucose Tolerance Test|Application of 125mg sucralose solved in 300ml water
214667568|NCT05733091|BEHAVIORAL|Standard of Care|Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
214883915|NCT05425511|BEHAVIORAL|sophrology / neurolinguistic programming intervention|"2 sessions will be offered per week at 2 different time and will last 1 hour. They can take place in a seated or standing position, without physical contact. The sessions will consist of breathing exercises, visualization, dynamic relaxation and concentration exercises. The program is standardized:~1. Dialogue between the sophrologist and the participants. It is possible to specify the objective(s) of the session. The sophrologist can ask more specific questions to adapt the session.~2. Presentation of the conduct of the session (possible variations) and instructions promoting autonomy~3. Guided by the sophrologist, the goal is to help free yourself from tensions, to play down a situation that worries and finally to realize that we can deal with. Exercises are adapted to the difficulties encountered by the participants.~4. Time for free expression after the practice to promote the integration of the technique while giving elements to the sophrologist to guide the future sessions."
214883916|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention Training|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI Group Training is comprised of three components: TBRI Youth Group Training (youth only), Caregiver Training (caregivers only), and Nurture Groups (youth-caregiver joint roleplay activities), which is conducted prior to youth's release."
214883917|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention In-Home Structured Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Structured Training includes four structured in-home coaching sessions."
214883918|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention In-Home Responsive Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Responsive Training includes at least 2 structured in-home coaching sessions plus additional sessions indefinitely as needed."
214883919|NCT04669041|DRUG|Rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
214883920|NCT04669041|DRUG|SPC ezetimibe/rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
214883921|NCT04669041|DRUG|Rosuvastatin active capsule|Pharmaceutical form:Capsule Route of administration: Oral
214883922|NCT04669041|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
214883923|NCT04669041|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
214883924|NCT01282697|DRUG|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
214883925|NCT02479204|DRUG|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
214883926|NCT02479204|DRUG|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
214883927|NCT02479204|DRUG|Placebo|ACT-33441-matching placebo
214883928|NCT02479204|DRUG|Atenolol|film-coated tablet containing atenolol at a strength of 50 mg
214883929|NCT02479204|DRUG|Diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
214667569|NCT03417765|DRUG|FE 203799|GLP-2 analogue, once weekly, subcutaneous administration
214667570|NCT06964789|DEVICE|Mechatronic Remote Physiotherapy System (MRPS)|The MRPS is an Online Rehabilitation Platform for neurology patients. The platform has been designed to provide supervised and monitored remote rehabilitation therapy, initially focusing on patients who have suffered a stroke. The system comprises of a patent pending mirror therapy strengthening device, which is a neural therapy device using mirror therapy and exercise apparatus for upper limb rehabilitation. The platform also permits the addition of modules beneficial to the patients' recovery. A sensory substitution balance apparatus and motion detecting sensors are also being designed to connect to the system to allow for lower limb rehabilitation.
214883930|NCT06438874|OTHER|Exercise Test|Exercise capacity will be measured as peak oxygen consumption (peakVO2) using an incremental exercise test on a cycle ergometer with an open-circuit spirometry system (TrueOne, Parvo Medics, Sandy, UT) to analyze expired gases. Exercise testing will follow the American College of Sports Medicine and American Heart Association guidelines. The investigators will use a graded protocol, starting with a warm-up at 0 watts for 5 minutes, followed by 15 watt increments every 2 minutes until volitional fatigue.
214883931|NCT06294574|DEVICE|HydroMARK Plus Clip|Each patient will undergo a breast localization procedure, and a HydroMARK plus clip will be placed.
214883932|NCT06247111|OTHER|Remote Blood Pressure Monitoring + Telehealth|Remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
214883933|NCT06247111|OTHER|Usual care|Participants receive usual care, no intervention.
214883934|NCT06215846|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 VP, 5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
214883935|NCT06500962|BEHAVIORAL|Usual Care|Participants will receive a message sent to their electronic health record portal with instructions about how to sign up for a food is medicine program.
214883936|NCT06500962|BEHAVIORAL|Navigation|Participants will receive a weekly phone call from a navigator to promote enrollment in the food is medicine program and address any barriers to participation.
214883937|NCT06500962|BEHAVIORAL|Text Messaging|Participants will receive two text messages per week to promote healthy eating, enrolling in a food is medicine program, and continuing to participate in a food is medicine program.
214883938|NCT06419907|BEHAVIORAL|Type 2 Live Well (structured diabetes self management education programme)|Structured diabetes self management education programme designed to support those with type 2 diabetes self care and prevent long term associated complications.
214883939|NCT04273061|DRUG|Atezolizumab|1200 mg by intravenous infusion every 3 weeks as tolerated
214883940|NCT04253379|DIAGNOSTIC_TEST|Neuropsychological evaluation , Evaluation of theory of mind, Evaluation of executive functions, Evaluation of verbal skills|Several tests will be used: Raven's Advanced Progressive Matrices, auditory attention subtest of the NEPSY II, Peabody Picture Vocabulary test, specific comprehension test The cognitive TOM will be evaluated with questions about 4 stories of false beliefs. The affective TOM will be evaluated with a specific emotion inference task 4 adapted subtests from several validated scales will be used to investigate inhibition, cognitive flexibility and working memory The semantic and pragmatic competences will be evaluated with 4 comprehension tasks.
214883941|NCT06553209|BIOLOGICAL|CM512|CM512 injection
214883942|NCT06553209|DRUG|Placebo|Placebo
214883943|NCT06217874|OTHER|Non-Interventional Study|Non-interventional study
214883944|NCT02311933|DRUG|Endoxifen Hydrochloride|Given PO
214883945|NCT02311933|OTHER|Laboratory Biomarker Analysis|Correlative studies
214883946|NCT02311933|OTHER|Pharmacological Study|Correlative studies
214883947|NCT02311933|DRUG|Tamoxifen Citrate|Given PO
214883948|NCT03716180|DRUG|Paclitaxel|"Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
214883949|NCT03716180|DRUG|Trastuzumab|Trastuzumab works by targeting the HER2/neu receptor on cancer cells
214883950|NCT03716180|DRUG|Pertuzumab|Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
214883951|NCT03431688|DRUG|PAM|treatment with PPI, metonidazole, amoxicillin
214883952|NCT03431688|DRUG|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
214883953|NCT06085222|BEHAVIORAL|Emotional Engagement Distress Tolerance Intervention|2.5 hour computerized intervention with smart phone support focused on building tolerance of emotional distress
214883954|NCT06085222|BEHAVIORAL|Health Education Intervention|2.5 hour computerized intervention with smart phone support focused on building healthy habits that support stress management
214883955|NCT05194111|DRUG|Sacubitril-valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
214883956|NCT05194111|DRUG|Valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
214883957|NCT05398809|DRUG|Ruxolitinib|Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
214883958|NCT06475742|DRUG|Cenerimod|Film-coated tablets at a dose of 4 mg.
215046411|NCT00609752|DIETARY_SUPPLEMENT|Alicalm (polymeric liquid formula)|"Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks."
215046412|NCT03901638|DRUG|Tllsh2910|Tllsh2910 80mg twice per day orally for 12 weeks
215046413|NCT03901638|DRUG|Placebo|Placebo
215046414|NCT02669498|PROCEDURE|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
215046415|NCT05680467|OTHER|Manual Therapy|"The protocol will last 30 minutes and will include the application of the following manual techniques:~* Lumbar soft tissue and joint cranial and lateral mobilization with the patient in the supine position~* Bilateral medial lumbar soft tissue mobilization~* Functional massage on the quadratus lumborum muscle with the patient in a lateral position on both sides~* Extension with coupled sidebending mobilization of the thoracic area with the patient in a lateral position on both sides~* Soft tissue lateral mobilization of the thoracic area with the patient in a lateral position on both sides"
214883959|NCT05420766|BEHAVIORAL|Shortened Sleep|In this experimental condition, children go to bed 90 minutes later than their typical bedtime during Week 2 of the 4-week protocol.
214883960|NCT05420766|BEHAVIORAL|Stabilized sleep|In this control condition, children go to bed at their usual time throughout the 4-week protocol.
214883961|NCT05516537|BEHAVIORAL|Guidelines for Exercise in Multiple Sclerosis (GEMS)|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.
214883962|NCT05516537|BEHAVIORAL|FLEX Stretching and Toning Program|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.
214883963|NCT05929651|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection
214883964|NCT06001814|BEHAVIORAL|One-Mind One-Heart|One-Mind One-Heart will include mindfulness and behavior change skills to address psychological distress, physical activity, diet, and substance use.
214883965|NCT06001814|OTHER|Education|Education will be provided on behavioral cardiovascular disease risk reduction strategies, such as increasing physical activity, reducing salt intake in diet, and reduce/stop alcohol and tobacco-use.
214883966|NCT03517475|BEHAVIORAL|SHS Low-Income|An intervention to train caregivers to supervise their children appropriately.
215046416|NCT05680467|OTHER|Manual Therapy plus TECAR|The participants of this group will be given the same manual protocol as the first group in combination with the application of high frequency current. Soft tissue mobilization manipulations will be applied in combination with a capacitive conventional electrode and with a special electrode bracelet that makes the therapist's own hand as an antistatic electrode. The frequencies of the high frequency current will be 300khz, 500khz, and 1MHz, while as a reference electrode a flexible self-adhesive ground will be used placed on the abdomen
215046417|NCT05680467|OTHER|Control|Participants in this group will only receive general instructions about managing their back pain and counseling about avoiding activities that may worsen their symptoms.
214477064|NCT06825923|OTHER|Clinical and Endotypic Assessmen|This observational study involves a detailed clinical and endotypic assessment of patients diagnosed with Obstructive Sleep Apnea (OSA). Assessments include polysomnography (PSG) to measure sleep patterns and disturbances, drug-induced sleep endoscopy (DISE) to evaluate upper airway obstruction, and various biomarker analyses to characterize endotypic traits. The study aims to collect comprehensive phenotypic and endotypic data to develop predictive models for OSA patient characterization and management.
214477065|NCT06825026|BEHAVIORAL|Pragmatic exercise trial|As part of the broader Observatory of the Older Person cohort, we aim to conduct a pragmatic exercise trial in a subgroup of nursing home residents. This trial seeks to evaluate the effectiveness of a concurrent exercise intervention on frailty, functional capacity, independence in activities of daily living and falls rate in real-world settings.
214477066|NCT06820268|DRUG|XS-04 tablet|Each treatment cycle is 28 days, with continuous oral administration, twice daily.
214477067|NCT06824025|DRUG|lidocaine group ( nebulized lidocaine + saline) total volume 4 ml|nebulization of 60 mg lidocaine in 4ml saline 0.9%
214883967|NCT06520488|DRUG|HRS-4642|Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG
214883968|NCT06120764|OTHER|guided imagery|The children in the experimental group will listen to the first part of the 'Guided Imagery CD' prepared by the Turkish Psychological Association for relaxation 30 minutes before the chemotherapy infusion starts. The suggestions given in the first part of the CD will help the patients relax and focus their attention on their breathing. Patients will be positioned in a supine or semi-fowler position and will listen to the CD with headphones from a laptop. Once the chemotherapy infusion starts, relaxing light background music with the sound of a river or sea will be played based on the patients' preference, and imagery will be applied to the patients. Patients will be encouraged to think of various images, such as imagining that the treatment is over, visualizing themselves as much healthier and recovering quickly, returning to their old life, and doing whatever they want to do first after recovery. If there is an object, person, event, situation, or food that will make them feel good,
215046418|NCT06174675|PROCEDURE|combined bilateral infraorbital and infratrochlear nerve blocks|"Filling the block labelled syringe with 8 mL of bupivacaine 0.25%. Starting with Infraorbital nerve block using an extraoral approach.Inserting a 25-gauge needle laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. Positioning of the index finger of the non-dominant hand above the infraorbital foramen and advancing the needle feeling it beneath the finger to avoid globe penetration injury. Injecting 3 mL of the study solution slowly after confirming negative aspiration of blood and taking care not to inject into the foramen itself.~Shifting to infratrochlear nerve block by inserting the needle 1 cm above the inner canthus targeting the junction of the orbit and the nasal bone. Injecting 1mL of the study solution after confirming negative aspiration of blood.~Performing contralateral nerve block in the same manner. Applying pressure to four injection points for one minute to prevent hematoma."
215046419|NCT06521216|DRUG|Ferrous sulfate|all patients will receive 200 mg elemental iron (ferrous sulphate)
214883969|NCT06069700|OTHER|Non-pharmacological Individualized rehabilitative therapy|Treatments will be standardized but components of the treatments will be individualized to the participants based on what subgroup they're classified into at baseline based on their initial clinical examination and self-reported dominant impairment. \*Physiological group - Participants will receive supervised sub-symptom aerobic exercise 20-minutes twice per week and mindfulness-based training 20-minutes twice per week. \*Cervical group - Participants will receive physical therapy to the cervical spine. Physical therapy will include soft tissue therapy directed to the cervical myofascial tissues, and graded cervical spine facet mobilizations. \*Vestibulo-Ocular group - Patients classified to vestibulo-ocular subgroup will receive bi-weekly 30-minute individualized oculomotor, vestibular and balance exercises including adaptation exercises, gaze stability exercises, visual-vestibular integration exercises, habituation exercises, static and dynamic balance exercises.
214883970|NCT06069700|OTHER|Non-pharmacological Usual care therapy|"All participants in the active control group will receive 'usual care', (twice a week for 6 weeks), which will consist of reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour. Additionally, participants will be afforded weekly 20-minute supervised progressive sub-symptom aerobic exercise sessions at the KITE clinic under the supervision of study coordinator NM. They will be instructed to also perform daily 20-minutes of subsymptom aerobic exercise outside the supervised exercise sessions."
214883971|NCT05929521|OTHER|C-PrEP+|Rather than a one-on-one PrEP care visit, a cohort of 8-12 patients meet with the same providers at each visit for individual health assessments, linkages to services, and 75-90 minutes of group interactive learning and skill-building that centers patients' experiences. This approach to healthcare has great potential meet sex workers' HIV prevention needs, including optimal use of PrEP
214883972|NCT06475781|DRUG|Mirivadelgat|Selective aldehyde dehydrogenase 2 (ALDH2) activator
214883973|NCT06475781|DRUG|placebo|placebo
214883974|NCT02186470|RADIATION|accelerated partial breast irradiation|Undergo image-guided intensity-modulated APBI
214883975|NCT02186470|RADIATION|intensity-modulated radiation therapy|Undergo image-guided intensity-modulated APBI
214883976|NCT02186470|RADIATION|image-guided radiation therapy|Undergo image-guided intensity-modulated APBI
214883977|NCT02186470|PROCEDURE|therapeutic conventional surgery|Lumpectomy
214883978|NCT06436313|OTHER|Educational Sessions|"Two online educational sessions will be organized before DBS surgery. These will be scheduled between consultation with the neurologist and the consultation with the neurosurgeon. Each virtual session will last about 1 hour. Patients can login from home, together with their caregivers. The virtual sessions will be held on MS Teams virtual platform.~One of the sessions will include a DBS patient where patients will have the opportunity to ask peer-to-peer questions. The session includes testimonials from patient before and after their surgery.~The second session (about two weeks later) is a summary presentation, a quiz and time for Q\&A. During one of the sessions (first or second), a DBS patient (who has been implanted) can be invited to participate togive the attendees the opportunity to ask peer-to-peer questions. The quiz contains questions to assess the patients' knowledge of DBS."
215046420|NCT06141551|PROCEDURE|total laminectomy decompression|Surgical decompression
215046421|NCT02679378|DEVICE|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
215046422|NCT06202469|DIETARY_SUPPLEMENT|Supplement 1|Creatine monohydrate (5 g/day)
215046423|NCT06202469|DIETARY_SUPPLEMENT|Supplement 2|Creatine monohydrate (5 g/day) plus ubiquinol (200 mg/day)
215046424|NCT06202469|DIETARY_SUPPLEMENT|Placebo|Placebo (inulin)
215046425|NCT00390897|DRUG|Glivec|
215046426|NCT00390897|DRUG|Interferon|
215046427|NCT05647499|BEHAVIORAL|The Back 2 School program for problematic school absenteeism|We will use the Danish version of the revised manual developed within the B2S study in Aarhus, Denmark. The B2S program consists of a 3 to 3,5 -hour initial clinical assessment, a clinical conference, 11 sessions where the youth and/or parent are attending, and a booster session after three months including youth and parent. The B2S manual comprise four school meetings with the child, parents, school staff and therapists present. In the Norwegian pilot study, we will add an extended school module to the B2S-program. The school module includes a pre-meeting interview with the schools in week 1 and session 1 with the school in week 2 or 3. The B2S counselor and the school will decide whether there is a need for an additional meeting between school meetings 1 and 2. There is also a booster session with the child, parents, the school and the B2S team 3 months after the program.
215046428|NCT02776046|DRUG|High FiO2|High FiO2 with a perioperative open lung strategy
215046429|NCT02776046|DRUG|Conventional FiO2|Conventional FiO2 with a perioperative open lung strategy
215046430|NCT04528238|OTHER|Relaxing Visual Immersion|During the intravenous treatment for cancer, a nature movie will be projected on the ceiling of the room, along with natural sounds or a relaxing music. The patient will choose the movie or movies he wants to watch and can decide to stop the Relaxing Visual Immersion (RVI) at any time. The RVI is a system that does not isolate the patient from his familiar or medical entourage and which integrates virtual scenarios in the environment of care.
215046431|NCT03683810|DIETARY_SUPPLEMENT|Lactoferrin|Lactoferrin in tablets 4g/daily
215046432|NCT03683810|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin (rHuEPO, epoetin alfa)
215046433|NCT04709510|DIAGNOSTIC_TEST|Duplex Ultrasound|Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
215046434|NCT01166217|DRUG|PF-04620110|"The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state."
215046435|NCT03367169|PROCEDURE|minimally invasive method|type of surgical technique
215046436|NCT03367169|PROCEDURE|open reduction method|type of surgical technique
214667571|NCT06964789|OTHER|Early Supported Discharge|ESD is a multidisciplinary service providing medically stable patients continued therapy and healthcare in the community.
214883979|NCT06565988|DEVICE|Decoria Voluma|"Decoria® Voluma medical device is a sterile, single use Hyaloronic acid based dermal filler intended for aesthetic use, provided in the form of a nonpyrogenic, viscoelastic gel. It is composed of highly purified sodium hyaluronate of high molecular weight, dissolved in a physiological buffer at pH 6.0-7.5. The sodium hyaluronate is derived from microbial fermentation and is stabilized by crosslinking with the chemical agent BDDE (1,4 Butanediol Diglycidyl Ether).~Decoria® Voluma dermal fillers are injected into dermal tissue for the correction of midface volume deficit by tissue augmentation in cheek region, supporting overlying tissue to shape facial contours to desired level of correction. This is possible due to the capacity of HA to attract and bind large amounts of water, forming a viscous gel.~Appropriate injection volume for the cheek region(s) will be determined by the Treating investigator according to IFU."
214883980|NCT05946941|DRUG|Deucravacitinib|Specified dose on specified days
214883981|NCT05946941|OTHER|Placebo|Specified dose on specified days
214883982|NCT04980027|DRUG|Insulin glargine (U300)|Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
214883983|NCT03757793|DEVICE|FORE-SIGHT ELITE monitor|At end of surgery, one sensor of the FORE-SIGHT Elite monitor is placed on the DIEP flap or two sensors in case of bilateral DIEP flaps for monitoring perfusion and oxygen consumption in the free flap. A control sensor of the FORE-SIGHT Elite monitor placed on the abdomen where tissue is taken to perform the DIEP flap. This sensor reflects normal tissue oxygenation. Data obtained from the FORE-SIGHT Elite monitor will be compared to data obtained from physical examination, which is standard of care for flap monitoring.
214883984|NCT04199624|DRUG|Omeprazole 20mg|Omeprazole twice daily x 5 days
214883985|NCT04199624|DIETARY_SUPPLEMENT|Vitamin C|Ascorbic acid x 1 on day 5
214883986|NCT02260570|DRUG|Tolcapone|COMT Inhibitor
214883987|NCT02260570|DRUG|Placebo|A pill that contains no active ingredient
214883988|NCT04795973|BEHAVIORAL|5:2 intermittent fasting|All subjects received 5:2 IF. They followed a normal diet for 5 days each week and practiced IF for 2 days discontinuously. On normal eating days, women consumed 1200 to 1500 kcal/day and men consumed 1500 to 1800 kcal/day, with macro-nutrient distribution of 45% to 50% carbohydrate, 20% protein, and 30% to 35% fat. They consumed 500 kcal and at least 50 g of protein on a light fasting day. Noncaloric beverages like water and unsweetened tea were allowed without restriction. A nutritionist provided diet guidance and documented any discomfort symptoms throughout the study.
214883989|NCT05026177|DRUG|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.
214883990|NCT05026177|DRUG|Placebo|Matching placebo given b.i.d. for 76 weeks
214883991|NCT04856917|DRUG|Imsidolimab|Humanized Monoclonal Antibody
214883992|NCT04856917|BIOLOGICAL|Placebo|Placebo
214883993|NCT06562075|DEVICE|Decoria Intense Strong|"Decoria® Intense Strong is a HA-based, BDDE-crosslinked dermal filler. Decoria® Intense Strong dermal fillers are injected into dermal tissue to improve and define contouring of jawline profile, supporting overlying tissue to shape facial contours to desired level of correction.~Appropriate injection volume for the jawline will be determined by the Treating investigator according to IFU"
214883994|NCT03793179|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214883995|NCT03793179|DRUG|Carboplatin|Given IV
214883996|NCT03793179|PROCEDURE|Computed Tomography|Undergo CT scan
214883997|NCT03793179|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214883998|NCT03793179|BIOLOGICAL|Pembrolizumab|Given IV
214883999|NCT03793179|DRUG|Pemetrexed|Given IV
214884000|NCT03793179|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214884001|NCT01169337|OTHER|Clinical Observation|Undergo observation
214884002|NCT01169337|DRUG|Lenalidomide|Given PO
214884003|NCT01169337|OTHER|Quality-of-Life Assessment|Ancillary studies
214884004|NCT03737981|DRUG|Ibrutinib|Given PO
214884005|NCT03737981|BIOLOGICAL|Obinutuzumab|Given IV
214884006|NCT03737981|OTHER|Observation Activity|Undergo observation
214884007|NCT03737981|DRUG|Venetoclax|Given PO
214884008|NCT06540222|PROCEDURE|Sustained cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
214884009|NCT06540222|PROCEDURE|Routine (< 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
214884010|NCT04008030|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214884011|NCT04008030|DRUG|Oxaliplatin|Specified dose on specified days
214884012|NCT04008030|DRUG|Leucovorin|Specified dose on specified days
214884013|NCT04008030|DRUG|Fluorouracil|Specified dose on specified days
214884014|NCT04008030|DRUG|Irinotecan|Specified dose on specified days
214884015|NCT04008030|DRUG|Bevacizumab|Specified dose on specified days
214884016|NCT04008030|DRUG|Cetuximab|Specified dose on specified days
214884017|NCT04008030|BIOLOGICAL|Nivolumab|Specified dose on specified days
214884018|NCT03560037|DEVICE|Endocuff Vision Assisted Colonoscopy|Detachable device that is fixed to the end of colonoscope. The device has single-row of soft, hair-like projections that flatten colonic folds during colonoscope withdrawal which can aid in detection of colon polyps.
214884019|NCT04034927|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884020|NCT04034927|PROCEDURE|Computed Tomography|Undergo CT
214884021|NCT04034927|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884022|NCT04034927|DRUG|Olaparib|Given PO
214884023|NCT04034927|BIOLOGICAL|Tremelimumab|Given IV
214884024|NCT06556563|DEVICE|Optune® device|Optune® device delivering TTFields therapy at 200 kHz.
214884025|NCT06556563|DRUG|Temozolomide|Temozolomide per approved labeling.
214884026|NCT06556563|DRUG|Pembrolizumab|Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
214884027|NCT06556563|DRUG|Placebo|Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
214884028|NCT05660408|BIOLOGICAL|pp65 RNA LP (DP1)|This is an off the shelf RNA-LP vaccine used to prime for the immune response while we produce the patient specific pp65/tumor mRNA RNA-LP (DP2)
214477068|NCT06826222|DIETARY_SUPPLEMENT|Sodium Bicarbonate (NaHCO3)|Participants will complete two interventions: sodium bicarbonate (SB) and placebo (PL). In the SB condition, participants will receive 0.3 g/kg SB, while in the PL condition, they will receive 0.03 g/kg table salt, administered double-blind.
214884029|NCT05660408|BIOLOGICAL|pp65/tumor mRNA RNA-LP (DP2)|This is a patient specific RNA-LP vaccine generated from the patient's tumor RNA.
214884030|NCT05660408|PROCEDURE|Surgical Biopsy/Resection|Eligible participants will be enrolled and undergo sterile collection of tumor material .
214884031|NCT06484088|OTHER|Frustration task|The experimental manipulation for this study is the frustration task. The frustration task is designed to elicit the emotional state of frustrative non-reward (FNR). During the task, participants are asked to use button press (left or right) to alternately press one of the two doors displayed on the monitor. The task has two non-frustration blocks (Block 1 and 2) and one frustration block (Block 3). During the non-frustration blocks, participants earn money for correct press on a fixed schedule. During the frustrative block, participants will not always receive reward for correct press.
214884032|NCT03463317|DEVICE|CE-mark approved LAA closure devices|LAA closure with post procedure treatment
214884033|NCT03463317|DRUG|Acetylsalicylic acid|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
214884034|NCT03463317|DRUG|Clopidogrel|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
214884035|NCT03463317|DRUG|Dabigatran|Patients allocated to the best medical care group receive either NOAC therapy or VKA
214884036|NCT03463317|DRUG|Rivaroxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
214884037|NCT03463317|DRUG|Apixaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
215046437|NCT01616212|OTHER|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
215046438|NCT01616212|OTHER|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
215046439|NCT01616212|OTHER|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
215046440|NCT01616212|OTHER|Drug Education for adolescents|Drug Education for adolescents
215046441|NCT02804490|DIETARY_SUPPLEMENT|Conventional white maize|Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
215046442|NCT02804490|DIETARY_SUPPLEMENT|Provitamin A carotenoid biofortified maize|Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
215046443|NCT02804490|DIETARY_SUPPLEMENT|Preformed vitamin A fortified maize|Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
215046444|NCT05911971|OTHER|Experimental|specific reeducation (not detailed to maintain blinding of participants)
214884038|NCT03463317|DRUG|Edoxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
215046445|NCT05911971|OTHER|Sham comparator|sham reeducation (not detailed to maintain blinding of participants)
215046446|NCT00255905|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|
214884039|NCT03463317|DRUG|Phenprocoumon|Patients allocated to the best medical care group receive either NOAC therapy or VKA
214884040|NCT03463317|DRUG|Warfarin|Patients allocated to the best medical care group receive either NOAC therapy or VKA
214884041|NCT06216301|DEVICE|NovoTTF-200T|The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death.
214884042|NCT06216301|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
214884043|NCT06216301|DRUG|Platinum based chemotherapy|Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer
214884044|NCT05184582|BEHAVIORAL|Physical training|Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
214884045|NCT05698563|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scan with contrast of the foot or feet
214884046|NCT05698563|DIAGNOSTIC_TEST|Ultrasound|Ultrasound scan of the feet
215046447|NCT00255905|BEHAVIORAL|Clinician monitoring|
215046448|NCT00413439|DRUG|Isavuconazole|Intravenous solution or oral capsules
215046449|NCT06419452|OTHER|Unilateral resistance training programme|A method of training that increases muscle strength and endurance by using external resistance to a unilateral limb or movement.
214477069|NCT06826222|DIETARY_SUPPLEMENT|Sodium Chloride|Participants will complete two interventions: sodium bicarbonate (SB) and placebo (PL). In the SB condition, participants will receive 0.3 g/kg SB, while in the PL condition, they will receive 0.03 g/kg table salt, administered double-blind.
214884047|NCT05698563|DRUG|Corticosteroid injection|Administered ultrasound guided to patients with intermetatarsal bursitis
214884048|NCT05698563|OTHER|Clinical foot evaluation|An examination of the feet
214884049|NCT05698563|OTHER|Picture of the feet|To evaluate the presence of V-sign/spreading toes
215046450|NCT06419452|OTHER|Bilateral resistance training programme|A training method that increases muscle strength and endurance by using external resistance on both limbs or movements,
215046451|NCT06419452|OTHER|Combined（UL+BL） resistance training programme|A method of training that uses limbs or movements to increase muscle strength and endurance by external resistance using unilateral and bilateral combined forms,
215046452|NCT02457338|DIETARY_SUPPLEMENT|Bifidobacterium|
215046453|NCT00730054|DRUG|Remifentanil+clonidine|iv Remifentanil+ iv clonidine
215046454|NCT01595087|DRUG|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
215046455|NCT02840279|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
215046456|NCT02840279|DRUG|Placebo|
215046457|NCT01459094|DRUG|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
214884050|NCT05118672|DRUG|Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)|Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine \[09\] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one \[01\] film-coated tablet every eight \[08\] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
214884051|NCT05118672|DRUG|Placebo|Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine \[09\] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one \[01\] film-coated tablet every eight \[08\] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
214884052|NCT06730217|DEVICE|Intervention : mechanical insufflator|Participants randomized to the intervention group will benefit from a mechanical insufflator during airway clearance sessions (EOVE-70®, Air Liquide Medical Systems France).
214884053|NCT06730217|OTHER|Control : standard care|Participants randomized to the control group will receive standard care
214884054|NCT06837987|OTHER|Modified transplantation system|Modified transplantation conditioning include: Fludarabine 30mg/m2\*6 day, Melphalan 100mg/m2\*1 day, cyclophosphamide 50mg/kg\*2 day.
214884055|NCT06831760|DEVICE|SOC and Type-I Collagen-based Skin Substitute|The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
215046458|NCT01459094|DRUG|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
215046459|NCT03326063|DRUG|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
215046460|NCT03326063|DRUG|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
215046461|NCT06141512|BEHAVIORAL|Reduced-exertion high-intensity interval training (REHIT)|Description same as Arm description.
215046462|NCT04277312|BEHAVIORAL|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
214477070|NCT06825156|DRUG|Empagliflozin 10 MG|Patients receive 10mg Empagliflozin(SLGT-2i) daily from 3 days prior to surgery untill 2 days post-surgery which includes day of surgery.
215046463|NCT04277312|BEHAVIORAL|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
214884056|NCT06831760|DEVICE|SOC and Human Amnion/Chorion Membrane|The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
215046464|NCT06565364|DIAGNOSTIC_TEST|"ZYMUTEST™ HIA immunoglobulin g ELISA (enzyme-linked immunosorbent assay )"|The enzyme-linked immunosorbent assay is an in vitro test done in the laboratory to detect specific antibodies against heparin/platelet factor-4 and protamine/heparin complexes.
215046465|NCT05111067|GENETIC|DNA and whole transcriptome mRNA sequencing|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).
214884057|NCT06188689|DIAGNOSTIC_TEST|Pacing|"1. Ventricular 10 beat burst at 500ms (120bpm)~2. Ventricular 10 beat burst at 400ms (150bpm)~3. Atrial 10 beat burst at 500ms (120bpm)~4. Atrial 10 beat burst at 400ms (150bpm)."
214884058|NCT06154122|DEVICE|Virtual Reality Upper Limb Rehabilitation Games|"A VR upper limb rehabilitation programme prescribed by the therapist with games chosen depending on the exercise task required and the level of difficulty adapted to the ability of the individual. The participant will use the VR system's user interface to navigate through menus to set their gameplay preferences and select which games to play.~The games of the intervention will involve facilitating and replicating upper limb movements including gross movements of the shoulder, such as rotation, abduction and addiction, movements of the upper and lower arms, such as flexion and extension of the elbow, and hand, wrist and finger movements, including wrist pronation supination, and finger flexion and extension, as well as tenodesis movements, grasping, and pinching."
214884059|NCT06154122|OTHER|Upper Limb Rehabilitation|Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
214884060|NCT03573648|DRUG|Avelumab|Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.
214667572|NCT06963684|DEVICE|Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT)|This is the first clinical study to evaluate repeat bilateral Direct Selective Laser Trabeculoplasty (DSLT) in treatment-naïve patients, using a paired-eye design. Unlike prior SLT studies, which focused on monocular treatment or repeat treatment following IOP rebound, this study randomizes one eye to receive a second DSLT treatment three months after the first, while the fellow eye receives only a single treatment. This allows for a direct intra-subject comparison of efficacy and durability. Existing studies, including GLAUrious and LiGHT, suggest the potential benefits of repeat laser, but no data currently exist for early, scheduled repeat treatment with DSLT. This trial uniquely investigates whether proactively repeating the procedure in a controlled eye extends IOP reduction and delays or reduces the need for topical medications.
214667573|NCT00717470|DRUG|Prograf®|oral
214667574|NCT00717470|DRUG|Advagraf®|oral
214667575|NCT00717470|DRUG|Mycophenolate Mofetil|oral
214667576|NCT00717470|DRUG|Simulect|oral
214667577|NCT00717470|DRUG|methylprednisolone / prednisone|oral
214884061|NCT03573648|DRUG|Endocrine therapy|"The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~* Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~* Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~* Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~\- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)"
214884062|NCT03573648|DRUG|Palbociclib|Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
214667578|NCT05443399|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
214667579|NCT05443399|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
214667580|NCT05443399|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 2D
214667581|NCT04493619|DRUG|PLX2853|PLX2853 tablets
214667582|NCT04493619|DRUG|Carboplatin|Carboplatin IV injection, 5 mg•min/mL
214667583|NCT04704076|OTHER|ESVS|Breastfeeding with up to 59-mL formula daily for the first 30 days, followed by exclusive breastfeeding through 6 months of age
214667584|NCT04704076|OTHER|Exclusive breastfeeding|Breastfeeding exclusively without any other food or fluid except vitamins, minerals and medications through 6 months of age
214667585|NCT03590457|DEVICE|Airvo 2; High-Flow nasal cannula system|Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
214667586|NCT03707717|DRUG|Bimekizumab|Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
214884063|NCT04554927|OTHER|WEB-Application|The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
214477071|NCT06604975|PROCEDURE|Measure of Basal Copeptin level|"Copeptin test is performed after solid fasting since midnight without water restriction. After blood collection on heparin tube used for biological inclusion criteria, heparinized plasma is transferred to Timone University hospital (transport temperature +4°C) for screening copeptin assay.~The basal copeptin level determines the next step:~1. copeptin ≥ 30 pmol/L defines the diagnosis of NDI and results in a specific care;~2. copeptin \&lt; 30 pmol/L defines the group of eligible patients for arginine stimulation"
214884064|NCT04554927|OTHER|Standard accompaniment|Personalized schedule of medical follow-up given to the patient
214884065|NCT05066061|OTHER|control arm|usual process
214884066|NCT05066061|OTHER|anxiolytic and analgesic gas|add relaxing gas
214884067|NCT05066061|DEVICE|Virtual reality mask|use Virtual reality mask Oculus Quest with age-appropriate software
214884068|NCT06531434|COMBINATION_PRODUCT|"Docetaxel, Cisplatin, fluorouracil, Radiation"|Induction chemotherapy with Docetaxel, Cisplatin, and fluorouracil for 4 to 8 cycles, followed by concurrent chemoradiotherapy with Cisplatin and Radiation 30.6-40 Gy.
215046466|NCT02094391|DRUG|Ipilimumab|Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
215046467|NCT06145594|OTHER|EMA Monitoring|Weekly prompts to participants' smart phones for collection of PHQ-9 data
215046468|NCT06145594|OTHER|Scheduling Maintenance TMS sessions|When threshold score is reached, the participants is offered TMS maintenance treatments
215046469|NCT00185094|DRUG|Olmesartan medoxomil|
215046470|NCT00185094|DRUG|Losartan potassium|
215046471|NCT00185094|DRUG|Atenolol|
215046472|NCT02657148|DRUG|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
215046473|NCT02657148|DRUG|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at \> 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time \> 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time \> 6 weeks after delivery.
215046474|NCT00114491|DRUG|Rosuvastatin|
214884069|NCT03374267|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
214884070|NCT06432036|PROCEDURE|Angiogram|Undergo angiogram
214884071|NCT06432036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884072|NCT06432036|PROCEDURE|Computed Tomography|Undergo CT scan
214884073|NCT06432036|RADIATION|Radioembolization|Undergo radioembolization
214884074|NCT06432036|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
214884075|NCT06432036|OTHER|Survey Administration|Ancillary study
214884076|NCT06432036|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
214884077|NCT04108156|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
214884078|NCT04108156|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
214884079|NCT04108156|DRUG|Ranibizumab refill exchange|Will be administered as per the schedule described in individual arm.
214884080|NCT06210776|DRUG|Trastuzumab deruxtecan|Intravenous infusion
214884081|NCT05522660|RADIATION|Stereotactic radiosurgery|"Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of \>20 mm or for \>4 brain metastases.~For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation."
214884082|NCT05522660|DRUG|Immune checkpoint inhibitor|"Systemic therapy follows the current standard of care, according to the type of the primary tumour.~* For patients with melanoma, with or without BRAF-mutation, systemic therapy consists of~  * an approved immune-checkpoint inhibition combination therapy (cohort 1a) or~ * an approved immune-checkpoint inhibition monotherapy (cohort 1b).~* For patients with NSCLC and a targetable oncogenic driver alteration (cohort 2a), systemic therapy consists of an approved targeted therapy (for example: EGFR-, ALK- or ROS1-targeted treatment).~* For patients with NSCLC without a targetable oncogenic driver alteration (cohort 2b), systemic therapy consists of an approved immune-checkpoint inhibition therapy (with or without chemotherapy)."
214884083|NCT05738239|DEVICE|Laser therapy|Biological effects of low-level LASER therapy have been studied for various clinical indications, including musculoskeletal conditions and some acute pain conditions. PBMT includes low level LASER (works on pain) and light-emitting diodes (LED) (works on wound healing).
214884084|NCT05732103|DRUG|CTX-712|CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 once or twice weekly, depending on their dose level assignment, during each 28-day cycle.
214884085|NCT06075745|DRUG|CMV-MVA Triplex|The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
214884086|NCT06075745|DRUG|Placebo for CMV-MVA Triplex|Arm 2 participants receive two doses of matching placebo CMV-MVA Triplex
214884087|NCT03823742|OTHER|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT): Study treatments for the child will be conducted by a psychologist or master's level therapist. Therapists will be provided with a standardized protocol for each session . CBT treatment will be given over 1 hour, once a week, for three weeks .
214884088|NCT03823742|OTHER|Low FODMAP Diet|Low FODMAP Diet Condition: Subjects will receive detailed education by a dietitian about following a low FODMAP diet including a definition of FODMAPs, how to select low FODMAP foods, and how to read food labels to identify FODMAPS. The dietitian will contact the family for 1 hour, once a week, for three weeks.
214884089|NCT03996447|DRUG|gadopiclenol|single intravenous (IV) bolus injection at a rate of 2ml/second
214884090|NCT03996447|DRUG|Gadobutrol 1Mmol/mL Solution for Injection Vial|single intravenous (IV) bolus injection at a rate of 2ml/second
214884091|NCT06148623|DEVICE|Philips FAST SpO2 with Masimo Pulse Oximetry Sensors|Noninvasive pulse oximeter
214884092|NCT04770766|OTHER|Non-medical practitioners|All observational research activity in each cohort is related to the exposure of non-medical practitioners in the Emergency Department or Urgent Treatment Centre
214884093|NCT04269551|DRUG|BIVV020|Pharmaceutical form:solution for injection Route of administration: intravenous
214884094|NCT04613596|DRUG|Adagrasib|Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)
214884095|NCT04613596|DRUG|Adagrasib|Adagrasib 600 mg BID monotherapy (Cohort 1b)
214884096|NCT04613596|DRUG|Adagrasib|adagrasib 400 mg BID in combination with pembrolizumab
214884097|NCT04613596|DRUG|Adagrasib|Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W
215046475|NCT03507582|OTHER|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
215046476|NCT03507582|OTHER|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
215046477|NCT04951531|PROCEDURE|BPTB double-bundle allograft|The patient underwent surgery of arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
215046478|NCT04951531|PROCEDURE|BPTB single-bundle allograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
215046479|NCT04951531|PROCEDURE|BPTB single-bundle autograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
215046480|NCT02750514|BIOLOGICAL|Nivolumab|Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
215046481|NCT02750514|DRUG|Dasatinib|
215046482|NCT02750514|BIOLOGICAL|Relatlimab|
215046483|NCT02750514|BIOLOGICAL|Ipilimumab|
215046484|NCT02750514|DRUG|BMS-986205|Specified dose on specified days
215046485|NCT06350448|DRUG|Washed Microbiota Transplantation|Washed microbiota suspension (5U) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5U, three times.
215046486|NCT02553629|DRUG|Rocuronium|
215046487|NCT06086964|OTHER|therapeutic diet.|gluten and casein free diet.
214884098|NCT04613596|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Q3W
214884099|NCT03816878|BIOLOGICAL|H5N1 pISV|Administered as an intramuscular (IM) injection
214884100|NCT00397111|DEVICE|7T Magnetic Resonance Imaging scanner|Non-significant risk device used for brain imaging
215046488|NCT06086964|OTHER|physiotherapy|specific physiotherapy developmental program according to the pre evaluation of gross motor status.
214884101|NCT03814252|DEVICE|MRI-TULSA|"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"
214477072|NCT06604975|PROCEDURE|Measure of arginine-stimulated copeptin|The arginine-stimulated copeptin test start at 8 am, after solid fasting since midnight without water restriction, and 30 min of rest in decubitus position. A dose of 0.5 g/kg of arginine (maximum 40g) diluted in 0.9% NaCl is infused over 30 min through a peripheral venous line. Copeptin is measured at T0 (before infusion), T45, T60, T90, and T120 min after infusion.
214884102|NCT04846517|DEVICE|Transcranial Magnetic Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC~LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
214884103|NCT03038802|BIOLOGICAL|Therapeutic hepatitis B vaccine|HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
214884104|NCT03038802|BIOLOGICAL|Commercial Hepatitis B vaccine|Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
214884105|NCT05929820|BEHAVIORAL|Protect Your Colon™|Protect Your Colon™ is an online decision aid focused on CRC screening. The site will first educate patients on the importance of CRC screening and offer information on the advantages and disadvantages of the available test options. Protect Your Colon™ will then present an interactive conjoint analysis-a quantitative survey technique that elucidates how individuals make complex decisions-to precisely determine individuals' latent preferences regarding CRC screening options. Afterwards, the app will generate a personalized report that rank orders the importance of each test attribute (e.g., accuracy, invasiveness, test frequency) in patients' decision making and identifies the screening modality that best matches their preferences. The report will also be shareable with physicians, enabling patients and providers to engage in shared decision making surrounding CRC screening in the clinic.
214884106|NCT06264180|BIOLOGICAL|Vusolimogene Oderparepvec|Genetically modified Herpes Simplex Type 1 Virus.
214884107|NCT06264180|BIOLOGICAL|Nivolumab|Anti-PD-1 Monoclonal Antibody
214884108|NCT06264180|BIOLOGICAL|Nivolumab + Relatlimab|Nivolumab: Anti-PD-1 Monoclonal antibody. Relatlimab: A lymphocyte activation gene-3 (LAG-3) blocking antibody.
214884109|NCT06264180|BIOLOGICAL|Pembrolizumab|A programmed death receptor-1 (PD-1)-blocking antibody indicated.
214884110|NCT06264180|DRUG|Single-agent chemotherapy|Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.
214884111|NCT03355469|DRUG|Metformin|Oral metformin 2000 mg/d for 16 weeks. Metformin dosage will follow 500 mg/d ramp up progression: Week 1 = 500 mg/d; Week 2 = 1,000 mg/d; Week 3 = 1500 mg/d; Week 4-16 = 2000 mg/d.
214884112|NCT03355469|DRUG|Placebo|Oral placebo for 16 weeks. Placebo tablets will follow a four-stage progression: Week 1 = 1 tablet; Week 2 = 2 tablets; Week 3 = 3 tablets; Week 4-16 = 4 tablets.
214884113|NCT03355469|BEHAVIORAL|Low Intensity Exercise|Low intensity exercise will consist of 16 weeks of walking at \~55% of each participant's predetermined VO2max and monitored via heart rate. Supervised exercised will occur on a treadmill 3d/wk and the duration will be determined based on individual fitness levels to expand 400 kcals. Supervised exercise training will follow a three-phase progression: Weeks 1-2 = 3 supervised sessions at 75% duration; Week 3-4 = 3 supervised sessions at 87% duration; Weeks 5-16 = 3 supervised sessions at 100% duration. Unsupervised exercised will be 2d/wk and the duration will half the time of the supervised training sessions.
214884114|NCT03355469|BEHAVIORAL|High Intensity Exercise|High intensity exercise will consist of 16 weeks of walking at \~85% of each participant's predetermined VO2max and monitored via heart rate. Supervised exercised will occur on a treadmill 3d/wk and the duration will be determined based on individual fitness levels to expand 400 kcals. Supervised exercise training will follow a three-phase progression: Weeks 1-2 = 3 supervised sessions at 75% duration; Week 3-4 = 3 supervised sessions at 87% duration; Weeks 5-16 = 3 supervised sessions at 100% duration. Unsupervised exercised will be 2d/wk and the duration will half the time of the supervised training sessions.
214884115|NCT05780684|OTHER|FOX dose-escalation algorithm|Chemotherapy dose-escalation algorithm based on the FOLFOX and FOLFOXIRI regimens
214884116|NCT06476808|DRUG|BMS-986463|Specified dose on specified days
214884117|NCT06365723|BEHAVIORAL|Nature-based Walking|All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated nature-based, or 'green', urban environment.
215046489|NCT02801786|DRUG|Placebo|The arm will be composed of 03 women who used placebo capsules and gel.
215046490|NCT02801786|DRUG|Lidocaine|The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.
215046491|NCT02801786|DRUG|Tamoxifen|The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
215046492|NCT05222685|BEHAVIORAL|Better Together Physician Coaching|Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
215046493|NCT03140111|DEVICE|LAMELLEYE|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
214667587|NCT06956833|OTHER|Ìmmersive virtual reality simulation with self-guided debriefing|"* Familiarization with immersive virtual reality simulation (1 hour)~* Video tutorial introducing paediatric Airway, Breathing, Circulation, Disability, Exposure (ABCDE) assessment, emergency teamwork and communication, and core elements in debriefing (1 hour)~* Three immersive virtual reality simulation-based pediatric emergency team training scenarios with self-guided debriefing (2 hours)"
214667588|NCT06956833|OTHER|Ìmmersive virtual reality simulation with facilitator-guided debriefing|"* Familiarization with immersive virtual reality simulation (1 hour)~* Video tutorial introducing paediatric ABCDE assessment, emergency teamwork and communication, and core elements in debriefing (1 hour)~* Three immersive virtual reality simulation-based pediatric emergency team training scenarios with facilitator-guided debriefing (2 hours)"
214884118|NCT06365723|BEHAVIORAL|Built-environment/Commercial Walking|All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated built-environment/commercial, or 'Gray', urban environment.
214884119|NCT04754906|OTHER|Sequence 1|perform arm movements towards a target
214884120|NCT04754906|OTHER|Sequence 2|judge the verticality of an object
214884121|NCT04754906|OTHER|Sequence 3|In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
214884122|NCT05976984|OTHER|Aim 1 (case-cohort study)|"* Cases: All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020~* Subcohort: A random sample of all Medicaid enrollees age 15 years or older irrespective of their stimulant overdose history during 2016-2020"
214884123|NCT05976984|OTHER|Aim 2 (case-crossover study)|"* Case period: 60 days before the date of stimulant overdose through the day before the date of stimulant overdose~* Control period: 179 days before the date of stimulant overdose through 120 days before the date of stimulant overdose~* Washout period: 119 days before the date of stimulant overdose through 61 days before the date of stimulant overdose"
214884124|NCT05976984|OTHER|Aim 3 (cohort study)|All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020
214884125|NCT05137054|DRUG|Linvoseltamab|Linvoseltamab is administered by intravenous (IV) infusion
214884126|NCT05137054|DRUG|Daratumumab|Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection may be used after a minimum of 2 cycles of IV administration at the investigator's discretion.
214884127|NCT05137054|DRUG|Carfilzomib|Carfilzomib is administered by IV infusion
214884128|NCT05137054|DRUG|Lenalidomide|Lenalidomide is administered by mouth (PO) as a capsule
214884129|NCT05137054|DRUG|Bortezomib|Bortezomib is administered by IV infusion or SC injection
214884130|NCT05137054|DRUG|Pomalidomide|Pomalidomide is administered by mouth (PO) as a capsule
214884131|NCT05137054|DRUG|Isatuximab|Isatuximab is administered by IV infusion
214884132|NCT05137054|DRUG|Fianlimab|Fianlimab is administered by IV infusion
214884133|NCT05137054|DRUG|Cemiplimab|Cemiplimab is administered by IV infusion
214884134|NCT05137054|DRUG|Nirogacestat|Nirogacestat is administered by mouth (PO) as a tablet
214884135|NCT05137054|DRUG|Cevostamab|Cevostamab is administered by IV infusion
214884136|NCT05780073|DRUG|Dasatinib 70 mg|Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind
214884137|NCT05780073|OTHER|Placebo|Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.
214884138|NCT01708941|BIOLOGICAL|Ipilimumab|Given IV
214884139|NCT01708941|OTHER|Laboratory Biomarker Analysis|Correlative studies
214884140|NCT01708941|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV or SC
214884141|NCT00018044|DRUG|Clofazimine|
214884142|NCT01575548|PROCEDURE|Computed Tomography|Undergo CT
214884143|NCT01575548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884144|NCT01575548|DRUG|Pazopanib Hydrochloride|Given PO
214884145|NCT01575548|OTHER|Placebo Administration|Given PO
214884146|NCT01575548|OTHER|Questionnaire Administration|Ancillary studies
214884147|NCT05309421|DRUG|EVX-01|Investigational drug given in combination with standard of care
214884148|NCT05309421|DRUG|Pembrolizumab 25 MG/ML|Standard of care
215046494|NCT03140111|DEVICE|OPTIVE FUSION|Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
214884149|NCT04772456|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
215046495|NCT01932684|OTHER|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
215046496|NCT01932684|OTHER|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
215046497|NCT01932684|DEVICE|5000 Voldyne ® Sherwood Medical, USA|
215046498|NCT01932684|DEVICE|Silicone face mask|
215046499|NCT01812057|DRUG|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
215046500|NCT01812057|DRUG|Placebo|Sodium Chloride 0.9% -5 ml
215046501|NCT02348203|DRUG|Aspirin|Given PO
215046502|NCT02348203|OTHER|Laboratory Biomarker Analysis|Correlative studies
215046503|NCT02348203|OTHER|Placebo Administration|Given aspirin placebo PO
215046504|NCT02348203|OTHER|Placebo Administration|Given zileuton placebo PO
215046505|NCT02348203|DRUG|Zileuton|Given PO
215046506|NCT03025126|OTHER|Multimedial Rehabilitation|
215046507|NCT03025126|OTHER|Usual care program|Usual care at home program according to healthcare professional's advice
215046508|NCT03819309|PROCEDURE|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
215046509|NCT03819309|PROCEDURE|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
215046510|NCT05759780|DEVICE|Optical imaging of the tissues|OCT vibrography
215046511|NCT01882465|DEVICE|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
215046512|NCT01882465|DEVICE|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
215046513|NCT01882465|DEVICE|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
215046514|NCT03166930|BEHAVIORAL|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
215046515|NCT03166930|BEHAVIORAL|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management from the manual.
215046516|NCT01814956|DRUG|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
215046517|NCT01814956|DRUG|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
215046518|NCT00000276|DRUG|Bupropion|
215046519|NCT02148588|DRUG|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)~Assessment of spontaneous and evoked pain responses~Completion of NPSI questionnaire~Mapping of the affected limb"
215046520|NCT05915611|OTHER|Combined physical and psychological intervention|"Physical therapy components will include splinting, tendon and nerve gliding exercises.~Psychological components will include cognitive-behavioral therapy (CBT), delivered in individual sessions, targeting pain catastrophizing and fear of movement.~Participants will attend 2 physical therapy sessions and one CBT session per week. for a period of 12 weeks"
215046521|NCT05915611|OTHER|Standard care|Participants will be asked to wear a prefabricated wrist splint during the night and during strenuous activity. Also, they will receive tendon and nerve gliding exercises
215046522|NCT05021952|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
215046523|NCT01138410|BIOLOGICAL|SCIB1|Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
215046524|NCT02987582|BEHAVIORAL|Emotion-focused mindfulness group|Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
215046525|NCT02563782|BIOLOGICAL|Sub-retinal transplantation of MA09-hRPE cells|transplantation
215046526|NCT02563782|DRUG|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
215046527|NCT02563782|DRUG|Placebo tacrolimus and mycophenolate mofetil|placebo
215046528|NCT02563782|PROCEDURE|Sham Surgery|Sham surgery
215046529|NCT00002219|DRUG|Nelfinavir mesylate|
215046530|NCT00002219|DRUG|Levocarnitine|
215046531|NCT00002219|DRUG|Adefovir dipivoxil|
215046532|NCT00617864|DRUG|Human Albumin Infusion|Group will receive single infusion of albumin at the time of oocyte retrieval.
214884150|NCT05697406|DRUG|Hyperpolarized 13C-Pyruvate|Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
214884151|NCT05321342|BEHAVIORAL|Bullying Classroom Check-Up (BCCU)|BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, \& Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator \[developed at the University of Central Florida (UCF); Dieker, Hynes, Hughes, \& Smith, 2008\], and self-monitoring) and utilizing motivational interviewing (Miller \& Rollnick, 2012) to empower teacher practice change.
214884152|NCT04684368|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood samples
214884153|NCT04684368|DRUG|Carboplatin|Given IV
215046533|NCT00617864|DRUG|Saline Infusion|Group will receive single infusion of saline at the time of oocyte retrieval.
215046534|NCT03763747|DEVICE|Scoreflex NC Scoring PTCA catheter|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
215046535|NCT02633735|OTHER|Appy CDS|See description under arm/group section
215046536|NCT05500651|OTHER|Dance and Movement Therapy (DMT)|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
215046537|NCT00029250|DRUG|Garlic powder standardized to allicin|
215046538|NCT00839969|PROCEDURE|Cystoscopy|Saline cystoscopy under general anaesthesia
215046539|NCT00839969|PROCEDURE|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
215046540|NCT02812914|OTHER|Low-cost gas stove|Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas
215046541|NCT02812914|BEHAVIORAL|Peer education classes|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution
215046542|NCT02812914|BEHAVIORAL|Resource-intensive behavioral intervention approach|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
215046543|NCT05104827|OTHER|Complementary Integrative Medicine|30-minute individually tailored integrative medicine care, including acupuncture, acupressure, reflexology, movement therapies like QiGong or Feldenkrais as well as Anthroposophic Medicine and mind-body treatments.
215046544|NCT00834821|BEHAVIORAL|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
215046545|NCT00834821|BEHAVIORAL|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
215046546|NCT04270422|OTHER|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial approach
215046547|NCT04270422|OTHER|Usual physiotherapy|Usual evidence based physiotherapy
215046548|NCT02259114|DRUG|Birabresib|Birabresib 10, 20 and/or 40 mg oral capsules
215046549|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
215046550|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
214667589|NCT00227461|DRUG|Wait first, then levetiracetam|Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
214884154|NCT04684368|DRUG|Etoposide|Given IV
214884155|NCT04684368|BIOLOGICAL|Filgrastim|Given subcutaneously (SC) or IV
214884156|NCT04684368|DRUG|Ifosfamide|Given IV
214884157|NCT04684368|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884158|NCT04684368|DRUG|Mesna|Given IV or orally
214884159|NCT04684368|BIOLOGICAL|Pegfilgrastim|Given SC
214884160|NCT04684368|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
214884161|NCT04684368|OTHER|Questionnaire Administration|Ancillary studies
215046551|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
215046552|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
215046553|NCT03937479|DRUG|Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
215046554|NCT02578901|DRUG|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
215046555|NCT02578901|DRUG|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
215046556|NCT05691387|BEHAVIORAL|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
215046557|NCT05691387|BEHAVIORAL|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
215046558|NCT03048773|DEVICE|shockwave therapy|Intervention with shockwave therapy
215046559|NCT03048773|OTHER|PT|Physical therapy 3 times per week for 3 weeks
215046560|NCT03048773|OTHER|placebo|sham shockwave therapy
215046561|NCT00147329|DRUG|MM-093|
214477073|NCT06604975|PROCEDURE|IRM|"Based on our previous study, patients with basal copeptin value over 3.53 pmol/L are considered as positive diagnosis of PP (Se 100%, Sp 87.4%) and cerebral MRI is not performed for this group of patients (PP group).~A cerebral and pituitary MRI performed according to reference procedures (without and with contrast medium used in routine care) for patients considered as an uncertain diagnosis (UD) based on basal copeptin value (\&amp;lt; 3.53 pmol/L). MRI interpretation is performed by two independent neuroradiologists (one from the recruiting center and one from the pilot center). In case of discrepancies, a third independent interpretation will be performed by a neuroradiologist from the coordinating center. Abnormal pituitary MRI (thickened pituitary stalk pituitary tumor, ectopic neurohypophysis, septo-optic dysplasia, empty sellar, Rathke pouch) allows a diagnosis of CDI leading to etiological investigations and AVP treatment."
214884162|NCT04684368|RADIATION|Radiation Therapy|Undergo WVSCI radiation therapy
214884163|NCT04684368|RADIATION|Radiation Therapy|Undergo radiation therapy
214884164|NCT04684368|PROCEDURE|Second-Look Surgery|Undergo second-look surgery if needed
214884165|NCT04684368|DRUG|Thiotepa|Given IV
214884166|NCT04175912|DRUG|Carboplatin|Given IV
214884167|NCT04175912|DRUG|Paclitaxel|Given IV
214884168|NCT04175912|DRUG|Pevonedistat|Given IV
214884169|NCT05004311|DRUG|Cenerimod|A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions
214884170|NCT03952585|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214884171|NCT03952585|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884172|NCT03952585|DRUG|Cisplatin|Given IV
214884173|NCT03952585|PROCEDURE|Computed Tomography|Undergo CT
214884174|NCT03952585|OTHER|Fludeoxyglucose F-18|Receive FDG
214884175|NCT03952585|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
214884176|NCT03952585|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214884177|NCT03952585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884178|NCT03952585|BIOLOGICAL|Nivolumab|Given IV
214884179|NCT03952585|PROCEDURE|Positron Emission Tomography|Undergo PET
214884180|NCT03952585|OTHER|Quality-of-Life Assessment|Ancillary studies
214884181|NCT03952585|OTHER|Questionnaire Administration|Ancillary studies
214884182|NCT05273307|DIETARY_SUPPLEMENT|Miraculin|Given orally
214884183|NCT05273307|DIETARY_SUPPLEMENT|Miracle Fruit Placebo Cube|Given orally
214884184|NCT02048813|DRUG|Cyclophosphamide|Given IV
214884185|NCT02048813|DRUG|Fludarabine Phosphate|Given IV
214884186|NCT02048813|DRUG|Ibrutinib|Given PO
214884187|NCT02048813|OTHER|Laboratory Biomarker Analysis|Correlative studies
215046562|NCT04546100|OTHER|Maternal-Infant Exercise Program|"Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
214884188|NCT02048813|OTHER|Pharmacogenomic Study|Correlative studies
214884189|NCT02048813|OTHER|Quality-of-Life Assessment|Ancillary studies
214884190|NCT02048813|BIOLOGICAL|Rituximab|Given IV
214884191|NCT05425550|DEVICE|medidux™ app|Use of the regular medidux™ application for 12 (maximum 16) weeks
214884192|NCT04310007|PROCEDURE|Biospecimen Collection|Undergo blood collection
214884193|NCT04310007|DRUG|Cabozantinib S-malate|Given PO
214884194|NCT04310007|PROCEDURE|Computed Tomography|Undergo CT
214884195|NCT04310007|DRUG|Docetaxel|Given IV
214884196|NCT04310007|PROCEDURE|Echocardiography Test|Undergo ECHO
214884197|NCT04310007|DRUG|Gemcitabine Hydrochloride|Given PO
214884198|NCT04310007|DRUG|Nab-paclitaxel|Given IV
214884199|NCT04310007|BIOLOGICAL|Nivolumab|Given IV
214884200|NCT04310007|DRUG|Paclitaxel|Given IV
214884201|NCT04310007|BIOLOGICAL|Ramucirumab|Given IV
215046563|NCT00922961|BIOLOGICAL|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
215046564|NCT00922961|PROCEDURE|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
214884202|NCT06557057|OTHER|Non-Interventional Study|Non-Interventional Study
214884203|NCT01708954|DRUG|Cabozantinib S-malate|Given PO
214884204|NCT01708954|DRUG|Erlotinib Hydrochloride|Given PO
214667590|NCT00227461|DRUG|Levetiracetam first, then wait|subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
214884205|NCT01708954|OTHER|Laboratory Biomarker Analysis|Correlative studies
214884206|NCT05909748|DEVICE|GEMINUS Transcatheter Aortic Valve Implantation system|Implantation of the GEMINUS Transcatheter Aortic Valve Implantation system
215046565|NCT00740181|DRUG|chemotherapy|
214884207|NCT05488366|DRUG|Pembrolizumab|Given IV
214884208|NCT05488366|RADIATION|Radiation therapy|Single target will be selected by the treating radiation oncologist. A lesion causing symptoms or expected to become symptomatic will be favored for target selection.
214884209|NCT01896999|PROCEDURE|Biopsy Procedure|Undergo biopsy
214884210|NCT01896999|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214884211|NCT01896999|DRUG|Brentuximab Vedotin|Given IV
214884212|NCT01896999|PROCEDURE|Computed Tomography|Undergo CT
214884213|NCT01896999|BIOLOGICAL|Ipilimumab|Given IV
214884214|NCT01896999|BIOLOGICAL|Nivolumab|Given IV
214884215|NCT01896999|PROCEDURE|Positron Emission Tomography|Undergo PET
214884216|NCT04710758|PROCEDURE|Laparoscopic total gastrectomy|LTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
214884217|NCT04710758|PROCEDURE|Open total gastrectomy|OTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
214884218|NCT03326492|DRUG|Antivenom serum Inoserp Pan-Africa® injection|Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
214884219|NCT06400251|PROCEDURE|Biopsy Procedure|Undergo biopsy
214884220|NCT06400251|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884221|NCT06400251|PROCEDURE|Computed Tomography|Undergo CT scan
214884222|NCT06400251|DRUG|Ipatasertib|Given PO
214884223|NCT06400251|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884224|NCT01794403|RADIATION|Extended Hypofractionation Radiotherapy|A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
214884225|NCT01794403|RADIATION|Accelerated Hypofractionation Radiotherapy|A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
214884226|NCT06517875|DRUG|Momelotinib|Momelotinib will be administered orally.
214884227|NCT06517875|DRUG|Luspatercept|Luspatercept will be administered subcutaneously.
214884228|NCT05558124|DRUG|Vyxeos|Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
215046566|NCT04062058|RADIATION|SIB-IMRT|45Gy in 25 fractions using intensity-modulated radiotherapy to the radiation target
215046567|NCT04062058|DRUG|S-1|40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment
215046568|NCT04062058|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
215046569|NCT04062058|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
215046570|NCT01378117|DRUG|Sitagliptin|Sitagliptin 50-100mg po once daily
215046571|NCT01378117|DRUG|glargine|glargine once daily
215046572|NCT01378117|DRUG|lispro|lispro before meals
214292207|NCT03485768|PROCEDURE|percutaneous disc decompression with coblation nucleoplasty|PDCN was performed using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA) under local anesthesia. The introducer cannula was then pierced into the target intervertebral disc through an anterior lateral approach. The tip of the cannula stylet was aimed for the center of the nucleus in both the coronal and sagittal planes. The stylet was withdrawn from the introducer cannula and replaced with the Perc-DC SpineWand. The wand was advanced until its tip extended approximately 5 mm beyond the tip of the cannula. A short initial coagulation was performed upon wand insertion to ensure correct placement, if stimulation or movement was detected, the wand was repositioned. As the wand was drawn back out through the disc, ablation energy was set to level three and three ablation cycles of 5-12soconds each were performed, rotating the wand tip 180 degree each time to form three consecutive pockets within the disc.
214292208|NCT03485768|PROCEDURE|Manual Therapy (SNAGs plus PJMs)|"(1) sustained natural apophyseal glides (SNAGs): Use the methods described in Mulligan BR. Manual therapy NAGS, SNAGS, MWMS etc. 5th ed. Wellington, New Zealand: Plane View Services; 2004. Three sessions per week and for a total of four to six weeks according to the patients' condition, they were asked to continue the self-SNAG once daily until the last follow-up, and recorded in a diary. (2) passive joint mobilisations (PJMs): Use the methods described in Maitland G. Vertebral manipulation. 6th ed. Oxford: Butterworth Heinemann; 2001. For three repetitions weekly and for a total of four to six weeks according to the patients' condition, then once a day were commenced as a home exercise to be continued until the last follow-up, and recorded in a diary."
214292209|NCT00826215|DEVICE|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
214292210|NCT00826215|DEVICE|Sham laser acupuncture|Sham laser acupuncture
214292211|NCT04675840|PROCEDURE|Robotic-assisted hysterectomy|Robotic-assisted surgery
214292212|NCT03905603|DRUG|ACTH|ACTH (Cosyntropin) 250 mcg will be given once during the study.
214292213|NCT03905603|DRUG|rhCG|rhCG (Ovidrel) 250 mcg will be given once during the study.
214292214|NCT02468323|DRUG|Placebo|Patients will receive regular spinal anesthesia
214292215|NCT02468323|DRUG|Ondansetron|Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
214292216|NCT02468323|DRUG|Palonosetron|Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
214884229|NCT05558124|DRUG|Gemtuzumab Ozogamicin|"Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7"
214292217|NCT00246727|DRUG|Selected Vegetable and Herb Mix|The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
214292218|NCT00207207|PROCEDURE|Alternate site blood glucose testing|
214292219|NCT05533281|DRUG|tropisetron|One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
214292220|NCT05533281|DRUG|metoclopramide|One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
214292221|NCT05533281|DRUG|dexamethasone|One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
214292222|NCT05533281|OTHER|normal saline|Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
214292223|NCT00805103|RADIATION|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
214292224|NCT05833191|DEVICE|Auricular vagus stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
214477074|NCT06604975|BEHAVIORAL|Water reduction at home|Patients with basal copeptin ≥ 3.53 pmol/l (PP group), and UD patients with normal MRI have gradual reduction of water intake at home without AVP treatment : gradual reduction with 20% in the first week, 30% in the second, 40% in the third, reaching 50% of daily fluid in the last week including restriction overnight, deletion drink before sleep. Some recommendations will be provided to help physicians. For all these latest patients, a clinical reassessment (weight, height, heart rate, blood pressure, input/output 24 hours balance) is performed one month later.
214477075|NCT03761017|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
214667591|NCT01187368|DEVICE|EVAHEART Left Ventricular Assist System (LVAS)|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
214884230|NCT06629103|DIETARY_SUPPLEMENT|life's Omega 1035DS|A natural triglyceride derived from microalgae with minimum 365 mg DHA, minimum 100 mg EPA, and minimum 520 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
214884231|NCT06629103|DIETARY_SUPPLEMENT|Fish Oil|Commercially available fish oil product MEG-3 1812 TG with a minimum 100 mg DHA/capsule, minimum 160 mg EPA/capsule, and minimum 300 mg/g DHA+EPA. Participants receive 600mg/d of omega-3 fatty acids from the fish oil.
214884232|NCT06629103|OTHER|Placebo|The placebo capsules will be a mixture of corn and soybean oils. Participants receive 600mg/d of omega-3 fatty acids from the corn/soy placebo.
215046573|NCT03305484|OTHER|No intervention|No intervention, observation only
214884233|NCT06629103|DIETARY_SUPPLEMENT|life's Omega O3020DS|A natural triglyceride derived from microalgae with minimum 210 mg DHA, minimum 300 mg EPA, and minimum 510 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
214884234|NCT04808245|DRUG|Tecentriq 1200 MG in 20 ML Injection|One vial of Tecentriq® (1200 mg) will be administered as an intravenous (i.v.) infusion over 60 minutes every 3 weeks starting 4 weeks after radiotherapy. If the first infusion is tolerated, all subsequent infusions will be delivered over 30 minutes.
214884235|NCT04808245|BIOLOGICAL|H3K27M peptide vaccine|The H3K27M peptide vaccine is injected subcutaneously (s.c.). For a single vaccination 300 μg of the peptide will be emulsified in a total volume of 1 ml.
214884236|NCT04808245|OTHER|Imiquimod (5%)|One sachet of Aldara® cream (250 mg) will be applied to an area of 5 x 5 cm around the injection site of the H3K27M peptide vaccine 15 min after vaccination and left on the skin for approximately 8 hours according to the instructions in the SmPC. 24 hours after the vaccination a second sachet of Aldara® will be applied by the patient as instructed above and left on the skin for approximately 8 hours.
214884237|NCT03631199|DRUG|canakinumab|canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)
214884238|NCT03631199|DRUG|canakinumab-matching placebo|canakinumab placebo every 3 weeks (squamous and non-squamous)
214884239|NCT03631199|DRUG|pembrolizumab|200 mg every 3 weeks (squamous and non-squamous)
214884240|NCT03631199|DRUG|carboplatin|Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)
214884241|NCT03631199|DRUG|cisplatin|75 mg/m\^2 every 3 weeks (non-squamous)
214884242|NCT03631199|DRUG|paclitaxel|200 mg/m\^2 every 3 weeks (squamous)
214292225|NCT05833191|DEVICE|Tibial Nerve Stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
214884243|NCT03631199|DRUG|nab-paclitaxel|100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)
214884244|NCT03631199|DRUG|pemetrexed|500 mg/m\^2 every 3 weeks (non-squamous)
214884245|NCT04648449|OTHER|Artificial intelligence on emergency calls|AI listens to all calls to Bergen EMCC, detecting calls regarding possible stroke.
214884246|NCT04127604|BEHAVIORAL|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
214292226|NCT01293721|DEVICE|Low-magnitude high - frequency vibration treatment|stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
214667592|NCT01187368|DEVICE|HeartMate 3|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
214884247|NCT04127604|BEHAVIORAL|Safety Assessment and Follow-up Evaluation (SAFE)|Measurement-based care assessment and evaluation.
214884248|NCT05664594|DEVICE|Computerized Cognitive Training|Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.
214667593|NCT05394077|DIAGNOSTIC_TEST|Active Release Technique|Using Active Release Technique
214884249|NCT05533671|PROCEDURE|medial patellofemoral reconstruction|Surgery to correct dislocated (knocked out of place) knee cap. This surgery anchors the kneecap back into the correct position and supports the kneecap.
214884250|NCT05533671|PROCEDURE|Non-operative group|Physical therapy by following a specific regimen.
214884251|NCT06045221|DRUG|Orforglipron|Administered orally
214884252|NCT06045221|DRUG|Semaglutide|Administered orally
214884253|NCT06585488|DRUG|BGB-53038|Administered orally
214884254|NCT06585488|DRUG|Tislelizumab|administered by intravenous infusion
214884255|NCT06585488|DRUG|Cetuximab|administered by intravenous infusion
214884256|NCT02567435|DRUG|Cyclophosphamide|Given IV and PO
214884257|NCT02567435|BIOLOGICAL|Dactinomycin|Given IV
214884258|NCT02567435|DRUG|Irinotecan Hydrochloride|Given IV
214884259|NCT02567435|OTHER|Laboratory Biomarker Analysis|Correlative studies
214884260|NCT02567435|OTHER|Questionnaire Administration|Ancillary studies
214884261|NCT02567435|RADIATION|Radiation Therapy|Undergo RT
214884262|NCT02567435|DRUG|Temsirolimus|Given IV
214884263|NCT02567435|DRUG|Vincristine Sulfate|Given IV
214884264|NCT02567435|DRUG|Vinorelbine|Given IV
214292227|NCT00292695|OTHER|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
214667594|NCT05394077|DIAGNOSTIC_TEST|Abdominal Drawing-Maneuver|Using Abdominal Drawing-Maneuver Technique
214667595|NCT01419171|DEVICE|OMEGA™ Monorail Coronary Stent System|All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
214667596|NCT01836601|BEHAVIORAL|Family-centered nighttime communication bundle|
214667597|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day|Participants receive 3 EMA survey prompts daily for the duration of the study.
214667598|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day|Participants receive 6 EMA survey prompts daily for the duration of the study.
214884265|NCT05004896|DRUG|Ketamine Hydrochloride|36 patients will receive ketamine hydrochloride, over four infusions, flexibly dosed between 0.5 mg/kg to 0.75 mg/kg
214884266|NCT05004896|DRUG|Midazolam Hydrochloride|36 patients will receive midazolam hydrochloride, over four infusions, flexibly dosed between 0.02 mg/kg to 0.03 mg/kg
214884267|NCT05787665|OTHER|phone call at 3 months|patients will be called at 3 months to know if they are alive and to know if they have been rehospitalized
214884268|NCT06253611|DRUG|Nivolumab|Nivolumab 240 mg IV; every 2 weeks
214884269|NCT06253611|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks
214884270|NCT06253611|BIOLOGICAL|EXL01|Orally 1 capsule/day, starting on day 1 of each FOLFOX/nivolumab treatment.
214884271|NCT06112743|DRUG|Mavacamten|Specified dose on specified days
214884272|NCT05612685|BEHAVIORAL|Healthcare provider referral to a tax filing app|Healthcare providers offer a referral to a tax filing app and briefly describe the potential benefits of tax credit receipt
214884273|NCT02091791|PROCEDURE|Traction sessions|
214884274|NCT02512718|DRUG|Omegaven|Comparison of FOLE vs. SOLE
214884275|NCT02512718|DRUG|Soybean oil lipid emulsion|Comparison of FOLE vs. SOLE
214884276|NCT05877729|OTHER|Standard of Care|The SOC arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression). At each assessment, the investigators will review 149 SOC participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, the investigators will also do monthly check-ins to improve retention and check contact information.
214884277|NCT05877729|BEHAVIORAL|Video-counseling+app|"The intervention tailors the telehealth counseling according to the individual's needs. Tailoring occurs based on the participant's baseline MH, SU, and HIV knowledge/outcomes and assessment responses inform the sessions on these topics. Participants choose from a list identified in the menu sessions: HIV care, MH, SU, lifestyle, health, social support, family of origin, romantic and sexual relationships, self-identity and disclosure, subsistence needs, education and vocation, and a wildcard session.~WYZ contains 3 main features: My Health, My Team, and My Community. Tailoring is achieved based on the individual's needs at a given time (e.g., My Community may be used more if social isolation is a barrier)."
214884278|NCT03681535|RADIATION|Radiation Therapy|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve complete response and have a negative post-chemotherapy PET scan following 3 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
214884279|NCT05339074|DRUG|Ketamine Hydrochloride|60 patients will receive ketamine hydrochloride over 12 weeks, flexible dosed between 0.5 mg/kg to 1.0 mg/kg
214884280|NCT04458922|DRUG|Atezolizumab|Given IV
214667599|NCT04884087|BEHAVIORAL|Incentive Structure - fixed|"Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week."
214667600|NCT04884087|BEHAVIORAL|Incentive Structure - prize based|"Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90)."
214667601|NCT00216008|DRUG|docetaxel|
214667602|NCT00216008|DRUG|cisplatin|
214667603|NCT00216008|PROCEDURE|radiation|
214667604|NCT00216008|PROCEDURE|surgery|
214667605|NCT02128490|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
214667606|NCT02128490|DRUG|Febuxostat XR|Febuxostat over-encapsulated capsules
214667607|NCT02128490|DRUG|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
214667608|NCT02128490|DRUG|Colchicine|Colchicine tablets
214667609|NCT02128490|DRUG|Naproxen|Naproxen tablets
214667610|NCT02128490|DRUG|Lansoprazole|Lansoprazole capsules
214667611|NCT03719573|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
214667612|NCT02243176|DRUG|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd.
214667613|NCT02243176|DRUG|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
214667614|NCT03533790|DRUG|DEP-Ru|"* Drug: ruxolitinib~* Drug: doxorubicin~* Drug: etoposide~* Drug: methylprednisolone"
214884281|NCT04458922|PROCEDURE|Biopsy Procedure|Correlative studies
214884282|NCT04458922|PROCEDURE|Biospecimen Collection|Correlative studies
214884283|NCT04458922|PROCEDURE|Computed Tomography|Undergo CT scan
214292228|NCT06119360|PROCEDURE|Face-to-face approach|A front-facing approach and insert the lightwand following the patient's tongue base curvature without scooping movement
214292229|NCT06119360|PROCEDURE|Conventional approach|Patients were positioned supine and the intubator stood above the patient's head. Opening the mouth and slightly pulling the mandible with one hand, the intubator inserted the lightwand-tracheal tube assembly at midline into the patient's mouth under the ambient light being turned off. To identify the location of the lighted tip, the intubator could move the lightwand back and forth gently, Once the red light of the tip was located at the midline of the patient's neck, the pre-launched tube was inserted smoothly into the patient's airway unless there was no resistance
214292230|NCT05322304|DIETARY_SUPPLEMENT|Almond|Intervention (almond supplementation) and Isocaloric diets (control)
214292231|NCT02986399|OTHER|Fast track patient pathway|Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
214292232|NCT02405845|RADIATION|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
214292233|NCT01607086|DRUG|Cherry lamotrigine ODT|25mg, taken orally on one study visit
214292234|NCT01607086|DRUG|Cherry Placebo|Taken orally on one study visit
214292235|NCT03089450|DEVICE|CGBio stent|Percutaneous Coronary Intervention
214292236|NCT03089450|DEVICE|Biomatrix flex|Percutaneous Coronary Intervention
214884284|NCT02701088|DRUG|5Fluorouracile and Mitomycin-C|All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
214884285|NCT02701088|RADIATION|Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy|SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
214884286|NCT05849454|DEVICE|Messy Memories Intervention|"Messy Memories is a mobile application that allows users to self-administer exposure therapy techniques outside of the traditional psychotherapy context. Participants are asked to audio record a difficult (messy) memory, including what they did, felt, thought, smelled, saw, etc. They are then asked questions about what it was like to re-experience the memory, such as what emotions were elicited (e.g., sadness, anger, fear). Next, participants are asked to process what the memory means to them. They are then instructed to listen to their recording as often as they like, until the memory becomes easier to re-experience. They respond to processing questions each time they listen to their prior difficult memory."
214292237|NCT04337749|DRUG|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
214292238|NCT04337749|DEVICE|ZnO-NPs socks|ZnO-NPs socks were given to patients for 2 weeks
214292239|NCT04337749|COMBINATION_PRODUCT|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks were given to patients for 2 weeks
214292240|NCT04337749|DEVICE|Placebo socks|Placebo socks were given to patients for 2 weeks
214292241|NCT01761110|BEHAVIORAL|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
214292242|NCT05749445|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir-Ritonavir
214292243|NCT01901497|DEVICE|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
214292244|NCT01260285|DRUG|Vardenafil|10 mg PO once
214667615|NCT02040246|DRUG|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
214667616|NCT02040246|DRUG|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
214667617|NCT00639067|DEVICE|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
214884287|NCT03852147|PROCEDURE|: hemodynamic management|"Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.~Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine."
214884288|NCT02179086|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo standard-dose 3D-CRT
214884289|NCT02179086|RADIATION|Intensity-Modulated Radiation Therapy|Undergo standard-dose IMRT
214884290|NCT02179086|RADIATION|Intensity-Modulated Radiation Therapy|Undergo dose-escalated and -intensified photon IMRT
214884291|NCT02179086|OTHER|Laboratory Biomarker Analysis|Correlative studies
214884292|NCT02179086|RADIATION|Photon Beam Radiation Therapy|Undergo dose-escalated and -intensified photon IMRT
214884293|NCT02179086|RADIATION|Proton Beam Radiation Therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
214884294|NCT02179086|OTHER|Quality-of-Life Assessment|Ancillary studies
214884295|NCT02179086|OTHER|Questionnaire Administration|Ancillary studies
215046574|NCT00233532|DRUG|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
214884296|NCT02179086|DRUG|Temozolomide|Given PO
214884297|NCT03651700|DEVICE|Active TMS|Active TMS will be at 90% motor threshold
214884298|NCT03651700|DEVICE|Sham TMS|Sham TMS will be administered
214884299|NCT03651700|BEHAVIORAL|CILT|60-90 minutes of CILT will be administered during each treatment session
215046575|NCT03322163|OTHER|Exposure is maternal iodine|The exposure is preconception maternal iodine status There is no intervention in this observational study
214292245|NCT03295578|OTHER|Personalized feedback|"The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake."
214292246|NCT03295578|OTHER|Generic feedback|The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
214292247|NCT03295578|DEVICE|Continuous glucose monitoring device|This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
214292248|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 13|HBM9161 680 mg qw by q2w from week 13
214292249|NCT05015127|DRUG|Placebo|Placebo
214292250|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 7|HBM9161 680 mg qw by q2w from week 7
214292251|NCT05015127|DRUG|Placebo|Placebo qw by HBM9161 680mg qw from week 12
214292252|NCT04333823|DRUG|Dapagliflozin 5mg|Dapagliflozin tablet
214292253|NCT04333823|DRUG|Placebo|Sugar pill manufactured to mimic Dapagliflozin 5mg tablet
214292254|NCT04155112|BEHAVIORAL|Physical activity|Increased physical activity to the minimum recommended by health authorities (≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week).
214292255|NCT04155112|BEHAVIORAL|Hypocaloric Mediterranean diet|Energy deficit to reach 5-10% weight loss within 6 months, based on the Mediterranean diet pattern.
214667618|NCT01810809|PROCEDURE|articular lavage with saline injection|Patients will receive articular lavage with saline injection
214884300|NCT04838223|OTHER|Hyperosmolar Response|A single drop of hypertonic sodium chloride solution at room temperature will be instilled in each eye and change in pain/other symptoms after up to 90 seconds of application (to account for any initial irritation symptoms) will be observed.
214884301|NCT04838223|OTHER|Proparacaine Challenge Test|A single drop of Proparacaine hydrochloride ophthalmic solution, (Alcaine®, 0.5%) will be used on each eye respectively and any change in pain/other symptoms will be noted after 90 seconds (to account for initial discomfort from the preservative in Proparacaine solution).
214884302|NCT04838223|OTHER|Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Optional; only for Contact Lens Wearers|The CLDEQ-8 is a validated eight-item scaled questionnaire developed to reflect the overall opinion of soft contact lenses.
214884303|NCT04838223|OTHER|Ocular Pain Assessment Survey (OPAS)|Twenty seven-item quantitative questionnaire designed to provide an assessment of the symptoms and quality of life effect of ocular pain \[18\]. The 27 items of the OPAS questionnaire are graded on a scale of 0 to 10, or 10 to 100, where 0 indicates none and 10 or 100 indicate maximum.
214884304|NCT04838223|OTHER|Visual Analogue Questionnaire|Symptoms of ocular comfort and dryness will be graded for each eye on a scale of 0-10, where 0=extremely uncomfortable, extremely dry and 10=excellent comfort, no dryness. An average rating will be provided for the morning, afternoon and evening.
215046576|NCT04464551|DRUG|[14C]D-0316 suspension|Before administration, the drug preparation was placed at room temperature, and 40ml drinking water was added into each bottle to prepare suspension for the subjects to take. 40ml pure water was injected again. After washing the container, the subjects took orally. Repeat the previous step, and then used 160ml purified water. After the administration container was moistened for several times, the subjects took all the moistening lotion. Pay attention not to splash the liquid during mixing outside the bottle
215046577|NCT04044157|OTHER|non-invasive measurement of cardiac output|cardiac output will be non-invasivaly measured by means of electrical cardiometry
214292256|NCT04237441|OTHER|number of participants with surgical complications|observation before and after multidisplinary team conference (MDT) was implemented
214292257|NCT03343808|PROCEDURE|cooled radiofrequency ablation of genicular nerves|Cooled RF consists of creating an injury in the nerve trough a high frequency flow. Unlike conventional RF, in cooled RF through a closed circuit where intravenous flows, we can create an injury for a longer period of time, at a lower temperature (standard RFA 90º C, cooled RFA 60º C) and within an area 8 times larger. As the lesion is spherical, and larger (about 10-12 mm in diameter), the chances of neurolysis of the nerve increase.
214292258|NCT05792371|PROCEDURE|induced membrane technique|Masquelet technique, also called an induced membrane technique (IMT), was first introduced to treat critical size bone defect up to 25 cm in 1986 by Pr. Alain Charles Masquelet et al. IMT is a two-stage surgical operation that recently provides a more popular option for the treatment of critical size bone defect as well as fracture nonunion. Basically, first stage of IMT comprises the implantation of a polymethylmethacrylate (PMMA) cement spacer loaded with antibiotics into defect site. During 6 to 8 weeks, this spacer induces the formation and maturation of a thin layer called induced membrane surrounding it via a foreign body immune response. In stage II, the spacer is carefully removed while keeping induced membrane at the fracture site, autologous bone graft is then performed to provoke bone healing.
214292259|NCT05792371|PROCEDURE|Bone graft (Stage II of IMT)|Bone graft is only performed in this group to provoke bone healing, as same as demonstrated in the stage II of IMT.
214292260|NCT03527966|BIOLOGICAL|5cc Vivigen and local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft
214292261|NCT03527966|BIOLOGICAL|Small kit rhBMP-2 with local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft
214292262|NCT05820308|BEHAVIORAL|Companion Dog Walking|Participants will be asked to walk their dog three times per week, for a minimum of 30 minutes each day of walking, over an 8-week period.
214667619|NCT01810809|DRUG|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
214667620|NCT01810809|DRUG|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
214667621|NCT01810809|DRUG|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
214292263|NCT05820308|BEHAVIORAL|Attention Control Group|Participants will be asked to read educational materials on dog health once per week, over an 8-week period.
214292264|NCT05516706|OTHER|Dynamic stretching|Participants in this group performed a 10 minutes warm-up followed by 15 minutes of dynamic stretching exercises which included arm cross-over, scapular scaption, upper body twist walking lunges, cat and cow pose, and rotator cuff movements.
214292265|NCT05516706|OTHER|Plyometric push up|Participants in this group performed 10 minutes of warm-up followed by 15 minutes of plyometric push training which included one-arm push-ups and depth push up
214667622|NCT06511388|OTHER|Non-Interventional Study|Non-interventional study
215046578|NCT03151031|PROCEDURE|Cryotherapy|The cooling procedure for the knee joint will be initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant will lie supine and the investigator will apply the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack will be removed, and the participants will perform SEBT for the second time.
215046579|NCT02150239|PROCEDURE|operation|
215046580|NCT03988946|DEVICE|Transcatheter Mitral Valve Replacement via Transseptal Access|The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
215046581|NCT02961244|OTHER|Prewarming and perioperative warming with Forced Air Warming device and its blankets.|
215046582|NCT02961244|DEVICE|Forced Air Warming blanket|
215046583|NCT01854528|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
215046584|NCT01854528|DRUG|Ribavirin|Tablet
215046585|NCT01854528|DRUG|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
215046586|NCT01854528|DRUG|Telaprevir|Film-coated tablet
215046587|NCT03767049|OTHER|Colection of clinical data|Colection of clinical data
215046588|NCT02017184|BIOLOGICAL|Noninvasive core temperature thermistor|
215046589|NCT03789292|BIOLOGICAL|CT-P17 SC|Subcutaneous injection of Adalimumab 40mg every two weeks
215046590|NCT03789292|BIOLOGICAL|Humira SC|Subcutaneous injection of Adalimumab 40mg every two weeks
215046591|NCT05597384|PROCEDURE|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
215046592|NCT02717325|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-08)
215046593|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
215046594|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
215046595|NCT03012750|DRUG|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
215046596|NCT02832414|BEHAVIORAL|Intensive weight loss program|behavioral and dietary supplement
215046597|NCT02828384|OTHER|low fodmap diet|dietary teaching
215046598|NCT02828384|DIETARY_SUPPLEMENT|Psyllium|7.1g of psyllium daily
214884305|NCT04555551|BIOLOGICAL|Infusion of MCARH109 T cells|Patients will be admitted to Memorial Hospital as inpatient prior to the infusion of CAR T cells. The T cell infusion will be planned to start at 2 days following the completion of the conditioning chemotherapy (up to 7 days is allowed if clinically indicated to delay).Cohorts of 3-6 patients each will be treated with escalating doses of modified T cells.
214884306|NCT05512234|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
214884307|NCT05512234|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
214884308|NCT04763343|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride will be given as an intravenous infusion using a standard regimen given in most studies conducted: 0.5 mg/kg over 40 minutes. Ketamine infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
214884309|NCT04763343|DRUG|Saline|Subjects randomized to placebo will be administered a saline (0.9% sodium chloride) drip for 40 minutes. Saline placebo infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
215046599|NCT00465673|DRUG|Liposomal Doxorubicin|40mg/m2 over 1 hour infusion for 21 days
215046600|NCT06239558|OTHER|Qualitative exploration|Semi-structured Interviews and focus group
215046601|NCT01497834|DRUG|BMS-790052 (Daclatasvir)|Tablets, Oral, 60mg, Once daily, 24 weeks
215046602|NCT01497834|DRUG|BMS-650032 (Asunaprevir)|Capsules, Oral, 100mg, Twice daily, 24 weeks
215046603|NCT01909544|OTHER|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
215046604|NCT05796687|BEHAVIORAL|My Future Self|My Future Self is based upon the Theory of Possible Selves, which promotes the capacity of young people to construct goals for a successful adulthood. Youth who hold a balanced set of negative and positive images of their future have both a) a positive goal to strive for and b) awareness of the personally relevant consequences of not meeting that goal. My Future Self also includes two new supportive gaming elements that reinforce learning of relevant knowledge and skills as well as provide opportunities for youth to individually practice these skills in a personalized virtual environment. Gaming interventions using interactive technology can significantly increase self-reported abstinence and lower reports of diagnosed STD in young women, as well as reduce risky sex in high-risk young men who have sex with men. Youth will participate in these gaming elements on tablets provided by CHLA. My Future Self will be implemented as a ninety-minute small group 5-week program.
215046605|NCT01855386|OTHER|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
215046606|NCT01855386|OTHER|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
215046607|NCT00157118|DRUG|Protein C Concentrate (Human) Vapor Heated|
215046608|NCT04123730|OTHER|Fixed-dose compared to variable oxygen flow supplementation during walking|"At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT"
215046609|NCT02449941|DRUG|PPI (proton pump inhibitor)|"1. Pre ESD (endoscopic submucosal dissection)~   * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~  * Use of PPI for 2 months~2. Post ESD 1 (After 2 months)~   * Assess the distribution of helicobacter pylori after using PPI.~  * Stop of PPI~3. Post ESD 2 (After 4 months)~   * Assess the distribution of helicobacter pylori after stop of PPI."
215046610|NCT02375100|PROCEDURE|Spinal Anesthesia|All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
215046611|NCT02375100|PROCEDURE|Transversus Abdominis Plane Block|Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
215046612|NCT02375100|PROCEDURE|Ilioinguinal Nerve Block|Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
215046613|NCT02375100|DRUG|Bupivacaine %0.5 (hyperbaric)|
215046614|NCT02375100|DRUG|Bupivacaine %0.25 (isobaric)|
215046615|NCT02375100|DEVICE|25G Quincke needle|
215046616|NCT02375100|DEVICE|Echogenic Needle with 30° bevel|
215046617|NCT02375100|DRUG|Acetaminophen|Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
215046618|NCT02375100|DRUG|Tramadol|Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
214292266|NCT03884218|OTHER|Infra red thermal imaging|thermal image using a non-touch, non-ionising, thermal camera system
214292267|NCT06103357|OTHER|blood sample collection|Before and after angioplasty, blood samples upstream and downstream of the coronary lesion will be taken, arterial sampling at the aortic root level will be performed, and peripheral venous blood will be collected.
214884310|NCT04763343|BEHAVIORAL|CAMS Therapy|CAMS weekly sessions will also be started immediately as an inpatient at the start of the study while receiving ketamine or saline. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk \< 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
214884311|NCT05525390|BEHAVIORAL|Extended Reality-Enhanced Behavioral Activation|"Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc."
214884312|NCT05525390|BEHAVIORAL|Traditional Behavioral Activation|Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
214884313|NCT05592392|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
214884314|NCT06120504|DRUG|PF-08046045|Given into the vein (IV; intravenously)
214884315|NCT04942093|DIETARY_SUPPLEMENT|With low-calorie, high-protein diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
214884316|NCT04942093|DIETARY_SUPPLEMENT|Without low-calorie, high-protein diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
214884317|NCT05102747|RADIATION|Hypofractionated SRT (stereotactic radiotherapy)|3\*10Gy over 1 week
214884318|NCT05102747|RADIATION|Historical single-dose SRS (stereotactic radiosurgery)|20 to 25Gy/1 fraction
214884319|NCT05002933|DRUG|Insulin glargine 300 U/ml|Solution for injection Subcutaneous injection
214884320|NCT03814603|PROCEDURE|PET-MR Scan|Participants will undergo PET-MR scans at baseline and two-year follow up to examine brain amyloid deposition longitudinally.
214884321|NCT03814603|DRUG|PiB|Subjects will receive a single dose of 555 MBq of PiB and perform a dynamic 30 min PiB PET-MR scan 60 min after injection.
214884322|NCT06139809|PROCEDURE|Intubation|Intubation will take place according to our local standard protocol for nasal intubation using NIPPV delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the SpO2 and HR.
215046619|NCT05236166|DRUG|Rapid withdrawal of antiepileptic|"Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
215046620|NCT05236166|DRUG|Slow withdrawal of antiepileptic|"Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
215046621|NCT00956761|BIOLOGICAL|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
215046622|NCT01904721|DRUG|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
215046623|NCT01904721|DRUG|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
215046624|NCT01904721|DRUG|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
215046625|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
215046626|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
215046627|NCT04418895|OTHER|Chemoradiation|Subjects will receive neoadjuvant chemoradiation per standard of care. This is typically comprised of radiotherapy of 5040 cGy (centigray) with concurrent capecitabine 825 mg/m2 by mouth (po) two times daily (bid) (typically rounded to the nearest 500 mg dose) or infusional 5-fluorouracil (5FU). However, dosing and administration are at the discretion of the treating medical and radiation oncologist.
215046628|NCT04418895|RADIATION|short course radiation therapy|An acceptable alternative approach is short-course radiation therapy per standard of care, which is typically comprised of radiotherapy of 25 Gy (gray) in 5 fractions, with surgery within 1 week of completion of therapy or delayed for 6-8 weeks. Selection of the optimal radiation therapy approach is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist. However, generally, short-course radiation therapy is not recommended for low-lying tumors less than 5 centimeters (cm) from the anal verge.
215046629|NCT04418895|DRUG|mFOLFOX6|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
215046630|NCT04418895|DRUG|CAPOX|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
215046631|NCT04418895|DRUG|fluoropyrimidine +/- oxaliplatin|possible adjuvant chemotherapy regimen. Subjects who do not receive preoperative mFOLFOX6 or CAPOX typically receive postoperative adjuvant chemotherapy with a fluoropyrimidine +/- oxaliplatin for an additional 16-18 weeks of therapy, if permitted based on recovery after surgical resection and post-surgical performance status. This treatment is at the discretion of the treating medical oncologist. Subjects will remain on study regardless of postoperative therapy administration or duration.
215046632|NCT01082614|DEVICE|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV \> 12%.
215046633|NCT04927221|DRUG|DC371739 Tablets|Participants received one of 5 dose levels of DC371739 administered as single oral doses.
215046634|NCT04927221|DRUG|Placebo|Placebo orally administered as comparison
215046635|NCT05713461|BEHAVIORAL|exercise training program|"Adapted Interval Training Intervention, three days a week, 10 weeks.~Warm-up 10': Joint mobility and cardiovascular activation~Main part:~Resistance training circuit for strengthening the main muscle groups.~Cool down Flexibility and CORE"
214292268|NCT00558025|DRUG|Pramipexole Extended Release|
214884323|NCT05004116|DRUG|Repotrectinib|TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).
214884324|NCT05004116|DRUG|Irinotecan and temozolomide|Irinotecan and temozolomide will be given as per institutional standard.
214292269|NCT00558025|DRUG|Pramipexole Immediate Release|
214884325|NCT05703425|DRUG|Sulfasalazine|Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
214292270|NCT02821481|DIETARY_SUPPLEMENT|Beta-alanine|
214292271|NCT02821481|DIETARY_SUPPLEMENT|Placebo|
214884326|NCT05398692|OTHER|On Site Exercise Rehabilitation|The subject will receive on site standard pulmonary and exercise rehabilitation, educational instruction on balance and strength training, stretching, nutrition, hydration, pacing, proper breathing, small or mini-lectures, and information on relaxation techniques.
214884327|NCT06139497|BEHAVIORAL|Physical activity programme|48-week exercise programme including aerobic, resistance, balance and flexibility exercises twice to three times per week. The sessions are supervised by a coach at least once a week during the first 6 months then monthly. The other session of the PA programme is performed at home and the overall weekly PA is reviewed with the coach at the end of the supervised session.
214292272|NCT02821481|BEHAVIORAL|Muscular endurance exercise|
214292273|NCT04782089|DRUG|Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors|Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable
214884328|NCT06139497|BEHAVIORAL|Home-based physical activity|48-week exercise programme including aerobic, resistance, balance and flexibility exercises twice to three times per week. Participants have to perform the exercise programme at home exclusively. They are called every week by a research assistant to review the activities performed, collect information on their adherence and perception on the programme.
214884329|NCT04856930|BIOLOGICAL|Imsidolimab|Humanized Monoclonal Antibody
214884330|NCT04856930|BIOLOGICAL|Placebo|Placebo
214884331|NCT02091518|BEHAVIORAL|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
215046636|NCT05713461|BEHAVIORAL|Feeding training|Two workshops on healthy eating habits (Week 1 and week 5). Food Frequency Questionnaires (weekly). Feedback weekly. Mediterranean Diet Adherence Screener (MEDAS). The dietary intervention will be based on the nutritional recommendations based on the Mediterranean diet, according to the evidence from the PREDIMED trial.
214292274|NCT04389567|DRUG|Famotidine|Use of oral Famotidine.
214292275|NCT00416559|OTHER|clinical observation|
214292276|NCT05353231|BEHAVIORAL|Attention Feedback Awareness and Control Training (A-FACT)|"A-FACT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control.~Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Following a fixation que, the auditory neutral or negative simulated thought stimulus is delivered, and 500ms prior to termination of the auditory stimulus, a visual stimulus is presented until participants categorize the visual stimulus as greater than or smaller than 5 objects. Latency to disengage attention from each thought stimuli, at the trial-level, is repeatedly measured, and after each negative thought stimulus, trial-level feedback on the latency to disengage is delivered back to participants through a visual scale representing their attentional bias. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial."
214884332|NCT02091518|DEVICE|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
214884333|NCT04953637|OTHER|Physiotherapy|Participants in the physiotherapy group will receive gait and balance focused physiotherapy at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks.
214884334|NCT03965689|DRUG|Carboplatin|Given IV
214884335|NCT03965689|DRUG|Paclitaxel|Given IV
214884336|NCT03965689|DRUG|Pevonedistat|Given IV
214884337|NCT04667000|OTHER|Forced Air Warming|We will use Forced Air Warming for cesarean patient
214667623|NCT04832438|DRUG|9-ING-41|15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle
214667624|NCT04832438|DRUG|Carboplatin|Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
214884338|NCT03757351|DRUG|DNL747|Repeating oral dose
214884339|NCT03757351|DRUG|Placebo|Repeating oral dose
214884340|NCT04862221|DRUG|High-dose methylprednisolone|Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
214884341|NCT04862221|DRUG|Equine anti-thymocyte globulin|Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.
214884342|NCT04862221|DRUG|Prednisolone|"Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.~Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
215046637|NCT02524561|DRUG|CEE pill|Conjugated equine estrogens 0.45 mg/day
214667625|NCT00679562|DRUG|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
214667626|NCT00679562|OTHER|Distilled water|Application of patches containing distilled water for 24 hours
215046638|NCT02524561|DRUG|Estradiol patch|Climara 50 mcg/day
215046639|NCT02524561|DRUG|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
215046640|NCT02524561|OTHER|Placebo tablet|Placebo tablet
215046641|NCT02524561|OTHER|Placebo patch|placebo patch
214884343|NCT04862221|DRUG|Placebo for prednisolone|"Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.~Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
214292277|NCT05353231|BEHAVIORAL|Mindful Disengagement from Thoughts Training (MDTT)|MDTT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Participants will first learn and practice a focused attention on the breath meditation. Then, participants will practice pressing a button each time they notice an inhalation or exhalation during the focused attention meditation. Next, during the meditation, participants will be presented the auditory neutral or negative simulated thought stimuli and will train internal attentional control by repeatedly disengaging their attention from these stimuli and back to their breath MDTT will thus entail 80 trials (40 negative, 40 neutral, ITI ≈ 10sec) during the focused attention on the breath meditation.
214884344|NCT04862221|DRUG|Placebo for infusions|Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
214884345|NCT04862221|DRUG|Diphenhydramine|Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.
214884346|NCT04862221|DRUG|Methylprednisolone|Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.
214884347|NCT04812470|DRUG|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion
214884348|NCT04812470|DRUG|Melphalan|Melphalan will be administered once as an intravenous infusion.
214884349|NCT04812470|DRUG|Interleukin-2|After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.
215046642|NCT02524561|OTHER|Placebo progesterone|placebo progesterone
214292278|NCT05353231|BEHAVIORAL|Placebo-Control|The condition is designed as a placebo control for the Attention Feedback Awareness and Control Training (A-FACT) training condition. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Rather than the quantity categorization task with trial-level feedback, participants only engage in the quantity categorization task. The task is identical in all other ways to the A-FACT condition. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial.
214292279|NCT06215599|OTHER|Survey|The survey consisted of 14 questions that thoroughly examined the participants' knowledge levels of these conditions, as well as their indication preferences related to BAHIs.
214292280|NCT01942291|DRUG|Niacin|The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
214292281|NCT05248412|OTHER|COVID-19 outbreaks|The intervention of the study is the COVID-19 outbreaks in Hong Kong. The pre-and post-COVID-19 outbreak periods will be defined as 1 January 2010 - 31 December 2019 and 1 January 2020 - 31 December 2024, respectively.
214292282|NCT01848002|DRUG|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
214292283|NCT01848002|DRUG|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
214667627|NCT04309721|DRUG|Perampanel|Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
214667628|NCT04309721|DRUG|Placebo|Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
214884350|NCT04328805|DRUG|ibuprofen tablets|oral tablet
214884351|NCT04328805|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb
214884352|NCT06315075|BEHAVIORAL|Dialectical behavior therapy for adolescents (DBT-A)|A 20-week DBT-A with a weekly individual session (45 minutes), a weekly session of multifamily skills training groups with a caregiver (120 minutes), and telephone consultation with individual therapists outside therapy sessions as needed. The treatment consists of four components and is delivered according to the manual except for the phone coaching that PBU offers workdays until 8 pm.
214884353|NCT04541537|DIAGNOSTIC_TEST|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry
214884354|NCT04541537|DIAGNOSTIC_TEST|Dog Detection|Analysed by the dogs of Curie Institute at the training centers
214884355|NCT03104400|DRUG|Adalimumab|Administered by subcutaneous injection
214884356|NCT03104400|DRUG|Upadacitinib|Oral tablet
214884357|NCT03104400|DRUG|Placebo to Upadacitinib|Oral tablet
214884358|NCT03104400|DRUG|Placebo to Adalimumab|Administered by subcutaneous injection
214884359|NCT05551715|DEVICE|Software development for individualized refractive surgery|Software development for individualized refractive surgery
215046643|NCT01361984|DRUG|Nebulized arformoterol|Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is \~9 minutes
215046644|NCT01361984|DRUG|Salmeterol|Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
215046645|NCT03475602|DIAGNOSTIC_TEST|PLA2R|Determination of serum concentration of anti PLA2R antibody
214884360|NCT04725396|DEVICE|Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP).|PVP-assisted mandibular reconstruction includes the production of the surgical cutting guides required for mandibular resection and fibula free-flap conformation and of the preformed plates for flap osteosynthesis (for all patients, PVP will be done by the same laboratory).
214884361|NCT04725396|DEVICE|Conventional Mandibular Reconstruction (MR without PVP)|Conventional Mandibular Reconstruction
215046646|NCT03475602|DIAGNOSTIC_TEST|TSHD7A|Determination of serum concentration of anti TSHD7A antibody
215046647|NCT02826616|DRUG|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
215046648|NCT02616731|DRUG|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
214292284|NCT03886376|OTHER|Deep Massage|The deep massage group received 12 minutes of massage on the legs, arms and the back with three different sliding pressures.
214884362|NCT05677919|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, stool, and saliva samples
215046649|NCT02616731|DRUG|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
215046650|NCT01246882|BEHAVIORAL|Augmented activity feedback|Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
215046651|NCT01246882|BEHAVIORAL|Speed-only feedback|Feedback about walking speed will be provided 3 times per week.
215046652|NCT03979300|OTHER|Learning process during role play on psychiatric interview|"Methodology: Mixed method study with:~* Quantitative features:~  * Self-reported questionnaries :  Learning Effectiveness Inventory Scale  (18)~ * Sociodemographical data and others questions~* Qualitative : Grounded Theory~  * Video-record of simulation and audio-record and briefing and debriefing, quoted with conversational analysis~ * Semi-structured interview of learners and teachers"
215046653|NCT01357343|OTHER|Chiropractic|Spinal manipulation and active and passive therapy.
214884363|NCT05677919|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214884364|NCT05677919|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214884365|NCT05677919|PROCEDURE|Computed Tomography|Undergo CT scan
214884366|NCT05677919|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
215046654|NCT01357343|OTHER|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
215046655|NCT00811720|DRUG|Placebo|as-needed use, tablets, orally, 6 months
215046656|NCT00811720|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
215046657|NCT01343212|OTHER|stiffness measurement using ARFI|Stiffness measurement will be performed for HCC using ARFI technique.
214292285|NCT03886376|OTHER|Superficial Massage|The superficial massage group received 12 minutes of only one sliding pressure performed on the legs, arms and the back.
214292286|NCT01897740|DRUG|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
214292287|NCT00541073|DIETARY_SUPPLEMENT|vitamin B12|
214292288|NCT00541073|DRUG|cisplatin|
214292289|NCT00541073|DRUG|pemetrexed disodium|
214292290|NCT00541073|GENETIC|gene expression analysis|
214292291|NCT00541073|OTHER|laboratory biomarker analysis|
214884367|NCT05677919|DRUG|Pirtobrutinib|Given PO
214292292|NCT00541073|OTHER|pharmacological study|
214292293|NCT02558257|BEHAVIORAL|Survey|Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
214292294|NCT02299609|OTHER|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
214292295|NCT01806831|DEVICE|"Biocellulose Mask, Farhorm®"|
214292296|NCT00596570|PROCEDURE|PCI|Percutaneous coronary interventiom
214884368|NCT05677919|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214884369|NCT05677919|DRUG|Venetoclax|Given PO
214884370|NCT05677919|PROCEDURE|Echocardiography|Undergo ECHO
214884371|NCT05677919|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214884372|NCT05677919|PROCEDURE|Biopsy|Undergo tissue biopsy
215046658|NCT01077063|PROCEDURE|paracentesis|surgical drainage of malignant ascites
215046659|NCT01077063|DEVICE|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
215046660|NCT03555058|OTHER|Treatment escalation|Treatment escalation per TDM and physician's decision.
215046661|NCT04127526|OTHER|Connection to Environment with Cognitive Therapy (CONNECT)|8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
214884373|NCT05827614|DRUG|BBI-355|Oral CHK1 inhibitor
214884374|NCT05827614|DRUG|Erlotinib|EGFR Inhibitor
214884375|NCT05827614|DRUG|Futibatinib|FGFR1-4 Inhibitor
214884376|NCT05827614|DRUG|BBI-825|Oral RNR Inhibitor
214884377|NCT06068491|OTHER|Vet-CALD|Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
214884378|NCT05132244|PROCEDURE|Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)|Standard anti-hyperglycemic treatment given as directed by an endocrinologist to maintain blood glucose level within 4-10 mmol/L based on data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Participants will have access to their glucose data from the CGM.
214884379|NCT05132244|OTHER|Standard Care|Standard anti-hyperglycemic treatment given only if blood glucose level is greater than 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a continuous glucose monitor (CGM) but will not have access to their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
214884380|NCT05869903|DRUG|Orforglipron|Administered orally.
214884381|NCT05869903|DRUG|Placebo|Administered orally.
214884382|NCT04140500|DRUG|RO7247669|Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
214884383|NCT03263650|DRUG|Cabazitaxel|25mg/m2 administered intravenously over 60 minutes on day 1 of cycles 1-6; given before carboplatin.
214884384|NCT03263650|DRUG|Carboplatin|AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6
215046662|NCT02066649|DRUG|Carvedilol|Administering carvedilol to patients diagnosed with large varices on endoscopy
215046663|NCT02066649|PROCEDURE|Variceal band ligation|Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
215046664|NCT05874726|DIAGNOSTIC_TEST|Blood Collection|Blood collection via venipuncture
215046665|NCT05874726|DIAGNOSTIC_TEST|Urine Collection|Free catch urine sample collection
214884385|NCT03263650|DRUG|Prednisone 5Mg|5 mg administered by mouth twice daily on days 1-21 of cycles 1-6.
214884386|NCT03263650|DRUG|Olaparib|Administered by mouth twice daily at a dose of 300 mg by mouth twice daily, dispensed on Day 1 of cycle 7 to participants randomized to receive olaparib maintenance and every 21 days thereafter until the participant completes the study, withdraws from the study or the closure of the study.
214884387|NCT04285281|DRUG|Gabapentin oral capsules|Oral capsule pharmaceutical treatment.
214884388|NCT04285281|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
214884389|NCT04948333|DRUG|ABL001 40mg BID|One tablet of 40 mg will be taken orally twice a day (BID)
214884390|NCT04948333|DRUG|ABL001 80mg QD|Two tablets of 40 mg will be taken orally once a day (QD)
214884391|NCT04948333|DRUG|ABL001 200mg QD|Five tablets of 40 mg will be taken orally once a day (QD)
214884392|NCT05927571|DRUG|Cevostamab|Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.
214884393|NCT05927571|DRUG|Elranatamab|Elranatamab solution for injection will be administered SC as specified in each treatment arm.
214884394|NCT05927571|DRUG|Tocilizumab|Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
214884395|NCT05854381|BIOLOGICAL|VIR-1388|VIR-1388 is given by subcutaneous injection
214884396|NCT05854381|BIOLOGICAL|Placebo|The HT Diluent Placebo is HT buffer (20 mM histidine, 10% trehalose-dihydrate, pH 7.2) and contains no active ingredient and will be administered by subcutaneous injection
214884397|NCT05674097|OTHER|no intervention|no intervention
214884398|NCT05022264|DIAGNOSTIC_TEST|RIA-VS|Measuring vital signs with a new contactless camera technique
215046666|NCT05874726|DIAGNOSTIC_TEST|Tissue Sample Collection|Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.
215046667|NCT05503329|DIAGNOSTIC_TEST|arterial lactate level|an arterial lactate level measured from arterial sample from STEMI patients
215046668|NCT00287924|DRUG|methotrexate|
215046669|NCT00287924|PROCEDURE|adjuvant therapy|
215046670|NCT05562115|OTHER|Tear collection|Collection of tears by Schirmer strip (2 to 4 mm).
214884399|NCT06619106|OTHER|Cognitive test|Cognitive test based on building blocks
214884400|NCT06399575|OTHER|Apnea Following Isocapnic Hypoxia|Decreasing end-tidal partial pressure of oxygen to 50 mmHg for five minutes, targeting 80-85% peripheral oxygen saturation. The end-tidal partial pressure of carbon dioxide will remain +1 mmHg above baseline levels. After five minutes of hypoxia, participants will complete an apnea.
214884401|NCT02759393|DRUG|Dexlansoprazole|receiving 8-week PPI
214884402|NCT02759393|DRUG|Lansoprazole|receiving 8-week PPI
214884403|NCT01625988|DRUG|LY2951742|
214884404|NCT01625988|DRUG|Placebo|
214884405|NCT04196881|OTHER|Knowledge Improvement Program about ADHD|This training program will cover an overview of ADHD, prevalence, causes, symptoms, risk factors, associated impairment, prognosis, and treatment options including behavioral interventions and medication.
215046671|NCT02750930|DRUG|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
215046672|NCT02750930|DEVICE|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
215046673|NCT01355614|DRUG|QAX576|
215046674|NCT01355614|DRUG|Infliximab|
214884406|NCT05316610|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a five-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10 girls. The organizations will work with the community partner and researchers on how to schedule the intervention over a five-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sport organizations. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Skills (20 mins), Game Time (20 mins), and The Final Score (15 mins). A variety of activity modalities are utilized to convey learning outcomes, including group and individual activities, and discussion-, writing- and movement-based activities.
214884407|NCT01495702|DRUG|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
214884408|NCT01495702|DRUG|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
215046675|NCT05609357|DEVICE|Head-up Cardiopulmonary Resuscitation|Elevate patient's head to 30 degrees by EleGARD System during cardiopulmonary resuscitation
214667629|NCT03708692|BEHAVIORAL|Group F|After general anesthesia, the time of return of the behaviors such as opening the eyes, fulfilling the orders or saying the age will be recorded and evaluated as the recovery criteria. In the postop recovery period, the patient will be subjected to mini mental state testing (MMST) and cognitive functions will be evaluated.
214667630|NCT06350162|DRUG|Serplulimab|4.5mg/kg,IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days.
215046676|NCT03894891|DRUG|Nivolumab|Nivolumab is a type of immunotherapy.
215046677|NCT03894891|DRUG|Cisplatin|Cisplatin is a chemotherapy drug.
215046678|NCT03894891|DRUG|Docetaxel|Docetaxel is a chemotherapy drug.
215046679|NCT03894891|RADIATION|Intensity-modulated radiotherapy|IMRT is definitive treatment for head and neck cancer.
214292297|NCT05519423|BEHAVIORAL|Physical Activity Incentive Program|Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
214292298|NCT00237874|DRUG|Aripiprazole|
214292299|NCT02097810|DRUG|Entrectinib|
214292300|NCT05520931|OTHER|Questionnaire and register-based data assessment|Primary data will be collected via a generic questionnaire from the two groups. Secondary data will consist of register-based socio-economic data and medical charts data collected from the Danish Health Data Authority and Denmark' Statistics.
214667631|NCT06350162|RADIATION|Chest Radiation|30Gy-45Gy/QD/3Gy
214667632|NCT02261480|OTHER|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
215046680|NCT02750969|DEVICE|Lidoderm patch (Lidocaine 5% patch)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
215046681|NCT02750969|OTHER|Tegaderm patch. (neutral patch, containing no drug)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
214292301|NCT03982823|PROCEDURE|Hand-Sewn Sleeve Gastrectomy|After laparoscopic sleeve gastrectomy, gastrectomy site is hand-sewn with 3/0 polypropylene suture and the specimen is removed transorally.
214292302|NCT03982823|PROCEDURE|Stapled Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy is performed via 60 mm linear stapler (Endo GIATM Ultra, Covidien) .
214292303|NCT02950454|OTHER|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
214667633|NCT02261480|OTHER|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
214667634|NCT03943667|DRUG|Gemcitabine|1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
214667635|NCT03943667|DRUG|Paclitaxel|80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
214667636|NCT01893788|DRUG|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
214667637|NCT01893788|DRUG|Eplerenone|50 to 100 mg daily for 48 weeks
214667638|NCT01207544|BEHAVIORAL|Fitball exercise|Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
215046682|NCT02750969|PROCEDURE|blood test- serum lidocain levels|"each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests."
214477076|NCT03958539|DEVICE|3D printed insoles for normal footware|"Imprints are low-cost, bespoke, 3D-printed orthotics designed to prevent diabetic foot ulceration by redistributing and lowering peak foot pressures. This is achieved by using different density zones designed specifically for the patient. The patient's foot shape and pressure zone are capture by a 3D imaging system. Once scanned the software automatically identifies the peak pressure zones, matches these with the correct material and stiffness (densities), fits the insole arch to the patient and generates the insole.~The imprints insole is divided into four pressure zones: heel, midfoot, metatarsal head region and toes. These zones are printed with different stiffness to account for the difference in loading between them. The design of the pressure zones is automatically matched to the shape of each individual foot with the help of the 3D scan."
214477077|NCT06818162|OTHER|normative data|Ultra sonography of ulnar nerve along its course to obtain normative values for the CSA
214884409|NCT01495702|DRUG|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
214884410|NCT01644617|DRUG|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
214884411|NCT01644617|DRUG|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
214884412|NCT01644617|DRUG|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
214884413|NCT05531656|DRUG|CT1812|Study Drug
214884414|NCT05531656|DRUG|Placebo|Non-active study drug
215046683|NCT02750969|OTHER|Hearing tests|each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
215046684|NCT00656682|BEHAVIORAL|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
215046685|NCT00656682|BEHAVIORAL|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
214884415|NCT00900419|OTHER|immunohistochemistry staining method|Laboratory test
214884416|NCT00900419|OTHER|laboratory biomarker analysis|Laboratory Test
214884417|NCT00900419|OTHER|sputum cytology|Laboratory Test
214884418|NCT00900419|PROCEDURE|biopsy|Laboratory Test
214477078|NCT06596980|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
214884419|NCT01095302|DRUG|OMBRABULIN (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
214884420|NCT01095302|DRUG|cisplatin|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
214884421|NCT01095302|DRUG|docetaxel|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
214884422|NCT04931979|DRUG|Pembrolizumab Injection [Keytruda]|Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)
214884423|NCT04931979|RADIATION|Salvage Radiation Therapy (SRT)|SRT according to standard of care (SRT with at least 66 Gy)
215046686|NCT03122938|DIETARY_SUPPLEMENT|lactoferrin-supplemented formula|Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
215046687|NCT03122938|DIETARY_SUPPLEMENT|formula without lactoferrin supplementation|Subjects consume formula without lactoferrin supplementation (\<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
215046688|NCT00120133|DRUG|Atorvastatin|
214477079|NCT06601127|DRUG|Tiprogrel|Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.
214477080|NCT06601127|DRUG|Tiprogrel|Drug: Tiprogrel and Aspirin Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.
214477081|NCT06601127|DRUG|Clopidogrel|Day 1, loading dose of Clopidogrel and loading dose of aspirin; Day 2-21, daily maintenance dose of Clopidogrel and daily maintenance dose of aspirin; D22-90: daily maintenance dose of Clopidogrel.
214477082|NCT06586970|BEHAVIORAL|Meals + RD services|Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education
214477083|NCT06586970|BEHAVIORAL|Meals + OT services|Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies
214884424|NCT03723356|DIAGNOSTIC_TEST|Siemens Biograph mMR (molecular MR)|5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,
214884425|NCT03723356|DIAGNOSTIC_TEST|fMRI|High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.
214884426|NCT03723356|DIAGNOSTIC_TEST|Diffusion Spectrum Imaging (DSI)|DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
214884427|NCT06067165|BEHAVIORAL|POET feeling|"POET is adapted from online Emotion Regulation Individual Therapy for Adolescents developed by the research group (ClinicalTrials.gov Identifier: NCT03353961).~POET is also based on the Modal model of emotion and Process model of emotion regulation that provides a framework for understanding how emotions are generated, experienced and how they can be regulated. The youth component of POET will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective support and responding to their adolescent's and their own emotions."
215046689|NCT03017105|OTHER|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
214292304|NCT02950454|OTHER|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
214477084|NCT06586970|BEHAVIORAL|Meals + RD + OT services|A combination of tailored registered dietitian and occupational therapy services will be provided
214884428|NCT06067165|BEHAVIORAL|Supportive treatment|The treatment will include educative material on mental health and self-reflection on themes such as school, family and friends. The parent component will include educative material and self reflection in how to support their adolescent.
214884429|NCT02291991|DRUG|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
214292305|NCT01482039|PROCEDURE|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
214292306|NCT01482039|PROCEDURE|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
214292307|NCT03231033|DRUG|Pioglitazone|Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
214884430|NCT02291991|DRUG|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
215046690|NCT03017105|OTHER|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
214292308|NCT03766555|PROCEDURE|Microwave ablation|Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding.
214292309|NCT03766555|PROCEDURE|Liver resection|Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen.
214292310|NCT00170053|DRUG|Sirolimus|10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
214667639|NCT01207544|BEHAVIORAL|task-oriented motor training program|Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
214884431|NCT00534950|RADIATION|5 vs 6 weekly fraction of RT|Chemotherapy
214884432|NCT01948115|DRUG|equimolar mixture of oxygen and nitrous oxide or medical air|"We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention."
214884433|NCT06281015|DIAGNOSTIC_TEST|Whole-body bone single photon emission tomography (SPECT) for detection or follow-up of bone metastasis|Cancer patients referred to fast whole-body bone for detection or follow-up of bone metastasis were retrospectively included in this study.
214884434|NCT04522726|DRUG|Weiyang Yuping Fang|Weiyang Yuping fang is a combination of the classic ancient Yuping dispersion used to prevent qi deficiency and susceptibility and Bushen Naqi granules optimized formated by Professor Shao Changrong's experience in treating chronic cough and asthma.
214884435|NCT05246670|DRUG|Palmidrol|Given PEA PO
214884436|NCT05246670|DRUG|Placebo Administration|Given PO
215046691|NCT01585402|DRUG|Etidronate|Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
215046692|NCT01585402|DEVICE|MRI Scan|Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.
215046693|NCT02805543|DEVICE|Color doppler imaging|
214884437|NCT05246670|OTHER|Quality-of-Life Assessment|Ancillary studies
215046694|NCT01287494|DRUG|Sertraline|dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
215046695|NCT06011083|DRUG|Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm|using topical ointment containing calcipotriol and betamethasone dipropionate for plaque psoriasis.
215046696|NCT06011083|DEVICE|Fractional carbon dioxide (CO2) laser|fractional CO2 laser sessions once per month for 3 months over a similar psoriatic plaque
214884438|NCT05305066|DRUG|TNFi|TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
214884439|NCT05305066|DRUG|Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
214884440|NCT05305066|DRUG|JAKi|JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
214884441|NCT03362814|DRUG|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
214884442|NCT03362814|DRUG|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
214884443|NCT03362814|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
214884444|NCT03362814|DRUG|Ribavirin 100 MG|Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 1000mg and ≥75kg = 1200mg)
214884445|NCT03362814|DRUG|Ravidasvir Placebo|Ravidasvir Placebo tablet administered orally once daily
214884446|NCT03362814|DRUG|Danoprevir Placebo|Danoprevir Placebo tablet administered orally twice daily
214884447|NCT03362814|DRUG|Ritonavir Placebo|Ritonavir Placebo tablet administered orally twice daily
214884448|NCT03362814|DRUG|Ribavirin Placebo|Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 5 tablets and ≥75kg = 6 tablets)
214884449|NCT01916525|BEHAVIORAL|Exercise based cardiac rehabilitation|The cost-effectiveness between the exercise training vs. control groups
214884450|NCT05736835|BIOLOGICAL|CVXGA|CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
214884451|NCT05532189|PROCEDURE|ACL reconstruction with BTB autograft with internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft), and the graft will be fortified by suture tape during the surgery in order to strengthen it.
214884452|NCT05532189|PROCEDURE|ACL reconstruction with BTB autograft without internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft). The graft will not be fortified by suture tape in this group. It will be used as is without any modification.
214884453|NCT05532189|OTHER|Standardized Rehabilitation Protocol|Participants will undergo a standardized rehabilitation protocol with twice weekly physical therapy
214884454|NCT05916430|DIAGNOSTIC_TEST|EarliPoint Investigational Device|Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
214884455|NCT05488964|BEHAVIORAL|Exercise|Supervised endurance training with moderate-to-high intensity 3-4 times weekly.
214884456|NCT05879991|DRUG|zongertinib (C-14)|Oral solution
214884457|NCT05879991|DRUG|zongertinib|Film-coated tablet
214884458|NCT05879991|DRUG|zongertinib (C-14)|Solution for infusion
214884459|NCT04152291|DIETARY_SUPPLEMENT|Ethyl-Eicosapentaenoic Acid (E-EPA)|3,9 grams of E-EPA (Icosapent ethyl) is added to participants' normal diet.
214884460|NCT03502460|OTHER|Operating Room Fluid Administration Lung Ultrasound|Use of lung ultrasound to limited fluid administration
215046697|NCT00553631|BIOLOGICAL|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
214292311|NCT02592785|DRUG|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
214292312|NCT00569699|DRUG|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25 m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
214292313|NCT04079829|OTHER|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data|No interventions
214884461|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
214884462|NCT04097145|DRUG|Optimal Medical Therapy|Optimal Medical Therapy alone in patients with tricuspid regurgitation
214884463|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT
214884464|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
215046698|NCT00553631|BIOLOGICAL|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
215046699|NCT00682149|DIETARY_SUPPLEMENT|PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)|1 tablet/day for 3 months
215046700|NCT02761642|DRUG|Epoetin Beta|All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
215046701|NCT00820547|BIOLOGICAL|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
215046702|NCT00820547|DRUG|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
215046703|NCT00820547|DRUG|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
214884465|NCT02463266|BEHAVIORAL|SUSTAIN Monitoring and Care Management|Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
214884466|NCT06279572|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884467|NCT06279572|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
215046704|NCT00820547|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
215046705|NCT00820547|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
215046706|NCT05845112|DIAGNOSTIC_TEST|Molecular Diagnostics|pooled sputum samples will be used at the site of sample collection on the EDGE platform using Xpert ULTRA cartridges
215046707|NCT05845112|DIAGNOSTIC_TEST|Qualitative C-Reactive Protein (CRP)|CRP qualitative (POC) rapid tests are immunochromatographic based assays for qualitative or semiquantitative determination of CRP circulating in blood, serum or plasma at the Point of Care with a time to result in 5 minutes.
215046708|NCT05845112|DIAGNOSTIC_TEST|Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP|CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.
214292314|NCT06346990|OTHER|Holy Quran Recital|Holy Quran recital for four days. Typically, the second, third, fourth- and fifth-days following CABG. The daily sessions were done at 2 PM and 8 PM for 20 minutes each
214884468|NCT06279572|OTHER|Electronic Health Record Review|Medical records are reviewed
214884469|NCT05992415|OTHER|Virtual Automated Navigator Intervention with Health Education|Consented participants referred for follow-up to in-office appointments from the 10 developments randomized to the Virtual Automated Navigator Intervention with Health Education Arm will receive text messaging support via REDCAP with all aspects of follow-up appointments at either Columbia University Irving Medical Center or Harlem Hospital, specifically appointment scheduling and education about hypertension and/or glaucoma/suspect over a 1 year period.
214884470|NCT05992415|OTHER|Usual Care|Consented participants referred for follow-up to in-office appointments from the 4 developments randomized to the Usual Care Arm will only be scheduled for their initial appointments at either Columbia University Irving Medical Center or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1 year period.
214884471|NCT06294392|BEHAVIORAL|KEEP-CK|The KEEP-CK model focuses on optimizing the role of kinship parents as the agents of positive change for children and youth. KEEP-CK groups for kinship parents are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-12 kinship parents attends each week. Each KEEP-CK group follows a manualized curriculum that emphasizes tailoring the content to the unique needs and cultures of the parent in the group and the youth in their care. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting. The key services connection elements of the model include: (a) parent discussions of services they are using or have used and (b) KEEP-CK group leaders share examples from a list of statewide and national services.
214884472|NCT05382559|DRUG|ASP3082|Intravenous Infusion
214292315|NCT02622542|DEVICE|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
214292316|NCT02622542|OTHER|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
214884473|NCT05382559|DRUG|Cetuximab|Intravenous Infusion
214884474|NCT05382559|DRUG|Leucovorin|Intravenous Infusion
214884475|NCT05382559|DRUG|Oxaplatin|Intravenous Infusion
214884476|NCT05382559|DRUG|Fluorouracil|Intravenous Infusion
214884477|NCT05382559|DRUG|Irinotecan|Intravenous Infusion
214884478|NCT05382559|DRUG|Nanoparticle albumin-bound-paclitaxel|Intravenous Infusion
214884479|NCT05382559|DRUG|Gemcitabine|Intravenous Infusion
214292317|NCT05016921|DEVICE|TcMS|Transcutaneous magnetic stimulation targeting the stellate ganglion
214884480|NCT05382559|DRUG|Docetaxel|Intravenous Infusion
214884481|NCT05382559|DRUG|Pembrolizumab|Intravenous Infusion
214884482|NCT05382559|DRUG|Cisplatin|Intravenous Infusion
214884483|NCT05382559|DRUG|Carboplatin|Intravenous Infusion
214884484|NCT05382559|DRUG|Pemetrexed|Intravenous Infusion
214884485|NCT05024552|DRUG|Gilteritinib|Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation
214884486|NCT05024552|DRUG|Vyxeos|Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.
215046709|NCT05845112|DIAGNOSTIC_TEST|Urine lateral flow tests|The assay combines a pair of high affinity monoclonal antibodies directed towards largely Mycobacterium tuberculosis-specific lipoarabinomannan epitopes and a silver-amplification step that increases the visibility of test and control lines. This enables the detection of urinary lipoarabinomannan concentrations that are approximately 30 times lower than that detected by a previous test called AlereLAM and improved analytical specificity compared with AlereLAM.
214884487|NCT05696626|DRUG|Lasofoxifene in combination with abemaciclib|5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
214292318|NCT06013540|COMBINATION_PRODUCT|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)
214292319|NCT06013540|COMBINATION_PRODUCT|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
214292320|NCT01863212|PROCEDURE|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
214884488|NCT05696626|DRUG|Fulvestrant in combination with abemaciclib|Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
215046710|NCT05845112|DIAGNOSTIC_TEST|Portable Chest X Ray Image Acquisition|Qure.ai (Qure.ai, New York, USA) is a computer aided detection (CAD) software for the automated screening of tuberculosis. Qure.ai is a mobile based interpretation software that screens chest X-Ray to detect TB in less than a minute. Qure.ai can distinguish abnormal scans from normal and detect abnormalities in the lungs, pleura, mediastinum, bones, diaphragm, and heart.
215046711|NCT00950651|DRUG|Tramadol HCl Contramid® Once A Day|The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
215046712|NCT00950651|DRUG|Tramadol HCl Twice a day|The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
215046713|NCT00209937|DRUG|Gaboxadol|
215046714|NCT02453893|DRUG|Iloperidone|
215046715|NCT02453893|DRUG|Risperidone|
215046716|NCT02184676|BIOLOGICAL|Analysis of early immune modifications|"* blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)~* cord blood sampling~* stool sampling in mothers and newborns at birth (day 7)~* blood and stool sampling in children at the age of 8, 18, 30 and 42 months"
215046717|NCT02184676|OTHER|Collection of clinical and socio-demographic data|"1. Questionnaire filled in by clinicians at enrollment and at birth~2. Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42"
214667640|NCT02229994|OTHER|Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.|"Evaluation will be performed on a group of 200 patients deriving from 4 samples.~* From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).~* From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment."
214667641|NCT01612793|DEVICE|AlphaCore Device|multiple stimulation treatments per day for duration of hospitalization
214667642|NCT06512857|OTHER|Hand puppet method|Children in the experimental group were shown a hand puppet to distract them during the skin test for allergy.
214667643|NCT06512857|OTHER|Kaleidoscope method|Children in the other experimental group were look at kaleidoscope to distract them during the skin test for allergy.
214667644|NCT03806569|BEHAVIORAL|MAC-cbt group treatment for adult ADHD|Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.
214884489|NCT06567912|BEHAVIORAL|TEE simulation curriculum|The curriculum comprised of one-hour lecture and 3-hour hands-on training on a simulation model.
214884490|NCT04444921|DRUG|Carboplatin|Given IV
214884491|NCT04444921|BIOLOGICAL|Nivolumab|Given IV
214884492|NCT04444921|DRUG|Paclitaxel|Given IV
214884493|NCT06965413|DRUG|RO7204239|RO7204239 or matching placebo will be administered as per the schedule specified in the arms.
214884494|NCT06965413|DRUG|RO7204239 Matching Placebo|RO7204239 matching placebo will be administered as per the schedule specified in the arm.
214884495|NCT06965413|DRUG|Tirzepatide|Tirzepatide will be administered as per the schedule specified in the arms.
215046718|NCT05345548|DIAGNOSTIC_TEST|Cold Pressor test|Cold Pressor test will be done for 3 minute duration maximum
215046719|NCT00298636|DRUG|adenosine|
215046720|NCT03678545|DRUG|Dupilumab (blinded)|Subcutaneous injection every two weeks as follows: 600 mg initial dose, and 300 mg subsequent doses for a total of 6 injections.
215046721|NCT03678545|DRUG|Placebo (blinded)|Placebo is matched to the active drug (dupilumab), and is given in the same manner: a subcutaneous injection every two weeks for a total of 6 injections.
215046722|NCT03678545|DRUG|Dupilumab (open-label)|After completing 6 doses of blinded study drug (dupilumab or placebo), participants can continue into the open-label portion of the study, in which all subjects will receive 12 doses (every 2 weeks for 24 weeks) of dupilumab.
215046723|NCT00368030|DRUG|Eszopiclone|Eszopiclone 3 mg QD
215046724|NCT00368030|OTHER|Placebo|Placebo tablet
214292321|NCT01863212|BEHAVIORAL|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
214292322|NCT01863212|OTHER|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
214292323|NCT04996888|DEVICE|AI based preoperative automatic reminder system|the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time. The system is an non-invasive AI system.
215046725|NCT00411424|DRUG|ASK8007|IV
215046726|NCT00411424|DRUG|Placebo|IV
215046727|NCT05922605|DRUG|S-ketamine & Ropivacaine|The experiment group (Group E) will receive a mixture of ropivacaine 0.2% 0.7 ml／kg and preservative-free S-ketamine 0.5 mg/kg caudally for postoperative analgesia.
215046728|NCT05922605|DRUG|Ropivacaine|The experiment group (Group C) will receive ropivacaine 0.2% 0.7 ml／kg plain and equial volume saline caudally for postoperative analgesia.
215046729|NCT05486390|BEHAVIORAL|Nudge, health coaching and shared decision-making|"The EMPOWER app aims to nudge the participant towards successful self-management of their diabetes condition by encouraging and reinforcing positive lifestyle behaviors in 3 main aspects - diet, physical activity, medication adherence. Notifications included content based on behavioural change technique including feedback on performance, positive reinforcement, and prompts to self-monitor. Each notification focused on a single behaviour (physical activity, medication adherence or diet).~The participants in the intervention group will also interact with health coach throughout the study duration. In this study, the health coach will be responsible for the following roles :~1. Goal setting and action plan~2. After-visit summary~A report card summarizing the lifestyle behaviour, goals will be made available to facilitate shared decision making."
215046730|NCT01111643|DEVICE|Echocardiogram|An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
214667645|NCT03806569|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson in 8 sessions
215046731|NCT06104137|OTHER|course (MOOC) patient education|this is a massive open online course created by us for patient education. Patients will be given a login and password to access the MOOC from their own computer. The MOOC has 3.5 hours of content and patients will be given 3 weeks to complete.
215046732|NCT06104137|OTHER|standard patient consent process|standard consenting and shared decision making in the clinic
215046733|NCT04249401|DRUG|Rivaroxaban (Xarelto)|NOAC, reduced dose
215046734|NCT04249401|DRUG|Apixaban|NOAC, reduced dose
215046735|NCT04249401|DRUG|Dabigatran|NOAC, reduced dose
215046736|NCT04249401|DRUG|Warfarin|VKA
215046737|NCT00159926|PROCEDURE|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
215046738|NCT00159926|PROCEDURE|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
215046739|NCT01060943|DEVICE|KOKEN|"atelocollagen filler~1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year."
215046740|NCT01060943|DEVICE|Atelocollagen Filler|1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
215046741|NCT06230484|DEVICE|Invisalign first palatal expander|Most recently, a new design of a removable expander by Align was brought to our attention. In this prospective clinical study, the investigators will compare the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions. With this study, the investigators will have a better understanding of this newly developed appliance and its application in early orthodontic treatment.
215046742|NCT06230484|DEVICE|Conventional rapid maxillary expansion|Malocclusions with narrow upper arches are usually treated in the mixed dentition with a traditional bonded maxillary expander.
215046743|NCT02774434|DEVICE|JM-105|Measurement of TcB via the JM-105 device
215046744|NCT04645173|DEVICE|CIED envelope|Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.
215046745|NCT05173376|BEHAVIORAL|Portion size manipulation|The intervention was administered via changing portion sizes of foods served to participants.
215046746|NCT01597726|DRUG|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D\&E, repeated once 3 hours after the first dose if needed
214667646|NCT03705494|OTHER|Home-based peer counselling (web-based) intervention|The intervention consists of 5-6 home based visits (web-based) over 6 months by trained peer counsellors who will focus on breastfeeding among mothers who have already decided to breastfeed and are interested in this programme.
215046747|NCT01597726|DEVICE|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D\&E
215046748|NCT02099084|DRUG|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
215046749|NCT02099084|DRUG|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
215046750|NCT00235222|DRUG|stavudine|
215046751|NCT06185426|DRUG|Methyprednisolon and low level laser theraphy|All rats will be anesthetized with ketamine hydrochloride at a dose of 50 mg/kg (i.p) (Ketalar ®, Eczacıbaşı Parke-Davis, İstanbul, Türkiye) and Xylazine HCl (Alfazyne ®, Alfasan International B.V. Woerden, Hollanda) at a dose of 10 mg/kg (intraperitoneal). A right postauricular incision will made under general anesthesia, and an external trunk of the facial nerve will be found. In the DCG and other experimental groups, the facial nerve was dissected, and it will be clamped with an average force of 150 g for about 1 minute. Afterward, the surgical area will be sutured in all rats in the DCG, L, S, and LSG groups. At the end of the 4 weeks of study, tissue samples will be taken from the facial nerve trunk in the control and experimental groups with a second surgical procedure preserved in formalin solution and sent for histopathological and biochemical examination.
215046752|NCT00997789|DRUG|Rebamide|Rebamipide 100 mg Tablet, three times a day
215046753|NCT01205503|DRUG|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
215046754|NCT01205503|DRUG|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
215046755|NCT01205503|DRUG|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
215046756|NCT01205503|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
215046757|NCT05278026|OTHER|guideline recommended routine treatment|
215046758|NCT02365181|PROCEDURE|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
215046759|NCT02365181|PROCEDURE|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
215046760|NCT02365181|DRUG|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
215046761|NCT05850143|DRUG|Dexamethasone|Oral Dexamethasone a longer and potent corticosteroid with lesser sideffects and good compliance
215046762|NCT05850143|DRUG|Prednisolone|Oral Multidose Prednisolone
215046763|NCT04305977|BEHAVIORAL|WAVE-TW|The WAVE-TW open pilot trial of the intervention consists of 5 sessions conducted individually with each part participant. Each session lasts approximately 30-50 minutes. The first session will be the LifeSteps Adherence session that focuses on cognitive-behavioral and problem-solving techniques to promote adherence. The next four sessions will be dedicated to trauma writing.
214667647|NCT06468579|DRUG|GT20029|Stage 1: GT20029 gel single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
214884496|NCT06491680|DRUG|Dapagliflozin 10mg Tab|"Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.~taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose."
214884497|NCT05672576|DRUG|Cenerimod|Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.
214884498|NCT05672576|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
214884499|NCT04897009|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
215046764|NCT06160141|OTHER|Resistance training|"Resistance training program. The RT program was performed over 48 weeks, three times per week (Mondays, Wednesdays, and Fridays), during the morning, in the University fitness facility. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise) with substantial RT experience to ensure consistent and safe exercise performance.~Participants performed four exercises for the trunk and upper limbs and four exercises for the lower limbs in three sets of 8-12 repetitions. T Rest intervals were 1-2 and 2-3 min between sets and exercises. The training load was individually adjusted for each exercise weekly, according to the number of repetitions performed during the last training session, to ensure that the subjects kept performing at the ideal intensity for the repetition zone. In these situations, training loads were increased by 2-5% for upper-limb exercises and 5-10% for lower-limb exercises."
215046765|NCT06307847|DRUG|SP5M001 inj|pre-filled syringe
215046766|NCT06307847|DRUG|Synovian inj|pre-filled syringe
214667648|NCT06468579|DRUG|GT20029 matching placebo|Stage 1: GT20029 gel matching placebo single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution matching placebo multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
214667649|NCT02101606|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
215046767|NCT05074017|DEVICE|3 nasopharyngeal swab|3 nasopharyngeal swabs to conduct 2 rapid antigen tests for SARS-CoV-2 and a RT-PCR
215046768|NCT02356536|DEVICE|Agilitas|WCD trial
215046769|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide test|Collagen peptides from bovine skin with an average molecular weight of approx. 2,000 g/mol. Average particle size is about 150 μm.
215046770|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide placebo|collagen peptide placebo
215046771|NCT04379154|DEVICE|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air by electronic noses
215046772|NCT01344798|BIOLOGICAL|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
215046773|NCT04530201|DEVICE|Colli-Pee Small Volumes (10 mL) device|Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.
215046774|NCT01999933|RADIATION|Radiation|Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
215046775|NCT01999933|DRUG|cisplatin（DDP） weekly|concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
215046776|NCT01999933|DRUG|docetaxel plus cisplatin|concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
215046777|NCT01999933|DRUG|docetaxel plus cisplatin|adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
215046778|NCT03159182|DEVICE|Pressure garment and silicone insert|Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
215046779|NCT03159182|DEVICE|Pressure garment|Custom made fabric pressure garment
215046780|NCT00429754|DRUG|Aprepitant|
215046781|NCT00921726|DRUG|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
215046782|NCT00921726|DRUG|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
215046783|NCT05924139|DIETARY_SUPPLEMENT|Omega-3 fatty acid|6 capsules per day of 3840 mg that included 1950 mg EPA and 1350 mg DHA
215046784|NCT05924139|DIETARY_SUPPLEMENT|Placebo|4 capsules per day of coconut oil
214884500|NCT00370240|DRUG|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
214884501|NCT00370240|OTHER|placebo|The PCB group received saline solution in equal volume.
214884502|NCT05565482|BEHAVIORAL|Work Chat: An Interactive Virtual Workday|Study participants will receive Standard Transition Services plus Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
214884503|NCT05124691|COMBINATION_PRODUCT|Albendazole and Ivermectin fixed dose coformulation|400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin
214884504|NCT05124691|DRUG|Albendazole|Albendazole 400mg single dose
214884505|NCT05567367|COMBINATION_PRODUCT|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
215046785|NCT02172391|DRUG|Tiotropium inhalation powder capsules|
215046786|NCT02172391|DRUG|Placebo inhalation powder capsules|
214292324|NCT03966001|OTHER|Transvaginal sonography at six months after cesarean section|In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
214884506|NCT05567367|DRUG|Vardenafil Oral Tablet|20 mg oral vardenafil tablet.
215046787|NCT06093464|OTHER|Natural Compound A (Hinoki essential oil)|"Participants will use Natural Compound A in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
214884507|NCT05847582|BEHAVIORAL|Standard inpatient psychiatric care|All participants involved in this study will receive standard of care treatment at Duke University Medical Center's Behavioral Health Inpatient Program.
214667650|NCT02199522|PROCEDURE|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
214667651|NCT05640986|BEHAVIORAL|BART-EEG at V1 + V2|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 + V2 for Parkinsonian patients
214667652|NCT05640986|BEHAVIORAL|BART-EEG at V1 only|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 only for healthy volunteers
214667653|NCT05986344|DEVICE|Copper intrauterine contraceptive device|copper T-380 IUD
214667654|NCT05986344|DEVICE|LNG-IUS|Levonorgestrel Intrauterine System
214667655|NCT03551418|BEHAVIORAL|Watching a video|Watching a video of an adult with DS washing his hands
214667656|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
214667657|NCT04795804|DIETARY_SUPPLEMENT|Maltodextrin|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
214667658|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide and resistant starch|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
214884508|NCT05847582|BEHAVIORAL|Inpatient Skills Training|Inpatient skills training will be completed while participants are receiving inpatient treatment at BHIP. Skills training includes content designed to improve emotional regulation skills.
214667659|NCT03704051|BEHAVIORAL|Mode of Feeding (breastfeeding versus bottle-feeding)|Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
214667660|NCT02385695|PROCEDURE|Posterior Dynamic Stabilization|
214667661|NCT02385695|PROCEDURE|Internal Fixation and Fusion|
214884509|NCT05847582|BEHAVIORAL|mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)|mSTARS includes inpatient skills training and a mobile health (mHealth) telephone app designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.
214884510|NCT06252948|OTHER|Non-interventional study (observational)|Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
214884511|NCT04724941|OTHER|No intervention|No intervention
214667662|NCT01712386|DIETARY_SUPPLEMENT|Beetroot|
214667663|NCT01712386|DIETARY_SUPPLEMENT|Beetroot placebo|
214884512|NCT05888805|OTHER|DIMS spectacle lens|DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
214884513|NCT03509467|BEHAVIORAL|Personalized Information|Personalized information about ways that participants can protect themselves and their child from developing melanoma.
214884514|NCT03509467|BEHAVIORAL|Standard Information|Standard information about ways that participants can protect themselves and their child from developing melanoma.
214884515|NCT03509467|OTHER|DNA Extraction Determination of MC1R Genotypes|After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
214884516|NCT05271630|OTHER|Autologous Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT
214884517|NCT05271630|DRUG|Immunomodulatory Agent|ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
214884518|NCT05271630|DRUG|Proteasome Inhibitor|ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
214292325|NCT03966001|OTHER|Transvaginal sonography at twelve months after cesarean section|In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
214292326|NCT04123054|DEVICE|Mobile App|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator.
214292327|NCT04123054|DEVICE|Mobile App + Basal-Bolus Optimization Algorithm|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator. In addition, participants will receive weekly app notifications with personalized recommendations for insulin parameter adjustments made by the optimization algorithm.
214292328|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation B|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214292329|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation C|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214292330|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation A|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214667664|NCT05409885|OTHER|General anesthesia|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
214667665|NCT05409885|OTHER|Spinal anesthesia|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
214667666|NCT03170336|DRUG|Amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
214667667|NCT03170336|DRUG|Hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
214884519|NCT05240209|OTHER|The researcher will give training to the training group about skin cancer, skin self-examination and sun protection behaviors.|Materials used in education; Colorful brochures on the subject will be given to reinforce the slide show and post-training information.
214884520|NCT02829918|DRUG|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
214884521|NCT06970106|DRUG|PYC-001|PYC-001 is a peptide-phosphorodiamidate morpholino oligonucleotide administered intravitreally
214292331|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation D|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214292332|NCT03958799|BIOLOGICAL|Licensed Tdap vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214292333|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
214667668|NCT06442709|DRUG|Tocilizumab Asprin|"Tocilizumab alone, Asprin alone, Tocilizumab combined with Asprin. Tocilizumab, an IL6R inhibitor, injected once a month at a dose of 4mg/kg in advanced NPC patients.~Asprin，an anticoagulant, taken orally once daily at a dose of 100mg in advanced NPC patients."
214667669|NCT06442709|OTHER|Placebo|Placebo replaces tocilizumab and asprin in advanced NPC patients.
214884522|NCT06821568|OTHER|Personalized Transcranial Direct Current Stimulation (tDCS)|Home-based transcranial direct current stimulation (tDCS) tailored to target the left dlPFC.
214884523|NCT06821568|OTHER|Active-Sham|Stimulation administered in very low-level currents (0.5 mA total) designed to not significantly influence cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
214884524|NCT05087212|DRUG|plerixafor + G-CSF|subcutaneous (SC) injection
214884525|NCT05114096|DRUG|Celestone + placebo|"After the first intramuscular injection of Celestone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
214884526|NCT05114096|DRUG|Celestone + Celestone|"After the first intramuscular injection of Celestone, participants randomized to the Active Comparator group will receive 1 intramuscular injection of Celestone."
214884527|NCT04151667|DRUG|Daratumumab Injection|Patient will receive daratumumab (1800 mg in 15 ml) administered by manual subcutaneous injections weekly for the first 8 weeks, every other week for the next 16 weeks and every 4 weeks after.
214884528|NCT04151667|DRUG|Dexamethasone Oral|The dexamethasone starting dose will be 20 mg PO once a week. Commercial dexamethasone will be used. Dexamethasone is often supplied in 4 mg tablets. Accordingly, patients will take 5 (4 mg tablets) one day of the week prior to the administration of daratumumab if this corresponds to a daratumumab dosing days. In non daratumumab dosing days, dexamethasone will be taken by the patient at home, usually in the morning with breakfast.
214884529|NCT04151667|DRUG|Lenalidomide Pill|"Lenalidomide will be given orally on days 1-21 of a 28 days cycle. The starting dose of lenalidomide will be based on the patient creatinine clearance per the package insert.~Specifically patients with a creatinine clearance ≥ 50 ml/min will receive 25 mg of lenalidomide PO Days 1-21. Patients with a creatinine clearance ≥ 30 but less than 50 ml/min will receive 10 mg of lenalidomide.~Patients with a creatinine clearance \< 30 ml/min are not eligible but patients who experience a deterioration in the renal function during screening or treatment may continue on lenalidomide therapy as long as the risk / benefit profile is deemed acceptable, that study therapy is in the best interest of the patient and after discussion with the study principal investigator / sponsor."
214884530|NCT04151667|DRUG|Bortezomib Injection|Bortezomib will be given weekly subcutaneously in an effort to decrease the toxicity of the therapy. Specifically patients will receive a starting dose of bortezomib of 1.3 mg/m\^2 Days 1,8,15 of a 28 day cycle. Bortezomib will be administered in the cancer center per standard of care procedures.
214292334|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
214292335|NCT03315208|BEHAVIORAL|Unified Protocol (UP)|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.
214292336|NCT03315208|OTHER|Treatment as Usual (TAU)|Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
214292337|NCT03234751|DRUG|Continous IV infusion of Nesiritide|Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
214292338|NCT03234751|DRUG|Hyperinsulinemic euglycemic clamp|48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
214292339|NCT03234751|DRUG|Placebo|48 hours of placebo.
214292340|NCT02059460|DRUG|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
214884531|NCT05635708|DRUG|Tislelizumab|Administered by intravenous infusion
214884532|NCT05635708|DRUG|BGB-A445|Administered by intravenous infusion
214884533|NCT05635708|DRUG|LBL-007|Administered by intravenous infusion
214884534|NCT05635708|DRUG|Carboplatin|Investigator's choice; administered by intravenous infusion
214884535|NCT05635708|DRUG|Cisplatin|Investigator's choice; administered by intravenous infusion
214884536|NCT05635708|DRUG|pemetrexed|Investigator's choice; administered by intravenous infusion
214884537|NCT05635708|DRUG|Paclitaxel|Investigator's choice; administered by intravenous infusion
214884538|NCT05635708|DRUG|Nab paclitaxel|Investigator's choice; administered by intravenous infusion
214884539|NCT05635708|DRUG|BGB-15025|Administered Orally
214884540|NCT04452825|BEHAVIORAL|Cancer and Aging: Reflections for Elders (CARE) Intervention|For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
214884541|NCT04452825|BEHAVIORAL|Social Work and Supportive Counseling (SWSC) Intervention|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months). Training case participants will follow a slightly condensed schedule.
214884542|NCT05831774|DRUG|Intervention - Intraosseous (IO) administration of vancomycin|"* IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision~* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* Injection will take place into the proximal humerus"
214884543|NCT05831774|DRUG|Control - Standard IV administration of vancomycin|Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[6,7\] generally 1000-1750mg in 500mL NS).
214884544|NCT06670170|DRUG|PF-07976016 Formulation A|PF-07976016; formulation A - current/reference
214884545|NCT06670170|DRUG|PF-07976016 Formulation B|PF-07976016; Formulation B - new/test
214884546|NCT04223752|DRUG|Ceftolozane/Tazobactam|"Participants 12 to \<18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.~Participants \<12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g)."
214884547|NCT04519164|DRUG|Eplerenone|mineralocorticoid receptor antagonist and potassium-sparing diuretic
214884548|NCT04519164|DRUG|Chlorthalidone with potassium chloride|potassium-wasting diuretic with potassium chloride
214884549|NCT04759703|DRUG|Pramipexole|0.25 mg pramipexole tablets
214884550|NCT04759703|DRUG|Placebo|Matching placebo tablets
214884551|NCT04954313|DRUG|Subgingival chlorhexidine irrigation|The dose information for the Chlorhexidine gluconate will be 0.12% with 1 mL in each dental pocket at a frequency of every 3 months for the duration of the study (18 months).
214884552|NCT04954313|OTHER|Dental Supplies|Subjects in the Treatment Group will receive a commercial electric toothbrush (Colgate hum), toothpaste (Colgate Renewal), mouthwash (Colgate Zero), proxabrush (Colgate), and floss (Colgate Palmolive brand) to be used at home along with instructions on their use. Brush heads for the electric toothbrush will be replaced every 3 months and products (toothpaste, mouthwash, proxabrush, and floss) will be replenished at every site visit.
214884553|NCT04954313|OTHER|Periodonal Treatment|Initial periodontal treatment consisting of a pre-procedural rinse and scaling \& root planing (SRP).
214884554|NCT01999634|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
214884555|NCT05961839|DRUG|SGR-2921|SGR-2921 will be administered orally.
214884556|NCT06559215|DRUG|Exparel|Patients will be randomized to receive Exparel intraoperatively via local infiltration.
214884557|NCT05381909|DRUG|BGB-24714|administered orally
214884558|NCT05381909|DRUG|Paclitaxel|administered intravenously
214884559|NCT05381909|DRUG|Carboplatin|administered intravenously
214292341|NCT02059460|DRUG|placebo|
214884560|NCT05381909|DRUG|Docetaxel|administered intravenously
214884561|NCT01673412|OTHER|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
214884562|NCT06421935|DRUG|M9466|Participants will be administered M9466 orally.
214884563|NCT06421935|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
214884564|NCT06421935|DRUG|Abiraterone acetate|Participants will be administered with Abiraterone acetate orally.
214884565|NCT06421935|DRUG|Prednisone/Prednisolone|Participants will be administered with prednisone/prednisolone orally.
214884566|NCT04975555|DRUG|Siltuximab|Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.
214884567|NCT05320406|RADIATION|Radiation therapy|Undergo radiation therapy
214884568|NCT05320406|DRUG|Leuprolide|Given IM or SC
214884569|NCT05320406|DRUG|Relugolix|Given PO
214884570|NCT05810870|DRUG|MEN1611|MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.
214884571|NCT05810870|DRUG|Eribulin|Eribulin mesylate (eribulin), a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastics, suppresses microtubule growth and sequesters tubulin into nonfunctional aggregates, preventing mitotic spindle formation with subsequent G2-M stop and apoptosis.
214884572|NCT05093270|DRUG|BGB-23339|Administered orally as a tablet
214884573|NCT05093270|DRUG|Placebo|Administered orally as a tablet
214884574|NCT03985852|OTHER|Patient Directed Standard of Care|The pre-test genetic counseling visit will be conducted through access to an automated genetics education assistant accessed through the patient portal. The automated approach will address all the components of the pre-test counseling and contains content designed by the genetic counselors at the University of Utah and NYU. Patients will have the option to contact genetic counselors through the patient portal, by phone, or in person but this will not be required. All results will be reviewed by a genetic counselor. Negative results will be returned by the automated genetics education assistant. Genetic counselors will return results for pathogenic variants and variants of uncertain significance via phone.
214884575|NCT04345913|PROCEDURE|Biopsy Procedure|Undergo biopsy
214884576|NCT04345913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884577|NCT04345913|PROCEDURE|Computed Tomography|Undergo CT scan
214884578|NCT04345913|DRUG|Copanlisib Hydrochloride|Given IV
214884579|NCT04345913|DRUG|Eribulin Mesylate|Given IV
214292342|NCT01930747|DRUG|rocuronium|measure effect on laparoscopic workspace
214884580|NCT04345913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215046788|NCT06093464|OTHER|Natural Compound B (Lemon essential oil)|"Participants will use Natural Compound B in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
214292343|NCT01930747|DRUG|Sevoflurane|1 MAC sevoflurane inhalation is given
214477085|NCT06599099|DEVICE|Medtronic Percept RC System|"Medtronic Percept RC System includes:~Percept RC neurostimulator SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Extension Kit (with and without marker; 40cm, 60cm, and 95cm lengths) Percept DBS Handset and Communicator Kit (patient programmer) SenSight Extension Tunneler Kit SenSight Burr Hole Device Kit Clinician Programmer Application (application runs on Model CT900 Tablet) Percept RC Recharger Kit Recharge Application Software Clinician Communicator/Telemetry Module"
215046789|NCT06093464|OTHER|Natural Compound C (Control/Water)|"Participants will use Natural Compound C in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
215046790|NCT03175107|DEVICE|Exergaming|
214884581|NCT05686512|BEHAVIORAL|Step-by-Step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given. See Figure 1 for a schematic representation of the stepped care approach, and Table 2 for an overview of session content.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
214884582|NCT05686512|BEHAVIORAL|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (120 minutes)"
214292344|NCT01930747|DRUG|remifentanyl|remifentanyl is given in infusion
214884583|NCT03495427|DRUG|F-DCFPyL Injection|F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.
214884584|NCT03495427|DIAGNOSTIC_TEST|PSMA PET|PSMA PET imaging (for men with high GC \>0.45) will be done after 2 years post-treatment, then yearly up to 5 years.
215046791|NCT03965182|DRUG|PEG|2 sachets of PEG will be used as the bowel prep regimen.
215046792|NCT03965182|DRUG|PEG plus SPMC|one sachet of PEG and one sachet will be administered as the bowel prep regimen
215046793|NCT03965182|DRUG|SPMC|2 sachets will be administered as the bowel prep regimen.
215046794|NCT00529269|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214292345|NCT04653805|OTHER|Current clinical practice in primary care of patients with type 2 diabetes mellitus|
214292346|NCT06263751|OTHER|Product prescription program- NutriConnect Credit|Patient is given $20 credit to their Schnucks (grocery) Rewards account every other week for F\&V shopping. The Rewards credit can be used either through the Schnucks App or in store.
215046795|NCT05055076|DEVICE|PODEYE TORIC|Patients will be contacted consecutively and will be enrolled after the patient informed leaflet has been given to them and after obtaining their consent to the scientific use of their data collected retrospectively (preoperative, surgery, postoperative routine visits). Patients will only be enrolled after the routine 4-6 months visit has been performed.
215046796|NCT05361850|PROCEDURE|Extubation|Removal of the endotracheal tube
215046797|NCT00270127|DRUG|Epoetin alfa|
215046798|NCT02850978|DRUG|Spiolto|
215046799|NCT05754476|OTHER|Low-dose GBCA levels|MRI examinations for patients at two dose levels: low-dose (10% or 25%）can be chosen.
214884585|NCT06622421|DEVICE|Piezoelectric surgery|Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures
215046800|NCT03775499|DIETARY_SUPPLEMENT|Intervention 1 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
215046801|NCT03775499|OTHER|Intervention 1 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
215046802|NCT03775499|DIETARY_SUPPLEMENT|Intervention 2 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
215046803|NCT03775499|OTHER|Intervention 2 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
214884586|NCT06622421|PROCEDURE|Conventional surgery|Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures
214884587|NCT05789589|DRUG|Azeliragon|"Dosing will begin on Day 0 with the loading dose and continue daily through Day 7. Starting on Day 8, dosing will resume with the continuous dose until disease progression or 8 weeks. If there is evidence of antitumor effect at 8 weeks, dosing may continue for up 2 two years.~All doses are taken orally. There are three levels of dosing, including a starting dose and two lower levels of dosing. Participants will start with the starting dose, and in the event of the dose limiting toxicities, the dose will be reduced as described below.~Starting Dose Level: 30 mg twice daily (Loading Dose) or 20 mg once daily (Continuous Dose) Dose Level -1: 15 mg twice daily (Loading Dose) or 10 mg once daily (Continuous Dose) Dose Level -2: 15 mg once daily (Loading Dose) or 5 mg once daily (Continuous Dose)"
214884588|NCT05789589|RADIATION|Stereotactic radiosurgery|Patients will undergo standard of care SRS as per the treating facility's policies.
214884589|NCT05789589|DRUG|Corticosteroid|"Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT).~LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT)."
214884590|NCT06976060|BEHAVIORAL|High-Intensity Interval Training|High-intensity interval training (HIIT) sessions will occur twice per week, on non-consecutive days. Each training session will last 45-60 minutes and consist of eight functional movement exercises incorporating the entire body (upper body, lower body, core/stability, cycling, and agility). Participants will complete two rounds of the 8-exercise circuit with 2-minutes of rest between rounds. The load/resistance used for each exercise will be self-selected by the participants that equates to 15-18 on the RPE scale. During each round, participants will have 1 minute to complete as many repetitions as possible of a given exercise and then have 1 minute of rest before completing the next exercise - giving the participants a 1:1 exercise-to-rest ratio.
214884591|NCT06972420|BEHAVIORAL|Hypnosis session|Within the two weeks prior to surgery, in addition to the standard preoperative care currently in place, the patient will receive a 30-minute visit from a nurse anesthetist trained in hypnosis. This is an added procedure complementing the anesthesia consultation. The visit is divided into two parts: 10 minutes to review and clarify the explanations given by the anesthesiologist and surgeon, and 20 minutes of a formal hypnosis session. A personalized liaison form will be completed to facilitate communication between the consultation and the operating room.
214884592|NCT02143466|DRUG|Part A - AZD9291 in combination with AZD6094|Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.
214884593|NCT02143466|DRUG|Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.
215046804|NCT02616939|OTHER|Cardiac CT scanning (with the SpotLight CT)|Cardiac CT scanning
215046805|NCT01123226|PROCEDURE|spinal manipulation|A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
215046806|NCT01123226|PROCEDURE|trigger point therapy|The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
215046807|NCT05233124|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15mg
215046808|NCT05233124|DRUG|Acetylsalicylic acid 100mg|Acetylsalicylic acid 100mg
215046809|NCT05233124|DRUG|Clopidogrel 75 Mg Oral Tablet|Clopidogrel 75mg
215046810|NCT02404168|DRUG|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
214884594|NCT02143466|DRUG|Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.
214884595|NCT02143466|DRUG|Part A - AZD9291 in combination with intermittent selumetinib|Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
214884596|NCT02143466|DRUG|Part A - AZD9291 in combination with MEDI4736|"Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
214884597|NCT02143466|DRUG|Part B - AZD9291 in combination with AZD6094|Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
214884598|NCT02143466|DRUG|Part B - AZD9291 in combination with selumetinib|Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent \[4 days on/3 days off\]) to further investigate the safety and tolerability of this combination.
214884599|NCT02143466|DRUG|Part B - AZD9291 in combination with MEDI4736|"Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
214884600|NCT02143466|DRUG|Part C - AZD6094 monotherapy (Japan only)|Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.
215046811|NCT02404168|DRUG|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
215046812|NCT00318669|DRUG|Paroxetine hydrochloride hydrate|
215046813|NCT04906031|DRUG|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
214292347|NCT06263751|OTHER|Product prescription program- NutriConnect Delivery|Patient receives produce (F\&V) box (equivalent $20 value) delivered to home every other week. The items in the box will be pre-selected by Schnucks and the NutriConnect dieticians.
215046814|NCT05670639|BEHAVIORAL|CAPABLE Care Partner|The CAPABLE Care Partner intervention consists of three components: 1) up to 3 sessions with a Care Partner Support person focused on developing action plans for self-care goals of the care partner 2) educational materials provided in a folder at the beginning of the program 3) inclusion in the CAPABLE clinician visits as deemed appropriate by the client, CAPABLE clinicians, and care partner
215046815|NCT03754322|DIAGNOSTIC_TEST|LAMP|LAMP testing involves taking a blood specimen using venous puncture, extracting DNA and performing a commercial CE-marked LAMP malaria assay to obtain a malaria result (presence/absence of parasite DNA) at the species level
215046816|NCT03754322|DIAGNOSTIC_TEST|Microscopy/RDT|Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
215046817|NCT04157881|DRUG|RABEprazole 20 Mg Oral Delayed Release Tablet|Absorption of APO-Dabigatran measured with and without influence of rabeprazole
215046818|NCT04157881|DRUG|APO-Dabigatran 150mg|Absorption of APO-Dabigatran post single dose
215046819|NCT01197547|DEVICE|Genesys HTA|Genesys HTA Endometrial Ablation
215046820|NCT03215498|DRUG|Faster-acting insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
215046821|NCT03215498|DRUG|Insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
215046822|NCT03938818|BEHAVIORAL|Tu'Washindi intervention|"The intervention includes the following components:~1. PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~2. Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~3. Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders."
215046823|NCT03938818|OTHER|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
215046824|NCT06468787|DEVICE|Kosmos Anatomical Object Labeling and View Identification Algorithms|Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers. Algorithm's performance on the view identification task and the object labeling task is compared to majority opinion of 5 radiologists.
215046825|NCT01953211|DRUG|combined oral contraceptives|
215046826|NCT02974829|OTHER|follow-up|
215046827|NCT05325762|DRUG|Propofol|At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
215046828|NCT05325762|DRUG|Dexmedetomidine|Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
215046829|NCT05325762|DRUG|Saline|At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
215046830|NCT01936883|RADIATION|HDR|High dose rate brachytherapy
214292348|NCT00982592|DRUG|oxaliplatin|Given IV
214292349|NCT00982592|DRUG|leucovorin calcium|Given IV
214884601|NCT02143466|DRUG|Part C - AZD9291 in combination with AZD6094 (Japan only)|Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.
214884602|NCT02143466|DRUG|Part D - AZD9291 in combination with AZD6094|Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.
214884603|NCT06101264|DEVICE|Control|Control patients following spinal fusion for adolescent idiopathic scoliosis that receive no virtual reality sessions.
214884604|NCT06101264|DEVICE|Virtual Reality|Patients will undergo a 20 minute virtual reality session prior to each physical therapy session following spinal fusion for adolescent idiopathic scoliosis. Virtual reality sessions will continue until functionally cleared by physical therapy.
214884605|NCT06004804|BEHAVIORAL|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
214884606|NCT06004804|BEHAVIORAL|Mindfulness Meditation|Seeks to help individuals achieve present moment awareness, self-compassion, and acceptance of chronic pain. It will use techniques such as the body scan, grounding, mindful breathing, mindful walking, loving kindness, and compassionate breathing.
214884607|NCT06004804|BEHAVIORAL|Cognitive Behavioral Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
214884608|NCT05526885|DIAGNOSTIC_TEST|CAD4TB|A posterior anterior digital chest X-ray incoporated in a mobile diagnostic unit is analysed by CAD4TB version 7 (Delft Imaging, NL). A trained and qualified person in compliance with national regulations will operate the digital chest X-ray.
214884609|NCT05526885|DIAGNOSTIC_TEST|POC-CRP|A quantitative POC-CRP LumiraDx (LumiraDx Limited, UK) triage test will be performed by finger-prick if CAD4TB scores is within the defined threshold window of study approach 2 triage testing
214884610|NCT05526885|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra|Depending on CAD4TB (approach 1 \& 2) or POC-CRP score (approach 2) a confirmatory Xpert MTB/RIF Ultra(Cepheid, USA) rapid sputum molecular testing follows for both Mycobacterium tuberculosis complex and rifampicin resistance;
214884611|NCT05157594|BIOLOGICAL|Blood sample|Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.
214884612|NCT06456034|BEHAVIORAL|Perinatal palliative care|Intervention group will receive specialized perinatal palliative care support from moment of severe perinatal diagnosis. This intervention is aimed at 5 major care components, namely 1. Support offered by a fixed perinatal palliative care team, 2. that team has received specialized perinatal palliative care training, 3. care is structured within a new perinatal palliative care approach or pathway, including fixed means of communication with team members, 4. psychological support is structurally being offered to parents and healthcare providers, and 5. debriefings after every perinatal death are being organized in the involved team.
214884613|NCT06435286|DRUG|Proflavine Hemisulfate|Approximately 5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
214884614|NCT06435286|DEVICE|Artificial Intelligence Mobile High-Resolution Microendoscope|The AI-mHRME will be inserted through the endoscope biopsy channel and gently placed against the mucosa where proflavine was sprayed. The probe will transmit images to the computer/laptop for the clinician to observe any abnormal tissues and save photos of these tissues.
214884615|NCT06133127|OTHER|Frailty assessment|Assessments for all patients : isometric quadriceps strength, malnutrition by RFH-NPT and MNA questionnaires, body composition by circumference and triceps skinfold, frailty by LFI and SPPB, muscle cramps by Cramp questionnaire.
214292350|NCT00982592|DRUG|fluorouracil|Given IV
214884616|NCT06502366|DRUG|BDA MDI HFO 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFO
214884617|NCT06502366|DRUG|BDA MDI HFA 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFA
214884618|NCT06502366|DRUG|Placebo MDI HFA|Placebo pressurized inhalation suspension, HFA
214884619|NCT06030336|BEHAVIORAL|Home Health Report|The Home Health Report has been described in the intervention arm description.
214884620|NCT04487067|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
214292351|NCT00982592|OTHER|placebo|Given PO
214292352|NCT00982592|DRUG|vismodegib|Given PO
214292353|NCT00982592|OTHER|laboratory biomarker analysis|Correlative studies
214292354|NCT02248610|OTHER|Non-interventional study|
214292355|NCT03116607|OTHER|patient education/ recommendations to the health team|The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
214477086|NCT06599099|BEHAVIORAL|One Month Blinded Discontinuation Period|The investigators will use blinded discontinuation at 12 months rather than sham control to establish evidence that response is dependent on ongoing DBS. The open-label design allows for personalized optimization of programming settings - a strength of this design as related to our study goals. Although one of the goals of this study is to use neural recordings to inform programming, currently, unblinded programming is needed to maximize response and minimize side effects. Adverse events will be elicited at each study visit using a standardized instrument, the Patient-Rated Inventory of Side Effects (PRISE). In addition to monitoring for adverse events related to surgery and stimulation, the investigators will track quality of life (QOLS), global functioning (SDS), and necessary adjustments of medications. The behavioral changes of the subject based on these scales will provide insight to the intervention levels provided from discontinuing the therapy from the device.
214477087|NCT04265807|DEVICE|Active Remote Ischemic Conditioning|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on a upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
214477088|NCT04265807|DEVICE|Sham Remote Ischemic Conditioning|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
214477089|NCT00412607|DEVICE|NAVISTAR® THERMOCOOL® Catheter|The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
214884621|NCT04487067|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV Q3W
214884622|NCT04877457|DRUG|Ocrelizumab|The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.
214884623|NCT04877457|OTHER|Placebo|Placebo will be administered at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given at Weeks 24 and 48.
214884624|NCT06116630|DIAGNOSTIC_TEST|DCE-MRI|Both groups will undergo DCE-MRIs.
214884625|NCT03852732|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
214884626|NCT03905577|BEHAVIORAL|Action Observation|Action Observation training
214884627|NCT03905577|BEHAVIORAL|Motor imagery|Motor imagery protocol
214884628|NCT03905577|BEHAVIORAL|Placebo Action observation|Placebo Action Observation
214884629|NCT03924687|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) bibliotherapy for chronic pain|"The intervention consisted of the book Libérez-vous de la douleur par la méditation et l'ACT (Dionne, 2014) and a participant workbook, along with two phone calls of approximately 15 minutes each and weekly e-mails presenting the week's content. Participants also had access to audio meditation exercises on the book's website (http://liberezvousdeladouleur.com/meditations/)."
214884630|NCT05746832|PROCEDURE|Endoscopic stenting Retrograde Cholangiopancreatography (ERCP)|Assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large \[≥ 20 mm\] or multiple \[≥ 3 sized ≥ 15 mm\] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
214884631|NCT06805305|BIOLOGICAL|DOC1021|Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method
214884632|NCT06805305|PROCEDURE|Tumor resection|SOC brain tumor resection
214884633|NCT06805305|DRUG|Temodar (Temozolomide)|SOC concomitant temozolomide during radiation and adjuvant temozolomide after radiation
214884634|NCT06805305|RADIATION|SOC cranial radiation|60Gy radiation over 6 weeks in 2Gy fractions
214884635|NCT05870059|DRUG|Propolis mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use 5ml of propolis mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
214884636|NCT05870059|DRUG|Chlorhexidine mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use chlorhexidine mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
214884637|NCT00769587|DRUG|thalidomide|
214884638|NCT03153475|DEVICE|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
214884639|NCT03709043|DRUG|Standardized kudzu|Standardized kudzu
214884640|NCT03709043|OTHER|Placebo|Placebo
215046831|NCT01936883|RADIATION|LDR|Low dose rate brachytherapy boost
215046832|NCT02669589|DRUG|Heparin|
215046833|NCT02669589|DRUG|Citrate|
215046834|NCT04161690|DRUG|Dexketoprofen Trometamol|intravenous dexketoprofen 50mg or intrathecal
215046835|NCT04161690|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|Local Infiltration Analgesia
215046836|NCT02307448|PROCEDURE|Platelet Rich Plasma|Patients will receive weekly PRP treatments with standard of care.
215046837|NCT02307448|PROCEDURE|Standard of Care|Patients will receive weekly standard of care.
215046838|NCT01842373|DRUG|LMX4|
215046839|NCT01842373|DRUG|BLT|
214667670|NCT03990662|OTHER|Physiotherapy - Manual Therapy|Participants will receive four sessions of manual therapy applied to craniomandibular structures over four weeks. The application of manual therapy aims to decrease pain by treating masticatory muscle trigger points, muscle tightness, and restricted temporomandibular joint movements. Several techniques will be considered, including ventral and caudal anterior glide temporomandibular joint mobilisation, soft tissue interventions for the management of trigger points in masticatory muscles and myofascial induction therapy applied to craniomandibular structures. The structures targeted in the treatment sessions will be the temporomandibular joint, temporal muscles, masseter muscles, medial and lateral pterygoid muscles and suprahyoid muscles.
214884641|NCT03709043|DIAGNOSTIC_TEST|Sexually transmitted infection testing:|At baseline and month 3 visits, all participants will be tested for syphilis (serum RPR), Neisseria gonorrhea and Chlamydia trachomatis (urine, pharyngeal swab, and rectal swab nucleic acid amplification \[NAAT\]) through an established protocol that has been validated by our Public Health Laboratory (PHL) and others.145-149
214667671|NCT06047691|BEHAVIORAL|Abbreviated, Intensive, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy for PTSD|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format. Couples are provided with psychoeducation about PTSD and relationship functioning and are taught cognitive and behavioral skills to address the manifestation of PTSD in the couple relationship. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and once 1-2 weeks after the retreat.
214667672|NCT06047691|BEHAVIORAL|Prevention and Relationship Education Program|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format.The content of PREP and workshop experiences focuses on helping couples communicate effectively, manage conflict without harming their relationship, preserve and act on commitment, improve relationship decision-making, increase understanding of differences between partners, and protect positive connections between partners. Approximately 12 hours of PREP content will be delivered over 2 consecutive days in a multi-couple group retreat format. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and will check in with a member of the study staff 1-2 weeks after the retreat.
214292356|NCT03128346|PROCEDURE|Transthoracic Transversus Plane Block|The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
214292357|NCT03128346|DRUG|Hydromorphone Hydrochloride|IV, Hydromorphone
215046840|NCT03188263|OTHER|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
215046841|NCT03188263|OTHER|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
215046842|NCT00407719|DRUG|Bevacizumab|
215046843|NCT01778998|PROCEDURE|MICS-group|Micro incision cataract surgery is done
215046844|NCT01778998|PROCEDURE|SICS-group|small incision cataract surgery is done
215046845|NCT01778998|PROCEDURE|SICS pre-cut|Small incision cataract surgery with pre-cut is done
215046846|NCT01778998|PROCEDURE|SICS stab-incision|Small incision cataract surgery with stab-incision is done
215046847|NCT01664754|DRUG|exemestane|Given PO
215046848|NCT01664754|DRUG|pemetrexed disodium|Given IV
215046849|NCT01664754|DRUG|carboplatin|Given IV
215046850|NCT01664754|OTHER|laboratory biomarker analysis|Correlative studies
215046851|NCT01664754|OTHER|pharmacological study|Correlative studies
215046852|NCT01664754|OTHER|questionnaire administration|Ancillary studies
215046853|NCT01664754|PROCEDURE|quality-of-life assessment|Ancillary studies
215046854|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
215046855|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
215046856|NCT06312189|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
215046857|NCT05152251|OTHER|Evaluation|Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.
215046858|NCT00296218|DRUG|Irbesartan|
215046859|NCT00539240|DRUG|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
215046860|NCT00539240|DRUG|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast \& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
215046861|NCT00539240|DRUG|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
215046862|NCT05820048|DRUG|Lansoprazole 15 mg|"1. Short-term treatment of active duodenal ulcer~2. Short-term treatment of active benign gastric ulcers~3. Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~4. Maintain duodenal ulcer after treatmentLaw~5. Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~6. Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~7. Short-term treatment of gastroesophageal reflux disease~8. Short-term treatment of erosive reflux esophagitis~9. Post-treatment maintenance therapy for erosive reflux esophagitis~10. Pathological hyperdivision, including Zolinger Ellison syndrome"
215046863|NCT06167577|DIAGNOSTIC_TEST|Psychometric scales (BPRS, MRS, HAM-D, SES, and GAF) monthly|we will correlate the clinical/neuropsychological response to antipsychotics with the presence of the functional DysBray haplotype of the DTNBP1 gene
215046864|NCT01628523|OTHER|For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.|Mechanical ventilation via an endotracheal tube or tracheostomy tube
215046865|NCT00325507|BIOLOGICAL|TroVax|TroVax 1 x 10E9 TCID 50mL
215046866|NCT00325507|DRUG|IL-2|IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
215046867|NCT04831905|DEVICE|Micro-wave ablation|Micro-wave ablation
214292358|NCT03128346|DRUG|Aspirin|Oral Aspirin
214292359|NCT03128346|DRUG|Acetaminophen|Oral acetaminophen
214477090|NCT06878014|PROCEDURE|Spinal Anesthesia (bupivacaine)|Patients were positioned in sitting position on operating table, interspinous space was identified using anatomical landmarks (intercristal line) and palpation. Entire procedure was conducted with aseptic technique, puncture site was prepared with izopropyl alcohol solution. Skin was anesthetized with subcutaneous injection of 1% lidocaine. Spinal puncture was achieved using median or paramedian technique with 27G pencil-point spinal needle. After confirmation of free flow of cerebrospinal fluid 15 mg of 0,5% bupivacaine was administered intrathecaly. Block level was assessed by lack of sensation to alcohol swab in periumbilical area and complete motor block (Bromage 3).
214477091|NCT06878014|DRUG|Postoperative pain management with acetaminophen|Postoperatively patients received 1,0g of paracetamol every 6 hours,
214477092|NCT06878014|DEVICE|PCA IV Oxycodone|All patients were equipped with PCA capable syringe pump (Perfusor Space, B. Braun) with 40 milligrams of oxycodone. Care provider explained thoroughly how to operate the device and educated about possible adverse effects.
214477093|NCT06878014|DRUG|Postoperative pain management with dexketoprofen|Postoperatively patients received 50mg of dexketoprofen intravenously every 8 hours.
214884642|NCT03709043|BEHAVIORAL|Medical Management (MM) counseling for alcohol use:|MM has been used in a targeted pharmacotherapy trial98 and our team has successfully used MM in AUD trials. MM is a low-intensity supportive program designed to increase problem recognition and enhance motivation to change maladaptive alcohol use patterns. Participants will receive individual 20 minute MM sessions weekly from trained staff supervised by a clinical psychologist.
214884643|NCT03709043|DIAGNOSTIC_TEST|Urinalysis for novel alcohol biochemical markers for recent alcohol use:|Urine samples will be collected at Enrollment, Month 1, Month 2 and Month 3 visits and tested for ethyl glucuronide (EtG) to determine recent alcohol consumption in the past three days. EtG is a relatively novel, highly sensitive indicator for recent alcohol consumption; this alcohol biomarker is detectable in urine for approximately 72 hours.
214884644|NCT03709043|DIAGNOSTIC_TEST|Dried Blood Spot (DBS) Testing for PEth:|DBS samples will be collected at enrollment, weeks 12, and post-treatment visits at month 3. Samples will be dried overnight using standardized methods. PEth testing of DBS samples will be conducted at the United States Drug Testing Laboratories in Des Plaines, IL using liquid chromatography-tandem mass spectrometry system following extraction into methanol.
214884645|NCT03709043|BEHAVIORAL|Behavioral survey measurements:|Standardized and validated behavioral measures will be assessed using audio computer administered surveys (ACASI) to minimize underreporting of risk activities and standardize data collection.152,153 To minimize potential social desirability bias, staff will not have access to data during the trial. The draft of the ACASI survey instrument is included in the appendix.
214884646|NCT03709043|BEHAVIORAL|Ecological Momentary Assessment procedure:|Participants will receive daily SMS texts to collect data on alcohol consumption, number of drinks on drinking days, targeted medication administration prior to anticipated drinking sessions, and sexual risk behaviors
215046868|NCT04539834|OTHER|electrolytes|measuring level of electrolytes
214292360|NCT03128346|DRUG|Fentanyl|IV, fentanyl
214292361|NCT00276159|DRUG|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
214477094|NCT06878014|DRUG|Postoperative pain management with metamizole|Postoperatively patients received 1,0g of metamizole intravenously every 6 hours.
214667678|NCT06513598|PROCEDURE|Major visceral surgery for gastrointestinal cancer|This is a longitudinal observational study of the patients undergoing major visceral surgery for gastrointestinal cancer. Biological samples will be collected to compare gastrointestinal and infection site metastases and develop biomarkers for postoperative infections.
214667679|NCT04640597|DEVICE|BioMimics 3D Vascular Stent System|Patients with BioMimics 3D Vascular Stent System
214292362|NCT04356690|DRUG|Etoposide|Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.
214667680|NCT02629393|DRUG|ORGN001 (formerly ALXN1101)|
214667681|NCT02060825|DEVICE|Regional saturation monitor|
214884647|NCT05930561|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.
214884648|NCT05930561|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator
214884649|NCT05532150|PROCEDURE|Arthroscopic Bankart repair|Participants in this group will undergo minimally invasive surgery to repair their shoulder with a technique called a Bankart repair.
214292363|NCT04059679|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
215046869|NCT01600404|DRUG|antimuscarinic treatment|
215046870|NCT01215656|DIETARY_SUPPLEMENT|Lactobacillus fermentum|
214292364|NCT04059679|DRUG|Aspirin 81 mg|EC aspirin 81 mg qd
214292365|NCT00333866|DRUG|pregabalin|600mg/day
214292366|NCT00333866|DRUG|pregabalin|450mg/day
214292367|NCT00333866|DRUG|pregabalin|300mg/day
214292368|NCT00333866|DRUG|placebo|placebo
214292369|NCT03508817|DRUG|Atropine Sulfate 0.01% Eye Drops|atropine eye drop in study eye once nightly for two years.
214292370|NCT02533947|BEHAVIORAL|Exercise|The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.
214292371|NCT02533947|BEHAVIORAL|Control|A waitlist control group will get the intervention after 7 month of treatment as usual.
214477095|NCT06878014|DRUG|Preemptive Analgesics|After securing intravenous line each patient received preemptive analgesia with 1,0g paracetamol and 1,0g metamizole.
214477096|NCT06878014|DEVICE|Patient monitor|Postoperatively each patient's vital signs were monitored continuously using patient monitor for 48 hours.
214477097|NCT06587256|DEVICE|Mouth Tape|A single piece of silicone tape placed vertically over the lips. When positioned properly the participant can still inhale/exhale and cough around the tape if needed, but will tend to keep mouth closed otherwise.
215046871|NCT01215656|DIETARY_SUPPLEMENT|Follow on formula without probiotics|
215046872|NCT02811822|DRUG|GMI-1271|
215046873|NCT02487160|DEVICE|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
215046874|NCT02487160|DEVICE|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
215046875|NCT01518387|DRUG|Lanthanum Carbonate (BAY77-1931)|
215046876|NCT03431597|DIETARY_SUPPLEMENT|novel micronutrient|The supplements will be supplied to participants on a daily basis. The novel micronutrient supplement will be provided in powder form with instructions to dissolve one sachet in 250ml of clean water
214667682|NCT05284110|BEHAVIORAL|Physical activity|Multiple bouts of 3-min brisk walking, every 30 min, for 4 hours.
214884650|NCT05532150|PROCEDURE|Physical therapy|Participants in this group will follow a specific physical therapy rehabilitation protocol
215046877|NCT03431597|DIETARY_SUPPLEMENT|existing micronutrient supplement, UNIMMAP|UNIMMAP will be provided in tablet form and given one daily
215046878|NCT05670327|OTHER|Diaphragmatic ultrasound assessment|TFdi, diaphragmatic dysplacement, NAVA assessment, respiratory paramenters
214884651|NCT02490501|PROCEDURE|SC0806 and rehabilitation|
214884652|NCT02490501|OTHER|Rehabilitation only|
214884653|NCT05634707|DRUG|Fluoxetine|"Patients randomized to the experimental arm will receive fluoxetine 20mg/day for 5 days before escalation to a maintenance dose at day 6. On day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12)~* Arm 2A (n=10) - Escalate to maintenance 40mg/day fluoxetine on day 6~* Arm 2B (n=10) - This arm will be opened as long as there are less than 3/10 dose limiting toxicities in Arm 2A. Patients will escalate to maintenance 60mg/day fluoxetine on day 6"
214884654|NCT05634707|DRUG|Temozolomide|Patients randomized to the control arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
214884655|NCT02914223|DRUG|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
214884656|NCT05953259|DEVICE|Combination of STERN FIX and wires|Closure of the median sternotomy using a combination of at least one STERN FIX device and wires for a total of 5 fixation points.
214884657|NCT05953259|DEVICE|Wires|Closure of the median sternotomy using the standard of care with steel wires.
214884658|NCT04158362|DRUG|Paclitaxel injection|Paclitaxel is administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle
214884659|NCT04158362|DRUG|Capecitabine tablets|Capecitabine is given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks
214884660|NCT04158362|DRUG|Letrozole 2.5mg|Letrozole is administered orally at 2.5 mg/day continuous for patients nonsteroidal aromatase inhibitor naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
214884661|NCT04158362|DRUG|Anastrozole 1mg|Anastrozole is administered orally at 1 mg/day continous for patients nonsteroidal aromatase inhibitor (NSAI) naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
214884662|NCT04158362|DRUG|Fulvestrant Prefilled Syringe|Fulvestrant is administered at the dose of 500 mg intramuscular on D1-D15-D29 (as a loading dose), and then 500 mg every 28 days (as a maintenance dose) for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.
214884663|NCT04158362|DRUG|Abemaciclib|Oral 150 mg BID continuous
214884664|NCT06385483|DRUG|Afatinib|Given PO
214884665|NCT06385483|PROCEDURE|Biopsy Procedure|Undergo biopsy
214884666|NCT06385483|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884667|NCT06385483|PROCEDURE|Computed Tomography|Undergo CT scan
215046879|NCT01063790|BEHAVIORAL|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
215046880|NCT00285844|BEHAVIORAL|weight loss|
215046881|NCT00285844|DRUG|thiazolidinedione|
215046882|NCT06209294|DRUG|AK104|AK104(10 mg/kg) d1,22
215046883|NCT06209294|DRUG|Carboplatin|AUC=2 d1,8,15,22, 29, 36
215046884|NCT06209294|DRUG|Nab paclitaxel|125mg／m2 d1,8,15,22,29,36
214884668|NCT06385483|PROCEDURE|Echocardiography Test|Undergo ECHO
214884669|NCT06385483|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884670|NCT06385483|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
214884671|NCT01920529|OTHER|aerobic exercise|Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.
214884672|NCT00507533|PROCEDURE|Continuous positive airway pressure|
214884673|NCT01221389|DRUG|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
214884674|NCT06578143|OTHER|Placebo|Placebo is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
215046885|NCT03129542|DRUG|Midodrine Hydrochloride 10 milligrams|Three doses taken every 8 hours.
215046886|NCT03129542|DRUG|Placebo capsule|Three doses taken every 8 hours.
215046887|NCT01055613|DEVICE|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
215046888|NCT01055613|DEVICE|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
215046889|NCT02765399|DRUG|Liraglutide|
215046890|NCT02765399|DRUG|Placebo|
215046891|NCT03707886|BEHAVIORAL|Pain SMART|Pain SMART is a brief, one-visit shared medical appointment where providers in primary care and a behavioral health specialist (e.g., a psychologist) meet with a group of patients with chronic pain to discuss pain management approaches.
215046892|NCT03707886|OTHER|minimally enhanced usual care|The minimally enhanced usual care group will receive educational information via mail about non-pharmacological approaches to pain management.
215046893|NCT02393339|DRUG|paracetamol|Pre-operative administration of Paracetamol syrup
215046894|NCT02393339|DRUG|placebo|Pre-operative administration of placebo syrup
215046895|NCT00768261|DRUG|Memantine (Namenda®)|Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
215046896|NCT00768261|DRUG|Donepezil (Aricept®)|5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
215046897|NCT04858373|OTHER|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
215046898|NCT04858373|OTHER|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Greek emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214292372|NCT01710956|RADIATION|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
214292373|NCT01454947|BEHAVIORAL|Clinical Decision Support (CDS): Accountable Justifications|Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
214292374|NCT01454947|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
214292375|NCT01454947|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
214292376|NCT02370979|BIOLOGICAL|Blood samples|
214292377|NCT05492331|OTHER|Music Therapy|Patient preferred artist or music genre to be playing from an iPad
214292378|NCT04247581|DEVICE|1-lead ECG|"1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions."
214292379|NCT05590754|DEVICE|Hyper-buoyancy Floatation (HBF)|Participants remained on a waterbed encased within a wooden frame partially (≈50%) filled with water super-saturated with magnesium sulphate at a temperature between 34-36°C regulated by an ultra-thin underbed heater. Participants remained supine and motionless when lay on the HBF except for temporary passive re-orientation to/and back from the prone position for vertebral compliance assessment
214477098|NCT06592807|OTHER|Perioperative Warm Socks|The socks to be used in the study were provided by the researcher. The socks were suitable for foot sizes 36-45. The socks were white and made of cotton fabric. The socks were sterilized in an autoclave before use. The socks were put on the patients just before the surgery. The socks were heated to 40 degrees with an intravenous fluid warming machine.The socks remained on the patients feet throughout the surgery. After the surgery, the patients socks were removed and new heated socks were put on. The socks were kept on the patients feet for 1 hour. All socks were used for single use.
214884675|NCT06578143|OTHER|Synbiotics|Synbiotics is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
214884676|NCT04519073|BIOLOGICAL|V-306 candidate vaccine|"Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker."
214884677|NCT07134153|DRUG|T-DXd|Evaluating safety and efficacy of intrathecal or ommaya reservoir administration of T-DXd in patients with HER2-expressing breast cancer with active leptomeningeal and/or brain metastases based on systemic therapy
214884678|NCT07018050|DRUG|QLS32015|QLS32015 will be administered subcutaneously
214292380|NCT05590754|DEVICE|Axial Load after 4h of HBF|Participants from observational sat upright in a chair without back support for 15 min before post testing (1G), whilst experimental group participants performed a 30s seated squat with 50% of their body weight (BW) before returning to the upright seated position.
214292381|NCT01517269|BEHAVIORAL|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
214292382|NCT01517269|BEHAVIORAL|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
214292383|NCT06064474|BEHAVIORAL|High ventilation breathwork with retention (HVBR)|Intervention
214292384|NCT06064474|BEHAVIORAL|Placebo HVBR|Placebo
214884679|NCT07018050|DRUG|Pomalidomide|Pomalidomide will be self-administered as a single dose orally
214884680|NCT07018050|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously
214292385|NCT06408623|DRUG|chidamide combined with Sintilimab and bevacizumab|chidamide combined with Sintilimab and bevacizumab
214477099|NCT06590077|OTHER|Aromatherapy|The test intervention is an aromatherapy cosmetic product containing a blend of 5 essential oils (orange, lavender, frankincense, vetiver, and neroli), diluted in apricot kernel oil. It was formulated by a clinical aromatherapist. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
214477100|NCT06590077|OTHER|Control (placebo) group|Juniper essential oil in apricot kernel oil in low concentration with a faint aroma - presentation as a rollerball. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
214667683|NCT02522910|DRUG|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
214884681|NCT07018050|DRUG|QL2109 or Daratumumab|QL2109 or Daratumumab will be administered subcutaneously.
214884682|NCT07018050|DRUG|Bortezomib|Bortezomib will be administered subcutaneously
214884683|NCT07018050|DRUG|Lenalidomide|Lenalidomide will be self-administered as a single dose orally
214884684|NCT07018713|DRUG|Xeomin|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
214884685|NCT07018713|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
214884686|NCT07021989|DRUG|Pembrolizumab|Given intravenously
214884687|NCT07021989|RADIATION|Non-investigational, involved site radiotherapy (ISRT)|Undergo possible, standard of care, non-investigational radiation therapy
214884688|NCT07021989|DRUG|Gemcitabine|Given IV
215046899|NCT04858373|OTHER|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Italian emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
215046900|NCT04858373|OTHER|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from whole wheat commercial bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214292386|NCT02969512|OTHER|HIPPER|Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.
214884689|NCT07021989|DRUG|Vinorelbine|Given IV
214884690|NCT07021989|DRUG|Liposomal Doxorubicin|Given IV
215046901|NCT04476381|PROCEDURE|Dry needling|Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
215046902|NCT02810795|OTHER|Diagnostic detection of coronary artery disease|Myocardial perfusion defect on dynamic CT perfusion imaging, and diagnostic accuracy as compared invasive FFR.
215046903|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.05% for 2 consecutive days
214292387|NCT02969512|OTHER|OASIS Online Educational Webinars|2-hour online educational large group sessions
214292388|NCT00940394|BEHAVIORAL|mutual support group|bi-weekly, 12-session, family-led mutual support group
214292389|NCT00940394|BEHAVIORAL|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
214292390|NCT00940394|OTHER|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
214292391|NCT00000233|DRUG|Buprenorphine|
214292392|NCT00229632|DRUG|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
214292393|NCT00456547|PROCEDURE|Blood Draw|Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
214292394|NCT01727973|DRUG|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
214292395|NCT01359449|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
214292396|NCT01359449|BIOLOGICAL|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
214884691|NCT07021989|DEVICE|Foresight CLARITY™ LDT|Foresight CLARITY LDT, a laboratory-developed test (LDT),by Foresight Diagnostics, is an ultra-sensitive liquid biopsy and tissue platform that detects MRD in patients with B-cell lymphomas
214884692|NCT07021989|DRUG|Pegfilgrastim|Given IV for supportive care
214884693|NCT07021989|PROCEDURE|Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)|Undergo imaging
214884694|NCT06629493|BEHAVIORAL|Fitbit Versa 3|Fitbit Versa 3 is a commercially available activity tracker
214884695|NCT06629493|BEHAVIORAL|In-patient alcohol use disorder treatment|In-patient alcohol use disorder treatment, including group therapy, counseling, and occupational activities
214884696|NCT07026318|DRUG|Tirofiban|After endovascular treatment, tirofiban is infused at a rate of 0.4 μg/kg/min for 30 minutes, followed by a maintenance infusion at 0.1 μg/kg/min until 24 hours postoperatively.
214884697|NCT07026318|DRUG|Placebo|Following endovascular treatment, patients receive normal saline placebo, with the dosage calculated in the same manner as that of tirofiban in the experimental group.
214884698|NCT06632509|DEVICE|BD SiteRite(TM) 9|Ultrasound-guided vascular access device placement procedure using the BD SiteRite(TM) 9.
214884699|NCT07018700|DRUG|Xeomin|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
214884700|NCT07018700|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
214884701|NCT06875310|DRUG|Adagrasib|Specified dose on specified days
214884702|NCT06875310|DRUG|Pembrolizumab|Specified dose on specified days
214884703|NCT06875310|DRUG|Carboplatin|Specified dose on specified days
214884704|NCT06875310|DRUG|Pemetrexed|Specified dose on specified days
214884705|NCT06875310|DRUG|Placebo|Specified dose on specified days
215046904|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.015% for 3 consecutive days
215046905|NCT04898478|BEHAVIORAL|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|The investigators will design a culturally grounded treatment seeking intervention for Pacific Islanders with OUDs
215046906|NCT00989976|BEHAVIORAL|normal sleep times|8.5 h bedtimes
214292397|NCT01035203|BEHAVIORAL|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
214884706|NCT06875310|DRUG|Cisplatin|Specified dose on specified days
214884707|NCT03996070|PROCEDURE|Laser therapy|Erbium YAG laser
214884708|NCT06037941|DIAGNOSTIC_TEST|E-Nose testing|At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.
214884709|NCT06037941|DIAGNOSTIC_TEST|Research blood|Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.
215046907|NCT00989976|BEHAVIORAL|bedtime restriction|4.5 h restricted bedtimes
215046908|NCT05267535|DRUG|Piromelatine 20 mg|Tablets
215046909|NCT05267535|DRUG|Placebo|Tablets
214292398|NCT01035203|BEHAVIORAL|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
214884710|NCT06693531|DRUG|dupilumab|No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.
214884711|NCT05458674|DRUG|Tucatinib|taken orally
214884712|NCT05458674|DRUG|Eribulin|taknen intravenously
214884713|NCT05458674|DRUG|Trastuzumab|taken intravenously
214884714|NCT02503787|DEVICE|Spinal Cord Stimulation (SCS)|SCS programming options
214884715|NCT05404321|OTHER|Establishment of ex vivo breast cancer organoid models|This study includes 2 steps: The constitution of a collection of tumor and blood samples and the analysis of the ex vivo response of the tumor samples to the treatments for the development of functional tests and the research of predictive biomarkers of this response
214884716|NCT07135349|DRUG|BW-20507 with/without NUC|• BW-20507 with/without NUCs will be administrated for 48 weeks
214884717|NCT07135349|DRUG|BW-20507 with/without NUC, Peg-IFNa|• BW-20507 with/without NUC will be administrated for 48 weeks, Peg-IFNa will be administrated.
214884718|NCT06709469|BIOLOGICAL|Autologous CD19/CD22 CAR T cells|A total of two doses of autologous CD19/CD22 CAR T cells (first dose of up to 0.75x106/kg fresh cells), and a second infusion of unfrozen cells (same dose) if there has been no ≥ grade 1 cytokine-release syndrome (CRS) in the next 72 h; intravenously.
215046910|NCT03331991|BIOLOGICAL|influenza vaccine|exposure to influenza vaccine
214292399|NCT00330564|DRUG|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
215046911|NCT02636010|DRUG|Pembrolizumab|
215046912|NCT04915638|DIETARY_SUPPLEMENT|Experimental intervention group with enriched cookies|Enriched cookies containing a micronutrients formula (vitamins, minerals, antioxidants, and omega-3 fatty acids) each day (Monday to Friday).
215046913|NCT01080417|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
215046914|NCT05023057|BEHAVIORAL|Multidomain intervention|For 24 weeks, participants will receive cognitive training using the tablet PC application twice a week, exercise 3 times a week, nutrition education 12 times, anthropometric measurements and alcohol and smoking monitoring every 4 weeks, motivation reinforcement training 4 times.
215046915|NCT02374125|DEVICE|Diacutaneous Fibrolysis|Applied only around teres major muscle.
215046916|NCT02374125|OTHER|Trigger Point Pressure Release|Applied only in teres major muscle trigger points.
215046917|NCT02374125|OTHER|Protocolized physiotherapy|Exercises, TENS and cryotherapy
215046918|NCT04240691|BEHAVIORAL|60-Minutes-For-Health|Refer to description under Groups
214477101|NCT05181748|BIOLOGICAL|Autologous platelet rich plasma|Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.
214477102|NCT06843135|DEVICE|Ventricular pacing|Participants will undergo conductionsystem pacing and right ventricular pacing in a randomized sequence, each for six months. After each phase, patients will undergo a CMR scan and advanced ECG imaging
214477103|NCT06530589|OTHER|Tupler's Technique|Patient will wear diastasis rehab splint and will follow Tupler's techniqe protocol for 6 weeks. In the first 2 weeks both elevator and contracting exercises will be performed and after 2 weeks in the 3rd week only contracting exercises will be perform and for these exercises we divide abdomen into 6 floors and will patient have to contract her tummy towards the 3rd to 5th floor in first week, towards the 4th to 5th floor in 2nd week and from 5th to 6th floor in the 3rd week. in the wek 4 to week 6 head lifts will also be started along with contracting exercises from 5th to 6th floor.
214477104|NCT06530589|OTHER|Traditional Exercises|The traditional treatment includes traditional abdominal exercises that patient will be perform for 6 weeks and three times per week with 15 repetitions of each exercise. These exercises includes posterior pelvic tilt' static abdominal contractions', reverse sit up exercise, kegals, russian twist , trunk twist and reverse trunk twist.
214477105|NCT06842225|OTHER|reduced physical activity|Each participant will undergo a three-week study. For the first week (day -7 to day 0), participants will be instructed to maintain their normal level of physical activity. For the second week (day 0 to day 7), the reduced physical activity (RPA) week, participants' schedules will be examined, and strategies designed to reduce steps (by at least 2000 steps) and physical activity (by taking elevators and short-cuts, etc.) by increasing sitting time \>10%. To assist in reducing walking and increased sitting, participants will be given seated electric scooters to use whenever they normally walk. The scooters will be returned on the third week (day 7 to day 14), and participants will be instructed to resume their normal physical activity. During the entire three weeks, participants will wear a continuous glucose monitor (CGM) and a physical activity monitor (ActivPal).
214884719|NCT06709469|BIOLOGICAL|Allogeneic CART-NKG2D cells|A total of up to 3x106/kg allogeneic CART-NKG2D cells divided in three doses of up to 1x106/kg will be infused; intravenously. First infusion of fresh cells, and the 2nd and 3rd infusion of unfrozen cells (same dose) if there has been no ≥ grade 1 CRS (every 48 hours).
214884720|NCT04787627|DEVICE|Power Knee|Powered microprocessor controlled prosthetic knee
214884721|NCT07019064|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
214884722|NCT03759717|OTHER|Observation|Understanding the biology of skull base tumors will teach the investigators about the genesis and/or mechanisms of treatment resistance. The investigators hope to ultimately identify new targets which will add to the armamentarium by which to treat these tumors.
214884723|NCT05533827|OTHER|Kaleidoscope|Kaleidoscope
214884724|NCT05533827|OTHER|Music|Music
214884725|NCT05533827|OTHER|Virtual reality glasses|Virtual reality glasses
214884726|NCT06714955|DRUG|Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.|Drug: BGM0504 Administered SC
215046919|NCT04240691|OTHER|Time-and-Attention Control Session|Refer to description under Groups
214884727|NCT06714955|DRUG|Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.|Drug: BGM0504 Administered SC
215046920|NCT03243227|OTHER|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
215046921|NCT03243227|OTHER|Exercise therapy|AROM exercise stretching exercise strengthening exercise 4 sessions
215046922|NCT03484728|BEHAVIORAL|placebo manipulation|application of nonactive body cream on forearm
214884728|NCT06714955|DRUG|Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.|Drug: Placebo Administered SC
214884729|NCT04762017|DRUG|OCS-05 +SoC (corticosteroid) IV administration|OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days
214884730|NCT04762017|OTHER|Placebo + SoC (corticosteroid) IV administration|Placebo + SoC (corticosteroid) IV administration for 5 consecutive days
214884731|NCT00925080|DEVICE|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
214884732|NCT05214105|OTHER|Biospecimen/DNA collection and analysis|Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
214884733|NCT03553953|DEVICE|BIS device|Recording data from BIS device from patients who undergo elective surgery under general anesthesia
214884734|NCT03648853|DEVICE|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
214884735|NCT04943276|DEVICE|Embr Device|The Embr thermal device will be worn at all times from study start to the study endpoint.
214884736|NCT04479553|DRUG|Qizhi Tongluo Capsules|Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
214884737|NCT02258854|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
214884738|NCT06728683|OTHER|ASSIST-MH|The goal of this SBIR is to create Assist-MH, a new interactive digital support system for SMH providers. Assist-MH will offer an innovative suite of diverse MH strategies to help providers address the clinical needs of youth in distress. In Phase I, the focus will be on depression and anxiety for students ages 12 to 17 years. These MH problems are among the most common for youth, and have shown increasing prevalence in recent years among this age group. Investigators will conduct user-centered testing to determine the set of MH strategies most needed by SMH providers, create a sampling of these resources, and test the usability and promise of the proposed Assist-MH product prior to Phase II full development and pilot testing.
214884739|NCT00516373|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
214884740|NCT00990860|DRUG|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
214884741|NCT00990860|PROCEDURE|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
214884742|NCT02647827|OTHER|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
215046923|NCT05497375|DIAGNOSTIC_TEST|The amount of intraoperative bleeding|Total amount of intraoperative bleeding will be calculated in milliliters after the end of surgery.
215046924|NCT05497375|DIAGNOSTIC_TEST|Quality of the intraoperative surgical field|Quality of the intraoperative surgical field will be measured on a grade of 0-10 (0-1. no bleeding, 2-3. mild bleeding, 4-5. Mild to moderate bleeding, 6-7. moderate bleeding, 8-9. moderate to severe bleeding, 10. Severe bleeding)
215046925|NCT05497375|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon Satisfaction will be measured on a grade of 0-5 (1= very bad, 2= bad, 3= moderate, 4= good, 5= very good).
214884743|NCT02647827|DEVICE|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
214884744|NCT02647827|DRUG|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
214884745|NCT05855122|DRUG|Tocilizumab|Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
214884746|NCT00021827|DRUG|Parathyroid hormone-related protein or ''PTHrP''|
214884747|NCT00506792|DRUG|QAU145|
214884748|NCT00506792|DRUG|Placebo|
215046926|NCT05497375|DIAGNOSTIC_TEST|Heart rate|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
214477106|NCT06843122|BIOLOGICAL|A - Allogenic ADSC cells in fibrin solution - two times administration ADSC/ASC|ADSC/ASC will be administered twice, at two-week intervals - during V0 and V2 visits The first dose will be administered one week after the randomisation visit. Control visits after administration will be performed every week, up to V6 visit (up to 6 weeks after V0).
214884749|NCT02424110|PROCEDURE|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
214884750|NCT02424110|PROCEDURE|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
214884751|NCT02424110|DEVICE|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
215046927|NCT05497375|DIAGNOSTIC_TEST|Mean arterial pressure|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
215046928|NCT05497375|DIAGNOSTIC_TEST|Peripheral oxygen saturation|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
215046929|NCT05364398|PROCEDURE|ACL reconstruction|Use of hamstring tendons graft to replace the torn ACL and being passed and fixed through the femoral and tibial sides
214884752|NCT02424110|DEVICE|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
214884753|NCT00177359|BEHAVIORAL|gait intervention|
215046930|NCT01832610|DEVICE|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
215046931|NCT04155476|DRUG|Nitroglycerin Topical Product|application of NG topical to dorsals pedis and posterior tibial arteries.
215046932|NCT02656667|DEVICE|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
215046933|NCT02656667|DEVICE|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
215046934|NCT02656667|OTHER|Conventional pulmonary rehabilitation|excercise training on treadmill
215046935|NCT05253404|DEVICE|Ambu® AuraOnce™ Disposable Laryngeal Mask|Switching endotracheal tube to laryngeal mask at sevoflurane 2.63-2.97%, Removing endotracheal tube when spontaneously generating tidal volume of \>4ml/kg, EtCO2\<45mmHg, Train of four ratio \>70-90%.
215046936|NCT02525679|DRUG|BI 655130 (spesolimab)|
215046937|NCT02525679|DRUG|Placebo|
215046938|NCT02940925|OTHER|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
215046939|NCT02940925|OTHER|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
214292400|NCT01804374|DRUG|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
214292401|NCT01804374|DRUG|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
214292402|NCT02716571|OTHER|Leukapheresis or Plasmapheresis|"Leukapheresis: Donate 5x10\^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE)."
214292403|NCT00529854|OTHER|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
214292404|NCT03394807|DRUG|Levobupivacaine|Levobupivacaine injection to Transversus abdominis plane and rectus sheath
214292405|NCT03394807|DRUG|Placebo|Saline injection to Transversus abdominis plane and rectus sheath
214292406|NCT04826705|DEVICE|Drug-coated Balloon|To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.
214667684|NCT02097199|OTHER|Increased sports workload|"At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study."
214884754|NCT00919854|DRUG|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and \<20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
214884755|NCT00919854|DRUG|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
214884756|NCT00985491|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
214884757|NCT02037386|DEVICE|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
214884758|NCT05391386|PROCEDURE|modified bonding technique|adding a layer of compomer adhesive at the molar/tube interface.
214884759|NCT06888466|BEHAVIORAL|The result of the Polygenic Risk Score will be communicated to the patient with the aim of encouraging a change in behavior|Blood samples collected for the calculation of the genetic predisposition profile for Cardiovascular risk will be used for DNA extraction and genotyping, and the PRS will subsequently be calculated. Based on the results, individuals will be classified into three main CVD risk categories (high risk, intermediate risk, low risk)
214884760|NCT06742996|DRUG|Sonrotoclax|Administered orally
214884761|NCT06742996|DRUG|Zanubrutinib|Administered orally
214884762|NCT06742996|DRUG|Placebo|Administered orally
214884763|NCT06894875|DIETARY_SUPPLEMENT|Lentil protein hydrolysate|Plant protein hydrolysate
214884764|NCT06894875|DIETARY_SUPPLEMENT|Placebo MCC micro-crystalline cellulose|Placebo MCC micro-crystalline cellulose
214884765|NCT07052292|DEVICE|DuraTouch®|Participants will subcutaneously inject the insulin using DuraTouch®.
214884766|NCT06724601|DEVICE|Electrical Impedance Tomography|Electrical Impedance Tomography data and the physiological and clinical parameters will be recorded continuously in three different positions (supine 1, car seat, supine 2) to assess alterations in lung volume and cardiorespiratory events.
214884767|NCT05155332|DRUG|BI 1831169|BI 1831169
215046940|NCT05691933|PROCEDURE|Block group|Patient will be subjected to bilateral external oblique intercostal plane block
214292407|NCT00455364|DRUG|Voriconazole|
214292408|NCT04199572|DRUG|Diclofenac and Paracetamol|analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
214292409|NCT00256191|DRUG|TPI 287 Injection|
214292410|NCT02145364|DEVICE|Ultherapy® treatment|Microfocused ultrasound treatment
214667685|NCT04573777|DRUG|Repatha|140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
214884768|NCT05155332|DRUG|anti-PD-1 antibody|anti-PD-1 antibody
214884769|NCT06360081|DRUG|Zongertinib manufacturer 1|Zongertinib
214884770|NCT06360081|DRUG|Zongertinib manufacturer 2|Zongertinib
214667686|NCT03493503|DRUG|Salbutamol|Intravenous Salbutamol loading dose
214667687|NCT03493503|DRUG|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
214884771|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
214884772|NCT04771130|DRUG|Azacitidine|Intravenous or subcutaneous administration for 7 days.
214884773|NCT04771130|DRUG|Posaconazole|Oral administration for 8 days on second cycle only.
214884774|NCT04771130|DRUG|BGB-11417|Oral administration for 28 days on a 28-day cycle.
214884775|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 14 or 21 days on a 28-day
214884776|NCT05327010|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214884777|NCT05327010|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
215046941|NCT05691933|PROCEDURE|Morphine infusion|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
215046942|NCT04540367|DEVICE|Blood flow restriction therapy|The study group underwent the same exercises as the control group modified by the use of a tourniquet for blood flow restriction during those exercises.
214292411|NCT04404296|DEVICE|25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy|Pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
214292412|NCT01619683|DRUG|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
214292413|NCT01619683|DRUG|Placebo|1 placebo capsule per day, oral
214292414|NCT02393547|DRUG|Varenicline|All subjects receive Varenicline
214292415|NCT02393547|DRUG|Lorcaserin|All subjects receive Lorcaserin
214292416|NCT01967212|DEVICE|Game-based swallow biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator."
214292417|NCT01967212|BEHAVIORAL|Swallow training without biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Mendelsohn's maneuver and effortful swallow without biofeedback 30 min."
214292418|NCT01455142|DRUG|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
214292419|NCT01271660|DRUG|Pregabalin|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
214292420|NCT01271660|DRUG|Placebo|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
214477107|NCT06843122|BIOLOGICAL|B - Allogenic ADSC cells in fibrin solution - one time administration of ADSC/ASC, one time of placebo|ADSC/ASC will be administered once, at the time of the second application patients will receive a placebo - during V0 and V2 visits The first dose will be administered one week after the randomisation visit. Control visits after administration will be performed weekly, up to V6 visit (up to 6 weeks after V0)
214477108|NCT06843122|OTHER|C - Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.|Placebo will be administered twice, at two-week intervals - during V0 and V2 visits The first dose will be administered one week after the randomisation visit. Control visits after administration will be performed every week, up to V6 visit (up to 6 weeks after V0).
214477109|NCT06841081|OTHER|Enhanced Usual Care|Offer written instructions to the patient and refer the patient to their clinical team if they have unresolved issues.
214477110|NCT06841081|OTHER|Super Supporter Support|Assist and troubleshoot with the patient including a practice video visit.
214292421|NCT03753529|OTHER|Deep friction massage|Submitted to three session weekly 30-minute sessions of therapy will performed by the administration of sliding and kneading maneuvers of the masseter and temporalis muscles, bilaterally,lateral pterygoid and digastric over four consecutive weeks (total:12 sessions) Sliding consisted of a unidirectional movement in which part of the therapist's hand (mainly the fingertips) will used, moving from the proximal to the distal portion of the face with constant, progressive pressure compatible with the status of each tissue. The degree of pressure varied depending on the level of pain, sensitivity and tension in each individual. Kneading consisted of a gripping maneuver of a muscle group or portion of a muscle.Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
214667688|NCT04412603|OTHER|Conventional Mirror Therapy|The Conventional Mirror Therapy was carried out with a mirror box and the Mirror Therapy Virtual Reality was carried out with virtual reality glasses and mobile application: Mirror Therapy VR.
214667689|NCT03947879|DRUG|L-glutamine|15 g of L-glutamine twice daily by mouth for 3 months.
214667690|NCT03947879|OTHER|No L-glutamine|The same patients will be given no L-glutamine for 3 months.
214667691|NCT03343821|OTHER|Balance and daily life questionnaire|Patients complete questionnaire
214667692|NCT04746326|PROCEDURE|Failure conservative treatment|Surgery was performed in patients who failed conservative treatment.
214884778|NCT05327010|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884779|NCT05327010|PROCEDURE|Diagnostic Imaging Testing|Undergo diagnostic imaging
214884780|NCT05327010|DRUG|Talazoparib|Given PO
214884781|NCT07109219|COMBINATION_PRODUCT|AZD4512 monotherapy|Patients will receive AZD4512 as monotherapy via intravenous infusion. AZD4512 is an antibody-drug conjugate targeting CD22
214884782|NCT07101172|PROCEDURE|stress ball|Patients will be provided with an explanation, and verbal and written consent will be obtained. A patient identification form will be completed 10 minutes before the procedure. Pain levels will be determined with a pre-test VAS, anxiety levels will be determined with a STAI-S, and vital signs will be measured and recorded. The patient will be undressed and helped into a surgical gown to protect their privacy. The patient will be placed in a left lateral position on a stretcher with both legs drawn up toward their abdomen. The environment will be quiet and free from external stimuli. During the biopsy procedure, the patient will be asked to squeeze and release the Stre ball once every five counts for 10 minutes. Because blood pressure may drop or dizziness may occur after the procedure, the patient will be taken to the recovery room and monitored for bleeding. Fifteen minutes after the procedure, the severity of pain and anxiety levels during the procedure will be determined, and vital
214884783|NCT07110571|DRUG|Adebrelimab Injection|Adebrelimab injection.
214884784|NCT07110571|DRUG|SHR-A1811 for Injection|SHR-A1811 for injection.
214884785|NCT07110571|DRUG|SHR-A1904 for Injection|SHR-A1904 for injection.
214884786|NCT07110571|DRUG|SHR-8068 Injection|SHR-8068 injection.
214884787|NCT06903819|DRUG|Ketamine|Participants in this group will receive a single intravenous (IV) dose of ketamine at 0.5 mg/kg, administered within 30 minutes of anesthesia induction during surgical fixation for musculoskeletal trauma. The purpose of the intervention is to evaluate ketamine's effect on postoperative pain, opioid consumption, and psychological recovery, including symptoms of depression and post-traumatic stress disorder (PTSD).
214477111|NCT06841432|PROCEDURE|adenoidectomy using coblatioion|One hundred and five patients underwent a Coblation-assisted adenoidectomy procedure. The child was positioned in Rose's position, which helped retract the soft palate and improve visibility of the nasopharynx. Two soft rubber catheters were inserted into the patient's mouth, with the distal and proximal ends crossed externally and secured with a clamp. The COBLATOR™ II surgery system Model EC8000-01 was used, with a power setting of nine for ablation and five for coagulation. Under general anesthesia, the adenoidectomy was performed using either a 4 mm, 70-degree angled endoscope inserted orally or a zero-degree endoscope inserted through the nose, providing effective visualization of the nasopharynx. After the procedure, hemostasis was achieved by using a combination of the coagulation and ablation modes.
214477112|NCT06841432|PROCEDURE|adenoidectomy by Suction diathermy|One hundred and five patients underwent a suction diathermy adenoidectomy procedure. The soft palate was gently retracted using two suction catheters, allowing a 70-degree angled endoscope (Storz, Germany) placed in the oropharynx to provide a clear view of the adenoidal tissue and surrounding structures in the nasopharynx. Using a malleable size 10 or 12 French hand-switching suction coagulator, the adenoidal tissue was carefully ablated, starting from the uppermost part. The procedure was completed when the posterior choanae were clearly visible, and the nasopharynx had a smooth, unobstructed appearance. Great care was taken to avoid injuring the Eustachian tube orifice, posterior septum, choanae, inferior turbinate, palate, and posterior pharyngeal wall. Continuous irrigation with saline, either through the mouth or the nose, helped minimize any thermal damage caused by the diathermy machine.
214477113|NCT04810624|BEHAVIORAL|Relapse Prevention and Changing Habits (REACH+)|Psychotherapy
214477114|NCT06841679|DRUG|Utidelone Capsule|UTD2 40 mg/m2/d, po, qd, day 1-5, q3w
214884788|NCT06903819|DRUG|standard general anesthesia|Participants in this group will receive standard general anesthesia during surgical fixation for musculoskeletal trauma. No ketamine will be administered. This group serves as a comparison to evaluate the effects of ketamine on pain, opioid use, and psychological recovery.
214884789|NCT07112404|OTHER|Dry Needling|Dry needling is a therapeutic technique where thin, solid filiform needles are inserted into trigger points, tight muscle bands, or areas of muscle tension without injecting any medication. The procedure aims to release muscle knots, reduce pain, and improve muscle function by stimulating the body's natural healing response.
214477115|NCT06841679|DRUG|Utidelone Capsule|50 mg/m2/d, po, qd, day 1-5, q3w
214477116|NCT06841679|DRUG|Utidelone Capsule|60 mg/m2/d, po, qd, day 1-5, q3w
214477117|NCT06841679|DRUG|Capecitabine|1000 mg/m2, po, bid, day 1-14, q3w
214884790|NCT07112404|OTHER|Dry needling with high-rate PENS|"Dry needling is a therapeutic technique where thin, solid filiform needles are inserted into trigger points, tight muscle bands, or areas of muscle tension without injecting any medication. The procedure aims to release muscle knots, reduce pain, and improve muscle function by stimulating the body's natural healing response.~When combined with high-rate percutaneous electrical nerve stimulation (PENS), the needles serve as electrodes for delivering a controlled, high-frequency electrical current directly to the targeted tissues. This electrical stimulation further modulates pain signals, promotes muscle relaxation, and can enhance the effectiveness of dry needling, especially for persistent pain and neuromuscular dysfunction."
214884791|NCT07112404|OTHER|Dry needling with low-rate PENS|"Dry needling is a therapeutic technique where thin, solid filiform needles are inserted into trigger points, tight muscle bands, or areas of muscle tension without injecting any medication. The procedure aims to release muscle knots, reduce pain, and improve muscle function by stimulating the body's natural healing response.~When combined with low-rate percutaneous electrical nerve stimulation (PENS), the needles serve as electrodes for delivering a controlled, low-frequency electrical current directly to the targeted tissues. This electrical stimulation further modulates pain signals, promotes muscle relaxation, and can enhance the effectiveness of dry needling, especially for persistent pain and neuromuscular dysfunction."
214884792|NCT07167732|DIAGNOSTIC_TEST|A General Medical and Neurological Assessment|Clinical assessments will consist of gathering demographic data, detailed relevant medical history, and parents' perspectives on treatment priorities, clinical trial interest, and acceptability of risk in future clinical trials. A general medical and neurological examination will be performed by a trained and skilled physician with a valid Good Clinical Practice Certification.
214884793|NCT07167732|DIAGNOSTIC_TEST|World Health Organisation (WHO) Motor Milestones|Ages of six WHO Motor milestones achievements - sitting without support, hands and knees crawling, standing with support, walking with support, standing independently, and walking independently - will be assessed. The age of milestone achievement will be compared to normative variations in age as recommended by the WHO (WHO, 2006).
215046943|NCT02001246|BEHAVIORAL|Real Deal program for Anger Management|Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
215046944|NCT02001246|BEHAVIORAL|Mind-body Bridging (MBB) program|MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
214477118|NCT06841679|DRUG|Oxaliplatin|130 mg/m2/d, iv, day1, q3w, oxaliplatin will be given up to 6 cycles
214477119|NCT06841679|DRUG|Utidelone Capsule|UTD2 po, on d1-5, q3w (dose decided after the phase II)
214884794|NCT07167732|DIAGNOSTIC_TEST|Burke-Fahn-Marsden Dystonia Rating Scale|The Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS; Burke, Fahn, Marsden et. al, 1985) is a universally applied biomarker for the severity of dystonia in children and adults. The scale consists of a movement and disability subscale (Burke-Fahn-Marsden Movement Scale \[BFMMS\] and Burke-Fahn-Marsden Disability Scale \[BFMDS\], respectively. Only the BFMMS will be assessed. The BFMMS measures dystonia in nine body regions (including the eyes, mouth, speech and swallowing, neck, trunk, arms, and legs) with scores ranging from 0 (minimum) to 120 (maximum).
215046945|NCT05654584|PROCEDURE|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery will be performed by a single surgeon.
215046946|NCT01563055|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
215046947|NCT01563055|DRUG|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
215046948|NCT00406796|DRUG|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
215046949|NCT05293340|DIETARY_SUPPLEMENT|Avocado Vouchers|Food as Medicine to demonstrate clinically meaningful benefits for underserved communities. Avocados are fruits with fats, fiber, micronutrients, and bioactive phytochemicals.
214667693|NCT04746326|PROCEDURE|Surgery|Surgery was performed in patients who had generalized peritonitis and perforation.
214884795|NCT07167732|DIAGNOSTIC_TEST|Spastic Paraplegia Rating Scale|The Spastic Paraplegia Rating Scale (SPRS; Schüle et al., 2006) is a 13-item scale used to measure disease severity in spastic paraplegia. The items include walking distance without pause, gait quality, maximum gait speed, climbing stars, arising from chair, spasticity of hip adductor and knee flexion muscles, weakness of hip abduction and foot dorsiflexion, contracture of lower limbs, pain related to spasticity, and bladder and bowel function. Each item has a score ranging from 0 to 4, where 0 represents no dysfunction and 4 represents most severe dysfunction. The score result is calculated by adding single scores of each of the 13 items. The total score varies between 0 (no dysfunction) and 52 (most severe dysfunction).
214884796|NCT07167732|DIAGNOSTIC_TEST|5. CTNNB1-Related Neurodevelopmental Disorder (NEDSDV) Cardiac Health Questionnaire|In a recent study (Sinibaldi et al., 2023), several patients with NEDSDV showed heart abnormalities. To expand on that, investigators developed a parent report questionnaire on the presence of potential heart defects.
214884797|NCT07167732|DIAGNOSTIC_TEST|10m Walk-Run Test|The 10m Walk-Run Test is is a performance measure used to assess walking or gait speed in meters per second over a short distance. It involves measuring the time it takes for a person to walk the distance, with results reported in meters/second (m/s). The patient's ability to walk at both comfortable and fast speeds can be measured, and assistive devices can be used. The test will be performed in ambulant children by an experienced physiotherapist.
214884798|NCT07167732|DIAGNOSTIC_TEST|The Nine Hole Peg Test|The Nine-Hole Peg Test (9-HPT; Kellor et al., 1971) is a standardized, quantitative assessment used to measure finger dexterity. It is administered by asking the client to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. The 9-HPT has been validated for children above the age of 4 years (Poole et al., 2006). The test will be performed in children over 4 years old by a trained investigator.
214884799|NCT07167732|DIAGNOSTIC_TEST|The Gross Motor Function Classification System|The Gross Motor Function Classification System (GMFCS; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to \< 4 years, 4 to \< 6 years, 6 to \< 12 years, and 12 to 18 years.
214884800|NCT07167732|DIAGNOSTIC_TEST|Bayley Scales of Infant and Toddler Development-4: Fine Motor, Gross Motor, Language, and Cognitive Scales|Bayley Scales of Infant and Toddler Development-4 (BSID-4; Bayley et al., 2019) is an extensive formal developmental assessment tool for diagnosing developmental delays in early childhood. It consists of 419 items across 5 scales, each of which can be administered separately - Cognitive Scale (81 items), Language Scale (79 items), Motor Scale (104 items), Social-Emotional Scale (35 items), and Adaptive Behavior Scale (120 items). In our study, Motor, Language and Cognitive scales will be performed by a trained psychologist - if possible, at the patient's home country and in their native language.
215046950|NCT00420186|DRUG|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
215046951|NCT00897884|DRUG|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
215046952|NCT06544070|DEVICE|Entia Liberty System|Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
215046953|NCT03200470|OTHER|No intervention: sample collection study|Sample collection and collection of laboratory values
215046954|NCT01678521|PROCEDURE|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
215046955|NCT00342134|PROCEDURE|Stem Cell Transplanataion|
215046956|NCT03958331|BEHAVIORAL|Automated Digital Reminders|Reminders from electronic monitors via texts or alarms/lights
215046957|NCT03958331|BEHAVIORAL|Individualized Adherence Feedback Report|Feedback report on individual adherence behaviors
215046958|NCT03958331|BEHAVIORAL|Individual Adherence Feedback Report with Social Norms|Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
215046959|NCT04268914|DEVICE|Oculus Go VR|The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.
215046960|NCT04268914|DEVICE|Mira Prism VR|The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
215046961|NCT05204121|DRUG|Elpida|elsulfavirine, capsules
215046962|NCT03560492|OTHER|Exercises|5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
214667694|NCT04746326|OTHER|Conservative treatment|Conservative treatment was performed in patients who had no generalized peritonitis and perforation.
214884801|NCT07167732|DIAGNOSTIC_TEST|Wechsler Non-Verbal Scale of Ability|Wechsler Nonverbal Scale of Ability (WNV, Wechsler et al., 2006) is a standardized, individually administered test designed to assess general cognitive ability in individuals aged 4 to 21 years, particularly those who may have language, cultural, or communication challenges that make traditional verbal IQ tests less appropriate. It consists of six different subtests that are utilized based on the participant's age. In our study, the test will be performed in children above the age of 4 years by a trained psychologist - if possible, at the patient's home country and in their native language.
214884802|NCT07167732|DIAGNOSTIC_TEST|The Vineland Adaptive Behaviour Scales - 3|The Vineland Adaptive Behaviour Scales (VABS-3; Sparrow et al., 2018) is a standardized assessment tool that utilizes semi-structured interview to measure adaptive behaviour and support the diagnosis of intellectual and developmental disabilities, autism, and developmental delays. It is validated for children of all ages and consists of five primary domains (Communication, Daily Living Skills, Socialization, Motor Skills, and Adaptive Behavior Composit).
214292422|NCT03753529|OTHER|Pressure release|First, using a pincer grasp moved throughout the fibers of the pterygoid, masseter, digastric and temporalis muscles to palpate the muscle aiming to locate a trigger point . A common location is detected according to Simon and Travell book. Once located on the trigger point, apply an IC by gradually applying pressure to the trigger point with your thumb. Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points were treated. Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
214292423|NCT03753529|OTHER|control group|Stretching and transcutaneous electrical nerve stimulation
214292424|NCT06363006|DRUG|TKI+Cardunilimab|Cardonilizumab 6mg/kg, IV, Q2W + lenvatinib 8mg (body weight \< 60kg) or 12mg(body weight ≥60kg) PO, QD, / Sorafenib 400mg, PO, BID/ Regorafenib 160mg, PO, QD/ Donafenib 200mg, PO, BID。 omniscience
214292425|NCT04343963|DRUG|Pyridostigmine Bromide|One 60mg tablet P.O. once per day for 14 days
214884803|NCT07167732|DIAGNOSTIC_TEST|Aberrant Behaviour Checklist -Community|"The Aberrant Behaviour Checklist-Community (ABC-C) is a parent report behavioural rating scale designed to assess problem behaviours in individuals with developmental disabilities. It consists of 58 likert-type items across five domains (Irritability, Social Withdrawal, Stereotypic Behaviour, Hyperactivity, and Inappropriate Speech) with responses ranging from not at all a problem to the problem is severe in degree."
214884804|NCT07167732|DIAGNOSTIC_TEST|The Modified Checklist for Autism in Toddlers|The Modified Checklist for Autism in Toddlers (M-CHAT; Robins, Fein, \& Barton, 2009) is a 2-stage parent report screening tool to assess risk for autism spectrum disorder (ASD). It is validated for children 16-30 months old.
214292426|NCT04343963|DRUG|Placebo|One tablet P.O. once per day for 14 days
214884805|NCT07167732|DIAGNOSTIC_TEST|The Autism Spectrum Quotient Questionnaire -Children's Version|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent report questionnaire that aims to quantify autistic traits in children 4 - 11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
214884806|NCT07167732|DIAGNOSTIC_TEST|The Autism-Spectrum Quotient (AQ)-Adolescent Version|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent report questionnaire that aims to quantify autistic traits in children 12 - 15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
215046963|NCT03560492|DEVICE|Posture garment|Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
215046964|NCT04456907|OTHER|platelet rich plasma|Autologous platelet-rich plasma (PRP) was prepared using the RegenKit THT system (RegenLab SA, Le Mont-sur-Lausanne, Switzerland) following the manufacturer's instructions. Medical technicians, who had been well-trained by the manufacturer, were responsible for the process of PRP preparation. For each patient, 8-10 mL of venous blood was drawn and collected to the commercial RegnLab THT tube, which contained 1 mL sodium citrate. After single centrifugation at 3400 revolutions per minute (rpm) for 8 minutes, 4-5 mL of PRP was yielded with leukocytes maintained at physiological levels and red blood cells depleted. Then, the blood components were separated, with the platelet pellet resting on the separating gel. PRP for later application was obtained by re-suspending the platelet pellet in the plasma supernatant by gently inverting the unopened RegenKit THT tube 5 to 10 times.
215046965|NCT04456907|OTHER|saline injection|saline injection
214477120|NCT06841484|PROCEDURE|Arm I (Assistant-Controlled Laparoscopic Instrumentation)|In this group, robotic distal gastrectomy is performed with assistant-controlled laparoscopic instrumentation. The assistant conducts vascular clipping using articulating Hemolock clip appliers (Livsmed) or Challenger® clip appliers (B.Braun). For gastrointestinal anastomosis, the assistant operates an Echelon stapling system (Johnson \& Johnson) via the assistant port. The surgeon controls the robotic console for all other surgical steps. This method utilizes a hybrid approach, combining robotic precision with laparoscopic efficiency.
214477121|NCT06841484|PROCEDURE|Arm II (Assistant-Controlled Laparoscopic Instrumentation)|"In this group, all surgical steps, including vascular clipping and anastomosis, are performed using the robotic system. The surgeon utilizes the Da Vinci Xi system and switches robotic instruments as needed. Vascular clipping is performed with robotic Hemolock or Hemoclip appliers, and anastomosis is conducted using the SureForm robotic stapler. This fully robotic technique eliminates laparoscopic assistance and utilizes only robotic arms for the entire procedure.~Both groups follow the same postoperative care protocols, including standardized pain management and recovery assessments."
214477122|NCT06843005|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Based on the assessment of plaque progression after follow-up CCTA examination, patients will be given either intensive treatment or routine treatment.
214884807|NCT07167732|DIAGNOSTIC_TEST|Continuous Movement Monitoring (Actimyo/Syde)|Continuous movement data will be collected using the ActiMyo/Syde® device (Servais et al., 2022), which is attached to the ankles and uses magneto-inertial sensors to quantify movement. At the first study visit, 20 ambulant patients older than 2 years old will be fitted with a Syde device to each ankle and their carers will be provided with training on use and care of the device. It will be worn for 30 days and then repeated in one year.
214884808|NCT07167732|DIAGNOSTIC_TEST|Sleep Disturbance Scale for Children|"The Sleep Disturbance Scale for Children (SDSC; Bruni et al., 1996) is a parent report questionnaire used to identify sleep disorders in children. It contains 26 likert-type items with responses ranging from never to always (daily). The items are divided in six categories - disorders of initiating and maintaining sleep, sleep breathing disorders, disorders of arousal/nightmares, sleep-wake transition disorders, disorders of excessive somnolence, and sleep hyperhidrosis (nighttime sweating)."
214884809|NCT07167732|DIAGNOSTIC_TEST|Seizure Diary|A 28-day seizure diary is a self-reported tool used to record seizure activity to obtain insight into the patient's seizure triggers and severity, monitor medication side effects, and promote medication adherence. Patients are asked to record their seizure occurrence, duration, and type of seizures.
214884810|NCT07167732|DIAGNOSTIC_TEST|30min EEG Recording|Recording will take place in the hospital's EEG department in a quiet room with low-light levels. If children will be unable to lay still, melatonin or dexmedetomidine may be used, as per standard department protocol. An EEG cap with international system 10-20 electrodes, ECG and respiratory electrodes will be placed on the head and chest respectively. Data will be recorded for at least 30 minutes, and an attempt will be made to capture both wakefulness and sleep. Intermittent photic stimulation will be performed as per standard protocol.
215046966|NCT04256447|DIAGNOSTIC_TEST|Urinary sodium concentrations|The urinary sodium excretion was measured using an immunochemical methodology
215046967|NCT01346124|RADIATION|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
215046968|NCT03940716|BEHAVIORAL|IntERact|"This intervention integrates motivational interviewing, cognitive behavioral skills therapy, and care management into a single behavioral counseling intervention delivered by a therapist. The intervention is delivered either in the emergency department or remotely over the subsequent 5 weeks for a total of six therapy sessions (\~30 min each). A smartphone app is also loaded on the participant's phone and delivers additional behavioral intervention content, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact encouragement, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
214292427|NCT02986568|PROCEDURE|Cervical cancer|"If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles), then perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above.~If tumor size \< 5cm, perform Fusion Total mesometrial resection (TMMR)~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
214292428|NCT02986568|PROCEDURE|Uterine cancer|"Perform Fusion Peritoneal mesometrial resection (PMMR).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
214292429|NCT02986568|PROCEDURE|Cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy. Patients with primary disease will be treated with adjvuant chemotherapy. In case of recurrent disease, bevacizumab, paclitaxel, and cisplaitn will be administered regardless of the pathologic report (bevacizumab 15mg/kg on day 1, paclitaxel 135mg/m2 on day 1, and cisplatin 50mg/m2 on day 2, of each 21 day cycle).~If not, no adjuvant therapy."
214292430|NCT02986568|PROCEDURE|Non-cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, appropriate adjuvant chemotherapy will be administered depending on the tumor type."
214292431|NCT05127889|DRUG|curodont|"* To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs."
214292432|NCT01876342|PROCEDURE|open repair|2-0 sutures
214292433|NCT01876342|PROCEDURE|endoscopic TEP repair|mesh
214292434|NCT05747729|DRUG|Surufatinib and Serplulimab|"Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks."
214292435|NCT02877823|BEHAVIORAL|Treatment|Healthy Lifestyle Education, bottled water, pedometer, family navigator service
214292436|NCT02877823|BEHAVIORAL|Control|Healthy Lifestyle Education
214884811|NCT07167732|DIAGNOSTIC_TEST|PedsQL Family Impact Module|"The PedsQL Family Impact Module is a parent report standardized questionnaire designed to measure the impact of paediatric chronic health conditions on the health-related quality of life (HRQOL) of parents and the functioning of the family as a whole. It consists of 36 likert-like items over 8 domains (Physical Functioning, Emotional Functioning, Social Functioning, Cognitive Functioning, Communication, Worry, Daily Activities, Family Relationships). The items are scored with responses ranging from never a problem to always a problem."
215046969|NCT01877174|DEVICE|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
215046970|NCT01877174|PROCEDURE|transcarotid stenting|
214292437|NCT05037734|DEVICE|Persona Partial Knee System|Unicompartmental Knee Replacement
214292438|NCT03296930|DRUG|Sofosbuvir 400 MG Oral Tablet,|Interferon free direct acting antiviral drugs used for treatment of HCV.
214292439|NCT03296930|DRUG|Ombitasvir/paritaprevir/ritonavir|Interferon free direct acting antiviral drugs used for treatment of HCV.
214292440|NCT00068497|DRUG|gefitinib|Given orally
214477123|NCT06843005|OTHER|Current clinical guidelines|Patients will be treated according to the 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes.
215046971|NCT01931917|BEHAVIORAL|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
214292441|NCT00203125|DRUG|rasagiline mesylate|0.5 or 1 mg oral, once-daily
214292442|NCT00203125|OTHER|tyramine|50 mg once daily
214292443|NCT03453710|PROCEDURE|Bankart Repair plus Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
214292444|NCT03453710|PROCEDURE|Latarjet coracoid transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
214292445|NCT02927431|DRUG|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
214292446|NCT02927431|DRUG|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
214477124|NCT06841783|PROCEDURE|nerve block|ultrasound guided nerve block
214477125|NCT06409442|OTHER|Standard Physiotherapy Program|Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.
214477126|NCT06409442|OTHER|Kinesio Taping|In addition to the standard physiotherapy program, kinesio taping (device) will be applied.
214477127|NCT06409442|OTHER|Local Vibration Therapy|In addition to the standard physiotherapy program, local vibration (device) will be applied.
215046972|NCT01931917|BEHAVIORAL|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
214884812|NCT07167732|DIAGNOSTIC_TEST|PedsQL Core Module|"The PedsQL™ (Pediatric Quality of Life Inventory) Core Module is a health-related quality of life (HRQOL) questionnaire designed for children and adolescents. It assesses physical, emotional, social, and school functioning by using 23 likert-like items across 4 subscales (Physical Functioning, Emotional Functioning, Social Functioning, School Functioning). The items are scored with responses ranging from never a problem to always a problem. Items differ across age groups - toddlers (2-4 years), young children (5-7 years), children (8-12 years), teens (13-18 years), and young adults (18-25 years). In toddlers, the parents serve as proxy, and in young children, a three-point scale with faces is used instead of likert-type responses."
214884813|NCT07167732|DIAGNOSTIC_TEST|Blood Sample Collection|"Venepuncture will be performed by a qualified member of the research team on all participants at each visit and 2x 5ml of blood will be collected (\< 0.8 ml/kg) for analysis of DNA methylation and RNA expression, and analysis of serum for neurofilaments, b-catenin, and zinc. All blood samples will be labelled with the study ID and visit number and processed at the laboratory of the UMCL following the protocol CTNNB1."
215046973|NCT02234765|OTHER|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
214292447|NCT02927431|DRUG|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
214884814|NCT07167732|DIAGNOSTIC_TEST|Optical Coherence Tomography|To test for FEVR, the participants will be asked to perform Optical Coherence Tomography in their home countries at baseline and before or after every subsequent visit. OCT will only be performed in patients who will be able to cooperate - focus gaze for about 5 seconds.
214884815|NCT07167732|DIAGNOSTIC_TEST|Brain MRI|If a participant has had a brain MRI performed prior to enrolling in our study, pictorial data will be analysed. If the participant will plan to have an MRI performed as a standard procedure in their native country, they will be asked to follow the CTNNB1 MRI protocol: T1 MPRAGE sequence, 3D FLAIR sequence, T2 axial planeartane, SWI, DWI, and DTI with at least 64, but preferably 90 diffusion directions. MRI will not be performed on site.
214884816|NCT07169591|DIAGNOSTIC_TEST|Oral Glucose Tolerance test (75g 2-hour)|Standard oral glucose tolerance test with blood draws every 15-30 minutes for a 2-hour span
214884817|NCT07167758|DRUG|TRIV-509|TRIV-509 (Subcutaneous injection)
214884818|NCT07167758|DRUG|Placebo|Drug: Placebo (Matching Placebo subcutaneous injection)
215046974|NCT02234765|OTHER|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
215046975|NCT04039529|DEVICE|SCENERGY-guided Biopsy|Use of SCENERGY during a lung, liver or kidney biopsy
215046976|NCT01143220|OTHER|No specific interventions|Observational investigation, only procedures according to local hospital standard.
215046977|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2
215046978|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+5
215046979|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
215046980|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+1
215046981|NCT03381118|BIOLOGICAL|G-CSF mobilized HLA-haploidentical donor PBSC|G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
215046982|NCT05570032|DEVICE|Virtual Reality Training|In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
214292448|NCT02927431|DRUG|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
215046983|NCT05448456|DRUG|Tranexamic acid|1 gram of tranexamic acid in 100 ml of 0.9% normal saline
215046984|NCT05448456|DRUG|Placebo|100 ml of 0.9% normal saline
215046985|NCT05425017|OTHER|Range of motion with spinal adjustment|With accelerometers affixed to spine recording vibrations, the participants complete range of motion. After completing, they receive a low back spinal adjustment and repeat range of motion
215046986|NCT04047056|OTHER|Labor Kinesiotherapy|"The intervention group will perform 5 minutes of warm-up with free active exercises, 10 minutes of specific resistance exercises for the cervical and upper limbs and 5 minutes of stretching and muscle relaxation.The initial free active exercises will be performed in 3 sets of 15 repetitions; Resistance exercises will be performed in 3 sets of 10 repetitions and stretching will be performed in 3 sets of 30 seconds.~Regarding the intervals between exercises, active recovery will be adopted to counteract the effects of muscle fatigue."
215046987|NCT00578032|BEHAVIORAL|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
215046988|NCT05511779|DRUG|Brincidofovir|BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
215046989|NCT03747367|BEHAVIORAL|Insufficient Sleep|
215046990|NCT05326737|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
214292449|NCT06361485|BIOLOGICAL|Lumbar Injections with 10cc's of Wharton's Jelly Allograft|Low Back Injections with Minimal Manipulation Umbilical Cord Tissue
214292450|NCT00005094|DRUG|celecoxib|Given orally
214292451|NCT00005094|OTHER|placebo|Given orally
214292452|NCT04287491|OTHER|Oculus Go Virtual Reality System|The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.
214292453|NCT04134468|DRUG|Pegvorhyaluronidase alfa|IV infusion
214292454|NCT04134468|DRUG|Abraxane|IV infusion
214292455|NCT04134468|DRUG|Gemcitabine|IV infusion
214884819|NCT07175454|OTHER|Questionnaire|"Patients/research nurses will complete questionnaires detailing their medical history including mental health and describing their IBD.~Patients will complete baseline scoring questionnaires for depression and anxiety (HADS) and perceived stress (PSS-10).~Patients will also complete a patient reported outcome tool to assess their current disease activity level (PRO-2)"
214292456|NCT02202408|DRUG|SKI2670|Oral, Single Dose
214292457|NCT02202408|DRUG|Placebo|Same shape as the experimental drug
214292458|NCT01421108|BEHAVIORAL|Framing (Gain-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
214292459|NCT01421108|BEHAVIORAL|Framing (Loss-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.~The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing."
214884820|NCT07177742|OTHER|Observation|Observation.
214884821|NCT07175584|RADIATION|anal canal-sparing techniques|To contour anal canal and rectum separately and deliver different doses as two single OARs in pelvic radiation therapy planning.
214884822|NCT07177365|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy (ICBT)|An 8-week Internet-based Cognitive Behavioral Therapy (ICBT) program delivered via the National Health Research Institutes (NHRI) secure online platform. The program consists of 12 sequential modules released every 5 days, covering core CBT techniques such as cognitive restructuring, emotion regulation, behavioral activation, mindfulness, and self-compassion. Participants receive automated email notifications for new modules and supplementary review materials. Progress is monitored through the platform, and participants complete standardized self-report assessments at baseline, mid-intervention (week 5), post-intervention (week 9), and 3-month follow-up.
214884823|NCT07177365|OTHER|Treatment as Usual (TAU) Only|Routine clinical care provided by a psychiatrist, which may include pharmacological treatment, psychoeducation, and regular follow-up visits according to clinical judgment. No ICBT intervention is provided during the study period. Participants follow the same assessment schedule as the experimental group. After the 3-month follow-up, participants in this group may request access to the ICBT program.
214884824|NCT01821690|DRUG|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
214884825|NCT01821690|DRUG|Placebo|The placebo tablets taste and look identical to buspirone.
214884826|NCT06247670|DRUG|CMP-CPS-001|CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.
214884827|NCT06247670|OTHER|Placebo|Placebo is 0.9% normal saline solution and will be administered subcutaneously.
214884828|NCT06830577|DRUG|Usage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy|Intraureteric aminophylline installation prior to ureteric dilatation
214884829|NCT06830577|DEVICE|Sequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy|traditional ureteral dilators will be used. We will start by ureteral dilator 6 fr and gradually increase the size up to 12 Fr
214884830|NCT06830577|OTHER|Aminophylline instillation and Ureteral dilators together|Aminophylline will be instilled as in group (A) then followed by traditional ureteral dilatation as in group (B) prior to placing the ureteric access sheath
214884831|NCT03597399|BIOLOGICAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.
214884832|NCT00000971|DRUG|Clarithromycin|
214884833|NCT00000971|DRUG|Zidovudine|
214884834|NCT00000971|DRUG|Didanosine|
214884835|NCT04140032|BEHAVIORAL|Multi-level preschool obesity control intervention|The multi-level intervention is a preschool-based program that integrates healthy nutrition and physical activity policies and practices into preschool operations via the Sesame Street Healthy Habits for Life curriculum. In addition to the curriculum, the intervention includes coaching sessions to enhance teacher lesson planning to routinely include nutrition and physical activity; as well as assist preschool site directors with implementing policy changes and parent engagement sessions.
214884836|NCT06526988|BEHAVIORAL|EPIC-HF Patient-facing Tool|A brief, animated video designed to engage and activate patients around their HFrEF medication prescribing sent prior to routine cardiology clinic visit, accompanied by a one-page HeartMeds Guide checklist.
215046991|NCT05326737|OTHER|In hospital questionnaires|Patients are required to fill out the PCS questionnaire between on day -1 or +1.
215046992|NCT05326737|OTHER|Telephone contact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires DN4 and EQ5D5L.
215046993|NCT00587119|DRUG|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
215046994|NCT05081921|DRUG|MesoCellA-Ortho administration|"Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups."
215046995|NCT05081921|DRUG|HA administration|"Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups."
215046996|NCT00544856|BEHAVIORAL|complex cognitive training|
215046997|NCT04035889|DIETARY_SUPPLEMENT|Melatonin|Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.
215046998|NCT04035889|DIETARY_SUPPLEMENT|Placebo|Placebo
215046999|NCT02701205|BIOLOGICAL|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
214477128|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 1|Participants will use their Radicle Rest Placebo Control Form 1 as directed for a period of 6 weeks.
214884837|NCT06526988|BEHAVIORAL|PROMPT-HF Clinician-facing Alert|A best practice alert will appear for each eligible patient upon opening of the order entry screen in the patient's medical record. This alerts the provider of the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence-based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
215047000|NCT02701205|BIOLOGICAL|etanercept (half dose)|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
215047001|NCT02701205|DRUG|placebo|two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
215047002|NCT02685397|DRUG|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
215047003|NCT02685397|DRUG|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
215047004|NCT02685397|DRUG|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
215047005|NCT02685397|DRUG|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
215047006|NCT02685397|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
215047007|NCT06482086|DRUG|Anlotinib|8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
215047008|NCT06482086|DRUG|Lenvatinib|8/12 mg qd, po.
215047009|NCT06482086|DRUG|Sorafenib|0.4 g bid, po.
215047010|NCT06482086|DRUG|Donafenib|0.3 g bid, po.
215047011|NCT06482086|DRUG|Everolimus|10 mg qd, po.
215047012|NCT06482086|DRUG|Apatinib|500 mg qd, po.
215047013|NCT06482086|DRUG|Dabrafenib + Trametinib|Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.
215047014|NCT06482086|DRUG|Cabozantinib|Cabozantinib 60mg qd, po.
215047015|NCT06482086|DRUG|Vandetanib|Vandetanib 300mg qd, po.
215047016|NCT06482086|DRUG|Entrectinib|Entrectinib 600mg qd，po.
215047017|NCT06482086|DRUG|Pralsetinib|400mg qd, po.
215047018|NCT06482086|DRUG|Larotrectinib|100mg qd，po
214477129|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 1.1 Usage|Participants will use their Radicle Rest Active Study Product 1.1 as directed for a period of 6 weeks.
214477130|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 2|Participants will use their Radicle Rest Placebo Control Form 2 as directed for a period of 6 weeks.
215047019|NCT04273360|OTHER|Systematic use group|Patients in this group will be subjected to initial systematic PR, which will be re-evaluated every day every day between day 0 and day 14
215047020|NCT04273360|OTHER|Restrictive use group|Patients in this group will be subjected to PR only in case of severe agitation, defined by a RASS ≥ +3 on any given day between day 0 and day 14
215047021|NCT04351594|DRUG|Biofreeze 4 % Topical Gel|Biofreeze gel with active manufactured ingredient (Menthol 4%)
215047022|NCT04351594|OTHER|Biofreeze placebo gel|Biofreeze gel with no active manufactured to have the same look, feel and odour as Biofreeze topical gel.
215047023|NCT02794571|DRUG|Atezolizumab|Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.
214477131|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 2.1 Usage|Participants will use their Radicle Rest Active Study Product 2.1 as directed for a period of 6 weeks.
214292460|NCT05717374|DRUG|caudal block using dexamethasone|patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus
214292461|NCT05717374|DRUG|caudal block using methylprednisolone|patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
214292462|NCT05423028|PROCEDURE|Ultrasound-guided nerve hydrodissection|Peri- median nerve injection for hydrorelease and decompression
214292463|NCT00429104|DRUG|Herceptin|4 mg/kg IV Over 90 Minutes
214292464|NCT00429104|DRUG|GM-CSF|250 mcg/m\^2 Subcutaneously
214292465|NCT05612984|COMBINATION_PRODUCT|Calcium aspirin multiple micronutrients|Women randomized to CAMMS will receive weekly blister cards containing all 3 components: 1 81 mg aspirin tablet, 1 UNIMMAP MMS, and 1 500-mg elemental calcium tablets. Blister packages will be labeled with times of day and days of week when tablets are to be taken. 4 weekly blister cards will be packaged in one unit box.
214292466|NCT05612984|DIETARY_SUPPLEMENT|Iron-folic Acid|Women randomized to IFA will receive monthly (28-day) blister cards containing containing 1 combined IFA tablet to be taken each day. 1 4-weekly blister card will be packaged in one unit box.
214292467|NCT05167214|DEVICE|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain
214292468|NCT00937612|RADIATION|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
214292469|NCT05320120|DRUG|56mg esketamine (2x Spravato® 28 mg nasal spray)|56mg esketamine (2x Spravato® 28 mg nasal spray)
214292470|NCT05320120|DRUG|0.9% saline solution nasal spray|0.9% saline solution nasal spray
214292471|NCT05241496|DIAGNOSTIC_TEST|The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration|Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
214292472|NCT02648178|DEVICE|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
214292473|NCT00271583|DRUG|CDB-2914|
214292474|NCT00271583|DRUG|levonorgestrel|
214292475|NCT00933374|DRUG|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
214292476|NCT00933374|DRUG|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
214292477|NCT03766308|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet
214292478|NCT03766308|DIETARY_SUPPLEMENT|ADA diet|ADA diet
214292479|NCT01723592|DIETARY_SUPPLEMENT|Probiotics|Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
214292480|NCT01723592|DIETARY_SUPPLEMENT|Oral lactose placebo|Placebo
214292481|NCT06088706|PROCEDURE|Intra-articular injection of ozone|the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
214292482|NCT04655274|DIAGNOSTIC_TEST|The Quality of Vision questionnaire|The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.
214477132|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control 4.1.0|Participants will use their Radicle Rest Active Study Product 4.1.1 as directed for a period of 6 weeks.
214884838|NCT06952868|DRUG|Drug: B10 L-BPA Injection|"The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.~This single arm of the study is designed to evaluate the therapeutic efficacy of BNCT, wherein patients receive B10 L-BPA administration followed by neutron irradiation."
214477133|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 4.1.1 Usage|Participants will use their Radicle Rest Active Study Product 4.1.1 as directed for a period of 6 weeks.
214477134|NCT04704271|DRUG|Inhaled THC|4 mg inhaled THC
214292483|NCT00699621|BIOLOGICAL|platelets|Four units of fresh platelets will be infused immediately
214477135|NCT04704271|DRUG|Placebo|Inhaled placebo (no active cannabinoids)
214477136|NCT05940324|DRUG|Ketamine|Ketamine is an FDA-approved dissociative anesthetic.
214477137|NCT05940324|DRUG|Naltrexone Pill|Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
214477138|NCT05940324|OTHER|Placebo pill|An oral inactive placebo pill will be administered to preserve the blinded nature of the study.
214477139|NCT05643287|PROCEDURE|Periodontal treatment|Non-surgical periodontal treatment
214477140|NCT04028414|OTHER|Early Weight Bearing|Patients will be instruction to weight bear as tolerated while in a boot.
214477141|NCT05670782|DRUG|KM-819|Participants will receive oral doses of KM-819 once-daily
215047024|NCT02794571|DRUG|Tiragolumab|Several dose levels will be evaluated for tiragolumab administered as a single agent and in combination with atezolizumab and/or other anti-cancer therapies. Tiragolumab will be given via IV infusion on Day 1 of each cycle (21-day or 28-day depending on study cohort and phase) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent tiragolumab may receive combination treatment with tiragolumab and atezolizumab and/or other anti-cancer therapies. Combination treatment may continue until disease progression or loss of clinical benefit.
214292484|NCT02226055|DEVICE|Arterial Stiffness Assessment|"The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).~We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated."
214292485|NCT03222050|OTHER|Distraction technique|
214292486|NCT01285310|DRUG|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
214292487|NCT01285310|DRUG|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
214292488|NCT01285310|DRUG|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
214292489|NCT00208039|DRUG|Infasurf|Infasurf 3 cc/kg instilled via endotracheal tube, repeated 3 and 7 days later if infant stable and continues to meet criteria
214292490|NCT00143403|DRUG|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
214292491|NCT00143403|DRUG|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
214884842|NCT03701282|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215047025|NCT02794571|DRUG|Carboplatin|Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab IV infusion.
215047026|NCT02794571|DRUG|Cisplatin|Cisplatin 75 milligram per square meter (mg/m\^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
215047027|NCT02794571|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and tiragolumab.
214292492|NCT00514540|DRUG|Docetaxel|75 mg/m\^2 IV over 60 Minutes on Day 1 of 21 day cycle.
214292493|NCT00514540|DRUG|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.
214292494|NCT00514540|DRUG|Etoposide|120 mg/m\^2 daily for 3 days of 21 day cycle.
214292495|NCT00514540|DRUG|Cisplatin|25 mg/m\^2 for 3 days of 21 day cycle.
214292496|NCT05505214|DRUG|Bacterial decolonization|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
214292497|NCT05505214|DRUG|Mometasone furoate 0.1% cream|Mometasone furoate 0.1% cream to be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
214477142|NCT05670782|DRUG|Placebo|Participants will receive matching placebo once-daily
214884843|NCT03701282|PROCEDURE|Bone Marrow Biopsy|Undergo biopsy
214884844|NCT03701282|PROCEDURE|Computed Tomography|Undergo CT
215047028|NCT02794571|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.
215047029|NCT02794571|DRUG|Etoposide|Etoposide 100 mg/m\^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.
215047030|NCT02794571|DRUG|Capecitabine|Capecitabine 1250 mg/m\^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.
215047031|NCT02794571|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
214884845|NCT03701282|DRUG|Ibrutinib|Given PO
214884846|NCT03701282|BIOLOGICAL|Obinutuzumab|Given IV
214884847|NCT03701282|OTHER|Quality-of-Life Assessment|Ancillary studies
214884848|NCT03701282|DRUG|Venetoclax|Given PO
214884849|NCT05160129|DEVICE|Selective focal stimulation of ALIC-pathways|DBS will be applied selectively to different electrode contacts/ segments to evaluate clinical, behavioral, and electrocortical responses of specific pathways within the ALIC.
214884850|NCT06964412|OTHER|Artificial-intelligence (AI)|Utilizing the addition of artificial intelligence during prostate contouring.
215047032|NCT02794571|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.
215047033|NCT03120845|PROCEDURE|One visit RCT|Root canal treatment in one vist
215047034|NCT03120845|PROCEDURE|Post operative pain in two-visits RCT|Root canal treatment in Two visits
215047035|NCT02177383|DIETARY_SUPPLEMENT|Docosahexaenoic acid diet supplementation|"Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
214292498|NCT05505214|DRUG|Bacterial decolonization and Mometasone furoate 0.1% cream|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT. Also, mometasone furoate 0.1% cream will be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
215047036|NCT02177383|DIETARY_SUPPLEMENT|Placebo supplementation|"Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
214884893|NCT03793166|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214884894|NCT03793166|PROCEDURE|Bone Scan|Undergo bone scan
214884895|NCT03793166|DRUG|Cabozantinib|Given PO
214884896|NCT03793166|PROCEDURE|Computed Tomography|Undergo CT scan
214884897|NCT03793166|BIOLOGICAL|Ipilimumab|Given IV
214884898|NCT03793166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884899|NCT03793166|BIOLOGICAL|Nivolumab|Given IV
214884900|NCT03793166|OTHER|Quality-of-Life Assessment|Ancillary studies
214884901|NCT03793166|OTHER|Questionnaire Administration|Ancillary studies
214884902|NCT00588770|BIOLOGICAL|Bevacizumab|Given IV
214884903|NCT00588770|DRUG|Carboplatin|Given IV
214884904|NCT00588770|DRUG|Cisplatin|Given IV
214884905|NCT00588770|DRUG|Docetaxel|Given IV
214884906|NCT00588770|DRUG|Fluorouracil|Given IV
214884907|NCT00588770|OTHER|Laboratory Biomarker Analysis|Correlative studies
214884908|NCT03698019|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214884909|NCT03698019|PROCEDURE|Computed Tomography|Undergo CT
214884910|NCT03698019|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884911|NCT03698019|BIOLOGICAL|Pembrolizumab|Given IV
214884912|NCT03698019|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214884913|NCT03233711|PROCEDURE|Biopsy Procedure|Undergo biopsy
214884914|NCT03233711|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884915|NCT03233711|PROCEDURE|Colonoscopy|Undergo colonoscopy
214884916|NCT03233711|PROCEDURE|Computed Tomography|Undergo CT scan
214884917|NCT03233711|PROCEDURE|Digital Rectal Examination|Undergo digital rectal examination
214884918|NCT03233711|PROCEDURE|High Resolution Anoscopy|Undergo anoscopy
214884919|NCT03233711|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884920|NCT03233711|BIOLOGICAL|Nivolumab|Given IV
214884921|NCT03233711|OTHER|Patient Observation|Undergo observation
214884922|NCT03233711|PROCEDURE|Proctoscopy|Undergo proctoscopy
214884923|NCT03233711|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
214884924|NCT03233711|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
214884925|NCT06409000|OTHER|Electronic Health Record Review|Medical records reviewed
214884926|NCT06409000|PROCEDURE|Three-Dimensional Imaging|Undergo 3D surface scans
214884927|NCT01856192|DRUG|Cyclophosphamide|Given IV
214884928|NCT01856192|DRUG|Doxorubicin Hydrochloride|Given IV
214884929|NCT01856192|OTHER|Laboratory Biomarker Analysis|Correlative studies
214884930|NCT01856192|DRUG|Lenalidomide|Given PO
214884931|NCT01856192|DRUG|Prednisone|Given PO
214884932|NCT01856192|BIOLOGICAL|Rituximab|Given IV
214884933|NCT01856192|DRUG|Vincristine Sulfate|Given IV
214884934|NCT05397951|DEVICE|Multi-modality Noninvasive Biosensor|The wearable sensor devices will be placed on the finger, wrist, temple, subclavian, arm, neck, and thigh of the participant and will provide continuous tissue mechanics, heart rate, respiration rate, blood flow, and pulse oxygenation measurements continuously throughout the experimental period.
214884935|NCT05397951|DEVICE|Oximeter|The oximeter device will be placed on the right middle finger of the participant and will provide continuous pulse oxygenation and heart rate measurements continuously throughout the experimental period.
215047037|NCT05910658|BEHAVIORAL|Competence in Romance and Understanding Sexual Health (CRUSH)|Manualized curriculum targeting sexual health and behavior in intimate relationships designed to meet the specific needs of autistic adults
215047038|NCT01911351|DRUG|Nitrous Oxide|Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
214884936|NCT05397951|DEVICE|Portable Blood Pressure Monitor|The blood pressure monitor device will be placed on the left arm of the participant and will take a blood pressure measurement every 5 minutes throughout the 15 minute experimental period, and every 15 minutes throughout the 2 hour experimental period.
214884937|NCT05397951|DEVICE|Vicorder Pulse Wave Velocity Monitor|The pulse wave velocity monitor device will be placed on the right side of the neck and the right thigh and will provide measurements continuously throughout the experimental period.
214884938|NCT02642042|DRUG|Docetaxel|Given IV
214884939|NCT02642042|OTHER|Laboratory Biomarker Analysis|Correlative studies
214884940|NCT02642042|DRUG|Trametinib|Given PO
214884941|NCT04844190|DIAGNOSTIC_TEST|EndoFLIP|During pre-G-POEM upper endoscopy, an EndoLIP catheter will be inserted through the patient's mouth into the stomach and across the pylorus. Once results of EndoFLIP are obtained, the catheter will be removed (5 minutes).
214884942|NCT04844190|DIAGNOSTIC_TEST|Antroduodenal Manometry|Following removal the EndoFLIP catheter, a manometry catheter will then be placed through the nose and advanced across the pylorus. Once catheter positioning is confirmed on endoscopy, the endoscope will be withdrawn. The manometry catheter will be taped to the nose and sedation stopped. The patient will be brought to the recovery area where they will wake-up with the catheter in place. In a private recovery room, the patient will have the catheter in place (no positioning or movement restrictions). When pyloric spasms are documented (0.5-4 hours), they will be given a standard small meal (water, toast/bread). Once motility is assessed with eating, the manometry catheter will be removed.
214884943|NCT05602766|DRUG|NGENLA (Somatrogon)|Dosage, Frequency: Refer to the latest package insert.
214884944|NCT06511882|DRUG|Azacitidine|Standard of Care Intravenous (IV) infusion
214884945|NCT06511882|DRUG|Decitabine|Standard of Care Intravenous (IV) infusion
214884946|NCT06511882|DRUG|Venetoclax|Standard of Care PO (By Mouth)
214884947|NCT03694561|OTHER|Observational|This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy and childhood
214884948|NCT04976621|BEHAVIORAL|Behavioral Activation|BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. BA protocol components include: goal setting (especially for activities that promote social connectedness), creation of a plan (broken down into steps), strategies for implementation of steps, identification of potential barriers, tactics to overcome them, activity monitoring and scheduling, and emotion regulation strategies. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in person in an office at the VA rehabilitation clinic, virtually by VA Video Connect, or in person in the home, depending on the veteran's preference.
214884949|NCT04976621|OTHER|Treatment as Usual|Treatment as Usual refers to usual care provided by the VA medical center.
214884950|NCT05992623|DEVICE|Zoll external defibrillator|Patients with AF will be randomized to receive a full output synchronized 200J shock using a RBW waveform from a Zoll defibrillator
214884951|NCT05992623|DEVICE|Lifepak external defibrillator|Patients with AF will be randomized to receive a full output synchronized 360J shock using a BTE waveform from a Lifepak defibrillator
214884952|NCT03348631|PROCEDURE|Computed Tomography|Undergo CT scan
214884953|NCT03348631|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214884954|NCT03348631|DRUG|Tazemetostat|Given PO
214884955|NCT04726241|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or bone marrow samples
215047039|NCT04641091|DEVICE|Multispectral Optoacustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
215047040|NCT00012441|PROCEDURE|hemodialysis|
215047041|NCT03266029|DEVICE|Cordio App|
215047042|NCT06218979|DRUG|Risperidone oral solution|See arm/group descriptions
214292499|NCT03030872|DEVICE|Investigational software|The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.
214884956|NCT06680596|DRUG|trastuzumab derxutecan|T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment).
214884957|NCT05648500|DRUG|Cenerimod|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
214884958|NCT05648500|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
215047043|NCT04422431|DRUG|Bis-Choline Tetrathiomolybdate|Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
214884959|NCT05183035|DRUG|Fludarabine|Intravenous (IV) infusion
214884960|NCT05183035|DRUG|Cytarabine|Intravenous (IV) infusion
214884961|NCT05183035|DRUG|Gemtuzumab Ozogamicin|Intravenous (IV) infusion
214884962|NCT05183035|DRUG|Azacitidine|Intravenous (IV) infusion or subcutaneous injection
214884963|NCT05183035|DRUG|Venetoclax|Orally via tablet or powder suspension
214884964|NCT05819606|OTHER|Immunohistochemistry (IHC) analysis|Setting of the percentage amount of PSMA expression on the primary tumor cell surface on post-surgical samples by the Immunohistochemistry method (IHC)
214884965|NCT06184399|DRUG|Ivermectin 1.5 mg ODT|Oro-dispersible tablets of 1.5 mg ivermectin
215047044|NCT06565468|DEVICE|Cold water immersion pool.|Participants will complete a session of cold-water immersion within one hour of finishing the last training session of the day. Cold water immersion will consist of ten minutes of submersion to the neck in a cold-water tub with a target temperature of 55 degrees Fahrenheit (daily temperatures will be recorded at the time of each session). The acceptable range for the cold water immersion protocol will be from 53-57 degrees Fahrenheit. The immersion process will not be completed if the temperature of the water is outside of this range. Participants will complete five sessions per week, with a total of 10 sessions to be completed over the 14-day intervention.
215047045|NCT06325215|OTHER|Hidrocolloid Bant|In this group, after the columella and nasal area of preterm infants were cleaned and dried with sterile water, hydrocolloid dressings were applied to the areas in contact with the nasal cannula. NasalNem nasal ointment was applied twice a day to the nasal passages in contact with the cannula. If the hydrocolloid dressings melted or peeled off, they were removed, the area was cleaned, and then reapplied.
215047046|NCT02740270|DRUG|GWN323|
215047047|NCT02740270|DRUG|PDR001|
215047048|NCT03168139|DRUG|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
215047049|NCT03168139|DRUG|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
214884966|NCT06184399|DRUG|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
214884967|NCT06184399|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
215047050|NCT03447873|DRUG|Continue with triple therapy|To continue with triple therapy
215047051|NCT03447873|DRUG|Switch to DTG + 3TC|Switch to dolutegravir + lamivudine once daily
215047052|NCT03447873|DRUG|Switch to DRV/cobicistat + 3TC|Switch to darunavir/cobicistat + lamivudine once daily
215047053|NCT02152748|GENETIC|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
214292500|NCT00587639|DEVICE|rTMS Treatment|Active rTMS treatment.
214884968|NCT06184399|DRUG|Placebo Ivermectin ODT|Placebo for ivermectin ODT
214884969|NCT06145178|BIOLOGICAL|SPYVAC01|Novel vaccine SPYVLP01
214884970|NCT06365736|BEHAVIORAL|Contemplating in nature|"Participants will spend 30 minutes in nature per day for 10 times over 14 days.~Each time, participants will walk for 10 minutes and then choose a nice spot to sit for 10 minutes. During these minutes they will be asked to be silently present and observe trees, plants, flowers or other aspects of nature and contemplate their connectedness to nature and their own awareness. Then walk back 10 minutes."
214884971|NCT02570594|OTHER|questionary|
214884972|NCT06410313|DEVICE|ChampioNIR Ridaforolimus Eluting Peripheral Stent System|ChampioNIR implantation in Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal Artery disease
214884973|NCT06143839|DRUG|Vyxeos liposomal|Standard of care JZP351 administered intravenously over 90 minutes.
214884974|NCT06535477|DEVICE|Fall risk assessment|"Assessing frailty in elderly patients using Fried Frailty and Short Emergency Geriatric Assessment scales combined with measurement - via the AbilyCare device - of the two markers of balance and gait"
214884975|NCT01143454|DEVICE|NSR IDE-MRI: Research pulse sequences|NSR IDE-MRI: Research pulse sequences, Device Manufacturer NIH. Research pulse sequences are customized pulse sequences and analysis software developed by NIH scientists.
215047054|NCT00147576|DRUG|CP-866,087|
215047055|NCT01480167|DEVICE|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
215047056|NCT01480167|OTHER|Non-operative Management|Conservative Care
215047057|NCT00688714|DRUG|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
215047058|NCT00688714|DRUG|Placebo|
215047059|NCT04594746|DRUG|Amiodarone Hydrochloride|Amiodarone hydrochloride 2000 mg PO to be given as a 10-capsule dose pack and ingested in a single sitting with food
215047060|NCT04594746|DRUG|Placebo|Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food
215047061|NCT02199041|DRUG|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
215047062|NCT02199041|DRUG|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
214292501|NCT03656328|DIETARY_SUPPLEMENT|Lactobacillus Reuteri 4659|supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
214884976|NCT02595944|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214884977|NCT02595944|PROCEDURE|Computed Tomography|Undergo CT
214884978|NCT02595944|PROCEDURE|Echocardiography Test|Undergo ECHO
214884979|NCT02595944|BIOLOGICAL|Nivolumab|Given IV
214884980|NCT02595944|OTHER|Observation Activity|Undergo observation
214884981|NCT02595944|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
214884982|NCT06376682|PROCEDURE|CT-guided bone percutaneous procedure|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures (thermal ablation, bone consolidation, biopsy procedures).
214884983|NCT04219163|BIOLOGICAL|CLL-1.CAR T cells|"Dose escalation study with 3 dose levels:~DL1: 1x10\^7 cells/m2, DL2: 3x10\^7 cells/m2, DL3: 1x10\^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10\^6 cells/m2"
214884984|NCT03635892|DRUG|cabozantinib|cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
215047063|NCT02199041|DRUG|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
215047064|NCT02199041|DRUG|Melphalan|Given by intravenous infusion as part of the preparative regimen.
215047065|NCT02199041|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
215047066|NCT02199041|BIOLOGICAL|G-CSF|Given either by intravenous infusion or subcutaneously daily until absolute neutrophil count (ANC) \>2000 for 3 consecutive days.
215047067|NCT02199041|DRUG|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
215047068|NCT02199041|DRUG|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
215047069|NCT02199041|DRUG|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
215047070|NCT02199041|RADIATION|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
215047071|NCT02199041|BIOLOGICAL|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
215047072|NCT02199041|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
215047073|NCT01226108|DEVICE|Patch|"One patch per day, Duration: three weeks, Administration: behind the ear~\--------------------------------------------------------------------------------"
215047074|NCT03210701|OTHER|A HIV POCT program adapted for & provided by community pharmacists|Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
215047075|NCT02317627|DRUG|KD025|
215047076|NCT01903005|DRUG|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
215047077|NCT00191711|DRUG|Gemcitabine|
215047078|NCT06471543|DRUG|RN0361|Placebo
215047079|NCT06818331|OTHER|SMES+PTX|This intervention involves the combined use of medication and device, where the specific mode electroacupuncture stimulation (SMES) intervention is administered simultaneously with the intravenous infusion of paclitaxel.
215047080|NCT06818331|DRUG|Paclitaxel|Paclitaxel is administered intravenously at a dose of 135-175mg/m², repeated every 3 weeks.
215047081|NCT06818331|DEVICE|Specific mode electroacupuncture stimulation|"Patients assume a supine position. After routine skin disinfection with 75% ethanol, a stainless steel needle (size 0.25mm×40mm) is inserted into GV20 (Baihui), and another stainless steel needle (size 0.25mm×25mm, as described above) is inserted into GV26 (Shuigou). The acupoints are manually stimulated until the patient experiences soreness, distension, or heaviness (the De Qi response). Subsequently, the needles are stimulated using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng Ltd., China) at a frequency of 2/100 Hz and an intensity of 3 mA for 40 minutes (a homemade relay cycled power supply to the electrode, with 6 seconds on and 6 seconds off). The intervention is administered every three weeks, concurrently with paclitaxel treatment"
215047082|NCT06996197|OTHER|Bioimpedance analysis|BIA parameters were measured within the first 24h of ICU admission, once the patient was receiving NIV support.
215047083|NCT06590038|BEHAVIORAL|Single Session Psychotherapy Intervention|This is a single session intervention which incorporates elements from second- and third wave psychotherapies (Acceptance and Commitment Therapy and Behavioral Activation), as well as basic psychoeducation. Session will take approximately three hours in total, with the option for breaks between blocks of session.
215057312|NCT04778891|OTHER|Comprehensive Medication Management services|Comprehensive Medication Management services (CMM services) is an evidence-based and patient-centred service which involves an assessment of patient's medications to determine that each medication is appropriate, effective for the medical condition being treated, safe for the patient in the presence of other medications and co-morbidities, and that the patient is able and willing to take the medications as intended. As all patient care providers need a structured, rational thought process for sound clinical decision retrieval, the Pharmacotherapy Workup was developed and adopted as a systematic problem-solving process. This process represents the cognitive work taking place in the mind of the practitioner, and is used to identify, resolve, and prevent drug therapy problems (DTP), establish therapy goals, select interventions and evaluate outcomes.
214884985|NCT03635892|DRUG|nivolumab|Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
214884986|NCT04955730|DEVICE|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy is a single use NPWT that produces a negative pressure at -80 mmHg. Participants will have their fascia and skin closed in the same manner as the control arm participants, and will wear the NPWT dressing for 7 days after surgery.
214884987|NCT05284266|PROCEDURE|Liposuction early|Liposuction 6-9 months after inclusion
214884988|NCT05284266|PROCEDURE|Liposuction late|Liposuction 18-21 months after inclusion
214884989|NCT05284266|OTHER|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, including compression garment and exercise program, Self-care program"
214884990|NCT05284266|OTHER|Standard conservative treatment with Intermittent Pneumatic Compression (IPC)|Physical therapy, including compression garment and exercise program, Self-care program and Intermittent Pneumatic Compression (IPC)
214884991|NCT05223920|DRUG|Bomedemstat|Capsule (oral)
214292502|NCT03656328|DIETARY_SUPPLEMENT|Placebo|supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
214292503|NCT03402386|DRUG|MT-6548|Oral tablet
214292504|NCT06190639|DRUG|sintilimab|200 mg once on day 1, every 21 days
214292505|NCT00804830|DRUG|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
214292506|NCT04937829|DRUG|BI 1569912|BI 1569912
214292507|NCT04937829|DRUG|Placebo|Placebo
214292508|NCT00536406|BEHAVIORAL|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
214884992|NCT05476926|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
215047084|NCT06666231|PROCEDURE|QL (quadratus lumborum) block administration|"After endotracheal intubation, patients in the supine position will be given a lateral tilt and the areas to be treated will be cleaned with surgical antiseptic solution. The convex USG probe will be covered in a sterile manner. Then, the sterile probe will be placed transversely on the crista iliaca. The probe will be directed cranially until the external oblique muscle, internal oblique muscle and transverse abdominis muscle are clearly visualized. The psoas major muscle and the transverse process of the vertebra will be visualized. The QL muscle will be visualized between the aponeuros of the transverse abdominis muscle and the psoas major muscle. A 20 G 100 mm block needle will be advanced from posterolateral to anteromedial using the in-plane technique. The needle will be directed between the QL muscle and the psoas major muscles. 20 ml of 0.25% bupivacaine (Buvasin®, Vem İlaç, Turkey) will be injected on each side between the fasciae of these two muscles and the LA distribution"
215047085|NCT06666231|PROCEDURE|External Oblique Intercostal Plane Block|After endotracheal intubation, a 20-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
215047086|NCT03162432|DRUG|Vitamin D3|Oral Vitamin D3 therapy.
215047087|NCT06633393|OTHER|Feedback on Predicted High Myopia Risk at Age 18 Using the Myopia Prediction System|At baseline and six months, participants will be provided with the results of their predicted risk of high myopia at age 18 based on the myopia prediction system.
214884993|NCT05476926|COMBINATION_PRODUCT|Port Delivery System with Ranibizumab|The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
214884994|NCT03790657|BEHAVIORAL|practice of a complex walking task|walking over obstacles
215047088|NCT06633393|OTHER|Feedback on Ophthalmic Examinations|At baseline and six months, participants will be provided with the results of their ophthalmic examinations.
215047089|NCT06715319|DRUG|OCA|OCA 5 mg once daily in combination with UDCA for 12 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
215047090|NCT06715319|DRUG|UDCA|13\~15 mg/kg/day
215047091|NCT06715319|DRUG|Placebo|Once a day (QD) by mouth (PO)
215047092|NCT06717711|DEVICE|Low-intensity Extracorporeal Shock Wave Therapy (LiESWT)|LiESWT will be performed with PiezoWave2 from Richard Wolf and ELvation® Medical. In a single session 12,000 shocks with an energy flux density of 0.16 mJ/mm2 will be applied (4,000 over the crura of the penis and 8,000 to the penil shaft). The penis is placed in a dedicated penile holder, stretched, and shockwaves are administered with a linear therapy source (applicator) using the linear shockwave tissue coverage (LSTC-ED®) technique which makes it possible to administer shockwaves homogenously to all of the erectile tissue.
214884995|NCT03790657|DEVICE|Active transcranial direct current stimulation (Active tDCS)|mild electrical stimulation delivered to the frontal region of the brain
215047093|NCT06717711|DRUG|PDE5 inhibitor (tadalafil)|Phosphodiesterase-5 (PDE5) inhibitors
215047094|NCT01088906|DRUG|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
215047095|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone IV drip
215047096|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
215047097|NCT02784340|DRUG|Saline (IV fluids)|IV fluids 500 cc saline infusion
215047098|NCT02784340|DRUG|Bupivicaine and Fentany|
214884996|NCT03790657|DEVICE|Sham transcranial direct current stimulation (Sham tDCS)|30 seconds of mild electrical stimulation delivered to the frontal region of the brain
214884997|NCT00984724|BEHAVIORAL|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
214884998|NCT00984724|BEHAVIORAL|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
214884999|NCT00984724|BEHAVIORAL|Quitline|Letter referring participants to a Quitline providing quit smoking services.
214885000|NCT00984724|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
215047099|NCT02784340|DEVICE|25G spinal needles|
215047100|NCT05638828|DRUG|RD14-01 Cell injection|RD14-01 Cell injection
215047101|NCT00027560|BIOLOGICAL|alemtuzumab|"Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.~Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours."
215047102|NCT00027560|DRUG|cyclosporine|Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
214292509|NCT00536406|BEHAVIORAL|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
214292510|NCT01486251|DRUG|axitinib|"Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade \> 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
214292511|NCT02877420|OTHER|Non-Technical Skills Training Curriculum|
214292512|NCT02877420|OTHER|Conventional Simulation Training Group|
214885001|NCT04203134|DEVICE|Mouthguard|The mouthguard is a thin clear acrylic protector fabricated from an impression of a patient's upper teeth and palate. The acrylic protector will be trimmed and will fit onto the patient's upper teeth and palate for use during the day, except when eating to minimize trauma to the tongue that exacerbates burning tongue pain.
214292513|NCT02396901|OTHER|Goal Direct Therapy|Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
214667695|NCT02752542|BEHAVIORAL|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
214885002|NCT00877591|DRUG|Fosamprenavir/Ritonavir|1400/200 mg once daily for 15 days total
214885003|NCT00877591|DRUG|Darunavir/Ritonavir|800/100 mg once daily for 15 days total
214885004|NCT00877591|DRUG|Rifampin|600 mg once daily for 15 days total
214885005|NCT00877591|DRUG|Rifabutin|300 mg once daily for 15 days total
214885006|NCT00877591|DRUG|Buprenorphine|"FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days"
214885007|NCT01264510|OTHER|audiological test battery|routine audiological measurements.
215047103|NCT00027560|DRUG|fludarabine phosphate|Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.
215047104|NCT00027560|DRUG|melphalan|Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.
215047105|NCT00027560|PROCEDURE|allogeneic bone marrow transplantation|
215047106|NCT00027560|PROCEDURE|peripheral blood stem cell transplantation|
215047107|NCT04217434|PROCEDURE|400 µm fibre length will be used in continuous contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
215047108|NCT04217434|PROCEDURE|400 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
215047109|NCT04217434|PROCEDURE|300 µm fibre length will be used in continuous mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used continous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
215057313|NCT01671709|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
215057314|NCT02671006|OTHER|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
215057315|NCT02081508|BEHAVIORAL|Interference onset|Temporal duration of interference onset.
215057316|NCT03275090|DRUG|Smoflipid ®|
215057317|NCT06096090|DRUG|Interleukin-2|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
215057318|NCT06096090|DRUG|Placebo|Placebo administration
215057319|NCT00789152|DRUG|desloratadine|desloratadine 5 mg daily x 8 days
215057320|NCT00789152|DRUG|levocetirizine|levocetirizine 5 mg daily x 8 days
215057321|NCT00735553|DRUG|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
215057322|NCT00735553|DRUG|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
215057323|NCT00735553|DRUG|Placebo|Two placebo capsules orally daily for up to four months
215057324|NCT06004258|OTHER|Painless Vaccination|"Structural adaptation of the vaccination areas and cozy decoration (colorful room, mobiles to hang on the ceiling) Nursing uniforms decorated with children's pictures Introduction of toys, stuffed animals, stamps and reward stickers, drawings and crayons, soothing music in the background~Antalgic measures by age ranges:~0-6M (FLACC scale) Breastfeed for two minutes if infant is breastfeeding Glucose 33% or 50% or if rotavirus vaccination, on mother's pacifier or gloved finger (non-nutritive sucking) Comfort between vaccinations 6-15M (FLACC scale) Position infant sitting on guardian's lap facing forward Distraction techniques: stuffed animals, toys, audiovisual devices 3-6Y (Wong-Baker scale) Involve child, explain Child sits on tutor's lap facing forward Distraction techniques: audiovisual devices, drawings 6-14Y (VAS scale)Always seated. Distraction method: audio-visual devices, breathing"
215057325|NCT02180204|DRUG|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
215057326|NCT02180204|DRUG|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
214292514|NCT03054389|OTHER|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
214292515|NCT03054389|OTHER|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
214292516|NCT06399978|BEHAVIORAL|Brain Blossom - Gamified Differential Outcome Training|Digital cognitive training with a gamified DOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
214292517|NCT06399978|BEHAVIORAL|Gamified Non-Differential Outcome Training|Digital cognitive training with a gamified NDOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
214667696|NCT02752542|DRUG|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
214885008|NCT04575610|DRUG|PF-06650833|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric \[NG\] tube, orogastric \[OG\] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
214885009|NCT04575610|DRUG|Placebo|Matching placebo tablets will be administered.
214885010|NCT02832011|DIETARY_SUPPLEMENT|olive oil|The infants fed with olive oil will have received same amount of calorie with infants who will receive eoprotin-fortified breast milk.
214885011|NCT02832011|DIETARY_SUPPLEMENT|Eoprotin|Low birth weight infants are premature infants that born with birth weight less than 1500 g. Because these infants have low birth weight, weight gain can be increased by fortifying breast milk after post-natal 7 with eoprotin.
215047110|NCT04217434|PROCEDURE|300 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. .Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
215047111|NCT03703557|DIAGNOSTIC_TEST|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.
214292518|NCT05003076|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
214885012|NCT02018419|BIOLOGICAL|AlloStim|AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.
215047112|NCT03703557|DIAGNOSTIC_TEST|Odour sampling|Analyzed by the dogs of Curie Institute at the training centers
214292519|NCT05003076|DRUG|Placebo|Participants will be given a placebo capsule that will only contain lactose.
214885013|NCT02018419|PROCEDURE|Cryoablation|Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.
215047113|NCT04705805|BEHAVIORAL|Self-assessment of olfactory disorders through two questionnaires.|"* Assessment of sense of smell or loss of smell using an Analogue Visual Scale~* Carrying out the objective smell test (Sniffin' sticks test) (gold standard)~* Information from two self-questionnaires translated into French: a quality of life questionnaire (The Questionnaire Olfactory Disorders (QOD)) and a self-assessment questionnaire of his olfactory capacities (Self-Mini Olfactory Questionnaire (Self-MOQ))"
214292520|NCT01896531|DRUG|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
214292521|NCT01896531|DRUG|Ipatasertib|Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
214292522|NCT01896531|DRUG|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
214885014|NCT03347682|OTHER|Satisfaction with Prosthesis -SATPRO|questionnaire 1
214885015|NCT03347682|OTHER|Nottingham Health Profile-NHP|questionnaire 2
214885016|NCT03347682|OTHER|Prosthesis donning and doffing questionnaire|questionnaire 3
215047114|NCT01790607|DRUG|ONO-2745 /CNS 7056|
215047115|NCT05648812|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
215047116|NCT05648812|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
214292523|NCT01896531|DRUG|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
214292524|NCT01896531|DRUG|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
214292525|NCT02697786|DEVICE|Transcranial doppler|Prolonged de airing to decrease the number of MES
214885017|NCT01809912|DRUG|Recombinant human apolipoprotein(a) Kringle V|
214477143|NCT06824766|OTHER|Visual Analogue Scale|The pain intensity of the participants will be assessed using the Visual Analogue Scale, which is a simple, reliable and short-term method commonly used to measure pain intensity in the clinic. The participant is told that the most severe pain he/she experiences is 10 and if there is no pain, the pain intensity is 0. The participant will be asked to tick a number between 0 and 10 corresponding to the intensity of pain felt in the masticatory muscles at rest and during chewing.
214477144|NCT06824766|OTHER|Autonomic nervous system activity assessment|All participants included in the study will undergo a 5-minute test with the Polar H10 chest strap device for autonomic nervous system activity assessment (heart rate variability assessment). The data obtained after the measurement will be analysed with Kubios software. Stress index (cardiovascular system stress), PNS index (parasympathetic nervous system dominance), SNS index (sympathetic nervous system dominance), LF power (sympathetic activity), HF power (parasympathetic activity) and LF/HF ratio (sympathetic/parasympathetic balance) parameters will be used in the evaluation of HRV in Kubios programme.
214885018|NCT02253004|DRUG|Cilostazol|Single oral administration of active or placebo one week apart
214885019|NCT02253004|DRUG|Placebo|
214885020|NCT03484091|DRUG|Hyruan-One|single dose intra-articular injection
214885021|NCT03484091|DRUG|Hylan G-F 20|single dose intra-articular injection
214885022|NCT03484091|DRUG|Normal saline|single dose intra-articular injection
214885023|NCT06180356|DRUG|Niraparib oral tablets|Niraparib 300 or 200 mg according to body weight or platelet count. Tablets will be taken orally, once daily, continuously (in 28-day cycles).
214885024|NCT06418204|OTHER|Non-interventional Study|Non-interventional study
214477145|NCT06824766|OTHER|Masticatory muscles assessment|The Myoton PRO device will be used to objectively assess the biomechanical properties of the participants' masticatory muscles such as tone, stiffness and elasticity. The masseter and temporalis muscles will be evaluated bilaterally in the sitting position. Three measurements will be recorded at one second intervals and the average value will be used for analysis.
214477146|NCT06825689|DEVICE|Self-sampling with urine|Urine is self-collected at home using a urine sample cup.
214477147|NCT06825689|DEVICE|Self-sampling with swab|A vaginal cell sample is self-collected at home using a swab and collection tube.
214885025|NCT05422469|DEVICE|Medtronic Percept RC neurostimulator|Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
214885026|NCT06475053|DEVICE|NaturalVue Enhanced Multifocal 1 Day contact lens|Daily disposable multifocal contact lens
214885027|NCT06475053|DEVICE|MiSight 1 Day contact lens|Daily disposable dual-focus contact lens
214885028|NCT06642519|OTHER|Brain Stimulation|Studies will be conducted using ECoG, with a bidirectional interface, both recording (aim/phase 1) and stimulating (aim/phase 2), during real-world gait and FOG in PD patients over the course of 7-days of gait experiments.
214885029|NCT06976320|OTHER|Intravenous morphine patient control analgesia|24-hour morphine consumption will be recorded
214885030|NCT06976320|OTHER|Intravenous patient control analgesia|24-hour morphine consumption will be recorded
214885031|NCT06976320|OTHER|Deep rectus sheath block|Deep rectus sheath block will be administered at the end of the surgery.
214885032|NCT06132763|BEHAVIORAL|Hydration Intervention|"Teacher \& student ambassadors: serve as hydration role models, identify Hydration Heroes, monitor filter lights on hydration stations, \& update the water meter visual.~Kick-off event: event to kick off the hydration intervention to include water bottles distribution with a station to personalize, experiential activities, and information about the intervention.~Social marketing: student-developed marketing campaign Make water your superpower will be placed in high-traffic areas of the school. Hydration Headquarters will be located in the lunchroom displaying a water meter illustrating bottle refills from the school's hydration stations.~Behavioral reinforcement: on random days, students drinking water and/or with a water bottle will receive small incentives.~Education and outreach: Hydration Tip Sheets, hydration signage in classrooms, and hydration trivia on hydration stations. Teachers will deliver 1 hydration lesson per month that align with Standards of Learning."
214477148|NCT06825689|DEVICE|In-clinic Pap/HPV co-testing|Cervico-vaginal cell samples are collected by a clinician during a Pap smear/HPV co-test appointment.
214477149|NCT06818526|DEVICE|Huandao Conditioning Application|"Mobile Application Intervention: Huandao Conditioning App for Allergic Rhinitis Treatment~Type: Software Application (Mobile App) Purpose: Energy balancing therapy based on traditional Chinese medicine meridian theory Application Method: Self-administered via smartphone Duration: 5-10 minutes per session"
214667697|NCT04935736|DEVICE|root canal sealer : CORTISOMOL SP|The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.
214885033|NCT06132763|OTHER|Control - Assessments Only|Assessments only
214885034|NCT05867368|BEHAVIORAL|HABIT-VR|HABIT-VR is a suite of video games designed on the principals of HABIT treatments. The games are delivered in virtual reality, because these systems provide a way to track the movements of both hands and build software that requires both hands to succeed.
214885035|NCT05867368|BEHAVIORAL|Standard HABIT|HABIT is a camp where children play self-select activities that require both hands to succeed.
214885036|NCT06804655|DEVICE|Pharmacoscopy 1.0|The intervention is the submission of freshly obtained surgical material to ex vivo drug profiling which we term pharmacoscopy (PCY). The performance study is interventional as the test results shall influence patient management decisions and/or may be used to guide treatment.
214885037|NCT05081193|DRUG|Testosterone Undecanoate|198mg taken twice daily
214885038|NCT05081193|DRUG|Enzalutamide|160mg taken once daily
214885039|NCT03071406|DRUG|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
214885040|NCT03071406|DRUG|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
214885041|NCT03071406|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
215047117|NCT06640179|OTHER|Standard medical care|Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
215047118|NCT06640179|BEHAVIORAL|Monitoring Contacts|Participants will receive brief conducts (\<10 minutes) remotely (telephone or video platform) with the research staff at weeks 6, 12, and 18.
214292526|NCT00632411|DRUG|Nicotine Patch|"Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment."
214885042|NCT06719869|DEVICE|Midline intravenous catheter|Patients in the intervention group receive a 10 cm PowerGlide Pro™ Midline Catheter (Becton Dickinson). Catheters are inserted with ultrasound-guidance by an anesthesiologist using sterile gloves, mask, and large drape. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. All catheters are secured with using a StatLock™ Stabilization device (Becton Dickinson), and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. Choice of insertion site on arm below or above the elbow avoiding catheter across joints and at the clinician's discretion.
214292527|NCT00632411|BEHAVIORAL|Tobacco Quit Line Program|"Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention."
214477150|NCT06818526|DEVICE|Placebo Huandao Conditioning App|"Mobile Application Intervention: Placebo Huandao Conditioning App for Allergic Rhinitis Treatment~Type: Software Application (Mobile App) Purpose: Energy balancing therapy based on traditional Chinese medicine meridian theory Application Method: Self-administered via smartphone Duration: 5-10 minutes per session"
214477151|NCT06610903|DRUG|Hemay005|In the first cycle, 15mg (1 tablet/person) was given on an empty stomach for Hemay005-T1 or Hemay005-T2, and the second cycle was crossed over
214477152|NCT06610955|OTHER|High intensity interval training|After a 10 minutes warm up exercise, participants will exercise with a bicycle ergometry device at 80% of their maximum heart rate for 4 minutes, and the active recovery period will be 3 minutes (4x4 minutes). During the recovery period, the participant will exercise with the Ergoline bicycle ergometry system for 4 sets at 60% of their maximum heart rate for 3 minutes. A total of 45 minutes exercise session will be completed with a 10 minutes cool down exercise. Exercise will be done 5 days a week for a total of 8 weeks. In the first 4 weeks, exercise will be done at 80% intensity, and in the following weeks, the exercise intensity will be increased by 5% each week, respectively, to 85%, 90%, 95%, and 100% in the last week.
214477153|NCT06610955|OTHER|Moderate intensity continuous training|Following a 10 minutes warm up exercise, participants will exercise continuously for 30 minutes at 65% of their maximum heart rate with the Ergoline bicycle ergometry system. A 5 minutes cool down exercise will end the 45 minutes exercise session. The exercise duration is 5 days a week for a total of 8 weeks.
214667698|NCT04935736|DEVICE|root canal sealer : SEALITE REGULAR|The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.
214667699|NCT00065910|BEHAVIORAL|Caregiver joint attention intervention|
215047119|NCT06640179|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly individual behavioral sessions during the 6-month intervention to assist in supporting recommended changes in energy intake (diet) and physical activity.
215047120|NCT06640179|BEHAVIORAL|Diet|An energy balanced diet to meet energy needs that will allow for weight maintenance will be prescribed. This will be estimated using the Mifflin-St. Joer equation to estimate resting metabolic rate and for most participants we anticipate using a physical activity correction of 1.3 to account for energy needs for physical activity. This will provide the initial estimate of energy intake needs to maintain weight stability; however, the prescribed level of energy intake will be adjusted at 4-week intervals across the intervention based on the observed changes in weight, eating behaviors, and physical activity patterns in an effort to prevent excessive weight gain. Within the context of this level of energy intake, we will prescribe a diet that is consistent with the dietary recommendations of the National Kidney Foundation.
215047121|NCT06640179|BEHAVIORAL|Physical Activity|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress in 4-week intervals from an initial amount of 50 minutes per week to 150 minutes per week across the initial 6 months of the intervention. Moderate intensity will be prescribed, and will be anchored using RPE (rating of perceived exertion) to allow intensity to be self-regulated according to the participant's capacity. Physical activity will be prescribed in the form of walking; however, the participant will be permitted to engage in other forms of physical activity that meet the recommended dose and intensity.
215047122|NCT05120492|PROCEDURE|bariatric surgery followed by total knee replacement|The only intervention is the randomization of the priority of the 2 procedures.
214292528|NCT03012425|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
214292529|NCT03012425|PROCEDURE|Acupuncture|
214292530|NCT03012425|BEHAVIORAL|questionnaires|
214667700|NCT03638011|DRUG|Exparel|Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
214667701|NCT00252863|DRUG|Symbicort, used twice daily (b.i.d) and as needed (prn)|
214667702|NCT00252863|DRUG|Budesonide Turbuhaler 200 µg|
214667703|NCT00252863|DRUG|Fluticasone Discus 250 µg|
214292531|NCT03012425|OTHER|Diurnal Cortisol|saliva test
214667704|NCT00252863|DRUG|Formoterol Turbuhaler 4.5 µg|
214667705|NCT00252863|DRUG|Terbutaline Turbuhaler 0.5 mg|
214667706|NCT00252863|DRUG|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
214667707|NCT00252863|DRUG|Salmeterol Discus 50 µg|
214292532|NCT03233906|DIETARY_SUPPLEMENT|Chia Seeds- Salvia Hispanica|Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
214292533|NCT00415103|DRUG|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
214885043|NCT06719869|DEVICE|Central Venous Catheter (CVC):|Patients in the control group receive a Celsite 320 or 315 (B. Braun) or Pressure Injectable Arrowg+ard Blue Plus+ (Arrow). Catheters are inserted with ultrasound-guidance by an anesthesiologist with maximal sterile precautions (cap, mask, gown, gloves, and large drape) using the Seldinger technique. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. Catheters are secured with monofilament sutures, and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. The choice of insertion site is at the clinician's discretion
214292534|NCT00415103|DRUG|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
214292535|NCT00415103|DRUG|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
214885044|NCT04945018|BIOLOGICAL|HS-001 CS|Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension
214885045|NCT04945018|DEVICE|HS-001-D needle, HS-001-D Adaptor|Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors
214885046|NCT03617458|DRUG|Metformin|Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.
214885047|NCT03617458|DRUG|Placebo|A treatment with no active ingredients or therapeutic effect.
214885048|NCT03617458|DEVICE|mHealth Intervention|Our Health Insurance Portability and Accountability Act (HIPAA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
214292536|NCT00042172|DRUG|Donepezil|
214885049|NCT03617458|DEVICE|Usual Care|Our HIPAA data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.
214885050|NCT06427941|DRUG|BGB-B2033|Administered by intravenous infusion
214885051|NCT06427941|DRUG|Tislelizumab|Administered by intravenous infusion
214292537|NCT00042172|DRUG|Ginkgo Biloba Extract|
214292538|NCT03153254|DEVICE|Test upper limb robot assisted therapy device|During 1 session of 1/2 hour.
214292539|NCT03153254|DEVICE|Training with new upper limb robot assisted therapy device|During 2 to 5 sessions of 1/2 hour.
214292540|NCT06405061|DRUG|Adebrelimab|Adebrelimab: 1200 mg, IV, q3w
214292541|NCT01858090|DRUG|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
214292542|NCT01858090|DRUG|Group Fentanyl|
214292543|NCT01858090|DRUG|Group sufentanil|
214292544|NCT01858090|DRUG|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.
214292545|NCT01858090|DRUG|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
214292546|NCT01858090|DRUG|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
214885052|NCT05835362|BEHAVIORAL|Question prompt list|A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.
214885053|NCT05835362|BEHAVIORAL|Pre-visit video|The 11-minute video has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD.
214885054|NCT05835362|BEHAVIORAL|Combined question prompt list/video|"A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.~And the video is an 11-minute video that has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD."
214885055|NCT05673226|OTHER|Surface disinfection with Organosilane|Organosilane will be sprayed on the surfaces, using an atomizer. When the environment has been completely covered (i.e., when all surfaces and equipment have a slightly damp film), we will proceed with the second phase of the disinfection of all heavily touched surfaces. surfaces of the bed, with a microfiber cloth with organosilane.
214885056|NCT06048822|BEHAVIORAL|Pickleball|Participants will be encouraged to attend ≥2 pickleball sessions per week, with the YMCA offering 5 sessions per week. Sessions will last 2 hours, with participants encouraged to attend ≥1 hour. New players will receive instruction from a YMCA exercise trainer with a USA Pickleball Association Instructor Certification during sessions. At the end of each session, the YMCA trainer will note on attendance sheets whether participants engaged in training/skill development, open play, or both. Participants will be encouraged to engage in 5-10 minutes of structured warm-up exercise (i.e., walking laps around the courts and dynamic and static muscle stretches) prior to playing in each session, and they will be encouraged to perform cool-down stretches after they complete each session.
214885057|NCT04366934|OTHER|Nasal swab|Nasal swab
214885058|NCT04366934|OTHER|Taste and olfactory function evaluation|Taste and olfactory function evaluation
214885059|NCT05358795|BEHAVIORAL|Family Connections|Family Connections is based on the WHO endorsed Positive Connections manual.
214885060|NCT05681026|BEHAVIORAL|Yoga Sessions|Participants will have up to 12 sessions, 3 sessions per week starting two weeks before the transplant and throughout the first 30 days of your hospitalization.
214885061|NCT05681026|BEHAVIORAL|Questionnaries|Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.
214885062|NCT05681026|BEHAVIORAL|Interviews|Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).
214885063|NCT04186845|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
214885064|NCT04186845|DIAGNOSTIC_TEST|Positron emission tomography scan|Imaging scan with radioligand
214885065|NCT04052360|DRUG|Cenerimod|A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
214885066|NCT04052360|DRUG|Matching Placebo|A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
214885067|NCT03431493|BEHAVIORAL|Behavioral Activation - Rehabilitation|"Participants will first receive a home visit from a physical therapist (PT) who will evaluate home safety and establish/verify the participant's exercise prescription. Within 1 week, an occupational therapist (OT) will visit the home to: 1) explain the purpose of behavioral activation (BA); 2) help the participant identify long-term recovery goals regarding valued activities; and 3) then, using the principles of BA, identify short-term goals for the next week and an action plan. The OT will then call the participant weekly (weeks 2-5) to review the status of the prior week's goals and use BA to set new goals for the upcoming week. The PT and OT will repeat home visits at week 6 to assess the participant's progress, and the OT will conduct phone calls every 2 weeks for weeks 8-12."
214885068|NCT05061420|DRUG|Pembrolizumab|Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion
214885069|NCT05061420|DRUG|SAR444245 (Thor-707)|Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion
215047123|NCT06931106|BEHAVIORAL|HAPA and CEI behavioral intervention|The intervention group will receive a 3-month technology-facilitated PrEP intervention and tailored messages will be developed using BCTs based on theoretical guidance. PrEP teleconsultations will be delivered by certified healthcare professionals, including infectious disease specialists, CDC-affiliated prevention officers, and MSM community leaders. Participants will be stratified into peer cohorts through algorithm-driven grouping based on demographic characteristics. Six participants will form a peer group, and the economic incentive amount will be based on the group-level PrEP initiation rates (verified by physician prescriptions). The economic incentive will decrease progressively based on the average completion rate within the group and will be divided into three tiers: 22 USD (completion rate of 80-100%), 11 USD (completion rate of 50-79%), and 0 USD (completion rate \<50%).
215047124|NCT06931106|BEHAVIORAL|HAPA-based intervention|This group receives information pushes via a mini-program (3 messages per week) and two brief PrEP consultations; the first brief consultation is delivered jointly by community volunteers and a physician immediately after the baseline survey completion, based on a standardized consultation outline, and the second brief consultation is delivered jointly by community volunteers and a physician after the completion of the first monthly assessment (conducted within the mini-program), based on the standardized consultation outline and the results of that monthly assessment.
215047125|NCT06947811|DRUG|Almonertinib|Patients will be treated with Almonertinib, 110 mg p.o., daily
215047126|NCT06947811|DRUG|Palbociclib|Patients will be treated with Palbociclib, 125 mg(dose determined from Part one of study) p.o., daily
214885070|NCT05061420|DRUG|Cetuximab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous Infusion
214885071|NCT05862727|BEHAVIORAL|Telehealth Intervention|Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.
214885072|NCT00422500|BEHAVIORAL|Questionnaire|Surveys about symptoms, mood, and quality of life.
214885073|NCT00422500|BEHAVIORAL|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
214292547|NCT01858090|DRUG|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
214885074|NCT00422500|OTHER|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
214885075|NCT06115772|OTHER|Non-Interventional Study|Non-interventional study
214885076|NCT05942625|DRUG|HS-10390 tablet|Oral administration of specified dose of HS-10390
214885077|NCT05942625|DRUG|Placebo tablet|Oral administration of matching dose ofplacebo
214885078|NCT05200364|DRUG|STRO-002|intravenous antibody drug conjugate
214292548|NCT01858090|DRUG|Diphenhydramine|for severe pruritus
214292549|NCT01858090|DRUG|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
214885079|NCT05200364|DRUG|Bevacizumab|anti-VEGF agent
214885080|NCT04169152|PROCEDURE|Cap-assisted endoscopic sclerotherapy|Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
214885081|NCT02859142|DRUG|Chantix|Chantix given alongside standard smoking cessation treatment, and administered per manufacturer's instructions \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
214885082|NCT02859142|BEHAVIORAL|Behavioral Counseling Sessions|One-to-one behavioral counseling sessions with a trained therapist
214667708|NCT00252863|DRUG|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
214667709|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 250/50 µg|
214885083|NCT02859142|DRUG|NicodermCQ|Nicotine patches provided over 12 week participation
214885084|NCT02859142|DRUG|Placebo|Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
214885085|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - in addition to standard of care|Up to 3 Tesla (T) MRI
214885086|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - not in addition to standard of care|Up to 3 Tesla (T) MRI
214885087|NCT03290079|DRUG|Pembrolizumab|200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle.
214885088|NCT03290079|DRUG|Lenvatinib|20 mg Lenvatinib by mouth every day of each 3 week cycle
214885089|NCT06442215|OTHER|Data collection|Collection of preoperative demographic, clinical, and radiological variables from patients who meet the inclusion criteria in order to identify possible risk factors for suboptimal surgical treatment
214885090|NCT02466685|DRUG|JNJ-18038683|JNJ-18038683 10-20 mg/day tablet for 8 weeks
214885091|NCT02466685|DRUG|Placebo|placebo tablet daily
214885092|NCT02479529|DRUG|Norepinephrine|Administration and weaning of norepinephrine is based on dynamic arterial elastance
214885093|NCT02479529|DRUG|Norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
214885094|NCT04521738|DRUG|SAR441255|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
214885095|NCT04521738|DRUG|placebo|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
214885096|NCT05126329|DRUG|amcenestrant|tablet for oral use
215047127|NCT06951542|BEHAVIORAL|Stigma Reduction Counseling|The stigma reduction counseling sessions will include psychoeducation and activities to challenge myths and stereotypes, cope with experiences of discrimination, and overcome self-stigma.
215047128|NCT03906357|DRUG|Pemigatinib|
215047129|NCT05861141|OTHER|Selected physical therapy program|"Patients will receive a selected physical therapy program for 1 hr, 3 times per week, for 3 successive months in the form of:~* Balance and postural control exercises for 15 minutes, including the following:~  * Standing on balance board.~ * Stoop and recovery.~* Gait training for 45 minutes, including the following:~  * Forward, backward, and sideways walking.~ * Walking with obstacles using wedges and rolls with different diameters and heights."
215047130|NCT05861141|DEVICE|Aerobic training|"Patients will receive the same selected physical therapy program as the control group for 15 minutes in addition to treadmill training for 45 minutes, 3 times per week, for 3 successive months.~Treadmill training: Will be practiced according to the following stages:~A- Warm up: 5 minutes.~B- The exercise phase: 35 minutes (three-minute stages), the speed will be increased gradually every 3 minutes intervals until the child no longer be able to walk at the current stage.~C- Cool down: 5 minutes."
215047131|NCT01520467|DRUG|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
215047132|NCT01520467|DRUG|Placebo|1 placebo tablet /day administered orally for 18 months.
215047133|NCT03384875|DEVICE|CytoSorb|To evaluate the safety and performance of the CytoSorb® device to decrease the incidence or severity of acute kidney injury (AKI)
215047134|NCT05373212|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
215047135|NCT05373212|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
214292550|NCT01858090|DRUG|Diclofenac sodium|as additional analgesic among cases in which VAS\>3(Postoperatively)
214667710|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 500/50 µg|
214667711|NCT00252863|DRUG|Theophylline 200 mg|
214667712|NCT00252863|DRUG|Theophylline 300 mg|
214667713|NCT00252863|DRUG|Singulair 10 mg|
214667714|NCT03715257|DEVICE|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
214885097|NCT04142086|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
214885098|NCT04142086|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
214885099|NCT04142086|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
214885100|NCT04142086|BIOLOGICAL|Yellow fever vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
214885101|NCT01596790|OTHER|Blood analysis by EPISPOT and Cellsearch|For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
214885102|NCT04819893|BIOLOGICAL|Maternal blood sampling|5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
214885103|NCT04819893|BIOLOGICAL|Umbilical cord blood sampling|0.5mL sample from the umbilical cord after childbirth standard protocols
214885104|NCT04819893|BIOLOGICAL|Placenta sampling|Sampling of 3 cotyledons by cutting across the thickness of the placenta
214885105|NCT04819893|OTHER|Data collection|Newborn, Maternal and Premature Retinopathy Screening Data Collection
214885106|NCT06245915|BIOLOGICAL|AB-2100|autologous T cell therapy
214885107|NCT06371911|OTHER|Cureety telemonitoring|The digital telemonitoring platform, Cureety, has been designed to facilitate the monitoring of signs and symptoms of treatment-specific AEs and disease progression. The platform integrates Cureety TechCare, a CE marked algorithm that is a class I medical device
214885108|NCT06371911|OTHER|OPTIMA or equivalent programs|"The programs consist of three stages:~1. The medical team make structured telephone calls with patients 2 to 3 days before the planned administration of injectable treatment. Adverse events and other relevant data are collected.~2. Patients undergo biological tests within 48 hours of the appointment and the results are sent by the laboratory to the centre.~3. Then, the physician assesses the data and decides whether to anticipate and validate the prescription of injectable treatments."
214885109|NCT06465303|DRUG|RTP-026|Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;
214885110|NCT06465303|DRUG|Placebo|Intervention is for each subject administered as three 30-minutes infusions of placebo
214885111|NCT02155621|GENETIC|Genome sequencing|Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis
214885112|NCT02869802|PROCEDURE|Tumour Biopsy|If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.
215047136|NCT04120129|DEVICE|TMS|Transcranial Magnetic Stimulation (TMS) is a noninvasive brain stimulation technique which produces short pulsatile magnetic fields (similar to that of an MRI) via two extracranial, figure 8-shaped electric coils which can induce a small, temporary, electric current in the brain currently approved and used for depression.
215047137|NCT04120129|DEVICE|sham TMS coil|The sham TMS does cause some stimulation to the participant so that the participants get the sensation of treatment without any cortical excitation that TMS delivers. The sensation experienced is similar to the muscle twitching or finger tapping experienced by TMS participants.
215047138|NCT04812327|DIAGNOSTIC_TEST|BD Veritor Plus System for Rapid Detection of SARS CoV-2|Nasal Sawb for the conduct of the Veritor Antigen Test
215047139|NCT04812327|DIAGNOSTIC_TEST|rt-PCR|Nasopharyngeal Swab for the conduct of a rt-PCR
215047140|NCT04812327|DIAGNOSTIC_TEST|viral culture|Nasopharyngeal Swab for the conduct of viral culture
215047141|NCT06119516|OTHER|Esophageal pressure-guided strategy,|A catheter-balloon system will be positioned and calibrated in all included patients. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. A connection line will be inserted between the catheter (either esophageal or gastric balloon port) and the auxiliary pressure port of the mechanical ventilator (General Electric, R860, available in each center). Numeric recording of the respiratory signals will be achieved via the OhmedaCom Research Tool software, helping for centralization of the analyses, therefore ensuring reproducibility of the results.
215047142|NCT04818957|DIETARY_SUPPLEMENT|Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)|Study participants will receive vitamin D OTF weekly for a maximum of 12 weeks. The dose may be increased or decreased based on the dosing schema.
215047143|NCT04772209|DRUG|Sodium bicarbonate|Dialysis catheter lumen will be filled (locked) by sodium bicarbonate solution. The amount of solution depends on the diameter and length and will be in accordance with the manufacturer's specifications.
214292551|NCT01195415|DRUG|Gemcitabine Hydrochloride|Given IV
214292552|NCT01195415|OTHER|Laboratory Biomarker Analysis|Correlative studies
214292553|NCT01195415|DRUG|Vismodegib|Given PO
214292554|NCT04447261|DRUG|BI 1356225|BI 1356225
214292555|NCT04447261|DRUG|Placebo|Placebo
214292556|NCT02939898|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
214292557|NCT02939898|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
214292558|NCT05320523|DEVICE|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.
214292559|NCT05320523|DEVICE|GPi stimulation|Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system
214292560|NCT05320523|DEVICE|NBM stimulation|Bilateral low-frequency neurostimulation of the NBM using a Vercise neurostimulation system
214885113|NCT02869802|OTHER|Serial Collection of Plasma and Serum Samples|Participants will undergo serial collection of plasma and serum samples at baseline and every cycle of chemotherapy or every 4 weeks, whichever is longer, until end of study.
214885114|NCT06171126|DIETARY_SUPPLEMENT|Placebo|By gastroscopy
214292561|NCT05320523|DEVICE|Sham stimulation|Ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
214292562|NCT02155842|BEHAVIORAL|High intensity endurance exercise|
214885115|NCT06171126|DIETARY_SUPPLEMENT|Faeces from donor A|By gastroscopy
214292563|NCT02155842|BEHAVIORAL|Moderate continuous endurance exercise|
214292564|NCT00167882|DRUG|5-aminosalicylate (Pentasa, Ferring)|
214292565|NCT00533845|DRUG|On-Q Pain Pump|Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
214292566|NCT00036504|DRUG|Insulin Lispro low mixture|
214292567|NCT02956486|DRUG|Elenbecestat|Oral tablet.
214292568|NCT02956486|DRUG|Placebo|Oral tablet.
214292569|NCT04541576|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
214292570|NCT01373372|DRUG|Acthrel|Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
214667715|NCT03715257|DEVICE|Tube changing catheter|"Tube changing catheter Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
214292571|NCT06080607|BEHAVIORAL|Patient Reported Outcome (PRO)|Quality of Life evaluation
214292572|NCT06185504|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows~1. The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~2. Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~3. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~4. Direct feeding training: with powdered milk, once a day, 5 days a week."
214292573|NCT06185504|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
214885116|NCT06171126|DIETARY_SUPPLEMENT|Faeces from donor B|By gastroscopy
214885117|NCT06171126|DIETARY_SUPPLEMENT|Faeces from donor C|By gastroscopy
214885118|NCT03545464|DRUG|Placebo Oral Tablet|Placebo of cortancyl Oral Tablet 20mg
214885119|NCT03545464|DRUG|Cortancyl Oral Tablet|Cortancyl oral Tablet 20 mg
214885120|NCT03545464|DRUG|Levocetirizine Oral Tablet|Levocetirizine Oral Tablet 5 mg
214885121|NCT04697069|BIOLOGICAL|Imsidolimab|Humanized monoclonal antibody
214885122|NCT04697069|BIOLOGICAL|Placebo|Placebo
214885123|NCT05385705|DRUG|Cyclophosphamide|Cyclophosphamide at a single dose of 600mg/m2 IV between days -5 and -3 before NK cell infusion for preconditioning the tumoral microenvironment by reducing the levels of lymphocyte T regulators (Tregs FOXP3+, CD3+, CD4+, CD25+).
214477154|NCT06668597|BEHAVIORAL|Motivational educational program to improve sleep quality in OSA patients through adherence to CPAP|Phase 1 (Pre-adaptation Psychoeducation): The participant will be shown, within two days prior to the home visit by the provider, which usually takes place within three days of the visit with the pulmonologist, the necessary materials (device, masks, and tubing), along with an educational video on the topic of OSA (duration 25 minutes); Phase 2 (Motivational Interview): Following the first night of titration and use of the CPAP, the participant will be contacted by phone for a brief motivational interview (duration 25 minutes); Phase 3 (Psychological Support Interview): One week after the provider's intervention and the start of the CPAP adaptation period, the participant will be contacted again for a support interview regarding the adaptation process to CPAP (duration 40 minutes). The first week of adaptation is considered a high-risk period for abandonment of device use; Phase 4 (Monitoring Interview): Two weeks after the provider's intervention and the start o
214477155|NCT06609486|DEVICE|Blood pressure measurement group|"In this study, the protocol applied to automatic electronic blood pressure system module BN1 for performance evaluation is ISO's proposed ISO 81060-2:2018 Non-invasive sphygmomanometers- Part2: Clinical investment of internal automatic measurement type. The initial BP measurement is performed alternately, measuring the blood pressure by the measurer and the test device once each, and measuring blood pressure by the measurer four times by the observer and three times by the test device."
214477156|NCT05707195|OTHER|Questionnaire|"A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit"
214477157|NCT06609512|DRUG|Enlicitide|Oral Tablet
214667716|NCT05528276|PROCEDURE|Repair surgery|"1. a circumscribing skin incision was made 2 mm below the hypospadias meatus,~2. penile degloving,~3. the para-urethral plate incision was made,~4. A vertical midline incision of the urethral plate was made from within the hypospadiac meatus and extended up to the mid-glans.~5. The urethral plate was tubularised, beginning proximally, and closed in two layers using 6/0 polyglactin 910 suture.~6. The neomeatus was formed on a catheter 2 F larger than the urethral stent.~7. A flap was harvested from the prepuce to cover the neourethra and finally glanuloplasty.~8. A suitable urethral stent was left in situ for 7-10 days, with a compressive dressing applied.~   * Grafted tubularised incised-plate .~1.Same steps but adding a graft (dorsal inlay) , 2. The graft will be taken from the inner preputial skin . 3. The graft will be sutured to overlying plate incision line from the old meatus to the tip of the glans."
214667717|NCT06319911|DEVICE|AETOS|The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration
214885124|NCT05385705|DRUG|Trastuzumab|Trastuzumab at a dose of 8mg/kg IV for the loading dose on Day 1, and 6mg/kg IV for the maintenance dose every 3 weeks (Q3W).
214667718|NCT01327430|DIETARY_SUPPLEMENT|Milk phospholipid|During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
214667719|NCT00929292|OTHER|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
214292574|NCT06185504|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
214292575|NCT03241342|DRUG|GTx 024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
214292576|NCT03241342|DRUG|Placebo|Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
214667720|NCT00929292|OTHER|Modilac 1|Infant formula used for non breastfed children
214885125|NCT05385705|DRUG|Pertuzumab|Pertuzumab at a dose of 840mg IV for the loading dose on Day 1, and 420 mg IV for the maintenance dose every 3 weeks (Q3W).
214885126|NCT05385705|BIOLOGICAL|NK cells|NK product is a cellular investigational product comprising a live cell suspension of allogenic NK cells derived from a compatible donor that will be infused on Day 2.
214292577|NCT01267812|DRUG|bortezomib|Given SC or IV
214885127|NCT05385705|DRUG|Interleukin-2|IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.
214885128|NCT05180227|DEVICE|DS8R|transcutaneous stimulation of the spinal cord.
214667721|NCT01981187|DRUG|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
214292578|NCT01267812|BIOLOGICAL|rituximab|Given IV
214292579|NCT01267812|OTHER|laboratory biomarker analysis|Correlative studies
214292580|NCT01267812|OTHER|immunohistochemistry staining method|Correlative studies
214667722|NCT03576872|OTHER|Psychoeducational|Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
214667723|NCT05624372|DIAGNOSTIC_TEST|hearing and cognitive assessment|psychiatric assessment, hearing assessment and brief cognitive assessment
214667724|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
214667725|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
214667726|NCT03440112|DRUG|Clarithromycin (Not used as of 4/2020)|Clarithromycin (generic) capsule 250mg each
214667727|NCT03440112|DRUG|Placebo (Not used as of 4/2020)|Lactose in a gel capsule
214667728|NCT03440112|DRUG|Transdermal flumazenil (Added 4/2020)|Transdermal flumazenil 24mg/mL
214667729|NCT03440112|DRUG|Placebo (Added 4/2020)|Transdermal placebo
214885129|NCT04586530|BEHAVIORAL|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
214885130|NCT04586530|BEHAVIORAL|Supportive Therapy (ST)|Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
214885131|NCT05848011|BIOLOGICAL|lorigerlimab|Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4
214885132|NCT05848011|DRUG|docetaxel|Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
214885133|NCT05848011|DRUG|Prednisone|A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
214885134|NCT03992404|DRUG|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214885135|NCT03992404|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214885136|NCT01218854|DEVICE|Needle angle measurement|The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
214885137|NCT07123129|DRUG|SHR-7782 Injection|SHR-7782 injection.
214292581|NCT01267812|GENETIC|RNA analysis|Correlative studies
214292582|NCT01267812|GENETIC|gene expression analysis|Correlative studies
214292583|NCT01267812|GENETIC|DNA analysis|Correlative studies
214292584|NCT01267812|OTHER|pharmacological study|Correlative studies
214292585|NCT01267812|OTHER|pharmacogenomic studies|Correlative studies
214292586|NCT01267812|OTHER|Questionnaire Administration|
214292587|NCT05833295|PROCEDURE|Downhill walking|Change in the H/M ratio after a downhill walk.
214292588|NCT05833295|PROCEDURE|Walking on flat ground|Change in the H/M ratio after a Walking on flat ground
214292589|NCT01719523|DRUG|EPI-743|
214292590|NCT00849810|DRUG|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
214477158|NCT06832501|OTHER|Henna|The day-care unit of the University of Hacettepe's oncology hospital is being trained by educational nurses on the treatment of patients receiving capecitabine a day before the application of chemotherapy. All the patients were questioned about their individual and disease-related characteristics using the Patient Information Form, and The National Cancer Institute common terminology criteria for adverse events - version 4.03 (NCICTCAE v4.03), EORTC C30 Cancer Quality of Life Scale, and The Hand-Foot Syndrome-14 (HFS-14) were used by face-to-face interview technique.On the 21st day and the 63rd day after the first treatment course, patients who developed hand-foot syndrome constituted the case-control group, including patients who applied henna and patients who did not apply henna.
214477159|NCT03240003|BEHAVIORAL|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of GC-MRT
214477160|NCT03240003|BEHAVIORAL|modified GC-MRT|group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
214477161|NCT03240003|BEHAVIORAL|Non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
214477162|NCT06658431|BEHAVIORAL|music group therapy|90 minutes music group therapy
214667730|NCT01943539|DEVICE|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
214667731|NCT02413255|DRUG|TAK-020|TAK-020 oral solution
214885138|NCT04614480|GENETIC|Exome analysis|Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment
214885139|NCT07132567|DRUG|Poteligeo 20mg|Poteligeo 20mg
214885140|NCT02963883|OTHER|SVO2 group / control group|
214885141|NCT04678362|DRUG|Talazoparib + Avelumab|Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
214885142|NCT06854562|BEHAVIORAL|Therapeutic Robot Intervention|This intervention involves the use of a therapeutic robot seal, PARO, to interact with pediatric patients in the Pediatric Intensive Care Unit (PICU). The intervention is designed to alleviate stress and anxiety in children during their hospital stay. The robot provides emotional support by engaging in 30-minute sessions, where children can interact with the robot, give it a name, and express their emotions. The therapeutic interaction is repeated twice on consecutive days.
214885143|NCT06854562|BEHAVIORAL|Toy Seal Intervention|In this group, children interact with a plush toy seal. The plush seal is used to provide emotional comfort and reduce anxiety during their stay in the PICU. The interaction happens over two consecutive days for 30 minutes per session.
214292591|NCT00849810|DRUG|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
214292592|NCT03234764|OTHER|Immunotherapy|
214292593|NCT04333784|OTHER|Exercise training|Exercise with blood flow restriction (with a pneumatic cuff).
214885144|NCT06854562|BEHAVIORAL|Standard Care|Children in this group will receive standard care and routine interventions provided by healthcare professionals in the PICU, without the use of therapeutic robots or plush toys.
214292594|NCT00864045|DRUG|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
214292595|NCT00864045|DRUG|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
214292596|NCT02519192|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
214292597|NCT02519192|PROCEDURE|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
214292598|NCT02519192|PROCEDURE|ostomy bag|Non Vac Arm will receive ostomy bag applications.
214667732|NCT02413255|DRUG|TAK-020 Placebo|TAK-020 placebo-matching oral solution
214667733|NCT06282380|DEVICE|FibriCheck Mobile Application|PPG measurement with reference diagnosis
214667734|NCT02333331|DRUG|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
214667735|NCT02333331|OTHER|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
214667736|NCT03644576|DRUG|ozanimod|ozanimod
214667737|NCT03644576|DRUG|Pseudoephedrine|Pseudoephedrine
214477163|NCT06858631|BEHAVIORAL|Physical Aerobic Exercise|30-minute net aerobic exercise sessions at moderate intensity (3-5 METS, 60%-70% of maximum heart rate) three times per week. Walking, cycling, or swimming, with the option to alternate activities to enhance adherence to the program. Each session will include 10 minutes of warm-up (gradual increase in intensity); 30 minutes of aerobic exercise and 10 minutes of cool-down (gradual reduction of intensity and optional stretching). Total weekly exercise duration will be 150 minutes
214477164|NCT06859944|OTHER|Embryo transfer|Frozen embryo transfer
214292599|NCT02519192|PROCEDURE|wet to dry dressings|Non Vac arm will receive wet to dry dressing changes.
214292600|NCT05487781|COMBINATION_PRODUCT|Tirfostina/L-Carnitina|Estudio clínico fase 1 para describir la seguridad biológica y la farmacocinética de la tirfostina AG-17
214292601|NCT01846611|DRUG|Trabectedin|1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
214292602|NCT01846611|DRUG|DOXIL|30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
214292603|NCT01846611|DRUG|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
214292604|NCT01846611|DRUG|DOXIL|50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
214477165|NCT06859944|OTHER|Embryo transfer|Frozen Embryo transfer
214477166|NCT06658080|DIAGNOSTIC_TEST|organoid drug test|Before initiating therapy, patients diagnosed with metastatic breast cancer patients with hydrothorax and ascite fluid. The hydrothorax and ascite fluid is utilized to establish organoids and conduct drug testing.
214885145|NCT05567796|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
214885146|NCT05567796|DRUG|Semaglutide|Participants will recieve semaglutide subcutaneously.
214477167|NCT06658353|DRUG|VC004 Capsules|VC004 Capsules BID
214885147|NCT05567796|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide.
214885148|NCT05567796|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide.
214885149|NCT06587204|OTHER|Control Group|Participants will receive standard of care.
215047144|NCT04772209|DRUG|Heparin|Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.
215047145|NCT02835586|DRUG|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
214292605|NCT04021589|DRUG|Weileshu|a probiotics products which help to rebuild homeostasis of gut microbiome
214292606|NCT04021589|DRUG|Chemotherapy|chemotherapy
214292607|NCT05489055|DRUG|Iopamidol|A contrast bolus of iopamidol-370 (370 mg I/ml) (iopamidol injection; Consun Pharmaceutical, China) was injected at a ﬂow rate of 4.5-6 mL/s through an 18-20-gauge intravenous antecubital catheter by using a power injector (Ulrich, Germany). The total dose of iopamidol-370 was approximately 0.9 ml /kg body weight.
214292608|NCT06175260|DIAGNOSTIC_TEST|oral carnitine challenge test|Urine samples will be collected to quantify trimethylamine N-oxide (TMAO) levels at four time points: before, and 24, 48, and 72 hours after the oral administration of 1500 mg of L-carnitine.
214292609|NCT00901446|DEVICE|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
214477170|NCT06658301|OTHER|plyometric push up exercises|The subjects will starts with push-up position with hands on the floor, place slightly wider than shoulder width apart and their feet together. Keeping their back flat, slowly lower the body toward the ground. Then in one explosive movement, push-up and away from the floor as quickly as possible, bring their hands off the floor.
214667738|NCT03644576|DRUG|ozanimod placebo|ozanimod placebo
214667739|NCT05542615|DRUG|Prolonged-Release Pirfenidone|1200 mg / day of Pirfenidone (KitosCell® LP)
214885150|NCT06587204|BEHAVIORAL|Decentralized Group|Participants will receive a one time digital lifestyle management program that will be used for the rest of the intervention. The Digital lifestyle management program is a virtual application that manages nutrition, exercise, and sleep. Participants will be using the application at least 1 hour each day.
214885151|NCT06587204|BEHAVIORAL|Digital Literacy Navigation Group|Participants will receive a one time digital literacy training virtual learning digital health education for the rest of the intervention . The digital literacy training is a digital health education program that will be given 1 hour a day for 3 weeks.
214885152|NCT06587204|BEHAVIORAL|Social Care Navigation Group|Participants will receive a one time social care navigation application that will be used for the rest of the intervention. The Social Care Navigation application is a digital application that provides social care resources in the community to participants. The application is used 1 hour a day, each day.
214885153|NCT06532656|DRUG|Lenacapavir|Tablets administered orally without regard to food
214885154|NCT06532656|DRUG|BIC/LEN FDC|Tablets administered orally without regard to food
214885155|NCT06592911|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
214885156|NCT05968326|DRUG|Autogene cevumeran|Autogene cevumeran will be administered intravenously (IV) at a recommended dose at specified timepoints.
214885157|NCT05968326|DRUG|Atezolizumab|Atezolizumab will be administered IV at a dose of 1680 milligrams (mg) at specified timepoints.
215047146|NCT00484796|PROCEDURE|MED-SEP|intraoperative neurophysiological monitoring
215047147|NCT00484796|PROCEDURE|TRI-SEP|intraoperative neurophysiologic monitoring
215047148|NCT00484796|PROCEDURE|neuropsychological tests|neurological short- and longterm outcome
215047149|NCT03756116|PROCEDURE|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
214885158|NCT05968326|DRUG|mFOLFIRINOX|mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.
214885159|NCT05324332|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
214885160|NCT05324332|DRUG|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
214885161|NCT05889013|DEVICE|Nasal Nitric Oxide testing|Collection of already performed clinical data and nNO testing
215047150|NCT03756116|PROCEDURE|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
215047151|NCT01014702|DEVICE|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
215047152|NCT01014702|DEVICE|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
215047153|NCT05399966|DIETARY_SUPPLEMENT|Monarda Didyma extract|Monarda Didyma extract; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
215047154|NCT05399966|DIETARY_SUPPLEMENT|Placebo|Maltodextrin; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
215047155|NCT01041950|PROCEDURE|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
215047156|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum precipitated autoclaved L. major
214477171|NCT06658301|OTHER|swiss ball push up exercises|. The subjects will start with kneeling position so that they will face the ball. Place their hands on top of the ball so that they can bend their elbows towards the body. Straight the legs out and raise themselves slightly higher so that they can be on their toes. Stay in neutral position. Straighten their arms at the elbows, so that they can push themselves up from the ball.
214885162|NCT04739800|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214885163|NCT04739800|DRUG|Cediranib Maleate|Given PO
214885164|NCT04739800|PROCEDURE|Computed Tomography|Undergo CT
214885165|NCT04739800|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
214885166|NCT04739800|BIOLOGICAL|Durvalumab|Given IV
214885167|NCT04739800|PROCEDURE|Echocardiography Test|Undergo ECHO
214885168|NCT04739800|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214885169|NCT04739800|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214885170|NCT04739800|DRUG|Olaparib|Given PO
214885171|NCT04739800|DRUG|Paclitaxel|Given IV
214885172|NCT04739800|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214885173|NCT04739800|DRUG|Topotecan Hydrochloride|Given IV
214885174|NCT02779855|BIOLOGICAL|Talimogene laherparepvec|Talimogene laherparepvec injection. Phase I: Dose escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD) from Phase I. The MTD dose level is defined as the highest dose level with ≤1 out of 6 patients experiencing a dose limiting toxicity (DLT).
215047157|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
215047158|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum-ALM + BCG
215047159|NCT00180037|DRUG|Coenzyme Q10 Nanodispersion (Nanoquinone)|
215047160|NCT00180037|DRUG|Placebo|
215047161|NCT02095756|OTHER|755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)|
215047162|NCT02095756|OTHER|Lytera Skin Brightening System (Non-hydroquinone topical therapy)|
214885175|NCT02779855|DRUG|Paclitaxel|Paclitaxel chemotherapy infusion. The paclitaxel weekly dose is fixed at 80 mg/m\^2.
214885176|NCT06658522|DRUG|Sotatercept|Participants will receive open label subcutaneous sotatercept (starting dose, 0.3 mg per kilogram of body weight; target dose, 0.7 mg per kilogram) for 24 weeks
215047163|NCT04160104|OTHER|Questionnaire|Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.
214292610|NCT03922425|OTHER|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
214292611|NCT03355651|DIETARY_SUPPLEMENT|PROGEN|Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
214292612|NCT05745779|DIAGNOSTIC_TEST|HbA1c, Vitamin D, Vitamin B12|Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.
214292613|NCT04672928|DRUG|paclitaxel|80mg/m\^2,iv,Q4W
214292614|NCT04672928|DRUG|IBI318|300mg,iv,Q4W
214292615|NCT04049123|DRUG|LY900014|Administered SC
214292616|NCT04049123|DRUG|Insulin Lispro|Administered SC
214292617|NCT02855333|OTHER|EORTC and QLQ-C30 / QLQ-OES24 questionnaire|EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
214292618|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units of Vitamin D3 weekly
214292619|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 units weekly
214292620|NCT00298051|PROCEDURE|Delayed umbilical cord clamping|
214292621|NCT01466855|DRUG|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
214477172|NCT06660615|BEHAVIORAL|MIDWIFE-LED CARE|The birth process will be followed by the same midwife from the beginning of the intrapartum period until the birth of the baby and placenta. In this process, positive respectful maternal care will be included in line with the recommendations of WHO (İsbir \& Sercekuş, 2017).
214477173|NCT06859450|DRUG|Levofloxacin|Add-on treatment of inhaled Levofloxacin 240mg twice daily or placebo (saline) twice daily for up to 3 days while admitted.
214477174|NCT06859450|DRUG|Placebo|Add-on treatment of inhaled Levofloxacin 240mg twice daily or placebo (saline) twice daily for up to 3 days while admitted.
214885177|NCT06658782|DIAGNOSTIC_TEST|non contrast enhanced MRI|6 monthly non contrast enhance MRI
214885178|NCT06660199|BEHAVIORAL|Text-based intervention|Parents randomized to the texting intervention will receive up to 3 messages each day for 6 weeks: The intervention is comprised of adolescent-centered (A-C) texts focusing on parental adherence to recommended suicide prevention strategies to promote adolescents' safety and parent-centered (P-C) texts focused on improving parents' own well-being.
215047164|NCT04160104|OTHER|Questionnair|Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
215047165|NCT06209489|OTHER|White cover|"* A white cover will be covered over the incubator during phototherapy.~* Baby massage will be applied during phototherapy."
215047166|NCT03861182|BIOLOGICAL|Biological functionalization of the prosthetic materials by PRF|The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.
214292622|NCT01502189|OTHER|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
214292623|NCT01355341|DRUG|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
214292624|NCT00137748|DRUG|CMV-Ig|Drug: CMV-Ig
214292625|NCT03590379|DRUG|CHF 5993 DPI|BDP/FF/GB DPI
214292626|NCT03590379|DRUG|CHF5993 pMDI|BDP/FF/GB pMDI
214292627|NCT03590379|DRUG|CHF 1535 pMDI|BDP/FF pMDI
214292628|NCT03590379|DRUG|Placebo DPI|CHF 5993 DPI matched placebo
214292629|NCT03590379|DRUG|Placebo pMDI|CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
214292630|NCT00378196|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
214292631|NCT00378196|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
214292632|NCT03145350|OTHER|High-fat, low-carbohydrate|Dietary intervention: 4 week
214477175|NCT06825663|BIOLOGICAL|Blood punction|At each annual visit (+/- 3 months), 4X10 mL blood will be taken (1 dry tube, 1 heparinised tube, 2 EDTA tubes)
214885179|NCT00240279|DRUG|Rosuvastatin|
214885180|NCT00240279|PROCEDURE|aortic pulse wave velocity measurements|
214885181|NCT01224730|DRUG|perifosine|100 mg daily
214885182|NCT01254383|DRUG|Sildenafil Tablet|Tablet, 50 mg, Single Dose
214885183|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
215047167|NCT02164526|OTHER|Routine therapy|Routine therapy
215047168|NCT00394576|BEHAVIORAL|Internet-based nutrition module along with usual care|usual care plus Internet-based nutrition module
215047169|NCT00394576|BEHAVIORAL|usual care|usual care
214885184|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
214885185|NCT04204538|OTHER|Dietary habits|Data collected using food frequency questionnaire
214885186|NCT04204538|OTHER|Risk factors associated with metabolic syndrome|Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome
214885187|NCT04966689|BEHAVIORAL|combined speech and music therapy|he telerehabilitation intervention that include both speech therapy and music therapy at the same time
214885188|NCT04966689|BEHAVIORAL|speech therapy|A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
214885189|NCT04966689|BEHAVIORAL|music therapy|music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
214885190|NCT04557033|OTHER|Mindfulness intervention|My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
214885191|NCT05708716|BEHAVIORAL|Modified ketogenic diet using an exogenous ketogenic formula|Participants will follow a modified ketogenic diet consuming a daily exogenous ketogenic meal replacement formula while limiting their carbohydrate intake for 12 weeks.
214885192|NCT05708716|BEHAVIORAL|Online cognitive training|Participants will complete a daily session of 5 online cognitive training tasks for 12 weeks.
214885193|NCT05981703|DRUG|BGB-26808|Planned doses administered orally as a tablet daily.
214885194|NCT05981703|DRUG|Tislelizumab|Planned doses administered by intravenous infusion.
214885195|NCT05981703|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
214885196|NCT06608745|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty performed with conventional technique
214885197|NCT06608745|PROCEDURE|computer-assisted total knee arthroplasty|total knee arthroplasty performed with imageless computer-assisted surgery
214885198|NCT06983990|OTHER|No intervention (observational monitoring only)|No intervention is applied. This is an observational study evaluating the correlation between non-invasive monitoring parameters and arterial blood gas values during apnea testing.
215047170|NCT04152486|BIOLOGICAL|Ad26.ZEBOV, MVA-BN-Filo vaccine|"Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV."
214292633|NCT03145350|OTHER|Low-fat, high-carbohydrate|Dietary intervention: 4 week
214292634|NCT00931814|OTHER|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
214292635|NCT05459324|DEVICE|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
214885199|NCT06333236|OTHER|Food for Special Medical Purposes: Kron®|Citicoline 40mg/ml + Nicotinamide 15 mg/ml oral solution
214885200|NCT03340506|DRUG|dabrafenib|dabrafenib is available in capsules (50mg and 75mg) taken twice a day
214885201|NCT03340506|DRUG|trametinib|trametinib is available in tablets (0.5mg, 2mg dose)
214885202|NCT06235281|DRUG|Mogamulizumab-Kpkc|Participants will receive 8 total cycles of Mogamulizumab-Kpkc over approximately 224 days.
214885203|NCT06235281|DEVICE|Phototherapy|Participants will begin receiving Phototherapy on day 56 and will continue until day 224. Participants with Complete response (CR) or Partial response (PR) to therapy at day 224 will remain on phototherapy maintenance.
214885204|NCT06653699|DRUG|2 DOSES OF DEXAMETHASONE AND TRANEXAMIC ACID|In group B, 2 doses of 10 mg intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
214885205|NCT06653699|DRUG|1 DOSE OF DEXAMETHASONE AND TRANEXAMIC ACID|In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
214885206|NCT06859268|DRUG|Retatrutide|Administered SC
214885207|NCT06859268|DRUG|Placebo|Administered SC
215047171|NCT02969642|DEVICE|Argus Migraine Treatment device|treatment of Migraines targeting Sphenopalatine ganglion
214885208|NCT06984562|RADIATION|Adaptive Radiation Therapy|"Adaptive Radiation Therapy (ART) creates a personalized radiation plan for each treatment session. This means the plan can change from day to day to more precisely target the tumor while protecting the surrounding healthy tissue.~By closely shaping the radiation to match the tumor's location, ART may reduce the amount of radiation reaching nearby normal tissues. This can allow for higher, more focused doses of radiation to the tumor itself, which may help improve treatment effectiveness while reducing side effects."
214885209|NCT06856499|DRUG|Cirtuvivint|Cirtuvivint (SM08502) is a first in class pan CDC-like kinase (CLK) and dual specificity tyrosine kinase (DYRK) inhibitor with suspected multiple anti-tumor mechanisms of action, including Wnt inhibition.
214885210|NCT06856499|DRUG|Olaparib|NCI Definition - A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
214885211|NCT06670001|BEHAVIORAL|Gamification plus social incentive|Participants in the Gamification plus social incentive intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
214885212|NCT06670001|BEHAVIORAL|Gamification plus competition|Participants in the Gamification plus competition intervention arm will receive gamification and a competition as part of the intervention. See arm descriptions for more detail.
214885213|NCT05159765|DEVICE|Single vision contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
214885214|NCT05159765|DEVICE|Multifocal contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
214885215|NCT06763341|DRUG|Azacitidine|Given IV
214885216|NCT06763341|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214885217|NCT06763341|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214885218|NCT06763341|DRUG|PCNA Inhibitor AOH1996|Given PO
214885219|NCT06763341|DRUG|Venetoclax|Given PO
214885220|NCT06598332|DRUG|5-Azacytidine|"Patients will be treated with 5 azacytidine at a dose of 32 mg/m2 SQ or IV. The investigators aim to start AZA on Day 1 of steroids but it can be started up to 72 hours after steroids are started . Patients will be premedicated with antiemetics.~Patients must receive steroids at a minimum dose of prednisone 2 mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day IV) divided into 1-2 daily doses as therapy for acute GVHD. For patients that weigh over 100 kg, maximal starting dose of prednisone will be 200 mg (or methylprednisolone-equivalent).~Steroid Taper for responding patients (Prednisone/Methylprednisolone) Days 1-5 2 mg/kg/day (taper cannot start until 3 days after enrollment) Days 6-10 1.5 mg/kg/day Day 11-15 1.0 mg/kg/day Days 16-20 0.5 mg/kg/day Days 21-28\* 0.25 mg/kg/day Days 29-56 Gradual further taper with a goal of reaching \< 0.2 mg/kg/day of prednisone (or \< 0.16 mg/kg/day of methylprednisolone) by Day 56."
214885221|NCT06860386|DRUG|Pembrolizumab|200 mg every 3 weeks IV infusion (Q3W + or -3 days)
214885222|NCT06860386|DRUG|Axitinib|5 mg twice daily (BID) by mouth
214885223|NCT06861075|DRUG|Carvedilol|"Carvedilol per os, day 1:3.125 mg once, day 2 to day 8: 6.25 mg/day (3.125 mg twice a day), day 9 to day 90 (end of study visit): 12.5 mg/day (6.25 mg twice a day).~After the end of the study, treatment with Carvedilol will be prescribed by a cardiologist and continued at the dose of 12.5 mg/day.~The follow-up of the patient will be then done according to the standard practice."
214885224|NCT06613568|DEVICE|Moda-flx Hemodialysis System™|The Moda-flx Hemodialysis System™ is a portable hemodialysis system
214885225|NCT06397911|DRUG|FB825|The study treatment will be administered as 5 SC doses in total 12 weeks
214885226|NCT06397911|DRUG|Placebo|The study treatment will be administered as 5 SC doses in total 12 weeks
214885227|NCT06994676|DRUG|CBX-250|subcutaneous CBX-250
214292636|NCT04211051|DEVICE|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
214885228|NCT06993688|BEHAVIORAL|Prognostic Communication-Patient/parent|"* Patient/parent identifies and selects a communication preferences companion (CPC)~* CPC and patient/parent meet for a Communication Preferences Visit (CPV)~* Oncologist, patient/parent, and CPC attend next disease re-evaluation visit together."
214885229|NCT06993688|BEHAVIORAL|Prognostic Communication-CPC|"* CPC reviews intervention materials and conversation guide with the research team~* CPC and patient/parent meet for a CPV, and CPC documents patient/parent preferences in a templated form~* CPC and oncologist discuss the CPV form~* Oncologist, patient/parent, and CPC attend next disease re-evaluation visit together."
214885230|NCT06993688|BEHAVIORAL|Prognostic Communication-Oncologist|"* CPC and oncologist discuss the CPV form~* Oncologist, patient/parent, and CPC attend next disease re-evaluation visit together"
214885231|NCT06539429|BIOLOGICAL|ANT-301|Administration on Day 1
214885232|NCT06992141|BIOLOGICAL|Streptococcus pyogenes M1UK strain MCRI0102|Human challenge with S. pyogenes M1UK strain MCRI0102
214885233|NCT01546454|DRUG|Ethinyl Estradiol-Levonorgestrel combination|0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
214292637|NCT04411875|DRUG|Amlodipine 10 mg|The subjects randomly received single oral administration of amlodipine 10 mg.
214292638|NCT04411875|DRUG|Levamlodipine 5 mg|The subjects randomly received single oral administration of levamlodipine 5 mg.
214292639|NCT04400240|BEHAVIORAL|CALLS|The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
214292640|NCT03668314|DRUG|RDN-929|Single dose from 2 mg to TBD
214885234|NCT01546454|DRUG|leuprolide acetate|single 22.5 mg subcutaneous depot suspension
214885235|NCT01546454|DRUG|Estradiol|0.05 to 0.3 mg transdermal daily for 26 days
214885236|NCT01546454|DRUG|Progesterone|50 to 100 mg vaginal suppositories twice daily for 13 days
214885237|NCT04074187|DRUG|Caplacizumab (ALX-0081)|Pharmaceutical form:Lyophilized powder for solution for injection Route of administration: IV (first dose), SC (all subsequent doses)
214885238|NCT04074187|DRUG|Plasma exchange (PE)|Pharmaceutical form:Plasma (e.g. fresh frozen plasma) Route of administration: Plasma exchange
214885239|NCT04074187|DRUG|Corticosteroid treatment (Methylprednisolone or prednisolone)|Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
214885240|NCT04074187|DRUG|Immunosuppressive treatment (eg, rituximab)|Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
214885241|NCT06422520|DRUG|BGB-C354|Administered by intravenous infusion
214885242|NCT06422520|DRUG|Tislelizumab|Administered by intravenous infusion
215047172|NCT01369043|DIETARY_SUPPLEMENT|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
215047173|NCT02418520|DEVICE|Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
215047174|NCT06239038|PROCEDURE|total knee arthroplasty|total knee arthroplasty surgery with Police Arthroplasty joint academy center(PAJAC) Subvastus Approach
214292641|NCT03668314|DRUG|Placebo oral capsule|Matching placebo Single dose
214292642|NCT03668314|DRUG|RDN-929 TBD dose|Fed vs fast dose TBD based upon results of previous cohorts
214292643|NCT03668314|DRUG|RDN-929|Multiple dose based on results of previous cohorts
214885243|NCT06674538|DRUG|Moonshot antibodies|Chimeric antibodies
214885244|NCT03910933|OTHER|elearning patient information|The videos will standardize patient teaching about anticoagulants, warfarin, INR testing, and warfarin safety for Patient Self-Testing, and Patient Self-Management. eKITE, will provide a user-friendly interface to provide health education about anticoagulation. eKITE will teach concepts to the patient, facilitate sustained patient knowledge (6 month evaluation), reduce stress associated with learning, actively engage patients in their anticoagulant management (preference, satisfaction and knowledge).
215047175|NCT03426527|DRUG|Levobupivacaine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine
215047176|NCT03426527|DRUG|Levobupivacaine-Dexmedetomidine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine in conjunction with dexmedetomidine
215047177|NCT03426527|OTHER|General Anaesthesia|Using propofol, fentanyl and atracurium
214292644|NCT03668314|DRUG|Placebo oral capsule|Matching placebo multiple dose
214292645|NCT04620720|DRUG|capule gabapentin|neuropathic analgesic
214292646|NCT01075945|DRUG|Dihydroartemisinin- piperaquine|three tablets per day
214477176|NCT06858358|PROCEDURE|Robotic assisted total knee arthroplasty|• ROSA RATKA with Zimmer Biomet Persona Medial Congruent
214477177|NCT06858358|PROCEDURE|Conventional total knee arthroplasty (cTKA)|cTKA with Microport Evolution Medial-Pivot
214477178|NCT06859905|OTHER|blood flow restriction training|"Position of the patient The vascular occlusion pressure required for the full blockage of upper extremity blood flow will be measured at rest, with the individual relaxed in a sitting position(Sieljacks et al., 2018).~Position of the of the cuff during BFRT~Placing a 5 to 6 cm wide cuff on the more proximal part of the affected upper limb, it should be around the bulk of biceps muscle above the cubital fossa .~BFRT Cuff Pressure The upper arm external pressure of the cuff (100-130 mmHg) will be selected concerning the subject's resting blood pressure as described previously by Yasuda et al. 2008 (Yasuda et al., 2008).~BFRT exercises prescription~1. Exercise frequency and duration~   -The study group (BFRT G) will be subjected to supervised exercises with low-load blood flow restriction training LIBFR (three days per week for 8 weeks),~2. Exercise intensity -Low load blood flow restriction training LIBFR (20%-40% of 10 repetition maximum (10 RM) BFR training for the study group,"
214885245|NCT02669797|BEHAVIORAL|In-home Visits and Food Preparation Activities|"Families will participate in eight in-home education activities. The visits will focus on family meal quality (dietary, interpersonal) and quantity (meal frequency) factors found in prior studies to be associated with child weight and weight-related behaviors. Eight of the visits (every other week) will be delivered by a CHW and will last 90 minutes. Additionally, a family meal food preparation activity will occur to help support families in learning skills to increase family meal quality and quantity. On weeks opposite of the in-home education visits with a CHW, families will be given a Try it Yourself activity to reinforce the messages (e.g., use family meals as a family connection time) and skills (e.g., recipe that requires families to steam vegetables) taught by the CHW during the in-home education visits."
214885246|NCT02669797|BEHAVIORAL|Ecological Momentary Intervention|Parents will receive daily EMI messages regarding suggestions for increasing meal quality/quantity via a smartphone application, based on the stress level and source of stress they reported earlier in the day. Specifically, parents will receive two push notifications in the morning to report their stress level and type/source of stress (e.g., work, children, finances). Then, based on the reported stress level and source of stress, parents will be texted tips/ideas for carrying out a nutritionally and emotionally healthful family meal the same night, in the face of stress. If parents report no stress on their EMI measure earlier in the day, they will be provided with a menu of options regarding what type of meal tip they would prefer later in the day (e.g., recipe ideas, meal prep tips, mealtime conversation starters. Parents will be able to respond to the EMI messages indicating preferred tips so that EMI tips become more meaningful/relevant to the needs of each family.
214885247|NCT02669797|BEHAVIORAL|Feedback on Video-recorded Family Meals|Parents will video-record and upload via their cellphone one family meal every other week, which will be watched by intervention staff. Using Motivational Interviewing, CHWs will give specific feedback on how to adapt negative mealtime behaviors and provide reinforcement for positive behaviors seen in the videos, based on a validated interpersonal coding tool called the Iowa Family Interaction Rating Scales (IFIRS). Additionally, feedback will be given on the dietary healthfulness of the meal, based on a validated coding tool called the Healthfulness of Meal Index (HOM). After feedback, family members will be taught specific skills to improve their family meal processes and behaviors that vary from food preparation skills, to increasing healthful food options at meals, or role-playing family interactions to improve the emotional atmosphere at the meal. Families will also set SMART goals at each visit regarding family meal quality and quantity.
214885248|NCT02669797|BEHAVIORAL|Maintenance|After 16 weeks, EMI family meal tips for all arms will be reduced to only the days in which parent's report their highest stress levels. Stress profiles will be created for each parent in order to tailor the EMI family meals tips to days in which they experience their highest levels of stress. For example, during the 16-weeks of EMI, a parent may report their highest stress levels on Tuesdays and Thursdays. The stress profile that would be created for the parent during the maintenance phase would include receiving text messages only on Tuesdays and Thursdays. The parent would then receive these EMI family meal tips only on Tuesdays and Thursdays throughout the 8-week maintenance phase..
214885249|NCT06661343|BEHAVIORAL|C4 Program|The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.
214885250|NCT06661343|BEHAVIORAL|C4 + 3MV Program|This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.
214885251|NCT06858501|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214885252|NCT06858501|PROCEDURE|Computed Tomography|Undergo PET/CT
214885253|NCT06858501|RADIATION|Florbenguane F18|Given IV
214885254|NCT06858501|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214667740|NCT05309668|DRUG|Selumetinib granule formulation|"Selumetinib granule formulation will be administered using BSA-based dosing. The granule formulation dose schema to be used in the study will be established in the dose finding phase.~At enrolment participants must have a BSA within the range 0.40 to 1.09 m2; once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment."
214667741|NCT05309668|DRUG|Selumetinib capsule formulation|Selumetinib capsule formulation will be administered using BSA-based dosing. Once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment.
214292647|NCT01075945|DRUG|artemether- lumefantrine|twenty tablet in eight doses
214292650|NCT00258531|DEVICE|Olympus ScopeGuide®, 3-dimentional magnetic imager|
214292651|NCT04772755|DEVICE|Buzzy® and Electronic Game|Buzzy® was applied according to manufacturers directions and an electronic game was played. The participant was observed for 20 minutes post vaccination.
214885255|NCT06858501|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
214292652|NCT03438175|BEHAVIORAL|Enhanced communication by brochure, website and posters|Several instruments to improve communication toward ICU patients' families were prepared for this study: a brochure of 12 pages, a website with 80 webpages, 8 posters for the waiting room, 1 sign for the ICU door. All these instruments are made to have more correct comprehension and to legitimize emotions of ICU patients' families.
214885256|NCT06858501|OTHER|Questionnaire Administration|Ancillary studies
214885257|NCT06855212|DRUG|Cemiplimab|Given by IV infusion.
214885258|NCT06855212|DRUG|Cetuximab|Given by IV infusion.
214885259|NCT03248310|BEHAVIORAL|Quality of Life Assessments|Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
214885260|NCT05664178|BEHAVIORAL|Tele-Resistance Training|Tele-Resistance training sessions will be supervised and guided by a certified exercise trainer via smartphone, tablet or laptop. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously. Participants will engage in brief warm up exercises lasting 2-3 minutes prior to each RT session and will rest at least 1 minute between sets of the same exercise to aid muscle recovery. Participants will perform at least 2 sets of 12 repetitions for each of 6 exercises. Including warm up, training sets, and rest, sessions will last approximately 30 minutes. RT will include six target exercises focusing on major muscle groups of the upper body, lower body, and core.
214885261|NCT07000448|PROCEDURE|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|For optimal individual PEEP titration, dynamic compliance values observed on the ventilator monitor were recorded when PEEP reached 20 cmH₂O.
214885262|NCT07000448|PROCEDURE|standardized 5 PEEP|Patients in the PEEP 5 group were applied a fixed 5 cmH2O PEEP and no recruitment maneuver was performed.
214885263|NCT04083495|BIOLOGICAL|ATLCAR.CD30 T cells|Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10\^8 CAR-T/m\^2 with a maximum dose of 5 × 10\^8 CAR-T cells
214885264|NCT04083495|DRUG|Bendamustine|70 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
215047178|NCT01078727|DEVICE|A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).|The subjects meeting our criteria will be randomly assigned to either the experimental group or the control group. First stage (3 months after onset), the subjects in the experimental group will receive an upper extremity Thermal Stimulation (TS) protocol for 30 minutes (3 times a week for 8 weeks). The subjects in the control group will receive a lower extremity TS protocol.
214292653|NCT05071989|BEHAVIORAL|Sleep Education|A single-blind school- based randomized controlled design
214292654|NCT01905657|BIOLOGICAL|Pembrolizumab|IV infusion
214292655|NCT01905657|DRUG|Docetaxel|IV infusion
214292656|NCT02589951|OTHER|admission to non-psychiatric service|
214292657|NCT05063747|OTHER|No intervention.|Observational study. No intervention.
214292658|NCT01778881|OTHER|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
214292659|NCT01778881|OTHER|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
214292660|NCT01778881|OTHER|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
214885265|NCT04083495|DRUG|Fludarabine|30 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
214885266|NCT04083495|DRUG|Cyclophosphamide|300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
214885267|NCT07002060|BIOLOGICAL|Yellow fever vaccine (live)|Powder and solvent for solution for injection Subcutaneous
214885268|NCT07002060|BIOLOGICAL|YF vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
214885269|NCT04025203|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
214885270|NCT04025203|DRUG|Ibuprofen Arginine|Oral tablets
214885271|NCT04025203|DRUG|Gabapentin|oral capsules
214885272|NCT00307021|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|3-dose intramuscular injection, 2 different formulations
214885273|NCT04387656|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214885274|NCT04387656|OTHER|Data Collection|Undergo collection of medical information and imaging
214885275|NCT04387656|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
214885276|NCT04387656|OTHER|Questionnaire Administration|Complete quality of life questionnaires
214885277|NCT06417216|BEHAVIORAL|Head-cancelled virtual reality|Scene in virtual reality moves with the head while performing visual tasks.
215047179|NCT02472912|BIOLOGICAL|BMO-2|Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
214292661|NCT01778881|OTHER|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
214885278|NCT05933525|BIOLOGICAL|Travelan|6 Travelan tablets (1200mg) administered orally for 7 days
214885279|NCT05933525|OTHER|Placebo|6 tablets of placebo (1200mg) administered orally for 7 days
214885280|NCT03396718|RADIATION|De-escalation radio(chemo)therapy - Level 1|55/ 59,4 Gy (intermediate / high risk group)
214885281|NCT03396718|RADIATION|De-escalation radio(chemo)therapy - Level 2|48,4/ 55 Gy (intermediate / high risk group)
215047180|NCT02472912|BIOLOGICAL|EU-Humira|Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
215047181|NCT02472912|BIOLOGICAL|US-Humira|Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
214885282|NCT03396718|RADIATION|Standard radio(chemotherapy)|60/ 66 Gy (intermediate / high risk group)
214885283|NCT07133386|DEVICE|transcatheter edge to edge repair|Implantation of a tricuspid transcatheter edge to edge device
215047182|NCT03186105|OTHER|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
214885284|NCT07133386|DEVICE|Placebo|placebo
214885285|NCT06680921|DRUG|SIM0270|Experimental
214885286|NCT06680921|DRUG|Everolimus (Afinitor®)|Experimental and Active comparator
214885287|NCT06680921|DRUG|Exemestane tablets|Active Comparator
214477179|NCT06859905|OTHER|regular exercises|"the routine rehabilitation will be applied 3 times per week for 8 weeks, including the following training~1. Appropriate neurodevelopmental techniques as needed by each patient~2. Progressive resistance exercise for muscles in the affected upper extremity using sandbags, free weights, or elastic resistance bands according to each patient's abilities~3. prolonged stretching using splints if needed~4. Functional electrical stimulation (FES)"
214477180|NCT06856135|DRUG|Vedolizumab IV|"Participants will continue to receive vedolizumab IV at the same dose administered at the end of Trial Vedolizumab-2005 (NCT03196427), at a frequency of every 8 weeks.~• Other Names:~* MLN0002~* ENTYVIO~* KYNTELES"
214477181|NCT06069622|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure|24-hour ambulatory blood pressure, blood, and urine will be obtained prior to semaglutide therapy and after 20 weeks of semaglutide therapy.
214885288|NCT06680921|DRUG|Fulvestrant injection|Active Comparator
214885289|NCT06681051|DEVICE|OSTENIL® TENDON|OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation.
214885290|NCT07005713|DRUG|BGB-16673|Administered orally
214885291|NCT07005713|DRUG|Placebo|Administered orally
214885292|NCT07006311|DEVICE|Robotic-assisted bronchoscopy under propofol|In this study, patients will undergo a robotic-assisted bronchoscopy under moderate sedation with propofol. While the use of propofol as a sedative is common for manual bronchoscopies, robotic-assisted bronchoscopy is only permitted under general anesthesia. In the study intervention, the investigators want to test the feasibility of the combination of robotic-assisted bronchoscopy under propofol.
214885293|NCT02950649|DEVICE|invasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences|Experimental: Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
214885294|NCT02950649|DEVICE|No Hemodynamic Monitored Guided Assesment|Arm: Active Comparator: No Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
214885295|NCT01906515|DEVICE|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
214885296|NCT06646289|BIOLOGICAL|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered sub-retinally.
214885297|NCT06646289|OTHER|No intervention (Follow-Up assessment)|Participants will not receive any intervention and will undergo follow-up assessment.
215047183|NCT00098033|DRUG|clofarabine|
215057327|NCT03466398|BEHAVIORAL|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
214477182|NCT06069622|DIETARY_SUPPLEMENT|Liberal salt diet|Participants will be on a liberal salt (about 200 mEq sodium/day) diet for 7 days.
214477183|NCT06655480|DRUG|[ARNI + SGLTi + AMR]|Empagliflozin 10mg tablet, Valsartan+Sacubitril 100-200-400 mg tablet, Finerenone 20-40 mg tablet
214477184|NCT06655480|DRUG|[SGLTi + previously taken RAAS blocker]|Empagliflozin 10mg tablet, previously taken RAAS inhibitor
214667742|NCT06379256|RADIATION|Photon or proton radiotherapy|"* 39.6-72.6 Gy (or Cobalt Gray Equivalent, CGE) in 22 fractions for tumors ≤1 cm from hepatic hilum, bowel, and heart.~* 30-66 Gy (or CGE) in 10 fractions for tumors \>1 cm from hepatic hilum, bowel, and heart.~* 27.5-60 Gy (or CGE) in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
214885298|NCT06871020|OTHER|Mandibular removable partial denture retained on OT extracoronal attachment made from fiber-reinforced composite resin|Bilateral OT extracoronal attachments will be milled from fiber-reinforced composite resin after obtaining impressions of the prepared abutments. This will be followed by an overall impression of fabricating a Co-Cr removable partial denture to be retained in the attachments.
214885299|NCT06871020|OTHER|Mandibular removable partial denture retained on OT extracoronal attachment made from porcelain-fused to metal|Bilateral OT attachments manufactured from porcelain fused to metal by conventional technique after obtaining impressions of the prepared abutments. This will be followed by an overall impression of fabricating a Co-Cr removable partial denture to be retained in the attachments.
214885300|NCT06919354|BIOLOGICAL|GNTI-122|GNTI-122 is an investigational cell therapy manufactured from a participant's own blood cells and is intended to help correct an imbalance of certain types of cells found in participants with Type 1 Diabetes.
214885301|NCT04645862|DIAGNOSTIC_TEST|CT scans|4D CTA imaging
214885302|NCT07009704|BEHAVIORAL|Mobile-based social support|Participants will be invited to join an encrypted group chat where they will be encouraged to provide and receive social support related to glucose management during early pregnancy. Other study participants and study team members will be in the group chat.
215057328|NCT01692106|PROCEDURE|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
214885303|NCT07009704|BEHAVIORAL|Real-time continuous glucose monitoring|Participants will receive a real-time continuous glucose monitor that pairs with an existing smartphone app that shows minute-by-minute glucose levels and records glucose levels in 5 minute increments.
214885304|NCT06873451|PROCEDURE|Surgery First|One month after surgery, patients were called for an appointment and lower and upper brackets were placed. Treatment was completed when right-left Class I canine and molar relationships and ideal overjet and overbite relationships were achieved.
214885305|NCT06873451|PROCEDURE|Surgery Early|The patients were directed to surgery with the upper and lower bonds applied at their first appointment and the brackets in their mouths. After surgery, treatment continued until the right-left Class I canine and molar relationship and the ideal overjet and overbite relationship were achieved.
214885306|NCT07013201|DRUG|Delgocitinib cream|Topical application
215047184|NCT04797377|BIOLOGICAL|Autologous ovarian PRP injection|The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
214885307|NCT07013201|DRUG|Vehicle cream|Topical application
214885308|NCT07016412|DRUG|Ensifentrine 3 mg|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
214885309|NCT07016412|DRUG|Glycopyrrolate 21.25 mcg|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
214885310|NCT07016412|DRUG|Glycopyrrolate 42.5 mcg|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
214885311|NCT07016412|DRUG|Placebo|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
214885312|NCT06684847|BIOLOGICAL|Efgartigimod PH20 SC|subcutaneous efgartigimod PH20 SC given by prefilled syringe
214885313|NCT06684847|OTHER|Placebo PH20 SC|subcutaneous placebo PH20 SC given by prefilled syringe
214885314|NCT06627179|DRUG|Intravitreal Injection of Ultevursen|Up to 4 doses over a 24-month period
214885315|NCT06627179|OTHER|No intervention, will not receive any active study intervention|Sham-procedure (no experimental drug administered)
214885316|NCT06619587|DRUG|Phase I Arm A|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
214885317|NCT06619587|DRUG|Phase I Arm B|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
214885318|NCT06873867|DEVICE|High Purity Type-I Collagen based Skin Substitute|In this wound care is covering with High Purity Type-I Collagen based Skin Substitute followed by a layer of non-adherent and porous dressing. After 5-7 days, wound examined and procedure is repeated as needed
214885319|NCT06873867|DEVICE|Negative Pressure Wound Therapy|In this wound care is by application of Negative Pressure Wound Therapy using a standard polyurethane foam. The NPWT will be removed after 5-7 days, wound examined and procedure is repeated as needed
214885320|NCT06692179|DRUG|Orally administered preparation of fecal microbiota (MTP-101P)|As per standard of care, patients will receive MBP and OA the day prior to surgery as well as IV antibiotics at the time of surgery. MTP-101P will be given 48 hours after the administration of the dose of IV antibiotics to avoid the undesired bactericidal effects of antibiotics on the bacterial load from MTP-101P.
214885321|NCT04125134|DRUG|Preservative-free Refresh Optive Advanced Lubricant Eye Drops|over the counter artificial tear
215047185|NCT00291031|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|"Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments."
215047186|NCT00323531|PROCEDURE|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
215047187|NCT00323531|PROCEDURE|VATS decortication|thoracoscopic decortication
214885322|NCT06687655|DIETARY_SUPPLEMENT|Ketone-IQ|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Ketone-IQ (1,3 Butanediol) intervention.
214885323|NCT06687655|DIETARY_SUPPLEMENT|Placebo|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Placebo intervention.
215047188|NCT06349824|DRUG|injection Dextrose water|dextrose will be injected around median nerve in wrist
215047189|NCT06349824|DEVICE|USG machine|usg guided nerve hydrdissection
215047190|NCT00682279|DRUG|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
215047191|NCT05547412|DEVICE|NovaGuide 2 Intelligent Ultrasound System|The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.
215047192|NCT04085146|PROCEDURE|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
214885324|NCT06872840|BEHAVIORAL|Parent Fear of Recurrence Therapy (Parent-FORT)|7 weekly sessions of 120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
214292662|NCT02123745|DEVICE|The ivWatch Model 400|The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
214292663|NCT01010516|DRUG|High-dose rosuvastatin|40 of rosuvastatin daily
214667743|NCT03707340|DRUG|Flibanserin Pill|Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.
214667744|NCT03486236|DRUG|VX-440|VX-440 was administered in TC with TEZ and IVA.
214885325|NCT07017686|DEVICE|abdominal vagus nerve stimulation (aVNS)|Participants will receive aVNS, delivered by a commercially available stimulator placed under the skin, and a custom-designed electrode array attached to the abdominal vagus nerve. Stimulation will commence 2 weeks after laparoscopic surgical implantation of the device, and occur daily for 22-weeks stimulation in the initial phase of the study.
214292664|NCT01010516|DRUG|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
215047193|NCT04085146|PROCEDURE|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
214885326|NCT07027527|DRUG|APG777|Subcutaneous (SC) injection
214292665|NCT01010516|DRUG|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
214292666|NCT00432471|PROCEDURE|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
214292667|NCT03705507|DRUG|Selumetinib|Selumetinib is a small molecule inhibitor of the MEK protein
214292668|NCT03705507|DRUG|Dexamethasone|Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
214292669|NCT00165243|PROCEDURE|Tangential radiation|Radiation given over 6 1/2 weeks
214292670|NCT03388879|DEVICE|Taylor Spatial Frame|Circular external fixator
214885327|NCT07027527|DRUG|APG990|SC injection
214885328|NCT07027527|DRUG|Dupilumab|SC injection
214292671|NCT03388879|DEVICE|Intramedullary nail|Antegrade intramedullary nail
214885329|NCT05160740|DRUG|Indocyanine green for injection|ICG will be injected to participants preoperatively for molecular fluorescence image
214292672|NCT04358133|DRUG|Chlorhydrate de morphine|The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol
214292673|NCT04358133|DRUG|NaCl 0,9%,|The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm
214292674|NCT04953221|DRUG|YJ001|Skin spray
214292675|NCT02744391|DRUG|Levodopa|
214292676|NCT03493009|DEVICE|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
214292677|NCT04041804|PROCEDURE|semirapid maxillary expansion (SRME)|A Banded Hyrax is going to be used in order to provide an increase in the maxillary transverse dimension
214292678|NCT01996709|DEVICE|Hydrogen peroxide-based contact lens solution|
214477185|NCT06856434|DIETARY_SUPPLEMENT|Lactobacillus plantarum sp Probiotic|Once daily consumption
214885330|NCT07029178|DRUG|Taurine granule|24 grams of taurine granule + 2 Gray radiation dose each time.
214885331|NCT07029178|DRUG|Placebo granule|24 grams of placebo granule + 2 Gray radiation dose each time.
214885332|NCT07029737|DRUG|Acalabrutinib + R-CHOP standard of care|Acalabrutinib will be administered 100 mg twice per day (BID) orally (PO) until disease progression if medically appropriate, along with R-CHOP standard of care up to six 21-day cycles of the induction phase.
214885333|NCT07029737|DRUG|Acalabrutinib combination with Rituximab|If the subject achieves response during the induction phase, acalabrutinib will be administered 100 mg BID PO until disease progression and rituximab 375 mg/m2 on Day 1 of every other 28-day cycle for a maximum of 12 additional doses.
214885334|NCT07029737|DRUG|Acalabrutinib monotherapy|If the subject does not achive response during the induction phase, monotherapy acalabrutinib will be administered 100 mg BID PO until disease progression.
214885335|NCT07022418|DRUG|Formoterol furmarate (20 μg)|Investigators chose to use the long-acting β2-AR agonist, formoterol, because of its efficacy and safety profile in patients with COPD and because formoterol showed the most association with protection from progression of CKD in our retrospective study.
214292679|NCT01996709|DEVICE|Habitual contact lens solution|Biguanide-preserved
214292680|NCT01996709|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
214292681|NCT02397759|OTHER|Blood draw and cerebrospinal fluid draw|
214292682|NCT04811625|DRUG|PL-ASA|Pharmacologic profile of different aspirin formulations
214292683|NCT04702997|DRUG|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status
214477186|NCT06856434|OTHER|Placebo Group|Group who received a placebo intervention
214667745|NCT03486236|DRUG|TEZ|TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
214667746|NCT03486236|DRUG|IVA|IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
214667747|NCT03486236|DRUG|Matched Placebos|Placebos matched to VX-440, TEZ, and IVA.
214667748|NCT06408792|DEVICE|Deepithelized graft and protection technique|To obtain the graft in all cases, on the day of surgery, 4% articaine with epinephrine 1:100,000 will be administered to block the greater palatine nerve. Gingival grafts from all groups will be deepithelialized intraorally using a sterile 834 turbine diamond bur. This drill will go deeper into the palatal mucosa 0.5mm (half of the outermost active part of the drill). The gingival grafts will be obtained with the surgical technique described by Zucchelli et al. 2010.
214667749|NCT02014948|OTHER|Exercises|The individuals who make up this group performed exercises for 10 consecutive sessions.
214667750|NCT04392414|BIOLOGICAL|COVID-19 convalescent hyperimmune plasma|Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
214885336|NCT03610152|BEHAVIORAL|Hospital Policy change|Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
214885337|NCT06879665|BEHAVIORAL|Well-Beans for Caregivers Program|This is a brief behavioral intervention consisting of 3 weekly 2-hour sessions. The sessions are based on Acceptance and Commitment Therapy (ACT) and are designed to improve psychological flexibility in caregivers. This in turn is designed to help them connect with their difficult emotions and experiences in a flexible way, and improve emotional well-being.
214885338|NCT06877663|DEVICE|Virtual Reality Device|Patients who will receive entertainment videos via VR headset in the preoperative room before surgery.
214885339|NCT06705998|DRUG|BAR502 single dose|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 150 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 3, 10 and 50mg. A maximum of 4 dose levels are pre-planned (3, 10, 30 and 60mg)."
214885340|NCT06705998|DRUG|Placebo single dose|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
214885341|NCT06705998|DRUG|BAR502 multiple doses|The 2 multiple ascending doses selected based on results of study part A will be administered to 2 study cohorts of 10 subjects each. The IMP will be orally administered once a day from Day 1 to Day 14, at 8:00±1 h, for a total of 14 doses.
214885342|NCT06706817|COMBINATION_PRODUCT|Tezepelumab|IMP. Subcutaneous injection. Unit dose strengths 210 mg.
215047194|NCT05542446|DRUG|Colistin|"Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection."
215047195|NCT00002493|DRUG|cisplatin|
215047196|NCT00002493|DRUG|doxorubicin hydrochloride|
215047197|NCT00002493|RADIATION|low-LET photon therapy|
215047198|NCT02598141|BIOLOGICAL|Biological sampling grinding|One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
215047199|NCT02598141|BIOLOGICAL|Biological sampling with standard procedures|One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
215047200|NCT06118645|DRUG|cadonilimab combined +paclitaxel (albumin-bound)|"1. In the safe induction phase6 subjects will receive cadonilimab (10mg/kg, Q3W, intravenous infusion, up to 2 years) and paclitaxel (albumin-bound type)(125 mg/m2,Days1, 8,Q3w, intravenous infusion, up to 8 cycles).~2. If the safety and tolerability are good, and the initial efficacy signal is observed, the extended enrollment phase will enter the extended enrollment phase of drug administration and the safety introduction phase"
215047201|NCT00940550|DRUG|Prolonged-release melatonin|2 mg tablet, once.
215047202|NCT00940550|DRUG|Temazepam|20 mg capsule, once
215047203|NCT00940550|DRUG|Zolpidem|10 mg capsule, once
215047204|NCT00940550|DRUG|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
215047205|NCT00142337|DRUG|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
215047206|NCT00142337|DRUG|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight \>60 kg) once daily, starting at the onset of labor and for one month postpartum
214292684|NCT04702997|DRUG|Placebo oral capsule|Capsule containing an inert placebo
214667751|NCT04392414|BIOLOGICAL|Non-convalescent fresh frozen plasma (Standard plasma)|Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
215047207|NCT02808923|OTHER|Foam Rolling|"Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller."
215047208|NCT02808923|OTHER|Static Stretching|Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
215047209|NCT03299478|OTHER|Will look for immune infiltration|
215047210|NCT00848887|BIOLOGICAL|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
215047211|NCT01322724|PROCEDURE|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
214292685|NCT02538250|DIETARY_SUPPLEMENT|Nutricomp Drink Plus|Oral nutritional supplementation
214292686|NCT00237094|BEHAVIORAL|Nurse Practitioner led multidisciplinary team approach|
214667752|NCT05957640|COMBINATION_PRODUCT|Yttrium-90 carbon microspheres SIRT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
214292687|NCT01754623|DRUG|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
214667753|NCT04038346|DRUG|Naproxen|Patients will be randomized to an NSAID (naproxen)
214667754|NCT04038346|DRUG|Acetaminophen|Patients will be randomized to acetaminophen
214667755|NCT03815292|DRUG|MMH-MAP|Oral administration
214885343|NCT06718101|DRUG|Lutikizumab|Subcutaneous (SC) Injection
214885344|NCT06718101|DRUG|Placebo|Subcutaneous (SC) Injection
214885345|NCT06882785|DRUG|KarXT|Specified dose on specified days
214477187|NCT06859216|BEHAVIORAL|AI-Generated Plain Language Summaries|Participants receive standard ophthalmology notes plus an AI-generated summary that explains medical information in simpler language. Each summary is reviewed by an ophthalmologist for accuracy before being given to the participant. The goal is to help participants better understand their diagnosis, treatment plan, and follow-up instructions.
214885346|NCT06882785|OTHER|Placebo|Specified dose on specified days
214885347|NCT07042776|DEVICE|EMMA (Expert Manipulative Massage Automation)|For the EMMA massage, the subject lies down on the robot platform in a prone position. A therapist sets the robot parameters. The EMMA electronic massager applies massage to the focus points on the back of the participants guided by cameras and computer programs. Treatment lasts approximately 20-30 minutes.
214885348|NCT07042776|OTHER|Therapist-delivered massage|For the therapist-delivered massage treatment, the licensed massage therapist will follow standard of care protocol. Treatment lasts approximately 20-30 minutes.
214885349|NCT06719128|DRUG|Olomorasib|Administered orally.
214885350|NCT07047118|DRUG|JSB462|Administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision
214885351|NCT07047118|DRUG|AAA617|administered at 7.4 GBq intravenously every 6 weeks for up to 6 doses, unless there is disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision
214885352|NCT01021059|BIOLOGICAL|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
214885353|NCT06887959|DRUG|Suzetrigine|Tablets for oral administration.
214885354|NCT07048093|OTHER|Exercise|Average of 10 minutes relaxation exercises guided with a standard audio record based on reciprocal and autogenic muscle inhibition, proprioceptive training and postural training.
214885355|NCT07048093|OTHER|Sham (No Treatment)|This group take no treatment between actual before and after measurements.
215047212|NCT02895516|DEVICE|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
215047213|NCT01007175|BIOLOGICAL|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
215047214|NCT01007175|BIOLOGICAL|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
215047215|NCT01007175|BIOLOGICAL|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
215047216|NCT01007175|BIOLOGICAL|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
215047217|NCT01007175|BIOLOGICAL|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
215047218|NCT00483678|OTHER|counseling intervention|
215047219|NCT00483678|OTHER|questionnaire administration|
215047220|NCT00483678|PROCEDURE|psychosocial assessment and care|
215047221|NCT02125955|DIETARY_SUPPLEMENT|Prebiotic fiber|Dissolved in water.
215047222|NCT02125955|DIETARY_SUPPLEMENT|Placebo|Dissolved in water
215047223|NCT03181971|BEHAVIORAL|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
215047224|NCT02543853|OTHER|direct trocar entry|direct trocar entry to provide pneumoperitoneum
215047225|NCT02543853|OTHER|veres needle entry|veres needle entry to provide pneumoperitoneum
215047226|NCT03130829|DIETARY_SUPPLEMENT|Oligo Fucoidan|Oral, twice daily
215047227|NCT03130829|DIETARY_SUPPLEMENT|Placebo|Oral, twice daily
215047228|NCT01004536|DEVICE|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
215047229|NCT01004536|OTHER|no treatment|left untreated during the study period
215047230|NCT04230967|BEHAVIORAL|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals
215047231|NCT04230967|BEHAVIORAL|Routine Care|No encouragement to ambulate will be provided to subjects. Their movement will be recorded
215047232|NCT02886910|OTHER|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
215047233|NCT02886910|OTHER|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
215047234|NCT02291133|PROCEDURE|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
215047235|NCT02291133|DEVICE|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization."
215047236|NCT02291133|DRUG|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
214292688|NCT01754623|DRUG|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
214292689|NCT01754623|DRUG|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
214292690|NCT01754623|RADIATION|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
214292691|NCT01754623|OTHER|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
214292692|NCT01754623|PROCEDURE|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
214885356|NCT05506150|BEHAVIORAL|Interviews|"Focused conversations to understand features of a GI bleed that are important to patients and families.~Patients and family members are invited to participate in focused conversations. For interviews and focus groups, criterion sampling will be used. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data includes self-reported demographic characteristics of the patient and family members. Qualitative data about participants will be obtained through individual interviews and focused groups and project team field notes."
215047237|NCT01772550|DEVICE|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
214292693|NCT01754623|DRUG|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
214667756|NCT03815292|DRUG|Placebo|Oral administration
214667757|NCT03437928|DEVICE|Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
214667758|NCT01401140|DRUG|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
215047238|NCT01772550|DEVICE|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
215047239|NCT04156334|PROCEDURE|Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia|QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
215047240|NCT00704067|BEHAVIORAL|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
215047241|NCT00704067|BEHAVIORAL|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
215047242|NCT00486356|DRUG|capecitabine|
214292694|NCT00011076|DRUG|Pirfenidone|
214292695|NCT03220360|PROCEDURE|indirect pulp capping|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
214292696|NCT03220360|PROCEDURE|direct pulp capping|Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
214292697|NCT03220360|PROCEDURE|vital pulpotomy|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
214292698|NCT05230290|BIOLOGICAL|KD6001 Injection|Solution for intravenous injection
214292699|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
214885357|NCT04207489|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer|Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
214885358|NCT04234048|DRUG|Fenretinide|"Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort"
215047243|NCT00486356|DRUG|carboplatin|
215047244|NCT00486356|DRUG|epirubicin hydrochloride|
215047245|NCT00486356|GENETIC|microarray analysis|
215047246|NCT00486356|GENETIC|polymorphism analysis|
215047247|NCT00486356|OTHER|pharmacological study|
214885359|NCT06738862|OTHER|PET|\[18F\] - FD17 PET imaging
214885360|NCT05461989|OTHER|Anthropometric measurement|It will be measured with the Xiaomi Body Composition Scale II, and a total of 9 measurements will be made as a result of the measurements.
214885361|NCT05461989|OTHER|Level of Physical Activity|The scale to be used for this purpose is the Child Physical Activity Questionnaire (CPAQ) developed by Kowalski et al. It is a seven-day self-reported recall scale designed to assess moderate-intensity physical activity in children aged 8-14 years. CFAQ is designed to be implemented throughout the school year.
214885362|NCT05461989|OTHER|Physical Activity Barriers Scale|"It consists of three surveys in total, which are:~A) Scale of Expectations Regarding Physical Activity for Children~B) Children's perception of family support regarding physical activity scale~C) Physical Activity Barriers Scale for Parents"
214885363|NCT05461989|OTHER|Hand Grip Strength|Hand grip strength will be measured using a hand dynamometer (Jamar, Sammons Preston, Rolyon, Bolingbrook, IL).
214885364|NCT05461989|OTHER|Arterial stiffness|Arterial stiffness will be evaluated using the pulse wave velocity (PWV) technique with the blood pressure holter-ABPM (Mobil-O-Graph, I.E.M., Stolberg, Germany) device. The measurement is made from the non-dominant arm based on the principle of blood pressure measurement with the appropriate cuff determined according to the arm diameter. After two consecutive measurements taken 30 seconds apart, the average of the measurement values will be recorded.
214885365|NCT03477604|DEVICE|MicroStent and Standard PTA|Self-expanding stent and standard PTA balloon
214885366|NCT03477604|DEVICE|Standard PTA|Standard PTA balloon
214885367|NCT05769777|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
214885368|NCT06714253|BIOLOGICAL|RXRG001|Circular ribonucleic acid encoding human aquaporin 1 encapsulated in a lipid nanoparticle
214885369|NCT06714253|BIOLOGICAL|Placebo|Placebo (saline)
214885370|NCT06851754|DRUG|Progesterone|Oral micronized progesterone will be added (100 mg/day for 12 days/month) in the event of spontaneous vaginal bleeding and/or at 12 months over the 2-year protocol.
215047248|NCT01670669|DRUG|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
215047249|NCT03481842|BIOLOGICAL|Linifanib|in a minimally sufficient therapeutic dose
215047250|NCT03481842|DRUG|BIBW2992|in a minimally sufficient therapeutic dose
215047251|NCT03481842|DRUG|Axitinib|in a minimally sufficient therapeutic dose
215047252|NCT02554799|DRUG|MMV390048 formulation A|MMV390048 formulation A, tablet
215047253|NCT02554799|DRUG|MMV390048 formulation B|MMV390048 formulation B, tablet
215047254|NCT00241072|DRUG|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
215047255|NCT05447390|DIAGNOSTIC_TEST|Handgrip strength test|The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
215047256|NCT04047368|PROCEDURE|Rotablation|Percutaneous Coronary Intervention using Rotablation
215047257|NCT04047368|PROCEDURE|Coronary Lithoplasty|Percutaneous Coronary Intervention using Lithoplasty
215047258|NCT00595296|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
215047259|NCT00710398|BEHAVIORAL|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
214292700|NCT01507597|DRUG|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
214292701|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
214292702|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
214292703|NCT00002581|DRUG|cyclophosphamide|
214292704|NCT00002581|DRUG|fluorouracil|
214292705|NCT00002581|DRUG|methotrexate|
214292706|NCT00002581|DRUG|tamoxifen citrate|
214292707|NCT00002581|PROCEDURE|conventional surgery|
214292708|NCT00002581|RADIATION|radiation therapy|
214885371|NCT06851754|DRUG|Estrogen Patch|participants with POI (n=85) will receive transdermal 17 beta-estradiol (beginning at a dose of 25 microgram/patch applied weekly), with the dose increased at 3 months to 50 microgram, and thereafter every 6 months to 75 and 100 microgram/patch for pubertal induction or estrogen replacement (with 100 microgram/patch representing a full adolescent or young adult estradiol dose). The continued escalation of the estradiol dose and patch strength will be guided by the clinical presentation and physical examination (by the PI or designated AI).
214292709|NCT02215187|BEHAVIORAL|Problem-Solving Training (PST)|Training in problem-solving skills to be applied to military caregiver problems.
214667759|NCT01401140|DRUG|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
214667760|NCT05736549|DRUG|Bupivacaine-Liposomal Bupivacaine|A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
214885372|NCT06858397|DRUG|HM15421/GC1134A|SC
214667761|NCT05736549|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
214885373|NCT06750939|OTHER|propofol|"The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,"
214885374|NCT06750939|OTHER|ketamine|"The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,"
214885375|NCT06764186|DRUG|Fulvestrant|2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
214885376|NCT06764186|DRUG|Capivasertib|400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle
214292710|NCT02215187|BEHAVIORAL|Attention Control|Social contact control (health education/no skill training)
214292711|NCT01343498|DRUG|BEZ235|BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
214292712|NCT05937204|OTHER|Nursing Teaching|A nursing teaching scheme refers to a systematic and structured plan developed by nurses to provide teaching and instruction to patients. The components of a nursing teaching scheme typically include assessing learning needs, setting learning objectives, developing teaching materials, delivering information using various teaching methods, demonstrating skills, providing written instructions, assessing learning outcomes, and conducting follow-up
214292713|NCT01808989|OTHER|Exercise oxymetry|
214292714|NCT01305902|BEHAVIORAL|contingency management|Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
214292715|NCT00818818|DRUG|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
214292716|NCT02309502|DEVICE|Green Pascal|"Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
214885377|NCT06759649|DRUG|COM503|Intravenous Infusion
214885378|NCT06759649|DRUG|Zimberelimab|Intravenous infusion
214885379|NCT06124157|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214885380|NCT06124157|BIOLOGICAL|Blinatumomab|Receive IV
215047260|NCT00710398|BEHAVIORAL|Dietary - Caloric Restriction|"Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.~Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake."
215047261|NCT01461746|DRUG|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
215047262|NCT01461746|DRUG|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
215047263|NCT01461746|RADIATION|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
215047264|NCT00535535|DIETARY_SUPPLEMENT|Fructose|Fructose, 0.5 g/kg
215047265|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
215047266|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
215047267|NCT04555863|DEVICE|haMSter smartphone app|the app tracks patient reported outcomes
215047268|NCT03930381|OTHER|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
215047269|NCT04172350|OTHER|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
215047270|NCT04172350|OTHER|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
215047271|NCT05328869|OTHER|Relaxation training|Relaxation training will be performed under the supervision of a physiotherapist. The training is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
215047272|NCT05328869|OTHER|No intervention|No intervention will be applied. The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
215047273|NCT03374358|DRUG|Raltegravir|The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
215047274|NCT01367379|PROCEDURE|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
215047275|NCT01367379|OTHER|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2\~4 times/month)
215047276|NCT03183063|DEVICE|4DCT and SPECT/CT|Each patient will receive two 4DCT followed by SPECT/CT.
215047277|NCT03183063|DEVICE|4DCT with BiPAP and SPECT/CT|Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
214885381|NCT06124157|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214885382|NCT06124157|DRUG|Calaspargase Pegol|Receive IV
214885383|NCT06124157|DRUG|Cyclophosphamide|Receive IV
215047278|NCT03183063|DEVICE|4DCT with CTA in suspected PE|Each patient will receive 4DCT before or after CTA for suspected PE
215047279|NCT03326635|OTHER|Frailty in elderly (≥70 y) patients in ICU|Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
215047280|NCT01799486|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
215047281|NCT01799486|DRUG|Enecavir|0.5 mg monotherapy supplied in tablets.
215047282|NCT01799486|DRUG|Adefovir|10 mg monotherapy supplied in tablets.
215047283|NCT01127633|DRUG|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
215047284|NCT01127633|DRUG|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
214477188|NCT06859749|OTHER|Education|"Students will be given a question-answer application. In order to perform the Escape game for students, 4 stations were prepared in the skills laboratory: Pulse, Respiration-Oxygen Saturation, Blood Pressure, Body Temperature. Separate scenarios will be prepared for each station."
214885384|NCT06124157|DRUG|Cytarabine|Receive IV or subcutaneously
214885385|NCT06124157|DRUG|Dasatinib|Receive PO
214885386|NCT06124157|DRUG|Daunorubicin|Receive IV
214885387|NCT06124157|DRUG|Doxorubicin|Receive IV
214885388|NCT06124157|PROCEDURE|Echocardiography Test|Undergo ECHO
214885389|NCT06124157|DRUG|Imatinib|Given PO
214885390|NCT06124157|DRUG|Leucovorin|Receive PO or IV
214885391|NCT06124157|DRUG|Mercaptopurine|Receive PO
215047285|NCT02676648|BEHAVIORAL|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
215047286|NCT02676648|BEHAVIORAL|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
214477189|NCT06859996|BEHAVIORAL|Tools for Rehabilitation and Cognitive Care (On-TRACC)|The On-TRACC intervention is administered one-on-one with a skilled clinician via telehealth and consists of an introductory session followed by 5 treatment sessions. Participants in the On-TRACC intervention will review various health and lifestyle factors that can affect cognitive functioning, learn and practice skills for managing cognitive and emotional symptoms, and develop personalized goals to support optimal cognitive functioning.
215047287|NCT02676648|BEHAVIORAL|Text messages|We will send participants text messages, to support intervention adherence.
215047288|NCT02676648|BEHAVIORAL|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
215047289|NCT00037440|GENETIC|Polymorphisms measured|
215047290|NCT01805687|DRUG|Zileuton extended release|
215047291|NCT00481455|DRUG|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
215047292|NCT00481455|DRUG|Temozolomide|Fixed dose
215047293|NCT00688467|DRUG|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
215047294|NCT00688467|DRUG|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
215047295|NCT03903549|DRUG|[18F]P17-059|Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning
215047296|NCT02163577|BIOLOGICAL|burosumab|solution for SC injection
215047297|NCT02026947|DRUG|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
215047298|NCT02026947|DRUG|Placebo|
214885392|NCT06124157|DRUG|Methotrexate|Receive IT or IV or PO
215047299|NCT05656183|DIAGNOSTIC_TEST|TruGenome Cardiovascular Disease test|The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
215047300|NCT02181946|DRUG|Fluconazole|
215047301|NCT02181946|DRUG|Nevirapine|
215047302|NCT01794624|BEHAVIORAL|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
215047303|NCT01794624|BEHAVIORAL|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
214885393|NCT06124157|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214885394|NCT06124157|DRUG|Pegaspargase|Receive IV or intramuscularly
214885395|NCT06124157|DRUG|Prednisolone|Receive PO
214885396|NCT06124157|DRUG|Prednisone|Receive PO
215047304|NCT05280821|DIETARY_SUPPLEMENT|daily ferrous sulfate|Daily intake of 100 mg ferrous sulfate capsules for 3 months
215047305|NCT05280821|DIETARY_SUPPLEMENT|alternate day ferrous sulfate|Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
214885397|NCT06124157|RADIATION|Radiation Therapy|Undergo radiation therapy
214885398|NCT06124157|DRUG|Thioguanine|Receive PO
214885399|NCT06124157|DRUG|Vincristine|Receive IV
214885400|NCT06749145|DIAGNOSTIC_TEST|Portable 1-lead electrocardiogram|Portable 1-lead electrocardiogram (ECG) performed with the FDA-approved AliveCor KardiaMobile device.
214477190|NCT06859996|BEHAVIORAL|Brain Health psychoeducation|The Brain Health intervention is administered one-on-one with a skilled clinician via telehealth and consists of an introductory session followed by 5 treatment sessions. Participants in the Brain Health psychoeducation treatment will learn about various health and lifestyle factors that can affect brain health and cognitive functioning. In addition, they will be provided with resources and strategies for managing relevant factors and supporting optimal cognitive functioning.
214477191|NCT06859190|DRUG|estazolam 1-2 mg|oral estazolam 1-2 mg daily at bedtime for 8 weeks.
214885401|NCT06749145|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed with the FDA-approved VScan Air device.
214885402|NCT06749145|OTHER|AI-ECG risk algorithm|Artificial intelligence (AI) risk algorithm for aortic stenosis using a 1-lead electrocardiogram
214885403|NCT06749145|OTHER|AI-POCUS|Artificial intelligence (AI) risk algorithm for aortic stenosis using cardiac ultrasound plax videos.
214885404|NCT07059325|DEVICE|Transcranial Magnetic Stimulation|Participants will receive 6 to 10 sessions per day (i.e., theta burst; 600 pulses per session; 6000 pulses per day) over 3 to 5 treatment days using a MagVenture MagPro TMS System. Treatment will consist of a total of 30 sessions (18,000 total pulses). A single session is defined as 600 pulses at 50 Hz for 2s (i.e., 5 Hz triplets) and repeated every 10s for a total of 190s per session to l-dlPFC at 120% rMT with 15-minute intersession intervals. TMS will be targeted to Beam F3 for comparison to the bulk of the literature and to most mimic replicable clinical use.
214885405|NCT06749405|BIOLOGICAL|Transfusion algorithm based on Quantra®|"In addition to routine coagulation tests, a Quantra Qstat® analysis will be performed at baseline (before incision), at the end of native liver dissection, and after unclamping of the venous anastomoses. In the event of bleeding, additional Quantra Qstat® analyses may be conducted until bleeding control is achieved.~Transfusion and administration of blood-derived medications will be guided by the results of the Quantra Qstat® analyses."
214885406|NCT06749405|BIOLOGICAL|Conventional transfusion algorithm|Transfusion and blood-derived medications will be guided by the results of routine coagulation tests.
214885407|NCT06126276|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214885408|NCT06126276|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215047306|NCT04284137|BEHAVIORAL|Modified FE-SaLiR|Participants will attend a 60-minute exercise program (modified Wu Qin Xi and Ba Duan Jin) in a non-clinical community setting twice a week and will perform the exercises at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
215047307|NCT04284137|BEHAVIORAL|Unmodified Chinese Medicine Exercise|Participants will attend a 60-minute exercise program (Wu Qin Xi and Ba Duan Jin published by the General Administration of Sport of China) in a non-clinical community setting twice a week and will be expected to practice exercise at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
215047308|NCT04284137|BEHAVIORAL|Active Control|Participants will attend a 60-minute health education program once a week.
215047309|NCT03190135|BEHAVIORAL|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
215047310|NCT03190135|BEHAVIORAL|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
215047311|NCT00690794|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
215047312|NCT00690794|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
215047313|NCT03078439|OTHER|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
215047314|NCT01247454|BEHAVIORAL|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
215047315|NCT01247454|BEHAVIORAL|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
214477192|NCT06859190|PROCEDURE|Auricular pressure bean combined with electroacupuncture|Electroacupuncture treatment will be performed on seven acupoints, including Baihui (GV20), Shenting (GV24), Yintang (GV29), Anmian (EX-HN22), Shenmen (HT7), Neiguan (PC6), and Sanyinjiao (SP6). Each session lasts for 30 minutes and is conducted twice a week.In addition, auricular point seed-pressing therapy will be applied to bilateral auricular points related to insomnia (Shenmen, Heart, and Sympathetic). Each auricular point will be pressed for 1 minute, three times a day. The total treatment course is eight weeks.
214292717|NCT02309502|DEVICE|Yellow Pascal|": Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
214292718|NCT03915496|DRUG|PF-04965842 200 mg|PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
214292719|NCT03915496|DRUG|PF-04965842 100 mg|PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
214667762|NCT05093127|DEVICE|Carotid Artery Stenting|R-OneTM system is a tool available to physicians for performing CAS without changing the treatment of the pathology. R-OneTM system is designed to remotely deliver and manipulate guidewires and stent/balloon devices during Carotid Artery Stenting. The system is composed of the R-OneTM robotic platform used in combination with two accessories, the Mobile radioprotection screen and a sterile and single-use R-OneTM consumable kit. The physician, seated at the remote radio-protected control station, manipulates guidewires and/or balloon/stent catheters using joysticks on the Command unit.
214885409|NCT06126276|PROCEDURE|Computed Tomography|Undergo CT scan
214477193|NCT06859671|DRUG|Standard of Care (SOC)|14 days of antifungal therapy after the 1st negative blood culture
214477194|NCT06859671|DRUG|Shortened duration of antifungal therapy|7 days of antifungal therapy after the 1st negative blood culture
214477195|NCT06668935|DEVICE|To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists|All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.
214477196|NCT06669234|DRUG|ALN-F1202|Administered per the protocol
214667763|NCT04988373|DEVICE|Modified aligner appliance|Patients will be treated using a single aligner appliance with NiTi Springs in order to align their crowding teeth.
214885410|NCT06126276|PROCEDURE|Echocardiography Test|Undergo ECHO
214885411|NCT06126276|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214885412|NCT06126276|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214885413|NCT06126276|DRUG|Neratinib Maleate|Given PO
214885414|NCT06126276|DRUG|Palbociclib|Given PO
214885415|NCT04245839|DRUG|Fludarabine|Fludarabine
214885416|NCT04245839|DRUG|Cyclophosphamide|Cyclophosphamide
214885417|NCT04245839|DRUG|JCAR017|JCAR017
214292720|NCT03915496|DRUG|Placebo|Placebo administered as two tablets to be taken orally once daily for 12 weeks
214292721|NCT01880840|DRUG|205.5 mcg of azelastine hydrochloride|nasal spray
214292722|NCT01880840|DRUG|137 mcg of azelastine hydrochloride|nasal spray
214477197|NCT06669234|DRUG|Matching Placebo|Administered per the protocol
214885418|NCT07063511|DEVICE|Restylane Injectables|Participants will receive multilayering treatment (i.e., one product will be placed deep and one in a more superficial plane) in area of primary deficit (i.e., the midface or lower face), in isolation or combination with other treatment areas.
214885419|NCT06752603|DRUG|ONO-1110|ONO-1110 tablets once a day
214885420|NCT06752603|DRUG|Placebo|Placebo tablets once daily
214885421|NCT06899126|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
214885422|NCT06899126|DRUG|pembrolizumab|pembrolizumab will be administered at a dose of 200 mg IV Q3W
214885423|NCT06899126|DRUG|Pemetrexed|Pemetrexed will be administered at a dose of 500 mg/m2 IV Q3W
214885424|NCT06899126|DRUG|Chemotherapy|"One of the following two will be administered in Arm B:~Cisplatin at a dose of 75 mg/m2 IV or carboplatin AUC at a dose of 5 mg/mL/min IV"
214292723|NCT06036771|DEVICE|Voice-activated Intelligent Personal Assistant (VIPA)|Apple HomePod mini is selected as the intervention medium of this study as it is the only available smart speaker that supports Cantonese
214292724|NCT00833885|DEVICE|Masks|Wearing of surgical masks
214292725|NCT00833885|DEVICE|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
214292726|NCT00833885|OTHER|Control|General information about virus transmission in households and basic means to prevent it
214292727|NCT01300598|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
214885425|NCT06033833|DRUG|Amlitelimab|Injection Solution: by subcutaneous injection (SCI)
214885426|NCT06033833|DRUG|Placebo|Injection Solution: by subcutaneous injection (SCI)
214885427|NCT06574607|DEVICE|Interactive Educational Material for Decision-Making|Using severe bleeding from abdominal-pelvic trauma as a scenario case, implementing decision-making teaching strategies to guide learners, and examining the intervention through this research
214885428|NCT06574607|DEVICE|Interactive Educational Material|Teaching with scenario-based interactive materials without incorporating any teaching strategies
214885429|NCT05698914|BEHAVIORAL|Telehealth mindfulness-based intervention (MBI)|The telehealth MBI is adapted from Mindfulness-based cognitive therapy for chronic pain and consists of eight, weekly 75-minute individual sessions (90 minutes allotted for the first session) with a mindfulness interventionist delivering the intervention over telehealth (online with audio and video camera) in addition to the patient receiving their usual postsurgical care. Participants will begin the intervention after completing the 2-week postoperative assessment and within 4 weeks after surgery. Participants will be asked to practice skills between sessions approximately 20-40 minutes per day.
214477198|NCT06669416|BEHAVIORAL|Taste Alteration Self-Assessment|The nurse-led intervention involves using a valid/reliable TA assessment tool (Chemotherapy-induced Taste Alterations Scale (CiTAS) and teaching the patient to select assessment-driven interventions to manage TA symptoms.
214292728|NCT03276156|DRUG|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
214477199|NCT06669416|BEHAVIORAL|Taste Alternation Self-Management|The nurse-led intervention involves teaching the patient to use the assessments and the evidence-based Patient Education Sheet to select assessment-driven interventions to manage their symptoms. Data will be collected about the specific actions prescribed in the teaching tool and to identify which interventions were used and their overall impact.
214667764|NCT04988373|DEVICE|Traditional fixed appliance|Patients will undergo typical orthodontic treatment using an MBT-prescription of metallic brackets.
214885430|NCT05698914|BEHAVIORAL|Telehealth Education|Participants will receive a written educational booklet at the time of randomization (within 2-4 weeks after surgery) and 8, weekly telehealth sessions lasting 30 minutes in addition to usual postsurgical care. The educational materials are reviewed individually with the participant during weekly telehealth sessions (online with audio and video camera) by a physical therapist.
214885431|NCT04540835|DEVICE|Teethmate Desensitizer (Kuraray)|Calcium phosphate desensitizer applied after caries removal. After restored using an oblique incremental technique with a composite resin (Filtek Z250, 3M Espe, USA)
214885432|NCT05579470|BEHAVIORAL|NIATx|For each country, the learning collaborative will be comprised of a Chief Narcologist from each region where the investigators will initially train them and the coaches using all the tools from the NIATx Academy (2-3-day training). The national coach for each country will receive ongoing and in-depth coaching from a US-based super coach. A nationwide Nominal Group Technique (NGT) will be conducted to assess barriers and potential targets to guide decision-making about changes. At the end of the initial meeting, each Chief Narcologist (CN) will be able to identify a change target for Plan, Do, Study, Act (PDSA) (entry, retention) and create a Change Project Form to state what will be done (e.g. flowcharting), who is involved (team), what are the measures and timeframe (\<4 weeks).
214885433|NCT04858334|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214292729|NCT00358124|DRUG|insulin glargine|
214292730|NCT00358124|DRUG|rosiglitazone|
214292731|NCT00358124|DRUG|metformin|
214292732|NCT04646889|DRUG|AR882 Single Dose|A single dose of AR882
214292733|NCT04646889|DRUG|AR882 Multiple Dose|AR882 taken once daily for 14 days
214292734|NCT01579175|OTHER|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
214477200|NCT06669806|DEVICE|TIPS Stent Graft|a covered TIPS stent graft
214477201|NCT04109066|BIOLOGICAL|nivolumab|Specified Dose on Specified days
214477202|NCT04109066|DRUG|paclitaxel (PTX)|Specified dose on Specified days
214477203|NCT04109066|OTHER|nivolumab placebo|Specified dose on Specified days
214477204|NCT04109066|DRUG|anthracycline|Specified dose on Specified days
214477205|NCT04109066|DRUG|cyclophosphamide|Specified dose on Specified days
214885434|NCT04858334|PROCEDURE|Computed Tomography|Undergo CT or CT/MRI
214885435|NCT04858334|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
214885436|NCT04858334|DRUG|Olaparib|Given PO
214477206|NCT04109066|DRUG|Endocrine Therapy|Variable endocrine therapy of investigators choice
214667765|NCT00454597|PROCEDURE|omentectomy|surgery omentectomy
214667766|NCT02083276|DRUG|Pivmecillinamhydrochlorid|PO 400 mg x3 for 7 days
214292735|NCT05541952|BIOLOGICAL|BCG|Revaccination with BCG, using the immunobiological used in the Brazilian public health network, strain Russia.
214292736|NCT06284291|DIAGNOSTIC_TEST|transcranial magnetic stimulation (TMS)|The STM9000 Standard-BI stimulator with 70 mm refrigerated butterfly stimulator (EB Neuro, Florence, Italy) controlled by Galileo Netbrain 9000 hardware and software (EB Neuro, Florence, Italy) is used. EMG data are recorded from the contralateral dorsal first interosseous muscle using gelled surface electrodes. EEG data are recorded by using the BE PLUS PRO Advanced EEG/EMG/EP amplifier (EB Neuro, Florence, Italy IT).
214292737|NCT00155350|DRUG|pioglitazone|
214292738|NCT02893878|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
214292739|NCT00179634|BEHAVIORAL|Visualization relaxation|
214292740|NCT00179634|BEHAVIORAL|Visual Milieu Enhancement (Fine art photograph)|
214292741|NCT01892228|BEHAVIORAL|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
214477207|NCT04109066|PROCEDURE|Surgery|Surgery for breast cancer
214477208|NCT05419050|DRUG|denosumab|monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis
214667767|NCT02574221|DRUG|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
214667768|NCT02574221|DRUG|cavity protection toothpaste|0.243% sodium fluoride toothpaste
214885437|NCT04858334|DRUG|Placebo Administration|Given PO
215047316|NCT01247454|BEHAVIORAL|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
215047317|NCT01187654|BIOLOGICAL|AC133|intra coronary injection of bone marrow derived AC133+ cells
215047318|NCT01187654|BIOLOGICAL|MNC|intra coronary injection of bone marrow derived MNC
215047319|NCT01187654|BIOLOGICAL|CONTROL|autologous serum injection
214477209|NCT06421324|BEHAVIORAL|Health reccommendations|Patients are given recommendations according to their risk group, based on the model which already predicted health indicators. This information will be sent to the patient's treating physician so that treatment and recommendations are aligned with the clinical care practice based on the European Code of Cancer guidelines, the H. pylori best practices guidelines and European GIM guidelines
214477210|NCT06234995|DRUG|Levodopa|Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.
214477211|NCT06234995|DEVICE|Clinical DBS Setting|Deep brain stimulation performed with the patients' optimized clinical setting.
214477212|NCT06234995|DEVICE|Sham DBS|Deep brain stimulation performed with sham stimulation.
214477213|NCT06234995|DEVICE|DBS Setting Maximizing Prefrontal Activation|Deep brain stimulation performed to maximize the activation of the prefrontal cortico-STN projections.
214477214|NCT06234995|DEVICE|DBS Setting Minimizing Prefrontal Activation|Deep brain stimulation performed to minimize the activation of the prefrontal cortico-STN projections.
214667769|NCT05854134|DIAGNOSTIC_TEST|Closed Chain|Effectiveness of Closed Chain for Strengthening and Improving Quality of Life in Post Stroke Patients
214667770|NCT05854134|DIAGNOSTIC_TEST|Aerobic Exercise|Effectiveness of Aerobic Exercise for Strengthening and Improving Quality of Life in Post Stroke Patients
215047320|NCT05704153|DEVICE|Parasym 1Hz|Transcutaneous auricular vagus nerve stimulation of 1Hz
215047321|NCT05704153|DEVICE|Parasym 30Hz|Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz
215047322|NCT05704153|DEVICE|Sham Intervention|Sham stimulation
215047323|NCT01544673|DRUG|linezolid|600 mg oral tablet twice daily for 4.5 days
215047324|NCT01544673|DRUG|Placebo|500 mg oral placebo twice daily for 4.5 days
215047325|NCT03855943|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
215047326|NCT03855943|BEHAVIORAL|CBT|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
215047327|NCT03394742|BEHAVIORAL|Peer support|Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
215047328|NCT03940560|DEVICE|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
215047329|NCT01823107|DEVICE|Meso BioMatrix Device|
215047330|NCT04474639|DEVICE|echocardiographic examination|conducting an echocardiographic study according to a standard protocol with the determination of diastolic dysfunction of the left ventricle
215047331|NCT00819429|DIETARY_SUPPLEMENT|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
215047332|NCT00819429|BEHAVIORAL|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
215047333|NCT00819429|OTHER|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
215047334|NCT00154349|DRUG|Imatinib Mesylate|
215047335|NCT05689879|DRUG|STOP arm|TNF-alpha antagonists withdrawal
214292742|NCT03164252|RADIATION|Grupo I- Lower laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
214292743|NCT03164252|RADIATION|Grupo II- Greater laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
214477215|NCT06454227|PROCEDURE|Subcutaneous washing|subcutaneous washing with chlorhexidine gluconate prior to skin closure
214477216|NCT06454227|PROCEDURE|no subcutaneous washing|no washing
214477217|NCT04076956|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw
214667771|NCT06114654|BEHAVIORAL|Physical Therapy|Specific physical tests to assess muscle strength, ankle stability and activation of the lower extremity musculature: Single Leg Stance Test, Hurdle Step test and Single leg vertical jump.
214667772|NCT03963544|DRUG|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR
214667773|NCT03361501|DRUG|CaPre|4 x 1 g capsules administered orally once daily for 26 weeks
214667774|NCT03361501|DRUG|Placebo|4 x 1 g capsules administered orally once daily for 26 weeks
214667775|NCT06478953|DIAGNOSTIC_TEST|FA Pneumonia Panel|A single BioFire® FilmArray® Pneumonia Panel assay will be performed on a respiratory clinical specimen.
214667776|NCT01403077|DEVICE|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
214667777|NCT05000320|DIAGNOSTIC_TEST|Neuronal Injury Panel|A panel of neuronal and astroglial assays that may be a marker of brain injury.
214667778|NCT06369155|DRUG|Azenosertib|Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.
215047336|NCT06344637|DRUG|10 % lidocaine spray without adrenaline|Pateint with indication for manual vacuum aspiration aged between 20-60 years will received a standard injection of pethidine along with 1% lidocaine spray without adrenaline on cervical os to compare pain scores with placebo. Along with measuring side effects immediately and 30 minutes after receiving 1% lidocaine without adrenaline.
215047337|NCT06344637|OTHER|Placebo|4 puffs of normal saline apply on cervical os before manual vacuum aspiration
214885438|NCT07077655|OTHER|Marmet Technique|One of the traditional and natural efforts mothers can make to facilitate breast milk production postpartum is the Marmet technique. This technique embraces the principles of massage and stimulation of the milk ejection reflex (Widiastuti et al., 2015; Hairunisyah \& Kusumawaty, 2022). Furthermore, this technique provides a relaxing effect, reactivating the milk ejection reflex, which in turn stimulates spontaneous milk flow (Yuliani et al., 2015). In other words, the Marmet technique is a combination of expressing milk and massaging the breast by emptying the lactiferous sinuses located under the areola. The Marmet technique stimulates prolactin secretion and helps maximize the milk ejection reflex. The more milk that is withdrawn or emptied from the breast, the greater the milk production (Widiastuti et al., 2015).
214292744|NCT03164252|RADIATION|Grupo III- Laser sham|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
214292745|NCT04810845|DEVICE|Application of Class II A device SmartCardia|Application of SmartCardia monitor patch 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Non invasive recording of single-lead ECG, respiratory rate, pulse transit time, heart rate would occur pre, during and post (30 minutes) primary angioplasty procedure
214292746|NCT00355693|DEVICE|Pump for propofol delivery|
214292747|NCT05286281|DRUG|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
214292748|NCT00248014|DEVICE|Mandibular Advancement Via A Functional Appliance|Functional appliance
214292749|NCT00929799|DRUG|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
214292750|NCT03254004|DRUG|Pembrolizumab|pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
214885439|NCT07077655|OTHER|Oxytocin Massage|Oxytocin massage is a type of massage performed to increase breast milk production. The massage is applied to the sides of the spine and the fifth to sixth ribs, and it stimulates the prolactin and oxytocin hormones after birth (Kosova et al., 2016). This massage serves to increase the oxytocin hormone, which can calm the mother, leading to an automatic flow of breast milk (Kilci \& Sevil, 2021). Research conducted by Azizah and Ambarika (2022) shows that a combination of the Marmet technique and oxytocin massage can increase breast milk production. Massaging or stimulating the spine sends a message to the hypothalamus in the posterior pituitary by directly stimulating the medulla oblongata via neurotransmitters to release oxytocin, which then causes milk secretion from the breasts (Lestari \& Linar, 2024).
214885440|NCT07077655|OTHER|Plasebo|No intervention will be made to the participants in this group. Superficial touch will be performed on women's wrists, elbows, and shoulders.
214885441|NCT03514017|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
214885442|NCT03514017|DRUG|Ibrutinib|Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
214885443|NCT06704191|BIOLOGICAL|BCG Solution|Given intravesically
214885444|NCT06704191|PROCEDURE|Cystoscopy|Undergo cystoscopy
214885445|NCT06704191|DRUG|Docetaxel|Given intravesically
214885446|NCT06704191|DRUG|Gemcitabine|Given intravesically
214885447|NCT06704191|OTHER|Home Health Encounter|Receive access to CCBW home health visits
214885448|NCT06704191|DRUG|Mitomycin|Given intravesically
214885449|NCT06704191|OTHER|Questionnaire Administration|Ancillary studies
214885450|NCT06821815|OTHER|Video Game Based Therapy|Video game based therapy interventions includes active video games for rehabilitation. Leap Motion Controller based rehabilitative games, Xbox Kinect Games and Kinect Based Custom Rehabilitative Games will be applied to the participants
215047338|NCT00659282|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
214292751|NCT01024452|DEVICE|DAWN AC|computerized dosing management system for anticoagulation clinics
214292752|NCT01024452|DEVICE|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
214292753|NCT03949361|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
214292754|NCT03949361|DIAGNOSTIC_TEST|Skin Temperature|Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer
214292755|NCT03949361|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
214292756|NCT03949361|DIAGNOSTIC_TEST|Blood Sampling|thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)
214292757|NCT03949361|DIAGNOSTIC_TEST|FDG-PET|Dynamic PET scanning of the neck-region
214292758|NCT03949361|DIAGNOSTIC_TEST|Capillary glucose|Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
214292759|NCT03949361|DIAGNOSTIC_TEST|Biopsy of supraclavicular adipose tissue (optional)|Ultrasound guided biopsy of the supraclavicular adipose tissue
214292760|NCT06076057|DIAGNOSTIC_TEST|vital signs monitoring|Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors
214292761|NCT00349284|DRUG|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
214885451|NCT06821815|OTHER|Bimanual Intensive Therapy|This intervention includes goal directed activity based exercises for upper extremity functions. This intervention also includes exercises for postural control
214885452|NCT05271409|DRUG|Satralizumab|Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
214885453|NCT05271409|OTHER|Placebo|Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
215047339|NCT02990650|BEHAVIORAL|Balance Task Training with therapist guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The therapist will provide guarding support"
214885454|NCT03389347|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow aspirate and blood
214885455|NCT03389347|DEVICE|High Throughput Screening|Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay
214885456|NCT03389347|OTHER|Laboratory Biomarker Analysis|Correlative studies
214885457|NCT06818812|DRUG|INCB186748|INCB186748 will be administered at protocol defined dose.
214885458|NCT06818812|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
214885459|NCT06818812|DRUG|GEMNabP|GEMNabP will be administered at protocol defined dose.
214885460|NCT06818812|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered at protocol defined dose.
214885461|NCT02463708|BEHAVIORAL|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
214885462|NCT07124468|DRUG|Meropenem-Pralubactam|The study is designed to enroll approximately 16 healthy participants. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Meropenem-Pralubactam
214885463|NCT05733702|OTHER|All participants will be asked to provide data and samples for collection and analysis.|During the first year from the date of inclusion, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at 3 months, and at 12 months. Patient-Reported Outcomes (PROs) with voice recordings will be collected at different time points in-between clinical visits using the Colive application. Participants will be asked to provide biological samples (i.e., blood, dried blood spots and stool are mandatory; saliva, urine and hair are optional), tissue samples from endoscopic biopsy and imaging data (if performed as per standard of care) at three timepoints (baseline; 3 months; 12 months). One unscheduled visit may be included in the study in case of occurrence of flare or treatment change.A long-term follow-up (starting from month 12 and up to 4 years after month 12) will include the collection of medical data on a yearly basis, collection of PROs with voice recording every 6 months and continuous collection of data using the smartwatch.
214885464|NCT06925100|DRUG|Bempedoic acid 180 mg tablet|180 mg tablet, once daily administered for 12 weeks
215047340|NCT02990650|BEHAVIORAL|Balance task training with robotic guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
214885467|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
214885468|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
214885469|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
214885470|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
214885471|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
214885472|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
214885473|NCT05351827|OTHER|Mild Intermittent Hypoxia|Participants will breathe 8% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. 100% oxygen and carbon dioxide are titrated into the system to ensure the appropriate hypoxic and hypercapnic stimulus is delivered. The investigators will lower oxygen to 55-60 mmHg and maintain end-tidal carbon dioxide 1-3 mmHg above individual baseline values. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
215047341|NCT02990650|BEHAVIORAL|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
215047342|NCT01343888|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
215047343|NCT01343888|DRUG|BI 201335|BI 201335 once daily high dose
215047344|NCT01343888|DRUG|BI 201335|BI 201335 once daily low dose
215047345|NCT01343888|DRUG|Placebo|
215047346|NCT02217618|DRUG|LY2409021|
214885474|NCT05351827|OTHER|Sham|Participants will breathe 21% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. No supplemental oxygen or carbon dioxide will be used during the sham protocol. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
214885475|NCT06257264|DRUG|BG-68501|Planned doses administered orally.
214885476|NCT06257264|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
214885477|NCT06257264|DRUG|BGB-43395|Planned doses administered orally.
214885478|NCT06833138|PROCEDURE|pacemaker implantation|The Medtronic 3830 lead should be used as the Conduction System Pacing lead. However, in case of unsuccessful implantation with the 3830 lead, a stylet-driven lead can be used as an alternative.
214885479|NCT06833138|PROCEDURE|atrioventricular node ablation|Right-sided atrioventricular junction ablation will be attempted first with a radiofrequency catheter. The choice of the catheter will be at the discretion of the physician. The catheter will be advanced to the His Bundle and then slightly withdrawn proximally and caudally in order to target the compact atrioventricular node. Repeated ablation procedures will be recommended during follow-up if regression of atrioventricular block occurs.
214885480|NCT06833138|DEVICE|Pacemaker programming|The pacemaker device will be programmed in VVIR mode at a lower rate of 75 beats per minute in bipolar mode for sensing and pacing
214885481|NCT07089875|DRUG|Allopurinol|Over-encapsulated tablets containing active drug substance administered orally (PO).
214885482|NCT07089875|DRUG|Dotinurad|Over-encapsulated tablets containing active drug substance administered PO.
214885483|NCT07089888|DRUG|Allopurinol|Over-encapsulated tablets containing active drug substance administered orally (PO).
214885484|NCT07089888|DRUG|Dotinurad|Over-encapsulated tablets containing active drug substance administered PO.
214885485|NCT07088731|DRUG|Sintilimab|neoadjuvent chemotherapy plus sintilimab for 2 cycles followed by radical surgery
214885486|NCT07088731|RADIATION|Concurrent chemo-radiotherapy|EBRT+BT+cisplatin
215047347|NCT03204760|DRUG|Dexamethasone 8Mg Solution for Injection|Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
214292762|NCT03018171|DRUG|Clonidine|Intrathecal clonidine addiction
214292763|NCT03018171|DRUG|Sufentanil|Intrathecal
214292764|NCT06998225|DIETARY_SUPPLEMENT|Dietary intervention using cookies containing milk or egg low dose.|Baked Group 1: consumed a daily fixed low dose of baked milk or egg (0.0375 g of milk protein or 0.11 g of egg protein) for 6 months, followed by an additional increase at that time (0.075 g or 0.22 g).
214292765|NCT06998225|DIETARY_SUPPLEMENT|Dietary intervention with cow's milk or egg baked cookies high dose|Baked Group 2: continued a daily high dose of baked milk (0.55 g of milk protein or 1.1g egg protein) for 6 months. An increase dose is given at that time (1.1g cow's milk or 2g egg protein).
214292766|NCT03032705|DEVICE|SonicFill™ 2|The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.
214292767|NCT03032705|DEVICE|Filtek™ Supreme|The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
214292768|NCT01334268|DEVICE|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
214292769|NCT01334268|DEVICE|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
214292770|NCT05030974|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccination
214292771|NCT05030974|BIOLOGICAL|Ad26.COV2.S vaccine|SARS-CoV-2 vaccination
214885487|NCT05430477|DEVICE|Electrical impedance imaging using Non-Significant Risk device (EII probe)|novel small field-of-view Non-Significant Risk device (EII probe)
214885488|NCT03739814|BIOLOGICAL|Blinatumomab|Given IV
214885489|NCT03739814|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214885490|NCT02193282|OTHER|Clinical Observation|Undergo observation
214885491|NCT02193282|DRUG|Erlotinib Hydrochloride|Given PO
214885492|NCT02193282|OTHER|Laboratory Biomarker Analysis|Correlative studies
214885493|NCT02193282|OTHER|Placebo Administration|Given PO
214885494|NCT06325202|DEVICE|Omnipod 5 or Medtronic 780G|Omnipod 5 and Medtronic 780G are hybrid closed loop devices that provide automated insulin delivery.
214885495|NCT06325202|BEHAVIORAL|My HypoCOMPaSS Education|My HypoCOMPaSS is a brief, standardized psycho-educational program delivered in small groups. Facilitated discussions focus on advocating rigorous avoidance of hypoglycemia while maintaining time in target glycemic range.
215047348|NCT03204760|DRUG|Prednisolone Oral, Per 5 Mg|Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
215047349|NCT01677260|DRUG|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
214667779|NCT06510335|OTHER|Lavender essential oil-based product system|"Participants used the study products in a sequential, additive manner approximately 30-60 minutes before bedtime each night for 6 weeks. Usage consists of the following:~* 20 drops of essential oil blend in approximately 250 mL of water in a diffuser, which operated for 8 hours at nighttime.~* 3 x 6 swipes of the topical stick on the upper chest area, and 2 x 3 swipes on the inside of each wrist for topical application.~* 2 capsules of the dietary supplement.~Participants used the essential oil blend alone for 1 week, then added the topical stick for another 1 week. Finally, participants used the essential oil blend, the topical stick, and the dietary supplement for four weeks."
214885496|NCT06325202|BEHAVIORAL|HARPdoc Education|The HARPdoc program targets cognitions around hypoglycemia that act as barriers to hypoglycemia avoidance and recovery of awareness using motivational and cognitive approaches, delivered by diabetes educators, trained and supported by a clinical psychologist, in small group format.
214885497|NCT07089173|DRUG|Intravenous normal saline (NS 0.9)|Under target-controlled infusion (TCI) of remifentanil, anesthesia induction is performed using placebo (normal saline) combined with etomidate (0.3 mg/kg).
215047350|NCT01677260|DRUG|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
215047351|NCT03579758|DRUG|Capecitabine|Given PO
214667780|NCT04939896|OTHER|observation|Observed patients' compliance with rehabilitation at different time
214667781|NCT03115645|OTHER|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
215047352|NCT03579758|DRUG|Cisplatin|Given IV
215047353|NCT03579758|DRUG|Gemcitabine|Given IV
215047354|NCT00519727|DRUG|ISIS 325568|"4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride"
215047355|NCT05998486|DIAGNOSTIC_TEST|EMG in wrist flexor-pronators and extensor-supinators|The subject is asked to perform a series of tasks: resting posture, symmetrical posture arms forward, unilateral distal movement. Each task lasts 10 seconds.
215047356|NCT00417768|DRUG|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
215047357|NCT00417768|OTHER|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
215047358|NCT03645538|OTHER|Parkinson's disease patients|"The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
215047359|NCT03645538|OTHER|No drug|The neurophysiological evaluation in healthy subjects will be conducted by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.
215047360|NCT01394380|OTHER|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
215047361|NCT00497900|DRUG|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
215047362|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
215047363|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
215047364|NCT04097652|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
214667782|NCT04526522|OTHER|No intervention|No intervention
214885498|NCT07089173|DRUG|intravenous sufentanil|Under target-controlled infusion (TCI) of remifentanil, anesthesia induction is performed using sufentanil (0.2μg/kg) combined with etomidate (0.3 mg/kg).
215047365|NCT01056614|DRUG|fludarabine phosphate|Given IV
215047366|NCT01056614|DRUG|busulfan|Given IV
215047367|NCT01056614|BIOLOGICAL|anti-thymocyte globulin|Given IV
215047368|NCT01056614|DRUG|tacrolimus|Given IV and orally
215047369|NCT01056614|DRUG|methotrexate|Given IV
214667783|NCT01092442|PROCEDURE|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
214667784|NCT00002042|DRUG|Epoetin alfa|
214667785|NCT00598130|BIOLOGICAL|Fleece|Fibrin Patch
214885499|NCT07089173|DRUG|Intravenous lidocaine|Under target-controlled infusion (TCI) of remifentanil, anesthesia induction is performed using lidocaine (1.5 mg/kg) combined with etomidate (0.3 mg/kg).
215047370|NCT01056614|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
215047371|NCT01056614|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
215047372|NCT01056614|OTHER|laboratory biomarker analysis|Correlative studies
215047373|NCT04411303|BEHAVIORAL|Step length biofeedback|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
215047374|NCT04411303|BEHAVIORAL|Propulsive force biofeedback|Participants will be provided with real-time visual feedback of anterior-posterior ground reaction forces of the paretic limb during stance phase on a screen in front of a treadmill.
215047375|NCT04411303|BEHAVIORAL|Interlimb asymmetry biofeedback|Participants will be provided with visual feedback of stride-by-stride values of their interlimb asymmetry on a screen in front of a treadmill.
215047376|NCT04411303|BEHAVIORAL|Aerobic intensity-based walking|Participants will walk at three different aerobic intensities. Aerobic intensity will be set based on target heart rate zones calculated with the Karvonen Formula. For low intensity, participants will walk at 30-40% intensity. In moderate intensity conditions, participants will walk at a 50-60% intensity level. In vigorous intensity conditions, participants will walk at an 70-80% intensity level. Aerobic intensity will be manipulated by changing walking speed.
215047377|NCT03563092|PROCEDURE|Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery|Standardized minimally invasive approach to inguinal hernia repair
214885500|NCT07091370|DRUG|Inaticabtagene Autoleucel Injection|"The dose was incremented according to the 3+3 principle, and the three dose levels A, B and C were given in sequence at one time, which were respectively:~A-1 dose group: 0.25×10\^6 CAR-T live cells /kg body weight~Group A (initial dose) : 0.5×10\^6 CAR-T live cells /kg body weight~Group B: 1.0×10\^6 CAR-T live cells /kg body weight~Group C: 1.5×10\^6 CAR-T live cells /kg body weight"
214885501|NCT07082868|DRUG|ibrutinib|Ibrutinib should be self-administered daily by the participant and should be taken at approximately the same time each day
214885502|NCT07082868|DRUG|Epcoritamab|Epcoritamab will be administered at the study site clinic, as a SC injection
214885503|NCT06210815|DRUG|HLX42|HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214885504|NCT06765057|DIETARY_SUPPLEMENT|Winclove's Ecologic® Barrier Probiotics|The investigational product is a multispecies probiotic formulation consisting of 9 selected probiotic strains: the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58.
214885505|NCT06765057|DIETARY_SUPPLEMENT|Winclove's Ecologic® Barrier Probiotics Placebo|The placebo is composed of the carrier of the probiotic product that are identical in physical appearance, it includes maize starch and maltodextrins but contains no bacteria.
214885506|NCT07101640|DRUG|montelukast 4 mg granule|Montelukast sodium (4 mg oral granules) dissolved into 5mL of breast milk/formula yielding a solution concentration of 0.8mg/mL. Dosed once daily by weight, montelukast (0.75 mg/kg/day) or placebo .
214885507|NCT07101640|DRUG|Placebo|Plain breast milk or formula
214885508|NCT06589596|DRUG|BGB-58067|Planned doses administered on specified days per protocol.
214885509|NCT06589596|DRUG|BG-89894|Planned doses administered on specified days per protocol.
214885510|NCT06589596|DRUG|Standard of Care Therapy|Administered in accordance with relevant local guidelines and/or prescribing information.
214885511|NCT07104162|DRUG|Cefiderocol/Xeruborbactam|A fixed dose combination of intravenous cefiderocol and intravenous xeruborbactam
214885512|NCT06256705|OTHER|Simultaneous 68Ga-DOTATOC PET-MRI|on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
214885513|NCT03040973|DRUG|Capmatinib|Tablet for oral use; 150 mg, 200 mg; twice a day
214885514|NCT03040973|DRUG|Nazartinib|Capsule for oral use; 25 mg, 50 mg; once a day
214885515|NCT03040973|DRUG|Gefitinib|tablets for oral use; 250mg; once a day
214885516|NCT03040973|DRUG|Osimertinib|Tablets for oral use; 40 mg, 80 mg; once a day.
214885517|NCT07106125|DRUG|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Kidney transplant recipients will continue to take TMP-SMX daily from months 6-12 after transplant
214885518|NCT07106125|OTHER|Usual Care|Participants will take a placebo from months 6-12 after transplant and continue to receive all standard usual care related to their kidney transplant status
214885519|NCT05100862|DRUG|Zanubrutinib|Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
214885520|NCT05100862|DRUG|Rituximab|Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
215047378|NCT04097990|OTHER|blood sample|a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
215047379|NCT05017064|DEVICE|Cryotherapy group|The use of intraoral ice pack during root canal treatment
215047380|NCT05017064|OTHER|Control group|No cryotherapy will be used
215047381|NCT02714660|OTHER|none, observational study|
214885521|NCT05100862|DRUG|Lenalidomide|Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
214885522|NCT05100862|DRUG|Obinutuzumab|Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
214885523|NCT06596473|DRUG|BG-C477|Administered intravenously.
214885524|NCT06596473|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
214885525|NCT05345002|DRUG|Retifanlimab|Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
214292772|NCT04683536|PROCEDURE|Obturator nerve blockade|We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer
214885526|NCT05345002|DRUG|All-trans retinoic acid|All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
214885527|NCT07108920|OTHER|Functional clinical tests|"Functional clinical tests:~* Time Up and Go test~* Berg Balance Scale (BBS)~* Stair climb and descent time test (SCT)~* Number of falls via a questionnaire"
215047382|NCT00538057|DRUG|GW685698X & GW642444M|study drug
215047383|NCT00102661|DRUG|Campath-1H|15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
215047384|NCT02133469|BIOLOGICAL|PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)|injection 0.5 mL, single dose
215047385|NCT02133469|BIOLOGICAL|Hib Vaccine|Single Dose
214885528|NCT07113067|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active)|Active treatment will consist of high-dose iTBS-rTMS to left dmPFC delivered in runs of 600 pulses at an intensity of 120% resting motor threshold (rMT). iTBS triplets at 50 Hz will be delivered for 2 seconds, repeated every 10 seconds for a total of 190 seconds. Each session will be separated by at least 10-15 minutes and a total of 12 sessions will be given on each treatment day (3-4 hours per study day). A total of 43,200 pulses will be delivered over the entire six days of treatment.
214292773|NCT02853591|PROCEDURE|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
214292774|NCT01479153|PROCEDURE|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
214885529|NCT07113067|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham)|"For the sham stimulation group, a focal electric sham will be used which is indistinguishable from active TMS including a pretreatment individualized sham titration, sham outputs noises synchronized to pulse delivery, and an individualized level of sham stimulation throughout the treatment.~Technicians administering active vs sham TMS will be masked by using a random code generated by the statistician that will indicate whether to use the active or sham side of the coil. Treatments will appear identical to the technician regardless of whether active or sham TMS is administered."
214885530|NCT07113067|OTHER|Brainsight Neuronavigation System|A brainsight neuronavigation system will be used during TMS treatments to target treatment location using individual MRI data
214292775|NCT01947439|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
214292776|NCT02378701|BEHAVIORAL|QUALMS-1 Questionnaire|Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.
214885531|NCT07112885|PROCEDURE|Arthroscopic Microfracture Combined with Autologous SVF Injection|This procedure involved arthroscopic debridement and microfracture of the knee joint. After microfracture, autologous SVF, isolated from adipose tissue through mechanical digestion and centrifugation, was administered intra-articularly under sterile conditions
214292777|NCT02378701|BEHAVIORAL|FACT-An Questionnaire|Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.
214292778|NCT03613935|OTHER|Product 1|Comparison with products 2, 3, and 4
214292779|NCT03613935|OTHER|Product 2|Comparison with products 1, 3, and 4
214292780|NCT03613935|OTHER|Product 3|Comparison with products 1, 2, and 4
214292781|NCT03613935|OTHER|Product 4|Comparison with products 1, 2, and 3
214292782|NCT03670303|BEHAVIORAL|Educational intervention|"Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~1. Lectures on importance of spectacles use including visual materials such as pictures and videos.~2. An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~3. Posters~4. Brochures"
214667786|NCT02066662|DRUG|Rivaroxaban or Marcumar|"Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0."
214885532|NCT07112885|PROCEDURE|Arthroscopic Debridement Followed by Autologous SVF Injection|This procedure included only arthroscopic debridement of the knee joint. After debridement, autologous SVF, isolated in the same manner from adipose tissue, was injected into the joint space intra-articularly without microfracture.
214885533|NCT06876714|BIOLOGICAL|Trastuzumab (Herceptin)|Given IV or SC
214885534|NCT06876714|BIOLOGICAL|Pertuzumab|Given IV or SC
214885535|NCT06876714|PROCEDURE|Echocardiography|Undergo ECHO
215047386|NCT05269186|DEVICE|Virtual reality software|The patient will undergo a 20-minute virtual reality session before the planning CT scan
214292783|NCT06359470|OTHER|Positioning technique|"First time of testing: Firstly, the patients were scanned in the conventional neutral supine position and a 3D-CT scan was taken.~Second time of testing: after 10 minutes, the patients were scanned in the modified reversed contralateral rotation (side-lying on a hard pillow with side bending to the non-affected side and rotation to non affected side). This is achieved through instructing the participant to first lie on the side lying on a wedge pillow (that is flexible with dimensions of 30 cm in height and 75 cm in length) to achieve trunk side bending to non-affected side this pillow is the same for all patients, then the patient/participant rotated to the affected side (pelvis on the trunk rotation), and 3D-CT scan.~Third time of testing: after 48 hours, the patients were scanned in the modified reversed contralateral rotation."
214292784|NCT04931862|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide (ASO)
214292785|NCT04931862|DRUG|Placebo|Artificial cerebrospinal fluid (aCSF)
214292786|NCT04475653|BEHAVIORAL|Physical Activity using an Activity Tracker|
214292787|NCT02635945|DRUG|PBF-680|
214292788|NCT02635945|DRUG|Placebo|
214667787|NCT05890391|OTHER|Time-Restricted Eating|They were fed ad libitum between 10.00 a.m-06.00 p.m and fasted between 06.00 p.m-10.00 a.m.
214667788|NCT05890391|OTHER|Energy-Restricted Diet|The total energy expenditure (TEE) of individuals was determined using the 'Resting Energy Expenditure (REE) x Physical Activity Level (PAL) ' formulation. 'TEE-500 kcal' formulation was used for the diet to be given to individuals.
214885536|NCT06876714|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214885537|NCT06876714|PROCEDURE|Mammography|Undergo mammography
214885538|NCT06876714|PROCEDURE|Ultrasound|Undergo ultrasound
214885539|NCT06876714|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214885540|NCT06876714|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214885541|NCT06876714|OTHER|Questionnaire Administration|Ancillary studies
214667789|NCT04243369|DEVICE|Non-diagnostic software solution|Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
214667790|NCT02112266|OTHER|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
214667791|NCT02112266|OTHER|no mail support|follow-up without mail support
214292789|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: exposure in vivo|Behavioral, chronic pain rehabilitation therapy
214292790|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: graded activity|Behavioral, chronic pain rehabilitation therapy
214292791|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: acceptance and commitment therapy|Behavioral, chronic pain rehabilitation therapy
214292792|NCT03111901|DRUG|Pembrolizumab|Pembrolizumab solution
214667792|NCT04329949|DRUG|Relacorilant, 100 mg and 25 mg|Relacorilant is supplied as capsules for oral dosing.
214885542|NCT06915454|DEVICE|Intra-op PET/CT Specimen Scanner|Once the tumor or cancer is resected, it will then be imaged with the XEOS Aura 10 PET/CT Imaging Device. Imaging will be obtained utilizing a XEOS AURA 10 scanner in real time while in the operating room with the surgery team still present.
214885543|NCT05123703|DRUG|Ocrelizumab|Ocrelizumab 300 milligrams (mg) will be administered by IV infusion to participants who weigh \< 35 kilograms (kg) and ocrelizumab 600 mg IV will be administered to participants who weigh ≥ 35 kg on Days 1 and 15 (half the dose, 2 weeks apart) and Q24W thereafter.
214292793|NCT03111901|DRUG|Interleukin-2|Interleukin-2 solution
214292794|NCT01711970|DRUG|Paclitaxel|
214292795|NCT05783778|DIAGNOSTIC_TEST|Free testosterone levels and toxoplasma igG|Free testosterone levels and toxoplasma igG in serum by ELISA
214292796|NCT03903705|DRUG|Fruquintinib in Combination with Sintilimab|"Fruquintinib plus Sintilimab:~Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2weeks on/1 weeks off + Sintilimab 200mg Q3W, intravenous dosing~Cohort E: Fruquintinib 3 mg QD, continuous, oral dosing, + Sintilimab 200mg Q3W, intravenous dosing~Fruquintinib monotherapy arm:~Fruquintinib 5 mg QD, oral dosing, 3 weeks on/1 weeks off~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
214292797|NCT02825992|DEVICE|AcQMap System|3D imaging and mapping system for cardiac chambers
214292798|NCT05451368|OTHER|Coronary artery calcification lesions|Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.
214667793|NCT04329949|DRUG|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
214667794|NCT00029796|DRUG|soy isoflavones|
214667795|NCT01825434|DIETARY_SUPPLEMENT|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
214667796|NCT02234401|DEVICE|Bi level pressure support|
214667797|NCT02234401|OTHER|Standard Care|
214667798|NCT02556086|DRUG|Daclatasvir|
214667799|NCT02556086|DRUG|Sofosbuvir|
214667800|NCT03851744|OTHER|Sea Level|Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
214667801|NCT03851744|OTHER|High Altitude|Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
214667802|NCT02688569|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Widespread Pain|CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
214667803|NCT04527757|PROCEDURE|Inhalation induction|For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
214667804|NCT04527757|PROCEDURE|Intravenous induction|For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
214667805|NCT03180736|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
214667806|NCT03180736|DRUG|Pomalidomide|Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.
214667807|NCT03180736|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
214885544|NCT05123703|OTHER|Ocrelizumab Placebo|Ocrelizumab matching placebo will be administered by IV infusion on Day 1 and Day 15 and Q24W thereafter.
214292799|NCT02050776|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
214292800|NCT02279173|DRUG|Romiplostim|Romiplostim subcutaneous weekly injection
214292801|NCT06401395|DEVICE|DIGIPARK MONITOR|remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.
214292802|NCT02090660|OTHER|ICG Localization with Spy thoracoscope localization|
214292803|NCT00188149|DRUG|Combined chemotherapy (ABVD, BACOPP-D)|
214292804|NCT00188149|PROCEDURE|Radiation therapy|
214292805|NCT00280462|DRUG|Nifedipine (drug)|Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
214292806|NCT00280462|DRUG|L-Arginin (drug)|L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
214292807|NCT00280462|DRUG|Placebo|Placebo
214292808|NCT02545790|PROCEDURE|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
214292809|NCT02545790|BIOLOGICAL|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
214292810|NCT02390401|DEVICE|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
214292811|NCT02390401|DEVICE|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
214292812|NCT04882267|BEHAVIORAL|Team and Technology|Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
214292813|NCT05802667|DIAGNOSTIC_TEST|Tryptase|Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa
214292814|NCT04234581|DIETARY_SUPPLEMENT|Lysulin|Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
214292815|NCT03249766|OTHER|Observational|Observational study
214292816|NCT00847054|DRUG|MORAb-004 (monoclonal antibody to TEM1)|Intravenous administration
214292817|NCT02990091|DRUG|Omega 3 fatty acid|LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
214667808|NCT03421548|DEVICE|EyeMate|Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.
214292818|NCT02990091|DIETARY_SUPPLEMENT|Safflower seed oil|Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
214667809|NCT04627545|OTHER|2h exposure to sperm for IVF|Oocytes will only be briefly (2h) exposed to progressive motile sperm for insemination
214667810|NCT04627545|OTHER|overnight exposure to sperm for IVF|Oocytes will be exposed for a longer duration (overnight, 16-20h) to progressive motile sperm for insemination
214667811|NCT00174941|DRUG|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
215047387|NCT04372303|BEHAVIORAL|Compassion Fatigue Resiliency Program (CFRP)|The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.
214292819|NCT02999945|DIETARY_SUPPLEMENT|SGA-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
214292820|NCT02999945|DIETARY_SUPPLEMENT|IUGR-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
215047388|NCT06448975|PROCEDURE|Deep cervical Lymphovenous Bypass|Deep cervical lymph-vein bypass surgery, connecting deep cervical lymph input vein vessel
215047389|NCT06101368|BEHAVIORAL|Phsical Activity|Combined Aerobic and Resistance Training
214292821|NCT02999945|OTHER|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
214292822|NCT02999945|OTHER|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
214292823|NCT03787251|DRUG|Apatinib|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
214885545|NCT05123703|DRUG|Fingolimod|Fingolimod will be administered daily as a capsule per the prescribing information (0.25 mg to participants who weigh ≤ 40 kg and 0.5 mg to participants who weigh \> 40 kg).
214885546|NCT05123703|OTHER|Fingolimod Placebo|Fingolimod matching placebo will be administered daily as a capsule.
214885547|NCT07109388|DRUG|Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasound|Participants in the PENG group will first receive a sham sciatic injection; the needle will be inserted into the subcutaneous tissue and 3 ml of 0.9% NaCl will be injected. They will then receive a PENG nerve block in the supine position. A low-frequency (2-5 MHz) curvilinear ultrasound probe (BK Ultrasound) will be used to identify the anterior inferior iliac spine, the pubic eminence, and the psoas tendon with its fascial plane. A 22-gauge, 50 mm needle (SonoPlex® Pajunk) will be inserted into the fascial plane to inject 20 ml of 0.75% ropivacaine (Fresenius Kabi).
214885548|NCT07109388|DRUG|Femoral, sciatic and lateral femoral cutaneous nerve block with 0.375% ropivacaine|Participants in the combined group will first receive a sciatic nerve block performed with the patient in a semi-prone position, the lower limb flexed at 90° (hip and knee), elevated with a cushion placed between the legs. A straight line will be drawn between the greater trochanter and the ischial tuberosity. The sciatic nerve is located approximately at the midpoint of this line. Under ultrasound guidance, the ischial tuberosity will be identified medially, the greater trochanter laterally, the gluteus maximus muscle superficially beneath the adipose tissue, and the quadratus femoris muscle in depth. A 22-gauge, 50 mm needle will then be inserted into the fascial plane to inject 20 ml of 0.375% ropivacaine. The patient is then placed supine for femoral and lateral femoral cutaneous nerve blocks. 15 ml of local anaesthetics will be injected around the femoral nerve and 5 around the lateral femoral cutaneous nerve.
215047390|NCT06101368|DRUG|Medication|The drug will maintain their usual activity level, foot care, diet, and blood glucose diary on a regular basis. Continue the prescribed medication
214292824|NCT03787251|DRUG|The chemotherapeutic drug chosen by the investigator.|"The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice."
214292825|NCT03140644|OTHER|Patients with thoracic sarcoidosis|Ultra-low dose CT scan and MRI with UTE
214292826|NCT00005622|DRUG|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
214292827|NCT00005622|RADIATION|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
214292828|NCT04673331|OTHER|exercise capacity|3minute step test and 1minute sit to stand test used assessment of exercise capacity.
214292829|NCT06503419|OTHER|non-intervention|non-intervention
214292830|NCT00994292|DRUG|YM150|oral
214885549|NCT06920628|DRUG|11C-PS13|Injected IV followed by PET scanning.
214885550|NCT07117162|OTHER|ADRD Care Delivery Protocol|1\. Included in arm/group descriptions
214885551|NCT07122076|BIOLOGICAL|GT719 Injection|GT719 Injection
214885552|NCT06931132|OTHER|Real-life forest bathing|Participants will experience the elements (olfactory, acoustic and haptic) of forest bathing for 30 minutes (sitting) in a forested area. The forests have been previously selected near Stuttgart and Würzburg and are comparable to each other.
214292831|NCT00994292|DRUG|Placebo|oral
214292832|NCT04137003|OTHER|Rouge et Or Program|It is a detailed, structured and precise training program. It is used from the third-month post ACL surgery to the sixth month.
214292833|NCT04137003|OTHER|CHU intervention guide|From the third month to the sixth month, it outlines the progression to have in the training without precise information on exercises, parameter or frequency.
214292834|NCT00300586|DRUG|observation|observation, second line chemotherapy if progression
214292835|NCT00300586|DRUG|gemcitabine|1250 mg/m² D1, D8 q21 days
214292836|NCT00300586|DRUG|erlotinib|150 mg daily
214292837|NCT03527095|DRUG|FDL169|CFTR corrector
214292838|NCT01866501|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
214885553|NCT06931132|OTHER|Simulated FOREST bathing (Virtual Reality)|Using virtual reality goggles, a FOREST bathing experience will be simulated. The simulation will have elements of the classic FOREST bathing (olfatory, acoustic and haptic) and will last 30 minutes.
214667812|NCT00174941|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
214667813|NCT00174941|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
215047391|NCT02782442|BEHAVIORAL|Structured Cognitive Training & PRIME|The treatment condition-- 30-35 hours of CT over 16 weeks (\~2 hours per week) is a structured program of 20 hours of auditory processing exercises followed by 10 hours of social cognition exercises, combined with the personalized PRIME coaching application
215047392|NCT02782442|BEHAVIORAL|Computer Games Control & PRIME|Computer games control condition which comes in the official PositScience wrapper. 30-35 hours of games over 16 weeks (\~2 hours per week), combined with the personalized PRIME coaching application.
214292839|NCT01866501|DEVICE|EZ-IO|
214292840|NCT00157950|BIOLOGICAL|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
214292841|NCT00157950|BIOLOGICAL|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
214292842|NCT03573895|OTHER|Foam-Roller|Application of foam roller in the posterior part of thigh.
214292843|NCT03573895|OTHER|Neuromuscular stretching|Use of a neuromuscular stretching applied to the hamstring muscles
214292844|NCT03573895|OTHER|Pasive stretching|Use of a pasive stretching applied to the hamstring muscles
214292845|NCT02892760|DEVICE|C-Brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
214292846|NCT06160960|OTHER|OCT Scan, Video of pupil movement, video of toric lens|A picture of the central macular area is taken, video of pupil movment, video of toric lens rotation.
214292847|NCT02105792|DRUG|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
214292848|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
214477218|NCT05864040|DEVICE|Bitrack System-assisted laparoscopic radical/simple nephrectomy|Robot-Assisted Laparoscopic Transperitoneal Radical/Simple Nephrectomy is performed under general anesthesia. Using blunt dissection, the inferior pole of the kidney is lifted, and ureter and gonadal veins released from fat and connective tissue. The ureter is dissected caudally and sectioned after being sealed with a distal endoscopic clip. Dissection proceeds along the psoas muscle with anterior elevation of the ureter and lower renal pole towards the hilium. Main hilar are circumferentially dissected and sectioned and the kidney is entirely mobilized and released. Gerota´s capsule and suprarenal gland may be preserved if oncologically safe. Once the specimen is completely released, a laparoscopic bag is introduced by the assistant and the specimen entrapped. The robot is undocked, gas evacuated from the abdomen and specimen retrieved.
214477219|NCT04282811|DRUG|Venetoclax|Patients treated with venetoclax-based regimens outside clinical trials in Italy
214477220|NCT05818462|DIAGNOSTIC_TEST|Uroflow testing|Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.
214477221|NCT05818462|DIAGNOSTIC_TEST|Bladder Scan|Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.
214477222|NCT05818462|OTHER|Dysfunctional Voiding Scoring System Survey|The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.
214477223|NCT05818462|DIAGNOSTIC_TEST|DEXA Scan of pelvis and sacral spine|DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.
214477224|NCT05818462|DIAGNOSTIC_TEST|Urine tests for specific biomarkers|Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
214477225|NCT05070247|DRUG|TAK-500|TAK-500 intravenous infusion.
214885554|NCT06931132|OTHER|Imaging FOREST bathing|A therapist will lead an imaginative exercise in which participants will imagine a FOREST bathing. The imaginative exercise will include elements of the classic FOREST bathing (olfactory, acoustic and haptic) and will last 30 minutes.
214885555|NCT07125053|BEHAVIORAL|Education (self-guided)|"The self-guided eduction program consists of a mailed booklet entitled, Learning to live with COPD, along with two additional mailings with information on the ALA's Patient and Caregiver Network and the Respiratory Health Association's COPD Caregiver's Toolkit."
214885556|NCT07125053|BEHAVIORAL|Education (counselor-led)|The counselor-led education program combines mailings with phone counseling delivered by ALA Lung Helpline counselors. Three phone sessions (20-30 minutes each) are completed over the course of 6 weeks in the main treatment phase, with two additional optional booster sessions offered between 6 and 12-weeks post-randomization. The counselor-led program follows a structured outline of curriculum for each session, focusing on the topic areas of developing a COPD exacerbation action plan, recognizing COPD exacerbations, and coping with breathlessness.
214885557|NCT07125053|BEHAVIORAL|Physical Activity|The physical activity program will consist of a personalized prescription for home-based exercise following published guidelines, consisting of aerobic, strengthening, and flexibility exercises, tailored to participants' current fitness level and dyspnea symptoms. Aerobic exercise will incorporate ground-based walking training, a well-established, safe, and feasible physical activity program for individuals with COPD. Participants will complete three videoconference sessions (30-45 minutes each) over the course of 6 weeks in the main treatment phase, with two additional optional booster sessions between week 6 and 12.
215047393|NCT02549079|OTHER|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
215047394|NCT01132352|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
215047395|NCT06226961|DEVICE|cupping|The dynamic cupping will be performed for ten minutes, at a slow pace, and consisted of applying a small amount of massage cream (ATL®) over the entire shoulder (to obtain the ideal sliding surface for cupping application), insufflation of the suction cup, with two pumps, and sliding it in the direction of the muscle fibers around the shoulder and also in the transversal direction.
214292849|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
214292850|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
214292851|NCT05704608|OTHER|Aerobic training|Exercises on a treadmill at different speeds and inclination were performed.
214292852|NCT01499667|DRUG|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
214292853|NCT01499667|DRUG|Placebo|Matching placebo in capsules for oral administration once daily.
214292854|NCT02673489|DRUG|DCV|
214477226|NCT05070247|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
214477227|NCT05741294|DRUG|Tirbanibulin 2.5 mg ointment|Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.
214477228|NCT02768038|OTHER|Observational|Blood, stool ja biopsy specimens
214477229|NCT05852808|DRUG|Intra-articular steroid injections|"The patient will be placed in prone position and the facet joints will be imaged by pa-radiation path with attention to radiation protection. 20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints. The patient is monitored after the intervention for another 30 minutes before leaving the hospital. In order to track the pain level, the patient will be instructed to keep a pain diary. The patient will be contacted via telephone 72h after the intervention and asked about the pain level.~The intervention is finished after one consultation."
214667814|NCT01594099|RADIATION|irradiation|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10)."
214292855|NCT02673489|DRUG|SOF|
214292856|NCT02673489|DRUG|RBV|
214885558|NCT07125053|BEHAVIORAL|Inhaler Training|Participants will receive inhaler technique education using a virtual teach-to-goal method. In each session, individuals are observed using their inhaler, provided feedback, and then observed again. Inhaler technique is scored using a checklist specific to each inhaler device. Participants will complete two inhaler training sessions via videoconference at week 1 and week 4, with an optional booster session offered at week 8.
214292857|NCT00293254|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
214885559|NCT07126951|PROCEDURE|Ultrasound-guided Deep Pharmacopuncture Treatment|"Participants in this group will receive ultrasound-guided deep pharmacopuncture in addition to integrative Korean medicine treatment (acupuncture, herbal medicine, and Chuna therapy). The pharmacopuncture involves injecting 4 cc of herbal extract into deep lumbar tissues, targeting the posterior facet joint of the most symptomatic segment.~Using a real-time ultrasound-guided in-plane technique, the needle path and tip are visualized to ensure accurate and safe delivery. Treatment is administered once daily for up to 3 days (hospital Days 2-4).~This intervention differs from conventional methods by using ultrasound to guide precise, deep-tissue injection, enhancing both safety and treatment accuracy."
214885560|NCT07126951|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
214885561|NCT07132138|OTHER|Scooter Board Activities|"Scooter board bear walk. Scooter board crab walk. Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~Cross sitting on scooter board, pulls along the rope using his/her hands Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~8- Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~Supine flexion on scooter board, Clip clothespins to a rope hanging above."
214885562|NCT07132138|OTHER|Core Stability Exercises|Bridges Bird-dog Sit-ups on therapy ball Static and dynamic trunk holds
214292858|NCT00293254|DRUG|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
214292859|NCT02335489|DEVICE|Implantation with the commercially available Axium neurostimulator|
214292860|NCT02259582|DRUG|Pemetrexed|
214292861|NCT02259582|DRUG|Carboplatin|
214477230|NCT05852808|RADIATION|Low-dose radiation therapy|The treatment consists of an informing consultation, a planning CT scan and a series of 10 radiation sessions delivered over 3.5 weeks ( = 12 visits in total). The clinical target volume (CTV) will be defined based on the MRI and SPECT/CT. Planning target volume (PTV) will be expanded in all directions by 0.5 cm beyond the CTV. Patients will be treated in a supine position with minimum 6 MV photons and a 3D-technique or volumetric modulated arc therapy (VMAT)-technique. A kilovolt (kV) and in exception a cone-beam CT will be performed before each treatment for positioning accuracy. A dose of 0.5 Gy x 10 fractions (3 times per week) will be delivered over 3.5 weeks. Each radiotherapy treatment session takes approximately 15 minutes. If a second radiotherapy series will be done (NRS 4-10 at visit 4), the radiotherapy dose und fractionation will be the same as the first series.
214477231|NCT04325815|DEVICE|CADDIE- Computer Aided (AI) Device used in Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
214477232|NCT06862440|DEVICE|Kegg|Fertility status monitor
214477233|NCT06861036|PROCEDURE|Biospecimen|"* 1 or 2 tumoral specimen (depending on the size of the tumor)~* 1 specimen of the healthy oral mucosa~* 1 leucoplakia specimen if applicable.~The biospecimens will be collected at the time of the surgery organised for the standard routine medical care."
214477234|NCT06861036|PROCEDURE|Blood sampling|Blood sampling (6 mL), taken from a routine biological exam.
214477235|NCT06860919|OTHER|Follow-up of the patients during 3 years|"Evaluation of PTSD prevalence, anxiety-depressive state, quality of life, look for a correlation between their clinical history and PTSD.~Analysis of the nutritional, gastrointestinal and respiratory status."
215047396|NCT04904172|DEVICE|Masimo O3 Regional Oximetry|wo electrodes will be attached to the forehead area and connected to the Near Infrared Spectroscopy device after the consent of the patients who apply to Ege University Hospital Emergency Service with acute ischemic stroke and who are planned to have intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments, and / or their caregivers.
215047397|NCT02764996|DEVICE|Acupuncture|
215047398|NCT00761488|DEVICE|AcrySof® Toric IOL|Implanted into the study eye
214292862|NCT02259582|DRUG|demcizumab|
214292863|NCT04850131|PROCEDURE|Desarda repair|Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
214292864|NCT00243789|DRUG|Pentoxifylline|"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."
214292865|NCT00759863|BEHAVIORAL|Lifezig|Personalized Reminiscence Video
214292866|NCT02653391|DRUG|Part A Elamipretide 1.0% Ophthalmic Solution|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
214292867|NCT02653391|DRUG|Part B Elamipretide 3.0% Ophthalmic Solution|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
214292868|NCT02653391|DRUG|Part A Placebo|Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
214292869|NCT02653391|DRUG|Part B Placebo|Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
214292870|NCT04213365|OTHER|Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
214477236|NCT06861023|OTHER|Patients who have undergone extensive nail resection with reconstruction|The investigators studied a population of 10 patients who underwent nail and nail matrix excision surgery as part of the treatment of subungual melanoma, as well as the reconstruction, the investigators opted for. The specific intervention of this study is based on late postoperative questions (after 3 months)
214885563|NCT07132762|DEVICE|Radial Extracorporeal Shock Wave Therapy|"A total of 6 sessions of ESWT, applied twice a week. Each ESWT session will last approximately 15 minutes. ESWT will be administered with the patient in the prone position, using an energy density of 0.15 mJ/mm², at 4 Hz frequency, and 1,500 shock waves per session.~The ESWT application will be performed on the right and left paravertebral muscles between the L3 and S1 segments."
215047399|NCT00800735|DRUG|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
214477237|NCT04474574|DEVICE|Simultaneous recording of nocturnal SpO2|The intervention will consist in performing a simultaneous recording of nocturnal SpO2 and pulse rate for at least 4 hours with 3 different devices.
214477238|NCT06859892|DRUG|Dexmedetomidine-esketamine combination|Dexmedetomidine 0.4 μg/kg and esketamine 0.2 mg/kg is infused over 10 minutes before anesthesia induction. Dexmedetomidine 0.20 μg/kg/h and esketamine 0.10 mg/kg/h is then infused until 60 minutes before the expected end of surgery. Patient-controlled intravenous analgesia is established with 100 μg dexmedetomidine, 50 mg esketamine, and 100 μg sufentanil, diluted to 100 mL with normal saline, and programmed to deliver 2-mL boluses with a lock-out interval of 8 minutes and background infusion rate at 1 mL/h for up to 72 hours after surgery.
214477239|NCT06859892|DRUG|Placebo|Placebo (normal saline) is administered in the same rate and volume as that in the dexmedetomidine-esketamine group. Patient-controlled intravenous analgesia is established with 100 μg sufentanil, diluted to 100 mL with normal saline, and programmed to deliver 2-mL boluses with a lock-out interval of 8 minutes and background infusion rate at 1 mL/h for up to 72 hours after surgery.
214667815|NCT01594099|DRUG|Cisplatin|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy."
214667816|NCT01594099|DRUG|liposome paclitaxel|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy."
214667817|NCT00969722|BIOLOGICAL|MAb-3F8|
215047400|NCT00800735|DRUG|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing \< 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
215047401|NCT02805790|DRUG|Elamipretide|4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously
214667818|NCT00969722|BIOLOGICAL|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
214885564|NCT07132762|OTHER|Conventional rehabilitation|A total of 15 sessions of conventional physical therapy will be administered, five times per week. Each session will include 20 minutes of hot pack application, 20 minutes of conventional transcutaneous electrical nerve stimulation (TENS), 5 minutes of ultrasound therapy at 1.5 W/cm², and core stabilization exercises performed under the supervision of a physiotherapist. The treatment will be applied over a total period of 3 weeks.
215047402|NCT02805790|DRUG|Placebo|4 weeks of treatment with placebo administered once daily subcutaneously
215047403|NCT01196195|DRUG|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
215047404|NCT01196195|DRUG|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
215047405|NCT04161209|DRUG|Citalopram|Single dose administration of citalopram (20mg)
215047406|NCT04161209|OTHER|Placebo|Lactose placebo tablet
215047407|NCT01385150|GENETIC|mutation analysis|
214667819|NCT00969722|BIOLOGICAL|13-cis-Retinoic Acid|
214667820|NCT00131443|DRUG|Topiramate|
214667821|NCT04230538|DEVICE|DJO Walker|
214667822|NCT04230538|DEVICE|Traditional plaster cast|
215047408|NCT01385150|GENETIC|protein analysis|
215047409|NCT01385150|OTHER|laboratory biomarker analysis|
215047410|NCT01385150|OTHER|liquid chromatography|
215047411|NCT01385150|OTHER|mass spectrometry|
215047412|NCT04275076|PROCEDURE|Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia|comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate
215047413|NCT00051714|BEHAVIORAL|Family-Based Preventive Intervention|
215047414|NCT04460183|DRUG|RESP301, a Nitric Oxide generating solution|Product application requires inhalation using a standard handheld nebulizer.
215047415|NCT04460183|OTHER|Standard of Care|Participants will receive institutional SOC for the treatment of COVID-19.
215047416|NCT03387215|DRUG|ITI-214|Oral
215047417|NCT03387215|OTHER|Placebo|Oral
215047418|NCT00702832|BEHAVIORAL|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
215047419|NCT00702832|OTHER|standard treatment|treatment as usual
215047420|NCT03307538|RADIATION|Stereotactic body radiation therapy|15 fractions of 3-4,5 Gy (risk-adapted)
215047421|NCT03986125|BEHAVIORAL|Emotional Awareness & Expression Therapy|emotion-focused
215047422|NCT03986125|BEHAVIORAL|Mindfulness Meditation Training|meditation training and practice
214885565|NCT07140419|DIAGNOSTIC_TEST|Coronary computed tomographic angiography with CT - derived fractional flow reserve|A non-invasive coronary computed tomography angiography (CCTA) protocol that visualizes coronary anatomy to evaluate the presence, location, and severity of atherosclerotic stenosis, coupled with CT-derived fractional flow reserve (CT-FFR) analysis-a computational fluid dynamics method applied to CCTA datasets-to assess the hemodynamic significance of identified stenoses and identify lesions likely to induce myocardial ischemia.
214885566|NCT06941376|DRUG|Methotrexate (MTX)|Weekly methotrexate dose of 20 mg (oral or subcutaneous).
214885567|NCT06941376|DRUG|Azathioprine (AZA)|Azathioprine dose will be 2-3 mg/kg body weight per day.
214885568|NCT06941376|BIOLOGICAL|Adalimumab|Adalimumab dose will be 40 mg subcutaneously every 1-2 weeks
214885569|NCT06941376|BIOLOGICAL|Infliximab|Infliximab dose will be 5mg/kg at week 0 and week 2, and then every 4-8 weeks.
214885570|NCT06941376|BIOLOGICAL|Tocilizumab|Tocilizumab dose will be 162 mg subcutaneous injection every week or 4-8 mg/kg every 4 weeks
214885571|NCT06943872|DRUG|Sonrotoclax|Administered orally
214885572|NCT06943872|DRUG|Obinutuzumab|Administered intravenously
215047423|NCT00369837|DRUG|clevidipine|Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
215047424|NCT01884363|OTHER|Once ounce per day of walnuts|
215047425|NCT00506038|PROCEDURE|fine needle technique|
215047426|NCT01716364|BIOLOGICAL|Anti-LeY- scFv-CD28-ζ vector,.|
215047427|NCT01267474|OTHER|Nutritional education|"A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts."
215047428|NCT01267474|OTHER|Control|The control group received only three one-hour general sessions on health issues.
214885573|NCT06943872|DRUG|Rituximab|Administered intravenously
214885574|NCT06943872|DRUG|Venetoclax|Administered Orally
214885575|NCT05192889|DRUG|Venetoclax|Given oral (PO).
214885576|NCT05192889|DRUG|Navitoclax|Given oral (PO).
214885577|NCT05192889|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
214885578|NCT05192889|DRUG|Vincristine|Given intravenously (IV).
214885579|NCT05192889|DRUG|Calaspargase Pegol|Given intravenously (IV).
214885580|NCT05192889|DRUG|Dasatinib|Given oral (PO).
215047429|NCT02734329|PROCEDURE|conventional laparoscopic partial nephrectomy|renal artery will be clamped during surgery.
215047430|NCT02734329|PROCEDURE|zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)|
215047431|NCT00856323|DRUG|Truvada|At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
215047432|NCT00856323|BEHAVIORAL|CM|Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
215047433|NCT04941105|DRUG|Evolocumab|A single subcutaneous administration of 140 mg evolocumab
215047434|NCT04941105|DRUG|Saline solution|A single subcutaneous injection of 1ml of 0,9% saline solution
214292871|NCT01973647|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Six weekly sessions of cognitive behavioral therapy for insomnia
214292872|NCT01973647|BEHAVIORAL|COPD Education|Six weekly sessions of COPD education
214292873|NCT01973647|BEHAVIORAL|Attention Control|Six weekly sessions of non-sleep, non-COPD health education
214885581|NCT05192889|DRUG|Cytarabine|Given intravenously (IV) or Intrathecal (IT).
214885582|NCT05192889|BIOLOGICAL|Blinatumomab|Given intravenously (IV).
214885583|NCT05192889|DRUG|Methotrexate|Given intravenously (IV), oral (PO), or Intrathecal (IT).
214885584|NCT05192889|DRUG|Mercaptopurine|Given oral (PO).
214885585|NCT05192889|DRUG|Cyclophosphamide|Given intravenously (IV).
214885586|NCT05192889|DRUG|Etoposide|Given intravenously (IV).
214885587|NCT05192889|DRUG|Leucovorin|Given oral (PO) or intravenously (IV).
214885588|NCT05192889|DRUG|Intrathecal Triples|Given Intrathecal (IT).
214885589|NCT05192889|DRUG|Pegaspargase|May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
214885590|NCT05192889|DRUG|Erwinia asparaginase|To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
214885591|NCT05192889|RADIATION|Radiation|See detailed description section.
214885592|NCT07146191|DRUG|2-[14C]-RE104 for Injection|Single, subcutaneous dose of 2-\[14C\]-RE104 for Injection
214885593|NCT06767358|DRUG|ketamine hydrochloride|Continuous adjunctive ketamine infusion at a fixed dose of 0.50mg/kg/hour
214292874|NCT05111158|DIAGNOSTIC_TEST|mfERG|mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)
214292875|NCT02845245|OTHER|3D printed plastic model prototype|
214477240|NCT06857617|BIOLOGICAL|(Part C) MET097|"Participants will receive 13 once-weekly subcutaneous injections of MET097 as follows:~* 12 once-weekly doses of 0.6mg followed by a 13th dose of 1.2mg~* 12 once-weekly doses of 0.6mg followed by a 13th dose of 2.4 mg~* 12 once-weekly doses of 0.8 mg followed by a 13th dose of 1.6 mg~* 12 once-weekly doses of 0.8 mg followed by a 13th dose of 3.2 mg~* 12 once-weekly doses of 1.0 mg followed by a 13th dose of 2.0 mg~* 12 once-weekly doses of 1.0 mg followed by a 13th dose of 4.0 mg~* 12 once-weekly doses of 1.2 mg followed by a 13th dose of 2.4 mg~* 12 once-weekly doses of 1.2 mg followed by a 13th dose of 4.8 mg~* Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 2.4mg~* Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 4.8mg"
214477241|NCT06857617|BIOLOGICAL|(Part C) Placebo|Participants will receive 13 once-weekly subcutaneous injections of matching placebo
214477242|NCT06860659|DRUG|0.28% Sodium Hyaluronate , preservative free eye drops|0.28% Sodium Hyaluronate , preservative free eye drops
214477243|NCT06860659|DRUG|0.18% Sodium Hyaluronate , preservative free eye drops|0.18% Sodium Hyaluronate , preservative free eye drops
214477244|NCT06861907|DEVICE|Virtual Reality|Virtual Reality Modules created to simulate HAZWOPER PowerPoint scenarios
214477245|NCT06862856|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|This is a PET scan with flotufolastat F 18 injection.
214477246|NCT06860438|DRUG|Vasoconstrictor Agents|vasopressor agents will be started in patients with sepsis who will not improved using the resuscitation fluids
214477247|NCT06861296|BEHAVIORAL|Intervention Group|(Flipped Learning Model Based Training Group)-Arm Description: This group will receive training on postpartum hemorrhage management using the reverse learning
214477248|NCT06666296|BEHAVIORAL|Digital collection of recipes|The digital recipe collection is created for private use. This collection contains recipes for every meal of the day to ensure a Planetary Health Diet throughout the day. This includes digital weekly plans with corresponding dishes, including shopping lists, to simplify implementation in everyday life. This enables participants to make quick meal choices and simplify their shopping. Employees are encouraged to use this digital recipe collection to prepare their meals over a defined period of time. In addition, the kitchen management of the university hospital will be asked to assist with the creation of the recipes. The project benefits from the experience of the kitchen staff. Popular recipes can be used across projects.
214477249|NCT06666296|BEHAVIORAL|E-Mail-Newsletter|"The e-mail newsletter contains information on the Planetary Health Diet (background, urgency, goals, etc.). Regular contact by e-mail enables a fast, uncomplicated and personal exchange with the participants, uncomplicated and personal exchange with the participants. The e-mail support encourages participants to actively engage with the topic. The newsletter is supplemented by instructional kitchen videos (one person cooks a recipe from the recipe collection), checklists (e.g. How sustainable am I already acting?), tasks (e.g. three possible measures for a more sustainable diet) or food information (e.g. seasonal plan for fruit and vegetables). This provides participants with important information at regular intervals and ensures compliance."
214885594|NCT06767358|OTHER|Normal saline placebo|Normal saline placebo infusion
214292876|NCT02845245|OTHER|3D CT scan|
214292877|NCT02845245|OTHER|Plain film radiographs|
214667823|NCT03295422|PROCEDURE|RF ablation PVI alone|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
214885595|NCT07146984|BEHAVIORAL|Behavioral (Educational Training Program)|A structured training program for emergency medicine residents based on the Plan-Do-Check-Act (PDCA) cycle. The intervention includes didactic teaching, simulation-based airway management practice, supervised clinical intubation, iterative performance assessment, and feedback-driven improvement.
214885596|NCT06990867|DRUG|JX10|JX10 is a thrombolytic agent.
214885597|NCT06990867|DRUG|Placebo|Placebo is being used as the comparator.
214292878|NCT05070117|BEHAVIORAL|Exercise training|Study participants perform resistance/strength exercises 2-3 times per week for one hour, for one year.
214885598|NCT07142642|DRUG|Teprotumumab|Administered via IV infusion.
214885599|NCT07142642|DRUG|Placebo|Administered via IV infusion.
214885600|NCT07152730|DRUG|Lutrepulse|Lutrepulse administered via the OmniPod delivery pump
214885601|NCT07153783|DIAGNOSTIC_TEST|AI-human collaboration for CE-CTs diagnosis|The system automatically processes all eligible same-day scans and generates results for review the following day. To maintain efficient AI-human collaboration while preserving the standard clinical workflow, the conventional radiological interpretation process remains unchanged (first-line radiologists provide initial reports followed by senior radiologists' review). A dedicated senior radiologist then evaluates any discordances between AI findings and primary radiological report. For complex cases, the review process escalates to a consensus review panel (i.e., pre-designated senior radiologists, Multidisciplinary Team (MDT)). The MDT can recommend clinical interventions including follow-up (e.g., additional imaging examinations, active surveillance), surgical procedures, or adjustments to adjuvant therapy (initiation or modification of treatment regimens). All discordant cases and their outcomes are systematically documented for longitudinal tracking and follow-up analysis.
214292879|NCT02040454|DRUG|Paclitaxel|
214292880|NCT02040454|PROCEDURE|Standard Therapy|
214292881|NCT02680743|OTHER|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
214292882|NCT04791566|DRUG|Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
214292883|NCT04791566|DRUG|Physiologic saline|100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
214292884|NCT02014896|OTHER|Biomarker blood draw|Comparison of gene expression profiles using RNA isolated from whole blood.
214885602|NCT07156461|DEVICE|Cochlear™ Osia® System (Osia® 2)|Consists of Osia 2 Sound Processor, Osia 2 Sound Processor Magnets, and Osia Fitting Software 2.
214292885|NCT02184182|PROCEDURE|VLS ablation/portal ligation/hepatectomy|"Step1:~* exploratory laparoscopy to exclude extrahepatic disease~* right portal vein ligation if surgically feasible~* RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~* radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight \> 0.5~\- laparoscopic/laparotomic right trisectionectomy"
214885603|NCT07156461|DEVICE|Cochlear™ Osia® System (Osia® 3)|Consists of Osia 3 Sound Processor, Osia 3 Sound Processor Magnets, Osia 3 Charger, and Osia Fitting Software 3.
214885604|NCT07154446|DRUG|Parestat(generic parecoxib)|This arm will receive IV Parestat 40mg during surgery
214885605|NCT07154446|DRUG|Dynastat (original Parecoxib)|This arm will receive IV Dynastat 40mg during surgery
214885606|NCT07154706|DRUG|Taletrectinib|Intervention Label: Taletrectinib Intervention Name: Taletrectinib Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level (s): 400 mg QD Route of Administration: Oral Use: Experimental IMP and NIMP/AxMP : IMP Former Name(s) or Alias(es): AB-106.
214885607|NCT07154706|DRUG|Placebo|Intervention Label: Placebo Intervention Name: Placebo Type: Drug Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level(s): 400 mg QD Route of Administration: Oral Use: Placebo Comparator IMP and NIMP/AxMP: IMP Former Name(s) or Alias(es): Placebo
214885608|NCT04776694|DRUG|Dupilumab|
214885609|NCT07158047|OTHER|Heat therapy|30 sessions of far infrared sauna bathing (45-60C) for up to 45 min
214885610|NCT03839758|PROCEDURE|TSA standard|Glenoid preparation will be done with 2D CT-Scan
214885611|NCT03839758|PROCEDURE|RTSA standard|Glenoid preparation will be done with 2D CT-Scan
214885612|NCT03839758|PROCEDURE|TSA Blueprint|Glenoid preparation will be done with Blueprint software
215047435|NCT01087593|DRUG|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
215047436|NCT05118113|PROCEDURE|Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers|Mobilisation of hematopoietic stem cells by injection of filgrastim (authorized auxiliary medicinal product) for 4 consecutive days and leukapheresis on Day 5
215047437|NCT04143230|OTHER|Screening for PC by means of two different screening tools|Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
214292886|NCT00953446|PROCEDURE|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
214292887|NCT05618964|OTHER|Deep Neck Flexors & Extensors exercises|"Deep neck flexor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck flexor muscle in supine Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck extensors in quadruped position Segmented extension movement with the head bent down onto their chest in a horizontal direction,"
214292888|NCT05620550|PROCEDURE|ozonated oil|Post operative scar treatment with ozonated oil
214885613|NCT03839758|PROCEDURE|RTSA Blueprint|Glenoid preparation will be done with 2D CT-Scan
214885614|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment 0.05%
214885615|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment 0.01%
214885616|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment 0.03%
214885617|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment placebo
214885618|NCT07162857|DEVICE|non-invasive cardiac output monitoring|Monitoring commenced immediately after enrollment, with baseline parameters recorded after signal stabilization (≤5 minutes), including cardiac output (CO), stroke volume (SV), stroke volume variation (SVV), and systemic vascular resistance (SVR). The system automatically updated these parameters every 30 seconds and displayed them in real-time on the monitor screen. Fluid resuscitation was dynamically adjusted according to these continuous measurements until achieving the predefined therapeutic targets.
214885619|NCT07162857|DEVICE|Ultrasonic technology|In the critical care ultrasound group, patients underwent immediate bedside This protocol ensured real-time, comprehensive evaluation of both cardiac function and fluid status to guide resuscitation.Ultrasound reassessment was performed every 1-2 hours to dynamically adjust both the volume and rate of fluid administration until predefined resuscitation targets were achieved.
214885620|NCT07163637|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri DSM 17648|One capsule containing L. reuteri DSM 17648 should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
214885621|NCT07163637|DIETARY_SUPPLEMENT|Placebo|One capsule of placebo should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
215047438|NCT03619993|DEVICE|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
215047439|NCT03619993|DEVICE|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
215047440|NCT00564109|PROCEDURE|retrospective Observation|retrospective Observation
215047441|NCT00134615|BEHAVIORAL|RQP patient health education module|
214885622|NCT07168018|BIOLOGICAL|Coadministration of ChAdOx2 RabG and licensed inactivated rabies vaccine (IRV)|A single visit of coadministration of 5×10\^10 vp ChAdOx2 RabG (2 site IM) and licensed IRV (2 site IM).
214885623|NCT07168018|BIOLOGICAL|Inactivated Rabies Vaccine (IRV)|A World Health Organization (WHO) prequalified IRV at two anatomical sites (2 site ID) on days 0, 3 and 7.
214885624|NCT07161258|DRUG|Fenebrutinib|Fenebrutinib will be administered orally.
214885625|NCT07170085|OTHER|positioning|The children will be positioned in the supine and prone position
214885626|NCT07166549|DRUG|Experimental Intervention|"The study intervention includes:~* Lymphapheresis~* Lymphodepleting chemotherapy~* CAR-T infusion~Lymphocytes will be collected from the patients by lymphapheresis to produce a personalized IMP, bispecific anti-CD19, anti-CD20 CAR T cells, which will be manufactured at the GMP facility of the University Hospital Basel.~Patients receive a preparative lymphodepleting chemotherapy of intravenous cyclophosphamide and fludarabine from day -5 until day -3 (or Bendamustine on day -3 and day -2), before anti-CD19/20 CAR T cells are infused (day 0 = day of infusion).~Participants will undergo lymphapheresis 2-8 weeks prior to CAR T cell infusion."
214885627|NCT07167641|OTHER|Cognitive Behavioral Therapy for Caregivers|"The intervention includes four Foundational Sessions delivered to all participants: Orientation and Engagement, Narrative Exploration, and Goal Setting Sessions at the beginning of treatment, followed by a structured Closing Session at the end of treatment. Beyond the four foundational sessions, caregiver clients complete an additional module based on their top area of need. These modules are called Core Sessions and are selected through a collaborative process that draws on caregiver preferences, clinical judgment, and assessment results to ensure treatment is tailored to each caregiver's unique experiences, interests, and goals."
214885628|NCT07169188|DRUG|Test Fluoride Toothpaste|Toothpaste containing 0.454% SnF2, 0.3% zinc chloride (ZnCl2) and 1% alumina.
214885629|NCT07169188|DRUG|Colgate Cavity Protection Toothpaste|Regular fluoride toothpaste containing 0.76% sodium monofluorophosphate.
215047442|NCT04838184|DEVICE|Dental Implants (Straumann Roxolid® / SLActive®)|"In this study the 4 mm implants will be inserted in the area surrounding 36/46. The implant diameters will be defined based on the patient's situation.~In the interforaminal region, two implants of conventional length with a minimum of 10 mm will be inserted. The implant diameter and the length will be defined based on the patient's situation."
214885630|NCT07177937|DRUG|DXC014|Dose Escalation DXC014, Cohort Expansion DXC014
215047443|NCT01230320|PROCEDURE|Denture fabrication technique|"Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~1. the reproduction of denture-bearing tissues by means of impression techniques and casts;~2. the registration of maxillo-mandibular relations;~3. try-in of artificial teeth and carved denture bases."
215047444|NCT06332976|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
214292889|NCT05620550|PROCEDURE|non ozonated oil|Post operative scar treatment with non ozonated oil
214292890|NCT03857191|DIETARY_SUPPLEMENT|Nutritional psychocomportemental rehabilitation|Nutritional psychocomportemental rehabilitation
214292891|NCT00108667|DRUG|IV Levodopa|
214885631|NCT07178535|DEVICE|Feasibility of Two Types of Real-Time Visual Feedback in an Augmented Reality|"Participants will walk in a corridor (45 m), equipped with Xsens inertial sensors recording their kinematics and an HTC Vive Elite-XR AR headset superimposing virtual feedback onto the real world. Three real-time feedback conditions (3 trials/condition) will be evaluated randomly: (1) an avatar reflecting the participant's movements; (2) visual bars indicating step lengths; (3) control condition without feedback. Participants take part in an evaluation/intervention session."
214885632|NCT07179185|DIAGNOSTIC_TEST|AI-Assisted ECG Interpretation (AI-ECG)|Neural network-based AI software that analyzes ECG tracings and provides a classification as normal suggestion to the interpreting specialist.
214885633|NCT07179185|DIAGNOSTIC_TEST|Specialist ECG Interpretation Without AI|Manual interpretation of ECGs by specialists without AI support, following standard diagnostic procedures
214292892|NCT00108667|DRUG|Talampanel|
214292893|NCT00834860|DRUG|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
214292894|NCT00503308|PROCEDURE|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
214292895|NCT03645980|DRUG|DKN-01 300 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
214292896|NCT03645980|DRUG|DKN-01 600 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
214292897|NCT03645980|DRUG|Sorafenib|For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
215047445|NCT00981721|DRUG|cediranib (RECENTIN TM, AZD2171)|20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
215047446|NCT02972710|OTHER|Supine thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
215047447|NCT02972710|OTHER|Seated thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
215047448|NCT05624983|DIAGNOSTIC_TEST|acoustic otoemisions|TOAE and DPOAE
214885634|NCT07179302|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|evaluate the role of the left atrial coupling index (LACI) and left ventricular speckle tracking echocardiography (LVSTE) in enhancing outcome prediction in patients undergoing TAVI.
214885635|NCT07173543|OTHER|Intermittent Hypoxia 1 (IH1)|Intermittent Hypoxia 1 (IH1): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 8 weeks
214885636|NCT07173543|OTHER|Intermittent Hypoxia 2 (IH2)|Intermittent Hypoxia 1 (IH2): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 4 weeks
214885637|NCT07173543|OTHER|SHAM - normoxia|Participants will receive normoxia (no hypoxia) over 50 minutes.
214885638|NCT07179874|PROCEDURE|Remote Ischemic Preconditioning|"This intervention involves a non-invasive, mechanical stimulus applied to an upper limb with the goal of activating systemic protective pathways against contrast-induced nephropathy in diabetic patients. Unlike pharmacologic or device-based interventions, RIPC:~* Does not involve any drugs, biologics, or implants~* Is performed using a standard blood pressure cuff, inflated to 50 mmHg above systolic pressure, specifically designed to induce repetitive transient limb ischemia~* Consists of four alternating cycles of 5 minutes inflation followed by 5 minutes reperfusion~* Is applied 45 minutes before coronary catheterization, timed to optimize systemic renal protection prior to exposure to contrast media~* Targets activation of the heme oxygenase-1 (HO-1) enzymatic pathway, linking limb ischemia with antioxidant renal defense mechanisms Unlike interventions that rely solely on hydration or pharmacological antioxidants, this approach seeks to prime endogenous protective systems through is"
214885639|NCT07181122|DRUG|Androgen Receptor Pathway Inhibitors (ARPIs)|Men with metastatic hormone-sensitive prostate cancer will receive androgen receptor pathway inhibitors (abiraterone acetate, apalutamide, enzalutamide, or darolutamide) in addition to standard androgen deprivation therapy. The choice of ARPI will be determined by routine clinical practice. The study does not assign treatments; it observes patient outcomes under real-world conditions.
214885640|NCT02690441|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
214885641|NCT02690441|BEHAVIORAL|Physical Exercise|Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
214885642|NCT02690441|BEHAVIORAL|Placebo control|One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
214885643|NCT07176299|PROCEDURE|Unilateral laparoscopic TAP block (0.25% bupivacaine)|Injection of 20 mL 0.25% bupivacaine into the transversus abdominis plane under direct laparoscopic vision.
214885644|NCT07176299|PROCEDURE|Local anesthetic infiltration (0.25% bupivacaine)|Injection of 20 mL 0.25% bupivacaine distributed across trocar insertion sites under laparoscopic guidance.
214885645|NCT07176299|PROCEDURE|Combined TAP block and local anesthetic infiltration (0.25% bupivacaine)|10 mL of 0.25% bupivacaine given as a TAP block and 10 mL administered as local infiltration at trocar sites.
215047449|NCT05624983|DIAGNOSTIC_TEST|Otoscopy|presence of earwax checked by video otoscop
214292898|NCT04900194|BEHAVIORAL|mindfulness-based sexual counseling|Mindfulness-based sexual counseling was planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session lasted 30-40 minutes on average. The sessions were carried out individually by determining the appropriate days of pregnant women in the pregnancy class.In the study, the meditation techniques of the Mindfulness Therapy constituted the backbone/framework of the psychoeducation program. Body and breath, body scanning, mindfulness movement and three-minute respiration techniques were practiced during the psychoeducation program, practically every session in accordance with the researchers' directives.
214292899|NCT02031926|DEVICE|Positive expiratory pressure|
214292900|NCT00726076|BEHAVIORAL|WebEase|"Computer-based epilepsy self-management program~The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment"
214292901|NCT00726076|BEHAVIORAL|WebEase|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
214292902|NCT01842256|DRUG|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"* 3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
214292903|NCT01842256|DRUG|atorvastatin 40mg|"* 1 Tablet (atorvastatin 40mg),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
214292904|NCT02579850|DRUG|CHF 5993 + Ultibro matched placebo|Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
214292905|NCT02579850|DRUG|Ultibro + CHF 5993 matched placebo|Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
214292906|NCT02579850|PROCEDURE|Central spirometry|Central spirometry to assess forced expiratory volume at one second and forced vital capacity
214292907|NCT02579850|OTHER|COPD assessment test|COPD assessment test (CAT) at visit 1
214292908|NCT02579850|PROCEDURE|Local laboratory Assessments|ECG + Standard Haematology and Biochemistry
214885646|NCT07177131|BEHAVIORAL|Relative Dehydration Protocol|Participants will abstain from water intake for 12 hours prior to the study visit. Food is allowed, but fluid intake is limited to a maximum of 250 ml until 20:00 h on the previous evening. Eye measurements will be performed in the morning (8-10 h).
214885647|NCT07177131|BEHAVIORAL|Hyperhydration Protocol|Participants will consume 2 liters of water within 4 hours prior to the study visit. Eye measurements will be performed in the morning (8-10 h).
215047450|NCT05624983|DIAGNOSTIC_TEST|Audiometry|Hearing Threshold will be measured with the AD528 interacoustics
215047451|NCT05624983|DIAGNOSTIC_TEST|Tympanometry|Tympanic mobility will be measyred with the Titan interacoustics
215047452|NCT00002139|DRUG|Azithromycin|
215047453|NCT00263003|DRUG|Irbesartan/hydrochlorothiazide|
215047454|NCT00263003|DRUG|Irbesartan|
215047455|NCT02605356|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|
215047456|NCT02605356|DRUG|Placebo|
215047457|NCT02605356|DRUG|Bortezomib|
215047458|NCT02605356|DRUG|Dexamethasone|
215047459|NCT01847092|DRUG|AZD1722|
215047460|NCT01847092|DRUG|Placebo|Placebo for AZD1722
215047461|NCT03540420|DRUG|Atezolizumab|atezolizumab 1200 mg intravenous every 3 weeks in 12 months
214885648|NCT07160205|BIOLOGICAL|ULSC (1.5 x 10^8 cells/dose)|Allogeneic umbilical-cord lining stem cells (ULSC) are cryopreserved and supplied in vials to be thawed and prepared for infusion at point of use. Each dose of 1.5 x 10\^8 ULSC will be added into 250 sterile saline IV bag for infusion (total volume of 260 mL volume).
214885649|NCT07160205|BIOLOGICAL|Placebo (no cells)|The Placebo will be 250 ml sterile saline with vehicle (total volume of 260 mL) IV bag for infusion.
214292909|NCT02579850|OTHER|Saint George's Respiratory Questionnaire|Saint George's Respiratory Questionnaire
214292910|NCT02579850|OTHER|EXACT-pro questionnaire|daily from randomization (Visit 2) to end of study (Visit 7)
214292911|NCT02671591|BEHAVIORAL|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
214292912|NCT02671591|BEHAVIORAL|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
214292913|NCT03877289|DRUG|Oxybutynin|Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
214292914|NCT03877289|OTHER|"Orasweet Liquid Placebo"|A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
214885650|NCT07177573|OTHER|Virtual Reality|The demographic information of the participants will be collected through face-to-face interviews. Pain and comfort levels will be assessed using the Visual Analog Scale (VAS) prior to the intervention. Additionally, anxiety levels will be measured with the Spielberger State-Trait Anxiety Inventory, and vital signs will be recorded. Patients included in the study will be informed about the use of virtual reality (VR) goggles and introduced to the videos that will be viewed. During the Continuous Passive Motion (CPM) application, patients will be positioned in a semi-Fowler's position with a pillow placed under the head for support. Through virtual reality, patients will watch the video Forest Walk along the Middle Fork Snoqualmie River Trail with Relaxing Sounds and the accompanying sounds will be delivered through headphones integrated into the goggles.
214885651|NCT07177846|BEHAVIORAL|LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Program|LiveWell: Adapted DBT Skills Training for Patients with Metastatic Lung Cancer
214885652|NCT07178353|OTHER|Bedrest|5 days of strict bedrest. Participants are allowed to sit up in bed, but will perform any bathing or bathroom activities in a wheelchair.
215047462|NCT03030898|DIAGNOSTIC_TEST|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
215047463|NCT00825994|DRUG|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), PO \[by mouth\], qd \[every day\]
215047464|NCT03436901|DIAGNOSTIC_TEST|MRI with DWI vs CT|MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
215047465|NCT03194399|BEHAVIORAL|Personalized health care service|Physical activity coaching, other functional outcome observation
215047466|NCT02982811|DEVICE|i-ACT|3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
215047467|NCT03199794|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
215047468|NCT02409433|DRUG|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
215047469|NCT02409433|DRUG|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
215047470|NCT05545410|OTHER|MRI calibration|Non-injected thoracic aorta MRI calibration
215047471|NCT02818465|OTHER|Vascular calcifications by Xray|
215047472|NCT02818465|OTHER|Vascular calcifications by tomodentimetry|
215047473|NCT02818465|BIOLOGICAL|Blood sample withdrawn|
215047474|NCT06078475|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
215047475|NCT01466283|GENETIC|DNA methylation analysis|
215047476|NCT01466283|GENETIC|fluorescence in situ hybridization|
215047477|NCT01466283|GENETIC|gene expression analysis|
215047478|NCT01466283|GENETIC|reverse transcriptase-polymerase chain reaction|
215047479|NCT01466283|OTHER|laboratory biomarker analysis|
215047480|NCT00535418|DRUG|Letrozole|
215047481|NCT05733637|OTHER|No intervention|There will be no intervention apply to study participants.
215047482|NCT00152204|DRUG|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
215047483|NCT00152204|DRUG|IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
214885653|NCT07185581|DIAGNOSTIC_TEST|Impulse Oscillometry|Impulse Oscillometry (IOS) is a simple, non-invasive, effort-independent method that uses sound waves to detect airway changes quickly. It only requires the patient to breathe normally to assess lung function by measuring both resistance and reactance of the airways. 6,7 These features of IOS suggest it may be a useful test for assessing patient respiratory function during exacerbation periods when airway resistance, airflow limitation, and respiratory muscle weakness further impair breathing.
214885654|NCT07185529|OTHER|Data of the patients were obtained from patient observation files and hospital information system database.|Data of the patients were obtained from patient observation files and hospital information system database.
214885655|NCT07186478|DRUG|Investigational Drug|IFALMIN® is a standardized herbal preparation derived from Channa micropeltes (ikan toman), containing natural albumin. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.
214885656|NCT07186478|DRUG|Placebo|Placebo capsule containing inert ingredients (such as starch/lactose), identical in appearance, size, and color to IFALMIN® capsule. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.
214885657|NCT07186231|DEVICE|Low-load resistance training with Blood flow Restriction|Each session began with a warm-up including mobility and stretching exercises for the shoulders and upper limbs. During the first session, the one-repetition maximum (1RM) for each participant and exercise was determined using a failure-to-repetition method with applied coefficients. Training was performed at 30 percent 1RM, following a standardized sequence of three shoulder-targeted exercises (shoulder abduction, external rotation, Dumbbell Overhead Press), totaling 75 repetition per session (30/15/15/15), 30-second rest intervals per sets. Movements were executed at a controlled 4-sec. tempo (2 seconds concentric, 2 seconds eccentric). BFR was applied using pneumatic cuffs, maintained during each exercise, released for 60 seconds between exercises, and reapplied for the next. Participants rated exercise difficulty, including pain, tension, and numbness, using a 0-10 numeric scale, with protocol adjustments or session cancellation if symptoms exceeded 7/10.
214292915|NCT03877289|DRUG|Antibiotics|"All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin."
214885658|NCT07186231|OTHER|High-load resistance training.|Each session began with a warm-up including mobility and stretching exercises for the shoulders and upper limbs. During the first session, the 1RM for each participant and exercise was determined using a failure-to-repetition method with applied coefficients. Training was performed at 70 percent following a standardized sequence of three shoulder-targeted exercises (shoulder abduction and external rotation, and Dumbbell Overhead Press). Four sets of 8 to 10 repetitions were completed for each exercise, with 2-minutes rest between sets and exercises. Movement speed was moderate (1-second concentric, 2-second eccentric).
214885659|NCT07185451|DEVICE|tACS|"This intervention uses the NEXALIN ADI alternating current stimulation device from Beijing Naisilin Technology Co., Ltd., to deliver targeted stimulation to the prefrontal cortex and bilateral mastoid regions. The prefrontal cortex electrode directly stimulates the cerebral cortex, while the mastoid electrodes ensure the synchronized activation of bilateral neural pathways. Stimulation is applied at a frequency of 77.5 Hz and a current intensity of 15 mA, aiming to optimize brainwave synchronization and modulate brain activity.~Participants will undergo daily sessions lasting approximately 40 minutes each, for a total of 20 sessions over 4 weeks. The non-invasive nature of the intervention, combined with its precise targeting of specific brain regions, distinguishes it from other neuromodulation therapies. The treatment aims to enhance neural synchronization, promote neuroplasticity, and provide a non-pharmacological therapeutic alternative for patients."
214885660|NCT07185451|DEVICE|tACS|In the sham stimulation group, participants will receive intervention using a sham device that is identical in appearance, operation, and stimulation protocol to the real tACS device, but does not deliver any current. Both participants and operators will be unable to distinguish between real and sham stimulation based on the device's appearance, sound, or tactile feedback. Device allocation will follow a randomized code generated in advance to ensure blinding and proper group assignment.
214885661|NCT07185204|OTHER|Early detection and management of postpartum preeclampsia bundle|Remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.
214885662|NCT07185763|BEHAVIORAL|Nano-Learning interventional program|AI-based Nano-learning videos involves designing ultra-short, single-focus lessons (not exceeding 2 minutes). Each session was delivered in form of some videos.
215047484|NCT00210847|DRUG|tramadol, acetaminophen|
215047485|NCT01776853|DIETARY_SUPPLEMENT|Glucose|
215047486|NCT01776853|DIETARY_SUPPLEMENT|Fructose|
215047487|NCT01776853|DIETARY_SUPPLEMENT|Fructans|
215047488|NCT06498115|DRUG|Norepinephrine|Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
215047489|NCT03415503|DRUG|Medox® Anthocyanin capsules|Subjects were orally administered Medox® capsules daily for 12 weeks.
215047490|NCT05087498|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 32 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (2-10×107cells/kg) within 24 hours after birth
215047491|NCT05087498|BIOLOGICAL|normal saline|preterm neonates less than 32 weeks are assigned to receive normal saline within 24 hours after birth
214292916|NCT03838133|DRUG|TLC590|TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
214292917|NCT03838133|DRUG|Naropin®|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
214292918|NCT03838133|DRUG|Normal Saline|Normal Saline (0.9% sodium chloride, 10ml)
214292919|NCT03838133|DRUG|Bupivacaine|Bupivacaine 50 mg (0.5%, 10 mL)
214292920|NCT04566081|OTHER|iTALKbetter: deterministic|A word retrieval therapy application
214292921|NCT04566081|OTHER|iTALKbetter: reactive|A word retrieval therapy application
214885663|NCT07185659|DEVICE|Elastic band|"Thera-Band® elastic band exercise protocol:~First stage (weeks 1-4): Participants performed leg resistance stretching exercises with a red elastic band. In weeks 1-2, exercises were performed 3 times per week, with 2 sets per session; in weeks 3-4, 3 times per week, with 3 sets per session.~Second stage (weeks 5-8): Participants performed leg resistance stretching exercises with a green elastic band. In weeks 5-6, exercises were performed 3 times per week, with 2 sets per session; in weeks 7-8, 3 times per week, with 3 sets per session.~Third stage (weeks 9-12): Participants performed leg resistance stretching exercises with a blue elastic band. In weeks 9-10, exercises were performed 3 times per week, with 2 sets per session; in weeks 11-12, 3 times per week, with 3 sets per session."
214885664|NCT07185659|DEVICE|Xiaomi Mi Band 4 wearable device|The Xiaomi Mi Band 4 wearable device has been certified by the National Communications Commission (Certification No. CCAG19LP0080T6). From weeks 1 to 12, participants' daily walking steps were monitored using the Xiaomi Mi Band 4 wearable device.
214885665|NCT07185659|BEHAVIORAL|Walking|Walking exercise plan
214885666|NCT07185698|DIAGNOSTIC_TEST|3D Ultrasound|Virtual Organ Computer-aided AnaLysis (VOCAL) to assess flow and velocity characteristics of the urethral blood supply
215047492|NCT04620889|DEVICE|AV Access|Arteriovenous shunting for blood access.
215047493|NCT04620889|DEVICE|PVP|Bypass or reconstruction of diseased or occluded blood vessels
215047494|NCT02047448|PROCEDURE|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
215047495|NCT04414540|DRUG|Metformin Extended Release Oral Tablet|Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily
215047496|NCT04414540|DRUG|Pembrolizumab|Pembrolizumab q 3 weeks
215047497|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
215047498|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
215047499|NCT01331681|PROCEDURE|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
214292922|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|"The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session)."
214292923|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
214292924|NCT02046356|PROCEDURE|MESS-RFA|
214292925|NCT02045706|OTHER|Community Health Worker Trainings|
214292926|NCT05087784|COMBINATION_PRODUCT|Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps|Patient-centered, technology-supported integrated survivorship- and care management
214292927|NCT00060112|BIOLOGICAL|oblimersen sodium|Given IV
214292928|NCT00060112|DRUG|gemcitabine hydrochloride|Given IV
214885667|NCT07186543|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Worksheets|The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
215047500|NCT01495325|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
215047501|NCT01495325|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
215047502|NCT05531500|DRUG|Injection|Injection of local anesthetic + steroids
215047503|NCT05531500|DEVICE|Radiofrequency|Application of radiofrequency on the diseased nerve
215047504|NCT04748692|PROCEDURE|Local exercise therapy|The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.
214885668|NCT07186543|BEHAVIORAL|Practice Experiences for School Reintegration (PrESR)|Participants will receive an overview of cognitive behavioral therapy skills in virtual reality (VR) and then have the opportunity to practice using skills in a brief immersive experience designed to mimic difficult school and social experiences. Session begin with goal setting and conclude with a debrief summary following the VR experience. Prior to discharge and following the conclusion of the VR sessions, the participant will be invited to collaborate on a safety planning intervention for school settings.
214667824|NCT03295422|PROCEDURE|RF ablation PVI plus LPAW|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
214667825|NCT04524741|DEVICE|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
215047505|NCT04748692|PROCEDURE|Spinal manual therapy|The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
215047506|NCT03790644|DEVICE|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
215047507|NCT02862977|DRUG|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
215047508|NCT02862977|DRUG|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
215047509|NCT03395028|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
215047510|NCT05175274|DRUG|Colchicine|Colchicine 0.5mg/tablet
215047511|NCT05175274|DRUG|Placebo|matching placebo
215047512|NCT02054975|DRUG|Vitamin D2 + vitamin D3|higher dose vitamin D
215047513|NCT02054975|DRUG|Vitamin D3|lower dose vitamin D
215047514|NCT05927987|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011; Tol et al., 2013). The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem-solving, stress management, behavioural activation, and accessing social support. PM+ has three core features. It is brief (five sessions given in five weeks), delivered by paraprofessionals (PM+ helpers) and transdiagnostic. The PM+ helpers will be supervised by mental health care specialists.
215047515|NCT03486353|DRUG|FF-10501-01|FF-10501-01 round film-coated tablets are immediate release and come in 3 dosage strengths: 50 mg (tan), 100 mg tablets (red) and 200 mg (yellow). Each tablet contains the active ingredient (FF-10501-01 white crystalline powder) and other excipients. All dosage strengths are packaged 32 tablets to a bottle. FF-10501-01 should be stored at room temperature (20 - 25 °C).
214667826|NCT00427661|OTHER|Busulfan; Fludarabine; cyclosporine A and MMF|Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
215047516|NCT03486353|DRUG|Azacitidine|azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days
215047517|NCT02439905|DRUG|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
215047518|NCT02439905|DRUG|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
214667827|NCT01569204|DRUG|Etoposide|
214667828|NCT01569204|DRUG|Cyclophosphamide|
214667829|NCT01569204|DRUG|Doxorubicin|
214667830|NCT01569204|DRUG|Prednisone|
214667831|NCT01569204|DRUG|Procarbazine|
214667832|NCT01569204|DRUG|Dexamethasone|
214667833|NCT01569204|DRUG|Dacarbazine|
214885669|NCT07187193|DRUG|Cytarabine (Ara-C)|The treatment regimen consists of Ara-C administered at a dose of 100 mg/m² from days 1 to 5, combined with thalidomide at a dose of 100 mg from days 1 to 35, repeated every 35 days for a total of 12 cycles. Following this, thalidomide will be given as monotherapy at a dose of 100 mg from days 1 to 28, administered every 28 days for an additional 12 cycles of maintenance treatment. In total, participants will undergo 24 cycles of treatment.
214885670|NCT07187193|DRUG|Thalidomide (100mg)|The treatment regimen consists of AraC administered at a dose of 100 mg/m² from days 1 to 5, combined with thalidomide at a dose of 100 mg from days 1 to 35, repeated every 35 days for a total of 12 cycles. Following this, thalidomide will be given as monotherapy at a dose of 100 mg from days 1 to 28, administered every 28 days for an additional 12 cycles of maintenance treatment. In total, participants will undergo 24 cycles of treatment.
214885671|NCT07186985|COMBINATION_PRODUCT|Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy|"Group 1:~* Patients were instructed to identify and sense their pelvic floor muscles and to perform contraction-hold-relaxation exercises.~* Exercises were performed at a frequency of 8 sets per session, 3 sessions per week, progressing from the supine position (month 1), to sitting (month 2), and to standing (month 3). Training was monitored by an electronic diary app. (Appendix)~* Six individual 45-minute intervention sessions at the center using biofeedback, under the supervision of a physical therapy technician. (Appendix)~* The training program consisted of two parts: resistance training and pre-contraction training (the Knack technique). (Appendix)~* Patients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen:~* First 4 weeks: insert one 0.5 mg tablet nightly at bedtime.~* Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses"
214885672|NCT07186985|DRUG|Vaginal estrogen|"Patients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen:~First 4 weeks: insert one 0.5 mg tablet nightly at bedtime. Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses."
214885673|NCT07176455|BEHAVIORAL|Anti-frailty dietary behavior intervention|Design intervention measures based on the mechanism of dietary behavior changes related to frailty
214885674|NCT07185386|DIETARY_SUPPLEMENT|combination of diosmin, hesperidin, bromelain, and Ruscus aculeatus (Vesvein Gambe)|Although there is extensive clinical and pharmacological evidence regarding the activity of the individual components of the product, the specific effect of the fixed combination of diosmin, hesperidin, bromelain, and Ruscus aculeatus as a single entity on quality of life in subjects with symptoms compatible with the early stages of Chronic Venous Disease (CVD) has not yet been explored.
215047519|NCT02132403|DRUG|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
215047520|NCT02132403|DRUG|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
215047521|NCT02132403|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
215047522|NCT02054065|OTHER|CAUTI Decision Support|Decision support used to prevent Catheter Associated Urinary Tract Infections
215047523|NCT01976871|DRUG|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
214292929|NCT00060112|OTHER|pharmacological study|Correlative studies
214292930|NCT00060112|OTHER|laboratory biomarker analysis|Correlative studies
214292931|NCT00475176|DRUG|Peginterferon alfa-2a|
214292932|NCT00475176|DRUG|Ribavirin|
214292933|NCT00475176|DRUG|S-adenosyl methionine for Chronic Liver Disease|
214292934|NCT00003514|DRUG|antineoplaston A10|
214292935|NCT00003514|DRUG|antineoplaston AS2-1|
214292936|NCT00003514|PROCEDURE|alternative product therapy|
214292937|NCT00003514|PROCEDURE|biological therapy|
214292938|NCT00003514|PROCEDURE|biologically based therapies|
214292939|NCT00003514|PROCEDURE|cancer prevention intervention|
214292940|NCT00003514|PROCEDURE|complementary and alternative therapy|
214292941|NCT00003514|PROCEDURE|differentiation therapy|
214292942|NCT05060159|OTHER|Hemofiltration|Postdilutional Hemofiltration
214292943|NCT01725438|OTHER|sample blood|
214292944|NCT01431833|DRUG|TR-701 FA|Oral single dose 200 mg
214292945|NCT02461108|BEHAVIORAL|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
214667834|NCT01569204|DRUG|Brentuximab Vedotin|
214292946|NCT02461108|BEHAVIORAL|Tax|Frame the price difference as a 10% tax on less nutritious food items.
214292947|NCT02461108|BEHAVIORAL|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
214292948|NCT02436889|DRUG|Mirabegron|
214292949|NCT02436889|DRUG|Tolterodine Tartrate|
214292950|NCT01655979|DIETARY_SUPPLEMENT|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
214292951|NCT01655979|OTHER|Control|Bed rest without dietary supplement
214292952|NCT01806324|DRUG|HL040XC|single dose
214292953|NCT01806324|DRUG|Losartan + Atorvastatin|Single dose
214292954|NCT03412487|PROCEDURE|laparoscopy|under general anesthesia. CO2 pneumoperitoneum, the laparoscope inserted through the umbilicus and a thorough evaluation of the abdominal cavity and pelvis was performed. a grasper was inserted; the utero-ovarian ligament was stabilized with the round biopter will be introduced. The tip of the biopsy instrument was placed on an area of the ovary free of cysts; the hilar area was avoided because it is deficient in small follicles. After correct placement was verified, the inner protecting trocar was removed to expose the sharp leading edge of the round sheath. Gentle circular movements were made cutting through the ovarian cortex to produce a 5-mm disk of 2-3 mm in thickness.
214667835|NCT06205875|PROCEDURE|High dose serratus anterior plane block (2.4 mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% plus epinephrine solution will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% plus epinephrine solution will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound. In total a dose of 2.4mg/kg patient ideal body weight will be administered. There is a maximal dose of 200 mg adrenalized bupivacaine for patients with an ideal body weight of 83 kg or more.
214667836|NCT06205875|PROCEDURE|Low dose serratus anterior plane block (1.2mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.
214667837|NCT06205875|DRUG|PCIA with morphine|A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
214667838|NCT05174806|DRUG|Topical Pravibismane|Topical Pravibismane
214667839|NCT05174806|OTHER|Standard of Care|Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.
214667840|NCT00428168|DRUG|Betahistine|Betahistine 24mg BID
215047524|NCT04280991|OTHER|Moderate intensity exercise under mild normobaric hypoxia and normoxia|The participant will perform the exercise interventions consisting of cycling at the heart rate corresponding with 50%WMAX (normoxia) or heart rate corresponding with 50% WMAX (hypoxia) for 30 minutes, twice a day, for 4 consecutive days. 24h glucose concentration will be monitored continuously.
214292955|NCT01034462|DRUG|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
214292956|NCT01034462|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
214292957|NCT03582072|BEHAVIORAL|letter from the CMO|informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.\*
214292958|NCT05609045|BIOLOGICAL|Lyophilized COVID-19 mRNA Vaccine|RH109 is a mRNA-based vaccine encoding the N-Terminal Domain (NTD) - Receptor Binding Domain (RBD) derived from Spike (S) protein of SARS-CoV-2 Omicron variant.
214292959|NCT05609045|DRUG|Sodium chloride|0.9% sodium chloride
214292960|NCT01229059|DIETARY_SUPPLEMENT|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
214292961|NCT04688307|BEHAVIORAL|Motivational interviewing|Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight
214292962|NCT03206645|DRUG|Unesbulin|Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
214292963|NCT04914104|BEHAVIORAL|Mindfulness Training - Headspace App|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
214292964|NCT04918550|OTHER|no drug and device|there is no intervention
214292965|NCT03502226|BEHAVIORAL|Tailored feedback|"Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing."
214292966|NCT00213083|DRUG|Carraguard (PC-515)|
214292967|NCT04723550|DEVICE|Hospital telemedicine management system|Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.
214292968|NCT04723550|OTHER|Usual care|Outpatient/telephone follow-up：continued care, as usual, from their primary care provider through out duration of action 6 months intervention period
214667841|NCT03186456|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 \*10\^6/kg. once a month, total 3 times.
214667842|NCT03186456|DRUG|Aspirin Tablet|Drug: Aspirin Tablet, 100 mg/d
214292969|NCT01219920|DRUG|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
214292970|NCT01219920|DRUG|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
214292971|NCT01550796|BEHAVIORAL|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
214292972|NCT05692765|BEHAVIORAL|smartphone application to enhance fruit and vegetables intake among adolescents|"This randomized intervention study was conducted in an urban area of Jeddah, Saudi Arabia. We included 104 adolescents aged 13-18 years, who were randomized into intervention (n=55) or control (n=49) arms. We examined the effects of a smartphone application (My Plate) on fruit and vegetable intake over 6 weeks in the intervention group. Pre- and postintervention questionnaires were used in the intervention and control groups."
214292973|NCT04273217|DRUG|AV-1|Single dose, administered by IV infusion (volume: 250 mL)
214292974|NCT04273217|DRUG|Placebo|0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
214292975|NCT02393833|PROCEDURE|Blood samples collection|"Blood samples to be collected at the following time points:~1. Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~2. Months 12, 18 and 36 after start of induction chemotherapy~3. At time of confirmatory evidence of progression"
215047525|NCT04188249|DRUG|Golimumab|This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.
215047526|NCT03632707|RADIATION|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
215047527|NCT03632707|PROCEDURE|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
215057329|NCT05406739|OTHER|Test Meals|"For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water."
215057330|NCT00090961|OTHER|educational intervention|
215057331|NCT00090961|OTHER|supervised exercise program|
215057332|NCT01173107|DRUG|colchicine|colchicine 1T tid
214292976|NCT06208059|OTHER|manual acupuncture|In manual acupuncture, the scalp motor area on the lesion side will be needled and left in place for 30 minutes after obtaining qi. During the needle retention, the needles will be twisted intermittently for 2 minutes twice, at a frequency of approximately 200 r/min.
214292977|NCT06208059|OTHER|electroacupuncture|In electroacupuncture, the scalp motor area will be needled, and after obtaining qi, the treatment will involve applying electroacupuncture stimulation using a continuous wave with a frequency of 2 Hz. The intensity of the stimulation will be adjusted based on the patient's tolerance, and each treatment session will last for 30 minutes.
214292978|NCT04751825|BEHAVIORAL|I-EAET|See information in arm description.
214292979|NCT01741922|DRUG|ASA evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
214477250|NCT06666296|BEHAVIORAL|digital/hybrid teaching kitchen|Recipes, cooking techniques, shopping tips and recommendations for implementing the Planetary Health Diet are taught in the digital/hybrid teaching kitchen. The focus here is on fun, good taste and interesting experiences. A shared experience can be created through such cooking events. The teaching kitchen events can be supplemented by the participation of the kitchen management in order to benefit from their special cooking skills and wealth of experience. The positive aspect of the digital training kitchen is the easy access to information, as this does not have to be read, but is conveyed visually.
214667843|NCT04281537|DRUG|Enzyme Replacement Therapy (ERT)|ERT infusion every other week
214667844|NCT03230097|DRUG|BI 409306|50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
214477251|NCT06666296|BEHAVIORAL|Digital events (digital cafés)|"Events are planned that will be set up via the digital café for in-depth discussions and exchanges about the content. Fixed dates are planned at which the study participants can meet digitally. In this protected setting, the topics of the study will be discussed in a convivial atmosphere. The personal exchange enables a deeper examination of the topic. The online events give participants the opportunity to interact directly with the study coordinators and other participants in order to effectively and sustainably change the participants' perception and awareness of sustainable nutrition through the various intervention points."
214667845|NCT03230097|DRUG|Placebo|placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
214667846|NCT01481571|DEVICE|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
214667847|NCT04456322|DRUG|RT plus Nimotuzumab|Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
214667848|NCT04456322|DRUG|RT plus Cisplatin|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
214667849|NCT05187533|OTHER|Osteopathic protocol of Sphenopalatine Ganglion Stimulation|Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
214667850|NCT04819828|PROCEDURE|Extracorporeal shock wave lithotripsy|A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.
214667851|NCT04819828|DRUG|Diclofenac|Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
214667852|NCT04819828|DRUG|Tamsulosin|Oral tamsulosin (0.4 mg/day) for eight weeks.
214667853|NCT05912816|DRUG|RC48 Combined With Tislelizumab|"In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour."
214667854|NCT00671151|DRUG|Theophylline|Theophylline 100 mg bid for 3 months
214667855|NCT02950129|OTHER|SIJ pain diagnostic tests|The subjects will undergo a specific physical exam of tests reported to be diagnostic of sacroiliac joint (SIJ) pain prior to receiving the routine injection in the SIJ; all tests will be repeated after the SIJ injection
214667856|NCT04509089|DEVICE|Suremedix Device|Performing measurements using the Suremedix Device by applying gradually ascending air pressure to the subject lungs through a mouse piece while measuring respiratory chest motion, PPG and ECG.
214667857|NCT02654925|PROCEDURE|Adipose Tissue Biopsy|
214667858|NCT02569034|OTHER|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
214667859|NCT02569034|OTHER|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
214667860|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
214667861|NCT00982566|DRUG|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
214885675|NCT07184996|DRUG|Duvakitug|Pharmaceutical form:Solution for Injection-Route of administration:SC injection
214885676|NCT07184996|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:SC injection
214885677|NCT07184632|DRUG|NNC0662-0419|NNC0662-0419 will be administered subcutaneously.
214885678|NCT07184632|DRUG|Placebo|Placebo matched to NNC0662-0419 will be administered subcutaneously.
214292980|NCT01741922|DRUG|Acetylsalicylic morning|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
214477252|NCT06666296|BEHAVIORAL|Social-Media|A dedicated Instagram account for this project will be created for the center, where valuable content on the Planetary Health Diet will be shared regularly. The test subjects can also use this platform to exchange information.
214477253|NCT05535816|DIAGNOSTIC_TEST|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound instead of fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
214667862|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
214667863|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
214667864|NCT04520789|DIAGNOSTIC_TEST|RPE cell collection and single cell heterogeneity study|Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.
214667865|NCT04520789|PROCEDURE|Postoperative intervention|Early local steroids drug intervention in patients with severe postoperative PVR
214667866|NCT04520789|PROCEDURE|Conventional Surgery for Retinal Detachment|Conventional Surgery for Retinal Detachment
214667867|NCT00548912|DRUG|Spironolactone|
214667868|NCT00319163|DRUG|levonorgestrel/ethinyl estradiol|
214667869|NCT03380858|DEVICE|colectomy|colectomy resection
214667870|NCT01561638|PROCEDURE|Conventional Radiofrequency|pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
214667871|NCT01561638|PROCEDURE|Pulsed Dose Radiofrequency|pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
214667872|NCT01561638|PROCEDURE|Sham|will receive puncture for 4 minutes
214667873|NCT04341610|DRUG|Stem Cell Product|100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
214667874|NCT03886077|DRUG|glecaprevir/pibrentasivir|12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
214667875|NCT04837391|DEVICE|Near Infrared Spectroscopy (NIRS)|Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.
214667876|NCT04837391|DIAGNOSTIC_TEST|Blood sample|Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.
214667877|NCT04837391|DIAGNOSTIC_TEST|Addenbrooke Cognitive Examination III (ACE-III)|ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.
214667878|NCT04837391|DIAGNOSTIC_TEST|Confusion Assessment Method|Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
214667879|NCT05959499|DRUG|BR6002A|One tablet administered alone
214667880|NCT05959499|DRUG|BR6002B|One tablet administered alone
214667881|NCT05959499|DRUG|BR6002|One capsule administered alone
214667882|NCT04718064|DRUG|Fingolimod|fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
214667883|NCT04718064|DRUG|placebo|placebo once daily, for three consecutive days,
214667884|NCT00163540|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
214667885|NCT03295097|OTHER|Clinical Decision Support System|The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.
214667886|NCT03501212|DRUG|Topical Anesthetic|EMLA Cream 2.5 gr applied to both wrists
214667887|NCT03501212|DRUG|Placebo|Placebo Cream 2.5gr applied to both wrist
214885679|NCT07185282|DRUG|MH004 Ointment|MH004 1% ointment applied topically to the affected area as a thin film twice daily.
214885680|NCT07185282|DRUG|Vehicle Ointment|Matching vehicle ointment applied topically to the affected area as a thin film twice daily.
214885681|NCT07186361|DEVICE|Symptom Assessment and Management Program (SAM-CKD) which is delivered via Smart Kidney mobile app|An intervention program delivered through a mobile app to support symptom assessment and management for adults with CKD. The SAM-CKD program has three components - introduction, symptom tracker and symptom management. A list of 17 common symptoms will be assessed. Users can self-assess symptoms and rate these according to the severity level (overwhelmingly, severely, moderately, slightly, and not at all). The SAM-CKD program will provide symptom management strategies based on symptoms reported by patients. The intervention's duration is 6 weeks.
214885682|NCT07186621|DRUG|Sintilimab|concurrent sintilimab 200mg q3w for 2 cycles followed by maintenance sintilimab 200mg q3w for 15 cycles (approximately 1 year total treatment duration) until disease progression or unacceptable toxicity
214885683|NCT07186621|RADIATION|radiotherapy|The experimental group will initiate radiotherapy within 4 months postoperatively with prescribed doses of 44-50Gy in 22-25 fractions to the tumor bed and 56-60Gy in 22-25 fractions to narrow-margin areas adjacent to major blood vessels
214885684|NCT07186621|PROCEDURE|TACE|The control group will receive the first TACE procedure within 4 months postoperatively, with the decision on administering a second TACE to be determined by the investigator based on the patient's condition and first TACE response assessment.
214885685|NCT07186920|PROCEDURE|PEEP titration for Minimum Driving Pressure|"This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP Initially 8 cm H2O. Afterwards, the lungs are recruited with the aforementioned maneuver. During subsequent derecruitment, PEEP is decreased by 2 cm H20 and compliance is noted in each stage. The goal is to find PEEP with maximum compliance (Cmax). A new recruitment maneuver follows and during derecruitment PEEP is set at the optimum value that was previously defined.~VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuver (as described) every hour"
215047528|NCT04941469|DEVICE|Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types."
215047529|NCT04941469|DEVICE|Plain off-the-counter foot orthosis (Medical grade foot orthosis)|The control device for this study would be the plain original Formthotics (Original Dual Hard).
215047530|NCT00373048|DRUG|mefloquine|tablet, once weekly
215047531|NCT00373048|DRUG|placebo|tablet, once weekly
214477254|NCT04708834|DRUG|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily following first 2 weeks
214885686|NCT07186920|PROCEDURE|Lung Protective Ventilation|This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP 8 cm H2O. VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuvers (as described) every hour
214885687|NCT07184931|DRUG|Duvakitug|Pharmaceutical form:Injection solution Route of administration:SC injection
214885688|NCT07184931|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration:SC injection
215047532|NCT04231071|DEVICE|Onlay Mesh group|Primary suture repair with a small only mesh on the closed defect
215047533|NCT05225883|GENETIC|GWAS|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
214477255|NCT05956574|BEHAVIORAL|Nutrigenomix, personalized dietary plan|Personalized dietary plan.
215047534|NCT05225519|DEVICE|long-sleeved white shirt impregnated with a long-infrared irradiation|Usage of an experimental shirt for a period of 12 weeks.
215047535|NCT05225519|DEVICE|long-sleeved white shirt|Usage of an experimental shirt for a period of 12 weeks.
215047536|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
215047537|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
215047538|NCT01967745|PROCEDURE|laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
215047539|NCT01967745|PROCEDURE|open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
215047540|NCT01946659|BEHAVIORAL|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
215047541|NCT01946659|OTHER|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
214885689|NCT07186166|COMBINATION_PRODUCT|30% HA+70% β-TCP (Osteon II, Dentium, Korea)|A prospective analysis was performed on a single-arm clinical trial involving 60 posterior maxillary edentulous sites in 42 patients with a residual bone height of \<4 mm. All sites were treated with lateral window sinus floor augmentation (LWSFA), followed by grafting using a 1:1 ratio of 30% HA with 70% β-TCP (Osteon II, Dentium, Korea). At 6 months postoperatively, core biopsies were harvested during implant placement to assess the histological outcomes of the grafted sites.
215047542|NCT05946161|BEHAVIORAL|e-Health intervention to promote mental and sexual health of prostate cancer survivors|An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
215047543|NCT01063348|DRUG|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
215047544|NCT01063348|DRUG|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
215047545|NCT05309681|OTHER|Epworth's sleepiness scale; unstimulated saliva sample|Unstimulated saliva sample; Epworth's sleepiness scale
215047546|NCT06124222|PROCEDURE|Prosthetic oral rehabilitation|Prosthetic rehabilitation with fixed and/or removable prosthesis.
215047547|NCT03731052|DRUG|188-0551 Spray|Topical Spray containing active drug
215047548|NCT03731052|DRUG|Vehicle Spray|Topical Spray containing no active drug
215047549|NCT06206850|DRUG|Osimertinib|Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).
215047550|NCT06476288|OTHER|Low-intensity resistance exercise training|The intervention protocol will consist of 60 minutes of low-intensity resistance exercise training 3x/week for 6 weeks.
215047551|NCT06476288|OTHER|High-Dose Remote ischemic conditioning (RIC)|Treatment dose of RIC- the RIC cuff will be inflated to 20 mmHg over the participant's systolic blood pressure. The treatment dose of RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
215047552|NCT06476288|OTHER|Low-Dose Remote ischemic conditioning (RIC)|This dose will be the control for the study. Low-dose RIC- the RIC cuff will be inflated to 10 mmHg below the participant's diastolic blood pressure. The low-dose RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
215047553|NCT04952571|DRUG|Camrelizumab and Bevacizumab|"Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion."
215047554|NCT05122546|DRUG|Cabozantinib S-malate|Given PO
215047555|NCT05122546|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
215047556|NCT05122546|BIOLOGICAL|Nivolumab|Given IV
215047557|NCT05387746|BEHAVIORAL|Caring Science, Mindful Practice and Reiki Training|Participants will complete a) 4 week internet-based course on Caring Science Mindful Practice and b) 12 hour Reiki training. The participants will also complete online post-training survey with the same questions included in pre-training survey.
215047558|NCT01356394|OTHER|dietary intervention|12-week calorie-restricted diet consisting of 50% carbohydrate, 20-25% protein, and 25-30% fat
215047559|NCT04663594|OTHER|WofB|Online experience designed to reduce anxiety and depression and support mental health and wellbeing
215047560|NCT04663594|OTHER|Ashmolean Website|A generic museum website owned by the Ashmolean Museum of Art and Archaeology at the University of Oxford.
215047561|NCT01767896|BIOLOGICAL|ASP7374|subcutaneous (sc)
215047562|NCT01767896|BIOLOGICAL|approved egg-derived TIV|subcutaneous (sc)
215057333|NCT03966209|DRUG|JS001(PD-1 inhibitor)|240mg I.V. Q3W
215057334|NCT00042016|DRUG|decitabine (5-aza-2'deoxycytidine)|
214477256|NCT05956574|BEHAVIORAL|Physical Activity|Participate in an exercise program to work up to 300 min/week of moderate-intensity activity.
214477257|NCT05956574|BEHAVIORAL|Behavioral counseling|Review behavioral counseling videos and participate in worksheets to assist with behavioral change.
214885690|NCT07186803|DEVICE|Artificial Intelligence Guidance Models|The intervention will involve the use of two artificial intelligence (AI) models to provide surgical guidance during laparoscopic cholecystectomy procedures. The AI models will provide real-time feedback based on the live surgical feed (internal patient anatomy captured by laparoscopic camera) displayed on an operating room monitor. The GoNoGoNet model identifies safe and unsafe zones of dissection. This is done by showcasing a green overlay over safe zones of dissection, and a red overlay over unsafe zones of dissection. The DeepCVS model provides text-based feedback based on its assessment of the following three criteria defining the Critical View of Safety: 1) complete clearance of the hepatocystic triangle from fat and fibrous tissue, 2) only two structures visible entering the gallbladder (cystic artery and duct) and 3) the lower third of the gallbladder must be dissected off the liver bed, exposing the cystic plate.
214885691|NCT07186868|BIOLOGICAL|Iparomlimab and Tuvonralimab (QL1706) + Nab-Paclitaxelwith or without Bevacizumab|All participants will receive the study intervention: Iparomlimab and Tuvonralimab (QL1706) at 5.0 mg/kg IV Q3W + Nab-Paclitaxel at 260 mg/m² IV Q3W, with or without Bevacizumab (7.5-15 mg/kg IV Q3W) per investigator's choice, for 6 cycles. This is followed by maintenance therapy with QL1706 ± Bevacizumab until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
214885692|NCT07185425|DEVICE|NeuroCuple|Device around the abdomen over c-section bandages in the PACU
214885693|NCT07185425|DEVICE|Sham|Device around the abdomen over c-section bandages in the PACU
214885694|NCT07185932|DRUG|Rifaximin (Xifaxan)|Participants will receive oral rifaximin at a dosage of 1200 mg/day (400 mg, three times daily) for 24 weeks.
215047563|NCT03840213|BEHAVIORAL|Filling a questionnaire and interviewDescription|"The questionnaire focuses on the dietary practices of patients treated with chemotherapy. It consists of 35 questions, completing an average of 20 minutes.~Interviews will be conducted with patients who have changed their diet since the beginning of their treatment in order to further develop the results of the quantitative survey."
215047564|NCT06301503|DRUG|USG Guided Combined LPB-SNB with Isobaric Bupivacaine|Local anesthetic infiltration of 2% lidocaine (3ml) along with injection anaesthetic agent consisting of isobaric bupivacaine 0.25% (20 ml)
214292981|NCT01741922|DRUG|Placebos morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
214292982|NCT01741922|DRUG|Placebo evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
214885695|NCT07186894|DRUG|Antistaphylococcal penicillins|It in not an interventional study. This project is a phase IV, retrospective, descriptive, and multicentric study.
214885696|NCT07186894|DRUG|Cefazolin|It in not an interventional study. This project is a phase IV, retrospective, descriptive, and multicentric study.
214885697|NCT07185139|DRUG|MSCohi-O Lenses|Each subject will wear MSCohi-O Lenses for 12 hours a day, totally 14 wearings.
214885698|NCT07184918|DRUG|Continuing Ramipril|Participants in this group will continue taking Ramipril at their usual dose before, during, and after the coronary angiography. The objective is to evaluate the renal effects of uninterrupted ACE inhibitor therapy during contrast exposure.
214885699|NCT07184918|DRUG|Withholding Ramipril|Participants in this group will stop taking Ramipril 48 hours before the angiography procedure and resume it 72 hours after. This intervention is used to evaluate whether temporarily withholding ACE inhibitors reduces the risk of contrast-induced nephropathy.
214885700|NCT07186127|DRUG|Drug: Methotrexate (MTX) Patients received methotrexate treatment according to institutional protocols. Dosage and administration routes were recorded retrospectively. For patients who did not respond|MTX medical treatment Laparoscopic salpingectomy Laparoscopic salpingostomy
214885701|NCT07185607|PROCEDURE|Erector spinae plane block (ESPB)|Erector spinae plane block is not a drug or a device. It is a regional method for anesthesia/analgesia. Before block application, patients were placed in a sitting position. A preliminary examination with a high-frequency linear probe was performed to identify the application site. Sterile conditions were then established. An ultrasound probe was longitudinally placed approximately 2 cm lateral to the T11 spinous process. The transverse process was visualized. 1 ml of 2% lidocaine was applied to the estimated needle entry site. The needle was then guided toward the transverse process using an out-of-plane method using a blocking needle (Stimuplex® Ultra 360® 22G 80 mm, Melsungen, Germany). After bone contact was achieved, facial hydrodissection was observed with 1-2 ml of saline solution to verify the correct injection site. 20 ml of 0.25% bupivacaine was injected into the plane. The distribution of the drug was visualised by USG.
214885702|NCT07186595|DEVICE|JUVÉDERM VOLUX XC|Injections
214885703|NCT07186595|DEVICE|JUVÉDERM VOLUMA XC|Injections
214885704|NCT07186595|DEVICE|JUVÉDERM VOLBELLA XC|Injections
214885705|NCT07186595|DEVICE|JUVÉDERM VOLLURE XC|Injections
214885706|NCT07186595|DEVICE|SKINVIVE by JUVÉDERM|Injections
214885707|NCT07186595|DEVICE|JUVÉDERM ULTRA XC|Injections
214885708|NCT07186595|DEVICE|JUVÉDERM ULTRA PLUS XC|Injections
214885709|NCT07186088|DEVICE|Eyerising RS-200-2A|Eyerising RS-200-2A,1 time,2 times, 3 times a day
214885710|NCT07186088|DEVICE|Airdoc Sky-n1201|Eyerising RS-200-2A,2 times a day
214885711|NCT07185074|DRUG|Cisatracurium 0.05 mg/kg IV|Single bolus at induction; used in the experimental arm. Approximate potency reference: 0.05 mg/kg is about 1 x ED95.
214885712|NCT07185074|DRUG|Cisatracurium 0.15 mg/kg IV|Single bolus at induction; used in the active comparator arm. Approximate potency reference: 0.15 mg/kg is about 3 x ED95.
214885713|NCT07185074|DRUG|Lidocaine aerosol 2.4% topical|Three sprays to the glottic area immediately before intubation; used only in the experimental arm.
215047565|NCT06301503|DRUG|Control|Local anesthetic infiltration of 2% lidocaine (3ml)
214885714|NCT07187102|OTHER|SNAG ( sustained natural apopheseal glide )|SNAG : type of mobilization of vertebral coulmn
214885715|NCT07185048|BEHAVIORAL|Conventional Foot Care Control Group|Standard Foot Care with Regular Follow-up
214885716|NCT07185048|BEHAVIORAL|Digital Foot Care (Low-Intensity)|On the basis of routine management, the digital intervention modules will be added
214885717|NCT07185048|BEHAVIORAL|Digital Foot Care (Moderate-Intensity)|Further integration of AI image analysis for auxiliary judgment and remote physician response.
214885718|NCT07185620|PROCEDURE|Third molar surgery with piezoelectric system|For the surgical removal of the third molar with a mucoperiosteal flap, osteotomy was performed using a piezoelectric system under continuous irrigation. The mucoperiosteal flap was then repositioned and closed primarily with sutures.
214885719|NCT07185620|PROCEDURE|Third molar surgery with Conventional Rotary System|For the surgical removal of the third molar with a mucoperiosteal flap, osteotomy was performed using a conventional rotary system under continuous irrigation. The mucoperiosteal flap was then repositioned and closed primarily with sutures.
214885720|NCT07185191|DEVICE|RDM36|Patients treated with RDM36; two perpendicular infiltrations (buccal, palatal) of a quantity of 0.2 ml of PN HPT
214885721|NCT07185191|DRUG|Saline Solution (NaCl 0,9%)|patients treated with saline solution; two perpendicular infiltrations (buccal, palatal) of a quantity of 0.2 ml of saline solution
214885722|NCT07185126|BEHAVIORAL|Reconsolidation of traumatic memories|"The intervention begins with a parent session to review history, provide orientation, and obtain consent. Each child then attends six individual therapy sessions with a trained RTM specialist. Sessions use imagination exercises, film-like replay of traumatic memories in modified formats (e.g., black-and-white, fast-forward, backwards), and structured state-interruption techniques to reduce fear and distress. Animated instructions and cardboard cinema and skreen models may be used to support comprehension if needed."
215047566|NCT04228458|DEVICE|Thermal Imaging|Testing the effectiveness of using a Thermal Imaging camera in participants with Juvenile Arthritis.
215047567|NCT02827721|DEVICE|impulse oscillometry|
215047568|NCT02827721|DEVICE|multiple breath washout test|
215047569|NCT02827721|DEVICE|body plethysmography|
215047570|NCT06319781|OTHER|Observational|The study is a prospective non-interventional, observational study.
215047571|NCT04173182|DIAGNOSTIC_TEST|Probe-based confocal laser endomicroscopy evaluation|Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease
215047572|NCT02325063|DRUG|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
215047573|NCT02325063|DRUG|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
215047574|NCT02325063|DRUG|Corticoid injection|Patients will be treated with an injection of Corticoids.
215047575|NCT05968846|DRUG|Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)|124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.
215047576|NCT05990244|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Undergo MRE and routine MRI
215047577|NCT05990244|PROCEDURE|Assessment and Recording|Undergo recording of tumor stiffness during surgery and molecular pathological classification through genetic analysis
215047578|NCT03795493|BEHAVIORAL|Short-term diet and exercise intervention|Participants assigned to the intervention group will perform both the diet and acute exercise interventions. The interventions will be applied prior to up to six chemotherapy cycles of a consistent protocol. The total number of treatments of a given protocol received prior to treatment conclusion is dependent on patient condition and oncologic care preferences.
215047579|NCT03139058|OTHER|Evaluation of the hepatic fibrosis|Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)
215047580|NCT03585387|PROCEDURE|Navigation|Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
214885723|NCT07185945|DRUG|Zanzalintinib|60 mg orally once daily
214885724|NCT07185347|DRUG|Fampridine 10 mg prolonged-release tablet (per os)|Patients randomized in the experimental arm will take 1 tablet twice a day, 12 hours apart, on an empty stomach, for 12 weeks.
214885725|NCT07185347|DRUG|Placebo (tablets per os)|Patients randomized in the control arm will take 1 tablet twice a day, 12 hours apart, on an empty stomach, for 12 weeks.
215047581|NCT01876381|DRUG|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
215047582|NCT00185341|DRUG|CCR1-Antagonist (BAY86-5047, ZK811752)|Given orally in a dose of 600 mg three times daily over 12 weeks
215047583|NCT00185341|DRUG|Placebo|Placebo
215047584|NCT00006021|DIETARY_SUPPLEMENT|ascorbic acid|
215047585|NCT00006021|DRUG|arsenic trioxide|
215047586|NCT00011544|PROCEDURE|Performance Measure|
215047587|NCT06357104|DEVICE|electroencephalogram biofeedback|EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.
215047588|NCT06357104|DEVICE|electrical brain stimulation|EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.
215047589|NCT06357104|DEVICE|ultra-low frequency transcranial magnetic stimulation|ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.
215047590|NCT06357104|DRUG|Sertraline Hydrochloride|Sertraline is taken in the morning for 150 mg per day.
214667888|NCT05370157|BEHAVIORAL|TeamTRACS|TeamTRACS is a team training intervention adapted from TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), a widely used evidence-based team training developed by the Agency for Healthcare Research and Quality. TeamTRACS targets knowledge, skills, and attitudes related to team member roles, shared awareness, communication, mutual support, and goal-setting. TeamTRACS is structured, easy to use, flexible in length and intensity, and requires few resources. It incorporates didactic instruction, discussion, and interactive activities and can be delivered virtually or in-person.
214667889|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
214667890|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
214667891|NCT03652454|DEVICE|micro-osteoperforation|Propel device (ABD) using for regional acceleratory phenomenon
214885726|NCT07186816|DEVICE|Behavioral: Supported dCBT|In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
214885727|NCT07186816|DEVICE|Behavioral: Unsupported dCBT|Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
214885728|NCT07184671|BIOLOGICAL|blood sampling|22mL peripheral blood will be collected
214885729|NCT07184671|BIOLOGICAL|broncho-alveolar lavage sampling|Collected on resected tissue
214885730|NCT07184671|BIOLOGICAL|lung parenchyma sampling|Collected on resected tissue
214885731|NCT07185230|DRUG|Atosiban|Participants in the atosiban group will receive an intravenous bolus injection of atosiban (37.5 mg/5 mL, , Tractocile®，Ferring Pharma,Geneva, Switzerland) at a rate of 6.75 mg/0.9 mL 30 minutes prior to embryo transfer, followed by a 1-hour intravenous infusion at a rate of 18 mg/h. After 1 hour, the atosiban infusion rate will be reduced to 6 mg/h, with a total dose of 37.5 mg.
214885732|NCT07185230|DRUG|Placebo Control|Participants in the placebo group will receive an identical saline infusion over the same timeframe. Specifically, saline will be administered intravenously 30 minutes prior to embryo transfer (ET), followed by a continuous intravenous infusion for one hour. This will be succeeded by a further continuous intravenous infusion of saline for 2.125 hours.
214885733|NCT07185295|PROCEDURE|To maintain anticoagulant therapy during the polypectomy of colorectal lesions|Group A
214885734|NCT07185542|PROCEDURE|Superficial parotidectomy|Superficial parotidectomy (SP), the traditional approach, involves facial nerve dissection and removal of the superficial lobe. Though effective, it carries risks like nerve dysfunction, Frey's syndrome, and cosmetic concerns
214885735|NCT07185542|PROCEDURE|Intracapsular parotidectomy (ICP)|"ICP excises the tumor along its capsule without dissecting the facial nerve, thereby minimizing trauma and preserving glandular tissue.~ICP is recommended for small, mobile, and superficially located benign tumors with low suspicion of malignancy. However, concerns remain regarding capsular rupture and recurrence, particularly in pleomorphic adenomas with microscopic extensions"
214885736|NCT07186036|DEVICE|soft lumbosacral orthosis|The effect of trunk corsets on postural control and walking, GYA independence
214885737|NCT07185217|OTHER|class mate teaching subjects only|the participants receive educational classmate subjects.
214885738|NCT07184528|DEVICE|Endobronchial Blood Patch|This component of the procedure involves sealing persistent air leak (PAL) defects using autologous blood delivered via a balloon catheter. After identifying the target segment, carefully noting the airway angle and distal carina, a sizing balloon is deployed and inflated to ensure a tight seal. Under anesthesia, 30 mL of fresh blood is prepared and infused into the target airway until either visible extravasation occurs or the full volume is delivered. Following this, up to 10 mL of tranexamic acid (TXA) may be administered, again until extravasation occurs or the volume is fully instilled. The balloon remains inflated for 3-5 minutes after the instillation to allow clot formation and sealing of the defect.
215047591|NCT06357104|DRUG|Clonazepam|Clonazepam is taken in the morning for 1 mg per day.
215047592|NCT06357104|DRUG|Alprazolam|Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.
214292983|NCT03090854|DIAGNOSTIC_TEST|ADASCog|Neuropsychological test
214292984|NCT04922203|OTHER|in Situ Simulation|2 sessions of in situ simulation with 4 crisis scenarios and debriefing focused on non technical skills
214292985|NCT01830660|DRUG|Hetrombopag Olamine Tablets|
214292986|NCT01830660|DRUG|placebo|
214292987|NCT04497077|DIETARY_SUPPLEMENT|tart cherry|Either tart cherry juice or freeze dried powdered tart cherry in capsule was given
214292988|NCT04497077|DIETARY_SUPPLEMENT|placebo|either cornstarch capsule or kool-aid
214667892|NCT03652454|OTHER|conventional fixed appliance treatment|conventional fixed appliance treatment
214667893|NCT03583424|DRUG|Carmustine|Given IV
214667894|NCT03583424|DRUG|Cytarabine|Given IV
214667895|NCT03583424|DRUG|Etoposide|Given IV
214667896|NCT03583424|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
214667897|NCT03583424|DRUG|Melphalan|Given IV
214667898|NCT03583424|DRUG|Venetoclax|Given PO
214667899|NCT06227923|DEVICE|PRO-HOME intervention|Patients are transferred to the apartment inside the hospital setting and are evaluated and assessed also using technological devices
214667900|NCT01144637|BIOLOGICAL|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
214667901|NCT01144637|OTHER|Placebo|0.5 ml TBS
214667902|NCT00722176|DRUG|BL-1020|10 mg
214667903|NCT00722176|DRUG|BL-1020 10-30 mg|BL-1020 10-30 mg
214667904|NCT00722176|DRUG|risperidone|risperidone
214885739|NCT07184528|DEVICE|Spiration Valve System (SVS) Placement|Once the blood patch component is complete and the balloon is deflated, a Spiration Valve System (SVS) is placed proximally in the airway. The valve acts as a one-way device that decompresses the targeted lung segment while stabilizing the clot created by the blood patch. This supports durable resolution of the air leak, particularly in cases where collateral ventilation might otherwise reduce the efficacy of valve therapy alone.
214885740|NCT07186972|PROCEDURE|Mild therapeutic hypothermia|Before percutaneous coronary intervention, cooling was maintained with venous-arterial extracorporeal membrane oxygenation in patients receiving mild therapeutic hypothermia. By protocol, cooling down to the target temperature of 33°C-34°C was set at the maximum possible cooling rate. After the target temperature was reached, it was maintained for 24 hours with the temperature regulation function of the extracorporeal membrane oxygenation system by central temperature measurement in the urinary bladder. After 24 hours, rewarming was initiated with a speed of 0.25°C/h to a target temperature of 36.5℃ (± 0.3℃). To avoid shivering in the mild therapeutic hypothermia group, the patients were treated with a protocol including deep sedation and optional muscle relaxation.
214885741|NCT07186907|DEVICE|Hydrocolloid dressing|Hydrocolloid dressing was used for diaper dermatitis
214885742|NCT07186907|DRUG|Zinc oxide cream %40|Zinc oxide cream was used in diaper dermatitis.
215047593|NCT06357104|DRUG|Metoprolol|Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.
215047594|NCT06357104|DRUG|Olanzapine|Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.
214667905|NCT01364467|DRUG|Placebo|Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
214667906|NCT01364467|DRUG|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
214667907|NCT04956484|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg
215047595|NCT06357104|DRUG|Pravastatin Sodium 20 MG|Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
215047596|NCT06357104|DRUG|Sacubitril Valsartan Sodium Hydrate|Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.
214667908|NCT04956484|DRUG|Standard of care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
214667909|NCT01048229|DRUG|Rasagiline|1 mg rasagiline once daily (plus placebo twice daily)
215047597|NCT00943644|DEVICE|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
214667910|NCT01048229|DRUG|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
215047598|NCT00943644|DEVICE|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
215047599|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure and orthodontic treatment|subepithelial connective tissue graft and orthodontic tooth levelling and alignment
215047600|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure|subepithelial connective tissue graft procedure
214292989|NCT01053689|DRUG|Glimepiride tablets 1 mg|
214292990|NCT02618434|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
214292991|NCT02618434|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
214667911|NCT03842137|DEVICE|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
214667912|NCT03842137|DEVICE|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
214885743|NCT07186504|BEHAVIORAL|Adapted Physical Activity|Group-based, weekly supervised 60-minute sessions including mobility, stability, strengthening, and aerobic exercises adapted for pregnancy and pelvic girdle pain.
215057335|NCT06553586|OTHER|Data collection|"Data of the proposed study will be collected from two main sites, namely they:~1. All emergency departments of health service outlets received the concerned victims of RTAs in Riyadh Region throughout the last five years (2019-2023). The records and documents of these hospitals will be reviewed and the researcher will determine and pick up the victims of RTAs only and record them in a relevant form designed to fit with the proposed study.~2. The General Administration of Traffic in Riyadh Region."
215057336|NCT00648921|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fasting
215057337|NCT00648921|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fasting
215057338|NCT02044952|DRUG|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
215057339|NCT05050968|OTHER|Physical activity|Between V1 and V2 (i.e. 12 weeks), the APAG (Adapted Physical Activity Group) will participate at a physical training program, 3 sessions of 1h30 per week consisting of endurance activities (60-75% of VO2 peak) and muscle strengthening while the CG will not perform any controlled physical training program. Then, between V2 and V3, no APA (Adapted Physical Activity) program will be offered to both groups.
215057340|NCT02480413|OTHER|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
215057341|NCT03697005|OTHER|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
215057342|NCT03697005|OTHER|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
214885744|NCT07186504|BEHAVIORAL|Pelvic Floor Rehabilitation|Individual physiotherapy sessions using the PERFECT scheme to assess and retrain pelvic floor muscle function, including education, manual therapy, relaxation, and strengthening
214885745|NCT07186504|OTHER|Standard Care (in control arm)|Usual prenatal care provided by obstetricians or midwives according to local practice.
214885746|NCT07186504|OTHER|Educational Flyer|Written information with evidence-based international guidelines on physical activity during pregnancy.
214885747|NCT07184697|DEVICE|HD ctACS|Participants received High-Definition closed-loop transcranial Alternating Current Stimulation (HD-ctACS) for 30 minutes daily, 5 days per week. A 4x1 ring electrode montage was used, with the center electrode placed over the bilateral temporal cortices. Stimulation was delivered as a sinusoidal alternating current at a 2 mA peak amplitude, with the frequency individualized for each participant based on their baseline EEG. The stimulation was administered in a closed-loop, task-specific manner: a 500 ms burst of stimulation was triggered only when a subliminal negative facial stimulus was presented and the participant's real-time Nucleus Accumbens gamma power exceeded their baseline by two standard deviations.
214885748|NCT07184697|DEVICE|HD ctACS sham|Participants received High-Definition transcranial Alternating Current Stimulation (HD-tACS) in 30-minute sessions once daily, 5 days per week. A 4x1 ring electrode layout was used to target the bilateral temporal cortices. The stimulation consisted of a sinusoidal alternating current with a 2 mA peak intensity, delivered at an individualized gamma frequency determined from a baseline EEG. The intervention was administered using a closed-loop, task-specific paradigm: upon presentation of a subliminal negative facial stimulus while the real-time Nucleus Accumbens gamma power exceeded a baseline threshold of +2 SD, a 500 ms stimulation was delivered following a random delay of 1000-2000 ms.
214885749|NCT07186881|OTHER|Recommendation from the infectious diseases team|"No commercial product was evaluated in this study. We are assessing the benefits and consequences of a change in clinical practice implemented at the hospital level. At our institution, it is now recommended that TBE serology be performed in all cases of undocumented meningitis or meningoencephalitis.~The infectious diseases team at our hospital simply advises the clinicians responsible for patient care to perform this test."
214885750|NCT07184879|DEVICE|Conventional Dental Syringe|Palatal infiltration anesthesia using a conventional dental syringe with a 27G needle. A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was administered manually over 15-20 seconds following aspiration.
214885751|NCT07184879|DEVICE|Spring-Activated Syringe (PCJ, PAROJECT™)|Palatal infiltration using a spring-activated push-button syringe (PAROJECT™). Two calibrated 0.2 mL doses of articaine 4% with epinephrine 1:100,000 were administered following aspiration.
214885752|NCT07184879|DEVICE|Needle-Free Jet Injector (NFI, Comfort-in™)|Palatal infiltration using a needle-free jet injector (Comfort-in™). A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was delivered in less than one second at 4-5 bar pressure. Aspiration not applicable.
215047601|NCT02462226|BEHAVIORAL|The-Optimal-Lymph-Flow|"The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI."
215047602|NCT02462226|BEHAVIORAL|Arm Precaution|"The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb."
215047603|NCT02394561|BIOLOGICAL|Secukinumab|Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
215047604|NCT00501644|DRUG|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
215047605|NCT00501644|DRUG|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
215047606|NCT00501644|DRUG|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
215047607|NCT05532969|OTHER|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
215047608|NCT02142088|DEVICE|GlySure Intravascular Continuous glucose monitoring sensor|Comparator device is an iSTAT device from Abbott Diagnostics
215047609|NCT00239603|DEVICE|OV-Watch|
215047610|NCT00872300|DRUG|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
215047611|NCT04577781|DRUG|GLPG3970|GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
215047612|NCT04577781|DRUG|Placebo|Placebo powder and solvent for oral solution to be reconstituted prior to use.
215047613|NCT00811460|DRUG|Placebo|sc for 4 days
215047614|NCT00811460|DRUG|taspoglutide|300micrograms/day sc for 2 days
215047615|NCT00811460|DRUG|taspoglutide|800 micrograms/day sc for 2 days
215047616|NCT00928967|DRUG|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
215047617|NCT00001561|DRUG|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
215047618|NCT00001561|DRUG|GM-CSF|
215047619|NCT05100134|DRUG|ceritinib|Patients receive ceritinib
214477258|NCT05956574|BEHAVIORAL|Standard Dietary plan|Receive a standard dietary plan
214885753|NCT07184879|DEVICE|Computer-Controlled Local Anesthetic Delivery (CCLAD, CALAJECT™)|Palatal infiltration using a computer-controlled local anesthetic delivery system (CALAJECT™, Program I) with a 30G, 16 mm needle. AutoFlow rate 0.006-0.009 mL/s, with automatic aspiration after 5 seconds and constant microprocessor-controlled pressure. A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was administered.
214885754|NCT07184879|DEVICE|Manual Pressure Syringe (MCJ, ASPIJECT™)|Palatal infiltration using a manual pressure-controlled syringe (ASPIJECT™) with a 30G, 16 mm needle. A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was administered manually over 15-20 seconds with aspiration.
214885755|NCT07185165|PROCEDURE|Computed Tomography|Undergo PET/CT
214885756|NCT07185165|DRUG|Fluorine F 18 Flotufolastat|Given IV
214885757|NCT07185165|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214885758|NCT07185165|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo PET/CT/ultrasound fusion biopsy
215047620|NCT01957865|DEVICE|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
215047621|NCT01957865|DEVICE|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
215047622|NCT01465009|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
215047623|NCT01465009|DRUG|Paracetamol|Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
215047624|NCT01465009|DRUG|Placebo|Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
215047625|NCT01730872|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
215047626|NCT01730872|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
215047627|NCT03155763|PROCEDURE|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
215047628|NCT02844985|OTHER|No Intervention|
215047629|NCT01044030|DRUG|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
215047630|NCT01044030|DRUG|Placebo|7.5 mL by mouth three times daily
215047631|NCT03051958|BEHAVIORAL|Internet mindfulness&exposure treatment|"See description under Arm."
215047632|NCT03051958|OTHER|Treatment as usual|Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
215047633|NCT01937520|DEVICE|acupuncture|One half of subjects will receive a standardized acupuncture regiment
215047634|NCT01937520|DEVICE|no acupuncture|placebo
215047635|NCT02756403|DRUG|Azithromycin|500 mg
214292992|NCT02618434|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
214292993|NCT04357392|DRUG|Prednisone|Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
214477259|NCT04675034|DRUG|MEDI7352|Participants will receive SC injection of MEDI7352 as stated in arm description.
214667913|NCT01793987|DEVICE|Coblation polypectomy|
214885759|NCT07185334|PROCEDURE|Subcutaneous mastectomy using a fluoropolymer-coated polyester mesh endoprosthesis with simultaneous prepectoral placement of textured implants.|For this group of patients, the planned volume of surgical intervention is: subcutaneous mastectomy using a polyester mesh endoprosthesis with a fluoropolymer coating and one-stage prepectoral installation of textured implants.
214885760|NCT07185334|PROCEDURE|Subcutaneous mastectomy with simultaneous prepectoral placement of textured implants.|This group of patients will undergo surgical intervention in deep subcutaneous mastectomy with simultaneous prepectoral placement of textured implants.
214885761|NCT07184801|DRUG|Dexmedetomidine|The patient will receive dexmedetomidine bolus dose of 1 µg /Kg over 10 minutes followed by 0.5 µg /kg/hr infusion titrated to desired sedation level (RSS 3). For patients who do not achieve an RSS of 3, we will give 1 mg bolus of midazolam. All additional boluses will be recorded. The patient will initially receive a bolus of 2 mL 0.9% normal saline intravenously for blinding purpose
214885762|NCT07184801|DRUG|Midazolam|The patient will receive midazolam bolus dose of 2 mg IV. They will receive an infusion of normal saline over 10 minutes for blinding purpose. Further need of sedation (as assessed by RSS) will be met by additional IV boluses of 1 mg midazolam. During the procedure they will receive continuous infusion of normal saline at a rate of 0.5 µg /Kg/Hr as placebo.
214885763|NCT07185594|DRUG|HRS-2129 Tablets|HRS-2129 tablets.
214885764|NCT07185594|DRUG|Blank Preparation.|Blank preparation.
214885765|NCT07185594|DRUG|Tramadol Hydrochloride SR Tablets|Tramadol Hydrochloride SR tablets.
215047636|NCT02756403|DRUG|Doxycycline|200 mg
215047637|NCT02756403|DRUG|Metronidazole|500 mg
215047638|NCT02756403|DRUG|Placebo|Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
215047639|NCT01644643|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
215047640|NCT01644643|DRUG|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
215047641|NCT01644643|DRUG|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
215047642|NCT00276432|DEVICE|iSTAT point of care analyzer|
214477260|NCT04675034|OTHER|Placebo|Participants will receive SC injection of placebo as stated in arm description.
214667914|NCT04755374|OTHER|Discharged ≤ 21 days|Discharged from palliative care unit in equal less than 21 days
214885766|NCT07186101|DRUG|LY4268989|Administered PO
214885767|NCT07186101|DRUG|Mirikizumab|Administered IV then SC
214885768|NCT07186101|DRUG|LY4268989 Placebo|Administered PO
214885769|NCT07186673|DEVICE|Stainless steel crown placement using Hall Technique|Preformed stainless steel crowns are placed on permanent first molars without local anesthesia, caries removal, or tooth preparation. Orthodontic separators are used as needed, and crowns are cemented with glass ionomer cement
214885770|NCT07186673|DEVICE|Stainless steel crown placement using conventional method|Preformed stainless steel crowns are placed after administering local anesthesia and performing standard tooth preparation, including occlusal and proximal reduction. Crowns are cemented with glass ionomer cement.
214477261|NCT04975607|BEHAVIORAL|Music Therapy|The three live music therapy sessions will be provided after lung transplant. All three music therapy sessions will employ a variety of data-based interventions to address pain, anxiety, and improve relaxation. Music therapy interventions may include patient preferred live music, active music listening, singing or other active music-making, and guided breathing and relaxation.
214667915|NCT04755374|OTHER|Prolonged discharge|Discharged from palliative care unit in longer than 21 days
214885771|NCT07187284|COMBINATION_PRODUCT|EDN combined with TACE/HAIC and Immuno-Targeted Therapy|"Experimental Intervention (Treatment Group):~This arm evaluates a novel combination strategy. Participants will undergo a single session of Endovascular Denervation (EDN) in conjunction with standard care. The complete intervention includes:~Endovascular Denervation (EDN): A one-time, catheter-based percutaneous procedure for the ablation of peri-arterial sympathetic nerves surrounding the common hepatic artery and/or proper hepatic artery. The procedure utilizes a multi-electrode radiofrequency ablation system (e.g., Netrod®). Ablation parameters are set to 60°C for 120 seconds per site, with a minimum of 20 ablations performed to ensure adequate denervation.~On-demand Transarterial Intervention: Following EDN, participants will receive either Transarterial Chemoembolization (TACE) or Hepatic Arterial Infusion Chemotherapy (HAIC), as determined by the treating investigator based on individual patient anatomy and tumor characteristics."
214885772|NCT07187284|COMBINATION_PRODUCT|TACE/HAIC plus Immuno-Targeted Therapy|This is the active comparator intervention representing the current standard-of-care regimen for the study population. Participants randomized to the control group will receive a combination of locoregional and systemic therapy, specifically excluding the experimental Endovascular Denervation (EDN) procedure.
214885773|NCT07187167|DRUG|Lenalidomide|The combination therapy period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. Combined with Dexamethasone: 40mg, orally, D1, 8, 15, 22, every 28 days per cycle. The single-agent maintenance period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. The total treatment duration is 24 cycles or until disease progression, death, or the occurrence of intolerable toxicity.
215047643|NCT03489044|DRUG|Levetiracetam|To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
215047644|NCT03489044|DRUG|Placebo Oral Tablet|To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
214477262|NCT03494959|DRUG|Pentaglobin|Antimicrobial treatment active against the multidrug-resistant strain should be started in case of neutropenic fever (oral temperature ≥38.3°C or temperature ≥38.0°C sustained over a one-hour period). Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days. Empirical treatment should be subsequently streamlined according to microbiological results (both positive and negative). Pentaglobin should be started within 12h from the onset of fever, regardless of the presence of hemodynamic stability.
214477263|NCT06862167|PROCEDURE|Desarda's technique|Patients will undergo Desarda's technique.
214667916|NCT02755402|DEVICE|Xpert HCV Viral load|HCV viral load testing
214667917|NCT02755402|DEVICE|Transient elastography|Evaluation of liver fibrosis
214667918|NCT05574140|DIAGNOSTIC_TEST|Cardiac MRI|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
215047645|NCT00985647|DRUG|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
215047646|NCT01891981|DRUG|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
214885774|NCT07187167|DRUG|Dexamethasone|The combination therapy period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. Combined with Dexamethasone: 40mg, orally, D1, 8, 15, 22, every 28 days per cycle. The single-agent maintenance period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. The total treatment duration is 24 cycles or until disease progression, death, or the occurrence of intolerable toxicity.
214885775|NCT07186452|DRUG|HS-20093|All participants will receive intravenous infusion of HS-20093 at a dose of 8 mg/kg every 3 weeks (Q3W), with each treatment cycle lasting 21 days.
214885776|NCT07186452|DRUG|Itraconazole|Participants will then take itraconazole capsules orally at 200 mg per dose during C2D17-C3D21
214477264|NCT06862167|PROCEDURE|Lichtenstein's technique|Patients will undergo Lichtenstein's technique.
214667919|NCT01543321|DRUG|Tetrabenazine|"Treatment with tetrabenazine consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
214667920|NCT01543321|DRUG|Placebo|"Treatment with placebo consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
214885777|NCT07187141|DRUG|Protollin|For the 0.1, 0.5, and 1.0 mg dose groups, Protollin (450 μL per vial) in an aqueous buffer will be administered in two, 0.1 μL sprays, one per nostril. For the 1.5 mg dose group, Protollin (450 muL per vial) in an aqueous buffer will be administered in three, 0.1 μL sprays, two in one nostril and one in the other nostril.
214885778|NCT07186426|DRUG|HSK21542|Patients administrated with HSK21542
214885779|NCT07186426|DRUG|Placebo|Patients administrated with placebo
214885780|NCT07186426|DRUG|morphine|Patients administrated with morphine
214885781|NCT07185009|DRUG|Duvakitug|Pharmaceutical form: Injection solution Route of administration: SC injection
214885782|NCT07185009|DRUG|Placebo|Pharmaceutical form:Injection solution-Route of administration:SC injection
214885783|NCT07185477|BIOLOGICAL|QLS32015|QLS32015 is a GPRC5D × CD3 bispecific antibody.
215047647|NCT02471313|DRUG|[18F] FMISO|\[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.
215047648|NCT04865666|DEVICE|movr mHealth App|The exercises prescribed through the movr app were accompanied with videos, images, and detailed instructions on how to complete them. These exercises consisted of basic movement and mobility patterns and are designed to promote functional movement. Participants were instructed to complete a total of four 'Minis' and two workout 'Builder' sessions per week. Workout Builders are designed to be longer exercise sessions tailored to the user's desired exercise time (15, 30, 45 or 60 min), equipment available (TRX Band, kettlebell, chin-up bar, dumbbells, foam roller, or none), target body region (lower, upper, or whole body), and specific exercise goal ('get sweaty,' 'build strength,' or 'develop mobility'). Version 3.6 of the movr app was used at the start of data collection and was updated to Version 4.1 over the course of the trial. No significant changes were made to the app or to the exercise prescription functionality throughout those updates.
215047649|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day
215047650|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
215047651|NCT00114127|DRUG|Placebo|60mg placebo 1x per day
215047652|NCT03971162|DRUG|3+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
215047653|NCT03971162|DRUG|6+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
215047654|NCT05968248|PROCEDURE|MLR-DBS|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices~(1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
215047655|NCT05968248|PROCEDURE|Conventional rehabilitation group|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
215047656|NCT00699413|DRUG|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
215047657|NCT00699413|DRUG|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
214477265|NCT06781164|DEVICE|telemedicine|Recording of the ear of each patient with an ear problem
214885784|NCT07185724|DRUG|Ketorolac 30 mg IV|We will be evaluating the effect of post-oocyte retrieval ketorolac administration on clinical outcomes in fresh embryo transfer cycles.
215047658|NCT06090955|DRUG|Dexmedetomidine Injection [Precedex]|The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
215047659|NCT06090955|DRUG|Lidocaine IV|The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
215047660|NCT06090955|DRUG|normal saline|The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
215047661|NCT00881894|DRUG|Rotigotine transdermal patch|Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours
215047662|NCT01943786|DRUG|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
215047663|NCT00421148|DRUG|Sugammadex 0.5 mg/kg|IV infusion
214885785|NCT07186608|DIETARY_SUPPLEMENT|Dietary fiber intervention|Ten patients with short bowel syndrome in clinical practice were subjected to dietary fiber intervention. Blood and fecal samples were collected before and after the dietary fiber intervention, and nutritional and intestinal barrier-related indicators were also collected to observe the improvement effect of dietary fiber on these patients.
214477266|NCT06661421|DEVICE|Dry Needling|This intervention combines Dry Needling Therapy (DNT) with routine physical therapy for children with spastic cerebral palsy. The experimental group will receive DNT alongside physical therapy, while the control group will undergo only physical therapy. Routine Physical Therapy includes a warm-up, stretching, and strengthening exercises like hamstring stretches and squats, adjusted over a month with increasing intensity. Dry Needling targets the gastrocnemius muscle using a fast-in, fast-out technique with sterile needles, applied weekly for 10 weeks. This combined approach aims to reduce spasticity, improve mobility, and enhance range of motion, distinguishing it from standard therapies.
214477267|NCT06661421|OTHER|Cerebral Palsy conventional Treatment|Sessions will include a 5-minute warm-up, stretching, and strengthening exercises. Hamstring stretches will be done with the child supine, one leg flat, and the opposite hip flexed to 90°. Active knee extension will be held for 5 seconds, followed by a 40-second assisted stretch, repeated five times. If a short psoas is detected, a prone psoas stretch will involve assisted hip extension for 5 seconds, followed by a 40-second hold, repeated five times. Strengthening exercises like squats, heel rises, and step-ups with a loaded backpack will target the lower extremities. The program will last one month, with three sessions per week, focusing on hamstring stretches and progressive resistance exercises.
214885786|NCT07185880|DRUG|MT-125|This is an investigational new drug under IND 170975.
214885787|NCT07185360|OTHER|blood sampling for volunteers|A 38.5 ml blood sample will be taken to test for research taken to test for research
214885788|NCT07185360|OTHER|blood sampling for diabetics patients with F3/F4 fibrosis|32.5 ml will be sampled at inclusion, at one year visit and two year visit
214885789|NCT07185360|OTHER|blood sampling for patients with liver disease|A blood sample of 35.5 mL maximum will be taken for research purposes at the inclusion visit, M1 visit and M3 visit.
214885790|NCT07187258|DRUG|tranexamic acid (1 g diluted in 100 mL of 0.9% saline|The pharmacist also prepared indistinguishable infusion bags containing tranexamic acid (1 g diluted in 100 mL of 0.9% saline) . The infusion was administered intravenously over 10-15 minutes immediately after induction of anesthesia and before skin incision, at a maximum rate of 100 mg per minute
214885791|NCT07187258|DRUG|placebo (100 mL of 0.9% saline).|The pharmacist also prepared indistinguishable infusion bags containing placebo (100 mL of 0.9% saline). The infusion was administered intravenously over 10-15 minutes immediately after induction of anesthesia and before skin incision, at a maximum rate of 100 mg per minute
214885792|NCT07184762|PROCEDURE|open reduction and internal fixation with bone plate|mandibular fracture were reduced and fixed with bone plates.
214885793|NCT07184762|PROCEDURE|z-plates.|mandibular fracture were reduced and fixed with z-plate miniplates.
214885794|NCT07184762|PROCEDURE|conventional miniplates.|mandibular fracture were reduced and fixed with conventional two miniplates.
215047664|NCT00421148|DRUG|Sugammadex 1 mg/kg|IV infusion
215047665|NCT00421148|DRUG|Sugammadex 2 mg/kg|IV infusion
215047666|NCT00421148|DRUG|Sugammadex 4 mg/kg|IV infusion
215047667|NCT00421148|DRUG|Placebo|IV infusion
215047668|NCT00421148|DRUG|Rocuronium bromide|IV infusion
215047669|NCT01196013|DRUG|Clofarabine|Intravenous, 30 mg/m2, 52 mg/m2
215047670|NCT04991220|PROCEDURE|Preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
215047671|NCT03576261|OTHER|Preoperative colloid fluid bolus (Gelofusine)|Preoperative colloid fluid bolus
215047672|NCT03576261|DIAGNOSTIC_TEST|Preoperative transthoracic echocardiography|Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
214885795|NCT07185373|DRUG|Teniposide|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
214885796|NCT07185373|DRUG|Orelabrutinib|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
214885797|NCT07185373|DRUG|MTX|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
215047673|NCT03222674|BIOLOGICAL|Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells|Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
215047674|NCT00844103|DRUG|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
215047675|NCT00844103|DRUG|Placebo|10ml oral solution administered once a day over 10 days.
215047676|NCT01769053|OTHER|Variable Ventilation|
215047677|NCT04005586|DEVICE|Light Delivery Device (LDD)|Study eye will undergo Light delivery Device treatments
214477268|NCT06615037|OTHER|Assess Hip joint strength by Biodex isokinetic dynamometer (System 4 Pro)|"Assessment of the strength of hip flexors and extensors muscles:~* Participants will be in a supine-lying position, the highest reliability (ICC = 0.90) according to the results of the meta-analysis (Contreras et al., 2021).~* Seat orientation 0°.~* Dynamometer tilt 0° and orientation 0°.~* The axis of the dynamometer on the greater trochanter of the femur.~* The test parameters included a 0-90 degree range of motion.~* During the isokinetic testing movement, the hip was first flexed from a neutral (starting) position to 90° (for hip flexion) and then the direction of the movement was reversed (for hip extension)~* Angular speed at 120°/s which shows excellent reliability (ICC = 95%) with concentric contraction mode (Contreras et al., 2021) ."
214477269|NCT06400602|BEHAVIORAL|Usual ED Care plus Health Coaching|Patients will participate in eight remotely-delivered sessions of health coaching after ED discharge. Patients will receive usual care during their ED visit.
215047678|NCT00216918|DRUG|Atomoxetine Hydrochloride|
215047679|NCT02109289|DRUG|etanercept|Etanercept is a tumor necrosis factor antagonist
215047680|NCT01343836|OTHER|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
215047681|NCT01343836|OTHER|Saline|Intratendinous saline injection with eccentric exercises
215047682|NCT00977639|PROCEDURE|Pathwork TOO test|
215047683|NCT00469833|DRUG|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
215047684|NCT01799343|OTHER|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
215047685|NCT04123301|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: first, continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
215047686|NCT04123301|DEVICE|Sham Theta Burst Stimulation (TBS)|The sham-TBS sessions will be performed using an identical coil that produces SHAM Stimulation: first, sham continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by sham intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
215047687|NCT01253369|DRUG|Pazopanib|
215047688|NCT04268069|DRUG|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.
215047689|NCT04268069|DRUG|Placebo Ophthalmic Solution|Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
215047690|NCT03308682|DRUG|177Lu-DOTA-EB-TATE|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
215047691|NCT02965638|OTHER|Oxygen|The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
215047692|NCT03289533|DRUG|Avelumab (MSB0010718C)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
214477270|NCT06400602|BEHAVIORAL|Usual ED Care plus Education|Patients will participate in eight remotely-delivered sessions of education after ED discharge. Patients will receive usual care during their ED visit.
215047693|NCT03289533|DRUG|Axitinib (AG-013736)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
215047694|NCT05165095|DEVICE|Pacemaker implantation|De novo implantation, device upgrade to dual chamber or device replacement
214292994|NCT04588402|BIOLOGICAL|The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals.|"Women will be approached one time only, when they will attend the gynecology out-patients department for various reasons. After signing the informed consent, the participants will fill in a risk factor questionnaire to study the socio-demographic information, sexual history and HPV vaccination history and the determinent of HPV infection. The questionnaire will be administered by a trained social worker or nurse.~A gynecologist will collect cervical cells from the participant's cervix during a gynecological examination. The cervical specimen will be examined for presence of specific HPV genotypes and Chlamydia infection."
214292995|NCT03454919|DRUG|Palbociclib|"Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance."
214885798|NCT07185373|DRUG|Rituximab (R)|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
214885799|NCT07185373|DRUG|Dexamethasone|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
214885800|NCT07186686|OTHER|Participants will receive the AMENUCED program including medical care, nutritional counseling, and structured sessions focused on behavioral change and diabetes education.|"Medical Attention: Medical management will be provided by a physician who will assess the participant at the beginning and end of the intervention. The physician will be responsible for pharmacological treatment and follow-up throughout the process.~Nutritional Attention: Nutritional consultations will be provided by a registered nutritionist over a three-month period, with sessions held weekly. During each consultation, the participant will receive an individualized nutrition plan based on scientific evidence and dietary recommendations. The plan will be tailored to the participant's specific needs, including metabolic control and a hypocaloric intake (ranging from 1200 to 1800 kcal), with the goal of achieving a 5-10% reduction in body weight.~Behavioral Lifestyle Change Program: The behavior modification program used in the Action for Health in Diabetes Program (Look AHEAD) study will be adapted to include diabetes self-management activities through a structured manual."
214885801|NCT07184853|DRUG|Ruxolitinib (JAKAVI®)|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (approximately every 12 hours), with or without food. Dose modifications are allowed according to protocol-defined safety and efficacy criteria. Ruxolitinib may be continued for up to 24 weeks, with tapering guided by patient response and GVHD status.
215047695|NCT04193735|DIAGNOSTIC_TEST|MRI scans after a liquid meal|Participants will be scanned fasted, then receive a liquid meal, then be scanned every half hour, seven times
215047696|NCT06450743|DIAGNOSTIC_TEST|Lymphocyte Immunophenotyping Test|Absolute enumeration of peripheral blood lymphocyte subpopulations
215047697|NCT04095702|OTHER|Weighted Pacifier|The weighted pacifier is a standard of care pacifier with a weighted, breathable star attachment to help keep the pacifier from popping out of the neonates mouth during non-nutritive suck.
215047698|NCT04095702|OTHER|Non-Weighted Pacifier|The non-weighted pacifier is a standard of care pacifier that a neonate would receive if they were not part of this study.
215047699|NCT04912544|DEVICE|Noninvasive Ventilation Mask Microphone|Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study
215047700|NCT04442568|OTHER|ERAS|early mobilisation, early oral intake, early discharge
215047701|NCT00891696|DRUG|Rapamycin|Single 16-mg oral dose
214292996|NCT02604524|DEVICE|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
214667921|NCT01397019|DRUG|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
214667922|NCT02594592|OTHER|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
214667923|NCT02234037|DRUG|Decitabine|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
215047702|NCT00891696|OTHER|Amino acid supplementation|Nutritional drink containing essential amino acids
214292997|NCT02604524|OTHER|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
215047703|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
215047704|NCT00891696|DRUG|Sodium nitroprusside|Variable rate for 3 hours
215047705|NCT00891696|DEVICE|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
215047706|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
215047707|NCT02812745|DEVICE|recording of cardiac output|
215047708|NCT02812745|DEVICE|other parameters|BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
215047709|NCT06342765|DEVICE|Pedicle fixation surgery|Pedicle fixation surgery indicates a surgical approach in the thoracic spine down to sacral spine to either support interbody fusion (fusion of the discal space between two vertebrae) , or to correct spinal deformity.
215047710|NCT00561522|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
214885802|NCT07184853|DRUG|Etanercept (Enbrel)|Etanercept will be administered as a subcutaneous injection at a dose of 25 mg twice weekly for 4 weeks (total 8 doses). For patients with partial response at day 28, treatment may be extended once weekly for an additional 2-4 weeks at the investigator's discretion.
214885803|NCT07187024|BEHAVIORAL|mCare PTOA Intervention|The mCare PTOA intervention includes five evidence-based modules that focus on 1) basic joint health following injury, 2) self-management strategies, 3) weight management, 4) physical activity, and 5) occupational management. These educational modules will serve as the primary intervention in this study.
214885804|NCT07185854|DRUG|Artificial tears|Topical artificial tears were administered as standard therapy for moderate dry eye disease.
215047711|NCT00561522|OTHER|No other preventive treatment|No other preventive treatment
215047712|NCT01658085|DEVICE|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
215047713|NCT01658085|DEVICE|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
215047714|NCT01668160|PROCEDURE|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
215047715|NCT06495073|OTHER|PROMIS-10 and TOPICS-SF|"There will be no intervention. The participants will be asked to fill in questionnaires at two time points: the first time will be after informed consent when they are at the hospital for diagnostic evaluation of the TIA or ischemic stroke, and the second time will be 4 weeks later, with a window of 2 weeks (allowing a range of 2-6 weeks). The second time point is chosen because the investigators suspect that by then, around 50% will be in the improved group. At the first time point, the participants will be asked to fill in the PROMIS-10 and element D and E of the TOPICS-SF - which are the elements used to determine the functional limitations and the psychological wellbeing. At the second time point, the participants will be asked to answer the same questions, as well as three additional anchor questions."
214885805|NCT07185854|OTHER|Traditional Chinese Medicine Acupuncture|Acupuncture therapy performed by a certified specialist using sterile disposable needles at predefined local and systemic acupoints (BL2, ST1, GB1, SJ23, Ex-HN5, LI4, ST36, SP6, LIV3, GB37, GB40, Ex-HN3, Du23, BL64). Sessions were delivered twice weekly for a total of 10 sessions, each lasting 20 minutes. Deqi sensation was obtained by manual stimulation. No additional systemic or topical treatments were provided to participants in this arm.
214885806|NCT07184775|DEVICE|Continuous glucose monitor|Continuous glucose monitors are sensors that detect interstitial blood glucose measurements and relay values from their sensor to a receiver (typically a cell phone) to document values every 5 minutes.
214885807|NCT07184775|DEVICE|Glucometer|Glucometer measurement involves a patient performing a finger stick with a lancet to draw blood. They then apply blood to a test strip which is analyzed by a glucometer. The glucose measurement provided by the glucometer is then recorded by the patient in a glucose log.
214885808|NCT07185490|BIOLOGICAL|CT103d|CT103d is a personalized, BCMA-targeted, genetically modified autologous T-cell immunotherapy product.
214885809|NCT07187180|DEVICE|holmium laser|Prostate enucleation will holmium laser (control)
214885810|NCT07187180|DEVICE|pulsed thulium laser|experimental group - pulsed thulium laser prostate enucleation
214885811|NCT07187050|OTHER|Template-Based LLM Assistant|This study uses CocktailAI, a template-based LLM assistant co-developed by the Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, and Fitting Cloud Inc. (Kyoto, Japan). It is designed to extract relevant information from EHRs using LLMs and embed the extracted content into predefined templates. In this trial, the inputs are six simulated patient records (no real patient data). Text generation uses Gemini-2.0-flash-lite. Templates for discharge summaries and discharge referrals are pre-defined by a team member.
214885812|NCT07187050|OTHER|Manual Writing|The same document templates are provided; however, all LLM instruction prompts are removed in advance. Clinicians manually write the documents, following the template structure, for each of the six simulated cases.
214885813|NCT07187011|DRUG|PT150|Glucorticoid antagonist 900 mg
214885814|NCT07187011|DRUG|Placebo|900 mg
214885815|NCT07187128|DEVICE|drug coating balloon angioplasty|The subjects underwent drug coating balloon angioplasty to treat femoropopliteal artery stenosis or occlusive lesions
214885816|NCT07184658|PROCEDURE|Ultrasound-guided peritendinous saline injection|Under ultrasound guidance, 1 mL of sterile normal saline will be injected peritendinously at the tendon repair site at 7, 14, and 21 days after surgery to reduce adhesion formation and preserve tendon healing.
214885817|NCT07184606|DRUG|¼ of the full (target) dose (solution, 5 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive ¼ of the full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive ¼ of the full (target) dose of the study drug (parenteral administration)."
214885818|NCT07184606|DRUG|½ of the full (target) dose (solution, 10 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive ½ of the full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive ½ of the full (target) dose of the study drug (parenteral administration)."
215047716|NCT04016714|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
215047717|NCT04016714|DRUG|Prevenar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
214885819|NCT07184606|DRUG|full dose (solution, 20 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive full (target) dose of the study drug (parenteral administration)."
214885820|NCT07184606|DRUG|1 ½ of the full (target) dose (solution, 30 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive 1 ½ of the full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive 1 ½ of the full (target) dose of the study drug (parenteral administration)."
214885821|NCT07184606|DRUG|2 full doses (solution, 40 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive 2 full (target) doses of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive 2 full (target) dose of the study drug (parenteral administration)."
214885822|NCT07184606|DRUG|course administration of the selected dose|10 healthy volunteers will receive course administration of the selected dose, and 1 healthy volunteer will receive placebo.
214885823|NCT07184606|OTHER|Placebo|1 healthy volunteer from the 1st cohort of each group will receive placebo (parenteral administration)
214885824|NCT07185672|RADIATION|Peptide Receptor Radionuclide Therapy with Lu177 DOTATATE|Radionuclide Therapy
214885825|NCT07185672|DRUG|Capecitabine plus temozolamide|Chemotherapy
214885826|NCT07186062|DRUG|Levosimendan|"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~•Levosimendan: loading dose 6-12 microgram/ kg then continuous infusion of 0.05-0.2 µg/kg/min."
214885827|NCT07186062|DRUG|Dobutamine|"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~• Dobutamine: continuous infusion starting at 2.5 µg/kg/min, titrated up to 20 µg/kg/min as needed."
214885828|NCT07186062|DRUG|Milrinone|"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~• Milrinone: 50 mcg/kg loading dose, then 0.375-0.75 mcg/kg/min IV according to patient response."
215047718|NCT04016714|DRUG|Vaxelis™|Intramuscular 0.5 mL single dose
215047719|NCT04016714|DRUG|M-M-R®II|Subcutaneous 0.5 mL single dose
215047720|NCT04016714|DRUG|VARIVAX™|Subcutaneous 0.5 mL single dose
215047721|NCT04138511|DEVICE|ECOFISIO|The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
214885829|NCT07185061|DEVICE|Acoustic Stimulation|Using hearing loss detection and tinnitus matching data as input parameters, the system automatically generates personalized sound stimulation audio signals through composite signal amplitude, frequency, phase control processing, and notch filtering. The audio tone is fine-tuned based on the patient's initial treatment response to identify their most comfortable range.
214885830|NCT07187037|DRUG|Methylprednisolone (MP)|Methylprednisolone 1 mg/kg IV (diluted to 5 mL with saline) will be administered at induction of anesthesia. Neuromuscular blockade will be achieved with rocuronium. Reversal will be performed with sugammadex 2 mg/kg IV at the reappearance of the second twitch in train of four monitoring.
214885831|NCT07187037|DRUG|Dexamethasone|Dexamethasone 0.2 mg/kg IV (diluted to 5 mL with saline) will be administered at induction of anesthesia. Neuromuscular blockade will be achieved with rocuronium. Reversal will be performed with sugammadex 2 mg/kg IV at the reappearance of second twitch in train of four monitoring.
214885832|NCT07184892|BEHAVIORAL|Daily life actual swallowing movement observation therapy|This group adds the therapy of observing actual swallowing movements in daily life, that is, in real daily life, observing the real eating and swallowing movements of relatives. They select meals that the patient likes or those that are complete in color, aroma and taste and look appetizing. The swallowing movements should be as slow and exaggerated as possible, and a look of savoring and enjoying the food should be shown, so that the patient can better observe the movements of the mouth and larynx during swallowing. Then, the patient imitates the swallowing movements.
214885833|NCT07184892|BEHAVIORAL|Video swallowing action observation therapy|Video swallowing action observation therapy
214885834|NCT07184892|BEHAVIORAL|Traditional swallowing training|Traditional swallowing training
214885835|NCT07186335|OTHER|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients
214885836|NCT07186387|DRUG|LW402|LW402 tablets
214885837|NCT07186387|DRUG|LW402 placebo|LW402 placebo tablets
214885838|NCT07185321|DRUG|Mosliciguat|Dose level for inhalation
214885839|NCT07185321|DRUG|14C mosliciguat|Dose level
214885840|NCT07185321|DEVICE|Dry Powder Inhaler|Dry powder inhaler for mosliciguat
214885841|NCT07185958|DIAGNOSTIC_TEST|Dual-energy CT (DECT)|Additional DECT scan performed for tumor and OAR delineation.
214885842|NCT07185958|DRUG|Iodine-based contrast agent|Administered intravenously with DECT for enhanced imaging.
214885843|NCT07185958|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Additional MRI scan performed for tumor and OAR delineation.
214885844|NCT07185958|DRUG|Gadolinium-based contrast agent|Administered intravenously with MRI for enhanced imaging.
214885845|NCT07185737|BEHAVIORAL|Adapted RUBI-Telehealth|The Adapted RUBI Parent Training is a culturally tailored version of the Research Units in Behavioral Intervention (RUBI) program, designed for Spanish-speaking caregivers of young autistic children. The intervention consists of 8 weekly sessions delivered virtually in Spanish by trained behavioral therapists. Each session incorporates behavioral skills training methods (instruction, modeling, role-play, and feedback). Caregivers use a Spanish-language RUBI handbook to complete weekly home practice activities and receive feedback during sessions. The program focuses on helping caregivers understand the functions of challenging behavior and apply evidence-based strategies to reduce these behaviors and promote positive child outcomes.
215047722|NCT04029207|PROCEDURE|Cesarean section|Abdominal, operative delivery of the fetus
215047723|NCT06373666|DEVICE|Spatz4 Adjustable Balloon System|Implantation of Spatz4 Adjustable Balloon system for weight loss treatment for Overweight and Obese patients and Adjustment of the balloon volume at week 16
215047724|NCT05836272|DRUG|Norepinephrine Bitartrate|"The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.~Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion."
215047725|NCT05836272|OTHER|Placebo|For the control group placebo: 250 ml of 5% glucose will be prepared and will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour.
214885846|NCT07187063|DIAGNOSTIC_TEST|UroAmp Test (Convergent Genomics, Inc.)|Non-invasive genomic urine test that can reliably detect, monitor, and predict the risk of urothelial cancer or its recurrence, potentially before signs and symptoms develop or become detectable by historical standards of care.
215047726|NCT04846335|DRUG|Doxycycline Hcl|tablets of DOXY hydrocloride (Bassado)
215047727|NCT04846335|DRUG|Placebo|tablets of placebo
215047728|NCT04078204|DRUG|Butylphthalide Soft Capsules|The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
215047729|NCT04078204|DRUG|placebo Soft Capsules|The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
214885847|NCT07187076|BEHAVIORAL|body awareness|"Body Awareness Therapy (BAT) is a somatic-based, movement-centered therapeutic approach that aims to improve individuals' physical, emotional, and psychological well-being by enhancing conscious awareness of bodily sensations, posture, breathing, movement, and internal states.~Originating from Scandinavian physiotherapy models - particularly the work of Berit Heir Bunkan, Roxendal, and Dropsy - BAT integrates principles from:~Proprioceptive neuromuscular retraining~Mindfulness-based movement~Sensorimotor integration~Psychomotor physiotherapy~BAT is not simply a set of physical exercises, but a neuropsychophysical method designed to promote:~Postural control and alignment~Somatic grounding and bodily coherence~Emotional regulation through movement~Enhanced interoception (awareness of internal bodily states)"
215057343|NCT06147128|PROCEDURE|Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model|Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system
214885848|NCT07186283|DRUG|CBD soft-gel capsules 600 mg|600 mg
215057344|NCT01503684|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
214667924|NCT02234037|BEHAVIORAL|Exercise|Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise \> 10 minutes of muscle strengthening, \> 10 minutes of aerobic exercise (treadmill walking or cycling), \> 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
214667925|NCT05637450|DIETARY_SUPPLEMENT|Blue Whiting Protein Hydrolysate|25g Blue Whiting Protein Hydrolysates mixed with an everyday food / drink product daily for 6 weeks
214667926|NCT05637450|DIETARY_SUPPLEMENT|Placebo|Isocalorific maltodextrin citrus flavoured powder mixed with an everyday food / drink product for 6 weeks
214667927|NCT03560076|OTHER|SBIRT Training and Implementation Strategies|A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
214667928|NCT01472276|BEHAVIORAL|Web-based program|Provided with the web-based program
214667929|NCT00903084|DRUG|Tenofovir Disoproxil Fumarate|300-mg tablet
214885849|NCT07186283|DRUG|CBD soft-gel capsules 900 mg|900 mg
214885850|NCT07186283|DRUG|Epidyolex|25 mg/kg
214885851|NCT07185867|BEHAVIORAL|Pandora-1 app with high levels of personalization, interaction, monitoring and feedback|Pandora-1 is a behavioral, self-guided and transdiagnostic intervention delivered via an app. It includes predictive risk algorithms, decision support systems (DSS), monitoring and feedback to implement personalized prevention plans (PPP) for anxiety and depression. The intervention has a biopsychosocial approach and offers 4 interactive modules: move more, sleep better, improve relationships and emotional well-being. Participants will receive personalized feedback at baseline, 1, 6 and 12 months, including their levels of depressive and anxiety symptoms over the past two weeks, their predicted risk of developing these disorders in the next year, and related modifiable risk factors (e.g. sedentary lifestyle, insomnia, low social support, poor mental quality of life). Based on this, the app offers suggestions (via DSS) and guides users to relevant content (PPP). Participants follow recommendations of choice, the app tracks these actions and provides feedback at baseline, 1 and 6 months.
215047730|NCT02348580|BEHAVIORAL|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
215047731|NCT01908010|DRUG|ABT-354|ABT-354 Low Dose
215047732|NCT01908010|DRUG|ABT-354|ABT-354 High Dose
215047733|NCT01908010|DRUG|Placebo|Placebo
215047734|NCT00002548|BIOLOGICAL|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)"
215047735|NCT00002548|DRUG|carmustine|20 mg/m2 I.V. day 1 q 35 days
214292998|NCT03893136|BIOLOGICAL|Tocilizumab|The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
215047736|NCT00002548|DRUG|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
214292999|NCT03893136|DRUG|Leflunomide|The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
214293000|NCT03034421|BEHAVIORAL|Bed rest|Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
214293001|NCT05217407|OTHER|Genomic sequence|Genomic sequence
214293002|NCT05667922|DRUG|Tacrolimus|0.05-0.10mg/kg/d, twice orally, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it is effective.
214293003|NCT02106728|BEHAVIORAL|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
214293004|NCT02106728|BEHAVIORAL|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
214293005|NCT03675490|BEHAVIORAL|ABLE - exercise with interactive technology|Multicomponent exercise with interactive technology - consists of wearable sensors and a screen displaying interaction. When the person does the exercises it produces an arts-based response on the screen (e.g., digital painting).,
214293006|NCT04644627|DRUG|Gentamicin Sulfate|Topical gentamicin ointment on wounds once daily for 6 weeks
214293007|NCT05488431|DRUG|Bempedoic acid|Bempedoic Acid is an oral first-in-class small molecular adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor which lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Inhibition of ACL by bempedoyl-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of LDL receptors and concomitant suppression of hepatic fatty acid biosynthesis. BA has been studied in \>4300 individuals and is currently being studied in \>14,000 individuals in CLEAR Outcomes (NCT02993406).
214293008|NCT05488431|OTHER|Placebo|Placebo
214293009|NCT01847222|BIOLOGICAL|SANGUINATE™|PEG-bHb-CO
214293010|NCT01847222|DRUG|Normal Saline Solution|Placebo
214293011|NCT02023398|DEVICE|BTL-9000 HFT|Deep tissue heating with the BTL-9000 HFT for HFT group
214293012|NCT02023398|DEVICE|sham BTL-9000 HFT|sham deep tissue heating with BTL-9000 HFT in Placebo group
214293013|NCT05780112|OTHER|breathing exercise|"* Place one hand on your chest and the other on your stomach.~* Slowly take a deep breath through the nose.~* During inhalation, your hand on your stomach should rise upwards as the air fills the lungs. If it is under your hand on the chest, there should not be much movement.~* Hold your breath and stretch your muscles in a second or two.~* Take air through your nose with your mouth closed and exhale slowly through your mouth by pursing your lips like a whistle.~* Set the time you use when exhaling air to be twice the time you use when exhaling.~* As you exhale, focus on the inward movement of your abdominal hand."
214293014|NCT06571799|OTHER|BENEV Exosome Regenerative Complex+|BENEV Exosome Regenerative Complex+® is an intensive dual-action complex formulated to absorb quickly into the skin and scalp delivering the concentrated power of stem cell derived lyophilized exosomes, potent growth factors, peptides, coenzymes, minerals, amino acids and vitamins.
214293015|NCT02776423|PROCEDURE|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
214885852|NCT07185867|OTHER|Pandora-2 app with low levels of personalization, interaction, monitoring and feedback|Pandora-2 is a psychoeducational self-guided and transdiagnostic intervention delivered via an app. This intervention also has a biopsychosocial orientation and includes a set of psychoeducational brochures for the prevention of anxiety and depression that can be used at any time. These read-only brochures will have contents on the same 4 intervention modules (move more, sleep better, improve relationships and emotional well-being). At baseline, 1 and 6, 12 months participants will also receive basic information about their level of depressive and anxiety symptoms over the past two weeks, their risk probability of depressive and anxiety episodes next year and some of their modifiable risk factors associated with such risk (e.g. sedentary lifestyle, insomnia, low social support and poor mental quality of life). However, in Pandora-2 intervention participants will have lower levels of interactive intervention components as suggestions from the DSS about PPP, monitoring and feedback.
214885853|NCT07185711|DIAGNOSTIC_TEST|Resonance Frequency Analysis (RFA)|Resonance frequency analysis performed with the Osstell™ device. SmartPeg was attached with composite resin to the occlusal surface of the tooth, and ISQ values were recorded in mesio-distal and bucco-lingual directions.
214885854|NCT07185711|DIAGNOSTIC_TEST|Bite Force Sensor|Assessment of maximum bite force using a bite force sensor. Measurements were performed on COD-associated teeth and contralateral healthy controls for comparison.
214885855|NCT07185984|DIAGNOSTIC_TEST|Sperm sellection|Small aliquots of 100 fresh human semen samples will be analysed using the SwimCount™ Harvester system, a CE-marked microfluidic technology patented by MCount and designed for routine clinical use.
214293016|NCT01564121|DRUG|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
214293017|NCT04517474|BEHAVIORAL|CANreduce|"CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying no to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised."
214293018|NCT04517474|BEHAVIORAL|psychological support|psychological support
214293019|NCT03606733|PROCEDURE|Custom suorachoroidal needle|Custom made Supra Choroidal Space needle
214293020|NCT03957707|PROCEDURE|stereotactic surgery plus thrombolysis|stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
215047737|NCT00002548|DRUG|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
215047738|NCT00002548|DRUG|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
215047739|NCT00002548|DRUG|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
215047740|NCT00002548|DRUG|prednisone|40 mg/m2 PO days 1-7 q 35 days
215047741|NCT00002548|DRUG|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
215047742|NCT00002548|PROCEDURE|allogeneic bone marrow transplantation|day 0
215047743|NCT00002548|PROCEDURE|autologous bone marrow transplantation|day 0
215047744|NCT00002548|PROCEDURE|peripheral blood stem cell transplantation|day 0
215047745|NCT00002548|RADIATION|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
214885856|NCT07185984|DIAGNOSTIC_TEST|DIAGNOSIS TOOL|"The diagnostic tool developed will be validated by analyzing small aliquots of 100 additional fresh semen samples processed with the integrated microfluidic system (SwimCount™ Harvester) and the CASA system with artificial intelligence. To evaluate the diagnostic efficiency of the tool, the results obtained from the semen quality analysis will be compared with those obtained from the analysis of these samples when processed using the reference technique, based on conventional methods employed by fertility specialists. Finally, to determine the effectiveness of the developed tool, the clinical results obtained from assisted reproduction treatment will be compared with the diagnosis predicted by the tool, with the aim of evaluating its predictive capacity.~Translated with DeepL.com (free version)"
214885857|NCT07186114|DRUG|MEBO Wound Ointment (MEBO)|MEBO® 0.25% Ointment (Gulf Pharmaceutical Industries) to be applied four times a day for two weeks
214885858|NCT07186114|DRUG|Tantum Verde® mouthwash|Tantum verde (EIPICO®) mouthwash. Patients were asked to swish it for at least five minutes, four times daily for two weeks.
214885859|NCT07186192|OTHER|Intervention Arm (Digital health intervention)|Patients and family caregivers that are randomized into the intervetnion arm (Digital health intervention) will receive a 90 day nurse-drive, digital health intervention.
215047746|NCT02128737|BEHAVIORAL|Sleep|
215047747|NCT02358993|DRUG|methenamine hippurate|A urinary antiseptic used for prevention of UTI
215047748|NCT02358993|DRUG|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
215047749|NCT04963023|OTHER|Physical examinations|BPCO physical examinations
215047750|NCT04963023|DIAGNOSTIC_TEST|blood test|blood test in order to study immunologic markers
214293021|NCT00399776|RADIATION|Bone Density Test|Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
215047751|NCT06361004|DEVICE|Deep Brain Stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (GPi, amGPi, pvGPi, Cm-Spv-Voi, Cm-Voi, NA-ALIC, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
215047752|NCT05895305|COMBINATION_PRODUCT|Paclitaxel-Coated Pulmonary Balloon Catheter|Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure
215047753|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nasal Aspirate Nylon Flocked swab
215047754|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nylon flocked swab Nasal Wash
215047755|NCT04133350|BEHAVIORAL|Active Patient Engagement|The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
215047756|NCT02246010|DIETARY_SUPPLEMENT|Lactose- free milk|Lactose- free milk
215047757|NCT05784181|DEVICE|bipolar transurethral resection and Laser enaculation by holmium: YAG laser|Laser enaculation by holmium: YAG laser
215047758|NCT04415554|DIAGNOSTIC_TEST|echocardiography|echocardiography exam of the infant
215047759|NCT03891888|PROCEDURE|Intramedullary Bone Graft|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
215047760|NCT04944576|DEVICE|Total Ankle Prosthesis, EasyMove®|Patients who will be implanted with a total ankle prosthesis, EasyMove.
214885860|NCT07186192|OTHER|Standard of Care Arm (Enhanced usual care)|Patients and family caregivers that are randomized into the Standard of Care Arm ( Enhanced usual care) will receive standard CAR-T print materials only.
214885861|NCT07186569|BEHAVIORAL|Digital Interactive Peer Support|Individually randomized participants receive digital interactive peer support.
214885862|NCT07186569|BEHAVIORAL|Face-to-Face Peer Support|Individually randomized participants receive face-to-face peer support.
214885863|NCT07186569|BEHAVIORAL|Standard Training (Control)|Standard Training (Usual Curriculum)-Participants receive usual curriculum-based training without structured peer support.
214885864|NCT07186764|OTHER|Questionnaires|questionnaires: WHOQOL-BREF (Quality of Life Study Questionnaire), FSFI (Female Sexual Function Index), FSDS-R (The Femala sexual distress scale-revised), Rosenberg scale (self-esteem assessment)
214885865|NCT07186764|OTHER|Semi-directed interview|Semi-directed interview on the treatment pathway and the impact of utero-vaginal aplasia on intimate and personal life
214885866|NCT07184840|DRUG|Intravenous Methylprednisolone (IVMP)|IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics
214885867|NCT07184840|DRUG|Complement protein C5 inhibitor|"IVMP+Eculizumab arm: eculizumab (900 mg) will be administered intravenously once per week for a total of four doses (days 1, 8, 15, and 22) in conjunction with IVMP and oral prednisone (60mg, 5mg weekly decline).~All enrolled patients will receive antibiotic prophylaxis against N meningitidis."
214885868|NCT07187089|DRUG|dupilumab|Administered per the protocol
214885869|NCT07187232|BEHAVIORAL|massage acupoints|The massage acupoints involved Zusanli (ST36), Fenglong (ST40), Zhongfu (LU1), Tanzhong (CV17), and Feishu (BL13). Each acupoint was massaged for 2 minutes, totaling 10 minutes per session. The routine care included chest physiotherapy and sputum suction as needed every 3 hours (PRN, Q3H).
214885870|NCT07187232|BEHAVIORAL|Routine care|The routine care included chest physiotherapy and sputum suction as needed every 3 hours (PRN, Q3H).
214885871|NCT07185516|OTHER|Airway ultrasound indices|Tongue thickness, hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), ratio of hyomental distance in both positions (HMDR), thyromental distance (TMD), ratio of tongue thickness to thyromental distance (TT/TMD), epiglottis thickness \&pre-epiglottic space thickness
214885872|NCT07185516|OTHER|Clinical airway assessment|Mallampati grading and thyromental distance (TMD). The glottic structures displayed during laryngoscopy will be classified according to the Cormack-Lehane
214885873|NCT07185633|DRUG|Gecacitinib-Corticosteroid|Gecacitinib po. 50mg bid at least 28 days
214885874|NCT07185633|DRUG|Methylprednisolone sodium succinate|Methylprednisolone sodium succinate IV 2mg/kg/d.
214885875|NCT07185152|OTHER|mechanical vibration|Mechanical vibration was applied to babies randomized to the mechanical vibration group before and during the vaccination procedure.
214885876|NCT07185152|OTHER|Flick tapping|Before the vaccination procedure, the vaccination site was placed on the nail of the middle finger in the babies randomized to the flick tapping group, and then the vaccination was stimulated with a quick tap using the upper nail part of the middle finger.
214885877|NCT07184866|DRUG|Vitamin C|Intravenous Vitamin C, 25 mg/kg (maximum 1.5 g) every 6 hours for 5 days, administered in addition to standard medical treatment
214885878|NCT07184866|OTHER|Standard of Care (SOC)|Supportive and guideline-based management of ACLF with septic shock and AKI, including antibiotics, fluids, vasopressors, renal replacement therapy as required, and other standard therapies
214885879|NCT07187206|DEVICE|FETO, Fetal Endoluminal Tracheal Occlusion|Fetal Endoluminal Tracheal Occlusion with Balloon placement for fetuses with congenital diaphragmatic hernia
214885880|NCT07187245|DEVICE|Reality PAWS Program via Meta Quest 3 VR|Reality PAWS is a mixed reality (MR) game that allows patients to interact with a virtual dog. It was developed at Children's Hospital Colorado to serve patients under isolation precautions who are unable to be visited by a facility dog in person. Patients can interact with the game through features such as walking the dog, providing commands, outfitting the dog, giving treats, playing fetch, petting the dog, and playing with others.
214885881|NCT07185997|DRUG|Firmonertinib|240 mg oral, daily firmonertinib tablet
214885882|NCT07185997|DRUG|EGFR-TKI inhibitor based on investigator's choice|osimertinib 80 mg oral, daily tablet OR afatinib 40 mg oral, daily tablet
214885883|NCT07185802|BIOLOGICAL|PRP injection|Ultrasound guided intraarticular PRP is given to the patient with partial ACL tear
214885884|NCT07185802|OTHER|conventional conservative method (physical therapy, functional bracing, lifestyle modification)|conventional conservative method (physical therapy, functional bracing, lifestyle modification)
214885885|NCT04569409|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Wagner grade 2 Foot Ulcer
214885886|NCT04569409|PROCEDURE|Vehicle Sheet|Application of Vehicle sheet to Diabetic Wagner grade 2 Foot Ulcer
214885887|NCT01290302|DRUG|Luitpold Azacitidine|Subcutaneous (SC) at a dose of 75 mg/m\^2 per day on days 1 and 2 of a treatment cycle
214885888|NCT01290302|DRUG|Vidaza®|Subcutaneous (SC) at a dose of 75 mg/m\^2 per day on days 1 and 2 of a treatment cycle
214885889|NCT03706755|DRUG|Norepinephrine: 1mcg/kg|intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
214885890|NCT03706755|DRUG|Norepinephrine 0,5mcg/kg|intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
214885891|NCT06517316|DEVICE|Nelfilcon A plano cosmetic contact lenses|Commercially approved colored contact lenses worn to alter or enhance the apparent color of the eye. Plano contact lenses do not contain visual correction and are worn for cosmetic purposes only.
215047761|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at preoperative visit for study group
215047762|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at 3 month visit as the cross-over group
215047763|NCT05270993|BEHAVIORAL|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
214885892|NCT06242678|DEVICE|SCS trial lead|placement of spinal cord stimulator trial leads to see if effective in the management of symptoms associated with stiff person syndrome
214885893|NCT01059786|DRUG|Pentostatin|28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
214885894|NCT01059786|DRUG|Rituximab|Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
215047764|NCT05270993|BEHAVIORAL|I-CREST group|A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
214885895|NCT01059786|DRUG|Bendamustine|1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
214885896|NCT01059786|DRUG|Acetaminophen|Treatment of infusion-related symptoms with acetaminophen is recommended.
214885897|NCT01059786|DRUG|Diphenhydramine|Treatment of infusion-related symptoms with diphenhydramine is recommended.
214885898|NCT01059786|DRUG|Epinephrine|Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
214885899|NCT01059786|DRUG|Antihistamines|Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
214885900|NCT01059786|DRUG|Corticosteroids|Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
214885901|NCT01059786|DRUG|Bronchodilators|Additional treatment with bronchodilators may be indicated.
214885902|NCT01059786|OTHER|Intravenous (IV) Saline|Additional treatment with intravenous (IV) saline may be indicated.
214885903|NCT05843500|OTHER|Survey|Patients who received medical, surgical or interventional treatment for chronic thromboembolic pulmonary hypertension will be followed and given quality of life questionnaires.
214885904|NCT05426525|DRUG|Empagliflozin|Participants will take 10mg empagliflozin per day for 2 weeks. Absent contraindications, dosing will be increased to 25 mg empagliflozin per day for the next 11 weeks.
214885905|NCT05426525|DRUG|Multivitamin-Placebo|Participants will take 1 multivitamin per day for 13 weeks.
214885906|NCT05291845|BIOLOGICAL|Candida antigen vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
214885907|NCT05291845|BIOLOGICAL|Bivalent HPV vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
214885909|NCT05756634|BEHAVIORAL|Care Coordination after Preterm Birth (CCAPB)|For participants randomized to CCAPB, the care coordinator will follow a manualized intervention to support care planning, health care access, and wellbeing. Contact with participants will be initiated as soon as possible after enrollment, and will continue until six months after enrollment.
214885910|NCT00784004|OTHER|Breathing Patterns|"All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~1. Breathing in through the nose only and out through the mouth only~2. Breathing in through the mouth only and out through the nose only~3. Breathing in and out through the nose only~4. Breathing in and out through the mouth only"
214885911|NCT02018991|PROCEDURE|Everolimus-Eluting Stent (EES)|Patients treated with EES
214885912|NCT02018991|PROCEDURE|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
214885913|NCT02018991|PROCEDURE|Biolimus-Eluting-Stent (BES)|Patients treated with BES
214885914|NCT00449904|DRUG|Liprotamase|Administered orally
214885915|NCT00263354|DRUG|Oxaliplatin|
214885916|NCT04037280|OTHER|Exercise|Four type of exercises will be delivered to patients. These exercises differ for posology and typology.
214885917|NCT02881398|DEVICE|mHealth|After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
215047765|NCT02093260|BIOLOGICAL|Vaccine|"Flubio (Influenza HA) Vaccine~The vaccine will be given intramuscularly."
215047766|NCT03396159|DIAGNOSTIC_TEST|mini fluid challenge|mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
214885918|NCT02881398|OTHER|Standard-Care|After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
214885919|NCT04802486|OTHER|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
214885920|NCT05797181|OTHER|medical nutrition therapy in kidney diseases|Planning and implementation of diets containing high protein, low potassium, low phosphorus, personalized adjusted carbohydrates
214885921|NCT03758664|DRUG|ICP-192|"Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,"
214885922|NCT02905240|DEVICE|nSTRIDE APS|single intra-articular injection
214885923|NCT02905240|DEVICE|Saline|single intra-articular injection
214885924|NCT00048373|DRUG|Etanercept|
214885925|NCT05728034|BEHAVIORAL|Injectable PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about injectable PrEP), visit those pages, and return to the main results page.
214885926|NCT05728034|BEHAVIORAL|Oral PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about oral PrEP), visit those pages, and return to the main results page.
214885927|NCT02454608|DRUG|Verapamil HCl|Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.
214885928|NCT02454608|OTHER|Placebo|Capsule with the same characteristics (size, color, smell) as Verapamil HCl.
214885929|NCT01531517|DRUG|Royal Jelly and Panthenol (PedyPhar® Ointment)|"the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer"
214885930|NCT01531517|DRUG|Panthenol Ointment|"the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer"
214885931|NCT06512792|BEHAVIORAL|Telemedicine management through Mobile APP|According to the patient's electronic health records, each participating center researcher conducts personalized medication reminders and follow-up reminders for enrolled patients on a one-on-one basis. Simultaneously, patients are advised to monitor their health at home, regularly record and upload changes in clinical symptoms, medication, diet, exercise, etc., on the Mobile APP platform. Periodically, self-assessment scales are distributed through the Questionnaire Star platform to assess and record the patient's disease activity, quality of life, sleep, psychological status, etc., and update the information in the electronic health records.Based on the patient's clinical symptoms, self-assessment scales, and feedback from medical institution tests and examinations, each participating center researcher will promptly assess potential health risks, send warning alerts, and provide targeted informational support and interventions.
214885932|NCT04018378|DRUG|varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
214885933|NCT04018378|DRUG|varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
214885934|NCT00005598|DRUG|amifostine trihydrate|
214885935|NCT00005598|DRUG|azacitidine|
214885936|NCT04827498|DIAGNOSTIC_TEST|Invasive coronary endothelium-dependent and non-endothelium-dependent physiological assessment|Coronary hemodynamics and vessel anatomical measures obtained during adenosine and acetylcholine evaluation with a dedicated physiology wire
214885937|NCT01769456|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
214885938|NCT01769456|DRUG|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
215047767|NCT05318508|OTHER|Measurements of sagittal spinopelvic parameters|Sagittal spinopelvic parameters will be measured from lateral cervicothoracolumbar radiographs of patients with lower extremity amputation.
215047768|NCT00624858|DRUG|naltrexone SR 32 mg/ bupropion SR 360 mg daily|"All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.~During the study, subjects will receive ancillary therapy including advice on diet and exercise"
215047769|NCT04908293|OTHER|Biorepair toothpaste|Use of New Biorepair Advanced Sensitive for home oral care.
215047770|NCT04908293|OTHER|Colgate toothpaste|Use of Colgate toothpaste for home oral care.
215047771|NCT03391999|OTHER|A questionnaire; CHU9D|Measuring Health Related Quality of Life
215047772|NCT00447967|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
215047773|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
215047774|NCT00447967|DRUG|Fluorouracil|Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
215047775|NCT00447967|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
215047776|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
214885939|NCT02377297|PROCEDURE|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
214885940|NCT02377297|PROCEDURE|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
214885941|NCT02377297|PROCEDURE|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
214885942|NCT00324077|DRUG|Dasatinib in combination with imatinib|
214885943|NCT03688048|DEVICE|Bright light treatment lamp|Exposure to bright white light (1 hour, 10 000 lux)
214885944|NCT03688048|DEVICE|Sham negative ion generator|Placebo treatment with deactivated negative ion generator (1 hour, audible hum, no ions emitted)
214885945|NCT02134652|OTHER|diagnostic bedside ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck."
214885946|NCT06263452|DRUG|Propranolol|Tablet encapsulated to visually look identical to the placebo.
214885947|NCT06263452|DRUG|Placebo|Encapsulated sugar pill to visually look identical to the experimental condition.
214885948|NCT03771287|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
214885949|NCT03771287|DEVICE|Oticon omni-directional microphone algorithm|Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
214885950|NCT02185339|DRUG|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.
214885951|NCT02185339|DRUG|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.
214885952|NCT03478722|OTHER|Protein Meal|Ingestion of mixed meal containing 20 g of dietary protein
214885953|NCT03478722|OTHER|Stable Isotope Amino Acid Infusion|Continuous infusion of L-\[1-13C\]leucine (0.13 μmol⋅kg⋅min) and L-\[ring- 2H5\]phenylalanine (0.05 μmol⋅kg⋅min)
214885954|NCT01602068|DRUG|Dexamethasone Phosphate Ophthalmic|Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
214885955|NCT01602068|DRUG|100 mM Sodium Citrate Buffer|Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
214885956|NCT04077554|GENETIC|gene expression|determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
214885957|NCT05624645|DEVICE|Pelex Upp|Patients were given the Pelex Upp is a non-invasive device that is designed to guide a user through personalized pelvic floor strengthening exercises. Patients used device for four weeks to treat stress urinary incontinence
214885958|NCT00910676|DRUG|Diprosone|"* Start of treatment: as soon as the EGF-R inhibitors treatment begins~* Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening~* Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.~* Period of treatment: 8 weeks"
214885959|NCT02923232|DEVICE|Accommodative contact lens|Different downgaze angles will be experimented to determine whether the accommodative contact lens can alter its optical refraction at downgaze angles.
214885960|NCT05082818|COMBINATION_PRODUCT|Chemotherapy, Radiotherapy and surgery|Trans urethral resection of the tumour or radical cystectomy
214885961|NCT03660319|OTHER|Environmental Music Therapy|Experiencing Environmental Music Therapy during wait time in radiation oncology waiting room.
215047777|NCT03322982|BEHAVIORAL|Low-fat diet|less than 20% calories from fat daily
214885962|NCT06514534|DRUG|ABL001/Asciminib|"The study treatment for this clinical trial is an investigational drug called asciminib, which is marketed under the brand name Scemblix®. Asciminib is a compound that is being evaluated for its efficacy and safety in the treatment of the target condition.~The minimum dose of asciminib to be administered in this study is 200 mg, while the maximum dose is 400 mg. The dose is planned as 200 mg twice a day (BID).~The drug will be administered orally, allowing for convenient and non-invasive administration."
214885963|NCT06355674|BEHAVIORAL|Breastfeeding education provided with Lactation Simulation Model|The Lactation Simulation Model (LSM) is a high-fidelity simulator designed for interactive education, which educators can utilize for practical and wearable breastfeeding training. It is wearable like a shirt and is secured onto the chest by passing it over the shoulders and fastening it with a safety belt from the back. This allows the safety belt to be adjusted according to different body types and weights.
214885964|NCT05803421|DRUG|Orforglipron|Administered orally once daily
214885965|NCT05803421|DRUG|Insulin Glargine|Administered SC once daily
214885966|NCT00143923|BEHAVIORAL|Nutrition, Exercise, Stress Management Counseling|Individualized advice
214885967|NCT00143923|OTHER|usual care|usual care
214885968|NCT03719768|DRUG|Avelumab|Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
214885969|NCT03719768|RADIATION|Whole Brain Radiotherapy|Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
215047778|NCT01822665|DRUG|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
215047779|NCT01822665|DRUG|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
215047780|NCT01822665|OTHER|Placebo|Placebo tablets
214885970|NCT06069063|DRUG|Zafirlukast|Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander
215047781|NCT04781348|PROCEDURE|Platelet Rich Plasma plus fat grafting|The study participants fulfilling the inclusion criteria giving consent will be randomly divided into two groups, one group will receive only fat grafting whereas another group will receive Platelet Rich Plasma plus fat grafting.
215047782|NCT01828840|DRUG|epidural morphine via PCEA|
215047783|NCT01828840|DRUG|epidural fentanyl via PCEA|
215047784|NCT01828840|DRUG|epidural methadone via PCEA|
214293022|NCT04233645|OTHER|5-minute educational video|The 5-minute educational video depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
214293023|NCT04233645|OTHER|Usual Care|The groups will be given a standard scripted verbal and identical written instructions as per usual care.
214293024|NCT04904887|PROCEDURE|phacoemulsification|phacoemulsification with implantation of EYEHANCE IOL
214293025|NCT02482987|DEVICE|dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|ridge preservation intervention using the dPTFE membrane device
214293026|NCT02482987|DEVICE|human amniotic-tissue derived membrane BioXclude|ridge preservation intervention using the dPTFE membrane device
214477271|NCT04807881|DRUG|Keynatinib|All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is \> 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
214477272|NCT06669091|DRUG|Ecopipam tablet|A single ecopipam 89.6 mg tablet (equivalent to ecopipam HCl 100 mg)
214477273|NCT06668961|DRUG|SI-B001|Administration by intravenous infusion
214477274|NCT06668961|DRUG|SI-B003|Administration by intravenous infusion
214477275|NCT06670092|OTHER|Vojta Therapy|"The intervention is carried out using Vojta therapy for one month, with one session per day, 5 days a week. This therapy is carried out by an expert physiotherapist. Vojta therapy is a non-experimental, painless, non-invasive therapy with no adverse effects, which is based on triggering repeated motor reactions or innate movement patterns (reflex locomotion patterns) in the trunk and limbs based on defined stimuli and starting from specific postures.~Both groups will undertake a pre-treatment assessment, a post-treatment assessment at the end of the one-month intervention period, and a final follow-up assessment one month after the end of the intervention."
214477276|NCT06670092|OTHER|No intervetion|No intervetion group
214477277|NCT04163991|DRUG|VIB4920|liquid for IV infusion following dilution in normal saline
214477278|NCT04163991|DRUG|Placebo|0.9% saline for IV infusion
214477279|NCT05876039|DRUG|Initial remifentanil effect-site concentration|Different initial remifentanil effect-site concentration
214885971|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Full|Participants in this active treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 2.0 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
214885972|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Sham|Participants in the sham condition arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT) 21% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session receiving less than a fully pressurized 100% oxygen dose.
214885973|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Partial Pressure|Participants in this partial treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
214885974|NCT04821089|BIOLOGICAL|IPN10200|"Stage 1: Several different doses will be administrated in a dose-escalation manner.~One single injection will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."
214885975|NCT04821089|BIOLOGICAL|IPN10200 Placebo|"Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."
214885976|NCT04821089|BIOLOGICAL|Dysport|Single administration of study intervention in stage 1 / step 2 and 3 only
214885977|NCT03909919|PROCEDURE|Standard Care or Usual Clinical Practice|The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
214885978|NCT05490771|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214885979|NCT05490771|PROCEDURE|Computed Tomography|Undergo CT
214885980|NCT05490771|DRUG|Copanlisib Hydrochloride|Given IV
214885981|NCT05490771|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214885982|NCT02898818|OTHER|vaginal and oral swab sample, questionnaire|vaginal and oral swab sample and questionnaire
214885983|NCT02898818|OTHER|papa smear|Papnicolaou Papa Smear test
214885984|NCT06579534|OTHER|Health education strategy|Based on the concept of precise health care, investigators design risk awareness, self-health management and fall prevention care measures, and provide inpatients with high-risk groups with frailty and falls with health education guidance on muscle endurance training and fall prevention. This study adopts purposive sampling, randomization, assignment, and parallel experiments to divide into a control group and an experimental group. The control group uses conventional health education guidance to provide fall prevention education, and the experimental group uses multimedia health education videos to provide education to patients or primary caregivers. Provide health education on the risk, management and prevention of falls.
215047785|NCT01828840|DRUG|intravenous morphine via PCA|
214293027|NCT02482987|PROCEDURE|Ridge Preservation with overlay graft|ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
214293028|NCT02482987|PROCEDURE|Ridge Preservation without overlay graft|ridge preservation without overlay graft / traditional FDBA placement into the socket only
214293029|NCT00064376|DRUG|paricalcitol|
214293030|NCT06157723|OTHER|None (Observational study)|"Data related to the knee osteoarthritis will be extracted from patients' medical records:~The sociodemographic and clinical participants' characteristics: age, weight, height, duration of the condition, and occupational activity.~The healthcare costs: the number of visits in primary and specialized care, diagnostic tests, surgical interventions, and emergencies at both health centers and hospitals, physical rehabilitation and number of sessions.~Charlson Comorbidity Index (CCI). Pharmacotherapy (type of drug and dose). Work absences (temporary and permanent)."
214293031|NCT02891083|DRUG|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
214477280|NCT02728635|OTHER|Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS)|A DEXA scan for body composition will also be completed. After a MRI safety screening a whole body MRI for the volumetric measurement of visceral fat, subcutaneous fat, liver, kidneys, heart, brain, skeletal muscle and intramuscular adipose tissue (IMAT) and hepatic lipid by MRS will be performed. Whole body imaging will include low resolution positioning images, followed by several sets of 3D images which will be digitally connected to create a 3D image the entire length of the body. The liver spectroscopy will be performed using PRESS (point resolved spectroscopy) and STEAM (Stimulated Echo Acquisition Mode) sequence during the same imaging session, using the whole body images for positioning.
214667930|NCT01647763|PROCEDURE|Hemorrhoidal artery ligation with rectoanal repair|"Hemorrhoidal arteries will be detected using an ultrasound Doppler probe. The arteries will be sutured with at least 4 Z-sutures.~In the area with the 3 largest knots a purse string suture will be placed."
214667931|NCT01647763|PROCEDURE|Stapled hemorrhoidopexy|A purse string suture will be placed just below the hemorrhoidal cushion. Fixing the suture around the shaft of a circular PPH 03 stapler (Ethicon Endo-Surgery). Hemorrhoids will be removed by firing the stapler. Sufficiency of the stapler line will be examined through a proctoscope. Eventual sources of bleeding will be sutured.
214885985|NCT03231488|OTHER|Mindfulness intervention|A 10 minute mindfulness of breath exercise
214885986|NCT03231488|OTHER|Control intervention (unfocused attention)|A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
214885987|NCT02368418|PROCEDURE|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
214885988|NCT02368418|PROCEDURE|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
214885989|NCT00001021|BIOLOGICAL|rgp120/HIV-1IIIB|
214885990|NCT00001021|BIOLOGICAL|rgp120/HIV-1MN|
214885991|NCT01221207|DEVICE|Total Contact Cast|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
214885992|NCT01221207|DEVICE|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
214885993|NCT01221207|DEVICE|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
214885994|NCT04759807|DRUG|Placebo Comparator|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
215047786|NCT05572840|OTHER|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (powerpoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (powerpoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
214293032|NCT02891083|RADIATION|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d"
214293033|NCT02891083|OTHER|Control group (Surgery alone)|
214293034|NCT03157258|BEHAVIORAL|Social Network Training|Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
214667932|NCT04354454|OTHER|Fitbit|Participants will select a daily step goal and track their steps every day for 4.5 months.
214885995|NCT04759807|DRUG|PUR1800 250 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 250 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
215047787|NCT03257384|OTHER|Black box recording of surgery|Time delays will be recorded from the moment the patient is draped and enters the operating room to the moment they exit the operating room.
215047788|NCT04908150|OTHER|Core training|A total of 12 sessions were carried out, which lasted for 4 weeks, with a frequency of 3 sessions/ week. The duration of each session was 11 minutes 30 seconds. The working time of each exercise was 30 seconds with a 5 seconds rest between exercises, meaning that each exercise cycle lasted for 2.50 seconds. Three exercise cycles were performed with a 90 seconds rest between each one of them
214293035|NCT03157258|BEHAVIORAL|Single Care-Related Counseling Session and Referral to Care|Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
214885996|NCT04759807|DRUG|PUR1800 500 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 500 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
214885997|NCT05506293|PROCEDURE|percutaneous paravalvular leak closure|"the procedure consists of deployment of an occluder or a vascular plug within the cardiac paravalvular leak. The device is inserted percutaneously from a femoral vascular approach or from a trans-apical approach. The device is deployed through a delivery sheath within the leak. Stability and efficacy to occlude the leak are assessed by transoesophageal echocardiography prior to device release.~Type of devices to be inserted varied :~* Amplatzer vascular plug 3~* occlutech paravalvular leak device~* amplatzer vascular plug 2~* amplatzer muscular ventricular septal defect~* amplatzer vascular plug 4~Devices to be implanted are under the responsability of the local investigator and are not based on the study design."
214885998|NCT04511585|BEHAVIORAL|Great Live and Move Challenge|Physical activity program for children
214885999|NCT00661193|DRUG|carboplatin|given IV
214293036|NCT01503268|DEVICE|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
214886000|NCT00661193|DRUG|erlotinib hydrochloride|given orally
214886001|NCT00661193|DRUG|paclitaxel|given IV
214886002|NCT02191293|DRUG|Viramune® tablets|
214886003|NCT02893085|BIOLOGICAL|bile sample analysis|tumor mutation profile tumor genotype
214886004|NCT02893085|BIOLOGICAL|biochemical markers, VEGF and MMPs, in bile samples|
214886005|NCT05397678|BIOLOGICAL|BCG-Denmark|AJ vaccines, Copenhagen 1331 strain
215047789|NCT00508092|PROCEDURE|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
215047790|NCT05423184|OTHER|Exercise Therapy For Lower Extremities|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg raise with theraband, squat, lunge walk and static balance exercises. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
214293037|NCT01503268|PROCEDURE|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
214293038|NCT01503268|PROCEDURE|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
214886006|NCT05397678|BIOLOGICAL|BCG-Bulgaria|BB-NCIPD Ltd., BCG-SL 222 Sofia strain
214886007|NCT04101409|OTHER|Decision aids|Shared decision making with decision aids
214886008|NCT03345693|DEVICE|MoTrack Therapy|A software that runs on a tablet or computer that reads information from a Universal Serial Bus external sensor and instructs patients in their exercises, giving patients feedback as necessary, and recording patient progress and activity.
214886009|NCT01108783|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
214886010|NCT01108783|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
214886011|NCT01108783|DRUG|Placebo|(encapsulated) Tablets QD/14 days
214886012|NCT06582836|BEHAVIORAL|The objective of the study was to investigate the effect of prior engagement of tooth with orthodontic appliance on post extraction pain among orthodontic patients|In this randomized clinical trial, 44 patients were recruited who needed bilateral extractions of first premolars in upper arches. Patients were divided into two groups based on the timing of extractions. Group A needed extractions before alignment while Group B needed extractions for retraction of anterior teeth. Group A was sent for extractions first while Group B went for orthodontic bonding and banding procedures for orthodontic treatment. After series of aligning wires (0.014, 0.016, 17x25, 19x25 Heat activated NiTi and 19x25 SS) patients from group B were sent for extractions. For pain assessment, an 11-point numerical rating scale (NRS) were given to record pain intensity at 2, 4, 8, 12 and then 24 hours after extraction for the next 7 days.
214886013|NCT04078321|OTHER|Mollii ®|The garment claims to have a 48 hours lasting effect of an hour of treatment. The garment should be worn for at least 1 hour every other day. All participants receive individually tailored garments and individually tailored appropriate training towards specific goals set in connection to study start. The garment is used in the home environment and the family is responsible for documentation of use in a diary. Measurements is performed following an ABAB design for four weeks. Measurement performed at 12 occasions during the four weeks are; spasticity, physical function, pain, sleep and adherence. Standardized protocols for the intervention are provided to involved physical therapists.
214886014|NCT04510532|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment
214886015|NCT03240783|DRUG|Betamethasone OR Dexamethasone Injectable|Procedural agents. The steroid and local anaesthetic preparation will be standardized to replicate current radiology interventional practices that use either particulate or non-particulate steroids. Betamethasone Sodium Phosphate/Acetate 5.7 mg/ml Injectable is a particulate corticosteroid and is used with the local anaesthetic bupivacaine 0.5% (1ml). Dexamethasone 4mg (1ml) is a non-particulate corticosteroid and is used with the local anaesthetic lignocaine 1% (1ml).
214293039|NCT05120297|DRUG|AK101|Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.
214293040|NCT05120297|DRUG|Placebo|Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
215047791|NCT05423184|OTHER|Exercise Therapy For Myofascial Chains|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their structered exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg and arm raise with theraband, squat with arm participation using theraband, lunge walk with arm participation using theraband and static balance exercises with arm participation using theraband. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
215047792|NCT04089020|BEHAVIORAL|Support for walking to school|5 modules that address psychosocial skills, with ongoing text messaging.
215047793|NCT00646126|DRUG|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
215047794|NCT00646126|DRUG|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
215047795|NCT01601184|DRUG|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
215047796|NCT01601184|DRUG|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
214886016|NCT03240783|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Procedural agents. The local anaesthetic preparation used with the Normal Saline Flush, 0.9% Injectable Solution, will be standardized to replicate current radiology interventional practices: either local anaesthetic bupivacaine 0.5% (1ml) or local anaesthetic lignocaine 1% (1ml).
214886017|NCT03240783|DRUG|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet: 15 day taper dosing is: days 1-5 8mg (4mg bd) , days 6-10 4 mg (2mg bd), and days 11-15 2 mg (1mg bd). The dexamethasone is over-encapsulated in a gelatine capsule that is identical to the placebo capsule in appearance.
215047797|NCT04672135|DRUG|REM0046127|Oral solution: 100 mg/mL REM0046127
215047798|NCT04672135|DRUG|Placebo|Oral solution with 0 mg/mL REM0046127
215047799|NCT05074225|OTHER|Electrodesiccation and Curettage vs Excision|"Factorial Assignment.~At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS)."
215047800|NCT02116179|BEHAVIORAL|DVD Intervention|Participants will be randomly assigned, with a baseline and 3 month follow up assessments
215047801|NCT06547762|OTHER|Hybrid approach (in-person and remote) to pediatric rehabilitation: A look beyond the COVID-19 crisis|Hybrid rehabilitation. Out patients will receive one day a week of remote therapy and the remaining (1-4 days) in person at rehabilitation hospital
215047802|NCT01335126|OTHER|Emulsion type artificial tear|2 types of artificial tears
215047803|NCT00959907|DRUG|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~* Dysport®: 4 units will be injected in the left or right forehead side.~* Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
215047804|NCT04244266|OTHER|NO INTERVENTION, it is an observational study|No intervention
214886018|NCT03240783|OTHER|Sham Injection and/or oral placebo|The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
214886019|NCT03608397|BIOLOGICAL|DaxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
214293041|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
214293042|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
214293043|NCT02248389|DEVICE|Sonatherm 600i ablation system|HIFU ablation of tumor.
214667933|NCT04354454|OTHER|Fitbit + Game + Support from a Teammate|"Daily Fitbit tracking for 4.5 months, divided into 2 parts.~* 3 months on active intervention with Fitbit, a Game, and Support from a self-selected Teammate and pre-designed game.~* 1.5 month follow-up period with Fitbit and social support teammate only"
214667934|NCT06851013|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
214667935|NCT02585427|DIETARY_SUPPLEMENT|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
214886020|NCT03608397|BIOLOGICAL|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
214886021|NCT00512577|OTHER|Red blood cell transfusion|Pre-operative red blood cell transfusion
214886022|NCT00115453|RADIATION|irradiation|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
214886023|NCT03001453|DRUG|Liposomal Bupivacaine|266mg liposomal bupivacaine
214886024|NCT03001453|DRUG|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
214886025|NCT03001453|DRUG|Saline|Normal saline
214886026|NCT03270969|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive daily TDF/FTC for 14 days
214886027|NCT03849157|PROCEDURE|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
214886028|NCT03710980|DEVICE|Oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding arterial blood draw samples to assess oximeter accuracy.
214886029|NCT00317694|DRUG|Fermagate|Film coated tablet 500mg
214886030|NCT00317694|DRUG|Placebo|Oral administration, film coated tablet, 0mg
214886031|NCT05041920|DRUG|famitinib、omeprazole|famitinib malate, 25 mg on study day 1; omeprazole, 40 mg, qd on study day 10-14, 16-22; famotine malate together with omeprazole, on study day 15.
214886032|NCT02862730|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
214886033|NCT02862730|DEVICE|Subject's insulin pump|Subject will continue on their subcutaneous delivery of insulin on his/her own insulin pump using their own basal rates and carb ratios for meal boluses, managing their blood sugar as they normally would.
214886034|NCT02862730|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
215047805|NCT01914250|DRUG|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
215047806|NCT04025892|BEHAVIORAL|Daily weighing|Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
214293044|NCT06065033|BEHAVIORAL|Exercise|"Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR).~* Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions.~* Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~* Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2.~* Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance."
214477281|NCT02728635|PROCEDURE|Adipose tissue biopsies|Two biopsies will be performed to collect fat tissue from the abdomen and thigh region.
214667936|NCT04322708|OTHER|Placebo|Placebo
214667937|NCT04322708|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
214667938|NCT06849557|BEHAVIORAL|Exergaming|This intervention will last 12 weeks. Frail/ pre-frail participants will engage in supervised chair-bound exergaming.
215057345|NCT04960748|BEHAVIORAL|WOMEN FIGHTING TO STOP CERVICAL CANCER|The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
215057346|NCT03654040|BIOLOGICAL|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
214667939|NCT00746538|DEVICE|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
214667940|NCT01907685|DRUG|AVE8062|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
214667941|NCT01907685|DRUG|Docetaxel|"Pharmaceutical form: solution for infusion~Route of administration: Intravenous"
214886035|NCT02862730|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
214886036|NCT03484546|PROCEDURE|laparoscopic endometrioma cyst excision|laparoscopic resection of ovarian endometrioma
214886037|NCT04975295|DRUG|LY3361237|Administered SC
214886038|NCT04975295|DRUG|Placebo|Administered SC
214886039|NCT03839966|BEHAVIORAL|Interpretation Bias Modification for Loneliness|Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard \& Amir, 2008 and Beard, Weisberg, \& Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
214886040|NCT03839966|BEHAVIORAL|Healthy Habits Psychoeducation and Relaxation|Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
214886041|NCT03685344|DRUG|Loncastuximab Tesirine and Durvalumab|intravenous infusion
214886042|NCT03474874|DEVICE|NeoMatriX Collagen Dressing|Collagen wound dressing
214886043|NCT03151174|DRUG|Vitamin D 10000 UNT|10000 IU Vitamin D per day
214886044|NCT03151174|DRUG|Vitamin D 5000 UNT|5000 IU Vitamin D per day
214886045|NCT01493869|DRUG|cabozantinib|3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
214886046|NCT01936350|DRUG|Sildenafil|The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
214886047|NCT01936350|DRUG|Placebo|This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
214886048|NCT00533286|DRUG|benzodiacepine|diazepam (2 x 5 mg/ die)
214886049|NCT02499796|DEVICE|Hygrovent Gold|
214886050|NCT02499796|DEVICE|Heated and moisture exchanger (HME)|
214886051|NCT02499796|DEVICE|Heated humidifier (HH)|
214886052|NCT03126435|DRUG|EndoTAG-1|twice weekly
214886053|NCT03126435|DRUG|Gemcitabine|once weekly
214886054|NCT02044913|BEHAVIORAL|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
214886055|NCT03835702|OTHER|SAM Clinic Intervention|SAM Clinic is a sleep provider led team comprised of either a sleep clinician or sleep nurse practitioner along with sleep nurses and or durable medical equipment representative. The provider interacts with each patient personally. Various modes of trouble shooting of PAP related issues are tailored to solve PAP adherence issues including mask complaints, nasal issues, pressure intolerance, anxiety, and other related barriers to PAP adherence. When the provider is seeing patients individually other patients have the opportunity to interact and offer informal interpersonal support to other participants in dealing with similar PAP issues. The provider makes an individualized follow-up plan for each patient, which may include another SAM visit or referral back to the non-sleep provider.
214293045|NCT03630575|PROCEDURE|Umbilical cord blood and hair collection|At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
214293046|NCT05188690|OTHER|Data collection from medical records|Data collection from medical records
214293047|NCT03743389|DEVICE|12G pigtail catheter|12G pigtail catheter would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with the traditional 16F chest tube.
214293048|NCT03743389|DEVICE|16F chest tube|16F chest tube would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with 12G pigtail catheter.
214477282|NCT02728635|OTHER|FSIGTT/ RMR|Insertion of two intravenous (IV) catheters for performing a Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT) to measure the acute insulin response to glucose (AIRg) and insulin sensitivity (Si) will be performed. Resting metabolic rate (RMR) will be used to measure metabolic flexibility. Point of care blood glucose measurements will be taken frequently to ensure safety.
214477283|NCT04961840|OTHER|No Intervention|This is a non-interventional study.
214477284|NCT04691323|OTHER|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
214477285|NCT06258811|DRUG|albumin paclitaxel, cispatin, tislelizumab|Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year)
214477286|NCT03117972|DRUG|FOLFOXIRI|12 cycles
214477287|NCT03117972|DRUG|FOLFOX|12 cycles
214477288|NCT03117972|DRUG|FOLFIRI|12 cycles
214886056|NCT04365803|PROCEDURE|vacuum-assisted breast biopsy|patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery
214886057|NCT02969421|OTHER|Cough method for placement of tenaculum|The intervention in this arm is the placement of tenaculum via cough method
214886058|NCT02969421|OTHER|Slow Tenaculum Placement of tenaculum|The intervention in this arm is the placement of tenaculum via slow method
214886059|NCT06250218|OTHER|Video Interactive Guidance (VIG)|"Video interaction guidance (VIG) is a video feedback intervention through which a guider helps a client to enhance communication within relationships. The client is guided to analyse and reflect on video clips of their own interactions."
214886060|NCT03576664|DRUG|Carvedilol 25mg|Cross-over, randomized, placebo-controlled study.
214477289|NCT03117972|DRUG|Bevacizumab|12 cycles
214477290|NCT03117972|DRUG|LV5FU2|Maintenance chemotherapy
214477291|NCT03117972|DRUG|Capecitabine|Maintenance chemotherapy
214477292|NCT05755191|DRUG|NEU-411|Oral Doses
214477293|NCT05755191|DRUG|Placebo|Oral Doses
214886061|NCT03576664|DRUG|Placebo oral capsule|Cross-over, randomized, placebo-controlled study.
214886062|NCT02567279|DRUG|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
214886063|NCT02567279|DRUG|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
214886064|NCT05373199|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
214886065|NCT05373199|DRUG|Euglycemic clamp with Lantus®|Administration of a single dose of Lantus® during an euglycemic clamp procedure.
214886066|NCT05373199|DRUG|Euglycemic clamp with Humalog®|Administration of a single dose of Humalog® during an euglycemic clamp procedure.
214477294|NCT05122962|DIAGNOSTIC_TEST|Remote Heart Rhythm Monitoring|We will be looking to see if remote heart rhythm monitoring for 30 days at baseline, 12, and 24 months, helps for early identification of adverse cardiac events.
214477295|NCT06863922|DIETARY_SUPPLEMENT|Berberine|Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care
214477296|NCT06863922|DIETARY_SUPPLEMENT|Berberine|Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care
214477297|NCT06863623|OTHER|İmmersive Virtaul Reality Applications|To apply immersive virtual reality applications (Scenarios)
214477298|NCT06863623|OTHER|Relaxing Videos|To watch relaxing videos including pictures and sounds prepared by researcher
214477299|NCT06864390|PROCEDURE|genicular nerve neurolysis|The superior medial genicular nerve (SMGN), superior lateral genicular nerve (SLGN), and inferior medial genicular nerve (IMGN) will be blocked either by phenol neurolysis or radiofrequency ablation
214886067|NCT05361915|DRUG|Abivertinib|Abivertinib is a small molecule inhibitor
214886068|NCT05361915|DRUG|Abiraterone|Hormone-based chemotherapy
214293049|NCT02566655|BIOLOGICAL|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
214293050|NCT05757947|PROCEDURE|Сoronary bypass surgery according to the I-graft method|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and the formation of an anastomosis of the stump of the right internal mammary artery and end-to-end saphenous vein graft."
214293051|NCT05757947|PROCEDURE|Сoronary bypass surgery by the method of free conduit|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and anastomosis of the saphenous vein graft to aorta."
214886069|NCT01407237|DRUG|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
214886070|NCT03907371|DRUG|Donepezil Hydrochloride|Donepezil will be used with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24).
214886071|NCT03907371|OTHER|Placebo|Placebo will be used with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24).
214886072|NCT06498882|OTHER|Press Needle Acupoint Stimulation Combined with Breast Massage|Press needle acupoint stimulation and breast massage were administered. Key press needle acupoints were identified for selection: Dan zhong (RN17), bilateral Ru gen (ST18), bilateral Shao ze (SI1), bilateral Zu san li (ST36) and bilateral San yin jiao (SP6). The areas were sterilized with 75% alcohol before installing 0.22\*1.55mm press needles. Within 4-6 hours post-surgery, mothers received acupoint stimulation through needle pressing. This procedure was administered by nurses who had undergone six-month standardized training in traditional Chinese medicine techniques. Instructions were then given to mothers and their family members to stimulate the acupoints pulsatively every 3-4 hours for 20-30 minutes per session, removing the press needles after 24 hours. Additionally, a specialized nurse massaged the back, both breast areas, and armpits for 10-15 minutes, three times daily over three days, using a circular and oscillating breast massage device.
214886073|NCT06498882|OTHER|routine care|Very early skin-to-skin contact was initiated by researchers within 30 to 40 minutes after birth, with newborns, optionally wearing caps, being placed on the mothers' chests. Mothers were encouraged to breastfeed 8 to 10 times per day to ensure steady milk production. It was ensured by researchers that mothers completely emptied one breast before switching to the other to maintain cleanliness. Additionally, mothers were guided by researchers on maintaining a well-balanced diet, achieving emotional stability, and securing adequate sleep to facilitate effective breastfeeding.
214886074|NCT02574065|DRUG|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
214886075|NCT02574065|OTHER|The placebo consists of an identical formulation without L. reuteri DSM 17938|
214886076|NCT03971474|DRUG|Docetaxel|Given IV
214886077|NCT03971474|DRUG|Gemcitabine|Given IV
214886078|NCT03971474|DRUG|Gemcitabine Hydrochloride|Given IV
214886079|NCT03971474|BIOLOGICAL|Pembrolizumab|Given IV
214886080|NCT03971474|DRUG|Pemetrexed|Given IV
214886081|NCT03971474|DRUG|Pemetrexed Disodium|Given IV
214886082|NCT03971474|BIOLOGICAL|Ramucirumab|Given IV
214886083|NCT03162874|DRUG|Placebo oral capsule|BID
214886084|NCT03162874|DRUG|PXT002331 - dose 1|Oral
214886085|NCT03162874|DRUG|PXT002331 - dose 2|Oral
214886086|NCT02371382|DEVICE|Arthroplasty hip|Hip replacement
214886087|NCT04623892|DRUG|TQB2618 injection|TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
214886088|NCT03251001|PROCEDURE|Control|Free epithelized gingival graft, harvested from palate, was grafted in a site with lack of keratinized gingiva
215047807|NCT03765047|BEHAVIORAL|Intervention Arm|"The physical activity intervention consists of:~1. School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~2. Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~3. PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~4. Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed"
215047808|NCT04074564|COMBINATION_PRODUCT|MASCT-I, Camrelizumab,Apatinib|"Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) is a sequential immune cell therapy.~Camrelizumab is an immune checkpoint inhibitors against PD-1.~Apatinib is a highly selective tyrosine kinase inhibitor targeting VEGFR2."
215047809|NCT01003223|OTHER|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
215057347|NCT03654040|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
215057348|NCT03654040|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
214293052|NCT01083394|DEVICE|PTA|PTA using a conventional balloon
214886089|NCT03251001|DEVICE|Acellular Dermal Matrix|Acellular Dermal Matrix was grafted in a site with lack of keratinized gingiva, in substitution of an autogenous graft from patient palate
214886090|NCT00181701|DRUG|Paclitaxel|
214886091|NCT00181701|DRUG|Carboplatin|
214886092|NCT02045901|DRUG|Diclegis|On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
214886093|NCT02045901|DRUG|Placebo (Sugar Pill)|On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
214886094|NCT00261950|DRUG|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
214886095|NCT01375946|DRUG|AG200-15|There will be three treatment periods. Subjects will be randomly assigned to one of the five conditions for the treatment period. The subject will be exposed daily to the condition assigned while wearing the patch. The study patch will be worn for a 7 day treatment period, followed by a 7 day washout period. The total duration of the study is 6 weeks.
214886096|NCT02237586|BIOLOGICAL|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
214886097|NCT02299323|DEVICE|INDEPENDENCE|Lumbar Integrated plate and spacer, with percutaneous screws and rods.
214886098|NCT05661370|OTHER|Dermloop Learn|Educational Mobile Application with a library of digital patient-cases and written learning modules the user can access on 36 common skin lesions, both benign and malignant.
214886099|NCT04612907|RADIATION|Moderate hypo-fractionation|Patients will receive four weeks of radiotherapy
214886100|NCT04612907|RADIATION|Ultra-hypo-fractionation|Patients will receive two and a half weeks of radiotherapy
214886101|NCT01937871|DRUG|5 mg Tadalafil|Administered orally
214886102|NCT01937871|DRUG|Placebo|Administered orally
215047810|NCT05736393|DEVICE|Back Exosuit|The device is worn like a backpack. It weighs 6 pounds. Participants will be able to perform movements naturally in the device. A ribbon serves as an external muscle to reduce the load and effort during lifting. As participants bend forward, the device assists the participant by supporting some of their body weight by gently pulling back. As participants stand up, the device assists them by gently pulling their trunk upright. Participants will feel the level of assistance change slightly as they move faster or slower. Participants will use this device during 20-40 minutes of physical therapy exercises during 12 visits over 4-6 weeks. Once it is fit and adjusted to each participant's comfort, the physical therapist will control the level of assistance the device provides similarly to how they would adapt any given exercise. Participants may start with more assistance and wean down over the course of the study.
214293053|NCT01083394|DEVICE|PTA with PEB|PTA using a paclitaxel eluting balloon
214886103|NCT01937871|DRUG|0.2 mg Tamsulosin|Administered orally
214293054|NCT01083394|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
214293055|NCT01125384|OTHER|additional swabbing|physician swabs patient's throat according to standard rules before referral of the patient to throat swabbing by nurse.
214667942|NCT04512261|DRUG|Tucatinib|Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
214886104|NCT00037583|DRUG|Gemtuzumab Ozogamicin|
214886105|NCT02705261|BEHAVIORAL|cognitive-behavior therapy|Internet based program to support parents in developing strategies to help their children
214886106|NCT05273411|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|Single-dose pharmacokinetic study over 4 hours.
214886107|NCT05273411|DIETARY_SUPPLEMENT|Beta-hydroxybutyric acid|Beta-hydroxybutyric acid
214886108|NCT05273411|DIETARY_SUPPLEMENT|1,3-Butanediol|1,3-Butanediol
214886109|NCT04754841|OTHER|platelet cryopreservation|The cryopreservation of platelets will be carried out using as alternatives of cryopreservative solution: 5% dimethylsulfoxide alone (solution 1) or combined with 5% dextrose 160 mg (solution 2) or with 2% albumin (solution 3) and then be frozen at -80 ° C
214886110|NCT00577863|DRUG|teriparatide|Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
214886111|NCT04795895|DIAGNOSTIC_TEST|ultrasonography (US)|US evaluation was performed after insertion of the tube via subxiphoid approach for tube passing esophagogastric (EG) junction. The tube insertion procedure will be repeated no more than three attempts if no visualization by US.
214886112|NCT04795895|DIAGNOSTIC_TEST|Standard routine (SR)|Standard routine (SR)
214886113|NCT03523936|DIETARY_SUPPLEMENT|Prebiotic product|Prebiotic product used during the course of antibiotic treatment
214886114|NCT03523936|DIETARY_SUPPLEMENT|Placebo|Placebo
214886115|NCT03439956|PROCEDURE|Transvaginal specimen extraction|Previous transvaginal specimen extraction through posterior colpotomy.
214293056|NCT04492839|DEVICE|Intestinal adsorbent|Participants will consume the 15ml of the intestinal adsorbent (3.5 g Silicon dioxide in 100 ml Silicic acid gel, Preservatives: Sorbic acid (E 200), Sodium benzoate (E 211). ) three times daily for 10 days. There are no known side effects of the medical device. The product is a class IIa medical device under the European council directive and the product will be used within it's current indications.
214293057|NCT00877877|PROCEDURE|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
214293058|NCT02610179|DIETARY_SUPPLEMENT|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
214293059|NCT02610179|DIETARY_SUPPLEMENT|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
214293060|NCT02953054|DRUG|DMTS|DMTS applied before surgery and worn for 72 hours
214293061|NCT02953054|DRUG|Placebo|Matching patches that have no active drug applied before surgery and worn for 72 hours.
214293062|NCT04109755|DRUG|Pembrolizumab|5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
214293063|NCT02935088|DEVICE|Fractional Flow Reserve|Measurement of physiologic parameters
214293064|NCT02969304|DRUG|dimethyl fumarate|"Off-Label Use: All participants \<18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants \>18 years of age with an MS diagnosis who are prescribed dimethyl fumarate"
214293065|NCT00965588|BIOLOGICAL|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
214293066|NCT01057550|PROCEDURE|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
214293067|NCT01057550|PROCEDURE|TVT|Standard TVT as described by Ulmsten 1996
214293068|NCT01057550|PROCEDURE|Pelvicol|retropubic mid urethral sling made from Pelvicol
214477300|NCT06862999|BEHAVIORAL|No Incentive Email|Participant will receive an email describing a hypothetical experience sampling study that will happen in King's Cross where he or she is an inhabitant as a worker, resident, or visitor. However, this email will not include any promised compensation for future participation in the hypothetical wellbeing study in the neighbourhood. This group serves as the control group to compare the effects of incentives on participation rates.
214477301|NCT06862999|BEHAVIORAL|Financial Incentive Email|Participant will receive an email describing a hypothetical experience sampling study that will happen in King\&amp;amp;#39;s Cross where he or she is an inhabitant as a worker, resident, or visitor. This email will include a paragraph that describes a compensation for participation in the future study. The type of compensation that will be offered is a financial compensation, which is a chance of enter a prize draw to win a 4 X £100 voucher which can be used to purchase goods and services within the King\&amp;amp;#39;s Cross neighbourhood in London.
214886116|NCT02868957|OTHER|impression data from reference scanner|To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
214886117|NCT02868957|DEVICE|iTero|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
215047811|NCT02559973|DRUG|RBP-6000|RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
215047812|NCT02559973|DRUG|SUBOXONE Sublingual Film|Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
214667943|NCT04512261|DRUG|Pembrolizumab|Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
214886118|NCT02868957|DEVICE|Trios|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
215047813|NCT02025374|DRUG|Hyperbaric levobupivacaine|
215047814|NCT02025374|DRUG|Hyperbaric bupivacaine % 0.5|
215047815|NCT02221973|DIETARY_SUPPLEMENT|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
215047816|NCT01722929|DEVICE|Skin sensor|
215047817|NCT01079364|DRUG|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
215047818|NCT01079364|DRUG|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
215047819|NCT01079364|DRUG|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
214293069|NCT05484973|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
214293070|NCT05944341|DRUG|articaine hydrochloride 4% with epinephrine 1:100 000|Local anesthetic agent
214293071|NCT05944341|DRUG|Lidocaine hydrochloride 2% with epinephrine 1:100 000|Local anesthetic agent
214293072|NCT03296657|DRUG|stannous fluoride|subjects will brush with paste twice daily for 2 weeks
214293073|NCT02135146|DRUG|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
214293074|NCT02135146|DRUG|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
214886119|NCT03154125|DRUG|Sayana® Press|The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
214886120|NCT00805324|DRUG|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
214477302|NCT06862999|BEHAVIORAL|Social Incentive Email|Participant will receive an email describing a hypothetical experience sampling study that will happen in King\&#39;s Cross where he or she is an inhabitant as a worker, resident, or visitor. This email will include a paragraph that describes a compensation for participation in the future study. The type of compensation that will be offered is a non-financial compensation, which is an invitation to participate in a social event that will be organised by the researchers and the neighbourhood asset manager team at the end of the research project. This event will be exclusive and it will be an opportunity for participants to socialize with other study participants in the neighbourhood. It will also be an opportunity for the study participants to feel they are contributing a change to the neighbourhood and will be able to articulate their views about the wellbeing research findings which is expected to be used to inform future interventions in the neighbourhood.
214886121|NCT00002817|BIOLOGICAL|sargramostim|
214886122|NCT00002817|BIOLOGICAL|vaccinia-GM-CSF vaccine|
214886123|NCT06031558|DRUG|SY-5007|a RET selective Inhibitor
214886124|NCT02597829|DRUG|Certolizumab Pegol|Subcutaneous Injection
214886125|NCT05969535|BEHAVIORAL|Birth preparation education according to travelbee human-human relations theory|human-to-human communication and psychoeducation-assisted birth preparation training
215047820|NCT01529229|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
214886126|NCT04362228|BEHAVIORAL|Whole-body exercise|10-week one-on-one, virtual, whole-body exercise class, 3x/week, focused on increasing respiratory rate through moderate-intensity aerobic exercises.
214886127|NCT04835974|DIAGNOSTIC_TEST|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured:~1. LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio.~2. Glycemia will be assessed : RBS ( random blood sugar ) .~3. Serum Uric acid : S .UA"
214886128|NCT06430593|PROCEDURE|low-flow anesthesia|0,5 l/min \>1 l/min
214886129|NCT02635412|OTHER|Scheduled timing of delivery|
215047821|NCT01529229|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
215047822|NCT01171677|BEHAVIORAL|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
215047823|NCT04720378|BIOLOGICAL|ST266|1X ST266
215047824|NCT02308293|BEHAVIORAL|High intensity exercise|3x30 seconds 'all out' sprints
215047825|NCT02308293|BEHAVIORAL|Lay down comfortably|rest
215047826|NCT02194114|OTHER|Protein Diet|Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
215047827|NCT01847443|DRUG|Nicotine (2 mg)|2 mg nicotine gum in two formulations
215047828|NCT01847443|DRUG|Nicotine (4 mg)|4 mg nicotine gum in two formulations
215047829|NCT03534388|OTHER|Sodium Hypochlorite Cleanser|Cleansing with CLn BodyWash
214886130|NCT04529135|DRUG|Dexmedetomidine|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
214886131|NCT04529135|DRUG|Remifentanil|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
214886132|NCT00474500|DRUG|Coca, Cola, Diet Coke|
214886133|NCT04908592|DRUG|Dexamethasone|Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
215047830|NCT05960487|OTHER|Cervical multifidus muscle area measurement at 3 levels (C4-C5, C5-C6, C6-C7)|Cervical multifidus muscle area measurement will be performed from both the side affected by radiculopathy and the unaffected side using the magnetic resonance (MR) imaging. Measurements will be made by two researchers, independent of each other.
215047831|NCT03771339|PROCEDURE|Continuous Epidural analgesia|Continuous Epidural catheter is inserted at the Thoracic 11-T12 level, using Ropivacaine 0.375% 3 mL bolus followed by Ropivacaine 0.2% with rate 6 mL/hour for 24 hours after laparoscopic nephrectomy
215047832|NCT03771339|PROCEDURE|Bilateral Quadratus Lumborum block|Bilateral anterior Quadratus Lumborum block using Ropivacaine 0.375% 20 mL each injection as postoperative analgesia treatment for 24 hours
214886134|NCT04908592|OTHER|Placebo|Patients will receive 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
214886135|NCT04355260|PROCEDURE|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).
214886136|NCT05219448|BEHAVIORAL|Education and self-efficacy coaching|"Children and their caregiver(s) in the intervention communities will receive a culturally-adapted, 5-session program consisting of video-based health education and self-efficacy coaching delivered by an indigenous Community Health Worker. Families will be introduced to sugar-free water enhancers that are commercially available and come in the same flavors as regular Tang and Kool-Aid. The sessions will include conversations on related topics, interactive hands-on activities, and homework assignments. Additionally, four brief check-ins will keep families engaged. Local stores in the intervention communities only will carry the sugar-free water enhancers that are highlighted in the health education."
214886137|NCT02653248|RADIATION|Stereotactic Body Radiation Therapy|Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
214886138|NCT02042118|DEVICE|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
214886139|NCT02042118|DEVICE|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
214886140|NCT02198937|OTHER|Blood sample|
214886141|NCT02287922|BIOLOGICAL|ALX-0061|
214886142|NCT02287922|BIOLOGICAL|Placebo|
214886143|NCT02287922|BIOLOGICAL|Tocilizumab|
214886144|NCT03409588|DRUG|Adempas|After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
214886145|NCT02881502|OTHER|severe asthma group|No intervention
214886146|NCT03337061|OTHER|Mindfulness Meditation|Mindfulness Meditation delivered through a mobile application
214886147|NCT01854476|DEVICE|pad-gauze with tranexamic acid (Hemostopan™)|The use of pad-gauze containing tranexamic acid (Hemostopan™)
214886148|NCT05030792|OTHER|Attention-restorative therapy (ART)-based virtual reality (VR)|The ART-based VR intervention will be provided using an Oculus Go™ which is a commercially available, all-in-one VR headset with a handheld controller.
214886149|NCT00668317|DRUG|Omeprazole|20 mg BD tablet 8 weeks duration
214886150|NCT00668317|DRUG|Ranitidine|300 mg od nocte tablet 8weeks duration
214886151|NCT04759196|DRUG|Topamax|TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.
214886152|NCT04759196|DRUG|Levetiracetam|LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.
214477303|NCT06863597|OTHER|Video content|Video content produced by media professionals using expert opinions.
214886153|NCT00398424|DRUG|S-1/Cisplatin|"PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.~On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.~Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
214886154|NCT00064896|PROCEDURE|MRI|
214886155|NCT01690702|DRUG|Epirubicin|
214886156|NCT01690702|DRUG|nab-Paclitaxel|
214886157|NCT01690702|DRUG|Cyclophosphamide|
214886158|NCT01690702|DRUG|Docetaxel|
214886159|NCT04767399|BEHAVIORAL|protaper next|rotary systems used on patients need root canal treatment
214477304|NCT06863597|OTHER|Written content|Written content produced by healthcare professionals with experience in health education.
214886160|NCT01864707|OTHER|Usual care + acupuncture|Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
214477305|NCT06863597|OTHER|Podcast content|Podcast content created by media experts based on expert opinions.
214477306|NCT06863597|OTHER|Illustration (information leaflet) content|Illustration-based content created by media experts using expert opinions.
214477307|NCT06861595|DEVICE|accuvein|intravenous route with accuvein
214477308|NCT06861595|OTHER|with out accuvein|intravenous route with out accuvein
214886161|NCT01864707|OTHER|usual care+mbsr|Patients of this group receive mindfulness based stress reduction in addition to usual care
214886162|NCT01864707|OTHER|usual care|Patients in this group will follow the same treatment for fatigue they received at study entry
214886163|NCT01565356|DRUG|florbetapir F 18|IV injection, 111 or 370MBq (3 or 10mCi), single dose
214886164|NCT00248261|DRUG|ziprasidone, sertraline|
214886165|NCT06052293|DRUG|ANG003|To evaluate four possible combinations of lipase, protease and amylase.
214886166|NCT04247373|DRUG|Ropivacaine|According to previous patient's response, the investigators will allocate the concentration of ropivacaine of next patient during Co2 insufflation. And, for this allocation of concentration of ropivacaine the investigators use biased coin design up-and-down method.
214886167|NCT02254980|DEVICE|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
214886168|NCT02254980|DEVICE|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
214886169|NCT02924831|OTHER|Acupuncture|Stimulating acupoints by using stainless steel needles with manual manipulation.
214886170|NCT02924831|OTHER|moxibustion|Stimulating acupoints by using burned moxa
214886171|NCT02924831|OTHER|placebo|Stimulating acupoints by using stainless steel needles without manual manipulation.
214886172|NCT04451148|OTHER|Obese with or without metabolic syndromesubjects|Children with obesity and with or without metabolic syndrome
214886173|NCT03037593|DRUG|4000 IU vitamin D3|vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin
214886174|NCT04540653|BIOLOGICAL|Standard vaccination schedule|Administer a standard vaccination schedule (three doses of 20 μg of the hepatitis B vaccine, in months 0, 1, 6) at an age of ≥50 years and evaluate a production kinetics after each dose administered in the period of about 30 to 60 days.
214886175|NCT04540653|BIOLOGICAL|Reinforced vaccination schedule|Administer an enhanced vaccination schedule (three doses of 40 μg of the hepatitis B vaccine, in months 0, 1, 6) in individuals aged ≥50 years and assess the kinetics of antibody production after each dose administered in the period of approximately 30 to 60 days.
214886176|NCT01894087|BEHAVIORAL|TBI - Cohort 1|
214886177|NCT01894087|BEHAVIORAL|TBI - Cohort 2|
214886178|NCT02646605|OTHER|depression screening|Patient Health Questionnaire
214886179|NCT00277693|DRUG|Spironolactone (drug)|
214886180|NCT03892603|OTHER|Strengthening exercises program|Participants from this group will be given a progressive shoulder strengthening exercises program based on 1 RM that will involve isometric, concentric and eccentric contractions. The exercises will target shoulder internal/external rotators and abductors and the scapular muscles. They will have to exercise every other day for 12 weeks. At each session with the therapist (6 over a 12 week period), strength will be reassessed and the program will be progressed accordingly. Any questions or concerns will also be addressed and participants will be requested to complete a paper based or digital record of their exercise participation.
214886181|NCT03892603|OTHER|Motor control exercises program|Each session will start with a series of clinical tests that will look at the influence of different corrections to alleviate symptoms during upper limb movements.The tests will be performed in a sequential format through four key areas: thoracic repositioning, scapula facilitation, humeral head procedures and neuromodulatory techniques. If a correction reduces pain, that technique will then be performed as exercises and incorporated into the participant's functional movement. In addition, motor control exercises during arm elevation, progressed through a standardized 6-phase retraining sequence, will be executed. Retraining phases will be graded according to: 1) resistance applied on the shoulder; and 2) use or non-use of feedback. Once participants reach pain free execution, the program will be progressed into re-education exercises according to the participants' work, sport and activities of daily living and will incorporate activities involving the upper and lower limbs.
214886182|NCT03892603|OTHER|Education and advice|Each participant will be given written information about the shoulder (anatomy and function), basic pain science and will be directed to the Internet to watch a series of carefully selected educational videos. Comprehensive written advice will include: Information about the shoulder and the condition; Pain neuroscience; Activity modification (when to increase and decrease); Pain management (night and day); A series of educational videos to watch with 2 questions to answer per video: a) what was the most important message? and b) was there anything you didn't understand in the video?
214886183|NCT03883503|OTHER|Beer 5%o|Weight adjusted beer to reach 0.8 blood alcohol content will be given over the time course of 1 hour to the participants
214886184|NCT03883503|OTHER|Beer 8.5%o and water|Weight adjusted beer to reach 0.8 blood alcohol content and water will be given over the time course of 1 hour to the participants
214477309|NCT06671184|OTHER|Observations on clinicopathological factors influencing the difficulty of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
214886185|NCT03883503|OTHER|Beer 8.5%o and stock|Weight adjusted beer to reach 0.8 blood alcohol content and stock will be given over the time course of 1 hour to the participants
214886186|NCT03883503|OTHER|Water|Water equivalent to the calculated volume of beer will be given over the time course of 1 hour to the participants
214886187|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
214886188|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
214886189|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
214886190|NCT05015686|BIOLOGICAL|Placebo|Sodium chloride and distilled water
214886191|NCT00697151|DRUG|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
214886192|NCT00697151|DRUG|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
214886193|NCT05534061|BEHAVIORAL|Connect2Test|Brief motivational enhancement intervention to improve the likelihood of testing and vaccination among syringe exchange clients
214886194|NCT05311904|OTHER|Survey|1 initial questionnaire and 1 monthly follow-up questionnaire for 11 months
214886195|NCT01412086|DRUG|No Intervention|No Intervention.
214886196|NCT03210792|DEVICE|Application of Rib Splint|Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
214886197|NCT00309855|DRUG|Placebo|im and orally
214886198|NCT00309855|DRUG|Testosterone|injections
214886199|NCT00309855|DRUG|Anastrazole|orally x 21 days
214886200|NCT00309855|DRUG|Dutasteride|orally x 21 days
214886201|NCT01027598|DRUG|Pazopanib|Pazopanib: 600 mg orally daily
214886202|NCT01027598|DRUG|Erlotinib|Erlotinib: 150 mg orally daily
214886203|NCT06585501|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
214886204|NCT06080256|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
214886205|NCT06080256|DRUG|Atorvastatin|Atorvastatin 20-40mg
214886206|NCT00938249|DIETARY_SUPPLEMENT|Monascus Garlic Fermented Extract|
214886207|NCT00938249|DIETARY_SUPPLEMENT|Placebo|
214886208|NCT06463002|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring and Montreal Cognitive Assessment|Noninvasive tests to assess blood pressure control and cognition
214886209|NCT01814553|DRUG|afatinib|Daily treatment starting 40 mg per day
214886210|NCT01814553|DRUG|loperamide|Follow cohort assignment and diarrhea management guidelines
214886211|NCT00576446|BIOLOGICAL|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
215047833|NCT03571971|OTHER|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
215047834|NCT03571971|OTHER|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
215047835|NCT04264039|BIOLOGICAL|anti-CD19 UCAR-T cells|Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
215047836|NCT04264039|DRUG|Fludarabine|30mg/m\^2 per day for 6 days
215047837|NCT04264039|DRUG|Cytoxan|300mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
215047838|NCT04264039|DRUG|Melphalan|50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
215047839|NCT06158867|DEVICE|FMD WK|micro-needle patches containing active anti-wrinkle ingredients
215047840|NCT06341400|DRUG|DisitamabVedotinForIicction Toripalimab|Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.
215047841|NCT05889091|OTHER|HRQOL instruments|These instruments include Face Q for Appearance, Eating \& drinking, Swallowing, and Saliva (patient-reported); the Neck Dissection Impairment Index (patient-reported); the Long-term ENT-Subjective/Objective/Management/Analysis (LENT-SOMA) for skin-subcutaneous tissue, muscle-soft tissue, mucosa - oral and pharyngeal, salivary gland, and mandible (patient- and clinician-reported); modified barium swallow study (8-point penetration aspiration scale).
215047842|NCT05889091|OTHER|LENT SOMA instrument|LENT SOMA instrument will also be provided to summarize objective quality-of-life-related measures recorded at 12 months postoperatively, including interincisor distance (mm); neck range of motion measured in degrees of flexion, extension, lateral flexion, and rotation to both sides; and shoulder range of motion, measured in degrees of abduction.
215047843|NCT04826198|DRUG|AsiDNA|Unit dose: Vial containing 100 mg of AsiDNA™ (free acid) Regimen: 3 consecutive infusions (D1, D2, D3) followed by a once a week iv infusion on D8 and D15 of a 21 day-treatment cycle at first cycle, then weekly iv infusion in the absence of disease progression or unacceptable toxicity Mode/route: 1 hour intravenous (iv) infusion
215047844|NCT04826198|DRUG|Niraparib|"Unit dose: Hard capsule containing 100mg of Niraparib Regimen: The last dose given during the 6 previous months of Niraparib 200 mg/day or 300 mg/day, (or 100 mg/day only if the patient has received this dose since at least 6 months) Daily, 1, 2 or 3 hard capsules at 100mg once daily at approximately the same time each day.~Mode/route: Per os"
215047845|NCT04826198|DRUG|Olaparib|Product name: Olaparib Pharmaceutical form: Tablets containing 100 or 150mg of Olaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Olaparib 600 mg/day or 500 mg/day, (or 400 mg/day only if the patient has received this dose since at least 6 months) Two times daily (300mg or 250 mg or 200mg) at approximately the same time each day.
215047846|NCT04826198|DRUG|Rucaparib|Product name: Rucaparib Pharmaceutical form: Tablets containing 200 or 250 or 300mg of Rucaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Rucaparib 1200 mg/day or 1000 mg/day, or 800mg/day (or 600 mg/day only if the patient has received this dose since at least 6 months) Two times daily (600mg or 500mg or 400mg or 300mg) at approximately the same time each day.
214886212|NCT04138823|DRUG|BI 891065|film-coated tablets
214886213|NCT03874273|DRUG|Crizotinib|Crizotinib 280mg/m2 twice a day (for 24 months maximum)
214886214|NCT06206629|DIAGNOSTIC_TEST|blink reflex evaluation|A blink reflex evaluation will be performed in all subjects
214886215|NCT00590512|DIETARY_SUPPLEMENT|High sodium|
214886216|NCT00590512|DIETARY_SUPPLEMENT|Low sodium|
214886217|NCT01509014|BEHAVIORAL|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
214886218|NCT02803658|BEHAVIORAL|smoking behavior|
214886219|NCT02803658|BIOLOGICAL|Sperm collection|
214477310|NCT05941377|OTHER|blood pressure lowering|For EBPL group, patients are required to keep blood pressure at 100-120 mmHg. For SBPL group, patients are required to keep blood pressure at 120-140 mmHg.
214886220|NCT04202055|OTHER|Biomarker analysis|Detection of biomarker in cerebrospinal fluid
214886221|NCT00606164|DRUG|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
214886222|NCT00606164|DRUG|Placebo|A single one-hour intravenous infusion of placebo on Day 1
214886223|NCT05024357|DRUG|Dasatinib|Take Dasatinib orally for 1 year or 6 months post-HSCT.
214886224|NCT05326555|DIAGNOSTIC_TEST|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
214886225|NCT02889523|DRUG|Tazemetostat|Tablets 200 mg, to be administrated per os
214886226|NCT02889523|DRUG|Rituximab|375 mg/m²/dose, D1
214886227|NCT02889523|DRUG|Cyclophosphamide|750 mg/m²/dose, D1
214886228|NCT02889523|DRUG|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
214886229|NCT02889523|DRUG|Doxorubicin|50 mg/m²/dose, D1
214886230|NCT02889523|DRUG|Prednisolone|40 mg/m2 in the morning D1 to D5
214886231|NCT02018380|OTHER|Shock Absorbing Insole (SofSole Athletes Plus)|The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
214886232|NCT00791544|DRUG|AVE1642|intravenous infusion
214886233|NCT00791544|DRUG|sorafenib|oral intake
214886234|NCT00791544|DRUG|erlotinib|oral intake
214886235|NCT03814655|PROCEDURE|Full digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.
214886236|NCT03814655|PROCEDURE|Partially digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
214886237|NCT05264181|DEVICE|Percutaneous pulmonary valve implantation|Percutaneous pulmonary valve implantation using SAPIEN 3 valve in the context of routine care of patients with congenital heart diseases
214886238|NCT06632717|DRUG|Cisplatin|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
214886239|NCT06632717|DRUG|5-fluorouracil|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
214886240|NCT06632717|PROCEDURE|Lipiodol embolization|"Lipiodol embolization protocol~* Lipiodol embolization will be performed on day 3 after completion of 5-FU infusion, up to 4 cycles. Fixed dose lipiodol of 10mL will be given on day 3 followed by 30mL normal saline flush.~* The administration of lipiodol is mandatory on cycle 1. The administration of lipiodol on cycle 2 to cycle 4 will depend on the discretion of the treating physician and the presence of adverse effects from lipiodol embolization."
214886241|NCT03502434|DRUG|SM04755|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
214886242|NCT03502434|OTHER|Vehicle|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
214886243|NCT03502434|OTHER|White Petrolatum|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
214886244|NCT03502434|OTHER|Sodium lauryl sulfate|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
214886245|NCT03864016|DRUG|Induction and maintenance of anesthesia|The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
214886246|NCT03864016|DRUG|Adaptation of sufentanil doses according to the usual protocol|At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
214886247|NCT03864016|DRUG|Adjustment of sufentanil doses according to pupillometry|At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
215047847|NCT02279056|BEHAVIORAL|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
215047848|NCT02279056|BEHAVIORAL|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
215047849|NCT01752803|DIETARY_SUPPLEMENT|Probiotic|mix probiotic
215047850|NCT01752803|DIETARY_SUPPLEMENT|Placebo|placebo
215047851|NCT02421757|DEVICE|Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device|Transcutaneous Magnetic Stimulation
215047852|NCT02421757|DEVICE|Placebo|The placebo Transcutaneous device
215047853|NCT03846661|DEVICE|Physiomesh|difference in risk for recurrence and postoperative complication
215047854|NCT02681393|BEHAVIORAL|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
215047855|NCT02681393|BEHAVIORAL|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
215047856|NCT04940728|OTHER|Creative thinking techniques intervention program|The intervention program based on creative thinking techniques was designed to consist of four stages: preparation, theoretical briefing, skill development and evaluation. In the first stage of the program, acquaintance and information meeting, in the second stage, the theoretical part lasts for two weeks, in the third stage, various creative thinking techniques are applied for four weeks to gain creative thinking skills.
214477311|NCT06542653|PROCEDURE|PCI|successful percutaneous coronary intervention (PCI) in Coronary chronic total occlusions (CTOs) patients
214477312|NCT06542653|DRUG|OMT|optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.
214667944|NCT04512261|DRUG|Trastuzumab|Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
214886248|NCT02925039|OTHER|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
214886249|NCT02925039|OTHER|Treatment as usual|Treatment as usual
214886250|NCT04868500|DEVICE|AMAZE™ Application|Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
214886251|NCT04868500|DEVICE|AMAZE™ Dashboard|Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
214293075|NCT02848157|DRUG|Dexmedetomidine|Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.
214293076|NCT02848157|DRUG|plain ropivacaine|ropivacaine and normal saline equivalent doses of dexmedetomidine
214667945|NCT00243737|DRUG|Artesunate-Mefloquine|
214667946|NCT03247400|DRUG|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb
214886252|NCT00097032|DRUG|risperidone; quetiapine|
214886253|NCT06157190|OTHER|Unsupervised monitoring|"This study introduces technology-assisted rehabilitation for patients post-total hip or knee arthroplasty, utilizing wearable sensors and mobile health tech. The intervention includes:~Technology-Assisted Rehabilitation: Utilizing wearable sensors and mobile health technologies, the intervention promotes unsupervised, real-world assessments after total hip or knee replacement. It shifts from traditional supervised clinical assessments. The moveUP digital therapies platform, featuring a dedicated mobile app, acts as the primary interface for patients in rehabilitation.~Digital Biomarkers: The intervention involves gathering digital biomarkers from wearable sensors and mobile health tech. These biomarkers offer continuous, objective measurements of patients' biological and physiological data. Examples include mobility and activity level data."
214886254|NCT04325932|DRUG|Urinary Kallikrein|
214886255|NCT01368315|DRUG|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
214886256|NCT01368315|DRUG|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
214886257|NCT01368315|DRUG|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
214886258|NCT01368315|DRUG|No intervention|No intervention to one out of four test fields marked on the patient's back.
214886259|NCT03340974|DRUG|GC4419|90 mg Avasopasem (GC4419) per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
214886260|NCT03340974|DRUG|Placebo|Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
214293077|NCT02848157|DRUG|Ropivacaine|
214886261|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 50 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
214886262|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 55 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
214886263|NCT02676765|DRUG|allergen extract tablet|1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
214886264|NCT02676765|DRUG|Placebo tablet|1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
214886265|NCT02366273|OTHER|PASI and HOMA index|
214886266|NCT02391987|DEVICE|Tele-monitoring and health coaching|"Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.~Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management."
214886267|NCT05741177|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound score
214886268|NCT04187547|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)"
214886269|NCT04187547|DRUG|Placebo|Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
214886270|NCT03122977|PROCEDURE|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
214886271|NCT03122977|PROCEDURE|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
214886272|NCT05712798|OTHER|No intervention|No intervention
214293078|NCT03593707|DRUG|Metformin|Metformin
214293079|NCT03593707|DRUG|PF-06865571|PF-06865571
214886273|NCT04641598|PROCEDURE|Endometrial Scratch|"An endometrial biopsy pipelle will be used to create endometrial injury in the form of a scratch."
214886274|NCT04641598|PROCEDURE|Sham procedure|Motions of performing an endometrial scratch will be performed including speculum placement and cervix cleansing, however, placement of the tenaculum and the endometrial scratch will not be performed.
214886275|NCT02965937|OTHER|Story-centred care intervention program|"Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks."
214886276|NCT02965937|OTHER|Health consultation control condition|The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
214886277|NCT01799837|DRUG|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
214886278|NCT02096432|BEHAVIORAL|Behavior Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
214886279|NCT02096432|BEHAVIORAL|Usual Community Care|Community standard care as usual
214886280|NCT01255137|DRUG|Axitinib|5 mg tab orally twice a day with food every 28 days
214886281|NCT03473015|DEVICE|PICSO|The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
214886282|NCT06164366|DEVICE|0 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 0 degrees
214886283|NCT06164366|DEVICE|45 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 45 degrees
214293080|NCT01388764|DRUG|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
214293081|NCT00022633|DRUG|gemcitabine hydrochloride|
214293082|NCT00022633|DRUG|paclitaxel|
214477313|NCT05215197|DRUG|intracochlear platelet rich fibrin administration|intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
214886284|NCT03854630|DRUG|Engerix-B|The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.
214886285|NCT03044626|DRUG|Radiotherapy|"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
214886286|NCT03044626|DRUG|Nivolumab|Nivolumab 240 mg fixed dose (q2w)
214886287|NCT03010683|DRUG|Liraglutide|Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
214886288|NCT03010683|DRUG|Metformin|Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
215047857|NCT02382588|DRUG|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
215047858|NCT02382588|DRUG|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
215047859|NCT03864068|OTHER|Placebo|Placebo
214293083|NCT01676844|DRUG|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
214477314|NCT06349980|DRUG|HLX53 (1000mg)|HLX53 will be administered by IV infusion at a fixed dose of 1000 mg on Day 1 of each 21-day cycle.
214886289|NCT03490578|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.
214886290|NCT03490578|DEVICE|Intensive treadmill training|Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
214886291|NCT02405130|OTHER|intracoronary epinephrine|after failure of standard therapy patients will treated with epinephrine
214886292|NCT02405130|OTHER|no intracoronary epinephrine|patients will receive standard therapy only
214886293|NCT00052598|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
214886294|NCT00052598|BIOLOGICAL|aldesleukin|Given SC
214886295|NCT00052598|OTHER|laboratory biomarker analysis|Correlative studies
214886296|NCT00052598|OTHER|flow cytometry|Correlative studies
214886297|NCT03456505|BEHAVIORAL|Mindfulness Meditation Training|A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.
214886298|NCT03456505|BEHAVIORAL|Active Listening|A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
214886299|NCT01563497|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
214886300|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fasted
214886301|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fed
214886302|NCT05299528|BEHAVIORAL|Direct Feedback|Procedure-specific direct feedback will be provided to surgeon participants through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
214886303|NCT00600587|DRUG|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
214886304|NCT00600587|DRUG|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
214293084|NCT01676844|DRUG|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
214293085|NCT03682445|OTHER|exercise|Aerobic tyep of exercise will be made at different intensities in 2 groups.
214293086|NCT04857905|PROCEDURE|Microsurgical resection|Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.
214293087|NCT04857905|PROCEDURE|Gamma Knife radiosurgery|Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.
214477315|NCT06349980|DRUG|HLX53 (2000mg)|HLX53 will be administered by IV infusion at a fixed dose of 2000 mg on Day 1 of each 21-day cycle.
214477316|NCT06349980|DRUG|HLX10|HLX10 will be administered by IV infusion at a fixed dose of 300 mg on Day 1 of each 21-day cycle.
214477317|NCT06349980|DRUG|HLX04|HLX04 will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
214477318|NCT06349980|OTHER|Placebo|Placebo matching HLX53 will be administered by IV infusion on Day 1 of each 21-day cycle.
214477319|NCT05562739|DIETARY_SUPPLEMENT|Postbiotic|multistrain postbiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 6 weeks.
214477320|NCT05562739|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 6 weeks.
214886305|NCT00159224|DRUG|Lopinavir/ritonavir simplification strategy|Simplification
214886306|NCT00314210|DRUG|Quetiapine SR|
214886307|NCT01888939|OTHER|Walking on a Treadmill|
214886308|NCT01888939|OTHER|Sedendary Activities Only|
214886309|NCT03209895|DIETARY_SUPPLEMENT|Joint Health Product|Krill oil, Astaxanthin, Hyaluronic Acid Formulation, 353 mg per day; Softgel capsule
214886310|NCT03209895|DIETARY_SUPPLEMENT|Placebo|Palm oil Softgel capsule
214886311|NCT03209895|DIETARY_SUPPLEMENT|Glucosamine / Chondroitin|Glucosamine 1500 mg, Chondroitin 1200 mg per day
214886312|NCT03173157|OTHER|Value Feedback Email|a biweekly email to three house staff-run cardiology services at VUMC presenting the in-hospital charges and appropriate use of echocardiography. A weekly email will also be sent to the intervention services detailing their team's in-hospital charges for echocardiograms during the preceeding week.
214886313|NCT04960293|PROCEDURE|uterine artery embolization using spherical gelfoam|Uterine artery embolization is performed using spherical gelfoam. All other processes are same.
214886314|NCT04960293|PROCEDURE|uterine artery embolization using tri-acryl gelatin microsphere|Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.
214886315|NCT01793493|OTHER|Cognitive stimulation|"Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.~Meetings (each lasting about 2 hours) have a common structure:~* body awakening (10 minutes)~* cognitive stimulation (1 hour and a half) scheduled as follow:~  * temporospatial orientation~ * attentional abilities~ * one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)"
214886316|NCT01793493|OTHER|Sanitary education|Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
214886317|NCT04470063|DRUG|DDO-3055 tablets|Multi-dose for DDO-3055 tablets
214886318|NCT04470063|DRUG|Placebo|Multi-dose for Placebo
215047860|NCT03864068|DRUG|Inositol|1gm/bid, 2gm/bid or 3gm/bid of Inositol powder
215047861|NCT05135728|BEHAVIORAL|Unstuck and On Target: Preschool|Unstuck \& On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
215047862|NCT04722783|BEHAVIORAL|Parent-Child-Interaction Therapy adapted for children with autism spectrum disorder (PCIT-A)|PCIT is a behavioral family therapy approach emphasizing the integration of traditional child play therapy techniques within a behavioral framework of parent-child therapy and was developed by Eyberg (1988). It is based on attachment theory, social learning theory, and parenting styles theory. Recently, the intervention was adapted to children with ASD by our team (McNeil, Quetsch, \& Anderson, 2019). PCIT-A will last about 8 months, 1 day per week, 60min per day (see Study Protocol, Fig. 2).
215047863|NCT04722783|BEHAVIORAL|Early Start Denver Model (ESDM) intervention|ESDM intervention provides intensive teaching by trained therapists and parents during natural play and relationship-focused daily routines. It is evidence-based and uses principles of developmental psychology and applied behavior analysis. It was designed for toddlers and preschoolers with autism spectrum disorder by Rogers and Dawson (2010). The first intensive part of ESDM intervention (20h per week) will last 40 weeks of intervention within a period of 12 months. It includes 2 days per week for 6h a day clinic therapy, and 5 days per week for 1h homework tasks, and 2 days per week for 1.5h an early special needs education at home. After the first 12 months, children receive the second lower intensity part of ESDM (7 hours per week). It includes 1 days every two weeks 1h day clinic therapy, and 5 days per week for 1h homework tasks, and 1 days per week for 1.5h an early special needs education at home (see Study Protocol, Fig. 2).
215047864|NCT04722783|BEHAVIORAL|1-hour ESDM|The active control group for PCIT-A stays in the ESDM day clinic therapy for the 12 hours per week while the PCIT-A group will receive 11 hours of ESDM day clinic therapy and 1 hour PCIT-A per week (see Study Protocol, Fig. 2).
215047865|NCT04722783|BEHAVIORAL|Early special needs education (ESNE)|The wait-list control group will receive early special needs education. It consists of a 90-minute visit at participants' homes once a week by an employee educated in early special needs education. As soon as space in ESDM is available children will receive the ESDM intervention (stepped-wedge design, see Study Protocol, Fig. 2).
215047866|NCT04056247|OTHER|Plasma sample collection|Collect at least two plasma samples
215047867|NCT02530255|DIETARY_SUPPLEMENT|cycloastragenol|Oral telomerase activator - cycloastragenol.
214293088|NCT05130619|DIETARY_SUPPLEMENT|Ethanol|Crossover meal study
214293089|NCT04790760|DIETARY_SUPPLEMENT|Supplement Consumption|Participants will consume one 500 mg cinnamon capsule and one 300 mg aloe vera capsule twice per day for weeks 3-6.
214293090|NCT04790760|DEVICE|Continuous Glucose Monitors|Participants will wear a CGM on the back of their left and right arm for weeks 1-6.
214667947|NCT03247400|DRUG|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb
214886319|NCT03307226|BEHAVIORAL|Youth Development Accounts (YDA)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)
214886320|NCT03307226|BEHAVIORAL|YDA + Multiple Family Groups (MFG)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development 12 Financial Management workshops on asset-building, saving and investing in Income Generating Activities (IGAs) 18 Multiple Family Groups sessions focused on strengthening family relationships and mental health
215047868|NCT02530255|DIETARY_SUPPLEMENT|placebo (for cycloastragenol)|placebo comparator, placebo for cycloastragenol.
215047869|NCT05182918|OTHER|Substance use disorder treatment|The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
214293091|NCT04197934|PROCEDURE|Biospecimen Collection - blood samples|Undergo collection of blood samples
214293092|NCT04197934|PROCEDURE|Biospecimen Collection - CSF samples|Undergo collection of CSF samples
214293093|NCT04197934|PROCEDURE|Computed Tomography|Undergo CT
214293094|NCT04197934|DRUG|EGFR/EGFRvIII Inhibitor WSD0922-FU|Given PO
214293095|NCT04197934|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214293096|NCT04197934|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214886321|NCT01549717|DEVICE|Fitting of a wireless telemetry device|Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
214886322|NCT04222426|OTHER|89Zr-atezolizumab PET scans|Patients receive a total amount of 10 mg unlabeled atezolizumab, this will be added to the tracer to prevent rapid clearance during imaging. A labeled dose of 37 Megabequerell (MBq) 89Zr-atezolizumab (±10%; 1 Millicurie) will then be administered. The tracer will be administered intravenously (i.v.). All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. After each tracer injection, 89Zr-atezolizumab PET scans will be performed on day 4 (96 ± 6h after tracer administration).
214886323|NCT01199146|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg by mouth per day
214886324|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with capsules containing rosemary and alkylglycerol|
214886325|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with control capsules|
214886326|NCT06633380|BEHAVIORAL|Standard Physical Activity - Fasted|30 minutes of walking at a self-selected pace that they must have completed 15 minutes prior to consumption of first meal in the morning.
214293097|NCT01276353|DRUG|E2020|Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
214293098|NCT01276353|DRUG|E2020|10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
214293099|NCT01624389|DRUG|F18-AV45|"This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
214293100|NCT02041611|PROCEDURE|Blood collections|pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
214886327|NCT06633380|BEHAVIORAL|Standard Physical Activity - Post-Meal|30 minutes of walking at a self-selected pace to start 30 minutes after the start of the first meal in the morning.
214886328|NCT06633380|BEHAVIORAL|Dispersed Physical Activity|10 minutes of walking at a self-selected pace to start 30 minutes after the start of each main meal throughout the day (i.e., three bouts total).
214886329|NCT06633380|BEHAVIORAL|Physical Activity Snacks|2 minutes of walking or marching on the spot at a self-selected pace every 30 minutes throughout the day for 7.5 waking hours.
214886330|NCT06633380|BEHAVIORAL|Muscle Strengthening|30 minutes of muscle strengthening exercises targeting the major muscle groups of the whole body, to start 30 minutes after the start of the first meal in the morning.
214886331|NCT02895152|BEHAVIORAL|Feedback|Will receive feedback on the amount of activity that has been undertaken in the last week, will specialist advice on steps taken, active minutes each day, how much device has been worn and tailored advice on how to improve activity levels
214886332|NCT06634264|DEVICE|Soft Oral Appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
214886333|NCT00321191|DRUG|No nitrous oxide|
214886334|NCT00321191|DRUG|Administration of N2O|
214886335|NCT05139888|DEVICE|Single wavelength light (red) only|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy red light (640-660 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months.
214886336|NCT05139888|DEVICE|Dual wavelength light (red/blue)|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy dual wavelength light (640-660 nm and 405-450 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months..
214886337|NCT01192867|DRUG|Placebo|Placebo will be administered orally QD for 56 weeks
214886338|NCT01192867|DRUG|RO4917838|RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
214886339|NCT01192867|DRUG|Antipshychotics (Standard of Care)|Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
214886340|NCT00253721|DRUG|Melphalan|"All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days"
214886341|NCT02875691|DIETARY_SUPPLEMENT|green tea extract|Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
214886342|NCT02875691|DIETARY_SUPPLEMENT|placebo|Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
214886343|NCT05880329|DIAGNOSTIC_TEST|Candidate POCTs for detecting UTI|POCT performance will be evaluated in participants who experience possible UTI.
214886344|NCT05734651|DEVICE|PROMIS Stem|Primary Total Hip Arthroplasty with the PROMIS Stem (Fa. Falcon Medical, Mödling, Austria)
214886345|NCT03899909|DRUG|GLPG3121 SAD|GLPG3121 oral suspension, single ascending doses
214293101|NCT04341389|BIOLOGICAL|Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Intramuscular injection
214293102|NCT04341389|OTHER|Placebo|Intramuscular injection
214293103|NCT04264637|DRUG|Azelastine hydrochloride (BAYR9258)|Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.
214293104|NCT04264637|DRUG|Placebo|Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
214293105|NCT04034381|OTHER|No intervention (descriptive survey only)|No intervention
214293106|NCT03327649|DEVICE|low level transcutaneous vagus nerve stimulation|Stimulation of the auricular branch of the vagus nerve
214886346|NCT03899909|DRUG|Placebo SAD|Placebo oral suspension
214886347|NCT03899909|DRUG|GLPG3121 MAD|GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
214886348|NCT03899909|DRUG|Placebo MAD|Placebo oral suspension, daily for 13 days
214886349|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
215047870|NCT05578014|PROCEDURE|Acupuncture|To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture the sham acupoint (EX-B2 T3 point) or Dazhui point.
214293107|NCT01735513|DEVICE|Intra-aortic embolic protection management system; Embol-X|"The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream."
214477321|NCT06616402|DEVICE|prototype prosthetic group|"These 3 sessions will commence only upon successful completion of the prosthesis safety and reliability tests conducted in the preceding sessions.~For each module combination, a session will be conducted to assess motor performance through the acquisition of spatiotemporal parameters and energy efficiency parameters of gait. Motor performance will be evaluated using functional assessment tests and data will be recorded during the following activities:~* parallel bar walking on flat ground~* parallel bar walking on an inclined surface~* treadmill walking with a safety harness~* stair climbing/descending with a handrail~* standing up and sitting down from a chair within parallel bars At the end of each session, satisfaction questionnaires (ad hoc questionnaire) will be completed. At the end of the experiment, a usability scale for the devices (ad hoc System Usability Scale) will be completed.~Each session is expected to last approximately 2.5 hours."
214886350|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
214477322|NCT06616311|DEVICE|Radiofrequency microneedling|The target population is skin of color patients with melasma. Patients will receive 5 consecutive RFMN treatments over a period of 5 months.
214477323|NCT03825601|DIAGNOSTIC_TEST|PET with [11C]Flumazenil|7T MRI sequences : TSE, T2w FLAIR GRE-T2\* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.
214477324|NCT04078152|DRUG|Durvalumab|IV infusion q4w with 1500mg durvalumab until progressive disease
214886351|NCT06671912|DRUG|Anastrozole|Given PO
214886352|NCT06671912|DRUG|Letrozole|Given PO
215047871|NCT03848455|DIAGNOSTIC_TEST|genetic diagnosis|The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
215047872|NCT04821167|PROCEDURE|laparoscopic orchiopexy for intra-canalicular testis|laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
214293108|NCT04803097|DIAGNOSTIC_TEST||We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
214477325|NCT05827874|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
214477326|NCT05827874|BIOLOGICAL|Tdap|Tdap will be administered as an IM injection.
214477327|NCT05827874|BIOLOGICAL|PPSV23|PPSV23 will be administered as an IM injection.
214477328|NCT02510235|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
214886353|NCT06671912|DRUG|Exemestane|Given PO
214886354|NCT06671912|DRUG|Tamoxifen|Given PO
214886355|NCT06671912|PROCEDURE|Mammogram|Undergo mammogram
214886356|NCT06671912|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214886357|NCT06671912|BIOLOGICAL|Dual X-ray Absorptiometry|Undergo DEXA
214886358|NCT06671912|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214886359|NCT06671912|OTHER|Questionnaire Administration|Ancillary studies
214886360|NCT02386293|DRUG|Irbesartan|Double blind placebo controlled cross over trial to determine effectiveness of an angiotensin receptor blocker in obese hypertensive African American patients.
214886361|NCT02386293|OTHER|Placebo|Sugar pill made to look identical to irbesartan intervention.
214886362|NCT02035358|BIOLOGICAL|HyperAcute®-Renal (HAR) Immunotherapy|"HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization."
214886363|NCT02953119|OTHER|Prehabilitation|
214886364|NCT01289379|PROCEDURE|High Frequency Jet Ventilation|
215047873|NCT05539326|OTHER|Performance Clinical Outcome Test|Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
215047874|NCT02947191|BIOLOGICAL|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
214477329|NCT02510235|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
214886365|NCT01289379|PROCEDURE|HFJV|
214886366|NCT02478879|DRUG|ZP-PTH|Patch applied daily for 30 minutes, 14 days
214886367|NCT02478879|DRUG|FORTEO|Subcutaneous injection administration daily for 14 days
214886368|NCT02042456|DEVICE|Digital Breast Tomosynthesis|digital breast tomosynthesis technology
214886369|NCT02042456|DEVICE|Automated Whole Breast Ultrasound|Automated Whole Breast Ultrasound
214886370|NCT02042456|DEVICE|Full Field Digital Mammography|
214886371|NCT00869336|DRUG|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
214886372|NCT00869336|DRUG|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
214886373|NCT00869336|DRUG|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
215047875|NCT01329861|BEHAVIORAL|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
214293109|NCT03638024|DIAGNOSTIC_TEST|Maternal plasma cell free fetal DNA levels|Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
214293110|NCT05354752|DRUG|VC005 tablets|VC005 groups repeat administration for 7 days
214293111|NCT05354752|DRUG|VC005 Placebo tablets|VC005 placebo groups repeat administration for 7 days
214477330|NCT06608992|DRUG|SURGICEL® Powder|SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
214886374|NCT00869336|DRUG|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
214293112|NCT03612297|DIAGNOSTIC_TEST|Selective reporting of Antibiotic Susceptibility Tests|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
214293113|NCT03876431|DEVICE|Easy-Flex|The Easy-Flex device will be used to increase knee flexion and extension ROM.
214293114|NCT03876431|OTHER|Exercise|After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
214293115|NCT05202743|OTHER|Observational for ALS patients|Open to ALS patients interested in mindfulness training.
214293116|NCT00044356|GENETIC|Allovectin-7®|
214886375|NCT04005014|OTHER|Myopia prediction algorithm|Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
214886376|NCT05645133|DEVICE|Diagnostic Test|Diagnostic device to monitor coagulation properties of a whole blood sample at the point of care
214886377|NCT05375253|BIOLOGICAL|Donor Enriched Activated Natural Killer Cell Infusion|αβ TCR/CD19 depleted (DEA-NK) cells on day +7 post T-cell replete Haplo-Tx with PTCY
214886378|NCT04422041|OTHER|Time to discharge less than 24 hours|Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
214886379|NCT04422041|OTHER|Discharge time between 24 and 48 hours|Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
214886380|NCT00493896|DRUG|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
214886381|NCT00493896|DRUG|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
214886382|NCT06253806|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 1% mepivacaine will be injected near the stellate ganglion.
214886383|NCT06253806|DRUG|Placebo Sham Injection|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 0.9% saline will be injected near the stellate ganglion.
214886384|NCT01434914|DRUG|octenisept®|Cutaneous solution
214886385|NCT01434914|DRUG|Placebo|Cutaneous use
214886386|NCT01024257|RADIATION|beta-irradiation|
214886387|NCT01024257|PROCEDURE|conjunctival autograft|
214886388|NCT02445963|BIOLOGICAL|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
214886389|NCT02128321|DRUG|Isavuconazole|oral
214886390|NCT02128321|DRUG|Repaglinide|oral
214886391|NCT02128321|DRUG|Caffeine|oral
214886392|NCT00987779|DRUG|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
214886393|NCT00987779|DRUG|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
214886394|NCT01957176|DRUG|Eltrombopag (ELT)|Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
214886395|NCT03964064|RADIATION|Stereotactic Radiotherapy|"GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report"
214477331|NCT06370702|OTHER|Handgrip Exercises|Participants will firmly grip and squeeze the ball for 10 seconds, relax for 10 seconds and repeat for 10 minutes. They will be instructed to do this 3 times per day.
215047876|NCT02330614|OTHER|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
214886396|NCT03964064|RADIATION|3D-printing Template-assisted CT-guided I125 Seed Implantation|CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
214886397|NCT06044012|PROCEDURE|Double layer of buccal myomucosal Flap and buccal pad of fat|The buccal myomucosal flap will be harvested from cheek below stenson papilla and will be sutured over buccal pad of fat which will be sutured at palatal mucosa after complete curettage of infected fistulous tract.
214886398|NCT01490983|BEHAVIORAL|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
214886399|NCT01490983|BEHAVIORAL|eMedonline access|patients will be given access to eMedonline use for 3 months
214886400|NCT03307265|DEVICE|Personalized weighted jacket|Patients in this group will wear a jacket with weights (1,5 to 2% of the total body mass) strategically placed in order to correct their imbalance.
214886401|NCT03307265|DEVICE|Control jacket|Patients in this group will wear a jacket with weights (200 grams maximum) evenly distributed.
214886402|NCT01458873|DRUG|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
214886403|NCT01458873|DRUG|diluted sodium bicarbonate 2.1%|50ml
214886404|NCT01458873|DRUG|normal saline|50ml
214886405|NCT00146497|DRUG|Budesonide-Surfactant|
214886406|NCT03546920|BEHAVIORAL|ALIGN Intervention Phase|"Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives."
215047877|NCT02330614|OTHER|Nothing - control group|Only NEO-FFI test , data used as control
215047878|NCT04046939|DRUG|Dexpramipexole|dexpramipexole twice daily oral dosing for up to 12 weeks
215047879|NCT04046939|DRUG|Placebo|placebo twice daily oral dosing for up to 12 weeks
215047880|NCT03895073|OTHER|healthy volunteers|the questionnaire has been assessed by both groups, healthy and heart failure
215047881|NCT04049773|PROCEDURE|haemodialysis|haemodialysis, thrice weekly in-center
215047882|NCT06347913|RADIATION|ultrasound|Umbilical Artery Systolic/Diastolic Ratio and Amniotic Fluid Index in Prediction of Fetal Outcome in Term Pregnancies
215047883|NCT00403130|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
214477332|NCT06611618|OTHER|Muscle power assessment|Isokinetic dynamometry test Stair ascent/descent on instrumented stairs
214886407|NCT04859829|OTHER|Current Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dysmotility that are receiving Intravenous Immunoglobulin (IVIG) treatment.
214886408|NCT04859829|OTHER|No Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dismotility that are not receiving Intravenous Immunoglobulin (IVIG) treatment.
215047884|NCT00403130|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
215047885|NCT00403130|DRUG|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
215047886|NCT03704493|DIAGNOSTIC_TEST|Video Group|A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
215047887|NCT02622789|OTHER|Pilates Exercises|Pilates method based stability exercise intervention
215047888|NCT00806260|DRUG|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
215047889|NCT00806260|DRUG|Placebo|Placebo daily for 4 weeks
214477333|NCT06611618|OTHER|Muscle force assessment|Isometric dynamometry (Maximal Voluntary Isometric Contraction)
214477334|NCT06611618|OTHER|Home-based mobility monitoring|Mobility monitoring with wearable sensors
215047890|NCT00806260|OTHER|Alcohol|
215047891|NCT00806260|OTHER|alcohol placebo|fruit juice
215047892|NCT02162706|OTHER|Non intervention study|
215047893|NCT00767026|BEHAVIORAL|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
215057349|NCT03654040|DRUG|mesna|"Mesna is administered:~* Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~* In conjunction with the cyclophosphamide, per institutional practice with CTX."
214293117|NCT01905384|DEVICE|Covered Self-expanding metal biliary stents (C-SEMS)|Used for palliation of inoperable malignant distal bile duct obstruction.
214293118|NCT01905384|DEVICE|Uncovered Self-expanding metal biliary stents (U-SEMS)|Used for palliation of inoperable malignant distal bile duct obstructions.
214293119|NCT03325075|BIOLOGICAL|VAL-181388|Escalating dose levels
214293120|NCT03325075|OTHER|Placebo|Saline
214293121|NCT00422591|DRUG|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age \<60 years) or days 1-3 (age \> 60 years).
214293122|NCT00422591|DRUG|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
214293123|NCT03579589|DRUG|Sugammadex vs Neostigmine|Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.
214293124|NCT00345254|PROCEDURE|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
214293125|NCT02985164|RADIATION|PDSa|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).
214886409|NCT02359994|DEVICE|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.
214293126|NCT02985164|RADIATION|PDSb|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
214293127|NCT00041327|BIOLOGICAL|filgrastim|5 ug/kg/d
214293128|NCT00041327|BIOLOGICAL|recombinant interferon alfa|9 mU subcutaneously per day for one year
214293129|NCT00041327|DRUG|Etoposide|50 mg/m2/day continuous 96 hr infusion, days 1-4
214293130|NCT00041327|DRUG|cyclophosphamide|750 mg/m2 IV on day 5
214293131|NCT00041327|DRUG|doxorubicin hydrochloride|10 mg/m2/day as a continuous 96-hour infusion days 1-4
214293132|NCT00041327|DRUG|lamivudine|150 mg bid
214293133|NCT00041327|DRUG|prednisone|60 mg/m2 given orally days 1-5
214293134|NCT00041327|DRUG|vincristine sulfate|0.4 mg/m2/day as a 96-hour continuous infusion days 1-4
214293135|NCT00041327|DRUG|zidovudine|300 mg bid
214293136|NCT02769325|DRUG|Atropine|IV atropine 0.1%, 10 ml
214293137|NCT02769325|DRUG|Placebo|IV saline, 10 ml
214293138|NCT02769325|DRUG|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
214293139|NCT02769325|DRUG|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
214293140|NCT02769325|DRUG|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
214293141|NCT02769325|DRUG|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
214886410|NCT02359994|DEVICE|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
214886411|NCT00492440|BIOLOGICAL|recombinant interleukin-7|
214293142|NCT02769325|DRUG|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
214293143|NCT02769325|DRUG|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
214293144|NCT02659631|DRUG|PF-06671008|Dose Escalation Phase - Part 1
214293145|NCT02659631|DRUG|PF-06671008|Dose Expansion Phase - Part 2
214886412|NCT00492440|GENETIC|gene expression analysis|
214886413|NCT00492440|GENETIC|polymerase chain reaction|
214886414|NCT00492440|GENETIC|protein expression analysis|
214886415|NCT00492440|OTHER|flow cytometry|
214886416|NCT00492440|OTHER|immunoenzyme technique|
214886417|NCT00492440|OTHER|immunologic technique|
214886418|NCT00492440|OTHER|laboratory biomarker analysis|
214293146|NCT02377466|DRUG|Retosiban IV infusion|Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
214293147|NCT02377466|DRUG|Placebo IV infusion|0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
214293148|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 65 mg|"Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
214886419|NCT00492440|OTHER|pharmacological study|
214886420|NCT01810757|RADIATION|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
214886421|NCT01810757|RADIATION|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
214886422|NCT04597632|DRUG|brolucizumab|brolucizumab 6 mg/0.05 mL solution for intravitreal injection
214886423|NCT00038532|DRUG|Amprenavir/ritonavir|
214293149|NCT04465851|DIETARY_SUPPLEMENT|Curcumin|"HydroCurc™ 500 mg formulated curcumin~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
214293150|NCT04465851|OTHER|Placebo (Ferrous Sulphate)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
214293151|NCT04465851|OTHER|Placebo (Curcumin)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
214886424|NCT00038532|DRUG|Saquinavir/ritonavir|
214886425|NCT00038532|DRUG|Efavirenz|
214886426|NCT00080314|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
214886427|NCT00080314|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
214886428|NCT01672216|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
214886429|NCT01672216|DEVICE|EMG-biofeedback alone|
214886430|NCT04719455|BEHAVIORAL|Adherence Improving self-Management Strategy|An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.
214886431|NCT04719455|OTHER|Regular care|Treatment as usual (appointments with nurse/nurse practioner with regular content)
214886432|NCT04702308|OTHER|Clinical Decision Rule Alerts|The
214886433|NCT01823835|DRUG|GDC-0810|GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
214886434|NCT01823835|DRUG|LHRH Agonist|LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
214886435|NCT01823835|DRUG|Palbociclib|Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
214886436|NCT05822258|OTHER|Walk under 3 conditions (normal, physical tasks, verbal tasks)|"Each patient will have 2 visits :~* First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~* A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~* Normal condition without addition of additional physical and verbal tasks~* Condition with added physical tasks: The physical task of holding a ball in the center of a tray~* Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions."
214886437|NCT00524732|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
214886438|NCT03639454|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
214886439|NCT03639454|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
214886440|NCT03127683|OTHER|Neutral position|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
214886441|NCT03127683|OTHER|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
214886442|NCT03127683|OTHER|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
214886443|NCT03127683|OTHER|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
215047894|NCT00767026|BEHAVIORAL|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
215047895|NCT03250143|DRUG|cyclosporine vs azathioprine|Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
215047896|NCT01571622|DIETARY_SUPPLEMENT|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
214293152|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 18mg|"Oral ferrous salt supplement~Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
214293153|NCT06024421|DRUG|favipiravir|Light yellow, film-coated tablet, each containing 200 mg of favipiravir
214293154|NCT06024421|DRUG|Placebo|Light yellow, film-coated tablet
214293155|NCT03078647|DEVICE|Profound|The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
214477335|NCT06611618|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Full lower limb MRI
214477336|NCT06611618|OTHER|Gait assessment|Motion capture, surface EMG and gorund reaction force data
214886444|NCT03127683|DEVICE|Ambu AuraGain TM|Single Use Laryngeal Mask Sterile
214886445|NCT00911027|DRUG|Contrast-enhanced ultrasound guided biopsy|"One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part"
215047897|NCT01571622|DIETARY_SUPPLEMENT|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
214293156|NCT05805982|BEHAVIORAL|Educational Video|Pre-recorded educational video including hereditary cancer information, genetic cancer testing candidates, types of testing, type of results, benefits and risks, recommendations according to results, inheritance and common questions.
215047898|NCT00002429|DRUG|Lamivudine/Zidovudine|
215047899|NCT00002429|DRUG|Nelfinavir mesylate|
215047900|NCT00002429|DRUG|Stavudine|
215047901|NCT00002429|DRUG|Didanosine|
215047902|NCT00708409|PROCEDURE|Cardiac valve surgery|Different autograft implantation techniques.
215047903|NCT01344343|OTHER|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
215047904|NCT01470105|OTHER|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
215047905|NCT02590289|DRUG|BBI-5000|BBI-5000 low dose, middle dose, or high doses
215047906|NCT06590181|OTHER|Yoga Nidra|This protocol is derived from The Origin and Clinical Relevance of Yoga Nidra (Pandi-Perumal, S. R. 2022)
214293157|NCT05805982|BEHAVIORAL|In person genetic cancer counseling|"Includes:~Family history of cancer (3-generation family tree) Personal Cancer Risk Assessment Education on inheritance and expression of disease Types of tests Preparation on possible outcomes according to results Obtaining consent for test Opportunity to solve doubts"
214293158|NCT03173599|DRUG|PNA 40mg|The beginning dose is 40mg.
214886446|NCT00911027|PROCEDURE|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
214886447|NCT03115268|BEHAVIORAL|Social support groups delivered in EVA Park|Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
215047907|NCT06590181|OTHER|Yoga Nidra with Pain Acceptance Intention|Yoga Nidra with Pain Acceptance Intention
214886448|NCT04780282|OTHER|Scapular Stabilization Group|Participants will apply the 5 exercises given.
215047908|NCT06590181|OTHER|Yoga Nidra with Pain Acceptance Intervention and Motor Imagery|Yoga Nidra with Pain Acceptance Intervention and Motor Imagery
214293159|NCT03173599|DRUG|PNA 80mg|The single dose is 80mg.
214293160|NCT03173599|DRUG|PNA 160mg|The single dose is 160mg.
214293161|NCT03173599|DRUG|PNA 240mg|The single dose is 240mg.
214293162|NCT03173599|DRUG|PNA 360mg|The single dose is 360mg.
214293163|NCT03173599|DRUG|PNA 480mg|The single dose is 480mg.
214886449|NCT05612373|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
214886450|NCT03017612|DEVICE|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
214886451|NCT04216667|PROCEDURE|Catheter ablation|Catheter ablation
214886452|NCT01595763|OTHER|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
214886453|NCT00135863|DRUG|tinzaparin|
215047909|NCT05814237|OTHER|Data collection|Data collection from study participants to characterise diagnostic and therapeutic practices.
214293164|NCT03173599|DRUG|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
214293165|NCT04969549|OTHER|Theta burst stimulation|It consists of 20 sessions of iTBS over the dlPFC.
214293166|NCT05247268|DRUG|Megestrol Acetate 160 MG Oral Tablet|At a dosage of 160 mg/day
214293167|NCT05247268|DRUG|Medroxyprogesterone Acetate 500 MG|At a dosage of 500 mg/day
214293168|NCT05247268|DRUG|Triprorelin Acetate|Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses
214293169|NCT05247268|DRUG|Letrozole 2.5mg|At a dosage of 2.5mg/day and no more than 24 weeks
214293170|NCT01521455|DRUG|HCP0910|250/50, BID for 2 weeks
214293171|NCT01521455|DRUG|Seretide Diskus|250/50, BID for 2 weeks
214293172|NCT01454869|DRUG|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
214477337|NCT05970601|DIETARY_SUPPLEMENT|Soup|Intake of a single soup with different sodium chloride and potassium chloride content
214477338|NCT06674681|DIAGNOSTIC_TEST|HPV Self-Collection|HPV self-collection program for in-clinic and mailed cervical cancer screening.
214886454|NCT01682486|DEVICE|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
214886455|NCT01682486|PROCEDURE|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
214293173|NCT01454869|DRUG|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
214886456|NCT01085721|DRUG|Dexchlorpheniramine, pseudoephedrine, guaifenesin|5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days
214886457|NCT01085721|DRUG|Dexchlorpheniramine|5 mL (2 mg dexchlorpheniramine) qid for 5 days
214886458|NCT04895982|BIOLOGICAL|BNT162b2|Intramuscular Injection
214886459|NCT00080873|DRUG|Traumeel S|
214886460|NCT00080873|OTHER|Placebo|
214886461|NCT01649960|DRUG|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
214886462|NCT05667675|BEHAVIORAL|Community Support Worker|Participants in the intervention group will have a structured review of their financially related needs and resources with a trained CSW, who will have a thorough understanding of potential income supports and community support agencies. The CSW will use a structured approach to identify financial needs and benefits for which the family is eligible The CSW will work intensively with families in the intervention arm to identify and meet their goals. They will conduct weekly meetings to complete forms, and provide advocacy (in person and by telephone) as needed up to six meetings as needed for system navigation.
214886463|NCT05667675|BEHAVIORAL|Control|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. For this proposal, participants in the comparator group will receive Usual care, defined as: Participants in both groups will receive a written summary of available resources.
214886464|NCT05786209|OTHER|Whole-body Balm|Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.
214886465|NCT05786209|OTHER|Wash and Shampoo|"Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method."
214886466|NCT02863783|DEVICE|EUS with Fiducial|EUS will be used to place fiducial into pancreas tumor at time of biopsy
214886467|NCT02943928|DEVICE|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
214293174|NCT05534529|DRUG|Rezafungin Acetate|This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.
214886468|NCT02943928|DEVICE|traditional method by experience|Operator inserted the double lumen tube by experience
214886469|NCT04807647|OTHER|"Orhan OSMAN's track Don't Let Your Baby Cry in the Kolik album will be played on the music player."|white noise will be played while breastfeeding
214886470|NCT04693897|DRUG|Mirabegron 50 MG|Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
214886471|NCT04693897|DRUG|Solifenacin Succinate 5 MG|Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
214886472|NCT03460080|DIAGNOSTIC_TEST|AFP-L3 and PIVKA-II in HCC|"Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI"
214886473|NCT02662660|DRUG|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
214293175|NCT04427527|BEHAVIORAL|Multi-level intervention to increase CRC screening|Intervention for the community, providers, patients, clinics and systems
214293176|NCT01184625|OTHER|Physical Exercise|12 weeks of physical exercise.
214293177|NCT04419454|DEVICE|BodyTite|retrospectively evaluate this novel treatment approach to improve the appearance of cellulite on the thighs and buttocks by tightening the SFS using RFAL.
214886474|NCT02662660|DRUG|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
214886475|NCT02662660|DRUG|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
214886476|NCT02045589|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
214886477|NCT02045589|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
214886478|NCT02045589|DRUG|Abraxane®|125 mg/m2 intravenous administration
214886479|NCT01910246|DRUG|Metformin|
214886480|NCT01893346|DRUG|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
214886481|NCT02213289|DRUG|Trastuzumab|Trastuzumab
214886482|NCT02213289|DRUG|ABT-806|ABT-806
214293178|NCT00676351|PROCEDURE|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
214293179|NCT04282993|DEVICE|Wearable devices for identifying and measuring risk factors for ischemic stroke|Identifying and monitoring cerebrovascular risk factors using wearable devices
214293180|NCT04282993|OTHER|Standard of care monitoring|Periodical medical examinations
214293181|NCT02211001|OTHER|Pilates Group|The exercises were applied once a week during eight weeks.
214293182|NCT02211001|OTHER|Segmented Dynamic Exercises Group|The exercises were applied once a week during eight weeks. once a week for eight weeks.
214293183|NCT02211001|OTHER|Global Postural Reeducation|The exercises were applied once a week during eight weeks.
214886483|NCT02213289|DRUG|Bemarituzumab|Bemarituzumab
214886484|NCT02213289|DRUG|Ramucirumab|Ramucirumab
214886485|NCT02213289|DRUG|Nivolumab|Nivolumab
214886486|NCT02213289|DRUG|Standard cytotherapy|FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
214886487|NCT01449812|BIOLOGICAL|Infanrix+Hib™|Intramuscular, one dose
214886488|NCT01449812|BIOLOGICAL|Poliorix™|Intramuscular, one dose
214886489|NCT04743492|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.
214477339|NCT05694169|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
214477340|NCT05640375|DRUG|Methylprednisolone|Single dose, 1 mg/kg
214886490|NCT04666389|DRUG|Atorvastatin|To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
214886491|NCT03638726|DRUG|Atropine sulfate and epinephrine|Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.
214886492|NCT03638726|DRUG|Topical cyclopentolate and phenylephrine|Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.
214886493|NCT05917600|OTHER|APN intervention|"Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
214886494|NCT00148005|PROCEDURE|Questionnaire and micturition and drinking diaries|
214886495|NCT00148005|PROCEDURE|Clinical and functional examination (uroflowmetry, bladder scan and video-urodynamic examination)|
214886496|NCT00148005|BEHAVIORAL|Adaptation of the drinking scheme|
214886497|NCT00148005|DRUG|Anticholinergic therapy|
214886498|NCT00148005|BEHAVIORAL|Micturition clock|
214886499|NCT02851745|DRUG|Linagliptin|
214886500|NCT02851745|DRUG|Placebo|
214477341|NCT05890105|DRUG|PF-07853578|PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
214477342|NCT05890105|DRUG|Placebo|Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
214477343|NCT06549023|PROCEDURE|Single-session panretinal PRP (SS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.
214477344|NCT06549023|PROCEDURE|Multiple-session panretinal PRP (MS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.
214477345|NCT06607822|DEVICE|A patient-centered assistant system based on Large-Language Model (LLM)|Participants will engage in a 10-minute medical consultation using LLM model interface embedded in a tablet device before their regular face-to-face consulation with physicians. During the trials, participants could engage in free conversations covering aspects including risk factors, symptoms, diagnosis, examinations, treatment, advice and caution, etc. Participants who have completed the ophthalmic imaging examination will be asked to input results into the assistant model to generate structured reports.
214886501|NCT01866098|DRUG|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
214886502|NCT01866098|DRUG|Placebo|
214886503|NCT04239027|DRUG|RTH258/Brolucizumab|"Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients were treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment every 8 weeks (Q8W) or every 12 weeks (Q12W) depending on disease activity from Week 16/Week20 to Week 40/Week 44.~Brolucizumab was administered by an intravitreal (IVT) injection to the study. eye."
214886504|NCT04392427|DRUG|Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :|"Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.~* Sample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.~* Randomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)~* Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days"
214886505|NCT03361774|DRUG|Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).|"Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to."
214886506|NCT03361774|DRUG|Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).|Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
214886507|NCT05551663|OTHER|Isometric exercise training|Participants randomised to the intervention will perform a 4-week programme of isometric exercise training.
214886508|NCT03449446|DRUG|SEL|18 mg tablet administered orally once daily without regard to food
214886509|NCT03449446|DRUG|FIR|20 mg tablet administered orally once daily without regard to food
214886510|NCT03449446|DRUG|CILO|30 mg tablet administered orally once daily without regard to food
214886511|NCT03449446|DRUG|Placebo to match FIR|Tablet administered orally once daily without regard to food
214477346|NCT06746857|DEVICE|repetitive transcranial magnetic stimulation|Bilateral dorsolateral prefrontal cortex Intermitten Theta Burst Stimulation to
214886512|NCT03449446|DRUG|Placebo to match CILO|Tablet administered orally once daily without regard to food
214886513|NCT03449446|DRUG|Placebo to match SEL|Tablet administered orally once daily without regard to food
214886514|NCT03883802|DRUG|Foxy-5|Lyophilized powder for solution for intravenous infusion
214886515|NCT03883802|DRUG|FOLFOX regimen|6 months treatment regimen
214886516|NCT03883802|PROCEDURE|Tumour resection (colon cancer surgery)|Surgical removal of patients colon cancer
214477347|NCT06856824|PROCEDURE|injection in the bicipital groove guided by anatomic landmarks|Anatomical landmark-guided puncture involves patient positioning and palpation, whereas ultrasound-guided involves identifying the biceps tendon's axis and inserting the needle parallel to the transducer.
214886517|NCT01579747|PROCEDURE|Ultrasound|Using ultrasound for nerve localization when performing a sciatic nerve block via the lateral popliteal approach
214477348|NCT06856824|PROCEDURE|injection in the bicipital groove guided by ultrasound|Anatomical landmark-guided puncture involves patient positioning and palpation, whereas ultrasound-guided involves identifying the biceps tendon's axis and inserting the needle parallel to the transducer.
214477349|NCT06858891|PROCEDURE|Transversus abdominis plane (TAP) block|Under ultrasound guidance, 20 cc of 0.25% bupivacaine was planned to be administered between the internal oblique and transversus abdominis fascial planes on both lateral aspects of the anterior abdominal wall.
214477350|NCT06861114|DIAGNOSTIC_TEST|Urine proteomics|Patients with hepatocellular carcinoma amenable to radical resection were included according to the inclusion exclusion criteria, and preoperative urine and postoperative urine from consecutive patients were collected at the marker time (before receiving postoperative adjuvant therapy after radical surgery for hepatocellular carcinoma) and at the longitudinal time (at the time point of 3 months after radical surgery), and the different samples were preprocessed, followed by mass spectrometry-based urinary proteomics to detect the differences in urinary proteins, and the data were recorded to compare the differences.
214477351|NCT06862843|OTHER|Collecting questionnaires and biological samples|For each family member will be collected a 3-days food diary, a food frequencies questionnaire and a questionnaire assessing the adherence to the mediterranean diet. Additionally, a blood sample for trascriptomic analysis and a fecal sample for gut microbiota analysis will be collected
214886518|NCT01579747|PROCEDURE|Nerve stimulation|Using nerve stimulation for nerve localization in sciatic nerve blocks via the lateral popliteal approach
214886519|NCT04182334|OTHER|Slow Tempo Music|For up to seven days, enrolled subjects will receive one-hour slow tempo music listening sessions twice daily through noise-cancelling headphones.
214886520|NCT04182334|OTHER|Attention Control|Subjects will receive a noise cancellation headphone-applied condition identical to the music intervention experimental treatment in twice daily one hour-sessions for up to seven days.
214886521|NCT02839707|DRUG|Atezolizumab|Given IV
214886522|NCT02839707|BIOLOGICAL|Bevacizumab|Given IV
214886523|NCT02839707|PROCEDURE|Computed Tomography|Undergo CT
214886524|NCT02839707|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214886525|NCT02839707|OTHER|Quality-of-Life Assessment|Ancillary studies
214886526|NCT06771336|OTHER|Questionnaires|Quality of life questionnaires, questionnaires for assessing functional results, micro-costing questionnaire, informal support assessment questionnaires
214886527|NCT06575673|BEHAVIORAL|Internet-based dialectical behaviour therapy-informed skills training|Adaptive applications of DBT-ST for smokers with psychological distress
214886528|NCT06575673|BEHAVIORAL|Monthly health education|General health information and sharing sessions
214886529|NCT06604494|BEHAVIORAL|early feeding resumption|Resumption of food on the 3rd or 4th day post-operatively with a mixed diet.
214886530|NCT06604494|BEHAVIORAL|late feeding resumption|Resumption of food on the 7th day post-operatively with a mixed diet.
214886531|NCT06780033|DRUG|ART-101 - SAD|Forty participants will be enrolled across 5 SAD cohorts. The planned doses across 5 cohorts are as follows- include 20mg (SAD Cohort 1), 60mg (SAD Cohort 2). 150mg (SAD Cohort 3). 300mg (SAD Cohort 4) and 500 mg (SAD Cohort 5).
214886532|NCT06780033|OTHER|Placebo|Participants will receive matching placebo subcutaneously on Day 1 after 8 hour fast.
214886533|NCT07134686|OTHER|Joint consultation|Joint consultation with pneumologist and ENT at baseline.
214886534|NCT07134686|PROCEDURE|Mucus sampling|Mucus sampling at baseline and one year follow-up
214886535|NCT07134686|PROCEDURE|Nasal brushing|Nasal brushing at baseline and one year follow-up
214886536|NCT05041309|BIOLOGICAL|Axicabtagene Ciloleucel|No investigational product will be administered
214886537|NCT05041309|BIOLOGICAL|Brexucabtagene Autoleucel|No investigational product will be administered
214886538|NCT05041309|BIOLOGICAL|Anitocabtagene autleucel|No investigational product will be administered
214886539|NCT05041309|BIOLOGICAL|KITE-753|No investigational product will be administered
214886540|NCT05041309|BIOLOGICAL|KITE-197|No investigational product will be administered
214886541|NCT05041309|BIOLOGICAL|KITE-363|No investigational product will be administered
214886542|NCT07082439|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenous administration on day 1 of each 3-week cycle until disease progression, unacceptable toxicity or participant withdrawal. Participants who complete study intervention after 2 years of pembrolizumab and odetiglucan without disease progression and subsequently experience disease progression while off of treatment are eligible for up to 1 year of additional pembrolizumab and odetiglucan (second course).
214886543|NCT07082439|DRUG|Odetiglucan|Odetiglucan 4 mg/kg intravenous administration on day 1 of each 3-week cycle until disease progression, unacceptable toxicity or participant withdrawal. Participants who complete study intervention after 2 years of pembrolizumab and odetiglucan without disease progression and subsequently experience disease progression while off of treatment are eligible for up to 1 year of additional pembrolizumab and odetiglucan (second course).
214886544|NCT07110922|DIAGNOSTIC_TEST|Angiography only|Superior vena cava (SVC) angiogram will be used to anatomically identify the BB region
214886545|NCT07110922|DIAGNOSTIC_TEST|Angiography and ECG|Superior vena cava (SVC) angiogram will be used to anatomically identify the BB region and correlate with electrogram guidance for BBP
214886546|NCT07123883|PROCEDURE|Dry Needling|Dry Needling
214886547|NCT07123883|OTHER|sham needling|In the SG, a validated sham needling procedure was simulated.
214886548|NCT07086079|DRUG|DOR/ISL|Oral tablet
214886549|NCT03640416|DEVICE|Fitbit® Charge HR smart watch|The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
214886550|NCT06904365|DEVICE|HyperSight cone beam computed tomography (CBCT) scan|HyperSight is a novel onboard imaging platform with a rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for simulation and treatment.
214886551|NCT06904365|DEVICE|ETHOS 2.0|ETHOS 2.0, an artificial intelligence treatment planning system, will be utilized in an emulator to create SCRT plans to determine the feasibility of clinically significant ovarian dose reductions in-silico.
214886552|NCT07095283|DIAGNOSTIC_TEST|Short International Consultation on Incontinence Questionnaire (ICIQ-SF)|This is a self-administered questionnaire with four questions and a total score ranging from 0 \[best\] to 21 \[worst\] that identifies people with urinary incontinence and its impact on quality of life.
214293184|NCT06297733|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the inventory and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
214293185|NCT06297733|OTHER|Validity|The inventory will be applied by face-to-face technique and convergent validity will be evaluated. Construct validity will be evaluated through exploratory and confirmatory factor analysis. Coefficients of fit will be calculated.
214293186|NCT06297733|OTHER|Reliability|The reliability of the items will be tested with Cronbach alpha. Test-retest reliability will be measured by ICC.
214293187|NCT05447637|DIAGNOSTIC_TEST|Invitae multi-cancer gene panel|Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
214293188|NCT04224311|BIOLOGICAL|Menactra|0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.
214886553|NCT07095283|DIAGNOSTIC_TEST|King's Health Questionnaire (KHQ)|The KHQ is a self-administered instrument specifically designed to assess quality of life in women with UI. It consists of 21 items distributed across 9 dimensions: perception of overall health (1 item), impact of UI (1 item), limitations in daily activities (2 items), physical limitations (2 items), social limitations (2 items), personal relationships (3 items), emotions (3 items), sleep/energy (2 items), and severity of UI (5 items). The score range for each dimension is from 0 (lowest impact of UI and therefore best quality of life) to 100 (highest impact, worst quality of life). This questionnaire provides an overall value for the quality of life of the patient with UI (Overall Score-OS) and another specific value for each dimension on a scale with the following range: 0: Best possible quality of life - 100: Worst possible quality of life.
215047910|NCT06608589|OTHER|CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers|COMPAS+ is a collaborative approach to improving healthcare quality. It brings together around 30 individuals, including healthcare professionals, deciders, and patient partners, to identify improvement goals, develop action plans, and enhance the prevention and management of chronic diseases. In this study, the investigators adapt COMPAS+ to focus on improving care transitions for patients with major neurocognitive disorders (MNCDs) and their caregivers. Through reflective workshops and collaborative problem-solving, this diverse group will identify best practices and create action plans to enhance care quality.
215047911|NCT02311725|BEHAVIORAL|aTAU + sTVi|Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
214293189|NCT01485770|DRUG|ADX-N05|150 mg once a day for seven days followed by 300 mg once a day for seven days
214293190|NCT01485770|DRUG|Placebo|Placebo to match ADX-N05 once a day for 2 consecutive weeks
214293191|NCT01860651|BEHAVIORAL|Web-monitoring|During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
214293192|NCT06437860|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
214293193|NCT06437860|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
214293194|NCT05845684|OTHER|Physiotherapy application|massage, oral and intraoral tactile stimuli and non-nutritive sucking will be performed to stimulate sucking, and massage applications and neurodevelopmental therapy for motor development.
214293195|NCT05845684|OTHER|Control Group|standard daily applications will be performed on patients
214886554|NCT07095283|DIAGNOSTIC_TEST|Ultrasound evaluation|A two-dimensional (2D) ultrasound system with B-mode capability and cine-loop function, a 3.5 to 6 MHz curved convex probe transducer, was used for the perineal image. The examination will be performed in the dorsal lithotomy position, with the hips flexed and slightly abducted and the heels placed close to the buttocks, or in a standing position if necessary.
214293196|NCT05201560|DRUG|Butorphanol Tartrate Injection|Patients of this group will receive Butorphanol Tartrate Injection
214293197|NCT05201560|DRUG|Fentanyl|Patients of this group will receive Fentanyl
214293198|NCT02485574|PROCEDURE|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.
214293199|NCT03107325|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
214886555|NCT07097792|BEHAVIORAL|CRISP (Concussion Recovery and Support Program)|Mental health intervention targeting suppressed emotion with a goal of facilitating recovery.
214293200|NCT03107325|DRUG|F-18 Fluorodeoxyglucose|Participants will be asked to be imaged at an additional time point during an FDG PET study
214886556|NCT06507137|OTHER|Fractal|Walking in a treadmill while synchronizing their steps with fractal external visual cues
214886557|NCT06507137|OTHER|Isochronous|Walking in a treadmill while synchronizing their steps with isochronous external visual cues
214886558|NCT06507137|OTHER|Control|Walking in a treadmill
214886559|NCT06730100|PROCEDURE|Biopsy Procedure|Undergo biopsy
214886560|NCT06730100|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214886561|NCT06730100|PROCEDURE|Computed Tomography|Undergo CT scan
214477352|NCT06861803|DRUG|Letrozole tablets|The intervention in this study is ovulation induction using letrozole, an aromatase inhibitor commonly used in women with polycystic ovary syndrome (PCOS) to stimulate ovulation. Participants will receive letrozole at an initial dose of 2.5 mg/day for five days, starting on day 3 of the menstrual cycle. If ovulation is not achieved, the dose will be incrementally increased up to a maximum of 7.5 mg/day over a maximum of three cycles. Ovulation will be monitored through serial transvaginal ultrasounds to assess follicular development, and confirmed by measuring mid-luteal serum progesterone levels (\>3 ng/mL). Based on the response to letrozole, participants will be classified as either letrozole-sensitive (ovulatory) or letrozole-resistant (anovulatory) to identify potential predictors of resistance and improve individualized treatment strategies for PCOS-related infertility.
214477353|NCT06863948|OTHER|Teribenin method|"Intervention: Terebenin's Method~* Format:~* Duration: 8 weeks, 1 session/week (2-3 hours).~* Group size: 8-12 participants + 1-2 facilitators.~* Structure of Each Session:~* Introduction (10-15 min): Check-in, brief emotional reflection.~* Main Phase (90-120 min): Psychodrama-like enactments, systemic constellation exercises, body-oriented practices, directive interpretation by the therapist.~* Conclusion (15-20 min): Group reflection, integration, feedback.~* Quality Assurance:~* Audio/video recording (with consent) for supervision.~* A standard protocol/manual specifying core techniques"
214477354|NCT06863948|OTHER|Control Interventions|"1\. Active Control (Preferred):~* Group psychotherapy (CBT, Gestalt, or another recognized approach) matching the same 8-week schedule. 2. Waitlist Control (If Active Control Unavailable):~* Participants receive no active intervention during the 8 weeks, then are offered therapy afterward (if applicable)"
214886562|NCT06730100|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214886563|NCT06730100|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
214886564|NCT06730100|PROCEDURE|X-Ray Imaging|Undergo chest x-rays
214886565|NCT02506127|DEVICE|Neuronetics XPLOR system|Transcranial magnetic stimulation system
214886566|NCT07098910|PROCEDURE|Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA)|While the infant is spontaneously breathing on nasal CPAP, the NICU physician will place the supraglottic airway device (SAD) and assess airway adequacy via CO₂ detection, chest movement, bilateral breath sounds, gastric insufflation, oxygen saturation, and heart rate. Each placement attempt should last no more than 30 seconds, with up to two attempts allowed. Surfactant (Curosurf 200 mg/kg) will be given slowly in 1-2 ml aliquots via a CE-marked preterm-sized SAD, Neo i-gel® (sizes 0.85, 0.75, 0.65; Intersurgical Ltd). The infant should primarily breathe spontaneously with PEEP from a T-piece resuscitator and receive gentle PPV if needed. PPV is continued for 30 seconds after surfactant administration before SAD removal. A reservoir bag may be used secondarily to provide PPV. If surfactant delivery via SALSA fails, the INSURE method (Intubation-Surfactant-Extubation) will be attempted.
214886567|NCT07098910|PROCEDURE|Intubation - Surfactant administration - Extubation (INSURE)|Study participants will receive surfactant therapy administered via brief endotracheal intubation - surfactant administration - and extubation (INSURE). Infants will be ventilated using a T-piece resuscitator with PEEP of 6 cm H20 and positive pressure ventilation (20 cm H20) for a couple of minutes (no more than 15 minutes) with adjustable FiO2. No mechanical ventilation will be used. Secondarily a reservoir-bag will be used for ventilation.
214886568|NCT03384563|DRUG|Dexmedetomidine|Dexmedetomidine 9 arms
214886569|NCT01950390|BIOLOGICAL|Bevacizumab|Given IV
215047912|NCT02311725|BEHAVIORAL|aTAU + Attention Control Videos|Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
215047913|NCT03721822|DRUG|[18F]NOS|\[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
215047914|NCT06715995|DEVICE|Gamma Wave Stimulation Table Lamp (Aleddra, Inc., USA)|Participants will receive light stimulation using the Gamma Wave Stimulation Table Lamp (Aleddra, Inc., USA) for 1 hour per day, 7 days a week, over 4 weeks, for a total of 28 hours.
214886570|NCT01950390|BIOLOGICAL|Ipilimumab|Given IV
214886571|NCT07093749|DEVICE|Garmin Smartwatch|Garmin Venu 3 - Worn for the duration of antibiotic course
215047915|NCT06715774|DEVICE|Impact of Twin Block and Motion above Hyoid bone|All patients were submitted to preoperative and postoperative lateral teleradiography (Vatech D052SB, Puteaux, France), with the following exposure parameters: 75KV, Intensity10mA, exposition times 11s28, 112,8 mAs, using the Frankfort plane as reference parallel to the floor; moreover, patients were required to avoid moving and swallowing. Afterwards, digital datasets were uploaded and aligned into a digital therapeutic planning software (Orthalis®, Orqualceph®,group orqual) to accurately record the position changes of the hyoid bone at horizontal, vertical, and angular level, according the gender, facial biotype and airway complex, by measuring the following anatomical references:
215047916|NCT05618444|BEHAVIORAL|Automated Management (AM)|A tele-management intervention that will deliver two-way messages to participants via a bot - a computer program that simulates human activity. Programmed AM messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
215047917|NCT03303729|DIETARY_SUPPLEMENT|Meat Hydrolysate|25 grams of meat hydrolysate to maximally stimulate protein synthesis.
215047918|NCT03303729|DIETARY_SUPPLEMENT|Cluster Dextrin|75 grams of Cluster Dextrin
215047919|NCT03303729|DIETARY_SUPPLEMENT|Placebo|75 grams of Glucose
215047920|NCT03559270|DRUG|Baricitinib|Administered orally
215047921|NCT01850953|DRUG|Varenicline|This is an approved smoking cessation medication.
214886572|NCT03951324|OTHER|Interobserver agreement or Interrater agreement|Interobserver agreement or Interrater agreement using 9 visual criteria for diagnosing VLE clips that feature indeterminate biliary or pancreatic duct strictures
214886573|NCT00134004|DRUG|cyclophosphamide|
214886574|NCT00134004|DRUG|fludarabine phosphate|
215047922|NCT01850953|DRUG|Placebo|
214886575|NCT00134004|DRUG|mycophenolate mofetil|
214886576|NCT00134004|DRUG|tacrolimus|
214886577|NCT00134004|PROCEDURE|allogeneic bone marrow transplantation|
215047923|NCT03836404|DEVICE|Iliac crest reconstruction surgery|When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
214477355|NCT06592742|BEHAVIORAL|Pulmonary rehabilitation (alone)|The Pulmonary Rehabilitation (PR) program for the control group includes daily aerobic exercises such as treadmill walking or cycling for 20-30 minutes at moderate intensity, tailored to improve cardiovascular fitness and respiratory function. Strength training focuses on major muscle groups with resistance exercises lasting 15-20 minutes, promoting muscle strength and endurance. Airway clearance techniques are performed for 15-20 minutes daily, using methods like chest physiotherapy or positive expiratory pressure (PEP) to clear mucus from the lungs. Breathing exercises, including diaphragmatic and pursed-lip breathing, are practiced for 10-15 minutes to improve breathing efficiency. Participants also receive education on disease management and nutritional support to meet caloric needs.
215047924|NCT00548535|PROCEDURE|Reliability of complication assessment|
215047925|NCT04750083|DRUG|HX008|HX008 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles
215047926|NCT04750083|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on Day 1 of Q3W for up to 35 cycles
215047927|NCT04750083|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV on Day 1 of Q3W for up to 35 cycles
215047928|NCT04750083|DRUG|cisplatin/carboplatin|cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles
214477356|NCT06592742|BEHAVIORAL|Intervention group (PR + PMR)|The intervention group will follow a Pulmonary Rehabilitation (PR) program combined with Progressive Muscle Relaxation (PMR). Daily aerobic exercises like treadmill walking or cycling will be performed for 20-30 minutes at moderate intensity, improving cardiovascular fitness and lung function. Strength training for major muscle groups will be included, with 15-20 minutes of resistance exercises to enhance muscle strength. Airway clearance techniques, such as chest physiotherapy or PEP, will help clear mucus from the lungs in daily 15-20 minute sessions. Breathing exercises, including diaphragmatic and pursed-lip breathing, will be practiced for 10-15 minutes to improve breathing efficiency. The PMR component involves daily 20-30 minute guided sessions to reduce stress and anxiety through muscle relaxation techniques.
214477357|NCT06865235|PROCEDURE|360º goniotomy assisted transluminal trabeculotomy|Open the Schlemm Canal for 360º with a polipropilen 5-0 suture via trabecular meshwork.
214477358|NCT06865235|PROCEDURE|Phacoemulsification|Cataract Surgery
214886578|NCT00134004|RADIATION|radiation therapy|
214886579|NCT04684043|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
214886580|NCT00289120|DRUG|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
214886581|NCT00289120|DRUG|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
214886582|NCT04135846|DRUG|Doxazosin|16 mg or maximum tolerated dose (MTD)
214886583|NCT04135846|DRUG|Placebo|Matching placebo
214477359|NCT06865235|PROCEDURE|180º gonioscopy assisted transluminal trabeculotomy|Open the Schlemm Canal for 180º with a polipropilen 5-0 suture via trabecular meshwork.
214477360|NCT06863792|OTHER|ChatGPT|Students in the intervention group will answer the questions from the Hypertension Prevention Attitude Scale using ChatGPT.
214477361|NCT06863363|DRUG|PEG-rhGH Injection + Semaglutide Injection|"Polyethylene Glycol Recombinant Human Growth Hormone Injection (PEG-rhGH Injection), 54 IU/9.0 mg/1.0 mL/amp.; Subcutaneous injection using pen-injector, once weekly at a dose of 2 mg per week (weeks 1-40).~Semaglutide Injection, 0.68 mg/mL，1.5 mL；1.34 mg/mL，1.5 mL；1.34 mg/mL，3 mL；2.27 mg/mL，3 mL；3.2 mg/mL，3 mL; Subcutaneous injection once weekly using pre-filled pen including dosage escalation period (W1-W16): starting dose 0.25 mg, increasing every 4 weeks (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) and maintenance treatment period (W17-W40): at a dose of 2.4 mg for 24 weeks"
214477362|NCT06863363|DRUG|Semaglutide Injection|Semaglutide Injection, 0.68 mg/mL，1.5 mL；1.34 mg/mL，1.5 mL；1.34 mg/mL，3 mL；2.27 mg/mL，3 mL；3.2 mg/mL，3 mL; Subcutaneous injection once weekly using pre-filled pen including dosage escalation period (W1-W16): starting dose 0.25 mg, increasing every 4 weeks (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) and maintenance treatment period (W17-W40): at a dose of 2.4 mg for 24 weeks
214477363|NCT06865040|DRUG|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|"Administration in the interventional arm of long-acting inhaled ß-2 mimetics:~FORMOTEROL FUMARATE 12 µg pwd inhalation capsule (FORMOTEROL VIATRIS®), taken twice a day intraoperatively from Day-2 to Day 7."
214477364|NCT06865040|OTHER|Usual treatment|usual treatment
214886584|NCT06940622|DIETARY_SUPPLEMENT|D-Mannose|D-mannose (2g, i.e., 4 x 500mg capsules) daily for 12 months.
214886585|NCT06940622|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 12 months.
214886586|NCT07146932|DEVICE|Pediatric Lower Limb Exoskeleton (Bambini Teens)|The Bambini Teens Exoskeleton is a wearable robotic device developed to assist lower limb movement and facilitate gait training for pediatric patients with mobility impairments such as cerebral palsy. The device provides powered assistance at the hip, knee, and ankle joints, supports adjustable gait parameters, and is designed for use in clinical rehabilitation settings under professional supervision.
214886587|NCT07144618|DEVICE|National Cheng Kung University Abdominal Muscle Group Medical Imaging Analysis Software|Phase 2: The second phase will involve a prospective multicenter clinical trial, enrolling 294 patients with endometrial or ovarian cancer.Patients will be randomized into two groups (at least 147 per group): AI-assisted group (treatment group): Preoperative CT imaging will be used to assess body composition and classify patients into high-risk or low-risk categories.Chemotherapy dosing will be adjusted accordingly to evaluate treatment-related adverse effects and dose modifications. Non-AI-assisted group (control group): Patients will receive chemotherapy chemotherapy dosing adjustments based on standard clinical care.
214886588|NCT02167334|DEVICE|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
214886589|NCT02167334|PROCEDURE|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
214886590|NCT06948175|DEVICE|Abdominal transcutaneous electrical stimulation (TES)|Low-intensity sensory abdominal transcutaneous electrical stimulation (TES)
214886591|NCT06951347|DIETARY_SUPPLEMENT|Oral Rehydration Solution|one sachet every day for 3 days
214886592|NCT07153822|DEVICE|Collagen-based adhesion barrier|Porcine Atelocollagen (Type I)
214886593|NCT07153822|DEVICE|Sodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier|Sodium Hyaluronate(HA) + Sodium Carboxymethylcellulose(CMC)
214886594|NCT07167719|BEHAVIORAL|Cognitive Behavioral Therapy|Brief Cognitive-Behavioral Therapy (CBT) focused on building resiliency in response to the effects of institutionalization
214886595|NCT07166393|DRUG|Valproic Acid (VPA)|VPA (in 250 ml 0.9% sodium chloride solution)
215047929|NCT03436342|DRUG|68Ga-Pentixafor|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga-Pentixafor will be used to image lesions of MM and lymphoma by PET/CT.
214477365|NCT06590870|DRUG|Fentanyl|The fentanyl solution for administration will be prepared by diluting 2 mL of fentanyl 50 µg/mL with 8 mL of normal saline (bacteriostatic 0.9% sodium chloride) for a fentanyl solution of 10 µg/mL.
214477366|NCT06590870|DRUG|Normal saline|The normal saline solution for administration will be bacteriostatic 0.9% sodium chloride.
214477367|NCT06865196|BEHAVIORAL|Positive Parenting Seminar Series|Selected Teen Triple P Positive Parenting Seminar Series Delivered Through Telehealth
214886596|NCT07166393|OTHER|Standard of care treatment + normal saline|Standard of care treatment + normal saline (0.9% sodium chloride solution) vehicle (250 ml)
214886597|NCT07166289|OTHER|Low-intensity focused ultrasound|80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
214886598|NCT07174258|OTHER|Manual myofascial release group|Manual myofascial release techniques were applied to Group I on the feet, legs, and thighs, twice a week for 4 weeks.
214886599|NCT07174258|OTHER|Graston group|Graston was applied to the gastrocnemius and hamstring muscles, and before the application, solid petroleum jelly was applied to the area to lubricate the surface. A stainless steel Graston instrument was used for the application, using a superficial sweep technique at a 30-degree angle for 2 minutes, followed by a deep sweep for 30 seconds.
214886600|NCT07174258|OTHER|Home based exercise group|Group III received a home exercise program that included stretching exercises. They were asked to perform the exercises twice a week for four weeks, with 15-20 repetitions, without any intervention from a physiotherapist.
214477368|NCT06863935|DIETARY_SUPPLEMENT|High-dose omega-3 PUFA supplementation|High-dose omega-3 PUFA supplementation (2-4 g/day EPA+DHA) for 12 weeks in addition to standard lipid-lowering therapy
214477369|NCT06863935|DIETARY_SUPPLEMENT|High-dose omega-3 PUFA supplementation|High-dose omega-3 PUFA supplementation (2-4 g/day EPA+DHA) for 12 weeks in addition to standard lipid-lowering therapy
214477370|NCT06861426|DRUG|Ginkgo Diterpene Lactone Meglumine|The specific administration protocol (including time of initiation, dosage, and treatment duration) should be strictly adhered to as per the physician's prescription and meticulously documented in the case report forms (CRFs).
214477371|NCT02287090|OTHER|Observational Cohort|
215047930|NCT06278493|DRUG|AL2846 capsules|AL2846 is a multi -target receptor tyrosine kinase inhibitor.
215047931|NCT06278493|DRUG|Gemzar|It is a chemotherapeutic drug.
215047932|NCT05726474|BEHAVIORAL|Combined exercise|Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
215047933|NCT05726474|BEHAVIORAL|High interval training|Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
215047934|NCT06165055|DIAGNOSTIC_TEST|DNA Sample Collection + DNA genotyping|Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.
215047935|NCT03414203|OTHER|tDCS|Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
214477372|NCT06219616|DIAGNOSTIC_TEST|BKV immune monitoring|Blood will be drawn and investigated for BKV-specific T cell response.
214477373|NCT06860997|DIAGNOSTIC_TEST|Tissue Doppler Imaging (TDI) S' Wave Echocardiography|This intervention involves bedside echocardiographic assessment using TDI S' wave velocity to evaluate its diagnostic accuracy for acute coronary syndrome (ACS) in patients presenting with acute chest pain in the emergency department (ED).
214886601|NCT07164612|OTHER|Occupation-Based Bilateral Upper Limb Training (OBBT)|Intervention sessions for experimental group will be conducted 5 times per week over 6 weeks. OBBT will be used to engage both upper limbs simultaneously in simulate real-life functional tasks which tailored to individual needs, focusing on improving the patient's ability to perform daily activities such as dressing, washing, and cooking. The training will emphasize occupation-specific repetitive practice for at least two selected occupations and encouraged active participation of both hands during functional tasks to improve use of both upper limb motor functions and activity participation. Additionally, it will seek to support stroke survivors in their pursuit of an independent, productive, and functional recover.
214886602|NCT07164612|OTHER|Conventional therapy group|Conventional therapy includes passive and active range of motion exercises, strengthening exercises, basic functional activities and mobility training, and activities designed to improve muscle tone and mobility in the affected upper limb among stroke survivors. The conventional therapy sessions will be delivered 5 times per week for 90 minutes over 6 weeks. Therapy sessions will be individualized to the participant's needs and will be provided by senior occupational therapists.
214886603|NCT07172763|DEVICE|Siliconepad|Plantar pressure measurement
214886604|NCT07172763|DEVICE|Felted foam|Plantar pressure measurement
214477374|NCT06672666|DRUG|Hemp Derived Cannabidiol Extract|Participants will be given the study drug in a titrated method of 50-150mgs per day for 4 weeks
214477375|NCT06672666|DRUG|Placebo|Partcipants will be given placebo substance to be taken with titrated instructions that mimic IP dispensing method daily for 4 weeks
214477376|NCT04066881|BIOLOGICAL|Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)|"1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~2. AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant."
214886605|NCT07175441|DRUG|RBS2418|RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.
214886606|NCT07175441|DRUG|STRIDE (durvalumab + tremelimumab)|STRIDE: Tremelimumab 300 mg IV (Cycle 1 Day 1 only) Plus Durvalumab 1500 mg IV every 4 weeks
214886607|NCT07186153|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) after treatment with SGLT2 inhibitors
214886608|NCT07184736|PROCEDURE|Active Manual Syringe Aspiration|For the Active Manual Syringe Aspiration, the operator manually withdraws pleural fluid using a syringe attached to a 3-way stopcock and transfusion set. The fluid is then expelled into a collection bag.
214886609|NCT07184736|PROCEDURE|Passive Gravity Drainage|In Passive Gravity Drainage, after confirming proper needle placement with initial aspiration, the syringe is detached, and pleural fluid is allowed to drain passively by gravity through the transfusion set into a collection bag.
214886610|NCT07184905|BIOLOGICAL|Oral administration of inactive Bifidobacterium longum group|1×10\^11 CFU of inactive Bifidobacterium longum was given orally once daily for one month
214886611|NCT07184905|BIOLOGICAL|Oral Bifidobacterium longum group|1×10\^11 CFU of Bifidobacterium longum was given orally once daily for one month
214293201|NCT00264329|OTHER|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
214293202|NCT04052893|PROCEDURE|Expanded Mckissock surgery|Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
214293203|NCT04052893|PROCEDURE|Modified radical mastectomy|The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
214293204|NCT06504758|OTHER|Breathing Retraining Program|"* 1st to 5th week - Breathing Retraining 10 repetitions (Pursed Lip Breathing, Diaphragmatic Breathing)~* Two days / a week The total duration of 5 weeks."
214293205|NCT06504758|OTHER|Postural Exerises Program (Stretching and Strengthening Exercises)|"* TheraBand® or Free Weight~* 1st week - neck isometrics, chin tuck, SCM - upper trapezius - pectoral major stretching, scapular retraction without weight, rowing with yellow TheraBand®, wall squat / mini squat (5 repetitions - 15 second hold for stretching exercises, 10 repetitions for strengthening exercises)~* 2nd and 3rd week - same exercises (5 repetitions - 15 second hold for stretching exercises, 15 repetitions for strengthening exercises)~* 4th and 5th week - same exercises (10 repetitions - 15 second hold for stretching exercises, 20 repetitions for strengthening exercises)~* Two days / a week,The total duration of 5 weeks"
214293206|NCT04465539|DRUG|Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]|Hydroxyethyl starch dose is 500 cc in 6 hours
214886612|NCT07186075|BEHAVIORAL|Phubbing and Mental Health Literacy Education for Adolescents|Phubbing and Mental Health Literacy Education for Adolescents
214886613|NCT07186075|BEHAVIORAL|no training was provided|no training was provided
214293207|NCT04465539|DRUG|Hydrocortisone|Hydrocortisone dose is 200-300 mg /day intravenously
214886614|NCT07186933|PROCEDURE|PEEP titration for Minimum Driving Pressure|"This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP Initially 8 cm H2O. Afterwards, the lungs are recruited with the aforementioned maneuver. During subsequent derecruitment, PEEP is decreased by 2 cm H20 and compliance is noted in each stage. The goal is to find PEEP with maximum compliance (Cmax). A new recruitment maneuver follows and during derecruitment PEEP is set at the optimum value that was previously defined.~VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuver (as described) every hour"
214886615|NCT07186933|PROCEDURE|Lung Protective Ventilation|This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP 8 cm H2O. VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuvers (as described) every hour
214886616|NCT07184502|DRUG|ZT003|ZT003 is administered as a single subcutaneous injection at different dose levels.
214293208|NCT04465539|DRUG|Placebo|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
214886617|NCT07184502|DRUG|ZT003|ZT003 administered as multiple subcutaneous injections at different dose levels.
214886618|NCT07184502|DRUG|Placebo|Matching placebo administered subcutaneously.
214886619|NCT07186829|DEVICE|Percutanous pinning|Similar to arm - closed reduction, two percutaneous pins
214886620|NCT07186829|DEVICE|Locked plate|Similar to arm - open reduction, dorsal approach, 3 screws proximal and distal
214886621|NCT07186829|DEVICE|Intramedullary screw|Similar to arm - 1 cm dorsal incision, closed reduction, internal compression screw
214886622|NCT07186751|DRUG|Pregabalin|In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.
215047936|NCT06186908|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
215047937|NCT00896012|PROCEDURE|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
215047938|NCT00896012|DRUG|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
214293209|NCT05529043|BEHAVIORAL|MINISTOP app|The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.
214886623|NCT07186751|DRUG|Pregabalin with venlafaxine|In the pregabalin with venlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Venlafaxine will be administered at 75 mg daily with breakfast initially. If the initial dose is well-tolerated, the dose could be further escalated by 75 mg per day after 4 days, up to a maximum of 225 mg per day. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and desvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.
214886624|NCT07184788|DRUG|Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy|Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Gemcitabine (1000 mg/m2 iv qd d2), Oxaliplatin (100 mg/m2 iv qd d2) as induction therapy.
214886625|NCT07185750|OTHER|Questionnaire application for JIA cases and their parents|Scales will be applied to cases diagnosed with JIA and their parents
214886626|NCT07185113|DRUG|GEn-1124|GEn-1124 will be administered to one single dose group of subjects dosed under fed (standardized meal) conditions. GEn-1124 will be administered as an oral capsule formulation containing GEn-1124.
214886627|NCT07185503|DRUG|liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole|The intervention in this study is a tailored antifungal regimen combining liposomal amphotericin B (L-AmB) (3-5 mg/kg/day IV) with posaconazole or isavuconazole (300 mg/200 mg daily, oral or IV), designed to optimize efficacy and safety in immunocompromised adults with blood cancers and mucormycosis. Dosing and duration are personalized based on clinical response, immune recovery, and organ function, with a focus on transitioning to oral therapy to reduce hospitalization. The study emphasizes rigorous safety monitoring, prohibited unauthorized antifungal co-medications, and explores prognostic factors to advance treatment strategies for this high-risk population.
214886628|NCT07184827|DRUG|U101|One capsule (100 mg) of U101 will be administered orally three times per day (TID) for 8 weeks followed by one capsule of U101 twice per day (BID) for 16 weeks.
214886629|NCT07184827|OTHER|Placebo|One capsule of Placebo will be administered orally three times per day (TID) for 8 weeks followed by one capsule of placebo twice per day (BID) for 16 weeks.
214886630|NCT07185789|BEHAVIORAL|Healthy and Sustainable Eating|Animated projections, snacks that incorporate fruits and/or vegetables, measuring their hydration status through images where they can observe the color of their urine and relate it to the amount of plain water they have consumed, as well as activities through the mobile messaging platform, WhatsApp.
214886631|NCT07185789|BEHAVIORAL|Movement behaviors|Animated projections, snacks that incorporate fruits and/or vegetables, measuring their hydration status through images where they can observe the color of their urine and relate it to the amount of plain water they have consumed, as well as activities through the mobile messaging platform, WhatsApp.
214886632|NCT07185789|BEHAVIORAL|Psychosocial determinants|Workshops on key topics of psychosocial determinants in children, virtual workshops on topics of psychosocial determinants such as obesity and healthy eating.
215047939|NCT00896012|DRUG|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
215047940|NCT03938831|DRUG|Dexmedetomidine|dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
215047941|NCT03938831|DRUG|Fentanyl-based PCA infusion|Fentanyl-based PCA infusion
214293210|NCT05529043|BEHAVIORAL|MINISTOP Plus Program|Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
214293211|NCT03238508|PROCEDURE|Deferred stenting|Previously described
214293212|NCT01680523|PROCEDURE|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
214293213|NCT01680523|RADIATION|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
214886633|NCT07186179|DRUG|Mobilization Regimen|"This study will utilize a standard mobilization regimen that is used for peripheral blood stem cell mobilization in patients with a variety of underlying conditions.~Upon study initiation, participants will undergo a peripheral blood draw and bone marrow aspiration and biopsy. They will then begin the following mobilization regimen:~1. Granulocyte-colony stimulating factor (G-CSF; filgrastim) dosed at 10mcg/kg/day administered subcutaneously in the morning for 5-7 days~2. Plerixafor dosed at 0.24mg/kg/day administered subcutaneously in the evening for 1-4 days~Participants will undergo daily blood draws until criteria for study completion is achieved."
214886634|NCT07186413|DRUG|Trifarotene|Trifarotene cream applied QD topically.
215047942|NCT00148863|DRUG|Peg-interferon alpha 2a (drug)|
214886635|NCT07186413|DRUG|Vehicle Cream|Vehicle cream applied QD topically.
215047943|NCT00148863|DRUG|Ribavirin (drug)|
215047944|NCT00148863|DRUG|Interferon gamma (drug)|
214886636|NCT07186322|PROCEDURE|Fat Graft|Non-regenerative standard treatment for post-burn sequelae, involving either corticosteroid injection to reduce scar inflammation and fibrosis, or surgical release for contractures. The procedure type will be chosen based on the clinical indication and severity.
214886637|NCT07186842|DRUG|BNT329|Intravenous (IV) infusion
214886638|NCT07186842|DRUG|CA19-9-targeting monoclonal antibody|Monoclonal antibody
214886639|NCT07185399|BIOLOGICAL|Moderna RSV vaccine|Participants will receive the MRESVIA vaccine (Moderna RSV vaccine) as part of the study. The vaccine will be administered by trained clinical personnel at the Hope Clinic. MRESVIA is FDA-approved and will be used in accordance with its licensed indication for adults aged 60 years and older. MRESVIA is an mRNA-based RSV vaccine containing 50 micrograms (mcg) of nucleoside-modified mRNA encoding the RSV prefusion F glycoprotein. It is supplied as a frozen injectable suspension in single-dose, pre-filled syringes. The vaccine is administered as a single 0.5 milliliter (mL) intramuscular injection.
214886640|NCT07185178|OTHER|Video game-based breathing exercises|"Twenty individuals will be enrolled in the video game-based breathing exercise program. Participants in the study group will undergo the Breathing Games exercise program twice a week for 8 weeks, with each session lasting approximately 50 minutes. This video game-based breathing exercise program includes warm-up, cool-down, and five breathing games designed for the target patients.From the second week onward, posture exercises combined with the breathing games will be added.Thus, the exercise program will consist of a warm-up phase lasting approximately 10 minutes, including breathing control, stretching exercises, and rest; 25-30 minutes of five breathing games combined with posture exercises; followed by a cool-down phase of about 10 minutes with breathing control, stretching exercises, and rest.Additionally, participants will be provided with a home exercise program to be performed twice daily for 30 minutes, three days a week, over 8 weeks."
214886641|NCT07185178|OTHER|Control group|"Participants in the control group will receive a 30-45 minute patient education session after the assessment. The content of the education will include:~Providing general information about Asthma-COPD Overlap Syndrome (ACOS) Teaching dyspnea-relieving positions Instruction in diaphragmatic breathing techniques Teaching secretion clearance methods (Active Cycle of Breathing Techniques - ACBT) Educating on energy conservation strategies Providing information on correct posture Counseling on lifestyle modifications (e.g., smoking cessation, physical activity recommendations) To maintain and improve physical activity levels, patients will be advised to engage in walking activities for 30 minutes, twice a week After covering these topics, participants will be given brochures containing this information. Additionally, follow-up will be conducted by phone every two weeks. All assessments will be repeated at the end of the 8-week period."
214886642|NCT07186023|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction
214886643|NCT07186023|BEHAVIORAL|MBWC|Mindfulness-Based Well-Being Curriculum
214886644|NCT07186023|BEHAVIORAL|MBCI|Mindfulness-Based Curriculum for Insomnia
214886645|NCT07186023|DEVICE|BSI|Brain Stimulation Intervention
214886646|NCT07185906|BEHAVIORAL|education|WhatsApp-based training was provided
214886647|NCT07185568|PROCEDURE|IOUS HydroMark™|"IOUS HydroMarkTM allows marking the tissue during percutaneous breast biopsy. This is a sterile, single-use marker made of resorbable hydrogel, which expands upon contact with bodily fluids and is then gradually absorbed. The hydrogel is visible on ultrasound. Inside the hydrogel, there is a metallic spiral (titanium/steel) that remains permanently visible in radiographic and MRI examinations even after the hydrogel has been fully absorbed.~The HydroMARK Breast Biopsy Site Marker is made of a resorbable hydrogel that expands with fluid and is then resorbed. The hydrogel material is visible under ultrasound. Embedded in the hydrogel is a coiled metallic wire that will be permanently visible under x-ray and MRI when the hydrogel is resorbed. The HydroMARK Biopsy Site Marker is a permanent implant and is not intended to be removed unless the marked tissue is determined to require surgical removal. The marker is supplied pre-loaded in applicator devices designed."
214886648|NCT07185568|PROCEDURE|Magnetic Sirius Pintuition Seed®|"The Pintuition Localization System is intended as a magnetic soft tissue localization system.~The magnetic Pintuition Seed is indicated for preoperative percutaneous implantation into soft tissue (glandular, fibrous or fatty tissue of breast; lymph nodes in the axillary and inguinal region; subcutaneous tissue and skeletal muscle tissue) for temporary marking (\<180 days) of a tissue of interest (e.g. tumor or a suspected lesion) indicated for surgical removal. Using the Pintuition Detector as magnetic guidance or, alternatively, image guidance (ultrasound or x-ray), the Pintuition Seed can be intra-operatively localized and removed together with the tissue of interest."
214886649|NCT07185568|PROCEDURE|Wire localization (WL)|Single-use, repositionable needle for preoperative localization of breast nodules with a single hook, equipped with a depth limiter. Designed for the localization of non-palpable breast lesions in the preoperative phase. It includes a fixation clamp to stabilize the positioning of the wire.
214886650|NCT07187219|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - active|rTMS session active on the primary motor cortex
214886651|NCT07187219|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - inactive|rTMS session inactive on the primary motor cortex
214886652|NCT07186218|BEHAVIORAL|Electronic patient-reported outcome measure (ePROM) for symptom monitoring|Patients randomized to the ePROM intervention arm will be asked to complete monthly reporting of their CKD-associated symptoms using an electronic version of the Integrated Patient Outcome Scale (IPOS)-Renal survey. Their responses will be provided in summary form to their nephrology clinicians at regular intervals and prior to any nephrology clinic visits. Clinicians will be provided with guidance on symptom management and will have the option to participate in an informational session on how to interpret patient symptom responses.
215047945|NCT01880151|DEVICE|EEG|EEG recorded during a resting condition and during an episodic memory task condition
215047946|NCT02735421|DRUG|ABPO Forte Gel|Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
215047947|NCT02735421|DRUG|Vehicle gel|Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
215047948|NCT01417221|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
215047949|NCT01169480|BEHAVIORAL|Give a massage|Participants in this arm will give a 50-minute Swedish massage to a volunteer.
215047950|NCT02962245|DRUG|berberine|
215047951|NCT02962245|DRUG|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
214667948|NCT01193764|DIETARY_SUPPLEMENT|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
215047952|NCT03274011|DRUG|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
215047953|NCT05272397|DRUG|Methylphenidate 20 Mg Oral Tablet|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
215047954|NCT05272397|DRUG|Placebo|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
215047955|NCT05272397|BEHAVIORAL|Language Task|The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
215047956|NCT05272397|BEHAVIORAL|Rest Recording|Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
214293214|NCT01680523|RADIATION|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
214293215|NCT04987957|OTHER|Music Therapy|Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
214293216|NCT05526612|OTHER|Group 1 Motor imagery and Bobath Therapeutic Approach (BTA+MI)|Motor imagery (MI) is the mental rehearsal of motor abilities to improve function. Without revealing any movement in the body, the representation of the movement is created in the mind, the person imagines that he/she is performing the movement. Eating activity will be applied in motor imagery. Individualized therapy sessions in the Bobath Therapeutic Approach will also be received by the Physiotherapist along with Motor imagery. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
214293217|NCT05526612|OTHER|Group 2 Motor imagery, Bobath Therapeutic Approach and Physical practice (BTA+MI+PP)|Individualized therapy sessions in the Bobath Therapeutic Approach with motor imagery will be performed by the physiotherapist, and in addition to these, 5 repetitions of the eating activity used in motor imagery will be practiced. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
214293218|NCT05395468|OTHER|photographs of each eye|All subjects included will take 5 photographs of each eye according to a standardised procedure in terms of distance, lighting and framing
214293219|NCT02029950|DRUG|Cytarabine|Given IV
214293220|NCT02029950|DRUG|Daunorubicin Hydrochloride|Given IV
214293221|NCT02029950|DRUG|Etoposide|Given IV
214293222|NCT02029950|DRUG|Idarubicin Hydrochloride|Given IV
214293223|NCT02029950|OTHER|Laboratory Biomarker Analysis|Correlative studies
214293224|NCT02029950|OTHER|Pharmacological Study|Correlative studies
214293225|NCT02029950|DRUG|Pomalidomide|Given PO
214667949|NCT01193764|DIETARY_SUPPLEMENT|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
214667950|NCT00587223|DEVICE|Apligraf|Up to 3 applications: Day 0, Month 1, Month 2.
214667951|NCT00587223|OTHER|Standard dressing regimen|Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
214667952|NCT05760495|OTHER|blood sampling|Blood sampling for evaluation of oxidative stress markers
214667953|NCT05167201|DEVICE|Nasal High Flow|High flow nasal cannula (NHF) is a device that delivers warmed and humid air through a high air flow rate, through the nose. It is used as a non-invasive ventilatory approach, which is relatively comfortable, in the management of respiratory failure and has been investigated in several studies evaluating the outcomes as domiciliary treatment in patients with COPD.
214667954|NCT06432777|OTHER|Characteristics of patients and Campylobacter bacteraemia episodes|Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease \[IBD\]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)
214667955|NCT05307744|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>3 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.
214667956|NCT05307744|OTHER|Placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
214667957|NCT05063370|DRUG|Levosimendan|Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
214667958|NCT05063370|DRUG|Standard Care|Patients will not receive Levosimendan and will receive standard care according to the institution protocol
214667959|NCT00883753|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
214886653|NCT07185464|DEVICE|tACS|This intervention uses the NEXALIN ADI alternating current stimulation device from Beijing Naisilin Technology Co., Ltd., to deliver targeted stimulation to the prefrontal cortex and bilateral mastoid regions. The prefrontal cortex electrode directly stimulates the cerebral cortex, while the mastoid electrodes ensure the synchronized activation of bilateral neural pathways. Stimulation is applied at a frequency of 77.5 Hz and a current intensity of 15 mA, aiming to optimize brainwave synchronization and modulate brain activity. Participants will undergo daily sessions lasting approximately 40 minutes each, for a total of 20 sessions over 4 weeks. The non-invasive nature of the intervention, combined with its precise targeting of specific brain regions, distinguishes it from other neuromodulation therapies. The treatment aims to enhance neural synchronization, promote neuroplasticity, and provide a non-pharmacological therapeutic alternative for patients.
214886654|NCT07185464|DEVICE|tACS|In the sham stimulation group, participants will receive intervention using a sham device that is identical in appearance, operation, and stimulation protocol to the real tACS device, but does not deliver any current. Both participants and operators will be unable to distinguish between real and sham stimulation based on the device's appearance, sound, or tactile feedback. Device allocation will follow a randomized code generated in advance to ensure blinding and proper group assignment.
214886655|NCT07185815|DRUG|Cariprazine Depot|One single dose of 22 mg
214886656|NCT07185815|DRUG|Cariprazine Depot|One single dose of 44 mg
214886657|NCT07185815|DRUG|Cariprazine Depot MTD|Three monthly doses of MTD (maximum tolerated dose)
214886658|NCT07185815|DRUG|Oral Cariprazine 3 mg/day|Oral Cariprazine 3 mg/day for three months
214886659|NCT07185412|DEVICE|Pulsed Field ablation: Ablation to treat atrial fibrillation|Pulsed Field Ablation
214886660|NCT07186296|DIAGNOSTIC_TEST|EXoPred|Performing invitro Diagnostics with devices developed by EXoPERT.
214886661|NCT07186738|DEVICE|EPOCA telemonitoring|EPOCA is a telemonitoring and tele-coordination platform for medical, paramedical, and social care, enabling the follow-up of acute or chronic patients at home-whether after hospital discharge, as an alternative to hospitalization, or for long-term monitoring. The EPOCA solution relies on connected devices, a digital platform for analyzing incoming data, and a team of medical and paramedical professionals for monitoring and coordination. Remote medical monitoring includes teleconsultations, at-home paramedical care, guidance and support for families, nursing homes, or long-term care facilities, and 24/7 management of home emergencies
214886662|NCT07185971|DEVICE|PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display|PAVE (Parallactic Visual-Field Enhancement) treatment is visual stimulation using a virtual reality head mounted display. The treatment is weekly and entails two 7 minute session separated by a minimum 1 minute intermission. The actual therapy is preceded by a visual field assessment and is followed by a second visual field assessment.
214886663|NCT07185971|DEVICE|PAVE Placebo|The placebo uses the same PAVE software but the functional aspect of the software that is intended to produce the effect in the test group is absent.
214886664|NCT07186309|DEVICE|Diagnostic Test: Enlighten|"The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results (elevated risk or low risk) at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point."
214886665|NCT07187154|DEVICE|Smart Symptom Management Program|"During the first six months after surgery, patients in the experimental group will use a WeChat mini-program to proactively self-report their symptoms regularly using the Chinese version of the MD Anderson Symptom Inventory for Esophageal Cancer (MDASI-EC). Based on the reported scores and the pre-defined algorithms in the Post-Esophagectomy Symptom Grading Management Manual, the system will automatically provide personalized self-management guidance for low-grade symptoms. For more severe symptoms, the system will generate alerts to prompt dedicated study nurses to initiate proactive telephone follow-up and provide tailored health coaching."
214886666|NCT07185438|DEVICE|Experimental target rTMS treatment|Participants will undergo MRI-guided identification of the voxel in the left dorsolateral prefrontal cortex (DLPFC) that is most negatively correlated with the functional connectivity of the subgenual anterior cingulate cortex (sgACC) as the stimulation site.
214886667|NCT07185438|DEVICE|Conventional target rTMS treatment|Participants will undergo MRI-guided identification of the standard F3 target in the dorsolateral prefrontal cortex (DLPFC) as the stimulation site.
215047957|NCT05272397|BEHAVIORAL|Go/No-Go Task|A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall \& Smith (2011) will be employed.
214293226|NCT04060550|BIOLOGICAL|Xolair|This is in vitro mechanistic study. No drug will be given in vivo to patients.
214293227|NCT00862745|DRUG|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
214293228|NCT00862745|DRUG|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
214293229|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 30 ug/day|
214293230|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 10 ug/day|
214667960|NCT00648310|DRUG|Tolterodine 4 mg|
214667961|NCT00648310|DRUG|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
214667962|NCT00760175|BIOLOGICAL|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
214886668|NCT07185438|DEVICE|Sham stimulation treatment|Participants will receive a sham stimulation treatment designed to simulate the rTMS procedure without generating an effective magnetic field output.
214886669|NCT07186959|PROCEDURE|endoscopic gastric purse-string suturing|A dual-tail endoloop will be introduced into the stomach with endoscopic forceps, and will be secured to the gastric wall using endoscopic clips. An endoscope hook was used to tighten both tails of the endoloop until all the clips converged.
214886670|NCT07184645|DRUG|OPA-15406|0.3% foam or 1% foam, topical, twice daily, for 8 weeks
214886671|NCT07184645|DRUG|Vehicle|vehicle, topical, twice daily, for 8 weeks
214886672|NCT07185269|DRUG|626|626 subcutaneous (SC) injection. Placebo subcutaneous (SC) injection.
214886673|NCT07185269|DRUG|626|626 subcutaneous (SC) injection.
214886674|NCT07185269|DRUG|Placebo|Placebo subcutaneous (SC) injection.
214886675|NCT07184944|DRUG|Duvakitug|Pharmaceutical form:Injection solution-Route of administration:SC injection
214886676|NCT07184944|DRUG|Placebo|Pharmaceutical form:Injection solution-Route of administration:SC injection
214886677|NCT07186582|DIAGNOSTIC_TEST|Coronary physiology assessment using Fractional Flow Reserve (FFR) as per standard of care and angiography-derived FFR|Functional assessment of coronary lesions performed using invasive FFR or angiography-derived FFR during coronary angiography as part of routine clinical care. No active intervention or treatment is assigned by the study.
214886678|NCT07186556|BEHAVIORAL|RISE-YA Intervention|Participants will receive energy conservation (EC) counseling, behavior coaching, and exercise training.
214886679|NCT07186556|BEHAVIORAL|Survivorship Education|During weeks 1-6 and 1 time a week during Weeks 7-12, participants will receive a video call which will last about 60 minutes.
214886680|NCT07185893|DRUG|Human Interleukin-11|Human Interleukin-11 for Injection (rhlL-11) 25 - 50 μg/kg, subcutaneous injection, once a day, for at least 7 - 10 days.
214886681|NCT07185893|DRUG|Romiplostim N01|Administer Romiplostim N01 subcutaneously in the abdominal area. The initial dose is 3 μg/kg, once a week. The subsequent dose will be adjusted according to the patient's platelet count
214886682|NCT07184684|PROCEDURE|Sinonasal microbiome transplant procedure.|A sinonasal microbiome transplant obtained from a healthy donor and administered as a nasal lavage once daily for five consecutive days.
214886683|NCT07184684|OTHER|Placebo saline transplant|Placebo transplant containing saline administered as a nasala lavage once daily for five consecutive days.
214886684|NCT07185243|BIOLOGICAL|recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
214886685|NCT07186348|PROCEDURE|Ice packing|10 minutes ice packing application after surgery
214886686|NCT07186348|PROCEDURE|Standard Care (in control arm)|Standard Care (in control arm)
214293231|NCT03893422|OTHER|WB-010|Medical food formulation
214886687|NCT07186855|OTHER|Blood Sample Collection for CTC Detection|Blood Sample Collection for CTC Detection
214886688|NCT07185035|BIOLOGICAL|KN5001|"Subjects will receive KN5001 on day0, 3, and 6. Multiple Doses of KN5001 will infused using the 3 + 3 dose-escalation strategy."
214886689|NCT03712605|OTHER|Best Practice|Receive standard of care observation
214886690|NCT03712605|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214886691|NCT03712605|PROCEDURE|Computed Tomography|Undergo PET-CT or CT
214886692|NCT03712605|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214886693|NCT03712605|BIOLOGICAL|Pembrolizumab|Given IV
214886694|NCT03712605|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
214886695|NCT03712605|RADIATION|Radiation Therapy|Undergo radiation therapy
214886696|NCT04228172|GENETIC|DNA/GeneticTesting|Subjects will be tested for GBA and LRRK2 mutation status at baseline.
214886697|NCT04228172|RADIATION|FDG PET scan|18F-Fluoro-2-deoxy-glucose (FDG) PET scan is a nuclear medicine test that measures glucose metabolism (energy) in your brain at baseline and 18 months later.
214886698|NCT04228172|OTHER|MRI scan|Magnetic Resonance Imaging (MRI) is a noninvasive scan which produces detailed pictures of the brain using a magnetic field. In addition, a special type of MRI, called resting state functional MRI (rs-fMRI), will measure and map brain activity. Conducted at baseline and 18 months later.
214886699|NCT04228172|OTHER|Clinical and neuropsychological assessments|Investigator will evaluate subjects according to the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the standard clinical tool used to measure the severity and progression of PD. Neuropsychological evaluation will assess how one's brain functions (via pencil and paper testing), which indirectly yields information about the structural and functional integrity of the brain. Conducted at baseline and 18 months later.
214886700|NCT03584165|GENETIC|BIIB111|Administered as specified in the treatment arm.
214886701|NCT03584165|GENETIC|BIIB112|Administered as specified in the treatment arm.
214293232|NCT03893422|OTHER|WB-011|WB-011 medical food product
214293233|NCT03893422|OTHER|Placebo|Placebo Capsules identical to those containing WB-010 and WB-011.
214293234|NCT05332509|DEVICE|C-BRACE|The C-BRACE is a custom made Knee-Ankle-Foot-Orthosis with a microprocessor-controlled hydraulic knee-joint articulation. The C-BRACE technology offers to a patient with knee locking deficiencies the following advantages: approximation of the physiological gait pattern, stability while standing and walking, adaptation to various surfaces, inclines, gait situations and walking speeds.
214293235|NCT05332509|DEVICE|SCO|The SCO is a custom made Knee-Ankle-Foot-Orthosis with a knee-joint locked during stance phase and released during swing phase.
214886702|NCT05490641|BEHAVIORAL|Glucose-based biofeedback|Participants will wear a Fitbit activity tracker and receive personalized text messages over a 12-week period. During the first 4 weeks of the study period, participants will also wear a continuous glucose monitor to check their glucose levels in real-time and receive text messages based on their activity and glucose data.
214886703|NCT05490641|BEHAVIORAL|Standard feedback|Participants will wear a Fitbit activity tracker and receive non-personalized text messages over a 12-week period.
214886704|NCT04021238|DRUG|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
214886705|NCT04021238|DRUG|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
214886706|NCT04346797|DRUG|Eculizumab|"Intravenous administration as follows:~Induction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22"
214886707|NCT04009148|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
214886708|NCT02586688|DEVICE|Active NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
214886709|NCT02586688|DEVICE|Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
214886710|NCT05253053|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
214886711|NCT05253053|DRUG|Combination Product: Atezolizumab|Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
214886712|NCT05253053|DRUG|Combination Product: Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
214886713|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
214886714|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)|The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
214886715|NCT02333084|DIETARY_SUPPLEMENT|PRN Joint Health Formula|
214886716|NCT02333084|DIETARY_SUPPLEMENT|placebo|
214886717|NCT02333084|DIETARY_SUPPLEMENT|PRN Flex Omega Benefits® combination|
214886718|NCT01944111|DEVICE|Plication|Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
214886719|NCT06013098|DRUG|30%Oxygen|60%FiO2 in one lung ventilation and 30% FIO2 in both lungs ventilation
214886720|NCT06013098|DRUG|60%Oxygen|100%FiO2 in one lung ventilation and 60% FIO2 in both lungs ventilation
214886721|NCT05603325|OTHER|Person Centered Practice|"Staff will be asked to:~* Complete two surveys on two occasions, once before the intervention sessions and once following the last session. The first survey is views on patient feedback and the other is about the workplace culture and how person-centred it is.~* Attend 6 x 2 hour facilitated workshops which will involve getting ready to work with patient feedback, establishing values and visions for the intervention group, critically reviewing the ways patients are offered the opportunity to give feedback~* Engage in changes in practice (e.g. how staff offer patients the opportunity to provide feedback and the way staff make changes in response to this feedback);~* Attend a final focus group to evaluate the workshop programme."
214886722|NCT05603325|OTHER|Interview|Interviews will be used to gather views about how easy or difficult it is to give feedback and how it feels to consider and/or give feedback
214886723|NCT02074280|DRUG|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
214886724|NCT01226030|DRUG|M2ES 7.5mg|M2ES 7.5mg
214886725|NCT01226030|DRUG|M2ES 15mg|M2ES 15mg
214886726|NCT01226030|DRUG|M2ES 30mg|M2ES 30mg
214886727|NCT01226030|DRUG|M2ES 60mg|M2ES 60mg
214886728|NCT02371655|PROCEDURE|Diet|A low-fibre diet for three days before the examination
214886729|NCT02371655|DRUG|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
214886730|NCT02371655|DRUG|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
214886731|NCT02371655|PROCEDURE|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
214886732|NCT02795338|PROCEDURE|brain mapping|pre-operative and intra-operative brain mapping to identify eloquent areas
214293236|NCT04358848|DEVICE|X-PLO2R|Portable Oxygen Concentrator (POC)
214293237|NCT02689024|DRUG|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
215047958|NCT05272397|BEHAVIORAL|Processing Speed|A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
215047959|NCT05272397|BEHAVIORAL|Operation Span|In the operation span task, participants are instructed to solve math operations (e.g., (1\*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
215047960|NCT05272397|BEHAVIORAL|Reading Span|Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
215047961|NCT05272397|BEHAVIORAL|Barratt Impulsiveness Scale|The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
214667963|NCT05426343|BIOLOGICAL|MVC-COV1901|Approximately 125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
214667964|NCT05426343|BIOLOGICAL|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
214667965|NCT04720352|DEVICE|Active treatment|Active treatment delivers radiofrequency and cryogen
214886733|NCT01838850|DRUG|CS8635 20/5/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day."
214886734|NCT01838850|DRUG|Olmetec® Plus 20/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day."
214886735|NCT01433055|DRUG|Minocycline|"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
214886736|NCT01433055|DRUG|Placebo|"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
214886737|NCT02717455|DRUG|LBH589|"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."
214886738|NCT00005603|DRUG|asparaginase|
214886739|NCT00005603|DRUG|cyclophosphamide|
215047962|NCT05182450|OTHER|Mango leaf extract capsule|Single dose
215047963|NCT05182450|OTHER|Placebo capsule|Single dose
214667966|NCT04720352|DEVICE|Sham|Sham delivers non therapeutic levels of radiofrequency and cryogen
214293238|NCT02689024|DRUG|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
214293239|NCT02689024|DRUG|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
214886740|NCT00005603|DRUG|cytarabine|
214886741|NCT00005603|DRUG|daunorubicin hydrochloride|
214886742|NCT00005603|DRUG|dexamethasone|
214886743|NCT00005603|DRUG|doxorubicin hydrochloride|
214293240|NCT02689024|DRUG|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
214293241|NCT02689024|DRUG|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
214293242|NCT02689024|DRUG|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
214293243|NCT02689024|DRUG|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
214293244|NCT02689024|DRUG|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
214293245|NCT02689024|DRUG|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
214293246|NCT02689024|DRUG|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
214293247|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin|Augmentation of horizontal deficient anterior maxilla using the conventional protocol of cortical shell technique
214477377|NCT04066881|BIOLOGICAL|Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)|"1. DNA-HIV-PT123 (see above)~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.~3. MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional)."
214477378|NCT04066881|BIOLOGICAL|Vaccine Group C: Saline placebo (weeks 0,4,24,48)|Sodium Chloride (NaCl) for injection, 0.9%
214477379|NCT04066881|DRUG|Control PrEP:TDF/FTC once daily (weeks 0-26)|Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
214886744|NCT00005603|DRUG|mercaptopurine|
214293248|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin using patient specific surgical guide then positioned with another guide|using a patient-specific surgical guide to harvest bone cortical shell from the chin and another patient-specific surgical guide to fix it in the atrophied maxillary anterior area
214293249|NCT06522048|OTHER|Observational studies do not require intervention|This is an observational retrospective study and does not require any intervention.
214477380|NCT04066881|DRUG|Experimental PrEP:TAF/FTC once daily (weeks 0-26)|Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
214477381|NCT06290583|DRUG|Bupivacaine|Spinal anesthesia with standard dose of bupivacaine
214477382|NCT06290583|DRUG|Prilocaine|Spinal anesthesia with 50 mg dose of Prilocaine.
214886745|NCT00005603|DRUG|methotrexate|
214886746|NCT00005603|DRUG|prednisone|
214886747|NCT00005603|DRUG|thioguanine|
214886748|NCT00005603|DRUG|vincristine sulfate|
214886749|NCT02663843|DEVICE|i-gel airway|Fibreoptic intubation via i-gel airway device
214886750|NCT02663843|DEVICE|air-Q airway|Fibreoptic intubation via air-Q airway device
214293250|NCT03417453|DEVICE|Eye Drop Dispenser TYPE Opticare|"Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners."
214293251|NCT03417453|DEVICE|Eye Drop Dispenser Autodrop|Eye Drop Dispenser Autodrop
214293252|NCT03092531|BEHAVIORAL|Positive STEPS|Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
214293253|NCT04731168|DEVICE|Mandibular advancement device|Patients will have a mandibular advancement device during the first postoperative night
214293254|NCT02730325|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
214293255|NCT02730325|OTHER|Placebo|
214886751|NCT04940988|OTHER|Real-time benefits check|Prescribers practicing in outpatient departments assigned to the intervention arm will be shown popup alerts with their patient's insurance benefit design-specific out-of-pocket cost for the drug being ordered as well as out-of-pocket costs for up to 3 lower-cost alternatives if available. Alternatives will only be shown when available and when the patient and his or her benefit design information can be matched by the electronic health record system to accurately query out-of-pocket cost information.
214886752|NCT01391715|DRUG|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
214886753|NCT01391715|DRUG|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
214886754|NCT06032078|DEVICE|Cutera laser machine|1064nm Nd: YAG laser
214886755|NCT02872428|DRUG|Valproic Acid|By infusion over 1 hour
214886756|NCT02872428|DRUG|Isotonic saline solution|By infusion over 1 hour
214886757|NCT00573261|DRUG|Pregabalin|Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
214886758|NCT00573261|DRUG|Placebo|Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
214886759|NCT05076461|DRUG|Ondansetron|Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
214293256|NCT03371992|DRUG|Nivolumab|Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.
214477383|NCT06613516|DRUG|Capivasertib|Capivasertib is a selective inhibitor of the kinase activity of the serine/threonine Akt/PKB pathway that may potentially provide clinical benefit over a range of therapeutic indications. Capivasertib comes in capsule form in two forms; 160mg or 200mg
214477384|NCT06681558|DEVICE|Group Nasal Cannula|"Oxygen administered during the endoscopic retrograde cholangiopancreatography (ERCP) procedure will be delivered through a conventional oxygen mask.~The nasal cannula is a device that provides oxygen to patients through the nasal passages."
214477385|NCT06681558|DEVICE|Group Procedural Oxygen Mask|Oxygen administered during the endoscopic retrograde cholangiopancreatography (ERCP) procedure will be delivered through a Procedural Oxygen Mask (POM® ELITE MF). The procedural oxygen mask is a device that covers both the mouth and nose to deliver oxygen to the patient. Its reservoir feature increases the concentration of delivered oxygen
214477386|NCT06746961|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|5mg/kg , iv, q3w
214477387|NCT06746961|DRUG|Lenvatinib|8 mg or 12 mg QD via oral capsule
214477388|NCT03030066|DRUG|DS-1001b|Generic not assigned
214477389|NCT02243852|DRUG|Growth Hormone Replacement Therapy|An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
214886760|NCT00486525|PROCEDURE|Yoga Therapy|Patients will undergo yoga therapy
214886761|NCT01366131|DRUG|MEGF0444A|Intravenous repeating dose
215047964|NCT01911650|OTHER|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
214477390|NCT06619834|BEHAVIORAL|Financial Navigation and Peer Support|A combined intervention of technology-supported financial navigation and peer support: A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks. Participants will also be matched with a Peer Supporter to help improve the participants\&#39; diabetes self-management.
214886762|NCT01366131|DRUG|bevacizumab|Intravenous repeating dose
214886763|NCT01366131|DRUG|carboplatin|Intravenous repeating dose
214886764|NCT01366131|DRUG|paclitaxel|Intravenous repeating dose
214293257|NCT03371992|DIAGNOSTIC_TEST|3D-EX|Analysis of drug-mediated changes in the tumor microenvironment.
214477391|NCT06619834|BEHAVIORAL|Financial Navigation Only|A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks.
214477392|NCT06621186|OTHER|No intervention measures|No intervention measures
214477393|NCT01944332|PROCEDURE|gamete treatment|Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The spermatozoa will be prepared in the standard fashion and utilized for injection or intrauterine insemination after exposure to a membrane permeabilizing agent. Human recombinant PLC-zeta will also be used if the spermatozoa have been confirmed to be PLC-zeta deficient. The injected oocytes will then be exposed to activating agents for the purpose of inducing embryo development. The oocyte activating agent is calcium ionophore and for sperm membrane permeabilization to assist in sperm DNA decondensation is streptolysin O (SLO).
214477394|NCT06372314|DRUG|Total parenteral nutrition (TPN): this is total nutrition provided by central vein.|isoleucine, leucine, valine and tryptophan intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
214886765|NCT01366131|DRUG|placebo|Intravenous repeating dose
214886766|NCT03400592|DRUG|Irinotecan|180 mg/m2 IV once every 2 weeks until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
214886767|NCT03400592|DRUG|nimotuzumab|400mg IV once weekly until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
215047965|NCT01911650|OTHER|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
215047966|NCT01911650|OTHER|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
215047967|NCT03294005|DIAGNOSTIC_TEST|Thyroid ultrasonography|Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients.
215047968|NCT01820650|DEVICE|iTotal G2 CR Knee Replacement System|Total Knee replacement
214293258|NCT03371992|OTHER|Evaluation of Response by RECIST|Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.
214293259|NCT06114355|PROCEDURE|EUS Portal pressure measurement|Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM)
215047969|NCT06457477|DRUG|Sintilimab|100mg/10ml/1bottle
215047970|NCT06457477|DRUG|NAs|tablets
215047971|NCT06457477|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
215047972|NCT00283946|DRUG|Zolpidem MR|Oral
214293260|NCT06250231|OTHER|No intervention|No intervention
214293261|NCT04831203|DIETARY_SUPPLEMENT|An egg-protein hydrolysate (NWT-03)|As described in the experimental arm
215047973|NCT00283946|DRUG|Zolpidem|Oral
215047974|NCT01212965|DRUG|Selenium|400 μg once a day for 6 months by mouth
215047975|NCT02359032|DRUG|ASP6858|Oral tablets
214886768|NCT00002376|DRUG|Indinavir sulfate|
214886769|NCT00002376|DRUG|Lamivudine|
215047976|NCT02359032|DRUG|Placebo|Oral tablets
215047977|NCT05010070|BEHAVIORAL|diet and lifestyle program|See description of main arm.
215047978|NCT00939107|PROCEDURE|spinal manipulation|Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
215047979|NCT00939107|PROCEDURE|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
215047980|NCT06392906|RADIATION|Short course radiation therapy|5 daily radiation treatments
215047981|NCT06392906|RADIATION|Standard course radiation therapy|10 daily radiation treatments
215047982|NCT00628498|DRUG|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
215047983|NCT00628498|DRUG|Defibrotide|
215047984|NCT05742412|DEVICE|Video streaming (smartphone camera)|Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
214886770|NCT00002376|DRUG|Stavudine|
214886771|NCT00002376|DRUG|Zidovudine|
215047985|NCT05742412|DEVICE|Telephone (telephone microphone)|Usual care: Audio-based-only communication using telephone during emergency medical dispatch
214886772|NCT00002376|DRUG|Didanosine|
214886773|NCT00233948|DRUG|nelfinavir mesylate|Given orally
215047986|NCT06005532|DRUG|Adalimumab|Adalimumab injection 40 mg / 0.8 ml
215047987|NCT06005532|DRUG|Humira|Adalimumab injection 40 mg / 0.4 ml
214293262|NCT04831203|DIETARY_SUPPLEMENT|Placebo|As described in the Control arm
214293263|NCT00366288|DRUG|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
214293264|NCT05283668|BIOLOGICAL|i-PRF|"* Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~* The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
214886774|NCT00233948|PROCEDURE|biopsy|Correlative studies
214886775|NCT00233948|OTHER|laboratory biomarker analysis|Correlative studies
214886776|NCT00233948|OTHER|pharmacological study|Correlative studies
214886777|NCT00233948|GENETIC|gene expression analysis|Correlative studies
214886778|NCT00233948|GENETIC|western blotting|Correlative studies
214886779|NCT00233948|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
214886780|NCT00233948|OTHER|immunoenzyme technique|Correlative studies
215047988|NCT03352232|COMBINATION_PRODUCT|HBOT and OMT|Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.
215047989|NCT04629391|DEVICE|Total shoulder arthroplasty|A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
215047990|NCT03142841|OTHER|RESCUE Problem Solving Intervention|This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
214886781|NCT03573830|BEHAVIORAL|Transport Canada material|The current Transport Canada booster seat education material focuses on imparting guidelines; that is, it describes, in plain language, the minimum and maximum ages, heights, and weights to determine when a child should use a booster seat, and when it is safe for a child to use only the seat belt. This material does not describe the principle of operation of seat belts (i.e., redirecting crash forces to the rib cage and pelvis), nor the principle of operation of booster seats (i.e., ensuring the seat belt is placed correctly across the chest and hips).
215047991|NCT02094118|BIOLOGICAL|Point-of-care washed red blood cell transfusion.|
215047992|NCT02094118|BIOLOGICAL|Standard of care red blood cell transfusion.|
215047993|NCT03023306|OTHER|Antiemetics perioperatively|Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
215047994|NCT01575639|DRUG|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
215047995|NCT01861665|DRUG|Marcaine- 0.25%|Marcaine 0.25% administered pre-incision.
214477395|NCT06450444|DEVICE|PRIMUS|The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.
214477396|NCT06428097|DRUG|Levothyroxine|Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
214886782|NCT03573830|BEHAVIORAL|Enhanced material|Enhancements to the booster seat education material were developed based on the hypothesis that parents would better appreciate the additional injury risk reduction afforded by booster seats, if they understand that: (1) seat belts prevent injuries by redirecting crash forces to stronger parts of the body (i.e., rib cage and pelvis); and (2), without booster seats, children would wear the seat belt on their abdomen and neck, which directs crash forces to more vulnerable anatomical structures (i.e., internal organs and spine).
214886783|NCT03229226|OTHER|Verbal versus procedural assessment|Faculty were assessed on both verbal and simulated performance of procedures.
214886784|NCT01728844|DEVICE|beta-tricalcium phosphate alone|
214886785|NCT01728844|DEVICE|GFeBGS 0.1%|
214886786|NCT01728844|DEVICE|GFeBGS 0.3%|
214886787|NCT01728844|DEVICE|GFeBGS 0.4%|
214886788|NCT00842166|OTHER|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
214886789|NCT01204567|OTHER|Aerobic training|Group-based Aerobic Interval Training twice a week in 12 weeks, based on the Ulleval model. The Norwegian Ulleval Model is a group-based aerobic interval training program which is widely used in Scandinavian hospitals for patients with coronary disease. It is designed to improve physical capacity, body awareness and emotional well-being.
214886790|NCT03929068|DRUG|carbidopa-levodopa|Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.
214886791|NCT03929068|DRUG|Placebo Oral Tablet|Placebo will be given to maintain blinding of participants and study team.
214886792|NCT00073346|BEHAVIORAL|Cognitive Behavioral Treatment|
214886793|NCT03807726|BEHAVIORAL|Simulation breastfeeding education|The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy.
214886794|NCT00929461|DRUG|Lipovenoes® 10% and Omegaven®,|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
215047996|NCT01861665|DRUG|Marcaine 0.25%.|Marcaine 0.25% administered post-incision.
215047997|NCT06275776|DEVICE|Ethicon Monocryl Smooth Suture|Monocryl Smooth Suture 3-0 antibacterial with PS-2 needle. Monofilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
215047998|NCT06275776|DEVICE|Ethicon Vicryl Rapide Braided Suture|Vicryl Rapide Braided Suture 3-0 with FS-2 needle. Multifilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
215047999|NCT06275776|DEVICE|Flexifuze Indermil Topical Skin Adhesive|Flexifuze Indermil Topical Skin Adhesive. The skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.
214477397|NCT06428097|DRUG|Normal saline|Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
214886795|NCT06170697|DRUG|Camrelizumab|200mg, iv, d1, q3w
214886796|NCT06170697|DRUG|Cisplatin|80-100mg/m2, iv, q3w, 2-3 cycles in total
214886797|NCT06170697|DRUG|Carboplatin|AUC 2, iv, q1w, 5-7 cycles in total
214477398|NCT03367156|DRUG|Dexamethasone|Given PO
214477399|NCT03367156|OTHER|Placebo|Given PO
214477400|NCT03367156|OTHER|Questionnaire Administration|Ancillary studies
214667967|NCT04696406|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
214886798|NCT06170697|DRUG|Lobaplatin|30mg/m2, iv, q3w, 2-3 cycles in total
214886799|NCT06170697|DRUG|Nedaplatin|25-30 mg/m2, iv, q1w, 5-7 cycles in total
214886800|NCT06170697|RADIATION|Radiotherapy|PGTVp/PGTVnd 66-70Gy/2-2.2Gy/30-35F；PTV1 60Gy/1.8-2.0Gy/30-33F；PTV2 50Gy/1.8-20Gy/25-28F；Start 1-2 weeks after the start of immunotherapy, 1 time before the start of simultaneous chemotherapy, up to 3 times during the concurrent chemoradiotherapy
214477401|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Palbociclib|Continuation of CDK4/6 inhibitor Palbociclib
214477402|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Palbociclib|Discontinuation of CDK4/6 inhibitor Palbociclib
214477403|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor -Palbociclib|Continuation of CDK4/6 inhibitor -Palbociclib
214477404|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor -Palbociclib|Discontinuation of CDK4/6 inhibitor -Palbociclib
214667968|NCT02256358|DRUG|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
214667969|NCT02256358|DRUG|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
214667970|NCT03959189|DRUG|ERX-963|Active medicine
214667971|NCT03959189|DRUG|Placebo|Comparator
214667972|NCT01302275|DRUG|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
214667973|NCT01815684|DRUG|ASP3652|Oral
214886801|NCT06306261|OTHER|questionnaire|UC patients will be subjected to a questionnaire each month about their habits.
214477405|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Abemaciclib|Continuation of CDK4/6 inhibitor Abemaciclib
214477406|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Abemaciclib|Discontinuation of CDK4/6 inhibitor Abemaciclib
214477407|NCT05843578|DRUG|AGMB-129|Oral capsule
214477408|NCT05843578|DRUG|Placebo|Matching oral capsule
214477409|NCT05507437|BIOLOGICAL|TIN816 70 mg lyophilisate powder|Recombinant human CD39 enzyme
214886802|NCT05264883|DRUG|Venetoclax-Decitabine/Azacitidine-Aclarubicin Association|Treatment with Venetoclax+Decitabine/Azacitidine+Aclarubicin
214886803|NCT05264883|DRUG|Venetoclax-Decitabine/Azacitidine Association|Treatment with Venetoclax+Decitabine/Azacitidine
215048000|NCT06275776|DEVICE|Dermabond Prineo Skin Closure System|Dermabond Prineo Skin Closure System. Novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
215048001|NCT06275776|DEVICE|Stryker Zip Skin Closure System|Stryker Zip Skin Closure System. Novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
215048002|NCT03401203|PROCEDURE|Rotational atherectomy followed by balloon angioplasty|Percutaneous coronary intervention
215048003|NCT03401203|PROCEDURE|Balloon angioplasty|Percutaneous coronary intervention
215048004|NCT01033929|BIOLOGICAL|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
214477410|NCT05507437|OTHER|Placebo|0.9% sterile sodium chloride solution
214477411|NCT05454566|GENETIC|ICM-203|Intra-articular injection
214477412|NCT05895981|DEVICE|G132 system, Beijing PINS Medical Co., China|Neuromodulation was performed according to the usual protocol
214886804|NCT00956111|BIOLOGICAL|split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
214886805|NCT00956111|BIOLOGICAL|split-virion, adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
214477413|NCT04276805|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|a non-invasive and safe technique that transiently enhances brain GABA and noradrenaline levels.
214477414|NCT04276805|BEHAVIORAL|cognitive training|A program of regular mental activities purported to maintain or improve one's cognitive abilities.
214477415|NCT06952595|BEHAVIORAL|five exercises prescribed and taught to carers and participants|Up to five exercises prescribed and taught to carers and participants in an acute hospital setting fort hem to continue to practice as able.
214477416|NCT06835712|OTHER|The virtual reality|During the PIK application, 3D visual and audio videos of the beach will be played with an Oculus Go brand virtual reality (VR) headset until the procedure is completed. The video that starts at the beginning of the procedure is planned to last approximately 2-3 minutes during the application. During this time, patients will be asked to close their eyes and take a comfortable position. The VR headset will be disinfected after each application and used on the other patient.
214667974|NCT01815684|DRUG|Placebo|Oral
214667975|NCT02037945|PROCEDURE|18F-FCH PET Scan|
214886806|NCT00956111|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
214886807|NCT00956111|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
214886808|NCT00956111|BIOLOGICAL|whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose|100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
214886809|NCT00956111|BIOLOGICAL|whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose|100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
214886810|NCT00956111|BIOLOGICAL|placebo control|100 adults were assigned to receive 2 doses of placebo 21 days apart.
214886811|NCT03684577|BEHAVIORAL|Hypnotherapy for Agoraphobia|see description of the experimental arm
214886812|NCT02983747|OTHER|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
214886813|NCT02983747|DRUG|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
214886814|NCT03159247|BEHAVIORAL|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
214886815|NCT06343753|DRUG|Opioid free analgesia|o Group OFA: Opioid free anesthesia Analgesia will be provided by syringe containing ketamine, Lidocaine and Dexmedetomidine in induction and maintenance according to lean body weight (LBW).
214477417|NCT06835712|OTHER|The guided imagery|Patients in this group will be played an audio clip that helps them imagine walking on a beach and gives instructions during the walk until the procedure is completed, using an MP3 player and headphones. The audio clip aims to activate the imagination of patients by allowing them to use their senses. For example, the temperature of the sun (feeling), the texture of the sand (touching), the color of the sea (seeing), the sound of the waves (hearing), and the smell of the sea (smell) are some examples of this. The audio clip will be voiced by a professional voice artist with good diction. It is planned that the audio clip will be played for approximately 2-3 minutes during the application. During this time, patients will be allowed to close their eyes and take a comfortable position. The headphones of the MP3 player will be disinfected after each application and used on the other patient.
214477418|NCT06964269|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Study intervention is twice weekly injections of Acthar Gel via single-dose pre-filled SelfJect injector for 12 weeks.
214886816|NCT06343753|DRUG|Opioid based Anesthesia|o Group TBA: Traditional balanced anesthesia Analgesia will be provided by fentanyl in induction and maintenance according to Ideal Body Weight (IBW)
214886817|NCT00136253|BEHAVIORAL|Help dietitians and patients address specific nutritional barriers|
214886818|NCT01096797|DRUG|Sevoflurane|"* Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.~* Anaesthesia maintenance: sevoflurane 2-3 %~* Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg~* Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg"
214886819|NCT04552353|DRUG|Vaway|Drug: Voriconazole. Pharmacokinetic study under fasting conditions
214886820|NCT00387777|DRUG|Patch with centrally acting analgesic|
214886821|NCT00387777|DRUG|Transtec(R) PRO (buprenorphine)|
214886822|NCT01214577|DRUG|PEP005 (ingenol mebutate) Gel|0.015%
214886823|NCT06011447|OTHER|Device to view the skin|Application of device to help view the wound area better
214886824|NCT04113577|OTHER|usability survey|usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.
214886825|NCT01068548|OTHER|reminder|computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
214886826|NCT01205087|DRUG|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
214886827|NCT05622487|OTHER|Neural Therapy|Neural therapy is a form of treatment that aims to act on the autonomic nervous system, by injecting local anesthetics into certain parts of the body.
214886828|NCT05622487|OTHER|Kinesio taping|Kinesiotape is used for injury prevention, rehabilitation and performance enhancement. It has been shown to be clinically effective in increasing joint movements, increasing muscle activity, inducing muscle maximum torque earlier, and improving functional performance
214886829|NCT01624025|OTHER|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
214886830|NCT00484068|DRUG|enalapril|
214886831|NCT00484068|PROCEDURE|chicken diet|
214886832|NCT03397225|BEHAVIORAL|Lifestyle intervention|The educational sessions and individual sessions including dietary management and physical activity advices.
214886833|NCT04082897|DRUG|Obinutuzumab 25 MG/ML [Gazyva]|Obinutuzumab will be administered from C1 to C8
214886834|NCT04082897|DRUG|Atezolizumab 60 MG/ML [Tecentriq]|Atezolizumab will be administered iv from C1 to C18
214886835|NCT04082897|DRUG|Venetoclax Oral Tablet|Venetoclax will be administered from day 15 cycle 1) until day 21 of cycle 35
214886836|NCT05105997|DRUG|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
214886837|NCT05105997|DRUG|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
214886838|NCT06583005|DEVICE|Vibrotactile Coordinated Reset|The Stanford CR glove is designed to administer vibrotactile coordinated reset stimulation, which consists of vibratory stimulation of the fingertips delivered in a specific pattern which is design to disrupt and normalize abnormal brain synchrony.
214886839|NCT02465398|PROCEDURE|Fracture Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Fracture System
214886840|NCT06388005|OTHER|emotional freedom technique (EFT)|The emotional freedom technique (EFT), founded by American scholar Gary Craig, is based on the methods of meridian science in traditional Chinese medicine (TCM) and Western psychology. Guided by the TCM theory of meridians, it quickly releases negative emotions by combining acupoint stimulation with neuro-linguistic programming, and its effectiveness has been confirmed by multiple studies.
214477419|NCT04756856|OTHER|Muscle-target oral nutritional supplementation|Patients will receive daily for 12 weeks two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D. Patients will be also followed for 12 weeks after the suspension of supplementation.
214477420|NCT06953635|PROCEDURE|Quadratus Lumborum (QL) Block|"The intervention arm will receive bilateral quadratus lumborum blocks in the preoperative holding area prior to surgery. The syringe will contain a total of 60 mL of 0.25% Ropivacaine with 4 mg of Decadron. The anesthesiology pain team provider will administer 30 mL on the left side and 30 mL on the right side of the abdominal wall. The patient will receive one injection site per flank. During the procedure, the patient is placed in the left and then right lateral decubitus position and the ultrasound probe is placed above the iliac crest at the mid axillary line. The pain team provider will move the probe posteriorly to identify the shamrock sign. Under ultrasound guidance, a needle is inserted in an in- plane approach through the quadratus lumborum (QL) muscle until reaching the middle of the thoracolumbar fascia layer between QL and psoas muscle. After negative aspiration for blood, injection will allow the spread of local anesthetic between the QL and psoas muscle on each side."
214477421|NCT06953635|PROCEDURE|Placebo|"The placebo control group will receive the same quadratus lumborum (QL) block procedure as the intervention group, with the only difference being the injection of 60 mL of saline instead of local anesthetic. The anesthesiology team will administer 30 mL on each side of the abdominal wall, with one injection site per flank. The patient will be positioned in the left and right lateral decubitus positions, and the ultrasound probe will be placed above the iliac crest at the mid-axillary line to identify the shamrock sign. The needle will be inserted through the QL muscle to the thoracolumbar fascia layer, between the QL and psoas muscle. After negative aspiration for blood, saline will be injected, allowing spread between the QL and psoas muscle on each side."
214477422|NCT06952738|OTHER|Not applicable- observational study|The investigators are only looking to see the rate of positivity of the cultures as well as what the organisms that are found in the cultures are.
214477423|NCT06965231|DRUG|Toripalimab combined with Endostar|"1. Neoadjuvant Phase: 2 doses of toripalimab (240 mg IV, Q2W) before surgery.~2. Surgery: Tumor resection within 2 weeks after the last neoadjuvant dose.~3. Adjuvant Phase: 1) Toripalimab: 240 mg IV every 2 weeks (up to 11 cycles); 2) Endostar: 210 mg (72-hour continuous IV infusion) every 4 weeks (up to 6 cycles)."
214477424|NCT03610789|DEVICE|REDAPT|REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
214477425|NCT04547959|DEVICE|cervical interbody cage C-CURVE|ACDF: Anterior Cervical Discectomy and Fusion with a C-CURVE cage
214477426|NCT04866940|OTHER|Sequences test|the realization of preliminary acquisitions to validate the feasibility of clinical or cognitive research protocols
214477427|NCT01659606|BIOLOGICAL|alemtuzumab|Conditioning: alemtuzumab 0.2 mg/kg/dose IV/SC x 5 doses
214886841|NCT02617797|DEVICE|Radiofrequency|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
214886842|NCT02617797|DEVICE|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
215048005|NCT05152511|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy is a specially designed cabinet for infants and neonates with a barometric pressure equal to 760 mmHg for 20 minutes daily, then gradually increase up to one hour daily for 5 days per week (fig. 1). The chamber was kept warm. The babies were fed before entering the chamber and if signs of hunger appear during therapy. The baby was continuously monitored with pulse oximeter. Older children are managed in the conventional Hyperbaric oxygen chamber with the same regimen.
215048006|NCT03247829|DEVICE|Hemodynamic management using CardioMEMS HF System|Using the CardioMEMS HF System, clinicians will treat to target PA pressure ranges
215048007|NCT00495703|BEHAVIORAL|Exercise|6-months of regular aerobic exercise
215048008|NCT00495703|BEHAVIORAL|Usual Care|6-months of behavioral strategies to aid memory/cognition
214477428|NCT01659606|DRUG|Fludarabine|fludarabine 30 mg/m2/dose IV x 6 doses
214886843|NCT04005001|OTHER|HindSight|HindSight will examine the dynamic trends of clinical measurements taken from a patient's EHR and analyzes correlations between vital signs to alert for the onset of sepsis.This machine learning based tool is optimized by encoder and utilizes periodic retraining to improve its performance over time.
214886844|NCT04005001|OTHER|InSight|Compared to the ability of the InSight software's recognition of sepsis onset to HindSight's performance. The study determines if the HindSight software has equivalent or better performance than the InSight software.
215048009|NCT01783444|DRUG|Capecitabine|Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
215048010|NCT01783444|DRUG|Exemestane|Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
215048011|NCT01783444|DRUG|Everolimus|Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
215048012|NCT04222530|DIAGNOSTIC_TEST|Linear EUS first|Linear endoscopic ultrasonography followed by magnifying narrow band endoscopy are used to determine the depth of invasion of early rectal cancer.
215048013|NCT04222530|DIAGNOSTIC_TEST|ME-NBI first|Magnifying narrow band endoscopy followed by linear endoscopic ultrasonography are used to determine the depth of invasion of early rectal cancer.
214477429|NCT01659606|DRUG|Cyclosporins|
214477430|NCT01659606|DRUG|Mycophenolate mofetil|
214477431|NCT01659606|DRUG|Tacrolimus|
214477432|NCT06424587|BEHAVIORAL|Music intervention|: In addition to the routine practice of the clinic, the pediatric patients in this group listened to music through headphones for 20 minutes just before the procedure to reduce the child's anxiety and fear. The therapeutic effect of music was used. Before the study, children between the ages of 6 and 12 who were inpatients at the clinic were asked what music they most liked to listen to, what kind of music they liked, and what their favorite artists and songs were. The music was selected based on the children's answers. In addition, the researcher added children's songs by a musician named Banu Kanıbelli
214477433|NCT06574035|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.
214477434|NCT06574035|BEHAVIORAL|Exercise|Research demonstrates a preference for physical activity interventions among men with chronic illnesses, while highlighting limited access to fitness facilities in low-income urban areas as a barrier to participation. Online physical activity interventions have shown efficacy and cost-effectiveness in improving health behaviors, with virtual exercise programs for low-income African American populations demonstrating significant reductions in depressive symptoms. Therefore participants will receive exercise to help improve their diabetes self-management behaviors and depressive symptoms.
214477435|NCT06574035|BEHAVIORAL|Group Discussions - Ongoing Support|Participants will join group discussions that will serve as on-going support. The small group component is designed to foster self-efficacy, autonomous motivation, and enjoyment by integrating skills building, personal values, spirituality, and goal setting. This approach has shown positive outcomes in previous pilot studies with African American men, serving as a source of vicarious learning and social support.
214477436|NCT04980872|DRUG|Miransertib|Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
214886845|NCT04682392|DEVICE|Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group|A Delphi Personal Tourniquet system for blood flow restriction (BFR) therapy will be applied to each treatment session for this group. They will do 3-5 exercises with the BFR system on the surgical or both lower extremities for bilateral or unilateral movements.
214886846|NCT04682392|OTHER|Standard ACL rehab|Standard accelerated ACL protocol
214886847|NCT01744301|DRUG|Risk of seizure|Patients newly prescribed PPI and H2RA, respectively
214886848|NCT00801567|DEVICE|Magnetic resonance spectroscopy (MRS)|90-minute magnetic resonance scan.
214886849|NCT04641104|DRUG|Thiamine 500 MG|A solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9% will be administered post-cardiac surgery in patients with lactate levels ≥ 2 mmol / L in the first 6 hours post-ICU admission.
214886850|NCT04641104|DRUG|Placebo|100 ml of NaCl 0.9% will be administered in the placebo group.
214886851|NCT04768192|PROCEDURE|Physical Rehabilitation without lokomat|"Conventional physiotherapy is performed in 10 weekly sessions (45 minutes each) over 4 weeks(total 40 sessions).~Specific exercises are administered to improve gait, balance and functional abilities focusing on:~strengthening the gluteus and quadriceps muscles stretching the hip flexor and hamstrings muscles increasing static balance increasing dynamic balance increasing functional abilities improving ground gait going up and down the stairs.~Physiotherapists can choose from a list of 25 standard exercises, according to some constraints:~1. strengthening exercises had to involve all the lower limb joints (no segmental intervention)~2. during each session, at least 4 out of the 7 categories above had to be delivered~3. the impossibility to perform any of the categories above during any session had to be recorded in the patient's treatment diary.~Physiotherapists of the treatments group discuss patients' diaries during weekly meetings."
214886852|NCT04768192|PROCEDURE|Physical Rehabilitation with Lokomat|"The rehabilitation protocol consists of 20 sessions of robotic training alternated with 20 sessions of conventional physiotherapy (CP). Each treatment is performed in 5 weekly sessions (45 minutes each) over 4 weeks.~Robotic training aimed to recovery/improve walking capacity from the initial Gross Motor Function Classification System (GMFCS) level. It is performed using the Lokomat® (Hocoma AG, Volketswil, Switzerland) gait orthosis. Initial set ups includes 50% body weight unload, gait velocity adjusted on the patient individual capability (1.5 km/h on average) and 100% guidance force. Both weight unload and guidance force are gradually reduced across sessions according to patient recovery of muscle strength and allowing patients to work harden and move more freely.~Children engagement, active participation and motivation were reinforced through frequent encouragement by therapists and performance feedback implemented in the exercise video-games."
214886853|NCT05895201|DRUG|Sitagliptin|600 or 400 (or MTD) mg PO every 12 hours on days -1 to +14 depending on dose level assignment.
214886854|NCT05895201|DRUG|Bortezomib|1.3 or 1.0 mg/m2 (or MTD) IV push 6 hours after graft infusion completion (day 0), and 72 hours thereafter depending on dose level assignment.
214886855|NCT05895201|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on days +3 and +4
214886856|NCT04348201|OTHER|foot reflexology|foot reflexology session which takes about 20 minutes. The position of the patient during reflexology session was a relaxed comfortable supine lying position. The therapist was sitting position at the level of the feet. The Session of reflexology was done on three points at both feet.
215048014|NCT02722408|DRUG|Gemcabene|300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
214477437|NCT05285358|DRUG|Cisplatin|Given IV
214477438|NCT05285358|DRUG|Gemcitabine|Given IV
214477439|NCT05285358|DRUG|Nab-paclitaxel|Given via PIPAC
214477440|NCT05285358|OTHER|Quality-of-Life Assessment|Ancillary studies
214477441|NCT05285358|OTHER|Questionnaire Administration|Ancillary studies
214477442|NCT04890236|DRUG|Duvelisib|Given PO
215048015|NCT05035043|OTHER|Determination of the economic burden NAFLD patients|Determination of the economic burden NAFLD patients (Healthcare costs, patient costs, burden of disease
215048016|NCT01058239|DRUG|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
215048017|NCT01058239|DRUG|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
215048018|NCT02314676|BIOLOGICAL|PEG-somatropin|
214477443|NCT04890236|BIOLOGICAL|Tisagenlecleucel|Given via infusion
214477444|NCT04276935|OTHER|Interview|Participate in cognitive interview
214886857|NCT04348201|DIETARY_SUPPLEMENT|dietary modification|diet must be rich in vitamins as fish and beans, calcium as milk and chess, low fat food through decrease oil in meals, high fiber food through all types of vegetables and fruits and restrict caffeine
214886858|NCT05191004|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
214886859|NCT05191004|DRUG|Fulvestrant|Fulvestrant
214886860|NCT00876330|OTHER|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
214886861|NCT00876330|OTHER|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
214886862|NCT00876330|OTHER|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
214886863|NCT00876330|OTHER|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
214886864|NCT00599248|BIOLOGICAL|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
214886865|NCT00599248|BIOLOGICAL|Placebo|Placebo control (DMEM)
215048019|NCT01900067|DEVICE|BARRIER® EasyWarm Active Self-Warming Blanket|
214477445|NCT04276935|OTHER|Quality-of-Life Assessment|Ancillary studies
214477446|NCT04276935|OTHER|Questionnaire Administration|Ancillary studies
214477447|NCT06650891|DRUG|Quercetin|oral quercetin prior to surgery
214477448|NCT06650891|OTHER|Placebo|capsule identical looking to quercetin
214477449|NCT04205604|DRUG|18F-Fluoro Dopa Imaging|Imaging with 18F-Fluoro Dopa PET Imaging
214477450|NCT06653114|OTHER|Education in Chronic Musculoskeletal Pain|Improving Knowledge and Skills in Chronic Musculoskeletal Pain (Assessment and Management)
214477451|NCT06653114|OTHER|Education in Communication Skills|Developing Communication Skills (Empathy, Motivational Interviewing, Shared Decision-making)
214477452|NCT06812702|OTHER|Observational|Observational
214477453|NCT06812702|PROCEDURE|Skin Biopsy|Participants may consent to additional skin biopsy at baseline and at the one-year follow-up. Skin will be taken paravertebrally at approximately the C8 level.
214477454|NCT06854263|DEVICE|skin marking for radiotherapy treatment|skin marking for radiotherapy treatment
214477455|NCT06853600|DIETARY_SUPPLEMENT|Rhodiola Rosea Capsules|One of the most practical and accessible options for mitigating the occurrence of mental fatigue is the strategic use of nutritional supplements. Several nutritional supplements have been shown to reduce behavioural or subjective markers of mental fatigue, including caffeine, creatine, panax ginseng, and various vitamins or minerals. Among these, Rhodiola Rosea (RR), a supplement with purported adaptogenic and ergogenic properties, has gained attention. Several randomized controlled trials have reported reductions in mental fatigue after RR supplementation without adverse effects. The main objective of this study was to explore the effects of four days of Golden Root Extract (RR) supplementation on mental fatigue, visuo-cognitive processing, strength performance, and perceived exertion in young, healthy individuals.
214477456|NCT04084574|BEHAVIORAL|DASH diet counseling|Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
214477457|NCT06812273|BEHAVIORAL|STM Training|This condition consists of an up/down spectral-temporal modulations (STM) presented both in quiet and with competing background noise
214477458|NCT06812273|BEHAVIORAL|Speech Training|Participants will train on the identification of three sets of speech stimuli of increasing linguistic complexity: individual phonemes (vowels), spondaic words, and matrix sentences.
214477459|NCT06812273|BEHAVIORAL|Mixed Training|This condition involves both the STM and the speech training, described above, and an additional module training localization.
214886866|NCT04809922|DEVICE|cardiac wearable devices|"five cardiac wearable devices~* Apple Watch, Apple Inc., Model Number: A1977 / A1978~* Kardia Mobile, AliveCor Inc., AC-009/Kardia Mobile 6L, AliveCor Inc., AC-019~* Fitbit Sense, Fitbit, Inc, Model Number: FB512~* Samsung Galaxy Watch 3 Samsung Inc., Model Number: SM-R855F~* Withings Scanwatch, Withings SA, Model Number: HWA09 Used for recording of one single-lead ECG. The results will be 274 compared to a simultaneous 12-lead ECG, which is considered the gold standard for detecting AF. There is no comparator in this trial."
214886867|NCT05244122|BEHAVIORAL|Feedback|presence or absence of trial by trial feedback
214886868|NCT05244122|BEHAVIORAL|Prevalence|"In some blocks, skin cancer target images were present on 50% of trials (high prevalence). In other blocks, disease prevalence was 20%."
214886869|NCT02038257|PROCEDURE|MKTP (melanocyte keratinocyte transplant procedure)|Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).
214886870|NCT02038257|DEVICE|Collagen Dressing|Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
215048020|NCT05346328|DRUG|Injection of A166|4.8 mg/kg for each 21 (±3) -day cycle
215048021|NCT03557125|OTHER|QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
215048022|NCT03557125|OTHER|Saline Skin Wheel|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
215048023|NCT06022094|OTHER|2 months of reduced carb menus|Participants will eat a reduced carb menu for 2 months
215048024|NCT04084535|OTHER|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
215048025|NCT04084535|OTHER|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
214886871|NCT02038257|DEVICE|Vaseline Impregnated Gauze|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.
214886872|NCT02038257|DEVICE|Carbon Dioxide Laser|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.
214886873|NCT02038257|DEVICE|Dermabrasion|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.
214886874|NCT00290004|DRUG|motexafin gadolinium|
214886875|NCT05807204|DIETARY_SUPPLEMENT|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
214886876|NCT05807204|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
214886877|NCT00296972|DRUG|peg interferon plus ribavirin|
214886878|NCT05954520|DEVICE|Tympan|Participants will wear a prototype hearing aid (called the Tympan)
214886879|NCT01261897|PROCEDURE|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
214886880|NCT01261897|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
214886881|NCT02750137|DRUG|Tetracaine|Application of Ametop prior to intravenous cannulation
214886882|NCT02983786|DRUG|Indocyanine Green|ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
214886883|NCT01491360|PROCEDURE|LaserACE(R)|Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.
214886884|NCT06274294|DRUG|CT-P13|Induction treatment.
214886885|NCT06550557|BEHAVIORAL|counselling sessions|the counselling sessions were adopted from the health belief model with the cues of action depending on mobile phones as muting notifications, removing social media and using computers instead if possible.
214886886|NCT03727789|DRUG|FACT Complex-targeting Curaxin CBL0137|Given IA
214886887|NCT03321149|OTHER|RiseTx|Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.
214886888|NCT02812563|OTHER|genetic|Galilee exam - Corn analysis with Optiwave Refractive Analysis
214886889|NCT03525886|DRUG|NBI-74788|Capsule, administered daily.
214886890|NCT05840458|PROCEDURE|PENG Block|Patient will be placed in the supine position and the ultrasound probe will be placed in the transverse plane over the anterior inferior iliac spine (AIIS) and aligned with the pubic ramus by rotating the probe counterclockwise by approximately 45 degrees. A 22-gauge, 100 mm needle will be inserted using the plane approach from lateral to medial, between the psoas tendon anteriorly and the pubic ramus posteriorly. Following a negative aspiration, 20 mL of 0.375% ropivacaine will be injected. The needle position will be confirmed by visualizing the separation of layers with the dispersion of the injected volume.
214886891|NCT02219412|DRUG|ticagrelor|90 mg bid for 2 weeks
214886892|NCT02219412|DRUG|Aspirin|100mg Qd for 2 weeks.
214886893|NCT06581302|DEVICE|Magnetic seizure therapy by Magnetic stimulator|The seizure is induced by Magnetic stimulator of MagPro MST(XP)，MagVenture A/S, Farum, Denmark. It is administered in combinations with antipsychotic medications
215048026|NCT03733938|OTHER|endodontic microsurgery|teeth with failed root canal treatment will be treated by endodontic microsurgery
214886894|NCT06581302|DRUG|Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)|It mainly includes second-generation antipsychotic medications, such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc, but except clozapine.
214886895|NCT00422110|DRUG|Seletracetam|
214886896|NCT03517410|OTHER|Smart phone use|Patients will be asked to use the smart phone while seated for either: (1) 10 minutes or (2) 30 minutes.
214886897|NCT00089804|DRUG|abetimus sodium (LJP 394) and/or placebo solution|300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks
214886898|NCT00089804|DRUG|abetimus sodium (LJP 394)|900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.
214886899|NCT00089804|DRUG|Phosphate-buffered saline|A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
214886900|NCT00684281|OTHER|Neurological and neuropsychological consultation, MRI|Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
214886901|NCT00684281|OTHER|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
214886902|NCT01041144|BEHAVIORAL|lifestyle counseling|supporting diabetes patients using Internet communication
214886903|NCT03304925|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
214886904|NCT06016647|OTHER|Musculoskeletal-specific WSIB programs of care|Clinicians within this network provide care under a standardized framework that limits confounding from different interventions and the researchers will not manipulate treatment decisions.
214886905|NCT05067413|PROCEDURE|Transanterior obturator nerve gateway approach|Distal rectal transection of cases in the experimental group will be performed using transanterior obturator nerve gateway approach
214886906|NCT05067413|PROCEDURE|Total mesorectal excision approach|Distal rectal transection of cases in the control group will be performed using total mesorectal excision approach
214886907|NCT06582082|OTHER|pulmonary rehabilitation|The study group will receive pulmonary rehabilitation
214886908|NCT06582082|OTHER|pursed lip breathing|the control group will stick to pursed lip breathing only
215048027|NCT02868853|BEHAVIORAL|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
214886909|NCT02969382|DRUG|SEP-363856|One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
214886910|NCT02969382|DRUG|Placebo - Cap|One Placebo capsule daily for 4 weeks
214886911|NCT04545840|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
214886912|NCT04405882|PROCEDURE|topographic guided trans epithelial excimer laser|In this retrospective study 8 eyes affected by cornea ectasia of 8 patients (mean age 31.50±14.73 years) underwent simultaneous CCR and CXL. Preoperative and 6 month postoperative uncorrected distance visual acuity (UDVC) and distance corrected visual acuity (DCVA) were measured using the Efficacy and Safety index. Objective and subjective quality of vision were respectively evaluated through preoperative and 6 month postoperative corneal morphological irregularity index (CMI), National Eye Institute Visual Function NEI-VFQ25 and NEI-VFQ39 questionnaires.
214886913|NCT04664322|DEVICE|non invasive ventilation and high flow nasal canulae oxygen therapy|patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy
214477460|NCT06812273|BEHAVIORAL|Gamified Training|"This uses auditory training within a game experience where players control a game avatar (the wisp) that appears to fly through a landscape. Players were asked to help the wisp avoid obstacles or choose from among options based on a variety of sound cues."
214477461|NCT06812273|BEHAVIORAL|Foraging Training|This adds a component to the game where participants navigate the wisp to the location on the screen that relates to the target stimulus. The concept here is that searching for targets with manual movements, ecologically stimulates sensori-motor loops where the actions of the participants generates the auditory stimuli that are heard.
214886914|NCT04390776|DRUG|PF-06651600|PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.
214886915|NCT05800886|OTHER|Early mobilization and tea consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea (black tea 2 g, caffeine amount: 45-55 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
214886916|NCT05800886|OTHER|Early mobilization and coffee consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee (ınstant coffee 2 g, caffeine amount: 60/80 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
214886917|NCT05800886|OTHER|Early mobilization and warm water consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water (37 centigrade) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
214886918|NCT05800886|OTHER|Ongoing treatment|The first mobilization and oral intake of the patients in the control group started at the 8th hour.
214477462|NCT06854198|OTHER|Glaucoma screening with optical coherence tomography (OCT), color fundus photography, and tonometry|Participants will be called and offered a screening appointment. At the appointment, visual acuity, OCT, color fundus photography, tonometry, and visual field testing will be performed. The images will be assessed for abnormalities. Participants meeting referral criteria will be referred for a comprehensive eye examination with an eye care provider.
214477463|NCT06854198|OTHER|Educational Brochure|A brochure about glaucoma screening will be mailed to participants. The brochure will include contact information of a staff member who can schedule an appointment for a comprehensive eye examination.
214477464|NCT06813326|PROCEDURE|catheter insertion|success of catheter insertion
214477465|NCT06853977|BEHAVIORAL|Cognitive tasks|Cognitive tasks performed during intracerebral voltammetric recordings
214477466|NCT06808334|OTHER|CLAIR|Subject will have retinal images obtained and uploaded to CLAiR Software. Subjects are not directly in contact with CLAiR software. There is no medical intervention.
214477467|NCT06812624|OTHER|There is no intervention in this study.|This study is planned as a retrospective cross sectional study. Only the information of the patients will be used.
215048028|NCT02868853|BEHAVIORAL|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
215048029|NCT02868853|BEHAVIORAL|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
215048030|NCT01964183|DRUG|tolterodine|Oral
215048031|NCT01964183|DRUG|mirabegron|Oral
215048032|NCT06042426|DRUG|Dexamethasone|Two 8 mg doses. One dose applied prior to incision and the other at POD1
215048033|NCT06042426|DRUG|Morphine|Morphine 0.1 mg per kg intravenous every 6 hours
215048034|NCT06042426|DRUG|Oxycodone and acetaminophen|2 tabs of oral oxycodone combined with acetaminophen every 6 hours (the same pill includes both drugs)
215048035|NCT02399787|OTHER|blastocyst biopsy|Performed on day 5
215048036|NCT06199128|DIETARY_SUPPLEMENT|carboxymethyl β-glucan|It is a vaginal spray gel designed for the prevention and treatment of cervical lesions caused by HPV. This is achieved by controlling the physiological conditions of the transformation zone of the cervico-vaginal mucosa. The composition of the gel, which includes polycarbophil and carboxymethyl-beta-glucan, effectively shields the cervico-vaginal mucosa from the damaging effects of external agents due to its bioadhesive capacity. Additionally, it contributes to the re-epithelialization and regression of cervical lesions
215048037|NCT04011592|DRUG|Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg)
215048038|NCT04011592|DRUG|Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg)
215048039|NCT01096108|BEHAVIORAL|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
214886919|NCT01250210|DRUG|levonorgestrel and ethinyl estradiol|pregnancy prevention
214886920|NCT01859338|RADIATION|cone-beam computed tomography|Undergo CBCT
214886921|NCT01859338|RADIATION|magnetic resonance imaging|Undergo MRI
214886922|NCT01859338|RADIATION|computed tomography|Undergo fan beam computed tomography
214886923|NCT01116063|DRUG|Inhaled iloprost|Inhalation Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose; administer 6 times daily
215048040|NCT01096108|BEHAVIORAL|Motivational and Problem-Solving|Counseling phone calls
215048041|NCT01096108|BEHAVIORAL|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
215048042|NCT03644719|BEHAVIORAL|Cognitive behavioral skills training|A brief cognitive behavioral skills training was applied to teach ketamine abusers about stimulus control, refusal skills, communication skills, decisional balance, and infectious diseases prevention.
214293265|NCT05283668|PROCEDURE|Diode Laser|"Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
214293266|NCT03970798|DRUG|Midazolam|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
214293267|NCT03970798|DRUG|Caffeine|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
215048043|NCT02135744|BEHAVIORAL|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
215048044|NCT02664480|OTHER|Salivary alpha-Amylases|Investigators will collect Salivary alpha-Amylases before and after ovulation
215048045|NCT00427011|DRUG|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
215048046|NCT05302427|BEHAVIORAL|Infant Massage|The training will start with a leg massage in the first session and the mother will be asked to do this once a day until the next lesson. The next week, the new massage movement will be shown to the mother and the training will continue, and the mother will be told to do the application throughout the week by integrating it with the previous movement this time, and the four-week training will be completed in this way. After the training, which massage movement was taught to the mothers every week, the application pictures of this part will be sent and at the end of the four-week training, the baby massage video and the baby massage guide will be sent to the mothers by e-mail.
215048047|NCT02886650|PROCEDURE|Thermocoagulation|Thermocoagulation During pre-surgical Invasive EEG Monitoring
215048048|NCT00066339|DRUG|gefitinib|
215048049|NCT01302327|DRUG|Exenatide|Exenatide
215048050|NCT04587206|DRUG|CKD-348|QD, PO
215048051|NCT04587206|DRUG|CKD-828, D097, D337|QD, PO
214293268|NCT03970798|DRUG|Rosuvastatin|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
214293269|NCT03970798|DRUG|KW-6356|In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.
214293270|NCT01177917|OTHER|Infant Formula|
214293271|NCT01680705|OTHER|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
214293272|NCT02403154|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
214293273|NCT02403154|PROCEDURE|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
214293274|NCT00376662|DRUG|Hormone Replacement Therapy and Etidronate|
214886924|NCT02267018|DEVICE|Drager VN500 Ventilator|This ventilator is capable of providing both nCPAP and NIHFV support.
214886925|NCT05881824|BEHAVIORAL|MDG intervention|6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet
214886926|NCT06352021|DEVICE|kaleidoscope|The children in the kaleidoscope group were shown the kaleidoscope by the researcher five minutes before the blood sampling, and they were encouraged to look at the kaleidoscope during the procedure and describe the patterns they saw. All children in the Kaleidoscope group agreed to participate in the study. All children in the kaleidoscope group were asked to look at the kaleidoscope just before the tourniquet was placed on their arms before the blood sampling procedure and to describe the patterns, they saw in it by turning it slowly during the procedure.
215048052|NCT03053557|BEHAVIORAL|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
215048053|NCT04608292|DIAGNOSTIC_TEST|Single-voxel MRS|Diagnostic test is a single voxel MRS scan
215048054|NCT04608292|DIAGNOSTIC_TEST|Multi-voxel MRSI|Diagnostic test is a multi-voxel MRS imaging scan
215048055|NCT04608292|DIAGNOSTIC_TEST|Magnetization Transfer Imaging|Diagnostic test is a set of magnetic transfer weighted images
215048056|NCT04608292|OTHER|Alcohol ingestion|Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
215048057|NCT04608292|DEVICE|ClearMate|Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
215048058|NCT04608292|DIAGNOSTIC_TEST|Blood sampling|Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
215048059|NCT04177589|OTHER|Incidence of Delirium in Inpatient Elderly Patients|Study design: prospective cohort study.
215048060|NCT00888706|BEHAVIORAL|Control Condition|The group participated in the usual nursing home activities and routines.
214886927|NCT02847260|DRUG|Remodulin|Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
214477468|NCT06811246|DRUG|Islatravir (ISL)|Oral administration of a single dose in period 1 and period 2
214886928|NCT04160650|BEHAVIORAL|Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer|"This is an educational intervention which aims to answer the questions:~1. In patients with CRC what is the effect of empowering education versus standard education on knowledge level in 4 months follow-up?~2. In patients with CRC what is the effect of empowering education versus standard education on activation level related to nutrition impact side effects' self-care in 4 months follow-up?~3. In patients with CRC what is the effect of empowering education versus standard education on malnutrition risk in 4 months follow-up?~4. In patients with CRC what is the effect of empowering education versus standard education on QoL in 4 months follow-up?"
214886929|NCT02871011|DRUG|Nitric Oxide|Delivered as a footbath
214886930|NCT02871011|DRUG|Water|Delivered as a footbath
214886931|NCT00886015|DEVICE|TT Clamp|trichiasis surgery performed with TT clamp
214886932|NCT00886015|PROCEDURE|Standard BLTR Technique|bilamellar tarsal rotation procedure in trichiasis surgery
214886933|NCT03260556|DRUG|Pirfenidone|Increasing doses
214886934|NCT03260556|DRUG|Placebos|Increasing doses
215048061|NCT00888706|BEHAVIORAL|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
215048062|NCT00888706|BEHAVIORAL|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
215048063|NCT00888706|BEHAVIORAL|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
215048064|NCT01047007|DRUG|adavosertib 20 mg|Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
215048065|NCT01047007|DRUG|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
215048066|NCT01047007|DRUG|CDDP|CDDP 60 mg/m\^2 to 100 mg/m\^2 administered as an IV infusion on Day 1.
215048067|NCT01047007|DRUG|adavosertib 65 mg|Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
215048068|NCT05829005|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
215057350|NCT03654040|DRUG|everolimus|EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
214293275|NCT05545696|DEVICE|AI on algorithm|The mandibles of the participants were scanned with ''AI on'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
214293276|NCT05545696|DEVICE|AI off algorithm|The mandibles of the participants were scanned with ''AI off'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
214293277|NCT04376710|OTHER|Completion of pre-pandemic survey|Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.
214293278|NCT04376710|OTHER|Completion of survey after peak of pandemic|Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.
214293279|NCT04376710|OTHER|Completion of post telemedicine encounter survey|Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
214293280|NCT03872167|DEVICE|BIPAP, Intelligent automatic mode defined by assured volume with pressure support|Correction of night ventilation through an automatic mode of ventilation with assured volume with pressure support
214293281|NCT03872167|DEVICE|BIPAP, manual tritration.|Correction of night ventilation through a manual titration of non-invasive mechanical ventilation using polysomnography.
214293282|NCT03764865|PROCEDURE|day 3 uterine transfer|uterine transfer of embryo on day 3 after fertilization (cleavage stage)
214293283|NCT03764865|PROCEDURE|day 5 uterine transfer|uterine transfer of embryo on day 5 after fertilization (blastocyst stage)
214293284|NCT05316753|PROCEDURE|Cardioversion with a pulsed biphasic waveform|Cardioversion with a pulsed biphasic waveform
214293285|NCT05316753|PROCEDURE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion with a biphasic truncated exponential waveform
214293286|NCT01250834|DRUG|Atorvastatin|Administered orally.
214293287|NCT01250834|BIOLOGICAL|LY2189265|Administered subcutaneously.
214293288|NCT01135199|DRUG|pomalidomide (CC-4047|
214886935|NCT02174640|DIETARY_SUPPLEMENT|Coffee|Coffee Beverage
214886936|NCT02174640|DIETARY_SUPPLEMENT|Water|Water
214886937|NCT01692626|DRUG|Pimecrolimus|Pimecrolimus 1% topical cream applied twice daily for four weeks on one side of the face.
215048069|NCT04776161|BEHAVIORAL|Cue-Reward Intervention|"Patients in the first intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Patients will also receive text messages reminding them of the habit they decided to link to their medication-taking.~Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf."
215048070|NCT04776161|BEHAVIORAL|Cue-Reward Intervention with possible intensification|"Patients in the second intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf.~After 6 weeks, patients who demonstrate an adherence under 80% to study medications (as measured by the electronic pill bottle) will begin receiving text messages reminding them of their selected cue."
215048071|NCT00960544|DRUG|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
215048072|NCT01334554|DRUG|Sildenafil|20 mg three times a day.
215048073|NCT01334554|DRUG|Placebo|No active drug
215048074|NCT02071901|DRUG|eltrombopag olamine|Given PO
215048075|NCT02393859|DRUG|Blinatumomab|15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
215048076|NCT02393859|DRUG|Dexamethasone|10 mg/m\^2/day intravenous (IV) on Days 1-6
215048077|NCT02393859|DRUG|Vincrisitne|1.5 mg/m\^2/day IV on Days 1 and 6
214293289|NCT05199298|OTHER|"Mandala Activity-Based Breastfeeding Program"|Training modules for breastfeeding and Maternal -infant attachment will be implemented with pregnant women in the study group at 32-36 weeks of gestation. The training will be explained by the researchers by shooting a video. In addition, for each week, mandala drawings will be videotaped by the researcher who received mindfulness-based art therapy training and will be sent to the Whatsapp accounts of the pregnant women. t 36 weeks of gestation, the Prenatal Attachment Scale and Spielberger State Anxiety Inventories will be sent to mothers as Google forms. The mother will be called 24 hours after the birth and the situation of having a problem with breastfeeding will be determined. In the first week, in the first and second months after the birth, questionnaire forms and online questionnaires will be applied to the mothers, apart from the follow-up and counseling in the postpartum 2nd month, the posttests of the scales
214293290|NCT00110149|BIOLOGICAL|rituximab|
214293291|NCT00110149|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214477469|NCT06811246|DRUG|Lamivudine (3TC)|Oral administration of multiple daily doses for 27 days
214477470|NCT06654596|DRUG|Telitacicept 240mg|Patients in telitacicept group will be treated with maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and/or angiotensin II receptor blocker ( ARB ) combined with telitacicept. 240 mg telitacicept will be used once a week for 40 weeks.
215048078|NCT02393859|DRUG|Daunorubicin|30 mg/m\^2 IV over 24 hours on Day 5
215048079|NCT02393859|DRUG|Methotrexate|1 g/m\^2 IV over 36 hours on Day 1
214477471|NCT06654596|DRUG|Glucocorticoid|Patients in glucocorticoid group will be treated with ACEI/ARB and glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d). After 8 weeks, reduce the dosage by 5 mg per month for a total of 28-40 weeks.
214886938|NCT01692626|DRUG|Placebo|Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
214886939|NCT00022594|DRUG|liposomal lurtotecan|
214886940|NCT02681861|DRUG|ASP6294 Intravenous|Intravenous (IV)
214886941|NCT02681861|DRUG|ASP6294 Subcutaneous|Subcutaneous (SC)
214886942|NCT02681861|DRUG|Placebo Intravenous|Intravenous (IV)
214886943|NCT02681861|DRUG|Placebo Subcutaneous|Subcutaneous (SC)
214886944|NCT03260660|DEVICE|Magnetic Resonance Elastography|The investigators plan to prospectively assess the agreement of liver stiffness measurements obtained using standard of care MR elastography techniques vs. MR elastography with varying amounts of imaging acceleration using compressed sensing in adult volunteers
215048080|NCT02393859|DRUG|Ifosfamide|800 mg/m\^2 IV for 1 hour on Days 2-4
215048081|NCT02393859|DRUG|PEG-asparaginase|1000 U/m\^2 IV for 2 hours or intramuscularly (IM) on Day 6
215048082|NCT02393859|DRUG|Erwinia-asparaginase|In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
215048083|NCT05520684|DIAGNOSTIC_TEST|urine culture and urinalysis|urine culture and urinalysis
215048084|NCT05013814|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Tactile function was evaluated mainly as tactile registration by using 20-item Semmes-Weinstein monofilament (SWM) kit. The monofilament was applied three times with a pseudorandom order to distal pad of the thumb, index, 4th and 5th digits (C6, C7 and C8 dermatomes). The lowest value of monofilament was recorded which the child was able to correctly identify at least one touch out of three
214886945|NCT00855894|DRUG|Pertuzumab|After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).
214477472|NCT06810791|DRUG|HVA|Homoharringtonine (HHT) is given by venous drip daily at 1 mg/m2 from day 1 to 7. Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 14. Azacitidine (AZA) is given 75 mg/m2 subcutaneously from day 1 to 7.
214477473|NCT06810791|DRUG|VA|VEN is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 28, and AZA (75 mg/m2) is given subcutaneously from day 1 to 7.
214886946|NCT00855894|DRUG|Erlotinib|Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
214886947|NCT01981460|PROCEDURE|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
214886948|NCT04169269|DRUG|Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters|anticoagulant, subcutaneous injection
214886949|NCT04169269|DRUG|Rivaroxaban 10 milligram Oral Tablet|anticoagulant, oral
214886950|NCT03669510|OTHER|computer guided IAN lateralization surgical technique|Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique
214886951|NCT05644561|DRUG|Ravulizumab|Ravulizumab will be administered by intravenous (IV) infusion.
214886952|NCT05308511|DEVICE|PC-I and COLON2|First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
214886953|NCT05308511|DEVICE|COLON2 and PC-I|First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
215048085|NCT05013814|DIAGNOSTIC_TEST|Box and Block Test|Box and Block Test (BBT) was used for dexterity assessment. The BBT measures unilateral gross manual dexterity. The child was asked to move, one by one, the maximum number of blocks from one compartment of a box to another of equal size within 60 seconds
215048086|NCT05013814|DIAGNOSTIC_TEST|9-Hole Peg Test|9-Hole Peg Test (9-HPT) is used to measure finger dexterity. Firstly, the child takes the pegs from a container, one by one, and place them in the holes on the board; then participant removes the pegs from the holes and replaces them back into the container. The total time taken to complete the test is recorded in seconds.
215048087|NCT05013814|DIAGNOSTIC_TEST|Duruöz Hand Index (DHI)|Duruöz Hand Index (DHI) is an 18-item self-report questionnaire regarding ability to carry out manual tasks. Individual items are scored on a 6-point Likert scale where 0=without difficulty and 5=impossible. The total score ranges from 0-90 with higher scores indicating poorer hand function.
215048088|NCT05013814|DIAGNOSTIC_TEST|Jamar hand dynamometer|Hand grip strength was measured by using Jamar hydraulic hand dynamometer. Measurement was done with the participant in sitting position and the elbow at 90 degrees of flexion. The force has most commonly been measured in kilograms according to the amount of static force that the hand can squeeze around the dynamometer.
215048089|NCT05013814|DIAGNOSTIC_TEST|Hydraulic pinch gauge|Hydraulic pinch gauge is used for evaluation of finger grip strength. The evaluation method was the same as Jamar hand dynamometer.
214293292|NCT00563381|DRUG|Tiotropium bromide|18 mcg/daily
214886954|NCT05606783|BEHAVIORAL|Telehealth Follow-up Visits|"• Follow-up with patients once per week for six (6) weeks via scheduled 20-minute telehealth appointment with each patient via the HIPAA secure and compliant platform, VSee~o During this telehealth appointment, the study pharmacists will counsel the patients on their blood pressure readings for that week and provide lifestyle education focusing on patient-specific diet and exercise recommendations"
214886955|NCT05606783|BEHAVIORAL|Surveys|"A pre- and post-survey will be given at the initial and final in-person appointments, respectively~• These surveys will collect basic patient demographics, knowledge of blood pressure, comfort with checking blood pressure at home, and previous experience working with a pharmacist"
215048090|NCT00954447|DRUG|Placebo|Placebo, identical to Linagliptin tablet
215048091|NCT00954447|DRUG|Linagliptin|intended final marketed dose
215048092|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App|The electronic Asthma SDM App will ask questions related to medicine-related, non-medicine-related, and COVID-19-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment. They may also use the Asthma SDM app to find information about asthma, medication management, COVID-19 and COVID-19 vaccines.
214293293|NCT00563381|DRUG|Salmeterol|100 mcg/daily
214293294|NCT00563381|DRUG|Placebo Salmeterol|Placebo identical to Salmeterol device
214886956|NCT05606783|DEVICE|Devices|"Smart Phones with Apple Health Software will be used to monitor blood pressure once a day, and results will be sent automatically to the patients EHR (Epic)~• The Omron 10 Series Wireless Upper Arm Blood Pressure Device will be given to the patient to monitor blood pressure at home daily"
214886957|NCT03395288|DRUG|D-Mannose|A total of 2 g D-mannose daily
214886958|NCT01983566|DRUG|BI 207127 high fat|BI 207127 as a single dose after a high fat breakfast
214886959|NCT01983566|DRUG|BI 207127 with Omeprazole|BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
214886960|NCT01983566|DRUG|BI 207127|BI 207127 as a single dose in fasted state
214886961|NCT01983566|DRUG|BI 207127 low fat|BI 207127 as a single dose after a low fat breakfast
214886962|NCT04456777|DRUG|Vortioxetine|vortioxetine will be administreted for 3 months
214886963|NCT00925639|DRUG|Isoflavone|150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.
214886964|NCT00925639|DRUG|Placebo|Starch pill
214293295|NCT00563381|DRUG|Placebo Tiotropium|Placebo identical to Tiotropium device
214293296|NCT03477877|BEHAVIORAL|Indashyikirwa Couples Training|A training curriculum for heterosexual couples in Rwanda comprising 20 3-hour modules (60 hours total) delivered to groups of 15 couples (30 people). Each module facilitated by male and 1 female facilitator. Curriculum topics include: types and uses of personal and interpersonal power (power within, power over, power with, power to), gender, gender based violence, triggers for intimate partner violence, conflict management, economic development, sexuality, alcohol, social norms and community change. Delivered by RWAMREC.
214886965|NCT05277662|DIAGNOSTIC_TEST|cell and molecular diagnostics in accordance with functional test results|"Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1)."
215048093|NCT04951102|BEHAVIORAL|Shared Decision Making Physician Training Video|Training video to educate physicians on Shared Decision-Making and the use of Shared Decision-Making tools.
215048094|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App- Patient Data|Data from the pre-visit electronic Asthma SDM app completed by the patients. Data includes medicine-related, non-medicine-related, and COVID-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment.
214886966|NCT04405297|DEVICE|Adipose-derived regenerative cells|Adipose-derived regenerative cells will be obtained from a small-volume lipoaspirate procedure. The lipoaspirate will then be enzymatically digested to produce a stromal vascular fraction (SVF) that will be injected into the targeted joint.
215048095|NCT04951102|BEHAVIORAL|Standard Care|Standard Care for asthma.
214886967|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg|single-dose:1mg/kg
215048096|NCT04754763|DRUG|Dentin-Bonding Agents|3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
215048097|NCT04754763|DRUG|Propolis|Propolis was obtained from Margalla hills, Islamabad by NARC (National Agriculture Research Council, Islamabad). Plant source origin is Acacia modesta and Apis mellifera bees collect it. The 30% ethanolic extract of propolis from raw propolis was obtained in Pakistan Council of Scientific \& Industrial Research (PCSIR) by dissolving the propolis in 95% ethanol and straining out the precipitate
215048098|NCT04592341|DRUG|Gantenerumab|Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.
215048099|NCT04203589|BEHAVIORAL|The Explorer Baby Early Intervention Program|Centered based intervention, once or twice a month, 6 months follow up
214886968|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg|single-dose: 3mg/kg
214886969|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg|single-dose:10mg/kg
214886970|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg, q2w*6|multiple dosing: 1mg/kg, q2w\*6
214886971|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w*6|multiple dosing: 3mg/kg, q2w\*6
214293297|NCT03477877|BEHAVIORAL|Indashyikirwa Activist Training|This training is offered to a subset of individuals who complete the couples curriculum (randomly selected from among those who are are willing and eligible). These individuals are trained to serve as community activists, teach peers about the types of power (power within, power over, power with, power to), and advocate for community change to prevent intimate partner violence. Delivered by RWAMREC.
215048100|NCT04203589|OTHER|Neurodevelopmental Therapy|Centered based intervention, once or twice a month, 6 months follow up
214293298|NCT03477877|BEHAVIORAL|Indashyikirwa Opinion Leader Training|"Training delivered to opinion leaders (political office holders, religious leaders, service providers), in intervention communities. Training comprised 8 x 3 hour sessions (24 hours) delivered for groups of up to 40 participants. Introduces Opinion Leaders to the concepts of power (power within, power over, power with, power to) and to essential concepts around women's legal rights. Delivered by Rwanda Women's Network."
214293299|NCT03477877|OTHER|Indashyikirwa Women's Spaces|"Establishment of 1 Women's Space per intervention sector -- a physical space with trained facilitators on duty from which support and referrals for women experiencing IPV could be offered and ad hoc programming responsive to community needs and interest can be run. Typical activities include once-off open trainings for community members on the concepts of power (power within, power over, power with, power to), essential concepts around women's legal rights, conflict management in families, etc. Delivered by Rwanda Women's Network."
214886972|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg, , q2w*6|multiple dosing: 10mg/kg, , q2w\*6
214886973|NCT03374007|BIOLOGICAL|Geptanolimab Injection 280mg, q3w|multiple dosing: 280mg, q3w
214886974|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w|multiple dosing: 3mg/kg, q2w
214886975|NCT04795947|BEHAVIORAL|Behavioral|There is no intervention in this study
214886976|NCT03994822|DEVICE|Mechanical Thrombectomy using the pRESET Thrombectomy device|Clot removal using the pRESET Thrombectomy device
214886977|NCT03994822|DEVICE|Mechanical Thrombectomy using the Solitaire Revascularization Device|Clot removal using the Solitaire Revascularization Device
215048101|NCT01405183|OTHER|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
215048102|NCT04592406|OTHER|CVP screening|An appropriate dual screening process including both renal and cardiac parameters to minimize the risks of post-contrast renal adverse outcomes and of prophylactic hydration in eGFR\<30mL/min/1.73m2 patients.
215048103|NCT03313414|DRUG|Sofosbuvir/Velpatasvir Treatment for 14 days|14 day therapy with Sofosbuvir/Velpatasvir
215048104|NCT02971709|BEHAVIORAL|Shade Sail|Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
215048105|NCT00003929|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
215048106|NCT00003929|DRUG|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
215048107|NCT00003929|DRUG|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
215048108|NCT00003929|RADIATION|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
214886978|NCT02031419|DRUG|CC-122|2mg or 3 mg administered orally once daily
214886979|NCT02031419|DRUG|CC-223|20mg or 30mg administered orally once daily.
214886980|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
214886981|NCT02031419|DRUG|CC-122|2mg or 3mg administered orally once daily.
214886982|NCT02031419|DRUG|CC-292|500 mg twice a day administered orally.
214886983|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
214886984|NCT02031419|DRUG|CC-223|20mg or 30mg per day administered orally daily.
214886985|NCT02031419|DRUG|CC-292|500 mg twice a day administered orally.
215048109|NCT02879513|DRUG|Paclitaxel|
215048110|NCT02879513|DRUG|Cisplatin|
215048111|NCT02879513|DRUG|Epirubicin|
215048112|NCT02879513|DRUG|Cyclophosphamide|
215048113|NCT02879513|DRUG|5-fluoruracil|
215048114|NCT00710983|BIOLOGICAL|Oral polio vaccine|
215048115|NCT00692003|DRUG|Zonisamide|"25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg; \>= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
215048116|NCT00692003|DRUG|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg Zonisamide Placebo; \>= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
215048117|NCT02890277|DEVICE|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
215048118|NCT02890277|DRUG|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
214886986|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
214886987|NCT01905436|DRUG|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
214886988|NCT06372184|DRUG|Washed Microbiota Transplantation|Patients take four capsules containing washed microbiota once a day for five consecutive days
214886989|NCT06372184|DRUG|Placebo|Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days
214886990|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|Traditional motivational face-to-face workshops with lifestyle (nutritional, physical activity, sleep) advice every 3 months
215048119|NCT03672149|DRUG|Cefazolin|Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion
214886991|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|E-learning and digital (with videos -YouTube channel or WhatsApp/text message) educational workshops with lifestyle (nutritional, physical activity, sleep) advice every 15 days
214886992|NCT06210022|DIAGNOSTIC_TEST|Neuropsychological Assessment|Cognitive evaluation and clinical monitoring of seizure frequency
214886993|NCT03377257|DRUG|zolmitriptan by sublingual administration|Experimental group
214886994|NCT03377257|DRUG|zolmitriptan by oral|Active group
214886995|NCT06438835|DIAGNOSTIC_TEST|PneuFlex AFO Assist|It features a pneumatic artificial muscle designed to enhance ankle foot orthosis functionally for patients with mobility issues.
214886996|NCT02129322|DRUG|Sorafenib|
214886997|NCT02129322|DRUG|S-1|
214886998|NCT02129322|DRUG|Oxaliplatin|
214886999|NCT00743717|DEVICE|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
215048120|NCT04677998|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.
215048121|NCT04630925|OTHER|isCGM|As previously described
215048122|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
215048123|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP|1 x 10\^10 PU administered in deltoid
214887000|NCT00743717|DEVICE|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
214887001|NCT01662219|OTHER|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
214887002|NCT00959218|DRUG|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
214887003|NCT00959218|DRUG|Placebo|oral solution
214887004|NCT00781807|OTHER|multi-module rehabilitation program|"The multi-module rehabilitation program includes:~1. Nutrition management~2. Home-based ergometer training program~3. Psychosocial support"
214887005|NCT01873378|DRUG|Triptorelin 3.75 mg|
214887006|NCT03938909|GENETIC|cif mtDNA biomarker|The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
215048124|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
214293300|NCT03477877|BEHAVIORAL|Village Savings and Loan Association (VSLA)|A standard Village Savings and Loan Association program as run nationwide by CARE Rwanda.
214293301|NCT00569478|OTHER|rehabilitation|Nursing consultations and physical training
215048125|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
215048126|NCT03895190|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
215048127|NCT01248793|DRUG|Placebo|Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
215048128|NCT01248793|DRUG|Golimumab|Golimumab 50 mg SC injection every 4 weeks for 48 weeks
214293302|NCT00667368|DRUG|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
214887007|NCT00032383|BEHAVIORAL|Tai Chi|
214887008|NCT01105793|DRUG|Danazol|High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
214887009|NCT00444587|DRUG|Second line chemotherapy|As prescribed
214887010|NCT00444587|DRUG|trastuzumab [Herceptin]|6mg/kg iv every 3 weeks
214887011|NCT05952531|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image IIM lesions in skeletal muscle, heart, lung, skin and potential tumor by PET/CT.
214887012|NCT03512873|DRUG|Tranilast|Subjects will be treated with tranilast
214887013|NCT04407273|DRUG|observational|observational study
214887014|NCT04170465|DRUG|Metformin Hydrochloride 850 mg Tablets|Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
214887015|NCT04170465|DRUG|AC-T chemotherapy regimen|AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
214887016|NCT00261560|DRUG|acetaminophen|
214887017|NCT00582660|DRUG|Celecoxib|400 mg twice a day for 7 days prior to surgery
214887018|NCT00582660|DRUG|Placebo|one tablet of placebo will be given for 7 days prior to surgery
214887019|NCT02666729|PROCEDURE|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
214887020|NCT02666729|PROCEDURE|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
214887021|NCT05356507|OTHER|Patient population|Questionnaires, standard of care
214887022|NCT01208805|BEHAVIORAL|Recording spinal cord evoked potentials|Recording spinal cord evoked potentials from patients suffering from intractable pain in whom epidural electrodes have already been implanted
214887023|NCT02229461|DRUG|Naproxen Sodium (Aleve, BAY117031)|Naproxen sodium 220 mg qd or bid
214887024|NCT02229461|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|ASA 81 mg qd
215048129|NCT01248793|DRUG|Golimumab (placebo group)|Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
215048130|NCT04616937|DIETARY_SUPPLEMENT|GOS|Prebiotic
215048131|NCT04616937|DIETARY_SUPPLEMENT|Placebo|Placebo
214887025|NCT00667680|DEVICE|Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator|real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
214887026|NCT01842529|BIOLOGICAL|botulinum toxin injection|
214887027|NCT01842529|BIOLOGICAL|0.9% normal saline injection|
214887028|NCT01842529|DEVICE|Implantable loop recorder|
214887029|NCT04768660|OTHER|gum|Other: Chewing gum ChiczaTM organic chewing gum 6 pieces a day Other: Glucose 12ml glucose solution (13,6g) per day
214887030|NCT02633592|OTHER|HRARM|Patients and healthy volunteers are investigated in the seated and lying position during HRAM
214293303|NCT03336853|DEVICE|HybenX|"The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
214293304|NCT03336853|OTHER|Placebo control|"The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
214293305|NCT02793141|OTHER|No intervention|No intervention will be administered
214887031|NCT02633592|OTHER|MRI Defecography|Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
214887032|NCT02909244|BIOLOGICAL|Biological sampling|Biological sampling
214887033|NCT05258201|OTHER|Strain-counterstrain|Strain-counterstrain is also used for manual Trigger Point processing. This involves identifying active TRP and then applying pressure until a ridiculous reaction occurs. The area is then positioned to reduce tension in the injured muscle and later reduce tripod pain. When the pain subsides, the tissues that are most stressed feel relaxed and there is a local decrease in the ground
214887034|NCT05258201|OTHER|Muscle Energy Technique|Muscle Energy Technique is a common way to achieve muscle tension release (stop) before stretching other's adductor muscles
214887035|NCT04695769|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.
214887036|NCT04695769|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.
214887037|NCT05013125|DIAGNOSTIC_TEST|ENDO-AID CADe assisted Colonoscopy|ENDO-AID is a dedicated endoscopy Computer-Aided Diagnosis (CADe) system where suspicious lesions are automatically detected and highlighted on the main monitor in real-time, alerting the endoscopist during the procedure.
215048132|NCT04016701|DEVICE|Floreo Joint Attention Module|Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long
214293306|NCT01448811|DEVICE|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI\>40, titrate up propofol dosage, AAI\<25, titrated down propofol dosage.
214293307|NCT01448811|PROCEDURE|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
214887038|NCT01720225|DRUG|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
214667976|NCT02426606|OTHER|Various lentil varieties (varying in slow digested starch content)|"Randomized, cross-over block design.~Comparison of glycemic and insulinemic responses following meals composed of:~* white rice or white rice combined with 1 of 3 different lentil varieties or~* white potato or white potato combined with 1 of 3 different lentil varieties~Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.~Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit)."
214887039|NCT01720225|DRUG|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
214887040|NCT04174625|DIETARY_SUPPLEMENT|Dietary Supplement: Omega3-FA|Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
214887041|NCT02104570|OTHER|Kinesio taping with tension|
214887042|NCT02104570|OTHER|Kinesio taping without tension|
214887043|NCT02104570|OTHER|Fatigue protocol|
214887044|NCT03024788|DEVICE|syringe, fundus camera etc|Physical examination, fundus examination, blood and urine samples collection
214887045|NCT01473407|BIOLOGICAL|Epoetin Hospira|Variable dose
214887046|NCT01473407|BIOLOGICAL|Epogen (Amgen)|Variable dose
214887047|NCT00003056|DRUG|cyclosporine|
214887048|NCT00003056|DRUG|cyclosporine and methotrexate|
214887049|NCT04385537|DIETARY_SUPPLEMENT|PECAN|Raw pecan halves without other changes to their habitual diet.
214887050|NCT06068556|BIOLOGICAL|GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition|Two intramuscular injections of GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition will be performed. 1st injection - component I, 2nd injection - component II.
215048133|NCT04016701|BEHAVIORAL|Regularly Scheduled Therapy|therapy as regularly scheduled at therapy center
214887051|NCT02825771|BEHAVIORAL|Caring Contacts Messages|Text messages expressing care and support are sent following initial meeting on the following schedule: next day, 6 weekly, 9 bi-weekly, 7 monthly; one each on birthday, holiday, and seasonal (total of 25)
215048134|NCT00517699|DRUG|rituximab [MabThera/Rituxan]|750mg/m2 iv
215048135|NCT00517699|DRUG|Methotrexate|8g/m2 iv
215048136|NCT00517699|DRUG|Cytarabine|2g/m2 iv
214293308|NCT05089760|OTHER|No intervention|This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.
215048137|NCT05498532|DIAGNOSTIC_TEST|Functional MRI|Anatomical MRI : T2 fiesta, SSFE, HASTE ; 3D T2 ; T1 FAT SAT ; LAVA Functional MRI : T1 FAT SAT with gadolinium
214293309|NCT02678260|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
214293310|NCT05599607|DIETARY_SUPPLEMENT|Probiotic mixture|Mixture of strains of lactobacillus and bifidobacteria
214293311|NCT05599607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214293312|NCT03479606|BEHAVIORAL|Online Emotion Regulation Skills-training|Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
214293313|NCT05125978|DRUG|Canadá|Canadá association 1 tablet twice a day
214293314|NCT05125978|OTHER|Canadá placebo|Placebo of Canadá association 1 tablet twice a day
214293315|NCT05125978|DRUG|Dipyrone|Dipyrone 1 tablet twice a day
214667977|NCT04477122|OTHER|Manual therapy and extracorporeal radial shock waves therapy|25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)
214887052|NCT02825771|BEHAVIORAL|Usual Care|Usual care consists of services available to the participant in their community to reduce their suicide risk and improve their behavioral health
215048138|NCT00140023|DRUG|Azithromycin microspheres 2.0 single dose|
215048139|NCT06112470|OTHER|Interview|Semi-structured interview on experiences, perceptions, beliefs and knowledge of drug allergy and barriers to allergological testing, with a view to content analysis.
214293316|NCT05125978|OTHER|Dipyrone placebo|Placebo of dipyrone 1 tablet twice a day
214667978|NCT04606121|COMBINATION_PRODUCT|enhanced day care of TCM include acupuncture, massage, tai ji quan, TCM herbal medicine|acupuncture twice in enhanced day care of TCM massage twice in enhanced day care of TCM tai ji quan one time in enhanced day care of TCM TCM herbal powder three times a day
214887053|NCT00002397|DRUG|Nelfinavir mesylate|
214887054|NCT00002397|DRUG|Saquinavir|
215048140|NCT02905279|BEHAVIORAL|Biofeedback Relaxation Training|Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.
215048141|NCT02905279|BEHAVIORAL|Exposure Therapy|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.
214293317|NCT05125978|DRUG|Tramadol hydrochloride|Tramadol 1 coated tablet twice a day
214293318|NCT05125978|OTHER|Tramadol hydrochloride placebo|Placebo of tramadol 1 coated tablet twice a day
215048142|NCT02905279|BEHAVIORAL|Exposure with Threat-Relevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
215048143|NCT02905279|BEHAVIORAL|Exposure with Threat-Irrelevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
214293319|NCT06494839|PROCEDURE|Bipolar electrocautery tonsillectomy technique|The BED tonsillectomy procedures were done under general anesthesia, and the patient's position was the same as in the other method. The bipolar machine was adjusted to 30 watts, and a mucosal incision was cauterized with a single straight or stepped bipolar forceps. After carefully cauterizing the tissue, the palatine tonsil was located and removed from the superior to the inferior pole. Most of the identifiable vessels supplying the tonsil were cauterized before being separated from the tonsil. Point coagulation was used to maintain hemostasis. By using point coagulation, hemostasis was maintained. To avoid bias stemming from competence, consultants performed all of these tonsillectomies.
214477474|NCT06810791|DRUG|Standard Chemotherapy|Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is given by venous drip daily at 60mg/m2, from day 1-3, combined with Ara-C at 100mg/m2 by continuously venous drip from day 1-7.
214887055|NCT00002397|DRUG|Lamivudine|
214887056|NCT00002397|DRUG|Stavudine|
214887057|NCT03742193|DRUG|Apatinib|Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.
214887058|NCT03742193|DRUG|GD regimen|"One cycle: gemcitabine 900 mg/m\^2 over 90 min on Day 1, and gemcitabine 900 mg/m\^2 and docetaxel 75 mg/m\^2 on Day 8. Every 21 days were eligible.~1\~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken."
214887059|NCT04071405|OTHER|Non-intervention|Non-intervention observational study
214293320|NCT06494839|PROCEDURE|Cold steel dissection technique|The cold steel blunt dissection tonsillectomy was carried out under general anesthesia while the patient was in the Rose position and had an endotracheal intubation. The tonsil was retracted medially with a tonsil holding forceps, and in the upper pole, the mucosal incision was made. To protect the tonsillar pillars, a delicate dissection was performed, and the suction tip was used to stop the hemorrhage. The tonsillar fossa was packed with swabs. The other palatine tonsil was then similarly removed. Hemostasis was secured by silk ligation and bipolar electrocautery.
214293321|NCT04326348|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
214293322|NCT01765205|DEVICE|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
214887060|NCT04327011|BIOLOGICAL|Toca 511 vector|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
214887061|NCT04327011|DRUG|Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine|Toca FC is an extended-release formulation of flucytosine.
214887062|NCT02720497|BEHAVIORAL|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
214887063|NCT02720497|BEHAVIORAL|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
214887064|NCT02422797|DRUG|DTG 50 mg|Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
214887065|NCT02422797|DRUG|RPV 25 mg|"Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV."
214887066|NCT02422797|DRUG|CAR|CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
214887067|NCT03842644|DEVICE|Tension reduction device|Continue using this device for 3 months post surgery.
214887068|NCT05294666|DRUG|Cyclosporine|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
214887069|NCT05294666|DRUG|tacrolimus|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
214887070|NCT04391296|PROCEDURE|Arm I (Prepectoral), Arm II (Subpectoral)|"Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia."
214887071|NCT05096650|PROCEDURE|mesotherapy of platelet rich plasma and platelet poor plasma|Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
215048144|NCT00540696|DRUG|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
215048145|NCT03951610|DEVICE|Test lens|contact lens
215048146|NCT03951610|DEVICE|Control lens|contact lens
215048147|NCT02332187|DEVICE|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
214293323|NCT00363922|BEHAVIORAL|Rehabilitation in institution|Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
214293324|NCT00363922|BEHAVIORAL|Rehabilitation at home|Subjects get a written prescription of exercise training, diet, etc. to follow at home.
214477475|NCT06811883|DEVICE|LIGHTBACK|This group will perform a standard 20-minute warm-up, and the LIGHTBACK protocol is also included.
215048148|NCT02332187|DEVICE|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
215048149|NCT01506024|PROCEDURE|Total hip arthroplasty direct lateral approach|
215048150|NCT01506024|PROCEDURE|Total hip arthroplasty posterior approach|
215048151|NCT01506024|PROCEDURE|Total hip arthroplasty, anterior approach|
215048152|NCT02250976|DRUG|Livasupril Cap.160/2mg|Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
215048153|NCT02250976|DRUG|Lipilfen cap. 160mg|Micronized fenofibrate 160mg
215048154|NCT02250976|DRUG|Livaro tab. 2mg|Pitavastatin Ca 2mg
214477476|NCT06811883|DEVICE|Placebo|This group will perform a standard 20-minute warm-up, but the LIGHTBACK protocol is not included and a similar placebo is used.
215048155|NCT05141838|DRUG|Vitamin D|Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state
214477477|NCT06811753|PROCEDURE|robotic surgery|minimally invasive surgery
214887072|NCT00372814|BEHAVIORAL|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
214887073|NCT00372814|BEHAVIORAL|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
214887074|NCT01783795|OTHER|Genetic Analysis|
214887075|NCT05583825|OTHER|Rebozo App|It is a non-invasive, non-drug practical application made with Rebozo, a long and colorful fabric, two meters long and 70 cm wide, worn by Mexican women on their head and shoulders.
214887076|NCT00369941|DRUG|MK-0518|400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
214477478|NCT00942877|DRUG|AZD2171|Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS).
214887077|NCT00369941|DRUG|Comparator: efavirenz|600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
214887078|NCT00369941|DRUG|Comparator: Truvada|One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
214887079|NCT00369941|DRUG|Comparator: Placebo to MK-0518|Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks
214887080|NCT00369941|DRUG|Comparator: Placebo to efavirenz|Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
214887081|NCT01707017|OTHER|Strength training|
214887082|NCT05477043|DIAGNOSTIC_TEST|Transabdominal ultrasound and cistoscopy|Ultrasound detection of the bilateral ureteral jets vs absence of the ureteral jet on one side compared with the presence of bilateral ureteral jet on cystoscopy vs absence on one side.
214887083|NCT01027702|BIOLOGICAL|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10\^4, 4 x 10\^4, 5 x 10\^4, 6 X 10\^4, 8 x 10\^4, and 10 X10\^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
214887084|NCT02186002|DRUG|ACT-451840 10 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
214887085|NCT02186002|DRUG|ACT-451840 50 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
214887086|NCT02186002|DRUG|ACT-451840 200 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
214887087|NCT02186002|DRUG|ACT-451840 500 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
214887088|NCT02186002|DRUG|ACT-451840 1000 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
214887089|NCT02186002|DRUG|ACT-451840 (Dose to be determined)|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
214887090|NCT02186002|DRUG|Placebo|
214887091|NCT00403585|DRUG|adefovir dipivoxil 10mg|
214477479|NCT06455085|BEHAVIORAL|Augmented-Fracture Liaison Service Arm|Patients are contacted by a patient navigator (serving as the liaison) and referred to a bone health clinician.
214887092|NCT05792111|DRUG|Trigger point injection (lidocaine)|trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.
214887093|NCT05792111|DRUG|Caudal epidural Group (bupivacaine + triamcinolone + NaCl)|It will be advanced towards the sacral hiatus and local anesthesia of the skin and subcutaneous tissue will be provided with 2% lidocaine. The caudal epidural space will be entered by puncturing the sacrococcygeal ligament with the tip of a 22 G black needle from the appropriate area and taking a pop sensation. It will be confirmed that there is no bleeding or cerebrospinal fluid in this area by applying saline in real-time sonography and after the caudal epidural spread is observed, aspiration is performed. Afterward, a 10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space
214887094|NCT00129571|DRUG|XL820|
214887095|NCT03678571|OTHER|Latrunculin A supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Latrunculin A
214887096|NCT03578393|DEVICE|Virtual Reality Educational Program|The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
214887097|NCT00843661|DRUG|ezetimibe|10 mg ezetimibe/day
214887098|NCT00843661|DRUG|fenofibrate|200 mg fenofibrate/day
215048156|NCT05141838|DIETARY_SUPPLEMENT|Oral nutritional supplement|Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition
215048157|NCT00161889|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
215048158|NCT05067881|PROCEDURE|Pulmonary resection|Resection of pneumohematocele
214887099|NCT00843661|DRUG|pravastatin|40 mg pravastatin/day
214887100|NCT04875351|DIAGNOSTIC_TEST|Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test|The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (\>5 year) endocrine therapy.
214887101|NCT00005811|DRUG|topotecan hydrochloride|Given IT
214887102|NCT00005811|OTHER|laboratory biomarker analysis|Correlative studies
215048159|NCT01102595|DRUG|Temozolomide|"* Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~* Temozolomide 75 mg/m2/d x 42-49 days~* Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
215048160|NCT01102595|DRUG|Bevacizumab|"* 2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~* Bevacizumab 10 mg/kg every 15 days, three dosis."
214293325|NCT00363922|BEHAVIORAL|Out-patient rehabilitation at the hospital|This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
214293326|NCT00732615|DRUG|Placebo|Placebo for subcutaneous injection
214293327|NCT00732615|DRUG|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
214293328|NCT02703389|BEHAVIORAL|Video|Animated video explaining acute otitis media and antimicrobial stewardship.
214887103|NCT02461251|DEVICE|Rotational Thromboelastometry (ROTEM)|A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
214293329|NCT02703389|BEHAVIORAL|Pamphlet|Contains same information as video.
214293330|NCT04304391|PROCEDURE|Resective Gingival Surgery|Gingivectomy and gingivoplasty:Resective gingival surgical procedured
214293331|NCT03600610|DEVICE|gadolinium-enhanced cardiac MRI|cardiac magnetic resonance imaging with gadolinium injection used T1-Mapping
214293332|NCT01031732|PROCEDURE|MIS-2 THA|MIS two-incision THA
214293333|NCT01031732|PROCEDURE|MIS-WJ|MIS-Watson Jones THA
214293334|NCT01031732|PROCEDURE|MIS-AL THA|Transgluteal approach
214293335|NCT01031732|PROCEDURE|MIS-PL THA|Posterolateral approach
214293336|NCT05416320|DRUG|Calcipotriol|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
214293337|NCT05416320|DRUG|Subject's already prescribed drug|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
214293338|NCT04544254|PROCEDURE|Bilateral transversus thoracis muscle plane block|The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided. Twenty milliliters bupivacaine 0.5% 1mg/body weight will be injected between internal intercostal muscle and transversus thoracis muscle on both sides.
214293339|NCT04544254|PROCEDURE|Control|A needle will be place in the similar area to the transversus thoracis muscle plane block, but no drugs will be injected to the area
214293340|NCT05240456|DRUG|Beta3-Agonists, Adrenergic|The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
214293341|NCT05240456|DRUG|Anticholinergic drug, Solifenacin|Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
214293342|NCT02988505|OTHER|Standard care|
214293343|NCT03009435|OTHER|prophylactic manual rotation|
214293344|NCT03740958|DRUG|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA
214293345|NCT03740958|DRUG|Argatroban|100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
214667979|NCT01600781|DIETARY_SUPPLEMENT|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
214887104|NCT00980031|DRUG|Eplerenone|25mg PO daily (QD)for 6 months
214887105|NCT00980031|DRUG|Lactose Tablet|Lactose tablet
214887106|NCT05063474|DIAGNOSTIC_TEST|No Intervention-Clinical Assessments only|No Intervention. Clinical Assessments include: vital signs, near infrared spectrometry, general leg strength, and 6-minute walking test.
214293346|NCT01981291|PROCEDURE|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
214293347|NCT01981291|PROCEDURE|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
214293348|NCT01981291|PROCEDURE|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
214293349|NCT01981291|PROCEDURE|Patient-controlled postoperative analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
214293350|NCT01981291|DRUG|Mepivacaine|Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
214887107|NCT04018651|BEHAVIORAL|PrEP Master Adherence Intervention|"The PrEP Master Adherence Intervention consists of 4 face to face individual education sessions and a series of telephone contacts to identify barriers and facilitators to optimal PrEP adherence over a six-month period. Each PrEP Master education session includes a review of an individualized plan to reduce risk, review of information about PrEP, and different discussion points. Key messages include:~1. Importance of daily adherence;~2. Three week delay for full effectiveness describing PrEP like taking the birth control pill;~3. Condom use for other sexually transmitted infection (STI) prevention;~4. Pregnancy prevention plans;~5. Plans for follow up calls~6. Referral to other treatment services if necessary"
214887108|NCT00249431|DRUG|Sertraline|Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
214293351|NCT02829281|DRUG|Botulinum Toxin Type A|Joint injection of Botulinum Toxin Type A
214293352|NCT02829281|DRUG|Triamcinolone hexacetonide|Joint injection of triamcinolone hexacetonide
214293353|NCT02829281|DRUG|Saline|Joint injection of Saline
214477480|NCT06455085|BEHAVIORAL|Enhanced Usual Care Arm|Patients will be mailed education materials and encouraged to follow up with their primary care physician.
214667980|NCT00971321|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
214887109|NCT00249431|BEHAVIORAL|Relapse Prevention Therapy|Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
214293354|NCT05576493|PROCEDURE|phaco+MP-TSCPC|The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
214293355|NCT05576493|PROCEDURE|phaco+TSCPC|The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
214293356|NCT05576493|PROCEDURE|phaco+endocyclophotocoagulation|phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
214293357|NCT05576493|PROCEDURE|phaco GSL|phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
214293358|NCT03109574|DEVICE|BioFlo DuraMax Chronic Hemodialysis Catheter|
214293359|NCT03109574|DEVICE|Standard of Care Catheter|
214293360|NCT00528333|DRUG|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
214293361|NCT00528333|DRUG|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
214293362|NCT00528333|DRUG|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
214293363|NCT03566823|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
214293364|NCT03566823|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
214293365|NCT01269060|PROCEDURE|Single Incision Laparoscopic Surgery|Single Incision Laparoscopic Sigmoidectomy
214293366|NCT01348347|DRUG|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
214887110|NCT06101160|DRUG|onaBoNT-A|injection under ultrasonography
214887111|NCT06581276|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is an evidence-based behavioral pain treatment intervention for Chronic Pain, anxiety and depression, and substance use disorders, being studied as a group-based therapy delivered by substance use counselors in an opioid treatment program.
214887112|NCT03514966|BEHAVIORAL|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
214293367|NCT01348347|DRUG|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
214293368|NCT01348347|DRUG|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
214293369|NCT02507674|DEVICE|ultrasound|
214293370|NCT02539277|DRUG|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
214293371|NCT02539277|DRUG|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
214293372|NCT02539277|DRUG|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
214293373|NCT02539277|DRUG|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
214293374|NCT03418298|BEHAVIORAL|Prehabilitation group|Subjects will performed an internet-based exercise program before surgery
214293375|NCT01683955|DRUG|Tranexamic acid|Topical tranexamic acid (2g/100mL 0.9% saline)
214887113|NCT04019626|OTHER|Continue-smoking|Ad-libitum use of subjects' usual brand combustible cigarette
214887114|NCT04019626|OTHER|myblu Tobacco 2.5%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine
214887115|NCT04019626|OTHER|myblu Tobacco 4.0%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine
214293376|NCT01683955|DRUG|Placebo|100mL 0.9% sterile saline
214293377|NCT03402685|DEVICE|ClearSight|Patients in the intervention group receive management of volume and vasopressor settings according to the non-invasive ClearSight system.
214293378|NCT00278083|DRUG|Study drug administration|
214293379|NCT00278083|PROCEDURE|Tuberculin intradermal skin test|
214293380|NCT00278083|PROCEDURE|Lung function test for FEV1|
214293381|NCT00278083|PROCEDURE|Asthma symptom scores diary|
214293382|NCT00278083|PROCEDURE|Quality of life diary|
214293383|NCT00278083|PROCEDURE|Breath nitric oxide|
214293384|NCT00278083|PROCEDURE|Breath condensate|
214293385|NCT00278083|PROCEDURE|Sputum induction|
214293386|NCT00278083|PROCEDURE|Blood sampling|
214293387|NCT00278083|PROCEDURE|Urinalysis|
214477481|NCT04784416|DEVICE|Active tPBM-2.0|The NIR continuous wave (average irradiance = 300 mW/cm2) will be used. The duration or irradiation will be for \~11 minutes (666 seconds).
214477482|NCT04784416|DEVICE|Sham tPBM-2.0|"The sham mode (0 mW/cm2) will be used. The duration or sham irradiation will be for \~11 minutes (666 seconds)."
214477483|NCT04784416|DRUG|18F-MK-6240|PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
214477484|NCT06617416|DRUG|Cadonilimab (AK104)|AK104 ivgtt Q3W
214477485|NCT06617416|DRUG|Sugemalimab|1200mg Q3W
214887116|NCT04019626|OTHER|myblu Honeymoon 2.5%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
214887117|NCT04019626|OTHER|myblu Honeymoon 4.0%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
214887118|NCT04019626|OTHER|JUUL 5%|Ad-libitum use of JUUL 5% e-cigarette
214887119|NCT02964312|DEVICE|Nasal Implant|Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
214887120|NCT06465836|PROCEDURE|O, lreay suture|bilateral uterine artery ligations as described by O- lreay technique in addition to standard conservative methods. Briefly two large vicryl stitches were passed using a large sized needle below and lateral to the lower edge of the uterine incision angle in anteroposterior direction and then redirected from back to the front through avascular window in the posterior leaf of the broad ligament just lateral to the uterine border taking care to avoid injury to bowel posteriorly or bladder/ureter anteriorly. The stitches were tied securely anteriorly
214887121|NCT06465836|PROCEDURE|modified O, lreay suture|"1. Pack Douglas- pouch with a towel.~2. Straight the used vicryl needle mostly no 1.~3. Try to compress and approximate anterior and posterior uterine walls.~4. Start from anterior to posterior 3- 4 cm medial to lateral uterine margin and then pass from posterior to anterior through avascular area in the broad ligament. And we repeat the procedure on the other side. We can repeat this method of uterine ligation at another different plane if needed."
214887122|NCT06113835|PROCEDURE|CTO PCI|percutaneous coronary intervention
214887123|NCT05536999|OTHER|Blood sample taking , like to measure hormonal level like LH, FSH, Perlakan ,in a follicular fluid after the oocyte retrival|Blood test measure basal FSH, follicular fluid testing
214887124|NCT00139893|DRUG|Reglan ODT|
214887125|NCT06551194|OTHER|prevalence of difficult-to-treat IBD|To assess the prevalence and risk factors of difficult-to-treat IBD patients
214887126|NCT04290455|DEVICE|Microblepharoexfoliative procedure with BlephEx™|The device will be used to clean both upper and lower eyelid in the office visit.
214887127|NCT04290455|PROCEDURE|Eyelid cleansing with eyelid wipes (Optase)|Eyelid cleansing will be done with eyelid wipes (Optase) by one clinician
214887128|NCT04290455|PROCEDURE|Daily eyelid cleansing with eyelid wipes (Optase)|Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
214887129|NCT01228617|DRUG|Nicotine|Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day
214887130|NCT01228617|DRUG|Nicotine Gum|Following a 12-hour nicotine abstinence period, subjects will be instructed to chew the gum once every 2 seconds, for 30 minutes.
214887131|NCT00368758|DRUG|Probiotic bacteria (Trevis R)|
214887132|NCT05470608|DRUG|SL-1002|SL-1002 injectable solution
214887133|NCT05470608|DRUG|Placebo|Matching placebo injectable solution
215048161|NCT01102595|RADIATION|Standard radiation therapy|42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
215048162|NCT01840943|DRUG|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
215048163|NCT01840943|DRUG|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
215048164|NCT04860115|PROCEDURE|Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)|"PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered.~PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes."
215048165|NCT05580354|DRUG|BCG combined with Tislelizumab|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
215048166|NCT02735018|DRUG|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
214887134|NCT00948532|BIOLOGICAL|biologic, Osteocel Plus|Osteocel® Plus
215048167|NCT02735018|DRUG|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
215048168|NCT00421512|DRUG|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
215048169|NCT03433547|PROCEDURE|Buckle|Surgical procedures of macular buckling
215048170|NCT03433547|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy
215048171|NCT03433547|OTHER|Limbal paracentesis|Drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis
215048172|NCT03433547|OTHER|Gas injection|Inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous cavity through pars plana.
215048173|NCT03433547|OTHER|Peeling internal limiting membrane|Peeling internal limiting membrane with forceps
214887135|NCT02276807|BEHAVIORAL|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
214887136|NCT02276807|OTHER|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
214887137|NCT02497911|PROCEDURE|Adductor Canal Catheter|0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
214887138|NCT02497911|PROCEDURE|Intraarticular Catheter|0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
214887139|NCT02497911|DRUG|Ropivicaine|
214887140|NCT02497911|DRUG|Bupivicaine|
214887141|NCT01458353|PROCEDURE|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
214887142|NCT01458353|PROCEDURE|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
214887143|NCT04235244|OTHER|Thermo mechanical device|The thermomechanical-analgesia device will be placed and operated 30 seconds before the injection into the abdominal area,and injection will be applied by sliding the device to the side of the selected region during the injection,
214887144|NCT04235244|OTHER|local coolant spray|Coolant spray will be applied to the abdominal area for 5 seconds at a distance of 15 cm.
214887145|NCT04235244|OTHER|ıce battery|abdominal bölgeye uygulamadan önce ve sonra 5 dk. lokal soğuk uygulama
214887146|NCT04292444|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.
214887147|NCT04292444|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
214887148|NCT01103492|DEVICE|HALO90 Ablation catheter|FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.
214887149|NCT01848925|BIOLOGICAL|SANGUINATE™|40 mg/mL intravenous infusion.
214887150|NCT01848925|DRUG|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
214887151|NCT00015886|DRUG|docetaxel|75 milligrams per meter squared intraveneously
214887152|NCT00015886|DRUG|fluorouracil|350 milligrams intraveneously
214887153|NCT01525914|DRUG|Dutasteride|dutasteride 0.5mg daily
214887154|NCT00052455|DRUG|lomustine|
214887155|NCT00052455|DRUG|procarbazine hydrochloride|
214887156|NCT00052455|DRUG|temozolomide|
214887157|NCT00052455|DRUG|vincristine sulfate|
214887158|NCT01023035|DRUG|Boceprevir|800 mg given three times a day (TID), orally (PO)
214887159|NCT01023035|DRUG|Peginterferon alfa-2b (PEG2b)|1.5 µg/kg/week given subcutaneously (SC)
214477486|NCT03595202|DRUG|TS-143|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
214477487|NCT03595202|DRUG|Placebo|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
214887160|NCT01023035|DRUG|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
214887161|NCT01023035|DRUG|Erythropoietin|Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
214887162|NCT02398864|PROCEDURE|EBUS with TBNA|endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
214887163|NCT02134990|DRUG|Oshadi D and Oshadi R|Anti cancer agents
214887164|NCT02134990|DRUG|Docetaxel|Chemotheraphy
214887165|NCT03409354|BEHAVIORAL|Tele-rehabilitation|There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.
214887166|NCT03409354|BEHAVIORAL|Usual care|Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
214887167|NCT03340090|DEVICE|Medical Device Hemopatch-PEG-coated collagen patch|Two pieces of PEG-coated collagen patch Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of LIMA harvesting and second piece of Hemopatch will be placed beneath the sternum.
214887168|NCT03493412|DRUG|Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)|5 mg/kg will be used as the dose of BH4
214887169|NCT03493412|DRUG|Placebo|Placebo
214887170|NCT01901926|PROCEDURE|Non Surgical Periodontal Treatment|one time intervention in the form of scaling and root planing
214887171|NCT00198055|DRUG|aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
214887172|NCT06489210|PROCEDURE|popliteal block|using ultrasound to detect sciatic nerve and popliteal fossa through different approaches using 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
214887173|NCT00512122|OTHER|Withholding PN during the first week of ICU stay|Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.
214887174|NCT00512122|DRUG|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E|PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
214887175|NCT04081909|DRUG|Fentanyl，Remifentanil|Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.
214887176|NCT04081909|DRUG|Ketamine,Dexmedetomidine|Patients in OFA,anesthesia induction will receive ketamine 1 mg/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , dexmedetomidine of 0.4-0.8ug/ kg/ hr.
214887177|NCT00778388|BIOLOGICAL|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
214887178|NCT00778388|DRUG|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
215048174|NCT03433547|OTHER|Gas tamponade|Filling the vitreous cavity with gas (C3F8, 14%)
215048175|NCT04606927|OTHER|Natriuresis|Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.
214477488|NCT05388812|OTHER|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
214477489|NCT05388812|OTHER|Individual Placement and Support (IPS)|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
214477490|NCT04502186|BEHAVIORAL|Raising Our Spirits Together|Raising Our Spirits Together (ROST) is an 8-session computer-assisted cognitive behavioral therapy for depression. Core CBT content, including behavioral activation, cognitive restructuring, and problem solving, are delivered via the computer-assisted platform using video and text-based elements. The computer-assisted intervention is complemented by a workbook that includes in-session exercises as well as homework/action plans. ROST is delivered weekly, either virtually or in-person at a local church, and facilitated by a local pastor.
214477491|NCT04502186|OTHER|Enhanced Control Condition|The Enhanced Control Condition intervention consists of providing participants randomized to this condition with a self-help book for depression (The Depression Helpbook; Katon et al, 2008) that is widely used and found to be beneficial, a local resource guide, and referrals.
214477492|NCT06313060|DIETARY_SUPPLEMENT|Coca-cola|200 ml of Coca-Cola will be administered and must be ingested within a maximum of 10 minutes
214477493|NCT03233854|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22 CAR T cells IV
214477494|NCT03233854|DRUG|Cyclophosphamide|Given IV
214477495|NCT03233854|DRUG|Fludarabine Phosphate|Given IV
214477496|NCT03233854|OTHER|Laboratory Biomarker Analysis|Correlative studies
214477497|NCT03233854|OTHER|Questionnaire Administration|Ancillary studies
214887179|NCT03595007|BEHAVIORAL|Kids Kicking Cancer program|Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.
214887180|NCT05084157|DIAGNOSTIC_TEST|Echocardiography|Patients will undergo Doppler echocardiography
214477498|NCT03233854|DRUG|NKTR-255|Given IV
214477499|NCT06774664|BIOLOGICAL|SCTC21C|Drug: SCTC21C Administered SC
214477500|NCT04175470|DRUG|Bevacizumab|10 mg/kg intravenously every three weeks
214477501|NCT04175470|DIETARY_SUPPLEMENT|Tocotrienol|Capsules, 300 mg orally three times daily
214477502|NCT06056011|DEVICE|Connex CSVM with Timmy3 module|Connex Vital Signs Monitor with the Timmy3 Investigational module
214477503|NCT06595706|DRUG|Lucid-21-302|Capsule containing a small molecule inhibitor of hypercitrullination
214477504|NCT06595706|DRUG|Placebo|Capsule containing only Silicified Microcrystalline Cellulose
214887181|NCT00524420|DEVICE|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
214887182|NCT00524420|DEVICE|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
214887183|NCT00003126|DRUG|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
214887184|NCT00274339|DRUG|Prevacid 30mg BID|
214887185|NCT00274339|BEHAVIORAL|Lifestyle changes of exercise and diet changes for weight loss and avoidance of reflux inducing foods.|
214887186|NCT01090414|DRUG|Idelalisib|Idelalisib tablets or capsules administered orally
214887187|NCT05036512|DRUG|GBT021601|Administered orally with water as a single dose in the morning.
214887188|NCT04620408|DRUG|SHR4640|Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
214887189|NCT00897910|OTHER|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
214477505|NCT00887198|DRUG|Abiraterone acetate|1000 mg per day (4 x 250-mg tablets) taken orally.
214477506|NCT00887198|DRUG|Placebo|4 placebo tablets per day taken orally.
214477507|NCT00887198|DRUG|Prednisone|5 mg tablet orally twice daily.
214477508|NCT06588140|DEVICE|Duplicated refitted complete denture made from conventionally heat-cured polymethyl methacrylate.|The duplication of a refitted complete removable denture will be performed using conventional heat-cured polymethyl methacrylate through the conventional heat-cured polymerization technique.
214887190|NCT00897910|OTHER|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
214887191|NCT00897910|OTHER|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
214887192|NCT03481010|PROCEDURE|PAO with hip arthroscopy|Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.
214887193|NCT03481010|PROCEDURE|PAO without hip arthroscopy|"Participants who are randomized to the PAO-only group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia."
214887194|NCT03127514|DRUG|AMX0035|AMX0035
214887195|NCT03127514|OTHER|Placebo|Matching Placebo Comparator
214293388|NCT03580317|OTHER|EA+ Carbamazepine|"Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily."
214293389|NCT03580317|OTHER|EA+Placebo|In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
214293390|NCT03580317|OTHER|sham EA+Carbamazepine|"Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part."
214293391|NCT03580317|OTHER|sham EA+Placebo|The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
214293392|NCT00552916|DEVICE|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
214293393|NCT00552916|DEVICE|Compex Motion Stimulator|'False' FES
214293394|NCT04391127|DRUG|Hydroxychloroquine|Hydroxychloroquine: 400 mg PO every 12 hours for one day. Subsequently 200 mg every 12 hours per 4 more days.
214293395|NCT04391127|DRUG|Ivermectin|Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.
214293396|NCT04391127|DRUG|Placebo|Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
214887196|NCT02848209|PROCEDURE|TCA 20% Peeling|TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
214293397|NCT01649661|BEHAVIORAL|questionnaire|
214293398|NCT03551054|BEHAVIORAL|Healthy for Two, Healthy for You|Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
214293399|NCT03551054|BEHAVIORAL|Health Education|
214293400|NCT02769455|OTHER|Reference intakes|"FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.~The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label."
214477509|NCT06588140|DEVICE|Duplicated refitted complete denture made from 3D-printed CAD/CAM pink polymethylmethacrylate acrylic resin.|The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed separately with pink polymethyl methacrylate resin, and the teeth are printed as a single unit using tooth-colored resin, followed by the assembly of the two components.
214887197|NCT02848209|PROCEDURE|Phenol/croton oil Peeling|Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.
214887198|NCT02848209|PROCEDURE|TCA 40% Peeling|TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
215048176|NCT03100318|DRUG|FYU-981|Oral daily dosing for 14 weeks
215048177|NCT03100318|DRUG|Benzbromarone|Oral daily dosing for 14 weeks
215048178|NCT01508208|OTHER|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
215048179|NCT05617118|DRUG|Baclofen 10mg|Baclofen is a medication, a central myorelaxant, a GABAb stimulator.
215048180|NCT05617118|DRUG|Botulinum toxin type A|Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.
215048181|NCT01674504|DRUG|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
215048182|NCT02580877|DRUG|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
215048183|NCT02580877|DRUG|500mg oral insulin crystals every other week|human insulin crystals in capsules
215048184|NCT00980148|DRUG|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
215048185|NCT00980148|DRUG|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
215048186|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|0.1 mL, Intradermal (ID)
215048187|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|0.1 mL, Intradermal (ID)
215048188|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
215048189|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (High-dose)|0.5 mL, Intramuscular (IM)
215048190|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
215048191|NCT04899726|DEVICE|Rectoscope (P201630551)|Rectoscope (P201630551) allows the identification of the distal section margin in oncological rectal surgery.
214887199|NCT04080739|DRUG|ropivicaine 0.2%|2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
214887200|NCT02439021|DEVICE|COBRA|
214887201|NCT02439021|DEVICE|LMA|
214887202|NCT03014843|DRUG|Naloxone|20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
215048192|NCT02903823|DRUG|Baclofen bolus injection|A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
214293401|NCT02769455|OTHER|5-CNL|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.~The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant."
214293402|NCT00722033|DRUG|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
214293403|NCT00004860|DRUG|leucovorin calcium|
214293404|NCT00004860|DRUG|tegafur-uracil|
214293405|NCT00191789|DRUG|gemcitabine|1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
214887203|NCT03014843|DRUG|Methylnaltrexone Bromide|12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
214293406|NCT00191789|DRUG|doxorubicin|60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)
214293407|NCT00191789|DRUG|cisplatin|70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)
214293408|NCT00191789|PROCEDURE|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
214293409|NCT05999136|OTHER|Pulses diet|Subjects in the PulD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PulD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with servings of pulses.
214293410|NCT05999136|OTHER|Plant proteins diet|Subjects in the PPD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PPD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with a mixture of pulses and plant-based meat substitutes.
214293411|NCT05999136|OTHER|Habitual diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
214887204|NCT03014843|OTHER|Placebo|0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
214887205|NCT02665221|OTHER|No Treatment Arm|Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.
214887206|NCT02665221|DRUG|Topical Preparation H arm|Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
214887207|NCT00754078|RADIATION|Tomotherapy|30 fractions of tomotherapy treatment
215048193|NCT01781377|DRUG|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
215048194|NCT01781377|DRUG|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
215048195|NCT01781377|DRUG|PLACEBO|SALINE INFUSION
215048196|NCT05280665|OTHER|Specialization|"* Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~* Who identified themselves as primarily gastric surgeons during the study period~* Whose annual gastric cancer surgery volume is more than 21"
214887208|NCT03408171|DEVICE|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
214887209|NCT03408171|DEVICE|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
214887210|NCT02413229|DRUG|DSXS1411|DSXS (Taro Pharmaceuticals Inc.)
214887211|NCT02413229|DRUG|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
214887212|NCT04742829|DIETARY_SUPPLEMENT|INTRAVIT ®|2 tablets per day morning and evening before meals
214887213|NCT02932462|DRUG|DSXS|topical product
214887214|NCT02932462|DRUG|Placebo|topical product
214887215|NCT05209529|DRUG|olaparib|olaparib 300 mg per os BID
215048197|NCT00356070|DRUG|Strattera|
215048198|NCT02690766|BEHAVIORAL|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
215048199|NCT00002286|DRUG|Zidovudine|
215048200|NCT04165863|PROCEDURE|total knee replacement surgery|total knee replacement surgery
215048201|NCT01747915|DRUG|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
214887216|NCT05209529|DRUG|Durvalumab|durvalumab 1500 mg IV Q4 weeks
214293412|NCT00759811|DRUG|Methotrexate|"Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
214293413|NCT00759811|DRUG|Placebo|"Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
214293414|NCT03577353|BEHAVIORAL|Dual Task Walking (DTW)|Each training session began with 8 min of general warm-up and 2 min walk around the gym. Then, for safety reasons, the participants were attached to a harness. The participants began walking slowly on the treadmill for 3 min. In the following phases the participants walked at the same speed, while training with 3 VR games. Each session lasted 3 min, and 3 min of single walking was performed between VR sessions. After the final VR session, 2 min of single-task walking was performed in order to allow for recovery. The time walked in each trial from the starting point to the destination was kept constant at 20 min.
214887217|NCT01145469|GENETIC|DNA analysis|
214887218|NCT01145469|GENETIC|gene expression analysis|
215048202|NCT01747915|DRUG|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
214293415|NCT03577353|BEHAVIORAL|Single-task Treadmill Walking (TMW)|this intervention, participants performed 8 min of general warm-up and 2 min walk around the gym, and then continued to walk for another 20 min on the treadmill at a speed that was equivalent to the intensity of 60%-70% of their heart rate reserve.
214293416|NCT02236195|DRUG|Mocetinostat|
214293417|NCT02468544|OTHER|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
214293418|NCT00992576|DRUG|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
214293419|NCT00992576|DRUG|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
214293420|NCT01124136|DEVICE|Neurostimulation + Medication Management (Standard of Care)|In addition to medication management, adding investigational implanted neurostimulator to heart
214293421|NCT01124136|DRUG|Standard of Care (Control)|Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
214293422|NCT02668133|DIETARY_SUPPLEMENT|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
214293423|NCT02668133|DIETARY_SUPPLEMENT|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration \~500 FTU/20 g SQ-LNS) added during manufacturing
214293424|NCT02668133|DIETARY_SUPPLEMENT|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
214293425|NCT02668133|DIETARY_SUPPLEMENT|1 mg isotopically enriched 68Zn|administered intravenously
214293426|NCT02801240|OTHER|Nutrition support product|Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
214293427|NCT04010682|OTHER|urine sample collection|no drug/devise intervention. sample collection study only
214293428|NCT05682781|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Oral Nutritional Supplement
214293429|NCT05682781|OTHER|Dietary Counseling|Dietary Counseling
214293430|NCT02650362|OTHER|fMRI|
214293431|NCT04565860|OTHER|Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)|"Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations)."
214293432|NCT02908503|OTHER|Placebo Film|placebo vaginal films
214887219|NCT01145469|GENETIC|polymorphism analysis|
214887220|NCT01145469|OTHER|laboratory biomarker analysis|
214887221|NCT01145469|OTHER|medical chart review|
214887222|NCT00555165|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
214887223|NCT04072081|DEVICE|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
214887224|NCT04072081|DEVICE|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
214887225|NCT02037412|DRUG|Ticagrelor|Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months
215048203|NCT01747915|DRUG|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
214887226|NCT02037412|DRUG|Clopidogrel|Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
214887227|NCT03064724|BEHAVIORAL|"Interactive Mobile Doctor (iMD)"|"iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient."
215048204|NCT03341637|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
214293433|NCT03180151|PROCEDURE|piezotome assisted orthodontic tooth movement|"Surgical procedure~1. After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.~2. The incisions will be kept minimal.~3. The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.~4. A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.~5. As we will not use bone graft so we don't need use suturing after cortication.~6. We give patient antibiotic and analgesic cover."
214293434|NCT05281185|DRUG|Extended half-life FVIII concentrates with PK-guided dosing|Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis
214293435|NCT05281185|DRUG|standard half-life FVIII concentrates with weight-based dosing|standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
214293436|NCT06379178|PROCEDURE|Oral colostrum application 2 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 2 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
214293437|NCT06379178|PROCEDURE|Oral colostrum application 4 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 4 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
214293438|NCT03528993|OTHER|exercise by hippotherapy device|Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
214293439|NCT03528993|OTHER|conventional rehabilitation|Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
214293440|NCT03528993|OTHER|postural control exercises|perturbation on four directions, weight bearing exercises on standing positions
214293441|NCT00923598|DRUG|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
214293442|NCT00959621|DRUG|Aspirin|ASA 100 mg once daily per os
214293443|NCT00959621|DRUG|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
214293444|NCT00959621|DRUG|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
214293445|NCT04939402|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity
215048205|NCT03341637|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
215048206|NCT05020301|DEVICE|external meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
215048207|NCT05020301|DEVICE|internal meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
215048208|NCT00222976|DRUG|Naproxen|Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
215048209|NCT01330095|DIETARY_SUPPLEMENT|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
215048210|NCT04878107|DRUG|Camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd
215048211|NCT04878107|DRUG|Apatinib|Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor
214293446|NCT03383198|DRUG|Liposomal bupivacaine right injection|Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
214293447|NCT03383198|DRUG|Liposomal bupivacaine left injection|Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
214293448|NCT02697032|DRUG|Bicalutamide|150mg
214293449|NCT02697032|PROCEDURE|FDHT PET|PET scan
214293450|NCT01935271|DIETARY_SUPPLEMENT|Muscle Armor Supplement|
214293451|NCT01935271|DIETARY_SUPPLEMENT|Placebo|
214293452|NCT00976092|DRUG|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
214293453|NCT00976092|DRUG|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
214293454|NCT00976092|DRUG|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
214293455|NCT00976092|DRUG|Heparin|i.v. bolus of 70-100 IU/kg body weight
214293456|NCT00102882|DRUG|fluticasone propionate/salmeterol|
214293457|NCT00102882|DRUG|salmeterol xinafoate|
214293458|NCT00258245|DIETARY_SUPPLEMENT|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide \[ATO\] days 1, 4, 8, 11
214293459|NCT00258245|DRUG|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
215048212|NCT04878107|DRUG|Docetaxel injection|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
215048213|NCT04878107|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.
214293460|NCT00258245|DRUG|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
214293461|NCT00258245|DRUG|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
214293462|NCT00258245|DRUG|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
214293463|NCT00258245|DRUG|Aspirin|Aspirin - 325 mg by mouth (PO) every day
214293464|NCT01516346|DRUG|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
214293465|NCT01516346|DRUG|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
214293466|NCT01516346|DRUG|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
214293467|NCT04541862|OTHER|Intensive care|intensive care for critically ill patients in the intensive care units
214293468|NCT01915082|DRUG|Azithromycin|"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
214477510|NCT06588140|DEVICE|Duplicated refitted complete denture made from 3D-printed CAD/CAM white polymethylmethacrylate acrylic resin.|The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed as a single unit using tooth-colored resin, and the denture flange will be veneered with pink polymethyl methacrylate resin.
214477511|NCT06597786|OTHER|Exercise therapy|Patients will receive a study kit which includes a smart watch (for monitoring of mobility / lifestyle patterns), heart rate monitor, blood pressure cuff, scale, and e-tablet. Patients may receive a treadmill to perform exercise therapy sessions. The treadmills and study kits are MSK owned equipment that will be deployed to the patients' homes and returned at the end of the study.
214477512|NCT03334695|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp in single-use vials.
214477513|NCT03334695|DRUG|Placebo|Placebo will be administered as sterile 0.9% saline for injection.
214477514|NCT05007080|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as intramuscular (IM) injection.
214477515|NCT06589271|BIOLOGICAL|human umbilical cord mesenchymal stem cell suspension|2 \* 10\^7 cells (2ml)
214477516|NCT06589271|PROCEDURE|total endoscopic extraction of lumbar nucleus pulposus|hUC-MSCs are injected into the opposite side of the minimally invasive surgical site immediately after surgery, and the puncture needle remains for 1 minute after injection and then pull out to prevent cell suspension leakage
214477517|NCT02874742|DRUG|Lenalidomide|Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
214477518|NCT02874742|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
214477519|NCT02874742|DRUG|Dexamethasone|Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
214477520|NCT02874742|DRUG|Daratumumab|Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
214477521|NCT05814432|DRUG|Single high dose of liposomal amphotericin B|Single high dose (10 mg/kg) of liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
214667981|NCT01968876|OTHER|Medication Adherence Smartphone App|MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
214293469|NCT01915082|DRUG|Ora-Plus|"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
214667982|NCT00677950|PROCEDURE|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
214667983|NCT00004046|DRUG|exatecan mesylate|
214667984|NCT03679494|OTHER|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
214667985|NCT01750021|DIETARY_SUPPLEMENT|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
214667986|NCT01750021|DIETARY_SUPPLEMENT|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
214667987|NCT04403867|PROCEDURE|Sentinel lymph node (SLN) biosy +/- lymphadenectomy|Evaluation of type and volume of lymph nodal disease
214667988|NCT00208468|DEVICE|European Hip|A cementless femoral component for use in total hip replacement
214667989|NCT00208468|DEVICE|Zweymüller|A cementless femoral component for use in total hip replacement
214667990|NCT00208468|DEVICE|CLS Spotorno|A cementless femoral component for use in total hip replacement
215048214|NCT04878107|RADIATION|LDRT|low dose radation therapy
215048215|NCT04032886|OTHER|kinesio tape|This is a taping method used for correction of rounded shoulders.
214887228|NCT06371625|PROCEDURE|Transeversus Thoracic Plane Block (TTPB) and Pectoral Nerves (PECS) Block|The TTP block will be performed in a supine position before general anesthesia. First, a high linear probe of the ultrasound system will be attached at sagittal plane to the sternum and counted from T2 near the clavicle to T5. Then the linear probe will be rotated by 90° and attached between the forth and the fifth costal cartilages connecting at the sternum near nipple. Then, the transversus thoracic muscle and the internal intercostal muscle will be identified. A total of 15 mL of 0.25% bupivacaine will be injected into the interfascial plane, between the transversus thoracic muscle and the internal intercostal muscle between the fourth and fifth costal cartilages connecting at the sternum. Pleural downward displacement will be used as an ultrasound endpoint.
214887229|NCT06371625|PROCEDURE|Pectoral Nerves (PECS) Block|Patients positioned supine with the ipsilateral arm abducted and externally rotated. The infra-clavicular and axillary regions will be cleaned with chlorhexidine. The skin point of and once the structures are identified with ultrasound, the probe will be positioned under the lateral third of the clavicle. After locating the subclavian artery, the axillary artery and the axillary vein we will move the probe distally towards the axilla, until the pectorals major muscle is identified. We will start counting the ribs, from 1st rib under the axillary artery and maintaining the pectorals major. Serratus anterior muscle cover 2nd, 3rd, 4th rib, this point being the entrance into the anterior axillary line we will use atraumatic needle with extension line and electrode for nerve stimulator (Stimuplex D). We will inject 10ml of 0.25% bupivacaine between the pectorals muscles first, then inject 20ml of 0.25% bupivacaine.
214887230|NCT05573958|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban 2.5 mg oral tablet will be administered twice daily
214887231|NCT05573958|DRUG|Clopidogrel tablet|Clopidogrel 75 mg once daily orally
214887232|NCT05573958|DRUG|Aspirin tablet|Aspirin 81 mg tablet once daily
214887233|NCT02652949|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
214887234|NCT06045013|DRUG|5% dextrose injection|Single ultrasound-guided injection of 4 ml 5% dextrose in carpal tunnel via ulnar approach.
214887235|NCT06045013|DRUG|5% dextrose injections with methylprednisolone acetate 40 mg/ml|Single ultrasound-guided injection of 3 ml 5% dextrose with 1 ml 40 mg/ml methylprednisolone acetate in carpal tunnel via ulnar approach.
214887236|NCT05531864|PROCEDURE|Ultrasound-guided continuous low serratus anterior plane block|Low anterior serratus plane block, move the mid-axillary line 4 and 5 intercostal puncture points are moved down and the puncture is changed to 7 and 8 intercostal.
214887237|NCT05531864|PROCEDURE|Ultrasound-guided single serratus anterior plane block|Ultrasound-guided single anterior saw plane block was performed, and a needle was injected between the 4th and 5th costals in the midaxillary line.
214887238|NCT05635487|DRUG|SHR-A1811|SHR-A1811
214887239|NCT05635487|DRUG|Pyrotinib|Pyrotinib
214887240|NCT04040556|OTHER|Simulation class|Pediatric anesthesia simulation class for anesthesia residences
214887241|NCT05751707|DEVICE|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System is a clinical device which consists in a pump which generates high frequency oscillations and connected to a jacket worn by the patient, intended to facilitate airway secretions clearance by detaching them from the bronchial wall and moving them upwards in the bronchial system.
214887242|NCT03561077|OTHER|Mindfulness-based interventions (MBI's)|Mindfulness Based Intervention with eight sessions (one session per week) of two hours dedicated to adolescents will be provided. The intervention will focus on skill building and will incorporate mindfulness meditation, exercises and activities specially adapted to teenagers with chronic pain. Topics will include mind body connection, the effect of stress on pain, living in the present moment, focused awareness, responding versus reacting to pain and/ or difficult situations, non judgement, gratitude, kindness and compassion towards self and others.
214887243|NCT05212077|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
214887244|NCT05212077|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
214887245|NCT01546428|DRUG|INC280|
214887246|NCT06133361|BIOLOGICAL|PRP injection|The PRP will be prepared according to a well-established technique and then injected into the palatal mucosa of the upper anterior teeth before retraction.
214887247|NCT06133361|PROCEDURE|En-masse retraction of upper anterior teeth|The anterior teeth will be moved backward in an en-masse retraction way using a frictionless method. The anterior teeth will be manipulated as one block. Coil springs will be stretched between the power arms (in the anterior area) to the miniscrews placed in the posterior area bilaterally.
214887248|NCT04436601|DRUG|Polyethylene Glycols|Polyethylene glycol will be administered to half of the study patients, and their response recorded and compared with that of the Lactulose arm.
214887249|NCT04436601|DRUG|Lactulose|Lactulose (standard of care) will be administered to half of the study patients and their response recorded.
214887250|NCT02688946|OTHER|Not provided|
214887251|NCT05436795|DEVICE|Abbott Panbio rapid antigen self-tests|COVID-19 self-testing will be performed using investigational Abbott Panbio rapid antigen self-test kits that require self-sampled nasal swabs.
214887252|NCT05436795|OTHER|COVIDSmart CARE! app|Guided by the application that connects, educates, and communicates a digital, contactless open access strategy, participants will have the opportunity to self-test and assess their risk level of COVID-19 infection, as well as the option to refer their close contacts to testing for those who are COVID-19 positive, through the study platform.
214887253|NCT01937221|OTHER|spectral-domain optical coherence tomography (SD-OCT)|Intervention same to all groups.
214887254|NCT00101426|DRUG|ranirestat, (AS-3201)|
214887255|NCT03980652|PROCEDURE|Change of gloves and sterile instruments|Change of gloves and use of separate , sterile instruments before closing the abdominal wall
214887256|NCT00721071|DRUG|Hypertonic Saline|After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
214887257|NCT06084793|OTHER|Music|In the pre-transfer room, the personalized playlist will be played through earphones or speakers, according to the patient´s preference. In the transfer room, the personalized playlist will be played through speakers at a volume that is loud enough for the participant to hear but soft enough to ensure clear communication between the patient and doctor, without causing any disturbance to the doctor.
214477522|NCT05814432|DRUG|L-AmB standard dose|Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
214477523|NCT06746025|BEHAVIORAL|Quit Center cessation program|Lifestyle modifications based on the Quit Center cessation program.
214477524|NCT01950234|DRUG|ACTH|Acthar gel
214477525|NCT01950234|DRUG|Placebo|Placebo
214477526|NCT06814938|DRUG|Semaglutide|2.4 mg subcutaneous weekly
214477527|NCT06814938|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly
214477528|NCT06815523|OTHER|Machine learning and logistic regression for the training/testing cohort and validation cohort|Machine learning and logistic regression for the validation cohort
214477529|NCT06813196|BEHAVIORAL|Forest Bathing|Forest bathing intervention is a group structured psychosocial intervention. Its core therapeutic element is its nature-based activities that took place in an outdoor green space. During the session, participants would be guided by a trained forest therapy guide to engage in nature-based activities, such as walking in the woods, listening to the nature, and interacting with objects in the nature through different sensations.
214477530|NCT06813196|BEHAVIORAL|Art activity|Art activity intervention is a group semi-structured psychosocial intervention. Its main therapeutic element is its engagement in art-based activites. During the session, participants would be guided in individual or collaborative art activities of different forms, such as painting, paper arts, and dried flower art, by an experienced interventionist in an activity room.
214477531|NCT04142307|DEVICE|Biofeedback Training|Microperimeter biofeedback training as described provides to the patient a variable frequency sound and a luminous stimulus that vary according to the eyes position, thus guides the oculomotor control and fixation stability accordingly.
214477532|NCT04142307|DEVICE|Sham - simulated BT|The simulated biofeedback training for Group B involves the following: each session includes presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button.
214477533|NCT05883956|DRUG|Subcutaneous azacitidine|Subcutaneous azacitidine, 75mg/m2, 7 days
214887258|NCT02087657|DEVICE|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
214887259|NCT02224989|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
214887260|NCT05085379|DEVICE|Ossiview|Imaging of the ear using Optical Coherence Tomography
214477534|NCT05883956|DRUG|Oral decitabine/cedazuridine|Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days
214477535|NCT06005948|OTHER|exercise|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 8 weeks
214477536|NCT06005948|OTHER|control|No intervention will be made.
214477537|NCT06605170|OTHER|Questionnaire|Translate and culturally adapt the original English version of the traumatic injuries distress scale to Turkish
214477538|NCT02561611|BEHAVIORAL|Intervention Group|The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
214477539|NCT06816355|PROCEDURE|Orchiectomy|CPT:54520
214477540|NCT06816355|PROCEDURE|Hysterectomy|CPT:1013911
214477541|NCT06816355|PROCEDURE|Augmentation mammoplasty|CPT:19325
214477542|NCT06814210|DEVICE|Cerebral Embolic Protection|Subjects will undergo M-TEER following placement of the cerebral embolic protection device.
214477543|NCT06817811|DRUG|Apixaban 5 mg Film-Coated Tablet (produced by PT Dexa Medica)|One tablet of the test drug was given orally under fasting condition
214477544|NCT06817811|DRUG|Eliquis® 5 mg film-coated tablet (Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia)|One tablet of the reference drug was given orally under fasting condition
214887261|NCT06012188|OTHER|sleep toy|The parents of the children in the experimental group will be given a sleeping companion toy to present to their children. At the end of 15 days, the Children's Sleep Habits scale will be applied as a post-test to evaluate the effect of the sleep companion toy.
214477545|NCT06336148|DRUG|ACTM-838|Escalating doses of ACTM-838 in Part 1a and recommended dose in Part 1b
214667991|NCT04047992|DEVICE|Indego™ Exoskeleton|The Indego® is a powered exoskeleton that can be used as a mode of therapy in an institutional setting. Proper walking in this device requires the user to manipulate their center of gravity and balance by postural trunk excursions in order for the legs to take steps.
214887262|NCT01740245|DEVICE|Chlorhexidine vaginal suppositories|
214887263|NCT01740245|DEVICE|Polyhexamethylene biguanide vaginal suppositories|
214887264|NCT02411916|BIOLOGICAL|misoprostol|rectal insertion
215048216|NCT04032886|OTHER|exercise|Exercises include basic postural exercises.
215048217|NCT03504228|DEVICE|Roadsaver|Dual layer micromesh Roadsaver carotid stent
215048218|NCT01211561|DRUG|Selenium, selenomethionine|Patients will receive one 200 ug pill of Selenomethionine
215048219|NCT01211561|DRUG|placebo|Patients will be given one 200 ug placebo pill each day for 6 months
215048220|NCT02759445|OTHER|routine treatment|No intervention, only observation and describing
215048221|NCT01690754|OTHER|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
215048222|NCT03030456|DEVICE|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
215048223|NCT05208008|OTHER|With service dog|No intervention
215048224|NCT03712774|OTHER|EORTC QLQ C30|standardized questionaire
215048225|NCT03712774|OTHER|EORTC QLQ OES-18|standardized questionaire
215048226|NCT03712774|OTHER|EORTC OG-25|standardized questionaire
215048227|NCT00887159|DRUG|Cisplatin|Given IV
215048228|NCT00887159|BIOLOGICAL|Cixutumumab|Given IV
215048229|NCT00887159|DRUG|Etoposide|Given IV
215048230|NCT00887159|OTHER|Laboratory Biomarker Analysis|Correlative studies
215048231|NCT00887159|DRUG|Vismodegib|Given PO
215048232|NCT01564251|DRUG|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
215048233|NCT01564251|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.
215048234|NCT04454346|DEVICE|Double Foley Catheter For Ripening The Unfavorable Cervix|New method
215048235|NCT06375395|DEVICE|Active tACS Device|Transcranial Alternating Current Stimulation
215048236|NCT06375395|DEVICE|Sham tACS Device|Placebo Device that simulates active tACS treatment
215048237|NCT00644839|DRUG|CP-945,598|Administration of CP-945,598 alone in period 1
215048238|NCT00644839|DRUG|CP-945,598|Adminstration of CP-945,598 with omeprazole in period 2
215048239|NCT05083078|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
215048240|NCT05083078|DRUG|Risankizumab|Risankizumab will be administered subcutaneously.
215048241|NCT04258852|DRUG|Low strength nicotine e-liquid|Low strength nicotine e-liquid
215048242|NCT04258852|DRUG|High strength nicotine e-liquid|High strength nicotine e-liquid
215048243|NCT02030132|BEHAVIORAL|Feedback compared to 75th percentile|
215048244|NCT02030132|BEHAVIORAL|Forgiveness|
215048245|NCT02030132|BEHAVIORAL|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
215048246|NCT02030132|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
215048247|NCT01643681|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
215048248|NCT04274595|DRUG|Generic antiretroviral|200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
215048249|NCT04681989|BEHAVIORAL|Moving On After Breast Cancer|"After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~1. Instructions on how to use the physical therapy-based education materials by a research staff member~2. a range of motion wand~3. a small ball~4. MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment."
215048250|NCT02361671|OTHER|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
215048251|NCT04635137|PROCEDURE|Ablation and Cementoplasty|Percutaneous thermal ablation with subsequent cementoplasty in a single procedure
215048252|NCT00835289|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids|Omax3\[TM\] (Cenestra Health \[TM\]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
215048253|NCT00835289|OTHER|Placebo|3 capsules of matching corn oil placebo
215048254|NCT00441766|DRUG|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
215048255|NCT00441766|DRUG|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
215048256|NCT00441766|DRUG|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
215048257|NCT00441766|DRUG|placebo|Part A: placebo capsule every 12 hours for 4 weeks
215048258|NCT01732991|DEVICE|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
215048259|NCT04658927|DRUG|Dexamethasone, 0.4mg|iLUX + dextenza
215048260|NCT04658927|DRUG|Prednisone acetate|Prednisolone acetate 1% and iLux
215048261|NCT04658927|OTHER|Control|iLUX alone.
215048262|NCT03500211|DRUG|Lidoderm 5 % Topical Patch|Lidocaine patch after cesarean section delivery.
215048263|NCT03500211|OTHER|Sham Topical Patch|Sham patch after cesarean section delivery.
215048264|NCT05857566|DRUG|RDX-002|A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
215048265|NCT04985084|BEHAVIORAL|The intervention group|The intervention will last for four weeks and target six dietary behaviors related to gastric cancer. The intervention components include one session of face-to-face education prior to discharge and three sessions of telephone counselling after discharge. The face-to-face education will last for 20 to 30 minutes and each session of telephone counselling will last for 10 to 20 minutes. All the interventional sessions are individual based.
215048266|NCT04985084|OTHER|Usual care|General dietary advice provided as routine by the ward nurses before discharge from the hospital.
215048267|NCT02250872|DRUG|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
214887265|NCT03886740|PROCEDURE|Reducing symptoms of Eustachian tube dysfunction|One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
214887266|NCT02465138|DRUG|Ketorolac|Intravenous ketorolac
214887267|NCT02465138|DRUG|Placebo|Intravenous saline
215048268|NCT02250872|DRUG|Placebo|100mg in 2 divided doses plus cisplatin
215048269|NCT02250872|DRUG|Cisplatin|All patients will receive intravenous cisplatin
214293470|NCT05988099|DIETARY_SUPPLEMENT|Complex product|400 mg of chokeberry extract in liposomal formulation and L-arginine, vitamin E, vitamin A, folic acid, chromium
214293471|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in liposomal formulation|400 mg of chokeberry extract in liposomal formulation
215048270|NCT02115035|DRUG|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
215048271|NCT04614844|BEHAVIORAL|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
215048272|NCT04614844|BEHAVIORAL|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
215048273|NCT00225914|DRUG|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
215048274|NCT00225914|DRUG|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
215048275|NCT03420742|DRUG|Midazolam|Midazolam syrup.
215048276|NCT03420742|DRUG|Brigatinib|Brigatinib tablets.
215048277|NCT01550601|PROCEDURE|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
215048278|NCT05192421|BEHAVIORAL|Wellness Education|Receive wellness education through a weekly email and web portal content.
215048279|NCT05192421|BEHAVIORAL|Exercise Videos|Receive pre-recorded exercise videos through a weekly email and web portal content.
215048280|NCT05192421|BEHAVIORAL|Livestream Classes|Receive 3 videoconference group exercise classes per week for 8 weeks.
214293472|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in traditional formulation|400 mg of chokeberry extract in traditional formulation
214293473|NCT05988099|OTHER|Placebo|Placebo
214293474|NCT02703662|DEVICE|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
214293475|NCT02703662|DEVICE|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
215048281|NCT02799550|BIOLOGICAL|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
215048282|NCT04593121|DRUG|BIIB107|Administered as specified in the treatment arm.
215048283|NCT04593121|DRUG|Placebo|Administered as specified in the treatment arm.
215048284|NCT03284060|BEHAVIORAL|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~1. pen and paper tasks focusing on specific emotion recognition component (20 min),~2. computerized tasks focusing on the same process (20 min),~3. a proposal of a home-based task (during 20 min)."
215048285|NCT06251414|BEHAVIORAL|Exercise Intervention|Blood Flow Restriction (BFR) training, also known as occlusion training or restricted blood flow training, involves applying external pressure to a limb using inflatable cuffs or elastic bands. This pressure partially restricts arterial blood flow while occluding venous blood flow in the pressured limb. The goal is to increase muscle strength and size by creating metabolic stress and promoting physiological adaptations, such as muscle hypertrophy, with lighter loads than traditional resistance training.
214293476|NCT00002014|DRUG|Zidovudine|
214293477|NCT00002014|DRUG|Didanosine|
214887268|NCT06427850|DRUG|Tranexamic acid|receive an injection of Tranexamic acid into the surgical site
214887269|NCT06427850|DRUG|Normal saline|receive an injection of Normal saline into the surgical site
214887270|NCT04298268|DEVICE|CUSA Clarity Ultrasonic Surgical Aspirator System use|Assessment of the CUSA® Clarity Ultrasonic Surgical Aspirator System use during urological or general surgery for soft tissue removal
214887271|NCT00511732|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder
214887272|NCT00511732|DRUG|Technosphere Placebo|Technosphere Inhalation Powder
214887273|NCT01845688|DRUG|Losartan Tablets & QingReMoShen Granule|
214887274|NCT01845688|DRUG|Losartan Tablets & Placebo Granule|
214887275|NCT02403258|OTHER|Plum-blossom needle group|Plum-blossom needle is a method of shallow insertion with multiple needles. It is made of five or seven stainless steel needles arranged in a pattern like the shape of plum blossom, thus named as 'plum-blossom needle'. Plum-blossom needle treat diseases by tapping specific skin areas or acupoints according to different illness based on the theory of meridian.
214887276|NCT02403258|BEHAVIORAL|HRT group|HRT consisted of (1) self-monitoring, (2) competing responses, (3) relaxation training, (4) contingency management.
214887277|NCT00022282|DRUG|shark cartilage extract AE-941|
214887278|NCT01657812|DRUG|dexmedetomidine|"Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery."
214887279|NCT05015452|DEVICE|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
214887280|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
214887281|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
214887282|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
214887283|NCT03436056|DRUG|Pembrolizumab|Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
214887284|NCT00150787|DRUG|LEVETIRACETAM|
214887285|NCT02054286|BIOLOGICAL|THV01-1|Intramuscular injection of THV01-1 (week 0)
214887286|NCT02054286|BIOLOGICAL|THV01-2|Intramuscular injection of THV01-2 (week 8)
214887287|NCT02054286|BIOLOGICAL|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
214887288|NCT05123378|BEHAVIORAL|Liberia National Community Health Assistant Program|Through the National Community Health Assistant Program (NCHAP), members of remote communities select Community Health Assistants (CHAs). Once selected, CHAs are trained to deliver direct services which include; treatment of diarrhea, ARI, and malaria following Integrated Community Case Management (iCCM) protocols, referrals for patients with clinical danger signs, family planning for women of childbearing age and birth preparedness and education for pregnant women. CHAs are also trained to deliver indirect services which include; health education, active surveillance, referral for mental health and other special conditions for all age groups. Since 2020 COVID-education has also been included in the CHAs work.
214887289|NCT01433367|DEVICE|CerPass® Total Disc Replacement|Single level cervical disc disease
215048286|NCT06251414|BEHAVIORAL|Instrument-Assisted Soft Tissue Mobilization|Instrument-Assisted Soft Tissue Mobilization (IASTM) is a therapeutic technique that involves the use of specially designed tools or instruments to apply controlled mechanical pressure to soft tissues in the body. These tools are typically made of stainless steel or other materials and have various shapes and edges. The primary aim of IASTM is to address musculoskeletal conditions by breaking down scar tissue, fascial restrictions, and adhesions in the soft tissues. Practitioners use the instruments to detect and treat areas of tissue dysfunction, promoting improved range of motion, reduced pain, and enhanced functional mobility.
215048287|NCT06251414|BEHAVIORAL|Tuinal|Tuinal, also known as Tui Na or Chinese therapeutic massage, is a traditional Chinese medicine (TCM) healing technique that involves manual manipulation of the body's soft tissues, including muscles and tendons. It is a form of bodywork that aims to balance the flow of vital energy (Qi) within the body and promote overall well-being. Tuina techniques may include kneading, rolling, pressing, and brushing, and they are applied to specific acupressure points or along the body's meridians. Tuina is used to address various health concerns, alleviate pain, improve circulation, and enhance the body's natural healing processes, making it an integral part of traditional Chinese medicine.
215048288|NCT04927676|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, a hormone status is determined.
214887290|NCT06577922|OTHER|Establishment of a simulation lab and provision of simulation based trainings|In each hospital, the investigators will perform an initial need assessment to identify the existing skills labs' space, equipment and trained human resources. Then, maternal and neonatal health simulation labs will be established in each hospital. One simulation lab will have 5 rooms- one auditorium hall, one debrief room, two simulation rooms, and one high fidelity simulation room. Equipment and manikins required for practicing maternal and neonatal health related skills will be installed in the simulation lab, along with guidance/ checklists for skills practice. After completion of lab set-up, trainings will be provided to trainers/ MNH staff of each hospital on simulation based methodology, especially focusing on Essential Care for Labor and Birth (ECLB), Bleeding after Birth (BAB), and Helping Babies Breathe (HBB) modules. Similarly, the investigators will also provide training for simulation lab operation and maintenance.
214293478|NCT00828347|DRUG|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
214293479|NCT00828347|DRUG|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
214293480|NCT01411904|DEVICE|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
214477546|NCT06476600|DRUG|Dexmedetomidine injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
214887291|NCT04304092|OTHER|Exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
214887292|NCT03557112|DRUG|Nimotuzumab|TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
214887293|NCT03557112|DRUG|Cisplatin|TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
214887294|NCT00959478|BEHAVIORAL|Educational Tool & Carbon Monoxide Alarm|Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
214887295|NCT00302289|DRUG|tyrosine, green tea, caffeine|
214887296|NCT01487525|DEVICE|Double leg press with partial blood flow restriction|double isotonic and isokinetic leg press extension with application of partial blood flow restriction to the upper leg
214887297|NCT01487525|OTHER|Double leg press without partial blood flow restriction|double isotonic and isokinetic leg press extension without application of partial blood flow restriction to the upper leg
214887298|NCT05298865|BEHAVIORAL|Positive imagination stimulation|The intervention messages aim to generate participants' positive mental image toward their life and also to relieve parental stress by shifting their attention to positive life events. The positive affect cues will be developed based on qualitative interviews with 30 parents from our previous study during pandemic and also extended literatures on positive psychology. Our previous qualitative interview aimed to understand parental concerns on flu and COVID-19 vaccination, parental life stressors throughout the pandemic were also explored. The positive cues will be discussed and evaluated by the research team with an aim to cover major positive life events that are personal relevant to parents, including positive social support (friendship), positive family support (family gathering), qualified time spent with children (here we will also embed a gratitude practice to elicit strong positive feelings), and cultivate positive self by imagining achieving personal goals in the future.
214887299|NCT05298865|BEHAVIORAL|Neutral recall message|The control message aims to equate time and attention as in the intervention group. Therefore, a recall task will be assigned to participants. Brief texts will be provided to guide participants to memorize their life senarios but not to induce emotions. Messages include the following: recall the breakfast and lunch you had yesterday; recall the clothes and shoes you wore yesterday; recall the kitchen in your home; recall one of the chairs in your home; recall the routes to the nearest supermarket and subway of your house.
214887300|NCT01772290|DRUG|fluconazole|Multiple oral doses
214887301|NCT01772290|DRUG|itraconazole|Multiple oral doses
214887302|NCT01772290|DRUG|rabeprazole|Multiple oral doses
214887303|NCT01772290|DRUG|vismodegib|Multiple oral doses
214887304|NCT04650204|DRUG|Anticonvulsant Agent|Given ASD
214887305|NCT04650204|DRUG|Perampanel|Given PO
214887306|NCT04650204|OTHER|Quality-of-Life Assessment|Ancillary studies
214887307|NCT04650204|OTHER|Questionnaire Administration|Ancillary studies
214887308|NCT00728234|DEVICE|aEEG recording|weekly recordings with aEEG
215048289|NCT00099021|DRUG|pioglitazone hydrochloride|Given PO
215048290|NCT04298489|DIAGNOSTIC_TEST|Personalized drug sensitivity test|"The patients underwent surgery to remove tumor and took out tumor specimens for research. The tumor cells were expanded ex vivo drug sensitivity assay.~The drugs used in the study were 5-fluorouracil, Oxaliplatin, and irinotecan at C0 = 10 mM, 2.5 mM and 0.02 mM, respectively. They were applied either as single agents or in combinations of 5-fluorouracil and Oxaliplatin, 5-fluorouracil and irinotecan, or all three agents, or others. After 7 days of treatment, the tumor cells were stained with EdU, Hoechst and EpCAM with the Cell Quantitative Detection Kit. Images were acquired with an automated microscopic image-scanning system and analyzed with the built-in software."
215048291|NCT02189889|DRUG|EPO|The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.
215048292|NCT02189889|DRUG|Feraheme|Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
214293481|NCT02012075|DRUG|Extended-Release Carvedilol Sulfate|
215048293|NCT06209944|PROCEDURE|Cardiopulmonary resuscitation|cardiac compression, endotracheal intubation, defibrillation, and use of cardiovascular medications, to restore circulation in patients with cardiac arrest
215048294|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of 0.3μg/kg, 1μg/kg, 3μg/kg, 6μg/kg, 12μg/kg, 24μg/kg, 36μg/kg, 48μg/kg or 64μg/kg until disease progresses or unacceptable tolerability occurs;
215048295|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
215048296|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected subcutaneously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
215048297|NCT00381654|DRUG|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
215048298|NCT03224364|PROCEDURE|nonsolo LA|This patient is scheduled to undergo nonsolo laparoscpic appendectomy.
215048299|NCT03224364|PROCEDURE|solo LA|This patient is scheduled to undergo solo laparoscpic appendectomy.
215048300|NCT03725956|PROCEDURE|Endoscopic sinus surgery|"Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice"
215048301|NCT04419545|DIAGNOSTIC_TEST|Neural network diagnosis algorithm|we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
215048302|NCT06159257|DIAGNOSTIC_TEST|Blood test|"Whenever possible, samples will be collected by the nurse in the patient's home, according to the study visit schedule. However, if this is not possible, patients will be asked to come in for sample collection at another mutually convenient time at the CERBA ALLIANCE LABORATORY closest to the patient's address.~Venous blood will be drawn on each visit."
215048303|NCT00003365|DIETARY_SUPPLEMENT|curcumin|
215048304|NCT00003365|DIETARY_SUPPLEMENT|rutin|
215048305|NCT00003365|DRUG|quercetin|
215048306|NCT00003365|DRUG|sulindac|
215048307|NCT04608877|BEHAVIORAL|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
215048308|NCT04608877|BEHAVIORAL|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
215048309|NCT03492047|DIETARY_SUPPLEMENT|low dose N-acetylcysteine|N-acetylcysteine 600mg twice daily
215048310|NCT03492047|DIETARY_SUPPLEMENT|high dose N-acetylcysteine|N-acetylcysteine 1200mg twice daily
215048311|NCT03492047|DRUG|Paclitaxel|Paclitaxel 80mg /m2 IV
215048312|NCT06439121|PROCEDURE|4-7-8 Breathing Technique|Patients will be instructed to practice the 4-7-8 breathing technique once per hour (4 breaths) post-surgery. Pain and nausea-vomiting will be monitored at 0, 2, 6, 12, and 24 hours during their 24-hour hospital stay.
215048313|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
215048314|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
215048315|NCT00477815|BIOLOGICAL|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
215048316|NCT00477815|DRUG|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
215048317|NCT00477815|BIOLOGICAL|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
215048318|NCT00477815|BIOLOGICAL|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
215048319|NCT00477815|RADIATION|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
215048320|NCT00477815|BIOLOGICAL|111In Zevalin|5.0 mCi by IV
215048321|NCT01883700|OTHER|Boiled Pasta|
215048322|NCT01883700|OTHER|Boiled Chickpeas with Oil|
215048323|NCT01883700|OTHER|Instant Mashed Potatoes|
215048324|NCT01883700|OTHER|Instant Mashed Potatoes with Egg Whites|
214293482|NCT02012075|DRUG|Sustained-release Metoprolol Succinate|
214293483|NCT03471130|DRUG|MT-8554 Low dose|Oral, 7 days
214293484|NCT03471130|DRUG|MT-8554 High dose|Oral, 7 days
214293485|NCT03471130|DRUG|Placebo|Oral, 7 days
214477547|NCT06476600|DRUG|Nalbuphine Injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
215048325|NCT02070497|OTHER|case management|case management group will accept the case manager's service; the control group will just accept the routine care
215048326|NCT04177537|DEVICE|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
215048327|NCT02398526|DRUG|Radium-223 dichloride, (Xofigo, BAY88-8223)|Dosage and treatment duration according to the decision of the treating physician
215048328|NCT00194467|DRUG|valganciclovir|900 mg once a day for 8 weeks
215048329|NCT00194467|DRUG|placebo|matching placebo, once a day for 8 weeks
215048330|NCT00775268|PROCEDURE|Biopsy|Biopsy taken
215048331|NCT00775268|DIAGNOSTIC_TEST|fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography|Imaging
215048332|NCT00775268|OTHER|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
215048333|NCT00775268|PROCEDURE|computed tomography|Undergo scans
215048334|NCT00775268|PROCEDURE|fine-needle aspiration|sample collected
214887309|NCT05933954|RADIATION|5GFR2 non ionizing EMW exposure|"A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not. The exposure time is 20 minutes.~After the exposure, the participants will wait one hour and a 7.5-mm biopsy by punch (two pieces: one 5-mm punch + half a 5-mm punch) will be performed under local anesthesia on each arm. The wound will be closed by a simple suture. A second set of samples will be taken 24h after the exposure, using the same procedure.~For each participant, 1 full biopsy per arm and per time-point will be used for single-cell-RNA-sequencing analysis. The selected method uses generic probed sequencing and does not generate patient-specific genomic information."
215048335|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under conscious sedation|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
214477548|NCT04801368|DRUG|Randomization of two local anesthetics.|Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
214477549|NCT06651164|DIAGNOSTIC_TEST|psychosocial risk screening|"* combined tablet-based screening questionnaire for psychosomatic screening and social service screening~* in case of positive psychosomatic or social service screening subsequent psychosomatic and / or social service consultation"
214477550|NCT06855992|DEVICE|Laser|60-minute 635 nm red laser intervention 3 times per week for 8 weeks
214887310|NCT01330303|DRUG|Reference formulation|SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
214887311|NCT01330303|DRUG|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
214887312|NCT01107197|DIETARY_SUPPLEMENT|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
214887313|NCT01107197|DIETARY_SUPPLEMENT|Control formula|Isonitrogenous isocaloric oral formula
214887314|NCT01708551|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
214887315|NCT03726853|DRUG|CKD-497 200mg|CKD-497 200mg
214887316|NCT03726853|DRUG|CKD-497 300mg|CKD-497 300mg
214887317|NCT03726853|DRUG|CKD-497 placebo|Placebo of CKD-497
215048336|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under local anesthesia|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
215048337|NCT03604497|BEHAVIORAL|beacon alerts|alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection
215048338|NCT03604497|BEHAVIORAL|no alerts retention|no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
215048339|NCT02921295|DEVICE|Sidekick Stubbies|
215048340|NCT05937529|OTHER|Cream containing madecassoside and 5 % panthenol|Immediately after daylight PDT, Cicaplast is administrated as post treatment. The patients are instructed to apply the cream twice daily for 14 days.
215048341|NCT05937529|OTHER|Daylight PDT|Daylight PDT performed with 2 hours of artifical indoor light.
215048342|NCT00895362|DRUG|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
215048343|NCT00895362|DRUG|Cetuximab|Loading dose of 200 mg/m\^2 (maintenance 125 mg/m\^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
215048344|NCT05921617|OTHER|No intervention|Routine care
215048345|NCT04106544|PROCEDURE|Investigational Procedures|The investigational assessments will be performed
215048346|NCT00636103|DRUG|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
215048347|NCT00636103|OTHER|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
215048348|NCT06170151|DIAGNOSTIC_TEST|Diagnostic accuracy|evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment in patients with relapsed/refractory multiple myeloma.
215048349|NCT00196677|DRUG|Vitamins, minerals and medical herbs|
215048350|NCT05411107|PROCEDURE|Biospecimen Collection|Undergo collection of sputum sample
215048351|NCT05411107|PROCEDURE|Bronchial Brush Biopsy|Undergo bronchial brush biopsy
215048352|NCT05411107|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
215048353|NCT05411107|DRUG|Iloprost|Given PO
215048354|NCT05411107|DRUG|Placebo Administration|Given PO
215048355|NCT05411107|OTHER|Questionnaire Administration|Ancillary studies
215048356|NCT00848419|DRUG|Epidural administration of bolus|
214887318|NCT03726853|DRUG|Comparator|Comparator
214887319|NCT03726853|DRUG|Comparator placebo|Comparator placebo
214887320|NCT04395066|DIAGNOSTIC_TEST|CD55|CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.
214887321|NCT05349045|DRUG|an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor|This is an observational study
214887322|NCT00054405|BIOLOGICAL|recombinant interleukin-12|Given IV
214887323|NCT00054405|BIOLOGICAL|aldesleukin|Given IV
215048357|NCT03632096|RADIATION|Photobiomodulation|The parameters are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
215048358|NCT03632096|RADIATION|Sham|The sham group will have a simulation of laser application, following the same procedures as the active group, but with the device switched off.
215048359|NCT00968773|DEVICE|Rebound HRD|Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
215048360|NCT00968773|DEVICE|Standard hernia mesh (VitaMesh)|Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
215048361|NCT00286897|DRUG|E2007|
215048362|NCT03420937|DRUG|Sugammadex|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
215048363|NCT03420937|DRUG|Neostigmine, Atropin Biotika|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
215048364|NCT06352697|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
215048365|NCT06352697|DIETARY_SUPPLEMENT|Placebo|Placebo
215048366|NCT01100333|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
215048367|NCT02901691|OTHER|musical rhythmic stimulation|
215048368|NCT01642550|DRUG|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
215048369|NCT01642550|DRUG|Placebo|
215048370|NCT01651286|PROCEDURE|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
215048371|NCT01651286|PROCEDURE|full face mask|using a standard full face mask during the induction of general anesthesia.
215048372|NCT04766320|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes.
215048373|NCT04834908|BIOLOGICAL|Equine COVID-19 Antiserum|Equine COVID-19 antiserum is a polyclonal antibody and it contains Equine COVID-19 immune globulin G.
215048374|NCT04834908|DRUG|Standard of care|Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
215048375|NCT01194245|DRUG|Insulin lispro|
214887324|NCT00997867|PROCEDURE|Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip|Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
214887325|NCT06656780|BEHAVIORAL|SIT|"Participants will undergo 2 day (8 hours each) Stress Inoculation Training . This will be done in 3 steps:~Step 1: focus on education about the human body and brain and shift to hands on skills practice to improve performance in stressful conditions and is designed to improve self-and-situational awareness and the ability to manipulate reactions and responses in the body on purpose to enhance performance~Step 2: focuses on improving mental self-awareness and gaining skills in Mental Agility and Mental Flexibility~Step 3: participants will have specific simulations and real-world opportunities to practice the skills learnt."
214887326|NCT06656780|BEHAVIORAL|DCA-FF|Participants will undergo 8-week Standard Firefighting Training
214887327|NCT00235677|PROCEDURE|Endoscopic gastroplication|
214887328|NCT05475860|DEVICE|implantable cardiac electronic device recipients|implantable cardiac electronic device recipients for any clinical indication
214887329|NCT03548337|BIOLOGICAL|13vPnC|13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
214887330|NCT03834454|DRUG|Bupivacaine|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
214887331|NCT03834454|DRUG|Bupivacaine|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
215048376|NCT01194245|DRUG|recombinant human hyaluronidase PH20|
215048377|NCT01194245|DRUG|Insulin aspart|
215048378|NCT01194245|DRUG|Insulin glulisine|
215048379|NCT01194245|DRUG|Insulin glargine|
215048380|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|"\- Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
215048381|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)|"\- Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
215048382|NCT01018654|BEHAVIORAL|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
215048383|NCT01018654|BEHAVIORAL|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
215048384|NCT03381664|DRUG|AVP-923|capsule
215048385|NCT01094834|DRUG|DWP05195|tablets, oral administration, multiple administration
215048386|NCT03482986|BEHAVIORAL|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
215048387|NCT00269087|DRUG|fluticasone propionate/salmeterol combination DISKUS|
214667992|NCT06970691|DIAGNOSTIC_TEST|panoramic radiograph|Panoramic radiographs for aggressive periodontitis previously diagnosed cases were interpreted by single examiner (NY). The included radiographs had to fulfill the following; 1) sufficient image quality; 2) All teeth with the surrounding alveolar bone had to be clear enough to facilitate alveolar bone tracing; 3) Only pre-operative radiographs were enrolled (before the surgical management of bony defects).
214667993|NCT06970067|BEHAVIORAL|Active Middle School Communities|This intervention will engage multi-sectoral and multi-generational community members and middle school students to co-produce (co-design, co-implementation, and co-evaluation) contextually-responsive intervention strategies to improve access to active transport and leisure, resulting in increased physical activity and decreased risk for chronic disease in middle school communities. This intervention will use community-based participatory methods, with resources provided for changes in the built environment around the school catchment area.
214667994|NCT06969937|DRUG|Ketamine|A single dose of ketamine 0.8 mg ketamine (i.v.) per kilogram bodyweight
214887332|NCT00791895|DRUG|biphasic insulin aspart 30|Treat-to-target dose titration scheme
214887333|NCT02985671|DRUG|orphenadrine, acetaminophen, caffeine and diclofenac sodium|orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
214887334|NCT02985671|DRUG|Diclofenac Sodium 50 MG|Voltaren (diclofenac sodium 50mg) tablet
214887335|NCT02985671|DRUG|Placebo (for experimental drug)|tablet without active substances, manufactured to mimic experimental product tablet
214293486|NCT05862415|OTHER|therapeutic Exercise|"The circular training method was used in the resistance training phase. During the aerobic training phase, a series of movements from moderate intensity to vigorous intensity was performed. The step loading periodization principle was taken into account in both resistance training and aerobic exercises.~The RT lasted approximately 20-25 min per session and included two sets of 8-20 repetitions, with a rest interval of 1-2 min. The RT exercises included: squat, barbell bent-over row, overhead press, plank, lateral pull down, triceps push down, barbell curl, leg extension, leg curl, lunge, barbell bench press, crunches etc.~For the aerobic training: Intensity was established between 50-65% and 80-85% of HRmax for both groups (SAG and ASG). Aerobic training includes walking and running periods and was carried out on a 400 m outdoor track. In periodization, especially 1st-4th."
214293487|NCT03068481|DRUG|KDT-3594|Oral administration
214293488|NCT03068481|DRUG|Placebo|Oral administration
214293489|NCT00002416|DRUG|Emtricitabine|
214887336|NCT02985671|DRUG|Placebo (for Voltaren)|tablet without active substances, manufactured to mimic Voltaren 50mg tablet
214887337|NCT04305353|OTHER|Diary (blank journal) plus PTSD psycho-education|A blank journal where a prospective account of a patient's ICU course (everyday events) can be documented by family members and healthcare providers
214887338|NCT04305353|OTHER|PTSD psycho-education alone|"We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015."
214887339|NCT01061476|DEVICE|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
215048388|NCT01173510|DRUG|Raltegravir plus Truvada|Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
215048389|NCT01173510|DRUG|Atripla|Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
215048390|NCT03971929|DRUG|SHR0532|once daily(QD) for 4weeks
215048391|NCT03971929|DRUG|SHR placebo|once daily(QD) for 4weeks
214293490|NCT00002416|DRUG|Lamivudine|
214293491|NCT00304993|DRUG|fenofibrate|
214293492|NCT00304993|DRUG|niacin|
214293493|NCT00304993|DRUG|rosiglitazone|
214667995|NCT06969937|BEHAVIORAL|Real-time fMRI Neurofeedback Training|Participants will undergo a closed-loop rt-fMRI paradigm over 25 minutes. Participants will be instructed to use strategies to downregulate cue-induced cravings. The Intensity of cues will adjust based on the participants neural activity in response to cues. This dynamic feedback mechanism allows for personalized training aimed at improving the participant's ability to manage cravings.
214887340|NCT01061476|OTHER|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
215048392|NCT03971929|DRUG|Hydrochlorothiazide 25 mg|once daily(QD) for 4weeks
215048393|NCT05069649|DRUG|Ergoferon|Tablet for oral use.
215048394|NCT05069649|DRUG|Placebo|Tablet for oral use.
215048395|NCT00870480|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
215048396|NCT00870480|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
215048397|NCT04555174|DEVICE|Orsiro Mission DES|Percutaneous Coronary Intervention (PCI)
214887341|NCT01061476|OTHER|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
214293494|NCT05655962|OTHER|STARS|STARS is a structured framework for assessment of rehabilitation and sicklisting, applied by primarily the rehabilitation coordinators working at the primary health care centers.
214293495|NCT01129960|DRUG|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
214293496|NCT01129960|DRUG|Placebo|Tablets will be used.
214293497|NCT03259776|OTHER|Qualitative interviews and questionnaire survey|Qualitative interviews and questionnaire survey
214293498|NCT00892762|DRUG|Travoprost APS 40 micrograms/ml eye drop solution|non-BAK (benzalkonium chloride) medication
214293499|NCT00892762|DRUG|Latanoprost 50 micrograms/ml eye drop solution|BAK-preserved medication
214293500|NCT02790203|DRUG|Celecoxib|NSAIDS
214293501|NCT02790203|DRUG|Placebo|Placebo
214293502|NCT02974517|DEVICE|EmbryoScope®|The intervention is EmbryoScope® versus conventional incubators.
214667996|NCT06969937|DRUG|Placebo|Single dose of placebo (0.9% NaCl infusion)
214667997|NCT06969937|BEHAVIORAL|Sham Neurofeedback Training/ Ketamine|Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive 0.8 mg ketamine (i.v.) per kilogram bodyweight. The use of sham-NFT allows for a rigorous assessment of the specific effects of combined rt-fMRI NFT and ketamine by controlling for non-specific factors such as expectancy effects or the therapeutic context.
214887342|NCT01675648|DRUG|Lofexidine|
214887343|NCT01675648|DRUG|Diazepam|
214887344|NCT01675648|DRUG|Placebo for Lofexidine|
214887345|NCT01675648|DRUG|Placebo for Diazepam|
214293503|NCT04450368|DEVICE|Sylvee|The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
214293504|NCT04429139|DRUG|photodynamic therapy|PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
214293505|NCT01895569|DRUG|Metformin|Metformin will be added to therapy for the first threre months.
214293506|NCT01895569|DRUG|Pioglitazone|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin, pioglitazone will be added.
214293507|NCT01895569|DRUG|Sitagliptin|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
214293508|NCT01074112|DEVICE|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
214293509|NCT01074112|DEVICE|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
214293510|NCT01074112|PROCEDURE|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
214293511|NCT01074112|DEVICE|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
214293512|NCT01074112|DEVICE|Cardiac Ultrasound|Ultrasound views of the heart
214887346|NCT02171780|DRUG|BI 1744 CL|
214887347|NCT02171780|DRUG|Placebo|
214887348|NCT04548765|BEHAVIORAL|Letter|Recipients receive a letter promoting CRC screening.
214887349|NCT04548765|BEHAVIORAL|Loss Frame and Fear Appeals|The letter is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
214887350|NCT04548765|BEHAVIORAL|Transparency|The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
214293513|NCT02870296|BEHAVIORAL|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
214293514|NCT00165776|DRUG|BOTULINUM TOXIN TYPE B|
214477551|NCT06855992|DEVICE|Red Light|60-minute red light sham intervention three times per week for 8 weeks
214477552|NCT06820736|DEVICE|Drain|A drain is a small flexible tube that is placed next to where the spine was operated upon.
214477553|NCT06815978|DIAGNOSTIC_TEST|DXA|Dual energy X-ray absorptiometry
214887351|NCT04548765|BEHAVIORAL|Default Effect and Presentation of Alternatives|The pros and cons for screening with FIT kits and colonoscopy are presented. By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer). In this situation, inaction is no longer the default option. Changing the default option increases the chance that the FIT kit is used. In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
214887352|NCT04548765|BEHAVIORAL|Enhanced Fear Appeals and Decoy Effect|Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed. Inaction is presented as a decoy, which has worse outcomes than either of the screening options. Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
214887353|NCT00137176|DRUG|Rebif|Rebif 44mcg TIW
214887354|NCT01562938|DRUG|Placebo|Placebo
214887355|NCT01562938|DRUG|MEDI-557|MEDI-557 low-dose
214887356|NCT01562938|DRUG|MEDI-557|MEDI-557 high-dose
214887357|NCT03479801|PROCEDURE|Thyroid Surgical Methods|Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.
214477554|NCT06815978|DIAGNOSTIC_TEST|ultrasonography|ultrasonography
214477555|NCT06815978|DIAGNOSTIC_TEST|indirect calorimetry|indirect calorimetry
214887358|NCT01911273|DRUG|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
214887359|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
214887360|NCT01911273|OTHER|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
214887361|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
214887362|NCT06387134|DRUG|Lifei Xiaoji Wan|The Lifei Xiaoji Wan consists of ginseng, blackhead,rhubarb, aster, forehu, and thin on.
214887363|NCT06387134|DRUG|Conventional treatment with Western medicine|"Recommended treatment protocols for patients with Stage Ia NSCLC in the Chinese Society of Oncology Branch of Lung Cancer Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2021 edition) and the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Diagnosis and Treatment Guidelines 2021."
214887364|NCT00125515|DRUG|Memantine|One arm receives 30 mg bid and the other arm receives receives 15mg bid
214887365|NCT00125515|DRUG|Naltrexone|Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
214887366|NCT01378247|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
214887367|NCT02571192|DRUG|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
214887368|NCT02571192|RADIATION|5.95 μCi RAD|
214887369|NCT01941082|DRUG|RO6867461|Single or multiple ascending dose by intravitreal injection
214887370|NCT03654820|DEVICE|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
214887371|NCT03654820|DEVICE|SDF solution|Annual application of 38% SDF solution
214887372|NCT02304393|DRUG|Atezolizumab|Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
214887373|NCT02304393|DRUG|Selicrelumab|Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
214887374|NCT03399071|DRUG|FLOT-A|This is a single-arm study with all patients receiving combination FLOT-A
214887375|NCT03278691|DRUG|Saline|1 ml saline IV Q6H
214887376|NCT03278691|DRUG|Ketorolac|15 mg (15 mg/ml) IV Q6H
214887377|NCT04304040|DRUG|Orelabrutinib|BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
214887378|NCT04304040|DRUG|Recombinant humanized monoclonal antibody MIL62 injection|Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
214887379|NCT02930967|BIOLOGICAL|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
214887380|NCT04928716|OTHER|voiding phase evaluation|Assessment of voiding phase in multiple sclerosis patients
214887381|NCT03697863|PROCEDURE|Noninvasive Respiratory Support|Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
214887382|NCT05102812|BEHAVIORAL|Breakfast Group Intervention|An actionable toolkit encompassing an assessment, a personalised care plan and a range of outcome measures.
215048398|NCT05262413|DRUG|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
214477556|NCT06815978|DIAGNOSTIC_TEST|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
214887383|NCT04407208|BIOLOGICAL|Convalescent plasma|The minimum titer of specific antibody is 1/80
214887384|NCT05323279|DEVICE|artificial intelligence assistance system|The artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed and feedback the overspeed percentage.
214887385|NCT03651830|DEVICE|Prosthetic Foot Emulator|Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
214887386|NCT03651830|DEVICE|Commercially available prosthetic feet|"Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet."
214887387|NCT06049979|OTHER|Acute gastrointestinal injury|AGIUS score\>2
214887388|NCT06398275|DRUG|Remimazolam 20 MG Injection [Byfavo]|Remimazolam 0.1 mg/kg intravenous injection
214887389|NCT06398275|DRUG|NaCl 0.9%|NaCl 0.9% 0.04 mL/kg
214887390|NCT04421300|BEHAVIORAL|smile exercise|"Launch the smile face recognition APP on smart phone, after user guidance and pretest, a smile exercise will display on the phone, while facing the front camera on the phone, participant will do an exercise emphasizing facial movements, as exaggerated as possible. The exercise last for 8 weeks and 4 times a day"
214887391|NCT04421300|DRUG|0.1% sodium hyaluronate eye drop|0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.
214887392|NCT05629897|OTHER|Sessions of cognitive stimulation|40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
214887393|NCT00001028|DRUG|Pentamidine isethionate|
214887394|NCT00001028|DRUG|Dapsone|
214887395|NCT02167854|DRUG|BYL719|
214887396|NCT02167854|DRUG|LJM716|
214887397|NCT02167854|DRUG|TRASTUZUMAB|
214887398|NCT05567276|BEHAVIORAL|Non-Violent Resistance parental training|Non-Violent Resistance parental training
215048399|NCT02603276|DIETARY_SUPPLEMENT|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
214887399|NCT06633952|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
214477557|NCT06815978|DIAGNOSTIC_TEST|bioimpedentiometry|bioimpedentiometry
214887400|NCT06633952|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
215048400|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
215048401|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
215048402|NCT04749147|OTHER|Black and White Printed Survey|This survey will feature black and white text and graphics.
214887401|NCT06633952|DEVICE|noninvasive neurostimulation device|A noninvasive neurostimulation device will be used to deliver theta frequency stimulation or sham stimulation to the frontal part of the brain.
214887402|NCT06633952|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
214887403|NCT01855828|DRUG|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
214887404|NCT01855828|DRUG|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
214887405|NCT01855828|DRUG|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
214887406|NCT01855828|DRUG|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
214887407|NCT01855828|DRUG|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
214887408|NCT01855828|DRUG|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
215048403|NCT04749147|OTHER|Red Printed Survey|This survey will feature red text and graphics.
215048404|NCT01728285|DEVICE|Electronic compliance device (Memozax®)|An electronic compliance device is distributed to patients allocated to the active arm
215048405|NCT05207111|DRUG|Revefenacin Inhalation Solution|Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.
215048406|NCT06450015|DEVICE|Vacuum Assisted Closure|VAC applied after debridement and saline packing
215048407|NCT06450015|OTHER|Saline Dressing|Wound was managed by saline dressing
215048408|NCT01886235|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
215048409|NCT01886235|DRUG|Fluorescein Sodium Injection|Given IV
215048410|NCT01886235|OTHER|Laboratory Biomarker Analysis|Correlative studies
214293515|NCT00492583|DRUG|Bifidobacterium lactis (BB-12)|The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
214293516|NCT00492583|DRUG|Placebo|The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
214293517|NCT00442078|DEVICE|I-STOP TOMS male sling|Bulbus urethral compression with polypropylene mesh
214293518|NCT00767637|DRUG|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
214293519|NCT01681225|OTHER|Esophageal-pressure guided mechanical ventilation|
214293520|NCT01681225|OTHER|High PEEP mechanical ventilation|
214293521|NCT06431490|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
214293522|NCT03330769|DRUG|New course of treatment|Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
214293523|NCT00479076|DRUG|aflibercept (AVE0005)|intravenous infusion
214293524|NCT00479076|DRUG|S-1|oral administration
215048411|NCT01886235|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
215048412|NCT01460069|DRUG|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
215048413|NCT01460069|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
215048414|NCT02780934|OTHER|Pressure Dressing|Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
215048415|NCT02780934|OTHER|Simple Adhesive Dressing|Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
215048416|NCT02051478|OTHER|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
215048417|NCT02051478|OTHER|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
215048418|NCT01662739|BEHAVIORAL|Questionnaire|
214293525|NCT05677724|DIAGNOSTIC_TEST|HBV DNA Sequencing|"Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed."
214293526|NCT00349804|OTHER|cool dry air|cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
214477558|NCT06857318|BIOLOGICAL|Colostrum Nasal Spray|24 hours use of nasal spray of colostrum from MERS-CoV positive camels- 6 doses total
214477559|NCT06857318|OTHER|Water for injection|24 hours use of a nasal spray of water for injection- 6 doses total
215048419|NCT01813695|PROCEDURE|Preemptive genotyping in medical record|
215048420|NCT01813695|PROCEDURE|Genotyping not included in electronic medical record|
214293527|NCT02622321|DRUG|Emicizumab|Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
214887409|NCT03649347|BEHAVIORAL|Augmented reality exposure therapy|Exposure therapy via utilization of augmented reality. Virtual objects will be placed on the patient's real environment for exposure therapy.
214293528|NCT02622321|DRUG|rFVIIa|Participants will continue to receive rFVIIa.
214293529|NCT02622321|DRUG|aPCC|Participants will continue to receive aPCC.
214293530|NCT04464369|DRUG|itopride|itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide
214293531|NCT04464369|DRUG|Placebo|placebo pills matching the look and weight of the itopride tablets
214293532|NCT05070299|BEHAVIORAL|Psychosexual Educational Partner Program (PEPP)|A communication and intimacy promotion kit consisting of three modules devoted to information sharing, partner communication and activities for building intimacy.
214293533|NCT00886899|DEVICE|Recanalization of a coronary chronic total occlusion|Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
214293534|NCT02835404|DRUG|Nedaplatin|Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
214293535|NCT02835404|RADIATION|Pelvic External Radiotherapy|patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
214293536|NCT02835404|RADIATION|252-Cf Neutron Intracavitary Brachytherapy|total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
214293537|NCT00965718|BIOLOGICAL|Activated T lymphocyte|Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.
214293538|NCT02148198|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
214293539|NCT02148198|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
214887410|NCT04215276|OTHER|Valsalva maneuver|pressure during Valsalva maneuver was measure using sphygmomanometer
214887411|NCT04215276|OTHER|Control|patient was not given any intervention
214887412|NCT03629080|BIOLOGICAL|HB-101 vaccine|HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
214887413|NCT03629080|BIOLOGICAL|placebo|Saline will be used for placebo.
214887414|NCT01948531|DRUG|Gynomunal® gel|A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
214293540|NCT00138203|DRUG|vorinostat|Given PO
214293541|NCT00138203|OTHER|laboratory biomarker analysis|Correlative studies
214477560|NCT06855888|PROCEDURE|Modified Blumgart suture method|During pancreaticoduodenectomy, the modified Blumgart suture method is used for pancreaticojejunostomy. For anastomosis, 5-0PDS is used for pancreatic duct mucosal anastomosis, and 3-0 or 4-0 monofilament non-absorbable suture is used for pancreaticojejunal mattress anastomosis.
214477561|NCT06855888|PROCEDURE|Three-sided mattress suture|At the time of pancreaticoduodenectomy, the three-sided mattress suture is used as the pancreaticojejunostomy method. In addition to the conventional Blumgart modified suture, the three-sided mattress suture method adds a mattress anastomosis with 3-0 or 4-0 monofilament non-absorbable suture to the cranial and caudal sides of the pancreaticojejunostomy site.
214887415|NCT00224289|DRUG|Latanoprost 0.005%|Latanoprost 0.005% ophthalmic solution QHS 8 weeks
214887416|NCT01505582|OTHER|Inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
214667998|NCT06970054|DEVICE|OPEP|-Patients are provided with a networked handheld respiratory training device. -Patients are provided with a wearable device for monitoring data. -Patients receive an OPEP training plan and instructions on using the respiratory training device. -Training on the OPEP device is conducted: -Inpatients: Twice daily training during hospitalization. -Outpatients: At least 3 training sessions in the clinic after enrollment. -Treatment compliance is monitored remotely via the IoT system for 8 weeks. -Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).
214887417|NCT01505582|OTHER|Sham inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
214887418|NCT05389631|OTHER|no intervention|no intervention
214887419|NCT04639492|DIETARY_SUPPLEMENT|MBS oral solution|Oral BIDAC, twice a day before breakfast and dinner times
214887420|NCT02002286|DRUG|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
214887421|NCT02002286|DRUG|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
214887422|NCT00764686|OTHER|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
214293542|NCT00241280|DEVICE|etafilcon A|
214293543|NCT00241280|DEVICE|galyfilcon A|
214887423|NCT00764686|OTHER|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
214887424|NCT02517463|DRUG|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
214887425|NCT05410886|OTHER|Questionnaire|A questionnaire including up to 20 questions will be distributed to study participants. This questionnaire will be used to identify women with FHA.
214887426|NCT04920500|DRUG|Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. d1,3,5 Induction 2: \[100 U/m²\] i.v. d1,3
214887427|NCT04920500|DRUG|Vyxeos、Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. Vyxeos（d1）,Daunorubicin Cytarabine liposome for injection（d3、d5） Induction 2: \[100 U/m²\] i.v. Daunorubicin Cytarabine liposome for injection（d1、d3 ）
214293544|NCT01092611|PROCEDURE|Blood collection|Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
214293545|NCT01092611|BIOLOGICAL|GSK HIV vaccine 732462|No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
214293546|NCT05712616|DRUG|Strontium Ranelate|Dual mode of action, anabolic and anti-resorptive
214293547|NCT05712616|DRUG|Lacto-N-Hexaose|Placebo look alike drug
214293548|NCT02820272|PROCEDURE|NPWT with cold water|Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
214293549|NCT02820272|PROCEDURE|NPWT with normal saline room temp|Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change
214293550|NCT02820272|PROCEDURE|NPWT without other intervention|Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
214477562|NCT06816238|OTHER|Interactive education|interactive education based on a medical knowledge model, utilizing intelligent medical agents and interactive Q\&A
214477563|NCT06816238|OTHER|Traditional health education|traditional health education methods without the use of the interactive medical model and intelligent Q\&A system
214293551|NCT06121687|PROCEDURE|Shaeer-I|Ligation of the internal pudendal vein under the Gluteus Maximus muscle as it courses above the scar-spinous ligament.
214293552|NCT06121687|PROCEDURE|PPI|Penile prosthesis implantation (PPI) will be performed
214293553|NCT02385552|BEHAVIORAL|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
214293554|NCT03498300|BIOLOGICAL|Tdap vaccine|A single dose of Tdap vaccine at GA 27 - 36 weeks
214293555|NCT01414855|DRUG|obinutuzumab|1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
214293556|NCT01414855|DRUG|cyclophosphamide|750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
214293557|NCT01414855|DRUG|doxorubicin|50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
214293558|NCT01414855|DRUG|prednisone|100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
214293559|NCT01414855|DRUG|vincristine|1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.
214293560|NCT03012256|OTHER|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
214293561|NCT03669172|BIOLOGICAL|Donor IL-15 stimulated NK cells infusion|DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT
214293562|NCT03544502|DEVICE|CD player|CD player opened during anesthesia induction and continued until postoperative 15 minute
214293563|NCT03544502|DEVICE|CEL-480 Sound Level Meter Sonometre|Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.
214293564|NCT03544502|DEVICE|Earplug|the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.
214293565|NCT03544502|PROCEDURE|Ambient operating room noise|patients were exposed to the ambient operating room noise.
214293566|NCT04740502|PROCEDURE|Parahtyroidectomy|Parathyroidectomy
214293567|NCT06089928|PROCEDURE|vertical augmentation|sandwich osteotomy with an Interpositional inlay graft
214293568|NCT00368355|DRUG|Ara-C|"day-8 through day-5~3 g/m2 q 12 hours"
214887428|NCT04752059|DRUG|Trastuzumab deruxtecan|Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death
214887429|NCT05758233|PROCEDURE|Patients undergoing transversalis fascia plane block|The investigators applied a transversalis fascia plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
214887430|NCT05758233|PROCEDURE|Patients undergoing transversus abdominis plane block|The investigators applied a transversus abdominis plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
215048421|NCT02378285|DEVICE|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
214293569|NCT00368355|DRUG|Cyclophosphamide|"day-7 and day-6~45 mg/kg"
214293570|NCT00368355|BIOLOGICAL|Campath-1H|"day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~\>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS"
214293571|NCT00368355|RADIATION|Total Body Irradiation|"day-4 through day-1~175 cGy x 2 at 24 cGy/min"
214293572|NCT00368355|PROCEDURE|Stem Cell Infusion|Stem cells are infused on day 0
214293573|NCT03218007|BIOLOGICAL|blood samples|to evaluate expression and functionnaly activity of A2AR
214293574|NCT03579160|DRUG|0.25% timolol gel with full-thickness skin grafts|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied.
214293575|NCT03579160|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied.
214293576|NCT02317068|DEVICE|HBR|
214293577|NCT02317068|DEVICE|DD|
214293578|NCT04342364|OTHER|Vitrification via slush nitrogen|oocytes will be vitrified using slush nitrogen
214293579|NCT04342364|OTHER|Vitrification via liquid nitrogen|oocytes will be vitrified using liquid nitrogen which is currently routine practice
214667999|NCT06970054|BEHAVIORAL|Aerobic Exercise|-Patients are provided with a wearable device for monitoring data. -Patients receive an aerobic exercise training plan and instructions on using the device. -Exercise training is conducted: -Inpatients: Daily aerobic exercise during hospitalization. -Outpatients: At least 3 training sessions in the clinic after enrollment. -Treatment compliance is monitored remotely via the IoT system for 8 weeks. -Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).
214887431|NCT01241747|BEHAVIORAL|Walking Exercise|3 times per week for 3 months
214887432|NCT01241747|BEHAVIORAL|Control|Resistance training 3 times per week for 3 months
214887433|NCT04492657|OTHER|no intervention|Natural exposure of iodine.
215048422|NCT02378285|OTHER|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
215048423|NCT00041470|DRUG|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
214293580|NCT00774644|DRUG|Clarithromycin 500mg|
214293581|NCT01488682|PROCEDURE|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
214293582|NCT01488682|PROCEDURE|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
214887434|NCT03349086|BEHAVIORAL|Voice Exercise|Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
214668000|NCT06971822|DIETARY_SUPPLEMENT|Protein Supplementation|We are assessing the supplementation of a controlled diet with beta-lactoglobulin protein compared to regular isonitrogenous whey protein. We will make these comparisons over both the 24 hour rested and 24 hour post-exercise states. Beta-lactoglobulin has a higher leucine content than traditional whey protein, with this leucine amino acid thought to have a critical role as an anabolic stimulus to initiate muscle protein synthesis.
214668001|NCT03115190|DIAGNOSTIC_TEST|General Practitioner diagnosis with Heart score|All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
214887435|NCT02735785|BEHAVIORAL|Harnessing Online Peer Education (HOPE) Social Media Intervention|
214887436|NCT04419012|OTHER|observation|observation
214887437|NCT02318212|DEVICE|Dilapan-S|Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion
214887438|NCT04493567|DRUG|BMS-986036|Specified dose on specified days
214887439|NCT01453179|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
214887440|NCT01453179|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
214887441|NCT06176651|DRUG|Miebo|Subjects will be instructed to use the Miebo eye drop four times per day in both eyes during their participation in clinical trial. The subjects will be required to remove their contact lenses prior to instillation of the Miebo eye drop and must wait 30 minutes before reinserting their contact lenses.
214887442|NCT02448368|DRUG|RDEA3170,10 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
214887443|NCT02448368|DRUG|RDEA3170, 2.5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
214887444|NCT02448368|DRUG|RDEA3170, 5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
214887445|NCT02448368|DRUG|RDEA3170, 10 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
214887446|NCT02448368|DRUG|RDEA3170, 2.5 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
214887447|NCT04201626|PROCEDURE|Adapted ERAS|"Each woman in the intervention group will attend a preoperative counseling session with nurse and doctors. In addition to the standard preoperative counseling, explaining the purpose, process, and the importance of ERAS protocol compliance will be added to the session. Preoperative nutrition and laboratory assessment will be done according to adapted ERAS protocol on that same visit.~During admission, the intervention group participants are provided with care according to adapted ERAS protocol including no bowel preparation, no extended fasting before surgery, balanced intravenous crystalloid, thromboprophylaxis, multimodal pain control reducing opioid usage, multimodal anti-emetics medications, stepping diet up to regular diet within 24 hours, chewing gum for post-operative ileus prevention, early removal of Foley's catheter, and promote early ambulation using care checklist plan."
214668002|NCT03796403|OTHER|Diclofenac|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
214668003|NCT00420914|PROCEDURE|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
214668004|NCT02732158|OTHER|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
214887448|NCT05332873|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
214887449|NCT03146429|DIAGNOSTIC_TEST|I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter
214887450|NCT00002231|BIOLOGICAL|APL 400-003|
214887451|NCT04871256|PROCEDURE|Septorhinoplasty|This intervention will be performed by the same surgeon, after signing of patient inform consent.
214887452|NCT04619212|DEVICE|breast pumping as per SoC but on new software for the pump|breast pumping as per SoC but on new software for the pump
214887453|NCT00727597|DRUG|Efavirenz 600mg|"QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
214887454|NCT00727597|DRUG|Boosted Lexiva|"Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
214887455|NCT00001797|DRUG|Recombinant human interleukin-10|
215048424|NCT00041470|DRUG|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
214887456|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
214293583|NCT00194064|DRUG|Olanzapine|
214293584|NCT04867538|OTHER|no intervention|No intervention
214293585|NCT02931968|DEVICE|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
214293586|NCT05466526|PROCEDURE|High frequency deep sclerotomy (HFDS)|The surgery was performed using the abee® glaucoma tip of Oertli phacoemulsiﬁcation machine (Cata-rhex3, Switzerland) and goniolens. During the procedures, nasal six pockets penetrating 1mm deep from the trabecular meshwork to Schlemm's canal will be formed to promote the aqueous humor outflow.
214293587|NCT00860964|DRUG|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
214293588|NCT00860964|DRUG|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
214293589|NCT01596608|DEVICE|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
214293590|NCT05810142|DRUG|furquimatinib and sintilimab|furquimatinib and sintilimab
214293591|NCT04899921|DRUG|Ipilimumab|Intravenous injection
214293592|NCT04899921|DRUG|Nivolumab|Intravenously (IV) into the vein
214293593|NCT04899921|DRUG|Troriluzole|Taken orally
214293594|NCT04899921|DRUG|Placebo|Taken orally
214293595|NCT03907553|DIAGNOSTIC_TEST|targeted genome sequencing|
214293596|NCT06323278|BEHAVIORAL|Cognitive training|The training, provided by normal clinical practice, will consist of two cycles of cognitive stimulation (8 sessions each) structured and aimed at maintaining and learning compensatory strategies that take advantage of the integrated cognitive skills.
214293597|NCT02856230|DEVICE|Ranger SL DEB|BTK angioplasty using Ranger SL DEB
214293598|NCT01885143|RADIATION|Digital Breast Tomosynthesis|
214293599|NCT05678894|OTHER|Scanner and EOS imaging|Cross-sectional imaging and 3D reconstruction to measure and compare acetabular anteversion in 4 functional pelvic positions.
214293600|NCT02563275|OTHER|motion analysis system|
214668005|NCT05508152|DRUG|Wound irrigation with amoxicillin-clavulanate in saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes."
214887457|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
214887458|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
214887459|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
214887460|NCT02754843|DEVICE|Phonak's equivalent newly developped power BTE|
214293601|NCT02563275|OTHER|parabolic flight|
214293602|NCT01403714|PROCEDURE|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
214293603|NCT00967525|PROCEDURE|cord blood infusion|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
214293604|NCT02388945|OTHER|APD|PDGO APD machines used in the PD patients for 8 weeks
214293605|NCT02388945|OTHER|CAPD|CAPD used in the PD Patients for 8 weeks
214293606|NCT02999854|BIOLOGICAL|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
214293607|NCT02999854|DRUG|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
214293608|NCT02999854|PROCEDURE|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
214293609|NCT02999854|PROCEDURE|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
214887461|NCT02754843|DEVICE|Equivalent competitor device|
214887462|NCT03189992|DRUG|Bushen-Jianpi Dedoction|A traditional chinese medicine prescription
214887463|NCT03189992|DRUG|cinobufotalin injection|an effective Chinese preparation to treat malignant tumor.
214887464|NCT02890355|DRUG|Fluorouracil|Given IV
214887465|NCT02890355|DRUG|Fluorouracil|Given IV bolus
214887466|NCT02890355|DRUG|Irinotecan Hydrochloride|Given IV
214887467|NCT02890355|OTHER|Laboratory Biomarker Analysis|Correlative studies
214887468|NCT02890355|DRUG|Leucovorin Calcium|Given IV
214887469|NCT02890355|DRUG|Veliparib|Given PO
214293610|NCT02136524|DRUG|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
214293611|NCT02136524|DRUG|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
214293612|NCT05470426|OTHER|COVID-19 Omicron Recurrence|COVID-19 Omicron Recurrence
214668006|NCT05508152|DRUG|Wound irrigation with a saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes."
214668007|NCT00667277|DRUG|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
214293613|NCT05945914|PROCEDURE|Oncoplastic Entirely Robot-Assisted Approach (OPERA)|Robotic-assisted surgery in both mastectomy and free DIEP flap harvest, so-called Oncoplastic Entirely Robot-Assisted Approach (OPERA).
214293614|NCT04065906|BEHAVIORAL|NIRS neurofeedback|Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
214293615|NCT04065906|DRUG|Methylphenidate or Tomoxetine|Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
214293616|NCT02045134|DIETARY_SUPPLEMENT|Placebo|Soluble corn flour not rich in anthocyanins
214293617|NCT02045134|DIETARY_SUPPLEMENT|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
214293618|NCT03393741|DRUG|Taxane|Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
214668008|NCT05116969|DRUG|PTX-35|PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
214668009|NCT05329792|DRUG|L19IL2/L19TNF|Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks
214887470|NCT06138873|PROCEDURE|Ablation-index guided ventricular tachycardia ablation|As described in arms descriptions
214293619|NCT03393741|DRUG|Vinorelbine|Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
214293620|NCT03393741|DRUG|Ixabepilone|Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
214293621|NCT03393741|DRUG|Eribulin|Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
214293622|NCT03393741|DRUG|Chemotherapy|Chemotherapy is used to treat various stages of breast cancer.
214293623|NCT05070533|BEHAVIORAL|Individual treatment|Participants will receive 7 home visits to implement the program.
214293624|NCT05070533|BEHAVIORAL|Groupal treatment|Subjects will participate in groups of about 8 - 12 to implement the program.
214293625|NCT02724306|BEHAVIORAL|Active Lifestyle Programme|
214293626|NCT01013701|DRUG|fluticasone furoate|nasal steroid spray
214293627|NCT01013701|OTHER|placebo|nasal steroid vehicle without drug
214293628|NCT04140851|DIETARY_SUPPLEMENT|Dietary fiber intervention|Dietary intervention
214293629|NCT04140851|DIETARY_SUPPLEMENT|Normal diet|Normal diet
214293630|NCT03459248|OTHER|Dual therapy|combination of 10 mg metoclopramide with 4 mg ondansetron
214293631|NCT03459248|OTHER|Monotherapy|10 mg metoclopramide
214293632|NCT03459248|OTHER|General anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation.
214293633|NCT00850668|BIOLOGICAL|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
214887471|NCT06138873|PROCEDURE|Ventricular tachycardia ablation with no AI-guidance|As described in arms descriptions
214887472|NCT05707377|DRUG|Zanubrutinib|Zanubrutinib capsules administered orally.
214887473|NCT05707377|DRUG|Tacrolimus|Tacrolimus capsules administered orally.
215048425|NCT00041470|DRUG|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
215048426|NCT00041470|DRUG|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
214293634|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate|Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
214293635|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate protein|Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
214293636|NCT01949350|DIETARY_SUPPLEMENT|Starved|Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
214293637|NCT01386554|DRUG|Repository Corticotropin Injection|Acthar given SC for 6 months
214293638|NCT01386554|DRUG|Placebo|"Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week)."
214293639|NCT04020198|OTHER|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
214293640|NCT01157936|DRUG|Allopurinol|daily dosage
214293641|NCT01157936|OTHER|placebo|daily dosage
215048427|NCT06431191|PROCEDURE|lateral raw|lateral raw repair for full tear rotator cuff combined microfracture procedure, without medial raw
214887474|NCT06560359|DIETARY_SUPPLEMENT|F&V|The intervention includes the healthy breakfast plan (daily delivery of balanced breakfast containing at least one piece of fruits, vegetables and other regular diet). Meals were centrally prepared by a professional catering service and delivered every morning, seven days a week, to participants' homes, ensuring consistency in portion size and quality. The selection of fruits and vegetables will consider seasonal availability to ensure freshness and variety. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
214293642|NCT05615779|OTHER|Placebo Comparator: Randomized pectin diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin
214668010|NCT06674356|BEHAVIORAL|chin tuck against resistance exercise|"Both groups of patients will receive traditional swallowing rehabilitation therapy; however, the experimental group will additionally perform CTAR exercises. The procedure is as follows:Ask the patient to sit, then, press the chin firmly against the inflatable rubber ball, for isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. And for isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions. Performing both isometric and isotonic exercises constitutes one set of exercises.~For isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. For isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions."
214668011|NCT01476787|DRUG|Rituximab|375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
214668012|NCT01476787|DRUG|Lenalidomide|20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
214887475|NCT06560359|DIETARY_SUPPLEMENT|No F&V|The intervention only includes breakfast plan (daily delivery of balanced breakfast containing regular diet without fruits and vegetables) for 12 weeks. Meals were centrally prepared by a professional catering service and delivered every morning, seven days a week, to participants' homes, ensuring consistency in portion size and quality. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
214887476|NCT07076277|DEVICE|Clareon PanOptix Pro and Clareon Vivity Intraocular Lens|Bilateral cataract surgery with contralateral implantation: Alcon Clareon PanOptix Pro (or PanOptix Pro Toric) intraocular lens in one eye and Alcon Clareon Vivity (or Vivity Toric) intraocular lens i
214887477|NCT07076277|DEVICE|Clareon PanOptix Pro Intraocular Lenses|Bilateral cataract surgery with implantation of Alcon Clareon PanOptix Pro (or PanOptix Pro Toric) intraocular lenses in both eyes. All surgeries target emmetropia with residual astigmatism ≤0.50 diopters using toric IOLs or arcuate incisions as needed.
214887478|NCT01128179|DRUG|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
214887479|NCT01128179|DRUG|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
214887480|NCT06551883|PROCEDURE|different bowel preparation regime|Patients in Group B receive the 3L of PEG in a single dose
214887481|NCT06551883|PROCEDURE|traditional bowel preparation regime|Patients in Group A receive the 3L of PEG in a split dose
214887482|NCT00413881|PROCEDURE|WAVEFRONT- GUIDED LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
214887483|NCT00413881|PROCEDURE|CONVENTIONAL LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
214887484|NCT05755347|OTHER|General health survey questionnaires|Patient-reported outcome survey will be offered at baseline.
214887485|NCT05755347|OTHER|PROMIS Cancer Function Brief 3D profile questionnaires|Patient-reported outcome survey will be offered at baseline.
214887486|NCT05755347|OTHER|FACT-G questionnaires|Patient-reported outcome survey will be offered at baseline.
214887487|NCT05755347|OTHER|Godin Leisure-Time Exercise Questionnaire|Patient-reported outcome survey will be offered at baseline.
214887488|NCT05755347|OTHER|REAP-S questionnaires|Patient-reported outcome survey will be offered at baseline.
214887489|NCT05440201|OTHER|Amount of anticoagulant Clexane|Change (increase/decrease) the amount of Clexane administered at the dialysis start.
214668013|NCT01476787|DRUG|Rituximab-CHOP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
214668014|NCT01476787|DRUG|Rituximab-CVP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
214668015|NCT01476787|DRUG|Rituximab-Bendamustine|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
214887490|NCT00720382|DRUG|0.15% azelastine hydrochloride|1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
214887491|NCT00720382|DRUG|Mometasone furoate|200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
214887492|NCT01443897|DIETARY_SUPPLEMENT|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
214887493|NCT01443897|DIETARY_SUPPLEMENT|placebo capsule|0 IU vitamin D2
214887494|NCT01443897|OTHER|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
214887495|NCT01443897|OTHER|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
214668016|NCT04004052|OTHER|Ultrasound guided injection|
214668017|NCT04004052|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|
214668018|NCT04004052|OTHER|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
214887496|NCT01443897|OTHER|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
214887497|NCT04526847|BEHAVIORAL|Intermittent energy restriction (IER) : 5:2 diet pattern|Participants in the IER group will be provided menus on fasting day that provide \~25% of the individual energy requirement (400 kcal/day for females and 600 kcal/day for males) that means \~75% energy restriction per week (Sundfør et al., 2018; Svendsen, 2018; Templeman, Gonzalez, Thompson, \& Betts, 2020). The recommended fasting day may be on two non-consecutive days (Mondays and Thursdays) per week and remaining five days of the week will be based on the usual diet plan. All participants will be instructed to complete all food by 12 pm and then fast until 8 am the following day (Svendsen, 2018).Thus, the weekly average calorie intake will correspond to \~75% of the normal energy requirements. They will receive a diet plan that recommended \~50 gm protein/day from chicken breast, lean meat, lean fish, fat-free yogurt, cottage cheese, egg or legumes, and vegetables to increase satiety on fasting days.
214887498|NCT04526847|BEHAVIORAL|Continuous energy restricted (CER) group|Participants in the CER group will be advised to reduce total energy intake to 1200-1550 kcal in all seven days a week. They will be provided diet plan calculated in relation to each person's estimated energy requirements. Menus will be divided into breakfast, lunch, dinner, and snacks in line with their individualized energy recommendations. They will be requested to consume \~75% of the individual energy requirements daily (25% energy restriction of calculated baseline energy requirements daily) over six months. Thus, the overall energy restriction will similar between the groups at an estimated reduction of 25% of requirements. Participants will be randomized in a 1:1 ratio, and assigned to an intermittent or continuous energy restriction group randomly.
214887499|NCT03493256|OTHER|exposure to type 2 neurological complications|exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
215048428|NCT06431191|PROCEDURE|double raw|double raw repair for full tear rotator cuff combined microfracture procedure
215048429|NCT03044275|OTHER|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
214293643|NCT05615779|OTHER|Randomized B-fructan diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan
214293644|NCT05615779|OTHER|Personalized pectin diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline
214293645|NCT05615779|OTHER|Personalized B-fructan diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline
215048430|NCT03044275|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
215048431|NCT00044369|PROCEDURE|Varicocele repair|
215048432|NCT04963816|PROCEDURE|ultrasound guided quadratus lumborum block|Ultrasound guided quadratus lumborum block will be done to all groups using curved array transducer 5\_2 MHz with the patient in supine position and the block will be done by anterior approach
215048433|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given intravenously in group A
215048434|NCT04963816|DRUG|Bupivacaine Injection|Bupivacaine will be given to all groups locally with QLB
214293646|NCT01848587|OTHER|acupuncture|
214293647|NCT01848587|OTHER|usual care|
215048435|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution locally|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given locally in Group B
215048436|NCT06462313|DRUG|Dobutamine|Patients with septic shock in Dobutamine group will be initiated on Dobutamine at 5 mcg/kg/min when electrocardiogram, invasive blood pressure, and oxygen saturation were monitored.
215048437|NCT06462313|DRUG|Norepinephrine|Norepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more in both groups.
215048438|NCT03573245|DRUG|Tranexamic Acid|Tranexamic acid effect on perioperative bleeding in orthopedic surgery
214293648|NCT05780333|PROCEDURE|TAP block|Bilateral tap block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
214293649|NCT05780333|PROCEDURE|ESP block|Bilateral esp block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
214293650|NCT00001596|DRUG|Pirfenidone|Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
214293651|NCT00001596|DRUG|Placebo|Placebo (3 pills), three times daily.
214293652|NCT06288464|DIETARY_SUPPLEMENT|Soluble Fibre|Patients will be assigned to stoma feeding by the Colorectal Surgeon, which will be managed by the stoma nurses for the duration, approximately 4 weeks, of feeding. For the final 7-14 days (minimum 7 days) of feeding, 10g of soluble fibre will be added to 100ml of Ensure™ (or equivalent liquid nutrient feed) before instillation into the stoma on a daily basis. The soluble fibre will be provided in 10g portions and should be added to the newly-opened bottle of ensure and shaken to mix well.
214293653|NCT03867981|BEHAVIORAL|Internet-based weight loss program|12-month, Internet-based weight loss/maintenance program.
214887500|NCT02971020|OTHER|Observational/Cognitive Assessment|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
214887501|NCT01298414|GENETIC|RNA analysis|
214887502|NCT01298414|OTHER|laboratory biomarker analysis|
214887503|NCT05004883|BEHAVIORAL|Regulation of Cues Enhanced|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to treat high Food Responsiveness and low Satiety Responsiveness. BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure exercises.
214887504|NCT05004883|BEHAVIORAL|Behavioral Weight Loss|The BWL program includes dietary, physical activity, and behavioral change recommendations. All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories, and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
214293654|NCT03867981|BEHAVIORAL|Brief phone coaching|Some individuals will receive 3 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
214293655|NCT03867981|BEHAVIORAL|Extended phone coaching|Some individuals will receive 12 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
214293656|NCT04372680|DIAGNOSTIC_TEST|CTUS examination|fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
214293657|NCT05302154|BEHAVIORAL|Distraction by dentist|Basic behavior orientation techniques (tell-show-do) is applied by the dentist during the treatment.
214293658|NCT05302154|BEHAVIORAL|Distraction by cartoon movie|Children watch cartoons on a screen mounted dental unit during the treatment.
214293659|NCT05302154|BEHAVIORAL|Distraction by virtual reality glasses|During the treatment visual and auditory stimuli provide information about treatment to the patient with the help of avatars (characters) and environmental elements placed within the VRG application. In a vivid dentist room, the explanatory introduction part takes place while the movies are watched in a fairy world or a futuristic world to separate the user from the actual location and context. The application was designed to function in such a way as not to require outside intervention. From start to finish, the application interacts with the user through gaze selection and head tracking mechanisms. The avatar characters provide information related to the dental treatment in a joyful manner. Gamification elements such as gaining stars and collecting rewards have been used to keep the patient engaged. Motion blur feature ensures the patient to keep head still as sudden movements are dangerous and undesired by the dentist during the treatment.
214293660|NCT01694641|OTHER|time-lapse morphokinetic evaluation|embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
214293661|NCT04279951|OTHER|Resistance exercise|High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
214293662|NCT04279951|DIETARY_SUPPLEMENT|Omega-3|1 gram of omega-3 per day for 20 weeks
214293663|NCT04279951|DIETARY_SUPPLEMENT|Placebo|1 gram of sunflower oleic oil per day for 20 weeks
214293664|NCT00237757|BEHAVIORAL|Information feedback|The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.
214293665|NCT00237757|BEHAVIORAL|Information feedback|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
214293666|NCT00180414|DEVICE|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
214293667|NCT00306761|DEVICE|Dynamic Wheelchair Seating System|
214293668|NCT02936245|OTHER|no specific intervention|We will not assign specific intervention in this research. We will record their baseline characteristics, received treatment, and assess the outcomes to analysis the predictors of outcome and natural history in patients with cervical spondylotic myelopathy.
214887505|NCT05004883|BEHAVIORAL|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
214887506|NCT04460885|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.
214887507|NCT04460885|DRUG|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks
214668019|NCT04626063|DRUG|Magnesium|Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
214293669|NCT02033122|OTHER|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
214293670|NCT02033122|OTHER|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
214293671|NCT02161627|DEVICE|Saluda Medical External Trial System|
214293672|NCT02161627|DEVICE|Saluda Medical External Trial System|
214293673|NCT05072561|DIAGNOSTIC_TEST|Sentinel lymph node scintigraphy|"During the surgery, right after the identification of the primary, 18-37 MBq of 99mTc-Nanocolloids in two ml will be injected at four peritumoral locations. After a brief waiting time (5-10'), the thoracic surgeon will perform the clinical intervention, including the lobectomy (the injection sites will be resected alongside the tumour) and lymphadenectomy, according to the best clinical practice. All the excised lymph nodes will be ex vivo counted using a gamma probe: those with a detectable activity (at least 10% of the hottest lymph node) will be considered as SLN. Thereafter, the mediastinum will be scanned using the gamma probe and a handheld gamma-camera (the latter will not be employed in case of robotic-assisted surgery); any further source of radioactivity will be investigated and, should further lymph nodes be identified, these will be also resected and classified in SLN or non-SLN, based on ex vivo activity."
214293674|NCT02792556|DEVICE|Urine pregnancy test|Urine pregnancy test Check Top after transvaginal ultrasound
214293675|NCT02927080|DRUG|ACE-083|Recombinant fusion protein.
214668020|NCT04626063|DRUG|NSAID|Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
214887508|NCT04559347|DRUG|Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single shot for erector spinae block
214887509|NCT04559347|DRUG|Ropivacaine (0.5% bolus followed by 0.2% infusion)|Continuous catheter infusion for erector spinae plane block
214887510|NCT03340012|DEVICE|GTR + radiation-sterilize allogenic bone graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and radiation-sterilized allogenic bone graft from the Central Tissue Bank in Warsaw
214887511|NCT03340012|DEVICE|GTR + xenogenic graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and xenogenic graft (Bio-Oss®, Geistlich Biomaterials)
214887512|NCT03721523|DIAGNOSTIC_TEST|3 Dimensional tomographic Ultrasound|3-D tUS at five timepoints following acute ipsilateral stroke or Transient Ischaemic attack (TIA) to document carotid plaque volume and presence or absence of adverse plaque features.
214887513|NCT03721523|DIAGNOSTIC_TEST|Platelet Aggregometry|Blood test to test for platelet resistance to aspirin or clopidogrel and to measure effect of acute inflammatory response post event.
214887514|NCT03912363|OTHER|Rotating fluids protocol|"IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 100 mg/dL or less: IV fluids with 5% dextrose~* For blood glucose between 101-140 mg/dL: IV fluids without 5% dextrose~* For blood glucose \> 140 mg/dL on two consecutive occasions: insulin infusion protocol (Study arm 2)"
214887515|NCT03912363|OTHER|Insulin infusion protocol|"Regular insulin at 1 unit/ml AND IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 80 mg/dL: No insulin AND IV fluids with 5% dextrose~* For blood glucose 80-100 mg/dL: Insulin at 0.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 101-140 mg/dL: Insulin at 1.0 U/hr AND IV fluids with 5% dextrose~* For blood glucose 141-180 mg/dL: Insulin at 1.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 181-220 mg/dL: Insulin at 2.0 U/hr AND IV fluid without dextrose~* For blood glucose \> 220 mg/dL: Insulin at 2.5 U/hr AND IV fluids without dextrose"
214668021|NCT04626063|DRUG|paracetamol|Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
214668022|NCT00470821|DRUG|Oral melatonin 3mg BID|Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
214668023|NCT00470821|DRUG|Placebo|Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
214668024|NCT00315861|DRUG|pemetrexed|
214668025|NCT00315861|DRUG|topotecan|
214668026|NCT00368706|DRUG|solifenacin succinate|Oral
214668027|NCT00368706|DRUG|tolterodine|oral
215048439|NCT04187261|PROCEDURE|hip fracture surgeries|fixation or replacement
215048440|NCT06357845|OTHER|Survey|Participants will complete a brief web-based survey asking about their experiences related to the February 3, 2023 train derailment, health experiences and concerns following the derailment, and background information regarding their health history. The survey will last approximately 15 minutes.
214477564|NCT05224440|BEHAVIORAL|Veteran Sponsorship Initiative|Consistent with preventive, universal and public health approaches to suicide, the VA's TSMV Sponsorship Initiative establishes public-private partnerships with federal and community organizations to provide TSMVs with one-on-one, certified and volunteer sponsors in their post-military hometowns. Sponsors are assigned approximately six months prior to discharge and help TSMVs to accomplish reintegration tasks pre-and post-discharge. After certification, sponsors are assigned to and managed by a community integration coordinator (CIC), which is a local organization. CICs recruit sponsors, manage sponsors and match sponsors with TSMVs moving to the local region. After being matched with a TSMV, sponsors then integrate their skills during regular contact with matched TSMVs and monthly video or in-person sessions and help TSMVs identify SMART goals and develop reintegration action plans and ensure TSMVs attend VA healthcare appointments.
214477565|NCT06824883|DRUG|Immunochemotherapy|"P-P-GemOx regimen Sintilimab 200mg iv D1; Pegaspargase 3750U im D1; GemOx regimen: Gemcitabine 1000mg/m2 iv D1, Oxaliplatin 100mg/m2 iv D1 This regimen is administered every 3 weeks.~For patients with stage I-II (localized) disease:~A sandwich approach incorporating radiotherapy is employed. Patients initially receive 2 cycles of the P-P-GemOx regimen. If the interim evaluation demonstrates a complete response (CR) or partial response (PR), patients will proceed to intensity-modulated radiotherapy (IMRT). Following radiotherapy, an additional 2 cycles of the P-P-GemOx regimen are administered.~For patients with stage III-IV (advanced) disease. Patients are planned to receive 6 cycles of the P-P-GemOx regimen. For those achieving CR or PR following 6 cycles of immunochemotherapy, subsequent treatment options include autologous hematopoietic stem cell transplantation (auto-HSCT) or PD-1 monoclonal antibody maintenance therapy, determined based on age and overall physical condition."
214477566|NCT06824961|OTHER|5-second ventilation pause duration during mechanical CPR|The intervention is a 5-second lasting ventilation pause during mechanical CPR
214477567|NCT06824961|OTHER|3-second ventilation pause duration during mechanical CPR|The intervention is a 3-second lasting ventilation pause during mechanical CPR
214477568|NCT06824454|DRUG|Dipyridamole 75 MG|Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.
214477569|NCT06824558|OTHER|primiparous pregnant woman following virgin mary|It is thought that the application of the motherwort during birth shortens the duration of labor and reduces pain and fear during birth. In the study, the pregnant women in the intervention group watched the opening of the motherwort in water during birth.
214477570|NCT06824558|OTHER|primiparous pregnant|Only midwifery care was applied to pregnant women in the control group.
214477571|NCT00560118|DRUG|fotemustine|
214477572|NCT06817733|PROCEDURE|Transurethral Thermal Vaporization of the Prostate|After anesthesia, the patient is placed in the lithotomy position, and standard aseptic preparation and draping are performed. A cystoscope and a transrectal ultrasound (TRUS) probe are inserted. Following real-time image fusion and localization according to the preoperative plan, needles are inserted to deliver thermal vaporization to the prostate. Each needle treatment lasts 8 seconds, and the entire procedure is completed within 200 seconds after activation of the needle pathway.
214887520|NCT06173869|DRUG|FE 999049|FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.
214887521|NCT06173869|DRUG|GONAL-F|"GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days.~Coasting was not allowed."
214477573|NCT06411054|DEVICE|Acu-TENS|After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 4-12mA, and pulse width of 300µS will be delivered continually for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).
214477574|NCT06411054|DEVICE|Sham acu-TENS|"After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair.~In the sham acu-TENS, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current. The pads will be stuck on the acupoints for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed)."
214477575|NCT06816914|DRUG|NALIRIFOX|Patient in upfront surgery arm will receive operation followed by adjuvant chemotherapy with NALIRIFOX; patient in experimental arm will receive neoadjuvant NALIRIFOX followed by operation than adjuvant NALIRIFOX after operation.
214477576|NCT06589791|OTHER|No treatment given|Online self-completion survey
214887522|NCT04514679|BEHAVIORAL|Dietician / Health Coach|The order of visit for the two types of providers is first Dietician then Health Coach.
214887523|NCT04514679|BEHAVIORAL|Health Coach / Dietician|The order of visit for the two types of providers is first Health Coach then Dietician.
214887524|NCT03956355|DRUG|Tapinarof|Tapinarof cream, 1%, applied once daily
214887525|NCT03956355|DRUG|Vehicle Cream|Vehicle cream applied once daily
214477577|NCT06603766|DRUG|IV Magnesium Sulfate|MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.
214887526|NCT06960057|BEHAVIORAL|Virtual Reality Exposure|Participants will be exposed to a standardized 5-minute virtual reality (VR) session using a commercially available VR headset. The session features a calming, immersive environment intended to reduce anxiety and lower office blood pressure (OBP) during a clinical visit. The VR experience is delivered after the return of an ambulatory blood pressure monitoring (ABPM) device and before the final BP measurements are obtained. Blood pressure and anxiety scores are assessed immediately before and after VR exposure.
214668028|NCT03030040|BEHAVIORAL|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
214887527|NCT06409702|DRUG|Carfilzomib|"Induction:~ASCT：20mg/56mg/m2 ,D1,8,15，C2-4; non ASCT: 20mg/36mg/m2 ,D1,8,15，C2-4;~Consolidation:~ASCT: 56mg/m2 ,D1,8,15，C5-6; non ASCT: 36mg/m2 ,D1,8,15，C5-8;~Maintenance:~ASCT: 70mg/m2 ，D1，15; non-ASCT：56mg/m2 ，D1，15 After consolidation therapy, if MRD negativity is sustained for more than 1 year, carfilzomib will be discontinued"
215048441|NCT06357845|OTHER|Biological specimen collection|Participants may possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings. Participants will be asked which samples they are interested in providing. Participants will receive a specific sample collection kit based on their selection. For blood samples, participants will receive a mailed collection kit at their mailing address. A member of the research team will reach out to schedule blood sample collection, which may take place at home with a trained phlebotomist or at a designated collection site. A total of 1-2 teaspoons of blood (5-10 milliliters) will be collected at a one-time blood draw. For either saliva, hair, and/or toenail clippings, participants will be sent a sample collection kit and receive instructions at their mailing address. This kit also includes a return mailing envelope. Participants will provide the selected samples in the collection kits, place them in the return mailing envelope, and send them back to the research team.
215048442|NCT06357845|OTHER|Communications about study updates and future research opportunities|By consenting to participate in this study, the research team will send updates about the research results and any additional study opportunities to participants.
215048443|NCT06357845|OTHER|Qualitative interview|A total of 40 study participants will be recruited to participate in a 90-minute interview with open-ended questions. The interviews will be video and audio-recorded.
215048444|NCT00977210|DRUG|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
215048445|NCT02614820|PROCEDURE|Remote Ischemic Preconditioning Training Apparatus|
215048446|NCT03051191|DIAGNOSTIC_TEST|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
215048447|NCT05722587|OTHER|Pain science education|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
215048448|NCT02590107|DIETARY_SUPPLEMENT|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
215048449|NCT02590107|DIETARY_SUPPLEMENT|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
214477578|NCT06603766|DRUG|Inhalational magnesium sulfate|It gives us the same mechanism of action as IV MgSO4 with less side effects.
214477579|NCT06598657|OTHER|Mobilization with Movement MWM|Mobilization with Movement MWM of Talocrural joint in non-weight bearing position to improve Dorsiflexion Range of Motion (3 sets of 6 repetitions were applied, with a 1-minute break between sets/3 times a week) and conventional therapy which includes stretching, strengthening, balance training exercise.
214668029|NCT01870466|DRUG|Cilostazol|cilostazol bid for 7 days
214668030|NCT01870466|DRUG|Simvastatin|simvastatin qd for 7 days
214668031|NCT01870466|DRUG|Rosuvastatin|rosuvastatin qd for 7 days
215048450|NCT02590107|DIETARY_SUPPLEMENT|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
215048451|NCT02590107|OTHER|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
215048452|NCT01896973|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
215048453|NCT00443742|PROCEDURE|Validation|
215048454|NCT06458556|DEVICE|Treatment with Morpheus|Radiofrequency device treatment
214668032|NCT05107180|DIAGNOSTIC_TEST|drug screen|urine sample
214668033|NCT01936740|PROCEDURE|cataract surgery|
214668034|NCT05021926|DEVICE|DKL crosslinked sodium hyaluronate 26|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 26 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
214887528|NCT06409702|DRUG|Daratumumab|"28d/Cycle~Induction:~16mg/kg, D1,8,15,22，C 2-3，16mg/kg, D1,15, C4;~Consolidation:~ASCT: 16mg/kg/d, D1,15,C5-6; non ASCT: 16mg/kg/d, D1,15,C5-8;~Maintenance:~16mg/kg, D1,monthly After consolidation therapy, if MRD negativity is sustained for more than 1 year, daratumumab will be discontinued"
214887529|NCT06409702|DRUG|Lenalidomide|"28d/Cycle~Induction:~25mg qd d1-21 C2-C4;~Consolidation:~ASCT: 10mg d1-21，C5-6; non ASCT: 25 mg d1-21，C5-8;~Maintenance: 10mgqd D1-21~After consolidation therapy, if MRD negativity is sustained for more than 1 year, lenalidomide monotherapy will be maintained until disease progression"
214887530|NCT06409702|DRUG|Dexamethasone|"28d/Cycle~Induction:~ASCT：40mg qd, po/iv，D1,8,15,22，C2-4; non ASCT:20mg qd, po/iv，D1,8,15,22，C2-4;~Consolidation:~ASCT: 40mg qd, po/iv，D1,8,15,22，C5-6; non ASCT:20mg qd, po/iv，D1,8,15,22，C5-8"
214887531|NCT06409702|DRUG|VRD for first-cycle induction therapy|"Induction:~C1, 28d/cycle Bortezomib(V）:1.3 mg/m2，H，d1、4、8、11； Lenalidomide(R)：25mg，po. qd d1-14; Dexamethasone(D)：20 mg，po/iv，D1，2, 4，5, 8，9, 11,12。"
215048455|NCT03796910|DRUG|SPR720 for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
215048456|NCT03796910|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
214887532|NCT05898776|DEVICE|Lung transplantation after 10°C donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.
215048457|NCT03796910|DRUG|SPR720 for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
215048458|NCT03796910|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
215048459|NCT02373592|BEHAVIORAL|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
215048460|NCT02373592|DEVICE|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
215048461|NCT01240057|PROCEDURE|fetal endoluminal tracheal occlusion|percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
215048462|NCT01240057|OTHER|watchful waiting during pregnancy|pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
215048463|NCT01499537|DEVICE|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
215048464|NCT01499537|DEVICE|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
215048465|NCT00734448|DIETARY_SUPPLEMENT|myo-inositol|2 g twice a day until delivery
215048466|NCT01470157|DRUG|Ketamine|5mg/kg as oral suspension
215048467|NCT01470157|DRUG|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
215048468|NCT05568329|DEVICE|Hearing Aid Program|"Each subject will listen to recordings of music processed by seven different hearing aid brands set to the default Speech in Quiet program and the default Music program. Recordings (hearing aid brand x program x music sample) will be randomized from trial to trial."
215048469|NCT00461708|DRUG|Erlotinib|100 mg, PO, once per day
215048470|NCT00461708|DRUG|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
215048471|NCT06297876|BEHAVIORAL|Storytelling|Narrative stories will be videos that are 2-3 minutes long and will show community members speaking based on community identified themes.
215048472|NCT06297876|BEHAVIORAL|Learn More (Active Comparator)|Informational videos that are of similar length and on the same topic as the storytelling videos.
215048473|NCT04427293|DRUG|Lenvatinib|Lenvatinib 12mg daily for 7 days prior to surgery
215048474|NCT04427293|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on day 1
215048475|NCT03515161|DEVICE|closed-loop|Vasopressor admnistration in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of vasopressor the patient receives using feedback from standard operating room monitors.
215048476|NCT02040389|BEHAVIORAL|Picture book|Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team
214887533|NCT05898776|DEVICE|Lung transplantation after standard ice cooler donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (\~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
215048477|NCT02040389|BEHAVIORAL|Standard preoperative education|Arm with standard, verbal explaining for a parents about perioperative site/wound view
215048478|NCT02803203|DRUG|osimertinib|
215048479|NCT02803203|DRUG|Bevacizumab|
215048480|NCT02022540|DRUG|PAN-90806 Ophthalmic Solution|
215048481|NCT02022540|DRUG|Lucentis|
215048482|NCT02299310|DRUG|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
215048483|NCT02299310|DRUG|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
215048484|NCT02642211|PROCEDURE|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
215048485|NCT02003482|RADIATION|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
214887534|NCT06491264|DEVICE|Transcranial electrical stimulation|We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.
214887535|NCT06558279|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
214887536|NCT06558279|OTHER|Placebo PH20 SC|Subcutaneous placebo PH20 SC given by prefilled syringe
214887537|NCT01437046|DRUG|Doxazosin|Doxazosin were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.
214887538|NCT01437046|DRUG|Placebo|Matched placebo were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin or matched placebo was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.
215048486|NCT02003482|DEVICE|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
215048487|NCT05987982|PROCEDURE|Oral exercises and oral hygiene|The patients will be required to perform oral exercises and maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
214293676|NCT02927080|DRUG|ACE-083 or placebo|Recombinant fusion protein or normal saline.
214293677|NCT02180633|OTHER|Optical Coherence Tomography Scan|As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
214293678|NCT04469114|DRUG|Tofacitinib 10 mg|Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge
214293679|NCT04469114|DRUG|Placebo|Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
214293680|NCT01199289|DRUG|AMG 827|SC injection.
214293681|NCT01199289|DRUG|Placebo|SC injection.
214293682|NCT03980457|DEVICE|Indego Exoskeleton|Powered generated orthosis
214293683|NCT03980457|OTHER|Standard Rehabilitation|Standard Rehabilitation
214293684|NCT02074787|DEVICE|Thermography|Standard thermographic images
214293685|NCT02074787|DEVICE|Laser Doppler|standard laser doppler analysis
214293686|NCT02074787|DEVICE|Spectrophotometric Intracutaneous analysis|standard SIA scope imaging
214293687|NCT05569187|DRUG|Ribociclib|Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
214293688|NCT04983576|PROCEDURE|spinal fusion|patients undergoing spinal fusion
214668035|NCT05021926|DEVICE|Juvéderm Voluma™ with lidocaine (Allergan, Inc)|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Voluma™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
214293689|NCT02602860|RADIATION|[11C]UCB-J|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 20 mCi~* Route of Administration: iv"
214293690|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 10 mg/ml~* Route of Administration: iv"
214293691|NCT02602860|DRUG|Levetiracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 100 mg/ml~* Route of Administration: iv"
214293692|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Tablets for oral intake~* Concentration: 25 mg~* Route of Administration: oral"
214668036|NCT02830802|OTHER|Dr. Hauschka Med Mundspüllösung Salbei / cosmetics|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash. Rinse the mouth vigorously for 30 seconds, for easier timekeeping use the hourglass. Then spit out the mouthwash, do not rinse."
214668037|NCT02830802|OTHER|Placebo|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash."
214668038|NCT00886990|DRUG|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
214668039|NCT00886990|DRUG|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
214887539|NCT04952480|RADIATION|Dose-escalated adaptive radiotherapy|Adaptive planning of Radiation Therapy with two re-plans of the treatment field through course of therapy with the shrinking treatment fields according to tumor response to escalate dose, as allowed by dose to organs-at-risk.
214887540|NCT04952480|DRUG|Chemotherapy|Concurrent standard of care platinum doublet based therapy
214887541|NCT03999996|BIOLOGICAL|Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)|TDV subcutaneous injection
214887542|NCT03999996|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
214887543|NCT06804018|OTHER|Mandala coloring|Pregnant women who will paint mandalas
214293693|NCT03879655|DRUG|VTS-270|Administered IT via LP infusion of VTS-270
214293694|NCT02785107|BEHAVIORAL|M-PAC Group|Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
214293695|NCT02310685|OTHER|Comprehensive e-health wellness program|"Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest."
214293696|NCT02290509|BIOLOGICAL|Flublok Quadrivalent|Intramuscular injection of study vaccine
214293697|NCT02290509|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
214887544|NCT05659173|DIAGNOSTIC_TEST|Blood taking|Blood test for vitamin D level and DNA extraction for VDR gene polymorphism
214293698|NCT02533037|OTHER|Traditional Instability Tools|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
214293699|NCT02533037|OTHER|Ankle Destabilization Shoes|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
214293700|NCT04972084|DEVICE|Powerscope group|Treatment of Class II malocclusions using Powerscope appliance
214293701|NCT06371053|BEHAVIORAL|Community Intervention|"The intervention includes Cognitive Training: Activities targeting memory, attention, language, and executive functions to maintain cognitive abilities. This could involve cognitive games, memory exercises, and daily tasks.~Life Skills Training: Assistance in maintaining or relearning daily life skills such as personal hygiene, dressing, eating, and household chores. This could be through structured training programs and daily guidance.~Physical Exercise: Providing appropriate physical activities and exercises to maintain physical health and function, including walking, balance training, and light strength training.~Social Support: Organizing social activities and support groups to facilitate interaction and reduce social isolation and loneliness.~Emotional Support: Offering mental health support and psychosocial services to help individuals cope with emotional challenges such as anxiety and depression."
214293702|NCT01453257|DRUG|Tailored Chemotherapy|"Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU"
214293703|NCT03362398|DRUG|Omarigliptin 25 mg|Once weekly new anti-diabetic drug approved only in Japan
214293704|NCT03362398|DRUG|Trelagliptin 100 mg|Once weekly new anti-diabetic drug approved only in Japan
214293705|NCT04500834|BIOLOGICAL|Metal Panel T.R.U.E. Test|Diagnostic patch test
214293706|NCT03281954|DRUG|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~\+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
214293707|NCT03281954|DRUG|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~\+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
214293708|NCT00127712|DRUG|Amiodarone|
214477580|NCT06598657|OTHER|Conventional Treatment|"* Stretches of Hamstrings, Gastrocnemius, Soleus and hip adductors with duration of 20 sec hold/ 5 reps and Frequency: 3 times/week. Stretches will be performed passively~* Strengthening exercises of Quadriceps and abdominal muscles three times a week.~* Static balance exercises including single leg balance, tandem stance, weight shifting with Duration: 10 sec hold/ 5 reps Frequency: 3 times/week"
214477581|NCT06501794|DEVICE|Quantitative measurement of eye movements|Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
214887547|NCT01557985|DRUG|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
214887549|NCT05192382|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
215048488|NCT05987982|PROCEDURE|Oral care|The patients will be required to maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
214668040|NCT03530514|DRUG|REGN4461|REGN4461
214668041|NCT03530514|DRUG|Placebo|Placebo-matching REGN4461
214668042|NCT05312502|OTHER|Birth Ball|During labour, the pregnant woman was positioned using a birth ball.
214668043|NCT05384301|OTHER|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
214668044|NCT00263926|BIOLOGICAL|wasp venom|
214887550|NCT05192382|DRUG|Placebo|Placebo, tablets, once daily by mouth
214887551|NCT06137144|DRUG|AZD3470|AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
214887552|NCT04297761|OTHER|Filtered Air|Ambient air will be filtered and used for control exposure.
214887553|NCT04297761|OTHER|Wood Smoke|Wood smoke is generated by smoldering dry white oak logs and the exposure level will be maintained at an average of 500 µg/m\^3 for 2 hours.
214887554|NCT00003131|DRUG|chemotherapy|
214887555|NCT00003131|DRUG|gemtuzumab ozogamicin|
214887556|NCT00733005|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
214887557|NCT00733005|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
215048489|NCT03115918|DEVICE|Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm to have a PD stent placed.
214887558|NCT00993356|DRUG|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection \[starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH \> 5 mU/L on GH day curve (GHDC)\] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
214887559|NCT00993356|PROCEDURE|Transsphenoidal surgery|
214887560|NCT04418102|DIETARY_SUPPLEMENT|Palmitic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period
214887561|NCT04418102|DIETARY_SUPPLEMENT|Stearic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period.
214887562|NCT00042601|DRUG|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
214887563|NCT00042601|DRUG|Placebo|placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
215048490|NCT03115918|OTHER|No Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm and not receive PD placement.
215048491|NCT03800030|DEVICE|Theta-gamma tACS|NeuroConn technologies, direct current-stimulator plus
215048492|NCT03800030|DEVICE|Delta-beta tACS|NeuroConn technologies, direct current-stimulator plus
215048493|NCT03800030|DEVICE|Sham tACS|NeuroConn technologies, direct current-stimulator plus
215048494|NCT03965845|DRUG|Telaglenestat (CB-839)|Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
214887564|NCT02480101|BIOLOGICAL|H7N9 live influenza vaccine|H7N9 live influenza vaccine
214887565|NCT02480101|BIOLOGICAL|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
214887566|NCT06139146|OTHER|Muscle energy technique (MET)|"MET treatment protocol of pectoral major:~The patient's position was supine lying. Starting with the position which took the affected fibres to just short of their restriction barrier, the patient introduced a light contraction involving adduction of the arm against resistance from the therapist for 7-10 seconds. As the patient exhaled the therapist stretched across the new barrier.~MET treatment protocol of upper trapezius:~The patient moved the stabilized shoulder in a shrug motion toward the ear, and the ear toward the shoulder, with a light resistance (20% of possible strength). The contraction was sustained for 7-1 0 seconds MET treatment protocol of levator scapula The patient was in a supine position, with the hand supinated and the arm of the side to be tested extended alongside the trunk.~Strengthening of deep neck flexors: Patient was instructed to his nod head to flatten the neck's curve. 10 reps for 10 sec."
214887567|NCT06139146|OTHER|Core stability exercises:|"Warm up: The cat and camel stretches~Exercises:~* It included Crook lying, abdominal bracing, and 10 second - 20 repetitions (reps).~* Crook lying, abdominal Bracing with leg lifts holding the position for 3 second for 10 reps.~* Crook lying, abdominal Bracing with bridging with 10 reps with a 10 second hold.~* It included a Quadruped position with abdominal bracing for 10 s - 10 reps~* Quadruped position arm lifts with abdominal bracing 10 reps on each side.~* Quadruped position leg lifts with abdominal bracing 10 reps on each side.~* Quadruped position alternate arm and leg lifts with abdominal bracing holding position for 3 s - 10 reps on each side.~* The curl-up in hook lying, Fold arms across the torso. Lift shoulder blades off the ground. 1 to 2 seconds holds - 10 reps.~* Side plank on knees; holding position for 10 s - 5 reps ."
214887568|NCT01109446|BIOLOGICAL|Platelet Rich Plasma|27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
214887569|NCT01109446|PROCEDURE|Isotonic Saline Solutions|3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
214887570|NCT01109446|DRUG|Triamcinolonacetonid|Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
214887571|NCT03410056|DRUG|Efavaleukin alfa|Efavaleukin alfa administered as a subcutaneous injection.
214887572|NCT03410056|DRUG|Placebo|Placebo administered as a subcutaneous injection.
214887573|NCT00266630|DRUG|olanzapine|oral, daily
214887574|NCT00266630|DRUG|lithium|Dose adjusted according to local package insert
214887575|NCT00266630|DRUG|valproate|Dose adjusted according to local package insert
214887576|NCT00266630|DRUG|carbamazepine|Dose adjusted according to local package insert
214887577|NCT00327366|PROCEDURE|Light therapy|
214887578|NCT06341816|OTHER|VEXUS score|The VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
214887579|NCT06341816|DIAGNOSTIC_TEST|NGAL|Neutrophil gelatinase-associated lipocalin
215048495|NCT03965845|DRUG|Palbociclib Oral Capsule or Tablet [Ibrance]|Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.
215048496|NCT02230189|BIOLOGICAL|Segmental airway allergen challenge|
215048497|NCT02230189|PROCEDURE|Bronchoscopy|
215048498|NCT02230189|DIAGNOSTIC_TEST|Methacholine challenge test|
215048499|NCT02230189|DIAGNOSTIC_TEST|Spirometry|
215048500|NCT02230189|DIAGNOSTIC_TEST|Allergen skin prick test|
215048501|NCT01074125|DRUG|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
214887580|NCT04983134|BEHAVIORAL|Enhanced CHW Intervention|community-based intervention
215048502|NCT00432393|DRUG|levodopa-carbidopa|
215048503|NCT02985411|BEHAVIORAL|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
215048504|NCT02985411|OTHER|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
215048505|NCT01555866|DRUG|isavuconazole|IV
215048506|NCT04266522|OTHER|Informational Intervention|Receive printed materials
214477582|NCT06826144|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is applied to the contralateral upper limb, consisting of 5 cycles per session, 2 sessions per day. Each cycle includes 5 minutes of ischemia followed by 5 minutes of reperfusion. The pressure used to occlude the brachial artery is set at 200 mmHg or exceeds baseline systolic pressure by 35 mmHg (intervention group).At least 4 sessions of actual RIC treatment before the procedure.Continued RIC treatment for a minimum of 4 weeks postoperatively.
214477583|NCT06826144|PROCEDURE|Sham treatment|Remote ischemic conditioning (RIC) is applied to the contralateral upper limb, consisting of 5 cycles per session, 2 sessions per day. Each cycle includes 5 minutes of ischemia followed by 5 minutes of reperfusion. The pressure used to occlude the brachial artery is set at 20 mmHg.At least 4 sessions of sham RIC treatment before the procedure.Continued sham RIC treatment for a minimum of 4 weeks postoperatively.
214477584|NCT06592183|BEHAVIORAL|Smart-phone based, self-driven speech rehabilitation|Participants will perform the speech exercises for 60 min per day. Participants may complete the speech exercises all at once or split them into several sessions. Thus, participants assigned to the intervention group will use the application for 30-60 min daily, 5 days per week, for 4 consecutive weeks.
214477585|NCT06824792|DRUG|Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE.|Quasar is a biologically-informed multi-agent system developed based on multi-omics and multi-modal data. By integrating multidimensional information such as patients' demographic, clinical, and omics data (including DNA genotyping, whole-exome sequencing, transcriptome sequencing, etc.), it prioritizes standard treatment plans and recommends the optimal personalized treatment plan. Including targeted drugs, chemotherapy, immunotherapy approved by China CDE.
214477586|NCT06825169|BIOLOGICAL|NCR101 injection|Subjects will receive one NCR101 injection in Single Ascending Dose（SAD）and receive 4 NCR101 injections in Multiple Ascending Dose(SAD).
214477587|NCT06820346|OTHER|Manual and instrumental evaluation of hip adduction|The intervention consists of a new manual test for assessing iliotibial band (ITB) tension and hip abductor extensibility. The patient lies supine on the edge of a treatment table with the non-tested leg flexed at the hip and knee, stabilizing the pelvis. The tested leg remains extended. The examiner stabilizes the non-tested leg with one hand and adducts the tested leg until a resistance is felt, ensuring no pain. The hip adduction angle is visually assessed and recorded. A subset of participants also undergoes the modified Ober test for comparison. Inertial motion sensors are used to validate the accuracy of visual assessments. The primary outcomes include intra-rater and inter-rater reliability, while secondary outcomes evaluate the test's accuracy and pelvic movement reduction.
214477588|NCT06825637|DEVICE|Kandoo|Kandoo is an app that allows patients to track their activities in an engaging and gamified platform.
214477589|NCT06599333|BEHAVIORAL|Adherence to Care|"Questionnaire to assess the perception and readiness of patients in Lebanon towards the effectiveness of digital marketing strategies to improve their adherence to medications they take chronically~The following sections will be considered:~* General Characteristics of the Participants~* Medical and medication history~* Assessment of adherence to chronic medications (Likert scale)~* Digital Marketing Strategies to improve adherence to chronic medications (Likert scale)~* Perceived barriers to adopting digital marketing strategies in Lebanon (Likert scale)"
214477590|NCT06816862|DEVICE|SYMPHONY™ OCT System|Internal fixation system for surgical stabilisation of upper spine instabilities
214477591|NCT06593769|DIETARY_SUPPLEMENT|whey-protein microgel|The product used in this study is a liquid 125 mL whey protein microgel (WPM) formulation that will be delivered in a ready-to-drink formulation. The WPM is dairy based and, aside from milk and lactose, no other allergens are present Whey proteins and caseinates are two major fractions of cow milk proteins.
214477592|NCT06593769|OTHER|Placebo|Water (isovoloumous amount)
214668045|NCT01591330|DRUG|LY2140023 Reference form|80-mg tablet administered orally
214668046|NCT01591330|DRUG|LY2140023 Test-Low|80-mg tablet administered orally
214668047|NCT01591330|DRUG|LY2140023 Test-Medium|80-mg tablet administered orally
214668048|NCT01591330|DRUG|LY2140023 Test-High|80-mg tablet administered orally
214668049|NCT02520479|DRUG|P-CHOP|Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
214668050|NCT02520479|RADIATION|Radiotherapy|Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
214668051|NCT02520479|DRUG|P-CHOP|"Two consolidation cycles of P-CHOP are given after radiotherapy"
214887581|NCT03284723|DRUG|PF-06804103|Dose Escalation Part - 1A Dose Expansion Part - 2A
214887582|NCT03284723|DRUG|PF-06804103 + Palbociclib +Letrozole|Dose Escalation - Part 1B Dose Expansion - Part 2B
214887583|NCT06486714|PROCEDURE|Total knee arthroplasty|All patients indicated for primary total knee arthroplasty will receive a cruciate-retaining cemented or cementless implant system, utilizing either MA or KA methodology.
214887584|NCT00101634|DRUG|Paliperidone palmitate|
214668052|NCT05676710|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
214668053|NCT05005884|DRUG|Oral intake of medication|Prescription of oral phenolics 250 mg two times daily
214668054|NCT05005884|DRUG|Placebo|Prescription of oral phenolics 250 mg two times daily
214668055|NCT00175981|DRUG|sildenafil, fluvoxamine|
214668056|NCT02567695|DRUG|GBT440|Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
214887585|NCT04949412|DIAGNOSTIC_TEST|Vitamin D|serum vitamin D level
214887586|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
214887587|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
214887588|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
214887589|NCT00615199|DRUG|Placebo|administration via oral route twice daily
214887590|NCT01216735|DRUG|Fluticasone|220 ug twice a day for 3 weeks
214887591|NCT01216735|DRUG|Placebo|Placebo for 3 weeks
214887592|NCT03668678|OTHER|iGrow Readers Curriculum|As part of the iGrow Readers curriculum, the primary teacher first reads a book as a group with a specific health behavior theme. Then, children participate in nutrition and physical activities that relate and reinforce the lessons learned in the book. Informational newsletters highlighting healthy behaviors from the stories' themes are provided to parents. All implementation strategies are reinforced by research to promote positive choices in young children's health behaviors through the use of literature and language strategies and modeling of others in the children's microsystems.
214887593|NCT04133857|OTHER|aerobic exercise|aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
214887594|NCT06191289|DRUG|Transdermal Estradiol|"1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test~Other Names:~Climara"
214887595|NCT06191289|OTHER|Placebo|Weekly application of a placebo patch for 14 days starting day 7 after positive urine luteinizing hormone test
214887596|NCT02986529|DRUG|GV-971|
214887597|NCT02986529|DRUG|Placebos|
214887598|NCT05309811|DEVICE|RLRL therapy|Each RLRL treatment lasts three minutes. RLRL treatments will be performed twice a day, with at least four hours between each RLRL treatment.
214887599|NCT05309811|DRUG|Routine IOP-lowering medications|Medications prescribed for IOP control by glaucoma specialists in the outpatient.
214887600|NCT00050128|DEVICE|rTMS, Magstim|
214887601|NCT02194361|DRUG|Anthocyan capsules|Bilberry extract capsules, 160 mg (25% anthocyanosides)
214887602|NCT02194361|DRUG|Placebo|
214887603|NCT05975411|OTHER|Anesthesia Consultation with telemedicine|Anesthesia Consultation with telemedicine
214887604|NCT05177185|RADIATION|Hippocampal-sparing|Dose constraint placed on hippocampi to minimize dose to hippocampi, while maintaining target coverage (at least 98% of brain metastasis volume must receive 100% of prescription dose).
214887605|NCT05177185|RADIATION|Stereotactic radiosurgery|Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
214887606|NCT02342301|BEHAVIORAL|Standing Desk|Participants will be provided with a standing desk for 3 months
214887607|NCT02342301|BEHAVIORAL|Traditional Desk|Participants will use a traditional seated desk for 3 months
214887608|NCT00141050|DRUG|Focalin XR|
214887609|NCT05239611|DIAGNOSTIC_TEST|Xenon MRI|Study participants will be randomized to a 12 week exercise intervention versus usual care. Participants will have Xenon MRI at study start and completion to evaluate impact of exercise on lung function. The exercise intervention for all participants will be delivered by two pulmonary rehabilitation coaches (PR-coach) including a registered respiratory therapist and clinical registered dietitian who've been trained in exercise training as recommended by the AACVPR and American College of Sports Medicine (ACSM). Each TR participant will be assigned a PR-coach, and receive one weekly exercise consulting session during the 12-week intervention.
214887610|NCT01170988|PROCEDURE|T-Graft|T-Graft
214887611|NCT00618488|DIETARY_SUPPLEMENT|Probiotic BB12 - Bifidobacterium lactis|Bifidobacterium lactis (3.1 oz yogurt) administered once a day for 6 weeks
215048507|NCT04266522|OTHER|Counseling|Receive direct physicist interactions to describe the technical aspects of the treatment
215048508|NCT04266522|OTHER|Questionnaire Administration|Ancillary studies
215048509|NCT01193101|DRUG|LCZ696|LCZ696
215048510|NCT01193101|DRUG|Placebo|matching placebo to LCZ696
215048511|NCT00746187|DEVICE|ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|
215048512|NCT00746187|DEVICE|3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm|
215048513|NCT02347085|DRUG|GFF MDI (PT003)|
215048514|NCT02347085|DRUG|Placebo MDI|
215048515|NCT01220492|DRUG|conventional plus MSC treatment|received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.
215048516|NCT01220492|DRUG|conventional plus placebo treatment|received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
214887612|NCT00618488|DIETARY_SUPPLEMENT|Placebo|Placebo administered once a day for 6 weeks
214887613|NCT03348878|OTHER|assessment of drug compliance|assessment of drug compliance using electronic monitoring devices (2 months duration)
214887614|NCT04015271|BEHAVIORAL|Action Observation + Repetitive Task Practice|Observing a video of another person performing a functional task and physically repetitively performing the same task for upper extremity hemiparesis
215048517|NCT01459692|OTHER|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
215048518|NCT02710188|DRUG|HTL0009936 modified release|HTL0009936 modified release
215048519|NCT02710188|DRUG|HTL0009936 immediate release|HTL0009936 immediate release
215048520|NCT01480102|DRUG|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
215048521|NCT01480102|OTHER|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
215048522|NCT02170844|DRUG|BIBR 1048 MS|
215048523|NCT02170844|DRUG|Placebo of BIBR 1048 MS|
215048524|NCT02340884|BEHAVIORAL|Promoting Resilience In Stress Management (PRISM)|"The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding."
215048525|NCT02834819|DRUG|3% Nebulized Hypertonic Saline|
214668057|NCT01747902|PROCEDURE|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
214887615|NCT04015271|BEHAVIORAL|Placebo Video + Repetitive Task Practice|Observing a video of static images and physically repetitively performing functional task for upper extremity hemiparesis
214887616|NCT03435887|BEHAVIORAL|Alere q HIV-1/2 Detect for point of care infant testing|The investigators will pilot the Alere q HIV-1/2 Detect mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4-8 weeks postnatal) for analysis with Alere q HIV-1/2 Detect, with results available within 1-2 hours to enable mother notification at the same clinic visit.
214887617|NCT03435887|BEHAVIORAL|GeneXpert HIV-1 Qual for point of care infant testing|The investigators will pilot the GeneXpert HIV-1 Qual mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4 to \<24 weeks postnatal) for analysis with GeneXpert HIV-1 Qual, with results available within 1-2 hours to enable mother notification at the same clinic visit.
214887618|NCT03435887|BEHAVIORAL|HIV DNA PCR testing (Standard of Care)|This is the standard of care for infant HIV testing. A dried blood spot sample will be collected from the infant and shipped to a central laboratory for HIV DNA PCR testing. Results will then be returned to the hospital.
214887619|NCT00419497|BEHAVIORAL|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
214887620|NCT01731639|OTHER|MSOME|The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form \> 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
214887621|NCT04844112|PROCEDURE|automatic CT/MRI-US fusion system guided radiofrequency ablation|automatic CT/MRI-US fusion system guided radiofrequency ablation
214887622|NCT03911830|OTHER|Exercise followed cold water immersion|Rehabilitation program of 17 sessions with 30 minutes of exercise followed by 15 minutes of submerged recovery at 17 ° C (3 sessions per week / 6 weeks).
214887623|NCT03194919|OTHER|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
214887624|NCT03897283|DRUG|TQB2450|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle
214887625|NCT03897283|DRUG|Anlotinib|Anlotinib capsules given orally in fasting conditions, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). Initial dose is 10 mg. If there are no patients with DLT in first treatment cycle , begin to explore dose of 12 mg. If there are 2 or more patients in 3 patients with DLT, 8 mg dose is to explore.
214887626|NCT01231893|PROCEDURE|olfactory mucosa ensheathing cell grafting, rehabilitation|In this group patients are planned to underwent a biopsy of their own olfactory mucosa for isolation and culture of olfactory ensheathing cells and olfactory fibroblasts. The suspension of these cells will be next transplanted into the focus of spinal cord injury. Before and after surgery the patients will undergo an intense neurorehabilitation program.
214887627|NCT01231893|OTHER|rehabilitation|In this group the patients will not undergo any surgical procedure. They will participate in the same rehabilitation protocol that is planned for the patients from the experimental group.
214887628|NCT04716647|OTHER|Ayurveda|Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.
214887629|NCT05850325|OTHER|Group 1 Elbow Flexed at 90 Degrees|subjects will be instructed to exercise the forearm with the elbow positioned by their side, in 90° of flexion.
214887630|NCT05850325|OTHER|Group 2 Elbow Fully Flexed|subjects will be instructed to exercise the forearm with their elbow fully flexed to achieve supination and the elbow extended to achieve pronation.
214668058|NCT01747902|PROCEDURE|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
214887631|NCT02720666|DRUG|K-001|In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.
214887632|NCT01802021|DRUG|Astagalus-based Formula: Qingshu-Yiqi-Tang|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months"
214887633|NCT04999059|OTHER|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
214887634|NCT00064987|PROCEDURE|Testicular biopsy|Outpatient surgical procedure.
214887635|NCT00064987|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
214887636|NCT00064987|DRUG|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
214887637|NCT05366452|DEVICE|IMPELLA CP|Implantation of the IMPELLA CP will be performed using the femoral route in most patients. Echo guided puncture to gain access for IMPELLA CP will be encouraged and a local angiography will be promoted to check the feasibility of device implantation. The implantation will follow gold standard after obtaining an ACT \>250 s. As soon as the device is in place it will be started.
214887638|NCT05366452|OTHER|Conventional therapy|The patients will receive up to date management according to the consensus of care regarding inotropes and vasopressors in CS (2,4). A dedicated protocol will ensure that management is similar between centers and in both groups. The shock team will be in charge of all therapeutic decisions.
214477593|NCT06594744|PROCEDURE|Endoscopic variceal ligation|EVL will be performed and repeated every 3 to 4 weeks until the EVs are eradicated. Following this, patients will undergo regular upper gastrointestinal endoscopic surveillance, initially every three months for a total of two sessions, then every six months for a total of two sessions, and subsequently annually. If EVs are found to recur during surveillance, additional EVL will be performed every 3 to 4 weeks until the varices are again eradicated endoscopically.
214887639|NCT01197352|BEHAVIORAL|Motivational and Normative Feedback|Weekly feedback based on their frequency and degree of at-risk drinking behavior using normative, educational and motivational feedback
214887640|NCT01197352|BEHAVIORAL|Self-Awareness|Weekly queries to raise awareness and allow self-reflection about drinking habits
214887641|NCT00020631|DRUG|pirfenidone|
214887642|NCT00209040|BEHAVIORAL|Acoustic Startle Testing|See protocol description for methodological details
214887643|NCT04045769|DRUG|Saroglitazar magnesium 4mg|1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
214887644|NCT04045769|DRUG|Placebos|5 tablets of placebo to be administered orally
214293709|NCT02526407|BEHAVIORAL|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
214293710|NCT02526407|BEHAVIORAL|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
214293711|NCT03197506|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
214293712|NCT03197506|OTHER|Laboratory Biomarker Analysis|Correlative studies
214293713|NCT03197506|BIOLOGICAL|Pembrolizumab|Given IV
214293714|NCT03197506|RADIATION|Radiation Therapy|Undergo radiation therapy
214293715|NCT03197506|DRUG|Temozolomide|Given PO
214293716|NCT03197506|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214293717|NCT05140031|OTHER|PNE4Adults|"It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain."
214293718|NCT05686447|OTHER|Observational studies, no intervention|Observational studies, no intervention
214293719|NCT05497713|OTHER|Mindsets|The primary objective of this trial is to determine whether mindsets sustain the feasibility of taking cold showers over a 3-month period.
214293720|NCT03433768|GENETIC|Real time PCR|We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.
214293721|NCT06346964|OTHER|Health education|Health education prepared for chronic disease self-management aims to improve the health behaviors of older adults.
214293722|NCT02642614|DRUG|BI 1026706|
214293723|NCT02642614|DRUG|Placebo|
214293724|NCT02642614|DRUG|Placebo|For blinding purposes
214293725|NCT02123498|DRUG|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
214293726|NCT02123498|DRUG|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
214293727|NCT02123498|DRUG|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
214293728|NCT02123498|PROCEDURE|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
214293729|NCT02123498|PROCEDURE|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
214668059|NCT04990739|DRUG|MTB-9655|"MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime."
214668060|NCT01645761|DRUG|Endonase|PPI- based triple therapy with endonase
214887645|NCT04045769|DRUG|Moxifloxacin 400mg|1 tablet of 400 mg Moxifloxacin to be administered orally
214293730|NCT05563233|OTHER|Helfer skin tap technique|Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.
214293731|NCT05563233|DEVICE|Shot Blocker|Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
214293732|NCT05063669|BEHAVIORAL|Cognitive Occupational Therapy|In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
214293733|NCT00850824|BEHAVIORAL|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
214293734|NCT03767530|DEVICE|Mibo Thermoflo|Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.
214293735|NCT03767530|OTHER|Warm compresses and eyelid massage|Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.
214293736|NCT03967964|DRUG|Dehydroepiandrosterone 2.2 g|Vaginal ring with 2.2 grams DHEA.
214293737|NCT03967964|DRUG|Dehydroepiandrosterone 1.5 g/Testosterone 25 mg|Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
214293738|NCT03967964|DRUG|Testosterone|Vaginal ring with 35 mg testosterone.
214293739|NCT03967964|DRUG|Testosterone Topical Gel|Gel containing 1% testosterone.
214293740|NCT03967964|DRUG|Dehydroepiandrosterone Oral Capsule|Capsule containing 25 mg DHEA
214293741|NCT02045368|DRUG|IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
214293742|NCT03951740|DEVICE|Fitbit Charge 2|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
214293743|NCT03951740|DEVICE|Mio Slice|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
214293744|NCT03951740|DEVICE|Oxycon Mobile|"The Oxycon Mobile will be used as the reference method/golden standard to calculate energy expenditure (kcal). This device (consisting of a face mask and gas analyzer unit) will be worn during the entire laboratory activity protocol.~Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF)."
214293745|NCT00489398|DRUG|epinastine HCL and olopatadine HCL|
214293746|NCT00672789|BEHAVIORAL|Blood smear education|education at baseline and three month follow-up
214293747|NCT00672789|OTHER|standard education|standard education
214887646|NCT04045769|DRUG|Saroglitazar magnesium 20 mg|5 tablets of 4 mg Saroglitazar magnesium to be administered orally
214887647|NCT05637372|RADIATION|CBCT|CBCT scan
214887648|NCT00347646|DRUG|Plasmin|27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
214887649|NCT01214655|DRUG|LY2523355|Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
214887650|NCT00764881|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose
214887651|NCT00764881|DRUG|Microgynon|Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
215048526|NCT05545748|BEHAVIORAL|Zero (0) Tolerance Program (SToP)|"1. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.~2. Giving reminder objects (Magnet, sticker): For example; at the entrance door of the house: 0 TOLERANCE magnet to cigarettes; No smoking in my home label.~3. Informative materials (information notes and brochures): Brochures on the harms of second-hand smoking (SHS) and third-hand smoking (THS), the diseases they cause, and how to protect them~4. Informative telephone text messages: Reminder phone messages related to SHS and THS"
215048527|NCT05545748|BEHAVIORAL|Exposure Feedback Group|1\. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.
214293748|NCT04693325|PROCEDURE|Prolonged normothermic machine perfusion|First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted \[NMP1\]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) \[PNMP3\] and consequently 6 hours (n=6) \[PNMP6\].
214887652|NCT00764881|DRUG|Placebo|Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
214293749|NCT01941901|DRUG|Calcium electroporation|Intratumoral injection, once only treatment.
214293750|NCT01941901|DRUG|Electrochemotherapy with bleomycin|Intratumoral injection, once only treatment
214887653|NCT01696123|DRUG|MLC601|It was described
215048528|NCT01267786|PROCEDURE|Liver surgery|hepatectomy
215048529|NCT00183014|BEHAVIORAL|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
215048530|NCT00183014|BEHAVIORAL|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
214293751|NCT05796765|BIOLOGICAL|Micronized DHACM 40 mg|Injection of 40 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
214293752|NCT05796765|BIOLOGICAL|Micronized DHACM 100 mg|Injection of 100 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
214293753|NCT05796765|DRUG|Saline|Injection of 2.5 ml, 0.9% Sodium Chloride, USP
214293754|NCT04067544|DEVICE|Acupuncture|"The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion."
214477594|NCT06594744|DRUG|Carvedilol|The initial dosage of carvedilol is set at 6.25 mg daily. In the absence of hypotension (systolic blood pressure \&lt; 90 mmHg), bradycardia (resting heart rate \&lt; 55 beats per minute), or other adverse effects, hospitalized patients may have their dosage increased to 12.5 mg daily after 3 days, while outpatient patients may increase their dosage to 12.5 mg daily after 7 days. This dosage represents the target dose for the trial.
214887654|NCT02737241|PROCEDURE|Low power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 50W holmium laser energy.
214887655|NCT02737241|PROCEDURE|High power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 100W holmium laser energy.
214887656|NCT02274883|DIETARY_SUPPLEMENT|Enriched Protein Fractions|Enriched protein fractions
214887657|NCT02274883|DIETARY_SUPPLEMENT|Protein Fractions|Protein fractions
214887658|NCT02031861|DRUG|nifedipine CR tablets (Xin Ran)|
214887659|NCT02031861|DRUG|nifedipine CR tablets (Adalat)|
214887660|NCT00300924|DRUG|Rizatriptan co-administered with Acetaminophen|
214293755|NCT02655562|DRUG|Montelukast|"Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients."
214293756|NCT06208891|PROCEDURE|Robotic myomectomy|Robotic assisted laparoscopic myomectomy
214293757|NCT05100524|OTHER|Motivational interview|The motivational interviewing technique is a client-focused, directive form of counseling to create behavior change. Its main goal is to discover and solve ambivalence. This method is especially useful for people who are reluctant or ambivalent to change.
214293758|NCT05100524|OTHER|Ongoing treatment|Patients with total knee replacement receive standard nurse care. Treatment is applied. He does his own exercises at home.
214293759|NCT03218553|DRUG|Dexamethasone|Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
214293760|NCT03218553|DRUG|Placebos|placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
214293761|NCT02941965|PROCEDURE|ICSI without PGS|Selection of embryos are based on morphology criteria on the 5th day of ICSI.
214293762|NCT02941965|PROCEDURE|ICSI with PGS|PGS will be applied to selected embryos on the 5th day of ICSI.
214293763|NCT06293170|OTHER|DETECT|DETECT periodically processes real-time data from the corresponding electronic medical record system to screen for a combination of coma, indicated by a Richmond Agitation Sedation Scale (RASS) score of - 4 or - 5 or Glasgow Coma Scale (GCS) score of 6-3, along with manually assessed absence of bilateral pupillary light reflexes. Both findings are considered early indicators of impending ILBF. In case of positive screening results, an automated notification will be sent via the hospital's email server to the corresponding transplant coordinators and intensivists. The email sent aims to prompt clinical assessment of the reported patient and, if necessary, initiate a guideline-based ILBF examination.
214477595|NCT06590129|PROCEDURE|hydrodissection of median nerve|Ultrasound guided hydrodissection of median nerve in carpal tunnel with 5% dextrose solution
214668061|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head with smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone was activated in the PTB with the app group
214668062|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone were not activated in the PTB without the app group.
214293764|NCT06293170|OTHER|Conventional care|Conventional care
214887661|NCT06144138|BEHAVIORAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
214887662|NCT01418417|DRUG|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
215048531|NCT01663792|OTHER|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
214293765|NCT01320085|DRUG|MEK162|
214477596|NCT06590129|OTHER|Physiotherapy|5-20 sessions in rehabilitation area with physical media: paraffin glove (10 coats for 15min), mobilizations of wrist and fingers, strectching of wrist and fingers tendons/muscles, muscle stregthening whit isometric or isotonic excercises to intrinsic muscles of the hand an forearm, and occupational therapy with techniques for sensory return, nerve and tendon sliding techniques, activities aimed at improving basic hand functions and work simulation activities.
214477597|NCT06600880|DEVICE|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
214477598|NCT06600880|DRUG|Lumason|New packages of Lumason microbubbles will be shipped from Bracco Diagnostics Inc. and will be used in conjunction with the ultrasound transducer to temporarily open the BBB. Lumason microbubbles will be freshly activated before treatment sonication and will be drawn using a 10-ml syringe to reach the desired dosage of 0.1mL/kg right before the intravenous injection.
214887663|NCT03916718|BEHAVIORAL|Care EcoSystem|This is a care management program and health care outcomes feasibility study utilizing the dementia Care Ecosystem (CE) program developed at UCSF and tailored to high need Ochsner PWD (patient with dementia) and their CGs (caregivers). Dyads (CGs and PWD) will receive a tailored clinical assessment addressing dementia severity, PWD and CG needs, education/strategies to management common dementia issues, medical issues and medication reconciliation, caregiver wellness strategies, linkages to community-based resources, advance care planning, education about the risk of ED and hospitalization, and care coordination with other specialties. Dyads will be followed on a monthly basis to monitor needs, provide support, and problem solve issues.
215048532|NCT01663792|OTHER|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
215048533|NCT01663792|OTHER|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
215048534|NCT00754689|DRUG|Rimonabant|Tablet, oral administration
215048535|NCT00754689|DRUG|Metformin|Tablet, oral administration
215048536|NCT00754689|DRUG|placebo|Tablet, oral administration
214887664|NCT05230381|DRUG|Continous infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by 5mg/kg/h tranexamic acid infusion.
214887665|NCT05230381|DRUG|Single infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by same volume of 0.9% saline.
214887666|NCT05230381|DRUG|Placebo|The 0.9% saline is administered with the same volume at the same speed as the other group.
214887667|NCT05989464|DIAGNOSTIC_TEST|Self-swab for genital HPV|Participants will insert a swab in the vagina to collect a sample for HPV testing.
214887668|NCT02330497|PROCEDURE|Radiofrequency Ablation under EUS|Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
214477599|NCT06600880|OTHER|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|"A high-resolution MRI (with and without gadolinium (Dotarem) contrast agent) will be acquired prior to BBB opening on the GE SIGNATM Premier (3T) (same scanner as in the NHP study) for pre-treatment planning and screening purposes. Then, a second MRI (with and without gadolinium) will be acquired and read by a Board-Certified Radiologist immediately after the treatment sonication in order to assess the BBB opening and safety. Finally, a final follow-up MRI (with and without gadolinium) will be conducted 3 days (±1 day) after the treatment to confirm BBB closing and/or safety. This will be read by a Board-Certified Radiologist as well.~All MRI procedures will be performed at the CUIMC/Neurological Institute of New York."
214477600|NCT06600880|RADIATION|Positron Emission Tomography (PET)|A first PET/CT scan with Amyvid (18F-Florbetapir) and MK-6240 (F18-Florquinitau) tracers will be performed on the SIEMENS Biograph 64 to assess the baseline amyloid plaque load and tau load before the treatment, respectively. Finally, two follow-up PET/CT scans will be conducted 3 weeks (±1 week) and 3 months (±2 weeks) post-treatment to assess amyloid plaque load (using Amyvid) and tau load (using MK-6240).
214477601|NCT06600880|DRUG|Amyvid|Amyloid PET tracer Amyvid (18F- Florbetapir) will be stored in their original container with proper radiation shielding at 25 °C and only handled by properly trained personnel in the handling and administration of radioactive materials, which requires employing proper radiation protection procedures.
214668063|NCT05150132|DEVICE|Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. They were instructed to brush with the Modified Bass technique.
214887669|NCT00005985|BIOLOGICAL|filgrastim|
214887670|NCT00005985|DRUG|carmustine|
214887671|NCT00005985|DRUG|cyclophosphamide|
214887672|NCT00005985|DRUG|cytarabine|
214887673|NCT00005985|DRUG|dexamethasone|
214887674|NCT00005985|DRUG|etoposide|
214887675|NCT00005985|DRUG|mitoxantrone hydrochloride|
214887676|NCT00005985|PROCEDURE|peripheral blood stem cell transplantation|
214887677|NCT00005985|RADIATION|radiation therapy|
214887678|NCT05256134|DRUG|Gantenerumab|Gantenerumab will be administered as per the dosing schedule described in the Arm description.
214887679|NCT05256134|DRUG|Placebo|Placebo will be administered as per the dosing schedule described in the Arm description.
214887680|NCT01628432|PROCEDURE|conservative hysterectomy I|conservative hysterectomy for benign disease
214887681|NCT01628432|PROCEDURE|Conservative hysterectomy II|bilateral salpingectomy during hysterectomy without conservation of the ovaries
214668064|NCT01450137|DRUG|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
214668065|NCT01450137|DRUG|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
214668066|NCT01129752|OTHER|No intervention|there is no intervention for this study
214887682|NCT00304252|DRUG|Interferon beta-1a|
214887683|NCT06079411|DEVICE|virtual reality non-embodied|the non-embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with passive navigation of 8 sessions of 30/40 minutes 3 times a week.
214887684|NCT06079411|DEVICE|virtual reality embodied|the embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with active navigation of 8 sessions of 30/40 minutes 3 times a week.
214887685|NCT06079411|OTHER|treatment as usual|"the treatment as usual (TAU; i.e., visuospatial paper and pencil stimulation) will consist of paper and pencil exercises"
214887686|NCT03870880|DRUG|Risperidone ISM 75 mg|Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.
214887687|NCT03870880|DRUG|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
214887688|NCT01818882|OTHER|Standard care|Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.
214887689|NCT01818882|DEVICE|Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI)|Standard care (as described for the other intervention) + pleuropulmonary ultrasound using the Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI).
215048537|NCT02590536|DRUG|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
214887690|NCT05395260|DRUG|FL-101|FL-101 200mg IV
214887691|NCT01567462|DEVICE|Monopolar electrocautery loop in Transurethral resection of bladder tumors|Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
214887692|NCT01567462|DEVICE|PK Button Vaporization Electrode in transurethral resection of bladder tumors|PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
214887693|NCT04369274|DEVICE|Mechanical ventilation with the automated BVM compressor|Mechanical ventilation is accomplished with a device that mechanically squeezes a manual bag valve instead of by hand. The rate and volume of compression are adjustable, and the device has appropriate alarms and safety features.
215048538|NCT02590536|DRUG|placebo|
214887694|NCT05425212|OTHER|Functional activation with kinesio tapping|These exercises will be carried out thrice a week for 4 weeks. The exercises will be performed for approximately 35-45 minutes, 1 to 2 times a day, in sitting or standing position
214887695|NCT05425212|OTHER|Conventional physical therapy|strengthening and stretching, combined with Ankle ranges and Hip strengthening. (6) The exercises performed will be Calf stretches, Heel and Toe raises, Hip marching in sitting/standing; 4 days a week for 4 weeks
214887696|NCT03412695|DEVICE|MyFood|Patients included in the intervention group will use the MyFood app to record their dietary intake. Nurses will use the report and recommendations in the MyFood tool to follow up the nutritional treatment of the patients.
214887697|NCT00281281|DRUG|vancomycin|
214887698|NCT00421161|DRUG|olive oil and omega 3 in a combined cream|
214887699|NCT01307332|DRUG|MabCampath-1h|Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
214887700|NCT03820128|OTHER|Early diet intervention|Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.
214668067|NCT03580447|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
214887701|NCT05819970|DRUG|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament
214293766|NCT03626922|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
214293767|NCT03626922|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
214887702|NCT05819970|DRUG|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament
214887703|NCT03613181|DRUG|ANG1005|Investigational drug
214293768|NCT03626922|DRUG|Oxaliplatin|"Oxaliplatin-Dose level1: 85 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~Dose level 2: 120 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~The MTD dose of oxaliplatin in the study combination of Cohort 2 will be the recommended Phase II dose (RP2D) for the cohort expansion."
214293769|NCT03626922|DRUG|Dexamethasone|Dexamethasone-4 mg by mouth twice daily on: the day before, the day of, and the day after each dose of pemetrexed.
214293770|NCT03626922|DIETARY_SUPPLEMENT|Folic Acid|Folic Acid-400 micrograms by mouth daily starting 5 days prior to first dose of pemetrexed and continue daily to include 21 days after the last dose of pemetrexed.
214293771|NCT03626922|DIETARY_SUPPLEMENT|Vitamin B-12|1000 micrograms administered intramuscularly 7 days prior to the first dose of pemetrexed, every 9 weeks, and should continue until 3 weeks after the last dose of pemetrexed.
214293772|NCT03187093|DRUG|Vortioxetine|10-20 mg once daily for 8 weeks
214293773|NCT03187093|DRUG|Escitalopram|10-20 mg once daily for 8 weeks
214293774|NCT03807466|BEHAVIORAL|Dynamic/Interactive vs. Static/Paginated Report|Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
214293775|NCT03807466|BEHAVIORAL|LTC Physicians Enrolled vs. Not Enrolled in Reports|Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
214887704|NCT03613181|DRUG|Physician's Best Choice|Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.
214887705|NCT00021385|DRUG|carboplatin|
214293776|NCT03966378|OTHER|Grape seeds extract|Grape seeds extract powder
214293777|NCT03966378|OTHER|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste
214887706|NCT00021385|DRUG|squalamine lactate|
214887707|NCT01977417|DRUG|Salsalate|
214293778|NCT04949126|BEHAVIORAL|questionnaire|questionnaires of precarity, dental anxiety, self medication, pain
214293779|NCT05956860|PROCEDURE|abdominopelvic vascular intervention through the radial artery access|"According to the pathological changes and needs of the subjects (any abdominal and pelvic arterial intervention that can be performed through the radial artery access, including but not limited to:~1. hepatic intervention, such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), etc.;~2. Other visceral intervention, such as spleen, kidney, mesentery, etc.;~3. Pelvic intervention, such as uterine artery embolism, prostatic artery embolism, etc.;~4. Others, such as preoperative embolization of bone tumors (lumbar, sacral vertebra), etc."
214293780|NCT03785431|DEVICE|PCI with Phantom Bioresorbable Scaffold|Once baseline angiography is performed and all eligibility criteria are met, the patient is included in the study. The target lesion should be crossed with a standard coronary guidewire. Next, the NIRS/IVUS and OCT probe is inserted and a pullback is being performed to evaluate the lesion and vessel morphology. The predilatation with 1:1 non-compliant or semi-compliant balloon is mandatory. Thereafter the scaffold should be inserted and position across the target lesion. Lesions up to 14 mm should be covered with the 18 mm device, for lesions of 15-20 mm a 24 mm device should be used. The scaffold will be deployed with intent to achieve the inner diameter to the reference vessel ration of 1:1 using a single inflation. Post-dilatation using a non-compliant balloon should be performed to achieve complete scaffold apposition and reduce the residual angiographic stenosis below 20%. The final NIRS/IVUS and OCT of the target vessel should be performed.
214887708|NCT01977417|DRUG|Placebo|
214887709|NCT03065855|PROCEDURE|Early removal group|Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.
214887710|NCT03065855|PROCEDURE|Normal removal group|Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
214887711|NCT05928065|OTHER|Collection of datas|Collection of datas: datas of physical examination (swelling, hematoma, edema), benign trauma (non deforming and closed fractures), ultrasound and radiographic images and evaluation of pain.
214887712|NCT03500068|DIAGNOSTIC_TEST|biopsies & blood analyses|They will take blood and a biopsy from the metastase in the patient
214887713|NCT03397589|BEHAVIORAL|Community Health Worker (CHW) services|CHWs are non-clinical people who provide education, care coordination, and support to families.
214887714|NCT03182933|DRUG|Peripheral Nerve Blockade|Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
214887715|NCT03182933|BEHAVIORAL|10 meter walk test on post-operative day 1|Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist
214887716|NCT03182933|OTHER|In person and over the phone questionnaire|Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores
214887717|NCT03182933|DEVICE|Force transduction of quadriceps strength|Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1
214887718|NCT02748304|OTHER|control|just follow up
214293781|NCT04235049|DRUG|Glecaprevir/pibrentasvir|Treatment for HCV Infection
214293782|NCT00618059|DRUG|Pilocarpine|
214293783|NCT02352714|DRUG|Paracervical Nerve Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
214293784|NCT02352714|DRUG|Sham Paracervical Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
214668068|NCT03580447|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
215048539|NCT05431647|OTHER|Sensory integration therapy|The individuals were divided into two as randomized controlled. Both physiotherapy and sensory integration therapy were applied to the intervention group. Each treatment was applied as 2 sessions per week, 2 days a week for 8 weeks. In the control group, only physiotherapy treatment was applied for 8 weeks, 2 days a week, 2 sessions per week.
214293785|NCT03316131|DRUG|Verinurad|Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
214293786|NCT03316131|DRUG|Febuxostat|Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
214293787|NCT03316131|DRUG|Dapagliflozin|Randomized patients will receive orally once daily fixed dose of dapagliflozin in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
214293788|NCT03316131|OTHER|Dapagliflozin matched placebo|Randomized patients will receive orally once daily fixed dose of dapagliflozin matched placebo in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
214293789|NCT02329561|DRUG|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
214887719|NCT02748304|DRUG|sorafenib|sorafenib 400mg bid po
214887720|NCT02748304|DRUG|aspirin|aspirin 100mg qd po
214293790|NCT02329561|BEHAVIORAL|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
214293791|NCT02329561|DRUG|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
214293792|NCT06036459|OTHER|uterine peristalsis|Transabdominal us followed by Transvaginal ultrasonography scans (Sono Ace R5 ) of uterine peristalsis will performed on the day of embryo transfer while the patient lying relaxed in lithotomy position. The probe will be introduced into the vagina as gently as possible to avoid stimulating the cervix. After scanning the mid-sagittal plane of the uterus, the probe will be fixed as steady as possible while a 3 min video of uterine peristalsis will be recorded simultaneously. The records will be analyzed at 4X regular speed using a Video player application by two independent experienced observers. The uterine peristaltic wave frequency will be the mean of the results from each observer.
214477602|NCT06600880|DRUG|MK-6240|\[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection. The radiotracer \[18F\]MK-6240 is supplied in a sterile, ready-to-use solution, direct from the Columbia University PET Center. It is supplied for a targeted calibration time, the precise volume to be administered at a given time can be calculated based on the decay of F-18. Only personnel properly trained in the handling and administration of radioactive materials should handle \[18F\]MK-6240. Usual radiation protection procedures should be used for handling radiotracers, including shielding (lead or tungsten containers/shields), and personal protective equipment including gloves. There are no specific procedures required for the handling of \[18F\]MK-6240. The expiry of \[18F\]MK-6240 is eight hours from the time at End of Synthesis (EOS).
214477603|NCT06600880|DRUG|Dotarem|FDA-approved medication. Dotarem will be handled in accordance with the CUMC Research Pharmacy procedures and NYP policy P168, Version 4. Dotarem will be used according to its labeling. 0.2 ml/kg.
214477604|NCT06600880|DIAGNOSTIC_TEST|Blood draw|Blood samples will be collected through an intravenous catheter or a finger prick during screening, on the day of the FUS treatment and the follow up examinations (week 3 and month 3). These samples will be processed to assess any blood content changes induced by the focused ultrasound treatment.
214887721|NCT03519412|DRUG|temozolomide (induction),|temozolomide is administered to MGMT promoter methylation-positive MMRp patients orally, once daily, at the dose of 150-200 mg/m2/day for 5 consecutive days of each treatment cycle A treatment cycle will comprise 5 days of temozolomide administration (Day 1 to 5) followed by 23 days of rest for a total of 28 days (4 weeks) period (dose-schedule: 150 mg/m2 day 1-5 q28),until disease progression or unacceptable toxicity whichever comes first.
214887722|NCT03519412|BIOLOGICAL|pembrolizumab (treatment)|pembrolizumab is administered to MGMT-IHC-negative, MGMT promoter methylation-positive MMRp patients with TMB\>20 Mut/Mb after Temozolomide treatment, and to MMRd. Patients receive pembrolizumab IV , 200 mg Q3W, Day 1 of each 3 week cycle for maximum 35 cycles, until disease progression or unacceptable toxicity whichever comes first.
214887723|NCT05408130|DEVICE|Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|All patients randomized to intervention arm will receive 5 cycles of ischemia/reperfusion in non-paralysed upper limb or if no upper limb paralysis non-dominant arm. They will receive it once daily for a period of 7 days or during hospital stay whichever is shorter.
214887724|NCT05408130|DEVICE|Sham Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|In the sham group subjects will receive pressure sensation by keeping the pressure at 30 mmHg for 3 min in both arms All patients in sham and intervention group will receive standard of care management for ischemic stroke
214887725|NCT06254716|PROCEDURE|disc resection|disc resection refers to the full-thickness resection of the lesion and the intestinal wall, usually anterior rectal wall. During the operation, the anterior intestinal wall is opened and then sutured or anastomosed with a stapler. Segmental bowel resection for the treatment of intestinal endometriosis was first reported by Redwine and Sharpe in 1991, which requires the maximum removal of endometriosis lesions.
214887726|NCT06254716|PROCEDURE|segmental resection|Segmental bowel resection for the treatment of intestinal endometriosis was first reported by Redwine and Sharpe in 1991, which requires the maximum removal of endometriosis lesions.
214887727|NCT03242408|DRUG|LPCN 1021|Oral testosterone undecanoate
214887728|NCT04427540|DRUG|Oxytocin|Oxytocin 10 micrograms IM
214293793|NCT00478569|DRUG|Parathyroid Hormone (PTH) (1-84)|Adherence to PTH(1-84) treatment in Usual Clinical Settings
214293794|NCT01486914|DRUG|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
214887729|NCT03386552|DRUG|Isifera+|Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer
214887730|NCT03386552|DRUG|Buffer|Pertubation solution of Ringer-Acetate buffer
214293795|NCT02566226|DRUG|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
214293796|NCT02566226|DRUG|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
214293797|NCT03021421|PROCEDURE|intratechal (subarachnoidal )injection|10 mg (2 cc) intrathecal single shot injection
214293798|NCT03021421|PROCEDURE|lombar plexus and sciatic nerve injection|USG -guided lumbar plexus visualised and 20 ml local anaesthetic mixture (15 cc %0,5 Bupivacaine Hydrochloride 5 cc and %2 Lidocaine 5 cc ) for lombar plexus single shot injection
214293799|NCT00454610|BEHAVIORAL|FLOW|
214293800|NCT00454610|BEHAVIORAL|SelfHelp|
214293801|NCT05947812|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
214293802|NCT05947812|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
214293803|NCT01317082|DEVICE|Acupressure|P 6 Pressure Point
214293804|NCT06793748|COMBINATION_PRODUCT|PEP-TISSEEL|Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)
214293805|NCT06793748|DRUG|TISSEEL Fibrin Sealant KIT|Fibrin Sealant (TISSEEL® VH SD Kit)
214293806|NCT06793748|COMBINATION_PRODUCT|PEP-TISSEEL|Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)
214293807|NCT06793748|DRUG|TISSEEL Fibrin Sealant KIT|Fibrin Sealant (TISSEEL® VH SD Kit)
214293808|NCT02070692|DRUG|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
214293809|NCT02070692|DRUG|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
214887731|NCT04321629|COMBINATION_PRODUCT|autologous adipose tissue transfer|experimental group: liposuction, adipose tissue preparation and intra-articular injection
214887732|NCT04321629|COMBINATION_PRODUCT|PRP injections|control group: blood collection, blood preparation and intra-articular PRP injection
214887733|NCT05514561|DIAGNOSTIC_TEST|Fecal calprotectin|To calculate the diagnostic accuracy of fecal calprotectin in the diagnosis of significant ileocolonic lesions
214887734|NCT05514561|DIAGNOSTIC_TEST|Fecal immunochemical test|To calculate the diagnostic accuracy of the fecal immunochemical test in the diagnosis of significant ileocolonic lesions
215048540|NCT05818826|DRUG|normal saline solution|Prepare 100 ml of normal saline solution, packed out in the same format, dose, and administration of the drug were exactly the same as in the conventional cessation group.
214293810|NCT04615923|DRUG|Pridopidine|"Administration: Oral~Dose: 45mg twice daily"
214293811|NCT04615923|DRUG|Matching Placebo|"Administration: Oral~Dose: one capsule twice daily"
214293812|NCT02597348|PROCEDURE|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
214293813|NCT03618992|OTHER|Cholesterol-containing moisturizers|Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
214293814|NCT00933309|DRUG|Exemestane|25 mg tablets orally once a day
214477605|NCT06600880|DEVICE|UR5e|Universal Robots robotic arm used for the accurate positioning of the neuronavigation-guided single-element focused ultrasound transducer with respect to the patient's head.
214477606|NCT06600880|DIAGNOSTIC_TEST|Urine test|Urine test required following the MRI and PET Centers policy used clinically for pregnancy screening
214887735|NCT00703651|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years
214887736|NCT00703651|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years.
214887737|NCT00703651|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.5 mL, IM. 1 injection/year for 3 years
214887738|NCT06582017|BIOLOGICAL|QXL138AM Injection every 2 weeks by IV Infusion|masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a
214887739|NCT04122040|DRUG|Roxithromycin 300 MG|Roxithromycin 300 mg oral per day
214293815|NCT00933309|DRUG|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
214293816|NCT04142853|OTHER|Training intervention + Dance intervention|Training intervention + Dance intervention
214293817|NCT05877794|DEVICE|central venous catheter insertion|All patients were under trendlenburg position (10 degrees) and disinfected for CVC catheterization. After attaching 2 suture wings of 18G single catheter set to the insertion needle in the 7 Fr or 8 Fr central catheter set, check the IJV to be punctured with an ultrasonic probe. The IJV is punctured using a cross sectional image confirmed at the cricoid cartilage level. After confirming the needle tip on the ultrasound image and blood coming out, the guide wire is mounted on the IJV and then a CVC catheter (arrow international INC) ., USA) is inserted. All actions are performed by a specialist who has more than 30 CVC catheterization experiences using ultrasound, and the occurrence of side effects and the time from puncture to guide wire entry are recorded by another researcher. After the procedure, the researcher who directly performed the procedure records the difficulty or difference compared to when using a conventional needle that does not have a suture wing installed.
214293818|NCT05411679|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
214887740|NCT04122040|DRUG|Placebo|Placebo one table oral once dialy
214887741|NCT03241641|DRUG|Tenofovir Alafenamide|25mg, Daily Oral
214887742|NCT03241641|DRUG|Tenofovir Disoproxil Fumarate|300mg, Daily Oral
215048541|NCT05818826|DRUG|Hydrocortisone and normal saline solution|Prepare hydrocortisone with normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min.
214477607|NCT06600074|BEHAVIORAL|Back care advice|All patients in both groups will be advised to use proper lifting techniques, avoid prolonged sitting or standing, maintain a healthy weight, quit smoking, practice good posture, take breaks, spread housekeeping duties over the whole week, and sleep in supportive positions.
214477608|NCT06600074|OTHER|Postural correction exercises|All patients in both groups will be instructed to perform postural correction exercise. They will be performed from different positions (crock lying, supine lying, supine, sitting and standing position). They will lie in crock lying position for example and the physical therapist will instruct them to do chin in , open out ribs through costal breathing, contract abdominal muscles, contract glutei, hold for 6 seconds and relax and repeat 10 times.
214477609|NCT06600074|OTHER|Retro-walking|Patients in the experimental group only will practice walking backward on a treadmill, starting with a 5-minute warm-up at a self-selected speed, then gradually increasing speed from 1.2 to 1.6 m/s based on comfort and progress.
214477610|NCT06599931|DEVICE|tACS Transcranial alternating stimulation|session of 20 minutes
214887743|NCT02834325|PROCEDURE|mechanical ventilation|
214887744|NCT04757597|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 10-14 days after enrollment.
214887745|NCT02548156|OTHER|Test Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
214477611|NCT06588595|DRUG|Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81-mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients with an ABCD-GENE 10 or more will continue prasugrel 10 mg qd/ticagrelor 90 mg BID and drop aspirin; and patients with an ABCD-GENE less than10 will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd.
214477612|NCT06588595|DRUG|Aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81 mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90 mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd, irrespective of ABCD-GENE score.
214477613|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, single dose
214477614|NCT06597422|DRUG|STSP-0902 Placebo|Eye drop, single dose
214477615|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, three times daily for a total of 8 days
214477616|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, six times daily for a total of 8 days
214477617|NCT06597422|DRUG|STSP-0902 Placebo|Eye drop, multiple doses
214477618|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, single dose, tear samples will be collected
214887746|NCT02548156|OTHER|Reference Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
214887747|NCT02548156|OTHER|Comparator Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
214887748|NCT02548156|OTHER|Orange Juice|Teeth will be rinsed with orange juice followed by rinsing with de-ionised water in test dentifrice and comparator dentifrice arms.
214477619|NCT06601842|DEVICE|ICP monitoring|ICP monitoring
214477620|NCT06820359|OTHER|Bowel Preparation|Individuals will perform a bowel preparation using a Fleet saline enema.
214477621|NCT06820359|OTHER|No bowel preparation|Subjects will not be required to perform bowel preparation before surgery.
214887749|NCT02548156|OTHER|De-ionised water|Teeth will be rinsed with de-ionised water followed by reference dentifrice and followed by rinsing with orange juice in test dentifrice and comparator dentifrice arms.
214887750|NCT06512753|DRUG|Hydroxychloroquine|HCQ (15) is administered orally at a dosage of 400 mg daily.
214887751|NCT06512753|DRUG|Methotrexate|MTX (16) is given at a dose of 15 mg per week, orally or subcutaneously. Additionally, folate supplementation is administered concurrently as part of standard care, with folate 10 mg/week administered 24 hours after MTX intake.
214887752|NCT02937311|OTHER|NMES|Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles
214887753|NCT02937311|OTHER|Kinesiotape|The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.
214887754|NCT02937311|OTHER|Standardized Physiotherapy|All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
214887755|NCT05348083|PROCEDURE|ESPB|Echo-guided bilateral ESPB performed at T9 level at the end of surgery with a mixture of ropivacaine 0.375% and epinephrine 5 mcg/mL 20 mL each side.
214668069|NCT03251547|DRUG|NovoSeven|To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
214668070|NCT05907915|DEVICE|low level laser therapy|They recieved LLLT 1 session daily, 3 session per week for 3 weeks,with the following parameters( 650 nm wavelength, 150 mw power output, 0.25 cm2 radiation area, 0.6 W/cm2 power density, continuous mode, 2 j/ cm2, 90 seconds / cm2) in addition to the conventional medical treatment and traditional wound care (dressing)
214887756|NCT00581750|OTHER|Tissue specimen|Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
214887757|NCT02323425|DEVICE|Remote ischemic postconditioning|Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
214887758|NCT03896529|BEHAVIORAL|Anticipatory psychological stress|Unpredictable delivery of low-level electrical stimulation to left ankle periodically throughout psychology tasks (virtual navigation). Established procedure for inducing anticipatory stress.
214887759|NCT01068262|DRUG|Odanacatib|Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
214887760|NCT01068262|DRUG|Comparator: Placebo|Oral Placebo tablet administered once weekly for 4 consecutive weeks
214887761|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
214887762|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
214887763|NCT06496880|DIETARY_SUPPLEMENT|Oxyjun TM|One capsule daily to be taken after breakfast for 56 days
214887764|NCT06496880|DIETARY_SUPPLEMENT|Placebo|One capsule daily to be taken after breakfast for 56 days
214887765|NCT00452556|DRUG|Docetaxel|Weekly
214887766|NCT00452556|DRUG|Leuprolide Acetate (Eligard®)|2.5 years
214887767|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
214887768|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
214887769|NCT04828174|DRUG|anti-TRBC1 CAR-T cell therapy|TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
214887770|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
214887771|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
215048542|NCT01313507|BIOLOGICAL|NewGam|The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
214668071|NCT05907915|BEHAVIORAL|placebo|They received placebo laser 1 session daily, 3 session per week for 3 weeks in addition to the conventional medical treatment and traditional wound care (dressing)
214668072|NCT05430867|DRUG|Memantine Oral Tablet|Memantine 20mg once-daily
214668073|NCT05430867|DRUG|GV-971 capsule|GV-971 450mg twice a day
214668074|NCT04124367|DRUG|Cerebrolysin|30 ml once daily (+70 ml 0.9% saline)
214668075|NCT04124367|DEVICE|non-invasive brain stimulation|2 mA/35 cm² for 2x20 minutes, once daily
214668076|NCT04124367|DRUG|Placebo|100 ml once daily 0.9% saline
214887772|NCT03759938|DRUG|Direct oral anticoagulant (DOAC)|Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
214887773|NCT03314909|PROCEDURE|Hemodialysis|Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.
214887774|NCT03314909|PROCEDURE|Hemoperfusion|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
214887775|NCT03314909|PROCEDURE|HP-HD|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
214887776|NCT03581019|PROCEDURE|uterus transplantation|uterus transplantation from deceased donor
214887777|NCT03335137|DIAGNOSTIC_TEST|Drug Level Monitoring|Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission
214887778|NCT04338360|BIOLOGICAL|COVID-19 convalescent plasma|COVID-19 convalescent plasma
214887779|NCT04099004|OTHER|Neural Imaging|During the acquisition of magnetic resonance (MR) images, the study participants will lie on the scanner table. For most portions of MR acquisition, the study participants will be instructed to lie still. For other parts of the acquisition, study participants will be asked to complete a combined knee and hip flexion/extension movement and a quadriceps contraction task in which they will be asked to 'squeeze' their quadriceps while keeping the rest of their body still. For the last 15 minutes of MR acquisition, the researcher will place one hand above the participants' knee and apply intermittent pressure to their quadriceps and medial aspect of the patella. Pain scales will be administered after every fMRI task to assess subjective perceptions of pain. Peripheral pulse oximetry and respiration waveforms will be collected for data analysis in order to minimize the potential confounding effect from the physiological changes.
214887780|NCT05044702|OTHER|Retro walking|Retro walking will be performed on treadmill for 15 min per day for 3 days per week for 4 weeks at self-paced speed.
214887781|NCT05044702|OTHER|conventional physical therapy|"hot pack for 10 mints and conventional exercise program Conventional physiotherapeutic exercise program which consist of exercises such as~* prone leg extension~* prone lying chest elevation~* prone extension with alternate arm and leg lift~* supine bridging, bridging with one leg lift Each exercise will be performed as 2 sets of 12 repetitions of each exercise, each exercise position maintained for 10 s, and a rest of 1 min between the sets will be perform. No external load/resistance will be provided for the exercises, and the participants will be perform the exercise within their available range of motion"
215048543|NCT02525640|DEVICE|Hearing Aid|Hearing aid comparison
215048544|NCT04412681|DIAGNOSTIC_TEST|Enhanced PE Screening|To better identify women at risk for pre-eclampsia during pregnancy.
215048545|NCT04236089|DEVICE|robotic hand|mirror therapy with robotic hand
214887782|NCT03450473|DEVICE|SurgiMend® MP|SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
214887783|NCT01153425|OTHER|Virtual Bone Biopsy|MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
214887784|NCT01153425|DRUG|Teriparatide|Participants are clinically indicated for treatment.
214887785|NCT01153425|DRUG|Zoledronic Acid|Participants are clinically indicated for treatment.
214887786|NCT00814268|DRUG|Clopidogrel|75mg tablet, oral administration once daily
214887787|NCT00814268|DRUG|Clopidogrel placebo|Matching tablet, oral administration once daily
214887788|NCT00814268|DRUG|Aspirin|100mg tablet, oral administration once daily
214887789|NCT00956072|DRUG|imatinib mesylate|Patients receive imatinib mesylate
214887790|NCT00956072|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
214887791|NCT05172115|PROCEDURE|Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA)|Conventional catheter-directed thrombolysis with fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours
214887792|NCT05172115|DRUG|Enoxaparin|Subcutaneous enoxaparin twice-daily (1mg/kg)
214887793|NCT00165555|DRUG|Cisplatin|Given as a heated one-hour lavage to the hemithorax after surgery.
214887794|NCT00165555|DRUG|Sodium Thiosulfate|Given intravenously over 6 hours after the cisplatin lavage.
214887795|NCT01232452|DRUG|Pemetrexed|Administered intravenously (IV)
214887796|NCT01232452|DRUG|Cisplatin|Administered IV
214887797|NCT01232452|DRUG|Cixutumumab|Administered IV
214887798|NCT01662687|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy."
214668077|NCT04124367|DEVICE|sham intervention|0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
214668078|NCT00230763|PROCEDURE|GSS questionnaire|D0, D30 and D84
214668079|NCT00230763|PROCEDURE|IOP|D0, D30 and D84
214887799|NCT01662687|DRUG|Kytril inj.+Kytril tab.|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~* Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~* Kytril tab. 1mg: administered twice a day by orally at Day 2\~4."
214887800|NCT02807337|DRUG|Caphosol|
214887801|NCT02807337|DRUG|0,9% NaCl|
214887802|NCT04492228|OTHER|Ketogenic diet|Eucaloric Ketogenic diet % composition : protein (27%), lipids (67%), carbohydrates (6%: \<30g/day). In pts in artificial nutrition : Eucaloric Ketogenic parenteral nutrition % composition : aminoacids (27%), lipids (67%), carbohydrates (6%: \<30g/day)
214887803|NCT05886205|DRUG|iPSC-Exos|iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
214887804|NCT05024747|DRUG|NicoDerm CQ patch (GSK Dungarvan)|A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm\^2) surface area will be placed topically.
214887805|NCT05024747|DRUG|NicoDerm CQ (Alza)|A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm\^2 surface area will be placed topically.
214887806|NCT03073824|DEVICE|vSculpt|Pelvic Floor Toning and Vaginal Rejuvenation Device
214887807|NCT04667624|DRUG|Twynsta|Manufactured by Boehringer Ingelheim
214887808|NCT04667624|DRUG|LodineT|•Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea
214887809|NCT05927870|PROCEDURE|pigtail|placing a small amount of local anaesthetic subcutaneously at the site of the gallbladder, a skin incision was made through which the catheter was introduced. A 7-Fr pigtail catheter was used in all cases . If possible, the catheter was introduced into the gallbladder after passing through the liver. The catheter was thereafter fixed, either by an internal locking device or by means of a suture to the skin. The catheter was rinsed with saline solution daily in order to prevent clogging.
214887810|NCT02728700|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
214887811|NCT02728700|OTHER|Laboratory Biomarker Analysis|Correlative studies
214887812|NCT02728700|DRUG|Mycophenolate Mofetil|Given IV
214887813|NCT02728700|DRUG|Sirolimus|Given PO
214887814|NCT00257400|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
214887815|NCT00257400|BEHAVIORAL|Individual Psychotherapy|Individual Psychotherapy
214887816|NCT04019171|BEHAVIORAL|exercise training|6 weeks of physical exercise training. 3 sessions per week. Session duration : 40 minutes. Self-regulated exercise intensity using Borg's ratings of perceived exertion (RPE)
214887817|NCT02172807|DRUG|Tiotropium low|Tiotropium 18 µg inhalation capsule
214887818|NCT02172807|DRUG|Tiotropium high|Tiotropium 36 µg inhalation capsule
214887819|NCT02172807|DRUG|Placebo MDI|Placebo metered dose inhaler (MDI)
214668080|NCT00230763|DRUG|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
214887820|NCT02172807|DRUG|Placebo inhalation capsule|
214887821|NCT02172807|DRUG|Oxitropium|Oxitropium MDI (100 µg/puff)
214887822|NCT04893473|DEVICE|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.
214887823|NCT05081050|OTHER|Only Follow-up|No intervention is planned.
214477622|NCT06597981|BEHAVIORAL|Dyadic empowerment-based sport stacking|For the intervention group, the care dyads will receive an 18-week dyadic empowerment-based sport stacking program, which is divided into two phases: the active phase (weeks 1-12) and the maintenance phase (weeks 13-18). In the active phase, the care dyads will engage in three online sessions in small groups (3-5 dyads/group) and three check-up/support sessions. Three online sessions will be scheduled at weeks 1, 3, and 9 during the 12-week active phase. They will also be required to engage in self-practice at home for at least 30 minutes per day, five times per week during this time according to their training schedule. In the maintenance phase, there will be three online sessions in small groups (3-5 dyads/group). Three online sessions will be scheduled at weeks 13, 16, and 18. The dyads will continue their self-practice at home (at least 30 minutes/day, five times/week) for 6 weeks.
214477623|NCT06597981|OTHER|Basic education|Participants in the control group will receive basic education on dementia caregiving, which will comprise three group-based (3-5 dyads/group) online meetings in the same schedule as the intervention group (1st, 3rd, 9th week).
214477624|NCT05070741|BEHAVIORAL|Heat Therapy|Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (\~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged \~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted \~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
214477625|NCT06842992|DRUG|NH102|5 mg twice daily over 6 weeks, followed by a 1-week tapering period.
214477626|NCT06842992|DRUG|NH102|10 mg twice daily over 6 weeks, followed by a 1-week tapering period.
214477627|NCT06842992|DRUG|NH102|15 mg twice daily over 6 weeks, followed by a 1-week tapering period.
214477628|NCT06842992|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule|30 mg twice daily for 6 weeks, followed by a 1-week tapering period.
214477629|NCT06842992|DRUG|Placebo|Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.
214887824|NCT04051203|BIOLOGICAL|Autologous Platelet Rich Plasma Injection|60mL of blood will be drawn from the antecubital vein and processed via centrifugation. Samples will be centrifuged as per manufacturer instructions, yielding 5mL of PRP.
214887825|NCT04051203|DRUG|Depo-Medrol and lidocaine|Steroid injections will be prepared to include 20mg Depo-Medrol and 2mL 2% lidocaine.
214887826|NCT04051203|OTHER|Normal Saline|2mL normal saline.
214887827|NCT05824624|OTHER|ANIMAL-ASSISTED INTERVENTION|It will be ensured that the child is introduced to the goldfish when he is lying in the observation room, that the child will name the fish, and that he will communicate and feed the fish during his stay. Thus, it is aimed to turn the attention of the child to the goldfish while in the emergency room, to distract the child with the fish while all nursing interventions are presented, and to reduce the fear.
214477630|NCT05029336|BIOLOGICAL|Depletion of CD3/CD19 in an autologous stem cell transplant|The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.
214477631|NCT06842069|BEHAVIORAL|Decision Aid Supported Education|Dialysis Education
214668081|NCT00230763|PROCEDURE|Visual acuity|D0 and D84
215048546|NCT02694601|DIETARY_SUPPLEMENT|Control|4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
214293819|NCT05411679|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor) Other names: Lynparza
214293820|NCT01223989|OTHER|hypocaloric diet balanced + nutrition education + ruled physical activity|
214668082|NCT01926886|DRUG|Trastuzumab|Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
214668083|NCT01450540|DEVICE|REMstar Auto A-Flex|Standard CPAP
214887828|NCT05824624|OTHER|Routine Care|Routine nursing care will be provided.
214887829|NCT00494702|PROCEDURE|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
214887830|NCT00494702|PROCEDURE|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
215048547|NCT02694601|DIETARY_SUPPLEMENT|Caffeine low dose|4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
215048548|NCT02694601|DIETARY_SUPPLEMENT|Caffeine high dose|4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
215048549|NCT04858399|DIAGNOSTIC_TEST|Evaluation|To examine the differences in respiratory functions, orofacial muscle tone changes, anxiety/ depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
215048550|NCT03168802|PROCEDURE|MRgFUS ablation|Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
215048551|NCT03168802|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation therapy under C-arm navigation for facet joint syndrome.
214293821|NCT02282020|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
214293822|NCT02282020|DRUG|Single agent chemotherapy|Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
214477632|NCT06842069|BEHAVIORAL|Dialysis Education for Urgent Dialysis Start Patient|"Education provided in two consequtive educational session. During first 30-minute session, the aim of the training program was explained with an overview of CKD, sparing time for potential patient questions. The second training day was scheduled according to patients' agenda and their next hemodialysis session.~Second Interview: RRT options were explained in the 30-minute , followed by interactive discussion with patients, ensuring that patients understood the information. When the training was completed, a guidebook (Treatment Options in Kidney Failure-Conscious Choice, Conscious Start) was distributed to participants. The third interview date and time was scheduled with the patients in the DTSEP group."
214477633|NCT06842914|OTHER|postural training|postural training
214477634|NCT05786040|PROCEDURE|Biopsy|Undergo biopsy
214887831|NCT01791309|DRUG|combination panitumumab and vemurafenib|Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
214293823|NCT04843423|DRUG|Cariprazine|"At the screening visit, those who are eligible will enter an open-label trial with cariprazine in doses ranging from 1.5mg to 3 mg. The study will begin with a single week of cariprazine 1.5 mg oral tablets. After the first week the participants' dosage may be increased up to a maximum of 3 mg daily. This dose will remain fixed after 4 weeks of treatment until week 8, at which time the medication will be discontinued.~Because the drug is not yet available to market in Canada, participants will be dispensed the drug in appropriately labelled 7-day tablet containers with the appropriate dose, including 3 additional tablets to account for scheduling conflicts. Participants will be instructed to return the tablet containers at each Study Visit in order to assess drug compliance. They will then be newly dispensed the appropriate quantity according to their next scheduled study visit."
214293824|NCT03506607|OTHER|Exercise in hypoxia 1500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
214477635|NCT05786040|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214477636|NCT05786040|PROCEDURE|Computed Tomography|Undergo CT
214477637|NCT05786040|PROCEDURE|Positron Emission Tomography|Undergo PET
214477638|NCT05786040|BIOLOGICAL|Rituximab|Given IV or SC
214477639|NCT05786040|BIOLOGICAL|Tafasitamab|Given IV
214477640|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with polyphenol supplement (PPS)|Test meal with polyphenol supplement
214477641|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with placebo|Test meal with placebo (maltodextrin) supplement
214477642|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with PPS|Test drink with polyphenol supplement
214477643|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with placebo|Test drink with placebo (maltodextrin) supplement
214477644|NCT05657795|DEVICE|Closed-loop automated oxygen control (Oxygenie, SLE6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
214887832|NCT03022370|BEHAVIORAL|Stepping Stones and Creating Futures|"Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending."
214887833|NCT00894712|OTHER|Sulforaphane-containing broccoli sprout extracts (active agent)|Topical application, prepared with acetone, 280 nml daily, 3 times a week.
214887834|NCT00894712|DEVICE|Vehicle (inactive control)|Subjects will have measurements of skin erythema using a device called a chromometer
214887835|NCT02897024|OTHER|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
214477645|NCT05443685|DRUG|ADX-629|"Particpants 10-50 years old will be administered ADX-629 250 mg tablets twice daily.~Participants 5-9 years old will be administered ADX-629 125 mg tablets twice daily."
214477646|NCT06824831|DRUG|Patients receive microporous polysaccharide hemospheres.|Patients were randomized to receive microporous polysaccharide hemospheres, after mastectomy was done.
214477647|NCT06824831|DRUG|Patients DO NOT receive microporous polysaccharide hemospheres.|Patients were randomized to NOT receive microporous polysaccharide hemispheres after mastectomy was done.
214887836|NCT01002924|DRUG|EC145|EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
214887837|NCT01019434|DRUG|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
214887838|NCT01019434|DRUG|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
214668084|NCT01450540|DEVICE|modified REMstar Auto A-Flex with AGPAP|Modified device -Software upgrade to GP 12
214668085|NCT00430534|BIOLOGICAL|EBV vaccine (268664)|
214668086|NCT04562363|PROCEDURE|Suturing of a laparotomic wound with modified methods|Suturing the white line of the abdomen with the help of developed techniques aimed at preventing hernias and eventrations
214477648|NCT06825351|BEHAVIORAL|Psychological First Aid versus Dialectal behavioral Intervention|"PFA is an immediate, supportive intervention aimed at helping individuals in distress. It focuses on providing emotional support and practical assistance in the aftermath of a crisis.~Key Components:~Safety and Comfort: Ensuring that participants feel safe and secure in their environment.~Active Listening: Engaging in empathetic listening to validate participants' feelings and experiences.~Assessment of Needs: Identifying immediate needs and concerns, including emotional and practical aspects.~Information and Resources: Providing clear information about available resources, such as mental health services and coping strategies.~Encouragement of Social Support: Guiding participants to connect with friends, family, or support groups."
214477649|NCT06824753|OTHER|oxygenator and tubing set blood transfusion|blood from the oxygenator and tubing set was collected into a 1000 cc Ringer lactate bag, originally used as the pump's priming solution, under sterile conditions using a roller pump
214477650|NCT06819033|DEVICE|PBM Therapy|patients will receive PBM therapy using the Biolase Epic pro laser. An average power of 0.6w (peak power = 80w, rep. rate= 20Hz). Each aphthous ulcer will be irradiated one time for a total of 30 seconds via continuous wave.
214477651|NCT06819033|DRUG|Maalox plus Benadryl|1:1 mixture of Maalox and Benadryl will be applied to the ulcer as needed for pain. Applications typically will be applied before eating to form a dissolvable oral band-aid that lasts for up to 30 minutes. 10 milliliters of 1:1 Maalox: Benadryl solution will be provided to the family. During the presenting appointment, the patient/family will be shown how to use the 1:1 Maalox: Benadryl solution. It will be applied topically with no rinsing needed.
214887839|NCT01416519|PROCEDURE|Continuous Positive Airway Pressure (CPAP) facial mask|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
214887840|NCT01416519|PROCEDURE|Assisted deep inspiration technique|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
214887841|NCT00699816|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
214887842|NCT00371436|PROCEDURE|Progressive Audiologic Tinnitus Management|The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
215048552|NCT00527618|DRUG|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
215048553|NCT00527618|DRUG|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
215048554|NCT04642521|DEVICE|Jamar hydraulic hand dynamometer|"The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg."
215048555|NCT00750230|DIETARY_SUPPLEMENT|NEM|see Treatment Arm
215048556|NCT01198821|DRUG|Sodium bicarbonate (g/kg/day)|Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0
215048557|NCT01198821|DRUG|Gemcitabine (mg/m²)|Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
214477652|NCT06819436|DRUG|Dexamethasone|Intravenous dexamethasone 8mg given to participants before spinal anesthesia
214477653|NCT06819436|OTHER|Placebo|Intravenous placebo given to the participants before spinal anesthesia
214477654|NCT06264232|DEVICE|Cataract Surgery|Bilateral removal of age related cataractous lenses with the implantation of intraocular lenses to improve visual acuity.
214477655|NCT05875922|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
214477656|NCT05875922|DEVICE|IOL implantation active comparator (TECNIS Eyhance)|Implantation of EDOF IOL TECNIS Eyhance
214887843|NCT00371436|PROCEDURE|Usual Care|Typical audiologic care that would be received in a VA Audiology Clinic.
214887844|NCT02251600|DRUG|Deflazacort|Oral deflazacort administered once daily at 0.9 mg/kg for eight days
214887845|NCT02962518|DEVICE|Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws."
214887846|NCT02962518|PROCEDURE|Fillet Technique|"Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed."
215048558|NCT05252286|OTHER|video watching|"Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance."
215048559|NCT05252286|OTHER|paper group|In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
215048560|NCT05252286|OTHER|oral education group|the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
215048561|NCT05249205|BEHAVIORAL|REHIT1|This intervention involves a single REHIT exercise session per week. REHIT involves 10 minutes of unloaded cycling on a stationary bike interspersed with two 20-second 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
214668087|NCT03968146|PROCEDURE|Erector Spinae Plane Block|The linear multi-frequency 6-13 megahertz transducer will be used. In the prone position,under aseptic conditions, the probe will be placed in a longitudinal position 2-3 cm lateral to the vertebral column. The transverse processes of the vertebrae at (mid) level of surgery, the Erector Spinae muscle and the psoas muscle are identified. A 22 gauge echogenic needle will be inserted in an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, A test dose of 5% dextrose in water can expand the fascial plane and confirm needle-tip location prior to injection of local anaesthetic. Then, 0.5 ml/kg of bupivacaine 0.25% with 0.1 mg/kg dexamethasone and adrenaline 1 : 200000 will be injected between erector spinea muscle and transverse process, taking in consideration not exceeding the toxic dose of bupivacaine; 4 mg/kg . the same procedure will be repeated on the contralateral side.
214887847|NCT02962518|DRUG|Triamcinolone|All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
214887848|NCT04727385|DEVICE|Double Crosslink Microgel|"DXM hydrogel is a pH responsive Double Cross-Linked microgel based on single internally cross-linked microspheres (comprising a methacrylic acid-methyl methacrylate-ethylene glycol dimethacrylate copolymer)~The DXM gel is injected into the intervertebral disc (IVD) space via a standardised procedure similar to the routinely-performed Discography procedure. The disc approach described in the discography procedure has been reported to allow the injection of a solution in the centre of the disc. The injection of the gel takes about 2 min."
214887849|NCT02454933|DRUG|AZD9291|Once daily tablet 80 mg
214887850|NCT02454933|DRUG|MEDI4736|10mg/kg q2w (IV) infusion
214887851|NCT01311687|DRUG|pomalidomide|4 mg pomalidomide capsules administered orally
214887852|NCT01311687|DRUG|Dexamethasone|40 mg dexamethasone (or 20 mg for participants \> 75 years of age) tablets administered orally
214668088|NCT03968146|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
214887853|NCT02260661|DRUG|AZD8835|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
214887854|NCT02260661|DRUG|AZD8835|AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
214887855|NCT02260661|DRUG|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
214887856|NCT02260661|DRUG|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
215048562|NCT05249205|BEHAVIORAL|REHIT2|This intervention is the same as that for the REHIT1 intervention, but with 2 sessions per week instead of 1.
214887857|NCT01057511|DRUG|Crinone 8%|Crinone 8%, 90mg / p.v. / Qd, 7 days totally.
214887858|NCT01057511|DRUG|Progesterone|Progesterone 20mg/ i.m./ Qd, 7 days totally.
214887859|NCT03098160|DRUG|Evofosfamide|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
214887860|NCT03098160|DRUG|Ipilimumab|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
214887861|NCT05915260|DIAGNOSTIC_TEST|All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion|This is a observational follow up study accordingly all subjects will undergo the same examinations
215048563|NCT02706925|DRUG|BI 443651|
215048564|NCT02706925|DRUG|Placebo|
215048565|NCT01111162|BIOLOGICAL|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
215048566|NCT04877327|PROCEDURE|Ablation|Cryotherapy and radiofrequency
215048567|NCT04731896|PROCEDURE|Amniotomy|artificial rupture of the amniotic sac
215048568|NCT04773548|OTHER|VR-JIT|Job interview with virtual interviewer
215048569|NCT04612829|DEVICE|Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic
215048570|NCT00039169|DRUG|ortataxel|
215048571|NCT04765566|DEVICE|Endovascular revascularization of peripheral arteries|Endovascular revascularization of peripheral arteries involves placement of a self-expanding Nitinol Stent encapsulated with ePTFE in diseased vessel segments
215048572|NCT06103344|BEHAVIORAL|4-7-8 Breathing Exercise Training|Participants in the intervention group will be taught 4-7-8 breathing exercises collectively, and the training will be repeated on specified days (twice a week for a total of 4 weeks). During the training, it will be checked whether each participant in the intervention group can perform the breathing exercise correctly and feedback will be given. Participants who fail to implement the exercise will be excluded from the study. 4-7-8 breathing exercise training, prepared in accordance with the literature, will be given by the assistant researcher who has training and certification in breathing exercises. Training will be planned in an empty classroom, for approximately 20 minutes and at the students' end time. Thus, educational activities in the institution will not be disrupted.
215048573|NCT00608049|BEHAVIORAL|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
215048574|NCT00608049|BEHAVIORAL|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
215048575|NCT00608049|BEHAVIORAL|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
215048576|NCT00608049|BEHAVIORAL|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
214293825|NCT03506607|OTHER|Exercise in hypoxia 2500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
214293826|NCT03506607|OTHER|Exercise in normoxia|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
214887862|NCT01644682|OTHER|IWFPL|Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
214293827|NCT00492687|DRUG|carboplatin|
214293828|NCT00492687|DRUG|tamoxifen citrate|
214293829|NCT00492687|DRUG|temozolomide|
214887863|NCT01644682|OTHER|IDWL|Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
214887864|NCT01644682|OTHER|ITN|Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
214887865|NCT03017768|DIETARY_SUPPLEMENT|Acute tryptophan depletion|an amino-acid mixture will be administered without tryptophan (active comparator). After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of depleted tryptophan levels on esophageal sensitivity
214887866|NCT03017768|DIETARY_SUPPLEMENT|Placebo|an amino-acid mixture with tryptophan (placebo mixture) will be administered. After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation
214293830|NCT00492687|PROCEDURE|adjuvant therapy|
214293831|NCT00492687|RADIATION|radiation therapy|
214293832|NCT01356745|DRUG|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
214293833|NCT01356745|DRUG|medical air|inhalation gas for inhalation use
214477657|NCT05195034|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
214887867|NCT03017768|DEVICE|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
214887868|NCT02952469|DRUG|(68Ga)PSMA-HBED-CC|Experimental radiotracer for imaging prostate cancer
214887869|NCT03856723|OTHER|Renal Replacement Therapy|"Indications for RRT were defined as previously reported.~1. Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 ;~2. severe sepsis, persistence of hypotension (for more than 6 h) despite preload optimization and use of vasopressors or catecholamines (norepinephrine or epinephrine \>0.1 μg/kg/min),~3. refractory fluid overload (worsening pulmonary edema, PaO2/FiO2 \<300 mm Hg or fluid balance \>10% of body weight),~4. low probability of rapid renal recovery according to the judgment of the intensivists and nephrologists."
214887870|NCT06550817|OTHER|Growth mindset intervention|Online intervention is implemented and it lasts about 20 minutes each time, while face-to-face intervention lasts about 30 minutes each time, and they are carried out for a total of six weeks, face-to-face or telephone intervention is implemented once every two weeks for about 15 minutes each time
214887871|NCT06550817|OTHER|E-health Program|face-to-face e-health teaching in the first 6 weeks, and telephone follow-up were conducted once a week, for about 10 minutes each time in the last 6 weeks
214887872|NCT01851083|BIOLOGICAL|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10\^6 cells/kg or 10x10\^6 cells/kg weight.
214887873|NCT01851083|OTHER|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
214887874|NCT03023072|OTHER|Incontinence Detection System|
214293834|NCT03914781|BEHAVIORAL|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
214477658|NCT05195034|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
214477659|NCT05123807|OTHER|Cytoreductive surgery|(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
214477660|NCT05416385|OTHER|Carotid Contrast Enhanced Ultrasound|Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
215048577|NCT00363311|DRUG|Dutasteride|Dutasteride 0.5mg
215048578|NCT00363311|DRUG|Matching placebo|Matching placebo
214477661|NCT02768844|DEVICE|Stochastic Vibrotactile Stimulation (SVS)|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by Wyss Institute, Harvard University, Cofab Design LLC) to provide gentle vibrations and sounds during mattress stimulations.
214477662|NCT02768844|OTHER|Control|Absence of mattress Stochastic Vibratory Stimulation (SVS)
214887875|NCT06326346|DRUG|Liporaxel|Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)
214887876|NCT03370640|DRUG|SEP-363856|An oral 25 or 50mg dose of SEP 363856
214887877|NCT01526655|PROCEDURE|Abdominal total hysterectomy|Abdominal total hysterectomy through a low transverse abdominal wall incision
214887878|NCT01526655|PROCEDURE|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
214887879|NCT03233893|OTHER|light activated calcium silicate|"for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration."
214887880|NCT03544723|DRUG|Ad-p53|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.
214887881|NCT00133965|BEHAVIORAL|Dignity Psychotherapy|At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires.will also receive three visits by a mental health professional over a period of five to seven days. You will be asked to fill out some brief questionnaires during this session which ask about feelings about your illness, symptoms, emotional reactions, and support you have available. The second meeting will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the Research Staff.The third meeting you will also be asked to fill out several questionnaires,including a specific questionnaire regarding your thoughts about the Dignity Psychotherapy Intervention. Total time commitment for this study should be approximately 120-150 minutes.
214887882|NCT00133965|BEHAVIORAL|Supportive Psychotherapy|you will receive the standard care you normally would receive, but will also receive three visits by a mental health professional over a period of five to seven days. The initial visit will take approximately 45 minutes. You will be asked to fill out brief questionnaires (described above) during this session.A second contact will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the research staff. During this second session, you will have the opportunity to discuss with a supportive research therapist issues or topics relevant to your experience of coping with cancer.The third and final contact,you will be asked you to fill out questionnaires similar to those you filled out at the beginning of the study. Total time commitment for this study should be approximately 120-150 minutes.
215048579|NCT01816425|DEVICE|Thermoplastic partial denture|
215048580|NCT01816425|DEVICE|CoCr partial denture|
215048581|NCT03249194|DRUG|Direct acting Anti-Viral Therapy using Epclusa or Zepatier|All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
215048582|NCT05843461|OTHER|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery. PIMR of the right and left pulmonary arteries will be obtained.
214668089|NCT03968146|DRUG|additional Fentanyl|patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
215048583|NCT05843461|OTHER|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
215048584|NCT05843461|OTHER|Pulmonary artery OCT|OCT of the pulmonary artery involves advancing an OCT catheter over the pressure wire to image the pulmonary artery. OCT of the right and left pulmonary arteries will be performed.
215048585|NCT01823380|PROCEDURE|Blood test|Blood test
215048586|NCT04624308|DRUG|Toripalimab|Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
215048587|NCT04882943|OTHER|questionnaires|Quality of life questionnaires
215048588|NCT03313973|PROCEDURE|with self stretching same muscle|with self stretching
215048589|NCT03313973|PROCEDURE|with self stretching of forearm muscles|without self stretching
214887883|NCT00133965|BEHAVIORAL|Standard Palliative Care|"If you are in the Standard Palliative Care group you will receive the standard care that is usually provided here at Memorial Hospital. This can include services such as consultations by physicians, nurses and other healthcare professionals. In addition, referrals to community resources and services can also be made. The study period will be between five and seven days. At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires as described above. Total time commitment for this study should be approximately 60-90 minutes."
214887884|NCT03067025|DEVICE|Actigraphy|Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
215048590|NCT00726128|DEVICE|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
215048591|NCT03175731|DRUG|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
215048592|NCT03175731|DRUG|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
215048593|NCT01027858|BEHAVIORAL|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
215048594|NCT01027858|BEHAVIORAL|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
215048595|NCT04088799|OTHER|No intervention|No intervention
214887885|NCT05214625|OTHER|Questionnaire|Questionnaire concerning artificial intelligence and its implementation in healthcare. GI patients and GI physicians will be provided with slightly different questionnaires.
214293835|NCT03724539|DEVICE|STRIPA intervention|"STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients.~Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices."
214887886|NCT00918424|DRUG|Oxcarbazepine Extended Release|OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.
214887887|NCT04753216|BIOLOGICAL|Bevacizumab|Given IV
214887888|NCT04753216|DRUG|Irinotecan Sucrosofate|Given IV
214477663|NCT05757791|DRUG|Empagliflozin|The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
214887889|NCT00310921|DRUG|Misoprostol|
214887890|NCT02142608|DRUG|BR55|Ultrasound contrast agent
214887891|NCT02365987|DIETARY_SUPPLEMENT|Interesterified blend of palm kernal and plam stearin|50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
214887892|NCT02365987|DIETARY_SUPPLEMENT|Un-interesterified blend of palm kernal and plam stearin|50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
214887893|NCT02001987|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
214477664|NCT04170374|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
214668090|NCT03968146|DRUG|Morphine|After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
214668091|NCT03968146|DRUG|rescue Morphine|Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
214668092|NCT03968146|DRUG|pethidine|After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
214887894|NCT02001987|DRUG|Methotrexate|Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
214887895|NCT02001987|DRUG|csDMARDs|csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
214887896|NCT03203317|DRUG|Insulin|2 h insulin clamp
215048596|NCT03980782|OTHER|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
215048597|NCT03009461|PROCEDURE|HAIC|Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
215048598|NCT03009461|DRUG|Sorafenib|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
215048599|NCT06388239|DRUG|Apixaban 5MG|Apixaban 5 mg Film-coated tablets
215048600|NCT03130725|PROCEDURE|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
215048601|NCT03130725|PROCEDURE|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
214887897|NCT03203317|OTHER|Exercise|Cycling exercise
214887898|NCT06074393|BEHAVIORAL|Tailored Support Group|Participants engage in a secure, confidential environment, sharing caregiving insights and knowledge. Expert-led sessions, lasting 90 minutes, occur biweekly for 16 weeks, held via Zoom and at the University of Calgary's Cumming School of Medicine. These sessions take place twice annually, emphasizing the structured nature of the support group. Weekly themes include self-care, adaptation, coping skills, emotions, anticipatory grief, forgiveness, mindfulness, boundaries, and closure. Care partners actively participate by sharing experiences and asking questions in each session.
214887899|NCT00301197|BEHAVIORAL|Behavioral Skills Maintenance|
214887900|NCT00301197|BEHAVIORAL|Social Facilitation Maintenance|
214887901|NCT02613247|DEVICE|Hylan G-F 20|Intra-articular injection of 6 mL Hylan G-F 20
214887902|NCT04763629|OTHER|Physical exercise|Patients of both arms will undergo two different modalities of exercise during the 12 weeks study period.
214887903|NCT00955929|DRUG|Placebo QHS and sildenafil and questionnaires|Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
214887904|NCT00955929|DRUG|Sildenafil and questionnaire|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window
215048602|NCT00120627|BEHAVIORAL|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
214293836|NCT03724539|OTHER|Sham intervention|Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.
214293837|NCT00534989|PROCEDURE|FDG PET|FDG PET
214477665|NCT04170374|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
215048603|NCT00120627|OTHER|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
215048604|NCT03167788|DEVICE|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
215048605|NCT03167788|OTHER|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood \& Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
215048606|NCT05634473|DRUG|Methacholine Chloride|Cholinergic agonists
215048607|NCT00442923|DRUG|Coreg|
215048608|NCT02377557|DRUG|Topical Steroids|
214477666|NCT06144411|OTHER|prevalence of preoperative malnutrition|prevalence of preoperative malnutrition
214668093|NCT03968146|DRUG|Ketorolac|patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
214668094|NCT03968146|DRUG|Acetaminophen|patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
214668095|NCT02551848|DRUG|Botulinum toxin type A|
215048609|NCT01508910|BIOLOGICAL|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
215048610|NCT01508910|BIOLOGICAL|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
215048611|NCT01508910|OTHER|Standard of care|Standard of care for refractory angina
215048612|NCT01595529|DRUG|Cefixime|Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.
215048613|NCT01595529|DRUG|Cephalexin|Cephalexin 50mg/kg/day in 3 divided doses
214477667|NCT06667960|DRUG|JK06|Biparatopic anti-5T4 antibody
214477668|NCT06594783|OTHER|Carvedilol plus endoscopic variceal ligation|Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
215048614|NCT01595529|OTHER|Placebo|Placebo to match the other four active treatments
215048615|NCT01595529|DRUG|Trimethoprim/Sulfamethoxazole|8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
214293838|NCT03367481|DEVICE|Toothbrush type|In this cross-over study, the participants will use either a soft brush (control) and the medium brush (test).
214293839|NCT05949242|DEVICE|OMNI canaloplasty|OMNI device is used to catheterize Schlemm's canal for 180 degrees and perform canaloplasty. Viscoelastic is eluded upon retraction of the catheter performing viscodilation of the canal
214293840|NCT05949242|DEVICE|Hydrus microstent|Hydrus stent is introduced into Schlemm's canal to scaffold open the canal
214668096|NCT03518515|OTHER|White potato (french fries)|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) each day for 30 days as a part of their usual dietary intake. French fries will be portioned and provided to participants.
215048616|NCT02073812|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
215048617|NCT01203709|DRUG|low dose combination of MMF and Tac|mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
215048618|NCT02067507|BEHAVIORAL|Tailored education and referral|LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
215048619|NCT02067507|BEHAVIORAL|Staff training and patient reminders|AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities
215048620|NCT02067507|BEHAVIORAL|Clinic-level reminder systems|Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
215048621|NCT02273921|OTHER|EEG recording|EEG is recorded once for each participant
214887905|NCT00955929|DRUG|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires|Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
214887906|NCT00876889|DRUG|Riluzole|50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).
214887907|NCT05056116|DRUG|Surufatinib Toripalimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
214887908|NCT03936010|DRUG|Canagliflozin|Canagliflozin dispensing claim is exposure
214887909|NCT03936010|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
214887910|NCT05586555|OTHER|Pupillometry (Eve-tracking measurements)|Pupillometry measurements are carried out by a dedicated device (eye tracker), which includes cameras allowing the measurement of pupillary dilation. The subject stands in front of a screen and fixes a point in the center of the screen, the cameras placed on the screen allowing a measurement of the pupillary dilation in a non-invasive way. These eye-tracking measurements are performed simultaneously with an auditory task and allow to study the pupil's response to different stimuli.
214887911|NCT05204212|OTHER|Left Atrial Appendage closure|Percutaneous closure of the LAA
214887912|NCT06100523|BEHAVIORAL|Visioconsulation|Meeting by videoconsultation with professionals adapted to the exposures highlighted by the questionnaires for patients who responded on the dedicated application (Arm A)
214887913|NCT06100523|BEHAVIORAL|self-assessment questionnaire|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
214887914|NCT06100523|BIOLOGICAL|hair sampling|hair sampling from the 2 members of the couple
214887915|NCT06100523|BEHAVIORAL|self-assessment questionnaire on dedicated application|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
214887916|NCT06100523|BEHAVIORAL|Specialized follow-up|proactive healthcare pathway : active support of corrective measures implemented with couples by the platform, with the help of the application
214887917|NCT06100523|BEHAVIORAL|self-assessment questionnaire for follow-up|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
215048622|NCT05669040|OTHER|Pharmacological education|Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.
215048623|NCT05669040|OTHER|Training in the use of MyPlan Aplication|Review of the use of the aplication
215048624|NCT05669040|OTHER|Patient Experience|"* How do you feel?~* Sad feelings and frustration.~* Achievements day by day, think positive.~* Importance of interpersonal relationships.~* Explain activities to relax the mind"
215048625|NCT04707079|DRUG|Duvelisib|Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
215048626|NCT00730886|DEVICE|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
215048627|NCT00730886|PROCEDURE|Myomectomy|Invasive surgical procedure for fibroid removal
215048628|NCT03992950|OTHER|Maneuvers for occluding esophagus|Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
215048629|NCT04278248|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine|1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
215048630|NCT01991483|DRUG|LY2928057|Administered intravenously
215048631|NCT01991483|DRUG|Placebo|Administered intravenously
215048632|NCT00390377|PROCEDURE|Cutting scalp hair|
215048633|NCT04344184|DRUG|L-ascorbic acid|50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
214887918|NCT06251440|DRUG|Fetal Reduction|Under ultrasound guidance, intracardiac injection of 0.2 to 3.0 ml of 15% weight/volume (2 miliequivalent/mililiter ) potassium chloride (KCl) was administered via transabdominal route
215048634|NCT04344184|OTHER|Placebo|Dextrose 5% Water
215048635|NCT05115266|BEHAVIORAL|Animal-assisted therapy (AAT|The activity program consists of 10 sessions with a duration of about 60 minutes. During the 10 sessions the animal is presented, in this case a dog. They caress it, dress it, educate it ...
215048636|NCT05115266|BEHAVIORAL|Usual treatment|receive usual treatment (group activities)
215048637|NCT02665260|DRUG|Cantharidin|cantharidin 0.7% topical liquid
214293841|NCT00100815|BIOLOGICAL|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
214887919|NCT04513301|DRUG|Sintilimab|Sintilimab (200 mg q3w ×2 cycle)
214887920|NCT04513301|RADIATION|Radiotherapy|RT 50-60Gy/25-30f
214887921|NCT00522730|OTHER|Parenteral nutrition|Duration : 5 days
214887922|NCT00522730|OTHER|Enteral nutrition|Duration : 5 days
215048638|NCT02665260|DRUG|Placebo|Placebo topical liquid
215048639|NCT02665260|DEVICE|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
215048640|NCT05528575|DIETARY_SUPPLEMENT|Blueberry, cranberry, green tea extract, cocoa|tablet supplements, available readily.
215048641|NCT05528575|DIETARY_SUPPLEMENT|GOS, Inulin, RS2|Prebiotic combination, Inulin, GOS and RS2
215048642|NCT05528575|DIETARY_SUPPLEMENT|prebiotics and polyphenols|combination of the same prebiotics and polyphenols as above
215048643|NCT05528575|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin, 10g per day
215048644|NCT02305186|DRUG|Pembrolizumab|Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
215048645|NCT02305186|RADIATION|Neoadjuvant Chemoradiation|Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
214887923|NCT06582303|DEVICE|Virtual reality Game intervention plus conventional physical therapy|The experimental group initially got VR intervention by playing all four easy-level games named hitting a rolling ball, grasping a balloon, swapping hands, and gripping twice for three minutes each during the first and second weeks. This group again underwent VR intervention by playing all four same games with a difficulty level twice 5 min duration for the third, fourth, fifth, and sixth weeks. The experimental group had an intervention of 24 sessions, lasting 4 days/week for a total of 6 weeks. During the first two weeks, patients received 24 minutes of VR hand games and 24 minutes of therapy sessions per day and for the next four weeks, this group received 40 minutes of VR hand games and 40 minutes of conventional therapy session per day. This group received conventional physical therapy that consists of range of motion, stretching, resistance, and strengthening exercises. At follow-up of two weeks this group only received conventional physical therapy.
214887924|NCT06582303|DEVICE|Conventional Physical Therapy|The control group received conventional physical therapy, which consists of range of motion, stretching, resistance, and strengthening exercises by using powerweb, thera putty, and occupational therapy equipment. The CPT group had a conventional intervention of 24 sessions, lasting 4 days/week for a total of 6 weeks. The CPT group was given 48 minutes of conventional physical therapy sessions per day for weeks 1 and 2 followed by 80 minutes of conventional physical therapy sessions per day for the next 4 weeks. At follow-up of two weeks, this group also received conventional physical therapy.
214887925|NCT05134415|OTHER|RELX ENDS Tobacco Flavor 1|2-week ad libitum use of the RELX ENDS tobacco flavor 1
214887926|NCT05134415|OTHER|RELX ENDS Tobacco Flavor 2|2-week ad libitum use of the RELX ENDS tobacco flavor 2
214887927|NCT05134415|OTHER|RELX ENDS Menthol Flavor 1|2-week ad libitum use of the RELX ENDS menthol flavor 1
214887928|NCT05134415|OTHER|RELX ENDS Menthol Flavor 2|2-week ad libitum use of the RELX ENDS menthol flavor 2
214887929|NCT01483443|PROCEDURE|Oophrectomy|Both oophrectomy
214887930|NCT00440661|DRUG|Diacerhein|
214293842|NCT00100815|DRUG|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
214293843|NCT00100815|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
214293844|NCT06131242|OTHER|It is an observational study|It is an observational study
214887931|NCT05716308|BEHAVIORAL|A continuous nursing intervention group was established.|Intervention group: Continuous nursing intervention was performed on the basis of the control group: ①A continuous nursing intervention group was established. The group members included chief physician, attending physician, head nurse, specialist nurse and nutritionist. ②The establishment of patient records, patients admitted to hospital by the primary nurse to record the basic situation of patients, including name, age, history of diabetes, DR staging, vision and blood glucose before treatment and other information. ③Personalized nursing intervention was given during hospitalization. Systematic health education was carried out for patients on admission. Targeted psychological counseling was given to some patients. ④After discharge to give continuous care, organize patients to join the WeChat group, group to share knowledge of DR-related diseases, to understand the patient 's medication, diet, vision, the patient 's questions and problems to guide and improve.
214887932|NCT01576354|DRUG|Prolonged-release Fampridine|10mg tablet twice a day (every 12 hours), orally
214887933|NCT01576354|DRUG|Placebo|tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
214887934|NCT01366820|DRUG|NNZ-2566|"Solution for intravenous infusion.~Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours."
214887935|NCT01366820|DRUG|Placebo|Sodium Chloride 0.9% Injection
214887936|NCT00972374|DRUG|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
214293845|NCT00815945|DRUG|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
214293846|NCT00815945|DRUG|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
214293847|NCT05933512|BIOLOGICAL|SCTV01E-2|intramuscular injection
214293848|NCT05933512|BIOLOGICAL|SCTV01E|intramuscular injection
214293849|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
214293850|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
214293851|NCT01141439|DRUG|Fluticasone propionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
214293852|NCT01141439|DRUG|Beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
214887937|NCT00972374|DRUG|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
214887938|NCT00972374|OTHER|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
214887939|NCT03520257|DRUG|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.
214887940|NCT03520257|DEVICE|Radiotherapy|Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities.
214887941|NCT00631215|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
215048646|NCT01932788|DRUG|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
215048647|NCT01932788|DRUG|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
215048648|NCT01977378|DRUG|Sustained-Release Desvenlafaxine Hydrochloride|
215048649|NCT01977378|DRUG|Sustained-Release Venlafaxine Hydrochloride|
215048650|NCT01471964|DRUG|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
215048651|NCT04819113|BIOLOGICAL|Nimenrix|MenACWY-TT vaccine
215048652|NCT04141319|DRUG|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
215048653|NCT04141319|DRUG|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
214293853|NCT01141439|DRUG|fluticasone propionate|Initiation of FP (any dose) via MDI in steroid naive patient
214293854|NCT01141439|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
214293855|NCT00996047|GENETIC|cytogenetic analysis|
214293856|NCT00996047|GENETIC|fluorescence in situ hybridization|
214293857|NCT05615571|GENETIC|Establishment of mitochondrial markers|Establishment of mitochondrial markers from fibroblasts in culture, obtained from a skin biopsy. Establishment of yeast models to show biochemical mitochondrial alterations: introduction of missense variants in the pantothenate kinase yeast gene Cab1 whose deletion is lethal, followed by growth of mutant strains on fermentation and respiratory media.
215048654|NCT04141319|DRUG|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
214293858|NCT05615571|GENETIC|Sequencing tests|sequencing tests of a panel of 22 genes (9 already known and 13 new genes) using a dedicated custom capture and a medium throughput sequencing protocol.
214293859|NCT01647282|DRUG|locally-applied minocycline HCl (1 mg)|
214293860|NCT01647282|PROCEDURE|scaling and root planing (Sc/RP)|
214293861|NCT00394628|DRUG|AQ4N|
214293862|NCT00394628|DRUG|Temozolomide|
214293863|NCT00394628|PROCEDURE|Radiotherapy|
214477669|NCT06594783|DRUG|Carvedilol alone|Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
215048655|NCT05014373|COMBINATION_PRODUCT|Favipiravir + Standard of Care|"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care"
215048656|NCT05014373|PROCEDURE|Standard of Care|Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
215048657|NCT02055950|PROCEDURE|Storage of kidney in refrigerated solution|
215048658|NCT02055950|PROCEDURE|Kidney perfused by pulsatile machine|
214293864|NCT02105428|BEHAVIORAL|Aerobic Exercise Training|A progressive increase in duration, frequency and intensity so the last 8 weeks of exercise are performed for 60 min, 5 days per week and at 80% of aerobic capacity. The duration includes a 5 minute warm up and 5 minute cool down. All exercise will be performed on a stationary bicycle (i.e., cycle ergometer).
214293865|NCT00128570|BEHAVIORAL|behavioral dietary intervention|
214293866|NCT00128570|OTHER|educational intervention|
214293867|NCT00128570|OTHER|internet-based intervention|
214293868|NCT00128570|OTHER|preventative dietary intervention|
214293869|NCT00128570|PROCEDURE|evaluation of cancer risk factors|
214293870|NCT00311623|DRUG|Rapamycin 3mg|Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
214293871|NCT00311623|DRUG|Rapamycin 6mg|Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
214293872|NCT00311623|PROCEDURE|Radical prostatectomy|Radical prostatectomy performed on Day 15
214293873|NCT02389348|DRUG|DSM265|Single oral doses of DSM265
214293874|NCT02389348|DRUG|OZ439|Single oral doses of OZ439
214887942|NCT06510699|OTHER|genotype-directed dosing with dosing software based on therapeutic drug monitoring|Genotype-directed dosing with dosing software based on therapeutic drug monitoring
214887943|NCT04209452|BEHAVIORAL|Rehearsal strategy|Teaching children to cumulatively rehearse numbers as they are being said.
214887944|NCT04209452|BEHAVIORAL|Reinforcement|Providing reinforcement for correct recall after a delay.
214887945|NCT04209452|BEHAVIORAL|Rehearsal strategy and reinforcement|Teaching children to cumulatively rehearse numbers as they are being said, AND providing reinforcement for correct recall after a delay.
214887946|NCT05023915|DRUG|dexamethasone|40 mg qd for 4 days
214887947|NCT05023915|DRUG|diammonium glycyrrhizinate enteric-coated capsule|150mg tid for 3 months
214887948|NCT02929771|DEVICE|Samsung GearVR|VR with head mounted display (HMD) and headphones. Treatment
214887949|NCT02929771|DEVICE|iPad|iPad with headphones. Control
214887950|NCT00576589|DRUG|CE-326,597|CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
214887951|NCT00576589|DRUG|Placebo|CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
214887952|NCT01963546|OTHER|different types of anesthesia|
214887953|NCT01963546|DRUG|Dexmedetomidine|After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
215048659|NCT04601116|DRUG|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg per day for 2 years
214477670|NCT06667232|OTHER|Single-pulse stimulation|Investigators use single-pulse electrical stimulations at 1Hz to elicit cortico-cortical evoked potentials
214477671|NCT06667232|OTHER|Paired-pulse stimulation|The repetitive delivery of pairs of stimulation pulses is DES patten with a 5-50 ms interval between each pulse, constitutes repetitive paired-pulse stimulation.
214477672|NCT06667232|OTHER|Stepwise frequency stimulation|Stepwise incremental stimulation ranging from 5 Hz to 145 Hz following a cyclic pattern.
214887954|NCT03305965|BEHAVIORAL|Patient navigation|Consultations with a specifically trained oncology nurse (i.e. patient navigator), who assesses patients' needs for supportive cancer care, provides information on supportive cancer care, and guides patients through the supportive cancer care system. Consultations with the patient navigator take place at the start, halfway through, and at the end of treatment.
215048660|NCT04601116|DRUG|Placebo oral tablet|Placebo 1 tablet per day for 2 years
214887955|NCT02288325|DRUG|Levomilnacipran ER|Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.
214887956|NCT02288325|DRUG|Placebo|Dose-matched placebo taken orally once daily.
214887957|NCT00717288|DRUG|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
214887958|NCT00717288|DRUG|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
214887959|NCT00717288|DRUG|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
214887960|NCT02685228|DRUG|Decitabine|decitabine 5mg/m2,d1-d5;
214887961|NCT02685228|DRUG|Gemcitabine|gemcitabine 1.0g/m2, d8,d15,d22
214887962|NCT01880892|PROCEDURE|Cricopharyngeal myotomy|Endoscopic laser cricopharyngeal myotomy is one of the standard treatments for Zenker's Diverticulum. It takes about 30 minutes and at our institution requires a one night of observation in the hospital.
214293875|NCT03715010|DIETARY_SUPPLEMENT|BCAA|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa
214293876|NCT03998189|OTHER|Breath Collection|Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
214293877|NCT03998189|OTHER|Saliva Collection|Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
214293878|NCT03998189|OTHER|Blood Collection|Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
214293879|NCT03998189|OTHER|Urine Collection|Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
214293880|NCT03998189|OTHER|Tumor Collection|During surgical tumor removal, a tumor tissue sample will be collected
214293881|NCT03998189|OTHER|Medical History Data Collection|Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
214293882|NCT03227029|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L|10\^6 plaque-forming units (PFU); administered as nose drops
214887963|NCT01880892|DIAGNOSTIC_TEST|PH probe Testing|24 hour PH probe testing, which will measure acid reflux following cricopharyngeal myotomy.
214887964|NCT04629378|DRUG|Meropenem Injection|Meropenem IV 6 grams
214887965|NCT04629378|DRUG|Amoxicillin Clavulanate|Amx/CA oral 1000/62.5mg 2 tablets
214887966|NCT04629378|DRUG|Pyrazinamide|Pyrazinamide 20-30mg/kg
214887967|NCT04629378|DRUG|Bedaquiline|Bedaquiline 400mg
214293883|NCT03227029|BIOLOGICAL|RSV 276|10\^5 PFU; administered as nose drops
214293884|NCT03227029|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
214293885|NCT00367094|DRUG|Benazepril plus hydrochlorothiazide|
214293886|NCT05683379|DIAGNOSTIC_TEST|AAV8 DetectCDx|An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
214293887|NCT03330808|OTHER|Epidural anesthesia|After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
214293888|NCT03686371|PROCEDURE|posterior surgery for spinal arthrodesis|posterior surgery for spinal arthrodesis
214293889|NCT03348033|BIOLOGICAL|Chronic Myeloid Leukemia + NK cell|Patients with chronic phase chronic myeloid leukemia who lost response to the second line of treatment with tyrosine kinase inhibitor with indication of bone marrow transplantation or refractory. Infusion of autologous natural killer cells, expanded in the laboratory, after chemotherapeutic conditioning.
214293890|NCT03879122|DRUG|Ipilimumab 5 MG/ML|Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
214293891|NCT03879122|DRUG|Nivolumab 10 MG/ML|Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
214887968|NCT04629378|DRUG|Rifafour|Rifafour (HRZE) Standard dose
214887969|NCT06225219|BEHAVIORAL|Counseling|To introduce a model of holistic care to the patient populations served by the GCAC through chaplain interventions that focus on spiritual and emotional health.
214887970|NCT04526015|PROCEDURE|Iliohypogastric and ilioinguinal nerve block|Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side
214887971|NCT04526015|PROCEDURE|Controlled Group|Each patient will receive spinal anesthesia alone with no block.
214887972|NCT04020887|DEVICE|Alertwatch - Interaction|Decision-support software, customized for the PACU environment, Interaction between the telemedicine center and the PACU
214887973|NCT00002382|DRUG|Saquinavir|
214887974|NCT02859766|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
214887975|NCT05302531|DRUG|Amoxicillin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
214887976|NCT05302531|DRUG|Levofloxacin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
214887977|NCT05302531|DRUG|Ofloxacin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
214887978|NCT05302531|DRUG|Sulfamethoxazole trimethoprim|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
214887979|NCT05479825|PROCEDURE|inflation- deflation line combined with ICG fluorography|Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
214887980|NCT00419991|DRUG|Tigecycline|All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
214887981|NCT04024046|DIETARY_SUPPLEMENT|Uqora|Participants will receive 1 Placebo Drink-Mix and 2 Placebo Capsules Daily
214887982|NCT04024046|DIETARY_SUPPLEMENT|Group1|Participants will receive 1 Uqora Drink-Mix and 2 Placebo Capsules Daily
214887983|NCT04024046|DIETARY_SUPPLEMENT|Group 2|Participants will receive 1 Uqora Drink-Mix and 2 Uqora Capsules Daily
214887984|NCT05211726|OTHER|Low Added Sugar Diet|Consumption of 10 days of a diet low in added sugars (5% of total caloric intake)
214887985|NCT05211726|OTHER|High Added Sugar Diet|Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
214887986|NCT01335334|DRUG|bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole|Pylera capsule contains bismuth subcitrate potassium, 140 mg (q.i.d.), metronidazole, 125mg (q.i.d.), tetracycline hydrochloride, 125mg (q.i.d.). Generic omeprazole (20mg, b.i.d) tablets
214887987|NCT05042258|DRUG|Dupilumab|12 week dupilumab administration
214887988|NCT04384835|BIOLOGICAL|Blood sample collection (one tube)|Collection of one tube of 7.5 ml blood in addition to a blood sample made in clinical practice
214887989|NCT04384835|BIOLOGICAL|Blood sample collection (five tubes)|Collection of five tubes of 7.5 ml blood in addition to a blood sample made in clinical practice
214293892|NCT03879122|DRUG|Docetaxel|"Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1."
214293893|NCT03879122|DRUG|ADT (androgen deprivation therapy)|Androgen deprivation therapy per the standard of care
214293894|NCT03414424|DEVICE|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
214293895|NCT03414424|DEVICE|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
214293896|NCT01923220|DRUG|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
214293897|NCT01923220|OTHER|Aloe Vera Jel|To be applied topically once daily
214293898|NCT01113801|DRUG|LY2382770|Subcutaneous injection given monthly for 12 months
214293899|NCT01113801|DRUG|Placebo|Subcutaneous injection given monthly for 12 months
214293900|NCT03833973|BEHAVIORAL|Overtraining Monitoring|Athletes will be thoroughly monitored (i.e. training workload, match activities or event/race performance, markers of inflammation and oxidative stress as well as cell-free DNA) throughout the season in order to establish novel biomarkers that could function as either predictors or diagnostic tools of overtraining.
214293901|NCT01465087|OTHER|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
214293902|NCT03294733|PROCEDURE|Ultrasound|This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
214293904|NCT02475577|DEVICE|Peripherals with HealthInterlink technology|home remote monitoring
214293905|NCT04905212|DRUG|Telitacicept 160mg|Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.
214477673|NCT06667232|OTHER|Burst stimulation|Burst stimulation pattern consisting of short bursts delivered once a second and an intraburst frequency of 50 Hz, 100 Hz, 150 Hz, 175 Hz and 200 Hz
214293906|NCT04905212|DRUG|Telitacicept 240mg|Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.
214293907|NCT04905212|DRUG|Placebo|Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
214293908|NCT03946033|DIAGNOSTIC_TEST|Immunoscore Colon Test|Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
214293909|NCT01362374|DRUG|5-FU|5-FU at a dose level of 400 mg/m\^2 as intravenous (IV) injection followed by a dose of 2400 mg/m\^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
214293910|NCT01362374|DRUG|Docetaxel|Docetaxel will be administered at dose level of 75 mg/m\^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
214293911|NCT01362374|DRUG|Enzalutamide|Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
214293912|NCT01362374|DRUG|Ipatasertib|Ipatasertib will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
214293913|NCT01362374|DRUG|Leucovorin|Leucovorin at a dose level of 400 mg/m\^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
214293914|NCT01362374|DRUG|Oxaliplatin|Oxaliplatin at a dose level of 85 mg/m\^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
214293915|NCT01362374|DRUG|Paclitaxel|Paclitaxel at a dose of 90 mg/m\^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
214293916|NCT00970333|DRUG|[18F]-FEPPA|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) of \[18F\]-FEPPA followed by serial PET imaging
214293917|NCT01430156|DRUG|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
214293918|NCT01430156|DRUG|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
214293919|NCT00407823|PROCEDURE|Central venous oxygen saturation continuous monitoring|
214477674|NCT06609083|DRUG|THC 30mg|High dose of THC (30 mg)
214477675|NCT06609083|DRUG|THC 5mg|Low dose of THC (5 mg)
214477676|NCT06609083|DRUG|THC 0mg|Placebo dose of THC (0 mg)
214887990|NCT04328701|BEHAVIORAL|Mindfulness-based Cognitive Behavioral Therapy|Mindfulness-based CBT methods are based on pain self-management paradigms, and involve the identification and reduction of maladaptive pain-related cognitions (i.e., catastrophizing), the enhancement of self-efficacy for managing pain, and training in the use of adaptive pain-coping strategies such as relaxation, distraction, and self-talk.
214887991|NCT02040077|BEHAVIORAL|Computer + Fluency|
214887992|NCT02040077|BEHAVIORAL|Computer Only|
214887993|NCT02040077|BEHAVIORAL|Treatment as Usual|
214887994|NCT03857815|RADIATION|anti-PD-1 antibody|"In patients with inoperable hepatocellular carcinoma or recurrence after local or regional therapy, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 Evaluable lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (IBI308) is injected intravenously 200mg every three weeks."
214887995|NCT02683421|DRUG|Tilmanocept|
214887996|NCT04003493|OTHER|Nutrition and oral health intervention|The interventions included individualised nutrition and oral health care.
215048661|NCT03539757|DEVICE|Non-Contrast Magnetic Resonance Imaging|The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
215048662|NCT05958589|DRUG|Caudal block with levobupivacaine|After the introduction of general anesthesia, a single shot caudal block will be performed with levobupivacaine 0.25% (2.5 mg/kg; maximal dose 75 mg).
215048663|NCT05958589|DRUG|General anesthesia|On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).
215048664|NCT05958589|PROCEDURE|Inguinal hernioplasty|Elective inguinal hernioplasty
215048665|NCT00833027|DRUG|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
215048666|NCT04321005|PROCEDURE|arthroscopic rotator cuff reconstruction|arthroscopic rotator cuff reconstruction and assessment with evaluation and prediction of core outcomes
215048667|NCT02996812|DRUG|Exendin (9-39)|
215048668|NCT06252376|DIAGNOSTIC_TEST|Head-up tilt table|Different versions of cognitive assessments will be administered in the supine and upright positions while the participant is on the tilt table.
215048669|NCT05555446|DIETARY_SUPPLEMENT|Bovine colostrum|Subject will receive bovine colostrum with gluten.
215048670|NCT05555446|DIETARY_SUPPLEMENT|Placebo|Subject will receive a placebo with gluten.
215048671|NCT03092180|DRUG|Intravenous Infusion|Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
215048672|NCT06433583|DEVICE|transcutaneous auricular vagal nerve stimulation|"The use of TENS ECO PLUS and the vagus nerve ear electrode medical devices for transcutaneous auricular vagal nerve stimulation (taVNS) everyday for 10 minutes twice a day or 20 minutes for 8 successive weeks. Patients are included at week 0, use taVNS between week 2 and 10, and are followed up until week 22.~Patient adherence: percentage of patients performing 20 minutes of daily stimulation on at least 5 days a week for at least 6 cumulative weeks."
214477677|NCT06609083|DRUG|Cigarette Full Nicotine|Full nicotine cigarette
214477678|NCT06609083|DRUG|Cigarette Reduced Nicotine|Reduced nicotine cigarette
214668097|NCT03518515|OTHER|White potato (French fries), +seasoning|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) with added potential glycemia modifying seasoning mix each day for 30 days as a part of their usual dietary intake. French fries and seasoning will be portioned and provided to participants.
214887997|NCT05323669|DIAGNOSTIC_TEST|Molecular testing|Molecular testing of thyroid nodules
214887998|NCT00344448|DRUG|Raptiva|During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
214887999|NCT02213159|DRUG|Dexmedetomidine|
214888000|NCT02213159|DRUG|Morphine|
214888001|NCT06440993|DRUG|Gemcitabine|Gemcitabine, 1,000 mg/m2 IV
214888002|NCT06440993|DRUG|Cisplatin|Cisplatin, 25 mg/m2 IV
214888003|NCT06440993|DRUG|Durvalumab|Durvalumab, 1,500 mg IV
214888004|NCT06440993|PROCEDURE|ID-RFA|endoscopic intraductal RFA
214888005|NCT03411135|OTHER|VES and VASI scores as assessment methods for vitiligo|compare VES and VASI scores as assessment methods for vitiligo
214888006|NCT01724086|DRUG|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
214888007|NCT01724086|DRUG|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
214888008|NCT01724086|DRUG|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
215048673|NCT01661543|DIETARY_SUPPLEMENT|Beans|120g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
215048674|NCT01661543|DIETARY_SUPPLEMENT|Control (rice)|110g (3/4 c) of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group. This amount of rice equates to a similar volume as 120g of cooked beans or peas.
215048675|NCT01661543|DIETARY_SUPPLEMENT|Peas|120 grams of peas will be consumed 5 out of 7 days per week
214293920|NCT05245747|DEVICE|Vitls Tego Device|The Tégo VSS Sensor is a battery-operated adhesive patch with integrated sensors and wireless transceiver which is worn on the upper body and records heart rate (HR), respiration rate, blood oxygen levels (SpO2), and body temperature. The Tégo VSS Sensor continuously gathers multiparameter physiological data from the person being monitored and then transmits the encrypted data via bi-directional communication to a third-party connectivity relay.
214293921|NCT05846906|DRUG|Sildenafil Citrate|oral sildenafil (Respatio® 20mg )
214293922|NCT05846906|DRUG|Clomiphene Citrate 50mg|used for ovionulation induct
214293923|NCT03622307|DEVICE|Subcutaneous ICD Therapy Combined with VT Ablation|S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
214293924|NCT04124120|PROCEDURE|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
214293925|NCT04124120|PROCEDURE|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
214293926|NCT05913180|DRUG|Ascorbic Acid 1000 MG|1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
214477679|NCT05825989|BEHAVIORAL|Healthy Beat Acupunch Regimen|The Healthy Beat Acupunch (HBA) regimen, developed by Chen et al. (2017), is based on the Meridian Theory or Jing-Luo Theory. The HBA regimen focuses on body movement with hands swinging, resulting in the natural swinging of fists that hit on acupoints. There are three phases: phase 1 is activating qi and blood; phase 2 is punching meridians; phase 3 is relaxing body and mind.
214477680|NCT04782375|DRUG|Stop group|discontinue antiviral treatment
214477681|NCT04556526|BIOLOGICAL|Ad26.ZEBOV|Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
214477682|NCT04556526|BIOLOGICAL|MVA-BN-Filo|Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
214668098|NCT03518515|OTHER|Almond|If randomized to this group, participants will be asked to consume 1 serving of almonds that is calorically-matched to the French fries (\~300 kcal) serving in the other arms each day for 30 days as a part of their usual dietary intake. Almonds will be portioned and provided to participants.
214888009|NCT01724086|DRUG|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
214888010|NCT01724086|DRUG|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
214888011|NCT01724086|DRUG|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
214888012|NCT03804814|BEHAVIORAL|Motivational Interviewing Training|"Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions.~A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers."
214888013|NCT04144361|PROCEDURE|sleeve with plication|sleeve with plication
214888014|NCT04144361|PROCEDURE|sleeve without plication|sleeve without plication
214888015|NCT00548470|DRUG|Varenicline|Varenicline 1-2 mg/day
214888016|NCT00004315|DRUG|ursodiol|
214668099|NCT04802746|DRUG|Alprazolam|Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.
214888017|NCT02885766|DRUG|PF-114|
214293927|NCT05913180|DRUG|Placebo|Placebo tablet daily starting day of elective gynecological surgery for 10 days
214668100|NCT04802746|OTHER|Placebo|Study participants will receive Staccato placebo at pre-specified time points in Part A and Part B matching the pre-specified Staccato alprazolam dosing.
214668101|NCT04429932|OTHER|Myblu flavor A_2.4|Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
214293928|NCT03752359|DIETARY_SUPPLEMENT|whey protein|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
214293929|NCT03752359|DIETARY_SUPPLEMENT|placebo|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
214293930|NCT02657382|BEHAVIORAL|Heart Rate Variability (HRV) Biofeedback (BF)|Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
214888018|NCT02565511|BIOLOGICAL|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
214888019|NCT02565511|OTHER|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
214888020|NCT02565511|DRUG|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
214888021|NCT02565511|OTHER|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
214888022|NCT02565511|OTHER|Alum|Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
214888023|NCT00686361|DRUG|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
214888024|NCT00383305|DEVICE|Cool-Cap|
214888025|NCT00638053|GENETIC|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
214888026|NCT01307345|BEHAVIORAL|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
214888027|NCT05435690|DEVICE|Computer-assisted arthroplasty|Computer-assisted arthroplasty
214888028|NCT02850185|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
214888029|NCT02850185|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
214888030|NCT02850185|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
214888031|NCT02770898|BEHAVIORAL|Family Holistic Health|Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
214888032|NCT04770675|DIAGNOSTIC_TEST|Bronchoscopy|All subjects who are scheduled for a bronchoscopy may be eligible.
215048676|NCT06289400|DEVICE|Magnetic field application|The applicator (Size: 15x15 cm) has placed 1-3 cm above the skin surface at the painful area. During the treatment, treatment has applied with ready-made protocols included in the device.
215048677|NCT06289400|OTHER|Conventional treatment|Within the scope of conventional treatment, hotpack application, transcutaneous electrical stimulation (TENS), interferential current and ultrasound treatment modalities will be applied. In addition, strengthening exercises will be applied to the muscles around the hip and knee and stretching exercises will be applied to the short muscle groups.
215048678|NCT05119582|DEVICE|TOOsonix System ONE-M|Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.
215048679|NCT04857554|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
215048680|NCT04857554|OTHER|White bread as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
215048681|NCT04857554|OTHER|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread together with apricot jam along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
214888033|NCT03482115|RADIATION|PET examination with radiopharmaceutical drug [18F] DPA-714|Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection
214888034|NCT03482115|DIAGNOSTIC_TEST|MRI examination|MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).
214888035|NCT03482115|BIOLOGICAL|Blood samples|Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity
214888036|NCT02750956|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
214888037|NCT04805515|BEHAVIORAL|Nicotine Corrective Messages|Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
214888038|NCT04087915|DRUG|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
214888039|NCT04807400|DRUG|Inclisiran|Inclisiran Sodium 300mg on Day 1 and Day 90 by subcutaneous injection
214888040|NCT04807400|BEHAVIORAL|Behavioural Support|Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.
214888041|NCT04807400|DRUG|Background lipid lowering therapy|lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
214888042|NCT02568605|DIETARY_SUPPLEMENT|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
214888043|NCT02568605|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214888044|NCT02568605|BEHAVIORAL|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
215048682|NCT04857554|OTHER|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from a cereal bar with cranberries along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
215048683|NCT04857554|OTHER|Cocoa drink|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from cocoa powder mixed with 500ml fat-free milk, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
215048684|NCT05019209|DRUG|House Dust Mite Allergen|D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
215048685|NCT05019209|OTHER|Allergen-free air|No allergen added to room ventilation of allergen challenge chamber
215048686|NCT03564236|DEVICE|Nasal High Flow Therapy|Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates\[2\] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).\[3\]
215048687|NCT03564236|OTHER|Standard care|Standard regular care of a COPD exacerbation
215048688|NCT03096886|BEHAVIORAL|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
214888045|NCT01960309|OTHER|Minimal invasive cardiac imaging|"* Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography"
215048689|NCT01939145|DRUG|Normal saline|Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
215048690|NCT01939145|DEVICE|Prontosan|Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
215048691|NCT03358082|DRUG|Tacrolimus 0.03% Ointment|topical tacrolimus 0.03% twice daily for 6 months
214668102|NCT04429932|OTHER|Myblu flavor B_2.4|Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
214888046|NCT04881487|RADIATION|Additional stereotactic body radiation therapy|5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
214888047|NCT03838497|BIOLOGICAL|Prevenar13|Prevenar13 for both arms
214888048|NCT02443987|OTHER|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
214888049|NCT01601340|DRUG|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
214888050|NCT01601340|DRUG|Placebo|Placebo tablets, twice daily for 48 weeks
214888051|NCT03656744|DRUG|HTD1801|HTD1801 tablets, 250mg
214888052|NCT03656744|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
214293931|NCT02657382|OTHER|Mental Stress Protocol|Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
214888053|NCT02186444|OTHER|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
214888054|NCT02186444|OTHER|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
214888055|NCT00706589|DRUG|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
214888056|NCT00706589|DRUG|placebo|Initial dose: 2mg, Maximum dose:20mg
214888057|NCT04583189|DIAGNOSTIC_TEST|Performance of the test antigenic and test RT-PCR|Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
214888058|NCT00549432|DEVICE|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
214888059|NCT03076775|OTHER|Maternal glycemic control|Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
214888060|NCT00399633|DRUG|sumatriptan|
214888061|NCT04441151|BEHAVIORAL|Pulmonary rehabilitation therapy|Comprehensive interventions based on comprehensive evaluation and customization of patients, including, but not limited to, exercise training, education and behavioral changes, aimed at improving the physiological and psychological status of patients with chronic respiratory diseases, and urge patients to adhere to health promotion activities for a long time.
214888062|NCT01696760|DRUG|acetylsalicylic acid|325 mg twice a day
214888063|NCT01696760|DRUG|enoxaparin|40 mg once daily
214888064|NCT01696760|DEVICE|PCD|Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
214888065|NCT00231543|PROCEDURE|Laparoscopic fundoplication|
215048692|NCT03358082|DRUG|Hydrocortisone Acetate 1% Ointment|hydrocortisone acetate 1% ointment twice daily for 6 months
215048693|NCT02806414|DRUG|Ivermectin|
214293932|NCT00132184|DRUG|Vitamin D|
214888066|NCT00231543|PROCEDURE|open Nissen fundoplication|
214888067|NCT06458647|OTHER|Video Streaming with Virtual Reality|In the study, patients in the intervention group will be watched videos of natural landscapes such as mountains, beaches and waterfalls with virtual reality goggles before the angiography procedure.
214888068|NCT00430066|DRUG|Imatinib Mesylate|400 mg/die for 6 months
214888069|NCT01319526|GENETIC|DNA analysis|
214888070|NCT01319526|GENETIC|RNA analysis|
214888071|NCT01319526|OTHER|laboratory biomarker analysis|
214888072|NCT01332292|DRUG|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
214888073|NCT01332292|DRUG|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
215048694|NCT06497309|DEVICE|Treadmill training|Therapy with treadmill-based advanced technology device.
215048695|NCT06497309|DEVICE|Overground training|Therapy using an advanced technological device enables exercise on the ground.
215048696|NCT06497309|DEVICE|DIERS|The examination starts and ends with the DIERS motion analysis system, a light-optical scanning method based on VRS (Video Raster Stereography) and a sensor-equipped treadmill that allows the measurement of several parameters of gait and balancing ability.
215048697|NCT06497309|OTHER|Traditional physiotherapy assessments|Traditional physiotherapy assessment methods (Timed Up and Go, Berg Balance Test, 6-minute gait test, 10-metre gait test, Functional Independence Measure, Barthel) are used to assess gait pattern and self-sufficiency.
214293933|NCT00805623|DIETARY_SUPPLEMENT|sucrose|1 cc of sucrose 33.5% with or without pacifier
214293934|NCT01926314|DEVICE|PHENIX Neuromuscular Stimulation Therapy System device|
214293935|NCT01926314|OTHER|usual home care without device|
214668103|NCT04429932|OTHER|Myblu flavor C_2.4|Use of Myblu e-cigarette with flavor C at 2.4% nicotine
214668104|NCT04429932|OTHER|Myblu flavor D_2.4|Use of Myblu e-cigarette with flavor D at 2.4% nicotine
214888074|NCT03561324|DEVICE|Imaging Beta Probe (IBP)|Using IBP for imaging of PET positive lymph nodes
214668105|NCT04429932|OTHER|Myblu flavor E_1.2|Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine
214668106|NCT04429932|OTHER|Myblu flavor F_1.2|Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
214668107|NCT04429932|OTHER|Myblu flavor G_2.4|Use of Myblu e-cigarette with flavor G at 2.4% nicotine
214668108|NCT04429932|OTHER|Myblu flavor H_2.4|Use of Myblu e-cigarette with flavor H at 2.4% nicotine
214668109|NCT05134623|DIAGNOSTIC_TEST|immunohistochemistry of tumors samples|routine resection of tumors, further analysis and immunohisochemical staining of the tissue slides.
214668110|NCT06428773|OTHER|Exercise|Participants were randomly divided into two groups: the exercise group and the control group. The exercise group performed moderate-intensity aerobic exercise on a stationary bicycle ergometer for 30 minutes during hemodialysis sessions, three days a week over 12 weeks. Additionally, the exercise group engaged in walking exercise for 30 minutes, three days a week outside of hemodialysis sessions, maintaining the heart rate between 50-60%. The exercise group also performed isolated exercises to expand wrist vessels, including wrist and elbow flexion, extension, and rotation, repeated 10 times, 2-3 days a week outside of hemodialysis sessions.
214293936|NCT05938933|BEHAVIORAL|PHP|personalized health planning (PHP)
214293937|NCT05938933|BEHAVIORAL|SMA|shared medical appointments (SMAs)
214293938|NCT00459784|PROCEDURE|Dementia Training Program|
214293939|NCT06636045|OTHER|Not applicable- observational study|No intervention. Observational study.
214293940|NCT04468204|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
214293941|NCT04468204|DEVICE|Sham SinuSonic Device|Sham positive expiratory pressure intervention using the SinuSonic Device.
214293942|NCT00791167|DRUG|Paliperidone ER|
214293943|NCT00073554|DRUG|Alfimeprase|
214293944|NCT05810623|DRUG|Intravesical Solution|Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
214668111|NCT01477450|DEVICE|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
214888075|NCT03295630|DEVICE|Accelerometer|Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count.
214888076|NCT00978614|DRUG|Neramexane|"Dosage form:~25 mg immediate release \[IR\] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"
214888077|NCT03979755|OTHER|Application of questionnaires|Application of questionnaires described by telephone.
214888078|NCT04794036|OTHER|Asynchronous telerehabilitation programme|Home-based physical rehabilitation programme using a telerehabilitation platform
214888079|NCT04794036|OTHER|Rehabilitation programme|Home-based physical rehabilitation programme by means of an explanatory booklet
215048698|NCT03974269|PROCEDURE|TAVI : Transcatether Aortic Valve Implantation|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
214293945|NCT00770289|OTHER|Cohort|Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
214293946|NCT05733624|DRUG|SCAI-001 0.01% eyedrop|BID for 12weeks
214293947|NCT05733624|DRUG|SCAI-001 0.02% eyedrop|BID for 12weeks
214668112|NCT01477450|DEVICE|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
214668113|NCT05261217|DEVICE|The motion 3D II appliance|The motion 3D II appliance treating class II malocclusion
214293948|NCT05733624|DRUG|Restasis 0.05% eyedrop|BID for 12weeks
214293949|NCT02477254|BIOLOGICAL|Vaccination|A quadrivalent HPV vaccine
214668114|NCT01381107|DRUG|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
214668115|NCT01381107|DRUG|Placebo|Sublingual administration once daily for 7 consecutive days.
214668116|NCT01955486|OTHER|flight simulation|
214668117|NCT03533166|OTHER|Chlorhexidine|0.03% Chlorhexidine + 0.05% CPC mouth rinse
214668118|NCT03533166|OTHER|Placebo|Placebo mouth rinse
214668119|NCT01167127|DRUG|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release|OXN Tablet, oral, BID, flexible dose design
214888080|NCT03104855|DRUG|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
214293950|NCT00495170|DRUG|Carboplatin|2 area under curve (AUC) by vein Weekly
214888081|NCT01080183|OTHER|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
214888082|NCT06632652|BEHAVIORAL|Health Education|"Provide 'Health Education' for acquisition of self-management skills, acquiring knowledge of both the disease and self-care. By making self-supported decisions, the patients are able to manage their diet, exercise and medication.~Patients will start implementing diabetes management right after the group education. Each patient will develop monthly goal settings (behavior change plan) related to their diabetes management, daily practice them, and record the results every day on the self-monitoring notebook. The nurses call each patient on the scheduled day, ask/evaluate his/her behavior changes and monitored data, then make step-up goals for the next month. In addition, based on his/her knowledge and practice level, the nurses provide education using the education booklet. Patients and the nurses repeat these activities during 6 months."
215048699|NCT00246363|DRUG|Silymarin|Silymarin (milk thistle)
215048700|NCT00246363|DRUG|Placebo|Placebo
215048701|NCT03487094|OTHER|Infant formula|Multi-centered, prospective, randomized clinical trial
214293951|NCT00495170|RADIATION|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
214293952|NCT00495170|DRUG|Paclitaxel|50 mg/m\^2 by vein Weekly
214293953|NCT00103181|RADIATION|3-dimensional conformal accelerated partial breast irradiation|
214293954|NCT00103181|RADIATION|brachytherapy|
214293955|NCT00103181|RADIATION|whole breast irradiation|Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks
214293956|NCT00103181|RADIATION|MammoSite or other single-entry intracavitary device|
214293957|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv BID
214293958|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv TID
214293959|NCT02308254|DRUG|Lixisenatide|Abdominal administration
214293960|NCT02308254|DRUG|Placebo|Abdominal administration
214293961|NCT01878058|OTHER|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
214293962|NCT01950845|DEVICE|Closed loop automated System (LIR®: learning intravenous resuscitator)|Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
214293963|NCT01950845|DEVICE|manual current practice by anesthesiologist team|The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
214293964|NCT01408914|DRUG|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
214293965|NCT02312895|OTHER|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
214293966|NCT02312895|OTHER|Dry needling|Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.
214293967|NCT02312895|OTHER|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
214293968|NCT06249425|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214668120|NCT05863247|OTHER|Patient Reported Outcomes / Biometric data revision|Multivariate statistical analysis will be done to identify the reported biomarkers to characterize patients into the following categories: satisfied without dysphotopsias, unsatisfied with dysphotopsias, satisfied with dysphotopsias, unsatisfied without dysphotopsias.Main outcome measures will be photic phenomena at 6 months of follow-up in correlation with the following pre-surgical parameters: macular ganglion cell complex thickness and/or total ocular and corneal higher-order aberrations (coma, trefoil, spherical aberration). Patients with known contributing factors for the development of dysphotopsias (such as residual refractive error, IOL decentration, posterior capsular opacification) will be excluded from the analyzis.
214668121|NCT02554305|DEVICE|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
214668122|NCT02554305|DEVICE|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
214668123|NCT01935219|BEHAVIORAL|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
214668124|NCT01935219|BEHAVIORAL|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
214668125|NCT01935219|BEHAVIORAL|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
214668126|NCT01323296|OTHER|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
214668127|NCT03875235|DRUG|Durvalumab|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
214293969|NCT06249425|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214477683|NCT06661369|OTHER|Sensory Perceptual Motor Training on Group|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
214888083|NCT02375165|PROCEDURE|phlebotomy|phlebotomy for collection of plasma and serum, \~30 cc
214888084|NCT03910673|DRUG|Fosfomycin disodium|Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
214888085|NCT04010474|PROCEDURE|Modified Surgical APGAR Score|"Four intraoperative factors~1. Lowest heart rate (HR),~2. Lowest mean arterial pressure (MAP)~3. Estimated blood loss~4. Operation time"
214888086|NCT05752825|RADIATION|HR-pQCT|HR-pQCT is a 3-dimensional imaging modality that can be applied to bone and joints in vivo, in order to non-invasively assess the quantity and quality of trabecular and cortical bone compartments separately. HR-pQCT will be applied to peripheral skeletal sites, namely the distal radius and tibia, where image slices equivalent to 9 mm of bone will be acquired. From this, parameters such as volumetric bone mineral density (vBMD), cortical density, cortical porosity, trabecular density, trabecular thickness, trabecular spacing and others will be calculated using specialized software. In the same scanning session, images of the wrist and ankle joints will be produced and analyzed for features of arthrosis, such as erosions, osteophytosis and others.
214888087|NCT05752825|RADIATION|DXA scan|Through DXA scans, we will obtain information regarding body composition, hip and spine bone mineral density, as well as examine any previous vertebral fractures using vertebral fracture assessment (VFA). VFA is a function of DXA scanners which allows for visualization of thoracic and lumbar vertebrae (usually T4-L4) in order to detect vertebral fractures34. Vertebral fractures can then be classified as either mild, moderate or severe using the method described by Genant et al35.
214888088|NCT05752825|DIAGNOSTIC_TEST|Bone microindentation|Using the OsteoProbe®, we will by microindentation measure the bone material strength index (BMSi), an in vivo surrogate measure of the fracture resistance of the cortical bone in the tibia. The participant is placed in a supine position with the examined leg rotated slightly outward. After identifying the site of interest, located midway between the medial tibial plateau and the medial malleolus, disinfectant is applied to the skin of the tibia being examined. Finally, under local anesthesia and fully sterile conditions, a test probe is inserted through the skin and onto the midshaft of the tibia, and the fracture resistance of the bone tissue is measured.
214888089|NCT05752825|DIAGNOSTIC_TEST|Hand grip and leg extension strength|Hand grip strength will be assessed using a digital hand dynamometer as a measure of peripheral muscle strength. Leg extensor strength will be examined using the peak torque measured by an isometric dynamometer mounted on a fixed chair. 3 attempts will be given for each method, and the maximum value recorded.
214888090|NCT05752825|DIAGNOSTIC_TEST|Timed up-and-go test|The TUG test is a functional test frequently used to assess balance in older individuals and is performed by measuring the time it takes for an individual to go from sitting to standing position, walk 3 meters, turn around and return to sitting position. A TUG score of \>13,5 seconds is associated with an increased risk of falls.
215048702|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
215048703|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
215048704|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days."
214668128|NCT03875235|DRUG|Placebo|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
214668129|NCT00246168|DRUG|tramadol hydrochloride + acetaminophen|
214668130|NCT02503891|DEVICE|MP-1 Polymer on Ceramic Articulation system|MP-1 Polymer liner on Ceramic head
214888091|NCT05752825|DIAGNOSTIC_TEST|Stabilometry|Postural control will be assessed by means of a force platform that registers Center of Pressure (CoP) as a measure of postural stability. Measurements are performed under a variety of conditions, including eyes open/closed and on different surfaces. From the CoP measurements, parameters such as CoP range and CoP velocity in both antero-posterior and medial-lateral directions will be calculated using specialized software.
214668131|NCT02858479|OTHER|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
214668132|NCT02858479|OTHER|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
214668133|NCT02858479|RADIATION|MRI scan|"2 sessions for 10 minutes :~* 11 controls stimulations for 6 s each spaced 20 s without stimulation.~* 11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
214293970|NCT06249425|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
214293971|NCT00330616|DRUG|323U66 SR|
214293972|NCT05091099|DRUG|Alendronate|On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
214293973|NCT00697203|DRUG|Placebo|po daily for 12 weeks
214293974|NCT00697203|DRUG|Pravastatin|40mg po daily for 12 weeks
214293975|NCT00697203|DRUG|Dalcetrapib|300mg po daily for 12 weeks
214293976|NCT00697203|DRUG|Dalcetrapib|600mg po daily for 12 weeks
214293977|NCT00697203|DRUG|Dalcetrapib|900mg po daily for 12 weeks
214293978|NCT01831999|BEHAVIORAL|RecoveryTrack - Extended Care (RT-E)|Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
214293979|NCT03993431|DRUG|Bio-active cement|A cement used for crown cementation, specially recommended for pediatric esthetic crowns
214293980|NCT03993431|DRUG|Packable glass ionomer|Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
214293981|NCT05422599|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
214293982|NCT05422599|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
214293983|NCT05822219|BEHAVIORAL|COVID-19 vaccine and booster training, and importance|COVID-19 vaccine and booster information training
214668134|NCT04937270|DEVICE|High frequency therapy (5 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 5 minutes using a 500 kHz resistive electric transfer (RET).
214888092|NCT05752825|DIAGNOSTIC_TEST|Nerve conduction test|To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.
214888093|NCT05752825|DIAGNOSTIC_TEST|Visual acuity test|Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
214888094|NCT00098774|BIOLOGICAL|filgrastim|5 mcg/kg subQ injection daily Day 14 until ANC \> or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
214888095|NCT00098774|BIOLOGICAL|rituximab|375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, \& 24 of Cycle 1 nad Days 3 \& 10 of Cycle 2
214888096|NCT00098774|DRUG|cytarabine|2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
214293984|NCT04062721|DRUG|Chemotherapy|Chemotherapy (at the investigator's choice) for ≥ 2 months before RFA (with controlled disease) and resumed 4-6 weeks after RFA to achieve 6-month total duration.
214293985|NCT04062721|PROCEDURE|Radiofrequency ablation (RFA)|Complete macroscopic ablation by RFA.
214293986|NCT04062721|DRUG|In situ immunotherapy|Hydrogel combining TLR or NOD2 agonist and GM-CSF will be injected in 1, 2 or 3 distinct lesions after RFA.
214293987|NCT00811473|DRUG|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
214293988|NCT00811473|DRUG|Placebo|Oral treatment once daily in the evening
214293989|NCT01163487|DRUG|Dichloroacetate|25-50mg/kg per day; oral
214293990|NCT01163487|DEVICE|EF5|21 mg/kg; IV
214293991|NCT04801108|PROCEDURE|Robotic or VATS lobar fissure completion|The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.
214293992|NCT04801108|DEVICE|Endobronchial valves placement|Endobronchial valves will be placed in the target lobe after the fissure completion.
214293993|NCT04127331|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
214888097|NCT00098774|DRUG|etoposide|5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
214888098|NCT00098774|DRUG|leucovorin calcium|100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX \< or = 0.05uM Cycles 1-5.
214888099|NCT00098774|DRUG|methotrexate|8 g/sq m IV infusion over 4 hrs Days 1 \& 15 Cycles 1, 2, \& 3; Day 15 Cycle 4 and Day 1 Cycle 5.
214888100|NCT00098774|DRUG|temozolomide|150 mg/sq m PO Days 7-11 Cycles 1-5.
214293994|NCT03038230|DRUG|MCLA-117 bispecific antibody|MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
214293995|NCT03103607|DIAGNOSTIC_TEST|Ophthalmological evaluation|exophthalmometry, evaluation of the Clinical Activity Score (CAS), assessment of diplopia, measurement of visual acuity, assessment of the corneal status; examination of the fundi
214888101|NCT06581562|DRUG|AB-101|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
214888102|NCT06581562|DRUG|Rituximab|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
215048705|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days."
215048706|NCT00067561|DRUG|Alosetron|
215048707|NCT02544854|DRUG|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended."
215048708|NCT04270344|DRUG|Pitavastatin 4mg|combination therapy with pitavastatin/valsartan (LivaloV)
215048709|NCT06393842|DEVICE|Cardiopulmonary Management Wearable Device|Fluid status and congestion can be determined by the CPM wearable device and correlates with non-invasive measures and biochemical markers of congestion and changes in congestion.
214293996|NCT03103607|DIAGNOSTIC_TEST|Questionnaire|Patients were asked to fill a questionnaire on self-perception related to GO with the following questions: i) are your eyes identical to the way they were before GO appeared?; ii) are your eyes normal? iii) do you have any limitations in daily activities related to your eyes?; iv) do you have any limitations in social life related to your eyes?
215048710|NCT03212976|PROCEDURE|Phase contrast magnetic resonance imaging|Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
215048711|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
215048712|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
215048713|NCT04289779|DRUG|Cabozantinib|Cabozantinib 40 mg orally daily for 3 cycles
215048714|NCT04289779|DRUG|Atezolizumab|Atezolizumab 1200 mg IV every 3 weeks for 3 cycles
215048715|NCT04289779|PROCEDURE|Cystectomy|Patients will receive three cycles of treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw consent.
215048716|NCT06381336|DEVICE|TRAK-SILVER platform|"The Experimental Group used TRAK-SILVER, a cross-platform web application that empowers healthcare professionals and patients. It facilitates the management of a patient's condition by providing therapeutic exercises, monitoring activity, and administering clinical assessment scales and questionnaires. The platform's advanced artificial vision algorithm, known for its precision, enhances patient engagement with real-time measurements and corrections during exercise.~Physiotherapists monitored the sessions through the TRAK-SILVER platform's monitoring system and weekly phone calls. The TRAK-SILVER platform had an alert notification system.~The program's second part involved weekly uploads of health-promoting information pills to the platform."
214293997|NCT00548925|DRUG|ABT-894|6 mg BID tablets, 8 weeks of treatment
215048717|NCT04287413|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination.~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
215048718|NCT04287413|BEHAVIORAL|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
215048719|NCT06284759|OTHER|post-discharge telenursing intervention|Tele-nursing based on Orem's Self-Care Theory was applied to patients with lower extremity fracture surgery. Phone/video calls 24-48 after discharge. hours, 7-10. day,18-21. day, 28-30th day and 40-45th day. day was made. Telephone or video conference interviews were held on the day and time convenient for the patient. After each meeting, the date and time of the next meeting was planned. The video conferencing method (zoom, skype, whatsapp, etc.) was presented to the patient's preference and the decision was made together. In phone/video conference calls, patients were informed about their current problems. Additionally, patients' questions were answered. Prior to tele-nursing monitoring, the researchers identified emergent or urgent situations; Patients were informed that they should consult their doctor if this occurs. The interview with each patient lasted an average of 30 minutes.
215048720|NCT06556485|PROCEDURE|Catheter ablation|Preventive ablation therapy
215048721|NCT06556485|DRUG|Medical therapy|Optimal medical therapy
214888103|NCT06581562|DRUG|Cyclophosphamide|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
215048722|NCT04516603|DRUG|Fampridine SR|Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
215048723|NCT04516603|DRUG|Placebo|no active component
215048724|NCT03092479|BEHAVIORAL|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
215048725|NCT01337778|BEHAVIORAL|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
215048726|NCT01337778|BEHAVIORAL|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
215048727|NCT03404713|BEHAVIORAL|Pathways to Health|Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.
215048728|NCT03404713|BEHAVIORAL|Be4U|This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
215048729|NCT06255769|DEVICE|Magnetocardiography|Magnetocardiography
214293998|NCT00548925|DRUG|placebo|BID tablets, 8 weeks of treatment
214293999|NCT02188251|DIETARY_SUPPLEMENT|Activamp|
214668135|NCT04937270|DEVICE|High frequency therapy (7 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 7 minutes using a 500 kHz resistive electric transfer (RET).
214668136|NCT04937270|DEVICE|High frequency therapy (9 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 9 minutes using a 500 kHz resistive electric transfer (RET).
214668137|NCT04937270|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
215048730|NCT06255769|DEVICE|Single photon emission computed tomography (SPECT)|Single photon emission computed tomography (SPECT)
215048731|NCT04683913|BEHAVIORAL|Foot rotation modification|"The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable."
215048732|NCT04683913|OTHER|Waiting Period - Delayed Group|Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
215048733|NCT06368401|DEVICE|Versa Implant|The Versa Vascular Implant and Delivery System consists of a percutaneously delivered, permanent right-atrial implant and the delivery catheter that is used to first position the implant over the native valve orifice and to then place the implant.
215048734|NCT06572293|BEHAVIORAL|Nurse-led intervention|Nurse-led intervention involves patient education, collecting Patient Reported Outcomes (PRO) and evaluating them by specialists nurses, as well as navigating patients to services that can assist with their symptoms. During three-five planned appointments, the nurse will talk with you about adjusting to life after complete the radiotherapy of nasopharyngeal carcinoma, including symptoms of relapse and how to deal with them.In the first year, PROs will be collected every six months on recurrences and late effects, and thereafter every 12 months. PRO will be administered to patients for three years after the nurse appointments are finalized.
215048735|NCT05859178|OTHER|Exercise group|Along with nerve transfer surgery, individuals in the exercise group will undergo handgrip exercise for 30 minutes a day, 5 days a week for a total of 12 weeks.
215048736|NCT04848402|DEVICE|On-Body Delivery System (OBDS)/Multiple Bolus Injector|Used to administer placebo SC.
214668138|NCT00583739|BEHAVIORAL|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
214294000|NCT02188251|OTHER|Placebo|
214888104|NCT06581562|DRUG|Fludarabine|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
214888105|NCT03240029|OTHER|Questionnaires|SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
214888106|NCT02158715|DEVICE|Site of smartphone on chest compressor' arm|
215048737|NCT04848402|DEVICE|Single Auto Injector|Used to administer placebo SC.
215048738|NCT04848402|DRUG|Placebo|Administered SC.
215048739|NCT03655847|DRUG|Dexmedetomidine|Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
215048740|NCT06656637|BEHAVIORAL|Memory Drilling|"The experimental group will receive the additional intervention during their seven sessions with their care providers. The intervention is computerized memory drills training. This training includes the completion of a list learning memory task (HVLT) and then a PM practice task conducted on the computer at each session."
215048741|NCT06656637|BEHAVIORAL|Compensatory Strategies|Participants learn compensatory strategies to assist with their memory performance. This involves both external strategies, such as calendering and setting alarms, and internal strategies, like imagery and mnemonics.
214888107|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention face-to-face|
214888108|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention delivered via DVD|
214888109|NCT00006286|DRUG|Fluoxetine|
214668139|NCT02429505|DRUG|Miltefosine|miltefosine: target 2.5 mg/kg/day for 28 days
214888110|NCT00006286|BEHAVIORAL|Psychotherapy|
214888111|NCT00102622|BIOLOGICAL|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m\^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
214888112|NCT00102622|DRUG|Paclitaxel|80 mg/m\^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
214888113|NCT02324582|DRUG|Intravenous MK-3475/ Intravesical BCG|6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembrolizumab.
214888114|NCT00062530|BIOLOGICAL|SCBaL/M9|Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
214888115|NCT00380835|DRUG|Amrubicin|
214888116|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
214888117|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
214888118|NCT03912935|OTHER|comparison between two different intubating position|Comparing to different position (sniffing and BUHE) in endotracheal intubation for rapid sequence induction in simulated emergency cases
214888119|NCT03068728|DEVICE|Arista|
215048742|NCT06656637|BEHAVIORAL|Cognitive Processing Therapy|This is PTSD-targeted therapy.
215048743|NCT05187299|OTHER|observer tool|The observer tool is paper-based and is divided in columns (each column filled out for a dyad observed) with lines representing the above-described steps of learning and presented with visual incremental actions to be performed. The observer tool will only be used to reinforce learning and will not be used for summative evaluation. Instructors have already been involved in previous simulation studies performed in our center, and especially those in which an observer tool has been assessed (one study published, two manuscripts in preparation).
215048744|NCT06902376|BIOLOGICAL|Cemiplimab|Cemiplimab will be administered at a dose of 350mg intravenous over 30 minutes every 3 weeks for 3 cycles (cycle length is 21 days) at weeks 1, 4, and 7.
214294001|NCT04671225|BEHAVIORAL|Groups Psychoeducation|Manual-structured group psychoeducation with 8 sessions of 90 minutes over the course of 8 weeks (at one session per week). The manual is centred on behavioural principles from social education and self-regulation philosophies. All groups will have 6-8 participants and two health professionals to conduct the sessions; a psychiatric nurse and either a psychologist or a psychiatric resident. Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives.
214668140|NCT02514070|DRUG|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
214888120|NCT03068728|DEVICE|Nexfoam|
214888121|NCT03068728|DEVICE|Nasopore|
215048745|NCT06902376|DRUG|XL092|XL092 will be administered at a dose of 100mg PO daily for 8 weeks (weeks 1-8)
214888122|NCT02443597|OTHER|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
215048746|NCT04743011|DRUG|Heparin sodium|Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
214668141|NCT02514070|DRUG|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
214668142|NCT01574781|PROCEDURE|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
214668143|NCT01574781|PROCEDURE|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
214888123|NCT03593889|BEHAVIORAL|Collaborative stepped care and peer support programme|"For at-risk group, 4 weeks of selective prevention group sessions will be provided at the elderly service level by trained peer supporters with registered social worker supervision, on wellness topics tailored to the person's concern as entry point, packaged with mental health information, followed by a review.~For mild group, 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided. For moderate group, 6-8 weeks high-intensity cognitive behavioral therapy (CBT) would be provided. All intervention for depressed elderly would be conducted by registered social workers. The trained peer supporters will be matched to individual older adults to walk them through the process with regular follow-up for 1 year."
214888124|NCT03593889|OTHER|Treatment as usual|The control group will receive treatment as usual, which will be determined by the responsible workers from NGO units.
214888125|NCT06099392|DEVICE|digital stimulators (SNM-FDC01, Ningbo MaidaMedical Device, Inc, Ningbo, China)|TEA at Zusanli(ST 36) 45 min when drinking Polyethylene Glycol Electrolytes Powder
214888126|NCT02326636|BIOLOGICAL|Fecal Microbial Transplantation|Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema.
215048747|NCT04743011|DRUG|Placebo|Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
214888127|NCT05983354|DRUG|Oral metoclopramide and ibuprofen|10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml normal saline IV administered over 15 minutes.
214888128|NCT05983354|DRUG|Intravenous metoclopramide and ketorolac|10 mg of metoclopramide IV in 50 ml normal saline, 10 mg ketorolac IV in 50 ml normal saline administered over 15 minutes, with 2 placebo tablets.
214888129|NCT01497769|BIOLOGICAL|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10\^7 pfu and intradermal saline placebo
214888130|NCT01497769|BIOLOGICAL|Intradermal MVA85A|Intradermal MVA85A 1 x 10\^7 pfu and inhaled aerosol saline placebo
214888131|NCT02939794|DRUG|Ferinject|1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
214888132|NCT02939794|DRUG|Placebo|Saline (normal saline, sodium chloride)
214888133|NCT02022878|PROCEDURE|PCI of CTO|
214888134|NCT01531088|BEHAVIORAL|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
214888135|NCT01382888|DRUG|Heparin 2,400 IU /ml Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
214888136|NCT01382888|DRUG|Placebo Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
214888137|NCT01777178|OTHER|Low bicarbonate dialysis|
214888138|NCT04138381|DRUG|Selinexor|oral selinexor given once weekly (Cohort A), oral selinexor given BIW (Cohort B)
214888139|NCT04138381|DRUG|Imatinib|imatinib 400 mg, once daily (Cohort A)
214888140|NCT04594681|DRUG|Placebo|Placebo is administered once daily or three times daily.
215048748|NCT03910075|BEHAVIORAL|I-ACQUIRE - High Dosage|Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
215048749|NCT03910075|BEHAVIORAL|I-ACQUIRE - Moderate Dosage|Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
215048750|NCT03910075|BEHAVIORAL|Usual & Customary Treatment (U&CT)|Children in this group will receive the same U\&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
215048751|NCT03539679|OTHER|Encouraging physical activity.|Encouraging physical activity with motion sensor's feedback.
215048752|NCT05815888|DIAGNOSTIC_TEST|Lung Ultrasound Score|"one hemithorax is consisted of 6 scanning zones. Each of them are evaluated via ultrasonography in terms of presence of vertical B lines (\<4 B lines: 1 point; \>3 B lines or thick B lines: 2 points; marked disturbance in pleural line: 3 points). Higher scores reflect worse outcomes such as atelectasis and consolidation, and totally 12 zones are evaluated.~Three different time points are defined for LUS:~T1: 5 minutes after orotracheal intubation T2: At the end of surgery, before extubation T3: 30 minutes after extubation, in postanesthesia care unit.~DeltaT= T2LUS-T1LUS~Blood gas analysis will be evaluated hourly throughout the surgery"
215048753|NCT06927661|BEHAVIORAL|Consumption of vegetables|ENSAND 2.0 is designed to address challenges of low consumption of vegetables in both variety and quantity by working with smallholder farmers to increase production and promoting healthier diets through greater vegetable consumption. The project will build the capacity of smallholder farmers in vegetable production through collaborating with lead farmers to establish demonstration plots that showcase advanced agricultural techniques and technologies. These plots will serve as training hubs for other farmers in vegetable production, postharvest handling, as well as business and market planning. ENSAND aims to increase consumption among neighbors of the smallholder farmers by asking the farmers to recruit at least one neighbor family to whom they will regularly sell vegetables.
215048754|NCT02982226|OTHER|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
214888141|NCT04594681|DRUG|KHK4951|KHK4951 is administered once daily or three times daily.
214888142|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP|Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation.
214888143|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP + Coaching|"Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; ongoing technical assistance in CBT implementation; and weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
214888144|NCT03541317|BEHAVIORAL|Stage 2 Strategy: Augment with Facilitation|In addition to first-line treatment (REP or REP + Coaching), schools will also receive support from a Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support SPs in strategic thinking and leadership skills to address organizational barriers.
214888145|NCT03541317|BEHAVIORAL|Stage 2 Strategy: No augmentation|Schools will continue to receive their first-line treatment (REP or REP + Coaching); no additional support will be offered.
214888146|NCT02556957|BEHAVIORAL|HealthScouts|
214888147|NCT02556957|OTHER|Standard of Care|
214888148|NCT04359394|OTHER|biological sampling|In order to investigate the level of molecular pathophysiology, blood and punch biopsies will be collected of each patient. In up to two relatives per patient, 30mL blood will be collected only once.
214888149|NCT04359394|OTHER|Phenotypic description|Phenotypic characterization of the patient's clinical features
214888150|NCT04359394|OTHER|Photography|All affected areas will be photographed at each visit with 2-dimensional standardized photography
214888151|NCT03422614|DIAGNOSTIC_TEST|Diagnostic Test|Characterisation of cellular and functional phenotype in different PIDs
214888152|NCT01805843|OTHER|Echo, exercise echo, and if indicated, right heart catheter|routine echocardiography and special measurements of the right heart are performed at rest and during exercise
214888153|NCT04521894|DEVICE|Positron emission tomography/computerized tomography (PET/CT)|"1. Genetic factors and age:~   Epidemiological studies have shown that if an immediate family member (brother or father) suffers from prostate cancer, the risk of prostate cancer will be more than doubled. Age is a relatively strong risk factor for PCa.~2. Prostatitis: Prostatitis is related to PCa. Cancer is usually found in the tissues where inflammation is found.~3. Obesity: Research has found that obese patients have a low grade of PCa, but their risk of developing aggressive cancer is higher.~4. Infection:~5. Exercise: Most studies have found that exercise does not reduce the risk of prostate cancer, but some studies have shown that.~6. Daily diet: The corrective mechanism of diet in PCa is not very clear.~7. Drinking history:"
214294002|NCT04671225|BEHAVIORAL|Waiting-list|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
214888154|NCT05274633|DRUG|Ravulizumab|Participants will be observed for 52 weeks after the start of ravulizumab.
214888155|NCT04031755|DRUG|Minocycline|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
214888156|NCT04031755|DRUG|Placebos|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
215048755|NCT02982226|OTHER|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
215048756|NCT06132464|BEHAVIORAL|Expanding Communication and Language Generated in Conversation Treatment|ECoLoGiC Treatment is a behavioral therapy developed to improve language abilities in everyday conversation for people with aphasia. It is delivered through therapeutic use of spontaneous conversational interactions between a speech-language pathologist and a person with aphasia. ECoLoGiC Treatment is based on theories of conversational interaction in adults without communication disorders, as well as on theories of neuroplasticity, rehabilitation, and learning. The therapy consists of two components: a) Therapeutic Conversation, during which the pair discuss any topic of interest to the person with aphasia, while the speech-language pathologist uses techniques to promote social interaction; and b) Therapeutic Repair, used when communication breakdown occurs. At this time, the speech-language pathologist implements the intervention's 7-step least-to-most hierarchy, supporting the person's independence and learning in communicative problem-solving to communicate the desired idea.
215048757|NCT04118829|DRUG|Perampanel|"For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day."
215048758|NCT03412825|DIETARY_SUPPLEMENT|Egg supplementation|Participants will required to consume 2 eggs per day, 5 days a week (a total of 10 eggs per week).
215048759|NCT00441272|DRUG|Pioglitazone|
215048760|NCT01198782|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
215048761|NCT01856322|DRUG|Sulindac|one tablet 150mg twice daily
215048762|NCT01856322|DRUG|Placebo|One tablet twice daily
215048763|NCT01856322|OTHER|Validate assays and shipping methods|
214294003|NCT00296478|DRUG|Endometrin|Endometrin 100mg BID x 10weeks
214294004|NCT00296478|DRUG|Endometrin|Endometrin 100mg TID x 10weeks
214294005|NCT00296478|DRUG|Crinone|Crinone QD x 10weeks
214294006|NCT01585194|BIOLOGICAL|Ipilimumab|Given IV
214294007|NCT01585194|OTHER|Laboratory Biomarker Analysis|Correlative studies
214294008|NCT01585194|BIOLOGICAL|Nivolumab|Given IV
214294009|NCT00000854|DRUG|Nandrolone decanoate|
214294010|NCT06471894|RADIATION|Magnetic resonance imaging scanning|Perform brain diffusion imaging, magnetic resonance spectroscopy, and functional magnetic resonance imaging scans on all individuals
214294011|NCT06471894|DRUG|FMT Protocol|Treatment of disease groups (UC and CD) using prepared fecal microbiota transplantation solution
214294012|NCT02604108|BEHAVIORAL|Physical Exercise|"The Physical Exercise arm includes a training workshop and electronic health messages related to positive psychology and physical activity for all participants in physical exercise group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
214888157|NCT02836210|DEVICE|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
214888158|NCT05603533|OTHER|Music and video-based group exercise therapy|Each exercise session will last up to 45min. The participants will follow this group exercise therapy twice a week for four months.
214888159|NCT02928445|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
214888160|NCT02928445|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
214888161|NCT02554162|OTHER|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
214888162|NCT02965417|DRUG|Sym004|Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
214888163|NCT02885402|OTHER|MRI Sodium ( 23Na )|
214888164|NCT06469632|OTHER|Active Comparator: Experimental Group 1|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique."
214888165|NCT06469632|OTHER|Experimental: Experimental Group 2|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique.~Non-ablative radiofrequency: using capacitive superficial electrodes and resistive superficial and intravaginal electrodes."
214888166|NCT04237935|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg dispensing claim is used as the exposure group
214888167|NCT04237935|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
214888168|NCT00000691|DRUG|Foscarnet sodium|
214888169|NCT01168752|DRUG|Debio 0932|"Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met."
215048764|NCT04738994|DIETARY_SUPPLEMENT|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
215048765|NCT04738994|OTHER|Control group|Standard hospital diet
214294013|NCT02604108|BEHAVIORAL|Healthy Diet|"The Healthy Diet arm includes a training workshop and electronic health messages related to positive psychology and health diet for all participants in healthy diet group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
214888170|NCT02986477|OTHER|Contrast Ultrasound|For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
214888171|NCT02123446|DRUG|Cephalexin|Administered orally.
214888172|NCT04663191|PROCEDURE|anatomical resection|Anatomical resection with systematic lymph-node dissection
214888173|NCT04388553|PROCEDURE|single shot lumbar Erector Spinae Plane block|unilateral (operative side), performed at L1 level, under ultrasound guidance
214888174|NCT01000948|DRUG|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
214888175|NCT05629819|DEVICE|Non-invasive phrenic nerve stimulation|Some studies have shown that PNS can relieve diaphragmatic atrophy and reverse diaphragmatic dysfunction.
214888176|NCT02864355|DEVICE|Goal Directed Therapy|Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
214888177|NCT02818101|BEHAVIORAL|Hypnosis session|
214888178|NCT04502212|DEVICE|Hepatic Ultrasound Insonification|Hepatic ultrasound insonification will be performed after an overnight fast (no food or drinks except for water for at least 10 hours) at approximately the same time on each day for three days.
214888179|NCT05443178|DRUG|Nivaquine ® (Chloroquine)|dose escalation and extension trial
214888180|NCT03516656|DRUG|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
214888181|NCT03516656|DRUG|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
214888182|NCT03638544|DIETARY_SUPPLEMENT|Reduced gluten bread and Pasta compared o normal gluten bread and Pasta|Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
214888183|NCT02483546|DEVICE|Laerdal®|simulation- based educational intervention
215048766|NCT02790840|DRUG|Omeprazole|20 mg oral capsules administered once daily for 10 days
215048767|NCT02790840|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 10 days
215048768|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
215048769|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
214477684|NCT06661369|OTHER|Sensory Perceptual Motor Training on Individual|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
214477685|NCT06858930|PROCEDURE|ACL footprint localization after preoperative navigation executed by robotic arm|Anterior cruciate ligament (ACL) reconstruction is performed using the preoperative navigation of Naton Robotics, followed by random assignment to either robotic surgery or traditional manual surgery. The difference between the two lies in whether the localization of the ACL footprint is performed by a human or by the robotic arm. The surgical technique is standardized as double-bundle reconstruction.
214477686|NCT06858930|PROCEDURE|ACL footprint localization after preoperative navigation executed by rmanual execution|Anterior cruciate ligament (ACL) reconstruction is performed using the preoperative navigation of Naton Robotics, followed by random assignment to either robotic surgery or traditional manual surgery. The difference between the two lies in whether the localization of the ACL footprint is performed by a human or by the robotic arm. The surgical technique is standardized as double-bundle reconstruction.
214477687|NCT06856408|BEHAVIORAL|FinnPog|The aim of the study is to find out how intervention affects the early childhood educators' self-efficacy teamwork and the changes in children's behavioral challenges. This RCT study has two parallel groups where teams of the daycare centres are randomized to intervention or control group. The research data is collected using electronic surveys and interviews.
214477688|NCT06858618|COMBINATION_PRODUCT|FCN-338 + Azacitidine|FCN-338 (400 or 600 mg, PO, QD, D1-28) combined with azacitidine (75mg/m², SC, QD, D1-7), 28 days/cycle
214888184|NCT02483546|BEHAVIORAL|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
214888185|NCT02483546|BEHAVIORAL|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
214888186|NCT00060983|PROCEDURE|Body weight supported locomotor training|
214888187|NCT00060983|PROCEDURE|Functional electrical stimulation|
214888188|NCT00006183|PROCEDURE|Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits|
214888189|NCT00006183|PROCEDURE|Thoracic Surgery|
214888190|NCT06329427|OTHER|Dragon Ambient eXperience (DAX) Copilot|The tool (DAX) listens to the conversation between a clinician and patient/caregiver during their visit, provides transcriptions between different speakers for the clinician to review, edit, and included in the final EHR notes.
214888191|NCT01363882|OTHER|Sleep study-guided adjustment of NIV|Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
214888192|NCT01363882|OTHER|Standard initiation of NIV|NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
214888193|NCT04820660|OTHER|Task orientated strengthening training|"1. Standing and reaching in different directions for objects located beyond arm's length to promote loading of the lower limbs and activation of lower limb muscles;~2. Sit-to-stand from various chair heights to strengthen the lower limb extensor muscles;~3. Stepping forward and backward onto blocks of various heights to strengthen the lower limb muscles;~4. Stepping sideways onto blocks of various heights to strengthen the lower limb muscles;~5. forward step-up onto blocks of various heights to strengthen the lower limb muscles;~6. heel(s) raise and lower while maintaining in a standing posture to strengthen the plantar- flexor muscles.~Each workstation was 5 min in duration for each exercise class. Each subject participated in a one-to-one therapy."
214888194|NCT04820660|OTHER|Balance training exercises|"1. Stepping forward, backward, and sideways on the exercise step;~2. Stepping over blocks of various heights;~3. Standing up from a chair, walking four steps forward, performing a bilateral stool touch and walking backwards to the chair;~4. Standing up from a chair, walking four steps forward, turning to the right, stepping over the exercise step, turning to the right again and walking forwards to the chair (repeat the exercise circuit in opposite direction);~5. From a sitting position on a 65-cm Swiss ball, performing a range of motion and balance exercises (forward and backward rolling of the~6. Arms; bending the trunk forward and side to side);~7. Performing double-legged stance for 10 s;~8. Performing tandem stance for 10 s;~9. Rising from a chair without the use of the arms;~10. Walking forward and backward with a tandem walking pattern (toes of one foot touching the heel of the foot in front);~11. Performing single- legged stance for 10 s."
214888195|NCT02535793|OTHER|blood test (four dry tubes 7ml) and prick tests|
214477689|NCT06858618|COMBINATION_PRODUCT|FCN-338 + erythromycin+ Ara-C|"Induction phase: FCN-338(600 mg, QD, D1-14) , erythromycin (60 mg/m², IV, QD , D1-3) and Ara-C (100 mg/m², IV, QD, D1-7) for 1 to 2 cycles.~Consolidation phase: FCN-338(600 mg, QD, D1-14) ,Ara-C (1 to 3 g/m²/12h, 6 doses) for 3 to 4 cycles Maintenance phase:FCN-338(600 mg, QD, D1-14) , azacitidine (50 mg/m², SC, QD, D1-5) for the first 12 cycles and FCN-338 (600 mg, QD, D1-14) alone for the rest 12 cycles"
214477690|NCT06856655|DEVICE|Scorpion Portal Vein Access Kit|Procedure/Surgery: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
214477691|NCT06856395|OTHER|intervention group|Robotic distraction during vaccination process
214477692|NCT06857916|OTHER|Traditional|Traditional rehabilitation course will occur.
214477693|NCT06857916|OTHER|cycle with biofeedback|Individuals will receive biofeedback about their power production and power symmetry while participating in a 32 minute recumbent cycling session in inpatient rehabilitation facility.
214477694|NCT06857552|OTHER|Visual biofeedback using transperineal ultrasound (TPUS)|The intervention (study) arm will recieve coached maternal pushing via transperineal ultrasound (US) with visual biofeedback
214477695|NCT06860152|DEVICE|Cochlear implant|Cochlear implant
214477696|NCT06858293|BEHAVIORAL|Mental Imagery Open Chain|Participants will receive a paper packet with instructions to imagine themselves performing seated maximal leg extension exercises. They will be instructed to imagine the feeling of the exercise for 5 seconds, rest for 5 seconds, and repeat this 50 times with a 2-minute rest period after the 25th repetition. They will also be asked to keep track of the exercises with tallies on a table within the packet and also to record on this table if they did not complete the exercises for that day. The participant is asked to perform the exercises on five consecutive days.
214888196|NCT04697082|PROCEDURE|Open surgery|Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
214888197|NCT04697082|PROCEDURE|Minimal invasive surgery|In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured
214888198|NCT04697082|OTHER|Platelet rich plasma administration|Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
214888199|NCT02329626|DEVICE|PET CT 18 FDG|"Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography.~This intervention is required for the observational needs of the study."
214888200|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
214888201|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
214888202|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
214888203|NCT01012310|DRUG|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
214888204|NCT02713555|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
214888205|NCT02713555|PROCEDURE|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
214888206|NCT05959252|DRUG|Unfractionated heparin|Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
214888207|NCT05959252|DRUG|Bivalirudin|Bivalirudin protocol with target aPTT 50-70 seconds
214888208|NCT02826512|DRUG|Niraparib|niraparib 300 mg QD continuously
214888209|NCT06451211|DRUG|Tislelizumab|Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants
214888210|NCT06451211|DRUG|Oxaliplatin|Oxaliplatin 150 mg will be administered systemically on day 1 of each cycle in all participants
214888211|NCT06451211|DRUG|S-1|S-1 40 mg will be administered orally on day 1-14 of each cycle in all participants
214888212|NCT06451211|DRUG|Capecitabine|Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants
214888213|NCT00001946|PROCEDURE|Magnetic resonance angiography|
214888214|NCT00930163|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
214888215|NCT00930163|DRUG|placebo|Subcutaneous repeating dose
214888216|NCT03048552|BEHAVIORAL|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
215048770|NCT02425787|BEHAVIORAL|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
214668144|NCT06655077|OTHER|RA PRO Dashboard|The RA PRO Dashboard was developed by UCSF rheumatology investigators in collaboration with the UCSF SOMTech Unit. Briefly, investigators used a human-centered design approach to build a new, EHR-integrated, patient-facing visualization tool that displays RA outcome data to RA patients during clinical visits. The RA PRO dashboard was tailored for deployment at the UCSF Health's rheumatology clinic using a EHR side-car application (Salesforce). The dashboard was launched into the production environment in August 2021. With the launch, investigators integrated quality improvement, user monitoring, and lean management techniques to promote use of RA outcomes and the dashboard (for clinicians granted access) during clinical visits.
214888217|NCT04667754|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
215048771|NCT02425787|BEHAVIORAL|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~1. With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews \&/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~2. With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
214668145|NCT04248166|DEVICE|Photoacoustic imaging|"1. Photoacoustic image of thyroid nodule is obtained by using probe of photoacoustic imaging equipment and image data and data are stored in the device.~2. The patient's examination is the same as the general ultrasound, and the patient is asked to hold his breath for about 3-4 seconds to get the photoacoustic image."
214888218|NCT01499433|DRUG|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
214888219|NCT06080854|DRUG|Toripalimab|Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks
214888220|NCT06080854|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks
214888221|NCT06080854|DRUG|Nab paclitaxel|Nab paclitaxel 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
215048772|NCT02425787|BEHAVIORAL|Interview|The interview will be conducted by study team members and will center around legacy item-related questions.
215048773|NCT01364480|DEVICE|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
215048774|NCT04892524|OTHER|Virtual multidisciplinary review|The virtual multidisciplinary review involves participants being reviewed by a multi-disciplinary team of specialist doctors, nurses and radiologists in a virtual environment. The team will analyse radiologic scans and make a recommendations for any follow-up scans, procedures or appointments that may be required
215048775|NCT06421519|OTHER|BiPAP setting|"Infants in this arm of the study will each rotate through three different BiPAP settings. The following BiPAP settings will be used:~13cmH2O / 5cmH2O, 10cmH2O / 5cmH2O, 7cmH2O / 5cmH2O"
215048776|NCT03203811|DRUG|HTI-2088|3 dose levels
215048777|NCT03203811|DRUG|Placebo|placebo oral tablet
215048778|NCT00705913|DEVICE|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
215048779|NCT00705913|DEVICE|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
215048780|NCT01106989|DRUG|Heated lidocaine/tetracaine patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
215048781|NCT05155124|DRUG|Cetuximab + trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
215048782|NCT03211819|PROCEDURE|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
215048783|NCT02649452|OTHER|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
214888222|NCT06080854|OTHER|SBRT|SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions
214888223|NCT01958073|DRUG|Conjugated Estrogen Vaginal Cream|
214888224|NCT01958073|DRUG|Estradiol Ring|
214888225|NCT01958073|DRUG|Placebo|
214294014|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer|Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
214294015|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%|Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
214294016|NCT01957553|DEVICE|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
214294017|NCT01957553|DEVICE|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
214294018|NCT05911776|DRUG|Nasal packing Dexmedetomidine|patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
214294019|NCT05911776|DRUG|Intravenous Dexmedetomidine|patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
214294020|NCT02398851|BEHAVIORAL|TacTic care model|Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
214888226|NCT04525573|DEVICE|LLLT Combination Red/Gold/IR Therapy|Three LLLT combination treatments per week over the course of two consecutive weeks, and a final follow up on day-15 (total of 7 treatments).
214888227|NCT06634329|OTHER|Oro or Nasogastric tube feeding|Parental involvement in their premature baby's feeding
214888228|NCT03281395|PROCEDURE|Rapid ventricular pacing (RVP)|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.
215048784|NCT02907658|BEHAVIORAL|PROTECT intervention group|The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
215048785|NCT01030120|DRUG|etanercept|etanercept 50mg BIW S.Q.
215048786|NCT01030120|DRUG|placebo|placebo
215048787|NCT03663855|DRUG|Tiopronin|Phase 1: No medication, Phase 2: 500mg PO daily x 7 days (total 500mg), Phase 3: 500mg PO BID x 7 days (total 1g), Phase 4: 1g PO BID x 7 days (total 2g)
215048788|NCT05595850|BEHAVIORAL|Mindfulness|Online non-meditation mindfulness program
215048789|NCT05595850|BEHAVIORAL|Mindful Learning|Online learning program
214294021|NCT02398851|BEHAVIORAL|Standard of care|Patients receive care in a patient-centered, coordinated care model without the integration of technology
214294022|NCT00132587|DEVICE|cement Palacos R40 and LV40|
214294023|NCT03254927|DRUG|CDX-3379 and cetuximab|Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
214294024|NCT00187811|PROCEDURE|Delta amino leavulinic acid photodynamic therapy|
214294025|NCT00993291|PROCEDURE|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
214294026|NCT00993291|PROCEDURE|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
214294027|NCT01490957|OTHER|Database|Database
214294028|NCT00446290|DRUG|Docetaxel, Capecitabine and Oxaliplatin|
214294029|NCT01904682|DRUG|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
214294030|NCT00670865|OTHER|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
214294031|NCT01333059|DRUG|Midazolam|
214294032|NCT01333059|DRUG|Normal saline|
214294033|NCT01333059|DRUG|Fentanyl|
214294034|NCT02697175|DEVICE|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
214294035|NCT02697175|OTHER|No Live Video-Colposcopy|The TV will be shut off during colposcopy
214477697|NCT06858293|BEHAVIORAL|Mental Imagery Closed Chain|Participants will receive a paper packet with instructions to imagine themselves performing maximal standing squat exercises. They will be instructed to imagine the feeling of the exercise for 5 seconds, rest for 5 seconds, and repeat this 50 times with a 2-minute rest period after the 25th repetition. They will also be asked to keep track of the exercises with tallies on a table within the packet and also to record on this table if they did not complete the exercises for that day. The participant is asked to perform the exercises on five consecutive days.
214888229|NCT03281395|PROCEDURE|No rapid ventricular pacing|
214888230|NCT01965054|DIETARY_SUPPLEMENT|Fish Oil Supplement Group|1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
214888231|NCT01734161|DRUG|Dexamethasone|8mg IV dexamethesone given
214888232|NCT01734161|DRUG|Placebo|Subjects randomized to placebo receive 50cc normal saline
214888233|NCT03448887|DEVICE|Theranova|Extended HD with theranova
214888234|NCT03448887|DEVICE|Online hemodiafiltration|Online hemodiafiltration
214888235|NCT03403647|DIETARY_SUPPLEMENT|Vitamin D|Oral daily vitamin D
214888236|NCT03739047|BEHAVIORAL|Desensitization with flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by desensitization. Desensitization will be conducted for 3, 45-minute treatment meals. Puree will be presented on a flipped EZ spoon after the desensitization sessions are completed. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
214888237|NCT03739047|BEHAVIORAL|flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by puree being presented from a flipped EZ spoon. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
214888238|NCT00386347|DRUG|GSK364735 oral solution and oral tablets|
214888239|NCT00324727|DRUG|melphalan|Given throug isolated hepatic artery infusion
214888240|NCT00324727|DRUG|regional chemotherapy|Patients receive the best alternative therapy
214888241|NCT00324727|DRUG|systemic chemotherapy|Patients receive the best alternative therapy
215048790|NCT05382884|OTHER|Postpartumcare.ca (Web-Enabled Intervention)|Postpartumcare.ca is a web-enabled intervention accessible via computer, tablet or smartphone devices. The content and design of postpartumcare.ca were created based on the needs, opinions, and desires of birthing parents in British Columbia affected by postpartum depression and/or anxiety, which were solicited previously in phases 1 \& 2 of the SUPPORT study.
215048791|NCT04343092|DRUG|Ivermectin (IVM)|Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
214477698|NCT06858605|OTHER|Kaltenborn-Evjenth Orthopedic Manual Therapy (KEOMT)|Kaltenborn's biomechanical approach to diagnosis and treatment emphasizes ergonomic principles and trial-based techniques. His mobilization methods, classified into Grades I-III, target pain relief (Grades I-II) and joint hypomobility (Grade III) by enhancing glide and tissue elasticity. The Kaltenborn-Evjenth Orthopedic Manual Therapy (KEOMT) further refines this approach using arthrokinematic principles to restore physiological joint motion based on the concave-convex rule.
214477699|NCT03582033|DRUG|SEA-BCMA|Given into the vein (IV; intravenously)
214477700|NCT03582033|DRUG|dexamethasone|Given by mouth (orally) or by IV
214477701|NCT03582033|DRUG|pomalidomide|Given orally
214477702|NCT06669663|DRUG|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Participants will receive Pimonidazole (non-CTIMP) prior to their surgery for OG cancer and then undergo intra-operative sampling.
214477703|NCT06248515|DRUG|Sacituzumab govitecan-hziy|10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles
214477704|NCT03812614|BEHAVIORAL|FAM ACT|Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
214477705|NCT03812614|BEHAVIORAL|I-DSMES|Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
214477706|NCT02695940|DRUG|LEO 124249 ointment 30 mg/g|
214477707|NCT02695940|OTHER|LEO 124249 ointment vehicle|
214477708|NCT05890131|OTHER|Digital letter|A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
214477709|NCT05453929|DRUG|Rocuronium for deep NMB|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
214477710|NCT05453929|DRUG|Rocuronium for moderate NMB|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
214888242|NCT00324727|PROCEDURE|hepatic artery embolization|Patients receive the best alternative therapy
214477711|NCT05205161|DRUG|AZD0466|All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
215048792|NCT02377024|DIETARY_SUPPLEMENT|TF 600mg|
215048793|NCT02377024|DIETARY_SUPPLEMENT|TF 1200mg|
215048794|NCT02377024|DIETARY_SUPPLEMENT|placebo|
215048795|NCT04861779|DRUG|HSK29116|Oral HSK29116
214477712|NCT04727242|DRUG|Gemcitabine|Hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine. Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.
214477713|NCT04727242|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles given IV
214477714|NCT04727242|PROCEDURE|Cytoreductive Surgery|Surgery for cancer removal
214477715|NCT04727242|BEHAVIORAL|Functional Assessment of Cancer Therapy (FACT) G questionnaire|Preoperative and Postoperative FACT G questionnaire to assess QoL
214477716|NCT04727242|PROCEDURE|Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan|Radiologic imaging after Cycle 3 and 6 and at each follow up visit
214477717|NCT04727242|DRUG|Gadolinium|Contrast Agent
215048796|NCT03235453|OTHER|Binary rhythm|The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.
215048797|NCT03235453|OTHER|Quaternary rhythm|The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
215048798|NCT06069180|DRUG|Busulfan|Conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
215048799|NCT06069180|DRUG|Flu/Cy/ATG or Cy/ATG|Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
215048800|NCT06080763|PROCEDURE|Physical Therapy Management|Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.
214294036|NCT06137716|DEVICE|Training with a Robotic Hand Exoskeleton|The rehabilitation program extended over six consecutive weeks. Each therapy session, lasting 45 minutes, occurred four times per week, resulting in a total of 24 sessions. Within each session, a total of six exercises, consisting of three passive exercises and three bilateral exercises, were performed in an alternating manner. The exercises were executed in the following sequence: 1) Bilateral hand opening and closing; 2) Passive independent finger opening and closing; 3) Bilateral pinch; 4) Passive hand opening and closing; 5) Bilateral hand opening and closing based on a VR-based game involving squeezing an orange; 6) Passive pinch.
214888243|NCT02389231|DRUG|Interleukine-2|"Four courses of IL2 ( \[Proleukin, Novartis\]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out."
214888244|NCT03511092|DIETARY_SUPPLEMENT|HMB-FA|One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
214888245|NCT03511092|DIETARY_SUPPLEMENT|HMB-Ca|One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
214888246|NCT03511092|DIETARY_SUPPLEMENT|alfa-HICA|Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.
214888247|NCT03511092|OTHER|Placebo comparator|One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
214888248|NCT06174467|BEHAVIORAL|SEELearning Training|"This group will receive the Learning Training for Hearts and Minds and will be submitted to assessments and questionnaires that measure the improvement of well-being, reduction of stress and literacy in the contents and human values taught in the training.~The program aims to increase participants' awareness, compassion and engagement. Compassion refers to cultivating a way of relating to oneself, others and humanity through kindness, empathy and genuine care for the happiness and suffering of these individuals. Awareness refers to cultivating a detailed, first-person understanding of thoughts, feelings, and emotions."
214888249|NCT06174467|BEHAVIORAL|Waiting list group of the intervention|The group will remain on a waiting list and will respond to questionnaires about well-being and other items before receiving the training and, in the second semester, during the period in which it will receive the training
214888250|NCT03131804|OTHER|Intradialytic aerobic low intensity exercise|Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
214888251|NCT02945969|BEHAVIORAL|Low Sodium Diet|Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
214888252|NCT03366441|OTHER|Telephone call|From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group
214888253|NCT03366441|OTHER|SMS|Text messages were sent to an equal number of donors in the SMS group
214888254|NCT00100880|DRUG|lenalidomide|Given PO
215048801|NCT02364037|BEHAVIORAL|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
215048802|NCT02364037|BEHAVIORAL|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
214477718|NCT03209791|OTHER|Biopsies|Biopsy will be done on the Vastus Lateralis muscle in all groups
214888255|NCT00100880|PROCEDURE|perfusion-weighted magnetic resonance imaging|Correlative studies
214888256|NCT00100880|PROCEDURE|diffusion-weighted magnetic resonance imaging|Correlative studies
214888257|NCT00100880|OTHER|laboratory biomarker analysis|Correlative studies
214888258|NCT01182376|DRUG|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
214888259|NCT01182376|DRUG|Placebo|Placebo will be administered by the patient's team according to established guidelines.
215048803|NCT02364037|DEVICE|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
215048804|NCT00619944|DRUG|Lumefantrine - lopinavir/ritonavir drug interaction|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
215048805|NCT00619944|DRUG|Lumefantrine only arm|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
215048806|NCT05056558|DRUG|Baricitinib|Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
214888260|NCT03458182|OTHER|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
214294037|NCT04990154|BEHAVIORAL|a 12-week intradialytic exercise|a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
214294038|NCT02733367|DRUG|Infacort®|Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
214294039|NCT05298280|DEVICE|Pendulum appliance|In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires. The 0.032-inch TMA wires were activated 45 degrees to produce a force of 200-250g per side. On average, intraoral reactivation of the distalizing springs was performed twice during the procedure. When a super Class I molar relationship was obtained, pendulum was replaced by a Nance holding arch. The average treatment duration was 8 months followed by bracket conventional therapy.
214294040|NCT05298280|DEVICE|clear aligners|The standardized orthodontic intervention was represented by the maxillary molar distalization protocol proposed by Align Technology: it was planned in order to obtain a sequential distalization on the upper arch, and the staging was set at 0.25 mm per aligner. During sequential distalization aligners are set up to distalize one tooth at a time. The attachments were engineered by Align Technology to achieve predictable tooth movements. Each couple of aligners was worn for 7 days.
214294041|NCT02310945|OTHER|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
214294042|NCT06489652|DRUG|89Zr-Oxine-RY_SW01 Cell Injection|Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY\_SW01 cells injection
214294043|NCT05395520|OTHER|Retrospective chart review|Retrospective chart review to be conducted at Methodist Charlton Medical Center (MCMC) in Dallas, TX. Adult patients who received vancomycin while inpatient at MCMC with at least one corresponding vancomycin trough level taken at steady state will be included. All vancomycin orders by providers are entered as pharmacy to dose; thus dosing and routine monitoring is conducted by pharmacists.
214294044|NCT01341262|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200"
214294045|NCT01341262|DRUG|Dexamethasone|"* INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)~* AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
214477719|NCT05417828|DEVICE|Emulation of Active Daily Living tasks with a robotic device (SPINDLE)|SPINDLE will provide an assistive and resistive force to aid in rehabilitating the subject's upper limb
214477720|NCT04843527|DEVICE|FreeStyle Libre System|FreeStyle Libre Flash Glucose Monitoring System
214888261|NCT02487225|DRUG|Pentoxifylline|Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
215048807|NCT05056558|DRUG|Placebo|Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
214294046|NCT01341262|DRUG|Zoledronic acid|"* INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)~* AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
214294047|NCT01341262|DRUG|Cyclophosphamide|Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
214294048|NCT01341262|DRUG|Melphalan|Melphalan 200 mg/sqm on day -1 for first and second ASCT
214294049|NCT06313931|DEVICE|cognitive training via immersive virtual reality|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using the cupboard task application.
214294050|NCT06313931|OTHER|cognitive training via paper and pencil|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using cards.
214294051|NCT06313931|OTHER|motor stimulation|motor stimulation for 12 sessions (20 minutes per session)
214477721|NCT04843527|DEVICE|FreeStyle Libre System plus food app|FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application
214477722|NCT06746311|DRUG|HT-101|Single dose of HT-101 administered subcutaneously.
214477723|NCT06746311|DRUG|HT-101|Multiple dose of HT-101 administered subcutaneously.
214477724|NCT06746311|DRUG|Placebo|Placebo, containing no active ingredient, administered subcutaneouly
214888262|NCT02487225|DRUG|Placebo|A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
214888263|NCT02128672|PROCEDURE|Spinal Cord Stimulator Lead Placement|
214888264|NCT01015469|PROCEDURE|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
214888265|NCT01015469|PROCEDURE|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
214888266|NCT04015310|DEVICE|Quantitative Multi parametric MRI and enhanced MRCP|Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
214888267|NCT05429866|DRUG|Checkpoint Blockade, Immune|Immune checkpoint blockade drugs target the immune system by blocking control pathways regulating anti-tumor immunity and thereby reinvigorate their activities against cancer.
214888268|NCT04208750|DEVICE|Vision R-800 Phoropter|Refraction utilizing the Vision R-800 Phoropter with resulting glasses
214888269|NCT04208750|DEVICE|Standard Phoropter|Refraction utilizing the standard phoropter with resulting glasses
214477725|NCT06085404|PROCEDURE|Blood sample|Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
214888270|NCT06632366|OTHER|Sexual Dysfunction in the Postpartum Period|The experimental group will receive mindfulness-based self-compassion training. The control group will not receive any intervention.
214888271|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)|mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
214477726|NCT06442241|BIOLOGICAL|LYB005 low dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
214477727|NCT06442241|BIOLOGICAL|LYB005 middle dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
214477728|NCT06442241|BIOLOGICAL|LYB005 high dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
214888272|NCT04977479|OTHER|Placebo|Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.
214888273|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine, Bivalent|mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.
214888274|NCT03590054|DRUG|Abexinostat|Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
214888275|NCT03590054|BIOLOGICAL|Pembrolizumab|Given IV on day 1 of every 21 day cycle
214888276|NCT05745597|OTHER|Follow up|Four samples of cervical exfoliated cells and fornix secretions were collected from all subjects at enrollment, 6 months, 12 months and 24 months for HPV integration status and vaginal microbiota diversity sequencing, and two additional samples of peripheral blood (whole blood + serum) were collected at enrollment.
214888277|NCT04796298|PROCEDURE|Ballistic Hamstring Stretching|Athletes were asked to reach the floor in the BS group by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes were requested to make small rebounding motion at degrees between 3°-5° for half a minute.
214888278|NCT04796298|PROCEDURE|Hamstring Extender Exercise|Athletes were asked to applied 12 repetitions and 3 sets of hamstring extender exercise. Firstly athlete lies on his/her back. Then, athlete is asked to do 90 degrees of knee and hip flexion at the same time. Finally, the person is expected to perform slow repetitive knee extension to the point of maximal possible extension.
214888279|NCT04796298|PROCEDURE|Kinesiotape|Kinesio tape is applied on the hamstring muscle with a Y shape and %25 tension force.
214888280|NCT02699073|DRUG|regorafenib|"160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity."
215048808|NCT03444545|DEVICE|Capnodynamic method|"Expired carbon dioxide is measured with a mainstream infrared sensor (Capnostat-3, Respironics Inc, Wallingford, CT, USA) and gas flow analysed with the flow sensor incorporated in the ventilator (Servo-i, Maquet Critical Care, Solna, Sweden) which was connected to a computer where all the mathematical analysis is carried out with a software written in Matlab™ (The Mathworks Inc, Natick, MA, USA).~Instead of a fixed ratio between inspiration and expiration, three breaths out of every nine are prolonged with a 3-4 seconds longer expiration creating small changes in end- expiratory CO2"
215048809|NCT03444545|DEVICE|Transpulmonary thermodilution|Each cardiac output measurement comprises an average of three thermodilutions performed successively one after another. TPTD is performed with a PiCCO2 monitor (Pulsion Medical Systems SE, Feldkirchen, Germany)
215048810|NCT04849637|DRUG|Virgin Coconut Oil|Oral supplementation of virgin coconut oil to COVID-19 patients
215048811|NCT02248896|DRUG|Telmisartan|
215048812|NCT02248896|DRUG|Other angiotensin-receptor blockers (ARBs)|
215048813|NCT02248896|DRUG|Angiotensin-converting enzyme inhibitors (ACEIs)|
214477729|NCT06442241|BIOLOGICAL|LYB005 low dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
214888281|NCT03007992|DRUG|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
215048814|NCT02248896|DRUG|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
215048815|NCT03238989|OTHER|monitoring changes in clinical symptoms, pulmonary function, and chest radiography|For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.
214888282|NCT02018965|DRUG|Niacin|"• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
214888283|NCT02018965|DRUG|Niacin|"• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
214888284|NCT03762694|DEVICE|Acupuncture|Electroacupuncture (EA) and Auricular Acupuncture (AA)
214888285|NCT05965973|OTHER|Low fat diet|During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat
214888286|NCT05965973|OTHER|High fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat
214668146|NCT04082247|BEHAVIORAL|The education and training of early childhood educators and their intervention on children|"A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes."
214668147|NCT00191529|DRUG|somatropin|
214888287|NCT06623474|DIAGNOSTIC_TEST|diagnosed by traditional diagnostic markers（such as AFP or CT etc.）|A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).
214888288|NCT03649984|BEHAVIORAL|Symptom Navi© Program|Trained nurses provide two semi-structured patient education consultations with Symptom Navi© Flyers. Patients will use the Symptom Navi© Flyers individually at home.
214888289|NCT03451214|OTHER|Diet Zinc|4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
214888290|NCT05967884|DRUG|Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab|Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery
214888291|NCT03980535|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214888292|NCT03980535|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
214888293|NCT05796076|DEVICE|Virtual reality|Participants in the intervention group will be received VR during the suturing procedure. Virtual reality is a three dimensions of width, height and depth that is generated digitally in a computer-generated environment that allows a user to interact with it 16.
214888294|NCT02442180|DRUG|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
214888295|NCT02442180|DRUG|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
214888296|NCT02442180|DRUG|placebo|equivalent to G-CSF doses
214888297|NCT03513094|OTHER|Transversus Abdominis Contraction|Participants were educated on how to contract their transversus abdominis (TA) muscle after having a surface EMG biofeedback device placed on their abdomen to provide audible biofeedback. Participants were asked to ambulate while maintaining TA contraction while ambulating at 50% of maximal volitional isometric contraction.
214888298|NCT04650594|PROCEDURE|MUTARS® modular reconstruction prostheses|Patients with MUTARS® modular reconstruction prostheses following primary or secondary knee bone malignancy with minimal follow-up of one year
214294052|NCT00539409|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
214294053|NCT05034770|OTHER|major ozone autohemotherapy|This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.
214294054|NCT01840709|BEHAVIORAL|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
214294055|NCT04152603|BEHAVIORAL|BRIEF Educational Module|The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).
214668148|NCT04494165|OTHER|massage with frankincense and myyrh essential oil|In addition to the standard physical therapy session, 30 patients in aromatherapy group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
214888299|NCT05054504|DEVICE|Butterfly iQ|The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
214294056|NCT03181854|BEHAVIORAL|Telephone coaching|Telephone coaching about overcoming the crisis is provided once a week for 3 months and once in 2 weeks for another 3 months.
214294057|NCT03181854|BEHAVIORAL|Consultation with PCT doctor|Consultation with PCT physician every 3 weeks.
214888300|NCT00372840|OTHER|educational intervention|
214294058|NCT05657678|DRUG|Vitamin D3 - 750 000 IU|a single administration of 750,000 IU of vitamin D3
214888301|NCT00372840|PROCEDURE|psychosocial assessment and care|
214888302|NCT00372840|PROCEDURE|quality-of-life assessment|
214888303|NCT03104712|OTHER|Glucose #1|50g available carbohydrate
214888304|NCT03104712|OTHER|Glucose #2|50g available carbohydrate
214888305|NCT03104712|OTHER|Glucose #3|50g available carbohydrate
214888306|NCT03104712|OTHER|Spaghetti|50g available carbohydrate
214888307|NCT03104712|OTHER|Rice|50g available carbohydrate
214888308|NCT03104712|OTHER|Spaghetti + Tomato Sauce|50g available carbohydrate
214888309|NCT03104712|OTHER|Rice + Tomato Sauce|50g available carbohydrate
214888310|NCT03104712|OTHER|Spaghetti + Pesto|50g available carbohydrate
214888311|NCT03104712|OTHER|Rice + Pesto|50g available carbohydrate
214888312|NCT00367978|DRUG|Amlodipine/benazepril|
214888313|NCT00191607|DRUG|Gemcitabine|
214888314|NCT00191607|DRUG|liposomal doxorubicin|
214888315|NCT01971047|DRUG|Regular Insulin|"Group 1 Treatment Arm,Follow dosing for BG \>180 per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
214888316|NCT01971047|DRUG|Humalog|"Group 2 treatment arm. Follow dosing for Blood glucose \> 180, per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
214888317|NCT00855907|OTHER|clinical evaluation|"Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography."
214294059|NCT05657678|DRUG|Vitamin D3 - 500 000 IU|a single administration of 500,000 IU of vitamin D3
214294060|NCT01214018|OTHER|Questionnaires and interview|Questionnaires and interview
214294061|NCT00293644|DRUG|Diclectin®|Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
214888318|NCT03558438|OTHER|No interventions|No interventions
214888319|NCT04280640|OTHER|Blood Draw|A blood sample will be collected once, prior to treatment.
214888320|NCT06138691|COMBINATION_PRODUCT|Ketamine Infusion plus RO DBT|The participant will receive 4 weeks of 0.5mg/kg intravenous ketamine given over 40 minutes, as is routinely done in ketamine treatment and four months of RO DBT treatment.
214888321|NCT03270839|DRUG|Bonine 25Mg Chewable Tablet|Motion sickness drug
214888322|NCT03270839|DRUG|Kwells|Motion sickness drug
214888323|NCT03270839|DRUG|Placebo Oral Tablet|No active substance in the tablet
214888324|NCT04993313|OTHER|Counseling|Undergo verbal counseling
214888325|NCT04993313|OTHER|Educational Intervention|View photo guide
214888326|NCT04993313|BEHAVIORAL|Questionnaire|Complete questionnaires
214888327|NCT05939713|DEVICE|Cera™ VSD occluder implantation|To collect data from patients who have implanted with the device before 2022.
214888328|NCT06834698|DRUG|Betamethasone Cream|Betamethasone 0.1% cream was administered to the external meatus twice per day for a duration of 21 days.
214888329|NCT06834698|PROCEDURE|meatotomy|"In the event of steroid therapy failure, a meatotomy was performed under general anesthesia. The procedure involved squashing the ventral aspect of the pinpoint meatus for approximately 3-5 millimeters for 10 seconds and then incising it. The mucosal margins were sutured with absorbable sutures to avoid renarrowing.~Urethral catheterization was not employed, and the procedure was performed on an outpatient basis. Patients were discharged following urination."
214888330|NCT05680740|DRUG|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
214294062|NCT04337983|DEVICE|Transpulmonary thermodilution|Obtained by averaging the results of three thermodilution measurements. Each thermodilution is performed by injecting a bolus (15 mL) of cold saline (less than 10°C)
214294063|NCT04337983|DEVICE|Echocardiography|Daily echocardiography evaluation
214294064|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 1|Containing macro and micronutrients
214294065|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 2|Containing macro and micronutrients
214294066|NCT02051777|DIETARY_SUPPLEMENT|Dietary Advice|
214294067|NCT06211348|DEVICE|Genomic Sequencing|Individuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered genomic sequencing (GS) as an option to assess for additional disease risk.
214294068|NCT03760783|OTHER|Parabolic flight|Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
214294069|NCT02095574|DRUG|[14C]ABT-199 (GDC-0199)|\[14C\]ABT-199 will be administered as a single oral administration
214294070|NCT00748033|DEVICE|Reference catheter: LoFric PVC, Nelaton 40 cm, CH 12|The subjects were first catheterized with this reference catheter.
214294071|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 5 seconds|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 5 seconds
214477730|NCT06442241|BIOLOGICAL|LYB005 middle dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
214477731|NCT06442241|BIOLOGICAL|LYB005 high dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
215048816|NCT02611102|DIETARY_SUPPLEMENT|MCT oil + Butter in Coffee|2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
215048817|NCT02280993|DRUG|DHAP|DHAP
215048818|NCT02280993|DRUG|Brentuximab Vedotin|Brentuximab Vedotin
214294072|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 24 hours|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 24 hours
214294073|NCT02104713|BIOLOGICAL|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose~1. Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.~2. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.~3. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.~4. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.~Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
214294074|NCT03038958|DRUG|Isobaric 2-chloroprocaine|intrathecal injection of 50 mg isobaric 2-Chloroprocaine
214294075|NCT03038958|DRUG|Hyperbaric prilocaine|intrathecal injection of 50 mg hyperbaric prilocaine 2%
214294076|NCT01474057|BEHAVIORAL|DESTRESS-PC|"An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician."
214294077|NCT01474057|OTHER|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
215048819|NCT02280993|OTHER|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
215048820|NCT02830243|DRUG|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
214477732|NCT06442241|BIOLOGICAL|Placebo|0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
214477733|NCT06442241|BIOLOGICAL|Positive control|AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
214477734|NCT06530381|OTHER|Pilates Exercises With Face-to-Face|The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed face to face.
214477735|NCT06530381|OTHER|Pilates Exercises With Telerehabilitation|The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed as telerehabilitation.
214477736|NCT06612229|PROCEDURE|Conservative surgical treatment of liver echinococcosis, verification of occult biliary fistulas and their elimination by weaving and using medical cyanoacrylate glue|In conservative surgical operations for liver echinococcosis, the biliary fistula is identified, onto which a U-shaped suture is applied, after which medical cyanoacrylate glue is applied between the suture stitches to the fibrous capsule in the fistula area and the suture threads are tied.
214668149|NCT04494165|OTHER|massage with carrier oil|In addition to the standard physical therapy session, 31 patients in placebo group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
215048821|NCT02830243|DRUG|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
215048822|NCT05363488|DRUG|Bosutinib|Patients receiving bosutinib treatment
215048823|NCT04794738|DRUG|SHR8554|SHR8554 Injection; high dose
215048824|NCT04794738|DRUG|SHR8554|SHR8554 Injection; low dose
215048825|NCT04794738|DRUG|Saline Solution|Saline Solution
214888331|NCT04771728|DRUG|Metronidazole vaginal suppositories|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
214294078|NCT04433650|DEVICE|Pictorial support in person-centred care for children (PicPecc)|"Phase A: The child has the protocol for methotrexate treatment, the healthcare professionals have one workshop that containing person-centred care, universal design, distress, symptom management and the digital reporting and communication tool.~Phase B: The child has everything in phase A. In addition, the child use the digital reporting and communication tool that has a thermometer (graded from zero (green) to ten (red)). The result of the assessment is visualized as a face (mimic and colour represents the intensity of the symptom and/or emotion (i.e., anxiety, appetite, fear/worries, how I´m feeling today, nausea, pain, sleep, and tiredness)). The digital reporting and communication tool has a body figure for location of pain, pictures for the type of pain, and an open question. There is an avatar and a gamification part, e.g., the child gets a pet after assessing the symptoms/emotions. The child reports in the app, and the child decides the frequency of assessments."
214888332|NCT04771728|DRUG|Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days）
214888333|NCT05765877|DRUG|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
214888334|NCT01968772|OTHER|Transdermal Magnesium Chloride|Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
214888335|NCT00548639|OTHER|Statin Choice Decision Aid|Paper based instrument with pictures indicating level of risk.
214888336|NCT00548639|OTHER|Control Pamphlet|ADA Diabetes Sheet
214294079|NCT01958320|OTHER|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
214294080|NCT01958320|OTHER|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
214477737|NCT06612866|DIETARY_SUPPLEMENT|Keratin hydrolysate|The clinical study will be conducted in two phases. The first phase will aim at characterizing the metabolites present in human serum after consumption of the Kera-Diet® ingredient and at determining the overall absorption peak of the tested ingredient. The second phase will involve collecting sera enriched with metabolites at the absorption peak, following the ingestion of the ingredient. Subsequently, the final objective will be to characterize the influence of these sera enriched with metabolites of interest on the behavior of human skin cell and intestinal epithelial cell cultures.
214477738|NCT05566964|DEVICE|ME&MGopen smartphone application|Smartphone application includes digital tests and e-questionnaires
214888337|NCT01436097|BEHAVIORAL|Information provision intervention|Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
214888338|NCT01436097|BEHAVIORAL|information provision + flat incentive|Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
214888339|NCT01436097|BEHAVIORAL|Information provision + tiered incentive|In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.
214888340|NCT01436097|BEHAVIORAL|Usual Care|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
214888341|NCT04622605|DEVICE|Trabecular bypass and Schlemm's canal stent|ab interno Microstent placement after cataract surgery
214888342|NCT05789576|DRUG|VTAMA (tapinarof) cream, 1%|VTAMA (tapinarof) cream, 1% applied topically once daily
214888343|NCT06503731|COMBINATION_PRODUCT|Efgartigimod PH20 SC - prefilled syringe|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
214888344|NCT06503731|OTHER|Placebo PH20 SC - prefilled syringe|Subcutaneous placebo PH20 SC given by prefilled syringe
214888345|NCT05377749|BEHAVIORAL|FACT|Families Addressing Cancer Together (FACT) is a web-based intervention that provides tailored communication support for parents with cancer.
214294081|NCT01958320|DRUG|NSAID|Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
214888346|NCT00416390|DIETARY_SUPPLEMENT|lycopene|
214477739|NCT06391710|DRUG|HRS9531|subcutaneous
214888347|NCT00416390|OTHER|laboratory biomarker analysis|
214888348|NCT00416390|PROCEDURE|biopsy|
214888349|NCT00964067|OTHER|Exercise training|Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
214294082|NCT01443988|DEVICE|iStent|Implantation of two iStent devices
214477740|NCT06391710|DRUG|Placebo|subcutaneous
214668150|NCT04226352|DRUG|Dextromethorphan|Dextromethorphan will be administered and its tolerability evaluated.
214668151|NCT02212418|OTHER|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
214888350|NCT01345201|BIOLOGICAL|OMP-18R5|IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.
214888351|NCT03766295|DRUG|Masitinib|
214888352|NCT03766295|DRUG|Gemcitabine|
214888353|NCT03766295|DRUG|Placebo|
214888354|NCT00402077|DRUG|pramlintide acetate|subcutaneous injection, three times a day, 120mcg
214888355|NCT00402077|DRUG|sibutramine|oral tablet, once a day, 10mg
215048826|NCT04794738|DRUG|Morphine|Morphine
214294083|NCT01443988|DRUG|Travoprost|Travoprost drops
214294084|NCT00241813|BEHAVIORAL|Mindfulness Meditation (MM) Program|Participants will take part in a mindfulness meditation (MM) program.
214294085|NCT00241813|BEHAVIORAL|Health Education Control Program (CTL)|Participants will take part in a health education control program (CTL)
214294086|NCT00241813|BEHAVIORAL|Lifeskills Program (LP)|Participants will take part in a lifeskills program (LP).
214294087|NCT01334814|DEVICE|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
214294088|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product|PARTICIPANTS WILL USE A EUGENOL BASED product PRIOR TO TOOTHBRUSHING
214294089|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base|toothbrushing 2x a day for 2 minutes each time
214294090|NCT00267384|DRUG|Oral N-Acetylcysteine|
214294091|NCT05284149|DIETARY_SUPPLEMENT|Hirsutella Sinensis Nutrient Supplements|"This randomized control study will be conducted in 2 years. We expect to recruit 50 participants with age ≥ 50 years old. Enrolled participants will be recruited into Hirsutella Sinensis nutrient supplement group (50 patients H.S. suppl.) . The medication will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving Hirsutella Sinensis nutrient supplement."
214294092|NCT05284149|DIETARY_SUPPLEMENT|Placebo|"We expect to recruit 50 placebo participants with age ≥ 50 years old. This randomized control study will be conducted in 2 years. The placebo will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving placebo."
214294093|NCT00007657|PROCEDURE|Intensive medical therapy|
214294094|NCT00007657|PROCEDURE|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy|
214888356|NCT00402077|DRUG|phentermine|oral tablet, once a day, 37.5mg
214888357|NCT00402077|DRUG|placebo|subcutaneous injection, three times a day
214888358|NCT01834625|DIAGNOSTIC_TEST|PET scan|
214888359|NCT00847964|DEVICE|Algisyl-LVR|method of left ventricular restoration in patients with dilated cardiomyopathy
214888360|NCT00422825|DRUG|imatinib|
214888361|NCT03825718|BIOLOGICAL|GC007F|GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.
214888362|NCT05743010|DRUG|APL-1401|APL-1401 capsules orally once daily
214888363|NCT05743010|DRUG|Placebo|Placebo capsules orally once daily
214888364|NCT01439581|DEVICE|Mapping System|Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
214888365|NCT01439581|DEVICE|Non-Mapping System|Standard ICU bed with no mapping system
214888366|NCT00829725|DEVICE|screws-internal fixation|3-4-screws-internal fixation
214888367|NCT00829725|DEVICE|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
214888368|NCT01833663|DRUG|Solifenacin Succinate Tablets|
215048827|NCT04882865|DEVICE|assist|A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
215048828|NCT06563947|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
214294095|NCT02049957|DRUG|Sapanisertib|Sapnisertib capsules
214294096|NCT02049957|DRUG|Fulvestrant|Fulvestrant IM injection.
214294097|NCT02049957|DRUG|Exemestane|Exemestane tablets.
214294098|NCT03929575|DIETARY_SUPPLEMENT|Placebo of calcium|Ingestion of 250 mg of calcium
214294099|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola|Ingestion of 250 mg of Rhodiola
214294100|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola and Cordyceps|Ingestion of 250 mg of Rhodiola and 225 mg of Cordyceps
214294101|NCT00235898|DRUG|CoFactor|
214294102|NCT00235898|DRUG|5-FU|
214294103|NCT00235898|DRUG|Leucovorin|
214294104|NCT00721552|DRUG|Sitagliptin 100 mg|28 days administration of 100 mg daily
214294105|NCT00721552|DRUG|Prednisolone 30 mg|14 days administration of 30 mg daily
214294106|NCT00721552|DRUG|Sitagliptin-placebo|28 days administration once daily
214294107|NCT00721552|DRUG|Prednisolone-placebo|14 days administration once daily
214294108|NCT01922206|BEHAVIORAL|TRACK Intervention|"TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
214294109|NCT01180491|DEVICE|K101 nail solution|
214888369|NCT01833663|DRUG|Estrogen|
214888370|NCT01699958|BEHAVIORAL|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
214888371|NCT06370741|DEVICE|Stretching with/without device|Participants will be divided into two groups: Achilles tendon stretching and plantar fascia specific stretching. Within these two groups, participants will stretch their dominant side with the help of the designed tool. On the non-dominant side, the Achilles tendon group will complete the Achilles tendon stretching without a tool and the plantar fascia-specific stretching group will complete the self plantar fascia stretching exercise. Each stretching exercise will be performed for 10 seconds and 10 repetitions 3 days a week for 2 weeks.
214888372|NCT02301390|DRUG|Amiodarone|Amiodarone is a Class III antiarrhythmic agent.
214888373|NCT02301390|DEVICE|Catheter Ablation|The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.
214888374|NCT05443815|DEVICE|HaemoCer-PLUS|HaemoCer-PLUS
214888375|NCT05292807|BEHAVIORAL|Imaginal exposure for memories|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.
214888376|NCT05292807|BEHAVIORAL|Imaginal exposure for future events|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.
214888377|NCT05292807|BEHAVIORAL|Imagery rescripting for memories|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.
214294110|NCT03557151|OTHER|Usual Care|Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is \< 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
214294111|NCT03557151|BEHAVIORAL|Transdisciplinary Care-In Person & Telehealth|TC participants will receive all elements of the Usual Care intervention but they will do so in the context of face to face or telehealth delivery of TC follow-up visits with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
214294112|NCT01414075|DRUG|Roxadustat|Tiered, weight-based dosing per schedule specified in the arm.
214294113|NCT01414075|DRUG|Oral Iron|Administered per oral dose and schedule specified in the arm.
214294114|NCT01414075|DRUG|IV Iron|Administered per IV dose and schedule specified in the arm.
214888378|NCT05292807|BEHAVIORAL|Imagery rescripting for future events|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.
214888379|NCT01968564|DRUG|Placebo pill|sugar and other inert substances
214888380|NCT01968564|DRUG|High-dose curcumin pill|2000mg curcumin pill/day
214888381|NCT01968564|DRUG|Low-dose curcumin pill|500mg curcumin pill/day
214888382|NCT01875328|OTHER|Telemedicine|Post stroke follow up in home using telemedicine.
214888383|NCT01875328|OTHER|Clinic|Post stroke clinic group follow up
214888384|NCT05786014|BEHAVIORAL|High Intensity Interval Exercise|Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home. The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose. Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.
215048829|NCT05587660|PROCEDURE|Fully threaded cannulated screws|The most popular method in undisplaced neck of femur fracture include internal fixation by cannulated screws in which screws can be inserted relatively simply and atraumatically as compared to other methods. Screws can be used partially threaded or fully threaded; however studies on fully threaded screw fixation method are inconclusive.
215048830|NCT03505333|PROCEDURE|conventional suture|we use Liga-sure device for hysterectomy
214294115|NCT03283228|DIAGNOSTIC_TEST|Cd11b and Cd56 markers|The expression of CD11b and CD56 in newly diadnosed cases of AML
214294116|NCT03847233|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
215048831|NCT04567524|DRUG|LYN-005|LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
215048832|NCT06183398|OTHER|Skin prick test|Specific skin prick tests for 6 raw food: peach, apple, sesame, carrot, lemon and orange
215048833|NCT00059631|DRUG|Mitoxantrone (Novantrone)|Starting dose of 3 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
215048834|NCT00059631|DRUG|Bortezomib (PS-341)|Starting Dose of 1.4 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
215048835|NCT01739894|DRUG|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
215048836|NCT00901303|DRUG|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
215048837|NCT03534050|RADIATION|postoperative adjuvant RT|
215048838|NCT04199585|DRUG|Lu AF95245|solution, single dose, orally
215048839|NCT04199585|DRUG|Lu AF95245 14C radiolabelled spiked dosage|solution, single dose, orally
215048840|NCT04199585|DRUG|Placebo|solution, single dose, orally
214888385|NCT05786014|BEHAVIORAL|Moderate Intensity Walking|Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity. Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test). The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging. Participants will also receive a gift card to be used to purchase a pair of walking shoes to facilitate their engagement.
214888386|NCT05991791|OTHER|Early Start Denver Model (ESDM)|"Phase A~* 4 individual sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~Phase B :~* 11 sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM with the help of the robot Pepper~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~Phase C :~* 4 sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM without the help of the robot Pepper~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~* All sessions will also be filmed and recorded"
214888387|NCT04465981|DIAGNOSTIC_TEST|Sampling|Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.
214888388|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed porcine protein from blood|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
214294117|NCT00375076|DRUG|enoxaparin|
214888389|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed porcine protein from muscle|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
215048841|NCT02452073|OTHER|Thyroid function tests|
214888390|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed whey protein|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
214888391|NCT03027024|DEVICE|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
214888392|NCT00205387|PROCEDURE|cardiac elastography and echocardiography|standard echocardiogram
215048842|NCT00290810|BIOLOGICAL|bevacizumab|Given IV
215048843|NCT01861847|DRUG|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
215048844|NCT01861847|DRUG|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
215048845|NCT01798381|DIETARY_SUPPLEMENT|Essential fatty acids|
215048846|NCT01639469|BEHAVIORAL|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
215048847|NCT01639469|BEHAVIORAL|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
215048848|NCT04923243|PROCEDURE|hip/knee replacement|hip/knee replacement
214294118|NCT03151460|DRUG|Dopamine Agent|"Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists."
214294119|NCT06145776|OTHER|tDCS + tredmill training (Standart trehab training)|Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.
214294120|NCT06145776|OTHER|Cognitite-motor Dual Task Training (DT training)|The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)
214294121|NCT01822405|DRUG|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
214294122|NCT01822405|OTHER|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|"pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment."
214294123|NCT05532839|OTHER|High intensity interval training|The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.
214294124|NCT05532839|OTHER|Moderate intensity continuous training|The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.
214294125|NCT01133301|DRUG|Naltrexone|50 mg/d Naltrexone will be administrated during three weeks.
214294126|NCT01133301|DRUG|Placebo|During 3 weeks of the study, Placebo will be administrated (daily)
214294127|NCT06001476|PROCEDURE|Cold snare polypectomy|For eligible patients, use cold snare polypectomy to resect 5-9mm short-pedicled, broad-pedicled or sessile small bowel polyps
214294128|NCT02454881|DRUG|Dexmedetomidine|
214294129|NCT02454881|DRUG|Oxycodone|
214294130|NCT05008250|DRUG|Tongmai Yangxin Pill (TMYXP)|"TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction."
214294131|NCT05008250|DRUG|metoprolol tartrate|metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
214888393|NCT03833778|OTHER|intervention group|The CED patients play the tablet-CED-quiz, while they wait for their doctor's appointment, so that gaps in the CED knowledge can be clarified during the doctor's consultation.
214477741|NCT06642662|DIAGNOSTIC_TEST|Somascan 5.0|This observational study will test patient plasma using the SomaScan platform, a highly multiplexed proteomic tool that uses SOMAmers (Slow Off-rate Modified Aptamers) to bind with high specificity and affinity to preselected proteins to quantify levels. SomaScan v5.0 quantifies 10,778 clinically relevant human proteins, with several thousand proteins linked to inflammation and immune system functions, across a wide range of concentrations (\>10 logs) with high sensitivity (\<1 pg/mL) and reproducibility (median coefficient of variation \< 5%). Individual protein concentrations are transformed into a corresponding SOMAmer concentration and quantified using a DNA microarray read-out.
214294132|NCT05008250|DRUG|placebo|simulated pills
214294133|NCT06346496|OTHER|Douyin Xinqing AI dialog bot|"Douyin Xinqing is an AI dialog bot. Users can start chatting with the Douyin companion bot by clicking on the Direct Message on the homepage of their accounts on Douyin app.~After a user sends any message to the Douyin companion bot, it first asks the user about his or her mood and guides him or her to start chatting around his or her emotions. According to the situation described by the user, the companion bot expresses empathy, asks questions to guide the user to talk, and provides suggestions at the appropriate time. Users can also record their emotions every day and look back regularly to observe changes in their inner feelings. In addition, the Douyin companion bot can also identify crisis situations such as suicide and severe mental illness and, if necessary, guide users to call the hotline to obtain professional psychological assistance."
214477742|NCT06827769|DIAGNOSTIC_TEST|serum zinc and magnesium|participants will be subjected to laboratory investigations (complete blood picture, liver and kidney function tests, Prothrombin time, international normalized ratio (INR), serum zinc, and magnesium).
214477743|NCT05868460|DEVICE|High intensity laser|patients will receive Nd: YAG with wavelength 1064 nm, peak power 3KW, energy density 360-1780 mJ/cm2, a short duration 120-150 micro sec, a mean power 10.5 W, a low frequency 10-40 HZ, a duty cycle of 0.1%, a probe diameter of 0.5 cm and spot size of 0.2 cm2. The treatment will be applied into 3 phases in each session. In addition to the traditional physical therapy exercise program (passive and active ROM exercises, stretching and strengthening exercises) for 20 minutes, total session time is 35 minutes, 3 days/ week for 4 weeks.
214477744|NCT05868460|OTHER|traditional physical therapy exercise program|passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.
214477745|NCT05868460|DEVICE|placebo High intensity laser|patients will receive placebo HILT including the same treatment as in group A but the laser device will be turned off.
214477746|NCT06429631|DEVICE|mobile application on telephone|"when patient discharge from the hospital, mobile application downloaded their telephone. then researcher give feedback about patients CIC outputs.~also mobile application include 2 animations, videos, frequently asked questions and ask the expert section."
214477747|NCT06607237|DEVICE|DM-28|1 drop in each eye, 4 to 6 times per day
214888394|NCT01930201|PROCEDURE|Caudal epidural block|
214888395|NCT01930201|OTHER|General anesthesia|
215048849|NCT04942132|BEHAVIORAL|Cognitive-behavioral (CBT)|Treatment includes a smartphone-delivered CBT program designed to improve the quality of life of individuals with chronic pain. The treatment is condensed in nine weeks, and contains the following modules or units of treatment: sleep quality, anxiety management, pain coping, medication use, physical conditioning, mood regulation, problem solving, decision-making and relationships with others. All the content and settings are written in Spanish.
215048850|NCT03092310|DEVICE|Artificial Pancreas Device|Artificial Pancreas Device
215048851|NCT06388252|PROCEDURE|Electrochemotherapy with Intratumoral Cysplatin|ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
214477748|NCT06606808|DRUG|Risankizumab-800CW 4.5 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
214477749|NCT06606808|DRUG|Risankizumab-800CW 15 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
214888396|NCT02121652|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
214888397|NCT02121652|BEHAVIORAL|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
214888398|NCT02532309|DRUG|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C\>1.1mmol/L and \<1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
214888399|NCT02532309|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
214888400|NCT06550583|DIAGNOSTIC_TEST|Pap smear /Test|"Patients will be placed in the lithotomy position, and a sterile bivalve speculum will be inserted into the vagina.~• A sample will be taken from the ectocervix by rotating a wooden Ayre spatula 360°. The sample will be quickly smeared onto a labeled glass slide and fixed with 95% ethyl alcohol in a jar to be sent to the Department of Pathology for cytopathological examination"
214888401|NCT04814173|OTHER|One-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the one-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the maxillary arch between the roots of 2nd premolar and 1st molar and closer to the molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals).
214888402|NCT04814173|OTHER|Two-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the tow-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the mandibular arch between the 2nd premolar and 1st molar, then, a class II elastics 3/16 and 6.5oz will be use from the TAD to the hook of canines brackets).
214477750|NCT06606808|DRUG|Risankizumab-800CW 25 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
214294134|NCT06346496|OTHER|Douyin Xinqing AI dialog bot for delayed intervention|Only the users in the waiting group had the task of waiting for the first four weeks, and they completed the three questionnaires at exactly the same point in time as those in the intervention group. Only after the first four weeks of intervention did the waiting group begin to receive the 28-day conversational intervention, and no additional questionnaires were interspersed in between.
214294135|NCT02425657|BEHAVIORAL|Training of junior doctors|Training program
214294136|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for operated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
214477751|NCT06606808|DRUG|Risankizumab-800CW optimal dose|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
214477752|NCT03898583|DRUG|Microarray patch A|Microarray patch
214477753|NCT03898583|DRUG|Microarray patch B|Microarray patch
214477754|NCT03898583|DRUG|Placebo|Microarray patch vehicle
214477755|NCT03898583|DRUG|Daivobet|Daivobet Gel
214888403|NCT04814173|OTHER|en-mass retraction|A group of patients in which participants will be undergo to the en-mass retraction with first premolars extraction with mini-implants in the maxillary arch inserted between the 2nd premolar and 1st molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals .
214888404|NCT01479231|DRUG|dexlansoprazole|Dexlansoprazole 60 mg daily for 6 weeks
214888405|NCT04798092|PROCEDURE|parathyroidectomy|surgical removal of parathyroid adenoma(s) with postoperative biological cure
214888406|NCT05808322|DRUG|Ropeginterferon alfa-2b|A maximum of 3 doses of ropeginterferon alfa-2b will be given biweekly during the whole study period. A single dose of 250 μg ropeginterferon alfa-2b will be subcutaneous administrated at Day 1 visit. SARS-CoV-2 antigen test will be conducted at D15 and D29 visits. For patients who still have positive result in SARS-CoV-2 antigen test at Day 15 visit, the second dose of ropeginterferon alfa-2b at 350 μg will be subsequently administered at Day 15 visit. For patients who still have positive result in SARS-CoV-2 antigen test at Day 29 visit, the third dose of ropeginterferon alfa-2b at 500 μg will be administered at Day 29 visit.
214888407|NCT05808322|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
214888408|NCT01379846|BIOLOGICAL|TAK-816+ DPT-TAKEDA|TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
215048852|NCT06388252|PROCEDURE|Electrochemotherapy with Intravenous Bleomycin|ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
214888409|NCT01379846|BIOLOGICAL|ActHIB+ DPT-TAKEDA|ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
214888410|NCT05697614|DRUG|Valproic acid|valproic acid is used for general epilepsy type, used in experimental group
215048853|NCT01201551|DRUG|Brimonidine|Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
215048854|NCT01201551|DRUG|Latanoprost|Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
215048855|NCT01201551|DRUG|Placebo|Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
215048856|NCT02156193|PROCEDURE|Prophylactic clip|Prophylactic clipping
215048857|NCT02156193|PROCEDURE|No prophylactic management|No prophylaxis
215048858|NCT00420381|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
215048859|NCT03500289|DRUG|Ketamine|One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes
215048860|NCT03500289|DRUG|Midazolam|One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
215048861|NCT03024424|BEHAVIORAL|Early disclosure|
215048862|NCT03024424|BEHAVIORAL|Late disclosure|
215048863|NCT00173017|DEVICE|wearing N95 masks|
214294137|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for nonoperated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
214888411|NCT05697614|DRUG|Carbamazepin|carbamazepine is used for focal type epilepsy, used in experimental group
214294138|NCT01487226|DRUG|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks \* 6 cycles
214294139|NCT01487226|DRUG|Cisplatin 50mg/m2|"Cisplatin 50mg/m2~Repeat every 3 weeks \* 6 cycles"
214294140|NCT00353912|DRUG|valsartan + amlodipine|
214294141|NCT00940251|DRUG|Mersina|capsule, 3g/day, 3 months
214294142|NCT02546557|PROCEDURE|Coronary Artery Bypass Graft surgery|
214668152|NCT03851510|DEVICE|Vector ventilator|The Vector ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with the primary cause being COPD. This device is not intended for life support. It may be used to screened for the presence and abolishment of expiratory flow limitation. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments. The vector ventilator will titrate and treat EFL using non-invasive ventilatory support.
214668153|NCT03851510|DEVICE|Resmon Pro|The Resmon Pro uses the forced oscillation technique (FOT) which is a noninvasive method to measure the mechanical properties of the lung and airways during tidal breathing. In addition to measuring total impedance (resistance and reactance), the Resmon Pro can measure expiratory flow limitation which is a key index of respiratory obstruction
214888412|NCT05697614|DRUG|Phenytoin|phenytoin is used for both general or focal epilepsy in case valproic acid or carbamazepine is contraindicated, used in experimental group
214888413|NCT05697614|DRUG|Lamotrigine|lamotrigine is used for general epilepsy type, used in control group
215048864|NCT05298943|OTHER|walking in 4 situations|Recording of cerebral hemodynamic with fNIRS during gait in exoskeleton with Four strength levels of aid : total aid (A100%), partial aid (A50%), no aid (A0%) and resistance of 25 % (R25%) to walking from the exoskeleton. Each subject are recorded during 8 trials for each level (32 trials). The order is counterbalanced among the subjects
215048865|NCT01789242|DRUG|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
215048866|NCT01789242|DRUG|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.
215048867|NCT05001971|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
214294143|NCT00807157|DIETARY_SUPPLEMENT|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
214294144|NCT00807157|DIETARY_SUPPLEMENT|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
214294145|NCT02532933|DEVICE|DePuy Synthes Attune PS RP|
214294146|NCT01669733|OTHER|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
214294147|NCT01669733|OTHER|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
214294148|NCT04885686|DEVICE|Endomethasone N RCS|Root canal sealer
214294149|NCT04885686|DEVICE|Endomethasone SP RCS|Root canal sealer
214294150|NCT05855850|DEVICE|Brainsway H4-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H4-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
214294151|NCT05855850|DEVICE|Brainsway H7-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H7-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
214294152|NCT00081380|DRUG|Seroquel®, quetiapine fumarate (atypical antipsychotic)|
214294153|NCT00081380|DRUG|lithium (mood stabilizer)|
214294154|NCT00081380|DRUG|divalproex (mood stabilizer)|
214294155|NCT00338702|PROCEDURE|Autologous Platelet Gel|
214888414|NCT05697614|DRUG|Clobazam|clobazam is used for both general or focal epilepsy in case if lamotrigine or oxcarbazepine is not possible to be administered and is used particularly in myoclonic jerk , used in control group
214888415|NCT05697614|DRUG|Oxcarbazepine|oxcarbazepine is used for focal type epilepsy, used in control group
214888416|NCT02941835|RADIATION|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
215048868|NCT02078752|DRUG|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
215048869|NCT02078752|DRUG|PF-06647263|Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
214294156|NCT04106921|OTHER|Universal Health Coverage Mode|"In the intervention arm, the CHW's household list will appear differently within the app in the following ways:~The CHW will be able to filter and order households by the date of the most recent home visit.~A color-coded visual icon will display the number of home visits in the past month for each household.~A red exclamation mark will be displayed for every household that has not reached 2 visits in the past month (default at the start of every month).~Text displayed below each household showing the date of last visit will turn red if more than 30 days have passed since last visit. When more than 60 days have passed since the most recent visit, the text displayed below each household showing the date of last visit will be changed to date of last visit is unknown in red.~The family profile will also contain the date of last visit, and the visits they have received in that month"
214294157|NCT00678054|DRUG|GM-CSF|Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
214294158|NCT03760120|DEVICE|PEP-MASK|
214294159|NCT01922089|DRUG|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
214294160|NCT05083104|DIAGNOSTIC_TEST|laboratory investigations on coagulation profiles|CBC ,PT ,aPTT ,Protein C .Protein S ,ATIII and vWF
214294161|NCT04715763|DRUG|Telmisartan Oral Product|Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction
214294162|NCT04715763|DRUG|Placebo|Gelatin capsules filled with an inactive ingredient
214294163|NCT00645073|DRUG|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
214294164|NCT00645073|DRUG|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
214294165|NCT02394847|DRUG|propofol|
214294166|NCT01763216|OTHER|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
214294167|NCT01763216|OTHER|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
214294168|NCT04425174|PROCEDURE|Quadratous lumborum block|Quadratus Lumborum (QL) block is a new technique for analgesia of the abdominal wall muscles. Its mechanism depends on the injection of the local anesthetic agent between the abdominal wall muscles into the thoracolumbar fascia surrounding the Quadratus Lumborum muscle by ultrasound (US) guided technique.
214294169|NCT04425174|PROCEDURE|Epidural anesthesia|Epidural analgesia is a gold standard analgesic technique for the majority of abdominal surgeries, yet it has some limitations in some surgeries as colorectal surgeries due to delayed ambulation due to muscular weakness and postural hypotension.
214294170|NCT03022565|DRUG|Vorinostat|Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.
214888417|NCT03996902|BEHAVIORAL|Tailored intervention|Brief motivational smoking intervention tailored to address smoking in the context of pain. Included a novel pain-smoking psycho education component, personalized feedback component, and elicitation of participant's pain-related goals to develop discrepancy between continued smoking and desired pain outcomes.
214888418|NCT03996902|BEHAVIORAL|Ask-Advise-Refer|The Ask-Advise-Refer intervention is commonly used in standard clinical practice.
214888419|NCT02875990|BIOLOGICAL|Blood sample|
214888420|NCT02936908|OTHER|Ventilatory support|Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)
214888421|NCT00525980|BEHAVIORAL|Computer Program|"Participants will be given a program to learn about breast cancer risk and genetic testing.~Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor)."
214888422|NCT00525980|BEHAVIORAL|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
214888423|NCT00525980|OTHER|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
214294171|NCT06228547|OTHER|Questionnaire|Standardized questionnaire specifically made for the study. The interview lasts approximately 15 minutes. The form gathers baseline characteristics of the patients such as socio-demographic information, symptoms, lifestyle factors and gynecological history. The questionnaire focuses also on the manner in which the diagnosis was revealed to the patient and their experience of this disclosure. Lastly, the questionnaire includes items issued from French practice guidelines concerning etiological investigations, fertility assessment, osteoporotic and cardiovascular complications, HRT use, and residual symptoms
214294172|NCT04458233|PROCEDURE|long axis FNA method|"). A long-axis view (i.e., a longitudinal image of the needle) is obtained by placing the US probe in a parallel position relative to the course of the needle. Short-axis and long-axis views can be used for both US assistance and guidance of FNA procedure. Correspondingly, approaching the nodule with the needle from the lateral or frontal aspect results in either a long axis or short axis view of the needle on the US screen"
214294173|NCT02408458|DEVICE|MIROMESH®|
214294174|NCT02662946|PROCEDURE|ICG- angiography|Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
214294175|NCT02662946|PROCEDURE|No angiography|Extension of resection based on subjective measures
214294176|NCT01590238|BIOLOGICAL|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
214668154|NCT02232789|DRUG|Mephedrone|Single oral dose mephedrone
214668155|NCT02232789|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
214668156|NCT02232789|DRUG|Placebo|Single oal dose placebo
214668157|NCT03643887|DRUG|FMT Capsule DE|30 capsule one-time oral dose
214888424|NCT00525980|BEHAVIORAL|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
214888425|NCT05584189|DEVICE|Rapid SARS-CoV-2 Antigen Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person.
214888426|NCT00003610|DIETARY_SUPPLEMENT|capsaicin|
214888427|NCT00003610|OTHER|placebo|
214888428|NCT00003610|RADIATION|radiation therapy|
215048870|NCT05524077|PROCEDURE|Ablation|"Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation."
215048871|NCT05524077|DRUG|Anti-arrhythmic Drugs (AADs)|"Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial)."
215048872|NCT05404971|OTHER|Joint integrity exercises|patients with three strokes followed by 3 sec rest period. Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set.
214888429|NCT05153525|DRUG|Intermittent boluses of Cisatracurium|Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
214888430|NCT05153525|DRUG|Intravenous infusion of Cisatracurium for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
214888431|NCT02275169|DRUG|Urofollitropin|Urofollitropin 75 IU 2 ampoules three times a week for three months
214888432|NCT02275169|OTHER|Placebo|Placebo ampoules administered three times a week for three months
214888433|NCT02163265|PROCEDURE|Surgery|Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
214888434|NCT01089465|OTHER|Collection of the bedbugs and dermatological follow-up of the stings|Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
214888435|NCT04254848|OTHER|oral stereognostic test|Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
214888436|NCT04975204|DRUG|TQB3909 Tablets|TQB3909 is an inhibitor targeting BCL-2 protein
214888437|NCT03719625|DRUG|Ephedrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
214888438|NCT03719625|DRUG|Norepinephrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
214668158|NCT03643887|DRUG|Placebo oral capsule|30 capsule one-time oral dose
214888439|NCT05477836|DEVICE|MiWEndo-assisted colonoscopy|"All colonoscopies will be performed with high-definition technology. The MiWEndo System (MiWEndo Solutions, Barcelona) will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System.~At the beginning of the extubation, the MiWEndo System will be turned on. During extubation, each segment will be carefully examined with both white light and MiWEndo. In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
214888440|NCT03894644|OTHER|Simulation technology|The intervention involves three consecutive sessions of the PeriopSim™ Instrument Trainer, followed by two consecutive sessions of the PeriopSim™ for Burr Hole Surgery (https://periopsim.com).
214888441|NCT04515134|DIAGNOSTIC_TEST|assessment of follicular level of coenzyme Q10 in the ovaries in females undergoing ICSI|human coenzyme Q10 (CoQ10) ELISA kit
214888442|NCT01044550|PROCEDURE|Laparoscopy|Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
214888443|NCT01044550|OTHER|Clinical follow up|Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
214888444|NCT01542814|DEVICE|3Dimensional Mammography|The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.
214888445|NCT01542814|DEVICE|2D FFDM|Standard of care screening mammogram.
214888446|NCT03295955|DRUG|Amoxicillin Clavulanate|"Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery"
214888447|NCT00786214|OTHER|Acupuncture|Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists
214888448|NCT00786214|OTHER|Sham acupuncture|Patients will be given sham acupuncture treatment at dummy acupuncture points
214888449|NCT00436410|BIOLOGICAL|colloidal gold-bound tumor necrosis factor|
214888450|NCT00436410|OTHER|electron microscopy|
214888451|NCT00436410|OTHER|pharmacological study|
214888452|NCT00436410|PROCEDURE|conventional surgery|
214888453|NCT05452018|OTHER|Intervention group|In healthy volunteers, activity measurement of muscles of interest by intramuscular electromyography during predefined swallowing tasks
214888454|NCT06272721|DIAGNOSTIC_TEST|Griffiths Scale|The Griffiths Mental Development Scales II are key tools for assessing children's psychomotor development from ages 0 to 6, praised for their strong psychometric properties. They evaluate various functional areas through six subscales, combining parental reports and direct observations of the child's behavior. The areas include locomotion, personal-social interaction, learning and language, eye-hand coordination, and performance, excluding the optional practical reasoning section for older children in this study. The Development Quotient (DQ), calculated by comparing mental and chronological ages, indicates developmental progress or delay, with an average score around 100 ± 15.
215048873|NCT05404971|OTHER|Mirror therapy|A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
214888455|NCT05460702|DIAGNOSTIC_TEST|Soluble immune checkpoints|Blood collection from breast cancer patients with stage I-II
214888456|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 40 and 50 ug.
214888457|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 20 ug.
214888458|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
214888459|NCT05177679|DIETARY_SUPPLEMENT|Active supplement|Carotenoid supplement comprised of 10mg lutein and 2mg zeaxanthin.
214888460|NCT05177679|DIETARY_SUPPLEMENT|Placebo control|Placebo control supplement
214888461|NCT06582537|PROCEDURE|Participants sample collection|A skeletal muscle biopsy and a venous blood sample will be collected. The skin biopsy will be obtained during the incision needed for the muscle biopsy.
214888462|NCT05423132|DRUG|Ropivacaine injection|The patients will receive 15 ml of Ropivacaine 0.375 % on each side.
214888463|NCT05423132|DRUG|Physiological serum injection|The patients will receive 15 ml of physiological serum (NaCl 0.9 %) on each side.
214888464|NCT01037452|DRUG|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
214888465|NCT01037452|DRUG|Lansoprazole|Tablet
214888466|NCT01037452|DRUG|Calcium carbonate/magnesium hydroxide|Tablet
215048874|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
215048875|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
215048876|NCT00439335|DRUG|Placebo (IM)|The placebo will be 0.1 mL of saline administered by the IM route.
215048877|NCT00439335|DRUG|Placebo (ID)|The placebo will be 0.1 mL of saline administered by the ID route.
214294177|NCT05200520|BEHAVIORAL|Appetite Self-Regulation Intervention|The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
214888467|NCT01037452|DRUG|Placebo|Tablet
214888468|NCT04108299|BEHAVIORAL|Wait-list control group|For patient participants, they will continue to receive the standard of usual care for their T2D at the CBWCHC during the course of our study. For family/friend participants, they will continue to receive their routine care with their own doctors during the study. At the end of the study, the wait-list control group (both patient and family/friend participants) will be provided the opportunity to receive the counseling videos delivered to them via SMS links.
214888469|NCT04108299|BEHAVIORAL|SMS intervention|2-3 SMS-based diabetes videos will be sent to patients each week for 12 weeks (each video within 10 minutes in duration) to both patients and their family members. Patients and their family members will receive the same intervention videos, including basic information about T2D, importance of diabetes self-management at home, behavioral techniques, and family-oriented sessions. BrainShark will be used to determine whether participants view these,videos. For participants who miss 3 consecutive videos, the study team will follow-up with a phone call to identify barriers to watching the video and remind them to review the video.
214888470|NCT00013442|PROCEDURE|Auditory Evoked Response|
214888471|NCT03076632|DEVICE|Cervical plus transcranial stimulation|Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.
214888472|NCT03076632|DEVICE|Cervical stimulation plus hand/wrist exercise|Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.
214888473|NCT03076632|DEVICE|Electromyographic (EMG)-triggered (closed-loop) stimulation|Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.
214888474|NCT02258711|DEVICE|SIMPLE 2.0|SIMPLE 2.0 psychoeducative and self-monitoring smart-phone application plus treatment as usual.
214888475|NCT00247676|DRUG|Sunitinib (SU011248)|Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
215048878|NCT01615744|PROCEDURE|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
215048879|NCT01615744|PROCEDURE|Non-surgical management|Early active exercises and elevation to decrease swelling
214888476|NCT04123405|DRUG|acetylcysteine|600 mg tablet
214888477|NCT04123405|DRUG|Placebo|Placebo to acetylcysteine
214888478|NCT06366763|PROCEDURE|Questionnaires|Questionnaires to assess the quality of life (CIVIQ-14 and VCSS scores )
214888479|NCT05924724|DEVICE|Flash Glucose Monitoring|The FGM is a non-invasive device typically worn on the upper arm, designed to continuously measure blood glucose levels without the need for fingerstick capillary measurements.
214888480|NCT03786887|DRUG|Nalbuphine|dosage of nalbuphine
214888481|NCT06582290|DIAGNOSTIC_TEST|Oxford Virtual Autism Assessment Tool (OVAAT)|The OVAAT is an online ASD diagnostic tool that has been designed to identify both the external/observable features of autism but also the internal/experiential features of autism.
214888482|NCT06278896|DRUG|Cessation of antibiotics|Stop antibiotic therapy after episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
214888483|NCT05027152|OTHER|Resistance training|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise. The repetitive task training group will carry out exercises involving upper and lower limbs.
214888484|NCT05027152|OTHER|Repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
214888485|NCT01494259|DRUG|Bupivacaine|Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
214888486|NCT01494259|DRUG|Saline|Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
214888487|NCT00440349|DRUG|Tamoxifen|
214888488|NCT00440349|DRUG|Prednisone|
214888489|NCT01927900|DIETARY_SUPPLEMENT|HMO|
214888490|NCT01927900|DIETARY_SUPPLEMENT|Glucose|
214888491|NCT03532152|DEVICE|Pure Purr VR technology|"The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.~The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate."
215048880|NCT00753948|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
215048881|NCT00881985|DEVICE|continuous positive airway pressure|Use CPAP whenever sleep
214888492|NCT03532152|DEVICE|Sham VR technology|The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
214888493|NCT00662649|DRUG|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
214888494|NCT00662649|DRUG|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
214888495|NCT04191811|BEHAVIORAL|Internet-delivered cognitive behavioral therapy for major depressive disorder|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
214888496|NCT04191811|BEHAVIORAL|Internet-delivered cognitive behavioral therapy for insomnia|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
214888497|NCT04191811|BEHAVIORAL|Internet-delivered cognitive behavioral therapy for social anxiety disorder|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
214294178|NCT03716882|DEVICE|Song Meter (SM)4|Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights. This record will take place at 15 days of life, 1 and half months, 2 and half months and 3 and half months.
214294179|NCT02904473|OTHER|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
214294180|NCT02619292|BEHAVIORAL|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
214294181|NCT03735433|DRUG|162mg aspirin dose|2 pills of 81mg aspirin
214294182|NCT03241251|OTHER|questionnaire|Questionnaire of psychosocial risk factors
214294183|NCT05624203|DEVICE|Extracorporeal cardiac shock wave therapy(ECSW)|Extracorporeal cardiac shock wave therapy (CSWT) is a cutting-edge technology developed in the world for more than 20 years. It is mainly used in the treatment of refractory angina pectoris of coronary heart disease. The mechanism of extracorporeal cardiac shock wave therapy is mainly due to the small attenuation, small shear stress and strong penetration force of shock wave when propagating in human tissues. Shear stress and hole effect are generated in the focal area of shock wave, which leads to the repeated formation/rupture of microbubbles in tissue/cell microenvironment, resulting in various physical and biological effects. These physical mechanisms trigger a series of biological effects, such as promoting the expression of various intracellular cytokines and angiogenic factors, activating related signal transduction pathways, inhibiting apoptosis and oxidative stress, and finally increasing the number of new blood vessels in the treatment area and improving the ischemic state.
214294184|NCT02234453|DEVICE|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
214294185|NCT04903626|DRUG|Glecaprevir/Pibrentasvir (GLE/PIB)|Oral tablets
214294186|NCT05246761|DEVICE|Balloon catheter|In the two groups, if their bishop score \<6, they will receive the cervical riening by the balloon catheter, and then the oxytocin if necessary.
214294187|NCT01701557|OTHER|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
214294188|NCT01701557|OTHER|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
214294189|NCT02966990|DEVICE|Hand Orthotic Devices|Orthotic device made to provide the patient with better hand function
214294190|NCT00573534|DRUG|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
214294191|NCT05747781|BEHAVIORAL|Pilot Phase: standardized behavioral task|"Pilot Phase:~* Mobility under variable light conditions (scotopic, photopic, glare, dark adaptation), performed in a virtual environment.~* Visual search for objects in real life scenes (office, kitchen, living room) performed in a virtual environment.~* Ability to drive (UFOV and DVFAT psychophysical tests)."
214294192|NCT05747781|BEHAVIORAL|Validation Phase: standardized behavioral task|"Validation Phase:~* Mobility in variable light conditions (photopic and scotopic), performed in real and virtual environments.~* Visual search for objects in real scenes (office, kitchen, bedroom, living room) performed in a virtual environment.~* Driving ability (two psychophysical tests UFOV and DVFAT, one supervised road test)."
214294193|NCT04358380|OTHER|Liver injury|LFTs elevation or liver decompensation
214294194|NCT01572220|OTHER|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
214294195|NCT02642952|OTHER|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
214294196|NCT02151760|DRUG|18F-DCFPyL|
214294197|NCT00310791|DRUG|Hormone replacement therapy (estrogen/progestin)|Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
214294198|NCT00310791|OTHER|Placebo (Sugar Pill)|Placebo (sugar pill)
214294199|NCT00310791|DRUG|Dehydroepiandrosterone (DHEA)|50 mg tablet, 1 daily
214294200|NCT00086320|DRUG|Paliperidone ER|
214888498|NCT03594071|DEVICE|The Q-Fix™ All-Suture Anchor|Observational, post-market, clinical follow-up study
214888499|NCT02713685|PROCEDURE|Subarachnoid block|Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia
215048882|NCT01981798|BEHAVIORAL|Physiotherapy and occupational therapy|Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
215048883|NCT06198062|OTHER|Paraffin wax bath therapy|this group receive paraffin wax. Each session will last between 40 and 50 min, 2 sessions per week, for total 6 weeks
214477756|NCT04763772|DIAGNOSTIC_TEST|Body Fat Distribution Imaging Report|Those randomized to body fat distribution imaging will be scanned on a 1.5 Tesla Siemens Aera MRI scanner (Siemens, Erlangen, Germany), located in the Center for Advanced Heart and Vascular Care using a 6-minute dual-echo Dixon Vibe protocol providing a water and fat separated volumetric data set covering neck to knees, and a multiecho Dixon acquisition for proton density fat fraction assessment in the liver. Images of the liver will be acquired using a 16-channel SENSE extra large Torso coil and images from the rest of the body will be acquired using the body coil. Volumetric imaging datasets of the body derived by MRI will be generated and adipose tissue/fat depots will be quantified: abdominal subcutaneous compartment (ASAT), visceral compartment (VAT), and hips and buttocks (lower body fat); proton density fat fraction of the liver (i.e. hepatic steatosis) as well as the quality of lean (skeletal muscle) including muscle volume and degree of fat infiltration.
214477757|NCT04763772|DIAGNOSTIC_TEST|Basic Weight Information|Body weight and body mass index
214477758|NCT04763772|BEHAVIORAL|Patient Provided|Body weight/fat distribution information will be provided directly to the patient
214477759|NCT04763772|BEHAVIORAL|Physician Provided|Body weight/fat distribution information will be provided directly to the physician
214888500|NCT02713685|PROCEDURE|combined Femoral and Sciatic nerve block|Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
215048884|NCT06198062|OTHER|Paraffin Wax Bath Therapy and Muscle Energy Techniques|This group receive paraffin wax bath therapy along with muscle energy techniques. Each session will be conducted for 40 to 50 mins, 3 sessions in a week for total 6 weeks
215048885|NCT00572429|DIETARY_SUPPLEMENT|l-carnitine|3 gram daily dose
214668159|NCT06463912|OTHER|Does not apply|A descriptive cross-sectional study will be carried out in the city of Armenia-Colombia. A total of 205 PWID, 18 years to 65 years old will be included. They will be selected through the implementation of the respondent-driven sampling (RDS).
214668160|NCT01151137|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
214888501|NCT02581605|DEVICE|Custom-made 'cutting block'|To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
214888502|NCT01026194|DRUG|Placebo / Teneli (Teneligliptin) + pio (pioglitazone)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
214888503|NCT01026194|DRUG|Teneli / Teneli + pio|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
215048886|NCT03314610|OTHER|Gait speed|No intervention, only propose water and wait for need to void
215048887|NCT05672940|BEHAVIORAL|Aerobic plus resistance training|Aerobic plus resistance training
214888504|NCT00657189|DRUG|MEDI-545|100 mg once; SC Placebo × 12 doses on other weeks
214888505|NCT00657189|DRUG|MEDI-545|100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
215048888|NCT05672940|BEHAVIORAL|Stretching plus breathing training|Stretching plus breathing training
215048889|NCT00060710|DRUG|CP-461|
214888506|NCT00657189|DRUG|MEDI-545|100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
214888507|NCT00657189|DRUG|MEDI-545|100 mg every week × 13 doses
215048890|NCT04365686|DRUG|Ketofol as induction agent|Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
214294201|NCT04226378|DEVICE|Omnipod|Switch from MDI therapy to an Omnipod as part of usual clinical practice. An Omnipod is a patch pump that consists of a handheld controller and a disposable pod that delivers insulin.
214294202|NCT04226378|OTHER|MDI|Continued use of MDI therapy (traditional basal/bolus insulin regimen).
214294203|NCT03796429|DRUG|GS+Toripalimab|"Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid\*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years)."
214888508|NCT00657189|DRUG|Placebo|SC Placebo every week × 13 doses
214888509|NCT03252067|DRUG|azithromycin eyedrop|Tear samples will be collected using the strips.
214888510|NCT00269646|BEHAVIORAL|Low-carbohydrate and high-carbohydrate diets|Each subject will consume two different ad libitum diets, each for four weeks, with a 4-week washout period inbetween each diet.
214888511|NCT06575543|RADIATION|CT|3D CT scan have been used to evaluate the tunnels location after ACL reconstruction, as they can provide excellent perspective of the tunnel aperture, good visualization of bony structure and shape of the intercondylar notch, that preclude the use of a conventional 2-dimensional CT scan for measurement of the ACL tunnels location
214888512|NCT00988416|PROCEDURE|PET-CT|Pancreas Protocol PET-CT
214888513|NCT00486850|OTHER|Extubation to Nasal IPPV|Comparison of extubation to NIPPV versus NCPAP
214888514|NCT03895814|BEHAVIORAL|Protective Step Training|Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
214888515|NCT04376658|OTHER|COVID-19 Severity|Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death
214888516|NCT03170934|BEHAVIORAL|Psychotherapy skills class|Rapid access, large-scale, psychotherapy classes that are open format and delivered in lecture style. One class - Managing Difficult Emotions (MDE) - is an 8-session, DBT-informed program. The other class - Mindfulness-Based Cognitive Behavioral Therapy (CBTm) - is a 4-session program.
214888517|NCT03399513|DRUG|Ibrutinib Oral Capsule [Imbruvica]|Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)
214888518|NCT03399513|DRUG|R-CHOEP chemotherapy|Immunochemotherapy
214888519|NCT04349202|DIAGNOSTIC_TEST|EUROIMMUN assay|Serology testing to detect SARS-CoV-2 antibodies
214888520|NCT01750190|DRUG|Roxadustat|Oral tablets
215048891|NCT04365686|DRUG|Propofol as induction agent|Patients who received propofol (2mg/kg) only at the induction of general anesthesia.
214294204|NCT06034236|OTHER|Resistance training|"Task oriented resistance training will be performed, there will be 10 workstations:~1. Sitting at a table and reaching in different directions for objects located beyond arm's length.~2. Sit to stand from various chair heights~3. Stepping forward, backward and sideways onto blocks of various heights.~4. Heel lifts in standing~5. Standing with narrow base of support, feet in parallel and tandem stance and reaching for objects, including down to the floor.~6. Reciprocal leg flexion and extension.~7. Sit ups~8. Standing up from chair, walking a short distance and returning to the chair.~9. Walking races between participants~10. Walking over various surfaces and obstacles"
214294205|NCT06034236|OTHER|Otago Exercises|"It has total 17 exercises, out of which 12 exercises are performed to improve balance and 5 are performed to improve strength.~1\. First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~2\. Second component is muscle strengthening exercises, it includes: i. Front knee strengthening exercise ii. Back knee strengthening exercise iii. Side hip strengthening exercise iv. Calf raises (with support and without support) v. Toe raise (with support and without support). 3. Third component is balance exercises, it includes: i. Knee bends ii. Backward walking iii. Heel toe standing iv. Heel toe walking v. One leg stand vi. Heel walking vii. Sideways walk viii. Toe walking ix. Heel toe walking backwards x. Walk and turn around (figure of 8) xi. Sit to stand xii. Stair walks"
214294206|NCT02573298|DEVICE|ice|local ice application for 30 minutes
214294207|NCT02573298|DEVICE|cold gas|local cold gas application for 2 minutes
214477760|NCT06599268|BEHAVIORAL|Survey using a questionnaire.|"Questionnaire to assess the barriers and enablers for women reaching top executive positions in pharmaceutical companies and pharmacies~The following sections will be considered:~* General Characteristics of the Participants~* Work-related characteristics~* Barriers faced by women to reach top executive positions (Likert scale)~* Enablers for women to reach top executive positions (Likert scale)~* Conception of women in the pharmaceutical sector (Likert scale)"
214477761|NCT06588504|DRUG|Dasiglucagon|Participants will receive s.c. injection of dasiglucagon.
214888521|NCT01750190|DRUG|Placebo|Oral tablets
214888522|NCT04816643|BIOLOGICAL|Biological/Vaccine: BNT162b2 10mcg|BNT162b2 Low/Mid-Dose (10mcg) level
214888523|NCT04816643|BIOLOGICAL|BNT162b2 20mcg|BNT162b2 Mid-Dose (20mcg) level
214888524|NCT04816643|BIOLOGICAL|BNT162b2 30mcg|BNT162b2 High-Dose (30mcg) level
214888525|NCT04816643|OTHER|Placebo|Intramuscular injection
214888526|NCT04816643|BIOLOGICAL|Biological/Vaccine: BNT162b2 3mcg|BNT162b2 Low-Dose (3mcg) level
215048892|NCT05408273|DIAGNOSTIC_TEST|Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device|We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
215048893|NCT01069393|OTHER|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
215048894|NCT04439864|DEVICE|MyIDEA|An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
215048895|NCT02994745|DRUG|Fimasartan, Atorvastatin|
214477762|NCT06588504|DRUG|Glucagon|Participants will receive i.m. injection of glucagon.
214888527|NCT04584684|OTHER|0.9% w/v NaCL Saline|saline placebo rinse
214888528|NCT04584684|DRUG|1.5% w/v Hydrogen Peroxide|Over-the-counter antiseptic mouth rinse
214294208|NCT04940351|PROCEDURE|GROUP - A: PIEZOCISION GROUP|This group will receive piezocisions after placement of initial arch wire, in between the roots of mandibular anteriors (in a vertical line) i.e., between mandibular canine and lateral incisors bilaterally, lateral incisors and central incisors bilaterally and between two cental incisors with the help of piezotome. These piezocisions will be performed on the labial cortical bone only, 4mm below the interdental papilla under 2% lidocaine with 1:100,000 epinephrine and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle. A piezosurgical microsaw with piezosurgical drill will be placed over that incision with irrigation. Then, vertical 5- to 8-mm and 3mm deep corticotomies will be perform using periapical radiographs as a guide to avoid penetrating into the adjacent roots. No subsequent sutures required.
214294209|NCT04940351|PROCEDURE|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive MOPs after initial arch wire placement. These MOPs will be performed under local anesthesia with standard asepsis, using a self drilling 1.6mm x 8mm orthodontic mini-implants and mini-implant screw driver and no flap will be raised. MOP's will be placed on five sites i.e., interproximally between mandibular canine and lateral incisors bilaterally, central incisor and lateral incisor bilaterally and between two central incisors. Each site will receive two MOP's, first 2mm apical to alveolar crest and second 2mm below the first in a vertical line and 2mm deep into the bone. Then the mini-implant will be removed by rotating the screw driver anticlockwise and pressure will be applied to achieve hemostasis.
214294210|NCT02759679|OTHER|Human breath samples|
214294211|NCT01092559|DRUG|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
214294212|NCT03123653|DRUG|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
214294213|NCT05037591|DRUG|Sea grapes extract 1.68 g/70kg BW|Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
214294214|NCT05037591|DRUG|Placebo|placebo lactose powder (1.68 g/70kg BW day-1).
214294215|NCT02814851|DEVICE|Transesophageal echocardiogram|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.
214888529|NCT04584684|DRUG|0.12% Chlorohexidine Gluconate|Dentist prescribed antimicrobial mouth rinse
214888530|NCT04584684|DRUG|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
214294216|NCT02814851|DEVICE|Thermistor-tipped catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.
214294217|NCT02814851|DEVICE|Pressure/volume catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.
214888531|NCT04584684|DRUG|0.5% w/v Povidone-iodide|Over-the-counter antiseptic mouth rinse
214888532|NCT04584684|DRUG|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
214888533|NCT02726659|DRUG|Celecoxib|Adjunct celecoxib
214888534|NCT02726659|DRUG|Placebo|Adjunct placebo
214888535|NCT03249532|DEVICE|standard hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
214888536|NCT03249532|DEVICE|cool hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
214888537|NCT03249532|DEVICE|low volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
214888538|NCT03249532|DEVICE|high volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
214888539|NCT01851252|DEVICE|Methacetin (with Breath testing device)|The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.
214888540|NCT00457132|DEVICE|APOS biomechanical gait system|
214888541|NCT04970615|DEVICE|Three-dimensional printed model|Three-dimensional printers are able to print physical objects in real size and colours. As a respresentative of the real tumor, a personalized three-dimensional model enables visualization of the patient-specific tumor and eloquent areas.
214888542|NCT00379314|PROCEDURE|TVT and TVT-O minimally invasive surgical procedures|
214888543|NCT00379314|PROCEDURE|Surgery for female stress urinary incontinence|
214888544|NCT02009722|DRUG|Morphine|Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
214888545|NCT02009722|DRUG|Hydromorphone|Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
214888546|NCT02955212|DRUG|Upadacitinib|Tablets for oral administration
214888547|NCT02955212|DRUG|Placebo|Tablets for oral administration
214888548|NCT06568510|PROCEDURE|Continuous peripheral nerve block|A perineurial catheter is placed to a nerve structure through a Touchy needle
214888549|NCT05712239|OTHER|Advices|The advices will include patient's reassurance and description of possible causes of neck pain such as poor working ergonomics, common bad postures especially while using electronic devices for long periods and not adjustable sleeping pillows. Also, patient will be educated how to modify these different causes and asked to apply gentle neck range of motion exercises
215048896|NCT02658552|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
214294218|NCT02814851|DEVICE|Transthoracic echocardiography|"A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).~During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany)."
214294219|NCT00851383|BIOLOGICAL|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
214294220|NCT00851383|BIOLOGICAL|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
214477763|NCT06600438|DEVICE|Slow-SPEED app|Gamified motivational smartphone app
214477764|NCT04945239|BEHAVIORAL|Amplification of Positivity Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
214477765|NCT04945239|BEHAVIORAL|Stress Management Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
214477766|NCT06593197|COMBINATION_PRODUCT|Apremilast with NB-UVB|Tab Apremilast 30 mg twice a day with NBUVB twice per week for 8 months
214477767|NCT06593197|DEVICE|NB-UVB|NBUVB only will be given twice per week for 8 months
214888550|NCT05712239|OTHER|Cervical and Scapular Stabilization Exercises|"Deep neck flexor training will be performed in neurodevelopment stages (supine at first week using pressure biofeedback unit , prone at second week, quadrupedal at third week, bipedal at fourth week).~Scapular stabilization exercises will include modified prone cobra, trapezius muscle exercise progression (3 stages), wall press and extension of the thoracic spine using foam roller. The modified prone cobra and the first stage of trapezius muscle exercise progression will be applied during the first two weeks. The second and third stages of trapezius muscle exercise will be applied during the last two weeks of our rehabilitation program. All exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets with 20 sec rest between each set. While wall press and thoracic extension exercises will be applied throughout the 4 weeks for 3 sets of 10 repetitions with 20 sec rest between each set."
214888551|NCT05712239|OTHER|Lumber Core Stability Program|"The program will be performed in three stages: activation, dynamic stabilization, and advanced core strengthening stages. Each stage will be applied for 4 sessions.~The activation stage will be based on the learning to activate transversus abdominis muscle from crock lying position using pressure biofeedback unit. In the dynamic stabilization stage, the patient will be instructed to slowly raise both arms in the scapular plan then return to the sides while maintaining the transversus abdominis muscle activation. Also, the patient will apply bridging exercise in this stage. The advanced core strengthening stage will include prone plank and side plank (right and left sides). All the exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets. The rest of 20 sec will be taken between each set."
214888552|NCT03342885|BEHAVIORAL|Specific sleep ergonomics guidance|Participants receive a detailed instruction in sleep ergonomics. Participants are instructed to maintain either side lying or supine sleeping posture, depending on which is less painful. Neutral position of spine supported by specific placement of body pillow. Changing of posture during sleep is prevented. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
214888553|NCT03342885|BEHAVIORAL|General sleep ergonomics guidance|Participants are instructed find most comfortable sleeping posture by personal preference and to avoid painful posture. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
214888554|NCT02570802|PROCEDURE|Ultrasonographic examination|
214888555|NCT02477956|DIETARY_SUPPLEMENT|vitamin D3 (Replesta)|vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
214888556|NCT02477956|DIETARY_SUPPLEMENT|vitamin D|
214888557|NCT03692507|DIETARY_SUPPLEMENT|HMB|Patients in the first group (HMB only) will take 3 capsules of HMB by VitaMonk™ (1000mg/capsule) daily (morning, noon, and night) for 5 days prior to surgery.
214294221|NCT04205071|DRUG|Lorcaserin|Given PO
214294222|NCT04205071|DRUG|Lorcaserin Hydrochloride|Given PO
214294223|NCT04205071|OTHER|Questionnaire Administration|Ancillary studies
214294224|NCT02630498|PROCEDURE|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
214477768|NCT06586606|DRUG|MK-1708|Oral administration
214294225|NCT03578601|OTHER|Thyroid surgery|Patient undergoing thyroid surgery
214294226|NCT00149084|DRUG|Lansoprazole, clarithromycin, amoxicillin|
214294227|NCT05909098|COMBINATION_PRODUCT|autologous NK cell|autologous NK cell
214294228|NCT00467259|DRUG|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
214294229|NCT00467259|DRUG|Placebo patch|placebo patch, changed twice a week for 52 weeks
214294230|NCT04694144|DEVICE|telescoping intramedullary nail|All osteogenesis imperfecta patients with lower limb skeletal deformities corrected with multiple corrective osteotomies and insertion of two parts male and female segments of intramedullary telescoping nail
214294231|NCT01150981|DRUG|Rosiglitazone|One 8mg capsule daily for 6 weeks.
214294232|NCT01150981|DRUG|Placebo|One capsule daily for 6 weeks.
214294233|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
214477769|NCT06586606|DRUG|Itraconazole|Oral administration
214668161|NCT01151137|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
214668162|NCT04409678|BEHAVIORAL|activity|physical activity
214668163|NCT00123201|DRUG|Dronabinol MDI|
214668164|NCT03478683|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
215048897|NCT02065492|DRUG|Standard Chelation|This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
215048898|NCT02065492|DRUG|Amlodipine|doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
215048899|NCT00827177|DRUG|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If \< 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
215048900|NCT06471959|DRUG|Psilocybin|Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.
215048901|NCT03842267|DRUG|Gemigliptin 50mg|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
215048902|NCT03842267|DRUG|Gemigliptin Placebo|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* \- The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
214668165|NCT03478683|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
214888558|NCT03692507|DIETARY_SUPPLEMENT|Protein and HMB|Patients in the second group (HMB + protein) will drink 2- 8oz bottles of Ensure Enlive daily (morning and night) for 5 days prior to surgery. Each bottle contains 1500mg of HMB and 20 g of protein.
214888559|NCT03692507|DIETARY_SUPPLEMENT|ERAS|Patients in the third group (High protein) will drink 2- 8oz bottles of Ensure surgery daily (morning and night) for 5 days prior to surgery. Each bottle contains 18g of protein. and a clear 50g Pre-surgery drink on the day of surgery
214888560|NCT01591083|DRUG|esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score \>=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days."
214888561|NCT00835393|DRUG|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
214888562|NCT00835393|DRUG|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
214888563|NCT03995277|DIETARY_SUPPLEMENT|Biotin|Daily intake of 10 mg or 50 µg per day
214888564|NCT02603016|DRUG|GLSE compound|
214888565|NCT02603016|DRUG|Maitake mushroom extract compound|
214888566|NCT02603016|DRUG|Ginseng compound|
214888567|NCT03556124|DEVICE|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
215048903|NCT03068897|DRUG|Metaxalone|Metaxalone 400-800mg
215048904|NCT03068897|DRUG|Tizanidine|Tizanidine 2-4mg
215048905|NCT03068897|DRUG|Baclofen|Baclofen 10-20mg
215048906|NCT03068897|DRUG|Ibuprofen 600 mg|Ibuprofen
215048907|NCT03068897|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health\_Info/Back\_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
215048908|NCT04280575|PROCEDURE|Percutaneous coronary intervention|Coronary artery stenting for stable angina
214668166|NCT03478683|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
214668167|NCT03478683|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
214668168|NCT03478683|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
214668169|NCT03478683|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
214888568|NCT03556124|DEVICE|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
214888569|NCT03556124|DEVICE|Active - Conventional tDCS|Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
214888570|NCT03556124|DEVICE|Sham - Conventional tDCS|Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
214888571|NCT02244281|DRUG|tamsulosin hydrochloride|
214888572|NCT02244281|DRUG|Placebo|
214888573|NCT01705795|DRUG|Mepolizumab (a-IL-5 antibody)|750mg mepolizumab four times over four months
214294234|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
214888574|NCT01705795|DRUG|Placebo|Nacl four times over four months
214888575|NCT01988181|DEVICE|BVM-UF biofeedback|The Fresenius 5008 uses an ultrasound and temperature monitor incorporated into the machine to detect ultrasonic velocity and temperature changes to derive the total protein concentration, which is a sum of total plasma proteins and hemoglobin. The relative blood volume is calculated at by dividing the initial concentration of total protein by the total protein concentration at any given time, multiplied by 100. The HD software is based on the critical blood volume entered at the beginning of the dialysis session for each individual patient. The UF rate is adjusted based on the changes in the relative blood volume to the patient's critical relative blood volume.
214888576|NCT01988181|DEVICE|Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)|For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
214888577|NCT02664181|DRUG|Nivolumab|Nivolumab will be given at 3mg/kg by IV every two weeks until progression
214888578|NCT02664181|DRUG|oral decitabine|oral decitabine \~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.
214888579|NCT02664181|DRUG|Tetrahydrouridine|Oral THU \~10 mg/kg twice weekly on consecutive days
214888580|NCT01113723|DEVICE|Fiberoptic bronchoscope|Fiberoptic bronchoscope device
214888581|NCT01113723|DEVICE|CMAC|CMAC Device
214888582|NCT01471743|DIETARY_SUPPLEMENT|Impact Advance Recovery (R)|
214888583|NCT01471743|DIETARY_SUPPLEMENT|Ensure Plus (R)|
214888584|NCT00545714|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
214888585|NCT00545714|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
214888586|NCT00545714|DRUG|Rituximab|Rituximab 375 mg/m\^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m\^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m\^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
214888587|NCT05736055|DIAGNOSTIC_TEST|Cambodia Version Five Minutes Hearing Test|The FMHT was developed by American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). The FMHT is composed of 15 questions. Each answer is scored as 0, 1, 2 or 3 according to the frequency of experience. If they answered 'never', the score was 0. The answer 'occasionally' scored 1, the answer 'half the time' scored 2, and the answer 'almost always' scored 3. Furthermore, it has shown more aspects, more reliability, and more assessments of the hearing impairment of the patients. is a standard hearing questionnaire. So, we plan to translate the FMHT into Cambodian language and validate by comparing its result with those of audiometry.
214888588|NCT02319317|BEHAVIORAL|Risky driving prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
214888589|NCT02319317|BEHAVIORAL|Control group general health promotion|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
214888590|NCT02593617|OTHER|Addiction Profile Index|
214888591|NCT02593617|OTHER|Alcohol Use Disorders Identification Test|
214294235|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
214888592|NCT02593617|OTHER|Barratt Impulsiveness Scale|
214888593|NCT02593617|OTHER|Zuckerman Sensation Seeking Scale|
214888594|NCT02593617|OTHER|Energy Drink Consumption Questionnaire|
214888595|NCT04428034|BEHAVIORAL|Learning Skills Together|Information provided in arm/group description.
214888596|NCT00995124|DRUG|NeutraLice Lotion|Head lice topical application to be applied once for 10 minutes.
214888597|NCT00995124|DRUG|NeutraLice Advance Solution|head lice application to be applied once for 10 minutes
214888598|NCT00995124|DRUG|Moov Head Lice Solution|Single application for head lice with 10 min application time.
214888599|NCT04873596|DRUG|Nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine.
214888600|NCT04873596|DRUG|Nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam.
214888601|NCT02484937|OTHER|Group 2 (PCP Treatment)|For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
214888602|NCT02484937|OTHER|Group 1 (PMS Treatment)|For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
214888603|NCT03528616|DRUG|adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.|drugs used for treatment of supraventricular tachycardia
214888604|NCT00261287|DRUG|Ciclesonide|
214888605|NCT00634699|PROCEDURE|Active Comparator, ischemic compressions|Ischemic Compressions,3 times a week,5 weeks.
214668170|NCT03478683|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
214668171|NCT03478683|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
214668172|NCT03478683|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
214668173|NCT03478683|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
214668174|NCT00986336|DRUG|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
214668175|NCT00986336|DRUG|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
214668176|NCT00986336|DRUG|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
214668177|NCT00986336|DRUG|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
214668178|NCT00337051|DRUG|Sevoflurane|General anesthesia using Sevoflurane (inhalation) as hypnotic
214668179|NCT00337051|DRUG|Propofol|General anesthesia with propofol TCI
214668180|NCT03690791|DRUG|MediCabilis CBD Oil|50 mg of CBD: \<2mg of THC in one ml. The cannabis oil consists of CBD extract in MCT oil.
214668181|NCT03690791|DRUG|Placebo Oil|Placebo will contain only hemp seed oil.
214668182|NCT06657066|DRUG|Beclomethasone 200mcg, salbutamol 100mcg , Beclomethasone 200 mcg/Formoterol 6 mcg, 250 mg of lyophilized saccharomyces boulardii|Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram plus Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii. It was given daily for three months
214668183|NCT06657066|DRUG|Control (Standard treatment)|The control arm will receive only standard treatment for asthma i.e Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.
214668184|NCT06656897|BEHAVIORAL|FallScape for Persons with Alzheimer's disease or a related Dementia (FS-D)|FS-D is a multimedia behavioral intervention for use by family Caregivers (CG) of Persons with Alzheimer's disease or a related dementia (PwADRD) who are living at home and classified as at moderate to high risk for falls. FS-D will create, customize and support CG-provided daily multimedia sessions for PwADRD using structured learning techniques.
214668185|NCT06656234|DRUG|Glofitamab|Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling.
214888606|NCT02017470|OTHER|Gender-tailored women's heart health outpatient programme|
214888607|NCT03409237|DRUG|Mannitol|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
214888608|NCT03409237|DRUG|Hypertonic saline solution|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
214888609|NCT02329028|DEVICE|Prehospital mini-EEG|Observational
214888610|NCT05714878|BEHAVIORAL|aerobic exercise; resistance exercise; nutritional support; psychological support|Patient with gastric cancer received two weeks of prehabilitation intervention. An individualized exercise program was established according to the FITT (Frequency, Intensity, Time and Type) principle. Aerobic exercise: 3-5 times/week, 30-60 min jogging or brisk walking per time, intensity based on heart rate and modified Borg-scale. Resistance exercise: 2-3 times/week, 10-12 RM per sets, 2-3 sets with 2 min interval rest, seated knee up, knee extension, etc. Nutritional support: 30kcal/kg/d, 1.5mg/kg/d protein, oral nutritional supplement with suggested recipes. Psychological support: provided with guidance on gastric cancer, regular online chat through Wechat, alcohol quitting, smoking cessation and light music.
215048909|NCT02996422|BEHAVIORAL|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
214668186|NCT06656234|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
214668187|NCT06656273|BEHAVIORAL|FT LCP|FT LCP is a behavior change software application, used as an adjunct to the standard National Diabetes Prevention Program
214668188|NCT00323661|DEVICE|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
214668189|NCT00323661|DEVICE|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
214888611|NCT04944173|DRUG|Durvalumab|Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
214888612|NCT04944173|RADIATION|Stereotactic Body Radiotherapy|Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.
215048910|NCT02996422|BEHAVIORAL|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
215048911|NCT01051037|RADIATION|Stereotactic Body Radiation|3 fraction of stereotactic body radiation therapy within 10 days.
215048912|NCT01051037|RADIATION|Radiofrequency Ablation|Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
214668190|NCT04804215|PROCEDURE|Intraductal transanastomotic stent group|When bile duct anastomosis is performed, a intraductal transanastomotic stent is inserted into the bile duct.
214668191|NCT04804215|PROCEDURE|No stent group|Do not insert a stent into the bile duct during anastomosis of the bile duct.
215048913|NCT01688297|BIOLOGICAL|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
214477770|NCT06600100|BEHAVIORAL|Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images of food and non-food appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
214477771|NCT06600100|BEHAVIORAL|Placebo Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Here, three separate categories of non-food items (stationery, flowers and clothing) would be Go signal (associated with green 100%), No-Go signal (associated with red 100%) and control (50% red 50% green) respectively.
214668192|NCT03820115|DEVICE|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
214888613|NCT04944173|DIAGNOSTIC_TEST|Circulating Tumor DNA assay|After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
214888614|NCT04478929|DIAGNOSTIC_TEST|Gastroscopy|Routine gastroscopy
214888615|NCT00560391|DRUG|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
214888616|NCT00560391|DRUG|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
214888617|NCT00560391|DRUG|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
214888618|NCT00560391|DRUG|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
214888619|NCT00560391|DRUG|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
215048914|NCT01688297|BIOLOGICAL|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
215048915|NCT02910141|DEVICE|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
215048916|NCT03657836|DIETARY_SUPPLEMENT|Sublimated mare milk supplement|The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
215048917|NCT03657836|DRUG|Standard antibiotic therapy|Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
215048918|NCT06487234|DEVICE|Functional band|Participants will wear the functional band for 1-hour electroacupuncture stimulation
215048919|NCT06487234|DEVICE|Placebo band|Participants will wear the nonfunctioning band for 1-hour with no electroacupuncture stimulation
215048920|NCT02566811|PROCEDURE|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
215048921|NCT02566811|PROCEDURE|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
215048922|NCT05975346|DRUG|Ketamine|description
215048923|NCT05975346|OTHER|saline nebulization|description
214888620|NCT04826367|OTHER|Telerehabilitation-based relaxation exercise group (EG)|the participants in this group will perform the relaxation exercises thrice a week, for 6 weeks.
215048924|NCT00616642|DRUG|rosiglitazone maleate|Given orally
215048925|NCT00886418|DRUG|muscle relaxant|muscle relaxant administration throughout anesthesia
215048926|NCT00886418|DRUG|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
215048927|NCT03856359|DRUG|Rifaximin 550 milligrams (MG)|Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
215048928|NCT04686344|DRUG|intermittent boluses of Hypertonic saline|intermittent boluses every 6 hours over 30 min for 48 hours
215048929|NCT04686344|DRUG|continuous infusion of Hypertonic saline|continuous infusion over a period of 48 hours
215048930|NCT04340492|OTHER|Education to Adapted Physical Activity|4 group sessions (5 patients) aiming at promoting physical activity, the first three focusing respectively on endurance, posture and balance and power re-enforcement at one-week interval. A fourth session, 3 months latter is a consolidating session aiming at identify and overcome obstacles to practice physical activity in everyday life.
215048931|NCT04340492|OTHER|Standard care|Standard care concerning Parkinson's disease and physical activity
214888621|NCT03369769|OTHER|Activity|10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
214888622|NCT05778201|BIOLOGICAL|Baby Drink group|1 packge (20 ml)/ day for 1 month
214888623|NCT05187104|BIOLOGICAL|Cultured retinal stem and progenitor cells|Cultured retinal stem and progenitor cells injected subretinally
214888624|NCT05187104|OTHER|Standard treatment according to the clinical protocols|Standard treatment of age-related macular degeneration according to the clinical protocols
214888625|NCT02556801|BIOLOGICAL|SUBLIVAC FIX Phleum Prat.|sublingual daily administration
214888626|NCT00580450|DRUG|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
214888627|NCT03997812|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
214888628|NCT03997812|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
214888629|NCT05217212|RADIATION|Radiochemotherapy|Primary radiotherapy of the primary tumor and nodal basin with curative intent with or without concomitant chemotherapy with cisplatin, carboplatin, or cetuximab weekly.
214888630|NCT01101412|DRUG|Edetate Calcium Disodium|Given through CVC or PVC.
214888631|NCT01101412|DRUG|Ethanol|Given through CVC or PVC
214888632|NCT01101412|DRUG|Trimethoprim-sulfamethoxazole|Given through CVC or PVC
214888633|NCT01101412|OTHER|Hypertonic Saline|Given through CVC or PVC
214888634|NCT02392585|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
214888635|NCT02392585|PROCEDURE|Triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
214477772|NCT06861348|DRUG|Inotuzumab Ozogamicin±Donor Lymphocyte Infusion|"Participants will receive Ino±DLI regimen:~* ① InO induction dose: the first cycle: 0.8mg/m2, intravenous infusion, d1; 0.5 mg/m2, intravenous infusion, d8, d15;~* ② If CR/CRi was reached after induction, the second cycle :0.5mg/m2, intravenous infusion, d1, d8，d15; If CR/CRi is not reached, Cycle 2 :0.8mg/m2, IV infusion, d1; 0.5 mg/m2, intravenous infusion, d8, d15;~* ③DLI dose: CD3 positive cells 1x10\^7/kg; DLI indication: no previous grade III-IV aGVHD, negative HLALOSS test and no present aGVHD and cGVHD;~* Lumbar puncture: cytarabine 50mg+dexamethasone 5mg+methotrexate 10mg, intrathecal injection, once a month after remission, a total of 4-6 courses of treatment."
214888636|NCT03668808|DRUG|Insulin Degludec|Subjects will use Insulin Degludec (Tresiba) with TRESIBA® FLEXTOUCH® pens as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
214888637|NCT03668808|DRUG|Insulin Glargine|Subjects will use Insulin Glargine (Lantus) with LANTUS® SOLOSTAR® INSULIN PEN as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
214888638|NCT03668808|DEVICE|TRESIBA® FLEXTOUCH®|Subjects will use Tresiba FlexTouch pens when using Tresiba as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
214888639|NCT03668808|DEVICE|LANTUS® SOLOSTAR® INSULIN PEN|Subjects will use Lantus SoloStar insulin pens when using Lantus as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
214888640|NCT01751256|DEVICE|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
214668193|NCT03505242|DEVICE|bronchial blocker for BB group|Using bronchial blocker to block right middle lower lobe during surgery.
215048932|NCT03391986|DEVICE|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
214668194|NCT03505242|DEVICE|double lumen tube for DLT group|Using double lumen tube to achieve single lung ventilation during surgery.
214888641|NCT06081478|DRUG|CD19/CD22-bispecific CAR-T cells|CD19/CD22-bispecific CAR-T cells were infused at the same day with 2×10e6/kg and 1×10e6/kg dosage, respectively.
214888642|NCT04362670|DRUG|OTX-CSI|OTX-CSI intracanalicular insert
214888643|NCT04362670|OTHER|Placebo Vehicle|Hydrogel Vehicle intracanalicular insert
214888644|NCT05274178|DEVICE|"Audeo P hearing aid labeled as Prescriptive"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as prescriptive in view of the participant."
214888645|NCT05274178|DEVICE|"Audeo P hearing aid labeled as OTC"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as OTC in view of the participant."
214888646|NCT06252883|OTHER|Serial bedside video call communication|Bedside video call with audio features, given to NICU parent/guardian 2-3 days a week for an 8-week period or till infant is discharged, whichever comes first.
214888647|NCT01133730|DRUG|Active treatment|US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
214888648|NCT01133730|DRUG|Placebo Arm|US-guided TFP block with 20ml of 5% dextrose solution
214888649|NCT03203967|PROCEDURE|Epidural morphine|2 mg of morphine (0.4 mg/ml morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.
214888650|NCT03203967|PROCEDURE|Epidural placebo|5 ml normal saline is administered through the epidural catheter at the end of surgery.
214888651|NCT03203967|PROCEDURE|Single femoral nerve block|Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
215048933|NCT03391986|PROCEDURE|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
214888652|NCT03203967|DRUG|Intravenous morphine analgesia|Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
214888653|NCT01618448|DRUG|Tolvaptan|Tolvaptan 15mg once daily
214888654|NCT01618448|DRUG|Placebo|Placebo
214888655|NCT06582004|DIETARY_SUPPLEMENT|CH2 vaginal gel|The usage frequency is 2 units per week, with a 3-day interval between each unit, for a total duration of 24 weeks
214888656|NCT06582004|DIETARY_SUPPLEMENT|Placebo hyaluronic acid gel|The usage frequency is 2 units per week, with a 3-day interval between each unit, for a total duration of 24 weeks
214888657|NCT02839772|OTHER|Current skin care regimen plus 2% glycerine added to soaking water|
214888658|NCT02839772|OTHER|Current skin care regimen|
214888659|NCT03359655|DRUG|Misoprostol|Rectal administration 2 jours before the procedure
214888660|NCT03359655|DRUG|Hyoscine butyl bromide|Rectal administration 2 jours before the procedure
214888661|NCT00302861|BIOLOGICAL|MyVax|
214888662|NCT00149461|BEHAVIORAL|Written Asthma Action Plan|
214888663|NCT00408512|DRUG|thiazides|Up to 25 mg per day
214888664|NCT00408512|PROCEDURE|Non thiazidic treatment|Amximum tolerated dosage as indicated from the label
214888665|NCT02532686|DRUG|DAAOI-2|500-2000mg/d, oral, for 6 weeks
214888666|NCT02532686|DRUG|placebo|oral, for 6 weeks
214888667|NCT04186312|BEHAVIORAL|ACCESS - Accessing Campus Connections & Empowering Student Success|Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions
214888668|NCT02277535|OTHER|Feedback/Reminder email.|
214888669|NCT01634841|DIETARY_SUPPLEMENT|Walnuts|30 to 60g (1 to 2 oz) per day of walnuts
215048934|NCT04284501|BEHAVIORAL|Non|questionnaire
215048935|NCT04845594|BEHAVIORAL|MySmileBuddy (MSB)|The technology-based MSB program equips community health workers (CHWs) with an iPad-based app that facilitates assessment of a child's early childhood caries (ECC).
215048936|NCT06257225|PROCEDURE|Guided Bone regeneration|After local anesthesia, a crestal incision will be performed followed by full-thickness mucoperiosteal flap elevation Flap advancement will be attained through periosteal scoring of the buccal; The resorbable collagen membrane (Bio Gide, Geistlich AG) will be trimmed to the defect size. Xenograft (Bio-Oss) together with scrapped autogenous bone will be mixed and placed at the surgical site. The membrane will positioned over the graft and tucked into the lingual flap. Patient allocation concealment will be broken and the patients will be randomly assigned into two groups Patients receiving horizontal bone augmentation with resorbable collagen membrane stabilized with no tacks. The first layer will be closed with horizontal mattress sutures placed 4 mm from the incision line, and single interrupted sutures are used to close the edges of the flap. Vertical incisions are closed using single interrupted sutures and mattress suture should remain in place for at least 2 to 3 weeks
215048937|NCT00001964|DRUG|Cyclosporine A|Cyclosporine A
215048938|NCT00001964|DRUG|ATG|ATG
215048939|NCT00001964|DRUG|MMF|MMF
215048940|NCT00915889|BEHAVIORAL|telephone-based intervention|Either 6 or 8 telephone educational sessions
215048941|NCT00915889|OTHER|counseling intervention|counseling and communications studies
215048942|NCT00915889|OTHER|questionnaire administration|Ancillary studies
215048943|NCT00915889|OTHER|study of socioeconomic and demographic variables|Ancillary Studies
215048944|NCT00915889|PROCEDURE|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
214888670|NCT01634841|OTHER|habitual diet|Dietary information will be provided
215048945|NCT04114175|OTHER|Exercise BE|Basic exercises related to amputation will be applied
214888671|NCT00554034|DRUG|periopatch|Patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study.
214888672|NCT06329570|DEVICE|NaviFUS System|Open the BBB using focused ultrasound and microbubble
214888673|NCT06329570|DRUG|Lumason|Open the BBB using focused ultrasound and microbubble
214888674|NCT06329570|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
214888675|NCT04975711|DRUG|HIP2105|Test drug
214888676|NCT04975711|DRUG|RLD2104|Reference drug
214888677|NCT04571853|BEHAVIORAL|PNE-explained group|There are 9 fact sheets overall. And each fact sheet incorporates two pages relating to one main concept. The first of two pages introduces the concept, and the second one quotes important ideas that emerge from the main concept. The 9 main concepts and consequent ideas presented in the fact sheets are based on current scientific research in pain science and have been selected and structured specifically for PNE education for chronic pain patients. The fact sheets have been fully developed and designed by Pain Revolution, a pain educator network founded by Professor Lorimer Moseley, group leader in Body in Mind Research Group from University of South Australia.
214888678|NCT04571853|BEHAVIORAL|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
214888679|NCT04571853|BEHAVIORAL|TAU group|Participants allocated to this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professiona
215048946|NCT04114175|OTHER|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
215048947|NCT06499103|DEVICE|Transcutaneous electrical nerve stimulation|The stimulation (TENS) will be performed by a physiotherapist using adhesive electrodes with an area of 5 cm2 in the region where the patient has the symptoms of neuropathy. Further, it will be will be on 10 days consequently, with the same physiotherapist for whole sessions. He will apply electrodes over the affected area, then he will increase the stimulation intensity gradually during the first session when he adjusts the settings till patient reach the maximum voltage that he/she will tolerate it. The evaluations for CIPN patients will be performed by a blinded evaluatorthe PI on the experimental groups at 3 time points; before the begging of the intervention, after 5 days, and after the last session. The intervention group will undergo TENS sessions daily for 10 days for 30 minutes each session ( Gibson et al., 2017). After session completed a structured interview will be conducted, by the primary investigator, to assess for CIPN using the CIPNAT.
215048948|NCT04169178|DRUG|HLX55|A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
214294236|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
214888680|NCT04010851|BEHAVIORAL|Peer co-led educational group|The intervention is delivered in a group format, which takes the form of a full day's training, focusing on ADHD diagnosis, its treatment, how to cope with the challenges related to living with ADHD, as well as coping with challenges of parenting a child with chronic health conditions. After this one day-intervention, the participants can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence. Participants are encouraged to adopt an active role in order to achieve a positive parent/provider partnership.
214888681|NCT04010851|BEHAVIORAL|Comparator treatment as usual|Control group will receive treatment as usual, including different treatment options that can help alleviate the symptoms of ADHD and arm families with the tools needed to better handle problem behaviors when they arise. These interventions include: medication, psychotherapy, or a combination of these two approaches.
214888682|NCT01965860|OTHER|additional curriculum (E-learning + simulation)|
214888683|NCT01965860|OTHER|additional E-learning|
214888684|NCT05487950|DRUG|Rivaroxaban group|Patients assigned in the Rivaroxaban group will receive 15 mg once day or 10 mg if dosage modification is needed due to renal insufficiency (Creatinine clairance calculated with the Cockroft formula between 30 or 49 ml/min).
214294237|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
214294238|NCT05449652|OTHER|To prescribe exercise prescription for CVD patients|To prescribe exercise intensity, frequency, session duration, program duration, and exercise type (endurance or strength training) for the same three patient cases
214294239|NCT01257997|BIOLOGICAL|15N-Thymidine, 2H-Water|"Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).~Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot)."
214294240|NCT05723237|OTHER|Breast Cancer Education|The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers.
214294241|NCT04011761|OTHER|expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
214294242|NCT00563979|DIETARY_SUPPLEMENT|VitaluxPlus®|1 tablet daily
214294243|NCT00563979|DIETARY_SUPPLEMENT|Omega 3|1 tablet daily
214294244|NCT02010554|BEHAVIORAL|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
214294245|NCT02010554|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
214477773|NCT04852601|OTHER|ToolboxDetect|The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
214668195|NCT06377995|OTHER|Placebo technique|The patient is in a supine position with a 90° knees flexion. The osteopath lies cephalad to the patient and places their hands on their shoulders.
214888685|NCT02271932|OTHER|Non-operative|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
214888686|NCT01018004|OTHER|follow-up care|
214888687|NCT01018004|OTHER|questionnaire administration|
214888688|NCT01018004|PROCEDURE|quality-of-life assessment|
214294246|NCT06501768|DRUG|Genistein|Escalation genistein dosing, followed by wash-out period
214294247|NCT04285879|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device following the Owens Recovery Science Protocol
214294248|NCT05740644|DEVICE|CM-1600|Healthy subjects undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline will be connected to the CM-1600 device.
214294249|NCT03009578|DRUG|Iron Sucrose Injection|iron Intramuscular injections
214294250|NCT03009578|DRUG|Ferrous Bisglycinate|oral iron tablets
214294251|NCT04673864|DRUG|CKD-386|QD, PO
214294252|NCT04673864|DRUG|D012, D326, D337|QD, PO
214294253|NCT00251550|DRUG|Pemetrexed|
214294254|NCT00251550|DRUG|Cisplatin|
214294255|NCT01185132|RADIATION|accelerated partial breast irradiation - 3D-conformal planning|38.5 Gy, 10 fractions over 5 days
214294256|NCT01185132|RADIATION|accelerated partial breast irradiation - IMRT planning|38.5 Gy, 10 fractions over 5 days
214294257|NCT04432896|OTHER|Dietary protocol|Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.
214294258|NCT01447602|BEHAVIORAL|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
214888689|NCT02526667|DRUG|Chlorhexidine gluconate|2% CHG solution on cloth
214888690|NCT02526667|DRUG|DynaHex-2|2% CHG solution
214888691|NCT02526667|OTHER|Vehicle|Excipients of CHG product only
214888692|NCT02665793|OTHER|DBPCFC to peanut cookie|
214888693|NCT02665793|OTHER|Single-dose DBPCFC to peanut flour|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
214888694|NCT02665793|OTHER|Single-dose DBPCFC to peanut butter|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
214888695|NCT05890651|DIAGNOSTIC_TEST|ECG|Describe the electrocardiography (ECG) changes 24 hours,1,6,12 months after VSD transcatheter device closure in a pediatric population.
214888696|NCT03867240|DRUG|Gabapentin|Gabapentin (10 mg/kg up to 600 mg) will be given 30 minutes prior to being transported to the operating room. The gabapentin will be in the standard liquid with a concentration of 250mg/5mL. Starting postoperative day 1, patients in the experimental group will receive gabapentin three times daily. Dose of gabapentin will be 100 mg for patients \<50 kg and 200 mg for patients \> 50 kg. Gabapentin will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with gabapentin for the remainder of their doses upon discharge.
214888697|NCT03867240|OTHER|Placebo|Placebo will be given 30 minutes prior to being transported to the operating room. Placebo will be identically appearing to gabapentin. Starting postoperative day 1, control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group. It will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with placebo for the remainder of their doses upon discharge.
214888698|NCT05322772|DEVICE|ECG|ii. 12 leads ECG: 12 leads ECG will be done to all infants \& children using (FUKUDA DENSHI, CARDIMAX, model FCP 7101). The electrocardiograms will be reviewed through the creation of descriptive reports and determination of the following variables: heart rate, QRS duration, The QT interval was measured from the onset of the QRS complex to the end of the T wave, defined by the return of the terminal T wave to the isoelectric T-P baseline. When U waves were present, the end of the T wave will be taken as the nadir between the T and U waves. Then QT interval will be corrected for heart rate using Bazett's formula Interpretation of every ECG paper
214888699|NCT03934346|OTHER|Zinc amino acid complex|Zinc in the form of a Zinc Amino Acid Complex (ZnAA) is provided with a test diet, and the amount of zinc that dissociates from the ZnAA and is thus absorbed via an ionic zinc transport pathway is determined based on the Hill transport kinetics for the respective subject.
214888700|NCT00962819|BIOLOGICAL|MMR vaccine|People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
214888701|NCT05602220|BEHAVIORAL|Brain training|Participants will play a few brain training games using an online interface each day. These games train attention, memory and other cognitive functions.
214888702|NCT05602220|BEHAVIORAL|Paced breathing|After completing brain training, they will then immediately do one 15-minute session of paced breathing, followed by a second 15-min session of paced breathing later in the day. During the paced breathing sessions, participants will clip a pulse monitor to their ear lobe and try to inhale and exhale in synchrony with a ball that moves up and down on the screen. They will receive heart rate biofeedback regarding whether they are achieving their relaxation/alertness goal.
214888703|NCT00282646|PROCEDURE|intraarterial stem cell therapy|catheter delivery of stem cells
214888704|NCT00282646|OTHER|Stem cells|intraarterial application of bone marrow mononuclear cells versus placebo
214888705|NCT00139451|DRUG|Pediasure|With the assistance of a research dietician, we will prescribe and monitor the use of a liquid food supplement (Pediasure). Adjustments to the supplementation will be made based on weight measurements in the clinic with subjects wearing paper gowns at 2 and 4w, and monthly thereafter, and repeat dietary intake and TEE assessment at 6 and 12mo.
214888706|NCT00139451|DRUG|GH|Growth Hormone will be 0.3mg/kg/week, given SC once daily.
214888707|NCT04570332|DRUG|BO-112 plus pembrolizumab|Patients will be treated with the combination of BO-112 and pembrolizumab. Order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles
214888708|NCT04570332|PROCEDURE|Tissue Biopsies|Pre and post (if feasible) treatment tumor tissue biopsies will be used for correlative research.
214888709|NCT04348877|OTHER|Antibody-Rich Plasma from COVID-19 recovered patients|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
214888710|NCT06008184|OTHER|24 hours sampling of 4 biological fluids (blood, ISF, sweat and saliva)|"24 hours sampling of 4 biological fluids:~* blood: sampling every 20 minutes (through a venous catheter)~* ISF: automated sampling every 20 minutes (microdialysis technique connected to U-Rhythm device)~* Sweat : collection of 1 to 3 samples at 4 differents timepoints~* Saliva : sampling every hour (except during the night)"
214888711|NCT06008184|OTHER|24 hours sampling of ISF or sweat (after validating the correlation with blood)|24 hours sampling in an ambulatory setting
214888712|NCT03735121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in arm or cohort.
214888713|NCT03735121|DRUG|rHuPH20|rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
214888714|NCT05721014|OTHER|OsteoStrong|"This training method is an isometric high-impact loading in four different training machines (Spectrum) and balance training on a vibration plate. The four machines are chest press, leg press, pull-down and deadlift. The participants press and/or pull isometrically for around 10-15 seconds 1-3 times on every machine.~The training session takes around 20 minutes and is performed individually by the participants with the help of a training instructor."
214294259|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
214888715|NCT05721014|OTHER|Individually Adapted and Combined Physical Training|"This training method is based on the current recommendations on physical activity for people with osteoporosis.~The training is divided into two training sessions:~Circuit training with ten stations with different exercises for the whole body (strength, balance, endurance, weight-bearing). The participants spend 40 seconds on each station. This is repeated during 40 minutes. The training session starts with a joint warm-up and ends with a cool-down.~Strength training with machines for the whole body with the intensity of up to 70-80 % of one repetition max (1RM). The training session starts with a joint warm-up and and a voluntary individual cool-down.~The training session takes around 60 minutes and is performed in a group with the help of a training instructor. The participants also have the option to do a home based exercise programme that they could do in a few cases when they were unable to attend the physical group training."
214888716|NCT06480292|OTHER|telerehabilitation exercise|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased.
214888717|NCT06480292|OTHER|routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
214888718|NCT05440890|OTHER|Best current rehabilitation protocol|Inflamation control and edema with physical agents, recover full pasive and active range of motion, normalize gait pattern, lower limb strengthening (specially quadriceps and hamstrings), neuromuscular control training, cycling, landings and running.
214888719|NCT05440890|OTHER|Cross-training protocol|Beginning on 2º week after ACLR, 3 times per week during 8 weeks, based on isotonic exercise at least to 80% of 1RM in leg extension. 5 sets o 6 repetions with 1,5 - 2 minutes between series.
214888720|NCT00390637|BEHAVIORAL|High or low Glycemic Index and high or low Protein Diet|
214888721|NCT03041428|DEVICE|Ultraprotective ventilation|Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
214888722|NCT04168879|DRUG|Bupivacaine 0.5% Preservative-Free Injectable Solution|1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used to block the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
214888723|NCT04168879|DRUG|normal saline|1.5 ml of normal saline is delivered to the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
214888724|NCT00271232|DEVICE|Cardiac resynchronization therapy|
214888725|NCT05581381|BEHAVIORAL|empathy training program|Empathy training, a total of 8 weeks of training (1 time a week, 1 hour each time)
214888726|NCT03044821|PROCEDURE|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
214888727|NCT00601887|DRUG|Meloxicam|
214888728|NCT01926405|PROCEDURE|saliva collection|collection of saliva
214888729|NCT02816983|RADIATION|SBRT|
214888730|NCT05889429|DIAGNOSTIC_TEST|MRI scans|The MRI protocol will include standard anatomical, functional, and diffusion imaging, and spectroscopy sequences.
214888731|NCT05889429|BEHAVIORAL|clinical assessments|Several clinical assessments will be performed to evaluate the recovery of motor functions. Initially and for screening, the cognitive ability will be assessed using the Montreal Cognitive Assessment (MoCA), and visuospatial neglect will be assessed using the Star Cancellation Test (SCT). eligible participants that meet all inclusion criteria will undergo a series of clinical function tests during each test session (t1-t4) to assess clinical outcomes.
214888732|NCT06387420|DRUG|AK117|Subjects receive AK117 intravenously.
214888733|NCT06387420|DRUG|Azacitidine|Subjects receive azacitidine subcutaneously.
214888734|NCT06387420|DRUG|Venetoclax|Subjects receive venetoclax orally.
214888735|NCT06387420|OTHER|Placebo|Subjects receive placebo intravenously.
214888736|NCT01060241|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
214888737|NCT03992365|DRUG|Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)|"The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets."
214888738|NCT03992365|DRUG|Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl|"The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes."
214888739|NCT00067041|DRUG|Remodulin (treprostinil sodium) Injection|
214888740|NCT00349219|DRUG|erlotinib|erlotinib 150 mg taken orally daily until disease progression
214888741|NCT00349219|DRUG|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks given in second-line therapy
214888742|NCT00349219|DRUG|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks, given in second-line
214888743|NCT00349219|DRUG|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks for 6 cycles
214888744|NCT00349219|DRUG|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks for 6 cycles
214888745|NCT00349219|DRUG|erlotinib|erlotinib 150 mg orally taken daily as second line therapy (after disease progression on chemotherapy)
214888746|NCT02845648|DRUG|anticholinergic|Initial anticholinergic therapy to all patients
214888747|NCT01137994|DRUG|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
214888748|NCT01137994|BIOLOGICAL|Trastuzumab|monoclonal antibody directed to HER2 receptor
214888749|NCT01137994|DRUG|Docetaxel|Taxane chemotherapy
214888750|NCT01137994|DRUG|Paclitaxel|Taxane chemotherapy
214888751|NCT01137994|DRUG|Vinorelbine|Vinka alkaloid
214294260|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
214477774|NCT06861491|BEHAVIORAL|Non-pharmacological|This intervention will be provided by student pharmacists. It will focus on lifestyle modifications, adherence, and education of disease state.
214888752|NCT05317338|BEHAVIORAL|Group-based exercise training during hospitalization|Multicomponent exercises for 5-7 days with acutely hospitalized older.
214888753|NCT02535286|DRUG|Umbralisib|A once daily oral agent
214888754|NCT02535286|BIOLOGICAL|ublituximab|IV anti-CD20 monoclonal antibody
214888755|NCT02535286|BIOLOGICAL|TG-1501|IV immunotherapy for cancer
214888756|NCT01528007|DRUG|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
214888757|NCT01528007|DRUG|Placebo|Placebo pill with no active ingredients.
214888758|NCT05517538|DEVICE|Electromyography-Needle Intramuscular Drug guidance|EMG-guided needle neurotoxin injection
214888759|NCT05517538|DRUG|Botulinum toxin type A|Botulinum toxin type A injection into the Corrugator Supercilii muscle
214888760|NCT04409314|DRUG|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
214888761|NCT04409314|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214888762|NCT03138655|DRUG|Vedolizumab|Vedolizumab IV infusion.
214888763|NCT04495881|DRUG|Sitagliptin 100mg|Sitagliptin 100mg Qd
214888764|NCT01008189|BEHAVIORAL|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
214294261|NCT04258722|OTHER|Resuscitation Personnel|Type of resuscitation team
214294262|NCT06170723|DRUG|BMS-986368|Specified dose on specified days
214294263|NCT06170723|DRUG|Itraconazole|Specified dose on specified days
214477775|NCT04761770|OTHER|Geriatric assessment (GA) pre-transplant|Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
214294264|NCT06170723|DRUG|Famotidine|Specified dose on specified days
214294265|NCT00408356|DRUG|Zinc|
214294266|NCT03053804|RADIATION|MR/PET|MR/PET with contrast media and FDG-18
214294267|NCT03725280|PROCEDURE|IVF|None interventional study (Collection of ovarian follicular fluid during IVF treatment)
214294268|NCT05803005|OTHER|inflammatory marker in autism spectrum disorder|Evaluate some Inflammatory markers \[IL-6, IL-8, TNF\_alpha\] in children with autism spectrum disorder
214294269|NCT01958008|DRUG|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
214294270|NCT01958008|DRUG|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
214294271|NCT01958008|DRUG|BI 113608 high dose b.i.d.|Film-coated tablet
214294272|NCT01958008|DRUG|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
214294273|NCT01958008|DRUG|BI 113608 low dose b.i.d.|Film-coated tablet
214294274|NCT01958008|DRUG|BI 113608 medium dose b.i.d.|Film-coated tablet
214294275|NCT00969202|RADIATION|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
214294276|NCT03552263|DRUG|T89 capsule|T89 capsules (75mg), orally, twice daily.
214294277|NCT03552263|DRUG|Placebo capsule|Placebo capsules (0mg), orally, twice daily.
214477776|NCT04761770|DRUG|conditioning regimen|"Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen~2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen"
214888765|NCT01008189|BEHAVIORAL|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
214888766|NCT03735004|DEVICE|Transcranial electrostimulation (TES)|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
214888767|NCT03151304|DRUG|Pracinostat|45 mg capsule
214888768|NCT03151304|DRUG|Azacitidine|SC or IV injection
214888769|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Low Dose|
214888770|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Medium dose|
214888771|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) High dose|
214888772|NCT01123915|OTHER|Dimethyl Sulfoxide|
214888773|NCT01721304|OTHER|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
214888774|NCT03796052|OTHER|Avena Sativa Skincare Regimen|Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)
214888775|NCT00030706|DRUG|ixabepilone|
214888776|NCT06115083|OTHER|Pelvic floor re-education using bio-feedback and home training|Pelvic floor re-education using bio-feedback and home training
214888777|NCT03519087|OTHER|Interdisciplinary Evaluation for Nonarthritic Hip Disease|The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.
214888778|NCT03519087|OTHER|Posture and Movement Training|Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.
214888779|NCT03519087|OTHER|Treatment-of-choice|Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.
214888781|NCT03694899|BEHAVIORAL|phone contact|patients will be called prior to their outpatient appointment
214888782|NCT04529837|OTHER|Gauze|placement of gauze
214888783|NCT04529837|OTHER|No gauze|no gauze
214888784|NCT02290457|BEHAVIORAL|core strength training|"Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only."
214888785|NCT01137071|BIOLOGICAL|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
214888786|NCT06325605|DRUG|Bifidobacterium|3 capsules, 3 times a day, for 8 consecutive weeks
214888787|NCT06325605|DEVICE|High-frequency rTMS|"In the rTMS treatment, the transcranial magnetic stimulation device with an 8-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks."
214294278|NCT01634360|DRUG|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
215048949|NCT01553292|DEVICE|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
215048950|NCT01553292|DEVICE|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
215048951|NCT01722344|BEHAVIORAL|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
215048952|NCT01722344|BEHAVIORAL|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
215048953|NCT05604573|DIAGNOSTIC_TEST|cell free DNA in blood, genetic mutation in tissue|Diagnostic test for cell free DNA in blood, genetic mutation in tissue
215048954|NCT00589797|DEVICE|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
214294279|NCT03553667|DEVICE|Standard group|Use radial arterial line to monitor mean arterial pressure
214294280|NCT03553667|DEVICE|ClearSight|Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)
214294281|NCT02563353|OTHER|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week."
214294282|NCT02563353|DRUG|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
214294283|NCT02028065|DRUG|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
214294284|NCT02028065|DRUG|Placebo|Placebo administered as a single IV bolus over 10 seconds
214294285|NCT01441505|DRUG|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
214294286|NCT01441505|DRUG|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
214294287|NCT03912116|OTHER|CLARIX FLO|100mg CLARIX FLO
214294288|NCT03912116|OTHER|Saline|Saline
214294289|NCT05877781|DIETARY_SUPPLEMENT|Palmitoylethanolamide|8-week treatment 3x400 mg per day
214294290|NCT04851314|DEVICE|ICU certified ventilator|Examine anesthetic consumption rates
214294291|NCT04851314|DEVICE|Non-ICU certified ventilator|Examine anesthetic consumption rates
214294292|NCT03027778|OTHER|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
214888788|NCT06325605|DRUG|Escitalopram Oxalate|Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks
214294293|NCT03236974|DRUG|Standard Arm - Fulvestrant|500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
214477777|NCT04761770|PROCEDURE|Allogeneic CD34+ selected stem cells|Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
214477778|NCT06598670|OTHER|tDCS|tDCS will be applied to the M1 area for 20 minutes with 5x7 cm electrodes. The intervention will be applied for eight weeks on alternate days
214477779|NCT06598670|OTHER|Conventional treatment|Breathing exercises will be performed
214477780|NCT06861140|DIETARY_SUPPLEMENT|Tryptophan 25mg/kg bodyweight|Tryptophan is supplemented during the treatment of chronic pouchitis with pro- and antibiotics
214477781|NCT06861140|OTHER|Placebo|standard treatment of chronic pouchitis using pro- and antibiotics.
214477782|NCT06860958|DRUG|Fluoxetine|Fluoxetine is an antidepressant and belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs)
214888789|NCT02057887|DRUG|HM10660A|
215048955|NCT00589797|DEVICE|ProDisc-L Total Disc Replacement or Charité Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
215048956|NCT01881009|DEVICE|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
215048957|NCT01881009|DEVICE|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
215048958|NCT02287194|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
215048959|NCT02052869|PROCEDURE|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
214294294|NCT03236974|DRUG|AZD9496|Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
214294295|NCT00877383|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214294296|NCT00877383|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
214477783|NCT06860958|DRUG|Roflumilast|Roflumilast is the first drug targeting PDE4 that was marketed for treatment of chronic obstructive pulmonary disease (COPD) with relatively weak potency inducing nausea and vomiting
214294297|NCT00877383|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214294298|NCT04255524|DEVICE|Optic coherence tomography angiography (OCTA)|Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map
214294299|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214294300|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214294301|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214477784|NCT06860958|DRUG|Placebo|Placebo
214477785|NCT06861322|BEHAVIORAL|Short Foot Exercise|"* Description: Short Foot Exercise is a therapeutic exercise designed to strengthen intrinsic foot muscles and improve medial longitudinal arch stability.~* Procedure: Participants will perform Short Foot Exercise twice daily, five times per week for four weeks. The exercise consists of progressive phases, starting with basic foot activation and advancing to resistance-based strengthening using bands.~* Purpose: To determine if strengthening the foot's intrinsic muscles positively impacts knee pain, muscle function, and balance in individuals with flexible flatfoot."
214888790|NCT02057887|DRUG|Pegasys|180 mcg Pegasys SC once weekly
214888791|NCT03080870|OTHER|Art|Multicomponent art intervention
214888792|NCT05676515|OTHER|culture media|spliting of biological material and use of three culture media
214888793|NCT03491657|BEHAVIORAL|virtual reality distraction (Yes VR)|
214888794|NCT03491657|BEHAVIORAL|music distraction (No VR)|
214888795|NCT04194645|DRUG|BI 474121 tablet|BI 474121 tablet
215048960|NCT06011317|DRUG|EDG-7500|EDG-7500 is administered orally once daily
215048961|NCT06011317|DRUG|Placebo|Placebo is administered orally once daily
215048962|NCT00572416|BEHAVIORAL|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
215048963|NCT00572416|BEHAVIORAL|Healthy Eating Control|Equal time and attention and information about healthy eating
215048964|NCT02141672|DRUG|Voclosporin High Dose|
215048965|NCT02141672|DRUG|Voclosporin Low Dose|
215048966|NCT02141672|DRUG|Placebo|
215048967|NCT05757180|BEHAVIORAL|Positive Events Training (PET)|PET is a group-based training program combining Memory Specificity Training (MEST; Raes, 2007) and Future Event Specificity Training (FEST; Dutch version of Hallford et al. (2020): Changing the Future: An initial test of Future Specificity Training). It comprises four sessions of 50 minutes each. The training is delivered in a standardized manner, using the Positive Event Training Manual developed for this study (content adapted from our MEST and FEST manuals). Following brief psychoeducation on the rationale, participants practice generating detailed specific memories and future events using neutral and positive cue-words. Participants are maximally supported and challenged by the trainer and by the other group-members to generate very specific and highly detailed memories and future events using mental imagery and drawing upon visual, olfactory, auditory and emotional elements of the events, including both contextual and sensory-perceptual details.
215048968|NCT05757180|BEHAVIORAL|CREAtive writing Training (CREAT)|CREAT follows the exact same format and length as the PET training (i.e., delivered by a trainer in group over 4 x 50-minute sessions, including homework exercises). Following brief psychoeducation on the (bogus\*) rationale behind PET, participants complete a series of creative writing exercises using funny and thought-provoking writing prompts. Just as in PET, participants are maximally supported and challenged by the trainer and by the other group-members, in this case to generate completions that are as creative and funny as possible. The investigators used CREAT successfully before in an online format as a bogus control training for a memory specificity training. (\*) The investigators tell participants that these creative writing exercises have been found to be beneficial for mental wellbeing, as creative writing exercises cultivate creativity and stimulate participants' imagination skills.
214294302|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214294303|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214294304|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214294305|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214294306|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214294307|NCT01678677|DRUG|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214294308|NCT02402127|DEVICE|Narafilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
214294309|NCT02402127|DEVICE|Stenfilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
214888796|NCT04194645|DRUG|Placebo tablet|Placebo tablet
214888797|NCT04194645|DRUG|BI 474121 oral solution|BI 474121 oral solution
214294310|NCT02402127|DEVICE|Somofilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
214294311|NCT02107482|DEVICE|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
214888798|NCT04194645|DRUG|Placebo solution|Placebo solution
214888799|NCT00645892|DRUG|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
214888800|NCT00645892|DRUG|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
214294312|NCT02107482|DEVICE|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
214294313|NCT06201702|DIETARY_SUPPLEMENT|pomegranate extract|Drink 2 mL of pomegranate extract three times a day for 10 days during the 3 menstrual cycles (from 7 days before to 3 days after the estimated onset of menstruation).
214294314|NCT01008007|DIETARY_SUPPLEMENT|Viusid|One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
214294315|NCT01008007|DRUG|Conventional treatment|Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
214294316|NCT04868890|BIOLOGICAL|Ampion|Inhaled Ampion
214888801|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
214888802|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
214888803|NCT01783886|PROCEDURE|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
214888804|NCT04542057|DRUG|Ensifentrine|"Dosage Formulation:~Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks"
214888805|NCT04542057|DRUG|Placebo|"Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks"
214888806|NCT01140165|OTHER|cheese|the effect of cheese intake versus butter intake on blood lipids (primarily)
214888807|NCT00104572|DRUG|Androgel (Testosterone Gel)|1 mg tablet for 12 months
214294317|NCT04868890|OTHER|Placebo|Inhaled Placebo
214294318|NCT00228059|DRUG|Licarbazepine|
214888808|NCT00104572|DRUG|Anastrozole (Aromatase Inhibitor)|
214888809|NCT00104572|DRUG|Placebo tablet|Daily for 12 months
214888810|NCT00104572|DRUG|Placebo gel|Daily for 12 months
214888811|NCT00104572|DIETARY_SUPPLEMENT|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
214888812|NCT04708015|OTHER|No Intervention|A retrospective chart review of medical records
214888813|NCT04167111|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D
214888814|NCT04045353|BEHAVIORAL|Low carbohydrate diet education|A 200 page informational document that connects with an online application will be provided to subjects.
214888815|NCT04045353|BEHAVIORAL|Low carbohydrate diet education with behavioral component|A 12 week course taught be a certified instructor will teach subjects about a low carbohydrate document. Subjects will also be given a 200 page informational document that connects with an online application.
214888816|NCT03815526|OTHER|Dynamic tape|Dynamic tape apply 1 time
214294319|NCT00867009|DRUG|Pemetrexed|Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
214294320|NCT00867009|DRUG|Cisplatin|Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
214294321|NCT00867009|DRUG|Cetuximab|"Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles~Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation"
214294322|NCT00140595|DRUG|rituximab|
214294323|NCT00140595|DRUG|doxorubicin|
214294324|NCT00140595|DRUG|cyclophosphamide|
214294325|NCT05117320|DEVICE|AI support|Images were allocated to participants. In randomized allocation, one half of the images for each participant are viewed with AI support and the other half is viewed without AI support on the first trial day. On the second trial day the same images are viewed without versus with AI, respectively. This ensures that all images are read twice by the same participant both with and without AI support.
214294326|NCT01194180|BIOLOGICAL|BCG: 100 microlitres ~ 2-8 x 105 pfu|BCG vaccination at day C (challenge day) then punch biopsy at day C+14
214294327|NCT01194180|BIOLOGICAL|MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu|MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
214294328|NCT00438113|DRUG|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
214294329|NCT03383172|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
214294330|NCT02715674|DEVICE|Plasti-med TRIFLO|
214294331|NCT02715674|DEVICE|BIPAP VISION|
214888817|NCT03815526|OTHER|Kinesio tape|Dynamic tape apply 1 time
214888818|NCT03815526|OTHER|Sport tape|Dynamic tape apply 1 time
214888819|NCT04469777|DRUG|erythropoietin|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
214888820|NCT02934464|DRUG|RAMUCIRUMAB|
214888821|NCT02934464|DRUG|Paclitaxel|Paclitaxel
214294332|NCT02715674|DEVICE|Plasti-med oxygen therapy mask|
214294333|NCT02418026|OTHER|hypnosis|Conversational hypnotic induction and therapeutic suggestions
214294334|NCT00147199|DRUG|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
214294335|NCT00147199|DRUG|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
214294336|NCT00470639|DEVICE|Transcranial Magnetic Stimulation|
214294337|NCT00268957|DRUG|Sevelamer carbonate (Renvela®)|sevelamer carbonate powder dosed once per day with largest meal
214294338|NCT00268957|DRUG|Sevelamer hydrochloride (Renagel®)|Sevelamer hydrochloride tablets dosed three times a day with meals
214294339|NCT01850524|DRUG|Ixazomib|IXAZOMIB capsules.
214294340|NCT01850524|DRUG|Placebo|IXAZOMIB matching-placebo capsules.
214294341|NCT01850524|DRUG|Dexamethasone|Dexamethasone tablets.
214294342|NCT01850524|DRUG|Lenalidomide|Lenalidomide capsules.
214888822|NCT02934464|DRUG|FOLFOX 4|
214888823|NCT02934464|DRUG|mFOLFOX 6|
214888824|NCT02934464|DRUG|XELOX|
214888825|NCT02914353|DRUG|EP=7041|Factor X!a Inhibitor
214294343|NCT02727751|DRUG|Tenapanor|
214294344|NCT03992742|BEHAVIORAL|Initial phase: personalized instant messaging (PIM)|"intervention Group participants will receive three months of personalized interaction through IM Apps (e.g. WhatsApp, WeChat). Our counsellors will trigger the conversation and encourage the participants to set a quit day. A total of pre-set 26 messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. These messages covered generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and encouragement to quit and use SC services.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PIM (subgroup C). Incomplete responders (smokers) will be randomized to continue PIM (subgroup B) or receive OCI (subgroup A)."
214888826|NCT02914353|DRUG|Placebo|Normal Saline
214888827|NCT01918566|DIETARY_SUPPLEMENT|tap water|
214888828|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
214888829|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
214888830|NCT01918566|DIETARY_SUPPLEMENT|25g Fructose in 300ml tap water|
214888831|NCT01918566|DIETARY_SUPPLEMENT|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
214888832|NCT01918566|DIETARY_SUPPLEMENT|300ml tap water with 450ppm lactisole|
214888833|NCT00940316|BIOLOGICAL|panitumumab|Given intravenously 6mg/kg every 2 weeks
214888834|NCT00940316|DRUG|erlotinib hydrochloride|Given orally 150mg daily
214888835|NCT00940316|DRUG|irinotecan hydrochloride|Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
214888836|NCT01907256|PROCEDURE|inverted V incision|It is a type of incision
214888837|NCT01907256|PROCEDURE|stair step incisions|It is a type of incision
214888838|NCT00425204|DRUG|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
214888839|NCT03897634|DEVICE|Remote Microphone|Experienced hearing aid users will be trained on and use a remote microphone for 30 days. Pre- and Post- measures will be taken to determine benefit. Participant characteristics will also be assessed (such as self-efficacy) to explore personality factors that may contribute to benefit from devices.
214294345|NCT03992742|BEHAVIORAL|Second phase: optional cocktail interventions (OCI)|For incomplete respondents (subgroup A) randomized to OCI, the available intervention options include multi-media messages, active referral plus financial incentive, phone counseling, family/peer support and medications (NRT). Participants will be guided by cessation counsellors at 1-month follow-up telephone survey to choose any combination of OCI based on their preference. If OCI participants cannot be followed up at 1-month, they will receive multi-media messages by default.
214294346|NCT03992742|BEHAVIORAL|Initial phase: regular instant messaging (RIM)|"Participants enrolled in the Control Group will receive regular messages via IM services (e.g. WhatsApp, WeChat) since initial contact and until 3-month after baseline with a tapering schedule: 1) Baseline to 4-week (1-month): 2 times/ week (8 in total); 2) 4-week to 12-week (2- \& 3-month): 1 time/week (8 in total).~SC messages will generally include benefits of SC, encouragement on abstinence and use of SC services, tips on avoiding/ handling craving and reminder of participating in telephone follow-up. A reminder to participate in the telephone follow-up will also be sent at 1-, 2-, 3- and 6-month, making up a total of 20 messages.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive RIM (subgroup F). Incomplete responders (smokers) will be second randomized to continue RIM (subgroup E) or receive PIM (subgroup D). Those who are unable to follow up at 1-month will be considered as nonresponsive to the intervention."
214888840|NCT00685386|OTHER|CO2 insufflation|The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
214888841|NCT00685386|OTHER|Room air insufflation|During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
214888842|NCT01426074|DRUG|Bevacizumab 5 mg/kg|Intravenously every two weeks
214888843|NCT05835674|DIAGNOSTIC_TEST|Early intervention program|"At enrollment visit: History and examination, MRI, evaluation of comorbidities, medication and genomic testing. HINE, GMA (if below 5 mo), AIMS, SHAI, PSS and DASS-21 questionnaire.~At 6 mo visit: Examination and evaluation of comorbidities, medication and HINE and AIMS~At 12 mo visit: Examination and evaluation of comorbidities, medication and HINE, AIMS, HAI, PSS and DASS-21 questionnaire.~At 18 mo visit: Examination and evaluation of comorbidities, medication and HINE~At 24 mo visit: Examination and evaluation of comorbidities, medication and HINE, PDMS-2, GMFM-66, BSID-IV-cog, MPOC-20 ,PSS, and DASS-21 questionnaire. GMFCS and Mini MACS if CP."
214888844|NCT04097873|OTHER|Diaphragm ultrasonography reeducation plus inspiratory training|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
214294347|NCT03992742|BEHAVIORAL|Second phase: personalized instant messaging (PIM)|"For incomplete responders allocated to PIM (subgroup D), participants will receive the same intervention as the Group A delivered at the initial stage. Participants will receive two months of personalized interaction through IM application. Please refer to Intervention Group Initial phase: personalized instant messaging (PIM) for details."
214888845|NCT04097873|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
214888846|NCT05146648|DEVICE|Gondola AMPS|One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
214888847|NCT04457037|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells
214888848|NCT02976948|OTHER|No intervention|
214888849|NCT00796757|DRUG|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
214888850|NCT00796757|DRUG|interferon alfa-2a|3 MIU sc t.i.w.
214888851|NCT04201730|PROCEDURE|Enhanced Recovery After Surgery （ERAS）|Preoperative education，Preoperative nutritional support，Preoperative bowel preparation，Preventative applying of antibiotics，Intraoperative warming，Goal-directed fluid therapy，Postoperative analgesia，Postoperative diet, drainage and activity management，Prevention of deep vein thrombosis.
214888852|NCT05134363|DRUG|Dexmedetomidine Hydrochloride 0.5 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a placebo group
214888853|NCT05134363|DRUG|Dexmedetomidine Hydrochloride 0.75 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
214888854|NCT05134363|DRUG|Placebo|equal volume of normal saline
215048969|NCT05844202|DRUG|Alveavax-v1.2|BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19
215048970|NCT05844202|DRUG|Janssen Ad26.COV2.S|COVID-19 vaccine by Janssen / Johnson \& Johnson
215048971|NCT00422188|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
215048972|NCT00422188|DRUG|Placebo|Administered via intralipomal injection.
214888855|NCT03792022|BEHAVIORAL|Adherence to timely vaccine uptake|Adherence to timely vaccine uptake
214888856|NCT01312558|BEHAVIORAL|Prudent diet group|
214888857|NCT01312558|BEHAVIORAL|Mediterranean diet group|
214888858|NCT00365703|PROCEDURE|Feeding tube insertion|"1. Orogastric feeding tube~2. Nasogastric feeding tube"
214888859|NCT03272178|DEVICE|Depuy total knee implant|patients from Dr Nunley's clinic will get a Depuy implant
214888860|NCT03272178|DEVICE|Triathlon total knee implant|patients from Dr Barrack's clinic will get a Triathlon implant
215048973|NCT06374680|PROCEDURE|laminectomy at C3 level|laminectomy at C3 level
215048974|NCT03947268|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.
215048975|NCT04992026|PROCEDURE|robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection|Robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection will be performed.
215048976|NCT04992026|DRUG|1.Abiraterone Acetate Tablets|1000mg(4 tablets, 250mg per tablet) daily for 6 cycles
215048977|NCT04992026|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets
215048978|NCT04992026|DRUG|Luteinizing Hormone-Releasing Hormone Analog|Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.
215048979|NCT03715725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Administration according to clinical practice
215048980|NCT03715725|DRUG|Apixaban (Eliquis)|Administration according to clinical practice
215048981|NCT03715725|DRUG|Dabigatran etexilate (Pradaxa)|Administration according to clinical practice
215048982|NCT03715725|DRUG|Warfarin (Marevan)|Administration according to clinical practice
214888861|NCT03595046|PROCEDURE|erector spinae plane block (20 mL of 0.25% ropivacaine with dexamethasone 5mg)|In group E, The patient was placed in a sitting position and a high-frequency linear ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the thoracic spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle was inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between transverse process and erector spinae muscles, as evidenced by visible linear spread of fluid between erector spinae muscles and the bony acoustic shadows of the transverse process. A total of 20 mL of 0.25% ropivacaine with dexamethasone 5mg was injected here.
214888862|NCT03595046|PROCEDURE|thoracic paravertebral block(10 mL 0.25% ropivacaine with dexamethasone 5mg)|2\) In group P, an appropriate thoracic spinous precess is located by positioning the probe in the transverse plane. Then the probe is moved laterally to locate the transverse process. The probe is manipulated slightly caudad or cephala to locate the intercostal space. The transverse process is visualized medially with the pleura dipping under the inferolateral aspect. The internal intercostal membrane, which is contiguous with the superior costotransverse ligament, was generally seen as a thin, radiopaque line extending from the transverse process, creating a wedge-shaped pocket, which represents the thoracic paravertebral space. A 22-gauge, facet-tip needle is advanced, in plane, from the lateral aspect of the ultrasound probe. When the needle pierced the internal intercostal membrane, and after aspiration demonstrated the absence of air or blood, 10 mL 0.25% ropivacaine with dexamethasone 5mg deposited in 5-mL increments.
214888863|NCT05748587|DIAGNOSTIC_TEST|Serum Iron|Serum iron levels in study groups
214888864|NCT05748587|DIAGNOSTIC_TEST|RBCs Alpha-synuclein|α-syn levels in RBCs
214888865|NCT05748587|DIAGNOSTIC_TEST|Serum Soluble lymphocyte activation gene|sLAG-3 in the serum of study groups
214888866|NCT05748587|RADIATION|Brain computed tomography|Brain CT of patients after admission
214888867|NCT05748587|DIAGNOSTIC_TEST|Brain Iron|Iron in brain homogenate of rats
214888868|NCT05748587|DIAGNOSTIC_TEST|Brain Alpha-synuclein|α-syn expression in rat's brain
214888869|NCT05748587|DIAGNOSTIC_TEST|Brain lymphocyte activation gene|LAG-3 expression in rat's brain
215048983|NCT02630069|DRUG|CDP-choline|CDP-choline 500mg once a day for 12 weeks
215048984|NCT02630069|DRUG|Placebo|Placebo 500mg once a day for 12 weeks
215048985|NCT02630069|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy 1 session/2 weeks for 12 weeks
215048986|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
215048987|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
215048988|NCT04333615|BEHAVIORAL|Exercise|Three conditions will be tested: self-selected exercise, walking with pain exercise, and control session.
215048989|NCT05045716|DRUG|Lecanemab|Lecanemab IV infusion.
215048990|NCT05045716|DRUG|Lecanemab|Lecanemab SC injection.
214888870|NCT05748587|DRUG|Deferoxamine|intramuscular deferoxamine (200 mg/kg) injection to rats
214888871|NCT04309617|PROCEDURE|nephrectomy|Surgery performed within the study period
214888872|NCT02827734|DEVICE|multiple breath washout tests|
214888873|NCT02827734|DEVICE|impulse oscillometry|
214888874|NCT02827734|DEVICE|body plethysmography|
215048991|NCT02864264|DRUG|BMS-986184|
215048992|NCT02864264|DRUG|Placebo matching BMS-986184|
215048993|NCT01158755|DRUG|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
215048994|NCT05651763|OTHER|Stimulation and exercise group|Exercise protocol + application of active direct current stimulation for 30 minutes.
215048995|NCT05651763|OTHER|Exercise and sham stimulation group|Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
215048996|NCT00705874|DRUG|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
215048997|NCT00705874|DRUG|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
215048998|NCT00705874|DRUG|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
215048999|NCT00705874|DRUG|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
215049000|NCT00705874|DRUG|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
214294348|NCT03992742|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
214294349|NCT03992742|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
214294350|NCT03992742|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
214888875|NCT03282500|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
214888876|NCT01924559|OTHER|standard clothing|
214888877|NCT01924559|OTHER|Biohazard gear|
214888878|NCT01924559|DEVICE|Direct Laryngoscopy|
214888879|NCT01924559|DEVICE|Glidescope|
214888880|NCT01924559|DEVICE|Supraglottic Airway|
214888881|NCT01660425|BEHAVIORAL|Enhancement with psychosocial intervention|
214888882|NCT05548387|DRUG|HCP2202|Take it once per period.
214888883|NCT05548387|DRUG|RLD2202|Take it once per period.
214888884|NCT05548387|DRUG|RLD2203|Take it once per period.
214888885|NCT00005805|DIETARY_SUPPLEMENT|St. John's wort|
214294351|NCT03992742|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
214294352|NCT03358290|DRUG|JTE-051|Active drug tablets containing JTE-051
214294353|NCT03358290|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
214294354|NCT01622153|PROCEDURE|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
214294355|NCT01622153|PROCEDURE|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
214294356|NCT01706081|PROCEDURE|Acupuncture|Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
214294357|NCT01706081|PROCEDURE|Wait-list|For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
214888886|NCT03916705|OTHER|High Velocity Low amplitude spinal manipulation (HVLA-SM)|HVLA-SM is a commonly used spinal manipulation treatment for patients with chronic low back pain.
214888887|NCT02290405|BEHAVIORAL|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
214888888|NCT01609868|DIETARY_SUPPLEMENT|Powder protein modular|Infants will receive powder protein modular to achieve 4 grm/kg/day
214888889|NCT01609868|DIETARY_SUPPLEMENT|Liquid protein modular|Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
214888890|NCT04393714|PROCEDURE|Alveolar ridge preservation after extraction|atraumatic extraction followed by graft material insertion
214888891|NCT02460146|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
214888892|NCT02460146|OTHER|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
214888893|NCT03789929|BEHAVIORAL|The Emotional Backpack|In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.
214888894|NCT03789929|BEHAVIORAL|Feelings as Powers|In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
214888895|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, one single dose
214888896|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, once daily for 5 days
214888897|NCT05925998|OTHER|Observational study: no interventions|Not applicable as observational study with no intervention
214888898|NCT02016183|DRUG|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
214888899|NCT06490978|RADIATION|CT Brain|Patient needs follow up ct brain , cbc , CRP
214888900|NCT00996489|DEVICE|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
214888901|NCT02535689|DRUG|Tofacitinib|Oral administration of tofacitinib, 5 mg
214888902|NCT02535689|DRUG|Placebo|
214888903|NCT03142191|DRUG|CC-90001|CC-90001 is a potent, selective inhibitor of JNK.
214888904|NCT03142191|OTHER|Placebo|Placebo
214888905|NCT05149391|BIOLOGICAL|CD19/CD20-directed Chimeric Antigen Receptor T Cells|Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously
214888906|NCT05682612|OTHER|outcome|hospital survivors and nonsurvivors
214888907|NCT05682612|OTHER|Subtype of COVID-19|Different subtype of COVID-19
214888908|NCT00825786|DRUG|Ropivacaine|ropivacaine (15 ml).
214888909|NCT00825786|DRUG|Mepivacaine|One syringe will contain mepivacaine (15 ml)
214888910|NCT06329739|DIAGNOSTIC_TEST|Clinical examinations and clinical scales administration|Psychometric assessment of cognitive and behavioral outcomes
214888911|NCT06582550|PROCEDURE|Minor Hand Procedure|Unilateral minor hand procedure (carpal tunnel release, trigger finger A1 pulley release, lesion excision)
214477786|NCT06861322|BEHAVIORAL|Conventional Physical Therapy|"* Description: Standard non-invasive physical therapy aimed at reducing knee pain, improving muscle relaxation, and enhancing lower limb function.~* Procedure: Participants will receive twice-weekly conventional physical therapy for ten minutes per session over four weeks. Treatment includes soft tissue mobilization, muscle relaxation techniques, and neuromuscular stimulation, as appropriate for knee pain relief.~* Purpose: To evaluate its effectiveness as a standalone treatment compared to the addition of Short Foot Exercise."
214888912|NCT02257281|DEVICE|Active Therapeutic Ultrasound|For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
214888913|NCT02257281|DEVICE|Non-active Therapeutic Ultrasound|For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
214888914|NCT02445534|BIOLOGICAL|Autologous stem cell therapy|All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.
214888915|NCT02569190|DEVICE|Walkbot|Robot assisted gait training
215049001|NCT00705874|DRUG|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
215049002|NCT00705874|DRUG|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
215049003|NCT00000438|DRUG|naltrexone (Revia)|
215049004|NCT04405531|OTHER|task-oriented training (TOT)|The study group received a TOT together with a conventional occupational therapy (COT). The study groups received a treatment for 20 sessions at a hospital setting.
215049005|NCT04405531|OTHER|conventional occupational therapy (COT)|The control group received only a COT program. The control groups received a treatment for 20 sessions at a hospital setting.
214294358|NCT04874727|PROCEDURE|Mandible slacked and captured with Correct Plus™ Impression Material Superfast|In order to simulate the supine position, patients are placed in a supine position (180 degrees) in a dental exam chair, and asked to relax their lower jaw, allowing it to drop back, simulating their jaw falling back while sleeping. That bite is then captured with a Correct Plus™ Impression Material Superfast. Once the bite material hardens, it locks the bite in place. The patient then stands upright, and CBCT is taken standing while the jaw placement is still pseudo sleep-supine, supported by the bite material.
214294359|NCT03731988|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
215049006|NCT04311450|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|This therapy is a weekly treatment which focuses on making gradual and modest lifestyle changes with goals of establishing regular patterns of eating, setting weekly goals, decreasing caloric intake, developing coping skills, and increasing physical activity.
215049007|NCT05611255|PROCEDURE|Systematic Intermittent Catheterization|A strategy that consists of draining urine only once, in all patients, after surgery (in the operating room).
215049008|NCT05611255|PROCEDURE|Bladder Scan Guided Catheterization|A strategy of standardized and reproducible assessment of bladder volume before discharge from the post anesthesia care unit, and draining urine only in patients who require it.
215049009|NCT05072899|PROCEDURE|platelet rich plasm|local injection of shoulder joint by platelet rich plasm
215049010|NCT05072899|PROCEDURE|Hyaluronic acid|local injection of shoulder joint by Hyaluronic acid
214477787|NCT06604156|DEVICE|EEG monitoring|During gastrointestinal endoscopy, electroencephalogram (EEG) monitoring will be conducted using qCON and qNOX technologies to assess patients\&amp;amp;#39; sedation and analgesia status while they undergo painless gastrointestinal endoscopy. This will be combined with visual assessments (such as cough reflex, respiratory depression, and limb movement) and clinical physiological monitoring (including vital signs and pulse oximetry) to explore and establish a stable and optimal depth of sedation for anesthesia.
214477788|NCT06862921|OTHER|Control|fawler position using a standard tourniquet
214477789|NCT06860412|BEHAVIORAL|Animal Assisted Intervention|This is a multimodal group intervention program that simultaneously carries out health education activities, physical activities, emotional activities and social interactions through the integration of a psychoeducational intervention and animal-assisted therapy for elderly people with unwanted loneliness.
214477790|NCT06860412|BEHAVIORAL|Psychoeducational Intervention as Usual|This psychoeducational intervention is a multimodal group intervention program that simultaneously carries out health education activities, physical activities, emotional activities and social interactions for elderly people with unwanted loneliness.
214477791|NCT06859567|OTHER|Evaluation|Comparison of the 6-minute walk test and Chester step test, one of the aerobic capacity tests
214294360|NCT03731988|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 5.5% or 11% or 22% laser density with 350 µm ablation depth, level 1 coagulation and a single pulse
214477792|NCT06855667|BIOLOGICAL|Plasma Exchange|3 to 5 sessions alternate day
214477793|NCT06855667|DRUG|Steroid|Steroid
214477794|NCT06855667|DIETARY_SUPPLEMENT|Diet|Diet
214477795|NCT03853434|PROCEDURE|Embolization|Angiographic embolization
214477796|NCT06858189|BEHAVIORAL|Walk-and-talk therapy|During the 10-week intervention, clients and therapists will engage in walk-and-talk therapy outdoors in natural settings during weekly therapy sessions. In addition, therapists will work with clients to set realistic goals for increased nature-based physical activity outside of the therapy setting. Therapists will check in with clients weekly regarding their progress and assist with goal revision, barrier planning, and self-monitoring.
214668196|NCT06377995|OTHER|Diaphragm protocol|The patient is in a supine position with a 90° knees flexion.To stretch the diaphragm, the osteopath stands at the head of the bed and places his hands on the lower edge of the ribcage and accompanies the lifting of the ribs during inhalation and maintains it during deep exhalation for up to 2 sets of 10 deep breaths separated by 1 minute. For the neuromuscular technique, the osteopath is positioned contralateral to the side to be treated and slides with the thumb under the lower part of the thorax, applying a force in the opposite direction.To inhibit the phrenic centre, the osteopath places one hand on the sternum in a caudal direction and the other in the projection of the phrenic centre in a cephalic direction.The participant inhales deeply and the osteopath presses in both directions during the expiratory phase for 10 respiratory cycles.
214888916|NCT02166710|DEVICE|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
214888917|NCT02166710|DEVICE|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
214888918|NCT01946932|OTHER|Temperature treatment|
214888919|NCT04298632|BEHAVIORAL|Safety Education Program|this is a pesticide safety education program
214888920|NCT04652778|DEVICE|Pulsed Field Ablation (PFA) using the Centauri System|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation; cavo-tricuspid isthmus (CTI) line ablation may be performed as needed
214888921|NCT02547532|OTHER|collection of sputum|
214888922|NCT05766137|PROCEDURE|Alveolar ridge preservation|Socket preservation
214888923|NCT00676832|DRUG|Placebo|Placebo solid capsule dosage form administered orally once daily.
215049011|NCT03978845|DRUG|Lidocaine|Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
215049012|NCT01985230|DEVICE|ReActiv8 Implantable Stimulation System implanted and activated.|
215049013|NCT00332696|DRUG|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
215049014|NCT00332696|DRUG|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
214294361|NCT03731988|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
214294362|NCT03731988|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
214294363|NCT03731988|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
214294364|NCT00029614|DRUG|Atomoxetine|
214294365|NCT01973166|DEVICE|Picosecond Q-switched Laser Treatment|
214294366|NCT01973166|DEVICE|Nanosecond Q-switched Laser Treatment|
214888924|NCT00676832|DRUG|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
214888925|NCT01277211|DRUG|ENG 120 µg + EE 15 µg intravaginal ring|13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
214888926|NCT01277211|DRUG|DRSP 3 mg + EE 30 µg|13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
214888927|NCT00698711|BIOLOGICAL|MUC-2-KLH|"The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.~After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient."
215049015|NCT00332696|DRUG|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
215049016|NCT00332696|DRUG|Placebo|Physiologic saline solution
215049017|NCT03433976|DRUG|spinal anesthesia|spinal anesthesia for planned cesarean sections
214294367|NCT05397756|OTHER|observer tool|The observer tool used will be the Anaesthetist Non-Technical Skills (ANTS) tool previously published by Fletcher et al. and translated in French. The ANTS scoring system uses four categories assessing task management, teamworking, situation awareness and decision-making. The observers will use an observer tool it when they will be not role role-playing
214888928|NCT00428233|PROCEDURE|Leukemia cell harvest|Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
214888929|NCT00770328|DRUG|Pentoxifylline|400mg PO TID x 8 weeks
214888930|NCT00770328|DRUG|Placebo|PO TID x 8 weeks
215049018|NCT03091361|OTHER|imaging, no intervention|no intervention
215049019|NCT06118658|DRUG|tislelizumab|About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
215049020|NCT04961905|DRUG|NVP-2002-R1+NVP-2002-R2|NVP-2002-R1 1 tablet, once daily and NVP-2002-R2 1 tablet, once daily
215049021|NCT04961905|DRUG|NVP-2002|NVP-2002 is a combination of NVP-2002-R1 and NVP-2002\_R2 NVP-2002, 1 tablet, once daily
215049022|NCT00724100|DRUG|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
215049023|NCT04582006|PROCEDURE|Bariatric surgery|Surgical treatment of morbid obesity.
215049024|NCT01061385|DEVICE|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
215049025|NCT01061385|OTHER|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
215049026|NCT04850326|DIETARY_SUPPLEMENT|AP green tea extract|single intake of AP green tea extract
215049027|NCT03512093|OTHER|Retrospective chart review|A retrospective chart review of preterm neonates born in one of the birthing SMRU unit between January 2008 and December 2017 and for whom a medical chart is available. In addition we propose to analyze the growth trajectory, the prevalence of anemia (Hct \< 33%) and the level of neurodevelopment achieved in the first year of life reported in the clinical charts of preterm neonates born \< 34+0 weeks of gestation.
215049028|NCT03512093|OTHER|Focus Group Discussion (FGD) of the medical staff|Focus Group Discussion (FGD) of the medical staff working in the SCBU firstly on the benefits and difficulties in using existing guidelines for preterm care and secondly on the feasibility and acceptability of changes in the guidelines 3-6 months after their implementation.
214294368|NCT03156673|BIOLOGICAL|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10\^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
214888931|NCT03688633|DRUG|Candesartan|Candesartan treatment with dose adjustments (8-16mg/day) during 6 months in accordance with adverse effects
215049029|NCT03512093|OTHER|Interviews of mothers|Interviews of mothers who delivered preterm neonates (\< 37+0 weeks of gestation) to understand the challenges they faced while caring for their child.
215049030|NCT00533429|DRUG|enzastaurin|1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
215049031|NCT00533429|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
215049032|NCT00533429|DRUG|carboplatin|Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
215049033|NCT00533429|DRUG|bevacizumab|15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
215049034|NCT00533429|DRUG|Placebo|oral, daily
215049035|NCT00602524|DRUG|Pilocarpine|
215049036|NCT01768949|DEVICE|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
215049037|NCT01464879|DRUG|Testosterone Gel (FE 999303)|
214668197|NCT01986530|DIETARY_SUPPLEMENT|Boost|After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion
214888932|NCT03688633|OTHER|Usual care|patients will be followed as usual
214888933|NCT05975528|DRUG|SGLT2 inhibitor|"For the SGLT2 inhibitor group, total drug adminstration days are 180 days, but non-SGLT2 inhibitor administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.~For the SGLT2 inhibitor group, empagliflozin 10mg or dapagliflozin 10mg once daily is administered."
214294369|NCT01952431|DEVICE|Total Lung Capacity (TLC) testing|Comparison of TLC results
214294370|NCT03102021|DRUG|erythropoietin|500 units/kg daily for 3 days at onset of acute kidney injury
214294371|NCT03102021|DRUG|saline|saline 10 ml for 3 days
214888934|NCT05975528|DRUG|Glimepiride|For non-SGLT2 inhibitor (glimepiride) administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.
214888935|NCT05574361|DEVICE|Hypothermic Machine Perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
214888936|NCT00594373|DRUG|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
214888937|NCT00594373|DRUG|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
214888938|NCT06449976|BEHAVIORAL|blue light defocus and blue light filtering|Subjects are asked to watch a terminal display device for 50 minutes, featuring texts and videos with different defocusing treatments. Specifically, they will start by watching text for 5 minutes, followed by 40 minutes of video, and then another 5 minutes of text, totaling a visual task duration of 50 minutes. The participants will complete a total of 4 sets of tests in a random order.
214888939|NCT02898376|OTHER|skin-oriented spa care|"standardized procedure : 72 care sessions over 18 days of treatment~+/- Additional care according to the specificity of each spa"
214888940|NCT02898376|DRUG|Pentoxifylline|400 mg bid during at least 6 months
214888941|NCT02898376|DRUG|Tocopherol acetate|500 mg bid during at least 6 months
214888942|NCT04109144|BIOLOGICAL|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin during the 2nd of 3 total paracentesis being monitored
214888943|NCT04109144|BIOLOGICAL|Albumin|Albumin will be used during the 1st and 3rd paracentesis
214888944|NCT04109144|PROCEDURE|Large Volume Paracentesis (LVP)|All participants who have this procedure, meet eligibility criteria and who consent
214888945|NCT05709210|OTHER|Recording of smartphone usage data|Recording of smartphone usage data
214888946|NCT04500717|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
215049038|NCT04024826|BEHAVIORAL|EFP|This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
214294372|NCT04140292|DRUG|Photodynamic therapy (PDT)|"PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered."
214294373|NCT04140292|DRUG|Vitamin D3|"D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment~Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result"
214668198|NCT01986530|OTHER|Aerobic exercise|After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
214668199|NCT00222846|BEHAVIORAL|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
214668200|NCT00222846|BEHAVIORAL|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
214888947|NCT04500717|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
214888948|NCT05208489|OTHER|there is no intervention involved in this study|there is no intervention involved in this study.
214888949|NCT05015829|DIAGNOSTIC_TEST|Dobutamine Stress Echocardiography|Change in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.
214888950|NCT01130493|DRUG|IPX066|experimental product
214888951|NCT01130493|DRUG|CLE|active comparator
214888952|NCT03452943|DRUG|TEV-50717|6, 9, 12, 15, and 18 mg oral tablets
214888953|NCT03452943|DRUG|Placebo|Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
214888954|NCT02589730|DEVICE|Welltang App|This App is a large platform of individualized diabetic management
214888955|NCT00283478|DRUG|Iscar Quercus|
214888956|NCT00283478|DRUG|Gemcitabine|
214888957|NCT03730207|DEVICE|Xpede™ Bone Cement|Xpede™ Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
214888958|NCT03730207|DEVICE|Mendec Spine Bone Cement|Mendec Spine Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
214888959|NCT02920801|DRUG|saxagliptin|5mg per day for 12 weeks
214888960|NCT02920801|DRUG|Metformin|1500mg per day for 12 weeks
214888961|NCT05031585|DEVICE|Roncoliv|The medical device with nasal spray solution should be used 1 time a day, before bedtime, for 30 days.
214888962|NCT05031585|DEVICE|Placebo|The medical device with placebo should be used 1 time a day, before bedtime, for 30 days.
215049039|NCT04024826|BEHAVIORAL|LFP|This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.
215049040|NCT04024826|BEHAVIORAL|ELP|This group will perform the Resistance training intervention on the day 18 of the menstrual cycle, which corresponds to the mid of early luteal phase
215049041|NCT04024826|BEHAVIORAL|LLP|This group will perform the Resistance training intervention on day 21 of the menstrual cycle, which corresponds to the mid of late luteal phase
215049042|NCT04877860|OTHER|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Finally, patients will have access to the PaiNEd system before the start of the program (to prepare them for treatment sessions) and during the development of the treatment program in which they will introduce their pain levels and their characteristics and also receive a series of educational advice and recommendations for its improvement."
214888963|NCT04894370|BIOLOGICAL|Sample collection|"PBMC collection at baseline, after radiotherapy 8 Gy (gray), at 6 months and at 12 months from inclusion: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection at baseline, after radiotherapy 8 Gy, at 6 months and at 12 months from inclusion: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection at baseline, at 2, 6 and 12 months from inclusion: two EDTA tube of 4 ml should be frozen in each investigation center for ctDNA collection."
214888964|NCT00879086|DRUG|Eribulin Mesylate|"E7389 (eribulin mesylate) given at a dose of 1.4 mg/m\^2 as a 2 to 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
214888965|NCT00879086|DRUG|Ixabepilone|"Ixabepilone given at a starting dose of 32 or 40 mg/m\^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
214888966|NCT06336265|DIAGNOSTIC_TEST|Diaphragm ultrasound|Respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment.
214888967|NCT03390335|OTHER|Pressure|Subjects undergo altitude exposure, diving exposure, and return to altitude. Altitudes: 8,000, 10,000, 12,000, or 15,000 feet Dives: 60 or 100 feet of sea water
214888968|NCT03390335|OTHER|Breathing Gas|Subjects will breathe air, 35% Oxygen, Balance Nitrogen, or 100% Oxygen during the diving exposure
214888969|NCT02959125|OTHER|NutFish Based Food Supplementation|Cookies contain 500 Calories and 15 gram protein make from nut and ocean fish
214888970|NCT02959125|DIETARY_SUPPLEMENT|Multiple micronutrients|Vitamin A 5000 iu, vitamin D 400 iu, vitamin C 100 mg, vitamin B1 7.5 mg, vitamin B2 3 mg, vitamin B6 10 mg, vitamin B12 10 mcg, fluoride 1 mg, Fe fumarate 91 mg, niacinamide 20 mg, Ca pantothenate 7.5 mg, folic acid 400 mcg, Zn 5 mg, Ca lactate 250 mg, copper 0.1 mg, iodine 0.1 mg
214888971|NCT02959125|BEHAVIORAL|Health Education in Pregnancy Class|Health education on pregnancy, complication, and breastfeeding by research team members
215049043|NCT04877860|OTHER|Multimodal rehabilitation program + traditional biomedical information|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Patients will receive a dossier with traditional biomedical recommendations on pain management and disability associated with the side effects of cancer treatment."
215049044|NCT04877860|OTHER|Control group|Waiting list of patients who have agreed to participate in the study. They will receive an information dossier with recommendations on pain control and improvement of dysfunction (similar to what was worked on in the experimental group). These recommendations will be distributed at the beginning of the study (initial assessment) and they will be summoned at 8 weeks for the next collection of variables. All patients will be invited to participate in the experimental phase at the end of the control phase.
214888972|NCT02959125|OTHER|Government Food Supplementation|Cookies contain 500 Calories and 5 gram protein make from flour and egg
214888973|NCT02959125|DIETARY_SUPPLEMENT|Fe Supplementation|Ferrous Fumarate 60mg and folic acid 0.400 mg
214888974|NCT06359301|DEVICE|DELTA Revision acetabular cup|Total hip arthroplasty
214888975|NCT02990429|PROCEDURE|Forced Air warmer|"* record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using forced air warmer (bair hugger)~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop bair hugger~* record core temperature before recovery room"
214888976|NCT02990429|PROCEDURE|Intravenous Fluid Warmer|"* record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using ranger warmer~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop ranger warmer~* record core temperature before recovery room"
214888977|NCT02333903|OTHER|Personalized Physical Activity|"1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.~Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises."
214888978|NCT01872923|DRUG|Amphinex|Photosensitiser
215049045|NCT01467336|PROCEDURE|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
215049046|NCT02271893|DRUG|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
215049047|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy)|We plan to apply painting art therapy as a health-related intervention to patients coming to our department for elective major surgery of the pancreatic and lower gastrointestinal tract for malignant pathologies. Patients will have 3 patient art therapy sessions: one before surgery, one on day 3-5 after surgery during the hospital stay and one during the follow-up 6 weeks postoperative
215049048|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy) - control|"usual care, no particular intervention during the perioperative setting. There will be 2-3 painting art therapy sessions after the follow-up 6 weeks postoperative. Therefore this group is called usual care- or delayed intervention group."
215049049|NCT04383093|DRUG|Tadalafil 5mg|Combination therapy of daily tadalafil plus tamsulosin
215049050|NCT00416117|PROCEDURE|Manual Physical Therapy and Exercise|
215049051|NCT00416117|PROCEDURE|Minimal Intervention|
215049052|NCT04451005|OTHER|0|Elderly patients with sarcopenia
215049053|NCT02118519|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
215049054|NCT03110705|BEHAVIORAL|sport|recreaational sport : diving or multisport
215049055|NCT00871078|DEVICE|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
215049056|NCT00871078|DEVICE|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
215049057|NCT05749640|OTHER|Precontoured sectional matrix EZ COAT|All teeth will be treated with (Palodent ® plus sectional matrix system) (sectional matrix, biting ring, plastic diamond wedge)
215049058|NCT05749640|OTHER|PerForm™|Treated with (PerForm™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
215049059|NCT05749640|OTHER|AdDent Trimax™|Treated with (AdDent Trimax™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
215049060|NCT05749640|OTHER|Contact Pro™|Treated with (Contact Pro™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
214294374|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
214888979|NCT01872923|DRUG|Bleomycin|Anticancer agent
214888980|NCT01872923|DEVICE|Laser|Laser that emits red light at 652 nm.
214888981|NCT01385774|PROCEDURE|Percutaneous Transluminal Angioplasty|The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
215049061|NCT04712747|PROCEDURE|Ophthalmological examinations|"* OCT (Optical Coherence Tomography): posterior pole OCT B scan , optic nerve and posterior pole OCT Angiography~* Adaptive optics (AO) : Image acquisition on the vessels at the exit of the optic nerve before the first upper temporal bifurcation OD or OG and evaluation of the photoreceptor mosaic. Adaptive optics may require dilatation of the pupil with a drop of tropicamide in the eye examined a few minutes before the examination.~* Color retinophotography~* Measurement of intraocular pressure~Patients with stroke : At the inclusion visit and 3 months after their stroke Control group : At the inclusion visit."
215049062|NCT04712747|PROCEDURE|Blood pressure measurement at rest|At the inclusion visit
215049063|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
215049064|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
215049065|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
215049066|NCT06246747|OTHER|In clinic physical therapy|Patients visit the clinic to receive traditional physical therapy treatment
215049067|NCT06246747|OTHER|Telerehabilitation only|Patients receive remote treatment using the Wizecare platform
215049068|NCT03506620|DRUG|Ropivacaine injection|Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc
215049069|NCT03506620|DRUG|Saline Solution for Injection|20 cc of saline will be injected in the form of a QL block as a placebo.
215049070|NCT01979679|DRUG|Lurasidone 80 mg|
215049071|NCT01979679|DRUG|Lurasidone 120 mg|
215049072|NCT01979679|DRUG|Lurasidone 160 mg|
215049073|NCT04067232|DIAGNOSTIC_TEST|4D-CT-scan|Both forearms of the subjects with posttraumatic forearm impairment are scanned with a 4D-CT scanning technique, during forearm rotation.
214888982|NCT01385774|OTHER|Supervised Exercise Therapy|Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
214888983|NCT06331169|DRUG|Anlotinib|Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
214888984|NCT06331169|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
214888985|NCT03415646|OTHER|Erector Spinae Plane Block|erector spinae plane block with double level injection will be administered before the surgery
214888986|NCT03415646|DEVICE|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
214888987|NCT00492505|DRUG|cisplatin|
214888988|NCT00492505|DRUG|sorafenib tosylate|
214888989|NCT00492505|DRUG|tamoxifen citrate|
214888990|NCT00492505|PROCEDURE|adjuvant therapy|
215049074|NCT03053778|OTHER|Early follow-up|Early follow-up until 4 weeks after discharge
215049075|NCT00328029|DRUG|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
215049076|NCT00328029|PROCEDURE|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
215049077|NCT00328029|PROCEDURE|pharmacokinetics, done during the treatment|"12 blood collections :~* after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.~* 3 hours after 2nd taken of Busulfan~* 3 hours after 3rd taken of Busulfan~* 3 hours after 4th taken of Busulfan~* 3 hours after 5th taken of Busulfan~* 3 hours after 6th taken of Busulfan."
214294375|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
214294376|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|"Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label)."
214294377|NCT02241174|DRUG|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
214294378|NCT05548829|BIOLOGICAL|Disease severity|Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
214294379|NCT00525707|DRUG|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
214294380|NCT01494194|OTHER|Air Structuring Protein|A novel food protein preparation
214294381|NCT01494194|OTHER|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
214294382|NCT01659463|OTHER|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
214294383|NCT01659463|BEHAVIORAL|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
214294384|NCT05759650|OTHER|Execution of different motor tasks typical of daily life and work|Patients with obesity will carry out different motor tasks typical of daily life and work and, using optoelectronic systems based on passive markers, force platforms and electromyographic systems, kinematic and kinetic parameters of movement will be recorded and analysed for the implementation of an integrated protocol for the clinical evaluation of subjects with obesity.
214294385|NCT00556712|DRUG|erlotinib [Tarceva]|150mg po daily
214294386|NCT00556712|DRUG|Placebo|po daily
214294387|NCT04744142|DRUG|Ketone supplementation|Subjects receive either placebo or ketone ester supplementation
214294388|NCT04744142|DIETARY_SUPPLEMENT|Increased protein intake|Subjects receive either normal or increased protein intake
214294389|NCT04604821|BEHAVIORAL|Enhanced Milieu Teaching|A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.
214294390|NCT04604821|BEHAVIORAL|Parent Education|Parents receive information on child developmental milestones.
214294391|NCT01961388|DRUG|Bay G5421 Glucobay|Oral, dosage of Acarbose as per the directions of treating physician
214294392|NCT01961388|DRUG|Metformin|Oral, dosage of Metformin as per the directions of treating physician
214294393|NCT04080297|DRUG|oral capsule of Q-122|
214294394|NCT00003623|DIETARY_SUPPLEMENT|multivitamin|
214294395|NCT00003623|OTHER|Placebo|
214294396|NCT05486858|OTHER|MSK ultrasonograpy|MSK ultrasonography was used to measure the thickness of diaphragm muscle in supine and sitting position and in a relaxed and in a contracted state.
214294397|NCT05486858|OTHER|sitting Functional and Lateral Reach Test|Sitting reach tests were used to measure the stability limits of the trunk in different directions. Functional reach test is for testing the forward direction and lateral reach tests are for testing the right and the left directions.
214294398|NCT03363204|DEVICE|BRUXENSE occlusal splint|Patients participating will put the BRUXENSE occlusal splint each night. During the night the device will collect data potentially related to bruxism. After each night the device will be cleaned with water and toothpaste and charged. This routine will be conducted over 10 consecutive nights.
214294399|NCT03130868|OTHER|Characterizing changes in the microbiome|Analyzing the microbial content from stool samples
214668201|NCT01887210|BEHAVIORAL|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
214477797|NCT06858592|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Dancers will then individually be screened for somatic dysfunctions (SD) by a physician and VCOM OMS-III student doctor under their direct supervision. OMS-III student investigators will receive training and be assessed on their abilities before performing OMT on subjects. This will take place at the dancers' place of practice in a private area equipped with an OMM table. The areas to be screened include the lumbar spine, hips, knees, ankles, and feet. All diagnoses in these areas will be documented with specific notation for the area of greatest restriction on paper. After making a diagnosis or multiple diagnoses, the dancer will be treated utilizing OMT for 15 minutes starting with the area of greatest restriction in the lower body by the OMS-III student doctor under direct supervision of a physician, should an adverse event take place. The type of treatment(s) used will be at the discretion of the supervising physician and the VCOM student doctor. They may use any OMT technique, exc
214477798|NCT06858943|PROCEDURE|arthroscopic meniscus reconstruction using a tendon autograft|arthroscopic meniscus reconstruction using a tendon autograft
214477799|NCT06858917|PROCEDURE|Ganglion Impar Block|Block of the ganglion impar is performed by injecting a mixture of steroid and local anaesthetic in front of the sacrococcygeal joint. This procedure is performed in a sterile operating theatre under ultrasound and/or fluoroscopic (X-ray) guidance. Radiopaque agents are also used during the procedure to confirm the location.
214477800|NCT06858917|PROCEDURE|Sacral Erector Spinae Plane Block|The sacral erector spina plan block is performed with ultrasound guidance by injecting a high volume mixture of local anaesthetic and steroid into the fascia under the erector spina muscles in the sacral region.
214477801|NCT06856941|DEVICE|cerebello-spinal direct current stimulation|Cerebello-spinal direct current stimulation is an electrical stimulus in the cerebellum as well as in the spinal cord that is used to improve functional mobility. To our knowledge, this is the first study to use this setup in individuals with Parkinsons disease.
214888991|NCT04574687|OTHER|Neurodevelopmental Techniques|)Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
214888992|NCT04574687|OTHER|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
214888993|NCT04274257|DRUG|Double-Blind Placebo|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
214888994|NCT04274257|DRUG|Double-Blind Rituximab|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of rituximab will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
214888995|NCT02536846|DRUG|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
215049078|NCT02960425|DIETARY_SUPPLEMENT|Delivra TM Livsport preworkout cream|High versus low dose topical creatine
215049079|NCT02960425|DIETARY_SUPPLEMENT|Placebo|Topical placebo
215049080|NCT05763680|DIAGNOSTIC_TEST|Molecular Culture|PCR based technique that amplifies the interspace region in bacterial DNA, that is located between the genes coding for 16S and 23S ribosomal subunits. Primers are used for the majority of known pathogenic phyla, i.e. FAFV, Bacteroidetes, Firmicutes and Proteobacteria. The nucleotide length of the Interspace region is species specific for bacterial single species. Bacteria all have one or multiple alleles for this interspace region. The combination of the amount of alleles, as well as the nucleotide strand length, makes for a specific profile that is distinctive for the species. Available software is able to match this profile to a particular pathogen, enabling confirmation and identification of bacteria in samples within 5 hours in our experimental workflow.
215049081|NCT00818493|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
214477802|NCT06856941|DEVICE|sham cerebello-spinal direct current stimulation|Sham cerebello-spinal direct current stimulation involves masking, where the total duration of stimulation is thirty seconds, which is sufficient to mimic the sensation of stimulation but without neuromodulatory effects
215049082|NCT00818493|DRUG|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
215049083|NCT00818493|DRUG|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
215049084|NCT05167812|OTHER|Observation of pregnancies after intake|Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss
215049085|NCT01192880|DRUG|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
214477803|NCT06859112|OTHER|logotherapy focused psychoeducation|8 sessions of online individual logotherapy focused psychoeducation program
214477804|NCT06860009|BEHAVIORAL|Multicomponent psychological intervention|The multicomponent intervention starts with 8 sessions of ACT (Acceptance and commitment therapy) once a week. After four weeks, patients start with graded activity and frequent napping. After eight weeks in the intervention period, patients will have consults with an IBD psychologist every two weeks. The intervention period is 14 weeks in total.
214668202|NCT01887210|BEHAVIORAL|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
214888996|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 weeks
214888997|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 g once a day for 8 weeks
214888998|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g + Maltodextrin 10 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 weeks
215049086|NCT01192880|DRUG|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
214888999|NCT04716868|DIETARY_SUPPLEMENT|Psyllium plantago|Psyllium plantago 15 g once a day for 8 weeks
214889000|NCT00775619|DRUG|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
214889001|NCT04607057|DRUG|Parenteral Nutrition Solutions|"* Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN"
214668203|NCT05631028|DRUG|Dexmedetomidine|Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
214668204|NCT05631028|DRUG|Remimazolam tosilate|Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
214889002|NCT03405922|DRUG|Placebo 40 mL Saline 0.9%|Injection of 40 mL 0.9% saline
214889003|NCT03405922|DRUG|40 mL Ropivacain 0.5%|Ropivacaine Hcl 0.5% Injection 40 mL
214668205|NCT05650827|BEHAVIORAL|Resistance training|10 weeks of resistance training 3 times pr. week.
214668206|NCT05650827|DIETARY_SUPPLEMENT|Protein supplement|A daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight
214889004|NCT05575232|BEHAVIORAL|Application Group (GA)|The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.
214889005|NCT03840564|OTHER|Point of care (POC)|All the analyzes will be done in delocalized
214889006|NCT03694756|DEVICE|TMEM-MRI|TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
214889007|NCT03694756|PROCEDURE|FNA|FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy. They will then present to radiology for ultrasound-guided core biopsy of the breast mass. FNA will be performed during this procedure. The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle. FNA will be performed by the radiologist under direct sonographic visualization of the mass. Five passes will be obtained with a 25 gauge needle. The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
214668207|NCT00770861|DRUG|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
214668208|NCT00770861|DRUG|Placebo|Matching placebo tablets, oral administration
214668209|NCT02062086|DIETARY_SUPPLEMENT|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
214668210|NCT00662155|DRUG|Zolpidem|sedative-hypnotic
214889008|NCT06499532|PROCEDURE|Monitoring and Surgical removal of mandibular impacted wisdom teeth, using Gow-Gates anesthesia technique|The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using Gow-Gates anesthesia technique. Patients were monitored for TCR during the procedure.
214889009|NCT06499532|PROCEDURE|Monitoring and Surgical removal of mandibular impacted wisdom teeth, using inferior alveolar nerve block anesthesia technique|The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using inferior alveolar nerve block anesthesia technique and supplemental anesthesia (buccal- mylohyoid). Patients were monitored for TCR during the procedure.
215049087|NCT01192880|DRUG|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
215049088|NCT04479592|OTHER|Particle counter|Particle counter to measure the aerosol generated
215049089|NCT06007417|DRUG|GenSci004|GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)
214294400|NCT01953133|BEHAVIORAL|Couples Counselling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
214294401|NCT05928897|DRUG|Disitamab Vedotin combined with Sintilimab|Disitamab Vedotin combined with Sintilimab
214294402|NCT02626520|DRUG|Gemcitabine and nanoparticle albumin bound paclitaxel|Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
214294403|NCT02626520|DRUG|5-fluorouracil and irinotecan|FOLFIRI.3 given every 14 days x 4 cycles
215049090|NCT06007417|DRUG|Genotropin|Genotropin
214294404|NCT02626520|RADIATION|Preoperative chemoradiation|Pre-operative chemoradiation to 40 Gy in 20 fractions
214294405|NCT02626520|PROCEDURE|Definitive resection|Definitive surgical resection of primary tumor
214294406|NCT02568150|BIOLOGICAL|Single group, open-label|
214294407|NCT01220882|RADIATION|Radiographic skeletal age assessment|bone age assessment from the elbow lateral radiograph
214294408|NCT01572545|DRUG|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
214294409|NCT01572545|DRUG|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
214294410|NCT03300479|DRUG|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
214294411|NCT03300479|DRUG|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
214294412|NCT04769544|DEVICE|total knee arthroplasty with medial pivot tibial insert or symmetrical insert|standard surgical implantation of total knee arthroplasty
214294413|NCT04802278|BIOLOGICAL|COVID-19 vaccine|Any COVID-19 vaccine
214294414|NCT01823185|DRUG|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
214477805|NCT06860009|BEHAVIORAL|Early start|Patients in the early group immediately start with the multicomponent psychological intervention
214294415|NCT01823185|DRUG|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
214294416|NCT01906151|DEVICE|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
214294417|NCT01479699|DIETARY_SUPPLEMENT|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
214294418|NCT04381598|DRUG|stevia rebaudiana bertoni|Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
214294419|NCT04381598|OTHER|placebo|A placebo without the active drug will be placed in the control sites.
214477806|NCT06860009|BEHAVIORAL|Late start (after 28 weeks)|Patients in the late intervention group will wait 28 weeks before starting the intervention
214477807|NCT06668363|BEHAVIORAL|Treat4All|An alcohol reduction evidence-based intervention integrated with HIV status-neutral counseling
214477808|NCT06668363|BEHAVIORAL|Standard of care (control arm)|Sexual risk reduction counseling
214668211|NCT00662155|DRUG|Placebos|Placebo
214668212|NCT06483893|PROCEDURE|US-guided thyroid cartilage plane block (group TCPB)|Participants in the (group TCPB) will receive US-guided thyroid cartilage plane block. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 3ml of 2% lidocaine is injected on the surface of the thyroid cartilage plate. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
214668213|NCT06483893|PROCEDURE|US-guided traditional superior laryngeal nerve block (group traditional SLNB)|Participants in the (group traditional SLNB) will receive US-guided traditional superior laryngeal nerve block. Traditional Superior Laryngeal Nerve Block is performed using the thyrohyoid muscle and thyrohyoid membrane as an anatomical landmark. The thyroid cartilage and the greater horn of hyoid bone are hyperechoic signals on sonography. 3ml of 2% lidocaine is injected above the thyrohyoid membrane next to the superior laryngeal artery between two hyperechoic structures. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
214889010|NCT06287398|DRUG|Epcoritamab|"Epcoritamab (Epcor) is a bispecific antibody recognizing the T-cell antigen CD3 and the B-cell antigen CD20. Epcor is a supplied as a concentrate for solution for intended subcutaneous injection. The dose must be prepared by a qualified pharmacist using aseptic technique.~Epcoritamab-Salvage treatment phase:~2-3 cycles of R-DHAOx therapy (rituximab, dexamethasone, cytarabine, oxaliplatin), given every 21 days combined with Epcoritamab subcutaneous weekly dosing (priming 0.16mg Cycle 1 Day 1, intermediate 0.8mg cycle 1 day 8, full dose 48mg from cycle 1 day 15 onwards)~Epcoritamab Consolidation phase:~6 cycles (28 days each) of subcutaneous Epcoritamab, commencing between 6-12 weeks post ASCT.~Epcoritamab dosing and timing for consolidation:~* Cycle 1 Day 1: Priming (0.16mg) dose~* Cycle 1 Day 8: intermediate (0.8mg) dose~* Cycle 1 Day 15: full dose 48mg~* Cycle 1 Day 22, Cycle 2-3 Days 1, 8, 15 and 22: 48mg~* Cycles 4 to 6 - Days 1 and 15 (fortnightly dosing): 48mg"
214889011|NCT06064305|OTHER|No study-specific interventions|Septic AKI patients, post-cardiothoracic AKI patients and non-AKI patients undergoing routine nephrectomy. Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians and the respective specialists.
214889012|NCT04940572|DRUG|Depakine|Refer to arm description.
214889013|NCT03987997|DEVICE|Early association of electrical muscle stimulation with cyclo-ergometer|Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
214889014|NCT05467085|DEVICE|BX Pulsar 1002|Imaging-Guided Low Intensity Focused Ultrasound Pulsation (LIFU) device
214889015|NCT06459492|BEHAVIORAL|puzzle game strategies|"One innovative approach uses puzzle game strategies, including crosswords, Sudoku, and other brain-teasing activities. These strategies have been shown to help maintain attention, improve memory, and keep older adults' thoughts clear and sharp. Additionally, engaging in these activities can provide psychological benefits by offering a sense of achievement, reducing stress, and fostering social interactions.~Given puzzle games' potential to enhance cognitive and psychological health, exploring their effectiveness as a non-pharmacological intervention for community-dwelling older adults is essential. This research aims to fill the gap by empirically investigating the impact of puzzle game strategies on cognitive functioning and psychological well-being in this demographic."
215049091|NCT05604443|OTHER|retrospective analyze|retrospective analyze of MS39 and Pentacam images
215049092|NCT00006356|DRUG|carboplatin|
214294420|NCT01000441|DRUG|infliximab, etanercept, adalimumab|
214294421|NCT01000441|DRUG|abatacept, rituximab or tocilizumab|
214294422|NCT00353262|DRUG|Avastin|7.5mg/kg iv (cycle 3 only)
214294423|NCT00353262|DRUG|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
214294424|NCT00353262|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
214294425|NCT01968590|DRUG|Cholecalciferol|DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
214294426|NCT00893087|DEVICE|Triggering mode of the ventilator|10 min of each triggering mode
214294427|NCT00893087|DEVICE|Triggering method of the ventilator|Flow triggering
214294428|NCT00893087|DEVICE|Triggering method of the ventilator|Pressure triggering
214294429|NCT00893087|DEVICE|Triggering method of the ventilator|NAVA triggering
214294430|NCT00320099|DRUG|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
214294431|NCT00320099|DRUG|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
214294432|NCT00320099|DRUG|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
214889016|NCT05019287|BIOLOGICAL|Allogeneic human menstrual blood stem cells secretome|This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.
214889017|NCT05019287|OTHER|Intravenous saline injection|Intravenous saline injection in addition to standard care
214889018|NCT00549744|DRUG|GSK256066|
214294433|NCT00320099|DRUG|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
214294434|NCT05439408|DRUG|Dasatinib ASD 100 mg|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation
214294435|NCT05439408|DRUG|Dasatinib 140 MG [Sprycel]|SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
214294436|NCT04465331|OTHER|Questionnaires|completion of Exercise Adherence Rating Scale (EARS)
214294437|NCT04348734|DIAGNOSTIC_TEST|pleural ultrasound|Patients will benefit from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm
214294438|NCT04785014|PROCEDURE|interventional|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.
214889019|NCT02593110|BEHAVIORAL|Supervised Treadmill Exercise Therapy|Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
214889020|NCT02593110|DRUG|Telmisartan|Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
214889021|NCT02593110|OTHER|"No exercise control group"|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
214294439|NCT03502044|DEVICE|Inactive Kinetic Oscillation Stimulation (KOS)|10 minutes inactive KOS treatment in each nasal cavity.
214889022|NCT02593110|DRUG|Placebo|
214889023|NCT06399744|PROCEDURE|sclerotherapy|injection of sclerosing agent (tetracycline or polidocanol) into ovarian cyst after aspiration of its contents
214294440|NCT03502044|DEVICE|Active Kinetic Oscillation Stimulation (KOS)|10 minutes active KOS treatment in each nasal cavity.
214294441|NCT02744235|DEVICE|Polysomnography Data|
214294442|NCT02744235|DEVICE|Jawbone UP®|
214294443|NCT02744235|DEVICE|Fitbit Charge ®|
214294444|NCT00511615|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|Tissue sample removed from cervix using LEEP and contrast agent.
214889024|NCT05450419|DIETARY_SUPPLEMENT|Vitamin D3|8pc (576,000 IU/40ml) vitamin D3 on week 1, then 1pc (72,000 IU/5ml) vitamin D3 on week 2, week 3 \& week 4.
214889025|NCT05450419|DIETARY_SUPPLEMENT|placebo|8pc placebo on week 1, then 1pc placebo on week 2, week 3 \& week 4.
214889026|NCT00562523|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
214889027|NCT04198259|PROCEDURE|interventional devascularization|Interventional devascularization (BRTO and its variations) is a procedure for treatment of fundal varices associated with a large gastro-/splenorenal collateral.
214889028|NCT04198259|PROCEDURE|TIPS|TIPS is very effective in the treatment of bleeding GV, with more than a 90% success rate for initial hemostasis. It frequently requires additional embolization of spontaneous collaterals feeding the varices. The incidence of encephalopathy was higher after TIPS.
214294445|NCT03026010|PROCEDURE|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
214294446|NCT00289315|BEHAVIORAL|Primary (Environmental) Weight Gain Prevention|School-based program that modifies the school environment to promote healthy eating and physical activity
214294447|NCT00289315|BEHAVIORAL|Secondary (Behavioral) Weight Gain Prevention|School-based environmental program to promote healthy eating and physical activity in the overweight students.
214294448|NCT00289315|BEHAVIORAL|Control|Control program that does not include an active intervention for promoting healthy eating and physical activity.
214294449|NCT03599024|PROCEDURE|PCEA|The patients were able to control the administration of analgesics by themselves.
214294450|NCT03599024|PROCEDURE|Non-PCEA|The patients were receiving analgesics according to the physician's prescription.
214294451|NCT03599024|PROCEDURE|Total hip replacement|All patients enrolled in the study were indicated for total hip replacement surgery.
214294452|NCT03095391|DEVICE|VFI|The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
214294453|NCT03095391|DEVICE|Iohexol|Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
214294454|NCT04383808|DIAGNOSTIC_TEST|Injected radiotracer with PET Insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
214294455|NCT04383808|DIAGNOSTIC_TEST|Pre-injected group with PET insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
214294456|NCT00812370|DRUG|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
214889029|NCT04358952|DIAGNOSTIC_TEST|Global Longitudinal Strain|Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction
214889030|NCT04604795|DRUG|GSK3915393 Capsules|GSK3915393 capsules will be given orally.
214889031|NCT04604795|DRUG|GSK3915393 Solution for Infusion|GSK3915393 solution for infusion will be administered intravenously.
214889032|NCT04604795|DRUG|Placebo capsules|Placebo matching GSK3915393 capsules will be given orally.
215049093|NCT00006356|DRUG|cisplatin|
214294457|NCT05485298|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
214294458|NCT06678113|DRUG|BSG005|Single arm dose escalation in patients with invasive fungal infection
214294459|NCT04704167|OTHER|fixation of double barrel vascularised fibula|3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
214294460|NCT01909154|BIOLOGICAL|Mesenchymal stromal cell therapy|Stem cells administration locally
214294461|NCT00463346|DRUG|Acamprosate|Acamprosate 1998 mg tid
214294462|NCT00463346|DRUG|Placebo|Placebo
214294463|NCT06216145|OTHER|formative evaluation|"Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method"
214294464|NCT01798199|OTHER|The training by Verve System|
214294465|NCT02949492|DRUG|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
214668214|NCT03358628|OTHER|Molecular Profiling & In Vivo drug testing in PDX|Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
214668215|NCT04596813|DEVICE|CytoSorb 300 mL device|Intra-and postoperative CytoSorb hemoadsorption
214668216|NCT03237403|OTHER|observational study|observational study between clinical criteria collected at SAMU regulation centre call and hospital orientation
214668217|NCT01468519|DRUG|Insulin|Insulin via continuous subcutaneous insulin infusion
214668218|NCT01468519|DRUG|Insulin|insulin via multiple daily injections
214889033|NCT04604795|DRUG|Itraconazole|Participants will be administered with GSK3915393 along with ITZ orally
214889034|NCT04604795|OTHER|Water|Participants will be administered with GSK3915393 along with water orally
214889035|NCT04604795|OTHER|Grape fruit juice|Participants will be administered with GSK3915393 along with GFJ orally
214889036|NCT02831426|DEVICE|Two-stage with Acellular Dermal Matrix (CELLIS® Breast)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
214889037|NCT02831426|DEVICE|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
215049094|NCT00006356|PROCEDURE|conventional surgery|
214889038|NCT05488093|DEVICE|X-sens sensor|"the procedure will include:~* 7 to 8 sensors (Foot, leg, thigh, pelvis and chest possibly).~* 5 movements/exercises for the patients, each exercise performed 3 times except walking~* Analysis of 20m walking cycle (normal speed, most natural arm movement, 4 return trips of 20m):~* Climbing up and down stairs (using the public stairs of the rheumatology access department, 6 steps of 20 cm height, at normal speed, without using the handrail)~* Getting up from a chair without the help of hands (start standing, then the patient sits, leans and stands up, feet together, without taking the feet off the floor, using one and the same chair for each patient with a height of 50 cm)"
214889039|NCT05671458|OTHER|intraoperative navigation and creation of tumor resection maps|TRM are based on intraoperative navigation data and yield anatomically accurate marks of the tumor resection margin and potential residual tumor areas on clinical imaging. These marks will be annotated with histopathological information. Subsequently, the resulting 3-dimensional TRM will be imported into the radiotherapy planning system as part of a multidisciplinary workflow.
214889040|NCT00611624|RADIATION|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
214889041|NCT02998086|BEHAVIORAL|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
214889042|NCT00719186|DRUG|Clomiphene citrate|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
214889043|NCT00719186|DRUG|Letrozole|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
214889044|NCT01558960|DRUG|IVit Melphalan|IVit injections of Melphalan
214294466|NCT01399138|DIETARY_SUPPLEMENT|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
214294467|NCT01572909|DRUG|Bendavia (MTP-131)|0.05 mg/kg/hr
214294468|NCT01572909|DRUG|Placebo|Identically appearing placebo
214889045|NCT03182777|PROCEDURE|Dental restorative procedure|Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.
215049095|NCT04327440|BIOLOGICAL|RTS,S/AS01 malaria vaccine|Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
214294469|NCT03641651|OTHER|Rehabilitation technology|"* Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~* With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~* A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~* The training can take place in an outpatient or inpatient setting.~* Training will be organized in individual one-to-one or group session"
214294470|NCT02734381|OTHER|Elderly patients|Elderly patients who visited the Emergency Department
215049096|NCT04327440|OTHER|PBO bed nets|PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
215049097|NCT01251302|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
214294471|NCT04779489|RADIATION|personalized ultrafractionated stereotactic ablative radiotherapy|next-generation stereotactic ablative radiotherapy to bladder and enlarged lymph nodes
214294472|NCT02984189|OTHER|Inspiratory muscle training|The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
215049098|NCT00548834|DRUG|CDP870|
215049099|NCT06054399|OTHER|educational program|Education resources in Spanish through social media directed to the targeted audience mentioned above. There will be at least three interventions along the study, one for each pregnancy trimester, including topics such as: Migraine criteria, management strategies, risks of medication overuse, alarm symptoms, etc. These educational interventions will be conducted by trained health care professionals, mainly using audio-visual media.
215049100|NCT02255669|DEVICE|partially covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
215049101|NCT02255669|DEVICE|fully covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
215049102|NCT04280003|OTHER|Alogenic adipose tissue-derived stem cells|Concentration of the cells: 10 million cells / ml
215049103|NCT04280003|DRUG|Placebo solution|Placebo intravenous solution, same appearance stem cells solution
215049104|NCT04547465|DIAGNOSTIC_TEST|Echocardiography|2D Speckle-tracking echocardiography
215049105|NCT06199024|DIETARY_SUPPLEMENT|Oral cinnamon supplementation|In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
214294473|NCT00951665|DRUG|paclitaxel|Intravenous repeating dose
214889046|NCT02109653|DRUG|LGX818|Oral LGX818 300mg daily
214889047|NCT03022916|DRUG|Nail Polish + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish
214889048|NCT03022916|OTHER|Nail polish|Application of nail polish only to both big toe nails
214889049|NCT03022916|DRUG|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat
214889050|NCT03022916|DRUG|Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
215049106|NCT01824290|DRUG|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
215049107|NCT01824290|DRUG|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
214294474|NCT00951665|DRUG|pertuzumab [Perjeta]|Intravenous repeating dose
214294475|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous escalating dose
214294476|NCT00951665|DRUG|paclitaxel|Intravenous escalating dose
214294477|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
214889051|NCT00111241|DRUG|aromatase inhibitors (letrozole, anastrozole)|Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
214889052|NCT06489236|BEHAVIORAL|Vaccine Confidence: Skills to Promote Vaccination in the Pediatric Consultations|Intervention mapping principles guided a multidisciplinary team through the development of the intervention. The intervention is a 12-hour training program focused on improving vaccination promotion and vaccine hesitancy management during pediatric consultations. The program comprises 10 hours of online education and 2 hours of in-person activities. Online training materials (short video lectures, video case studies, and readings) were structured in three learning modules covering vaccine and vaccine hesitancy technical information, vaccination promotion communication strategies, and practice organizational resources. In-person activities involved role-playings and group discussions. Intervention content is evidence-based. As a participation incentive, pediatric nurses and pediatricians who complete all program activities, including a multiple-choice final test, will receive 2,5 accredited continuing medical education credits.
214889053|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Oppanol
214889054|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
214889055|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
214889056|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
214889057|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Vistanex
214889058|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
214668219|NCT05032508|DRUG|Lidocaïne Aguettant 20 mg/ml|Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
215049108|NCT01824290|DRUG|ERA as specific PAH treatment|All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
215049109|NCT00800982|PROCEDURE|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
215049110|NCT00800982|DRUG|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
214294478|NCT01575665|DEVICE|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
214668220|NCT05032508|DRUG|NaCl 0,9%|Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
214668221|NCT06080750|GENETIC|Quantitative Real Time Polymerase chain reaction (qRT-PCR)|to study gene expression of NLRP3 inflammasome and IL-1B in blood
215049111|NCT03172273|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
214668222|NCT06080750|DIAGNOSTIC_TEST|ELISA and colorimeter|IL-6 and total LDH
214668223|NCT02291341|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
214668224|NCT02291341|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
214668225|NCT03942614|BEHAVIORAL|Nordic pole walking|
214889059|NCT04912232|DEVICE|Detection of Occult Hemorrhage in Trauma Patients|Non-invasive monitoring of trauma patients
214889060|NCT01994785|DIAGNOSTIC_TEST|Capnographic Monitoring|Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
214889061|NCT02462863|DIETARY_SUPPLEMENT|Arginine and fish oil|Dietary supplements
214889062|NCT00215423|DRUG|Formoterol Fumarate|
215049112|NCT03172273|PROCEDURE|paracentesis|paracentasis plus albumine invision
215049113|NCT02278315|DRUG|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
215049114|NCT02278315|DRUG|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
215049115|NCT02278315|DRUG|I-131-CLR1404|Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
215049116|NCT02343770|OTHER|blood sample for identifying biomarkers|
215049117|NCT03793686|DRUG|PBCLN-003|Investigational drug
215049118|NCT03793686|DRUG|Placebo|Placebo
215049119|NCT02606318|OTHER|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
215049120|NCT02606318|OTHER|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
214668226|NCT02119130|DEVICE|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
214294479|NCT04813094|OTHER|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Everyone have their own area to ensure the privacy of participants. The research nurse has sent messages every day to care about the participant's condition. In this area, when the participant have an emergency, it not only provided textual information, but also provided telephone coaching.
214668227|NCT00994188|PROCEDURE|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
214889063|NCT03108885|OTHER|Blood and Tissue Collection|Blood DNA will be isolated from plasma. Tumor DNA will be purified with a kit and amplified regions of 10 genes discovered to by mutated in whole exome sequencing.
214889064|NCT05276362|DEVICE|Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
215049121|NCT02819531|DEVICE|Rotational atherectomy|Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
214668228|NCT02952742|DRUG|Black Cohosh|Vital Nutrients Black Cohosh Extract
214889065|NCT05276362|DEVICE|Actiwatch|The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.
214889066|NCT06583057|PROCEDURE|Thermal ablation|Patients who underwent thermal ablation were performed in the outpatient clinic's operating room under local anesthesia. Thermal ablation was performed under real-time ultrasound-guided. The 18-G bipolar radiofrequency applicator with a 0.9 cm active tip (CelonProSurge micro 100-T09, Olympus Surgical Technologies Europe) , or a 16-G/17-G cooled microwave antenna with a 0.3 cm tip (ECO-100A1, YIGAO MWA system Co., Ltd; KY-2000, Kangyou Medical, Nanjing, China) was used during ablation.
214889067|NCT06583057|PROCEDURE|Thyroid lobectomy|Patients who underwent thyroid lobectomy were performed in the operating theater under general anesthesia. Lobectomy (or lobectomy plus isthmusectomy) with prophylactic central neck dissection were performed.
215049122|NCT02819531|DEVICE|Orbital atherectomy|Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
214668229|NCT02952742|OTHER|Placebo|Inactive comparator resembling the Black Cohosh formulation in appearance. Ingredients include: cellulose; caramel color; powdered yellow dye; and powdered red dye.
214889068|NCT02193217|DRUG|MT-1303-Low|
215049123|NCT02819531|DEVICE|Scoring balloon system|Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
215049124|NCT00051207|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|
215049125|NCT00051207|BEHAVIORAL|IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS)|
215049126|NCT00395109|DEVICE|PET/CT|All study participates will be scanned with PET/CT scan before surgery.
215049127|NCT04373343|BEHAVIORAL|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
215049128|NCT04256239|BEHAVIORAL|Dignity Therapy|Intervention aimed at enhancing patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress
215049129|NCT02920307|PROCEDURE|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
214294480|NCT04813094|OTHER|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
214294481|NCT01657279|OTHER|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome \[i.e. from low (\<10%) to high (\>50%) expected risk death at 30 days\].
214889069|NCT02193217|DRUG|MT-1303-High|
214889070|NCT02193217|DRUG|Fingolimod|
214889071|NCT02193217|DRUG|Placebo|
214889072|NCT01461447|BIOLOGICAL|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
215049130|NCT02920307|PROCEDURE|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
215049131|NCT02920307|PROCEDURE|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
215049132|NCT02920307|PROCEDURE|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
215049133|NCT02235571|BEHAVIORAL|iChoose Kidney Decision Aid|Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
215049134|NCT02537730|DEVICE|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
215049135|NCT02537730|DEVICE|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
215049136|NCT02537730|DEVICE|comfilcon A|contact lens
215049137|NCT02843412|PROCEDURE|choose two tumor tissue paraffin blocks|
215049138|NCT02793583|BIOLOGICAL|Ublituximab|
215049139|NCT02793583|DRUG|Umbralisib|
215049140|NCT02793583|BIOLOGICAL|Bendamustine|
215049141|NCT01022970|DRUG|QAX576 placebo|
215049142|NCT01022970|DRUG|QAX576|
215049143|NCT04924621|DEVICE|Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.|"The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists.~After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg."
215049144|NCT04924621|DEVICE|Mask ventilation|The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.
214889073|NCT07017959|DIETARY_SUPPLEMENT|LpD3.5 supplementation.|Dietary Supplement: LpD3.5 are in the form of capsule where LpD3.5 contains 167 mg of LpD3.5, with the remaining portion consisting of inactive ingredients like maltodextrin
214889074|NCT07017959|DIETARY_SUPPLEMENT|Placebo|Placebo capsules contain only inactive ingredient maltodextrin
214889075|NCT06405594|BEHAVIORAL|Language Condition|The intervention involves asking participants to speak and understand words and sentences with different linguistic manipulations such as morphological, semantic, phonological priming, predictability of the subject and object nouns associated with verbs, naming of verbs and nouns, production of sentences with past, future or present tense. Accuracy, response times and brain activity are the outcome measures.
214889076|NCT05632926|DRUG|40 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
214889077|NCT05632926|DRUG|60 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
214294482|NCT01586169|DRUG|triple co administration at once of the combination of Albendazole + ivermectin + azithromycin|Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once
214294483|NCT06376747|PROCEDURE|In line sampling|closed technique of sample collection
214294484|NCT06376747|PROCEDURE|Standard blood sampling technique|Blood draws using standard steps: blood withdrawal for catheter, decontamination (disposed),blood draw for laboratory analysis,catheter flush
214889078|NCT05632926|DRUG|80 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
214889079|NCT00952731|DRUG|oral placebo|Oral placebo taken daily for 4-10 weeks.
214889080|NCT00952731|DRUG|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
214889081|NCT00952731|DRUG|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
214889082|NCT00952731|DRUG|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
214889083|NCT03909880|OTHER|Kinesio tape|"Kinesio tape (kinesio taping; kinesio holding corporation,USA) was placed on the skin above muscle belly of finger flexor. There were three types of taping:~Taping20 condition - tape was pulled from the wrist to the proximal forearm. The two ends of the tape (\~5 cm) were held by the therapist and the middle area was pulled 20% additional tension.~TapingN condition - tape was pulled with neutral tension. Control condition - no taping."
215049145|NCT04924621|DRUG|Midazolam(T group)|Midazolam 0.05mg/kg, intravenous injection
215049146|NCT04924621|DRUG|Sufentani(T group)|Sufentanil 0.02-0.05ug/kg, intravenous injection
215049147|NCT04924621|DRUG|Propofol(T group)|Propofol 2-3ug/ml, intravenous injection
215049148|NCT04924621|DRUG|Rocuronium(T group)|Rocuronium 0.06mg/kg, intravenous injection
215049149|NCT04924621|DRUG|Drug use target(T group)|Make BIS \< 60 .
215049150|NCT04924621|DRUG|Sufentanil(C group)|Sufentanil 5ug, intravenous injection
215049151|NCT04924621|DRUG|Midazolam(C group)|Midazolam 0.05mg/kg, intravenous injection
215049152|NCT04924621|DRUG|Propofol|Propofol 1-2ug/ml, intravenous injection
215049153|NCT04924621|DRUG|Tetracaine(C group)|2ml tetracaine was injected with cyclothyroid membrane puncture.
215049154|NCT04924621|DRUG|Drug use target|Make the BIS between 70 and 80.
214294485|NCT04711473|BEHAVIORAL|Colonoscopy Only|Mailed letter asking participants to complete CRC screening by colonoscopy
214294486|NCT04711473|BEHAVIORAL|Choice|Mailed letter and FIT test asking participants to complete CRC screening by their choice of either colonoscopy or mailed FIT
214294487|NCT04711473|BEHAVIORAL|FIT Only|Mailed letter and FIT test asking participants to complete CRC screening by mailed FIT
214889084|NCT01450683|DRUG|Itraconazole|"600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-\[4-(4-{\[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl\]methoxy}phenyl)piperazin-1-yl\]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
214294488|NCT01882621|DRUG|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
214294489|NCT01882621|DRUG|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
214294490|NCT06368960|RADIATION|Radiotherapy|Radiation： Hypofractionated radiotherapy
214294491|NCT06368960|DRUG|BM201 injection|BM201 injection：Dose escalation：24mg to 240mg
214668230|NCT03738124|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
214477811|NCT06862492|DEVICE|Open surgical cut down technique|"The technique was performed following the descriptions of Farhadi et al. The infant was positioned in 30° (Trendelenburg's position), with a roll under his shoulders for neck extension and rotated to contralateral side of the surgical side to expose the incision site. Incision was done under sedation and pulse oximeter to monitor the oxygen saturation during the technique.~Under complete aseptic technique, a small transverse incision 1cm was made on triangle bordered by the clavicle inferiorly and by the sternal and clavicular heads of the sternomastoid muscle medially and laterally. With blunt dissection we separate the two heads of the sternomastoid exposing the internal jugular vein .~Then internal jugular vein cut down was performed and catheter inserted through it, all internal jugular vein venotomies were repaired as needed by 6/0 Polypropylene (Prolene®) suture and the wound was closed by absorbable polyglactin (Vicryl) suture"
214668231|NCT02464319|DRUG|hrIL-2 active|1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
214668232|NCT02464319|DRUG|hrIL-2 placebo|1 million U doses of placebo s.c. injection active group: placebo group =1:1
214668233|NCT06170255|BEHAVIORAL|Behavioral Activation (BA)|Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
214668234|NCT03858582|DRUG|pembrolizumab|pembrolizumab 200mg
214889085|NCT05222698|PROCEDURE|Facial reanimation surgery by free muscle trasfer.|Muscle flap harvesting from the back or from the thigh to be insetted to the paralyzed side of the face with microvascular anastomosis of the muscle pedicle to facial artery and vein.
214889086|NCT05475327|OTHER|Conventional Physical Therapy|"Heating pad~A total of 3 sessions per week were given for 15 to 20 mins"
215049155|NCT00648037|DRUG|Rituximab|Rituximab 375 mg/m\^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is \> 200 cells/ul or a maximum of 6 doses have been given.
214294492|NCT05581537|OTHER|Systematic Desensitization|"Systematic desensitization: 2 techniques~1. Jacobson's technique (progressive muscle relaxation):~   It involves tensing and releasing muscles that progress through the body throughout focusing on mental relaxation throughout releasing muscle tension~2. Guided imagery (vividly imagining):~It includes 2 types of imagery training/mental practice (MP) which includes visual imagery is based on the sensory (visual) perception of the imagined movement and Kinesthetic imagery is based on sensory-motor information (proprioceptive). MP will be conducted in a quiet room, where each patient will be given detailed instructions to perform both visual and kinesthetic practice"
214294493|NCT02723084|DRUG|ABT-493/ABT-530|Co-formulated tablet
214294494|NCT02723084|DRUG|sofosbuvir (SOF)|Tablet
214294495|NCT02723084|DRUG|ribavirin (RBV)|Capsule
214294496|NCT02659709|DEVICE|Interest in medical education through social media|Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
214294497|NCT05029986|BEHAVIORAL|Socialization phase|Control condition: does not involve speech-related exercises
214889087|NCT05475327|OTHER|Relaxation exercises|"The experimental group was given Progressive relaxation exercises along with Deep breathing exercises.~A total of 3 sessions per week were given for 15 to 20 mins."
214889088|NCT04860180|PROCEDURE|adrenalectomy|
214889089|NCT05176444|BEHAVIORAL|Music therapy|Individual music therapy sessions across 12-weeks with people with cognitive impairment/dementia. Music therapy training for care home staff at four time points across 12-weeks.
215049156|NCT06017882|OTHER|Partial sleep deprivation|
215049157|NCT05842746|DRUG|Elemene|Elemene of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
215049158|NCT05842746|DRUG|Placebo|Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
215049159|NCT01951898|DRUG|Montelukast|10mg/day, once a daily after dinner, for 28dyas
214294498|NCT05029986|BEHAVIORAL|Speech breathing intervention|Experimental condition: involves speech-related exercises
214294499|NCT01718847|DRUG|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
214294500|NCT01950923|DRUG|sildenafil citrate|Given PO
214294501|NCT01950923|OTHER|placebo|Given PO
214294502|NCT01950923|PROCEDURE|therapeutic conventional surgery|Undergo standard robotic partial nephrectomy
214294503|NCT02680028|DEVICE|targon pft nail|220 mm vs 175mm nail
214294504|NCT04012385|BEHAVIORAL|lifestyle counseling|Nutritional plan and Physical activity goals
214294505|NCT01326416|DIETARY_SUPPLEMENT|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
214294506|NCT01326416|OTHER|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
214294507|NCT02450903|DRUG|LDK378|Oral LDK378 750mg once daily
214294508|NCT00604539|DRUG|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
214294509|NCT00604539|DRUG|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
214294510|NCT04412720|OTHER|Aerobic and Breathing Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, Buteyko Breathing Technique also will be performed during 20 minutes each exercise, in the same treatment session. During the first two weeks, the patient will learn the technique supervised by a physical therapist. In addition, the patients will receive a breathing exercise booklet for in-home training. Before and after each session, patients will be evaluated in relation to blood pressure, heart rate, oxygen saturation and asthma symptoms.
214294511|NCT04412720|OTHER|Aerobic and Stretching Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, stretching exercises will be performing for major muscle groups, during 30 seconds each one. The patients will receive a stretching exercise booklet for in-home training.
214294512|NCT00421538|DRUG|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
214294513|NCT00421538|DRUG|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
214294514|NCT01164956|DRUG|methylphenidate|
214294515|NCT01164956|OTHER|Placebo|
214889090|NCT03883035|OTHER|automatic quality-control system|Automatic quality-control system could real-time measuring endoscopic inspection completeness, detecting gastric neoplasms and evaluating gastric mucosal visibility.
214294516|NCT00967798|DRUG|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
214294517|NCT03060239|OTHER|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
214294518|NCT01409564|DRUG|Cilostazol|Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
214294519|NCT01409564|DRUG|Placebo|Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
214294520|NCT04486781|DRUG|Pembrolizumab + sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
214294521|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 50mg/dose|Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
214294522|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 25mg/m2|Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children \< 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
214294523|NCT03867604|PROCEDURE|Sham injection|Injection to the subcutaneous layer at upper trapezium level
214294524|NCT03867604|PROCEDURE|Fascia injection|Injection to the fascia below upper trapezium muscle
214477812|NCT06862492|DEVICE|Modified Seldinger's technique|After proximal and distal control of the vein, a 24-G. cannula was carefully inserted directly to the internal jugular vein . The guidewire was inserted through the cannula, then the cannula was removed. A size 4-5 French short length catheter was passed and brought out through the guidewire, then the guidewire was removed. The wound was closed after the correct catheter position and good haemostasis was obtained; the area was covered with sterile dressing.
214889091|NCT00451646|DRUG|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
214889092|NCT02108912|OTHER|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
215049160|NCT03457077|BEHAVIORAL|Brief intervention|A brief motivational intervention with feedback about drinking levels compared to norms
214294525|NCT03733691|DRUG|Ixazomib|3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
214294526|NCT03733691|DRUG|Lenalidomide|Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
214294527|NCT00258882|BIOLOGICAL|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
214294528|NCT04154020|PROCEDURE|Flexor tenotomy|Tenotomy(cutting) of flexor tendons is performed with needle
214294529|NCT05990101|BEHAVIORAL|Awake prone position (APP)|Awake prone position for 4 or more hours per day for the first 72 hours following randomisation.
214294530|NCT02244489|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
214668235|NCT03858582|RADIATION|Radiation|52.8Gy/24Fx or 59.4Gy/27Fx
214889093|NCT02108912|OTHER|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
215049161|NCT02264743|DRUG|Femoston Conti|Ultra-low-dose oral E2/D \[Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg\] oral Femoston Conti 0.5mg Estradiol\&Dydrogesterone vs Oestradiol\&Norethisterone acetate
215049162|NCT02264743|DRUG|EVOREL® CONTI|Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
215049163|NCT02967679|DRUG|MD1003|
214889094|NCT06425965|OTHER|Advanced life support training with high reality simulator|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with a high reality simulator in line with the information (15 min), scenario implementation (15 min) and debriefing sessions (30 min), respectively.
214294531|NCT02244489|DRUG|Capecitabine|Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
214294532|NCT02244489|DRUG|Oxaliplatin|Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
214294533|NCT02305108|OTHER|fascial manipulation|"Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.~Specific points of fascial tissue will be treated with a deep friction to improve elasticity.~The number of point treated will be refered to a specific evaluation for each patient.~Fascial manipulation provide 3 session treatment (one treatment for week)."
214477813|NCT06862492|DEVICE|Closed Ultrasound guided CVC insertion|Ultrasound probe was connected to ultrasound unit and focused with ultrasonic gel and wrapped in a sterile plastic sheath. By wrapping the transducer in a sterile sheath, the probe place perpendicular to the long axis of the vessel, standard US two-dimensional (2D) imaging was used to visualize the vein in the short-axis view as a circle. Catheterization was performed under continuous dynamic observation of real-time 2D images. Insertion needle was advanced through the skin under US guidance into the internal jugular vein . A guidewire was then placed through the needle into the vein, and the needle was removed. Then catheter was inserted over the wire into internal jugular vein .
214477814|NCT06860334|DRUG|Favipiravir|6-fluoro-3-hydroxypyrazine-2-carboxamide, T-705
214477815|NCT06860334|DRUG|Ribavin|1-3,4-dihydroxy-5-1,2,4-triazole-3-carboxamide
214477816|NCT06860334|OTHER|Optimised Standard of Care|Optimised standard of care will include treatment per national guidelines for CCHF case management in Turkiye and Iraq, and any other supportive medication or therapies as required.
214477817|NCT06861400|BEHAVIORAL|Self-Reflective Resilience-Recovery Activity Promotion Training|Self-Reflective Resilience-Recovery Activity Promotion Training (SRR-RAPT) promotes finding positive meaning in stressors by building self-awareness of the coping and regulatory responses used to manage them; evaluating those responses; adapting them based upon their perceived effectiveness; and developing a plan for managing similar stressors in the future based on what can be learned from the current situation. In addition to prompting self-monitoring and active reflection on stressors and coping responses, SRR-RAPT encourages practicing recovery activities that permit a person's stressor induced strain level to return to baseline. SRR-RAPT is administered daily for 8 consecutive days.
214477818|NCT06861959|DEVICE|Device: Volume-Controlled Ventilation (VCV)|Tidal volume: 8 mL/kg of ideal body weight Respiratory rate adjusted to maintain an end-tidal CO₂ (EtCO₂) level of 30-35 mmHg Inspiratory-expiratory ratio: 1:2 PEEP: 5 cmH₂O Mechanical ventilation was provided using a Datex-Ohmeda Avance Anesthesia Machine (GE Healthcare, USA) Measurements were taken at four predefined time points (T1-T4)
214889095|NCT06425965|OTHER|Advanced life support training with web-based simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out by web-based simulation method. Students participate in the web-based simulation application developed by the researcher.
214889096|NCT06425965|OTHER|Advanced life support training with hybrid simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with the hybrid simulation method in which high reality simulator and web-based simulation method are applied together. Students first apply the web-based simulation developed by the researcher. Then they perform the practice on the high reality simulator.
214889097|NCT02523300|PROCEDURE|TEVAR|The patients will be undertaken TEVAR
214889098|NCT02523300|DRUG|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
215049164|NCT03351946|PROCEDURE|ZEEP|Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.
215049165|NCT03351946|PROCEDURE|PEEP|Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
214294534|NCT02305108|OTHER|standard treatment|"Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training."
215049166|NCT00133341|DRUG|Goldnatriomthiosulphate, MDBGN, parthenolide|
214294535|NCT06221904|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
214294536|NCT05744947|OTHER|Data collection|"Specific Readapt -DISCO complementary questionnaire rehabilitation"
214294537|NCT02328755|DRUG|peg-IFN-α|
214668236|NCT01160367|OTHER|TAILORED Patient Family Decision Making|Patient-family dyads will receive TAILORED intervention on health decision making
214294538|NCT02328755|PROCEDURE|Hematopoietic Cell Transplant (HCT)|
214294539|NCT02328755|DRUG|Tacrolimus|Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.
214294540|NCT02328755|DRUG|Methotrexate|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
214294541|NCT03707314|PROCEDURE|Angiography with follow-on revascularisation if indicated|Angiography with follow-on revascularisation (if indicated)
214294542|NCT03253887|DRUG|Ethanol-lock|This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
214294543|NCT02989675|DRUG|10% dextrose|Bolus of 10% dextrose 5mls/kg
214294544|NCT04345263|PROCEDURE|MTA pulpotomy|Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
214294545|NCT00788151|BIOLOGICAL|CYD Dengue Vaccine Serotypes 1, 2, 3, and 4|0.5 mL, Subcutaneous (SC)
214294546|NCT00788151|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL, SC
214294547|NCT02600377|OTHER|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
214294548|NCT00503009|DRUG|fluticasone propionate/salmeterol|comparator
214294549|NCT00503009|DRUG|fluticasone propionate|Comparator
214294550|NCT00503009|DRUG|placebo|Placebo
214294551|NCT01558388|DRUG|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
214889099|NCT02523300|DRUG|saline|The other 120 patients will be given saline as control group
214889100|NCT04983186|DEVICE|Wearable sensor and smartphone application|Empatica E4 wearable sensor and custom-made headache smartphone application
215049167|NCT01545765|DRUG|Lidocaine 7% + Tetracaine 7% cream|Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
214294552|NCT01558388|DRUG|Placebo|One vaginal tablet daily for 10 days.
214294553|NCT03413566|OTHER|Clinical diagnosis|A clinical diagnosis of cerebral palsy given by a pediatrician at a habilitation center in Norway.
214294554|NCT04275440|BEHAVIORAL|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
214294555|NCT04275440|BEHAVIORAL|Caloric restriction|"1. In the first two weeks, participants would reduce their daily energy intake to 100% -110% of his or her basal metabolic energy under instruction, and stick to it till the end of the intervention.~2. According to the dietary recommendation proposed by Chinese government, participants are required to take in cereals, vegetables, fruits, meat and eggs, while minimize the consumption of sugar-sweeten beverages.~3. Participants are instructed to arrange their three meals according to the recommended energy distribution (3:4:3)."
214294556|NCT02935322|DRUG|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
214294557|NCT02935322|DRUG|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
214294558|NCT02935322|DRUG|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
214294559|NCT02935322|OTHER|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
214294560|NCT00141076|BEHAVIORAL|low vs high glycemic index diet|
214294561|NCT05205746|BIOLOGICAL|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
214668237|NCT01160367|OTHER|standard of care|Patient-family dyads will receive standard of care in health decision-making
214889101|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
214889102|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
214889103|NCT00108706|DRUG|Candesartan|
214889104|NCT01119664|DRUG|SCH 721015|
214889105|NCT00869076|OTHER|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
214889106|NCT00869076|OTHER|Usual care|Patient was managed by their primary care physician as usual
215049168|NCT01654874|DRUG|99mTc-MIP-1404|
215049169|NCT04554459|DRUG|Ponatinib 15 MG Oral Tablet|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
215049170|NCT04319250|OTHER|ischemic compression|ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.
214889107|NCT03777163|BIOLOGICAL|Butantan Institute Trivalent Seasonal Influenza Vaccine|Butantan Institute and Pasteur-Mérieux (present, Sanofi Pasteur) established a technology transfer in 1999 for the production of a trivalent influenza vaccine of inactivated split-virion using embryonated eggs. The technology transfer followed a progressive approach from importing the finished product, to packaging and quality control test for release (1999), and, finally, to the first batch of influenza vaccine entirely produced by Butantan (2011). In 2013, the Butantan vaccine was registered by the Brazilian National Agency of Sanitary Surveillance (ANVISA).
214889108|NCT03777163|BIOLOGICAL|Sanofi Trivalent Seasonal Influenza Vaccine|VAXIGRIP® was launched in 1968 and since then has been licensed in more than 100 countries and prequalified by WHO in 2011. Several clinical studies by Sanofi Pasteur have examined the safety and immunogenicity of Vaxigrip® in older children (8-10 years), adults (18-59 years), elderly (\> 60 years),11,12 children (six months to three years) 13 and pregnant women.
214889109|NCT03308812|BEHAVIORAL|Health360x|Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
214889110|NCT03308812|BEHAVIORAL|Health Coach|Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
215049171|NCT04319250|OTHER|IASTM|"In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way."
215049172|NCT04319250|OTHER|Rehabilitation Program|A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
215049173|NCT02379195|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
215049174|NCT02379195|DRUG|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
215049175|NCT02379195|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
215049176|NCT02379195|DRUG|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
215049177|NCT02379195|DRUG|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
215049178|NCT00020150|DRUG|O6-benzylguanine|
215049179|NCT00020150|DRUG|temozolomide|
214668238|NCT05581719|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
214668239|NCT05581719|DRUG|Nivolumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
215049180|NCT06251622|OTHER|Volumetric ultrasound of the quadriceps and fitting of an accelerometer|The research procedure will simply involve a volumetric ultrasound of the quadriceps and the fitting of an accelerometer (watch worn on the wrist) for one week (collection of usual physical activities).
215049181|NCT04375956|DRUG|Pembrolizumab|Experimental
215049182|NCT05695170|BEHAVIORAL|PreventT2 (Individual intervention)|"PreventT2 will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the curriculum that will be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National Diabetes Prevention Program (DPP), which has full recognition from the CDC based on outcome data over the course of a number of years."
214889111|NCT01049646|DRUG|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
214889112|NCT01049646|DRUG|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
214889113|NCT00316927|DRUG|acetylsalicylic acid|
214889114|NCT00316927|DRUG|dexamethasone|
214294562|NCT05205746|BIOLOGICAL|Placebo|Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular
214889115|NCT00316927|DRUG|diethylstilbestrol|
214889116|NCT05884502|DRUG|combination of high-dose rosuvastatin and ezetimibe|combination of rosuvastatin 20mg and ezetimibe 10mg
214889117|NCT05884502|DRUG|high-dose rosuvastatin single administration|rosuvastatin 20mg monotherapy
214889118|NCT01246310|DIETARY_SUPPLEMENT|Inositol|
214889119|NCT01246310|DIETARY_SUPPLEMENT|Placebo|
214889120|NCT00852202|DRUG|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
214889121|NCT00852202|DRUG|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
214889122|NCT00852202|DRUG|placebo|placebo capsules, oral administration, once daily dosing
214889123|NCT00453050|DRUG|imiquimod|
214889124|NCT00453050|DRUG|indocyanine green solution|
214889125|NCT00453050|OTHER|flow cytometry|
214889126|NCT00453050|OTHER|immunologic technique|
214889127|NCT00453050|OTHER|laboratory biomarker analysis|
214889128|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
214889129|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
214294563|NCT04461171|PROCEDURE|Enhanced Recovery After Surgery|Undergo an enhanced recovery after surgery program
214294564|NCT03959020|PROCEDURE|Anti-reflux surgery|Anti-reflux surgery for verified GERD
214294565|NCT01349803|DRUG|PT005 MDI|PT005 MDI administered as two puffs BID for 14 days
214294566|NCT01349803|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 14 days
214294567|NCT01349803|DRUG|PT003 MDI|PT003 MDI administered as two puffs BID for 14 days
214294568|NCT01349803|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
214889130|NCT00022113|DRUG|cilengitide|Given IV
214889131|NCT00022113|OTHER|pharmacological study|Correlative studies
214889132|NCT00022113|OTHER|laboratory biomarker analysis|Correlative studies
214889133|NCT05293821|DIAGNOSTIC_TEST|TriQuik IVD|TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.
214889134|NCT04671121|PROCEDURE|Standart pressure pneumoperitoneum|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
214889135|NCT04671121|PROCEDURE|Low pressure pneumoperitoneum|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
214889136|NCT00836784|OTHER|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
214889137|NCT00836784|OTHER|New tooth brush|"The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes."
214889138|NCT02285374|DRUG|Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir|Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
214889139|NCT02972892|DEVICE|Et Control Feature|Subjects using Et Control option; the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the wellbeing of the subject. The clinician must continuously monitor measured inspired and end tidal oxygen and anesthetic concentrations to assess individual responses and compare to the target concentrations.
215049183|NCT05695170|BEHAVIORAL|PreventT2 Together (Couple-based intervention)|PreventT2 Together will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes and their partners. The curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevention type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
214294569|NCT05829889|PROCEDURE|FFR-Guided PCI|Fractional Flow Reserve-Guided PCI
214294570|NCT05829889|PROCEDURE|Angiography-Guided PCI|Angiography-Guided PCI
214668240|NCT05581719|DRUG|Tislelizumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
214668241|NCT01479972|BIOLOGICAL|VPM1002|Tuberculosis vaccine
214668242|NCT01479972|BIOLOGICAL|BCG|commercially available live vaccine BCG
214668243|NCT01287117|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
214668244|NCT01287117|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
214294571|NCT06495346|OTHER|self-questionnaires exploring|At each stage, subjects are asked to fill in self-questionnaires exploring the quality of their sleep, their potential distressing symptoms, their psychological state and the quality of their life at that moment. They complete the self-questionnaires at t
214668245|NCT02035943|DIETARY_SUPPLEMENT|Insulin separated|separate continuos infusion of insulin
214668246|NCT02035943|DIETARY_SUPPLEMENT|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
214294572|NCT02169739|DEVICE|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
214294573|NCT01565785|BEHAVIORAL|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
214294574|NCT02260050|DRUG|WAL 801 CL dry syrup new formulation|
214294575|NCT02260050|DRUG|WAL 801 CL dry syrup conventional formulation|
214294576|NCT01305850|DRUG|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
214294577|NCT01305850|DRUG|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
214294578|NCT01305850|DRUG|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
214294579|NCT01305850|DRUG|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
214889140|NCT02972892|DEVICE|Conventional Fresh Gas|"Subjects to undergo a surgical procedure with inhaled anesthesia meeting the American Society of Anesthesiologists status classification system 1-3. Subjects using conventional option; the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature. Machine log data collection will end, when an end case is confirmed on the Aisys CS2 at the end of the anesthesia case."
214294580|NCT01710033|DRUG|Placebo|Placebo tables twice daily (BID) for 28 days
214294581|NCT01710033|DRUG|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
214294582|NCT01710033|DRUG|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
214294583|NCT01710033|DRUG|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
214294584|NCT03356951|PROCEDURE|TAR through anterior approach and subtalar fusion|Simultaneous total ankle replacement through anterior approach and subtalar fusion
214294585|NCT03356951|PROCEDURE|TAR through lateral approach and subtalar fusion|Simultaneous total ankle replacement through lateral approach and subtalar fusion
214294586|NCT02880189|DEVICE|Orbera Intragastric Balloon|The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
214294587|NCT02880189|PROCEDURE|Endoscopic Ultrasound Guided Core Liver Biopsy|
214294588|NCT04396990|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
214294589|NCT04396990|DRUG|Topical Prednisolone|Standard of care topical drop treatment
214294590|NCT04890639|PROCEDURE|Acute Intermittent Hypoxia|Four hypoxia sessions, consisting of 15 cycles of hypoxia (21%, 17%, 13% or 9% O2), each of which lasts up to 60 seconds, interspersed with up to 90-second normoxic episodes.
214294591|NCT03009565|OTHER|coronary artery disease|
214668247|NCT02236624|BEHAVIORAL|Aerobic exercise|
214668248|NCT00630032|DRUG|cyclophosphamide|500 mg/m² every 3 weeks
214668249|NCT00630032|DRUG|Docetaxel|100 mg/m² every 3 weeks
214668250|NCT00630032|DRUG|epirubicin hydrochloride|100 mg/m² every 3 weeks
214668251|NCT00630032|DRUG|fluorouracil|500 mg/m² every 3 weeks
214668252|NCT00630032|DRUG|ixabepilone|40 mg/m² every 3 weeks
214668253|NCT00870493|DRUG|Aliskiren|Aliskiren 300 mg daily oral
214668254|NCT00870493|DRUG|Placebo|starch tablet, 300 mg/day
214668255|NCT01893177|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
214668256|NCT01355432|OTHER|Observation|There is no intervention, this is an observational study.
214668257|NCT02332915|BEHAVIORAL|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
214889141|NCT05379244|BEHAVIORAL|CBT-i|Behavioral intervention based on Cognitive Behavioral Therapy for insomnia, adjusted for psychiatric patients with anxiety disorders, affective disorders and trauma
214889142|NCT05725863|OTHER|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a structured group intervention developed by Segal et al. (2002). The intervention consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
214889143|NCT03878212|OTHER|mHealth application with interactivity|a mHealth device with interactivity with nurse case manager
214889144|NCT03878212|OTHER|mHealth application|a mHealth device
214889145|NCT05022212|DRUG|LACTIN-V|administered vaginally
214889146|NCT05022212|DRUG|Placebo|administered vaginally
214889147|NCT01362543|OTHER|Cognitive behavioural therapy (stress management)|Following a manual
214889148|NCT01362543|OTHER|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
214889149|NCT01979991|PROCEDURE|CT Imaging and Reconstruction|"Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.~Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used."
214889150|NCT04525937|OTHER|Patient Questionnaire|Patient Questionnaire
214889151|NCT04525937|OTHER|Provider Questionnaire|Provider Questionnaire
214889152|NCT03426189|PROCEDURE|Leukapheresis|Blood will be taken by a needle inserted into a vein in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out of the machine for purposes of this research. The rest of the blood will be returned through a needle in the other arm.
214889153|NCT03426189|PROCEDURE|Lymph node biopsy|Ultrasound will be used to localize the position of one lymph node in the groin. Under a light general anesthetic, one lymph node will be removed.
214889154|NCT06384833|DRUG|Ascorbic acid|Vitamin C (solution) 500 mg IV q4h for 4 doses PO d0 Vitamin C (tablet) 100mg 5 tab PO BID for 45 days
214889155|NCT06384833|DRUG|N-acetyl cysteine|NAC (effervescent) 600mg 1 tab PO OD for 45 days
214889156|NCT06384833|OTHER|placebo|pharmacologically inactive substance
214889157|NCT04611633|COMBINATION_PRODUCT|Trimbow|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
214889158|NCT01682811|DRUG|Part 1 Levulan injection|Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
214889159|NCT01682811|DRUG|Part 1 Levulan surface application|Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
214889160|NCT01682811|DRUG|Part 1 Levulan surface application twice|Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
214889161|NCT01682811|DRUG|Part 1 Levulan surface application twice with microneedling|Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
214889162|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
215049184|NCT04495686|BEHAVIORAL|Telehealth-delivered Care Coordination Program|"Participants in the interventional arms of this program will be assigned a Dementia Care Manager (DCM) who will work with caregivers to develop goals and plans that are aimed at providing the best support possible, specific to your needs. These services include supportive counseling, education on dementia, information and referrals to community-based organizations, behavioral symptom management training and assistance with finding available community and government-sponsored programs.~DCM's will meet with you at least once monthly and will be available if you need assistance between meetings. At the first meeting, your DCM will explain the questionnaires you will take and how to use the technology in the program. They will then provide a link, via email, where you will download the free teleconferencing software that will be used throughout the program. Questionnaires will then be sent via email invitations through a secure survey platform."
215049185|NCT02372695|DRUG|Paricalcitol|
214294592|NCT04976166|BEHAVIORAL|Education|More informed and detailed education
214294593|NCT04976166|BEHAVIORAL|Education|Shared decision making
214668258|NCT05113524|OTHER|Dance|The dance program consists of 3 months of dance classes. Classes are specifically designed for people with Parkisnon's and lead by a qualified dance instructor experienced in teaching this population. The in-person dance classes are conducted in an appropriate room with chairs and ballet barres once a week. In addition, the participants received a CD containing a video of the recorded dance routine to be performed at home once a week. The class typically included a warm-up (10-15 min.), barre ballet exercises (10-15 min.), general dance-related activities (15-20 min), and a cool-down (10-15 min).
214889163|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
215049186|NCT05945381|COMBINATION_PRODUCT|GIC on MIH|Subjects will be seated in a dental chair set-up using standard infection control guidelines. Then the study and its objectives will be explained to the patients and their caregivers. The tooth will be cleaned with a prophylactic paste and brush for complete debris and plaque removal. The tooth will then be dried with a cotton roll, as the patient doesn't tolerate the air-drying (which is the case in SCASS 2 and 3). Moisture control will be kept with cotton roll, the tooth is then sealed with a hard setting glass-ionomer cement (IonoStar Plus, VOCO, Germany) followed by an application of a surface coat (Easy Glaze, VOCO, Germany) for moisture and dehydration protection after sealant application. The distributed questionnaire will include questions regarding the attitude of the child's caregiver to the idea and their estimation of the child's fair regarding dental visit.
215049187|NCT00769795|DRUG|IMC-A12|IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
215049188|NCT00769795|DRUG|Bicalutamide|Bicalutamide 50 mg daily orally for 12 weeks
215049189|NCT00769795|DRUG|Goserelin|10.8 mg subcutaneous once
215049190|NCT04725019|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during 20 min of motor training.
215049191|NCT04725019|BEHAVIORAL|Motor training|Participants will engage in a high number of repetition of movements that use both hands while playing with toys and games. Training will be provided 20 min/day, for 5 consecutive days.
214294594|NCT04976166|BEHAVIORAL|Education|education as usual
214294595|NCT02956265|DEVICE|bimodal optical spectroscopy|an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
214294596|NCT00826020|DRUG|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
214294597|NCT00678119|BIOLOGICAL|AGS-003|Dendritic cell Immunotherapeutic
214294598|NCT00678119|DRUG|Sunitinib|An approved drug for the treatment of RCC
214294599|NCT05959330|OTHER|Neural Tension Technique(ulnar, median, radial)|Neural Tension Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
214668259|NCT05113524|OTHER|No intervention|Controls, not alter their personal lifestyle, but will undergo the same testing as the exercise intervention group.
215049192|NCT03483454|OTHER|Exercise class|Same as above.
215049193|NCT03483454|OTHER|Home exercise|Same as above.
215049194|NCT03138785|DRUG|topical voriconazole / levofloxacin systemic itraconazole|starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
215049195|NCT03138785|RADIATION|CXL|30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
215049196|NCT00003631|BIOLOGICAL|filgrastim|
215049197|NCT00003631|DRUG|carboplatin|
215049198|NCT00003631|DRUG|carmustine|
215049199|NCT00003631|DRUG|cyclophosphamide|
215049200|NCT00003631|DRUG|cytarabine|
215049201|NCT00003631|DRUG|etoposide|
215049202|NCT00003631|DRUG|ifosfamide|
215049203|NCT00003631|DRUG|melphalan|
215049204|NCT00003631|PROCEDURE|bone marrow ablation with stem cell support|
214477819|NCT06861959|DEVICE|Device: Pressure-Controlled Ventilation (PCV)|Initial peak inspiratory pressure adjusted to deliver a tidal volume of 8 mL/kg of ideal body weight Respiratory rate adjusted to maintain an end-tidal CO₂ (EtCO₂) level of 30-35 mmHg Inspiratory-expiratory ratio: 1:2 PEEP: 5 cmH₂O Mechanical ventilation was provided using a Datex-Ohmeda Avance Anesthesia Machine (GE Healthcare, USA) Measurements were taken at four predefined time points (T1-T4)
214889164|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
214889165|NCT04886661|OTHER|CHRONIC NECK PAIN|Demographic information will be collected. Neck Disability Index will be filled. Physical examination will be performed.
214889166|NCT02694328|DRUG|ALKS 3831|Daily dosing
215049205|NCT00003631|PROCEDURE|peripheral blood stem cell transplantation|
215049206|NCT00003631|RADIATION|radiation therapy|
215049207|NCT00600067|DRUG|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
215049208|NCT00600067|DRUG|Placebo|Oral placebo capsules, once daily, 28 weeks
215049209|NCT00869167|DRUG|Ramelteon|melatonin agonist
215049210|NCT05847647|OTHER|Retrograde Filling Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect.
215049211|NCT05847647|OTHER|Retrograde Filling+L-PRF Group|2\. Group: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect (
215049212|NCT05847647|OTHER|(Orthograde Filling Group / OG Group).|3\. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect
215049213|NCT05847647|OTHER|(Orthograde Filling+L-PRF Group|4\. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect
215049214|NCT04339413|DRUG|Gantenerumab|Gantenerumab was administered as SC injection Q4W.
215049215|NCT01684839|DEVICE|Pedicled nerve flap|This nerve flap is a vascularized nerve graft
215049216|NCT02043990|DEVICE|Noninvasive NAVA ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
214668260|NCT04095208|DRUG|Association of Nivolumab + Relatlimab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[80 mg\]."
214668261|NCT04095208|DRUG|Nivolumab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\]."
214668262|NCT05126095|RADIATION|Radical radiotherapy|Intensity-modulated radiation therapy (IMRT)
214668263|NCT02798081|BEHAVIORAL|Single arm study|In Step 1 the elderly will participate of eight conventional computer classes which they were spontaneously enrolled. In Step 2, 10 minutes of the next eight classes will be used to practice serious games using virtual reality, using physical interface (keyboard or mouse).
214668264|NCT03071432|DIAGNOSTIC_TEST|Paced breathing at 6, 10 and 15 breaths per minute|
214668265|NCT02769871|BEHAVIORAL|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
214889167|NCT02694328|DRUG|Olanzapine|Daily dosing
214889168|NCT00890604|OTHER|Stepwise normothermia protocol|Use of standard care interventions in a protocolized/step-wise fashion instead of ad hoc based on nurse decision making which may include antipyretics, physical cooling measures.
214889169|NCT00890604|DRUG|Ibuprofen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
214889170|NCT00890604|DRUG|Acetominophen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
214889171|NCT06468241|OTHER|Progressive relaxation exercise|For the progressive relaxation exercise group, a progressive relaxation exercise session will be applied to the participants 3 times a week for four weeks.
214889172|NCT06468241|OTHER|Listening to music|"For the music listening group, the participants will listen to the Turkish music makams (uşşak and rast) three times a week for four weeks."
214889173|NCT02303912|DRUG|Nuc-1031 and Carboplatin|Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
214889174|NCT00054457|DRUG|capecitabine|
214889175|NCT00054457|DRUG|docetaxel|
215049217|NCT02132897|DRUG|Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose|Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
215049218|NCT02132897|DRUG|Tegretol CR 400 Single Dose-Auration CR 400 Single Dose|Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
214294600|NCT05959330|OTHER|Neural Slider Technique (ulnar, median, radial)|Neural Slider Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
214294601|NCT05959330|OTHER|Neural Tension Technique and Neural Sliding Technique(ulnar, median, radial)|Neural Tension and Sliding Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
214889176|NCT05496491|RADIATION|Neoadjuvant Chemoradiotherapy|5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
214889177|NCT05496491|DRUG|Adjuvant Chemotherapy|8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)
214889178|NCT05496491|DRUG|Consolidation Chemotherapy|CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
214889179|NCT05220163|DIAGNOSTIC_TEST|CAD|It is an artificial intelligence (AI) system for detection of TB on CXR images. The system input is a frontal CXR, and the outputs are 1) a heatmap indicating suspicious regions on the image; and 2) a score (0-100) which implies the likelihood that the x-ray image shows TB.
214889180|NCT05220163|DIAGNOSTIC_TEST|Xpert|A novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at POC in a mobile van.
214889181|NCT02514447|DRUG|Trilaciclib|
214889182|NCT02514447|DRUG|Placebo|
214889183|NCT02514447|DRUG|Topotecan|
214889184|NCT05644548|OTHER|No intervention|No intervention
214889185|NCT01758081|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
214889186|NCT01758081|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
214889187|NCT01758081|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
214889188|NCT01758081|DIETARY_SUPPLEMENT|fish oil placebo|
214889189|NCT06846450|RADIATION|Intensity-modulated proton radiation therapy|Intensity-modulated proton therapy, will be delivered to the high risk area with a dose of 56 GyRBE in 28 fractions, and if applicable, to the low risk area with a dose of 50.4 GyRBE in 28 fractions.
214889190|NCT06846450|RADIATION|Intensity-modulated photon radiation therapy|Intensity-modulated photon therapy, will be delivered to the high risk area with a dose of 56 Gy in 28 fractions, and if applicable, to the low risk area with a dose of 50.4 Gy in 28 fractions.
214889191|NCT06846450|RADIATION|Intensity-modulated carbon ion radiation therapy|Intensity-modulated carbon ion radiation therapy will be delivered as a boost with a dose of 17.5 GyRBE in 5 fractions to gross tumor.
214889192|NCT06846450|DRUG|Concurrent chemotherapy|Concurrent chemotherapy will be administered on a weekly basis.
214889193|NCT06846450|DRUG|Induction chemotherapy|Cisplatin-based induction chemotherapy will be administered every three weekly.
214889194|NCT05208216|DEVICE|Geko device|A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
214889195|NCT05208216|DEVICE|Flowtron DVT|A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
214889196|NCT04523987|DRUG|Ciprofloxacin|Subjects enrolled will be administered oral ciprofloxacin twice a day throughout the course of each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy.
214889197|NCT04972721|OTHER|No treatment given|The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.
214889198|NCT03983837|OTHER|Neocate Splash|Neocate Splash is a hypoallergenic, amino acid based elemental liquid diet that is taken orally.
214889199|NCT05494346|DEVICE|Measurement of peak nasal flow.|Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
214889200|NCT06395168|OTHER|Combined Newborn and Lactation Visit|See Arm/Group Description
214889201|NCT06548776|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy (MRS) Scan|Participants will receive MRS Scan
214889202|NCT06218550|DRUG|Delta-9-THC|Acute self-administration of inhaled or oral ∆9-THC by healthy adult research volunteers
214889203|NCT06218550|DRUG|Delta-8-THC|Acute self-administration of inhaled or oral ∆8-THC by healthy adult research volunteers
214889204|NCT06218550|DRUG|Placebo|Consumption of a brownie or inhalation of ambient air through a cannabis vaporizer by health adult research volunteers
214889205|NCT06439277|DRUG|Tirzepatide|Administered SC
214889206|NCT06439277|DRUG|Placebo|Administered SC
214889207|NCT05706558|PROCEDURE|Esophagectomy|Esophagectomy
214889208|NCT06400329|OTHER|Pain Neuroscience Education|PNE focuses more on the neurophysiology of pain and approaches it from the perspective that knee OA pain is manageable, using neutral to positive language and emphasizes the importance of physical function and staying active
214889209|NCT06400329|OTHER|Standard Pain Education|In Standard Pain Education, the emphasis is on the structural pathology of knee OA and the outdated but common understanding of the disease process as a degenerative one, potentially conveying negative and threatening language
214889210|NCT06161441|DRUG|Fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
214889211|NCT06161441|DRUG|Cemiplimab|Administered IV Q3W
214889212|NCT06161441|DRUG|Pemetrexed|Administered IV Q3W
214889213|NCT06161441|DRUG|Paclitaxel|Administered IV Q3W
214889214|NCT06161441|DRUG|Carboplatin|Administered IV Q3W
214889215|NCT06161441|DRUG|Cisplatin|Administered IV Q3W
214889216|NCT06161441|DRUG|Placebo|Administered IV Q3W
214889217|NCT05405790|PROCEDURE|thoracic endovascular aortic repair|In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta.
214889218|NCT03404024|BIOLOGICAL|Stage 1-Low dose VM202RY|Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
214889219|NCT03404024|BIOLOGICAL|Stage 1-Middle dose VM202RY|Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
214889220|NCT03404024|BIOLOGICAL|Stage 1-High dose VM202RY|Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
214889221|NCT03404024|DRUG|Stage 2-Placebo|Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
214889222|NCT03404024|BIOLOGICAL|Stage 2-Low dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
214889223|NCT03404024|BIOLOGICAL|Stage 2-High dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
214889224|NCT03404024|DEVICE|C-Cathez® Catheter|Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
214889225|NCT05621096|RADIATION|Bridging radiation therapy|Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.
214889226|NCT05621096|BIOLOGICAL|Liso-cel|"Day 0: Patients will receive an infusion of liso-cel CAR T-cell product.~Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures."
214889227|NCT05621096|RADIATION|Post-infusion radiation|Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.
214889228|NCT04710043|DRUG|BNT152|intravenous
214889229|NCT04710043|DRUG|BNT153|intravenous
214889230|NCT04681131|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
214889231|NCT04681131|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
214889232|NCT05078957|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and annually during 5 years
214889233|NCT05078957|OTHER|Frailty phenotype|According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
214889234|NCT05078957|OTHER|Blood plasma collection|Blood plasma collection to measure persistent inflammation and immune activation
214889235|NCT02015117|OTHER|Laboratory Biomarker Analysis|Correlative studies
214889236|NCT02015117|OTHER|Pharmacological Study|Correlative studies
214889237|NCT02015117|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of the tumor
214889238|NCT02015117|DRUG|Trametinib|Given PO
214889239|NCT02015117|RADIATION|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
214889240|NCT06330441|PROCEDURE|endoscopic ultrasonography|endoscopic ultrasonography - frequency defined by arm
214889241|NCT06330441|PROCEDURE|magnetic resonance|magnetic resonance - frequency defined by arm
214889242|NCT06330441|DIAGNOSTIC_TEST|laboratory examination|hematology, biochemistry, Na+, K+, Cl-, Ca2+, bilirubin, ALT, AST, GGT, ALP, lactate dehydrogenase, creatinine, urea, fasting glycemia, HbA1c, alpha-amylase, LPS, albumin, total protein, CA19-9, CEA
214889243|NCT05336695|DIAGNOSTIC_TEST|PET/MR Imaging|PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol
214889244|NCT05336695|DRUG|64Cu-FBP8|Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
214889245|NCT05587127|BEHAVIORAL|Cognitive Behavioral Therapy|Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.
214889246|NCT05705570|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
214889247|NCT05705570|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
214889248|NCT05705570|BIOLOGICAL|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0"|"Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
214889249|NCT06557863|BEHAVIORAL|WeCareToFeedDysphagia web tool|The web tool uses written and video content, care-partner testimonials, frequently asked questions, and resource links to provide accurate information (e.g., dysphagia diets), set realistic expectations, identify/support feeding goals (quality of life considerations), acknowledge/support care-partner feelings, and provide competencies/skills for oropharyngeal dysphagia (OD) management.
214889256|NCT04677569|DRUG|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes
214889257|NCT04677569|DRUG|Azithromycin|Oral tablet
214889258|NCT04677569|DRUG|Ethambutol|Oral tablet
214889259|NCT04677569|DRUG|ELC (matching placebo for ALIS)|Inhalation via nebulization over approximately 6 to 15 minutes
214889260|NCT04069312|DRUG|Roflumilast|Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
214889261|NCT04069312|DRUG|Azithromycin|Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
214668266|NCT02769871|BEHAVIORAL|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
214889262|NCT06582693|OTHER|Refer2Quit|The Refer2Quit intervention consists of automatic connection to the adult participant's choice of any or all of four evidence-based tobacco treatment options (varenicline, NRT, quitline, and/or smokefreeTXT), as well as motivational counseling provided by the study team. Supportive and motivational text messaging is also included in the intervention to connect or reconnect adult participants to treatments as needed. Text messaging and support would also focus on supporting appropriate use of NRT and/or varenicline if indicated.
214889263|NCT05399992|OTHER|Inclisiran|Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.
214889264|NCT03367572|DRUG|Dexamethasone|Given PO
215049219|NCT06261008|BEHAVIORAL|TI group|CRC screening is arranged by referring the participants to the government-subsidized population-based CRC screening program. Our center is a PCP clinic offering FIT screenings under the Program. Colonoscopy is arranged if the FIT result is positive. Participants are instructed to repeat FIT at any PCP clinic 2 years after receiving a negative result. Based on the 34% local FIT screening adherence rate under SC and the assumption of improved FIT adherence to 49% after interactive TI, a minimum sample size of 332 subjects (166 per group) is required to achieve a statistical significance of p\<0.05 and power of 80%. Assuming that 10% of the subjects will drop out, be lost to follow-up, or have incomplete chatbot conversations, the required sample size is rounded up to 370 (185 per group)
214668267|NCT03299504|OTHER|Exercise|5 days per week, 2.5 hours per day strength, balance and endurance training on an outpatient basis
214668268|NCT02862912|DRUG|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
214668269|NCT02862912|DRUG|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
214889265|NCT03367572|OTHER|Laboratory Biomarker Analysis|Correlative studies
214889266|NCT03367572|DRUG|Netupitant/Palonosetron Hydrochloride|Given PO
214889267|NCT03367572|DRUG|Olanzapine|Given PO
214889268|NCT03367572|OTHER|Placebo|Given PO
214889269|NCT03367572|DRUG|Prochlorperazine|Given PO
214889270|NCT03367572|OTHER|Quality-of-Life Assessment|Ancillary studies
215049220|NCT03654118|OTHER|Phone follow-up|"Through a short phone interview :~* Determination of a complication (Infection, capsulitis, recurrence)~* Determination of the Rowe score~* Determination of the Walch-Duplay score"
215049221|NCT02644824|DEVICE|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
215049222|NCT01224236|DRUG|Iron Supplement|2 mg/kg/day elemental iron as multivitamin with iron solution
215049223|NCT01224236|DRUG|control|multivitamin solution without iron
214294602|NCT05554757|DEVICE|conventional rubber dam system|rubber dam is a protective sheet with a hole that a dental professional positions over a tooth during an endodontic procedureEndodontists . This allows to isolate the treatment area with a dental clamp around the tooth. The dental sheet is placed around the in the Dental Rubber Dams and then a u-shaped device is hooked around. This isolates the single tooth where dental treatment will be conducted.
214294603|NCT05554757|DEVICE|OPTRADAM|OptraDam Plus is a three-dimensional rubber dam that is flexible and has an anatomical shape, automatically stretched in an oral direction, an automatic hold of the device in the oral cavity is ensured.
214294604|NCT06176573|PROCEDURE|Chlorhexidine|Pre-operative and post-operative vaginal cleansing.
214668270|NCT02862912|DRUG|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
214668271|NCT02862912|DRUG|Saline|Preservative free normal saline (0.3 ml) to bring the volume to \~ 2 ml
214889271|NCT05229718|OTHER|Diabetes Collaborative Care Model for Young Adults|We designed a diabetes collaborative care model for young adults that incorporates a mental health provider alongside a diabetes care provider during joint office visits to facilitate screening and treatment of psychosocial determinants of diabetes management. The Massachusetts General Hospital (MGH) Diabetes Center will be piloting this model with a multi-disciplinary team of diabetologists, nurse practitioners, diabetes nurse educators, and mental health provider. Patients scheduled to be seen in the diabetes collaborative care model will continue to follow in the diabetes collaborative care model, with follow up visits every 3-4 months. All patients will receive routine diabetes care with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers.
214889272|NCT05229718|OTHER|Usual Care Model|Patients enrolled in this arm will receive routine diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center, with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers. In the usual care model, behavioral/mental health and social work services are available on a referral basis and are not integrated into a patients' routine appointment. Screening and treatment of psychosocial determinants of diabetes management are at done at the discretion of the patients' provider. Frequency of follow up visits is at the discretion of the patients' provider.
215049224|NCT06511947|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
215049225|NCT00107731|DRUG|quetiapine fumarate|
215049226|NCT00107731|DRUG|lithium|
215049227|NCT00107731|DRUG|divalproex|
214668272|NCT05073770|DEVICE|Titan Condom|"The test condoms have the following specifications throughout the study:~1. The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm.~2. The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
215049228|NCT05073939|DRUG|Oral Oxytocin|Administration of oxytocin (24 international units) orally
215049229|NCT05073939|DRUG|Oral Placebo|Administration of placebo orally
215049230|NCT03606148|DIAGNOSTIC_TEST|SurePathTM|In the liquid-phase cytology, a fine-aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
215049231|NCT04711239|DIAGNOSTIC_TEST|PGT-A / niPGT-A|PGT-A and niPGT-A will be performed using next generation sequencing (NGS) analysis for chromosome copy number variation (CNV). Embryo transfers will rely solely on the results of PGT-A for trophectoderm biopsies.
215049232|NCT03924544|DRUG|Decorin|Antifibrotic agent
215049233|NCT03924544|DRUG|Mitomycin c|Antifibrotic agent
215049234|NCT03291106|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2
215049235|NCT03291106|DIAGNOSTIC_TEST|tests of microsatellite instability|microsatellite instability in tissues of endometrial cancer
215049236|NCT03291106|DIAGNOSTIC_TEST|clinical criteria of Lynch syndromes|Amsterdam I or II criteria and Bethesda criteria
215049237|NCT03291106|DIAGNOSTIC_TEST|sequencing for mismatch repair genes|next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
215049238|NCT04304079|DEVICE|ARssist system|As stated in ARssist system arm description
215049239|NCT01111227|DRUG|Propofol and isoflurane|Comparison of two anesthetic drugs
215049240|NCT05085483|DIETARY_SUPPLEMENT|Nutritional Ketogenic Supplement|This trial has 5 steps: (1) a 4-week run-in baseline; (2) a 4-week intervention phase to either active or placebo (3) a 4-week phase of washout; (4) the cross-over to the second 4-week active or placebo phase; (5) a 4-week follow-up.
215049241|NCT05085483|DIETARY_SUPPLEMENT|Isocaloric placebo supplement|Isocaloric placebo supplement
215049242|NCT00401843|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
215049243|NCT00401843|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
215049244|NCT00401843|DRUG|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
214477820|NCT06861959|DEVICE|Device: Pressure-Controlled Volume-Guaranteed Ventilation (PCV-VG)|Pressure-controlled mode with volume guarantee to maintain a tidal volume of 8 mL/kg of ideal body weight Respiratory rate adjusted to maintain an end-tidal CO₂ (EtCO₂) level of 30-35 mmHg Inspiratory-expiratory ratio: 1:2 PEEP: 5 cmH₂O Mechanical ventilation was provided using a Datex-Ohmeda Avance Anesthesia Machine (GE Healthcare, USA) Measurements were taken at four predefined time points (T1-T4)
214889273|NCT05849259|OTHER|Dementia Care Quality at Home|Each of the two HBPC practices will identify at least two trained Dementia Care Quality at Home Champions who will be trained in the intervention comprised of 1) a standardized assessment tool to assess PLWD and caregiver needs; 2) six modules created to optimize the well-being of the PLWD and their caregiver; and 3) regular team-based review of persons participating in the program to address care challenges and a team-based case conference approach to solve these challenges.
214889274|NCT06472973|OTHER|Post-transplant addiction intervention|The first addiction consultation will be conducted using the BRENDA method which allows the addiction specialist to carry out a psychosocial assessment, to entrust the results of this assessment to the participant, to answer their questions and to evaluate their reactions. Risk factors for alcohol relapse will be collected: social determinants, male gender, psychiatric comorbidities, duration of alcohol abstinence before LT(≥ or \< 6 months) and young age (\< 40 years). If the addiction specialist notes the presence of at least 3 risk factors for alcohol relapse, targeted addiction follow-up will be proposed to the participant including outpatient consultations with motivational interview at least every 4 weeks +/- pharmacological treatment of alcohol use disorder.In case of alcohol relapse or a period of high vulnerability to relapse, specific hospitalizations can be scheduled. If the participant has \<3 risk factors, an addictology consultation every 6 months at most will be proposed.
214668273|NCT04210713|DRUG|Minocycline|200 mg/day
214889275|NCT06199921|DRUG|Atorvastatin 20mg|Participants will receive oral atorvastatin 20mg daily for 16 weeks
214889276|NCT06199921|DRUG|Atorvastatin 40mg|Participants will receive oral atorvastatin 40mg daily for 16 weeks
214889277|NCT06199921|DRUG|Atorvastatin 60mg|Participants will receive oral atorvastatin 60 mg daily for 16 weeks
214889278|NCT06199921|DRUG|Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)|Participants will receive 8 weeks of daily oral treatment with rifampin, isoniazid, pyrazinamide, ethambutol, followed by 16 weeks of daily oral treatment with rifampin, isoniazid
214889279|NCT05910840|OTHER|Support-t|Support-t plus usual diabetes care for 18 months
214889280|NCT06561334|PROCEDURE|Botulinum toxin injections|Botulinum toxin injection to ease spasms of vocal cord
214889281|NCT06568042|DRUG|LY3848575|Administered SC
215049245|NCT00401843|DRUG|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
215049246|NCT01534286|DRUG|Theramine|Theramine 2 capsules 3 times per day
215049247|NCT01534286|DRUG|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
215049248|NCT02014805|RADIATION|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
215049249|NCT04649658|BEHAVIORAL|Prone position|Prone position maintained at least 3 hours/day
214668274|NCT04210713|DRUG|Sugar pill|Matched placebo
214889282|NCT06568042|DRUG|Placebo|Administered SC
215049250|NCT02103062|DRUG|ABI-007|
215049251|NCT01862406|OTHER|Label|Participants were presented with either a generic label or a brand-name label
215049252|NCT04878601|OTHER|Home-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
215049253|NCT04878601|OTHER|Facility-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
214889283|NCT05866432|DRUG|Datopotamab deruxtecan|Will be given until PD or withdraw
214889284|NCT03504644|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214889285|NCT03504644|PROCEDURE|Computed Tomography|Undergo CT scan
214889286|NCT03504644|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214889287|NCT03504644|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214889288|NCT03504644|DRUG|Venetoclax|Given PO
214889289|NCT03504644|DRUG|Vincristine Liposomal|Given IV
214889290|NCT03504644|DRUG|Vincristine Sulfate|Given IV
214889291|NCT05186116|PROCEDURE|Living donor liver transplant, Split liver transplant, RAPID, DDLT|Transplantation of part of the liver from a living donor, or entire cadaveric graft
215049254|NCT02855658|DRUG|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
215049255|NCT02855658|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
215049256|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2|
215049257|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2|
214889292|NCT05967624|OTHER|Teleconsultation|Each subject will be remotely assessed by a Medical Control Physician (MCP) using Zoom Pro (HIPAA-compliant video-conferencing software) on tablet devices as a low-cost mobile telemedicine platform and the Respiratory Observation Checklist, validated for telemedicine use in emergency settings. All prehospital clinical decision making will be made at the discretion of evaluating paramedics as per standard state-approved protocols and procedures, independent of checklist results.
214889293|NCT06961331|DRUG|Tucatinib|As provided in real world practice.
215049258|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2|
214889294|NCT06961331|DRUG|Trastuzumab|As provided in real world practice.
215049259|NCT02422979|COMBINATION_PRODUCT|PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
215049260|NCT02422979|COMBINATION_PRODUCT|PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
215049261|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
215049262|NCT03844308|BEHAVIORAL|Isha Kriya Meditation|Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
215049263|NCT00761345|DRUG|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
215049264|NCT00761345|DRUG|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
215049265|NCT00761345|RADIATION|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
215049266|NCT00948077|DRUG|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---\> Treatment B (6th day) ; Treatment B (5th day) ---\> Treatment A (6th day)"
215049267|NCT04255771|DRUG|Gemcitabine|Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
215049268|NCT04255771|DRUG|Placebos|Use a placebo as a comparison
215049269|NCT05775302|OTHER|IASTM of Gastrocnemius + Conventional therapy|The SWEEP technique will be performed downwards from the popliteal region to the Achilles tendon for 60 seconds, 30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
214477821|NCT05115682|BEHAVIORAL|High-intensity Intermittent Exercise|The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).
214889295|NCT06961331|DRUG|Capecitabine|As provided in real world practice.
215049270|NCT05775302|OTHER|IASTM of AchillesTendon + Conventional Therapy|Participants will receive a maximum of 60 seconds\<30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
215049271|NCT06017492|BEHAVIORAL|video assisted discharge teaching|Patients will be educated using the video assisted discharge teaching. The educational content will be in English and will focus on the following topics: surgical process, medication use complication after surgery, pain management, wound care, nutrition, self-care after, surgery, home care after surgery and situations to refer to a physician.
215049272|NCT03435068|DEVICE|Ceramic rotary bur|Gingivoplasties were performed with the same ceramic burs to easily provide a knife-edge appearance with ceramic rotary bur
215049273|NCT03435068|DEVICE|Diode laser|The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power were used in the study.
215049274|NCT03435068|DEVICE|Scalpel|Scalpel surgery were performed as control group (conventioanl group).
214889296|NCT06453213|DRUG|Cenobamate|"The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a certain type of seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day).~The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a certain type of seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day)."
215049275|NCT02030821|DRUG|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
215049276|NCT02030821|DRUG|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
215049277|NCT00484263|DRUG|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
214294605|NCT00562939|BIOLOGICAL|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
214294606|NCT00562939|BIOLOGICAL|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
214294607|NCT04379089|OTHER|Observational study only|No Intervention
214294608|NCT01244906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
214294609|NCT04902716|BEHAVIORAL|Design course|Precision nursing is a new trend in nursing in recent years. It is based on individual differences in disease type, gender, lifestyle, family, race, social and cultural factors, etc., to provide the most suitable empirical-based nursing treatment.Diverse courses include music, breathing exercises, cognitive training, hand-made knitting, etc.
214294610|NCT06031454|DRUG|Midazolam|oral
214294611|NCT06031454|DRUG|Omeprazole|oral
214294612|NCT06031454|DRUG|Rosuvastatin|oral
214294613|NCT06031454|DRUG|Verapamil|oral
214294614|NCT06031454|DRUG|Rifampin|oral
214294615|NCT06031454|DRUG|Leritrelvir|oral
214294616|NCT00388635|DRUG|Velcade|Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)
214294617|NCT00388635|DRUG|Melphalan|Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II
214294618|NCT00388635|DRUG|Prednisone|Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)
214294619|NCT03040466|DEVICE|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
214294620|NCT03040466|DEVICE|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
214294621|NCT00810290|BEHAVIORAL|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
214294622|NCT00584142|BEHAVIORAL|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
214294623|NCT04237090|DRUG|Diphenhydramine|Drug identification number : 02369567
214477822|NCT02954939|DRUG|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
214889297|NCT06479070|OTHER|Blood samples|"A blood sample of 20 mL (2 tubes of 10 mL) for research purposes will be collected during:~* The day of the centering scan (Visit 1);~* During treatment at Week 2 and Week 6 (+/- 1 week) (Visit 2 and 3);~* The day of the post-therapeutic visit scheduled between 3 and 5 weeks after the end of radiotherapy, whether or not associated with concomitant treatment (Visit 4);~* At each monitoring visit following radiotherapy associated or not with concomitant treatment (every 3 months for 24 months (V5 to V12 ; V12 = final visit)~* When the disease progresses before initiation of the 2nd line of treatment."
214889298|NCT05714085|DRUG|Vericiguat tablet|2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
214294624|NCT04237090|DRUG|Cetirizine|Drug identification number : 02231603
214294625|NCT04237090|DRUG|Lactose pill|Natural product number : 00501190
214294626|NCT04237090|DRUG|Sodium chloride 0.9%|Drug identification number : 00037796
214294627|NCT05551494|DIAGNOSTIC_TEST|Urinary sample|"At study entry, we will collect urinary samples from women. Participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).~In addition, women will be asked to report about their habits about consumption of plastic"
214294628|NCT00517621|DRUG|Paclitaxel|
214294629|NCT00517621|DRUG|EPO|
214294630|NCT04983992|PROCEDURE|extracapsular release of lateral retinaculum|A new kind of surgery releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
214294631|NCT02492620|DRUG|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
214294632|NCT02505620|PROCEDURE|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
214294633|NCT02505620|PROCEDURE|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
214477823|NCT02954939|DRUG|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
214477824|NCT06614218|DEVICE|Minimally Invasive Micro Sclerostomy|The MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the eye.
214294634|NCT02947529|DRUG|Tranexamic Acid|intravenous dose
214294635|NCT02947529|OTHER|Placebo|intravenous dose
214294636|NCT00204347|DRUG|risperidone|
214294637|NCT00294073|PROCEDURE|Fascia Iliaca Block|
214294638|NCT00294073|PROCEDURE|Femoral Block (with stimulating catheter)|
214889299|NCT05714085|DRUG|Vericiguat suspension|0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
214889300|NCT05714085|DRUG|Placebo tablet|Placebo for vericiguat administered orally once daily in tablet form
214889301|NCT05714085|DRUG|Placebo suspension|Placebo for vericiguat administered orally once daily in suspension form
214889302|NCT01742975|DEVICE|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
214889303|NCT06312020|DRUG|HZN-1116|Subcutaneous Administration
214889304|NCT06312020|DRUG|Placebo|Subcutaneous Administration
214889305|NCT05403216|OTHER|no intervention|
214889306|NCT03784781|BIOLOGICAL|Biopsy|Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe
214889307|NCT03784781|BIOLOGICAL|Blood collection|Blood collection (+15mL/ current care)
214889308|NCT03784781|BIOLOGICAL|Bronchoalveolar lavage|Bronchoalveolar lavage fluid (3mL/Kg)
214889309|NCT06397378|OTHER|short videos related to HPV and the HPV vaccine|"Eight college students created and developed four videos on human papillomavirus (HPV) and the HPV vaccine, designed to increase their knowledge and attitude, shape subjective norms, enhance perceived behavioral control, and strengthen intentions to receive the HPV vaccine. Two months after the video intervention, we will follow up with participants to collect their self-reported vaccine uptake status.~Outcomes will be compared with those of another group whose participants will watch a video presenting CDC information on HPV and the HPV vaccine, adapted into a narrated voiceover format."
214889310|NCT06397378|OTHER|CDC HPV Fact Sheet|"We did not develop this intervention. Instead, we will use information from the CDC website on HPV and the HPV vaccine and convert it into a video with a narrated voiceover format.~Because our student advisory board will develop four short videos, participants who are randomly assigned to the CDC fact sheet group will watch the converted CDC video four times to ensure that all groups are exposed to the same number of videos.~Here is the CDC link: https://www.cdc.gov/hpv/vaccines/?CDC\_AAref\_Val=https://www.cdc.gov/hpv/parents/vaccinesafety.html"
215049278|NCT02913963|DEVICE|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
214889311|NCT06352411|DRUG|BI 456906|Solution for injection
214889312|NCT06268080|BEHAVIORAL|Depth of anesthesia titration using pEEG|Titration of maintenance anesthetic agent (propofol infusion)
214889313|NCT01002495|BIOLOGICAL|VM202|Endocardial injections on Day 0.
215049279|NCT02913963|DEVICE|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
214294639|NCT00294073|PROCEDURE|Femoral Block (without stimulating catheter)|
215049280|NCT04092114|OTHER|Control|Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered
214477825|NCT06669611|DRUG|Camrelizumab combined GP chemotherapy|Camrelizumab was intravenously given at dose of 200 mg on day 1. The GP regimen included gemcitabine administered at a dose of 1 g/m2 on day 1 and day 8, cisplatin at a dose of 80 mg/m2 on day 1.Q3W 1 cycle, 4-6 cycles.
215049281|NCT04092114|BEHAVIORAL|CHARISMA Intervention|"SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable:~* Module A: General Partner Communication and Relationship Skills~* Module B: Partner Disclosure and Communication around PrEP Use~* Module C: Responding to Intimate Partner Violence and Safety Planning"
215049282|NCT03192137|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
214889314|NCT04342026|OTHER|Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors|Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
214889315|NCT02668510|BIOLOGICAL|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
214889316|NCT02668510|DRUG|Normal saline|placebo injection of normal saline immediately following shockwave therapy
214889317|NCT06470815|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
214889318|NCT06286046|DRUG|Mitapivat|Tablets
215049283|NCT03192137|OTHER|Vehicle|Vehicle twice daily for 16 days
214477826|NCT06669611|DRUG|Camrelizumab combined TPC chemotherapy|Camrelizumab was intravenously given at dose of 200 mg on day 1. The TPC regimen included nab-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle. Q3W 1 cycle, 4-6 cycles.
214889319|NCT05022147|DEVICE|High-Frequency-Only Stimulation|Control condition, constant high-frequency DBS stimulation (130Hz)
214889320|NCT05022147|DEVICE|Low-Frequency-Only Stimulation|Experimental condition, constant low-frequency DBS stimulation (60 Hz)
214889321|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 10 seconds for low, respectively.
215049284|NCT04314817|DRUG|Any drug used to treat Covid-19|lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
214889322|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 50 seconds for low, respectively.
215049285|NCT02799589|DRUG|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
215049286|NCT02799589|DRUG|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
215049287|NCT02799589|DRUG|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
215049288|NCT03218969|DRUG|Ecopipam|oral drug in subjection currently experiencing dopamine agonist induced augmentation
214889323|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 50 seconds for low, respectively.
214889324|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 10 seconds for low, respectively.
214889325|NCT05022147|DRUG|OFF Dopaminergic Medication|All six device interventions will be performed in medication OFF state
214889326|NCT05022147|DRUG|ON Dopaminergic Medication|All six device interventions will be performed in medication ON state
214889327|NCT04015596|DRUG|Naproxen Sodium|Dosed by weight (10mg/kg), twice daily, for 8 weeks
215049289|NCT03218969|DRUG|Placebo|matching placebo
214889328|NCT04015596|OTHER|Placebo|Participants take placebo pills twice daily, for 8 weeks.
214889329|NCT05585164|BEHAVIORAL|Engage & Connect (E&C)|"Engage \& Connect, is a remotely-delivered extension of Engage psychotherapy. It is aimed to increase engagement in rewarding social activities and in turn, reduce postpartum depression. In each session, the therapist will work with the patient to develop action plans to pursue rewarding social activities of their choice with the goal of reducing social isolation."
214889330|NCT05585164|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|SPR is a remotely-delivered intervention aimed to increase knowledge of postpartum depression and monitor mental health changes. In each session, the therapist will review the participant's symptoms and discuss information related to postpartum depression and changes after birth.
214889331|NCT03593590|DRUG|Ocrelizumab|Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
214889332|NCT02731638|DRUG|Intrastromal voriconazole|Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
214889333|NCT02731638|DRUG|Natamycin|Subjects will receive topical 5% natamycin drops hourly for 3 days.
214889334|NCT04132206|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
214889335|NCT06577636|PROCEDURE|Propofol anesthesia|EEG-guided infusion of anesthestetics
214889336|NCT05160597|PROCEDURE|Biopsy of Prostate|Undergo image-guided prostate biopsy
214889337|NCT05160597|OTHER|Gallium Ga 68 Gozetotide|Given IV
214889338|NCT05160597|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo standard of care TRUS
214889339|NCT05844033|OTHER|Screening|Blood tests
214889340|NCT03909737|DRUG|Azithromycin to pregnant women|Azithromycin to pregnant women at antenatal care visits and during delivery
214889341|NCT03909737|DRUG|Azithromycin to infants|Azithromycin to infants at 6 and 14 week EPI visits
214889342|NCT03909737|OTHER|Placebo to pregnant women|Placebo to pregnant women at antenatal care visits and during delivery
214889343|NCT03909737|OTHER|Placebo to infants|Placebo to infants at 6 and 14 week EPI visits
214889344|NCT03909737|OTHER|No intervention to pregnant women|No intervention to pregnant women
214889345|NCT05510622|OTHER|Vaginal swab and endometrial biopsy|A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
214889346|NCT06516510|DRUG|lutetium (177Lu) rhPSMA 10.1 and Pluvicto®|Radiopharmaceutical
214889347|NCT05076175|DRUG|Ozanimod|Specified dose on specified days
215049290|NCT02153489|DRUG|Aclidinium bromide|
214889348|NCT05626231|BEHAVIORAL|Training Intervention|"The training intervention is a modular online asynchronous training intervention designed to increase mental health providers' use of evidence-based practices with youth patients (ages 12-25). It was developed using community-engaged and human-centered design methods with key stakeholders (youth, their parents, mental health providers). In this open trial, the training will be offered to mental health providers at a multisite mental health clinic in the U.S. (referred to as pilot site herein)."
214889349|NCT05878093|DRUG|Dupilumab|solution for subcutaneous injection
214889350|NCT05878093|DRUG|Placebo|solution for subcutaneous injection
214889351|NCT05878093|DRUG|Budesonide|nasal spray (suspension)
214889352|NCT04190563|BEHAVIORAL|Pain De-Catastrophizing|Experimenter-administered education and skill practice.
214889353|NCT04190563|BEHAVIORAL|Pain Education|Experimenter-administered education.
215049291|NCT02153489|DRUG|Placebo|
215049292|NCT04793516|OTHER|VR Therapy Game|Participants will complete 15 sessions of VR-based therapy modules developed for use in helping people with spatial neglect. These 15 sessions will be completed over 4-5 weeks.
214889354|NCT06297603|DRUG|Retatrutide|Administered SC
214889355|NCT06297603|DRUG|Placebo|Administered SC
214889356|NCT04995029|DRUG|Transmucosal Buprenorphine|Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)
215049293|NCT01591629|DRUG|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
215049294|NCT01591629|DRUG|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
215049295|NCT01591629|DRUG|Placebo|Placebo
215049296|NCT04302116|DRUG|Combination therapy with vigabatrin and prednisolone|High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
215049297|NCT04302116|DRUG|Vigabatrin Tablets|Vigabatrin (50-150 mg/kg/day) twice daily for 4 months
214889357|NCT04995029|DRUG|Extended-release Buprenorphine|Administered by subcutaneous injection
214889358|NCT06173388|OTHER|Structured exercise training program + The swallow resistance exercise program.|Structured exercise training program + The swallow resistance exercise program.
214889359|NCT06173388|OTHER|Only the swallow resistance exercise program.|Only the swallow resistance exercise program.
214889360|NCT05353322|BEHAVIORAL|Sedentary Break (Walking) Condition|For the sedentary break (walking) condition, participants will be randomized to 1 of 25 combinations of frequency (5 doses: sedentary break every 30, 45, 60, 90, or 120 minutes) and duration (5 doses: sedentary break duration of 1, 3, 5, 7, or 10 minutes). Participants will complete a 9-hour study visit and will remain seated throughout the lab visit and will take regular sedentary breaks by walking on a treadmill at 2.0 mph and 0% incline at specific frequency and duration (as determined by the randomization method) for the entirety of the visit.
214889361|NCT05353322|BEHAVIORAL|Sitting (Control) Condition|While completing the sitting (control) condition, participants will complete the 9-hour study visit by remaining seated and only standing up/walking to use the restroom at specified times.
214889362|NCT05353322|BEHAVIORAL|Controlled Diet|Participants in both the experimental and control groups will eat a controlled diet (breakfast, lunch, dinner, snacks) for two full days before each lab visit. They will also eat a controlled diet (breakfast, lunch) during each of the two lab visits. Participants will choose 1 of 3 dietary menus to eat for the study duration. Each meal will be individualized to meet 33% of daily estimated energy requirements. Target macronutrient profile will be 12-15% energy from protein, 55-58% from carbohydrate and 29-31% from fat; as well as 55 mmol of sodium and 24 mmol of potassium.
214889363|NCT06227052|DEVICE|Num Vapocoolant Spray|This is the study arm. Partipants in this arm will receive Num vapocoolant spray during their gynecologic procedure. They will receive the spray on their cervix right before the paracervical block. Num Vapocoolant spray is currently FDA approved to be used on skin prior to injections. The investigators are using it in the same fashion but in the vagina on the cervix to help with the pain of the paracervical block injection.
214889364|NCT06227052|OTHER|Placebo|This is the placebo. This group will receive Natures tear normal saline spray.
214889365|NCT05351983|PROCEDURE|Surgical biopsy of tumoral tissue for organoid generation|In surgically-resectable lesions, tumoral samples will be collected from the main surgical specimens, before sending it for final pathological examination. Patients with metastatic disease, will be offered to undergo port-a-cath implantation for chemotherapy delivery and concomitant laparoscopic surgical excisional biopsy of suspicious metastatic lesions. Intraoperative frozen section will confirm the presence of malignant cells in the sample. Part of the specimen will be sent for assessment of contamination by bacterial and/or fungal flora by the Microbiology Laboratory. The remaining tumour sample will be sent for patient-derived organoid (PDO) formation. Two patients' blood samples will be retrieved in ethylenediaminetetraacetic acid (EDTA) tubes and will be sent with the surgical specimen. All patients will then receive the standard of care (SOC) treatment according to the clinical judgement of the oncologist in charge, always within the framework of the international guidelines.
214889366|NCT06075537|DRUG|tividenofusp alfa|Intravenous repeating dose
214889367|NCT03751566|OTHER|Acupuncture|"Schedule of the acupuncture:~Acupuncture may be done ambulant or during hospitalisation . Acupuncture will be administered 1-3 times a week ( in case of severe toxicity and problems caused by the radiotherapy, it may continue also after the termination of the radiotherapy.) Acupuncture needles will be left for 5- 30 minutes, as per individual need of the patients.~Acupuncture will be performed by a physician trained in acupuncture."
215049298|NCT05784818|BEHAVIORAL|Up To Me Intervention + No Booster|Participants will complete two-hour sessions once a week over three weeks in which they complete modules in the Up To Me Workbook. These sessions are facilitated by a peer facilitator and a member of the USF Counseling center. Other members in the group sessions are university students who are peers who are also experiencing some form of shame around their mental health challenges.
215049299|NCT05784818|BEHAVIORAL|Up To Me Intervention + Booster|In addition to the Up To Me Intervention, participants also complete a booster/additional session where additional topics of the Up To Me workbook are covered. This additional session occurs four weeks after the completion of the third session.
215049300|NCT00657267|DRUG|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
215049301|NCT04373421|DRUG|Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
214294640|NCT04309656|DRUG|Pretomanid|"1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered."
214294641|NCT01678092|BIOLOGICAL|omalizumab|
214294642|NCT03772847|DRUG|ginkgolide|ginkgolide plus alteplase
214294643|NCT02164747|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
214889368|NCT03751566|DRUG|Standard supportive therapy|Standard supportive therapy
215049302|NCT04373421|PROCEDURE|St. John's wort oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
215049303|NCT04373421|PROCEDURE|Virgin olive oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
215049304|NCT03622047|DRUG|Dexmedetomidine ropivacaine|Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
215049305|NCT03622047|DRUG|No analgesia labor|No analgesia labor control group
215049306|NCT04794348|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Autologous units of fresh frozen plasma collected from the subject by plasmapheresis
215049307|NCT04794348|BIOLOGICAL|Freeze Dried Plasma (FDP)|Autologous units of freeze dried plasma manufactured from plasma collected from the subject by plasmapheresis
215049308|NCT04044014|DEVICE|Gellan sheet|Gellan sheet.
215049309|NCT04044014|DEVICE|Gellan fluid gel|Gellan fluid gel.
215049310|NCT04044014|DEVICE|Mepitel One|Control dressing-- Mepitel One.
215049311|NCT02737501|DRUG|Brigatinib|Brigatinib tablets
215049312|NCT02737501|DRUG|Crizotinib|Crizotinib tablets
215049313|NCT00437749|DRUG|CBT-1|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
215049314|NCT00437749|OTHER|Placebo|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
215049315|NCT01261975|PROCEDURE|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
215049316|NCT01261975|PROCEDURE|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
215049317|NCT01252082|PROCEDURE|Scaling and Rootplaning|All patients in the test group receive scaling and rootplaning under local anesthesia
215049318|NCT00716274|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
215049319|NCT00716274|DRUG|Placebo|oral, daily, for 16 weeks
215049320|NCT02785692|RADIATION|Radiation|preoperative Radiotherapy/ IMRT
215049321|NCT02152189|OTHER|Screening for Fabry disease|
214889369|NCT03056170|DEVICE|real tDCS|"In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code."
214889370|NCT04886895|OTHER|Let's Move Motor Intervention|Let's Move intervention will be administered and videotaped with infant/caregiver dyads. Therapy will occur weekly (30-60 minutes per session) for 16 weeks, alternating between clinic and home (video telehealth) sessions. Each month, we will attempt to schedule two clinic-based sessions followed by 2 telehealth-based sessions
214889371|NCT05144828|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYOS-L cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
215049322|NCT02582827|DRUG|ABI-011|ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
215049323|NCT00551889|DRUG|celecoxib|
215049324|NCT00551889|DRUG|cyclophosphamide|
215049325|NCT00551889|OTHER|laboratory biomarker analysis|
215049326|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (1RDA+CoQ10)|
215049327|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (3RDA)|
215049328|NCT02381964|DIETARY_SUPPLEMENT|Placebo|
215049329|NCT00405288|DRUG|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
215049330|NCT05960838|DEVICE|Ultrasling® Quadrant|Immobilization with the Ultrasling® Quadrant (DJO Global Switzerland Sàrl, Ecublens, Switzerland) shoulder brace after surgical treatment
215049331|NCT05960838|DEVICE|Bledsoe ARC®|Immobilization with the Bledsoe ARC® (Breg Inc., Carlsbad, CA USA) brace after surgical treatment
215049332|NCT03523689|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
215049333|NCT03523689|PROCEDURE|Radial Probe Endobronchial Ultrasound|Undergo RP-EBUS
215049334|NCT01637896|DEVICE|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
215049335|NCT01637896|DEVICE|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
215049336|NCT01642303|OTHER|vodcasting|listening to downloaded vodcasting files
215049337|NCT01642303|OTHER|no intervension|Listen to student book listening files
215049338|NCT03643835|DEVICE|Thermal Rehab Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
215049339|NCT03643835|OTHER|Forearm Ice Towels|Towels that are wetted with ice water and wrapped around participants forearms (length of arm from wrist to elbow)
215049340|NCT05527600|DIAGNOSTIC_TEST|intensity of acute pain evaluation|the facial expression of each patient will be collected from a short video of 10 seconds, follow by with the evaluation of the pain intensity.
214889372|NCT05144828|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
214889373|NCT06479135|DRUG|Navtemadlin|Navtemadlin is an investigational MDM2 inhibitor
214889374|NCT06479135|DRUG|Navtemadlin placebo|Navtemadlin placebo
214889375|NCT06479135|DRUG|Ruxolitinib|Ruxolitinib is a janus kinase 1/2 inhibitor
214889376|NCT03690388|DRUG|Cabozantinib|Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
214889377|NCT03690388|DRUG|Placebo|Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
214889378|NCT04291703|DRUG|Antithymocyte Globulin|Thymoglobulin
214889379|NCT04291703|DRUG|Placebo (for ATG)|Normal Saline administered by IV infusion to mimic ATG
214889380|NCT05453461|DIAGNOSTIC_TEST|Validation of new COMs for non ambulant FSHD patients|Monitoring of commonly used and news COMs in non ambulant patients with facioscapulohumeral muscular dystrophy
214889381|NCT06274411|PROCEDURE|Standby cannulated ECMO|Femoral cannulas are inserted and connected to the primed circuit. Clamps are kept on circuit, and ECMO is on standby during PCI. ECMO is initiated if needed.
214889382|NCT06274411|PROCEDURE|Prophylactic ECMO|Prophylactic ECMO procedures are performed in the catheterization laboratory before PCI.
214889383|NCT06425510|BEHAVIORAL|Translation: Living the Advantages of Technological Assistance (VIVE-AT)|It comprises 2-hour small group sessions of 8-10 participants, once a week, for six weeks of participatory discussions, experiential learning, multimodal instructions, and demonstration and practice with selected assistive technology devices (ATDs). The content of the VIVE-AT weekly sessions is as follows: Week 1 - Introduction to ATDs, funding, and resources; Week 2 - ATDs for self-care and toilet use; Week 3 - ATDs for mobility; Week 4 - ATDs for dressing; Week 6 - ATDs for cooking and home tasks. Each session is designed with the following components: monitoring of participants\&#39; weekly goals; providing information on ATDs, resources, and services; reflection on the advantages and disadvantages of using these ATDs; hands-on practice with selected ATDs; goal setting and addressing barriers to using ATDs. Group sessions will incorporate visual aids, including modeling and videos of older individuals using ATDs accessed through an AT web app in a tablet provided by this project.
214889384|NCT06425510|OTHER|Attention calls|Ten minutes of attention calls, once a week for six weeks, to the waitlist control participants will offer general health advice on topics like nutrition, exercise, sleep, stress, and social connections. These calls emphasize participant well-being without touching upon the specific VIVE-AT content, maintaining a clear distinction from the intervention group.
214889385|NCT03211663|DEVICE|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
214889386|NCT06649695|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
214889387|NCT03708302|PROCEDURE|Unilateral serratus plane block|Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration. Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sternum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration.
214889388|NCT03708302|PROCEDURE|Unilateral parasternal infrapectoral block|"Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane in 5 mls aliquot after aspiration.~Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sterum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane slowly in 5 ml aliquots after aspiration."
214889389|NCT01221610|DEVICE|Passeo-18 Lux DRB|
214889390|NCT01221610|DEVICE|Standard PTA (POBA)|
215049341|NCT00994864|DRUG|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
215049342|NCT00440817|OTHER|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
215049343|NCT02447185|DRUG|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
215049344|NCT02447185|DRUG|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
215049345|NCT03593148|OTHER|Lifestyle|Lifestyle treatment
215049346|NCT05545943|OTHER|2-days of zero calorie restriction and whole-body cold-water immersion|The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.
215049347|NCT05545943|OTHER|6-days of calorie restriction|The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
215049348|NCT05545943|OTHER|2-days of zero calorie restriction without whole-body cold-water immersion|2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .
214889391|NCT03514290|RADIATION|Low-lever laser|Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.
214889392|NCT03514290|OTHER|Tooth bleaching|Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
214889393|NCT03514290|OTHER|Placebo|The laser tip was positioned similarly to experimental group but without light irradiation
214889394|NCT04100018|BIOLOGICAL|Nivolumab|Specified dose on specified days
214889395|NCT04100018|DRUG|Prednisone|Specified dose on specified days
214889396|NCT04100018|DRUG|Docetaxel|Specified dose on specified days
214889397|NCT04100018|OTHER|Placebo|Specified dose on specified days
214889398|NCT05679050|DRUG|AG Followed by FOLFIRINOX|"AG（every 28 days) Nab-paclitaxel 125 mg/m2 i.v. over 30 min, gemcitabine hydrochloride 1g/m2 i.v. over 30 min, D1, 8 and 15 ; FOLFIRINOX(every 42 days) Oxaliplatin: 65 mg/m2 i.v. over 2h on D1, 15, 29; Tetrahydrofolate: 400 mg/m2 i.v.2h on D1, 15, 29; Irinotecan: 150 mg/m2 i.v. over 90 min every 42 days on D1, 15, 29; 5-FU: 2400 mg/m2 i.v. over 46h /14 days on D1-3, 15-17, and 29-31; After one round of above therapy, patients achieving stable disease and above without disease progression or unacceptable toxicity underwent pancreatectomy within 4-8 weeks; Patients who did not achieve stable disease and above were treated another round , and patients who achieved stable disease and above underwent pancreatectomy at 4-8 weeks.~Following pancreatectomy, patients underwent AG regimen (2 rounds, 56 days) followed by FOLFIRINOX regimen (42 days) in the absence of disease progression or unacceptable toxicity, and AG and FOLFIRINOX dosing as the preoperative therapy."
215049349|NCT05545943|OTHER|2-days of usual diet with whole-body cold-water immersion|Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.
215049350|NCT04379674|OTHER|FACILITATION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
215049351|NCT04379674|OTHER|INHIBITION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
215049352|NCT04379674|OTHER|PLACEBO TAPING|Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
215049353|NCT04067492|DRUG|RPH - 104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
215049354|NCT04067492|DRUG|Voltaren®|Enteric-coated tablets, 25 mg and 50 mg
214889399|NCT06550414|DRUG|Dexmedetomidine|Active comparator: dexmedetomidine group
214889400|NCT06550414|DRUG|Bupivacain|Placebo comparator: bupivacaine group
214889401|NCT04569734|PROCEDURE|WATCHMAN device implant procedure utilizing ICE probe|The study will be a prospective, non-randomized multicenter registry of 100 patients undergoing LAA closure with the WATCHMAN device (possibly with WATCHMAN FLX when approved) utilizing an intra-procedural ICE probe under moderate sedation.
214889402|NCT03196843|DRUG|Raltitrexed|Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
214889403|NCT03196843|RADIATION|Intensity Modulated Radiotherapy|Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
215049355|NCT04548427|DRUG|CKD-352|Eye Drop
215049356|NCT04548427|DRUG|Diquafosol Sodium 3%|Eye Drop
214889404|NCT02257775|GENETIC|n/a - observational|
215049357|NCT05831904|DEVICE|whole-body vibration|After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
215049358|NCT01406132|DRUG|ASP015K|oral
215049359|NCT01669694|OTHER|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
215049360|NCT01153035|DEVICE|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
215049361|NCT05324579|BEHAVIORAL|Behavioral testing during neuronal recordings|Participants undergoing clinically planned neurosurgical procedures will undergo single-neuronal recordings as they perform brief behavioral tasks.
215049362|NCT01461525|PROCEDURE|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
215049363|NCT01461525|PROCEDURE|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
215049364|NCT05488054|PROCEDURE|Physical Therapy|Patients will undergo physical therapy following surgical intervention
215049365|NCT05488054|PROCEDURE|Monitored Work-out|Healthy volunteers will undergo a monitored workout for comparison of data
215049366|NCT05488054|DEVICE|Moxy Oxygen Sensor Device|Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles
215049367|NCT04406987|PROCEDURE|decompression|surgical technique for neural decompression varied based on surgeon's preference, but always with preservation for spinous processes. Either open with or without microscope or using tubular retractors.
214477827|NCT05458622|BIOLOGICAL|Blood sample|"\- Total volume of blood (on each sampling occasion): 54,5mL.~* Whole blood will be collected in EDTA, 1 tube of 10 mL for DNA (genotyping, methylation arrays; at baseline for genotyping and at EOS visit for methylation arrays). From this, an aliquot of 0.5 mL for baseline cell numbers (cell proportions, CyTOF/flow cytometry) at all time points; capture of leukocytes for blood single cell RNA seq. at all time points and 5 mL for cell stimulations for cell metabolome (C13 to be added), and 1 tube of 10 mL for cell stimulations (CyTOF) at baseline.Tempus tube: 1 tube of 3 mL for RNA, 1 tube of 3mL for whole blood RNA seq.; to be taken at all time points. Plasma will be obtained and aliquoted from these tubes; to be obtained at all time points.~* Serum: 2 tubes of 10 mL without anticoagulant for measurements of anti-drug antibodies, hydroxychloroquine levels, cytokines and analytes, proteome, and autoantibodies; to be taken at all time points."
214477828|NCT05458622|BIOLOGICAL|Urine sample|\- Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted;
214889405|NCT05736861|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
214889406|NCT05736861|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
214889407|NCT03767660|DRUG|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
214889408|NCT03583476|DRUG|Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole|Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
214889409|NCT04622748|BEHAVIORAL|Trier Social Stress Test|8-min oral calculation and 5-min speech
214889410|NCT00036361|DRUG|Aripiprazole|
214889411|NCT00966472|DRUG|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
214889412|NCT04279210|DEVICE|Platelet-rich plasma|The RegenKit-THT (RegenLab SA, Switzerland) was used to separation of plasma and blood cells. 3mL PRP was extracted from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia.
214889413|NCT03015246|DRUG|Extended release morphine|Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.
214889414|NCT03015246|DRUG|Buprenorphine/Naloxone low dose|Buprenorphine/Naloxone dose of 1.4/0.36 mg/day
214889415|NCT03015246|DRUG|Buprenorphine/Naloxone moderate dose|Buprenorphine/Naloxone dose of 4.2/1.08 mg/day
214889416|NCT03015246|DRUG|Buprenorphine/Naloxone high dose|Buprenorphine/Naloxone dose of 12.8/3.16 mg/day
214889417|NCT03015246|DRUG|Active stressor|Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
214889418|NCT03015246|DRUG|Placebo stressor|Lactose
214889419|NCT01659957|BEHAVIORAL|Group Couples Counseling|
214889420|NCT01659957|BEHAVIORAL|One-on-One Couples Counseling|
214889421|NCT05869201|BIOLOGICAL|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
214889422|NCT05869201|BIOLOGICAL|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
214889423|NCT05869201|BIOLOGICAL|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
214889424|NCT06583226|DEVICE|Gelatin sponge stabilization with suture and cyanoacrylate|The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
214889425|NCT06583226|PROCEDURE|Gelatin sponge stabilization with suture and cyanoacrylate and coconut oil application|Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) and coconut oil (test group)
214889426|NCT00879255|BEHAVIORAL|Cognitive Processing Therapy Group Videoteleconference|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference.
214889427|NCT00879255|BEHAVIORAL|Cognitive Processing Therapy Group In-Person|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference.
214889428|NCT00038077|DRUG|Seloken ZOK/Toprol-XL|50 mg
214889429|NCT00038077|DRUG|Seloken ZOK/Toprol-XL|200 mg
214889430|NCT00038077|DRUG|Placebo|
215049368|NCT04406987|PROCEDURE|fusion|fusion techniques consisted besides decompression of additional implantation of pedicle screws with rods, with or without intervertebral fusion and cage(s). Non-instrumented technique with allograft bone. Fusion technique on surgeon's discretion.
215049369|NCT01302184|DEVICE|Lokomat®|"Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks"
214477829|NCT05458622|BIOLOGICAL|Saliva sample|\- Saliva: will be collect in special container for saliva microbiome and methylation;
214477830|NCT05458622|BIOLOGICAL|Stood sample|\- Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C
214889431|NCT05383612|PROCEDURE|Warm compresses|Commercial eye patch, 10 min before lid massage.Warm compresses and lid massage every 2 weeks，5 times in total（0，2, 4, 6, 8W）.
214889432|NCT05383612|DRUG|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops (DIQUAS ophthalmic solution 3%; Santen Pharmaceutical Co. Ltd, Osaka, Japan)，3% diquafosol was administered six times a day for 12 weeks.
214889433|NCT00063024|BEHAVIORAL|Increased calcium intake|
214889434|NCT00063024|BEHAVIORAL|Weight-bearing physical activity|
214889435|NCT03860974|DRUG|Serratus Plane block (single injection)|A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
214889436|NCT03860974|DRUG|Paravertebral block (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery). For paravertebral blocks without axillary involvement, this will be at the T3 and T5 levels. For paravertebral blocks with axillary involvement, this will be at the T2 and T4 levels. For unilateral PVBs, 10 mL of local anesthetic will be injected per level. For bilateral paravertebral blocks, 8 mL of local anesthetic will be injected per level.
214889437|NCT00467974|PROCEDURE|TEA with LEM|Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)
214889438|NCT00467974|PROCEDURE|TACE|Transarterial chemoembolisation (TACE)
214889439|NCT01258140|RADIATION|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
214889440|NCT01258140|RADIATION|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
214889441|NCT02653625|DRUG|Cenicriviroc 150 mg|One tablet of CVC 150 mg once daily taken with food in the morning.
214889442|NCT03707626|OTHER|Wellens Sign|presence or absence in presence of coronary collaterals to LAD
214889443|NCT01348048|OTHER|Specialised palliative care (SPC)|The interventions given by the SPC centres follow the the WHO and the EAPC guidelines for palliative care. It is not possible in advance to describe the interventions more specifically as these will be adjusted to each particular patient. As part of the study the medical records of all patients in the intervention group will be reviewed with the purpose of describing the interventions given for the different symptoms and problems.
215049370|NCT01302184|DEVICE|Treadmill|"Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks."
215049371|NCT02394158|DRUG|Metformin|
215049372|NCT02394158|DRUG|placebo|
215049373|NCT00786422|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
214889444|NCT06499402|OTHER|massage|sacral massage
214889445|NCT04783402|OTHER|e-OTCAT program|"The e-OTCAT program consists of a combination of cognitive training in terms of attention, memory and processing speed; and adaptive training based on metacognition and cognitive-behavioral strategies (psycho-education, relaxation techniques training, stress management, energy conservation techniques, time management, etc.).~This program also includes homework exercises consisting of a handbook of paper-and-pencil exercises, a cognitive training mobile app, and the practice of strategies seen in adaptive training sessions."
214889446|NCT04783402|OTHER|Educational handbook and standard care|At the beginning of chemotherapy, the participants will receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care.
214889447|NCT00174304|DRUG|Amlodipine/atorvastatin single pill|
214889448|NCT03194269|DEVICE|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
215049374|NCT06414044|DRUG|Atogepant 60 mg|Patients using atogepant 60 mg tablet daily as migraine prevention
215049375|NCT03941847|OTHER|music|listening music
215049376|NCT01646814|DRUG|PL2200|PL2200, containing 325 mg aspirin active ingredient
215049377|NCT01646814|DRUG|Aspirin tablets|325 mg aspirin tablets (USP)
215049378|NCT05658328|BEHAVIORAL|SHARP - Physical and social activity|Technology-enabled neighborhood walking 3x/week for 16 weeks with conversational reminiscence
215049379|NCT05942716|DRUG|Administration of a PET radiotracer|"A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic."
215049380|NCT01011608|OTHER|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
214477831|NCT05458622|PROCEDURE|Tissue sample|"\- Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
214477832|NCT04214418|DRUG|Cobimetinib|(40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2
214889449|NCT01665001|OTHER|Treatment strategy: induction, consolidation, HSCT, maintenance|"Patients \<55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD\>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD \<0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.~Patients \>55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.~Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT."
214889450|NCT02042352|OTHER|pH glove|
214889451|NCT01257620|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
214889452|NCT00096629|BIOLOGICAL|human prostate-specific membrane antigen plasmid DNA vaccine|
214889453|NCT00096629|BIOLOGICAL|mouse prostate-specific membrane antigen plasmid DNA vaccine|
214889454|NCT04821726|DEVICE|Drug eluting balloon (Vmoky)|Use Vmoky Drug Eluting Balloon to treat patients with symptomatic intracranial atherosclerosis stenosis
214889455|NCT06150248|OTHER|Education Intervention|"This intervention is based on the Social Cognitive Theory (SCT) and The Health Belief Model (HBM) to improve knowledge and promote lifestyle adherence in terms of healthy diet behaviour and physical activity among the undergraduate students. This program will include educational booklets and educational classes include six weeks of in-person education sessions and six weeks of social media messaging. The course will include six weekly teaching units (lectures and group discussions, 45-60 minutes each):~Topic 1: To understand the causes and prevention strategies for overweight and obesity.~Topic 2: To understand food based approaches to reduce or prevent overweight and obesity.~Topic 3: To understand the importance of regular physical activity. Topic 4: To demonstrate how snacking can be a healthy habit. Topic 5: To learn how to read and interpret food labels. Topic 6: To understand how to prepare healthy meals."
214889456|NCT06150248|OTHER|No intervention|They will have their regular curriculums and normal physical activity routine.
214889457|NCT05610540|DEVICE|TECNIS Synergy IOL|Implanted in one eye
215049381|NCT01011608|OTHER|standard hospital food|standard hospital diet ad. lib.
215049382|NCT02470702|DRUG|Oritavancin|
215049383|NCT02470702|DRUG|Placebo (D5W)|
215049384|NCT03051802|DEVICE|Navigated Endoscopy|Navigated endoscopy used to guide the placement of HDR applicators in the esophagus or lung as a replacement to current standard of practice using fluoroscopic imaging.
215049385|NCT06482567|BEHAVIORAL|iCOVER|"The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., I'm right here with you); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior."
215049386|NCT06482567|BEHAVIORAL|Physical Presence with Reassurance|The RA who performed randomization, initially approached the individual, and obtained assent will stay with the participant for the length of the iCOVER intervention (in order to ensure matching of the amount of time spent with individuals who receive the iCOVER intervention, which takes 60-120 seconds). During this time, the RA will provide supportive but passive statements. The RA will leave the participant after the length of the iCOVER intervention has elapsed. A separate blinded RA will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
215049387|NCT03648710|OTHER|Peer Community Health Worker|Participants will be communicating with their CHWs on a weekly basis, which is consistent with other successful community health worker protocols with published efficacy. Community Health Workers will be peers with sickle cell disease, who have successfully transitioned and are under 30 years of age.
215049388|NCT03648710|OTHER|Mobile Health|A mobile health application created as a resource for young adults transitioning.
215049389|NCT06060210|DRUG|normal Saline|50-ml Saline
215049390|NCT06060210|DRUG|Ketamine|50-ml volumes, and the ketamine concentration is 1 mg/ml
215049391|NCT00966459|PROCEDURE|Computed Tomography|1 low-dose CT is taken
215049392|NCT05067101|PROCEDURE|Capsule Sparing Cystectomy (CSC)|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
215049393|NCT05067101|PROCEDURE|Conventional Radical Cystoprostatectomy (CRC)|According to the consensus standard program, remove the accessory tissues including the bladder, prostate and seminal vesicles
215049394|NCT00156325|DRUG|Escitalopram (Lexapro)|
215049395|NCT00543985|PROCEDURE|Stress Echocardiography|Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
215049396|NCT03367884|PROCEDURE|Neck dissection followed by radiotherapy(50Gy) according to risk factors|Neck dissection followed by radiotherapy(50Gy) according to risk factors
214889458|NCT05610540|DEVICE|AcrySof PanOptix Trifocal IOL|Implanted in one eye
215049397|NCT03367884|RADIATION|Definitive radiotherapy|Definitive radiotherapy (70Gy)
215049398|NCT02015039|DRUG|BoNT Injections|
215049399|NCT02015039|PROCEDURE|Occupational Therapy|
214294644|NCT05559255|OTHER|Counterstrain manual manipulative treatment|"The steps required to perform counterstrain in any region of the body are as follows:~1. Find the tender point.~2. Assess the tenderness using a pain scale.~3. Passively and gently place the patient in a position-of-comfort that results in the greatest reduction of tenderness at the tender point. Approximate the position first, then fine-tune through small arcs of movement. Aim to achieve at least 70% tenderness reduction, with the goal of 100%.~4. Maintain the position for 90 seconds while continuing to monitor the patient's tender point.~5. Passively return the patient to a neutral position.~6. Re-test for tenderness at the tender point."
214294645|NCT03720470|DRUG|PF-04965842 100 mg|"PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 subjects take PF-04965842 100 mg from Week 16 to Week 20."
214477833|NCT04214418|DRUG|Hydroxychloroquine|(600mg) orally twice daily on days 1-28 of each 28-day cycle
214477834|NCT04214418|DRUG|Atezolizumab|840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)
214889459|NCT05397080|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
214889460|NCT05397080|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
214889461|NCT05397080|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU)~* 4 face-to-face sessions (1 per mounth) Standard pharmacological treatment usually provided to patients with fibromyalgia."
214889462|NCT04636476|PROCEDURE|Modified Nesbit's procedure and dorsal dartos flap|Modified Nesbit's procedure to correct the penile curvature and dorsal dartos flap to correct the associated penile torsion
214889463|NCT00795262|DRUG|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
214889464|NCT00795262|DRUG|accupril, placebo|accupril 40 mg
214889465|NCT00795262|DRUG|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
214889466|NCT01795404|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|
214889467|NCT04251104|OTHER|Images' personal relevance effectiveness in objective and subjective mood recovery|"After completing the PANAS, the negative mood induction phase (viewing a film clip) phase will begin. Before this phase, the participants will be encouraged to experience the feelings generated by the clip as intensely as possible. After viewing the film clip, participants will be asked to complete the PANAS again in order to assess the effectiveness of the negative mood induction procedure.~Following the negative mood induction phase, the emotional recovery phase will be initiated, in which the participants will look at a total of six pictures previously selected according to their experimental condition in order to generate specific positive autobiographical memories. At the end of this phase, participants will once more complete the PANAS in order to assess the effectiveness of the emotional recovery."
214889468|NCT02090725|DRUG|3-4 Diaminopyridine|
214889469|NCT04413786|DRUG|oxytocin treatment|intranasal administration of oxytocin (24IU)
214294646|NCT03720470|DRUG|PF-04965842 200 mg|"PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842 subjects take PF-04965842 200 mg from Week 16 to Week 20."
214477835|NCT02637609|OTHER|Likert Scale|Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
214889470|NCT04413786|DRUG|placebo treatment|intranasal administration of placebo (24IU)
214889471|NCT03499639|DRUG|Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet|"* Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily.~* Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks."
214889472|NCT04850339|BIOLOGICAL|ANXV|Intravenous infusion
214477836|NCT02637609|OTHER|Best-Worst Scaling (Case 1)|Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
214477837|NCT06856772|DRUG|Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Participants will be instructed to take their Statin daily at approx. 8PM-12AM.
214889473|NCT04850339|OTHER|Placebo|Intravenous infusion
214889474|NCT00314704|DRUG|dopamine versus norepinephrine|
214889475|NCT05517421|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
214889476|NCT05517421|DRUG|Placebo|Matching Placebo
214889477|NCT00218946|DRUG|Sucrose|30 % sucrose
214889478|NCT00218946|DEVICE|Pacifier|
214889479|NCT00218946|OTHER|sterile water|
214889480|NCT01499095|DRUG|Lantus (Insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
215049400|NCT04570384|DRUG|L-Citrulline|L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.
214889481|NCT01499095|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
214889482|NCT04234308|DRUG|Polyglycolic Acid|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
214889483|NCT04234308|DRUG|Catgut|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
214889484|NCT04234308|DRUG|Polytetrafluoroethylene|Periodontal and periimplant flaps closed with at least one suture with expanded Polytetrafluoroethylene Non absorbable suture, synthetic, 4-0. (TAGUM®)
214889485|NCT04234308|DRUG|Polyamide|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
214889486|NCT02724514|OTHER|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
215049401|NCT04570384|DRUG|Placebo|Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
215049402|NCT02568657|DEVICE|Celox group|
215049403|NCT02568657|DEVICE|Bakri Balloon|
214294647|NCT03720470|DRUG|Dupilumab|Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.
214889487|NCT01512017|DEVICE|Crystalline cellulose simple occlusive dressing|A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
214889488|NCT01512017|DEVICE|Vaseline|External use
214889489|NCT04688645|DRUG|Balanced crystalloid solution|Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
214889490|NCT04688645|DRUG|Normal saline|0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
215049404|NCT01935453|BIOLOGICAL|Recombinant hGM-CSF Herpes Simplex Virus Injection|
215049405|NCT03249818|DEVICE|HITT device|Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
215049406|NCT01673126|DEVICE|Anodal tDCS|patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
215049407|NCT01673126|DEVICE|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
215049408|NCT03836443|OTHER|"western diet meal"|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."
214889491|NCT02037425|DRUG|onabotulinumtoxinA|BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
214889492|NCT03885843|PROCEDURE|Renal nerve stimulation, mapping and denervation|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal nerve stimulation, mapping and denervation procedure after randomization.
215049409|NCT04462601|OTHER|Biomarker detection|Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
214889493|NCT03885843|PROCEDURE|Sham Procedure: Renal angiography|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal
215049410|NCT06214403|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a defined microbial community derived from healthy donor stool. MET capsules are orally administered mixtures of pure cultures of human-derived bacterial strains.
215049411|NCT06214403|DRUG|Placebo|Microcrystalline Cellulose
215049412|NCT02347384|DEVICE|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head \& SL-TWIN Stem
215049413|NCT02347384|DEVICE|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head \& SL-PLUS Stem
215049414|NCT06088329|BEHAVIORAL|Mindful Walking for Adults with Chronic Pain|Participants identified with chronic pain will complete 6 sessions of mindfulness based walking exercises.
215049415|NCT05158413|DIETARY_SUPPLEMENT|High dose|Patients will receive a high dose of sesame paste or flour (1200 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
215049416|NCT05158413|DIETARY_SUPPLEMENT|Low dose|Patients will receive a low dose of sesame paste or flour (300 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
215049417|NCT00003525|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
215049418|NCT00237042|BEHAVIORAL|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
215049419|NCT00237042|BEHAVIORAL|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
215049420|NCT00237042|DRUG|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
215049421|NCT01876212|BIOLOGICAL|DC vaccine|
215049422|NCT01876212|DRUG|Dasatinib|
215049423|NCT05376722|DRUG|pamiparib|pamiparib 40 mg orally, twice a day
214477838|NCT06856772|DRUG|Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Participants will be instructed to take their statin upon awakening/or with their breakfast (approx. 6AM-10AM).
214889494|NCT04358081|DRUG|HCQ|Hydroxychloroquine Monotherapy
214889495|NCT04358081|DRUG|HCQ+AZT|Hydroxychloroquine with azithromycin
214889496|NCT04358081|DRUG|Placebo|Placebo
214889497|NCT01817296|PROCEDURE|Testicular Biopsy|Micro-dissection testicular sperm extraction for sperm retrieval
215049424|NCT05376722|DRUG|abiraterone|biraterone acetate 1000 mg orally, once a day
215049425|NCT05376722|DRUG|prednisone|prednisone acetate tablets (prednisone) 5 mg, once a day
215049426|NCT03111316|DRUG|Cervidil 10 MG Vaginal Insert|Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
215049427|NCT03111316|DEVICE|Foley Catheter|The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
215049428|NCT05992129|OTHER|foot exercise|These are foot and ankle muscle strengthening exercises described and evaluated by the literature
214889498|NCT00221338|DRUG|Gabapentin|This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
214889499|NCT04040036|BEHAVIORAL|Children watch applications by wearing the virtual headset during the blood draw.|wearing the virtual headset
214889500|NCT01287806|DRUG|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days
214889501|NCT01287806|DRUG|blank group|standard treatment
214889502|NCT01348256|DRUG|Dendritic cells vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
214889503|NCT02346656|DEVICE|Implantation with the commercially available Axium neurostimulator|
214889504|NCT05124470|OTHER|cognitive remediation by musical training sessions|"The musical learning method Diapason \& Metronome is unprecedented. It was specially created by Florent Cholat. It aims an apprenticeship of a musical practice adapted to subjects with schizophrenia. The method does not require the handling of a musical instrument; it is based on the voice and the body. It is built on the three essential dimensions of music, which are rhythm, single sound and harmony. Rhythm concerns the division and management of time. The single sound allows work on the representation of a sound object as a singularity. Harmony allows you to work on the positioning of a sound in the globality of the chord to which it belongs and in the collective polyphony exercises."
214889505|NCT04314453|OTHER|percutaneous endoscopic lumbar discectomy|Resection of the hypertrophied faceted joints, osteophyte formation and ligamentum flavum (LF) hypertrophy, with or without disc protrusion for degenerative spinal stenosis.
214889506|NCT00626353|OTHER|Home-based rehabilitation|Rehabilitation at home during hospital stay and after discharge
214889507|NCT00626353|OTHER|Standard care|Standard care during hospital stay and in the municipality after discharge
215049429|NCT03322904|DIAGNOSTIC_TEST|iris photography|"The LF (0.04-0.15 Hz) and HF (0.16-0.4 Hz) ratings were recorded for 24 hours (day and night average) by Holter recording system~Photographs of both irises of the healthy volunteers were taken . An image software program was used to draw circular limits over the iris exterior circle (IEC), coloretta circle (CC), and pupil circle (PC) on digital photographs. The areas between the circles were measured. The likelihood that the IRIS ratio was equal to the LF/HF ratio was calculated using the formula \[IEC-PC¬\] - \[CC-PC\] / \[CC-PC\]."
215049430|NCT02167321|DRUG|Arm A : standard neoadjuvant chemoradiotherapy group|radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
214889508|NCT03652402|PROCEDURE|kidney transplantation|samples additional to the standard of care' (SOC)will be taken at each visit (Day 0, Month 3, Month12, clinical indication)
214889509|NCT00431470|BEHAVIORAL|Six classroom based character building education lessons|
215049431|NCT02167321|DRUG|Arm B : adjuvant FOLFOX group|FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
214889510|NCT02600975|BIOLOGICAL|R21 with ASO1B|R21 with ASO1B
214889511|NCT01130532|DRUG|Tadalafil|Administer orally
214889512|NCT01130532|DRUG|Placebo|Administer orally
214889513|NCT00404287|DRUG|Fluvastatin|
215049432|NCT00210444|BIOLOGICAL|Botulinum toxin type A|
214889514|NCT02691754|OTHER|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
214889515|NCT02762929|DRUG|HTX-011A|HTX-011A (bupivacaine/meloxicam), via injection.
214889516|NCT02762929|BIOLOGICAL|Saline Placebo|Saline placebo via injection.
214889517|NCT02762929|DRUG|HTX-011B|HTX-011B (bupivacaine/meloxicam), via injection or instillation.
214889518|NCT02762929|DRUG|HTX-002|HTX-002, via injection.
214889519|NCT02762929|DRUG|Bupivacaine HCl|Bupivacaine HCI, via injection.
214889520|NCT02762929|DRUG|HTX-009|HTX-009, via injection.
214889521|NCT03617094|DEVICE|Early percutaneous vertebroplasty (EPV)|Treatment consists of percutaneous acrylic bone cement injection using a trocar under scope control and general anesthesia.
214889522|NCT03617094|DEVICE|Standard Conservative treatment (CT)|Treatment consists of using a made-to-measure 3 point thoracolumbar corset,that is worn for 3 months: night and day during the first 6 week period of the treatment, and then only the day for the next 6 week period.
214889523|NCT01278186|PROCEDURE|Balloon angioplasty|Coronary angioplasty using the paclitaxel-coated balloon catheter
214889524|NCT01278186|PROCEDURE|Stent implantation|Coronary angioplasty using the paclitaxel-eluting stent
214889525|NCT03649672|DEVICE|TOF Watch SX|Neuromuscular monitoring via the TOF Watch SX device
214889526|NCT02656303|BIOLOGICAL|Ublituximab|Ublituximab IV infusion
214889527|NCT02656303|DRUG|Umbralisib|Umbralisib tablets
214889528|NCT01479075|DRUG|intransal insulin|4x 40mU intranasal insulin
214889529|NCT01479075|DRUG|Placebo|
214889530|NCT01479075|DEVICE|taVNS|
214889531|NCT01479075|DEVICE|sham stimulation|
214889532|NCT05021900|DRUG|Tenalisib 800mg|Tenalisib will be administered 800mg BID, orally
214889533|NCT05021900|DRUG|Tenalisib 1200mg|Tenalisib will be administered 1200mg BID, orally
214889534|NCT01873352|PROCEDURE|catheter ablation|Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.
214889535|NCT01873352|PROCEDURE|renal sympathetic denervation|Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
214889536|NCT03248687|OTHER|Follow up|The intervention will be method of follow up.
214889537|NCT01842438|BEHAVIORAL|Behavioral: psychosexual intervention|6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
214889538|NCT01622257|DEVICE|Cavitation US|The areas with localized fat are treated 2 times per week for 3 months using Aesthetic cavitation via ultrasonic cavitation machine (Cavi SMART, South Korea, supplied with one piece cavitation probe of 40 KHz, 3-6 watt(W)/cm\^2 adjustable, 60W with 20cm\^2 active surface).
214889539|NCT01622257|DRUG|Metformin|Metformin hydrochloride (Glucophage 500 mg/tablet, Bristol-Myers Squibb, New York, USA). Medication is initiated in a step-up fashion every 5 days, from one tablet per day to three. This dose is maintained as tolerated throughout the 3 months of the study.
214889540|NCT01622257|OTHER|Cavitation US + Metformin|Combination of both Cavitation US + Metformin. the treatment duration lasts 3 months
214889541|NCT00782626|DRUG|everolimus|
214889542|NCT02126514|DRUG|AZD3293|7 subjects will receive AZD3293
214889543|NCT05439096|OTHER|Functional Exercise|Among Functional Exercises, cobra position is most effective in reducing pelvic pain while others are cat and fish position.Kegel exercises along with other strengthening activities for pelvic floor muscles have been accounted for in writing to favorably affect primary dysmenorrheal.
214889544|NCT05439096|OTHER|High Frequency Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation, best treat primary dysmenorrhea. Transcutaneous Electrical Nerve Stimulation is proposed as an incredible spasm decrease, lessening torment, decline of analgesics and improving personal satisfaction in primary dysmenorrhea patients.
214889545|NCT00562848|DRUG|GSK962040|GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
214889546|NCT00562848|DRUG|Placebo|Subjects will receive placebo.
214889547|NCT04909853|DRUG|PF-07321332/ritonavir|PF-07321332 in combination with the PK boosting agent, ritonavir, being developed for the treatment of COVID-19
214889548|NCT01323400|DRUG|Pazopanib|Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
214889549|NCT01323400|OTHER|Best supportive care|"Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency."
214889550|NCT02253511|DRUG|Cidan capsule|
214889551|NCT05089383|DRUG|Utrogestan|PROSPECTIVE STUDY
214889552|NCT04054765|DEVICE|videogame|Invite Only VR videogame
214889553|NCT04054765|OTHER|treatment as usual|treatment as usual
214889554|NCT03485560|COMBINATION_PRODUCT|ACE CSD|Topical application of the ACE CSD 4 times daily.
214889555|NCT04945395|DEVICE|FES and Conventional training|The experimental group will be fitted with the Functional electrical stimulation system L300 Go to be used during 4 weeks of inpatient rehabilitation in the subacute phase after hemiplegic stroke. Settings will be adjusted continuously to enhance dorsiflexion of the affected foot during walking and mobility training.
214889556|NCT04945395|DEVICE|AFO and Conventional training|The control group will be fitted with an ankle-foot-orthosis (AFO) according to clinical practice to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions during 4 weeks of inpatient rehabilitation including walking and mobility training in the subacute phase after hemiplegic stroke
214889557|NCT04994769|DEVICE|Epitomee Capsule|Epitomee Capsule combined with lifestyle counseling.
214889558|NCT01593774|DRUG|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group
214889559|NCT01593774|DRUG|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
214889560|NCT06118801|DIETARY_SUPPLEMENT|Probiotic Product Supplement|Mothers of preterm babies who feed their babies only with breast milk will be given a probiotic product supplement once a day (80 ml probiotic product support containing the Actregularis (5×106 CFU\\mL) (lactobacillus bulgaricus, streptococcus thermophilus, lactococcus lactis and bifidobacterium lactis) strain)
214889561|NCT01198769|BIOLOGICAL|Rotarix TM|Oral, 2 doses
214889562|NCT02655913|DRUG|vitamin C|Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
214889563|NCT02655913|DEVICE|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
214889564|NCT02655913|OTHER|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
215049433|NCT04630821|OTHER|Dilute Sodium Hypochlorite solution|"Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.~While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers."
215049434|NCT03189732|DRUG|Metformin Oral|
215049435|NCT03189732|DRUG|Metformin local in AT|
215049436|NCT03189732|OTHER|Exercise|
215049437|NCT01045369|DRUG|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
215049438|NCT01468480|DRUG|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
214294648|NCT03720470|DRUG|Oral Placebo|"Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~1. In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~2. In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16."
214294649|NCT03720470|DRUG|Injectable Placebo|Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
214889565|NCT05202314|DRUG|Immunotherapy (Camrelizumab)|After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
214889566|NCT00077207|DRUG|carboplatin|Given IV
214889567|NCT00077207|DRUG|temozolomide|Given orally
214889568|NCT00077207|DRUG|vincristine sulfate|Given IV
214889569|NCT05809960|OTHER|Nursing support program|It was discussed about the operation and surgical menopause that the woman will undergo after hospitalization for the operation. Education was given including the problems experienced during menopause and the approaches used to cope with them. Progressive relaxation exercises were taught and practiced. In order to carry out these procedures, an interview of approximately 45-60 minutes was held with each woman. During the program, four planned meetings were held. One of them was face-to-face and the others were phone calls. During the phone calls, the symptoms experienced by the women and their coping methods were discussed and the questions of the women were answered. The average of each phone call was 20-30 minutes.
214889570|NCT05809960|OTHER|Routine nursing care|Routine nursing care was given to the control group. The clinical routine has not been exceeded. It includes discharge training for the surgery.
214889571|NCT04857658|PROCEDURE|extraction orthodontic treatment plan|patients will be referred for extraction of the upper and lower first premolars then orthodontic treatment will follow.
215049439|NCT01468480|DRUG|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
215049440|NCT01468480|DRUG|MultiCal|application of Multical in forth group as a pulp dressing agent
215049441|NCT01468480|DRUG|Dycal|application of Dycal in first group as a pulp dressing agent
215049442|NCT01758094|DRUG|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
215049443|NCT00295607|DRUG|Tacrolimus|immunosuppression
214889572|NCT05116072|PROCEDURE|total pancreatectomy|"The total pancreatectomy will be performed in two steps: The pancreatectomy will begin by a standard pancreaticoduodenectomy procedure.~The section margin will be sent for intraoperative histological analysis to confirm the absence of invasion of the left remnant pancreas.~When absence of tumor invasion is confirmed and the high-risk of postoperative pancreatic fistula is validated intraoperatively, the extended left distal pancreatectomy will be performed, with splenic preservation when possible.~Then, the left side of the pancreas will be resected and cooled (4-6°) in the preservation solution and shipped to Lille Biotherapy platform to perform islet isolation and purification. The reconstruction after total pancreatectomy will be done as usually performed by center expert surgeon."
214889573|NCT05116072|BIOLOGICAL|intraportal islet autotransplantation|The final islet preparation will be cultured and shipped 48 hours after total pancreatectomy from the Lille laboratory to the surgical center, and finally transplanted into the patient through a venous catheter placed in the portal trunk (91% of the total islet mass) and at the same time, a small fraction of the isolated islet (5% of the total islet mass) will be transplanted into the forearm muscle.
214294650|NCT02395718|OTHER|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
214294651|NCT02395718|OTHER|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
214294652|NCT04659889|DIAGNOSTIC_TEST|Blood sampling (venesection)|"All study participants will have a single blood test to analyse the following parameters:~(i) Serum biochemistry, CRP, Thyroid function and liver enzymes (ii) FBC, d-Dimer, ESR, Blood film (iii) SARS-CoV2 antibody status and serum save (iv) Peripheral blood immunophenotyping."
214294653|NCT01003509|PROCEDURE|modified shouldice and double|one arm modified shouldice, other one is double repair
214294654|NCT01226446|DRUG|vitamin D|Vitamin D on top of the standard treatment
214294655|NCT02959047|DRUG|Alirocumab|150mg SQ every 2 weeks
214294656|NCT02959047|DRUG|Matching placebo|SQ every 2 weeks
214294657|NCT01702701|DRUG|Montelukast|montelukast 10mg po pill q day for 12 weeks
214889574|NCT05303337|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and W52
214889575|NCT05303337|OTHER|Blood plasma collection|Blood plasma collection to assess persistent inflammation, immune activation and HIV reservoir at baseline,W24,W52
214889576|NCT04927832|OTHER|SUDOSCAN and EMG (electromyogram)|The participants are evaluated clinically by a neurologist with evaluation by DN4 questionnaire, treatments and comorbidities (alcohol consumption, diabetes, etc.). They undergo from exploration by SUDOSCAN according to the already established methodology and an EMG
215049444|NCT00295607|DRUG|steroids, monoclonal anti-IL2R antibody|immunosuppression
214294658|NCT01702701|DRUG|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
214294659|NCT03694860|OTHER|questionnaire|Members of European society of anaesthesiology care will obtain an electronic survey considering their clinical practice in RSI
214294660|NCT04804943|DEVICE|NOA-001|NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
214889577|NCT04821453|DEVICE|NAVA|NAVA mode of mechanical ventilation provide the trigger for a spontaneous breath from the diaphragmatic movement instead of diaphragm and allows the patient to control the dynamics of the breath generally set in CMV mode.
214889578|NCT04821453|DEVICE|CMV|CMV mode of mechanical ventilation that provides a trigger for a spontaneous breath from the airway flow sensor with dynamics of the breath set as required by the mode
214294661|NCT04464343|OTHER|no intervention|This is an observation study, with no intervention
214294662|NCT05394987|DEVICE|Spectacles|"Prescription of refractive error correction in spectacles. Refractive error to be determined as part of standard optometric eye exam (performed by registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group \[PEDIG\] amblyopia clinical trial protocols): Hypermetropia: not undercorrected by \>+1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia: full correction of the anisometropic difference. Astigmatism: cylinder power in each eye should be within ≤±0.50D of fully correcting the astigmatism for each eye. If cylinder power is ≥1.00D, the prescribed axis in both eyes should be within ≤±6 deg of the cycloplegic refraction axis.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., \>50% of waking hours) for the duration of the study."
214294663|NCT02408939|DRUG|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
214294664|NCT04028596|DRUG|Paracetamol|once, 1000mg, 2 h before ECT session
214294665|NCT04028596|DRUG|Nimotop|once, 60mg, 2 h before ECT session
214294666|NCT01971450|DRUG|Iloprost (Ventavis, BAYQ6256)|
215049445|NCT00411489|PROCEDURE|endolumenal surgery|
215049446|NCT01897532|DRUG|Placebo|placebo matching tablets
215049447|NCT01897532|DRUG|Linagliptin|
215049448|NCT01010607|DEVICE|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
214294667|NCT06291051|DEVICE|Electrical spinal cord stimulation|electrical spinal cord stimulation in Parkinson's patients presenting with painful camptocormia
214294668|NCT01782807|PROCEDURE|Salpingectomy or Fimbriectomy|
214294669|NCT00966173|DEVICE|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
214294670|NCT00453921|DRUG|Methylphenidate|Dosage dependent on weight
214294671|NCT00453921|BEHAVIORAL|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
214294672|NCT00453921|OTHER|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
214294673|NCT00891722|OTHER|biologic sample preservation procedure|
214294674|NCT00891722|OTHER|laboratory biomarker analysis|
214294675|NCT00891722|OTHER|questionnaire administration|
214294676|NCT03629821|OTHER|Ballet|The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
214294677|NCT05027412|DEVICE|En bloc TURBT Collins Loop|En bloc TURBT Collins Loop
214294678|NCT05027412|DEVICE|Conventional TURBT|Conventional TURBT
214294679|NCT01076881|BEHAVIORAL|exercise training|
214294680|NCT01938911|DRUG|Syntocinon-Spray|Intranasal oxytocin (24 IU)
214294681|NCT01938911|DRUG|Placebo of syntocinon|Intranasal administration
214477839|NCT06862973|DIAGNOSTIC_TEST|Digital Occlusal Analysis Using Medit i700 and OccluSense in Single-Tooth Implant Restorations|This study differs from other research through the comparison of two advanced digital occlusal analysis methods-OccluSense system and MEDIT i700 intraoral scanner-to measure occlusal force distribution both before and after the insertion of single-tooth implant restorations in the posterior segment. Unlike research based upon the use of articulation paper, this study employs pressure-sensitive sensor technology (OccluSense) and scanner-based occlusion analysis (MEDIT i700) to quantitatively measure occlusal contacts and force intensity using CloudCompare and ImageJ. With the analysis of the variations that take place within the pre-and-post implant occlusion, the study provides an understanding of occlusal adaptation and how to optimize occlusal adjustments to prevent implant overload and complications, differing from the research that has previously lacked both digital force mapping and longitudinal occlusal analysis.
214889579|NCT05813652|OTHER|Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
214477840|NCT06862154|DRUG|IV Analgesia- Fentanyl|Patients receive intravenous fentanyl at a dose of 1 mcg/kg, diluted in 100 mL normal saline, administered as a single dose for systemic analgesia. This intervention aims to control acute pain in hip fracture patients before surgical intervention.
214889580|NCT05813652|OTHER|Peri-pandemic time period (March 13, 2020 to December 3, 2021)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
214889581|NCT05930496|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214889582|NCT05930496|OTHER|Exercise Intervention|Receive exercise intervention
214294682|NCT01938911|BEHAVIORAL|Social support|Social support from the best friend
214294683|NCT00460031|DRUG|ketoconazole|400 tid
214477841|NCT06862154|PROCEDURE|Femoral Nerve Block|Patients undergo an ultrasound-guided, single-injection femoral nerve block with 20 mL of 0.5% bupivacaine. This regional anesthesia technique targets the femoral nerve, providing effective pain relief while reducing opioid requirements.
214889583|NCT05930496|OTHER|Exercise Intervention|Receive tele-coaching intervention
214889584|NCT05930496|BEHAVIORAL|Health Education|Receive health-related information
214889585|NCT05930496|OTHER|Interview|Ancillary studies
214889586|NCT05930496|OTHER|Questionnaire Administration|Ancillary studies
214889587|NCT05806567|DRUG|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
214889588|NCT05806567|DRUG|UGT1A1 victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
214889589|NCT05806567|DRUG|P-gp victim drug|Pharmaceutical form: Capsule; Route of administration: Oral
214294684|NCT00460031|DRUG|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
214294685|NCT00460031|DRUG|therapeutic hydrocortisone|20mg qam 10mg qhs
214294686|NCT01526265|BEHAVIORAL|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
214294687|NCT01526265|BEHAVIORAL|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
214294688|NCT01526265|BEHAVIORAL|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
214294689|NCT01526265|BEHAVIORAL|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
214294690|NCT01526265|BEHAVIORAL|Collaborative Rewards|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
214294691|NCT04532099|DEVICE|Lehfilcon A contact lenses|Investigational soft contact lenses for daily wear worn in Part A of the study
214294692|NCT04532099|DEVICE|Senofilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part A of the study
214294693|NCT04532099|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part B of the study
214294694|NCT04532099|DEVICE|Hydrogen peroxide-based cleaning and disinfecting solution|For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study
214889590|NCT05806567|DRUG|OATP1B1/BCRP victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
214668275|NCT05334589|DEVICE|Prewarming|When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
214889591|NCT04859205|BEHAVIORAL|Intervention|"Participants will have access to the SUPPORT-Pro self-guided online training platform addressing many aspects of type 1 diabetes care. The SUPPORT-Pro content was developped by a team of health professionals specialized in type 1 diabetes as well as patient partners. It's content is regularly updated, evidence-based and divided into 6 categories (medication, blood glucose monitoring, diet, physical activity, hypo and hyperglycemia, health and other particularities). In each category, users can pick between 3 levels (beginner, intermediate and advanced) according to their level of confidence and knowledge.~Participants will be asked to fill out questionnaires at baseline, 3-month, and 12-month of the intervention which include the following: Eligibility assessment, identification, background, confidence, platform satisfaction."
214889592|NCT03091374|DRUG|Somatotropin (Human)|
214889593|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
214889594|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
214889595|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|"Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56"
214889596|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
214889597|NCT01295112|DRUG|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
214889598|NCT01295112|DRUG|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
214889599|NCT06412874|OTHER|Screening tool|Participants will complete a screening tool survey
214889600|NCT06958822|DRUG|Ferric Carboxymaltose (FCM)|As this is an observational study, ferric carboxymaltose recipients are determined based on routine medical care practices. The researchers do not define which participants will receive ferric carboxymaltose.
214889601|NCT04182490|BIOLOGICAL|LMN-101|VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
214889602|NCT04182490|DRUG|Placebo|Identical appearing placebo
214889603|NCT00853099|BIOLOGICAL|adalimumab|
214889604|NCT00853099|DRUG|placebo|
214889605|NCT02489097|DRUG|Nitrous Oxide|Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
214889606|NCT02489097|OTHER|Placebo|Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
214889607|NCT00511823|DRUG|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
214889608|NCT00511823|DRUG|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
214889609|NCT00511823|DRUG|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
214294695|NCT04852458|DRUG|Intravenous (IV) hydrocortisone|"Participants (20) will be given IV hydrocortisone within 6-12 hours of the traumatic event.~90 - 150 mg. of intravenous hydrocortisone dosing regimen based on participant weight: 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg."
214294696|NCT00660582|DRUG|Cetuximab (Erbitux)|500 mg/m² every second week, intravenous infusion, 8 cycles
214294697|NCT00660582|DRUG|Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid|Given in combination day 1 and 2, every second week, 8 cycles
214294698|NCT04002531|OTHER|General and Neurological examination|Information about your general health, neurological symptoms and current medications with be collected
214294699|NCT04002531|OTHER|Vital signs|Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
214294700|NCT04002531|PROCEDURE|12 lead electrocardiogram|A non-invasive test that measures the electrical activity of the heart
214294701|NCT04002531|PROCEDURE|Echocardiogram|A non-invasive sonogram of the heart
214294702|NCT04002531|PROCEDURE|Blood draw|Blood will be drawn to evaluate general health and renal function (kidney health)
214294703|NCT04002531|PROCEDURE|Urine collection|Urine will be collection to evaluate renal function (kidney health)
214294704|NCT04002531|PROCEDURE|2-hour Holter Monitor|A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
214294705|NCT04002531|OTHER|Brief Pain Inventory questionnaire|A questionnaire about daily pain
214294706|NCT04002531|OTHER|Quality of Life questionnaire|A questionnaire about the impact of disease on their activities of daily living and quality of life
214294707|NCT01194479|DRUG|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
214889610|NCT00511823|DRUG|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
214889611|NCT02353910|PROCEDURE|Ultrasound|
214889612|NCT00313079|DRUG|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
215049449|NCT01010607|DEVICE|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
214294708|NCT01194479|OTHER|Placebo|Participants in both arms received placebo on 1 of the 2 visits.
214294709|NCT06279689|OTHER|Ultrasound scans|Ultrasound scans connected with an application enabling the measurement of the force applied.
214294710|NCT02086864|DRUG|lactose/sucrose granule (Individualized homeopathic medicine treatment)|The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
214294711|NCT02086864|DRUG|Placebo lactose/sucrose pill|
214294712|NCT02086864|BEHAVIORAL|Homeopathic consultation|
214294713|NCT05683288|OTHER|IASTM|IASTM will be applied to the upper trapezius and sternocleidomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute.
214294714|NCT05683288|OTHER|Myofascial Release|Basic movements will be performed for 3 minutes in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions.
214294715|NCT05683288|OTHER|250W infrared application|For 15 minutes, 250W infrared application will be applied on the cervical region from a distance of 50 cm
214294716|NCT05683288|DEVICE|TENS|TENS will be applied for 20 minutes at 80Hz frequency, with a current transit time of 150ms.
214294717|NCT05683288|OTHER|Home exercise|Cervical strengthening and stretching exercises five days a week will given
214294718|NCT04103632|DIAGNOSTIC_TEST|EVH test|"* Spirometry~* Skin prick test~* Peripheral blood test~* FeNO measurement"
214477842|NCT06864455|BEHAVIORAL|Guided Imagery Meditation|Audio meditation by Sheri Menelli, for 10-14minutes
214477843|NCT06864455|BEHAVIORAL|Religious Recitation|listen to Surah Ar-Rahman for 14 minutes
214477844|NCT06864455|BEHAVIORAL|Infant Video with Music|10 minutes of slides show of infant's image and video
214477845|NCT06864455|BEHAVIORAL|Distraction with News and Media|10 minutes of phone use
214668276|NCT00072969|DRUG|Daclizumab|
214889613|NCT00313079|DRUG|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
214907082|NCT03945227|DRUG|PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001|drug:PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. -For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
215049450|NCT01010607|DEVICE|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
215049451|NCT06277440|OTHER|cognitive training|cognitive training, 15 min, three times per week, for 12 weeks
215049452|NCT06277440|OTHER|active control|Traditional rehabilitation programs
215049453|NCT05772325|OTHER|Individually tailored diet counseling|Participants in the intervention group will receive a 60 min individually tailored heart-friendly diet consultation by a dietitian
215049454|NCT05772325|OTHER|The brief standardized 4-minute heart healthy dietary advice|The brief standardized 4-minute heart healthy dietary advice will be provided by an experienced cardiologist or rheumatologists
215049455|NCT02217969|BEHAVIORAL|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
215049456|NCT05739292|BIOLOGICAL|EuNmCV-5|0.5mL single intramuscular dose on Day 0
215049457|NCT05739292|BIOLOGICAL|Menveo|0.5mL single intramuscular dose on Day 0
214294719|NCT00326443|BIOLOGICAL|CVD 909|5 X 10\^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
214294720|NCT00326443|DRUG|Placebo|Buffer placebo administered on Day 0.
214294721|NCT00326443|BIOLOGICAL|Vi Polysaccharide|25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
214294722|NCT05547074|PROCEDURE|pancreatic cancer surgery|Surgical resection of pancreatic cancer，including radical or palliative surgery
214294723|NCT02450032|BIOLOGICAL|G17DT|
214294724|NCT03860428|DRUG|Ibuprofen|In the medical treatment arm the in-tention is to close the ductus arteriosus.
214294725|NCT03860428|DRUG|Paracetamol|In the medical treatment arm the in-tention is to close the ductus arteriosus.
214294726|NCT03860428|OTHER|Expectant Management|Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
214294727|NCT02607436|DRUG|Sarpogrelate|Sarpogrelate
214294728|NCT02607436|DRUG|Aspirin|Aspirin
214477846|NCT06864455|BEHAVIORAL|Control|All participants will ask to sit for 10minutes . Minimum distraction will be applied such as minimal or no chatting.
214477847|NCT01850849|DRUG|LEO 39652 cream|
214477848|NCT01850849|DRUG|cream vehicle|
214294729|NCT03380585|PROCEDURE|Reciprocating single-file system|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.The device in the experimental group moves in CW and CCW direction with different angles. It is a single-file endodontic file system. The intervention is reciprocating single-file system. A Reciproc single-file will be used for enlarging apical foramen. In the active comparator group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
214294730|NCT03380585|PROCEDURE|Rotational multi-file system.|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged. In this group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
214294731|NCT06609902|BEHAVIORAL|Future Self-BD|The Future Self group will attend 6 virtual sessions during which they will be encouraged to vividly generate personal and positive future events that they anticipate may be benefited by smoking cessation. All participants will complete the adjusting amount discounting task. All participants will also receive brief, CBT-based smoking cessation counseling. This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
214294732|NCT06609902|BEHAVIORAL|Daily Check-Ins|The Daily Check-Ins (DCI) group will attend 6 virtual sessions during which they will complete the adjusting amount discounting task and receive brief, CBT-based smoking cessation counseling (consistent with counseling received by Future Self-BD). This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
214294733|NCT04779840|OTHER|anemia assessment|evaluation of anemia status
214294734|NCT04446910|BEHAVIORAL|SMS Text Messaging|SMS text messaging intervention for a period of 90 days to promote attendance at community-based substance use or dual diagnosis treatment appointments through motivational messages.
214294735|NCT04446910|BEHAVIORAL|Standard of Care Engagement Practices|Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
214294736|NCT00644995|BEHAVIORAL|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
214294737|NCT00644995|BEHAVIORAL|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
214294738|NCT02226406|OTHER|A: Chair - Leg Cycle ergometer|
214477849|NCT06615843|DEVICE|Participants will receive post-emergency gynecological follow-up at home using a connected health app|The app will facilitate data collection and communication, including logging of vital signs, symptoms (such as pain, bleeding, and vomiting), and uploading of test results. Medical professionals will review the health data twice daily and provide care instructions through instant messaging. The app will also alert the medical team of any urgent updates or deviations from expected health patterns
214477850|NCT02293954|PROCEDURE|radionuclide imaging|Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
214477851|NCT02293954|PROCEDURE|positron emission tomography|Undergo PET
214477852|NCT02293954|OTHER|laboratory biomarker analysis|Correlative studies
214477853|NCT02293954|OTHER|pharmacological study|Correlative studies
214477854|NCT02293954|DRUG|Cu 64 anti-CEA monoclonal antibody M5A IV|Cu 64 anti-CEA monoclonal antibody M5A IV
214477855|NCT06617195|OTHER|Exercise|Young and older adults will perform a single bout of unaccustomed resistance exercise to evaluate molecular and cellular response in skeletal muscle
215049458|NCT05932173|BIOLOGICAL|Anti-CD19 Autologous CAR-T Cell Infusion|Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform
215049459|NCT04570618|DEVICE|Unblinded AlgoDx Sepsis Prediction Algorithm|When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.
214477856|NCT01907126|BEHAVIORAL|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
214668277|NCT06301126|OTHER|Virtual reality|The system included an Xbox 360® console, a sensor that detects motion (Kinect®), and a projector device with loudspeakers. The console, which was mounted on a table, reached 1 m tall. The Kinect® motion sensor was attached to the projector, which showed images onto a wall 2.5 metres distant from the playing field. The playing field was at least 1.8 m wide and 1.8 m long, with the Kinect® sensor situated 1.2 m away. The device was calibrated before each training session to accurately follow the motions of each subject.
214668278|NCT06301126|OTHER|conventional physical therapy exercise program|Participants will receive conventional physical therapy exercise program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.
214294739|NCT02226406|OTHER|B: Chair - Arm Cycle ergometer|
214294740|NCT02226406|OTHER|C: Walk in place|
214294741|NCT06215040|PROCEDURE|Endoscopic retrograde cholangiopancratography|common bile duct stone removal
214294742|NCT05376969|DRUG|DWP16001|DWP16001 Tablets
214294743|NCT02066233|DEVICE|EG Scan II (transnasal endoscopy)|
214668279|NCT06294925|DRUG|Etrasimod|As provided in real world practice
215049460|NCT04570618|OTHER|Blinded AlgoDx Sepsis Prediction Algorithm|Standard of Care, i.e. no sepsis prediction alert.
215049461|NCT05768594|OTHER|Blood sample|After blood sampling, patients will undergo a Color Doppler Echocardiogram, a non-invasive method
215049462|NCT03402100|DRUG|eye drops|children who received daily eye drops for myopia
215049463|NCT05964894|OTHER|ergonomic training|ergonomic education \& exercise training
214294744|NCT02066233|PROCEDURE|Standard Endoscopy|
214294745|NCT00295906|OTHER|educational intervention|
214294746|NCT00295906|OTHER|internet-based intervention|
214294747|NCT02772081|COMBINATION_PRODUCT|LISA combination product (Curosurf+catheter CHF6440)|Curosurf administration through brief insertion of a thin catheter into the trachea
214294748|NCT02772081|DRUG|Curosurf through conventional administration (endotracheal tube)|Curosurf through conventional administration (endotracheal tube), followed by rapid extubation
214668280|NCT02188446|BEHAVIORAL|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
214889614|NCT06582979|BEHAVIORAL|Computer-Based Game Therapy|Computer-based game intervention will be done three times a week, every morning before school lessons begin or during break time. Researchers will give a brief explanation of the rules on how to play the game before the intervention begins. In the game, participants will act as a fruit truck delivery driver and will have to sort out fruit delivery to different houses according to the instructions of the game. For example, the instruction starts with delivering a yellow-colored banana to a house with a red-colored roof, or delivering a purple-colored grape to a house with a blue-colored roof. Participants will first have to finish a minimum of three tutorial rounds reaching ≥75% correct delivery. Instructions will be divided into four stages; visual stimulus, auditory stimulus, visual stimulus with an obstacle, auditory stimulus with an obstacle. Each round will last for 2 minutes. Total time needed to complete a single computer-based intervention session is around 30-45 minutes.
214889615|NCT06582979|BEHAVIORAL|High-Intensity Interval Training|HIIT will be done two times a week during physical education hours (in the school's sports field) led by the school's physical education teacher and also certified physical trainers who have undergone training supervised by a sports medicine physician. Before the start of each HIIT session, participants will have their pulse rate assessed with a pulse oximetry and then undergo warm-up for 5 minutes. The duration of each HIIT session will be continuously extended starting at around 4 minutes (1 tabata block/8 moves) during the first week to 8 minutes (2 tabata block/16 moves) during the final week. A single tabata block moveset incorporates 8 total moves; squat jump, push up, high skipping, burpees, isometric front plank, multi jumps on bench, mountain climber in hand plank and lateral sprint (5m). Each move will be done for 20 seconds, followed by a 10 second rest. Pulse rate will be assessed again after the HIIT session and then participants will undergo cooling down and relaxation.
214889616|NCT05509517|DIAGNOSTIC_TEST|Photoplethysmography based smartphone application for heart rhythm analysis (FibriCheck™)|Heart Rhythm assessment using the FibriCheck™ application with the patient's proprietary smartphone, three times daily, from discharge until follow-up consultation (day 21-91 after discharge).
214889617|NCT02641652|DRUG|Sertraline|25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
214889618|NCT02641652|DRUG|Placebo|1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
214907083|NCT01205776|DEVICE|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
214907084|NCT01205776|PROCEDURE|CABG|Those patients receiving CABG
214907085|NCT04853082|DRUG|Limonene capsule|All the recruiters will be given treatment under the guidance of basic diet. Basic dietary guidelines include high-quality protein and fresh green leafy vegetables. It need to controlled sugar, various sweets and high-calorie foods, frying and other foods with high oil content and foods with high cholesterol content. Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
214907086|NCT04853082|DRUG|Limonene capsules(Placebo)|Limonene capsules(Placebo)
214907087|NCT04191174|OTHER|Hyperpolarized 129Xe MRI|Hyperpolarized 129Xe MRI to evaluate ventilation heterogeneity
214907088|NCT04191174|OTHER|Technegas V SPECT|Technegas V SPECT to evaluate ventilation heterogeneity
214907089|NCT04191174|OTHER|Sputum Induction|Sputum induction to evaluate luminal cellular inflammation
214294749|NCT01141907|BEHAVIORAL|Heart Failure Self Care Support|The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.
214889619|NCT04710615|DEVICE|Synapse platform|"The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.~The Synapse platform offers a panel of functions to help the doctor to prescribe medication."
214889620|NCT03513991|OTHER|Infant formula|
214889621|NCT02595801|OTHER|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
214889622|NCT04812301|RADIATION|Egg-white sandwich|1 mCi of Tc-99m sodium phytate is added into the egg-white sandwich
214889623|NCT04812301|RADIATION|Abbott Vital®|1 mCi of Tc-99m sodium phytate is added into the Abbott Vital®
214294750|NCT01141907|OTHER|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
214889624|NCT03845192|DEVICE|ORI measurement by Radical 97|"ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®."
214889625|NCT02295501|BIOLOGICAL|INTERCEPT Plasma|Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
214889626|NCT02771769|OTHER|blood draw|Participants will have a venous blood draw of \~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
214294751|NCT00314015|PROCEDURE|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
214294752|NCT00314015|PROCEDURE|Questionnaires|Questionnaires will be used
214294753|NCT04924647|DRUG|lenalidomide and dexamethasone|lenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22
214889627|NCT01811472|DRUG|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
214889628|NCT01811472|DRUG|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
214889629|NCT05664269|DIETARY_SUPPLEMENT|drink ingestion|drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker
214889630|NCT05664269|BEHAVIORAL|resistance-type exercise|Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
214889631|NCT03505086|DIAGNOSTIC_TEST|Blood withdrawal|"* Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure.~* Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time.~* Urine sampling will be for a maximum of 5 times per admission.~* Urine can be sampled from a catheter when present, or collected regular."
214889632|NCT03505086|OTHER|Questionnaire for former bleeding events|Questionnaire to investigate a bleeding tendency before diagnosis.
214889633|NCT03280264|DRUG|KHK7580|oral administration
214889634|NCT05855603|PROCEDURE|Cardioneuroablation|"Ganglionated plexi will be localized using an empirical anatomical approach and/or a fractionated electrogram-based strategy.~Point-by-point ablation will be performed using radiofrequency energy and an irrigated tip contact force sensing ablation catheter in a power control mode (35-50 W; AI, 350-500; LSI, 4.5-5.5). The right superior GP (RSGP), left superior GP (LSGP) and posterior left GP (PMLGP) will be targeted during CNA. Radiofrequency applications in other GPs will be left at the discretion of the operator.~At the end of the procedure, another EP study and atropine test will be performed. Clinical endpoints for completion of the CNA will be: 1) a HR increase \>20% if the CNA was performed under general anesthesia/deep sedation; 2) improved electrophysiological parameters; 3) significant reduction in atropine response (HR increase \<10% after atropine); and 4) in case of using extracardiac vagal stimulation, lack of response."
214889635|NCT05855603|DEVICE|Permanent pacemaker therapy|All patients in the pacemaker group will receive a dual-chamber pacemaker that has the ability to be programmed in the DDD-CLS algorithm mode (or failing this, a dual-chamber pacemaker with RDR algorithm).
214294754|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care group|Self-hypnosis/self-care
214294755|NCT04218227|BEHAVIORAL|Music/self-care|Music-therapy/self-care
214889636|NCT02574832|DRUG|Lidocaine Administration|The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
214889637|NCT01200173|OTHER|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
214889638|NCT01200173|OTHER|2-Non fermented dairy product (control)|
214889639|NCT01248676|OTHER|Multi-language Online Patient Education Module in addition to standard Patient Teaching|"Patients are usually be given a 5-10 minute new patient teaching before their radiation therapy simulation and planning appointment and before their first radiation therapy treatment appointment. Patients will be asked to view an online patient education module before their radiation therapy simulation and planning appointment or before their first radiation therapy treatment appointment. Then patients will be asked to participate in an interview session and fill out a survey (attached). They will still receive new patient teaching from the therapists before their radiation therapy simulation and planning or radiation therapy treatment appointment."
215049464|NCT05999331|OTHER|initial aspartate aminotransferase (AST) to platelet (PLT) ratio index|All eligible patients were given antibiotics therapy, actively control infection source, as well as other supportive therapy to maintain organ function.
214889640|NCT02071030|PROCEDURE|Third molar removal|Surgically removing the third molar in the lower jaw
214889641|NCT06033391|DEVICE|GGOC-AD (GG Obsessive-Compulsive Disorder - Adolescents)|"GGOC was originally designed to challenge maladaptive beliefs that underline OCD symptoms in adult population. It was adapted to adolescent population. It consists of statements that are presented to the user, and that can portray either negative (I can't trust myself) or positive beliefs (I have a lot of good characteristics). Users have to respond by either pulling these towards Accept or Reject."
214294756|NCT04218227|BEHAVIORAL|Self-care|Self-care
214907090|NCT03268980|OTHER|Questionnaire Hospital Staff group|One-page questionnaire with 15 questions about tobacco habits
214907091|NCT03268980|OTHER|Questionnaire students and patients group|One-page questionnaire with 17 questions about tobacco habits
214907092|NCT01358929|DRUG|Placebo|Placebo to RO6807952
214907093|NCT01358929|DRUG|RO6807952|Escalating subcutaneous dose
214907094|NCT00734994|DEVICE|Hyperthermia System|Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence
214907095|NCT00734994|DRUG|Mitomycin C|40 mg in 40 ml sterile water instilled into bladder
214907096|NCT02596360|DRUG|Pulmodexane® 30mg|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
214907097|NCT02596360|DRUG|lactose|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
214907098|NCT02021929|DRUG|Sorafenib|"Sorafenib is a kinase inhibitor indicated for the treatment of:~* Unresectable hepatocellular carcinoma~* Advanced renal cell carcinoma~* Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment"
214907099|NCT02021929|DRUG|Placebo|
214907100|NCT02081027|DRUG|Riluzole|
214907101|NCT02081027|OTHER|placebo|
214907102|NCT05925647|DRUG|Messenchymal stem cell secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
214907103|NCT05925647|DRUG|Placebo|NaCl 0,9% infusion
214907104|NCT01199627|DRUG|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
214907105|NCT01199627|DRUG|B|"Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
214907106|NCT01199627|DRUG|C|"Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
214907107|NCT06854783|DRUG|Cannabidiol|Cannabidiol
214907108|NCT07071649|OTHER|blood withdrawal|blood withdrawal
214907109|NCT07071974|DRUG|BI 456906 formulation A|BI 456906 formulation A
214907110|NCT07071974|DRUG|BI 456906 formulation B2|BI 456906 formulation B2
214907111|NCT06848530|OTHER|Prescribed Medications|participant's movement disorders medications, prescribed by their treating physician
214907112|NCT06848530|OTHER|Deep brain stimulation adjustment|Deep brain stimulator parameters may be adjusted within normal clinical limits
214907113|NCT04802759|DRUG|Giredestrant|30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
214907114|NCT04802759|DRUG|Abemaciclib|150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
214907115|NCT04802759|DRUG|Ipatasertib|400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
214907116|NCT04802759|DRUG|Inavolisib|9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
214907117|NCT04802759|DRUG|Ribociclib|600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
214907118|NCT04802759|DRUG|Everolimus|10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
214907119|NCT04802759|DRUG|Samuraciclib|360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
214907120|NCT04802759|DRUG|PH FDC SC|On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
214907121|NCT04802759|DRUG|Palbociclib|125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
214907122|NCT04802759|DRUG|Atezolizumab|840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
214477857|NCT01907126|BEHAVIORAL|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
214477858|NCT04603911|DRUG|Liposomal bupivacaine|The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.
214889642|NCT06033391|DEVICE|GGN-AD (GG Neutral - Adolescents)|"it was designed to have a comparison group. It consists of neutral statements such as Madrid is a Spanish city, that ought not to produce changes in the direction of our hypothesis. These have to be Accepted or Rejected based on their veracity."
214889643|NCT01043887|DRUG|ridaforolimus|single oral dose administration 10 mg ridaforolimus
214477859|NCT04603911|DRUG|Bupivacaine, epinephrine, dexamethasone, and clonidine|The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.
214477860|NCT05563584|BEHAVIORAL|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support
214477861|NCT05475678|DRUG|（Carrelizumab + TCb） regimen|Carrelizumab +docetaxel + carboplatin regimen
214477862|NCT05475678|DRUG|TCb regimen|docetaxel + carboplatin regimen
214477863|NCT04869488|DRUG|Fluzoparib|Fluzoparib Orally twice daily（Cohort 1、Cohort 4）
214477864|NCT04869488|DRUG|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）
214477865|NCT04869488|DRUG|Fluzoparib Combined With Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
214477866|NCT06071286|PROCEDURE|Blood samples|Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
214889644|NCT01377220|DRUG|11C-Choline|11C-Choline : 6MBq/kg on direct intravenous on one minute.
214889645|NCT04159246|DEVICE|Optical coherence tomography angiography|"Recent Optical coherence tomography angiography OCT-A will be performed to all patients before Treatment Administration.~* Examination will be performed using Optovue AngioVue® Optovue, Inc., Fremont, CA, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.~* The patient will be examined before and after finishing the treatment course"
214889646|NCT04159246|DRUG|Sofosbuvir (Sovaldi)|Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months
214477867|NCT05825079|BEHAVIORAL|Weight-Bearing Feedback|Feedback on how much weight patients are exerting on their crutch/injured lower extremity (measured via Smart Crutch Tip) will be delivered to their mobile phones.
214889647|NCT02180048|DIETARY_SUPPLEMENT|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
214889648|NCT02180048|DIETARY_SUPPLEMENT|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
214477868|NCT05825079|DEVICE|Smart Crutch Tip|The device is attached to the crutch and measures how much weight-bearing load is exerted onto its axis. The device is capable of transmitting this data into the patient and physicians' user interface.
214477869|NCT06674408|OTHER|Traditional physical therapy|"Control group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Finger Ladder Exercise, Codman's Pendulum Exercise, Towel Stretch Exercise and Wand Exercises 10 reps x 2 sets per session,~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week of treatment for outcome measures."
214668281|NCT02677740|DEVICE|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
214889649|NCT02180048|DIETARY_SUPPLEMENT|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
214889650|NCT01935830|RADIATION|[11c] LAAM|intravenous administration of 15-20 mCi of \[11c\] LAAM.
214889651|NCT01935830|DRUG|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
214889652|NCT01935830|DRUG|Efavirenz|Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
214889653|NCT05938114|OTHER|Bonalive|Bonalive® is a bioactive glass synthetic bone substitute material that has been shown to have a low substitution rate and antibacterial properties. It has been used successfully in the orthopaedics, craniofacial and ear nose and throat (ENT) specialities for the treatment of osteomyelitis, sinusitis and bony cyst cavities. There have also been a few maxillofacial surgery case reports on its usage in the jaws.
215049465|NCT06011265|DRUG|Myrbetriq 25Mg Extended-Release Tablet|Participants take 4x 25mg Myrbetriq 25Mg Extended-Release Tablet orally.
215049466|NCT06011265|DRUG|Placebo|Participants take empty capsule orally
214889654|NCT05938114|OTHER|Bio-Oss®|Bio-Oss® is a bovine xenogeneic bone graft substitute that is widely used in regenerative dentistry. Bio-Oss® is very similar to human bone in its structure and chemical make-up. The material's porosity allows for vascularisation and new bone formation.
214889655|NCT02738138|DRUG|ABT-493 coformulated with ABT-530|Tablet
214889656|NCT04030208|DEVICE|Umbulizer|Umbulizer is a reliable, user-friendly, and portable system that provides consistent air to the patient by quantitatively delivering a pre-determined tidal volume, inhale/exhale (I/E) ratio, peak pressure, and breathing rate (BPM). It can be configured to deliver either controlled ventilation or assist-controlled ventilation.
214889657|NCT04030208|DEVICE|Traditional Mechanical Ventilator|A medical device designed to artificially perform breathing functions for patients who are unable to adequately perform these functions on their own.
214889658|NCT01088958|DIETARY_SUPPLEMENT|Micronutrient powders (Sprinkles)|"Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:~Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg"
214889659|NCT00012922|BEHAVIORAL|Low Literacy Intervention for Colorectal Cancer Screening|
214889660|NCT01184651|BEHAVIORAL|Questionnaires/Interviews|Girls answer questions about activities and interests, school, feelings about being a girl, stage of physical development, and family relationships during a home interview , provide saliva samples, and participate in phone interviews to answer questions about daily activities .
214889661|NCT01184651|BEHAVIORAL|Questionnaires/Interviews|Parents complete questionnaires about their daughter's activities, interests, and behaviors, educational goals, family demographics and relationships, grades, diagnosis and treatment of her CAH, their own activities, interests, and thoughts and feelings about being male or female. Parents answer questions during phone interviews about their daughters daily activities.
214889662|NCT00381979|OTHER|Supportive Expressive Therapy|
214889663|NCT04364776|DRUG|Durvalumab|In this observational study, durvalumab will be administered according to current indications (PACIFIC phase III trial).
214889664|NCT03213444|DRUG|adjuvant chemotherapy with 5-FU isolated|Patients submitted to adjuvant chemotherapy with 5-FU isolated
214889665|NCT03213444|DRUG|adjuvant chemotherapy with 5-FU associated with oxaliplatin|Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
214889666|NCT03517501|DRUG|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
215049467|NCT02461199|BIOLOGICAL|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
215049468|NCT02928861|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
215049469|NCT01745653|DEVICE|Low level laser therapy|
215049470|NCT01745653|PROCEDURE|sham procedure|
215049471|NCT02392988|OTHER|acupuncture treatment|acupuncture treatment
214889667|NCT03517501|DRUG|Placebo Comparator - Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
214889668|NCT00599365|OTHER|Pharmacy care arm|"* The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.~* You will need to give a complete list of medications to the pharmacist.~* You will need to describe how you take these medications.~* The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.~* The pharmacist will give you a medication schedule, and other papers about your medications."
214889669|NCT02550301|OTHER|Mean Platelet Volume|Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
214889670|NCT00635310|PROCEDURE|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
214889671|NCT00635310|PROCEDURE|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
214889672|NCT03514095|OTHER|Individual Cognitive Stimulation Therapy Program|"This program unfolds in 3 weekly sessions of 30 minutes, for 12 weeks, thus completing a total of 36 sessions.~Over the 3 months, the dyad will need to be monitored for orientation / monitoring of intervention by an element of the research team. This monitoring will be bi-weekly, in person or by phone - here according to the choice of the dyad). After each session the caregiver has a questionnaire to complete (intervention monitoring strategy), with the objective of evaluating the acceptability and applicability of the program."
214889673|NCT05193838|DRUG|Allopurinol Tablet|examined patients with dilated cardiomyopathy will receive allopurinol for 6 months
214889674|NCT01995513|DRUG|Enzalutamide|160 mg by mouth once daily
214889675|NCT01995513|DRUG|Abiraterone|1000 mg by mouth once daily
214889676|NCT01995513|DRUG|Placebo for Enzalutamide|Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
214889677|NCT01995513|DRUG|Prednisone|5 mg by mouth twice daily
214889678|NCT03757858|DEVICE|Thermotron RF-8|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.
215049472|NCT02392988|OTHER|Placebo Comparator|Placebo Comparator
215049473|NCT03132467|BIOLOGICAL|Durvalumab|Given IV
214889679|NCT03757858|BIOLOGICAL|Adoptive cellular Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.
214889680|NCT03757858|DRUG|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
214889681|NCT03757858|DRUG|Chemotherapy|Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
214889682|NCT00960219|DRUG|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
214889683|NCT00960219|DRUG|placebo|1# BID, oral, for 6 weeks
214889684|NCT02120196|DRUG|Rifaximin|rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
214889685|NCT02120196|DRUG|Norfloxacin|FDA approved:400mg once daily
214889686|NCT03105518|DRUG|Fentanyl|0.5, 1 mcg/kg
214889687|NCT03105518|DRUG|Acetaminophen|Single + Oxycodone
214889688|NCT03105518|DRUG|Oxycodone|With Acetaminophen
214889689|NCT04534452|DRUG|Phenylephrine HCl (Sinus Comfort, BAY112476)|30 mg Extended Release Tablets, single oral dose
214889690|NCT03652337|DEVICE|BlephEx|Electronic lid margin debridement
214889691|NCT03652337|DEVICE|Manual debridement|Manual lid margin debridement
214889692|NCT04841837|BEHAVIORAL|Time-restricted feeding|limit daily food intake to a period of 10 hours
214889693|NCT00575237|PROCEDURE|Recruitment manouver|In the intervention group, CO2 was removed by means of Trendelenburg position (\> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
214889694|NCT05345106|PROCEDURE|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
214889695|NCT05675098|DRUG|Methylphenidate|This medication is a psychostimulant medication and is usually prescribed for individuals with Attention-Deficit/Hyperactivity Disorder to manage ADHD behavioral symptoms
214889696|NCT05675098|DRUG|Modafinil|This medication is a Central Nervous System stimulant and is usually used to treat neurological conditions, including Narcolepsy
214889697|NCT05675098|OTHER|Placebo|Participant will receive placebo tablets (Methylphenidate and Modafinil shape)
215049474|NCT03132467|BIOLOGICAL|Tremelimumab|Given IV
214889698|NCT03749889|OTHER|100 g carbs|Participants will be assigned a diet of 100g carbs max for the day
214889699|NCT03749889|OTHER|MyPlate|40-65% of daily intake is from carbohydrates
214889700|NCT02411825|DRUG|SAR425899|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214889701|NCT02411825|DRUG|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214889702|NCT02411825|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
214889703|NCT05387889|BEHAVIORAL|Mindfulness Meditation for Pulmonary Hypertension (MMPH)|Eight weeks of Mindfulness Meditation practice for patients with Pulmonary Hypertension condition. The content will focus on how to apply Mindfulness concepts to the everyday management of symptoms and stress.
214889704|NCT00208442|DEVICE|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
214889705|NCT00208442|DEVICE|Enduron|Standard polyethylene liner in a modular acetabular component
214889706|NCT03345771|COMBINATION_PRODUCT|Antimicrobial Barrier Dressing|Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.
214889707|NCT03345771|DEVICE|Negative Pressure Wound Therapy (NPWT)|PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing
214889708|NCT03715920|DEVICE|Electrical currents|The training was planned as HVPG current for the the first group (n = 16), as Russian current for the second group (n = 15) and as isometric strengthening for the third group (n = 15). All treatments were performed under physiotherapist supervision for a total of 15 sessions for 3 days a week for 5 weeks.
214889709|NCT02287714|PROCEDURE|Instep without gastrocnemius recession|Patient will receive an instep plantar fascial release without gastrocnemius recession.
214889710|NCT02287714|PROCEDURE|Instep with gastrocnemius recession|Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
214889711|NCT00634868|OTHER|Qray light therapy device|The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.
214889712|NCT00634868|DEVICE|Qray light therapy device-Sham|non curative light- the device emits the same broad light, but with very low intensity
214889713|NCT02744872|DRUG|Felodipine|Felodipine 10 mg once daily or identical placebo
214889714|NCT02744872|DRUG|Placebo|Placebo
214889715|NCT02045446|RADIATION|Stereotactic Body Radiation Therapy|
214889716|NCT02045446|DRUG|Maintenance chemotherapy|Maintenance chemotherapy
214889717|NCT02276456|BEHAVIORAL|Follow-up Appointment- early vs standard|Patient will undergo early follow-up (within 7 days of discharge) of discharge
214889718|NCT03198338|DRUG|0.25% Bupivacaine, 0.5mL/kg|Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
215049475|NCT04960670|OTHER|Evaluation of microbiome and maternal/infant lifestyle|Identification of the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with adiposity rebound vs children with early adiposity rebound.
215049476|NCT00038948|DRUG|Sirolimus|Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled
214294757|NCT04218227|BEHAVIORAL|Psycho-education|Psycho-education
214889719|NCT03198338|DRUG|Normal Saline|0.9% Normal Saline
214889720|NCT03198338|DEVICE|Ultrasound|Ultrasound guided TAP block
215049477|NCT00038948|DRUG|tacrolimus|
215049478|NCT00038948|DRUG|Cyclosporine A|
214889721|NCT06217913|DEVICE|wearable device to monitor the blood pressure|Pregnant women began to establish antenatal examination records (usually before 12 weeks of pregnancy), and were enrolled through randomized grouping. Pregnant women in the intervention group were provided with wearable blood pressure monitoring equipment, and ambulate blood pressure monitoring was conducted for at least 2 24 hours per week from 12 weeks of pregnancy until 28 weeks of pregnancy, after which blood pressure monitoring was carried out according to routine antenatal examination.
214889722|NCT00485511|DRUG|Hydroxyurea|
214889723|NCT05519748|BEHAVIORAL|Online psychoeducational program|The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.
214294758|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care motivation|Motivation to learn self-hypnosis/self-care
214294759|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC or intravenous injection.
214294760|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC injection.
214294761|NCT00770796|DRUG|Atorvastatin|80 mg die
214294762|NCT00770796|DRUG|Placebo|
214294763|NCT00176826|PROCEDURE|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
214294764|NCT00176826|DRUG|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
214889724|NCT03937505|DRUG|IS-001|intravenous injection of IS-001 investigational drug
214294765|NCT00191555|DRUG|olanzapine|
214889725|NCT03937505|DRUG|No treatment|no drug injection
214889726|NCT01404546|OTHER|cost free pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
214889727|NCT01404546|OTHER|usual care|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
214889728|NCT04855968|OTHER|In addition to standard post-op medication patient will have access to the head space meditation application.|Patients will receive access to head space meditation application in addition to standard pain medication post surgery.
214889729|NCT04855968|OTHER|Patients will take standard post-op pain medication|Standard post-op pain medication
214889730|NCT00002425|DRUG|Saquinavir|
214889731|NCT02071225|DRUG|bendamustine|70 milligrams per square meter (mg/m\^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
214889732|NCT02071225|DRUG|obinutuzumab|1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
214889733|NCT00004981|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
214889734|NCT00004981|DRUG|Lamivudine/Zidovudine|
214889735|NCT00004981|DRUG|Abacavir sulfate|
214889736|NCT02130908|OTHER|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
214294766|NCT00191555|DRUG|haloperidol|
214294767|NCT03876912|DRUG|GnRH antagonist|18F-PSMA 1007 PET/CT before, 3 weeks after ADT, at 1 year and at CRPC in 35 patients. 18F-FDG PET/CT in a subgroup of 20 patients before ADT.
214294768|NCT05704504|BEHAVIORAL|Group-based exercise intervention with EMA and personalized telephone support (SUP)|Participants in the SUP group will receive a 6-week group-based exercise intervention with EMA and personalized telephone support. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer and three 15-minute personalized telephone sessions delivered by research personnel. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and third group exercise sessions will include (1) reviewing exercise goals and EMA data, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
214294769|NCT05704504|BEHAVIORAL|Group-based exercise intervention (EXE)|Participants in the EXE group will receive a 6-week group-based exercise intervention. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer at the Chinese University of Hong Kong. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and the third group exercise sessions will include (1) reviewing exercise goals, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
214889737|NCT02130908|OTHER|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
214889738|NCT02130908|OTHER|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
214294770|NCT00094627|DRUG|gaboxadol|Duration of Treatment - 6 weeks
214889739|NCT00567008|DRUG|varenicline|1.0 mg BID for 8 weeks
214889740|NCT00567008|DRUG|placebo|placebo BID for 8 weeks
214889741|NCT00897650|GENETIC|DNA/RNA sequencing and expression levels|Lung tumor tissue will be collected.
214889742|NCT00897650|GENETIC|Protein expression analysis|Lung tumor tissue will be collected.
214889743|NCT00897650|PROCEDURE|Lung tumor biopsy|Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
214889744|NCT00897650|PROCEDURE|Blood sample|Patients will be asked for a venous blood sample
214889745|NCT02721342|DRUG|Ramipril, Irbesartan and Atorvastin|
214889746|NCT01417637|RADIATION|Low level laser therapy|Ga As diode laser (890 nm) Mustang 2000+, Russia), with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles. Laser therapy will be applied on all painful muscles three times a week for four weeks.
214889747|NCT01417637|RADIATION|Placebo group|In this group, the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects. Laser therapy will be applied on all painful muscles three times a week for four weeks.
214889748|NCT00458744|DRUG|talotrexin|
214889749|NCT00458744|PROCEDURE|chemotherapy|
214889750|NCT03327844|DRUG|RET using antibiotics (Ciprofloxacin and Metronidazole)|RET using antibiotics Ciprofloxacin and Metronidazole. First Treatment Visit: Local analgesic, tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal drying using paper points. Delivery of mixture of Bi antibiotic paste (Ciprofloxacin and Metronidazole with sterile water). Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstriction, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
214889751|NCT03327844|DRUG|RET using non-setting Calcium Hydroxide|First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
214889752|NCT01769248|DEVICE|Fine needle aspiration|Fine needle aspiration
214889753|NCT01769248|DEVICE|Fine needle biopsy|FNB
214889754|NCT05902286|BEHAVIORAL|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
214889755|NCT05902286|BEHAVIORAL|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
214889756|NCT02303457|PROCEDURE|CO2 Laser surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
214889757|NCT02303457|PROCEDURE|Open Surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
214889758|NCT02902224|DIETARY_SUPPLEMENT|Tap water|300ml tap water via nasogastric tube
214889759|NCT02902224|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g glucose via nasogastric tube
214889760|NCT02902224|DIETARY_SUPPLEMENT|Fructose|300ml tap water with 25g fructose via nasogastric tube
214889761|NCT00280735|DRUG|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
215049479|NCT03682965|BIOLOGICAL|Intra-lymphatic allergenic extract|Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.
214889762|NCT00280735|DRUG|docetaxel|75 mg/m² intravenously, once, every 3 weeks
215049480|NCT03682965|BIOLOGICAL|Intra-lymphatic placebo|The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.
215049481|NCT03271515|BIOLOGICAL|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
215049482|NCT05002725|DRUG|Lidocain|300mg (20ml) will be injected
215049483|NCT05522738|DRUG|Combination: Fruquintinib + FOLFIRI|"Phase 1b Fruquintinib was administered in a 3 + 3 dose escalation regimen at the following doses: L1:3 mg/d, L2:4 mg/d, L3:5 mg/d.~Fruquintinib: QD po q2w~FOLFIRI regimen:~Irinotecan：180 mg/m2, i.v. , d1, q2w LV：200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w~Phase II Fruquintinib: RP2D, QD po q2w~FOLFIRI regimen:~Irinotecan： 180 mg/m2, i.v. , d1, q2w LV： 200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w"
215049484|NCT00005935|DRUG|Mycophenolate mofetil|
215049485|NCT00005935|DRUG|Cyclosporine|
215049486|NCT06717607|DEVICE|low cylinder toric IOL|Clareon T2 toric IOL implantation
215049487|NCT06717607|DEVICE|non-toric IOL implantation|Clareon non-toric IOL
215049488|NCT01404234|DRUG|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
215049489|NCT02425397|GENETIC|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
214294771|NCT00094627|DRUG|Comparator: placebo (unspecified)|Duration of Treatment - 6 weeks
214889763|NCT04525534|OTHER|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment
215049490|NCT02425397|GENETIC|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
215049491|NCT06053528|DRUG|Antibiotic|Effect if treatment
215049492|NCT02670473|DEVICE|fanfilcon A (test)|contact lens
215049493|NCT02805452|DRUG|Succinate of Solifenacin|
215049494|NCT02805452|DRUG|Placebo of Succinate of Solifenacin|
215049495|NCT05678946|OTHER|Integrated face-to-face rehabilitation and telerehabilitation|Kela´s integrated face-to-face rehabilitation and telerehabilitation services for family caregivers include two 5-day periods of face-to-face rehabilitation and a 12-week telerehabilitation period between them. It is for those over the age of 18 who work as family caregivers on a daily basis and need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. The service, provided free of charge, is carried out in a Finnish rehabilitation centre and online over a period of 8 months, and it is implemented by a multidisciplinary team of rehabilitation experts. During the 12-week telerehabilitation period, the service providers utilise The Own Path, an acceptance and commitment therapy -based guided web intervention found beneficial for older Finnish family caregivers (Lappalainen et al. 2021). Telerehabilitation is independent of time and place.
215049496|NCT05678946|OTHER|Social Holidays|MTLH's Social Holidays for family caregivers are 5-day holidays in a Finnish hotel, spa, sports institute, or rehabilitation centre. The theme, content, and level of available assistance in Social Holidays vary, and the rehabilitation concept is lighter than that of Kela's rehabilitation services. Social Holidays include full-board accommodation and holiday activities, e.g. lectures, group discussions, instructed exercise, and a pampering treatment. MTLH organises Social Holidays for family caregivers as well as family caregivers and care recipients. The participants cover their travel expenses and pay a fixed sum of €125. Other than that, Social Holidays are provided free of charge. Social Holidays are intended for family caregivers who need recreational activities, rest, and peer support.
215049497|NCT05678946|OTHER|Face-to-face rehabilitation|Kela's rehabilitation services for family caregivers and the care recipients include three 5-day periods of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation centre over a 10-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation services for family caregivers and the care recipients are provided free of charge. The service is intended for persons over the age of 18 who work as family caregivers on a daily basis with or without family caregiver support and who need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation.
215049498|NCT06663449|PROCEDURE|subcostal transversus abdominis plane block|subcostal transversus abdominis plane block will be performed using 20 mL of 0.25 bupivacaine
215049499|NCT06663449|PROCEDURE|erector spinae plane block|erector spinae plane block will be performed using 20 mL of 0.25 bupivacaine
214889764|NCT02368964|DRUG|GnRH agonist 0.2 mg + hCG 250 mcg|Treatment for triggering
214889765|NCT02368964|DRUG|high dose hCG 500 mcg|Treatment for triggering
214889766|NCT03524170|DRUG|Bintrafusp Alfa|Given IV
214889767|NCT03524170|RADIATION|Radiation Therapy|Undergo radiation therapy
214889768|NCT03925675|DRUG|PET/CT with F-Fluciclovine (Axumin)|Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
214294772|NCT06267950|BEHAVIORAL|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214889769|NCT03648099|BEHAVIORAL|Labor dance|The dance group which involved pregnant women who performed the labor dance
214889770|NCT03648099|BEHAVIORAL|Music|The music group involving pregnant women who were exposed to music.
214889771|NCT04795037|DRUG|CU06-1004, Single dose|"Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5"
214889772|NCT04795037|DRUG|CU06-1004, Multiple doses|"Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD"
214889773|NCT04795037|DRUG|Placebo|Placebo matched to CU06-1004, oral capsule
214889774|NCT05156671|BIOLOGICAL|Adrecizumab (HAM 8101)|Drip infusion over 60 minutes.
214889775|NCT05156671|DRUG|Placebo|Drip infusion over 60 minutes
214889776|NCT04960371|DIAGNOSTIC_TEST|coronary flow reserve (CFR)|Coronary flow velocity profiles in the left anterior descending artery were obtained using colour-guided pulse wave Doppler. We measured peak diastolic coronary flow velocity of the diastolic coronary waveform at rest and after ATP infusion (140 µg/kg. min) for 2 min. The CFR was calculated as the ratio of hyperaemic peak diastolic velocity to resting baseline diastolic velocity. All patients abstained from caffeine-containing drinks for at least 24h before testing.
214889777|NCT05740111|OTHER|Annual surveillance|Annual surveillance includes annual MRI and/or an assessment new onset diabetes and unintended weight loss.
214889778|NCT01895777|DRUG|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
214889779|NCT01895777|DRUG|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
214889780|NCT02064296|DEVICE|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device (AS Super 4 digital needle stimulator).
214294773|NCT06267950|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214294774|NCT06267950|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214294775|NCT01982747|DRUG|MGN-Placebo|
214294776|NCT01982747|DRUG|Placebo-MGN|
214294777|NCT02256228|DRUG|Ropivacaine|Active Group
214889781|NCT02064296|DEVICE|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device (Vita Laser 650, Lhasa OMS) will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
214889782|NCT03412721|PROCEDURE|Laser analgesic procedure|"Water mist spray set to maximum, non-contact handpiece with sapphire tip. Tip-to-tissue distance 10 mm from the tooth neck, achieved by using a spacer. Energy is delivered to the enamel above the gingival margin adjacent to the cemento-enamel junction (perpendicularly towards the dental pulp) on each of the four line angles of the tooth for 30s, moving the laser handpiece in a sweeping action. Pulse energy - 0.2 W/ 10 Hz/ 20 mJ. Follows increase of energy and repetition of protocol - 0.6 W/ 15 Hz/ 40 mJ. Total duration of LA-induction - 240s."
214889783|NCT03412721|PROCEDURE|Placebo analgesic procedure|Performing imitation of laser analgesic procedure. No pulse energy applied, non-contact handpiece with sapphire tip. Moving the laser handpiece in a sweeping action towards the cemento-enamel junction (pointing perpendicularly towards the dental pulp) on each of the four line angles of the tooth. Total duration of placebo analgesia induction - 240s.
214889784|NCT02119013|DRUG|Octeotride|
214889785|NCT02119013|DRUG|Placebo|
214889786|NCT03606343|BEHAVIORAL|Teaching Academic Skills to Kids|Group treatment
214889787|NCT03552510|PROCEDURE|Oro-pharyngeal Administration of Mother's Milk|Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)
214889788|NCT03099109|DRUG|LY3321367|Administered IV
214889789|NCT03099109|DRUG|LY3300054|Administered IV
214889790|NCT01240759|DRUG|S-707106 Dose A|One S-707106 A tablet
214889791|NCT01240759|DRUG|S-707106 Dose B|One S-707106 B tablet
214889792|NCT01240759|DRUG|S-707106 Dose C|Four S-707106 4 X B tablets
214889793|NCT01240759|DRUG|Placebo A tablet|Up to 4 Placebo A tablets
214889794|NCT01240759|DRUG|Metformin|The standard of care dose of metformin for each patient
214889795|NCT03044028|DEVICE|CyMedica Orthopedics QB1 e-vive™ system|a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
214889796|NCT04149821|DRUG|Umbralisib|"* Lead-in cycle of 28 days (Cycle -1) of umbralisib monotherapy, 800mg oral daily~* Continued 800mg oral daily dosing in all subsequent cycles (combination therapy cycles 1-6, then continued monotherapy cycle 7 and beyond)"
214889797|NCT04149821|DRUG|Ublituximab|-Co-administered on days 1 and 2 (dose split over days 1 and 2), 8, 15 of cycle 1 then on day 1 for subsequent cycles 2-6
214889798|NCT00644215|DRUG|5-FU and Mitomycin|"* 5-FU injection 5mg~* Mitomycin drop 0.02%"
214889799|NCT00218387|DRUG|Modafinil|200mg Modafinil
214889800|NCT00218387|DRUG|Modafinil|400mg Modafinil
214889801|NCT00218387|DRUG|Matching Placebo|Matching Placebo
214889802|NCT03525561|DRUG|Acetazolamide Pill|Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude.
214889803|NCT03525561|DRUG|Placebo pill|Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.
214889804|NCT04145128|DRUG|AG881|AG-881 tablets.
214889805|NCT04466280|DRUG|Hydroxychloroquine|200 mg of hydroxychloroquine daily for participants in the intervention group 1
214889806|NCT04466280|DRUG|Mucodentol|Intervention Group 2 participants will place a thin layer of Dentol gel in the vestibular area of the mouth every 6 to 8 hours.
214889807|NCT04466280|DEVICE|Personal protective equipment|Personal protective equipment such as masks, gloves, protective shields
214889808|NCT01031329|PROCEDURE|Tympanocenthesis and urine collection|Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
214294778|NCT02256228|DRUG|Saline|Placebo Comparator
214294779|NCT03731884|OTHER|Time from the onset of symptoms to PCI|Patients will be divided in two groups according to the time from the onset of symptoms to PCI
214294780|NCT01012856|BEHAVIORAL|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
214294781|NCT01012856|BEHAVIORAL|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
214294782|NCT00001482|DRUG|Lamotrigine (Lamictal® (Registered Trademark)|
214889809|NCT01350362|DRUG|tideglusib|1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
214889810|NCT01350362|DRUG|tideglusib|1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
214889811|NCT01350362|DRUG|tideglusib|500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
214889812|NCT01350362|DRUG|Placebo|Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
214889813|NCT05663125|PROCEDURE|Laser interstitial thermal therapy|Ablation of the tumor will be done by MRI-guided laser interstitial thermal therapy with the assistance of neuro-navigation.
214889814|NCT05663125|DRUG|Temozolomide|Temozolomide will be administered continuously from the 1st to the 21st day after LITT surgery. The oral dose of temozolomide is 75 mg/m2. And then, it will be given at a routine dose from the second month after surgery.
214889815|NCT00918866|DRUG|Definity|one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
214889816|NCT03885661|DRUG|Icosapent Ethyl 1000 MG [Vascepa]|Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.
214889817|NCT01023009|PROCEDURE|vitrectomy|
214889818|NCT01893515|DRUG|PRC-4016|
214889819|NCT01893515|DRUG|Placebo|
214889820|NCT02054052|DRUG|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
214294783|NCT00001482|DRUG|Gabapentin (Neurontin® (Registered Trademark))|
214294784|NCT01011660|DRUG|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
214889821|NCT05695001|DEVICE|Efferon CT|Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross-linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.
214889822|NCT02607046|OTHER|Exercise training|The exercise program includes supervised and home-based walking and strength exercise.
215049500|NCT06604429|OTHER|Aerobic exercise|aerobic exercises in form of cycle ergometer training (Each girl started session with a 5 min of warm-up. The exercise phase is performed at 65-75% of age-predicted peak heart rate using an orbitrack device for 20 minutes). Finally, a 5 min cool-down period is permitted, the total session that would be applied about 30 min.
215049501|NCT06604429|OTHER|Diet Advice|Adolescent girls participated in the study receive diet advices based on a balanced low calorie diet (1500 Kcal)
215049502|NCT06604429|OTHER|Virtual reality exercise|Virtual reality game exercise involves 25 min of exercise where adolescent girl immersed in the game and did physical activities for the upper and lower extremities according to the game's requirements, and finally a 5 min cool-down part to lower the heart rate and end the session with static flexibility routines, the total session that would be applied about 30 min of Virtual reality exercises.
215049503|NCT03276442|OTHER|Low-fat dietary intervention|Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
214294785|NCT05104034|BEHAVIORAL|Osteoporosis screening and treatment as needed|All residents underwent screening using the Fracture Risk Assessment Tool (FRAX) and Mobile dual-energy X-ray absorptiometry (DXA) (Horizon Wi, Hologic Inc., Bedford, MA). Our study nurses actively assisted osteoporosis treatment if indicated.
214294786|NCT05104034|BEHAVIORAL|Sarcopenia|Sarcopenia assessment adhered to the 2019 Consensus Update on Sarcopenia Diagnosis and Treatment by the Asian Working Group for Sarcopenia guideline. Following screening, individuals identified with sarcopenia underwent tailored interventions involving exercise and nutrition as deemed necessary.
214294787|NCT05104034|BEHAVIORAL|Exercise|TheraBand (resistance band) was utilized as the exercise tool within the community. T
214294788|NCT05104034|DIETARY_SUPPLEMENT|Nutrition|Nutrition Nutritional education programs aim to increase protein food serving and the choice of those with insufficient dietary intake. Protein supplement was added if indicated.
214889823|NCT02607046|OTHER|NMES|This intervention consists of using neuromuscular electrical stimulation (NMES) as a form of passive exercise for muscles in the legs.
214889824|NCT01472692|DRUG|Febuxostat|80mg PO daily for 8 weeks
214889825|NCT06236425|BIOLOGICAL|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
214889826|NCT06236425|DRUG|Pembrolizumab|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
214889827|NCT06236425|DRUG|Platinum based chemotherapy|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
214889828|NCT06236425|DRUG|Cyclophosphamide|Participants who proceed to TBio-4101 treatment will receive Cyclophosphamide as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
214889829|NCT06236425|DRUG|Fludarabine|Participants who proceed to TBio-4101 treatment will receive Fludarabine as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
214889830|NCT06236425|DRUG|Aldesleukin|After completion of TBio-4101 infusion, Aldesleukin will be administered every 8 hours, for up to 6 doses.
214889831|NCT05514223|OTHER|Biomaterial collection for observational purpose|The semen will be collected to measure the free radical concentration in seminal plasma and sperm together with the diversity of microbiota. Both males with a normal semen analysis (SA) and abnormal SA according to the WHO guidelines (2010) will be included. Blood plasma will be collected to measure systemic radical concentration and all outcomes will be related to lifestyle factors and food intake acquired through hospital charts and routinely conducted questionnaires together with a food frequency Questionnaire (FFQ).
214889832|NCT04970303|DRUG|Methylphenidate|Retina or Concerta
214889833|NCT00320203|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|Single injection, anterior juxtascleral depot (AJD)
214889834|NCT00320203|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single injection, anterior juxtascleral depot (AJD)
215049504|NCT03276442|OTHER|High-fat dietary intervention|High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
215049505|NCT04971577|DRUG|Simvastatin 40mg|participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
215049506|NCT01627184|DEVICE|Dexcom G4 CGM System|
215049507|NCT06333548|DIAGNOSTIC_TEST|Appropriate for gestational age , small for gestational age, large for gestational age, Baby of mother diagnosed with GDM|No intervention
215049508|NCT05212792|BIOLOGICAL|COVID-19 vaccines|Any licensing COVID-19 vaccine platform
215049509|NCT00172809|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
215049510|NCT00172809|DRUG|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
215049511|NCT05710952|DEVICE|Review by Modjaw|A review by Modjaw's will be done before the braces treatment and after.
215049512|NCT03972527|DEVICE|Photobiomodulation|Provide photobiomodulation therapy to subjects prior to each radiation therapy session.
215049513|NCT03972527|OTHER|Routine Oral Care and Analgesia|Standard oral care, oral hygiene and oral pain protocols
214889835|NCT00320203|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single injection, anterior juxtascleral depot (AJD)
214889836|NCT00320203|OTHER|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
215049514|NCT05223673|BIOLOGICAL|Futuximab/modotuximab|Concentrate for solution for infusion, futuximab/modotuximab will be administered via IV route, once weekly of each cycle at 9 mg/kg/dose at Cycle 1 Day 1 and then at 6 mg/kg/dose. Each cycle is up to 28 days.
215049515|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
215049516|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
215049517|NCT00497003|DRUG|Treatment with either metoprolol or carvedilol|
215049518|NCT01786590|PROCEDURE|EBUS-TBNA|Currently EBUS-TBNA is performed in patients with CT and/or PET positive lymph nodes in the mediastinum or hilum. In this study, all patients being considered for SBRT will undergo EBUS-TBNA for the lymph node staging prior to SBRT.
214889837|NCT00199017|DRUG|Dexamethasone/Prednisolone|
214889838|NCT00199017|DRUG|Cyclophosphamide|
215049519|NCT00994903|DRUG|Simvastatin|40mg orally, given 3-7 days pre-op and continued till 14 days post-op
215049520|NCT00994903|DRUG|Placebo|Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
215049521|NCT01527994|DRUG|Aprepitant|Aprepitant 125 mg oral tablets
215049522|NCT01527994|DRUG|Placebo pill|Placebo oral pill- inactive compound
215049523|NCT01286597|DIETARY_SUPPLEMENT|dietary restriction|restrict intake of lactose
215049524|NCT02665091|BEHAVIORAL|Peer Education Program|
215049525|NCT06248151|BEHAVIORAL|Exercise session|Session will included aerobic, resistance and flexibility exercises and will last approximately 45 minutes. The session will begin with aerobic exercises (5 min jumping jacks and 5 min stationary walking). Then, nine strength exercises will be performed for the main muscle groups (3 times of 12 to 15 repetitions, with a 1-minute rest interval) and finally stretching for the main muscle groups
215049526|NCT06248151|BEHAVIORAL|Control session|Remain seated for 60 min
215049527|NCT06690307|PROCEDURE|patient controlled intravenous analgesia(PCIA)|Patients will receive sulfentanil for PCIA.
215049528|NCT06690307|PROCEDURE|patient controlled intravenous analgesia(PCIA)|Patients will receive oxycodone for PCIA.
214889839|NCT00199017|DRUG|Vincristine|
214889840|NCT00199017|DRUG|Daunorubicin|
215049529|NCT02305121|DEVICE|TFNA|All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery
214889841|NCT00199017|DRUG|Asparaginase|
214889842|NCT00199017|DRUG|G-CSF|
214889843|NCT00199017|DRUG|Mercaptopurine|
214889844|NCT00199017|DRUG|Cytarabine|
214889845|NCT00199017|DRUG|Methotrexate|
214889846|NCT00199017|DRUG|VP16|
214889847|NCT00199017|DRUG|Vindesine|
214889848|NCT00199017|DRUG|Adriamycin|
214889849|NCT00199017|DRUG|Thioguanine|
214889850|NCT00199017|DRUG|HDARAC|
214889851|NCT00199017|PROCEDURE|CNS irradiation|
214889852|NCT00199017|PROCEDURE|Mediastinal irradiation|
214889853|NCT00199017|DRUG|Cladribine|
214889854|NCT02286843|RADIATION|89Zr-trastuzumab|
215049530|NCT06715722|DEVICE|hexed non hexed|A 3-unit screw-retained implant bridge over two conical internal hex implants will be supported using one hexed and one non-hexed abutment.
215049531|NCT06715722|DEVICE|non-hexed non-hexed|a 3-unit screw-retained implant bridge over two conical internal hex implants will be supported using two non-hexed abutments
215049532|NCT06715813|PROCEDURE|pelvic floor strengthening|"pelvic floor strengthening exercises includes :~1. breathing exercises,~2. kegels exercises~3. bridging exercises~4. squatting~5. Elevator exercises"
215049533|NCT06715813|PROCEDURE|Transversus abdominal strengthening|core stabilization exercises for 2 weeks like stomach hallowing , dead bugs and pelvic tilt exercises and after 2 weeks dead bug progression, planks
215049534|NCT06715800|DIETARY_SUPPLEMENT|Honey|Functional content analyses were performed to identify the specific properties of the different types of honey used.
214889855|NCT02286843|DEVICE|PET/CT scan|
214889856|NCT02286843|RADIATION|89Zr-pertuzumab|
214889857|NCT06166524|PROCEDURE|Catheter ablation for atrial fibrillation using pulsed-field energy|Patients will undergo pulmonary vein isolation using pulsed-field energy
214889858|NCT06166524|PROCEDURE|Conservative arm|Patients will undergo electrical cardioversion with consequent treatment with antiarrhythmic drugs
214889859|NCT05547997|OTHER|Stretching exercises|Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times
214889860|NCT05547997|OTHER|Two way traction|During the traction, the head halter will be fixed posteriorly to cause slight distraction, retraction, and slight extension and at the same time a front anterior strap had weight will be applied over a pulley that allows transverse traction load to be applied to the apex of the participants cervical curve alteration. Weights will start at 15 lbs. (6.8 Kg) on the anterior strap and will increase over consecutive visits to patient tolerance or a maximum of 35 lbs. (15.9 Kg).
214889861|NCT03906110|BEHAVIORAL|Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) Materials|Educational materials (photonovella +DVD) + Fecal Immunochemical Test (FIT) kit. Offers colorectal cancer screening information using a novella format. Materials describe colorectal cancer and screening tests that are available, and procedures for completing FIT kit.
214889862|NCT03906110|BEHAVIORAL|Contact Message|Card with a general message about colorectal cancer screening. This same message will be delivered at 3 time points.
214889863|NCT03906110|BEHAVIORAL|Personalized One on One Education|"* Trained study coordinators will meet with participant for a brief 15 minute educational session delivered in clinic that summarizes information from the materials and demonstrates FIT collection.~* Email or text reminders with brief messages in clear language will be sent that aim to remind and prompt patients to complete FIT.~* For participants that are not responsive to above, trained study staff will address specific FIT specific hinderances by telephone or in clinic.~* Participants will receive a one page summary of key points of salience of repeat screening GET FIT AGAIN. Another FIT kit is provided."
214889864|NCT03906110|DIAGNOSTIC_TEST|Fecal Immunochemical Test (FIT)|The Fecal Immunochemical Test (FIT), is a screening test that detects hemoglobin in stool samples, only requiring one stool sample.
214889865|NCT03264807|PROCEDURE|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
214889866|NCT03264807|PROCEDURE|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
214889867|NCT06550765|DEVICE|Biodegradable Magnesium Metal Clips|The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
214889868|NCT00694200|DRUG|Vinorelbine|Vinorelbine per os 50 mg 3 times a week
214889869|NCT00694200|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 14 days
214294789|NCT05104034|BEHAVIORAL|Pharmaceutical care|We collected drug information of the elderly. Detailed and real-time prescription drug information was retrieved from the National Health Insurance PharmaCloud System. A pharmaceutical care team performed patient-centered drug review and discussion every three to six months.
214294790|NCT00638313|BIOLOGICAL|Placebo|Subjects will be given either Placebo or PF-04603629.
214294791|NCT00638313|BIOLOGICAL|PF-04603629|Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
214889870|NCT01850251|DIETARY_SUPPLEMENT|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
214889871|NCT01850251|DIETARY_SUPPLEMENT|Standard nutritional supplement|High protein, high calorie nutritional supplement.
214889872|NCT01632397|BEHAVIORAL|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
214889873|NCT01632397|BEHAVIORAL|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
214889874|NCT04725851|PROCEDURE|High concentration Oxygen therapy|FiO2 \>80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
214889875|NCT04725851|PROCEDURE|Control: Room Air or Low concentration Oxygen|FiO2 \<30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
214889876|NCT02796053|DRUG|TAB08|The TAB08 will be administered intravenously, by infusion.
214889877|NCT02796053|OTHER|Placebo|The Placebo to TAB08 will be administered intravenously, by infusion.
214889878|NCT06551337|DRUG|Vitamin D3|The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.
214889879|NCT06397495|OTHER|Education|Cervical region manual therapy training will be given with flipped learning models.
214889880|NCT04625244|OTHER|Video assisted home therapy|Subjects will follow along with prerecorded therapy videos.
214889881|NCT00426439|DRUG|Chloroquine|Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
214294792|NCT05243225|PROCEDURE|Laparoscopic versus open surgical management of post cholecystectomy bile duct injury|Comparison between laparoscopic and open surgical management of post cholecystectomy bile duct injury.
214889882|NCT00426439|DRUG|Artemether-lumefantrine (Coartem)|Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
215049535|NCT06717061|PROCEDURE|Harvesting of biological material|During the sampling of biological material, the test subjects will be under general anesthesia, which is why the sampling will not mean increased pain or discomfort other than what is standard after a gallbladder operation with the peephole technique. . The sampling is not planned to be repeated, but is performed at the time when the patients perform their biliary surgery. During the sampling, centimeter-sized pieces of skin, fatty tissue, connective tissue and muscle are taken. Furthermore, serum and plasma will be collected. Two tubes of blood samples (10 ml total) are taken, centrifuged and pipetted before being frozen for later analysis. Pieces of tissue are placed in formalin before transport to the laboratory. The study form regarding the patient\&#39;s basic state of health will be filled in by the operator on the day of surgery.
215049536|NCT06716294|DEVICE|Radiofrequency Ablation and Bone Augmentation|Percutaneous Tumor Ablation of Spine Lesions followed by Polymer Augmentation
215049537|NCT06717386|PROCEDURE|diagonal pelvic osteotomy|supraacetabular pelvic osteotomy in oblique shape
214889883|NCT00893269|DRUG|eszopiclone|Oral capsule at dose recommended for adults
214889884|NCT00893269|DRUG|Placebo|Participants receive placebo prior to sleep
214889885|NCT00893269|DRUG|ramelteon|ramelteon
214889886|NCT00893269|DRUG|zolpidem|zolpidem
214889887|NCT03927456|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
214889888|NCT03927456|DRUG|Placebo|Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
214889889|NCT03927456|DRUG|Fulvestrant|Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
214889890|NCT06677359|DIETARY_SUPPLEMENT|Creatine Group|Micronized creatine monohydrate supplementation.
214889891|NCT06677359|DIETARY_SUPPLEMENT|Placebo Group|Participants will recieved placebo supplementation
214889892|NCT06677359|OTHER|Multicomponent Training|Multicomponent physical exercise intervention
214889893|NCT03109561|OTHER|Resting State Indirect Calorimetry|The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.
215049538|NCT05900076|DIAGNOSTIC_TEST|Curettage for the evacuation of the product of conception|The product of conception taken during the intervention will be recovered at Day 1
214889894|NCT03109561|GENETIC|ApoE|The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.
215049539|NCT06715865|PROCEDURE|Thymus Transplantation|Thymus Transplantation
215049540|NCT06712342|OTHER|Neuromuscular Exercise Training|"This group will receive neuromuscular exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks.~Warm-up Program - 5 minutes Postural Control-Weight Transfer - 10-15 minutes Strength Training - 30-35 minutes Proprioception - Coordination - Reaction Speed 10-15 minutes Cool-down Program - 5 minutes"
215049541|NCT06712342|OTHER|Conventional Exercise Training|"This group will be given traditional strength exercise training consisting of 60-75 minute sessions per day, 2 days per week for 8 weeks.~Warm-up Program - 5 minutes Strength Training - 30-35 minutes Manuel Dexterity - 15-20 minutes Cool-down Program - 5 minutes"
214889895|NCT03109561|DIAGNOSTIC_TEST|Metabolism|To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.
214889896|NCT03109561|OTHER|Cognitive Challenge|Participants will be asked to follow simple instructions that are displayed on computer screen.
214889897|NCT05016739|DEVICE|CADISS|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5~2. Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
214889898|NCT04511598|DEVICE|"Bellus 3D Face Camera"|The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.
214889899|NCT04511598|DEVICE|"Planmeca ProMax 3D Proface"|The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
214889900|NCT03555292|DRUG|11C-PiB|11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
214889901|NCT00999427|DRUG|Povidone-iodine|Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
214889902|NCT04635527|DRUG|IBI318|before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W
214889903|NCT04635527|PROCEDURE|cTACE|conventional transarterial chemoembolization
214889904|NCT04635527|DRUG|placebo|before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
214889905|NCT02712580|DEVICE|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
214889906|NCT02712580|DEVICE|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
214889907|NCT02712580|DEVICE|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
214889908|NCT02712580|DEVICE|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
214889909|NCT02568839|DRUG|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
214889910|NCT02568839|DRUG|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
214889911|NCT00745784|BEHAVIORAL|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
214889912|NCT01670591|BEHAVIORAL|PS - Prevention in School|
214889913|NCT03172494|DRUG|Insulin degludec/liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
214889914|NCT03172494|DRUG|Insulin degludec|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
214889915|NCT03172494|DRUG|Liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
215049542|NCT06715631|DEVICE|Hands-free exoskeleton|Before the simulated-use test, the SCI user and his/her companion must attend five training sessions provided by a Wandercraft certified trainer. Training will be composed by a theoretical part including presentation and description of the personal exoskeleton and its use modes and a hands-on practice. Each session lasts between 1 to 2 hours, varying according to the user's learning pace and tolerance. The training program is representative of the intended training for the end product.
214889916|NCT00351455|BEHAVIORAL|smoking cessation|
214889917|NCT00351455|BEHAVIORAL|tighter diabetic control|
214889918|NCT00351455|BEHAVIORAL|diet and exercise program|
214889919|NCT04190017|OTHER|Cranial MRI|Cranial MRI
214889920|NCT06019884|DEVICE|Caries detection method: Intraoral camera|A specialized intraoral camera (C50) with fluorescence signal and selective chromatic amplification will be used to record intraoral structures in the form of videos and/or photos. The camera has four modes (Daylight, Daylight+, Perio and Caries modes) which can differentiate the color of tissues to provide a reliable diagnosis. The camera will be used in a systemic sequence to video record and capture photos of intraoral conditions in both arches. The intraoral camera will be connected to a laptop screen, and the captured videos and/ or photos will be transferred to an electronic platform.
214889921|NCT06019884|DEVICE|Caries detection method: Smartphone camera|This is a low-cost electronic system consisting of a smartphone positioned in front of the oral cavity to scan the upper and lower jaws from the cheek then the tongue sides. The smartphone camera resolution should be sensitive enough to capture the intraoral structures (at least 1000 pixels). The focus will be adjusted, and the inbuilt flash will be used to obtain clear and sharp images. The photos will be transferred to the electronic platform.
214889922|NCT06019884|OTHER|Referral pathway: User fee removal|The child's parent/ legal guardian will receive financial incentives. These a are designed to cover the costs of treatment and transportation and are tied to attending the preventive dental visit. The child will receive complete dental care.
214889923|NCT06019884|OTHER|Referral pathway: Conventional referral|Children will be referred without providing financial incentives following the current standard of care in dental clinics in the public sector in Egypt. Care is planned by the receiving/ treating dentist, based on available resources, and hospital/ clinic policies. The screening/ sending dentist will inform the family about the oral health condition/s and planned treatment costs for which the child needs care and of available public and private facilities that offer the required care.
214889924|NCT05478577|OTHER|Motor rehabilitation|Treatments for upper limb recovery (e.g. occupational therapy, technology devices, conventional therapy)
214889925|NCT03086551|DEVICE|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
215049543|NCT04254406|OTHER|Descriptive study|Evaluation of routine treatment
214889926|NCT03086551|DEVICE|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
214889927|NCT03086551|BEHAVIORAL|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
215049544|NCT03829592|DRUG|misoprostol in a neutral media|giving misoprostol in a neutral media
215049545|NCT03829592|DRUG|misoprostol in an acidic media|giving misoprostol in an acidic media
215049546|NCT03829592|DRUG|misoprostol in an alkaline media|giving misoprostol in an alkaline media
215049547|NCT05750407|BEHAVIORAL|Lifestyle change|Three modules target healthy eating, activity, and weight control behaviors
215049548|NCT02530177|OTHER|Clinical Assessments|
214889928|NCT04691154|COMBINATION_PRODUCT|L606 inhalation suspension|L606 inhalation suspension, twice daily dosing
214889929|NCT00933361|DRUG|ghrelin|As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
214889930|NCT02764151|DRUG|PF-06840003|Daily Oral PF-06840003
215049549|NCT02530177|BEHAVIORAL|Questionnaires|
215049550|NCT02530177|OTHER|Saliva sample|(only once, preferably at baseline)
214889931|NCT03912597|DEVICE|Virtual Reality|The 4-minute virtual reality video depicts a day in a life of a student with depression. The one-take video, filmed with a 360° camera, is designed to provide users with an immersive experience that simulates what it feels like to have depression. The user interface consisted of a Google Cardboard VR headset attached to a smartphone.
214889932|NCT03912597|DEVICE|Brochure|Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.
214889933|NCT03912597|DEVICE|Standard Video Control|The 4-minute standard video depicts a similar storyline as was shown in the VR video. The standard video is filmed from a third-party perspective with multiple takes edited into a final video, following the standard filming style of these videos. The standard video will be viewed from a laptop with headphones attached.
214294793|NCT00637507|OTHER|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., \>10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 \>150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
214294794|NCT02208947|BEHAVIORAL|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
214294795|NCT02208947|BEHAVIORAL|PREPARE|"PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library)."
214294796|NCT02852408|PROCEDURE|Laparoscopic cholecystectomy|
214294797|NCT03086889|OTHER|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
214294798|NCT03086889|OTHER|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
214668282|NCT02677740|DEVICE|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
214889934|NCT01315327|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
214889935|NCT01315327|DRUG|Olive oil|Placebo
214889936|NCT02614274|DIETARY_SUPPLEMENT|Nutraceutical joint health formulation|A Proprietary Blend
214889937|NCT01091324|DRUG|Dextromethorphan|60 mg, bid
214889938|NCT01091324|DRUG|Silymarin|150 mg , tid
214889939|NCT01091324|DRUG|sugar pill|placebo
214889940|NCT00364936|PROCEDURE|Palliative care service|
214889941|NCT01794559|DEVICE|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
214889942|NCT05194098|DEVICE|TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil|Active Session: Single session of standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes
214889943|NCT05194098|DEVICE|SHAM (inactive) TMS stimulation|Sham neurostimulation (SHAM) entails use of the sham side of the D-B80 A/P placed over the same anatomical target, without any active stimulation.
215049551|NCT00408980|BEHAVIORAL|Fat and calorie controlled diet|
215049552|NCT02267889|PROCEDURE|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
214294799|NCT05313594|DIAGNOSTIC_TEST|Mixed meal challenge test|Mixed meal consumption followed by postprandial blood sampling
214294800|NCT05313594|DIAGNOSTIC_TEST|MRI|MRI imaging
214294801|NCT05313594|DIAGNOSTIC_TEST|DEXA|DEXA scan
214294802|NCT05313594|DEVICE|Freestyle Libre|Continuous blood glucose measurement
214294803|NCT05313594|DEVICE|ActivPAL3|Continuous physical activity measurement
214889944|NCT01739127|DRUG|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
214889945|NCT01739127|DRUG|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
214889946|NCT06633627|OTHER|Recording of brain activity using electroencephalography (EEG)|Electroencephalography (EEG) responses to sensitivity stimuli applied to the teeth in patients with and without dentine hypersensitivity will be compared
215049553|NCT02267889|DEVICE|D-SPECT dedicated cardiac nuclear camera|
215049554|NCT00737932|DRUG|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
215049555|NCT00737932|OTHER|placebo|Matching placebo for 8 weeks of treatment
215049556|NCT00937495|DRUG|vorinostat|400 mg given PO
215049557|NCT00937495|DRUG|bortezomib|1.3 mg/m\^2 given IV
214668283|NCT04073212|OTHER|Dry Needling|Dry needling directly to the long head of the biceps tendon. The DN will be performed with disposable stainless-steel needles (.3 X 40mm; Seirin; Weymouth, MA) inserted into the skin over the most painful and/or thickened areas of the tendon, confirmed with palpation. Prior to insertion of the needle the overlying skin will be cleaned with alcohol. The needle will be inserted into the tendon. The technique will be a fast-in and fast-out technique described by Chiavaras et al.26 for 20-30 repetitions per session in up to 3 areas. An eccentric-concentric exercise program of the biceps muscle/tendon will follow each DN session and will be performed daily for the course of treatment and will be performed as described by McDevitt et al.
214889947|NCT04848727|OTHER|Detecting asymmetric lung disease like atelectasis or pneumothorax with electrical impedance tomography (EIT)|"The EIT system will be placed at the subject's bedside to collect EIT measurements: Ventilation distribution%, changes in regional aeration in arbitrary units (AU), dependent and non-dependent silent spaces. A data acquisition cart will also be placed at the subject's bedside to collect hemodynamic and respiratory parameters measurements including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices.~The LuMon belts for neonates are disposable single-patient use belts that are adhesive-free. EIT measurements and data will be collected on each timeperiods (t1 and t2) for approximately 15-30 minutes on invasive or non-invasive ventilatory support."
214889948|NCT00043810|PROCEDURE|Gelonin|Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10\^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
214889949|NCT00043810|DRUG|Busulfan|130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
214889950|NCT00043810|DRUG|Fludarabine|40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
214889951|NCT00442455|DRUG|Erlotinib chlorhydrate|150 mg/day for 7 weeks
214889952|NCT00442455|DRUG|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
214889953|NCT00442455|PROCEDURE|Radiation therapy|63 Gy, five days a week, for 7 weeks
214889954|NCT02201277|DEVICE|Filter Placed|
214889955|NCT03633097|OTHER|Acupuncture and Usual care|patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
214889956|NCT03633097|DRUG|Usual care|patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
214889957|NCT01984827|DRUG|Moxifloxacin|"1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~2. a single oral dose of 400mg Moxifloxacin plus C-peptide~3. a single oral dose of 400mg Moxifloxacin~4. placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m."
214889958|NCT01984827|OTHER|hyper-glycaemic clamp|a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
214889959|NCT02637531|DRUG|IPI-549 (eganelisib)|IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
214889960|NCT02637531|DRUG|Nivolumab|Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
214889961|NCT04843696|DEVICE|cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy)|the hospital-based NPV once per week in the maintenance program at least three times per month. The ventilator is set to the control model with a frequency of 12\~15 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot), and delivery of negative pressures ranging from -20 to -35 cm H2O.
214889962|NCT04843696|BEHAVIORAL|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)
214889963|NCT01958138|DRUG|comparison of group-I (low dose propofol with isoflurane)|Prior to LMA removal in group-I, isoflurane MAC awake (MAC less than 0.5) will be achieved in expiratory gases with 60% nitrous oxide and 40% oxygen. Propofol 1 mg/Kg will be combined with Isoflurane MAC awake and LMA will be removed after 20 seconds of propofol administration in group-I. The group-II LMA will be removed at end expiratory isoflurane MAC of 1.2% with 60% nitrous oxide and 40% oxygen
214889964|NCT00489255|DRUG|Tigan®|Oral capsule, 300mg three times daily
214889965|NCT00489255|DRUG|Placebo|Oral capsule, three times daily
214889966|NCT03062384|DIETARY_SUPPLEMENT|AT-001|
214889967|NCT03062384|DIETARY_SUPPLEMENT|Placebo|
214889968|NCT02297256|PROCEDURE|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
214889969|NCT02297256|PROCEDURE|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
215049558|NCT05526053|OTHER|Lung volume preservation|Extubate the patient connected to the ventilator and PEEP of 5 cmH2O after a successful SBT also using PEEP.
214889970|NCT00272051|DRUG|SR57746A|
214889971|NCT04975854|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Virtual reality scenarios consists of increasingly intense exposures to phobic stimuli (e.g., looking over railings from various floor levels) with the support of the therapist. The goal of VRET is sufficient reduction in anxiety to allow the patients to expose themselves to heights in everyday situations.
214889972|NCT04975854|OTHER|Information Session|This includes 20-minute information session about general principles of exposure therapy before the start of the study.
215049559|NCT06136143|PROCEDURE|Group 1: Autogenous bone graft|The maxillary sinus will be grafted with the autogenous bone graft.
215049560|NCT06136143|PROCEDURE|Group 2: Plenum® Osshp|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device.
215049561|NCT06136143|PROCEDURE|Group 3: Plenum® Osshp; + i-PRF|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with i-PRF.
215049562|NCT06136143|PROCEDURE|Group 4: Plenum® Osshp + autogenous bone graft|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with autogenous bone graft.
215049563|NCT01042067|OTHER|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
214477870|NCT06674408|OTHER|Prioprioceptive group|"Experimental group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Plyometric CKC shoulder exercise 10 seconds each x 5 reps x 2 sets per session, CKC exercise on the ball 10 seconds each x 5 reps x 2 sets per session, Open KC exercises 10 seconds each x 5 reps x 2 sets per session, Hand-eye coordination exercises for 30 minutes/per day for 5x/per week, Hand Function Exercises for 30 minutes/per day for 5x/per week.~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week"
214477871|NCT05840965|OTHER|Foot muscle strengthening|"A specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The exercises are: short foot exercise, toe spread out, first toe extension, second to fifth toe extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles."
214477872|NCT05840965|OTHER|Foot orthotics|Custom-made foot orthotics
214889973|NCT01171261|BEHAVIORAL|Health Games Field Trial|There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
214889974|NCT00273897|DEVICE|Phoresor II|
214889975|NCT04449211|DEVICE|Implantation|Reconstructing the long bone defect with 3D-printed customised Titanium alloy implant
214889976|NCT05808478|BEHAVIORAL|AAC + Eye Tracking|The AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.
214889977|NCT05808478|BEHAVIORAL|AAC|Treatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.
214889978|NCT06281197|PROCEDURE|Conventional|Le Fort I osteotomy performed with conventional Le Fort
214889979|NCT06281197|PROCEDURE|Subspinal|Osteotomy was performed in the subspinal Le Fort I group that is described by Mommaerts
214889980|NCT02561117|DRUG|Metronidazole|Administration once daily
214889981|NCT03778073|DRUG|Cosibelimab|Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle
214889982|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
214889983|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
214889984|NCT02344082|OTHER|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
214889985|NCT03305627|OTHER|Short PAP|Perioperative antibiotic prophylaxis for 24h
214889986|NCT03305627|OTHER|Extended PAP|Perioperative antibiotic prophylaxis for \>48h
214889987|NCT01845727|DRUG|Topical Amphotericin B at 3%|
214889988|NCT01959373|PROCEDURE|electroencephalograms (EEG)|
214889989|NCT01959373|PROCEDURE|electro-myography (EMG)|
214889990|NCT01320501|DRUG|Erlotinib|All patients will receive: TarcevaTM 150mg/day PO.
214889991|NCT01512160|DRUG|PF-04531083|2000 mg oral solution
214889992|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
214889993|NCT01512160|DRUG|PF-04531083|1000 mg oral solution
214889994|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
214889995|NCT01512160|DRUG|Ibuprofen|2 x 200 mg tablets
215049564|NCT00443703|DRUG|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
215049565|NCT00443703|DRUG|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
215049566|NCT00443703|DRUG|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
215049567|NCT00443703|DRUG|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
214889996|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
214889997|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
214889998|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
214889999|NCT03672591|OTHER|Renal clearance examination|Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
214890000|NCT02537691|DRUG|FP|ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.
214890001|NCT02537691|DRUG|LABA|LABA will be administered as per investigator discretion.
214890002|NCT02537691|DRUG|LTRA|LTRA will be administered as per investigator discretion.
214890003|NCT02537691|DRUG|LAMA|LAMA will be administered as per investigator discretion.
214890004|NCT02537691|DRUG|Theophylline|Theophylline will be administered as per investigator discretion.
214890005|NCT02537691|DRUG|Oral Corticosteroids|Oral corticosteroids will be administered as per investigator discretion.
214890006|NCT06551662|DEVICE|Paclitaxel drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
215049568|NCT03620032|DRUG|Nimotuzumab|humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)
214890007|NCT06551662|DEVICE|Sirolimus drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
215049569|NCT03620032|DRUG|Vinorelbine|Chemotherapy
214890008|NCT06551662|DEVICE|New generation drug-eluting stent|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
214890009|NCT05708430|DRUG|SVF injection into wrist|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
214890010|NCT00931645|PROCEDURE|Autologous stem cell transplantation|TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
214890011|NCT00931645|PROCEDURE|DHAP rescue and Autologous stem cell transplantation|DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
214890012|NCT00931645|PROCEDURE|DHAP rescue and F+C|DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) \& cyclophosphamide (300 mg/sqm)
215049570|NCT03620032|OTHER|Radiotherapy|RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS
215049571|NCT00196794|DRUG|Tolevamer potassium-sodium (GT267-004)|
215049572|NCT00942370|DEVICE|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~* EMG and MMG Signals of rectus abdominis of the abdomen,~* Respiratory flow,~* An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
215049573|NCT04317339|DRUG|Zhigancao Tang granule|"Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
215049574|NCT04317339|DRUG|Zhigancao Tang placebo granule|"Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
214294804|NCT04397653|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
214294805|NCT04397653|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
214294806|NCT04397653|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
214294807|NCT04417881|OTHER|MEESSI score|MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
214294808|NCT01988831|DRUG|Propranolol hydrochloride|This intervention apply to Propranolol group
214294809|NCT01988831|DRUG|Placebo pill|We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
214294810|NCT06131008|DIAGNOSTIC_TEST|Diastology|We will follow American Society of Echocardiography criteria to determine the degree of diastolic dysfunction after performing each focused echocardiogram.
214294811|NCT06131008|BEHAVIORAL|Diastology-Guided Diuresis|If the daily urine output or weight loss are less than study-specified targets, then the research team will recommend changes to the diuretic regimen based on the degree of diastolic dysfunction.
214294812|NCT06131008|BEHAVIORAL|Usual Care|Clinicians will rely on usual care metrics and parameters to guide diuresis.
214294813|NCT03644199|OTHER|Oral Glucose Tolerance Test (OGTT) assessment arm|Hormonal and motility responses to a standard OGTT evaluation arm
214294814|NCT03644199|OTHER|Mixed meal test evaluation test arm|Evaluate the hormonal and motility responses to a standard mixed meal test through the day
214294815|NCT03103919|DEVICE|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
214294816|NCT03103919|DEVICE|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
214294817|NCT03103919|DRUG|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
214294818|NCT05305950|OTHER|Patient population|Questionnaire, standard of care
214294819|NCT02428946|DRUG|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
214294820|NCT04003922|OTHER|Adalimumab treatment|Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.
214294821|NCT01569178|PROCEDURE|Bone Marrow aspiration and intracoronary reinfusion|Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
214294822|NCT05512611|DIAGNOSTIC_TEST|Finger photoplethysmography|Finger photoplethysmography in tested hand, noninvasive blood pressure and heart rate during blood donation.
214294823|NCT04276597|DRUG|177Lu-DOTATOC|177Lu labeled somatostatin receptors targeting ligand
214294824|NCT00005970|DRUG|Aromatase Inhibition Therapy|Given orally
214294825|NCT00005970|DRUG|Cyclophosphamide|Given IV
214477873|NCT04678336|BIOLOGICAL|CART123 cells; cyclophosphamide; fludarabine|CART123 cells following lymphodepleting chemotherapy in pediatric patients with relapsed/refractory AML. Subjects will be treated with a single IV dose of CART123 cells on Day 0.
214477874|NCT00450216|DRUG|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
214477875|NCT00450216|DRUG|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
214477876|NCT05966805|BEHAVIORAL|Exercise training group|12-Week Exercise intervention on mentaL, metabolic, physicaL, spiritual, social, and occupational well-being among shift-working acute care NURSE
214477877|NCT05966805|BEHAVIORAL|Wait-List Control Group|Control group
214477878|NCT05699837|DEVICE|Audio or visual alpha (10Hz) stimulation|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
214477879|NCT05623774|DRUG|Imatinib Mesylate|400mg tablet
214477880|NCT05623774|DRUG|IkT-001Pro|100mg or 400mg tablet
214477881|NCT05466838|DRUG|PERT at discharge|Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.
214477882|NCT05466838|OTHER|Standard of Care|Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.
214477883|NCT06660264|OTHER|Pharmacist Personalized Medication Review (PMR)|Pharmacist-provided review of current medications and assessment of potential medication related problems.
214477884|NCT06660264|OTHER|Discussion of Pharmacogenomic results during the PMR|Return of pharmacogenomic results and discussion of impact on medications.
214477885|NCT05016531|DEVICE|Low Intensity Focused Ultrasonic Stimulation|Brain stimulation using ultrasonic stimulation in a sequence of increasing intensity (sham, 1 W/CM2, 2 W/CM2, 4 W/CM2, 6 W/CM2, 8 W/CM2)
214477886|NCT05016531|DEVICE|Low Intensity Focused Ultrasonic Stimulation Frequency|Brain stimulation using ultrasonic stimulation of intensity level determined from intervention 1 at progressively increasing frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz)
214477887|NCT05819931|DEVICE|Mechanical In-Exsufflator treatment|"The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.~Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.~The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.~The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.~The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit."
214668284|NCT04073212|OTHER|Heavy Slow Load Exercise|Eccentric exercise protocols have been found to be an effective treatment for tendinopathies of the upper and lower extremities and recent evidence supports heavy slow resistance training (including the addition of a concentric phase) as having better outcomes over eccentric exercise alone. Patients will use 1-5 pound weights to perform slow and controlled concentric and eccentric exercise to biceps muscle.
214668285|NCT04073212|OTHER|Rotator cuff and scapular stabilization exercise program|Both groups will be treated with a stretching and strengthening program. The rotator cuff and scapular stabilization strengthening and flexibility program used in this study has 3 phases and patients progress in phases based on their ability to perform a number of exercises using theraband or body weight resistance.
214668286|NCT04073212|OTHER|Soft tissue mobilization|Both groups will receive soft tissue mobilization to the anterior shoulder.
214668287|NCT03352856|OTHER|Barley starch|Highly purified barley starch
214294826|NCT00005970|DRUG|Doxorubicin Hydrochloride|Given IV
214294827|NCT00005970|OTHER|Laboratory Biomarker Analysis|Correlative studies
214668288|NCT03352856|OTHER|Maize starch|Maize starch
214294828|NCT00005970|DRUG|Paclitaxel|Given IV
214294829|NCT00005970|DRUG|Tamoxifen Citrate|Given orally
214294830|NCT00005970|BIOLOGICAL|Trastuzumab|Given IV
214294831|NCT02095587|DRUG|IPI-145|25 mg single oral capsule
214294832|NCT00398060|BEHAVIORAL|Cognitive-behavioral life-style counseling|
214294833|NCT03846011|OTHER|24-h urine collection|Collecting 24-h urine prior and after stone removal surgery
214294834|NCT03476694|PROCEDURE|ultra sound guided supraclavicular brachial plexus block|ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
214294835|NCT03140384|BIOLOGICAL|Assess the efficacy and side effects of Misoprostol according to the route of administration|Assess the efficacy and side effects of Misoprostol according to the route of administration
214294836|NCT02992106|OTHER|Parental questionnaires|"We will provide parents with questionnaires depending on the age of their children:~* Children aged 0-6 years old:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Ages and Stages Questionnaire~ 5. Strengths and Difficulties Questionnaire~ 6. Questionnaire on developmental milestones~ 7. Questionnaire on behaviour~* Children older than 6 years:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Pediatric Quality of Life Questionnaire~ 5. Children's Behaviour Questionnaire in Dutch~ 6. Questionnaire on developmental milestones~ 7. Developmental Coordination Disorder Questionnaire~ 8. Strengths and Difficulties Questionnaire"
214668289|NCT03866551|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
214668290|NCT06997003|DEVICE|Anterior treatment mode|Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment
214890013|NCT04639011|DRUG|Duloxetine|Three doses of 60 mg of oral duloxetine will be given to participants (right before operation, postop day 1, postop day 2)
214294837|NCT02992106|OTHER|Blood sample|We will determine the following biochemical parameters: glucose, insulin, total cholesterol, LDL, HDL, triglycerides, uric acid, IGF-1, adiponectin, leptin, hs-CRP, IL-6, TNF-α and ICAM-1.
214294838|NCT02992106|OTHER|Urine sample|We will take a urine sample to evaluate the albumin to creatinin ratio.
214294839|NCT02992106|OTHER|Anthropometric measurements|We will measure weight, Height, hip, waist and neck circumference, blood pressure, 4-site skinfold measurements and BIA.
214294840|NCT02992106|OTHER|Ultrasound|We will do an abdominal ultrasound to measure the abdominal fat accumulation
214294841|NCT02992106|OTHER|EndoPAT|We will use the EndoPAT device to measure endothelial function, which is a non-invasive and innovative technique (peripheral pulse wave amplitude measurement).
214294842|NCT02992106|OTHER|Faces Pain Scale|After performing the measurements with the EndoPAT device, Harpender kalliper and ultrasound, the children will be asked to fill out a Faces Pain Scale, validated for children aged 4-16 years old and obtained for use from the International Association for the Study of Pain
214294843|NCT02234089|DRUG|Degarelix|According to medical practice
214294844|NCT02234089|DRUG|LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)|According to medical practice
214294845|NCT03512509|OTHER|Low glycaemic potato|The Carisma potato variety is used as the low glycaemic index potato.
214294846|NCT03512509|OTHER|High glycaemic potato|The Arizona potato variety is used as the high glycaemic index potato.
214294847|NCT04462549|BEHAVIORAL|Resource Facilitation|"RF involves working one on one with a brain injury specialist. This specialist is called a Resource Facilitator and works with clients to help set and achieve their own goals along with a team of professionals that specialize in this kind of injury. This may include brain injury education, family education, needs assessments, and service identification."
214294848|NCT00814528|DRUG|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
214294849|NCT00814528|DRUG|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
214294850|NCT04822064|DRUG|Intranasal dexmedetomidine and ketamine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
214294851|NCT04822064|DRUG|Oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
214668291|NCT06997003|DEVICE|Anterior treatment mode|Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment
214668292|NCT06997003|DEVICE|Total treatment mode|Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment
214890014|NCT04639011|OTHER|Placebo|Three doses of placebo will be given to participants (right before operation, postop day 1, postop day 2).
214890015|NCT04639011|OTHER|Standard of care (SOC) for tibial plateau surgery|Postoperative IV administration of opioids via a patient controlled analgesia (PCA) system which utilizes a hydromorphone pump.
214890016|NCT04884373|DIAGNOSTIC_TEST|Gastric ultrasound|An ultrasound exam will be performed before induction of anaesthesia. GUS results from selected patients will be systematically acquired and assessed following an algorithm (Appendix Ia). The ultrasound results will be collected on a standardized form (Appendix IIa). The technique is performed in the supine and right lateral decubitus position (Appendix Ib) and only by anesthesiologists with sufficient experience with ultrasound and the technique. The patient will be asked to indicate his/her satiety on a predetermined ten-point scale.
214890017|NCT04610333|BEHAVIORAL|Modified MBSR programme|1 hour group session once a week in 10 weeks
214294852|NCT01654094|DEVICE|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
214294853|NCT01654094|OTHER|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
214294854|NCT00471744|DRUG|Treatment with levetiracetam or sulthiame over a six-month period.|
214294855|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
214294856|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
214294857|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
214294858|NCT01291173|DRUG|Placebo|Placebo capsule taken once daily for up to 11 weeks
214890018|NCT06191029|BEHAVIORAL|Urdu translated cognitive failure questionnaire|Urdu Translated version of cognitive failure questionnaire will be given to adults to fill it accordingly and then it's reliability and validity will be checked
214890019|NCT00917774|DEVICE|Standard LPS flex TKA|TKA by Standard LPS flex TKA
214890020|NCT00917774|DEVICE|Gender specific LPS -Flex TKA|Total knee design created specific for female patients
214890021|NCT02385474|DRUG|12% SDF|12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
214890022|NCT02385474|DRUG|38% SDF|38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
214890023|NCT03708094|DIAGNOSTIC_TEST|molecular diagnosis|whole exome sequencing and data analysis to elucidating molecular diagnosis
214294859|NCT03913793|OTHER|Exercise based-cardiac rehabilitation (EB-CR) program|The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.\[19\] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.
214890024|NCT06278480|DEVICE|MegaCarti®|Medical devices containing allogeneic cartilage
214294860|NCT01250262|OTHER|normal medical care and follow up|physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
214294861|NCT01250262|OTHER|Isolated Lumbar Resistance Exercise Program|lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
214294862|NCT01250262|OTHER|Total Body Resistance Exercise Program|exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
214294863|NCT03280420|PROCEDURE|Early catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
214668293|NCT05370469|OTHER|Sensus Smartwatch Application|Sensus is capable of administering ecological momentary assessments (EMAs) on a schedule, randomly, or using sensor-triggers. In this way, Sensus will capture both active (patient-initiated) and passive data streams from native smartphone sensors. Passive streams may include, but are not limited to, GPS, accelerometer, gyroscope, and pedometer data. Participants will be able to log data such as their activity, symptoms and medication adherence via user-initiated surveys within the Sensus app. Sensus will also prompt users to record their medication adherence, symptoms, or activity. This will be done either at fixed intervals (e.g., three times daily) or whenever the onboard sensors detect potential changes in a user's physiological state (e.g., shaking / moving around).
214668294|NCT05370469|DEVICE|RX Cap|The RXCap medication event monitoring device will be used to collect data on participant adherence to their TKI medication. A small computer chip is included in the top of a pill bottle. When the cap is taken off of the pill bottle by turning it or unscrewing it, the cap records the time and date that it was removed.
214668295|NCT05370469|DEVICE|Fitbit Sense|The Fitbit Sense smartwatch will be used to collect data including steps, calories burned, total distance travelled, sleep (e.g. time spent sleeping and quality of sleep), flights of stairs climbed, active minutes, exercise (e.g. minutes spent exercising at various intensities), and average heart rate.
214668296|NCT05370469|OTHER|Surveys|Electronic and paper surveys will be administered throughout the study.
214668297|NCT06458140|PROCEDURE|Cardioneuroablation|Radiofrequency ablation of ganglionated plexi of the heart
214668298|NCT04282915|OTHER|Reducing Stigma among Healthcare Providers (RESHAPE)|Mental health service users are trained using Photo Voice to develop recovery story testimonials. They then participate in primary care providers mental health Gap Action Programme training. In addition, aspirational figures are trained to provider testimonials and conduct myth-busting.
214668299|NCT04282915|OTHER|mental health Gap Action Programme|The mental health Gap Action Programme is a training program for primary care providers in mental health services. The curriculum has been developed by the World Health Organization and was adapted in Nepal and certified by the Ministry of Health.
214668300|NCT06066736|OTHER|observational|No intervention, observational group
214668301|NCT06617481|DRUG|18F-rhPSMA-7.3 (Posluma)|PET Scan using Posluma for detection of early recurrence of prostate cancer.
214668302|NCT03011125|DRUG|dexlansoprazole injection|
214668303|NCT03011125|OTHER|placebo|
214668304|NCT05735054|PROCEDURE|endoscopic thyroidectomy|the patients who underwent endoscopic transaxillary thyroidectomy
214668305|NCT05436249|DEVICE|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~1. Overt finger tapping in time with a flashing cue.~2. Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
214668306|NCT05436249|BEHAVIORAL|At-home therapy|"Participants are assigned to groups where they will practice each day for 3 weeks at-home.~1. Group 1: Imagery only.~2. Group 2: Overt finger tapping only.~3. Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
214890025|NCT06278480|PROCEDURE|microfracture|microfracture
214890026|NCT00779831|DRUG|120 mg Pseudoephedrine hydrochloride extended release tablets|
214890027|NCT00001630|DEVICE|Isolex 300i|
214890028|NCT04904133|OTHER|Low/No Calorie Sweeteners|LNCS powdered and then dissolved in water.
214890029|NCT04904133|OTHER|Placebo Group|Water
214890030|NCT01061801|BEHAVIORAL|Emotional expression|Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
214890031|NCT00457548|BEHAVIORAL|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
214294864|NCT03280420|PROCEDURE|Late catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
214477888|NCT06608420|OTHER|Gradient Boosting Survival Analysis (GBSA),|It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t.
214477889|NCT06608420|OTHER|Concordance index|The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features.
214477890|NCT04898400|PROCEDURE|endoscopy sleeve gastroplasty|endoscopic procedure for weight loss
214890032|NCT06509503|DRUG|Combined oral contraceptive|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are regular users of COCs and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
214890033|NCT06509503|DRUG|Vaginal Ring|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are users of mechanical contraceptive methods and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
214890034|NCT03357744|OTHER|distress barometer|not applicable, observational study
214890035|NCT01845480|BEHAVIORAL|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
214890036|NCT05411146|DRUG|[14C]-etrumadenant|Administered as specified in the treatment arm.
214294865|NCT00504933|DRUG|bilastine|20 mg (encapsulated) tablets QD/14days
214294866|NCT00504933|DRUG|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
214294867|NCT00504933|DRUG|Placebo|(encapsulated) Tablets QD/14 days
214294868|NCT03468257|BEHAVIORAL|Pavlovian Conditioning|Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit
214294869|NCT02349581|PROCEDURE|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
214477891|NCT06608602|OTHER|tidal volume adjustment during surgery|tidal volume adjustment during surgery according to body weight or FVC
214890037|NCT01260701|DRUG|Akt Inhibitor MK2206|Given PO
214890038|NCT00612092|RADIATION|Spiral image acquisition|standard spiral scan protocol
214890039|NCT00612092|RADIATION|sequential image acquisition|sequential CT scan protocol
214890040|NCT03459456|BEHAVIORAL|Provocation OC task (Provoc)|used to evoke OC-related distress
214890041|NCT03459456|BEHAVIORAL|Trier Social Stress Test (TSST)|used to evoke anxiety unrelated to OCD (e.g., performance anxiety)
214890042|NCT03459456|BEHAVIORAL|Exposure provocation task|used to elicit overt OCD rituals
214890043|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT placebo|Patientes will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
214294870|NCT02349581|DRUG|Bupivacaine|
214294871|NCT00390858|DRUG|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
214294872|NCT05629624|DIETARY_SUPPLEMENT|Chickpea based RUSF|One group will receive locally produced RUSF, approximate at 50-100 kcal/kg/day, two of 50g packets daily (42) until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for maximum 3 months then immediately 1 packet / day SQLNS will be given throughout the study till the end of 2 years of follow-up.
214890044|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT|patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done only on one side of mouth using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
214890045|NCT04536376|BEHAVIORAL|Resilience Program|Subjects receive program devices, and will be asked to wear during rest and sleep on a nightly basis along with active use during daytime. Notifications are sent daily, individualized approach developed and sent to participants to participate on.
214890046|NCT05296174|OTHER|cognitive-oriented intervention program|The experimental group was offered six 40-minute courses once a week.
214890047|NCT05296174|OTHER|health education activities program|The control group was offered health education activities once a week.
214890048|NCT06525207|DEVICE|Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography|Global morpho-functional assessment of the anal sphincter complex using Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography
214890049|NCT05552625|DRUG|TADIOS|TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia
214890050|NCT05552625|DRUG|Placebo|Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
214890051|NCT06294821|DRUG|4-Aminopyridine|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
214890052|NCT06294821|OTHER|Placebo|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
214890053|NCT06775704|DEVICE|Hip resurfacing system|Hip resurfacing with ROMAX system
214890054|NCT06629038|BEHAVIORAL|observation alone|observation of maximal mouth opening, lateral excursion, and range of motion of shoulder abduction, neck joint
214890055|NCT06362265|DRUG|LY3209590|Administered SC.
214890056|NCT05291091|DRUG|Sevasemten 10 mg|Sevasemten is administered orally once per day
214890057|NCT05291091|DRUG|Sevasemten 5 mg|Sevasemten is administered orally once per day
214890058|NCT05291091|DRUG|Sevasemten 12.5 mg|Sevasemten is administered orally once per day
214890059|NCT05291091|DRUG|Placebo|Placebo is administered orally once per day
214890060|NCT06338995|DRUG|LY3650150|Administered SC.
214890061|NCT06338995|DRUG|Placebo|Administered SC.
214890062|NCT06338995|DRUG|Standard therapy for INCS|Administered as intranasal spray.
214890063|NCT05861999|DRUG|Risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
214890064|NCT05292664|DRUG|Venetoclax|Tablet taken orally
214890065|NCT05292664|DRUG|Azacitidine|Taken intravenously
214890066|NCT05292664|DRUG|Cytarabine|Lumbar Puncture
214890067|NCT05292664|DRUG|Methotrexate|Lumbar Puncture
214890068|NCT05292664|DRUG|Hydrocortisone|Lumbar Puncture
214890069|NCT05292664|DRUG|Leucovorin|Taken Orally or intravenously
214890070|NCT05292664|DRUG|Dexamethasone|Taken Orally or intravenously
214890071|NCT05292664|DRUG|Vincristine|Taken intravenously
215049575|NCT03420755|BEHAVIORAL|Mothers and Babies 1-on-1|MB 1-on-1 is a 12-session intervention divided into five modules. An introductory 2-session module establishes key concepts related to stress, monitoring of one's mood, and ways in which one's mood influences one's internal thoughts and external environment; three 3-session modules correspond with key cognitive-behavioral elements: pleasant activities, thoughts, and social support/contact with others; a 1-session summary reviews content and identifies areas for future use of MB skills. Throughout MB, mood management skills are integrated using psycho-educational activities that encourage participants to understand connections between their mood and their activities, thoughts, and contacts with others.
214294873|NCT05629624|DIETARY_SUPPLEMENT|E-RUSF|The other group will receive the E-RUSF at 50-100 kcal/kg/day which in this age group approximates one 92 g sachet daily until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for a of maximum 3 months, then immediately E-SQLNS 1 packet daily provided throughout the study till the end of 2 years of follow-up.
215049576|NCT03420755|BEHAVIORAL|Mothers and Babies Plus Text|MB 1-on-1 along with text enhancements, both in English and Spanish. These texts focus on: a) skill reinforcement (e.g., Some thoughts just come to us, but we can make a conscious effort to think of positive thoughts.); b) homework reminders (e.g., What pleasant activity will you try today?), and c) self-monitoring (e.g., On a scale of 1-9, how would you rate your mood?). These texts will be linked with the 12 MB sessions. Specifically, after completing each in-person session, 3 texts will be sent by a home visitor to her client; one text will focus on skill reinforcement, one will be a homework reminder, and one will focus on self-monitoring.
215049577|NCT01388179|DEVICE|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
214890072|NCT05292664|DRUG|Doxorubicin|Taken intravenously
214890073|NCT05292664|DRUG|Dexrazoxane|Taken intravenously
214890074|NCT05292664|DRUG|Calaspargase Pegol|Taken intravenously
214890075|NCT05292664|DRUG|Erwinia asparaginase|Given as intramuscular injection
214890076|NCT06341192|PROCEDURE|Single-bundle ACL combined anterolateral ligament reconstruction|"Single-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo reconstruction of the anterior cruciate ligament (ACL) using a single-bundle graft technique.~In addition, they will have the anterolateral ligament (ALL) reconstructed using a portion of the same graft material.~The single ACL bundle is typically positioned to replicate the anatomic footprint of the native ACL.~For the ALL reconstruction, a commonly used technique is the Sonnery-Cottet ALL reconstruction using a gracilis tendon graft.~This combines an intra-articular ACL reconstruction with an extra-articular lateral tenodesis to improve rotational instability."
214890077|NCT06341192|PROCEDURE|Double-bundle ACL combined anterolateral ligament reconstruction|"Double-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo anatomic double-bundle ACL reconstruction using two graft bundles to more anatomically replicate the native ACL\&#39;s anteromedial and posterolateral bundles.~Like the single-bundle group, they will also have supplemental ALL reconstruction performed using a portion of the graft material.~The double-bundle ACL reconstruction aims to better restore the ACL\&#39;s complex anatomic footprint and bundles\&#39; tension patterns."
214890078|NCT06524401|DEVICE|Limpet|Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.
214890079|NCT06524401|DEVICE|Control|Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.
214890080|NCT05740059|OTHER|Adjusted Transfusion|Patients assigned to the SvO2 group will be transfused if Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65%. Transfusion will be repeated whenever Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65% during surgery and in the ICU (until day 5). Central SvO2 will be measured on a blood sample obtained from the distal lumen of the central venous catheter. Oximetry will be used for measurement with a point-of-care of gas analysis.
214890081|NCT05126238|DRUG|Lithium Carbonate|In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
214890082|NCT05126238|DRUG|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
214890083|NCT02630628|DRUG|Tacrolimus|Dosage: start at 2mg twice a day, then titrated according to therapeutic drug level monitoring using 12-hour post-dose blood sampling
214294874|NCT05629624|DIETARY_SUPPLEMENT|Outcome reference group/RUSF|We will also recruit 70 three-year-old previously untreated MAM children WHZ \<-2 and ≥-3 z-score, and/or MUAC \<12.5 and ≥11.5 cm as an outcome reference group for a singular assessment. All children (both case \& control) will undergo a baseline nutritional, medical, biological and neuropsychological assessment (EF, ER, EEG and fNIRS). After all the assessments chick-pea based RUSF will be given for 2 months for nutritional rehabilitation.
214294875|NCT01883843|DEVICE|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
214294876|NCT01883843|DEVICE|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
214294877|NCT03664557|DEVICE|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
214294878|NCT06112444|OTHER|scale|The scale of Short Western Ontario Rotator Cuff İndex
215049578|NCT05007197|BEHAVIORAL|The Effect of Diabetes Education Based on Learning Modality|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet."
215049579|NCT04552041|DRUG|Prospekta|Oral administration.
214294879|NCT02728895|DRUG|Vedolizumab|Vedolizumab Injection.
214294880|NCT01862198|DEVICE|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
214294881|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily custom insulin titration instructions.
214294882|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily generic insulin reminders.
214294883|NCT03080311|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
214890084|NCT02630628|DRUG|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
214890085|NCT06191965|DRUG|MitoQ|"MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~2. CAS number: 444890-41-9 (phosphonium cation)~3. Molecular weight: 678.81~4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality\_safety/quality\_assurance/TRS986annex2.pdf?ua=1).~5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ."
214890086|NCT06191965|DRUG|Placebo|Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
214890087|NCT06336018|DRUG|Etavopivat|Participants will receive a single dose of etavopivat orally.
214890088|NCT06029244|DEVICE|EyeControl-Pro|Based on artificial intelligence (AI)-powered eye-tracking technology, the EyeControl-Pro wearable device and smart platform enable 24/7 customizable communication and monitoring between ventilated patients who cannot speak, their families, and medical teams
215049580|NCT04552041|DRUG|Placebo|Oral administration.
215049581|NCT06057805|DEVICE|Blinded Dexcom G7 CGM|CGM that records blood glucose but not visible to patient or provider in real time
215049582|NCT02603679|DRUG|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
215049583|NCT02603679|DRUG|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
214294884|NCT00403663|DRUG|bupivacaine 0.75% with fentanyl and morphine|the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
214294885|NCT02159690|DRUG|Enzalutamide|160mg
214294886|NCT02159690|DRUG|Abiraterone acetate|1000mg
214294887|NCT02159690|DRUG|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
214294888|NCT02159690|DRUG|Dutasteride|0.5mg
214294889|NCT02159690|DRUG|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
214294890|NCT01406431|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
214294891|NCT01406431|DRUG|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
214294892|NCT05854589|DRUG|Sodium Chloride Granules|Sodium Chloride crystals
214294893|NCT05854589|OTHER|Water|Plain distilled water
214294894|NCT05473338|DIAGNOSTIC_TEST|Stool and blood samples|fecal microbiome and metabolomics, as well as metabolites in plasma
214890089|NCT06029244|OTHER|Control|No intervention
214890090|NCT04100148|DEVICE|SyncAV programmed ON|For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.
214890091|NCT04100148|DEVICE|Fixed AV delay|For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
214890092|NCT04416568|DRUG|Nivolumab|"Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles.~Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle"
214890093|NCT04416568|DRUG|Ipilimumab|Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles
215049584|NCT02603679|DRUG|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
214890094|NCT05977218|OTHER|FoodSwitch|Access to the 'DiabetesSwitch' filter of the FoodSwitch app when grocery shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.
214890095|NCT03516279|DRUG|Dasatinib|Given PO
214890096|NCT03516279|DRUG|Imatinib Mesylate|Given PO
214890097|NCT03516279|OTHER|Laboratory Biomarker Analysis|Correlative studies
215049585|NCT02603679|DRUG|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
215049586|NCT02100293|DRUG|magnesium sulfate 30 mg/kg|Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
215049587|NCT02100293|DRUG|saline|Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
214890098|NCT03516279|DRUG|Nilotinib|Given PO
214890099|NCT03516279|BIOLOGICAL|Pembrolizumab|Given IV
214890100|NCT06275555|DRUG|bivalirudin|bivalirudin as an anticoagulant
215049588|NCT06218810|DRUG|Cadonilimab + bevacizumab + FOLFOX|Cadonilimab + bevacizumab + FOLFOX
214294895|NCT05473338|OTHER|Physical examination|physical examination performed by a physician to confirm CRPS diagnosis and assess patient's eligibility to participate in the study. The exam will include skin temperature measured using a laser/infrared skin thermometry.
214294896|NCT05473338|OTHER|Questionnaires|Questionnaires measuring pain level, sleep, mood and diet parameters.
214890101|NCT06275555|DRUG|unfractionated heparin|unfractionated heparin as an anticoagulant
215049589|NCT02492243|DEVICE|PCI|
215049590|NCT02492243|DEVICE|ILR implantation|
215049591|NCT05759208|DRUG|OK-101|Ophthalmic Solution
215049592|NCT05759208|DRUG|Placebo|Placebo
215049593|NCT04764721|DEVICE|18F-FDG PET-CT|Enrolled patients in Neurocog-Covid will receive a 18F-FDG PET-CT
215049594|NCT00661830|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
214294897|NCT05313074|BIOLOGICAL|CoronaVac vaccine|An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
214890102|NCT06052267|DRUG|TEV-56248|Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.
214890103|NCT06052267|DRUG|Albuterol sulfate|Oral inhalation powder
214890104|NCT03750708|DEVICE|Ara® KOLIBREE tooth brush|"Use of the Ara® KOLIBREE tooth brush by the child one month before alveolar bone graft up to the time of surgery.~The Ara® KOLIBREE tooth brush saves brush tracking data."
214890105|NCT06138587|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
214890106|NCT06138587|BIOLOGICAL|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.
214890107|NCT04190706|OTHER|bioactive components fortified food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
215049595|NCT00661830|DRUG|Placebo|Placebo
215049596|NCT00661830|DRUG|Sorafenib|Sorafenib 400 mg bid orally continuously
215049597|NCT02869321|DRUG|Fentanyl|
215049598|NCT02869321|DRUG|Morphine Sulfate|
215049599|NCT02869321|DRUG|Fentanyl placebo|
215049600|NCT02869321|DRUG|Morphine Sulfate placebo|
215049601|NCT02869321|PROCEDURE|Gastrostomy|
215049602|NCT00203385|DRUG|Divalproex|Depakote up to 2000mg/d
215049603|NCT00488514|DRUG|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
215049604|NCT04256525|DRUG|Rivaroxaban 10mg|10mg orally per day
214890108|NCT04190706|OTHER|control food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
214890109|NCT05453942|DRUG|SAR441566|Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
215049605|NCT04256525|DRUG|Aspirin 100mg|100mg orally per day
215049606|NCT04256525|DRUG|low molecule heparin|0.4ml per day subcutaneous injection
215049607|NCT04346511|OTHER|Acupuncture|Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.
215049608|NCT02527473|OTHER|Dispatcher-Assisted Basic Life Support CPR Education|"The training program focuses on working in a team with a dispatcher, re-enacting all steps during an emergency call from recognition of cardiac arrest to performing CPR.~The one hour training session is split into four parts:~1. Video self-instruction manikin practice (30 min), including a brief introduction to AED.~2. Practice in pairs (15 min): Role-playing a simulated emergency scenario as the dispatcher and the rescuer~3. Debriefing (15 min): Questions, answers and reflection~4. Homework: Information leaflet handed out including at-home tasks such as operating the speakerphone function on the layperson's own phone"
214890110|NCT05453942|DRUG|Placebo|Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
215049609|NCT01047189|DRUG|clindamycin phosphate 1.2% and tretinoin 0.025%|applied once daily for 12 weeks
215049610|NCT01047189|DRUG|clindamycin 1% gel|Topical clindamycin applied each morning for 12 weeks
215049611|NCT01047189|DRUG|tretinoin 0.025% cream|Tretinoin 0.025% cream each evening for 12 weeks
215049612|NCT01535287|DRUG|Dexmedetomidine|"Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider."
215049613|NCT05165732|BIOLOGICAL|Experimental vaccine 1|Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
215049614|NCT05165732|BIOLOGICAL|Experimental vaccine 2|Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd.4ug inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
215049615|NCT05165732|BIOLOGICAL|Experimental vaccine 3|Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.200WU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
215049616|NCT01370187|DRUG|Montelukast|Montelukast 4mg daily for 2 months
214294898|NCT00795522|DRUG|Desloratadine|Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
214890111|NCT06894849|BEHAVIORAL|Text-based depression screening|Starting 1 week prior to the scheduled clinic appointment, patients will receive a text message invitation from HCC to complete depression screening. Participants will be asked to click to continue to the screening PHQ-2. For text message screening cadence, reminder texts will be sent daily for 3 days. Those who screen positive (PHQ-2 \>/= 3) will complete the remainder of the items (i.e., PHQ-9).
214890112|NCT06894849|BEHAVIORAL|Usual care (UC)|Usual care (UC) will consist of in-person assessment of depression using a validated brief screening tool (e.g., PHQ-2) synchronous with a clinical encounter with the outpatient oncology team. Although the person completing the screening (e.g., nurse, medical assistant) and other workflow may vary slightly across settings, the 2-items are generally presented orally to the patient during routine intake for a clinical encounter and entered into the EHR. Patients who screen positive will be asked to complete the full PHQ-9.
214890113|NCT04186039|DIAGNOSTIC_TEST|Functional magnetic resonance imaging - Blood Oxygenation Level Dependent|"First Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence under ambient air.~Oxygenation of 5 minutes at a rate of 12 l / min. Second Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence."
214890114|NCT06964009|DRUG|DT2216|A proteolysis-targeting chimera (PROTAC) degrader, single-use vial, via intravenous (into the vein) infusion.
215049617|NCT02890459|OTHER|Prize incentive - Low|Low expected prize value.
215049618|NCT02890459|OTHER|Prize incentive - High|High expected prize value.
215049619|NCT02890459|OTHER|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
215049620|NCT02890459|OTHER|Travel Voucher|Travel voucher to assist with linkage to care.
215049621|NCT02890459|OTHER|Standard care|Includes HIV viral load and treatment adherence counseling.
214294899|NCT04931108|DRUG|Nitrendipine/Atenolol|Nitrendipine/Atenolol 5mg/10mg single-pill combination, oral tablet, one pill daily.
214294900|NCT04931108|DRUG|Nitrendipine|Nitrendipine 5mg, oral tablet, one pill daily.
214294901|NCT04931108|DRUG|Atenolol|Atenolol 25mg, oral tablet, one pill daily.
214890115|NCT06964009|DRUG|Paclitaxel|An antimicrotubule agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard.
214890116|NCT05645861|PROCEDURE|Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
215049622|NCT02890459|BEHAVIORAL|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
215049623|NCT02890459|BEHAVIORAL|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
215049624|NCT02890459|BEHAVIORAL|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
215049625|NCT02890459|BEHAVIORAL|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
215049626|NCT02890459|BEHAVIORAL|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
215049627|NCT03383250|DIETARY_SUPPLEMENT|Normal meal|
215049628|NCT01129492|DEVICE|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
215049629|NCT00052910|DRUG|cisplatin|Given IV
215049630|NCT00052910|DRUG|epirubicin hydrochloride|Given IV
215049631|NCT00052910|DRUG|fluorouracil|Given IV
215049632|NCT00052910|DRUG|leucovorin calcium|Given IV
215049633|NCT00052910|RADIATION|radiation therapy|Given 5 days a week for 5 weeks
215049634|NCT00047502|DRUG|Lonafarnib (SCH66336)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
214294902|NCT02225990|OTHER|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
214294903|NCT02225990|OTHER|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
214294904|NCT02225990|OTHER|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
214294905|NCT02225990|OTHER|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
214294906|NCT04899414|DRUG|Dexamethasone, azacytidine, Pegaspargase, Tislelizumab|Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.
214294907|NCT03559153|OTHER|Shiatsu massage|The shiatsu massage will be during the rest break by 15 minutes.
214294908|NCT03559153|OTHER|Physical Exercise|The Physical Exercise will be during the rest break by 15 minutes.
214294909|NCT02308852|DEVICE|tDCS|
214294910|NCT02677142|BEHAVIORAL|Structured social skills training program, SSIP|Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).
214294911|NCT02677142|BEHAVIORAL|CG - social skills activities|Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
214294912|NCT02734238|DRUG|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
214294913|NCT02734238|DRUG|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
214890117|NCT04204915|PROCEDURE|Aortic valve replacement|Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.
214890118|NCT05355532|GENETIC|different variants of SNPs that may be associated with the coronary microvascular obstruction development|Some variants of SNPs determine endothelial function, microcirculation, hemostasis, and inflammation in MI patients. They may be associated with the development of coronary microvascular obstruction during emergency PCI. A link between the different SNPs and the CMVO development will be established. SNP will be determined by real-time polymerase chain reaction with high-resolution melting curve analysis using TaqMan fluorescent probes.
214890119|NCT06311721|DRUG|ABP 234|Intravenous administration
214890120|NCT06311721|DRUG|Pembrolizumab (US)|Intravenous administration
214890121|NCT06311721|DRUG|Pembrolizumab (EU)|Intravenous administration
215049635|NCT00047502|DRUG|Imatinib Mesylate (Gleevec)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
215049636|NCT05964491|OTHER|No intervention|No intervention studied
215049637|NCT04961138|PROCEDURE|Transhepatic Arterial Chemotherapy And Embolization (TACE)|Receiving TACE and lenvatinib before surgery.
215049638|NCT04961138|PROCEDURE|Surgery|Removing tumor by surgery.
215049639|NCT03313635|DIAGNOSTIC_TEST|Men presenting with low-T|Evaluation of prealbumin levels.
215049640|NCT05140135|BEHAVIORAL|Recovery Oriented Cognitive Therapy (CT-R)|The CT-R that will be implemented in the present study will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. In CT-R, clinicians use techniques to engage the patient in the adaptive mode, which includes cognitions, affects, motivation, and behaviors that are activated when the individual is engaged in personally meaningful activities.
215049641|NCT05140135|OTHER|Treatment as Usual|All patients enrolled in the study who are randomized to the continued care as usual condition will continue to receive the treatments from their physician/treatment team at the Community Mental Health Center; however, they will not receive the adjunctive CT-R treatment.
215049642|NCT01187095|BEHAVIORAL|Expressive writing|3 consecutive days of writing
215049643|NCT01187095|BEHAVIORAL|Active ctrl|Control
215049644|NCT03549286|OTHER|Questionnaire passation|Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
215049645|NCT01559415|OTHER|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
215049646|NCT01559415|OTHER|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
215049647|NCT02420184|DEVICE|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
215049648|NCT02420184|OTHER|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
215049649|NCT00288886|BEHAVIORAL|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
215049650|NCT00288886|BEHAVIORAL|Control arm|Routine residential treatment and orientation to continuing care.
214294914|NCT01949051|DRUG|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
214890122|NCT06443567|DEVICE|impedance threshold device|impedance threshold device (ResQPOD, Zoll) applied to airway
214890123|NCT03244072|DRUG|Moxifloxacin|Intracameral injection
214890124|NCT03244072|DRUG|Placebo|intracameral injection
214890125|NCT06118281|DRUG|Ziltivekimab|Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.
215049651|NCT01475721|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
214890126|NCT06118281|DRUG|Placebo|Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
214890127|NCT05808634|DRUG|BA3182|Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
214890128|NCT06448572|DRUG|EXL01|1 capsule / day
215049652|NCT01475721|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
215049653|NCT01475721|DRUG|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
215049654|NCT01475721|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
215049655|NCT01475721|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
215049656|NCT01475721|DRUG|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
215049657|NCT00803738|DRUG|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
215049658|NCT00803738|DRUG|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
215049659|NCT04858438|PROCEDURE|Insufflation during surgery|This is the amount of insufflation using during the surgical procedure.
215049660|NCT03910725|OTHER|Electrocardiographic imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
215049661|NCT01583114|DRUG|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
215049662|NCT01583114|DRUG|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
215049663|NCT03551613|DIETARY_SUPPLEMENT|honey supplementation|honey supplementation
215049664|NCT06045065|OTHER|Fresh tumor sampling|Patient samples will be collected during neurosurgical resection. .
214890129|NCT06788756|DRUG|Placebo in combination with Cytarabine Injection|placebo (0.9% Sodium Chloride Injection, i.e., the diluent for L-Annamycin for Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
214890130|NCT06788756|DRUG|Liposomal Annamycin Injection in combination with Cytarabine Injection|190 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
214890131|NCT06788756|DRUG|Liposomal Annamycin Injection in combination with Cytarabine Injection|230 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
214890132|NCT06788756|DRUG|Liposomal Annamycin for Injection in combination with Cytarabine Injection.|optimal dosage regimen (as determined in Part A) of L Annamycin for Injection (190 mg/m2/day or 230 mg/m2/day) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 2 or 3, respectively, of Part A).
215049665|NCT02708316|GENETIC|sequencing faecal metagenome|sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
215049666|NCT04481607|DRUG|TQB3454|TQB3454 tablets is a small molecule oral drug.
215049667|NCT00565396|DRUG|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
215049668|NCT04413916|DIAGNOSTIC_TEST|miRNA expression|Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.
215049669|NCT00118638|DRUG|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
215049670|NCT00118638|DRUG|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
215049671|NCT00111072|DRUG|dexamethasone 0.01% solution|
215049672|NCT04941690|OTHER|A questionnaire method was used.|The questionnaire included general population information, International Index of Sexual Function-5 (IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), General Anxiety Disorder-7 and CPSI.
215049673|NCT01820806|DRUG|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
215049674|NCT01142440|BEHAVIORAL|behavioral intervention|"* Dietary instructions~* Oral hygiene instructions: GC plaque indicator kit~* Antibacterial therapy: medident sol. one week a month, for 6 months~* Fluorides: VOCO Profluorid varnish, once every 3 month~* Restoration~* Follow ups"
215049675|NCT04180111|DEVICE|CATS Tonometer|CATS Tonometer Prism
215049676|NCT02053844|OTHER|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
215049677|NCT02053844|OTHER|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
215049678|NCT00387088|DEVICE|Respimat|
214294915|NCT01949051|DRUG|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
214294916|NCT06495047|DRUG|Long-acting bronchodilator therapy (LABD)|Long-acting inhaler therapy
214890133|NCT04205812|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
215049679|NCT00387088|DRUG|Tiotropium|
215049680|NCT00551096|DRUG|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
215049681|NCT00551096|DRUG|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
215049682|NCT00551096|DRUG|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
215049683|NCT02015403|DRUG|Standard Care + NAC (N -ACETYLCYSTEINE)|
215049684|NCT02015403|DRUG|Standard Care (in control arm)|
215049685|NCT02663154|DRUG|Aromatherapy inhaler|Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
214294917|NCT06495047|DRUG|Short-acting bronchodilator therapy (SABD)|Short-acting inhaler therapy
214294918|NCT01639651|OTHER|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
214890134|NCT04205812|DRUG|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
214890135|NCT04205812|DRUG|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.
214890136|NCT04205812|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
214890137|NCT04205812|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
214890138|NCT04205812|DRUG|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
215049686|NCT02663154|DRUG|Saline inhaler|Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
215049687|NCT03679390|DRUG|Ketamine|With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.
215049688|NCT02178800|DRUG|GSK1265744 Tablets|30-mg tablets, taken orally
215049689|NCT02178800|DRUG|Injectable GSK1265744|"Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection"
215049690|NCT02178800|DRUG|Placebo for GSK1265744 Tablets|Taken orally
215049691|NCT02178800|DRUG|Injectable Placebo for GSK1265744|"Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection"
214890139|NCT04205812|DRUG|nab-Paclitaxel|nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
214890140|NCT04111809|BIOLOGICAL|Blood and urine collection|collected 10 mL of blood and 15 mL of urine every 2 months until 12 months
215049692|NCT05120700|BIOLOGICAL|Synovial Tissue and Fat Pad Stromal Vascular Fraction|Treatment of cartilage injury with a tissue engineering construct. It will be composed of stromal vascular fraction collected from the synovial membrane and infrapatellar fat of the injured knee, submitted to enzymatic processing in a single surgical time, associated with a collagen scaffold
215049693|NCT05988736|DEVICE|MaCintosh Laryngoscope (DL)|A conventional Laryngoscope. It is battery powered, with a detachable MaCintosh blade that contains a light source.
214890141|NCT03935997|OTHER|Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program|"Our team will work with long-term care homes in the study to implement the Strengthening a Palliative Approach in Long Term Care (SPA-LTC) which consists of the following core, evidence-informed components:~Palliative Champion Teams (to provide leadership and support implementation); Palliative Care Education (including illness trajectory pamphlets); Comfort Care Rounds with staff (for capacity building and reflection); Prognostic Tools to trigger end-of-life discussions; Palliative Care Conferences with families and residents; Bereavement Pamphlets; and Post-Bereavement Follow-Up for families, and staff."
214890142|NCT05221320|DRUG|Ulixertinib|small molecule ERK 1/2 inhibitor
214890143|NCT05221320|DRUG|Hydroxychloroquine|Autophagy inhibitor
214890144|NCT05104723|DRUG|XELJANZ (tofacitinib)|The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
215049694|NCT05988736|DEVICE|McGrath Laryngoscope (VL)|A video Laryngoscope that has a high-resolution video camera, and a light source at the cone end of the blade allowing for direct and indirect viewing of the glottis
214890145|NCT05063708|DEVICE|Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation|In the present study, VitalStim equipment will be used (VitalStim Therapy; Chattanooga Group, Chattanooga, TN, USA). Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation.
214890146|NCT05063708|DEVICE|Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulation|Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation. The training was given according to the manual of the manufacturer, the VitalStim certification course (http://www.vitalstim.com).
214890147|NCT06473519|BIOLOGICAL|RSVpreF MDV|RSVpreF with 2-PE formulated in an MDV
214890148|NCT06473519|BIOLOGICAL|RSVpreF SDV|RSVpreF without 2-PE formulated in an SDV
214890149|NCT03976843|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
214890150|NCT05924763|DEVICE|Biphasic Cartilage Repair Implant (BiCRI)|The Biphasic Cartilage Repair Implant (BiCRI) is a two-phase scaffold composed of poly(lactic-co-glycolic acid) (PLGA) and β-triCalcium phosphate (TCP).
214890151|NCT05630469|OTHER|Electroconvulsive therapy|repetitive induction of a generalized seizure under controlled conditions (muscle relaxation and sedation)
214890152|NCT06958536|DRUG|SAR442970|Route of Administration: Subcutaneous
214890153|NCT06958536|DRUG|Placebo|Route of Administration: Subcutaneous
214890154|NCT05238623|DIAGNOSTIC_TEST|additional EIT Measurement|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement. The lunghealthy Patients in the control group only receive a EIT.
214890155|NCT03184571|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor
214890156|NCT03184571|DRUG|Bemcentinib|Bemcentinib is a selective Axl kinase inhibitor;
214890157|NCT06246253|PROCEDURE|Virtual implant placement following safe angle concept|Virtual implant placement following safe angle concept in anterior maxillary teeth.
214890158|NCT06246253|PROCEDURE|actual implant placement following safe angle concept|actual implant placement following safe angle concept in anterior maxillary teeth
215049695|NCT05511012|OTHER|motion control fault tests|Patients make 6 motion control fault tests, in the same order. Each test is performed three times
214890159|NCT04582149|DEVICE|EyeControl Eye-tracking Device|The EyeControl is a new, wearable, eye-tracking device that facilitates communication by means of internal feedback to the patients with a bone-conducting speaker. In this way, the device can ask the patient what he or she wants to say, and the patient replies by eye gestures such as blinking or moving the eyes in a certain direction. Once the patient is able to operate the device, it will stay on the patient for as long as she or he would like it on, or until the patient is successfully extubated or discharged from the ICU, whichever is earliest.
214890160|NCT05247580|OTHER|Hicks self-confidence scale, Karasek survey, Maslach Burnout Inventory|Questionnaires (Hicks self-confidence scale, Karasek questionnaire, Maslach Burnout Inventory) sent to hospital staff caregivers before and after (at 3 and 6 months) their SUrVIS training.
214890161|NCT06070233|RADIATION|stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation|"Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing. Prescription dose is 50 Gy delivered in a single fraction to the target volume, prescribed to whatever isodose line produces optimal falloff (but not less than a 50% isodose line; dmax \<100Gy) .~All radiosurgery treatment will utilize the Varian Edge, Varian TrueBeam STx, or CyberKnife system"
214890162|NCT06070233|OTHER|Sham|Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing.
214890163|NCT05760612|DRUG|Trastuzumab and neratinib|Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and neratinib 240 mg orally once daily. The trastuzumab treatment will be continued for a total of 18 cycles, encompassing both the preoperative and adjuvant phases, while neratinib will be maintained throughout the adjuvant period.
214890164|NCT05760612|DRUG|Trastuzumab and Pertuzumab|Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and pertuzumab (840 mg IV loading dose, followed by 420 mg IV once every 3 weeks). This regimen will be repeated for a total of 18 cycles,encompassing both the preoperative and adjuvant phases.
214890165|NCT06157814|OTHER|STOMA Care web-based application|The STOMA Care App, with program software developed in collaboration with the Information Technology Department at Mount Sinai, is organized in a web-based app accessible on any smart-phone (e.g., Android and iOS), tablet, or computer device and consist of: 1) provision of information through text, and graphics; 2) videos of physicians and nurses answering questions; and 3) videos of patients describing their experiences and modelling competencies 4) mental health, support group, and ostomy supplier resources.
214890166|NCT06157814|OTHER|Usual Care|Patients and caregivers NOT given access to the web-based application.
214890167|NCT05932199|DRUG|Durvalumab / tremelimumab|"Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
214890168|NCT05932199|DRUG|Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab|"Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
214890169|NCT06221007|PROCEDURE|Use of bone cement in otosclerosis surgery|Surgical technique; It involves separating the sclerosed stapes from the oval window and incus under an endoscope or microscope and replacing it with a Teflon piston, which is a middle ear prosthesis. In this way, a new connection between the incus and the oval window ensures the transmission of sound to the inner ear. Bone cement has long been used in primary and revision ossiculoplasty, including stapedotomy of the middle ear. During stapedotomy, the part of the Teflon piston that places the teflon piston on the incus is fixed with bone cement, aiming to keep the prosthesis in place for a long time and prophylactic treatment of incus necrosis.
214890170|NCT06344000|OTHER|inapplicable|inapplicable
214890171|NCT05820438|DEVICE|Electromyography|"Disposable bipolar surface electrodes will be used.~The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres.Doing so the position of the electrodes results as follows:~Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient."
214890172|NCT04130893|BEHAVIORAL|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
214890173|NCT04130893|BEHAVIORAL|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
214890174|NCT04225156|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
214890175|NCT06430866|DRUG|ABP 234|Administered by intravenous (IV) injection.
214890176|NCT06430866|DRUG|Pembrolizumab|Administered by IV injection.
214890177|NCT05102760|PROCEDURE|Nerve Block using FIC Proceedure|Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
214890178|NCT05102760|PROCEDURE|Nerve Block using PENG Proceedure|Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
214890179|NCT03855111|OTHER|Standard Acupuncture / Moxibustion|Standard (Fixed) Active Acupuncture / Moxibustion protocol aimed at reducing lower limb neuropathic pain/discomfort.
214890180|NCT03855111|OTHER|Individualized (Tailored) Active Acupuncture / Moxibustion|Individualized (tailored) protocol Acu/Moxa - Active. Acu/Moxa prescription based on TCM assessment. Protocol aimed at reducing lower limb neuropathic pain/discomfort.
214890181|NCT04903288|GENETIC|Eladocagene Exuparvovec|Four 0.08 milliliters (mL) infusions at a dose of 0.45×10\^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10\^11 vg and a total volume of 320 μl per participant.
214890182|NCT03713593|DRUG|lenvatinib|Administered orally once a day
214890183|NCT03713593|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W
214890184|NCT03713593|DRUG|saline placebo|Administered as an IV infusion on Day 1 Q3W
214890185|NCT05749055|DRUG|ENX-102|Selective GABA-A alpha2,3,5 positive allosteric modulator
215049696|NCT05994768|OTHER|18F-FDG PET/CT|Patients who underwent an 18F-FDG PET/CT examination and a labeled leukocyte scintigraphy before and after antibiotic therapy in the case of management of an EO.
215049697|NCT04741932|OTHER|Dementia Care Management (DCM)|"A computerized Information and Care Management System (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care)."
215049698|NCT05233514|OTHER|Aerobic exercise in addition to Metformin treatment|The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
214890186|NCT05749055|DRUG|Placebo|Placebo
214890187|NCT04776148|DRUG|pembrolizumab|IV infusion
214890188|NCT04776148|DRUG|lenvatinib|oral capsule
214890189|NCT04776148|DRUG|regorafenib|oral tablet
214890190|NCT04776148|DRUG|TAS-102 (trifluridine and tipiracil)|oral tablet
214890191|NCT03274492|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
214890192|NCT03274492|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
214890193|NCT03274492|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
214890194|NCT03274492|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
214890195|NCT03274492|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
214890196|NCT03274492|DRUG|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
214890197|NCT03274492|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
214890198|NCT03274492|DRUG|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
214890199|NCT06474182|PROCEDURE|Blood sampling|Blood sampling
214890200|NCT06474182|DRUG|Apixaban|Treatment by Apixaban
214890201|NCT05239468|DRUG|Bezafibrate 100 mg|One tablet of bezafibrate 100 mg IR once daily
214890202|NCT05239468|DRUG|Bezafibrate 200 mg|Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR
214890203|NCT05239468|DRUG|Obeticholic Acid 5 mg|One tablet of obeticholic acid 5 mg tablet once daily.
214890204|NCT05239468|DRUG|Obeticholic Acid placebo|One tablet of obeticholic acid placebo tablet once daily
214890205|NCT05239468|DRUG|Bezafibrate Placebo|One tablet of bezafibrate placebo tablet once daily
214890206|NCT06452407|OTHER|Implementation of elleFA smartphone application|Participants will download the elleFA application on their smartphone. Through this application, the user will be prompted to complete a short modified Biberoglu and Behrman (B\&B) questionnaire and a longer EHP-30 questionnaire monthly, for a period of 6 months. Optionally, patients may complete an additional weekly summary of their mental health symptoms, pain localization, and other symptoms. Also optionally, they may record any daily symptoms, separated into categories from lifestyle to physical pain, objectified through a 5-point Likert scale.
214890207|NCT06625177|DRUG|TEV-53408|TEV-53408 injection administered subcutaneously
214890208|NCT04876781|DRUG|Tofacitinib XR|Tofacitinib XR 11mg
214890209|NCT06496295|DEVICE|Vaginal Speculum Exam|Evaluating the visibility of the cervix, ease-of-use, and comfort of a new vaginal speculum.
214907123|NCT07129785|BEHAVIORAL|Dynamic Surface Exercise Training (DSET)|DSET involves performing multi-planar trunk activation, postural control, and balance exercises on unstable surfaces such as Swiss/gym balls, bolsters, trampolines, and platform swings. Each session lasts 60 minutes, four times per week, for six weeks. Activities include optimal arousal (bouncing), high sitting with one- and two-hand reaching, sit-to-stand transitions, and lateral weight-shifting. The unstable surface provides postural perturbations that stimulate vestibular, proprioceptive, and visual systems to improve gross motor function and balance in children with spastic diplegic cerebral palsy.
214294919|NCT01639651|OTHER|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
214294920|NCT01506479|BEHAVIORAL|Moderate Exercise|Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
214294921|NCT01506479|BEHAVIORAL|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
214294922|NCT01506479|BEHAVIORAL|No Intervention|No-exercise control (i.e., usual care);
214294923|NCT00492661|DRUG|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
214294924|NCT03978429|OTHER|Community-based Pre-eclampsia/Eclampsia Detection and Management|Three Community Health Workers (CHWs) per health facility (cluster) will be equipped with android smartphones and blood pressure monitors. The CHWs will visit participant's home once per month until 6 weeks post-partum and complete a Case Report Form for signs and symptoms of pre-eclampsia and blood pressure. CHWs, Antenatal Care Nurses (ANC) at the woman's health facility and study coordinator will receive SMS message if the algorithm on our platform (informed by the Tanzanian Standard Treatment Guidelines (TSTG) deems she is at risk for pre-eclampsia. This message will indicate that the woman needs to be referred to her health facility if: participant has high blood pressure, a significant intrapatient rise in blood pressure or a combination of factors according to an algorithm. Woman's condition will be assessed and ANC will decide on the management, including rest at home with CHW monitoring. Women found to be at risk for pre-eclampsia will be visited twice monthly.
214294925|NCT03978429|OTHER|Strengthened Referral Network from Community to Referral hospital levels|ANC nurses and CHWs will play complementary roles in performing activities to meet key indicators and facilitate referrals. They will deliver a plan using the Pre-eclampsia application tool on their smart phone and then they can refer the pregnant woman for enrollment for facility care and track them as per key indicators. The key innovation is that the mHealth platform can detect increases in BP within each patient, and this ability to detect is brought down to the community level through CHWs. This will allow for earlier detection of PE as singular BPs. Nurses will receive protocolized instructions and education regarding when to refer a woman to a higher-level facility for further management. The program consists of SMS component delivered to provide information about participant's condition to relevant members of the referral pathway to enhance referrals and facilitate community level follow up.
214294926|NCT01548482|OTHER|Laboratory Biomarker Analysis|Correlative studies
214294927|NCT01548482|OTHER|Pharmacological Study|Correlative studies
214294928|NCT01548482|DRUG|Temsirolimus|Given IV
214294929|NCT01548482|BIOLOGICAL|Trebananib|Given IV
214294930|NCT01782859|DRUG|Prednisone|
214294931|NCT01782859|DRUG|Hydrocortisone|
214294932|NCT01782859|DRUG|Placebo (for Prednisone)|
214294933|NCT04053959|DRUG|AI assisted insulin system|The patients receive the insulin regime set by AI assisted insulin titration system
214294934|NCT04053959|DRUG|Physician based insulin regime|Patients receive the insulin regime recommended by physicians
214294935|NCT04905173|OTHER|Squat-to-stand maneuver|Subjects will squat for 5 seconds and then stand. The squat-to-stand exercise will be done up to 10 times, and then immediately undergo echocardiographic imaging.
214294936|NCT04905173|DRUG|Amyl nitrite inhalation|Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.
214294937|NCT04905173|OTHER|Valsalva|Subjects will undergo echocardiographic imaging while performing the Valsalva maneuver. This is according to current laboratory protocol and is part of standard of care.
214294938|NCT02838563|OTHER|SIWA|To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
214294939|NCT04994522|DRUG|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
214294940|NCT05953246|BEHAVIORAL|Neutral labels|Participants view neutral labels (QR codes with and without neutral text) for menu items
214890210|NCT05445999|DEVICE|High-Definition transcranial electrical stimulation|The first and final sessions will include clinical assessments and acquisition of MRI and EEG data. To minimize variability, each patient will undergo tDCS at a consistent time in the afternoon or evening and will remain lying in bed with eyes closed throughout stimulation. Stimulation will be delivered using the GTEN 200 system (Magstim EGI, Oregon, USA), which also enables simultaneous EEG recording. The stimulation current will be limited to 1.5 mA, with a maximum of 0.15 mA per electrode (up to 20 electrodes). Electrode placement and current intensity will be individualized to achieve the targeted electric field strength (0.1 or 0.2 V/m at SMHC;). Each session will include 5 min of resting-state EEG immediately before and after stimulation to assess tDCS-induced changes in brain dynamics. Current onset and offset will be gradual, with 2-s ramp-up and ramp-down periods.
214890211|NCT05536219|DIAGNOSTIC_TEST|Serum anti-IFN-I antibodies|Anti-IFN-I autoantibodies presence will be assessed through serological methods (ThermoFisher Kit)
214890212|NCT06636864|PROCEDURE|Intrathecal morphine|The patient was asked to lie on the side, the needle insertion point was located under the guidance of color ultrasound, and after local anesthesia, the needle was inserted into the subarachnoid space at the puncture point and morphine was injected.
214890213|NCT06636864|PROCEDURE|Intrathecal saline injection|After the patient was asked to lie on his side, the injection point was determined under the guidance of color ultrasound. After local anesthesia, the needle was injected into the subarachnoid space and then normal saline was injected.
214890214|NCT06636864|PROCEDURE|TAPB|The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes
214890215|NCT04770935|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:solution for injection Route of administration: intravenous injection
214890216|NCT05265273|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
214890217|NCT03130777|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 THV|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
214890218|NCT04609046|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
214890219|NCT04609046|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
214477892|NCT06855693|BEHAVIORAL|Delivering better oral health: an evidence-based toolkit for prevention|"The PHE Delivering Better Oral Health toolkit has been developed with the support of the 4 UK Chief Dental Officers. This is a general population approach to Oral Hygiene advice and includes the following:~Effective toothbrushing with a fluoride toothpaste is important to support oral health. The physical action of brushing removes plaque, which prevents gingivitis and periodontitis, and the fluoride in toothpaste is effective against tooth decay. The following key messages for the population include when and how to brush, specific habits associated with brushing, and, where necessary, assistance with brushing. There may be adaptations of toothbrushes, such as special grip handles, that are helpful to people who have limited manual dexterity."
214890220|NCT04609046|PROCEDURE|Echocardiography Test|Undergo ECHO
214890221|NCT04609046|DRUG|Lenalidomide|Given PO
214890222|NCT04609046|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214890223|NCT04609046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214890224|NCT04609046|DRUG|Methotrexate|Given IV or PO
214890225|NCT04609046|BIOLOGICAL|Nivolumab|Given IV
214890226|NCT04609046|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214890227|NCT04609046|BIOLOGICAL|Rituximab|Given IV
215049699|NCT05771532|BEHAVIORAL|Received the GS-SHEP|"The experimental group (n=33) received the GS-SHEP (a 10-15-minute individual sexual health education and a sexual health pamphlet). GS-SHEP effectiveness was examined using a self-report instrument to measure background information and three dependent variables: sexual knowledge, sexual attitudes, and sexual self-efficacy."
215049700|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
215049701|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
214890228|NCT04609046|PROCEDURE|Ultrasound Imaging|Undergo testicular ultrasound
214890229|NCT06418711|DRUG|Clofazimine Inhalation Suspension|Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
214890230|NCT06418711|DRUG|Placebo|Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
215049702|NCT01343745|DRUG|Placebo|pressurised metered dose inhaler
215049703|NCT00259844|BIOLOGICAL|TroVax|
215049704|NCT01176760|DRUG|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
215049705|NCT01176760|OTHER|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
215049706|NCT01490255|DRUG|Ranolazine|os, 750 mg, twice per day, for 15 days
214890233|NCT02835612|OTHER|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
214890234|NCT02835612|OTHER|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
214890235|NCT06567249|PROCEDURE|Intracoronary hypothermia|This trial stands apart from other studies of intracoronary hypothermia, mainly because it will establish the role of intracoronary hypothermia in reducing infarct size not only in the left anterior descending artery territory but in other vessels as well, including the right coronary artery and circumflex coronary artery.
214890236|NCT06567249|OTHER|Standard percutaneous coronary intervention|Percutaneous coronary intervention is performed in a standard manner.
214890237|NCT04007562|DRUG|Hydroxychloroquine Sulfate|"The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:~Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.~The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose."
214890238|NCT06549179|DIAGNOSTIC_TEST|AMSE|Evaluation of the performance of the French-language AMSE tool used by non-expert psychiatrists and psychologists, trained in the tool, in the identification of ASD in adults.
214890239|NCT06295367|OTHER|Best Practice|Receive PAF brochure describing financial navigation services
214890240|NCT06295367|OTHER|Financial Navigation|Receive CostCOM financial counseling
214890241|NCT06295367|OTHER|Interview|Participate in a 1 on 1 in-depth interview
214890242|NCT06295367|OTHER|Survey Administration|Ancillary studies
214890243|NCT06850805|DRUG|OPN-375|OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID
214890244|NCT06850805|DRUG|Placebo|Placebo solution administered via exhalation delivery system (EDS).
214890245|NCT03830775|PROCEDURE|Platelet-rich plasma (PRP)|"PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)"
214890246|NCT05269004|DRUG|Ocrelizumab|Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
214890247|NCT05821777|DRUG|LB101|Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101
214890248|NCT06538324|DIETARY_SUPPLEMENT|Omega-3|Dietary Supplement: Omega-3 In the marine Omega-3 fatty acid period, the participants will receive a capsule with 250 mg of EPA per day during 6 weeks.
214890249|NCT06538324|DIETARY_SUPPLEMENT|HOSO|Dietary Supplement: HOSO In the HOSO period, the participants will receive a capsule with the similar weight of HOSO per day during 6 weeks.
214890250|NCT05144256|DRUG|Mitapivat|Tablets or granules
214890251|NCT05144256|DRUG|Mitapivat-matching placebo|Tablets or granules
214890252|NCT05509439|OTHER|Home Transfusion Program Components|The Home Transfusion Program will include trained transfusion nurse(s) who will administer transfusions in the home setting. The transfusion nurse, who is part of the study team, will work closely with the DFCI/BWH Blood Bank and the hospice agency (Care Dimensions Inc.) that all study patients are enrolled in. The transfusion nurse will administer home transfusions using safe home transfusion practices endorsed by the AABB. The home transfusion program has 4 key aspects Initial home visit, (2) subsequent contact, (3) home transfusion assessment \& administration, (4) usual elements of hospice
214890253|NCT05253339|PROCEDURE|target-controlled infusion (one of the administration methods)|a method of administering cefoxitin while maintaining a constant target concentration.
214890254|NCT05253339|PROCEDURE|Standard administration method|Standard method of administering cefoxitin in the current clinical setting
214890255|NCT02498613|OTHER|18F-Fluoromisonidazole|Correlative studies
215049707|NCT01490255|DRUG|Amlodipine|os, 10 mg, once daily, 15 days
214890256|NCT02498613|DRUG|Cediranib Maleate|Given PO
214890257|NCT02498613|OTHER|Laboratory Biomarker Analysis|Correlative studies
214890258|NCT02498613|DRUG|Olaparib|Given PO
215049708|NCT03631264|DEVICE|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants to improve sucking and swallowing.
214294941|NCT05953246|BEHAVIORAL|Numeric text-only sustainability labels|Participants view labels with numeric text depicting the greenhouse gas emissions associated with production of the menu item
214890259|NCT02498613|PROCEDURE|Positron Emission Tomography|Correlative studies
214890260|NCT06504264|BEHAVIORAL|phonemic segmentation|during phonemic segmentation activities, articulatory gestures will be used while teaching letters and their sounds.
214890261|NCT05920356|DRUG|Sotorasib|Oral administration
214890262|NCT05920356|DRUG|Pembrolizumab|Intravenous administration
214890263|NCT05168202|DRUG|CC-95251|Specified dose on specified days
214890264|NCT05168202|DRUG|Azacitidine|Specified dose on specified days
214890265|NCT05168202|DRUG|Venetoclax|Specified dose on specified days
214890266|NCT04696731|GENETIC|ALLO-316|ALLO-316 is an allogeneic CAR T cell therapy targeting CD70
214890267|NCT04696731|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
214890268|NCT04696731|DRUG|Fludarabine|Chemotherapy for lymphodepletion
214890269|NCT04696731|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
214890270|NCT04946370|DRUG|225Ac-J591|Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
214890271|NCT04946370|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
214890272|NCT04946370|DRUG|Androgen receptor inhibitor|Patients will receive an oral androgen receptor inhibitor (ARI). Examples include enzalutamide, apalutamide, darolutamide. Dosing will be the standard dosing, as described by the package insert.
214890273|NCT04946370|DIAGNOSTIC_TEST|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
214890274|NCT04843436|DEVICE|Symani Surgical System|Robotically Assisted Microsurgery
214890275|NCT04760353|DIETARY_SUPPLEMENT|Probiotic mixture (OMNi-BiOTiC STRESS)|OMNi-BiOTiC STRESS containing 9 human bacterial strains \[Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)\] and vitamin B (B2, B6, B12),
214890276|NCT04760353|OTHER|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~* Powder portion bags are suitable for participants with intolerance to yeasts or lactose~* Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
214890277|NCT05239780|PROCEDURE|Brain stimulation|Brain stimulation will be performed after collection of clinical seizure data. Bipolar stimulation to one or several adjacent electrodes will be applied. Stimulation design will be either determined prior to testing or designed according to results from neurobehavioral assessments. Stimulation will consist of biphasic, constant-current trains of stimulation pulses at 100 Hz, with 100 ms pulse width or a sinusoidal wave of a predefined mean band frequency (i.e. 6Hz for θ, 11Hz for α, 20Hz for β, etc.). Stimulation intensity will be ≤6 mA, consistent with parameters used for clinical mapping, for the duration of the behavioral task or for short (2-3 s) periods of time at given epochs during the task (i.e. outcome evaluation). Clinical personnel will be available during stimulation to help monitor stimulation-induced after-discharges; if any are detected, stimulation intensity will be dialed down or terminated.
214890278|NCT03937635|BIOLOGICAL|Daratumumab|Given IV
214890279|NCT03937635|DRUG|Dexamethasone|Given PO
214890280|NCT03937635|DRUG|Lenalidomide|Given PO
214890281|NCT03937635|OTHER|Quality-of-Life Assessment|Ancillary studies
214890282|NCT03937635|OTHER|Questionnaire Administration|Ancillary studies
214890283|NCT06350721|DEVICE|DizzyVR|Each patient will receive a total of 8 sessions of vestibular rehabilitation with the DizzyVR system. Each session will last for 50 minutes, with a frequency of one session per week. The total duration of the intervention will be 10 weeks, with the initial assessment/T0 taking place in the first week and the final assessment/T2 in the tenth week. Similarly, the total expected participation time for each participant is set at 12 weeks (T3).
214890284|NCT04694248|DRUG|Rivaroxaban|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
215049709|NCT02837718|PROCEDURE|bupivakain % 0,5|Bupivacaine 0,5% The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
215049710|NCT02817178|OTHER|Additional biological samples|blood and tumor tissue samples
215049711|NCT00253916|BEHAVIORAL|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
215049712|NCT00253916|BEHAVIORAL|Resistance Exercise Program|Resistance Exercise Program
215049713|NCT02848092|BEHAVIORAL|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
215049714|NCT02848092|OTHER|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
214890285|NCT04694248|DRUG|Aspirin|For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
214890286|NCT05057234|DIAGNOSTIC_TEST|FoundationOne liquid CDx|FoundationOne liquid CDx testing
214294942|NCT05953246|BEHAVIORAL|Endorsement text-only sustainability labels|Participants view labels using text to endorse menu items as having low environmental impact
214294943|NCT05953246|BEHAVIORAL|Endorsement icon-only sustainability labels|Participants view labels using icons to endorse menu items as having low environmental impact
214890287|NCT05057234|BEHAVIORAL|Quality of life questionnaires|Quality of life questionnaire - EQ5D
215049715|NCT00607802|BIOLOGICAL|leukocyte therapy|
214890288|NCT06963112|DRUG|Midazolam|The intervention group patients were given 2mg midazolam injection (Jiangsu Enhua Pharmaceutical Co., Ltd.) during anesthesia induction
214890289|NCT06963112|DRUG|Saline|The control group patients were given 2 mL physiological saline.
214890290|NCT05109611|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
214890291|NCT05109611|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
214890292|NCT02557438|PROCEDURE|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
214890293|NCT02557438|PROCEDURE|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
214890294|NCT05081024|PROCEDURE|Biopsy|Undergo biopsy
214890295|NCT05081024|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or tissue samples
214890296|NCT05081024|OTHER|Electronic Health Record Review|Medical records are reviewed
214890297|NCT02495090|GENETIC|Exome sequencing|Plain DNA sequencing
214890298|NCT04578483|OTHER|ERDS group|After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
214890299|NCT05806164|DRUG|Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]|The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
214890300|NCT05806164|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
214294944|NCT05953246|BEHAVIORAL|Endorsement text-plus-icon sustainability labels|Participants view labels using text and icons to endorse menu items as having low environmental impact
214890301|NCT06644846|RADIATION|Spatially fractionated radiation therapy|"Spatially fractionated radiation therapy (SFRT) enables delivery of high-dose radiation to discrete sub-volumes inside a tumour target while restricting the remainder of the target to a safer lower dose. This technique results in generation of intentionally heterogeneous dose distribution with spatial areas of hot and cold spots within the tumour, thereby sparing nearby organs at risk."
214890302|NCT06171659|DRUG|FDG radiotracer|Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
214890303|NCT06171659|DEVICE|PET/MRI|positron emission tomography and magnetic resonance imaging
214890304|NCT06171659|DEVICE|PET/CT imaging|positron emission tomography and computed tomography imaging
214890305|NCT04640259|OTHER|Online Survey|Epidemiological Survey (approx 200 questions)
214890306|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Pre-training)|handgrip and treadmill walking 4 days per week
214890307|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Post-training)|handgrip and treadmill walking 4 days per week
214890308|NCT06801834|DRUG|Sacituzumab Govitecan (SG)|Administered intravenously
214890309|NCT06801834|DRUG|Topotecan|Administered intravenously
214294945|NCT02611778|BIOLOGICAL|ranibizumab|
214294946|NCT02921698|DEVICE|FRED®|Flow Re-Direction Endoluminal Device
214294947|NCT02746016|OTHER|Infant Formula supplemented with Oligosaccharides|sole source nutrition
214890310|NCT06801834|DRUG|Amrubicin (Japan only)|Administered intravenously
214890311|NCT06168578|DEVICE|ultrasound|Optic nerve diameter will be measured by ultrasound at certain stages of the operation in Group I (ARM-) and Group II (ARM+)
214890312|NCT06527404|DRUG|Rocatinlimab|SC Injection
214890313|NCT06527404|DRUG|Placebo|SC Injection
214890314|NCT06520449|DRUG|68Ga-NTA-476|The novel Prostate Specific Membrane Antigen (PSMA) targeting molecule, NTA-476, is comprised of a small peptide targeting moiety that is attached to a linker and dodecane tetraacetic acid (DOTA) cage which enables chelation of the radionuclide 68Ga for Positron Emission Tomography (PET) imaging.
214890315|NCT06433219|DRUG|Tuvusertib (M1774)|Tuvusertib will be administered orally.
214890316|NCT06433219|DRUG|Niraparib|Niraparib will be administered orally. If selected from Part A, Niraparib will be administered orally in combination with Tuvusertib.
214890317|NCT06433219|DRUG|Lartesertib (M4076)|Lartesertib will be administered orally. If selected from Part A, Lartesertib will be administered orally in combination with Tuvusertib
214890318|NCT06195930|DRUG|Vericiguat (BAY1021189) 5 mg|Vericiguat (BAY1021189) will be taken as 5 mg tablet 1x daily over at least 14 days up to 18 days (+ 4 days time window allowed)
214890319|NCT06242912|BEHAVIORAL|QOL - quality of life|QOL assessments using EQ5D (Euroqol 5 dimension) +/- ESAS (Edmonton Symptom Assessment Scale) +/- CPC (Canadian Problem Checklist) every 4-8 weeks +/- 2 weeks
214890320|NCT06242912|DIAGNOSTIC_TEST|Radiographic or laboratory evaluation|Radiographic or laboratory evaluation every 12 weeks +/- 2 weeks
214294948|NCT01311570|DRUG|Buprenorphine|"In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician."
215049716|NCT00607802|GENETIC|polymerase chain reaction|
215049717|NCT06131905|DRUG|Magnesium Sulfate|40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
215049718|NCT06131905|DRUG|Propofol|An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
215049719|NCT03345511|PROCEDURE|Ultrasound Guided Caudal Block|Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
214890321|NCT05770622|OTHER|First-dose trough dose adjustment calculator - using early TDM (first-dose trough) to determine an early dose adjustment if the predicted steady-state trough is outside of target range (10-20mg/L)|CALCULATOR: A 'First-dose trough dose adjustment calculator' was developed based on a population pharmacokinetic model. A participant's post-menstrual age, weight, creatinine, target trough concentration, dose, dosing interval and first-dose trough concentration (taken immediately before the second dose is due) are entered into the calculator. The calculator determines if a dose adjustment is required (based on whether the predicted steady-state trough concentration is \<10mg/L or \>20mg/L) and, if required, recommends a new adjusted dose.
214890322|NCT06486376|BEHAVIORAL|Water, Sanitation and Hygiene Education Against Diarrhoea, Undernutrition and Pneumonia|Intervention components include teacher training, stepdown training of teachers to children and distribution of IEC materials.
214890323|NCT06628440|OTHER|oral condition assessment tool|Use of the Mat assessment tool by a nurse on the participant
214890324|NCT05432284|DRUG|Placebo|Placebo (ambient air)
214890325|NCT05432284|DRUG|THC|Pure THC vapor
214890326|NCT05432284|DRUG|Beta-Myrcene|Pure beta-myrcene vapor
214890327|NCT05506683|OTHER|MotoMeds pediatric telemedicine and medication delivery service (TMDS)|The intervention is use of a pediatric TMDS. Eligible children experiencing acute illness are examined over the phone by EMTs who follow a set of clinical guidelines to triage, assess, and develop treatment plans for participants. To evaluate the TMDS and as a safety measure EMTs will also examine most participants in-person a their homes following the phone exam.
214890328|NCT02446249|BIOLOGICAL|AAV2hAQP1|Infusion of gene therapy
215049720|NCT00287950|DRUG|carboplatin|
215049721|NCT00287950|DRUG|cisplatin|
215049722|NCT00287950|DRUG|cyclophosphamide|
215049723|NCT00287950|DRUG|etoposide|
215049724|NCT00287950|DRUG|vincristine sulfate|
214890329|NCT06121375|DRUG|OCA|OCA will be administered.
214890330|NCT06121375|DRUG|Matching Placebo|Matching Placebo will be administered.
215049725|NCT00287950|PROCEDURE|adjuvant therapy|
215049726|NCT00287950|PROCEDURE|conventional surgery|
215049727|NCT00287950|PROCEDURE|neoadjuvant therapy|
215049728|NCT00287950|RADIATION|radiation therapy|
215049729|NCT03982017|OTHER|Mobile Health Technology Platform|When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
215049730|NCT03982017|OTHER|Usual care|Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
215049731|NCT03186430|BEHAVIORAL|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
215049732|NCT01244711|DRUG|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
215049733|NCT02768285|PROCEDURE|APICAL PATENCY|After determining the working length, a small and flexible size 10 K-file was inserted 1 mm beyond the WL.
214294949|NCT04774198|DIAGNOSTIC_TEST|blood sample|Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory molecules assed by Olink inflammation panel, leucocytes, differential count, hemoglobin, thrombocytes and CRP)
214294950|NCT05766982|OTHER|Platelet Rich Plasma|Platelet rich plasma will be applied to assess rate of wound healing.
214294951|NCT02426892|BIOLOGICAL|ISA 101|100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
214890331|NCT04233138|OTHER|SUPPORT online platform for people with type 1 diabetes|"All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).~The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform."
214890332|NCT04560322|DRUG|Venetoclax|Tablet, taken by mouth
214890333|NCT04560322|DRUG|Obinutuzumab|Intravenous infusion
214890334|NCT04560322|DRUG|Acalabrutinib|Capsule, taken by mouth
214890335|NCT05012371|DRUG|Cabozantinib|Given PO
214890336|NCT05012371|DRUG|Everolimus|Given PO
214890337|NCT05012371|DRUG|Lenvatinib|Given PO
214890338|NCT05012371|OTHER|Questionnaire Administration|Ancillary studies
214890339|NCT01122485|OTHER|PG201|two tablets
215049734|NCT04656587|DEVICE|Philips Respironics V60 Non-invasive ventilator, BPAP|Continuous albuterol will be administered through the BPAP circuit.
215049735|NCT04656587|OTHER|Standard Therapy|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
214890340|NCT01122485|OTHER|Placebo|two tablets
214890341|NCT05211466|OTHER|Digital healthcare platform|In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.
214294952|NCT02426892|DRUG|Nivolumab|3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
214890342|NCT05135702|DIETARY_SUPPLEMENT|Sodium Propionate|a 500 mg powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
214890343|NCT05135702|DIETARY_SUPPLEMENT|Placebo|a color, size, calorie, and consistency-matched powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
214890344|NCT06280703|DRUG|LY3938577|Administered Intravenously (IV)
214890345|NCT06280703|DRUG|Placebo|Administered Intravenously (IV)
214890346|NCT06280703|DRUG|Insulin Degludec|Administered Intravenously (IV)
214890347|NCT06280703|DRUG|Insulin Lispro|Administered Intravenously (IV)
214890348|NCT06280703|DRUG|LY3938577|Administered subcutaneously (SC)
214890349|NCT06280703|DRUG|Placebo|Administered subcutaneously (SC)
214890350|NCT06280703|DRUG|insulin degludec|Administered SC
214890351|NCT05864521|DIETARY_SUPPLEMENT|Active Beetroot Juice Supplement (aBRJ)|aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.
214890352|NCT05864521|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Supplement (pBRJ)|pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.
214890353|NCT03191682|DRUG|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
214890354|NCT06796686|BIOLOGICAL|426c.Mod.Core-C4b|426c.Mod.Core-C4b is supplied at a concentration of 2 mg/mL, 0.55 mL per vial.
214890355|NCT06796686|BIOLOGICAL|HxB2.WT.Core-C4b|HxB2.WT.Core-C4b is supplied at a concentration of 1 mg/mL, 0.5 mL per vial
214890356|NCT06796686|BIOLOGICAL|3M-052-AF adjuvant|immune response modifier (IRM)
214890357|NCT06796686|OTHER|Aluminum hydroxide suspension (Alum) adjuvant|Alhydrogel.
214890358|NCT06796686|OTHER|Diluent|Tris-NaCl buffer
214890359|NCT06256588|DRUG|Dostarlimab|Dostarlimab will be administered as an intravenous (IV) infusion
214890360|NCT06256588|DRUG|Placebo|Placebo will be administered as an IV infusion
214890361|NCT04954261|DIAGNOSTIC_TEST|CAPD|CAPD evaluation every day per 12hours during their stay in PICU
214890362|NCT05832879|BEHAVIORAL|OUD Telehealth Platform|The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
214890363|NCT06544733|DRUG|GS-1720|Tablets administered orally without regard to food
214890364|NCT06544733|DRUG|GS-4182|Tablets administered orally without regard to food
214890365|NCT06544733|DRUG|Placebo to Match BVY|Tablets administered orally without regard to food
214890366|NCT06544733|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Tablets administered orally without regard to food
214890367|NCT06544733|DRUG|GS-1720/GS-4182 FDC|Tablets administered orally without regard to food
214890368|NCT06544733|DRUG|Placebo to Match GS1720/GS-4182 FDC|Tablets administered orally without regard to food
214890369|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
214890370|NCT02487966|BEHAVIORAL|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
214890371|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
214890372|NCT02487966|BEHAVIORAL|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
214890373|NCT05407636|GENETIC|ABBV-RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
215049736|NCT05361265|OTHER|fetal movement counting|pregnant women were trained about fetal movements and fetal movement counting was taught. Pregnant women were asked to perform ten fetal movements by counting once a day. In the application of the study, it was ensured that the pregnant women in the experimental group performed fetal movement counting for at least four to six weeks. In this context, pregnant women were called every week to monitor and to motivate them to continue the counting.
215049737|NCT04967066|DIAGNOSTIC_TEST|Serum Levels of Adipocytokines|Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.
215049738|NCT00959426|DRUG|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
214890374|NCT05407636|GENETIC|ABBV-RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
214890375|NCT05407636|BIOLOGICAL|Aflibercept (EYLEA®)|2.0 mg (0.05 mLsolution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections
214890376|NCT05896826|DEVICE|Magnetometer|inspection equipment for magnetocardiography
214890377|NCT06276010|DRUG|nafamostat mesilate|Use nafamostat mesilate as an anticoagulant
214890378|NCT06276010|DRUG|unfractionated heparin group|Use unfractionated heparin as an anticoagulant
214890379|NCT05608395|DRUG|11C-Methionine PET/CT|11C-Methionine PET/CT will be applied in patients in 11C-Methionine PET/CT Arm, based on planning MRI, prior chemo/radiotherapy (2 weeks prior C1D1)
214890380|NCT03915652|BEHAVIORAL|Rheum iCMP|Selected iCMP nurses will receive a 4-hour training using unique educational materials already developed by our team that specifically address lupus-related racial, ethnic and socioeconomic disparities, as well as clinical information about lupus. These iCMP nurses will then reach out to high-risk lupus patients to ensure that patients attend scheduled rheumatology appointments, fill prescriptions for lupus-specific medications, and obtain recommended lupus screening labs and preventive care.
214890381|NCT06264921|DRUG|NKT3447|Oral CDK2 inhibitor
214890382|NCT05478239|DRUG|ArtemiCoffee|3 cups of Artemisia annua (Aa) coffee per day (1350mg) for 24 weeks.
214890383|NCT06335953|BEHAVIORAL|Pharmacist-led deprescribing intervention|The intervention consists of the following strategies: 1) Pharmacists will participate in a 20-minute webinar and receive a laminated tip sheet about the study; 2) Eligible patients and their care partners will receive a single deprescribing educational brochure by mail; 3) Patients and their care partners will have a single telemedicine visit in which the pharmacist will perform medication reconciliation and identify potential adverse effects and concerns related to medicines; 4) The pharmacist will send the PCP up to 3 deprescribing recommendations in the EHR using a standardized template; 5) With the PCP's approval, the pharmacist will call the patient or care partner to implement the deprescribing recommendations and document changes in the EHR.
214890384|NCT04814095|BEHAVIORAL|QOL|QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks
214890385|NCT04814095|DIAGNOSTIC_TEST|CT imaging|CT radiographic imaging every 12 weeks +/- 2 weeks
214890386|NCT06034119|BEHAVIORAL|Split belt treadmill|Participants will walk on a dual belt treadmill with each belt moving at a different speed which is known as a split belt treadmill to provide implicit modifications of the walking pattern
214890387|NCT06034119|BEHAVIORAL|Biofeedback|The Gait Real-time Analysis Interactive Lab (GRAIL) system has an immersive virtual reality screen that provides real-time information to participants of their walking pattern and provides visual instructions on how to walk more symmetrically
214890388|NCT06428396|DRUG|Belzutifan|Belzutifan 120 mg administered QD as an oral tablet.
214890389|NCT06428396|DRUG|Fulvestrant|Fulvestrant 500 mg administered as an IM injection.
214890390|NCT06428396|DRUG|Everolimus|Administered at 10mg via oral tablets QD.
214890391|NCT06428396|DRUG|Exemestane|Administered at 25 mg via oral tablets QD.
214890392|NCT06333951|DRUG|AMG 193|Administered PO
214890393|NCT06333951|DRUG|Carboplatin|Administered IV
214890394|NCT06333951|DRUG|Paclitaxel|Administered IV
214890395|NCT06333951|DRUG|Pembrolizumab|Administered IV
214890396|NCT06333951|DRUG|Pemetrexed|Administered IV
214890397|NCT06333951|DRUG|Sotorasib|Administered PO
214890398|NCT03041311|DRUG|Trilaciclib|Trilaciclib IV
214890399|NCT03041311|DRUG|Placebo|Placebo IV
214890400|NCT03041311|DRUG|Carboplatin|Carboplatin IV
214890401|NCT03041311|DRUG|Etoposide|Etoposide IV
214890402|NCT03041311|DRUG|Atezolizumab|Atezolizumab IV
214890403|NCT05733767|OTHER|Enhanced Usual Care (EUC)|Patients randomized to arm 1, enhanced care (EC), will receive the following intervention: 1) referral to the state quitline, 1-800-QUIT-NOW, 2) primary care physician notification of an ongoing quit attempt, and 3) enrolled in an assessment-only text message system. This text message system will assess medication use and self-reported smoking cessation outcomes, but will not provide any counseling, advice, or feedback. Participants in arm 1 will receive a text message at discharge, and then they will receive 1 text assessment at the following time points: day 7, month 1, and month 3.
214890404|NCT05733767|OTHER|Nurse Practitioner Tobacco Treatment Team (NPT3)|Patients randomized to arm 2, personalized care (PC), will receive a multi-component, multi-disciplinary smoking cessation intervention in addition to usual care. This intervention will include three main interventions. First, a nurse practitioner will assess all patients and then prescribe tailored medications for smoking cessation based on patient preferences. Patients will also then receive a sample ad-lib nicotine replacement therapy (NRT) packet for use as needed to their prescribed medications. Second, a Tobacco Treatment Counselor (TTC) will provide personalized advice, education, and coaching to the patient and encourage medication adherence. Third, patients will be enrolled in a smoking cessation text messaging program designed to maintain motivation, encourage medication adherence, and allow communication with the team. The text message program will last for 6 months and will include assessment at the following time points: day 7, month 1, and month 3.
214294953|NCT06397105|BEHAVIORAL|Problem Management Plus|"Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy will comprise a digital support program that participants can access via the internet."
214477893|NCT06855693|BEHAVIORAL|Mini Mouth Care Matters guide for special Education Settings|"2\. Oral hygiene guidance from a Clinical standard for autistic children and young people and/or those with a learning disability in special educational settings (Mini Mouth Care Matters Special Education Settings resources.~This is a specific approach to providing Oral Hygiene for children with sensory challenges.~This clinical standard supports the vision of universal access whereby everyone receives quality health services that meet their specific needs.~The clinical standard is designed to be used by all those involved in improving health outcomes and quality of life, including eating, speaking and socialising, for autistic children and young people, and those with a learning disability in England.~It is accompanied by a supporting package of tools, resources, and modules to support the delivery of the oral healthcare assessment (either face to face or remote) and to support teams in the development of complementary tailored mouthcare plans."
214477894|NCT06857162|BEHAVIORAL|Positioninng during Cs|"1. Group A (N=72): Immediate Supine Position (Control):~   Immediately after administering spinal anesthesia, participants will be placed in a supine position. To reduce the risk of aortocaval compression, a slight left lateral tilt (approximately 15 degrees) will be applied. This is the traditional positioning method and serves as the control group for comparison.~2. Group В (N=72): Sitting Position:~   After spinal anesthesia, participants will be positioned in a sitting position with the ack supported at a 90-degree angle for the first 2 minutes. Knees will be bent, and feet will be supported.~3. Group С (N=72): Semi-Sitting Position:~After spinal anesthesia, participants will be positioned in a semi-sitting position with the back supported at the back supported at for the first 2 minutes.~Similar to the sitting position, knees and feet will be flat."
214477895|NCT06858514|OTHER|Virtual reality|Students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses.
214477896|NCT06858514|OTHER|Escape room|Students will perform crossword puzzles, word hunt and matching activities related to subcutaneous injection practice.
214477897|NCT06862180|OTHER|Meal replacement therapy|A serving of Contro Eazy Now is equivalent to 5 scoops (50g) contains 26.5g of carbohydrate, 10g of protein and 8.9g of fat. It supplies 215kcal of energy per serving
214477898|NCT06861218|DRUG|pemetrexed|The pemetrexed is administrated by intrathecal injection with a dose of 50mg, once per week for 4 weeks, followed by every four weeks thereafter. The cerebrospinal fluid(CSF) samples are collected every 4 weeks and the cytology examination will be performed. If CSF cytology was negative, CSF cytology was tested again 1 week later. Two negative tests were considered as negative CSF cytology. If the cytology of cerebrospinal fluid was negative after 4 consecutive intrathecal injections, the intrathecal injection should be stopped. If positive, continue to give a intrathecal injection every 4 weeks until CSF cytology is negative. If CSF cytological positivity or worsening of neurological symptoms occurs again during discontinuation, or if new symptoms appear, the intrathecal injection should be resumed every 4 weeks.
214890405|NCT06383494|DEVICE|LMA supreme group|Patient in this group received LMA supreme (one of laryngeal airway management device) for airway management during general anesthesia
214890406|NCT06383494|DEVICE|I-gel group|Patient in this group received I-gel laryngeal (one of laryngeal airway management device) for airway management during general anesthesia
214890407|NCT06383494|DEVICE|GMA-Tulip|Patient in this group received GMA-Tulip (one of laryngeal airway management device) for airway management during general anesthesia
214890408|NCT05111574|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214890409|NCT05111574|PROCEDURE|Bone Scan|Undergo bone scan
214890410|NCT05111574|DRUG|Cabozantinib S-malate|Given PO
214890411|NCT05111574|PROCEDURE|Computed Tomography|Undergo CT
214890412|NCT05111574|PROCEDURE|Echocardiography Test|Undergo ECHO
214890413|NCT05111574|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214890414|NCT05111574|BIOLOGICAL|Nivolumab|Given IV
214890415|NCT05111574|DRUG|Placebo Administration|Given PO
214890416|NCT05111574|PROCEDURE|Positron Emission Tomography|Undergo PET
214890417|NCT06534060|BIOLOGICAL|Genetic: MB-105|MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.
214890418|NCT02264678|DRUG|Administration of ceralasertib|An oral formulation of ceralasertib will be used. In Module 2 Part A1, patients will receive a single dose of ceralasertib on Day 1, followed by 4 to 6 days washout, before multiple dosing.
215049739|NCT00959426|DRUG|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
215049740|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 1|\[¹⁴C\] BI 685509 formulation 1
215049741|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 2|\[¹⁴C\] BI 685509 formulation 2
214294954|NCT00702819|DRUG|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
215049742|NCT05515328|DRUG|BI 685509 formulation 3|BI 685509 formulation 3
214294955|NCT03950648|BEHAVIORAL|Spatial Cognitive Training|map reading and route-learning skills
214890419|NCT02264678|DRUG|Administration of ceralasertib in combination with olaparib|An oral formulations of ceralasertib and olaparib will be used. In Module 2 Part A2, patients will receive either a single or twice daily dose of ceralasertib followed by 4 to 6 days washout, before multiple dosing with ceralasertib and olaparib. In Module 2 Part B, patients will receive ceralasertib and olaparib at the dose, frequency and schedule recommended from Module 2 Part A2. Cycle 0 may be omitted at the discretion of the sponsor.
214294956|NCT00530764|DRUG|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
214294957|NCT00530764|DRUG|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
214890420|NCT02264678|DRUG|Administation of ceralasertib in combination with durvalumab|An oral formulation of ceralasertib will be used. Durvalumab is given via IV infusion. In Module 3 Part A, patients will receive an initial single dose of ceralasertib on Day 1, followed by multiple dosing in combination with durvalumab. In Module 3 Serial Tumour Biopsy Extension and Part B expansion cohorts, patients will receive ceralasertib at the dose, frequency and schedule recommended from Module 3 Part A, in combination with durvalumab.
214890421|NCT02264678|DRUG|Administration of ceralasertib monotherapy|Module 4 Part A and Module 4 Part B Cohort 3: During C0, patients will receive ceralasertib monotherapy orally once a day on 3 non-consecutive days and ceralasertib twice a day on 5 consecutive days. After the patients have completed C0 (Part A) they may transition to Module 4 Part B cohort 3 where they will continue to receive ceralasertib monotherapy
214890422|NCT02264678|DRUG|Administration of ceralasertib and olaparib|"Module 4 Part B Cohort 1:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with olaparib as decided by the investigator."
214890423|NCT02264678|DRUG|Administration of ceralasertib and durvalumab|"Module 4 Part B Cohort 2:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with durvalumab as decided by the investigator."
214890424|NCT02264678|DRUG|Administration of ceralasertib in combination with AZD5305|An oral formulations of ceralasertib and AZD5305 will be used. In Module 5 Part A, patients will receive a single dose of ceralasertib on cycle 0 Day 1 as per dose level cohort. In Module 5 Part B, patients will receive ceralasertib and AZD5305: C1 onwards (as per dose level cohort allocated).
214890425|NCT02264678|DRUG|Administration of ceralasertib in combination with carboplatin|An oral formulation of ceralasertib will be used. In Module 1 Part A, patients will receive a single dose of ceralasertib on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Module 1 Part B, patients will receive ceralasertib and carboplatin at the dose, frequency and schedule recommended from Module 1 Part A.
214890426|NCT05541081|DIAGNOSTIC_TEST|Point-of-care STI testing|"Testing for:~* Chlamydia and gonorrhoea using the GeneXpert platform (Cepheid)~* Trichomoniasis using the OSOM Trichomonas Rapid Test (Sekisui Diagnostics)~* HIV and syphilis using the SD BIOLINE HIV/Syphilis Duo (Abbott Diagnostics Medical Co. Ltd)~* Hepatitis B using the HBsAg2 rapid test (Abbott Diagnostics Medical Co. Ltd)"
214890427|NCT05128825|DRUG|azenosertib|Azenosertib (ZN-c3) will be administered orally.
214890428|NCT06128447|DRUG|ZP5-9676 600 mg dose|oral, chewable tablet formulation of flubendazole
215049743|NCT03613155|OTHER|Administration of MEOPA as part of the care|Patients should be managed by a SMUR team from Toulouse and benefit from MEOPA administration as part of their management, with a view to analgesia for a painful complaint or prevention of induced pain (for example during mobilization or venous route).
215049744|NCT01072721|OTHER|Elastometry|Fibrosis detection with FIBROSCANN
215049745|NCT02833883|DRUG|Enzalutamide|
214477899|NCT06861218|DRUG|vometinib|double dose of vometinib (160mg)
215049746|NCT02833883|DRUG|CC-115|
215049747|NCT00913510|DEVICE|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
215049748|NCT00913510|DRUG|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
215049749|NCT03888014|DEVICE|GLOW800|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
215049750|NCT03888014|DRUG|indocyanine green (ICG)|This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
215049751|NCT05074823|DRUG|Ketamine 0.1 mg|Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
215049752|NCT05074823|DRUG|Ketamine 0.2 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
215049753|NCT05074823|DRUG|Ketamine 0.3 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
215049754|NCT03155139|DIAGNOSTIC_TEST|Aldosterone/renin ratio (ARR) testing|Plasma aldosterone concentration tests, Direct renin concentration tests
215049755|NCT03155139|DIAGNOSTIC_TEST|Confirmatory tests|Captopril challenge test, Saline infusion test
215049756|NCT06187324|DIAGNOSTIC_TEST|biomarkers|by th use of perio paper GCF was collected and Biomarkers level was estimated
215049757|NCT01123343|DEVICE|TrueVision 3D Visualization and Guidance System for MicroSurgery|Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
215049758|NCT02791347|OTHER|Nutrition Intervention|
215049759|NCT05542459|DRUG|Biologics|Infliximab, adalimumab, vedolizumab, ustekinumab, and other biologics approved for IBD
215049760|NCT02329743|DRUG|RX-10045|topical therapy
215049761|NCT06286449|OTHER|Spinal tap|A spinal tap is performed on all enrolled study participants that meet the eligibility criteria
215049762|NCT05160363|DRUG|Pyronaridine Tetraphosphate|A total of 24 participants will be dosed with pyronaridine tetraphosphate, sixteen participants will be additionally be dosed with piperaquine tetraphosphate, eight patients will additionally be dosed with placebo.
215049763|NCT05160363|DRUG|Piperaquine tetraphosphate|A total of 24 participants will be dosed with piperaquine tetraphosphate, sixteen participants will be additionally be dosed with pyronaridine tetraphosphate, eight patients will additionally be dosed with placebo.
214890429|NCT06128447|DRUG|Placebo|Matching placebo
214890430|NCT05067283|DRUG|MK-1084|Oral dose
214890431|NCT05067283|BIOLOGICAL|Pembrolizumab|Intravenous infusion of 200 mg
214890432|NCT05067283|DRUG|carboplatin|Per label
214890433|NCT05067283|DRUG|pemetrexed|Per label
214890434|NCT05067283|BIOLOGICAL|cetuximab|Per label
215049764|NCT05160363|DRUG|Placebo|Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)
215049765|NCT00917319|OTHER|Bundling Infection Control Interventions|identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
215049766|NCT02540590|DEVICE|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
215049767|NCT02540590|DEVICE|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
215049768|NCT02656836|OTHER|Home tonometry, diagnostic study|Evaluating intraocular pressure
214294958|NCT00530764|DRUG|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
214294959|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 11
214294960|NCT05497674|DRUG|Rifampin|QD for 10 days
214294961|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 6
214294962|NCT05497674|DRUG|Probenecid|twice a day, for 5 days
214294963|NCT05255406|DRUG|Furmonertinib (160mg)|160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).
214294964|NCT01020851|BEHAVIORAL|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
214294965|NCT01020851|BEHAVIORAL|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
214294966|NCT06437899|DRUG|intravesical botulinum toxin A injection unter local anaesthesia|"Arm1: Botulinum toxin A injection under local anesthesia according to standard protocol:~Retrograde filling of the empty urinary bladder with a 1:1 mixture of 50 ml lidocaine 1% mixed with 50 ml sodium bicarbonate 8.4%, leave the local anesthetic mixture in the bladder for 15 minutes.~Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10 ml NaCl 0.9% into the detrusor at 10 points using a rigid 70 degree cystoscope~Arm 2: botulinum toxin A injection in sedoanalgesia according to the anesthesia standard protocol:~Intravenous administration of remifentanil (0.05-0.15µg/kg/min) and propofol. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10ml NaCl 0.9% into the detrusor."
214890435|NCT05067283|DRUG|oxaliplatin|Per label
214890436|NCT05067283|DRUG|leucovorin|Per label
214890437|NCT05067283|DRUG|5-fluorouracil|Per label
214890438|NCT06290934|DRUG|GS-1427|Administered orally
214890439|NCT06290934|DRUG|Placebo-to-match GS-1427|Administered orally
214890440|NCT06383390|DRUG|Retatrutide|Administered SC
214890441|NCT06383390|DRUG|Placebo|Administered SC
214890442|NCT04446962|DRUG|Lenalidomide|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
214890443|NCT04446962|DRUG|Ibrutinib|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
214890444|NCT02562118|DRUG|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
214890445|NCT03969329|DRUG|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
214890446|NCT06413706|DRUG|Abemaciclib|Administered orally
214890447|NCT06413706|DRUG|Temozolomide|Administered orally or IV
215049769|NCT03087175|DEVICE|MGuard stent|MGuard micronet mesh-covered stent in treatment of STE and NSTE-ACS
215049770|NCT03087175|DEVICE|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent in treatment of STE and NSTE-ACS For example, Resolute Onyx
215049771|NCT02011269|BIOLOGICAL|Trichuris Suis Ova|
215049772|NCT02462187|DRUG|NVN1000 8% Gel|once and twice daily
215049773|NCT02462187|DRUG|NVN1000 16%|once daily
215049774|NCT02462187|DRUG|Vehicle|placebo comparator
215049775|NCT02462187|DRUG|NVN1000 24%|once daily
215049776|NCT01428219|DRUG|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
214294967|NCT03655197|DRUG|Doxycycline|For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
214294968|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
214294969|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
214294970|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
214890448|NCT04925960|DRUG|Epalrestat|Epalrestat is a noncompetitive and reversible aldose reductase inhibitor (ARI) used for the treatment of diabetic neuropathy in Japan. The drug's ability to safely improve symptoms of neuropathy alone by reducing oxidative stress, increasing glutathione levels, and reducing intracellular sorbitol accumulation make it a desirable medication for PMM2-CDG patients who commonly suffer with various neuropathies. However, work recently conducted by Perlara, a public benefit company with the mandate to screen existing commercially available drugs for possible application in rare diseases, has demonstrated that Epalrestat can also elevate the level PMM2 produced endogenously. This may reduce the severity of the morbidities associated with PMM2-CDG.
214890449|NCT04925960|DRUG|Placebo|The placebo capsule with be identical in appearance to the Epalrestat capsule. It will contain microcrystalline cellulose filler in a gelatin capsule.
214890450|NCT03071692|DRUG|K-877|0.2mg tablet
214890451|NCT03071692|DRUG|Placebo|K-877 matching placebo tablet
214890452|NCT05645549|BEHAVIORAL|Centering Pregnancy with Care Navigation|Centering Pregnancy is a group based prenatal care intervention. Centering Pregnancy is an evidenced based intervention that has 10 group sessions for pregnant women. Each session has dedicated educational material relative to pregnancy, birth, and infant feeding. In addition, all participants will be provided a bilingual Marshallese care navigator to aid in enrolling them in social support services.
214294971|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
214294972|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
214294973|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
214294974|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
214890453|NCT04110730|DEVICE|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion.
214890454|NCT04110730|BEHAVIORAL|Home Intervention|An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
214890455|NCT04520269|DRUG|Pacritinib|3+3 design Dose Level 1 :200mg BD every 4 weeks Dose Level -1 :200mg OM, 100mg ON every 4 weeks Dose Level -2 :100mg BD every 4 weeks
214890456|NCT04676360|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.
214890457|NCT00295893|DRUG|cyclophosphamide|Given IV
214890458|NCT00295893|DRUG|docetaxel|Given IV
214890459|NCT00295893|DRUG|doxorubicin hydrochloride|Given IV
214890460|NCT00295893|BIOLOGICAL|Trastuzumab|Given IV
214890461|NCT00295893|DRUG|Carboplatin|Given IV
214890462|NCT00295893|DRUG|Paclitaxel|Given IV
214890463|NCT05389787|DEVICE|Transcranial Magnetic Stimulation|The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is \~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.
215049777|NCT05927116|OTHER|Mobile phone app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD)|TRIP is a mobile app-based intervention comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
215049778|NCT05036161|OTHER|Nasal high flow|Newborns with respiratory distress treated with NHF.
214890464|NCT05777993|DRUG|Mitapivat|Tablets
214890465|NCT06345729|DRUG|MK-1084|Oral tablets
214890466|NCT06345729|OTHER|Placebo|Oral tablets
214890467|NCT06345729|BIOLOGICAL|Pembrolizumab|IV infusion
214890468|NCT05248737|DIETARY_SUPPLEMENT|DHA/EPA fortified chicken plus Placebo|For participants who received DHA/EPA fortified chicken
214890469|NCT05248737|DIETARY_SUPPLEMENT|non-25(OH)D fortified chicken/eggs plus vitamin D3 supplement|Provided to participants in the group where they consumed non-fortified chicken/eggs
214890470|NCT05248737|DIETARY_SUPPLEMENT|non-DHA bio-enhanced chicken plus supplement DHA Omega-3|Used in the crossover part of the study given to the group who did not received DHA bio-enhanced chicken
214890471|NCT05248737|DIETARY_SUPPLEMENT|25(OH)D bioenhanced chicken and eggs plus placebo|participants will receive 25(OH)D bioenhanced chicken and eggs plus a placebo as a dietary intervention
214890472|NCT05248737|DIETARY_SUPPLEMENT|Dietary Supplement: DHA/EPA fortified eggs plus Placebo|For the participants who received DHA/EPA fortified eggs
214890473|NCT05248737|DIETARY_SUPPLEMENT|non-DHA bio-enhanced eggs plus supplement DHA Omega-3|for the participants who received non-DHA bio-enhanced eggs plus supplement DHA Omega-3
214890474|NCT05248737|OTHER|non-25(OH)D fortified chicken/eggs plus placebo|Provided to participants in the group where they consumed non-fortified chicken/eggs + placebo pills
214890475|NCT06372717|DRUG|APL-4098|APL-4098 is administered orally in 28-day cycles
214890476|NCT06372717|DRUG|Azacitidine and APL-4098|Azacitidine is administered at the standard dose of 75mg/m2 on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.
214890477|NCT06461026|BIOLOGICAL|L9LS|Administered intramuscularly one time.
214890478|NCT06461026|OTHER|Normal Saline|Administered intramuscularly one time.
214890479|NCT04383262|DRUG|Fosamprenavir Calcium|A repurposing approach, prospective, placebo-controlled clinical trial of FOS-SA (used at 1,400 mg fosamprenavir calcium, twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI \> 13, RFS \> 7 and MII-pH confirmed laryngeal reflux event\[s\]).
214890480|NCT04383262|OTHER|Placebo|Non-active placebo pill formulation
214890481|NCT03618550|DRUG|pembrolizumab|Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
214890482|NCT03618550|DRUG|gemcitabine|1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
214890483|NCT03618550|DRUG|vinorelbine|20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
214890484|NCT03618550|DRUG|liposomal doxorubicin|15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
214890485|NCT03618550|PROCEDURE|Stem cell mobilization and collection|Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
214890486|NCT04899154|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.
214890487|NCT04899154|OTHER|stool sampling|Participants will provide one stool sample at inclusion
214890488|NCT06838689|OTHER|Comparison of two standard of care regimens|Participatory Approaches to Qualitative Research (PAQ): Comparing Two Approaches to Patient, Public and Clinician Involvement (PPCI) in Qualitative Research: PAQ and CAB (Community Advisory Boards)
214890489|NCT05485831|DRUG|Epidiolex 100 mg/mL Oral Solution|As prescribed in routine clinical practice in Italy.
214890490|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub A)|The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.
214890491|NCT06100393|DEVICE|Cochlear Limited standard-of-care pre-processing algorithms|Automatic Gain Control, SNR-NR, Forward Focus
214890492|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub B)|Spatial Automation profile
214890493|NCT06100393|DEVICE|Investigational pre-processing algorithm (Sub D)|Microphone miscalibration profile with applied correction method
214890494|NCT06100393|DEVICE|Cochlear Limited standard-of-care pre-processing algorithms|Standard microphone calibration profile
214890495|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub C)|Spatial Automation profile and DNR algorithm
214890496|NCT06025123|DEVICE|Early transnasal evaporative cooling with the RhinoChill device|Early prehospital transnasal evaporative cooling followed by systemic hypothermia to 33 degrees Celsius for 24 hours and fever control for 72 hours
214890497|NCT03934541|BIOLOGICAL|MPER-656 Liposome Vaccine|Administered by intramuscular injection
214477900|NCT06862895|OTHER|chest physiotherapy|Chest Physiotherapy is including various techniques, in this study classical CPT was used to be applied to participants
214890498|NCT03934541|BIOLOGICAL|Placebo for MPER-656 Liposome Vaccine|Administered by intramuscular injection
214890499|NCT06300203|BIOLOGICAL|Interleukin-4 receptor responders|Interleukin-4 receptor was injected subcutaneously.
214890500|NCT06300203|OTHER|Placebo|Placebo was injected subcutaneously.
214890501|NCT06339008|DRUG|LY3650150|Administered SC
214890502|NCT06339008|DRUG|Placebo|Administered SC
214890503|NCT06339008|DRUG|Standard therapy for INCS|Administered as intranasal spray
214890504|NCT05515536|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
214890505|NCT06538116|DRUG|Mevidalen|Administered orally
214890506|NCT06538116|DRUG|Placebo|Administered orally
214890507|NCT05065216|DRUG|Recombinant human tissue kallikrein|DM199 administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21
214890508|NCT05065216|OTHER|Placebo for DM199 Solution for Injection|Placebo administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21.
214890509|NCT06052059|DRUG|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
214890510|NCT06052059|DRUG|IV Placebo|Placebo matching IV tulisokibart
214890511|NCT06052059|DRUG|SC Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
215049779|NCT05036161|OTHER|Continuous Positive Airway Pressure|Newborns with respiratory distress treated with CPAP.
214294975|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
214294976|NCT01634971|PROCEDURE|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
214294977|NCT00533195|DRUG|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
214294978|NCT00533195|DEVICE|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients."
214668307|NCT04413799|COMBINATION_PRODUCT|lidocaine, ketamine intravenous infusion|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to lidocaine/ketamine group, the anesthesiologist led Acute Pain Service (APS) will prescribe lidocaine/ ketamine infusion, which will be monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
214890512|NCT06052059|DRUG|SC Placebo|Placebo matching SC tulisokibart
214890513|NCT06373263|OTHER|Plain-language summary|Participants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be \< 500 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.
214890514|NCT06373263|OTHER|Dissemination Tool (Infographic)|The infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.
215049780|NCT04624516|OTHER|self-structured foot exercise|The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
215049781|NCT04954534|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
215049782|NCT01333410|DRUG|tacrolimus ointment|2 applications per days for 6 months
215049783|NCT01333410|DRUG|Mometasone furoate|2 applications per day for 6 months
214890515|NCT06027294|PROCEDURE|Ischemic Conditioning|A cuff will be inflated to a pressure of 225 mmHg.
214294979|NCT01119885|DRUG|fentanyl matrix|Knee osteoarthritis, starting with 12mcg/h (flexible dose)
214294980|NCT01119885|DRUG|fentanyl matrix|Hip osteoarthritis, starting with 12mcg/h (flexible dose)
214294981|NCT03198234|BIOLOGICAL|T-allo10|The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
214294982|NCT01340898|BIOLOGICAL|Meningococcal vaccine GSK 134612|Intramuscular injection
214294983|NCT01340898|BIOLOGICAL|SynflorixTM|Intramuscular injection
214294984|NCT01340898|BIOLOGICAL|Infanrix-IPV/HiberixTM|Intramuscular injection
214294985|NCT01573975|DRUG|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
214294986|NCT01573975|DRUG|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
214294987|NCT01573975|DRUG|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
214294988|NCT02056340|DRUG|Atorvastatin|
214294989|NCT02056340|DRUG|Placebo|
214294990|NCT01817621|BEHAVIORAL|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
214294991|NCT01817621|BEHAVIORAL|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
214477901|NCT06861179|DRUG|The formulation of Compound Phellinus igniarius decoction|The formulation of Compound Phellinus igniarius decoction is manufactured by Hangzhou Qianjifang Technology Co., Ltd, the composition includes Phellinus igniarius 12g, jujube 3g, wolfberry 3g, tangerine peel 1g. The dosage regimen was as follows: 4 Packs of the formulation of Compound Phellinus igniarius decoction (Phellinus igniarius Herbal Decoction Pieces) + 1 Pack of the formulation of Compound Phellinus igniarius decoction(Excipients) per day, administered twice daily throughout the entire course of radiotherapy until its completion.
214477902|NCT06862479|PROCEDURE|Endoscopic management of fistulas with stents or vacum therapy|A prospective registry of patients who develop fistulas after oncologic surgery on the stomach or esophagus as well as those after bariatric surgery and managed endoscopically with stents or endoscopic vacuum therapy will be evaluated to assess and compare the efficacy and safety of the Luso-Cor versus conventional partially or fully covered metallic stents or bariatric stents or endoscopic vacuum therapy.
214477903|NCT06596668|DRUG|bomedemstat|Oral tablet
214477904|NCT06596668|DRUG|carbamazepine|Oral extended-release capsule
214477905|NCT06587607|BEHAVIORAL|VA Compassionate Awareness Learning Module (VA CALM) a mindfulness curriculum.|VA CALM is a 9 week mindfulness curriculum typically delivered at a once/week module pace in group settings during sessions that last approximately 60-90 minutes. Module topics include: Program Introduction, Why mindfulness, Perception, What Makes Something a Pleasant Experience?, Being Stuck, Getting Unstuck, Communication, Mindfulness in Daily Life, and Today is the First Dat of the Rest of Your Life.
214477906|NCT06673082|DRUG|Oral zinc supplementation|Oral Zinc will be supplemented to the interventional group on a dose of 30 mg elemental zinc/day.
214890516|NCT05968924|DEVICE|Podimetrics SmartMat|Participants receive training for stepping on SmartMat each day for 6 months. Monthly phone calls will be conducted to assess foot health and mat.
214890517|NCT06430801|DRUG|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
214294992|NCT06163313|OTHER|Observation of patients suffering from kidney stones who undergo endoscopic surgery|Clinical data will therefore be acquired through a collection of medical history, physical examination, blood chemistry and instrumental test reports;
214477907|NCT06673082|OTHER|Placebo|Oral
214477908|NCT06863896|PROCEDURE|Hartmann's reversal|Colostomy reversal with laparoscopic technique after Hartmann's procedure ( procto-sigmoidectomy with end colostomy)
214477909|NCT06858410|DRUG|lorlatinib|Eligible patients will be registered to receive oral lorlatinib 100mg qd for 36 months during the treatment phase.
214890518|NCT06430801|DRUG|SC Tulisokibart|Humanized monoclonal antibody that binds human TL1A, administered subcutaneously
214890519|NCT06430801|OTHER|IV Placebo|Placebo matching IV tulisokibart
214890520|NCT06430801|OTHER|SC Placebo|Placebo matching SC tulisokibart
214890521|NCT04924075|DRUG|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
214890522|NCT05514470|OTHER|Skin biopsy|"A skin biopsy performed on the forearm or thigh depending on the patient's age and wishes, with a biopsy punch with a diameter of 3 to 4 mm depending on the child's age (3 for children under 3 years, 4 beyond).~Culture of fibroblasts and immortalization."
214890523|NCT06088199|DRUG|Apremilast|Oral tablet
214890524|NCT06495060|OTHER|No intervention (Only observation)|No intervention
214890525|NCT05270200|DRUG|Azacitidine|Patients will recieve six courses of azacitidine 50mg/m2 through a needle under skin on Days 1-3.Each course is 28 days long.
214890526|NCT05270200|DRUG|Chidamide|Patients will recieve oral chidamide 5mg per day for no more than 2 years.
214294993|NCT05838105|DRUG|GnRH agonist|125 mcg once at the day mentioned
214477910|NCT06858410|OTHER|concurrent/sequential platinum-based chemoradiotherapy|The choice of chemotherapy and will be determined by the investigator prior to treatment allocation and the radiotherapy also according to the clinical therapy regimen decided by the investigator.
214890527|NCT05797610|DRUG|Sefaxersen (RO7434656)|Sefaxersen (RO7434656) will be administered as SC injection per schedule as specified.
214890528|NCT05797610|DRUG|Placebo|Matching placebo will be administered as SC injection per schedule as specified.
214890529|NCT04111731|PROCEDURE|Cryoballoon pulmonary vein isolation|Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.
214890530|NCT04111731|PROCEDURE|Radiofrequency pulmonary vein isolation|Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases
214890531|NCT04111731|PROCEDURE|Repeat electrophysiological study|All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility
214890532|NCT04111731|PROCEDURE|Left atrial posterior wall isolation|The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
214890533|NCT04877522|DRUG|Asciminib single agent|Taken orally, twice daily (BID) or once daily (QD), in fasting state
214294994|NCT05838105|DRUG|hCG|dose as mentioned
214294995|NCT05838105|DRUG|Progesterone 100Mg Vag Tab|dose as mentioned
214294996|NCT02291198|DEVICE|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
214294997|NCT00089765|DRUG|Ranibizumab|
214294998|NCT02742324|DRUG|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
214890534|NCT04877522|DRUG|Imatinib|Taken orally, once daily, in the morning with low-fat meal
214890535|NCT04877522|DRUG|Nilotinib|Taken orally, twice daily, on an empty stomach
214294999|NCT02742324|DRUG|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
214295000|NCT02417701|OTHER|Laboratory Biomarker Analysis|Correlative studies
214295001|NCT02417701|OTHER|Pharmacological Study|Correlative studies
214295002|NCT02417701|DRUG|Sapanisertib|Given PO
214295003|NCT06347614|PROCEDURE|Two-step Radical Prostatectomy|The first step was the enucleation of the hyperplastic adenoma, followed by the anterograde radical prostatectomy of residual tissue
214295004|NCT00150982|DRUG|Mechanism of action of alefacept|
214295005|NCT00503802|PROCEDURE|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
214295006|NCT00503802|PROCEDURE|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
214295007|NCT01877499|OTHER|Optimization of HDF key parameters|"First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~1. Treatment time (up to 4 hours per session);~2. Blood flow rate (up to 400 mL/min;~3. Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits."
214295008|NCT05532007|DIETARY_SUPPLEMENT|Peanuts|2-3 ounces of peanuts to replace 20% of total daily energy intake
214890536|NCT04877522|DRUG|Bosutinib|Taken orally, once daily, with food
214890537|NCT04877522|DRUG|Dasatinib|Taken orally, once daily in a fasted state, 1 or 2 hours before a meal
214890538|NCT04877522|DRUG|Asciminib single agent pediatric formulation|Pediatric participants receive a body weight adjusted dose of 1.3 mg/kg of pediatric film coated granules with food twice daily (b.i.d.) or 2.6 mg/kg once daily (q.d.) in the morning.
214890539|NCT05754749|DRUG|Iohexol 350 Mg/mL Injectable Solution|Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
214890540|NCT05669664|PROCEDURE|Biopsy Procedure|Undergo biopsy
214890541|NCT05669664|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214890542|NCT05669664|PROCEDURE|Computed Tomography|Undergo CT
214890543|NCT05669664|DRUG|Darolutamide|Given PO
214890544|NCT05669664|DRUG|Leuprolide Acetate|Given IM
214890545|NCT05669664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214890546|NCT05624879|BEHAVIORAL|Accelerated Resolution Therapy|A brief psychotherapeutic intervention delivered by trained therapists in a maximum of 4 sessions. Sessions will focus on providing relief from the distress related to an anticipated loss and to shift focus from distress and loss back to the relationship.
214890547|NCT05624879|OTHER|Information and Support|4 sessions of a standardized social work intervention. Standard of care including education and active listening.
214890548|NCT06297590|DRUG|LY3954068|Administered IT
214890549|NCT06297590|DRUG|Placebo|Administered IT
214890550|NCT06297590|DRUG|Flortaucipir F18|Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan
214890551|NCT06972069|PROCEDURE|Combined Kidney/Bone Marrow Transplant|The conditioning regimen to be used in this protocol consists of an ordered series of procedures and treatments including thymic irradiation, low-dose cyclophosphamide, antibody administration (Siplizumab, rituximab and tegoprubart), and bone marrow cell infusion.
214295009|NCT05532007|OTHER|Habitual Diet|continue with habitual diet and abstain from eating peanuts
214295010|NCT02638727|DRUG|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
214890552|NCT06972069|PROCEDURE|Donation of Kidney / Bone Marrow|The donor will undergo nephrectomy and under general anesthesia. Donors will undergo bone marrow harvested under general anesthesia. Sufficient marrow will be obtained to provide at least 2 x 108 nucleated cells per kilogram weight of the recipient.
214295011|NCT02638727|DRUG|placebo|This group treat with placebo dayley
214295012|NCT02947997|DEVICE|OFDI capsule|Imaging of esophagus using OFDI capsule and system
214295013|NCT04352504|OTHER|Almond|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
214295014|NCT04352504|OTHER|Pretzel|Consume 2 oz. serving of pretzels (216 calories) daily for 12 weeks
214295015|NCT03728660|DEVICE|Virtual bioptic magnification with large field of view|The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).
214295016|NCT03728660|DEVICE|Full field magnification with small field of view|Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
214295017|NCT00830596|OTHER|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
214890553|NCT06972069|DRUG|Conditioning Regimen (Rituxan, Siplizumab, Cyclophosphamide, Tegoprubart)|Recipients will receive a conditioning regimen that includes rituximab on study day -6 and -2, Siplizumab (0.6mg/kg) on day -6, -1, 0 and +1, cyclophosphamide (CP, 22.5mg/kg) on days -5 and -4. Tegoprubart (Fc-modified anti-CD154 mAB, Eledon Pharm) 20mg/kg will be administered on days 0, 2, 5, 12 and 19).
214890554|NCT06657768|DRUG|LY4006895|Administered IV
214890555|NCT06657768|DRUG|Placebo|Administered IV
214890556|NCT06685029|DEVICE|Clear aligner treatment|Clear aligners are appliances that allow the teeth to be gradually moved to the desired final position, as planned in the computer program, in a way that each aligner will perform a part of the total movement with its use.
214295018|NCT00830596|OTHER|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
214295019|NCT00830596|OTHER|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
214295020|NCT03735225|DRUG|Dasiglucagon|Dasiglucagon injection
214295021|NCT03735225|DRUG|Placebo|Placebo for Dasiglucagon injection
214890557|NCT06685029|DEVICE|Fixed Orthodontic Appliance Treatment|Fixed orthodontic treatment is a type of orthodontic treatment performed by applying brackets and wires to the teeth and is considered the gold standard for orthodontic treatments.
214295022|NCT06507592|DIAGNOSTIC_TEST|Saliva samples collection|The first sample of saliva was be taken before the start of the treatment and considered as the control sample (T0); the second sample was be taken one month after the start of the treatment (T1) and the third one after three months (T2).
214890558|NCT05943535|DRUG|Placebo|Placebo administered QID
214890559|NCT05943535|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
214890560|NCT05943535|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
214890561|NCT02412553|OTHER|Specific carbohydrate diet|
214890562|NCT02412553|OTHER|Elemental diet|
214890563|NCT02673775|OTHER|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
214890564|NCT02673775|OTHER|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
214890565|NCT05842603|BEHAVIORAL|Cardiac Lifestyle Program|12-week, tailored nutrition and physical activity program comprised of virtual and in-person classes.
214890566|NCT04660994|OTHER|Educational game|"The Yapouni educational game is based on a hot air balloon that will fly according to the number of hours the child has slept with his/her CPAP / NIV. Thus, the longer the child sleeps with his/her CPAP / NIV, the farther and higher his/her hot air balloon will fly in the sky. The game includes wild cards and rewards that are worked out with the child and his/her parents for an optimal individualized adaptation.~The game is explained at Necker Hospital during the therapy education for CPAP/NIV and used at home for 1 month."
214890567|NCT03740347|BEHAVIORAL|Questionnaires|"Response to questionnaires evaluating chronic pain and its repercussion :~* anxiety questionnaire (Revised Children's Manifest Anxiety Scale),~* depression questionnaire (Children's Depression Inventory score),~* sleepiness questionnaire (Pediatric Daytime Sleepiness Scale),~* quality of life questionnaire (Pediatric Quality of Life inventory score)."
214295023|NCT03697629|DRUG|Daratumumab|"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."
214295024|NCT04698902|DEVICE|Intracoronary lithotripsy|Intracoronary lithotripsy involves the use of sonic pressure waves generated from emitters enclosed within a balloon delivery system. The generated sonic waves act to fracture calcium within the coronary artery wall.
214295025|NCT01594879|DEVICE|MIrena(LNG-IUS), oral MPA|"1. General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~2. General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate"
214295026|NCT05040997|DIAGNOSTIC_TEST|Small airways assessment|Small airways assessment
214890568|NCT04682145|DRUG|Turoctocog alfa pegol|Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
214890569|NCT04850755|DRUG|Selinexor in combination with nivolumab and ipilimumab|Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity
214890570|NCT05108298|OTHER|Questionnaires|Patients will complete questionnaires online through EASEE-PRO. There will be a set of fixed questionnaires at each timepoint for both arms. The patients will be asked to rank the 15 types of PROs according to their importance. The participants randomized to the choice arm will be asked to choose 5 of the 15 PROs to complete. The participants randomized to the fixed arm will be given a fixed 5 of the 15 PROs at each time point.
214890571|NCT03202940|DRUG|Alectinib|Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow
214890572|NCT03202940|DRUG|Cobimetinib|Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow
215049784|NCT02431546|BEHAVIORAL|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
215049785|NCT00641732|DRUG|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
215049786|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
214890573|NCT02441686|DRUG|Bortezomib|
214890574|NCT02441686|DRUG|Lenalidomide|
215049787|NCT00641732|DRUG|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
215049788|NCT00641732|DRUG|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
215049789|NCT00641732|DRUG|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
215049790|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
215049791|NCT00641732|DRUG|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
215049792|NCT06320600|OTHER|no intervention|It's an observational study, no intervention included
215049793|NCT01882335|BEHAVIORAL|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
215049794|NCT00512278|DRUG|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
215049795|NCT00512278|DRUG|Placebo|Placebo
214890575|NCT02441686|DRUG|Dexamethasone|
214890576|NCT02441686|PROCEDURE|Stem Cell Mobilization|
214890577|NCT02441686|PROCEDURE|Autologous Stem Cell Transplant|
214890578|NCT02501733|DEVICE|Medacta GMK Sphere® Medial Knee Prosthesis|"There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.~To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices."
214890579|NCT04875702|DRUG|Allopurinol|"For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.~For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial."
214890580|NCT04875702|DRUG|Naproxen 250 MG|Naproxen 250 mg p.o. twice daily
214890581|NCT04875702|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg p.o. once daily
215049796|NCT02443701|OTHER|Exercise|Warmup program, maximum isometric strengthening, and jump training
215049797|NCT02443701|OTHER|LASER|a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
215049798|NCT02443701|OTHER|NMES|electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
215049799|NCT04014426|OTHER|Blood sample|"Exposed group:~* 15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~* 2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~\- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)"
215049800|NCT04014426|OTHER|Urinary sample|"Exposed group:~* 15 to 30 min before the PIPAC procedure (T0)~* 2hours after the end of the procedure (T1)~* The next morning after the procedure (T2)~Non-exposed group:~\- During the morning (8 to 10 a.m) (T0)"
215049801|NCT03584347|BEHAVIORAL|Injection of filler material|Subjects will be blind folded and asked to deposit 0.2cc's of each of the four investigational products, in a randomized order. First, over a weight and then into a porcine membrane.
215049802|NCT02213614|DIETARY_SUPPLEMENT|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
215049803|NCT02213614|DIETARY_SUPPLEMENT|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
215049804|NCT02213614|OTHER|natural spring water|A group will drink natural spring water for 4 months
214890582|NCT04875702|DRUG|Colchicine 1.2 mg|Dose escalation to 0.6 mg p.o. twice daily for patients experiencing breakthrough flares or a dose decrease (0.6 mg p.o. every other day) for patients experiencing gastrointestinal intolerance.
214890583|NCT04875702|DRUG|Naproxen 500 Mg|dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.
214295027|NCT03041545|DEVICE|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
214295028|NCT04474704|DEVICE|Cheetah® non-invasive cardiac monitoring system|Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))
214295029|NCT04474704|OTHER|Standard of care|24 hours of postpartum magnesium sulfate
214295030|NCT06498947|OTHER|This study was observational with no intervention.|This study was observational with no intervention.
214295031|NCT02669433|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
214295032|NCT02669433|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
214295033|NCT02669433|DRUG|Placebo|once daily, oral, matching tablets
214295034|NCT02381249|DRUG|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
214295035|NCT02381249|DRUG|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
214890584|NCT04875702|DRUG|Prednisone 40 mg|For flare glucocorticoids: prednisone taper for 8 days, starting with 40mg (oral) daily.
214890585|NCT03005743|RADIATION|Magnetic Resonance Image based Brachytherapy|MRI based BT prescription will be in accordance to the GEC-ESTRO guidelines \[Intention will be to treat the whole cervix and the remaining residual tumour tissue at the primary site at the time of BT (high risk-clinical target volume) to a dose level analogue to the dose level previously prescribed for point-A\]
214890586|NCT03005743|RADIATION|Conventional Radiograph based Brachytherapy|The standard conventional radiography based prescription will be according to Manchester system Point A and bladder \& rectum ICRU point dose constraints
214295036|NCT01782144|OTHER|NutriSystem portion-controlled pre-packaged meals|
214295037|NCT03066271|OTHER|Exercise +|Usual care
214295038|NCT03066271|OTHER|Control +|Usual care
214295039|NCT03128892|DEVICE|Oxygen Reserve Index - RD Lite Sensors|
214295040|NCT02250365|OTHER|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
214890598|NCT06144944|DRUG|Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Pyrotinib 320 mg orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
214295041|NCT02250365|OTHER|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
214295042|NCT00459108|DRUG|dasatinib|Given orally
214295043|NCT03910608|DEVICE|MagPro X100 device (MagVenture, Farum, Denmark)|Each cPAS experimental session contained 100 pairs of stimuli at 0.2 Hz. The experimental conditions differed in the interstimulus interval of the paired pulses. DLPFC stimulation precedes IPL/MPFC stimulation by 10 ms (DLPFC+10) or by 4 ms (DLPFC+4), and IPL/MPFC stimulation precedes DLPFC stimulation by 4 ms (IPL/MPFC+4) or by 10 ms (IPL+10).
214295044|NCT05604690|BIOLOGICAL|Avacc 10|Intranasal application of either low dose or high dose of Covid 19 vaccine.
214295045|NCT05604690|COMBINATION_PRODUCT|Outer Membrane Vesicles (OMV) : OMV alone in vehicle|OMV will be administered via intranasal route.
214295046|NCT05604690|OTHER|Placebo|Placebo will be administered via intranasal route.
214295047|NCT00210002|DRUG|Darbepoetin alfa (Aranesp®)|
214295048|NCT00210002|DRUG|Ferric saccharose(Venofer®)|
214295049|NCT06474585|DEVICE|Plantar orthosis|Plantar orthosis taken in sitting position Plantar orthosis taken in standing position
214295050|NCT01641770|OTHER|Nutritional beverage 10003RF|2 sachets per day
214295051|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
214295052|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
214890599|NCT06144944|DRUG|Epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
214295053|NCT01239654|DEVICE|stent implantation|implantation of everolimus-eluting stent vs zotarolimus-eluting stent
214295054|NCT00735956|BEHAVIORAL|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
214295055|NCT05148754|DRUG|Elsulfavirine|Elsulfavirin 200 mg tablets.
214295056|NCT03585608|PROCEDURE|Neck extension|The neck extension is routine posture during palatoplasty. We will evaluate the change in optic nerve sheath diameters before and after neck extension.
214295057|NCT05552560|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection before the first consultation with the centre's psychologist.~This questionnaire includes questions on the socio-demographic characteristics, the motivations, as well as the procreative history of the patients."
214295058|NCT06231615|OTHER|Fascia exercises|Fascia exercises are slow and calm movements similar to yoga performed by the person herself/himself.
214668308|NCT04413799|DRUG|paravertebral block with ropivicaine|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to PVB, the anesthesiologist led Acute Pain Service (APS) will place a paravertebral block catheter. Ropivacaine infusion will be started, monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
214890602|NCT06973291|DRUG|Zasocitinib|Zasocitinib tablets.
214890603|NCT06973291|DRUG|Deucravacitinib|Deucravacitinib capsules.
214890604|NCT06973291|DRUG|Placebo to match zasocitinib|Zasocitinib matching placebo tablets.
214295059|NCT06231615|OTHER|Conventional physiotherapy and breathing exercises|Head and neck exercises and breathing exercises
214295060|NCT04856774|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined."
214890605|NCT06973291|DRUG|Placebo to match deucravacitinib|Deucravacitinib matching placebo capsules.
214890606|NCT01326468|DRUG|Temsirolimus|All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.
214890607|NCT01326468|DRUG|Cetuximab|"All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.~Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy."
214890608|NCT01326468|DRUG|Cisplatin|All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.
214890609|NCT01326468|DEVICE|Radiation Therapy|Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
214890610|NCT06184945|BEHAVIORAL|Realtime audit and feedback|ICUs randomized to this arm will receive and electronic dashboard that displays realtime ABCDEF bundle performance data
214890611|NCT06184945|BEHAVIORAL|RN Implementation Facilitator|ICUs randomized to this arm will receive a RN who will assist with ABCDEF bundle implementation
214295061|NCT01563003|OTHER|Cognitive Behavioral Therapy|This condition involves 16 weekly CBT sessions.
214295062|NCT01563003|OTHER|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
214295063|NCT01322360|DRUG|Morphine Sulfate|
214295064|NCT01457521|DRUG|Ibuprofen|Ibuprofen
214295065|NCT01880385|BIOLOGICAL|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
214295066|NCT01880385|DRUG|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
214890612|NCT05881304|DEVICE|Standardized research e-cigarette (SREC)|Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
214890613|NCT05716737|RADIATION|Irradiation|3 Gy in 6 fractions to the TMJ, every other day, LINAC based
214907124|NCT07129785|BEHAVIORAL|Static Surface Exercise Training (SSET)|SSET consists of functional strength, posture, and balance exercises performed on stable surfaces such as mats, benches, or stools. Each session lasts 60 minutes, four times per week, for six weeks. Activities include transfers between sitting and quadruped, high sitting with functional reaching, static and dynamic standing balance, ball-catching and kicking, and trunk activation tasks. Exercises aim to enhance gross motor function and balance through controlled, stable postural activities in children with spastic diplegic cerebral palsy.
214907125|NCT06564311|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRIIb, resulting in down regulation of B cell activity
214295067|NCT01880385|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
214295068|NCT01880385|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
214295069|NCT01880385|DRUG|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
214295070|NCT01880385|BIOLOGICAL|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
214295071|NCT02042885|DRUG|OPB-111001|
214295072|NCT03473808|BEHAVIORAL|task-practice therapy|Standardized hand therapy program
214890614|NCT06372119|PROCEDURE|Letrozole-stimulated cycle strategy|"Letrozole (Femara® 2.5 milligrams, Novartis, Switzerland or Lezra® 2.5 milligrams, Actavis, Rumani) 5 milligrams/day for 5 days, starting on the second to fourth day of the menstrual cycle.~Post-letrozole, ultrasound checks follicle growth. If ≥18mm, Ovitrelle® 250 mcg (Merck, Kenilworth, New Jersey, USA) induces ovulation.~Luteal phase support with vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day starting two days post-hCG.~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: no follicle development on day 21 from the day of starting letrozole, spontaneous ovulation, letrozole intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
214890615|NCT06372119|PROCEDURE|Artificial cycle strategy|"Oral estradiol valerate (Progynova® 2 milligrams, Bayer Pharma AG, Germany or Valiera® 2 milligrams, Laboratories Recalcine, Chile) 6 milligrams/day for 10 days, starting on the second to fourth day of the menstrual cycle.~Post-estradiol, ultrasound checks endometrial thickness. If ≥7mm, start vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day. If \<7mm, increase the dose of oral estradiol valerate to 8 milligrams/day (5-6 days) and 12 milligrams/day (5-6 days).~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: endometrial thickness \<7mm on day 21 of using estradiol, spontaneous ovulation, oral estradiol valerate intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
214890616|NCT05565638|BEHAVIORAL|Prolonged Fasting Intervention|promote a 14-hour fast during the nighttime hours
214890617|NCT05565638|BEHAVIORAL|EDUCATION CONTROL|introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living
214295073|NCT03473808|OTHER|Vibration|Peripheral vibration applied to the wrist skin at an imperceptible level
215049805|NCT06305585|OTHER|Primal Reflex Release Technique (PRRT)|Primal Reflex Release Technique (PRRT) is a non-invasive complementary hands-on treatment method intended to help relax the central nervous system by gently stimulating innate protective reflexes. A certified practitioner applies light tactile stimulation to targeted areas in a structured sequence postulated to help release hypertonic muscles, restore regulation of automatic responses, and enable a calm, parasympathetic state.
215049806|NCT00592631|DEVICE|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
215049807|NCT00592631|DEVICE|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
215049808|NCT00285285|DEVICE|Point of Care Device; i-Stat Analyzer|
215049809|NCT00878592|BEHAVIORAL|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (\<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of \~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
215049810|NCT00836394|DEVICE|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
215049811|NCT04862559|DEVICE|NovaCross|A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions
215049812|NCT00410189|DRUG|ZD6474|300 mg by mouth daily for 28 Days.
215049813|NCT03925272|PROCEDURE|Collection of samples (blood, stool, etc.)|
215049814|NCT03925272|GENETIC|Genetic determinants analysis|
215049815|NCT03925272|PROCEDURE|Sample obtained after surgery performed in the context of care|
215049816|NCT02351492|PROCEDURE|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
214295074|NCT02075450|DEVICE|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
214295075|NCT02075450|OTHER|Just in Time Video|CPR Just in Time training video administered before the simulation case
214295076|NCT02853578|DRUG|Busonid (budesonide 200mcg and 400mcg)|"cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks."
214295077|NCT02157298|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
214295078|NCT02157298|DRUG|Placebo tablet|Placebo tablet. Oral dose
215049817|NCT02351492|PROCEDURE|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
214295079|NCT02315378|BEHAVIORAL|TAU|Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.
214295080|NCT02315378|BEHAVIORAL|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
214477911|NCT06767995|DEVICE|Flexible fiberoptic bronchoscopy|If Flexible Intubation Video Endoscope® (FIVE) will be used, the appropriate endotracheal tube is loaded into the bronchoscope and made ready. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started when the FFB started to pass through the patient's mouth/nose, and as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, the stopwatch was stopped and this time was recorded as the successful intubation time. The time between passing FFB through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. The endotracheal tube passage time was defined as the intubation time minus the best glottic visualization time and recorded. Complications during the procedure were recorded.
214477912|NCT06767995|DEVICE|Glidescope|If GlideScope® Titanium is to be used, a 50-60° angle is applied with the appropriate stylet, and the appropriate one from 3 pediatric blade sizes is selected according to the clinical experience of the relevant practitioner. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started as soon as the videolaryngoscope started to pass through the patient's mouth, and the stopwatch was stopped as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, and this time was recorded as the successful intubation time. The time between passing the videolaryngoscope through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. Endotracheal tube transit time was defined as intubation time minus best glottic visualization time and recorded. Complications during the procedure were recorded.
214295081|NCT05178524|DRUG|BIFICO|Live combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
214477913|NCT06768983|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|10 sessions of remotely delivered CBT; each session is about 45 minutes in length. The aim of the sessions is to cultivate skills that promote activity and reduce fatigue and its impact on daily activities.
214477914|NCT05347069|DRUG|Aspirin|Aspirin 100 mg/day
214477915|NCT05347069|DRUG|No aspirin|No aspirin administered
214477916|NCT03532672|OTHER|Acute Fasting|The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice). The participants will fast for another 10 hours during daily activities.
214477917|NCT04206787|DRUG|Afatinib|drug
214477918|NCT06670196|DRUG|SKB264|4mg/kg, intravenous (IV) infusion
214477919|NCT06670196|DRUG|Osimertinib|80mg, QD
214890619|NCT06488911|DRUG|FDC tablet (OCA 5 mg + BZF 400 mg SR)|Participants will be administered with FDC tablets once daily.
214890620|NCT06211036|DRUG|Tarlatamab|Intravenous (IV) infusion
214890621|NCT06211036|DRUG|Durvalumab|IV infusion
214890622|NCT04699591|DRUG|Domperidone|Domperidone taken 4 times a day, dose based on body weight
214295082|NCT06395454|DIAGNOSTIC_TEST|Shorten antibiotics duration based on procalcitonin test levels|procalcitonin test will be taken on day 1 of recruitment as baseline, test done on day 5 will decide whether antibiotics will be withheld, followed by day 7 to determine rate of reinfection.
214295083|NCT03993340|DEVICE|Rescue stenting|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
214295084|NCT00491998|DRUG|V1512|6 doses of IMP at 2-hourly intervals
214295085|NCT00491998|DRUG|V1512|3-hourly dosing
214477920|NCT06676267|PROCEDURE|Laparoscopic surgery|The laparoscopic surgery system is applied to gynecology and 5G remote surgical treatment.
214890623|NCT03740529|DRUG|Pirtobrutinib|Oral
214890624|NCT03740529|DRUG|Venetoclax|Oral
214890625|NCT03740529|DRUG|Rituximab|IV
214890626|NCT03907475|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214890627|NCT03907475|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214890628|NCT03907475|DRUG|Capecitabine|Given PO
214890629|NCT03907475|DRUG|Carboplatin|Given IV
214890630|NCT03907475|PROCEDURE|Computed Tomography|Undergo CT
214890631|NCT03907475|BIOLOGICAL|Durvalumab|Given IV
214890632|NCT03907475|PROCEDURE|Echocardiography Test|Undergo ECHO
214890633|NCT03907475|DRUG|Gemcitabine Hydrochloride|Given IV
214890634|NCT03907475|DRUG|Nab-paclitaxel|Given IV
214890635|NCT03907475|DRUG|Paclitaxel|Given IV
214890636|NCT03907475|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214890637|NCT06292013|DRUG|Lepodisiran Sodium|Administered SC
214890638|NCT06292013|DRUG|Placebo|Administered SC
214295086|NCT00491998|DRUG|V1512 and Entacapone|4 doses of IMP and Entacapone at 3-hourly intervals
214295087|NCT02739204|DRUG|Celecoxib|200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
214890639|NCT04569747|COMBINATION_PRODUCT|Pertuzumab+TRASTUZUMAB|Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose
214890640|NCT04569747|DRUG|ADJUVANT ENDOCRINE THERAPY|Oral, daily per cycle
214890641|NCT04563520|DRUG|Emicizumab|HEMLIBRA® is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
214890642|NCT04563520|DRUG|FEIBA|"FEIBA™ is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia patients with inhibitors for: control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.~The max dose allowed for aPCC will be 50 U/kg dose given at a single visit."
214890643|NCT04563520|DRUG|rFVIIa|rFVIIa is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents with hemophilia with inhibitors.
214890644|NCT06975722|DRUG|SAR442970|Route of administration: Subcutaneous
214890645|NCT06975722|DRUG|Placebo|Route of administration: Subcutaneous
214295088|NCT01397032|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
214295089|NCT01397032|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
214477921|NCT06677164|PROCEDURE|Gluteus Maximus strengthening exercise|Maximus strengthening exercise for eight weeks using weight progression tools either elastic band or sand weight by assuming two modes of exercises (clamshell exercise, prone hip extension) with stretching exercise (hamstring, gastrocnemius, soleus, and plantar fascia) 2 sessions per week for 8 weeks
214477922|NCT06677164|DEVICE|high-intensity laser therapy|A 3-phase treatment program will be performed in each session on the plantar fascia area. Treatment of trigger points in phase 1 and 2 by using power of 9 watts, E2C mode for 6 minute of 2 phases. The draining and vascularization-promoting application involve the whole foot sole, starting from the heel area in phase three by using power of 9 watts, CW mode with energy of 100J/cm2.
214477923|NCT06677502|DRUG|Cerebrolysin|Patients were randomized into two groups: CBL - patients treated with cerebrolysin at the daily dose of 50 mL, and K - control patients treated without cerebrolysin. Cerebrolysin was administrated intravenously on the day the delirium was detected and then for seven consecutive days.
214477924|NCT06677502|OTHER|Saline Solution - IV|Patients enrolled in group K received the infusion of 0.9% Saline solution at a volume of 250 mL.
214477925|NCT06676241|PROCEDURE|endoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed immediately after ERCP with ES under general anesthesia.
214477926|NCT06676241|PROCEDURE|endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis no earlier than 7 days after ERCP
214477927|NCT05557578|DRUG|Tislelizumab combined with GEMOX (GOT) regimen|Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks
214477928|NCT05008055|DRUG|Capivasertib|Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.
214295090|NCT04128176|DRUG|Rituximab combined with Omalizumab|Rituximab 1000 mg will be administered by IV infusion 6 months after the patient's initial cycle of rituximab (received in the screening period).Omalizumab (300 mg) will be administered subcutaneously every 2 weeks starting on Day 1 until week 24 (primary endpoint) and again until week 52 (secondary endpoint).
214477929|NCT06675942|DEVICE|Oscillation and Lung Expansion|The OLE device (MetaNeb system) is a newer, noninvasive physiotherapy tool that combines mechanical and pharmacological interventions (aerosols) to help mobilize endobronchial secretions.
214477930|NCT06675942|DEVICE|High-frequency chest wall oscillation|High-frequency chest wall oscillation (HFCWO) is an airway clearance technique that uses external forces applied to the chest via an inflatable vest connected to a device that generates vibrations at varying frequencies and pressures.
214477931|NCT05097885|OTHER|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
214477932|NCT05117008|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered IV over approximately 30 minutes at the recommended dose of 2.5 mg/kg IV over 30 minutes on day 1 of every eight-week (+/- three days) cycle for a maximum of 12 cycles. Maintenance therapy with belantamab mafodotin will continue until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or end of study (maximum of 12 cycles), whichever occurs first.
214477933|NCT04452500|DRUG|CORT108297|CORT108297- 180mg daily for 7 days
214477934|NCT04452500|DRUG|Placebo|Placebo- 180mg daily for 7 days
214477935|NCT04987060|DEVICE|Intrastromal Fresh Human Lenticule Implantation|The stromal pocket diameter was set 8.0 mm and cap thickness was set to 140 μm from corneal surface and a 2mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 2 mm superior incision. Incision position changed according to the position of the highest K values.
214295091|NCT03176251|OTHER|Gamified-Integrated Curriculum|The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
214477936|NCT04635059|DRUG|Pacritinib|Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).
214477937|NCT04938609|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
214477938|NCT04938609|RADIATION|Stereotactic Body Radiation Therapy (5 days)|8Gy x 3 (Mon-Fri) GTV+3mm
214477939|NCT04938609|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
214477940|NCT04175327|DEVICE|CardioCel implantation|treatment of intracardiac defects; treatment of septal defects; valve and annulus repair; great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
214890646|NCT06307613|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
214890647|NCT06307613|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
214295092|NCT03763123|DRUG|Sevacizumab|Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg
214295093|NCT03763123|DRUG|Paclitaxel|paclitaxel 80mg/m2 as a \> 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;
214295094|NCT03763123|DRUG|Topotecan|topotecan 4 mg/m2 as a \>30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;
214295095|NCT05146401|OTHER|Plasma fatty acid concentration|Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
214295096|NCT01339429|DEVICE|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
214295097|NCT01849380|DRUG|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
214295098|NCT01849380|DRUG|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
214668309|NCT07020741|PROCEDURE|Indispensable Amino Acid Oxidation|Participants will ingest six hourly meals designed to provide 50% of the daily intake of 1.1 g·kgLBM. Additional energy (1.5x daily resting metabolic rate), carbohydrate (55%), and fat (35%) will be provided in beverages and protein-free cookies (for palatability). The first drink will contain priming doses of NaH13CO2 (0.176 mg·kg-1), \[13C\]phenylalanine (1.86 mg·kg-1), \[2H5\]phenylalanine (0.34 mg·kg-1) with all subsequent drinks containing 1.2 mg·kg-1 \[13C\]phenylalanine and 0.51 mg·kg-1 \[2H5\]phenylalanine.
214890648|NCT05249283|OTHER|Questionnaire Measures|Patients will complete the following questionnaires: CDS questionnaire, Niigata PPPD questionnaire, HAD (Hospital Anxiety and Depression) scale and DHI (Dizziness Handicap Inventory)
214890649|NCT04772079|DRUG|Deucravacitinib|Specified dose on specified days
214890650|NCT04772079|OTHER|Placebo matching deucravacitinib|Specified dose on specified days
214890651|NCT05685797|PROCEDURE|Herpes zoszter (acute)with inter vention|nerve block
214890652|NCT06575153|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
214890653|NCT03346954|OTHER|[11C]-Methionine PET/MRI|Implementation \[11C\]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon). The \[11C\]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
214890654|NCT06574984|DRUG|Turoctocog alfa|Turoctocog alfa was administered intravenously.
214890655|NCT06284954|BIOLOGICAL|Empasiprubart IV|Intravenous infusion with Empasiprubart IV
214890656|NCT06284954|OTHER|Placebo IV|Intravenous infusion with Placebo IV
214890657|NCT00707473|DRUG|Carboplatin|Given IV
214890658|NCT00707473|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
214890659|NCT00707473|DRUG|Cisplatin|Given IV
214890660|NCT00707473|PROCEDURE|Definitive Surgical Resection|Undergo surgery
214890661|NCT00707473|DRUG|Docetaxel|Given IV
214890662|NCT00707473|DRUG|Fluorouracil|Given IV
214890663|NCT00707473|PROCEDURE|Quality-of-Life Assessment|Correlative studies
214890664|NCT00707473|RADIATION|Radiation Therapy|Undergo radiation therapy
214890665|NCT04895709|DRUG|BMS-986340|Specified dose on specified days
214890666|NCT04895709|DRUG|BMS-936558-01|Specified dose on specified days
214890667|NCT04895709|DRUG|Docetaxel|Specified dose on specified days
214890668|NCT05272826|DRUG|Iberdomide|Available as formulated capsules and administered as oral medication
214890669|NCT05272826|DRUG|Bortezomib|Administered as subcutaneous injection
214890670|NCT05272826|DRUG|Dexamethasone|Administered as oral medication
214890671|NCT05272826|DRUG|Isatuximab|Administered as subcutaneous injection
214890672|NCT03520647|DRUG|Cyclophosphamide|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
214890673|NCT03520647|OTHER|Peripheral Blood Stem Cells|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
214890674|NCT02470338|PROCEDURE|MBP plus arthroscopy (Group A)|
214890675|NCT02470338|PROCEDURE|MBP alone (Group B)|
214890676|NCT06002828|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214890677|NCT06002828|OTHER|Quality-of-Life Assessment|Complete questionnaires
214890678|NCT06002828|OTHER|Questionnaire Administration|Complete questionnaires
214890679|NCT06976268|DRUG|BHV-8000|BHV-8000 10 mg. Participants will take blinded investigational product (IP) once daily
214890680|NCT06976268|DRUG|BHV-8000|BHV-8000 20 mg. Participants will take blinded investigational product (IP) once daily
214890681|NCT06976268|DRUG|Placebo|Matching placebo taken once daily
214890682|NCT06285253|COMBINATION_PRODUCT|miroliverELAP treatment|Subject's blood will be perfused through a bioengineered liver graft via an extracorporeal blood circuit.
214890683|NCT05490446|DRUG|Tebapivat|Tebapivat Tablet
214890684|NCT05272423|DIAGNOSTIC_TEST|FoundationOne® Liquid CDx|The FoundationOne® Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw.
214890685|NCT06319027|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
214890686|NCT06319027|OTHER|Fluciclovine F18|Given IV
214890687|NCT06319027|DRUG|Gadolinium-Chelate|Receive gadolinium-based contrast agent
214890688|NCT06319027|PROCEDURE|Magnetic Resonance Spectroscopy|Undergo MR spectroscopy
214890689|NCT06319027|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214890690|NCT06215235|OTHER|Bright light therapy|for 2 weeks the patient will take place for a 10.000lux lamp for 20-30 minutes.
214890691|NCT06462521|PROCEDURE|Cold Snare Piecemeal Resection (CSPR)|Qualifying polyps randomized to Cold Snare Piecemeal Resection (CSPR) will be removed using cold snare techniques (no electrocautery, no submucosal injection.)
214907126|NCT06564311|DRUG|Placebo|Placebo
214890692|NCT06462521|PROCEDURE|Cold Snare Endoscopic Mucosal Resection (Cold EMR)|Qualifying polyps randomized to Cold Snare Endoscopic Mucosal Resection (Cold EMR) will be removed using cold snare techniques (no electrocautery, with submucosal injection.)
214890693|NCT05982171|DEVICE|Exo + TSCS|Participants will receive TSCS delivered with the ONWARD Lift system at 1ms using a 10kHz carrier frequency delivered at 30Hz, with an amplitude set for each participant based on their ability to increase voluntary movement output.
215049818|NCT02351492|DEVICE|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
215049819|NCT02351492|DEVICE|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
215049820|NCT05290662|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
215049821|NCT05290662|DRUG|Cyclophosphamide/Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
214295099|NCT06340815|DEVICE|Radiation: Proton Therapy System (ProBeam)|"All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.~And long-term follow-up report will be submitted for future post market evaluation when requested by NMPA."
214295100|NCT01103791|DRUG|Docetaxel-PNP|Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
214295101|NCT02088255|PROCEDURE|Static surface|During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
214295102|NCT02088255|PROCEDURE|Dynamic surface|During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
214295103|NCT01497132|DRUG|Vitamin D3|Oral drops 30000 IU weekly
214295104|NCT01497132|DRUG|Placebo|Matching placebo
214295105|NCT01085591|DRUG|CB-183,315|
214295106|NCT01085591|DRUG|Placebo|
214295107|NCT01085591|DRUG|Vancomycin|
214295108|NCT00901160|PROCEDURE|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
214295109|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D and calcium|
214295110|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D|
214295111|NCT02662491|DIETARY_SUPPLEMENT|Calcium|
214295112|NCT02662491|DIETARY_SUPPLEMENT|Placebo|
214295113|NCT01744054|DEVICE|PET/MR|
214295114|NCT01744054|DEVICE|PET/CT|
214890694|NCT05982171|DEVICE|Exo + Sham|The ONWARD Lift system will also be used to deliver sham stimulation which will also be delivered at 1ms using a 10kHz carrier frequency delivered at 30Hz, and an amplitude of 1ma which has been used in other sham stimulation protocols and is not sufficient to induce activation of lumbosacral neuronal pools.
214295115|NCT05652946|DEVICE|Tyromotion, Fourier Intelligence, Thera-Trainer, EKSO Bionics|Participants to receive at least 5 sessions with advanced rehabilitation technology including at least one, or multiple, of the following devices: Amadeo, Diego, Myro, Arm Motus EMU, Pelma Motus, Tigo, Balo, EKSO NR. Sessions are 45 (+/- 5) minutes
214295116|NCT05652946|OTHER|Standard inpatient rehabilitation therapy|Standard inpatient rehabilitation therapy without advanced rehabilitation technology
214295117|NCT06304753|DEVICE|Telebot|"This is a mini-program based on a personal messenger, which is controlled by text commands in a chat on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure.~Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 6 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses."
214477941|NCT06275984|OTHER|online CPR-AED training|"The online CPR-AED training consists of successfully completing the online training course. To access the course, interested persons must register on a Moodle environment platform, with free and open access, through the following link: https://register.magnore.com/registre-curs-de-reanimacio -cardiopulmonary-dea/~Online training takes 3-4h and the participant will have access for 1 month (7x24h)."
214890695|NCT04927143|BEHAVIORAL|App-Based Contingency Management|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
215049822|NCT05025410|DRUG|Remimazolam|Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring
215049823|NCT03745768|DEVICE|Intermittent Theta Burst Stimulation|Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
214477942|NCT06527300|DRUG|NHWD-870 HCl|Administered P.O.
214668310|NCT07020741|PROCEDURE|Stable Isotope Oral Glucose Tolerance Test|Participants will consume a 75g glucose drink dissolved in 250 ml of water enriched with \[6,6\_2H2\]glucose and \[13C6\]glucose.
214668311|NCT01857895|DRUG|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
215049824|NCT03745768|DEVICE|sham stimulation|Sham stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
214890696|NCT04927143|BEHAVIORAL|Sham Control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
214890697|NCT04265703|PROCEDURE|Internal jugular vein catheterization|Catheterization of internal jugular vein with real-time (in-plane) method, with neutral neck position. Standard aseptic technique.
214890698|NCT04265703|PROCEDURE|Subclavian vein catheterization|Catheterization of subclavian/axillary vein with infra-clavicular approach with real-time (in-plane) method, without shoulder retraction. Standard aseptic technique.
214890699|NCT04265703|PROCEDURE|Innominate vein catheterization|Catheterization of innominate vein with supra-clavicular approach with real-time (in-plane) method, with neutral shoulder position and no shoulder retraction. Standard aseptic technique.
214890700|NCT05855824|OTHER|Applesauce Pouch|One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.
214890701|NCT05855824|OTHER|Fruit-vegetable puree blend|One 120 g pouch of fruit-vegetable puree blend provides 5 mg mixed carotenoids, 70 kcal, 4 mg vitamin C, and 2 g dietary fiber.
214890702|NCT01311323|PROCEDURE|PCI|Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging
214477943|NCT06252779|DEVICE|Plasma therapy equipment|The host of this product contains a high-voltage generator that can generate high-voltage electrical energy and deliver it to the treatment head. The air supply mechanism sends air to the ionization chamber inside the treatment head, which is ionized under the action of high-voltage electricity to generate thermal plasma, forming a particle flow mainly composed of active nitric oxide (pNO), which is then sprayed out from the nozzle of the treatment head to the target tissue of the human body. PNO particles can alter skin permeability, allowing them to act on specific parts of the body after transdermal absorption on the surface of the body.The patient will receive 14 days of treatment, with 20 minutes per day.
214890703|NCT01311323|PROCEDURE|CABG|Coronary Artery Bypass Graft
214890704|NCT06429293|BEHAVIORAL|Cognitive processing therapy|The active intervention is Cognitive Processing Therapy (CPT) is a gold-standard cognitive behavioral therapy for PTSD. The CPT intervention consists of 12 60-minute sessions teaching skills to challenge trauma-relevant cognitions that are distorted or unhelpful. Trauma-relevant cognitions fall into five themes that are highlighted during treatment: safety, trust, power/control, esteem, and intimacy. The empirical base for CPT is strong with numerous studies demonstrating that it results in significant reduction of PTSD symptoms regardless of trauma type and that it is 89% more effective than control treatment. CPT has been successfully implemented in virtual formats with comparable efficacy levels to that of in-person CPT. CPT sessions for this study will be conducted virtually by a CPT-trained clinician
214890705|NCT06451185|OTHER|A haemostatic mineral powder product.|The intervention is the addition of an approved and commercially available haemostatic powder product which is indicated for the temporary external control of bleeding. Recommended application is at central venous catheter insertion, prior to the site being covered with a transparent dressing. Comprising a hydrophilic polymer and potassium ferrate, once in contact with protein-rich body fluids, the mechanism of action of the powder is to dehydrate and to absorb exudate. This simultaneously forms a low pH seal barrier which is hostile to microbial penetration while also purporting to help maintain clean and dry environment beneath transparent site dressings.
214890706|NCT06459024|OTHER|Registration into the STREAM platform|All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.
214907127|NCT04093310|DEVICE|Word Catheter|Use of the Word catheter to remove the Bartholin's abscess
214668312|NCT04015141|DRUG|Perampanel Oral Suspension|Perampanel oral suspension.
214907128|NCT04093310|PROCEDURE|Incision-drainage|Incision-drainage to remove the Bartholin's abscess
214907129|NCT05609630|DRUG|Upadacitinib|Oral tablet or Oral solution
214907130|NCT05609630|DRUG|Tocilizumab|Subcutaneous injection or Intravenous infusion
214907131|NCT01622673|DRUG|Raltegravir|"Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
214907132|NCT01622673|DRUG|TUMS® Ultra Strength|"3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
214907133|NCT01622673|DRUG|MINTOX® Maximum Strength|"20 mL MINTOX® Maximum Strength (MS)~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
214907134|NCT04146012|DEVICE|Artegraft® Collagen Vascular Graft™ (Artegraft)|The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
214907135|NCT06053801|OTHER|Xolair|Prospective observational cohort study. There is no treatment allocation. Patients administered Xolair by prescription will be enrolled.
214907136|NCT01215773|DRUG|Placebo|Matching to HEA 200 mg tablet, oral administration
214907137|NCT01215773|DRUG|BI 671800|High dose oral administration
214907138|NCT01215773|DRUG|BI 671800|Medium dose oral administration
214890707|NCT05378958|OTHER|Individual interview|"Individual semi-directed explication interview with phenomenological questioning centered on lived experience.~The individual interview aims to collect data by questioning the participants using interview communication techniques, essentially on the reformulation technique. The interview is structured using an interview guide containing the list of open questions with prompts to be answered during the discussion."
214890708|NCT06115993|DRUG|AHB-137 injection|AHB-137 injection will be administered subcutaneously.
214890709|NCT06115993|DRUG|Placebo|Placebo will be administered subcutaneously.
214295118|NCT04013724|BEHAVIORAL|Group tobacco cessation interventions|"Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented."
214295119|NCT03314402|DRUG|Jaktinib Dihydrochloride Monohydrate|Active Substance
214295120|NCT03314402|DRUG|placebo|Placebo
214295121|NCT00177398|DRUG|Glargine insulin vs regular insulin|
214890710|NCT04905693|DRUG|Inhaled Treprostinil|Inhaled Treprostinil (6 mcg/breath) administered QID
214890711|NCT04905693|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
214890712|NCT05501821|DRUG|KBA1412|Part A, B, C
214890713|NCT05501821|DRUG|Pembrolizumab|Part C only
214890714|NCT06307626|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
214890715|NCT06307626|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
214890716|NCT04826692|DRUG|Metformin|Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
214890717|NCT04826692|DRUG|Placebo|425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
214890718|NCT06529471|OTHER|Massage group|The patient in the massage group will be visited by the practitioner 3 times at 10:00-14:00-20:00 on the first day after surgery and a back massage will be applied. The patient in the massage group will be placed in an orthopnea position during the application. The massage procedure lasts an average of 30 minutes and is applied to the cervical 3 and thoracic 12 vertebrae.
215049825|NCT00443118|DEVICE|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
214295122|NCT00396591|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
214295123|NCT05018299|BIOLOGICAL|FB704A placebo|Placebo
214295124|NCT05018299|BIOLOGICAL|FB704A|Anti-IL-6 antibody
214295125|NCT05545215|DEVICE|Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
214890719|NCT06442046|OTHER|Active Case Management|A case manager will work with families post-discharge to ensure that youth are connected to an appropriate community support. Case managers will also work with families to identify any social needs and provide support in accessing services as needed.
214890720|NCT06442046|OTHER|Treatment as usual|Subjects will receive a list of youth serving community service agencies and provided a recommendation to connect to them.
214890721|NCT05152147|DRUG|Zanidatamab|Administered IV
215049826|NCT00443118|DEVICE|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
214295126|NCT04608526|DIAGNOSTIC_TEST|Fractal analysis|Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
214477944|NCT06252779|DEVICE|Fake therapeutic device|False stimuli with the same appearance and pattern as Plasma therapy equipment.The patient will receive 14 days of treatment, with 20 minutes per day.
214477945|NCT06609460|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
214890722|NCT05152147|DRUG|Tislelizumab|Administered IV
214890723|NCT05152147|DRUG|Trastuzumab|Administered intravenously (IV)
214890724|NCT05152147|DRUG|Capecitabine|Administered orally (PO bid)
214890725|NCT05152147|DRUG|Oxaliplatin|Administered IV
214890726|NCT05152147|DRUG|Cisplatin|Administered IV
214890727|NCT05152147|DRUG|5-Fluorouracil|Administered IV
214890728|NCT06808477|DRUG|BBT001|BBT001 will be administered
214890729|NCT06808477|DRUG|Placebo|Placebo will be administered
214890730|NCT06350578|PROCEDURE|Hall Crown Technique|The Hall technique (HT) involves cementing Stainless Steel Crowns SSC on carious primary teeth without using rotary instruments nor local anaesthesia, thus eliminating discomfort, and increasing child's behavior.
214890731|NCT06350578|PROCEDURE|Conventional SSC Technique|The conventional technique involves complete removal of the carious lesion using rotary instruments and local anesthesia, then restoring the tooth with Stainless Steel Crown SSC.
214890732|NCT06854224|DRUG|Suvorexant (dual orexin receptor antagonist)|Veteran patients with Major Depressive Disorder and elevated risk of suicide will receive the FDA-approved drug Suvorexant (brand name: Belsomra), a dual orexin receptor antagonist, for four weeks. Participants will take 10mg of Surovexant nightly for the first two weeks and 20mg of Surovexant nightly for the second two weeks.
214295127|NCT04358653|OTHER|fall prevention exercise program|The intervention protocol was starting with a 10 minute warm up (5 minutes circular walking combined with neck rotation in clockwise and counterclockwise fashion and 5 minutes upper and lower limp stretching exercises) and was followed by 30 minutes of exercises that were aiming to muscle strengthening, balance improvement and functionability enhancement. The muscle strengthening routine consisted of exercises both from standing and sitting position using an elastic band, heel and toe standing, upper limb strengthening using dumbbells. Balance training consisted of standing on one leg, shifting weight laterally from one foot to the other, staggered stance, side stepping. Functionalibility improvement was promoted through walking upstairs and downstairs, standing up from sitting to upright position. At the end a 5 minute cool down procedure was following consisting of circular walking, mild head movements and upper and lower body stretching.
214295128|NCT02543008|PROCEDURE|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
214295129|NCT02543008|PROCEDURE|Physical activity|Information already included in arm/group descriptions.
214295130|NCT02543008|PROCEDURE|Placebo|Information already included in arm/group descriptions.
214295131|NCT04307693|DRUG|Lopinavir/ritonavir|Lopinavir / Ritonavir tablet
214295132|NCT04307693|DRUG|Hydroxychloroquine sulfate|Hydroxychloroquine sulfate tablet
214295133|NCT00848367|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
214295134|NCT02006745|DRUG|Ribavirin|24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
214295135|NCT02006745|DRUG|Telaprevir|12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA \>25 but \<1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA \>1000 iU/mL at week 4).
214477946|NCT06609460|COMBINATION_PRODUCT|Placebo|Placebo to match
214477947|NCT04195984|DEVICE|Mi-thos® valve and transapical delivery system|Transcatheter mitral valve replacement system
214477948|NCT05531058|BEHAVIORAL|AI-driven Vaccine Communicator|The intervention will include five modules web-based psychoeducation programme (two module sessions weekly, each module lasts for 15-20 minutes) and interact with an MI communication skills-based AI, digital assistant.
214477949|NCT05531058|BEHAVIORAL|Self-learning of COVID-19 vaccine knowledge|Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge (using multiple choices questions similar to the intervention group), and this is to ensure that participants from the control group also use time to search relevant information of covid-19 vaccines, also this is to control the time effects.
214477950|NCT03011034|DRUG|Talacotuzumab|Talacotuzumab 9 mg/kg will be administered as an IV infusion.
214477951|NCT03011034|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as an IV infusion.
214477952|NCT04699773|PROCEDURE|LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
214477953|NCT04699773|RADIATION|Hypofractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
214477954|NCT04497428|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
214890733|NCT00778882|DRUG|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
214890734|NCT06780098|BIOLOGICAL|R-DXD|IV Infusion
214890735|NCT06780098|BIOLOGICAL|I-DXD|IV Infusion
214890736|NCT06780098|DRUG|Docetaxel|IV Infusion
214890737|NCT06813924|DRUG|Etavopivat|Participants will receive a daily dose of etavopivat orally.
214890738|NCT06813924|DRUG|Digoxin|Participants will receive a single dose of digoxin orally.
214890739|NCT06813924|DRUG|Pitavastatin|Participants will receive a single dose of pitavastatin orally.
214295136|NCT00380614|DRUG|Lamivudine|
214295137|NCT04766801|PROCEDURE|Laparoscopic adjustable gastric banding|Weight-loss surgery, with the use of gastric banding
214295138|NCT03835494|OTHER|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
214295139|NCT05525143|PROCEDURE|Pregnant women who have given birth vaginally or by cesarean section|Full-term pregnant women who have given birth vaginally or by cesarean section with PPH. Descriptive statistics and possible causal factors
214295140|NCT01320761|DRUG|ATX-101-BA-free|ATX-101-BA-free
214295141|NCT01320761|DRUG|ATX-101-BA|ATX-101-BA
214477955|NCT04497428|OTHER|cTBS|continuous theta-burst stimulation
214477956|NCT06398470|DIAGNOSTIC_TEST|NeuroSAFE procedure|Frozen section analysis of the posterolateral surface of the prostate to guide nerve sparing decisions.
214477957|NCT06398470|DIAGNOSTIC_TEST|LaserSAFE procedure|The LaserSAFE procedure is performed using an FCM called the Histolog® scanner developed by Samantree® which can be placed within the operating room. The Histolog® scanner produces digital images with high, micrometre-range resolution and enables the visualization of tissue microstructures down to the cellular level.
214668313|NCT04015141|DRUG|Perampanel Tablet|Perampanel tablet.
214668314|NCT01613612|PROCEDURE|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
214295142|NCT00162201|DRUG|Abatacept|Parenteral, IV, 500 mg if \< 60 kg; 750 mg if \> 60 \& \< 100 kg; 1000 mg if \> 100 kg, Monthly, 4 months.
214890740|NCT06813924|DRUG|Metformin|Participants will receive a single dose of metformin orally.
214890741|NCT06813924|DRUG|Midazolam|Participants will receive a single dose of midazolam orally.
214890742|NCT06813924|DRUG|Rosuvastatin|Participants will receive a single dose of rosuvastatin orally.
214907139|NCT04092270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214907140|NCT04092270|PROCEDURE|Computed Tomography|Undergo CT scan
214907141|NCT04092270|PROCEDURE|Echocardiography Test|Undergo ECHO
214890743|NCT06978972|OTHER|Cognitive Stimulation Therapy|"CST is an evidence-based, cognitively stimulating therapeutic group intervention for individuals with mild-to-moderate dementia. Individuals participate in CST 2 times per week for 7 weeks. The CST sessions are administered by a variety of professionals who become certified through the St. Louis School of Medicine. The general structure of each session will follow the CST Manual called Making a Difference 1. Each session will be based on a theme and will include an introduction, theme song, current affairs activity, the main activity (physical games, sounds, food, being creative, word and number games, team quizzes, orientation, current affairs, ect.), suggested activities for home, and closure. These sessions are highly structured and will follow the introduction, theme song, current affairs activity, the main activity, suggested activities for home, and closure organization strictly. The participants will spend 45 minutes in each session."
214890744|NCT06982625|PROCEDURE|Ultrasound guided supra inguinal fascia iliaca block|The ultrasound probe is placed in a cephalo-caudal orientation, over the inguinal ligament, lateral to the femoral nerve. The iliacus muscle, which is covered caudally by the sartorius muscle and cephalically by the internal oblique muscle, is visualized in depth. Between these two muscles, an area is identified where the iliacus muscle is covered only by subcutaneous tissue. The needle is introduced in a cranio-caudal direction, and the injection is initiated in this area, beneath the fascia iliaca. The needle then advances through the space created by the injection, as far as possible in a cephalic direction, beneath the internal oblique muscle. An injection of 40 ml of 0.1% ropivacaine is administered.
214890745|NCT06982625|PROCEDURE|Placebo Injection|Five milliliters of saline are injected subcutaneously under ultrasound guidance
214890746|NCT06982625|PROCEDURE|Surgical and anesthetic protocol|"All patients receive standard general anesthesia:~* Induction of anesthesia by sufentanil, ketamine, propofol and tracrium if needed,~* Maintenance of anesthesia by sevoflurane and sufentanil if needed,~* Prevention of PONV by dexamethasone and droperidol,~* Post-operative analgesia by paracetamol, ketoprofene, nefopam, as indicated. Total hip arthroplasty is performed by anterior or postero-lateral approach, depending on surgeon preference.~In the post-anesthesia care unit, if numerical pain rating scale at rest is \>=4, patients are randomized to receive experimental or placebo intervention."
214890747|NCT06982859|DRUG|Retatrutide|Administered SC
214890748|NCT06982859|DRUG|Semaglutide|Administered SC
214890749|NCT06982859|DRUG|Placebo|Administered SC
214890750|NCT06814132|DRUG|MK-5684|Oral tablet
215049827|NCT00443118|DEVICE|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
215049828|NCT01770405|DEVICE|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
215049829|NCT06455722|DRUG|[68Ga]Ga-P15-041|Intravenous injection of one dose of 111-148 MBq (3-4 mCi) \[68Ga\]Ga-P15-041. Tracer doses of \[68Ga\]Ga-P15-041 will be used to image lesions by PET/CT.
214295143|NCT05744453|DIETARY_SUPPLEMENT|Olive Leaf Extract|experimental arm
214295144|NCT05744453|DIETARY_SUPPLEMENT|Cellulose|placebo comparator arm
215049830|NCT01100112|DRUG|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
215049831|NCT01673659|DRUG|Mometasone furoate|
215049832|NCT01673659|DRUG|Nasonex Nasal Spray|
215049833|NCT01673659|DRUG|Placebo nasal spray|
214295145|NCT01537029|DRUG|Doxorubicin|Dosed by the patient's treating physician according to local standard of care.
214295146|NCT01537029|DRUG|Cyclophosphamide|dosage form: IV, Dosage, frequency, and duration: According to local standard of care
214295147|NCT01045512|DRUG|fluvastatin|40-80mg once daily
215049834|NCT02825446|PROCEDURE|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
214295148|NCT04395469|DRUG|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after radiation treatment.
214295149|NCT03032094|PROCEDURE|connective tissue graft|palatal connective tissue graft to attain root coverage
214295150|NCT04337125|OTHER|Neuropsychological and attachment/parenting assessment|"Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment."
214295151|NCT05778123|OTHER|Type of disease|Different types of pathogen: brain injury by trauma or hydrocephalus due to various diseases.
214295152|NCT02888522|BIOLOGICAL|immunomodulation|Immunomodulation depending on chimerism
214295153|NCT04637789|BEHAVIORAL|the whole body vibration|most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.
214295154|NCT04637789|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
214295155|NCT02245490|DRUG|Tamsulosin HCl controlled release capsules|
214295156|NCT02245490|DRUG|Matching placebo capsule|
214295157|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
214295158|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
214295159|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
214890751|NCT06814132|DRUG|Prednisone|Oral tablet
214295160|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
214295161|NCT02031731|DRUG|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
214890752|NCT06814132|DRUG|Fludrocortisone acetate|Oral tablet
214890753|NCT06126315|DRUG|Acetyl-l-carnitine|Acetyl-l-carnitine
214890754|NCT06126315|DRUG|Placebo|placebo
214890755|NCT03164616|DRUG|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria
214890756|NCT03164616|DRUG|Tremelimumab|IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.
214295162|NCT02031731|DRUG|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
214295163|NCT02031731|DRUG|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
214295164|NCT03251066|OTHER|Proponent Nasal Spray|The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
214295165|NCT01879150|DEVICE|Cyclaplex bone anchor|Device implantation
214295166|NCT01472081|BIOLOGICAL|Nivolumab|
214295167|NCT01472081|BIOLOGICAL|Pazopanib|
214295168|NCT01472081|DRUG|Sunitinib|
214890757|NCT03164616|DRUG|Abraxane + carboplatin|Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
214890758|NCT03164616|DRUG|Gemcitabine + cisplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
214890759|NCT03164616|DRUG|Gemcitabine + carboplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
214295169|NCT01472081|BIOLOGICAL|Ipilimumab|
214295170|NCT02248194|DEVICE|Tactile electrosurgical ablation probe|
214295171|NCT02248194|DEVICE|Hysteroscopic endometrial ablation|
214295172|NCT05351762|DRUG|Nimotuzumab Combined With Neoadjuvant Chemotherapy|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
214295173|NCT04097808|DIETARY_SUPPLEMENT|collagen peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
214295174|NCT00425451|DRUG|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
214295175|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
214295176|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
214295177|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
214295178|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops
214295179|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray|Single intranasal dose on Day 1, by intranasal spray
214295180|NCT03852940|OTHER|Parenteral nutrition|
214295181|NCT03852940|OTHER|Enteral Nutrition|
214295182|NCT00863603|OTHER|oxygen|5 Liter/minute by nasal cannula for 6 wks
214295183|NCT03684954|OTHER|Prf|Take 10 cc blood from patient and gain prf
214890760|NCT03164616|DRUG|Pemetrexed + carboplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
214890761|NCT03164616|DRUG|Pemetrexed + cisplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
214295184|NCT01214954|OTHER|Supervised progressive resistance training|Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.
214295185|NCT01214954|OTHER|Control group|Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
214295186|NCT00541489|DRUG|Naproxcinod|750 mg, bid
214295187|NCT00541489|DRUG|Naproxen|500 mg, bid
214295188|NCT00541489|DRUG|Placebo|bid
214295189|NCT00616954|DRUG|ATG-F|ATG-f
214295190|NCT03293810|OTHER|Observational study|Post-Authorization Safety Study
214295191|NCT01518166|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
214295192|NCT01518166|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
214890762|NCT06817590|DRUG|deoxycytidine|Oral administration, in combination with deoxythymidine
214890763|NCT06817590|DRUG|deoxythymidine|Oral administration, in combination with deoxycytidine
214890764|NCT06656351|DRUG|Tafenoquine 100mg|Tafenoquine
214890765|NCT06655883|DRUG|Suvorexant|Oral Tablet
214890766|NCT06655883|DRUG|Placebo|Oral Tablet
214890767|NCT06649851|DRUG|Granulocyte Colony Stimulating Factor (G-CSF)|Subcutaneously injected study drug; standard target dose of 5-7 µg/kg/d.
214890768|NCT06649851|RADIATION|Radiation Therapy + Temozolomide|Standard of care chemoradiation is radiation therapy + Temozolomide (TMZ). Chemoradiation (chemo-RT) includes an initial 6-week cycle, followed by a 4-week break, and up to 6 additional cycles of TMZ.
214890769|NCT06660394|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
214890770|NCT06660394|DRUG|Placebo|Participants will be administered with matching placebo orally or through G-tube/ PEG tube
214890771|NCT05443295|OTHER|MoveUS Program|The MoveUS Program have 5 stages: 1 (approach stage), based on analytical movements, isometric peak contractions and learning/motor control; 2 (structural stage), based on muscular strength or resistance training through a cumulative work of short efforts, following with the analytical work of pushing or lifting/pulling; and ending in a closed kinetic chain; 3 (neural stage), that has two stage: 3A, based on a structural work that serves as a continuation of stage 2 and the work is focused on the training of increase cross-sectional muscular area; and 3B, based on a neural work focursed in an intra neuromuscular system highlighted motoneuron unit workout. Finally, stage 4 (functional stage), based on a functional readaptation to sports activity and/or work activity; or, failing that, to the activity of daily life with the highest demand.
215049835|NCT02825446|PROCEDURE|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
215049836|NCT01864083|PROCEDURE|Positron Emission Tomography (PET)|
215049837|NCT01864083|DRUG|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
215049838|NCT01864083|PROCEDURE|Positron emission mammography (PEM) When available|
215049839|NCT01864083|PROCEDURE|MR|
215049840|NCT05879952|BEHAVIORAL|TAU + BTsN session|BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.
214890772|NCT05443295|OTHER|Control intervention|The control intervention is based on following the conventional treatment guidelines for glenohumeral instability, where immobilization, taking non-steroidal anti-inflammatory drugs, cryotherapy, passive kinesitherapy and self-assisted, pendular exercises stand out and education.
214890773|NCT06588478|DRUG|Pirtobrutinib|Administered Orally.
214890774|NCT06586515|DRUG|LY3962673|Administered orally.
214890775|NCT06586515|DRUG|Cetuximab|Administered intravenously.
214890776|NCT06586515|DRUG|Gemcitabine|Administered intravenously.
214890777|NCT06586515|DRUG|nab-paclitaxel|Administered intravenously.
214890778|NCT06586515|DRUG|Oxaliplatin|Administered intravenously.
214890779|NCT06586515|DRUG|leucovorin|Administered intravenously.
215049841|NCT05879952|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
215049842|NCT04461353|DRUG|Aerolized Hydroxychloroquine Sulfate|sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.
215049843|NCT04461353|OTHER|Placebo|The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.
215049844|NCT04021446|OTHER|Exercise|personalized exercise prescription
215049845|NCT01718522|DEVICE|sensor augmented pump (SAP)|
215049846|NCT03882593|PROCEDURE|Analysis of arterial filters after CPB|At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
214890780|NCT06586515|DRUG|Irinotecan|Administered intravenously.
214890781|NCT06586515|DRUG|5-fluorouracil|Administered intravenously.
214890782|NCT06360094|DRUG|BI 1839100|BI 1839100
214295193|NCT01518166|DRUG|atorvastatin|One single dose of 40 mg. Tablet
214295194|NCT01518166|DRUG|lisinopril|One single dose of 20 mg. Tablet
214295195|NCT01518166|DRUG|griseofulvin|One single dose of 500 mg. Tablet
214890783|NCT06360094|DRUG|Placebo|Placebo
214890784|NCT04787744|PROCEDURE|PET-directed Local Therapy using Surgery|Surgery will be used to treat metastases.
214890785|NCT04787744|RADIATION|PET-directed Local Therapy using Radiation|"Radiation therapy will be used to treat metastases.~Radiation options include:~1. Stereotactic body radiotherapy (SBRT) using 1-10 fractions~2. Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes~The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran."
214890786|NCT04787744|OTHER|Salvage Local Therapy for locally recurrent disease|For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.
214477958|NCT04751903|BEHAVIORAL|oral motor stimulation|Oral motor stimulation (OMS) is defined as the sensorial stimulation of cheek, lip, jaw, upper-lower gum, internal cheek, tongue and soft palate that affects the physiology of oropharyngeal mechanisms and develops feeding functions.It took 15 minutes to apply the OMS by lightly touching their cheeks, lips, gums, and tongue with fingertips for the first 12 minutes, followed by letting the infant suck on a pacifier for the remaining 3 minutes. OMS used as an alternative or supplementary early intervention strategy to develop oral feeding skills in preterm infants.
214890787|NCT04787744|DRUG|Goserelin, Histrelin, Leuprolide & Triptorelin|Androgen deprivation therapy (ADT) using an LHRH agonist
214890788|NCT04787744|DRUG|ADT + Nilutamide, Flutamide, & Bicalutamide|ADT adding anti-androgen therapy to an LHRH agonist
214477959|NCT04262830|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging (MRI)|Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics
214890789|NCT04787744|DRUG|Degarelix & Relugolix|ADT using an LHRH Antagonist.
214890790|NCT04787744|DRUG|ADT + Docetaxel +/- prednisone|Enhanced SST using chemohormonal therapy
214890791|NCT04787744|DRUG|ADT + Abiraterone + Prednisone|Enhanced SST using Abiraterone + Prednisone
214890792|NCT04787744|DRUG|ADT + Abiraterone + Methylprednisolone|Enhanced SST using Abiraterone + Methylprednisolone
214890793|NCT04787744|DRUG|ADT + Apalutamide|Enhanced SST using ADT + Apalutamide
214890794|NCT04787744|DRUG|ADT + Enzalutamide|Enhanced SST using ADT + Enzalutamide
214890795|NCT04787744|RADIATION|Prostate-directed Radiation for De novo oligometastatic prostate cancer|"Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites.~Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions.~Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases."
214890796|NCT05203328|DEVICE|Vapotherm|Monitored anesthesia care with oxygen supplementation through a high-flow nasal cannula
214890797|NCT05203328|DEVICE|Regular nasal canula|Monitored anesthesia care with oxygen supplementation through a regular nasal cannula
214890798|NCT04768686|DRUG|FLX475|tablet
214890799|NCT04768686|DRUG|Pembrolizumab|IV infusion
214890800|NCT06860243|DRUG|Opevesostat|Oral film-coated tablet
214890801|NCT06860243|DRUG|Prednisone|Oral tablet
214295196|NCT01518166|DRUG|digoxin|One single dose of 1 mg. Tablet
214295197|NCT00001576|DRUG|Melphalan|
214295198|NCT00001576|DRUG|Floxuridine|
214295199|NCT00001576|DRUG|Leucovorin|
214295200|NCT02915276|PROCEDURE|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
214295201|NCT02915276|PROCEDURE|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
214295202|NCT02056704|DEVICE|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
214477960|NCT04262830|OTHER|Accelerometer physical activity monitoring|Measurement of physical activity using hip-worn accelerometer.
214477961|NCT04575883|DEVICE|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
214890802|NCT06860243|DRUG|Fludrocortisone acetate|Oral tablet
214890803|NCT06991205|BEHAVIORAL|Web-TIRELESS|This is a self-administered web-based intervention that consists of 4 on-demand sessions, each \~30 minutes long, that teach mind-body skills, cognitive-behavioral strategies (e.g., reframing, pain and substance use urge surfing), activity pacing, acceptance and commitment skills, and psychoeducation on the association between substance use and pain. The program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive substance use behaviors.
214890804|NCT06991205|OTHER|Web-MEUC|An educational information web-based pamphlet, containing brief, summarized information tailored for the respective patient population that follows topics including the trajectory of pain and adaptation after non-traumatic painful upper extremity conditions, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living.
214295203|NCT02584114|BEHAVIORAL|Peak app for memory training|
214890805|NCT06989424|DEVICE|Magnetic Flexible Endoscope (MFE)|The Magnetic Flexible Endoscope (MFE) is a single-use endoscope intended to integrate with other commercially available devices for visualization of the human colon in order to eliminate the need for passage of the much stiffer, non-intuitive, risk prone standard colonoscope. The MFE will be introduced into the colon and traverse from the rectum to the cecum.
214890806|NCT03522025|DEVICE|Unicompartmental Knee Arthroplasty (UKA)|Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
214890807|NCT06606106|DRUG|LY3537031|Administered SC
214890808|NCT06606106|DRUG|Placebo|Administered SC
214907142|NCT04092270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214295204|NCT02584114|BEHAVIORAL|Non-memory training group|
214295205|NCT00704158|DRUG|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
214907143|NCT04092270|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214907144|NCT04092270|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214907145|NCT04092270|DRUG|Peposertib|Given PO
214907146|NCT06349512|PROCEDURE|68Ga-FAPI-46 PET/CT imaging|The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.
214907147|NCT07091357|DRUG|SHR-1819 Injection|SHR-1819 injection.
214907148|NCT07091357|DRUG|SHR-1819 Injection Placebo|SHR-1819 injection placebo.
214907149|NCT06193603|OTHER|True dry cupping therapy|In the intervention group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. The therapist will perform 5 minutes of dry cupping therapy, moving the cups up and down using both hands. Participants will also receive routine physiotherapy, including a 20-minute session of transcutaneous electrical stimulation with a frequency of 100 pulses per second and a duration of 60 microseconds. The stimulation intensity will be adjusted for sensory stimulus. Stabilization exercises like abdominal hollowing and bridging will be included. The treatment will consist of 10 sessions, three times per week.
214295206|NCT04980859|DRUG|Zebutinib&BR or Zebutinib&FCR|Introduction period: Zebutinib 160 mg bid oral treatment for 3 months;Joint stage :6 sessions of Zebutinib FCR( under 60 years of age,Fludarabine 25 mg/m² Q3W, Cyclophosphamide 250 mg/m² Q3W,Rituximab 375 mg/m² Q3W) or BR (over 60 years of age, )(28 days and 1 cycle);Maintenance treatment: after the end of the combined phase, continue the treatment of zebutinib.
214295207|NCT05368857|DRUG|Afamelanotide|Up to 10 adult healthy volunteers will be enrolled in this study in which small areas of their skin will be exposed to UVR and skin samples taken. UV-induced DNA damage and repair will be analysed.
214890809|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Ripple Mapping guided.|Ripple Mapping is used to map the atrial tachycardia mechanism. Using the scar thresholding technique the Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.
214890810|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Conventional mapping guided.|Conventional activation mapping is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.
214890811|NCT06860542|DRUG|Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care|Budesonide (Pulmicort® Turbuhaler®) 800ug inhaled twice daily (BID) will be taken in addition to usual care for 36 weeks.
214890812|NCT06860542|OTHER|Arm 1- Usual care|The comparison arm will be usual care (UC) for Checkpoint inhibitor pneumonitis (CIP) (steroids).
214890813|NCT06997497|DRUG|MK-1084|Oral tablet
214890814|NCT06997497|DRUG|Oxaliplatin|Per label
214890815|NCT06997497|DRUG|Leucovorin/levofolinate calcium|Per label
214890816|NCT06997497|DRUG|5-Fluorouracil|Per label
214890817|NCT06997497|BIOLOGICAL|Cetuximab|Per label
214890818|NCT06997497|DRUG|Bevacizumab|Per label
214890819|NCT05934396|BEHAVIORAL|Safety Planning|Prior to discharge and following the conclusion of all Virtual Reality (VR) sessions, the participant will develop a safety planning intervention for school settings in collaboration with relevant individuals (e.g., the researcher, a school professional).
214890820|NCT05934396|BEHAVIORAL|VR Enhanced Affect Regulation|Participants will receive an overview of affect regulation in VR and then have the opportunity to practice using affect regulation in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
214890821|NCT05934396|BEHAVIORAL|VR Enhanced Cognitive Restructuring|Participants will receive an overview of cognitive restructuring in VR and then have the opportunity to practice using cognitive restructuring in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
214890822|NCT05934396|BEHAVIORAL|VR Enhanced Problem Solving|Participants will receive an overview of problem solving in VR and then have the opportunity to practice using problem solving in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
214890823|NCT05934396|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Worksheets|The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
214890824|NCT06993792|DRUG|Orforglipron|Administered orally
214890825|NCT06993792|DRUG|Placebo|Administered orally
214890826|NCT06004050|DRUG|Delgocitinib|Topical administration
214890827|NCT06004050|OTHER|Vehicle cream|Topical administration
214890828|NCT03740841|BEHAVIORAL|Interactive story teller LUNII|Use of the interactive story teller LUNII by the child from the pre-operative visit to the discharge.
214668315|NCT01613612|PROCEDURE|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
214890829|NCT03869957|DIETARY_SUPPLEMENT|Intervention group|0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
214890830|NCT04687969|DRUG|[18F]DCFPyL|will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination
214890831|NCT04687969|RADIATION|PET/MRI scanner|PET/MRI Scan with \[18F\]DCFPyL as directed by protocol
214890832|NCT06607185|DRUG|LY4066434.|Administered orally.
214890833|NCT06607185|DRUG|Cetuximab|Administered intravenously.
214890834|NCT06607185|DRUG|Nab paclitaxel|Administered intravenously.
214890835|NCT06607185|DRUG|Gemcitabine|Administered intravenously.
214890836|NCT06607185|DRUG|Oxaliplatin|Administered intravenously.
214890837|NCT06607185|DRUG|Leucovorin|Administered intravenously.
214477962|NCT06853392|COMBINATION_PRODUCT|Demineralized freeze dried allograft with collagen sponge|Demineralized freeze dried allograft,filling 2/3 of the socket covered with collagen sponge ,six months, one time
214890838|NCT06607185|DRUG|Irinotecan|Administered intravenously.
214890839|NCT06607185|DRUG|5Fluorouracil|Administered intravenously.
214890840|NCT06607185|DRUG|Carboplatin|Administered intravenously.
214890841|NCT06607185|DRUG|Cisplatin|Administered intravenously.
214890842|NCT06607185|DRUG|Pemetrexed|Administered intravenously.
214890843|NCT06607185|DRUG|Pembrolizumab|Administered intravenously.
214890844|NCT06598943|DRUG|Eltrekibart|Administered
214890845|NCT06598943|DRUG|Mirikizumab|Administered
214890846|NCT06598943|DRUG|Placebo|Administered
214890847|NCT06528314|DRUG|Efruxifermin|Administered by subcutaneous injection
214890848|NCT06528314|DRUG|Placebo|Administered by subcutaneous injection
214890849|NCT06614946|BEHAVIORAL|Electronic Safety Plan (ESP)|Participants will receive an electronic safety plan in the ED. ESP focuses on developing a personalized coping plan to manage suicidal thoughts and urges.
214890850|NCT06614946|BEHAVIORAL|Text support|Those in the text-based support program will receive up to 2 texts per day for a month with varying levels of tailoring, based on ESP and dynamic personalized feedback.
214890851|NCT06998498|BEHAVIORAL|Ready for Recovery|The Ready for Recovery program is a 6-week, multicomponent, tailored, prehabilitation intervention to promote the optimization of medical and psychological status prior to surgery. Its key components include education, enhancement of beneficial health behaviors, reduction of negative psychological symptoms, and the promotion of social support. Following an initial session, the team will develop a customized prehabilitation plan for each participant. Participants will work towards goals each week and will discuss progress with their study trainer via weekly phone sessions, which will continue until the scheduled surgical procedure.
214890852|NCT06069583|BEHAVIORAL|Support platform|"The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar.~Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D."
214890853|NCT06672549|DRUG|Orforglipron|Administered orally. ISA specific interventions will be listed in the ISA.
214890854|NCT06672549|DRUG|Placebo|Administered orally. ISA specific interventions will be listed in the ISA.
214890855|NCT06593860|BEHAVIORAL|Remote speech rehabilitation|Two types of intervention will be provided via online to 32 dyads of people with Parkinson's disease: (1) speech therapy (PD patients) and (2) family education/training (PD families). Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks.
214890856|NCT07007442|OTHER|Instrument assisted soft tissue mobilization|for application of IASTM. the patient will sit on chair in comfortable position, apply lubricant material on treated area (trapezius muscle). Apply IASTM in 30-60 angle for 40 to 120 sec until hyperemia occur for each side+ conventional therapy
214890857|NCT07007442|OTHER|dry cupping|the dry cupping will be aplied by using plastic cups that are placed over localized areas of skin. A vacuum suction is achieved with a manual handheld pump device to create a negative pressure, drawing localized skin and soft tissue structures into the cup+ conventional therapy
214890858|NCT07007442|OTHER|conventional therapy|the patients will receive Isometric strengthening exercises for cervical Extensors, Flexors, bilateral side Flexors and Rotators (resistance was about 50% of the patient's maximum strength, hold for 10 seconds, for 10 repetitions.Stretching of the upper fibers of trapezius (stretching was held for 30 seconds and repeated 3 times). postural correction exercises in the form of ; 1) Chin tucks exercise is quick and easy to do and it helps strengthening upper thoracic extensors, the muscles that align head over shoulders.2)Corner stretch: provides a deep stretch of the chest and shoulders, which can help maintain good posture.
214890859|NCT07127159|BEHAVIORAL|Intentional Music Listening|Participants will receive an iPad with Spotify (for music listening) and FaceTime. For 4 weeks (excluding weekends; 20 sessions), participants will listen to music for one hour per session, without multitasking (e.g., no chores or cooking), and will be encouraged to listen attentively. The investigators will collaborate with each participant to co-create a personalized playlist composed of self-selected, culturally relevant songs. This playlist can be updated at any time by the participant, either independently or with assistance from the team. During the music-listening session, participants will be on FaceTime with a team member, who will be available to provide support as needed. A custom Python script will continuously track the songs played by participants through Spotify, logging playback activity for research purposes.
215049847|NCT03911856|OTHER|Echocardiography|We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
215049848|NCT03911856|OTHER|Pulmonary Gas Exchange|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
214477963|NCT06853392|COMBINATION_PRODUCT|autogenous dentin graft with collagen sponge|autogenous mineralized dentin graft, filling 2/3 of the socket covered with collagen sponge , six months, one time
214668316|NCT02542995|OTHER|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
214890860|NCT07127159|BEHAVIORAL|Audiobook Listening|Participants will be provided with an iPad equipped with a Spotify (for audiobook listening) and FaceTime. For 4 weeks (excluding weekends; 20 sessions), participants will be asked to listen to an audiobook of their choice for one hour per session, without engaging in other activities such as chores or cooking. Participants will be instructed to listen attentively and avoid multitasking during the session. A team member will connect with each participant via FaceTime to offer support. Participants may update or change their audiobook selections at any time, either independently or with help from the team. A custom Python script will be used to continuously track audiobook playback activity for research and analysis.
214890861|NCT06865664|DRUG|fludarabine|30 mg/m2 per day IV on days -5, -4, -3, -2
214890862|NCT06865664|DRUG|cyclophosphamide|500 mg/m2 per day IV on days -4, -3, -2
214890863|NCT06865664|DRUG|cetuximab|"Participants Age \>=18 years, based on FDA approved dosing: Loading dose of 400 mg/m2 IV, followed by 250 mg/m2 IV weekly for a total of 4 doses.~Participants Age \<18 years, based on phase I data of cetuximab in children: Dose of 250 mg/m2 IV administered over 1 hour weekly for a total of 4 doses."
214890864|NCT06865664|BIOLOGICAL|FGFR4-CAR T Cells|Single intravenous (IV) infusion on Day 0
214890865|NCT07006792|DRUG|Lebrikizumab|Administered SC
214890866|NCT07005284|DRUG|LY3981314|Administered SC
214890867|NCT07005284|DRUG|Placebo|Administered SC
214890868|NCT07128524|DIETARY_SUPPLEMENT|Treatment with Ketone Supplement|Participants (n=25) will receive three doses of a ketone supplement drink daily for seven days.
214890869|NCT07128524|DIETARY_SUPPLEMENT|Treatment with Placebo|Participants (n=25) will receive three doses of a placebo drink for seven days.
214890870|NCT05314010|DRUG|MIL62|"Phase 1b: Participants will receive intravenous (IV) infusions of MIL62 at doses of 500 mg or 1000 mg on Week (W) 1 Day (D) 1, W3D1, W25D1, W27D1, W53D1, W79D1, W105D1, W131D1, W157D1, W183D1, and W209D1. Participants initially assigned to the 500 mg dose group who exhibit good tolerance may be escalated to the 1000 mg dose starting from W25D1.~Phase 3 (Randomised Controlled Period \[RCP\]): Participants will receive IV MIL62 1000 mg or placebo matched to MIL62 on W1D1, W3D1, W25D1, and W27D1. The administration protocol for placebo is identical to that of MIL62.~Phase 3 (Open-Label Period \[OLP\]): Participants who enter the OLP will receive IV MIL62 1000 mg on W1D1, W27D1, W53D1, W79D1, W105D1, and W131D1, along with matching placebo on W3D1."
214890871|NCT05314010|OTHER|Placebo|"Phase 3 (RCP): Participants will receive IV placebo matched to MIL62 on W1D1, W3D1, W25D1, and W27D1.~Phase 3 (OLP): Participants entering the OLP will receive IV MIL62 1000 mg on W1D1, W3D1, W27D1, W53D1, W79D1, W105D1, and W131D1."
214890872|NCT06987201|DEVICE|DigiVibe Vibration Anesthesia|DigiVibe Vibration Anesthesia
214890873|NCT05552118|PROCEDURE|Cochlear™ Remote care|"Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review.~Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit."
214890874|NCT05552118|PROCEDURE|Standard of care|Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
214890875|NCT05552118|DEVICE|Compatible Implant Series and Compatible Sound Processors|Individuals who are implanted with a compatible cochlear implant series and compatible sound processor are eligible to participate.
214890876|NCT06465069|DRUG|LY4052031|Intravenous
214890877|NCT04417465|DRUG|ABBV-CLS-579|Oral Capsule
214890878|NCT04417465|DRUG|PD-1 inhibitor|Intravenous (IV) infusion
215049849|NCT05915585|DEVICE|High-Intensity Laser Therapy|"The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session"
215049850|NCT02770027|DRUG|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
215049851|NCT02770027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
214295208|NCT03605303|DEVICE|Test/Control|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
214295209|NCT03605303|DEVICE|Control/Test|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
214477964|NCT03419052|BEHAVIORAL|Speed of processing training|Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) which tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.
214890879|NCT04417465|DRUG|VEGFR TKI|Oral Tablet
214890880|NCT06671236|BIOLOGICAL|Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)|Regulatory T cell therapy, intrathecal injection
215049852|NCT00225862|DRUG|ropinirole|
215049853|NCT03191162|DRUG|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
215049854|NCT00378638|DRUG|bevacizumab combined with dose dense chemotherapy|
215049855|NCT01023217|DRUG|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
215049856|NCT01023217|DRUG|Entecavir|Entecavir 1 mg/day orally
214890881|NCT07005128|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
214890882|NCT07005128|DRUG|Durvalumab|Durvalumab will be administered as an IV infusion.
214890883|NCT07005128|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion.
214890884|NCT07005128|DRUG|Etoposide|Etoposide will be administered as an IV infusion.
214890885|NCT07007702|DEVICE|T2769|Preservative-free combination of trehalose, sodium hyaluronate and N-Acetyl Aspartyl Glutamic Acid
215049857|NCT01023217|DRUG|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
214890888|NCT04400539|DEVICE|intrapleural photodynamic therapy with videothoracoscopy|MPM patients will be first administrated 20 mg/kg of oral photosensitizer, 5-Aminolevulinic Acid (5-ALA) {Gliolan®}, 4 to 6 hours prior undergoing thoracoscopy (VATS). During VATS procedure, after a qualitative control of the fluorescence of tumor lesions and some guided pleural tumor biopsies, the pleural cavity will be illuminated using a flexible probe and laser source at a specific wavelength for 5-ALA (400-500 nm; 25 J/cm2) during 15 minutes (6 fractions of 2.5 minutes separated by 5 pauses of 2 minutes each to improve tissue oxygenation for the PDT reaction). An IPC device (but no talc) will be inserted and used for pleurodesis and may permit to collect further pleural effusion samples. As 5-ALA has a short half-life and thus does not need extensive precautions to avoid patient photosensitivity, the patient would not stay longer than a standard procedure (about 2-3 days in the hospital)
214890889|NCT04400539|DRUG|Nivolumab Injection|Seven to 10 days after VATS, patients will start to be treated by Nivolumab 240mg IV every 2 weeks till progression (CT-scan reassessment every 8 cycles), unacceptable toxicity, or maximum 2 years.
214890890|NCT05836051|OTHER|Flavor|E-liquid flavor chemicals
215049858|NCT03269357|OTHER|LARC forward structured contraceptive counselling|Training of health care providers (HCPs), use of information material and counselling tools
215049859|NCT01990976|DEVICE|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
215049860|NCT01990976|PROCEDURE|Biopsy|biopsy of the vastus lateralis muscle
214295210|NCT03027726|BEHAVIORAL|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
214295211|NCT03027726|OTHER|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
214295212|NCT01606345|DRUG|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
214295213|NCT01913912|DRUG|LDX.|"In this study 3 different doses of LDX will be used:~* 30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~* 50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~* 70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
214295214|NCT01913912|DRUG|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
214295215|NCT01913912|DEVICE|computer task (Go/No-Go task)|
214295216|NCT01913912|DEVICE|EEG|event-related potentials (ERP) and heart rate measurements
214295217|NCT01913912|DEVICE|pupil size measurements (by using eye tracking)|
214295218|NCT05156489|DEVICE|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28±4) and at visit 4 (day 56±4) into vestibule, following the IFU of the device.
214295219|NCT00743314|OTHER|screening questionnaire administration|
214295220|NCT00743314|PROCEDURE|computed tomography|
214295221|NCT00743314|PROCEDURE|lymphoscintigraphy|
214295222|NCT00743314|PROCEDURE|single photon emission computed tomography|
214295223|NCT00743314|RADIATION|intensity-modulated radiation therapy|
214295224|NCT00743314|RADIATION|technetium Tc 99m sulfur colloid|
214295225|NCT04161560|DRUG|Cetuximab-IRDye800|does of Cetuximab-IRDye800
214295226|NCT05266742|OTHER|web based education|"An educative website was created for our study. The content of the website was accessible from www.diyabet.mumcu.net and the content of the website was brought together by scanning the literature. The content text was quoted from publicly available information and guides as ADA and IDF."
214295227|NCT00815009|BEHAVIORAL|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
214295228|NCT00815009|BEHAVIORAL|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
214295229|NCT00815009|BEHAVIORAL|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
214295230|NCT01491503|DRUG|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
214295231|NCT01491503|DRUG|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
214295232|NCT01491503|DRUG|Montelukast & levocetirizine|Montelukast sodium 10mg \& levocetirizine dihydrochloride 5mg PO. Single dose.
214295233|NCT03059654|PROCEDURE|tracheostomy|
214295234|NCT03414723|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
214295235|NCT03414723|DRUG|Ramipril|"Pharmaceutical form: tablets~Route of administration: oral"
214295236|NCT04961554|OTHER|loco-regional anesthesia|demonstrate that the mouth opening (measured in millimeters) of a patient treated for mandibular surgery with a very limited opening (defined by a threshold less than 20mm, not allowing the passage of a video laryngoscope blade per route buccal) is more important after locoregional anesthesia of the V3 than before anesthesia.
214668317|NCT02475200|DEVICE|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
214295237|NCT03388294|BEHAVIORAL|Parents and Infants Engaged|A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
214295238|NCT01409655|BEHAVIORAL|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
214295239|NCT00989339|DRUG|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
214295240|NCT00875251|DEVICE|body composition|Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
214295241|NCT01259323|BIOLOGICAL|REGN668|Dose 1: REGN668 or placebo
214295242|NCT01259323|BIOLOGICAL|REGN668|Dose 2: REGN668 or placebo
214295243|NCT01259323|BIOLOGICAL|REGN668|Dose 3: REGN668 or placebo
214295244|NCT02978261|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
214295245|NCT02018328|DIETARY_SUPPLEMENT|Curcumin|
214477965|NCT03419052|BEHAVIORAL|MIND foods|"The MIND diet (created by the Rush Aging \& Memory group) specifically emphasizes foods high in polyphenols such as berries, nuts, cocoa, black beans, olive oil, and green leafy vegetables. Participants select these foods from the digital study application and receive them through home delivery."
214890891|NCT03972345|DRUG|Norditropin® FlexPro®|Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
214890892|NCT07015957|BEHAVIORAL|In-person training|An in-person educational session.
214890893|NCT07015957|BEHAVIORAL|Virtual training|A virtual educational session.
214890894|NCT07015957|BEHAVIORAL|Coaching|Short video vignettes plus reinforcing messages
214890895|NCT07015957|BEHAVIORAL|Prompts|Visual aide to remind providers to vaccinate.
214890896|NCT07017517|DEVICE|Motomed Letto® servo-assisted cycling + standard physiotherapy|Servo-assisted cycling using the Motomed Letto® device with a cadence target of 30 revolutions per minute (rpm), performed for 60 minutes twice daily for 7 days. This intervention is administered in addition to standard ICU physiotherapy to critically ill patients at risk of critical illness myopathy (CIM).
214890897|NCT07017517|BEHAVIORAL|Standard physiotherapy|Standard physiotherapy including mobilization and passive/active range-of-motion exercises, delivered during routine ICU care for 7 days.
214890898|NCT07021547|DRUG|LY3867070|Administered orally
214890899|NCT07021547|DRUG|Placebo|Administered orally
214890900|NCT06691984|DRUG|Xaluritamig|Short-term IV infusion
214890901|NCT06691984|DRUG|Abiraterone|Oral tablets
214890902|NCT06691984|DRUG|Enzalutamide|Oral tablets
214890903|NCT06691984|DRUG|Cabazitaxel|IV infusion
214890904|NCT04567420|DRUG|Palbociclib|4 week cycles
215057351|NCT03174626|BEHAVIORAL|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
214295246|NCT04711408|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted displa|"For the study group, virtual reality content will be administered to the participant for the duration of the examination through a head-mounted display, RelieVRTM. The VR content for the trial will be swimming with dolphins."
214295247|NCT02299700|OTHER|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
214668318|NCT04561180|DRUG|EG-009A|Administered as an Intramuscular injection
214890905|NCT04567420|DRUG|Fulvestrant|4 week cycles
214890906|NCT04567420|DRUG|Adjuvant Therapy|Standard of Care
214890907|NCT06700343|DRUG|Ocrelizumab (US)|IV infusion
214890908|NCT06700343|DRUG|Ocrelizumab (EU)|IV infusion
214890909|NCT06700343|DRUG|ABP 692|IV infusion
214890910|NCT07031336|DEVICE|Photon-counting CT|The participants will receive a photon-counting CT scan as part of this protocol.
214890911|NCT07031336|DEVICE|Energy-integrating CT|The participants will receive an energy-integrating CT scan as part of the main study (NCT00608764).
214890912|NCT06694389|BIOLOGICAL|mRNA-1083|Suspension for injection
214890913|NCT06694389|OTHER|Placebo|0.9% sodium chloride suspension for injection
214890914|NCT06694389|BIOLOGICAL|Licensed Influenza Vaccine|Aqueous injectable (SC) or suspension for injection (IM)
214890915|NCT06694389|BIOLOGICAL|SARS-CoV-2 Vaccine|Suspension for injection
214890916|NCT05722418|BIOLOGICAL|CB-011|CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
214890917|NCT07032909|BEHAVIORAL|comfortable reading mode|Subjects are asked to read a terminal display device for 45 minutes, featuring texts with different reading mode treatments. Specifically, they will read the same text content for 45 minutes with different background and text color. The participants will complete a total of 4 sets of tests in a random order.
214890918|NCT06713837|DRUG|High intensity therapies|"* High and intermediate dose Cytarabine~* Mitoxantrone - Etoposide - Cytarabine (MEC)~* fludarabine - cytarabine - idarubicin - G-CSF (FLAG-IDA)~* cladribine - high dose cytarabine (2CDA+HDAraC)~* mitoxantrone - intermediate dose cytarabine (MiDAC)~* fludarabine - amsacrine - cytarabine (FLAMSA)~* Mitoxantrone - Intermediate-dose Cytarabine (HAM)~* 3+7 (cytarabine and daunorubicine or idarubicine)"
214295248|NCT03799770|DIAGNOSTIC_TEST|Optic nerve sheath diameter by ultrasound at 5 minutes post-reperfucion|"Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the ﬁnal ONSD value was calculated by average 4 measured values.~We measured the ONSD at 4 timings: (T1) Post induction and before surgical incision, (T2) Portal vein clamping, (T3) 5 minutes after reperfusion, and (T4) 30 min after reperfusion."
214295249|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level|50g added sugar
214890919|NCT06713837|DRUG|Low intensity therapies|"* Venetoclax+hypomethylating agent (decitabine, azacitidine)~* Venetoclax+low dose cytarabine~* Gilteritinib alone or in combination with low dose hypomethylating agent or low dose cytarabine~* 2CDA 5mg/sqm + low dose cytarabine~* Glasdegib+low dose cytarabine~* Ivosidenib alone or in combination with low dose hypomethylating agent or low dose cytarabine~* Single agent Gemtuzumab or Gemtuzumab in combination with alone or in combination with low dose hypomethylating agent or low dose cytarabine"
214295250|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + one serving sugar sweetened beverage|90 grams added sugar
214295251|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + two servings sugar sweetened beverage|130 grams added sugar
214295252|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + three serving sugar sweetened beverage|170 grams added sugar
214295253|NCT01065623|DRUG|BAY79-4620|1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
214890920|NCT07037433|DRUG|Maridebart Cafraglutide|Maridebart cafraglutide will be administered SC.
214890921|NCT07037433|DRUG|Placebo|Placebo will be administered SC.
214890922|NCT07035288|DEVICE|EAM based Pulmonary Vein Isolation|"20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to EAM by means of the PulseSelect catheter.~Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed"
214890923|NCT07035288|DEVICE|Fluoro based pulmonary vein ablation|"20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to Fluoroscopy by means of the PulseSelect catheter.~Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed"
214890924|NCT07030127|DRUG|LY3985863|Administered SC
214890925|NCT07030127|DRUG|Placebo|Administered SC
214890926|NCT07037459|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be administered SC.
214890927|NCT07037459|DRUG|Placebo|Placebo will be administered SC.
214890928|NCT07123480|BEHAVIORAL|Usual Care Group|Standard of care to encourage cardiac rehabilitation attendance.
214890929|NCT07123480|BEHAVIORAL|More Support and Tools|More Support and Tools includes the following: monetary incentive, text messages, case management, and physical activity coaching. The investigators will start providing support and tools while patients are still in the hospital and continue this support weekly after discharge. Intervention participants will receive a monetary incentive both in the hospital and upon attending cardiac rehabilitation. The support (case management) and tools (physical activity coaching and text messages) will continue for up to 3 months or until the individual attends cardiac rehabilitation, whichever occurs first. Participants can decline any or all support or tools.
214890930|NCT05518084|OTHER|Liponovo tissue product|Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
214890931|NCT06702969|DEVICE|Intra oral scanner|Immediate implant placement with customized healing abutment and after three months placement all ceramic crown by digital impression using intra oral scanner
214890932|NCT06702969|DEVICE|impression analog|Immediate implant placement with customized healing abutment and after three months placement of all ceramic crowns by conventional impression
214890933|NCT07035093|DRUG|Retatrutide|Administered SC
214890934|NCT07035093|DRUG|Placebo|Administered SC
214890935|NCT06881992|DRUG|Ersodetug|Ersodetug (9 mg/kg) + SOC
214890936|NCT06881992|DRUG|Ersodetug|Ersodetug (9 mg/kg) + SOC
214890937|NCT06881992|DRUG|Placebo|Placebo (9mg/kg) + SOC
214890938|NCT06884462|RADIATION|High-intensity laser (HIL)|The wavelength measured 1064 nm, accompanied by a power output of 5.00 W. The frequency employed was 25 Hz
214890939|NCT06884462|PROCEDURE|moderate-intensity aerobic exercise|walking on a treadmill at a speed of 3-4 miles per hour on a flat surface (0% incline) for 40 minutes, 3 times weekly over eight weeks
214295254|NCT02200445|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
214890940|NCT06712082|DRUG|PF-07264660|PF-07264660 solution for injection (single use only)
214295255|NCT03334903|DRUG|Gabapentin|600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
214295256|NCT00700661|DRUG|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
214890941|NCT06712082|OTHER|Placebo|Placebo solution for injection (single use only)
214890942|NCT06887192|DRUG|ML-007C-MA|ML-007C-MA dosed as 105/1.5 mg (one tablet of 105/1.5 mg ML-007C-MA), or 210/3 mg (two tablets of 105/1.5 mg ML-007C-MA )
214890943|NCT06887192|DRUG|Placebo|Placebo Tablets
214890944|NCT07038369|DRUG|ATV-1601|"Drug: ATV-1601~• Oral ATV-1601"
214890945|NCT07038369|COMBINATION_PRODUCT|ATV-1601 + Fulvestrant|"Drug: ATV-1601~* Oral ATV-1601 Drug: Fulvestrant~* Intramuscular Injection"
214890946|NCT06619769|BEHAVIORAL|eSense-Cancer CBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer CBT is an online, cognitive behavioural therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer CBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
214890947|NCT06619769|BEHAVIORAL|Navigator support for eSense-Cancer|The eSense digital health tool has been previously tested alongside the support of treatment navigators - trained undergraduate students, not licensed therapists, who provide encouragement and answer any questions users may have as they work through eSense.
214890948|NCT06619769|BEHAVIORAL|Behavioral: eSense-Cancer MBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer MBT is an online, mindfulness-based therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer MBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
214890949|NCT06628947|OTHER|Placebo (Sterile Saline or Balanced Salt Solution)|A control 50 μl injection of clear sterile saline or balanced salt solution (BSS) liquid.
214890950|NCT06628947|DRUG|100 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
214890951|NCT06628947|DRUG|50 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
214890952|NCT06728423|OTHER|Temporary target during an anaerobic training session|Temporary target during an anaerobic training session
214890953|NCT06728423|OTHER|SmartGuard during an anaerobic training session|SmartGuard during an anaerobic training session
214890954|NCT06924970|DRUG|Tebapivat|Oral tablets.
214890955|NCT06924970|DRUG|Tebapivat Matched Placebo|Oral tablets.
214890956|NCT07046923|DRUG|LY4175408|IV infusion
214890957|NCT03875547|DRUG|Refixia®|Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
214890958|NCT01650701|DRUG|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
214890959|NCT01650701|DRUG|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
214890960|NCT01650701|DRUG|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
214890961|NCT01650701|DRUG|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
214890962|NCT01650701|DRUG|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
214890963|NCT06730633|BEHAVIORAL|Heart Matters|Heart Matters is a lifestyle modification intervention guided by the theory of planned behavior. Designed to mitigate cardiovascular disease risk factors, the program strives to help participants consume nutritious foods, engage in a more active lifestyle, lose weight and lower their systolic or diastolic blood pressure. Lifestyle modifications can include weight loss, a reduction in percent calorie fat consumption and total sodium intake, improving diet and increasing physical activity, and reducing daily alcoholic beverage consumption.
214890964|NCT07041203|DRUG|sodium oxybate|Oral administration of sodium oxybate (1.5g, 2.0g, 2.5g, 3.0g)
214890965|NCT06732440|BEHAVIORAL|Subthreshold Vestibular Conditioning|The subthreshold vestibular conditioning protocols will be performed while seated on a motion platform in a dark room. A 0.5Hz whole-body tilt conditioning stimulus will be delivered. The stimulus will consist of whole-body sinusoidal motions (similar to those used when measuring tilt perceptual thresholds) delivered at 57.4% of the measured baseline threshold (e.g., 0.574°/s for a 1 °/s threshold); the frequency (0.5Hz) was chosen to match the baseline threshold tasks. The participants and experimenter will be blinded to the nature of the condition and will be informed that while the chair may vibrate or move slightly, the motion will not occur in any particular direction. Music, audiobooks, or podcasts of the subject's choosing will be played to further discourage attention to the conditioning stimulus.
214890966|NCT06732440|BEHAVIORAL|Balance Training|Balance training will consist of progressive exposure to continuous pseudorandom platform perturbations delivered using a 6DoF motion platform. Participants will stand on a MOOG hexapod motion platform and will be secured using a safety harness tethered to the ceiling and a full enclosure of safety rails. Balance training will be progressed by (a) gradually increasing the number of degrees of freedom (e.g., 1DOF to 6DOF) in the perturbation, (b) removing visual cues, (c) narrowing the base of support, and (d) increasing the amplitude, velocity, and/or acceleration of the platform motion. In the event that subject experiences a loss of balance, the level of difficulty will be modified accordingly. Each balance training block will include 5 minutes of perturbations followed by 3 minutes of rest, repeated 5 times for a total of 40 minutes of training.
214890967|NCT06731907|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg IV Infusion.
214890968|NCT06731907|DRUG|Carboplatin|Carboplatin IV infusion AUC5 or 6 mg/mL•min and not exceeding 900mg.
214890969|NCT06731907|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion.
214890970|NCT06731907|DRUG|Nab-paclitaxel|Nab-paclitaxel 100mg/m\^2 IV infusion.
214890971|NCT06731907|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2 IV infusion.
214890972|NCT06731907|BIOLOGICAL|HER3-DXd|HER3-Dxd 5.6mg/kg IV infusion.
214890973|NCT05703269|RADIATION|single fraction stereotactic radiosurgery (SSRS)|SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions.
215057352|NCT03174626|OTHER|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
214295257|NCT00700661|DRUG|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
214295258|NCT05782608|DRUG|IV ibuprofen|Group 1 will receive IV ibuprofen 400mg \\ 6 hours the first dose will be administrated immediately post operative.
214295259|NCT05782608|DRUG|IV ketorolac|Group 2 will receive 20 mg IV ketorolac\\ 6 hours the first dose will be administrated immediately post operative
214295260|NCT04649125|RADIATION|dose escalation|single fraction dose escalation to the tumour
214295261|NCT03517761|BIOLOGICAL|Bone Marrow Concentrate treatment|While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.
214295262|NCT03517761|OTHER|Sham Control|Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
214295263|NCT04767204|BEHAVIORAL|peer co-delivered vocational rehabilitation service|The services provided by the trained peers in the work training or problem-solving group, which integrates into a supported employment services
214295264|NCT03572140|DIAGNOSTIC_TEST|RAVS In relapsed and resistent cases|assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen
214295265|NCT00121550|DRUG|clarithromycin|
214295266|NCT02549183|DEVICE|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
214295267|NCT04138420|DRUG|Bevacizumab Injection|Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
214295268|NCT04365920|COMBINATION_PRODUCT|Recovery Management Checkups (RMC)|"The RMC model was designed to improve treatment linkage, engagement, and long-term treatment retention. The conceptual framework was based on the public health theory of chronic disease management, which utilizes ongoing assessment and monitoring through regular face-to-face checkups and early (re)intervention to facilitate detection of relapse, reduce the time to treatment re-entry, and consequently, improve long-term outcomes. The original RMC model includes: 1) a fixed schedule of face-to-face quarterly checkups to assess need for SUD treatment, 2) personalized feedback based on an assessment and motivational interviewing to increase treatment motivation, 3) problem solving around barriers to treatment access and retention, and 4) assistance with scheduling and linkage to treatment. Individuals were deemed to be in need of treatment if they reported weekly, or more frequent, substance use since the last checkup, any past-month SUD symptoms, or self-perceived need for treatment."
214295269|NCT04365920|COMBINATION_PRODUCT|RMC-Adaptive|"Participants in the RMC-Adaptive group will receive face-to-face monthly checkups during the first 2 months post-release with additional face-to-face checkups dependent upon the participant's progress. Based on the data presented in the prior section, as long as participants need treatment, they will receive monthly checkups.~In addition, for every checkup that a participant does NOT need treatment, the number of months before the next checkup will be increased by 1 month (e.g., after 2 checkups without need, they will receive the next checkup 2 months later, after 3 it will be 3 months, after 4 it will be 4 months, and so on). Based on these decision rules, individuals who have NO treatment need over 24 months will still receive 5 checkups."
214295270|NCT03723928|OTHER|Usual care disease monitoring|Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
214295271|NCT03723928|OTHER|Serum Tumor Marker directed disease monitoring|Serum tumor markers every 4-8 weeks without imaging
214295272|NCT03723928|OTHER|Quality-of-Life Assessment|Ancillary studies
214477966|NCT03419052|BEHAVIORAL|Cognitive training control|Control training is provided by the Internet-based BrainHQ program from Posit Science, Inc.These are inert games such as tic-tac-toe, connect 4, battleship, etc.
214295273|NCT03723928|OTHER|Anxiety Questionnaire Administration|Ancillary studies
214295274|NCT04870762|OTHER|Best Practice|Receive standard of care
214295275|NCT04870762|OTHER|Medical Device Usage and Evaluation|Wear 3D printed oral stent
214295276|NCT04959279|OTHER|ED-TREAT|Patients will be assessed and treated based on a clinical decision support system.
214295277|NCT04267926|DRUG|20 mg MitoQ|a third of subject will receive 20mg of oral MitoQ
214295278|NCT04267926|DRUG|Placebo|Subject will receive Placebo
214890974|NCT05703269|RADIATION|fractionated stereotactic radiosurgery (FSRS)|FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
214890975|NCT06919809|DEVICE|A microsurfaced ADM (acellular dermal matrix)|X A-DERM™ ADM has been resurfaced (Microsurfaced) instead of currently utilized smooth surface reconstructive grafts. Microsurfacing of regenerative tissue grafts increases the surface area at the graft-to-host interface and results in quicker absorption of blood into the graft, greater cellular infiltration, improved seal and wound bed preparedness.
215057353|NCT02802293|DEVICE|repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver repetitive electromagnetic pulses in this research study's treatment of major depressive disorder.
214295279|NCT04267926|DRUG|40mg of MitoQ|a third of subjects will receive 40mg of MitoQ
214295280|NCT05177419|DRUG|Lysergic Acid Diethylamide|100 micrograms LSD base
214295281|NCT05177419|DRUG|Lysergic Acid Diethylamide|Low dose of LSD base
214295282|NCT00459173|DRUG|rimonabant (SR141716)|
214295283|NCT00001339|DRUG|doxorubicin, vincristine, and etoposide with mitotane|
214295284|NCT02932033|PROCEDURE|Tack fixation of mesh|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
214477967|NCT03419052|BEHAVIORAL|Control foods|Foods contain low polyphenols. Participants select these foods from the digital study application and receive them through home delivery.
214668319|NCT04561180|DRUG|EG-009A Placebo|Administered as an Intramuscular injection
214295285|NCT02932033|PROCEDURE|Synthetic glue fixation|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
214295286|NCT01346839|BEHAVIORAL|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
214295287|NCT01988259|PROCEDURE|Bilateral approach for Laminoplasty|Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
214295288|NCT01988259|PROCEDURE|Unilateral approach for laminoplasty|Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
214295289|NCT01988259|PROCEDURE|Subperiosteal approach for foraminotomy|Unilateral subperiostal approach for single level foraminotomy
214890976|NCT07045740|OTHER|PT Navigator|Participants assigned to the intervention group will meet with the PT Navigator withing the first month of starting cancer treatment. Following a one-hour initial assessment, the PT Navigator will follow up every two-three weeks for a total of six sessions. The PT Navigator will administer outcome measures to screen for complications or side effects of treatment. If any complications or side-effects are identified, the PT Navigator will facilitate referrals to other health care practitioners, provide exercise and/or rehabilitation treatment, or provide education and continue monitoring.
214890977|NCT07047326|DRUG|Urokinase thrombolysis|The intravenous thrombolysis group was administered urokinase dissolved in 100 mL of saline via continuous intravenous infusion for 30 min, and the treatment was given within 6 h of stroke onset. The dose escalation plan includes the following increments: 15,000 IU/kg (maximum dose: 1.5 million IU), 20,000 IU/kg (maximum dose: 2.0 million IU), and 25,000 IU/kg (maximum dose: 2.5 million IU).
214890978|NCT07046559|DRUG|LY4066708|Administered IV
214890979|NCT07046559|DRUG|Placebo|Administered IV
214890980|NCT07046559|DRUG|LY4066708|Administered SC
214890981|NCT07046559|DRUG|Placebo|Administered SC
214890982|NCT06740253|DEVICE|Placebo intravaginal ring (IVR)|Antibody-Based Nonhormonal Placebo Contraceptive Intravaginal Ring
214890983|NCT07055165|BEHAVIORAL|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
214890984|NCT07055165|BEHAVIORAL|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
214890985|NCT07054606|DRUG|Perfluorohexyloctane ophthalmic solution|Eligible subjects will receive Miebo up to 4 times bilaterally on Day 1/Visit 1 (1 drop instilled bilaterally by site staff in-clinic while wearing contact lenses and the rest self-administered throughout the remainder of the day while wearing contact lenses). Starting on Day 2, subjects will self-administer the first drop of Miebo bilaterally before inserting contact lenses for the day. Subjects will wait 30 minutes after the first dose of Miebo to insert their contact lenses and will then instill 3 additional drops of Miebo while wearing contact lenses approximately evenly spaced throughout the rest of the day. Subjects will continue to self-administer Miebo QID bilaterally following the dosing schedule from Day 2 for approximately 30 days. Subjects are expected to record daily VAS assessments throughout the study. The VAS assessments will be collected by the sites at Visits 2, 3, and 4.
214890986|NCT07053917|DRUG|Psilocybin (Usona Institute)|Participants will receive psilocybin to test its safety. Secondary outcomes will assess recovery from post-stroke deficits.
214890987|NCT06788912|BIOLOGICAL|Pembrolizumab (neoadjuvant)|Before surgery neoadjuvant Pembrolizumab 200 mg by intravenous (IV) infusion on day 1 of each 21-day cycle for 4 cycles
214890988|NCT06788912|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles
215057354|NCT02802293|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
214295290|NCT01988259|PROCEDURE|Transmuscular approach for foraminotomy|Unilateral transmuscular approach for single level foraminotomy
214295291|NCT03420118|PROCEDURE|Tumour tissue collection|"Depending on the status of disease when participants join the study, a sample of tumour tissue may be collected from:~* A previous surgery for the disease,~* A biopsy for diagnosing the disease,~* Other surgical procedures done for clinical management or possible cancer related complications (e.g., bowel obstruction).~In addition:~* Patients undergoing pre-screening prior to diagnosis will have tumour sample collected at the time of surgery.~* At anytime participants require a biopsy as a part of their cancer care, a sample of that tumour tissue will be collected.~* New biopsies will be done to collect fresh tumour tissue each time participants' disease worsens."
214295292|NCT03420118|PROCEDURE|Blood draws|"Blood samples will be collected at the following different times points:~* All patient undergoing pre-screening for histological diagnosis will have blood samples collected.~* Before starting a new line of treatment for the disease,~* One week after starting a new line of treatment for the disease,~* During treatment, at each radiological assessment (imaging scan) that will be done to check the status of the disease,~* At the time the disease worsens or relapses (comes back)~* During observation/follow-up, at the time of any radiological assessments that will be done to check the status of the disease"
214295293|NCT00473460|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
214295294|NCT00473460|DRUG|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
215057355|NCT05498935|OTHER|CPB time|Cardiopulmonary bypass time
215057356|NCT01484496|BIOLOGICAL|Placebo|Placebo
215057357|NCT01484496|BIOLOGICAL|Belimumab 200 mg SC|Belimumab 200 mg SC
214295295|NCT04345796|DRUG|Carvedilol+Empagliflozin|Group A
214295296|NCT04345796|DRUG|Carvedilol|Group B
214295297|NCT04345796|DRUG|Empagliflozin|Group C
214295298|NCT04345796|DRUG|Placebo|Group D
214295299|NCT05325151|OTHER|Educational Intervention|Receive GCPP intervention videos
214295300|NCT05325151|OTHER|Genetic Counseling|Receive genetic counseling
214295301|NCT05325151|OTHER|Survey Administration|Ancillary studies
214295302|NCT00496093|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
214295303|NCT03590236|OTHER|Graded exposure therapy|Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
214295304|NCT03590236|OTHER|Physiotherapy|Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
214295305|NCT00623727|BIOLOGICAL|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
214890989|NCT06788912|DRUG|Gemcitabine|In squamous tumors Gemcitabine 1000 mg/m\^2 by IV infusion on day 1 and day 8 of each 21-day cycle for 4 cycles.
214890990|NCT06788912|DRUG|Pemetrexed|In nonsquamous tumors Pemetrexed 500 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles
214890991|NCT06788912|DRUG|Sacituzumab tirumotecan|Sacituzumab tirumotecan 4 mg/kg by IV infusion on day 1 of each 14-day cycle for up to 6 cycles
214890992|NCT06788912|DRUG|H1 receptor antagonist|Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
214890993|NCT06788912|DRUG|H2 receptor antagonist|Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
214890994|NCT06788912|DRUG|Acetaminophen (or equivalent)|Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
214890995|NCT06788912|DRUG|Dexamethasone (or equivalent)|Administered as rescue medication 8 -10 mg before Sacituzumab tirumotecan infusion per approved product label
214890996|NCT06788912|DRUG|Carboplatin|AUC 5 mg/mL min or AUC 6 mg/mL min by IV infusion on day 1 of each 21-day cycle for 4 cycles
214890997|NCT06788912|BIOLOGICAL|Pembrolizumab (adjuvant)|After surgery adjuvant Pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for 13 cycles
214890998|NCT06788912|DRUG|Paclitaxel|Paclitaxel 175 or 200 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles.
214890999|NCT06788912|DRUG|Steroid mouthwash (dexamethasone or equivalent)|Administered orally as rescue medication 2-5 mL 4 times daily
214891000|NCT06578728|DRUG|Methotrexate|25mg/mL intralesional injection into nail bed/nail matrix
214891001|NCT06578728|DRUG|Triamcinolone Acetonide 10mg/mL|10mg/mL intralesional injection into nail bed/nail matrix
214295306|NCT00623727|BIOLOGICAL|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
214295307|NCT06299774|OTHER|Emergency care at home|A mobile integrated health paramedic under the direction of a remote emergency care physician will arrive at the patient's home and deliver emergency care.
214295308|NCT06299774|OTHER|Emergency care at a brick-and-mortar emergency department|Standard emergency care delivered in a brick-and-mortar emergency department.
214295309|NCT01978587|DRUG|JTZ-951|
214295310|NCT04748315|OTHER|SEMT(1:1)|Soccer trainning protocolo will be performed on an work to rest ratio 1:1 and the trainning volume will consist of 1 set and 6 repetitions per set
214295311|NCT04748315|OTHER|SEMT (1:3)|Soccer trainning protocolo will be performed on an work to rest ratio 1:3 and the trainning volume will consist of 1 set and 6 repetitions per set
214295312|NCT04900688|DEVICE|LithoVue Elite|LithoVue Elite is a disposable flexible ureteroscope that offer novel pressure sensory capacity
214295313|NCT02428881|DRUG|onabotulinumtoxinA|Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
214295314|NCT00002670|DRUG|chemotherapy|
214295315|NCT00002670|DRUG|cisplatin|
214295316|NCT00002670|RADIATION|low-LET cobalt-60 gamma ray therapy|
214295317|NCT00002670|RADIATION|low-LET electron therapy|
214295318|NCT00002670|RADIATION|low-LET photon therapy|
214295319|NCT04821206|DRUG|DMARDs|New Initiation of a DMARDs
214295320|NCT04821206|DRUG|biologic DMARDs|New Initiation of a biologic DMARDs
214295321|NCT04821206|DRUG|JAK Inhibitor|New Initiation of a JAK Inhibitor
214295322|NCT01758783|DRUG|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
214295323|NCT00925418|PROCEDURE|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
214295324|NCT00501293|DRUG|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
214295325|NCT04571775|DEVICE|Qi-Shield user group|real device Qi-Shield (treatment)
214295326|NCT04571775|DEVICE|Sham Qi-Shield user group|sham device (placebo)
214295327|NCT00876954|PROCEDURE|Normothermia|Warming without increase in core temperature
214295328|NCT00876954|PROCEDURE|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
214295329|NCT06245590|DRUG|Albumin|20 grams/ week Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90).
214295330|NCT06245590|DRUG|Midodrine|Midodrine
214295331|NCT06245590|OTHER|Standard of Care|Standard of Care
214295332|NCT02013648|DRUG|Dasatinib|
214295333|NCT02013648|DRUG|Cytarabine|
214295334|NCT02013648|DRUG|Daunorubicin|
214295335|NCT02013648|DRUG|Idarubicin|
214668320|NCT04561180|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
214891002|NCT06578728|DRUG|Saline|saline intralesional injection into nail bed/nail matrix
214891003|NCT06746883|OTHER|Non-interventional|Non-interventional
214891004|NCT07058974|DRUG|lamivudine|Lamivudine (Epivir) is a drug used typically to treat HIV and Hepatitis B Virus (HBV). It has not been studied when given in combination with spermidine.
214891005|NCT07058974|DRUG|rapamycin|Rapamycin (Rapamune, Sirolimus) is an FDA-approved drug and indicated for use as an immune modulator.
214295336|NCT01459965|PROCEDURE|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
214295337|NCT01459965|PROCEDURE|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
214295338|NCT03558399|OTHER|FET according to ERA|Single euploid FET will be performed at the time indicated by the ERA test results.
214891006|NCT07058974|BEHAVIORAL|Exercise Regimen|All experimental groups will receive an exercise regimen combining high-intensity interval training (HIIT) (targeting aerobic fitness) and resistance training (targeting strength and skeletal muscle mass preservation). The HIIT exercise component will consist of 2 sessions per week totaling 20 minutes per session. The resistance training component will consist of 3 sessions per week totaling 40 minutes per session.
214891007|NCT07058974|DIETARY_SUPPLEMENT|Spermidine|Spermidine is a polyamine that forms naturally in plants, animals, and microorganisms as a byproduct of protein breakdown. Participants will take an oral dosage of 2mg/day for 180 days.
214295339|NCT03558399|OTHER|FET according to standard protocol|Single euploid FET will be performed according to our standard FET protocol.
214477968|NCT05646680|PROCEDURE|two step adnexectomy|instead of standard resection of salpinx and ovary, they are now separately excised
214891008|NCT07057557|OTHER|Aloe Vera Gel Dressing|Participants in this arm will receive Aloe Vera gel applied directly to the split-thickness skin graft (STSG) donor site immediately after graft harvesting. The Aloe Vera gel will be applied in a sterile manner, followed by secondary dressing with dry gauze and crepe bandage. Pain will be assessed on postoperative day 7 using the Visual Analogue Scale (VAS).
214891009|NCT07057557|OTHER|Paraffin-Based Tulle Dressing|Participants in this arm will receive a conventional paraffin-based tulle dressing impregnated with chlorhexidine applied to the STSG donor site. The dressing will be followed by secondary coverage with dry gauze and crepe bandage. Pain will be assessed on postoperative day 7 using the Visual Analogue Scale (VAS).
214891010|NCT06753955|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
214891011|NCT06753955|DRUG|Intravenous immunoglobulin (IVIG)|Administered as background treatment prior to the investigational product
214891012|NCT03258580|DEVICE|Medoc thermal stimulator|Heat pain stimulation for substudy 1
214891013|NCT03258580|DEVICE|Electric shock stimulator|Electric pain stimulation for substudy 1
214891014|NCT03258580|DEVICE|Cold water bath|Cold pain stimulation for substudy 1
214891015|NCT03258580|BEHAVIORAL|Pain assessment performance feedback|Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
214891016|NCT06492291|DRUG|Enlicitide Decanoate|Oral tablet
214891017|NCT06748976|OTHER|Positive sham neurofeedback|Participants receive simulated positive reinforcement feedback designed to mimic successful modulation of EEG alpha rhythms, despite the feedback not being directly based on their actual neural activity. This condition aims to create the perception of improved attentional control.
214891018|NCT06748976|OTHER|Negative sham neurofeedback|Participants receive simulated negative reinforcement feedback that mimics unsuccessful modulation of EEG alpha rhythms, regardless of their actual neural activity. This condition is intended to simulate reduced attentional control.
214295340|NCT06110988|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
214295341|NCT06268093|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
214295342|NCT00353405|BEHAVIORAL|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
214295343|NCT00353405|BEHAVIORAL|Mass media|Mass media provides messages that support sexual health skills.
214295344|NCT00353405|BEHAVIORAL|Control|Control group received no social skills training and no media mass media messages.
214295345|NCT02101645|PROCEDURE|Periodical low intensity direct current (LIDC) stimulation of wound.|Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
214477969|NCT05045820|DEVICE|needling acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis."
214295346|NCT02101645|PROCEDURE|Compression therapy of swollen limbs.|Compression bandage is used for reducing swelling of the limbs.
214295347|NCT04851886|DEVICE|BURT|Robot-assisted upper-limb individual (i.e. one-on-one) rehabilitation will be delivered using the BURT system by Barrett Technology
214295348|NCT04851886|DEVICE|BURT + PostureCheck|Robot-assisted upper-limb group (i.e. up to three subjects) rehabilitation will be delivered using the BURT system by Barrett Technology + PostureChek (a camera-based system to track the quality of the exercises)
214477970|NCT05045820|DEVICE|laser acupuncture|Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
214891019|NCT06748976|OTHER|Control|Participants perform the same attentional task but without receiving any feedback. This condition serves as a baseline to evaluate the effects of the sham neurofeedback interventions on EEG alpha rhythm modulation.
214891020|NCT06721156|DRUG|MK-1167|MK-1167 oral capsule
214891021|NCT06721156|DRUG|Placebo|Placebo oral capsule
214891022|NCT06814145|BIOLOGICAL|Sotatercept|subcutaneous injection
214891023|NCT06890403|BEHAVIORAL|Informational Animation Video|The informational animation video will also take several minutes and will cover human papillomavirus (HPV) disease, address specific concerns when identified, and the importance and safety of HPV vaccines.
215057358|NCT01484496|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
214891024|NCT06890403|BEHAVIORAL|Personal Narrative Video|Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.
215049861|NCT05640362|OTHER|Natural enzymes mouthwash|Natural enzymes mouthwash contains numerous natural protein-enzymes, including lactoferrin, lysozyme, lactoperoxidase, glucose oxidase. These active ingredients were proposed to render this mouthwash to act as salivary substitutes by reinforcing the functions of available saliva, hence reinforcing the immune system in the oral cavity. It was expected to relieve the symptoms in xerostomia patients, and even more if the patients have salivary flow reduction by improving the functions of the limited amount of saliva. The potential mechanisms of action of the mouthwash to treat xerostomia may be related to: (1) lubrication effects to wet the oral mucosal surfaces; (2) antimicrobial properties that will reduce risks of mucosal irritation by infections; (3) absence of alcohol in the mouthwash Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
215049862|NCT05640362|OTHER|Benzydamine mouthwash|Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
215049863|NCT05412043|BEHAVIORAL|Dance therapy|The dance group will attend choreo-based dance therapy which includes both cognitive training to remember the choreo's and motor training to execute them (with and without music). Each session will consist of a ten-minute warm up, dance training and a ten-minute cool down. The participants will be taught three choreographies, which will increase in difficulty level. 1) floor work on a slow rhythm with focus on proprioception, abdominal muscle strength, coordination and working memory. 2) slow paced with a group part and a canon part with focus on working memory, static and dynamic balance and strength. Furthermore, it will require dynamic balance, walking and cognition. 3) higher rhythm and will be danced with a cane which will require more speed, coordination and dual tasking.
215049864|NCT05412043|OTHER|Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability|The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests
215049865|NCT06512610|OTHER|Middle Eastern or North Coast of Africa patients with newly AML|Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia in MENAFC patients
215049866|NCT03159546|DEVICE|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
215049867|NCT02281656|PROCEDURE|Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer|
214295349|NCT02211573|OTHER|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
214295350|NCT02626637|OTHER|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
214891025|NCT06758310|OTHER|Individualized Exercise|Each participant will be prescribed an individualized exercise program related to their fitness testing results and personal interests.
214891026|NCT06766747|OTHER|Intermittent Fasting|Participants in the alternate-day fasting group will receive biweekly telecounseling to ensure adherence to the prescribed dietary plan and to monitor for potential adverse events. During the 12-week weight loss phase, patients are instructed to restrict calories to 75% of usual intake 2 days per week. A daily intake of at least 2 liters of low-energy beverages (water, caffeine- and sugar-free beverages) is generally recommended on fasting days. Usual physical activity is encourage
214891027|NCT06766747|OTHER|Continuous calorie restriction|Participants in the continuous calorie restriction group will receive biweekly nutritional counseling via Telecoaching to ensure adherence to the prescribed dietary plan. Based on weekly caloric intake obtained from the 7-day log, a model menu will be prescribed with a 25% daily calorie restriction divided among 3 meals every day consisting of macronutrient intake, with 20% of energy as fat, 40 to 50% as carbohydrate, and 20 to 30% as protein. They will be instructed to continue their usual physical activity.
214891028|NCT04929041|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214891029|NCT04929041|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214891030|NCT04929041|PROCEDURE|Computed Tomography|Undergo CT
214891031|NCT04929041|PROCEDURE|Echocardiography Test|Undergo ECHO
214891032|NCT04929041|BIOLOGICAL|Ipilimumab|Given IV
214477971|NCT06862778|DIAGNOSTIC_TEST|SERS|Spectroscopic assessment of serum samples from healthy and diabetic patients to identify characteristics for diagnosis.
214477972|NCT05662306|DRUG|Aripiprazole Lauroxil|1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
214891033|NCT04929041|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214295351|NCT02751515|OTHER|Bain De Soliel - Solid|0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
214891034|NCT04929041|BIOLOGICAL|Nivolumab|Given IV
214295352|NCT02751515|OTHER|Untreated skin|One site is patched without treatment as control
214295353|NCT01188694|DRUG|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
214295354|NCT01188694|BEHAVIORAL|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
214295355|NCT01188694|BEHAVIORAL|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
214295356|NCT06429501|DRUG|Bupivacaine/Epinephrine|injection
214295357|NCT06429501|DRUG|Saline|injection
214295358|NCT05098145|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
214295359|NCT01577667|DEVICE|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
214295360|NCT00545857|DRUG|pioglitazone|Pioglitazone daily; dose varies with size
214295361|NCT00545857|DRUG|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
214295362|NCT01104636|DRUG|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
214295363|NCT06061393|DRUG|Venofer 200 MG Per 10 ML Injection|treat anemia with venofer up to 5 doses
214477973|NCT05662306|BEHAVIORAL|Computerized cognitive and functional skills training|Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.
214477974|NCT06862882|BEHAVIORAL|Community-Based Primary Health Care|Mediation between citizens and health workers to allow an orderly and appropriate use of social and health services
214477975|NCT06860620|DRUG|Zinc supplementation plus standard treatment|children were given 5 mg of elemental zinc sulfate as a single daily dose for children less than 4 years of age and 10 mg for children more than 4 years of age for a total duration of 6 months, along with standard therapy.
214891035|NCT04929041|PROCEDURE|Positron Emission Tomography|Undergo PET
214891036|NCT04929041|OTHER|Quality-of-Life Assessment|Ancillary studies
214668321|NCT04561180|DRUG|Dexamethasone|The comparator, Administered as an Intravenous infusion
214891037|NCT04929041|RADIATION|Radiation Therapy|Undergo radiation therapy
214891038|NCT06664619|DRUG|Fp/ABS|Inhalation powder
214891039|NCT06664619|DRUG|FP|Inhalation powder
214891040|NCT06664619|DRUG|ABS|Inhalation powder
214891041|NCT06664619|DRUG|Placebo|Inhalation powder
214891042|NCT07064707|DRUG|Mesalamine|Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.
214891043|NCT07064707|DRUG|Rupatadine|Rupatadine, a dual histamine H1 receptor and platelet-activating factor (PAF) receptor antagonist, has shown promising anti-inflammatory effects beyond its conventional use in allergic conditions
214891044|NCT07067398|BEHAVIORAL|Peer Coaching Delivered Life's Essential 8 Program|This intervention includes structured bi-weekly peer coach (PC) Zoom or telephone sessions and a cardiovascular health curriculum including links to AHA resources. During the 1:1 session, PCs will elicit participants' challenges and successes from the previous week, track progress, and set goals (behavioral targets). PCs will use cognitive training techniques to teach participants how to manage negative thinking and replace it with positive thinking and goal setting. They will be encouraged to work towards these goals and monitor their progress (i.e. getting more physical activity on the job).
214891045|NCT07066176|DRUG|Aspirin|Aspirin 650mg prior mixed meal beverage
214891046|NCT07066176|DIETARY_SUPPLEMENT|Mixed meal beverage|Mixed meal beverage
214891047|NCT06786637|DRUG|Nociceptin Receptor Antagonist (LY-2940094)|Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist LY-2940094. Peak concentrations are achieved 2-4 hours post-administration.
214295364|NCT06061393|DRUG|Ferinject|ferinject 500 mg, once a week for 2 weeks
214295365|NCT05947136|BEHAVIORAL|Interpretation of the results from the detection visit|"\- An interpretation of the results of the detection tests concerning~* the 7 complications of interest assessed at T1, T2, T3 and T4 ;~* the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;"
214295366|NCT05947136|BEHAVIORAL|Explaining detection results and referrals to the patient|"Explanation of results and directions to the patient using plain language;The aims of this call are as follows:~* Clearly explain the results of the detection visit and the action to be taken for each referral;~* Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;~* Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications."
214295367|NCT05947136|BEHAVIORAL|Early medical care through the network|Early, proactive medical care through a network of dedicated healthcare professionals.
214295368|NCT05947136|BEHAVIORAL|Transmission of results from each detection visit to the referring onco-haematologists - Control Group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.
214891048|NCT06786637|DEVICE|DS8R Biphasic Constant Current Stimulator|As part of the fear conditioning task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). This model has been safely implemented in studies within McLean Hospital and Massachusetts General Hospital.
214891049|NCT06589986|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
214891050|NCT06589986|DRUG|Placebo|Placebo matching IV afimkibart. Placebo matching SC afimkibart.
214891051|NCT07072585|PROCEDURE|Biopsy Procedure|Undergo biopsy
214891052|NCT07072585|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214891053|NCT07072585|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214891054|NCT07072585|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214891055|NCT07072585|PROCEDURE|Bone Scan|Undergo bone scan
214891056|NCT07072585|DRUG|Bortezomib|Given IV or SC
214891057|NCT07072585|DRUG|Calaspargase Pegol|Given IV
214891058|NCT07072585|PROCEDURE|Computed Tomography|Undergo CT
214891059|NCT07072585|DRUG|Cyclophosphamide|Given IV
214891060|NCT07072585|DRUG|Cytarabine|Given IT or IV or SC
214891061|NCT07072585|BIOLOGICAL|Daratumumab|Given IV
214891062|NCT07072585|DRUG|Daunorubicin Hydrochloride|Given IV
214891063|NCT07072585|DRUG|Dexamethasone|Given PO or IV
215049868|NCT02281656|PROCEDURE|Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.|
215049869|NCT03375931|BEHAVIORAL|Prayer|If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.
214295369|NCT02187588|DRUG|Eschscholtzia Californica - low dose|
214295370|NCT02187588|DRUG|Eschscholtzia Californica - high dose|
214295371|NCT02187588|DRUG|Ibuprofen|
214891064|NCT07072585|DRUG|Doxorubicin Hydrochloride|Given IV
214891065|NCT07072585|PROCEDURE|Echocardiography Test|Undergo ECHO
214891066|NCT07072585|PROCEDURE|Lumbar Puncture|Under lumbar puncture
214891067|NCT07072585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214891068|NCT07072585|DRUG|Mercaptopurine Oral Suspension|Given PO
214295372|NCT02187588|DRUG|Eschscholtzia Californica - low dose Placebo|
214295373|NCT02187588|DRUG|Eschscholtzia Californica - high dose Placebo|
214295374|NCT02187588|DRUG|Ibuprofen Placebo|
214295375|NCT04538066|DRUG|Bryostatin 1|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
214295376|NCT04538066|OTHER|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
215049870|NCT03375931|BEHAVIORAL|non-prayer|If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
215049871|NCT01913847|DRUG|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
215049872|NCT01913847|DRUG|Placebo|Oral placebo TID for 12 weeks
215049873|NCT01106157|DRUG|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
214295377|NCT05268159|OTHER|Cognitive assessment|Assessment of unilateral spatial neglect, attention, executive functions and memory
214891069|NCT07072585|DRUG|Methotrexate|Given IT or IV or PO
214891070|NCT07072585|DRUG|Methylprednisolone|Given IV
214891071|NCT07072585|DRUG|Nelarabine|Given IV
214891072|NCT07072585|DRUG|Pegaspargase|Given IV or IM
214891073|NCT07072585|PROCEDURE|Positron Emission Tomography|Undergo PET or PET-CT
214891074|NCT07072585|DRUG|Prednisolone|Given PO or IV
214891075|NCT07072585|DRUG|Prednisone|Given PO or IV
214891076|NCT07072585|OTHER|Questionnaire Administration|Ancillary studies
214891077|NCT07072585|RADIATION|Radiation Therapy|Undergo radiation therapy
214891078|NCT07072585|DRUG|Therapeutic Hydrocortisone|Given IT
214891079|NCT07072585|DRUG|Thioguanine|Given PO
214891080|NCT07072585|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
214891081|NCT07072585|DRUG|Vincristine Sulfate|Given IV
214891082|NCT04537871|PROCEDURE|Bioelectric Impedance Analysis|Undergo bioelectric impedance analysis
214891083|NCT04537871|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215049874|NCT01106157|DRUG|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
215049875|NCT01106157|DRUG|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
215049876|NCT04867083|DRUG|ARV bitherapie|"1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day"
215049877|NCT01154335|DRUG|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
214891084|NCT04537871|PROCEDURE|Cardiopulmonary Exercise Testing|Undergo cardiopulmonary exercise test
214891085|NCT04537871|PROCEDURE|Echocardiography|Undergo echocardiogram
214891086|NCT04537871|PROCEDURE|Physical Performance Testing|Undergo physical function tests
214891087|NCT04537871|PROCEDURE|Pulmonary Function Test|Undergo pulmonary function test
214891088|NCT04537871|OTHER|Questionnaire Administration|Ancillary studies
214891089|NCT04537871|PROCEDURE|Ultrasound|Undergo musculoskeletal ultrasound
215049878|NCT01154335|DRUG|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
215049879|NCT01104480|DRUG|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
214891090|NCT06780085|BIOLOGICAL|Raludotatug Deruxtecan|IV Infusion
215049880|NCT06049550|OTHER|no intervention|no intervention
214891091|NCT06780085|BIOLOGICAL|Ifinatamab Deruxtecan|IV Infusion
214891092|NCT06780085|DRUG|Docetetaxel|IV Infusion
214295378|NCT03786016|BEHAVIORAL|8-Days in an Isolation, Confinement Unit|"Subjects will spend 8 days/7 nights continuously in an isolated and confined unit with up to 3 other subjects. Subjects will participate in daily, timed activities such as space-relevant computer simulations, team tasks, and cognitive performance testing. Subjects will also experience altered environmental conditions (such as changes in lighting, sound and ambient temperature) while in the isolation unit. Subjects will receive orders from mission control who will monitor activity in the isolation unit and direct subjects throughout the 8-day study."
214891093|NCT06830746|DEVICE|LBBAP Implant with a CSP ICD Lead|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
214891094|NCT04729959|BIOLOGICAL|Atezolizumab|Given IV
214891095|NCT04729959|PROCEDURE|Biospecimen Collection|Undergo blood sample and tumor tissue collection
214891096|NCT04729959|PROCEDURE|Conventional Surgery|Undergo surgery
214891097|NCT04729959|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FSRT
214891098|NCT04729959|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214891099|NCT04729959|BIOLOGICAL|Tocilizumab|Given IV
214891100|NCT06811545|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Children with CP can have trouble with daily tasks such as walking. This raises their risk of disability as they age into their teens. Current treatments are not very effective. In this study, children with CP will walk on a treadmill while receiving NMES on their lower limb muscles, using surface electrodes, while their gait dynamics are assessed. Our proposed study aims to gather preliminary evidence to support the potential efficacy of NMES assistance to muscles across all lower limb joints during walking, i.e., multi-joint NMES assistance. Additionally, the investigators aim to investigate the optimal level of intensity.
214891101|NCT07067229|DEVICE|Personalized rTMS|Personalized repetitive transcranial magnetic stimulation (TMS) together with mixed-reality (MR) exercise
215049881|NCT01673646|DRUG|Pasireotide LAR|Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
215049882|NCT01899781|DRUG|Antibiotic-Cefamezin|
215049883|NCT05504681|OTHER|Observational study|It takes the patient on average 15 minutes to complete the Brainlab Cognition app.
215049884|NCT06199804|BEHAVIORAL|Toy Hygiene Training|The training was given to the mothers in 2 sessions (morning and afternoon), each lasting approximately 30 minutes, accompanied by the Toy Hygiene Guide. The sessions were presented face to face in the mother's room in the form of explaining, showing, question and answer and power point, at a time convenient for the mother and the child, outside the morning and afternoon treatment and care hours. After the first session was completed, an appointment was made with the mother for the afternoon session. In the second session, the information in the book that was not given in the first session was presented to the mothers face to face in the mother's room, outside the treatment and care hours, at a time convenient for the mother and the child. After the training was completed, a final five-minute discussion was held with the mothers in the form of a general question and answer session. The training book was given to the mothers in the experimental group on the first day.
214295379|NCT02331225|OTHER|No intervention given|There is no intervention for this study
214295380|NCT04814134|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
214295381|NCT04814134|OTHER|Standard of care|Available standard treatment
214295382|NCT05438056|OTHER|education with mobile application|providing training to mothers of premature babies with a mobile application
214295383|NCT00696696|DRUG|Gemcitabine|1000 mg/m\^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
214295384|NCT00696696|DRUG|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
214295385|NCT00696696|DRUG|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
214891102|NCT07067229|DEVICE|Standard rTMS|Standard repetitive transcranial magnetic stimulation (TMS) together with mixed-reality (MR) exercise
214891103|NCT07067229|DEVICE|Sham rTMS|Sham rTMS together with mixed-reality (MR) exercise
214891104|NCT06018129|BIOLOGICAL|GEN3017|Subcutaneous injection
214891105|NCT06782087|DRUG|nano chitosan|nano chitosan
214891106|NCT07075640|DRUG|AG-236|Subcutaneous (SC) Injection
214891107|NCT07075640|DRUG|Placebo|SC Injection
214891108|NCT06928662|DRUG|Decitabine|Given IV
214891109|NCT06928662|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and/or biopsies
214891110|NCT06928662|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and/or biopsies
214891111|NCT06928662|PROCEDURE|Chest Radiography|Undergo chest X-rays
214891112|NCT06928662|DRUG|Cytarabine|Given IV
214891113|NCT06928662|PROCEDURE|Echocardiography Test|Undergo ECHO
214477976|NCT06858852|DRUG|ET-26HCl 0.8mg/kg group|The initial dose was 0.8 mg/kg administered as a single IV infusion over a period of 1 minute ±5 seconds. If needed, up to 50% of the starting dose was increased (30-seconds ± 5-seconds bolus)
214477977|NCT06858852|DRUG|Etomidate Injectable Product 0.3mg/kg group|The initial dose was 0.3 mg/kg administered as a single IV infusion over a period of 1 minute ±5 seconds. If needed, up to 50% of the starting dose was increased (30-seconds ± 5-seconds bolus)
214891114|NCT06928662|BIOLOGICAL|Filgrastim|Given SC
214891115|NCT06928662|DRUG|Fludarabine|Given IV
214477978|NCT06856642|OTHER|Conservative Physical Therapy|"Transcutaneous Electrical Nerve Stimulation (TENS):It is an electrotherapy modality commonly used in pain management. Conventional TENS will be applied to our patients. The frequency of Conventional TENS will be 50 Hz, the pulse duration will be 80 µs, the amplitude will be of mild to moderate intensity as perceived by the patient, and the duration will be 20 minutes.~Hot Pack:It is a superficial heat therapy method commonly used to reduce muscle spasms, increase circulation, and alleviate pain.The packs, which are kept in hydrocollator tanks, will be applied at a temperature that will not harm the patient.The application time is 20 minutes.~Therapeutic Ultrasound:This method, which uses sound waves to support tissue healing, creates heating and healing effects in deep tissues and is commonly used to reduce pain and relieve muscle spasmsThe frequency of the applied ultrasound will be 1 MHz, with an intensity of 1.5 W/cm², and it will be applied for 8 minutes in continuous mode"
214668322|NCT07030569|DRUG|Trastuzumab deruxtecan (DS-8201a)|A subgroup of the study cohort treated with Trastuzumab Deruxtecan in the metastatic setting
214668323|NCT07031609|BEHAVIORAL|Robot-assisted gait training using Lokomat|This intervention involves robotic-assisted gait training with the Lokomat device. Sessions will last 40 minutes, twice a week for 6 weeks. The intervention targets lower extremity motor function in children with spastic hemiparetic cerebral palsy. The robotic system provides adjustable support and real-time feedback to improve gait patterns and mobility.
214891116|NCT06928662|PROCEDURE|Hematopoietic Cell Transplantation|Given via infusion
214891117|NCT06928662|DRUG|Idarubicin|Given IV
214891118|NCT06928662|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214891119|NCT06928662|PROCEDURE|Pheresis|Undergo apheresis
214891120|NCT06928662|RADIATION|Total-Body Irradiation|Undergo TBI
214891121|NCT06928662|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214891122|NCT07074886|DRUG|Ocrelizumab Test Formulation|Ocrelizumab test formulation will be administered as per the schedule specified in the respective arm.
214891123|NCT07074886|DRUG|Ocrelizumab Reference Formulation|Ocrelizumab reference formulation will be administered as per the schedule specified in the respective arm.
214891124|NCT06719141|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
214891125|NCT06719141|DRUG|Placebo|Participants will be administered with matching placebo orally or through G-tube/ PEG tube.
214891126|NCT07079735|DRUG|Letermovir|CMV prophylaxis
214891127|NCT07079735|DRUG|Valganciclovir|Standard therapy for CMV prophylaxis
214891128|NCT06682780|DRUG|LM-2417|Q2W/Q3W,Intravenous Drip
214891129|NCT06682780|DRUG|Docetaxel|Q3W,Intravenous Drip
214891130|NCT06682780|DRUG|Toripalimab/Tirelizumab|Q3W,Intravenous Drip
214891131|NCT06682780|DRUG|Carboplatin|Q3W,Intravenous Drip
214891132|NCT06682780|DRUG|Niraparib|QD,Oral Administration
214891133|NCT06682780|DRUG|Lenvatinib|QD,Oral Administration
214891134|NCT07086131|DEVICE|Powerbreathe|The breathing training will consist of using the PowerBreathe for 12 weeks. The PowerBreathe is an inspiratory pressure threshold trainer. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
214891135|NCT07083011|DRUG|68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)|68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan
214891136|NCT06899750|BEHAVIORAL|E3 Multidisciplinary Team|The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, and nurse working together with patients via a remote monitoring, educational hypertension phone app to overcome barriers to hypertension control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
214891137|NCT06899750|BEHAVIORAL|E3 Self-Guided Hypertension Education Program|Patients will receive timed, mailed educational materials on hypertension self-monitoring, diet and lifestyle modifications to supplement usual clinic-based hypertension care with their primary care doctor. A research assistant will ensure patients have home blood pressure monitors on enrollment, and will remind patients to check their blood pressures and follow-up with their primary care doctors at 3 months and 6 months.
214891138|NCT05196984|DEVICE|GENUS device (Active Settings)|Participants in the active condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to active 40Hz settings for 30-60 minutes.
214891139|NCT05196984|DEVICE|GENUS device (Sham Settings)|Participants in the control condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to sham settings for 30-60 minutes.
214891140|NCT06930638|DEVICE|Ischemic Conditioning|The cuff will be placed around the proximal, non-affected thigh and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
214891141|NCT06930638|DIETARY_SUPPLEMENT|Antioxidant Supplement|MitoQ is an over the counter supplement that increases delivery to the mitochondria. Similar to studies performed in middle age/older adults and individuals with peripheral arterial disease, we will administer 1 single oral dose of 80mg of MitoQ or a placebo pill. As MitoQ reaches peak concentrations at \~40 to 60 minutes after ingestion, we will wait 45 minutes (time matched to Ischemic conditioning).
214891142|NCT07086248|DEVICE|Radiesse|Radiesse injections diluted 1:2 with sterile saline.
214891143|NCT06805773|OTHER|Educational videos|Participants will be provided with four educational videos in clinic prior to their initial medical oncology consult.
214891144|NCT06805773|OTHER|Standard of Care|Participants in the control arm will be provided with the educational videos after their consult with the medical oncologist.
214891145|NCT04729114|DRUG|PRL-02 injection|abiraterone decanoate for intramuscular injection
214295386|NCT04061200|DRUG|Semaglutide, 1.34 mg/mL|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
214295387|NCT04061200|OTHER|Placebo, 1,34 mg/mL|Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
214295388|NCT04061200|DRUG|Empagliflozin 25 MG|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
214295389|NCT05407467|DIETARY_SUPPLEMENT|Curcumin and virgin coconut oil extract (KurCo Smart)|we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
214295390|NCT03026608|BEHAVIORAL|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
214295391|NCT05752201|BIOLOGICAL|Gamma Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
214295392|NCT05752201|BIOLOGICAL|Omicron Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
214295393|NCT05752201|BIOLOGICAL|Bivalent RBD-based ARVAC-CG vaccine|Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
214295394|NCT05752201|OTHER|Placebo (Alum)|Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
214668324|NCT07031609|BEHAVIORAL|Hydrotherapy|Participants will engage in supervised aquatic therapy including structured exercises in a therapeutic pool. Each session lasts 40 minutes, twice a week, for 6 weeks. Exercises include water walking, floating resistance training, jumping, and balance activities designed for children with spastic hemiparetic cerebral palsy to improve strength, coordination, and functional mobility.
214891146|NCT04729114|DRUG|prednisone|Oral dose
214891147|NCT04729114|DRUG|dexamethasone|Oral dose
214891148|NCT04729114|DRUG|enzalutamide|Oral capsule
214891149|NCT07085091|DRUG|ALX2004|ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV Infusion
214891150|NCT07085091|DRUG|ALX2004|ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV infusion
214891151|NCT07085091|DRUG|ALX2004|ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV infusion
214891152|NCT07084818|DEVICE|Reia System pessary self-care management|The Reia-System pessary is an FDA-cleared device to manage pelvic organ prolapse which is collapsible and intended to be more easily removed, with less discomfort.
214891153|NCT07084818|DEVICE|Standard pessary office-based management|These subjects will continue with the current pessary they are using to manage their prolapse, with office-based care.
214891154|NCT06538740|PROCEDURE|Ventilating the patient with lower (40 or 70%) oxygen concentration during the wash out phase, before extubation|The investigated intervention is the application of 70% inspired oxygen compared to 100% inspired oxygen during the anesthetic washout, right before extubation of the patient for the first 24 enrolled patients, and 40% inspired oxygen compared to 100% inspired oxygen for the subsequently enrolled 24 patients. Before and after the intervention EIT measurements are performed at designated time points to assess lung aeration and calculate the center of ventilation. This information allows assumptions on atelectasis formation in the patients' lung.
214891155|NCT07089485|OTHER|effects of sound|The surgical trainees will perform four 15-minute surgical sequences in a controlled environment, with varying sound levels (64, 67, 73, and 75 dB(A)) randomized across the sequences to assess the surgeons' responses.
214891156|NCT04917861|BIOLOGICAL|mRNA-1893|Solution for injection
214891157|NCT04917861|BIOLOGICAL|Placebo|0.9% sodium chloride solution for injection
214891158|NCT06901505|DRUG|Erythropoiesis-Stimulating Agent (ESA)|Administered by intra-venous (IV) infusion.
214891159|NCT06901505|DRUG|Vadadustat|300mg, oral tablets
214295395|NCT05631886|BIOLOGICAL|TP53-EphA-2-CAR-DC|5\~10 × 10\^6 CAR DCs per dose will be administered by intravenous injection.
214295396|NCT05631886|DRUG|Abraxane|Intravenous abraxane 125 mg/m\^2/day on day-5.
214295397|NCT05631886|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
214295398|NCT05631886|DRUG|anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
214295399|NCT05631886|DRUG|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
214891160|NCT06906601|PROCEDURE|magnetic clip localization|magnetic clip localization for preoperative localization for breast cancer surgery
214891161|NCT06906601|PROCEDURE|metallic wire localization.|metallic wire localization for preoperative localization for breast cancer surgery
214891162|NCT06906601|PROCEDURE|Breast cancer surgery|Patient with invasive or in situ breast carcinoma, presenting with a unifocal and unilateral lesion, requiring a first-line breast-conserving treatment with preoperative localization, regardless of the associated lymph node procedure
214891163|NCT07091851|BEHAVIORAL|Group medical visits and home blood pressure monitoring|This arm will receive instructions for home blood pressure monitoring but also be enrolled in group medical visits.
214891164|NCT06887569|BEHAVIORAL|Rewards|Financial rewards for attending therapy
214891165|NCT06887569|BEHAVIORAL|Screening|Information about screening for depression and anxiety
214891166|NCT06389487|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1.
215049885|NCT03541278|PROCEDURE|MIT|periareolar intraparenchymal, high volume and ultrasonographic guidance
215049886|NCT03541278|PROCEDURE|IM-SLNB|IM-SLNB was performed for IMLN visualized patients
214295400|NCT04533308|BEHAVIORAL|Relaxation in virtual reality|Natural 360-degrees scenes from different locations in the world with or without interactions with animals in the virtual reality
214295401|NCT05633524|OTHER|blood sample analysis|All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
214295402|NCT01577823|DEVICE|Foley Catheter|
214295403|NCT04358666|PROCEDURE|surgery and focal radiosurgery of the surgical bed|hypofractionned radiosurgery of the lesion
214477979|NCT06856642|OTHER|Abdominal Draw-in Manuever|Starting Position: The patient lies in a supine position with knees bent and feet flat on the ground. The neck and spine are kept in a neutral position. Breath Control: The patient focuses on abdominal expansion while inhaling and flattening the abdomen while exhaling. Transversus Abdominis Activation: The patient attempts to draw the abdominal muscles inward (pulling the navel toward the spine). During this movement, care should be taken to avoid pressing the lower back against the ground or contracting the hip muscles. The goal is to activate only the deep abdominal muscles. Checking for Proper Muscle Activation: The patient can place their fingertips on the lower abdominal region (just above the pelvic bone) to feel whether the transversus abdominis muscle is activating correctly. Maintaining the Position: The patient holds this activation for 5-10 seconds while continuing to breathe naturally, then relaxes. Muscles should be fully relaxed between repetitions.
214477980|NCT06856642|OTHER|Real-Time Ultrasound Biofeedback with Abdominal Draw-In Manuever|The patient, who has been instructed on the abdominal drawing-in exercise, assumes a supine position with knees bent. The ultrasound screen is positioned so that both the practitioner and the patient can see it. The researcher places the linear ultrasound probe on the patient's transversus abdominis muscle to obtain an image, which is then shown to the patient for awareness. The patient is instructed to keep their eyes on the screen and follow their muscle activity throughout the exercise. During the exercise, the patient's muscle is displayed on the screen, and they are asked to hold the contraction at its maximum level for 10 seconds. After the contraction phase, the patient is instructed to relax and rest for 2 minutes. The treatment is completed with a total of 10 repetitions.
214477981|NCT06858722|DRUG|ripertamab|On Day 1 of the treatment period, an intravenous infusion of Ripertamab at a dose of 375 mg/m² body surface area will be administered.
214477982|NCT06858722|DRUG|Placebo|On Day 1 of the treatment period, an intravenous infusion of Placebo at a dose of 375 mg/m² body surface area will be administered.
214477983|NCT04099732|DRUG|Rosuvastatin|Tablet
214477984|NCT04099732|DRUG|BI 1358894|Tablet
214477985|NCT04099732|DEVICE|Dabigatran etexilate|Capsule
214477986|NCT05565209|OTHER|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
214477987|NCT04822350|DRUG|Avelumab|As provided in real world practice
214668325|NCT07031609|BEHAVIORAL|Conventional Physiotherapy|This intervention includes 20 minutes of faradic electrical stimulation and 20 minutes of therapeutic exercises such as stretching, positioning, range of motion, and gait training. Administered twice a week for 6 weeks. The protocol aims to support neuromuscular activation and improve gait and mobility in children with spastic hemiparetic cerebral palsy.
214891167|NCT04585711|DRUG|Etanercept Optimal dosing|Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
214891168|NCT02914808|OTHER|Patients will undergo a lower limb MRI and blood tests|
214891169|NCT05357170|OTHER|Human feces collection|Oral swab and saliva, human feces collection and blood sampling
214891170|NCT06544499|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
214891171|NCT06544499|OTHER|Placebo IV|Intravenous infusion of placebo
214891172|NCT06392386|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injections
214891173|NCT04599647|BIOLOGICAL|PVSRIPO|PVSRIPO (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
214891174|NCT06353373|OTHER|Application of the modified DeVTEcare system|The modified DeVTEcare system, which incorporates bundled guideline-based VTE prevention measures, will be utilized to assist healthcare providers in VTE prophylaxis after September 2024.
214477988|NCT06671262|RADIATION|SBRT|Target the primary tumor region with a single dose of 8Gy, or deliver a dose of 3Gy to the axillary lymph nodes, administered once a day for three consecutive days.
214477989|NCT06671262|DRUG|Immuno-chemotherapy|Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by epirubicin, cyclophosphamide, and toripalimab for another four cycles.
214477990|NCT06155916|DRUG|Pregabalin|Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.
214477991|NCT05123027|BEHAVIORAL|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|Participants will meet with the PILOT Peer consistently throughout the 6 months of study participation.
214477992|NCT05123027|BEHAVIORAL|Treatment As Usual Peer|Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.
214477993|NCT06544863|OTHER|Data collection and blood sample|In addition to collecting medical data, additional blood samples will be collected in order to create a biological collection and identify biomarkers associated with the occurrence of cirrhosis-related complications, progression to TH and follow-up.
215057359|NCT01645735|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
214477994|NCT06678789|BEHAVIORAL|High Nicotine Dose|Will receive a 5-week supply of 6 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])
214668326|NCT07031882|DEVICE|Liberty Analyzer WBC System|Participants will donate capillary samples to be analysed by the Liberty Analyzer System WBC
214891175|NCT06493383|DEVICE|Lotrafilcon B plano cosmetic contact lenses|Commercially approved colored contact lenses worn for cosmetic purposes to alter or enhance the apparent color of the eye
214891176|NCT06014931|BEHAVIORAL|Telemedicine ICU Recovery Clinic Visit|Multidisciplinary clinic visit that encompasses a medical examination, medication management, neuropsychological exam with focused psychotherapy, case management, and patient-centered consultation.
214891177|NCT05394909|DRUG|Tocilizumab 162Mg/0.9Ml Autoinjector|Patients will receive high-dose pulse intravenous methylprednisolone (500 mg ) for 3 consecutive days (Day 0-1-2) and subsequently will be treated weekly with Tocilizumab 162 mg s.c. for 52-weeks and then following according to SOC
214891178|NCT05419492|DRUG|ETX101|ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
214891179|NCT05790213|DRUG|Androgen Deprivation Therapy (ADT)|ADT will be given for 3 months. Participants will receive a standard ADT as chosen by their study doctor.
214891180|NCT05790213|PROCEDURE|Focal prostate ablation (focal therapy)|Focal prostate ablation (focal therapy) is a surgical procedure to destroy cancer cells by destroying a portion of the prostate instead of the whole prostate.
214891181|NCT04765514|OTHER|Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy)|Temozolomide or Radiotherapy
214295404|NCT00005892|DRUG|cyclophosphamide|
214295405|NCT00005892|PROCEDURE|Allogeneic Bone Marrow Transplantation|
214295406|NCT01138631|DEVICE|Embryoscope|The embryoscope is an incubator with in-built photographic equipment
214295407|NCT00536601|DRUG|etoposide|Given IV
214295408|NCT00536601|DRUG|cyclophosphamide|Given IV
214891182|NCT04765514|COMBINATION_PRODUCT|Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide.|Temozolomide will be administered at a dose of 75 mg/m2 daily for a total of 21 days. This will be followed by adjuvant temozolomide (150-200 mg/m2 daily for 5 day
214295409|NCT00536601|DRUG|carmustine|Given IV
214295410|NCT00536601|DRUG|melphalan|Given IV
214295411|NCT00536601|DRUG|busulfan|Given IV
214295412|NCT00536601|DRUG|carboplatin|Given IV
214891183|NCT05841862|DEVICE|2C-QD|Quantum Dot
214891184|NCT05841862|DEVICE|Sham 2C-QD|Sham Intravitreal Injection
214891185|NCT05616793|BIOLOGICAL|AAV8.hLCA5|Adeno-associated virus vector expressing human LCA5 gene
214891186|NCT02555579|BEHAVIORAL|Dietary Protein Counting and Free Fruits and Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
214295413|NCT00536601|DRUG|thiotepa|Given IV
214891189|NCT04546971|BEHAVIORAL|Brief Intervention|Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking
214295414|NCT00536601|RADIATION|total-body irradiation|Undergo TBI
214295415|NCT00536601|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo ASCT
214295416|NCT00536601|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo tandem ASCT
214295417|NCT02529514|DRUG|Baclofen|25 mg for 7 days at 10 pm every day
214295418|NCT02529514|DRUG|Placebo|Placebo for 7 days at 10 pm every day
214295419|NCT01313767|DRUG|Botulinum toxin type A|Botulinum toxin type A
214295420|NCT01313767|DRUG|Botulinum Toxin type A|Botulinum Toxin type A
214295421|NCT01389544|DRUG|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
214295422|NCT01389544|DRUG|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
214295423|NCT01389544|DRUG|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
214295424|NCT00319917|DRUG|tacrolimus|oral
214891190|NCT04546971|BEHAVIORAL|Telehealth Counseling|5 sessions of counseling on alcohol use based on Motivational Interviewing.
214891191|NCT04546971|BEHAVIORAL|Text messaging|A daily and then monthly text messaging program designed to help participants monitor drinking, set goals, and reinforce successful reduction or abstinence.
214891192|NCT06389396|DEVICE|CP362 Test Catheter|The investigational device is intended to perform TAI procedures together with the CE-marked Peristeen Plus TAI system.
214295425|NCT00319917|DRUG|placebo|oral
214295426|NCT00320983|DRUG|Topotecan|Topotecan
214295427|NCT00320983|DRUG|Cisplatin|Cisplatin
214295428|NCT06280573|COMBINATION_PRODUCT|Wim Hoff method|breathing exercises, cold exposure, and meditation
214295429|NCT01648907|OTHER|Imaging exams|"Radiological examinations:~* Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front~* MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.~Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.~Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.~Biological tests :~* Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.~* Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.~* Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
214295430|NCT02366845|BIOLOGICAL|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
214891193|NCT06525246|DRUG|ONO-7475|Specified dose, once daily
214891194|NCT06525246|DRUG|Osimertinib Mesylate|Specified dose, once daily
214295431|NCT02366845|DIAGNOSTIC_TEST|Pre-Transfusion International Normalized Ratio (INR)|INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.
214295432|NCT02366845|DIAGNOSTIC_TEST|Post-Transfusion International Normalized Ratio (INR)|INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.
214295433|NCT03861715|DIAGNOSTIC_TEST|live birth rate|The blastulation rate and live birth rate according to the protocol of COS
214295434|NCT01453634|DRUG|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
214295435|NCT01453634|DRUG|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
214295436|NCT04466254|DRUG|CPGJ602|Q2W/QW iv
214295437|NCT04466254|DRUG|cetuximab|QW iv
214295438|NCT04733092|DRUG|Lipiodol|Lipiodol in emulsion with contrast agent
214295439|NCT05872672|BEHAVIORAL|Sleep Program|Participants will complete the Headspace Health Sleep Program, which is an 18 day program based on CBTi, and includes the following intervention components: 1) a sleep diary to monitor sleep and associated factors; 2) cognitive interventions to address maladaptive thoughts related to sleep; 3) behavioral interventions to address maladaptive behaviors related to sleep (e.g., sleep hygiene, stimulus control, and sleep restriction); 4) de-arousal techniques (e.g., mindfulness, breathing, and muscle relaxation exercises).
214295440|NCT05872672|OTHER|Waitlist|Participants will continue their regular sleep routines for an 18 day period and will not be assigned to an intervention.
214891195|NCT05989841|BEHAVIORAL|RISE Guide|Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
214891196|NCT05989841|BEHAVIORAL|Relaxation Control|"Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention."
214891197|NCT01894802|DEVICE|Implantation of CRS Arrays|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
214891198|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
214477995|NCT06678789|BEHAVIORAL|Low Nicotine Dose|Will receive a 5-week supply of 3 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])
214891199|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
214891200|NCT05144685|DEVICE|OTX-202|Experimental Pscyhoeducation and Intervention App
214891201|NCT05144685|DEVICE|OTX-000|Other Pscyhoeducation App
215049887|NCT05255692|DIAGNOSTIC_TEST|invasive urodynamic evaluation|Invasive urodynamic evaluation to define maximum cystometric capacity. By means of catheterisation the bladder gets filled and volumes en pressures are measured.
215049888|NCT05255692|DIAGNOSTIC_TEST|functional magnetic resonance imaging during bladder filling|Functional MRI is used to capture brain activity during tasks. The task in the current study is bladder infusion and withdrawal by means of the INFSYS-2 infusion/withdrawal pump (Leitner et al. 2017)
215049889|NCT05796258|DIAGNOSTIC_TEST|NTRK fusion assessment|To evaluate NTRK fusion presence by MCG, Immunohistochemistry or NGS
215049890|NCT00002811|DRUG|liposomal T4N5 lotion|
215049891|NCT05554302|DRUG|18F-Fluciclovine|Patients will receive 5-mCi dose (+/- 20%) of 18F-Fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-Fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-Fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
215057360|NCT01645735|DRUG|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
215057361|NCT05562206|DEVICE|CGMIS (Continuous Glucose Monitoring Infusion Set)|An integrated combination CGM/insulin infusion system
214891202|NCT05144685|BEHAVIORAL|Treatment as Usual|Treatment as usual may include appointments with psychiatrists and other mental health clinicians, suicide risk assessment, supportive listening, crisis resources, clinician assessment, and referral to outpatient treatment.
214891203|NCT00194402|DRUG|Slo-Niacin, atorvastatin|Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
214891208|NCT05839626|DRUG|SAR445514|Powder for solution for injection. Sub Cutaneous administration.
214891209|NCT04479852|DRUG|SP-624|Oral capsule
214891210|NCT04479852|DRUG|Placebo|Oral capsule
214891211|NCT05342675|PROCEDURE|Rapid Rollover|Repositioning of the participant post biopsy
214891212|NCT06475703|DEVICE|Isla wound prioritisation module|The intervention group will use the artificial intelligence enabled platform with the new wound prioritisation module for 30 days after surgery in addition to standard post-operative wound follow-up care for 60 days after surgery.
214891213|NCT06475703|OTHER|Standard follow-up|Standard care, mapped during the economic scoping exercise may include; out-patient appointments, advised to contact GP, or no follow-up.
214891214|NCT00001521|DRUG|Fludrocortisone|Mineralocorticoid needed to replace aldosterone deficiency. Patients will continue to receive an optimal fludrocortisone dose
214891215|NCT00001521|DRUG|Hydrocortisone|Glucocorticoid needed to replace cortisol deficiency. Reduced hydrocortisone dose might normalize the growth and adult stature of children with congenital adrenal hyperplasia
214891216|NCT00001521|DRUG|Letrozole|Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.
214891217|NCT00001521|DRUG|Flutamide|Non steroidal anti-androgen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol
214891218|NCT00001521|DRUG|Testolactone|Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.
214891219|NCT03089710|OTHER|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
214891220|NCT00865761|DRUG|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
214891221|NCT00865761|DRUG|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under fasting conditions
214891222|NCT00108004|DRUG|pramlintide acetate|Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
214891223|NCT05516186|OTHER|Scapular-focused exercise protocol with EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol with the aid of the electromyographic biofeedback
214891224|NCT05516186|OTHER|Control Therapy|manual and exercise therapy
214891225|NCT05516186|OTHER|Scapular-focused exercise protocol without EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol
214891226|NCT05846035|DIAGNOSTIC_TEST|Triphasic C.T abdomen and pelvis|for cirrhotic patients to ensure hepatocellular carcinoma
214891227|NCT05596656|DIAGNOSTIC_TEST|skin prick test|"Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet."
214891228|NCT02413567|DEVICE|DMR Procedure (Fractyl)|Endoscopic procedure
214891229|NCT01917682|PROCEDURE|CorPath-assisted Percutaneous Coronary Intervention|Robotic-assisted Percutaneous Coronary Intervention
214891230|NCT01379157|DRUG|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
214891231|NCT01379157|DRUG|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
214891232|NCT04553393|DRUG|Chidamide|Chidamide will be added 1 month after responding to CART cells infusion
214891233|NCT04553393|DRUG|Decitabine|Decitabine will be added 1 month after responding to CART cells infusion
214891234|NCT04553393|DRUG|Chidamide and Decitabine|Both chidamide and decitabine will be added 1 month after responding to CART cells infusion
214891235|NCT04553393|BIOLOGICAL|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem CAR19/20 engineered T cells
214891236|NCT00970593|DRUG|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
215049892|NCT05282667|PROCEDURE|Reconstructive therapy of peri-implantitis by means of bone graft (and barrier membrane in the test group)|"A full-thickness flap was raised to ensure sufficient access. Debridement of granulation tissue was subsequently conducted using a mini-five curette (Hu-Friedy) and site-specific Gracey curettes (Hu-Friedy). The surgical approach was tailored to the clinical scenario. Specifically, resective therapy by means of implantoplasty was performed for supracrestal defects (Meisinger LLC, Nauss, Germany). Surface detoxification was performed with 3% hydrogen peroxide during 2 minutes and irrigation with 0.12% chlorhexidine. The intraosseous compartment was grafted using mineralized and demineralized bone graft (LifeNet Health, Virginia, USA). The graft was compartmentalized in the test group with a collagen porcine resorbable membrane (RTM, Cytoplast, California, USA) adapted to the defect morphology. Nylon 5.0 (Resorba Sutures, Osteogenics Biomedical, Lubbock, Texas) was used for suturing, ensuring primary wound closure"
215049893|NCT06135948|DRUG|Extra dose of L-thyroxine, 25 mcg during Ramadan|Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
214891237|NCT00970593|DRUG|placebo comparator|Group 1 \& 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
214891238|NCT00897182|GENETIC|microarray analysis|
214295441|NCT01549093|DRUG|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2\*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
214891239|NCT00897182|GENETIC|polymerase chain reaction|
214891240|NCT05436730|DEVICE|Ambulatory blood pressure measurement device|Assessment of the 24-h blood pressure profile
214891241|NCT05436730|DEVICE|Sphygmocor|Assessment of the arterial stiffness
214891242|NCT05436730|DEVICE|VaSera-VS|Assessment of the arterial stiffness
214891243|NCT05436730|DEVICE|Somnocheck|Assessment of the sleep breath disturbances
214891244|NCT02262455|DRUG|STM 434|STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.
214891245|NCT02262455|DRUG|Liposomal doxorubicin|Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
214891246|NCT03595956|OTHER|Medical gender affirmation|The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).
214295442|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
214891247|NCT04177407|PROCEDURE|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
214891248|NCT03027960|DRUG|Empagliflozin|10mg empagliflozin for a 2-week period
214891249|NCT03027960|DRUG|Placebo Oral Capsule|10 mg placebo for a 2-week period
214891250|NCT00614640|BIOLOGICAL|DermaVir patch|DNA Vaccine
214891251|NCT00614640|BIOLOGICAL|Placebo patch|10% dextrose (D-glucose) solution
215049894|NCT02651116|DRUG|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
215049895|NCT02651116|DRUG|Placebo|10 mL Placebo
215049896|NCT02651116|DEVICE|Cough recording device|FDA approved device validated for use in adults and children
215049897|NCT01184976|BIOLOGICAL|VGX-3400|Plasmid DNA delivered via IM injection with electroporation
215049898|NCT04336657|OTHER|Questionnaire|Survey to identify number of people who got unusual severe flu- like illness in last October- November
215049899|NCT04336657|DIAGNOSTIC_TEST|IgG|Measure the past immunity of the disease (if possible)
215049900|NCT03749824|DIETARY_SUPPLEMENT|Omega-3|Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
214295443|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
214295444|NCT02029625|DRUG|NVP-1205|rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
214295445|NCT02029625|DRUG|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
214295446|NCT00223951|DRUG|R89674 (generic name not yet established)|
214295447|NCT01531374|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
214295448|NCT05415085|PROCEDURE|Culprit-first PCI|PCI to the culprit artery prior to the demonstration of the whole coronary tree.
214295449|NCT00277888|PROCEDURE|Femoral route for hemodialysis|
214295450|NCT00277888|PROCEDURE|Jugular route for hemodialysis|
214891252|NCT06551792|OTHER|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection
215049901|NCT03749824|DIETARY_SUPPLEMENT|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
214295451|NCT05369455|PROCEDURE|erector spinae plane block|determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
214295452|NCT05369455|PROCEDURE|ultrasound guided caudal block|determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
214891253|NCT06128161|DEVICE|Hearing Aid|Contralateral Hearing Aid to Cochlear Implant
214891254|NCT04069650|PROCEDURE|Free flap|Free flap reconstruction of the oral cavity
215049902|NCT04992468|DRUG|Ovulation triggering with GnRH-a+rhCG|recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)
215049903|NCT04992468|DRUG|Ovulation triggering with GnRH-a|rFSH 225-300 IU (Gonal-F®/Puregon®/Ovaleap®/ Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®)
215049904|NCT04209374|DEVICE|THA with SYMBOL CUP DM HA|
215049905|NCT03952403|DRUG|HLX10, an engineered anti-PD-1 antibody|HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
215049906|NCT03952403|DRUG|HLX04, a bevacizumab biosimilar|HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
215049907|NCT03952403|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
215049908|NCT03952403|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
214295453|NCT01287897|DRUG|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
214295454|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
214477996|NCT05932342|BEHAVIORAL|Integrated program of cognitive remediation, physical exercise and socially stimulating activity|"Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport."
214477997|NCT04362774|DEVICE|ORBERA365|Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)
214891255|NCT02801123|BEHAVIORAL|Mindfulness Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
214891256|NCT02801123|BEHAVIORAL|Tai Chi/Qigong (TCQ) for Cancer Patients|"TCQ involves a series of slow specific movements or forms done in a meditative fashion. It is purported that focusing the mind solely on the movements of the form helps to bring about a state of mental calm and clarity. The practice itself has been separated from its martial arts roots and is widely taught as a health behavior practice and exercise. Qigong exercises generally have three components: a posture (whether moving or stationary), breathing techniques, and mental focus on guiding qi through the body. Our program, developed specifically for a cancer patient population, incorporates simple Tai Chi elements within a healing framework stemming from Qigong principles."
215049909|NCT02457247|DRUG|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
215049910|NCT02457247|DRUG|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
215049911|NCT02457247|DRUG|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
215049912|NCT00269607|DRUG|Implantation of naltrexone implants|
215049913|NCT03587896|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
215049914|NCT01893710|PROCEDURE|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
215049915|NCT06101134|DRUG|relatlimab+nivolumab|Specified dose on specified days
214295455|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
214477998|NCT06857123|BEHAVIORAL|Exercise with Rest|Participants in this arm exercise 3 times a week for 12 weeks. Exercise program consists of warm-up, strengthening exercises of the lower major extremity muscle groups, and aerobic training using a treadmill. These sessions include two 45 minute rest periods between exercises and take about two and a half hours.
214477999|NCT06857123|BEHAVIORAL|Exercise without Rest|Participants in this arm exercise 3 times a week for 12 weeks. Exercise program consists of warm-up, strengthening exercises of the lower major extremity muscle groups, and aerobic training using a treadmill. These sessions include minimal resting periods between exercises and take about one hour.
215049916|NCT06101134|DRUG|relatlimab+nivolumab+rHuPH20|Specified dose on specified days
215049917|NCT06101134|DRUG|nivolumab|Specified dose on specified days
215049918|NCT06101134|DRUG|nivolumab+rHuPH20|Specified dose on specified days
214295456|NCT00934154|DRUG|Thalidomide|100 mg/day continuously for 12 months
214295457|NCT00934154|DRUG|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
214478000|NCT06678906|BEHAVIORAL|Intervention arm|All patients in the intervention group will benefit from the standard information phase on physical activity and sedentary behavior, as well as personalized support for behavior change in the form of a serious game and remote coaching.
214891257|NCT04582032|DRUG|Dexketoprofen (KETAVEL 50 mg/2 ml)|intravenous dexketoprofen (KETAVEL 50 mg/2 ml)
214891258|NCT04582032|DRUG|Saline (Isotonic Saline Solution 0.9% )|intravenous 2 ml of saline
214891259|NCT06583252|DEVICE|multimodal monitoring cluster management|All patients will be monitored for baseline TCD at admission and at least once a day during treatment to assess changes in cerebral blood flow dynamics. Brain Oxygen Monitoring, Equipment \&amp;amp; Frequency: Continuous monitoring of partial pressure of oxygen (PbtO2) in brain tissue using near-infrared spectroscopy (NIRS). qEEG monitoring，Frequency and timing of monitoring. Baseline monitoring: All patients will undergo a baseline qEEG test at the time of admission. Continuous monitoring: In the ICU, for critically ill patients, qEEG will be performed continuously to monitor changes in EEG activity in real time. Monitoring brain activity: qEEG is able to detect subtle changes in brain waves that can be used to assess brain functional status, such as EEG quiescence, abnormal electrical discharges (e.g., epileptiform activity), etc. Abnormal parameters: focus on abnormal rhythms (e.g., high-amplitude slow-wave activity), acute asymmetric activity, and epileptiform discharge.
214891260|NCT05079048|OTHER|PEEK retentive elements|received implant-supported mandibular overdenture retained by PEEK retentive element and housings
214891261|NCT05626842|OTHER|Total Diet Replacement (800kcal/day)|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly for a further 36 weeks. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks.
214891262|NCT00379392|BEHAVIORAL|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
214891263|NCT00379392|PROCEDURE|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
214891264|NCT06227039|OTHER|Vibroacoustic stimulation on|Mechanical stimulus is provided to the patient through a vibroacoustic device via vibration around the neck.
214891265|NCT06227039|OTHER|Augmented Reality on|Visual stimulus is provided through augmented reality glasses in the form of a game.
214891266|NCT06227039|OTHER|Vibroacoustic stimulation off|Vibroacoustic device is worn but turned off.
214891267|NCT06227039|OTHER|Augmented reality off|Augmented reality glasses are worn but turned off.
214891268|NCT05334030|DEVICE|High Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
214891269|NCT05334030|DEVICE|Neutral Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
214891270|NCT05334030|DEVICE|High Swing Resistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
214891271|NCT05334030|DEVICE|Max Trajectory Control|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - Bilateral;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
214891272|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.
214891273|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.
214891274|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.
214295458|NCT01819077|PROCEDURE|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
214295459|NCT04669483|OTHER|evidence-based informed consent form|Evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures will be developed. The design of the evidence-based informed consent forms will be guided by an existing guideline on how to present evidence-based health information (guideline evidence-based health information) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo. Verbal presentations of risks lead to overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.
214478001|NCT06544941|DEVICE|Smart Bassinet|The SNOO will respond to a crying or fussing infant in order to soothe and calm it down.
214478002|NCT06544941|DEVICE|HALO|The HALO is a commercially available bassinet
214891275|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.
214891276|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.
214891277|NCT04176250|DRUG|HRZE|Participants will receive Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days, based on weight as 40-54 kilograms (kg): 3 tablets; 55-70 kg: 4 tablets and 71 kg and over: 5 tablets.
214891278|NCT05175105|DRUG|Mitapivat|Tablets or granules
214891279|NCT05175105|DRUG|Mitapivat-matching placebo|Tablets or granules
214891280|NCT00633997|DRUG|Vildagliptin|50 mg orally twice daily for 10 days (last dose morning of day 10)
214891281|NCT00633997|DRUG|Vildagliptin|
214891282|NCT01144611|DRUG|bIAP bolus and 8h infusion|intravenous as a bolus of bIAP (bovine intestinal alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
214891283|NCT01144611|DRUG|placebo bolus and 8h infusion|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
215049919|NCT00419055|PROCEDURE|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
214891284|NCT03423797|DRUG|25% AgNO3 solution followed by 5% NaF|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).
214891285|NCT03423797|DRUG|25% AgNO3 solution followed by 5% NaF with fTCP|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
214891286|NCT03304145|OTHER|The Carevive CPS|The Carevive Care Planning System (CPS) was developed to overcome challenges by providing an efficient, clinically integrated solution for both psychosocial and physical symptom distress screening and management through the delivery of personalized and evidence-based care plans at the point of care. The Carevive CPS simultaneously collects and aggregates discrete data for quality reporting and improvement.
214891287|NCT04406077|DEVICE|Ligasure|Using ligasure to treat hydrocele
214891288|NCT03241992|BEHAVIORAL|MyChart Disease Specific|Subjects receive targeted IBD information and reminders as well as mood questionnaires.
214891289|NCT04090125|BEHAVIORAL|PAS Intervention|The PAS program will be initiated during the final usual care PT visits. The PAS content will be included within the last two routine PT visits (Sessions 1 and 2). Session 1 will emphasize the importance of PA in TKA recovery, work with participants to establish SMART goals regarding overall PA and provide community-based and other resources to support overall PA. Session 2 will include balance exercise content to improve joint loading symmetry and home exercises will be assigned. Then, PAS participants will receive a follow-up phone call after 4 weeks (to assist with activity progression and problem-solving) and an additional in-person visit after 8 weeks (to visually monitor exercise performance and re-assess proportional weight-bearing ability).
214891290|NCT04090125|BEHAVIORAL|Attention Control|This will include usual in-person post TKA PT followed by 2 additional contacts (Session 1 and 2) with the physical therapist. Session 1 (phone) will review recovery benchmarks, assessment of participants' daily activities and reminders about symptoms that should trigger contacting a medical professional. Session 2 (in-person) will involve physical performance tests and comparison to appropriate normative values.
214891291|NCT00634946|DRUG|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
214891292|NCT00634946|DRUG|Placebo|Placebo is administrated into the nucleus pulposus of an intervertebral disc.
214891293|NCT01134250|DRUG|F16IL2 in combination with paclitaxel|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
215049920|NCT03893981|OTHER|Proprioception and Balance Program|Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.
215049921|NCT03893981|OTHER|Strengthening Program|Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
214295460|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation with virtual reality|Efficacy of Behavioral Self-Activation with virtual reality
214295461|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation without virtual reality|Efficacy of Behavioral Self-Activation without virtual reality
214295462|NCT00308503|DRUG|eplivanserin (SR46349)|oral administration
214295463|NCT00308503|DRUG|placebo|oral administration
214295464|NCT02622516|OTHER|Intervention Group (IG)|"Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
214295465|NCT02622516|OTHER|Control Group (CG)|"The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
214295466|NCT00507754|OTHER|T-SPOT TB test|Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
214295467|NCT04906044|DRUG|Sintilimab|Sintilimab combined withTotal Neoadjuvant Treatment
214891294|NCT04549350|OTHER|PSQI|Assessment of sleep quality using Pittsburgh Sleep Quality Index (PSQI): It is a simple tool which assess the sleep quality over one month period. It included seven components with a global PSQI score \> 5 is indicative of poor sleep quality
214295468|NCT05335564|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
214295469|NCT01304901|DRUG|montelukast 4 mg granule|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
214295470|NCT01304901|DRUG|Montelukast placebo granüle|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
214891295|NCT01482416|DRUG|Estrogens, Conjugated (USP)|Experimental group will use 0.625mg/day during 30 days
214891296|NCT01482416|DRUG|Placebo|Placebo group will use placebo once/day during 30 days
214891297|NCT01342081|DRUG|DE-111 ophthalmic solution|
214891298|NCT01342081|DRUG|Tafluprost ophthalmic solution 0.0015%|
214891299|NCT01342081|DRUG|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%|
214891300|NCT06042543|DIAGNOSTIC_TEST|Screening with HPV test|Women aged 25-49 yrs will be screened with a validated HPV test. They will also provide urine samples for HPV test. Women HPV positive in either sample will be referred to colposcopy for disease ascertainment.
214891301|NCT03432143|OTHER|Community Reviewers|Intervention manuscripts will be reviewed by both a trained community member and scientific reviewers. Community reviewers will follow each journal's instructions regarding electronic access to manuscripts, use of drop-down menus and free-text boxes to address specific aspects of the review, and completion within the time frame specified by the journal.The journal editorial team will use all reviews to make decisions about acceptance, revision, or rejection of manuscripts.
214891302|NCT03236090|DIETARY_SUPPLEMENT|Vivomixx|Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
214891303|NCT01228058|PROCEDURE|RapidTEG test|The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
214891304|NCT05609513|OTHER|HTN-BASIC|The HTN-BASIC intervention will consist of providing consistent access to diagnostic equipment and evidence-based antihypertensive drugs at no cost to the hypertensive patients. Access to a consistent supply of three anti-hypertensive drugs (amlodipine 5, 10mg; valsartan 80, 160mg; and hydrochlorothiazide 12.5, 25mg) will be supplied to each clinic in the trial.
214295471|NCT01714154|DRUG|danoprevir|100 mg orally every 12 hours
214295472|NCT01714154|DRUG|ritonavir|100 mg orally every 12 hours
214295473|NCT01714154|DRUG|setrobuvir|200 mg orally every 12 hours
214295474|NCT05620004|DRUG|Bifidobacterium Bifidum Oral Product|experimental group use Bifidobacterium Bifidum Oral Product and control group without Bifidobacterium Bifidum Oral Product
214478003|NCT06547632|DEVICE|ClearPetra Ureteral access sheath|Patients will be randomly assigned (1:1) to vacuum-assisted (ClearPetra) or traditional approach group for retrograde intrarenal surgery according to standard of care.
214891305|NCT05609513|OTHER|HTN-PLUS|In addition to receiving all the components of HTN-BASIC, HTN-PLUS sites will receive an enhanced, more human-resource intensive package of interventions that have been developed in consultation with key stakeholders during our human-centered design phase. The intervention components will include four broad categories- (1) hypertension training, (2) differentiated service delivery and (3) remote patient monitoring for hypertension and (4) Performance Improvement Program. Uptake of all components will be assessed on a monthly basis during the intervention period. These interventions will by nature cost more, and so cost data will be rigorously collected as well.
214891306|NCT02041819|DRUG|Nimotuzumab|Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
214891307|NCT03845205|BEHAVIORAL|Integrated AUD Treatment|IAT will include computer-delivered BI in the hospital, nurse-delivered alcohol monitoring counseling at each outpatient LT follow-up visit, and at-home participation in web-based, 7-session CBT4CBT, supplemented by tailored text messages.
215049922|NCT04660734|PROCEDURE|Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.|Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
215049923|NCT04662164|DRUG|hepalatide|3 different dosage will be given sequentially to T2D patients
215049924|NCT01492088|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
214295475|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
214295476|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
214478004|NCT06867029|PROCEDURE|Onlay Mesh|to compare between two techniques of mesh placement in uncomplicated ventral hernias, onlay (mesh on external oblique) versus sublay (mesh in the retromuscular space).
214891308|NCT03379402|OTHER|Specimens collection|"On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.~Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3."
214891309|NCT03063008|DEVICE|PEEK|"Procedure/Surgery:~TLIF fusion with common PEEK cages."
214891310|NCT03063008|DEVICE|TiPEEK|"Procedure/Surgery:~TLIF fusion with titanium coated PEEK cages."
214891311|NCT01221870|DRUG|Tesetaxel once every 3 weeks|Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
214891312|NCT01221870|DRUG|Tesetaxel once weekly|Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
214891313|NCT02611908|DRUG|ibrutinib|Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily
214891314|NCT02611908|DRUG|obinutuzumab|obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
214891315|NCT05206123|OTHER|Interview|Patients will be interviewed with a semi-structured qualitative interview in order to know how they lived their first sexual experiences and their sex lives during their adolescence
214891316|NCT01608100|DEVICE|ARCHITECT STAT High Sensitive Troponin I Assay|"Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.~Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit."
214891317|NCT02790437|DRUG|IdeS|One dose of 0.25 mg/kg BW IdeS on study day 0. If negative crossmatch is not achieved, a second dose can be given within 2 days of the first infusion.
214891318|NCT02790437|PROCEDURE|Kidney transplantation|Performed following IdeS treatment
214891319|NCT01202175|DRUG|Nebivolol|Oral nebivolol 2.5-5mg once daily
214891320|NCT06086106|PROCEDURE|caudal block|The caudal block involves the injection of a local anesthetic Bupivacaine dose of 0.75 to 1 ml/kg the maximum volume was 10 mL with 0.25% concentration into the caudal epidural space, targeting the sacral nerve roots. to provide a high effect and duration of analgesia
214891321|NCT06086106|PROCEDURE|Dorsal Penile Nerve Block DPNB|DPNB is A type of pain control post-operative, often performed as a circumferential infiltration of the root of the penis (ring block). Two skin wheals are raised at the dorsal base of the penis, one on each side just below and medial to the pubic spine. A 25-gauge, 37.5-mm needle is introduced on each side, and the bupivacaine (1 to 1.5 mL) maximum dose 2 ml concentration 0.25% for infants is injected superficially and deep along the lower border of the pubic ramus to anesthetize the dorsal nerve. For a complete ring of infiltration,
214891322|NCT06086106|DRUG|Systemic opioids|Systemic opioids belong to a class of analgesics, they act by attaching to opioid receptors in the brain and spinal cord. For relief of pain, they are frequently utilized in a variety of surgical procedures and can be given intravenously, and in intramuscular injections. Although opioids are considered highly effective in pain control, they can lead to several adverse effects, such as nausea, vertigo, and respiratory depression, some of which can be dangerous.
214891323|NCT04719442|BEHAVIORAL|Building Healthy Families|Building Healthy Families (BHF) is a family based obesity treatment program which includes key behavior change strategies including goal setting for both behavior change and weight loss, self-monitoring, rewards/contingency management, role modeling, and stimulus control/ modifying the environment. BHF includes a minimum of 32 contact hours consisting of three main program components: nutrition education, behavior modification, and physical activity. Participants and parents are expected to attend 12 continuous weeks of education (2 hours/session) followed by 12 weeks of relapse prevention refresher courses. Relapse prevention refresher sessions are every three weeks for one hour to re-evaluate goals, discuss rewards/contingency management and changes in stimulus control with seasonal changes and holidays. A final follow-up check-in session is conducted at 12 months for approximately 1 hour.
214891324|NCT05314231|DRUG|ALXN1720|All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).
214891325|NCT01631760|GENETIC|no intervention|We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
215049925|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Eurofarma)|
215049926|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Zodic)|
215049927|NCT01406600|DRUG|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
215049928|NCT02184065|DRUG|Meloxicam|
215049929|NCT05180513|BEHAVIORAL|Teleconference Mindfulness Intervention|The teleconference intervention is administered by a trained interventionist via Zoom and is based on a manual adapted from a traditional MBSR version. Practices and activities include meditations, mindful breathing exercises and movements, discussions, and reflections, which participants learn at weekly sessions and practice on their own throughout the week. To adapt the traditional MBSR program for the target community population, intervention materials were reviewed for feedback from community stakeholders, and modified according to their feedback.
215049930|NCT05180513|BEHAVIORAL|Smartphone App Mindfulness Intervention|The smartphone app intervention is administered through the app. The smartphone app aligns with the traditional MBSR format, but training and practice is done individually and independently by members of this group. To adapt the traditional MBSR program for the target community population, the app was tested by community stakeholders and modified according to their feedback.
215049931|NCT04791293|OTHER|MELD-Na score|MELD-Na scores will be compared between the groups
215049932|NCT02132286|DRUG|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
215049933|NCT03053934|BEHAVIORAL|Online video-based counselling|Videoconferencing facilitates communication between individuals (i.e., the counsellor and the client) in different geographical locations enabling them to interact simultaneously with each other on a computer monitor in real time. In other words, both the client and the therapist communicate live using both visual and audio aids simulating in-person therapy albeit from two separate geographical locations.
214295477|NCT00249444|DRUG|Mirtazapine|Mirtazapine
214295478|NCT00249444|DRUG|Placebo|placebo
214295479|NCT03398395|PROCEDURE|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
214295480|NCT03398395|PROCEDURE|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
214295481|NCT03081507|BEHAVIORAL|SM-LHW|Will not receive additional follow-up from the LHW, but will be encouraged during the session to make an appointment with their provider to schedule a mammogram and Pap test, or to consult the MARHABA webpage for information on low-cost and culturally appropriate referral sources of screening. Individuals assigned to this arm who did not attend an educational seminar will be mailed a packet containing a palm card, brochure, and letter encouraging them to speak with their provider about breast and cervical cancer screening and/or going to the MARHABA webpage. LHWs will complete a follow-up survey with participants by phone or in-person at 4 months after baseline
214891326|NCT05544474|OTHER|Delphi questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of radical right colectomy. The Delphi questionnaire will be administered via www.surveymonkey.com.~In the first survey, panel members will agree on surgical steps, definition of surgical steps and nomenclature for radical right colectomy In subsequent surveys, panel expert will agree on a common definition, nomenclature and reporting for right colectomy. Multiple rounds will be conducted until consensus is reached. After each round, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 70% in the first round or need further explanation, additional rounds of the survey may be performed."
214295482|NCT03081507|BEHAVIORAL|PN-LHW|PNLHW participants will receive three planned contacts with LHWs that focus on navigation for obtaining mammogram and/or Pap testing.The initial contact will be made by phone and will focus on motivating participants to make an appointment with their primary care provider and/or obstetrician/gynecologist (OB/GYN), as well as provide information on low-cost or free care if necessary. The second contact will discuss the process of going to the appointment and the third contact will focus on the process of obtaining and interpreting. The second and third contacts will be either made by phone or in-person, depending on participant needs.
214295483|NCT04941235|DEVICE|ultrasound and nerve stimulator|nerve stimulator and ultrasound guided interscalene brachial plexus block
214295484|NCT02747706|BEHAVIORAL|Parent-to-parent mentoring|phone, SMS/text, and smartphone-based support
214478005|NCT06618898|OTHER|online questionnaire|The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.
214478006|NCT06867692|OTHER|Aerobic Exercise|"Warm-Up (5 minutes): Marching in Place: 2 minutes of marching to elevate heart rate. Arm Circles: 1 minute of small and large arm circles. Side Steps with Arm Swings: 2 minutes of stepping side to side with gentle arm swings. Main Exercise Routine (35 minutes): Walking/Jogging Intervals: 10 minutes alternating between 1 minute of walking and 1 minute of jogging. Jumping rope: 10 minutes of rope jumping. As a pre-determined routine to maintain consistency. Aerobic Games: 10 minutes of structured games like:~1. Simon Says: Incorporating aerobic movements like jumping jacks, running in place, etc.~2. Obstacle Course: Pre-planned course involving stepping over objects, crawling, and balancing. Ball Activities: 5 minutes of activities such as throwing and catching, or dribbling a ball around cones.~3. Cool Down (5 minutes) Stretching: Gentle stretching of major muscle groups, holding each stretch for 20-30 seconds."
214668327|NCT07031232|PROCEDURE|Bone-Level Implant Placement with Transmucosal Abutment and One Abutment-One Time Protocol Using Healing Abutments|"All participants will receive a single bone-level dental implant placed in a healed posterior site of the maxilla or mandible. The implants will be placed using a biological drilling protocol and inserted with a final torque of at least 30 Ncm. A 2 mm transmucosal one-piece abutment (mono-block) will be connected at the time of surgery, following a one abutment-one time philosophy.~Each patient will receive a healing abutment immediately after implant placement according to their allocated study group (standard, wide, or customized). The assigned healing abutment will not be removed throughout the healing period. All procedures will be carried out under local anesthesia in a standard clinical setting."
214891327|NCT05012046|OTHER|Orange juice|Matched for volume (240 mL/ 8 oz) of other test beverages. 100% orange juice.
215049934|NCT03053934|BEHAVIORAL|Traditional in-person counselling|"Traditional in-person counselling is often referred to as face-to-face and can be loosely defined as any mental health intervention, whereby the clinician is in the same room with a client. The terms in-person and same room are used less frequently, but it has been argued that these terms are more descriptive (since in videoconferencing, clients are also seen face-to-face on screen). Therefore, the current study uses the term in-person to describe traditional, face-to-face counselling."
214295485|NCT05398601|OTHER|MOBILIZATION with MOVEMENT|"They would be receiving conventional treatment as follow:~TENS (Transcutaneous electrical nerve stimulation) applied asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold - 10 mins Hot Pack - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive MWM techniques for Knee~1. Medial glide~2. Medial+ Internal rotation glide~3. Lateral Glide+ Internal Rotation glide~4. Anterior glide~5. Posterior glide"
214891328|NCT05012046|OTHER|Orange flavoured drink|Matched for volume (240 mL/ 8 oz) of other test beverages. Orange flavoured drink
214891329|NCT05012046|OTHER|Water|Matched for volume (240 mL/ 8 oz) of other test beverages. Water control
214891330|NCT04991246|OTHER|Antigenic tests (on saliva samples)|SARS-CoV-2 screening tests: two massive antigenic tests campaigns (on salivary samples).
214891331|NCT04991246|OTHER|Individual electronic sensor port|Individual electronic sensor recording contacts but not their location (in the form of a bracelet, a key ring or a badge) Contact data collection points (5 maximum, located at compulsory passage points for participants). When a sensor is close to one of these terminals, it discharges its contacts in seconds.
215049935|NCT05232656|BEHAVIORAL|Pre-Discharge Checklist and Patient Safety Dashboard|Pre-discharge preparation checklist for patients to assess discharge readiness. Patient safety dashboard for clinicians to proactively identify at-risk patients.
214891332|NCT04991246|OTHER|Atmospheric measurements of CO2|Atmospheric measurements of CO2 in the relevant closed places of the faculty (lectures / practical work / BU / refectory): battery operated sensors. When a sensor is installed in a place, the ventilation conditions (number of open windows, etc.) as well as the number of people present will be noted.
214891333|NCT00004667|DRUG|von Willebrand factor|
214891334|NCT03440840|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Application of a small electrical current (1-2 mA) across the head.
214891335|NCT03440840|BEHAVIORAL|Computer-based Cognitive Training|Use of computer-delivered games or exercises with the goal of improving cognitive performance.
214891336|NCT03440840|BEHAVIORAL|Watching Educational Videos|Watching educational videos and answering questions about them
214891337|NCT00743925|DRUG|Varespladib Methyl (A-002)|2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
214891338|NCT00806429|PROCEDURE|transvaginal appendectomy|patient undergoes transvaginal appendectomy
214891339|NCT02317003|BEHAVIORAL|Intervention PPIL|
214891340|NCT02317003|BEHAVIORAL|Control OR|
214891341|NCT00738179|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP worn nightly
214891342|NCT00738179|OTHER|Standard care|Standard care of cardiovascular risk factors
214891343|NCT03879785|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
214891344|NCT03530683|DRUG|Maplirpacept (PF-07901801)|maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
214891345|NCT03530683|DRUG|Azacitidine|intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks
214891346|NCT03530683|DRUG|Venetoclax|orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole
214891347|NCT03530683|DRUG|Carfilzomib|Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.
214891348|NCT03530683|DRUG|Dexamethasone|starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles
214891349|NCT03530683|DRUG|Anti-CD20 Targeting agent|Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
214891350|NCT03530683|DRUG|Isatuximab|"F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1."
214891351|NCT04720053|DEVICE|Wearable brain sensing wellness device headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
214891352|NCT01091194|OTHER|Interval-based aerobic exercise|High intensity interval-based aerobic exercise training. Duration: 1 year. Three 8-weeks supervised periods of physical training 3 times per week. Individual training 2 times per week between these periods.
215049936|NCT05363592|DRUG|CT-L01 12.5/500 mg|FDC tablet, 2 tablets at a time, oral administration
215049937|NCT05363592|DRUG|Alogliptin Benzoate 12.5 mg|Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration
215049938|NCT05363592|DRUG|Metformin HCl XR 500 mg|Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
215049939|NCT04324892|DRUG|Treat to target|All patient will received protocolized treatment with an aim to achieve SDAI remission
215049940|NCT03824392|BIOLOGICAL|Efzofitimod 1.0 mg/kg or Placebo|Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
215049941|NCT03824392|BIOLOGICAL|Efzofitimod 3.0 mg/kg or Placebo|Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
215049942|NCT03824392|BIOLOGICAL|Efzofitimod 5.0 mg/kg or Placebo|Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
215049943|NCT00127855|BIOLOGICAL|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
214891353|NCT02802410|DEVICE|IQ-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
215049944|NCT00127855|BIOLOGICAL|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
215049945|NCT00127855|BIOLOGICAL|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
215049946|NCT00127855|BIOLOGICAL|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
215049947|NCT00127855|BIOLOGICAL|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
215049948|NCT00127855|BIOLOGICAL|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
215049949|NCT00127855|BIOLOGICAL|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
215049950|NCT02007304|BEHAVIORAL|Eccentric exercise training|12 weeks of lower leg eccentric training
215049951|NCT01527630|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
215049952|NCT02343302|DEVICE|Jackson-Pratt Drain|"A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain"
215049953|NCT02343302|DEVICE|Non-suctioning drainage|"A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain"
214295486|NCT05398601|OTHER|Periosteal electrical dry needling|"They would be receiving conventional treatment as follow:~TENS (asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold) - 10 mins HOT PACK - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive periosteal electrical dry needling 4 point technique for Knee~Four sterile, single-use 30-gauge dry needles would be inserted into the following locations of the symptomatic knee(s) until they touch bone:~1. Medial femoral condyle~2. Lateral femoral condyle~3. Flare of the tibia~4. Head of the fibula Needles would be stimulated with 100 Hz for 30 minutes. The intensity of the stimulus would be adjusted so that it would be clearly felt but would not cause discomfort. The stimulus intensity would be adjusted periodically so that it is perceptible for the entire 30 minutes of PST."
214668328|NCT07031700|DRUG|Mosunetuzumab|"* Cycle 1: Day 1: 1 mg; Day 8: 2 mg; Day 15: 30 mg~* Cycles 2-8: 30 mg every 3 weeks~* Cycles 9-17: 30 mg every 3 weeks (if applicable） A treatment cycle is 21 days. Patients achieving complete remission (CR) by cycle 8 will stop treatment, while those with partial response (PR) or stable disease (SD) may continue up to 17 cycles or until disease progression or intolerable toxicity occurs."
214295487|NCT00082355|DRUG|Alteplase (Activase, Genentech)|Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
214295488|NCT06443840|DEVICE|AutonHome® device|The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.
214295489|NCT01051050|BEHAVIORAL|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
214295490|NCT01051050|BEHAVIORAL|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
214295491|NCT01969240|OTHER|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
214295492|NCT01207765|DRUG|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
214295493|NCT01207765|DRUG|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
214668329|NCT07031700|DRUG|Tislelizumab|\- Cycles 2-8: 200 mg IV every 3 weeks
214668330|NCT07032181|PROCEDURE|Virtual reality, guided imagery|"Before the procedure, children will be informed via the Child Consent Form, and parents through the Informed Consent Form. Verbal and written consents will be obtained, and data will be recorded in the Child Patient Introductory Information Form. Pre-procedural pain will be assessed using the Faces Pain Scale-Revised scale, and the child will mark their pain. Parents will use the VAS scale for pain assessment. The CFS scale will be explained to both the child and parent to assess the child's fear. A pulse oximeter will measure SPO2 and pulse one minute before the procedure.~The blood collection procedure will be performed by an experienced nurse, and heart rate and oxygen saturation will be recorded in the Application Record Form.~After the procedure, measurements will be taken immediately after the procedure and one minute later.~Children will mark their pain and fear levels on the FPS-R and CFS scales. Parents and observers will also assess the child's pain (VAS) and fear (CFS)."
214668331|NCT07031752|OTHER|Postprandial Vegan Meat|Postprandial responses to one single intake of vegan meat (VM) under fasting conditions.
214668332|NCT07031752|OTHER|Postprandial Meat|Postprandial responses to one single intake of genuine meat (GM) under fasting conditions,
214668333|NCT07031050|DEVICE|sacrocolpopexy or sacrocervicopexy|Robotic-assisted sacrocolpopexy or sacrocervicopexy with the Dexter robotic surgery system
214668334|NCT07030361|BEHAVIORAL|suit group|elbise giydirme ve video izletme uygulaması
214668335|NCT07030361|BEHAVIORAL|training group|video izletme uygulaması
214668336|NCT07030361|BEHAVIORAL|control group|rutin hemş bakımı uygulaması, herhangi bir müdahale yok
214668337|NCT07031661|OTHER|This was an observational study with no intervention.|This was an observational study with no intervention.
214668338|NCT07031596|DIETARY_SUPPLEMENT|WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100).|"Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100). Ingredients : Stachyose, fructooligosaccharides, isomaltooligosaccharides, maltodextrin, Lactiplantibacillus plantarum CECT7527, Lactiplantibacillus plantarum CECT7528, Lactiplantibacillus plantarum CECT7529, Lactobacillus acidophilus GOLDGUT-LA100, and Epigallocatechin gallate (EGCG).~Administration : Twice daily (2 bottles per dose) after meals for 12 weeks."
214668339|NCT07031596|DIETARY_SUPPLEMENT|WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.|"Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.~Ingredients :~S100 Components : As above. Weight Management Components : Isomaltooligosaccharides, fructooligosaccharides, maltodextrin, Lactobacillus fermentum K7-Lb1, Lactobacillus fermentum K8-Lb1, Lactobacillus fermentum K11-Lb3, Euglena gracilis, and phosphatidylserine.~Administration : Twice daily (2 bottles per dose) after meals for 12 weeks."
214295494|NCT04489667|OTHER|+STEP Implementation|All patients receiving care at five RWHAP-funded clinics will receive the intervention (+STEP), in which patient-reported outcomes (PROs) on mental health and substance use disorder (SUD) will be integrated into routine care, targeted training will be provided for frontline clinicians on best practices for mental health and SUD treatment, and telemedicine for mental health and SUD will be offered to patients in need of expanded access to services.
214295495|NCT01938599|DRUG|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
214891354|NCT02802410|DEVICE|Kinesiotape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
214891355|NCT02802410|OTHER|No-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
214891356|NCT02283723|OTHER|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.
214891357|NCT02283723|OTHER|Usual care|While waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
214891358|NCT01582035|DRUG|TMC647055|type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
214891359|NCT01582035|DRUG|TMC647055|type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
214891360|NCT01582035|DRUG|TVR|type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
214891361|NCT01582035|DRUG|TVR|type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
214891362|NCT01582035|DRUG|TVR|type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
214891363|NCT01582035|DRUG|PegFN|type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
214891364|NCT01582035|DRUG|RBV|type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
214891365|NCT00750425|DRUG|cediranib (RECENTIN TM, AZD2171)|20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
214891366|NCT02016534|DRUG|AMG 337|AMG 337 300mg orally daily.
214891367|NCT02530502|OTHER|Laboratory Biomarker Analysis|Correlative studies
214891368|NCT02530502|BIOLOGICAL|Pembrolizumab|Given IV
214891369|NCT02530502|RADIATION|Radiation Therapy|Undergo focal RT
214891370|NCT02530502|DRUG|Temozolomide|Given PO
215049954|NCT02363530|DEVICE|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
214891371|NCT04467502|OTHER|cognitive-behavioral therapy for gambling disorder|6 sessions of cognitive-behavioral therapy for gambling disorder
214891372|NCT04467502|OTHER|imaginal exposure therapy focus on gambling cues|6 sessions of imaginal exposure therapy focus on gambling cues
214891373|NCT04467502|OTHER|virtual reality exposure therapy focus on gambling cues|6 sessions of virtual reality exposure therapy focus on gambling cues
214891374|NCT02426502|DRUG|Conversion to Advagraf|Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
214891375|NCT02426502|DRUG|conversion of non-immunosuppressant drugs to once daily|"* Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~* Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative."
215049955|NCT02363530|DEVICE|BSS|Balanced Salt Solution including normal saline and glucose
215049956|NCT04660760|DRUG|Paclitaxel|Given IV
215049957|NCT04660760|OTHER|Quality-of-Life Assessment|Complete questionnaires
215049958|NCT04660760|BIOLOGICAL|Ramucirumab|Given IV
215049959|NCT04660760|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
215049960|NCT04559061|DEVICE|Cardiac ablation procedure|Retrospective data will be collected from cases where successful ablation was completed.
214295496|NCT01938599|DRUG|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
214668340|NCT07031596|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of maltodextrin-based placebo (identical in taste, appearance, and packaging to probiotic products) twice daily (2 bottles per dose) for 12 weeks.
214668341|NCT07030491|OTHER|Lactation Cookies|Participants will consume 2 cookies per day (approximately 40g daily) for 30 consecutive days. The lactation cookies contain ingredients commonly believed to enhance milk production, including moringa, fenugreek, and ginger.
214668342|NCT07030491|OTHER|Control Cookies|Participants in the control group will consume 2 cookies per day (approximately 40g total) for 30 consecutive days. These cookies are matched in taste, appearance, and caloric content but do not contain any known galactagogue ingredients.
215057362|NCT01884324|OTHER|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
214891376|NCT02426502|DRUG|Conversion to once daily MPA|"* Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~* Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~* Patients taking azathioprine will be maintained on the same dose.~* Patients will be maintained on the same prednisone dose."
214891377|NCT03349021|DEVICE|Bougiecap|Treatment of esophagel Stenosis by Bougiecap
214295497|NCT00936910|DRUG|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome \[2 mg/ml\]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
214295498|NCT04843644|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
214891378|NCT01495299|DEVICE|Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish|Phacoemulsification (standard cataract extraction surgery)
214891379|NCT05494996|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet and the five-item relationship satisfaction scale(RS5) .
214295499|NCT04843644|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
214891380|NCT03694509|OTHER|Breakfast tea with full fat milk|Assessment of gastric emptying using ultrasound. Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
214891381|NCT03694509|OTHER|Water|Water 250ml.
214891382|NCT05471999|PROCEDURE|surgery|interventional or surgical treatment
214891383|NCT00387335|DRUG|sunitinib malate|Given orally
214891384|NCT03449732|DEVICE|PDR measurement|"PDR measurement at two standardized times perioperatively:~1. Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~2. Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth"
214295500|NCT04843644|BEHAVIORAL|Control|usual care
214891385|NCT00821561|DRUG|Nexagon®|
214891386|NCT00821561|DRUG|Nexagon® vehicle|
214891387|NCT00666328|DRUG|clevidipine|"Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours."
214891388|NCT05064397|DRUG|Eptinezumab|Eptinezumab will be administered per schedule specified in the arm description.
214891389|NCT04820725|DIAGNOSTIC_TEST|Plantar pressure and gait|Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated using Win-Track platform (MEDICAPTEURS Technology, France).
214295501|NCT00745147|DRUG|Chinese herbal formula (CCH1)|initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
214295502|NCT00745147|DRUG|Duphalac|initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
214295503|NCT04436185|BEHAVIORAL|Comparisons of procedural pain|This randomized experimental study with placebo and control groups
214295504|NCT00412854|BIOLOGICAL|Infanrix™/Hib|
214295505|NCT00412854|BIOLOGICAL|Infanrix|
214668343|NCT07030660|OTHER|Model-Informed Precision Dosing (MIPD)|Model-Informed Precision Dosing (MIPD) of tacrolimus in kidney transplantation
214668344|NCT07030478|DRUG|EP0089-101|EP0089 will be initially administered by intravenous (IV) infusion once every 2 weeks (Q2W)
214891390|NCT05021835|DRUG|Ziltivekimab B|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
214891391|NCT05021835|DRUG|Ziltivekimab C|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
214891392|NCT05021835|DRUG|Placebo (Ziltivekimab B)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
214891393|NCT05021835|DRUG|Placebo (Ziltivekimab C)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
214891394|NCT06388785|OTHER|No Intervention|This is a non-interventional study.
214891395|NCT06440239|DRUG|PMS-101|PMS-101
214891396|NCT06440239|OTHER|Standard treatment|Standard treatment according to physicians
214891397|NCT06007716|OTHER|reflexology massage|5 minutes of classic message on the left foot, 15 minutes of reflexology message, and 5 minutes of classic message on the right foot, 15 minutes of reflexology message, a total of 40 minutes of massage. 30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, reflexology massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
215057363|NCT01472354|BEHAVIORAL|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
214295506|NCT00412854|BIOLOGICAL|Hiberix|
214295507|NCT03483883|DRUG|Avelumab|Avelumab IV 10 mg/kg every 2 weeks
214295508|NCT03483883|DRUG|Gemcitabine|Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks
214891398|NCT06007716|OTHER|Placebo massage|Placebo reflexology massage was applied to each foot for 20 minutes, for a total of 40 minutes.30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, Placebo massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
214891399|NCT01795417|DEVICE|RF XP200|Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
214891400|NCT01795417|DEVICE|XP200 RF device|4 RF treatments of periorbital region on one side of the face
214891401|NCT02665104|DEVICE|transcranial Doppler (TCD) and INVOS monitor|Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
214891402|NCT04206917|DEVICE|Multi Pulse Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
214891403|NCT04632576|OTHER|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will given.
214891404|NCT06368011|BEHAVIORAL|acceptance and commitment therapy|Psychoeducation was delivered in 8 sessions lasting 90 minutes to two separate groups of 8-10 individuals in the experimental group.Group sessions were conducted once a week at the community mental health center under the leadership of the researcher.In total, the psychoeducation lasted 10 weeks, including make-up sessions.
214891405|NCT03996811|OTHER|Exercise education|weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
214891406|NCT04757974|DRUG|Fostemsavir 600 mg|Fostemsavir tablets will be administered via oral route.
214891407|NCT04757974|DRUG|Fostemsavir 200 mg|Fostemsavir tablets will be administered via oral route.
214891408|NCT01400542|DEVICE|CPAP Treatment|Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.
214295509|NCT05109507|BEHAVIORAL|Visitor Mindset|Single-session, self-guided intervention
214295510|NCT05109507|BEHAVIORAL|Relaxing with Nature|Single-session, self-guided intervention
214891409|NCT01400542|DEVICE|No treatment|no treatment
214295511|NCT02561650|DRUG|COV155|COV155 tablets
214295512|NCT02986789|DEVICE|In vivo SpHb and PVi Monitoring|Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
214295513|NCT02452346|DRUG|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
214295514|NCT04898257|DIETARY_SUPPLEMENT|Multistrain probiotic|After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).
214891410|NCT00144729|PROCEDURE|Bone marrow transplant|
214891411|NCT00399126|DRUG|Perifosine|Perifosine oral dose
214891412|NCT00399126|DRUG|Paclitaxel|Paclitaxel IV
214891413|NCT05409729|BEHAVIORAL|retrospective charts reviewing|
214891414|NCT00383253|BEHAVIORAL|caloric restriction - 10%|Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
214295515|NCT03529240|DEVICE|Kinesiology Taping|Kinesiology taping (KT) which was developed by Dr. Kenzo Kase, is a new application of elastic and adhesive taping. KT is applied by specialized physiotherapists and physicians. This type of taping is a very frequently used technique to accelerate recovery after musculoskeletal injuries. Also, this technique is usually used as an alternative to athletic taping to support fascias, muscles, and joints for many purpose such as positioning, inhibition, and fascilitation
214295516|NCT00468572|BEHAVIORAL|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
214891415|NCT00383253|BEHAVIORAL|caloric restriction - 25%|Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
214891416|NCT00383253|BEHAVIORAL|caloric restriction - 50%|Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
214891417|NCT00383253|BEHAVIORAL|caloric restriction - Control|Subjects maintained on their baseline caloric intake (caloric restriction = none)
214891418|NCT01996930|DRUG|Haelan tape (steroid impregnated tape)|Medicated plaster applied daily. Max daily dose = 0.1mg (25cm squared per day)Maximum duration of treatment = 28 days
214891419|NCT01996930|DRUG|Silver Nitrate|Cautery with silver nitrate cutaneous stick undertaken twice weekly for a maximum duration of treatment = 28 days
214891420|NCT06518447|DEVICE|Digital occlusal splints (CAD/CAM)|Consists of occlusal stabilization intra-oral splints fabricated using a fully digital workflow, involving intraoral scanning, virtual design, and 3D printing to ensure precise fit and comfort.
214891421|NCT06518447|DEVICE|Conventional occlusal splints|Consists of occlusal stabilization splints fabricated using traditional analog methods, including physical impressions, plaster models, and manual processing with heat-cured acrylic resin to achieve the desired occlusal arrangement.
214891422|NCT04141826|DIETARY_SUPPLEMENT|Hydrolysed whey|500 mL solution of 25 gram hydrolysed whey per day during 4 weeks
214891423|NCT04141826|DIETARY_SUPPLEMENT|Intact whey|500 mL solution of 25 gram intact whey per day during 4 weeks
214891424|NCT04141826|DIETARY_SUPPLEMENT|Caseinate|500 mL solution of 25 gram casein ate per day during 4 weeks
214295517|NCT00468572|BEHAVIORAL|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
214295518|NCT05967611|DIAGNOSTIC_TEST|Trendelenburg hip abduction test|The Trendelenburg test performed at different hip flexion, extension, adduction and abduction angles.
214295519|NCT04028076|BEHAVIORAL|Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence|An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
214891425|NCT03164538|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
214295520|NCT02461901|OTHER|Environmental sampling|Sampling of five sites in the patient's immediate environment for C. difficile spores
214295521|NCT02461901|OTHER|Skin swab sampling|Collection of swabs from three sites on the skin for C. difficile spores
214295522|NCT02461901|OTHER|Fecal sampling|Collection of fecal samples for C. difficile spores
214478007|NCT06867692|OTHER|Light Physical Activity Plan|"Warm-Up (5 minutes): Gentle Walking: 2 minutes at a slow pace. Light Arm Movements: 1 minute of gently moving arms up and down. Side Steps: 2 minutes of gentle side stepping.~2\. Main Activity Routine (35 minutes): Stretching Exercises: 10 minutes of gentle stretching, focusing on flexibility. Balance Activities: 10 minutes of activities such as: Standing on One Leg: Holding balance for 10-15 seconds on each leg. Heel-to-Toe Walking: Walking in a straight line, placing the heel of one foot directly in front of the toes of the other foot. 3. Light Coordination Games: 10 minutes of low-intensity activities like: Passing a Ball: Gently passing a ball back and forth with a partner. Basic Catch and Throw: Simple throw and catch exercises with a soft ball. Guided Relaxation: 5 minutes of guided relaxation techniques, including deep breathing and visualization. 4. Cool Down (5 minutes) Gentle Stretching: Stretching major muscle groups, holding each stretch for 20-30 second"
214478008|NCT06868329|OTHER|Superficial moist heat|Twenty minutes of automatic moist hot pack (Besmed© BE-267, Taiwan) of suitable size was used to apply superficial heat. The heat level was adjusted to the medium level. While the moist environment was assured by placing a moist sponge layer between the pack and its cotton outer coverage. The duration was calculated after 8 minutes of warming up (when the temperature reaches its maximum level). The patient-reported sensation should be moderate warmth. A thermal sensation test using two test tubes was performed before applying heat therapy to avoid any adverse effects
214478009|NCT06868329|OTHER|Hamstring and back muscles stretching|Patients received manual passive stretch for the hamstring and lower back muscles. Three repetitions per session with every repetition sustained for 30 s. The patient assumed a long sitting position with both knees in full extension and feet together. The patient was then asked to bend forward from the hips to reach the furthest point towards the feet. The therapist applied over pressure by pressing hands on the patient's upper back and pushing forward.
214478010|NCT06868329|OTHER|posterior pelvic tilting exercises regular procedures|Patients will be asked to assume the supine position with both knees semi-flexed. A small billow will be placed under the low back, another billow will be placed under the flexed knees for comfort. The patient will be asked to tuck the abdominal muscles inward and press with the low back on the underlying billow and hold for six seconds, then relax. after a few seconds of rest, the patient should repeat this procedure for 3 sets X 10 repetitions per session during the first 2 weeks. the number of sets will be increased according to the adaptation of each patient and his/her fatigue threshold.
214891426|NCT03164538|BEHAVIORAL|Diabetes Education|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
214891427|NCT00535405|DRUG|Atorvastatin 10 mg|Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
214891428|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 20 mg|Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
214891429|NCT00535405|DRUG|Atorvastatin 20 mg|Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
215057364|NCT03535311|PROCEDURE|Measurement of sternal-notch to umbilicus distance|"* The sternal notch to upper border of umbilicus length measurement in centimetres.~* The length of the umbilical stump in centimetres.~* The length of the UVC and/or UAC inserted in centimetres which will be identified using the printed markers on the catheter. The marker which is closest to the end of the umbilical stump will be the recorded value.~* The length of the UVC and/or UAC in centimetres when the umbilical stump length is subtracted."
214295523|NCT04225351|PROCEDURE|MCAF+CM|CAF procedure + collagen matrix
214295524|NCT04225351|PROCEDURE|MCAT+CM|Tunnel procedure + collagen matrix
214295525|NCT04483011|DIETARY_SUPPLEMENT|RiaGev|Dietary supplementation
214295526|NCT05187793|DRUG|Olokizumab|Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
214295527|NCT05187793|DRUG|Standard therapy|"Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV"
215049961|NCT03984773|BEHAVIORAL|Nudge|Oncology practices will be randomly assigned to receive an intervention, in which individual clinicians will receive a weekly audit email detailing how many serious illness conversations (SIC) they have had compared to the recommended level, and a link to a list of their patients scheduled in clinic next week at high risk of short-term mortality as identified by a mortality prediction algorithm. Clinicians will have the chance to review the opt-out list and pre-commit to a serious illness conversation with appropriate patients. Clinicians will receive nudge on the day of the patient visit via text message reminding them of their pre-commitment to conduct a serious illness conversation.
214295528|NCT05003154|OTHER|Digitalized management|"In addition to conventional management, Patients also receive digitalized management, which provides personalized guidance in diet, excercise, prenatal visit, blood glucose monitoring,etc., from artificail intelliegence (AI) supevised by obstetricians, through a smartphone application and some werable devices (like sports bracelet).~The pivotal AI are based on clinical experience from obstetricians, therapeutic principle from official Guidelines and abundant data in previous work, and it will works under strict supervision."
214295529|NCT04425265|PROCEDURE|Plasma radiofrequency ablation|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.
214295530|NCT04425265|PROCEDURE|Electrocautery block resection|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the soft palate under the inferior margin, investigators horizontally cut the mucosa of the posterior wall of the nasopharynx, and completely frees the entire soft tissue of the posterior wall of the nasopharynx.
214295531|NCT03637972|OTHER|Ventilated cigarettes only|Participants given vouchers that are exchanged for ventilated cigarettes study cigarettes.
214295532|NCT03637972|OTHER|Unventilated cigarettes only|Participants given vouchers that are exchanged for unventilated cigarettes study cigarettes.
214295533|NCT03637972|OTHER|Access to Experimental Marketplace: Ventilated cigarettes + alternative nicotine delivery systems|Participants given vouchers that are exchanged for ventilated cigarettes + alternative nicotine delivery systems cigarettes.
214295534|NCT03637972|OTHER|Access to Experimental Marketplace: Unventilated cigarettes + ANDS|Participants given vouchers that are exchanged for unventilated cigarettes + ANDS.
214295535|NCT03657758|DRUG|EPA and rosuvastatin|To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
215049962|NCT01887717|DEVICE|TheraSphere®|Intrahepatic treatment of advanced hepatocellular carcinoma
214891430|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 40 mg|Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
214295536|NCT03657758|DRUG|High dose rosuvastatin|To take high dose rosuvastatin (10mg/day) for ９ months.
214295537|NCT04128384|DIAGNOSTIC_TEST|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR|For the purpose of obtaining intracardiac measurements, the quadripolar diagnostic catheter used as temporary pacemaker wire (5F, Woven, Boston Scientific) during TAVR was retracted from the apex and positioned at the His bundle to measure HV- and AH-intervals.
214295538|NCT01857466|PROCEDURE|Floseal|
214295539|NCT01857466|PROCEDURE|Bipolar coagulation|
214295540|NCT03439020|PROCEDURE|Plastic stent anchoring|Insert an additional plastic stent to anchor the fully covered self expandable metal stent.
214295541|NCT03439020|PROCEDURE|FCSEMS|Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
214295542|NCT05931679|DEVICE|VR Headset|A VR headset will be used for participants in the Interactive VR and 360 degree video groups.
214295543|NCT05931679|OTHER|Traditional Theatre-based simulation|Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
214295544|NCT01120912|DRUG|Oshadi Oral Insulin|Oral insulin single administration
214295545|NCT03518073|DRUG|Zagotenemab|Administered IV
214295546|NCT03518073|DRUG|Placebo|Administered IV
214295547|NCT01436981|PROCEDURE|CABG|Preparation of artery mammaria interna
214295548|NCT00658593|DRUG|capecitabine|
214295549|NCT00658593|DRUG|gemcitabine hydrochloride|
214295550|NCT00658593|PROCEDURE|quality-of-life assessment|
214478011|NCT06868329|OTHER|Postural correction with lumbar stabilization using TBed|These exercises consisted of pelvic rocking, and activation of the upper back and interscapular muscles. TBed from Techno body©, Italy was used to assist the patient to perform these exercises through VR video gaming interface. The patients in the experimental group will be asked to contract the targeted muscles and push down on the surface of the TBed. Patient's pressure will activate the sensors inserted inside the TBed, which will be reflected on the game as triggering of the gun that targets flying fruits. The game consists of three levels, easy, medium, and hard. The patient will be asked to play the game for the lower back where pushing the lower back against the bed (posterior pelvic tilting) triggered the gun and for the upper back where pushing the scapula against the bed was the triggering action.
214891431|NCT00535405|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
214891432|NCT02671929|BEHAVIORAL|self-help program|Access to the internet-based self-help program
214891433|NCT02671929|BEHAVIORAL|therapeutic feedback|Therapeutic feedback on the written information sent to the online therapist
214295551|NCT03916757|BIOLOGICAL|V-Boost|Open label setting
214891434|NCT00327756|DRUG|Coenzyme Q10|
214891435|NCT01404676|DRUG|Add Vildagliptin|Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
214891436|NCT01404676|DRUG|Add Glimepiride|Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
214891437|NCT00866944|DRUG|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
214891438|NCT00866944|DRUG|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
214295552|NCT03045081|BEHAVIORAL|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
214891439|NCT00866944|DRUG|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
214891440|NCT03298217|DEVICE|Measurement of the peak tidal inspiratory flow (PTIF)|"In patients with bronchiolitis sverity mWCAS / 3-5 :~Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF)."
214891441|NCT03875924|OTHER|VWD treatments|Modalities and types of treatments in VWD patients for severe hemorrhagic events: INN, quantities, duration of treatment
214891442|NCT03404674|BIOLOGICAL|CssBA|Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B
214891443|NCT03404674|BIOLOGICAL|dmLT|Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211
214891444|NCT01340131|DRUG|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
214891445|NCT01340131|DRUG|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
214891446|NCT00226096|DRUG|Labetalol Hydrochloride|
214891447|NCT00226096|DRUG|Metoprolol tartrate|
214891448|NCT00226096|DRUG|Hydralazine Hydrochloride|
214891449|NCT00226096|DRUG|Glycerol Trinitrate|
214891450|NCT00226096|DRUG|Phentolamine mesylate|
214891451|NCT00226096|DRUG|Nicardipine|
214891452|NCT00226096|DRUG|Urapidil|
214891453|NCT00226096|DRUG|Esmolol|
214891454|NCT00226096|DRUG|Clonidine|
214891455|NCT00226096|DRUG|Enalaprilat|
214891456|NCT00226096|DRUG|Nitroprusside|
214891457|NCT06359912|DRUG|EPCs|IV
214891458|NCT06359912|BEHAVIORAL|Clinical standard treatment (CST)|Clinical standard treatment
214891459|NCT03858010|DIAGNOSTIC_TEST|Wheeze and me questionnaire|validation of questionnaire assessing disease control and quality of life in preschool children with recurrent wheeze
214891460|NCT00264901|DRUG|insulin detemir|
214295553|NCT03531307|OTHER|Data correlation|Correlation between lactate levels and Ki-67 index
214891461|NCT02012270|PROCEDURE|PRINCIPLES technique|"Principles technique for closure of midline laparotomy incisions~* closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)~* the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other~* the SL/WL ratio should be at least 4/1~* SL/WL = (150cm x number of sutures used) - (the suture remnants)~* the mean stitch length should be less than 4 cm (suture length / number of stitches placed)"
214891462|NCT02012270|PROCEDURE|Conventional group|the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
214891463|NCT01832571|DRUG|Once daily Truvada®|At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
214891464|NCT03091179|DEVICE|THRIVE|active nasal oxygen delivery system
214891465|NCT03091179|DEVICE|Endotracheal tube|a plastic tube for mechanical ventilation
214891466|NCT00173511|DEVICE|24 hr Holter monitor|
214891467|NCT02819089|DRUG|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
214891468|NCT02819089|OTHER|NSS|NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
214891469|NCT05469334|BEHAVIORAL|DeStress for Health Program Participants|Behavioral: DeStress for Health Program The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals, with an additional class five as a check in that will be used for survey completion. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
214891470|NCT04459741|DIETARY_SUPPLEMENT|Dietary salt (Sodium chloride)|Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.
214891471|NCT03904290|OTHER|PFO Closure|Subject will undergo percutaneous closure of PFO/ASD utilizing FDA-approved PFO/ASD closure device(s).
215049963|NCT01887717|DRUG|Sorafenib|Standard of care therapy for treatment of advanced hepatocellular carcinoma
214295554|NCT03959293|DRUG|Durvalumab|1500 mg by 1-hour IV infusion - Every 4 weeks
214295555|NCT03959293|DRUG|Tremelimumab|75 mg by 1-hour IV infusion - Every 4 weeks
214295556|NCT03959293|DRUG|FOLFIRI Protocol|"* Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
214295557|NCT01108601|DRUG|Ringer's Lactate (0.03% Ciprofloxacin)|For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
214295558|NCT00484211|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
214295559|NCT05400954|PROCEDURE|Breast reconstruction with silicone breast implant|(i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant.
214295560|NCT05400954|PROCEDURE|Breast conserving surgery/Mastectomy/Autologous reconstruction|(iv) simple mastectomy without reconstruction, (v) autologous reconstruction and (vi) breast conserving surgery,
214295561|NCT05400954|PROCEDURE|Breast Augmentation|(vii) cosmetic augmentation with silicone breast implants
214295562|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of the tracer [99mTc] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml)|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
214295563|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of [99mTc] Tc-albumin nanocoloid (6mCi, 8ml).|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
214295564|NCT05660564|PROCEDURE|DIGU Dorsal inlay preputial graft urethroplasty|"Using a scalpel, a midline incision is made from the meatus to the end of the plate .~The edge of the distal glans should not be incised to avoid meatal stenosis. The depth of this relaxing incision depends on the plate's width and depth, but in all cases, it extends down to the corpora cavernosa. Degloving of the penile skin to the penoscrotal junction If a minimal chord is present, it should be corrected.~From the inner prepuce, a free graft was measured, harvested, defatted, and stitched to the UP. With interrupted 6/0 polyglactin sutures running from the old meatus to the tip of the glans, the graft was secured to the medial edges of the incised plate. Depending on the location of the meatus, the characteristics of the UP, and the depth of the midline incision, the graft width and length varied in each case."
214295565|NCT03186833|OTHER|no intervention|no intervention
214295566|NCT02977689|DRUG|IDH305|study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
214295567|NCT05881603|OTHER|" VExUS score  (Venous Excess Ultrasound Score)"|" VExUS score  (Venous Excess Ultrasound Score)"
214295568|NCT01378351|OTHER|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
214295569|NCT01397123|OTHER|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
214295570|NCT01802723|DRUG|Drug: salmeterol xinafoate|
214891472|NCT02765256|DRUG|Fluconazole|400mg orally once daily (Day 1-14)
214891473|NCT02765256|DRUG|Vancomycin|500mg oral suspension 4 times daily (Day 1-14)
214668345|NCT06017869|BIOLOGICAL|MNV-201|Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by leukapheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.
214891474|NCT02765256|DRUG|Neomycin|neomycin 1000 mg orally three times daily (Days 1-3)
214891475|NCT02765256|DRUG|Ciprofloxacin|ciprofloxacin 750 mg orally twice daily (Day 4-14)
214891476|NCT02765256|DRUG|Polyethylene Glycol 3350|238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2
214891477|NCT02765256|DRUG|Promethazine|PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
214891478|NCT02765256|DRUG|Fluconazole placebo|Once daily
214891479|NCT02534389|DIETARY_SUPPLEMENT|omega-3 fish oil|2,4g of EPA + DHA
214891480|NCT00478517|DRUG|Erythropoetin (rHuEPO, EPREX®)|
214891481|NCT04139824|DRUG|Xanthine Oxidase Inhibitor|LC350189 200mg qd
214891482|NCT04139824|DRUG|nonsteroidal anti-inflammatory drug|Naproxen 500mg BID
214891483|NCT04662814|OTHER|shock wave therapy|Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.
214891484|NCT04662814|OTHER|dietary modification|Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months
214891485|NCT04728802|DRUG|Proxalutamide|Proxalutamide 300mg q.d
214891486|NCT04728802|DRUG|Placebo|Placebo pill
214295571|NCT01802723|DRUG|Drug: Placebo|
214295572|NCT00002418|DRUG|Emivirine|
214891487|NCT01176513|DRUG|GE-148 (18F)|All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
214891488|NCT06188221|DRUG|Lidocaine|The group with the lidocaine will get a combined injection with a corticosteroid and lidocaine. The dosages depend on the disease.
214891489|NCT06188221|DRUG|Corticoids|The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
215057365|NCT02111915|BEHAVIORAL|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
215057366|NCT02111915|OTHER|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
214295573|NCT00002418|DRUG|Hydroxyurea|
214295574|NCT00002418|DRUG|Nevirapine|
214295575|NCT00002418|DRUG|Stavudine|
214295576|NCT00002418|DRUG|Didanosine|
214295577|NCT01485640|DRUG|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
214295578|NCT01853046|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
214295579|NCT05992610|OTHER|Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy|"Chemotherapy based on carboplatin 6 AUC + paclitaxel 75 mg/m2.~Radiotherapy:~D:1 - 2 x 0,5 Gy (first dose up to one hour after the end of the carboplatin infusion, second dose 3 to 6 hours later), D:2 - 2 x 0,5 Gy (interval between doses not less than 3 hours), D:8 and D:15 - 2 x 0,5 Gy (first dose up to one hour after the end of the chemotherapeutic infusion, second dose 3 to 6 hours later)."
214295580|NCT05359666|DEVICE|Irrisept|"Irrisept® is a manual, self-contained irrigation device designed for wound cleansing and irrigation. The solution is 0.05% Chlorhexidine Gluconate (CHG) in sterile water for irrigation, USP (99.95%). Irrisept contents include the solution, a 450 mL bottle, and the Irriprobe applicator. Irrisept is a manual, self-contained irrigation device that can produce 7-8 psi of pressure for effective wound cleansing and irrigation. The user squeezes the bottle to create streams of solution and directs the fluid from the applicator onto a wound. The mechanical action of the streams of fluid being applied over a wound removes particulates and debris.~Subjects randomized to Irrisept on study protocol IRR-CT-901-2013-01 used the device, per the provided Instructions for Use. Those randomized to SoC received routine care, per the discretion of the investigator, and in accordance with the institution's guidelines."
214891490|NCT04588168|DRUG|Chemotherapy|Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.
214891491|NCT04588168|DIAGNOSTIC_TEST|Immediate Multiparametric MRI|Within 24 hours after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive an immediate mpMRI scan.
214891492|NCT04588168|PROCEDURE|Cystectomy and Lymphadenectomy|The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.
214891493|NCT04588168|DIAGNOSTIC_TEST|conventional Multiparametric MRI|After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.
214891494|NCT04588168|DIAGNOSTIC_TEST|Baseline Multiparametric MRI|Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.
214891495|NCT00316758|DRUG|GK Activator (2)|Escalating doses bid
214891496|NCT00316758|DRUG|Metformin|As prescribed, in patients who were in study BM18249
214891497|NCT06492122|DRUG|[225Ac]Ac-FL-020|\[225Ac\]Ac-FL-020 injected intravenously
214891498|NCT06492122|DRUG|Blood samples for PK|Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.
214891499|NCT06492122|DRUG|[111In]In-FL-020|A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation
214891500|NCT06492122|PROCEDURE|Blood and urine samples collection|For dosimetry evaluation and urine excretion assessment, blood and urine samples will be collected after the injection of \[111In\]In-FL-020
214891501|NCT06492122|PROCEDURE|SPECT/CT images|For dosimetry evaluation, SPECT/CTs will be performed following the injection of \[111In\]In-FL-020.
214891502|NCT04423952|OTHER|COMQ-12 questionnaire|Subjects respond to COMQ-12 questionnaire twice at 15 days apart. COMQ-12 : quality of life measurement questionnaire related to chronic otitis media.
214891503|NCT03714919|DRUG|Dextromethorphan|Preoperative oral dextromethorphan 1 mg/kg
214891504|NCT03714919|DRUG|Acetaminophen|Preoperative oral acetaminophen 15 mg/kg
214891505|NCT03714919|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine 0.5 μg/kg
214891506|NCT03714919|DRUG|Ketamine|Intraoperative intravenous ketamine 0.5 mg/kg
214891507|NCT03282916|DRUG|Valacyclovir|Valacyclovir hydrochloride 500mg caplet
214891508|NCT03282916|DRUG|Placebo|Placebo sugar pill 500mg caplet
214891509|NCT06653153|DRUG|Remternetug|Administered SC
214891510|NCT06653153|DRUG|Placebo|Administered SC
214891511|NCT06481293|DEVICE|Diode laser therapy|Dual wavelength laser diode therapy device
214891512|NCT06481293|COMBINATION_PRODUCT|Alveogyl dressing|Alveogyl is a haemostatic-analgesic alveolar dressing
214891513|NCT03452774|OTHER|Clinical Trial Matching|Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
214295581|NCT05359666|DEVICE|Standard of Care|"Subjects randomized to SoC on study protocol IRR-CT-901-2013-01 used any SoC type, per the investigator's discretion. SoC types were not standardized. Sites recorded SoC information as free text. The following were recorded as SoC types: Saline (recorded as normal, warm and/or sterile saline or saline solution); Sodium Chloride (recorded as sodium chloride (NACL) or NACL 0.9%); SoC; Irrisept (recorded as normal saline \& Irrisept and Irrisept); Chloraprep; Gentamicin \& saline; unknown; and none."
214295582|NCT01711177|DRUG|placebo|Placebo
214295583|NCT01711177|DRUG|travoprost|Travatan Z is administered to newly diagnosed glaucoma patient
214891514|NCT04323943|DEVICE|Ankle Foot orthosis (AFO)|"The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~* 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~* 6MWT where energy cost will be measured~* 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed"
214891515|NCT01954862|OTHER|Air Insufflation method.|Air Insufflation method.
214891516|NCT01954862|OTHER|CO2 insufflation|CO2 insufflation.
214891517|NCT01954862|OTHER|Water Immersion/CO2|Water Immersion during insertion, CO2 insufflation during withdrawal.
214891518|NCT01954862|OTHER|Water Exchange/CO2|Water Exchange during insertion, CO2 insufflation during withdrawal.
214891519|NCT01954862|OTHER|Water Immersion/AI|Water Immersion during insertion, AI insufflation during withdrawal.
214891520|NCT01954862|OTHER|Water Exchange/AI|Water Exchange during insertion, AI insufflation during withdrawal.
214891521|NCT02419534|DRUG|Polyethylene glycol|Laxative to treat constipation
214295584|NCT05022784|DRUG|Nintedanib|Nintedanib
214295585|NCT05217433|OTHER|Olive leaf extract|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
214295586|NCT05217433|OTHER|Placebo|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
214891522|NCT02419534|DRUG|Polyethylene glycol with Diltiazem|Laxative and topical calcium channel blocker
214891523|NCT06541379|OTHER|No intervention|
214891524|NCT05027204|DRUG|Docetaxel|Docetaxel for Injection (Albumin-bound), Q3W, i.v. 60 min
214891525|NCT05027204|DRUG|Nivolumab|Nivolumab, Q3W, i.v. 30 min
214891526|NCT06252649|DRUG|FOLFIRI Regimen|Combination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W.
215057367|NCT01202201|OTHER|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
214295587|NCT02295150|DRUG|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
214295588|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose|50μg/dose
214668346|NCT04266574|DEVICE|Near Infrared Spectroscopy (NIRS)|"The anesthesiologist will apply optodes before induction of anesthesia and before preoxygenation, to detect baseline NIRS level, NIRS will be monitored continuously up to post-anaesthesia care unit (PACU) discharge, or up to three the investigator's after ICU admission.~When a decrease in NIRS value over 10% is detected, or if NIRS value is below 60%, patients will start hemodynamic optimization, to reverse the reduction in NIRS and return to baseline values, according to a predefined protocol."
214891527|NCT06252649|DRUG|Sotorasib|Immediate-release solid dosage form administered orally.
214891528|NCT06252649|DRUG|Panitumumab|Administered via IV infusion Q2W.
214891529|NCT06252649|DRUG|Bevacizumab-awwb|Administered via IV infusion Q2W.
214891530|NCT07017712|PROCEDURE|Complex esophageal surgery for carcinoma|Appropriate combination of ICD-10 code (C15, C16.0) and medical procedure code (5-423, 5-424, 5-425, 5-426, 5-427.0, 5-427.1, 5-438.0, 5-438.1, 5-438.x)
214891531|NCT07017712|PROCEDURE|Rectum resection for carcinoma|Appropriate combination of ICD-10 code (C19, C20, C218, D011, D012) and medical procedure code (5-484, 5-485)
214891532|NCT07017712|PROCEDURE|Colon resection for carcinoma|Appropriate combination of ICD-10 code (C18, D01.0) and medical procedure code (5-455, 5-456, 5-458)
214891533|NCT07017712|PROCEDURE|Pancreatic resection for carcinoma|Appropriate combination of ICD-10 code (C25, C24.1) and medical procedure code (5-524, 5-525.0, 5-525.1, 5-525.2, 5-525.x, 5-525.y, 5-528)
214891534|NCT07017712|PROCEDURE|Gastric resection for carcinoma|Appropriate combination of ICD-10 code (C16) and medical procedure code (5-436, 5-437, 5-438)
214891535|NCT07016711|BEHAVIORAL|Lifestyle and Nutrition Promotion|Adherence to the Mediterranean diet
214891536|NCT07017101|OTHER|PILATES BASED EXERCISE TRAINING WITH REFORMER|"Participants will only be given training on pilates-based exercises with reformers. Breathing, which are the 5 key elements of clinical pilates exercises after the first evaluation to individuals,~Focus, rib cage placement, shoulder placement, head and neck placement will be taught. Whole~Participants will be informed about the reformer instrument and work schedule. Exercises 2 days a week, 6~Will be applied throughout the week."
214907150|NCT06193603|OTHER|Sham cupping therapy|In the control group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. However, unlike the intervention group, the cups in the control group will not be moved and will remain stationary for 5 minutes. The cups will have small holes (\<2mm in diameter) to release negative pressure quickly. Double-sided tapes will be used to secure the cups and maintain contact with the skin.
215057368|NCT04463940|OTHER|No intervention|No intervention
215057369|NCT01997593|DRUG|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
214295589|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose|100μg/dose
214295590|NCT05549206|DRUG|Placebo|Saline solution
214907151|NCT05514873|DRUG|zilucoplan (RA101495)|Subcutaneous injection
214907152|NCT06193902|BIOLOGICAL|LEU011|Immunotherapy
214295591|NCT03020407|PROCEDURE|IVC Ultrasound-guided|IVC is identified in longitudinal section in the subcostal area of a patient using the curvilinear probe of standard ultrasound. The selected area of IVC diameter measurement is set at 2 centimeters distal to the confluence of hepatic vein by M-mode coupled by two-dimensional mode on frozen screen images using the Sonosite® X-porte.
214295592|NCT03020407|DRUG|Antibiotics|Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
214891537|NCT07017101|OTHER|NEUROPHYSIOLOGICAL FASCILITATION TECHNIQUES|"In addition to reformer-based pilates training, participants will be given Neurophysiological facilitation techniques training. Neurophysiological facilitation techniques are non-invasive, easy to apply, the physiotherapist is active~It consists of exercises made with guidance and active participation of the patient. These techniques are any~Does not contain an electrotherapy current. In this study, the neurophysiological~Facilitation techniques, perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, medium~Graded manual pressure and abdominal co-contraction techniques and each technique for 15 seconds~Will be applied. Neurophysiological facilitation techniques are used to repeat 10 sessions each session throughout the treatment.~It will be done."
214891538|NCT06683092|OTHER|RETRIAL-MH|Participants will complete: daily diaries for 6 weeks, from about 2 weeks prior to starting VTD to about 4 weeks after; biweekly surveys, from about 2 weeks prior to starting VTD to 6 months after, and 2 quarterly surveys (at 9mo and 12mo post-initiation of VTD).
214891539|NCT06683092|OTHER|RETRIAL-Liver|Participants may have a research liver function test done prior to starting VTD and 28 days after, if not done clinically.
214891540|NCT06683092|OTHER|RETRIAL-Neuro|participants will complete a neurocognitive assessment prior to starting VTD and 28 days after.
214891541|NCT07017426|DRUG|Fuzheng Huayu tablets|Fuzheng Huayu Tablets are composed of various medicinal ingredients such as Salvia miltiorrhiza, Prunus persica seed, Gynostemma pentaphyllum, pine pollen, Cordyceps sinensis, and Schisandra chinensis. They have the functions of promoting blood circulation and removing blood stasis, nourishing the liver and enriching essence, and can be used to treat chronic liver diseases, anti-fibrosis, and patients with liver cirrhosis.
214891542|NCT07017426|OTHER|Placebo Comparator|placebo combined with conventional antiviral therapy
214891543|NCT07018414|BEHAVIORAL|Abdominal Massage|Non-pharmacological intervention involving manual massage of the abdomen to support gastric motility and reduce gastric residual volume and abdominal distension in enterally fed surgical ICU patients.
214891544|NCT04416282|DRUG|Terlipressin|Injection terlipressin 2 mg/24 hours infusion
214891545|NCT04416282|BIOLOGICAL|Albumin|i/v albumin 1g/Kg/day
214891546|NCT07022678|OTHER|Best Practice|Given standard chemotherapy
214891547|NCT07022678|PROCEDURE|Biospecimen Collection|Undergo saliva sample collection
214295593|NCT03020407|DRUG|Vasopressor|The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
214295594|NCT04488289|OTHER|Lifestyle|Cardiovascular risk and lifestyle
214295595|NCT05195112|DRUG|MT921|Active ingredient
214295596|NCT05195112|DRUG|Placebo|Normal Saline
214295597|NCT05715008|OTHER|Kefir|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
214295598|NCT05715008|OTHER|Placebo|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
214891548|NCT07022678|DRUG|Cytarabine|Given IV
214295599|NCT03823352|DRUG|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
214295600|NCT03835585|DEVICE|Gun lock|A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.
214295601|NCT03835585|OTHER|Suicide Risk Assessment|Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
214668347|NCT04266574|DEVICE|Standard Care|Controls will be treated according to standard of care, maintaining a MAP≥65 and an adequate cardiac output according to the hemodynamic monitoring chosen by the anesthesiologist (invasive blood pressure monitoring or pulse contour monitors). NIRS will be recorded also in controls, but caring anesthesiologists will be blinded to NIRS.
214668348|NCT05575310|PROCEDURE|Total Knee Arthroplasty|Articular knee surface replacement
214891549|NCT07022678|OTHER|Electronic Health Record Review|Ancillary studies
214891550|NCT07022678|DRUG|Placebo Administration|Given intraorally
214891551|NCT07022678|OTHER|Xylitol-containing Oral Wipe|Given intraorally
214891552|NCT04164290|DRUG|Jiashen Tablets|1 tablet
214891553|NCT04164290|DRUG|Jiashen Tablets|2 tablets
214891554|NCT04164290|DRUG|Jiashen Tablets|4 tablets
214891555|NCT04164290|DRUG|Jiashen Tablets|6 tablets
214891556|NCT04164290|DRUG|Jiashen Tablets|8 tablets
214891557|NCT04164290|DRUG|Jiashen Tablets|9 tablets
214891558|NCT04164290|DRUG|Jiashen Tablets Placebo|1 tablet
214891559|NCT04164290|DRUG|Jiashen Tablets Placebo|2 tablets
214891560|NCT04164290|DRUG|Jiashen Tablets Placebo|4 tablets
214891561|NCT04164290|DRUG|Jiashen Tablets Placebo|6 tablets
215057370|NCT00524888|PROCEDURE|suturing laceration|suturing simple lacerations of the hand
215057371|NCT00524888|PROCEDURE|bioadhesive|using bioadhesive on simple lacerations of the hand
214891562|NCT04164290|DRUG|Jiashen Tablets Placebo|8 tablets
214891563|NCT04164290|DRUG|Jiashen Tablets Placebo|9 tablets
214891564|NCT00766740|DEVICE|thrombectomy devices|mechanical or manual devices able to remove thrombus from the coronary arteries.
214891565|NCT00766740|DEVICE|angioplasty|percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
214891566|NCT06551207|DRUG|Fruquintinib|Fruquintinib:5mg ,qd,po, d1-d14, q3w
214891567|NCT06551207|DRUG|Cadonilimab|Cadonilimab:10mg/kg, ivgtt, d1, q3w
214891568|NCT06551207|RADIATION|SBRT|SBRT:8-10Gy×5F, god, in 10 days
214295602|NCT03835585|BEHAVIORAL|Safety Planning|A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley \& Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
214295603|NCT03835585|BEHAVIORAL|Lethal Means Counseling|A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
214891569|NCT04286711|DRUG|Albumin-paclitaxel, Apatinib, Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8, Repeat the therapeutic schedule every 3 weeks; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day, Q3W;
214891570|NCT01259479|DRUG|Satraplatin|Orally, once daily for 5 days repeated every 28 days, dose-escalation
214907153|NCT06908681|PROCEDURE|Bilateral Intertransverse Process Block (ITPB)|A bilateral intertransverse process block (ITPB) will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine per side prior to coronary artery bypass grafting. The block targets the dorsal rami of thoracic spinal nerves to provide postoperative analgesia.
214907154|NCT06908681|PROCEDURE|placebo saline injection|A bilateral placebo injection (20 mL of 0.9% saline per side) will be administered at the same anatomical site under ultrasound guidance prior to coronary artery bypass grafting, mimicking the ITPB procedure without active drug.
214907155|NCT03625037|BIOLOGICAL|Epcoritamab|Administered as specified in the treatment arm.
214907156|NCT06098144|DRUG|Nicorette|"Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition."
214907157|NCT06098144|BEHAVIORAL|Tobacco Quit-line|The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.
214907158|NCT06098144|BEHAVIORAL|Brief Behavioral Counseling|"The counseling session will discuss preparing to quit, coping with job-related stress, getting social support, the 5A's for preventing relapse (Avoid, Alter, Alternatives, Anticipate, and Active), proper use of NRT, and last approximately 30 minutes."
214907159|NCT06098144|BEHAVIORAL|Intensive Behavioral Counseling|Participants will receive four weekly counseling sessions which include information about how to quit, challenges, and short and long-term relapse prevention. Each session will last approximately 20 minutes.
214907160|NCT05425927|DEVICE|SyMRI 15 (3D)|Neurological MRI image collection
214891571|NCT06370611|DEVICE|Early mobile health intervention supplemented by weekly calls from a physiotherapist|"Six-week home-based rehabilitation program using the ICURA app and sensor-based technology (ICURA ApS, Copenhagen, Denmark). During the hospital stay patients in the intervention group are introduced to the app's usage, and an individualized training plan is collaboratively created and subsequently tailored by a physiotherapist.~The comprehensive mobile health intervention includes customized training programs, activity tracking, visualization of exercises with videos, and a password-protected webpage for physiotherapists to customize training programs and track patient activity.~The patients will receive two calls from a physiotherapist per week for the first two weeks and as required the following four weeks."
214891572|NCT03231111|OTHER|Preventive Multimedia Teaching Program|Preventive Multimedia Teaching Program
214891573|NCT00488189|DRUG|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
214891574|NCT00366795|DRUG|Satavaptan|oral administration once daily
214891575|NCT00366795|DRUG|placebo|oral administration once daily
214891576|NCT02398266|DRUG|Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)|Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
214891577|NCT00479986|DRUG|pioglitazone|
214891578|NCT00479986|DRUG|placebo|
214891579|NCT01328184|DRUG|levonorgestrel|multiple doses
214891580|NCT01328184|DRUG|levonorgestrel|multiple doses
214891581|NCT01328184|DRUG|Ethinylestradiol|multiple doses
214891582|NCT01328184|DRUG|Microgynon + BI 10773|multiple doses BI 10773
214891583|NCT01328184|DRUG|Ethinylestradiol|multiple doses
214891584|NCT03807570|DIETARY_SUPPLEMENT|Morus Alba L. Extract|Morus Alba L. Extract 30 ml/day for 12 weeks.
214891585|NCT03807570|DIETARY_SUPPLEMENT|Placebo|Placebo 30 ml/day for 12 weeks.
214891586|NCT04652960|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214891587|NCT04652960|PROCEDURE|Computed Tomography|Undergo CT scan
214891588|NCT04652960|DRUG|Duvelisib|Given PO
214891589|NCT04652960|BIOLOGICAL|Nivolumab|Given IV
214891590|NCT04652960|PROCEDURE|Positron Emission Tomography|Undergo PET
214891591|NCT04652960|PROCEDURE|Punch Biopsy|Undergo punch biopsies
214891598|NCT01739712|BEHAVIORAL|Sleep extension|There will be a consultation with families to help youth to be successful in extending their sleep.
214891599|NCT01739712|BEHAVIORAL|Fixed Sleep Duration|There will be a consultation with families to instruct youth to maintain the same average nightly sleep duration during the modification week. The purpose is to control for time and attention.
214891600|NCT04639284|DRUG|Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies|Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
214891601|NCT03630380|OTHER|Clinical History|We will collect clinical history for each patient (days of illness, history of fever, cough, difficulty breathing, vomiting, chest pain).
214891602|NCT03630380|OTHER|Physical Exam Findings|We will collect physical exam findings including vital signs, WHO criteria for diagnosing pneumonia, and lung auscultation findings.
214891603|NCT03630380|OTHER|Laboratory Findings|We will collect laboratory findings (white blood cell counts, differential, and c-reactive protein) if ordered by the clinician.
214891604|NCT03630380|OTHER|Lung Ultrasound|We will perform lung ultrasound on all patients.
214891605|NCT01959295|DRUG|ASP2151|200 mg once daily
214891606|NCT01959295|DRUG|ASP2151 placebo|once daily
214891607|NCT02698033|DRUG|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
214891608|NCT02698033|OTHER|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
214891609|NCT03008759|OTHER|Dentifrice 100% Nano-F|Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.
214891610|NCT03008759|OTHER|Dentifrice 50% Nano-F|Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.
214891611|NCT03008759|OTHER|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
214891612|NCT06908304|DRUG|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
214891613|NCT06908304|DRUG|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
214891614|NCT06908304|DRUG|Docetaxel|Chemotherapy drug; inhibits cell division by stabilizing microtubules. Used for breast, lung, and prostate cancers.
214891615|NCT06908304|DRUG|Vinorelbine|Chemotherapy drug; disrupts microtubule formation, inhibiting cell division. Used for non-small cell lung cancer and breast cancer.
214891616|NCT06908304|DRUG|Gemcitabine alone|Chemotherapy drug; inhibits DNA synthesis. Used for pancreatic, lung, breast, and ovarian cancers.
214891617|NCT06901531|DRUG|zolbetuximab|Participants will receive an IV infusion of zolbetuximab on Cycle 1 Day 1 (C1D1) followed by subsequent IV infusion every 2 weeks or every 3 weeks.
214891618|NCT06901531|DRUG|Pembrolizumab|Participants will receive an IV infusion of pembrolizumab every 3 weeks or every 6 weeks.
214891619|NCT06901531|DRUG|Capecitabine|Participants receiving CAPOX regimen of chemotherapy will receive capecitabine Tablet twice daily orally on days 1 through 14 and days 22 through 35 of each cycle.
214891620|NCT06901531|DRUG|Oxaliplatin|Participants receiving CAPOX or mFOLFOX6 regimen of chemotherapy will receive an IV infusion of oxaliplatin once every 2 or 3 weeks.
214891621|NCT06901531|DRUG|Folinic acid (leucovorin or local equivalent)|Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion of Folinic acid (leucovorin or local equivalent) once every 2 weeks.
214891622|NCT06901531|DRUG|5-fluorouracil (5-FU)|Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion, or IV bolus of 5-FU once every 2 weeks.
214891623|NCT06901531|DRUG|Placebo|Participants will receive an IV infusion of placebo (0.9% of sodium chloride) on C1D1 followed by subsequent IV infusion every 2 weeks or every 3 weeks.
214891624|NCT07097701|DRUG|Granular powder in unit dose foil-lined sachet Mexiletine (PR)|Mexiletine (PR)
214891625|NCT07097701|DRUG|Oral Capsule Mexiletine (IR)|Mexiletine (IR)
214891626|NCT07097259|COMBINATION_PRODUCT|Test: Follitropin alfa|It is a solution for injection in prefilled pen. Participants will receive follitropin alfa on Day 1 in Study Period 1 or Study Period 2. A washout period of at least 23 days will be maintained between period 1 and 2.
214891627|NCT07097259|DRUG|Reference: Follitropin alfa|It is a powder and diluent for solution for injection in multidose vial. Participants will receive follitropin alfa on Day 1 in Study Period 1 or Study Period 2. A washout period of 23 days will be maintained between period 1 and 2.
214891628|NCT07097259|DRUG|Zoladex|It is a auxiliary medicinal product. Participants will receive Zoladex injection on Day -11 in down regulation period, and on Day 17 prior to the start of Period 2.
214891629|NCT07136012|DRUG|Olpasiran|Olpasiran will be administered via SC injection.
214891630|NCT07136012|DRUG|Placebo|Placebo will be administered via SC injection.
214891631|NCT06345807|OTHER|Individuals activity programs|activity program will be adjusted every week by practitioner for each patient following data coming from the wearable device ( connected whatch and bellt for 12 months)
214891632|NCT06345807|OTHER|activity program|pre established program without adjustement. The patient has connected whatch and bellt for 12 months
214891633|NCT06345807|OTHER|no Physical Activity program|no Physical Activity (PA)program but just PA recommendations.PA is carried out independently (common practice).The patient has connected whatch and bellt for 12 months
214891634|NCT07089784|DRUG|MK-2828|Oral capsule of MK-2828 taken once per day for 28 days.
214891635|NCT07089784|DRUG|Placebo|Placebo to match MK-2828 oral capsule, taken once per day for 28 days.
214891636|NCT06765070|DEVICE|EXPLORER|Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.
214891637|NCT06819254|DRUG|Fisetin followed by Placebo|Fisetin 20 mg/kg per dose twice daily on two consecutive days for two consecutive weeks. Participants will return on day 14 for a blood draw followed by a 14-day wash-out. At the 4-week visit participants will receive a cross-over placebo-controlled dosing regimen to be taken twice daily on two consecutive days for two consecutive weeks.
215057372|NCT04921852|PROCEDURE|costoclavicular brachial plexus block|A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.
214668349|NCT06518161|OTHER|Voluntary|Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
214891638|NCT06819254|DRUG|Placebo followed by Fisetin|Placebo twice daily on two consecutive days for two consecutive weeks. Participants will return on day 14 for a blood draw followed by a 14-day wash-out. At the 4-week visit participants will receive a cross-over Fisetin 20 mg/kg per dose twice daily on two consecutive days for two consecutive weeks.
214891639|NCT06849713|DRUG|Zanubrutinib|Bruton's Tyrosine Kinase (BTK) inhibitor
214891640|NCT06849713|DRUG|Sonrotoclax|B-cell lymphoma 2 (BCL2) protein inhibitor
214891641|NCT06849713|DRUG|Obinutuzumab|Anti-CD20 monoclonal antibody
214891642|NCT07077447|PROCEDURE|Kidney sparing surgery for high-risk upper urinary tract urothelial carcinoma|"This is an observational cohort study with no direct intervention assigned by the investigators. The study compares two groups of patients in our cohort diagnosed with high-risk pTa upper tract urothelial carcinoma (UTUC), as defined by the European Association of Urology (EAU) guidelines. The experimental group includes patients who, due to imperative indications (e.g., solitary kidney, impaired renal function, or comorbidities), undergo kidney-sparing surgery. These patients are compared to a reference group treated with radical nephroureterectomy, which is considered standard of care."
214891643|NCT06087029|PROCEDURE|TEVAR|Thoracic endovascular aortic repair
214891644|NCT06087029|OTHER|Guideline directed medical therapy and surveillance of dissection|Routine clinical care with suggested antihypertensive therapy and cardiovascular risk factor reduction as per appropriate cardiovascular guidelines.
214891645|NCT07095504|BEHAVIORAL|Virtual World-based Cardiac Rehabilitation (VWCR) program|36 Virtual World-based Cardiac Rehabilitation sessions over the course of 12 weeks (3 sessions/week)
214891646|NCT01611779|DEVICE|Encore Tongue Suspension System|The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
214891647|NCT03576079|DEVICE|Laser therapy|epic model biolase with an output of 4W, 1800 J wavelength with a continuous Laser mode.
214891648|NCT03576079|DEVICE|anterior re-positioning splint|hard acrylic anterior re-positioning splint
214891649|NCT03576079|DEVICE|inactive Laser therapy|sham Laser, with inactive beam
214891650|NCT05608473|OTHER|Posture Exercises|A 10-minute video consisted of 14 cervical and thoracal postural exercises was uploaded to the computers of the participants. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
214891651|NCT00262665|DRUG|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
214891652|NCT00262665|DRUG|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
214891653|NCT02644915|DRUG|Edaravone|Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
214891654|NCT02644915|DRUG|0.9%%NaCl solution|"100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)\> 6 mmHg"
214891655|NCT03475992|DEVICE|Low-power microwave breast imaging system|Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
214891656|NCT03791684|DEVICE|Cross linking|Cross linking strategy either standard or accelerated
214891657|NCT07100106|DRUG|GDC-4198|GDC-4198 will be administered orally.
214891658|NCT07100106|DRUG|Giredestrant|Giredestrant will be administered orally.
214891659|NCT07100106|DRUG|Abemaciclib|Abemaciclib will be administered orally.
214891660|NCT06892548|BIOLOGICAL|BNT324|Intravenous infusion
214891661|NCT06892548|BIOLOGICAL|BNT327|Intravenous infusion
214668350|NCT02082561|BEHAVIORAL|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
214891662|NCT07101328|DRUG|LY4152199 - IV|Administered by IV infusion
214891663|NCT07101328|DRUG|LY4152199 - SC|Administered by SC injection
214891664|NCT07104838|PROCEDURE|Non-intubated spontaneous ventilation anesthesia|Non-intubated spontaneous ventilation anesthesia
214891665|NCT02698111|DRUG|Donafenib|donafenib 200mg，bid
214891666|NCT05026827|OTHER|Iyengar Yoga|Participation in Iyengar Yoga classes
214891667|NCT05026827|OTHER|Socialization Control|Participation in socialization control group sessions
214891668|NCT06747949|DRUG|Dazodalibep|Dazodalibep will be given intravenously (IV).
214891669|NCT06908096|BIOLOGICAL|EBV gp350-ferritin vaccine with ALFQ adjuvant|The adjuvanted gH/gL/gp42-ferritin nanoparticle vaccine is given with gp350-ferritin intramuscularly into the deltoid muscle at 0, 1, and 4 months.
214891670|NCT06908096|BIOLOGICAL|EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant|The adjuvanted gH/gL/gp42-ferritin nanoparticle vaccine is given with gp350-ferritin intramuscularly into the deltoid muscle at 0, 1, and 4 months.
214891671|NCT05409976|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.
214891672|NCT05531565|DRUG|Litifilimab|Administered as specified in the treatment arm.
214891673|NCT05531565|DRUG|Placebo|Administered as specified in the treatment arm.
214891674|NCT04743960|DIETARY_SUPPLEMENT|Time-of-day of parenteral nutrition provision|Parenteral nutrition will be provided during the nighttime followed by daytime.
214891675|NCT06667700|DRUG|Molnupiravir|Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
214891676|NCT06667700|DRUG|Placebo|Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
215057373|NCT04921852|PROCEDURE|lateral sagittal infraclavicular block|A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
214891677|NCT06917222|PROCEDURE|Slide tracheoplasty|Management of tracheal stenosis by slide tracheoplasty
214891678|NCT06917222|PROCEDURE|Tracheal resection anastomosis|Management of tracheal stenosis by tracheal resection anastomosis
214891679|NCT07106658|OTHER|TEAS + Urgent Endoscopy|Participants receive real Transcutaneous Electrical Acupoint Stimulation (TEAS) delivered via surface electrodes bilaterally at four predefined acupoints (Hegu \[LI4\], Neiguan \[PC6\], Zusanli \[ST36\], Gongsun \[SP4\]). Stimulation (dense-disperse wave, 2/100Hz frequency, intensity 5-15mA based on tolerance) begins 30 minutes before urgent endoscopy and continues throughout the procedure. All participants receive standard medical management and urgent endoscopy.
214891680|NCT07106658|OTHER|Sham TEAS + Urgent Endoscopy|Participants receive placebo TEAS. Electrodes are placed identically to the Active TEAS Group at the same four acupoints (Hegu \[LI4\], Neiguan \[PC6\], Zusanli \[ST36\], Gongsun \[SP4\]) using the same device, but no electrical current is delivered. The device appears active to maintain blinding. All participants receive standard medical management and urgent endoscopy.
214891681|NCT07106658|OTHER|Urgent Endoscopy Only|Participants receive standard urgent endoscopy care only, with no TEAS electrodes or device applied. They receive identical standard medical management and urgent endoscopy as the other groups.
214891682|NCT07107737|BEHAVIORAL|Physician Consultation|Every other month will be randomized to either Physician Consultation or Standard of Care. During the months designated for Physician Consultation, direct communication between the patient and a designated physician by phone will be implemented when a patient refuses transport in cases where the EMS clinician feels that physician consultation is warranted for further guidance. The physician will attempt to address patient concerns and provide additional medical advice.
214891683|NCT07107737|BEHAVIORAL|Standard of Care|Every other month will be randomized to either Physician Consultation or Standard of Care. During the months designated for Standard of Care, physician intervention will not be provided. For safety reasons, if physicians or EMS MEDIC clinicians feel that speaking with the patient is important to provide additional clinical benefit, they may do so without hesitation and can override the designated intervention month.
214891684|NCT07105878|PROCEDURE|Epidural Electrical Stimulation|Epidural Electrical Stimulation (EES) is a medical technology that involves delivering controlled electrical impulses to the spinal cord through electrodes implanted in the epidural space-the area between the outermost membrane of the spinal cord (dura mater) and the vertebrae. This technique aims to modulate the activity of spinal neural networks, thereby regulating neurological functions and promoting functional recovery, particularly in individuals with spinal cord injuries or certain neurological disorders.
214891685|NCT07105878|PROCEDURE|Standard Rehabilitation Therapy|A structured, multidisciplinary rehabilitation program designed to improve motor function, mobility, and independence in participants with paralysis. The therapy typically includes physical Therapy and occupational Therapy.
214891686|NCT07105878|RADIATION|positron emission tomography-computed tomography (PET-CT)|PET-CT is an advanced hybrid imaging modality that combines metabolic information from positron emission tomography with anatomical details from computed tomography.
214891687|NCT07105878|RADIATION|Diffusion Tensor Imaging (DTI)|DTI is an advanced MRI technique that maps white matter tracts by measuring the directionality (anisotropy) and magnitude of water molecule diffusion in neural tissues. It provides quantitative metrics of fibers.
214891688|NCT07105878|PROCEDURE|Somatosensory Evoked Potentials (SEPs)|SEPs are electrophysiological responses recorded from the central or peripheral nervous system following electrical stimulation of sensory nerves. They assess the functional integrity of somatosensory pathways.
214891689|NCT07105878|PROCEDURE|Motor Evoked Potentials (MEPs)|MEPs are electrophysiological responses elicited by transcranial magnetic stimulation or electrical stimulation of the motor cortex, recorded from peripheral muscles or the spinal cord. They evaluate the integrity of corticospinal tracts.
214907161|NCT07098351|DRUG|Remitch|Nalfurafine 2.5μg daily for 2 weeks. Afterwards, the dose can be increased to 5μg daily if necessary (maximum dose not exceeding 5μg daily), continued for another 2 weeks.
214907162|NCT07094984|OTHER|Fecal microbiota transplantation (FMT)|FMT administered after antibiotic pre-treatment and bowel cleansing. Delivered either in capsule form or via colonoscopy to restore healthy gut microbiota and support decolonization of ARB.
214907163|NCT07094984|DIETARY_SUPPLEMENT|Probiotic Therapy|Oral administration of a high-dose multistrain probiotic containing Lactobacillus, Bifidobacterium, and Streptococcus strains for 20 days following bowel cleansing.
214907164|NCT07094984|OTHER|Gut Microbiota Boosting Diet|A structured 38-day diet designed to promote eubiosis and support spontaneous ARB decolonization. Meals are tailored and delivered to patients based on clinical nutrition protocols.
214907165|NCT05636267|DRUG|AK119|AK119 IV every 3 weeks.
214907166|NCT05636267|DRUG|AK112|AK112 IV every 3 weeks.
214907167|NCT05636267|DRUG|Pemetrexed|Pemetrexed IV every 3 weeks.
214907168|NCT05636267|DRUG|Carboplatin|Carboplatin IV every 3 weeks.
214907169|NCT07106970|PROCEDURE|Linear ablation|Linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device.EIVOM could be performed additionally before or after PFA at the operator's discretion.
214907170|NCT07106970|PROCEDURE|PVI alone|Undergo PVI with the study device
214907171|NCT07142356|DRUG|RTN-001|A potent and selective PDE5 inhibitor.
214907172|NCT07142356|DRUG|Matching placebo control|The reference/comparator product is a matching placebo tablet with similar appearance and weight as the RTN-001 oral tablet.
214907173|NCT07142369|PROCEDURE|Synovial Fluid withdrawal at the preoperative clinic visit|Synovial Fluid withdrawal at the preoperative clinic visit
214907174|NCT07142369|PROCEDURE|Platelet-Rich Plasma (PRP) preparation and injection|Platelet-Rich Plasma (PRP) preparation and injection
214907175|NCT07142369|PROCEDURE|Synovial fluid withdrawal at the time of surgery|Synovial fluid withdrawal at the time of surgery
214907176|NCT07142369|PROCEDURE|3mL synovial fluid withdrawn at the preoperative visit|3mL synovial fluid withdrawn at the preoperative visit
214907177|NCT07142148|DIAGNOSTIC_TEST|CDAT - phase 1|"The English version of the Celiac Dietary Adherence Test (CDAT) will be translated into Polish using the forward-backwards-forward translation model, with the author's consent (already obtained by the applicants). The Polish translation will be performed by two native bilingual speakers of Polish and English. Both translations will be compared and standardised. The Polish version will then be translated into English by two native bilingual speakers of English who are unfamiliar with the original English version. The translation and original will be compared to clarify discrepancies and ensure conceptual equivalence between the versions. The agreed-upon translation will be culturally adapted, if necessary. The items will be reviewed by five experts, and an I-CVI of at least 0.78 will be considered satisfactory content validity."
214907178|NCT07142148|OTHER|CDAT - phase 2|"In the next step, 10 coeliac disease (CD) patients aged 10 years and older and 10 caregivers/parents of CD patients under 10 years of age will be asked to rate the clarity of each statement on a Likert scale \[1 = unclear to 5 = very clear\]. Questions with a mean score \<4.0 will be rephrased and re-evaluated.~Internal consistency analysis using Cronbach's alpha and the mean inter-item correlation (AIC) will be used to assess reliability. Convergent validity will be assessed by comparing scale scores with serological marker levels. Confirmatory factor analysis (CFA) will be conducted, taking into account the SRMR fit index."
214907179|NCT07141992|OTHER|Active Neural Mobilzations|Participants in this group will receive active neural mobilization in the form of neural flossing techniques. These involve controlled, repeated movements performed actively by the patient to mobilize peripheral nerves without placing them under excessive tension. The goal is to restore neural mobility, reduce mechanosensitivity, and relieve neuropathic symptoms such as burning pain.
214907180|NCT07141992|OTHER|Passive Neural Mobilzations|Participants in this group will receive passive neural mobilization using neural tensioning techniques. These techniques involve therapist-applied passive limb movements that place a controlled tensile load on the neural structures. The objective is to improve neural gliding, reduce nerve compression, and decrease neuropathic pain, particularly in cases of restricted neural tissue mobility.
214891690|NCT07112742|DEVICE|High-Intensity Laser Therapy and Exercise|High-intensity laser therapy will be applied to the painful and affected joint of the participants. A Class IV high-intensity laser device will be used. The parameters to be applied have been determined based on the relevant guidelines: average power 3 W, in analgesic mode, wavelength of 1064 nm, frequency of 2 Hz, energy dose of 75 J per session, spot size of 5 cm², and treatment will be administered three times per week for a total of 4 weeks. The total treatment duration will be 160 seconds. A standard exercise program including range of motion, stretching, and strengthening exercises will be administered to the participant during the treatment sessions. Strengthening exercises will be performed using a therapy ball to improve grip and pinch strength.
214478012|NCT06867744|PROCEDURE|Extracapsular Supradiscal Subperiosteal Surgical Procedure for Temporomandibular Joint Internal Derangement Correction|Patients in a supine extended position with nasotracheal intubation; oral intubation in such cases is not suitable as it makes dissection and disc repositioning difficult and compromises the surgery results. Periauricular incision with postauricular extension; after infiltration with noradrenaline 1/200000 solution with or without zylocaine which gives better exposure and better aesthetic results. Dissection down the wound till reach the temporal fascia starting posteriorlay till the fascia blended with the zygomatic arch anteriorly; identification of temporal root of zygomatic arch using fine dissector followed by subperiosteal dissection of zygomatic arch till five mm anterior to the articular eminence of TMJ. Accurate identification of TMJ followed by meticulous subperiosteal dissection of superior margin of TMJ capsule then the dissection continued posteriorly till posterior margin; no need to dissect the bilaminar zone, and the dissection continued anteriorly down the skull base t
214295604|NCT05951010|DEVICE|Transcranial Direct Current Stimulation|Anodal stimulation was delivered by a battery-driven stimulator (Neuroelectrics, Barcellona, Spain) through a pair of saline-soaked surface sponge electrodes (7 x 5 cm2) producing a constant current of 2 mA for 20 min. The anode was placed 2 cm under the inion and the cathode was placed over the right deltoid muscle (CD-tDCS) or the spinal lumbar enlargement (2 cm under T11) as described by Benussi et al. (CS-tDCS). An electroconductive gel was applied to the electrodes to reduce contact impedance and the electrodes were held in place using elastic gauzes.
214891691|NCT07112742|DEVICE|High-Intensity Laser Therapy at a Non-Therapeutic Dose Combined With Exercise|Participants will receive high-intensity laser therapy at an ineffective dose to the painful and affected joint. Due to the absence of a placebo mode in the laser device used in hospital, the lowest possible parameters will be applied to simulate an ineffective dose. For the ineffective dose, the device parameters will be set as follows: average power 0.5 W, in analgesic mode, wavelength of 1064 nm, frequency of 1 Hz, energy dose of 12 J per session, spot size of 5 cm², and treatment will be administered three times per week for a total of 4 weeks. The treatment duration will be the same as that of the intervention group. A standard exercise program including range of motion, stretching, and strengthening exercises will be administered to the participant during the treatment sessions. Strengthening exercises will be performed using a therapy ball to improve grip and pinch strength.
214891692|NCT07114601|DRUG|LY4257496|Administered IV
214891693|NCT07114601|DRUG|Standard of Care Anticancer Therapies|Fulvestrant, Imlunestrant, Aromatase Inhibitors, Capecitabine, Abemaciclib
214891694|NCT06923306|BEHAVIORAL|Virtual reality exposure|This is a single case design and there is only one intervention. In the no-treatment arm, participants will only have assessment but no virtual reality exposure therapy.
214891696|NCT06926699|PROCEDURE|Medial Patellofemoral Ligament Reconstruction|An initial evaluation with a diagnostic knee arthroscopy is done to ensure there are no loose bodies or osteochondral lesions missed on MRI that require removal or fixation. Graft harvest and preparation is done using either an autograft or allograft tendon as per a shared decision-making approach between the surgeon and patient. A 2cm longitudinal incision is made over the anteromedial aspect of the patella and dissection done between the second and third layers. Fixation (variable depending on surgeon preference) is performed over the proximal half of the patella. Another skin incision is then made over the medial femoral epicondyle with a guide pin passed through Schottle's point. The proximal femoral cortex is then drilled overtop of the guide pin to a diameter equal to the graft diameter with the remainder of the femoral tunnel drilled to 4.5mm.The graft ends are tied to the patellar fixation and shuttled through the second and third layers and fixed to the femur.
214891697|NCT06926699|OTHER|Rehabilitation|Patients will be initially placed in a patellar stabilizing brace and told to remain non weight-bearing for the first two weeks. Subjects will be permitted to perform gentle ROM exercises while in the knee brace with progressive weight-bearing as tolerated permitted at the 2-week mark. Formal physiotherapy commences at 2-weeks post-enrollment, with a goal of return to activities or sport at 6-months post-enrollment.
214891698|NCT06932263|DRUG|Tozorakimab|The drug will be administered subcutaneously.
214891699|NCT06932263|DRUG|Placebo|Placebo will be administered subcutaneously.
214891700|NCT06932250|OTHER|Leg heating|Participants will perform home-based leg heating using a portable sauna blanket set at different temperature.
214891701|NCT07128368|OTHER|Resistance Exercise Training|Participants will undergo resistance exercise training 3 days a week for approximately 1 hour each day for 8 weeks.
214891702|NCT07140679|PROCEDURE|Biopsy Procedure|Undergo biopsy
214891703|NCT07140679|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214891704|NCT07140679|PROCEDURE|Colonoscopy|Undergo colonoscopy
214891705|NCT07140679|PROCEDURE|Computed Tomography|Undergo CT
214891706|NCT07140679|OTHER|Questionnaire Administration|Ancillary studies
214891707|NCT07140679|DRUG|Toripalimab|Given IV
214891708|NCT04004403|OTHER|Alternate day fasting|"The diet involves consuming 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
214891709|NCT04004403|OTHER|Exercise|The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
215057374|NCT03043690|DIETARY_SUPPLEMENT|Ammonium succinate|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
214891710|NCT04872985|DRUG|Pyrotinib|400 mg orally once per day. Pyrotinib starts with a dose of 240 mg once daily for one week, followed by 320 mg once daily for the next week, before transitioning to 400 mg once daily as maintenance therapy.
214891711|NCT04872985|DRUG|Epirubicin|100 mg/m2,q3W\*4
214891712|NCT04872985|DRUG|Doxorubicin Hydrochloride Liposome Injection|30mg/m2, q3w\*4
214891713|NCT04872985|DRUG|Cyclophosphamide|600 mg/m2, q3w\*4
214891714|NCT04872985|DRUG|Docetaxel|100 mg/m2, q3w\*4
214891715|NCT04872985|DRUG|Nab paclitaxel|120mg/m2 qw\*12 or 260mg/m2 q3w\*4
214891716|NCT04872985|DRUG|Placebo|400 mg orally once per day
214891717|NCT06938399|DEVICE|Silicone gel-filled breast implants - Motiva Implants®|Breast Surgery
214295605|NCT05221814|DIAGNOSTIC_TEST|gross pathologic photo based deep learning model|Whether apply gross pathologic photo based deep learning model to predict pathologic subtype
214891718|NCT06938399|OTHER|Aesthetic Surgery|Aesthetic procedure other than breast implant surgery
214891719|NCT06942910|DRUG|Zibotentan/Dapagliflozin|Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
214891720|NCT06942910|DRUG|Dapagliflozin|Participants will receive dapagliflozin in fixed-dose combination as per the arms they are randomized to
214891721|NCT06942078|PROCEDURE|Cryoneurolysis|Targeting of specific nerves related to surgical procedure using very low temperatures
214891722|NCT07143604|DRUG|AZD0901|Participants will receive AZD0901 IV, Q3W
214891723|NCT07144293|DRUG|Dasatinib|Dasatinib will be administered as one 100 mg capsule.
214891724|NCT07144293|DRUG|Quercetin|Quercetin will be administered as five 250 mg capsules.
214891725|NCT07144293|OTHER|Placebo - Dasatinib|Matching Placebo for Dasatinib will be administered as one 100 mg capsule.
214891726|NCT07144293|OTHER|Placebo - Quercetin|Matching Placebo for Quercetin will be administered as five 250 mg capsules.
214891727|NCT07139314|DRUG|Early anticoagulation|Early initiation of direct oral anticoagulants will be started within 4 weeks after symptom onset.
214891728|NCT07139314|DRUG|Delayed anticoagulation|Delayed initiation of direct oral anticoagulants will be started between 4-8 weeks after symptom onset.
214891729|NCT07146581|BEHAVIORAL|SIRENS|The SIRENS intervention is a technology intervention designed specifically for caregivers of those with dementia, providing them with easy access to expert-reviewed information and helpful resources. The content includes take-home messages summarizing the main points discussed and a goal-setting feature that encourages the care givers to establish small, actionable goals.
214891730|NCT06946056|OTHER|biofiller prp|Ten ml of the patient's blood was drawn in a syringe pre-filled with 1 mLacid citrate dextrose(anticoagulant). It wascentrifuged firstat 3500 rotations per minute (RPM)for 15 min and thenat 1500 RPM for 5 min. The upper part,i.e.,platelet-poor plasma (PPP) waswithdrawn in a 5 mL syringe. PPP wasincubated in hot water at 100a °C for 5 min and then cooled in a refrigerator for 5 min.The PRP injection was performed in a standardized manner and injected into the IA surface of the affected knee joint
214891731|NCT01942421|PROCEDURE|Cultivated mucosal epithelial transplantation|cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
214891732|NCT04207307|BEHAVIORAL|Multimodal exercise program|Multimodal exercise intervention (machine-based resistance, coordination and endurance training).
214891733|NCT04207307|BEHAVIORAL|Usual Care|General recommendations for healthy ageing, no machine-based strength training intervention.
214891734|NCT00251121|OTHER|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
214891735|NCT00251121|OTHER|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
214295606|NCT00607529|OTHER|hand-held POC creatinine analyzer-blood test|"This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis."
214295607|NCT04375189|OTHER|High Risk Clinic|"Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations"
214295608|NCT06085079|DRUG|Ixekizumab Prefilled Syringe|Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.
214295609|NCT00708162|DRUG|Elvitegravir|Elvitegravir (EVG) tablet administered orally once daily with food
214295610|NCT00708162|DRUG|Raltegravir|Raltegravir tablet administered orally twice daily according to prescribing information
214295611|NCT00708162|DRUG|EVG placebo|Placebo to match elvitegravir administered orally once daily
214295612|NCT00708162|DRUG|RAL placebo|RAL placebo administered orally twice daily.
214891736|NCT07148024|DEVICE|ETT cuff pressure 0 mmHg|In this group, the endotracheal tube (ETT) cuff pressure will be maintained at 0 mmHg during cardiopulmonary bypass (CPB)
214891737|NCT07148024|DEVICE|ETT cuff pressure 20-30 mmHg|In this group, the endotracheal tube (ETT) cuff pressure will be maintained at 20-30 mmHg during cardiopulmonary bypass (CPB)
214891738|NCT06954948|BEHAVIORAL|pulmonary rehabilitation (PR)|PR is an exercise and education programme designed for people with lung disease who experience symptoms of breathlessness.
214891739|NCT06953453|DRUG|Inhaled Fentanyl Aerosol|The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg Fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg Fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.
214891740|NCT06953453|DRUG|Fentanyl Citrate Injection|The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.
214891741|NCT07143838|DEVICE|Transcranial Electrical Stimulation (TES)|Using the Sleep WISP device, transcranial electrical stimulation will be delivered during sleep as 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
214891742|NCT07142252|DRUG|Rezpegaldesleukin|Rezpegaldesleukin will be dosed at 12 μg/kg for subcutaneous injection. Rezpegaldesleukin will be provided as a 1.5 mg/mL sterile solution in a vial for injection preparation. Study agent injections will be administered in the abdomen, back of the upper arm or the upper thigh of the participant.
214478013|NCT06867146|DRUG|Three-drug chemotherapy group|Three-drug chemotherapy group, mFOLFIRINOX, including 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.
214891743|NCT07142252|DRUG|Placebo|Sterile saline for injection. Placebo will be administered in the same volume and as the active comparator to maintain treatment masking.
214891744|NCT07149350|BEHAVIORAL|FAVORes Workshop|The FAVORes (Food Access, Value, and Optimization of Resources) Workshop is a 4-week, in-person group coaching program for caregivers of children in food-insecure households. The intervention focuses on financial and nutrition literacy, community resource navigation, healthy eating habits, and setting family goals.
214891745|NCT07152132|PROCEDURE|Trabeculectomy|Trabeculectomy with mitomycin c application
214891746|NCT07152132|PROCEDURE|Slow coagulation trans-scleral cyclophotocoagulation|Slow coagulation trans-scleral cyclophotocoagulation
214891747|NCT07157930|BEHAVIORAL|The Beighton Scoring system|The Beighton Scoring System is widely used to distinguish individuals with generalized joint hypermobility from those without. The Beighton Scoring System consists of: • Passive dorsiflexion of the fifth metacarpophalangeal joint • Passive hyperextension of the elbow • Passive hyperextension of the knee joint • Passive placement of the thumb on the flexor side of the forearm • Forward flexion of the trunk In adults up to 50 years of age, a score of ≥5 out of 9 indicates joint hypermobility, while in adults over 50, a score of ≥4 out of 9 is considered positive for joint hypermobility.
214891748|NCT07157930|BEHAVIORAL|2D:4D Digit Ratio|The lengths of the second (2D) and fourth (4D) digits will be measured separately on both hands. Measurements will be taken with the participants' hands placed on a flat surface with the palms facing upward. Digit length will be defined as the distance from the midpoint of the proximal crease at the base of the finger to the distal tip of the finger. A digital caliper with a precision of 0.01 mm will be used, and two separate measurements will be obtained for each finger, with the mean value recorded. Based on these measurements, the 2D:4D digit ratio will be calculated for each hand by dividing the length of the second digit by that of the fourth digit. To enhance reliability, assessments will be performed independently by two different researchers, and inter-rater agreement will be evaluated.
214891749|NCT07157930|BEHAVIORAL|Pittsburgh Sleep Quality Index|The Pittsburgh Sleep Quality Index is a self-report questionnaire that assesses sleep quality over a one-month period. The measure consists of 19 items divided into 7 components that produce a single overall score and takes 5-10 minutes to complete. Component scores are as follows: • Subjective sleep quality • Sleep latency (time to fall asleep) • Sleep duration • Habitual sleep efficiency (percentage of time spent in bed) • Sleep disturbances • Use of sleeping pills • Daytime dysfunction Each item is scored on a 0-3 scale. The seven component scores are then summed to create an overall score ranging from 0-21, with lower scores indicating better sleep quality
214891750|NCT07160257|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be administered SC.
214891751|NCT07160257|DRUG|Placebo|Placebo will be administered SC.
214891752|NCT07161960|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is the definite treatment for acute cholecystitis. According to Tokyo Guideline 2018, the proper timing of delay LC remains unclear due to lack to proper evidence.
214891753|NCT07165041|PROCEDURE|SPSIP Block|Ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block performed prior to cardiac implantable electronic device (CIED) implantation. A total of 30 mL of 0.25% bupivacaine will be injected into the interfascial plane between the rhomboid major and serratus posterior superior muscles under sterile conditions.
214891754|NCT07165041|PROCEDURE|Sham procedure|Sham procedure with 1 mL saline injection at the same anatomical site, without administration of local anesthetic, prior to CIED implantation.
214891755|NCT07171125|DRUG|Liposomal bupivacaine (local infiltration)|"Patients will receive a pre-closure local infiltration of 266 mg liposomal bupivacaine (20 mL for single-level surgery; 30 mL for two-level surgery) combined with 25 mg bupivacaine hydrochloride (10 mL total volume). The drug will be injected bilateral into the paraspinal muscles and subcutaneous tissues prior to wound closure. This provides both immediate (bupivacaine HCl) and prolonged (liposomal) analgesia."
214891756|NCT07171125|DRUG|ropivacaine (local infiltration)|Patients will receive 120 mg ropivacaine diluted to 30 mL (single-level) or 40 mL (two-level) with normal saline. The solution will be infiltrated bilateral into the paraspinal muscles and subcutaneous tissues using the same technique as the experimental arm, ensuring consistent injection depth and distribution.
214891757|NCT07163845|BIOLOGICAL|Live-attenuated CHIKV vaccine VLA1553|Non-interventional study: VLA1553 is used in the pilot vaccination strategy which is carried out after this observational study.
214478014|NCT06867146|DRUG|two-drug chemotherapy group|two-drug chemotherapy group, including gemcitabine-based combination regimens (predominately gemcitabine/nab-paclitaxel or gemcitabine/capecitabine)
214478015|NCT06867302|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|An infusion given all through intraoperative time
214478016|NCT06867302|DRUG|Dexmedetomidine Injection [Precedex]|Single dose given 15 minutes before end of surgery
214891758|NCT07163299|PROCEDURE|Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml).|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 350 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min.
214295613|NCT00708162|DRUG|Background regimen|Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
214295614|NCT03858088|PROCEDURE|Liver transplantation|Liver transplantation from deceased donors
214295615|NCT04332354|OTHER|routine care. No intervention|no intervention
214295616|NCT04528654|OTHER|Mobile Health Application|The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
214295617|NCT02425150|PROCEDURE|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
214295618|NCT02425150|PROCEDURE|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
214295619|NCT05870709|OTHER|sacubitril/valsartan|There is no treatment allocation. Patients with a first ambulatory sacubitril/valsartan prescription who are interested in study participation will be enrolled.
214891759|NCT07163299|PROCEDURE|Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml).|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 500 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min. Then pause for 5 min, followed by another 5 min of infusion at the original rate.
214891760|NCT07163299|PROCEDURE|Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml).|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 650 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min. Then pause for 5 min, followed by intermittent infusion at the original rate for another 5 min twice. The interval between two times is also 5 min.
214891761|NCT07176559|BEHAVIORAL|Chaplain Intervention Group|Eligible and consented participants that are randomized to the Chaplain Intervention Group will receive a total of 4 visits with a board-certified or board-eligible chaplain. These visits will occur weekly for approximately 4 weeks either in person, by telephone, or through a HIPAA compliant video platform. The visits will last an average of 30 minutes each.
214891762|NCT07173361|DRUG|Micronized progesterone (oral capsules)|Two doses of 400 mg total micronized progesterone, administered as 2 × 200 mg capsules \~34 hours and \~10 hours prior to infusion trial, taken with a standardized nutritional drink.
214891763|NCT07173361|DRUG|placebo capsule|Matched oral placebo capsules administered on the same schedule (\~34 and \~10 hours prior to infusion trial) with a standardized nutritional drink.
214295620|NCT05590065|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
214891764|NCT07170891|DEVICE|Morning Running and IMT|Inspiratory muscle training was performed in addition to morning running
214295621|NCT04212247|BEHAVIORAL|Well-Being Therapy|Well-Being Therapy (WBT) is a short-term psychotherapeutic strategy, that emphasizes self-observation with the use of a structured diary, interaction between patients and therapists and homework. WBT was based on the model of psychological well-being that was originally developed by Jahoda in 1958 and further refined by Ryff in 2014. The standard number of sessions is 8. The initial phase is concerned with self-observation of psychological well-being. Then, the patient is encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of wellbeing. The final part involves cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
214295622|NCT04212247|BEHAVIORAL|Control condition|The control condition will include 8 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drug misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
214295623|NCT00818233|DEVICE|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
214295624|NCT00830843|DRUG|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
214295625|NCT00830843|DRUG|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
214295626|NCT04320381|BEHAVIORAL|Qualitative Interview|2 Semi-Structured Qualitative Interviews
214295627|NCT04634747|DRUG|PVX-410|PVX-410 in combination with pembrolizumab and chemotherapy
214295628|NCT02699554|PROCEDURE|Single-event multilevel surgery|
214295629|NCT00708643|DEVICE|Habitual Silicone Hydrogel Contact Lens|contact lens
214295630|NCT00708643|DEVICE|narafilcon A|contact lens
214295631|NCT00149487|BEHAVIORAL|Tailored Problem Solving Intervention|
214891765|NCT07170891|DEVICE|Inspiratory muscle training and evening running|Inspiratory muscle training was performed in addition to evening running
214891766|NCT07170891|OTHER|Control|non-exercise group
214891767|NCT07176286|DRUG|18F-MFBG|Intravenous injection of 222-370 MBq (6-10 mCi) 18F-mFBG followed by whole body PET imaging.
214295632|NCT00149487|BEHAVIORAL|Family Education Intervention|
214891768|NCT07179523|COMBINATION_PRODUCT|Hemostatic gelatin sponge|Colisorb® exhibits optimal pore structure, number and size, which results in its structure being highly porous with low density. In addition, Colisorb® possesses optimal mechanical integrity allowing it to swell to its maximal absorption capacity while maintaining mechanical stability. The sponge can absorb fluids in the blood resulting in prompt recruitment of clotting factors, hence accelerating the body's natural blood clotting cascade. Colisorb® was configured in a way to imitate natural adhesive mechanism without the use of co-agulants, it provides a safer and a more efficient alternative for minimizing post-operative complications and enhancing recovery. Upon performing the tooth extraction, oral surgeon instantly applied the sponge. Patients were prescribed, antibiotics, and antacid, if needed, for 3 days and analgesics for 5 days, followed by a mouth wash routine of warm water with salt to enhance healing outcomes. Patients visited the clinic three days after surgery.
214295633|NCT02063490|BEHAVIORAL|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~\+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
214295634|NCT03324854|PROCEDURE|Rives technique|Open ventral hernia repair followed by the placement of the mesh.
214295635|NCT03324854|PROCEDURE|Drainage|Placement of active-close drainage in surgical site.
214891769|NCT07179523|COMBINATION_PRODUCT|Hemostatic Agent|"Gelatin sponge that may be soaked with sterile physiological solution. Biocompatible and easy to use for 5 to 10 minute bleeding control rate.~Upon performing the tooth extraction, oral surgeon instantly applied the sponge in the socket where the tooth was extracted to facilitate hemostasis. Patients were prescribed, antibiotics, and antacid, if needed, for 3 days and analgesics for 5 days, followed by a mouth wash routine of warm water with salt to enhance healing outcomes. Patients visited the clinic three days after surgery."
214891770|NCT07183826|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (Internet-delivered)|A 6-week (42 days), unguided online adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program. The intervention consisted of six sequential modules delivered through a secure web platform, including guided mindfulness meditations, body scan, mindful movement, and cognitive-behavioral exercises. Participants received audio recordings, written materials, and reflective tasks, along with automated reminder emails. No therapist guidance was provided.
214295636|NCT03324854|DRUG|Prophylactic|Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
214295637|NCT01772303|DRUG|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
214478017|NCT06867549|DRUG|Propofol|Targeted propofol infusion in TRD patients will induce sedation. Dosage of propofol is determined based upon EEG markers and treatment arm.
214891771|NCT07183826|BEHAVIORAL|No intervention|Participants in this arm received no active intervention during the 6-week waitlist period but completed all study assessments on the same schedule as intervention arms. After the waiting period, participants were offered to take part in the online MBCT program.
214907181|NCT02147977|DIETARY_SUPPLEMENT|dietary supplement: n-3 PUFA|
214295638|NCT04309643|DRUG|CTP-543|Investigational Drug
214295639|NCT04309643|DRUG|Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)|Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
214295640|NCT03351179|COMBINATION_PRODUCT|clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes|The differences of data(clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were conducted. The differences between two groups were compared (clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were compared, and then found the risk factors. Following,the incidence of clinical outcomes and mortality were compared. Then, univariate logistic regression and multivariate logistic regression analysis adjusted for significant risk factors were performed to find out the independent predictive factors. Finally, the ROC was constructed, and the area was evaluated to assess the predicted probability of regression model.
214478018|NCT06867549|DIAGNOSTIC_TEST|Electroencephalography (EEG)|EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
214478019|NCT06867549|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Trained staff will provide evaluation and up to 3 follow up appointments of BBTI for all participants. These will be done remotely to assess behavioral approaches to improve overall sleep habits.
214478020|NCT06867419|RADIATION|Transient Elastography|participants will be subjected to anthropometric measurements, laboratory investigations (complete blood count, liver and kidney functions, lipid profile, virology tests, fasting insulin, fasting sugar, 2 hour postprandial sugar, HbA1c, and HOMA-IR), radiological examination (abdominal ultrasound, Fibroscan). the NAFLD fibrosis score, APRI, FIB-4 score, and FAST score will be calculated.
214907182|NCT02147977|DIETARY_SUPPLEMENT|olive oil|
214295641|NCT03619187|DRUG|Ivabradine|Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
214295642|NCT05882240|OTHER|choice of initial position|current practice of correct application and interpretation of the PLR in critical care patients
214295643|NCT04474067|OTHER|No intervention|This is an observational study, with no intervention.
214295644|NCT01545284|DRUG|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
214295645|NCT00065507|DRUG|Entecavir (ETV)|Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
214295646|NCT00065507|DRUG|Adefovir (ADV)|Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
214295647|NCT05916391|GENETIC|FT-003|Administration via intraocular injection
214295648|NCT05726812|BEHAVIORAL|Plan My Life Together|A group training for adolescents with ADHD in which they learn to plan and organize. The training consists of 8 weekly sessions of 90 minutes for the adolescent and 2 parent sessions of 90 minutes.
214295649|NCT03255486|BIOLOGICAL|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
214295650|NCT05846061|OTHER|Prevalence study population|No intervention
214295651|NCT05047679|BEHAVIORAL|Perioperative Pain Neuroscience Education|Perioperative pain neuroscience education addresses modifiable preoperative risk factors, and in particular cognitive and emotional risk factors, such as fear of movement and pain catastrophizing (i.e., excessively negative orientation toward pain). This education is a cognitive-based therapeutic intervention which reconceptualizes pain, informs patients about what to expect from the evolution of their pain, de-emphasizes the patho-anatomical content and focuses on factors contributing to the development of pain. It explains this all within a biopsychosocial framework, which means that it aims to optimize patients' beliefs. Furthermore, it intends to reassure the patient about the decision to have surgery, to potentially decrease perioperative distress.
214295652|NCT05047679|BEHAVIORAL|Perioperative Biomedical Education|Perioperative biomedical education will discuss the anatomy, physiology and biomechanics of the lumbar spine with the patient. Additionally, the content of this education includes the expected course of postoperative back and leg pain, as well as ergonomic advice on patient-specific daily activities. This education will be given within a biomedical framework, which means that it aims to explain the patients' complaints and recovery while focusing on anatomy and biomechanics, as opposed to patients' beliefs and cognitions.
214295653|NCT02537054|DRUG|Aflibercept|Intravitreal injection
214295654|NCT05570565|PROCEDURE|Erector spinae plane block|ultrasound guided injection of local anesthestics drugs (mixture of lidocaine and bupivacaine) in the Erector spinae plane which lies between the Erector spinae muscle and lumbar transverse process
214295655|NCT05570565|PROCEDURE|local field block|infiltration of local anesthestic drugs( mixture of lidocaine and bupivacaine) in the surgical field before surgical incision
214295656|NCT04378140|OTHER|zirconia wing bridge|The zirconia wing bridge consists of an artificial tooth made out of zirconia and porcelain on the front side with two zirconia wings that are bonded (glued) onto the back of the two adjacent teeth in the patient's mouth.
214478021|NCT06865638|PROCEDURE|Intraoperative leak testing|◦After anastomosis was completed, the integrity of anastomosis was tested intraoperatively. The methods include directly observing the integrity of the anastomosis under gastroscopy, immersing the anastomosis in 500 - 1000 mL of warm saline and temporarily occluding the distal end, filling the anastomotic bowel with air, and injecting 60 mL of methylene blue through colonoscopy. Wrapping a white gauze pad around the anastomosis and observing for methylene blue leakage.
214478022|NCT06866808|OTHER|talocrural MWM and Therapeutic US|Mobilization with movement alongwith the therapeutic ultrasound
214478023|NCT06866808|OTHER|Conventional physiotherapy|Ankle isometrics, calf stretches, icing
214478024|NCT06866002|OTHER|Biological analysis, Physical examination and Questionnaires|Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
214478025|NCT06866002|OTHER|Physical examination and Questionnaires|In addition to exams for the main group, there will be 2 additional examinations (arterial stiffness) for the patients of the subgroup and others questionnaires.
214478026|NCT06866418|DEVICE|1. Phagenyx® System Group Patients|Patients who have undergone Pharyngeal Electrical Stimulation (PES) treatment for severe dysphagia using the Phagenyx® System
214478027|NCT06867315|DEVICE|steep pulse therapy system|"1. Use steep pulse system to ablate the transitional zone of the prostate to treat BPH~2. The steep pulse generator employs irreversible electroporation technology, which involves inserting electrodes into the tumor and delivering high-voltage electrical pulses to create nanoscale permanent pores on the lipid bilayer of tumor cell membranes. This disrupts the intracellular balance and induces cell apoptosis"
214295657|NCT03635957|BIOLOGICAL|Pegloticase|pegloticase administered intravenously (IV)
214295658|NCT03635957|DRUG|Methotrexate (MTX)|oral MTX
214295659|NCT03635957|DRUG|Standard Gout Flare Prophylaxis|It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al.2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.
214478028|NCT06867315|DRUG|Tamsulosin Hydrochloride|"1. use Tamsulosin Hydrochloride Sustained-Release Capsules to treat BPH~2. the brand name is Harnal®~3. the specification is 0.2mg per capsule"
214478029|NCT06867224|DEVICE|Shame TUS-vmPFC|The sham stimulation protocol maintained identical parameter settings to the active treatment group with equivalent application of ultrasound coupling gel at the left vmPFC site localized via the FP1 electrode. Crucially, the ultrasound transducer's output trigger was disabled during sham sessions, ensuring identical device operation procedures without acoustic energy delivery. Participants received daily 15-minute sham sessions matching the active group's 10-day treatment schedule.
214668351|NCT02459171|OTHER|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
214907183|NCT06942143|BIOLOGICAL|Super1 TCR-T|All participators received lymphoid-depleted preconditioning before Super1 TCR-T cells infusion. Super1 TCR-T cells were infused 3 days later. Concomitant administration of interleukin for 7 consecutive days.
214907184|NCT02496663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214295660|NCT03635957|DRUG|Infusion Reaction (IR) Prophylaxis|For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.
214295661|NCT03635957|DIETARY_SUPPLEMENT|Folic Acid|Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
214295662|NCT00350636|DRUG|Oxybutynin topical gel|1 application daily to skin for 12 weeks
214295663|NCT00350636|OTHER|Placebo topical gel|1 application daily to skin for 12 weeks
214295664|NCT05939375|BEHAVIORAL|FCC educational training|An educational training, grounded in six weeks of nurse-centered interactions, was implemented.
214295665|NCT03164343|DEVICE|Pain Neuroscience Education for children|Children and their parent will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
214295666|NCT04138329|PROCEDURE|Lichtenstein Technique|In this group was used the Lichtenstein technique for inguinal repair
214295667|NCT04138329|PROCEDURE|Onstep Technique|In this group was used the Onstep technique for inguinal repair
214295668|NCT02445482|PROCEDURE|Biopsy|archival tissue or fresh biospsy
214295669|NCT02133027|PROCEDURE|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
214295670|NCT02133027|DEVICE|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
214295671|NCT05767892|DRUG|YK-209A tablet|YK-029A 200 milligram (mg) , orally without food，once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
214295672|NCT05767892|DRUG|Pemetrexed+carboplatin/Cisplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
214295673|NCT01197053|BIOLOGICAL|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
214478030|NCT06867224|DEVICE|Active TUS-vmPFC|Participants in the active stimulation group will receive the transcranial ultrasound stimulation (TUS) targeted the left ventromededial prefrontal cortex (vmPFC), localized via the FP1 electrode position of the International 10-20 EEG system. The TUS will be delivered in the form of pulsed sinusoidal waves, with a fundamental frequency of 0.5 MHz and an intensity of 8 W/cm² (spatial peak pulse average intensity \[Isppa\]). The pulse duration will be 500 microseconds, and the sonication bursts will consist of 50 tone bursts per session, with a duty cycle of 5%. Each burst (pulse repetition frequency: 100 Hz) was followed by an 8-second inter-burst interval, yielding a total session duration of 15 minutes. Participants underwent one daily session for 10 consecutive days.
214295674|NCT01197053|BIOLOGICAL|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
214295675|NCT02334007|DRUG|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
214295676|NCT02334007|OTHER|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
214295677|NCT05931250|DEVICE|DC-Stimulator Plus (NeuroConn GmbH, Germany)|Transcranial alternating current stimulation
214295678|NCT05931250|DEVICE|Sooma direct current stimulator (Sooma, Finland)|Transcranial direct current stimulation
214295679|NCT01525550|DRUG|sunitinib|Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
214295680|NCT06120816|DRUG|Nitric Oxide|Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days. The intervention solution will be poured into their mouth from a medication cup containing 20 mL of the solution. Total exposure to study intervention will be a maximum of 63 treatments totaling 1,260 mL. All participants will be monitored for 7 days post-last treatment dose (to Day 28).
214295681|NCT00111592|PROCEDURE|current usual care|current usual care
214478031|NCT06866977|DRUG|Oncolytic virus VRT106|VRT106, IV
214478032|NCT06866977|DRUG|Chemotherapy|21 days/cycle
214907185|NCT02496663|PROCEDURE|Computed Tomography|Undergo CT scan
214907186|NCT02496663|PROCEDURE|Echocardiography Test|Undergo ECHO
214295682|NCT00111592|PROCEDURE|treatment protocol with clear indications for therapy|treatment protocol with clear indications for therapy
214295683|NCT06066645|DRUG|Travoprost Intraocular Implant|anchored intracameral implant containing travoprost in subjects who successfully received iStent infinite
214295684|NCT06066645|OTHER|Sham procedure|Sham procedure (to mimic placement of travoprost intraocular implant) in subjects who successfully received iStent infinite
214891772|NCT07184229|BEHAVIORAL|motivational interviewing-based family planning counseling|This intervention consists of motivational interviewing-based family planning counseling aimed at women currently using traditional contraceptive methods. The counseling sessions are designed to enhance participants' motivation and readiness to adopt modern contraceptive methods by addressing their concerns, increasing knowledge, and resolving ambivalence. The comparator group will receive only standard family planning counseling.
214891773|NCT07184229|BEHAVIORAL|standard family planning counseling.|The comparator group will receive only standard family planning counseling.
214891774|NCT07180212|DIAGNOSTIC_TEST|utDNA testing + Urine Cytology|Participants undergo urine tumor DNA (utDNA) testing and urine cytology every 3 months, and cystoscopy once per year. If either utDNA or urine cytology is positive, an additional cystoscopy will be performed. If urine cytology is positive but cystoscopy is negative, or if two consecutive utDNA tests are positive while cystoscopy remains negative, participants will undergo computed tomography urography (CTU) to evaluate the upper urinary tract.
214891775|NCT07180212|DIAGNOSTIC_TEST|Cystoscopy + Urine Cytology|Participants undergo cystoscopy and urine cytology every 3 months as per standard high-risk NMIBC surveillance. If urine cytology is positive but cystoscopy is negative, participants will undergo computed tomography urography (CTU) to evaluate the upper urinary tract.
214891776|NCT07183436|DRUG|Intra-articular Hyaluronic Acid and Ketorolac|Single intra-articular injection containing 2 mL moderate-molecular-weight hyaluronic acid (20 mg/2 mL), 1 mL ketorolac (30 mg/mL), and 2 mL lidocaine (10 mg/mL), total volume 5 mL. Administered under aseptic technique (ultrasound-guided or landmark-based) followed by standardized rehabilitation program.
214891777|NCT07183436|DRUG|Intra-articular Ketorolac|single intra-articular injection containing 1 mL ketorolac (30 mg/mL), 2 mL lidocaine (10 mg/mL), and 2 mL normal saline, total volume 5 mL. Administered under aseptic technique (ultrasound-guided or landmark-based) followed by standardized rehabilitation program.
214891778|NCT07180849|PROCEDURE|Fluoride varnish|Group A will receive conventional fluoride varnish for antiplaque effects.Plaque will be assessed quantitatively by modified plaque index.
214891779|NCT07180849|PROCEDURE|Novel titania nanoparticle infused fluoride varnish|Group B will receive topical application of titania nanoparticle infused fluoride varnish for antiplaque effects.Plaque will be assessed quantitatively by modified plaque index.
214891780|NCT07181668|DEVICE|Low-Level Light Therapy|The intervention consists of non-invasive periocular photobiomodulation using the Eye-light® device (Espansione Marketing S.p.A., Italy), which delivers low-level monochromatic red light (633 ± 10 nm) through a specially designed mask. Participants receive two 15-minute sessions, one 7 days before and one 7 days after femtosecond laser-assisted in situ keratomileusis (Femto-LASIK). The treatment is designed to stimulate meibomian gland activity, improve tear film stability, and reduce ocular surface inflammation. This protocol is unique compared to standard post-refractive surgery care because it targets cellular mitochondrial activity to enhance tissue repair and anti-inflammatory effects. It is non-pharmacological, non-contact, and well-tolerated, making it suitable for perioperative application. The light is delivered through closed eyelids, ensuring safety and comfort, and the device used is CE-marked for ophthalmic applications.
214891781|NCT07181668|DEVICE|Sham (No Treatment)|Participants in the Control group underwent the same procedural setup as the LLLT group, using the Eye-light® device (Espansione Marketing S.p.A., Italy). Instead of delivering therapeutic light energy, the device operated in demo mode, emitting less than 30% of the full treatment power. This configuration mimicked the visual and sensory aspects of a low-level light therapy session without producing biologically effective photobiomodulation. Sham treatment consisted of two 15-minute sessions, one 7 days before and one 7 days after Femto-LASIK. This design ensured masking of participants and investigators while preventing active therapeutic exposure in the control group.
214891782|NCT07181148|DRUG|MSP01-R|Total 20 tablets, split-dose administration over 2 days: 14 tablets the day before colonoscopy, 14 tablets on the morning of colonoscopy, oral intake.
214891783|NCT07181148|DRUG|MSP01-T|Total 20 tablets, split-dose administration over 2 days: 10 tablets the day before colonoscopy, 10 tablets on the morning of colonoscopy, oral intake.
214891784|NCT07186530|OTHER|Best Practice|Receive usual care
214295685|NCT06066645|DEVICE|iStent infinite|Successful iStent infinite surgery
214295686|NCT05356455|BEHAVIORAL|motivational interview technique|Difference between pre-test and post-test
214891785|NCT07186530|OTHER|Communication Intervention|Receive portal message
214891786|NCT07186530|OTHER|Electronic Health Record Review|EHR reviewed to assess whether recommended follow-up was completed, if follow-up was indicated.
214891787|NCT07186530|PROCEDURE|HPV Self-Collection|Complete HPV self-collection
214295687|NCT03593265|OTHER|MUNIX|Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
214891788|NCT07186530|PROCEDURE|Standard Follow-Up Care|Receive standard follow-up care
214891789|NCT07185308|DIETARY_SUPPLEMENT|Postbiotics, 2.5 g per dose, three times per day|Postbiotics oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).
214295688|NCT01533233|PROCEDURE|thoracoscopic lobectomy and mediastinal lymph node dissection|
214478033|NCT06864702|BEHAVIORAL|Whether the patient received diagnosis and treatment at Zhujiang Hospital of Southern Medical University and retained medical images such as abdominal|The construction of a deep learning model for semantic segmentation of images during laparoscopic hepatobiliary and pancreatic surgery, focusing on classifying surgical stages, anatomical structures, surgical instruments, and surgical gestures, along with the validation of model performance (Intersection over Union, Dice score, accuracy, precision, recall, and F1 score).
214478034|NCT06342921|DRUG|15 mg ADC189|Use only once during the whole study.
214478035|NCT06342921|DRUG|45 mg ADC189|Use only once during the whole study.
214891790|NCT07185308|DIETARY_SUPPLEMENT|Placebo, 2.5 g per dose, three times per day|Placebo made of cyclodextrine, oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).
214891791|NCT07186465|DRUG|Nitrofurantoin|Nightly oral nitrofurantoin 100 mg for 6 months as prophylaxis for recurrent UTI in postmenopausal women. If symptomatic UTI occurs, treat per standard care and, once resolved, continue assigned prophylaxis to complete 6 months. Monitoring per protocol: baseline and month-6 visits with urinalysis, urine culture, urinary microbiome, and kidney function; twice-weekly phone/Line check-ins for adherence, symptoms, and adverse events.
214891792|NCT07186465|DRUG|Gynoflor|Vaginal tablet containing Lactobacillus with ultra-low-dose estriol. Insert 1 tablet nightly for 14 days, then twice weekly through month 6 as prophylaxis against recurrent urinary tract infection. If a symptomatic UTI occurs, treat per standard of care; after resolution, continue assigned prophylaxis to complete 6 months. Monitoring identical to comparator.
214891793|NCT07181031|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Participants in the HIIT group engaged in a 12-week resistance-based high intensity interval training program, designed to target both aerobic and anaerobic energy systems. Training sessions were conducted twice per week in addition to the athletes' regular volleyball practice schedule. Each session commenced with a standardized 10-minute warm-up involving low-intensity jogging and dynamic stretching, and concluded with a 5-minute cool-down of light jogging and static stretching to promote recovery. The main training component consisted of short, repeated high intensity bouts (30 s) of multi-modal exercises-including sprint drills, plyometric movements, functional bodyweight resistance exercises, multi-joint strength movements, agility drills, and aerobic conditioning-performed at 85-95% of maximal heart rate (HRmax) \[28,13\]. Each bout was followed by 30 s of active recovery (e.g., walking or light movement).
214907187|NCT02496663|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
214907188|NCT02496663|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214907189|NCT02496663|BIOLOGICAL|Necitumumab|Given IV
215049964|NCT03201120|BEHAVIORAL|Outdoor Sun Behavior|Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
215049965|NCT03201120|BEHAVIORAL|Indoor Tanning Behavior|Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
215049966|NCT02448147|BEHAVIORAL|Interval training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
215049967|NCT02448147|BEHAVIORAL|Continuous training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
215049968|NCT01564342|PROCEDURE|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
214907190|NCT02496663|DRUG|Osimertinib|Given PO
214907191|NCT06941025|OTHER|Not applicable- observational study|Not applicable - observational study
215049969|NCT02374541|BEHAVIORAL|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
215049970|NCT04163939|OTHER|Vista Therapy Collar|The patient will wear the cervical collar
215049971|NCT04163939|OTHER|Placebo|The patient will not wear the cervical collar
215049972|NCT06135584|DRUG|Pioglitazone metformin tablets|Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
215049973|NCT06135584|DRUG|Other drugs|Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
215049974|NCT06135584|OTHER|Drug-free|Drug-free
215049975|NCT01258673|DRUG|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
215049976|NCT01258673|DRUG|Fimasartan|Fimasartan 60mg, 120mg
215049977|NCT00308334|DRUG|Domperidone|10 mg po TID X 14 days
215049978|NCT00308334|DRUG|Placebo- Sugar pill|placebo po TID x 14 days
215057375|NCT03043690|OTHER|Placebo|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
215057376|NCT06391580|DEVICE|Poly-L-lactin Acid (PLLA) Based Facial Injectable|Poly-L-lactin Acid (PLLA) Based Facial Injectable
214478036|NCT06342921|DRUG|Placebo|Use only once during the whole study.
215049979|NCT05518006|DIETARY_SUPPLEMENT|PreMama Balance|Premama Balance is a blend of the following: Vitex (Chasteberry Extract), commonly used to help regulate hormones; Antioxidants, Selenium, and Magnesium, also help support the cleansing of hormonal birth control from the liver and help strengthen the uterine lining.
214891794|NCT07181031|BEHAVIORAL|High-Intensity Functional Training (HIFT)|Participants completed a 12-week high intensity functional training program aimed at developing aerobic capacity, anaerobic power, muscular strength, and agility. Training sessions were performed twice weekly in addition to regular volleyball practices. Each training session followed a standardized structure, beginning with a 10-minute warm-up of light jogging and dynamic mobility exercises, followed by a main training phase consisting of circuit-style functional workouts that combined sprint drills, plyometric exercises, bodyweight resistance movements, multi-joint strength exercises, agility drills, and aerobic activities; each exercise was performed for 30 seconds at maximal effort with no fixed rest between exercises (≤10 seconds transition allowed), and participants completed 4-6 sets per session with 1-2 minutes of rest between sets, while emphasizing maximal movement speed and explosive execution of all repetitions, and concluding with a 5-minute cool-down of low-intensity joggi
214891797|NCT07186205|DIAGNOSTIC_TEST|Standard blood test|Blood test will measure haemoglobin and other parameters
214891798|NCT07186205|OTHER|Imaging and videography of anatomical sites|Images and videos of anatomical sites will be collected to develop algorithms to estimate iron status
214891799|NCT07178782|OTHER|Dual-Task Training Program|the participant will receive dual task program in form of balance and hand function program
214891800|NCT07178782|OTHER|rehabilitation program|designed rehabilitation program
214891801|NCT07192120|DRUG|MHB048C for Injection|IV administration of MHB048C Q2W or Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214891802|NCT07193485|OTHER|Buteyko breathing|twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. Also, group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.
214891803|NCT07193485|OTHER|usual care|twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group II and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks.
214891804|NCT07193186|DRUG|Anlotinib and Benmelstobart|Patients will receive Benmelstobart (1200mg, d1, q3w) in combination with Anlotinib (12mg, qd, d1-14, q3w). Treatment will continue until disease progression, voluntary withdrawal of informed consent, intolerable toxicity, or until the investigator determines that the patient no longer benefits.
214891805|NCT07193251|OTHER|Core Stabilization Exercises|Participants will receive supervised core stabilization exercises twice weekly for 8 weeks (≈50 min: 10 min warm-up, 30 min stabilization, 10 min cool-down), progressing from basic trunk activation and bridging to plank and ball-assisted tasks. A daily 60-min home program with illustrated handouts will be prescribed.
214891806|NCT07193251|OTHER|Connective tissue massage|each supervised session will include 20 min of connective tissue massage (CTM) applied bilaterally to lumbar and lower thoracic regions using oblique and transverse pulls at connective tissue reflex zones. CTM will be performed in seated or prone position depending on patient comfort
214891807|NCT07192991|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
214891808|NCT07192224|DEVICE|Hypothermia|This study involves the comparison of 2 groups, one receiving warm fluids while the other group receiving room temperature fluids during surgeries.
214478037|NCT06865300|DRUG|Lidocain 40 mg|We injected 40 mg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.
214478038|NCT06865300|DRUG|lidocain 1 mg/kg|We injected 1 mg/kg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.
214891809|NCT07192224|DEVICE|Hotline|Used as a fluid warmer.
214891810|NCT07192640|DRUG|After induction of anaesthesia tranexamic acid will be administered at the start of surgery to reduce intraoperative bleeding. loading dose of 10 mg/kg for high BMI patients who are undergoing bariatr|This intervention will be applied for High-risk patients, with obesity, BMI more than 45, Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.
214891811|NCT07192328|DEVICE|rTMS and rTLSMS administered using a Magstim Rapid2 repetitive stimulator at pre-identified hotspots (cortical, lumbar, and sacral regions bilaterally).|rTMS and rTLSMS administered using a Magstim Rapid2 repetitive stimulator at pre-identified hotspots (cortical, lumbar, and sacral regions bilaterally. rTMS delivered with 250 pulses via the same double-cone coil used for the neurophysiological study, at either 1 Hz or 5 Hz. For rTLSMS (lumbar and sacral), 2400 pulses (600 per hotspot) were applied at 1 Hz, 5 Hz, or 10 Hz using a 70mm refrigerated air film coil (Magstim, UK). Each dose and stimulation site (cortical or peripheral) were tested in separate sessions.
215049980|NCT05518006|DIETARY_SUPPLEMENT|Placebo Drink|Blended Placebo drink
215057377|NCT05617989|OTHER|lung ultrasound|non-invasive ventilation and diuretic
215057378|NCT02056028|PROCEDURE|Hepatic resection|
215057379|NCT02402803|OTHER|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
215057380|NCT04227275|BIOLOGICAL|CART-PSMA-TGFβRDN|Intravenous administration of genetically modified autologous T cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA), as well as a dominant negative TGFβ receptor
214295689|NCT05474742|OTHER|The Nori Health app|The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention.
214891812|NCT07192458|BIOLOGICAL|High Dose Inactivated Influenza Vaccine|Fluzone High-Dose (Influenza Vaccine) for intramuscular use is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus- containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus containing hemagglutinin (HA) antigen is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step to obtain a higher HA antigen concentration. The purified split virus from the three strains included in the vaccine are produced separately and then combined to make the trivalent formulation.
214891813|NCT07192458|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine|Fluzone Standard Dose is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine.
214891814|NCT07193108|DEVICE|Inspiratory Muscle Warm-Up|Inspiratory Muscle Warm-Up (IWU) The POWERbreathe® device (IMT Technologies Ltd., Birmingham, UK) was used for the inspiratory muscle warm-up (IWU). For the IWU protocol, the resistance of the POWERbreathe® device was set to 40% of the participant's maximal inspiratory pressure (MIP). While standing, participants were instructed to perform two sets of 30 breaths (inspiratory and expiratory), with a 60-second rest interval between sets (Yılmaz et al., 2025).
214891815|NCT07193108|DEVICE|Control|Inspiratory Muscle Warm-Up Non-treated group, Control
214891816|NCT07192055|BEHAVIORAL|Self-sampling|Self-sampling instructions will be provided to participants who will insert the swab into the anus to collect cells. Then the participant will put the swab in a vial of transport fluid for assessment at a laboratory.
214891817|NCT07192055|OTHER|Nylon-flocked Swab|At the cytology appointment, participants may receive self-sampling or clinician sampling with 1 of 2 kinds of swabs. The nylon-flocked swab is the intervention and will be assessed on patient acceptability and patient and clinician ability to collect an adequate sample.
214891818|NCT07192523|OTHER|Restrictive fluid therapy|Group Restrictive (Group R) received 3ml/kg/hr, crystalloid (Ringer Lactate).
214891819|NCT07192523|OTHER|Liberal fluid therapy|Group Restrictive liberal received 8ml/kg/hr, crystalloid (Ringer Lactate).
215049981|NCT01306695|BEHAVIORAL|New York University Caregiver Intervention (NYUCI)|"The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
214478039|NCT06865300|DRUG|serum physiologic|We injected serum physiologic before rocuronium injection. Then we recorded pain score by using visual analog scale.
215049982|NCT01306695|OTHER|Community Health Worker (CHW) Case Management|The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
214295690|NCT05372848|DIAGNOSTIC_TEST|Manual toothbrush|volunteers who used manual toothbrush for at least 2 years
214295691|NCT05372848|DIAGNOSTIC_TEST|Electric toothbrush|volunteers who used electric toothbrush for at least 2 years
214295692|NCT04833621|DEVICE|NMES GROUP|The effects of NMES and muscle strengthening and standard physiotherapy exercises on the development of ICU-AW were observed
214295693|NCT00111618|DRUG|AS1404 (DMXAA)|
214478040|NCT06864364|OTHER|CGM feedback visualization|The subject will have CGM feedback visualization
214478041|NCT06864364|DIETARY_SUPPLEMENT|milk supplemented with mulberry leaves extract|milk supplemented with mulberry leaves extract
214478042|NCT06864364|OTHER|blinded CGM feedback visualization|The subject will have blinded CGM feedback visualization
214478043|NCT06863077|PROCEDURE|MCL Pie-Crusting|Percutaneous MCL Pie-Crusting
214478044|NCT06863064|DRUG|Dexmedetomidine|During the surgery, target-controlled infusion (TCI) pumps were used, employing the Dyck model for continuous infusion of propofol, with the target plasma concentration maintained at 0.2 ng/ml. Postoperatively, propofol was infused at a rate of 0.2-0.4 mcg/kg/hr according to the intensive care unit's protocol, until the patient had the endotracheal tube removed.
214891820|NCT07192510|OTHER|Pancake oral immunotherapy|The baked egg tolerant group underwent a 4-dose initial escalation (at intervals of 20-30 minutes) with pancakes in hospital (37.5 mg, 75 mg, 150 mg, 300 mg egg protein) to determine the home starting dose of pancake. The dose tolerated was one which resulted in no more than mild transient (not lasting more than 20 minutes) symptoms (e.g. itchy mouth) - transient Grade 1 symptoms. The home starting dose (taken daily at home) was one step below the tolerated dose, to minimise risk of allergic reactions at home, particularly as the presence of co-factors might decrease reaction threshold. Those reacting at 37.5 mg or 75 mg would not begin OIT with pancakes but instead began with cookies. Updosing visits were performed in the hospital at approximately 4 weekly intervals. Participants were kept at the pancake daily maintenance dose (2500 mg) for a minimum of 16 weeks, or total OIT duration of 18 months, whichever earlier
214295694|NCT06246318|OTHER|virtual reality|The virtual reality protocol here is based on perceptual-motor activities, supported by Nintendo Wii resources. The user will be able to control a game character in a virtual environment using a remote control with a motion sensor. Wii Fit Plus requires the use of the Wii Balance Board that the player stands on during gameplay. The Wii Balance Board is not a wobbly balance board, but is able to detect and track the user's center of balance, a feature used extensively in the game. Wii Fit Plus includes more than 40 activities including yoga, strength training, aerobics and balance games. During the virtual reality application, different games will be preferred in each session depending on the duration of the games. Virtual reality application will be carried out in a corner prepared for virtual reality application in the room where the conventional occupational therapy session is held. Families have the right to observe and attend all sessions whenever they wish.
214295695|NCT06246318|OTHER|conventional occupational therapy|"Sensory integration and gross motor training approaches will be used in the conventional occupational therapy program. A manualized protocol based on Ayres sensory integration principles will be followed (Schaaf et al., 2012). The intervention will be carried out by a licensed occupational therapist trained in sensory integration.~This approach suggests that if a child engages in individually adapted sensorimotor activities, the nervous system is better able to modulate, organize, and integrate sensory information and is also more likely to use sensory information in adaptive ways (Ayres, 1972). Components of the intervention include a sensory-rich, playful, child-centered approach, providing a decision challenge, and facilitating increasingly complex adaptive behaviors by engaging the child in individually tailored, developmentally appropriate play interactions"
214295696|NCT03889158|BIOLOGICAL|Typhoid Vaccine|All participants will receive the typhoid vaccine.
214295697|NCT03889158|DIETARY_SUPPLEMENT|Ascorbic Acid|All participants will receive ascorbic acid.
214295698|NCT06154954|DIAGNOSTIC_TEST|Semen analysis|Semen analysis for extracellular matrix proteins analysis
214891821|NCT07193017|DEVICE|BIPAP|After BIPAP Prescribed By A Physician, Diaphragmatic Functions Will Be Evaluated With Ultrasound In The Early And Late Periods
214891822|NCT07191665|OTHER|Acute nutrition intervention|The products (investigational and placebo) consists of three capsules that should be taken with water at two separate visits, with a wash-out period in between. The placebo product will comprise of microcrystalline cellulose (bulk). The investigational products will contain either caffeine and microcrystalline cellulose or caffeine, L-Arginine, and microcrystalline cellulose.
214891823|NCT07192016|DRUG|fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg|The investigational drug is a single Ellipta inhaler containing 100 ug fluticasone furoate(inhaled corticosteroid), 62.5 ug umeclidinium(long-acting muscarinic antagonist) and 25 ug vilanterol(long-acting β2-adrenergic agonist). The drug is delivered in an Ellipta inhaler in a single dose once daily.
214891824|NCT07193446|BEHAVIORAL|D-stress study: The detection, prevention and management of diabetes distress for adults living with type 1 diabetes.|Enhanced Usual Care intervention aims to train health care professionals to detect and prevent, and manage diabetes distress in routine diabetes care, in the UK NHS. The REDUCE programme aims to prevent and manage elevated diabetes distress.
214891825|NCT07184554|PROCEDURE|us-guided espb|Hemodynamic monitoring is provided. The lumbar region where the procedure will be performed is cleaned with povidone iodine. Sterile draping is provided. For the lumbar erector spinae plane block application, a 5 Hz convex ultrasound probe is first placed sagittally over the desired level of the lumbar vertebra. After the spinous processes are visualized, the ultrasound probe is laterally shifted in the sagittal plane, first visualizing the laminae, then the facet joints, and finally the transverse processes. The erector spinae muscles are visualized over the transverse processes. The skin and subcutaneous tissue are then anesthetized with 2 cc of 2% lidocaine. A spinal needle is inserted from the anesthetized area in the same plane as the ultrasound probe (in plane) and contacts the relevant transverse process. Thanks to the real-time imaging advantage of ultrasound, a certain distance is maintained from the nerves and vascular structures. Once the appropriate location is reached, a m
214891826|NCT07184554|PROCEDURE|fl-guided Ilesi|For lumbar interlaminar epidural steroid injection, the anterior view of the desired level is obtained under fluoroscopy to visualize the relevant interlaminar epidural space. The skin and subcutaneous tissue are anesthetized with a local anesthetic. A paramedian approach is used to enter the target interlaminar space with an epidural needle using a negative pressure injector. The lateral view is checked using fluoroscopy. 2 cc of opaque material is administered, and its presence in the epidural space is confirmed from the lateral and anterior-posterior views. A mixture of steroid and local anesthetic (8 mg dexamethasone, 3 cc 5mg/ml bupivacaine, and SF for a total of 10 cc) is injected. The needle is removed in a controlled manner and the needle site is closed. After the procedure, patients are monitored in the recovery unit for 60 minutes and then transferred to the ward for follow-up. Patients who have completed their 1-hour follow-up in the ward are discharged.
214891827|NCT07192159|DEVICE|Quantitative ultrasound (DeepUSFF)|"\*\*Novel Quantitative Ultrasound Technology Assessment\*\*~This study evaluates Samsung Medison's proprietary DeepUSFF (Deep Learning-based Ultrasound Fat Fraction) technology, a next-generation quantitative ultrasound method for liver fat assessment that differs from conventional ultrasound approaches in several key aspects: advanced RF data analysis, proprietary technology, standardized protocol, direct MRI-PDFF correlation, specific MSALD poopulation and multicenter design."
214478045|NCT06863064|DRUG|Normal Saline|During the surgery, equal volumes of saline were injected. After the surgery, the patient was transferred to the intensive care unit, where propofol was continuously infused at a rate of 0.2-0.4 mcg/kg/hr according to the ICU protocol, until the endotracheal tube was removed.
214891828|NCT07191912|DRUG|Govorestat|Govorestat will be provided as a liquid suspension (200mg/mL) for weight-based administration and administered orally at 20 mg/kg QD (every 24 hours)
214891829|NCT07191912|DRUG|Placebo Control|Placebo will also be provided as a matching liquid suspension to be taken orally QD
214891830|NCT07193082|DEVICE|Experimental Inspiratory Muscle Training (IMT Group)|Experimental (IMT Group): Inspiratory Muscle Training (POWERbreathe® device, twice daily, 30 breaths per session, 5 days/week, 4 weeks, resistance starting at 40% of MIP and increased weekly).
214891831|NCT07193082|DEVICE|Control Group: No inspiratory muscle training.|Control Group: No inspiratory muscle training.
215049983|NCT02655887|DEVICE|VENOVO™ Venous Stent|VENOVO™ Venous stent placement
214891832|NCT07192302|PROCEDURE|Arthroscopy|Early Surgical Intervention in Patients with Partial Rotator Cuff Tears and Concomitant Shoulder Stiffness.
214891833|NCT07192302|DRUG|Drugs administration|Oral Medication for Conservative Management of Partial Rotator Cuff Tears with Concomitant Shoulder Stiffness.
214891834|NCT07192601|BEHAVIORAL|E-cigarette Cessation Manual|E-cigarette cessation manual development. Empirically supported treatment content. We anticipate grounding the intervention in an empirically supported psychosocial smoking cessation program (i.e., Cognitive Behavior Therapy; CBT), which has been found to be effective with both adults and adolescents to quit cigarette smoking (Vinci, 2020). We anticipate including sessions that teach CBT skills to help adolescents quit e-cigarette use. These CBT skills and format will be adapted from prior manualized CBT smoking cessation interventions for adolescent smoking cessation and manualized CBT e-cigarette intervention for adolescents and young adults that are currently ongoing (e.g., Kong et al., 2017; Kong et al., 2021; Bold et al., 2022). The structure and content of the e-cigarette cessation manual will be further informed by themes and sub-themes from the focus group data analysis relating to both surface and deep structure cultural modifications.
214891835|NCT07193394|DRUG|Tucatinib (ONT-380)|Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
214891836|NCT07193394|DRUG|Trastuzumab (Herceptin)|Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
214891837|NCT07192926|DRUG|Immune Checkpoint Inhibitors|Retrospective analysis of patients with metastatic non-small cell lung cancer (mNSCLC) who received standard-of-care immune checkpoint inhibitors, including PD-1 and PD-L1 inhibitors (e.g., nivolumab, pembrolizumab, atezolizumab, durvalumab). Patients received these agents as part of routine clinical practice; no experimental intervention was administered in this study.
214891838|NCT07185841|DRUG|HX9428 tablet|Subjects will receive HX9428 orally every day. The total treatment period is tentatively set at 25 weeks..
214891839|NCT07191587|DIETARY_SUPPLEMENT|Vitamin B Complex|Vitamin B complex given as prophylaxis in prophylactic arm and as treatment in non-prophylactic arm.
214891840|NCT07193134|DRUG|Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS)|Wound debridement will be performed, followed by the application of temporary allogeneic skin grafts for 3-5 days. The allografts will then be removed, and the GMEB-SASS grafts will be applied.
214891841|NCT07192692|DIETARY_SUPPLEMENT|fast|fast state
214891842|NCT07192692|DIETARY_SUPPLEMENT|low fat meal|take HSK47388 with low fat meal
214891843|NCT07192692|DIETARY_SUPPLEMENT|take meal after HSK47388 administration|take meal after HSK47388 administration at specific time
214891844|NCT07191925|BEHAVIORAL|Community Co-designed Physical Activity and Diet Intervention Package|A package of 4-6 diet and physical activity interventions selected from a long-list of potential interventions and adapted to the unique school and neighborhood context via consultation with community stakeholders. Intervention packages are multi-level (i.e. targeting at least two of individual, external and structural environments), target elements of both diet and physical activity, and are health equity oriented in terms of both access and improvement. Long-list potential interventions include items related to school intramural programming, active transport, health education, community recreational programming, and structural/public space design improvements.
214891845|NCT07192263|DRUG|IN-B00009|Test drug
214891846|NCT07192263|DRUG|Placebo|Placebo drug
214907192|NCT07141147|RADIATION|Radiation|"1. Technique:Linear accelerator with volumetric modulated arc therapy for irradiation.~2. Target Volume Delineation (Two-phase irradiation):~Clinical Target Volume 1 (CTV1):Encompasses tumor bed (preoperative MRI/CT-defined ACC extent) + regional lymphatics (ipsilateral para-aortic nodes).~Clinical Target Volume 2 (CTV2):Tumor bed only (preoperative MRI/CT-defined ACC extent).~Planning Target Volume (PTV):PTV1: CTV1 + 0.6 cm margin.PTV2: CTV2 + 0.6 cm margin.~4.Organs at Risk (OARs):Stomach, liver, bilateral kidneys, pancreas, spinal cord, and bowel/colon within radiation fields.~5.Prescription Dose: Phase 1: PTV1 → 45 Gy in 25 fractions (1.8 Gy/fraction), 5 fractions/week. Phase 2: PTV2 → 10 Gy in 5 fractions (2.0 Gy/fraction), 5 fractions/week."
215049984|NCT03332121|BIOLOGICAL|B001|4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
215049985|NCT03565172|DIAGNOSTIC_TEST|isokinetic dynamometer with ultrasound|children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.
214478046|NCT06862466|OTHER|Education intervention|Knowledge, Attitude, and Practice Questionnaire (KAPQ) Regarding Renal Nutrition will be used to collect the data at baseline, after the intervention, and three months follow-up, which is adjusted for clustering.
214478047|NCT06862544|DEVICE|Smartwatch (Withings Scanwatch 2)|All-day monitoring of patients via smartwatch and migraine diary app
215049986|NCT03565172|OTHER|Visual Analog Scale (VAS)|the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort
215049987|NCT03565172|DIAGNOSTIC_TEST|Stretching|the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
215057381|NCT04227275|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
214295699|NCT02054416|DEVICE|ArtAssist© Device|The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
214891847|NCT07191782|BEHAVIORAL|Universal, classroom-based, Bullying and Aggression Prevention Program|PRAISE is a universal, classroom-based aggression and bullying prevention program that addresses all forms (physical, verbal, relational, cyber), with a strong focus on the relational and reactive behaviors. All emotional and social skills taught focus on applying and practicing the skills within peer relationships. This program has gone through iterative development and adaptations using a community-based participatory approach whereby the elementary students and staff were active partners with researchers in refining the program. Specific attention was paid to ensuring that the program is feasible for schools to implement and sustain while also being relevant and relatable for students from a variety of backgrounds and school communities (e.g., under-resourced, higher levels of community violence). This updated PRAISE includes \~14 sessions (amounts can vary by grade) and training and coaching for school-based facilitators of the program.
214891848|NCT07192185|DRUG|FOLFOX|oxaliplatin 85mg/m2 + leucovorin 400mg/m2 + 5-fu 400mg/m2 + 5-fu 2400mg/m2 46h iv.drip Q3W
214891849|NCT07192185|DRUG|Atezolizumab & Bevacizumab|Atezolizumab 1200mg iv.drip + Bevacizumab 15mg/kg iv.drip Q3w
214891850|NCT07193420|DRUG|Cyclophosphamide 35mg/kg/day|Cyclophosphamide will be administered intravenously (IV) post-HSCT at the experimental dose (70 mg/kg, divided into two doses of 35 mg/kg/day on days +3 and +4).
214891851|NCT07193420|DRUG|Cyclophosphamide 50mg/kg/day|Cyclophosphamide will be administered intravenously (IV) post-HSCT at the standard dose (100 mg/kg, divided into two doses of 50 mg/kg/day on days +3 and +4).
214891852|NCT07192900|BIOLOGICAL|locally manufactured adoptive cellular therapy (ACT) product|Single dose, intrapleural delivery (via indwelling pleural catheter) of adoptive cellular therapy (ACT) product derived from autologous pleural infiltrating T-cells.
214891853|NCT07192900|DRUG|Interleukin-2|Low dose Interleukin-2 (IL-2) will also be administered intrapleural at the dose of 20 milliliters (mL) at 1 x 10⁵ International Units (IU)/mL starting approximately 2 hours after ACT infusion and every 8 to 16 hours thereafter, as tolerated, for up to 4 doses (total 8 x 10⁶ IU).
214891855|NCT07191691|DIAGNOSTIC_TEST|Bayley Scales of Infant and toddler Development, fourth edition (BSID-4)|"The BSID-4 is a test that evaluates three areas of child's development, divided into three scales:~* The Motor Scale, which includes the fine motor and gross motor subtests;~* The Cognitive Scale, which consists of items assessing sensorimotor development, object exploration and manipulation, concept formation, memory, and other primary functions from which the child's reasoning abilities emerge;~* The Language Scale, which includes the receptive communication and expressive communication subtests.~The administration of the BSID-4 involves the standardized delivery of items. The BSID-4 standardization does not specify a fixed order for administering the scales: depending on the child's temperament and spontaneous interest, the examiner adapts the order in which the motor, language, and cognitive scales are administered."
214907193|NCT06946823|DEVICE|Just-In-Time Adaptive Intervention for Adolescent Anxiety|A JITAI smartphone app to reduce anxiety levels among rural adolescents by delivering somatic-based activity recommendations
214295700|NCT00383279|OTHER|counseling intervention|
214295701|NCT00383279|OTHER|study of socioeconomic and demographic variables|
214295702|NCT05308745|DIETARY_SUPPLEMENT|Yakult®|Fermented milk drink containing over 6.5×10\^9 CFUs of L. casei Shirota/65 ml
214295703|NCT05308745|DIETARY_SUPPLEMENT|Placebo|Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
214295704|NCT01857349|OTHER|Chlora Prep|Surgical Scrub skin preparation
214295705|NCT01857349|OTHER|Dura Prep|Surgical Scrub skin preparation
214295706|NCT04022447|DRUG|Dupilumab|retrospective data collection
214295707|NCT03878914|DRUG|Corticosteroids|Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
214907194|NCT03825354|BEHAVIORAL|BIC|World Health Organization, WHO, Brief Intervention and Contact (BIC)
214907195|NCT07141472|DIETARY_SUPPLEMENT|GB|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
214907196|NCT07141472|DIETARY_SUPPLEMENT|Placebo|Placebo is a product that resemble active GB but does not contain any of the active ingredients
214907197|NCT07148791|BIOLOGICAL|Anti-BCMA-CD19 CAR-T cells|Anti-BCMA-CD19 CAR-T cell injection is an autologous, dual-target chimeric antigen receptor T-cell therapy designed to target CD19 and BCMA antigens. Peripheral blood mononuclear cells (PBMCs) are collected from each participant and modified ex vivo using lentiviral transduction to express the CAR construct. Lymphodepletion with cyclophosphamide (250 mg/m\^2/day, IV) and fludarabine (30 mg/m\^2/day, IV) is administered for 3 days (Day -5 to Day -3). The doses of fludarabine and cyclophosphamide may be adjusted based on the patient's clinical condition. CAR-T cells are infused intravenously on Day 0 at one of three dose levels (1x10\^6, 2x10\^6, or 3x10\^6 CAR+ T cells/kg, ±20%). This product is being investigated in patients with relapsed or refractory IgG4-related disease (IgG4-RD) to assess safety and preliminary efficacy.
214295708|NCT05352009|OTHER|Sling exercise training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of sling exercise training and 10 min treadmill training.
214295709|NCT05352009|OTHER|Conventional balance training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of balance exercise training and 10 min treadmill training.
214891856|NCT07192848|DRUG|Adebrelimab + Apatinib|"Adebrelimab: A fixed dose of 1200 mg is administered as an intravenous infusion over 30 minutes (not less than 20 minutes and not more than 60 minutes, including the flushing phase), once every 3 weeks (Q3W). The interval between two administrations should not be less than 12 days.~The maximum treatment duration is 6 courses.~Apatinib: 250 mg, once daily (QD), taken orally within half an hour after a meal, continuously, with a 3 - week (21 - day) cycle.~The maximum treatment duration is 6 courses."
214891857|NCT07193368|BIOLOGICAL|Polyacrylamide hydrogel 2.5% intra-articular injection|A single intra-articular injection of 2.5% cross-linked polyacrylamide hydrogel (iPAAG), composed of 2.5% polyacrylamide and 97.5% non-pyrogenic water. The product (Arthrosamid®, Contura, Denmark) was administered under ultrasound guidance into the knee joint. Patients were followed retrospectively for 12 months to evaluate safety and effectiveness in reducing pain (VAS) and improving function (WOMAC).
214891858|NCT07192835|DIETARY_SUPPLEMENT|Juice from untreated control fruits|Participants will consume 300 g of juice prepared from untreated fruits (lemon, blood orange, or sweet cherry) under fasting conditions on the intervention day. Urine samples will be collected at 0-3.5 h, 3.5-12 h, and 12-24 h post-consumption to assess absorption and metabolism of bioactive compounds.
214891859|NCT07192835|DIETARY_SUPPLEMENT|Juice from melatonin-treated fruits|Participants will consume 300 g of juice prepared from fruits (lemon, blood orange, or sweet cherry) treated preharvest with melatonin (0.1, 0.3, or 0.5 mM). Juice will be consumed under fasting conditions on the intervention day. Urine samples will be collected at 0-3.5 h, 3.5-12 h, and 12-24 h post-consumption to assess absorption and metabolism of bioactive compounds.
214891860|NCT07192497|OTHER|DRY NEEDLING|Myofacial trigger point dry needling used to treat taught bands superficial or deep inside of muscles .
214891861|NCT07192497|OTHER|Acupressure|Acupressure therapy based on traditional Chinese principles
214891862|NCT07192497|OTHER|Dry needling and Acupressure therapy|combination of dry needling and acupressure therapy on cervical trigger points
214891863|NCT07192497|OTHER|Hot Pack|Hot fermentation will be applied on cervical pain area
214891864|NCT07193277|DRUG|Butylphthalide|Butylphthalide soft capsules (0.1g per capsule) manufactured by CSPC NBP Pharmaceutical Co., Ltd. Participants take 2 capsules (0.2g total) orally three times daily, 15-30 minutes before meals, for 48 weeks. This represents off-label use for cognitive impairment comorbid with epilepsy, as the drug is currently approved in China only for acute ischemic stroke treatment.
214891865|NCT07193277|DRUG|Placebo|Matching placebo capsules identical in appearance, weight, and odor to butylphthalide soft capsules, manufactured by the same company following GMP standards. Participants take 2 capsules orally three times daily, 15-30 minutes before meals, for 48 weeks. Placebo contains starch and appropriate excipients.
214891866|NCT07191548|DEVICE|Irreversible Electroporation|"Irreversible electroporation (IRE) is a procedure which involves the passage of short intense electrical pulses between probes to destabilize cell membranes by creating nanopores which leads to cell destabilisation and cell death.~IRE can be used to selectively damage cancerous cells whilst sparing adjacent supporting connective tissue in vessels and bile ducts allowing a more targeted treatment compared to other types of ablation. IRE also avoids the heat-sink phenomenon which compromises the effectiveness of thermal ablation and possibly reduces the risks of biliary injury."
214891867|NCT07193121|DEVICE|Inspiratory Muscle Warm-Up|The POWERbreathe device (IMT Technologies Ltd., Birmingham, UK) was used for inspiratory muscle warm-up (IWU). For the IWU protocol, the resistance of the POWERbreathe device was set to 40% of the participant's maximal inspiratory pressure (MIP). While standing, participants were instructed to perform two sets of 30 breaths (inspiratory and expiratory), with a 60-second rest interval between sets (Koizumi \& Ohya, 2023).
214891868|NCT07193121|DEVICE|Control|No intervention
214907198|NCT02702128|DRUG|Tranexamic Acid|1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
214295710|NCT03474120|PROCEDURE|IVF treatment|Relationship between IVF treatment outcome and genotypes in POI//DOR/ovarian dysgenesis patients
214907199|NCT02702128|DRUG|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
214907200|NCT06952348|BEHAVIORAL|Stair and brisk walking combined|See arms.
214295711|NCT01843751|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
214295712|NCT03794414|PROCEDURE|PEEP challenge|apply PEEP 10 mmHg in one-lung ventilating patients.
214891869|NCT07192003|DEVICE|Floss Band Group (FBG)|Participants in this arm will perform the standardized Floss Band (FBG) protocol. While seated with the shoulder at 90° abduction, the researcher will apply a compressive elastic band made of 100% polymer gel (T.P.E), measuring 210 cm in length, 5 cm in width, and 1.3 mm in thickness. The first anchor is placed two fingers medial to the acromion, and the band is wrapped around the shoulder until the second anchor at the end of the band is fixed. After the application, the participant will perform sport-specific movements (spike and serve) for 2 minutes. Following the completion of the compression period, the band will be removed. Assessments will be conducted at baseline and immediately post-intervention, including shoulder range of motion using a digital inclinometer, perception of movement fluency using a Visual Analogue Scale (VAS), and sport-specific performance tests (One-arm Seated Shot Put Test and Functional Throwing Performance Index).
214891870|NCT07192003|OTHER|Mobilization with Movement (MWM) Group|Participants in this arm will perform the standardized Mobilization with Movement (MWM) protocol. While seated in a chair with back support and hips, knees, and ankles at 90° flexion, the researcher will stabilize the scapula with one hand and apply a posterolateral glide to the anterior humeral head with the other hand during active shoulder elevation in the scapular plane. The intervention consists of 3 sets of 10 repetitions, with a 1-minute rest interval between sets. Assessments will be conducted at baseline and immediately post-intervention, including shoulder range of motion using a digital inclinometer, perception of movement fluency using a Visual Analogue Scale (VAS), and sport-specific performance tests (One-arm Seated Shot Put Test and Functional Throwing Performance Index).
214891871|NCT07191522|PROCEDURE|Mechanical debridment with titanium curettes and ultrasounds|Removal of deposits above and below the gum line using hand or ultrasonic tools to reduce the inflammatory parameters
214891872|NCT07191522|PROCEDURE|Mechanical debridment with titanium curettes and ultrasounds + aPDT (antimicrobial photodynamic therapy)|Non-invasive treatment that uses a combination of a light-sensitive compound (photosensitizer), specific light and oxygen to generate reactive oxygen species (ROS) that kill bacteria
214891873|NCT07191873|DRUG|Tirzepatide|Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months
214891874|NCT07191873|DRUG|Tirzepatide Placebo|Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months
214295713|NCT03113019|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
214295714|NCT00524550|DIETARY_SUPPLEMENT|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
214295715|NCT00527007|OTHER|External cooling|External cooling
214478048|NCT03735979|DRUG|Argatroban|Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.
214891875|NCT07193459|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily
214891876|NCT07193459|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily
214891877|NCT07193459|DRUG|Placebo|Placebo tablets, once daily
214891878|NCT07192965|RADIATION|Non-ECG-gated computed tomography|Scanning with a Revolution Apex Elite system (GE Healthcare, WI, USA), using hyperdrive pulmonary CT angiography (523mm/s with 0.28s/rotation gantry speed). Images will be acquired using the ECG-less Cardiac software (GE Healthcare, WI, USA), without the need for patient-attached ECG leads. The system uses a wide detector coverage of 160mm to provide full heart coverage and a fast gantry speed of 0.23 seconds per rotation to perform imaging in a single cardiac cycle. An estimation of the heart rhythm must be provided, based on the heart rhythm the scanner simulates an ECG signal. This simulated ECG signal provides virtual gating of the scan. Advanced software tools including SmartPhase (automated phase selection) and SnapShot Freeze 2 (optimized volume registration) will be used. After a short delay of 5-12 sec, allowing contrast to pass from the pulmonary circulation into the aorta and coronary arteries, a coronary CT angiography will be performed using the same contrast bolus.
214891879|NCT07192133|DIAGNOSTIC_TEST|CT scan|Dynamic contrast-free chest CT scan
214891880|NCT07193433|OTHER|CSNAT-I|CSNAT-I will be conducted in five stages, including an introduction of the CSNAT, family caregivers' consideration of needs, prioritize needs, a shared care plan, and a shared review for effectiveness and subsequent actions .
214891881|NCT07192718|BEHAVIORAL|Empowered Relief|The participants will attend a pain relief skills intervention (Empowered Relief). The two-hour session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
214891882|NCT07192718|OTHER|Education|Educational content: Participants view videos online focusing on specific areas of postpartum recovery (Sleep, Mental Health, Physical Therapy, Obstetric care).
214891883|NCT07192783|OTHER|Lavender|Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) using a standardized diffuser. This intervention is provided in addition to routine care for primary hypertension. Outcomes measured include anxiety, sleep quality, and blood pressure before and after the intervention.
214891884|NCT07191756|DRUG|Amphotericin B|This is a retrospective observational study. Patients in this cohort received various formulations of amphotericin B as part of their standard medical care.
214891885|NCT07191756|DRUG|Isavuconazole|This is a retrospective observational study. Patients in this cohort received isavuconazole as part of their standard medical care.
214891886|NCT07192913|DEVICE|Transcranial Magnetic Stimulation|"TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.~Device: Transcranial Magnetic Stimulation (Sham)~TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant. For sham, the side of the coil that does not deliver pulses will be used."
214891887|NCT07192549|DRUG|Sevoflurane group|Patients fasted for 6 hours and abstained from clear fluids for 3 hours preoperatively. Upon entering the operating room, oxygen was administered via an appropriately sized face mask at a flow rate of 6-8 L/min. Anesthesia was induced by sequential intravenous injection of remimazolam, sufentanil, and rocuronium. A laryngeal mask was inserted after the disappearance of the eyelash reflex. Anesthesia was maintained with sevoflurane (Inhalation Sevoflurane, Brand: Kaiteli, Specification: 120 mL, Approval Number: National Drug Approval H20070172, Manufacturer: Shanghai Hengrui Pharmaceutical) combined with continuous intravenous infusion of remifentanil. During surgery, vital signs and body movement responses were closely monitored, and the inhaled concentration of sevoflurane was adjusted as needed (maintained at 1%-3%). Administration of anesthetics was discontinued 5 minutes before the end of surgery.
214891888|NCT07192549|DRUG|Propofol group|Preoperative preparation was identical to that of the Sevoflurane Group. Anesthesia induction was performed using the same sequence of intravenous injections of remimazolam, sufentanil, and rocuronium, followed by laryngeal mask insertion after the disappearance of the eyelash reflex. Anesthesia was maintained with remifentanil combined with continuous intravenous infusion of propofol at a maintenance dose of 0.5 mg/(kg·h). The infusion rate was dynamically adjusted based on intraoperative vital signs. Administration of anesthetics was stopped 5 minutes before the end of surgery.
214891889|NCT07192653|PROCEDURE|nonanatomical anastomosis|In Period 1 (2016-2019, n=41), nonanatomical anastomosis was performed if portal flow was insufficient.
214891890|NCT07192653|PROCEDURE|LTH-based EVT|In Period 2 (2019-2024, n=34), patients with persistent hypoperfusion underwent additional LTH-based EVT (stenting or shunt occlusion)
214891891|NCT07192627|PROCEDURE|Endoscopic mucosal dissection|Removal of lesions extending down to submucosa
214891892|NCT07191769|PROCEDURE|general anaesthesia|Patients undergoing general anaesthesia
214891893|NCT07191769|PROCEDURE|regional anaesthesia|Patients undergoing regional anaesthesia
214891894|NCT07192575|BEHAVIORAL|Perioperative Pulmonary Physiotherapy in Laparoscopic Liver Surgery|The intervention includes pulmonary physiotherapy training 7 days prior to surgery and 7 days postoperatively. Patients receive physiotherapy education in a single session preoperatively or via an educational video, to guide pulmonary training at home. The pulmonary training includes deep breathing, and coughing, pursed lip breathing and positive expiratory pressure (PEP) therapy. The exercise session (10min) is to be performed two times daily for a total of 14 days.
214891895|NCT07193342|PROCEDURE|computer controlled automatic injection (Star pen® system)|local anesthesia will be administered using computer controlled automatic injection(Star pen® system ) to provide slow and consistent anesthetic flow, aiming to reduce pain and anxiety during pediatric dental treatment.
214891896|NCT07193342|PROCEDURE|conventional anesthetic syringe|local anesthesia will be administered using a standard manual dental syringe , following conventional injection techniques for pediatric dental patients.
214907201|NCT06952348|BEHAVIORAL|Brisk walking|See arms.
214907202|NCT06952348|BEHAVIORAL|Standard care|See arms.
214478049|NCT03735979|DRUG|Eptifibatide|GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (\~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.
214478050|NCT03735979|DRUG|Placebo|IV placebo solution
214478051|NCT05921201|BEHAVIORAL|Relax, Reflect, and Empower mobile application|Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily wellness check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
214891897|NCT07193095|BEHAVIORAL|Brief Mindfulness Oriented Recovery Enhancement|B-MORE is a 2-hour, single session adaptation of the traditional MORE program.
214891898|NCT07193095|BEHAVIORAL|Empowered Relief|ER is an evidence-based 2-hour single session intervention for chronic pain.
214891899|NCT07193095|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE is an 8-week evidence-based treatment for chronic pain.
214891900|NCT07192380|DEVICE|Electroencephalogram|EEG measurement to assess attentional state
215049988|NCT05011149|DRUG|Ibuprofen|"Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent."
215049989|NCT05722366|OTHER|Active video game|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
214478052|NCT02531542|DEVICE|Echocardiography according to the READ method.|"* Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.~* A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels."
214478053|NCT06861192|DRUG|Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy|On the 1st to 5th day, Fasudil hydrochloride (10mg of fasudil hydrochloride) was treated, and on the 5th day, PD-1 monoclonal antibody (triprilizumab, 3mg/kg, intravenous drip) was treated. The treatment was repeated every 21 days for a total of 4 times
214478054|NCT06861192|DRUG|Placebo combined with androgen deprivation therapy|Days 1 to 5 were treated with placebo (0.9% sodium chloride 10mg), and days 5 were treated with placebo (0.9% sodium chloride 3mg/kg). The treatment was repeated every 21 days for a total of 4 times.
214478055|NCT06861192|PROCEDURE|radical prostatectomy|Radical prostatectomy was performed 3 weeks (±7 days) after the treatment cycle
214478056|NCT06618872|DIAGNOSTIC_TEST|PET/CT with RO958 (experimental)|the participant will have 2 PET (one with an experimental radiotracer- Tau PET), one with a standard radiotracer (amyloid-PET)
214891901|NCT07192380|DEVICE|Actigraphy|Evaluation of sleep-wake phases 24 hours prior to eye tracking measurement
215049990|NCT05722366|OTHER|aerobic exercise|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
215057382|NCT04227275|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
215057383|NCT04227275|DRUG|Anakinra|In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
215057384|NCT02039167|DEVICE|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
215057385|NCT03101189|DRUG|ACT-541468|Capsule
215057386|NCT03101189|DRUG|placebo|Matching placebo capsule
215057387|NCT03399864|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
215057388|NCT03399864|OTHER|usual care|The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
215057389|NCT06282237|OTHER|survey|Quality of life survey and motor performace survey
215057390|NCT05797051|DIAGNOSTIC_TEST|Microscopic hyperspectral imaging system|Microscopic hyperspectral imaging system
215057391|NCT05128864|PROCEDURE|High Tibial Osteotomy|Surgery procedure - High Tibial Osteotomy
215057392|NCT06339086|DRUG|Semaglutide Injection|"The subject will receive either a dose of semaglutide subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
215057393|NCT06339086|DRUG|Semaglutide Injection(Ozempic®)|"The subject will receive either a dose of Ozempic® subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
215057394|NCT06339086|DRUG|Metformin|"Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.~Treatment duration 32 weeks."
215057395|NCT03644498|OTHER|Non-Interventional|Non-Interventional
215057396|NCT02419378|DRUG|Alemtuzumab|
215057397|NCT04073862|OTHER|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
215057398|NCT04633135|DEVICE|Philips stove|Philips Smokeless stove HD4012LS
215057399|NCT04633135|DEVICE|Gyapa stove|Wood stove made in Ghana
214891902|NCT07192380|DEVICE|Eye Tracking|"Assessment of ocular parameters during controlled eye tracking: guided saccade task followed by analysis of chest scans to detect pulmonary embolism. Measurement of ocular saccade parameters (distance, velocity), fixation time and pupil diameter.~Measurements performed twice: after a night on call and after a night of rest."
214891903|NCT07192380|OTHER|Questionnaires|"Measurements of sleepiness (Karolinska Sleep Scale KSS, Epworth Sleep Scale ESS), mental fatigue (EVA Scale), insomnia (Insomnia Severity Index, ISI) and chronotype (Morningness Eveningness Questionnaire, MEQ)~* Inclusion visit: MEQ~* Before the first evaluation: ISI, KSS, ESS, EVA~* Before the second evaluation: ISI, KSS, ESS, EVA"
214891905|NCT07192666|DRUG|Exosome Preparation|Each subject will have a single designated study eye; this eye will receive multiple instillations-one drop four times daily for 14 consecutive days.
214891906|NCT07185828|BEHAVIORAL|Contact your PCP|Text messages will be sent and discharge paperwork will be modified to encourage contacting a primary care provider.
214891907|NCT07185828|BEHAVIORAL|Use Intelligent Triage|Text messages will be sent and discharge paperwork will be modified to encourage using Intelligent Triage.
214891908|NCT07193355|OTHER|Mental Imagery Application Protocol|"Before the GYKO test, the patient will be asked to perform mental imagery to visualize a 3-meter distance for five cycles, and the time will be recorded. The TKYT will be administered according to standard protocols.~Mental Imagery Application Protocol:~1. Awareness:~   The therapist will show a video of a typical normal gait for an adult male or female without pathology and compare it with a video of the patient's own gait.~2. Problem Identification/Explanation In the EG, subjects will identify gait problems and compare their gait with their typical gait. They will then use the comparative information for feedback.~3. Progressive Relaxation~4. Mental Imagery of Gait~5. Physıcal Performance Of The gait This protocol will be implemented the day after the initial assessment and will be conducted in 12 training sessions of no more than 90 minutes, three times per week for 4 weeks."
214891909|NCT07192731|DEVICE|Irreversible Electroporation|"Irreversible electroporation (IRE) is a procedure which involves the passage of short intense electrical pulses between probes to destabilize cell membranes by creating nanopores which leads to cell destabilisation and cell death.~IRE can be used to selectively damage cancerous cells whilst sparing adjacent supporting connective tissue in vessels and bile ducts allowing a more targeted treatment compared to other types of ablation. IRE also avoids the heat-sink phenomenon which compromises the effectiveness of thermal ablation and possibly reduces the risks of biliary injury."
214891910|NCT07192770|BIOLOGICAL|Granulocyte colony-stimulating factor (G-CSF)|Patients receive chemotherapy with prophylactic G-CSF (granulocyte colony-stimulating factor) as part of routine clinical care. Both short-acting (filgrastim) and long-acting formulations (pegfilgrastim, lipegfilgrastim) may be used according to standard oncology practice. The study does not assign the intervention but observes supportive care strategies and patient-reported outcomes related to G-CSF-induced bone pain.
214891911|NCT07192770|OTHER|Supportive Care (Analgesic and Non-Pharmacological Strategies)|Supportive care strategies including analgesic use (NSAIDs, opioids, antihistamines) and non-pharmacological interventions (rest, exercise, local heat/cold, relaxation techniques) will be recorded as part of routine practice. The study does not randomize or assign supportive care but documents their use and association with bone pain outcomes.
214891912|NCT07191613|BEHAVIORAL|HAPPY GO GO Somatosensory Game|"Participants in the intervention group will engage in the HAPPY GO GO somatosensory exergame program. The intervention consists of structured game-based physical activity sessions, conducted once per week for a total duration of 12 weeks. Each session includes interactive, movement-based tasks designed to promote physical health, and mental well-being among community-dwelling older adults."
214891913|NCT07192822|BEHAVIORAL|Virtual Reality distraction|Participants goes into an immersive virtual reality during a brief painful stimulus
214891914|NCT07192822|BEHAVIORAL|No Virtual Reality|Participant receives a brief thermal stimulus during no treatment
214891915|NCT07192822|BEHAVIORAL|One brief pain stimulus|patient receives one brief pain stimulus with no simultaneous second stimulus
214891916|NCT07192822|BEHAVIORAL|Two simultaneous brief thermal stimuli|Participants receive two brief thermal stimuli at the same time
214891917|NCT07186634|DRUG|Liberal inspired oxygen|The concentration of Oxygen will differ according to the randomisation
214891918|NCT07186634|DRUG|Conservative inspired oxygen|Conservative inspired oxygen
214891919|NCT07186634|DRUG|Intermediate inspired oxygen|Intermediate inspired oxygen
214891920|NCT07192315|OTHER|Bloodsampling|Blood will be sampled At Visit 1, 2, 3 and 4. For patients presenting immuno-induced adverse events (iRAEs), an additionnal visit V tox will be planned will a blood sampling.
214891921|NCT07192315|OTHER|Pharyngeal swab sampling|Pharyngeal swab will be sampled at visit 4 for patients without immuno-induced adverse events (iRAEs) Pharyngeal swab will be sampled at visit Tox for patients presenting immuno-induced adverse events (iRAEs)
214891922|NCT07192315|OTHER|Cuteanous swab sampling|"Cuteanous swab will be sampled at visit 1, 2, 3 and 4 for patients without immuno-induced adverse events (iRAEs).~Cuteanous swab will be sampled at visit 1, 2, 3 and tox for patients presenting immuno-induced adverse events (iRAEs)."
214891923|NCT07192315|OTHER|Stools sample collection|"Stools sample will be collected at visit 1, 2, 3 and 4 for patients without immuno-induced adverse events (iRAEs).~Stools sample will be collected at visit 1, 2, 3 and tox for patients presenting immuno-induced adverse events (iRAEs)."
214891924|NCT07192939|DRUG|HRS-9813 capsules|HRS-9813 capsule; High dose
214891925|NCT07192939|DRUG|HRS-9813 capsules|HRS-9813 capsule; Low dose
214891926|NCT07192939|DRUG|HRS-9813 capsule mimetic|HRS-9813 capsule mimetic
214891927|NCT07191860|COMBINATION_PRODUCT|The Airiver Pulmonary drug-coated balloon (DCB) dilation|drug coated balloon dilation
214891928|NCT07191860|DEVICE|Commercial airway balloon dilation|uncoated airway balloon dilation
214891929|NCT07192068|DRUG|Zanidatamab|"Single arm study where the experimental regimen used for all patients will be zanidatamab, administered intravenously every 3 weeks :~* Patients \<70 kg: 1800 mg IV Q3W on Day 1 of each 21-day cycle~* Patients ≥70 kg: 2400 mg IV Q3W on Day 1 of each 21-day cycle."
214891930|NCT07191639|OTHER|completion of the QOL-HHT questionnaire|filling in the QOL-HHT questionnaire when they come for consultation
214891931|NCT07193290|OTHER|Lifestyle Questionnaire|All subjects will complete the lifestyle questionnaire
214891932|NCT07193290|OTHER|Self-portrait image (Face and Hair)|All subjects will take one self-portrait image of their face and hair
214891933|NCT07193290|DIAGNOSTIC_TEST|Skin microbiome collection|Subjects randomly assigned in the skin microbiome subset will complete the skin microbiome collection
214891934|NCT07192250|PROCEDURE|short segment TPF|short segment transpedicular screw fixation with one or two screws in fractured vertebra
214891935|NCT07192250|PROCEDURE|conservative management|brace and bed rest with mobilization as tolerated
214891936|NCT07191951|OTHER|Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.|Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.
214891937|NCT07192536|DEVICE|Transcranial magnetic stimulation|Intermittent theta burst stimulation (iTBS) will be delivered via the Magstim Horizon 3.0 Transcranial Magnetic Stimulation device. This device has been authorized by Health Canada (License No.: 111334, Type: System, Device class: 3 Device first issue date 2024-06-04, License name: HORIZON 3.0 TMS THERAPY SYSTEM) and is indicated for use in treating mild depressive disorder. The device will be used off-label as a potential treatment for Post-Traumatic Stress Disorder (PTSD) and chronic pain in this Investigator-Initiated study. rTMS will be delivered using modified intermittent theta burst accelerated bilateral treatments (MITAB), combining low frequency 1HZ to the right dorsolateral prefrontal cortex (dlPFC) with high frequency intermittent theta burst to the left dlPFC, up to 6 times per day for 5 days.
214891938|NCT07191964|PROCEDURE|Supra-Sartorial Subcutaneous Infiltration (SSSI)|20 mL ropivacaine or saline infiltrated lateral-to-medial subcutaneously above sartorius at femoral triangle apex using inject-as-you-advance technique, avoiding hyperechoic nerves.
214891939|NCT07191964|PROCEDURE|intermittent adductor canal block (iACB)|An adductor canal catheter is inserted proximal-to-distally over a distance of 6-10 cm at femoral triangle apex, with an initial bolus of 10 mL of 0.3% ropivacaine administered in PACU. The following doses start at 9:00 PM on the day of surgery and are repeated every 12 hours,
214891940|NCT07191964|PROCEDURE|posterior capsule local infiltration analgesia (PC-LIA)|PC-LIA consists of two 10 mL injections of 0.3% ropivacaine delivered intraoperatively to the posteromedial and posterolateral aspects of the posterior capsule before cementation. The target injection plane is the potential space between the posterior capsule and the popliteal artery.
214891941|NCT07193160|DRUG|Sacituzumab Tirumotecan|fixed dosage 4mg/kg iv, D1, D15, each 4 weeks one cycle. Drug reduction will be implemented according to the research plan.
214891942|NCT07193160|DRUG|Furmonertinib|160mg QD or 80mg QD, each 4 weeks one cycle, according to the safety run-in phase, until confirmed by the investigator as imaging disease progression, intolerable toxicity, subject's request to terrminate treatment, or other treatment termination criteria specified in the protocol. Drug reduction will be implemented according to the research plan.
214891943|NCT07192094|BEHAVIORAL|Mindfulness Sessions - 8 Week Program|A culturally, and developmentally adapted Mindfulness-Based Stress Reduction (MBSR) program for Hispanic (self-identified) emerging adult (EA) participants (ages 18-25 years old) over 8 weeks (1.5 hours/week).
214891944|NCT07192354|OTHER|Questionnaire and Physical Exam|Participants will be administered the Cyberchondria Severity Scale Short Form (CSS-12), Health Perception Scale, and State and Trait Anxiety Scale online via Google form.
214891945|NCT07193212|OTHER|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a hands-on approach where a trained physician uses techniques such as gentle pressure, stretching, and guided movements to improve mobility, reduce pain, and support the body's natural healing. It focuses on the interconnectedness of muscles, joints, and fascia to restore balance and function.
214891946|NCT07192172|DEVICE|Bipolar radiofrequency ablation using twin internally cooled perfusion electrodes|"Device: Twin Internally Cooled-Perfusion (TICP) Electrodes~Two 17-gauge internally cooled-perfusion electrodes Multichannel RF generator (RF Medical Co., Seoul, Korea) Bipolar mode application Saline perfusion rate: approximately 1 cc/min"
214891947|NCT07192445|OTHER|Reading of Mental Health Graphic Novels|Participants read carefully selected excerpts from graphic novels focused on mental health. These excerpts integrate written narratives with visual storytelling to illustrate daily life challenges, symptoms, interpersonal relationships, and treatment experiences in mental health contexts. The intervention is conducted individually in a supervised classroom environment. Along with the graphic novel, a guide is provided with questions designed to encourage focused and reflective reading.
214891948|NCT07191626|PROCEDURE|PFA - PV + SVCI|Catheter ablation procedure using a Pulsed Field Ablation system to achieve electrical isolation of all four pulmonary veins AND the superior vena cava.
214891949|NCT07191626|PROCEDURE|PFA - PVI only|Catheter ablation procedure using a Pulsed Field Ablation system to achieve electrical isolation of all four pulmonary veins only. No ablation is performed in the superior vena cava.
215057400|NCT05242835|PROCEDURE|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
215057401|NCT05242835|PROCEDURE|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
214478057|NCT06867250|DIAGNOSTIC_TEST|The patients' periodontal clinical parameters were recorded. PISF samples were collected, and the evaluations of 25(OH)D and LL-37 were conducted using enzyme-linked immunosorbent assay.|In vitro studies have shown that vitamin D promotes the release of antimicrobial peptides from gingival epithelial cells, no clinical research has specifically examined its effect on LL-37 levels in peri-implant tissue diseases. This study seeks to investigate the relationship between vitamin D levels in peri-implant sulcus fluid and clinical parameters in individuals with both peri-implant health and disease. Additionally, it aims to assess the correlation between vitamin D and the antimicrobial peptide LL-37.
214295716|NCT04290884|DRUG|Tranexamic Acid|The recruited patients will be randomly assigned to two groups, 50% chance to the experimental group (use of tranexamic acid) and 50% chance to the control group (use of normal saline). After the reduction of the intertrochanteric fracture, 10ml of tranexamic acid is injected under the deep fascia around the fracture area before inserting a drain. As for the control group, 10ml of normal saline is injected instead. Blood will be taken on the third day post operation, and the patient will be seen at 6 weeks, and 3 months.
214295717|NCT04937621|DIAGNOSTIC_TEST|ECG data analysis|Baseline ECG as well as follow-up ECG are analysed
214295718|NCT04937621|DRUG|Treatment data collect|Baseline treatment data as well as follow-up treatment data are collected
214295719|NCT04937621|BIOLOGICAL|Biological check-up data collect|Baseline Biological check-up data as well as follow-up data are collected
214295720|NCT04937621|OTHER|Collection of clinical events of interest|Clinical events of interest at the baseline as well as follow-up clinical events are collected
214891950|NCT07191535|DRUG|linvemastat|Matrix Metalloproteinase-12 inhibitor
214891951|NCT07191535|DRUG|Placebo|Placebo
214891952|NCT07191847|BIOLOGICAL|eye drops|apply 2 drops 3 times daily for 12 weeks
214891953|NCT07191808|OTHER|Low Level Laser Therapy|cluster method
214891954|NCT07193225|DEVICE|Ultrasound localization microscopy, circle of Willis|Ultrasound localization microscopy sequences coupled with SonoVue® injection of the circle of Willis before carotid endarterectomy
214891955|NCT07193225|DEVICE|Ultrasound localization microscopy, coronary arteries|ultrasound localization microscopy sequences coupled with SonoVue® injection of coronary arteries before carotid endarterectomy
214891960|NCT07192562|BEHAVIORAL|Virtual Reality-Based Exercise Program|"Participants in the VR Exercise Group received a virtual reality-based physical activity intervention using the Meta Quest 2 headset. Two exergames, Beat Saber and PowerBeatsVR, were implemented twice a week for six weeks, totalling 12 exercise sessions. Each session lasted 30-35 minutes and was conducted individually during work hours. Beat Saber provided rhythm-based tasks involving block slicing and obstacle dodging, while PowerBeatsVR included high-intensity punching, squatting, and side-stepping movements. Game difficulty increased weekly."
214891962|NCT07191509|DEVICE|Speaking Valve ，Tracheostomy Tube Occlusion ，Tracheostomy Tube Ventilation|"Speaking Valve:~Participants are assessed while breathing through a one-way speaking valve attached to the tracheostomy tube. The valve directs exhaled air through the upper airway, restoring phonation and more closely simulating post-decannulation airflow. The assessment is performed for up to 4 hours to evaluate tolerance and respiratory function prior to tracheostomy tube removal.~Tracheostomy Tube Occlusion:~Participants undergo a capping trial, in which the tracheostomy tube is completely occluded. During this intervention, patients must breathe entirely through their natural upper airway, which increases airway resistance and tests their ability to tolerate decannulation. The capping trial is conducted for 24-48 hours, with monitoring for signs of intolerance.~Tracheostomy Tube Ventilation:~This intervention involves assessment of respiratory function while the participant breathes directly through the open tracheostomy tube, representing the baseline state prior to any decannu"
214891963|NCT07193316|OTHER|no intervention|no intervention
215057402|NCT03804242|BEHAVIORAL|Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience|This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
215057403|NCT04830215|DRUG|Brexpiprazole|Oral brexpiprazole tablets as adjunctive therapy to ADT
214295721|NCT04251598|BEHAVIORAL|I Am Protecting My Child from the Sun|"The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband."
214295722|NCT04251598|BEHAVIORAL|SMS for sun protection|While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
214295723|NCT06336603|DRUG|Winlevi (clascoterone) 1% & Adapalene 0.3% gel|Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)
214478058|NCT06868095|OTHER|Surgical resection|Histologically confirmed EOCRC
214668352|NCT02459171|OTHER|Blood sample|"Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.~For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs."
214668353|NCT02459171|OTHER|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
215049991|NCT05547113|DIAGNOSTIC_TEST|posturography|In our stabilometric laboratory we use for the posturography two Kistler stabilometric platforms (type 5619A, Switzerland) along with MARS software (version 5.0, Switzerland). We use the SYNAPSIS Subjective Vertical device (version 1.3.2, France) to examine the perception of the subjective visual vertical. The patients should also full fill 5 questionnaires to subjective evaluation of non-vestibular symptoms within ADL and QoL, namely for difficulties related to dizziness, tinnitus, orofacial function disorders and the occurrence of anxiety and depression. For this purpose we use Dizziness Handicap Inventory, Tinnitus Handicap Inventory, Facial Disability Index, Beck's Anxiety Inventory and Beck's Depression Inventory.
215049992|NCT02757807|BEHAVIORAL|Utilization of Serenita for Relaxation|Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
215049993|NCT01734824|DRUG|Denosumab|sc RANKL-inhibitor
215049994|NCT01734824|DRUG|Teriparatide|daily subcutaneous injection of teriparatide
214891964|NCT07192107|DRUG|MHB042C for Injection|IV administration of MHB042C Q2W or Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214891965|NCT07191717|DRUG|Abemaciclib|Given PO
214891966|NCT07191717|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214891967|NCT07191717|DRUG|Imlunestrant|Given PO
214891968|NCT07191717|OTHER|Questionnaire Administration|Ancillary studies
214891969|NCT07191717|PROCEDURE|Radiologic Imaging Procedure|Undergo radiologic scans
214891970|NCT07192211|BIOLOGICAL|Mesenchymal stem cell|ADR-002K administration
214891971|NCT07192211|BIOLOGICAL|Placebo|Placebo
214891972|NCT07192614|DRUG|AZD6621|A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8
215049995|NCT01734824|DRUG|Placebo Denosumab|one subcutaneous injection denosumab placebo
215049996|NCT01734824|DRUG|Placebo Teriparatide|daily subcutaneous placebo injection
215049997|NCT03637491|DRUG|Avelumab|IV treatment
215049998|NCT03637491|DRUG|Binimetinib|Oral treatment
214295724|NCT02646280|OTHER|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
214295725|NCT02646280|OTHER|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
214295726|NCT02527460|DRUG|Anakinra|Participants will self-administer daily subcutaneous injections of anakinra for 8 weeks. The dose will be increased over the first four weeks to minimize injection site reactions. The target dose after four weeks is 300mg daily.
214295727|NCT03643276|DRUG|Blinatumomab|Experimental therapy in randomizations R-HR and R-MR
214295728|NCT03643276|DRUG|Bortezomib|Experimental therapy in randomization R-eHR
214295729|NCT03643276|DRUG|Cyclophosphamide|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
214891973|NCT07192289|PROCEDURE|Using advanced platelet-rich fibrin (A-PRF+) or injectable platelet-rich fibrin (i-PRF) in regenerative endodontic treatment in mature permanent teeth.|"After obtaining informed consent, the study will be conducted over 2 appointments, 2-4 weeks apart.~The first appointment will focus on infection control and inflammation reduction. The canal will be instrumented with a single-file system. The canal will be then irrigated sequentially with 3% sodium hypochlorite (NaOCl), saline, and 17% ethylenediaminetetraacetic Acid (EDTA) to ensure thorough disinfection. Finally, a temporary filling of Glass Ionomer Cement will be placed over an intracanal dressing of calcium hydroxide.~At the second appointment, the final treatment will be performed based on the patient's group:~Control Group - Blood clot method for regenerative endodontics. Experimental Group 1 - Regenerative endodontics using advanced platelet-rich fibrin (A-PRF+).~Experimental Group 2 - Regenerative endodontics using injectable platelet-rich fibrin (i-PRF).~All three groups will be then sealed with mineral trioxide aggregate (MTA) and a final composite resin filling."
214891974|NCT07191483|DRUG|KYN-5356 low dose|oral tablet
214891975|NCT07191483|OTHER|Placebo|Oral tablet
214891976|NCT07191483|DRUG|KYN-5356 Medium Dose|oral tablet
215049999|NCT03637491|DRUG|Talazoparib|Oral treatment
215050000|NCT00405249|DRUG|elvucitabine|
214295730|NCT03643276|DRUG|Cytarabine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
214295731|NCT03643276|DRUG|Daunorubicin|Part of standard chemotherapy
214295732|NCT03643276|DRUG|Myocet|Part of intensification block Myocet-FLA for patients with very high relapse risk
214295733|NCT03643276|DRUG|Dexamethasone|Part of standard chemotherapy
214295734|NCT03643276|DRUG|Doxorubicin|Part of standard chemotherapy
214295735|NCT03643276|DRUG|Etoposide|Part of standard chemotherapy
214295736|NCT03643276|DRUG|Fludarabine Phosphate|Part of intensification block Myocet-FLA for patients with very high relapse risk
214295737|NCT03643276|DRUG|Ifosfamide|Part of standard chemotherapy
214295738|NCT03643276|DRUG|6-Mercaptopurine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
214295739|NCT03643276|DRUG|Methotrexate|Part of standard chemotherapy
214295740|NCT03643276|DRUG|Pegaspargase|Part of standard chemotherapy
214295741|NCT03643276|DRUG|Prednisolone|Part of standard chemotherapy
214295742|NCT03643276|DRUG|Tioguanin|Part of standard chemotherapy
214295743|NCT03643276|DRUG|Vincristine|Part of standard chemotherapy
214295744|NCT03643276|DRUG|Vindesine|Part of standard chemotherapy
214295745|NCT03643276|DRUG|Erwinase|Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
214295746|NCT03826979|OTHER|Pliates method treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
214891977|NCT07191483|DRUG|KYN-5356 High Dose|oral tablet
214891978|NCT07193303|OTHER|mental imagination|The Nine-Hole Peg Test (9 DPT) will be performed with a mental chronometer.the duration between actually physically performing the movement and mentally imagining the same movement will be recorded.
214891979|NCT07192796|BEHAVIORAL|Pilates Exercise Program|A 6-week supervised Pilates exercise program, with 18 sessions. Exercises focused on core stabilization, posture, and lower limb alignment using mat-based and resistance band movements.
214891980|NCT07192796|BEHAVIORAL|Neuromuscular Exercise Program|A 6-week supervised neuromuscular training program, 18 sessions . Training emphasized balance, proprioception, dynamic stability, and strengthening of lower extremity muscles.
214891981|NCT07192484|BEHAVIORAL|KT group|Receiving additional KT
214891982|NCT07192484|BEHAVIORAL|Conventional group|Conventional physical therapy
214891983|NCT07192081|DRUG|Labetalol|Labetalol 0.25 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.
214891984|NCT07192081|DRUG|Lignocaine|Lignocaine 1.5 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.
214891985|NCT07192952|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 270±7 days.
214891986|NCT07192367|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants receive structured Virtual Reality Exposure Therapy sessions using a VR headset. The intervention provides simulated social situations (e.g., public speaking, group interactions) to gradually expose participants to anxiety-provoking scenarios. The sessions are guided and standardized to target symptoms of social anxiety disorder.
214891987|NCT07192367|DRUG|Sertraline (Oral Antidepressant)|Participants receive pharmacological treatment with Sertraline, a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for social anxiety disorder. Dosage and administration will follow clinical guidelines and physician judgment.
214891988|NCT07191938|PROCEDURE|Ultrasound guided penile block|The penile block is performed supine. After skin disinfection, the Buck's fascia is sonographically located, and the local anesthetic is injected close to the dorsal nerve of the penis in the plane after a negative aspiration test (16). The recommended dose is 0.1 ml/kg per side of ropivacaine 2 mg/ml (8). Injection is performed bilaterally. A subcutaneous injection of 1ml ropivacaine 2mg/ml (i.e. 2mg) is made at the base of the penis to ensure blockage of the perineal fibers.
214891989|NCT07191938|PROCEDURE|Neurostimulation guided pudendal block|The pudendal block is performed in the supine position, with the legs flexed. After skin disinfection and palpation of the ischial tuberosity, the neurostimulator needle, set at 0.5 mA, is inserted 1 cm medial to the tuberosity. Contraction of the anal sphincter enables the proximity of the pudendal nerve, originating from the S2, S3 and S4 roots, to be identified. Once contraction has been obtained, local anaesthetic is injected using ropivacaine 2 mg/ml at a dose of 0.2 ml/kg per side, in the absence of blood reflux.
214891990|NCT07191990|PROCEDURE|Final irrigation by cryotreated NaOcl.|Final irrigation by cryotreated NaOcl (2.6%) at 2-4 °C for 1 min
215050001|NCT00532844|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
215050002|NCT00532844|DRUG|Sapropterin Dihydrochloride and Vitamin C|Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
215050003|NCT03988426|BIOLOGICAL|Octanorm|Octanorm
214891991|NCT07191990|PROCEDURE|Final irrigation by preheated NaOcl|Final irrigation by preheated 60°C(15) NaOcl (2.6%) for 1 min.
214891992|NCT07191990|PROCEDURE|Final irrigation with ultrasonic activation of NaOcl|Final irrigation with ultrasonic activation of NaOcl(2.6%) for 1 min
214891993|NCT07191990|PROCEDURE|Final irrigation by NaOcl at room temperature|Final irrigation by NaOcl (2.6%) at room temperature 24 °C for 1 min
214907203|NCT07143630|DEVICE|Neuromuscular Electrical Stimulation|NMES will be applied to the abdominal muscles using a multichannel stimulator. Each session will last approximately 20 minutes, administered 5 times per week for a total of 15 sessions, in addition to core stabilization exercise program performed with the same frequency.
214907204|NCT07143630|BEHAVIORAL|Core Stabilization Exercises|Participants will perform a structured core stabilization exercise program. The program will be administered 5 times per week for a total of 15 sessions.
214907205|NCT07142031|OTHER|BioHPP|Onlay restorations fabricated from BioHPP polymer will be applied to 20 patients. Following the 6- and 12-month follow-ups, the collected data will be analyzed according to clinical evaluation criteria.
215050004|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
215050005|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
214478059|NCT06865846|DEVICE|TeleMedBot|The patient will receive a questionnaire daily containing a list of questions about blood pressure and heart rate. For this purpose, a messaging application will be installed on the patients' smartphones before the study begins. All patients will be instructed and trained to use the application. Every day at 12 noon, patients will receive a questionnaire containing 2 questions. Patients can start, pause, and continue answering for 12 hours before the next questionnaire appears. For security reasons, no personal data of patients is entered or saved in the program. The research physician will receive daily information about the patient's self-monitoring results and make decisions about the need to adjust therapy.
214478060|NCT06867952|DIETARY_SUPPLEMENT|Vitamin K2 plus vitamin D3|Intervention: Vitamin K2 (menaquinone-7), 100-200 µg/day plus vitamin D3 (800- 1000 IU/day) for 6-9 months.
214478061|NCT06867952|DIETARY_SUPPLEMENT|Vitamin K2 plus vitamin D3|Intervention: Vitamin K2 (menaquinone-7), 100-200 µg/day plus vitamin D3 (800- 1000 IU/day) for 6-9 months.
214478062|NCT06865508|DEVICE|Laser therapy|Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\].
214891994|NCT07193238|OTHER|The Ethics and Moral Course based on the Ashridge training model|Based on the three-stage characteristics of the Ashridge training model, the developed the content of this ethics course. (1) Discrete stage (within 3 months of employment): This stage aims to initially cultivate the professional identity of new nurses, stimulating humanistic awareness. It primarily involves self-study, supplemented by instructor supervision and implicit positive guidance. (2) Integrated stage (4-6 months of employment): This stage combines professional identity with actual work, enhancing humanistic care abilities in practice. It emphasizes mutual sharing between instructors and new nurses, utilizing diverse training methods to promote experience and reflection. (3) Cumulative stage (7-12 months of employment): This stage develops critical thinking and ethical problem-solving abilities. It focuses on assessing comprehensive abilities in complex nursing situations, providing feedback on the teaching plan, and evaluating training effectiveness.
214891995|NCT07191977|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.
214891996|NCT07191977|DRUG|Palbociclib|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
214891997|NCT07191899|DRUG|KN060|The dose was calculated based on the fasting body weight of the subject D1, and the corresponding volume of KN060 was drawn and added to 0.9% sodium chloride injection to prepare a 100 ml solution by intravenous drip every two weeks
214891998|NCT07191899|DRUG|0.9% Sodium Chloride Injection|0.9% sodium chloride 100ml was administered as placebo by intravenous drip every two weeks
214891999|NCT07192588|DRUG|GR1014-CG 2.4%|Topical gel formulation of amifostine thiol (GR1014) at 25 mg/mL
214892000|NCT07192588|DRUG|Vehicle Gel|The same topical formulation as GR1014-CG without the active ingredient amifostine thiol
214892001|NCT07192588|RADIATION|Radiation Therapy|Ultra hypofractionated RT, 26 Gy in 5 daily fractions (5.2 Gy) given over 1 week on the whole breast
214892002|NCT07192588|DRUG|GR1014-CG 4.7%|Topical gel formulation of amifostine thiol (GR1014) at 50 mg/mL
214478063|NCT06865508|DEVICE|zinc oxide eugenol dressing.|zinc oxide eugenol dressing.
214668354|NCT02459171|OTHER|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
214892003|NCT07192471|DRUG|KK2223|Intravenous infusion
214892004|NCT07192237|DRUG|Blinatumomab|Given by IV
214892005|NCT07192809|OTHER|Stabilisation exercise, resistance exercise and distraction task|The 8-week exercise intervention consists of 25 minutes non supervised training while distracting their attention with a knowledge based application
214892006|NCT07192809|OTHER|stabilisation exercise and resistance exercises|The 8-week exercise intervention consists of 25 minutes non supervised training without distracting their attention with a knowledge based application
214892007|NCT07193043|BEHAVIORAL|Body Image Program (BIP)|The Body Image Program (BIP) is a culturally adapted, dissonance-based group intervention derived from the Body Project. It is delivered in two weekly sessions of 120 minutes each, in small groups of 7-10 participants, by trained health professionals with experience in eating disorders. Activities include verbal, written, and behavioral exercises to critique sociocultural appearance ideals, reduce thin-ideal internalization, and promote more adaptive body image. Each session ends with homework: after Session 1, tasks include a behavioral challenge and reflective writing; after Session 2, a commitment activity (e.g., self-affirmation or body activism) is completed within one week and submitted by email. Participants in the waitlist control arm complete the same assessments but receive the BIP between weeks 6 and 8, after the final follow-up.
214892008|NCT07192757|DEVICE|transcutaneous auricular vagus nerve stimulation|active electrical stimulation applied to the cymba conchae of the left ear
214892009|NCT07192757|DEVICE|Sham Control|electrical stimulation applied to a location on the ear not innervated by the auricular vagus
214892010|NCT07193147|DRUG|GZR4|GZR4 s.c., single-dose
214892011|NCT07186699|OTHER|Non-Interventional Study|Non-interventional study
214892012|NCT07192744|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
214907206|NCT07142031|OTHER|Lithium Disilicate|Onlay restorations fabricated from lithium disilicate will be applied to 20 patients and will serve as the control group for comparison with the BioHPP onlay restorations. Following the 6- and 12-month follow-ups, the collected data will be analyzed according to clinical evaluation criteria.
214907207|NCT07142278|BIOLOGICAL|DUVAX 200 µg|Intramuscular injection of 200 µg DUVAX formulated with Adjuvant, administered at Weeks 0, 4, and 22
214892013|NCT07191795|OTHER|Gait analysis|Participants with unilateral amputations and a control group will undergo a comprehensive walking analysis. In a lab setting (on a treadmill or floor), their gait will be recorded using inertial sensors, EMG, force plates, and motion capture, while an EEG cap and a NASA-TLX questionnaire will assess cognitive load. Capable participants will also perform a walking test on a real-world outdoor course with varied terrain. The data will be analyzed to compare walking patterns between groups (amputees vs. controls, and amputees with vs. without phantom limbs). Finally, participants will describe any interactions they perceived between their phantom sensations and walking during the tests.
214892014|NCT07191795|OTHER|Mapping of referred sensations.|Participants reporting referred sensations in gait analysis phase will undergo further testing. The study will investigate whether prosthesis pressure or a specific socket interaction causes these sensations. A 3x3 cm grid will be drawn on the residual limb to systematically map referred sensations using various stimuli (brush, pressure tip, electrical stimulation). Participants will rate the intensity and describe the location of any resulting phantom sensations. This mapping will be repeated after 6 months to assess the stability of these sensations over time, with the ultimate goal of potentially using them to provide sensory feedback for prosthesis users. The session will last approximately 2 hours.
214892015|NCT07191795|OTHER|Exploration of the areas of the brain activated during referred sensations|Unilateral transfemoral amputees with detailed referred sensation maps will have their brain activity recorded using a 64-electrode EEG cap. Non-invasive stimuli will be applied to four specific sites: an area on the residual limb that elicits a referred sensation, the corresponding location on the intact foot, a neutral area on the residual limb, and its corresponding location on the intact thigh. This process, involving 400 total stimulations, will be repeated after 6 months to track cortical changes. Non-amputee participants will also be tested as a control group to check for symmetry in brain responses to thigh stimulation. Each session lasts about 2 hours.
214892016|NCT07191795|OTHER|Evaluation of the effects of socket modifications on phantom sensations and walking|This phase will evaluate how socket modifications affect phantom sensations and walking in 10 transfemoral amputees. First, the best material to comfortably induce referred sensations will be determined in a small sub-study. Then, each participant will be tested under four conditions: their usual socket and a socket with different rigidity, both with and without a specific local pressure point added inside. The location of this pressure point is based on the user's sensation map. Participants' walking will be analyzed in both lab and real-world environments for each condition, and they will provide feedback on their sensations and which setup they find most helpful. The evaluation involves 4 sessions over 2-3 months
214892017|NCT07191795|OTHER|Phantom limb interview|A semi-structured interview will be conducted to ask participants to describe their phantom limb sensations (type, location, intensity) under three conditions: without their prosthesis, while standing with it, and while walking with it. This aims to identify factors influencing these sensations. Additionally, a brief physical examination of the residual limb will be performed to see if touch in specific areas triggers any referred sensations.
214892019|NCT07191600|BEHAVIORAL|Talking Pen Audio-Interactive Oral Frailty Care Program|Participants in the intervention group will receive a structured oral frailty delay care program integrated with talking pen audio-interactive technology. The program includes bilingual (Mandarin and Taiwanese) teaching materials with audio support to enhance comprehension and engagement. Training sessions will focus on oral frailty prevention, oral function exercises, and related health education. The intervention is delivered over 3 to 6 months, with outcomes measured at baseline, 3 months, and 6 months.
214892021|NCT07192029|PROCEDURE|Balloon guide catheter combined with conventional thrombectomy treatment|The experimental group will use balloon guide catheter combined with conventional thrombectomy treatment.
214892022|NCT07192029|PROCEDURE|Standard guide catheter or neurovascular sheath combined with conventional thrombectomy treatment|use standard guide catheter or neurovascular sheath combined with conventional thrombectomy treatment
215050006|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
215050007|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
215050008|NCT02077231|DRUG|Vitamin A|use one drop in the eye
215050009|NCT02077231|DRUG|carbomer eye gel|use one drop in the eye
215050010|NCT03335202|DIAGNOSTIC_TEST|analysis of microbiome|microbial profiling by next generation sequencing
215050011|NCT00853892|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
215050012|NCT00853892|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
215050013|NCT02162654|PROCEDURE|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
215050014|NCT02162654|PROCEDURE|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
215050015|NCT01428310|DIETARY_SUPPLEMENT|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
215050016|NCT01428310|DIETARY_SUPPLEMENT|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
214892023|NCT07189845|DIAGNOSTIC_TEST|BIS GROUP|In the BIS group, monitoring will be visible and anesthesia depth will be maintained within a BIS value range of 40-60.
214892024|NCT07189845|DIAGNOSTIC_TEST|CONTROL GROUP|In the control group, the BIS monitor will be applied with the screen concealed from the investigator, and anesthesia depth will be guided solely by clinical parameters.
214892025|NCT07192198|DRUG|Methoxyflurane|Penthrox is a brand name for a drug called methoxyflurane. It is an inhaled analgesic (pain-relieving) agent used primarily for the relief of moderate to severe pain, typically in emergency medical situations or during minor medical procedures. Penthrox is administered by inhaling the vapors through a hand-held inhaler device. It acts quickly to provide pain relief and has a relatively short duration of action.
214892026|NCT07192198|OTHER|Control|This intervention will be the control group, only receiving local infiltration.
214892027|NCT05308927|DRUG|Norditropin|Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.
214892028|NCT05995899|DRUG|Tenapanor|IBS-C patients will ingest one capsule of tenapanor (50 mg per dose), twice daily, before breakfast and dinner for a total of 8 weeks
214892029|NCT06431269|OTHER|Screening for neurodevelopmental disorders by an advanced practice nurse|Screening for neurodevelopmental disorders by an advanced practice nurse with Ages \& Stages Questionnaires (ASQ-3) and Haute Autorité de Santé (HAS) identification scale
214892030|NCT00595491|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
214892031|NCT04956640|DRUG|LY3537982|Oral
214892032|NCT04956640|DRUG|Pembrolizumab|Intravenous
214892033|NCT04956640|DRUG|Cetuximab|Intravenous
214892034|NCT04956640|DRUG|Pemetrexed|Intravenous
214892035|NCT04956640|DRUG|Cisplatin|Intravenous
214892036|NCT04956640|DRUG|Carboplatin|Intravenous
214892037|NCT03922724|DRUG|ATL-RIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5mcg /kg/day subcutaneous on days -12, -8, and -4, ruxolitinib 45 mg/day from day -12 through day -2, and zidovudine 300mg orally three times a day from day -1 through day +50.
214892038|NCT03922724|DRUG|mRIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, lowdose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous on days -12, -8, and -4.
214892039|NCT03922724|PROCEDURE|allo HCT|Stem cell transplant
214892040|NCT03922724|DRUG|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Pentostatin 4mg /m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally daily on days -11 through -4. Busulfan IV, pharmacokinetically dosed, on days -3 and -2.
214892041|NCT03922724|DRUG|GVHD prophylaxis|"High-dose, post-transplantation cyclophosphamide (PTCy) on days +3~and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on~days +5 through +25."
214892042|NCT03922724|DRUG|IOC|e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
214295747|NCT05647473|BEHAVIORAL|Routine treatment|Participants will be educated on ways to avoid induced hypotensive states, such as avoiding prolonged standing, standing after exercise, being nervous, eating several carbohydrate-rich foods, drinking alcohol, and being in a warm environment (such as a sauna). Participants will be encouraged in a comfortable home environment, such as a sit-down bath. If there are no contraindications, they are advised to increase their salt intake to approximately 10 grams per day and adjust their fluid intake to 2-3 liters per day. They will also be encouraged to perform lower-body strength training and moderate, non-strenuous activities. Seriously ill patients will be proposed to raise the head of their bed during sleep, wear tight clothing, eat small meals, and reduce alcohol intake.Concomitant treatment with cholinesterase inhibitors, memantine, or both was allowed.
214295748|NCT05647473|DRUG|add-on low dose Astragalus|Participants received an additional 10g of astragalus per day.
214295749|NCT05647473|DRUG|add-on high dose Astragalus|Participants received an additional 20g of astragalus per day.
214892043|NCT05958368|OTHER|Avocado|The Hass Avocado group will consume 7 avocados a week (1 / day; \~240 kcals/d).
214892044|NCT05958368|OTHER|Other Fruit(s)|The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).
214892045|NCT04049591|DRUG|Higher Dose UFH|Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
214892046|NCT04049591|DRUG|Lower Dose UFH|Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
214892047|NCT06481033|BEHAVIORAL|Real Time fMRI Neurofeedback|The proposed pilot study is designed to collect feasibility and acceptability data regarding the utility of real-time functional magnetic resonance imaging (rt-fMRI) feedback in reducing suicide-specific rumination in veterans. Fifteen veterans will receive 2 rt-fMRI neurofeedback sessions while attempting to alter connectivity in brain regions that play a role in rumination. Pre- and post-treatment assessments of suicide, disability, functional impairment, and quality of life will be collected.
214892048|NCT04209218|DRUG|Dexamethasone|Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
214892049|NCT04209218|OTHER|Targeted blood pressure management|Blood pressure is maintained within ±10% from baseline.
214295750|NCT01811173|OTHER|Nurse-physician comprehensive care|"Components of the intervention include:~1. Complete assessment of the patient's and family's needs conducted by the nurse.~2. Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~3. Multimorbid care plan integrating all care aspects.~4. Action Plan for patients, supporting self management~5. Proactive monitoring according to the plan."
214892050|NCT04209218|DRUG|Placebo|Placebo (2 ml normal saline) is administered before anesthesia induction.
214892051|NCT04209218|OTHER|Routine blood presure management|Blood pressure is maintained according to routine practice.
214892052|NCT06034405|DIAGNOSTIC_TEST|Tc99-PYP or Tc99-HDMP Scan|Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.
214892053|NCT05781399|DRUG|JNT-517 Suspension|JNT-517 in on-site compounded suspension
214892054|NCT05781399|DRUG|Placebo Suspension|On-site compounded placebo suspension
214892055|NCT05781399|DRUG|JNT-517 Tablet|JNT-517 tablets, 25 mg and 75 mg
214892056|NCT05781399|DRUG|Placebo Tablet|Matching film-coated placebo tablet
214892057|NCT06384885|DIAGNOSTIC_TEST|Ultrasound|Lung ultrasound
214295751|NCT06220422|PROCEDURE|Standard Department procedure for managing direct-acting oral anticoagulants|Standard Department procedure for managing direct-acting oral anticoagulants (NACO \< 50 ng/mL) in the management of fractures before September 2021
214295752|NCT06220422|PROCEDURE|New Department procedure for managing direct-acting oral anticoagulants|New Department procedure for managing direct-acting oral anticoagulants (NACO \< 100 ng/mL) in the management of fractures after September 2021
214892058|NCT04011722|DEVICE|Portico™ NG (Navitor) Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
214892059|NCT04011722|DEVICE|Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
214892060|NCT06030804|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
214892061|NCT06030804|DRUG|Placebo|Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
214892062|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-10 mg/kg per dose
214295753|NCT03711045|BEHAVIORAL|eye-tracking|"After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded."
214295754|NCT03410940|DEVICE|CLS Brevius stem with Kinectiv technology|
214295755|NCT04577118|DEVICE|iotaSOFT Insertion System|Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
214295756|NCT04695925|DRUG|Osimertinib 80 MG [Tagrisso]|osimertinib 80 mg po qd until disease progression
214892063|NCT05478720|DRUG|Placebo|Single intravenous dose of saline
214892064|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
214892065|NCT04528680|DEVICE|Sonication for opening of blood-brain barrier|Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles
214892066|NCT04528680|DRUG|Chemotherapy, albumin-bound paclitaxel|Intravenous infusion of ABX over 30 minutes
214892067|NCT04528680|DRUG|Chemotherapy, carboplatin|Intravenous infusion of carboplatin over 30 minutes
214892068|NCT06639828|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Following unenhanced (pre-contrast) ultrasound imaging of the target focal liver lesions (FLL), Sonazoid™ will be intravenously administered and a contrast-enhanced examination will be performed.
214892069|NCT05327894|DRUG|Blinatumomab|1st cycle: 15 μg/m2/day as a 4 week continuous IV infusion for patients with a M1 marrow. For patients with a M2/M3 marrow a step-dosing strategy is required with a dose of 5 μg/m2/day in week 1 followed by 15 μg/m2/day in weeks 2, 3, and 4.
214892070|NCT05327894|DRUG|Blinatumomab|2nd cycle: 15 μg/m2/day as a 4 week continuous iv infusion
214892071|NCT05961527|DRUG|MDMA|Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose
214892072|NCT05961527|BEHAVIORAL|Group Therapy|Standardized group psychotherapy performed by therapist team in combination with non-directive MDMA therapy
214892073|NCT05061134|DRUG|Ceralasertib|Ceralasertib (240 mg) will be administered orally twice daily.
214892074|NCT05061134|BIOLOGICAL|Durvalumab|Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above \> 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.
214892075|NCT06154239|DEVICE|DAYE Diagnostic Tampon|The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746). The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion.
214892076|NCT06154239|DIAGNOSTIC_TEST|Vaginal self-swab|A vaginal self-swab typically consists of a long, slender, and flexible stick or handle, often made of plastic or a similar material. At one end, there's a soft, absorbent tip made of cotton or synthetic material. This tip is designed to collect a sample from the vaginal walls or cervix.
214892077|NCT06154239|DIAGNOSTIC_TEST|Clinician vaginal swab|"A clinician vaginal swab is a medical tool used by healthcare professionals to collect samples from the vaginal canal for diagnostic purposes. It's typically a long, thin, and flexible instrument. At one end, there's a cotton, rayon, or synthetic tip designed to collect cells, discharge, or other materials from the vaginal walls, cervix, or other areas within the vaginal canal.~The clinician swab is not taken in sub-study participants."
214892078|NCT04865107|BIOLOGICAL|UC-MSCs|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
214892079|NCT04865107|BIOLOGICAL|Placebo|PlasmaLyte A and 5% Human Albumin
214892080|NCT01013077|OTHER|Optive, Soothe, New Emulsion|One week without artificial tear use followed by Optive use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by Soothe use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by the New Emulsion use a minimum of 2 drops per day for 1 month.
214892081|NCT01013077|OTHER|Soothe, New Emulsion, Optive|One week without artificial tear use followed by Soothe use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by New Emulsion use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by the Optive use a minimum of 2 drops per day for 1 month.
214892082|NCT01013077|OTHER|New Emulsion, Optive, Soothe|One week without artificial tear use followed by New Emulsion use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by Optive use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by the Soothe use a minimum of 2 drops per day for 1 month.
214892083|NCT06407323|DIAGNOSTIC_TEST|Personalized vibration therapy powered by AI|A target frequency of either 20 Hz or 25 Hz, and amplitude 2-4 mm The whole treatment session will be around 20 minutes along with hot pack as a baseline treatment, consisted of 6 sessions per week for total 8 weeks of duration
214892084|NCT06407323|OTHER|Physical therapy treatment|A selected physical therapy treatment program for spastic diplegic CP.
215050017|NCT06546475|DRUG|N-Acetylcysteine|regular dose or high dose add-on
215050018|NCT02581436|OTHER|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
214295757|NCT04695925|DRUG|Pemetrexed 500 MG Injection|pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression
214295758|NCT04695925|DRUG|Carboplatin|carboplatin area under curve 5 intravenously every 3 weeks for four cycles
214295759|NCT04742933|OTHER|There is no intervention in this observational trial|There is no intervention in this observational trial
214295760|NCT01337947|DRUG|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
214295761|NCT04995133|DRUG|Colistin|intravenous administration
214295762|NCT05890937|DIAGNOSTIC_TEST|Oral and practical exam|Oral and practical exam that performed at the end of the semester
214295763|NCT02826031|DRUG|Sodium Hyaluronate Injection|
214295764|NCT02826031|DRUG|DICL-SR|
214892085|NCT02769520|DRUG|Pembrolizumab|200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
214295765|NCT03742154|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
214892086|NCT05699200|OTHER|Arterial Tonometry|We will measure arterial stiffness using arterial tonometry.
214892087|NCT05699200|DIAGNOSTIC_TEST|Echocardiogram|We will collect limited ultrasound images of the heart.
214892088|NCT05699200|DIAGNOSTIC_TEST|Carotid Ultrasounds|We will perform ultrasound imaging of the carotid artery.
214892089|NCT05699200|DIAGNOSTIC_TEST|Elastography|We will measure the elastic properties of the arteries using elastography.
214892090|NCT05699200|OTHER|Ankle-Brachial Index|We will measure the ankle-brachial index to assess peripheral artery blood flow.
214892091|NCT05699200|OTHER|Microneurography with sympathoexcitatory maneuvers|We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.
214892092|NCT04848480|DRUG|insulin icodec|insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
214892093|NCT04848480|DRUG|insulin degludec|insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
214892094|NCT04848480|DRUG|insulin aspart|insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
214892095|NCT00293787|DRUG|Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
214892096|NCT00293787|OTHER|Timolol Vehicle|Placebo
214892097|NCT00293787|DRUG|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
214892098|NCT00293787|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
214892099|NCT01368497|DRUG|Entecavir and peginterferon|Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
214295766|NCT00439426|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
214295767|NCT00439426|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
214295768|NCT01080690|PROCEDURE|EGD|In this arm EGD will be performed before EUS.
214295769|NCT01080690|PROCEDURE|EUS|In this arm EUS will be performed before EGD.
214295770|NCT00988455|RADIATION|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
214295771|NCT03779464|DRUG|S1 or Gemcitabine|Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area \< 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area \>1.5 m²; D1-14, q3w)
214295772|NCT00614315|DEVICE|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
214295773|NCT03108027|DRUG|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
214295774|NCT03108027|DRUG|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
214295775|NCT03108027|DRUG|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
214295776|NCT02536352|DRUG|Prenatal vitamin-mineral containing 3 mg fluoride|Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
214295777|NCT02536352|DIETARY_SUPPLEMENT|Prenatal vitamin-mineral containing 0 mg fluoride|Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
214892100|NCT02729298|DRUG|TP-0903|Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
214892101|NCT00459563|DRUG|Vitamin D|200,000 IU once weekly for 3 weeks (600,000 IU total dose)
214892102|NCT00459563|DRUG|calcitriol|calcitriol 0.5 mcg twice a day for 1 week
214892103|NCT00459563|DRUG|Placebo|Placebo once a week for 3 weeks
214892104|NCT05335824|OTHER|The platelet-rich plasma (PRP)|"Twenty ml of venous blood was drawn from each patient with the use of PRP tubes that contain anticoagulant citrate dextrose. The double-spin technique was used to prepare the PRP. The injection areas were anesthetized with lidocaine 2% with epinephrine 1/80000 and left for 10 minutes. 15 units (0. 15 mL) of PRP were injected interaligamentlly in the middle, distobuccal, and distopalatal areas of the distal surface of the upper canines (5 units in each area) together with submucosal injections buccally and palatally (100 units and 50 units~, respectively)."
214892105|NCT05335824|OTHER|The injectable platelet-rich fibrin (I-PRF) group|"Twenty ml of venous blood was drawn from each patient in this experimental group.~I-PRF was prepared with the use of 20 ml of blood drawn from the patient in dry sterile tubes without anticoagulant (quickly before coagulation starts) by following the centrifugation protocol requires one cycle only (700 RPM for 3 minutes) Injection procedures, sites, and time were similar to the PRP group."
214907208|NCT07142278|BIOLOGICAL|DUVAX 400 µg|Intramuscular injection of 400 µg DUVAX formulated with Adjuvant, administered at Weeks 0, 4, and 22
214907209|NCT07142278|BIOLOGICAL|Placebo (Adjuvant only)|Intramuscular injection of placebo consisting of Adjuvant formulation in phosphate-buffered saline without active antigen, administered at Weeks 0, 4, and 22
214907210|NCT07149246|OTHER|Nutrition intervention|Frequent follow-up from a dietitian during ICU and hospital stay, and after discharge, up to 6 months after ICU admission.
214907211|NCT07091916|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
214907212|NCT07101250|DRUG|Acetazolamide 500 MG Extended Release Oral Capsule|Active Drug
214907213|NCT07101250|DRUG|Placebo|Inactive Drug
214892106|NCT05335824|DEVICE|The control group|NiTi closed-coil springs (American Orthodontics, Sheboygan, WI) were used to impose 150 g force from the first molar band hook to the bracket of canine on each side on 0.019\*0.025-in SS archwire Patients' follow-up appointments were two weeks intervals; at each visit, the force produced by the coil was checked and readjusted when needed in order to keep it at 150-g level and the appliances were examined for any deformation or change in the position because of chewing. Canine retraction continued until achieving Class I canine relationship.
214892107|NCT01383720|DEVICE|Lotus Valve System|The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
214892108|NCT03397030|OTHER|Home-Based Exercise Program|The intervention will include a combination of both aerobic and body-weight based exercises. The aerobic portion of the intervention will include 5 days of light to moderate intensity walking for 30 mins. Intensity will be set at 40-60% of the individual's heart rate reserve. The body-weight based exercises will be done 3 times a week and will consist of 3 sets of 15 reps of bodyweight squats, incline push-ups, and hip thrusts. If these exercises cannot be performed, lower intensity exercises such as sit-to-stand, wall push up and pelvic tilt can be replaced. Individuals in this group will be given a pocket guide with instructions on how to safely perform the exercises and document their completion.
214892109|NCT00270946|DEVICE|Bilayered Cellular Matrix (OrCel)|
214892110|NCT04378972|OTHER|curcumin, homotaurine, vitamin D3|ELISA tests on supernatants of 25 vitreous biopsies incubated with bioactive molecules at 37 ° C for 20 h. The concentration of soluble mediators was calculated from a calibration curve.
214892111|NCT04378972|OTHER|control|ELISA tests on supernatants of 25 vitreous biopsies. The concentration of soluble mediators was calculated from a calibration curve.
214892112|NCT01435850|PROCEDURE|primary total hip arthroplasty|All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
214892113|NCT02366689|DRUG|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
214892114|NCT02366689|DRUG|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
214892115|NCT02366689|DRUG|fluoride only toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
214892116|NCT02366689|DRUG|Cetylpyridinium chloride mouthwash|Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
214892117|NCT02366689|DRUG|Fluoride only mouthwash|Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
214892118|NCT02989220|OTHER|Positive Reappraisal Coping Intervention|
214892119|NCT04146792|BEHAVIORAL|body acceptance program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
214892120|NCT04146792|BEHAVIORAL|writing creatively program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
215050019|NCT02581436|OTHER|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine \>25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
215050020|NCT04300387|BEHAVIORAL|multidisciplinary care|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
215050021|NCT01750125|DEVICE|measure ascending aortic blood flow with pulse wave Doppler|
215050022|NCT02621437|OTHER|Osteopathy sessions|\- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
214892121|NCT03535792|DRUG|Fentanyl/Hyperbaric bupivacaine|Intrathecal Fentanyl/Hyperbaric bupivacaine and Tibial internal fixation.
214892122|NCT03535792|DRUG|Nalbuphine/Hyperbaric bupivacaine|Intrathecal Nalbuphine/Hyperbaric bupivacaine and Tibial internal fixation.
214892123|NCT06338501|OTHER|Specifical Functional Training Exercises|"Strength Training: Include compound exercises like squats, deadlifts, lunges, and bench presses to build overall strength and muscle mass. Focus on functional movements that mimic the actions used in Muay Thai.~Core Stability Exercises: A strong core is essential for generating power and maintaining balance during strikes and defensive maneuvers.~Plyometric Training: Jumping exercises such as box jumps, squat jumps, and split jumps help improve explosive power and enhance muscular endurance, crucial for delivering swift and powerful strikes.~Flexibility and Mobility Training: Incorporate stretching exercises to improve flexibility, joint range of motion, and prevent injuries.~Interval Training: Perform high-intensity interval training (HIIT) sessions that combine cardiovascular exercises."
214892124|NCT06013475|DRUG|Apalutamide|Decision by the treating physician
214892125|NCT06013475|DRUG|Darolutamide (BAY 1841788)|Decision by the treating physician
214892126|NCT06013475|DRUG|Enzalutamide|Decision by treating physician
215050023|NCT02621437|OTHER|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire"
215050024|NCT04643847|DRUG|Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
215050025|NCT01100281|BEHAVIORAL|Neuropsychological examination|Examination including especially concept formation
215050026|NCT01100281|OTHER|MRI|MRI performed in T1-weighted three dimensional sequence
214892127|NCT06172712|OTHER|Variations in daily life activity signals detected by unobtrusive sensors|Patients will be equipped with unobtrusive devices for a duration of 12 months. Throughout this period, they will attend scheduled visits every three months following the baseline visit. These assessments will focus on determining the frequency of exacerbations, evaluating exercise capacity, measuring the severity of dyspnea, and assessing health-related quality of life. The data gathered from the sensors embedded in these unobtrusive devices will be instrumental in developing AI-based models. These models aim to accurately predict COPD exacerbations and effectively estimate the progression of the previously mentioned health outcome.
214892128|NCT02363218|RADIATION|CyberKnife|Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
214892129|NCT06578221|OTHER|Kegel Pelvic Floor Muscle Exercise Group|After the surgery, the patients will be taken to the clinic room in a supine position and the researcher will perform the Kegel pelvic floor muscle exercises three times at the 1st, 4th and 7th hours within the first 8 hours after the patients are taken to the clinic room.
214892130|NCT01576679|DRUG|Cathflo (Alteplase)|
214892131|NCT01576679|DRUG|Saline|
214892132|NCT03283566|DRUG|Hydroxychloroquine|Subjects will receive a pre-transplant 200 mg daily dose of HCQ 30 days before TPAIT and will continue on the drug for 3 months after surgery.
214892133|NCT03283566|DRUG|Placebo|Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
214892134|NCT03718832|OTHER|Fresh Food Farmacy|Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
214892135|NCT01231646|OTHER|No intervention|No intervention. This is a cross-sectional study.
214892136|NCT02934672|OTHER|Survey|Internet panelists, who self-reported that they or another adult in their household has osteoarthritis, were sent an email invitation to the survey site.
214892137|NCT00128401|DRUG|D-Cycloserine|
214892138|NCT00128401|DRUG|Placebo|
214892139|NCT03288714|DEVICE|Synchronized Transcranial Magnetic Stimulation (sTMS)|sTMS delivers brain stimulation via a continuous magnetic field created by the device and set to the individual patient's intrinsic alpha frequency (IAF).
214892140|NCT03288714|DEVICE|Sham Stimulation|Sham stimulation is designed to look, sound and feel like the investigational device, but does not deliver magnetic stimulation to the brain.
214892141|NCT00023413|DRUG|Rifabutin|
214892142|NCT00023413|DRUG|Efavirenz|
214892143|NCT00814476|OTHER|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
214892144|NCT00814476|OTHER|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
214295778|NCT04447079|BEHAVIORAL|Assertive Community Treatment (ACT)|"Assertive Community Treatment (ACT) is part of a 6-month program ARFAs will undergo.~ACT teams will engage with ARFAs on a dedicated schedule. Each visit would last an average of 60 minutes. There will not be a re-arrangement of no-show visits. ACT teams will re-engage the ARFA over the phone to plan for the next visit as per the schedule.~In keeping with principles of ACT, ARFA's will be assertively sought out in the community and provided intensive engagement, with holistic and supportive care alongside a harm reduction approach. Care will also involve case management and involvement of SSA's.~Each interaction during the treatment period will focus on various aspects covering physical health, mental health, and addiction"
214892145|NCT02706444|DEVICE|Conventional Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
214892146|NCT02706444|DEVICE|Drug-coated Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
214892147|NCT01806194|BEHAVIORAL|Lifestyle Counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers
215050027|NCT05362357|BEHAVIORAL|iSTART Web-app|30-day substance prevention web-app for students at a Hispanic Serving Institution.
215050028|NCT02020590|DRUG|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
215050029|NCT02308761|DRUG|RO6870810|Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
215050030|NCT01709526|BEHAVIORAL|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
215050031|NCT00598819|DEVICE|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
214295779|NCT05922787|OTHER|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
215050032|NCT04408677|DEVICE|Zilia Ocular|Measurement of the oxygen saturation in the eye fundus
215050033|NCT04389866|DEVICE|JUVÉDERM VOLUMA™ XC|Injectable gel
215050034|NCT05745766|OTHER|Panoramic and lateral cephalometric radiography|The 2D-based assessments of the impacted maxillary canine will be achieved using panoramic and lateral cephalometric radiographs.
215050035|NCT05745766|OTHER|Cone beam computed tomography|The 3D-based assessments of the impacted maxillary canine will be achieved using a cone beam computed tomography (CBCT) image.
214892148|NCT01806194|BEHAVIORAL|Educational Control Arm|16 mailings of diabetes educational materials but no regular contact with community health workers
214892149|NCT01169792|DRUG|tamoxifen|
214892150|NCT04882241|BIOLOGICAL|Pembrolizumab|IV infusion
214892151|NCT04882241|DRUG|Placebo|IV infusion
214892152|NCT04882241|DRUG|Cisplatin|IV infusion
214892153|NCT04882241|DRUG|Capecitabine|Oral tablets
214892154|NCT04882241|DRUG|5-fluorouracil|IV infusion
214892155|NCT04882241|DRUG|Docetaxel|IV infusion
214892156|NCT04882241|DRUG|Oxaliplatin|IV infusion
214892157|NCT04882241|DRUG|Leucovorin|IV infusion
214892158|NCT05506670|OTHER|Diagnostic test and phone call|Viral diagnostic test will be performed at inclusion. In case of RSV positive results, follow up phone calls will be scheduled at day 14 and day 30 to collect data.
214892159|NCT05506670|DIAGNOSTIC_TEST|Diagnostic test|Viral diagnostic test will be performed at inclusion. In case of RSV negative result, no more intervention will be required.
214892160|NCT04766645|DEVICE|Robotic assisted intervention|Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
214892161|NCT04766645|GENETIC|epigenetic analyses|Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
214892162|NCT04766645|DIAGNOSTIC_TEST|biochemical analyses|Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
214892163|NCT03530839|PROCEDURE|Arthrodesis|see study group description
214892164|NCT03530839|PROCEDURE|Resection arthroplasty|see study group description
214892165|NCT04213495|OTHER|Anesthesia|Patients undergoing anesthesia from the cooperating Anesthesia center
215050036|NCT05745766|OTHER|Surgery|The surgical exposure will be accomplished, and the impacted maxillary canine will be assessed by a direct vision.
215050037|NCT01680926|DIETARY_SUPPLEMENT|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
215050038|NCT05200312|DRUG|Zanubrutinib|160 mg capsules administered by mouth twice daily (21-day cycles).
215050039|NCT05200312|DRUG|Lenalidomide|25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)
214892166|NCT01436955|DRUG|Placebo|multiple oral doses
214892167|NCT01436955|DRUG|RG1662|Cohorts receiving multiple oral doses
214892168|NCT03590210|DRUG|Trabectedin|Cycle 1 to 16 1.5mg/m² IV over 24 hours, q3w
215050040|NCT05200312|DRUG|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
215050041|NCT05200312|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
215050042|NCT05200312|DRUG|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
214295780|NCT00279890|DRUG|Topical SR-01|
214892169|NCT03590210|DRUG|Nivolumab|Cycle 2 to 16 240 mg IV over 30 minutes, q3w
214892170|NCT05193955|OTHER|Laughter Yoga|Laughter yoga is one of the methods that is among the complementary therapy and supportive care practices in the world and is used increasingly. Laughter yoga is a non-invasive and non-pharmacological method that combines unconditional laughter with yoga breathing techniques. In laughter yoga, one can laugh without being humorous, joking, or funny. Laughter is simulated by starting out as a physical exercise and making eye contact with other members of the group and playing games with them. The body cannot distinguish between real and unreal laughter and laughter begins.
214892171|NCT05285423|PROCEDURE|Novel technique of Vocal cord Laterlization with Prolene suture.|The procedure will be performed under General anesthesia, preferably with a tracheostomy so that the extent of vocal cord lateralization could be ascertained intraoperatively.
214892172|NCT00442208|DRUG|PN 200|
214892173|NCT00074308|DRUG|imatinib mesylate|Given orally
214892174|NCT00074308|BIOLOGICAL|bevacizumab|Given IV
214892175|NCT00074308|OTHER|pharmacological study|Correlative studies
214892176|NCT00074308|OTHER|laboratory biomarker analysis|Correlative studies
214892177|NCT05669235|DIAGNOSTIC_TEST|Questionnaires|A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
214892178|NCT01910818|DEVICE|Fractional CO2 laser treatment|Patient will be treated with fractional laser treatment over the areas with fibrosis.
214892179|NCT01910818|OTHER|No treatment|Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
215050043|NCT05200312|DRUG|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
215050044|NCT05200312|DRUG|Prednisone (or equivalent)|40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
214892180|NCT02521415|DRUG|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
214892181|NCT02521415|DRUG|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
214892182|NCT02521415|DRUG|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
214892183|NCT05966415|DIETARY_SUPPLEMENT|Endocalyx Pro|4 capsules once daily OR 2 capsules twice daily.
214892184|NCT05966415|OTHER|placebo|4 capsules once daily OR 2 capsules twice daily
214892185|NCT04402411|PROCEDURE|Quadratus lumborum block|The patient will be placed in a lateral position with the side to be blocked facing upwards. The ultrasound probe will be properly sterilized and with sterile covers. An 18-20 gauge blunt tipped block needle or a Tuohy needle is advanced under ultrasound guidance on the posterior aspect of the Quadratus Lumborum. The QL muscle is identified with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the QL muscle adherent to the apex of the transverse process, a well recognisable pattern of a shamrock with three leaves can be seen.
214892186|NCT04402411|PROCEDURE|Transversus abdominis plane block|"The patient will be supine while performing the block and sterilization of the site of the ultrasound and needle entry will be performed.~The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest.~The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles."
214892187|NCT04402411|DRUG|Intravenous opioid|Patients will receive morphine 0.1 mg/kg
214892188|NCT04068493|BEHAVIORAL|Enhanced Project Health|A dissonance-based obesity intervention consisting of eight weekly groups sessions (1.5 hours).
214892189|NCT00172029|DRUG|Zoledronic acid|
214892190|NCT02543944|DRUG|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
215050045|NCT02901600|OTHER|Detection of the expression of DMTB1 by immunohistochemistry|
215050046|NCT01339936|DEVICE|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
215050047|NCT04133025|OTHER|Vestibular Rehabilitation|Vestibular Exercises and Software in vestibular rehabilitation
215050048|NCT03661177|OTHER|Sovereign nation diet|We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
215050049|NCT05187260|DRUG|Nusinersen|SPINRAZA® (nusinersen) prescribed as part of standard of care
215050050|NCT04845672|OTHER|2% chlorhexidine gluconate|Children in 2% chlorhexidine gluconate group , which is the routine practice of the hospital, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
215050051|NCT04845672|OTHER|soap-free body cleaning solution|Children in a wiping bath with soap-free body washing solution group, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
215050052|NCT01122979|DRUG|INSULIN GLARGINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
215050053|NCT01122979|DRUG|NPH insulin (insulin isophane)|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
215050054|NCT01122979|DRUG|INSULIN GLULISINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
215050055|NCT01122979|DRUG|Regular insulin|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
215050056|NCT04197284|DEVICE|Biofeedback, Myomed 632|"Biofeedback is a mind-body technique that involves using visual or auditory feedback to gain control over involuntary bodily functions.~Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses."
215050057|NCT04197284|DEVICE|device for electrical stimulation, BTL 4000 Smart|Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses. Electrodes, controlled by a unit, are placed on the skin over a predetermined area. Electrical current is then sent from the unit to the electrodes and delivered into the muscle causing a contraction.
215050058|NCT04197284|OTHER|kinesitherapy|isometric exercise of the quadriceps muscle
215050059|NCT00467376|DRUG|Insulin Glulisine|3 times a day before each meal
215050060|NCT00467376|DRUG|Lispro|3 times a day before each meal
214295781|NCT05389345|BEHAVIORAL|Transcranial direct current stimulation|Participants will receive bilateral prefrontal anodal stimulation with cathode placed on the back of the upper neck. Transcranial direct current stimulation (tDCS) will be delivered by a research assistant under the supervision of a psychiatrist.
214892191|NCT02543944|DRUG|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
214892192|NCT02543944|DRUG|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
214892193|NCT02543944|DRUG|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
214892194|NCT02543944|DRUG|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
214892195|NCT02543944|DRUG|Placebo|Microcrystalline cellulose
214892196|NCT00118326|BIOLOGICAL|filgrastim|
214892197|NCT00118326|PROCEDURE|allogeneic bone marrow transplantation|
214892198|NCT02203357|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
214892199|NCT01612065|DRUG|Misoprostol|200 ug
214892200|NCT01612065|DRUG|Misoprostol|Misoprostol vaginally, 400 ug
214892201|NCT01648530|OTHER|No Treatment|No Treatment
214892202|NCT04555434|DIETARY_SUPPLEMENT|Probiotics|"* Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10\^9 CFU / day)~* Control group Main ingredient: Crystalline cellulose"
214892203|NCT05963724|DEVICE|Real-Time Computer Aided Detection|This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)
214892204|NCT05963724|PROCEDURE|Stanford Colonoscopy|This involves white-light colonoscopy
214892205|NCT03225417|DRUG|Ixazomib|Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.
214892206|NCT03225417|DRUG|Tacrolimus|Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
214892207|NCT03225417|DRUG|Sirolimus|Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
214892208|NCT03225417|DRUG|Any prophylaxis for GVHD|Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
214892209|NCT02591524|OTHER|Bronchoalveolar and Nasal Lavage|A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
214892210|NCT03266796|BEHAVIORAL|goal setting process|goal setting process during the first consultation
214892211|NCT00629018|BIOLOGICAL|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
214892212|NCT00629018|DRUG|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
214892213|NCT00629018|BIOLOGICAL|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
214892214|NCT01561716|DEVICE|Wii Fit|This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
214892215|NCT06191588|PROCEDURE|INFANT CIMT/BIT|Constraint induced movement therapy (CIMT) and Bimanual Intensive therapy (BIT)
214892216|NCT04163965|DEVICE|Capacitive ECG|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology.
214892217|NCT00149474|BEHAVIORAL|Peak Flow Monitoring|
214892218|NCT01117974|PROCEDURE|liposuction of the neck|Liposuction will be performed to the surgical endpoint (skin thickness in the suctioned areas similar to that of surrounding non-treated skin).
214892219|NCT03347201|DEVICE|HMS Plus|Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.
214668355|NCT05282212|DIAGNOSTIC_TEST|Ultrasound Scan|Within 90 days before the revision surgery, a calibrated examiner will ultrasonically scan the implants. The ultrasound device has been validated for its usability and design on human subjects in our recent clinical study (the University of Michigan Institutional Review Board under the number HUM00139630 and was registered with the National Institutes of Health U.S. National Library of Medicine database for clinical trials (clinicaltrials.gov) under the following identifier: NCT03558282) Coupling will be achieved with commercially available sterilized US gel (Sterile Aquasonic, Fairfield, NJ). The US probe will be mounted on an adjustable arm attached to a fixed stand. The probe is navigated by a calibrated examiner at the implant of interest and then will execute a total ±5 mm linear mesio-distal and coronal-apical translations to create 3D cross-sectional and transverse volumes, respectively and stored as an imageframe series, i.e., a DICOM format cineloop.
214892220|NCT06487169|DIAGNOSTIC_TEST|Urine analysis to determine the presence of hexafluoroisopropanol|analysis of sevoflurane metabolites in urine
214892221|NCT02766114|PROCEDURE|Carpal tunnel release through Mini Transverse Approach|Carpal tunnel release through a transverse cosmetic small incision over the distal wrist crease.
214892222|NCT04001036|DRUG|1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One bag for nocturnal (long-dwell) exchange.
214892223|NCT04001036|DRUG|0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One to three, daily (short-dwell) exchanges
215050061|NCT00467376|DRUG|Insulin Glargine|once daily
215050062|NCT01186250|DRUG|Pioglitazone|15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
215050063|NCT01186250|DRUG|Placebo|placebo taken daily for one year
215050064|NCT04800393|DRUG|Sevoflurane|induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery
215050065|NCT04800393|DRUG|Propofol|propofol-based total intravenous anesthesia during breast cancer surgery
215050066|NCT01234493|PROCEDURE|fixation|Syndesmosis fixation with one 3.5mm fully threaded three cortical screw
215050067|NCT01234493|PROCEDURE|no fixation|No syndesmosis fixation.
215050068|NCT05490758|OTHER|sensorimotor training|sensorimotor training include activities like play with dough, peg games, puzzles for 5 days a week for 4 week.
215050069|NCT05490758|OTHER|constraint induced movement therapy|constraint induced movement therapy in which arm was constraint for 6 hours a day for 5 days a week for 4 week.
215050070|NCT02273102|DRUG|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
214668356|NCT02574299|OTHER|E-learning|Management of auditory processing disorders with serious game (E-learning)
215050071|NCT02273102|DRUG|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
214668357|NCT02574299|DEVICE|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
214668358|NCT01956643|OTHER|gum chewing|gum chewing
214668359|NCT01956643|OTHER|Control|Routine care during NPO
214668360|NCT05738512|PROCEDURE|Medial Flap Coblation Turbinoplasty|Reduction of the inferior turbinate to manage inferior turbinate hypertrophy
214668361|NCT05738512|PROCEDURE|Submucous Resection|Submucous Resection
214668362|NCT06425744|OTHER|self-myofascial release combined reformer Pilates|"The self-myofascial release combined reformer Pilates group performs 10 minutes of self-myofascial release using the BALLance© method before beginning 20 minutes of Reformer Pilates. The 6-week program includes warm-up and breathing, main supine exercises 1 and 2, and movements targeting the sacroiliac and hip joints.~All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants attend twice a week for 6 weeks, for a total of 12 sessions.~And all participants performed home exercise program follows the guidelines of Geroge et al (2021) and includes myofascial release and Pilates Reformer exercises, as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
214668363|NCT06425744|OTHER|Reformer Pilates|"The reformer Pilates group will do 30 minutes of Pilates on the Reformer. All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants also attend twice a week for 6 weeks, for a total of 12 sessions.~The home exercise program follows the guidelines of Geroge et al (2021) as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
214668364|NCT03063385|BEHAVIORAL|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
214668365|NCT03063385|BEHAVIORAL|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
214668366|NCT02627846|DEVICE|EVLA|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
214668367|NCT02627846|DEVICE|ClariVein®|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
214668368|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
214668369|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
214668370|NCT02627846|DRUG|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
214668371|NCT02627846|DRUG|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
214668372|NCT03345862|BEHAVIORAL|non-pharmacological multicomponent|Following the proposal of Nicholson \& Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home \[30-60 minutes\] for 16 weeks (1 fortnightly session) and 5 telephone sessions \[20 min.\] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
214668373|NCT00001332|PROCEDURE|CHPP with cisplatin|
214668374|NCT02342171|OTHER|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
214668375|NCT03667651|DRUG|EpiCeram|Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
214668376|NCT03550339|PROCEDURE|SURG|bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
215050072|NCT00997854|OTHER|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
215050073|NCT05295264|OTHER|Moderate exercise program|"Exercise program All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation, and final talk (comments and sharing) will be performed (12-15 minutes).~Healthy lifestyle advise This intervention consists of providing guidelines and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations, and fundamental exercises to perform during pregnancy."
215050074|NCT00002170|DRUG|Nelfinavir mesylate|
215050075|NCT00286377|DRUG|prosaptide|
215050076|NCT05497661|OTHER|448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.|448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.
215050077|NCT05497661|OTHER|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
215050078|NCT03457714|BEHAVIORAL|Guided ICBT for persons with Spinal Cord Injury|An 8-week guided internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a guide with experience delivering ICBT will provide support by email or telephone once a week. The guide will spend approximately 15 minutes per week/per client.
214295782|NCT05389345|BEHAVIORAL|Executive function training|The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
214295783|NCT01727453|DRUG|warfarin|Warfarin in anticoagulant dose
214668377|NCT03550339|BEHAVIORAL|DIET|dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
214668378|NCT03550339|BEHAVIORAL|HAES|treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
215050079|NCT03457714|OTHER|Survey|Caregiver burden and mental health will be assessed through online questionnaires.
215050080|NCT02681081|OTHER|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
215050081|NCT02681081|OTHER|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
215050082|NCT02681081|OTHER|Control|Normal food intake
215050083|NCT03465722|DRUG|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
215050084|NCT03465722|DRUG|regorafenib|Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
215050085|NCT05887037|DIAGNOSTIC_TEST|mNGS|mNGS is the direct extraction of nucleic acid from clinical samples. High-throughput sequencing technology and bioinformatics analysis were adopted to complete the detection of pathogens such as bacteria, fungi, viruses and parasites at one time
215050086|NCT05887037|DIAGNOSTIC_TEST|The traditional microbiological cultures|Traditional microbial culture is the gold standard for the diagnosis of central nervous system infection, but the traditional microbiological culture time is long and the detection rate is low.
215050087|NCT02965066|DEVICE|Coloplast Test Catheter|Newly developed intermittent catheter
215050088|NCT02965066|DEVICE|Coloplast Speedicath|Marketed Coloplast Speedicath catheter
214892224|NCT06404918|PROCEDURE|Erector spinae plane group|The patients were placed in lateral decubitus position with the operation site up. The probe was placed vertically 3 cm lateral to the T5 spinous process, and the transverse process was identified as an oval hyperechoic sonographic structure. The needle was introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. 0.5 mL of normal saline was injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. A total of 0.4 mL kg-1 of 0.25% bupivacaine was injected. between the erector spinae muscle and transverse process.
214892225|NCT06404918|PROCEDURE|Serratus anterior plane group|Serratus anterior plane block was administered to patient in the supine position with ipsilateral arm abducted to 90°. Under aseptic precautions, linear probe was placed over the midclavicular region in the sagittal plane. Ribs were counted inferiorly and laterally until the fifth rib was identified in midaxillary line. Latissimus dorsi, teres major, and serratus anterior muscles were identified overlying the fifth rib. The intended puncture site was infiltrated with 2 mL of 2% lignocaine, and using ultrasound-guided in-plane approach, the needle was introduced in caudal to cranial direction until the tip was placed between the serratus anterior muscle and external intercostal muscle.
215050089|NCT00499200|DRUG|SRA-444|
215050090|NCT04144114|DIETARY_SUPPLEMENT|ProHydrolase®|Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
215050091|NCT04144114|DIETARY_SUPPLEMENT|Whey protein|Subjects received 25g of whey protein powder mixed to together in a drink
215050092|NCT04144114|DIETARY_SUPPLEMENT|Placebo|Placebo
215050093|NCT02745873|DRUG|Ascorbic Acid|Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
215050094|NCT00131521|DRUG|mucomyst|
215050095|NCT00131521|DRUG|sodium chloride (saline)|
214668379|NCT02240498|DRUG|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
215050096|NCT03659110|BIOLOGICAL|HPV 4|1000 subjects will be received the HPV 4 vaccine
215050097|NCT01490918|DRUG|Acarbose|Acarbose 50mg b.i.d at first, at the 2nd week 50mg t.i.d and the 4th week, 100mg tid.
215050098|NCT01490918|DRUG|Placebo acarbose|acarbose placebo
214668380|NCT02240498|DRUG|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
215050099|NCT01490918|DRUG|placebo metformin|metformin placebo
215050100|NCT03154671|OTHER|Geriatric assessment and management|Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
215050101|NCT01476410|DRUG|brentuximab vedotin|Given IV
215050102|NCT01476410|DRUG|doxorubicin hydrochloride|Given IV
215050103|NCT01476410|DRUG|vinblastine|Given IV
215050104|NCT01476410|DRUG|dacarbazine|Given IV
215050105|NCT01476410|PROCEDURE|quality-of-life assessment|Ancillary studies
215050106|NCT01476410|GENETIC|DNA analysis|Optional correlative studies
215050107|NCT01476410|GENETIC|RNA analysis|Optional correlative studies
215050108|NCT01476410|RADIATION|fludeoxyglucose F 18|Correlative studies
215050109|NCT01476410|PROCEDURE|positron emission tomography|Correlative studies
215050110|NCT01476410|OTHER|laboratory biomarker analysis|Optional correlative studies
215050111|NCT01476410|OTHER|immunohistochemistry staining method|Optional correlative studies
215050112|NCT01476410|GENETIC|polymorphism analysis|Optional correlative studies
215050113|NCT03046836|DRUG|Oxytocin|40 IU oxytocin nasal spray
215050114|NCT03046836|DRUG|Placebo|Saline
215050115|NCT03650868|PROCEDURE|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
215050116|NCT03542019|DEVICE|Dental prosthesis|Replacement of missing tooth structure using Lithium disilicate porcelain
215050117|NCT03542019|DEVICE|Dental crown|Replacement og missing tooth structure using monolithic zirconia
215050118|NCT03542019|DEVICE|Hybrid ceramic|Restroration of endodontically treated teeth using hybrid ceramic
215050119|NCT01768910|OTHER|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
215050120|NCT01768910|OTHER|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
215050121|NCT01768910|OTHER|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
215050122|NCT01768910|OTHER|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
214668381|NCT02240498|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
214892226|NCT00200902|DRUG|Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
215050123|NCT06270238|DEVICE|High-Frequency1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
215050124|NCT06270238|DEVICE|cTBS1|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
214892227|NCT00200902|OTHER|Placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
214892228|NCT00200902|BEHAVIORAL|Interpersonal Clinical Interaction (ICI)|Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
215050125|NCT06270238|DEVICE|High-Frequency2|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral premotor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
215050126|NCT06270238|DEVICE|cTBS2|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
215050127|NCT06270238|DEVICE|High-Frequency3|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
215050128|NCT06270238|DEVICE|cTBS3|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
215050129|NCT03962959|DEVICE|TBS|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
214668382|NCT02240498|DEVICE|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
214668383|NCT02240498|DEVICE|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
214892229|NCT05924321|DRUG|Carbetocin|Single infusion of Carbetocin
214892230|NCT05924321|DRUG|Placebo|Single IV infusion of matching placebo
214892231|NCT05924321|DRUG|Placebo and Moxifloxacin|Single IV infusion of matching placebo in combination with Single Oral dose of Moxifloxacin
214892232|NCT06382532|DIAGNOSTIC_TEST|Niacin skin reaction test|Nicotinic skin reaction, also known as nicotinic flush reaction, occurs when a solution of nicotinic acid methyl ester briefly contacts the skin. Following penetration through the skin barrier into the subcutaneous tissue, it generates nicotinic acid (vitamin B3). Under the action of phospholipase A2 (PLA2), cyclooxygenase (COX), and other enzymes, arachidonic acid (AA) on the cell membrane is cleaved to produce prostaglandins, leading to local vasodilation, increased blood perfusion, and the transient appearance of erythema on the skin.
214892233|NCT00470535|DRUG|erlotinib hydrochloride|Oral
214892234|NCT00470535|OTHER|immunohistochemistry staining method|Correlative Study
214892235|NCT00470535|OTHER|laboratory biomarker analysis|Correlative Study
214892236|NCT04648787|BEHAVIORAL|family-integrated care|One week after admission, the parents of premature infants were informed by telephone one day in advance to enter the ward for family participation nursing, and the guidance of daily life nursing for premature infants was given on the same day, including hand hygiene, breast feeding, pacification, changing diapers, bathing and establishment of parent-child relationship. Before discharge, theparents of premature infants should be informed by telephone one day in advance to enter the ward again for family participation nursing, and half a day's guidance was given, including observation and treatment of common symptoms and signs, guidance of home safety prevention and learning to write diary of premature infants.
214892237|NCT04648787|BEHAVIORAL|traditional nursing|In hospital education: the health education manual for premature infants will be issued at the time of discharge; the patient's condition will be answered by telephone from 14:00 to 16:00 every day.
214892238|NCT06392529|DRUG|Voriconazole Powder|The drug will be topically applied for vagina of patients suffering from vaginal Candidasis albican
214892239|NCT02531529|DRUG|dexmedetomedine|intraoperative infusion
215050130|NCT01293136|PROCEDURE|Femoral nerve block|Ropivacaine
215050131|NCT01293136|DRUG|Intravenous opioids|Whatever opioids prescribed
215050132|NCT03141255|DEVICE|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
215050133|NCT03141255|DEVICE|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
215050134|NCT00532701|DRUG|Peg-IFN + WB RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 5-16"
215050135|NCT00532701|DRUG|Peg-IFN + LD RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-6~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
215050136|NCT00532701|DRUG|Peg-IFN + WB RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
214295784|NCT01727453|DRUG|Bemiparina|"Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.~Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer."
214892240|NCT02531529|DRUG|Fentanyl|
214892241|NCT01299012|DRUG|Liraglutide|Liraglutide s/c 0.6mg once daily.
214892242|NCT05688917|DIETARY_SUPPLEMENT|Green coffee been extract|supportive treatment
214892243|NCT05688917|OTHER|Placebo|Placebo capsule
214892244|NCT04463758|OTHER|An auto-questionnaire comprising three psychometric scales|"three psychometric scales validated in French: \_depression (Edinburgh Postpartum Depression Scale (EPDS)), anxiety (State-Trait Anxiety Inventory (STAI)~\- and Impact of Event Scale (Revised) (IES-R)"
214892245|NCT03348332|BEHAVIORAL|Exercise pregnant women|A supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 10 to 39) was conducted. Each session consisted of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training. Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor during the training sessions to control the intensity.
214892246|NCT00308178|DRUG|Abraxane|Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
214892247|NCT04658134|DIETARY_SUPPLEMENT|Glycine|Oral glycine tablets (100 mg/kg/day) in divided doses
214892248|NCT01669187|OTHER|Education brochure|
214892249|NCT01669187|OTHER|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
214892250|NCT00186732|PROCEDURE|Subcuticular Suture|
214892251|NCT00186732|PROCEDURE|Surgical Staples|
214892252|NCT05262387|DRUG|Lyumjev with 50% basal rate reduction|Administered SC.
214892253|NCT05262387|DRUG|Humalog with 50% basal rate reduction|Administered SC.
214892254|NCT05262387|DRUG|Humalog with 100% basal rate reduction|Administered SC.
214892255|NCT05262387|DRUG|Lyumjev with 100% basal rate reduction|Administered SC.
214892256|NCT03593837|DRUG|Huang qi gui zhi wu wu granule|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
214892257|NCT03593837|DRUG|Huang qi gui zhi wu wu granule placebo|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
214295785|NCT00098085|BIOLOGICAL|HSPPC-96|
214892258|NCT01437293|DRUG|L-dopa / carbidopa / entacapone (LCE)|For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
214892259|NCT05778461|DRUG|L-ornithine L-Aspartate|LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
214892260|NCT05778461|DRUG|Placebo|Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
214295786|NCT02354989|DEVICE|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
214892261|NCT02941471|DEVICE|Interferential Stimulation|Transabdominal interferential electrcial stimulation
214892262|NCT02941471|DEVICE|TENS stimulation|Transabdominal standard electrical stimulation
214892263|NCT00055731|DRUG|bicalutamide|
214892264|NCT00055731|DRUG|Goserelin Acetate|
214892265|NCT00055731|DRUG|docetaxel|
214892266|NCT00055731|DRUG|Estramustine phosphate sodium|
214892267|NCT00055731|DRUG|acetylsalicylic acid|
214892268|NCT00055731|PROCEDURE|conventional surgery|
214295787|NCT02354989|DEVICE|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
214295788|NCT00075049|BIOLOGICAL|RTS,S with AS02A/AS01B adjuvant|
214295789|NCT00231595|DRUG|topiramate|
214295790|NCT03491241|DIETARY_SUPPLEMENT|hypocaloric diet therapy|all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.
214668384|NCT02240498|DEVICE|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
214892269|NCT00055731|RADIATION|radiation therapy|
214892270|NCT02070965|DRUG|DFD01 Spray|
214892271|NCT02070965|DRUG|Comp01 Lotion|
214892272|NCT03256604|DIAGNOSTIC_TEST|left-over sputum|Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
214892273|NCT05523115|DIETARY_SUPPLEMENT|Heights Smart Supplement|"The ingredient list of the product includes the following:~Algae oil Blueberry Extract Methylcobalamin (Vitamin B12) Cholecalciferol (Vitamin D3) Ascorbic acid (Vitamin C) Retinol acetate (Vitamin A) Calcium L-methylfolate (Folic Acid) D-biotin Pyridoxine hydrochloride (Vitamin B6) Calcium pantothenate (Vitamin B5) Nicotinamide (Vitamin B3) Riboflavin (Vitamin B2) Thiamine hydrochloride (Vitamin B1) D-Alpha tocopheryl acetate (Vitamin E) Chromium picolinate Potassium iodide Iron Citrate Sodium selenite Zinc citrate"
214892274|NCT03693417|DEVICE|Heated circuit on|Heated circuit will be turned on.
214892275|NCT03693417|DEVICE|Heated circuit off|Heated circuit will be turned off.
214892276|NCT04756947|PROCEDURE|surgical treatment according to standard indication criteria|internal fixation according to standard indication criteria
214892277|NCT04756947|PROCEDURE|conservative treatment according to standard indication criteria|conservative therapy according to standard indication criteria
214892278|NCT06551597|PROCEDURE|Extremely low frequency electromagnetic fields stimulation|"* In Group MT1, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - head, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* In Group MT2, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - pelvis, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* The control group participants will receive only neurological rehabilitation."
214892279|NCT02515331|DRUG|LHW090|Capsule - oral dose
214892280|NCT02515331|DRUG|Placebo|Capsule - oral dose
215050137|NCT00532701|DRUG|Peg-IFN + WB RBV for 48 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
215050138|NCT00532701|DRUG|Peg-IFN + LD RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~2. Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
214478064|NCT06865833|OTHER|Tai Chi and Relaxation Intervention|"This Tai Chi and Relaxation Intervention specifically targets adolescents with chronic somatoform disorders, utilizing a combination of mind-body practices designed to reduce pain and alleviate psychological distress. The intervention is distinct in the following ways:~Target Population: It focuses specifically on adolescents aged 12-19 years experiencing unexplained physical symptoms, such as chronic pain, headaches, and fatigue, that are not attributable to any identifiable medical condition.~Non-pharmacological Approach: Unlike traditional medical treatments that may involve medications or invasive procedures, this intervention is entirely non-medical, aiming to address both the physical and psychological aspects of chronic somatoform disorders without using drugs.~Structured Workshops: The intervention consists of weekly Tai Chi and relaxation workshops (1 hour 15 minutes per session) over a 5-week period. The approach emphasizes gentle, controlled movements, relaxation techniqu"
214478065|NCT04930783|DRUG|CDX-301|Administered as an injection given underneath the skin
214478066|NCT04930783|BIOLOGICAL|NEOVAX|Personalized neoantigen vaccine administered as an injection given underneath the skin
214478067|NCT04930783|DRUG|Nivolumab|Administered intravenously (IV)
215050139|NCT02391324|PROCEDURE|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
215050140|NCT02391324|PROCEDURE|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
215050141|NCT02391324|PROCEDURE|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
214478068|NCT04930783|DRUG|Pembrolizumab|Administered intravenously (IV)
214478069|NCT04621006|DIAGNOSTIC_TEST|Continuously assessment of disease activity|Continuous measures of disease activity and activity in the contact activation system.
214668385|NCT02240498|DEVICE|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
214668386|NCT02240498|DEVICE|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
214668387|NCT02240498|DEVICE|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
214668388|NCT02240498|DEVICE|Optical spectroscopy measurement|A fiber-optic probe that has undergone high-level disinfection will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity white light will be delivered by a tungsten halogen lamp by a single fiber within the probe, and detected by eight other fibers within the probe. Following this, low-power laser light will be delivered by a fiber-coupled laser diode at 640 nm in order to excite methylene blue fluorescence. Emitted fluorescence will similarly be collected by the eight detection fibers contained within the probe. Upon completion of these measurements, the fiber-optic probe will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
214668389|NCT04002453|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
214668390|NCT01448551|BEHAVIORAL|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
214668391|NCT03110822|DRUG|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
214668392|NCT03110822|DRUG|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
214668393|NCT03110822|DRUG|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
214668394|NCT00693212|DRUG|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
214668395|NCT00693212|DRUG|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
214668396|NCT00693212|DRUG|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
214668397|NCT04776369|DRUG|Lidocaine IV|single-bolus of lidocaine IV 4 mg/kg
214668398|NCT04776369|DRUG|Magnesium Sulfate Injection|single-bolus of magnesium sulfate IV 30 mg / kg
214668399|NCT04776369|DRUG|IV saline|Saline IV 50 ml
214668400|NCT04215549|OTHER|No intervention|cross sectional study，no intervention
214668401|NCT06481189|BIOLOGICAL|GNR-086|The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.
214668402|NCT06481189|BIOLOGICAL|Ilaris®|The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.
214668403|NCT03636594|OTHER|Dance|The dance program consisted of one-hour dance classes delivered twice a week for 8 weeks. The classes featured different dance types (such as partnered and non-partnered) and genres (such as salsa, ballroom and jazz) with increasing complexity.
214892281|NCT00771498|DRUG|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
215050142|NCT04940130|BIOLOGICAL|Sanaria® PfSPZ Vaccine|non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).
215050143|NCT04940130|OTHER|Normal Saline|placebo control- saline
215050144|NCT02240121|DRUG|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
215050145|NCT02240121|DRUG|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
215050146|NCT05459441|BIOLOGICAL|Autologous progenitor expansion -T|After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
215050147|NCT05459441|DRUG|pemetrexed|For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
214478070|NCT06674980|OTHER|Standard of Care - DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214478071|NCT06674980|OTHER|AM/Single - DFU|Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214892282|NCT00124748|DRUG|Imatinib mesylate|Imatinib is packaged in bottles as 100mg and 400mg tablets
214892283|NCT05125640|DRUG|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Orally, with 240 mL of water at dosing in sitting position
214892284|NCT05125640|DRUG|Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Orally, with 240 mL of water at dosing in sitting position
214892285|NCT03942601|DRUG|Temsirolimus|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
214892286|NCT03942601|DRUG|Temsirolimus and dexamethasone sodium phosphate|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
214892287|NCT03684850|OTHER|Home-based exercise|Home-based exercises three times per week.
214892288|NCT03684850|DEVICE|Knee brace|Progressive use of knee brace each day during activities of daily living.
214892289|NCT03684850|DEVICE|Biomechanical footwear device|Progressive use of footwear each day during activities of daily living.
214892290|NCT05620446|PROCEDURE|endoscopy|the technique was done by two doctor the patients were sedated then colonoscopy was done for the patients while the patients were put in lithotomy position , we identified the site of sigmoid colon fixation by radiological colongraphy then tip of artery forceps was moved at outer skin at anterior abdominal wall at left lower quadrant to meet tip of colonscopy at multiple point where fixation was done . fixation was done by exploratory puncture of skin by scalpel about (2-3 mm puncture) at site of these points then widening the puncture by artery forceps at level of subcutaneous tissue. A 2- shot anchor device was used to fix the sigmoid colon against anterior abdominal wall. The 2-shot anchor device was passed through the puncture to be entered inside the sigmoid colon and the thread with a metal T-bar was detachd and pulled towards the anterior abdominal wall. This was repeated at multiple point of fixation .
214892291|NCT02441010|DEVICE|meridian therapy instrument|The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.
214892292|NCT02441010|OTHER|health information push technology|The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
214892293|NCT02441010|DEVICE|monitoring device|The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
214892294|NCT04185155|BEHAVIORAL|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
214892295|NCT04185155|BEHAVIORAL|Attention placebo|Smartphone activity for same amount of time.
214892296|NCT01186237|PROCEDURE|Early urinary catheter removal|All patients will have foley catheters removed between 0600 and midnight of post-operative day 3 (Day 0 being the day of operation).
214892297|NCT06195137|DIETARY_SUPPLEMENT|Caffeine|caffeine supplementation
214892298|NCT06195137|DRUG|Alpha Lipoic Acid|600-800 mg ALA
214892299|NCT05944471|OTHER|Providing breastfeeding support with Telehealth|After discharge, training videos on the importance of breast milk and breastfeeding prepared in line with the literature and explained by experts, and written documents (e-brochure, plain text version of breastfeeding trainings) were sent to individual mothers once a week between 10.00-14.00 hours via telehealth application. At the same time intervals, visualised messages explaining breastfeeding and that breast milk is sufficient for the baby were sent via telehealth application five days a week. In addition, if the mothers requested at 10.00-17.00 on weekdays, they were given live support by the researcher for the issues they were curious about breastfeeding by calling the researcher via telehealth application.
215050148|NCT02329093|PROCEDURE|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
215050149|NCT00295282|DRUG|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
215050150|NCT03152123|DRUG|Pitolisant|Pitolisant 40 mg or 240 mg (tablets over-capsuled)
214892300|NCT03701893|DIETARY_SUPPLEMENT|Lactobacillus PS11610|7 months and a half intervention study. A 6 months intervention period preceded by a period of sampling and analysis of vaginal, seminal and gland swabs of 6 weeks. During the 6 months of intervention the men participants will intake one capsule that contains 1\*10E9 colony forming unit (CFU) of Lactobacillus PS11610 and the women participating will intake two capsules of the same product (each 12 hours). If the couple stay pregnant during the intervention the man will end the product intake and the woman will reduce the dose to one capsule with 1\*10E9 CFU of Lactobacillus PS11610 per day during 12 additional weeks.
214892301|NCT04671589|DRUG|Meropenem Injection|"Administration Intravenous meropenem 1gram every 8 hours together with standard care;~."
214892302|NCT04004481|DRUG|Postoperative analgesia using tramadol|Tramadol 100 mg will be given to the patients in the postoperative period.
214892303|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (0.1%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
214892304|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
214892305|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (3.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
214892306|NCT03889886|DRUG|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
214892307|NCT04527510|DIAGNOSTIC_TEST|Conventional-reading|Two radiologists interpret at least three views of each breast without AI independently.
214892308|NCT04527510|DIAGNOSTIC_TEST|Second-reading|One radiologist reads AB US images without AI first, then combines the indications of AI marks to make the final decision.
214892309|NCT04527510|DIAGNOSTIC_TEST|Concurrent-reading|One radiologist identifies CAD marks first, then quickly browses the entire AB US examination to make the final decision.
214892310|NCT04527510|DIAGNOSTIC_TEST|Tow views-reading|Two radiologists interpret only two views of each breast without AI independently.
214892311|NCT04527510|DIAGNOSTIC_TEST|Handheld US-screening|One radiologist screens the breast cancer using Handheld US and interprets images immediately.
214892312|NCT03572686|DRUG|Ropivacaine 0.5% 20mL|In Group RH, participants received supraclavicular brachial plexus block with ropivacaine 0.5% 20ml at the end of surgery.
214892313|NCT03572686|DRUG|Ropivacaine 0.25% 20ml|In Group RL, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml at the end of surgery.
215050151|NCT03152123|DRUG|Placebos|tablets over-capsuled
215050152|NCT03152123|DRUG|Phentermine|Phentermine 60 mg (capsule over-capsuled)
215050153|NCT03117959|DEVICE|Stryker ShapeMatch Technology|Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
215050154|NCT03117959|DEVICE|Stryker Triathlon Custom Fit Knee|
215050155|NCT04581785|BIOLOGICAL|hLB-001|hLB-001 via IV infusion
214892314|NCT03572686|DRUG|Ropivacaine 0.25% 20ml + dexamethasone 8mg|In Group RLD, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml + dexamethasone 8mg at the end of surgery.
214892315|NCT01977495|BEHAVIORAL|Financial Incentive: Fixed Lottery|Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.
214892316|NCT00758524|DRUG|LCI699|LCI699 oral capsules
214892317|NCT00758524|DRUG|Eplerenone|Eplerenone oral capsules
214892318|NCT00758524|DRUG|LCI699-matching Placebo|LCI699-matching placebo oral capsules
214892319|NCT00758524|DRUG|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
214892320|NCT01339403|OTHER|non-interventional trial|No study specific intervention, non-interventional trial
214892321|NCT01339403|OTHER|non-interventional trial|No study specific intervention, non-interventional trial
214892322|NCT00871208|DRUG|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
214892323|NCT00871208|DRUG|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
215050156|NCT03278548|DRUG|Volulyte 6%|Solution for infusion
215050157|NCT03278548|DRUG|Ionolyte|Solution for infusion
215050158|NCT02156024|DRUG|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
214478072|NCT06674980|OTHER|AM/Double - DFU|Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214668404|NCT05165394|DRUG|Placebo|Tablets for oral administration
214668405|NCT05165394|DRUG|NBI-1065846|Tablets for oral administration
215050159|NCT02485587|BEHAVIORAL|Individualized Arousal-Biofeedback|biofeedback of biological measures of arousal (electrodermal activity)
215050160|NCT02485587|BEHAVIORAL|Treatment as usual|counseling, psychoeducation
215050161|NCT00334568|DRUG|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
215050162|NCT00334568|DRUG|Placebo|Placebo
215050163|NCT02228161|BEHAVIORAL|Yoga|Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
215050164|NCT01308359|DRUG|IV glucose 5%|500 ml glucose 5% within 30 minutes
214892324|NCT03277443|PROCEDURE|Computer guided surgery|Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly
214892325|NCT03277443|PROCEDURE|Conventional model surgery|preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.
214892326|NCT03277443|DEVICE|2D cephalometric radiograph|2D cephalometric radiograph
214892327|NCT03277443|DEVICE|3D computerized tomography|3D computerized tomography
214892328|NCT03495375|DIETARY_SUPPLEMENT|Treatment with a probiotic|All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
214892329|NCT03495375|OTHER|Treatment with placebo|All participants will take the placebo once daily for 10 weeks.
214892330|NCT06025071|DRUG|colchicine|Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.
214892331|NCT03304405|DIAGNOSTIC_TEST|Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
214892332|NCT05641298|DRUG|Sodium Fusidate|Tablets
214892333|NCT05641298|DRUG|Placebo|Tablets
214892334|NCT05217576|DEVICE|NBM-200|Finger Prick and Venipuncture
214892335|NCT03983980|DRUG|Tapinarof|Tapinarof cream, 1%, applied once daily
214892336|NCT03983980|DRUG|Vehicle Cream|Vehicle cream applied once daily
214892337|NCT04801992|DEVICE|MINI WELL Ready (SIFI SpA, Italy)|Implantation during cataract surgery of the progressive extended depth of focus intraocular lens for the posterior chamber to replace the crystalline lens in the correction of aphakia in adult patients.
214892338|NCT00190762|DRUG|Pemetrexed|
214892339|NCT01121250|BEHAVIORAL|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
214892340|NCT01121250|BEHAVIORAL|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
214892341|NCT02074150|DRUG|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs."
215050165|NCT01308359|DRUG|saline|saline
215050166|NCT01925768|DRUG|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
215050167|NCT01925768|DRUG|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
214295791|NCT04688710|BEHAVIORAL|Self-Hypnosis (HYP)|"Self-Hypnosis (HYP) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn new strategies for influencing fatigue and its effects on their lives. The Self-Hypnosis recordings will start with a relaxation hypnotic induction (e.g., Notice how with each breath, you are feeling more and more relaxed …) followed by hypnotic suggestions (e.g., for experiencing more energy, improved sleep, more comfort or less pain, etc.). The goal of Self-Hypnosis is to change participant's experiences. To the extent that participants respond to the suggestions, participants would then get more control over their feelings of energy, sleep quality, and comfort levels."
214295792|NCT04688710|BEHAVIORAL|Mindfulness Meditation (MM)|"Mindfulness Meditation (MM) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn about a new way to live with chronic fatigue and new ways to relate to how fatigue may influence their thoughts, feelings, and behavior. The mindfulness techniques train the mind to non-judgmentally observe experience (e.g., symptoms of fatigue or pain, etc.) on a moment-to-moment basis, with an attitude of acceptance. The goal of Mindfulness Meditation is not to alter experiences, but rather to change how someone responds to their experiences. With practice, automatic, kneejerk reactions to symptoms are replaced with mindful choices about how best to respond to symptoms. This will lighten the load of living with the symptoms, moving participants in the valued direction of their choosing."
214295793|NCT05991076|OTHER|Latin Dance|The Activate Bailando class is a dance-focused exercise class that is offered once per week for one hour. The program has been developed by dance educators in the Madison area.
214668406|NCT02967120|OTHER|no intervention|
215050168|NCT03511001|OTHER|E-Cigarette Vs. Smoking as Usual|6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
215050169|NCT03468777|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
215050170|NCT03468777|DRUG|Lansoprazole|Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
215050171|NCT03468777|DRUG|Ranitidine|Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
215050172|NCT00366210|BEHAVIORAL|Constraint-Induced Movement (CI) Therapy|
215050173|NCT00366210|BEHAVIORAL|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
215050174|NCT00581022|PROCEDURE|Polysomnography|Overnight Sleep Study
215050175|NCT03396627|DIAGNOSTIC_TEST|pathological examination|fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
214892342|NCT02074150|DRUG|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
214892343|NCT02074150|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
214892344|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox intramuscularly at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
214892345|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 12,|Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
214892346|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
214892347|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
214892348|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
214892349|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox subdermally at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
214892350|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox subdermally at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
214892351|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
214892352|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
214892353|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox subdermally at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
215050176|NCT04494828|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
215050177|NCT04494828|DRUG|Normal saline group|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
215050178|NCT03579069|OTHER|Ductus venosus Doppler|Ductus venosus Doppler
215050179|NCT03506139|RADIATION|External beam radiation therapy|Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
214295794|NCT03499223|DRUG|Ranibizumab 0.5mg|3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart
214295795|NCT03499223|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
214295796|NCT03499223|DRUG|Sham injection|3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
214295797|NCT02786251|OTHER|Cold exposure|During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
214295798|NCT02786251|OTHER|Exposure to thermoneutral conditions|For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (\~26-28°C).
214295799|NCT02011737|DRUG|naftopidil 75mg|
214295800|NCT05945693|DIETARY_SUPPLEMENT|Placebo|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule for 16 weeks.
214295801|NCT05945693|DIETARY_SUPPLEMENT|Omega-3|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA for 16 weeks.
214295802|NCT05945693|DIETARY_SUPPLEMENT|Aerobic exercise|The participants will perform aerobic-type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day for 16 weeks.
214295803|NCT00268996|DRUG|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
214295804|NCT00268996|DRUG|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
214295805|NCT01588808|BEHAVIORAL|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
214295806|NCT01182545|PROCEDURE|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
214295807|NCT03692364|DEVICE|Ceramic-on-ceramic uncemented hip arthroplasty|
214295808|NCT03692364|DEVICE|Metal-on-polyethylene uncemented total hip arthroplasty|
214295809|NCT03448822|PROCEDURE|sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis
214295810|NCT00679146|DRUG|Thiocolchicoside+Ketoprofen|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
214892354|NCT02074150|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
214892355|NCT02074150|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
214892356|NCT04827823|OTHER|Retrospective evaluation of amalgam and composite restorations|Multi-surface restorations that were performed by dental students and that are in function for the last five years will be clinically evaluated with mirrors and probes according to the modified USPHS criteria.
214892357|NCT06282939|DEVICE|OPTIMA and OPTIMAX Coils manufactured by Balt USA|\*Percentage from protocol
214295811|NCT00679146|DRUG|Thiocolchicoside|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
215050180|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
215050181|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
215050182|NCT00251693|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
214295812|NCT05230810|DRUG|Alpelisib|Orally twice a day
214295813|NCT05230810|DRUG|Tucatinib|Orally once a day
214295814|NCT05230810|DRUG|Fulvestrant|"500 mg intramuscularly into the buttocks slowly~\*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer"
214295815|NCT01096225|BIOLOGICAL|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
214892358|NCT00348725|DRUG|fenofibrate and metformin fixed combination (drug)|
215050183|NCT02217813|DRUG|Tafamidis|20 mg of current commercial formulation
215050184|NCT02217813|DRUG|Tafamidis|20 mg of new formulation
215050185|NCT06186583|DRUG|Pimicotinib（ABSK021）|A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
215050186|NCT04944147|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA)
215050187|NCT04944147|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants
215050188|NCT04944147|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions
215050189|NCT04944147|BEHAVIORAL|Progressive muscle relaxation (PMR)|Standardized instructed PMR training, 9 sessions
215050190|NCT00255216|DRUG|Policosanol supplement (oral capsule) vs. placebo|
215050191|NCT00224081|DRUG|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
215050192|NCT02779777|DRUG|Tipifarnib|Oral tablet
214295816|NCT00913003|DRUG|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
214295817|NCT00913003|DRUG|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
214295818|NCT05301426|OTHER|Stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
214295819|NCT05301426|OTHER|Neural slippage of the sciatic nerve.|Neurodynamic technique on the sciatic nerve.
214295820|NCT05301426|OTHER|Passive upper limb mobilisations.|Passive mobilisations performed on the upper limbs used as a placebo.
214295821|NCT05670990|OTHER|Equine assisted therapy|"A structured program that has been developed under several years at Humlamaden horse farm, for further information see under the description of the experimental group."
214295822|NCT02308410|PROCEDURE|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
214295823|NCT06193369|BEHAVIORAL|Digital Peer Navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for cancer. Participants will be matched through a digital app with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Patients will communicate with their peer navigator through digital direct messaging, videoconference or by telephone. Participants will also have access to a health resource library on the digital app that contains local and national resources about cancer.
215050193|NCT01280786|DRUG|Elesclomol Sodium|Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
215050194|NCT01364129|PROCEDURE|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
214892359|NCT00974116|BEHAVIORAL|MEND Childhood Obesity Program|The number of children who are obese in the UK is steadily increasing with both short and long term consequences for health. The aim of this study is to determine whether the MEND Programme (a new national initiative for the treatment of childhood obesity) is a successful and sustainable treatment for childhood obesity and obesity related health problems.
214892360|NCT00974116|BEHAVIORAL|Control Group|No intervention
214892361|NCT03864419|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
214892362|NCT03864419|DRUG|Cyclophosphamide|Given IV
214892363|NCT03864419|DRUG|Vincristine|Given IV
214892364|NCT03864419|DRUG|Methotrexate|Given IV
214892365|NCT03864419|DRUG|Doxorubicin|Given IV
214892366|NCT03864419|DRUG|Doxorubicin Hydrochloride|Given IV
214892367|NCT03864419|DRUG|Prednisone|Given PO
214892368|NCT03864419|DRUG|Etoposide|Given IV
214892369|NCT03864419|BIOLOGICAL|Rituximab|Given IV
214892370|NCT00354913|DRUG|hydroxyurea|Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
214892371|NCT00354913|DRUG|imatinib mesylate|"Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.~Dose for Imatinib:~Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.~If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately."
214892372|NCT03901313|DRUG|Treatment A - 400 mg Fasting|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions
214892373|NCT03901313|DRUG|Treatment B - 400 mg Fed|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
214892374|NCT03901313|DRUG|Treatment C - 200 mg Fed|Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
214892375|NCT04747470|DRUG|GS-3583|Administered as an intravenous (IV) infusion
214892376|NCT04747470|DRUG|Zimberelimab|Administered as an IV infusion
214892377|NCT04747470|DRUG|Cisplatin|Administered as an IV infusion
214892378|NCT04747470|DRUG|Carboplatin|Administered as an IV infusion
214892379|NCT04747470|DRUG|5-Fluorouracil|Administered as an IV infusion
214295824|NCT01450839|DRUG|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
214892380|NCT04747470|DRUG|Docetaxel|Administered as an IV infusion
214892381|NCT03727074|DRUG|5-FU Cream|topical cream twice a day
214892382|NCT03727074|DRUG|Efudex®|topical cream twice a day
214295825|NCT01450839|DRUG|Placebo|Matching Placebo tablets and tape
214295826|NCT01065233|GENETIC|DNA extraction|DNA extraction of blood sample for DNAship analysis
214892383|NCT03727074|DRUG|Vehicle|topical cream twice a day
214892384|NCT05760963|OTHER|Collection of datas|"Analysis lumbar echographies results by Trident ans Shamrock techniques.~Costiform processes on T12 to L5 were spotted and noted. For Trident technique, quality of image, depth of lumbar plexus and presence of vessels were noted.~Shamrock technique was performed, the projection of C line (line obtained with a probe put on the iliac crest) was noted with the invisible ink pen. Then the probe was oriented cephalically (for line \>C) and caudally (line \<C). For each lines, quality of image, depth of lumbar plexus and presence of vessels were also noted.~The projections of C, \>C, \<C on the costiform processes were noted."
214892385|NCT02329509|PROCEDURE|two stage palate surgical repair|two stage palate surgical repair with a hard palate closure at 3 to 4 years old
214892386|NCT02329509|PROCEDURE|One stage Palate Surgical repair|One stage palate repair at the age of 9 to 24 months old
214892387|NCT02497586|RADIATION|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
214892388|NCT04818125|OTHER|Patients with breast cancer (stage I, II III or IV)|"Blood samples will be collected at different times:~* at Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients);~* at the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV)~For each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study."
214892389|NCT01706406|BEHAVIORAL|Brief psychoeducational intervention for female sexual arousal disorder|four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
214892390|NCT02633007|DRUG|CVT-301 (levodopa inhalation powder)|Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
214892391|NCT02633007|DRUG|Carbidopa|Administered orally according to the carbidopa dosing schedule.
214892392|NCT02633007|OTHER|Placebo|Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
214892393|NCT04931693|DRUG|paracetamol|iv post operative analgesia
214892394|NCT04931693|PROCEDURE|modifiedPECs block|sonar guided pectoral nerve block
214892395|NCT03258411|DEVICE|Rapid Expansion of palatal suture|
214892396|NCT01522911|DEVICE|WATCHMAN LAA system (Percutaneous left atrial appendage closure)|The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
214892397|NCT04654793|DEVICE|Robot assisted inclined bed treatment and FES|FES was performed at the same time as the robot-assisted inclined bed treatment once a day for 30 minutes, 5 days a week for 4 weeks.
214892398|NCT04654793|DEVICE|conventional inclined bed treatment|conventional inclined bed treatment for 30 minutes once a day for 4 weeks, 5 days a week
214892399|NCT01942993|DRUG|Vemurafenib|Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
214892400|NCT05289505|DEVICE|MUSIC-CARE|This device allows the listening of music using different sequences of instrumental music created specifically, and using principles based on hypno-analgesia, that is to say the association of hypnotic techniques and approaches to help or analgesic, medicated or not. It consists of a tablet application containing instrumental music pieces, specially created and recorded for Music-Care. Each piece is at least 20 minutes long. The music can be played through headphones or speakers.
214892401|NCT02716961|DRUG|Gemcitabine, cisplatin|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
214892402|NCT02764593|DRUG|Nivolumab|Anti-PD-1 targeted immunotherapy
214892403|NCT02764593|DRUG|Cisplatin|Anti-cancer alkylating agent
214892404|NCT02764593|DRUG|Cetuximab|Epidermal Growth Factor Receptor (EGFR) antagonist
214892405|NCT02764593|RADIATION|IMRT|High-precision radiotherapy
214892406|NCT02143128|OTHER|Efficacy Safety Score|Evaluation using the score for postoperative patients
214892407|NCT02143128|OTHER|Verbal Numeric Rating Scale|Patients assessed for postoperative pain using VNRS (0-10)
214892408|NCT01146171|DRUG|BMS-844203 (CT-322)|Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent
214892409|NCT01350271|DRUG|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
214892410|NCT01350271|DRUG|Mebendazole polymorph C|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
214892411|NCT01350271|DRUG|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
214892412|NCT00977093|OTHER|Perfusion CMR for detection of coronary artery disease|Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
214892413|NCT00977093|OTHER|Perfusion cardiac magnetic resonance imaging|Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
214892414|NCT05362071|OTHER|Remote Exercise Group|The intervention will have a weekly frequency of two sessions on non-consecutive days during the first six weeks and three sessions on non-consecutive days for the remaining six weeks. The exercise intervention will consist of four 3-week mesocycles. The session's structure will consist of a warm-up, the main part, in which a combined training program will be carried out, consisting of three distinct blocks, and at the end, stretching. Blocks 1 and 2 will consist of three strength exercises with bodyweight and alternative materials and aerobic training. Between blocks 1 and 2, and later in block 3, participants will take a free walk with displacement in the space they have available in their own home. The session will end with stretching exercises for the main muscle groups. The sessions will last 37 to 57 minutes over 12 weeks, with approximately 5 min of warm-up and stretching, and the main part ranging from 27 min to 47 min throughout the intervention.
215050195|NCT04257643|OTHER|aquatic based exercise.|exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
215050196|NCT04257643|OTHER|land-based exercise.|land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
214892415|NCT05362071|OTHER|Group control|"Participants allocated to the GC will receive recommendations for the practice of physical activity based on information from three specific chapters of the Physical Activity Guide for the Brazilian Population (2021). The GC will receive through Whatsapp the information that is available in chapters 1, 4, and 5, which address the following topics: Understanding Physical Activity, Physical Activity for Adults, and Physical Activity for the Elderly. If sending via Whatsapp is not possible, the booklet will be printed and delivered to the participant. At the end of the 12 weeks, the same booklet will be made available to IG participants."
214295827|NCT03438812|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.
214295828|NCT00164190|PROCEDURE|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
214478073|NCT06674980|OTHER|Standard of Care - VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214892416|NCT02906670|DRUG|Sym013|Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
214892417|NCT02711631|BEHAVIORAL|MedBIKE|MedBIKE is an exercise cardiac rehabilitation system that allows participants to perform clinical cardiac rehabilitation at home or at a local center, instead of having to travel to the hospital. It provides a high level of physiological monitoring to allow patient safety to be continually monitored while exercising.
214892418|NCT05092789|OTHER|Kinesio taping group|"Participants in this group will receive treatment through standardised therapeutic kinesio taping along with conventional therapy.~Tape will place over the posterior cervical extensor muscle, from insertion to the origin, with the patient's neck in cervical contralateral side-bending and rotation.~Duration of kinesio tape will be of 48 hours with 50-100% tension.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions."
214892419|NCT05092789|OTHER|Cervical thrust manipulation group|"Participants of this group will receive treatment via cervical thrust manipulation along with conventional therapy.~For mid cervical spine thrust manipulation, the patient will be in supine lying position,with cervical spine in neutral position.~The therapist will cradle the patients head with the other hand. Gentle ipsilateral cervical side flexion and contralateral rotation will introduce until tension will perceive in target tissues at contact point. A high velocity, low amplitude thrust manipulation, will direct upward and medially in direction of subject's contralateral eye.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This intervention protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions with 1 month follow up."
214892420|NCT05092789|OTHER|Conventional therapy group|"Participants of this group will receive only conventional therapy which will include:~Hot pack for 10 minutes Stretching Exercises of neck muscles. For sternocleidomastoid stretching, the subject will ask to sit or stand facing forward, exhale and slowly turn your head to right, by keeping shoulder relaxed and down,inhale and return to the center, then turn to look at your left shoulder, ask to hold this position for 30 seconds and do 3 repetitions.~For Trapezius stretching, patient is seated upright, therapist then passively move right ear to right shoulder.~This study includes interventional protocol of 6 weeks. The session will be given twice a week making it a total of 12 sessions with 1 month follow up."
214892421|NCT01349192|DRUG|Rifampin|Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: \<40kg : 15mg/kg daily for 14 days divided every 12 hours.
214892422|NCT01349192|DRUG|Trimethoprim/Sulfamethoxazole|Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: \<40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.
214892423|NCT01349192|DRUG|Minocycline|"only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.~Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: \< 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day."
214892424|NCT01349192|DRUG|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.
214892425|NCT01349192|DRUG|chlorhexidine gluconate oral rinse|for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.
214892426|NCT01349192|DRUG|2% Chlorhexidine solution wipes|whole body wash solution wipes once daily for first 5 days.
214892427|NCT01349192|BEHAVIORAL|Environmental Decontamination|"wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days.~wash all linens and towels in hot water once weekly for three weeks."
214892428|NCT04395820|DIAGNOSTIC_TEST|Lung function test|MBW
214892429|NCT04395820|DIAGNOSTIC_TEST|Imaging|MP-MRI
214892430|NCT04383548|OTHER|hyper immunoglobulins containing anti-Corona VS2 immunoglobulin|Prospective randomized clinical study for efficacy of anti-SARS-CoV-2 hyper immunoglobulins prepared from COVID19 convalescent plasma using VIPS Mini-Pool IVIG medical device
214892431|NCT03749330|BEHAVIORAL|CICU Team And Loved Ones Communicating (CICU TALC)|When the necessary pre-intervention clinical encounters are completed, clinicians will go through the interprofessional team training to improve communication skills and teamwork in developing care plans and communicating with families in family meetings. The first step in the study is co-design of the intervention, so it will evolve as the study continues.
214892432|NCT03566030|DRUG|Tenofovir disoproxil fumarate 300mg|Administered Tenofovir disoproxil fumarate 300 mg QD
214892433|NCT03566030|DRUG|Tenofovir Alafenamide 25 mg|Administered Tenofovir Alafenamide 25 mg QD
214295829|NCT05544240|DRUG|SV-101|SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
214295830|NCT03447132|DRUG|Fulvestrant 500mg|All patients in all arms will receive Fulvestrant 500mg
214295831|NCT03447132|DRUG|Palbociclib 125mg|Dose reduction to 100 mg and 75 mg
214295832|NCT03447132|DRUG|Goserelin 3.6 MG|Only for pre or peri menopausal patient
214295833|NCT03447132|DRUG|Placebos|Placebo
214478074|NCT06674980|OTHER|AM/Single - VLU|Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214478075|NCT06674980|OTHER|AM/Double - VLU|Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214478076|NCT05958927|OTHER|tear test and eye measurement|tear test and eye measurement
214892434|NCT04174274|OTHER|ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
214892435|NCT04174274|OTHER|not ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
214892436|NCT06271148|OTHER|Interview|We made multiple interviews with randomly selected surgical candidates
214892437|NCT03771092|DIETARY_SUPPLEMENT|SunActive®Fe|SunActive® Fe is a colorless, odorless, tasteless iron fortifier in a powder form. This product is most commonly used to increase the amount of iron in food, beverage, and dietary supplement applications.
214892438|NCT03771092|DIETARY_SUPPLEMENT|Lipofer®|Lipofer® is a micronized and microencapsulated source of iron, enhances the bioavailability of iron and does not taste metallic or oxidize unsaturated fats.
215050197|NCT01117194|DEVICE|Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)|Use an intelligent robot to assist upper limb rehabilitation.
215050198|NCT04571060|DRUG|Zavegepant|One dose of zavegepant
215050199|NCT04571060|DRUG|Placebo|One dose of matching placebo
215050200|NCT05834985|PROCEDURE|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
215050201|NCT03184883|PROCEDURE|single conventional denture|mandibular conventional denture with soft liner
215050202|NCT03184883|PROCEDURE|single flexible denture|mandibular flexible compete denture
215050203|NCT06364397|PROCEDURE|ERCP|Participants will undergo ERCP and indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place.
215050204|NCT06364397|COMBINATION_PRODUCT|Health education and conservative management of clinical routines|Participants will be given health education and conservative management of clinical routines. Clinical management is based on the pancreatic endocrine and exocrine function.
215050205|NCT00932074|DRUG|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
215050206|NCT02154165|OTHER|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
215050207|NCT02393820|DRUG|pazopanib|treatment will be given until progression or unacceptable toxicity .
215050208|NCT02634242|OTHER|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
215050209|NCT02634242|OTHER|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
214892439|NCT03771092|DIETARY_SUPPLEMENT|Intravenous ferric gluconate|Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 - 440,000 daltons on gel chromatography. It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate.
214892440|NCT02026401|BIOLOGICAL|NGM282|
215050210|NCT00974155|DRUG|Escitalopram, venlafaxine, lithium|oral application, highest tolerable dose, once daily
215050211|NCT00974155|DRUG|Escitalopram, venlafaxine|oral application, highest tolerable dose, once daily
215050212|NCT00525434|DEVICE|Seraffix LTB|wounds closure by using laser and albumin
215050213|NCT00973336|DRUG|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
215050214|NCT04410159|DRUG|Povidone-Iodine|Gargle
215050215|NCT04410159|DRUG|Essential oils|Gargle
214892441|NCT02026401|BIOLOGICAL|Placebo|
214892442|NCT03364101|DIETARY_SUPPLEMENT|Placebo Capsule|Composition of the placebo is 100% organic rice flour, manufactured at a facility New York State licensed to produce pharmaceuticals. Capsules will be instructed to commence on day 7 of the study after baseline appointment.
215050216|NCT04410159|OTHER|Tap water|Gargle
215050217|NCT04347343|PROCEDURE|Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction|"Subjects will begin a standardized protocol on post-op day 2. Outpatient visits will be 2x/wk for weeks 0-4 and then 1x/wk for weeks 5-8.~Subjects will utilize NMES on the quadriceps in the home setting 2x/day for the first 3-4 weeks during isometric contractions at their highest tolerated intensity. Total treatment will begin at 10 minutes.~At the end of post-op week 2, subjects will be exposed in clinic to BFR on the surgical limb increasing to 80% limb occlusion pressure over weeks 3-4 as tolerated. Initially, BFR and NMES will be performed simultaneously. BFR will then be progressed using active exercises. After completing a safety checklist, subjects will be issued a home BFR unit for use 2x/week (3x total including clinic visit) at which time NMES will be discontinued. BFR exercise intensity will be progressed as tolerated to maintain 20-30% of 1RM."
215050218|NCT01705340|DRUG|Akt inhibitor MK2206|Given PO
215050219|NCT01705340|BIOLOGICAL|trastuzumab|Given IV
215050220|NCT01705340|DRUG|lapatinib ditosylate|Given PO
215050221|NCT01705340|OTHER|laboratory biomarker analysis|Optional correlative studies
215050222|NCT01361217|DRUG|Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan|"1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water."
215050223|NCT00087698|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
215050224|NCT00087698|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
215050225|NCT05110573|PROCEDURE|pancreatoduodenectomy|Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
215050226|NCT05753514|OTHER|ESWT|ESWT
214892443|NCT03364101|DIETARY_SUPPLEMENT|POWEROFF Capsule|blend of California Poppy Aerial Part Extract, L-Cystine, L-Theanine,GABA (proprietary Phosphatidylcholine-Palmitic Acid-Oleic Acid Complex), 5-HTP, Magnolia Officinalis Bark Extract, Glycine, Melatonin with 0.5mg of Vitamin B6 (as pyridoxal-5-phosphate).
214892444|NCT01973439|OTHER|Intervention 1: PK assessment while on Twice Daily Abacavir|Week 0
214892445|NCT01973439|OTHER|Intervention 2: PK assessment while on Once Daily Abacavir|Week 4
214892446|NCT05027308|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection
214892447|NCT05474014|PROCEDURE|superior trunk block|Local anesthetic injection will be applied to the superior trunk of the brachial plexus accompanied by ultrasonography.
214892448|NCT05474014|DRUG|intravenous patient-controlled analgesia|Analgesics will be given using a patient-controlled analgesia device.
214892449|NCT02144714|BIOLOGICAL|SB5|
214892450|NCT02144714|BIOLOGICAL|EU sourced Humira®|
214892451|NCT02144714|BIOLOGICAL|US sourced Humira®|
214892452|NCT01001650|BIOLOGICAL|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|"Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose."
214892453|NCT01354210|BEHAVIORAL|SMS Text Message Reminder|Daily
214892454|NCT02038010|DRUG|PI3K inhibitor BYL719|Given PO
214892455|NCT02038010|BIOLOGICAL|ado-trastuzumab emtansine|Given IV
214892456|NCT02038010|OTHER|pharmacological study|Correlative studies
214892457|NCT02038010|OTHER|laboratory biomarker analysis|Optional correlative studies
214892458|NCT05577559|PROCEDURE|intermediate cervical plexus block|patients will receive bilateral ultrasound guided intermediate cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
214892459|NCT05577559|PROCEDURE|Cervical Erector spinae block|patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
214892460|NCT01472861|PROCEDURE|AECC (Autologous endometrial coculture)|endometrial biopsy with autologous endometrial coculture
214892461|NCT01472861|OTHER|no endometrial biopsy or Autologous endometrial coculture (AECC) performed|routine procedures with out biopsy
214892462|NCT04406428|PROCEDURE|NKI followed by EBD|Needle-knife incision therapy followed by endoscopic bougie dilation
214892463|NCT04881474|DRUG|Ibuprofen 800 mg|30-minute lasting iv infusion of 800 mg ibuprofen diluted with 0,9% saline via intravenous route every 6 hours.
214892464|NCT00718874|OTHER|Dietary|modification of macronutrient content
214892465|NCT00683865|DRUG|Ofloxacin|Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
214892466|NCT00683865|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg po od for 14 days
214892467|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo single dose
214892468|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo single dose with food effect
214892469|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo multiple dose
214892470|NCT03365362|DRUG|Long-Term Varenicline|Varenicline tablet x 24 weeks
214892471|NCT03365362|DRUG|Short-Term Varenicline|varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg tablet
214892472|NCT03365362|BEHAVIORAL|Directly Observed Therapy|Varenicline doses are administered by opioid treatment program nurses
214892473|NCT03365362|BEHAVIORAL|Self Administered Therapy|Varenicline doses are self-administered
214892474|NCT05839444|OTHER|BioPB-01|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
214892475|NCT05839444|OTHER|Placebo|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
214892476|NCT02000726|DRUG|Placebo|
214892477|NCT02000726|DRUG|Citalopram|
214892478|NCT02000726|DRUG|Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session|Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
214892479|NCT05302960|DEVICE|Fitbit|The use of Fitbit sensors to see if activity levels can be improved to track recovery from COVID
214892480|NCT04748640|PROCEDURE|Gamma Knife VIM thalamotomy|Ablation of contralateral VIM nucleus of thalamus with GK using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
214892481|NCT02352701|DRUG|Noltec tab. 10mg|Ilaprazole 10mg BID dosage form : delayed release tablet
214892482|NCT02352701|DRUG|Chongkundang Amoxicillin Cap. 500mg|Amoxicillin 1000mg, BID dosage form : capsule
214892483|NCT02352701|DRUG|Cravit Tab. 500mg|Levofloxacin 500mg, BID dosage form : film coated tablet
214907214|NCT07153289|BIOLOGICAL|CD318-CAR-T cells|Autologous T cells collected by leukapheresis, genetically modified using a GMP-manufactured lentiviral vector encoding a fully human CD318-specific chimeric antigen receptor (CAR), and expanded on the CliniMACS Prodigy system. After lymphodepleting chemotherapy (fludarabine/cyclophosphamide), participants receive (Phase I) a single CAR-T infusion per BOIN dose-escalation to determine MTD/RP2D; (Phase IIa) an expansion at RP2D with a predefined dual-dosing schedule (two infusions) separated by a protocol-defined interval.
214907215|NCT07152054|DEVICE|virtual forest bathing|"Virtual reality (VR) is an advanced computer technology and a novel technique used in healthcare to alleviate pain and provide patient comfort. It enables individuals to interact with a 360-degree virtual environment through a headset device. It has been observed that painful or emotionally stressful stimuli from the external world are diminished within the VR environment, with the individual's attention redirected and focused on this immersive setting.~In our study, a 20-minute VR video will be used, providing the sensation of walking through a calming 360-degree virtual forest environment accompanied by natural sounds, viewed through VR headsets. Unlike some commercially available VR headsets, the Oculus Quest 2 model will be utilized, as it serves as both the computer and display system, eliminating the need for a smartphone. This device is preferred for its ability to deliver high-quality video without interruptions that might negatively affect the VR experience.~After explaining"
215050227|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
215050228|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
214892484|NCT01275846|DEVICE|Health Guide using AHA heart failure protocols and content|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
214892485|NCT01750801|DRUG|Propolis|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
214892486|NCT01750801|DRUG|chlorhexidine|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
214892487|NCT03908125|DEVICE|Eversense® CGM System|Continuous Glucose monitoring device
214295834|NCT04006197|OTHER|laryngostroboscopy and histoh-pathology|videolaryngoscopy and laryngostroboscoby will be performed .the latter will be pathological in case of highly reduced or abolished amplitudes of vocal fold vibration and if there is reduction of mucosal wave propagation.also direct microlaryngoscopy under general anathesia will be done and excesional biobsy will be taken followed by histopatholpgical examination .the histological finding will be catagorized into the following categories according to (WHO): squamous cell hyperplasia with non dysplasia,mild dysplasia,moderate dysplasia,sever dysplasia,carcinoma in situ and squamous cell carcinoma.
214295835|NCT01554150|BEHAVIORAL|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
214892488|NCT02262325|RADIATION|hypofractionated radiation therapy|Radiation boost in week 1 (days 1-5)
214892489|NCT02262325|DRUG|cisplatin|Given IV
215050229|NCT02357199|OTHER|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
215050230|NCT03139032|DRUG|APD334|APD334 active treatment for 12 weeks.
214295836|NCT02763189|OTHER|Expert mentoring|Experts will provide personalized instructional review on how to use the new device for changing endotracheal tubes.
214295837|NCT02763189|OTHER|Self-study|All subjects will receive self-study
214892490|NCT02262325|DRUG|etoposide|Given IV
214892491|NCT02262325|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
214892492|NCT02262325|OTHER|laboratory biomarker analysis|Correlative studies
215050231|NCT03411018|OTHER|Mechanical ventilation exposure|
214892493|NCT04677335|DIETARY_SUPPLEMENT|AB-LIFE with Monacolin K|Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
214892494|NCT04677335|OTHER|Placebo|Placebo capsules containing maltodextrin carrier only. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
214892495|NCT01695616|DRUG|Placebo|
214892496|NCT01695616|DRUG|Active drug|
214892497|NCT06494475|DRUG|GBS-NN/NN2 vaccine|Intramuscular injection.
214892498|NCT06494475|DRUG|Tdap vaccine|Intramuscular injection.
214892499|NCT06494475|DRUG|Placebo|Intramuscular injection.
214892500|NCT02815995|DRUG|Durvalumab|Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).
214892501|NCT02815995|DRUG|Tremelimumab|Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
214892502|NCT05834556|BEHAVIORAL|Prehabilitation|Everyone will participate in a home-based prehab program with individual video sessions with a physiotherapist at 4 time points over a period of 3 weeks. The initial session will take an hour and consist of a subjective and physical assessment followed by an individualized exercise program demonstration and education. Patients will be instructed to complete the exercises independently 3x/week. The second and third sessions will be 30 minutes in duration and will check in on activity progress, the presence of abnormal responses to exercise, review exercise technique, address barriers and facilitators to activity completion as well as provide support and encouragement for the current level of activity. The final session will take 30 minutes and will review exercise progress, presence of abnormal responses to exercise followed by a reassessment of physical function.
214892503|NCT00795899|DRUG|Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab|"Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d"
214892504|NCT04507399|BEHAVIORAL|Liquid Model|"To study the perception of whey beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying)~Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein and whey permeate beverages."
214892505|NCT06550999|PROCEDURE|Laceration repair with adhesive strips|Repair of the patient's facial laceration with adhesive strips
214892506|NCT06550999|PROCEDURE|Laceration repair with sutures|Repair of the patient's facial laceration with sutures
214892507|NCT01296087|DRUG|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
214892508|NCT01296087|DRUG|Placebo|Matching placebo capsule given once daily on Days 1 to 28
214892509|NCT00578591|DRUG|Rituximab|"Rituximab 375 mg/m\^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).~Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver."
214892510|NCT02623062|DRUG|Compound Sodium Alginate Oral Suspension sachet|Contents of 2 sachets taken four times daily for 7 days
214892511|NCT02623062|DRUG|Matched placebo|Contents of 2 sachets taken four times daily for 7 days
214892512|NCT05435027|DRUG|GRT-R912, samRNA-Spikebeta-TCE11|IM injection of GRT-R912. Doses will be decided after safety review of Part A.
214892513|NCT05435027|DRUG|GRT-R914, samRNA-Spikebeta-TCE9|"Part A: 3 microgram (mcg), 10 mcg, or 30 mcg intramuscular (IM) injection of GRT-R914.~Part C: IM injection of GRT-R914. Doses decided after safety review of Part A."
214892514|NCT05435027|DRUG|GRT-R918, samRNA-SpikeOmicron-N-TCE11|IM injection of GRT-R918. Doses will be decided after safety review of Part A.
214892515|NCT01499264|DEVICE|MySkin patch|Hydrogel and polyurethane film
214892516|NCT01499264|DEVICE|Traditional Dressing|Gauze and Patch
214892517|NCT03074578|BEHAVIORAL|Watching Video-clip 1|Video -clip 1 contains violent images and text
215050232|NCT03810846|BEHAVIORAL|Walking football exercise program|Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
214295838|NCT02645214|OTHER|Non-antiseptic scrubs|
214295839|NCT02645214|OTHER|Antiseptic scrubs|
214295840|NCT04853979|OTHER|PRONE POSITION|Any combination of prone or side position for 3 hours, 3 times a day for 3 days
214892518|NCT03074578|BEHAVIORAL|Watching Video-clip 2|Video -clip 2 contains neutral images and text
214892519|NCT04110015|DEVICE|virtual visual field|Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.
214892520|NCT01071915|DRUG|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
214892521|NCT05576688|OTHER|Balance|Balance was evaluated with Berg Balance Scale (BBS), Functional Reach Test (FRT), One Leg Stance Test (OLST) and Five-Repeat Sit-and-Stand Test (5STS). BBS consists of 14 functional tasks of increasing difficulty, each scored on a scale ranging from 0 to 4. The maximum possible score is 56, indicating no identifiable balance difficulties. FRT measures the maximum distance that participants can reach forward with their dominant arm raised to 90 degrees without moving their feet, which were positioned 10 cm apart. OLST measures the time one is able to stand on one lower limb without support. The test was repeated for both sides. 5STS assesses the time it takes to get up and sit from the chair five times. Measurements were repeated 3 times and the average duration was calculated as a patient score.
214892522|NCT05576688|OTHER|Trunk control|Trunk control was evaluated with Trunk Impairment Scale (TIS).TIS evaluates static sitting balance, dynamic sitting balance, and trunk coordination on a scale from 0 to 23 points, a higher score indicating a better performance.
214295841|NCT04658277|DRUG|Clarithromycin|Patients in the intervention arm will take Clarithromycin 250mg daily.
214295842|NCT04658277|OTHER|Usual care|Patients will receive usual medical care
214295843|NCT04053205|DRUG|Gentuximab|Administered intravenously (IV)
214295844|NCT04053205|DRUG|Paclitaxel|Administered intravenously (IV)
214295845|NCT00220402|DRUG|SPM 907|
214295846|NCT05392998|DEVICE|Cataract surgery with Vivity intraocular lens implantation|Cataract surgery with Vivity intraocular lens implantation
214892523|NCT05576688|OTHER|Gait|Gait was evaluated with Dynamic Gait Index (DGI). DGI has 8 items: walking, walking while changing speed, walking while turning the head horizontally and vertically, walking with pivot turn, walking over and around obstacles, and stair climbing. The scoring of the DGI is based on a 4-point scale ranging from 0 to 3, with 0 indicating severe impairment and 3 indicating normal ability. The best performance total score is 24. A low composite DGI score indicates greater impairment in gait.
214892524|NCT05576688|OTHER|Functional mobility|Functional mobility was evaluated with Timed Up and Go Test (TUG). TUG is a test of the time required for an individual to stand up from a chair with armrests, walk 3 m, turn, walk back to the chair, and sit down. The stopwatch timing started when the participant's bottom left the chair and ended when the bottom made contact with the chair after the walk.
214892525|NCT05576688|OTHER|Fear of falling|Fear of falling was evaluated with the Falls Efficacy Scale-International (FES-I). FES-I was used to assess the level of concern about falls during 16 activities of daily living, ranging from basic to more demanding activities including social activities that may contribute to quality of life. It was administered as a self-report questionnaire.
214892526|NCT02242253|DRUG|Tiotropium|administered via HandiHaler®
214892527|NCT02242253|DRUG|Salmeterol|administered via metered dose inhaler (MDI)
214892528|NCT02242253|DRUG|Placebo-MDI|
214892529|NCT02242253|DRUG|Placebo HandiHaler®|
214892530|NCT05738733|DEVICE|MsChief Classic Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
214892531|NCT05738733|DEVICE|MsChief Ylang Ylang Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
214892532|NCT05738733|DEVICE|MsChief Vanilla & Citrus Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
214892533|NCT05738733|DEVICE|MsChief Tea & Peach Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
214892534|NCT02094482|DEVICE|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
214892535|NCT01510951|DRUG|AMG 811 or Placebo|Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
214892536|NCT03327701|DRUG|Benralizumab|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
214892537|NCT04298944|DIAGNOSTIC_TEST|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
214892538|NCT04298944|DIAGNOSTIC_TEST|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep
214892539|NCT04298944|DIAGNOSTIC_TEST|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
214892540|NCT04298944|BEHAVIORAL|Emotional/ Behavioural assessments|Emotional /Behavioral well being will be determined by questionnaires: Pediatrics Adverse Childhood Experiences Questionnaire (ACEs Q), Childrens Emotion Management Scale Questionnaire (CEMS) and Behavior Assessment System for Children (BASC)
214892541|NCT03866889|OTHER|Strength|"In the performance of the squat exercise (Back Squat), the subjects will be standing, with an Olympic bar behind their neck, supported on both trapezoids, while the hands will help to hold and stabilize the bar, taking it from below.~For hamstring curl, the subject will be in the prone position, clinging to the backrest, with the legs under the arm that lifts the weight.~The deadlift exercise will be performed from the standing posture, holding the bar with your arms extended and the trunk straight, while your hands will hold the bar at the height and separation of the hips.~Finally, in the quadriceps chair the subject will find himself sitting with his back straight and supported on the back of the seat, while the legs will go under the arm that lifts the weight."
215050233|NCT02073162|PROCEDURE|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
215050234|NCT02804633|DRUG|IV Acetaminophen|1 gram every 6 hours
215050235|NCT02804633|DRUG|Placebo|100 ml of normal saline every 6 hours
214892542|NCT03866889|OTHER|Normal activity|The subjects included in the control group will continue to perform the same strength training plan that they did before starting this one. The periodicity will be the same (4 days / week) and with the same intensity.
214892543|NCT00608101|DRUG|Fludrocortisone|Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
214892544|NCT00608101|DRUG|Dexamethasone|Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
214892545|NCT03632369|DIAGNOSTIC_TEST|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.
215050236|NCT04233528|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
215050237|NCT01233024|DIETARY_SUPPLEMENT|Control|Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
215050238|NCT01233024|DIETARY_SUPPLEMENT|Soluble corn fiber|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
214295847|NCT00875225|BEHAVIORAL|DVD|Control group will receive usual care DVD from health professionals
214295848|NCT00875225|BEHAVIORAL|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
214295849|NCT05633121|PROCEDURE|Rheopheresis|Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
214295850|NCT04925128|OTHER|Moderate Physical Activity + Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain Moderate physical activity on treadmill, brisk walk was performed 5 days a week for 30 minutes at 4 mph speed (3-6 METs) with warm up for a 5 minutes at low speed and then at the end speed was also decreased for a 5 minutes"
214892546|NCT00114140|DRUG|Temozolomide|"Concurrent chemoradiotherapy temozolomide given 75 mg/m\^2 daily during radiotherapy for 6 weeks.~Post-Radiation Temozolomide given 150 mg/m2 daily on days 1-5 every 28 days with cycle one beginning 28 days post-radiotherapy. In the absence of grade 3 or 4 adverse events, a single dose escalation to 200 mg/m2/day could be attempted for cycle 2 and, if tolerated, that dose should continue for all subsequent cycles. Cycles were repeated every 28 days (+/- 2 days) for a total of 12 cycles."
214892547|NCT00114140|RADIATION|Radiation therapy|One treatment of 1.8 Gy given daily, 5 days per week (over 6 weeks) for a total dose of 54.0 Gy.
214892548|NCT04150172|DRUG|Rebamipide SR 150mg|Test drug
214892549|NCT04150172|DRUG|Rebamipide IR 100mg|Reference Drug
214892550|NCT02261272|BEHAVIORAL|CBT for insomnia SHUTi|SHUTi
214892551|NCT02261272|BEHAVIORAL|passive patient education/sleep hygiene|
215050239|NCT01233024|DIETARY_SUPPLEMENT|Resistant starch|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
215050240|NCT01233024|DIETARY_SUPPLEMENT|Fructooligosaccharide|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
215050241|NCT01233024|DIETARY_SUPPLEMENT|Inulin|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
215050242|NCT06440603|DIAGNOSTIC_TEST|PCR|"Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System"
215050243|NCT03491033|DRUG|chemotherapy|All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
214892552|NCT01878357|DRUG|dihydroartemisinin-piperaquine|Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).
214892553|NCT01878357|DRUG|primaquine|One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
214892554|NCT00600730|PROCEDURE|Hyperinsulinemic euglycemic clamp with fMRi|Hyperinsulinemic euglycemic clamp on day 1 with morning fMRi
214892555|NCT00600730|PROCEDURE|Hyperinsulinemic hypoglycemic clamp study with fMRi|Hyperinsulinemic hypoglycemic clamp on day1 with fMRi in morning
214892556|NCT06147193|OTHER|with baseline intervention and power training interventions|"Group A (with power training ) was treated with~* squats jump,~* change of direction speed,~* countermovement jump,~* bench press,~* Romanian deadlift~* barbell squats,~* resistance band sprints,~* stair sprints~* weighted sled pulls"
214892557|NCT06147193|OTHER|baseline interventions and without power training interventions|"Group B (without power training) was treated with~* squats jump~* change of direction speed~* countermovement jump~* barbell squats~* resistance band sprints~* stair sprints~* Weighted sled pulls."
214892558|NCT03885986|RADIATION|Ultrasound|role of ultrasound in comparison to magnetic resonance imaging in diagnosis of benign cystic lesions of knee
214892559|NCT03321318|DRUG|AK-R215|Investigational product is prescribed to all ofrandomized subjects
214295851|NCT04925128|OTHER|Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain"
214295852|NCT04885972|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
214295853|NCT04885972|DRUG|Zilretta|Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.
214295854|NCT04885972|DRUG|Placebo|Vehicle solution
214668407|NCT05336370|BEHAVIORAL|Hypnosis|The hypnosis will be conducted by clinical psychologists who have the formal competence and training in hypnosis. We will be using a tailored hypnosis script designed for this particular study, with a duration of 10-15 minutes. The script involves a hypnotic induction (relaxation-based), imagery (suggestions for pleasant visual imagery), a deepening procedure, and symptom-specific suggestions. The introduction begins by having the hypnotist debunk many of the common myths and misconceptions that patients may hold about hypnosis, and provide a description of hypnosis. Hypnosis is described as focused attention and concentration - like being so lost in a book or movie that it is easy to lose track of what is going on around you. Once the patient is deeply hypnotized, the therapist offers suggestions to reduce distress and improve pain tolerance.
214295855|NCT03744923|PROCEDURE|transmuscular QL block|"Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate)."
214295856|NCT03744923|PROCEDURE|Transversus Abdominus Plane block|"Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning."
214295857|NCT00403793|DRUG|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
214295858|NCT00403793|DRUG|Placebo|42 or 44 weeks with placebo implant and placebo injections
214295859|NCT00478985|BEHAVIORAL|Imatinib ending|Interruption of the treatment by Imatinib
214295860|NCT03748147|DRUG|Misoprostol|prostaglandin e1
214668408|NCT05336370|DEVICE|Vagus nerve stimulation|A CE approved tVNS device will be used to stimulate the afferent auricular branch of the vagus nerve located medial of the tragus at the entry of the acoustic meatus \[36\]. A standardized intensity of 10 mA with a pulse width of 250 μs and a consistent stimulation frequency of 25 Hz will be used for optimal stimulation. The stimulation will constantly alternate between active stimulation for 30 seconds, followed by a break of 30 seconds \[37\], and will have a duration of 15 minutes. Active tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing downward. The bipolar stimulation electrode is placed correctly within the concha of the left ear. Participants are instructed to breathe normally while not talking or making any movements during their session.
214668409|NCT05336370|DEVICE|Sham control|Sham tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing upward. The bipolar stimulation electrode is placed correctly within the concha of the left ear, but no actual stimulation will be performed. The electrode will be left on for 15 minutes. Participants are instructed to breathe normally while not talking or making any movements during their session
214668410|NCT03819283|DIAGNOSTIC_TEST|Hepatic evaluation|Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)
214668411|NCT00492622|DRUG|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
214668412|NCT00492622|DRUG|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
214668413|NCT01332435|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
214668414|NCT04510727|DEVICE|Optical Coherence Tomography (OCT)|VivoSight Dx OCT system from Michelson Diagnostics Ltd. OCT will be used to visualize the tumor and lesion in the skin.
214668415|NCT04510727|PROCEDURE|Curettage & Desiccation (C&D) Procedure|Standard of care C\&D where the basal cell carcinoma lesion will be scraped to its base using a Fox dermal curette and an electrodesiccation machine.
214668416|NCT05829720|DIETARY_SUPPLEMENT|a2 Full Cream Milk|Mothers in this arm will drink a2 Full Cream Milk twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
214668417|NCT05829720|DIETARY_SUPPLEMENT|Conventional Milk (Weidendorf)|Mothers in this arm will drink Conventional Milk (Weidendorf) twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
214668418|NCT04745442|DRUG|Antithrombin + best available treatment|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
214668419|NCT04745442|DRUG|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
214668420|NCT02376439|OTHER|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
214668421|NCT02831868|DEVICE|HAVAI|implantation of the HAVAI device to correct the IMA angle
214295861|NCT03128775|BEHAVIORAL|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~1. arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~2. Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
214295862|NCT03128775|BEHAVIORAL|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
214295863|NCT03128775|BEHAVIORAL|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
214295864|NCT03973385|DEVICE|Cryotherapy|patients recieving cryotherapy for skin anesthesia for artérial blood gas
214295865|NCT00050518|BIOLOGICAL|Aventis Pasteur Smallpox Vaccine|
214295866|NCT00945048|DEVICE|electrical velocimetry|determination of cardiac output by electrical velocimetry
214295867|NCT00945048|DEVICE|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
214295868|NCT00945048|DEVICE|spirometry|spirometry for testing the ventilatory function
214295869|NCT00945048|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
215050244|NCT01484457|DEVICE|Closed-loop session|"Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose \< 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.~Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.~After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia."
215050245|NCT04970069|OTHER|Video on analgesic education|A four minute video informing the patient about opioids.
215050246|NCT04970069|OTHER|Video on general perioperative education|A four minute video informing the patient about general perioperative process.
214295870|NCT05606497|DRUG|Corticosteroid|Antenatal corticosteroids are administered to pregnancies at risk for preterm birth in order to reduce risks of neonatal morbidity and mortality following preterm birth.
214295871|NCT02852785|BEHAVIORAL|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
214295872|NCT02852785|BEHAVIORAL|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
214295873|NCT02852785|BEHAVIORAL|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
214295874|NCT02852785|BEHAVIORAL|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
214295875|NCT04900220|DRUG|Betamethasone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)
214295876|NCT04900220|DRUG|Methylprednisolone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
214295877|NCT02645110|DEVICE|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
214892560|NCT03321318|DRUG|Bazedoxifene 20 mg|Investigational product is prescribed to all of randomized subjects
214892561|NCT03321318|DRUG|Cholecalciferol 800IU|Investigational product is prescribed to all of randomized subjects
214892562|NCT02957383|OTHER|Wavelength|wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
214892563|NCT02957383|OTHER|Intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2
215050247|NCT04750863|OTHER|diagnosis criteria performance|
215050248|NCT01992224|OTHER|early mechanical Ventilation|"Fulfillment of three or more criteria below:~respiratory rate \> 28 per minute serum lactate \> 3 mmol/L PaO2/FiO2 Index \<300 mmHg SvO2 \< 65% lung infiltration or atelectasis, pleural exudation"
215050249|NCT01992224|OTHER|Conventional Mechanical Ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate \> 28 bpm dyspnea PaO2/FiO2 Index \<200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
215050250|NCT00495235|BEHAVIORAL|Questionnaire|Questionnaire taking about 20 minutes to complete.
215050251|NCT04550897|DRUG|BM7PE|BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.
214295878|NCT02645110|DEVICE|Tap water|Washing hand with water alone in comparison to hand washing with soap
215050252|NCT05842486|OTHER|Anti-C5 antibody treatment|Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)
215050253|NCT05229809|DRUG|Yiqi Wenyang Jiedu prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
214295879|NCT00136617|DRUG|chlordiazepoxide|
214295880|NCT04120545|DEVICE|Microcurrents|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7, L3 or S1.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
214295881|NCT04120545|DEVICE|Placebo Microcurrents|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
214295882|NCT00303277|DRUG|simvastatin|simvastatin 40 mg tablets once per day for 12 weeks
214295883|NCT00303277|DRUG|pravastatin|pravastatin 80 mg tablets once per day for 12 weeks
214295884|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
214295885|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
214295886|NCT01214629|DRUG|pegfilgrastim|6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
214892564|NCT05434988|PROCEDURE|appendectomy|Open or Laparoscopic appendectomy procedure is typically performed under general anaesthesia. in the laparoscopic approach, the main principle is the triangulation of instrument ports to visualize and expose the appendix clearly. The first trocar (10 mm) for the optical device is introduced peri-umbilically, followed by two 5 mm trocars, one in the right lower quadrant just above the pubis (to grasp the appendix) and the other in the left iliac fossa (for the (right-handed) surgeon's right hand), assuming the appendix is in its normal anatomic position. The locations of the 5 mm trocars can be changed based on the anatomic position of the appendix as determined before to surgery (for example a subhepatic appendix could lead to placing the trocars as for cholecystectomy)
214892565|NCT01831661|DRUG|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
214892566|NCT01831661|DRUG|GLUCOPHAGE®XR|GLUCOPHAGE®XR 750 mg once a day
214892567|NCT02481206|DEVICE|Wearable Cardioverter Defibrillator|Wearable Cardioverter Defibrillator
214892568|NCT04085237|DRUG|Ropivacaine injection|30ml of 0.375% ropivacaine with 5mcg/ml of epinephrine will be injected into the fascial plane on the anterior spinae muscle.
214892569|NCT04085237|OTHER|Sham|Saline will be used at the same amounts as the ropivacaine arm.
214892570|NCT04990453|OTHER|RPD frameworks fabricated from PEEK material|extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
214295887|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
214295888|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
214295889|NCT05135897|DEVICE|Electroconvulsive therapy|Treatment with Electroconvulsive therapy
214295890|NCT05135897|DEVICE|rTMS|repetitive Transcranial Magnetic Stimulation
215050254|NCT05229809|DRUG|Simulation agent of Yiqi Wenyang Jiedu prescription|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
214295891|NCT01636804|DEVICE|Quicksite|St. Jude Medical produced lead called Quicksite
214295892|NCT01636804|DEVICE|Quickflex|St. Jude Medical produced lead called Quickflex
214295893|NCT00039364|DRUG|imatinib mesylate|
214295894|NCT01803919|DEVICE|Silver Alloy-Coated Urinary Catheters|
214295895|NCT01803919|DEVICE|Conventional Urinary Catheter|
214295896|NCT00576927|DRUG|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
214295897|NCT00576927|DRUG|Placebo|
214295898|NCT01622972|DRUG|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
214295899|NCT03266094|DEVICE|BiZact™: A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
214295900|NCT05071456|OTHER|Collects of skin's hydration|Collects of skin's hydration will be made by using patch using electrochemistry.
214892571|NCT03797170|OTHER|Gut microbiota samples|Gut microbiota analysis from diagnosis to follow up after first line-chemo-immuntherapy
214295901|NCT04661657|OTHER|Transthoracic echocardiogram (TTE)|Subjects will undergo TTE imaging.
214295902|NCT04661657|OTHER|Cardiovascular Magnetic Resonance (CMR) Imaging|Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
214892572|NCT02088762|PROCEDURE|surgical excision|comparison of safety margin 1 versus 2 cm
214295903|NCT02707510|OTHER|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
214295904|NCT02850029|OTHER|Observational study, no intervention|
214295905|NCT00097110|DRUG|Vitamin C and E|
214295906|NCT00788476|OTHER|Survey|"Survey packets to adult (\>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18."
214295907|NCT02654522|DRUG|Hylenex|1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
214295908|NCT03265275|OTHER|Fast track patient pathway|Prehospital services establish a working diagnosis of hip fracture and initiate first line treatment. In the emergency department a specially trained nurse triages the patient. Patients without signs of other acute disease or trauma and who have not previously been operated in the same hip are directly transported to the x-ray suite. The x-rays are reviewed by the radiographer and in case of an obvious fracture of the hip the patient is transported directly to the orthopedic ward where the patient is received by a nurse and seen by an orthopedic surgeon. The pathway includes standard procedures for blood sampling, pain relief, including a fascia iliaca compartment block, intravenous fluids, transfusion triggers, management of anticoagulants and premedication. The pathway puts focus on prevention of pressure sores, a short preoperative fasting period and early mobilization. Screening tools are used to assess for delirium, nutritional status and fall risk.
214295909|NCT01847417|DRUG|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
214668422|NCT01828125|PROCEDURE|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-\[6,6-2H2\] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-\[6,6-2H2\] glucose. A third catheter will be inserted for sampling. D-\[6,6-2H2\] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
214668423|NCT01828125|DRUG|Glucagon|
214668424|NCT02047123|DIETARY_SUPPLEMENT|Raw Flaxseed|The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
214668425|NCT02135640|DRUG|denosumab 60mg|solution
214668426|NCT02135640|DRUG|denosumab 120 mg|solution
214668427|NCT02135640|DRUG|placebo|solution
214668428|NCT05202977|DEVICE|SinocrownTM Transcatheter Aortic Valve Replacement System|Subjects receiving SinocrownTM Transcatheter Aortic Valve Replacement System of Lepu Medical
214668429|NCT02517515|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
214668430|NCT02517515|DRUG|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
214668431|NCT04291300|DRUG|Lutetium-177-PSMA-I&T|4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
214668432|NCT06287424|DIETARY_SUPPLEMENT|Aged Garlic Extract|Subjects will be instructed to continue using their regular home oral hygiene products until the Product Distribution Visit (Visit 2). They will also be instructed not to add or change any of their regular home oral hygiene products during that time.
214668433|NCT06287424|DIETARY_SUPPLEMENT|Placebo|Placebo
214668434|NCT05658029|DRUG|ARINA-1|Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
214892573|NCT04681716|OTHER|ELDOA|For Spinal Segment L4-L5 and L5-S1 proper ELDOA position was instructed to the experiment group patients.ELDOA stands for Elongation Longitudinaux Avec Decoaption Osteo Articulaire, or LOADS (Longitudinal Osteo-articular De-coaptation Stretching). ... They can be described as fascial stretch that localizes tension at the level of a specific spinal segmental.
214892574|NCT04681716|OTHER|CONVENTIONAL PHYSIOTHERAPY|"Transcutaneous Electrical Nerve Stimulation (TENS):~120Z dual channel TENS unit made in Japan was used in the research. Electrodes of TENS were placed on lumbar region and TENS was given for 15 minutes on Constant mode. Intensity was adjusted according to patient's comfort.~Hot pack was applied on the lumbar region for 10 - 15 minutes.Lumbar Mobilization (CPA) was given on spinous process of L1- L5 vertebrae and L5-S1. For every session given 3 sets of 10 repetitions of each lumbar vertebra was performed."
214892575|NCT05900778|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
214892576|NCT05900778|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
214892577|NCT00769379|OTHER|Laboratory Biomarker Analysis|Correlative studies
214892578|NCT00769379|BIOLOGICAL|Trastuzumab|Given IV
214892579|NCT00769379|RADIATION|Whole Breast Irradiation|Undergo standard whole breast irradiation
214892580|NCT01928472|BIOLOGICAL|H7N9c low dose with adjuvant|
214892581|NCT01928472|BIOLOGICAL|H7N9c medium dose with adjuvant|
214892582|NCT01928472|BIOLOGICAL|H7N9c high dose with adjuvant|
214892583|NCT01928472|BIOLOGICAL|H7N9c high dose without adjuvant|
214892584|NCT04117438|OTHER|no intervention|There is no intervention. We are just asking breast cancer patients what their food story is.
214892585|NCT02301013|PROCEDURE|Urinary incontience surgery|Surgery for stress or mixed urinary incontience
214892586|NCT02301013|DRUG|300 cc saline|
214892587|NCT06134687|PROCEDURE|Endoscopic Submucosal Dissection|Removal of study eligible lesions per endoscopic submucosal dissection
214892588|NCT06134687|DEVICE|Novel Rigidizing Overtube|Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection
214892589|NCT06174766|DRUG|HGP2102-1|Test drug
214892590|NCT06174766|DRUG|HGP2102-2|Test drug
214892591|NCT06174766|DRUG|RLD2209-1|Control drug
214892592|NCT06174766|DRUG|RLD2209-2|Control drug
214892593|NCT05809479|OTHER|No intervention|No intervention
214892594|NCT01308424|DRUG|BTL TML HSV|Sublingual micro-dosing for 7 days
214892595|NCT01308424|DRUG|Matching placebo|sublingual dosing for 7 days
214892596|NCT00713037|PROCEDURE|Fluoromisonidazole-PET/CT|2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
214892597|NCT04215887|DEVICE|Contactless Portable Respiratory rate Monitor|Novel hand-held respiratory rate monitor
214892598|NCT05355376|PROCEDURE|Bundle of measures to decreased SSI|
214892599|NCT04661644|BIOLOGICAL|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|Dose: 1 x 10\^7 cells/1 mL/vial (1,000 clusters of adipose-derived mesenchymal stem cells)
214892600|NCT04661644|BIOLOGICAL|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)|Dose: 1 x 10\^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)
215050255|NCT04796038|DEVICE|Balloon dilatation|Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation.
215050256|NCT02826408|DRUG|Rabeprazole sodium|WIll study effect of the medication on palpittions
215050257|NCT02826408|DRUG|Pacebo|Placebo comparison to active treatment
214295910|NCT01847417|DRUG|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
214892601|NCT02770482|BIOLOGICAL|spinal fluid collection|
214892602|NCT00095446|DRUG|insulin aspart|
214892603|NCT03970577|DRUG|Rituximab|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
214892604|NCT03970577|DRUG|Prednisone|exclusive oral steroid therapy (progressively tapered with the same procedure for all patients) for a total exposure of 24 weeks (taking into account the initial oral steroid therapy administered during 8 weeks in addition with the oral steroid treatment given after randomization). Each patient will be followed up until 18 months after randomization.
214892605|NCT02007525|BEHAVIORAL|Yoga intervention|Participants will attend one weekly 60 minute hatha yoga class taught by a certified yoga instructor for 6 weeks. Each participant is to practice yoga at home 3-5 days per week. Paper logs will be provided to record date, time and duration of yoga practice each week.
214892606|NCT01253902|DRUG|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
214892607|NCT01253902|DRUG|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
214892608|NCT01253902|DRUG|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
214892609|NCT04053088|DEVICE|INSPIRIS RESILIA Aortic Valve™|Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
214892610|NCT06196879|DRUG|Verekitug (UPB-101)|Verekitug (UPB-101) formulated solution
214892611|NCT06196879|DRUG|Placebo|Verekitug (UPB-101) matching placebo
214892612|NCT05989711|DRUG|Pemvidutide|Administered by subcutaneous injection
214892613|NCT05989711|DRUG|Placebo|Administered by subcutaneous injection
214892614|NCT01654172|DIETARY_SUPPLEMENT|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is \~900mg
214892615|NCT01654172|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|
214892616|NCT06243848|PROCEDURE|Minimal Incision Surgery for median nerve decompression|Classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.
214892617|NCT06243848|PROCEDURE|Ultrasound-guided perineural injection with 5 cc 5% Dextrose|The median nerve will be identified using ultrasound at the proximal entrance of the carpal tunnel. Using an ulnar approach with the in-plane technique, it was planned to inject 5 cc of 5% dextrose around the median nerve.
214892618|NCT05184881|OTHER|Retrolaminar block|2- Cervical retrolaminar block: will be performed on prone-positioned patients. Under fluoroscopic visualization, after identification of the lamina at the desired level, a 25-gauge, 3.5-inch spinal needle was introduced and when the needle tip will be confirmed at the posterior aspect of the cervical lamina corresponding to cervical facet arthropathy level. 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) will be injected.
214892619|NCT05184881|OTHER|Medial Branch Block|1- Cervical medial branch block: will be performed on prone-positioned patients using a posterior approach. Under fluoroscopic visualization, after identification of the waists of the articular pillars at the desired levels, each medial branch block was administered with a 25-gauge, 3.5-inch spinal needle. When the place of the needle tip will be confirmed at the mid-point of the waists of articular pillars, 1 ml of the mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml) will be injected at each level.
214892620|NCT04856046|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214892621|NCT04856046|OTHER|Electronic Health Record Review|Review of medical records
214892622|NCT05167097|OTHER|ASSIST-linked Brief Intervention|WHO's ASSIST-linked Brief Intervention (with and without Steps 6-9, the decisional balance element)
214892623|NCT05167097|OTHER|Mindset Intervention|Standard mindset manipulation as used in research by Peter M. Gollwitzer and colleagues
215050258|NCT00003109|DRUG|irinotecan hydrochloride|
215050259|NCT00003109|DRUG|raltitrexed|
215050260|NCT01409408|DRUG|Aliskiren|300 mg of aliskiren daily for 8 weeks.
215050261|NCT01409408|DRUG|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
214295911|NCT01847417|DRUG|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
214892624|NCT05037825|DRUG|Checkpoint Inhibitor, Immune|anti-PD-1, anti-PD-L1, or anti-CTLA-4 as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent
214892625|NCT03591042|DIAGNOSTIC_TEST|cervical length screening|transvaginal ultrasound cervical length
214892626|NCT01289145|BEHAVIORAL|Motivational intervention|The motivational intervention promotes positive outcome expectancies on physical activity.
214892627|NCT01289145|BEHAVIORAL|Volitional intervention|The volitional intervention promotes the formulation of action plans for physical activity.
214892628|NCT01289145|BEHAVIORAL|Active Control|Participants receive a quiz on physical activity and sports.
214892629|NCT03788343|DIETARY_SUPPLEMENT|Phenylalanine|The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.
214892630|NCT03788343|DRUG|Placebo|Placebo capsules are indistinguishable in their appearance from Phe capsules
214892631|NCT00129545|DEVICE|WATCHMAN Left Atrial Appendage Closure Technology|Implant of WATCHMAN Left Atrial Appendage Closure Technology
214295912|NCT01847417|DRUG|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
214295913|NCT03680573|DRUG|Control: Lacated Ringers|This site will serve as the control site
214295914|NCT03680573|DRUG|Apocynin|This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.
214892632|NCT00129545|DRUG|Warfarin|Subjects receive warfarin
214892633|NCT05528978|BEHAVIORAL|Shambhavi Kriya|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
214892634|NCT01841593|DRUG|Raltegravir|Isentress 400mg tablet taken twice daily
215050262|NCT04330209|OTHER|weight loss diets|The ketogenic diet group were instructed to consume \<35g of carbohydrates per day, and \<10% of total calories were from saturated fats. Daily protein intake was set at 1.2g/kg bodyweight for females, and 1.5g/kg bodyweight for males. The low-GI nutrigenetic diet group had individualised dietary instructions based on their genetic results
215050263|NCT02771405|DRUG|Sofosbuvir|Sofosbuvir 400 mg orally once daily
215050264|NCT02771405|DRUG|Ribavirin|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
215050265|NCT02771405|DRUG|Simeprevir|Simeprevir 150 mg orally once daily
215050266|NCT02771405|DRUG|daclatasvir|Daclatasvir 60 mg orally once daily
215050267|NCT02771405|DRUG|Ledipasvir|Ledipasvir 90 mg orally once daily
215050268|NCT00893854|DRUG|Diclophenac|
215050269|NCT00893854|DRUG|Triamcinolone|
214295915|NCT03680573|DRUG|Allopurinol|This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.
214295916|NCT03680573|DRUG|BH4|This site will be use to locally supplement BH4.
214295917|NCT03680573|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
214295918|NCT03680573|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
214295919|NCT03680573|DRUG|Acetyl-ß-methylcholine chloride|Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
214295920|NCT00426491|DRUG|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
214478077|NCT06071013|DRUG|Nintedanib, gefitinib, erlotinib, afatinib, osimertinib|"Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration.~Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells."
214892635|NCT01841593|DRUG|Amlodipine|generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
214892636|NCT00523939|DRUG|cytarabine liposome injection|50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
214892637|NCT00548613|BIOLOGICAL|MESENDO|Intracoronary transplantation of autologous stem cells via balloon catheter
214892638|NCT00548613|BIOLOGICAL|MESENDO|Intracardiac transplantation of autologous stem cells via direct injection
214892639|NCT03561649|DRUG|Adalimumab|This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.
214892640|NCT01915030|OTHER|High protein diet|controlled feeding trail. Both arms are caloric restricted
214892641|NCT01915030|OTHER|standard protein diet|
214892642|NCT06354517|OTHER|SENSE group|Parents of babies in this group will be given SENSE program training. After the training, parents will care for their babies within the scope of the SENSE program. These babies will receive care from their parents with positive sensory exposures within the scope of the SENSE program from admission to the clinic until discharge. Data collection forms will be administered to babies and their parents.
214892643|NCT00307086|DRUG|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
214892644|NCT00307086|DRUG|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
214892645|NCT00307086|PROCEDURE|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
214892646|NCT02263963|DRUG|Exparel|In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
214892647|NCT02263963|PROCEDURE|TAP Block|no intervention will be done to this arm.
215050270|NCT03783598|BEHAVIORAL|Person centered, occupation based intervention support with problem solving therapy|This program that was developed from the occupational therapy perspective which is person centered and occupation based for T2D intervention was designed as 6 modules. The intervention group received person centered, occupation based intervention support with problem solving therapy as 6 modules. The control group had not any intervention, just had a education about effect of diabetes on life.
215050271|NCT06112301|DIAGNOSTIC_TEST|IdentiClone Dx IGH (IC IGH Dx) Assay|The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease
215050272|NCT01846702|DRUG|Placebo|Given as a SC injection.
215050273|NCT01846702|DRUG|LY3084077|Given as a SC injection.
214892648|NCT02969044|DRUG|Placebo|
214892649|NCT02969044|DRUG|PF-06651600|200mg pill every day (QD) for 8 weeks
214892650|NCT00327418|DRUG|Atorvastatin|
214892651|NCT00717717|BEHAVIORAL|Intervention|One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
214892652|NCT06488287|DEVICE|Transcranial direct current stimulation (brain stimulation)|The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). The 2mA continuous current will be applied during the active stimulation condition via gradual ramps that start and stop after 30 seconds of stimulation (current ramps). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
214892653|NCT06488287|DEVICE|sham Transcranial direct current stimulation (brain stimulation)|The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
214892654|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
214892655|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
214892656|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
214892657|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
214892658|NCT05782777|DRUG|ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.
214892659|NCT05782777|DRUG|high-intensity statin monotherapy (atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
214892660|NCT03809689|OTHER|68Ga-NODAGA-RGD PET/CT|intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection
214892661|NCT03809689|DIAGNOSTIC_TEST|82-Rb PET/CT as part of standard care, not a comparator|2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition
214892662|NCT01304056|DEVICE|Ventilatory therapy|
215050274|NCT01328743|BEHAVIORAL|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
215050275|NCT06646952|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
215050276|NCT01218269|DEVICE|nitinol u-clip|The U-clip is comprised of nitinol, an alloy of nickel and titanium.
214478078|NCT06854497|DIAGNOSTIC_TEST|MMSE (Mini-Mental State Examination),NIHSS (NIH Stroke Scale) and mRS (Mordified Rankin Score), Confusion Assessment Methods (CAM), PSQI Pittsburgh Sleep Quality Index, Respiratory polygraphy|Respiratory polygraphy will be performed during acute stroke period, to evaluate the relationship between sleep apnea and stroke evolution.
214478079|NCT00319111|DRUG|bosentan|"Oral bosentan~* Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~* Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)"
214295921|NCT05248022|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
214892663|NCT03881293|DRUG|lidocaine 2% gel|Transurethral instillation of 5 ml lidocaine 2% gel
214892664|NCT03881293|DRUG|water soluble lubricant|Transurethral instillation of 5 ml water soluble lubricant
214892665|NCT00312338|DRUG|VIGAMOX|1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
214892666|NCT03308214|DRUG|Imipenem|Imipenem 1.0 q 8h
214892667|NCT00262028|BIOLOGICAL|MenACWY-CRM Vaccine|
214892668|NCT00262028|BIOLOGICAL|MenACWY-PS Vaccine|
214892669|NCT04968613|DRUG|Madopar monotherapy|In addition to basic treatment, the patient also received Madopar treatment
214892670|NCT04968613|DRUG|senfrol monotherapy|In addition to the basic treatment, the patient also received the rofosson treatment
214892671|NCT04968613|DRUG|placebo monotherapy|In addition to basic treatment, the patient also received selegiline treatment
214892672|NCT02292693|DEVICE|MIL|Direct laryngoscopy. Laryngoscopy with Miller blade
214892673|NCT02292693|DEVICE|MAC|Direct laryngoscopy. Laryngoscopy with Macintosh blade
214892674|NCT02292693|DEVICE|McCoy|Direct laryngoscopy. Laryngoscopy with McCoy blade
214892675|NCT02960009|DEVICE|HD-tDCS|Different stimulation protocols will be applied to the primary motor cortex of stroke patients. After 20-minute stimulation, EMG-driven robot hand training will be conducted.
214892676|NCT05148221|OTHER|Questionnaires|Once each participant signs an informed consent form upon agreeing to participate in the study, they will be asked to complete a simple demographic questionnaire including year in program, work schedule, self-reported height and weight, age, and sex. They will also be interviewed by a faculty of university of Wisconsin-Eau Claire (UWEC) regarding their current and past exercise habits, exercise preferences, and perceived exercise barriers. Two questionnaires listed above (Occupational Fatigue Exhaustion Recovery (OFER 15) and Maslach Burnout Inventory (MBI)) will also be completed by each participant on Qualtrics online platform.
214892677|NCT05148221|OTHER|Actigraph and activPAL devices|Actigraph and activPAL devices will be set up based on the demographic information and will be provided to each participant to wear for 7 consecutive days during all waking hours and sleep, except when bathing or swimming. If the first 7-day monitoring period was an overnight inpatient week, the second 7-day monitoring period will be scheduled during a non-overnight week. A day before the first day of the second monitoring period, a new set of Actigraph and activPAL devices will be delivered to each participant. Once the second monitoring period ends, devices will be retrieved from each participant, and data will be downloaded from devices.
214892678|NCT04708704|DIETARY_SUPPLEMENT|Erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be obtained from Roxy \& Rich Inc. (Intense Water-Soluble Food Colorant - Pink), which is certified to be edible and complies with US FDA, Health Canada, and European food safety standards. The erythrosine will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.69 mg/kg bw.
214892679|NCT04708704|DIETARY_SUPPLEMENT|SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be SODIS-treated to produce photobleached erythrosine. Transparent 500 mL polyethylene terephthalate (PET) plastic water bottles will be commercially purchased (Kirkland Signature Purified Water). All branding information and labeling will be removed from the bottles. Water bottles will be dosed with \~41 mg erythrosine (0.69 mg/kg bw) using an erythrosine stock solution (8.2 g/L) and will be shaken to mix. The erythrosine-dosed bottles will be placed on a metal shelf and exposed to natural sunlight on the roof of Yale Engineering. Sunlight exposure will be conducted until the absorbance value of erythrosine at the absorption maximum of 526 nm falls below 0.05 above baseline, as measured by ultraviolet-visible spectroscopy. The water bottles containing photobleached erythrosine will be stored under refrigeration in the dark until consumption by participants.
214892680|NCT04708704|DIETARY_SUPPLEMENT|Iodine, prepared in drinking water 0.075 mg/kg bw/day)|Iodine used in the study will be in the form of FCC-grade potassium iodide, which will be obtained from VWR. FCC grade potassium iodide meets the requirements set by the Food Chemical Codex and is suitable for all applications in foods and beverages. Iodine (control exposure) will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.75 mg/kg bw.
215050277|NCT03787329|OTHER|Core decompression surgery with bone marrow concentration|Core decompression surgery with bone marrow concentration
214892681|NCT01679990|BIOLOGICAL|PLX-PAD Low dose|
214892682|NCT01679990|BIOLOGICAL|PLX-PAD high doses|
214892683|NCT01679990|BIOLOGICAL|Double Placebo|
214892684|NCT01679990|BIOLOGICAL|high dose +Placebo|
215050278|NCT03787329|OTHER|Core decompression surgery|Core decompression surgery only
214892685|NCT02922920|OTHER|Tart cherry juice|16 fl. oz of tart cherry juice
214892686|NCT02922920|OTHER|Placebo|16 fl. oz of placebo
215050279|NCT00011583|DEVICE|Robot-assisted therapy|1 hour/day of mechanically-assisted upper limb therapy
215050280|NCT00011583|DEVICE|Traditional therapy|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
215050281|NCT05105321|DRUG|Berberine|The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
215050282|NCT05105321|BEHAVIORAL|Healthy lifestyle intervention|"Healthy lifestyle intervention will be launched according to the Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019, including health lectures, health information promotion, health manual and so on."
215050283|NCT00299364|DRUG|Black Cohosh (iCR) or tibolone|
215050284|NCT01478022|DRUG|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
214295922|NCT05248022|DRUG|Programmed Cell Death Protein 1 Inhibitor|Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
214295923|NCT03171415|DRUG|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
214295924|NCT03171415|DRUG|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
214295925|NCT03677505|DEVICE|KoMAC videolaryngoscope|Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope
214892687|NCT05712499|BEHAVIORAL|mindfulness-based psychoeducation program|Mindful awareness is a mind and body practice that involves increasing attention to what is happening at the moment and accepting what is perceived without judgment. Mindfulness includes awareness and attention; Awareness is the mechanism that constantly controls the of the state of consciousness. Mindfulness-based cognitive therapies are evidence-based psychoeducation. Psychoeducation was organized in 2 consecutive sessions once a week for 8 weeks, and each session was 60 minutes, in total 16 sessions. The content of the psychoeducation program was explained in detail, and techniques such as presentation and question-answer narrative techniques, video, audio recording, mindfulness assignments for the next session were used in the training.
214295926|NCT03677505|DEVICE|Macintosh Laryngoscope|Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
214892688|NCT05712499|BEHAVIORAL|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
214295927|NCT01554553|PROCEDURE|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
214295928|NCT03715764|OTHER|Physical therapy assessment|Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.
214892689|NCT02401269|DRUG|Aspirin|
214892690|NCT02401269|DRUG|Placebo|
214892691|NCT05878457|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System|Treatment will consist 12 approximately-three-minute sessions on each of three treatment days within a seven-day period. To promote participant adherence and retention, treatment days will not need to be contiguous. A single session consists of 600 pulses delivered to the dmPFC at an intensity of 120% resting motor threshold (rMT). 50 hz triphasic bursts will be delivered for two seconds, followed by an 8 second inter-train interval. Trains will be repeated every 10 seconds, 10 times total, for a total of 190 seconds per session. An intersession interval of at least 15 minutes will be employed between each of the 12 sessions. Each treatment day will thus last approximately 3-4 hours in duration.
214892692|NCT05590364|DEVICE|Profhilo® Body|Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.
214892693|NCT05702944|DRUG|Phenoxybenzamine|Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
214892694|NCT01897805|DRUG|Heart-protecting Musk Pill|
214892695|NCT01897805|DRUG|Placebo|
214295929|NCT03715764|OTHER|Physician assessment|Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
214295930|NCT02856503|DRUG|Vitamin D3|Weekly oral dose of Vitamin D3 per protocol.
214295931|NCT00667004|DRUG|ecabet ophthalmic solution|sterile ophthalmic solution
214295932|NCT00667004|DRUG|placebo|sterile ophthalmic solution
214295933|NCT01463553|PROCEDURE|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
214295934|NCT04212104|OTHER|watch a mukbang|watch the dim sum mukbang
214295935|NCT04212104|OTHER|watch a non-food video|watch the Big Bang Theory video
214295936|NCT02234960|DRUG|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
214295937|NCT01000389|DEVICE|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
214295938|NCT01338493|PROCEDURE|lumbar spinal arthroplasty + Maverick™|All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
214892696|NCT01308801|DEVICE|active rTMS + rehabilitation exercise|14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
214892697|NCT01308801|DEVICE|placebo rTMS+ rehabilitation exercise|14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
214892698|NCT03020771|BIOLOGICAL|KIRIM-KONGO-VAX|Crimean-Congo Hemorrhagic Fever Vaccine
215050285|NCT01478022|DRUG|Ibuprofen|Ibuprofen 200 mg daily, capsules
214295939|NCT04299412|DEVICE|DPP Fever Panel II assay|Multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds
215050286|NCT01478022|OTHER|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
214295940|NCT00630279|DRUG|Placebo|Placebo
214892699|NCT03020771|OTHER|Placebo|
214892700|NCT01679652|DRUG|Nebivolol|Tablet i blinded in capsula
214892701|NCT01679652|DRUG|placebo|
214892702|NCT02308124|DRUG|Midodrine|
214892703|NCT02308124|DRUG|Pyridostigmine Bromide|
214892704|NCT02308124|DRUG|Midodrine + pyridostigmine|
214295941|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
214892705|NCT00455156|DRUG|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
214892706|NCT03716856|GENETIC|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
214892707|NCT03716856|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
214892708|NCT03716856|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion
214892709|NCT01029743|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
214892710|NCT01029743|DRUG|Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)|Daily dose, dosage frequency and duration will be decided by physicians
214892711|NCT03567928|DEVICE|Sedation with Gastro Cuff Pilot Laryngeal Mask|This specific type of laryngeal mask allows to separate the gastric and respiratory tract and allows the anesthesiologist to support patient's ventilation as (and only if) necessary.
214892712|NCT03567928|DRUG|Propofol|Target controlled infusion (TCI) with propofol
214892713|NCT04499469|PROCEDURE|Spreader Graft|To place and attach with 5.0 PDS suture 2 grafts in the middle third of the nose
215050287|NCT03518021|DRUG|Naloxone, intranasal|"Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
214892714|NCT06810726|DEVICE|Platelet Rich Plasma|Tropocells(R) Autologous Platelet-Rich Fibrin
214892715|NCT00255554|BEHAVIORAL|Dialectical Behavioral Therapy|
214892716|NCT00255554|DRUG|Escitalopram|
214892717|NCT01974973|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|Intrathecal autologous bone marrow mononuclear cell transplantation
214892718|NCT00033085|DRUG|Ondansetron|
214892719|NCT00028171|DRUG|Tacrolimus|
214892720|NCT07018388|DEVICE|NervioX-2400|To design the individualized STN-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data are used to determine the STN-tTIS montage and stimulation settings through computational modeling.
214892721|NCT07018388|DEVICE|NervioX-2400|To design the individualized GPi-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data is used to determine the GPi-tTIS montage and stimulation settings via computational modeling.
214892722|NCT07017348|OTHER|Clinical assessments|dermatitis atopic scores will be evaluated on the entire body and on target areas by the investigator
214892723|NCT07017348|OTHER|Biometrological measurements|Measurements will be performed on the target areas
215050288|NCT03518021|DRUG|placebo, intranasal|"Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
215050289|NCT03518021|DRUG|Naloxone, intramuscular|Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM
215050290|NCT03518021|DRUG|placebo, intramuscular|Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
215050291|NCT01900665|DRUG|Solanezumab|Administered Intravenously (IV)
215050292|NCT01900665|DRUG|Placebo|Administered IV
215050293|NCT02481258|DRUG|Ataciguat (HMR1766)|
215050294|NCT02481258|OTHER|Placebo Comparator: Matching Placebo|
215050295|NCT05106348|DIAGNOSTIC_TEST|Aerobic Fitness Test|aerobic fitness test to assess wheelchair rugby players capacity
215050296|NCT03076606|DIAGNOSTIC_TEST|ophthalmologist examination|ophthalmologist examination after geriatric consultation
214295942|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
214295943|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
214295944|NCT05339594|DEVICE|NeuraGen|NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
214295945|NCT05339594|DEVICE|NeuraGen 3D|NeuraGen 3D Nerve guide matrix is a resorbable implant for the repair of peripheral nerve gaps.
214892724|NCT07017348|OTHER|Biological sampling|Skin and faecal samples will be performed
214892725|NCT07017348|OTHER|Questionnaires|dietary habits, health and lifestyle, and digestive health
214892726|NCT01329900|DRUG|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
214892727|NCT01329900|DRUG|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
214892728|NCT01329900|DRUG|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
214892729|NCT01329900|DRUG|Mesna|"2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose."
214892730|NCT01329900|DRUG|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
214892731|NCT01329900|PROCEDURE|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
214892732|NCT06634173|DIAGNOSTIC_TEST|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated Cancer associated fibroblasts as a marker of Tumor Micro-Environment and indirectly as a marker for malignancies.
214892733|NCT05290727|OTHER|Aquoral Lipo (Esteve)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
214892734|NCT05290727|OTHER|Hyabak (Thea)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
214892735|NCT06054165|OTHER|Clinical pathway|Evidence-based and expert-opinion-based clinical pathway regarding the diagnostic and treatment strategy
214892736|NCT03609320|BEHAVIORAL|The STOP-HPV Trial 5: Bundle Intervention|This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
214892737|NCT04932057|OTHER|Action observation Training|Action observation training is a relatively new rehabilitation approach in which the subject is asked to carefully observe the actions presented through a video clip or performed by an operator.
214892738|NCT04932057|OTHER|Action Practice|Participants perform an upper extremity functionality test a couple of times.
214892739|NCT04932057|OTHER|Observation|Participants will watch a slide show of landscape
214892740|NCT02558530|OTHER|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
214892741|NCT05275920|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
214892742|NCT05275920|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
214892743|NCT06738628|PROCEDURE|(Esophageal or Gastric) Per-Oral Endoscopic Myotomy|Performing Per-Oral Endoscopic Myotomy for the treatment of either achalasia of the esophagus, or gastroparesis of the stomach.
214892744|NCT00596076|BEHAVIORAL|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
214892745|NCT00424229|DRUG|LENALIDOMIDE|
214892746|NCT03958292|DEVICE|IODIM|Eye drops containing polyvinylpyrrolidone-Iodine (PVP-Iodine), hyaluronic acid and triglycerides
214892747|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
215050297|NCT04282850|PROCEDURE|Pulmonary Vein Isolation|The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.
214892748|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand rubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
214892749|NCT06634290|DEVICE|intramedullary nailing augmentation|Treatment of pertrochanteric hip fractures with intramedullary nailing with cephalic augmentation with bone cement
214892750|NCT06634290|DEVICE|intramedullary nailing|Treatment of pertrochanteric hip fractures with intramedullary nailing without cephalic augmentation
214892751|NCT00736437|DRUG|ME-609|Cream applied topically 6 times daily over the UVR exposed area
214892752|NCT00736437|DRUG|Vehicle|Treatment applied 6 times daily over the UVR exposed area
214892753|NCT03452878|BEHAVIORAL|Aggressive behavior|Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
215050298|NCT02606630|DRUG|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
215050299|NCT01039389|DRUG|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
215050300|NCT01039389|DRUG|Placebo|bid placebo
215050301|NCT04617080|PROCEDURE|SUPRACOR Regular|SUPRACOR algorithm with regular (100%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
215050302|NCT04617080|PROCEDURE|SUPRACOR Strong|SUPRACOR algorithm with strong (130%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
215050303|NCT03132285|DEVICE|PrePex|Prepex is a non surgical male circumcision device
215050304|NCT02908581|DRUG|Placebo|Administered orally once daily
215050305|NCT02908581|DRUG|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
215050306|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2|One capsule of 75 mg Vitamin B2 once a day for 4 weeks
214892754|NCT06235827|DIETARY_SUPPLEMENT|Green tean group|Patients in Group A will have to consume two cups (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes. They are only allowed to consume as hot drink, not for iced tea. Any sweetener or sugar is not allowed to mix in the drink. The green tea bag will be distributed to patient at beginning of research and at every visit. Patient will be reminded weekly using text messages or phone call by a research assistant for green tea consumption.
214892755|NCT06235827|DIETARY_SUPPLEMENT|Control group|Patients in Group B will not be consuming green tea during 6 months of study period.
214892756|NCT04060290|OTHER|Observational study|Observational study of this study, no interventions involved
214892757|NCT00240565|DRUG|Tositumomab 450 mg|Unlabeled TST
214892758|NCT00240565|DRUG|Tositumomab 35 mg|TST labeled with 185 megaBecqueral (mbq) of iodine 131
214892759|NCT04810065|OTHER|SingStrong: Strong lungs through Song|"Participants who have been clinically diagnosed with Covid-19 and who continue to suffer residual adverse effects on the lung health will be invited to participate in the study.~The intervention will involve biweekly hour-long breathing and singing classes that are designed to correct dis-ordered breathing, and retrain the principal muscles of respiration.~Pre and post evaluation of participant bio-psychosocial health and wellness will be conducted. Triangulation of data using focus groups and individual interviews will be conducted after conclusion of the intervention,"
214892760|NCT04233073|DRUG|andexanet alfa|Andexanet is a recombinant version of human FXa
214892761|NCT02644473|DRUG|Tranexamic Acid|
214892762|NCT02644473|DRUG|Normal saline|Control
214892763|NCT02307773|DRUG|Case Group|Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
214892764|NCT04980989|DEVICE|Mobile software for follow-up of early breast cancer|The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
214892765|NCT04357548|DEVICE|FEEDBACK|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
214892766|NCT00143390|DRUG|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
214892767|NCT00143390|DRUG|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
214892768|NCT03860324|PROCEDURE|Single-shot erector spinae plane block|Single-shot Erector Spinae Plane block with 30ml of ropivacaine 0,5% + adrenaline 150mcg.
214892769|NCT03860324|PROCEDURE|Single-shot fascia iliaca block|Single-shot Fascia Iliaca block with 40ml of ropivacaine 0,2%
215050307|NCT03668964|DIETARY_SUPPLEMENT|Vitamin C|One capsule of 500 mg Vitamin C once a day for 4 weeks
215050308|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2 + C|One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
214295946|NCT04348929|OTHER|Self-administered questionnaires|Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
214892770|NCT00939016|OTHER|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
214892771|NCT03417687|DRUG|129Xe MRI|Evaluation of pulmonary function
214892772|NCT03417687|DRUG|133 Xe scintigraphy|Evaluation of pulmonary function
214892773|NCT03848494|PROCEDURE|Surgery|Laparoscopic floppy Nissen, laparoscopic-left thoracoscopic Collis-Nissen, laparoscopic gastric fundus wrapped around the stomach
214892774|NCT00041132|BIOLOGICAL|filgrastim|5 ug/kg
214892775|NCT00041132|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 of cycles 1-6
214892776|NCT00041132|DRUG|cyclophosphamide|300 mg/m\^2 on days 2-4 of cycles 1,3,5,7
214892777|NCT00041132|DRUG|cytarabine|12 g/m\^2 over days 3-4 of cycles 2,4,6,8
214892778|NCT00041132|DRUG|dexamethasone|40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
214892779|NCT00041132|DRUG|doxorubicin|16.6 mg/m\^2/day for days 5-7 of cycles 1,3,5,7
214892780|NCT00041132|DRUG|leucovorin|170 mg over days 3-5 of cycles 2,4,6,8
215050309|NCT03668964|DIETARY_SUPPLEMENT|Vitamin A|One capsule of 250 µg Vitamin A once a day for 4 weeks
215050310|NCT03668964|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of 60 µg Vitamin D3 once a day for 4 weeks
215050311|NCT03668964|DIETARY_SUPPLEMENT|Vitamin E|One capsule of 100 mg Vitamin E once a day for 4 weeks
215050312|NCT03668964|DIETARY_SUPPLEMENT|Placebo|One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
215050313|NCT01079312|DEVICE|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
214295947|NCT01705652|DRUG|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
214478080|NCT06087952|OTHER|Randomised treatment advice (discontinue vs continue after 3 months)|Randomisation to continue or discontinue anticoagulant therapy in 1:1 ratio stratified on risk category of L-TRRiP and VTE-BLEED score
214478081|NCT06087952|DIAGNOSTIC_TEST|VTE-BLEED score|Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score
214478082|NCT06087952|DIAGNOSTIC_TEST|L-TRRiP score|Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score
214892781|NCT00041132|DRUG|methotrexate|1000 mg/m\^2 over days 2-3 of cycles 2,4,6,8
214892782|NCT00041132|DRUG|vincristine|1.4 mg/m\^2 on days 5 and 12 of cycles 1,3,5,7
214892783|NCT03997851|DRUG|Acetaminophen|Topical acetaminophen gel
214892784|NCT03997851|DRUG|Carbomer 980|Topical vehicle gel
214892785|NCT03620045|BEHAVIORAL|Acute moderate physical activity|For 20 minutes, participants will walk on a treadmill at a moderate intensity based on a combination of evidence-based and pre-determined parameters, including ratings of perceived exertion and heart rate
214892786|NCT00146276|DRUG|gemcitabine|
214892787|NCT04053127|DEVICE|RAVANS|Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.
214892788|NCT03350607|OTHER|Non interventional study|Non interventional study (collect of data)
214892789|NCT04746144|PROCEDURE|Total knee arthroplasty|
214892790|NCT04252339|DRUG|RLY-1971|RLY-1971 is an oral inhibitor of SHP2.
214892791|NCT00681031|BIOLOGICAL|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
214892792|NCT04684472|BIOLOGICAL|Modified anti-CD19 CAR T cells|intravenous infusion
214892793|NCT03097146|OTHER|comprehensive multidisciplinary stroke care|"Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies."
214892794|NCT05019950|DRUG|NIM-1324|Once daily oral tablet
214892795|NCT05019950|DRUG|Placebo|Once daily oral tablet
214892796|NCT01290159|OTHER|heat tolerance test (HTT)|An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
214892797|NCT06265259|DRUG|Initiation of vasopressine as a first vasoconstrictive drug|The group (arm 1) where vasopressin (1 amp in 50 mlN/S) (1st vasoconstrictor) will be administered first up to a maximum dose of 0.03 IU/min (2.3 ml/h) for the treatment of hemodynamic instability. Then, if the patient remains unstable, noradrenaline (2nd vasoconstrictor) will be started. The dose of vasopressin will not be increased further than the above mentioned limit.
214892798|NCT06265259|DRUG|Initiation of noradrenaline as a first vasoconstrictive drug|ii. In the group (arm 2) where the treatment of haemodynamic instability will be performed by first administering noradrenaline (1st vasoconstrictor) up to 0,5 mcg/kg/min and then, if the patient is still unstable, adding vasopressin (2nd vasoconstrictor) at a maximum dose of 0.03 IU/min (2.3ml/h). If haemodynamic instability persists, treatment will involve further increase of the noradrenaline dose.
214892799|NCT05607745|OTHER|FMT and placebo|Similar healthy diet counseling is given to all participants in both FMT and placebo group. FMT to placebo is given in 2:1.
214892800|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
214892801|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
214892802|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
214892803|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
214892804|NCT06432816|DIETARY_SUPPLEMENT|NANO-PSO|NANO-PSO or Oil of pomegranate seed with nanotechnology, they are capsules with a net content of 640 mg with a dosage indicated by sponsor of 2 capsules in fast
214892805|NCT06432816|OTHER|PLACEBO|"Placebo physically identical to NANO-PSO capsules:~Soft gelatin capsules 640 mg edible oil 35for PLACEBO Oil edible, oval shape, 640 mg."
214892806|NCT03420521|DRUG|Nivolumab|240mg IV over 60 minutes Q2W
215050314|NCT01079312|DEVICE|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
215050315|NCT01079312|DRUG|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
215050316|NCT01079312|DRUG|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
214892807|NCT03420521|DRUG|Ipilimumab|1mg/kg IV over 30 minutes Q6W
214892808|NCT03414476|OTHER|Hair follicles sampling|The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath
214892809|NCT03437473|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
214892810|NCT05186792|OTHER|Test:mycoplasma|Retrospective analysis of records of recruits to a previous mycoplasma study.
214892811|NCT03377101|DRUG|Copanlisib|Given IV
214892812|NCT03377101|DRUG|Fulvestrant|Given IM
214892813|NCT03377101|OTHER|Laboratory Biomarker Analysis|Correlative studies
214892814|NCT03377101|DRUG|Palbociclib|Given PO
214892815|NCT00269984|DRUG|Epoetin alfa|
214892816|NCT03953612|DRUG|Pregnenolone (PREG)|2 doses of PREG (300 or 500 mg/day)
214892817|NCT03953612|DRUG|Placebos|placebo
214892818|NCT00641446|DRUG|budesonide|
214892819|NCT00641446|DRUG|varicella zoster virus|
214892820|NCT03885583|PROCEDURE|thoracic epidural block|thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound
214892821|NCT03885583|PROCEDURE|paravertebral block|paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
214892822|NCT02404480|DRUG|PTC596|PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
214892823|NCT01774162|DEVICE|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
214892824|NCT01774162|DEVICE|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
214892825|NCT04277962|DEVICE|Triton L and D system for estimation of blood loss at time of vaginal delivery|The Triton L\&D system (Gauss Surgical, Inc., Menlo Park, CA) is an FDA-cleared mobile application on a tablet computer (iPad) that facilitates quantification of blood loss (QBL) by providing an easy to use process and user interface. Dry weights of all potential blood containing substrates are built-in to the device allowing batch weighing with automatic subtraction of dry weights. There is also a V-drape simulator accounting for collected fluids with automatic subtraction of a measured amount of amniotic fluid.
214892826|NCT02317029|DEVICE|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
214892827|NCT02317029|PROCEDURE|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
214892828|NCT02317029|DEVICE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
214892829|NCT02317029|PROCEDURE|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
214892830|NCT04273191|DRUG|Brexanolone|Brexanolone will be initiated and administered per the USPI and the associated REMS.
215050317|NCT01079312|DRUG|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
215050318|NCT01079312|DRUG|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
215050319|NCT05573139|DIAGNOSTIC_TEST|Assessment of muscle strength by manual dynamometry|The reliability and validation of a new manual dynamometer was verified, compared to one already used, in the muscle groups: knee extensors and flexors; hip extensors, flexors, abductors, adductors, internal and external rotators.
215050320|NCT06047743|OTHER|Alternating unilateral Isometric Handgrip Exercise|Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
215050321|NCT06047743|OTHER|Dominant knee extension Isometric Exercise|Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
215050322|NCT02795494|BEHAVIORAL|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
215050323|NCT02795494|BEHAVIORAL|ASK-P questionnaire at baseline|Patient-reported activity level score
215050324|NCT02795494|BEHAVIORAL|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
215050325|NCT02550015|BEHAVIORAL|High intensity interval training|Uphill treadmill walking
215050326|NCT02550015|BEHAVIORAL|General information|Standard care
214295948|NCT04406961|PROCEDURE|Endoscopic transpapillary antegrade sphincterotomy developed by Dr. Dovbenko.|Sph. Oddi consists of a longitudinal and circular smooth muscle layers. Circular muscle fibers form the pancreatic and duodenal parts. Anatomical justification was cutting of only the circular layer of sph Oddi by special sphincterotome. Papillary stenosis and stenosis terminal part of common bile duct due to damage only circular layer sph Oddi. Anterograde direction and hooked form of sphincterotome (endoscopic antegrade sphincterotomy- ASD) allows to capture only need layer and control depth. Also ASD was performed patient with SOD (I-III) with preservation of the longitudinal muscular layer sph Oddi and septum of papilla.
215050327|NCT04795401|DEVICE|FRAME FR IFU|The surgeon will use the medical device FRAME to perform the plication procedure. The device will be selected and implanted according to the product IFU.
215050328|NCT06168240|OTHER|Manual lymphatic drainage. will be applied three days per week for four weeks.|Training will applied 3 days a week, for a total of 4 weeks.
215050329|NCT06274983|DEVICE|IVR platform trial|8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform. Patients will receive device training and then use the VR device at home for 12 weeks. Physiotherapists will conduct pre (visit 1) and post (visit 2) assessments to assess changes using a Goniometer (measures ankle range of movement), PEDSQL quality of life data, GAD-7 anxiety questions and the NorthStar Ambulatory Assessment.
215050330|NCT04326062|OTHER|Main Study|The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.
215050331|NCT04326062|OTHER|PROM Study|For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
214295949|NCT04406961|DEVICE|The antegrade sphincterotome developed by Dr. Dovbenko.|A device is represented by a teflon catheter in the distal part of which a double tube of variable shape is created. The proximal part of the ASD sphincterotome consists of a handle, and a metal wire is located inside the teflon catheter for connection to an electrosurgical unit. On the distal part, the teflon catheter is formed of a double tube length is 10 to 35 mm. The metal wire exits the catheter at a distance 10 to 35 mm from the tip and enters into the tip the second teflon tube. The distal part of the knife is formed shape a hook. A metal cutting wire is located between two tubes. Moving the handle the metal wire is shifted. Pushing the metal wire or approaching in the distal part the second tube sets the depth of cut. The incision is made by moving on guidewire in bile duct. The power settings vary.
214478083|NCT06087952|OTHER|Advise to continue anticoagulant treatment after 3 months|Advise to continue anticoagulant treatment after 3 months for patients with high VTE recurrence and low bleeding risk
214478084|NCT06087952|OTHER|Advise to discontinue anticoagulant treatment after 3 months|Advise to discontinue anticoagulant treatment after 3 months for patients with low VTE recurrence risk
214668435|NCT02363647|OTHER|Tumor Genomic Analysis|"Tumor mutations identified by deep DNA and RNA sequencing of individual tumors are screened for tumor drivers, which are then incorporated into the personal Drosophila model and tested against a library of FDA approved drugs. Fly mortality is used as a surrogate for toxicity and increased survival to adulthood; improvements in tumor mutation-linked eye and/or wing abnormalities serve to quantify efficacy. This allows rapid and parallel screening of FDA approved drugs and subsequent drug combinations. The most efficacious and least toxic combinations are tested in xenograft models and a multidisciplinary tumor board of experts select the best therapeutic option. The objective is to demonstrate that the personalized drosophila model approach is superior to the current standard. Patient will be offered an unique personalized single drug or combination of drugs, all FDA approved, based on the Drosophila drug screening process."
214668436|NCT02786537|DRUG|SOF/LDV (sofosbuvir/ledipasvir)|Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
214668437|NCT02786537|DRUG|PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)|Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
214668438|NCT02786537|DRUG|EBR/GZR (elbasvir/grazoprevir)|Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
214668439|NCT02786537|DRUG|Ribavirin|200 mg pills (1-3 pills, 1-2 times per day)
214668440|NCT02638012|DRUG|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
214668441|NCT02638012|OTHER|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
214668442|NCT00443560|OTHER|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
214668443|NCT02641704|BEHAVIORAL|Multidisciplinary program|Coordinated multidisciplinary program
214668444|NCT03016715|DRUG|Sirolimus 2%|
214668445|NCT03016715|DRUG|Vehicle|
214668446|NCT01494038|DRUG|Isoniazid (INH)|300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
214668447|NCT01494038|DRUG|Placebo for isoniazid (INH)|Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
214668448|NCT01147965|BIOLOGICAL|AD5 CEA Vaccine|AD5\[E1-, E2b-\]-CEA Vector Vaccine
214668449|NCT02968030|OTHER|Muscle strength|"Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.~n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip."
214668450|NCT01950936|OTHER|Discontinuation of Antibiotcs|Discontinuation of Antibiotcs against lower respiratory tract infections
214668451|NCT01516450|DRUG|GSK1550188 IV|Single IV dose of belimumab 200 mg
214668452|NCT01516450|DRUG|GSK1550188 SC|Single SC dose of belimumab 200mg
214668453|NCT03841877|PROCEDURE|endodontic treatment|The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
214668454|NCT04020432|BEHAVIORAL|questionary|"A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
214668455|NCT05299892|DEVICE|Phonak Audeo P or Naida P hearing aid|"Commercially available hearing aid that has access to speech enhancer feature settings off, moderate and strong"
214668456|NCT03099759|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D2/D3
214668457|NCT03405103|BEHAVIORAL|Striving|
214668458|NCT03405103|BEHAVIORAL|Boning-Up|
214668459|NCT03405103|BEHAVIORAL|Personal Choice|
214892831|NCT02028676|OTHER|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
214892832|NCT02028676|OTHER|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
214892833|NCT02028676|DRUG|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
214892834|NCT02028676|DRUG|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
214892835|NCT02028676|DRUG|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
214892836|NCT02028676|DRUG|Once-daily ABC+3TC|
214892837|NCT02028676|DRUG|Twice-daily ABC+3TC|
214892838|NCT02028676|DRUG|Continued cotrimoxazole prophylaxis|
214892839|NCT02028676|OTHER|Stopped cotrimoxazole prophylaxis|
215050332|NCT01070342|DEVICE|Spacelabs 90217|Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
215050333|NCT05691920|PROCEDURE|Pectointercostal plane block and external oblique intercostal plane block|Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks
215050334|NCT05691920|PROCEDURE|Fentanyl infusion|Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
214892840|NCT00971373|OTHER|Vestagen scrubs|antimicrobial impregnated textile
214892841|NCT00626457|BEHAVIORAL|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
214892842|NCT00773474|DRUG|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
214892843|NCT05847348|DRUG|68Ga-PSMA-11|A single dose of 111 - 259 MBq administered intravenously over 3 -5 minutes
215050335|NCT01298843|DRUG|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
215050336|NCT04303975|OTHER|clinical measurements|Only clinical parameters were recorded, no intervention was made.
215050337|NCT06669455|BEHAVIORAL|Personalized and combined lifestyle approach|In the SENSS approach five different and complementary lifestyle domains (self-management, exercise, nutrition, sleep and stress) are combined. The process will be guided by a lifestyle coach. The intervention is personalised for each participant. The personal goals are decided based on 'shared decision making' together with the lifestyle coach after using a Parkinson lifestyle decision aid. The level of guidance needed throughout the intervention is based on a 'stepped care approach'.
215050338|NCT05599100|BEHAVIORAL|STAR-Caregivers Virtual Training & Follow-up (STAR-VTF)|For 6-8 weeks, caregivers will complete online training modules asynchronously. Caregivers will be instructed to complete one module per week. The content of the modules is as follows: Module 1 introduces caregivers to the behavioral treatment of dementia, realistic expectations, and effective communication; Module 2 covers the ABC (antecedents, behaviors, consequences) approach to problem-solving, including rationale and development of an ABC plan; Module 3 instructs caregivers to review the ABC plan and revise as needed; Module 4 covers pleasant events and managing negative thinking; Module 5 instructs caregivers to review the ABC plan, pleasant activities schedule, and to revise as needed; Module 6 covers coping with caregiving and maintaining gains. Each module takes about 45 minutes to complete. The modules use text, pictures, and illustrations with a voiceover presentation. Caregivers will receive the online training modules in their preferred language (English or Spanish).
214892844|NCT05847348|OTHER|PET/CT or PET/MRI|PET/CT or PET/MRI will be acquired no sooner than 50 minutes post injection and not later than 100 minutes post injection with 68Ga-PSMA-11
214892845|NCT00288730|DRUG|nesiritide|
214892846|NCT02748148|OTHER|Medication therapy management|Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
214892847|NCT05133674|DRUG|Tamoxifen 20 mg|i) a self-testing capillary kit, the rhelise™ kit for measuring the concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen and ii) a patient interactive digital tool (app) mBraze to collect data about symptoms and guide breast cancer patients on adjuvant tamoxifen.
214892848|NCT06633874|DIAGNOSTIC_TEST|TD Playing the Serious Game APSOU|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then, the child may interact with the Serious Game. Typically developed (TD) children engage under the clinician's face-to-face supervision with the serious game APSOU, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for TD children to play the whole game is estimated to be 45 minutes.
214295950|NCT04406961|PROCEDURE|Endoscopic sphincterotomy.|Endoscopic standard sphincterotomy aims at opening bile duct or pancreatic duct by cutting the papilla and sphincter muscles. After deep bile duct cannulation, the standard sphincterotome is retracted until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary. The extent of the sphincterotomy is limited by the length of the intraduodenal portion of the common bile duct.
214295951|NCT04406961|DEVICE|The standard sphincterotome.|"The standard sphincterotome, the Erlangen pull-type model, consists of a catheter containing a cautery wire exposed 15 to 25 mm near the tip of the instrument. The leading tip distal to the wire, the nose, is 5 to 10 mm in diameter. After deep bile duct cannulation, the sphincterotome is retracted slowly, until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made by lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary."
214668460|NCT06112925|OTHER|Medication Therapy Management|The medication therapy management intervention was delivered via the five (5) core components which include medication therapy review, personal medication record, medication-related action plan, intervention, and documentation and follow-up. The interventions was also given via educating patients about diabetes, hypertension, complications of diabetes and hypertension, impact of having diabetes and hypertension, antidiabetes and antihypertensive medications, goals of therapy for diabetes and hypertension, health promoting behaviours (healthy diet, regular exercise, salt reduction, \& smoking cessation), drug adherence, and self-monitoring of the diseases.
214892849|NCT06633874|DIAGNOSTIC_TEST|Non-TD Playing Serious Game|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then the child may interact with the serious game. Non-typically developed (non-TD) children engage under the clinician's face-to-face supervision with the serious game Apsou, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for non-TD children to play the whole game is estimated to be over an hour.
214892850|NCT06400030|PROCEDURE|Root canal treatment with AH Plus sealer|\- AH Plus sealer Group: the base and accelerator of AH Plus Sealer was mixed, then the walls of the canal were coated with the AH Plus sealer using K-File, then lateral condensation was performed through a number of gutta-percha cones.
214892851|NCT06400030|PROCEDURE|Root canal treatment with BioCeramic sealer|\- BioCeramic Sealer Group: the canals in this group were filled using BioCeramic-based sealer and a single gutta-percha cone, and gently insert it into the root canal to the preselected working length without applying pressure.
215050339|NCT06714305|DEVICE|Group B will be assigned to rotary instrumentation.|group B, NiTi rotary protaper system will be used for canal preparation by crown down technique.
215050340|NCT06714305|DEVICE|will be assigned to rotary instrumentation.|the canal will be prepared by conventional hedstorm files manually by step back technique.
215050341|NCT06716125|BEHAVIORAL|aerobic treadmill walking plus low calorie diet|this group (n =20 for the group) will administer low calorie diet for 12 weeks plus additionally administering supervised walking treadmill aerobic training for 45 minutes 3 times per week for 12 weeks).
215050342|NCT06716125|BEHAVIORAL|low calorie diet|this group (n =20 for the group) will administer low calorie diet for 12 weeks
215050343|NCT06719024|DRUG|Ruxolitinib Cream 1.5%|a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
215050344|NCT06719024|DRUG|Aqueous cream|a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
214295952|NCT00541034|BIOLOGICAL|rituximab|
214295953|NCT00541034|DRUG|cyclophosphamide|
214295954|NCT00541034|DRUG|pentostatin|
214295955|NCT02269020|PROCEDURE|Neck Dissection|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
214295956|NCT00656474|DRUG|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
214295957|NCT00656474|DRUG|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
214668461|NCT02682810|DEVICE|DNA PCR HIV diagnostic test|standard of care
214668462|NCT02682810|DEVICE|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
214668463|NCT01458340|DRUG|TD-9855|Once daily
214668464|NCT01458340|DRUG|TD-9855|Once daily
214668465|NCT01458340|DRUG|Placebo|Once daily
214892852|NCT03008174|OTHER|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
214892853|NCT02565940|OTHER|biopsy|
214892854|NCT04469504|OTHER|Prehabilitation program|4-week trimodal prehabilitation program: Exercise, nutritional supplementation, and psychological support
214892855|NCT04469504|DIETARY_SUPPLEMENT|Oral Impact|perioperative immunonutrition by ORAL IMPACT
214892856|NCT06582667|PROCEDURE|PENG block|US guided PENG block in hip fracture without anti thrombotic therapy
214892857|NCT01828801|DEVICE|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
214892858|NCT04727801|DEVICE|Verily Patch|The Verily Patch is an investigational wearable temperature sensor that consists of a Patch (Verily Patch), with swappable adhesives, as well as an app (Verily Patch app).
215050345|NCT06719271|DEVICE|Participants this group will receive gait training in robotic assisted gait training (RAGT) three times per week for eight weeks|Robotic Assited Gait Training is a device used to train children with CP how to walk in effective manner by connecting their body to the harness, robotic devices that attached to the electronic treadmill
214892859|NCT00973063|BEHAVIORAL|Routine sterile gloving|routinely new sterile gloving just before sampling
214892860|NCT05282563|PROCEDURE|double and a half layered esophagojejunal anastomosis|After the end of esophagojejunostomy, 3/0 barbed suture or absorbable suture was used. First, the anastomotic site was sutured continuously for one circle, with the suture spacing of 3-4 mm and the width of 4-5 mm. Then, the continuous horizontal mattress type seromuscular layer varus suture was used to embed the anastomotic stoma for one circle, and the suture width was 5\~8 mm above and below the anastomotic stoma. After the completion of esophagojejunostomy, the full-thickness reinforcement of the anastomosis and the embedding of the seromuscular layer can ensure the complete anastomosis of the mucosal layer of the anastomosis. The embedding of the seromuscular layer can also improve the anti-pressure and anti-tension of the anastomosis, and provide a guarantee for the primary healing of the anastomosis.
214892861|NCT02459938|DRUG|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
214892862|NCT02459938|DRUG|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
214892863|NCT04359797|OTHER|Prone|Provider-recommended guidance on prone positioning of patients
214892864|NCT04359797|OTHER|Usual Care|No provider-recommendation, patients will remain in their natural choice of position
215050346|NCT06719271|DEVICE|Body Weight Supported Treadmill Training|Participants in this group will receive gait training on conventional treadmill three times per week for eight weeks
215050347|NCT04749745|DRUG|L-theanine|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.
215050348|NCT04749745|DRUG|Placebo|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
215050349|NCT00226356|DRUG|Supplements of L-methionine, betaine and folate|
215050350|NCT00003156|DRUG|topotecan hydrochloride|
215050351|NCT04541667|OTHER|Air|Air will be used for luminal inflation.
215050352|NCT04541667|OTHER|Carbon Dioxide|Carbon dioxide will be used for luminal inflation.
214295958|NCT01972503|DRUG|5-FU and oxaliplatin|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
214892865|NCT01912261|DRUG|Placebo|one capsule orally daily times 84 days
214892866|NCT01912261|DRUG|Polysaccharide iron complex|150 mg daily orally times 84 days
214295959|NCT01972503|PROCEDURE|colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
214295960|NCT01777256|DRUG|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
214892867|NCT04615351|DRUG|Metformin|Medication
214892868|NCT01609205|BIOLOGICAL|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
214892869|NCT05522127|OTHER|Colonoscopy|Colonoscopy
214892870|NCT05522127|OTHER|Sedoanalgesia|Ketamine, fentanil, midazolam, propofol
214892871|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with ALL plasty|ACL reconstruction with hamstrings combined anterolateral plasty using the ALL reconstruction technique (Gracilis throught the femur tunnel of the ACL graft and fixed to the tibia by an anchor on its point of isometry on the tibia).
214892872|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with modified Lemaire's LET|ACL reconstruction with hamstrings combined with modified Lemaire's lateral extra-articular tenodesis technique (Fascia lata strip pedicled to the Gerdy and fixed to the femur throught the tunnel of the ACL graft).
215050353|NCT04167254|BEHAVIORAL|Sit Down and Play|Brief health care-based program that aims to promote key parenting behaviors that promote early childhood development
214892873|NCT01108627|DRUG|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
215050354|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
215050355|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
214892874|NCT01108627|DRUG|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
214892875|NCT01108627|DRUG|foradil|open-labeled inhaled corticosteroids (ICS); foradil
214892876|NCT02083627|DRUG|rosuvastatin|Oral
214892877|NCT02083627|DRUG|fidaxomicin|Oral
214892878|NCT03691727|DRUG|tirofiban hydrochloride (AGGRASTAT®)|Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
214892879|NCT03691727|DIAGNOSTIC_TEST|MRI|Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
214892880|NCT03691727|DIAGNOSTIC_TEST|Neurological Exam|Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
215050356|NCT00914576|DRUG|Placebo|2 capsules/day for 14 days
215050357|NCT00914576|DRUG|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
214295961|NCT01777256|DRUG|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
214892881|NCT03691727|BEHAVIORAL|Questionnaires|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
215050358|NCT00914576|DRUG|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
215050359|NCT04494685|DEVICE|Intervention group (Robotic rehabilitation)|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland). The training protocol has a progression of the board inclination up to 90º associated with flexion/extension movements of the knees and hips, with time evolution of up to 40 minutes. Such equipment is associated with electrostimulation of the quadriceps, hamstrings, sural triceps and anterior tibialis.
215050360|NCT04494685|OTHER|Control group (Conventional physiotherapy)|Knee and hip flexion and extension movements, hip adduction, and abduction, respecting the articular physiology of each joint. Weight transfer will also be performed in the sitting and standing position, mini squat, and gait training. All exercises will have a total of 10 repetitions in three sets. In the end, stretching of the upper and lower limbs will be performed.
215050361|NCT01186276|DIETARY_SUPPLEMENT|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
215050362|NCT01186276|DIETARY_SUPPLEMENT|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
214892882|NCT03691727|DIAGNOSTIC_TEST|Vital Signs|Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
214892883|NCT03691727|OTHER|Standard of Care Treatment|Participants will receive standard of care treatment and will not receive study drug.
214892884|NCT00006760|BIOLOGICAL|filgrastim|subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
214892885|NCT00006760|DRUG|ifosfamide|V over 24 hours on days 1-4
214892886|NCT00006760|DRUG|vinorelbine tartrate|IV over 6-10 minutes on days 1 and 5.
214892887|NCT03200717|DRUG|Pazopanib|Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.
214892888|NCT02110784|DRUG|Eurartesim tablets|dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
214892889|NCT04597697|DRUG|Insulin icodec|Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
214892890|NCT02660905|DRUG|E/C/F/TAF;|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
214892891|NCT02660905|DRUG|Ledipasvir-Sofosbuvir|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
214892892|NCT03219827|OTHER|Human biological samples|Blood samples collection
214892893|NCT03580473|DRUG|SATURNO II association|opthalmic solution, 4 times a day
214892894|NCT03580473|DRUG|Vigadexa®|opthalmic solution, 4 times a day
214892895|NCT04663230|DIAGNOSTIC_TEST|cardiac magnetic resonance imaging|right atrial late gadolinium enhancement in % and cm2
214892896|NCT03657225|DEVICE|Utilization of the mini CPB circuit|Comparison of the mini CPB circuit to conventional circuit
214892897|NCT03657225|DRUG|Utilization of the conventional circuit|Comparison of the mini CPB circuit to conventional circuit
214892898|NCT02471040|DRUG|Beta-hydroxybutyrate|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
214892899|NCT02471040|OTHER|Normal Saline|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
214892900|NCT05919615|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
214892901|NCT05919615|DRUG|Normal saline|0.9% sodium chloride normal saline
214295962|NCT01777256|DRUG|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
214892902|NCT02449850|OTHER|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
214892903|NCT02449850|OTHER|Skin care|Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
214892904|NCT01050959|DEVICE|bion|
214892905|NCT03126448|DIAGNOSTIC_TEST|Highly Sensitive Assays|Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.
214892906|NCT03051672|DRUG|Pembrolizumab|Pembrolizumab (formerly MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD1 and its ligands, PD-L1 and PD-L2.
214892907|NCT03051672|RADIATION|Palliative radiotherapy|Palliative radiotherapy aims to shrink cancer, slow down its growth or control symptoms.
214892908|NCT06280339|BEHAVIORAL|Test two food cravings strategies during dietary weight loss|The intervention includes 12 online nutrition education sessions using the MealPlot App to track food intake and view the daily weight charts. Participants need to weigh themselves daily using a Wi-Fi scale. Participants will complete 12 asynchronous online diet improvement sessions (eText) lasting 45 minutes each. The 12 sessions will be conducted weekly for the intervention period (12 weeks). The following four sessions will be focused on creating consistent eating and sleeping patterns related to timing, frequency, and portion, as well as daily self-monitoring of weight. After that, participants will continue to complete the rest of asynchronous online diet improvement sessions, including personalized weight loss diets from their kitchen based on their diet practice and food preference, safe and efficient weight loss, weight maintenance and healthy eating, skills to select foods and create meals that prevent overeating, all to be completed by the end of 12 weeks.
215050363|NCT04050384|DEVICE|Baby GentleStick|The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
215050364|NCT05281913|OTHER|Psychoeducational Game|Psychoeducational Game
215050365|NCT01336816|OTHER|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
214295963|NCT01777256|DRUG|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
214295964|NCT01777256|DRUG|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
214295965|NCT00811551|DEVICE|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
214295966|NCT01962207|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
214295967|NCT00820131|PROCEDURE|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
214295968|NCT00820131|PROCEDURE|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
214295969|NCT01894451|DRUG|89Zr-bevacizumab|89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). 89Zr-bevacizumab-PET/CT will be performed in this study at baseline, after 2 cycles of preoperative chemotherapy and at the completion of chemotherapy.
214892909|NCT06280339|BEHAVIORAL|Dietary weight loss program +Food cravings strategies|The intervention includes 12 online nutrition education sessions using the MealPlot App to track food intake and view the daily weight charts. Participants need to weigh themselves daily using a Wi-Fi scale. Participants will complete 12 asynchronous online diet improvement sessions (eText) lasting 45 minutes each. The 12 sessions will be conducted weekly for the intervention period (12 weeks). The following four sessions will be focused on creating consistent eating and sleeping patterns related to timing, frequency, and portion, as well as daily self-monitoring of weight. After that, participants will continue to complete the rest of asynchronous online diet improvement sessions, including personalized weight loss diets from their kitchen based on their diet practice and food preference, safe and efficient weight loss, weight maintenance and healthy eating, skills to select foods and create meals that prevent overeating, all to be completed by the end of 12 weeks.
214892910|NCT03406754|BEHAVIORAL|rehabilitation programs|an 8-week multidisciplinary inpatient rehabilitation program
214892911|NCT03087500|OTHER|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
214892912|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 25 mg, once daily, 24 weeks
214892913|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 24 weeks
214892914|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 100 mg, once daily, 24 weeks
215050366|NCT01336816|OTHER|Placebo Wintergreen|Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
215050367|NCT05528406|DRUG|HLX208|900mg bid po
214892915|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 125 mg, once daily, 24 weeks
214892916|NCT00810147|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 24 weeks
214892917|NCT01395927|DRUG|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
214892918|NCT01395927|DRUG|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
214892919|NCT03248427|DRUG|Ribociclib|Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
214892920|NCT03248427|DRUG|Letrozole 2.5mg|Daily continuous
214892921|NCT03248427|DRUG|Doxorubicin|60 mg/m2 as a continuous IV perfusion
214892922|NCT03248427|DRUG|Cyclophosphamide|600 MG/M2 in a 30 minutes IV infusion
215050368|NCT01926743|PROCEDURE|Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy|0.75mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
214892923|NCT03248427|DRUG|Paclitaxel|80 mg/m2, in one hour IV infusion
214892924|NCT05311189|DRUG|HLX10, Trastuzumab and Chemotherapy|HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
214892925|NCT00317629|DRUG|controlled nitric oxide releasing patch|daily nitric oxide patch application during 20 days
214892926|NCT00317629|DRUG|meglumine antimoniate|20mg/kg daily during 20 days
214892927|NCT04211831|DRUG|URO-902|intradetrusor injection
214892928|NCT04211831|DRUG|Placebo|intradetrusor injection
214892929|NCT00898287|DRUG|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
215050369|NCT03816176|DRUG|Isavuconazonium sulfate|Intravenous (IV) infusion
215050370|NCT03816176|DRUG|Isavuconazonium sulfate|Oral capsule
214892930|NCT00898287|DRUG|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
214892931|NCT03697031|DRUG|Follitropin Delta|"The Intervention (solution for injection) is delivered with an injection pen. For women with AMH \<15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms."
215050371|NCT05178784|DEVICE|External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation|Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
215050372|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
214478085|NCT06392945|DEVICE|Cognitive Treadmill Walking Training with Rhythmic Auditory Cueing (CTW+RAC) group|Participants in the CTW+RAC group participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. To increase adaptability to rhythmic auditory cueing prior to cognitive treadmill walking training, participants are required to keep stepping on their feet while listening to the auditory cueing using a metronome program (Metronome APP) for 5 minutes of warm up. Then they start walking on a treadmill with a target speed and perform a cognitive task concurrently while listening rhythmic auditory cueing. According to previous research, the target treadmill speed at week 1, week 2, week 3, and week 4 is gradually increased from 90%, 100%, 110%, to 120% baseline walking speed of comfortable walking on the ground. The beat of rhythmic auditory cueing using the Metronome APP on the smartphone is set at 110% of baseline cadence of comfortable walking on the ground based on a previous study in individuals with stroke.
214892932|NCT05536063|PROCEDURE|bilateral erector spinae plane block in pediatric cardiac surgeries|The ESPB will be performed after induction of anesthesia, endotracheal tube insertion and before the start of operation, with the child in a right lateral decubitus position under aseptic precautions. A high frequency linear ultrasound transducer will be placed over the T4 transverse process lateral to the spinous process. After identifying the muscles above the hyperechoic transverse process image, a 5-cm 22 gauge needle will be inserted in-plane in a cephalo-caudad direction. The endpoint is defined as the needle pointing to the tip of transverse process piercing the erector spinae muscle. The local anesthetic will be deposited at this position, After careful negative aspiration, local anesthetic, according to study groups , The process will be repeated on thecontralateral side
214892933|NCT02833337|RADIATION|Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.
214892934|NCT01256879|DRUG|Drug: cimetidine|cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
214892935|NCT00397514|PROCEDURE|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
214892936|NCT01191450|DRUG|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
214892937|NCT01191450|DRUG|Higroton® Laboratório Novartis|Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
214892938|NCT02598050|OTHER|No Interventions as this is a observational study|
214892939|NCT06404099|DRUG|Modafinil|"Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks."
214892940|NCT06404099|DRUG|Modafinil Placebo|"The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
214892941|NCT06404099|DRUG|Solriamfetol|"The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase."
214892942|NCT06404099|DRUG|Solriamfetol Placebo|"The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
215050373|NCT05741476|OTHER|Placebo|DBV712 matching placebo epicutaneous system.
215050374|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
215050375|NCT03423433|BEHAVIORAL|Heel raise intervention|A daily heel-raise programme for ten weeks to determine any chronic effects of heel raises on the previously mentioned variables.
215050376|NCT05365516|OTHER|Implementing medical safety huddles|These short, virtual huddles are led by a huddle leader and occur on a weekly or once every two week basis. Each site will be adapting the Medical Safety Huddles for their context and workflow to specifically engage physicians.
215050377|NCT04810364|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
215050378|NCT05677477|OTHER|simulation training|A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
214295970|NCT01894451|PROCEDURE|FDG-PET/CT|FDG-PET/CT scan: Pictures of your organs will be taken using a PET (Positron Emission Tomography) scanner. At the same time, a CT (computed tomography) scan will be performed. FDG, a radioactive substance similar to glucose (or sugar), will be injected into your vein using a needle prior to performing the PET/CT scan. After the injection, you will be asked to sit quietly for one hour to let the FDG absorb into the body. After this hour, you will be asked to lie flat on your back for up to 50 minutes while the PET and CT images are being taken. This FDG-PET/CT scan is part of regular cancer care. If you have had this test within 14 days of study enrollment, you may or may not have to have this test repeated.
214478086|NCT06392945|DEVICE|Cognitive Treadmill Walking Training (CTW) group|Participants in the CTW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed and perform a cognitive task concurrently without rhythmic auditory cueing. Same cognitive training and target treadmill speed will be used as the CTW+RAC group during cognitive dual-task treadmill walking. Three cognitive training programs will be the verbal fluency, arithmetic, and visual distinguish tasks. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the 10 meters walk test at week 4.
214478087|NCT06392945|DEVICE|Treadmill Walking Training (TW)|Participants in the TW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed only, without concurrent performing a cognitive task and no listening rhythmic auditory cueing. Same target treadmill speed will be used as the other two groups during treadmill walking. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the ground.
214478088|NCT05138848|BEHAVIORAL|Time in Bed Restriction|Participants will undergo a 4-week sleep intervention that includes specified in- and out-of-bed times as well as a restriction to their habitual time in bed (average sleep opportunity including naps). This will be truncated equally at the beginning and end of the night.
214478089|NCT05138848|BEHAVIORAL|Sleep Schedule|Participants will maintain their typical sleep schedule for 4-weeks.
214892943|NCT05108831|DEVICE|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
214892944|NCT05650476|DRUG|Talazoparib|capsules
214892945|NCT03493685|DRUG|sparsentan|Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
214892946|NCT03493685|DRUG|Irbesartan|target dose of 300 mg daily
214892947|NCT05969821|OTHER|observational cohort study|observational cohort study
214892948|NCT05814627|DRUG|Upadacitinib|Oral Tablets
214892949|NCT05814627|DRUG|Adalimumab|Subcutaneous Injection
214892950|NCT05814627|DRUG|Upadacitinib Matching Placebo|Oral Tablets
215050379|NCT05441423|RADIATION|CBCT|CBCT Scans. conventional \& ultra low dose
215050380|NCT06467071|BEHAVIORAL|SH+ combined with a session for PMLD|The intervention integrates WHO's Self Help Plus (SH+) and a session for Post-Migration Living Difficulties (PMLD) for Syrian women. SH+ is a guided self-help program with five weekly sessions led by facilitators, aimed at managing stress and psychological distress without requiring a diagnosis. This scalable intervention is based on solid research, proven effective in reducing stress and preventing mental health disorders (Tol et al., 2020; Turrini et al., 2019). The PMLD session, based on WHO's Problem Management Plus (PM+), involves focus groups to identify post-migration challenges. Participants share experiences, learn coping strategies, discover local resources, and strengthen social support networks. This integrated approach aims to enhance mental health, address post-migration difficulties, and improve stress reduction skills, supporting adaptation to a new country.
215050381|NCT06395896|OTHER|Breast Cancer Prevention Journey Program Group|"The researcher will invite individuals to the study at Necip Fazıl Family Center and conduct a pre-test application. The day and time for the Fight Against Breast Cancer training, which is structured based on the Health Belief Model prepared by the researchers, will be determined and announced to the participants. The training will be held in a single session of 45-60 minutes. Slide presentation and a breast model showing the symptoms of breast cancer will be used as training materials. At the end of the training, it will be announced that free shuttle service will be provided for mammography screening and individuals will be invited to screening. On the specified day and time, participants will be taken to the Cancer Early Diagnosis, Screening and Education Center (KETEM) in Mamak and mammography screening will be performed. After the screening, a post-test will be performed."
214892951|NCT05814627|DRUG|Adalimumab Matching Placebo|Subcutaneous Injection
215050382|NCT06395896|OTHER|Routine Cancer Screening Program Group|Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. Health Ministry of Türkiye offers free mammography screening for breast cancer to women over the age of 40. In this context, women are called to the centers by phone and mammography screening is performed free of charge.
215050383|NCT00817323|PROCEDURE|Dietary amino-acid depletion|See detailed description
214892952|NCT04000880|BEHAVIORAL|Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
214892953|NCT04000880|OTHER|Diet-Exercise|Diet-Exercise
214892954|NCT04000880|OTHER|Exercise-Diet|Exercise-Diet
214892955|NCT04000880|OTHER|Combined Diet and Exercise|Combined Diet and Exercise
214892956|NCT03300817|OTHER|Laboratory Biomarker Analysis|Correlative studies
214892957|NCT03300817|BIOLOGICAL|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
214892958|NCT00265759|DRUG|anastrozole|Given PO
214892959|NCT00265759|DRUG|exemestane|Given PO
214892960|NCT00265759|DRUG|letrozole|Given PO
214892961|NCT00265759|PROCEDURE|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
214892962|NCT03802526|DRUG|NVP-1805-R1|1 tablet, multiple oral dosing
214892963|NCT03802526|DRUG|NVP-1805-R2|1 tablet, multiple oral dosing
214892964|NCT03802526|DRUG|NVP-1805-R1 and NVP-1805-R2|NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing
214892965|NCT06437015|DIAGNOSTIC_TEST|Constraint-Induced Movement Therapy|patient's unaffected hand is tied with a triangular bandage or splint and the patient asks to perform the exercise through the affected hand. for up to 6 hours a day for 5days week /4 weeks and the patient nonparetic arm restrained from the use by having the patient placing a mitt on the hand or a sling on the unaffected hand, forcing the use of the affected limb to promote purposeful movements when performing functional tasks.
214892966|NCT06437015|OTHER|Mirror Therapy|In this group training was given for 45min a day for 5 days a week for 4 weeks. Mirror box which was of 18×24inch \[was placed on the learning table and exercises were carried out by the patient looking into the mirror where an unaffected limb is placed in front of the mirror, through looking into the mirror patient assumes the reflection of the unaffected limb as the paretic limb. Exercises performed were hand opening and closing, wrist extension and flexion, squeezing, opposition, the calculation
214892967|NCT01159730|DRUG|VB-201 or Placebo|
214892968|NCT04430959|DRUG|Candesartan|Candesartan 4 mg, tablets, orally, once daily for 4 weeks
214892969|NCT04430959|DRUG|Placebo|Candesartan placebo-matching tablets, orally, once daily for 4 weeks
214892970|NCT04009759|DRUG|Morphine|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
214892971|NCT04009759|DRUG|Ketamine Injectable Solution|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
214892972|NCT04009759|DRUG|Saline 0.9%|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
214892973|NCT03847467|DRUG|2'-Fucosyllactose|Human milk oligosaccharide prebiotic dietary supplement
214892974|NCT03847467|OTHER|Placebo|Dextrose
215050384|NCT04472650|DRUG|Sitravatinib|Administered orally as a free base capsule
215050385|NCT04472650|DRUG|Sitravatinib|Administered orally as a malate salt capsule
215050386|NCT03121144|DEVICE|Masimo Centroid System|Noninvasive positional monitoring device
215050387|NCT00143000|DRUG|Peginterferon alfa-2a 40KD and Ribavirin|
215050388|NCT02159625|DEVICE|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
214295971|NCT01894451|PROCEDURE|MRI scan|• MRI Scan: MRI (Magnetic Resonance Imaging) scans of the breast will be taken. You will receive an injection of a dye before the MRI. You will be asked to lie flat on your back in the scanner for up to 30 minutes for pictures to be taken. This MRI scan is part of regular cancer care. If you have had this test within 14 days of study enrollment , you may or may not have to have this test repeated.
214295972|NCT01894451|PROCEDURE|Tumor biopsies|Tumor biopsies: Prior to starting your treatment, a radiologist will use breast MRI or ultrasound imaging to localize an area of your tumor in the breast for a research biopsy. The biopsy procedure is done in an outpatient setting using a done using a needle to obtain tissue. A local anesthetic will be given to minimize any pain; however, after the procedure you can expect some discomfort and possible bruising. This biopsy is part of research.
214295973|NCT03382392|OTHER|Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.|
214892975|NCT06021405|PROCEDURE|Tape stripping|a small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema
214892976|NCT03122730|COMBINATION_PRODUCT|VentaProst|epoprostenol for inhalation via custom drug delivery system
214892977|NCT05798182|DIAGNOSTIC_TEST|Ultrasound measurement|Study was conducted with Mindray T7 ultrasound machine using linear probe. Vascular ultrasound mode was used with settings depth of 50 mm and gain of 40 dB during the entire study period. The diameter and flow velocity of the brachial artery and wrist edema of the fist were measured within 24 hours of admission and the following day.
214892978|NCT01437436|PROCEDURE|ventilation tube|ventilation tube insertion
215050389|NCT01889394|PROCEDURE|secondary wound healing|secondary wound healing
215050390|NCT01889394|PROCEDURE|primary wound closure using a limberg flap|primary wound closure using a limberg flap
215050391|NCT01121055|DRUG|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
215050392|NCT01121055|DRUG|Control|Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
215050393|NCT02954224|OTHER|CPAP treatment|Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3
215050394|NCT03725072|DRUG|Evobrutinib|Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.
215050395|NCT03929354|BEHAVIORAL|Risk Factors Modification Programme|12-week supervised risk factor modification programme derived from the EuroAction Study standards.
215050396|NCT03929354|BEHAVIORAL|Standard Care|Patients advised to adjust lifestyle without the support of the structured supervised programme.
215050397|NCT02018484|PROCEDURE|Unicompartmental Knee Replacement|
214892979|NCT05642897|BEHAVIORAL|Mind|ACT, mindfulness, and compassion-based intervention
214892980|NCT05642897|BEHAVIORAL|Support Group|This intervention promotes the sharing of cancer-related experiences, active listening and a sense of community between participants.
214892981|NCT06404398|OTHER|OMNICHROMA, Ceram. x spectra|Each patient had two types of veneers.
214892982|NCT01861223|DRUG|afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)|
214892983|NCT01581437|PROCEDURE|64 pole basket catheter|The 64 pole basket catheter expands into a small flexible balloon that conforms to the atrial anatomy.
214892984|NCT04203342|DRUG|Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
214892985|NCT04203342|DRUG|Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
215050398|NCT01101672|PROCEDURE|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
215050399|NCT01101672|PROCEDURE|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
215050400|NCT00288015|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
215050401|NCT01333722|DRUG|Hydrocodone/Acetaminophen Extended Release|
214892986|NCT04203342|DRUG|Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)|Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
214892987|NCT03729596|BIOLOGICAL|vobramitamab duocarmazine|Anti-B7H3 antibody drug conjugate
214892988|NCT04704453|DRUG|Capsaïcin patch (Qutenza®)|Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).
214892989|NCT04704453|DRUG|Amitriptyline (Laroxyl®)|Treatment by amitriptyline (oral solution 40mg/ml), for 9 months at the recommended dose of 25 mg to 75 mg daily.
214892990|NCT04467840|DRUG|Opaganib|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
214892991|NCT04467840|DRUG|Placebo|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
214892992|NCT04961515|DRUG|Orelabrutinib|Orelabrutinib: 150 mg orally once daily
215050402|NCT01333722|DRUG|Placebo|Placebo tablet
215050403|NCT01440673|DRUG|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
215050404|NCT01478464|OTHER|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
215050405|NCT01374321|DRUG|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
215050406|NCT01374321|DRUG|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
215050407|NCT05653245|DRUG|RGD Peptide|adhesion molecules
215050408|NCT03865433|OTHER|Aerobic Exercise|Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
215050409|NCT03865433|OTHER|Placebo/Stretching|A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
214295974|NCT04926350|BEHAVIORAL|Resistance Exercise|8 total resistance exercises that target all major muscle groups
215050410|NCT03955783|DRUG|Venetoclax|Given by mouth
215050411|NCT03955783|DRUG|Selinexor|Given by mouth
214295975|NCT00924456|BEHAVIORAL|Transcendental Meditation program|a natural effortless mental technique
214295976|NCT04193657|OTHER|Daily and weekly triggered symptom monitoring|Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.
214295977|NCT03715166|DRUG|Bumetanide Oral Solution|Oral Solution dosed at 0.5mg/mL Taken twice daily
214295978|NCT03715166|DRUG|Placebo|Oral Solution Taken twice daily
214295979|NCT02484729|DRUG|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
214295980|NCT02484729|DRUG|Placebo, oral suspension|Matching placebo
214295981|NCT02484729|DRUG|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
214295982|NCT02760667|DRUG|Cisplatinum|Cisplatin 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
214478090|NCT03946358|BIOLOGICAL|Blood sample collection|"Four blood samples will be collected at:~* baseline~* 2 months from inclusion (+/- 1 week)~* 4 months from inclusion (+/- 1 week)~* the end of vaccination visit (+/- 1 week).~A total of 8 EDTA (ethylenediaminetetraacetic acid) tubes of 6 ml will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: One 6 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
214892993|NCT04961515|DRUG|Sintilimab|Sintilimab: 200 mg intravenously every 3 weeks
214892994|NCT04961515|DRUG|Temozolomide (TMZ)|Temozolomide: 150 mg/m² orally on days 1-5 of each 21-day cycle
214892995|NCT06556199|DRUG|Selinexor|Selinexor dose escalation: 40,60,80mg respectively every week, and dose expansion at the RP2D of Selinexor,every 3 weeks for 6 cycles.
214892996|NCT06556199|DRUG|Temozolomide|Temozolomide 150mg/m2 po d1-5 every 3 weeks for 6 cycles.
214892997|NCT06556199|DRUG|Anti-PD-1 monoclonal antibody|The dose of anti-PD-1 monoclonal antibody is fixed dose 200 mg intravenously every 3 weeks until until disease progression or recurrence, intolerance of toxicity, death, loss of follow-up, withdrawal of notification (whatever happened first).
214892998|NCT06650007|DRUG|HRS9531 Injection|HRS9531 Injection
214892999|NCT06650007|DRUG|HRS9531 Placebo Injection|HRS9531 Placebo Injection
214893000|NCT04025905|BEHAVIORAL|Social Cognition Training|Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.
214893001|NCT04025905|BEHAVIORAL|Informations|informations about work environment, social environment, stress management, sleep management, treatments
214893002|NCT04408183|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
214893003|NCT04408183|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
214893004|NCT04987229|DRUG|OLZ/SAM|Olanzapine and Samidorphan fixed dose coated tablet taken once daily
214893005|NCT06261970|BEHAVIORAL|Connect|Community level enhancements
215050412|NCT01641107|DRUG|Ponatinib|"Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion."
215050413|NCT03598049|DEVICE|densah burs osseo densification drills|osseo densification of the alveolar bone in maxillary posterior ridge during implant placement
215050414|NCT03598049|DEVICE|conventional surgical burs drilling|conventional implant osteotomy site drilling with implant surgical kit
214893006|NCT06794658|DEVICE|software|Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to diabetes.
215050415|NCT03819387|DRUG|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
215050416|NCT02268110|OTHER|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
215050417|NCT02268110|OTHER|Abdominal binding|Wearing an abdominal binder for 12 weeks
215050418|NCT04380623|BEHAVIORAL|Mobile Phone-Based Web-Page: HPV vaccine|Website to be accessed via mobile phone to deliver tailored educational material
214893007|NCT02593565|OTHER|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
214893008|NCT05732064|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
214893009|NCT05732064|DRUG|Esketamine|Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
214893010|NCT05732064|DRUG|Normal saline|Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
214893011|NCT06447103|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214893012|NCT06447103|PROCEDURE|Bone Scan|Undergo bone scan
214893013|NCT06447103|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and CT of the brain
214893014|NCT06447103|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI of the brain
214893015|NCT06447103|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214893016|NCT06447103|OTHER|Questionnaire Administration|Ancillary studies
214893017|NCT06447103|DRUG|Zirconium Zr 89 Girentuximab|Given IV
214893018|NCT06482749|DEVICE|Repetitive transcranial magnetic stimulation|"Repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 6-8 pm\], no intervention on the day of the surgery). Parameters of rTMS: 8 shaped coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
214893019|NCT06482749|DEVICE|Sham stimulation|"Sham repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 6-8 pm\], no intervention on the day of the surgery). Parameters of rTMS: 8 shaped sham coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
214295983|NCT02760667|DRUG|Docetaxel|Docetaxel 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
214295984|NCT02760667|DRUG|Carboplatin|Carboplatin AUC=5 every 3 weeks for a maximum of 3 cycles during the induction phase (if subject are unable to tolerate cisplatin)
214295985|NCT02760667|PROCEDURE|Transoral Robotic Assisted Surgery|TORS will be performed for the patients who responded to the induction treatment (80% reduction)
214295986|NCT03194698|DEVICE|Intense Pulsed Light Treatment (IPL)|IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.
214295987|NCT03194698|PROCEDURE|Meibomian Gland Expression|Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
214893020|NCT04213625|OTHER|Surgeon Personal Background|"Experimental group will receive an information sheet with their surgeon's educational and personal background.~Personal Background~* Favorite outdoor activity/form of exercise~* Favorite hobby~* Family information (children, pets)~* Single sentence about how the clinician conceptualizes excellent patient care"
214893021|NCT05537155|PROCEDURE|Buccal acupuncture in addition to routine care|"Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed."
214893022|NCT05537155|OTHER|Routine care|Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
214893023|NCT05793151|BEHAVIORAL|ENDURE|ENDURE provides patient education through the ENDURE Patient Resource Guide and social support by linking patients to community resources (patient-level), standardizes discussions about expectations for PORT and clinical documentation to enhance communication and care coordination within and across interprofessional cancer teams (team-level), and implements referral tracking across fragmented health systems (organization-level). To facilitate care coordination, ENDURE modifies existing standard of care patient navigation (an evidence-based intervention that addresses barriers to timely cancer care) by adding PORT-focused navigation at three key care transitions: into the cancer care system; from inpatient to outpatient after surgery; and from the surgical team to the radiation oncology team.
214893024|NCT05527041|DEVICE|EyeBOX Lens (EBLens)|"The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:~* Gaze coordinates~* Pupil sizes~* Accelerometer data~* Gyroscopic data~* Rotation data~* Blink data"
214893025|NCT06540196|DIAGNOSTIC_TEST|NodeAI|The ultrasound video and images of each LN will be analyzed by NodeAI, which will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
214295988|NCT05899309|DIAGNOSTIC_TEST|liver and spleen stiffness test and laboratory test|Diagnosis of cirrhosis can be based on liver biopsy,radiological ,clinical or liver stiffness measurement (LMS)
214295989|NCT06187727|DRUG|Henagliflozin|After primary PCI, Henggliflozin or Placebo was administered within 24 hours, followed by daily oral administration until 6 months post-acute myocardial infarction.
214295990|NCT06128395|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
214295991|NCT06138106|DIETARY_SUPPLEMENT|Natural Product Supplement|Participants will have blood drawn before and one hour after consuming the natural product supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
214295992|NCT06138106|DIETARY_SUPPLEMENT|Placebo control|Participants will have blood drawn before and one hour after consuming the placebo supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
214295993|NCT00696176|DRUG|STAT 3 DECOY|single administration to a head and neck tumor
214295994|NCT01980875|DRUG|Idelalisib|150 mg tablet administered orally twice daily
214295995|NCT01980875|DRUG|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
214478091|NCT03946358|PROCEDURE|Tumor biopsies|A tumor biopsy will be realized and centralized at baseline and at 2 months. Collection of tumor biopsies will be guided by ultrasound or CT scan
214478092|NCT03946358|OTHER|CT scan|"A CT scan will be planned~* at baseline~* at tumor evaluation visit (8 weeks)~* every 8 weeks (+/- 1 week)~* at end of treatment visit."
214478093|NCT03946358|DRUG|Atezolizumab|"Induction phase: Atezolizumab 1200 mg intravenous every 3 weeks since day 1~Boost phase: Atezolizumab 1200 mg intravenous every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
214295996|NCT01980875|DRUG|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
214295997|NCT02625259|DRUG|TAK-117|TAK-117 capsules
214295998|NCT02625259|DRUG|Lansoprazole|Lansoprazole capsules
214295999|NCT02625259|DRUG|TAK-117|TAK-117 tablets
214296000|NCT00665847|DRUG|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
214893026|NCT06540196|DIAGNOSTIC_TEST|Surgeon|The ultrasound video and images of each LN will first be analyzed by the surgeon, who will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
214893027|NCT05319509|DEVICE|gameChange|Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus. Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete. The participant will put on the Oculus headset, and go through a preliminary orientation game. The headset will be casted to an external monitor. Once they start gameChange, it will take the participants to the virtual therapist's room. They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario. Research staff will be taking event sampling-style observations of the participant. After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.
214893028|NCT04500119|BEHAVIORAL|Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator|Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried), apply intermittent electrical stimulation (Blackrock Cerestim)
214893029|NCT04673175|DRUG|Ceftolozane / Tazobactam Injection|Zerbaxa (ceftolozane/tazobactam) for injection is supplied as a white to yellow sterile powder for reconstitution in single-use vials; each vial contains 1 g ceftolozane (equivalent to 1.147 g of ceftolozane sulfate) and 0.5 g tazobactam (equivalent to 0.537 g of tazobactam sodium).
214893030|NCT05150704|DRUG|Methylprednisolone|Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care
214893031|NCT05150704|DRUG|saline solution|Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
214893032|NCT05126693|OTHER|Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.|BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks. During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
214893033|NCT04483583|DRUG|Ticagrelor 60mg|Patients will be administered a 180 mg loading dose followed by a 60 mg bid for the duration of the study.
214893034|NCT04483583|DRUG|Clopidogrel|Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.
214893035|NCT04761926|DEVICE|Audiometry|"Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit.~Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)).~Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off."
214893036|NCT00765687|DRUG|bisphosphates|any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
214893037|NCT06437054|DRUG|Dexamethasone|Dexamethasone 5mg/ml
214893038|NCT06437054|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
214893039|NCT06437054|OTHER|Indocyanine green(ICG)|ICG 25mg
214478094|NCT03946358|DRUG|UCPVax|"Induction phase: UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase: UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)."
214893040|NCT06377241|DEVICE|ScentAware|ScentAware is a smell test
214893041|NCT06377241|DEVICE|UPSIT|UPSIT is a smell test
214893042|NCT05327530|DRUG|Avelumab|Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
214893043|NCT05327530|DRUG|Sacituzumab Govitecan|Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
214893044|NCT05327530|DRUG|M6223|Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
214893045|NCT05327530|DRUG|NKTR-255|Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
214893046|NCT02732730|DRUG|Truvada|400 women who accept to initiate PrEP
214893047|NCT02732730|BEHAVIORAL|Drug level counseling at Weeks 8 and 13|Women who are randomized to enhanced counselling will have adherence monitoring based on plasma TFV levels obtained 4 and 8 weeks after PrEP acceptance
215050419|NCT05940506|DRUG|KX-826-2.5 mg (0.25%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
214296001|NCT00665847|DRUG|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir \[LPV\], darunavir \[DRV\], atazanavir \[ATV\] or saquinavir \[SQV\]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N\[t\]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
214296002|NCT04890223|BEHAVIORAL|Brief MI intervention|Brief MI intervention
214296003|NCT04890223|BEHAVIORAL|Placebo intervention|Generic health advice consultations and self-help smoking cessation booklets
214478095|NCT06622252|OTHER|13-week session program|The newly designed intervention was split into three major components - Healthy Literacy, Caregiver Wellness, and Culturally Competent Care and is delivered throughout a 13-session program delivered via Zoom. Sessions are guided by a psychologist, nutritionist, spirituality specialist, social worker, case coordinator, oncologist and traditional Chinese medicine practitioner. Sessions are intended for caregivers specifically, however, other members of the family may join if they choose to.
214668466|NCT05154747|DRUG|Cabotegravir, Rilpivirine Drug Combination|"Cabotegravir LA 600mg as a 3mL IM injection. The product is packaged in a 3mL USP Type I glass vial. Each vial is for single-dose use. CAB LA injectable suspension is to be stored according to the product label at room temperature (\<30oC). CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol3350, mannitol, and water for injection.~Rilpivirine LA 900mg as a 3mL IM injection. Each single-dose vial contains 900mg/3mL rilpivirine. RPV LA injectable suspension should be stored according to the product label refrigerated at 2-8oC and should be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, and water for injection.~Cabotegravir Long-Acting (CAB LA) will be given IM into one buttock, and Rilpivirine Long-Acting (RPV LA) will be given IM into the opposite buttock."
214668467|NCT05154747|DRUG|TLD|Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination or Dolutegravir 50mg oral with tenofovir alafenamide fumarate (25mg) and lamivudine (300mg) (l/TAF) oral in a fixed dose combination
214668468|NCT04282928|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Definitive Human umbilical cord mesenchymal stem cells selected by immunomodulatory assay through coculture with BV2 cell
214296004|NCT03404557|OTHER|Proteomic analysis|Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
214478096|NCT06869460|RADIATION|Stereotactic Body Radiotherapy/Radiosurgery|Stereotactic Body Radiotherapy/Radiosurgery
214893048|NCT00218933|BEHAVIORAL|Moderate intensity exercise training|12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)
214893049|NCT00218933|BEHAVIORAL|High intensity exercise training|12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
214893050|NCT04335890|BIOLOGICAL|Vaccination with IKKb matured Dendritic Cells|IKKb matured autologous monocyte derived dendritic cells loaded with RNAs; intravenous Infusion with a dose escalation starting with 7.5 mio Dendritic Cells for the first vaccination up to 30 mio cells per vaccination
214893051|NCT03262428|OTHER|Semi-structured interviews|Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.
214893052|NCT00929968|BIOLOGICAL|Placebo|
214893053|NCT00929968|BIOLOGICAL|VAK694|
214893054|NCT00929968|DRUG|Fluticasone|
214893055|NCT03523741|DRUG|Clozapine|Clozapine is administered orally according to individual prescribed dosing regimens.
214893056|NCT04937413|DRUG|Evolocumab|Evolocumab subcutaneous injection
214893057|NCT06336434|DRUG|CAB LA 600mg|600mg (3mL) IM Injection
214893058|NCT06336434|DRUG|RPV LA 900mg|900mg (3mL) IM Injection
214893059|NCT06336434|DRUG|CAB LA 400mg|400mg (2mL) IM Injection
214893060|NCT06336434|DRUG|RPV LA 600mg|600mg (2mL) IM injection
214893061|NCT03582462|DRUG|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection
214893062|NCT03582462|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
214893063|NCT00443729|DRUG|Comparator: raltegravir|raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
214893064|NCT00443729|DRUG|Comparator: placebo|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
214893065|NCT00443729|DRUG|Comparator: lopinavir (+) ritonavir|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
214893066|NCT00443729|DRUG|Comparator: placebo|raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
214893067|NCT01090778|DRUG|Norditropin SimpleXx (growth hormone)|3mg/subject/day over two consecutive days
214893068|NCT00834509|DEVICE|CPAP|Use CPAP for 4-6 weeks as clinically prescribed.
214893069|NCT02632266|DIETARY_SUPPLEMENT|Powder HMF|powder human milk fortifier
214893070|NCT02632266|DIETARY_SUPPLEMENT|Liquid HMF|Liquid human milk fortifier
214893071|NCT04487613|DRUG|Moringa oleifera leaf|450 mg capsule
214893072|NCT04487613|DRUG|Placebo|placebo capsule
214893073|NCT06069219|DRUG|Epidural administration of sufentanil|The epidural cannulations were placed by anesthesiologists before general anesthesia. Correct positioning of the catheters were tested and confirmed by negative aspiration and injection of 3 mL of 2% Lidocaine. The epidural infusion (solution of 0.2 % ropivacaine 5 ml with 25 to 50 mcg sufentanil in 50 ml of 0,9% NaCl) was started with bolus of 5 ml over 5 minutes and then continuous infusion was maintained was throughout the surgery at 3-12 mL/h and 2-12 mL/h after the surgery. Single dose of sufentanil was given when needed.
214668469|NCT04282928|PROCEDURE|Routine treatment|"According toInfluenza diagnosis and treatment plan (2019 version)"
214668470|NCT05869643|DRUG|Low-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
214668471|NCT05869643|DRUG|Medium-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
214668472|NCT05869643|DRUG|High-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
214668473|NCT05869643|DRUG|Placebo|Matching placebo capsule, taken orally once daily after breakfast
214893074|NCT04347577|DRUG|duloxetine|open-label study
214893075|NCT01666626|PROCEDURE|Ultrasound stiffness imaging|Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
214893076|NCT05295225|DEVICE|Green Light Emitting Diode|GLED exposure for two hours
214893077|NCT05295225|DEVICE|White Light Emitting Diode|WLED exposure for two hours
214893078|NCT01158235|DRUG|LTX-109|1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.
214893079|NCT03482518|OTHER|custom slippers with perforated synthetic leather cover.|the intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover.
214893080|NCT05430243|DRUG|Empagliflozin 10 MG|once daily empagliflozin 10mg+/- diuretics
214893081|NCT05430243|DRUG|Diuretics|diuretics as clinically indicated
214893082|NCT01356823|BIOLOGICAL|30μg HPV|Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
214893083|NCT01356823|BIOLOGICAL|60μg HPV|Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
214893084|NCT01356823|BIOLOGICAL|90μg HPV|Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
214893085|NCT01356823|BIOLOGICAL|Hepatitis B vaccine|Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
214893086|NCT03098719|BEHAVIORAL|Active Mobility|see detailed discription
214893087|NCT01365819|DRUG|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
214893088|NCT01365819|DRUG|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
214893089|NCT01159808|DRUG|INX-08189|3, 25 and 100 mg capsules; oral administration, single dose
214893090|NCT01159808|DRUG|Placebo|matching placebo capsules, oral administration, single dose
214893091|NCT04311372|BEHAVIORAL|Educational Sesssion+Material+Videos|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
214893092|NCT04311372|BEHAVIORAL|Educational Sesssion+Material ONLY|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
214893093|NCT02673736|DRUG|PLX73086|
214893094|NCT04485442|OTHER|data collection by questionnaires|psychological well-being in patients evaluated by Patient Reported Outcomes (PRO)
214893095|NCT04485442|OTHER|data collection (photos of the patients' tumors)|photos of the patients' tumors will be taken at baseline and at follow-up after the surgery
214893096|NCT05389137|BIOLOGICAL|Inavtivated Quadrivalent Influenza Virus Split Vaccine|Prevent influenza caused by H1N1, H3N2, B (V), B (Y) strain virus infection.
214478097|NCT06869395|OTHER|Questionnaire|"The responses obtained will be recorded as follows:~\- Referred to a dentist~\- Referred to a physician~\- Prescribed an over the counter (OTC) preparation~\- Prescribed an OTC preparation and referred to a dentist or a physician~\- Wanted to see the patient~\- Other answers: ……….."
214668474|NCT03951571|DRUG|Anlotinib Hydrochloride|Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
214893097|NCT00815932|DEVICE|TDCS/sham procedure on five consecutive days|The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
214893098|NCT02708628|DRUG|extract of allium cepae, allantoin and heparin|prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
214893099|NCT02708628|PROCEDURE|Scar excision|Scar excision in second c-section
214893100|NCT03244761|PROCEDURE|The modified HFT|The HFT was modified by increasing the expiratory resistance.
214893101|NCT01629628|DRUG|Adalimumab|Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
214668475|NCT03951571|DRUG|Placebo Oral Tablet|Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
214893102|NCT01629628|DRUG|6 Mercaptopurine|"6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~\--------------------------------------------------------------------------------"
214893103|NCT03045211|DEVICE|Dynamic Standing Table|The dynamic standing table is a height-adjustable standing table which gives periodic cues to the user to make stepping movements.
214893104|NCT06381206|DRUG|Silodosin|Selective Alpha Blocker drug
214893105|NCT01858844|OTHER|CHEST COMPRESSION TECHNIQUE (CCT)|The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.
214893106|NCT00902772|DRUG|Lorazepam|mg, oral dose
214893107|NCT00902772|DRUG|AZD7325|mg, oral dose
214893108|NCT00902772|DRUG|Placebo|
214893109|NCT04140305|DRUG|RPC-1063|Oral capsule
214668476|NCT06562816|DRUG|Trypsin-Chymotrypsin|100000 IU
214668477|NCT06562816|DRUG|Naproxen Sodium 550mg|550mg
214893110|NCT05481853|PROCEDURE|One Anastomosis Gastric Bypass|
214893111|NCT05526638|RADIATION|ultraviolet phototherapy|thrice weekly sessions of ultraviolet phototherapy
214893112|NCT00100672|DRUG|LErafAON-ETU|
214893113|NCT03503669|BEHAVIORAL|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
214478098|NCT06871150|DEVICE|Flotrac sensor|"Traditional management of hemodynamic parameters and intraoperative fluids without the aid of predictive tools based on artificial intelligence.~Possibility of having advanced hemodynamic analysis tools such as SV (stroke volume), SVV (stroke volume variation), PPV (pulse pressure variation), CO (cardiac output).~The anesthetist will decide whether to administer fluids, vasopressors, or other pharmacological interventions to maintain hemodynamic stability basing on clinical hemodynamic parameters derived from pulse contour systems, in accordance with a specific flowchart.~Interventions will be applied when blood pressure decreases, or clinical signs of instability are observed"
214668478|NCT03806452|DRUG|Hydroxycarbamide|Hydroxycarbamide tablets of 100 and 1000 mg
214668479|NCT03806452|DRUG|Placebo Oral Tablet|Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
214668480|NCT06445322|DIAGNOSTIC_TEST|Prescreening Assessments|Various genetic and visual assessments.
214668481|NCT02749487|OTHER|Neutrophil Lymphocyte Ratio|Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
214893114|NCT03503669|BEHAVIORAL|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
214893115|NCT04968834|GENETIC|Genomic profiling|Genomic profiling using CLIA assay
214893116|NCT03689465|DRUG|ATG|In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
214893117|NCT03689465|DRUG|CTX|In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
214893118|NCT03689465|DRUG|Mycophenolate Mofetil|In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
214893119|NCT03689465|DRUG|Ciclosporin A (CsA)|In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
214893120|NCT03689465|DRUG|methotrexate (MTX)|In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
214893121|NCT01027325|OTHER|Dietary Intervention|Starch digestibility and carbohydrate quantity
214893122|NCT01108614|BEHAVIORAL|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
214893123|NCT04016519|OTHER|Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
214893124|NCT01951924|DRUG|Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
214893125|NCT01951924|DRUG|Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
214893126|NCT00738387|DRUG|ASA404|1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
214893127|NCT00738387|DRUG|Placebo|Placebo i.v. on day 1 of each 21 day cycle
214893128|NCT00738387|DRUG|docetaxel|75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
214893129|NCT03469232|DRUG|Huanglian-Jiedu Decoction|Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
214893130|NCT03977948|OTHER|semi-structured systemic interview|Semi-structured systemic interviews will be conducted with families who have benefited from the preparation for surgery through play. Other tools such as the logbook and the socio-demographic questionnaire will also be used. The themes that will emerge from these interviews will provide a better understanding of what these families are going through, how the proposed intervention may or may not have met their expectations, and provide insights so that health care services can build their own surgical preparation programs.
214893131|NCT03575208|BIOLOGICAL|hepatitis B immune globulin (HBIg)|HBIg 20,000 U/L iv. Dosing interval will depend on anti-HBs levels.
214893132|NCT03575208|DRUG|Pegylated interferon alfa (pegIFN)|peginterferon alfa-2a 180 mcg weekly for 24 weeks
214893133|NCT04898699|DEVICE|UrSure Rapid Urine Tenofovir Test|A point of care urine immunoassay to measure PrEP drug levels for adherence in participant urine samples over the preceding seven days will be done at all follow-up visits. At enrollment, study staff will explain the use of this experimental measurement of PrEP drug level in urine samples. Participants will receive results of the test at the same study visit during which it is performed.
214893134|NCT04898699|DEVICE|OraQuick Rapid HIV Self-test kit|Participants will be provided with HIV self-testing kits to use at their discretion and, in case of multi-month dispensing, prior to start of new bottle of PrEP medication, in between study visits. HIV self-testing kits will be provided to confirm their HIV-negative status and make a connection between PrEP use and protection against HIV. Participants will receive detailed, interactive training on HIVST with pictorial elements, including instructions to contact study staff immediately in event of a reactive test for confirmation as per Kenya guidelines.
214893135|NCT04898699|DRUG|Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®]|Information will be provided regarding dosing of PrEP medications, importance of daily adherence, importance of frequent HIV testing, and signs and symptoms of drug toxicity, acute HIV infection and STIs. An initial one-month supply (30 pills) of FTC/TDF will be given to all PrEP study participants. At the one-month study assessment, a two-month supply of daily oral FTC/TDF will be given to each participant, after HIV testing, assessment for acute HIV infection and review of side effects and adherence, following national guidelines and procedures for PrEP services. At Month 3 assessment, a three-month supply of oral FTC/TDF will be given.
214893136|NCT04898699|BEHAVIORAL|2-way text message reminders|"All participants will receive weekly SMS visit reminders to support PrEP adherence. Participants will be asked at study enrollment for a primary contact telephone number and an alternate number for contact. Participants without cell phones will be provided an inexpensive cell phone (although cell phone ownership is very high in Kenya). Participants will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, use of HIV self-test kit, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with any questions, concerns or messages that they have for the study staff."
214893137|NCT04898699|BEHAVIORAL|HIV risk-reduction counseling|All study participants will be provided with brief interactive counseling at each study visit, tailored to the results of their urine assay.
214893138|NCT05236335|DIETARY_SUPPLEMENT|Ketone ester|Commercially available ketone supplement
214893139|NCT05236335|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
214893140|NCT03158103|DRUG|MEK162|MEK162 at 30mg twice daily
214893141|NCT03158103|DRUG|Pexidartinib|pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)
214893142|NCT05580250|DRUG|LY3526318|Administered orally.
214893143|NCT05580250|DRUG|Placebo|Administered orally.
214893144|NCT05580250|DRUG|Iohexol|Administered intravenously (IV).
214893145|NCT05580250|DRUG|Simvastatin|Administered orally.
214893146|NCT05580250|DRUG|Metformin|Administered orally.
214893147|NCT00004012|DRUG|capecitabine|
214668482|NCT05113004|DRUG|Hydroxychloroquine 400mg/d|Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
214668483|NCT05113004|DRUG|Leflunomide 20mg/d|Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
214668484|NCT05113004|DRUG|Mycophenolate mofetil 2000mg/d|Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
214668485|NCT05113004|DRUG|Placebo of Hydroxychloroquine 400mg/d|Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
214668486|NCT05113004|DRUG|Placebo of Leflunomide 20mg/d|Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
214668487|NCT05113004|DRUG|Placebo of Mycophenolate mofetil 2000mg/d|Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
214668488|NCT03389334|OTHER|massage|The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
214668489|NCT06272214|RADIATION|Adjuvant radiotherapy|"The start time for radiotherapy is 4-6 weeks after surgery, typically not exceeding 8 weeks. Intensity-modulated radiation therapy (IMRT) will be used, with a total dose of 45Gy administered in 25 fractions, five times per week.~The recommended target delineation for radiotherapy is based on the Chinese guidelines for radiation therapy of esophageal cancer, which mainly covers the high-risk lymph node area."
214668490|NCT06272214|OTHER|Observation|Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year or until tumor progression.
214668491|NCT04186208|DRUG|NOVOCART 3D|Autologous Chondrocyte Implantation
214668492|NCT04069767|PROCEDURE|ICoreDIST|"The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~1. Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~2. Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~3. Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~4. Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~5. Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~6. Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking."
214668493|NCT04069767|PROCEDURE|Standard Care|According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
214668494|NCT04513418|DIETARY_SUPPLEMENT|Preoperative immunonutrition|Preoperative immunonutrition includes an omega-3 fatty-acid enriched enteral nutritional emulsion given by oral intake, nasogastric feeding tube or jejunostomy 600ml per day, lasting for the whole period of neoadjuvant chemoradiation. Meanwhile, oral intake is encouraged to reach 25-30kcal/kg through regular food.
214668495|NCT06145425|OTHER|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based mindfulness training (audio files).
214668496|NCT04363307|DEVICE|AF Ablation|Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT
214668497|NCT04363307|DEVICE|MRI|Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation
214668498|NCT03351244|DRUG|BI 409306|28 week treatment period
214668499|NCT03351244|DRUG|Placebo|28 week treatment period
214668500|NCT06584279|DIAGNOSTIC_TEST|Biopsy of the prostate and pathological diagnosis|Whether the index-lesion-contralateral systematic biopsy was performed
214668501|NCT04998656|DEVICE|Werewolf FLOW 50|Use of Werewolf FLOW 50 electrocautery device during surgical treatment for ACL injury. This device is often used as standard of care when our other standard of care approach (use of no electrocautery device) is not used.
214668502|NCT04998656|OTHER|Control|Use of no electrocautery device during surgical treatment for ACL injury. This approach is often used as standard of care when our other standard of care approach (use of Werewolf FLOW 50 electrocautery device) is not used.
214668503|NCT04788628|OTHER|Baseline|Hippocampal and scalp EEG monitoring during overnight sleep
214668504|NCT04788628|OTHER|Motor procedural memory task|Training on the finger tapping MST prior to monitored overnight sleep with MST testing the following morning
214668505|NCT04788628|OTHER|Motor procedural memory task plus auditory stimulation|Training on the finger tapping MST prior to monitored overnight sleep that includes auditory stimulation, with MST testing the following morning
214668506|NCT05772494|OTHER|Assessment of activity limitations, SDO and DOA|The assessment is made with two instruments (DOA, SDO), and finally the occupational therapist includes the analysis and summary of activity limitations to the sickness certificate. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
214668507|NCT05772494|OTHER|Control group|All assessments concerning activity limitations are made using usual routines, primarily by the sick-listing physician. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
214668508|NCT06161415|DRUG|Laquinimod eye drops|n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned
214668509|NCT04291157|OTHER|CVD risk estimation incorporating the PRS and guideline based preventive interventions.|Total CVD risk estimation using SCORE plus PRS and European Society of Cardiology (ESC) CVD prevention guideline based interventions.
214668510|NCT04291157|OTHER|Standard GP care|Usual GP care (opportunistic CVD prevention)
214668511|NCT01241539|DRUG|Dabigatran etexilate|150 mg capsule
214668512|NCT01241539|DRUG|Dabigatran etexilate|75 mg capsule
214668513|NCT01241539|DRUG|Dabigatran etexilate|110 mg capsule
214668514|NCT01349738|DRUG|Antibiotic|Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
215050420|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL QD|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.
215050421|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
214296005|NCT00935844|DRUG|TAK-901|"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
214296006|NCT02530554|DRUG|CHG|Single application
214296007|NCT04432857|DRUG|AN0025|oral administration
214296008|NCT04432857|DRUG|Pembrolizumab|Infusion
214296009|NCT01441310|PROCEDURE|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
214296010|NCT04878588|OTHER|patients received high resolution impedance manometry|patients received the above two examination at the same time
214296011|NCT02987920|DRUG|Dextromethorphan|Additional medication to perioperative analgesic regimen in Group B
214296012|NCT02987920|DRUG|Placebo - Concentrate|Additional medication to perioperative analgesic regimen to Group A
214296013|NCT02987920|DRUG|Acetaminophen|Multimodal analgesic regimen to Group A and Group B
214296014|NCT02987920|DRUG|Oxycodone|Multimodal analgesic regimen to Group A and Group B
214296015|NCT02987920|DRUG|Celecoxib|Multimodal analgesic regimen to Group A and Group B
214296016|NCT02987920|DRUG|Pantoprazole|Multimodal analgesic regimen to Group A and Group B
214296017|NCT02987920|DRUG|Ketorolac|Multimodal analgesic regimen to Group A and Group B
214296018|NCT02987920|DRUG|Gabapentin|Multimodal analgesic regimen to Group A and Group B
214296019|NCT02987920|DRUG|Hydromorphone|Multimodal analgesic regimen to Group A and Group B
214296020|NCT02707250|DRUG|Placebo|Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
214296021|NCT02707250|DRUG|Bupivacaine|Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
214296022|NCT02707250|DRUG|Pethidine|Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
214296023|NCT02707250|DRUG|Pethidine Local Infiltration (L.I)|Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
214296024|NCT03359447|DRUG|Weekly Ferrous Sulfate|Drops
214296025|NCT03359447|DRUG|Daily Ferrous Sulfate|Drops
214296026|NCT04845789|OTHER|Non-interventional|Non-interventional. Interview would be conducted for data collection.
214296027|NCT04802460|DEVICE|Virtual reality headset (The Guided Meditation VR App through Oculus Go headset)|Patients assigned to the VR condition will engage with the VR using The Guided Meditation VR App through Oculus Go headset. They will enjoy up to a 10 minute video of an environment of their choosing. During this video they will listen to calming music and a guided meditation session.
214296028|NCT05886608|DEVICE|AI 500™ SINGLE-DOSE GEL|AI500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, intended to provide relief in cases of pain due to tension in muscles and adjacent tissues, to improve movement and function.
214668515|NCT04621747|OTHER|Battery of neurophysiological explorations|"Visit 1: Biometry collection: gender, age, weight, height, eye colour.~* Questionnaires : the State and Trait Anxiety Inventory and the Pain Sensitivity~* Threshold of unpleasant light brightness, mechanical sensitivity threshold (von Frey hair).~* Training to estimate unpleasantness Under nociceptive and tickling stimuli, to use the handgrip.~* Mechanical pain threshold (electronic von Frey), heat pain threshold (Medoc Pathway).~* 48 stimulations applied to the back skin, following a predetermined plan with 12 different pathways, imbricated with 4 different speeds of movement.~Visit 2 (1 to 8 days later) :~* 42 stimulations applied to the back skin, to test the effect of stimulation intensity, the side of application, continuity break of the contact, and distraction by other cutaneous stimuli. The stimuli will follow the best paradigm as identified at the previous visit.~* 12 stimulations applied to forearm, cheeks, lower limbs, also testing the effect of hairiness."
214668516|NCT04847115|PROCEDURE|Operative|Intramedullary screw fixation
214893148|NCT05032300|DEVICE|Focused shockwave|Procedure: Focused shockwave therapy received shock wave therapy once a week: first locate, touch on the heel of the patient Tenderness points, take tenderness points as treatment points;Then ask the patient to take the lower limbs straight sitting or prone position, Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, Total of 3000 pulses; rest for 20 minutes after the treatment
214893149|NCT05032300|OTHER|Home therapy|Stretching and ice massage
214893150|NCT04089449|DRUG|PRT811|PRT811 will be administered orally
214893151|NCT03923140|DRUG|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
214893152|NCT06155201|BEHAVIORAL|functional training|Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.
214893153|NCT06155201|OTHER|Observation|Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.
214893154|NCT04332315|PROCEDURE|Vaginally assisted laparoscopic sacrocolpopexy|"The VALS procedure consists of two steps. First, vaginal hysterectomy or laparoscopically assisted vaginal hysterectomy performed, anterior vaginal wall dissected up to bladder neck starting from initial vaginal incision, posterior vaginal wall dissected from rectum starting from initial vaginal incision up to distal third of posterior vaginal wall.The free arms of fixed meshes are introduced to the peritoneal cavity and the vaginal vault is closed with absorbable polyglactin suture. laparoscopy phase was performed with one intraumbilical (10 mm), 3 lateral abdominal (5 mm) trocars. Two mesh strips fixated to anterior longitudinal ligament of the sacrum with two separate no: 1 polypropylene sutures without tension.~AS was performed via Pfannenstiel incision after total or subtotal abdominal hysterectomy"
214893155|NCT02009189|DRUG|2% Taurolidine Lock|Catheter lock with 2% Taurolidine
214893156|NCT02009189|DRUG|1.35% Taurolidine|Catheter lock with 1.35% Taurolidine + citrate
214893157|NCT05362604|PROCEDURE|scheduled delivery at a tertiary center|Neonatal units in French hospitals are classified in three levels. The intention is for infants requiring high level care to receive it in a tertiary neonatal unit within the same network when appropriate. In case of known fetal gastro-intestinal artesia, the prenatal care includes obstetric consultation and level 3 ultrasound scheduled every four weeks at our unit until the end of the pregnancy, antenatal consultations with a specialized multidisciplinary team, and an antenatal visit of the birth center to reduce the parental anxiety.
214893158|NCT05583461|PROCEDURE|Positive end-expiratory pressure titration|Positive end-expiratory pressure level
214893159|NCT01269918|DRUG|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
214893160|NCT01269918|DRUG|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
214893161|NCT05001893|DEVICE|S53P4 bioactive glass putty|Bonalive putty/putty MIS paste is a synthetic, bioactive, osteoconductive, osteostimulative bone void filler for filling, reconstruction, and regeneration of bone defects.
214893162|NCT03571828|DRUG|AMG 562|AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
215050422|NCT05940506|OTHER|Placebo|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm),starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily for QD dose groups, and once in the morning and once in the evening for the BID dose groups.
214296029|NCT01671189|OTHER|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
214893163|NCT01901640|DRUG|DA-8159 (Udenafil)|
214893164|NCT04154683|DEVICE|Cellvizio®|use of the Cellvizio® optical biopsy
214893165|NCT04471428|DRUG|Cabozantinib|Cabozantinib will be administered orally, once daily at a dose of 40 mg on Days 1-21 of each cycle.
214893166|NCT04471428|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
214296030|NCT05814939|DRUG|VC005 tablets|VC005 groups repeat administration for 12 weeks
214296031|NCT05814939|DRUG|Tofacitinib Citrate Tablets|Tofacitinib Citrate groups repeat administration for 12 weeks
214893167|NCT04471428|DRUG|Docetaxel|Docetaxel will be administered by IV infusion at a starting dose of 75mg/m2 on Day 1 of each 21-day cycle.
214893168|NCT05357846|DRUG|Sintilimab|Sintilimab 200mg, IV (in the vein) on day 1 and day 22
214296032|NCT05814939|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
214296033|NCT02331836|DEVICE|Arc Endocuff (AEC 110, 120, 130, 140)|
214296034|NCT02331836|DEVICE|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
214296035|NCT02331836|DEVICE|Standard colonoscope|
214296036|NCT02463474|BEHAVIORAL|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
214296037|NCT03212612|DIAGNOSTIC_TEST|samples obtained by laparoscopy or punch biopsy for analysis by ELISA|Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
214296038|NCT03474354|DEVICE|chemoembolization|correlation of necrosis with the deposition of beads
214296039|NCT01364207|OTHER|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
214893169|NCT05357846|RADIATION|Preoperative radiotherapy|External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.
214893170|NCT05357846|DRUG|Paclitaxel|50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22
214893171|NCT05357846|DRUG|Cisplatin|25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22
214893172|NCT05357846|PROCEDURE|esophagectomy|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
215050423|NCT01683136|DEVICE|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
215050424|NCT02827812|OTHER|Comprehensive evaluation|At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
214668517|NCT04847115|OTHER|Walking boot orthosis|Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.
214668518|NCT00091793|DRUG|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
214893173|NCT05321004|OTHER|Semi-structured interviews will be conducted - there will be no intervention.|The use of semi structured interviews and questionnaires
214296040|NCT01364207|OTHER|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
214893174|NCT06372210|DRUG|Placebo IEM tablet|Oral placebo-embedded IEM tablet.
214893175|NCT06372210|DRUG|Abilify MyCite®|Oral aripiprazole-embedded IEM tablet.
214893176|NCT06372210|DEVICE|D-Tect Patch|The D-Tect patch is a wearable sensor (WS) capable of detecting the ingestion of the IEM and measuring physiologic parameters. The WS automatically logs and stores the time when the IEM reaches the stomach and transmits the data to a smartphone.
214893177|NCT05814731|DRUG|MA-BUCY2|Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
214893178|NCT05814731|DRUG|BUCY2|Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
214296041|NCT05557461|DEVICE|End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility|"(0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test."
214668519|NCT00091793|DRUG|Placebo|Placebo given at day 1, month 6, month 12 and month 18
214893179|NCT02143544|DEVICE|Intra-aortic balloon pump.|Preoperative placement of the intra-aortic balloon pump.
214893180|NCT03315078|BIOLOGICAL|CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT|Administered by intravenous (IV) infusion
214893181|NCT03315078|DRUG|Palifermin|Administered by IV infusion at a dose of 60 mg/kg/day
214893182|NCT03315078|DRUG|Busulfan|Administered by IV infusion at a dose of approximately 3 mg/kg per day
215050425|NCT02827812|OTHER|Physical Intervention at home|A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
215050426|NCT02827812|OTHER|Home-Based telemedicine program|"1. A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~2. A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences."
214668520|NCT00378729|DRUG|Metformin and FSHr|treatment for infertility
214668521|NCT00378729|PROCEDURE|Ovarian drilling by FERTILOSCOPY|surgical ovarian drilling
214668522|NCT04306042|DRUG|Nivolumab or Pembrolizumab|Nivolumab or Pembrolizumab
214668523|NCT04120688|DEVICE|3D generated tooth replica|3D generated tooth replicas are compared to conventional procedure
214668524|NCT00154505|DEVICE|Lateral trunk support of wheelchair seating|
214296042|NCT06386133|DEVICE|MS Boost|remote monitoring digital tool based on functional tests (walking, dexterity, vision and cognition). These digital tests may be combined with a fatigue assessment via questionnaires and, if needed, a telerehabilitation program. This program includes an algorithm comprising fatigue management advice and/or physical activity recommendations personalised to the patients, aimed at improving fatigue-related symptoms. The patient can use the telerehabilitation program without supervision
214668525|NCT03002506|DRUG|Ceftolozane/tazobactam|Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
214668526|NCT00288340|DEVICE|functional magnetic resonance imaging|
214668527|NCT02957708|OTHER|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
214893183|NCT06443229|BEHAVIORAL|Graded Activity based in exercises and educational approach|"Exercises for warming up, strengthening, and relaxation, along with informational sessions incorporating an educational approach for low back pain using Telerehabilitation platform. Participants will be randomized into two groups: the Experimental Group (EG), which will receive graded activity along with the educational approach, three times a week, over 12 sessions, totaling 4 weeks.~The intervention will involve adapting a protocol from an exercise program based on gradual activity with progressively increasing exercise intensity using web applications from Physitrack® Ltd., LDN, United Kingdom (used by the physiotherapist/researcher) and Physiapp® (used by the participant). Participants will be provided with (i) a welcome letter outlining the intervention/group components they are allocated to; (ii) instructions on how to use the Physiapp® web application (web browser, Android or iOS app) at home."
214893184|NCT06443229|OTHER|Educational Approach|Educational approach for low back pain using Telerehabilitation platform. Participants will receive educational materials with an isolated educational approach, with the delivery of the materials occurring three times a week.
214893185|NCT04584411|DIAGNOSTIC_TEST|Cardiac Magnetic resonance imaging|"The following basic sequences will be conducted:~* Cine imaging using SSFP sequence for cardiac structure and function.~* Tissue characterization imaging, T1 and T2.~* Myocardial perfusion imaging.~* Late gadolinium enhancement.~Diagnosis of myocarditis will be based on the modified Lake Louise criteria:~T2-weighted: any of the following standard T2 sequences: regional high signal standard T2 sequences: global signal intensity ratio (myocardium/skeletal muscle) ≥2 T2 mapping: increased T2 relaxation times T1-weighted: any of the following late enhancement imaging: non-ischemic (subepicardial or mid myocardial) late enhancement native T1 mapping: increased T1 relaxation times or extracellular volume supportive criteria: signs of pericarditis: effusion or pericardial late enhancement regional or global wall motion abnormalities\[5\]"
214893186|NCT04020523|OTHER|MRI sequence|The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
214893187|NCT00890617|PROCEDURE|Cryotherapy (PTC)|CT-guided PTC with the intent to eradicate the entire tumor(s).
214893188|NCT00890617|DRUG|Prednisone|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
214893189|NCT04943133|DEVICE|Blood pressure measurement and collection of the oscillometric curve for later SFATI analysis|Brachial systolic arterial blood pressure will be systematically taken with acquisition of the oscillometric curve for analysis and measurement with the SFATI system and simultaneous electronic recording of the Korotkoff sound (auscultatory method) and a search for SFATI arterial stiffness markers for all patients. Brachial systolic arterial blood pressure will be measured with the help of a cuff equipped with a Biopac SS30L electronic stethoscope and a MA-300 phonocardiographic microphone, placed side-by-side immediately downstream from the brachial occlusion cuff. The various signals (pneumatic cuff, oscillometric signal and Korotkoff sounds) will be digitalized by an MP35 system.
214893190|NCT04943133|DEVICE|Blood pressure measurement with the usual equipment used in the department|Brachial systolic blood pressure will be taken via the conventional oscillometric method, only for hospitalized women. Blood pressure will be measured on the same arm with the help of a conventional Dinamap-type automat (GE), with at least 2 minutes between the end of the first measurement and the start of the second inflation.
214893191|NCT04943133|DEVICE|systematic measurement of pulse wave velocity (aortic and brachial)|"Carotid to femoral and carotid to radial pulse wave velocity (Complior) will be systematically determined for hospitalized women and offered to all women seen for consultation.~Pulse wave velocity will be measured with the help of a Complior tonometric system (Alam Medical, Vincennes, France), with which the aorta and the arterial axes of the upper limb used to measure blood pressure can also be measured."
214893192|NCT01870778|DRUG|RLX030|1 mg/mL solution in 6 mL vials
214893193|NCT01870778|DRUG|Placebo|Matching placebo solution to serelaxin
214893194|NCT02770378|DRUG|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
214893195|NCT02770378|DRUG|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
214893196|NCT02770378|DRUG|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
214296043|NCT06386133|OTHER|Standard of care|General fatigue tips are given to patients who suffering from chronic fatigue such as stop smoking, eat a healthy diet...
214893197|NCT02770378|DRUG|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
214893198|NCT02770378|DRUG|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
215050427|NCT03724279|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening."
215050428|NCT05179278|OTHER|Post-surgical nurse follow-up|Follow-up face-to-face consultation or follow-up telephone consultation a month after the intervention and telephone consultation at one year
215050429|NCT01104402|DEVICE|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
215050430|NCT04868942|OTHER|Assisting to the event|"Participant will attend a concert respecting the Following measures :~* Individual protection kit: disposable FFP2 masks (3), Hydroalcoholic solution, disposable tissues, garbage bag, water bottle~* Health mediation, information on barrier measures~* Physical distancing (sitting participation)~* Person flow management"
215050431|NCT03561155|DEVICE|Robot assisted treatment (Amadeo®)|"The protocol will consist of exercises as follows:~passive modality , passive/plus modality , assisted therapy and Balloon."
215050432|NCT03561155|OTHER|Conventional treatment|"The protocol will consist of exercises as follow:~upper limb mobilization, facilitation of movements and active tasks. The exercises will be focused on improving muscle strength, finger extension and flexion and motor control"
215050433|NCT03401437|BEHAVIORAL|SF-36|Evaluation of the quality of life with an auto-questionnaire validated, with 8 dimensions: physical activity ; limitations due to physical condition; physical pain; perceived health; vitality; life and relationship with others; limitations due to physical condition; psychic health as well as the assessment of perceived health compared to a year ago. Evaluation done pre-operatively, at M1 and M3
215050434|NCT03401437|BEHAVIORAL|HAD|Evaluation of anxiety and depression with a scale validated with 14 items assess between 0 and 3. Evaluation done pre-operatively and at M3.
214668528|NCT02957708|OTHER|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
215050435|NCT03401437|OTHER|ANSM|Additional information requested by the ANSM (french National Agency for Medicines and Health Products Safety) following a materiovigilance report. Evaluation done pre-operatively and at M3.
215050436|NCT02665533|DRUG|Dexamethasone|Dexamethasone 8 mg
215050437|NCT02665533|DRUG|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg
215050438|NCT02477527|DRUG|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
215050439|NCT02044679|OTHER|Water|
215050440|NCT02044679|OTHER|No intervention|
215050441|NCT05480176|OTHER|Comprehensive intervention and management Ⅰ|Mainly health advisory.
215050442|NCT05480176|OTHER|Comprehensive intervention and management Ⅱ|Health advisory and regular follow-ups.
215050443|NCT05480176|OTHER|Comprehensive intervention and management Ⅲ|Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
215050444|NCT01399112|BEHAVIORAL|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
215050445|NCT04157699|DRUG|TDF tablet|TDF tablet 300mg QD
215050446|NCT04157699|DRUG|QL-007|QL-007 tablet
215050447|NCT00728156|DRUG|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
214668529|NCT03684083|PROCEDURE|bronchial biopsies|bronchial fibroscopy with bronchial biopsies
214893199|NCT02770378|DRUG|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
214893200|NCT02770378|DRUG|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
214893201|NCT02770378|DRUG|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
214893202|NCT02770378|DRUG|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
214893203|NCT02770378|DRUG|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
214893204|NCT00258726|BIOLOGICAL|MMR-II|
214893205|NCT00258726|BIOLOGICAL|Pro-Quad|
214893206|NCT00258726|BIOLOGICAL|Varivax|
215050448|NCT00728156|DRUG|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
215050449|NCT04144283|BEHAVIORAL|NAP|"For experiment 1, the NAP group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') without cues.~For experiment 2 the NAP+TMR group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') with auditory TMR. The learning related sounds will be presented to participants at 140% of their minimal auditory detection threshold during stage 2 and stage 3 of NREM sleep."
215050450|NCT04144283|BEHAVIORAL|WAKE|For experiment 1, the WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness without cues.
215050451|NCT02458872|BEHAVIORAL|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
215050452|NCT05894057|OTHER|Data collection on acceptability of midazolam administration by 2- to 10-year-old pediatric patients at UKBB|On the day of entry to the Anesthesiology Unit for an elective surgery, or before an intervention at the Emergency Unit, all children, irrespective of their participation to the present study, will receive standard midazolam dose of 0.3-0.5 mg/kg as prescribed by the treating clinician at UKBB in line with clinical practice (as oral syrup, rectal suppository or ODMT). The children's spontaneous reactions after intake of midazolam (e.g., positive comments, spitting out of medication, crying) will be observed and recorded by the research staff. Children who are able to understand the Hedonic Scale (FHS) will be questioned on how they liked the medication by pointing to the appropriate face of a Facial Hedonic Scale (FHS) at the time of midazolam intake.
215050453|NCT00835458|PROCEDURE|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
215050454|NCT02102958|BEHAVIORAL|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
215050455|NCT02102958|BEHAVIORAL|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
215050456|NCT00114725|PROCEDURE|Laser-assisted intracytoplasmic sperm injection|
214296044|NCT02286505|DEVICE|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
214296045|NCT02286505|OTHER|Standard radiological assessment|Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
214296046|NCT04434794|BIOLOGICAL|mesenchymal stem cells|autologous mesenchymal stem cells
214668530|NCT00540215|OTHER|Glucagonlike peptide|450 nmol native form, synthetic
214296047|NCT04434794|OTHER|standard treatment|standard treatment according to clinical protocols
214296048|NCT00492115|DEVICE|Continuous positive airway pressure (CPAP)|therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks
214668531|NCT05111314|RADIATION|Gallium Ga 68 Gozetotide|Given IA
214893207|NCT03862924|DEVICE|Standardized Research Electronic Cigarette|Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
214893208|NCT02248987|OTHER|patients treated with antipsychotics|
214893209|NCT03674398|BEHAVIORAL|Exercise+CT|The exercise+CT group is asked to participate in 30 minutes of aerobic exercise followed by a 20-minute cognitive training (CT) program that targets attention and memory. Training will take place following exercise due to elevated levels of brain-derived neurotrophic factor and increased arousal, which is theorized to benefit cognitive task performance. Computerized CT exercises will be delivered using participants' smartphone. Adherence to the computerized CT program is monitored using electronic data upload after each training session. Participants are asked to engage in three sessions per week with the first week taking place in a lab-setting. Participants are asked to continue the aerobic exercise and CT program at home for the subsequent three weeks.
215050457|NCT00083980|DRUG|Venlafaxine ER|75 to 225 mg daily
215050458|NCT00083980|DRUG|Sugar pill|Upto 3 per day for venlafainxe and 4 per day for kava placebos.
215050459|NCT00083980|DRUG|Kava|140 to 280 mg per day
214893210|NCT03674398|BEHAVIORAL|Exercise only|The exercise only group will receive the same exercise prescription as the exercise+CT group. Participants in this group are asked to watch 20 minutes of health-related educational videos post-exercise. Videos are administered via participants' smartphones. After each video session, participants answer multiple-choice questions that assess engagement. Following the first week of treatment in-lab, participants are asked to continue watching health-related videos, post-exercise, for three weeks at home.
214893211|NCT00564512|BIOLOGICAL|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
214668532|NCT05111314|PROCEDURE|Hepatic Artery Embolization|Undergo hepatic artery embolization
214893212|NCT00564512|BIOLOGICAL|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
214893213|NCT00564512|DRUG|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
214893214|NCT00564512|DRUG|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
214893215|NCT06319560|DRUG|Hydroxychloroquine Oral Tablet|200mg daily
214893216|NCT06841770|BIOLOGICAL|OPC1|One injection of 10 million LCTOPC1 cells will be delivered to the target injection site of the damaged spinal tissue.
214893217|NCT06588439|OTHER|Cognitive-motor training|Cognitive-motor training is that cognitive tasks incorporated into motor tasks.
214893218|NCT06588439|OTHER|Conventional physiotherapy|Conventional physiotherapy includes stretching, ROM exercise, strengthening exercise, and eye-hand coordination.
214893221|NCT04806516|DEVICE|Summit RC+S System with ECoG Paddles|"Summit RC+S System with ECoG Paddles consists of:~* Olympus RC+S implantable pulse generator (IPG), Model B35300R: 2 per subject x 5 subjects = 10 units~* Extension Leads, Model 37087: 2 per subject X 5 subjects = 10 units~* DBS Leads, Model 3387: 2 per subject X 5 subjects = 10 units~* Patient Therapy Manager (PTM), Model 4NR009: 1 per subject x 5 subjects = 5 units~* Recharge Therapy Manager (RTM), Model 97755: 1 per subject x 5 subjects = 5 units~* Clinician Telemetry Module (CTM), Model 4NR011: 1 per subject x 5 subjects = 5 units~* Research Lab Programmer (RLP), Model 4NR010: 1 unit~* Research Software Development Kit (RDK), Model 4NR013: 2 units~* Subdural Quadripolar Paddle Lead, Model 09130: 2 per subject x 5 subjects = 10 units"
214893222|NCT04806516|OTHER|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
214893223|NCT06367985|OTHER|Air Oxygen Concentration CAPA-IVM culture|"* Group 1A: COC will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 1B: COCs will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and in the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
214893224|NCT06367985|OTHER|Low Oxygen Concentration CAPA-IVM culture|"* Group 2A: COC will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 2B: COCs will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
214893225|NCT01447043|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
214893226|NCT03354715|DEVICE|Rapid prototyping Denture base|The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology, which mainly depends on addition of layers of materials which would be polymerized using a light curing unit. It consists of a bath of photo polymerized liquid and ultraviolet unit for curing these layers, that would bond to each other till forming the full object. SLA has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.
214893227|NCT03354715|DEVICE|Heat Cured Conventional Complete Denture|it is the main treatment for most of completely edentoulous Cases
214893228|NCT04628091|OTHER|Sampling on surgery day|"In the morning, the day of the surgery (the patient will be fasting):~* Occipital hair sample (without roots)~* Venous blood sample (3 tubes of 7mL)~During the surgery:~* Sample of 0.5 to 1 cm3 of subcutaneous adipose tissue during laparoscopic umbilical access~* Collection of a portion of Ampulla proximal part and Isthmus distal part in order to obtain a piece of approximately 4 cm long (2cm of ampulla and 2 cm of isthmus) for each tube."
214893229|NCT04077580|DRUG|Methenamine Hippurate 1000 MG|Methenamine and placebo is taken 1 tablet morning and evening for 180 days
214893230|NCT02074007|DRUG|AR01|drops administered as needed for pain
214893231|NCT02074007|DRUG|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
214893232|NCT00808951|DRUG|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
214893233|NCT00808951|DRUG|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
214893234|NCT01331993|DRUG|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
214893235|NCT01331993|DRUG|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
214893236|NCT01331993|DRUG|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
214296049|NCT00492115|DEVICE|Placebo CPAP|Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks
214668533|NCT05111314|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
214478099|NCT06871150|DEVICE|HPI|"The Hypotension Prediction Index (HPI) is an advanced arterial waveform analysis algorithm that uses machine learning to predict hypotensive episodes (defined as mean arterial pressure \[MAP\] \< 65 mmHg) five minutes in advance, achieving high sensitivity and specificity. This technology is based on patient demographic data (e.g., age, height, weight) and hemodynamic parameters derived from arterial waveform analysis.~* HPI uses demographic information and hemodynamic signals obtained via a radial arterial catheter.~* The signals are analyzed using Edwards Lifesciences' Acumen IQ software, which has been further developed to include prediction of hypotensive episodes.~The algorithm provides a numerical value (0-100) reflecting the risk of imminent hypotension. An HPI value above 85 signals a high likelihood of hypotension.~The system also provides advanced hemodynamic data, including cardiac output, dynamic arterial elastance, dP/dtmax (systolic slope), and stroke volume."
214893237|NCT05082974|DRUG|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 (varenicline 0.6mg/ml) nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of Drye Eye Disease. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
214893238|NCT05082974|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray \[control\]
214893239|NCT06357585|OTHER|Web based education|Web-based training will be provided to the parents in the experimental group regarding care practices for children diagnosed with leukemia.
214893240|NCT06357585|OTHER|inactive group|Parents in the control group will continue to receive routine care and treatment.
214893241|NCT04640870|DRUG|Afatinib|Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC
215050460|NCT04884503|DRUG|Clonazepam tablets|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
215050461|NCT04884503|DEVICE|tongue pads|wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
215050462|NCT03111004|OTHER|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
215050463|NCT01760577|DRUG|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
215050464|NCT01760577|DRUG|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
215050465|NCT05302310|OTHER|integrated care|"i) Screening of older people for risk of frailty using a frailty screening tool, to identify the appropriate care they will require:~* Older adults with low risk of frailty will receive health promotion and preventive care from the Information and Advice Center nurse and/or social worker.~* Older adults at risk will receive the following:~ii) a Comprehensive Geriatric Assessment (CGA) delivered by the Information and Advice Center nurse and social worker over the course of multiple appointments, to identify the health and social care needs and goals of the older person; iii) Development of an individualized care plan by a multidisciplinary team, which will include evidence-based interventions and be coordinated by the Information and Advice Center nurse and/or the social worker; and iv) follow-up depending on the situation of each older person, and adaptation of the individualized care plan, as needed."
215050466|NCT00912626|BEHAVIORAL|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
215050467|NCT05608954|OTHER|Bobath Concept|Handling of the Bobath Concept
215050468|NCT05608954|OTHER|Pediasuit|Pediasuit
215050469|NCT05608954|OTHER|Locomotor training|Locomotor training
215050470|NCT05608954|OTHER|Stretching|Active, passive, active-assisted stretching
215050471|NCT05608954|OTHER|Psychomotricity|Psychomotor skills
215050472|NCT05608954|OTHER|Virtual reality|Virtual reality
215050473|NCT02654496|OTHER|Meal challenge|Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
214296050|NCT04521075|BIOLOGICAL|Fecal Microbial Transplantation by capsules|"Cohorts A and B - Patients will receive 30 oral capsules per administration for two consecutive days (Days 1-2) Cohort C - Patients will receive FMT via colonscopy (Day 1), followed the day after by adnistration of 12 oral capsules (Day 2)~Combination cycles: 6 combined cycles Q2W of FMT maintenance followed by treatment with anti-PD1. Anti-PD-1 will be administered at least one day and up to 3 days after the FMT.~Maintenance of FMT by oral capsules: 12 capsules per administration. Anti PD-1 therapy: A dose of 240 mg Nivolumab will be administrated by intravenous infusion."
214893242|NCT01258309|DRUG|olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
214893243|NCT01258309|DRUG|olopatadine hydrochloride 0.1% ophthalmic solution|One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
214893244|NCT01627678|DRUG|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
214893245|NCT01627678|DRUG|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
214893246|NCT00028977|DRUG|herba scutellaria barbata|
214893247|NCT00028977|OTHER|herba scutellaria Barbatae (HSB)|
214893248|NCT01050439|PROCEDURE|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
214893249|NCT01050439|OTHER|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
214893250|NCT00481117|DRUG|LY2405319|
214893251|NCT00481117|DRUG|Placebo|
214893252|NCT03081780|BIOLOGICAL|FATE-NK100|"Preparative regimen:~* Fludarabine 25 mg/m2 x 5 days start Day -6~* Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
214893253|NCT00207519|BEHAVIORAL|weekly behavioral modification group|
214893254|NCT00207519|BEHAVIORAL|liquid meal replacements|
214893255|NCT01669291|DRUG|Bravelle and Menopur|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
214893256|NCT01669291|DRUG|Agonist|Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
214893257|NCT01669291|DRUG|Antagonist|Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
214893258|NCT02642172|DIETARY_SUPPLEMENT|ITF (Inulin/OFS 75/25)|Participants will consume 16 g/day ITF
214893259|NCT02642172|DIETARY_SUPPLEMENT|Placebo|Participants will consume 16 g/day maltodextrin
214893260|NCT03333434|DEVICE|Carbon Ankle Seven spring (A7 - Otto Bock, Germany)|
214296051|NCT03564145|DRUG|S5G4T-1|Once a day topical cream
214296052|NCT03143569|DEVICE|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
214296053|NCT03143569|DEVICE|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
214893261|NCT03333434|DEVICE|Hinged AFO|
214893262|NCT00248872|BEHAVIORAL|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
214893263|NCT02176265|DEVICE|Qvanteq bioactive coronary stent|PCI
214893264|NCT05012020|DEVICE|mHealth Remote Monitoring platform|Clinic Portal and Mobile Application for remote monitoring of Chronic Kidney Disease patients and patients on Peritoneal Dialysis
214893265|NCT04032015|DEVICE|TMS|Device used to administer electromagnetic fields to the brain to alter connectivity patterns
214893266|NCT05361590|DEVICE|Lumoral device|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
214893267|NCT02881684|DEVICE|Aspiration Therapy (AspireAssist®)|Use of the AspireAssist device in aspiration therapy
214893268|NCT02881684|BEHAVIORAL|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
214893269|NCT00302653|DRUG|Rasburicase|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
214893270|NCT01506388|DEVICE|foley catheter|foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours
214893271|NCT01506388|DRUG|Misoprostol|misoprostol 50 Ug , vaginally every 4-6 hours
214893272|NCT01506388|DRUG|Vaginal IMN|IMN vaginal 40 mg every 4-6 hours
214893273|NCT02961998|DRUG|Celecoxib|Patients from experimental group will take celecoxib, except for sorafenib
214893274|NCT02961998|DRUG|Sorafenib|Each group will receive sorafenib as basic treatment.
214893275|NCT01564043|BEHAVIORAL|website and pedometer|use of pedometer and website
214893276|NCT05510284|OTHER|Doula-coordinated, midwife-delivered postpartum care|A doula will coordinate all postpartum care and provide support to the participant. A midwife will be available on-site in the NICU to provide postpartum care.
214893277|NCT04201197|DRUG|Inje cocktail|Acute drug exposure
214893278|NCT04201197|DRUG|THC Cannabis extract|Acute drug exposure
214893279|NCT04201197|DRUG|THC/CBD Cannabis Extract|Acute drug exposure
214893280|NCT03123068|DRUG|CocoaVia®|CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
214893281|NCT03123068|OTHER|Placebo|The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
214893282|NCT04810715|OTHER|Patients with Ankylosing Spondylitis|Observational study, not applicable
214893283|NCT06079892|PROCEDURE|radiofrequency|haemorrhoidal removal using radiofrequency
214893284|NCT05308433|DEVICE|Functional MRI|The volunteer will have to imagine the smells evoked by different visual aids. This task will be carried out during 2 acquisition runs of about 10 minutes each. The volunteer should note (on a scale from 1 to 4) the pleasantness of the smell evoked.
214893285|NCT05308433|OTHER|Virtual Reality: control|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. In the center of the maritime scene, it will be visible the black outlines of a frame. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
214893286|NCT05308433|OTHER|Virtual Reality: experimental|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. The visual support inserted in the center of the virtual scene will be the one defined as being the most facilitator of the olfactory imagination during the fMRI examination. The volunteer will be asked to concentrate on the smell evoked by this support. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
214893287|NCT04722497|OTHER|Sound Education|All physicians and nurses involved in cesarean births will be given an education intervention explaining the impact of noise levels on stress and focus. The SoundEar device will be used as an intervention tool to inform operating room physicians and nurses when the noise level is above the desired level.
214893288|NCT06530797|DRUG|First-line Adebrelimab regiment for advanced stage ES-SCLC|First-line Adebrelimab in any regiment for advanced stage ES-SCLC
215050474|NCT04739930|PROCEDURE|Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
214893289|NCT06530797|DRUG|Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC|Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC
214893290|NCT02553772|DRUG|Carboxymethylcellulose Based Eye Drop|Carboxymethylcellulose based eye drop (OM3 Tear) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
215050475|NCT04739930|PROCEDURE|Control group incision|0.5cm sham incision over the iliac crest
215050476|NCT02652910|DRUG|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
215050477|NCT02433912|PROCEDURE|Test - Laterally positioned flap|Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
215050478|NCT02433912|PROCEDURE|Control-Coronally positioned flap|Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
215050479|NCT02433912|DRUG|750 mg paracetamol|Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
215050480|NCT02433912|DRUG|chlorhexidine gluconate|chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
215050481|NCT00953810|OTHER|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
215050482|NCT01797757|DIETARY_SUPPLEMENT|Fish oil enriched with EPA|
215050483|NCT01797757|DIETARY_SUPPLEMENT|MAG-EPA oil|
214296054|NCT05780567|DRUG|TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|"TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors.~Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer."
214893291|NCT02553772|DRUG|Carboxymethylcellulose Sodium 0.5%|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
214893292|NCT03035188|DRUG|Vismodegib|1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
214893293|NCT01295398|DEVICE|nebulisations|
214893294|NCT00002422|DRUG|HE2000|
214893295|NCT04493164|DRUG|Ivosidenib|Given PO
215050484|NCT01797757|DRUG|Orlistat|
215050485|NCT02575729|DRUG|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
215050486|NCT02523989|OTHER|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
215050487|NCT04393038|DRUG|ABX464|ABX464 50mg QD for 28 days + Standard of Care
215050488|NCT04393038|DRUG|Placebo|Placebo 50mg QD for 28 days + Standard of Care
215050489|NCT06401499|DRUG|etoricoxib 60mg|investigator will compare effects of etoricoxib alone and in combination with pregabalin on pain relief in chronic low back pain participants
215050490|NCT00437398|BIOLOGICAL|Islet Transplant|Purified pancreatic islets
215050491|NCT03102983|OTHER|MRI functional|vowels records and MRI session
215050492|NCT03486782|DEVICE|IFG stimulation|stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
215050493|NCT03486782|DEVICE|DLPFC stimulation|stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
215050494|NCT03486782|BEHAVIORAL|aphasia therapy|aphasia therapy for 30 minutes during transcranial direct current stimulation
215050495|NCT02432937|DRUG|Corever|Corever
215050496|NCT03722381|DRUG|Amlodipine Besylate|Pharmacokinetics
215050497|NCT04594629|DRUG|Nitroglycerin|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
215050498|NCT04594629|DRUG|PGI2|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
215050499|NCT06386926|OTHER|Electro Therapy|radial shockwave 3 sessions one session per week for four consecutive weeks ,receive Ultrasound phonophoresis using diclofenac Na+ 12 session, 3 sessions per week and conventional physical therapy modalities in the form of 3 sessions every week for 8 weeks
215050500|NCT03811522|OTHER|carbon dioxide insufflation|Receives CO2 insufflation
215050501|NCT03811522|OTHER|Air insufflation|Receives air insufflation
214296055|NCT05780567|DRUG|Placebo capsules, Letrozole, Anastrozole, Tamoxifen|Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.
214296056|NCT04982198|PROCEDURE|ROSA assisted TKA|Robotic assisted total knee arthroplasty
214296057|NCT00099346|DRUG|MK0457, VX-680 (Aurora Kinase Inhibitor)|
214296058|NCT00602706|BIOLOGICAL|sargramostim|
214668534|NCT05162235|DEVICE|Augmented Reality-assisted localization of solitary pulmonary nodule|In this study, AR was utilized to assist in the localization of SPNs during sublobectomy lung resection in patient to assess the safety and effectiveness of the technique.
214668535|NCT01220778|BEHAVIORAL|Exercise|
215050502|NCT03292003|DEVICE|Journey II BCS Total Knee System|
214296059|NCT00602706|DRUG|melphalan|
214296060|NCT00602706|PROCEDURE|autologous hematopoietic stem cell transplantation|
214296061|NCT00602706|PROCEDURE|peripheral blood stem cell transplantation|
214296062|NCT00602706|RADIATION|samarium Sm 153 lexidronam pentasodium|
214296063|NCT02663674|DRUG|Fluconazole|Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
214296064|NCT02663674|OTHER|Placebo|Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
214668536|NCT03636815|OTHER|physical therapy|Cardiopulmonary rehabilitation for patients who receive left ventricle assist device
214668537|NCT01052064|DEVICE|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
214668538|NCT00006812|DRUG|capecitabine|
214668539|NCT02910440|DRUG|DCL-101 vs Golytely|
214668540|NCT00610636|PROCEDURE|Hepatic resection|Hepatic resection
214893296|NCT04493164|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214893297|NCT00786409|BIOLOGICAL|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
214893298|NCT01765335|DEVICE|NICaS system|NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
214893299|NCT00031148|DRUG|Recombinant Human Keratinocyte Growth Factor (rHuKGF)|
214893300|NCT00610129|DRUG|MK-0646|MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.
214893301|NCT07128342|DEVICE|CGM Group|This group of patients will receive a CGM device to monitor their blood glucoses
214893302|NCT07128342|DEVICE|FSBG group|This group of patients will receive a fingerstick blood glucose (FSBG) device for glucose monitoring
214893303|NCT07008768|PROCEDURE|Cataract surgery and refractive lens exchange surgery|Cataract surgery or refractive lens exchange surgery was performed with standard phacoemulsification procedure using micro coaxial surgical technique. After superior clear corneal incision, anterior capsulorexis and lens phacoemulsification, the IOL was implanted into the capsular bag using an injector in all cases. Ophthalmic Viscosurgical Device (OVD) was completely removed by irrigation and aspiration. All incisions were self-closing.
214893304|NCT07008768|DEVICE|TRIFOCAL IOL|1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, trifocal
214893305|NCT07008768|DEVICE|EROV IOL|1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, extended range of vision (EROV)
214893306|NCT07008768|DEVICE|BIFOCAL IOL|1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, bifocal with low addition
214893307|NCT07008768|DEVICE|MONOFOCAL IOL|Control lens: 1-piece aspheric hydrophobic monofocal aspheric IOL
214893308|NCT03752697|BEHAVIORAL|metacognitive performance|Paper and pencil/computerized tests of metacognition
214893309|NCT02449278|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-site radiotherapy (ISRT).~Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
214893310|NCT02449278|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-field radiotherapy (IFRT).~Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
214296065|NCT00763308|BEHAVIORAL|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
214296066|NCT01031069|BIOLOGICAL|GSK Biologicals' HPV vaccine 580299|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
214296067|NCT01031069|BIOLOGICAL|Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
214296068|NCT05526495|BEHAVIORAL|Reducing preoperative low-value test ordering|A multi-component approach will be used:1) An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing non-urgent surgery will be ordered at the discretion of an anesthesiologist based on their clinical assessment. Adoption of the policy change will be facilitated by a local champion using an engagement and education program for anesthesiologists, surgeons, pre-admission clinic nurses and administrative staff; 2) The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies. A train-the-trainer model will be used; 3) The departments will commit to supporting the change in policy. Nurses within preoperative clinic will be coached to feel comfortable calling the anesthesiologist about any pre-op tests ordered, and the Pre-Admission Unit will have the authority to cancel tests that deem unnecessary. Check boxes will be removed from medical order forms
214296069|NCT01659515|DRUG|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
214668541|NCT05309083|BEHAVIORAL|Mindfulness Based Walking Therapy (MBWT)|MBWT will be a modified form of the typical Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking meditations and is acceptable for people with Parkinson disease and freezing of gait.
214893311|NCT02449278|DRUG|cyclophosphamide|Patients in both arms will be given cyclophosphamide chemotherapy
214893312|NCT02449278|DRUG|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy
214893313|NCT02449278|DRUG|vincristine|Patients in both arms will be given vincristine chemotherapy
214893314|NCT02449278|DRUG|prednisone|Patients in both arms will be given prednisone chemotherapy
214893315|NCT00324220|DRUG|MGCD0103|MGCD0103 Oral administration 3 times per week.
214893316|NCT00004263|DRUG|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
214893317|NCT00004263|DRUG|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
214893318|NCT02216097|DRUG|PF-04457845|4mg PF-04457845 tablet taken once daily for 7 days.
214893319|NCT02216097|DRUG|Placebo|Matching placebo tablet taken once daily for 7 days.
215050503|NCT01162551|DRUG|Sirolimus and Methotrexate|"Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days."
214296070|NCT03755492|OTHER|Absorbent pad for urinary incontinence|6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
214296071|NCT05286307|DRUG|IPACK block|IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee
214668542|NCT05738980|BIOLOGICAL|Autologous RAK cells|Autologous RAK cells were treated by intravenous reinfusion
214893320|NCT02297997|DRUG|cetylpyridinium chloride|Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
214893321|NCT02297997|DRUG|Placebo|Control group takes the placebo for the same period.
214893322|NCT07011680|DIETARY_SUPPLEMENT|Phospholipid-rich dairy milk extract|Dietary phospholipid-rich dairy milk extract 500 mg/day for 12 weeks
214893323|NCT07011680|DIETARY_SUPPLEMENT|Placebo|Placebo (Grape seed oil) 500 mg/day for 12 weeks
214893324|NCT07011121|BEHAVIORAL|CenteringPregnancy|. CenteringPregnancy, a group prenatal care model, is a promising alternative that challenges the standard model of one-on-one prenatal counseling. Previous research has documented that group prenatal care is associated with a lower prevalence of preterm birth and low birth weight infants. 18,39 Group prenatal care also has been associated with improved maternal mental health, breastfeeding, optimal pregnancy weight gain, improved postpartum weight loss, better birth spacing, and higher patient satisfaction. 18,39 All participants will attend routine one-on-one prenatal appointments prior to the intervention. The sessions occur from week 14 of pregnancy through birth with women of similar gestational age, following the same schedule as standard care. Once the groups of women are formed (5 per group), the participants attend all appointments together for the duration of their pregnancies. Mobile health clinic located at FBOs will provide a location for providers to provide brief one-on-
214893325|NCT04508738|OTHER|ERP|"The ERP intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~ERP: 1) neck cooling with an iced gel pad, 2) drinking a ∼ 6% CHO solution, 3) mouth-rinsing with a ∼10% CHO, ∼6 mg ･ kg -1 caffeine solution, 4) performing submaximal squats and 5) hyperventilating a hyperoxic mixture"
214893326|NCT04508738|OTHER|Placebo|"The control intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~1\) neck cooling with room temperature gel pack, 2) drinking an artificially sweetened solution, 3) mouth-rinsing with artificially sweetened solution (containing no caffeine), 4) performing unloaded squat manoeuvres, 5) deep breaths with room air"
214893327|NCT00707616|OTHER|Oral glucose tolerance test|one time 75g oral glucose tolerance test for measurement of insulin secretion and action
214893328|NCT04640415|DEVICE|Active Alarms|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds for more than a set duration. Continuous vital sign data will also be available to clinical staff.
214893329|NCT04328090|OTHER|Computer based Antimicrobial stewardship (AMS) intervention system|"1. Re-evaluation alerts and decision support for the duration of antimicrobial treatment.~2. Re-evaluation alerts and decision support for the choice of antimicrobial.~3. Quality control audit and feedback."
214893330|NCT07016867|DRUG|l-carnitine|to compare the efficacy of medical treatment (l-carnitine and antioxidants) versus surgical treatment (varicocelectomy) versus surgical treatment and medical treatment (varicocelectomy with adjuvant medications) on pregnancy rate on varicocele related subfertility patients with isolated teratozoospermia.
214893331|NCT07017920|DIAGNOSTIC_TEST|Vitamin D Levels measurement|Patient will have a vitamin D level drawn with their other prenatal labs during an OB visit. If vitamin D insufficiency (less than 30 ng/mL) or deficiency (less than 20 ng/mL) is detected, the patient will be prescribed and provided a supplementation of 2000 IU of vitamin D daily for the remainder of the pregnancy.
214893332|NCT07018427|DRUG|Sacituzumab Govitecan Monotherapy or Combination Therapy|The interventions in this study comprised either Sacituzumab Govitecan monotherapy or combination therapy. The specific combination regimens were determined based on real - world clinical practice patterns.
214893333|NCT07017738|OTHER|Corrective exercises|The corrective exercise program will include various positions: in standing, scapular retraction and arms overhead; in sitting, chin tuck and thoracic extension; in supine, arms in a W shape and horizontal abduction with external rotation; in side-lying, forward flexion starting with arms parallel to the body; and in prone, scapular retraction and depression in a T shape, extension from 90° forward flexion, and horizontal abduction at 90° with external rotation. Exercises will start with three repetitions held for 10 seconds and progress to six repetitions held for 25 seconds, based on overload principles and individual needs. Participants experiencing pain may stop and rest until symptoms subside.
214893334|NCT07017738|OTHER|Neural mobilization|Median nerve mobilization will be performed with the patient in a supine position, shoulder abducted to 90°, elbow flexed at 90°, and both wrist and head in a neutral position. The therapist will mobilize the nerve by extending the elbow to 45°, while the patient performs ipsilateral cervical lateral flexion to unload the nervous system.
214893335|NCT07012668|PROCEDURE|Interventional or surgical treatment|Simultaneous interventional or surgical treatment/staged interventional or surgical treatment
214893336|NCT07012668|PROCEDURE|Interventional or surgical treatment|Interventional or surgical treatment
214893337|NCT07017855|RADIATION|Stereotactic Arrhythmia Radioablation (STAR)|"Radiotherapy Implementation: During treatment on a TrueBeam™ linear accelerator (Varian Medical Systems, Palo Alto, CA, USA), a planned radiation dose of 25 Gy will be delivered to the defined planning target volume (PTV) using highly conformal stereotactic techniques. Image-guided radiotherapy (IGRT), respiratory gating, and Triggered Tracking will be utilized, targeting the previously delineated defibrillation lead of the implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D), with position verification every 15 degrees of gantry rotation.~Patient positioning will be performed using kV-kV imaging, based on pre-determined fiducial markers on the ICD/CRT-D defibrillation lead, followed by verification using gated cone-beam computed tomography (CBCT). Continuous ECG monitoring will be conducted throughout the treatment, and the patient will remain under cardiologist supervision."
214893338|NCT07017855|PROCEDURE|Catheter Ablation|CA will be conducted in an electrophysiology laboratory and will routinely follow diagnostic procedures, including an electrophysiological study (EPS) and three-dimensional electroanatomical mapping (3D-EAM). Once sufficient data on the nature and location of the arrhythmic substrate have been obtained from the three primary mapping modules-voltage, activation, and propagation-spatial 3D-EAM maps will be integrated with a 3D left ventricular reconstruction from multislice computed tomography (MSCT) or cardiac magnetic resonance (CMR). Subsequently, ablation will be performed by delivering energy to predefined target sites identified as the arrhythmia source to close the sVT isthmus or eliminate late potentials (LPs) and/or low-amplitude ventricular activities (LAVAs). Following CA, a repeat induction attempt of sVT using programmed ventricular pacing (VP) will be conducted to verify procedural efficacy.
214893339|NCT07018687|OTHER|day hospital|This multidisciplinary day hospital consists of 3 information workshops focused on balanced nutrition, oral nutritional supplements and enrichments as well as artificial feeding. During this day hospital, patients will meet with an endocrinologist nutritionist, a dietitian, and a teacher in adapted physical activity.
214893340|NCT07018687|OTHER|dietician consultation|dietician consultation
214893341|NCT07016854|PROCEDURE|Endovascular treatment|Endovascular treatment could be performed with any recanalization strategy, such as thrombectomy with aspiration or stent and angioplasty with balloon dilation or stent implantation, depending on the operator's choice and anatomical and radiological circumstances. In the setting of emergency stenting, the use of antiplatelet agents will depend on operator preference, anatomy, and bleeding risk.
214893342|NCT07016854|DRUG|The best medical treatment|Medical treatment includes intravenous thrombolysis, anticoagulant or antiplatelet drugs, etc. which is determined by the attending physician according to the Chinese guidelines or expert consensus.
214893343|NCT07016737|DRUG|Sintilimab Combined With Docetaxel Monotherapy|79 patients will receive treatment with a PD-1 inhibitor (sintilimab or camrelizumab 200mg, d1, q3w) combined with monotherapy chemotherapy (paclitaxel 175mg/m2 or docetaxel 75mg/m2 or irinotecan 270mg/m2, d1, q3w) for 4 cycles, followed by a 2-year maintenance treatment with PD-1 inhibitors. During this period, patients diagnosed with esophageal wall thickening and identified as having progressive disease (PD) have the option to undergo salvage radiotherapy (45-50.4 Gy/25-28/F/5-5.5 weeks) in conjunction with a dual-agent chemotherapy (paclitaxel 50 mg/m2, d1 + carboplatin AUC 2, d1, qw) for 5 cycles.
214296072|NCT06508216|DRUG|Dato-DXd|Patients in module 1 \& 2 will receive Datopotamab Deruxtecan (Dato-DXd) 6mg/kg every 21 days
214296073|NCT06508216|DRUG|Durvalumab|Patients in module 2 only will receive Durvalumab 1120mg every 21 days
214296074|NCT01103284|DRUG|DiaPep277|1.0 mg dose in 0.5 mL of solution
214296075|NCT01103284|DRUG|Placebo|"40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
214296076|NCT02801942|PROCEDURE|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
214478100|NCT06871150|DEVICE|HPI-AFM|"HPI: Provides a predictive index (from 0 to 100) based on real-time hemodynamic data, indicating the probability of the patient developing a hypotensive episode (MAP \< 65 mmHg) within the next 10-15 minutes.~AFM: In addition to hypotension prediction, continuously monitors parameters such as stroke volume and cardiac output, providing indications for optimal fluid administration. It is programmed to suggest the quantity and the speed of fluid administration based on real-time data and patient conditions.~In conjunction with the HPI system, the AFM suggests administering a specific fluid volume to correct the patient's hemodynamic status.~The AFM uses a predictive algorithm to calculate the patient's response to fluid administration, enabling anesthetists to dynamically adjust therapy.~The AFM system is based on assisted clinical decisions, where anesthetist receive algorithm-based AI recommendations to proactively administer fluids, avoiding the traditional reactive approach."
214478101|NCT06097637|OTHER|underwater endoscopic mucosal resection|underwater endoscopic mucosal resection achieves similar rates of complete resection with comparable safety, with lower rates of recurrence and fewer repeat procedures.
214478102|NCT06097637|OTHER|hot snare polypectomy|Current guidelines recommend preoperative hot snare polypectomy after preoperative saline injection, nylon ring, or metal clip ligation of the tip and pedicle of the polyps
214478103|NCT05310097|BEHAVIORAL|CPT|CPT will be delivered over the course of 12 one-hour weekly sessions (maximum of 18 weeks to complete treatment). Participants will have the option of receiving CPT in-person or via videoconferencing.
214478104|NCT05310097|BEHAVIORAL|MS|The MS protocol consists of eight strategies: categorization, evaluation, application, cue-based reminders, practice remembering, attention recruitment, praising recall, and repetitions.
214478105|NCT03167164|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
214893344|NCT07017309|BEHAVIORAL|Telerehabilitation Protocol for Diastasis Recti|12-week telerehabilitation program combining synchronous (live, supervised by physiotherapists) and asynchronous (video -recorded) therapeutic exercise sessions focused on progressive inner core exercises (i.e. transversus abdominis, pelvic floor muscle retraining), outer core strengthening, and functional retraining.
214893345|NCT07016893|OTHER|Healthy aging interventions|In our study workshop activities conducted for eight weeks and included an Exercise Workshop (Music-Based Exercise Workshop, Exercise Training with Active Video Games (Exergaming), Clinical Pilates Training Workshop, Cognitive Exercise Therapy Approach Workshop, Nordic walking, dance therapy), Skill-Oriented Art Workshop (Systemic Calligraphy Therapy Workshop, soap-candle making workshop, culinary arts workshop), and Disease Awareness Studies (disease awareness information and education, the process from diagnosis to acceptance, experiences of patients and relatives, use of daily life technologies, home adjustments against falls, introduction of municipal services for the elderly).
214893346|NCT07018115|OTHER|Basic Preoperative Information|Participants receive a brief, non-detailed explanation of the surgical procedure.
214893347|NCT07018115|OTHER|Detailed Verbal Preoperative Information|Participants receive a detailed verbal explanation covering the surgical procedure, including anesthesia, incision, bone removal, tooth sectioning, and suturing.
214893348|NCT07018115|OTHER|Visual Preoperative Information (2D Animation)|Participants receive a 2D animated video illustrating the surgical procedure in addition to the detailed verbal explanation.
214893349|NCT07018115|DRUG|Articaine 4% with epinephrine 1:100,000|A local anesthetic solution (Ultracain D-S; Aventis) administered in a dose of 2 ml for all patients. The anesthetic was injected to achieve regional nerve block anesthesia (inferior alveolar, lingual, and buccal nerves) prior to the surgical extraction of impacted mandibular third molars. The solution contains epinephrine as a vasoconstrictor to prolong anesthetic effect and minimize intraoperative bleeding.
214893350|NCT07018115|PROCEDURE|Surgical extraction of impacted mandibular third molar|A standardized surgical protocol was followed for the removal of impacted mandibular third molars. All procedures were performed under local anesthesia using a mucoperiosteal flap approach. The surgery included a linear or triangular incision, elevation of the mucoperiosteal flap, ostectomy using rotary instruments as needed, and tooth sectioning in cases of difficult extraction. The socket was irrigated with sterile saline solution, and hemostasis was achieved. Wound closure was performed with 4.0 silk sutures. All surgeries were conducted by experienced oral and maxillofacial surgeons without sedation or premedication. The entire procedure was monitored for hemodynamic parameters including heart rate, blood pressure, and oxygen saturation.
214893351|NCT07018115|DEVICE|Multiparameter patient monitor|A hospital-grade multiparameter monitor was used to measure and record patients' vital signs at five defined surgical stages: before surgery, after information delivery, after local anesthesia, during tooth extraction, and postoperatively. The monitor continuously recorded heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), and peripheral oxygen saturation (SpO₂). The collected data were used to evaluate physiological responses associated with anxiety and surgical stress.
214893352|NCT07018609|BEHAVIORAL|Zen Den Experience|The Zen Den is a dedicated safe space for healthcare staff to decompress and recharge during shifts, addressing the growing issue of workplace stress. It has soft warm lighting, sound machines and aroma therapy, relaxing furnishings centered around a faux fireplace to create a stress-free environment.
214893353|NCT07018609|BEHAVIORAL|Music Therapy Experience|The music therapy experience will consist of either Music Minutes which have music therapists available on specific units and circulating amongst staff across flexible shift times. Intervention choices will include relaxation songs, motivation songs, music, mindfulness, breathing to music, dance-a-minute, and brief song rewrites. Notes for Resilience will be scheduled group sessions that follow a more structured format and are 30 to 60 minutes in length. Involvement and coping will be emphasized through active forms of music participation, including drum circles, unit playlist creation, song writing, jam sessions, and song discussion.
214478106|NCT03167164|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
214478107|NCT03167164|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214478108|NCT03167164|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
214478109|NCT03167164|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214478110|NCT03167164|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214478111|NCT03167164|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
214296077|NCT02801942|PROCEDURE|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
214296078|NCT02801942|PROCEDURE|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
214296079|NCT02801942|OTHER|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
214296080|NCT00730782|BIOLOGICAL|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
214296081|NCT05192746|OTHER|control group|Exercise Therapy and hot pack This tendon exercise program is very effective if done consistently. There are five steps to the program: warm up, stretching exercise, strengthening exercise, stretching exercise, and heat.
214478112|NCT03167164|DRUG|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
214893354|NCT04153019|OTHER|Psychoeducational and rehabilitative intervention|Psycho-educational session: 3 weekly face-to-face consultations between a dyads and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
214893355|NCT07017504|DEVICE|proprioception-enhancing assistive orthosis|A wearable device that provides mechanical vibration to the tendons around the knee and ankle to enhance proprioceptive feedback. Vibration intensity and timing are controlled automatically based on body tilt measured by an IMU sensor. The device is applied during balance and joint sense assessments conducted across three visits.
214893356|NCT03173209|BEHAVIORAL|professional development in Calm Moments Cards program|Professional development (lecture and coaching)was used in combination with informal coaching by occupational therapy practitioners to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
214893357|NCT04851873|GENETIC|OAV101|Gene Therapy - 1.1e14 vector genome (vg)/kg as a one-time IV infusion was administered over approximately 60 minutes.
214893358|NCT00950131|OTHER|Presentation of information about drug approval and level of warning|Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
214893359|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
214893360|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
214893361|NCT03656588|DRUG|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
214893362|NCT03656588|DRUG|Iodine scrub and ChloraPrep alone|Iodine scrub and ChloraPrep alone
214893363|NCT01761760|BEHAVIORAL|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
214296082|NCT05192746|DEVICE|extracorporeal shock wave therapy|Shock Master 500 device will be applied once a week for four weeks in total. Each treatment consists of 2000 shocks 3 bar pressure, 20 Hz. Each rESWT session will take about 10 minutes. rESWT application will be performed on the supraspinatus trigger point. In successive treatments, there will be using of an energy density equal to 0.28 mJ/mm2
214296083|NCT05192746|DEVICE|high power pain threshold ultrasound|"High-power, pain-threshold, ultrasound therapy application (in W/cm2) in continuousmodes, to elicit threshold pain, the ultrasound probe must be kept static on the tendon.~Intensity will be gradually increased to the level of maximum pain the patient could bear. It will be kept at that level for 4 to 5 seconds and then will be reduced to the half-intensitylevel for another 15 seconds. This procedure will be repeated 3 times.High-power,"
214296084|NCT06825806|DEVICE|Femoral artery Doppler|Right common femoral artery will be examined before and after spinal anesthesia to evaluate pulsatility index, resisitive index, and waveform morphology
214296085|NCT04895215|DRUG|AB-2004|Taken 3 times daily with food
214893364|NCT01213277|OTHER|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
214893365|NCT01213277|OTHER|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
214893366|NCT03785327|DEVICE|tDCS|Participants either complete active and sham tDCS sessions one week apart or an autism training program.
214893367|NCT03785327|BEHAVIORAL|Autism Training|Autism Information Presentation developed by Dr. Grace Iarocci's Autism \& Developmental Disorders Lab at Simon Fraser University
214893368|NCT03590769|DRUG|18F-FDG|All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
214893369|NCT04880473|DEVICE|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
214296086|NCT04895215|DRUG|Placebo|Take 3 times daily with food
214478113|NCT03167164|DRUG|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
214478114|NCT03167164|RADIATION|Stereotactic Body Radiation Therapy|radiation
214478115|NCT03167164|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214478116|NCT03167164|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
214478117|NCT03167164|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
214296087|NCT00911495|DRUG|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
214296088|NCT05584176|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
214893370|NCT04935229|DRUG|SD-101|SD-101 doses will be delivered via hepatic artery infusion using pressure enabled drug delivery using the TriNav device
214893371|NCT04935229|BIOLOGICAL|Nivolumab|During Cohort B, nivolumab will be administered together with SD-101 and during Cohort C, it will be administered with ipilimumab and SD-101
214893372|NCT04935229|BIOLOGICAL|Ipilimumab|During Cohort C, ipilimumab will be administered together with nivolumab and SD-101
214893373|NCT04935229|BIOLOGICAL|Nivolumab and Relatlimab|During optional Cohort C1, nivolumab and relatlimab will be administered with SD-101
214893374|NCT01534130|DEVICE|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
214893375|NCT01534130|DEVICE|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
214893376|NCT00484640|DRUG|Coumadin|
214893377|NCT02198963|DRUG|Hypochlorous acid solution 106 mg/L|test product
214893378|NCT02198963|DRUG|0.1% (w/v) Sodium Lauryl Sulfate|positive control
214893379|NCT02198963|DRUG|0.9% Physiological Saline, USP|negative control
214893380|NCT02628886|BIOLOGICAL|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
214893381|NCT02628886|BIOLOGICAL|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
214893382|NCT02628886|OTHER|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
214296089|NCT05584176|DEVICE|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
214893383|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL ECT)|
214893384|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL LAP ECT)|
214893385|NCT03240263|PROCEDURE|Inspiratory Muscle Training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Resistance adjusted to the highest tolerable load.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
214893386|NCT03240263|PROCEDURE|Endurance training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Low training resistance adjusted to \<10% maximal inspiratory pressure.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
214893387|NCT03982992|DRUG|Blinatumomab in combination with donor lymphocyte infusion|Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion
214893388|NCT06632119|DEVICE|high-intensity laser therapy|high-intensity laser therapy (HILT) machine, ASA laser
214893389|NCT06632119|DEVICE|Sham-HILT|Sham-HILT, HILT machine without laser release
214893390|NCT03555110|BEHAVIORAL|Personality Factor Battery Test (PFB Test)|Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.
214893391|NCT03555110|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy (EMDR)|"It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory."
214893392|NCT00736632|DRUG|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
214893393|NCT00736632|DRUG|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
214296090|NCT02057198|DRUG|Fidaxomicin|
214296091|NCT02057198|DRUG|Metronidazole|
214296092|NCT02057198|DRUG|Vancomycin|
214296093|NCT01985581|DRUG|Guanfacine extended release|
214296094|NCT01985581|DRUG|Placebo|
214296095|NCT01985581|DRUG|Stimulant therapy|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
214478118|NCT03167164|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
214893394|NCT06403254|PROCEDURE|There isn't an intervention name because the study is observational and has only one group.|Follow-up after surgey
214893395|NCT04957030|DIAGNOSTIC_TEST|ULDCT group|underwent ultralow-dose chest CT
214893396|NCT00281957|DRUG|sorafenib tosylate|Given orally
214893397|NCT00281957|DRUG|tipifarnib|Given orally
214893398|NCT00281957|DRUG|temsirolimus|Given IV
214893399|NCT03065946|OTHER|Early wakening|By using an intravascular device to administer mild TH for 24 hours, patients can safely have their medically induced coma reversed early at 12 hours, allowing an accurate neurological assessment to be performed
214893400|NCT00797589|DRUG|HES|20ml/kg as prime fluid
214893401|NCT00797589|DRUG|Ringer lactate|
214296096|NCT04388267|DRUG|Fluid challenge|"All patients who met the inclusion criteria will receive a standardised bolus of 250 ml of crystalloid in 5 minutes administered by hand with a 50 ml syringe.~During the study period, hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected for 20 minutes prior to the intervention (fluid challenge), during the fluid challenge and 25 minutes after completion.~The total duration of the intervention (fluid loading) is 5 min. The total duration of hemodynamic parameters recording is 60 min."
214296097|NCT05283798|DEVICE|IUD|Postpartum intra-caesarean section insertion of copper T380 versus multiload 375
214296098|NCT03878745|DEVICE|Terumo Nanopass® 34G pen needle|Insulin pen needle
214478119|NCT03167164|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
214478120|NCT06001125|DRUG|Methotrexate|Methotrexate 20 mg PO weekly
214478121|NCT06479629|DRUG|Piracetam|800mg oral tablet of Piracetam three times every day for 3 months
214478122|NCT06479629|DRUG|Placebo|starch tablet
214478123|NCT06677970|DRUG|BP lowering drugs (nicardipine, labetalol, urapidil)|After successful reperfusion, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
214893402|NCT02210624|BIOLOGICAL|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
215050504|NCT06284239|OTHER|Tell me about the game.|It is a game played with playing cards. On the game cards, there will be the word that the narrator student must explain to his group friends and five prohibited words right below this word. Prohibited words are synonyms, antonyms or close meanings of the word to be explained. According to the game rules, the student narrator will explain the word on the cards to his group friends without using prohibited words.
215050505|NCT02424058|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
214296099|NCT03878745|DEVICE|BD Nano™ PRO 32G pen needle|Insulin pen needle
214296100|NCT01264146|PROCEDURE|HBOT|Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)
214296101|NCT01264146|PROCEDURE|Placebo (Sham)|open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
214296102|NCT00022451|DRUG|tipifarnib|
214296103|NCT00001929|DRUG|Eliprodil|
214296104|NCT03540147|DEVICE|Hokanson Cuffs|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will be completed will be randomly assigned to the participant.
214296105|NCT03540147|DEVICE|BStrong Bands|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
214478124|NCT06677970|DRUG|BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)|After successful reperfusion, appropriate BP raising (20% increase in SBP, maximum of 180 from baseline SBP) are administered.
214478125|NCT06873711|BIOLOGICAL|vedolizumab|Intravenous injection of VDZ (300mg/time) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of VDZ every 8 weeks to maintain treatment.
214478126|NCT05439018|OTHER|Integrated Neuromuscular inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
214478127|NCT05439018|OTHER|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
214478128|NCT06755762|OTHER|Organoid 3D culture|Investigate different normal cells (lung, bone, soft tissue, liver, etc) as metastatic organs to simulate the behaviors of CTCs in metastatic sites
214478129|NCT06871826|DRUG|TIMP2 level|different TIMP2 level after on-pump cardiac surgery
214478130|NCT06873282|BIOLOGICAL|TB/Flu-05E|Participants will receive single intranasal injection of TB/Flu-05E vaccine in 0.5 ml, containing 7.7 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the TB10.4 and HspX antigens of M. tuberculosis
214478131|NCT06873282|OTHER|Placebo|Participants will receive single intranasal injection of physiological buffer in 0.5 ml
214478132|NCT06872957|DEVICE|Surface Electromyography Noraxon MiniDTS system|Trapezius muscle activities of 19 healthy individuals were measured with surface EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) in the ascending, stationary and descending phases of the wall slide exercise under different head posture conditions: natural head posture and corrected head posture.
214893403|NCT03103516|PROCEDURE|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
214893404|NCT03103516|PROCEDURE|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
214893405|NCT01476514|OTHER|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
214893406|NCT01876446|OTHER|Laboratory Biomarker Analysis|Correlative studies
215050506|NCT02424058|BEHAVIORAL|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
215050507|NCT02383862|OTHER|Feedback Group|The intervention will consist of feedback provided to clinicians in the form of patients' baseline PROMIS scores
214668543|NCT05190835|DEVICE|Optical scanner|During the visits (Day 0 before surgery, Day 8, Day 21, Day 45, Month 3 and Month 6 after surgery), a measurement of the volume and the perimeter of the patient's two feet is carried out (operated foot and control foot). The edema is measured by a non-invasive method using an optical scanner (camera + laser scanning). The image processing software accompanying this tool has an automatic calculation of the volumes and the different perimeters of the foot. The measurement time by the scanner is less than 4 seconds.
214668544|NCT02651610|BIOLOGICAL|Bavituximab|Biological: bavituximab
214296106|NCT04146025|BEHAVIORAL|Nature Coach Intervention|"1. Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~2. Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~3. Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
214296107|NCT05555212|DRUG|QLH11811|"In Ia phase, subjects will first receive oral single dose of QLH11811, then will be observed for 7 days. If the drug is tolerated by the subjects, the subjects will continue to receive the oral repeat dose of QLH11811 for 21 consecutive days. Upon the completion of observation for DLT in the subjects (DLT observation period is the 28 days after the first dose), the subjects will continue to receive the repeat dose of QLH11811 in Cycle 2 and subsequent cycles. The dosing frequency in Cycle 2 and subsequent cycles is once daily, and each cycle has 3 weeks.~The RP2D of QLH11811 is determined on the basis of comprehensive evaluation of all safety and tolerability data and all available PK, PD and efficacy data during the dose escalation phase. In phase 1b, the cohort expansion study is carried out for all cohorts in China and the United States concurrently according to the determined RP2D."
214296108|NCT01813539|DRUG|ARGX-110|ARGX-110 will be administered as an IV infusion.
214296109|NCT03054545|DRUG|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
214893407|NCT01876446|DRUG|Pegylated Irinotecan|Given IV
214893408|NCT01876446|OTHER|Pharmacological Study|Correlative studies
214668545|NCT02651610|DRUG|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
214668546|NCT01050777|DRUG|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
214893409|NCT00396643|DRUG|Omega 3 fatty acids|The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
214893410|NCT02457923|OTHER|Mobile phone counselling|i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
214893411|NCT02300155|DRUG|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
214893412|NCT02300155|DRUG|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
214893413|NCT03277755|DRUG|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
214893414|NCT03277755|DRUG|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
214893415|NCT03277755|DRUG|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
214893416|NCT05329259|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One dose of 13vPnC (0.5mL) will be administered intramuscularly.
214893417|NCT00695305|DRUG|rilapladib|250 mg oral dose once daily
214893418|NCT00695305|DRUG|placebo|placebo
214893419|NCT00695305|OTHER|18F Fluorodeoxylucose (FDG)-PET|FDG-PET
214893420|NCT03180645|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
214893421|NCT03180645|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
214893422|NCT03180645|OTHER|No treatment|No treatment
214893423|NCT02914860|DEVICE|Cardiac CT|"* Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map."
214668547|NCT01050777|DRUG|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
214668548|NCT01050777|DRUG|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
214668549|NCT01050777|DRUG|Placebo|Placebo
214893424|NCT02914860|PROCEDURE|Ablation Procedure|"1. CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~2. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~3. RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~4. Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~5. Control HFS~6. At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~7. Exit and entrance block confirmation~8. Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
214893425|NCT02914860|DEVICE|D-SPECT|
215050508|NCT03440073|OTHER|Mulligan Concept Intervention|The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.
215050509|NCT03440073|OTHER|Sham Mulligan Concept Treatment|The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
215050510|NCT01833494|DRUG|PA21|
214893426|NCT05052112|OTHER|E-PR-01|Active arm
214296110|NCT03191760|BEHAVIORAL|Behavioral Activation|Participants will be asked to attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
214296111|NCT04934345|DIAGNOSTIC_TEST|Fluid challenge|The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
214296112|NCT03885141|DRUG|Zolpidem|Zolpidem or Placebo if there is a wake up during the night
214296113|NCT03012412|BEHAVIORAL|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
214296114|NCT06320795|DEVICE|SOUNDI|Continuous monitoring of vital signs for diagnosis and follow-up of sleep-disordered breathing in adults.
214296115|NCT03585179|DRUG|Oral Tranexamic Acid|Participants will take a pill of 250 mg bid for 12 weeks
214893427|NCT05052112|OTHER|E- PR-02|Placebo arm
214893428|NCT05243446|DRUG|Losartan|losartan treatment
214893429|NCT01892280|BEHAVIORAL|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
214893430|NCT01892280|BEHAVIORAL|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
214296116|NCT03585179|DRUG|5% topical tranexamic acid|Participants will apply a layer of gel on the affected skin bid for 12 weeks
214296117|NCT03585179|DRUG|4% hydroquinone|Participants will apply a layer of cream on the affected skin once at night
214296118|NCT05852743|DEVICE|shear wave and strain elastography|shear wave elastography is a quantitative technique , while strain elastography is qualitative technique
214296119|NCT01214161|DRUG|2% lidocaine gel|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
214296120|NCT01214161|OTHER|placebo|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
214296121|NCT03575312|DRUG|Enrofloxacin|dermal application, inhalation rsp. oral administration of Enrofloxacin
214893431|NCT01028482|DRUG|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months"
214893432|NCT01028482|DRUG|placebo|placebo
214893433|NCT01028482|OTHER|psychotherapy|psychotherapy
214893434|NCT00858182|DRUG|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
214893435|NCT00858182|DRUG|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
214893436|NCT05327231|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
214893437|NCT05327231|DRUG|Docetaxel|Docetaxel 75mg/m2 every 21 days a cycle.
214296122|NCT03462550|DEVICE|Laryngeal mask|LMA insertion
214296123|NCT06197815|BEHAVIORAL|The assistance type during ERCP|The senior trainer guides the trainees during ERCP procedure outside the operating room using communication equipment and the screen displaying an endoscopic view.
214296124|NCT04645641|DEVICE|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
214296125|NCT03800927|DEVICE|Long duration ultrasound|Low-intensity long duration ultrasound treatment
214668550|NCT05257122|DRUG|Fruquintinib|Fruquintinib 5mg qd, d1-21, q28d
214893438|NCT00508131|OTHER|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
214893439|NCT03016273|PROCEDURE|creation of bladder flap|Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
215050511|NCT05866692|DRUG|TY-2699a|"TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results"
214893440|NCT00247780|PROCEDURE|Pulmonary vein isolation and cavotricuspid ishtmusblock|
214893441|NCT01808573|DRUG|neratinib|
214893442|NCT01808573|DRUG|capecitabine|
214893443|NCT01808573|DRUG|lapatinib|
214893444|NCT03216863|OTHER|Respiratory rehabilitation|It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
214893445|NCT05709197|PROCEDURE|Braun anastomosis|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. In addition to the reconstruction technique used, a side-to-side anastomosis will be created between the afferent and efferent jejunal limbs of the gastrojejunostomy (GJ) at 20 cm distance from the GJ. The anastomosis will be hand-sewn with monofilament PDS 3-0 one-layer running suture.
214893446|NCT05709197|PROCEDURE|Standard Child reconstruction|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. The surgeon is able to perform the PD as normally would be done (antecolic, retrocolic, pylorus-preserving or with distal gastric resecting).
214296126|NCT02937779|DRUG|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
214296127|NCT02937779|DEVICE|Rapid tests HBe Ag|For all HBs Ag positive women
214296128|NCT01042236|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
214668551|NCT02424487|PROCEDURE|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
214893447|NCT02208089|PROCEDURE|Transepithelial Photorefractive Keratectomy (TransPRK)|Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
214893448|NCT02208089|PROCEDURE|Corneal Collagen Cross-Linking (CXL)|"Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)"
214893449|NCT03009773|OTHER|rehabilitation multitasking walking.|rehabilitation multitasking walking.
214893450|NCT03009773|OTHER|Traditional walking rehabilitation|Traditional walking rehabilitation
214893451|NCT01153373|BEHAVIORAL|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only."
214893452|NCT01153373|BEHAVIORAL|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
214893453|NCT03905616|DEVICE|functional Magnetic Resonance Imaging|In a 2-hour session, the subject we be shown different control and experimental conditions (all being visual stimuli) in perceptive tasks.
214893454|NCT01593046|DRUG|GSK1265744 Oral|30mg tablet
214893455|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
214893456|NCT01593046|DRUG|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
214893457|NCT01593046|DRUG|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
214893458|NCT01593046|DRUG|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
214893459|NCT01593046|DRUG|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
214893460|NCT01593046|DRUG|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
214893461|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
214893462|NCT02720848|DEVICE|Stiffening wire|The stiffening wire will be inserted into the double/single balloon enteroscope.
214893463|NCT02720848|DEVICE|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
214893464|NCT01244503|DRUG|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
214893465|NCT01807312|DEVICE|Endoscopic CO2 regulation unit and accessories|Olympus UCR Endoscopic CO2 Regulation Unit
214893466|NCT01807312|DEVICE|Placebo|
214893467|NCT03629184|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days."
214893468|NCT03629184|DRUG|Oseltamivir|Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
214893469|NCT00972595|DRUG|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
215050512|NCT04357561|BEHAVIORAL|Exercise group (Schroth best practice)|Exercise program will be structured with scoliosis specific exercises (schroth best practice). Schroth best pratice is a pattern spesific scoliosis rehabilitation concept which aimes active self correction during curve pattern specific curve activities of daily life. Exercises for rotational breathing, everyday activities, spinal mobilization and corrective exercises will be specified based on the curve type and applied under the supervision of a physiotherapist.
214893470|NCT00972595|DRUG|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
214893471|NCT01590303|DRUG|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
214893472|NCT01590303|DRUG|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
214893473|NCT00462150|BEHAVIORAL|home-based emotional disclosure|
214893474|NCT00462150|BEHAVIORAL|time management control condition|
214893475|NCT00468364|DRUG|insulin glargine|
215050513|NCT02631291|BEHAVIORAL|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
214296129|NCT04063956|BEHAVIORAL|multi-domain internet-based adaptive training program|The training paradigms include a time perception task, visual search task, rapid serial presentation task, delayed match to sample task, paired-associate recall task, attention span task, digit span task, go-no go task, Stroop task, task switching, auditory span task and n-back working memory task. Each task has several difficulty levels. The tasks are grouped in different cognitive domains including: processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Participants in the cognitive training group will complete 40 min of training daily, 4 days a week for 12 weeks. When a high accuracy (80%) is achieved for each task, the level of difficulty will be upgraded for that task.
214893476|NCT00468364|DRUG|NPH insulin|
214893477|NCT04428814|BIOLOGICAL|CT-P43|45mg single dose
214893478|NCT04428814|BIOLOGICAL|EU-approved Stelara|45mg single dose
214893479|NCT04428814|BIOLOGICAL|US-licensed Stelara|45mg single dose
214893480|NCT03254264|BEHAVIORAL|Early Start Denver Model|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
214893481|NCT03254264|BEHAVIORAL|'as-usual' intervention|a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
214893482|NCT01884038|DRUG|treprostinil sodium|"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"
214893483|NCT01884038|DRUG|Placebo|
214893484|NCT05225779|DIAGNOSTIC_TEST|12- derivation Electrocardiography|6 precordial and 4 extremity electrodes will be placed at appropriate anatomical points and a total of 6 12-lead ECGs will be taken at different anesthesia depths before anesthesia induction and throughout the operation.
214893485|NCT05446259|OTHER|Standard clinical care procedures and outcome measurements.|Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
214668552|NCT02515695|DRUG|Interferon beta-1a|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
214893486|NCT00034008|BEHAVIORAL|Healing Touch|
214893487|NCT03132233|DIETARY_SUPPLEMENT|Beta-hydroxybutyrate calcium and magnesium salt|Exogenous ketone body in mineral salt form.
214893488|NCT03132233|OTHER|placebo powder|matched placebo powder to the IMP.
215050514|NCT02631291|BEHAVIORAL|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
215050515|NCT01154491|DRUG|Ferric carboxymaltose|"Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
215050516|NCT01154491|DRUG|Erythropoietin|Erythropoetin: 40,000 units subcutaneous (unique dose).
215050517|NCT01154491|DRUG|Placebo|"Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
215050518|NCT02135068|DEVICE|Medtronic MiniMed Closed Loop (CL) System|The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.
215050519|NCT02135068|OTHER|Snacking|Up to 45 g of oral glucose via Gatorade
215050520|NCT06167226|DRUG|Personalized Ayurveda treatment protocol|The treating physician decided and advised personalized Ayurveda treatment protocol based on disease and patient's condition
214893489|NCT03714243|DEVICE|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
214893490|NCT01461538|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
214893491|NCT01461538|DRUG|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
214893492|NCT01461538|DRUG|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
214893493|NCT02100488|DEVICE|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
214893494|NCT02100488|OTHER|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
214893495|NCT04107909|PROCEDURE|laparoscopic cholecystectomy|"Both four port and three port LC is performed With the patient in supine position, with the surgeon and assistant on the left side and the monitor on the right side. Head up and right up position is employed during surgery in both the groups. Pneumoperitoneum of 12mmHg is created using open Hassan's method through the umbilical port.~In 3 port a 5.5 mm umbilical visiport for 5 mm lens 30 degree A second 10 mm trocar is placed inferior to the sternum at the midline, while the third 5mm trocar is placed 4-5cm inferior to the right costal margin on the right midclavicular line. For the four port LC, additional 5mm port is placed in the sub costal region at the anterior axillary line. Posterior dissection and delineation of The Calot's triangle is done. Then, the cystic artery and cystic duct are identified, isolated, doubly clipped and divided. The gallbladder is removed through the umbilical port using a 10mm gallbladder extractor."
214893496|NCT03169088|OTHER|Coaching procedure|"In this study, the volunteers will be followed during one year.~The wellbeing will be followed with :~* survey like FFQ, IPAQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers"
214893497|NCT00141778|DRUG|Placebo|Matching placebo taken once a day
214893498|NCT00141778|DRUG|Ramipril|Taken orally, once a day
214893499|NCT00141778|DRUG|Spironolactone|Taken orally, once a day
214893500|NCT05816109|DIAGNOSTIC_TEST|superficial cervical block|After anesthesia and surgical procedures, bilateral superficial cervical plexus block will be applied to the lower border of the sternocleidomastoid muscle, accompanied by ultrasonography. After cleaning the area with povidone iodine before the block, the sternocleidomastoid muscle and carotid artery and other vascular structures are determined using a linear ultrasound probe. Local anesthetic will be administered between the lower border of the sternocleidomastoid muscle and the upper border of the prevertebral fascia with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection method with saline before local anesthesia is given. After the location of the needle is confirmed, 2 ml of saline will be injected, followed by 10 ml of 0.5% bupivacaine. The deep cervical fascia of the superficial lamina will appear to open.
214893501|NCT05816109|DIAGNOSTIC_TEST|without superficial cervical block|patients who underwent anterior cervical surgery and did not undergo superficial cervical block
215050521|NCT04726891|BEHAVIORAL|Movement-2-Music + Social Networking Support|The primary goal of the proposed research is to conduct a 12-week pilot study of the SMART-HEALTH intervention in 30 individuals with SCI. There are several unique features of this study design, including a novel adapted exercise program (M2M), instructor-led, individualized training (M2M Live; described in D.2.1), individualized behavioral coaching, and social networking support.
215050522|NCT04403308|BIOLOGICAL|ONO-7913|ONO-7913 will be administered by intravenous continuous infusion during the designated time.
215050523|NCT04708262|OTHER|Cognitive Analytic Therapy for Containing Self-Harm in Young People|The intervention will run over five sessions, each lasting around 30 - 40 minutes. Researchers will follow the CATCH-Y manualised treatment guide. CATCH-Y is a brief, five session psychological intervention based upon CAT principles and designed to help young people who have self-injured.
215050524|NCT00234130|PROCEDURE|nocturnal vs conventional dialysis|
215050525|NCT01694433|DRUG|Calcipotriene|1g daily BID
215050526|NCT01694433|DRUG|Placebo|1g daily BID
215050527|NCT03071861|DRUG|Darbepoetin Alfa|Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age
215050528|NCT03071861|DRUG|Normal Saline|Single dose of normal saline, IV, given at less than 24 hours of age
215050529|NCT01109186|OTHER|biological parameters|blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
215050530|NCT03021603|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
215050531|NCT03729986|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% of maximal inspiratory pressure in sitting and supine positions. The orders of the two loaded test conditions will be conducted in random order with at least 20 minute separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
215050532|NCT03673540|BEHAVIORAL|CBT+ application|Smartphone application that comprises electronic self-monitoring of food intake, eating disorder behaviors, and mood and ecological momentary interventions
215050533|NCT00476320|PROCEDURE|Magnetic Resonance Imaging|
215050534|NCT00476320|PROCEDURE|Revascularization|
215050535|NCT00476320|PROCEDURE|Echocardiography with myocardial deformation imaging|
214893502|NCT05209607|OTHER|Mobile Medical and bundle management|Based on the current follow-up management platform of respiratory disease, the WeChat official account will be designed and used to provide health education for patients, such as smoking cessation, reasonable diet, appropriate exercise, etc., and monitor some physiological indicators (such as body temperature, weight, the score of mMRC, etc.) and guide patients to standardize medication and pulmonary rehabilitation.
214893503|NCT05209607|OTHER|Mobile Medical and standard of care|Based on the mobile medical, participants will receive advice on standard medication only.
214893504|NCT02729909|DRUG|Lubiprostone|Lubiprostone capsules
214893505|NCT02729909|DRUG|Placebo|Lubiprostone placebo-matching capsules
214893506|NCT01723475|BIOLOGICAL|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
214893507|NCT01723475|BIOLOGICAL|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
215050536|NCT04361292|PROCEDURE|INTRAUTERINE INSEMINATION|Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.
215050537|NCT04406402|BEHAVIORAL|Acute dietary protocols and lifestyle modification|The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).
215050538|NCT06151470|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
215050539|NCT06151470|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
215050540|NCT06178367|DRUG|Low molecular weight hyaluronic acid|Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle
215050541|NCT06178367|DRUG|High molecular weight hyaluronic acid|Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle
214296130|NCT04063956|BEHAVIORAL|active-control program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
214296131|NCT02338960|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
214296132|NCT02338960|DRUG|Placebo|Placebo
214296133|NCT02307955|DEVICE|firefly|
214296134|NCT02307955|OTHER|Standard of care|
214296135|NCT03721315|BEHAVIORAL|Intervention|"The health literacy enhancement will comprise of the following:~* Practical day to day information to help manage the disease~* Benefits of medication and adherence~* Tips to improve managing shortness of breath~* Proper use of inhalers (if applicable)~* Managing daily activities"
214296136|NCT03037255|OTHER|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
214296137|NCT00227903|BEHAVIORAL|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
214296138|NCT00227903|BEHAVIORAL|Brief Advice|Advice and education
214296139|NCT01475331|DRUG|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
214296140|NCT01475331|DRUG|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
214668553|NCT02699775|OTHER|Motion Analysis|Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
214893508|NCT05994885|PROCEDURE|Root surface debridement|the included patients will undergo full-mouth supra- and subgingival debridement by using ultrasonic device and manual instrumentation at baseline. This is followed, after 1 week, by performing root surface debridement for all pockets with PPD = 4-6 mm for each patient. All patients will be instructed to brush their teeth twice daily and will be supplied with the same type of tooth paste and toothbrush, with suitable interdental aids.
214893509|NCT01391897|BEHAVIORAL|psychotherapy|"multimodal complex psychotherapy"
214296141|NCT01475331|DRUG|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
214893510|NCT04366947|DEVICE|NIO® (Intraosseous access)|obtaining intravascular access using a ready intravenous NIO needle set
214893511|NCT04366947|DEVICE|Standard of Care (Intravenous access)|obtaining intravascular access using a standard intravenous cannula
214893512|NCT06551233|DRUG|9MW2821|Patients will be evaluated from low dose to high dose through intravesical therapy and then select the suitable doses to expand according to study data.
214893513|NCT00003183|BIOLOGICAL|filgrastim|
214893514|NCT00003183|DRUG|mitoxantrone hydrochloride|
214893515|NCT05955183|DRUG|AZD5055|AZD5055 will be given orally to randomized participants as per the arm they are assigned.
214893516|NCT05955183|DRUG|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
214893517|NCT04763954|OTHER|Rethink therapeutic game|The Rethink therapeutic game is a 7 levels online game developed and tested for children. Each level is based on a specific skill and its efficiency has been previously studies in children.
214893518|NCT02655497|BEHAVIORAL|Cognitive training|
214893519|NCT02655497|BEHAVIORAL|Psychosocial education|
214893520|NCT03220854|RADIATION|Stereotactic radiotherapy|Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.
214893521|NCT03220854|OTHER|Biological: humanized anti-PD-1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
214893522|NCT03220854|OTHER|Biological: humanized anti-PD-L1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
214893523|NCT06353698|DIETARY_SUPPLEMENT|fasting mimicking diet|Fasting mimicking diet is limited calorie diet to enhance the effectiveness of chemotherapy
214893524|NCT00082277|DRUG|Anastrozole|1mg/Day Oral
214668554|NCT01165229|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
214668555|NCT01165229|BIOLOGICAL|Placebo|Intramuscular injection.
214668556|NCT02951923|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum vs. soy during rugby training
214893525|NCT00082277|DRUG|Risedronate Sodium|35mg/week, oral
214893526|NCT00368797|DRUG|XRP0038 (NV1FGF)|
214893527|NCT02085447|BEHAVIORAL|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
214893528|NCT02658760|DRUG|Dexmedetomidine|dexmedetomidine plus placebo
214893529|NCT02658760|DRUG|Bupivacaine|dexmedetomidine and Bupivacaine
214893530|NCT01321827|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
214893531|NCT01321827|DRUG|Itraconazole|Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
214893532|NCT04521127|OTHER|Kinesio Taping|Taping will be performed on sitting position with contralateral lateral flexion and flexion of the neck, using muscle technique with I strip and stretching the head at the maximum level in order to benefit from the muscle release effect. Kinesio tape was applied directly on muscle with 0% stretching.
215050542|NCT06178367|DRUG|Vehicle|Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
215050543|NCT01773954|DRUG|Intravitreal Aflibercept Injection|Increased or decreased time between visits
215050544|NCT03125499|OTHER|Previous treated with TPX-100|No intervention, only observational
214296142|NCT06398054|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg tablet
214668557|NCT02951923|DIETARY_SUPPLEMENT|Soy|
214296143|NCT06398054|DRUG|Hyoscine N-Butil Bromide|Hyoscine N-Butil Bromide 10 mg two tablets
214296144|NCT06398054|DRUG|placebo|Two tablets
214296145|NCT04853927|DRUG|Proxalutamide|Proxalutamide 300mg q.d suspension
214668558|NCT01451333|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
214668559|NCT01451333|DRUG|Efavirenz|400mg qd; 2 x 200mg
214668560|NCT02355340|OTHER|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
214668561|NCT02355340|OTHER|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
215050545|NCT03399279|PROCEDURE|Open flap debridment|Full mucoperiosteal flap reflected+ Debridement of infrabony defect
215050546|NCT03399279|OTHER|Perforated collagen membrane|Membrane perforations using dental needle
215050547|NCT03399279|OTHER|Occlusive membrane|Biotech collagen membrane
215050548|NCT03399279|OTHER|Nanohydroxyapetite|Nanbone Particles
215050549|NCT00871663|DRUG|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
215050550|NCT00560092|DRUG|intrathecal magnesium sulfate|intrathecal magnesium sulfate
214668562|NCT04510259|PROCEDURE|Selective Brachial plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1: 200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
214668563|NCT01277575|DEVICE|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
214668564|NCT01277575|DEVICE|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
215050551|NCT00869635|DRUG|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
215050552|NCT00869635|PROCEDURE|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
214668565|NCT01720251|DRUG|placebo|SC injections of placebo on days 1, 7, 14, 28 and 56
214668566|NCT01720251|DRUG|AllerT low dose|SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56
214668567|NCT01720251|DRUG|AllerT full dose|SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
214668568|NCT01370070|DRUG|MK-2206|200mg weekly repeated q 28 days
214668569|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
214668570|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
214668571|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
214668572|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
214668573|NCT00520598|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
214668574|NCT00520598|BIOLOGICAL|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
214668575|NCT01530490|DRUG|Cabergoline and Hydroxyethyl Starch|0.5mg
214668576|NCT01530490|DRUG|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
214668577|NCT01243476|DRUG|Lenalidomide|Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
214668578|NCT01243476|OTHER|Placebo|Placebo, oral use, daily during study treatment (104 weeks)
214668579|NCT00881205|DRUG|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
214668580|NCT00881205|DRUG|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
214668581|NCT00550238|DRUG|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
214668582|NCT03669393|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
214668583|NCT03502135|DRUG|Tetracaine HCl and oxymetazoline HCl nasal spray|Two intranasal sprays of anesthetic. Each spray delivers 0.2 mL of solution containing 6 mg tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride
214668584|NCT02966457|DRUG|Colistimethate Sodium|Selective oral intestinal decolonization
214668585|NCT04543448|OTHER|Traditional Rehabilitation for multiple sclerosis|Traditional rehabilitation program include strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs.
214668586|NCT04543448|OTHER|Cervical mobilization for multiple sclerosis|Cervical mobilization program include myofascial relaxation techniques and mobilization to cervical spine in addition to traditional program.
214668587|NCT02418494|OTHER|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
214668588|NCT02418494|OTHER|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
214668589|NCT00200681|DRUG|Velcade|
214668590|NCT03823638|DIETARY_SUPPLEMENT|Oral D-Mannitol of Placebo|Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
214668591|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein preservation|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
214668592|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein sacrifice (disconnection)|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
214668593|NCT04350203|PROCEDURE|Laparoscopic right colectomy with intracorporeal anastomosis (IA)|First, the right colon dissection was completed by laparoscopy. An isoperistaltic side-to-side ileocolonic mechanical anastomosis was then performed by using a linear cutting stapler. The enterotomy used to enter the stapler was closed with a running suture (3-0 absorbable monofilament or a 3-0 barbed suture). Finally, the specimen was extracted through a Pfannenstiel mini-laparotomy (4-5 cm).
215050553|NCT00869635|PROCEDURE|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
215050554|NCT06302465|DRUG|narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide|Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.
215050555|NCT06302465|DRUG|doxorubicin、cisplatin、methotrexate、ifosfamide|doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)
214893533|NCT04521127|OTHER|Dry needling|The trigger point on the taut band will be held with the thumb and forefinger from below and above. In the needling technique, a 0.25 \* 25-mm with nickel handle, disposable sterile steel acupuncture needle will be used. The needle tip will be inserted perpendicularly into the subcutaneous tissue and inserted into the muscle until the trigger point in the taut band was found. The same point will be pinned 8-10 times with fast needle movements inside and out. Then the needle tip will pulled back so that it did not come out of the skin, and the bottom, top and sides of the first entered point were also pinned. This procedure was applied to all trigger points in the trapeze muscle.
214296146|NCT04853927|DRUG|Placebo|Proxalutamide 300mg q.d placebo
214296147|NCT02261714|BIOLOGICAL|TG01|"TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
214296148|NCT02261714|BIOLOGICAL|TG01|"For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
214296149|NCT02345811|DEVICE|Sapphire|silicone-hydrogel contact lens
214893534|NCT05170282|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
214893535|NCT00329082|DRUG|LY2062430|"1. 100mg QW IV for 12 weeks~2. 100mg Q4W IV for 12 weeks~3. 400mg QW IV for 12 weeks~4. 400mg Q4W IV for 12 weeks"
214893536|NCT00329082|DRUG|Placebo|5: Placebo QW IV for 12 weeks
214893537|NCT03660176|DRUG|butyrate enemas + routine management|10ml/kg volume of butyrate enemas in addition to the colonic irrigations
214893538|NCT03660176|OTHER|routine management|the colonic irrigations
214893539|NCT01500473|DRUG|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
214893540|NCT03705429|DRUG|TC-H x Paclitaxel (P) + Trastuzumab(T)|chemotherapy
214893541|NCT00922740|DRUG|VA106483|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
214893542|NCT00922740|DRUG|Placebo|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
214893543|NCT00079430|PROCEDURE|adjuvant therapy|
214893544|NCT00079430|DRUG|paclitaxel|Given IV
214893545|NCT00079430|DRUG|carboplatin|Given intraperitoneally
214893546|NCT00079430|BIOLOGICAL|bevacizumab|Given IV
214893547|NCT06124729|DRUG|Bevacizumab Combined With PD-1 Monoclonal Antibody|Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS colorectal cancer with liver metastases
214893548|NCT00003274|BIOLOGICAL|gp100 antigen|
214893549|NCT00003274|BIOLOGICAL|incomplete Freund's adjuvant|
214893550|NCT00003274|BIOLOGICAL|sargramostim|
214893551|NCT00003274|BIOLOGICAL|tyrosinase peptide|
214893552|NCT05784025|DEVICE|AlterG|Experimental device reducing weight perception by inducing a no-gravity environment which facilitates the execution of rehabilitation programs
214893553|NCT03855267|DRUG|Propofol 20 MG/ML|Pump propofol to keep bispectral index within 40 # 60
214893554|NCT03855267|DRUG|Propofol 20 mg/ml , etomidate 2 mg/ml|Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.
214893555|NCT03529201|PROCEDURE|QLB|On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
214893556|NCT03529201|DEVICE|PCA|Patient-controlled analgesia
214893557|NCT03529201|PROCEDURE|GA|General anesthesia
214893558|NCT03529201|DRUG|Oxycodone|administered by PCA
214296150|NCT02345811|DEVICE|senofilcon A|contact lens
214296151|NCT03366376|RADIATION|WBRT with hippocampus-sparing and SIB|"Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy"
214296152|NCT02877082|BIOLOGICAL|Thymoglobulin|Given IV
214296153|NCT02877082|DRUG|Bortezomib|Given IV
214296154|NCT02877082|DRUG|Tacrolimus|Given IV and PO
214296155|NCT06244225|DRUG|Donafenib； Sintilimab； HAIC|"Drug: Sintilimab Q3W 200mg IV d1, Q3W~Drug: Donafenib 200 mg BID d1-21, Q3W~other: HAIC Q3W Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h."
214296156|NCT03633487|DRUG|Mucinex®|Mucinex® 1200 mg ER Bi-Layer tablet
214893559|NCT03529201|DRUG|Sevoflurane|Inhalational anesthetic during GA
214893560|NCT03529201|DRUG|Fentanyl|painkiller during GA
214893561|NCT03529201|DRUG|Rocuronium|muscle relaxant during GA
214893562|NCT03959969|OTHER|Educational video|An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.
214893563|NCT03959969|OTHER|Standard of care|The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.
214893564|NCT03959969|DRUG|Ibuprofen|Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
214893565|NCT03959969|DRUG|Oxycodone|Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
214893566|NCT00434369|DRUG|CoFactor (ANX-510)|
214893567|NCT01042769|DRUG|Aleglitazar|aleglitazar 150 micrograms po daily
214893568|NCT01042769|DRUG|Placebo|placebo control po daily
214296157|NCT04743427|OTHER|hot pack and exercises|20-minute hot pack,and three active exercises: (a) chin tucks in supine lying with the head in contact with the floor, (b) active Standing Shoulder pull back , and (c) scapular plane shoulder elevation. (3 sets of 10 repetitions for all the 3 exercises)
214296158|NCT04743427|DEVICE|body blade(BB)|The Body-blade (Classic, Mad Dogg Athletics, USA), an elastic pole exercise tool with 122 cm in length, 0.68 kg, 4.3 cm in width,based on oscillatory/vibration motions that have been used in training or rehabilitation.The body blade works by rapidly changing directions at a low-frequency rhythm of approximately 4.5 Hz (cycles per second )
214296159|NCT06430138|DIETARY_SUPPLEMENT|300ml Orange Juice|Acute intervention in populations with and without colon
214296160|NCT02489344|DRUG|GZ/SAR402671|"Pharmaceutical form:capsule~Route of administration: oral"
214296161|NCT03686163|DRUG|Nerve Growth Factors|the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
214893569|NCT06090201|OTHER|3-Tesla brain MRI and a comprehensive neuropsychological assessment|Patients with a moderate to severe form of congenital haemophilia A or B or a severe form of von Willebrand disease will be consecutively recruited in the study during a routine follow-up visit at the Haemostasis and Transfusion Department of the Lille University Hospital.
214296162|NCT03686163|DRUG|normal saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
214296163|NCT03480750|DRUG|trientine dihydrochloride|trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
214296164|NCT03480750|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg/m2 IV D1
214296165|NCT03480750|DRUG|carboplatin|carboplatin AUC 4 IV D1
214296166|NCT00798044|BEHAVIORAL|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
214296167|NCT00798044|BEHAVIORAL|Patient Feedback|Weekly feedback reports provided to counselors
214296168|NCT03896555|DEVICE|ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring
214296169|NCT00735774|DRUG|11C-ORM-13070|Single dose of i.v. solution
214296170|NCT00575913|DRUG|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
214296171|NCT04020679|BEHAVIORAL|Goals of Care Initiative|Can-GUIDE will provide videos on a number of SDM topics including interviews with patients and clinicians discussing patient involvement in SDM and how goal conversations can inform the decision making process. Furthermore, there will be instructional videos on how to complete the Goal conversations sheet. Accompanying the videos will be interactive elements which will help users consider the types of questions that they wish to ask their clinical teams. The goal conversation sheet allows patients to list their goals and priorities that they wish to bring up in the consultation with their clinical teams. The Goals of Care (GOC) tool is a communication aid for clinicians to summarise goals of care discussions such as those facilitated by the goals conversation sheet. The completed tool will then be logged onto the Electronic Patient Record (EPR) and is then disseminated to other HCPs involved in the patients care.
214296172|NCT06113432|DIAGNOSTIC_TEST|Arterial blood gases|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio
214893570|NCT02730663|DEVICE|Niti-S SPAXUS Stent|Endoscopic Ultrasound-Guided Transluminal drainage
214296173|NCT06113432|DIAGNOSTIC_TEST|Respiratory rate (RR)|Measurement of respiratory rate by waveform analysis using a ventilator
214296174|NCT06113432|DIAGNOSTIC_TEST|Pulseoximeter|Peripheral capillary oxygen saturation (SpO2) measurement and the ROX-index calculation (SpO2/FiO2/RR)
214893571|NCT02258763|DRUG|Amoxicillin-Potassium Clavulanate Combination|Oral antibiotic for 10 days
214893572|NCT02258763|DRUG|Placebo|Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
214893573|NCT00828165|DRUG|ARRY-300, MEK inhibitor; oral|single dose, escalating
214296175|NCT06113432|DIAGNOSTIC_TEST|Assessment of accessory respiratory muscles work|Patrick score calculation. Score: 0. No visible tonic or phasic use of neck muscles. 1. Neck muscles taut but with no respiratory modulation (i.e., tonic activity). 2. Mild respiratory modulation in neck muscle contraction. 3. Moderate phasic activity (no supraclavicular or intercostal indrawing). 4. Vigorous phasic activity with indrawing. 5. Vigorous phasic activity with abdominal paradox.
214893574|NCT00828165|DRUG|Placebo|matching placebo
214893575|NCT01308502|DEVICE|Dx-pH probe|Dx-pH probe with 24 hour recording
214296176|NCT06113432|DIAGNOSTIC_TEST|Esophageal pressure measurement|Esophageal pressure measurement on inspiration and expiration with calculation of delta esophageal pressure, transpulmonary pressure and delta transpulmonary pressure
214296177|NCT06113432|DIAGNOSTIC_TEST|Discomfort Visual Analog Scale (VAS)|From 1 to 10 points, where 1 point - maximal discomfort, 10 points - minimal discomfort.
214296178|NCT06113432|DIAGNOSTIC_TEST|Noninvasive blood pressure|Noninvasive blood pressure
214296179|NCT06113432|DIAGNOSTIC_TEST|Heart rate|Heart rate calculation using electrocardiogram monitoring
214296180|NCT00082654|PROCEDURE|psychosocial assessment and care|
214296181|NCT02647086|DRUG|Dupilumab|
214296182|NCT02647086|DRUG|Midazolam|Cytochrome P450 substrate
214296183|NCT02647086|DRUG|Omeprazole|Cytochrome P450 substrate
214296184|NCT02647086|DRUG|Warfarin|Cytochrome P450 substrate
214296185|NCT02647086|DRUG|Caffeine|Cytochrome P450 substrate
214296186|NCT02647086|DRUG|Metoprolol|Cytochrome P450 substrate
214893576|NCT01207310|BEHAVIORAL|smoking cessation counseling|two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
214893577|NCT01207310|DRUG|Nicotine patch|8 weeks' worth of nicotine patches
214893578|NCT01207310|DEVICE|alphanumeric pager|therapeutic messages to be delivered for three months
214893579|NCT00016081|DRUG|ribavirin|
214893580|NCT04580264|BEHAVIORAL|REINTERVENTION|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
214893581|NCT02046603|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
214893582|NCT02046603|DRUG|DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
214893583|NCT02046603|DRUG|Oral Corticosteroids|Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
214893584|NCT02046603|DRUG|Methotrexate|Methotrexate per investigator's discretion.
214893585|NCT05101343|BEHAVIORAL|Breathing meditation|Daily, 5-minute breathing meditation for one week.
214893586|NCT01323361|PROCEDURE|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
214893587|NCT02829645|OTHER|Clinical assessment|Clinical assessment with questionnaires
214893588|NCT02671747|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
214893589|NCT05843747|OTHER|Sampling|During thier bariatric surgery, samples of adipose tissue will be done
214893590|NCT00325247|DRUG|ZINC|
214893591|NCT02461160|DRUG|TAK-915 suspension|TAK-915 oral suspension
214893592|NCT02461160|DRUG|Midazolam|Midazolam oral solution
214893593|NCT02461160|DRUG|Placebo|Placebo-matching TAK-915 suspension
214893594|NCT02461160|DRUG|TAK-915 tablet|TAK-915 tablet
214893595|NCT06471374|BEHAVIORAL|Circadian rhythm assessment|Participants will arrive approximately 8 hours before participant's scheduled bedtime to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 66 hours (2.75 days). Upon awakening in the morning, participants will start a routine of up to 39 hours of wakefulness, under bedrest conditions. Saliva will be sampled frequently and blood will be drawn 3 times. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will be provided scheduled bathroom breaks when participants will use a commode next to the bed. Outside these scheduled bathroom breaks, participants will be provided a bedpan to use to go to the bathroom. At the end of the research procedures for Visit 4 participants will be given a recovery sleep opportunity and be discharged from the lab in the morning near participant's typical waketime.
214296187|NCT01132482|DRUG|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
214296188|NCT01132482|DRUG|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
214296189|NCT04623918|OTHER|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
214296190|NCT04623918|OTHER|Control rice|Control rice (C4), identical in appearance
214893596|NCT06471374|BEHAVIORAL|Light sensitivity assessment|Participants will arrive in the afternoon to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 48 hours (2 days). Upon awakening in the morning, participants will be exposed to dim candlelight and then later in the day alternating intensities of dim and room light when we keep participants awake for up to 23 hours (We will ask participants to remain in bed seated for \~12.5 hours). Saliva will be sampled frequently. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will then have a second 9-hour sleep opportunity.
214893597|NCT00714194|PROCEDURE|Normal continuous sedation|Normal continuous sedation.
214893598|NCT00714194|OTHER|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
214893599|NCT05183880|DIETARY_SUPPLEMENT|Phosphatidylcholine-lipid encapsulated vitamin C|Ingesting 1000 mg of vitamin C in phosphatidylcholine-lipid encapsulated form
214893600|NCT05183880|DIETARY_SUPPLEMENT|Crystalline vitamin C|Ingesting 1000 mg of vitamin C in crystalline form
214893601|NCT05851027|DRUG|QL0911|Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
214893602|NCT03204448|DEVICE|BioCLIA Ro60|BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
214893603|NCT01288404|DRUG|Fluorometholone|topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
214893604|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 1.25 mg/0.05mL
214893605|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 2.5 mg/0.1mL
214893606|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 3.75 mg/0.15mL
214893607|NCT04248530|DEVICE|Renal denervation|DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
214893608|NCT06628804|DIETARY_SUPPLEMENT|Artemisia and green tea extracts|Artemisia and green tea extracts 700 mg/day for 8 weeks
214893609|NCT06628804|DIETARY_SUPPLEMENT|Placebo|Placebo 700 mg/day for 8 weeks
214893610|NCT04997863|DEVICE|Sericin hydrogel sheet impregnated with EBN extract|Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
214893611|NCT04997863|DEVICE|Placebo hydrogel sheet|Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
214893612|NCT01649986|BEHAVIORAL|Non-pharmacologic intervention|Diet and physical exercise
214893613|NCT01649986|DRUG|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
214893614|NCT00193050|DRUG|Gemcitabine|Gemcitabine
214893615|NCT00193050|DRUG|Epirubicin|Epirubicin
214893616|NCT00193050|DRUG|Docetaxel|Docetaxel
214893617|NCT01705379|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
214893618|NCT00712790|DRUG|Sorafenib|Tablet, 400mg orally, twice daily
214893619|NCT00712790|RADIATION|SIR-Spheres|one time treatment and capped at 3.0 Gbq
214296191|NCT04278547|DIAGNOSTIC_TEST|ELISPOT IFN-γ assay|"ELISPOT IFN-γ diagnostic test: Evaluation of specific cellular immune response against the IE-1 antigen and the CMV pp65, using the technique ELISPOT IFN-γ and individualize the preventive strategy according to the result. In patients with a ELISPOT of low risk will be made advance therapy (preemptive therapy) guided by PCR of CMV In patients with a high risk ELISPOT, universal prophylaxis with valganciclovir will be performed oral (900 mg / 24h) or intravenous ganciclovir (5-10 mg / Kd / day) in case the oral route is not available."
214296192|NCT04025658|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
214893620|NCT01373138|DRUG|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
214893621|NCT05114733|BEHAVIORAL|InVEST|Individualized vocational and educational support and training -- participant works with BA level school/ work coach for four months
214893622|NCT00061932|DRUG|bortezomib|Given IV
214893623|NCT00061932|DRUG|irinotecan|Given IV
214296193|NCT01837979|PROCEDURE|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
214296194|NCT03348020|PROCEDURE|Blood Donation|Subjects will donate blood within \~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.
214296195|NCT01578395|RADIATION|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
214296196|NCT01578395|RADIATION|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
214478133|NCT06869980|PROCEDURE|mitral valve replacement through limited right anterior thoractomy|The incision is placed just lateral to the nipple over the fourth intercostal space (above the nipple in men and in the inframammary crease in most women) 6-10 cm in length, the pectoralis muscles are mobilized for fourth intercostal space thoracic entry-The pericardium is opened 2-cm ventral to the phrenic nerve under direct vision and carried cephalad to the aortic reflection. The anterior edge of the pericardium is tacked to incision edges using silk sutures-To initiate cardiopulmonary bypass, Cannulation of the femoral artery and femoral vein should be prior to mediastinal dissection-. The ascending aorta occluded with an external clamp. This aortic clamp passed through the thoracotomy incision if we use the aortic cross clamp and the anterograde cardioplegia delivered through a standard cardioplegia cannula secured with purse-string sutures in the ascending aorta.
214893624|NCT04359147|DRUG|"Yohimbine"|Effects on neural correlates of decision-making under risk and selective attention to threat
214893625|NCT04359147|DRUG|"Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
214893626|NCT04359147|DRUG|"Yohimbine + Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
214893627|NCT04359147|DRUG|"Placebo"|Effects on neural correlates of decision-making under risk and selective attention to threat
214893628|NCT04718454|DEVICE|dental attachment|This research aimed to evaluate the retentive power and wear of the smart box attachment use with tilted two implant assisted mandibular overdenture
214893629|NCT05880511|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
214893630|NCT05880511|DEVICE|Augmented Reality Sensorimotor Training|Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
214893631|NCT05880511|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
214893632|NCT04217954|DRUG|OXA, 5-FU and bevacizumab plus Toripalimab|"1. concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~   B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~   The concomitant treatment repeat every three week, up to 6 cycles.~2. Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks."
214893633|NCT04970628|OTHER|Medical records collection|Patient's medical records before and after surgery.
214893634|NCT00886509|BIOLOGICAL|pegfilgrastim|s.c. administration of pegylated G-CSF over 6 months
214893635|NCT00886509|OTHER|Placebo|Placebo control Arm 1: Collateral promotion; PCI after 6 months
214893636|NCT06187805|DEVICE|OSSIX Volumax|OSSIX Volumax is used in combination with autogenous bone collected during preparation of the implant osteotomy.
214893637|NCT03263676|DEVICE|Icon resuable underwear|Reusable incontinence underwear
214893638|NCT03263676|DEVICE|Disposable pad|Standard market disposable pad
214893639|NCT06048276|DRUG|Herbal medicines (e.g., Yunkang granules, Duzhong granules)|Herbal medicines (e.g., Yunkang granules, Duzhong granules) exposure at the early gestation.
214893640|NCT01226927|OTHER|Automated intermittent bolus|Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
214893641|NCT00932191|PROCEDURE|Standard phacoemulsification|Cataract nucleus removal using standard amounts of ultrasound energy
214893642|NCT00932191|PROCEDURE|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
214296197|NCT01578395|OTHER|No radiation exposure|Subjects not undergoing any radiation exposure
214296198|NCT04102215|DEVICE|HEARO|Robotic system for otological procedures
214296199|NCT04102215|DEVICE|OTOPLAN|Otological surgical planning software
214668594|NCT04350203|PROCEDURE|Laparoscopic right colectomy with extracorporeal anastomosis (EA)|First, the right colon was widely mobilized. A small laparotomy was performed in the mid/upper abdomen to exteriorize the colon and to perform a side-to-side mechanical anastomosis, using a linear cutting stapler (GIA). The bowel opening was closed either with a manual suture or by a second firing of the GIA.
214296200|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 10 mg, once daily
214296201|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 30 mg, once daily
214296202|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 100 mg, once daily
214296203|NCT01142700|DRUG|Placebo|Capsule, Oral, 0 mg, once daily
214296204|NCT01142700|DRUG|Peginterferon Alpha-2a|Syringe, subcutaneous 180 mcg/0.5 mL, weekly
214668595|NCT03702257|PROCEDURE|bronchoscopy.|gDSAs are studied on cryopreserved biopsies obtained during bronchoscopy. The technique is the one described by Visentin J.
215050556|NCT05064046|BEHAVIORAL|LuCa + Health Disparity module|"The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making."
214893643|NCT04379427|DEVICE|Sanmina Biosensor|non-invasive blood glucose measurement using the Sanmina Biosensor referenced with the invasive reference blood glucose device YSI 2400 Plus.
214893644|NCT03768362|PROCEDURE|Plication strabismus surgery|The technique was the same as resection up to muscle suturing, in the next step, the sutures were passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures. At the end, conjunctiva was repaired by vicryl 8/0.
214893645|NCT03768362|PROCEDURE|Resection strabismus surgery|resection strabismus surgery
214893646|NCT01370031|DRUG|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
214893647|NCT01370031|DRUG|Clenil® Modulite® via Volumatic™ spacer|Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
214893648|NCT01370031|DRUG|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
214893649|NCT01370031|DRUG|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
214893650|NCT02899962|DRUG|LEO 90100 aerosol foam|LEO 90100 aerosol foam twice weekly
214296205|NCT01142700|DRUG|Ribavirin|Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
214668596|NCT05011461|OTHER|Almond Oil|Almond Oil Pressed Cold
214893651|NCT02899962|DRUG|LEO 90100 aerosol foam vehicle|LEO 90100 aerosol foam vehicle twice weekly
214893652|NCT05347329|DIETARY_SUPPLEMENT|Tongkat Ali Maca Plus|Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
214893653|NCT02058329|OTHER|Home Visit|A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
214893654|NCT03872973|OTHER|Neuromuscular Training|"The experimental group will perform neuromuscular exercise for 6 weeks.~The other experimental group will perform neuromuscular exercises with strobe glasses."
214893655|NCT03872973|OTHER|Strobe Glasses|Stroboscopic glasses, which is characterized by intermittent vision obstruction, is a clinical tool that allows clinicians to examine sensory feedback in a progressive manner without fully seeing visual information.
214893656|NCT03623191|OTHER|Clinical examination|
214893657|NCT05873790|DRUG|Serplulimab plus chemotherapy|"Serplulimab: 4.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle. Chemotherapy drugs: etoposide + carboplatin/cisplatin Etoposide: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Carboplatin: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles."
214893658|NCT06398379|OTHER|Fecal Virome Transplantation|The primary steps of the production of fecal virome transplantation capsules is the same as when producing fecal microbiota transplantation capsules. Through an subsequent proces of filtering bacterial parts of the material are removed. The material, now called fecal virome transplanation material, has then been moved to capsules and stored in -80c untill use.
215050557|NCT02232971|DRUG|Glucagon|Glucagon is given in three different doses according to three research days.
215050558|NCT02232971|OTHER|Isotonic saline solution|Placebo
215050559|NCT04264923|OTHER|HyGIeaCare Prep|Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
214296206|NCT03130166|PROCEDURE|Intracorporeal anastomosis|Use of intracorporeal anastomosis technique
214296207|NCT03130166|PROCEDURE|Extracorporeal anastomosis|Use of the conventional extracorporeal anastomosis technique
214668597|NCT05966701|DRUG|SSGJ-613|SSGJ-613 subcutaneous injection.
214668598|NCT05966701|DRUG|Placebo|Placebo subcutaneous injection.
214668599|NCT02278978|DRUG|BIBF1120|BIBF1120 200 mg two times per day orally
214668600|NCT05413447|COMBINATION_PRODUCT|Digital consult|Consultations will be prepared digitally using the Mychart patient portal, an elearning and questionnaires. The consultation takes place via Teams.
214668601|NCT03903328|OTHER|Sarcopenia assessment|Sarcopenia assessment by measurement of Skeletal Muscle mass index, hand grip strength and usual gait speed for 5 meter distance, as per the guidelines of Asia Working group for Sarcopenia study, was carried out.
214668602|NCT06361459|BEHAVIORAL|Stop smoking|Sine fuma program is offered. nicotine is checked in urine
214668603|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
214668604|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
214893659|NCT06398379|OTHER|Fecal microbiota Transplantation|Donor fecal material is mixed with cryoprotectant and NaCl. Following processing the material transfered to capsules and is stored at -80c prior to use.
214893660|NCT00006038|DRUG|cisplatin|
214893661|NCT00006038|DRUG|docetaxel|
214893662|NCT00006038|DRUG|floxuridine|
214893663|NCT00006038|DRUG|fluorouracil|
214893664|NCT00006038|DRUG|leucovorin calcium|
215050560|NCT04738175|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
215050561|NCT04738175|DRUG|Placebo|Diluent solution
215050562|NCT04790747|DRUG|CAR-T cells|Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion
215050563|NCT03982277|DRUG|Rifampin 300 Mg Oral Capsule|High dose rifampicin at 35mg/kg
215050564|NCT02615977|BEHAVIORAL|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
214893665|NCT00006038|PROCEDURE|conventional surgery|
214893666|NCT00767403|BEHAVIORAL|Internet Intervention + Stepped Care|"Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones."
214893667|NCT00767403|BEHAVIORAL|Internet Intervention|"As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses."
214893668|NCT00767403|BEHAVIORAL|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
214893669|NCT04422600|OTHER|There is no other intervention, only clinical treatment.|The investigators will then correlate that exposure with neurodevelopmental outcomes.
214893670|NCT06461000|OTHER|Survey|online survey for participants
214893671|NCT03930537|DEVICE|Hip replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
214893672|NCT01849237|GENETIC|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10\^9/l).
214893673|NCT01849237|DRUG|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
214893674|NCT01245283|OTHER|normal activities and clinical care|Subjects will continue to participate in their normal activities and clinical care during the four month study. Telephone contact will be made weekly to encourage adherence to the knee management guidelines
214893675|NCT01245283|OTHER|Concentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
214893676|NCT01245283|OTHER|Eccentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
215050565|NCT02615977|BEHAVIORAL|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
215050566|NCT02789462|PROCEDURE|Laser-assisted percutaneous coronary interventions|Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
215050567|NCT04176107|BEHAVIORAL|Informative video|Exposure to informative video before cesarean delivery
215050568|NCT03302403|GENETIC|CAR-CD19 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
215050569|NCT03302403|GENETIC|CAR-BCMA T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
215050570|NCT03302403|GENETIC|CAR-GPC3 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
215050571|NCT03302403|GENETIC|CAR-CLD18 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
215050572|NCT03302403|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
215050573|NCT03302403|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
214668605|NCT06270225|DRUG|Colchicine 0.5 mg|Subjects will receive 0.5mg/d Colchicine for 12 weeks.
214668606|NCT02198144|OTHER|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
214893677|NCT02153983|DRUG|Colchicine 0.6Mg Cap|Colchicine 0.6 mg given twice daily
214478134|NCT06869980|PROCEDURE|mitral valve replacement through median sterntomy|The incision is begun approximately 2 cm below the sternal notch and extended approximately 2 cm beyond the distal tip of the xiphoid process and is usually extended with the electrocautery down to the sternal periosteum. A midline approach can be ensured by careful attention to the insertion points of the pectoralis major muscles onto the sternum; the incision should lie directly midway between these insertion points.After sternotomy, the pericardium is opened; the heart is cannulated for cardiopulmonary bypass. Arterial inflow is established by cannulation of the distal ascending aorta near the pericardial reflection. Double venous cannulation of the venae cavae by way of the right atrium is generally employed. In most adults a size 32 Fr cannula in the superior vena cava and a size 34-38 Fr cannula in the inferior vena cava provide excellent venous drainage and easy fit. Encircling of the venae cavae and their generous mobilization aid in the subsequent exposure of the mitral valve.
214893678|NCT02153983|DRUG|Placebo capsules given|Placebo capsules given twice daily
214893679|NCT02153983|DRUG|Colchicine 0.6Mg Tab|Open-label colchicine
214893680|NCT00091611|DRUG|IL-2 (interleukin-2)|
215050574|NCT03856463|BEHAVIORAL|Lay Navigator Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.
215050575|NCT03856463|OTHER|Usual Care|Usual care as provided by local oncologists
215050576|NCT01664247|DRUG|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
215050577|NCT01664247|DRUG|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
215050578|NCT01664247|DRUG|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
214478135|NCT05564208|DRUG|elafibranor|Oral Tablet
214478136|NCT05564208|DRUG|elafibranor|Oral Tablet
214478137|NCT06874634|DRUG|Human serum albumin injection|Infusion of human albumin injection into patients with abdominal sepsis admitted to the ICU
214478138|NCT04807777|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
214478139|NCT06628180|DEVICE|LIFU|Application of low-intensity focused ultrasound for neuromodulation
214478140|NCT06628180|DEVICE|Sham LIFU|Sham application of LIFU - will appear the same to participants.
214478141|NCT06875544|OTHER|Beautifil F00|Beautifil F00 is bioactive giomer resin composite.
214478142|NCT06875544|OTHER|G-aenial Universal Injectable Flowable Composite|Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component
214478143|NCT04743973|DEVICE|Muse S™ Headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
214668607|NCT06033443|OTHER|Collaborative Learning Group|The experimental group is the group that receives nursing education based on collaborative learning.
214893681|NCT00091611|DRUG|OKT3|
214893682|NCT00091611|DRUG|Cyclophosphamide|
214893683|NCT00091611|DRUG|Fludarabine|
214893684|NCT00091611|DRUG|Mesna|
214893685|NCT03672227|BEHAVIORAL|Mealtime Matters Training|This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
214893686|NCT01610492|DRUG|belimumab|10mg/kg administered intravenously
214893687|NCT01398046|DRUG|Dasatinib|dasatinib (100mg) PO x1
214893688|NCT01398046|DRUG|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
214893689|NCT01398046|DRUG|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
214893690|NCT01982955|DRUG|Tepotinib|Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.
214893691|NCT01982955|DRUG|Gefitinib|Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
214893692|NCT01982955|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
215050579|NCT03957863|BIOLOGICAL|Plasma collection for EPO assay|Plasma collection for EPO assay
215050580|NCT02607124|DRUG|Ribociclib|
215050581|NCT01885650|OTHER|Airway Clearance Techniques|
215050582|NCT01349205|DRUG|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
215050583|NCT01349205|DRUG|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
215050584|NCT01349205|DRUG|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
215050585|NCT03974074|DRUG|Albumin infusion|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
215050586|NCT05113654|DIAGNOSTIC_TEST|Sleep study|Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
215050587|NCT03770858|DRUG|Crisaborole|Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
215050588|NCT03770858|DEVICE|Scratch sensor|advanced, flexible and wearable skin sensor
215050589|NCT01212471|DRUG|Bromfenac Ophthalmic Solution A|sterile ophthalmic solution
215050590|NCT01212471|DRUG|Bromfenac Ophthalmic Solution B|sterile ophthalmic solution
215050591|NCT01212471|DRUG|Placebo Comparator|sterile ophthalmic solution
214296208|NCT03683758|OTHER|FIFA11+|"The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential."
214478144|NCT05654662|DRUG|Corsodyl Original Dentifrice|It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million \[ppm\] Fluoride ion \[F\])
214893693|NCT01982955|DRUG|Cisplatin|Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
214893694|NCT01982955|DRUG|Carboplatin|Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
215050592|NCT05237362|BEHAVIORAL|Saga Stories|Saga Stories in health talks consists of material for child healthcare nurses to use to facilitate the health talk with both the child and parent(s) and is complemented with take-home material. Every nurse will receive a large flip-chart with colourful pictures and text to facilitate their health talk at the 5-year check-up. The flip-chart will include information and questions regarding food, physical activity and sedentary behaviour, sleep, dental health, as well as bathroom habits. At the conclusion of the check-up the children will receive the book 'Saga Stories: Your amazing body and brain´ as well as games for the child to take home to promote healthy lifestyle behaviours (fruit and vegetable bingo and a physical activity fortune teller).
215050593|NCT06090630|PROCEDURE|Diffusion Weighted Imaging|Undergo DWI-MRI
215050594|NCT06090630|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopic imaging
214478145|NCT05654662|DRUG|Colgate Cavity Protection Dentifrice|It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
214893695|NCT06054321|DRUG|stepwise pharmacotherapy|In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
214893696|NCT06054321|DRUG|antidepressant monotherapy group|In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
214893697|NCT03700502|DIAGNOSTIC_TEST|resting-state functional Magnetic Resonance Imaging|The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
214893698|NCT04996979|DRUG|Ropivacaine 0.5% Injectable Solution|Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
214893699|NCT04996979|DRUG|Placebo|Standard care
215050595|NCT00028158|DRUG|G207, an oncolytic virus|
215050596|NCT06511960|OTHER|Astaxanthin (12 mg/day) intervention|12 mg/day astaxanthin was administrated to all participants in the astaxanthin 12 mg/day groupfor 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
215050597|NCT06511960|OTHER|36 mg/day astaxanthin intervention|36 mg/day astaxanthin was administrated to all participants in the astaxanthin 36 mg/day group for 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
214296209|NCT03683758|OTHER|'Usual' Soccer Warm-up|"This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement."
214296210|NCT06219057|BEHAVIORAL|The Wise Adolescent|The program encompasses 20 individual weekly sessions manualized. Its main objective is to help adolescents to create affiliative feelings towards themselves and to develop a more compassionate inner voice. Sessions are organized across 6 main domains: (1) placing ourselves in the challenges of life: evolutionary roots of our mind, how social circumstances and life experiences shape us; the 3-affect regulation systems; (2) understanding difficulties: compassion focused therapy case formulation; (3) understanding compassion: the three flows of compassion, its three pillars (caring commitment, wisdom, strength and courage); (4) compassionate mind training: cultivating the compassion skills (compassionate attention, imagery, reasoning, and behavior); (5) working with difficulties: fears, blocks and resistances to compassion; multiple selves; shame and self-criticism; (6) sustaining a compassionate mind: reviewing the gains and relapse prevention.
214893700|NCT04599075|DRUG|Insulin|IV Insulin Infusion
215050598|NCT06511960|OTHER|Placebo|12 mg/day placebo was administrated to all participants in the placebo group for 4 weeks. Following the placebo supplementation, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
215050599|NCT05224427|BEHAVIORAL|Near-Peer Coaching|Targeted coaching by near-peer medical students
215050600|NCT03084705|DEVICE|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
215050601|NCT03064074|DRUG|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
214296211|NCT05584644|DRUG|Palbociclib plus hormonal treatment - first line treatment|Palbociclib plus hormonal treatment
214296212|NCT05584644|DRUG|Palbociclib plus hormonal treatment - second line treatment|Palbociclib plus hormonal treatment
214296213|NCT00723892|BIOLOGICAL|Peginterferon alfa-2b (PegIntron)|Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg\^kg\^week
214296214|NCT00723892|DRUG|Rebetol (Ribavirin)|Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day
214296215|NCT00723892|BEHAVIORAL|Psychotherapy support program|Each site has implemented a psychotherapy support program.
214893701|NCT04599075|DRUG|Insulin|Continuous Subcutaneous Insulin Infusion (Pump)
214893702|NCT01456806|OTHER|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
214893703|NCT02719275|BEHAVIORAL|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
214893704|NCT04834609|PROCEDURE|Injection of autologous adipose tissue in anal fistula|
214893705|NCT02951754|DRUG|Immediate-release Methylphenidate|Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
214893706|NCT05250297|OTHER|no intervention|standard prenatal care
214296216|NCT05322642|BEHAVIORAL|UPA|UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
214296217|NCT05322642|BEHAVIORAL|Active control condition (Progressive Relaxation Training)|Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
214296218|NCT02594839|DRUG|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
214668608|NCT05255614|DEVICE|Virtual reality Simulator|LapSim is a device designed by Surgical Science Device \& software at Swedan
214296219|NCT02594839|DRUG|Placebo|intravenous infusion of 400 mL saline
214668609|NCT05255614|DEVICE|Pelvic trainer:|Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
214668610|NCT00779038|DRUG|Fentanyl ITS|40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
214668611|NCT04300725|OTHER|Video Counseling|Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
214668612|NCT00537745|DRUG|Vivitrol (Medication Therapy)|Vivitrol 380 mg/monthly
214668613|NCT00537745|OTHER|Medication Management Therapy|Medication Management Therapy once a month.
214668614|NCT00219180|DRUG|aliskiren|
214668615|NCT00816946|BEHAVIORAL|Enhanced education|"Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI \& protection against ARI"
214668616|NCT02047552|DRUG|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
214668617|NCT02047552|DRUG|Oxandrolone|10 mg PO Q12 hours for seven days
214668618|NCT02047552|DRUG|IV iron placebo|100 mL normal saline
214668619|NCT02047552|DRUG|Oxandrolone placebo|similar color and size sugar pill
214668620|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil|Split-scar fractional ablative erbium laser-assisted delivery of 50mg/mL of 5-fluorouracil solution to one half of the scar (4 treatments)
214668621|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide|Split-scar fractional ablative erbium laser-assisted delivery of 10 mg/mL of triamcinolone acetonide solution to the other half of the scar (4 treatments)
214668622|NCT02339298|OTHER|music application|music is applied during anaesthesia using headphones
214668623|NCT02339298|OTHER|only headphones|music is not applied, only headphones are placed
214668624|NCT02339298|DRUG|a caudal block|
214668625|NCT03564249|DEVICE|MiniCap|The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
214668626|NCT01905735|DRUG|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
214668627|NCT01905735|DRUG|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
214668628|NCT04468750|DEVICE|kinesiotape|During the rehabilitation program, all patients with GHS had kinesiotaping three times a week.
214668629|NCT00380159|DRUG|Elvucitabine|Elvucitabine 10 mg in combination with background ART
214668630|NCT00380159|DRUG|Lamivudine|
214668631|NCT00380159|DRUG|Emtricitabine|
214668632|NCT00004415|DEVICE|Medlink spinal cord electrode|
214668633|NCT03700892|OTHER|Cinnamaldehyde e-liquid|Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
214668634|NCT03700892|OTHER|PG/VG e-liquid|Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
214668635|NCT04098380|PROCEDURE|Small Bite|the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
214668636|NCT04098380|PROCEDURE|Larger bite|the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
214893707|NCT01548105|OTHER|Blood draw for the study participants|"These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels"
214893708|NCT03832205|DEVICE|Capaciflector monitoring|Non-invasive capaciflector monitoring of respiratory rate and heart rate.
214893709|NCT01605747|DIETARY_SUPPLEMENT|Culturelle|one capsule 2x per day per feeding tube
214893710|NCT01605747|DIETARY_SUPPLEMENT|Placebo|one placebo 2x per day per feeding tube
214893711|NCT04447560|PROCEDURE|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol and two researchers will measure the radius and area of those vessels separately. Researchers who are measuring the radius and area of vessels won't know whether those images belong to pre or post- ESP block. The results two researchers measure will be compared statistically and if there are no statistically significant differences, the mean value of their separate recordings will be taken into account for the statistical analysis.
214893712|NCT00932672|BEHAVIORAL|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
214893713|NCT03289819|DRUG|Pembrolizumab|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.
214893714|NCT03289819|DRUG|nab-paclitaxel|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
214893715|NCT03289819|DRUG|Epirubicin|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
214893716|NCT03289819|DRUG|Cyclophosphamide|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
214893717|NCT01790087|DRUG|ANX-188 Therapeutic Dose|
214893718|NCT01790087|DRUG|ANX-188 Supratherapeutic dose|
214893719|NCT01790087|DRUG|Saline|
214893720|NCT01790087|DRUG|Moxifloxacin|
214893721|NCT02245087|DRUG|Atorvastatin|20 mg of atorvastatin daily
214893722|NCT00866359|DRUG|Apremilast (CC-10004)|"Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)"
214893723|NCT00866359|DRUG|Placebo|"Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)"
214893724|NCT01747954|OTHER|Bag Squeezing|To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.
215050602|NCT03056833|DRUG|ribociclib|Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.
215050603|NCT03056833|DRUG|Paclitaxel|During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.
215050604|NCT03056833|DRUG|Carboplatin|During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.
215050605|NCT03990532|RADIATION|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
215050606|NCT03990532|RADIATION|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
215050607|NCT03368196|DRUG|DS-8201a|An antibody drug conjugate
215050608|NCT03576781|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
215050609|NCT03576781|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
215050610|NCT03576781|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
215050611|NCT03576781|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
214296220|NCT04609787|DEVICE|Immersive Virtual Reality|Participants are placed in three-dimensional, life-sized computer-generated environments via a computer headset shows potential as a treatment for chronic pain and central sensitization.
214893725|NCT01747954|OTHER|Thoracic vibrocompression|To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
214893726|NCT02046811|BEHAVIORAL|Patient activation and education (PAE)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface)
214893727|NCT02046811|BEHAVIORAL|PAE plus physician activation (PAE + MD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients
214893728|NCT02046811|BEHAVIORAL|PAE physician activation, plus teledermoscopy (PAE +MD +TD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients, and participant receipt of a dermoscopic lens
214893729|NCT00295997|BIOLOGICAL|anti-thymocyte globulin|
214893730|NCT00295997|BIOLOGICAL|filgrastim|
214893731|NCT00295997|BIOLOGICAL|graft-versus-tumor induction therapy|
214893732|NCT00295997|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214893733|NCT00295997|DRUG|busulfan|
215050612|NCT03190798|DRUG|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
215050613|NCT03190798|DRUG|Placebo|Placebo for Canagliflozin
215050614|NCT01227226|DRUG|Artificial tears|Instill one drop of artificial tears
215050615|NCT00885183|PROCEDURE|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
215050616|NCT04590599|DRUG|IBI310|IBI310 3 mg/kg,Q3W, for a total of 4 cycles
214478146|NCT05225792|BEHAVIORAL|Promis Physical Function Questionnaire|Patient reported physical function outcomes
214478147|NCT05225792|BEHAVIORAL|L Test|Performance based measure assessing general physical function and balance ability.
214893734|NCT00295997|DRUG|cyclophosphamide|
215050617|NCT04590599|DRUG|Placebo|Placebo Q3W, for a total of 4 cycles
215050618|NCT04590599|DRUG|Sintilimab|Sintilimab 200mg,Q3W
215050619|NCT03191942|DEVICE|Modified ortho-k lenses|KETT MC lens
215050620|NCT03191942|DEVICE|Ortho-k lenses|KATT BeFree lens
214478148|NCT05225792|BEHAVIORAL|Narrowing Beam Walking Test|Subjects attempt to walk along 4 progressively narrower beam segments with their arms crossed over their chest.
214478149|NCT05225792|BEHAVIORAL|PEQ-A|Survey on confidence, stumbles and falls.
214478150|NCT06624527|OTHER|Psychoeducation based on Cognitive Behavioral Therapy|A psycho-educational application based on Cognitive Behavior Therapy consisting of a total of 8 sessions prepared by the researcher.
214893735|NCT00295997|DRUG|fludarabine phosphate|
214893736|NCT00295997|DRUG|methotrexate|
214893737|NCT00295997|DRUG|mycophenolate mofetil|
214893738|NCT00295997|DRUG|tacrolimus|
214893739|NCT00295997|PROCEDURE|allogeneic bone marrow transplantation|
214893740|NCT00295997|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
214893741|NCT00295997|PROCEDURE|peripheral blood stem cell transplantation|
214893742|NCT02431377|OTHER|S-26 Gold|A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin
214893743|NCT00136227|BEHAVIORAL|small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention|
214893744|NCT01625091|DRUG|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
214893745|NCT01625091|DRUG|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
214893746|NCT02163057|BIOLOGICAL|INO-3112|1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.
214893747|NCT02163057|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.
214893748|NCT00768248|DRUG|perineural ropivacaine|ropivacaine 0.4%; the basal rate will be set at 7 mL/h
214893749|NCT00768248|DRUG|normal saline (placebo)|the basal rate will be set at 7 mL/h
214893750|NCT00469924|PROCEDURE|Real Time Clinical Alerting|
215050621|NCT04312503|DRUG|Lurasidone|Patients are treated with dosages according clinical practice
215050622|NCT04312503|DRUG|aripiprazole, olanzapine, quetiapine or risperidone|Patients are treated with dosages according clinical practice
215050623|NCT03177018|DIAGNOSTIC_TEST|Cardiomyocytes collection|collect intact cardiomyocytes from which high quality DNA extraction will be achieved
215050624|NCT01580410|DRUG|mitomycin C|Given by HIPEC
215050625|NCT01580410|DRUG|oxaliplatin|Given by HIPEC
215050626|NCT01580410|PROCEDURE|therapeutic conventional surgery|Undergo surgery
215050627|NCT01580410|OTHER|quality-of-life assessment|Ancillary studies
215050628|NCT01580410|DRUG|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
215050629|NCT03417466|DEVICE|Enlite 1 connected to iPro2 recorder|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
215050630|NCT01397227|BIOLOGICAL|Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
215050631|NCT01397227|BIOLOGICAL|Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
215050632|NCT01397227|BIOLOGICAL|Placebo|Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
214893751|NCT05806892|OTHER|Thera Pearl|"You can apply Thera°Pearl warm breast therapy before breastfeeding or during milking. You should do this application 4 times a day, in the morning, at noon, in the evening and at night before going to bed. Each application should be done on both breasts and should last at least 20 minutes.~Thera°Pearl Warm Breast Therapy has been developed to open milk ducts and accelerate milk flow.~Thermogel packs for Thera°Pearl hot therapy can be heated inside the fabric covers in the microwave for a maximum of 15 seconds or in hot water by removing the fabric covers. Packages that have been removed from the cover should be kept in boiling water for 1-2 minutes and then applied by putting them into the sheath."
214893752|NCT02962986|DRUG|Norepinephrine|Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
214893753|NCT02962986|DRUG|Phenylephrine|Phenylephrine diluted in 0.9% normal saline solution to a concentration of 100mcg/mL
214893754|NCT04092140|DEVICE|ultrasound|easy new non invasive tool
214893755|NCT04006002|OTHER|Metabolic and Hormonal profile|To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention
214893756|NCT04190121|DIETARY_SUPPLEMENT|prosure|The study group will receive the dietary supplement preoperatively and for three months after the operation
214893757|NCT06582108|GENETIC|DNA, RNA, ctDNA, metabolomics|The use of specific assays or global molecular profiling to identify novel biomarkers based on DNA, RNA, protein, lipids, or metabolites obtained from tumor tissue or body fluids
214893758|NCT04530643|DRUG|HY209 0.3%|25 subjects will be assigned to drug (HY209 0.3% gel).
215050633|NCT02137642|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
215050634|NCT02137642|DRUG|Placebo|Double blind placebo will be delivered once by injection during study procedure.
215050635|NCT02733549|OTHER|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
215050636|NCT06183151|DEVICE|Entia Liberty System|See arm/group description
214296221|NCT02901535|OTHER|Spirometry|Spirometry in baseline
214296222|NCT02901535|OTHER|telemonitoring|telemonitoring (phone call nurse - 45 and 90 days)
214296223|NCT02901535|OTHER|teleconsultation|teleconsultation (general practioner received phone call to respiratory care)
214296224|NCT02901535|OTHER|Spirometry - 20 weeks|Spirometry (20 weeks)
214296225|NCT01622699|DEVICE|Transcutaneous Bilirubinometer|If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
214296226|NCT01622699|OTHER|visual assessment of neonatal jaundice|To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
214296227|NCT00001960|DEVICE|Pacemaker therapy|
214296228|NCT03809442|DRUG|Ropivacaine + Ketamine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
214478151|NCT06695780|OTHER|survey on eating behavior, physical activity and health status|Participatory research: participants will carry out surveys, functional tests and urine and blood sampling completely independently
214478152|NCT06630260|DRUG|Avutometinib|Supplied as 0.8mg capsules.
214478153|NCT06630260|DRUG|Defactinib|Supplied as 200mg tablets.
214478154|NCT06630260|DRUG|Temozolomide|Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.
214478155|NCT06687070|DRUG|APG -2449|Orally once a day(QD), every 28 days as a cycle.
214893759|NCT04530643|DRUG|HY209 0.5%|25 subjects will be assigned to drug (HY209 0.5% gel).
214893760|NCT04530643|DRUG|Placebo|25 subjects will be assigned to drug (Placebo).
214893761|NCT01547390|DRUG|Aspirin|
214893762|NCT01547390|DRUG|placebo|
214893763|NCT06581679|DRUG|Triptorelin|GnRHa will be given as a subcutaneous injection of triptorelin in a dose of 3.75 mg monthly for three months.
214893764|NCT06581679|DEVICE|levonorgestrel-releasing intrauterine system|The levonorgestrel-releasing intrauterine system releasing 20 levonorgestrel daily.
214893765|NCT06581679|PROCEDURE|frozen embryo transfer|"Frozen embryo transfer (FET) where a previously frozen embryo is thawed and transferred into a woman's uterus.~The FET process involves hormone preparation to prepare the uterus for the transfer, embryo thawing, and the actual transfer of the embryo into the uterus. If the embryo implants and develops successfully, pregnancy can occur."
214893766|NCT06583200|DIAGNOSTIC_TEST|End Expiratory Occlusion Test|All studied mechanically ventilated patients under post operative sedation. EEO test will be applied to predict probable responder and probable non-responder according to pulse pressure variation in accordance to previous study where the response to volume expansion was defined as an increase in pulse pressure of 5% or more
214893767|NCT06583200|DIAGNOSTIC_TEST|Passive Leg Raising Test|All studied mechanically ventilated patients under post operative sedation.Passive leg raising test will be applied to predict probable responder and probable non-responder according to the PPV in accordance to previous study where the response to volume expansion was defined as an increase in pulse pressure of at least 10%
215050637|NCT02512289|DEVICE|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
215050638|NCT01887964|OTHER|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
215050639|NCT01887964|OTHER|Control flour|Wheat flour without resistant starch (type-4)
215050640|NCT01798095|BIOLOGICAL|Aplisol@ PPD material|Determine equivalency of materials
215050641|NCT01798095|BIOLOGICAL|Reference Standard|Reference standard material for comparison to newly produced materials.
215050642|NCT04633395|OTHER|Music|The participant can choose between 5 different soothing playlists
215050643|NCT04633395|BEHAVIORAL|Sleep hygiene|These are behavioural guidelines to help establish a better sleep pattern
214893768|NCT01459783|BEHAVIORAL|Dementia care management|Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
214893769|NCT03950154|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab injection
214893770|NCT03950154|DRUG|Oxaliplatin|Oxaliplatin injection
214893771|NCT03950154|DRUG|Capecitabine|Capecitabine oral agent
214893772|NCT03950154|BIOLOGICAL|PD1-T cells|PD1-T cells injection
214893773|NCT03309098|DIAGNOSTIC_TEST|Ligmaster Arthrometer Assessment|Perform an anterior drawer, inversion stress test and eversion stress test on the participant with an ankle arthrometer (LigMaster Version 1.26, Sport Tech, Inc, Charlottesville, Virginia).
214893774|NCT03487289|PROCEDURE|natural orifice|laparoscopic right colon surgery and patients who are removed from the natural orifice and conventional will gather
214893775|NCT04386382|PROCEDURE|ridge splitting flapless technique using interchangeable guide followed by implant placement|"An informed consent is taken from all the patients~I. Presurgical phase:~1. Proper dental and medical history.~2. Scaling and oral hygiene measurements.~3. Clinical examination.~4. Radiographic examination. Clinical bucco-lingual measurements was done using calipers to ensure the patients would meet our initial inclusion criteria prior to further investigations.~III. Fabrication of interchangeable surgical guide stent from primary impression:~1. Optical scanning of the dental casts was done using Ceramill map 400~2. surgical stent was designed using Mimics Innovation Suite 19 ™ software.~3. Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique.~All patients will be operated under local anesthesia, stent was placed on ridge and adapted well after disinfection osteotomy was done using piezotome splitting tips Implant-insertion was started immediately"
214893776|NCT05717569|DRUG|Vitamin D|o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.
214893777|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
215050644|NCT02909660|OTHER|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
215050645|NCT01725802|DRUG|Levodopa/carbidopa solution for SC administration|
215050646|NCT01725802|DRUG|Placebo|
215050647|NCT01118780|DRUG|Duloxetine|Administered by mouth, daily for 10 weeks
215050648|NCT01118780|DRUG|Placebo|Administered by mouth, daily for 10 weeks
215050649|NCT06289946|DRUG|NitroBid|We will apply nirobid to the wrist prior to left heart catheterization.
215050650|NCT06289946|DRUG|Placebo|We will apply placebo moisturizing cream to the wrist
215050651|NCT02318836|DRUG|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
215050652|NCT06140368|BEHAVIORAL|virtual reality|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
215050653|NCT00984776|OTHER|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
214478156|NCT06687070|DRUG|PLD|Injected on the first day of each cycle, every 28 days as a cycle.
215050654|NCT00272831|DRUG|Cilostazol|Cilostazol 100 mg twice daily
214893778|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
214893779|NCT06181773|BEHAVIORAL|EPO Feeding Program|The EPO Feeding program focused on providing parents with information based on scientific evidence and the most current nutritional recommendations regarding positive feeding practices and healthy eating during the preschool years.
215050655|NCT00272831|DRUG|Placebo|1 tablet twice daily
214893780|NCT04927845|BEHAVIORAL|StriveWeekly|"The intervention (app.striveweekly.com) delivers content via independent modules. Principles covered in content modules: Psychoeducation; Self-monitoring; Values-based goal-setting; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Relaxation strategies; Maintenance planning. Modules get released week-by-week, and participants are self-guided through content. To facilitate skills practice, every module is accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displays user progress, including self-rating graphs and a history log of skills practice. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity."
214893781|NCT01004744|DRUG|Anastrozole|1mg PO daily for two weeks prior to scheduled surgery
214893782|NCT05191277|DRUG|Treatment 'discontinuation of antidepressant medication'|Pharmacological intervention: Participants will discontinue their antidepressant medication.
214893783|NCT05191277|DRUG|Treatment 'continuation of antidepressant medication'|Pharmacological intervention: Participants will remain on their antidepressant medication.
214893784|NCT05191277|BEHAVIORAL|Expectation 'high'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).
214893785|NCT05191277|BEHAVIORAL|Expectation 'moderate'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
214668637|NCT04300218|BEHAVIORAL|internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)|"The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study."
214668638|NCT04300218|OTHER|Care as usual (CAU)|Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
215050656|NCT01531582|DRUG|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
215050657|NCT03885154|DRUG|Valproic Acid (VPA)|IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
215050658|NCT03885154|DRUG|Dihydroergotamine (DHE)|0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
215050659|NCT04841785|DIAGNOSTIC_TEST|mailer-based finger-prick|All participants in the antibody measurement study will be sent a mailer-based finger-prick set. The sets will be sent to the home address of the patient, including a return envelope. After collecting and returning the samples SARS-CoV-2 antibodies will be analysed quantitatively at the laboratory.
215050660|NCT02110849|RADIATION|Proton|Proton Therapy for Prostate Cancer
214668639|NCT01304862|BEHAVIORAL|eSMART-MH intervention|Involves simulated interactions between participants and the virtual health care providers (avatars).
214668640|NCT01304862|BEHAVIORAL|Educational videos about healthy living|20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
214668641|NCT05335525|DEVICE|Closure of the femoral arterial puncture site|Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.
214668642|NCT02556879|BIOLOGICAL|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
214668643|NCT02556879|BIOLOGICAL|Serum bank|Additional samples for serum bank at each visit if possible
214668644|NCT02556879|BIOLOGICAL|DNA bank|Additional sample for DNA bank at inclusion visit if possible
214668645|NCT02556879|PROCEDURE|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
214668646|NCT02556879|PROCEDURE|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
214893786|NCT06014112|DEVICE|Freestyle Libre Pro iQ|"Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed."
214893787|NCT05156970|DRUG|Camrelizumab|Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months
214893788|NCT05156970|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
214893789|NCT05156970|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
214893790|NCT05156970|DRUG|Apatinib Mesylate|Apatinib 250mg qd for up to 24 months
214893791|NCT05156970|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)
214893792|NCT06109948|DRUG|ABX1100 injection for IV infusion|Centyrin protein-siRNA conjugate
214893793|NCT06109948|DRUG|Placebo injection for IV infusion|placebo saline injection
214893794|NCT05536258|OTHER|Fluid|The investigators will titrate fluid administration to maintain a RI \> 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI \> 90 over at least 85% of the intraoperative period.
214893795|NCT06789731|BEHAVIORAL|Mindfulness Meditation|Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a loving kindness meditation adapted to apply to college communities and designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
214893796|NCT06789731|OTHER|Psychoeducation|In the psychoeducation arm, participants will receive information related to creating connections with campus community and managing anxiety and/or depression through a presentation. They will also receive information on resources for connecting with their community and treating anxiety and/or depression.
214893797|NCT06790017|OTHER|body temperature|Body temperature measurement will be performed in the preoperative and intraoperative periods.
214893798|NCT05277168|DRUG|SHR-A1904|Single Arm ：It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors
214893799|NCT04574089|DRUG|Experimental: Baofukang Suppository 7 days|Experimental: Baofukang Suppository 7 days
214893800|NCT04574089|DRUG|Experimental: Baofukang Suppository 14 days|Experimental: Baofukang Suppository 14 days
214893801|NCT06378996|DIAGNOSTIC_TEST|14-day rhythm monitoring|Eligible patients will be monitored during 14 days using the Byteflies patch ambulatory rhythm monitor.
214893802|NCT06397950|OTHER|Assessment of potential fatigue factors|"3 visits will be carried out: V0: Inclusion V1: Familiarization visit V2: Experimental visit~V1~* Completion of MFI-20 questionnaire for familiarisation.~* Information about accelerometry and activity journal use will be delivered to the patient.~* The participant will be equipped with an accelerometer and asked to complete the activity journal for seven days.~V2~* Completion of questionnaires: MFI-20, GATS tobacco consumption questionnaire, caffeine consumption questionnaire, Fatigue Catastrophizing Scale, PSQI.~* Assessment of cognitive function: Sustained Attention to Response Task (SART), AX-Continuous Performance Task (AX-CPT) and verbal fluency test (animals and P categories).~* Assessment of physical evaluation: isometric evaluation of maximal handgrip strength, one-minute sit-to-stand test, isometric evaluation of maximal quadriceps strength, QIF test.~Negative symptoms will be assessed. Calf circumference will be measured for sarcopenia risk."
214893803|NCT04595773|OTHER|Aerobic Exercise Training|Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.
214296229|NCT03809442|DRUG|Ropivacaine + Tramadol|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
214893804|NCT04595773|OTHER|Education|Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.
214893805|NCT06514547|BIOLOGICAL|Conjugate Pneumococcal Vaccine 20 (PCV20)|Vaccine
215050661|NCT00407615|DEVICE|Flex Pad/Static Magnet|
215050662|NCT06196151|BEHAVIORAL|Antenatal training|"Training hours: Training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be given online via Zoom application. The training will consist of a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Pregnant women in both the control and intervention groups will be asked to fill out the Women's Introductory Information Form. The data of the intervention group will be filled out before the first Antenatal education lesson and after all six-hour Antenatal education lessons are completed. The data of the control group will be filled in parallel with the intervention group.~Group to receive the training: Healthy pregnant women who are at the 20th gestational week at the earliest will be included in the training. Trainings will be carried out in closed groups."
214296230|NCT03809442|DRUG|Ropivacaine + Midazolam|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
214296231|NCT03809442|DRUG|Ropivacaine + Dexmedetomidine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
214296232|NCT03809442|DRUG|Ropivacaine + Dexamethasone|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
215050663|NCT01715688|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
215050664|NCT01715688|DRUG|Saline|Administration of saline in the endotracheal tube cuff
215050665|NCT03162133|OTHER|Baduanjin exercise|
214668647|NCT01486680|PROCEDURE|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
214893806|NCT06415058|DEVICE|HemoIV|A sterile, single use device. It is a non-patient stick blood collection device that attaches to a peripheral IV catheter (PIV catheter) and allows for blood sample collection to occur during continuous IV infusion therapy. The control blood sampling will occur via standard of care blood draws either through peripheral IV catheter or standard venipuncture.
214893807|NCT05351164|DRUG|Metreleptin|Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
214893808|NCT03568266|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
214893809|NCT05854498|DRUG|Liposomal irinotecan|50mg/m2 IV on days 1 and 15
214893810|NCT05854498|DRUG|TAS102|35mg/m2 PO BID on days 1-5 and 15-19
214893811|NCT05854498|DRUG|Bevacizumab|5mg/kg IV on days 1 and 15
214893812|NCT06288282|OTHER|No Intervention|No intervention will be used.
214893813|NCT04059952|DEVICE|Electroconvulsive Therapy|Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.
214893814|NCT04223518|DIETARY_SUPPLEMENT|Serum bovine immunoglobulin|Serum bovine immunoglobulin (SBI), also known by the brand name of Enteragam (Proliant Biologicals, Ankeny, Iowa) is derived from bovine serum and classified as a medical food composed of \>90% protein which consists primarily of immunoglobulins (\>50% of IgG) along with other bovine proteins and peptides similar to those commonly consumed by humans in beef products.
214893815|NCT04223518|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed Collagen
214893816|NCT04452669|DRUG|VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)|VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
214893817|NCT06290765|DRUG|Ropeginterferon alfa-2b|"Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), 250 µg at Day 1, 350 µg at Week 2, and target optimal dose of 500 µg at Week 4.~Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value."
214893818|NCT06290765|PROCEDURE|Phlebotomy and aspirin|Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value, or confirmed Hct ≥45% according to the standard of care for phlebotomy at the institution regardless of the magnitude of the increase compared with the baseline. The same standard or criteria for phlebotomy eligibility should be applied for patients during the study at each study site or institution.
215050666|NCT01127984|DRUG|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
215050667|NCT01127984|PROCEDURE|drainage system|application of vacuum drainage system
215050668|NCT05474287|PROCEDURE|SJOV|SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
215050669|NCT05474287|PROCEDURE|HFNO|HFNO is conducted. Oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%.
215050670|NCT00003262|BIOLOGICAL|bleomycin sulfate|
215050671|NCT00003262|BIOLOGICAL|filgrastim|
215050672|NCT00003262|DRUG|Stanford V regimen|
215050673|NCT00003262|DRUG|doxorubicin hydrochloride|
215050674|NCT00003262|DRUG|epirubicin hydrochloride|
215050675|NCT00003262|DRUG|etoposide|
215050676|NCT00003262|DRUG|mechlorethamine hydrochloride|
215050677|NCT00003262|DRUG|prednisone|
215050678|NCT00003262|DRUG|vinblastine sulfate|
215050679|NCT00003262|DRUG|vincristine sulfate|
215050680|NCT01605422|OTHER|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
215050681|NCT03279887|DIAGNOSTIC_TEST|Lung Ultrasound|
215050682|NCT03186092|OTHER|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
215050683|NCT03186092|OTHER|sham muscle training|sham comparator
215050684|NCT05947916|DEVICE|Real-time Continuous Glucose Monitoring System|The intervention group wore real-time CGM (120 cases) to monitor blood glucose, and was required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
215050685|NCT00083460|DRUG|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
215050686|NCT00083460|DRUG|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
215050687|NCT00083460|DRUG|Dexamethasone|A dose of 20mg for cylces 3-8.
214893819|NCT03829540|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
214893820|NCT05117476|DRUG|CLN-619|Anti-MICA/MICB monoclonal antibody
214893821|NCT05117476|DRUG|Pembrolizumab|Keytruda
214893822|NCT05117476|DRUG|Paclitaxel|Taxane
214893823|NCT05117476|DRUG|Carboplatin AUC 6|Platinum compound
214893824|NCT05117476|DRUG|pemetrexed|antifolate
214893825|NCT05117476|DRUG|Datopotamab deruxtecan-dlnk (Dato-DXd)|TROP-2 antibody-drug conjugate (ADC)
214893826|NCT04838730|DEVICE|Surgical procedure|Standard cataract extraction procedure will be performed under local anesthesia (at physician discretion) and CleaRing device will be implanted together with SeeLens AF IOL.
214893827|NCT04135677|DRUG|Rivaroxaban|Drug: Rivaroxaban 20mg Duration of treatment: 12 weeks(12 weeks for DAPT afterwards)
214893828|NCT04135677|DRUG|DAPT|Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:24 weeks
214893829|NCT04204798|DRUG|Dexmedetomidine|"1. Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~2. For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~3. For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events."
215050688|NCT06199232|DRUG|HAIC+targeted therapy+PD-1 inhibitor|"HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w."
215050689|NCT04656808|BEHAVIORAL|Guilt Focused Intervention|Psychotherapy, group intervention
214893830|NCT04204798|DRUG|Placebo|"1. Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~2. Propofol sedation is administered when considered necessary."
214893831|NCT05201794|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
214893832|NCT05201794|DRUG|Placebo|Matching placebo for each dose level as tablet will be administered orally.
214893833|NCT02205047|DRUG|Cisplatin|
214893834|NCT02205047|DRUG|5-fluorouracil or Capecitabine|
214893835|NCT02205047|DRUG|Trastuzumab|
214893836|NCT02205047|DRUG|Pertuzumab|
214893837|NCT02205047|PROCEDURE|gastrectomy|D2 gastrectomy
214893838|NCT06349382|DIETARY_SUPPLEMENT|carbohydrate-rich beverage|Patients in the OCHL group will drink a high-carbohydrate beverage (12.6% carbohydrates, 50 kcal/100 mL, 285 mOsm/kg; PreOp®, Nutricia, Zoetermeer, The Netherlands) 800 mL in the evening before surgery (between 9 p.m. and 11 p.m.), and 400 mL two hours before the induction of anesthesia.
214893839|NCT05730283|DRUG|ORC-13661|High-dose intervention (30mg daily)
214893840|NCT05730283|DRUG|ORC-13661|Low-dose intervention (12mg daily)
214893841|NCT05730283|DRUG|Placebo|Placebo intervention
214893842|NCT05079568|DEVICE|Oculus Go VR headset|Virtual reality programs consisting of interactive games, meditation and deep breathing exercises, and passive virtual reality experiences designed to facilitate relaxation.
214893843|NCT05079568|DEVICE|Sham Oculus Go VR headset|Virtual reality program with two-dimensional nature video
214893844|NCT06095986|DRUG|Aramchol meglumine|Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)
214893845|NCT06418529|DRUG|tofacitinib|New index treatment of tofacitinib
214893846|NCT06418529|DRUG|tumor necrosis factor inhibitors (TNFi)|New index treatment of TNFi
214893847|NCT06418529|DRUG|abatacept|New index treatment of abatacept
214893848|NCT06418529|DRUG|tocilizumab or sarilumab|New index treatment of tocilizumab or sarilumab
214893849|NCT04537741|PROCEDURE|Coronary CT angiography|all patients being included will undergo CCTA before invasive coronary angiography
214893850|NCT04537741|PROCEDURE|Invasive coronary angiography|all patients being included will undergo CCTA before invasive coronary angiography
214296233|NCT03809442|DRUG|Ropivacaine|Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
214668648|NCT01486680|PROCEDURE|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
214893851|NCT05758506|DEVICE|Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)|We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.
214893852|NCT06566469|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 µg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
214893853|NCT06566469|DRUG|Esketamine|Esketamine 0.2 mg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
214893854|NCT06566469|DRUG|Normal saline|Normal saline at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
214893855|NCT03492944|DRUG|Ultrasound Microbubble Contrast Agent|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
214893856|NCT03492944|DEVICE|Ultrasound Imaging|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
214893857|NCT04027647|DRUG|Dacomitinib|30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.
214893858|NCT06297265|OTHER|Lymphedema Management|Undergo MLD breast massage
214893859|NCT06297265|OTHER|Questionnaire Administration|Ancillary studies
214893860|NCT06297265|RADIATION|Adjuvant breast radiation therapy|Using standard 3D conformal or intensity modulated techniques, patients will receive standard fractionation or moderate hypofractionation radiation therapy. The radiation treatment will last for 3 to 6 weeks, with the length of treatment depending on patient's specific clinical situation.
214893861|NCT04653454|DEVICE|Continuous Glucose Monitor (CGM)|CGM data will be downloaded prior to discharge and it will be compared with hospital glucometer readings taken at the same time.
215050690|NCT04656808|BEHAVIORAL|Cognitive behavioral therapy|Psychotherapy, group intervention
215050691|NCT06026280|BEHAVIORAL|DRIVEN Application|Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.
214296234|NCT01172847|DRUG|oseltamivir [Tamiflu]|multiple oral doses
214296235|NCT01172847|DRUG|rimantadine|multiple oral doses
214296236|NCT00785109|DIETARY_SUPPLEMENT|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
214668649|NCT03426969|DRUG|Cyclophosphamide|Given IV
214668650|NCT03426969|BIOLOGICAL|Filgrastim|Given SC
214668651|NCT03426969|DRUG|Fludarabine Phosphate|Given IV
214668652|NCT03426969|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
214893862|NCT04436757|BEHAVIORAL|IPS program : Self-image and body representation|"The IPS program consists in 13 sessions of 2 hours over a 13-weeks period.~Sessions content is as follows :~1. : Introduction~2. : Sensory approach workshop~3. : Self presentation and personal hygiene~4. : Organisation of well-being, planning and pictograms~5. : Becoming aware of my body, my envelope~6. : Presentation and self-esteem (photolanguage)~7. : Self-presentation in social interactions: Social codes~8. : My ideas and desires for change~9. : Places of well-being and clothing hygiene~10. : Vocational insertion devices~11. : Daring change : presence of a Socio-hairdresser~12. : The awakening of color : presence of a Socio-aesthetician~13. : Development of practice sheets and the network"
214893863|NCT04436757|BEHAVIORAL|TAU|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by the health service. No additional session will be proposed.
214893864|NCT05513001|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
214893865|NCT05513001|DRUG|Placebo|Placebo
214893866|NCT05513001|DRUG|LOU064 (open label)|LOU064 (open-label) active treatment
214893867|NCT03620708|BEHAVIORAL|Motivational Interviewing|Participants are provided with a 35 minute counseling session designed to increase motivation to quit smoking and then provided with a written referral for tobacco dependence treatment.
214893868|NCT03620708|DRUG|Nicotine Replacement Therapy Sampling|Participants are provided with a two-week sample of over-the-counter nicotine replacement therapy (i.e., nicotine lozenge and nicotine patch) and then provided with a written referral for tobacco dependence treatment.
214893869|NCT03620708|BEHAVIORAL|Referral Only|Participants are provided with a written referral for tobacco dependence treatment.
214893870|NCT06191796|DRUG|zanzalintinib|Specified doses on specified days
214893871|NCT06191796|DRUG|AB521|Specified doses on specified days
214893872|NCT06191796|BIOLOGICAL|Nivolumab|Specified doses on specified days
214893873|NCT05755932|DRUG|HFO-1234ze(E)|"* Dose formulation: metered dose inhaler (MDI)~* Unit dose strength(s): Experimental (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA"
215050692|NCT06026280|OTHER|Career Resources|Participants will receive weekly information about job-searching skills and resources from a study coordinator for six weeks.
215050693|NCT05018689|OTHER|Aevidum curriculum|The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.
214668653|NCT03426969|DRUG|Melphalan|Given IV
214668654|NCT03426969|DRUG|Mycophenolate Mofetil|Given PO
214668655|NCT03426969|DRUG|Tacrolimus|IV or PO
214668656|NCT03426969|RADIATION|Total-Body Irradiation|Undergo TBI
214668657|NCT01634243|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
214668658|NCT04870151|PROCEDURE|Anterolateral approach|Cemented hemiarthroplasty using an anterolateral approach.
214668659|NCT04870151|PROCEDURE|Direct lateral approach|Cemented hemiarthroplasty using a direct lateral approach.
214893874|NCT05755932|DRUG|HFA-134a|"* Dose formulation: metered dose inhaler (MDI)~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA."
214893875|NCT03172897|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
214893876|NCT03172897|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
215050694|NCT05018689|OTHER|Club|Schools will identify ten students interested in participating in an Aevidum club. Following training of interested students, schools are asked to commit to running two Aevidum club activities during the school year.
215050695|NCT01170052|DRUG|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
215050696|NCT01170052|DRUG|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
215050697|NCT01170052|DRUG|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
215050698|NCT02557451|OTHER|Surgery|
215050699|NCT02557451|OTHER|Intravitreal injections of gas|
215050700|NCT02557451|PROCEDURE|injections of an antiangiogenic|
215050701|NCT05207098|OTHER|Neurocognitive Tests|Baseline only: WRAT Reading Test, WMS-IV Logical Memory Subtest, Hopkins Verbal Learning Test (HVLT), Oral Trailmaking - Part A and B, NAB Digit Span, Category Fluency Test, Oral Symbol Digit Modalities Test, Brief Test of Attention, FAS - Controlled Oral Word Association Test (COWAT), Verbal Naming, Enformia Cogsuite Battery
215050702|NCT05207098|OTHER|Questionnaires|Sociodemographics, Computerized Cognitive Training Programs Questionnaire, CDC Behavioral Risk Factor (Smoking Assessment), Alcohol Consumption CDC, Current Health Rating (KPS), OARS Physical Health section, COVID Medical History, Hospital Anxiety and Depression Scale (HADS), Fatigue Symptom Inventory (FSI), Functional Assessment of Cancer Therapy-General (FACT-G V4), Functional Assessment of Cancer Therapy-Cognition (FACT-Cog V3), Sensory Gating Inventory (SGI)
215050703|NCT03962855|DRUG|Ifetroban Sodium|Ifetroban sodium 250 mg capsule once daily for 4 weeks
214668660|NCT03993015|OTHER|Help to diagnosis software|Help to diagnosis software
214893877|NCT05336877|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
214893878|NCT05336877|DEVICE|Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
214893879|NCT06454734|DEVICE|Extracorporeal shock wave therapy by radial device|Patients will receive treatment by extracorporeal shock waves therapy (ESWT).
214893880|NCT06454734|DEVICE|Placebo extracorporeal shock wave therapy by radial device|Patients will receive treatment sham extracorporeal shock waves.
214893881|NCT06454734|OTHER|DLT|Patients will receive treatment with decongestive lymphatic therapy (DLT: manual lymphatic drainage, compression)
214893882|NCT06451003|BEHAVIORAL|Exposure to clinical decision support system and education|"Surgeons will receive education regarding post-discharge venous thromboembolism after cancer surgery. An electronic medical record based decision support tool with be initiated that will identify patients who have undergone major abdominopelvic cancer surgery. The tool will permit use of a risk stratification score and advise guideline concordant post-discharge venous thromboembolism prophylaxis strategies.~Patients will receive dedicated venous thromboembolism education at the time of discharge."
214893883|NCT05844449|DRUG|VNZ/TEZ/D-IVA|Fixed-dose combination tablets or granules for oral administration.
214893884|NCT04556188|PROCEDURE|Cardiac surgery|
214893885|NCT06082843|DRUG|Placebo|Placebo-matching Avenciguat
214893886|NCT06082843|DRUG|Avenciguat|1 millligram (mg), 2 mg, or 3 mg film-coated tablet
214893887|NCT05645003|DEVICE|High-frequency real-time rTMS protocol|It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
215050704|NCT03962855|DRUG|Placebo|Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
215050705|NCT06049173|DEVICE|Negative extra-abdominal pressure (NEXAP)-based lung recruitment maneuver|The ventilator mode was changed from SIMV to PSV before LRM. After that, the abdominal pressure cardiopulmonary resuscitation (CPR-LW100) instrument was adopted and adsorbed on the epigastrium of patients. The LRM was performed by pulling up (tension of 20-30 kg) and compressing downward (tension\<10 kg) alternately on the abdomen of the patients with a frequency of 12 times per minute to support and maintain breathing. The whole LRM procedure lasted for 3 minutes in total. After LRM, the ventilator mode was changed to its baseline settings.
214668661|NCT06637540|DEVICE|RescueDoppler|Continous handsfree pulsed wave Doppler of the common carotid artery during cardiac surgery
215050706|NCT06049173|OTHER|stepwise positive end-expiratory pressure (PEEP)-based lung recruitment maneuver|The ventilator mode was changed from SIMV to PSV before LRM. After that, PEEP was increased gradually (every 3-5cmH2O per 30s) from baseline (5-8 cmH2O) to 20cmH2O. The PEEP level was maintained at 20cmH2O for 60s, followed by decrements to baseline PEEP (every 3-5cmH2O per 30s). After LRM, the ventilator was changed to the baseline settings.
215050707|NCT06331156|COMBINATION_PRODUCT|HRV PCV-free|2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
214668662|NCT06637540|DEVICE|RescueDoppler|Continuous hands-free Doppler ultrasound of the common carotid artery during cardiac surgery
214668663|NCT01805271|DRUG|Everolimus|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
214668664|NCT01805271|DRUG|Placebo|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
214478157|NCT06875596|OTHER|Control: Exercise Program|The entire program begins with an assessment of scapulohumeral rhythm using a digital inclinometer, isometric strength testing, range of motion measurements, the Y-Balance Upper Quarter Test, and the Closed Kinetic Chain Upper Extremity Stability Test. The exercise program for the experimental group lasts eight weeks and is divided into four two-week phases with four sets of exercises targeting the dominant upper extremity only. After the initial assessment, participants will undergo scapular positioning correction for the dominant extremity. They are then introduced to the first set of exercises for the first two weeks. The handball players will be given an exercise sheet explaining each exercise, which they will complete daily after completing their assigned ten minutes of exercise. They will also be given two resistance bands to provide resistance during the assigned exercises. One band is for upper scapular rotation, while the other is for resisting
214478158|NCT06875596|OTHER|Experimental: Exercise Program|Participants in the active control group will begin the program in the same manner as the experimental group, beginning with scapulohumeral rhythm assessments using a digital inclinometer, isometric strength testing, range of motion measurements, the Y-Balance Upper Quarter Test, and the Closed Kinetic Chain Upper Extremity Stability Test. They will also follow an eight-week exercise program divided into four two-week phases with four sets of exercises targeting the dominant upper extremity only. The key difference is that the control group will not focus on correcting scapular position for upward rotation during the exercises. Specifically, they will skip the upward rotation exercises at the beginning of each set and will not incorporate the acquired upward rotation control into other movement exercises. You will also be given a resistance band to provide resistance during the assigned exercises.
214478159|NCT06874036|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is a procedure to see the ascending, transverse, decending, sigmoid, rectum of colon parts
214893888|NCT05645003|DEVICE|Sham rTMS Protocol|It was planned to apply a to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
214893889|NCT06220513|PROCEDURE|erector spinae plane block (ESP)|patients will receive Ultrasound-guided erector spinae plane block (ESP) block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
214893890|NCT06220513|PROCEDURE|transversus abdominis plane block(TAP)|patients will receive Ultrasound-guided transversus abdominis plane block(TAP) Block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
214893891|NCT03326791|DRUG|Acetylsalicylic acid|Trombyl 160 mg once daily
214893892|NCT03326791|DRUG|Placebo Oral Tablet|Placebo one tablet daily
214893893|NCT05969041|DRUG|MT-302 (A)|MT-302 is an investigational drug
215050708|NCT06331156|COMBINATION_PRODUCT|IPV|3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
215050709|NCT00777959|DRUG|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
215050710|NCT00777959|DRUG|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
215050711|NCT00777959|DRUG|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
215050712|NCT04469088|OTHER|Dry needling|Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.
215057404|NCT02075424|OTHER|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
214668665|NCT01983891|OTHER|Cooking course|6-week nutrition education and cooking course
214668666|NCT05269576|OTHER|Clinical practice|Period of 5 days where medical students carry out hospital clinical practices with real patients supervised by professionals who teach them at the same time.
214668667|NCT05269576|OTHER|Clinical simulation|Clinical simulation classes through 2 sessions of 5 simulated cases each day. All students actively participate in one or two of the simulation cases and observed and discussed all the cases in the debriefings of all of them.
214668668|NCT00693186|BIOLOGICAL|HBVaxPRO® 5 µg / 0.5 mL|5 µg / 0.5 mL
214668669|NCT00693186|BIOLOGICAL|Engerix B® 10 µg / 0.5 mL|10 µg
214668670|NCT00364260|DRUG|epoetin alfa|
214668671|NCT00997971|OTHER|Modilac Rose 1|Infant formula used for non-breastfed children
214668672|NCT02344810|DRUG|c-Met inhibitor AMG 337|Given PO
214668673|NCT02344810|OTHER|placebo|Given PO
214668674|NCT02344810|DRUG|oxaliplatin|Given IV
214668675|NCT02344810|DRUG|leucovorin calcium|Given IV
214668676|NCT02344810|DRUG|fluorouracil|Given IV
214668677|NCT02344810|OTHER|pharmacological study|Correlative studies
214668678|NCT02344810|OTHER|laboratory biomarker analysis|Correlative studies
214668679|NCT03731793|BIOLOGICAL|Non-Animal Chondroitin Sulphate|Mythocondro® is an ichthyic-like chondroitin sulfate produced by chemical sulfation of a non-sulfated chondroitin backbone obtained by thermo-acid hydrolysis of the capsular polysaccharide naturally produced by an Escherichia coli strain.
214893894|NCT05473182|OTHER|IndieTrainer system|The IndieTrainer system is comprised of the IndieGo device and video-game modules. The IndieGo device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. The video-game modules are integrated into the IndieGo device such that the video games can be played on a TV screen using the specific access method used to control the IndieGo (i.e., switch or joystick). The IndieTrainer system is designed to allow a child to practice power wheelchair skills as part of the video-game modules or as part of more traditional power wheelchair skills training activities wherein children are able to actively explore the environment and practice executing actual wheelchair skills.
214893895|NCT06577935|DRUG|AGA2118|Subcutaneous injection
215050713|NCT04469088|OTHER|Manual Therapy Treatment|Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
215050714|NCT03157050|OTHER|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
215050715|NCT04064476|DRUG|Paliperidone Palmitate|This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.
214296237|NCT04975360|DIETARY_SUPPLEMENT|Caffeine|The 160 mg caffeine pulsatile-release formulation was manufactured using a drug layering process. Caffeine and the excipients are dispersed in the coating media and then sprayed onto inert microcrystalline cellulose spheres using a fluid bed through a Wurster tube with continuous inlet air that dries the liquid in the dispersion, to obtain various layers consisting of caffeine and release-controlling polymers. The applied release-controlling polymeric system is based on methacrylate copolymers, which control the release of caffeine in pH-dependent and pH-independent manner. The release mechanism of the polymeric system is mainly driven by the swellability and permeability of the copolymers. The final micropellets are then encapsulated into hydroxypropylmethylcellulose capsules.
214668680|NCT03731793|OTHER|Placebo|Placebo
214893896|NCT06577935|OTHER|Placebo|Subcutaneous injection
214668681|NCT05855356|PROCEDURE|Rehabilitation|respiratory physiotherapy, personalized aerobic and strength training
214893897|NCT06022822|PROCEDURE|Biopsy Procedure|Undergo biopsy
214893898|NCT06022822|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214893899|NCT06022822|DRUG|Placebo Administration|Given PO
214668682|NCT05855356|PROCEDURE|Standard of Care|Behavioural and Medical management
214668683|NCT03888625|PROCEDURE|Conventional ILM Peeling|peeling with complete removal of the internal limiting membrane (ILM)
214893900|NCT06022822|DIETARY_SUPPLEMENT|Urolithin A Supplement|Given PO
214668684|NCT03888625|PROCEDURE|Inverted ILM Peeling|the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
214668685|NCT00780403|DRUG|Desloratadine|desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
214668686|NCT00780403|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
214296238|NCT04975360|OTHER|Placebo|Identical hydroxypropylmethylcellulose capsules without containing caffeine micropellets.
214478160|NCT05700760|BEHAVIORAL|ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)|Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.
214478161|NCT05700760|BEHAVIORAL|Enhanced Care as Usual (CAU)|Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
214296239|NCT05248841|DRUG|HEC-Glargine|Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
214893901|NCT06478251|DRUG|NW-301V|TCR-T cell targeting KRAS G12V mutation
214296240|NCT05248841|DRUG|US-Lantus|Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
214478162|NCT06397820|DEVICE|Percutaneous coronary intervention (PCI)|Revascularization by percutaneous coronary intervention for vessels with decreased PET-derived flow indexes
214478163|NCT03165955|DRUG|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
214478164|NCT06701318|DEVICE|Ultrasound shear wave elastography|An ultrasound machine (GE LogiQ S8) equipped with SWE technology will be used. A high-frequency linear transducer will be used and The machine settings will be optimized for musculoskeletal applications.
214478165|NCT06634004|OTHER|BOLD MRI|The study will utilize the MRI diagnostic reactivity test to evaluate cerebrovascular reactivity in patients with moyamoya and healthy controls. All participants (patients and controls) receive the same diagnostic scan, and there is no cross-over, factorial, or sequential nature to the study.
214478166|NCT06701955|OTHER|Questionnaire and Physical Exam|self administered questionnaires
214478167|NCT06876324|BEHAVIORAL|HealthMPowerment App|A mobile health app designed to facilitate increased PrEP use and adherence among AYAs
214478168|NCT06879054|OTHER|Healthy lifestyle education|Healthy lifestyle education via nutritional educational modules from the Gaples Institute.
214893902|NCT06478251|DRUG|NW-301D|TCR-T cell targeting KRAS G12D mutation
214893903|NCT05525520|DRUG|EP547|Once daily
214893904|NCT05525520|DRUG|Placebo|Once daily
214893905|NCT05574868|DEVICE|Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis|Treatment: Erectile dysfunction
214893906|NCT04194775|DRUG|Nofazinlimab (CS1003)+Lenvatinib|Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily
214893907|NCT04194775|DRUG|Nofazinlimab (CS1003) Placebo+Lenvatinib|Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
214893908|NCT06078137|OTHER|Usual PROMs and new PROMs strategy|Patients randomized to intervention receive both usual PROMs and new PROMs strategy
214893909|NCT05806138|DRUG|Vericiguat|A starting dose of vericiguat 2.5 mg will be administered in-clinic at the Day 1 visit. Titration visits will occur on Days 14 and 28, with dose escalation to 5 mg and 10 mg.
214893910|NCT05806138|OTHER|Optimal medical therapy|All subjects will be followed by a cardiologist throughout the study period and will receive optimal medical therapy for cardiomyopathy/heart failure following the ACCF/AHA and ESC Guidelines for the Management of Heart Failure recommendations, applied individually at the discretion of the treating investigator and in line with individual tolerability. This includes medications such as ßblockers, angiotensin converting enzyme inhibitors(ACEI), angiotensin receptor/neprilysin inhibitor (ARNI), angiotensin receptor blockers (ARB), and mineralocorticoid antagonists
214893911|NCT06117332|DEVICE|Visual prosthesis|"In response to the stimulation/image on the monitor, subjects will be asked to either make a perceptual judgment or perform a simple behavioral task. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, or walking to a target location. Both patient response and reaction time will be recorded.~In some cases, the investigators will also collect data measuring subjects' eye position. This is a noninvasive procedure that will be carried out using standard eye-tracking equipment via an infra-red camera that tracks the position of the subjects' pupil. Only measurements like eye position or eye blinks will be recorded, so these data do not contain identifiable information."
214296241|NCT01163279|BEHAVIORAL|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
214478169|NCT06878755|OTHER|Promoting Assertive Communication among Teens (PACT)|See Arm Description
214478170|NCT06878755|OTHER|Healthy Minds|See Arm Description
214478171|NCT06616623|BIOLOGICAL|Atezolizumab|Given IV
214478172|NCT06616623|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
214478173|NCT06616623|PROCEDURE|Computed Tomography|Undergo CT
214893912|NCT05859490|BIOLOGICAL|17D|Vaccine administration in subjects previously vaccinated with 17D.
214893913|NCT06404034|DRUG|Gallium Maltolate|GaM will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days) on an empty stomach. GaM should be taken at least 60 minutes before a meal and at least two hours after a meal. Liquids are allowed
214478174|NCT06616623|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214478175|NCT06616623|DRUG|Vismodegib|Given PO
214478176|NCT06694727|DIETARY_SUPPLEMENT|Coenzyme Q10 100 Milligrams Oral Capsule|100 mg capsules given twice daily, per oral use.
215050716|NCT03384186|DRUG|Danicopan Modified Release Prototype 1|Danicopan (400 milligrams \[mg\]) oral tablet.
215050717|NCT03384186|DRUG|Danicopan Modified Release Prototype 2|Danicopan (400 mg) oral tablet.
215050718|NCT03384186|DRUG|Danicopan Modified Release Prototype 3|Danicopan (800 mg) oral tablet.
214893914|NCT06529068|BEHAVIORAL|Isometric handgrip exercise|The participants will perform isometric handgrip exercises without blood flow restriction.
214893915|NCT06529068|BEHAVIORAL|Isometric handgrip exercise with a narrow-elastic band|The participants will perform isometric handgrip exercises with blood flow restriction using a narrow-elastic band.
214893916|NCT06529068|BEHAVIORAL|Isometric handgrip exercise with a wide-rigid cuff|The participants will perform isometric handgrip exercises with blood flow restriction using a wide-rigid cuff.
215050719|NCT02636296|OTHER|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
214893917|NCT04603625|OTHER|postural management|postural management in sitting position
215050720|NCT02636296|OTHER|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
214296242|NCT01163279|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
214296243|NCT00119392|BIOLOGICAL|rituximab|Given IV
214296244|NCT00119392|DRUG|cyclosporine|Given orally
214296245|NCT00119392|DRUG|fludarabine phosphate|Given IV
214478177|NCT06694727|DIETARY_SUPPLEMENT|Selenium 100 Micrograms Oral Tablets|100 μg tablets given twice daily, per oral use.
214478178|NCT04499521|DEVICE|BrachyGel VHPS|Packing system for administering brachytherapy in cervical cancer patients
214478179|NCT04503694|DRUG|Nivolumab 10 MG/ML Intravenous Solution|"Nivolumab will be given at a dose of 240 mg during the pre-operative phase only as indicated below:~* On day 1 and 15, during the Induction treatment~* On day 29, 43 and 57, during the Consolidation treatment"
214893918|NCT06430086|OTHER|Walnut consumption|Participants will add one serving (1 oz) of walnuts at their self-defined breakfast, lunch, and dinner for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.
214893919|NCT06430086|OTHER|HCHS consumption|"Participants will add one HCHS food (one PopTarts® pastry) to each of their 3 main meals of the day for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.~An energy-matched high-carbohydrate, high-sugar (HCHS) alternative, representative of a common US snack food, on sleep quality in adults with habitually poor sleep quality."
215050721|NCT00066326|DRUG|imatinib mesylate|
215050722|NCT00066326|DRUG|tanespimycin|
215050723|NCT02379052|DRUG|Dupilumab|
215050724|NCT02379052|DRUG|Placebo|
215050725|NCT01686113|OTHER|NEFA|
215050726|NCT01686113|OTHER|Sucrose|
214296246|NCT00119392|DRUG|mycophenolate mofetil|Given orally
214296247|NCT00119392|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
214296248|NCT00119392|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
214296249|NCT00119392|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
214296250|NCT00119392|RADIATION|total-body irradiation|Undergo TBI
214296251|NCT01237873|DRUG|Ali/Amlo 150/2.5 mg|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
214296252|NCT02526888|DRUG|ACT-541468|Oral capsule (25 mg) as single dose
214478180|NCT04503694|DRUG|Regorafenib 30 MG Oral Tablet|"Regorafenib will be administered orally once a day at a dose of 60 mg/day (2 tablets of 40 mg), during the pre-operative phase only as indicated below:~* From day 1 to 14, during the Induction treatment~* From day 29 to 49, during the Consolidation treatment"
214478181|NCT04503694|RADIATION|Radiotherapy|All study subjects will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy. Radiotherapy is to start on day 22 and to finish on day 26.
214668687|NCT05450068|OTHER|Mulligan's Mobilization with movement|The Mulligan's technique will be performed as described by Brian Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets.
215050727|NCT03119168|DRUG|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
215050728|NCT03119168|OTHER|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
215050729|NCT02861287|OTHER|Economic evaluation|
215050730|NCT01107067|DRUG|Sustanon|250 mg/21 days
215050731|NCT03069508|DRUG|Clemizole Hydrochloride|Clemizole Hydrochloride will be administered orally for up to 24 weeks
215050732|NCT05979961|RADIATION|IMRT and concurrent cisplatin|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated radiotherapy (IMRT)
215050733|NCT05979961|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy
215050734|NCT05939752|OTHER|ophthalmological examination|OCT-retinal angiography At inclusion, 3 months and 6 months
215050735|NCT05939752|BIOLOGICAL|blood test|"a 2-mL tube of blood will be taken to test for blood markers predisposing to cardiovascular complications.~At inclusion"
215050736|NCT02989181|DEVICE|Continues Positive Airway Pressure (CPAP)|Mask with positive airway pressure during exhalation which maintains the airway open
215050737|NCT04419467|BIOLOGICAL|CSL346|VEGF-B antagonist monoclonal antibody
215050738|NCT04419467|DRUG|Placebo|Normal saline
215057405|NCT02212366|DEVICE|Active TDCS|Active Stimulation
215057406|NCT02212366|DEVICE|Sham TDCS|Sham Stimulation
215057407|NCT03005236|DRUG|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
215057408|NCT03005236|DRUG|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
215057409|NCT05242341|BEHAVIORAL|application(APP) teaching|Teaching the use of the APP
214478182|NCT04503694|PROCEDURE|Surgery|Subject will undergo surgical resection of the primary tumour in the rectum between day 74 and 87. Surgery must be performed according to the principles of total mesorectal excision as described by Heald et al. The type of surgical approach (low anterior resection or abdominoperineal resection, etc.) will be left to the discretion of the treating surgeon.
214893920|NCT06041880|DEVICE|Passive calf muscle stretching device|Modified night splints will be used to passive stretch the calf muscle.
214893921|NCT06424184|DEVICE|Accelerated Repetitive Transcranial Magnetic Stimulation|"The rTMS protocol implemented in this study will include approximately 10-minute long sessions of intermittent theta burst stimulation (iTBS) with at least 50 minutes in between iTBS sessions.~Study participants will receive the rTMS intervention for up to 50 sessions across a three-week period. The total of 50 sessions will be administered as up to 4 sessions each day, up to 5 days per week over an up to 3-week-long period."
214893922|NCT05957848|DRUG|Guanfacine Extended Release Oral Tablet|Target dose 4 mg daily
214296253|NCT02526888|DRUG|Diltiazem|Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
215050739|NCT05724082|OTHER|Clean Air Intervention|"Based on findings from preliminary focus groups/in-depth interviews, staff will introduce various components of established clean air interventions to each household. Each household will receive interventions, depending on their known risk factors, exposures, and willingness to trial the intervention.~Study staff will ask the primary cook to complete a time-activity diary during the intervention period that includes cooking episodes, duration of cooking, stove(s) used, type of food cooked, and number of people for whom the meal was cooked. Staff will continuously monitor use of the LPG/pellet stove and any other stoves owned by the household with the Berkeley Stove Use Monitoring System, a temperature logger attached to the stove to quantify the number of stove uses / time of use . Study staff will use similar loggers to monitor use of other devices installed including the air purifiers, lighting etc."
215050740|NCT00981903|DRUG|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
214296254|NCT02411292|DRUG|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
214668688|NCT05450068|OTHER|Spencer's muscle energy technique|Muscle energy technique that is composed of 7 stages repeated on after the other will be performed. Each movement will be repeated 10 times with 1 minute rest between each set.
214668689|NCT05450068|OTHER|Conventional Therapy|Electrotherapy-Ultrasound (5-10 mins), Exercise therapy program (isometric, capsular stretching, pectoral stretch and scapular stabilization exercises)
215050741|NCT01559545|DRUG|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
215050742|NCT01559545|DRUG|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
215050743|NCT01559545|DRUG|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
214296255|NCT00361855|DRUG|NX-CP105|
214296256|NCT03030573|PROCEDURE|Reconstruction of the bile duct with the round ligament|In patients who had bile duct defect by injury or resection, the Round ligament will be used to reconstruct the defect. Surgical technique, the early and long term postoperative measures are detailed in the investigators protocol.
214296257|NCT03853447|DIAGNOSTIC_TEST|Diagnostic imaging|MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
214668690|NCT04327648|DEVICE|Social interaction treatment|Children in social interaction treatment group will have 30min social interaction each day for 3 months.
214668691|NCT04327648|DEVICE|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months.
214668692|NCT04327648|OTHER|Routine treatment|Children in routine treatment group will keep the same initial treatment.
214296258|NCT03304574|BEHAVIORAL|Integrated personalized feedback|Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
214296259|NCT02493608|DEVICE|scalpel|used to cut the abdominal wall.
214296260|NCT02493608|DEVICE|Diathermy|Diathermy used to cut , coagulate the tissue
214296261|NCT03816085|OTHER|Shoes|Shoes with different heel heights
214668693|NCT02094599|DRUG|Dronabinol 10 mg|Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
214893923|NCT05957848|BEHAVIORAL|Residential withdrawal|4-14 days in residential withdrawal treatment
214893924|NCT05957848|BEHAVIORAL|Engagement with alcohol and other drug services|Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study
214893925|NCT05957848|DRUG|Placebo|Placebo capsule taken daily
215050744|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product A
215050745|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product B
215050746|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product C
214296262|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system
214893926|NCT03407820|PROCEDURE|Absorbable Chromic gut sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received absorbable Chromic sutures are treated recording to the standard protocol and they are advised that they can start to gently rub the scab and suture line to encourage the sutures to fall off starting 10-14 days postoperatively.
215050747|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Spiriva 18 Mcg/capsule inhaled via HandiHaler
215050748|NCT06416228|DIETARY_SUPPLEMENT|Beetroot juice|Participants will take on dose in the morning and one in the afternoon, for 7 days during their final academic examinations
215050749|NCT03667989|DIAGNOSTIC_TEST|Assessment of cardiac sympathetic innervation by 123I-MIBG|Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
215050750|NCT01730612|DRUG|TF2 - 68 Ga-IMP-288:|ImmunoTEP
214296263|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
214296264|NCT01517009|DRUG|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
214893927|NCT03407820|PROCEDURE|Non-absorbable Nylon sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received Nylon sutures are treated recording to the standard protocol and sutures are removed after the usual time (10-14 days) of the received procedure.
214893928|NCT03441074|BEHAVIORAL|Odor Enrichment|Patients in intervention group will get odor enrichment during perioperative period (3 days before the surgery and 7 days after the surgery). Odor-enriched participants were exposed daily for 24 hours to different aromatic fragrances (phenyl ethyl alcohol - rose; eucalyptol - eucalyptus; citronellal - lemon; eugenol - cloves) referred to previous studies. Odors were changed for each subject after 24 hours. According to previous studies, 10 drops of the 100% essential oil (0.5 ml) were dropped on a fabric which was placed in tea bags hanging at the hospital bedside.
214893929|NCT04541082|DRUG|ONC206|ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
214893930|NCT05636020|BEHAVIORAL|ICARE Treatment|The treatment is 12 teletherapy sessions lasting approximately 60-90 minutes. Of the 12 treatment sessions, 7 of them will focus on training skills to help the participant with TBI better recognize emotions from facial expressions. The remaining 5 sessions will teach skills important for empathizing with others' thoughts and feelings, and how to be emotionally supportive. Role-playing will be a big part of these last 5 sessions. The care-partner will be expected to attend as many of these 5 empathy sessions with the participant with TBI as possible.
214893931|NCT03176134|DRUG|Tedizolid phosphate|Tedizolid phosphate IV solution or oral suspension
214893932|NCT03176134|DRUG|Comparator|Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
214893933|NCT02498912|PROCEDURE|Production of Genetically-modified T cells|
214893934|NCT02498912|DRUG|Cyclophosphamide|
214893935|NCT02498912|DEVICE|IP Catheter Insertion|
214893936|NCT02498912|GENETIC|Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells|Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.
214893937|NCT02498912|DRUG|Fludarabine|fludarabine dose 25-30 mg/m2 x 3 days
214893938|NCT06306300|DRUG|Specialist - Epclusa 400Mg-100Mg Tablet|HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by a specialized doctor.
214893939|NCT06306300|DRUG|Non- specialist - Epclusa 400Mg-100Mg Tablet|HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by non-specialized doctor.
214893940|NCT00000525|DRUG|hydrochlorothiazide|
214893941|NCT00000525|BEHAVIORAL|diet, potassium supplementation|
214893942|NCT00000525|BEHAVIORAL|diet, magnesium supplementation|
214893943|NCT00000525|DRUG|triamterene|
214893944|NCT00000525|DRUG|chlorthalidone|
214668694|NCT02094599|DRUG|Dronabinol 30 mg|Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
214668695|NCT02094599|DRUG|Placebo|Matching placebo provided in capsules or as an oral solution in syringes.
214893945|NCT02621866|DEVICE|Ultraviolet A radiation|Twice daily with 10 Joules/cm2. Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)
214893946|NCT02621866|DEVICE|Sham irradiation|As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of \<500nm, but permits visible light to pass.
214893947|NCT03657797|DRUG|NCX 470|NCX 470 Ophthalmic Solution
214893948|NCT03657797|DRUG|Latanoprost 0.005%|Latanoprost 0.005% Ophthalmic Solution
214893949|NCT05981235|BIOLOGICAL|AZD6422 CLDN18.2 CAR-T product|AZD6422 CAR-T product infusion after pre-conditioning
215050751|NCT00815048|DRUG|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
215050752|NCT00815048|DRUG|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
214296265|NCT01517009|DRUG|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
214296266|NCT01517009|DRUG|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
214296267|NCT01517009|PROCEDURE|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
214296268|NCT00854074|DEVICE|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
214296269|NCT04079153|DEVICE|Mandibular advancement Appliance|Advances the mandible at desired range at a fixed vertical dimension
214296270|NCT02149927|DRUG|Sevoflurane|
214296271|NCT01462721|DEVICE|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
214296272|NCT00049101|DRUG|erlotinib hydrochloride|
214296273|NCT00049101|DRUG|fluorouracil|
214296274|NCT00049101|DRUG|leucovorin calcium|
214296275|NCT00049101|DRUG|oxaliplatin|
214893950|NCT00118157|OTHER|Laboratory Biomarker Analysis|Correlative studies
214893951|NCT00118157|DRUG|Lapatinib Ditosylate|Given PO
214893952|NCT00118157|DRUG|Tamoxifen Citrate|Given PO
214893953|NCT03685916|OTHER|Control|Plain rice with plain water
214893954|NCT03685916|OTHER|Cumin Rice|Cumin rice with plain water
214893955|NCT03685916|OTHER|Cumin Drink|Cumin drink with plain rice
215050753|NCT02214069|DEVICE|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
215050754|NCT04728646|DRUG|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
214893956|NCT03685916|OTHER|Cornsilk Rice (Low dose)|Low dose cornsilk rice with plain water
214893957|NCT03685916|OTHER|Cornsilk Rice (High dose)|High dose cornsilk rice with plain water
214893958|NCT03685916|OTHER|Cornsilk Drink (Low dose)|Low dose cornsilk drink with plain rice
214893959|NCT03685916|OTHER|Cornsilk Drink (High dose)|High dose cornsilk drink with plain rice
214893960|NCT03685916|OTHER|Tamarind Rice|Tamarind rice with plain water
214893961|NCT03685916|OTHER|Tamarind Drink|Tamarind drink with plain rice
214893962|NCT01546818|BIOLOGICAL|SAV001-H|A whole-killed HIV
214893963|NCT01308203|DRUG|Extended release niacin/laropiprant|Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
214893964|NCT01308203|DRUG|placebo|Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
214893965|NCT02670616|DRUG|Ibrutinib|560 mg by mouth daily on day 1-21 per each cycle
214893966|NCT02670616|DRUG|Rituximab|375 mg/m2 IV, day 1
214893967|NCT02670616|DRUG|Cyclophosphamide|750 mg/m2 IV day 1
215050755|NCT04728646|DEVICE|Regular dissolvable intracanalicular plug|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
215050756|NCT00457678|DRUG|Visudyne|
215050757|NCT00457678|DRUG|Lucentis|
214893968|NCT02670616|DRUG|Doxorubicin|50 mg/m2 IV day 1
214893969|NCT02670616|DRUG|vincristine|1.4 mg/m2 IV on day 1
214893970|NCT02670616|DRUG|Prednisolone|100mg per day on day 1-5
214893971|NCT00944099|BEHAVIORAL|Behavioral weight loss intervention|both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
214893972|NCT00102219|DRUG|Pemetrexed|
214893973|NCT00102219|DRUG|Doxorubicin|
214893974|NCT01813617|DRUG|Immunosuppressive Agents|Patients in the cohort received medical treatment according to standard care.
214893975|NCT05989672|BIOLOGICAL|HSVTI Formulation 1|This investigational intervention was administered intramuscularly to HSVTI\_F1 Group.
214893976|NCT05989672|BIOLOGICAL|HSVTI Formulation 2|This investigational intervention was administered intramuscularly to HSVTI\_F2 Group.
214893977|NCT05989672|BIOLOGICAL|Placebo|This intervention was administered intramuscularly to Placebo group.
214893978|NCT01224405|DRUG|Docetaxel + LH-RH analogues|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration."
214893979|NCT01224405|DRUG|Docetaxel|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues."
214893980|NCT01224405|DRUG|Docetaxel|Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced \>50%. Docetaxel treatment will be resumed when the serum PSA will rise by \>50% from the lowest PSA level recorded and will be \>10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.
214893981|NCT01224405|DRUG|Continuous Docetaxel|Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
214893982|NCT01224405|DRUG|Continuous Docetaxel|Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
214893983|NCT00254787|DRUG|IR (Immediate-Release) quetiapine fumarate (drug)|
214893984|NCT00696423|BIOLOGICAL|Infanrix™|Intramuscular injection, one dose
214893985|NCT00696423|BIOLOGICAL|Hiberix™|Intramuscular injection, one dose
214893986|NCT03075371|OTHER|Glucose|75 g of glucose dissolved in 300 ml of water
215050758|NCT00457678|DRUG|Dexamethasone|
215050759|NCT02076854|BEHAVIORAL|Text-Message Intervention|
215050760|NCT01337193|OTHER|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
215050761|NCT01337193|OTHER|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
215050762|NCT02852798|DRUG|Apatinib Combined With Docetaxel|Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration
215050763|NCT00446329|DRUG|cinacalcet|Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
215050764|NCT05501639|DRUG|tiotropium|tiotropium
215050765|NCT05501639|DRUG|long-acting β2-agonists (LABA)|long-acting β2-agonists (LABA)
214893987|NCT03075371|OTHER|Placebo|300 ml of tap water
214668696|NCT02320578|PROCEDURE|3D Laparoscopy|3D Laparoscopy approach
214893988|NCT04182178|OTHER|10 years follow up|Questionnaires
214893989|NCT02897778|DRUG|Entinostat|Single, supratherapeutic dose of entinostat given orally.
214893990|NCT02897778|DRUG|Placebo|Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).
214893991|NCT03444311|DIETARY_SUPPLEMENT|A: 1 dosis|"1 dosis (3E+09 cfu/d + 6 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
214893992|NCT03444311|DIETARY_SUPPLEMENT|B: 2 dosis|"1 dosis (3E+09 cfu/d + 12 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
214893993|NCT02069639|OTHER|no treatment|
214893994|NCT03920514|DRUG|hCG|Women will be given hCG before or with IUI
214893995|NCT04885881|PROCEDURE|Ozone therapy|Patients in the ozone therapy group will be treated with ozone (O2-O3) in a volume of 5 ml and a dose of 10 µg / ml for three consecutive weeks in a weekly session to the most painful trigger point.
214893996|NCT04885881|PROCEDURE|Lidocaine injection group|Patients in the lidocaine injection group will be applied to the most painful trigger point in a volume of 2 ml of 1% lidocaine for three consecutive weeks, once a week.
214893997|NCT02363543|DEVICE|Hyalomatrix|
214893998|NCT02363543|DEVICE|Integra|
214893999|NCT03200990|DEVICE|iVAC2L pVAD|To determine the effects of the new PFLVAD PulseCath® iVAC2L on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
214894000|NCT03989102|BIOLOGICAL|PfSPZ Vaccine|PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.
214894001|NCT03989102|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe; and will be used as a placebo, rather than a comparator vaccine
215050766|NCT05501639|DRUG|inhaled corticosteroids (ICS)|inhaled corticosteroids (ICS)
215050767|NCT02069977|DRUG|Aripiprazole|
215050768|NCT04240106|DRUG|Niraparib|Niraparib orally daily beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
215050769|NCT04240106|DRUG|Aromatase Inhibitors|Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
215050770|NCT04292197|DRUG|18-MC Compound|18-MC
215050771|NCT02881736|OTHER|electroencephalographic,magnetic resonance imaging|
214668697|NCT02320578|PROCEDURE|Standard Laparoscopy|Standard laparoscopy approach
214668698|NCT00795730|DRUG|NSA-789|
214668699|NCT00795730|OTHER|placebo|
214894002|NCT03642262|DRUG|Mucinex®|Mucinex® 600 mg single dose ER bi-layer tablet
214894003|NCT03526328|OTHER|EMR and RFA effect on stem cell marker expression in BE/EAC|Observation of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
214894004|NCT04134533|OTHER|Gross Motor Function Measurement|These instruments will be used for determine the gross motor functional level and quality of life of the children with cerebral palsy and anxiety, depression levels of caregivers.
214894005|NCT00000520|DRUG|immunoglobulins, intravenous|
214894006|NCT00000520|DRUG|aspirin|
214894007|NCT06521060|PROCEDURE|tru cut biopsy|Proving that preoperative TCB could provide accurate information about the histological nature of the tumor would have great impact for setting an adequate, tailored, oncologically safe treatment approach.
214894008|NCT04047667|PROCEDURE|cone beam CT guided transbronchial cryobiopsy|CBCT images are acquried and reviewed in axial, coronal and sagittal planes to most accurately assess the cryoprobe position within the lung parenchyma and relative to other thoracic structures. The minimum probe-to-pleura distance will be measured. If the position of cryoprobe is proper, TBCB will be perfomed.
215050772|NCT01731847|PROCEDURE|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
215050773|NCT05115565|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) Application|Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
215050774|NCT04091191|DIETARY_SUPPLEMENT|Meta19.01|A specialized nutraceutical containing plant extracts, vitamins and fish oil
215050775|NCT00004927|DRUG|ixabepilone|
215050776|NCT00104390|BIOLOGICAL|Grass MATA MPL|
215050777|NCT04888806|DRUG|Camrelizumab|d1，200mg, iv, q3w
215050778|NCT04888806|PROCEDURE|ablation|the 37 enrolled patients received ablation of liver/lung metastases ，If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times.
214296276|NCT02695745|DRUG|V116517 aqueous suspension|300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
214296277|NCT02695745|DRUG|Celecoxib capsules|400 mg (2 capsules of 200 mg each) taken orally x 1 dose
214296278|NCT02695745|DRUG|Placebo|Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
214296279|NCT02695745|DRUG|Capsaicin|1% administered topically
214296280|NCT04086290|PROCEDURE|RARP|Radical prostatectomy + extended pelvic lymph node dissection
214296281|NCT04086290|RADIATION|SBRT|Stereotactic body radiotherapy to osseous lesions
214296282|NCT04086290|DRUG|ADT|six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
214478183|NCT04503694|PROCEDURE|Non-operative Management|"Subjects who achieve cCR after pre-operative treatment can, after discussion with the local investigator, decline surgery and opt for a non-operative management. cCR will need to be confirmed between day 67 and 74 by the following procedures per local practise:~* Digital rectal examination~* Rectal endoscopy~* Rectal MRI Subjects who achieve near cCR at the first assessment time point after pre-operative treatment, can be re-assessed 6 to 8 weeks later with the same procedures. If cCR is diagnosed, they can opt for watch \& wait, otherwise they would need to undergo surgical resection.~Subjects who opt for a non-operative management will be followed for tumour recurrence and survival for 5 years after end of treatment visit. Follow-up for these subjects will be more intensive than that for subjects undergoing surgery"
214478184|NCT06876051|BEHAVIORAL|Relaxation & Breastfeeding Education|"Pregnant women in this group will be trained in 10 individual interactive sessions, focusing on relaxation techniques and breastfeeding including:~1. Diaphragmatic breathing~2. Progressive muscle relaxation (PMR) - tailored for pregnant women.~3. Guided imagery~4. the analysis of the concept of stress and stress management strategies for pregnancy including Cognitive-behavioral approach (CBT principles)~5. Mindfulness-based pregnancy adaptation including positive thinking and wellbeing during pregnancy .~6. Pregnancy stages.~7. Benefits of breastfeeding.~8. Breastfeeding guide and practical applications.~9. Labor stages and childbirth preparation.~10. Newborn and infant needs at home Every relaxation technique training will last 20 minutes practice in every session Additionally pregnant women will be practiced at least 3 times weekly during pregnancy"
214894009|NCT06490848|PROCEDURE|Diagnostic cerebral angiography|In transradial access, no preprocedural upper extremity collateral blood supply testing was completed. When the radial access is unsuccessful, it is shifted to ulnar or femoral access. All right arms were secured in the fully supine position to allow access to both radial and ulnar arteries. At the conclusion of radial access procedures, a TR band was applied to close the access. Neurological exams as well as radial artery pulse and pulse oximeter of the right first finger were assessed during and on discharge by trained recovery nurses. Femoral access was performed in a standard manner. After the access (femoral or radial), a cerebral angiogram was performed in a standard manner using appropriate catheters (vertebral, bern, Simmons 2 or 3) according to the access. For the radial access, the patient was slightly sedated.
214296283|NCT04358887|PROCEDURE|piezoelectric surgery|after flap reflection bone and root end cutting are done with piezoelectric surgical insert
214296284|NCT04358887|PROCEDURE|conventional bur|after flap reflection bone and root end cutting are done with surgical bur
214478185|NCT06876051|BEHAVIORAL|Active comparator|"Participants in this group will receive only interactive online education, focusing exclusively on breastfeeding and newborn care. The Programme included ten remote sessions:~1. Pregnancy stages.~2. Benefits of breastfeeding.~3. Skin-to-skin contact and rooming-in during the first days.~4. The role of breastfeeding in maternal emotional well-being.~5. Breastfeeding guide and practical applications.~6. Maternal nutrition during breastfeeding.~7. Common breastfeeding challenges.~8. The father's role in breastfeeding support.~9. Labor stages and childbirth preparation~10. Newborn and infant needs at home."
214668700|NCT04910217|PROCEDURE|Conventional rehabilitation|Patients will undergo conventional rehabilitation
214894010|NCT06150586|OTHER|Skin Conductance (SC) Measurement|SC will be measured using a specific monitor and three self-adhesive electrodes on one foot of the infant (one plantar and two on the ankles). Peaks per second (the rate of firing in the sympathetic nerves), average amplitude (mean peaks) and area under curve (forcefulness of sympathetic nerve firing) will be automatically analyzed. Corresponding data will be transferred to a separate tablet computer via bluetooth.
214894011|NCT06150586|OTHER|Video Recording|The video recording for later N-PASS assessment will be done by a camera fixed above the incubator / resuscitation unit, not interfering with the LISA procedure. The video will show the full body of the newborn as well as the hands / forearms of the treating clinical team with the awareness and oral consent of the treating team.
214894012|NCT05459246|OTHER|Virtual reality glasses|"Beginning 1 minute before the start of the procedure, the patients will be watched (30-45 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30-45 minutes)."
214907216|NCT07151170|OTHER|Telerehabilitation Pelvic Floor Muscle Training (TR-PFMT) Group|The program will be delivered online in small groups by a physiotherapist. The program includes diaphragmatic breathing, pelvic mobility (pelvic tilts, hip circles, cat-cow), stretching (butterfly, child pose, deep squat), and progressive strengthening of phasic and tonic fibers through stationary PFMT (10-sec moderate-hold + 3 quick flicks, 8 sets in weeks 1-3, 10 sets in weeks 4-6, 10-sec rest) and home-based PFMT (10 fast contractions and 10 moderate-hold contractions, 2 sets in weeks 1-2 with weekly set increases, 10-sec rest), performed in prone lying, supine hook-lying, butterfly, sitting, and standing positions. All sessions will be recorded, and participants will submit weekly exercise diaries.
214296285|NCT05128877|OTHER|relaxation techniques|Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
214296286|NCT02190227|DEVICE|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
214296287|NCT03287167|DRUG|1 month DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
214296288|NCT03287167|DRUG|6 months DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
214296289|NCT05757921|DEVICE|Perisolv (A)|Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.
214478186|NCT06876051|OTHER|control group|This group will received only standard prenatal and postnatal care at a Baby-Friendly Hospital, which adheres to WHO and UNICEF guidelines for breastfeeding support. They did not participate in additional structured educational programs or relaxation training.
214478187|NCT06882993|DIAGNOSTIC_TEST|Panenteric capsule endoscopy|Panenteric capsule endoscopy
214478188|NCT06882993|DIAGNOSTIC_TEST|Ileocolonoscopy|Endoscopic examination of the colon and terminal ileum after bowel preparation.
214478189|NCT06882993|DIAGNOSTIC_TEST|MRI enterography|MRI of the small bowel
214478190|NCT06882993|DIAGNOSTIC_TEST|Small bowel capsule endoscopy|Capsule endoscopy of the small bowel
214478191|NCT06721572|DEVICE|TEA|Active TEA or sham TEA will be self-administered at home over two daily treatment sessions of 30 minutes each in the morning and evening. Active TEA will be delivered through an active stimulation acupoint that has previously shown to reduce abdominal pain in other patient populations. Sham TEA will be administered at a different point a few cm away from the active site and that has been shown to be ineffective in reducing pain. Other than the location, the anatomical location, application of TEA and sham will be identical. The device will be programmed by the study team to generate fixed frequency, pulse width, and time on/time off during the pulsed stimulation. The subject is only able to change the stimulation output in a range from 0-10 milliampere.
214894013|NCT04142736|OTHER|Prone Position|The best-fitting and most-tolerated oxygen interface will be used in the prone position--this could be different from patient to patient, and different from what is used in the supine position, and could differ between patients but also institutions (i.e., depending on the availability of masks with or without a reservoir bag and with or without the Venturi system, HFNO, CPAP or NIV). The patient will be placed in the prone position for at least 2 hours, which may be prolonged if the patient is comfortable or interrupted if the patient presents any criteria for prone position discontinuation. After the prone position period, the patient will be rotated to the semi-recumbent supine position for at least 2 hours and a maximum of 4 hours. This 2-hour time frame will depend on nursing availability, need for hygiene, complementary explorations, or diet.
214668701|NCT04910217|PROCEDURE|Leg/lower body exerciser device intervention.|Patients will undergo leg/lower body exerciser device therapy.
214894014|NCT01961219|PROCEDURE|Manipulation Under Anesthesia|Closed manipulation under anesthesia.
214894015|NCT01961219|PROCEDURE|Arthroscopic capsular release|Arthroscopic capsular release
214894016|NCT03973736|OTHER|application of a diagnostic and therapeutic protocol (multidisciplinary discussion and radiological CT review)|Since the introduction of the new protocol in 2012, a single central multidisciplinary team has been formalized, with weekly discussion of cases, including different specialists from all the provincial hospitals. CT scans of discussed cases are reviewed by one of two experienced radiologists based on pre-defined criteria.
214894017|NCT06353464|OTHER|Ensure and Water|Ensure, a liquid meal with 9 grams of protein in 8 ounces consumed 20 minutes before eating pizza; and water, 8 ounces consumed 20 minutes before eating pizza
214894018|NCT01582490|DRUG|Instillation - EXPAREL|Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
214894019|NCT01582490|DRUG|Infiltration - EXPAREL|IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
214894020|NCT00242138|BEHAVIORAL|Erectile Dysfunction|
214894021|NCT01783990|DRUG|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
214894022|NCT00001041|BIOLOGICAL|rgp120/HIV-1MN|
215050779|NCT04888806|DRUG|chemotherapy|standard treatment plan for mCRC, determined by the investigator
215050780|NCT05740046|DEVICE|INTORUS|INTERVENTION PROTOCOL WITH INTORUS
215050781|NCT00442416|DRUG|Epoetin alfa|As prescribed, SC
214478192|NCT06884241|DIETARY_SUPPLEMENT|Probiotic supplementation|The intervention consists of a 6-week supplementation with a specific combination of probiotics: Lactiplantibacillus plantarum P17630 49x109, Lacticaseibacillus paracasei I1688 1x109, Ligilactobacillus salivarius I1794 25x106. All participants were given a gluten-free, low FODMAPs diet. After 4 weeks (T1), foods containing gluten were reintroduced in the diet of all participants (at least 6 g/day of gluten), while the reduced FODMAP content was maintained
214478193|NCT06884241|OTHER|Placebo|"The participants received placebo for 6 weeks. Placebo was identical in appearance, texture, taste, and packaging to the probiotic treatment. All participants were given a gluten-free, low FODMAPs diet.~After 4 weeks (T1), foods containing gluten were reintroduced in the diet of all participants (at least 6 g/day of gluten), while the reduced FODMAP content was maintained"
215050782|NCT00442416|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
215050783|NCT00047905|BEHAVIORAL|examine the process of prenatal genetic counseling|
215050784|NCT03301779|DEVICE|Hemanext Red Blood Cell Processing System|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
215050785|NCT02342353|DRUG|Pacritinib|
215050786|NCT02342353|DRUG|Erlotinib|
215050787|NCT03941418|DIETARY_SUPPLEMENT|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
215050788|NCT03941418|DIETARY_SUPPLEMENT|Placebo|Patients will be administered with placebo of same appearance, colour and taste once daily.
215050789|NCT05657535|DEVICE|Low-intensity continuous ultrasound stimulator|Stimulation 5 minutes, 3 times a day for 4 weeks on the knee
215050790|NCT04256473|DRUG|mutant pro-urokinase|Intravenous administration
215050791|NCT04256473|DRUG|Alteplase|Intravenous administration
214296290|NCT05757921|OTHER|Standard (B)|Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
214296291|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the monitored group will receive an initial dose of 1000 IU of vit D. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). At 28±2 days of age, blood samples will be obtained for 25(OH)D concentration measurement, followed by measurements every 4 weeks and/or 35±1 weeks of PCA. In the monitored group, vit D doses will be appropriately modified, based on 25(OH)D levels, using the scheme described in the Polish recommendation. The intake from the diet will be calculated from the second month of life.
214296292|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the controlled group will receive 250 IU for very low birth weight infants and 500 IU for infants weighing above 1000 g. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). Infants assigned to the standard therapy group will undergo the same blood sample collection procedure as the monitored group, but without any alterations in their dosing regimen.
214478194|NCT06857019|OTHER|"Endotracheal Tube Position Anomaly Alerting System"|"The Endotracheal Tube Position Anomaly Alerting System (ETPAAS) is designed to assist healthcare providers in managing patients receiving mechanical ventilation via an endotracheal tube. This system integrates an artificial intelligence (AI) algorithm that automatically evaluates the appropriateness of endotracheal tube positioning whenever a patient's chest X-ray is uploaded. If the system detects that the distance between the endotracheal tube tip and the carina falls outside the optimal range, it promptly alerts healthcare providers, enabling timely intervention to correct the tube position and enhance patient safety."
214894023|NCT03063788|DRUG|3BNC117-Copper-64|3 mg/kg 3BNC117 combined with radio-isotope Copper-64
214894024|NCT00288535|PROCEDURE|PCI of bifurcated coronary lesions using sirolimus coated stents in modified T-Stenting -Technique|
214894025|NCT02453932|DRUG|Tianzhi granule and placebo identified to donepezil|1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
214894026|NCT02453932|DRUG|Donepezil and placebo identified to Tianzhi granule|donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
214894027|NCT02453932|DRUG|Placebo|placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
214894028|NCT03452761|DIETARY_SUPPLEMENT|Ketone Salts|Subjects will take 2 servings of ketone salts daily for 6 weeks
214894029|NCT03721861|DEVICE|Intra-operative neural cuff stimulation|A feasibility study consists of placing 2 electrodes around the radial or medial nerves intraoperatively. The movements caused by the electrical stimulation of these nerves are observed.
214894030|NCT00564642|DRUG|N Acetylcysteine|1200 mg, BD, 2weeks
214478195|NCT06855524|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214478196|NCT06855524|DIETARY_SUPPLEMENT|Oligo-fucoidan|Given PO
214894031|NCT06549842|DRUG|Heparin|The intervention for this study is the dose of heparin. Patients randomized to group 1 will receive a heparin dose of 50U/kg and those in group 2 will receive a lower dose of heparin at 25U/kg. Recovery period for group 1 would be 2 hours whereas for group 2 would be 1 hour.
214894032|NCT06549842|DEVICE|Terumo Radial Band|Group 1 will receive TR band post cardiac catheterization for radial hemostasis.
214894033|NCT06549842|DEVICE|Vaosband|Group 2 will receive Vasoband post cardiac catheterization for radial hemostasis.
214894034|NCT02332629|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
215050792|NCT04314245|OTHER|Active Comparator: Pathology|Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.
215050793|NCT04314245|OTHER|Active Comparator: Clinical Diagnosis|Routine clinical diagnosis and treatment of benign disease of the urinary system
215050794|NCT04314245|OTHER|Active Comparator: Clinical diagnosis|Routine urine test and imaging diagnostic techniques, such as B-ultrasound.
215050795|NCT04314245|OTHER|Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay|A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.
214478197|NCT06855524|DRUG|Placebo Administration|Given PO
214478198|NCT06855524|OTHER|Questionnaire Administration|Ancillary studies
214894035|NCT02332629|DRUG|Isotonic Sodium Chloride|Placebo
214894036|NCT03227081|BEHAVIORAL|Sleep Deprivation|Sleep Deprivation
214894037|NCT02223962|BEHAVIORAL|Physical activity|Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
214894038|NCT03863782|OTHER|No intervention|No specific intervention. Collection of clinical data
214894039|NCT03190525|OTHER|Quality of life questionnaires|QLQ-C30
214894040|NCT05342350|OTHER|GALAD Score|GALAD score, a blood-based biomarker panel (gender, age, AFP, AFP-L3%, DCP)
214894041|NCT05440123|OTHER|screening for bronchopulmonary cancer|The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
214296293|NCT00048295|DRUG|Alicaforsen|
214894042|NCT05492643|BIOLOGICAL|one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)|all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
214894043|NCT05492643|OTHER|Cellular Immunity|the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
214894044|NCT05492643|OTHER|Humoral Immunity|the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
214894045|NCT05492643|OTHER|Safety|all the 500 participants enrolled will undergo safety observation
214894046|NCT03983525|DIETARY_SUPPLEMENT|Goji berry|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take 28 grams of goji berry once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
214894047|NCT03983525|DIETARY_SUPPLEMENT|Lutein + zeaxanthin supplementation|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take one capsule of lutein + zeaxanthin supplementation once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
214894048|NCT04948346|OTHER|diagnosed with ALS|diagnosed with ALS
214296294|NCT02657707|DEVICE|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
214894049|NCT04126538|DRUG|pirfenidone capsule|In the patient group, pirfenidone capsule was taken orally once for 400mg
215050796|NCT02701244|RADIATION|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
215050797|NCT03940989|OTHER|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
215050798|NCT01669746|BIOLOGICAL|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
215050799|NCT05137691|OTHER|Adapted NHS weight management 1:1 programme|Adapted NHS 1:1 weight management programme with a low carbohydrate dietary focus, incorporating enhanced behaviour change via telehealth, step count and pedometer
215050800|NCT05137691|OTHER|NHS 1:1 weight management programme|NHS 1:1 weight management programme
214296295|NCT02657707|DEVICE|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
214668702|NCT04910217|PROCEDURE|Lokomat intervention|Patients will undergo therapy with Lokomat Pro FreeD device intervention.
215050801|NCT04217707|BEHAVIORAL|Pre- and Post-Surgical Transgender Therapeutic Support Group|Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
215050802|NCT02824523|DRUG|aspirin|
214668703|NCT03603132|DRUG|Hetrombopag Olamine|7.5mg in each cycle
214668704|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
214668705|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
214894050|NCT04126538|DRUG|pirfenidone capsule|Healthy subjects took pirfenidone capsule 400mg once orally
214894051|NCT04793711|DEVICE|EpiCeram|protective emollient
214296296|NCT00882193|DRUG|Betaine|Betaine 20 gm/day in 2 divided doses for 48 weeks
215050803|NCT06406244|DEVICE|TEAS group|Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30 min before anesthesia until be discharged from the post-anaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
214296297|NCT00882193|DRUG|Peginterferon alpha 2a|Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
214296298|NCT00882193|DRUG|Ribavirin|Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight \< or \> 75mg in 2 divided doses
214668706|NCT00845429|BIOLOGICAL|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
214668707|NCT00455637|BIOLOGICAL|Botulinum toxin type A|
214668708|NCT01532661|OTHER|observational study|data collected by investigators
214668709|NCT05784090|OTHER|blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases|"Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation."
214668710|NCT02882477|DRUG|Deferiprone|
214668711|NCT02882477|DRUG|Acetylcysteine|
214894052|NCT02760004|BEHAVIORAL|PRogram In Support of Moms (PRISM)|"* Access to MCPAP for Moms~* PRogram In Support of Moms Toolkit with Stepped Care Algorithms~* Support clinic specific implementation using the Addressing Problems Through Organizational Change (APTOC) platform~* Customization of depression screening for each practice~* Proactively engage and track all women who screen +ve on the Edinburgh Postnatal Depression Scale(EPDS)~* Employ psychoeducation and Motivational Interviewing to engage patients with depression~* medical assistant champion and psychiatrist contact bi-weekly to review cases~* Stepped care treatment to depression screening/assessment"
214894053|NCT02760004|BEHAVIORAL|MCPAP for Moms|"* 30-60 minute presentation on perinatal depression~* Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns~* Access to Ob/Gyn provider assessment and treatment recommendations via one-time face-face MCPAP for Moms psychiatrist patient evaluation~* Access to assessment and treatment protocols in Provider Toolkit~* Resource provision/referrals"
214894054|NCT04837040|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
214894055|NCT04837040|DRUG|Placebo|Placebo, tablets, once daily by mouth
214894056|NCT06002984|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
214894057|NCT04038463|BEHAVIORAL|EFP|This intervention will take place on day 4 of the participants' menstrual cycle. This will correspond to the mid-point of the early follicular phase (EFP).
214894058|NCT04038463|BEHAVIORAL|LFP|The intervention will take place on day 8 of the participants' menstrual cycle. This will correspond to the mid-point of the late follicular phase (LFP).
214894059|NCT04038463|BEHAVIORAL|ELP|The intervention will take place on day 18 of the participants' menstrual cycle. This will correspond to the mid-point of the early luteal phase (ELP).
214894060|NCT04038463|BEHAVIORAL|LLP|The intervention will take place on day 25 of the participants' menstrual cycle. This will correspond to the mid-point of the late luteal phase (LLP).
214894061|NCT06961864|BEHAVIORAL|Visual Adaptation|Presentation of visual stimuli to quantify the appearance of visual snow or its effects in the visual system of the brain.
214894062|NCT06961864|BEHAVIORAL|Assessments and Questionnaires|Administration of clinical assessments and questionnaires to gather information about visual and mental symptoms, cognitive, and sensory function.
214894063|NCT06961864|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|7 tesla fMRI data will be acquired during visual paradigms designed to measure neural responses with and without adaptation.
214894064|NCT06961864|DEVICE|Magnetic Resonance Imaging (MRS)|7 tesla MRS data will be acquired to quantify the concentrations of different brain chemicals in brain regions including visual cortex.
214894065|NCT02802813|DRUG|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)|
214894066|NCT02802813|DRUG|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo|
214296299|NCT02816840|RADIATION|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
214296300|NCT02816840|RADIATION|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
214296301|NCT02820896|DRUG|Placebo|Participants will receive single or multiple doses of RO7105705 matching placebo IV.
214894067|NCT06581315|DRUG|Donafenib|Donafenib 100 mg twice daily (BID)
214894068|NCT01050530|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
214894069|NCT01050530|DRUG|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
214894070|NCT02288312|DRUG|BIA 2-093|
214894071|NCT04464850|DRUG|Intravenous iron|"Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin \<500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin \>800 mg/dl: discontinue iron sucrose"
214894072|NCT04464850|DRUG|Oral iron|"1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin \<500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin \>800 mg/dl: discontinue iron fumarate"
214894073|NCT01276041|DRUG|pertuzumab in combination with trastuzumab and paclitaxel|The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
214894074|NCT00544635|DEVICE|no intervention|no intervention
214894075|NCT00544635|DEVICE|light|scars will be treated with light
214894076|NCT05087225|BIOLOGICAL|polyethelyene glycol|the excipients at covid-19 vaccines
214894077|NCT06294717|OTHER|Progressive relaxation exercises will be applied.|Progressive relaxation exercises will be not applied.
214894078|NCT00461916|DRUG|Half-Dose Depot Triptorelin|
214894079|NCT00461916|DRUG|Reduced-Dose Daily Buserelin|
214894080|NCT03936036|DRUG|Linagliptin|Linagliptin dispensing claim is used as the exposure
214894081|NCT03936036|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
214894082|NCT00485264|DRUG|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily.
214894083|NCT00485264|DRUG|Raltegravir chewable tablet|Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
214296302|NCT02820896|DRUG|RO7105705|Participants will receive single or multiple doses of RO7105705 IV or SC.
214296303|NCT02034955|RADIATION|Post-operative Adaptive Radiation Therapy|
214478199|NCT06648564|PROCEDURE|Bone regenerative surgery with a bone graft substitute and a resorbable membrane|Dental implants with a diagnosis peri-implantitis were treated with regenerative surgery.
214894084|NCT00485264|DRUG|Raltegravir oral granules for suspension (20 mg/mL)|Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
215050804|NCT06406244|DEVICE|sham group|Patients in the sham group will receive electrode attachment but without stimulation.
214894085|NCT00485264|DRUG|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants \< 25 kg were switched to a weight-based dose of the chewable tablet.
214894086|NCT01324778|DEVICE|OsseoSpeed TX|OsseoSpeedTM TX implants of lengths 6-17 mm
214894087|NCT01324778|DEVICE|OsseoSpeed|OsseoSpeedTM implants of lengths 6-17 mm
214894088|NCT05447104|BEHAVIORAL|Mastication|Chewing sugar-free gum for 20 min
214894089|NCT03738046|BEHAVIORAL|Cognitive Behavioral Therapy|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, \& Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, \& Wykes, 2016).
214894090|NCT00276484|DRUG|atorvastatin|Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
214894091|NCT00276484|DRUG|atorvastatin|Atorvastatin 40 mg by mouth, once a day for 6 weeks
214894092|NCT00276484|DRUG|ezetimibe|Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
214894093|NCT02440464|PROCEDURE|Allogeneic HSCT|Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
214894094|NCT02440464|DRUG|Fludarabine|Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
214894095|NCT02440464|DRUG|Melphalan|Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
215050805|NCT01284959|DRUG|risperidone|risperidone 3mg, PO, 3 times
215050806|NCT01284959|DRUG|paliperidone ER|paliperidone ER 6mg, PO,3 times
214478200|NCT06853678|DRUG|Adebrelimab|1200mg,d1,iv,q3w
214668712|NCT02882477|DRUG|Sitagliptin and Metformin|
214668713|NCT01161225|BEHAVIORAL|Peer-assisted asthma self-management program|Intervention group: An asthma self-management program (Power Breathing™) was implemented by trained peer leaders at an asthma day camp. The program consisted of 3 sessions (appx. 45-60 min/session): basic asthma education (pathophysiology, triggers); psychosocial issues of asthma; and asthma self-management (peak flow monitoring and medication). The program was delivered by trained peer leaders paired for each small group of 6-8 teens. Group activities involved discussion, strategic thinking, knowledge-testing games and role plays.
214894096|NCT02440464|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
214894097|NCT02440464|DRUG|Ixazomib|Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
214894098|NCT02440464|DRUG|Placebo|Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
214894099|NCT03333993|OTHER|Pilates Exercise|The Mat Pilates exercise will be performed twice a week and the duration of the sessions will be 60 minutes, consisting of 5 minutes of warm-up exercises, 50 minutes of strengthening exercises followed by 5 minutes of relaxation and stretching.
214894100|NCT03333993|OTHER|Home exercises|Exercises for upper limbs according to the institutional routine.
214894101|NCT05990829|DRUG|Ozurdex|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of Ozurdex will be performed at the end of the surgery.
214894102|NCT05990829|DRUG|Aflibercept|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of aflibercept will be performed at the end of the surgery.
215050807|NCT01284959|DRUG|placebo|lactose PO, 3times
215050808|NCT04074226|PROCEDURE|Erector Spinae Plane block|The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.
215050809|NCT04074226|PROCEDURE|Quadratus Lumborum Block|Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
215057410|NCT01403779|RADIATION|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
214478201|NCT06853678|DRUG|Selinexor|40mg,twice weekly,d1, d3,oral,q3w
214478202|NCT06853678|DRUG|Nab-paclitaxel|100mg/m2,d1,d8,d15,iv,q3w
214478203|NCT06346704|OTHER|Digital HealthTechnology|Subject will wear the Syde® for 1 month every 6 months
214478204|NCT06608797|BEHAVIORAL|Learning and memory training|The experimental group will receive memory retraining exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 training sessions).
214478205|NCT06608797|BEHAVIORAL|Sham Comparator|The sham comparator group will receive sham memory exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 placebo control sessions).
214478206|NCT06602466|DRUG|Test toothpaste|0.454% Stannous Fluoride, 0.3% Zinc Chloride,1% Alumina toothpaste containing 1100 parts per million (ppm) fluoride.
214894103|NCT05293119|DRUG|JAK-2 inhibitor|In this trial, one group will receive the tofacitinib 5 mg twice daily
214894104|NCT05293119|DRUG|Topical corticosteroid|Mometasone furoate 0.1% ointment once daily
214894105|NCT02659423|BEHAVIORAL|BIC 1|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
214894106|NCT02659423|BEHAVIORAL|BIC 2|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
214894107|NCT02659423|BEHAVIORAL|BIC 3|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
214894108|NCT03926299|DEVICE|FotonaSmooth SP® Spectro laser device|dual laser treatment with thermal Nd:YAG and ablative Er:YAG (Fotona medical device), 4 laser sessions 4-8 weeks apart.
214894109|NCT03926299|DRUG|Clobetasol propionate 0.05% ointment|6 months standard treatment with topical steroid cream (high dose for the first two months, medium dose for the next two months, low dose for the last two months)
214894110|NCT06346301|BEHAVIORAL|Imagery rescripting|In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 90 minutes.
214668714|NCT01161225|BEHAVIORAL|Adult-led asthma self-management program|Control group: The group attended an adult-led day camp where 2 NPs and a MD offered didactic asthma education based on the Power Breathing™ program.
214668715|NCT06221644|DIAGNOSTIC_TEST|[18F]SynVesT-1 PET/CT|60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment
214894111|NCT06582069|DEVICE|Bleaching|Bleaching
214668716|NCT04632147|OTHER|Ujjayi pranayama, Nadi-Shodhana pranayama, Sukha pranayama|Ujjayi pranayama:It is a pranayamic application that is performed by slightly twisting the throat and breathing through the nose. Nadi shodhana pranayama is breathing alternately through the right and left nostrils.Sukha pranayama is inhaled through the nose for 5 seconds, then given through the nose for 5 seconds. Thus, 6 times of inspiration and expiration is done per minute.
214668717|NCT00303810|DRUG|carboplatin|
214894112|NCT04136314|BEHAVIORAL|Decision-Framed Survey|Survey will ask all subjects for will be asked to indicate basic demographic information, such as age, sex, race, and education level. Also, subjects will indicate whether they have been diagnosed with psoriatic arthritis. Importantly, patients will complete the survey questions anonymously, and no direct patient identifiers or HIPPA-protected information will be collected. Subjects will then be asked to indicate their preference for a hypothetical injectable medication after exposure to \[A\] a gain-framed message or \[B\] a loss-framed message.
214894113|NCT00995917|OTHER|Vitamin K acupoint injection|Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.
214894114|NCT00995917|OTHER|Saline Injection|Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
214894115|NCT02969252|DRUG|Rifamycin SV-MMX® 600|
214894116|NCT04688671|DRUG|ETX-018810|Study Drug
214894117|NCT04688671|DRUG|Placebo|Matching Placebo
214894118|NCT01626690|DEVICE|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
215050810|NCT03480893|PROCEDURE|small size interarcuair decompression|A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.
215057411|NCT03741907|PROCEDURE|FAUCS|extraperitoneal cesarean with a paramedian left section
214894119|NCT01626690|DEVICE|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
214894120|NCT00202371|PROCEDURE|Red Blood Cell transfusion|
214894121|NCT01807403|PROCEDURE|Deep brain stimulation|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.
214894122|NCT06551532|OTHER|Multicomponent program|Lumbopelvic training (foam rolling, manual therapy, mobility, posture, and strength training) and sprint technique program.
214894123|NCT02251093|DRUG|Lcr Regenerans|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
214894124|NCT02251093|DRUG|Placebo|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
215057412|NCT03741907|PROCEDURE|MLC|Gold standard
214478207|NCT06602466|DRUG|Colgate Cavity Protection Toothpaste|Commercial toothpaste containing 1450 ppm fluoride.
214478208|NCT06842433|OTHER|General healthy diet|General healthy diet based on national health dietary guidelines.
214478209|NCT06842433|OTHER|Personalized diet|Personalized diet will be based on an algorithm considering the individuals' postprandial glucose, triglycerides and inflammation markers to each of the three study meals in the characterization phase (Phase I) matched with established knowledge about the effects of specific foods on such metabolic parameters.
214668718|NCT00303810|DRUG|cisplatin|
214668719|NCT00303810|DRUG|cyclophosphamide|
214668720|NCT00303810|DRUG|etoposide phosphate|
214668721|NCT00303810|DRUG|high-dose chemotherapy|
214668722|NCT00303810|DRUG|lomustine|
214668723|NCT00303810|DRUG|methotrexate|
214668724|NCT00303810|DRUG|thiotepa|
214668725|NCT00303810|DRUG|vincristine sulfate|
214668726|NCT00303810|RADIATION|radiation therapy|
214894125|NCT01605851|DEVICE|Closure, Foramen Ovale|
214894126|NCT01525329|DRUG|5-Fluorouracil|All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting \~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
214894127|NCT04055740|DEVICE|IVUS Imaging|IVUS or radial-ICE (intracardiac echocardiography) is a visualization tool used in many cardiac procedures including electrophysiology procedures (catheter ablation). Its utility in identifying ILA will be assessed in this study.
214894128|NCT05957601|OTHER|No intervention was made as it was a descriptive epidemiological study.|No intervention was made as it was a descriptive epidemiological study.
214894129|NCT00150605|DRUG|Extended-release carbamazepine|
214894130|NCT05383183|DRUG|Choline Alfoscerate 400mg|Oral administration
214296304|NCT01912417|OTHER|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
214894131|NCT05383183|DRUG|Placebo|Oral administration
214894132|NCT01708577|DEVICE|Validation of the IPANEMA - measurement system|Control of the body conditions under real life conditions during a sportive activity.
214894133|NCT06035692|DRUG|Ropivacaine|According to the results of the preliminary experiment, the BPB group was given ultrasound-guided BPB with 0.15% ropivacaine 20ml.The ropivacaine concentration was the 90% minimum effective concentration(MEC90) for preventing vasospasm during operation.
214894134|NCT01856725|PROCEDURE|Hemodynamic measurements for CRT device programming|
214894135|NCT01856725|DEVICE|CRT device implant with MultiPoint Pacing|
214668727|NCT03370146|BEHAVIORAL|Mental training based on Motor Imagery|Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
214668728|NCT03370146|BEHAVIORAL|Cognitive training|Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.
214894136|NCT02414958|DRUG|Empagliflozin|
214894137|NCT02414958|DRUG|Empagliflozin|
214894138|NCT02414958|DRUG|Placebo|
214894139|NCT03524443|BEHAVIORAL|Art Therapy treatment|"The main objective is to describe the evolution at 3 months on the alexithymic dimension in the course of a treatment in art therapy, in patients with anorexia nervosa or bulimia.~Art therapy is a generic term grouping different artistic disciplines adapted and used for therapeutic purposes. It is through commitment to creative work that the therapeutic work of elaboration and reflection takes place in contrast to verbal psychotherapies and mediated psychotherapies that use speech as the main therapeutic tool. All forms of practice referring to categories of art can be used: painting, music, modeling, dance, theater and writing"
214894140|NCT03786588|OTHER|Observation|The patients with the negative results of HPV infection, and assigned to different group according to the CPP manifestation.
214894141|NCT00923741|DRUG|Talactoferrin|
214894142|NCT00923741|PROCEDURE|Apheresis|
214894143|NCT01106079|DRUG|Intensive management or Tight control|Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
214894144|NCT01106079|DRUG|Standard management - Control group|The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
214894145|NCT04442464|DEVICE|Scleral Lens|15.0 mm diagnostic spherical rigid contact lens
214894146|NCT05477784|OTHER|Educational Intervention|Receive EC-PC program
214894147|NCT05477784|OTHER|Informational Intervention|Receive education booklet
214894148|NCT05477784|OTHER|Questionnaire Administration|Ancillary studies
214894149|NCT06970652|DEVICE|virtual reality|Participants in the intervention group received access to the MR smartphone application and a smartphone-compatible VR headset, both developed by MindCo Health.32 The application contained a stress reduction program that comprised a structured sequence of 77 modules designed to be completed over the course of 8 weeks. Each module was designed to be completed in approximately 7 minutes, and each module needed to be completed before progressing to the next module. Forty modules used VR, and for these modules, participants placed their personal smartphones running the MR application in the VR headset, and the smartphone provided all audiovisual content. All other modules used smartphones without the VR headset.
214894150|NCT05767905|DRUG|PF-06821497 Treatment A|A single dose of PF-06821497 administered under fasting conditions.
214894151|NCT05767905|DRUG|PF-06821497 Treatment B|A single dose of PF-06821497 administered under fasting conditions.
215057413|NCT06510803|DRUG|The case intervention is the sevoflurane concentrations with the Drager Apollo workstation|The increases in the sevoflurane concentrations during induction of anesthesia with the Drager Apollo compared with the GE Ohmeda workstations
214296305|NCT04145999|PROCEDURE|PRP application|The study participant will receive topical anesthesia with lidocaine ointment (50mg/g). After 5 minutes the face will be cleaned with 0.5% alcohol chlorhexidine solution. The newly obtained platelet-rich plasma activated with 10% calcium chloride packed in a 5mL syringe will be applied to the face using a 30G needle in the frontal, lateral periorbital, nasogenian sulcus, bilateral malar region and an infra-auricular point. 0.1ml per cm2 will be injected, totaling 43 points. Only one application of PRP will be performed at the defined points.
214894152|NCT05767905|DRUG|PF-06821497 Treatment C|A single dose of PF-06821497 administered under fasting conditions.
214894153|NCT05767905|DRUG|PF-06821497 Treatment D|A single dose of PF-06821497 administered under fasting conditions.
214894154|NCT05767905|DRUG|PF-06821497 Treatment E|A single dose of PF-06821497 administered after low fat meal
214296306|NCT04145999|OTHER|Placebo PRP application|Blood collection will be performed normally, the time between collection and application of saline will be the same as the PRP protocol, but in this case, the blood will be discarded, only a sample to quantify the number of platelets will be sent for analysis.
214894155|NCT05767905|DRUG|PF-06821497 Treatment F|A single dose of PF-06821497 administered after high fat meal.
214894156|NCT03762239|OTHER|Purifying the air with a Pure Airbox device (Zonair 3D)|Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)
214894157|NCT03762239|OTHER|Using a sham air purifier (same device without filters)|Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
214894158|NCT06183983|DIAGNOSTIC_TEST|Extended or additional MRI-scan (with contrast) prior to radiotherapy|The MRI-protocol before radiotherapy is extended with 20 minutes. Patients who would not have received an MRI-scan prior to radiotherapy, will get an extra MRI-scan when participating.
214894159|NCT06122363|DEVICE|hysteroscopy|uterine hysteroscopy right after Novasure endometrial ablation
214894160|NCT05195801|DEVICE|USG|Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
214894161|NCT03645863|DRUG|MT-6548|Oral tablet
214894162|NCT03645863|DRUG|Iron supplement A|Oral tablet
214894163|NCT03645863|DRUG|Iron supplement B|Oral tablet
214894164|NCT03645863|DRUG|Iron supplement C|Oral tablet
214894165|NCT03645863|DRUG|Iron supplement D|Oral tablet
214894166|NCT04756115|PROCEDURE|Vascular Surgery.|Open Vascular, endovascular or hybrid procedures.
214894167|NCT02171195|DRUG|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
214894168|NCT02171195|DRUG|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
215057414|NCT01097096|BIOLOGICAL|CAD106|150μg and 450μg doses were reconstituted and administered via intramuscular injection
215057415|NCT01097096|BIOLOGICAL|Placebo|Identical placebo to CAD106 administered via intramuscular injection
215057416|NCT01097096|BIOLOGICAL|Alum|An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106
214296307|NCT04145999|RADIATION|Photobiomodulation|Photobiomodulation will be applied with a Cosmedical LED face mask (São Paulo, Brazil) containing 92 red LEDs. The applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP or placebo.
214668729|NCT03370146|BEHAVIORAL|Evaluation of gait abilities|All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
214894169|NCT03624192|DEVICE|RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings
214894170|NCT03624192|OTHER|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
214894171|NCT03112473|BEHAVIORAL|Task-orientated training|Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.
214894172|NCT03112473|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY\&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study
214894173|NCT03112473|DEVICE|Sham electrical nerve stimulation|A identical-looking TENS devices that electrical circuit has been disconnected.
214894174|NCT04660331|OTHER|Communication Intervention|Undergo communication strategy intervention
214894175|NCT04660331|OTHER|Communication Skills Training|Undergo communication training sessions
214894176|NCT04660331|BEHAVIORAL|Healthcare Activity|Participate in interview
214894177|NCT04660331|BEHAVIORAL|Healthcare Activity|Undergo environmental scan
214894178|NCT04660331|OTHER|Survey Administration|Complete survey
214894179|NCT01491451|DEVICE|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
214894180|NCT01491451|DEVICE|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
214894181|NCT04952350|DRUG|Atorvastatin 40 Mg Oral Tablet|Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
214894182|NCT04952350|OTHER|Placebo|A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
214894183|NCT00000714|DRUG|Trimetrexate glucuronate|
214894184|NCT00000714|DRUG|Leucovorin calcium|
214894185|NCT02635984|DRUG|Olanzapine|Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
214894186|NCT02635984|DRUG|Placebo|Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
214894187|NCT06581744|OTHER|[18F]AlF-NOTA-Pentixather|inject 185\~370MBq \[18F\]AlF-NOTA-Pentixather
215057417|NCT01097096|BIOLOGICAL|MF59|An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
214894188|NCT05729490|RADIATION|Coronary computed tomography angiography|"All patients will be subjected to:~Two CT scans (coronary calcium scoring and angiography) using 128 or 160-row scanners with a slice thickness of 0.5 mm (Revolution Evo 128, GE Health care, Chicago, Illinois, USA) or (Aquilion 160, Canon Medical Systems, Tochigi, Japan). Calcium scoring will be performed with the use of prospective electrocardiographic gating with 400-ms gantry rotation, 120-kV tube voltage, and 300-mA tube current. For CTA, retrospective electrocardiographic gating will be used, with heart rate adjusted gantry rotations of 350 ms to 500 ms to enable adaptive multisegmented reconstruction.~Iopromide (Ultravist 370, Bayer AG, Berlin, Germany) is the intravenous contrast medium that will be used for CTA. Beta-blockers will be given if the resting heart rate is 70 beats/min."
214894189|NCT00291317|DEVICE|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD). Children were scheduled to attend three cycling sessions per week on non-consecutive days for up to 30 minutes per session over a 9 month period. The intervention was provided at Children's Specialized Hospital in Mountainside, and families were required to provide their own transportation. During the study, the participants continued to participate in their standard, primary rehabilitation program.
214894190|NCT06152432|DEVICE|Maxillary implant overdenture|Patients with an edentulous maxilla and problems with their conventional denture are treated with an implant overdenture either retained by bars or Locators
214894191|NCT01640249|DRUG|Placebo|Capsules administered orally
214894192|NCT01640249|DRUG|LY3006072|Capsules administered orally
214894193|NCT06030375|DRUG|KAND567|Continuous intravenous infusion for 6 hours
214894194|NCT06030375|OTHER|Placebo|Continuous intravenous infusion for 6 hours
214894195|NCT01776632|BEHAVIORAL|Physical activity|Promotoras led 6 free physical activity (PA) classes per week (2 walking groups, 2 cardio dance, and 2 strength training) at participating churches randomized to the intervention condition. Classes included prayer, warm-up, moderate-to-vigorous PA, cool-down, followed by discussion of a monthly health handout. Participants received copies of the handouts each month by mail, which promoted healthy PA habits. Promotoras conducted up to 5 motivational interviewing calls with each participant over the 2-year intervention using a guide to evaluate participants' PA engagement, barriers to being active, and solutions to those barriers. Promotoras advocated for changes to the social and built environments of the churches and surrounding neighborhoods in order to promote PA and healthy behaviors.
214907217|NCT07151170|OTHER|Supervised Pelvic Floor Muscle Training (S-PFMT) Group|In the supervised group, the protocol will be delivered by a physiotherapist in a clinical environment by face-to-face. The standardized Pelvic Floor Muscle Training protocol will be monitored exactly the same as Telerehabilitation group (TR-PFMT).
214907218|NCT07112170|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered as per institutional standard.
215057418|NCT01540786|PROCEDURE|High resolution urodynamic assessment|
215057419|NCT01540786|PROCEDURE|Conventional urodynamic assessment|
215057420|NCT00271908|BEHAVIORAL|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
215057421|NCT03782064|DRUG|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
214296308|NCT04145999|OTHER|Placebo Photobiomodulation|Participants will not be aware of whether or not they have received the PBM application as they will be using eye protection and the researcher will position the equipment at the irradiation locations on all participants. The characteristic sound of the device will be triggered by recording in the placebos groups for the PBM. The placebo applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP.
214296309|NCT04352855|DRUG|Ceftolozane/tazobactam|Administration
214296310|NCT00293696|DRUG|bicalutamide (Casodex), goserelin (Zoladex)|
214296311|NCT03864471|OTHER|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
214907219|NCT07151144|OTHER|Massage|During the active phase of labor (cervical dilation of 4-7 cm), participants received 15-minute sessions of light-pressure massage to the lower back, sacrum, and lumbar area at regular intervals.
214907220|NCT07151144|OTHER|Shower|During the same phase, participants were assisted to take a warm shower for approximately 20 minutes.
214296312|NCT03864471|OTHER|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
214296313|NCT03413813|DEVICE|Magmaris|Severe stenosis de novo, in native coronary arteries, treated with percutaneous coronary intervention with scaffold implantation.
214907221|NCT07153328|DRUG|Silver Diamine Fluoride (SDF, 38%) and Sodium Fluoride Varnish (NaF, 5%)|Application of 38% silver diamine fluoride (SDF) to all active carious lesions at baseline and every 6 months (months 0, 6, 12, and 18, 24). In addition, a 5% sodium fluoride varnish (NaF) is applied to all teeth at 3-month intervals (months 3, 9, 15, 21). Applications are performed by a dentist using standard microbrush or applicator techniques, ensuring lesions coverage for SDF and full dentition coverage for NaF varnish. This alternating protocol evaluates whether combining periodic SDF with regular fluoride varnish enhances caries arrest in primary teeth compared to semiannual SDF alone.
214907222|NCT07153328|DRUG|Silver Diamine Fluoride (SDF, 38%)|Application of 38% silver diamine fluoride (SDF) to all active carious lesions at baseline and every 6 months (months 0, 6, 12, and 18, 24). Applications are performed by a dentist using a microbrush to directly cover the lesion surface until fully saturated. No additional fluoride varnish is provided in this arm. The protocol evaluates the effectiveness of semiannual SDF application alone for arresting active caries in primary teeth of young, uncooperative pediatric patients.
214907223|NCT07152119|DRUG|Litfulo|as provided in real world practice.
214894196|NCT01776632|BEHAVIORAL|Cancer screening|Promotoras provided a 6-session group-based workshop series on cancer screening and prevention (breast, cervical, colorectal, and skin cancers) at participating churches randomized to the attention-control condition. Participants received informational handouts developed by American Cancer Society and the National Cancer Institute to reinforce learning in addition to lists of local cancer screening resources. Promotoras conducted up to 4 motivational interviewing calls with each participant over the 2-year intervention to encourage screening, help overcome barriers to screening, and provide support for goals.
214894197|NCT01683396|DRUG|Placebo|Solution for subcutaneous injection
215050811|NCT03480893|PROCEDURE|Laminectomy|A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.
215050812|NCT04342091|DEVICE|SOL Nova Device|A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
215050813|NCT04718740|DRUG|fluzoparib|Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
215050814|NCT03627949|BEHAVIORAL|E-intervention|The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
215050815|NCT05585073|OTHER|Whether lymph node dissection is qualified or not|Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND
215050816|NCT02578160|PROCEDURE|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
215050817|NCT04646577|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
215050818|NCT04646577|DEVICE|Transcranial Direct Current Stimulation (tDCS|Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
215050819|NCT04190823|DRUG|RC98|Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
214296314|NCT01367574|DRUG|SC MNTX|Dose 1
214668730|NCT06187818|DRUG|Crocin|According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group \[experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period\]
214668731|NCT02999503|BEHAVIORAL|Nutritional education|Nutritional education trough a personal online nutritional consultant
214668732|NCT00413751|DRUG|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
214894198|NCT01683396|DRUG|gevokizumab|Solution for subcutaneous injection
214894199|NCT02321059|DEVICE|Measurement of abdominal wall strength|Test-retest examination of the reliability of the Goodstrength trunk dynamometer
215050820|NCT02074943|BIOLOGICAL|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
215050821|NCT04680624|PROCEDURE|Fecal sample collection|During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected.
215050822|NCT05065073|DRUG|Iodixanol|Iso-osmolar Contrast Media
215050823|NCT05065073|DRUG|Iohexol|Low-Osmolar Contrast Media
215050824|NCT02849834|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
215050825|NCT01840488|DRUG|Irosustat (BN83495)|"Three parts (A, B \& C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression."
215050826|NCT00556803|PROCEDURE|radiofrequency ablation|radiofrequency ablation
215050827|NCT00556803|PROCEDURE|TACE after RFA|TACE after RFA within one month
215057422|NCT03782064|BIOLOGICAL|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
215057423|NCT00825695|DIETARY_SUPPLEMENT|cocoa|two servings of cocoa daily for one month
215057424|NCT02446769|DEVICE|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
214296315|NCT01367574|DRUG|SC MNTX|Dose 2
214296316|NCT01367574|DRUG|SC MNTX|Dose 3
214296317|NCT02232425|DRUG|IX-01|
214296318|NCT02232425|DRUG|Placebo|
214296319|NCT01908257|DRUG|lesinurad 400 mg|
214894200|NCT02190370|BEHAVIORAL|Resources activation|
214296320|NCT01908257|DRUG|ranitidine 150 mg|
214296321|NCT01908257|DRUG|lesinurad 400 mg + ranitidine 150 mg|
214296322|NCT05766774|OTHER|Low-added sugar, high-fat diet|Consist of \<5% kcal from added sugars as recommended by the American Heart Association, and the glycemic index will be 45 or lower (25% lower than typical CF diet). The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
214296323|NCT05766774|OTHER|High-added sugar, high-fat CF diet|Consist of ≥13% kcal from added sugars and the glycemic index will be \>60. The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
214296324|NCT01042730|DRUG|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
214296325|NCT04946357|RADIATION|Protons|proton irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
214296326|NCT04946357|RADIATION|carbon ions|carbon ion irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
214296327|NCT05749302|DRUG|Al18F-NOTA-FAPI|Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
214668733|NCT04666883|OTHER|Review of records and follow up|Follow up to identify patients who developed splenic hilar nodal metastases
214894201|NCT02315911|PROCEDURE|ATE|surgical removal of adenoids and tonsils
214894202|NCT02315911|PROCEDURE|APP|surgical removal of adenoids and tonsils and suturing of palatal pillars
214894203|NCT01363193|DRUG|Lean Body Weight-based heparin dose|"For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.~Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = \[9270 x weight (kg)\] / \[6680+216 x BMI\] Female = \[9270 x weight (kg)\] / \[8780+244 x BMI\]"
214894204|NCT00711295|BIOLOGICAL|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
214894205|NCT00711295|BIOLOGICAL|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 3.75 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
214894206|NCT05712083|DRUG|BCMA CAR-T cells|Each subject receive BCMA CAR T-cells by intravenous infusion
214894207|NCT01215136|DRUG|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
214894208|NCT01215136|DRUG|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
214894209|NCT01215136|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
214894210|NCT02851628|DEVICE|Alternative sizing model based trial mask|A trial full face mask to be used for this trial for the treatment of obstructive sleep apnea using CPAP therapy.
214894211|NCT02851628|DEVICE|Prototype Full Face Mask|A prototype full face mask with previous clinical trial experience used for the treatment of obstructive sleep apnea using CPAP therapy.
214894212|NCT01644851|BEHAVIORAL|Executive function training|Computer-based training in executive functions, administered via www.lumosity.com website.
214894213|NCT06421766|DEVICE|BAHS|Implantation of a percutaneous bone-anchored hearing system
214296328|NCT00665353|DRUG|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
214296329|NCT00665353|DRUG|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
214296330|NCT00665353|DRUG|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
214296331|NCT01108133|DRUG|10 mg HydrocortisoneHöchst|10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
214296332|NCT01108133|DRUG|Dexamethasone|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
214296333|NCT01108133|DRUG|Placebo|Placebo
214296334|NCT02784990|BIOLOGICAL|Lipase, amylase and CRP (C-reactive protein) dosages|
214296335|NCT01953341|DRUG|AMG 333|Oral administration available in varying dose strength.
214296336|NCT01953341|DRUG|Placebo|Placebo containing no active drug
214296337|NCT00257647|OTHER|SV40 vectors carrying siRNA|in vitro only use of gene therapy
214296338|NCT02015780|DRUG|Fasiglifam|Fasiglifam tablets
214296339|NCT02015780|DRUG|Placebo|Fasiglifam placebo-matching tablets
214296340|NCT02015780|DRUG|Antihyperglycemic therapy|Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
214296341|NCT03200496|DRUG|DA-5206(Fasting)|Test drug l : DA-5206(Fasting)
214296342|NCT03200496|DRUG|DA-5206(Fed)|Test drug ll : DA-5206(Fed)
214296343|NCT03200496|DRUG|TALION®|Reference drug : Talion®
214296344|NCT00279734|DRUG|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
214668734|NCT01233726|DIETARY_SUPPLEMENT|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
214668735|NCT01233726|DIETARY_SUPPLEMENT|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
214668736|NCT01233726|DIETARY_SUPPLEMENT|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
214296345|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
214894214|NCT03438019|DEVICE|PrO2|The PrO2 device is linked to a tablet via Bluetooth and provides the user with a graphic representation of their inspiratory effort throughout all of inspiration and real-time biofeedback. This device incorporates a standard 2mm leak to avoid glottal closure during maximal inspiration. The PrO2 provides measures of MIP (cmH2O), SMIP (PTU) and ID (seconds).
214894215|NCT03438019|DEVICE|Threshold Inspiratory Muscle Trainer|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
214894216|NCT05748951|DEVICE|Canalicular occlusion device|Occlusive device is inserted into the tear duct to block tear drainage
214894217|NCT00708110|DRUG|GSK1349572|GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
214894218|NCT00708110|DRUG|Placebo|Placebo is a tablet with no drug in it.
214894219|NCT04801511|DRUG|Vitamin C|High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
214894220|NCT01910428|DRUG|L-asparaginase encapsulated in RBC|"* 50 IU/kg IV~* 100 IU/kg IV~* 150 IU/kg IV~* 200 IU/kg IV"
214894221|NCT00613171|DRUG|STI571|STI571 tablets taken orally once a day
214894222|NCT00036153|DRUG|Tacrolimus (Prograf®)|
214894223|NCT00036153|DRUG|Methotrexate|
214894224|NCT00220389|DRUG|SPM 907|
214894225|NCT05712174|DRUG|[18]F-PSMA-1007|\[18\]F-PSMA-1007 is a diagnostic radiopharmaceutical for use with PET/CT or PET/MRI scanning to diagnose prostate cancer.
214894226|NCT06972810|OTHER|A/Texas/71/2017, clade 3C3a H3N2 influenza virus|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device. Participants will be admitted into an inpatient facility prior to the administration of the flu virus. Following inoculation, they will be quarantined for a minimum of 8 days prior to discharge. Participants will receive supportive care and PCR positive participants will receive an effective antiviral medication. Participants will be followed for a total of 6 months.
214894227|NCT06649344|DRUG|HRS9531 Injection|HRS9531 injected subcutaneously once weekly.
214894228|NCT06649344|DRUG|Semaglutide Injection|Semaglutide injected subcutaneously once weekly.
214894229|NCT00951496|BIOLOGICAL|Bevacizumab|Given IV
214894230|NCT00951496|DRUG|Carboplatin|Given IV
214894231|NCT00951496|DRUG|Carboplatin|Given IP
214894232|NCT00951496|DRUG|Cisplatin|Given IP
214894233|NCT00951496|OTHER|Laboratory Biomarker Analysis|Correlative studies
214894234|NCT00951496|DRUG|Paclitaxel|Given IV
214894235|NCT00951496|DRUG|Paclitaxel|Given IP
214894236|NCT00951496|OTHER|Quality-of-Life Assessment|Ancillary studies
214894237|NCT03575377|OTHER|Disposal Aid|Deterra® drug deactivation system
214894238|NCT02108184|DRUG|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
214296346|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
214894239|NCT02108184|DRUG|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
214894240|NCT02108184|DRUG|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
214894241|NCT02108184|DRUG|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
214894242|NCT01555697|DRUG|Memantine|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
214894243|NCT01555697|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
214894244|NCT06552182|DRUG|HUC2-344|per oral
214296347|NCT00279734|DRUG|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
214894245|NCT06552182|DRUG|HUC2-344-R1, HUC2-344-R2|per oral
214894246|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
214894247|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
214894248|NCT03198676|DRUG|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
214894249|NCT03198676|DRUG|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
214894250|NCT01573104|OTHER|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
214894251|NCT01573104|OTHER|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
214296348|NCT00312091|DRUG|Lamivudine, nevirapine, and stavudine fixed-dose tablet|7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
214296349|NCT00312091|DRUG|Lamivudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
214894252|NCT01573104|OTHER|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
214894253|NCT01232933|DEVICE|VPS System|Use of the navigational VPS system during catheter placement
214894254|NCT05001646|DEVICE|In-home resonance-based electromagnetic field protection device|Participants will have an in-home EMF protection device
214894255|NCT01748201|PROCEDURE|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
214894256|NCT02063750|OTHER|strengthening exercises using a Swiss ball|"This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM)."
214668737|NCT04773769|DIETARY_SUPPLEMENT|Tea Made of Graviola Leaves|"Graviola leaves will be supplied to the patient with instructions on how to prepare the tea which will consist of 10 guanabana leaves which the patient will boil in 1 liter of water for 3 minutes. Once boiled, the formulation will be stores in the refrigerator and once cool enough the patient will start drinking 100 cc two times per day.~The Treatment Period begins with Cycle 1 Day 1 dosing. Patients will take the tea continuously during a 28-day cycles, until there is an indication for treatment change based on response assessment."
214894257|NCT02063750|OTHER|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
214894258|NCT00006464|DRUG|7-hydroxystaurosporine|
214668738|NCT03946267|DEVICE|Inverted inner limiting membrane flap technique for large full thickness macular holes|The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.
214894259|NCT00006464|DRUG|cisplatin|
214894260|NCT03359408|BEHAVIORAL|Dementia Care Management (DCM)|"A specialised discharge management, based on Dementia Care Management (DCM; Thyrian et al. 2017, Eichler, Thyrian, Fredrich et al. 2014, Eichler, Thyrian, Dreier et al. 2014, Dreier et al. 2016, ) will be applied to subjects with cognitive impairment. Specifically qualified will conduct comprehensive data assessments during the hospital stay, assess recommendations at discharge and assess unmet needs at home. Supported by a a computerized Intervention Management (IMS) and in close cooperation with the discharging hospital, treating physicians and other care providers, they will develop, implement and monitor a treatment and care plan. Interventional home visits will take place at the participants homes."
214894261|NCT03738072|DIAGNOSTIC_TEST|StiMiC stimulation condition|This new condition of stimulation of electrical Brain Stimulation will be evaluate to determine if this stimulation is more efficient that standard stimulation condition
214894262|NCT04876638|DRUG|Minocyclin|10mg/kg minocycline up to 700mg for 4 days following aneurysmal subarachnoid hemorrhage
214894263|NCT06577233|DRUG|Bupivacaine Hydrochloride|10cc of 0.25% Bupivacaine Hydrochloride will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery
214894264|NCT06577233|DRUG|Normal saline|10cc of 0.9% normal saline will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery
214894265|NCT01738451|DRUG|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
214894266|NCT01738451|DRUG|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
214894267|NCT06998069|DRUG|Arm I Carboplatin, Paclitaxel, Pembrolizumab|Carboplatin, AUC 5, day 1 of each cycle, each cycle every 21 days for 4 cycles Paclitaxel, 175 mg/m2, day 1 of each cycle, each cycle every 21 days for 4 cycles Pembrolizumab, 200 mg, day 1 of each cycle, each cycle every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
214894268|NCT06998069|DRUG|Arm II Carboplatin, Paclitaxel, Cetuximab|Carboplatin, AUC 5, day 1 of each cycle, each cycle every 21 days for 4 cycles Paclitaxel, 175 mg/m2, day 1 of each cycle, each cycle every 21 days for 4 cycles Cetuximab 400 mg/m2, day 1 of the first cycle and then 250 mg/m2 days 1, 8, 15 every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
214894269|NCT06998069|DRUG|Arm III Pembrolizumab|Pembrolizumab, 200 mg, day 1 of each cycle, each cycle every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
214894270|NCT02984371|PROCEDURE|Coronary artery bypass grafting|
214894271|NCT02984371|PROCEDURE|Epicardial ganglionated plexi ablation|
214894272|NCT02984371|PROCEDURE|implantable loop recorder|
214894273|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
214894274|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
214894275|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
214894276|NCT06623994|BEHAVIORAL|Task sharing with Epilepsy Medical Record Systems|Training multiple cadres of healthcare workers in epilepsy treatment and management to enable a team-based approach to address access to care. Task sharing will be supported by epilepsy medical records system with patient tracking data to support care retention
214894277|NCT03047161|DEVICE|fetal MCG|assess fetal heart rate and rhythm
214894278|NCT07006077|BIOLOGICAL|Recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
214894279|NCT04813276|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.
214894280|NCT04813276|BEHAVIORAL|Enhanced Care as Usual|A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
214894281|NCT07012967|OTHER|Kinesiology Taping|"For thoracic kinesiology taping (KT), a 5 cm wide, 100% cotton, latex-free elastic tape will be used. Application sites will follow the technique and principles described by Kase. Participants will sit upright in an armless chair with knees at 90° flexion, feet flat on the floor, and arms relaxed.~The tape will be applied to the front and back of the body to facilitate respiratory muscles, primarily the diaphragm. On the anterior side, an I-shaped strip will be applied with 50-75% tension at the xiphoid process along the linea alba, and the tails will be laid over the subcostal area without tension. Posteriorly, another I-shaped strip will be applied from the projection of the 12th thoracic vertebra with 50-75% tension, and the ends placed toward the ribs without tension. Additionally, two more strips will be applied to the upper trapezius region between the neck and acromion bilaterally."
214894282|NCT07012967|OTHER|Diaphragmatic Breathing Exercises|Participants in the control group will receive diaphragmatic breathing exercises. Exercises will be taught and supervised by a physiotherapist. Sessions will be conducted twice weekly for four weeks, and participants will be instructed to continue home practice between sessions.
215050828|NCT06176846|BEHAVIORAL|Immersive Virtual Reality Exergaming Program|"Oculus Quest 3 glasses will be used as hardware for the IVR exergame program, and Boxing, HIIT, Combat, Sculpt and Dance, among the Fit-XR games that offer virtual reality experience for fitness, will be selected according to the physical fitness level of the subjects and personalized multicomponent ( balance, strength, agility, endurance) IVR exergame program will be created. The exercise program is limited to 25-30 minutes a day and will be applied 2 days a week for 8 weeks in the clinic under the supervision of a physiotherapist. The exergaming program will be progressed according to the difficulty level, duration and technical characteristics of the games."
215050829|NCT06176846|BEHAVIORAL|Home-Based Exercise Program|In the home-based exercise program, a personalized multicomponent (balance, strength, agility, endurance) exercise program will be applied according to the physical fitness level of the subjects. The exercises will progress by increasing the difficulty level and number of repetitions of the exercises. An e-brochure will be given to the subjects for the exercises, the exercises will be shown to the subjects on the 1st day, and exercise control will be carried out in the 1st week and the 4th week.
215050830|NCT02138812|DRUG|BAY1161909|Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
215050831|NCT02138812|DRUG|Paclitaxel|75 mg/m\^2 (initial dose escalation) or 90 mg/m\^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
215050832|NCT00736112|OTHER|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
215050833|NCT00736112|PROCEDURE|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
215050834|NCT00736112|PROCEDURE|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
214668739|NCT02818010|OTHER|Global Physical Activity Questionnaire|The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
215050835|NCT00599352|DIETARY_SUPPLEMENT|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
215050836|NCT00003869|DRUG|carboxyamidotriazole|Given PO
214668740|NCT02739139|DIETARY_SUPPLEMENT|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
214668741|NCT01813487|DRUG|HBsAg vaccine with Entecavir|
215050837|NCT00003869|OTHER|placebo|Given PO
215050838|NCT00003869|PROCEDURE|quality-of-life assessment|Ancillary studies
215050839|NCT00003869|OTHER|laboratory biomarker analysis|Correlative studies
215050840|NCT04364555|DRUG|Clobetasol Propionate|Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.
215050841|NCT04364555|DRUG|Placebo/Klobetasol APL oral gel 0.025%|Placebo/active
215050842|NCT04364555|DRUG|Placebo|Placebo/placebo
215050843|NCT04930146|OTHER|acupuncture and bloodletting|bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
215050844|NCT03573388|DEVICE|Optical coherence tomography (OCT)|Lesion OCT assessment
214668742|NCT05962307|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
214296350|NCT00312091|DRUG|Nevirapine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
215050845|NCT01619761|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic umbilical cord blood transplant
214296351|NCT00312091|DRUG|Stavudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
214296352|NCT06847698|DRUG|AVR-48|Investigational drug reconstituted in normal saline will be administered via IV
214296353|NCT06847698|DRUG|Placebo|Normal saline will be administered via IV
214296354|NCT04159233|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Participants will receive evidence-based 'Brief Behavioral Therapy for Insomnia' (BBTI), tailored to meet the needs of former football players. BBTi is a brief, efficacious treatment that focuses on modifying behaviors, rather than cognitive domains. The treatment emphasizes education, motivational tools, and specific behavioral recommendations (e.g., restricting time in bed) and will be administered through weekly phone calls with a trained sleep interventionist over 4-weeks.
214296355|NCT01981447|DRUG|IV Lacosamide|Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
214296356|NCT02007018|DEVICE|Negative Pressure Wound Therapy|Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
214668743|NCT03240081|DRUG|50mcg estradiol cream|Use of study drug nightly applied to vulvar vestibule
214668744|NCT03240081|DRUG|100mcg estradiol cream|Use of study drug nightly
214668745|NCT00944944|BEHAVIORAL|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
214668746|NCT00944944|BEHAVIORAL|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
214668747|NCT01370954|OTHER|CerefolinNAC®|CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
214668748|NCT01731015|DRUG|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience \~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
214668749|NCT00030758|BIOLOGICAL|filgrastim|
214668750|NCT00030758|BIOLOGICAL|pegfilgrastim|
214668751|NCT05981521|DIAGNOSTIC_TEST|Optimo prenatal screening test|Prenatal screening test done between weeks 11 and 13 of pregnancy to detect conditions such as trisomy 13, 18 and 21
214668752|NCT03867253|DRUG|ORY-2001 Low dose|0.6mg ORY-2001 capsule
214668753|NCT03867253|DRUG|ORY-2001 High dose|1.2mg ORY-2001 capsule
214668754|NCT03867253|DRUG|Placebo|Placebo capsule
214668755|NCT01771094|BEHAVIORAL|Effect of sweetness of the beverage in thirst sensation|"Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min."
214668756|NCT05412329|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
214668757|NCT01480180|DRUG|turoctocog alfa pegol|Administered i.v.
214668758|NCT01845389|DEVICE|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
214668759|NCT01845389|DEVICE|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
214668760|NCT03243903|DEVICE|QS-M insulin-free injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
214668761|NCT03243903|DEVICE|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
215050846|NCT01619761|DRUG|Cyclophosphamide|Given IV
215050847|NCT01619761|DRUG|Fludarabine Phosphate|Given IV
215050848|NCT01619761|OTHER|Laboratory Biomarker Analysis|Correlative studies
215050849|NCT01619761|DRUG|Lenalidomide|Given PO
215050850|NCT01619761|DRUG|Melphalan|Given IV
215050851|NCT01619761|DRUG|Mycophenolate Mofetil|Given IV or PO
215050852|NCT01619761|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
215050853|NCT01619761|BIOLOGICAL|Rituximab|Given IV
215050854|NCT01619761|DRUG|Tacrolimus|Given IV or PO
214894283|NCT07010627|PROCEDURE|Auriculotherapy for chronic pain treatment with laser stimulation of acupoints using red light|"This arm of the study will analyze the effectiveness of the treatment protocol for chronic pain in the shoulder, knee, or lumbar spine region in elderly individuals, using the application of laser acupuncture with low-power laser and red light on acupoints of Auriculotherapy.~As a criterion for the qualitative evaluation of the study, the McGill questionnaires (Annex A) and the Visual Analog Scale (Annex B) will be used to assess chronic pain, while the SF-36 instrument (Annex C) will allow for the evaluation of participants' quality of life before and after the treatment protocol.~For quantitative evaluation, thermographic images and the Ryodoraku System will be used. All proposed tools will be applied before the first treatment session (A1), before the fifth session (A2), and at the end of the tenth session (A3)."
214894284|NCT07010627|PROCEDURE|"Auriculotherapy for chronic pain treatment with stimulation of acupoints using mustard seeds."|"This arm of the study will analyze the effectiveness of the treatment protocol for chronic pain in the shoulder, knee, or lumbar spine regions in elderly individuals, utilizing the application of mustard seeds on Auriculotherapy acupoints.~As criteria for the qualitative evaluation of the study, the McGill questionnaires (Annex A) and the Visual Analog Scale (Annex B) will be used to assess chronic pain, while the SF-36 instrument (Annex C) will allow for the evaluation of participants' quality of life before and after the treatment protocol.~For quantitative evaluation, thermographic images and the Ryodoraku System will be utilized. All proposed tools will be applied before the first treatment session (A1), before the fifth session (A2), and at the end of the tenth session (A3)"
214894285|NCT07011537|BEHAVIORAL|Digital Musculoskeletal (MSK) Program|"Hinge Health is a digital MSK program to help participants manage chronic MSK pain through offering exercise therapy sessions, educational articles, and personal health coaching. Hinge Health delivers exercise therapy sessions and education through playlists accessed through the program app. Each playlist consists of three to seven exercises specific to the body region(s) the participant experiences pain in. Animations and videos, while paired with sensors and computer vision, demonstrate how to perform exercises, the number of repetitions for each exercise, and how long to hold positions. Playlists present more challenging exercises and/or more repetitions as participants progress further along in the program. After participants complete the exercises, the playlist delivers educational articles and resources focused on MSK pain-related topics, including lifestyle changes, pain neuroscience, and social support."
214894286|NCT07011537|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The Enso is a strong complement/enhancement to the Hinge Health program, as it helps users to better manage their pain in order to work through their exercise sessions in the program. The Enso device is not intended to be a stand-alone solution; it provides pain relief, but exercise therapy provides important long-term benefits. Participants will use the digital MSK program (Hinge Health) in combination with a pain management device (Enso).
214894287|NCT07011537|OTHER|Standard of Care (SOC)|The control group will continue to receive the access to traditional medical care for their MSK needs through their healthcare provider. Upon study completion, control group members who complete all follow-up surveys will receive Hinge Health membership and an Enso device for free for 12 months, starting at the conclusion of their participation in the study.
214894288|NCT07013071|DRUG|2% Mepivacaine with 1:100,000 epinephrine|A standard vasoconstrictor-containing local anesthetic used in dental procedures to minimize bleeding and prolong anesthetic effect.
214296357|NCT02007018|OTHER|Usual Care of Surgical Wound|Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending \> 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
214296358|NCT06506227|BEHAVIORAL|Low risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine
214894289|NCT07013071|DRUG|2% Mepivacaine with 1:55,000 Epinephrine Bitartrate|An alternative formulation of vasoconstrictor-containing local anesthetic evaluated for its safety and analgesic effectiveness in dental extractions.
214894290|NCT05117346|DRUG|CARDIX-101A, CARDIX-101B, CARDIX-101C|Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.
215050855|NCT01619761|RADIATION|Total-Body Irradiation|Undergo TBI
215050856|NCT01619761|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo allogeneic umbilical cord blood transplant
215050857|NCT03168893|DEVICE|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
215050858|NCT03168893|DEVICE|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
215050859|NCT03364231|DRUG|Umbralisib|Oral Daily Dose
215050860|NCT04068922|BEHAVIORAL|Resilience Intervention|Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
215050861|NCT03269773|BIOLOGICAL|FURESTEM-AD Inj.|"0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL"
215050862|NCT03269773|OTHER|Placebo|0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
215050863|NCT02272946|DRUG|Canakinumab|150mg Canakinumab received subcutaneously
215050864|NCT02272946|DRUG|Placebo|150mg Placebo received subcutaneously
215050865|NCT00720577|DRUG|Simvastatin|40 Mg. tablet, 1 tablet daily
215050866|NCT00720577|DRUG|Losartan|50 mg., tablets, 1 tablet once daily
215050867|NCT00720577|DRUG|Pioglitazone|30 mg, tablet, 1 tablet once daily
214296359|NCT06506227|BEHAVIORAL|Medium risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces
215050868|NCT04273165|DRUG|Etravirine Tablets|Daily etravirine BID with 100 or 200 tablets for 4 months
215050869|NCT05164315|PROCEDURE|Tailored surgery|Procedure: Tailored surgery based on intraoperative local excision/biopsy
215050870|NCT05164315|PROCEDURE|Total mesorectal excision (TME)|Procedure: Total mesorectal excision for all allocated patients
215050871|NCT04780529|BIOLOGICAL|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
215050872|NCT00585637|DRUG|Vitamin D|Taken orally every day for three months
215050873|NCT00585637|DIETARY_SUPPLEMENT|Placebo|Placebo pill taken once daily for 3 month
215050874|NCT04308018|PROCEDURE|S2alar-iliac screws|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
214668762|NCT04835272|PROCEDURE|the Decannulation Protocol With Suctioning|In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
214668763|NCT02334709|RADIATION|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
214668764|NCT00393822|DRUG|palifermin|dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
214668765|NCT00393822|DRUG|placebo|one bolus IV injection at 120 μg/kg/day of matched placebo
214668766|NCT06011070|BEHAVIORAL|Gambling Personalised Feedback|The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
214668767|NCT01341912|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
214668768|NCT03541577|DEVICE|TruePhysioTM Microcatheter|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
214668769|NCT03541577|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
214668770|NCT02436239|DRUG|Vilazodone|Vilazodone tablets, once daily, oral administration
214668771|NCT03935646|DRUG|Adderall IR 10mg|At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
214668772|NCT03935646|DRUG|Placebo|Placebo
214668773|NCT04129723|OTHER|Stopping biological therapy|Stopping biological therapy The primary endpoint is clinical relapse at 12 months
214668774|NCT02386423|DEVICE|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
214668775|NCT02131701|BEHAVIORAL|Physical activity|
214668776|NCT00003789|DRUG|isolated limb perfusion|Undergo isolated limb perfusion
214668777|NCT00003789|DRUG|melphalan|Given via limb perfusion
214668778|NCT00003789|BIOLOGICAL|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
214668779|NCT00003789|OTHER|pharmacological study|Correlative studies
214668780|NCT00003789|OTHER|laboratory biomarker analysis|Correlative studies
214668781|NCT03693027|DIETARY_SUPPLEMENT|PTx800 lozenges|PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
214668782|NCT03693027|DIETARY_SUPPLEMENT|Placebo control|The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
214668783|NCT02906046|DEVICE|Weight in Lower Limbs|
214668784|NCT02197962|DEVICE|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
214668785|NCT02197962|DEVICE|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
214668786|NCT00184054|DRUG|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
214668787|NCT00184054|DRUG|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
214668788|NCT01274377|BIOLOGICAL|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
214668789|NCT05804110|OTHER|Mindful Caring Education Program|A four-session education plan was prepared under the nature of action research. The Theory of Unitary Caring Science is transferred to practice through Caritas processes. In this context, ten Caritas processes and caring-healing modalities (meditation, reflection, etc.) were used in the study. The pilot study was carried out with six nurses face-to-face. The education program was conducted on an online platform. Each education took approximately 2.30-3 hours. The evaluation process in action research is an essential part of the change.
214668790|NCT05539053|DRUG|N Acetylcysteine A|paclitaxel + N-Acetylcysteine orally short course
215050875|NCT04308018|PROCEDURE|S1 screws|Caudal end of the instrumentation at S1
215050876|NCT04060004|OTHER|Dry needling|Dry needling is a technique used by physiotherapists.
214894291|NCT07017374|OTHER|Proteomic analysis, targeted temperature management|Biobank serum samples from patients that were included in the TTM trial will be used for proteomic analysis. TTM trial randomised patients to targeted temperature management of 33 °C or 36 °C.
214894292|NCT07018440|DIETARY_SUPPLEMENT|Low-Volume Oral Carbohydrate Loading (200 mL of 12.5% solution)|Patients were given Low Volume Oral Carbohydrate feeding (200 mL 12.5% solution) in the preoperative period.
214894293|NCT07017127|BEHAVIORAL|Mediterranean diet|Exclusion of highly processed food products and beverages, introduction of a diet according to the modern pyramid of the Mediterranean diet (44). Subjects will be recommended to reduce as much as possible the use of plastic food and drinks containers. The nutritionist will create personalized nutritional recommendation, with a moderate reduction in caloric intake (quantified by calculating the basal metabolism and ideal body mass of each subject, and the whole day's energy consumption). The goal of this part of the intervention is to achieve a weight loss of at least 0.5 kg every week, by reducing caloric intake by 300-500 kcal. The nutritionist will create sample menus throughout the day, for 30 days, to make it easier for subjects to follow this part of the intervention. In addition, each subject of the experimental group will receive a total of six liters of extra virgin olive oil (one liter per month for 6 months).
214894294|NCT07017127|BEHAVIORAL|Physical activity intervention|Participants will be involved in aerobic activities expertly guided by kinesiologist (Nordic walking) every day for 45-60 minutes, spent in nature or indoors in case of unfavorable weather. Along with Nordic walking, participants will be involved in organized muscle strength and endurance exercises twice a week for 60 minutes with the use of external loads (elastic bands, small weights), and mobility, balance and coordination will also be developed. All training programs will be conducted by trained kinesiologists who will instruct, monitor and correct participants in order to perform the exercises correctly and get the maximum effect on the targeted motor skills. Nordic walking, resistance exercise, and a combination of aerobic activity and resistance exercise have been shown to be effective in improving cardiometabolic parameters, physical fitness, and quality of life in people with DM2.
214894295|NCT07017127|BEHAVIORAL|Psychological intervention|Support group meetings discussing mental health topics and encouraging change through the adoption of healthy lifestyle habits. Psycho-educational component, stimulating group environment for sharing personal experiences, motivation and becoming aware of emotions and resistance. The specific topics of individual group meetings will be: stress and stress management, relaxation techniques (breathing techniques, autogenic training, progressive muscle relaxation techniques and guided fantasies), emotion management (recognition of negative beliefs and thought patterns, awareness and management of emotional reactions), interpersonal skills in the function of self-care (awareness and communication of one's own needs through assertive communication techniques), self-care through the adoption of healthy habits (motivation, adoption of habits and planning), conscious eating and the alike, creating a list of SMART goals (45).
214894296|NCT07017491|OTHER|Orange candy melon (Cucumis melo)|Participants will consume a portion of melon A containing 50g of available carbohydrates to evaluate postprandial glycemic response.
214894297|NCT07017491|OTHER|Rock melon ( Cucumis melo var.cantalupensis)|Participants will consume a portion of melon B containing 50g of available carbohydrates to evaluate postprandial glycemic response.
214894298|NCT07017491|OTHER|honey dew (cucumis melo L.)|Participants will consume a portion of melon C containing 50g of available carbohydrates to evaluate postprandial glycemic response.
214894299|NCT07018076|DIAGNOSTIC_TEST|RS ratio|We will evaluate the non-culture, sputum-based assay RS ratio, which measures ongoing Mycobacterium tuberculosis activity by quantifying the abundance of precursor rRNA relative to mature rRNA (an indicator of active rRNA synthesis).
214894300|NCT07018076|DIAGNOSTIC_TEST|Blood-based host immune response assays|We will evaluate blood-based assays measuring host immune response parameters for predicting mycobacterial activity.
214894301|NCT07012083|OTHER|survey|"This cross-sectional survey study will be conducted on a consecutive sample of physicians who treat patients with animal bites potentially requiring post-exposure anti-rabies prophylaxis. The sample will include emergency physicians, general practice or family physicians, and surgeons of both sexes, with varying degrees of experience and post-graduate clinical training.~All participants will consent to submit an anonymous Google Form-based questionnaire. The designed questionnaire will include introductory personal, academic, and work experience data about the physicians as gender, age, specialty, workplace, highest achieved medical-academic or training degree, and number of years of postgraduate clinical work experience. Candidates will be asked to reflect on their pre and postgraduate education/training quality and their confidence level in prescribing anti-rabies post-exposure prophylaxis treatment. (as a linear scale)."
214894302|NCT07016958|BEHAVIORAL|Carbohydrate Counting Training|Advanced Carbohydrate Counting Training is a meal planning training where individuals can calculate the amount of carbohydrates in foods based on their portion sizes, and the insulin doses they need to take based on their plasma glucose levels and the amount of carbohydrates they consume.
215050877|NCT04060004|OTHER|Sham dry needling|Sham dry needling is a technique used by physiotherapists to compare the effects of dry needling.
215050878|NCT04060004|OTHER|Electrotherapy + therapeutic exercise|Standard care of neck pain.
215050879|NCT00382317|DRUG|Iobitridol|
215050880|NCT02099825|DRUG|d-cycloserine and mifepristone|All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
215050881|NCT00400855|DRUG|Fluticasone propionate|Study drug
215050882|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,25%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 20 ml volume."
214296360|NCT06506227|GENETIC|High risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces + Specialized Inpatient Rehabilitation
214296361|NCT06506227|BEHAVIORAL|Control group COBB 10-20°|Specific Exercise Therapy
214296362|NCT06506227|BEHAVIORAL|Control group COBB 20-45°|Orthopedic Braces + Specific Exercise Therapy
214894303|NCT07017881|BEHAVIORAL|Psychosocial Skills Training|The 24-person intervention group was divided into three separate groups of 8 people (Group 1, Group 2, Group 3). Group 1 and Group 2 attended sessions on Tuesdays at different times, while Group 3 attended sessions on Thursdays. Psychosocial Skills Training consisted of eleven sessions in total, one session per week. Sessions lasted an average of 60 minutes for each group. In each session, 5-10 minute breaks were given for rest and eating and drinking, considering the attention span and fatigue of the patients. Psychosocial Skills Training was applied two days a week (Group 1-2: Tuesday, Group 3: Thursday) in order to ensure that the patients could get more benefit from the application.
214894304|NCT07016724|COMBINATION_PRODUCT|cadonilizumab combined with neoadjuvant radiochemotherapy|Subjects randomized to experimental arm will be treated with PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy before surgery.
214894305|NCT07016724|COMBINATION_PRODUCT|neoadjuvant radiochemotherapy|Subjects in the arm 2, the control arm, will be treated with neoadjuvant radiochemotherapy.
214894306|NCT07017296|OTHER|Placebo|150 mL of water during the breakfast
214296363|NCT06506227|BEHAVIORAL|Control group COBB >45°|Orthopedic Braces + Specific Exercise Therapy + Recommended Surgery
214296364|NCT06506227|OTHER|Experimental group (AIS group)|Molecular marker exploration and validation
214296365|NCT06506227|OTHER|Control group (healthy control)|Molecular marker exploration and validation
214894307|NCT07017296|DRUG|Positive control|Normal antihypertensive in 150 ml of water during the breakfast
214894308|NCT07017296|DIETARY_SUPPLEMENT|Active comparator|20 g microencapsulated pomegranate juice in 150 mL water
214894309|NCT07017296|DIETARY_SUPPLEMENT|Control|150 mL fresh pomegranate juice
214894310|NCT07017114|DRUG|Gel PKB171|"Subjects received a single dose of pentoxifylline PKB171 gel or placebo, in a one-dose form with an applicator device that allowed for vaginal administration following the randomisation list:~* First dose level: 2% (100 mg)~* Second dose level: 3% (150 mg)~* Third dose level: 4% (200 mg) The treatment was provided by a member of the investigator's staff and self-administered by volunteers under clinical supervision.~The dose-escalation process enabled to determine MTD or the highest dose that was safe to administer in later studies was determined. The results of this study helped to define the recommended doses to be used in the multiple-dose extension."
214894311|NCT07017114|DRUG|Gel PKB171 placebo|PKB vaginal gel at the MTD or placebo once every 24 hours for two consecutive days
214894312|NCT07016945|BEHAVIORAL|Stress and Mindfulness Intervention|Participants will be randomized to either the race-related stress condition or the non-race-related stress condition and the experimental group (7-minute pre-recorded audio file of a guided mindfulness practice) or the control group (7-minute pre-recorded neutral audio file). Thus there are four conditions total (RRS/Control Audio, RRS/Mindfulness Audio, Control Stress/Control Audio, Control Stress/Mindfulness Audio)
214894313|NCT07017543|OTHER|Psychotherapy Process-Outcome Study in Group Therapy|A manualized group dynamic psychotherapy conducted at the University Hospital in Kraków, focused on monitoring and enhancing therapeutic alliance and insight development. The intervention targeted patients diagnosed with neurotic and personality disorders. Psychological assessments were conducted at weeks 1, 4, 8, and 12 to track changes in symptoms, resilience, alliance, and insight. The psychotherapy emphasized the interplay between trait-like and state-like components of alliance and insight and their relationship to therapeutic outcomes (symptom reduction and resilience enhancement).
214894314|NCT07018505|DIAGNOSTIC_TEST|SERS detection|"Incubation: A mixture of 20 μL (0.5 mg/mL) magnetic beads (MB@RB20115UD), 40 μL SERS nanotags (Au-IR808@RB20115UC), and prepared sample is incubated for 5 min.~Washing: The supernatant is removed after magnetic separation (30 s), followed by washing with PBST (pH 7.4, 0.05% Tween-20).~Detection: The separated pellet is resuspended in 10 μL ultrapure water. Then 2 μL solution is spotted onto a 2.5 mm × 2.5 mm gold substrate for air-drying. Raman spectra are acquired using a portable spectrometer (785 nm laser, 500 mW power, 5 s acquisition time, triplicate measurements). Peak areas within 540-570 cm-1 are quantified."
214894315|NCT07018479|DIETARY_SUPPLEMENT|FemmeBalance Supplement Group|Participants will take two capsules daily of the FemmeBalance supplement with their evening meal for four menstrual cycles
214894316|NCT07017205|DEVICE|Application of oropharyngeal dye and tracheal aspirate collection|After intubation, 2 mL of blue dye will be applied to the oropharyngeal mucosa. Once hemodynamically stable (MAP \>65 mmHg), the first tracheal aspirate will be collected within 10 minutes by a blinded investigator for analysis.
214894317|NCT07017088|DIETARY_SUPPLEMENT|Leuconostoc mesenteroides|Control vs Experiment
214894318|NCT07017257|DEVICE|Active taVNS|Patients will receive active taVNS for 15 consecutive days, with each session lasting 30 minutes. The stimulation will target the cymba conchae of the left ear and will consist of alternating 30-second on and 30-second off periods. The current intensity will range from 1 to 3 mA, adjusted to the patient's pain threshold, with a pulse width of 250 μsec and a frequency of 25Hz.
214894319|NCT07017257|DEVICE|Sham taVNS|Patients will receive sham taVNS for 15 consecutive days, with each session lasting 30 minutes. The stimulation will target the cymba conchae of the left ear and will consist of alternating 30-second on and 30-second off periods. The current intensity will be fixed at 100 µA, with a pulse width of 250 μsec and a frequency of 25 Hz.
214894320|NCT07017530|OTHER|Cognitive training|Combined Intervention of Cognitive Training and Supervised Physical Exercise
214894321|NCT07017530|OTHER|Psychoeducational therapy|According to standard clinical practice
214894322|NCT07018011|PROCEDURE|Conventional open CTR|Conventional open CTR involved making a longitudinal incision in the wrist, typically along the median palmar crease, to access and release the transverse carpal ligament.
214296366|NCT06506227|OTHER|Controlled follow-up before and after AIS|Construction and validation of AIS risk prediction model completed
214296367|NCT04954274|DRUG|Cyclic peptide Fertiline|"Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule.~After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide."
214296368|NCT01170507|DRUG|vitamin D3 1000 IU orally daily for 5 months|
214296369|NCT01170507|DRUG|vitamin D3 3000 IU orally daily for 5 months|
214296370|NCT01170507|DRUG|vitamin D3 5000 IU orally daily for 5 months|
214296371|NCT01170507|DRUG|Placebo orally daily for 5 months|
214894323|NCT07018011|PROCEDURE|Transverse mini-incision technique|Mini-incision CTR involved a smaller incision than traditional CTR procedures, aiming to minimize scarring and improve recovery time.
214894324|NCT07017452|DRUG|Methoxyflurane - Penthrox|Penthrox is a brand name for a drug called methoxyflurane. It is an inhaled analgesic (pain-relieving) agent used primarily for the relief of moderate to severe pain, typically in emergency medical situations or during minor medical procedures. Penthrox is administered by inhaling the vapors through a hand-held inhaler device. It acts quickly to provide pain relief and has a relatively short duration of action.
214894325|NCT07017452|OTHER|Control|This intervention will be the control group only, receiving deep IV sedation.
214894326|NCT07017452|DRUG|Percocet Pill|Percocet will be given in conjunction with methoxyfluorane and lorazepam
214894327|NCT07017452|DRUG|Lorazepam (drug)|Lorazepam will be given in conjunction with penthrox and percocet.
214894328|NCT07018544|OTHER|semaglutide|Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
214296372|NCT03117712|DIAGNOSTIC_TEST|Delirium Scores|"* Confusion Assessment method for the ICU (CAM-ICU) and~* The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~1. Postoperative day (POD) 1~2. POD 2~3. POD 5"
214894329|NCT07018674|DIETARY_SUPPLEMENT|Experimental|Brain Edge, a cognition supporting supplement beverage formulated from herbs, vitamins, and amino acids.
214894330|NCT07018674|OTHER|Placebo|A sensory-matched placebo beverage formulated from flavors, colors, fillers, and excipients.
214894331|NCT07018674|OTHER|Water|Bottled Water
214894332|NCT07017049|BEHAVIORAL|Integrative Neuromuscular Training|Participants will receive a 12-week Integrative Neuromuscular Training (INT) program, conducted 3 times per week, each session lasting 1 hour. The intervention includes progressive exercises targeting balance, strength, plyometrics, speed, agility, and coordination. Training intensity increases from 55-65% HRmax in weeks 1-2, to 65-75% HRmax in weeks 3-5, and 70-85% HRmax in weeks 6-12. Exercises include single-leg balance, BOSU balance, box jumps (30-50 cm), lateral jumps, squats, Nordic hamstring exercises, sprints (20-30m), shuttle runs, and agility drills. Rest between sets is 30-60 seconds.
214894333|NCT07017049|BEHAVIORAL|Routine training intervention|"Participants in the control group will follow the standard physical training program of the school over a 12-week period, with sessions conducted 3 times per week, each lasting approximately 50 minutes (including warm-up and cool-down). The training intensity will progressively increase from 55%-65% HRmax in weeks 1-3, 65%-75% HRmax in weeks 4-8, and 75%-85% HRmax in weeks 9-12.~Each session includes:~Warm-up (10 minutes): Movement of hands and legs, small-sided games, ball handling, and stretching exercises.~Intervention (30 minutes):~Weeks 1-3: Barbell back squat, barbell deadlift, bench press, continuous broad jumps, continuous burpee jumps, frontal plank (60 sec), 50m sprinting (5 reps), 2 sets of each exercise with 30-60 seconds rest.~Weeks 4-5: Similar structure with increased repetitions (barbell exercises 6-10 reps, plank 70 sec).~Weeks 6-8: Barbell back squat, deadlift, bench press, broad jumps, each for 3 sets, 30-60 sec rest.~Weeks 9-12: Higher load with 8-12 reps per"
214894334|NCT07016841|DEVICE|pHA130 hemoperfusion device|HP once every 2 weeks.
214894335|NCT07016841|DEVICE|HD/HDF|HD twice weekly, HDF once weekly, with each session lasting 4 hours.
214894336|NCT07016841|DEVICE|HA130 hemoperfusion device|HP once every 2 weeks.
214894337|NCT07017036|DRUG|IVIG-VImmune|V-Immune will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose
214894338|NCT07017036|DRUG|IVIG-Immuglo|Immuglo will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose
214894339|NCT07018219|DEVICE|X ray device|X ray macjine : shimadzo corporation ( japan)
214894340|NCT07017699|DRUG|Deucravacitinib|According to product label
214894341|NCT07017699|DRUG|Other systemic treatments for PsO|According to product label
215050883|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,16%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,16% Bupivacaine will be used at 20 ml volume"
214296373|NCT03117712|DIAGNOSTIC_TEST|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~1. Before induction of anaesthesia~2. Before going on cardiopulmonary bypass (CBP)~3. During CPB, 5 min after aortic cross clamping~4. After CPB~5. 24 hours after CPB"
214296374|NCT03117712|DIAGNOSTIC_TEST|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~1. During cannulation of the ascending aorta~2. After aortic cross-clamp~3. After opening of the aortic cross-clamp~4. During decannulation"
214296375|NCT01601626|DRUG|Standard-dose Lopinavir/Ritonavir|Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
214296376|NCT01601626|DRUG|Double-dose Lopinavir/Ritonavir|Four LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry through Week 72.
214296377|NCT01601626|DRUG|Raltegravir|One 400 mg tablet orally twice daily from entry to Week 72.
214296378|NCT01601626|DRUG|Isoniazid|300 mg orally once daily from entry through Week 24.
214296379|NCT01601626|DRUG|Pyridoxine|25 mg orally once daily from entry to Week 24.
214296380|NCT01601626|DRUG|Pyrazinamide|20 to 30 mg/kg orally once daily (not to exceed 2 g per day) from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
214894342|NCT07018726|BEHAVIORAL|Resilient Together-YOD|This is a 6 session dyadic (patient and spousal care-partner) intervention that teaches resiliency and interpersonal communication skills early after YOD diagnoses. It aims to decrease heightened symptoms of depression and anxiety among dyads to help them engage in important decisions around long term care-planning and optimize adjustment. The goal is to equip dyads with the necessary skills to cope and engage in meaningful, challenging conversations around care-planning, symptom deterioration, work/family planning to improve well-being in both members of the dyad.
214894343|NCT07018726|BEHAVIORAL|Health Enhancement Program-YOD|This is a 6 session program that will deliver educational information to dyads and will mimic the dose and duration of Resilient Together. The program will not teach any individual and dyadic interpersonal skills, but will contain education on psychological distress and healthy behaviors. Sessions will also be delivered virtually.
214894344|NCT07018453|DRUG|SHR-3167|SHR-3167 Injection.
214894345|NCT07018453|DRUG|Insulin Degludec|Insulin Degludec Injection.
214894346|NCT07017075|DEVICE|Transesophageal ultrasound|Transesophageal ultrasound with built-in ultrasound software (Philips QLAB 3D quantification advance, Philips Healthcare, USA, speckle tracking echocardiography (STE,Speckle tracking echocardiography) to evaluate stroke volume and cardiac output in traditional CPR location and the better position
214894347|NCT07018154|OTHER|Musculoskeletal Assessment|Patients underwent a musculoskeletal Assessment.
214894348|NCT02577991|DRUG|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
214894349|NCT02577991|DRUG|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
214894350|NCT07017283|DEVICE|Tracheal intubation general anesthesia|Endotracheal intubation with general anesthesia was administered to the patient during the ERCP procedure.
214894351|NCT07017283|DEVICE|Nasopharyngeal airway ventilation|Nasopharyngeal airway-assisted anesthesia was employed for the patient during the ERCP procedure.
214894352|NCT07016698|DEVICE|Rotarex(TM) Rotational Excisional Atherectomy System|Subjects treated with Rotarex(TM) Rotational Excisional Atherectomy System
214894353|NCT04699240|DRUG|clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
215050884|NCT06163196|OTHER|acupressure|Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
215050885|NCT05851885|DIAGNOSTIC_TEST|AI-based reporting system|AI-based reporting system is a software platform for real-time analysis and records of abnormalities and landmarks during endoscopy.
214894354|NCT04699240|DRUG|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months
214894355|NCT05106192|DEVICE|Med-Jet Injector|The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue
214894356|NCT05106192|DRUG|Triamcinolone Acetonide|The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).
214894357|NCT05106192|DRUG|Bexarotene 1% Top Gel|Bexarotene can be applied up to four times daily according to patient tolerance directly to lesions. The gel is 1% bexarotene concentration.
215050886|NCT03154021|COMBINATION_PRODUCT|Next Science OTC Oral Rinse with Essential Oils|This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control
215050887|NCT03154021|COMBINATION_PRODUCT|OTC Oral Rinse Control|This group will receive OTC Oral Rinse Control
215050888|NCT01070979|DRUG|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
215050889|NCT01070979|DRUG|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
214296381|NCT01601626|DRUG|Ethambutol|15 to 20 mg/kg orally once daily from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
215050890|NCT01070979|DRUG|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
215050891|NCT00185887|DRUG|Terbutaline|Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
215050892|NCT02405988|DRUG|Intravenous naloxone|Administer 2,5 mL, dose intravenous naloxone 1,0 mg
215050893|NCT02405988|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
215050894|NCT01900886|OTHER|Peginterferon alfa-2a|Treatment as usual clinical practice
215050895|NCT01900886|DRUG|Ribavirin|Treatment as usual clinical practice
214894358|NCT05106192|DRUG|Nitrogen Mustard|Nitrogen mustard is applied once daily as patient tolerates. It is sold in a concentration of 0.016% gel.
214894359|NCT05106192|DEVICE|Conventional syringe|A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
214894360|NCT01042093|DRUG|Ropivacaine|Ropivacaine 5mg/ml (49.25 ml)
214894361|NCT01042093|DRUG|Toradol|Toradol 30mg/ml (1 ml)
214894362|NCT01042093|DRUG|Clonidine|Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
214894363|NCT01042093|DRUG|Epinephrine|Epinephrine 1 mg/ml (0.5 ml)
214894364|NCT02273388|DRUG|BI 6727|BI 6727
214894365|NCT05860738|OTHER|sterilization|autoclaving using the rapid cycle (4 mins, 134 oC) and the universal cycle (20 mins, 121 oC). The autoclave used in this study is (Anthos A-17 Autoclave, Italy).
214894366|NCT02435524|BEHAVIORAL|A&T infant and young child feeding intervention|"1. Interpersonal communication delivered by community workers and volunteers during home visits and at monthly mother's group meetings to:~   * Increase mother's knowledge about optimal breastfeeding and its benefits~  * Increase mother's self-efficacy related to breastfeeding~  * Improve mother's perceptions about social norms relating to breastfeeding~2. Community mobilisation activities to:~   \- Raise awareness of the benefits of optimal breastfeeding among opinion leaders, and family members, and increase the support they provide to breastfeeding mothers~3. Enhanced training of government health workers in infant and young child feeding to:~   * Improve their ability to support mothers and provide timely information about infant feeding"
214894367|NCT04854161|BEHAVIORAL|Empathic Attunement to Affect Training|"Empathic Attunement to Affect:~Empathy and neuroscience Therapeutic Presence~Opening receptivity channels Empathic reflections and landscapes (external, meaning and feeling)~Types of emotions: Primary (adaptive, maladaptive), Secondary. Emotion Scheme Types of experiential responses: conjectures, exploration.~Working with Core emotions Types of experiential responses: Evocation and Empathic affirmation,~Empathy and Emotion Productivity Types of experiential responses: Empathic formulation, process suggestion Difficult situations: working on assertive anger and self-soothing Types of experiential responses: Facilitative Congruence"
214894368|NCT04854161|BEHAVIORAL|Compassion Training|Compassion Training Introduction to Mindfulness Compassion toward a significant other Compassion toward a generic other Self-compassion Tonglen Compassion toward a difficult other
214894369|NCT04854161|BEHAVIORAL|Focusing Oriented Therapy Training|Focusing-Oriented Therapy training Introduction to focusing Acceptance and empathy as the main focusing attitudes Fels-sense markers Felt sense, handle and resonance Hakomi Therapy The Safe Place. Focusing with a challenging person
214894370|NCT00489632|BEHAVIORAL|Questionnaire|Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
215050896|NCT04796129|OTHER|the patients with hip osteoarthritis and their inflammatory status|The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
215050897|NCT02874443|OTHER|Knowledge Translation of labor management guidelines|
214894371|NCT05621876|DEVICE|IgG deficiency rapid screening test|We will be testing patients who have already been diagnossed iwth primary immunodeficiency (PID) disease. there are 400 types of PID. We will test their blood before they receive antibody transfusion to evaluate the accuracy of our new screening test. We are trying to develop easy to use, low-cost screening tests for doctors to use with patients to detect those with low IgG levels before they are given the oral polio vaccine. These patients must be prioritized for intramuscular injections of a polio vaccine to prevent potential spread of wild type polio.
214894372|NCT07016984|OTHER|standard phototherapy eye patches|Following the mydriasis procedure performed prior to ROP examination, the eyes were covered with these patches.
214894373|NCT04861623|OTHER|Orange juice|Orange juice will be purchased commercially.
214894374|NCT04861623|OTHER|Placebo juice (SunnyD)|SunnyD beverage will be purchased commercially.
214894375|NCT05963581|BEHAVIORAL|Salsa Dancing|Participants will complete salsa dancing classes in central Oxford with instructor(s) from the Oxford University Salsa Society
214894376|NCT00702988|DRUG|Org 36286|single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
214894377|NCT00702988|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38826)
214894378|NCT06274866|OTHER|exercise program|Study group were followed up with a personalized home-based exercise program for 6 weeks. IThe exercise program of the individuals in the study group was checked at two-week intervals and adjustments were made in the exercise program
214894379|NCT06274866|OTHER|control group|Individuals in the control group were followed up with an exercise training brochure.
214894380|NCT06882980|OTHER|Ciprofol group|In the Ciprofol group,children were given Ciprofol 0.6-0.8 mg/kg during anesthesia induction,and ciprofol 1.2-2 mg·kg-¹·h-¹for anesthesia maintenance.Throughout the entire process, we continuously monitor vital signs and IoC1/IoC2.
214894381|NCT06882980|OTHER|Propofol group|In the Propofol group,children were given Propofol 2.5-3.5 mg/kg during anesthesia induction,and propofol 6-10 mg·kg-¹·h-¹for anesthesia maintenance.Throughout the entire process, we continuously monitor vital signs and IoC1/IoC2.
214894382|NCT04900181|PROCEDURE|the same-day discharge surgery|the same-day discharge surgery is the procedure in which the patient is admitted, operated and discharged within 24 hours.
215050898|NCT03837990|DRUG|Helicobacter Pylori eradication therapy|Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
215050899|NCT02269696|DRUG|Metoprolol|Intraoperative metoprolol infusion.
215050900|NCT02269696|DRUG|Normal saline|Equal of volume compared to metoprolol.
215050901|NCT06094309|DRUG|Botulinum toxin type A injection|The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
214894383|NCT02966977|OTHER|Conventional microbiological identification by culture plate|Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
214894384|NCT02966977|OTHER|Direct mass spectrometry identification from urine sample|The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.
214894385|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; first study group: 10E7\_TCID50
214894386|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; second study group: 10E8\_TCID50
214894387|NCT00701961|DRUG|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
214668791|NCT05539053|DRUG|N Acetylcysteine B|paclitaxel +N Acetylcysteine orally long course
214894388|NCT01674218|DRUG|Moxifloxacin|Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
214894389|NCT01674218|DRUG|PA-824|PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
214894390|NCT01674218|OTHER|Placebo|Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
214894391|NCT00950365|DRUG|Erlotinib Hydrochloride|Given PO
214894392|NCT00950365|OTHER|Laboratory Biomarker Analysis|Correlative studies
215050902|NCT06176248|DRUG|Triamcinolone Acetonide|1 injection of local anaesthetic (5 ml levobupivacaine 2.5 mg/mL) opposite the subscapular nerve, under ultrasound control, in a lateral decubitus or sitting position. Subsequently, they underwent Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.
215050903|NCT06176248|DRUG|saline solution|intramuscular injection of 1 ml saline under ultrasound control under the same conditions as the experimental group. Subsequently, they will undergo Xray-controlled arthrodistension under the same conditions as the experimental group
215050904|NCT03447392|BEHAVIORAL|Discharge Education of Chinese Medicine|Discharge Education of Integrated Traditional and Western Medicine
215050905|NCT04933500|DEVICE|Whitacre spinal needle|25G Whitacre spinal needle
215050906|NCT05910047|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing molecular hydrogen and pyrroloquinoline quinone
215050907|NCT05910047|DIETARY_SUPPLEMENT|Placebo|Inert substance
215050908|NCT06138171|OTHER|Psychological self-reported measures assesment (questionnaire)|The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).
215050909|NCT02525926|PROCEDURE|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
215050910|NCT02525926|PROCEDURE|sham procedure|"Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
214894393|NCT00950365|DRUG|Pemetrexed Disodium|Given IV
214894394|NCT00408746|BEHAVIORAL|palatal development|Impressions of preterm and term palates.
214894395|NCT03597659|GENETIC|phenome-wide association study (PheWAS)|Phenome-wide association study (PheWAS) identifying clinical diagnoses associated with a polygenic predictor of TSH levels identified by a previously published genome-wide association study (GWAS) which included North American and European participants. A phenome-wide scanning of 1,318 phenotypes will be performed, using a cohort of 37,154 North American individuals of European ancestry with electronic-health-record (EHR) data.
214894396|NCT04589663|DRUG|Mometasone furoate|Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
214894397|NCT04589663|DRUG|QMF149|Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
214894398|NCT04589663|DRUG|Standard of Care (Soc)|Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
214668792|NCT02247830|OTHER|Chamomilla recutita gel|Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
214668793|NCT02247830|DRUG|Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
214296382|NCT01601626|DRUG|Rifabutin|300 mg of rifabutin orally once until LPV/RTV is started; then the dose will be reduced to 150 mg daily from the start of LPV/RTV through Week 24.
214296383|NCT01601626|DRUG|Rifampin|Weight-based dose; for weight \< 45 kg: 450 mg orally once daily; for weight \> 45 kg: 600 mg orally once daily, from entry to week 24.
214296384|NCT06053073|DEVICE|Cervical rippening at home|The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction
214296385|NCT06053073|DEVICE|Cervical rippening in the hospital|The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction
214296386|NCT04897360|BEHAVIORAL|Increased breathing|hyperventilation to lower ETCO2
214894399|NCT04226521|PROCEDURE|Extracoropreal photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
214894400|NCT02308995|PROCEDURE|Cystectomy using barbed sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
214894401|NCT02308995|PROCEDURE|Cystectomy using conventional sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
214894402|NCT02308995|DEVICE|V-Loc (Covidien, Mansfield, MA)|
214894403|NCT02308995|DEVICE|polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)|
214894404|NCT02852577|DRUG|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
214296387|NCT04897360|OTHER|sharpened Romberg test (SRT)|Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
214894405|NCT02852577|DRUG|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
214894406|NCT02336646|DRUG|Allogenic MSC|Hypoxia-cultured human bone marrow derived mesenchymal stem cells
214894407|NCT02336646|DRUG|Normal saline|
214894408|NCT00178282|PROCEDURE|Pelvic Floor Muscle exercises|
214894409|NCT03680612|DRUG|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Experimental drug
214894410|NCT03680612|DRUG|cefepime 1 g or cefepime 2 g|cefepime monotherapy
214894411|NCT00036192|DRUG|FK614|
214894412|NCT05863169|DEVICE|fNIRS-Neurofeedback|Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
214894413|NCT04934046|OTHER|Additional acquisition|Additional SPECT acquisition (30min added time approximately), with no added radiation
214894414|NCT00004212|BIOLOGICAL|filgrastim|
214894415|NCT00004212|DRUG|exatecan mesylate|
214894416|NCT03709212|OTHER|interviews|20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
214894417|NCT02513212|DEVICE|Potassium Oxalate|Professionally applied liquid
214894418|NCT02513212|DRUG|Stannous fluoride paste|SnF2 Paste
214894419|NCT02513212|DEVICE|Manual toothbrush|Marketed manual toothbrush
214894420|NCT02513212|DEVICE|Power toothbrush|Marketed power toothbrush
214894421|NCT05273450|BEHAVIORAL|Quitline Information with Reinforcement|The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
215050911|NCT06391268|BEHAVIORAL|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.
214296388|NCT01058889|DEVICE|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
214296389|NCT00189657|PROCEDURE|5FU/LV Mayo Clinic or LV5FU2|
214296390|NCT00189657|PROCEDURE|LV5FU2 + irinotecan|
214296391|NCT04432662|DRUG|Darbepoetin Alfa|Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.
214668794|NCT03183635|PROCEDURE|Balance training|Improvement of balance ability in stroke patients
214894422|NCT03245866|OTHER|Observational/ no intervention|
214894423|NCT01523002|DRUG|Metoprolol and pyronaridine-artesunate|"On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period."
214894424|NCT01523002|DRUG|pyronaridine-artesunate|"On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period."
214894425|NCT05904002|DRUG|pulmicort inhaler|Each woman in both groups (A\&B) will receive pulmicort inhaler on needs.
214894426|NCT05904002|DEVICE|Incentive spirometer treatment|Each patient in group B will be instructed about the effects of incentive spirometer to gain their cooperation during the study course.
214894427|NCT01256502|DEVICE|SERI® Surgical Scaffold|Breast reconstruction surgery
214894428|NCT05348447|DEVICE|cryoanalgesia|intraoperative intercostal nerve freezing for post-operative pain control
214894429|NCT05348447|OTHER|Standard of Care Pain Control|Standard of Care Pain Control Post-operatively
214894430|NCT05927597|DRUG|INS1007|Oral tablets.
214894431|NCT05927597|DRUG|Placebo|Oral tablets.
214894432|NCT02797197|PROCEDURE|handgrip strength test|
214894433|NCT02797197|DRUG|chemotherapy|
215050912|NCT03669887|BEHAVIORAL|Lifestyle Modification Program|The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
215050913|NCT04326790|DRUG|Colchicine|Low-dose colchicine treatment, 0.5 mg bid
215050914|NCT04326790|DRUG|Standard treatment|Standard treatment
215050915|NCT01333436|OTHER|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
215050916|NCT00444106|DRUG|Artesunate-mefloquine|
215050917|NCT00444106|DRUG|Atovaquone-proguanil|
215050918|NCT00444106|DRUG|Artemether-lumefantrine|
215050919|NCT02192957|DEVICE|Lifepak 20E Defibrillator, Licence No: 61944|"Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.~Ottawa AF Cardioversion"
215050920|NCT01402960|DEVICE|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|"Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~* For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~* For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~* For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)"
215050921|NCT04749914|DRUG|Lasmiditan|Administered orally.
215050922|NCT04749914|DRUG|Dabigatran Etexilate|Administered orally.
215050923|NCT04749914|DRUG|Rosuvastatin|Administered orally.
215050924|NCT05907811|PROCEDURE|Neuromuscular blocker usage|The patients were followed up, the total amount of muscle relaxant used was determined, intraoperative effects and postoperative analgesic usage
215050925|NCT00038844|DRUG|Campath-1 H (Alemtuzumab)|Starting Dose of 15 mg by vein daily, 3 days in a row.
215050926|NCT00038844|DRUG|Fludarabine|30 mg/m2 by vein daily, 3 days in a row.
215050927|NCT00038844|DRUG|Cyclophosphamide|1 gm/m2 by vein daily, 3 days in a row.
214894434|NCT03281876|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
214894435|NCT03281876|BIOLOGICAL|Placebo|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
214894436|NCT01736969|DEVICE|RD047-023|Experimental hydrogel
214894437|NCT01736969|DEVICE|Predicate Device|
214894438|NCT01229137|DEVICE|SRD-1 conversion|
214894439|NCT01478373|DRUG|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
214894440|NCT03098082|DEVICE|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
214894441|NCT03928301|BEHAVIORAL|Wholetones Music|Participants listened to the Wholetones music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
214894442|NCT03928301|BEHAVIORAL|Classical Music|Participants listened to the classical music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
214894443|NCT01467440|DEVICE|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
214894444|NCT01074944|DRUG|Eliglustat tartrate|Oral Capsule in 50 mg or 100 mg dosages
214894445|NCT01263938|DRUG|Atorvastatin|"For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day."
214894446|NCT02905032|BEHAVIORAL|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
214894447|NCT00934167|BIOLOGICAL|heparin sodium - Hipolabor|5.000 UI/0,25mL
214894448|NCT00934167|BIOLOGICAL|Heparin sodium - APP|5.000 USP/mL
214894449|NCT06036186|DEVICE|BaroPacing treatment|BaroPacing for the first 3 weeks (day 8 to day 28) and then crossover to standard treatment for another 3 weeks (day 29 to day 49).
214894450|NCT06036186|DEVICE|Standard treatment|Individual Standard treatment as prescribed by the Physician to each subject for the first 3 weeks (day 8 to day 28) and then crossover to BaroPacing for another 3 weeks (day 29 to day 49).
215050928|NCT00038844|DRUG|Rituximab|375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
214894451|NCT00550459|DRUG|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
214894452|NCT00550459|DRUG|Placebo|Placebo tablet given once daily for 21 days
214894453|NCT05096910|PROCEDURE|Uterine Closure with monofilament or polyfilament suture materials|Postoperative 6th-month isthmocele rates
214894454|NCT00147459|BIOLOGICAL|HBV vaccine booster|
214894455|NCT00154154|BEHAVIORAL|General Psychiatric Management|General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
214894456|NCT00154154|BEHAVIORAL|Dialectical Behaviour Therapy|Modification of behaviours achieved with reframing thoughts and impulses
214894457|NCT01452516|DEVICE|nanOss Bioactive Bone void filler|Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
214894458|NCT01452516|DEVICE|Interbody FCage|Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
214894459|NCT04184427|OTHER|Anterior Power Arm|Crimpable stainless steel hook placed on orthodontic base arch wire.
214894460|NCT06178627|DRUG|Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.|Different amphotericin B dosage
214894461|NCT06178627|DRUG|Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.|Different amphotericin B dosage
214894462|NCT01960660|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|
214894463|NCT00277329|DRUG|XL999|• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
214894464|NCT06060431|OTHER|Pain Science Education|The Pain Science Education program consists of two workshops, 90 and 60 minutes in length, one week apart. The content of the workshops aims to provide students with information about the contemporary pain paradigm and to re-conceptualize pain.
214894465|NCT02309307|DEVICE|Tissue Repair Device (VergenixTM STR)|Administration of Soft Tissue Repair Device
214894466|NCT00625820|DRUG|6R BH4|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
214894467|NCT00625820|DIETARY_SUPPLEMENT|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
214894468|NCT05717660|COMBINATION_PRODUCT|SBRT on all sites of metastatic disease+Apalutamide|oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.
214894469|NCT06751758|OTHER|C1-C2 Mobilization|Participants in both Group A and Group B will receive manual mobilization targeting the C1-C2 region. This specific mobilization technique is chosen for its potential to improve joint mobility and alleviate stiffness in the upper cervical spine. The mobilization will be performed by trained physiotherapists to ensure precision and safety.
214668795|NCT04937166|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
214894470|NCT06751758|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Following C1-C2 mobilization, each participant will undergo a 20-minute session of TENS. TENS involves the application of low-voltage electrical currents through electrodes placed on the skin. This modality aims to modulate pain perception by stimulating nerve fibers, leading to the release of endorphins - the body's natural painkillers. The 20-minute duration is chosen based on established guidelines for effective TENS application.
214894471|NCT06751758|OTHER|Suboccipital Distraction|"Suboccipital distraction is a manual technique aimed at relieving tension in the upper cervical spine. This intervention involves the gentle separation of the suboccipital muscles and associated structures, promoting relaxation and reducing pain. The technique is intended to enhance the range of motion in the cervical region by targeting the upper cervical structures.~Procedure:~5-7 repetitions of intermittent distraction 20-30 seconds on, 10-15 seconds off~Administration:~Suboccipital distraction will be performed by skilled physiotherapists trained in this technique. Close monitoring will ensure correct application and participant safety."
214894472|NCT06751758|OTHER|Traction|"Traction is a therapeutic technique that involves applying a controlled, manual force to stretch and mobilize the cervical spine. The primary goal of this intervention is to reduce compression on the cervical structures, alleviate pain, and improve the range of motion. It is typically used for its potential to decompress the spine and relieve pressure on nerves.~Procedure:~Traction will be administered manually by trained physiotherapists, who will ensure that the correct amount of force is applied and that the treatment is both safe and effective. The application will be carefully tailored to the individual's needs.~Administration:~Participants will undergo traction treatments with close monitoring throughout the study period, allowing for necessary adjustments to the treatment plan based on individual responses."
214894473|NCT00445146|DRUG|EVG|Elvitegravir (EVG) tablet administered orally once daily with food
214894474|NCT00445146|DRUG|RTV|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
214894475|NCT00445146|DRUG|ARV regimen|The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
214894476|NCT00115414|DRUG|pegfilgrastim|
214894477|NCT00115414|DRUG|docetaxel|
214894478|NCT00115414|DRUG|doxorubicin|
214894479|NCT00115414|DRUG|cyclophosphamide|
214894480|NCT03437408|DEVICE|Mapping and ablation|High density substrate map. Data collection during ablation
214894481|NCT02908971|BEHAVIORAL|soy based formula at infancy|The intervention is only past history of soy consumption
214894482|NCT05066360|DIAGNOSTIC_TEST|serum antimullerian hormone|serum antimullerian hormone will be analyzed for all participants
214894483|NCT05391373|BEHAVIORAL|Laughter therapy|Each session started with a 10-minute breathing exercise accompanied by relaxing music, followed by 20-minute laughing exercises. Afterwards, the session was ended with a 10-minute meditation accompanied by relaxing music.
214894484|NCT02814344|DEVICE|Electrohysterography|
214894485|NCT00967330|DRUG|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
214894486|NCT00967330|DRUG|irinotecan|125mg/m2 iv every 2 weeks
214894487|NCT00967330|DRUG|temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
214478210|NCT06882434|BEHAVIORAL|Local intervention program|"HI-HOPE Project introduces a three-phase intervention program Phase 1: Active Mind \& Body (12 Weeks) Focus: Cognitive enhancement, depression relief, and music-based movement therapy.~Delivery: Certified community instructors. Schedule: 1 session/week, 2 hours per session (total 12 sessions). Supplementary Exercise: High-intensity training by professional coaches (1 session/week, 1 hour per session).~Phase 2: Complete Senior Wellness (12 Weeks) Focus: Comprehensive functional improvement covering all six ICOPE domains. Delivery: Certified community instructors. Schedule: 1 session/week, 2 hours per session (total 12 sessions). Supplementary Exercise: High-intensity training by professional coaches (1 session/week, 1 hour per session).~Phase 3: Advanced Exercise Training (12 Weeks) Focus: Strengthening self-care abilities and increasing acceptance of medical interventions.~Delivery: Professional exercise coaches. Schedule: 2 sessions/week, 1 hour per session (total 24 sessions)."
214894488|NCT01243957|DRUG|LY2216684|LY2216684: 18 mg po QD on Days 1, 2, and 3 and Days 25-27
214894489|NCT01243957|DRUG|Fluoxetine|Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
214894490|NCT02623725|BIOLOGICAL|CYD Dengue Vaccine (5-dose formulation)|0.5 mL, Subcutaneous
214894491|NCT02623725|BIOLOGICAL|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
214894492|NCT03759392|DRUG|Omecamtiv Mecarbil|Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
214296392|NCT00498602|BIOLOGICAL|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
214296393|NCT00498602|BIOLOGICAL|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
214296394|NCT00498602|OTHER|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
214668796|NCT04937166|DRUG|Azacitidine|Azacitidine is an analog of the pyrimidine nucleoside cytidine.
214668797|NCT04937166|DRUG|Venetoclax|Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
214894493|NCT03759392|DRUG|Placebo|Oral placebo twice daily for up to 20 weeks
214894494|NCT03902665|DRUG|Up-front allogeneic hematopoietic stem cell transplantation (HSCT)|"Patients classified as fit/unfit are included in the HSCT program. There are two early approaches allowed. A) Patients will be left untreated until HSCT B) Patients will receive 1 short course of chemotherapy before HSCT (Ara-C and anthracycline).~Selection of strategy A or B, will be patient based on disease characteristics and dynamics or presence of high tumor load.~Conditioning for haplo-HSCT should be started as soon as possible, within day 45 after initial diagnosis. This is to avoid delayed transplantation. Two dosing levels of the Thiotepa-Busulfan-Fludarabine (TBF) based protocol are allowed based on the clinical condition of the patient: fit patients below 70 will receive the TBF with 2 days of Busulfan, whereas patients with poorer clinical condition or above the age of 70 will receive a dose-reduced TBF, in which Busulfan may be reduced to 1 day only."
214894495|NCT03573622|DRUG|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
214894496|NCT03573622|DRUG|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
214894497|NCT04565574|DRUG|E7090|Oral tablet.
214894498|NCT04565574|DRUG|Rabeprazole 20 mg|Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.
214894499|NCT04565574|DRUG|Rifampin 600 mg|Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.
214894500|NCT03732963|DRUG|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
214894501|NCT03732963|DRUG|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
214894502|NCT02183779|PROCEDURE|post-occlusive hyperemia|
214894503|NCT02183779|PROCEDURE|cooling box|
214894504|NCT02183779|DRUG|L-NMMA and Fluconazole dermic injection|
214296395|NCT00498602|BIOLOGICAL|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
214894505|NCT04183621|DIAGNOSTIC_TEST|high resolution impedance manometry|Two detailed swallow assessments to be carried out at between 2-4 months and 8-10 months of age
214894506|NCT01834833|OTHER|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
214894507|NCT03286153|OTHER|Ideal Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on ideal body weight. For participants age 12-19, ideal weight is calculated using the McLaren method. For participants age 20 and over, ideal weight is calculated using the following equation: \[50kg + (2.3kg\*every inch over 5 feet)\].
214894508|NCT03286153|OTHER|Actual Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on actual body weight.
214894509|NCT05457777|BEHAVIORAL|Motivational interview in digital game addiction|Motivational interviewing, which is a technique developed by William Miller that aims to change behavior by revealing the contradiction of problematic behavior with the value judgments of the person and creating motivation by the counselor, will be applied to the individuals with digital game addiction.
214894510|NCT03385889|PROCEDURE|Cervical Spine Mobilization|C1/2 graded mobilizations (Grade III/IV) provided to C1/2 segment on ipsilateral side of unilateral headache. Mobilizations will be completed for 3 sets of 30 seconds.
215050929|NCT03041935|PROCEDURE|Ilioinguinal/iliohypogastric nerve block|See arm description
215050930|NCT03041935|PROCEDURE|Caudal-epidural nerve block|See arm description
215050931|NCT03041935|DRUG|Acetaminophen|See arm description
215050932|NCT03041935|DRUG|Sevoflurane|See arm description
214296396|NCT04585022|DEVICE|Magnum, Zimmer Biomet, Warsaw, IN|
214296397|NCT04585022|DEVICE|Recap, Zimmer Biomet, Warsaw, IN|
215050933|NCT03041935|DRUG|Remifentanil|See arm description
215050934|NCT03041935|DRUG|Propofol|See arm description
215050935|NCT03041935|DRUG|Morphine|See arm description
215050936|NCT03041935|DRUG|Ondansetron|See arm description
215050937|NCT03041935|DRUG|Dexamethasone|See arm description
215050938|NCT03041935|DRUG|Ketorolac|See arm description
215050939|NCT03041935|DRUG|Ropivacaine|See arm description
215050940|NCT01650454|OTHER|2 night polysomnography|Polysomnography
215050941|NCT01650454|OTHER|battery of neuropsychological tests|
215050942|NCT01650454|OTHER|virtual reality test|
215050943|NCT01650454|OTHER|subjective evaluation of sleep and somnolence|
215050944|NCT01127620|DRUG|Bilastine|20 mg encapsulated tablets
214894511|NCT03385889|PROCEDURE|Cervical Spine Manipulation|C1/2 manipulation (Grade V) provided to C1/2 segment on ipsilateral side of unilateral headache. The goal of the manipulation technique is to elicit an audible cavitation. If no cavitation is achieved upon the first attempt, a second and final attempt will be completed. No more than two attempts will be utilized per each subject in this allocated group.
214296398|NCT02632552|BEHAVIORAL|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
214894512|NCT02120638|DRUG|Pyrazinamide containing regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
214894513|NCT02120638|DRUG|Regimen without Pyrazinamide|Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
214668798|NCT04241029|DIETARY_SUPPLEMENT|IDOFORM®Travel|Four capsules IDOFORM®Travel orally every 24 hour (12\*10\^9 cfu/day) for eight weeks.
214894514|NCT01237119|DRUG|Liraglutide|1.8 mg once daily, subcutaneous injection
214668799|NCT02843711|GENETIC|Sequencing|Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
214894515|NCT01237119|OTHER|Liraglutide-placebo|1.8 mg once-daily, subcutaneous injection
214894516|NCT02284477|OTHER|non- PVC containing packing materials|Beverage which was stored in glass bottle for 24 hours in 4 ℃.
214894517|NCT02284477|OTHER|PVC containing packing materials|Beverage which was stored in PVC blood bag for 24 hours in 4 ℃.
214894518|NCT06071624|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
214894519|NCT02000492|BEHAVIORAL|Football|
214894520|NCT02000492|BEHAVIORAL|Running|
215050945|NCT01127620|DRUG|Cetirizine|10 mg encapsulated tablets
215050946|NCT01127620|DRUG|Placebo|encapsulated tablets
215050947|NCT00882024|DRUG|Tranilast|150 mg tranilast tablets, bid, 12 weeks
215050948|NCT00882024|DRUG|Tranilast|75 mg tablets, bid, 12 weeks
214296399|NCT02632552|BEHAVIORAL|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
214296400|NCT00866411|PROCEDURE|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
214296401|NCT00866411|PROCEDURE|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
214296402|NCT02601742|OTHER|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
214668800|NCT03592238|OTHER|Aerobic Exercise Intervention|The protocol will include a 25-min bout of exercise at an intensity of 75% HRmax, such that participants will engage in a 1-min warm up and a 1-min cool down, with the majority of time (i.e., 23-min) spent exercising at 75% of HRmax.
214894521|NCT02000492|BEHAVIORAL|Circuit training|
214894522|NCT00800267|DRUG|latanoprost 0.005%|placebo in the morning and latanoprost .005% in the evening
214894523|NCT00800267|DRUG|fixed combination latanoprost-timolol|one drop in the morning and placebo in the evening
214894524|NCT00800267|DRUG|timolol 0.5%|one drop in the morning and evening
214894525|NCT02548143|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|LR769
214894526|NCT05522192|DRUG|Mitoxantrone liposome|Phase I: 24mg/m2, 30 mg/m2, 36mg/m2, IV, d1; Phase II: RP2D.
214894527|NCT05522192|DRUG|Venetoclax|Phase I/II: 100mg po d1，200mg po d2，400mg po d3-28.
214894528|NCT00366431|DRUG|MOA-728|
214894529|NCT06772233|DRUG|regorafenib combined with envafolimab|"-Regorafenib: Specification: 40 mg/tablet Dosage: 120 mg, taken orally once daily for 3 weeks, followed by 1 week off, until disease progression or intolerable toxicity occurs.~* Envafolimab:~Specification: 200 mg/vial Dosage: 200 mg, administered via subcutaneous injection once every 2 weeks, until disease progression or intolerable toxicity occurs."
214894530|NCT06772233|DRUG|Control Group|The governing principle for physician decision-making in the control group was selection based on prior medication tolerability, genotype, etc.: a. Continued maintenance therapy with the originally effective TKI at the same dose: The patient achieved at least stable disease (SD) or partial response (PR) during prior treatment, with progression-free survival (PFS) exceeding 6 months, and the adverse reactions were tolerable. b. Combination therapy with two TKIs: Different drugs were selected for maintenance based on distinct actionable mutations identified in the patient's tissue or peripheral blood genetic testing, OR a combination of drugs previously effective and well-tolerated was used, OR the combination therapy was chosen by referencing past tolerability.
215050949|NCT00882024|DRUG|Placebo|Placebo tablets, bid, 12 weeks
215050950|NCT02804061|BEHAVIORAL|NELIP|
215050951|NCT00947128|DRUG|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
215050952|NCT00947128|DRUG|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
215050953|NCT02619747|DRUG|Compound Sodium Alginate Oral Suspension sachet|
215050954|NCT02619747|DRUG|Matched placebo|
214894531|NCT06770036|BEHAVIORAL|Implementation Resource Package for Caregivers|The implementation resource package for caregivers is a set of resources provided to caregivers that aims to support their use of evidence-based behavior management practices and home-school communication strategies.
214894532|NCT02627651|OTHER|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
214894533|NCT05325827|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
214894534|NCT02649712|DEVICE|biliary stent|Self-expandable biliary nitinol alloys stent
214894535|NCT02795247|PROCEDURE|Anterior Cruciate Ligament Reconstruction|
214894536|NCT02552901|DRUG|0.1 mg/kg ICG Dose|least efficacious dose
214894537|NCT02552901|DRUG|0.5 mg/kg ICG dose|per package insert
214894538|NCT00619723|DRUG|Citicoline|Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
214894539|NCT00619723|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
214894540|NCT00619723|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
214894541|NCT06208540|DRUG|Cerebrolysin|Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 6 weeks till a maximum of 24 weeks.
214894542|NCT06208540|OTHER|olfactory and gustatory trainings|olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention
214894543|NCT06344273|BEHAVIORAL|ROM exercises|Each individual in the case group will have lower extremity ROM exercises, each of which will last 20 minutes, at the beginning of the session and at the beginning of the hour until the end of the session.
214894544|NCT06522217|DEVICE|nasoalveolar molding appliance|making impression then make the conventional lab procedures for group A for the production of conventional appliances
214894545|NCT06522217|DEVICE|digital nasoalveolar molding appliance|group B scanning the model and designing the appliances on 3shap and 3d printing the appliances
214296403|NCT02601742|OTHER|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
214296404|NCT06397898|OTHER|Educational video|Viewing an educational video before Novasure treatment
214894546|NCT07095049|DRUG|Apo-Si-K170A-C76|Apo-Si-K170A-C76 is an small interfering RNA (siRNA) against SARS-CoV-2
214894547|NCT07095049|DRUG|Placebo|5% glucose, 0.5% benzyl alcohol in RNase free water
214894548|NCT07097064|COMBINATION_PRODUCT|standard radiotherapy with chemotherapy|intensity-modulated conformal radiotherapy (IMRT) 50-54 Gy in 25-30 fractions with concomitant Xeloda 800-825 mg/m2 morning and evening 5d/7.
214894549|NCT07097064|RADIATION|MRI-guided adaptive stereotactic radiotherapy (SMART)|MRI-guided adaptive stereotactic radiotherapy (SMART) 50 Gy / 5 fractions without concomitant chemotherapy.
214894550|NCT07097090|BEHAVIORAL|Emotion Recognition Training Program: A structured school-based intervention designed to enhance children's ability to recognize emotions through facial expressions, tone of voice, and body language.|"Emotion Recognition Training Program Integrated CASEL-based activities with CBT principles and digital tools to enhance emotional attribution and recognition in primary school children.~The intervention consisted of three structured activities based on the CASEL framework (Collaborative for Academic, Social, and Emotional Learning), integrated with cognitive-behavioral principles inspired by the model of Albert Ellis. Sessions included interactive use of digital whiteboards and narrative tools (e.g., emotion-themed interactive stories), aimed at improving children's ability to attribute emotions to others and to emotionally evaluate events.~In addition, a neurostimulative component was included, exposing children to visual stimuli with either neutral or fear-inducing emotional valence. Participants were asked to rate the perceived emotional intensity, supporting the development of self-regulation and emotional differentiation."
214894551|NCT07097090|BEHAVIORAL|No Intervention: Observational Cohort|Control group received no intervention in order to serve as a baseline for comparison, isolating the effects of the emotion recognition training on behavioral and cognitive outcomes.
214296405|NCT00585819|PROCEDURE|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
214296406|NCT00585819|PROCEDURE|Freebreathing in Body fix mold|Freebreathing in Body fix mold
214296407|NCT01800240|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
214296408|NCT01721616|DRUG|Azithromycin|
214296409|NCT01721616|DRUG|Cefazolin|
214296410|NCT02375568|OTHER|103024-F|mesenchymal stem cell isolation
214296411|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
214668801|NCT03592238|OTHER|Trier Social Stress Test for Children|Participants will be asked to imagine that they are in a new class with 20 other students, and that their teacher has asked them to stand in front of the class and introduce themselves. The mental arithmetic task will entail asking children to serially subtract the number 5 from a larger number as quickly as possible.
214668802|NCT03592238|OTHER|Seated Rest|Children will be asked to sit quietly or read a book of their choosing.
214296412|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
214296413|NCT04864379|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01: 300 mcg per peptide
214668803|NCT06965933|PROCEDURE|ESP block group|The patient will undergo an ESP blockade under the control of ultrasound during the implementation of anesthetic support. A local anesthetic will be injected into the fascial space of the muscles straightening the spine: ropivacaine 0.375%, 3 mg / kg, on both sides.
215050955|NCT02965989|PROCEDURE|Online training of a nursing technique|The professionals with participant in the experimental arm receive an online training of a technique of extraction of blood culture and other arm the professionals no receive any training. They work as usual.
214668804|NCT06965933|DRUG|IV Lidocaine|During the implementation of anesthetic support, the patient will receive a constant intravenous infusion of lidocaine: a loading dose of 1.5 mg/kg/ h (1 hour), followed by an infusion of 1 mg/kg/h for 24 hours during the perioperative period.
215050956|NCT01913327|DRUG|Aripiprazole|
215050957|NCT01913327|DRUG|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
215050958|NCT01913327|DRUG|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
215050959|NCT02057926|DRUG|The effect of tetracycline in degradation and permeability of collagen membranes.|
215050960|NCT01381770|BIOLOGICAL|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
215050961|NCT01352286|GENETIC|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
215050962|NCT00672230|DIETARY_SUPPLEMENT|Lutein supplement|Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
215050963|NCT03069066|DEVICE|Bioresorbable vascular scaffold. Absorb GT1 (Abbott)|
215050964|NCT04593550|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215050965|NCT04593550|BEHAVIORAL|BrainCheck Cognitive Assessment|Undergo cognitive function assessment BrainCheck
215050966|NCT04593550|PROCEDURE|Cognitive Assessment|Undergo 3D-Confusion assessment
215050967|NCT04593550|PROCEDURE|Electroencephalography|Undergo EEG
214296414|NCT04864379|OTHER|GM-CSF|GM-CSF: 40 mcg
214296415|NCT04864379|DRUG|PD-1|PD-1: 200mg administered by intravenous infusion every 2 weeks.
214296416|NCT04864379|PROCEDURE|RFA|Radiofrequency ablation surgery
214296417|NCT04220008|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
214296418|NCT04220008|DRUG|Busulfan|Given IV
214296419|NCT04220008|DRUG|Clofarabine|Given IV
214668805|NCT02252861|OTHER|Percutaneous Left Atrial Appendage Closure in routine care|The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
214668806|NCT01392690|BEHAVIORAL|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
214668807|NCT04925570|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
214668808|NCT04925570|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
215050968|NCT00004227|BIOLOGICAL|cetuximab|
214296420|NCT04220008|DRUG|Cyclophosphamide|Given IV
214296421|NCT04220008|DRUG|Gemcitabine|Given IV
215050969|NCT00004227|PROCEDURE|conventional surgery|
215050970|NCT00004227|RADIATION|radiation therapy|
215050971|NCT05659849|OTHER|Manual therapy techniques|Passive joint mobilization techniques are applied to the affected knee joint. For the first week (three sessions), the joint mobilization exercises included grade I or II rhythmic oscillations. During the following weeks, grade III or IV oscillation techniques were applied, depending on the level of tolerance and pain of each patient. In knee distraction, the patients are in a prone position with 50° knee flexion, and the physical therapist applies the techniques. The dorsal and ventral glides was performed with the patient in a supine position.
215050972|NCT05659849|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) therapy treats pain using low-voltage electric currents. A small device administers the electrical current to or near nerves. TENS treatment inhibits or changes pain perception.
215050973|NCT02243683|DRUG|AX-024.HCl|
215050974|NCT02243683|OTHER|Placebo|
214296422|NCT04220008|DRUG|Mycophenolate Mofetil|Given IV
214296423|NCT04220008|BIOLOGICAL|Rituximab|Given IV
214296424|NCT04220008|DRUG|Tacrolimus|Given IV
214296425|NCT04220008|DRUG|Vorinostat|Given PO
214296426|NCT05325528|DRUG|Tislelizumab in Combination with Oxaliplatin and Tegafur|6 cycles of Tislelizumab plus SOX regimen every 21 days
214894552|NCT07096882|BIOLOGICAL|SDT-M001 injection|Cascade primed immune cells(CAPRI); SDT-M001 injection is administered at three dose levels:1.5e9 cells, 3e9 cells,6e9 cells. The cells will be reinfused in 3 divided doses, administered every other day, and the total process will take 5 days.
214894553|NCT07095387|BEHAVIORAL|Making room for climate emotions in the classroom|This intervention combined creative arts workshops using drawing, photography, painting and collage to introduce a theme related to climate change and promote emotional expression. The artistic creation was followed by a philosophical inquiry group discussion on a theme related to the artistic creation to allow critical thinking and sharing perceptions.
214894554|NCT07097597|DEVICE|Comparison 1: New Snoring Application|Measurements obtained from the snoring application under development
214894555|NCT07097597|DEVICE|Comparison 2: Commercially Available Snoring Application|Measurements from a commercially available snoring application
214894556|NCT07097597|DEVICE|Comparison 3: Polysomnography|Measures taken from home or in laboratory polysomnography
214894559|NCT07097805|BEHAVIORAL|GLITTER comprehensive management|The GLITTER comprehensive management represents a management approach that effectively combines multidisciplinary professional team care, diabetes technology empowerment, structured education steering, and peer support.
214894560|NCT07095205|DRUG|Nicotine transdermal patch|The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).
214894561|NCT07095205|DRUG|PET Scan with [18F] VAT|All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.
214296427|NCT04444596|DIAGNOSTIC_TEST|Conjunctival swab and nasopharyngeal swab|Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.
214296428|NCT03821792|DRUG|Abiraterone Acetate|Given PO
214296429|NCT03821792|DRUG|Apalutamide|Given PO
214296430|NCT03821792|DRUG|Prednisone|Given PO
214296431|NCT06678529|DEVICE|active tDCS|The active-tDCS group will receive a 15-second ramp up phase at the start, 2 mA of tDCS for 20 minutes and a 15-second ramp down phase at the end.
214668809|NCT04705480|DRUG|Pregabalin 50mg|Patients will receive 50 mg every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
214668810|NCT04705480|DRUG|Gabapentin 300mg|Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
214668811|NCT04705480|DRUG|Neither Pregabalin nor Gabapentin|Patients will receive neither Pregabalin nor Gabapentin.
214668812|NCT05802914|DEVICE|Back Exosuit|The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
214668813|NCT04620603|RADIATION|Low Dose Rate Brachytherapy (LDR)|LDR on treatment day 1
214668814|NCT04620603|DRUG|Standard-of-Care Immunotherapy|Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.
214668815|NCT06048159|DEVICE|HD-tACS|High definition tACS will be applied during speech therapy.
214668816|NCT06048159|DEVICE|Sham HD-tACS|Sham high definition tACS will be applied during speech therapy.
214668817|NCT02971358|PROCEDURE|Radical prostatectomy|Standard radical prostatectomy with extended lymph node dissection is performed.
214668818|NCT06970626|DRUG|Dexmedetomidine infusion|Dexmedetomidine will be maintained at 0.5 μg/kg/h ideal body weight via a syringe pump until trocar removal.
214668819|NCT06970626|PROCEDURE|Paragastric neural block|Paragastric neural block (PGNB) will be administered using a 25-gauge needle attached to a venous catheter extension, introduced through the left 12 mm port. Infiltration of 20 mL undiluted 0.5% bupivacaine will be performed at six levels in the fatty tissue of the paragastric area, including the lesser omentum, vagus nerve, esophago-gastric junction, proximal stomach, mid-stomach, distal antrum, hepatic artery, and left gastric artery, with the needle cap removed under direct vision throughout the procedure.
214668820|NCT06970626|PROCEDURE|Laparoscopic Transversus Abdominis Plane (LTAP) block|LTAP will be administered after insufflation before insertion of the right and left-handed ports. 30 mL of 0.25% bupivacaine will be injected into the posterolateral subcostal regions on both sides. The correct placement will be confirmed by observing the spread of fluid between the transversus abdominis and the internal oblique muscle layers laparoscopically
214668821|NCT06971562|DEVICE|Aquacel AG|Hydrocellulose wound dressing containing 1.2% cationic silver
214668822|NCT06971562|DEVICE|Aquacel|Hydrocellulose wound dressing
214296432|NCT06678529|DEVICE|sham tDCS|The sham-tDCS group will only receive the 15-second ramp up phase at the beginning and the 15-second ramp down phase at the end of each session, without the continuous 2 mA current for 20 minutes
214296433|NCT06196333|DEVICE|Non-contact specular microscopy|using specular microscope to do morphological examination of corneal endothelial cells
214894562|NCT07097194|BEHAVIORAL|EX program|Quit plan with interactive exercises, educational videos, and tailored text messages and emails; peer support; coach chatting; nicotine replacement therapy (patches, gum, or lozenges). All components are self-selected.
214894563|NCT07096609|DRUG|Lenvatinib Capsules|Lenvatinib will be administered orally once daily at a dose of 12 mg (for patients weighing ≥ 60 kg) or 8 mg (for patients weighing \< 60 kg). Each treatment cycle consists of 4 weeks (i.e., 28 days).
214894564|NCT07095400|OTHER|strength training|"An intervention based on the application of a strength training protocol for multi-joint and single-joint muscles will be implemented, performed with a slow-moderate execution speed. This intervention will be carried out over 12 weeks, with a total of 24 sessions (2 sessions per week), each lasting 45 minutes. In all of these sessions, free weights will be used, performing three sets at 60-80% of 1RM for 8-12 repetitions.~The exercise protocol will include:~* Squats~* Deadlifts~* Rows~* Bicep curls~* Bench press~* Shoulder press~Each set will be performed to muscular failure, progressing in the number of repetitions (from 8 to 12). Once 12 repetitions are reached, the load volume will be increased by adding 5% to the weight."
214894565|NCT07096583|BIOLOGICAL|METR-NK cell（metabolic remodeling nature killer cells）|100 mL METR-NK cells were diluted in 500 mL 0.9% sodium chloride normal saline at 37℃, and the infusion volume of METR-NK cells was not less than 2×107 cells/kg for 1 day as a course of treatment, and the infusion time was maintained for 30 minutes on the 10th day before chemotherapy.
214894566|NCT07095777|PROCEDURE|visual perceptual learning|Participants in the VPL group performed 40 minutes of daily monocular training at home for three months, with follow-up evaluations conducted at 1 month and 3 months after training initiation.
214894567|NCT07096154|BEHAVIORAL|Group CBT Anxiety Management|An 8-session Group Cognitive Behavioural Therapy for anxiety management.
214894568|NCT07097454|DEVICE|Hypotension Prediction Index Monitoring|HPI monitoring is performed using the Edwards Lifesciences HemoSphere platform to provide real-time hypotension prediction based on arterial pressure waveform analysis. Interventions such as fluid bolus or vasopressor are administered per protocol when HPI ≥ 85.
214894569|NCT07097454|OTHER|Standard PACU Monitoring|Standard monitoring in the post-anesthesia care unit (PACU), including non-invasive blood pressure, heart rate, and oxygen saturation measurements. No Hypotension Prediction Index (HPI) monitoring is used. Interventions are performed according to routine institutional practices.
214894570|NCT07095257|DRUG|ZX-7101A for oral suspension|ZX-7101A will be administered as oral suspension in a single dose on Day 1. Oseltamivir phosphate matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.
214894571|NCT07095257|DRUG|Oseltamivir phosphate for oral suspension|Oseltamivir phosphate will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive ZX-7101A matching placebo as oral suspension, single dose on Day 1.
214894572|NCT07096986|DRUG|Forxiga|dapagliflozin treatment at a dose of 10 mg per os daily for 6 months
215050975|NCT02558101|BEHAVIORAL|Control invitation materials|"In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:~1. a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes~2. an invitation letter with a pre-scheduled appointment plus the same information booklet~3. a reminder re-invitation letter for those who miss their appointment without cancelling"
215050976|NCT02558101|BEHAVIORAL|Intervention invitation materials|The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
215050977|NCT03302143|PROCEDURE|Guided bone regeneration with Bovine Bone Mineral|Guided bone regeneration with Bovine Bone Mineral
215050978|NCT03302143|PROCEDURE|Guided bone regeneration with freeze dried bone allograft|Guided bone regeneration with freeze dried bone allograft
214894573|NCT03398603|PROCEDURE|blood sample and ultrasound|When included in the study blood samples and ultrasound are taken every second day of the first and third menstrual cycle after inclusion.
215050979|NCT00000134|DRUG|Ganciclovir|intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
214296434|NCT04057391|DIAGNOSTIC_TEST|QT Scanner|Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
214894574|NCT00990925|BEHAVIORAL|Nutritional Lifestyle Modification Group|Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.
214894575|NCT00990925|OTHER|Usual Care|Care as usual
215050980|NCT00000134|DRUG|Foscarnet|intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
215050981|NCT01079325|DRUG|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
215050982|NCT01079325|OTHER|Saline|
215050983|NCT02459561|DEVICE|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
215050984|NCT02459561|OTHER|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
215050985|NCT05272189|BEHAVIORAL|Simulated Second Reader AI|In this experiment, in some conditions, the participant makes their decision in the presence of information about a simulated artificial intelligence decision.
215050986|NCT05272189|BEHAVIORAL|Target Prevalence|The frequency with which targets are presented varies from 10% to 90%
214296435|NCT01324336|DRUG|6-Mercaptopurine|75 mg/m2/dose/day
214668823|NCT06970444|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|Transcutaneous auricular vagus nerve stimulation (taVNS) is an emerging non-invasive therapy that modulates brain activity by delivering electrical impulses to the auricular branch of the vagus nerve at the outer ear (Badran et al., 2018). taVNS subsequently stimulates the nucleus of tractus solitarius via the afferent vagus nerve fibers. The nucleus solitarius sends outputs to the hypothalamus, which is critical for sensory processing, including auditory processing, and also activates various brain regions, including the locus coeruleus, resulting in the release of neurotransmitters such as norepinephrine and serotonin, which are involved in neural plasticity and cognitive function, which is important for CAP. Another theory for taVNS effects is the release of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, which may further help to balance abnormal neural activity in auditory circuits.
214894576|NCT04598386|OTHER|PR Lotion - AMP Human Performance|Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.
214894577|NCT04598386|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
214894578|NCT00226980|DRUG|Thalidomide|
214894579|NCT00226980|DRUG|Capecitabine|
214894580|NCT05620082|DIETARY_SUPPLEMENT|Standard liquid-based oral nutritional supplement|An anonymous ready-made drink supplement: 125g, 306kcal, 18.3g protein.
214894581|NCT05620082|DIETARY_SUPPLEMENT|Fortified porridge|Vital Daily High Protein Oats (Adams Vital Nutrition Ltd.): 157g, 230kcal, 15g protein.
214894582|NCT01532401|OTHER|sodium chloride|sodium chloride 500mg
214894583|NCT01532401|OTHER|Methylcellulose crystalline|Methylcellulose 37 ml
215050987|NCT06184191|OTHER|Robotic hand rehabilitation|Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.
215050988|NCT00207220|PROCEDURE|arterial tonometry|used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
215050989|NCT00207220|PROCEDURE|echocardiography|ultrasound test using sound waves to create a moving picture of the heart
215050990|NCT03037762|PROCEDURE|Flexible Endoscopic Evaluation of Swallowing|
215050991|NCT01465035|BIOLOGICAL|TIV and MVA-NP+M1|1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
215050992|NCT01465035|BIOLOGICAL|Saline placebo and seasonal influenza vaccine TIV|Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
215050993|NCT04546919|OTHER|sepsis|Body temperature higher than 38°C or lower than 36°C; Heart rate higher than 90/min; Hyperventilation evidenced by respiratory rate higher than 20/min or PaCO2 lower than 32 mmHg; White blood cell count higher than 12,000 cells/ µl or lower than 4,000/ µl.
215050994|NCT02264613|DRUG|ALRN-6924|ALRN-6924 will be administered as an IV infusion
214894584|NCT06011707|BEHAVIORAL|OPT-IN|Parents will be provided with online access to 6 compulsory video-based modules and 8 optional video-based modules. These modules will teach them about child development, behavioural principles, and naturalistic developmental intervention principles. These modules will promote skills that parents can use to increase their child's social and communication behaviours and minimize behaviours that interfere with learning (e.g., temper tantrums).
214894585|NCT06011707|OTHER|Psychoeducational control|This control intervention will provide parents with 6 compulsory and 8 optional modules that will teach them about autism and its developmental course.
214894586|NCT06774521|OTHER|control|There is no intervention
214894587|NCT06774521|OTHER|reformer|"Reformer exercises:~Foodwork Swan Short Spin Long Stretch Keen Stretch Hug Tree Bridge Pulling Straps Short Box Abdominal Hundred Twist Star"
214894588|NCT06774521|OTHER|mat|"Mat exercises:~Neck exercises Trunk stabilization exercises Shoulder exercises Posture exercises"
214894589|NCT03985540|BEHAVIORAL|Behavorial; memory exercise|Memory training twice a week for 5 weeks.
214894590|NCT03985540|BEHAVIORAL|Placebo; memory exercise|Placebo Memory training twice a week for 5 weeks
214894591|NCT03985540|BEHAVIORAL|Behavioral: speed exercises|Speed training twice a week for 5 weeks.
214894592|NCT03985540|BEHAVIORAL|Placebo speed training|Placebo Speed training twice a week for 5 weeks.
214894593|NCT06948136|DRUG|Delta-9-THC Low Dose|Active Delta-9-THC administered intravenously over 20 minutes.
215050995|NCT05476081|DRUG|Aspirin|Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
215050996|NCT05476081|DRUG|Clopidogrel|Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment
215050997|NCT05476081|DRUG|Ticagrelor|Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
215050998|NCT03081104|DEVICE|hystroscopy|The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
215050999|NCT03081104|DEVICE|ultrasound|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
214894594|NCT06948136|DRUG|Placebo|Small amount of sterile ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
214894595|NCT06948136|DRUG|Delta-9-THC Medium Dose|Active Delta-9-THC administered intravenously over 20 minutes
214894596|NCT03258502|DRUG|RV521|RV521 drug in capsules
214894597|NCT03258502|DRUG|Placebo|Placebo in capsules
214894598|NCT05954988|DRUG|LTI-03|Caveolin-1-Scaffolding-Protein-Derived Peptide
214894599|NCT05954988|DRUG|Placebo|Matching placebo
215051000|NCT03081104|PROCEDURE|Aspiration|The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
215051001|NCT01074931|DRUG|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
215051002|NCT03463837|OTHER|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%, ENDS for 5-days in confinement
215051003|NCT03463837|OTHER|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, ENDS for 5-days in confinement
215051004|NCT03463837|OTHER|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, ENDS for 5-days in confinement
215051005|NCT03463837|OTHER|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, ENDS for 5-days in confinement
215051006|NCT03463837|OTHER|Combustible cigarette|Exclusive use of combustible cigarette for 5 days in confinement.
215051007|NCT03463837|OTHER|Smoking Cessation|No smoking for 5-days in confinement.
215051008|NCT02862886|OTHER|myometrium biopsy|
215051009|NCT03888248|DEVICE|Whole-body vibration|Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week
214296436|NCT02054221|PROCEDURE|myoectomy|The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
214296437|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.
214296438|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
214296439|NCT04518150|DEVICE|Bakri balloon|the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
214296440|NCT04518150|PROCEDURE|Bilateral Uterine Artery Ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
214296441|NCT00546637|DRUG|Fesoterodine|Fesoterodine 4mg or 8mg
214296442|NCT00546637|DRUG|Placebo|Placebo
214296443|NCT01606930|BEHAVIORAL|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
214894600|NCT06263179|BEHAVIORAL|Target Heartrate Aerobic Exercise|Exercise program
214894601|NCT03528642|OTHER|Questionnaire Administration|Ancillary studies
214894602|NCT03528642|RADIATION|Radiation Therapy|Undergo RT
214894603|NCT03528642|DRUG|Telaglenastat Hydrochloride|Given PO
214894604|NCT03528642|DRUG|Temozolomide|Given PO
214894605|NCT02360215|RADIATION|Whole brain radiation therapy with hippocampal avoidance|Intensity modulated radiation therapy (IMRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately two week; starting within 21 calendar days after randomization.
214894606|NCT02360215|DRUG|Memantine|Given PO daily during and after radiation therapy for a total of 24 weeks. Week 1: 5 mg in the AM, none in the PM; Week 2: 5 mg in the AM, 5 mg in the PM; Week 3: 10 mg in the AM, 5 mg in the PM; Weeks 4-24: 10 mg in the AM, 10 mg in the PM. Should start the same day as radiation therapy, at latest before the fourth radiation treatment.
214894607|NCT02360215|RADIATION|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately 2 weeks
214894608|NCT05491915|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the occipital nerves. The SPRINT System includes up to two leads (small wires) that are placed through your skin at the top of your neck. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
214894609|NCT06297941|DRUG|REM-422|"REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~REM-422 will be administered orally once daily"
214894610|NCT02603146|DRUG|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
215051010|NCT03888248|OTHER|Muscle strengthening exercises|Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
215051011|NCT05158920|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Suicidal individuals (MBCT-S)|MBCT-S is a group intervention of 8 weekly sessions of 2 hours combining techniques of mindfulness with important elements of cognitive therapy (e.g. safety plan and homework).
215051012|NCT00953706|DRUG|Ivacaftor|Tablet
215051013|NCT00953706|DRUG|Placebo|Tablet
214894611|NCT02603146|DRUG|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
214894612|NCT05343260|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
214894613|NCT05343260|DRUG|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
215051014|NCT00001937|DRUG|FK463|
214894614|NCT06476730|OTHER|Telerehabilitation exercise program|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased
214894615|NCT06476730|OTHER|Routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
214894616|NCT04901455|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
215051015|NCT00001937|DRUG|Fluconazole|
215051016|NCT04859192|OTHER|gamified flipped classroom|moodle will be gamified
215051017|NCT05548764|PROCEDURE|Prevention Bundles for SSIs|10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.
215051018|NCT00921050|DRUG|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
215051019|NCT00921050|DRUG|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
215051020|NCT05007327|OTHER|Exposure to pollen and air pollution|For all subjects of the cohort, we will follow exposure to pollen and air pollution.
215051021|NCT04183712|DRUG|gemcitabine and oxaliplatin.|GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
215051022|NCT04183712|DRUG|Afatinib|Target therapy Drug: afatinib
215051023|NCT03490929|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|injection of Lumason (ultrasound contrast agent)
215051024|NCT03490929|DEVICE|contrast-enhanced ultrasound|ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
214296444|NCT04199611|PROCEDURE|Liposuction|This is a type of fat removal procedure used in plastic surgery.
214296445|NCT04199611|BEHAVIORAL|Cognitive Behavioral Therapy|This is a psycho-social intervention that aims to improve mental health.
214296446|NCT06319508|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
215051025|NCT04895371|OTHER|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
215051026|NCT04895371|OTHER|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
215051027|NCT03081689|DRUG|Nivolumab 360 mg|Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
215051028|NCT03081689|DRUG|Paclitaxel 200mg/m2|Paclitaxel 200mg/m2 IV Q3W
215051029|NCT03081689|DRUG|Carboplatin AUC 6|Carboplatin AUC 6 IV Q3W
215051030|NCT02137070|PROCEDURE|Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss
215051031|NCT02137070|OTHER|Non surgical/Community volunteers|Healthy adults with body mass index \>35 who will not undergo bariatric surgery for weight loss
215051032|NCT06022926|PROCEDURE|warmed with electric blankets|warmed with electric blankets
215051033|NCT06022926|OTHER|patients without warming|patients without warming: no electric blanket will be used, and no heating will be applied to this group of patients.
215051034|NCT05969275|BIOLOGICAL|Allogeneic umbilical cord-derived human mesenchymal stromal cells|Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
215051035|NCT05969275|OTHER|Placebo|Intravenous infusion of placebo, with excipients
215051036|NCT05961371|OTHER|Resistance Training|Twice weekly resistance training progressing to 5 sets of 5 repetitions of 80-90% of one repetition maximum.
214296447|NCT06319508|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
215051037|NCT06333496|DIETARY_SUPPLEMENT|GLP-1 Booster (GB)|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
214894617|NCT06425588|OTHER|Surgical/Procedure Mask Fit Testing|All participants will wear a surgical/procedure mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.
214894618|NCT06425588|OTHER|KN95 Mask Fit testing|All participants will wear a KN95 mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.
215051038|NCT06537791|BEHAVIORAL|Home-Based Rehabilitation Program|Physical Therapy: 32 sessions, 60 minutes each Occupational Therapy: 8 sessions, 60 minutes each Nutrition Counseling: 4 sessions, 60 minutes each Psychological Support: 8 sessions, 60 minutes each Nursing and Podiatry Care: 4 sessions, 60 minutes each Total Duration: Approximately 4 months
215051039|NCT05762432|DEVICE|Wound Dressing|RTD Wound Dressing that is being investigated
215051040|NCT05762432|DEVICE|NHS Standard Dressing|This is the standard dressing used by NHS staff when currently dealing with a diabetic foot ulcer
214296448|NCT06319508|DRUG|Lidocaine hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Once a day.
214894619|NCT04696536|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate cavity protection toothpaste for brushing teeth twice daily.
215051041|NCT03549780|DEVICE|Stomal Occlusion Device|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
215051042|NCT04543851|DEVICE|CARA - carbon fibre adjustable re-usable accessory for breast positioning|Breast positioning to alleviate infra-mammary fold and lateral breast sag
215051043|NCT03899415|BIOLOGICAL|TCR redirected T cells|HBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10\^4 - 5x10\^6 TCR redirected T cells by IV infusion.
215051044|NCT05124353|DRUG|Cerebrolysin|Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
214668824|NCT06970444|OTHER|Sham device|the control group received sham stimulation with the stimulator closed and electrodes placed in their left ear
214668825|NCT06971991|DEVICE|qDSA Blood Flow Measurement|The research intervention is limited to several additional qDSA image acquisitions, which include administration of additional iodinated contrast medium.
214894620|NCT04696536|OTHER|American Dental Association (ADA) Referenced Toothbrush|Participants will brush teeth at least one minute with provided toothbrush twice daily.
214894621|NCT04696536|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse as negative control for 30 sec twice a day after brushing.
214894622|NCT04696536|OTHER|REACH Dental Floss|Participants after brushing, rinse mouth with water and floss using Reach dental floss once a day.
214894623|NCT04696536|OTHER|Alcohol-containing Essential Oil (AEO) Mouth Rinse (Listerine Cool Mint, marketed)|Participants after brushing, rinse with 20mL of the AEO mouth rinse for 30 seconds twice a day.
214894624|NCT06458517|DEVICE|Photobiomodulation session - intraoral|use of CareMin650TM lightbox(NeoMedLight) in preventive and in case of occurence of grade 1 oral mucositis, in curative purpose
214894625|NCT06458517|DEVICE|Photobiomodulation session - transcutaneous|use of ATP38® phototherapy device (Swiss Bio Inov Europe) in preventive and in case of occurence of grade 1 oral mucositis, in curative purpose
215051045|NCT00361465|OTHER|EMG and Kinematics recording|"The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one)."
214668826|NCT06969586|DRUG|Netarsudil 0.02% Ophthalmic Solution|Topical Netarsudil 0.02% 1x daily for 30 days postoperatively
214668827|NCT06969586|DRUG|artificial tear substitute|Topical artificial tear substitute 1x daily for 30 days postoperatively.
214668828|NCT06971718|DIAGNOSTIC_TEST|Optical coherence tomography and pressure wire assessment of the vessel treated before and after treatment|OCT and pressure wire of the main vessel and side branch of the bifurcation are undertaken prior to and after treating the lesion and at 3-9 month follow up.
214668829|NCT06969690|OTHER|Survey questionnaire V1|Each version of the questionnaire includes a different order of statements about which study participants are asked to provide a Yes, No, or It depends response.
214894626|NCT03965195|BIOLOGICAL|Recombinant Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.
214894627|NCT03965195|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine
214894628|NCT03018184|OTHER|MRI and Muscle Dynamometer|
214894629|NCT01366118|DRUG|Therapeutic target tailored chemotherapy|"All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.~Ch combination schema was customized based on:~Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.~When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen"
214894630|NCT00919295|DRUG|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
214894631|NCT00919295|DRUG|placebo|placebo
214894632|NCT01950221|DIETARY_SUPPLEMENT|POMx|"POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract."
214894633|NCT01950221|OTHER|Placebo|
214894634|NCT03888846|DRUG|Pentoxifylline|Topical gel version of pentoxifylline to be administered intraorally.
214894635|NCT03888846|DRUG|Colchicine|Colchicine therapy is provided to patients with oral ulcers as part of supportive care routinely offered by Behcet's Clinic-Istanbul.
214894636|NCT03843060|DRUG|AZD9977|Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.
214894637|NCT03843060|DRUG|Itraconazole|Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
214894638|NCT04902001|BEHAVIORAL|Multidisciplinary weight loss|The adolescents will follow a 12-week intervention combining nutritional education, physical activity 3 times per week and psychological supports.
214894639|NCT01094704|DRUG|sodium chloride (7%)|4mL nebulized 7% sodium chloride
214894640|NCT04989543|DIAGNOSTIC_TEST|vaginal swabs|"Nugent score: Vaginal swabbing with the dry swab, make two smears on slides.~Cytobacteriological examination: swabbing at the exo-endocrine junction using the swab~Evaluation of the vaginal microbiota: swabbing at the exo-endocrine junction using the swab"
214894641|NCT01776710|BEHAVIORAL|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
214894642|NCT00245518|DRUG|Isoflavone|
214894643|NCT00245518|DRUG|Placebos|
214894644|NCT04069819|DRUG|Cilostazol 50 MG Oral Tablet|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
214894645|NCT04069819|DRUG|Escitalopram|Escitalopram 20 mg tablet once daily for 6 week
214894646|NCT04069819|DRUG|Placebo|placebo
214894647|NCT01332487|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
214894648|NCT05509530|OTHER|anti-BCMA/GPRC5D CAR-T CELL|anti-BCMA/GPRC5D autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy
214894649|NCT00654095|DRUG|Ezetimibe|Ezetimibe 10 mg once daily
214894650|NCT00654095|DRUG|atorvastatin|atorvastatin 20 mg once daily
214894651|NCT04353635|DEVICE|dolphin 3d|software
214894652|NCT00965887|DRUG|MK0974 Ethanolate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
214894653|NCT00965887|DRUG|Comparator: MK0974 Hydrate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
214894654|NCT00290017|DRUG|talabostat|
214894655|NCT00290017|DRUG|pemetrexed|
214894656|NCT02504528|OTHER|house dust mites|house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
214894657|NCT03726060|OTHER|control group|In the control group the patient will undergo gnathologic therapy for 6 months with neuromuscural splint every night for 3 months
214894658|NCT03726060|OTHER|test group|In the test group the patient will undergo gnathologic therapy with neuromuscural splint every night for 3 months in association with physical therapy
214894659|NCT04800081|DRUG|Sacubitril/Valsartan|Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.
214894660|NCT04800081|DRUG|Valsartan|Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.
214894661|NCT00002019|DRUG|Amphotericin B, Lipid-based|
214894662|NCT00002019|DRUG|Amphotericin B|
214894663|NCT04335513|OTHER|Early CGM-guided education and initiation of insulin therapy.|Careful monitoring of children progressing from stage 2 to stage 3 T1D using continuous glucose monitor (CGM) technology, staged education targeted to assist families in recognizing evolving dysglycemia, and addressing glycemic abnormalities with early initiation of insulin can substantially reduce the HbA1c and risk of DKA at diagnosis, thereby changing the trajectory of the disease course.
215051046|NCT02664519|BEHAVIORAL|Forearm exercise training|Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
215051047|NCT06073678|OTHER|Photobiomodulation|Irradiation with red laser on palate wound each 48h for 4 sessions.
214296449|NCT06319508|PROCEDURE|Placebo injection|The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. 1 milliliter of normal saline will be used for injection.
214296450|NCT00300937|DIETARY_SUPPLEMENT|Coenzyme Q10|100 mg oral BID starting at week 20 until delivery
214296451|NCT01773382|BEHAVIORAL|weight reduction|"1. Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~2. Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~3. Daily body weight measurement.~4. Record food diary"
214296452|NCT03145285|DRUG|Abiraterone Acetate|"Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
214296453|NCT05853198|OTHER|ctDNA analysis|ctDNA amount and mutations analysis
214668830|NCT06969690|OTHER|Survey questionnaire V2|Each version of the questionnaire includes a different order of statements about which study participants are asked to provide a Yes, No, or It depends response.
214668831|NCT06970002|DEVICE|Use of NIV during FOB as a respiratory support method|The aim of this project is to assess the safety, indications and contrindications to perform bronchofiberoscopy for diagnostic purposes in patient with chronic respiratory acidosis with the use of Non-invasive Ventilation (NIV) and High Flow Nasal Cannula (HNFC). In addition we want to determine the extent to which the usage of respiratory support during bronchofiberoscopy (BF) will help to avoid complications such as hypoxemia, decompensation of chronic respiratory failure, deterioration of gas exchange and hemodynamic instability, as well as intubation.
214894664|NCT04335513|OTHER|Usual care: glucometer surveillance and basic education.|"* Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK.~* Blinded CGM for 10 days every 3 months to collect data on glycemic profile with basic feedback regarding changes."
214894665|NCT04482764|DRUG|Valproic Acid|Treatment of children with frequent cyanotic breath holding spells (at least 4 spells per week) with 5 mg/kg/day for 6 months.
214894666|NCT00741000|PROCEDURE|Cervical Stairstep|Cervical low force mobilization procedure.
214894667|NCT02963779|DRUG|LY2775240|Administered orally
214894668|NCT02963779|DRUG|Placebo|Administered orally
214894669|NCT02963779|DRUG|Apremilast|Administered orally
214894670|NCT01431079|BEHAVIORAL|HPV vaccine acceptability|One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
214894671|NCT02389179|DRUG|Vitamin D3|The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
214894672|NCT00954759|PROCEDURE|Chiropractic treatment|
214894673|NCT00954759|PROCEDURE|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
214894674|NCT05433142|BIOLOGICAL|XmAb819|Monoclonal Bispecific Antibody
214894675|NCT00116506|DRUG|erlotinib|
214894676|NCT00116506|DRUG|FOLFOX|
214894677|NCT00116506|DRUG|bevacizumab|
214894678|NCT02423200|DRUG|VX-745|Orally-active P38 MAP kinase alpha-selective inhibitor
214894679|NCT03565900|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose.
215051048|NCT06073678|OTHER|Protection with surgical dressing|Protection of the palatal wound with surgical dressing for 7 days
215051049|NCT06292819|DEVICE|Bright light|Bright light will use a 5000-10,000 Lux LED light source. Exposure is for 60 minutes daily, between 7pm and 9pm.
215051050|NCT06292819|DEVICE|Near-infrared light|Near-infrared light will use a wavelength of 850nm and a dose range of 1 - 6.5 joules/cm2. It is fixed on the neck with a band, the light source contacts the back of the neck, and is used for 60 minutes before going to bed.
214668832|NCT06970002|DEVICE|Use of HFNC during FOB as a respiratory support method|The aim of this project is to assess the safety, indications and contrindications to perform bronchofiberoscopy for diagnostic purposes in patient with chronic respiratory acidosis with the use of Non-invasive Ventilation (NIV) and High Flow Nasal Cannula (HNFC). In addition we want to determine the extent to which the usage of respiratory support during bronchofiberoscopy (BF) will help to avoid complications such as hypoxemia, decompensation of chronic respiratory failure, deterioration of gas exchange and hemodynamic instability, as well as intubation.
214894680|NCT03565900|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
214894681|NCT03565900|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
214894682|NCT04775160|DEVICE|SmartSafe|"The SmartSafe Ecological Momentary Intervention is contained in the MEmind smartphone application and consists of a Safety plan, an Enhanced contact via app (app-EC) intervention, and a mental toolbox. The Safety plan is a set of personalized coping strategies that the patient can use in a suicidal crisis. Our safety plan was adapted to a digital environment, including the possibility to activate pre-recorded messages, lead to websites with health resources, or put the patient in contact with the emergency services. The Enhanced contact via app (app-EC) intervention is inspired by the SIAM project and consists in messages that will be sent via the MEmind app inquiring patients about their mental well-being and informing them of the means to request preferential or urgent care. The mental toolbox contains videos relaxation techniques videos and behavioral activation and mentalization exercises."
214894683|NCT01999920|DRUG|Vilazodone|10mg to 40mg per day for 12 weeks
214894684|NCT01999920|DRUG|Placebo|One to two pills per day for 12 weeks
214894685|NCT00364767|DIETARY_SUPPLEMENT|A|Alcohol consumption (32 g/day) for 4 weeks
214894686|NCT00364767|DIETARY_SUPPLEMENT|B|Water
214894687|NCT02892630|OTHER|No intervention|
214894688|NCT00343525|DRUG|bavituximab|
214894689|NCT03617666|DRUG|Avelumab|Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.
214894690|NCT02719886|DEVICE|Ultrasound|Estimation of fetal weight by ultrasound
214894691|NCT00620386|DEVICE|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
214894692|NCT00620386|DEVICE|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
215051051|NCT06292819|DEVICE|Bright light+ near-infrared light|After using the bright light device, then use the near-infrared light device on the back of the neck before going to bed.
215051052|NCT02112656|DRUG|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
214668833|NCT06382194|OTHER|Decision aid|The intervention is a newly developed decision aid designed to guide decisions about storage of firearms among older gun owners with early dementia and/or depression.
214894693|NCT03805386|DRUG|Physician directed opioid prescribing|Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
214894694|NCT03805386|DRUG|Patient directed opioid prescribing|Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
214894695|NCT01722630|DRUG|Dopamine|
214894696|NCT02851784|BIOLOGICAL|adoptive immunotherapy|HCC (D ≤5 cm, fewer than three tumors) patients were treated with radical MWA and 4-6 courses of immunotherapy with CIK every year.The immunotherapy were started at 2 weeks, 4 weeks, 6 weeks, 10 weeks, 14 weeks, 18 weeks and then every 12 weeks after MWA. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed DCs and effector cells. DC-CIK and CTL were injected into the abdominal cavity. CIK was infused intravenously.
214894697|NCT02851784|PROCEDURE|MWA|ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up
214894698|NCT06581510|PROCEDURE|esthetic dental crowns|Minimal Preparation of esthetic dental crown
214894699|NCT06581510|PROCEDURE|control group|Nuu smile ready-made zirconia crown with its well-known reduction
214894700|NCT04937881|DRUG|Tenofovir alafenamide|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)
214894701|NCT04937881|DRUG|Tenofovir Disoproxil Fumarate|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)
214894702|NCT05857683|PROCEDURE|cextension pin block|this is the technique for mallet finger where 2 pins are used, one for the extension block and other intramedullary for the extension posture
214894703|NCT05857683|PROCEDURE|pin orthosis- extension block pin|this is the technique for mallet finger where only 1 pin is used for extension block and an orthosis is applied for the extension posture
214894704|NCT02771873|BEHAVIORAL|Integrated cardiovascular disease risk management.|Health promotion intervention
215051053|NCT02112656|DRUG|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
215051054|NCT06622044|OTHER|Vision therapy group|accommodation and vergence exercise
215051055|NCT06622044|OTHER|Prism|wearing prism glasses
215051056|NCT06675461|BEHAVIORAL|Gold Card Intervention|A 4-session manualized intervention consisting of weekly scheduled 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support.
215051057|NCT06675461|BEHAVIORAL|Treatment as usual|Access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
215057425|NCT05402215|BEHAVIORAL|The flipped classroom model was used to teach students' clinical practice skills.|Videos for clinical applications have been prepared by researchers. These prepared videos were shared with the students in the experimental group one week before the lesson day of each application for preliminary study and the students were asked to work on these videos. On the day of the lesson, group work, question-answer and discussion activities were held with the students in the classroom environment. At the end of the lesson, the students were asked to do the applications on the simulation models of the application and the checklists were filled.
214894705|NCT04762667|PROCEDURE|reverse shoulder arthroplasty|"In our work, all patients are performs MSCT of the shoulder joint. The construction of a 3D model is carried out using the obtained data. Taking into account the individual features of the bone structure of the shoulder joint, images of the pilot wire guides, fixing screws and a resection template for the humerus are created. Holes for fixing spokes for the planned structures are also calculated.~Using a 3D printer, models of guides and a resection template are printed. During the reverse shoulder arthropalsty, instead of a standard guide, patient-specific instrumentation are used.~In the early postoperative period, all patients are performs MSCT of the shoulder joint. The obtained data are compared with the results of MSCT of the shoulder joints of patients previously operated on using the standard technique."
214894706|NCT03877835|PROCEDURE|Peripheral nerve blocks|LSIB + SSNB
214894707|NCT04512664|OTHER|cold application|cold application with gel pacs
214894708|NCT04196283|DRUG|ABBV-368|Intravenous (IV) infusion
214894709|NCT04196283|DRUG|Tilsotolimod|Intratumoral (IT) injection
214894710|NCT04196283|DRUG|Nab-paclitaxel|Intravenous (IV) infusion
214894711|NCT04196283|DRUG|ABBV-181|Intravenous (IV) infusion
214894712|NCT04998565|OTHER|Routine care|Reverse pressure applied to the areola
215051058|NCT06681649|BEHAVIORAL|Intervention|"The intervention group will receive follow-up care through the specialized post-ICU follow-up clinic at KHSC at approximately 1- and 3-months following ICU discharge. Caregivers will also be invited to participate in the follow-up clinic along with the ICU survivor participant.~In addition to receiving specialized follow-up clinical care, ICU survivor participants and their caregivers will also receive the following additional items as part of a bundled care intervention program (see Appendix):~* Informational pamphlet on critical illness and expectations following ICU discharge~* Flyer on critical illness and expectations following ICU discharge (brief version, which may be placed on the participant's refrigerator or other location at home as a consistent reminder)~* Diaries in which the healthcare team, family members, and the patient themselves are able to journal their experiences, updates, progress, and barriers in the ICU and following discharge"
215051059|NCT04486040|PROCEDURE|Drainage|Use of the suction drainage after hip revision arthroplasty
215051060|NCT04486040|PROCEDURE|No-drainage|Patients without drainage after surgery
215051061|NCT06324656|PROCEDURE|crystallized phenol + platelet rich plasma application|"At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.~For enhanced healing, crystallized phenol + platelet-rich plasma application patients will receive platelet-rich plasma injections to minimize infection risk and promote tissue regeneration, all under strict sterilization to maintain cleanliness and efficacy."
214296454|NCT04415255|OTHER|EABPI plus IABPI|If the patient was assigned to EPABI plus IABPI, while the extrapleural space was reached, \~ 15 ml of autologous blood was injected at the extrapleural space through the coaxial needle. Then the central stylet was reinserted and the coaxial needle was advanced into the lung parenchyma with a single puncture. The needle was stopped inside the proximal part of the target and the center needle was removed. A 20-G/16 cm fully-automated biopsy needle was introduced through the 19-G/13.8 cm coaxial needle and specimens were identically obtained. After specimens were collected, the biopsy needle was removed, and immediately the remaining autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
214668834|NCT06572267|DRUG|Mepolizumab low dose group|Meperizumab (0.05 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
214894713|NCT04998565|PROCEDURE|Electrical Acupuncture|Acupuncture on Hegu, Sanyinjiao, Zusanli and Taichong with electrical stimulation
214894714|NCT04998565|PROCEDURE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation over bil breasts
215057426|NCT05402215|BEHAVIORAL|control group|To the students in the control group, the application was explained by the researcher (instructor conducting the course) using presentation and demonstration methods. Each application was made on different days. The prepared checklists were filled by the other researcher.
214296455|NCT04415255|OTHER|IABPI-alone|If the patient was assigned to IABPI-alone, after collecting the biopsy specimens, immediately the autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
214894715|NCT01108172|OTHER|Virtual Ward|A multidisciplinary team to optimize medical and social care for patients residing in their own homes
214894716|NCT01108172|OTHER|Usual care|The usual care provided to patients after discharge from hospital
214894717|NCT01589458|DRUG|Toothpaste|1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
214894718|NCT00300807|DRUG|XTL 6865|
214894719|NCT00446693|DEVICE|EndoFast Reliant™ system for Pelvic Organ Prolapse repair|The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
214894720|NCT03976271|PROCEDURE|hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp|For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia. This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
214894721|NCT02764671|BIOLOGICAL|10μg/0.5ml recombinant hepatitis B vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
214894722|NCT03239093|OTHER|No intervention|Observational study using official data from the Federal Office of Statistics
214894723|NCT00815880|DEVICE|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
214894724|NCT04655560|OTHER|no intervention|qualitative study
214894725|NCT03246451|DRUG|Placebo Oral Tablet|2-4 tablets in 14 days
214894726|NCT03246451|DRUG|Metformin|1000-2000 mg in 14 days
214894727|NCT03246451|DRUG|Saline|9 mg/ml saline infusion during experimental days
214894728|NCT03246451|DRUG|Exendin (9-39)|Infusion of GLP-1 receptor antagonist used as a tool during experimental days
214894729|NCT02343653|BEHAVIORAL|Nutrition and strength training|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.~The intervention group will receive supervised training."
214894730|NCT02343653|BEHAVIORAL|Nutrition|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered."
214894731|NCT03383965|BIOLOGICAL|ICAR30 T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
214894732|NCT01375062|OTHER|analyse and proliferate the cells|"1. Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.~2. Digestion of the biopsies through controlled enzymes~3. Replication of the cells~4. Selection undifferentiated cells~5. Expansion of the purification cells population~6. Characterization of the cell population~7. Assessment of pluripotent and germinal cell potential.~8. Possible maturation of the cells."
214894733|NCT01601418|DRUG|YF476|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
214894734|NCT01601418|DRUG|Placebo|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
214894735|NCT00246818|PROCEDURE|Tai Chi Chuan|
214894736|NCT04688437|RADIATION|standard standing-sitting posteroanterior and lateral whole spine X-ray and lumbar MRI examination|Routine examination
214894737|NCT03224728|DEVICE|intraocular lens|
214894738|NCT02101944|DRUG|Carfilzomib|Given IV
214894739|NCT02101944|DRUG|Dexamethasone|Given IV
214894740|NCT02101944|OTHER|Laboratory Biomarker Analysis|Correlative studies
214894741|NCT02101944|BIOLOGICAL|Pelareorep|Given IV
214894742|NCT00245466|DRUG|Degarelix|Given as a subcutaneous injection once every 4 weeks.
214296456|NCT03874897|DRUG|CAR-CLDN18.2 T-Cells|"Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2"
214668835|NCT06572267|DRUG|Mepolizumab middle dose group|Meperizumab (0.1 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
214668836|NCT06572267|DRUG|Mepolizumab high dose group|Meperizumab (0.2 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
214668837|NCT06572267|DRUG|Saline|Intravenous infusion of saline 100 mL shall be completed within 30 to 60 min.
214668838|NCT02605525|BIOLOGICAL|SM101|Human soluble recombinant Fcγ Receptor IIB
214668839|NCT02605525|OTHER|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
214668840|NCT00876642|DRUG|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
214668841|NCT05502497|OTHER|Observational|No application will be made to the control group.
214894743|NCT00245466|DRUG|Degarelix|Given as a subcutaneous injection once every 4 weeks.
214894744|NCT00245466|DRUG|Degarelix|Given as a subcutaneous injection once every 4 weeks.
214894745|NCT01144065|PROCEDURE|Hair sampling for the measurement of cortisol and testosterone|Hair sampling for the measurement of cortisol and testosterone
214894746|NCT02150226|DEVICE|Lava plus (3M) crowns and bridges|Zirconia monolithic dental crowns and bridges evaluation
214894747|NCT03671161|DEVICE|Insulin Pump and flash glucose monitoring|Adults with type 1 diabetes, HbA1c \>9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.
214894748|NCT05112081|DRUG|Botulinum toxin type A|The group will receive a solution of 100 units BTX with 10 ml sterile saline close to the superficial inguinal ring.
214894749|NCT05112081|OTHER|Sterile saline|The group will receive a solution of 10 ml sterile saline close to the superficial inguinal ring.
214894750|NCT01958437|DEVICE|Transcranial direct current stimulation (tDCS)|Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
214894751|NCT03469635|OTHER|Nutritional deficiencies in pregnant women after bariatric surgery|compare maternal nutritional parameters and neonatal outcomes after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) and to assess the impact of nutritional alterations on fetal growth.
214894752|NCT05115851|OTHER|Anodal tDCS cerebellar stimulation group|three-session ctDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
214894753|NCT05115851|OTHER|Anodal tDCS cerebral (M1) stimulation group|three-session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
214668842|NCT05502497|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
214894754|NCT05115851|OTHER|Sham Group|three-session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
214894755|NCT04408729|OTHER|PrEP My Way|"Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, and 6 via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 6 and as needed (e.g., treatment for positive tests).~This intervention aims to increase adherence/persistence on PrEP. We hypothesize that removing the structural barriers and stigma associated with going to the clinic, women may be more likely to continue on PrEP."
214894756|NCT05048901|DRUG|Cabozantinib|Oral Cabozantinib 40-60 mg daily .every 4 weeks as a cycle
214894757|NCT05048901|DRUG|Lanreotide|Lanreotide 120 mg deep SC on day 1 every 4 weeks.every 4 weeks as a cycle
214894758|NCT06273319|DRUG|OXYGEN THERAPY|15 AND 30 LT OXYGEN TREATMENT
214894759|NCT04886596|BIOLOGICAL|Placebo|Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV\_1 dose group.
214894760|NCT04886596|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV\_annual group.
214894761|NCT00751062|DRUG|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
214894762|NCT00751062|DRUG|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
214296457|NCT03874897|DRUG|PD-1 Monoclonal Antibody|Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1
214296458|NCT03874897|DRUG|Chemotherapy|First-line systemic therapy according to physician's choice
214296459|NCT03817177|PROCEDURE|high flow nasal cannula oxygenation|high flow nasal cannula application in PACU
214296460|NCT03817177|PROCEDURE|nasal prong|conventional nasal prong application in PACU
214296461|NCT04192877|DIAGNOSTIC_TEST|Vagus Nerve Neurodynamic test|The VN-NDT has been developed starting from the VN morphology selecting the physiological movements that induce the greater mechanical tension on the nerve. The subjects will be assessed supine on an examination table with assessors standing at the cranial short side of the table. Upper cervical flexion and contralateral lateral flexion had been selected for loading the intracranial portion. The ipsilateral neck rotation had been selected for loading the cervical tract. Keeping the subject's head in the final movements combination gentle movements of the upper abdomen caudally and cranially had been selected for loading the thoracic tract and used as discrimination maneuver. The test will be declared positive (indicating abnormal responses) if symptoms will be felt in anatomical regions other than the neck on the same side of the test and discrimination maneuvers changed the subject's symptoms indicating a neurogenic source, otherwise it will be declared negative.
214296462|NCT00480597|DRUG|gemcitabine|
214296463|NCT00480597|DRUG|cisplatin|
214296464|NCT00480597|DRUG|vinorelbine|
214296465|NCT00480597|DRUG|capecitabine|
214296466|NCT03165279|PROCEDURE|Zenith Alpha Abdominal stentgraft|
214296467|NCT05522101|DEVICE|Mini-sized MCE|AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480\*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application
214296468|NCT05522101|DEVICE|Normal-sized MCE|Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340\*340, working time is not less than 8 hours.
214296469|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
214296470|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
214296471|NCT05540301|OTHER|Modified sleeper stretching|Modified sleeper stretching was performed on shoulder joint to increase internal rotation range of motion.
214296472|NCT05540301|OTHER|Modified cross-body adduction stretch|Modified cross-body adduction stretching was performed on shoulder joint to increase internal rotation range of motion.
214296473|NCT06230068|OTHER|Expressive writing|See description under arm/group description.
214296474|NCT04938557|DEVICE|Automated closed-loop insulin delivery (AiD)|Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.
214296475|NCT04938557|DEVICE|A standard insulin delivery system|Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.
214296476|NCT04880512|DRUG|SYHX 1901 tablets|SYHX 1901, oral tablets, in fasted state
214296477|NCT04880512|DRUG|Placebo|Matching placebo, oral tablets, in fasted state
214296478|NCT03909412|DRUG|Carfilzomib|Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
214296479|NCT03909412|DRUG|Cyclophosphamide|Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
214296480|NCT03909412|DRUG|Dexamethasone|Dexamethasone 40mg IV/PO to be administered as a premedication.
214296481|NCT03909412|DRUG|Granulocyte Colony-Stimulating Factor|On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
214668843|NCT00676507|BIOLOGICAL|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
215051062|NCT06324656|PROCEDURE|crystallized phenol|At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.
215051063|NCT05342298|OTHER|prediction model|Data will be pre-processed prior to final analysis, including data cleaning, imputation of missing values, dimensionality reduction, and removal of outliers. Data will be utilized as Xi and Yi where Xi presents input (features) and Yi presents dependent variables (outcomes). Different classification algorithms will be tested for accuracy to build the final model including logistic regression, SVM, XGboost and random forest algorithms. Data will be split at 0.8:0.2 for model training and testing, respectively.
215051064|NCT06625528|BIOLOGICAL|open flap debridement|does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not
215051065|NCT06685198|PROCEDURE|Titrated administration of propofol to an OAA/S score of 1 as the endpoint|Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 1, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
214296482|NCT05735392|OTHER|Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.|Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.
214668844|NCT00676507|OTHER|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
214668845|NCT04468477|DEVICE|6 Lead ECG|Patients will be assessed with the Kardiamobile device.
214894763|NCT04283630|DIETARY_SUPPLEMENT|Dietary nitrate in the form of beetroot juice for all participnats|participants asked to consume dietary nitrate in the form of beet juice everyday in the morning and then one hour later, the vitamin C capsules.
214894764|NCT04283630|DIETARY_SUPPLEMENT|Nature Made vitamin c 1000 mg|vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the daily vitamin C supplement (1000 mg) or placebo one-hour post beetroot juice supplementation.
215051066|NCT06685198|PROCEDURE|Titrated administration of propofol to an OAA/S score of 2 as the endpoint|Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 2, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
215051067|NCT06685198|PROCEDURE|Titrated administration of propofol to a BIS value ≤ 60 as the endpoint|Propofol is titrated at a rate of 0.5 mg/kg/min to achieve a BIS value ≤ 60, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
214296483|NCT04025307|DRUG|bacTRL-IL-12|bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
214296484|NCT04698720|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot).The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds.The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
214668846|NCT03569267|DRUG|OLX10010|A cell penetrating asymmetric siRNA (cp asiRNA)
214668847|NCT03569267|DRUG|Placebo|Placebo
215051068|NCT04576494|OTHER|Monthly assessments of functional motor abilities by a trained therapist|Monthly assessments of functional motor abilities in adult 5q-SMA type 2 and type 3 patients by a trained therapist
214668848|NCT00351715|DRUG|Sublingual Methadone|
214894765|NCT04283630|DIETARY_SUPPLEMENT|Placebo|Vitamin C matched Placebo capsules that made from starch.
214894766|NCT00981812|PROCEDURE|PEM Breast Biopsy|Breast biopsy using PEM guidance and Stereo Navigator software
214894767|NCT04933695|DRUG|Sotorasib|Oral tablet
214894768|NCT03702127|DEVICE|Transcranial magnetic stimulation|NIBS is applied to the brain.
214894769|NCT00948155|DRUG|Varenicline|Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
214894770|NCT06345911|BEHAVIORAL|Experimental group|The animal characters were shown to the child before the bloodletting procedure. The child was asked to choose one of them and the one chosen by the child was attached to the vacutainer. The child and their parents were taken to the blood collection room. During the bloodletting procedure, the child was asked to focus on the animal character they had chosen.
215051069|NCT04576494|DRUG|Nusinersen|nusinersen
215051070|NCT06159907|DIAGNOSTIC_TEST|the diagnostic and prognostic value of PET/MRI and PET/CT with 18F-FDG in patients presenting with gynecological tumors|"For the evaluation of patients affected by endometrial cancer, the correlations between semi-quantitative PET parameters (SUVmax, SUVmean, MTV and TLG calculated at different SUVmax thresholds) and histological data, such as for example myometrial invasion, will be investigated. lymph node invasion, tumor grade and type, risk level, probability of mutation of the p53 gene, etc.~In addition to traditional imaging parameters we will also investigate the usefulness of radiomic features, i.e. quantitative data extracted from PET images (PET/CT or PET/MRI), in predicting and explaining histological data"
214296485|NCT04698720|BEHAVIORAL|Hypnosis with Guided Imagery|"In the beginning of the first session we apply the Eye-Roll Test for Hypnotizability of Herbert Spiegel. Each session follows the Hypnotic Protocol with the following steps:Pre-talk/Absortion/Ratification/Aliciation/Dissociation/Awakening.~The four sessions train the participants in visual, auditory and kinesthetic perception on ulcer healing. The protocol also promotes medical treatment acceptance."
215051071|NCT01938261|DRUG|paracetamol|
214668849|NCT00828451|BIOLOGICAL|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
214668850|NCT03883061|OTHER|regular medical treatment|regular medical treatment
214668851|NCT00424307|DEVICE|HiResolution Bionic Ear System|
214894771|NCT05623501|DRUG|Dihydromyricetin|Dose-escalation and lysine preparation
214894772|NCT05215951|DRUG|osimertinib|Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration
214894773|NCT02406690|OTHER|Estradiol Valerate, Progesterone in Oil, Leuprolide|Patients will undergo a Leuprolide endometrial preparatory cycle using estradiol valerate, progesterone in oil and once completed will have a uterine aspiration and biopsy performed.
214894774|NCT02465905|OTHER|raw milk|
214894775|NCT02465905|OTHER|Heated milk|
214894776|NCT04610190|DEVICE|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
214894777|NCT02418884|DRUG|rosuvastatin|CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
214894778|NCT04620746|DRUG|Penicillin Major Determinant (PrePen) Skin Testing|Skin testing followed by oral challenge with amoxicillin 250 mg single dose
214894779|NCT04620746|DRUG|Direct Oral challenge|Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose
214894780|NCT01754155|RADIATION|RSA images|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
214894781|NCT03473925|DRUG|Navarixin|Oral capsules
214894782|NCT03473925|BIOLOGICAL|Pembrolizumab|Intravenous infusion
215051072|NCT01938261|DRUG|0.45 % saline solution|Placebo
214668852|NCT03721328|COMBINATION_PRODUCT|vancomycin hydrochloride and tobramycin sulfate|vancomycin hydrochloride and tobramycin sulfate via local irrigation
214668853|NCT02604966|DRUG|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
214668854|NCT02604966|DRUG|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
214894783|NCT01559077|DRUG|ALN-TTR02|Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
214894784|NCT01559077|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
215051073|NCT06037564|DRUG|DOR/DTG/3TC|Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
214296486|NCT04698720|BEHAVIORAL|Neutral Guided Imagery|This placebo consists of neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends, and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, positive or negative, which occurred before patient has the current DFU. Then, the patient is asked about a number of questions regarding the chosen episode in order to promote a more detailed reconstruction of the event. The patient is asked to imagine according to the instructions given by the Psychologist. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered regarding each of the questions.
214668855|NCT03191175|OTHER|blood sample|47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
214668856|NCT03852225|DIAGNOSTIC_TEST|Intra-arrest echocardiography|Intra-arrest echocardiography performed by portable ultrasound device during ongoing chest compressions.
214894785|NCT02614326|BEHAVIORAL|Autobiographical Memory Flexibility (MemFlex) training|As in experimental arm description
214894786|NCT02614326|BEHAVIORAL|Psychoeducation|As in experimental arm description
214894787|NCT06823349|DRUG|Dexmedetomidine|5 mic dexmedetomidine will be given intrathecally added to 2.5 mg bupivacaine
214296487|NCT01846507|DRUG|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
215051074|NCT03761056|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
214296488|NCT00649701|BEHAVIORAL|Standard Text-Based Prevention Web Page|A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
214296489|NCT00649701|BEHAVIORAL|The Morning After|A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
215051075|NCT03761056|DRUG|Fludarabine|Administered according to package insert
214296490|NCT00649701|BEHAVIORAL|Talking About HIV|A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
214296491|NCT00649701|BEHAVIORAL|Both Videos|Morning After and Talking About HIV videos
214296492|NCT00350714|OTHER|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
214296493|NCT01428089|DRUG|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
214296494|NCT01428089|DRUG|Placebo|Placebo
214296495|NCT00450450|PROCEDURE|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
214296496|NCT00450450|OTHER|laboratory biomarker analysis|Correlative studies
214296497|NCT00450450|BIOLOGICAL|filgrastim|Given IV
214296498|NCT00989794|DEVICE|GelrinC|Applied once during surgery
214296499|NCT04984993|DEVICE|MED3000 (Male)|Gel formulation
214296500|NCT04984993|DRUG|Tadalafil 5mg (Male)|Tablets
214296501|NCT04984993|DEVICE|MED3000 (Female)|Gel formulation
214296502|NCT04984993|DRUG|Tadalafil 5mg (Female)|Tablets
214668857|NCT05899725|DRUG|Corticosteroids|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
214668858|NCT05899725|DRUG|Corticosteroids and Ruxolitinib|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
214894788|NCT06823349|DRUG|fentanyl|25 mic of fentanyl will be given intrathecally added to 2.5 mg bupivacaine
214894789|NCT06823349|DRUG|Saline 0.9%|0.5 ml of saline 0.9% will be given intrathecally added to 2.5 mg of bupivacaine
215051076|NCT03761056|DRUG|Cyclophosphamide|Administered according to package insert
215051077|NCT03493139|BEHAVIORAL|Physical Activity Across the Curriculum|Activity breaks will be designed for delivery in the classroom without reconfiguration of the classroom space. Activities will emphasize whole body movements, using large muscle groups. Each break includes multiple activities. Each activity lasts about 2 minutes. There will be a total of about 20 minutes of physical activity done each school day.
214894790|NCT02691234|DEVICE|Extracorporeal Shockwave Therapy and debridement|
214894791|NCT02691234|OTHER|debridement and cleaning|
214894792|NCT03411863|DEVICE|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
214894793|NCT03411863|DEVICE|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
214894794|NCT06492109|BEHAVIORAL|Sleep manipulation|"This study will collect the MMSE results as a supplement to the MoCA. The sleep status of subjects will be screened using the Morningness-Eveningness Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS).~Subjects must maintain regular sleep and diet before sample collection. Peripheral blood samples will be taken the day before, the day of, and the day after acute sleep deprivation, whether experimentally induced (controlled) or naturally occurring (passive), along with assessment scales including anxiety and depression assessments.~For chronic sleep deprivation (≥7 days), blood samples will be collected before and after the deprivation period, with anxiety, depression, and cognitive assessments.~Experimentally induced sleep deprivation takes place under controlled laboratory conditions, whereas passive sleep deprivation arises from external factors such as aging or shift work."
214296503|NCT00963287|DRUG|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
214296504|NCT02402309|DRUG|Active topical NS2 1% dermatologic cream|
214296505|NCT02402309|DRUG|Vehicle placebo 0.0% NS2 dermatologic cream|
214894795|NCT04244461|BEHAVIORAL|Personalized Normative Feedback|The personalized normative feedback (PNF) focuses on behavioral norms, where participants see (1) how their perceptions compare to other same-gender veterans' actual drinking and (2) how their actual drinking compares to other same-gender veterans' actual drinking. The format of the intervention highlights typical days per week, drinks per occasion, and binge drinking as per traditional PNF interventions. PNF will also contain a video description of theories of normative influence (e.g., how individuals are affected by perceptions) and a description of the normative data sample. Participants also see enhanced PNF content that will focus on sharing with participants treatment information that the investigators obtained from a pilot sample.
214894796|NCT04584502|BEHAVIORAL|Mindful Moms Yoga Mindfulness Intervention|MMORE is an 8-session yoga-mindfulness intervention protocol, offered via Zoom over the course of 10 consecutive weeks at the partner maternity care practice or a nearby location. Each session will last approximately 60 minutes (8 - 10 participants per group). Intervention participants will also be asked to use a mobile companion app at least once each week of the intervention period.
214894797|NCT04852406|DRUG|Protocol-based management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.
214894798|NCT04852406|DRUG|Routine management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to current routine practice.
215051078|NCT06629688|DRUG|semaglutide|Patient demographic and clinical data was collected and entered into a database made specifically for the study. The patients were examined, and their vital signs and body measures were recorded. Before the introduction of semaglutide therapy all participants completed an oral absorption iron test (OIAT). As described in previous studies, OIAT was conducted in an outpatient setting. Following the initial OIAT therapy with semaglutide was started. Each subject received parenterally administered one-weekly semaglutide. To enhance glycaemic control, the therapy was up-titrated every four weeks. Initially, the dose was set at 0.25 mg once a week, four weeks later, it was raised to 0.5 mg once weekly, and four weeks after that, it was increased to 1 mg once weekly. After reaching the maximum maintenance dosage of 1 mg for two weeks, each T2DM patient completed a follow-up OIAT at week 10 of the study. Data from the first and subsequent OIATs were analysed statistically.
215051079|NCT06691126|OTHER|Terpinolene in olive oil|Single oral dose of 200mg food-grade terpinolene in 5ml of olive oil
215051080|NCT06717022|BIOLOGICAL|CHT102 allogeneic CAR T cells|CHT102 allogeneic CAR T cells
215051081|NCT06717035|DEVICE|EYE001|Defocus incorporated multiple segments (DIMS) clear vs DIMS photochromic
215051082|NCT06706167|DEVICE|stainless steel crown|Participants in this arm received a stainless steel crown for primary teeth restoration. The crowns were selected based on the clinical assessment of the patient's dental need.
215051083|NCT06706167|DEVICE|Zirconia crown|Participants in this arm received a zirconia crown for primary teeth restoration. The crowns were selected to provide a more aesthetic and durable option compared to stainless steel.
215051084|NCT06706167|DEVICE|Bioflx crown|Participants in this arm received a Bioflx crown, which is a flexible, biocompatible material often used for pediatric crowns.
215051085|NCT06712095|DEVICE|Video capsule investigation|Participants will undergo both a video capsule examination and a colonoscopy on the same day.
215051086|NCT06714721|DEVICE|Repetitive peripheral magnetic stimulation|"Repetitive peripheral magnetic stimulation treatment will be performed with the BTL-6000 Super Inductive System Elite available in our clinic. rPMS treatment will be adjusted to use the stimulus intensity above the motor threshold determined specifically for each patient by selecting the respiratory muscle strengthening protocol set in the device menu. The patient will be given a side-lying position, with the arms in front of the body and the elbows flexed, and the hips and knees in semiflexion. The applicator will be aligned to the diaphragm placement determined by ultrasonography (ninth intercostal space) and placed as close as possible to the skin, and rPMS will be applied for a total of 16 minutes, 8 minutes to the right diaphragm muscle and 8 minutes to the left diaphragm muscle. The treatment period is a total of 16 sessions according to the respiratory muscle strengthening protocol created by the company that developed the device."
214894799|NCT02777372|DRUG|Sertraline|Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine luteinizing hormone (LH) Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
214296506|NCT02360956|DRUG|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
214296507|NCT02360956|DRUG|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
214296508|NCT05707078|PROCEDURE|Neck dissection|Based on PET/CT scan patients will undergo neck dissection.
214296509|NCT06228378|OTHER|Raman microspectroscopy|Raman microspectroscopy is a non-destructive method for observing and characterising the molecular composition and external structure of a biological sample based on the phenomenon of inelastic light scattering (Raman effect).
214296510|NCT02865187|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 600IU/day
214894800|NCT06262204|PROCEDURE|Hallux Valgus Treatment with Shark Screw®|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
214894801|NCT06262204|PROCEDURE|Hallux Valgus Treatment with metal screw|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
214894802|NCT04661150|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 3 cycles prior to surgery and 5 cycles after surgery.
215051087|NCT06714721|OTHER|Sham (No Treatment)|rPMS will be applied to the sham group as sham and the device will not be operated, the applicator of the device will be positioned on the right and left diaphragm muscle for a total of 16 minutes in the same way as the patients in the treatment group, and the sounds recorded during the operation of the device will be played to the patients as if the device was operating in the background. The patients will not know which group they are in.
215051088|NCT06714981|DRUG|Opioid Free Anaesthesia|patients received opioid free anesthesia
215051089|NCT06714981|DRUG|Opioid based Anesthesia|patients received opioid based anesthesia
215051090|NCT06716372|DEVICE|DSiHy Silicone Hydrogel Soft Contact Lens|The daily wear, daily disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
215051091|NCT06716372|DEVICE|Daily Silicone Hydrogel Contact Lenses (oB)|The daily wear, daily disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
214296511|NCT02865187|DRUG|Hormonal contraception|Hormonal contraceptives
214296512|NCT00001054|DRUG|Valacyclovir hydrochloride|
214296513|NCT04751344|DRUG|Liposomal bupivacaine|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
214894803|NCT04661150|DRUG|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
214894804|NCT04661150|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.
214296514|NCT04751344|DRUG|Bupivacaine HCl|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
214296515|NCT04667520|BEHAVIORAL|Lifestyle Physical Activity (LPA)|This intervention has 3 components: (1) an orientation session to LPA and using the Fitbit; (2) Six telephone physical activity counseling sessions; and (3) monitoring activity with the Fitbit, which is provided to them during their study participation.
214296516|NCT04667520|BEHAVIORAL|Fitbit Only|Participants are provided with a Fitbit during their study participation.
214296517|NCT00067366|BEHAVIORAL|Cognitive-Behavioral treatment|Cognitive-Behavioral skills training for chronic pain
214894805|NCT04661150|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 will be administered by IV on Day 1 of a 21-day cycle.
215051092|NCT06717490|DRUG|Magnesium sulphate|"In patients allocated to the MS group, a fixed dose of magnesium sulfate diluted in a fixed volume of natural saline will be administered intravenously.~Thromboelastometry will be performed pre and post magnesium administration."
215051093|NCT06717490|OTHER|Placebo Drug|"In patients allocated to the NS group, a fixed dose of natural saline will be administered intravenously, through a fixed volume of solution.~Thromboelastometry will be performed pre and post magnesium administration."
215051094|NCT06719479|BIOLOGICAL|IAE0972+ Methotrexate|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Methotrexate is used according to the instructions.
214296518|NCT00067366|BEHAVIORAL|Attention and lifestyle counseling|Attention and lifestyle counseling added to Standard Care
214894806|NCT06362421|GENETIC|Pre-Radiation Dental Evaluation/Sample Collection|Collection of saliva samples and mouth swabs and pre-cancer dental evaluation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)
214894807|NCT06362421|OTHER|Pre-Study Visit|Collection of vital signs, medical history and current medications
215051095|NCT06719479|BIOLOGICAL|IAE0972+Docetaxel|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Docetaxel is used according to the instructions.
214894808|NCT06362421|GENETIC|Oral Medicine Consultation Visit/Sample Collection|Collection of saliva samples and mouth swab, complete oral medicine consultation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)
214894809|NCT04157595|OTHER|Reproductive Genetic Carrier Screening|Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
214894810|NCT00100828|DRUG|irinotecan hydrochloride|
214894811|NCT00857571|DRUG|150 mg Suspension|Single oral dose of 150 mg of PF-02413873 suspension
214894812|NCT00857571|DRUG|30 mg Suspension|Single oral dose of 30 mg of PF-02413873 suspension
214894813|NCT00857571|DRUG|400 mg Suspension|Single oral dose of 400 mg of PF-02413873 suspension
214894814|NCT00857571|DRUG|5 mg Suspension|Single oral dose of 5 mg of PF-02413873 suspension
214894815|NCT00857571|DRUG|750 mg Suspension|Single oral dose of 750 mg of PF-02413873 suspension
214894816|NCT00857571|DRUG|150 mg Tablet|Single oral dose of 150 mg of PF-02413873 tablets
214894817|NCT00857571|DRUG|30 mg Tablet|Single oral dose of 30 mg of PF-02413873 tablets
214894818|NCT00857571|DRUG|400 mg Tablet|Single oral dose of 400 mg of PF-02413873 tablets
214894819|NCT00857571|DRUG|5 mg Tablet|Single oral dose of 5 mg of PF-02413873 tablets
214894820|NCT00857571|DRUG|750 mg Tablet|Single oral dose of 750 mg of PF-02413873 tablets
215051096|NCT06719479|BIOLOGICAL|IAE0972+Gemcitabine|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Gemcitabine is used according to the instructions.
215051097|NCT06719479|BIOLOGICAL|IAE0972+Taxanes|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Taxanes is used according to the instructions.
215051098|NCT06719479|BIOLOGICAL|IAE0972+Capecitabine|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Capecitabine is used according to the instructions.
215051099|NCT06710210|DEVICE|PCI with a bioresorbable scaffold and drug-coated balloon(s)|Hybrid PCI combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik AG, Switzerland) and ≥1 paclitaxel-eluting drug-coated balloon(s) (Pantera Lux, Biotronik AG, Switzerland)
215051100|NCT06710210|DEVICE|PCI with drug-eluting stent(s)|PCI with \>1 newer-generation drug-eluting stent (Orsiro Mission, Biotronik AG, Switzerland)
215051101|NCT06716684|BEHAVIORAL|Cognitive-Behavioral Approach Based Psychoeducation Program|A 6 session cognitive-behavioral approach based psychoeducation program developed in line with the literature review is applied in the research. Group training sessions have been held once a week with each session 90 minutes on average. The techniques such as automatic thought recording, finding cognitive errors, thought-stopping, forming alternative thoughts, daydreaming, countdown, problem solving, role playing, modeling, deep breathing, relaxation exercises, summarizing, explaining, informing, homework were used in the sessions.
214894821|NCT00929851|DRUG|CHF1535|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
214894822|NCT00929851|DRUG|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
214894823|NCT01197911|DRUG|aleglitazar|single oral dose
214894824|NCT04548440|DRUG|Sintilimab|Route of administration: Intravenous
214894825|NCT04548440|DRUG|Nab paclitaxel|Route of administration: Intravenously over 30min
214894826|NCT04548440|DRUG|Cisplatin|Route of administration: Intravenous
214894827|NCT05441592|DRUG|Tranexamic acid injection|The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
214894828|NCT05441592|OTHER|No additional irrigation|There will be no additional irrigation after the standard surgical procedure.
214296519|NCT03311958|DRUG|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
214296520|NCT00256373|PROCEDURE|Mod. functional restoration-Individ. dynamic back-muscle|
214296521|NCT00144976|DRUG|Tarceva|Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
214296522|NCT05041504|BEHAVIORAL|Peer navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for prostate cancer via the True North Peer Navigation website. Participants will be matched with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Participants will also have access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer.
214668859|NCT00575679|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
214296523|NCT05041504|OTHER|Active wait list control|Participants in the active wait list control group will receive usual care and access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer. After completion of the study, patients in the active wait list control group will be matched with a peer navigator.
214296524|NCT01412346|OTHER|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
214296525|NCT05069454|BIOLOGICAL|COVID-19 vaccine Observation of individuals who receive the COVID-19 vaccine|To measure the effectiveness of COVID-19 vaccines against symptomatic laboratory-confirmed SARS-CoV-2 infection amongst hospital level health workers eligible for vaccination.
214668860|NCT00364910|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
214668861|NCT00364910|BEHAVIORAL|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
214668862|NCT02200107|BEHAVIORAL|self management education|
214668863|NCT02039388|PROCEDURE|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
214894829|NCT02212314|BEHAVIORAL|Response Inhibition Training|Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
214894830|NCT05248204|DEVICE|Scotchbond™ Universal Plus Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU+ treatment group will undergo restoration with Scotchbond™ Universal Plus Adhesive using self-etch mode and Filtek Universal Restorative
214894831|NCT05248204|DEVICE|Scotchbond™ Universal Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU control group will undergo restoration with Scotchbond™ Universal Adhesive using self-etch mode and Filtek Universal Restorative
214894832|NCT06987513|DRUG|Pemvidutide|Pemvidutide 2.4mg
214894833|NCT06987513|OTHER|Placebo|Subcutaneous injection
214894834|NCT06659263|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
214894835|NCT02286258|DRUG|Calcium EDTA|"Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
214894836|NCT02286258|DRUG|Gd-DOTA|"Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
214894837|NCT02792920|DEVICE|CoCr-EES|
214894838|NCT05330260|DIAGNOSTIC_TEST|neurocognitive test battery|Assessment of the incidence of late postoperative cognitive decline (LPOCD)
214894839|NCT05338931|DRUG|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
214894840|NCT02422134|OTHER|Cytokine group|Testing the efficacy of adding Cytokine to embryo transfer medium
214894841|NCT02020278|DRUG|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period."
214894842|NCT03506256|DRUG|Norfloxacin 400 MG|Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
214894843|NCT02791451|DEVICE|telemonitoring|To predict exacerbation of COPD with wireless telemonitoring
214894844|NCT00920491|BIOLOGICAL|biomarker-enhanced disposition decision with proADM|To compare the outcome of standard of care with an approach combining the standardized course and biomarker levels (biomarker-enhanced disposition decision with proADM) for the disposition of patients with non-specific complaints presenting to the emergency department (ED), in order to evaluate safety.
214894845|NCT00546663|DRUG|inhaled 7% hypertonic saline (HS)|"7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"
214894846|NCT04880486|OTHER|Education|Usual pulmonary rehabilitation education and pharmacological therapies, and taught them some limbs exercise, using social application to contact and suggestion giving as supervision.
214894847|NCT04880486|OTHER|Supervision upper limb weight training exercise with VR|Participant is supervised by physical therapist to conduct upper limb weight training exercise with VR.
214894848|NCT06401135|OTHER|Inspiratory muscle training|IMT will be conducted using a pressure threshold-loading device (POWERbreathe® Classic Low Resistance). The groups will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department. physiotherapist
214894849|NCT01526057|BIOLOGICAL|PF-05280586|1000 mg, IV on days 1 and 15
214894850|NCT01526057|BIOLOGICAL|MabThera|1000 mg, IV on days 1 and 15
214894851|NCT01526057|BIOLOGICAL|Rituxan|1000 mg, IV on days 1 and 15
215051102|NCT06716788|DRUG|68Ga-HSA|68Ga-HSA PET/CT: after intravenous injection of 2.22 MBq/kg body weight of quality-controlled 68Ga-HSA, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
215057427|NCT03072472|DEVICE|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
214296526|NCT00000954|DRUG|Bleomycin sulfate|
214894852|NCT01486225|DEVICE|Innothera's brand Stockings|15 patients having used Innothera branded Stocking
214894853|NCT01486225|OTHER|Stockings other than Innothera's brand|15 patients having used any other brand than Innothera's brand stockings
214894854|NCT01719614|DRUG|Metformin|Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
214894855|NCT01719614|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
214894856|NCT03660995|BEHAVIORAL|Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.|"Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child."
214894857|NCT04386850|DRUG|Oral 25-Hydroxyvitamin D3|Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.
214894858|NCT00571324|DRUG|Exendin-(9-39)|A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
214894859|NCT00571324|OTHER|Vehicle|A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
214894860|NCT06207721|DRUG|Polyethylene Glycols|Polyethylene Glycols syrup (0.7 g/kg daily)
214296527|NCT00000954|DRUG|Vincristine sulfate|
214296528|NCT00000954|DRUG|Doxorubicin hydrochloride|
214296529|NCT00000954|DRUG|Zalcitabine|
214296530|NCT00000954|DRUG|Didanosine|
214296531|NCT03020680|DIETARY_SUPPLEMENT|Coenzyme Q10|To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
214296532|NCT00549523|DRUG|Placebo|Capsules containing 0 mg bid (placebo)
214894861|NCT06207721|OTHER|Physical therapy program|The physical therapy program includes exercises and massage
214894862|NCT00584324|COMBINATION_PRODUCT|BIS 40|"Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
215057428|NCT00243139|DEVICE|Mandibular advancement device (activator)|
215057429|NCT00645840|DRUG|Anakinra|Patients will receive daily anakinra therapy for 28 days
214894863|NCT00584324|COMBINATION_PRODUCT|BIS 60|"Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
215051103|NCT06715137|BEHAVIORAL|Exercise training|Each participant received a personalized rehabilitation schedule combining aerobic interval cycle training and a dynamic strength exercise program, developed to ensure that the participants met the physical activity guidelines. For the aerobic training, the patients cycled for 30-45 minutes on an exercise bike at home 3 times a week. During each training session, the heart rate (HR) was continuously recorded using a chest strap and displayed in a smartphone application. The target HR zones were predefined with alternating intervals of intensive and extensive aerobic training. The program followed a progressive structure with the objective of completing 40 minutes of intensive aerobic training after 16 weeks. In the strength training program, 4 dynamic exercises targeting major muscle groups were performed 3 times a week. Every 2 weeks, these exercises were intensified by altering the starting position or adding extra weight.
215051104|NCT06718205|DRUG|Nimotuzumab|Combined chemotherapy phase Nimotuzumab 400mg，I.V.，D1，QW Maintenance treatment period:Until unbearable or PD Nimotuzumab 400mg，I.V.，D1，Q3W
215051105|NCT06718205|DRUG|Sintilimab|Sintilimab 200mg，I.V.，D1，Q3W，Until unbearable or PD
215051106|NCT06718205|DRUG|Paclitaxel-albumin|Paclitaxel-albumin 200 mg/m2，I.V.，D1，Q3W，4-6 Cycle
215051107|NCT06718205|DRUG|Cisplatin|Cisplatin:75 mg/m2，I.V.，D1,Q3W，4-6 Cycle
215051108|NCT06718608|DIAGNOSTIC_TEST|imaging|Magnetic resonance imaging (MRI) Shear wave elastography (SWE) Electronic oscillatory device (EOD)
215051109|NCT03584906|PROCEDURE|DGG Harvesting approach|An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
215051110|NCT03584906|PROCEDURE|ET harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
215051111|NCT03584906|PROCEDURE|TDT harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
215051112|NCT03584906|PROCEDURE|MT harvesting approach|An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
215051113|NCT03584906|PROCEDURE|Root coverage procedure|A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
215051114|NCT06717997|OTHER|ultrasound|The placenta thickness will be performed on transabdominal images obtained in a longitudinal plane. Three measurements will be performed at the thickest portion of the placenta. The average of these three measurements was used for statistical analysis. The cohorts will be classified into 1) thick placenta (\>4 cm) and average placenta (2-4 cm).
215051115|NCT06715046|DIAGNOSTIC_TEST|Sample collation for cfDNA methylation analysis|Sample collation for cfDNA methylation analysis
215051116|NCT06715046|DIAGNOSTIC_TEST|Sample collection for EV phenotype analysis|Analysis of the EV phenotype to evaluate their potential value as markers for GVHD, relapse and engraftment.
215051117|NCT06718725|DIAGNOSTIC_TEST|ROSE-AI system|The cytopathological slide images of the patients' ROSE samples will be identified by the ROSE-AI system.
214296533|NCT00549523|DRUG|Low Dose|Capsules containing 400 mg bid of L. frutescens.
214296534|NCT00549523|DRUG|Mid Dose|Capsules containing 800 mg bid of L. frutescens.
214296535|NCT00549523|DRUG|High Dose|Capsules containing 1200 mg bid of L. frutescens.
214478211|NCT06882434|BEHAVIORAL|Referral Process|"Self-referral tracking (1-2 weeks): Participants able to visit referral sites independently will be followed up to confirm completion.~Barrier assessment: If unable to attend, interviews will identify obstacles (e.g., transport, finances, willingness).~Transportation support: Solutions include volunteer transport with fuel subsidies, local transport networks, and government-assisted group referrals.~Financial assistance: Eligibility for social welfare aid will be assessed, with support for applications.~Personal willingness \& health literacy: Health education will address concerns about treatment or social stigma.~Telehealth consultations: Remote specialist consultations will be provided if in-person visits are not possible.~Hospital-based referral support: Group hospital visits will be arranged for those with referral difficulties.~Monthly tracking: Referral completion rates and outcomes will be monitored (e.g., treatments, assistive devices, social services)."
214478212|NCT06882434|BEHAVIORAL|Telehealth Education & Digital Integration|"Live-streamed health education across multiple community sites.~Digital health platforms for real-time intervention monitoring and professional feedback:~Polypharmacy management via medication usage tracking and pharmacist analysis. Nutritional assessment with dietitian recommendations. Health consultations provided remotely by specialists based on screening results."
214894864|NCT03328975|DRUG|Dexamethasone|The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
215057430|NCT03994211|DRUG|pamiparib 60 mg|Single dose of 60 mg pamiparib orally on Days 1 and 10
215057431|NCT03994211|DRUG|pamiparib 20 mg|Single dose of 20 mg pamiparib orally on days 1 and 7
215057432|NCT03994211|DRUG|itraconazole|200 mg itraconazole once a day al Day 3 to day 8
215057433|NCT03994211|DRUG|rifampin|600 mg rifampin once a day from days 3 to 11
214296536|NCT02051829|OTHER|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
214296537|NCT00938379|DRUG|20% deet insect repellent|skin-applied repellent lotion
214296538|NCT00938379|DRUG|placebo control|Identical base formulation of lotion but without any deet active
214296539|NCT04375137|DIAGNOSTIC_TEST|Oxidative Stress ELISA Kit|Checking oxidative stress markers and redox system status
214296540|NCT03032666|DRUG|sofosbuvir/velpatasvir|treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
214296541|NCT03318315|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
214296542|NCT03318315|BIOLOGICAL|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
214296543|NCT03318315|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
214296544|NCT03318315|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)
214296545|NCT00427258|DRUG|MOA-728|
214296546|NCT00687765|DRUG|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
214478213|NCT06647459|DIAGNOSTIC_TEST|EP Study|To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
214668864|NCT02267785|OTHER|Skill-Based Exercise|The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
214894865|NCT03328975|OTHER|Placebo|the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
214894866|NCT06632821|OTHER|No intervention will be used.|University students' health literacy, physical activity, back pain and posture habits will be evaluated.
214894867|NCT05080153|DIETARY_SUPPLEMENT|Ocufolin forte|start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)
214296547|NCT03327311|DEVICE|Bellafill|Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).
214296548|NCT01444326|OTHER|Dairy|"During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew)."
214296549|NCT02064647|OTHER|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
214296550|NCT02064647|OTHER|10/20% bolus adjustment|The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
214894868|NCT05727098|DRUG|Bupivacaine Hydrochloride|injection of Bupivacaine 0.25% in ESPB
214894869|NCT05727098|DRUG|Bupivacaine Hydrochloride and dexmedetomedine|injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
214894870|NCT05727098|DRUG|Bupivacaine Hydrochloride and ketamine|injection of Bupivacaine 0.25% and ketamine in ESPB
214894871|NCT05939765|DRUG|Antipsychotic|Participants will undergo a systematic neuropsychiatric assessement at regular intervals. Any change in medication, together with aggressive or dysfunctional behaviour will be continually recorded. The time period prior to the change in medication will be classified as control, the time after as case; therefore each patient becomes his own control.
214894872|NCT02587091|BEHAVIORAL|Portable obstetric ultrasound|This intervention was advertised at the cluster level
214894873|NCT02012426|BEHAVIORAL|Weight management program|
214894874|NCT01163864|BEHAVIORAL|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
214894875|NCT01163864|BEHAVIORAL|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
214894876|NCT02251899|BEHAVIORAL|Disease-Management intervention|The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
214296551|NCT02436356|DEVICE|Osteoprobe-Reference Point Indentation (RPI)|Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
214894877|NCT01595685|DRUG|Telbivudine|Telbivudine 600 mg Daily Oral
214894878|NCT01595685|DRUG|Entecavir|Entecavir 0.5 mg Daily Oral
214894879|NCT05466045|OTHER|Olive oil application in hemodialysis patients with pruritus|Experimental group: In addition to routine care, a brown glass bottle containing extra virgin olive oil was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
214894880|NCT05466045|OTHER|Normal saline application in hemodialysis patients with pruritus|Control group: In addition to routine care, a brown glass bottle containing normal saline was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
215051118|NCT06716827|PROCEDURE|In-office bleaching system|As the whitening agent, an in-office bleaching system containing 35% hydrogen peroxide (Whiteness HP, FGM) was chosen. The gingiva was isolated using an isolation material (Opaldam, Ultradent Products Inc.), which was light-cured with a standard curing light. The whitening gel was applied to the labial surfaces of the maxillary incisors and canines with a 1mm thickness and left for 20 minutes. After cleaning the teeth with an aspiration tip, the whitening procedure was repeated.
215051119|NCT06716827|PROCEDURE|Laser-assisted bleaching|Whitening was performed 10 days prior to treatment, with laser treatment applied without removing brackets in the fixed appliance group and without cleaning attachments in the aligner group. The laser was applied to the buccal surface of the teeth with a 1mm distance for 30 seconds in three applications. After a 10-minute rest, the laser procedure was repeated.
214296552|NCT02436356|RADIATION|Dual-energy X-ray absorptiometry (DXA) Scans|Assessment of Fracture Risk
214296553|NCT02436356|RADIATION|MRI|Determines bound water and pore water of bone.
214296554|NCT03941431|DRUG|Jueyin granules|Jueyin granules p.o. once a day for 8 weeks.
214296555|NCT03941431|DEVICE|moving cupping therapy|Moving cupping therapy three times per week for 8 weeks.
214894881|NCT01097512|DRUG|AS703569/gemcitabine|"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
214894882|NCT01097512|DRUG|AS703569/gemcitabine|"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
214894883|NCT05721911|GENETIC|whole genome sequencing|Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
214894884|NCT04762004|BEHAVIORAL|Maternal speech|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
214894885|NCT04762004|BEHAVIORAL|Maternal singing|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
215051120|NCT06716827|PROCEDURE|Home-bleaching|The whitening trays were custom-made for the fixed appliance patients, and they used them for 2-4 hours each evening after brushing their teeth. In the transparent aligner group, whitening was done using the aligners worn for treatment.
215051121|NCT06716827|OTHER|Control|This group of patients did not undergo any whitening procedures.
215051122|NCT06717009|DIAGNOSTIC_TEST|Preoperative three-dimensional reconstruction|On the basis of conventional CT/MRI, the patient will undergo 3D reconstruction within 48 hours before surgery. The surgeon/researcher will conduct surgical planning according to the results of the 3D reconstruction and perform robot-assisted laparoscopic nephron sparing surgery.
215051123|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Control|2 x algal oil gel capsules delivering 400mg DHA in total
215051124|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Treatment 1 - Semi-Solid food matrix|"Test Food 1: 200g serve soup + ingredient"
215051125|NCT04610983|DIETARY_SUPPLEMENT|Treatment 2 - Solid food matrix|"Test Food 2: 50g serve extruded snack (savoury snack) + ingredient"
215051126|NCT02478541|OTHER|Sugar study|Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
215051127|NCT01679483|DRUG|FloSeal application|At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
214296556|NCT03941431|DEVICE|NB-UVB therapy|NB-UVB phototherapy three times per week for 8 weeks.
214296557|NCT03941431|DRUG|Jueyin placebo granules|Jueyin placebo granules p.o. once a day for 8 weeks.
214894886|NCT04762004|BEHAVIORAL|Standard care|the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
215051128|NCT02551185|DRUG|ACY-241|
215051129|NCT01987076|DRUG|Prednisone|"Prednisone:~Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days."
215051130|NCT01987076|DRUG|Clobetasol|Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
215051131|NCT03670160|DRUG|Phenobarbital|Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
214894887|NCT04368338|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Polymerase chain reaction tests after reverse transcription for the detection of viral Covid-19 RNA (RT-PCR)
214894888|NCT04368338|PROCEDURE|lung ultrasound|lung ultrasound is standard practice to diagnose acute respiratory failure in Emergency room
215051132|NCT03670160|DRUG|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
215051133|NCT03719014|DEVICE|NovaCross|The NovaCross micro-catheter will be used during a standard of care Percutanous Coronary Intervention (PCI) on subjects diagnosed with at least one coronary chronic total occlusion (CTO), in order to assist the operator in guidewire stability and centralization.
214296558|NCT03941431|DEVICE|moving cupping placebo therapy|Moving cupping placebo therapy three times per week for 8 weeks.
214296559|NCT03941431|DEVICE|NB-UVB placebo phototherapy|NB-UVB placebo phototherapy three times per week for 8 weeks.
214296560|NCT03120819|BEHAVIORAL|Oncologist Recommendation|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist
214296561|NCT03120819|BEHAVIORAL|Oncologist Recommendation + DVD|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
214296562|NCT01093807|DRUG|Placebo|once daily for 10 weeks
214296563|NCT01093807|DRUG|Lercanidipine|10 mg once daily for 10 weeks
214296564|NCT01093807|DRUG|Lercanidipine|20 mg once daily for 10 weeks
214296565|NCT01093807|DRUG|Enalapril|10 mg once daily for 10 weeks
214296566|NCT01093807|DRUG|Enalapril|20 mg once daily for 10 weeks
214296567|NCT01093807|DRUG|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
214668865|NCT02267785|OTHER|Aerobic Exercise|The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.
214894889|NCT03171012|OTHER|Lower limbs CRT|cycle ergometer for lower limbs
214894890|NCT03171012|OTHER|Upper limbs CRT|cycle ergometer for upper limbs
214894891|NCT03171012|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
214894892|NCT03171012|OTHER|respiration|respiration
214894893|NCT02060812|PROCEDURE|Group I, SSNB & ANB|Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
214894894|NCT02060812|PROCEDURE|Group II, SSNB alone|This is same as the Group I, SSNB \& ANB, but ANB was performed with placebo(10mL normal saline).
214894895|NCT06462755|OTHER|No intervention|no intervention
214894896|NCT05662176|OTHER|Experimental: Supportive Care based on trauma informed care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care based on trauma informed care was provided to the experimental group during birth.
214894897|NCT05662176|OTHER|Standart care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
214894898|NCT03561038|DEVICE|Franseen Needle|Comparing 2 needles designed for tissue acquisition
214894899|NCT03561038|DEVICE|Fork-tip Needle|Comparing 2 needles designed for tissue acquisition
214894900|NCT02436343|OTHER|echocardiogram|"At each echocardiographic evaluation, the investigator will obtain the following parameters:~Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume"
214894901|NCT01875978|DIETARY_SUPPLEMENT|Phytosterols & placebo|Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
214894902|NCT04311294|DRUG|ANS-6637 Low Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
214894903|NCT04311294|DRUG|ANS-6637 High Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
214894904|NCT04311294|DRUG|Matched Placebo|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
214894905|NCT02574182|RADIATION|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters"
214894906|NCT06213376|BEHAVIORAL|Melodic Intonation Therapy|Melodic Intonation Therapy uses intonation and melody to aid individuals with aphasia with producing words.
214894907|NCT06213376|BEHAVIORAL|Video Feedback Performance Review|Participant will view recording to judge correct and incorrect productions of trained words and to identify motor techniques increasing intelligibility
214894908|NCT00047450|DRUG|Citalopram (Celexa)|Citalopram for 3 months
214296568|NCT01093807|DRUG|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
214296569|NCT01093807|DRUG|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
214296570|NCT01093807|DRUG|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
214296571|NCT00810407|DRUG|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."
214296572|NCT05625009|PROCEDURE|Procedure/Surgery: Transversus Abdominis Plane Block (TAPB)|Patients received TAPB postoperatively
214296573|NCT05625009|PROCEDURE|Procedure/Surgery: Erector Spinae Plane Block (ESPB)|Patients received ESPB postoperatively
214296574|NCT06061653|COMBINATION_PRODUCT|IPT plus HD-tDCS|psychotherapy plus device
214296575|NCT06061653|COMBINATION_PRODUCT|IPT plus sham HD-tDCS|psychotherapy plus sham device
214296576|NCT06456060|DRUG|Alvogyl|Alvogyl soaked in a sterile gauze will be applied to cover the socket.
214296577|NCT06456060|DRUG|Honey|Honey soaked in a sterile gauze will be applied to cover the socket.
214296578|NCT03654950|OTHER|No intervention|Interviews and questionnaires
214296579|NCT05548231|DRUG|LY3437943|Administered SC
214296580|NCT05548231|DRUG|Placebo|Administered SC
214296581|NCT02766062|OTHER|metabolic syndrome|metabolic syndrome
214296582|NCT04208399|DRUG|JNJ-56136379|JNJ-56136379 will be administered orally in fed condition.
214894909|NCT00047450|DRUG|Placebo|Placebo for 3 months
214296583|NCT04787029|DEVICE|Medical compression stocking (medical device name: mediven Harmony 734 (compression class1 AG armsleeve or with wide(735))|Compression stockings worn on the arm or partial swelling of the hand after trauma or surgery.
214478214|NCT05417282|DRUG|MW151|Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.
214894910|NCT04840381|BEHAVIORAL|Questionnaire administrations|Administration of an ad hoc questionnaire to register food frequency consumption and meal time, main recipes; phisical activity questionnaire and list of questions concerning the previous and actual health status of participants
214894911|NCT04429945|DEVICE|Virtual Reality|Virtual Reality Headset with Virtual Reality Applications
214894912|NCT06821100|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Ta1 is a naturally occurring peptide that has been evaluated for its immunomodulatory activities and related therapeutic potential in several conditions and diseases. Ta1 has been shown to provide increased response to vaccines.
214894913|NCT03367195|DRUG|Omeprazole|1 Omeprazole 20 mg capsules twice daily
214894914|NCT03367195|DRUG|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
214894915|NCT03367195|DRUG|Placebo capsule of Omeprazole|1 placebo capsule of omeprazole, twice daily
214894916|NCT03367195|DRUG|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
214894917|NCT03354598|DRUG|Sulopenem-Etzadroxil/Probenecid|Treatment of uncomplicated urinary tract infection
214894918|NCT03354598|DRUG|Ciprofloxacin|Treatment of uncomplicated urinary tract infection
214894919|NCT05475197|DEVICE|Kinesio taping|We planned to perform two different taping applications to evaluate the acute effect of kinesio taping application on the carpal tunnels of individuals with carpal tunnel syndrome.
214894920|NCT04870710|DEVICE|transcranial electrical stimulation|Electrical stimulation to the extrastriate visual cortex.
214894921|NCT00476190|DRUG|Doxorubicin|Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
214894922|NCT00476190|DRUG|Cytarabine|Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
214894923|NCT00476190|DRUG|Methotrexate|"Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks."
214894924|NCT00476190|DRUG|Vincristine|Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
214894925|NCT00476190|DRUG|Cyclophosphamide|Consolidation IB: Intravenously on day 1
214894926|NCT00476190|DRUG|Methylprednisone|Prophase: Intravenously on days 1-3
214894927|NCT00476190|DRUG|Hydrocortisone Sodium Succinate|Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
214894928|NCT00476190|DRUG|Dexamethasone|Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
214894929|NCT00476190|DRUG|6-MP|Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.
215057434|NCT03994211|DRUG|pamiparib|60 mg pamiparib orally twice a day in 28-day cycles
215057435|NCT01843166|DRUG|Premarin vaginal cream|2g at bedtime twice weekly
215057436|NCT01843166|DRUG|Placebo cream|2g at bedtime twice weekly
215057437|NCT05802420|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
215057438|NCT00761982|PROCEDURE|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
214296584|NCT05703256|DEVICE|Amygdala real-time fMRI neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
214296585|NCT05703256|DEVICE|Sham feedback|Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
214296586|NCT04843774|DRUG|SARS-COV-2 mRNA Vaccine|Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
214296587|NCT03784404|PROCEDURE|Transvaginal aspiration|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
214296588|NCT03784404|PROCEDURE|transvaginal aspiration and surgicel injection|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
214478215|NCT03990883|DEVICE|Princess Filler Lidocaine|correction of nasolabial folds
214478216|NCT06877416|OTHER|Non-intervention research|Non-intervention research
214478217|NCT06843291|GENETIC|Genetic Testing for hematological malignancies|combined skin punch biopsy/BM aspiration technique, followed by NGS and OGM.
214296589|NCT03784404|DRUG|Intracytoplasmic sperm injection|"Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance."
214296590|NCT01273402|DRUG|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
214296591|NCT03163615|DRUG|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
214296592|NCT03163615|DRUG|Placebo oral capsule|4 capsules, po, from admission up to 84 days
214296593|NCT01132157|DRUG|Desflurane|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
214296594|NCT01132157|DRUG|Propofol|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
214296595|NCT05681455|DEVICE|Neuromodulation NESA NXSIGNAL® device|"Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®.~The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire.~The directional electrode will be placed in the cervical area at the superficial level between C6 and C7."
214894930|NCT00476190|DRUG|PEG-Asparaginase|"Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.~Consolidation II: Intravenously every 3 weeks."
214296596|NCT02758015|OTHER|Standardized Meal|
214478218|NCT06809751|DRUG|melatonin 3mg|In this group, participants will be randomly assigned to take 3 mg tablets of melatonin twice a day for 1 month.
214894931|NCT00476190|DRUG|Imatinib|Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
214894932|NCT00476190|DRUG|Etoposide|Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
214894933|NCT00476190|PROCEDURE|Radiation Therapy|Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
214894934|NCT00476190|DRUG|E. coli Asparaginase|Intramuscularly Day 7 of Induction.
214894935|NCT06662968|OTHER|Lollipop group|In the Lollipop group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were given lollipops for sucking without chewing after waking up.Throughout the entire sucking process, we continuously monitor vital signs.
214894936|NCT06662968|OTHER|Control group|In the Control group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were received routine nursing treatment.
214894937|NCT00710268|DRUG|AZD2281|Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
214894938|NCT00710268|DRUG|Bevacizumab|IV administration10 mg/kg every 14 days
214296597|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
214296598|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
214296599|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
214296600|NCT04528979|OTHER|BioRoot RCS® root canal sealer|Root canal obturation with guttapercha and BioRoot RCS® root canal sealer
214296601|NCT04528979|OTHER|AH Plus® root canal sealer|Root canal obturation with guttapercha and AH Plus® root canal sealer
214478219|NCT06809751|DRUG|Placebo Drug|The placebo is also prepared in the form of tablets with similar packaging as melatonin by the pharmaceutical company. Participants will be randomly assigned to take placebo with the same frequency and duration as melatonin (twice a day for 1 month).
214894939|NCT02245607|BEHAVIORAL|Compensatory Cognitive Training|
214894940|NCT02245607|BEHAVIORAL|Recreational Therapy|
214894941|NCT00561119|DRUG|gemcitabine , paclitaxel|"Gemcitabine 1250 mg/m2 i.v. Day 1 \& 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks"
214894942|NCT03616457|DEVICE|Automated Breast Ultrasound (ABUS)|Participants will undergo imaging with ABUS.
214894943|NCT03357185|PROCEDURE|Femoral eversion|"The purpose of this database is to compile the data of patients followed at the René Dubos Hospital Center with symptomatic lower extremity arterial disease (AOMI) (Rutherford 2 to 5) who were operated on by the femoral tripod eversion technique.~The database will include data on the operation, possible complications, clinical course of patients and medical and surgical follow-up."
214894944|NCT02502032|DRUG|Cisatracurium|Different groups received different pretreatments of cisatracurium.
214894945|NCT03443349|DEVICE|Vibwife One|"Vibwife One is a powered rotation bed intended to be used to assist in active mobilization of delivering women. Vibwife One imitates manual mobilization and position techniques. It is integrated in the mattress and fixed to the pelvis area of the birthing bed. Vibwife One can be used, when manual mobilization and position techniques are deemed appropriate.~The device with all its functions is controlled over a remote control."
214894946|NCT04350411|DEVICE|Conventional diathermy|Abdominal free flap raise performed with conventional diathermy. Settings: cutting 40 Watt, coagulation 40 Watt.
214668866|NCT02267785|OTHER|Social Contact|The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
214894947|NCT04350411|DEVICE|PEAK PlasmaBlade™|Abdominal free flap raise performed with PEAK PlasmaBlade™ Settings: cutting 7 (35 Watt), coagulation 7 (35 Watt)
214894948|NCT06861478|DRUG|Omeprazol 40 mg IV|Daily until discharge
214894949|NCT06657937|OTHER|Questionnaire|"An initial questionnaire is completed on D0, the day of the patient's admission to the emergency department, by the practitioner in charge of the patient, and covers the patient's anamnesis, clinical examination, radiological examinations and treatment.~A follow-up telephone visit is then carried out at 30 days by an investigator, to gather information on the clinical and therapeutic evolution, and to evaluate the recovery and evolution of symptoms experienced by the patient in relation to the initial management."
214894950|NCT03622424|DEVICE|Gelesis200|Gelesis200: Three (3)Gelesis200 capsules (2.10 g) three (3) times per day (i.e., breakfast, lunch, and dinner)
214894951|NCT03622424|DEVICE|Placebo|Placebo: Three (3)placebo capsules three (3) times per day (i.e., breakfast, lunch, and dinner)
214894952|NCT03622424|DEVICE|Gelesis200 and Placebo|Placebo and Gelesis200: Three (3) placebo capsules at breakfast,and three (3) Gelesis200 capsules (2.10 g)two (2) times per day (i.e., lunch and dinner)
214894953|NCT00530205|OTHER|physiologic testing|
214894954|NCT00530205|OTHER|questionnaire administration|
214894955|NCT00530205|PROCEDURE|management of therapy complications|
214894956|NCT00530205|RADIATION|radiation therapy|
214894957|NCT04680572|PROCEDURE|arthroplasty|arthroplasty for fracture neck of femur
214894958|NCT05724589|DRUG|Epidermal Growth Factor|Apply facial twice daily.
214894959|NCT01970137|DRUG|KPS-0373, High dose|
214894960|NCT01970137|DRUG|KPS-0373, Low dose|
214894961|NCT04480242|DRUG|Inhaled Corticosteroids (ICs)|Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
214894962|NCT04480242|DRUG|Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)|Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
214894963|NCT04480242|DRUG|Other treatments|Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
214894964|NCT04480242|DRUG|Inhaler device|Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.
214894965|NCT04480242|BEHAVIORAL|Regularly monitoring of the Inhalation technique through mobile app|App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
214894966|NCT06254456|DIAGNOSTIC_TEST|End expiratory occlusion test|Fluid responsiveness test
214894967|NCT01427699|DRUG|T2-18C3 therapeutic antibody|1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
214668867|NCT04795180|DRUG|Irrigations trough the efferent limb of loop ileostomy|Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
214894968|NCT02329015|BEHAVIORAL|Yoga-informed Health and Wellness Program|The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).
214894969|NCT02329015|BEHAVIORAL|Physical Education Class|Standard physical education
214894970|NCT06919432|DEVICE|Active-tACS|Participants were comfortably positioned on a lounge chair and received alternating current stimulation using an FDA-approved tACS device (Nexalin Technology, Inc., Houston, TX, USA). Electrodes were evenly placed across the forehead and mastoid regions. Trained nurses administered the tACS according to standardized protocols.
214894971|NCT06919432|DEVICE|Sham-tACS|The sham tACS device will resemble the active stimulation device in appearance, weight, size, color, and odor, ensuring indistinguishability for the patients. Throughout the entire intervention period, each participant will be allocated to the same tACS device, regardless of whether it delivers active or sham stimulation.
214894972|NCT06546826|PROCEDURE|BARP|deep layers of collagen, medium-superficial heterologous bone graft, superficial collagen layer
214894973|NCT06546826|PROCEDURE|simple tooth extraction|tooth extraction without grafting procedure.
214894974|NCT06546826|PROCEDURE|tooth root and PRF|Autogenous roots derived from the extracted hopeless tooth and stabilized with osteosynthesis screws to reconstruct the missing buccal wall of the socket. The defect was then filled with PRF.
214894975|NCT06546826|PROCEDURE|Ice cream cone technique|xenogeneic granules and a resorbable collagen membrane
214894976|NCT07128316|DEVICE|Contoura Topolyzer with Phorcides|LASIK calculated ablation using Contoura Topolyzer with Phorcides
214894977|NCT07128316|DEVICE|iDesign|LASIK calculated ablation using iDesign Refractive Studio 2.0
214894978|NCT06997900|DRUG|Combination therapy : Follitropin delta and HP-hMG|Follitropin delta dose will be determined by age. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight.
215051134|NCT03554655|DEVICE|Momentum app|The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
214296602|NCT00385879|BEHAVIORAL|Case management|
214296603|NCT03208842|RADIATION|trans vaginal ultrasound|"trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity"
214668868|NCT06397261|DEVICE|LarynGuide|Artificial Intelligence assisted tracheal video intubation
214668869|NCT06970730|PROCEDURE|virtual surgical planning and patient specific implants in craniomaxillofacial reconstruction|Image acquisition by computed tomography (CT slice thickness 1 mm or less) + laser scanning of patient models. Virtual surgical planning and design of patient specific implants. Patient specific implants manufacturing (milling technique) and 3D printing of surgical guides and fit models.
214894979|NCT07005921|BEHAVIORAL|qEEG-neurofeedback|The participants will be submitted to a qEEG-neurofeedback intervention in order to verifify its feasibility to enhance cognition. The theta/beta ratio reduction protocol at electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4 will be performed, with 10 sessions of qEEG-neurofeedback training, 2 sessions for pre and post test, and 1 session for follow-up after 30 days of intervention. Each session will last approximately 1 hour. The Psychological Battery of Attention 2 (BPA-2) and Digit Span Test will be employed to measure attention and working memory levels. The Montreal Cognitive Assessment (Moca) will be used for neurological and cognitive assessment. Participants will receive feedback based on their theta/beta ratio in the frontal and central cortical areas (electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4).
215051135|NCT01594242|DRUG|Bortezomib|
215051136|NCT03653182|DIAGNOSTIC_TEST|Pulse, tongue image, and voice sound|They are four diagnosis methods of TCM
215051137|NCT03827239|OTHER|Activity/Moderate Exercise|3-hour sedentary period with 3 minute activity breaks of moderate exercise every 30 minutes
215051138|NCT02096978|PROCEDURE|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
215051139|NCT00577278|BIOLOGICAL|rituximab|Given IV
215051140|NCT00577278|DRUG|fludarabine phosphate|Given IV
215051141|NCT00577278|DRUG|melphalan|Given IV
215051142|NCT00577278|DRUG|sirolimus|Given PO
214668870|NCT03429075|DRUG|Psilocybin + Placebo|Multiple dosing days psilocybin vs 6 weeks of daily placebo
215051143|NCT00577278|DRUG|tacrolimus|Given PO or IV
214296604|NCT00878527|DEVICE|CircuLite Synergy Pocket Circulatory Assist Device|Goal of successful implantation and follow-up for at least three months
214296605|NCT00939081|BEHAVIORAL|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
214296606|NCT00939081|BEHAVIORAL|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
214296607|NCT00674661|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
214296608|NCT00674661|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
214296609|NCT01028365|OTHER|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
214296610|NCT03016286|OTHER|vibration|Whole body vibration at 25Hz frequency
214296611|NCT01797692|OTHER|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
214668871|NCT03429075|DRUG|Psilocybin + Escitalopram|Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
214894980|NCT07005921|BEHAVIORAL|SHAM qEEG-neurofeedback|The participant will be submitted to an inactive qEEG-neurofeedback that appears to be the same as a functional procedure or device. Participants will not receive feedback based on their theta/beta ratio in the frontal and central cortical areas (electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4).
214296612|NCT06175403|DRUG|Niacin|Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion
214296613|NCT01968668|DRUG|BAY94-8862|1.25 mg BAY94-8862 tablet once daily in the morning
214296614|NCT01968668|DRUG|BAY94-8862|2.5 mg BAY94-8862 tablet once daily in the morning
214894981|NCT03578302|DEVICE|BI Anterior Segment Mode|Single eye measurement in Anterior Segment Mode
214894982|NCT03578302|DEVICE|BI Anterior Segment and IOL Biometry Mode|Eye measurement 3 times with and without dilation in IOL biometry and Anterior Segment mode
214894983|NCT06668987|DRUG|B10 L-BPA Injection|The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.
214894984|NCT07005765|BEHAVIORAL|Video-Based Stabilization Exercise Program|Participants will follow a 6-week home exercise program focusing on stabilization exercises. The instructions and demonstrations will be delivered through video format, which participants can watch at their convenience. The program aims to improve pain, functionality, exercise adherence, kinesiophobia, and quality of life.
214894985|NCT07005765|BEHAVIORAL|Brochure-Based Stabilization Exercise Program|Participants will follow the same 6-week home exercise program using illustrated printed brochures that provide step-by-step instructions for stabilization exercises. This format allows participants to perform exercises independently. The program's effects on pain, functionality, exercise adherence, kinesiophobia, and quality of life will be evaluated.
214894986|NCT05024773|DRUG|ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)|Schedule: once a week for 12 consecutive weeks (induction phase). Patients who achieve a complete response at the end of the induction phase will enter the maintenance phase, during which ONCOFID-P-B is administered once a month for 12 months until recurrence or progression of the disease.
214894987|NCT01652547|DRUG|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
214894988|NCT01652547|DRUG|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
214894989|NCT05248347|DEVICE|Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
214894990|NCT05248347|DEVICE|The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
214894991|NCT03972761|DEVICE|Magnetic Resonance Imaging (MRI) 3 tesla|Functional neuroimaging objectifies the activation of specific areas of the brain
214894992|NCT07005414|DRUG|Bumetanide|Participants will receive bumetanide (0.5mg bid) for a period of three months.
214894993|NCT07005414|BEHAVIORAL|Treatment as usual (TAU)|Participants will undergo treatment as usual, such as behavioral interventions
214894994|NCT07003724|OTHER|Questionaire|Questionnaire evaluating level of awareness of patients towards using AI in dentistry
214894995|NCT06866288|BEHAVIORAL|Meditation|Each person will participate in seated meditation, then walking meditation, then return to seated meditation.
214894996|NCT06866288|BEHAVIORAL|Yoga|Each person will participate in a yoga sessions.
214296615|NCT01968668|DRUG|BAY94-8862|5 mg BAY94-8862 tablet once daily in the morning
214296616|NCT01968668|DRUG|BAY94-8862|7.5 mg BAY94-8862 tablet once daily in the morning
214894997|NCT07011927|DEVICE|Cochlear Implant|Eligible Cochlear Americas devices eligible for inclusion in this study include any Cochlear Americas device that has two ground electrodes.
214894998|NCT07011927|DEVICE|Modified Implant Procedure|Implant procedure will be modified to place ground electrode (ECE1) near Arnold's nerve.
215051144|NCT00577278|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo APBSCT
214296617|NCT01968668|DRUG|BAY94-8862|10 mg BAY94-8862 tablet once daily in the morning
214296618|NCT01968668|DRUG|Placebo|Placebo tablet once daily in the morning
215051145|NCT00577278|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
215051146|NCT00577278|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
215051147|NCT00577278|OTHER|laboratory biomarker analysis|Correlative Studies
214296619|NCT01968668|DRUG|BAY 94-8862|15 mg BAY 94-8862 tablet once daily in the morning
214296620|NCT01968668|DRUG|BAY 94-8862|20 mg BAY 94-8862 tablet once daily in the morning
214296621|NCT04777695|OTHER|Decibel Monitor|Placement of a TeckPro data logging sound decibel meter at all patient bed-spaces to measure concurrent sound levels 24 hours per day, over a one (1) month period. Peak and mean sound levels per hour will be collected by the decibel monitor. Sound collected every 5 minutes will be logged by the decibel monitor and downloaded onto manufacturer software daily; data will then be imported into Microsoft Excel for further data analysis.
214296622|NCT04967157|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
214296623|NCT04967157|DIETARY_SUPPLEMENT|Citicoline supplement|Cognizin ®
214894999|NCT03888963|PROCEDURE|PRF|patients will receive pulsed radiofrequency, 4 cycles (each cycle, 2 minutes) on the thoracic paravertebral nerves number 2,3, and 4 under fluroscopic guidance
214895000|NCT03888963|PROCEDURE|SHAM|patients will be subjected to the same procedure like PRF group without giving PRF
214895001|NCT07017062|OTHER|hybrid ceramic occlusal veneers|occlusal veneers cemented with self adhesive resin cements
214895002|NCT07018375|DRUG|Oliceridine|postoperative patient-controlled analgesia (PCA)
214895003|NCT07018375|DRUG|Sufentanil|Sufentanil
214895004|NCT07016659|DRUG|0.12% Chlorhexidine Mouthwash ( Hexitol )|About 10 ml will be administered, and participants will be asked to swish mouthwash for 30 seconds two times daily under the supervision of their parents, 30 to 45 minutes after toothbrushing for 2 weeks.
214895005|NCT07016659|DRUG|Triphila mouthwash|The participant will be instructed to administer 15 ml of the mouthwash and swish it for 30 seconds two times daily under the supervision of their parents, 30 to 45 minutes after toothbrushing for 2 weeks
214895006|NCT02008812|DEVICE|Ad sensor|"Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
214895007|NCT02513862|DEVICE|Autologous Platelet-Rich Plasma Harvest Technique|15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
214895008|NCT03618251|DIAGNOSTIC_TEST|specific MRI sequences|MRI with B 2000 of diffusion weighted imaging and the coefficient of apparent diffusion
214895009|NCT00115076|DRUG|Efalizumab|24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
214895010|NCT05164692|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
214895011|NCT05164692|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
214895012|NCT07016997|DRUG|CBA-1535|Dosing is increased from 0.1 µg/body until DLT or disease progression occurs.
214895013|NCT07016997|DRUG|CBA-1535+Pembrolizumab|"Drug：CBA-1535 First Dosing will be determined by Part 1. And dosing will be increased until DLT or disease progression occurs.~Drug：Pembrolizumab 200 mg/body"
214895014|NCT07018622|DRUG|Dapagliflozin 10 MG Oral Tablet|Participants in this arm will receive oral dapagliflozin 10 mg daily starting one day before platinum-based chemotherapy infusion (cisplatin or carboplatin) and continuing for 72 hours. The intervention aims to assess the potential nephroprotective effect of SGLT2 inhibition. Standard supportive care including hydration and magnesium supplementation will be provided to all participants.
214895015|NCT07018622|DRUG|Placebo Oral Tablet|Participants in this arm will receive a matched oral placebo starting one day before platinum-based chemotherapy infusion (cisplatin or carboplatin) and continuing for 72 hours. Standard supportive care including hydration and magnesium supplementation will also be provided. Investigators and participants will remain blinded to the group assignments.
214895016|NCT07018739|DRUG|Wharton's jelly-derived mesenchymal stem cells|MSCs (1x10\^7 cells/kg) in 10 mL 0.9%NSS administered intravenously within 10 days, postnatally after TH completion, every 24 h for 3 consecutive days
214296624|NCT03124433|DRUG|Apalutamide|Participants will receive oral apalutamide 240mg daily for 12 weeks
214895017|NCT07018739|DRUG|0.9 % Normal Saline|0.9%NSS 10 mL administered intravenously within 10 days, postnatally after TH completion, every 24 h for 3 consecutive days
214895018|NCT07016828|DEVICE|guided surgery technique|"* Clinical examination will be performed and preoperative CBCT will be taken for all the patients prior to the surgery to evaluate the posterior maxilla for the placement of the pterygoid implants.~* Ideal pterygoid implant placement will be planned using the BlueSky Bio software (USA) which will be mostly to emerge from the third molar position and to engage the dense pillar of bone formed by the pyramidal process and pterygoid process of sphenoid bone.~* surgical guide will be fabricated which will be either soft tissue without flap elevation."
214895019|NCT07016828|PROCEDURE|Free hand technique|the surgery will be done without the use of the surgical guides depending on the anatomical landmarks.
214895020|NCT07024173|DRUG|HRS-8080 Tablet|HRS-8080 tablet orally administered.
214895021|NCT07024173|DRUG|Fulvestrant injection|Fulvestrant injection.
214895022|NCT07024173|DRUG|Exemestane tablets|Exemestane tablets orally administered.
215051148|NCT02428829|PROCEDURE|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
215051149|NCT02428829|PROCEDURE|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
215051150|NCT03965403|DEVICE|Arm motor function retraining with BURT|Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
215051151|NCT05193006|OTHER|No intervention|No intervention
215051152|NCT02622269|DEVICE|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
214296625|NCT04382573|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
214296626|NCT02382679|DIETARY_SUPPLEMENT|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
214296627|NCT02382679|DIETARY_SUPPLEMENT|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
214296628|NCT02574247|PROCEDURE|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
214296629|NCT04758754|OTHER|Training|8-weeks iso-volume active (SLKE) or passive static stretching training (PST) involving lower limb muscles
214296630|NCT00252954|DRUG|Levetiracetam|Tablets 2000-3000 mg per day
214895023|NCT07024173|DRUG|Everolimus Tablets|Everolimus tablets orally administered.
214895024|NCT04331808|DRUG|Tocilizumab|Tocilizumab 8mg/kg on day 1 and if no response (no decrease of oxygen requirement) a second injection at day 3 (fixed dose of 400 mg)
214895025|NCT06153199|BEHAVIORAL|Self-management videos|Short video modules on self-management of back pain without medication and ergonomic adjustments for limiting back pain in nursery and landscape work
214895026|NCT06153199|BEHAVIORAL|Check lists for ergonomic options|Guidance on ergonomic choices appropriate for work tasks not currently being used that are the most difficult due to back pain, using a checklist
214895027|NCT06153199|BEHAVIORAL|Text reminders|Reminders to implement choices using graphics and gifs as well as motivational messages
214895028|NCT06153199|BEHAVIORAL|Video review|Participants will review videos of their movement during their most difficult work tasks to help problem solving to adjust ergonomic adjustments
214895029|NCT06103578|DIAGNOSTIC_TEST|GCF and saliva analysis|ELISA
214895030|NCT07030231|RADIATION|Intraoperative|Intraoperative radiotherapy with any device after conservative surgery in early breast cancer
214895031|NCT06208137|BEHAVIORAL|Health monitoring and regular return follow-up reminders|Health monitoring \& reminders for blood tests and follow-up visits until 1 year post-transplant
214895032|NCT02189837|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214895033|NCT02189837|DRUG|Atorvastatin|Administered by mouth
214895034|NCT02189837|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
214895035|NCT02189837|DRUG|Placebo to Atorvastatin|Administered by mouth
214895036|NCT02421055|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
214895037|NCT02421055|PROCEDURE|Laparoscopic Sleeve Gastrectomy|
214895038|NCT04991207|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
214296631|NCT05688046|DRUG|Immune checkpoint inhibitors plus angiogenesis inhibitors|PD-(L)1-based therapy plus Bevacizumab or Anlotinib
214895039|NCT04991207|DRUG|bosentan|Oral Tracleer (bosentan) 125 mg film coated tablets
214296632|NCT05688046|DRUG|Immune checkpoint inhibitors without angiogenesis inhibitors|PD-(L)1-based therapy
214296633|NCT01382446|DRUG|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
214296634|NCT01382446|OTHER|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
214296635|NCT06542120|DIAGNOSTIC_TEST|Heart Auscultation and Echocardiography|Heart auscultation will be done by pediatrician and echocardiography by echocardiologist
214296636|NCT06542120|DIAGNOSTIC_TEST|Chest Auscultation and Chest imaging examinations|Chest auscultation will be done by pediatrician and chest imaging examinations by radiologist
214296637|NCT06542120|DIAGNOSTIC_TEST|Abdominal Auscultation and Abdominal imaging examinations|Abdominal auscultation will be done by pediatrician and chest imaging examinations by radiologist
214296638|NCT05405205|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in drinking water
214296639|NCT05405205|DIETARY_SUPPLEMENT|probiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, maltodextrin, sucralose and flavour twice a day resolved in drinking water
214296640|NCT05405205|DIETARY_SUPPLEMENT|placebo|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in drinking water
214668872|NCT03114501|BEHAVIORAL|Yoga|Participants receive yoga sessions up to 5 days per week, based on the patient's schedule, over the course of patients' Radiation Therapy (up to 15 sessions, 45-60 min. each). Yoga sessions audio and video recorded.
214668873|NCT03114501|BEHAVIORAL|Yoga Questionnaire|Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
214895040|NCT01164696|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Zevalin was administered according to the directives in the approved package leaflet.
214895041|NCT06891755|DEVICE|Apreo BREATHE Airway Scaffold|The experimental treatment involves placement of up to 6 Apreo BREATHE Airway Scaffolds (up to 3 per lung), in a single procedure using bronchoscopy and fluoroscopy. Treatment group subjects will also receive optimal medical management (OMM).
214895042|NCT06891755|OTHER|Optimal Medical Management (OMM)|Subjects will receive optimal medical management tailored to patient needs and per standard of care and as outlined in the 2024 GOLD report. This may include smoking cessation, vaccination, long-acting bronchodilator therapy, corticosteroids (when appropriate), and participation in or maintenance of an exercise program or pulmonary rehabilitation program.
214895043|NCT01769560|BEHAVIORAL|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
214895044|NCT00275119|DRUG|fluorouracil|
214895045|NCT00275119|DRUG|gemcitabine hydrochloride|
214895046|NCT00275119|DRUG|oxaliplatin|
214895047|NCT00275119|RADIATION|radiation therapy|
214895048|NCT04243031|DEVICE|QFT Access|Measure of Interferon Gamma
214895049|NCT04769531|OTHER|Hip Joint Mobilizations|i. Anterior-posterior glide ii. Posterior-anterior glide iii. Caudal glide iv. Posterior-anterior glide with Abduction, flexion, and lateral rotation
214895050|NCT04769531|OTHER|Hip joint Muscle strength training|i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching
214895051|NCT04769531|OTHER|knee strengthening and flexibility exercises|"i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:"
214895052|NCT02871544|OTHER|BNP and NGAL|
215051153|NCT02622269|DEVICE|Standard compression device|Compression of the abdomen with the standard compression device
215051154|NCT02292537|DRUG|Nusinersen|Administered by intrathecal (IT) lumbar puncture (LP) injection
214895053|NCT01693510|BEHAVIORAL|Exercise and Nutrition Intervention|Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
214895054|NCT02376816|BIOLOGICAL|rAAVrh74.MCK.micro-Dystrophin|"Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter."
214895055|NCT05999487|DRUG|Dobutamine|"Patient randomization will be done by a computer based generation , serial enveloped numbers will be taken for the patients. Cardiac assessment will be done by a blinded pediatric cardiologist. If at any time the randomly assigned therapy considered to be failed or unsafe to continue, the treating physician will discontinue randomization and will continue with the appropriate medication according to the patients need.~Milrinone will start by 0.25 , 0.5 , 0.75 we can titrate up with time interval 3 hours after re-assessment.~Dobutamine will start by 5, 10 , 15, 20 we can titrate with time interval 15 mins after re-assesment."
214895056|NCT00619060|DRUG|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
214895057|NCT00619060|DRUG|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
214895058|NCT02892929|BEHAVIORAL|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
214895059|NCT02892929|BEHAVIORAL|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
214895060|NCT00822692|DRUG|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
214895061|NCT00822692|DRUG|placebo|matched placebo 2 pills PO BID x 7 days
214895062|NCT06318312|OTHER|Hypoxia|Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%
214895063|NCT03353012|DRUG|Etonogestrel Drug Implant|Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
214895064|NCT03353012|DRUG|Levonorgestrel Drug Implant|Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
214895065|NCT04524195|DRUG|[18F]F-AraG Injection|Single dose of 5 mCi+/- \[18F\]F-AraG IV injection followed by the PET/CT scan. A baseline \[18F\]F-AraG PET/CT will be performed at about 0-7 days before patient receives the first dose of PD-1/PD-L1 immunotherapy. A second \[18F\]F-AraG PET-CT will be performed at less than 14 days after the first dose of PD-1/PD-L1 immunotherapy is administered and before the second dose of PD-1/PD-L1 immunotherapy is given.
214895066|NCT01510782|DRUG|Placebo to BI 655064|intravenous infusion of escalating doses
214895067|NCT01510782|DRUG|Placebo to BI 655064|subcutaneous injection of escalating doses
214895068|NCT01510782|DRUG|BI 655064|intravenous infusion of escalating doses
214895069|NCT01510782|DRUG|BI 655064|subcutaneous injection of escalating doses
214895070|NCT02137876|PROCEDURE|Blood Draws|Patients will be asked to provide blood for immune tests.Patients will not take any study medications, all the research will be performed on blood donated for the study.Patients will donate about 20mls of blood (2 tbls)to be used to determine the subject's blood group and tissue typing (genetic).Results and the patient's contact information will be maintained in a database that is accessible only by the investigators and study personnel conducting the study.For the duration of this study, the investigator will contact patients by phone to request additional samples when needed. Study staff may ask patients donate more blood on short notice (1 day). This will consist of 60-120 ml (6-12 tbls) of blood.The frequency of blood collection will not exceed more than 2 times per week.The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups) within any eight week period throughout the two year timespan patients may be asked to participate in this study.
214478220|NCT06811142|DRUG|Botulinum Toxin Type A (BoNT-A)|This intervention involves the early administration of botulinum toxin type A (BoNT-A) within the first 12 weeks after a cerebrovascular event. The injections target muscles affected by spasticity, aiming to reduce abnormal tone, prevent contractures, and improve functional mobility. BoNT-A works by blocking acetylcholine release at the neuromuscular junction, resulting in muscle relaxation. Ultrasound guidance or anatomical landmarks will be used for accurate injection. This early intervention capitalizes on the neuroplastic window and is combined with standard rehabilitation to enhance motor recovery and prevent long-term complications.
214478221|NCT06857604|OTHER|Biological samples|Immunological Screening and Genetic analysis
214478222|NCT04351256|DRUG|Durvalumab Injection [Imfinzi]|Durvalumab fixed dose of 1,500 mg
214478223|NCT04351256|RADIATION|Thoracic Radiotherapy (TRT) conventionally|Conventionally fractionated TRT consisting of 30 x 2 Gy (60 Gy) within 6 weeks
214478224|NCT04351256|RADIATION|Thoracic Radiotherapy (TRT) hypofractionated|Hypofractionated TRT consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks
214895071|NCT00002031|DRUG|Dinitrochlorobenzene|
214895072|NCT05176873|DRUG|DZD8586|Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
214895073|NCT05176873|DRUG|Placebo|A single oral dose of placebo will be given.
214895074|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
214895075|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
214895076|NCT02443740|DRUG|BIIB118|Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
214895077|NCT02494167|BIOLOGICAL|MultiTAA-specific T cells|"The 5 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2; Dose Level Four: 5 x 107 cells/m2; Dose Level Five: 1 x 108 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.~If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart."
214895078|NCT05411341|DEVICE|Argos (Alcon Laboratories, Inc.)|An ocular biometry examination will be performed on the affected eyes using the Argos device.
214895079|NCT05411341|DEVICE|IOLMaster 500 (Carl Zeiss Meditec AG)|An ocular biometry examination will be performed on the affected eyes using the IOL Master 500 device.
214895080|NCT02741414|DEVICE|The result of H pylori culture based on gram staining and enzyme activity testing|This intervention aimed at patients with the positive result of 13C-urea breath test. Patients with negative result of H pylori culture was H pylori culture negative group. Patients with positive result of H pylori culture were belonged into the first successful eradication group and the refractory infection of H. pylori group.
214895081|NCT02741414|DEVICE|The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole|The intervention focused on the results from the result of 13C-urea breath test after treatment. The first successful eradication group and the refractory infection of H. pylori group were treated according to the antibiotic susceptibility testing and CYP2C19 gene polymorphism. Eight weeks after treatment, a 13C-urea breath test was performed on patients. The first successful eradication group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients with positive in 13C-urea breath tests after the second standardized treatment.
214895082|NCT02741414|DEVICE|The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing|The intervention focused on the results from the result of Amoxicillin susceptibility testing in vitro. In this study, the investigators selected the patients with Amoxicillin resistance from the first successful eradication group and the refractory infection of H. pylori group.
214895083|NCT02982837|DRUG|PEG-IFN & Nucleos(t)tide analogues|Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
215051155|NCT02292537|PROCEDURE|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
215051156|NCT01474967|DRUG|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
215051157|NCT01474967|DRUG|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
215051158|NCT00712478|DRUG|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
215051159|NCT03672630|DRUG|Azithromycin|Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]
215051160|NCT03672630|DRUG|Ethambutol|Ethambutol 25 mg/kg \[MYAMBUTOL\]
215051161|NCT03672630|DRUG|Rifampin|Rifampin 600 MG \[RIFADIN\]
215051162|NCT06518304|OTHER|GentleWave|GentleWave System employs a degassing process that removes dissolved gases from the solution. This optimization prevents the vapor-lock effect and ensures effective energy transmission through the root canal. As the solution enters the pulp chamber, hydrodynamic cavitation occurs, creating microbubbles that implode and generate sound waves across a broad frequency spectrum
214478225|NCT04905238|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure
214478226|NCT06329531|OTHER|Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)|Given by Questionnaire
214895084|NCT02982837|DRUG|Nucleos(t)tide analogues|Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
214895085|NCT00456300|DRUG|Exenatide|In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
214895086|NCT00456300|DRUG|Insulin|Each subject received a baseline study with insulin alone
214895087|NCT06156332|DRUG|surufatinib、serplulimab|"surufatinib:~250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab:~300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy.~Imaging was used every 6 weeks (±7 days) to evaluate tumor status until disease progression (RECIST 1.1) or death (during patient treatment), and tumor treatment and survival status after disease progression were recorded. The changes of neuroendocrine tumor markers were detected after treatment."
214895088|NCT03900052|DEVICE|Haptic cane|• A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.
214895089|NCT03900052|DEVICE|typical cane|Typical training cane loading training
214895090|NCT02784561|DRUG|Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|busulfan (3.2 mg/kg/day intravenously \[i.v.\], days -10 to -8)
214895091|NCT02784561|DRUG|Cytarabine(Actavis Italy S.p.A)|cytarabine (1.6 g/m2/day, days -7 to -3)
214895092|NCT02784561|DRUG|Fludarabine (Bayer)|fludarabine (30 mg/m2, day -7 to -3),
214895093|NCT02784561|DRUG|granulocyte colony-stimulating factor (KirinKunpeng)|granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
214895094|NCT02784561|DRUG|rabbit ATG（Sanofi/Genzyme）|ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
215051163|NCT06518304|OTHER|Conventional Protocol|Delivers irrigants (NaOCl, EDTA) through a needle-syringe system, often fails to reach the entire working length. This inadequacy can result in residual bacteria and necrotic tissue, potentially compromising treatment efficacy and increasing the risk of treatment failure.
215051164|NCT06184178|OTHER|Socio-health care|Socio-health care under TEC-MED model and an integral assessment
214296641|NCT02608749|BEHAVIORAL|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
214478227|NCT04637282|DRUG|PLX-200|15 mg/mL oral solution of experimental drug
214895095|NCT05503576|DEVICE|reminder mobile application|After thyroidectomy, patients will be reminded of medication and control appointments. In addition, patients will be able to access up-to-date and short trainings.
214895096|NCT04793594|OTHER|Berg Balance Test|Patients evaluate with Berg Balance Test for balance
214895097|NCT04793594|OTHER|Tinetti Balance And Gait Test|Patients evaluate with Tinetti Balance And Gait Test for balance
214895098|NCT04793594|OTHER|Time Up And Go Test|Patients evaluate with Time Up And Go Test for balance
214895099|NCT01199380|BEHAVIORAL|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
214478228|NCT04637282|DRUG|Placebo|Taste and color-matched drug-free solution
214895100|NCT01199380|BEHAVIORAL|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
215051165|NCT06114719|DRUG|Silymarin|Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
215051166|NCT05359315|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
215051167|NCT05140772|DRUG|Dipeptiven|IV administration daily for 7 days
215051168|NCT05140772|DRUG|normal Saline|IV administration daily for 7 days
215051169|NCT05770635|DEVICE|Embosphere and chemotherapy drug|chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition
215051170|NCT05770635|DEVICE|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition
215051171|NCT02173405|DRUG|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
215051172|NCT02173405|DRUG|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
215057439|NCT05530902|OTHER|Multidisciplinary Primary Rehabilitation Care|As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
214296642|NCT02608749|BEHAVIORAL|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
214895101|NCT01199380|DRUG|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
214895102|NCT03940131|DRUG|Panitumumab|FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFOX6 regimen will be repeated at 2-week intervals. FOLFIRI regimen consists of 2-hour infusion of irinotecan (180 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFIRI regimen will be repeated at 2-week intervals.
214895103|NCT05149326|DRUG|KN046|KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
214895104|NCT05149326|DRUG|placebo|placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
214895105|NCT00682474|BEHAVIORAL|Counseling Intervention|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
214895106|NCT00682474|BEHAVIORAL|Information Intervention|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
214895107|NCT02371473|DRUG|Acetazolamide-placebo|The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
215051173|NCT05607602|OTHER|Comparison of blood samples between the two groups|In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation\[18\]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
215051174|NCT01206829|BEHAVIORAL|8-session CBTcourse|Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.
215051175|NCT01206829|BEHAVIORAL|8 session cognitive behavioral therapy|8 sessions cognitive behavioral therapy in group
215051176|NCT01979614|DRUG|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
215051177|NCT01979614|OTHER|Placebo|5% v/v glucose solution
215051178|NCT03320187|DRUG|Nitroderm TTS|Transdermal nitroglycerin 5mg skin patch
215051179|NCT03320187|DRUG|Dinoprostone|Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
215051180|NCT04485845|DRUG|Vildagliptin|to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
215051181|NCT04485845|DRUG|Captopril Tablets|used to treat hypertension in metabolic syndrome patients and as a renal protector
215051182|NCT04485845|DRUG|MetFORMIN 500 Mg Oral Tablet|antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
215051183|NCT06442904|OTHER|Digital education program|The approximately six hours long digital education program will be available for three months and implies further education in intraoral radiographic examinations.
214296643|NCT02608749|BEHAVIORAL|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
214478229|NCT03500328|OTHER|Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq|Early Aggressive Therapy
214895108|NCT02371473|DRUG|Placebo-acetazolamide|The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
215051184|NCT01172444|DRUG|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
215051185|NCT01172444|DRUG|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
215051186|NCT01172444|DRUG|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
215051187|NCT03134859|BEHAVIORAL|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
215051188|NCT01056081|OTHER|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
215051189|NCT00666081|DRUG|GSK690693|Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
215051190|NCT02497222|DRUG|RNS60|
215051191|NCT02497222|DRUG|Normal Saline|
215051192|NCT00756275|DRUG|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
214895109|NCT06578273|DEVICE|NeuroGlove|"The NeuroGlove is a plastic chamber with multiple apertures along its length to allow for puffs of air to be directed to the volar surface of the distal forearm, the palm, and the fingers. The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development. A pneumatic pump delivers intermittent puffs of air cycling between one second on and two seconds off. The hand with the palm facing up is placed within the device chamber on a gel pad to provide a comfortable resting surface for the duration of the treatment, which lasts approximately thirty minutes.~The device facilitates the rehabilitation, improvement, or restoration of motion in patients with neurological disorders."
214668874|NCT03114501|BEHAVIORAL|Symptom Questionnaires|Symptom questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
214895110|NCT05600673|DRUG|Bimatoprost 0.03% solution|Topical Bimatoprost 0.03% solution
214895111|NCT05600673|DEVICE|CO2 fractional laser|CO2 fractional laser treatment
214895112|NCT01088230|OTHER|Botox®|the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
214895113|NCT01088230|OTHER|saline solution|the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
214895114|NCT05011604|DEVICE|Full-Digital Workflow in Single-Tooth Implant Rehabilitation|"For all patients included in the study, a digital impression was taken using an intraoral scanner. A CBCT exam was performed on the mandibular or maxillary jaw with the missing tooth. The stl. and the dicom. files were then superimposed to allow the surgical planning.~Then it was elevated and reflected to increase the volume on the buccal side and exposed the bone surface. After this point, the implant was inserted, and another digital impression was taken.~Sutures 6.0 were positioned after healing abutment positioning to stabilize the soft tissues.~The final abutment and the provisional were designed and manufactured using cad-cam technology. One week thereafter, definitive abutment was positioned. Provisional restoration was then cemented using provisional cement removing all the possible occlusal contacts both in protrusive and in lateral positions. Three months thereafter, once osteointegration was obtained, definitive zirconia restoration was positioned and cemented."
214895115|NCT01445704|DIETARY_SUPPLEMENT|Probiotics|"The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05."
214895116|NCT01445704|DIETARY_SUPPLEMENT|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
214895117|NCT03822104|DIETARY_SUPPLEMENT|Bovine Colostrum|Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.
215051193|NCT00756275|DRUG|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
215051194|NCT00756275|BEHAVIORAL|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
215051195|NCT01466465|DRUG|Cholecalciferol|given orally, once daily, before grass pollen season
215051196|NCT01466465|OTHER|middle-chain fatty acids (carrier)|given orally, once daily, before grass pollen season
215051197|NCT00376636|DRUG|SPP635 (drug)|
215051198|NCT02849002|DEVICE|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
215051199|NCT00566046|DRUG|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
215051200|NCT00566046|DRUG|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
215051201|NCT01242631|DRUG|Everolimus|Everolimus 10 mg orally per day.
215051202|NCT03375086|DRUG|APX3330|APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
215051203|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire for gastrointestinal tract|To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
214478230|NCT03500328|OTHER|Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod|Traditional Therapy
214668875|NCT06559436|DRUG|Intravenous thrombolysis|Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg,
215051204|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire|To assess quality of life, the SF-36 questionnaire will be applied
214668876|NCT06559436|OTHER|Standard medical management|Standard medical management
214895118|NCT03822104|DIETARY_SUPPLEMENT|FM85|Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
214895119|NCT02103855|DRUG|Belatacept|
214895120|NCT02348112|DEVICE|Altis Single Incision Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
214895121|NCT02348112|DEVICE|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
214895122|NCT03181412|DIAGNOSTIC_TEST|Questionnaire|"Tests from Cincinnati prehospital stroke severity scale (CPSSS) will be carried out by the physician at emergency medical services on telephone call with firemen, paramedics or the emergency medical services team for any stroke suspicion that meets the criteria for inclusion. Emergency department physician will have to follow a standardized questionnaire to complete the different items of the score. The score will not be calculated by emergency department physician and will not influence the orientation and management of patients.~The final diagnosis will be the presence or absence of a large vessel occlusion. This diagnosis will be done on cerebral imaging by a neurologist."
214895123|NCT00762112|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
214895124|NCT00745550|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
214895125|NCT02773602|DRUG|Dexamethasone|200 μgm/kg of dexamethasone in 1 ml saline
214895126|NCT02773602|DRUG|Clonidine|2 μg/kg of clonidine in 1 ml saline
214895127|NCT02773602|DRUG|Normal Saline|1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
215051205|NCT03487484|BEHAVIORAL|Faecal Incontinence Score|To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
215051206|NCT05646225|OTHER|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
214895128|NCT00470964|PROCEDURE|Titanium Sapphire laser trabeculoplasty|
214895129|NCT02598921|RADIATION|three dimensional ultrasound|
214895130|NCT02598921|DEVICE|Office hysteroscopy|
214895131|NCT02319278|DRUG|Ferumoxytol|Infusion following between paired MRI scans
214895132|NCT05019300|BIOLOGICAL|Exposure: COVID-19 severity|COVID-19 severity between 4 to 7 points according the seven-category scale of clinical status reported by Huang et al. (2021) and severe to critical symptomatic levels on spectrum of disease reported by Wu and McGoogan (2020).
214895133|NCT04477070|PROCEDURE|Air-polishing with ultrasonic debridement|Use of air-polishing and ultrasonic device (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) to remove plaque and calculus from the surface of the roots of teeth.
214895134|NCT04477070|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
214895135|NCT03741400|DEVICE|Neofect RAPAEL Smart Glove|The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
214895136|NCT01587287|DEVICE|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
214895137|NCT02523261|PROCEDURE|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
214895138|NCT02523261|PROCEDURE|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
215057440|NCT03235921|DRUG|Nitroglycerin patch 5mg|application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
215057441|NCT03235921|OTHER|placebo|no drug given to the control group
215057442|NCT03081663|PROCEDURE|Quads-Sparing Approach|Quadriceps-sparing mid-vastus approach for total knee arthroplasty
215057443|NCT03081663|PROCEDURE|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
215057444|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
215057445|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine|0.5 mL, IM
215057446|NCT01146184|DEVICE|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
215057447|NCT03977545|DIAGNOSTIC_TEST|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
215057448|NCT01653587|DEVICE|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
215057449|NCT01858441|DRUG|Abiraterone Acetate|
214296644|NCT02519530|BEHAVIORAL|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
214296645|NCT02116244|DRUG|Civamide Nasal Spray|
214895139|NCT03560128|DEVICE|Endocuff Vision device|Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.
214895140|NCT03560128|DEVICE|AmplifEYE device|Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
214895141|NCT05911061|BIOLOGICAL|High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
214895142|NCT05911061|BIOLOGICAL|Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
214895143|NCT05911061|BIOLOGICAL|control group|boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)
215051207|NCT05646225|OTHER|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes
215051208|NCT04103112|DEVICE|Graduated compression stocking|"Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling."
215051209|NCT00938912|DRUG|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
214296646|NCT05548842|DIETARY_SUPPLEMENT|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill 1,000 mg/day for 4 weeks
214296647|NCT05548842|DIETARY_SUPPLEMENT|Placebo group|Placebo 1,000 mg/day for 4 weeks
214296648|NCT01248377|PROCEDURE|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
214296649|NCT04352114|DRUG|LY3461767 - SC|Administered SC.
214895144|NCT05911061|BIOLOGICAL|Placebo group|saline
214895145|NCT03714828|DRUG|Injection of TVEC into target lesions - week 1-2|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient."
214895146|NCT03714828|DRUG|Injection of TVEC into target lesions 3wks after 1st injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the second and subsequent doses."
214895147|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 2nd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
214895148|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 3rd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
215051210|NCT00938912|DRUG|Lacosamide|"Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day."
215051211|NCT06315972|DRUG|clemastine (8 mg/day)|add-on clemastine (8 mg/day) + aerobic exercise training
214296650|NCT04352114|DRUG|LY3461767 - IV|Administered IV.
214296651|NCT04352114|DRUG|Placebo - SC|Administered SC.
214296652|NCT04923204|DIAGNOSTIC_TEST|Pharmacogenomic-testing with NEUROPHARMAGEN|"This observational retrospective study aims at evaluating the impact of the genetic variation in individual genes on the therapeutic response and side effects profile in a bipolar disorder cohort, using NEUROPHARMAGEN.~NEUROPHARMAGEN is a pharmacogenomic-based decision support tool that helps clinicians in the selection and dosing of psychoactive drugs based on the integration of pharmacogenetic information."
214296653|NCT04336982|DRUG|CC-90009|Injection
214296654|NCT04336982|DRUG|Venetoclax|Tablet
214296655|NCT04336982|DRUG|Azacitidine|Injection
214296656|NCT04336982|DRUG|Gilteritinib|Tablet
215051212|NCT06315972|DRUG|Placebo|add-on placebo + aerobic exercise training
215051213|NCT00456755|DRUG|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
215051214|NCT00456755|OTHER|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
215051215|NCT06164691|DEVICE|Blue light|Participants undergoing this intervention will be exposed to blue (442nm) light.
215051216|NCT06164691|DEVICE|Amber light|Participants undergoing this intervention will be exposed to amber (617nm) light.
215051217|NCT06164691|OTHER|Ambient White Light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments
214895149|NCT05871554|BEHAVIORAL|Mind-OP+|"Mind-OP is an online program designed to cultivate mindfulness and self-compassion developed by Beshai and his team. Mind-OP is self-guided, with four modules administered at a pace of one module per week (four weeks total). The version used for this study, Mind-OP+, is five weeks total, containing an extra module focused on connectedness.~The modules contain psychoeducational videos, guided audio meditations, goal-setting and motivational interviewing inspired exercises. Participants also have opportunities to engage with meditations and other exercises embedded within each module.~The first module (Week 1) introduces the concept of mindfulness. The second module (Week 2) focuses on attention to bodily sensations and thoughts. The third module (Week 3) introduces the concept of self-compassion. The fourth module (Week 4) focuses on the self-kindness component of self-compassion. The fifth module (Week 5) focuses on the concept of connectedness."
214895150|NCT05662527|DRUG|Pembrolizumab|One dosage of 4mg/kg (maximum of 400mg)
214895151|NCT03740373|DRUG|BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.
214895152|NCT03740373|DRUG|BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.
214895153|NCT03149276|OTHER|Interpreter services|
214895154|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Fumarate|Ferrous Fumarate - 300 mg
214895155|NCT06303531|DIETARY_SUPPLEMENT|Polysaccharide Iron|Polysaccharide Iron - 150 mg
214895156|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Ascorbate|Ferrous Ascorbate - 100 mg
214895157|NCT02732262|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
214895158|NCT02732262|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
214895159|NCT02732262|DRUG|Oxycodone, 0.02 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
214895160|NCT01526473|BIOLOGICAL|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
214895161|NCT03322644|BEHAVIORAL|Internet-based CBT intervention|The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
214895162|NCT03423940|BEHAVIORAL|Functional communication training|"During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior)."
214895163|NCT02986867|RADIATION|SAbR Treatment of Lesions|"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."
214895164|NCT01093092|DIETARY_SUPPLEMENT|Calcitriol|Given PO
214895165|NCT01093092|DRUG|Cisplatin|Given IV
214895166|NCT01093092|DRUG|Gemcitabine Hydrochloride|Given IV
214668877|NCT03486730|DRUG|BT1718|Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
214668878|NCT04068597|DRUG|CCS1477|Oral capsule
214895167|NCT01093092|OTHER|Pharmacological Study|Correlative studies
214895168|NCT01998841|DRUG|Crenezumab|Crenezumab will be administered as per the schedule specified in the treatment arm.
214895169|NCT01998841|DRUG|Placebo|Placebo will be administered as per the schedule specified in the treatment arm.
214895170|NCT04539912|DEVICE|angulated screw retained crown|ASC abutment was used in AG;
214895171|NCT04539912|DEVICE|cemented crown|prefabricated Ti abutment was used in CG
214895172|NCT02552121|DRUG|Tisotumab vedotin (HuMax-TF-ADC)|
214668879|NCT04068597|DRUG|Pomalidomide|oral capsule
214668880|NCT04068597|DRUG|Dexamethasone|oral tablet
214668881|NCT04068597|DRUG|Azacitidine|Powder suspension for Injection
214895173|NCT04892537|DEVICE|Coronary Sinus Reducer|Coronary Sinus Reducer implantation according to standard clinical protocols
214895174|NCT04892537|PROCEDURE|Placebo Procedure|A placebo procedure involving venous sheath implantation in the right internal jugular vein without proceeding to CSR implantation
214895175|NCT00559533|DRUG|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
214895176|NCT01358747|DRUG|BEACOPPesc|
214895177|NCT01358747|DRUG|BEACOPPesc - ABVD - PET2|
215051218|NCT01594840|DEVICE|Changing chat|Diapers with tips
214668882|NCT04068597|DRUG|Venetoclax|Oral tablet
214668883|NCT06396208|DRUG|Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)|Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle
214895178|NCT04141982|DIAGNOSTIC_TEST|T-Cell SelectTM Kit|The T-Cell Select kit is intended for the isolation of mononuclear immune cells from whole blood, using positive selection via a magnetic bead-based cell separation system, for use in the T-SPOT.TB assay.
215051219|NCT00879723|DIETARY_SUPPLEMENT|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
215051220|NCT04856605|PROCEDURE|surgery|regular surgery
215051221|NCT03533699|DRUG|Propranolol|
215051222|NCT03533699|DRUG|Placebo Oral Tablet|oral tablets with no active drug
214895179|NCT00153972|DRUG|Cabergoline|
214895180|NCT00153972|DRUG|Levodopa|
214895181|NCT02792582|RADIATION|Proton Therapy|The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
214895182|NCT02792582|PROCEDURE|Surgery|When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
214895183|NCT03447743|DRUG|XR-NTX community location|XR-NTX will be administered at the local health care clinic
214895184|NCT03062761|OTHER|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
215051223|NCT02970136|DEVICE|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
214895185|NCT03062761|OTHER|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
215051224|NCT02970136|DEVICE|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
214895186|NCT03377374|DIETARY_SUPPLEMENT|Probiotic|L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.
214895187|NCT03377374|OTHER|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
214895188|NCT02065076|DRUG|Sodium polystyrene sulfonate|
215051225|NCT02970136|DEVICE|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
215051226|NCT02970136|OTHER|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
214895189|NCT02065076|DRUG|Lactose with carob gum|
214895190|NCT02854527|DRUG|Digoxin|single dose
214895191|NCT02854527|DRUG|Furosemide|single dose
214895192|NCT02854527|DRUG|Metformin|single dose
214895193|NCT02854527|DRUG|Rosuvastatin|single dose
214895194|NCT02854527|DRUG|Digoxin|0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)
215051227|NCT02970136|DEVICE|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
215051228|NCT02970136|OTHER|Home Based Screening Tests|Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
214895195|NCT02854527|DRUG|Furosemide|1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)
215051229|NCT05587179|OTHER|recovery position|A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.
215051230|NCT03470350|DRUG|Galunisertib|treatment with capecitabine and galunisertib
215051231|NCT01684670|BEHAVIORAL|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
215051232|NCT03815747|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
214895196|NCT02854527|DRUG|Metformin hydrochloride|10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)
214895197|NCT02854527|DRUG|Rosuvastatin|10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
214895198|NCT02390882|DRUG|Placebo|Placebo
214895199|NCT02390882|DRUG|HGP0412 capsule|Tamsulon high dose
214895200|NCT02390882|DRUG|HIP1402 capsule|Tamsulon high dose
214895201|NCT00004073|DRUG|suramin|
215051233|NCT00705705|BEHAVIORAL|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
215051234|NCT00705705|BEHAVIORAL|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
215051235|NCT01798147|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
215051236|NCT01798147|PROCEDURE|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
215051237|NCT02126319|BEHAVIORAL|Cognitive Affective preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
214895202|NCT00004073|RADIATION|radiation therapy|
214895203|NCT01944163|OTHER|Applying a referral model|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
214895204|NCT06353763|OTHER|Immersive virtual reality learning program|The immersive virtual reality learning programme was developed by the research team and two nurse experts in chronic wounds, who designed the learning content and script and created six pressure ulcer (PU) cases. Based on the standards of the European Pressure Ulcer Advisory Panel (EPUAP), the National Pressure Ulcer Advisory Panel (NPUAP) and the National Group for the Study and Advice on Pressure Ulcers and Chronic Wounds (GNEAUPP), prevention of healthy skin (case one), management of grade I, II, III and IV PUs (cases two to five) and an infected PU (debridement intervention) were developed. For each case, there was a formative version with immediate feedback and an evaluative one. Before starting the training, the students learned how to use the virtual reality glasses, buttons and joystick by playing a game that trained different dexterity movements. The computer assembly IVR application was developed using Unity 3D and the virtual objects were designed in 3Ds Max.
214895205|NCT01949402|OTHER|Computed Tomography|"The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.~Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study visit."
214895206|NCT01949402|OTHER|Thoracic ultrasound|The ultrasound will be performed by a single operator. The patient's position will ideally be with the patient sitting up at 45°. Ultrasound images and clips will be recorded at 10 points over each hemithorax - the 2nd, 4th and 6th intercostal spaces (ICS) in the mid-clavicular line; the 2nd, 4th and 6th ICS in the mid-axillary line; and the 2nd, 5th, 7th and 9th ICS posteriorly. Ultrasound estimation of the height of the right internal jugular vein will be undertaken. Central venous pressure will be calculated by adding 5cm. Inferior vena cava diameter will also be measured at end-inspiration and expiration. The time taken to perform each ultrasound will be recorded. Control, COPD and ILD groups will be scanned on a single occasion. Haemodialysis group will have 4 scans.
214895207|NCT01949402|OTHER|Spirometry|All participants in the study will undergo basic spirometry as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
214895208|NCT01949402|OTHER|Blood tests|All participants in the study will undergo blood tests as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
214895209|NCT00121537|DEVICE|Wound Care -Wound Vacuum Assisted Closure (VAC)|
214895210|NCT00121537|PROCEDURE|Wound Care - Wet to Dry Dressing Changes|
214895211|NCT01480245|DRUG|GSK2402968|6mg/kg/week
214895212|NCT00003080|DRUG|endocrine-modulating drug therapy|
215051238|NCT02126319|BEHAVIORAL|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
215051239|NCT03816787|PROCEDURE|Negative pressure therapy|Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
215051240|NCT02609425|DEVICE|Stratafix PGA Suture|Subject leak Stricture rates post procedure
215051241|NCT03037866|BEHAVIORAL|LifeSkills Training for College|The intervention will consist of e-learning modules (self-guided) and small-group sessions (facilitator led). The intervention is designed for new college students and is aimed at providing tools and strategies to help them maximize opportunities and adeptly handle the challenges ahead. The intervention will teach them the knowledge and skills needed to stay safe from problems that are prevalent among new students on college campuses, such as alcohol and drug abuse and sexual violence.
214668884|NCT06396208|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
214668885|NCT05474092|DEVICE|Aeson Total Artificial Heart|Heart Replacement Therapy
214895213|NCT00003080|DRUG|melphalan|
214895214|NCT00003080|DRUG|mitoxantrone hydrochloride|
214895215|NCT00003080|DRUG|tamoxifen citrate|
214895216|NCT00003080|DRUG|thiotepa|
214296657|NCT02707991|BEHAVIORAL|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
214296658|NCT01396720|DRUG|fluvoxamine|Fluvoxamine 100mg daily, 7 days
214296659|NCT01396720|DRUG|citalopharm|Citalopharm 20mg daily, 7 days
214895217|NCT00003080|PROCEDURE|peripheral blood stem cell transplantation|
214895218|NCT02345876|OTHER|no intervention|
214895219|NCT02367976|DRUG|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
214895220|NCT00842192|DRUG|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
214895221|NCT03299582|DEVICE|Hypothermia|Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
214895222|NCT03299582|DEVICE|Cryocompression|Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
214895223|NCT02315131|DRUG|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
214895224|NCT02315131|DRUG|Placebo|Placebo Comparator
214895225|NCT04902937|RADIATION|Adjuvant radiotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
214895226|NCT04902937|DRUG|neoadjuvant and adjuvant chemotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
214895227|NCT02732873|DEVICE|FibroFix Meniscal Scaffold|FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
214895228|NCT03567980|DRUG|Crisaborole|Application of topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.
214895229|NCT01034020|DRUG|Nicotine|
214895230|NCT05999214|DIAGNOSTIC_TEST|99mTc-H7ND SPECT/CT imaging performed|99mTc-H7ND SPECT/CT imaging positive (+) was defined as the presence of at least one measurable lesion and the uptake of the lesion was greater than that of normal liver in the experimental group, and patients were divided into SD+ and SD-. According to the guidelines and routine clinical practice, SD- patients were treated with the original regimen or maintenance treatment, and SD+ patients were divided into continuation of the original regimen or second-line treatment according to the MDT discussion results.
214895231|NCT00580502|DEVICE|LAP-BAND® Adjustable Gastric Band (LAGB®)|Bariatric surgery for patient whose BMI is between 30 and 40 kg/m\^2
215051242|NCT03757507|DEVICE|MultiSpectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography is a new emerging imaging technique which uses laser light to heat up molecules with a high pulsed laser. The molecules undergo thermal expansion and produces sound waves, which can be detected by special transducers. The device can pick up different signals in different wavelength to produce images with anatomic and biological information.
215051243|NCT01803971|OTHER|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
214668886|NCT01041092|DRUG|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
214296661|NCT04084301|PROCEDURE|High CPB flow|Target CPB flow 2.9 L/min/m2 throughout the CPB period
214296662|NCT03542344|DRUG|BI 1015550|Single rising oral dose
214296663|NCT03542344|DRUG|Placebo|Single rising oral dose
214296664|NCT05115734|DIAGNOSTIC_TEST|Serum acylcarnitine profiling|"Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.~Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA)."
214668887|NCT00814710|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
214668888|NCT00814710|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
214668889|NCT00814710|BIOLOGICAL|Hiberix|Intramuscular injection, 3 doses
214895232|NCT05115175|BEHAVIORAL|Mindfulness-Based Stress Reduction|Participants engaged in meditation and self-led exercises to help them understand and cope with stress.
214895233|NCT02575833|DRUG|Erenumab|A single dose of erenumab 140 mg infused over approximately 60 minutes.
214895234|NCT02575833|DRUG|Placebo|A single dose of a matching volume of placebo infused over approximately 60 minutes.
214895235|NCT03093259|DRUG|ABX464|ABX464 is a new Anti-inflammatory drug
214895236|NCT03093259|DRUG|Placebo oral capsule|Placebo matching with ABX464
214895237|NCT04446247|DIAGNOSTIC_TEST|Owlet Smart Sock Sensor 3rd Generation|Pulse Oximetry
215051244|NCT01730911|OTHER|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
215051245|NCT05010083|BEHAVIORAL|diet and lifestyle program|See description of main arm.
215051246|NCT05575700|DRUG|Ibuprofen|400 mg tablet three times daily
215051247|NCT05575700|DRUG|Placebo|tablet three times daily
215051248|NCT00618007|DRUG|PF-00734200 30 mg QD|30 mg QD
215051249|NCT00618007|DRUG|PF-00734200 20 mg QD|20 mg QD
215051250|NCT00618007|DRUG|Placebo|Placebo
214895238|NCT06261645|OTHER|Early Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
214895239|NCT06261645|OTHER|Delayed Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
214895240|NCT05626205|DEVICE|PARO robot|PARO is an advanced interactive robot. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties. PARO has five kinds of sensors: tactile, light, audition, temperature, and posture sensors, with which it can perceive people and its environment. PARO can learn to behave in a way that the user prefers, and to respond to its new name.
214895241|NCT00002897|DRUG|cisplatin|
214895242|NCT00002897|DRUG|fluorouracil|
214895243|NCT00002897|PROCEDURE|conventional surgery|
214895244|NCT03330873|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter
214895245|NCT03330873|DEVICE|Foley catheter|Foley catheter can partly separate the sides of uterus wall.
214895246|NCT02557763|DEVICE|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
214895247|NCT04881786|DEVICE|Orthodontic forces|56g force and 224g force
214895248|NCT02633787|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
214895249|NCT02668575|BEHAVIORAL|Supportive Care Intervention|Patients in the intervention arm of the study will see a SC specialist during regularly-scheduled CF clinic visits; per usual care, these visits should occur on a quarterly basis. Using a structured intervention manual, these visits will span 30-60 minutes each. Each visit will have a specific focus, such as: 1) comprehensive palliative care assessment; 2) symptom assessment and self-management; 3) advance care planning; and, 4) coping and resilience. Patients requiring follow up with SC before the next CF appointment will receive telephone follow up or an extra SC visit at the discretion of the SC provider.
214895250|NCT01742897|DRUG|TTS-fentanyl|
214895251|NCT02404805|DRUG|dolutegravir|dolutegravir tablets 50mg, once daily x 7 days.
214895252|NCT02404805|DRUG|simeprevir|simeprevir tablets 150mg, once daily x 7 days.
214895253|NCT06581380|DRUG|JK-1201I|JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.
214895254|NCT06581380|DRUG|Topotecan|Topotecan will be administered per drug label.
214895255|NCT05131672|PROCEDURE|open reduction and internal fixation (ORIF)|open reduction and internal fixation with pin or screw fixation
215051251|NCT05065593|OTHER|resistance and aerobic exercise|Resistive exercises allow loading the muscle under suitable conditions with various weights or resistances. In order to increase the level of physical fitness with the increase of muscle strength and bone mass in individuals, resistance exercises were preferred. Aerobic exercises, on the other hand, are a special type of exercise that develops both the musculoskeletal system and the cardiovascular system, which includes large muscle groups and should be performed for at least 20 minutes when the heart rate accelerates at certain rates. Aerobic exercise was preferred in order to increase cardiovascular endurance, accelerate fat burning and reduce fatigue.
215051252|NCT05065593|OTHER|physical activity recommendation|Patients will be informed about the importance of lifestyle change in disease management, walking training will be given to increase their physical activity level, and participants will be asked to follow a 45-minute walking program every day within their own means.
215051253|NCT01424943|BEHAVIORAL|Stepping Stones Triple P|10-12 session manualized intervention delivered in client homes
214895256|NCT05131672|PROCEDURE|cast immobilization|immobilization in a cast without reduction
214895257|NCT00254592|DRUG|Doxorubicin|60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
214895258|NCT00254592|DRUG|Cyclophosphamide|600 mg/m2 IV once a day every 14 days x 2-4 cycles
214895259|NCT00254592|DRUG|Carboplatin|AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose
214895260|NCT00254592|DRUG|Nab-paclitaxel|100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose
214895261|NCT00254592|DRUG|GM-CSF|250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
215051254|NCT01424943|OTHER|BabyNet Services As usual|BabyNet services as usual based on IFSP
215051255|NCT01291108|DRUG|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
215051256|NCT01291108|DRUG|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
215051257|NCT01291108|DRUG|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
215051258|NCT05592821|PROCEDURE|dental implant placement|In both groups, dental implants of the same brand will be placed into the bone with the same protocol.
214895262|NCT00254592|DRUG|Trastuzumab|4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
215051259|NCT05910515|OTHER|Debriefing|Structured debriefing in non-technical skills. (This is an educational study)
215051260|NCT01144143|DRUG|Infliximab|the study drug will be injected into the joint through a needle
215051261|NCT01144143|DRUG|Placebo|the placebo will be injected into the joint through a needle
215051262|NCT01144143|DRUG|Standard of Care: Methylprednisolone acetate|Methylprednisolone acetate will be injected into the joint through a needle
214895263|NCT00254592|DRUG|Bevacizumab|10mg/kg q 2 wks
214895264|NCT00763633|DRUG|vitamin B6|high dose of vitamin B6
214895265|NCT00763633|DRUG|vitamin B6|low vitamin B6
214895266|NCT02102854|DRUG|rATG|Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation
214895267|NCT06361680|DRUG|Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets|Group A will take Soft gel capsules or tablets of Coenzyme Q10 in a dose of 100-200mg of natural factors or kirkman but group B will not take Coenzyme Q10 just observe them
214895268|NCT02601014|BIOLOGICAL|Ipilimumab|Given 1 mg/kg IV
214895269|NCT02601014|BIOLOGICAL|Nivolumab|Given 3 mg/kg IV
214895270|NCT02601014|DRUG|Enzalutamide|given orally per standard of care
214895271|NCT01168427|DEVICE|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
214895272|NCT03537131|DRUG|Dapagliflozin 10 MG Oral Tablet|taken once a day
214895273|NCT03190031|OTHER|Endurance respiratory muscle training|Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea
214895274|NCT03190031|OTHER|Resistance inspiratory muscle training|Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
214895275|NCT04951869|DRUG|Protescal gel|Protescal gel (0.5 mL) was again applied over the subcutaneous tissue prior to skin closure in Protescal group
214895276|NCT05489302|DEVICE|Maxillary skeletal expander with protraction face mask with Alt-RAMEC protocol.|The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by Alt-RAMEC protocol.
214895277|NCT05489302|DEVICE|Maxillary skeletal expander with protraction face mask with conventional protocol|The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by conventional protocol
214895278|NCT00316290|BEHAVIORAL|Integrated Parent Training|Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
214895279|NCT00316290|BEHAVIORAL|Behavioral Parent Training|Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
214895280|NCT06632964|BIOLOGICAL|Recombinant oncolytic adenovirus injection solution of VT-101|Active ingredient: VT-101 recombinant oncolytic adenovirus Specifications: 2×10\^10 IFU/ml, 0.5ml/ capsule Method of administration: intravesical perfusion
214895281|NCT00029003|DRUG|gefitinib|Given orally
214895282|NCT00029003|OTHER|laboratory biomarker analysis|Correlative studies
214895283|NCT00681421|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
214895284|NCT03654833|DRUG|Rucaparib|PARP inhibitor
214895285|NCT03654833|DRUG|Abemaciclib|CDK4/6 inhibitor
214895286|NCT03654833|DRUG|pembrolizumab & bemcentinib|PD1 checkpoint inhibitor, AXL inhibitor
214895287|NCT03654833|DRUG|Atezolizumab & Bevacizumab|PDL1 checkpoint inhibitor, VEGF inhibitor
214895288|NCT03654833|DRUG|Dostarlimab and Niraparib|IG Antibody, PARP Inhibitor
214668890|NCT00814710|BIOLOGICAL|Tritanrix-HepB|Intramuscular injection, 3 doses
214895289|NCT01068483|DRUG|BKM120|
214895290|NCT05611554|BEHAVIORAL|ACT|Psychological intervention focused on (a) values clarification, (b) defusion strategies, (c) training in flexible attention to the present moment (mindfulness), and (d) committed action and psychological acceptance through metaphors and experiential exercises.
214895291|NCT03744247|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
214895292|NCT03744247|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
214895293|NCT03744247|DRUG|Placebo|Intravenously every 2 weeks
214895294|NCT03434522|DEVICE|vBloc Maestro Rechargeable System|vBloc therapy consists of a neuromodulation device that delivers intermittent, controllable electrical blocking algorithms, to the intra-abdominal vagus nerve for the treatment of obesity.
214895295|NCT02456740|DRUG|Erenumab|Administered by subcutaneous injection once a month
214895296|NCT02456740|DRUG|Placebo|Administered by subcutaneous injection once a month
214895297|NCT03119402|BEHAVIORAL|Rhythmic Reading Training|RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
214895298|NCT03119402|DEVICE|Transcranial direct current stimulation|tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
214895299|NCT00286104|DEVICE|Antibiotics-impregnated ventricular catheter (Bactiseal®)|Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
214895300|NCT00286104|DEVICE|Plain ventricular catheter (Codman EDS II/III)|Plain ventricular catheter
214895301|NCT02046044|DRUG|Digoxin|
214895302|NCT02046044|DRUG|Ivabradine|
214895303|NCT02934243|DEVICE|laryngeal mask insertion|airway management with laryngeal mask
214895304|NCT00477880|BIOLOGICAL|Cetuximab|
214895305|NCT00308204|DRUG|Raptiva|injection
214895306|NCT04522440|OTHER|to relieve the pain of inpatients in the hospice Ward|This study will use pain scale, distress thermometer and POMS to understand whether the patient's pain status have changed.
215051263|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
214895307|NCT01780701|PROCEDURE|Magnetic Resonance Spectroscopy Imaging with rectal probe|
214895308|NCT03957044|OTHER|The education of sensory integration with vestibular education|"Tactical, proprioceptive, visual and auditory senses were used in sensory integrity training sessions. In this group, the training program on tactile, proprioceptive, visual and auditory sensory activities was carried out for 2 weeks and 40 minutes. Sensory integrity training was performed by the physiotherapist and in the sensory room.~At the end of the training sessions, mothers were informed about the application of sensory integrity training to daily activities.Sensory integrity therapy room added tactile, proprioceptive, visual and auditory sensory materials as well as materials for vestibular sensation. Vestibular sensory materials, skateboard, swing, hammock, bowl, ball, ball pool, slide, climbing bar, trampoline, and balance board were used."
214895309|NCT04196569|DEVICE|Alcon Trifocal and Trifocal Toric Intraocular Lenses|"Panoptix Model #TFAT00 for the UV Absorbing Trifocal IOL. Torics:~TFAT30, TFAT40, TFAT50, TFAT60"
214895310|NCT04385017|OTHER|COVID-19 patients|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
214895311|NCT02863796|DEVICE|WhiteSwell System|To promote movement of interstitial fluid to the intravascular space to allow for the body to remove it, in conjunction with a diuresis regimen.
214895312|NCT01364012|DRUG|Bevacizumab|Bevacizumab will be administered at 15 mg/kg IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
214895313|NCT01364012|DRUG|Carboplatin|Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.
214895314|NCT01364012|DRUG|Paclitaxel|Paclitaxel will be administered at 175 milligrams per square meter (mg/m\^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.
214895315|NCT01364012|DRUG|Placebo|Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
214895316|NCT04053621|DIETARY_SUPPLEMENT|Thiamine pyrophosphate|12 weeks of weekly dose of 1 gram of thiamine pyrophosphate administered in an intravenous manner with saline solution
214895317|NCT04053621|OTHER|Placebo|12 weeks of weekly dose of 275 ml of saline solution administered in an intravenous manner
214895318|NCT04053621|DRUG|Metformin|All participants will continue taking metformin in their previous established tolerated dose for the duration of the study
214895319|NCT04840303|BEHAVIORAL|LevelMind@JC Mental Wellness Youth Hubs|Mental Wellness Youth Hubs Intervention aims to set up a series of community-based hubs for young people to enhance cognitive abilities, personal strengths and overall mental well-being. Among the experimental group participants (hub users), they are further divided into three tiers according to their psychological distress level. Tier 1 are youths with mild psychological distress level, who will be invited to participate in some innovative and interesting youth projects and activities (e.g., board game and floral artistry). Tier 2 are youths who have moderate level of psychological distress, or at risk for mental illness. Trained social workers will offer them with specific interventions (e.g., CBT, sleep intervention) according to their needs. Tier 3 are youths with severe level of psychological distress who are at risk for mental disorders. Diagnostic and medical assessment services will be delivered by psychiatrist or clinical psychologists.
214895320|NCT00371579|DRUG|rosuvastatin|
215051264|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
214895321|NCT00471679|DRUG|ethanol|
214895322|NCT04748107|DIAGNOSTIC_TEST|Impendence Cardiography|ICG is a noninvasive method of determining the amount of blood flow using the Non-Invasive Cardiac System - Cardiac Surveyor (NICaS) system, which provides an assessment of the cardiovascular system, respiratory system, and fluid retention.
214895323|NCT06750107|BEHAVIORAL|Safe South Africa|"The Safe South Africa intervention is a gender- and developmentally-tailored, designed to reduce actual or intended HIV risk behaviors, actual or intended IPV perpetration frequency, and endorsement of IPV supportive attitudes. This intervention comprises 2-hour sessions, held once a week for a total of two weeks. The intervention also includes take-home activities to deepen behavioral engagement with received sessions and to prime the pump for up-coming sessions. Part 2 involves behavioral practice, including bystander intervention techniques."
215051265|NCT02245321|OTHER|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
215051266|NCT02245321|OTHER|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
215051267|NCT02245321|DIETARY_SUPPLEMENT|Placebo|Receive pills to take daily that contain 0 mg iron.
215051268|NCT06110559|DEVICE|Active transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received 1.5 mA stimulation for 30 minutes."
214296665|NCT01705821|DEVICE|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
214296666|NCT01705821|PROCEDURE|Removal of pituitary tumor using modified curette|
214668891|NCT05406908|BIOLOGICAL|tozinameran|Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
214895324|NCT02409927|DIETARY_SUPPLEMENT|MCT oil 10g|10 g of pure MCT oil mixed with skim milk in a standardized breakfast
215051269|NCT06110559|DEVICE|Sham transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received effective stimulation of 1.5 mA for 30 seconds, after which the current was switched off. The entire session lasted 30 minutes, with 29 minutes and 30 seconds without stimulation."
215051270|NCT01762683|OTHER|Myometrium biopsy and blood samples|"The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study."
215051271|NCT04704024|DRUG|Tenofovir Disoproxil Fumarate|oral TDF medication 300 mg daily
215051272|NCT04704024|DRUG|Lamivudine Oral Solution|Oral lamivudine with weight-based dosing BID from birth until 6 months of age
215051273|NCT00848458|OTHER|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
215051274|NCT00848458|OTHER|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
215051275|NCT01435174|DRUG|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
215051276|NCT01435174|PROCEDURE|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
215051277|NCT01435174|PROCEDURE|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
215051278|NCT02550444|DRUG|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
215051279|NCT02550444|DRUG|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
215051280|NCT02550444|DRUG|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
215051281|NCT01482195|BIOLOGICAL|Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.
215051282|NCT06288633|PROCEDURE|Ganglionated plexi ablation|"Through access in the femoral vein, a mapping or ablation-mapping catheter is inserted into the right atrium, and a three-dimensional reconstruction of the right atrium is performed using an electroanatomic mapping system. The inferior and superior vena cava, the coronary sinus are indicated.~Then a transeptal puncture is performed using a transeptal introducer and a needle for transeptal puncture under fluoroscopic control. A three-dimensional reconstruction of the left atrium is performed using an electroanatomic mapping system.~During or immediately after the creation of three-dimensional maps of both atria, areas of the typical concentration of ganglion plexuses (GP) are ablated using radiofrequency applications (30-50 Watts, 10-40 s each point). Ablated points are annotated on the three-dimensional map. GPs ablation zones are about 0.5 x 1.0 cm in size."
215051283|NCT06288633|DIAGNOSTIC_TEST|Electrophysiological study|Through access in the femoral vein, a diagnostic catheter is inserted in the area of the coronary sinus under fluoroscopic control. The effective refractory period (ERP) of the atria will be measured according to the method adopted in clinical practice, namely: using a ten-pole diagnostic electrode installed in the coronary sinus, a series of eight electrical pulses with the same amplitude and frequency is applied to the atrial myocardium. Then the ninth pulse is applied with a gradual decrease in the time interval until the absence of an atrial myocardium response to the pulse is registered. The cycle of an additional, ninth pulse, in which the atrial myocardium did not respond to an electrical impulse, is considered an atrial ERP.
215051284|NCT04884607|OTHER|subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes|"* Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~* Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart."
215051285|NCT04144738|DIAGNOSTIC_TEST|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
215051286|NCT04144738|DIAGNOSTIC_TEST|FIT test|Stool samples will be collected by the subject for the FIT test.
215051287|NCT04144738|PROCEDURE|Colonoscopy|Subjects will undergo a screening colonoscopy.
215051288|NCT04037098|DIETARY_SUPPLEMENT|Magnesium lactate.|2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months
215051289|NCT04037098|DIETARY_SUPPLEMENT|Placebo|2 tablets orally every 12 hours of on inert placebo for three months
215051290|NCT00005844|DRUG|oxaliplatin|
215057450|NCT00205153|BEHAVIORAL|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
214895325|NCT02409927|DIETARY_SUPPLEMENT|MCT homogenate 10g|10g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
214895326|NCT02409927|DIETARY_SUPPLEMENT|Control|vehicule (skim milk) with a standardized breakfast
214895327|NCT02409927|DIETARY_SUPPLEMENT|MCT oil 20g|20g of pure MCT oil mixed with skim milk in a standardized breakfast
214895328|NCT02409927|DIETARY_SUPPLEMENT|MCT homogenate 20g|20g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
214895329|NCT02409927|DIETARY_SUPPLEMENT|MCT oil 30g|30g of 100% pure MCT oil mixed with skim milk in a standardized breakfast
214895330|NCT02409927|DIETARY_SUPPLEMENT|MCT homogenate 30g|30g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
215051291|NCT04469205|OTHER|Coaching sessions|There are 3 sessions : the first session will last 1h30 and will be in consultation within the Institut Curie. The second session will last 1h30 and will be done remotely (by phone or by videoconference). The duration of the 3rd and last session will be adapted according to the needs of each patient and will last a maximum of 1 hour. It will also be done remotely (by phone or by videoconference).
214895331|NCT04871776|BEHAVIORAL|Messaging informed by construal level theory|"Messages are informed by construal level theory, which suggests that emphasizing why elicits more abstract thinking, or high-level construals, and can induce an emotional mindset, which could challenge an individual's sense of identity, autonomy, or political preferences. Conversely, emphasizing how is more cognitive and evokes concrete thinking, or low-level construals, and encourages a planning or implementation mindset, which may be better for encouraging vaccine uptake."
214895332|NCT04871776|BEHAVIORAL|Usual Care|Usual messaging sent by Mass General Brigham
214895333|NCT00886080|PROCEDURE|Pulmonary vein isolation using microwave energy|The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
214895334|NCT01043692|OTHER|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
214895335|NCT01741038|BIOLOGICAL|AlloStim®|AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
214895336|NCT01741038|PROCEDURE|cryoablation|percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
214895337|NCT01741038|OTHER|Physician's Choice (PC)|Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
214895338|NCT06020911|DRUG|Biodentine|17 primary second molars of 17 children will be capped with Biodentine
214895339|NCT06020911|DRUG|Theracal light cured|17 primary second molars of 17 children will be capped with Theracal light cured
214895340|NCT00692692|PROCEDURE|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
214895341|NCT00692692|PROCEDURE|standard of care tissue expander breast reconstruction surgery after mastectomy|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
214895342|NCT06033937|DEVICE|PFO occlusion|Patients in PFO occlusion group received PFO closure using devices.
214895343|NCT05393167|DEVICE|Echo_CT_MRI_US_x ray|Examination: General and systemic examinations of the studied neonates. Investigation will be done to the neonates according to the clinical examination including imaging studies as X-rays, U/S, echocardiography, CT and MRI studies
214895344|NCT06470451|DRUG|Hypericin|HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
215051292|NCT04778748|DIAGNOSTIC_TEST|Under-mattress sleep monitor|Under-mattress sleep monitor for patients with a confirmed diagnosis of Obstructive Sleep Apnea.
214895345|NCT06470451|DRUG|Placebo|Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
214895346|NCT06236438|DRUG|Livmoniplimab|Intravenously (IV) Infusion
214895347|NCT06236438|DRUG|Budigalimab|IV Infusion
214895348|NCT06236438|DRUG|Pembrolizumab|IV Infusion
215051293|NCT02666313|BEHAVIORAL|Exercise|"The physiotherapist will select exercises which are appropriate to that participant. Participants will complete online exercise diaries which are reviewed remotely by the physiotherapist. Depending on progress, exercises can be progressed, added or removed from the patient's individualised programme.~Participants will be encouraged to undertake their exercise programme, according to evidence base guidelines, five days/week for 30 minutes/day. Participants will receive weekly phone calls for the first two weeks of the programme. Thereafter, every two weeks the physiotherapist will review the exercise diary of each participant and remotely alter the participant's exercise programme as appropriate, by changing any combination of exercises, level of difficulty or number of repetitions."
215051294|NCT02533310|OTHER|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
215057451|NCT01720303|DRUG|repaglinide|2 mg (tablets) before each main meal
215057452|NCT01720303|DRUG|isophane human insulin|Injection s.c. (under the skin) at bedtime
215057453|NCT01720303|DRUG|insulin|Injection s.c. (under the skin) twice daily
214296667|NCT04766125|BEHAVIORAL|Adverse event information|All patients have access to the standard material about adverse events related to the surgery. One arm will additionally receive elaborated adverse event information from a nurse and a surgeon
214668892|NCT02437838|OTHER|No Intervention|No Intervention
214895349|NCT06236438|DRUG|Pemetrexed|IV Infusion
214895350|NCT06236438|DRUG|Cisplatin|IV Infusion
214895351|NCT06236438|DRUG|Carboplatin|IV Injection
214895352|NCT06236438|DRUG|Carboplatin|IV Infusion
214895353|NCT03440125|DRUG|Cayenne Pepper topical|20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
214895354|NCT03440125|DEVICE|Electrical stimulation|Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)
214895355|NCT03440125|PROCEDURE|Massage|10 minutes of classical massage of low back pain area.
214895356|NCT04935333|PROCEDURE|Collection of Leiomyoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
214895357|NCT04935333|PROCEDURE|Collection of Leiomyosarcoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
214895358|NCT04935333|PROCEDURE|Collection of control samples|Peripheral blood will be collected during an analysis or gynaecological consultation already planned by routine clinical practice. The sample will be sent to Igenomix for molecular analysis.
214895359|NCT04031625|OTHER|Metastatic Colorectal Cancer Database|Metastatic Colorectal Cancer Database
214895360|NCT06751173|OTHER|Static Core Stability exercises|"i. Plank: Press the hands and knees to the floor with the back in a neutral position and wrists aligned directly under the shoulders.~ii. Side Plank: Lie on the side with knees bent and prop the upper body up on the elbow.~iii. Shoulder Bridge: Raise the pelvis off the floor until only the head, neck, shoulders, and feet are touching the mat. Place the hands at the waist.~iv. Static Crunch: Lie on the back with feet flat on the floor and knees bent at a 90-degree angle.~v. Leg Lift: Lie straight on the floor, keep the arms at the sides, and slowly lift both legs into the air."
214895361|NCT06751173|OTHER|Mckenzie exercises|"i. Prone Extension (Positioned): Lie on the stomach with pillows placed under the chest for comfort.~ii. Prone Extension on Elbow: Keep the back and buttocks relaxed and rise up on the elbows as high as possible.~iii. Prone Press-ups: Place the hands beside the shoulders. Keep the back and buttocks relaxed, and use the arms to press up.~iv. Standing Extension: Stand with feet apart and hands on the small of the back with fingers pointing backward. Bend backward at the waist, supporting the trunk with the hands.~v. Side glide in Standing: Stand at a right angle to the wall about 2 feet away. Lean the shoulder into the wall."
214895362|NCT06751173|OTHER|Spinal Mobilization|Central-Unilateral posterio anterior and lateral glide
214895363|NCT02891668|DRUG|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
214895364|NCT04005066|DRUG|Elunate®|The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).
214895365|NCT05493501|DRUG|Aumolertinib monotherapy|Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
214895366|NCT05493501|DRUG|Osimertinib monotherapy|80 mg tablet administered orally, once daily
214895367|NCT05493501|DRUG|Pemetrexed|Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
214895368|NCT05493501|DRUG|Cisplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
214895369|NCT05493501|DRUG|Carboplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
214895370|NCT05493501|DRUG|Paclitaxel|Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
214895371|NCT05493501|DRUG|Nab paclitaxel|Administered by IV Infusion given over 4 fixed cycles per prescribing information.
214895372|NCT05493501|DRUG|Gemcitabine|Administered by IV Infusion over 4 fixed cycles per prescribing information.
214895373|NCT03145675|DRUG|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5+0.25 mg/kg administered intravenously.
214895374|NCT03145675|DRUG|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg administered intravenously.
214895375|NCT03145675|DRUG|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg administered intravenously.
214895376|NCT03145675|DRUG|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg administered intravenously.
214895377|NCT01509274|BIOLOGICAL|Plasma|3 ml plasma injected once into the plantar fascia
214895378|NCT01509274|BIOLOGICAL|Saline|3 ml of saline injected once into the plantar fascia
214895379|NCT01509274|OTHER|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
215051295|NCT02533310|OTHER|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
214668893|NCT02280811|DRUG|Fludarabine|Patients will receive Fludarabine 25 mg/m\^2/day for 5 days.
214895380|NCT02449980|PROCEDURE|Primary Surgery Group|Patients will receive surgical intervention during the initial hospital admission, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met
214895381|NCT02449980|PROCEDURE|Initial Non-operative management|Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
214895382|NCT03901976|DEVICE|bed exit detection|bed exit detection to avoid patients fall
214895383|NCT07088705|DEVICE|SML 577 nm|"A 577 nm yellow and 810 nm red lasers will be used for stimulation. The panmacular stimulation is planned, with the laser covering the entire central retina between the vascular arches, including the foveal region according to the study protocol.~Patient preparation will include obtaining informed consent, local anesthesia of the conjunctival sac with 0.05% proxymetacaine drops to reduce discomfort, and the administration of 0.1% tropicamide to dilate the pupil and increase access to the retina during laser stimulation. Next, a Volk macular contact lens (Volk Optical, Mentor, OH, USA) will be placed on the cornea using a viscoelastic agent. A modern 577 nm yellow laser (Supra Scan 577, Quantel Medical, Cedex, France) will be used for stimulation. The panmacular stimulation is planned, with the laser covering the entire central retinal area between the vascular arches, including the foveal region."
215051297|NCT01899430|DRUG|liraglutide|
214895384|NCT07088705|DEVICE|SML 810 nm|Preparation for SML using an 810 nm red laser will involve informed consent, local anesthesia of the conjunctival sac with 0.05% proxymetacaine drops to reduce discomfort during the procedure, and the administration of 0.1% tropicamide to dilate the pupil and increase access to the retina during laser stimulation. A Volk macular contact lens (Volk Optical, Mentor, OH, USA) will then be placed on the cornea using a viscoelastic agent. Central retinal stimulation will be performed using an 810 nm SML. The panmacular stimulation protocol will be used, with the laser covering the entire central retinal area between the vascular arcs, including the foveal region. During one session, approximately 1500-2000 confluent local applications of 200 μm diameter will be performed using 1.4 W of power with a duration of 0.15 seconds and a 5% duty cycle.
214895385|NCT07088705|OTHER|Sham SML|It is worth emphasizing that the experiment was designed as a factorial study design with the patient blinded. To this end, patient preparation, laser treatment duration, and auditory and visual sensations during the sham procedure will be the same as those experienced with a truly lasered eye. Consequently, fellow eye of an each RP eye that undergone the SML stimulation in either arm 1 or 2 will be included in the sham group (60 eyes).
214895386|NCT05197543|DIAGNOSTIC_TEST|Biomechanical rupture risk assessment|3D computational model is created from CT angiographic images available during standard AAA diagnostic process. Vascular wall stress is assessed based on the 3D model using Finite element method to identify highly stressed parts of AAA and results are compared to populational wall strength information (gathered from previous large histological study), thus rupture risk (stress/strength ratio) of each particular AAA is estimated. Other relevant factors such as gender, blood pressure, presence of intraluminal thrombus etc. are used during the calculation as well.
214895387|NCT03727451|COMBINATION_PRODUCT|iNO|inhaled nitric oxide
214895388|NCT07095803|DRUG|Ivonescimab (20mg/kg Q3W)|Patients received intravenous everciximab (20mg/kg Q3W) within 1 week before and after radiofrequency ablation.
214895389|NCT07095803|PROCEDURE|radiofrequency ablation|Patients received radiofrequency treatment for less than three lesions.
214895390|NCT07096960|BEHAVIORAL|STrAtegies for RelaTives (START) - Brazilian version|Eight individualized, weekly, home-based sessions will be delivered by trained community general health workers (CGHW). The intervention includes coping strategies, behavior management, and communication skills. Caregivers receive printed materials and structured exercises. CGHW receive a facilitator manual.
214895391|NCT07096531|OTHER|Suit therapy|Patients will receive suit therapy.
214895392|NCT07096531|OTHER|Suit therapy + Dual-task exercises|Patients will receive suit therapy in addition to dual-task exercises.
214895393|NCT07095998|DIAGNOSTIC_TEST|Threshold Tracking Nerve Conduction Studies|Measurement of nerve excitability parameters, including response to sub-threshold pre-pulses and other stimuli. The DS5 0 Isolated Bipolar Constant Current Stimulator is a non-invasive, non-therapeutic device that provides controlled electrical stimuli for detailed function assessment of the superficial radial, superficial peroneal, ulnar, and sural nerves.
214895394|NCT07096245|BEHAVIORAL|Vaccine Information Video Dissemination|"The intervention is a brief, community-informed educational video (2-3 minutes) focused on seasonal flu and COVID-19 vaccination. The video was developed using human-centered design and community-based participatory methods with Indigenous community members in California. It aims to promote trust in vaccines by presenting clear, culturally relevant health information.~The video is disseminated using three behavioral delivery strategies: (1) paid advertisements on Facebook and Instagram targeting adults in California, (2) peer-to-peer sharing by participants who previously enrolled in the study and are invited to serve as seeds who share the video with their personal contacts, and (3) distribution by trusted community-based organizations (CBOs) using their existing communication networks, including WhatsApp, social media, email, and newsletters. All viewers are prompted to complete a one-question trust poll and invited to participate in an optional anonymous survey on vaccine attitud"
214895395|NCT07096128|DRUG|[177Lu]Lu-PSMA-XT|\[177Lu\]Lu-PSMA-XT is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells.
214895396|NCT07096492|OTHER|Standard Swimming Training|Warm-Up: 1500 meters. Main set: 2000-3000 meters. Post-set: 1000 meters. Cool-Down: 200-400 meters.
214895397|NCT07096492|OTHER|Plyometric Training|The plyometric training intervention will focus on developing explosive power and reaction speed through various jumping and landing exercises. Progressive overload principles will be applied, with progression achieved through increasing sets and intensity. Plyometric exercises will be performed twice a week, similar to the strength group, and will begin with 3 sets of 3 repetitions in the first week. As the body adapts to the exercises, one additional set will be added each week until the third week, which will conclude with 5 sets. In the fourth week, a deload will be incorporated with 2 sets to allow for recovery. After the deload week, intensity will increase, either by performing exercises faster or exerting maximum effort during each repetition. Upper-body exercises will include the medicine ball slam, sitting medicine ball side passes, and medicine ball chest passes, focusing on explosive upper body movements. Lower-body exercises will consist of standing long jumps, partner med
215051298|NCT01899430|DRUG|metformin|
215051299|NCT04458246|OTHER|Exercise training group|Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
215051300|NCT04062188|OTHER|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire developed based on the combination of Barthel Index questionnaire and simplified modified Rankin Scale questionnaire with internal rules.
215051301|NCT04335630|DIAGNOSTIC_TEST|Electrocardiogram, telemetry, echocardiogram, laboratory values|Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
215051302|NCT00845247|OTHER|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
215051303|NCT03432494|DEVICE|Transcaval closure device (TCD)|Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
215051304|NCT02735057|DRUG|Carboplatin|
215051305|NCT00185237|DRUG|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
215051306|NCT00185237|DRUG|Placebo|Placebo patch
215051307|NCT00644943|DRUG|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
214895398|NCT07096492|OTHER|Strength Training|The strength training intervention was designed to supplement standard swim training with a structured, full-body resistance program aimed at enhancing muscular strength and swimming biomechanics through progressive overload. Participants in the strength group engaged in two sessions per week for each major muscle group. Training commenced with 3 sets of 8 repetitions per exercise during the first week, with weekly increases in training volume until the third week (5 sets), followed by a deload week (3 sets) to promote recovery. The subsequent four weeks maintained a consistent 5-set structure, with progression achieved through incremental increases in load. Each session began with lower-body exercises to prioritize large muscle group activation and maximize session efficiency. Lower-body exercises included dumbbell goblet squats, step-ups, Romanian deadlifts, TRX hamstring curls, and calf raises, while upper-body work featured push-ups, TRX rows, dumbbell rows, and dumbbell shoulder p
214895399|NCT07097311|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 1.0 gm/kg/day. The dose will be titrated from Day 1-24.
214895400|NCT07095348|OTHER|Serum Xanthine Oxidase Level Assessment|Blood samples were collected from each participant and serum was separated by centrifugation. Serum xanthine oxidase (XO) levels were measured using a Human XO ELISA Kit (Cat No. E3495Hu) according to the manufacturer's instructions. This intervention involved no therapeutic intent and was performed for observational biomarker analysis only.
214895401|NCT07095465|DRUG|ACP-204|Provided as 1 capsule, to be taken orally once daily
214895402|NCT07097363|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214668894|NCT02280811|DRUG|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
214668895|NCT02280811|BIOLOGICAL|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
214895403|NCT07097363|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214895404|NCT07097363|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215051308|NCT00644943|DRUG|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
215051309|NCT00912574|DRUG|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
215051310|NCT00912574|DRUG|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
215051311|NCT00912574|BIOLOGICAL|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
215051312|NCT00912574|DRUG|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
215051313|NCT05068986|BEHAVIORAL|Asthma education|All the study participants were subjected to an educational asthma program for 3 months for providing parents and children with information and skills to manage their asthma ,which was presented from the the first session, through providing a written asthma action plan, information about avoiding triggers, training in the correct use of medicines, including inhaler technique, information and support to maximize adherence . All patients were followed up by a phone call every 2 weeks and follow up visit monthly to confirm compliance to the educational program
214895405|NCT07097363|PROCEDURE|Computed Tomography|Undergo CT scan
214895406|NCT07097363|DRUG|Cyclophosphamide|Given IV
214895407|NCT07097363|DRUG|Doxorubicin|Given IV
214668896|NCT02280811|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
215051314|NCT06301308|DRUG|Intraurethral lidocaine gel alone|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
215051315|NCT06301308|DRUG|Intraurethral lidocaine gel + lidocaine 2% injection|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2% and using the injection of lidocaine 2% to irrigate the urethra using a 20 ml syringe.
215051316|NCT06301308|DRUG|intraurethral lidocaine gel + liquid paraffinl|Liquid paraffin were used to lubricate hte cystoscopy tube AND participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
215051317|NCT02733744|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
214668897|NCT00032929|DRUG|Selegiline|
214668898|NCT03746197|DEVICE|Project EVO Multi- Treatment|The EVO platform assesses perceptual discrimination while single-and multi-tasking. Visuomotor tracking involves navigating a character through a dynamically moving environment while avoiding obstacles. EVO uses adaptive algorithms to change game difficulty on a trial by trial and patient by patient basis for the tracking task and discrimination task with real-time feedback.
214895408|NCT07097363|PROCEDURE|Echocardiography Test|Undergo echocardiography
214296668|NCT00859768|OTHER|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
214895409|NCT07097363|BIOLOGICAL|Epcoritamab|Given SC
214895410|NCT07097363|DRUG|Etoposide|Given IV
214895411|NCT07097363|OTHER|Fludeoxyglucose F-18|Given fludeoxyglucose
214895412|NCT07097363|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214895413|NCT07097363|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214895414|NCT07097363|DRUG|Prednisone|Given PO
214895415|NCT07097363|BIOLOGICAL|Rituximab|Given IV
214895416|NCT07096635|DRUG|Melatonin|Patients will receive oral melatonin 10 mg (two 5 mg tablets) one hour before the operation plus intra-articular analgesia at the end of surgery.
214895417|NCT07096635|OTHER|Starch tablets|Patients will receive two oral inert starch tablets of the same shape and color one hour before the operation plus intra-articular analgesia at the end of surgery.
214296669|NCT04498611|DIAGNOSTIC_TEST|contrast-enhanced breast MRI|Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.
214296670|NCT01486628|DRUG|ND0612|levodopa and carbidopa solution for subcutaneous administration
214296671|NCT01486628|DRUG|Placebo|Saline solution for SC continuous administration
214296672|NCT05356247|BEHAVIORAL|Lausanne Trialogue Play Brief|The brief treatment program will consist of an LTP family assessment with video feedback to caregivers to address family interaction patterns and child mental health. Families will participate in four sessions conducted online using the Zoom for Healthcare platform. In the first session, families will engage in a family assessment in different groupings that will be recoded on zoom and used later in the treatment. In the second session, taking place one week later, families will take part in a mini assessment to learn more about the difficulties of the child. In the third session, the clinical team will share videos of the family assessment to the parents and discuss the families strengths, concerns, and goals for moving forward. In the fourth session, taking place one month after the third session, families will participate in a check-in session, debriefing the family assessment.
214296673|NCT05982509|DEVICE|EasyDew Regen MD Cream|For the study group, I received the prescription Easy Dew Regen MD Cream from Picosure Laser Apply an appropriate amount twice a day (morning and evening) to the skin of the area so that it can be absorbed well do. The control group is the non-chalant group. However, for one month after the procedure, it is not a medical device The normal moisturizer you use at home is available, and the area where you have undergone laser treatment Apply it twice a day (morning and evening) to the skin so that it can be absorbed well.
214296674|NCT01859754|BIOLOGICAL|Octagam 5%|Intravenous immunoglobulin 5%
214895418|NCT07095881|OTHER|Zirconia-based composite customized healing abutment|using Zirconia-based composite in customized healing abutment fabrication
214895419|NCT07095881|OTHER|Conventional composite customized healing abutment.|using conventional composite in customized healing abutment fabrication
214895420|NCT04957628|BEHAVIORAL|Harmful alcohol use treatment|Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C \> 6 (men) / \> 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.
214895421|NCT04957628|BEHAVIORAL|Non-prescribed psychoactive medicinal use treatment|Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.
214895422|NCT04031469|OTHER|There is no intervention in this study|There is no intervention in this study
214895423|NCT06507527|OTHER|Collection of variables|This is an observational study, so no interventions that are not routine clinical practice are performed. It is only about collecting information on variables that are already collected in normal clinical practice.
214895424|NCT05837845|DRUG|MDMA|Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
214895425|NCT05837845|BEHAVIORAL|Cognitive Processing Therapy|Participants will receive 8-15 (average of 12) sessions of Cognitive Processing Therapy
215057454|NCT03584815|PROCEDURE|Surgery/Fasciotomy|Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks
215057455|NCT03584815|OTHER|Physiotherapy|Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
215057456|NCT02508545|OTHER|perceived egocentric distance (PED) measurements|
215057457|NCT02508545|OTHER|Parabolic flight|
215057458|NCT01736267|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
215057459|NCT00411385|DRUG|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
215057460|NCT00411385|DRUG|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
215057461|NCT00411385|DRUG|Ribavirin|800mg/day for 24 weeks
214895426|NCT05837845|BEHAVIORAL|MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)|Participants assigned to MDMA-aCPT will undergo a therapeutic approach administered by trained therapists. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. MDMA can elicit feelings of empathy, love, and deep appreciation, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present. A combined treatment of MDMA and therapy may be especially useful for treating PTSD because MDMA can attenuate the fear response of a perceived threat to one's emotional integrity and decrease defensiveness without blocking access to memories or preventing a deep and genuine experience of emotion.
214895427|NCT05287230|BEHAVIORAL|CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging)|Investigators will use concepts from the LIFT and REFLECT interventions.
214895428|NCT05287230|BEHAVIORAL|Control|Participants will watch HIV and health related videos and discuss how it is related to aging with HIV.
214895429|NCT05733416|DIAGNOSTIC_TEST|FDG PET/CT|F-fluorodeoxyglucose positron emission/computed tomography
214895430|NCT05733416|DIAGNOSTIC_TEST|Usual Care|Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
214895431|NCT06146361|BEHAVIORAL|COVID-19 Group Problem Solving|"This group will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a plan of action to reduce their and their peers' risk for COVID-19 transmission. Navigation Component will consist of providing information and linking LDLs with social service providers that can help buffer some of the social and economic effects of the COVID-19 pandemic and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support, defined as encouraging social networks to provide informational, emotional, appraisal, and instrumental support as cited in the Taxonomy of Behavior Change Methods."
214895432|NCT06146361|BEHAVIORAL|Standard of Care|This group will receive a COVID-19 prevention flyer and social resources list only
214895433|NCT06146361|BEHAVIORAL|Booster session|"Participants will have a 10 - 15 minute booster' session about a week after engaging in the small group intervention. They will be contacted by phone and the booster will consist of brief prompts to engage participants in a discussion to encourage them to act on their personal commitments to protect themselves and others against COVID. They will also be encouraged to seek COVID related resources based on the information provided during the small group intervention."
214895434|NCT04150783|PROCEDURE|Surgical repair for nasal obstruction|Patient reported quality of life questionnaires
215051318|NCT03345446|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
215051319|NCT00856635|DRUG|Glatiramer Acetate|20 mg injected daily subcutaneously
215051320|NCT00856635|DRUG|placebo|injected daily subcutaneously
215051321|NCT04478903|OTHER|Questionnaire|Zarit Burden Inventory French version and SF12
215051322|NCT01643642|OTHER|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
215051323|NCT01643642|OTHER|Treatment As Usual|Other: Treatment As Usual
215051324|NCT05160506|DRUG|Hydrocortisone|Hydrocortisone is a steroid (corticosteroid) medication.
215051325|NCT05160506|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
215051326|NCT02229981|DRUG|ABC294640|
215051327|NCT02971319|DEVICE|Tc-99M-Tetrofosmin SPECT|
215051328|NCT02971319|DEVICE|F-18 FDG PET|
214296675|NCT01859754|BIOLOGICAL|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
214296676|NCT00101114|DRUG|sorafenib tosylate|Given PO
214296677|NCT00101114|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
214296678|NCT00101114|OTHER|laboratory biomarker analysis|Optional correlative studies
214296679|NCT05309564|DRUG|Botulinum toxin type A|Single intervention
214296680|NCT04210310|DRUG|Oxytocin|The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
214296681|NCT04210310|OTHER|Placebo nasal spray|A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.
214296682|NCT04426682|DIAGNOSTIC_TEST|urodynamics parameters|"Urodynamics evaluation is performed in the preoperative period in patients whose operation is planned due to incontinence.~Urodynamics evaluation is performed again in patients who applied with postoperative relapse due to surgery failure or different reasons.~It will be shown whether there is a difference between the urodynamics parameters of preoperatively examined patients and those of urodynamics examined in case of postoperative failure."
214296683|NCT03894579|BIOLOGICAL|Study Product: SNK01|SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
214296684|NCT01986660|DRUG|Ibuprofen Cream (SST-0225)|
214895435|NCT03328884|DRUG|Irinotecan (CPT-11) liposome|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered 50 mg/m2 on D1 of a 14-day cycle in monotherapy."
214895436|NCT05394519|DRUG|Cagrilintide|Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
214895437|NCT05394519|DRUG|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) once-weekly
214895438|NCT05394519|DRUG|Placebo cagrilintide|Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
214895439|NCT05394519|DRUG|Placebo semaglutide|Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
214895440|NCT05878015|DRUG|Acetaminophen|1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
214895441|NCT04067037|DRUG|Camrelizumab|30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
214895442|NCT04067037|DRUG|Epirubicin|35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
214895443|NCT04067037|DRUG|Vincristine|1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
214895444|NCT04067037|DRUG|Dacarbazine|375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
214895445|NCT05471856|DRUG|BI 1703880|BI 1703880
214895446|NCT05471856|DRUG|Ezabenlimab|Ezabenlimab
214895447|NCT04797039|PROCEDURE|MR guided cryoablation|MR guided cryoablation of focal biopsy proven prostate cancer
214895448|NCT03897244|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
214895449|NCT03897244|DRUG|Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)|Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
214895450|NCT03897244|DRUG|Amoxicillin-Metronidazole Bismuth quadruple therapy|Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
214895451|NCT05210764|DRUG|propofol|General anesthesia is induced and maintained mainly with propofol.
214895452|NCT05210764|DRUG|sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
214668899|NCT02677584|DRUG|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
214895453|NCT05210764|DRUG|S-ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
214895454|NCT03649048|DRUG|High-Dose Cisplatin|Intravenous administration of High-Dose Cisplatin
214895455|NCT03649048|DRUG|Low-Dose Cisplatin|Intravenous administration of Low-Dose Cisplatin
214296685|NCT00063973|DRUG|cilengitide|Given IV
214296686|NCT00063973|OTHER|laboratory biomarker analysis|Correlative studies
214895456|NCT03649048|RADIATION|Radiotherapy|Participating centres are to follow their local radiation treatment planning and delivery techniques.
214895457|NCT06819839|BEHAVIORAL|Village Health Worker (VHW) Care Model|VHW care model includes four components: (1) universal screening of all non-pregnant adults over 40 for elevated CVD risk (2) confirmatory visit to confirm diagnoses of hypertension, diabetes and elevated CVD risk (predicted 10-year risk \>10%) (3) monthly household visits by VHW; (4) an mHealth tool (tablet computer) to assist with determination of study eligibility and provide recommendations for initiation of medications according to local guidelines. VHW household visits include: health education on smoking cessation, healthy diet, physical activity and medication adherence; assessment of possible medication side effects, measurement of blood pressure and (when applicable) blood glucose; review monitoring results with the treating clinician household delivery of medications; and facilitate referral and transport to higher levels of care.
214895458|NCT06792084|BEHAVIORAL|motivational interviewing|Motivational interviewing is a directive and client-centered approach used to elicit behavioral change by helping the client explore and resolve ambivalence. Motivational interviewing is a specific method of helping individuals understand their problems and take action for change. In this study, the motivational interview program created in line with the literature (Li et al, 2023; Miller and Rollnick, 2013; Çelik Örücü, 2020) consists of 5 sessions in total, one session per week. There are specific goals and objectives for each session.
214895459|NCT05980078|OTHER|Interactive consent|They were randomized to complete an interactive consent.
214895460|NCT05980078|OTHER|Standard consent|They were randomized to complete a standard written consent.
214895461|NCT04075487|OTHER|Web-module for patient education and planning|Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
214895462|NCT06788340|DRUG|PK-model to decide when to dose Vedolizumab and Ustekinumab|the pharmacokinetic model will include information about inflammatory parameters both in blood- and fecal samples, as well as weight, sex, previous treatments and drug concentration.
215051329|NCT01389674|PROCEDURE|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
215051330|NCT02796833|DRUG|SMOFlipid20%|
215051331|NCT04660175|OTHER|non-resistance therapy|The non-resistance technique, created in Jaseng Hospital, is a combination of ischemic compression and mobilization It is a treatment that improves the limited range of motion of the cervical spine and relieves pain by applying ischemic pressure to the induration of the neck and at the same time firmly supporting the patient's head to give passive joint movements and completely relax.
215051332|NCT04660175|OTHER|acupuncture|According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.
214895463|NCT05579782|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.~Other Name: PTeye Device"
214895466|NCT04591990|DRUG|Administration of AVP|Administration of AVP
214895467|NCT04591990|DRUG|Administration of placebo AVP|Administration of placebo AVP
214895468|NCT04591990|DRUG|Administration of placebo hydrocortisone|Administration of placebo hydrocortisone
214895469|NCT04591990|DRUG|Administration of hydrocortisone|Administration of hydrocortisone
214296687|NCT00869531|OTHER|wholegrain|wholegrain wheat vs. refined wheat products
214895470|NCT02363335|OTHER|Placebo|mixed meal
214895471|NCT02363335|OTHER|Roflumilast/Sitagliptin|Both Roflumilast and Sitagliptin together
214296688|NCT00869531|OTHER|refined wheat|refined wheat products
214296689|NCT06478160|DEVICE|Closed-Blood Sampling Devices|blood collection with Closed-Blood Sampling System (CBSD)
214296690|NCT06478160|OTHER|Waste discard volume|Blood collection without CBSD, usual practice, need to waste discard volume
214296691|NCT01637467|OTHER|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
214296692|NCT01637467|OTHER|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
214296693|NCT00568750|DRUG|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
214296694|NCT05404919|DRUG|Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide|Anti-hepatitis B medications
214895472|NCT02363335|OTHER|Sitagliptin|This is already known to increase GLP-1 \&amp; GIP secretion.
214895473|NCT02363335|OTHER|Roflumilast|This is already known to increase GLP-1 \&amp; GIP secretion
214895474|NCT06438185|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Inferior Turbinate Hypertrophy with Nasal Obstruction.
214895475|NCT05344443|DRUG|Lemborexant|A dual orexin antagonist
214296695|NCT03342287|OTHER|questionnaires|Questionnaires rating IBS symptoms, constipation, anxiety and depression
214296696|NCT03342287|OTHER|cognitive evaluation|Administration of online cognitive battery
214895476|NCT05344443|DRUG|Placebo|A placebo that looks and tastes like Lemborexant tablets
214895477|NCT06393868|DRUG|Omeprazole 20 mg Oral Tablet|Omeprazole once daily for 90 days
214668900|NCT02677584|DRUG|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
215051333|NCT04660175|OTHER|chuna|Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.
215051334|NCT04660175|OTHER|pharmacoacupuncture|This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.
215051335|NCT04660175|DRUG|Korean herbal medicine|Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.
215051336|NCT01244035|DRUG|Treatment A|MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
214296697|NCT03342287|OTHER|Blood|Measurement of cytokines/inflammatory biomarkers
214296698|NCT03342287|OTHER|Fecal sample|Measurement of the gut microbiome
214296699|NCT01435109|BEHAVIORAL|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
214296700|NCT01435109|BEHAVIORAL|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
214296701|NCT01435109|BEHAVIORAL|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
214296702|NCT00114465|DRUG|VSL#3|VSL#3 1 sachet twice a day
214296703|NCT00114465|OTHER|Placebo|Placebo 1 sachel twice a day
214296704|NCT00641862|DIETARY_SUPPLEMENT|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
214296705|NCT00641862|OTHER|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
214296706|NCT06377956|OTHER|Observation without intervention|Observation of gut length, food intake, fecal and urine calories, body composition, microbiota, metabolic rate, metabolomics.
214296707|NCT05287867|BIOLOGICAL|Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)|Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.
214668901|NCT00513344|DIETARY_SUPPLEMENT|Dark Chocolate|1 portion
214668902|NCT00513344|DIETARY_SUPPLEMENT|Milk Chocolate|1 portion
214668903|NCT00513344|DIETARY_SUPPLEMENT|"Control (polyphenol-free) Chocolate"|one portion
214668904|NCT02964078|DRUG|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
214895478|NCT06393868|OTHER|Placebo|Placebo once daily for 90 days
214895479|NCT04932993|BEHAVIORAL|Writing down goals|Patient will write their health goals down before the visit.
214895482|NCT03183609|OTHER|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
214296708|NCT05287867|OTHER|Sham procedure|"Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything."
214296709|NCT03442907|PROCEDURE|24 hour blood pressure measurement, fluids, vasopressors|Targeting individual blood blood pressure values during surgical procedures
214296710|NCT03442907|PROCEDURE|Standard of Care|Treatment according to Standard of care at the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf
214895483|NCT03183609|OTHER|Rice Flour in Protein Shake|15 Grams Rice Flour BID
214895484|NCT06636175|DRUG|64Cu-LLP2A|64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
214895485|NCT06636175|DEVICE|PET/CT|The results of 64Cu-LLP2A-PET/CT will not be provided to the patient or the treating oncologist/surgeon unless, in the judgment of the principal investigator, the images demonstrate an unsuspected abnormality that may warrant further evaluation.
214895486|NCT04610736|DRUG|Temozolomide Oral Suspension|One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
214895487|NCT05792189|OTHER|Timed Up and Go Test on subjects with ORIF of distal femur fractures|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
215051337|NCT01244035|DRUG|Treatment B|MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
215051338|NCT01244035|DRUG|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
214296711|NCT02058576|DRUG|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
214296712|NCT02058576|DRUG|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
214668905|NCT02964078|DRUG|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
214668906|NCT02449330|DRUG|Teneligliptin|
214296713|NCT04797793|DRUG|Adapalene Gel 0.1%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
214668907|NCT04037085|DRUG|Ketamine|Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
214668908|NCT05077761|DEVICE|Active High-intensity laser therapy|"High-intensity laser therapy will be used in the contact method, with the laser beam irradiated over the hamstring muscle. Dosage and parameters for the laser will be calculated.~Parameters-~1. Wavelength- 980 nm~2. Intensity/Power density- 3W/cm2~3. Emission mode- Continuous Emission~4. Energy (Joules)- 490 J~5. Irradiation time- 70 Sec on each point~6. Peak power- 15 Watt~7. Irradiation points- 09"
214668909|NCT05077761|DEVICE|Sham High-intensity laser therapy|Sham High-intensity laser therapy will be used in the contact method, without the laser beam irradiation over the hamstring muscle.
214668910|NCT05694598|GENETIC|VGR-R01|CYP4v2-coding gene delivered by AAV vector
214668911|NCT03903471|DEVICE|22G-ProCore Endobronchial Ultrasound Needle|EchoTip Procore® Endobronchial HD Ultrasound Biopsy Needle, COOK
214668912|NCT03903471|DEVICE|22G-Standard Endobronchial Ultrasound Needle|EchoTip® Ultra Endobronchial High Definition Ultrasound Needle, COOK
214668913|NCT01939795|OTHER|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
214668914|NCT03426046|PROCEDURE|Partial Pulpotomy|Partial removal of inflamed pulp tissue in cariously exposed teeth
214668915|NCT03426046|DRUG|Pulp Capping Agents|Biocompatible materials
214668916|NCT05200767|OTHER|completing surveys|"The level of usual physical activity before the disease ( COVID-19- coronavirus disease 2019) will be analysed based on the IPAQ ( International Physical Activity Questionnaire) results."
214668917|NCT02609399|DRUG|Oseltamivir|Oral
214668918|NCT02609399|DRUG|Peramivir|"IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician."
214668919|NCT06457438|DIAGNOSTIC_TEST|Elecsys Anti-HEV IgG, IgM|Diagnostic test used to determine antibodies in blood and serum.
214668920|NCT00094120|DRUG|MSI-1256F (Squalamine Lactate)|
214668921|NCT02016287|OTHER|Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy|Sequential paclitaxel chemotherapy and radiotherapy
214668922|NCT03973450|OTHER|Registration of familial forms and associated neoplasia|Retrospective registration of associated endocrine and non-endocrine neoplasia and potential familial setting
214668923|NCT05056831|BEHAVIORAL|Behavioral Intervention|Attend face-to-face mind-body sessions
214668924|NCT05056831|OTHER|Best Practice|Receive usual care
214668925|NCT05056831|OTHER|Informational Intervention|Receive targeted text messages
214668926|NCT05056831|OTHER|Quality-of-Life Assessment|Ancillary studies
214668927|NCT05056831|OTHER|Questionnaire Administration|Ancillary studies
214296714|NCT04797793|DRUG|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
214895488|NCT05792189|OTHER|Koos Jr assesment on subjects with ORIF of distal femur fractures|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
214895489|NCT05792189|OTHER|Timed Up and Go Test on subjects with DFR of distal femur fracture|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
214895490|NCT05792189|OTHER|Koos Jr assesment on subjects with DFR of distal femur fracture|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
214895491|NCT05530486|DEVICE|CC|Application of placebo LASER
214895492|NCT05530486|DEVICE|LG1|Application of LASER GasAs 660nm 4 J/cm².
214895493|NCT05530486|DEVICE|LG2|Application of LASER GasAs 660nm 8 J/cm².
214895494|NCT05530486|DEVICE|LG3|Application of LASER GasAs 660nm 12 J/cm².
214895495|NCT05530486|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
214895496|NCT05687448|DRUG|Apixaban 5 MG Oral Tablet|Patients treated with apixaban 5 mg twice daily (BID)
214895497|NCT05687448|DRUG|Aspirin 75 to 100mg once a day|Patients treated with Aspirin 75 to 100mg once a day
214895498|NCT06149845|PROCEDURE|Full Pulpotomy|Pulpotomy is a more conservative pulp treatment option where only the coronal pulp is removed and a medicament placement over the remnant radicular pulp after haemostasis is achieved.
214895499|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
214895500|NCT06243666|OTHER|No intervention|No intervention was implemented.
214895501|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
214895502|NCT00533481|DRUG|MK0557|
214895503|NCT04928612|DRUG|CBP-1018|CBP-1018 for injection, IV infusion
214296715|NCT04797793|DRUG|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
214895504|NCT02897102|BEHAVIORAL|Training|Training program based on abacus and other activities
214895505|NCT02897102|OTHER|Different group activities|ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
214895506|NCT03741192|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
214895507|NCT04514913|RADIATION|Multidetector Computed Tomography (MDCT) Scan|This is a low-dose CT scan of the chest using no contract material.
214895508|NCT04514913|PROCEDURE|Virtual Navigation Bronchoscopy (VNB)|This is a procedure where a camera will be inserted into the lung in order to guide sample collection of bronchoalveolar lavages, bronchail brushes and endobronchial biopsies.
214895509|NCT04639986|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
214895510|NCT04639986|DRUG|Eribulin Mesylate Injection|Eribulin is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
214895511|NCT04639986|DRUG|Capecitabine Oral Product|Capecitabine is administered orally (PO) following recommended doses and regimens as per approved package inserts.
214895512|NCT04639986|DRUG|Gemcitabine Injection|Gemcitabine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
214895513|NCT04639986|DRUG|Vinorelbine injection|Vinorelbine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
214895514|NCT00613808|DRUG|Nitric Oxide 200ppm Group B|200 ppm, 8hrs / day for 6 weeks
214895515|NCT01121861|PROCEDURE|Phacoemulsification with implantation of toric IOL|
214895516|NCT02848001|DRUG|CC-90009|CC-90009
214895517|NCT00505830|OTHER|questionnaires|"Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score"
214895518|NCT03922542|COMBINATION_PRODUCT|riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes
214895519|NCT03922542|COMBINATION_PRODUCT|Riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes
215051339|NCT01244035|DRUG|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
215051340|NCT01244035|DRUG|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
214668928|NCT03977077|DRUG|Albumin binding taxol|125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
214895520|NCT00137501|DRUG|Nifedipine|"Arm A:~Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.~Arm B:~Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks."
214895521|NCT02338648|DRUG|SUN-131 1.5% TDS|Active transdermal patch
214895522|NCT02338648|DRUG|Placebo TDS|Placebo transdermal patch for blinding
215051341|NCT01244035|DRUG|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
215051342|NCT04751227|DRUG|Modafinil|100-200 mg oral daily for for Wakefulness in the Critical Care Units
215051343|NCT05407805|OTHER|Electronic Diary|Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
215051344|NCT05135039|DRUG|Canagliflozin|Canagliflozin 100mg/day/patient
214668929|NCT06498037|DRUG|Fentanyl|Administration of subcutaneously administered fentanyl loading boluses
215051345|NCT05135039|DRUG|Placebo|Placebo 100mg/day/patient
214895523|NCT05457504|BEHAVIORAL|Remote blood pressure monitoring|Participants assigned to this arm will participate in the experimental intervention
214895524|NCT05457504|BEHAVIORAL|Usual Care|Participants assigned to this arm will participate in a placebo intervention
214895525|NCT05659199|DEVICE|extracorporeal shockwave|Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.
215051346|NCT01696773|OTHER|Tangerine tomato juice|Post-prandial feeding study
215051347|NCT01696773|OTHER|Red tomato juice|Post-prandial feeding study
215051348|NCT00088491|DRUG|Intramuscular Olanzapine Depot|
215051349|NCT00088491|DRUG|Oral Olanzapine|
214668930|NCT05813470|BIOLOGICAL|Omalizumab (CinnaGen)|Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection
215051350|NCT04694118|OTHER|rebound therapy|3 days a week in 12 weeks
215051351|NCT00641108|DRUG|ADAM SPECT plus Cognitive Therapy|
215051352|NCT00641108|DRUG|ADAM SPECT plus No Therapy|
215051353|NCT05926063|OTHER|Comparison short vs extended EBAT treatment group|This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
215051354|NCT04527055|DRUG|Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
215051355|NCT04527055|DIETARY_SUPPLEMENT|Lactobacillus acidophilus and Bifidobacterium lactis Bb12|"The probiotic powder per oral twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
215051356|NCT04527055|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
215051357|NCT04527055|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
215051358|NCT04527055|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
215051359|NCT02234440|DRUG|Metformin|
215051360|NCT02234440|DRUG|Insulin|
215051361|NCT04572646|OTHER|NRT proposition and exhaled CO measurement|"Nicotine replacement therapy is proposed to every patient included in the study.~Whether the patient accepts the therapy or not, exhaled carbon monoxide is measured at the preoperative consultation (about 15 days before surgery) and the day of surgery by a nurse. These two measures are compared to assess efficacy of nicotine replacement therapy."
214668931|NCT05813470|BIOLOGICAL|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
215051362|NCT02370368|DEVICE|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
215051363|NCT02370368|OTHER|Agility Ladder Drills|Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
215051364|NCT03349255|BIOLOGICAL|autologous ET1402L1-CART cells|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
215051365|NCT01370304|OTHER|active rTMS and active Venlafaxine|"rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
215051366|NCT01370304|OTHER|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
214296716|NCT04443504|BEHAVIORAL|The Connected Family Series|The intervention is an online, self-paced post-adoption family intervention that occurs over a 4-week period to support adoptive families post-adoption.
214296717|NCT03533179|DRUG|Glucagon|"Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30."
214668932|NCT02049567|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
214668933|NCT02049567|PROCEDURE|Cataract Surgery|Performed using standard microsurgical techniques
214668934|NCT00003937|DRUG|cisplatin|
214668935|NCT00003937|DRUG|dexrazoxane hydrochloride|
214668936|NCT00003937|DRUG|doxorubicin hydrochloride|
214668937|NCT00003937|DRUG|etoposide|
214668938|NCT00003937|DRUG|ifosfamide|
214895526|NCT05659199|BEHAVIORAL|myofascial release|pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.
214895527|NCT01410097|BEHAVIORAL|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
214895528|NCT01410097|BEHAVIORAL|Diabetes Support Education|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
214895529|NCT06156397|OTHER|Standard Physiotherapy Exercise Group|At the beginning of the treatment, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions. Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks.
214895530|NCT06156397|OTHER|Telerehabilitation Based Supervised Exercise Group|Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks. In the telerehabilitation group, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks at the beginning of the treatment, through a meeting with the patients via zoom application. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights.
215051367|NCT01370304|OTHER|sham rTMS and active Venlafaxine|"rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
215051368|NCT02797756|PROCEDURE|Esophago-gastro-duodenoscopy (EGD) with biopsy|
215051369|NCT02797756|PROCEDURE|Esophageal Impedance Monitoring (EIM)|
214296718|NCT03533179|DRUG|Esmolol|Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or \>25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.
214668939|NCT00003937|DRUG|methotrexate|
214668940|NCT00003937|PROCEDURE|conventional surgery|
214668941|NCT05243329|DRUG|Psilocybin|10 mg or 25 mg oral aqueous psilocybin solution
214668942|NCT04125745|DRUG|CXA-10|Each subject will receive oral CXA-10 at the dose of 300 mg once daily for 12 weeks
214296719|NCT03533179|DRUG|Physiologic saline - glucagon dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.
214296720|NCT03533179|DRUG|Physiologic saline - esmolol dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
214296721|NCT04157608|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
214296722|NCT04157608|DEVICE|Energy-Harvesting Mesofluidic Impulse Prosthesis|e-MIP is an experimental lower limb ankle-foot prosthesis.
214668943|NCT01031095|OTHER|coronary intervention|elective coronary intervention
214668944|NCT02426086|DRUG|Imetelstat 4.7 mg/kg|Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.
214668945|NCT02426086|DRUG|Imetelstat 9.4 mg/kg|Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
214668946|NCT00524303|DRUG|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
214668947|NCT00524303|DRUG|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
214668948|NCT00524303|DRUG|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
214668949|NCT00524303|DRUG|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
214895531|NCT06156397|OTHER|Mobile Application Supported Exercise Group|With the videos uploaded to the Becure application, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied in the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. Between weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weight. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions.
214895532|NCT00725283|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|Intramuscular administration
215051370|NCT05544435|BEHAVIORAL|Motivational İnterviewing|Motivational Interviewing (MI), which is one of these methods, is an individual-based counselling approach that can easily be used by nurses who have been trained to help the management of disease in chronic diseases (Berhe et al., 2020; Kızılırmak \& Demir, 2018; Maslakpak et al., 2020). The core principles of MI includes expressing empathy by providing acceptance and understanding, realizing inconsistencies, avoiding discussions and supporting self-efficacy (Matinolli et al., 2012). The main purpose of MI is to identify the ambivalent emotions that occur in the patient in health-related activities, to strengthen and encourage insights of patients by supporting healthy lifestyle changes and self-confidence (R.Miller \& Rollnick, 2013). Because of its flexibility and ability to be applied in different behavioural aspects, MI can be administered individually and in groups by trained individuals (Maslakpak et al., 2020).
215051371|NCT03228862|DRUG|Ergocalciferol|Ergocalciferol 40000, 60000 and 80000 once weekly
215051372|NCT02745496|PROCEDURE|TRUS Biopsy|Standard of Care Treatment
215051373|NCT02745496|PROCEDURE|TRUS/FUSION Biopsy|Interventional Treatment
215051374|NCT00389753|DRUG|Application of Aruba Aloë formula F-BC-096 or control|
215051375|NCT03723980|DRUG|Propolis|it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
215051376|NCT03723980|DRUG|Calcium Hydroxide|it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
215051377|NCT00237237|DRUG|vildagliptin|
215051378|NCT04218812|DIAGNOSTIC_TEST|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT
215051379|NCT04218812|DIAGNOSTIC_TEST|Automated electrical source imaging (ESI)|"The automated source imaging consists of 2 phases~1. Automated detection of EDs~2. Source imaging of each spike cluster and seizure onset epoch."
215051380|NCT00347932|DRUG|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
214296723|NCT05951868|BEHAVIORAL|Continuum of support on breastfeeding.|A continuous support program for women from antenatal period till 6 months after delivery to initiate early breastfeeding, exclusively breastfeeding for 6 month and to continue breastfeeding till 2 years and beyond.
214296724|NCT05451147|DRUG|Chhinnavahni Kashaya Vati along with Agnimantha Kwatha|Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months
214296725|NCT05451147|DRUG|Metformin Hydrochloride|Drug: Metformin Form: Tablet Dose: 500mg BID/TDS, Before meals Mode of Administration: Oral Anupaan: Plain water Duration: 3 Months
214668950|NCT04760548|OTHER|Observational study|
214668951|NCT04361110|RADIATION|Computerized tomography scan of the abdomen|Non-specific abdominal ct´s with different phases and contrast +/-.
214668952|NCT04453644|OTHER|Muscle static stretching|On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
214668953|NCT01690832|DRUG|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
214668954|NCT01690832|DRUG|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
214668955|NCT00499915|BEHAVIORAL|Secondhand Smoke Reduction and Smoking Cessation Counseling|A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
214668956|NCT00499915|BEHAVIORAL|Asthma Education|Asthma education will be provided at NICU discharge.
214668957|NCT00833859|DRUG|GTX (gemcitabine, docetaxel and capecitabine)|GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
214668958|NCT00833859|RADIATION|stereotactic body radiation therapy|stereotactic body radiation therapy (SBRT) 25
214668959|NCT00984451|BIOLOGICAL|Plasma collection following infection or vaccination with influenza A|High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
214668960|NCT02652000|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
214478231|NCT04671303|DRUG|Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Furmonertinib Mesylate：The dose of Furmonertinib Mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
214478232|NCT04705220|DIETARY_SUPPLEMENT|MERIVA® Tablets|The treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
214478233|NCT04705220|OTHER|Placebo Tablets|The composition of placebo includes the same components of the treatment tablets, except for the active substance.
214478234|NCT05930509|DEVICE|Non-invasive transcranial direct current stimulation (tDCS)|Electrical stimulation
214478235|NCT06517082|OTHER|Artificial Intelligence|Ambient AI software intervention is implemented into the providers workflow. The software incorporates Automated Speech Recognition technology with Large Language Models to generate clinical documentation in real-time.
214296726|NCT05479955|OTHER|5 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. The women in this group received 5 minutes of skin-to-skin contact as a clinic routine.
214296727|NCT05479955|OTHER|60 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
214296728|NCT04319120|OTHER|questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed. A dedicated telephone line and e-mail address will be used as a support if necessary (for questionnaires, emails or sending photos). The referring nurse and the clinical research assistant of the service will be in charge of centralizing the data collected.
214296729|NCT05725850|OTHER|EG (Experimental A. Oleracea extract gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the EG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
214478236|NCT05713006|DRUG|Alectinib Oral Product|Alectinib is administered with a sequential dose escalation every 21 days from 300 to 600mg twice daily in the phase 1 portion. In phase 2, patients received an investigator-chosen dose based on the PK analysis.
214296730|NCT05725850|OTHER|GP (Gel placebo)|Prior to bleaching treatment with 35% hydrogen peroxide, the GP group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
214296731|NCT03577704|DRUG|HLX07+Gemcitabine+Cisplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly."
214478237|NCT06088381|OTHER|Experimental Observation|Patients on the experimental arm will be under observation only.
214478238|NCT06088381|OTHER|Observation per Standard of Care|The low-risk group of patients will be observed per standard of care.
214478239|NCT06088381|RADIATION|Adjuvant Treatment per Standard of Care|The high-risk group of patients will receive adjuvant treatment per standard of care (Radiation with or without chemotherapy)
214478240|NCT06088381|DIAGNOSTIC_TEST|Circulating Tumor DNA test (ctDNA test)|Blood test for diagnostic and surveillance purposes measuring expression of Cell free HPV tumor DNA (ctDNA) in the blood. Patients will undergo ctDNA within 90 days pre-transoral robotic surgery(TORS), 2-14 days post TORS, then every 3 months (except for at 21 months) for 2 year post completion of initial therapy or salvage therapy.
214478241|NCT06790368|BIOLOGICAL|VENOX|Treatment with allergy vaccine against Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
214478242|NCT06954545|BEHAVIORAL|Healthy Kids Programme|Our intervention was prepared by adopting an interactive curriculum shaped on role-play with visual materials and toy models of foods appropriate for the age of the children
214895533|NCT04337398|BEHAVIORAL|Exercise training for 12 weeks (wearables)|Activity trackers with adaptive weekly step goals, weekly walking groups and coaching.
214895534|NCT04337398|BEHAVIORAL|Exercise training for 12 weeks (wearables and exergames)|Activity trackers with adaptive weekly step goals, weekly walking groups, coaching and exercise programme based on exergames (aerobic, resistance and stretching training three weekly group sessions).
214296732|NCT03577704|DRUG|HLX07+Paclitaxel+Carboplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly."
214296733|NCT03577704|DRUG|HLX07+mFOLFOX6|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly."
214296734|NCT03540966|COMBINATION_PRODUCT|CapulinTM|a kind of camouflage agent
214296735|NCT03540966|OTHER|Chinese version of the vitiligo life quality index, VLQI-C|a questionaire designed for patients with vitiligo
214668961|NCT02510599|DRUG|solithromycin|
214895535|NCT01668745|BIOLOGICAL|Early measles vaccine|
214895536|NCT02289599|DRUG|E2307|
214895537|NCT02289599|DRUG|E2307 Matching Placebo|
214895538|NCT04776629|DRUG|Orticumab|A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
214895539|NCT04776629|DRUG|Placebo|Placebo for orticumab, containing all components of formulation except the active ingredient
214895540|NCT02571478|BEHAVIORAL|Marriage Checkup|The MC adapted for primary care consists of three 30-minute appointments with the IBHC. Session 1 consists of discussing the of the couple's relationship history and each partner's primary strengths. Session 2 focuses on each partner's primary concern about the relationship. Session 3 is dedicated to providing feedback for the couple that identifies strengths, areas for possible improvement, and a menu of possible strategies or resources for the couple to consider pursuing.
214895541|NCT02902588|OTHER|ICG-PULSION|Intravenous administration of indocyanine green
214895542|NCT02902588|DEVICE|LiMON, Pulsion Medical Systems|Application of near infrared light
214895543|NCT02902588|OTHER|Gadolinium (Gadovist, Bayer, Germany)|Injection of gadolinium
214895544|NCT04911517|COMBINATION_PRODUCT|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
214296736|NCT05453344|DEVICE|DexCom one|Provision of DexCom One for glucose monitoring
214296737|NCT01661192|DRUG|AAT( Alpha 1 Antitrypsin)|
214296738|NCT01528254|DRUG|Placebo of vildagliptin|
214296739|NCT01528254|DRUG|vildagliptin|One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
214296740|NCT01528254|DRUG|Metformin|Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
214296741|NCT01166763|DRUG|vitamin D3|oral capsules, 10,000 IU per week for 6 months
214296742|NCT04339296|DEVICE|Spencer|The MDS dispenses medications on time with visual and audio reminders. The audio alert get louder if the plastic medication packet is not dispensed from the system. The MDS allows participants to dispense their medications early if they are going to be away from home. The system also displays personalized and health-condition speciﬁc questions. The pre-packaged medications are delivered by pharmacy that inserted directly into the spencer device. Spencer system is non-inclusive and approved by Health Canada.
214296743|NCT02232542|DRUG|Duloxetine - low dose|
214296744|NCT02232542|DRUG|Duloxetine - high dose|
214296745|NCT02232542|DRUG|Placebo|
214296746|NCT01909479|DRUG|MOD-4023|Individualized once weekly dose of MOD-4023
214296747|NCT01909479|OTHER|Placebo|Once weekly administration of placebo
214296748|NCT02502539|PROCEDURE|Controlled physical activity|
214296749|NCT04320485|DIAGNOSTIC_TEST|Active Anthrax Detect™ Plus (AAD Plus)|A lateral flow immunoassay rapid test (AAD Plus) for early and presumptive diagnosis of inhalational anthrax.
214296750|NCT04571580|DRUG|Normal Saline|intracoronary infusion with normal saline
214296751|NCT04571580|DRUG|Reteplase Injection 9mg|low-dose intracoronary fibrinolytic therapy with reteplase 9mg
214668962|NCT00887042|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, \& -6)
214668963|NCT02986451|DRUG|clarithromycin|Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
214895545|NCT05343780|DRUG|Heptex|Dukung Anak 200 mg + Milk thistle 100 mg
214895546|NCT05343780|OTHER|Rice bran|Placebo
214296752|NCT04571580|DRUG|Reteplase Injection 18mg|low-dose intracoronary fibrinolytic therapy with reteplase 18mg
214296753|NCT01032876|PROCEDURE|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (\>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
214296754|NCT01032876|PROCEDURE|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
214296755|NCT00212030|DRUG|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
214296756|NCT00212030|DRUG|placebo|Control
214296757|NCT04446377|DRUG|Apilimod Dimesylate Capsule|LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
214296758|NCT04446377|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, Size 0 capsules
214296759|NCT01733407|DRUG|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
214296760|NCT01733407|DRUG|placebo|400mg/kg/d divided TID for year 1 only.
214296761|NCT04810676|DRUG|CKD-501, D745, D150|QD, PO
214296762|NCT04810676|DRUG|CKD-383|QD, PO
214296763|NCT05483855|OTHER|Objective 1 Only: Telehealth Satisfaction Survey|Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.
214296764|NCT05483855|OTHER|Objective 2 Only: ArthritisPower Joint Assessment|RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.
214296765|NCT01328821|DRUG|CTP-499|600 mg, 1200 mg, 1800 mg and 2400 mg
214296766|NCT01328821|DRUG|CTP-499|400 mg immediate release capsule
214296767|NCT01936103|DRUG|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
214296768|NCT01936103|DRUG|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
214668964|NCT02986451|DRUG|Lenalidomide|Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
214296769|NCT04804410|DEVICE|LCR Meter (Brand: Keysight, Serial Number:E498AL)|The LCR meter is used for electric property analysis of tissues. It works by measuring impedance on multiple sections of excised tissue and translating those measurement into dielectric properties.
214296770|NCT01129648|DRUG|Placebo|Administered daily for 21 days
214296771|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296772|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296773|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296774|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
214296775|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296776|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296777|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296778|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
214296779|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296780|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296781|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296782|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
214296783|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296784|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214296785|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
214668965|NCT02986451|DRUG|Dexamethasone|Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
214895547|NCT01626482|OTHER|Kinesio Taping|"The taping consisted of two strips of material in the form of I on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12."
214895548|NCT01626482|OTHER|Placebo|The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
214895549|NCT01050829|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Single administration at a dose of 0.1 mmol/kg
214895550|NCT01050829|DRUG|Gadopentetate Dimeglumine (Magnevist, BAY86-4882)|Single administration at a dose of 0.1 mmol/kg
214895551|NCT03558581|OTHER|Educational|
215051381|NCT00347932|DRUG|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
215051382|NCT02491177|BEHAVIORAL|cMM|Home visits from community mentor mothers
215051383|NCT02491177|BEHAVIORAL|Text Messaging|Text messages received on mobile phone
215051384|NCT00521677|PROCEDURE|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
215051385|NCT00521677|PROCEDURE|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
215051386|NCT02782845|DRUG|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
215051387|NCT02782845|DRUG|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
215051388|NCT02782845|DRUG|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
215051389|NCT04645511|PROCEDURE|Balloon sinuplasty of maxillary sinuses|A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.
215051390|NCT04645511|PROCEDURE|Sham surgery|"The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides."
215051391|NCT04462029|DRUG|BR4002|"* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours"
215051392|NCT04462029|DRUG|BR4002-1|Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
215051393|NCT04512001|DRUG|MSB11456|Participants will receive MSB11456 subcutaneously, once a week.
215051394|NCT04512001|DRUG|EU-approved RoActemra|Participants will receive EU-approved RoActemra® subcutaneously, once a week.
215051395|NCT01029912|DEVICE|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
215051396|NCT05772403|DIAGNOSTIC_TEST|CEUS|CEUS for atypical liver nodules
215051397|NCT05236322|DEVICE|soft tissue laser|Surgical laser used in excision purpose
215051398|NCT01431898|DRUG|GS-9669 tablets|
215051399|NCT01431898|DRUG|Placebo to Match GS-9669 tablet|
215051400|NCT04648917|DRUG|Caffeic acid|40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
215051401|NCT02019953|OTHER|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
215051402|NCT02019953|OTHER|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
215051403|NCT02019953|OTHER|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
215051404|NCT02507596|BIOLOGICAL|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
215051405|NCT02507596|PROCEDURE|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
215051406|NCT04998500|BIOLOGICAL|Growth hormone, saline and GH receptor blockade (Pegvisomant)|This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
215051407|NCT01261364|BEHAVIORAL|GeneSightRx|Multi-genetic pharmacogenomic panel
214895552|NCT05744518|OTHER|Response monitoring|Other: Response monitoring (no intervention)
214895553|NCT04623619|DIETARY_SUPPLEMENT|Acetyl L-Carnitine|Administering 2 gr of Acetyl L-Carnitine orally in addition to the standard of care therapy for 14 days
214895554|NCT01402570|DIETARY_SUPPLEMENT|Glutathione|glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
214895555|NCT03804957|OTHER|Autologous blood patch injection (ABPI)|Autologous blood patch injection (ABPI) through a coaxial needle at the site of biopsy
214895556|NCT03804957|OTHER|CT-guided core needle biopsy (CNB)|Standard 18g lung core biopsy
215051408|NCT01261364|BEHAVIORAL|Treatment as usual|Treatment as usual
215051409|NCT00506402|DRUG|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
215051410|NCT01065025|DRUG|4SC-205|Repeated ascending oral doses of 4SC-205.
214895557|NCT02236260|PROCEDURE|Electroacupuncture|Acupuncture will be performed using an electrical stimulator (generating electrical stimulation) for electroacupuncture.
214895558|NCT02236260|DRUG|Local Anesthesia (lidocaine hydrochloride)|All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.
214895559|NCT03514459|OTHER|Systems Analysis and Improvement Approach|SAIA has five steps. The first step uses an Excel-based tool to quantify drop- offs, or people who did not progress, in each step of a process (Figure 1). This tool also allows the user to see the downstream effect when improving one step in the cascade, and holding the other steps constant. Step 2 involves process flow mapping with clinic staff to identify modifiable bottlenecks in the process. Step 3 develops and implements a workflow modification to address a bottleneck identified in step 2 (continuous quality improvement \[CQI\] step). Step 4 assesses impact of the modification and recalculates the cascade analysis in step 1 (CQI step). Step 5 repeats the cycle for CQI. SAIA draws from systems engineering in the Toyota Production Systems and from research in LMICs. Studies in quality improvement in LMICs highlight that CQI processes led to more sustainable, effective, and appropriate interventions (42-44).
214895560|NCT02350101|DEVICE|Rotational thromboelastometry|In bleeding patients point of care measurements are performed, in this case Rotational Thromboelastometry (ROTEM) to guide the use of blood products and coagulation factors.
214895561|NCT06007001|DEVICE|Telemedicine|"Pilot 1a/b : the tele-rehabilitation intervention in BC or H\&N operated patients will consist of a series of exercises. The physiotherapist during teleconsultation rehabilitation program will explain to the patient how to perform the movements and regulate breathing. Practical advice on correct and incorrect habits will also be dispensed by the physiotherapist during the teleconsultation.~Pilot 2: the tele-rehabilitation intervention will consist of tele psychological support performed by a trained psychologist in each participating center It will consist of the learning of techniques for managing negative emotions, for relaxation and for implementing effective behavioural and coping strategies.~For each group, the TC will be scheduled every week for 8 weeks. The session will be available on a secure platform (Edumeet). Moreover, if they agree to, patients will also wear a smart watch to monitor physical parameters such as physical activity, sleeping and heart rate."
214895562|NCT02730910|OTHER|Purple Wheat Crackers|Whole grain crackers manufactured with purple wheat
214895563|NCT02730910|OTHER|Purple Wheat Granola Bars|Whole grain granola bars manufactured with purple wheat
214895564|NCT04618523|DRUG|Artesunate-amodiaquine|Artemisinin-based combination treatment
214895565|NCT04618523|DRUG|Artemether-lumefantrine|Artemisinin-based combination treatment
214895566|NCT02892955|DEVICE|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the MOMENTUM 3 IDE Study.
214895567|NCT05264038|DRUG|OC514 (Low dose)|Low dose level of OC514
214895568|NCT05264038|DRUG|OC514 (Mid dose)|Mid dose level of OC514
214895569|NCT05264038|DRUG|OC514 (High dose)|High dose level of OC514
214895570|NCT05264038|OTHER|Placebo|Placebo to match
214895571|NCT03648736|OTHER|blood withdrawal|"* peripheral-venous before TASH, day 1, 2, 3, one week and one month after TASH procedure~* central-venous during TASH"
214895572|NCT05368818|OTHER|Secukinumab|Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source
214895573|NCT05433818|BEHAVIORAL|Group A|Skin-to-Skin Contact (SSC) contributes to mother-infant interaction and can increase breastfeeding success
214895574|NCT05433818|OTHER|Group B|education with a structured and expert opinion-based breastfeeding brochure
214895575|NCT00376649|BEHAVIORAL|lifestyle changing workshop|
214895576|NCT03825939|DRUG|Intravenous Placebo|IV 0.9% sterile saline
214895577|NCT03825939|DRUG|Intravenous Tranexamic Acid|1g TXA IVPB (intravenous piggyback)
214895578|NCT06392022|OTHER|watching cartoons with music|The purpose of this study was to evaluate the effect of watching musical cartoons on anxiety and vital signs in children undergoing rectal irrigation.
214895579|NCT03334240|DRUG|CLS003|CLS003
214895580|NCT03334240|DRUG|Vehicle|Vehicle
214895581|NCT03239535|BIOLOGICAL|Mesenchymal stem cells|Intramuscular injection
214895582|NCT03239535|BIOLOGICAL|Normal saline|Intramuscular injection
215051411|NCT05234918|DEVICE|Pediatric Rotary File Systems|"* Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6"
215051412|NCT02385006|BIOLOGICAL|Blood sample|
214296786|NCT01129648|DRUG|BCX4208|Adminstered daily for 21 days
214895583|NCT02810626|DEVICE|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
214895584|NCT04179838|BEHAVIORAL|Sleep-Deprived|Sleep for 4 hours at home.
214895585|NCT04179838|BEHAVIORAL|Non-Sleep Deprived|Sleep for 8 hours at home.
214895586|NCT01606358|DRUG|Carboplatin and / or taxol chemotherapy|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
214895587|NCT03649035|DEVICE|HTP treatment|Elegible patients will undergo HTP treatment, followed by standard of care Chemo therapy and SBRT protocol.
214895588|NCT06162364|OTHER|VR|playing a video using VR
214895589|NCT06162364|OTHER|theoretical training|Training was provided through theoretical education
214895590|NCT06162364|OTHER|training with video|Training was given with two-dimensional video
214895591|NCT01667718|DRUG|Bismuth|Bismuth 220mg b.i.d for 2 weeks
214895592|NCT01667718|DRUG|Lansoprazole|Lansoprazole 30 mg b.i.d.for 2 weeks
214895593|NCT01667718|DRUG|Levoﬂoxacin|Levoﬂoxacin 0.5 q.d. for 2 weeks
214895594|NCT01667718|DRUG|Amoxicillin|Amoxicillin 1 g b.i.d. for 2 weeks
214895595|NCT03869619|OTHER|Real-life epidemiological platform of lymphoma in France|"The REALYSA database will be described with the following characteristics:~* Number of patients included per month in total and according to subtype of lymphoma~* Number of patients in each region in total and according to subtype of lymphoma"
215051413|NCT00412581|DRUG|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
214895596|NCT00324818|DRUG|metronidazole and azithromycin|
214895597|NCT06576518|OTHER|Therapeutic exercise|An individualised incremental exercise programme was simultaneously supported by an adherence plan to assess and promote compliance.
214895598|NCT00163618|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
214895599|NCT03456102|DRUG|Pravastatin|"Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated."
214895600|NCT03662802|OTHER|Neural Network Classifier|The convolutional neural network is configured to receive an electrocardiogram segment as an input and to generate an output indicative of whether the received electrocardiogram segment represents a cardiac arrhythmia. No specific features of the electrocardiogram are identified to the convolutional neural network, and the received electrocardiogram segment is not filtered, transformed, or processed prior to reception by the algorithm. The algorithm is trained in a similar manner - the electrocardiogram segments are the sole input to the convolutional neural network.
214895601|NCT05639049|DEVICE|Enova GF3|Enova GF3, monofocal IOL
214895602|NCT05639049|DEVICE|Tecnis 1-piece ZCB00|Tecnis 1-piece ZCB00, monofocal IOL
214895603|NCT03161470|OTHER|Standard Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
214895604|NCT03161470|OTHER|Mechanical Chair Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
214895605|NCT03161470|OTHER|Sham Treatment|Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
214895606|NCT04947215|DIAGNOSTIC_TEST|stress biomarkers|used to estimate the reference values of putative biomarkers of birth stress such asCTnT, CTnI, copeptin, NT-proBNP and hs-CRP in the cord blood of full term neonates
214895607|NCT06067256|DRUG|Female Contraceptive|Effimia® exerts its action by means of a gonadotropin suppression mechanism through the estrogenic and progestin action exerted by EE and NGM. The contraceptive effect of Effimia® is based on the interaction of various factors, the most important of which consist of ovulation inhibition and endometrial modifications.
214895608|NCT06119893|DRUG|submucosal 8 mg (2 mL) dexamethasone application|The mucoperiosteal flap was applied. After operation, submucosal dexamethasone 8 mg (2 mL) was applied to the operation area as a test group.
214895609|NCT06119893|DRUG|submucosal 2 mL 0.9% isotonic sodium chloride application|The mucoperiosteal flap was applied. After operation, 2 mL 0.9% isotonic sodium chloride was applied to the operation area as a control group
214895610|NCT05454891|DRUG|Extended bolus of insulin then standard bolus of insulin|For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.
214895611|NCT05454891|DRUG|Standard bolus of insulin then extended bolus of insulin|For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
214895612|NCT06352788|DEVICE|Modular Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will use a modular design that includes a full length foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg just below the knee.
214296787|NCT00006080|DRUG|fenretinide|
214296788|NCT01060930|DRUG|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
214296789|NCT00737282|DRUG|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
214895613|NCT06352788|DEVICE|Mono Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will use a mono design that includes a full length foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg just below the knee.
214296790|NCT00737282|DRUG|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
214296791|NCT00477282|DRUG|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
214296792|NCT00477282|DRUG|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
214895614|NCT05362188|DRUG|Nicotinamide Topical|"Patients with discoid lupus erythematosus (face \& scalp) will be given topical nicotinamide in two concentrations (2\&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream \& gel)."
214895615|NCT03205878|OTHER|Telecoaching|"Patients in the intervention arm will receive a step counter and a cell phone with an app on which the amount of steps are daily sent to.~Initial targets on steps per day will be discussed with the patient after an activity monitoring before the telecoaching procedure. Dependent whether the patient reaches his/her proposed goal each week, new goals are set."
214895616|NCT03205878|DEVICE|CPAP|Patients will receive CPAP according to standard care
215051414|NCT00412581|DRUG|Dacarbazine|600 mg/m\^2 intravenously on Day 1 of every study cycle.
215051415|NCT03822143|DIAGNOSTIC_TEST|Ultrasound|Use of ultrasound device to diagnosis anemia in a fetus
215051416|NCT03915158|PROCEDURE|bariatric surgery|sleeve gastrectomy
214668966|NCT00705900|DRUG|LCD|2 applications / day for 12 weeks
214895617|NCT01660633|DRUG|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.
214895618|NCT01660633|OTHER|Autologous Transplantation|Patients who are myeloablative conditioning in multiple myeloma undergoing autologous transplantation( patients own blood-forming stem cells are collected to replace diseased bone marrow or bone marrow damaged by cancer treatment)
214895619|NCT04692311|DEVICE|an intelligent client-centred task-oriented training|3 x 45min of training with i-ACT system
214895620|NCT04692311|OTHER|Semi-structured interview|Participants, patients and therapists, were invited to a semi-structured interview after training period.
214895621|NCT00954811|DRUG|300IU rec-LH|luteal alternate doses
214895622|NCT00954811|DRUG|progesterone 600mg|luteal support
214895623|NCT01353599|DRUG|Mometasone furoate|220mcg once daily, for eight weeks
214895624|NCT04992806|PROCEDURE|hip arthroscopy|Use epidural anesthesia or general anesthesia. The patient lies on the orthopedic traction bed to protect the perineum and perform traction of the lower limbs on the surgical side. Under arthroscopy, check the labrum, acetabular articular surface and femoral head cartilage, and round ligament in turn. The acetabular labrum with tear degeneration was treated with labrum suture or labrum revision surgery according to the injury. Perform femoral head and neck plastic or acetabular plastic surgery, osteoid osteoma debridement, etc.
214895625|NCT01290068|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
214895626|NCT01290068|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
214895627|NCT01290068|DEVICE|Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
215051417|NCT05040646|OTHER|Delphi exercise|"During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W\&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.~After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached."
214296793|NCT00528658|DRUG|Paracetamol|1g qid
214296794|NCT00528658|DRUG|Ibuprofen|400mg tid
214895628|NCT04797104|DRUG|lerodalcibep|300 mg Q4W
214895629|NCT04829968|OTHER|gingival conditions control|"Peri-implant mucositis: It was diagnosed on the basis of the following criteria:~1. Visual inspection demonstrating the following signs of inflammation in the peri-implant region: red as opposed to pink colour, swollen tissues as opposed to no swelling, and soft as opposed to firm tissue consistency.~2. Presence of profuse (line or drop) bleeding and/or suppuration on probing.~3. An increase in probing pocket depths (PPDs) compared to baseline. • Peri-implantitis: It was diagnosed on the basis of the following criteria:~1\. Visual inflammatory changes in the peri-implant soft tissues combined with bleeding on probing and/or suppuration.~2\. Increasing PPDs as compared to measurements recorded at the time of placement of supra-structures."
214895630|NCT06200194|DEVICE|MiyoSmart Spectacles|No power in the central optic zone of DIMS lens for premyopic children with normal vision. Before entering elementary school, eligible preschoolers are asked to wear the DIMS spectacles after kindergarten hours and during weekends and holidays. After entering elementary school, full-time mode wearing of DIMS spectacles is required.
214895631|NCT06200194|DRUG|0.01% atropine|daily use of non-preservative 0.01% atropine eye drop for each eye over the study period.
214895632|NCT05442151|DRUG|PET/CT ([F-18]FAPI-74)|PET/CT using \[18F\] FAPI-74 injection
214895633|NCT00009204|DRUG|Citalopram [Celexa]|
214296795|NCT00528658|DRUG|Paracetamol Placebo|equivalent to 1g qid
214296796|NCT00528658|DRUG|Ibuprofen placebo|Equivalent to 400mg tid
214296797|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
214668967|NCT00705900|DRUG|calcipotriol|2 applications / day for 12 weeks
214895634|NCT00009204|DRUG|Perphenazine [Trilafon]|
214895635|NCT01608750|DRUG|Pantoprazol|40mg/day, oral, 28 days
214895636|NCT01608750|DRUG|Folic Acid|5 mg/day, oral, 28 days
214895637|NCT04811872|BIOLOGICAL|Intact umbilical cord milking (I-UCM)|Umblical cord milking will be performed by holding the newborn at or ∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team.
214895638|NCT04811872|BIOLOGICAL|Cut-umbilical cord milking(C-UCM)|This technique involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM.
214668968|NCT04854655|OTHER|Conventional resin composite|nanofilled resin composite
214668969|NCT04854655|OTHER|Activa Presto|calcium and phosphate hybrid material
214668970|NCT04854655|OTHER|Giomer|fluoride releasing hybrid material
214668971|NCT02914743|BEHAVIORAL|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
214895639|NCT04811872|BIOLOGICAL|Delayed Cord Clamping (DCC)|Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60 seconds before clamping the cord.
215051418|NCT03110484|DRUG|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
215051419|NCT03110484|DRUG|Erlotinib|Erlotinib 100mg once daily
214296798|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
214296799|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.
214296800|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.
214296801|NCT01275391|BEHAVIORAL|Computer Screening, Brief Intervention, Referral toTreatment|A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
214296802|NCT03067649|BEHAVIORAL|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
214296803|NCT03067649|BEHAVIORAL|Information only control|Participants are provided with a pamphlet containing referral information
214296804|NCT03407105|BIOLOGICAL|MDX-010|Specified dose on specified days
214296805|NCT00719121|DRUG|Talarozole|Topical Application (20 mg)
214296806|NCT00719121|DRUG|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
214296807|NCT00278655|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
214296808|NCT04101825|DEVICE|Auralya|Hyaluronic Acid-Dermal Filler
214296809|NCT04399577|BIOLOGICAL|Candida antigen|Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention
214296810|NCT05993260|BEHAVIORAL|Behavioural science-informed text messages|Behaviourally-informed content in vaccination eligibility reminder text messages
214296811|NCT05993260|BEHAVIORAL|Control|Control vaccination eligibility reminder text message
214296812|NCT04827927|PROCEDURE|Procedure: INTELLiVENT-ASV|With INTELLiVENT-ASV, the patient's conditions, 'ARDS', 'Chronic Hypercapnia' or 'Traumatic Brain Injury' can be chosen, if applicable. The controllers for minute volume, PEEP and FiO2 are all activated, and the target shifts for etCO2 and SpO2 are adjusted, if necessary.
214296813|NCT04827927|PROCEDURE|Procedure: Conventional ventilation|With conventional ventilation, the same etCO2 and SpO2 levels are targeted as with INTELLiVENT-ASV, but here the caregiver is fully responsible for choosing the settings.
214296814|NCT03719976|OTHER|Group-based educational intervention|The group-based educational intervention will use a bilingual Community Health Worker (CHW) who will teach parents key skills needed to access health care for children. Parents will be invited to attend 6 small, closed-group sessions held over 12 weeks and lasting no more than 75 minutes. Sessions will be interactive, culturally-appropriate, and held in parents' preferred language.
214296815|NCT01914744|DRUG|Entecavir|entecavir 0.5 mg/day PO
214296816|NCT01914744|DRUG|Lamivudine|lamivudine 100 mg/day PO
214296817|NCT02810392|DRUG|Intranasal Insulin|Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.
214296818|NCT02810392|DRUG|Intranasal saline|Delivery is with the Vianase device, 0.5 cc of normal saline
214296819|NCT05752903|DRUG|Dexmedetomidine-propofol|1 microgram/kg dexmedetomidine+2.5 mg/kg propofol intravenous (IV) bolus, 0.5 microgram g/kg/h dexmedetomidine+2.5 mg/kg/h propofol infusion
214296820|NCT05752903|DRUG|Ketamine-Propofol|1 mg/kg ketamine+2.5 mg/kg propofol iv bolus, 0.25 mg/kg/h ketamine+2.5mg/kg/h propofol infusion
214296821|NCT05893433|DEVICE|Bedside cycling|"participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~1. Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~2. Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment."
214895640|NCT03610204|OTHER|Buffalo horn technique|The participants receive a 30-min massage session, twice a week for a total 6 sessions.
214296822|NCT05893433|OTHER|control|the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
214296823|NCT01490476|DRUG|RAD001|10 mg per os / day or 05mg per os / day with 12 month
214296824|NCT02814513|DEVICE|ANDAGO|Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
214296825|NCT02814513|DEVICE|ANDAGO|Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
214296826|NCT02814513|DEVICE|ANDAGO|Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
214296827|NCT02814513|DEVICE|ANDAGO|Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
214296828|NCT02814513|DEVICE|ANDAGO|To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
214296829|NCT00840294|DRUG|Ciprofloxacin|
214296830|NCT00001889|PROCEDURE|Myocardial contrast echocardiography|
214296831|NCT00001889|PROCEDURE|Stress echocardiography with dobutamine|
214296832|NCT06014489|DRUG|azacitidine|during run-in and extention phase: from Cycle 1 until relapse
214296833|NCT06014489|DRUG|Venetoclax|during run-in and extention phase: from Cycle 1 until relapse
214296834|NCT06014489|DRUG|Cobicistat|"during run-in phase: from cycle 2 until relapse~during extension phase: from cycle 1 until relapse"
214895641|NCT05399472|DIAGNOSTIC_TEST|Dorsiflexion lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the participant stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The participant is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The participant steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
214895642|NCT05399472|DIAGNOSTIC_TEST|Jack Test|The Jack Test will be used to measure the first toe dorsiflexion under load. The examiner pulled the proximal phalanx of the hallux to dorsiflexion with his hand until the maximal amount of mobility was reached with the subject standing. The static arm of the goniometer was placed along the first metatarsal longitudinal axis while the free movable arm followed the proximal phalanx of the hallux axes.
215051420|NCT03389308|DRUG|diacerein 1% ointment|"Topically apply study medication to lesions identified by the Investigator that require.~treatment"
215051421|NCT03100448|DEVICE|On1 Concept|NobelActive implant placement with simultaneous On1 Base placement
215051422|NCT01698931|DRUG|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
215051423|NCT01698931|DRUG|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
214668972|NCT02914743|PROCEDURE|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
214668973|NCT06713551|OTHER|Big Amplitude Calisthenic Group Exercise with Music|The exercise program will consist of balance and mobility-oriented exercises such as reaching forward and upward while sitting on a chair, taking steps forward, backward, sideways and backward while standing, transferring weight, counting in place, sit-to-stand exercises, walking, changing directions or walking over obstacles (Appendix: Exercise Program). This exercise program will be applied to the first group with the accompaniment of classical Western music, while the other group will be applied without music. The exercise programs will be performed for both groups for 40 minutes, two days a week and for eight weeks.
215051424|NCT01698931|DRUG|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
214895643|NCT02351414|DEVICE|Total Knee Arthroplasty (EVOLUTION®)|
214895644|NCT04755114|OTHER|Turkish Music|Turkish Music;In choosing the music, patients will be asked about their favorite vocalist and music pieces before the procedure. The researcher will then download these music pieces from YouTube and create a 30-minute list and listen to patients.
215051425|NCT01059006|PROCEDURE|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
215051426|NCT05060692|DIAGNOSTIC_TEST|Bloot testing|NFL measruments in serum
214895645|NCT04755114|OTHER|comedy movie|Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. In the selection of comedy films, the opinions of two experts from Mimar Sinan University, Faculty of Fine Arts, Department of Cinema and Television and İnönü University will be preferred, and the films Kemal Sunal and Şener Şen, one of the actors that Turkish people know closely, laugh most and have settled into their culture, will be preferred.
214895646|NCT03096938|DIAGNOSTIC_TEST|methylation markers screening|Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis
214895647|NCT06574750|DRUG|CUREAⓇ (ARIBIO, Ltd., Seoul, Republic of Korea)|Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
214895648|NCT06574750|DRUG|JuvedermⓇ (Q-Med AB, Uppsala, Sweden)|Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
214895649|NCT00513695|DRUG|sunitinib malate|Given PO
214895650|NCT00513695|DRUG|paclitaxel|Given IV
214895651|NCT00513695|DRUG|doxorubicin hydrochloride|Given IV
214895652|NCT00513695|DRUG|cyclophosphamide|Given PO
214895653|NCT00513695|BIOLOGICAL|filgrastim|Given SC
215051427|NCT01952743|PROCEDURE|AF ablation with Renal Denervation|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
215051428|NCT01952743|PROCEDURE|AF ablation alone|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
215051429|NCT03198767|DRUG|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
215051430|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 50%|50% carbohydrate in breakfast meal
215051431|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 25%|25% carbohydrate in breakfast meal
215051432|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 8%|8% carbohydrate in breakfast meal
215051433|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 0%|0% carbohydrate in breakfast meal
215051434|NCT03198767|DIETARY_SUPPLEMENT|Psyllium|Powder 6 grams
215051435|NCT03198767|DIETARY_SUPPLEMENT|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
215051436|NCT00570323|DRUG|Arimidex|Aromatase inhibitors
214895654|NCT00513695|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214895655|NCT00513695|OTHER|laboratory biomarker analysis|Correlative studies
214895656|NCT00513695|OTHER|flow cytometry|Correlative studies
214895657|NCT05948150|OTHER|using a breastfeeding pillow|To make the breastfeeding pillow group use the breastfeeding pillow from the 8th hour in the postnatal period and to make evaluations at 24 and 48 hours
214895658|NCT05948150|OTHER|not using a breastfeeding pillow|The non-breastfeeding pillow group was evaluated at 24 and 48 hours without the use of a breastfeeding pillow
214895659|NCT06524050|BEHAVIORAL|standard care|standard care
214895660|NCT01907490|DRUG|Ha44 Gel|Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
214895661|NCT00105859|BEHAVIORAL|Education and Counseling|
214895662|NCT01524159|DIETARY_SUPPLEMENT|bromelain capsule|Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
214895663|NCT01524159|DIETARY_SUPPLEMENT|placebo (wheat starch)|Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
215051437|NCT00570323|DRUG|Faslodex|Hormone Receptor
215051438|NCT04636567|DRUG|Nerindocianine for injection|Procedure: routine minimally invasive abdominopelvic surgery.
215051439|NCT03067792|DRUG|5-fluorouracil, irinotecan and leucovorin|In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
215051440|NCT03067792|DRUG|docetaxel and cisplatin|In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
215051441|NCT05734664|DEVICE|Pulsify sensor|A positioning system will move the 1X1 cm Pulsify sensor step-by-step over a marked area of 10x10 cm on the subjects' chest to record a complete 3D data set of the heart. For accurate 3D reconstruction, the ECG and breathing cycle are also recorded during the acquisition using commercially available devices (Bitalino HeartBIT + Respiration Sensor). From the 3D dataset of the heart, the end-systolic and end-diastolic volumes will be extracted automatically to calculate the cardiac output.
214296835|NCT00447642|DRUG|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
214296836|NCT00447642|OTHER|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
214296837|NCT05980650|OTHER|Reiki implication|Reiki will be implicate by researcher by putting hands on patient
214296838|NCT05117398|DRUG|Dalbavancin administration|"A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance \< 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg."
214296839|NCT05117398|DRUG|Standard antibiotic therapy|Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
214296840|NCT01526616|DRUG|Metformin|Metformin 850 mg twice a day for six months
214296841|NCT01526616|DRUG|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
214296842|NCT00713154|DRUG|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
214296843|NCT00713154|DRUG|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
214296844|NCT04225728|DRUG|Iron Sucrose IV|"Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14."
214296845|NCT04225728|DRUG|Ferric polymaltose hydroxide complex IM|Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
214296846|NCT04225728|OTHER|Saline solution|100 ml i.v. of normal saline administered at Day 0 and at day 14.
214296847|NCT05390879|OTHER|Meditation|After the circuit, a 6 minutes long meditation auto-guided video.
214296848|NCT05390879|OTHER|Control|After the circuit, a 6 minutes long emotionally neutral video.
214296849|NCT05569200|DEVICE|Haifu Focused Ultrasound tumor therapeutic System|The device used in this trial will be Haifu Focused Ultrasound tumor therapeutic System. In Uterine benign tumor female, the investigators will observe the possibility of complication and tumor response of treatment.
214296850|NCT06242587|DEVICE|Pericoccygeal nerve block|The coccygeal corneas are visualised with a linear probe under ultrasound guidance. The pericoccygeal nerves are located medial to the cornu and a combination of local anaesthetic and dexamethasone is injected.
214296851|NCT06242587|PROCEDURE|Impar ganglion block|The sacrum is visualised with fluoroscopy. A needle is inserted through the sacrococcygeal junction. The optimal image is obtained by administering contrast material. A combination of local anaesthetic and dexamethasone is injected.
214296852|NCT05612178|BIOLOGICAL|3BNC117-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
214296853|NCT05612178|BIOLOGICAL|10-1074-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10- 1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
214296854|NCT05612178|OTHER|Sterile Saline|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks, 20 and 40.
214895664|NCT02835547|OTHER|Data collection|Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
214895665|NCT02099786|OTHER|COMP-VA|Hearing testing at each treatment interval by the comp-va audiologist
214895666|NCT02099786|OTHER|Standard of care|Hearing testing done in the audiology clinic after oncology referral or patient self referral
214895667|NCT01590225|DRUG|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
214895668|NCT01590225|DRUG|Peginterferon alpha-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 24 weeks.
214895669|NCT01590225|DRUG|Ribavirin|The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 24 weeks.
214895670|NCT01590225|DRUG|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
214895671|NCT01590225|DRUG|Peginterferon alfa-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 48 weeks.
214895672|NCT01590225|DRUG|Ribavirin|"Drug: Ribavirin~The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 48 weeks."
214895673|NCT00080912|RADIATION|radiation therapy|Given in a single fraction or multiple fractions
214895674|NCT05335486|DEVICE|RELEARN Neurofeedback|"Standard care + The RELEARN intervention.~Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines.~During standard care, intervention group participants will be subject to the RELEARN intervention, consisting of encephalography (EEG) neurofeedback of cerebral movement evoked signatures of pain, where the participants will be instructed in attempting to manipulate these signatures to reduce pain perception."
214296855|NCT04048824|BEHAVIORAL|Inhibitory Learning-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on maximizing the mismatch between participant's feared outcome and what actually occurred (i.e., expectancy violation). This condition includes techniques that incorporate associative learning principles such as exposure to multiple feared stimuli (i.e., deepened extinction), exposure variability in contexts and stimuli, occasional reinforcement, and mental reinstatement of inhibitory learning.
214895675|NCT05335486|OTHER|Standard care control|"Standard Care control.~Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention"
214895676|NCT02569125|DRUG|Everolimus|4.5 mg/m² daily
214296856|NCT04048824|BEHAVIORAL|Habituation-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on fear reduction from initial fear ratings. This condition includes theoretically-consistent techniques such as staying in the situation until fear declines, repetition of exposures until fear has declined, and a gradual approach to feared stimuli using an exposure hierarchy.
214296857|NCT01187043|DRUG|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
214296858|NCT04087876|DRUG|derazantinib|derazantinib will be administered orally
214296859|NCT04576429|PROCEDURE|venous puncture|"Venous punctures will be performed:~for patients of cohort A and B1:~* before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~* between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~* each 3 months up to 12 months.~for patients of cohort B2:~* before the radiotherapy;~* within the 6 weeks after the end of radiotherapy;~* at the 2 following evaluations (every 3 months)."
214296860|NCT04576429|PROCEDURE|tumoral biopsy|Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
214296861|NCT00755287|DRUG|insulin glargine|starting dose 10 IU daily
214296862|NCT00755287|DRUG|metformin|As prescribed
214296863|NCT00755287|DRUG|taspoglutide|10 mg once weekly
214296864|NCT00755287|DRUG|taspoglutide|20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
214296865|NCT04600674|PROCEDURE|Delayed cord clamping|DCC performed at 60 sec after birth
214296866|NCT04600674|PROCEDURE|Early cord clamping|ECC performed at 15 sec after birth
214296867|NCT04357678|OTHER|Qi Gong Programme|"Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week."
214296868|NCT04357678|OTHER|Short Form Sun Style Tai Chi|"Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session."
214895677|NCT03836300|BEHAVIORAL|Parent-Infant Inter(X)action Intervention (PIXI)|Psychoeducation around the diagnosed disorder, early development, and service navigation along with parent-child interaction activities, parent coaching, and family/parent well-being support.
214296869|NCT02716064|BEHAVIORAL|TAP-CM Intervention|The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
214296870|NCT03019133|DEVICE|Sound reduction|Subjects will wear noise reduction headphones between the hours of 8:00 pm and 8:00 am.
214296871|NCT03019133|DEVICE|Sound masking|Subjects will wear wear headphones playing relaxing music between the hours of 8:00 pm and 8:00 am.
214296872|NCT05289180|OTHER|Questionnaires|A questionnaire will be administered post-procedure to assess for pain and anxiety. This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
214478243|NCT06953947|PROCEDURE|Costoclavicular block|"The costoclavicular block was first described by Karmakar et al. in 2015. It is a type of brachial plexus block that targets the three cords located lateral to the axillary artery within the costoclavicular space. The costoclavicular space is defined as the area between the middle third of the clavicle and the anterior thoracic wall. Within this space, the cords of the brachial plexus are situated lateral to the axillary artery, positioned between the pectoralis major, subclavius, and serratus anterior muscles.~In contrast to the traditional infraclavicular approach, the cords in the costoclavicular block are located more superficially and are more consistently clustered lateral to the axillary artery, which may facilitate visualization and needle targeting. After the needle is placed between the three cords under ultrasound guidance, the local anesthetic (20 mL of 0.25% bupivacaine) is injected."
214895678|NCT01417156|DRUG|Nintedanib|150 mg bid
214895679|NCT01417156|DRUG|Pirfenidoneone|Existing treatment
214895680|NCT00770783|DEVICE|Thymatron|Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
214478244|NCT06953947|PROCEDURE|Interscalene block|Originally described by Etienne in 1925, the technique was later refined into its modern clinical form by Alon Winnie in 1970. The interscalene approach, primarily preferred for shoulder surgeries, aims to target the upper roots of the brachial plexus (C5-C7). In interscalene block, a needle is placed under ultrasound guidance around the upper and middle trunks of the brachial plexus, which pass through the space between the anterior and middle scalene muscles, and the local anesthetic (20 mL of 0.25% bupivacaine) is injected while its spread is observed.
214895681|NCT00770783|DEVICE|Tonica MagPro MST|100% power, vertex placement, 3 times per week for 4 weeks
214895682|NCT04595188|OTHER|Sulphur amino acids|"For the total sulphur amino acid requirement, there are 7 different methionine test levels (without dietary cysteine) ranging from 5 to 40 mg of methionine per kilogram body weight per day.~For the minimum methionine requirement, there are 7 different methionine test levels (with excess dietary cysteine)."
214895683|NCT01837511|OTHER|Data acquisition and analysis|Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
214895684|NCT02447211|DRUG|Doxepin cream 5%|Patients use doxepin creamtwice daily for one weeks
214895685|NCT02447211|OTHER|Placebo|Patients use cream without doxepin ingredient twice daily for one weeks
214895686|NCT06198231|OTHER|Pilates exercises|Pilates exercises
214895687|NCT06198231|OTHER|Flexibility ,strength and endurance excercises|flexibility ,strength and endurance excercises
214895688|NCT01384474|OTHER|Diffusion of a surgical safety checklist|"* Assistance by a local caregiver investigator (i.e., surgeon, anaesthetist, nurse,...) responsible for the implementation of surgical safety checklist within the operatory rooms of his department ;~* A two-step CRM training of surgical teams (i.e., surgeons, anaesthetists, nurses,...) conducted by advisors from the world of air company using video support:~  * First month following randomization: a course about the implementation of surgical safety checklist (using online-available WHO short movies and other videos of surgical teams) and core concepts of CRM adapted to the operating room;~ * Sixth month following randomization: a feedback to surgical teams aiming at identifying and solving barriers related to the checklist implementation and interpersonal communication~* Written reminders including the systematic presence of an unfilled surgical safety checklist in the patient's medical report, stickers and wall posters in operatory rooms"
214895689|NCT03302169|PROCEDURE|Radical prostatectomy with posterior rhabdosphincter reconstruction|To suture the Denonvilliers fascia and bladder to the median dorsal raphe according to Rocco technique.
214895690|NCT03302169|PROCEDURE|Radical prostatectomy without posterior rhabdosphincter reconstruction|Standard technique with a running suture to perform the urethrovesical anastomosis
214895691|NCT00933023|DRUG|hydrocortisone|1%hydrocortisone topical once daily for 8 weeks
214895692|NCT00933023|DRUG|Betamethasone|Betamethasone 0.1% topical once daily for 8weeks
214895693|NCT01198223|DRUG|garlic , nystatin|mouthwash
214895694|NCT00038181|DRUG|Thalidomide|
214895695|NCT05063513|BIOLOGICAL|Autologous Hematopoietic Stem Cell Transplantation|Experimental arm will undergo mobilisation with CY 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
214895696|NCT05063513|DRUG|Rituximab|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
214895697|NCT00818766|DRUG|cefazolin or vancomycin|Cefazolin IV every eight hours post-operatively for 48 hours or until all chest tubes were removed, whichever occurred first. Participants under 80 kg received 1 gram of cefazolin and participants who were 80 kg or more received 2 grams of cefazolin. Participants who were penicillin-allergic received 1 gram of vancomycin every 12 hours for 48 hours or until all chest tubes were removed, whichever occurred first.
214895698|NCT00818766|DRUG|Placebo|Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
214895699|NCT03525405|DRUG|napabucasin|Single 240 mg dose containing 100 μCi of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.
214895700|NCT06328205|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
214296873|NCT05696678|DRUG|Intrathecal Morphine|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
214296874|NCT05696678|DRUG|Ropivacaine 0.2%|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
214296875|NCT04455802|DRUG|Buprenorphine or Placebo|The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
214296876|NCT04455802|DRUG|Morphine or Placebo|If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
214296877|NCT02196558|DRUG|E6011|
214296878|NCT01090960|DRUG|GDC-0068|Oral repeating dose
214296879|NCT03487029|OTHER|Short duration|exercise Short duration high intensity training
214296880|NCT03487029|OTHER|Long duration|exercise Long duration high intensity training
214296881|NCT00905398|DRUG|Nilotinib|400mg, Oral, Bid, Daily for three years
214895701|NCT06328205|PROCEDURE|Glossopharyngeal Nerve Block|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
214895702|NCT06328205|DRUG|Lidocaine Hydrochloride|When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\]. once a day. 1 ml per time.
214895703|NCT06328205|BEHAVIORAL|placebo injection|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. 1 milliliter of normal saline will be used for injection.
214895704|NCT04496804|BEHAVIORAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
214895705|NCT04496804|BEHAVIORAL|Wellness for MS (WellMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing wellness in people with MS.
214895706|NCT05350657|BEHAVIORAL|Ketogenic Diet|2 week isocaloric, high protein and low carbohydrate ketogenic diet
214296882|NCT02118051|DRUG|Ganirelix 0.25 mg.|Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle\> 14mm.
214296883|NCT02118051|DRUG|Recombinant choriogonadotropin alfa|Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles\> 17 mm are observed
214296884|NCT02118051|DRUG|Micronized natural progesterone.|Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
214296885|NCT05573789|GENETIC|Tumor molecular profiling|Tumor molecular profiling was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic
214895707|NCT05120986|OTHER|IND/GLY/MF|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study when attending participating community pharmacies with a first prescription of IND/GLY/MF with sensor or IND/GLY/MF without sensor
214895708|NCT05984524|BEHAVIORAL|Gamma-Music Based Intervention|Gamma or Control lights with Music-Based Intervention for 8 week period
214895709|NCT05884736|OTHER|Neuromonitoring|Multimodal neuromonitoring will include: Transcranial colour-coded Doppler (TCCD), Electroencephalography (EEG), and Somatosensory evoked potentials (SSEP) or brainstem auditory evoked potentials (BAEP)
214895710|NCT01866462|OTHER|NM504|NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
214296886|NCT01026467|DRUG|cisplatin|Given IV
214296887|NCT01026467|DRUG|carboplatin|Given IV
214296888|NCT01026467|OTHER|questionnaire administration|
214296889|NCT03935906|OTHER|Reach Pathway|Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.
214296890|NCT03935906|OTHER|Education-only Pathway|Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
214296891|NCT01988805|OTHER|Blood Draw|
214296892|NCT02229747|DRUG|Meloxicam|
214296893|NCT02229747|DRUG|Diclofenac|
214296894|NCT02229747|DRUG|Nimesulide|
215051442|NCT05734664|DEVICE|State-of-the-art ultrasound equipment|A complete 2D and 3D ultrasound data set using a GE Vivid E95 ultrasound machine, version 203 (General Electric Healthcare, Chicago, IL, United States) will be recorded. All data will be processed offline with a specialized software packet (EchoPAC, version 203, General Electric Healthcare, Chicago, IL, United States
214296895|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
214296896|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
214296897|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
214895711|NCT02236962|DRUG|Placebo|
214895712|NCT02236962|DRUG|Ephedrine, pioglitazone|
214895713|NCT01686672|BEHAVIORAL|Web Intervention|Behavioral
215051443|NCT05502003|OTHER|High Intensity Interval Training|Telerehabilitation-based high-intensity exercise training will be applied to the participants for 6 weeks, 3 times a week for 35 minutes, under the control of a physiotherapist.
215051444|NCT05502003|OTHER|Moderate Exercise Training|The participants will be given telerehabilitation-based moderate exercise training under the control of a physiotherapist for 55 minutes, 3 times a week for 6 weeks.
214296898|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
215051445|NCT05196373|DRUG|STP705|STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
215051446|NCT00402844|DEVICE|Transvaginal mesh- PROLIFT®-system|
215051447|NCT04702386|BEHAVIORAL|Focus groups|Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF
215051448|NCT04702386|BEHAVIORAL|Individual interviews|Interview led by the psychologist about being the child of a parent with CF
215051449|NCT01379807|DRUG|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
215051450|NCT04232943|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (IPV)|"IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units"
215051451|NCT04232943|BIOLOGICAL|E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)|"LT (R192G/L211A), or dmLT, is a protein toxoid derived from wild-type enterotoxigenic Escherichia coli (ETEC) labile toxin (LT). The LT toxin has been shown to have inherent mucosal adjuvant properties for co-administered antigens and thus has potential as a mucosal adjuvant for different co-administered vaccines. LT has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites, which are critical for activation of the secreted toxin molecules."
215051452|NCT04232943|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|"Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3."
215051453|NCT06004206|DEVICE|nPSV and PSV|Ventilation with neurally adjusted modes or pressure support modes
215051454|NCT06070818|OTHER|Healthy Body & Mind Program|12-week physical activity and lifestyle education program
215051455|NCT02695914|DRUG|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
215051456|NCT05976659|DEVICE|Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)|Transcranial electrical stimulation (tES), via direct and alternating current, will be administered to the participants in their home by trained caregivers/study companions administrators. All training and intervention sessions will take place in the participant's home.
215051457|NCT00435630|OTHER|LapSim training|complete curriculum training on LapSim surgical simulator
215051458|NCT00484341|DRUG|low-dose NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
215051459|NCT00484341|DRUG|high-dose NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
215051460|NCT00484341|DRUG|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
215051461|NCT03101319|DRUG|Vitamin D3 cholecalciferol|As mentioned in the description of the study arm
215051462|NCT03101319|DRUG|B Complex Oral Tablet|As mentioned in the description of the study arm
215051463|NCT02575443|DRUG|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
215051464|NCT02575443|DRUG|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
215051465|NCT01312727|OTHER|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
215051466|NCT00000226|DRUG|Buprenorphine|
215051467|NCT04164810|OTHER|Hydrotherapy|All sessions will be done by 3 physical therapists specialized in hydrotherapy under different modalities, and a pool equipped to perform this type of intervention. The most commonly used techniques in the institution are Bad Ragaz, for motor control, and the Watsu technique for relaxation and spasticity work.
215051468|NCT04164810|OTHER|Physical Therapy|All sessions will be done by 3 physical therapists expert in neurorehabilitation, following a physical therapy protocol, which includes stretching, aerobic excercise and muscle strengthening.
214296899|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
214895714|NCT01996241|BEHAVIORAL|Multi-level, structural and norms-based intervention|Receive multi-level, structural and norms-based intervention
214895715|NCT00086684|DRUG|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
214895716|NCT00086684|DRUG|Placebo|One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
214895717|NCT00086684|DRUG|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
214895718|NCT02340403|PROCEDURE|NMR Spectroscopy|
214296900|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
214296901|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
214296902|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
214296903|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
214296904|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
214296905|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
214296906|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
214296907|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
214296908|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
214895719|NCT04672837|PROCEDURE|Pediatric Integrative Manual Therapy and educational therapy|Pediatric Integrative Manual Therapy is a soft Orthopedic Manual Therapy approach por infants and children. It integrates joints soft mobilisation, myofascial release and neurodynamic mobilisation. Also the educational therapy.
214895720|NCT04672837|PROCEDURE|Stretching and educational therapy|It is a protocol of stretching based on literature research. Also the educational therapy with counter positioning, stimulation in prone position, positional care, etc.
214895721|NCT03823170|RADIATION|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
214895722|NCT03823170|PROCEDURE|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish, with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
214895723|NCT03823170|COMBINATION_PRODUCT|Laser therapy and Fluorotherapy|This group will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
214895724|NCT02809313|DIETARY_SUPPLEMENT|Treatment Gingivitis with Probiotic|gingivitis treatment (scaling and coronary polish) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months
214895725|NCT02809313|OTHER|Treatment Gingivitis conventional|gingivitis treatment (scaling and coronary polish) and one sachet containing Placebo (talc powder) per day during 3 months
214895726|NCT06018675|OTHER|kinesiotherapy|Group 1: Kinesiotherapy Group 2: Dry needling Group 3: lidocain injection
215051469|NCT00484783|PROCEDURE|Natural Orifice Transluminal Endoscopic Surgery (NOTES)|Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
214296909|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
214296910|NCT02886520|DEVICE|PVDF transobturator tape|
214296911|NCT02886520|DEVICE|Polypropylene transobturator tape|
214296912|NCT04684355|OTHER|Real-time colonoscopic optical diagnosis for colorectal neoplasm|Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
214296913|NCT00379574|DRUG|Bortezomib|"Bortezomib:~For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.~For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks."
214296914|NCT00379574|DRUG|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
214296915|NCT00379574|DRUG|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
214296916|NCT00379574|DRUG|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
214296917|NCT00379574|DRUG|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
214895727|NCT06362915|DRUG|Lidocaine|* Group (A) lidocaine : will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%.
214895728|NCT06362915|DRUG|Bupivacain|• Group (B),bupivacaine: will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivacaine 0.25% by an experienced anesthesiologist
214895729|NCT03465059|DRUG|Zanubrutinib|A single oral dose of 80 mg Zanubrutinib will be administered.
214895730|NCT05162703|DIAGNOSTIC_TEST|AsthmaTuner|Exercise challenge test using AsthmaTuner mobile phone app and spirometer.
215051470|NCT00484783|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery (NOTES)|chart review of historical data from control group
215051471|NCT04891913|DRUG|SY-007/ Placebo 15mg|15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
215051472|NCT04891913|DRUG|SY-007/ Placebo 30mg|30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
215051473|NCT04891913|DRUG|SY-007/ Placebo 60mg|60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
214296918|NCT00379574|DRUG|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
214296919|NCT03774511|OTHER|High-Intensity Interval Exercise & Moderate Intensity Interval Exercise|Different Interval intensities Exercise
214296920|NCT02980445|BEHAVIORAL|Outdoor activity 1|40-minute outdoor activity
214296921|NCT02980445|BEHAVIORAL|Outdoor activity 2|Dose 1 plus an additional 40-minute outdoor activities during recesses
214296922|NCT02429895|DRUG|ABT-122|Injection
214296923|NCT05999045|OTHER|Singing activity|The singing activity will involve a 1-hour performance, rehearsal, or lesson.
214296924|NCT04757064|OTHER|standard rehabilitation protocol|they will receive knee flexion exercises and increase the extensor strength
214296925|NCT04887051|OTHER|pulmonory based home exercises|web based telerehablitation
214296926|NCT02235012|DRUG|Ketamine|"KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
214895731|NCT03822585|DIAGNOSTIC_TEST|CBC, Iron Study, Serum Ferrittin, HPLC,Genitic Study|"high performance liquid chromatography (HPLC) has become the preferred technique, as it can detect most of the clinically significant variants. polymerase chain reaction (PCR)-based procedures detect Commonly occurring mutations of the HBB gene .~If targeted mutation analysis fails to detect the mutation, scanning or sequence analysis can be used. Sensitivity of both mutation scanning and sequence analysis is 99%."
214895732|NCT05751317|DIAGNOSTIC_TEST|Culture|"* Samples will be transported to Medical Microbiology and Immunology Laboratory and will be inoculated on MacConkey medium.~* Pink colonies will be inoculated on bile esculin agar medium.~* Enterococci produce blackening of the agar"
214895733|NCT05751317|DIAGNOSTIC_TEST|Staining:|The growing colonies on bile esculin agar medium will be examined microscopically after staining by Gram stain.
214895734|NCT05751317|DIAGNOSTIC_TEST|Biochemical reactions:|"* Catalase test.~* Salt tolerance test"
214895735|NCT05751317|DIAGNOSTIC_TEST|VITEK|Automated identification of Enterococci will be done with VITEK2 system.
214895736|NCT05751317|DIAGNOSTIC_TEST|Antibiotic sensitivity test|Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on Mueller-Hinton Agar.
214478245|NCT06953947|DRUG|Costoclavicular block|In costoclavicular block, the course of the three cords of the brachial plexus is visualized under ultrasound guidance, adjacent to the brachial artery beneath the clavicle. Subsequently, after the needle is placed under ultrasound guidance between the three cords, 20 mL of 0.25% bupivacaine is injected as the local anesthetic.
214895737|NCT05751317|DIAGNOSTIC_TEST|nanoparticles effect|The effect of nanoparticles on Enterococci antimicrobial resistance pattern
214895738|NCT05751317|DIAGNOSTIC_TEST|The biofilm formation activity|The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique
214895739|NCT05751317|DIAGNOSTIC_TEST|molecular diagnosis|Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR
214895740|NCT06074224|OTHER|Sleep assessment score|The patients in the intervention group will include those for whom their clinician was given their sleep questionnaire result before the visit.
214895741|NCT06074224|OTHER|No Score|The patients in the control group will include those for whom their clinician was not given their sleep questionnaire result before the visit.
214895742|NCT05659732|DRUG|PEP07|PEP07 is a selective Chk1 inhibitor maleate drug which is supplied as a hard gelatin capsule. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
214895743|NCT04025840|OTHER|Epidural block|Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.
214895744|NCT04025840|DRUG|Dexamethasone|Dexamethasone (10 mg) is administered intravenously before anesthesia induction.
214895745|NCT04515251|DIAGNOSTIC_TEST|Ultrasound measurements|ultrasound measurement at the level of the left renal vein on a sagittal plane according to age
215051474|NCT06368284|PROCEDURE|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident between January 2017 and December 2023, managed and followed up in France
214478246|NCT06953947|DRUG|Interscalene Nerve Block|In interscalene block, using an ultrasound probe placed on the neck, the course of the brachial plexus trunks between the anterior and middle scalene muscles is visualized. Then, after the needle is inserted under ultrasound guidance between the anterior and middle scalene muscles, 20 mL of 0.25% bupivacaine is injected as the local anesthetic.
214478247|NCT05848739|DRUG|ST316|IV
214478248|NCT05848739|DRUG|FOLFIRI regimen & bevacizumab|"FOLFIRI: Days 1 and 15 of each 28-day cycle:~* irinotecan 180 mg/m2 IV over 90 minutes concurrently with~* leucovorin 400 mg/m2 IV over 2 hours, and then~* 5-FU bolus 400mg/m2 (up to 15 min infusion)~* 5-FU 2400 mg/m2 IV over 46 hours~* bevacizumab should be administered as 5mg/kg."
215051475|NCT05186935|DEVICE|Injectable Hydrogel treatment|The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
214478249|NCT05848739|DRUG|Fruquintinib|5 mg once a day for the first 21 days of a 28-day cycle
214478250|NCT05848739|DRUG|Lonsurf & bevacizumab|Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316
214895746|NCT04690595|BIOLOGICAL|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-ALL
214895747|NCT00006207|DRUG|PRO 2000|
214895748|NCT04515147|BIOLOGICAL|CVnCoV 6 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
214895749|NCT04515147|BIOLOGICAL|CVnCoV 12 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
214895750|NCT04515147|BIOLOGICAL|Hepatitis A vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
214895751|NCT04515147|BIOLOGICAL|Pneumococcal vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
214895752|NCT04515147|BIOLOGICAL|CVnCoV 12μg|Participants will receive an intramuscular injection by needle in the deltoid area.
214895753|NCT03686605|OTHER|Thai version of the Edmontom Symptom Assessment System (ESAS)|Screening and diagnostic questionaire for depression
214895754|NCT06575205|BEHAVIORAL|Educational video|Participants will view a brief 3-to-5-minute educational video (VIDEO), covering information that is already printed on FDA labels for OTC NSAIDs, on their own device covering themes such as: defining OTC NSAIDs, potential harms of NSAIDs, and alternatives.
214296927|NCT02235012|DRUG|Placebo|"CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
214895755|NCT02866305|PROCEDURE|VATS bullectomy and mechanical pleuradesis.|Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.
214895756|NCT02866305|PROCEDURE|Chest tube insertion|Conventional chest tube insertion.
214895757|NCT02866305|DRUG|Epidural|All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
214895758|NCT02866305|RADIATION|High-resolution Computer Tomography|All participants included in this study had a HRCT performed.
214895759|NCT04713605|DEVICE|Critical closing pressure detection|Observational study that determines the critical closing pressure (CrCP) of the brain by comparison of the cerebral blood flow velocity (measured by TCD) and invasive blood pressure measurement (IABP)
214895760|NCT04032405|PROCEDURE|CAF+CTG+i-prf|combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
214895761|NCT06574451|DEVICE|VR-assisted postoperative analgesia|Patients will receive postoperative analgesic adjunctive therapy software to assist in pain control, with one postoperative analgesic adjunctive therapy software intervention at 24 hours and 48 hours after surgery, and pain evaluation within 30 minutes.
214895762|NCT03232359|DIAGNOSTIC_TEST|immature platelets fraction|IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
214895763|NCT04468022|PROCEDURE|Toric Trifocal IOL|Interventions are performed using a standard technique of sutureless phacoemulsification. In all cases, topical anesthesia was administered and pharmacologic mydriasis was induced using a combination of tropicamide and phenylephrine (10.0%). A mean clear corneal microincision of 2.2 mm was made with a knife according to position of the preop highest K value of the patient. A paracentesis was made 60 degree to 80 degree, clockwise from the main incision, and the anterior chamber was filled with an ophthalmic viscoelastic (OVD) after phacoemulsification/lensectomy and removal of clear lens. The IOL was subsequently implanted through the main incision using the BLUEMIXS 180 injector (Carl Zeiss meditec, Jena, Germany) for trifocal IOL , VISCOJECTTM BIO injector for toric trifocal IOL and then the OVD was removed. Postoperative pharmacologic treatment is performed with the combination of antibiotic and steroidal anti-inflammatory drops
214895764|NCT02094300|DEVICE|Zenith® Dissection Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
214895765|NCT01111318|DRUG|BI 10773|2 tablets BI 10773 25 mg single dose
214895766|NCT01892956|OTHER|Nutritional intervention|"2 dietary interventions~1. personalized diet based on algorithm predictions of glucose response to foods~2. Mediterranean-style diet"
214296928|NCT03626623|DEVICE|Cytal Wound Matrix 1-Layer|Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
214296929|NCT03626623|OTHER|Standard of Care (SOC)|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
214296930|NCT00128778|DRUG|Pegylated liposomal doxorubicin|
214296931|NCT01009125|OTHER|$2 cash|$2 cash incentive will be included in the mailed survey
214296932|NCT01009125|OTHER|$5 cash|$5 cash incentive will be included in the mailed survey
214296933|NCT04576832|BEHAVIORAL|Mindfulness-Based Attention Training (MBAT) web-course|Pre-recorded weekly sessions for 4 weeks. Each session will consist of approximately 2 hours of video content per week and weekly mindfulness exercises. This video will include MBAT program lectures, pre-recorded testimony from military leaders, and teaching materials. The course will also include 15-min daily mindfulness practice drills.
214895767|NCT02091856|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
214895768|NCT04238078|DRUG|Contraceptive|Oral contraceptive pill
214296934|NCT06469866|DEVICE|low-pressure pneumoperitoneum|low-pressure pneumoperitoneum (LPP) with deep NMB.
214296935|NCT06469866|DEVICE|standard-pressure pneumoperitoneum|standard-pressure pneumoperitoneum (SPP) with moderate NMB.
214296936|NCT02723669|DRUG|AR10|effervescent tablet
214895769|NCT00648778|DRUG|Loxapine Succinate Capsules 25 mg|25mg, single dose fasting
214895770|NCT00648778|DRUG|Loxitane® Capsules 25 mg|25mg, single dose fasting
214895771|NCT03532529|OTHER|not applicable, it is an observational study|not applicable, it is an observational study
215051476|NCT05334472|OTHER|Kesimpta|There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.
214296937|NCT02723669|DRUG|acetylcysteine|oral solution
215051477|NCT02448134|BEHAVIORAL|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
215051478|NCT03133585|DEVICE|2 piece appliance for stomy|Use of the Flexima®/Softima® 3S during 6 months following the patient's usually frequency of appliance change
214296938|NCT02384889|DRUG|Difluoromethylornithine|Active Therapy with DFMO
214296939|NCT02384889|DRUG|Placebo|Placebo Comparitor
214296940|NCT04867603|DRUG|[Ga-68]PSMA|The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.
214296941|NCT04867603|DEVICE|PET/CT imaging|PET/CT imaging procedure
214296942|NCT04059094|DRUG|BI 1265162|Inhalation solution
214296943|NCT04059094|DRUG|Placebo|Inhalation solution
214296944|NCT02994979|OTHER|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
214296945|NCT02994979|OTHER|Sham comparator|Usual care plus sham visits by CNA
214296946|NCT03876197|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells|Autologous adipose-derived mesenchymal stem/stromal cells
214296947|NCT03876197|OTHER|Placebo|Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%
214296948|NCT01038050|DRUG|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
214296949|NCT06220682|DIAGNOSTIC_TEST|The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs|using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay
214296950|NCT06357598|DRUG|Tislelizumab|Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, neoadjuvant therapy : 2-4 cycles; Adjuvant therapy: 16cycles at most.
214296951|NCT06357598|DRUG|Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.
214296952|NCT06357598|DRUG|Carboplatin or Cisplatin|"Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 of each 21-day cycle for 2-4 cycles.~Cisplatin: 75 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles."
214296953|NCT06357598|PROCEDURE|Surgery|Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
214296954|NCT05029440|OTHER|Pulsed Electromagnetic Field|PEMF was administered to the whole body for PEMF groups using a 1.8×0.6m mat 30 minutes/day, 3 times/week for 3 months.
214895772|NCT04703595|GENETIC|To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.|"To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.~For the molecular study of the DNA sample of the patients, two techniques will be used: standard Polymerase chain reaction amplification with primers flanking the intron 2 fragment of the RFC1 gene and amplification using Repeated Primed Polymerase chain reaction in 3 independent reactions."
214895773|NCT05702983|DRUG|STSA-1002 subcutaneous injection|Subjects will receive a single low dose on day 1 following protocol requirements.
214895774|NCT05702983|DRUG|STSA-1002 subcutaneous injection|Subjects will receive a single high dose on day 1 following protocol requirements.
214478251|NCT04729933|DEVICE|V-Wave Shunt Placement|After the MitraClip Placement and after final screening, the existing transseptal puncture used for MitraClip placement is used to place the V-WAVE Shunt device.
214895775|NCT03182426|DRUG|Plerixafor|Systemic CD34+ stem cell mobilization for beta-cell repair
214895776|NCT03182426|DRUG|Alemtuzumab|T-cell depletion
214895777|NCT03182426|DRUG|Anakinra|Anti-inflammatory
214895778|NCT03182426|DRUG|Etanercept|Anti-inflammatory
214895779|NCT03182426|DRUG|Liraglutide|Beta-cell regeneration
214895780|NCT04505969|OTHER|Questionnaire to assess needs|Two questionnaires have been developed to assess the specific needs of healthcare professionals working with SCD patients and of SCD patients or parents of children with SCD
214895781|NCT03405025|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|To establish if radiofreuqency ablation of aldosterone producing adrenal adenomas can be carried out via the endoscopic route and to assess safety of the procedure.
214895782|NCT03405025|DEVICE|ultrasound|ultrasound
214895783|NCT05832203|OTHER|Counseling on planetary health diet with calorie restriction|Counselling on planetary healthy diet, calorie restriction diet, and healthy lifestyle through mobile application
214895784|NCT05832203|OTHER|Counseling on balanced nutrition diet with calorie restriction|Counselling on balanced nutrition diet, calorie restriction diet, and healthy lifestyle materials through mobile app
214296955|NCT05029440|OTHER|Exercise Program|The exercise training program included treadmill and aerobic exercises for hip and upper limb and performed for 50 minutes.
214296956|NCT05029440|OTHER|Pulsed High Laser Therapy|High Laser was delivered with a total dose of energy of 3000 J was delivered in two treatment phases. The initial phase was performed with fast manual scanning at 510, 610, and 710 mJ/cm2 in three successive subphases and 500 J in each subphase for a total of 1500 J. The final phase was the same as the initial phase except that the scanning was slow. The average area for the upper thigh or lower back was 200 cm2 with an average fluency of 15 J/cm2 and the application time for each area was 18 min. HILT was applied using a HIRO 3 device (ASA, Arcugnano, Vicenza, Italy).
214478252|NCT06834386|OTHER|Best Practice|Receive standard of care
214478253|NCT06834386|OTHER|Electronic Health Record Review|Ancillary studies
214478254|NCT06834386|OTHER|Interview|Ancillary studies
214478255|NCT06834386|OTHER|Questionnaire Administration|Ancillary studies
214895785|NCT06134037|DRUG|Aminophylline|Patients will be observationally included in the Aminophylline or not Aminiophylline group depending on anesthesiologist's discretion.
214895786|NCT01753180|BIOLOGICAL|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
214895787|NCT01753180|DRUG|saline|Local intra-coronary administration of saline at or into the CTO
214895788|NCT00684372|DRUG|leflunomide|"Screening: If BK viremia (BK PCR \>10 000 copies/ml in serum) i. Reduced immunosuppression~1. MMF / AZA withdrawal~2. CNI reduction~   1. Tacrolimus 5 ng/ml in serum~  2. Cyclosporin 100 ng/ml in serum~3. Prednisolone to maintenance level~If effective =\> continue~* Stable renal function (P-Krea)~* \>50% reduction in PCR (copies/ml) at 4 weeks after diagnosis~* Negative PCR at \> 3 months after diagnosis~If failure =\> add leflunomide~* Deteriorating renal function (P-Krea) and positive PAD = BK nephropathy~* \<50% reduction in PCR at 4 weeks after diagnosis~* Positive PCR at \>3 months after diagnosis~Leflunomide dosing:~ii. Loading dose of 100 mgx1 PO daily for 5 days can be used or the patient can be directly started on iii. Maintenance dose (from day 1 or day 6)~1. Starting at 20 mgx1 PO daily~2. Thereafter adjusted between approximately 20-60 mgx1 PO daily according to serum levels of A77 1726 and the clinical situation a. Recommended level of A77 1726 \>40 ug/ml"
214895789|NCT06158893|DRUG|Salbutamol|inhalation anaesthesia
214895790|NCT06158893|DRUG|Budesonide|inhalation anaesthesia
215051479|NCT01623505|DRUG|Champix|"Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
215051480|NCT01623505|DRUG|Transdermal Nicoderm patch combined with gum or inhaler|"Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~\*Off-label dosage approved by Health Canada via No Objection letter."
215051481|NCT01623505|DRUG|Transdermal Nicoderm patch|"Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
215051482|NCT00267306|DRUG|Visilizumab|
215051483|NCT06260605|OTHER|Education|Nursing students learning about diabetes complications
215051484|NCT02930707|DRUG|Magnesium Sulfate|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
215051485|NCT02930707|DRUG|Bupivacaine|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
215051486|NCT03001661|DEVICE|Dilapan-S|DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
215051487|NCT03001661|DRUG|Dinoprostone|Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
215051488|NCT00017069|DRUG|arsenic trioxide|
214296957|NCT03305822|DRUG|LY900014|Administered SC
214895791|NCT06158893|OTHER|Saline|saline
214895792|NCT05902507|DIAGNOSTIC_TEST|Magnetic Resonance Imaging Simulation|Radiographic Image Simulation
214895793|NCT01280643|DRUG|fluorouracil|Given IV
214895794|NCT01280643|DRUG|leucovorin calcium|Given IV
214895795|NCT01280643|DRUG|oxaliplatin|Given IV
214895796|NCT01280643|DRUG|irinotecan hydrochloride|Given IV
215051489|NCT00017069|DRUG|dexamethasone|
215051490|NCT00382265|DRUG|tamsulosin|tamsulosin 0.4mg po qd for 28 days
214895797|NCT01280643|BIOLOGICAL|bevacizumab|Given IV
214895798|NCT01280643|BIOLOGICAL|cetuximab|Given IV
214895799|NCT01280643|DRUG|capecitabine|Given PO
214895800|NCT01280643|GENETIC|mutation analysis|Correlative studies
214895801|NCT01280643|GENETIC|gene expression analysis|Correlative studies
214296958|NCT03305822|DRUG|Insulin Lispro|Administered SC
214296959|NCT02593474|DRUG|Naltrexone|Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
214296960|NCT03445650|DRUG|ADX-102 1% Topical Dermal Cream (reproxalap)|ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
214478256|NCT06834386|DRUG|Suvorexant|Given PO
214895802|NCT01280643|OTHER|laboratory biomarker analysis|Correlative studies
214895803|NCT01280643|OTHER|immunohistochemistry staining method|Correlative studies
214895804|NCT01280643|GENETIC|nucleic acid sequencing|Correlative studies
214895805|NCT01280643|GENETIC|protein expression analysis|Correlative studies
214895806|NCT01280643|GENETIC|polymerase chain reaction|Correlative studies
214895807|NCT01280643|GENETIC|DNA analysis|Correlative studies
214895808|NCT04394403|BEHAVIORAL|Internet-based guided self-help based on CBT principles|Individuals are provided basic rationale of CBT to deal with stress, worry, anxiety, dysphoria, sleep difficulties, emotion dysregulation, and memories all related to COVID-19
214296961|NCT03445650|DRUG|Vehicle of ADX-102 Topical Dermal Cream|Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
214296962|NCT00512993|DRUG|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
215051491|NCT00382265|OTHER|Placebo|placebo po qd for 28 days
214296963|NCT03969394|DIAGNOSTIC_TEST|Medical imaging|Medical Imaging consisting of 1 MRI and 1 echocardiography at baseline
214296964|NCT02204163|DRUG|Eutropin|
214296965|NCT02204163|DRUG|Genotropin|
214296966|NCT01898728|DRUG|topical povidone-iodine after premedication with topical liquid eye drops|
214296967|NCT01898728|DRUG|topical povidone-iodine after premedication with topical gel|
214296968|NCT05712928|BEHAVIORAL|Dance/movement therapy (eMove)|Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove) delivered by a board-certified dance/movement therapist. eMove treatment protocol integrates movement techniques, creative embodiment, the non-verbal aspects of self-awareness and interpersonal communication in treatment. eMove sessions focus on helping the participant to increase physical activity level, increasing participants' energy levels and motivation to stay active and better cope with everyday activities, improving overall functioning; reducing severity of negative symptoms of schizophrenia; and providing participants with a sense of connection and social support by connecting with a therapist. In addition, sessions are individualized to the participant's presenting needs.
214296969|NCT01040897|BEHAVIORAL|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
214296970|NCT01040897|BEHAVIORAL|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
214478257|NCT05860829|BEHAVIORAL|Educational|Caregivers of children with ASD will be sampled that are enrolled in Autism specialized Schools or centers. Tools and group education sessions will be developed in Urdu, English and Sindhi language. A caregiver education program session will be conducted by a practicing dentist and a registered dietitian in Urdu1 and English. Considering the ease of caregivers, cost-effectiveness and managing flexible hours, tele-health will be practiced for education program. A post-test will be conducted to assess the impact of the educational program on the knowledge of caregivers.
215051492|NCT05265858|PROCEDURE|Total Hip Arthroplasty|Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
214296971|NCT00003903|PROCEDURE|management of therapy complications|
214296972|NCT02671994|OTHER|G8 screening|
214296973|NCT02671994|OTHER|Geriatric assessment|
214296974|NCT03463343|OTHER|Cervical spine manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
214296975|NCT03463343|OTHER|Cervical spine mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
214478258|NCT06954298|BEHAVIORAL|supervised lifestyle modification|Supervised lifestyle intervention will consist of regular exercise (3x a week), nutritional counselling (weekly), cognitive bahavioural therapy (monthly).
215051493|NCT06426446|DEVICE|Withings Body Comp Pro|Withings Body Comp Pro from which the following features will be used: body weight, body composition (fat, muscle and bone mass, cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), nervous health (electrochemical skin conductance)
215051494|NCT03525002|DRUG|Bromocriptine|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
214478259|NCT06953713|PROCEDURE|gallbladder extraction umbilical|extracting gallbladder via umbilical port site
215051495|NCT03525002|OTHER|Placebo|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
215051496|NCT03896477|BIOLOGICAL|Pneumosil|One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
215051497|NCT03896477|BIOLOGICAL|Prevenar 13|One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
215051498|NCT03896477|BIOLOGICAL|Synflorix|One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
215051499|NCT02938247|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
215051500|NCT01128725|OTHER|Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~* psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~* Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
215051501|NCT01739608|OTHER|Invitation to screening|Invitation to screening
215051502|NCT02229786|DRUG|Buscopan® plus|
215051503|NCT02229786|DRUG|Buscopan®|
215051504|NCT02229786|DRUG|Paracetamol|
215051505|NCT02229786|DRUG|Placebo|
215051506|NCT06512688|OTHER||This is a cross-sectional study without intervention.
214296976|NCT03463343|OTHER|Placebo intervention|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
214296977|NCT04832685|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
214296978|NCT01705288|PROCEDURE|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
214478260|NCT06953713|PROCEDURE|extracting gallbladder via epigastric port|extracting gallbladder via epigastric port
214478261|NCT06953362|DEVICE|Direct Neural Electrical Stimulation|We are not delivering treatment in this study. Direct neural electrical stimulation is being administered to determine its effect on neural circuit activity and connectivity.
214478262|NCT05505578|BEHAVIORAL|GamerFit Condition|Participants receive a Fitbit device, the GamerFit app on their mobile device, exergaming console and games (Nintendo Switch) (where applicable), and follow a 12-week exergaming curriculum provided by the app. Physical activity (PA) increases during the intervention up to 60 minutes/session. Other interventional aspects include weekly reminders, exercise and health related video materials, and weekly telehealth sessions with an intervention coach.
214478263|NCT05505578|BEHAVIORAL|Comparator Condition|Participants receive a Fitbit device, instructions on how to use it, and a booklet of healthy tips. They also get weekly reminders to charge, sync, and review their Fitbit data.
214478264|NCT05182463|DRUG|Peginterferon Alfa-2B|Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
214478265|NCT05182463|DRUG|Nucleoside Analogs|Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
214895809|NCT06013007|PROCEDURE|ICI-guided JINS approach|OCT- or IVUS-guided JINS approach in DES implantation (DES types including Healing-Targeted SUPREME/Infinity Sirolimus-Eluting Stent, GuReater™ Sirolimus-Eluting Stent, XIENCE Alpine Everolimus-Eluting Stent, Promus PREMIER™ Everolimus-Eluting Stent, Resolute Integrity™ Zotarolimus-Eluting Stent, Firebird 2™ Sirolimus-Eluting Stent, Firekingfisher™ Sirolimus-Eluting Stent).
214895810|NCT01277783|DEVICE|Endocardial Left Ventricular pacing|Subjects receive an endocardial LV lead placement via superior approach using Medtronic Model 3830 lead and Medtronic Model 6227ATS deflectable delivery catheter and Medtronic Model 6248HS, 6248JL, or 6248JS delivery catheter, using trans esophageal echo (TEE) or intra-cardiac echo (ICE) to guide the procedure.
214895811|NCT01715961|PROCEDURE|anthropometric measurement|To attest the muscular strength: hand grip test, balance test, up and go test
214895812|NCT04867005|BEHAVIORAL|Impact of a training program|Measurement of the effectiveness of a training program based on the skills and knowledge learning on advance care planning. A 10 hours online course was administered to both arms through an online platform; the 6 hours face-to-face course was administered to each primary care team (5) included in this arm. The 6 hours course was split into 2 sessions of 3 hours each.
214895813|NCT03218020|OTHER|No intervention assigned, this is an observational study.|No intervention assigned, this is an observational study.
214895814|NCT02890173|DRUG|CS-3150|
214895815|NCT02890173|DRUG|Eplerenone|
214895816|NCT04617457|DRUG|nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)|preoperative chemotherapy
214895817|NCT06211101|OTHER|Providing training on kangaroo care guide|Online training was given to neonatal nurses on the kangaroo care guide created by the researcher in line with the literature.
214895818|NCT01350882|DRUG|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
214895819|NCT01350882|DRUG|Physiological serum : sodium chloride, sodium citrate|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
214895820|NCT04200820|DIAGNOSTIC_TEST|Trampoline|During trampoline training that participants undergo constant change of vestibular stimulation. This triggers deep proprioception as well as other sensory inputs. This trigger might affect strength, body stability, muscle coordinative responses, joint movement amplitudes and spatial integration
214895821|NCT00596791|DRUG|tafluprost|prostaglandine analoque
214296979|NCT01705288|DRUG|intravenous narcotics|given for pain management after surgery per physician orders
214296980|NCT01705288|DRUG|standard anesthesia|inhalant or intravenous during surgery
214296981|NCT01705288|DRUG|regional anesthesia|given by spinal or epidural infusion
214296982|NCT01705288|DRUG|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
214296983|NCT02835274|DEVICE|BSC Deep Brain Stimulation System with Directional Lead|
214296984|NCT01182493|DEVICE|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
214296985|NCT01853826|DRUG|Afatinib|Patients received a daily dose of 40 milligrams (mg) of afatinib (Giotrif®), in the form of film-coated tablet over a 28 day cycle. Afatinib was taken orally with 250 milliliters (mL) of water at the same time of the day and without eating anything for at least 3 hours. Patients continued on treatment for as long as there was no disease progression or no other trial withdrawal criteria. The dose was reduced to 30 mg or 20 mg once daily when the initial dose was not tolerated by the patient.
214478266|NCT04804605|DRUG|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
214478267|NCT04427007|DEVICE|Moisture Management Liner|A prototype prosthetic liner designed to reduce and/or remove moisture and heat that builds up on the limb.
214478268|NCT04427007|DEVICE|Control Liner|The participant's usual prosthetic liner
214478269|NCT06151236|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
214478270|NCT02914483|BEHAVIORAL|Enhanced Usual Care|"Participants randomized into the EUC group will complete 8 weekly individual sessions by phone. Each weekly session consists of: brief check-in and review of AHA brochure- Women, Heart Disease and Stroke."
214895822|NCT05143060|DIETARY_SUPPLEMENT|Cereal powder|Eat or drink oral glucose (reference) the valley of fiber powder upgrade formula, perfect meals, by extraction shu cereal bars, light appearance suits (by extraction shu compound dietary fiber powder, feeding combination 1:1) and 17 extraction enzyme 6 kinds of food respectively in different periods.
214895823|NCT05143060|DIETARY_SUPPLEMENT|Pure glucose powder|Pure glucose powder
214296986|NCT06099327|DEVICE|Image-based vital sign monitoring|Unobtrusive, vital signs measurements with remote photoplethysmography
214296987|NCT06789692|OTHER|tobacco smoking substitution products|Offer of preference-based smoking substitution menu, consisting of e-cigarettes or nicotine pouches or nicotine patches in addition to standard of care. This menu will be offered by the treating physician during the routine cohort visit and the participant can choose one product to test as an alternative to tobacco smoking. The products will be handed out directly after the consultation and are provided free of charge for 6 months.
214895824|NCT00942357|DRUG|Carboplatin|Given IV
214296988|NCT04338295|DEVICE|Tattoo machine (SOL Nova Device)|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
214296989|NCT00360828|DRUG|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride \[CPT-11; CAMPTOSAR\] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
214296990|NCT00360828|DRUG|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
214895825|NCT00942357|DRUG|Cisplatin|Given IV
214895826|NCT00942357|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
214895827|NCT00942357|DRUG|Paclitaxel|Given IV
214296991|NCT02081690|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily
214296992|NCT01133054|PROCEDURE|revascularization|surgery or stenting
214296993|NCT04057404|DEVICE|Alivecor Heart Monitor|
214296994|NCT05828199|DRUG|Ketamine Hydrochloride|Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.
214296995|NCT05828199|DRUG|Dexmedetomidine|bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr
214296996|NCT06406673|DRUG|Cadonilimab+EC/ET+RT|Cohort\_1 patients with no history of previous systemic treatment for ES-SCLC received cadonilimab with EC/EP for two cycles (induction phase), then, those who did not progress received concurrent palliative RT and two cycles of cadonilimab with EC/EP (combination phase). Afterward they received cadonilimab every 3 weeks for a maximum of 2 years after study enrolment (maintenance phase).
214895828|NCT00942357|OTHER|Quality-of-Life Assessment|Ancillary studies
214895829|NCT00942357|RADIATION|Radiation Therapy|Undergo radiation therapy
214895830|NCT02570620|DEVICE|Ultrasonography of the cervix|
214296997|NCT06406673|DRUG|Cadonilimab+vorolanib|Cohort\_2 patients with recurrent SCLC and after at most one systemic treatment received cadonilimab plus vorolanib, until disease progression or unacceptable toxicity.
214296998|NCT00959842|DRUG|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
214296999|NCT05373420|OTHER|Education level|Educational level was classified using the International Standard Classification of Education (ISCED) : ISCED0 (less than primary education), ISCED1 (primary education), ISCED2 (lower secondary school), ISCED3 (upper secondary school), ISCED4 (post-secondary non tertiary education), ISCED5 (short-cycle tertiary education), ISCED6 (bachelor's or equivalent level), ISCED7 (master's or equivalent level), ISCED8 (doctoral or equivalent level). We merged these different categories into three main education level : low (ISCED0 to ISCED2), middle (ISCED3 to ISCED4) and high (ISCED5 to ISCED 8). This information is provided by STATBEL.
214297000|NCT05373420|OTHER|Household net income|Income information is available as deciles of the net income of the whole household. This indicator is further categorized into low income (deciles 1 to 4), middle income (deciles 5 to 7), and high income (deciles 8 to 10). This information is provided by STATBEL.
214297001|NCT05373420|OTHER|Gender|Male or female. This variable is obtained from the Belgian national registry.
214895831|NCT03207776|OTHER|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
214895832|NCT03207776|OTHER|COPD Clinical Pathway|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services.
214895833|NCT04601766|DRUG|APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
215051507|NCT04716608|OTHER|physiotherapy program|"physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program."
215051508|NCT04716608|OTHER|usual care treatment|stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
214895834|NCT04601766|DRUG|APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
214895835|NCT00428701|DRUG|Esomeprazole Sodium|
214895836|NCT00200863|DEVICE|Monochromatic visible light exposure|Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
214895837|NCT06404957|BEHAVIORAL|Mindfulness-based Applied|Mindfulness-Based Practices is planned to be an 8-week program of mindfulness meditation and gentle Hatha yoga taught in an online class for up to 14 participants.
214895838|NCT06404957|BEHAVIORAL|Active Comparator: Control groups|No intervention will be made in this group.
215051509|NCT00537160|BEHAVIORAL|Behavior modification, Nutrition Education, Exercise|
215051510|NCT03516578|OTHER|Cardiac magnetic resonance imaging|
215051511|NCT01616277|BIOLOGICAL|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
215051512|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
214297002|NCT05373420|OTHER|Migration background|Migration background is based on the first nationality and the parents' country of origin. This variable distinguishes between native-born individuals, second-generation migrants, first-generation European migrants, and first-generation non-European migrants. This information is provided by STATBEL.
214297003|NCT05373420|OTHER|Household type|Household type provides a partial picture of the social environment and is distinguished between one person, couples, couples with children, single parents, other, collectivity (prison, nursing homes, religious community, etc.). This information is provided by STATBEL.
214297004|NCT05373420|OTHER|Health literacy|Having a health care degree is used as a proxy for health literacy and is provided by CoBRHA. The scientific and medical background can lead to more preventive and responsible behaviors towards infectious diseases. Moreover, being a health professional can lead to the need to protect patients and themselves against infections, without necessarily having very advanced knowledge of infectious diseases and vaccines.
214297005|NCT01566955|PROCEDURE|transgastric adnexectomy|adnexectomy transgastrically with transvaginal support
214297006|NCT05305872|DRUG|Gandouling|The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
214895839|NCT01960257|DEVICE|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
214895840|NCT01960257|OTHER|SOC DOT|
214895841|NCT00780338|OTHER|Assets Getting To Outcomes|Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
214895842|NCT01397357|OTHER|Cardiac magnetic resonance - CINE MRI stress test.|Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
214895843|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Bifidobacterium Bifidum|Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
214895844|NCT01709825|DIETARY_SUPPLEMENT|Sugar Pill|Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
214895845|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
214895846|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
214895847|NCT06399835|DRUG|Enavogliflozin|Enavogliflozin 0.3mg once daily
215051513|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
215051514|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
215051515|NCT01616277|BIOLOGICAL|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
214297007|NCT00084565|DRUG|estramustine phosphate sodium|
214297008|NCT00084565|DRUG|paclitaxel|
214297009|NCT00084565|DRUG|topotecan hydrochloride|
214297010|NCT00982488|DRUG|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
214297011|NCT00982488|DRUG|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
214297012|NCT03204981|DEVICE|Intramural Needle Ablation|The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
214297013|NCT03204981|PROCEDURE|Ablation|standard ablation
214895848|NCT06399835|DRUG|Pioglitazone|Pioglitazone 15mg once daily
214895849|NCT02002221|DRUG|Vildagliptin (LAF237)|Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
214895850|NCT02002221|DRUG|Placebo|Matching placebo of vildagliptin 50 mg twice daily
214895851|NCT02002221|DRUG|Insulin|"Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion."
214895852|NCT02002221|DRUG|Metformin|Patients continued their prescribed metformin dose, if applicable.
214895853|NCT05584384|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
214895854|NCT05584384|DEVICE|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
214895855|NCT05553821|OTHER|Cold sand bag|A sand bag weighing 3.5-4 kg is applied to the CAG area of patients.
214895856|NCT05553821|OTHER|A sand bag|A sand bag
214895857|NCT01274702|OTHER|Visual Reconstitutions Therapy|
214895858|NCT01274702|OTHER|Saccadic Eye Movement Training|
214895859|NCT04858932|DEVICE|Continuous Glucose Monitor|a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
214895860|NCT04858932|DEVICE|Wrist Actigraphy Device|a watch like wearable sensor
214895861|NCT04858932|DEVICE|Food Weight Scale|a scale to measure food weight
214895862|NCT04858932|DEVICE|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
214895863|NCT03347110|DRUG|Bimekizumab|Bimekizumab at a prespecified dose.
214895864|NCT02892045|DEVICE|MMG|neuromuscular monitoring device
214895865|NCT03630497|DRUG|Comparison of BN201 treatment with Placebo|Single Dose or Multiple Dose of BN201 IV administration
214895866|NCT02901353|DEVICE|Sirolimus Eluting Coronary Stent System|Patient with Angina Pectoris will be enrolled for the intervention
214895867|NCT02591277|DRUG|Harvoni|Harvoni (90/400 mg) FDC tablet administered orally once daily
215051516|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
215051517|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
215051518|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
214297014|NCT01662908|DRUG|edoxaban tosylate|edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
214297015|NCT01662908|DRUG|enoxaparin/unfractionated heparin|enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
214297016|NCT01662908|DRUG|warfarin|tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
214297017|NCT06458608|DEVICE|virtual reality glasses|virtual reality glasses
214297018|NCT01832025|PROCEDURE|internal maxillary sinus floor elevation technique|The internal lift procedure uses a drilling instrument (a drill that cuts through bone) to break through the bone for where the implant will later go. This creates an opening in the necessary area to allow more bone material to be added, which will move the sinus up and allow for the implant to be securely placed.
214297019|NCT01832025|PROCEDURE|external maxillary sinus floor elevation technique|The external lift procedure involves cutting through the upper-most part of the gums to then cut through the bone to create an opening in the necessary area. The sinus will be manually lifted and the bone material will be added, which will allow for the implant to be securely placed.
214297020|NCT04208906|DEVICE|Masimo O3|"After anesthesia induction, a masimo O3 sensors are attached to the forehead (ScO2) and the sole of the foot (StO2). About 0.4 ml blood samples are obtained from arterial line and central venous line at three epochs before and after cardiopulmonary bypass (total 6 times)~* T1: before cardiopulmonary bypass (CPB), fraction of inspired oxygen (FiO2) 0.2~* T2: before CPB, FiO2 0.5~* T3: before CPB, FiO2 0.8~* T4: after CPB, FiO2 0.8~* T5: after CPB, FiO2 0.5~* T6: after CPB, FiO2 0.2~Hemoglobin oxygen saturation values are confirmed in each sample (arterial sample: SaO2, venous sample: SvO2). Each O3 values (ScO2 and StO2) are compared to the values of SvO2, 0.7 × SvO2 + 0.3 × SaO2."
214297021|NCT01148745|DRUG|ferumoxytol|510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
214478271|NCT02914483|BEHAVIORAL|Stress Management|Participants randomized into the stress management group will complete 8 weekly group sessions by phone. The intervention is a telephone adaptation of mindfulness-based cognitive therapy (MBCT) and focuses on building cognitive-behavioral and mindfulness skills to help manage and cope with stress. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and home-based practice assignment.
214895868|NCT01404767|DRUG|Esmolol|Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
214895869|NCT01404767|DRUG|Metoprolol|The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
214895870|NCT02877901|DRUG|long acting tolterodine 4 mg|receive one tablet at bed time for 4 weeks
214895871|NCT02877901|DRUG|placebo|one tablet at bed time
214895872|NCT01518322|DEVICE|NIOX MINO®|Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
214895873|NCT01320995|PROCEDURE|Perineal ultrasound|Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
214895874|NCT01308125|PROCEDURE|PICSO|"* Baseline (hemodynamic) measurement~* Intra coronary~* Blood sampling~* LAD occlusion: for 3 min or until pain with and without PICSO~* Break recovery: the patient can recover from pain for 3 min~* CFIp: by a ComboWire advanced in the center lumen of an occlusion balloon.~* PICSO: start automatically and continued for 10 min.~* PCI/PICSO: concomitantly for the whole duration of the PCI intervention.~* 24h Follow up: additional blood samples every 6 hours (4 times)~* 30 days follow up."
214895875|NCT04242277|DEVICE|Investigational WF-OCT device|Excised lumpectomy tissue will be imaged on an investigational WF-OCT device
214895876|NCT06578793|PROCEDURE|Catheter Ablation Combined with Marshall Vein Ethanol Ablation|This study involves two procedures. The first procedure is a combination of catheter ablation with ethanol ablation of the Marshall vein. The second procedure is catheter ablation alone. Both procedures involve standard techniques used to treat persistent atrial fibrillation, with the addition of Marshall vein ethanol ablation in the experimental group aimed at potentially improving outcomes by targeting additional arrhythmogenic substrates.
214895877|NCT05132062|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention is a catheter based technique widely used to restore coronary vessel patency. It is performed by fluoroscopic guidance and it requires the use of iodinated contrast medium. The use of iodinated contrast media has been historically linked to AKI occurring within days after their administration and typically referred to as CA-AKI. Furthermore, CA-AKI has been associated with long-term impairment of kidney function, need for renal replacement therapy, and subsequent all-cause mortality.
214895878|NCT03076840|OTHER|Kinesio tape|Kinesio Taping is another option for the treatment of poor hamstring extensibility, It was developed by Kenzo Kase in 1970 and gained a wide popularity by the elite athletes during the various championships and Olympic Games
214895879|NCT04666948|DEVICE|vancomycin model-informed precision dosing|A CE labelled dosing calculator is used for a priori and a posteriori calculation of vancomycin dose using a target AUC between 400-600 mg\*h/L
214895880|NCT04666948|DRUG|Vancomycin|Vancomycin treatment
214895881|NCT02344667|RADIATION|Stereotactic Body Radiotherapy|
214895882|NCT03104192|BEHAVIORAL|Develop & Refine MOWI w/o Amulet|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks.
215051519|NCT01616277|BIOLOGICAL|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
215051520|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
215051521|NCT01616277|BIOLOGICAL|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
215051522|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
214478272|NCT02914483|DIAGNOSTIC_TEST|Actigraph|The Actigraph (wGT3X-BT) will monitor sleep activity and will be worn by participants for 7 days, pre- and post stress based intervention.
214895883|NCT03104192|BEHAVIORAL|MOWI Weight Loss Maintenance|Participants who successfully completed the initial MOWI program will be offered the opportunity to participate in a 6-month weight management program. This program will consist of 8 group-based skills workshop sessions occurring approximately once monthly (every 3 weeks), which will be 90-120 minutes in length. The overall structure of the program will emphasize the following evidence-based weight management components: Goal setting/action planning, self-monitoring, receiving feedback regarding performance, reviewing relevant goals in the light of feedback, and e. psychological skills for increasing behavioral commitment (acceptance, willingness, thought monitoring, mindful decision making, and values clarification).
214895884|NCT03104192|BEHAVIORAL|Develop & Refine MOWI w Fitbit|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance.
214895885|NCT03104192|DIETARY_SUPPLEMENT|Develop & Refine MOWI w Fitbit/Protein|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance. We will provide whey protein 3x/week after exercise sessions.
214895886|NCT02042157|BEHAVIORAL|Bidet use|Participants used a bidet, a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.
214895887|NCT02042157|OTHER|Regular toileting|Patients in the control arm will toilet as usual.
214895888|NCT01113372|DRUG|Clopidogrel|Clopidogrel 75mg daily.
214895889|NCT06295172|DEVICE|Lafullen15|Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
214895890|NCT06295172|DEVICE|Lafullen|Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
214895891|NCT04138901|PROCEDURE|Ultrasound guided subcostal transversus abdominis plane block (TAPB)|At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.
214895892|NCT04138901|DRUG|Ropivacaine 0.75% Injectable Solution|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
214895893|NCT04138901|DEVICE|21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
214895894|NCT04868825|DEVICE|Ivory Dentin Graft|Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 900 μm porous particles or granules of hydroxyapatite and collagen which retain the natural form of the source porcine dentin and protein matrix. (Packed Vial: 1.00 gr; Packed Syringe: 1.0 gr)
214895895|NCT04868825|DEVICE|OsteoBiol Gen-Os|Comparator control device A natural porcine origin cortico-cancellous heterologous bone mix consists of sterile 250 - 1000 μm porous particles of hydroxyapatite and collagen (Packed Vial: 1.0 gr)
214895896|NCT04166786|DRUG|Testosterone gel|Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.
214895897|NCT04166786|DRUG|Ethanol Solution|Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.
215051523|NCT01616277|BIOLOGICAL|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
215051524|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
215051525|NCT01791660|DEVICE|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
215051526|NCT03842046|PROCEDURE|phenylephrine infusion|In parturients allocated to the phenylephrine group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
215051527|NCT03842046|PROCEDURE|norepinephrine infusion|In parturients allocated to the norepinephrine group group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
215051528|NCT01791517|OTHER|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
215051529|NCT01791517|OTHER|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
214478273|NCT04633278|DRUG|CMP-001|Subjects will receive CMP-001 10mg weekly for 2 doses after which CMP-001 will be administered every 3 weeks. The first dose of CMP-001 may be administered subcutaneously (SC) or Intratumorally (IT) at the discretion of Investigator. All subsequent doses will be injected intratumorally every 3 weeks (Q3W).
214895898|NCT04166786|DRUG|Testosterone placebo (vaseline)|Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.
214895899|NCT04166786|DRUG|Ethanol placebo (lemon-flavoured water)|Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.
214895900|NCT02507739|OTHER|no possibility to walk during labor|
214895901|NCT02507739|OTHER|possibility to walk during labor|
215051530|NCT01791517|OTHER|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
215051531|NCT01791517|OTHER|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
215051532|NCT02995512|DRUG|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
215051533|NCT04011735|DRUG|Respimat|Soft Mist Inhaler product
215051534|NCT04471376|DRUG|Sugammadex|Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
215051535|NCT02298868|DRUG|Baclofen|
214297022|NCT03510286|DIAGNOSTIC_TEST|Test-it™ PrCr Urinalysis Strips|The LifeAssay Diagnostics prototype PrCr dipstick has been designed to provide the measurement of both protein and creatinine while retaining a very low estimated cost that is comparable to the current protein-only dipsticks at $0.06-0.10 per test. In 2015, an initial laboratory-based validation study of the prototype LAD PrCr test was used on more than 500 characterized urine samples from pregnant women. This validation study demonstrated comparable accuracy for detection of severe proteinuria of the LAD PrCr test to the much more expensive commercial POC test available for PrCr determination, the Siemens Multistix® PRO 10LS. These results were compared to laboratory-based reference standard assays for proteinuria measurement.
214297023|NCT02756884|BIOLOGICAL|LoFU and aADSC|Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
214297024|NCT02756884|BIOLOGICAL|adipose derived stem cells|control arm will only received the adipose derived stem cells.
214297025|NCT02836899|DRUG|Nitric Oxide|Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
214297026|NCT02836899|OTHER|Placebo|This is the placebo group. Nitrogen will be added instead of nitric oxide.
214297027|NCT00397982|BIOLOGICAL|Bevacizumab|Given IV
214478274|NCT04633278|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV is administered Q3W.
214478275|NCT05937100|DRUG|Formocresol|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute
214895902|NCT05653557|OTHER|Shen Que Moxibustion|Herb-partitioned moxibustion was administered at RN8 (Shen Que), once every 72 hours from the beginning of previous menstrual cycle day 2 until oocyte retrieval. Approximately 10 moxa cones will be used for this procedure, which will take approximately two hours. It is recommended that patients close their eyes during the procedure and rest. Following moxibustion, the umbilicus will be affixed and sealed with a medical applicator and removed after 24 hours.
214895903|NCT00472563|DRUG|Bicarbinate 150 mEq/L|75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
214895904|NCT00110396|BIOLOGICAL|Interferon-beta-1a FBS-free/HSA-free|Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
214895905|NCT00882518|DRUG|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|200 mg or 300 mg, oral, single dose
214895906|NCT00882518|DRUG|Chlorpromazine|50 mg, oral, double dose
214895907|NCT04305132|DEVICE|Electroconvulsive therapy|Thymatron System IV electroconvulsive therapy device
214895908|NCT03330561|DRUG|PRS-343|PRS-343
214895909|NCT02137252|DRUG|Naltrexone|
214895910|NCT02137252|DRUG|Sugar Pill|
214895911|NCT05015816|DIAGNOSTIC_TEST|Total body photography|3 monthly TBP imaging
214895912|NCT03535740|DRUG|Brigatinib|Brigatinib Tablets
214895913|NCT06045689|DRUG|Luspatercept|Specified dose on specified days.
214895914|NCT04894734|DEVICE|EES on|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
214895915|NCT04894734|DEVICE|EES off|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
215051536|NCT02951234|OTHER|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
215051537|NCT02951234|OTHER|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
215051538|NCT01000506|BIOLOGICAL|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
215051539|NCT01000506|BIOLOGICAL|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
215051540|NCT01000506|BIOLOGICAL|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
215051541|NCT01000506|DRUG|Placebo saline|Placebo saline every four weeks by i.v.
214297028|NCT00397982|OTHER|Laboratory Biomarker Analysis|Correlative studies
214297029|NCT00397982|DRUG|Temsirolimus|Given IV
214297030|NCT00397982|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection
214297031|NCT00165893|DEVICE|Accu-Spina Device/IDD therapy|
214895916|NCT06120153|DIAGNOSTIC_TEST|POC PCR-test device|"The analysis will follow an intention-to-treat principle, that is, contacts in the intervention period will be analyzed as randomized, regardless of whether the POC PCR test was actually performed for a given contact. As sensitivity analysis, the data will be analyzed in a per-protocol spirit, defining the intervention at the contact level as a POC PCR test performed."
214895917|NCT06974760|DEVICE|IVUS|The Participants will receive IVUS examinations from Pulse and Boston
214895918|NCT06304883|DRUG|Experimental: ALZ-801|ALZ-801 265 mg BID tablet orally.
214895919|NCT05588024|DEVICE|Head Up CPR based bundle of care|All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
215051542|NCT01234181|PROCEDURE|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline
215051543|NCT00463086|DRUG|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
215051544|NCT00463086|DRUG|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
214895920|NCT06004674|DRUG|Lovenox 40mg|Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
214895921|NCT04481035|DRUG|N-acetylcysteine (NAC)|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the experimental phase/arm will receive 70 mg/kg/dose (max dose 900 mg) three times per day of NAC for eight (8) weeks.
215051545|NCT06138938|OTHER|Intraoperative abdominal irrigation|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
215051546|NCT02255929|RADIATION|Gamma Knife Radiosurgery|
215051547|NCT00905190|DRUG|Ondansetron|24 mg one time
215051548|NCT02994966|DEVICE|Surrosense|
215051549|NCT02994966|OTHER|Standard care|
215051550|NCT03116425|DEVICE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
215051551|NCT03116425|DEVICE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
215051552|NCT03116425|DEVICE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
215051553|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
215051554|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
215051555|NCT03116425|PROCEDURE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
215051556|NCT03149146|OTHER|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
215051557|NCT03149146|OTHER|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
215051558|NCT03577262|OTHER|[11C]-UCB-J|IV radioligand given prior to and during positron emission tomography (PET) scan
215051559|NCT00568594|DRUG|APL180|
215051560|NCT00568594|DRUG|Placebo|
215051561|NCT01336244|DRUG|GLPG0778|capsules containing 50 or 100 mg of GLPG0778
215051562|NCT01336244|DRUG|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
215051563|NCT06266559|OTHER|Chang Geng Healthy Drink|Chang Geng Healthy Drink consists of Zingiberis Rhizoma, Codonopsis pilosula, Atractylodis Macrocephalae Rhizoma, Poria cocos, Citri reticulatae Pericarpium
215051564|NCT00451399|DRUG|metformin|
215051565|NCT00451399|BEHAVIORAL|lifestyle intervention|
215051566|NCT04538131|DEVICE|sensor-driven position-adaptive SCS|Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
214297032|NCT00165893|PROCEDURE|Physical Therapy|
214297033|NCT05482633|OTHER|Inspiratory muscle training (IMT)|Treatment group will perform IMT every day for eight weeks. Initial load is going to be set as the 60% of maximal inspiratory pressure (PImax) and is going to be increased by %10 of the initial load every two weeks.
214297034|NCT00084981|DRUG|decitabine|Given IV
214297035|NCT00084981|DRUG|valproic acid|Given PO
214297036|NCT00084981|OTHER|pharmacological study|Correlative studies
214297037|NCT00084981|OTHER|laboratory biomarker analysis|Correlative studies
214478276|NCT05937100|DRUG|Biodentine|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
214895922|NCT04481035|OTHER|Placebo|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the placebo phase/arm will receive placebo (non-drug) three times per day for eight (8) weeks.
214895923|NCT06536465|DRUG|REC-3964|REC-3964 given at a dose of either 500 mg q12h or 250 mg q12h
214895924|NCT05437198|OTHER|collection of human exhalation|"the collection of the exhalation will be carried out with a non-invasive device manufactured by a Chinese company.~The collection of exhalation consists of the subject inhaling through the nose and exhaling gently through the mouth through a plastic straw for a time set at 5 min in the device"
214895925|NCT05807828|PROCEDURE|VR simulation on basic THA skills|The medical students' VR group will perform three VR simulation sessions on basic THA skills on the cup or stem implantation before actual implantation.
214895926|NCT06975683|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|On the day of the ovarian puncture of the 1st IVF cycle, intraovarian instillation of plasma rich in growth factors will be performed.
214895929|NCT04416581|DRUG|PPI|rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.
214895930|NCT04416581|DRUG|P-CAB 50|tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.
214895931|NCT04175041|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
214297038|NCT05113186|DRUG|Lenvatinib Pill|"The design of study is summarized as follows:~* Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~* PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~* Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)"
214297039|NCT01269697|DIETARY_SUPPLEMENT|Nutrof Total|2 capsules 2 times per day during 6 month
214895932|NCT05198518|DEVICE|Microcurrent TENS device|The study device is a handheld micro-current TENS emitter intended to be used for the relief of postoperative pain after FESS. The design of the study device was optimized to provide transcutaneous nerve stimulation to the regional areas associated with the sinuses.
214297040|NCT01269697|DIETARY_SUPPLEMENT|Placebo Nutrof total|2 capsules 2 times per day during 6 month
214297041|NCT04244786|DEVICE|Transcranial direct current stimulation|tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
214297042|NCT04244786|OTHER|No intervention|No intervention for participants who discontinued prior to randomization
214297043|NCT05584696|OTHER|Green light exposure|The experimental group wears green color glasses ten minutes before surgery until it ends.
214297044|NCT05584696|OTHER|Normal light exposure|The control group wears green color glasses ten minutes before surgery until it ends.
214297045|NCT01101347|DEVICE|Aneurysm-Embolization System|
214297046|NCT02659527|DRUG|68Ga- PSMA-HBED-CC|Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
214297047|NCT02659527|DEVICE|Biograph mMR, Siemens|All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
214297048|NCT05693714|DIAGNOSTIC_TEST|Pcr|Polymerase chain reaction
214297049|NCT01424254|DEVICE|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
214297050|NCT01424254|PROCEDURE|Push-Enteroscopy|currently recommended standard
214297051|NCT00264641|DRUG|Human insulin|Hyperinsulinaemic induced hypoglycaemia
214895933|NCT05198518|DEVICE|Sham Device|The sham device appears and operates identically to the active device, including indicator lights and haptic vibration, however it emits a weak direct current that is non-therapeutic.
214895934|NCT05024825|DRUG|Gabapentin|Patients in the gabapentin arm may at any point call the Pediatric ENT clinic if pain is not adequately controlled. Patients will be prescribed hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14 yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain. Patients will be informed to stop taking gabapentin.
215051567|NCT04538131|DEVICE|conventional SCS|Conventional SCS can not change the parameter when the body position changes.
215051568|NCT03926377|PROCEDURE|bone densitometry|Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).
215051569|NCT03926377|BIOLOGICAL|blood test|Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.
214297052|NCT02107027|DEVICE|nMARQ catheter|"In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted."
214297053|NCT02107027|DEVICE|Navistar catheter|"In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted."
214297054|NCT03376854|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
214297055|NCT03376854|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
214297056|NCT03376854|DEVICE|Standard of Care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
214297057|NCT03032367|DRUG|bedaquiline|
214297058|NCT01238679|DRUG|PF-04958242|Administered as specified in the treatment arm
214297059|NCT01238679|DRUG|Placebo|Administered as specified in the treatment arm
214297060|NCT02703909|DRUG|Rocuronium|Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
214478277|NCT05937100|DRUG|Hyaluronic acid gel|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes.
214895935|NCT05024825|DRUG|hydrocodone, acetaminophen and ibuprofen|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
214297061|NCT02703909|DEVICE|Insufflation pressure|The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
214297062|NCT01830582|PROCEDURE|Advanced MR Imaging|
214478278|NCT06292091|DRUG|Captopril 12.5 Mg|12.5 mg of captopril
214478279|NCT06292091|DRUG|Sodium bicarbonate 4 G|4 g of sodium bicarbonate
214478280|NCT06292091|DRUG|Torsemide 20 MG|20 mg of torsemide
214478281|NCT05124405|OTHER|Fitbit|wearable activity tracker
214478282|NCT05124405|OTHER|Continuous Glucose Monitor|wearable activity tracker
214478283|NCT04290403|DEVICE|Pull Ups|Participants will be asked to wear pull-ups continence products for the duration of four weeks
214668974|NCT06713551|OTHER|Big Amplitude Calisthenic Group Exercise|The exercise program will consist of balance and mobility-oriented exercises such as reaching forward and upward while sitting on a chair, taking steps forward, backward, sideways and backward while standing, transferring weight, counting in place, sit-to-stand exercises, walking, changing directions or walking over obstacles (Appendix: Exercise Program). This exercise program will be applied to the first group with the accompaniment of classical Western music, while the other group will be applied without music. The exercise programs will be performed for both groups for 40 minutes, two days a week and for eight weeks.
214668975|NCT06592833|DRUG|Psilocybin|Psilocybin, 25mg, given once orally.
214668976|NCT06592833|DRUG|Pimavanserin|Pimavanserin, 34mg, given once orally
214668977|NCT06592833|DRUG|Placebo|Matching placebo.
214895936|NCT06103045|OTHER|unilateral and bilateral mirror therapy|The mirror box is placed on a table in the sagittal plane of the participant. The affected upper extremity of the participant is hidden in the morror box and the unaffected upper extremity is placed symmetrically. During the unilateral or bilateral mirror therapy, the participant is requested to execute a serial of movements and tasks and pay attention on observing the reflection of the unaffected side in the mirror simultaneously. In the bilateral mirror therapy, the participant also has to move the affected upper extremity simultaneously; while in the unilateral mirror therapy, the participant only keeps the affected side relaxed.
214895937|NCT04659369|DRUG|CMAB819|for injection only
214895938|NCT04659369|DRUG|Nivolumab|for injection only
214895939|NCT06021418|DEVICE|DKB-119|Experimental and Acitve Comparator are applied 4 times to each of crow's feet on both sides of the subject.
214895940|NCT05856851|DRUG|Alteplase|See arm/group descriptions.
214895941|NCT02927470|DEVICE|Sham TMS condition|A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.
215051570|NCT03926377|PROCEDURE|radiographs of the thoracic and lumbar spine|standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.
215051571|NCT03926377|PROCEDURE|Clobetasol propionate|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
215051572|NCT05629455|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
215051573|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
215051574|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
214297063|NCT00613938|DRUG|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
214297064|NCT00613938|DRUG|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
214297065|NCT00613938|DRUG|oxycodone|10mg capsule q4-6 hrs for 3 days
214478284|NCT04290403|DEVICE|Styled Briefs with tapes|Participants will be asked to wear styled briefs with tapes for the duration of four weeks
214668978|NCT03803852|DEVICE|Intraocular Lens Implantation|"Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impressinto the capsular bag using an injector, after removing of the human cristalline lens.~Implantation of the Alcon Clareon toric and Rayner RayOne EMV toric IOL and PODEYE Toric IOL on the axis according to the steep meridian of the cornea"
214895942|NCT02927470|DEVICE|OffLine TMS Condition|A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.
214895943|NCT02927470|DEVICE|Online TMS condition|A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
214895944|NCT03168022|DRUG|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
214895945|NCT03168022|DRUG|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
214895946|NCT03214783|OTHER|Facial characteristics|The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
214895947|NCT05209789|BEHAVIORAL|HUGS|Group therapy with the participation of two therapist positively encouraging mother-baby interactions in a non-judgmental manner
214895948|NCT05209789|BEHAVIORAL|Playtime|Very little intervention from the therapists
214895949|NCT02188810|BIOLOGICAL|PAL|Single dose administered intramuscularly.
214895950|NCT02188810|BIOLOGICAL|TIV|Single dose administered intramuscularly .
214895951|NCT02677350|DRUG|Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)|Peri-fistula injections
215051575|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
215051576|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
215051577|NCT01419496|GENETIC|protein expression analysis|
215051578|NCT01419496|OTHER|flow cytometry|
214297066|NCT00613938|DRUG|placebo|1 capsule q4-6 hrs for 3 days
214668979|NCT03117933|DRUG|Olaparib|Tablet, 100mg and 150mg
214668980|NCT03117933|DRUG|Cediranib|Tablet 15mg and 20mg
214895952|NCT03427515|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|30 days of supplementation, 6x10\^9 CFU/day
214297067|NCT00480272|DRUG|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
214297068|NCT00480272|DRUG|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
214297069|NCT02939235|DRUG|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
214668981|NCT03117933|DRUG|Paclitaxel|Intravenous (IV)
214895953|NCT03427515|DIETARY_SUPPLEMENT|Saccharomyces boulardii (CNCM I-1079)|30 days of supplementation, 5x10\^9 CFU/day
214895954|NCT03427515|DIETARY_SUPPLEMENT|Placebo|30 days of supplementation
214895955|NCT02521649|DRUG|G17DT|
214895956|NCT04774484|OTHER|High Intensity Interval Training|After the acclimatization session and assessment of eligibility, a graded exercise test (GXT) will be given to the participant. After checking their vitals, the HIIT program will be performed on recumbent cycles. The first two weeks of training will consist of a gradual ramp where subjects will perform a moderate intensity cycling program consisting of a 5-minute warm up followed by progressively longer continuous cycling starting at 15 minutes and progressing up to 30 minutes prior to starting the HIIT training. For the HIIT training subjects will perform 5 minutes of low to moderate steady state cycling to warm up. Following the warm up, the subjects will complete the 4x4 HIIT program. This will consist of 4 minutes of cycling at 85% of the subject's maximum heart rate (HR) followed by 4 minutes of a low intensity cycling period for recovery.
215051579|NCT01419496|OTHER|laboratory biomarker analysis|
215051580|NCT06314854|OTHER|Running water sound|Running water sound for experimental group Standard care for control group
215051581|NCT00739310|DEVICE|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
215051582|NCT02622477|DRUG|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
214297070|NCT02939235|DRUG|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
214668982|NCT04865081|DEVICE|VACCIN box|The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
214895957|NCT02068313|RADIATION|Toxicity and outcome measures of IMRT|
214895958|NCT02223988|PROCEDURE|subglottic secretion removal|
215051583|NCT06311591|DEVICE|Jaspr App|Jaspr was designed to improve delivery of evidence-based, personalized suicide care in the ED. Jaspr (Dimeff, R44MH108222) is rooted in EBPs, including Collaborative Assessment and Management of Suicide (CAMS) and Dialectical Behavior Therapy (DBT). Briefly, Jaspr provides a patient interface, optimized for a tablet computer provided to the patient, which uses an avatar to administer: (1) the CAMS Suicide Status Form (SSF), an evidence-based suicide risk assessment; (2) crisis stabilization planning (CAMS' version of safety planning) or Stanley-Brown Safety Planning Intervention, depending on site choice; (3) lethal means safety counseling. Further, Jaspr teaches behavioral skills from DBT to manage imminent distress and has a library of over 40 racially and culturally diverse, inspirational videos of people with lived experience. Finally, Jaspr@home provides access to these resources after the visit during the high-risk transition to outpatient care.
214895959|NCT03910985|DRUG|Duovent HFA|bronchodilation
215051584|NCT01071954|BIOLOGICAL|Romiplostim|Administered by subcutaneous injection once a week.
215051585|NCT05070130|DEVICE|dPR and FFR|OpSens non-hyperemic dPR and/or OpSens FFR
215051586|NCT03156218|DRUG|Modulation of FiO2|Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
215051587|NCT02814188|OTHER|Carbohydrate Beverage|750 ml of a 13.5% carbohydrate (sucrose) beverage
215051588|NCT02814188|OTHER|Placebo Beverage|750 ml of an artificially-sweetened beverage
215051589|NCT00590967|RADIATION|IMRT extended field external beam radiation therapy|
215051590|NCT00590967|RADIATION|Brachytherapy|
215051591|NCT00590967|DRUG|Cisplatin|
215051592|NCT00664482|BIOLOGICAL|AGS-006|Autologous Therapy for Pancreatic Cancer
214297071|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of right HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.
214297072|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of left HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
214297073|NCT02636868|DRUG|Lucinactant delivered via investigational delivery device|Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)
214297074|NCT02636868|DRUG|nCPAP|Nasal CPAP
214668983|NCT06657742|OTHER|SCIM-SR|SCIM-SR was a self-reported scale that evaluated the independence of patients.
214668984|NCT06656962|DRUG|Telitacicept 160mg|Telitacicept for Injection combined with standard therapy (Prednisone and Cyclophosphamide) for the treatment of ANCA-associated nephritis (AAGN).
214668985|NCT06656962|DRUG|Prednisone (and methylprednisolone)|Methylprednisone shock therapy (500mg, 3 times), followed by Prednisone (1 mg·kg·d and a pre-determined tapering guideline \[PEXIVAS regimen\]).
215051593|NCT05228405|OTHER|All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness|All of the different type of disabled children's caregivers (cerebral palsy, muscular dystrophy, spina bifida and down syndrome) will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
215051594|NCT02045784|DIETARY_SUPPLEMENT|Infant formula|To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
215051595|NCT02045784|OTHER|Breast milk|Unlimited breast feeding
215051596|NCT06181981|DIAGNOSTIC_TEST|MRI fingerprinting|This method allows to get quantitative magnetic resonance imaging for the simultaneous measurement of multiple tissue properties in a single, time-efficient acquisition
214895960|NCT05228678|DIAGNOSTIC_TEST|cardiopulmonary exercise tests|"Spirometry~* forced expiratory volume in 1 second (FEV1) % predicted,~* forced vital capacity (FVC)% predicted,~* forced expiratory volume in 1 second /forced vital capacity FEV1 /FVC"
214895961|NCT02608411|DRUG|ARQ197|
214895962|NCT04942678|BEHAVIORAL|10-minute visit with therapy dog and child life specialist handler|A visit from a therapy dog and child life specialist will occur which will last for approximately 10 minutes. Parents and patients will be asked to sanitize their hand prior to the visit. The child life specialist will be instructed to have ad lib conversation with the family. The dog will remain on a leash during the visit. The patient will be free to pet the therapy dog if they wish.
214895963|NCT02756611|DRUG|Venetoclax|Tablets for oral administration
215051597|NCT00265915|BIOLOGICAL|rituximab|
215051598|NCT00265915|BIOLOGICAL|sargramostim|
215051599|NCT01685814|DRUG|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
215051600|NCT01685814|BIOLOGICAL|autologous stem cell transplant|
215051601|NCT01685814|BIOLOGICAL|allogeneic stem cell transplant|
215051602|NCT03538093|OTHER|Experimental: Local Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus a. activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase:4th-6th week: hot compress + electrotherapy IFT (fr: 4kHz, AMF 100Hz, modulation 20Hz, 20 mins), stabilizer training. Hamstring, quadriceps, gluteus maximus and psoas stretching, stationary bicycle without load. 7th-9th week: stabilizer training elevating a leg, stationary bicycle low load. 10th-12th week: 1kg to elevated leg on stabilizer training, stationary bicycle moderate load."
214895964|NCT04364178|BIOLOGICAL|Adenovirus Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
214297075|NCT00590109|OTHER|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
214297076|NCT00590109|OTHER|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
214668986|NCT06656962|DRUG|Cyclophosphamide|Cyclophosphamide, intravenous injection, once every 2 to 3 weeks, 0.75 g/m² each time, the maximum cumulative dose of 8g
214668987|NCT04515524|OTHER|Non-Interventional|No study treatment will be administered in this study
214668988|NCT03373812|PROCEDURE|Blepharoptosis repair|levator advancement or mullerectomy
214668989|NCT06653751|DEVICE|Reminder App|The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
214668990|NCT05240261|DRUG|Quetiapine|Quetiapine 25 mg / day
214668991|NCT02421250|DEVICE|Radical-7 Noninvasive Hgb Monitor|
214668992|NCT05501925|DEVICE|GlideSheath Slender® and conventional arterial sheath|Using the GlideSheath Slender® with the outside diameter 2.46mm
214895965|NCT04364178|BIOLOGICAL|Cytomegalovirus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
214895966|NCT06196489|BEHAVIORAL|adapted vaping cessation intervention|Behavioral intervention for vaping cessation
214895967|NCT02740192|PROCEDURE|Adductor Canal Block|Post-op adductor canal block using Bupivacaine
214895968|NCT02740192|PROCEDURE|Periarticular Injection|Intra-op periarticular injection of Ropivacaine
214895969|NCT02740192|DRUG|Ropivacaine|Ropivacaine was used for the periarticular injection
214895970|NCT02740192|DRUG|Bupivacaine|Bupivacaine was used for the periarticular injection
214895971|NCT05545189|DIAGNOSTIC_TEST|colonoscopy,polypectomy|polyp removal during colonoscopy
214895972|NCT06365528|PROCEDURE|Subcutaneous tunnelling|The Subcutaneous tunnelling group will undergo PICC placement under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe and place with additional subcutaneous tunnelling. After vein puncture with the access needle, a Nitinol guidewire will be placed as usual. We will make a tunnel distal to the initial venepuncture site using an additional 14-gauge needle. After resolution of the loop over the venepuncture site, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction plus the subcutaneous tunnel before being inserted in the usual manner.
214895973|NCT06365528|PROCEDURE|Non-tunnelling|The Non-tunnelling group will have PICC placement with the traditional method under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe. After vein puncture with the access needle, a Nitinol guidewire will be placed. After, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction.
214895974|NCT03125798|DEVICE|LigaSure™|LigaSure™ is supposed to provide improved closure of lymphatic and blood vessels during mediastinal lymph nodes dissection.
214895975|NCT03125798|DEVICE|Monopolar electrocautery|Monopolar electrocautery will be used according to the standard technique for the mediastinal lymph node dissection.
214895976|NCT05593744|OTHER|no intervention|This is an observational study so not involved intervention
214895977|NCT02463773|DEVICE|Ultrasound|Diaphragmatic excursion ultrasound assessment
214895978|NCT05211648|DEVICE|Aktiia Bracelet|Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The optical signals at the wrist are recorded non-invasively by means by the Aktiia bracelet. The Blood Pressure measurements are further determined from these optical signals and are compared to weekly and monthly Blood Pressure averages measured manually by traditional Home Blood Pressure Monitoring.
214895979|NCT01470092|DRUG|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
214895980|NCT02023931|DRUG|Broccoli Sprout Extract (BSE)|"1. The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~2. The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~3. The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane."
214895981|NCT03869944|DRUG|Lamivudine Oral Solution|"During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (\< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART."
214895982|NCT03412331|DEVICE|Ultrasonic|Cavitron® BOBCAT® Pro, Dentsply International, USA
214895983|NCT03412331|DEVICE|Hand Instruments|Gracey, SG 5/6, 7/8, 11/12, 13/14, Hu-Friedy Ins. Co., USA
214297077|NCT02443012|DRUG|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
214297078|NCT02443012|PROCEDURE|Laser|Grid/Focal Laser Photocoagulation
214668993|NCT05501925|DEVICE|Conventional arterial sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II )
214668994|NCT03650504|PROCEDURE|Above Artery Catheter Placement|Nerve catheter placed between superficial femoral artery and sartorial muscle
214668995|NCT03650504|PROCEDURE|Between Artery and Vein Placement|Nerve catheter placed between superficial femoral artery and femoral vein
214668996|NCT04176510|BEHAVIORAL|Health Coach Intervention|A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
214297079|NCT05124951|RADIATION|Whole-ventricle irradiation|Whole-ventricle irradiation will be applied in patients with localized basal ganglia germ cell tumors after induction chemotherapy
214297080|NCT05124951|DRUG|Carboplatin/etoposide|Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma
214297081|NCT05124951|DRUG|Ifosfamide/cisplatin/etoposide|Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.
214297082|NCT05124951|PROCEDURE|Second-look surgery|Second-look surgery would be applied to patients who presented residue disease after induction chemotherapy.
214297083|NCT01288950|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
214297084|NCT03220217|DRUG|Satoreotide trizoxetan 5-20μg|Positron emission tomography (PET) imaging agent
214668997|NCT03949777|DEVICE|Aer-O-Scope Colonoscopy|resection or biopsy of colonic abnormalities for histopathalogical evaluation
214668998|NCT04789824|BEHAVIORAL|eyelid hygiene|EH
214668999|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
214669000|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
214669001|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
214669002|NCT06605664|DIAGNOSTIC_TEST|Hyperpolarized 13C pyruvate MRI|The subject enrolled in this trial will receive DNP-MRI scanning for two times through hyperpolarized \[1-13C\]pyruvate injection (\~250 mM, 0.43 mL/Kg) before and 2-5 weeks after radiotherapy.
214669003|NCT05426044|DRUG|Metformin|"To investigate whether metformin has a neuroprotective effect in patients with primary open-angle glaucoma by comparing the rates of change of average retinal nerve fiber layer ganglion cell inner plexiform layer (RNFL-GCIPL) thickness (primary outcome measure) between patients randomized to receive metformin versus those randomized to receive placebo.~To identify the risk factors associated with progressive RNFL-GCIPL thinning and progressive decline in visual field mean deviation in patients with glaucoma."
214669004|NCT05426044|DEVICE|Placebo|This study takes 24 months. Participants will have 12 visits within 24 months. All of the investigations will be carried out at Grantham Hospital and Hong Kong Eye Hospital. Patients will be randomly assigned in a 1:1 ratio to receive, twice daily, oral metformin 750mg (i.e. 1500mg/day) or identical-appearing oral placebo. The investigators and patients will be blinded to the treatment assignment. Participants will be followed up at 2-month intervals for 24 months.
214669005|NCT01703312|DRUG|QGE031|Drug administered by subcutaneous injection
214669006|NCT01703312|DRUG|omalizumab|Drug administered by subcutaneous injection
214669007|NCT01703312|DRUG|placebo|Drug administered by subcutaneous injection
214669008|NCT03497169|DRUG|Lisdexamfetamine Dimesylate|Patients are tested for their normal prescription lisdexamphetamine medication
214669009|NCT00193505|DRUG|Ifosfamide|
214669010|NCT00193505|DRUG|Carboplatin|
214669011|NCT00193505|DRUG|Etoposide|
214669012|NCT00193505|DRUG|Rituximab|
214669013|NCT00193505|DRUG|90Y Zevalin|
214669014|NCT03670576|PROCEDURE|Optional Bronchoscopy|Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.
214669015|NCT03670576|OTHER|Quality of Life Questionnaires|MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,
214669016|NCT03670576|OTHER|Blood Samples for Biomarkers|a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.
214669017|NCT03670576|OTHER|Home Hand Held Spirometry|Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)
214669018|NCT00289705|PROCEDURE|Surgery|Laparoscopic Roux-en-Y gastric bypass
214669019|NCT05910463|OTHER|AXOMOVE Therapy Medical Device|Personalized exercise programs for the self-rehabilitation of low back pain patients
214297085|NCT03220217|DRUG|Satoreotide trizoxetan 30-45μg|Positron emission tomography (PET) imaging agent
214297086|NCT01755923|DRUG|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
214478285|NCT05947422|DIAGNOSTIC_TEST|High resolution CT Chest|"CT chest in our institution will be done with standard high resolution protocol . No I.V contrast will be given. Scans will be obtained during full inspiration in supine position from the thoracic inlet to the level of the diaphragm.~Patients with CT chest performed outside our institution will be reviewed in DICOM format and assessed for its compatibility to be integrated into the computer-based analysis software."
214297087|NCT01755923|DRUG|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
214297088|NCT04759872|OTHER|Hyperinsulinemic-euglycemic Clamp|Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).
214297089|NCT00376909|OTHER|educational intervention|
214297090|NCT00376909|OTHER|study of socioeconomic and demographic variables|
214297091|NCT03854656|OTHER|Time-restricted eating|"Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~1. The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~2. The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority."
214669020|NCT00840463|DRUG|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
214297092|NCT06308120|DEVICE|Ion Endoluminal System|Participants in the test arm will undergo a diagnostic bronchoscopy with ION™ Endoluminal System.
214297093|NCT06308120|DEVICE|superDimension Navigation System and Accessories|Participants in the control arm will undergo a diagnostic bronchoscopy with superDimension Navigation System and Accessories.
214297094|NCT03025542|DRUG|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
214297095|NCT03025542|OTHER|Placebo|Subjects will receive injections of Placebo.
214297096|NCT01384396|DRUG|KW-3357|Intravenous infusion once a day
214297097|NCT00616460|DRUG|Bivalirudin|Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250
214297098|NCT03745937|DRUG|MEDI0382|Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
214297099|NCT03745937|DRUG|Placebo|Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
214297100|NCT02635828|DRUG|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
214297101|NCT02635828|DRUG|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
214297102|NCT02635828|DRUG|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
214297103|NCT06036576|DRUG|Levothyroxine Pill|all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
214297104|NCT06051188|DEVICE|Flow-controlled ventilation|Flow-controlled ventilation (FCV)
214297105|NCT00239707|DRUG|GIP|One-time 20 ng/kg/min infusion over 3 hours
214297106|NCT00239707|DRUG|Modified GIP|One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
214478286|NCT05947422|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed using standard techniques according to ATS-ERS criteria 2019 . Spirometry device (Zan 300, NSPIRE HEALTH GMBH Co.) will be used. Percentage predicted values (%pred) will be calculated based on reference values for healthy adults. All patients will be required to undergo spirometry in a reproducible way, and the best values will be reported. Spirometry should meet international acceptability and repeatability standards
214669021|NCT00840463|OTHER|Placebo|Sugar pill
214669022|NCT03792009|DEVICE|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
214669023|NCT03792009|DRUG|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
214669024|NCT03792009|DRUG|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
214895984|NCT03412331|DEVICE|LED Source|LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark)
214297107|NCT00239707|DRUG|Normal Saline|one-time infusion over 3 hours
214895985|NCT02688738|DRUG|Doxycycline|
214297108|NCT05240404|DRUG|Toripalimab|toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
214297109|NCT05240404|PROCEDURE|Thermal ablation|The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.
214297110|NCT03880656|BIOLOGICAL|Intramuscular administration of autologous BM-MNCs|Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
214297111|NCT05456243|BIOLOGICAL|Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 1 x 10\^5 cells/kg
214895986|NCT00784108|DEVICE|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
214895987|NCT00784108|OTHER|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
214478287|NCT06003595|OTHER|Data collection on patient reported long-term outcome of SSRF hardware removal|One prospective follow-up visit will be performed. On this visit the patient reported long-term outcome will be documented through a health survey.
214478288|NCT06639633|OTHER|Anatomy Training with Enlarged %100 3D Printed Carpal Model Group|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 100% magnification on a 3D printer for 60 minutes.
214895988|NCT00399048|DRUG|OROS hydromorphone HCL ; OxyContin|
214669025|NCT02043574|BEHAVIORAL|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
214895989|NCT01587157|PROCEDURE|capnography|
214297112|NCT05456243|BIOLOGICAL|High dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 5 x 10\^5 cells/kg infused over 5 minutes
214297113|NCT04430933|DRUG|NC318|NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
214297114|NCT04430933|DRUG|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
214895990|NCT00401661|DRUG|Alfuzosin|One tablet of 10mg once daily at the end of evening meal
214297115|NCT04430933|DRUG|Nab paclitaxel/Carboplatin|Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
214297116|NCT04430933|DRUG|Docetaxel|Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
214895991|NCT05446558|PROCEDURE|Intracorporeal anastomosis|"Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.~Device:~Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis."
214895992|NCT05446558|PROCEDURE|Extracorporeal anastomosis|"A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.~Device:~Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis."
214895993|NCT03472781|OTHER|No intervention. A retrospective case review|No intervention. A retrospective case review on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in Singapore National Eye Centre from January 1989 to January 2017.
215051603|NCT03538093|OTHER|Experimental: Global Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: add obliques cross exercises in supine with contralateral leg, lumbopelvic bridge exercises, sitting on the edge of the bed. Day 3: add bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase: physiotherapy: 4th-6th week: hot compress + electrotherapy IFT, lumbopelvic bridge exercises, obliques cross exercises. Hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, stationary bicycle low load. 10th-12th week: physiotherapy, side plank, unilateral bridge, stationary bicycle moderate load."
215051604|NCT03538093|OTHER|Experimental: Mixed Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus abdominis activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~4th-6th week: hot compress + electrotherapy IFT, stabilizer training, hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, change stationary bicycle load to low load. 10th-12th week: physiotherapy, advanced global exercise (side plank), unilateral bridge,stationary bicycle moderate load."
215051605|NCT03847831|BEHAVIORAL|Active School Flag Program|Schools enrolled in the program take part in the 17 actions described in the PPASF.
215051606|NCT06486766|BEHAVIORAL|Norwegian SMS|Individuals receive a SMS in Norwegian language at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is applicable to all three populations (general population, immigrants born in Poland, immigrants born in Ukraine)
215051607|NCT06486766|BEHAVIORAL|Polish/Ukrainian SMS|Individuals receive an SMS in the official language of their native country (i.e., Polish or Ukrainian) at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is only applicable to the two immigrant populations (immigrants born in Poland, immigrants born in Ukraine)
215051608|NCT03479489|OTHER|Human dehydrated amnion chorion allograft|Closed hemorrhoidectomy patched with dehydrated human amnion chorion allograft
215051609|NCT01847755|DRUG|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
215051610|NCT02565992|BIOLOGICAL|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
215051611|NCT02565992|DRUG|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
215051612|NCT00920556|DRUG|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
215051613|NCT00920556|DRUG|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
215051614|NCT00509327|DRUG|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
215051615|NCT00509327|DRUG|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
215051616|NCT02961036|OTHER|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
215051617|NCT02961036|OTHER|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
215051618|NCT02961036|OTHER|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
215051619|NCT02961036|OTHER|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
215051620|NCT02961036|OTHER|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
215051621|NCT02961036|OTHER|Group A Reminder|One survey reminder at 14 days
215051622|NCT02961036|OTHER|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
215051623|NCT03882281|DRUG|HQP1351|Orally, single dose of 30mg on day 1 and day 8.
215051624|NCT04245709|DRUG|Clenbuterol|The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).
215051625|NCT01382771|DRUG|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
215051626|NCT01382771|DRUG|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
214297117|NCT03790527|PROCEDURE|CBM training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
214297118|NCT03790527|PROCEDURE|Sham training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
214297119|NCT05024058|DRUG|Ligelizumab|Ligelizumab treated groups and arms
214297120|NCT05024058|OTHER|Placebo|Placebo treated groups and arms
214297121|NCT05577676|DRUG|Ultrasound-guided Hydrodissection of the Median Nerve|Hydrodissection for CTS includes injecting fluid around the median nerve (MN) with 5 ml volume, 3 ml of which is given in between the transverse carpal ligament \& MN, and 2 ml below the MN under Ultrasound guidance in-plane ulnar approach.
214297122|NCT00139399|PROCEDURE|Coronary artery bypass graft (CABG) surgery|Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery
214297123|NCT06074913|OTHER|infrared thermography (IRT)|Temperatures and infrared thermograms were recorded in the region of the extremities of three groups of subjects by using an infrared thermographic camera.
214895994|NCT00332670|PROCEDURE|10.000lux blue 1 hour every day during three weeks|10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
214895995|NCT00332670|PROCEDURE|50lux dim red 1 hour every day during three weeks|50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
214895996|NCT03135015|OTHER|Placebo capsules|250ml water with 16 x 250mg placebo capsules
214895997|NCT03135015|OTHER|2g capsules|250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules
214895998|NCT03135015|OTHER|4g capsules|250ml water with 16 x 250mg capsules containing Axulin powder
214669026|NCT02043574|BEHAVIORAL|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
214895999|NCT03135015|OTHER|Water Control|250ml water
214896000|NCT03135015|OTHER|2g tablets|250ml water with 2 x 1g tablets containing Axulin powder
214896001|NCT03135015|OTHER|4g tablets|250ml water with 4 x 1g tablets containing Axulin powder
214896002|NCT03153358|DRUG|Icotinib|icotinib 125 milligram three times a day
214896003|NCT03153358|RADIATION|SBRT|given radiation for the primary lesion
214896004|NCT05560490|DEVICE|FibroFix Cartilage P Knee Implantation|The FibroFix Cartilage P instrument set (Drill set) is used for the preparation of an implant site and placement of the FibroFix Cartilage P Implant to resurface an articular cartilage lesion in the anterior and central regions of the femoral condyles of the knee.
214896005|NCT01172041|DEVICE|Real time position management system|Device to monitor respiration by using optical monitoring of a marker block placed on the abdomen of the patient.
214896006|NCT01172041|DEVICE|LS PET/CT|PET/CT scanner for acquiring CT and PET images (3D and 4D)
214896007|NCT01172041|DRUG|18-FDG|15mCi
214896008|NCT04488588|OTHER|Kaplan Meier analysis|Kaplan Meier survival analysis was conducted to calculate the cumulative overall survival rates using Log Rank test for comparison between age groups
214896009|NCT03855982|DRUG|Drug inducing myocarditis|Drugs susceptible to induce myocarditis
214896010|NCT04658966|OTHER|administration of a self-questionnaire|Women will have to fill in an online self questionnaire on pre-eclampsia
214896011|NCT05883124|DRUG|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
214896012|NCT05883124|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
214896013|NCT05481671|OTHER|Questionnaires|Participants will be asked to respond to the Demographic Information Sheet, Tampa Scale for Kinesiophobia, Numeric Rating Scale, Pain Catastrophizing Scale, Hospital Anxiety and Depression Scale, Resilience Scale , Pain Self-efficacy Questionnaires and Functional Exercise Compliance Scale for Orthopaedic Patients.
215051627|NCT04138095|DEVICE|Virtual Reality|Participants will have access to an Oculus Quest Virtual Reality Headset every second day as an alternative to opioids for pain management and benzodiazepines for anxiety management
214896014|NCT01174693|DRUG|Triflusal|Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
215051628|NCT05908838|DRUG|Modified Banxia Xiexin Decoction|The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.
214896015|NCT01174693|DRUG|Clopidogrel|Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
214896016|NCT05681598|DRUG|Hydroxyurea|The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.
215051629|NCT05908838|DRUG|combination chemotherapy with Placebo granules|combination chemotherapy with Placebo granules
215051630|NCT03734822|OTHER|End tidal CO2 (EtCO2)|End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
215051631|NCT03734822|DEVICE|Transcutaneous CO2 (TCO2)|Continuous and noninvasive real-time monitoring of transcutaneous CO2.
215051632|NCT03734822|DIAGNOSTIC_TEST|Capillary CO2 (CapCO2)|Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
215051633|NCT03734822|DIAGNOSTIC_TEST|Arterial blood gas (ABG)|Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
215051634|NCT00817934|DRUG|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
215051635|NCT02185534|DRUG|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
215051636|NCT01667341|BIOLOGICAL|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
215051637|NCT01667341|BIOLOGICAL|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
215051638|NCT01667341|BIOLOGICAL|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
215051639|NCT04596683|PROCEDURE|Same-day NSM or SSM|Discharge home same-day after nipple-sparing mastectomy (NSM), or skin-sparing mastectomy (SSM)
215051640|NCT05330871|BIOLOGICAL|1 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
215051641|NCT05330871|BIOLOGICAL|2 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
215051642|NCT05330871|BIOLOGICAL|3 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
215051643|NCT05330871|BIOLOGICAL|4 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
215051644|NCT05330871|BIOLOGICAL|5 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
215051645|NCT05330871|BIOLOGICAL|6 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
215051646|NCT05330871|BIOLOGICAL|7 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
215051647|NCT05330871|BIOLOGICAL|8 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
215051648|NCT05330871|BIOLOGICAL|9 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
215051649|NCT05330871|BIOLOGICAL|10 Intramuscular injection for booster groups|1 dose 0.5ml
215051650|NCT05330871|BIOLOGICAL|11 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
215051651|NCT05330871|BIOLOGICAL|12 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
215051652|NCT05330871|BIOLOGICAL|13 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
215051653|NCT05330871|BIOLOGICAL|14 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
215051654|NCT05330871|BIOLOGICAL|15 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
215051655|NCT05330871|BIOLOGICAL|16 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
215051656|NCT05330871|BIOLOGICAL|17 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
215051657|NCT05330871|BIOLOGICAL|18 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
215051658|NCT05330871|BIOLOGICAL|19 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
215051659|NCT05330871|BIOLOGICAL|20 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
215051660|NCT05330871|BIOLOGICAL|21 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
215051661|NCT05330871|BIOLOGICAL|22 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
215051662|NCT05330871|BIOLOGICAL|23 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
215051663|NCT05330871|BIOLOGICAL|24 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
215051664|NCT04236271|DEVICE|connected objects|a combination of connected devices for measuring physiological parameters and for clinical self-assessment by the patient, for early postoperative coronary bypass surgeries.
215051665|NCT00175929|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
215051666|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
215051667|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
215051668|NCT05455125|DIAGNOSTIC_TEST|CMR CGI|High resolution ECGI plus advanced CMR
215051669|NCT01833858|DRUG|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
215051670|NCT01833858|DRUG|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
215051671|NCT00198328|COMBINATION_PRODUCT|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
215051672|NCT00198328|PROCEDURE|Surgical Excision|Patients have their tumor surgically removed.
215051673|NCT04631315|DRUG|Difluprednate Ophthalmic Emulsion 0.05%|1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
214478289|NCT06639633|OTHER|Anatomy Training with Enlarged %50 3D Printed Carpal Model Group|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 30 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 50% magnification on a 3D printer for 60 minutes.
215051674|NCT04631315|DRUG|Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution|1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
215051675|NCT01023152|PROCEDURE|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
214896017|NCT03817645|OTHER|Zeolite|The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb\^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
214669027|NCT03485612|DIAGNOSTIC_TEST|Change of Optic Nerve Sheath Diameter|In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
214896018|NCT02226211|DEVICE|Air-Q intubation laryngeal airway|"The size selection of the air-Q ILA will follow the manufacture guideline to be size 3.5 for females and size 4.5 for males After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the air-Q, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using removal stylet ."
214896019|NCT02226211|DEVICE|Ambu-Aura i laryngeal mask|"The size selection of the device will follow the manufacture guideline according to the patient weight, size 4 for (50-70kg), size 5 (70-100) and size 6 (\> 100kg).~After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the aura-i, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using another ETT."
214896020|NCT06581445|BEHAVIORAL|Birdsongs|The participants listened to a clip of birdsongs from laughing thrushes.
214896021|NCT06581445|BEHAVIORAL|Music|The participants listened to a cheerful Cuckoo Waltz music.
214896022|NCT04356989|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The adminstration dose is decided by the attending physician in advance based on the patients' CrCl and in compliance with local market authorization of rivaroxaban.
214896023|NCT00065156|DRUG|lenalidomide|10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
214896024|NCT02735109|OTHER|photographies|cells description by taken photographies vith confocal microscope (VivaScope 3000)
214896025|NCT02735109|PROCEDURE|biopsy normal area|biopsy done to compare with abnormal area
214896026|NCT02436161|BEHAVIORAL|"Care management program PROMIC"|intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
214896027|NCT05592457|DIAGNOSTIC_TEST|MSCT|multislice computed tomography
214896028|NCT00191126|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
214896029|NCT00191126|DRUG|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
214896030|NCT00191126|PROCEDURE|surgery|surgery
214896031|NCT06042595|BEHAVIORAL|Psychotherapy|Patients treated at the inpatient psychotherapy unit of the University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers, and physiotherapists.
214896032|NCT03739281|DIAGNOSTIC_TEST|PET/MR|The included patients are imaged with PET/MR as part of the research protocol.
214896033|NCT03739281|DIAGNOSTIC_TEST|PET/CT|The included patients are imaged with PET/CT as part of normal clinical routine.
214896034|NCT01384110|DIETARY_SUPPLEMENT|Reduction of glycemic index of ingested foods|Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
214896035|NCT00179881|DRUG|Carboplatin|
214896036|NCT00179881|DRUG|Thalomid|
214297124|NCT06074913|PROCEDURE|Basal therapy+EA|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen. 2. Acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject.
214297125|NCT06074913|OTHER|Basal therapy|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen.
214297126|NCT05138679|PROCEDURE|Revascularization|Endovascular or surgical restoration of arterial blood flow.
214896037|NCT00179881|PROCEDURE|External Beam Radiation Therapy|
214297127|NCT05138679|PROCEDURE|Primary major amputation|Primary below- or above knee major amputation without prior revascularization.
214297128|NCT05138679|OTHER|Best medical treatment|Conservative treatment of acute lower limb ischemia - without prior revascularization.
214297129|NCT04471753|BEHAVIORAL|Coma Recovery Scale-Revised|Data were collected according to the Coma Recovery Scale-Revised operation guideline, the sum of the highest score on the evaluated subscales was taken as the final score, and the final diagnosis of patients was obtained (the highest score of each subscale was recorded). All participants were diagnosed by using CRS-R five times at least within 7 days. According to the results of the Coma Recovery Scale-Revised assessment, minimally conscious state and unresponsive wakefulness syndrome were distinguished.
214297130|NCT04592965|BEHAVIORAL|Clinical and neuropsychological assessments|The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.
214297131|NCT04592965|BEHAVIORAL|Induction of PH and associated bodily states|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls
214297132|NCT04592965|OTHER|Resting-state fMRI acquisition|Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls
214297133|NCT04592965|OTHER|Induction of PH and associated bodily states (MRI)|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
214297134|NCT04800003|DIAGNOSTIC_TEST|Gonial angle and submandibular fossa depth measurements from CBCT images|CBCT images were obtained from dry human mandibles
214297135|NCT04901494|DRUG|SSRI|Selective serotonin reuptake inhibitor
214297136|NCT04096625|DEVICE|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
214297137|NCT04096625|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.
214478290|NCT06639633|OTHER|Anatomy Training with Conventional Carpal Models|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. They will then have a 60 minutes practical lesson with a standard sized printed model.
214297138|NCT04096625|DEVICE|Sham tDCS|Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
214297139|NCT05424042|BEHAVIORAL|In-Person Caloric Restriction|20% CR delivered in-person by dietitian/coach
214297140|NCT05424042|BEHAVIORAL|Remote Caloric Restriction|20% reduction in caloric intake, meeting schedule, and physical activity goal delivered remotely.
214297141|NCT05424042|BEHAVIORAL|Time-restricted|8-hour TRE with ad libitum caloric intake. This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake.
214297142|NCT03595033|DEVICE|iPad app-based intervention|The 1-hour of home based intervention will break into three 20-min sessions, each including iPad apps targeting one of the three domains of deficits: visual attention, visual-spatial reasoning, and visual-motor skills.
214297143|NCT00539448|DRUG|insulin glargine|in combination with insulin Glulisine as bolus regimen
214297144|NCT00539448|DRUG|insulin glulisine|in combination with insulin Glargine as bolus regimen
214297145|NCT01942187|DRUG|Aripiprazole|Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.
214297146|NCT01942187|DRUG|Bupropion|Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.
214297147|NCT01942187|BEHAVIORAL|Problem Solving Therapy|Weekly specialized psychotherapy
214297148|NCT01437215|DEVICE|Ventana Fenestrated Stent Graft System|Endovascular repair of juxtarenal or pararenal aortic aneurysm
214297149|NCT00429507|DRUG|153 Sm-EDTMP|Tracer dose = 30 mCi by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose.
214297150|NCT00429507|BEHAVIORAL|Questionnaire|Questionnaires taking about 15 minutes to complete.
214478291|NCT06495658|DIETARY_SUPPLEMENT|Prebiotic|Participants will be asked to take a daily dose of prebiotic supplement for 8 weeks.
214896038|NCT04583735|BIOLOGICAL|TEPEZZA|Intravenous infusion
214896039|NCT04583735|DRUG|Placebo|Intravenous infusion
214896040|NCT02392117|DRUG|insulin degludec|Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
214297151|NCT00429507|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP.
214896041|NCT00124917|RADIATION|Radiation|Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 centigray (cGy) in 180 cGy daily fractions.\[1\]
214297152|NCT03042247|DIAGNOSTIC_TEST|FDG PET/TC and FDG PET/MRI|Combined assessment with FDG PET/TC and PET/MRI
214297153|NCT02480543|DRUG|Misoprostol (cytotec)|
214297154|NCT02734810|DRUG|Liprotamase Powder for Oral Solution|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
214297155|NCT05164042|BIOLOGICAL|Allogeneic CD19 CAR-T cells|infusion of allogeneic CD19 CAR-T cells
214297156|NCT00528398|DRUG|cytarabine|
214297157|NCT00528398|DRUG|idarubicin|
214297158|NCT00488345|DRUG|Tygacil|
214297159|NCT03781609|BEHAVIORAL|Roller system group (RG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions on the roller system per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
214896042|NCT05469672|OTHER|Low-level laser therapy|For LLLT, laser treatment will be applied using gallium-aluminum-arsenide (GaAIAs, infrared laser) diode laser (Chattanooga, Mexico, USA) at a wavelength of 904 nm, output power of 240 Mw and a frequency of 5000 Hz. The spot area is about 0.5 cm2. A total of 9 points will irradiated along the glenohumeral joint, with a power density of 3 j/cm2 at each point. The application time was 50 seconds to each point. The total dose per shoulder was 27 J per treatment. Three sessions of LILT therapy per week will administered over a three-week period.
214896043|NCT05469672|OTHER|High-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the shoulder area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first three sessions consisted of a 75-second intermittent phase analgesic effect at 8 W and 10 J/cm2 for a total energy of 100 J. The following six sessions consisted of a continuous 30-second bio stimulating effect with a dosage of 12 W 120 J/cm2. Over the course of three weeks, nine treatment sessions of HILT will be given.
214896044|NCT01389050|RADIATION|Intensity-Modulated Radiotherapy|Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.
214896045|NCT01389050|RADIATION|Daily Cone Beam CT|Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
214297160|NCT03781609|BEHAVIORAL|Overground group (OG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions overground per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
214297161|NCT03781609|BEHAVIORAL|Placebo - Wheelchair skills group (WSG)|They will receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented.
214297162|NCT05330338|BIOLOGICAL|Genetic analyses: whole genome sequencing|Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis
214297163|NCT02143908|DIETARY_SUPPLEMENT|lysine supplementation|
214297164|NCT02143908|DIETARY_SUPPLEMENT|Placebo|
214297165|NCT02138903|OTHER|trans thoracic echocardiography|
214297166|NCT03541018|PROCEDURE|Type of repositional maneuvre|Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
214297167|NCT05541549|BIOLOGICAL|CE-VST01-JC|CE-VST01-JC at a dose of 1 × 10\^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions
214297168|NCT03626714|DRUG|Sustained Release Injectable Tacrolimus|Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
214297169|NCT00860912|PROCEDURE|Collagen Matrix|surgical/reinforcing material
214297170|NCT05919303|RADIATION|CT Scan|CT scan study of abdomen
214297171|NCT00654173|DRUG|Rosuvastatin|
214297172|NCT00654173|DRUG|Simvastatin|
214297173|NCT00654173|DRUG|Atorvastatin|
214297174|NCT03070379|PROCEDURE|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
214297175|NCT05734079|OTHER|Standard of care|A written hand out containing all information required for bowel preparation
214297176|NCT05734079|OTHER|Standard of care + Video call|Standard of care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application)
214297177|NCT05734079|OTHER|Standard of care + Video call + Educational video film|Standard of care and in addition to a video call, an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer
214297178|NCT02127567|OTHER|online writing tool|The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.
214297179|NCT02127567|OTHER|writing with no specific support|The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
214297180|NCT03754712|DIETARY_SUPPLEMENT|Vitamin D3|Dietary supplement : Vitamin D3 one tablet of vitamin D3 (2000IU) per day for 8 weeks
214297181|NCT05578287|DRUG|Anti-HER2 ADC|Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
214297182|NCT02065232|DRUG|Tilmanocept|
214297183|NCT02065232|DRUG|Sulfur Colloid|
214297184|NCT06294418|DEVICE|Field Cycling Imaging (FCI)|FCI scan
214297185|NCT04250571|OTHER|"information about No treatment group"|Participants will receive no pills and will be told that they are in the no treatment group
214297186|NCT04250571|OTHER|imaginary pill technique|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence). Participants in this group receive daily e-mail reminders.
214297187|NCT04250571|OTHER|open label placebo|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo), combined with the following scientific rationale: (a) deceptive as well as open label placebos have been found to be effective in relieving symptoms in a variety of clinical conditions namely anxiety, depression, chronic pain (the placebo effect is powerful), (b) classical conditioning are one of the possible mechanism of this effect (the body automatically responds), (c) positive expectations may help but are not necessary, (suspend disbelief), (d) compliance with these instructions are important for outcome (taking the pills faithfully is important).~Participants in this group receive daily e-mail reminders."
214297188|NCT01161914|DRUG|Cerezyme®|administered by IV infusion for a dose of 60 U/kg
214297189|NCT01161914|DRUG|ISU302|administered by IV infusion for a dose of 60 U/kg
214297190|NCT00258453|OTHER|metabolic assessment|
214478292|NCT06876246|BEHAVIORAL|Family Check-Up Online|The Family Check-Up Online is a digital intervention that includes an assessment, computer-generated feedback, and intervention modules that focus on improving family relationships and parenting skills in order to reduce child mental health problems and to improve child self-regulation. These modules include Healthy Behaviors for Stressful Times, Positive Parenting, Rules and Consequences, Supporting School Success, and Communication.
214669028|NCT04201912|DIAGNOSTIC_TEST|saliva analysis for Toll like receptor activity|Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
215051676|NCT04188990|DIETARY_SUPPLEMENT|Nutritional dietary intervention|The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
215051677|NCT04188990|DIETARY_SUPPLEMENT|By demand|"In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now"
214297191|NCT00258453|OTHER|physiologic testing|
214297192|NCT00258453|PROCEDURE|biopsy|
214297193|NCT00258453|PROCEDURE|computed tomography|
214297194|NCT00258453|PROCEDURE|conventional surgery|
214297195|NCT00258453|PROCEDURE|magnetic resonance imaging|
214297196|NCT00258453|PROCEDURE|management of therapy complications|
214297197|NCT00258453|PROCEDURE|psychosocial assessment and care|
214297198|NCT00258453|PROCEDURE|quality-of-life assessment|
214297199|NCT00258453|RADIATION|radiation therapy|
214297200|NCT00903617|DRUG|GSK256073|5 mg for 8 weeks
214297201|NCT00903617|DRUG|GSK256073|50 mg for 8 weeks
214297202|NCT00903617|DRUG|GSK256073|150 mg for 8 weeks
214297203|NCT00903617|DRUG|Placebo|placebo for 8 weeks
214297204|NCT00903617|DRUG|Niaspan|1500 mg for 8 weeks
214297205|NCT00903617|DRUG|GSK256073|x mg for 8 weeks based from data from Part A
214297206|NCT00903617|DRUG|GSK256073|optional dose based on data from Part A
214297207|NCT01871610|DRUG|[18F]AV-45 PET amyloid binding imaging|
214297208|NCT00772356|DEVICE|Accu-Chek Spirit Insulin Pump|
214297209|NCT00772356|DEVICE|Comparator insulin pump|
214669029|NCT04966221|DIAGNOSTIC_TEST|Lung MRI scan|Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
214669030|NCT03554239|GENETIC|genotyping|Blood sample
214297210|NCT03197233|OTHER|Maternal vitamin A and D intake during pregnancy|Dietary exposures during pregnancy and infant supplement use were assessed from maternal questionnaire report
214297211|NCT01200628|BEHAVIORAL|DEPITAC|heteroevaluation scale by a nurse during hospitalization
214297212|NCT06460896|OTHER|pharmacokinetic study|Multicenter pharmacokinetic study of the bioavailability of four compounds in GBP patients: candesartan, amlodipine, metformin and rosuvastatin.
214297213|NCT02260284|OTHER|Yaotong points acupuncture|Patients receive the treatments of Yaotong points penetration
214297214|NCT02260284|OTHER|the usual care|participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
214297215|NCT02260284|OTHER|standardized acupuncture|Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
214297216|NCT04472936|PROCEDURE|Single catheter approach|Single venous femoral access will be obtained and the ablation will be performed similar to Group A. After the ablation line is over, we will confirm CTI block using the PRI. During atrial pacing (10 V, 1.5 ms) at a stable cycle length (range 500-700ms) from the tip of the ablation catheter with a sweep speed of 300mm/s, the ablation catheter will be placed first at 5 o'clock (medial to CTI line), then at 7 o'clock (lateral to CTI line), and finally at 9 o'clock position, and the corresponding PRIs will be measured for each pacing site. CTI block is assumed when: (i) the PRI at 7 o'clock is \>80ms longer than that at pacing sites of 5, and (ii) the PRI at 9 o'clock is shorter than the PRI at 7 o'clock.
214297217|NCT04472936|PROCEDURE|Traditional approach|Double venous femoral access will be obtained. A duodecapolar catheter will be positioned in the right atrium around the tricuspid valve annulus (TVA) to record activation sequence around the tricuspid annulus. An ablation catheter will be positioned using fluoroscopic guidance in the central CTI, 6 o'clock in a left anterior oblique view. The distal ablation electrode position will then be adjusted toward or away from the TVA, based on the ratio of atrial and ventricular electrogram amplitudes with an optimal ratio of 1:2 or 1:4 at the TVA. After the ablation catheter is positioned, it will be very slowly withdrawn during ablation toward the inferior vena cava while radiofrequency energy is applied continuously. CTI block will be evaluated after ablation by determining the right atrial activation sequence during pacing from the low lateral right atrium and coronary sinus ostium.
214297218|NCT01508975|OTHER|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
214297219|NCT00407563|DRUG|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
214297220|NCT00407563|DRUG|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
214297221|NCT02920268|OTHER|Dance and yoga intervention|
214297222|NCT02855749|PROCEDURE|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
214297223|NCT02512237|DRUG|ARX788|ARX788, an antibody drug conjugate
214297224|NCT03055260|DEVICE|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
214297225|NCT03055260|DEVICE|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
214297226|NCT00791245|BIOLOGICAL|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
214297227|NCT02507505|PROCEDURE|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
214297228|NCT02507505|PROCEDURE|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
214297229|NCT00002054|DRUG|Pentamidine isethionate|
214297230|NCT03182829|DIAGNOSTIC_TEST|DOAC Dipstick|"Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]"
214297231|NCT00254540|DRUG|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
214297232|NCT00225251|DRUG|bupropion XL|Antidepressant medication
214297233|NCT00225251|OTHER|Placebo|Placebo
214297234|NCT04778579|DRUG|ARI-0001 cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
214669031|NCT02312986|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
214896046|NCT03975933|DIAGNOSTIC_TEST|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
214478293|NCT06876246|BEHAVIORAL|FCU Online with Telehealth Coaching|This intervention is the Family Check-Up Online plus telehealth support from a parenting coach. The Family Check-Up Online is a digital intervention that includes an assessment, computer-generated feedback, and intervention modules that focus on improving family relationships and parenting skills in order to reduce child mental health problems and to improve child self-regulation. These modules include Healthy Behaviors for Stressful Times, Positive Parenting, Rules and Consequences, Supporting School Success, and Communication. A coach based at the child's school meets with caregivers via telehealth modality to provide motivation and to help caregivers tailor the content of the modules to their specific child and family's needs.
214478294|NCT05247034|DIETARY_SUPPLEMENT|Cocoa|Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.
214669032|NCT00533000|PROCEDURE|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
214669033|NCT02621333|BIOLOGICAL|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
214896047|NCT03975933|DIAGNOSTIC_TEST|Free pregnancy test for the future use|We will provide a free pregnancy test in for the future use.
214896048|NCT03975933|DIAGNOSTIC_TEST|Pregnancy test for the future use with randomzied price|We will provide an opportunity to buy a pregnancy test for the future use with randomized price.
214896049|NCT03119779|DRUG|MTA-Anglus|MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
214896050|NCT03119779|DRUG|TheraCal|TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
214896051|NCT04700670|BIOLOGICAL|measurement of anti-Xa activities|"The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~* STA-Liquid anti-Xa (STAGO) (not containing dextran)~* Biophen Heparin LRT (Hyphen) (reactive containing dextran)~* Berichrom (Siemens) with dextran~* Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits."
214896052|NCT04722432|DEVICE|Outside the Scope (OTS), Detachable Catheter System|Evaluation of Deployment Capability and Accuracy of an Outside the Scope (OTS), Detachable Catheter System for Ablation of Peripheral Lung Lesions: An Ex-Vivo Human Lung Model Study
214896053|NCT05899738|DRUG|Iberdomide|Specified dose on specified days
214896054|NCT00044408|DRUG|Ruboxistaurin mesylate|
214896055|NCT03518008|DEVICE|verofilcon A contact lenses|Investigational daily disposable soft contact lenses
214896056|NCT03518008|DEVICE|somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
214896057|NCT04967326|DRUG|Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)|
214896058|NCT03385317|BEHAVIORAL|Mindfulness|
214896059|NCT05611866|PROCEDURE|Fecal Microbiota Transplantation|FMT at Week 0
214896060|NCT00107848|DRUG|Modafinil|
214896061|NCT03376919|DEVICE|CLs++ gait training|CLs++ gait training
215051678|NCT04188990|DIETARY_SUPPLEMENT|Usual current care|"In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide"
215051679|NCT02274961|DRUG|S-pantoprazole 10mg|
215051680|NCT02274961|DRUG|Placebo|
215051681|NCT02753478|OTHER|intracoronary infusion with saline on 22 and 4°C|"Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed."
215051682|NCT02067143|DRUG|Prephase PDN + CY|
214896062|NCT00154661|DRUG|pentoxifylline|
214896063|NCT05976880|OTHER|Conventional treatment of isometric hand grip training exercises|In control group, conventional treatment perform by using isometric hand grip training exercises (putty grip and squeeze exercise, thumb pinch z strengthening exercises, isometric Hooks exercises, rubber band abduction and c thumb exercises) for 3times a week in one month.
215051683|NCT02067143|DRUG|Cycle 1 Induction|
214896064|NCT05976880|OTHER|Conventional treatment along with power ball training|In experimental group, 3sessions per week and total 12 training sessions in a month will be perform. In this session, conventional treatment perform with power ball exercise should be done for 3 minutes in a day, where power ball can initially alleviate the pain, then make them feel strong and in the end persons feel strengthen with pain free movements. Before start training with a power ball, hand held dynamometer will use prior to the first session, on 7th session of training and after 12th training session. So that changes in hand grip strength can be measured by dynamometer.
214896065|NCT03797911|COMBINATION_PRODUCT|Active resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Activated resistive capacitive monopolar radiofrequency is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
214896066|NCT03797911|COMBINATION_PRODUCT|Inactive resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Disactivated resistive capacitive monopolar radiofrequency inactived is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
214896067|NCT05398328|DEVICE|active metal appliance|fixed metal labial orthodontic appliance MBT 0.022'' slot
214896068|NCT05398328|DEVICE|active esthetic appliance|fixed ceramic labial orthodontic appliance MBT 0.022'' slot
214896069|NCT05398328|COMBINATION_PRODUCT|retention fixed appliance|fixed lingual metal retention appliance
214896070|NCT05398328|COMBINATION_PRODUCT|retention removable appliance|removable clear termoplastic retention appliance
214896071|NCT03629262|DRUG|Dexmedetomidine|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
215051684|NCT02067143|DRUG|Cycle 2 Induction / Early consolidation|
215051685|NCT02067143|DRUG|Cycle 3 Early consolidation|
215051686|NCT02067143|DRUG|Cycle 4 Consolidation|
215051687|NCT02067143|DRUG|Cycle 5 Consolidation|
215051688|NCT02067143|DRUG|Cycle 6 Consolidation|
215051689|NCT02067143|DRUG|Cycle 7 Consolidation|
215051690|NCT02067143|DRUG|Cycle 8 Reinduction|
215051691|NCT02067143|DRUG|Maintenance|If MRD negative MRD u/k SR
214896072|NCT03629262|DRUG|Placebo|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
214896073|NCT02813915|DEVICE|NICOM|Use of NICOM and PLR to obtain patient fluid status
214896074|NCT06491537|BEHAVIORAL|Early Time-Restricted Eating (eTRE)|12 weeks of eTRE intervention. Study staff will provide 7 support sessions with brief behavioral support, including evidence based strategies of problem-solving, action planning, and motivational interviewing.
214896075|NCT06491537|BEHAVIORAL|Control|The control group will be instructed to maintain their average eating window for the 12-week period. Study staff will contact participants 7 times to encourage maintenance.
214896076|NCT04124445|PROCEDURE|Pulsed Radiofrequency Ablation|"Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain."
214896077|NCT05806840|BEHAVIORAL|Rapid Adaptation to Prevent Drug Use (RAPD)|RAPD will include a novel bundle of implementation strategies to support rapid responses to urgent drug use events. The strategies deployed will be based on the first step of the After Action Review: critical analysis and reflection.
214896078|NCT05806840|BEHAVIORAL|Standard Implementation|Standard implementation of the Michigan Model for Health (MMH) includes curriculum materials and as-needed technical assistance provided by a school health coordinator.
214896079|NCT03577782|BIOLOGICAL|Entyvio (Vedolizumab)|"1. Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~2. Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48."
214896080|NCT04097340|DEVICE|Attentional Bias Retraining (ABR)|Participants randomized to this intervention will receive 2 weeks of ABR for opioids delivered via a mobile device.
214896081|NCT04097340|DEVICE|Control Training|Participants randomized to this intervention will receive 2 weeks of training without ABR, delivered via a mobile device.
214896082|NCT03106428|DRUG|MEDI7247|The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
214896083|NCT06577207|OTHER|Initial investigations for all cases|Initial investigations for all cases: 1. Pulse oximetry. 2. Complete blood count. 3. Electrolytes. 4. Kidney function test. 5. Random blood glucose 6. Other investigations ordered for certain cases according to clinical manifestation \& previous findings \> Lines of treatment will be recorded
214896084|NCT03051477|DRUG|Helixor® M|3-hour IV infusion on Monday, Wednesday, and Friday of each week.
214896085|NCT05944146|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
214896086|NCT05944146|DRUG|Dobutamine|infusion dobutamine
214896087|NCT04343131|BEHAVIORAL|Dietary intervention|Crossover dietary manipulation using three different types of diet for 7 days each
214896088|NCT01026246|DRUG|Placebo|The placebo used will be normal saline (0.9 percent NaCl).
214896089|NCT01026246|BIOLOGICAL|EBA-175 RII-NG Malaria Vaccine|EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
214896090|NCT02561325|DRUG|Sodium Bicarbonate and Sodium chloride|
214896091|NCT01555216|DRUG|Single injection posterior tibial nerve block|5 ml of 0.5% ropivacaine
215051692|NCT02067143|PROCEDURE|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
214896092|NCT01555216|DRUG|Posterior tibial nerve catheter|5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
214896093|NCT01553955|PROCEDURE|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
214896094|NCT02312414|DRUG|L-Canitine|Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
214896095|NCT06342687|PROCEDURE|High compliance with ERAS protocol|Patients were categorized into two groups based on their adherence to the ERAS protocol: group 1 with a compliance rate below 80% and group 2 with a compliance rate of 80% or above.
214896096|NCT01169350|RADIATION|fludeoxyglucose F 18|Undergo 18F FDG and 18F FMISO PET/CT scans
214896097|NCT01169350|OTHER|18F-fluoromisonidazole|Undergo 18F FDG and 18F FMISO PET/CT scans
214896098|NCT01169350|PROCEDURE|positron emission tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
214896099|NCT01169350|PROCEDURE|computed tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
214896100|NCT01169350|OTHER|laboratory biomarker analysis|Correlative studies
214896101|NCT02498002|DEVICE|Physical Activity Monitoring (Actiheart)|Monitor physical activity using an Actiheart monitor during the required periods.
215051693|NCT04464811|DIAGNOSTIC_TEST|Furosemide stress test|Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
215051694|NCT02041299|DRUG|Deferiprone|
215051695|NCT02041299|DRUG|Deferoxamine|
215051696|NCT05159258|OTHER||
215051697|NCT03123770|DRUG|Pegylated liposomal doxorubicin|a new kind of doxorubicin
215051698|NCT03123770|DRUG|Cyclophosphamide|traditional chemotherapy drug
214478295|NCT05247034|OTHER|Placebo|Each capsule contains 500 mg of methylcellulose
215051699|NCT03123770|DRUG|Epirubicin|traditional chemotherapy drug used in breast cancer
215051700|NCT03123770|DRUG|Docetaxel|traditional chemotherapy drug used in breast cancer
214669034|NCT02621333|DRUG|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
215051701|NCT02389465|DRUG|Escitalopram + Celecoxib|Participants will receive celecoxib in addition to escitalopram
215051702|NCT02389465|DRUG|Escitalopram + Placebo|Participants will receive a placebo in addition to escitalopram.
215051703|NCT03150147|OTHER|Non-ischemic preservation|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
215051704|NCT03150147|OTHER|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
215051705|NCT06073197|PROCEDURE|erector spinae plane block|Erector spinae plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block. Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
215051706|NCT06073197|PROCEDURE|combined deep and superficial serratus anterior plane block|Combined deep and superficial serratus anterior plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
215051707|NCT00846846|DEVICE|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
215051708|NCT06287372|OTHER|Cardioplegic solution|Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection
215051709|NCT02563145|BEHAVIORAL|Real-time fMRI feedback|feedback about activation patterns in brain regions related with instrumental aggression
215051710|NCT02563145|BEHAVIORAL|Treatment as usual|Psychoeducation, general counselling
215051711|NCT03855345|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
215051712|NCT03855345|RADIATION|aPDT|aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F \& A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
215051713|NCT02002988|PROCEDURE|endomyocardial BT injection|
215051714|NCT05211193|DEVICE|eTNM delivered by URIS I nerve stimulation device|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
215051715|NCT06525038|OTHER|All groups were observed for clinical end-points described in the study protocol|All groups were observed for clinical end-points (mortality, readmission to emergency service) described in the study protocol.
215051716|NCT00243191|DRUG|imatinib mesylate|400 mg orally twice a day for 10 - 14 days
215051717|NCT05434494|DRUG|Remimazolam|"Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19."
215051718|NCT05434494|DRUG|remifantanil|25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
214669035|NCT03329872|OTHER|Data collection|data collection about symptoms without any specific clinical or biological intervention
214669036|NCT02515669|DRUG|RO7239361|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
214669037|NCT02515669|DRUG|Placebo|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
214669038|NCT01739595|DRUG|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
215051719|NCT05490316|DRUG|IBI353 (Orismilast)|dose 1 or dose 2
215051720|NCT05490316|DRUG|placebo|placebo
215051721|NCT00188617|DRUG|GEFITINIB|250 mg once a day for 28 days before surgery
215051722|NCT04361448|OTHER|samling of oropharynx and nasopharynx|Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
215051723|NCT01746446|OTHER|Care team|Provides additional support to patients, family, and friends.
214297235|NCT04850690|DIAGNOSTIC_TEST|2D Gait analysis|"The gait with four different conditions (single gait, Cognitive Task, Motor Task and Cognitive Task\&Motor Task) was evaluated by Kinovea video analysis method on a 10-meter course.~* Single: Walking without task at a self-selected speed~* Cognitive Task (CT): Walking while counting down rhythmically from 20 in threes~* Motor Task (MT): Walking while carrying an empty box~* CT + MT: Walking while carrying an empty box and counting down rhythmically from 20 in threes"
214297236|NCT06401616|DRUG|OAC will be discontinued for the duration of the trial|Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
214297237|NCT03045328|DRUG|Ibrutinib|Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.
214896102|NCT02498002|OTHER|Energy Intake Monitoring|Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
214896103|NCT02498002|OTHER|Body Weight Monitoring|Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
214896104|NCT02498002|PROCEDURE|Intravenous Cannulation|Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
214896105|NCT02498002|PROCEDURE|Adipose Tissue Biopsy|This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
214896106|NCT02498002|DRUG|Lidocaine Hydrochloride|The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
214896107|NCT02498002|OTHER|Post-Prandial Meal Tests|Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
214896108|NCT02498002|RADIATION|DEXA Scan|Undergo a dual energy x-ray absorptiometry scan to examine body composition.
214896109|NCT02498002|OTHER|Actiheart Calibration|Submaximal treadmill test to calibrate monitoring equipment.
214896110|NCT02498002|OTHER|Daily Calorie Restriction|Reduce energy intake by 25% on a daily basis.
214896111|NCT02498002|OTHER|Intermittent Fasting with Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
214896112|NCT02498002|OTHER|Intermittent Fasting without Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
214896113|NCT04807920|DRUG|OnabotulinumtoxinA 100 UNT|Intravesical injection
214896114|NCT04807920|OTHER|Injectable saline|Intravesical injection
214896115|NCT03352674|DRUG|Insulin Glargine Ezelin|Insulin Glargine (Ezelin) once daily at individually adjusted dose
214896116|NCT03352674|DRUG|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
214896117|NCT00931411|OTHER|Formulation 609580 20|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
214896118|NCT00931411|OTHER|Formulation 609209 (Lipikar Baume)|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
214896119|NCT04119362|OTHER|Quality of live questionnaires|EORTC-Q30 questionnaire, additonal questionnaire on worries about quality of life impairments and on physical condition every 8 weeks. No additional visits will be carried out for questionnaires. Questionnaires will be handed out to patients during routine visits.
214896120|NCT04119362|OTHER|Optional translational project|Collection of archival tumor material for future translational projects. No biopsy will be performed in the context of this registry. Only tumor samples obtained in the context of standard of care and after explicit informed context will be used.
214896121|NCT05754268|PROCEDURE|Chinese version of the surgical risk assessment system|There is no need to interfere with the patient. Investigators can observe the outcome after using the system for evaluation.
214896122|NCT06445998|OTHER|task oriented training|Task-oriented training program: \[For study group\] Rocker board training Wobble board training Sit to stand Walk five steps forward Upstairs and downstairs three steps
214896123|NCT02280200|DEVICE|AFO to improve outcomes|Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
214896124|NCT00007631|DRUG|Tretinoin 0.1% cream or placebo|
214297238|NCT03045328|DRUG|Venetoclax|Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).
214297239|NCT06184815|BEHAVIORAL|Educational programme 12|Consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months and multidisciplinary treatment
214297240|NCT06184815|BEHAVIORAL|Standard education and treatment|Outpatient management and education in the office and consultation referral to nutrition and psychology
214478296|NCT06803537|OTHER|Fiber-reinforced composite|short fiber-reinforced composite used as base covered by conventional composite
214478297|NCT06803537|OTHER|indirect lab composite|indirect lab processed resin composite inlay restorations
214669039|NCT01739595|DRUG|Placebo|Oral capsule taken one time daily for 3 months
214896125|NCT00007631|OTHER|Placebo|Patients receive placebo for same amount of time
214896126|NCT03380065|DEVICE|Late deflation of TR band|"1. First 3ml of air is removed after TWO hour of sheath removal. Then, 3ml of air is removed every 15minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then a gap of 15minutes is observed for the next deflation."
214896127|NCT03380065|DEVICE|Early deflation of TR band|"1. First 2ml of air is removed from the band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 2ml of air should be pushed back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
214896128|NCT00516659|BIOLOGICAL|Heat-Labile Enterotoxin of Escherichia coli (LT)|Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
214896129|NCT00516659|BIOLOGICAL|Placebo|The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
214297241|NCT06092489|OTHER|graded motor imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
214297242|NCT06092489|OTHER|traditional physiotherapy method|This protocol included stretching and strengthening exercises. Self-stretching will encapsulate the upper trapezius, pectoralis minor, posterior. Each stretch will consist of 3 repetitions of 30 seconds with a 30 second break between repetitions. Strengthening exercises will be performed using elastic resistance bands (Theraband ®) with 4 levels of resistance (red, green, blue and grey). Sets can be easily changed (without the person reporting muscle fatigue) and progressed with resistance. The therapist will ask about the level of effort required for exercise exercises and whether it would be possible to increase the resistance level. The exercise consists of three sets of 10 repetitions and is completed with 1 rest between them. Strengthening exercises will include prone extension, prone external rotation with abduction, side lying external rotation and serratus anterior strengthening.
214297243|NCT03596528|PROCEDURE|Lung biopsy|Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
214297244|NCT04900831|DIAGNOSTIC_TEST|Omnipolar Eletroanatomical mapping|Analyse intracardiac EGMs collected with the HD Grid catheter (Abbott, Chicago, IL) during routine Atrial Flutter ablation using the Omnipolar algorithm.
214297245|NCT04090645|DEVICE|TheraSphere|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
214297246|NCT04246060|DRUG|Cysteamine Bitartrate|ERT
214297247|NCT00426192|DRUG|i.v. mannitol|
214297248|NCT00426192|PROCEDURE|hemofiltration|
214297249|NCT00592839|DRUG|SCE-B|0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
214297250|NCT00592839|DRUG|Placebo|Matching placebo for 0.3 mg and 0.625 mg tablets
214297251|NCT04893603|DEVICE|Transcatheter Aortic Valve System|Procedure: Transcatheter aortic valve replacement
214297252|NCT05152901|DRUG|EpiPen ®.|A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
214297253|NCT05152901|DRUG|Epinephrine (0.3mg) inhaled|Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2
214297254|NCT05152901|DRUG|Epinephrine (1.3mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.
214297255|NCT05152901|DRUG|Epinephrine (4mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
214896130|NCT05830786|DEVICE|Immersive virtual reality (IVR)|Using Oculus Quest 2 (Reality Labs, Meta Platforms, United States) headsets the PrecisionOS platform version 3.0 (PrecisionOS Technology, Canada) virtual reality surgical modules will be utilized.
214896131|NCT05830786|OTHER|Traditional hands on orthopaedic workshop group|Hands-on orthopaedic workshop sessions (including arthroscopy simulators, cadaveric models, and Sawbones®) in differing orthopaedic subspecialties (including sports, arthroplasty, and spine surgery).
214896132|NCT06211309|DRUG|co.mouthwas|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
214297256|NCT00851812|BEHAVIORAL|Exercise|Standard care monitoring
214297257|NCT00851812|BEHAVIORAL|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
214297258|NCT05789979|DEVICE|The resident-handling device|Care staff will perform resident-handling tasks using the new resident-handling devices. For low dependency during trial, the device helps care staff to assist residents in making a transition from a sit to a standing posture, vice versa. This device is used for functional activities and transferring and lifting participants. For high dependency during trial, when care staff are performing resident-handling tasks, the device moves with little force in any direction.
214297259|NCT00229099|DRUG|GerEPO|
214297260|NCT03331679|BEHAVIORAL|HIIT|2 Weeks of High Intensity Interval Training on a Cycle ergometer
214478298|NCT06803537|OTHER|Conventional resin composite|conventional microhybrid resin composite posterior restorations
214478299|NCT06571968|DEVICE|fully guided stent|All surgical procedures with drills were done through the stent., the implant was picked up from the implant holder and then installed, still with the surgical guide in situ, by using the ratchet and ratchet connector at a motor speed of 20 rpm, followed by cover screw placement without the need for sutures.
214669040|NCT00148239|BEHAVIORAL|Caregiver Only Intervention|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
214896133|NCT06211309|OTHER|Kin|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
214896134|NCT06211309|OTHER|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
214896135|NCT02247778|PROCEDURE|conventional plate osteosynthesis|Standard incision
214896136|NCT02247778|PROCEDURE|mini-incision-type osteosynthesis|Mini-incision
214297261|NCT06380088|OTHER|Isometric Task|The exercise required participants to keep their arm flexed at a 90° angle while holding a dumbbell loaded to 80% of their 1RM (One Rep Max) in a supine position on the dominant side of the body for as long as possible.
214297262|NCT04202991|OTHER|Exposure - pain|Groups are defined by their naturally occurring exposure to pain or not
214297263|NCT00786487|DRUG|20% lipid infusion|1.5 ml/min for 6 hours
214297264|NCT00786487|DRUG|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
214297265|NCT06309212|OTHER|Observation|Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
214297266|NCT03279328|DRUG|Topical Steroid Ointment|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
214297267|NCT03279328|OTHER|Vaseline|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
214297268|NCT03279328|DRUG|Skin Barrier Moisturier|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
214297269|NCT00785395|DRUG|Oxytocin infusion|Up-down dosing determination
214297270|NCT05800795|DEVICE|Er: YAG laser|surface treatment with Er: YAG laser for heating abutments
214297271|NCT05800795|DEVICE|plasma spray|surface treatment with plasma spray for heating abutments
214297272|NCT03940664|OTHER|immunohistochemistry on Formalin fixed and paraffin embedded blocks|
214297273|NCT02097407|DRUG|Group C : Saline + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment"
214297274|NCT02097407|DRUG|Group D : Dexmedetomidine + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment."
214297275|NCT05502393|DRUG|JS107|JS107, i.v., q3w
214297276|NCT05502393|DRUG|Toripalimab|Toripalimab i.v., q3w
214297277|NCT06125015|DIAGNOSTIC_TEST|Hearing Thresholds Assessments|Auditory Neuropathy Spectrum Disorder (ANSD) is a type of hearing disorder that affects the transmission of sound signals from the inner ear to the brain. In individuals with ANSD, the outer hair cells in the cochlea, which are responsible for amplifying sound, typically function properly. However, there is a disruption in the transmission of auditory information from the cochlea to the auditory nerve and then to the brain. It is characterized by a mismatch between the results of objective hearing tests, such as Auditory Brainstem Response (ABR), and subjective hearing experiences. In ABR tests, the responses of the auditory nerve to sounds may be abnormal, while the individual perceives their hearing to be better than suggested by the test results. In this study we showed ANSD patients with abnormal ABR results by using ABR, Otoacoustic Emissions, Tympanometry and behavioral test batteries.
214297278|NCT00026351|BIOLOGICAL|rituximab|
214297279|NCT00026351|DRUG|pentostatin|
214669041|NCT00148239|BEHAVIORAL|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
214896137|NCT06044142|DRUG|Curcumin|Curcumin and low laser therapy will be used on patients undergoing chemotherapy
214896138|NCT06044142|DEVICE|Laser|Low level laser therapy
214297280|NCT04886050|DRUG|LC350189 Tablet|Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5
214297281|NCT04886050|DRUG|LC350189 Capsule|Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5
214297282|NCT04563689|OTHER|CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|rinse 15 ml during 1 min during 5 days, twice daily
214297283|NCT04563689|OTHER|placebo rinse|destilled water rinse 15 ml during 1 min during 5 days, twice daily
214297284|NCT05851950|OTHER|group rumination focused cognitive behavioural therapy|Psychotherapy
214896139|NCT04338022|DRUG|Teriflunomide|Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period and followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in open label extension (OLE) period.
214297285|NCT05851950|OTHER|Treatment as usual|opus treatment
214297286|NCT00704925|DRUG|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
214297287|NCT05793320|PROCEDURE|Carpal Tunnel Release Surgery|Carpal tunnel release surgery used to take a biopsy to diagnose amyloidosis and determine whether or not carpal tunnel syndrome can predict who's at risk for having amyloidosis.
214297288|NCT05548166|OTHER|Interview and scale development|Interview and scale development
214297289|NCT00016146|BIOLOGICAL|GPI-0100|
214297290|NCT00016146|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
214297291|NCT01647412|DRUG|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
214297292|NCT01647412|DIETARY_SUPPLEMENT|Nutraceutical Combination|
214669042|NCT00148239|BEHAVIORAL|Control|Participants given written educational materials at beginning of study; no treatment beyond this
214669043|NCT01259739|OTHER|Cocoa|dissolved in water twice-daily intervention
214669044|NCT03880396|RADIATION|hypofractionated Rth with platinol|hypofractionated Rth with weekly cisplatin 40mg/m2
214669045|NCT00006061|DRUG|phosphatidylcholine|
214669046|NCT02415725|DRUG|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
214297293|NCT01647412|OTHER|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
214297294|NCT01647412|OTHER|Placebo Growth Hormone|
214297295|NCT03017950|DRUG|CKD-330|
214297296|NCT03017950|DRUG|D086|
214297297|NCT03017950|DRUG|CKD-330 + D086|
214297298|NCT03658850|DRUG|Hydrochlorothiazide 50Mg|for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
214297299|NCT03658850|DRUG|Placebos|for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
214297300|NCT04299204|PROCEDURE|Percutaneous nephrolitotomy|Pediatric PCNL
214297301|NCT05652998|BIOLOGICAL|C. albicans antigen|a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.
214297302|NCT05652998|OTHER|autologous PRP|patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.
214297303|NCT05652998|OTHER|saline|patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment
214297304|NCT03586388|OTHER|Oral immunotherapy protocol|"In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk."
214297305|NCT03459742|BEHAVIORAL|Gamification strategy|"The intervention is a gamification strategy, including game elements such as points, levels and rewards. Points are scored by completion of healthy challenges, i.e. a healthy snacks challenge, a steps challenge and activity challenge. Intervention takes place for 8 months from Mar to Nov. There will be three levels. Level 1 at baseline, level 2 expected at month 4 by 100% of participants and level 3 expected in month 8 by 70% of participants. A new cycle will start in 2019.~Rewards include an initial reward (Starting Kit), a structural reward and an activity reward. The Starting Kit is a box with souvenirs, information for students and teachers. A structural reward, at level 2, will be achieved collectively by all participating classes in one school. It consists of school infrastructure improvements to promote a healthy nutrition and PA (eg. climbing wall, shared bicycles, sports equipment). An activity reward (AR), when reaching level 3, consists of a fun and healthy activity."
214297306|NCT02355691|DEVICE|PREVENA|The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
214896140|NCT04338022|DRUG|Evobrutinib|Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period and followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in open label extension (OLE) period.
214896141|NCT00462917|BEHAVIORAL|Pleiotropic info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session."
214896142|NCT00462917|BEHAVIORAL|AD-only info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
214896143|NCT00462917|BEHAVIORAL|Pleiotropic info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session."
214896144|NCT00462917|BEHAVIORAL|AD-only info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
214896145|NCT02860546|DRUG|TAS-102|One Arm Only (of TAS 102 plus nivolumab)
214896146|NCT02860546|DRUG|nivolumab|One Arm Only (of TAS 102 plus nivolumab)
215051724|NCT02558062|OTHER|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
215051725|NCT01807325|PROCEDURE|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
214297307|NCT05275764|PROCEDURE|primary or secondary intraocular lens implantation surgery|primary or secondary intraocular lens implantation surgery
214297308|NCT03554226|BEHAVIORAL|NeuroPsychiatric Inventory Clinician (NPI-C)|All scales that will be administered to the patient during this study, (ADL, MMSE, QoL-AD, NPI and CMAI), are the subject of recommendations for the management of patients with AD (HAS 2009, HAS 2011)
214297309|NCT03415750|DRUG|Everolimus|Conversion from Mycophenolate mofetil to Everolimus
214297310|NCT03415750|DRUG|Mycophenolate mofetil|Patients will remain in Tacrolimus + Mycophenolate mofetil
214297311|NCT03415750|DRUG|Tacrolimus|
214297312|NCT05685082|BEHAVIORAL|Standardized patient simulation|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
214297313|NCT05685082|BEHAVIORAL|Manikin-based simulation|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
214669047|NCT02708511|DIAGNOSTIC_TEST|Computed Tomography|Undergo PET/CT
214297314|NCT00462761|DRUG|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
214297315|NCT04057079|COMBINATION_PRODUCT|Anugel, Hydrogel sponge|A calibrated sponge impregnated with hydrogel is inserted to the rectum post hemoroidectomy.
214297316|NCT04057079|COMBINATION_PRODUCT|Gelatine Sponge|A gelatine sponge is inserted in to the rectum pos hemoroidectomy.
214297317|NCT00366158|DEVICE|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
214297318|NCT00366158|DEVICE|Ventricular Intrinsic Preference|Programming of pacemaker
214297319|NCT04599920|DIETARY_SUPPLEMENT|Partial replacement of red meat with legume-based foods|560 g of cooked and boneless red meat is replaced with legume-based foods providing the equal amount of protein.
214297320|NCT04930354|DRUG|ECP-1014|Patients will be selected who (1) have failed all standard of care therapy (relapsed/refractory) or (2) have relapsed and are not a candidate for an available standard of care therapy as assessed by the investigator (such as, but not limited to, colorectal cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), head and neck, etc.) with COX-2 overexpression, ultimately resulting in elevated production of prostaglandin E2 (PGE2).
214297321|NCT02825927|OTHER|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
214297322|NCT03900000|OTHER|Physiotherapy|Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
214478300|NCT06571968|DEVICE|semiguided stent|"The first osteotomy was performed with the surgical guide in situ using a 1.95 mm pilot-drill. Successive color coded implant drills were used to prepare implant osteotomies. When using each twist drill, a removable sleeve having a diameter to coincide with the drill and inserted into the sleeve of the surgical guide.~The stereo lithographic guide template was removed and the receptor sites were irrigated with saline solution then the final drill of the implant system 3.5 mm diameter was used to finalize the osteotomy. The implant was gripped with the placement aid, released from the implant holder by 1/4 turn and manually inserted into the prepared implant site using a finger placement tool or hand ratchet. A torque of 45 N cm should not be exceeded during insertion procedure and cover screws were screwed over it."
214478301|NCT04511052|DIETARY_SUPPLEMENT|Probiotic|Daily intake of 10 x 10\^9 CFU of a proprietary strain for a total duration of 10 weeks
214478302|NCT04511052|OTHER|Placebo|1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
214896147|NCT01956474|OTHER|Theralight crosslinking and Riboflavin|Corneal Collagen cross linking with UV light and riboflavin
214896148|NCT02466321|PROCEDURE|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
214896149|NCT00716391|OTHER|TPF, radiotherapy and cisplatin.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days
214896150|NCT00716391|OTHER|TPF, radiotherapy and cetuximab.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
214896151|NCT04152967|DEVICE|new-designed PTFE valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
214896152|NCT04152967|DEVICE|Bovine jugular vein valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
214896153|NCT06071754|DEVICE|Masimo INVSENSOR00057|Masimo INVSENSOR00057 will be used to collect electrocardiogram measurements.
214297323|NCT00261677|DRUG|epoetin alfa|
214297324|NCT03060447|DRUG|Vesatolimod|Tablets Administered orally
214297325|NCT03060447|DRUG|Placebo|Tablets Administered orally
214297326|NCT03060447|DRUG|ART|ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.
214478303|NCT04511052|DIETARY_SUPPLEMENT|Carotenoid supplement|1 capsule daily containing \~20 mg of total carotenoids for a total duration of 10 weeks
214478304|NCT04337619|BEHAVIORAL|Behavioral Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
214478305|NCT04337619|BEHAVIORAL|Mindful Acceptance|Integration of acceptance and willingness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
214478306|NCT04337619|BEHAVIORAL|Values|Integration of values clarification and awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
214478307|NCT04337619|BEHAVIORAL|Mindful Awareness|Integration of mindfulness and present-moment awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
214478308|NCT05425615|DEVICE|Transcranial Magnetic Stimulation|Deymed DuoMag XT-100 rTMS
214669048|NCT02708511|DRUG|Copper Cu 64-DOTA B-Fab|Given IV
215051726|NCT02141165|DEVICE|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
215051727|NCT00943631|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
214297327|NCT01763437|DRUG|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
214297328|NCT04442204|OTHER|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health
214297329|NCT05636930|OTHER|Test the accuracy of the wearable device|No intervention was done for the subjects
214297330|NCT00010465|PROCEDURE|Craniosacral Osteopathic Manipulative Treatment|
214297331|NCT00010465|DRUG|Botanicals|
214896154|NCT07018271|DRUG|sulpegfilgrastim|On Day 1 of each oncological treatment cycle, after administration of the CD38 monoclonal antibody, a subcutaneous injection of Sulfubrolipoyl G-CSF will be given. The recommended fixed dose of Sulfubrolipoyl G-CSF is 6 mg per injection.
214297332|NCT02976623|OTHER|metric-based feedback training|Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
214297333|NCT04178746|DEVICE|Artemis Neuro Evacuation Device|"The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope."
214297334|NCT04983056|PROCEDURE|Necrotesectomy associated with cleanleness stoma|Excision of all necrotised tissues after stool diversion and wound dressing using
214297335|NCT00368056|DRUG|Eszopiclone|eszopiclone 3 mg
214896155|NCT04648267|OTHER|Cast and bolster placement duration|The intervention is increasing the duration of cast and bolster placement on split thickness skin graft sites.
214896156|NCT04648267|OTHER|Standard of care|This will be standard of care - the patient will have his cast and bolster on for 5-7 days
214896157|NCT06424860|DIETARY_SUPPLEMENT|Fish oil|For 12 months
214896158|NCT06424860|DRUG|Metformin|12 months
214896159|NCT06424860|COMBINATION_PRODUCT|Fish Oil and Metformin|12 months
215051728|NCT03388762|DIETARY_SUPPLEMENT|GlucoSupreme™ Herbal|This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
215051729|NCT03388762|OTHER|Placebo|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
215051730|NCT05475977|DIAGNOSTIC_TEST|MSCT chest|Multi slice Computed Tomography of the chest
215051731|NCT03800277|DIETARY_SUPPLEMENT|Cranberry|Supplementation of polyphenols from cranberry extract
215051732|NCT03800277|DIETARY_SUPPLEMENT|Agaves|Supplementation of inulin from Agaves powder
215051733|NCT03800277|DIETARY_SUPPLEMENT|Placebo|Supplementation with placebo
215051734|NCT06308744|BEHAVIORAL|Body-scan meditation|Participants listen to a 15-minute Body-Scan mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
215051735|NCT06308744|BEHAVIORAL|Mindful Breathing meditation|Participants listen to a 15-minute Mindful Breathing mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
215051736|NCT06308744|BEHAVIORAL|Loving Kindness meditation|Participants listen to a 15-minute Loving Kindness mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
215051737|NCT06308744|BEHAVIORAL|Mindful Walking|Participants listen to a 15-minute Mindful Walking mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
215051738|NCT06308744|BEHAVIORAL|Listening of a story|Participants listen to a 15-minute story. The audio track is embedded in the Qualtrics survey.
215051739|NCT06062381|PROCEDURE|Abdominal Massage|"The intervention period will be 3 days for intervention group. These patients will receive 20 minutes of abdominal massage twice a day, and the interval between two massages will be 2 hours. The outcome variable variable gastric residual volume will be measured every day, before the intervention and 1 hour after the second massage. the GRV will be measured in ml (via feeding syringe) and marked on checklist.~The abdominal massage technique will consist of five steps based on tensegrity principle.~The lubricant gel will be used to facilitate the massaging. The patient's position will be supine while going through abdominal massage. The angle between the bed and the patient's head will be 30 to 45 degrees, and the patient's legs will be placed on a pillow. This condition will help to relax the abdominal muscles."
215051740|NCT00530634|DRUG|cisplatin|
215051741|NCT00530634|DRUG|gemcitabine hydrochloride|
215051742|NCT00530634|GENETIC|gene expression analysis|
215051743|NCT00530634|GENETIC|reverse transcriptase-polymerase chain reaction|
215051744|NCT00530634|OTHER|immunohistochemistry staining method|
215051745|NCT00530634|PROCEDURE|adjuvant therapy|
215051746|NCT00530634|PROCEDURE|conventional surgery|
214896160|NCT05137392|OTHER|oral hygiene instruction|The treatment process is identical for both test and control groups except for the methods of oral hygiene instructions. In the control group, the participants will receive the following oral hygiene instructions at completion of debridement, at week-1 and week-3. In the test group, apart from the standard oral hygiene instructions at completion of debridement, at week-1 and week-3 , additional analysis of brushing data and provision of targeted brief interventions will be provided on a daily basis for the first week, 3 times/week until week 6 and once a week thereafter until 6 months after the debridement.
215051747|NCT00530634|RADIATION|radiation therapy|
215051748|NCT00122616|BIOLOGICAL|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
215051749|NCT00122616|DRUG|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
215051750|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
215051751|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
215051752|NCT05626179|DRUG|[14C] IBI351|The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions
214297336|NCT00368056|DRUG|Placebo|Placebo tablet
214297337|NCT03025061|OTHER|Assessment of E-nose measurements|Breath sampling through E-nose pneumopipe
214297338|NCT01109225|BIOLOGICAL|blood sample|
214297339|NCT01109225|PROCEDURE|MRI|
214297340|NCT01109225|PROCEDURE|echocardiography|
214297341|NCT01109225|BIOLOGICAL|urine sample|
214297342|NCT01109225|PROCEDURE|pulmonary echography|
214297343|NCT01109225|PROCEDURE|vascular check|
214297344|NCT01109225|PROCEDURE|renal echography|
214297345|NCT04328324|PROCEDURE|Endoscopy|Diagnostic upper Git endoscopy
214297346|NCT02681120|PROCEDURE|Biopsy|
214297347|NCT02681120|PROCEDURE|Blood draw|
214297348|NCT02681120|PROCEDURE|Mammogram|
214297349|NCT02681120|PROCEDURE|MRI|
214297350|NCT01290640|DEVICE|DePuy fixed-bearing Total Condylar III (TC3) TKA|
214297351|NCT01290640|DEVICE|DePuy PFC Rotating Platform TC3 TKA|
214297352|NCT06107712|OTHER|Online yoga exercise|"The basic yoga poses of Shivananda Yoga included in the online yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath.~In the scope of the study, the physiotherapist researcher who is a certified as the Shivananda Yoga instructor, performed the same yoga practice flow and steps in the both groups during six-week."
214297353|NCT06107712|OTHER|Face-to-face yoga exercise|"The basic yoga poses of Shivananda Yoga included in the face-to-face yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath."
214297354|NCT04411589|DEVICE|magnifying endoscopy with optical enhancement system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
214896161|NCT05970666|DRUG|TACE with adebrelimab and bevacizumab|TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
214896162|NCT05349552|RADIATION|stereotactic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
214896163|NCT06745063|DRUG|Empagliflozin|12 week treatment with 10mg empagliflozin daily
214896164|NCT06745063|DRUG|Placebo|12 week treatment with 10mg placebo daily
214896165|NCT05298761|DRUG|Lignocaine|Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs
215051753|NCT04793282|BEHAVIORAL|Telephone Follow-up|Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
214297355|NCT04411589|DEVICE|white light endoscopy system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
214297356|NCT05874661|OTHER|External Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an external focus being thinking about a target or outcome in the environment.
214297357|NCT05874661|OTHER|Internal Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an internal focus being thinking about what one's body is doing.
214297358|NCT01623323|DRUG|Fluticasone Propionate|Fluticasone Propionate 400 μg
214297359|NCT01364662|DRUG|SPN-810|administered orally
214297360|NCT01364662|DRUG|Placebo|administered orally
214297361|NCT02615054|DEVICE|2D Echocardiogram|All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
215051754|NCT00358059|BEHAVIORAL|Behavioral Family Systems Therapy for Diabetes|
214297362|NCT02615054|DEVICE|Cardiopulmonary exercise testing and post-CPET cardiac function|To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
214297363|NCT05503147|DRUG|Sativex|Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
214297364|NCT04954963|DIAGNOSTIC_TEST|Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
214478309|NCT06537648|BEHAVIORAL|Decreasing Alzheimer's Risk Through oNline Choreographed Exercise - Down Syndrome Program|Adults with Down syndrome will be asked to attend 35 minute, remotely delivered (Zoom®) group dance sessions twice weekly across 12 weeks. All sessions will be directed by an instructor experienced in leading 35 minute, group remote exercise sessions for individuals with intellectual disability as part of the ongoing exercise program for individuals with intellectual disability offered by the Division for Physical Activity and Weight Management.
214478310|NCT06427590|DRUG|ASC47|single subcutaneous injection of ASC47
214478311|NCT06427590|DRUG|Matching placebo|single subcutaneous injection of Placebo
215051755|NCT01366573|DRUG|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
215051756|NCT01366573|OTHER|Placebo|Placebo
215051757|NCT00757952|OTHER|Fourier transform ion cyclotron resonance mass spectrometry|
215051758|NCT00757952|OTHER|chromatography|
214297365|NCT03034720|BEHAVIORAL|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
214297366|NCT01426880|DRUG|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
214297367|NCT01426880|DRUG|background treatment|"background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients)."
214297368|NCT00873756|DRUG|FOLFOX regimen|Intravenous repeating dose
214297369|NCT00873756|DRUG|bevacizumab|Intravenous repeating dose
214297370|NCT00873756|DRUG|dulanermin|Intravenous repeating dose
214297371|NCT01635972|DRUG|Isavuconazole|oral
214297372|NCT01635972|DRUG|bupropion hydrochloride|oral
214478312|NCT00488072|DRUG|Mirtazapine|15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.
214478313|NCT00488072|DRUG|Placebo|One placebo tablet by mouth daily.
214478314|NCT06469034|DEVICE|conventional ultrasound|The operators in the control group will perform the procedure by visualizing the conventional ultrasound images displayed directly on the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. To standardize the approach, the ultrasound machine will be placed just to the right of the patient and operators will be asked to stand at the head of the patient and perform the procedure on the patient's internal jugular vein. Each operator could determine the height of the surgical table, and the posture during the procedure that will be most familiar to him/her to increase the success rate. Every procedure will be recorded by focusing on the participant's hands and faces.
214478315|NCT06469034|DEVICE|Head-mounted display ultrasound|In the HMD group, the ultrasound machine will be located behind the operator to remove the distraction, and the operator will not be allowed to see the ultrasound screen during the procedure. Images from the MR ultrasound machine will be transmitted to HMD via a novel connection developed specifically for this purpose. The operator will wear a pair of HMD and perform the procedure by visualizing the ultrasound images displayed on their HMD screen instead of the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. Every procedure will be recorded by focusing on the participant's hands and faces.
214478316|NCT05942339|DEVICE|Procedure/Surgery|The intervention involves the replacement of parts of the current implanted system with components of the ARC-IM Lumbar system.
214478317|NCT06318533|DRUG|anti-CD19 CAR NK cells|Patients will receive Fludarabine (30mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3, followed by Anti-CD19 CAR NK cells infusion.
214478318|NCT06963489|OTHER|Not applicable- observational study|Intervention is not applicable
214478319|NCT03505710|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.
214478320|NCT06965101|RADIATION|Radiotherapy to the spine in a single appointment|8Gy/ 1# to be delivered to all participants using a single posterior direct field.
214297373|NCT02228785|BIOLOGICAL|G17DT|
214297374|NCT00703079|DRUG|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
214297375|NCT00703079|PROCEDURE|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
214297376|NCT03274440|DRUG|Cannabis|"THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
214297377|NCT03274440|OTHER|Placebo|Placebo control group, not receiving THC or CBD.
214297378|NCT03383679|DRUG|Darolutamide|treatment with darolutamide
214297379|NCT03383679|DRUG|Capecitabine|treatment with capecitabine
214297380|NCT00622960|OTHER|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
214297381|NCT00622960|OTHER|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
214297382|NCT01453712|RADIATION|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
214297383|NCT01453712|RADIATION|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
214297384|NCT04665284|DRUG|Empagliflozin|Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
214297385|NCT04665284|DRUG|Usual care group|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
214478321|NCT06965439|BEHAVIORAL|AI-delivered emotional wellbeing support|Participants in this arm will complete four 20-minute sessions with an AI-powered chatbot designed to deliver CBT-based emotional wellbeing support. The chatbot provides conversational guidance using techniques such as cognitive restructuring, behavioural activation, and emotion validation. Sessions are delivered via Zoom, and participants receive structured homework after each session to reinforce learning. The chatbot was not custom-built for this study but is an existing tool provided to NUS students as part of their digital mental health benefits.
214478322|NCT06965439|OTHER|Neutral writing tasks|Participants in this arm will complete four 20-minute sessions of neutral writing tasks unrelated to mental health. Prompts include writing factually about daily routines or describing an object in detail. The content is emotionally neutral to act as a comparison for the chatbot intervention. Sessions are conducted online via Zoom.
215051759|NCT00757952|OTHER|diagnostic laboratory biomarker analysis|
214297386|NCT01433601|BEHAVIORAL|Enhanced Treatment Support (ETS)|"An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup."
214297387|NCT01110707|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day \[mg/day\]).
214297388|NCT01110707|DRUG|Recombinant human luteinizing hormone (r-hLH)|Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
214297389|NCT03264209|BEHAVIORAL|Smart After-Care (Mobile health)|Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
214297390|NCT04542655|OTHER|Ergometer Cycling followed by treadmill running|The participants undergo ergometer cycling, treadmill running and rest.
214297391|NCT04542655|OTHER|Treadmill Running followed by ergometer cycling|The participants undergo treadmill running, ergometer cycling and rest.
214896166|NCT05329662|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency|"* Patients in the two groups will receive two autologous AD-MSC administrations: the group A on day 0 and day 90 ± 7; the group B on day 180 ± 14 and day 270 ± 14.~* Dose: 1.0 x 106 cells/kg patient bodyweight.~* Route: intravenous infusion~ADSCs were collected after the third passage. On the day of transplantation, the ADSCs were harvested, washed twice with NaCl 0.9%, counted and resuspended in NaCl 0.9% in a total volume of 20 ml. Each participant received a dose of 1x10\^6 cells/kg body weight infused through the intravenous route within 30 minutes before being discharged after 24 hours"
214896167|NCT06581991|DIETARY_SUPPLEMENT|Valine oral solution (50mg/ml) and isoleucine oral solution (25mg/ml)|Subjects will take valine oral solution (50mg/ml) in place of usual powdered valine supplement for 28 days. Subjects will then take isoleucine oral solution (25mg/ml) in place of their usual powdered isoleucine supplement for 28 days.
215051760|NCT00757952|OTHER|questionnaire administration|
215051761|NCT01791491|DRUG|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
215051762|NCT02325024|DRUG|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
214297392|NCT04542655|OTHER|Rest|The participants undergo ergometer cycling, treadmill running and rest.
214297393|NCT04265274|DRUG|Disulfiram|dosing 400mg daily
215051763|NCT06292377|DIAGNOSTIC_TEST|ECG|An electrocardiogram (ECG) is a simple, non-invasive test that records the electrical activity of the heart.
215051764|NCT06292377|DIAGNOSTIC_TEST|Transthoracic echography (TTE)|A transthoracic echocardiogram (TTE) is a test that uses ultrasound (sound waves) to create images of the heart.
214297394|NCT04265274|DRUG|Vinorelbin|25mg/m2 day 1 and 8,
214297395|NCT04265274|DRUG|Cisplatin|75mg/m2 day 1
214297396|NCT04265274|DRUG|Copper|2 mg of elementary Copper daily
214297397|NCT01042704|DRUG|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
214297398|NCT01042704|DRUG|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
214896168|NCT02757326|DRUG|Opaganib|Opaganib, \[3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt\] is an orally available inhibitor of the enzyme SK2.
214896169|NCT02473926|BEHAVIORAL|Physical Activity|Physical Activity Program Intervention
215051765|NCT06292377|DIAGNOSTIC_TEST|Blood sampling|Blood sampling will include: complete blood count, serum creatinine and electrolytes, liver enzymes, fast lipid profile, glucose, HbA1C, thyroid-stimulating hormone (TSH), CRP, iron status, cardiac troponin (cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP).
215051766|NCT01715363|DRUG|Oxaliplatin|
215051767|NCT01715363|DRUG|Folinic Acid|
215051768|NCT01715363|DRUG|Fluorouracile|
215051769|NCT06172816|OTHER|SARS-CoV-2|a virus infection
215051770|NCT04379453|PROCEDURE|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention
215051771|NCT05679960|DIAGNOSTIC_TEST|Urine PolypDx machine Versus Colonoscopy|"1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups"
215051772|NCT04179305|BEHAVIORAL|Oncolo-GIST|"Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
215051773|NCT04179305|BEHAVIORAL|Usual Care Arm|Oncologists will provide care in non-specific manner.
215051774|NCT00361972|DRUG|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
215051775|NCT00361972|DRUG|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
215051776|NCT02501681|OTHER|priming solution during cardiovascular surgery|
215051777|NCT04420052|OTHER|Osteopathic manipulative treatment|"Osteopaths will executed several high velocity low amplitude (HVLA) techniques on the upper thoracic spine and cervical spine. These techniques are assumed to modulate the sympathetic cervical ganglia and reduce inflammation in chronic rhinosinusitis.~This procedure takes around 15 minutes."
215051778|NCT04420052|OTHER|Placebo manipulation|"The osteopath will lay hands without movement on the nose, the throat and the thorax of patients.~This procedure takes around 15 minutes."
214669049|NCT02708511|OTHER|Laboratory Biomarker Analysis|Correlative studies
214669050|NCT02708511|OTHER|Pharmacological Study|Correlative studies
214297399|NCT01042704|DRUG|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
215051779|NCT00004744|DRUG|immune globulin|
214297400|NCT01042704|DRUG|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
214297401|NCT01042704|DRUG|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
214297402|NCT01042704|DRUG|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
214297403|NCT01042704|OTHER|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
214896170|NCT02473926|BEHAVIORAL|Questionnaires|Participants in the usual care arm will receive three mailings during the intervention phase.
214896171|NCT00683657|DRUG|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
214896172|NCT00683657|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
214896173|NCT05467631|OTHER|Topical oil application|Topical Comparison
214896174|NCT03552848|BIOLOGICAL|MSC|MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
214896175|NCT00194779|DRUG|doxorubicin hydrochloride|Given IV
214896176|NCT00194779|DRUG|cyclophosphamide|Given PO
214896177|NCT00194779|DRUG|paclitaxel|Given IV
214896178|NCT00194779|BIOLOGICAL|filgrastim|Given SC
214896179|NCT00194779|DRUG|capecitabine|Given PO
214896180|NCT00194779|DRUG|methotrexate|Given IV
214896181|NCT00194779|DRUG|vinorelbine tartrate|Given IV
214896182|NCT00194779|PROCEDURE|needle biopsy|Correlative studies
214896183|NCT00194779|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
214896184|NCT00194779|OTHER|immunohistochemistry staining method|Correlative studies
214896185|NCT00194779|BIOLOGICAL|trastuzumab|Given IV
214896186|NCT00194779|DRUG|tamoxifen citrate|Given PO
214896187|NCT00194779|DRUG|letrozole|Given PO
214896188|NCT00194779|OTHER|laboratory biomarker analysis|Correlative studies
214896189|NCT03077139|DEVICE|Cardiac Resynchronization Therapy (CRT)|A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
214896190|NCT01408043|DRUG|plerixafor|Given SC
214896191|NCT01408043|BIOLOGICAL|filgrastim|Given SC
214896192|NCT01408043|DRUG|etoposide|Given IV
215051780|NCT01606904|BEHAVIORAL|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
215051781|NCT00503425|DRUG|Rituximab [MabThera/Rituxan]|1000 mg IV on days 1 and 15
214297404|NCT01042704|OTHER|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
214478323|NCT06751394|DRUG|PD-1 antibody (Toripalimab)|PD-1 antibody: (Toripalimab): 240mg q3w
214896193|NCT01408043|PROCEDURE|leukapheresis|Undergo apheresis
214896194|NCT02051621|DRUG|Antiarrhythmic drug|medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
214896195|NCT02051621|PROCEDURE|Cavo-tricuspid-isthmus-ablation|irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
214896196|NCT02051621|PROCEDURE|Pulmonary vein isolation|pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
214896197|NCT00739063|DRUG|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
214896198|NCT03169231|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
214896199|NCT03169231|OTHER|Placebo|Intravenously delivered
214896200|NCT00018538|DRUG|calcifidiol|
214896201|NCT03352687|PROCEDURE|anterior SSAX|block of the suprascapular nerve block for shoulder surgery by anterior way
214896202|NCT03352687|PROCEDURE|posterior SSAX|block of the suprascapular nerve block for shoulder surgery by posterior way
214896203|NCT05582070|OTHER|actigraphy|Actigraphy examination will be performed during 2 periods of 7 days before and after nose nasal desobstruction surgery (septoplasty, septorhinoplasty or total ethmoidectomy). Respectively 2 months before surgery (inclusion) and 4 months after surgery.
214896204|NCT02641327|DEVICE|EarlySense (Passive monitoring)|Passive contact-free monitoring
214896205|NCT07095907|PROCEDURE|Pars plana vitrectomy with epiretinal membrane peeling and controlled macular detachment|Currently, vitrectomy with epiretinal membrane peeling is the standard procedure; however, its ability to improve visual acuity in these patients remains limited. In this context, controlled macular detachment is emerging as a surgical alternative that could optimize the anatomical and functional restoration of the retina.
214896206|NCT07097298|BEHAVIORAL|empathy and compassion training|A 6-week empathy and compassion training will be designed and delivered involving PD patients and caregivers. During the compassion training participants will do mindfulness, writing and poetry exercises
214896207|NCT07096375|PROCEDURE|Adductor Canal Block (ACB) + iPACK Block|"Adductor Canal Block (ACB) in the immediate preoperative period under a high-frequency ultrasound guidance in which the adductor canal is identified beneath the sartorius muscle and 20 ml of bupivacaine 0.25% will be injected in the canal using a 22-gaugusing a 22-gauge 100-mm short-bevelled regional block needle.~IPACK Block which the patient will be placed in a supine position and knee will be placed in position of 90° flexion. A low-frequency ultrasound probe will be positioned in the popliteal crease, and a spinal needle will be inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle will be placed 1-2 cm beyond the lateral edge of the artery, and 15 ml of bupivacaine 0.25% will be injected after negative aspiration."
215051782|NCT05771805|OTHER|Vagus nerve stimulation with task oriented training|VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
215051783|NCT05771805|OTHER|Task oriented training|Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
215051784|NCT00817765|DRUG|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
215051785|NCT00817765|DRUG|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
215051786|NCT00817765|DRUG|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
215051787|NCT05424965|OTHER|no intervention|no intervention
215051788|NCT02122497|PROCEDURE|abdominal aortic surgery|
214297405|NCT01042704|OTHER|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
214297406|NCT01042704|OTHER|Post-Treatment Follow Up|"After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:~* Physical exam~* Performance status (check of ability to perform daily functions)~* Recording of any new symptoms and any new medications being taken~* Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)~* Urine test (24hr urine)~* Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).~* A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse."
214297407|NCT02982967|OTHER|Physical Activity|Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
214297408|NCT03585439|PROCEDURE|Observational study evaluating the results of an intervention for isthmic spondylolisthesis: surgical procedure with double approach: Anterior lumbar Interbody Fusion then postero-lateral fusion|First in supine position, an ALIF is performed: with a Pfannenstiel incision, through a retroperitoneal approach, a discectomy is performed at the level of the spondylolisthesis then a cage is placed between the two vertebral bodies. Then, in prone position, a standard posterior approach is performed, pedicle screws are placed to achieve a postero-lateral fusion. A decompression may be associated.
214297409|NCT02369341|BIOLOGICAL|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
214297410|NCT03913650|PROCEDURE|0.25% bupivacaine|nerve block procedure will be decided by patients' will for post-op pain
214297411|NCT04921254|DRUG|BSG005 or placebo|"SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level."
214297412|NCT03832621|DRUG|Temozolomide|temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
214297413|NCT03832621|DRUG|Nivolumab|nivolumab 480 mg i.v. every 4 weeks
214297414|NCT03832621|DRUG|Ipilimumab|low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
214297415|NCT05826899|OTHER|54Fe SO4|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe
214297416|NCT05826899|OTHER|57Fe Oat-1|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe
214297417|NCT05826899|OTHER|58Fe Oat-2|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.
214297418|NCT05826899|OTHER|54 FeSO4 + Acai puree with honey|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.
214896208|NCT07096375|PROCEDURE|Adductor Canal Block (ACB) + iPACK Block (sham injection)|All patients will receive Adductor Canal Block in the immediate preoperative period under a high-frequency ultrasound guidance in which the adductor canal is identified beneath the sartorius muscle and 20 ml of bupivacaine 0.25% will be injected in the canal using a 22-gauge 100-mm short-bevelled regional block needle IPACK block which the patient will be placed in a supine position and knee will be placed in position of 90° flexion. A low-frequency ultrasound probe will be positioned in the popliteal crease, and a spinal needle will be inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle will be placed 1-2 cm beyond the lateral edge of the artery, and 15 ml of normal saline will be injected after negative aspiration.
215051789|NCT02653339|DRUG|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
215051790|NCT02653339|DRUG|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
215051791|NCT04650997|BEHAVIORAL|Eccentric exercise|Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
215051792|NCT02705612|DRUG|Cisplatin|
214297419|NCT05826899|OTHER|57Fe Oat-1 + Acai puree with honey|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.
215051793|NCT02705612|RADIATION|External Beam Radiation Therapy|
214297420|NCT05826899|OTHER|58Fe Oat-2 + Acai puree with honey|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey
214297421|NCT05158114|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214297422|NCT01109199|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
214297423|NCT01109199|DIETARY_SUPPLEMENT|Rice flour|The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
214297424|NCT04093219|DRUG|IV acetaminophen|use of IV tylenol for pain
214297425|NCT04093219|OTHER|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
214297426|NCT04249310|DRUG|Tiotropium/Olodaterol|Soft Mist Inhaler product
214297427|NCT04249310|DRUG|Tiotropium|Soft Mist Inhaler product
214297428|NCT01477840|DRUG|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
214297429|NCT00750711|PROCEDURE|Radiofrequency ablation for atrial flutter by catheters|
214297430|NCT02710045|BIOLOGICAL|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
215051794|NCT02705612|RADIATION|Internal Radiation Therapy|
215051795|NCT02705612|DRUG|nimotuzumab|
215051796|NCT01214473|DIETARY_SUPPLEMENT|Synbiotics|Lactobacillus plantarum with fructo-oligosaccharide
215051797|NCT01214473|DIETARY_SUPPLEMENT|Maltodextrin|Only maltodextrin as placebo
215051798|NCT04904029|OTHER|Digital Assessment Routing Tool [DART]|"DART is a first contact web-based and mobile health system that uses clinical algorithms to triage patients and recommend management pathways. Participants complete an online web-based questionnaire that follows a clinical reasoning process commonly observed in face-to-face physiotherapy consultations. Based on the participant's answers, the clinical algorithm generates sets of questions, leading up to a triage disposition with recommended management pathway. The triage outcomes with management pathways are classified;~1. Medical care~   * A\&E referral~  * Urgent GP~  * Routine GP~  * Consultant review~2. Physiotherapy care~   * Post-fracture or surgery physiotherapy~  * Physiotherapy referral~  * Physiotherapy referral plus psychosocial support~3. Self-management~   * Self-management with SOS~  * Continue self-management advice"
215051799|NCT04904029|OTHER|Physiotherapy-led remote triage (usual care)|Participants will receive usual physiotherapy-led remote triage services by a registered health care professional. This service is either a telephone or video consult and includes any diagnostic procedure (e.g. patient history, remote assessments) and treatment, such as management advise or home-based exercise therapy. Participants may seek help elsewhere or opt-out the study at any point, which will not affect their usual physiotherapy-led remote care
215051800|NCT01474785|DRUG|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
215051801|NCT01474785|OTHER|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
215051802|NCT01474785|PROCEDURE|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
215051803|NCT05246878|DRUG|EDP-235|Oral administration
215051804|NCT05246878|DRUG|Placebo|Placebo to match EDP-235, oral administration
215051805|NCT00326599|DRUG|carboplatin|Given IV
215051806|NCT00326599|DRUG|cediranib maleate|Given orally
215051807|NCT00326599|DRUG|gemcitabine hydrochloride|Given IV
215051808|NCT02370472|OTHER|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
215051809|NCT05508646|BEHAVIORAL|Music therapy intervention|The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
215051810|NCT05508646|BEHAVIORAL|Personalized music CD|Participants will receive a personalized music CD that they keep and can listen to as they wish.
215051811|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
215051812|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
214297431|NCT02710045|BIOLOGICAL|DTP Vaccine at 9 months of age|Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age
215051813|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
215051814|NCT04522050|DRUG|Gemcitabine combined with cisplatin induction chemotherapy|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m², d1) every 3 weeks for 2 cycles before radiotherapy. And then intensity modulated radiotherapy (IMRT) is given a total dose of GTVnx 70Gy, GTVnd 66Gy, CTV1 60Gy and CTV2 54Gy for 33 times in total, concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. The patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
215051815|NCT04522050|DRUG|concurrent chemoradiotherapy with gemcitabine|followed by concurrent gemcitabine chemoradiotherapy
214297432|NCT02710045|BIOLOGICAL|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
214297433|NCT00158509|DRUG|Valacyclovir|
215051816|NCT03040089|DEVICE|PICO+4|picosecond, neodymium-doped yttrium aluminum garnet laser
215051817|NCT03040089|DRUG|Neoquine Cream 2%|2% hydroquinone cream
214297434|NCT02128633|DRUG|placebo gel|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
214297435|NCT02128633|DRUG|5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
214297436|NCT02128633|DRUG|Fluoride neutral NaF gel 2 %|The product had similar appearance and viscosity than others.
214297437|NCT04244279|OTHER|Ergonomic workshop|Participants will participate in a single meeting workshop regarding ergonomic principles in baby care.
214297438|NCT04244279|OTHER|Brochure|Participant will receive a brochure summarizing the main contents of the workshop.
214297439|NCT04244279|OTHER|Videos|During the next three months after the beginning of the research, they will receive videos that will be a reminder of the principles learned in the workshop.
214297440|NCT03178773|BEHAVIORAL|TExT-MED|messages designed to inspire motivation and behavior change
214297441|NCT03178773|BEHAVIORAL|FANS|SMS delivered messages to family members to improve social support
214297442|NCT04495842|OTHER|Essential Oil Blend|5 drops of on a tester strip
214297443|NCT04495842|OTHER|Control Blend|5 drops on a tester strip
214297444|NCT05199467|BEHAVIORAL|Health Coaching|Health coaches help people focus on goals, identify strengths and values, and work towards building the kind of life they wish to live.
214297445|NCT05199467|BEHAVIORAL|VA Benefits Information|Printed materials with information on VA benefits.
214297446|NCT05549934|DRUG|PF-06651600|tablets containing active drug (a combined JAK3/TEC inhibitor)
214896209|NCT07095673|BEHAVIORAL|HealthyWE|Following baseline assessment, 60 residents will be enrolled in HealthyWE Corps program. HealthyWE Corps includes training sessions on keeping a healthy weight, healthy diet, and mental health wellness. The content of the HealthyWE protocol was carefully designed choosing skills shown to be efficacious in keeping a healthy weight and reducing pain. Self-efficacy theory guides the intervention. Behavioral interventions for reducing and managing obesity focus on building adults' self-management skills to be implemented in their daily lives. To achieve the therapeutic effects, individuals have to execute self-management skills in their daily lives. Self-efficacy is defined as a person's belief in his/her ability to perform specific skills to reduce and manage obesity.
214896210|NCT07095647|PROCEDURE|Hysteroscopy|Hysteroscopic-guided suction evacuation and double-layer laparoscopic repair of the niche were performed concomitantly and followed by second-look hysteroscopy to ensure the competence of the repair.
214896211|NCT07096648|DEVICE|Continuous vital sign monitoring|Continuous monitoring of vital signs performed using up to three CE- and FDA approved devices measuring heart rate, respiratory rate, systolic- and diastolic blood pressure, and SpO2. Data is transmitted to a CE-approved smartphone application that generates alerts in response to deviations based on predefined thresholds for duration and severity.
214896212|NCT04952922|OTHER|Treatment for recurrent oropharyngeal cancer (curative/ palliative)|Open salvage surgery, transoral robotic surgery, palliative chemotherapy, immunotherapy.
214297447|NCT04890327|OTHER|Web-based family health history tool|Web-based tool that collects subject's family health history through a series of questions and generates a pedigree which documents a risk assessment report for the physician to use. The risk assessment report uses standard, validated risk scores including GAIL , CLAUS, BRCAPRO which measure breast cancer risk, and MMRPRO which measures endometrial cancer risk, MELAPRO which measures melanoma cancer risk, and PANCPRO which measures pancreatic cancer risk
214297448|NCT02850393|OTHER|Functional magnetic resonance imaging|
214297449|NCT02850393|BEHAVIORAL|behavioral measures|
214297450|NCT02850393|OTHER|physiological measurements|
214297451|NCT05106374|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
214297452|NCT05106374|PROCEDURE|Cognitive Assessment|Complete thinking test
214297453|NCT05106374|OTHER|Physical Performance Testing|Complete walking test
214297454|NCT05106374|OTHER|Quality-of-Life Assessment|Ancillary studies
214297455|NCT05106374|OTHER|Questionnaire Administration|Complete questionnaire
214297456|NCT06336460|PROCEDURE|Pericapsular Nerve Group (PENG) Block|"Under sterile technique, physician will identify relevant landmarks including the femoral artery, femoral vein, femoral nerve, ileopubic eminence (IPE), anterior inferior iliac spine (AIIS), psoas tendon (PT). Target area is bony space between AIIS and IPE adjacent to PT.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting fascial plane below the psoas tendon, above ilium bone. Landmark lies between the AIIS and IPE, just lateral to psoas tendon.~As needle tip reaches target, small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, lifting the psoas tendon from ilium, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush line of remaining anesthetic. Needle will then be withdrawn."
214297457|NCT06336460|PROCEDURE|Fascia Iliaca Compartment (FIC) Block for Patients with Isolated Hip Fractures|"Under sterile technique, physician will identify relevant landmarks, including femoral artery, femoral vein, femoral nerve, iliacus muscle with overlying fascia iliaca.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting the fascial plane above iliacus muscle.~As needle tip reaches the target, a small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush the line of remaining anesthetic. The needle will then be withdrawn."
214297458|NCT04994990|DRUG|OnabotulinumtoxinA Standard Dose|Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
214297459|NCT04994990|DRUG|OnabotulinumtoxinA Half Standard Dose|Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
214297460|NCT04349488|DEVICE|Anodal Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
214478324|NCT06751394|DRUG|Capecitabine|Capecitabine:1000mg/m² d1-14 q3w; Capecitabine:825mg/m² on the day of radiotherapy
215051818|NCT01177124|BEHAVIORAL|MBSR 6 Weeks Program|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
215051819|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
215051820|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
215051821|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
215051822|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
215051823|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
215051824|NCT03654144|DRUG|Dienogest|oral tablets
215051825|NCT03654144|DRUG|Combined Oral Contraceptive|oral tablets
215051826|NCT01862081|DRUG|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
215051827|NCT01862081|DRUG|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
215051828|NCT01862081|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
215051829|NCT04096105|DRUG|CC-93538|a single dose CC-93538 SC
215051830|NCT03680534|PROCEDURE|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
215051831|NCT04892030|BEHAVIORAL|Whole Food Plant-Based Behavioral Weight Loss Treatment|Over the course of 12-weeks, participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies through an e-learning platform. Each week, participants will also complete a 15-minute coaching call to provide positive reinforcement and problem-solving support.
215051832|NCT04170920|DEVICE|LifeExtend-AI|"LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
215051833|NCT01371058|DRUG|high maintenance clopidogrel|clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
215051834|NCT01371058|DRUG|routine dual antiplatelet|clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
215051835|NCT01371058|DRUG|policosanol plus dual antiplatelet|aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
214669051|NCT02708511|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo PET/CT
214297461|NCT05190380|OTHER|HIGH INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
214478325|NCT06751394|DRUG|Oxaliplatin|130 mg/m² q3w
215051836|NCT02691026|DRUG|Pembrolizumab|
215051837|NCT04618588|PROCEDURE|Low Window Sinus Lift technique|"Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement"
215051838|NCT02271061|DEVICE|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
214478326|NCT06751394|DRUG|Irinotecan|200 mg/m² q3w
215051839|NCT02271061|DEVICE|Control tape|Apply tape in same technique without tension.
215051840|NCT02636387|DRUG|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
215051841|NCT01474304|DRUG|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
215051842|NCT00142792|DEVICE|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
215051843|NCT01993134|PROCEDURE|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
215051844|NCT01993134|PROCEDURE|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
215051845|NCT01952938|PROCEDURE|LINK SL versus EnduRo|
214478327|NCT06751394|RADIATION|Radiation|45-50Gy/25Fx or 30Gy/15Fx
214669052|NCT04379583|DEVICE|HairDx Sample Collection Kit|Saliva collection using FDA OTC cleared sample collection device
215051846|NCT03376464|DEVICE|Xeomin Cosmetic|Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.
214896213|NCT06956560|RADIATION|PET/MRI or separate PET/CT and MRI|"PET/MRI or separate PET/CT and MRI using the following imaging protocol: 15O-H20 (myocardial perfusion, up to 10 min dynamic PET scan), \[68Ga\]Ga-DOTA-Cys-ATH001 (PDGFRß PET, up to 60 min dynamic + static full body PET scans), and Gd-MRI (extracellular volume in infarct, around 10 min MRI scan).~Cohort 1 and 2 are examined twice, first one week after PCI/stent and then a second examination 2 to 8 months after the first. Cohorts 3, and 4 are examined once."
214896214|NCT06796790|BEHAVIORAL|Media instruction|Caregivers will be asked to implement joint media sessions with their child four times per week for 12 weeks using lightly adapted versions of the commercially-available Super Why! program, which focuses on early literacy skills, including alphabet knowledge, rhyming, spelling, and print concepts. Sessions are anticipated to last 20 minutes. Caregivers will be trained by researchers on explicit strategies to use to promote children's learning. Caregivers will digitally log every session and audio record 1 session each week
214896215|NCT06796790|BEHAVIORAL|Storybook intervention|Caregivers will be asked to implement joint storybook reading sessions with their child four times per week for 12 weeks using adapted versions of the commercially -available Super-Why! storybooks, which focus on early literacy skills including alphabet knowledge, rhyming, spelling, and print concepts. Sessions are anticipated to last 20 minutes. Caregivers will be trained by researchers on explicit strategies to use to promote children's learning. Caregivers will digitally log every session and audio record 1 session each week.
214896216|NCT06279715|OTHER|Preimplantation Genetic Testing for Aneuploidy|PGT-A typically involves the biopsy of three to eight cells from the developing embryo after approximately five days of culture. This technology also allows for the identification of segmentally aneuploid embryos.
214896217|NCT06496139|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavioural therapy|The intervention consists of 8 weeks of therapist-guided self-help ICBT.
214896218|NCT05962372|BEHAVIORAL|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
214896219|NCT05962372|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate For A Healthy Puerto Rico dietary recommendations.
214896220|NCT04697680|BEHAVIORAL|Algorithm 1|A sleep extension algorithm (algorithm 1) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
214896221|NCT04697680|BEHAVIORAL|Algorithm 2|A sleep extension algorithm (algorithm 2) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
214896222|NCT04697680|BEHAVIORAL|Algorithm 3|A sleep extension algorithm (algorithm 3) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
215051847|NCT01881815|OTHER|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
215051848|NCT00437268|DRUG|enzastaurin|1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease
215051849|NCT00437268|DRUG|irinotecan|300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease
214297462|NCT05190380|OTHER|LOW INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
215051850|NCT00437268|DRUG|cetuximab|400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
215051851|NCT06068374|OTHER|Break of sedentary behavior with dual task|Patients will interrupt sedentary behavior performing walking and cognitive activities simultaneously
214669053|NCT02215629|DRUG|VS-4718|
215051852|NCT06068374|OTHER|Break of sedentary behavior with walking|Patients will interrupt sedentary behavior performing walking
214297463|NCT06800430|RADIATION|Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography|Patients undergo hybrid \[18F\]-GP1, \[68Ga\]-FAPI and \[68Ga\]-DOTATATE total body PET-CT imaging (Biograph Vision Quadra, Siemens) and contrast-enhanced electrocardiogram gated CT coronary angiogram (CTCA), within 28 days (+/- 28 days) of their CABG surgery and again at 12 month follow-up.
214669054|NCT04278573|DRUG|Vitamin D3|Intralesional injection of 0.3 ml 40,000 IU/ml vitamin D3 into one wart
214669055|NCT04278573|DRUG|Placebo|0.3 ml injection of sterilized sesame oil with no active study ingredient
215051853|NCT04538157|OTHER|Comprehensive Geriatric Assessment|A CGA is a diagnostic and therapeutic intervention which initially identifies an older person's medical, functional, psychosocial problems and then tailors coordinated management plans to address them.
215051854|NCT00057057|BEHAVIORAL|Telephone Care|
215051855|NCT05905237|PROCEDURE|Cataract surgery, Femtosecond-LASIK, SMILE|Cataract surgery includes both conventional and femtosecond laser assisted. Femtosecond-LASIK and SMILE are options for patients to correct myopia.
215051856|NCT06350422|OTHER|Head-Down tilt Bed Rest test|All of the volunteers underwent 60 days of the Head-Down tilt Bed Rest test.
215051857|NCT02832102|PROCEDURE|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
215051858|NCT00444925|DRUG|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
215051859|NCT00444925|DRUG|placebo|once daily (OD)for 12 weeks
215051860|NCT00444925|DRUG|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
214896223|NCT06411652|OTHER|Reflexology|"1. First, the patient's foot will be cleaned with cotton dipped in warm water,~2. In order not to disturb the patient, the hands will be warmed and one or two ccs of baby oil will be used to facilitate the massage.~3. Before applying the main technique, the first two minutes of each session will be spent using the relaxation technique, which involves back and forth movements with the palm of the palm on the outer edge of the foot, from the outer part of the ankle to the little toe, to relieve muscle tension and spasm.~4. Then, alternate pressure will be applied to the reflex points of the right thumb by taking the heel of one foot in the left hand."
215051861|NCT00227084|DRUG|Arista AH hemostasis powder|
215051862|NCT02116842|DRUG|0.1% bupivacaine|Epidural block in early labour.
215051863|NCT02116842|DRUG|0.075% bupivacaine|Epidural block in early labour.
215051864|NCT02116842|DRUG|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
215051865|NCT04573790|PROCEDURE|eFONA|Surgical Tracheotomy
215051866|NCT01991379|DRUG|MEK162|Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
215051867|NCT01991379|DRUG|Imatinib Mesylate (Gleevec®; STI571; NSC #716051)|
215051868|NCT01991379|OTHER|Blood draws|
215051869|NCT01991379|PROCEDURE|biopsy|Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
215051870|NCT05443971|BIOLOGICAL|Durvalumab|Given IV
215051871|NCT05443971|RADIATION|Radiation Therapy|Undergo grid therapy
215051872|NCT05443971|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214478328|NCT06751394|PROCEDURE|surgery|The type of surgery will depend on the site of recurrence and the involvement of adjacent structures, which will be determined by the surgeons.
214896224|NCT06411652|OTHER|Therapeutic Touch|"1. The procedure will be explained to the woman,~2. The procedure will be performed in the patient's bed.~3. The practitioner will center by making his body, mind and emotions quiet and focused, prepare himself for the practice and remain centered throughout the intervention,~4. There will be good intentions to help the woman get treatment,~5. In order to scan the energy field, the patient's entire body will be held with the palms of the practitioner's hands facing the patient, it will be moved with a soft movement from"
214896225|NCT06580509|DRUG|Tranexamic Acid Injectable Product|Participants will receive three doses of TXA 500 mg (5 mL of TXA 100mg/ml) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
215051873|NCT05670912|DRUG|Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
215051874|NCT05670912|DRUG|Placebo Comparator of Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
215051875|NCT05231876|OTHER|Recording of pathology-related information on the Wilson Register|Age, gender, date of diagnosis, clinical symptoms, ethnic charateristics and family tree will be collected and recorded on the Wilson Register during routine clinical care
215051876|NCT05828186|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) catheter|Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of Shockwave IVL catheter treatment by their physicians.
215051877|NCT05973201|DEVICE|Virtual reality headset|"A HEALTHY MIND® brand VR headset is dedicated to the study. The kit includes a noise-reducing audio headset, a face mask diffusing the visual part, a touchscreen tablet connected to the two VR headset systems, and a microphone connected to the tablet.~The available software allows patients to choose between 5 natural environments in which a hypnotic speech is broadcast, available in several languages (French, English, Spanish, Russian, Arabic)."
215051878|NCT05160701|OTHER|Medherent|Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
214478329|NCT05623189|DRUG|HTD1801|HTD1801,1250 mg, BID
214478330|NCT05623189|DRUG|Placebo|Placebo, BID
214478331|NCT05647044|DEVICE|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
214297464|NCT06800430|RADIATION|Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography|Patients undergo hybrid \[18F\]-GP1, \[68Ga\]-FAPI and \[68Ga\]-DOTATATE total body PET-CT imaging (Biograph Vision Quadra, Siemens) and contrast-enhanced electrocardiogram gated CT coronary angiogram (CTCA), prior to their clinical invasive coronary angiography.
214297465|NCT02715323|OTHER|Cross-sectional study|
214297466|NCT05894733|OTHER|study group|Calling with phone frequently(15.th day, 1 month , 3 month, 6 month ) and face to face interwiew on first, 3 th and 6th month
214478332|NCT05647044|DEVICE|placebo intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
214896226|NCT06580509|OTHER|Normal Saline|Participants will receive three 5 ml doses of placebo (normal saline) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
214896227|NCT06242808|BEHAVIORAL|Food resource coaching|Patients will meet with a food resource coach who will explain basic coaching principles including how to respond to financial crises, how to access various food resources, and the importance of consistent utilization of food resources. After the coaching session, the food resource coach will help patients select medically tailored groceries from the free community food market inventory.
214896228|NCT06242808|OTHER|Free community food support|Usual services include selecting up to 21 meals for each person in the household from Crossroads nutritious market once per month (e.g., approximately 100 pounds \[$250 United States dollars\] of food for a family of four)
214896229|NCT06242808|BEHAVIORAL|Medically tailored groceries|A pantry staff member helps patients select medically tailored groceries (MTG) from the free community food market inventory by prepopulating MTG in their pantry cart.
214896230|NCT03458117|GENETIC|Talimogene Laherparepvec (T-VEC)|a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)
214896231|NCT00931528|DRUG|Tadalafil|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
214896232|NCT00931528|OTHER|Placebo|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
214896233|NCT05771181|DRUG|Vitamin E|Vitamin E: 400mg (QD), oral, once daily, continued until disease progression or intolerable toxicity.
214896234|NCT05771181|DRUG|Fruquintinib|Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
214896235|NCT05771181|DRUG|Tislelizumab|Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
215051879|NCT03129464|DEVICE|Cold therapy via reusable cold gel pack|Patients in the experimental group will be asked to apply cold therapy to their abdominal incisions every 6 hours for the first 72 hours following their surgery (total laparoscopic hysterectomy). Cold therapy will be applied via a reusable cold gel pack.
215051880|NCT05008705|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive diary 2 doses of the protein supplement
215051881|NCT05008705|DEVICE|Neuromuscular electrostimulation.|Patients will receive diary sessions of neuromuscular electrostimulation.
215051882|NCT05008705|DIETARY_SUPPLEMENT|Placebo (isocaloric supplement)|Patients will receive diary 2 doses of the isocaloric supplement
215051883|NCT05008705|DEVICE|Sham for neuromuscular electrostimulation.|Patients will not receive neuromuscular electrostimulation.
215051884|NCT05858177|DRUG|Temozolomide capsule|Temozolomide was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.
214297467|NCT05894733|OTHER|control group|first and sixth month face to face interwiew
214896236|NCT05821231|COMBINATION_PRODUCT|SBRT + MEDI5752|"SBRT (5 fractions of 10 Gy every two or three days) will be delivered to one lung metastasis (12 days maximum) in combination with MEDI5752\* administered intravenously.~The first dose of MEDI5752 will be administered on the day of the last SBRT fraction, then every 3 weeks for up to a maximum of 12 months.~\* Dosing 500 mg or 750 mg, according to the recommended dose determined during the dose exploration phase"
214896237|NCT04837820|PROCEDURE|Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
214896238|NCT04837820|PROCEDURE|Sham Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
214896239|NCT04837820|OTHER|Wait-List Control (WLC)|Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians.
214896240|NCT04837820|OTHER|Questionnaires|Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 0, 10, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data; 20 minutes of these 30 minutes will be completed during the neurocognitive battery. Patients will complete PROs online using Research Electronic Data Capture (REDCap) or over the phone with the CRC. Biospecimens will be collected in person at assessment visits. The neurocognitive battery will be administered remotely.
214896241|NCT00627159|OTHER|High risk assessment|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.
214297468|NCT01679379|PROCEDURE|Absorbable suture group|Skin is closed with subcuticular stitches using \[Polyglactin 910 absorbable, synthetic, braided suture\]
214297469|NCT01679379|PROCEDURE|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
214297470|NCT04142021|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Surgery planning done based solely on coronary computed tomography angiography.
214297471|NCT01730209|DRUG|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
214297472|NCT01730209|DRUG|Placebo|
214478333|NCT06115395|DEVICE|non- invasive ventilator|Group 1 (hypoexemic patient who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
214478334|NCT06115395|DEVICE|fiber-optic bronchoscopy|Group 2 (hypoxemic patients who will undergo conventional bronchoscopy under conventional o2 therapy without NIV ) will be on conventional oxygen therapy half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
214478335|NCT06115395|DEVICE|non- invasive ventilator|Group 3 (non- hypoxemic patients who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
214896242|NCT00627159|OTHER|Low to moderate risk|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
214896243|NCT03759548|OTHER|Assessment of nutritional status|Observational study. Assessment of nutritional status.
214896244|NCT01195896|DEVICE|New NPWT system|According clinical routine (Instruction for Use)
214896245|NCT06379048|PROCEDURE|Mattress Suturing|Horizontal mattress suture in interrupted fashion
214896246|NCT06379048|PROCEDURE|Primary Suturing|Horizontal primary suture in interrupted fashion
214896247|NCT06379048|PROCEDURE|Continuous Subcutaneous Suturing|Subcutaneous suture in continuous fashion
214896248|NCT00749905|OTHER|low fiber diet|Low fiber diet for 5 days prior to colon capsule
214896249|NCT00749905|OTHER|regular diet|Regular diet until 1 day before colon capsule
214896250|NCT00659451|DRUG|Losartan|tablets; 50, 100 mg; od; 12 months
214896251|NCT00659451|DRUG|Amlodipine|tablets; 5, 10 mg; od; 12 months
214896252|NCT02471729|DEVICE|EnligHTN™ Renal Denervation System|The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
214896253|NCT06578299|DRUG|Inetetamab and Paclitaxel ± Pertuzumab|"Inetetamab and Paclitaxel ± Pertuzumab Inetetamab：was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Paclitaxel：Docetaxel 75mg/m2, albumin paclitaxel 260mg/m2, or paclitaxel liposomes 175mg/m2) is administered intravenously on the first day of every three weeks, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Pertuzumab：was administered as an intravenous (IV) loading dose of 840mg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420mg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination."
214896254|NCT05252299|OTHER|Rolling Fresher Group|The use of telemedicine to provide remote CSS installation instruction via audio and visual input by a Certified child passenger safety technician (CPST)
214896255|NCT02930499|DEVICE|Hyalomatrix extra-cellular matrix|An exta-cellular matrix made from hyaluronic acid
214896256|NCT02930499|DEVICE|Mepilex wound dressing|A siliconized non-adhesive foam wound dressing
214896257|NCT06548100|DRUG|mibavademab|Administered by intravenous (IV) infusion followed by subcutaneous (SC) injection
214896258|NCT01511042|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
215051885|NCT03870048|DEVICE|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
214478336|NCT06115395|DEVICE|fiber-optic bronchoscopy|Group 4 (non- hypoxemic patients who will undergo conventional bronchoscopy without non- invasive ventilation{NIV) will be on conventional oxygen therapy throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
214478337|NCT02107105|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
214896259|NCT01511042|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
214896260|NCT01511042|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
214896261|NCT01473914|DIETARY_SUPPLEMENT|Low dose: supplemental zinc, selenium and vitamin E|"1. ZINC 25mg (AS ZINC SULFATE)~2. SELENIUM 50 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
214896262|NCT01473914|DIETARY_SUPPLEMENT|Standard renal vitamin: B and C renal vitamin|"1. BIOTIN 300 MCG~2. D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~3. FOLIC ACID 1 MG~4. NIACINAMIDE 20 MG~5. VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~6. VITAMIN B12(CYANOCOBALAMIN) 6 MCG~7. VITAMIN B2 (RIBOFLAVIN) 1.7 MG~8. VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~9. VITAMIN C (ASCORBIC ACID) 100 MG~10. INERT FILLER (CORNSTARCH)"
214896263|NCT01473914|DIETARY_SUPPLEMENT|Medium dose: supplemental zinc, selenium and vitamin E|"1. ZINC 50 mg (AS ZINC SULFATE)~2. SELENIUM 75 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
214478338|NCT02107105|OTHER|Questionnaire Administration|Complete quality of life questionnaire
214478339|NCT05562310|DRUG|Total parenteral nutrition (TPN). This is total nutrition provided by central vein.|phenylalanine, methionine and histidine intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
214896264|NCT00711243|DRUG|docetaxel|Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
214896265|NCT00711243|DRUG|fluorouracil|Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
215051886|NCT06313203|DRUG|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution. The patients in this arm will also be given GemOX as systemic chemotherapy
215051887|NCT06313203|PROCEDURE|Selective Internal Radiation Therapy (SIRT)|Radioactive Yttrium 90 (Y-90) labeled particles are injected selectively into the feeding arteries of the tumour(s). This allows a high radiation dose in the lesions while limiting systemic side effects.
215051888|NCT01293812|DRUG|88% sucrose po solution|"88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
215051889|NCT01293812|DRUG|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
215051890|NCT05462899|OTHER|Purpose in life, goals, and expectations|There is no intervention. This is a cross-sectional study.
214297473|NCT05395806|OTHER|Health App|The intervention will include training health teams and patients in accessing and using a gamified health App 2-3 times a week. The App is based on a gamified character that improves its health if a patient checks its App, complies with her therapy, does regular exercise, and introduces normal levels of blood pressure, lipids level, and HbA1c levels. On the other hand, the character gets sick if the patient does not comply with her therapy or does not achieve certain levels of physical activity (i.e. 30 min moderate exercise 5 times a week or 2.5 hs a week or more than 9000 steps/day).
214297474|NCT05395806|OTHER|Usual Care|In this group, participants will receive their usual cardiovascular care according to the national guidelines. All patients receive free care at the primary care clinics and also receive free medications prescribed according to the national guidelines at the clinics. In addition, participants in this group will receive specific written information to improve their medication compliance, level of physical activity, blood pressure, HbA1c, and lipids level control.
214297475|NCT04844632|BIOLOGICAL|Vaccine anti-Covid19|Vaccination with AstraZeneca or Pfizer-Biontech anti-Covid19 vaccine
214478340|NCT03674723|OTHER|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from Mung beans and 3 levels from Mung beans with rice or wheat.
214896266|NCT00711243|DRUG|oxaliplatin|Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
215051891|NCT05914194|DRUG|NLS-2|Participants will receive NLS-2 tablets orally.
215051892|NCT05914194|DRUG|Placebo|Participants will receive NLS-2 matching placebo tablets orally.
214896267|NCT00982787|DRUG|Botanical extract from Passiflora incarnata|"Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period"
215051893|NCT04700150|OTHER|Tai Chi 2 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
215051894|NCT04700150|OTHER|Tai Chi 4 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
214896268|NCT03765489|DEVICE|electrical muscle stimulation|electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction
214896269|NCT03765489|PROCEDURE|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
214896270|NCT02661880|BEHAVIORAL|preferred music|listening to preferred music choices
214896271|NCT02764892|DRUG|V81444|Single oral dose of V81444
215051895|NCT02520778|DRUG|Navitoclax|Given PO
215051896|NCT02520778|DRUG|Osimertinib|Given PO
214297476|NCT01737788|PROCEDURE|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
214478341|NCT01907789|OTHER|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
214478342|NCT01907789|PROCEDURE|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
214896272|NCT05940181|BIOLOGICAL|XH001+ sintilimab|During treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).
214896273|NCT01164020|DIETARY_SUPPLEMENT|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
214896274|NCT01164020|OTHER|Placebo (Dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
214896275|NCT01164020|OTHER|Resistance training|resistance training twice a week for 24 weeks
214896276|NCT05739422|PROCEDURE|Neuropilates online exercise class|Online, remotely supervised neuropilates exercise class
214896277|NCT05739422|PROCEDURE|Online generalised exercise class|Online, remotely supervised generalised exercise class
214896278|NCT05739422|PROCEDURE|Unsupervised home exercise programme|Unsupervised, home based generalised exercise programme
214478343|NCT01907789|PROCEDURE|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
214478344|NCT01907789|BEHAVIORAL|Questionnaire|"Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery."
214896279|NCT06091813|BEHAVIORAL|Nutrition Counseling|Dietitian-led nutrition coaching via 5 Telenutrition visits, utilizing the Academy of Nutrition and Dietetics' Nutrition Care Process.
214896280|NCT04074941|OTHER|Dietary intervention|Intervention include low sodium or usual sodium diet
214896281|NCT01965743|BEHAVIORAL|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths
214896282|NCT04801303|DRUG|Calcitriol|Administration of Calcitrol 0.25mcg/24h for a year in Friedreich's Ataxia patients (n=20)
214896283|NCT04801303|OTHER|Blood analysis for frataxin's level measurement|"1. Five blood analysis in Friedreich's Ataxia patients: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment.~2. To validate the Frataxin's levels measurement, a blood analysis will also be done in two kind of controls for every Friedreich's Ataxia patient, only once at the beginning of the trial.~The control groups will be composed by:~* Heterozygous Ataxia's Friedreich controls (a close relative of the patient, either a heterozygous sibling or one of the parents)~* Age- and gender-matched controls (supposedly non-heterozygous)."
214896284|NCT04801303|DIAGNOSTIC_TEST|Blood analysis for hypercalcemia's control|Five blood analysis in Friedreich's Ataxia patients for monitoring the hypercalcemia risk (with measurement of Calcium, D Vitamin, renal function, albumin, protein, phosphate, sodium and potassium) Before starting the treatment, and after fifteen days, at 4 months, 8 months and 12 months of the treatment.
214896285|NCT03798015|OTHER|mitral valve surgery|assessment of ischemic or hemorrhagic stroke subsequent to mitral valve surgery
214896286|NCT01557504|DRUG|Sitagliptin/metformin XR|Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).
214896287|NCT01557504|DRUG|Placebo|Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
214896288|NCT01557504|DRUG|Metformin|Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
214896289|NCT01557504|DRUG|Thyroid hormone|Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
214896290|NCT03806114|PROCEDURE|Posterior Approach Precautions|These patients will be advised not to bend their leg or trunk more than 90 degrees, avoid crossing the leg or crossing midline, and rotating the leg inwards. Patients will also be instructed to put a pillow in between their legs while sleeping for 6 weeks and to avoid bathing for 6 weeks.
214896291|NCT03806114|PROCEDURE|Anterior Approach Precautions|These patients will be advised to avoid extending the leg back, rotating the leg outwards, and lifting their bottom when lying down after their surgery for 6 weeks.
214896292|NCT03806114|PROCEDURE|No Precautions|For the non-precautions group, there will be no mention of precautions by any providers before, during, and after surgery. No equipment will be given, but a list of self-care equipment will be available for 'comfort' purposes. Patients will be instructed to avoid bathing for 4 weeks. All groups will have instructions to use a walking aid and a toilet seat if needed, to weight-bear as tolerated, and to avoid driving for 3 weeks.
214896293|NCT01962103|DRUG|nab-paclitaxel|nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
214896294|NCT01962103|DRUG|nab-paclitaxel|IV infusion
214896295|NCT05994339|DRUG|Almonertinib|Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.
214896296|NCT01321749|PROCEDURE|Remote ischemic preconditioning (RIPC)|The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
215051897|NCT03484429|DEVICE|Peripheral nerve stimulation|Up to 60 days of peripheral nerve stimulation
215051898|NCT03484429|OTHER|Standard Medical Therapy|Medications, physical therapy, or other pain treatments
214478345|NCT01907789|PROCEDURE|Transvaginal Ultrasound|"Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline."
214478346|NCT01907789|BEHAVIORAL|Phone Call|"Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly."
215051899|NCT00708357|DRUG|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
215051900|NCT06506110|OTHER|Retrieving of retrospective data from Epic|Retrospective data from Epic will be extracted to determine the Patient Acceptable Symptom State (PASS) for the numeric rating scale (NRS) pain score in the first 48 hours after surgery in patients who received intravenous Patient Controlled Analgesia.
214297477|NCT05787691|OTHER|Individualised pain management|"TPS pain management consists in an evaluation by a pain physician, followed by specific measures for patients identified as having a particularly high risk of CPSP. The choice of these measures will be individualised according to specific risk factors and left to the discretion of the pain physician.~Potential measures: patient education, adjustment of analgesic therapy, referral to a psychiatrist or psychologist, cognitive behavioural therapy, hypnosis, use of locoregional analgesia for surgery, infusions of ketamine and/or lidocaine, introduction of gabapentins and/or antidepressants."
214297478|NCT04035681|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
214297479|NCT04035681|OTHER|Stroke-Related Health Education|The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
214297480|NCT04270123|OTHER|EORTC QLQ-BR45 questionnaire|The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
214297481|NCT02911181|OTHER|BIVA measurement|
214297482|NCT05901779|DRUG|live combined Bifidobacteriun, Lactobacillus and Enterococcus capsules|Probiotics capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Each capsule contained\>10,000,000 colony-forming units (CFUs). This drug can treat endoxemia caused by imbalance of intestinal flora.
214297483|NCT00845169|PROCEDURE|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
214297484|NCT03903731|DEVICE|Total knee arthroplasty with Journey II BCS Total Knee System|Journey II BCS Total Knee System
214297485|NCT03681392|DIETARY_SUPPLEMENT|Dr. Pyke's Supplement for Stream (S4S)|Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
214896297|NCT05740033|PROCEDURE|Split-Thickness Skin Graft for Radial Forearm Donor Site Closure|This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.
214896298|NCT05740033|PROCEDURE|Hatchet Flap for Radial Forearm Donor Site Closure|The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.
214896299|NCT03427294|OTHER|Delphi study|Delphi study on the optimal rehabilitation pathway following lumbar arthrodesis
214896300|NCT02571491|DRUG|Ketamine Hydrochloride|50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
214896301|NCT02571491|OTHER|Placebo|50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
214896302|NCT02571491|DRUG|Remifentanil|at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
214896303|NCT02571491|DRUG|Morphine hydrochloride|at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
214669056|NCT00815789|BEHAVIORAL|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
214297486|NCT05073991|PROCEDURE|Lung surgery|Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.
214297487|NCT05073991|PROCEDURE|Open aortic surgery|Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.
214297488|NCT05073991|PROCEDURE|TEVAR|Patients underwent TEVAR.
214297489|NCT05073991|PROCEDURE|EVAR|Patients underwent EVAR.
214297490|NCT00765375|DRUG|Botulinum Neurotoxin Type A|1.5-3 units of Botox/lesion
214297491|NCT00765375|DRUG|Bacteriostatic saline|.1 cc bacteriostatic saline/lesion
214478347|NCT03304717|DRUG|Tenofovir (TDF) and Emtricitabine (FTC)|"Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.~Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase."
214669057|NCT00863954|DEVICE|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
214297492|NCT00357487|DEVICE|peroperative scintillating probe|
214297493|NCT00357487|DEVICE|operative gamma camera|
214896304|NCT06504277|PROCEDURE|Low Pressure Penumoperitoneum|Maintained Pneumoperitoneum with low pressure of 10 mm Hg
214896305|NCT06504277|OTHER|Standard Pressure Group (No intervention- active comparator)|Maintained Pneumoperitoneum at standard pressure of 15 mm Hg
214896306|NCT05374317|BIOLOGICAL|Yellow Fever Vaccine|Administered subcutaneously once.
214896307|NCT03862313|DEVICE|active-rtACS treatment|For the active-rtACS treatment arm, a CE-certificated proprietary class IIa medical device will be used to apply transorbital symmetrical rectangular current pulses in bursts (NextWave® 1.1 system; EBS Technologies GmbH, Germany). The stimulation protocol will be patient-individualized, with a stimulation current strength of 125% of the phosphene threshold recorded during 5Hz stimulation and stimulation frequencies between the individual's EEG alpha frequency and their flicker fusion frequency.
215051901|NCT03533010|DIETARY_SUPPLEMENT|Ca500mg|subjects receive a daily dose of 500mg elemental calcium
214297494|NCT06135987|DEVICE|TLC-NOSF dressings (D'URGOSTART PLUS® BORDER, URGOSTART PLUS® PAD and URGOSTART INTERFACE®)|Clinical evaluation of the dressing in the local treatment of chronic wounds (DFU and VLU)
214297495|NCT01037608|DRUG|Sativex(Registered Trademark)|
214297496|NCT01037608|DRUG|THC|
214297497|NCT04902456|PROCEDURE|Power chain and Crimpable hook fro En-masse Retraction|"Retraction will start on a 0.017x0.025 stainless steel wire using elastomeric chain ( for applied will be 212 g per side ) extending between the cripmable hooks and the miniscrew"
214297498|NCT04902456|PROCEDURE|T-loop|closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine.
214297499|NCT04226274|DRUG|REN001|Once daily for 12 weeks
214297500|NCT01288794|DRUG|Diuretics plus human albumin|The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
214297501|NCT01288794|DRUG|Diuretics (standard medical treatment)|The patients will receive standard medical treatment (diuretics)
214297502|NCT01202305|PROCEDURE|Lymph node biopsy|Inguinal lymph node biopsy
214297503|NCT04735380|DEVICE|TCM-5 Flex monitor connected to a Sensor 84 (Radiometer Medical Aps, Brønshøj, Denmark)|Patients undergo 2-3 hrs of observation while wearing the device.
214297504|NCT05581849|BEHAVIORAL|Prolonged Nightly Fasting|"Participants will engage in 14+ hours a night of fasting and no calorie containing food or beverages for 8 weeks. Participants will be allotted one cheat day per week, during which they will not need to fast (or track their times)- the day may change weekly and will be based on participant preference. Study staff and study participants will engage in a weekly coaching call (via phone; 5-10 minutes). Weekly coaching calls will last through the duration of the 8-week intervention."
214297505|NCT05581849|BEHAVIORAL|Health Education Control|Participants in this group will receive weekly 15-minute videos (once weekly) focused on non-diet/non-fasting health educational content for 8 weeks. Participants will be asked to review the video at their convenience, prior to their weekly coaching call (5-10 minutes) with the study staff. Weekly topics will be as follows: Week 1: Sleep hygiene, Week 2: Sun safety, Week 3: Home safety, Week 4: Driving safety, Week 5: Hydration, Week 6: Dental health, Week 7: Working environment, Week 8: Communication.
214297506|NCT00483808|DEVICE|Ardian Symplicity™ Catheter|Renal denervation using the Symplicity Catheter
214478348|NCT03304717|OTHER|Placebo|Placebo for Tenofovir and Placebo for Emtricitabine
214669058|NCT03045146|OTHER|Multimodal brain imaging|Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
214669059|NCT06374810|BEHAVIORAL|Conscious Connected Breathwork|Participants were taught the Conscious Connected Breathwork Technique. 2 facilitators were monitoring and coaching the participants to ensure adherence to the technique
214669060|NCT06374810|OTHER|Placebo waitlist|Participants were told the study was full and that they were placed on a waiting list until the 1st cohort had completed the breathwork program
214669061|NCT01581411|DRUG|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
215051902|NCT03533010|DIETARY_SUPPLEMENT|VitD800IU|subjects receive a daily dose of 800IU VitD3
214297507|NCT02913391|OTHER|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
214297508|NCT02913391|OTHER|control group (CG)|After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
214478349|NCT05735652|DEVICE|SpaceOAR Hydrogel|The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum
215051903|NCT03533010|OTHER|Placebo|subjects receive placebo tablet
214478350|NCT06573047|OTHER|kinesotape|a- Kinesio-tape: cure tape (made in Korea) made from 100% gentle cotton fibre and 100% medical grade acrylic adhesive. its Hypoallergenic, water-resistant and does not limit range of motion (ROM), it is come with different colours and sizes. Kinesio Tape is safe enough for a baby's sensitive skin, and gentle enough for aging individuals, flexible enough for rehabilitation, durable enough to support working muscle, joint or ligament and strong enough for athletes at any level.
214669062|NCT04335825|PROCEDURE|phacotrabeculectomy|combined antiglaucoma procedure: trabeculectomy with phacoemulsification
214669063|NCT04335825|PROCEDURE|ExPress antiglaucoma surgery combined with phacoemulsification|combined antiglaucoma procedure: ExPress device implantation with phacoemulsification
215051904|NCT04276025|OTHER|Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
214669064|NCT02024581|DRUG|10% East Indian sandalwood oil cream|A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
214669065|NCT02024581|DRUG|Placebo Cream|A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
214669066|NCT01791439|OTHER|lidocaine|Application of lidocaine to the glossopharyngeal nerve.
214669067|NCT01791439|OTHER|placebo|
215051905|NCT05595928|OTHER|position|To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.
215051906|NCT00943761|DRUG|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
215051907|NCT00943761|DRUG|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
215051908|NCT00943761|DRUG|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
215051909|NCT00943761|DRUG|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks
214297509|NCT00784992|PROCEDURE|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
214297510|NCT00764153|PROCEDURE|Bipolar hemiarthroplasty|Lateral approach. FWB.
214297511|NCT00764153|PROCEDURE|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
214297512|NCT06166849|DEVICE|Experimental Fluoride Application|The two-step system, consisting of Component A and Component B, will be applied once on the white spot lesions
214297513|NCT02140229|DEVICE|US power doppler|Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
214297514|NCT02140229|OTHER|Usual care|Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
214297515|NCT02140229|OTHER|ACR/EULAR criteria|Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
214297516|NCT03035708|DRUG|Varenicline|1 mg BID
214297517|NCT03035708|DRUG|Placebo oral capsule|1 mg BID
214297518|NCT03779789|DRUG|Vortioxetine|"Antidepressant classified under the category other antidepressants according to the ATC/DDD index \[ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose\]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day)."
214297519|NCT03779789|DRUG|Sertraline|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day)."
214297520|NCT03779789|DRUG|citalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day)."
214297521|NCT03779789|DRUG|Escitalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day)."
214297522|NCT03779789|DRUG|Paroxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day)."
214297523|NCT03779789|DRUG|Fluoxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day)."
214669068|NCT04779021|OTHER|Hospitalisation for SARS-COV2 infection|Patients hospitalized for SARS-COV2 infection
214669069|NCT01962662|OTHER|EMG biofeedback training|EMG biofeedback assisted tibialis anterial force level control
214896308|NCT03862313|DEVICE|sham-rtACS treatment|For the sham-rtACS treatment arm, exactly the same medical device, setup, time schedule, etc. will be used as for the patients of the active-rtACS arm. However, sham-treated patients will receive no actual current stimulation during the therapy sessions.
214896309|NCT00075907|DRUG|Efavirenz + 2 NRTIs|
214896310|NCT00075907|DRUG|Lopinavir/Ritonavir + 2 NRTIs|
214896311|NCT00075907|PROCEDURE|Therapeutic Drug Monitoring|
214896312|NCT02750618|BIOLOGICAL|Burosumab|solution for subcutaneous injection
214297524|NCT03779789|DRUG|Fluvoxamine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day)."
214297525|NCT00795756|DRUG|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
214669070|NCT01962662|OTHER|U/E exercise|strengthening and stretching
214669071|NCT06510426|DRUG|Rebif 44 MCG Per 0.5 ML Prefilled Syringe|Rebif 44mcg per 0.5ml administered subcutaneously
214669072|NCT06510426|DRUG|Saline|0.5mL of saline administered subcutaneously
214669073|NCT05387330|DIAGNOSTIC_TEST|ELISA kit|Sandwich ELISA kit for the accurate quantitative detection of sCD62L and SPARC in human plasma and serum samples.
214669074|NCT00479362|DRUG|Warfarin|Warfarin is either interrupted or uninterrupted prior to device implantation
214669075|NCT00479362|DRUG|Aspirin|Aspirin is continued without interruption prior to device implantation
214896313|NCT00848913|OTHER|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
214896314|NCT00848913|OTHER|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
214297526|NCT00795756|DRUG|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
214297527|NCT01928329|DRUG|Exenatide (Bydureon®)|
214297528|NCT01928329|DRUG|Placebo|
214297529|NCT04512209|PROCEDURE|MRI|"Patients will undergo an MR scan before undergoing cytoreductive surgery. If neoadjuvant chemotherapy is administered, an extra MR scan is planned before the start of the neoadjuvant chemotherapy.~During surgery, tissue samples will be taken for interstitial fluid pressure (IFP) measurement, immunohistochemistry (IHC) and characterization of biophysical properties (viscoelastic properties and hydraulic conductivity)."
214297530|NCT03187262|DRUG|Daratumumab|Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
214297531|NCT05811390|DEVICE|erythritol jet|Use of an erythritol jet in the non-surgical treatment of periimplantitis together with systemic metronidazole
214297532|NCT05811390|DEVICE|Manual instrumentation|Use of manual instrumentation in the non-surgical treatment of periimplantitis together with systemic metronidazole
214297533|NCT03863990|DRUG|PAH medication|Any PAH-targeted medication
214297534|NCT00528099|DRUG|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
214297535|NCT00034333|DRUG|MTC-DOX for Injection|
214297536|NCT06200077|PROCEDURE|Modified Ridge-Splitting|Unlike the conventional ridge-splitting where bone grafting is done in the same visit after ridge splitting, modified ridge splitting involves splitting the ridge only at the first visit, then bone grafting is done either alone afterwards in the second visit (Modified 3-Staged Ridge-Splitting Group) and dental implants will be placed in the third visit, or, as in the Modified 2-Staged Ridge-Splitting Group, bone grafting and dental implants placement will be done in the second visit.
214297537|NCT01602250|DRUG|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
214297538|NCT01602250|DRUG|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
214297539|NCT02630355|OTHER|Remote Ischaemic Preconditioning|Inflation of blood pressure cuff in lower limb
214297540|NCT01180673|BEHAVIORAL|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
214297541|NCT01180673|BEHAVIORAL|Control Condition|"Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants."
214297542|NCT02981719|PROCEDURE|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment
214896315|NCT05908565|BEHAVIORAL|Demographic Matching|At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.
214896316|NCT05908565|BEHAVIORAL|Supervision Intensity|Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.
214896317|NCT06439550|DRUG|Serplulimab|300mg, q3w
214896318|NCT06439550|DRUG|Trastuzumab|First dose 8mg/kg, maintenance 6mg/kg, q3w
214896319|NCT06439550|DRUG|Oxaliplatin + Tegafur|oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w).
214896320|NCT06518460|DIAGNOSTIC_TEST|Functional Efficiency of Self-sufficiency Test|The Barthel Index has 10 items focusing on mobility, feeding, grooming, hygiene, dressing, bladder control and bowel control. It scores from 0-100 points. A higher score indicates better performance. The Action Research Arm Test is 19-item observational measure used for the assessment of UE performance in stroke recovery. Scores range from 0-57 points. A higher score indicates a better outcome.
215051910|NCT02793661|DEVICE|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
215051911|NCT02793661|OTHER|Control|Hydration protocol following ESC Guidelines 2014
214297543|NCT02981719|PROCEDURE|irreversible electroporation|percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.
214297544|NCT02336022|DEVICE|Respiratory Motion Inc|
214297545|NCT01782261|DRUG|Liraglutide|once daily subcutaneous injection
214297546|NCT01782261|DRUG|Saxagliptin|once daily tablet
214297547|NCT03688477|DEVICE|iovera°|iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
214297548|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with one DEXTENZA (lower eye lid canaliculus) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
214297549|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with two DEXTENZA (upper and lower canaliculi) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
214297550|NCT04501367|DRUG|Prednisone acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo vitrectomy with internal limiting membrane peel surgery
214669076|NCT00479362|DEVICE|Permanent pacemaker|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
215051912|NCT03099473|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
215051913|NCT03099473|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
215051914|NCT03099473|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
215051915|NCT02576873|OTHER|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
215051916|NCT02338388|PROCEDURE|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
215051917|NCT04581811|OTHER|Prolonged Proned Positioning|Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period
215051918|NCT04581811|OTHER|Traditional Proning Arm|Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
215051919|NCT00714948|DRUG|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) \> 2.1), after consultation with the Principal Investigator.
214896321|NCT04656756|BEHAVIORAL|Personalized Care|A clinical and standardized workflow was created for both experimental and control groups. This standardized workflow: consisted of services which included the management of basic medications, routine care regarding the postpartum period, newborn care and health education. After the standardized clinic workflow was formed, a personalized care plan was developed for the experimental group. Each care procedure was shared with the participants in the experimental group. Moreover, all potential alternative care plans were presented to the participants.
214896322|NCT03973125|DRUG|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
215051920|NCT03537638|BEHAVIORAL|Multicomponent intervention|Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
214297551|NCT02597322|DRUG|AXITINIB|Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.
214297552|NCT02646176|BEHAVIORAL|Inpatient rehabilitation|Inpatient rehabilitation includes activities and interventions provided by occupational, physical, therapeutic recreation and speech therapists, and psychologists.
214297553|NCT05665062|DRUG|SYNCAR-001|SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb
214896323|NCT00810667|DRUG|Lu AE58054|twice daily oral dose (60 mg BID: total dose 120 mg/day)
214896324|NCT00810667|DRUG|Placebo|twice daily oral dose
215051921|NCT04461496|PROCEDURE|Hybrid revascularization|The first stage is performed femoral-popliteal bypass surgery above the fissure of the knee joint according to conventional technology. Conduit is at the discretion of the operating surgeon. Intraoperatively bolus is administered sol. heparin 5000 IU. The second step is the puncture of the selected CFA with a retrograde installation of the introducer sheath. The iliac segment is recanalized with angioplasty and stent implantation in the affected area
215051922|NCT04461496|PROCEDURE|Full metall Jacket|The first step is the puncture contralateral CFA with a retrograde installation of the introducer. Intraoperatively bolus is administered sol. heparin 5000 IU. A conductor is placed in the contralateral iliac artery along the conductor. A stent is implanted in the iliac artery lesion. The second stage is the recanalization of the femoral-popliteal segment with angioplasty and stent implantation in the affected area.
215051923|NCT03246607|DEVICE|MicroEye & ContinuMon|Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
215051924|NCT00693888|BEHAVIORAL|advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)|initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
215051925|NCT05894603|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir/ritonavir
215051926|NCT05894603|DRUG|Molnupiravir|Molnupiravir
215051927|NCT01342926|DRUG|GSK933776|GSK933776
215051928|NCT01342926|DRUG|Placebo|Placebo
215051929|NCT03310944|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
215051930|NCT03382912|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Nivolumab
215051931|NCT03382912|DRUG|Nivolumab|Nivolumab Alone
215051932|NCT04839653|DRUG|Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h|The oral paste will be applied topically on the oropharyngeal mucosa q6h.
215051933|NCT04839653|DRUG|Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h|The suspension will be administered through the nasogastric tube q6h.
215051934|NCT04839653|DRUG|Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd|Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic
215051935|NCT01405430|BIOLOGICAL|Bevacizumab + blood samples|"Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab."
215051936|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
215051937|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
215051938|NCT05653700|DEVICE|Arena Strive|This second-generation platform provides frontline clinicians with a comprehensive journey to access the tools, training, and technology used by other high-pressure fields to increase performance and enhance resilience. The experimental intervention employed in this study will be a 12-week, multi-phased approach involving an asynchronous learning and coaching experience (6 weeks), and exploration phase (6 weeks).
215051939|NCT05653700|OTHER|Control Cohort|Participants randomized into the control cohort - survey at baseline and end of the study
215051940|NCT02317692|BEHAVIORAL|Parent training|
215051941|NCT05180968|DRUG|Nabilone 0.5 MG Oral Capsule|This intervention will consist of subjects receiving nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
215051942|NCT05180968|DRUG|Placebo Nabilone|This intervention will consist of subjects receiving placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
215051943|NCT02148848|DRUG|Risedronate|Take risedronate 35 mg orally every week
214297554|NCT05665062|DRUG|STK-009|STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
214297555|NCT05665062|DRUG|Cyclophosphamide|lymphodepletion
214297556|NCT05665062|DRUG|Fludarabine|lymphodepletion
214669077|NCT00479362|DEVICE|Implantable Cardioverter-defibrillator|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
215051944|NCT02573948|OTHER|no intervention is assessed|
215051945|NCT05962255|DRUG|Furosemide intravenous infusion|"At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics."
215051946|NCT05962255|DRUG|Continous intravenous infusion of 0.9% Sodium Chloride solution|Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
215051947|NCT05962255|DRUG|Continous intravenous infusion of 5% Glucose solution|Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
215051948|NCT02366325|DRUG|EPO-018B|
215051949|NCT04663074|DIAGNOSTIC_TEST|IVUS control|Intravascular Control of the bridging stentgrafts during branched EVAR
215051950|NCT00076440|DRUG|Leuprolide acetate|
214297557|NCT04822207|PROCEDURE|acupuncture|Patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. Every acupuncture lasts 20 minutes.
214297558|NCT05128851|PROCEDURE|HTO|Hight Tibial Osteotomy
214297559|NCT05128851|PROCEDURE|Arthroscopy treatment|Arthroscopy treatment
214297560|NCT05128851|PROCEDURE|Micro fractures|Micro fractures
214669078|NCT01676116|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
214669079|NCT01676116|DRUG|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
214669080|NCT01676116|DRUG|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
215051951|NCT00204529|DRUG|pegylated interferon-alpha-2a|
215051952|NCT00204529|DRUG|interferon-alpha-2a|
215051953|NCT00707993|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
215051954|NCT00707993|DRUG|Glipizide|Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
214478351|NCT06573047|BEHAVIORAL|Chest physiotherapy exercises|selected chest physiotherapy exercise three times per week for two weeks, each session will be about 20 minute which will include the following exercise ( huffing , coughing , percussion,and postural drainage)
214297561|NCT06259240|OTHER|Prone plank exercises|Patients in this group will recieve prone plank exercises, three times a week, for eight weeks, and with a moderate hard intensity. During the first four weeks, the exercises session began with light walking for five minutes followed by corrected exercises. Firstly, women will perform stable prone plank exercises. Secondly, women will be asked to apply the unilateral position of prone plank. Thirdly, using a 65 cm diameter Swiss ball, women will be asked to assume the prone bridge position. During the last four weeks, women will be asked to repeat the same program noting that the progressive prone plank exercises should be applied in a dosage of 20 repetitions, three sets, holding the contraction for one minute, and taking a break for two minutes.
214297562|NCT06259240|DEVICE|Electrical Stimulation|Electrical Stimulation
214478352|NCT06397768|BIOLOGICAL|RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
214478353|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214478354|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214478355|NCT06397768|BIOLOGICAL|Hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214478356|NCT06397768|BIOLOGICAL|Streptococcus pneumoniae vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214478357|NCT06397768|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form:Oral solution-Route of administration:Oral
214478358|NCT06397768|BIOLOGICAL|Measles, mumps, and rubella vaccine|Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular
214478359|NCT06397768|BIOLOGICAL|Varicella virus vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular
214478360|NCT06397768|BIOLOGICAL|Placebo|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
214478361|NCT06639516|DIETARY_SUPPLEMENT|Bifidobacterium longum|Bifidobacterium longum
214478362|NCT06639516|DIETARY_SUPPLEMENT|Placebo|Placebo
214478363|NCT06639516|COMBINATION_PRODUCT|Standard clinical treatment|Fasting, gastrointestinal decompression, rehydration, inhibition of pancreatic fluid and pancreatic enzyme secretion, improvement of microcirculation, and support of organ function if organ dysfunction occurs at a later stage (mechanical ventilation, continuous renal replacement therapy, and the use of vasoactive drugs).
214478364|NCT06793085|DIAGNOSTIC_TEST|Measurement of interleukin-6 (il-6) concentration in blood serum|Measurement of fasting interleukin-6 (il-6) concentration in fasting venous blood serum
214896325|NCT01080638|DRUG|glycoprotein IIb/IIIa inhibitor (abciximab)|patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
214896326|NCT01446536|OTHER|Checklist cohort|CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
214896327|NCT02619084|PROCEDURE|STN DBS|Bilateral STN DBS
214896328|NCT06575361|DIAGNOSTIC_TEST|Combination of targeted biopsy and systematic biopsy|Before prostate biopsy, the MR images of patients were independently reviewed by MRI-AI and urogenital radiologists. Then the images with suspicious lesions highlighted by MRI-AI and urogenital radiologists. Urologists conducted targeted biopsies for all suspicious lesions and systematic biopsies. Biopsies were performed under the guidance of transrectal ultrasound (TRUS) through the transrectal or transperineal route.
214896329|NCT04141241|DRUG|Ecklonia cava Phlorotannin|Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.
214896330|NCT02496078|DRUG|Daclatasvir|Daclatasvir tablet 60mg
214896331|NCT02496078|DRUG|Asunaprevir|Asunaprevir soft capsule 100 mg
214896332|NCT06424327|OTHER|Patient-Reported Outcomes Measurement Information System|Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
215051955|NCT04421404|BIOLOGICAL|COVID-19 Convalescent Plasma (CCP)|COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the purpose of preventing or treating the infectious disease it causes. Convalescent plasma for this trial will be obtained from Vitalant (or American Red Cross if necessary). Patients identified as having recovered from COVID-19 will serve as potential donors. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined.
215051956|NCT04421404|BIOLOGICAL|Placebo|Standard plasma will be obtained from Vitalant (or American Red Cross if necessary) and will be either collected prior to 12/1/2019 or tested and confirmed to be negative for anti-SARS-CoV-2.
215051957|NCT06058962|DRUG|Suramin Sodium|Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
214297563|NCT03574740|OTHER|Tobacco Smoking|Influence of Tobacco Smoking on the development of OSA
214297564|NCT05167734|DRUG|Iron Dextran|1000 mg IV
214297565|NCT05167734|DRUG|Erythropoietin (EPO)|40,000 units subcutaneous
214297566|NCT01198054|DRUG|Lenalidomide|"Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease"
214297567|NCT05025488|DRUG|Peptide-based vaccine|ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.
214297568|NCT05025488|DRUG|Poly ICLC|ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.
214297569|NCT03432546|OTHER|Non-interventional|Non-interventional
214297570|NCT02621411|DRUG|Substance use|Patients are found use of substances by preoperative screen
214297571|NCT06493266|BEHAVIORAL|neurolinguistic programmino|In this randomized controlled study, the group of patients with an indication for colposcopy in the Gynecological Oncology Department of Şanlıurfa Training and Research Hospital, Department of Gynecology and Obstetrics, will be divided into two groups and NLP training will be given before colposcopy in a double-blind manner, and after colposcopy, VAS (visual pain scale), fear of pain scale will be given. 3, evaluation will be made using the pain catastrophizing scale. NLP training will be given for approximately 20 minutes, and the group that will not receive NLP training will remain silent for 20 minutes. The results will be compared.
214297572|NCT01163708|DEVICE|Prophecy Technique|Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
214297573|NCT01163708|DEVICE|Navigation System|
214297574|NCT04882527|DEVICE|Non-invasive brain stimulation|Stimulation will be applied once per subject with one mA for 20 minutes over either the left inferior frontal lobe, the right inferior frontal lobe or the right superior parietal lobe.
214297575|NCT04882527|DEVICE|Sham stimulation|The electrode positions and the attachment procedures correspond to those of real tDCS but the electrical current will only be ramped up to 1 mA and switched off completely after 30 s of stimulation.
214297576|NCT02604212|DRUG|ARC-520|
214297577|NCT02604212|OTHER|Placebo|
214297578|NCT02604212|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
214297579|NCT02604212|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
214478365|NCT06793085|DIAGNOSTIC_TEST|Measurement of fasting tumor necrosis factor α (TNF-α) concentration|Measurement of fasting tumor necrosis factor α concentration in fasting venous blood serum
214478366|NCT06793085|DIAGNOSTIC_TEST|Measurement of interleukin-18 (il-18) concentration|Measurement of interleukin-18 (il-18) concentration in fasting venous blood serum
214478367|NCT06793085|DIAGNOSTIC_TEST|Measurement of interleukin-4 (il-4) concentration|Measurement of interleukin-4 (il-4) concentration in fasting venous blood plasma
214478368|NCT02358187|BIOLOGICAL|Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
214478369|NCT04536012|BEHAVIORAL|Gamification and Social Incentives|Participants in the intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
214297580|NCT02604212|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
214297581|NCT00451321|DRUG|Otelixizumab|Infusion
214297582|NCT03559946|DEVICE|percutaneous tibial nerve stimulation (PTNS)|The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
214297583|NCT03559946|DEVICE|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
214297584|NCT00598663|DEVICE|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
214669081|NCT01613105|DRUG|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
214669082|NCT00778999|DRUG|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
214669083|NCT02063555|BIOLOGICAL|DAR-901|
214669084|NCT02063555|BIOLOGICAL|BCG|
214297585|NCT00598663|DEVICE|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
214297586|NCT01669447|BIOLOGICAL|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
214297587|NCT05580341|BIOLOGICAL|Zerun HPV-9|Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris), 0.5mL, three doses, 0,2,6 months
214297588|NCT05580341|BIOLOGICAL|GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
214297589|NCT05173740|OTHER|Individually tailored rehabilitation intervention|Individually tailored rehabilitation intervention
214297590|NCT05173740|OTHER|Usual care|Usual care
214297591|NCT03927183|OTHER|person-centred practice|The structure and content of the intervention is constructed on principles for person-centredness. Each patients in the intervention are allocated a hospital-initiated nurse care manager during one year after surgery. Self-management support is primarily conducted between the patient and the nurse care manager. The primary goal of the support is to facilitate patients own resources in managing illness and health education on e.g. physical activity and diet. The support also comprises patient-held documentation and health plan. Other components of the intervention comprise accessibility and continuity which is secured by a structured clinical care pathway with planned care and defined care contacts. The patient has continuous access to the nurse care manager by telephone and face-to-face contact according to a structured follow-up plan. An interdisciplinary team as well as a patient education program constitutes distinct parts of the support during the year after surgery.
214896333|NCT02043795|DEVICE|BVS, Abbott Vascular|The aim of this study is to study the safety and clinical efficacy of a novel Bioabsorbable Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS, Abbott Vascular).
214896334|NCT02826486|DRUG|BL-8040|BL-8040 subcutaneous (SC) injections
214297592|NCT03933202|DRUG|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
214297593|NCT04800692|DRUG|Tetrahydrobiopterin 10 mg/kg|10mg/kg of Tetrahydrobiopterin daily.
214297594|NCT04800692|DRUG|Tetrahydrobiopterin 20 mg/kg|20mg/kg of Tetrahydrobiopterin daily.
214297595|NCT04800692|DRUG|L-Ascorbate|3300 mg of l-ascorbate once daily
214896335|NCT02826486|DRUG|Pembrolizumab|Pembrolizumab will be given as a 30-minute IV infusion
214297596|NCT04800692|DRUG|L-Arginine|3400mg of l-arginine once daily
214297597|NCT03353831|DRUG|Bevacizumab|Bevacizumab will be administered by intravenouse route at a dose of 10mg/kg q14 during the treatment period
214297598|NCT03353831|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous route at a dose of 840 mg q14 during the treatment period
214297599|NCT03353831|DRUG|Chemotherapy|Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28
214297600|NCT03353831|DRUG|Placebos|Placebo will be administered by intravenous route q14 during the treatment period
214297601|NCT06342531|BEHAVIORAL|eDASA+APP FI|A CDSS for nurses to assist in their daily short-term violence risk assessment and management, is integrated into an EPIC-based EHR system.
214896336|NCT02826486|DRUG|Chemotherapy|• IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
214896337|NCT00001271|DRUG|IgG-RFB4-SMPT-dgA|
214896338|NCT04132960|DRUG|DS-8201a|Anti-HER2-antibody drug conjugate (ADC)
214896339|NCT04066452|DIAGNOSTIC_TEST|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP).|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees.
214896340|NCT04066452|DIAGNOSTIC_TEST|Proteinogram and serum immunoglobulins. Light chains free in serum -Freelite-. Immunofixation in serum and urine|Analysis to rule out the presence of monoclonal protein in blood and urine.
214896341|NCT04197804|OTHER|Routine tests perform|The subjects of the Tourette group and control group are subjected to routine tests performed at Tourette Center and Extrapyramidal Diseases. Both groups are initially subjected to an evaluation that aims to identify the IQ and therefore 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) related to the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration about 3 minutes) the language field. These evaluations are in practice at the Center for Tourette patients; the tasks will be administered to both groups.
214896342|NCT00980863|BEHAVIORAL|lifestyle intervention to increase physical activity|
214896343|NCT05706272|OTHER|Comprehensive geriatric assessment (CGA)|The intervention includes a holistic comprehensive geriatric assessment using the PASTEL assessment tool that includes medical, psychiatric, functional and social aspects. Physical tests will include function, risk of falling, hand muscle strength, Timed up and Go (TUG), chair-stand test, blood pressure, saturation and BMI. A proactive person centered care plan will be established based on identified needs and the patients own priorities. A nurse will coordinate the care in the elderly team at the intervention practice with access to rehabilitation staff such as physiotherapist and occupational therapist. Follow-ups at the primary care practices will be carried out in accordance with the study plan. To strengthen care coordination, contact will be taken with other health care providers before the follow-ups.
214896344|NCT05706272|OTHER|Care as usual|The control group will receive care as usual at the matched control primary care centers
214896345|NCT03859167|OTHER|Stress Test|Participants will reach maximum exercise on a treadmill and results will be collected and recorded.
214896346|NCT03691701|OTHER|strict blood pressure control|Home SBP target \< 120 mmHg or 90th percentile for age and height (whichever is lower)
214297602|NCT04883190|OTHER|Fulfilling Questionaires|Fulfilling Questionaires PHQ-D (brief) and FSMC
214297603|NCT00811538|PROCEDURE|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
214297604|NCT00811538|PROCEDURE|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
215051958|NCT05948189|OTHER|exercise program|The participants of the intervention group received back health education (Back School) in the classroom. After the education program, they participated in exercise training for six weeks (one day a week).
214297605|NCT01636401|DRUG|aclidinium bromide 400 μg|
214297606|NCT01636401|DRUG|aclidinium bromide placebo|
214297607|NCT01621620|DRUG|Yohimbine|
214297608|NCT05891314|PROCEDURE|Botox Injectable Product|one group will have botox injection in the internal sphincter
214297609|NCT05891314|PROCEDURE|Internal sphincterotomy|this group will have internal sphincterotomy
214297610|NCT00514033|BIOLOGICAL|Poliomyelitis vaccine (inactivated) -PoliorixTM|Deep intramuscular injections for the primary vaccination and booster vaccination.
214297611|NCT06208228|DEVICE|Kinesiotaping|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
214478370|NCT05934487|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP)"
214896347|NCT02999750|OTHER|individual therapy|Patient will be treated with individual therapy.
214896348|NCT00328601|DRUG|Thioctic Acid|
214896349|NCT02943954|PROCEDURE|Angiography guided PCI|
214896350|NCT02943954|DEVICE|Fractional Flow Reserve (FFR)|
214896351|NCT01067105|DRUG|ciclesonide HFA 160 μg|ciclesonide HFA 160 μg once daily
214896352|NCT01225198|DIETARY_SUPPLEMENT|Multi-Vitamin/Mineral Supplement|A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
214896353|NCT01225198|OTHER|Liquid Placebo|The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
214896354|NCT01591278|OTHER|Pulpotomy|Comparison of two different pulp dressing agents
214297612|NCT05651451|DEVICE|Laser acupuncture|24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point
214669085|NCT02063555|BIOLOGICAL|Sterile saline|
215051959|NCT02224534|DRUG|Ticagrelor|Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
214297613|NCT05651451|DIETARY_SUPPLEMENT|energy-restricted diet|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
214297614|NCT00510133|BIOLOGICAL|GRNVAC1|Autologous dendritic cell vaccine
214297615|NCT00563251|DRUG|Azithromycin|
214297616|NCT00563251|DRUG|Placebo tablet|
214297617|NCT01119131|DRUG|Vitamin D3|Vitamin D3 at 10,000 IU a day
214297618|NCT01119131|DIETARY_SUPPLEMENT|calcium|1000mg calcium daily
214669086|NCT06672328|PROCEDURE|Training with Action Observation Therapy|"AOT based mobility and balance exercises along with conventional therapy consisting of simple lower limb stretchings and strengthening.~The fun based activities inlcude reaching for objects, tower building and taking turns in various stances."
214896355|NCT01591278|OTHER|Pulpotomy|Comparison of two different pulp dressing agents
214896356|NCT00593723|RADIATION|IMRT|
214896357|NCT01634048|DIETARY_SUPPLEMENT|High Protein, low calorie meal replacement|The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
214896358|NCT01268982|PROCEDURE|socket preservation|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket
214896359|NCT02730429|DRUG|Palbociclib/placebo|Palbociclib or a placebo is administered together with standard of care letrozole
214896360|NCT02730429|DRUG|Letrozole|Letrozole is standard of care in both arms
214896361|NCT02302833|DRUG|Cabozantinib S-malate|Given PO
214896362|NCT02302833|OTHER|Laboratory Biomarker Analysis|Correlative studies
214896363|NCT02302833|OTHER|Questionnaire Administration|Ancillary studies
215051960|NCT02224534|DRUG|Clopidogrel|Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
215051961|NCT00490581|OTHER|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
215051962|NCT03061292|PROCEDURE|Pectoral Nerve Block|
215051963|NCT03061292|PROCEDURE|Without Pectoral Nerve Block|
214896364|NCT06171243|DRUG|Lidocaine topical|"Patients who agree to participate, will be given the Lidocaine 23%/Tetracaine 7% formulation. The application of the cream will be carried out by a researcher in charge:~1. A skin area of 200 cm2 will be delimited for the application of the formulation throughout the study period.~2. 10 grams will be applied every 12 hours for a period of 48 hours."
214896365|NCT06468436|DRUG|Dexmedetomidine-Esketamine Combination|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
214896366|NCT06468436|DRUG|Dexmedetomidine|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
214896367|NCT00002881|DRUG|flutamide|
214896368|NCT00002881|DRUG|goserelin acetate|
214896369|NCT00002881|DRUG|leuprolide acetate|
214896370|NCT00002881|DRUG|suramin|
214297619|NCT01119131|OTHER|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
214478371|NCT05059002|DEVICE|Physiological signal monitoring and seizure detection|Data collection and as an adjunct to other methods of seizure monitoring
214478372|NCT04506424|OTHER|CT Guided Cochlear Implant Programming|Flat Panel (high resolution) CT scans of the temporal bones, including the inner ears, will be obtained. The research team will use the scans to generate custom cochlear implant (CI) programs for use by the participants.
214896371|NCT00002881|DRUG|therapeutic hydrocortisone|
214896372|NCT00002881|PROCEDURE|orchiectomy|
214896373|NCT04878432|DRUG|MBG453|Solution for intravenous infusion
214896374|NCT04878432|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous administration
214896375|NCT04878432|DRUG|Decitabine|Solution for intravenous administration
214896376|NCT04878432|DRUG|INQOVI (oral decitabine)|Tablet for oral administration
214896377|NCT04251364|DRUG|Acetazolamide|Daily acetazolamide pill intake
214896378|NCT04251364|DRUG|Atorvastatin|Daily atorvastatin pill intake
215051964|NCT05317598|OTHER|Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)|It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
215051965|NCT03730610|BEHAVIORAL|Exercise training|Subjects are required to exercise four times a week during six months. Exercise training consists of endurance training, resistance training and high-intensity interval training adjusted to subject's fitness level.
215051966|NCT02605408|DEVICE|LenSx® laser system|Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
215051967|NCT02605408|PROCEDURE|Phacoemulsification|Removal of the cataractous lens
215051968|NCT04892186|DRUG|Myo-inositol|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g + folic acid 200mcg twice daily for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
214896379|NCT04251364|DRUG|Placebo oral tablet|Daily placebo pill intake
215051969|NCT04892186|DRUG|Metformin|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin 850 mg twice a day for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
215051970|NCT04500457|BEHAVIORAL|Exposure-based Treatment for Perfectionism (ETP)|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
215051971|NCT05238415|DIAGNOSTIC_TEST|Psychological and Physiological Assessments|About N = 60 patients admitted to the study receive a 3-day assessment (a further examination) at the Kiliani-Klinik Bad Windsheim which considers physical and psychological parameters relevant for the diagnosis of a Post-/ Long-COVID Syndrom.
215051972|NCT05414175|DRUG|Mavacamten|Specified dose on specified days
215051973|NCT06663501|DEVICE|Assisted Motion with Enhanced Sensation training|During the AMES intervention, the AMES device will flex or extend the wrist/hand joint, and the participant's task will be to assist this motion. As the wrist/hand joint moves, the machine will be delivering a vibratory mechanical stimulus on the opposite side to the direction of movement. The activity of the muscles during the movement of the wrist/hand joint will be recorded by the device and it will be shown on a screen to be used as feedback during the training
215051974|NCT05852327|OTHER|Observation only|Observation only
214896380|NCT06169280|BIOLOGICAL|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.
214896381|NCT06169280|DIETARY_SUPPLEMENT|N-acetylcysteine amide (NACA)|N-acetylcysteine amide (NACA) 600 mg oral, is taken daily from registration to just prior to dose 2 of NSC-CRAd-S-pk7.
215051975|NCT06710080|DRUG|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.
215051976|NCT06710080|DRUG|Placebo|Placebo twice daily
215051977|NCT06715345|DEVICE|Bone graft materials and rhBMP-2|NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.
215051978|NCT06718231|BEHAVIORAL|Transcutaneous electrical acupoint stimulation|After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints, and sham acupoints. The target treatment acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery.
215051979|NCT06718231|BEHAVIORAL|Sham-TAES|After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral sham acupoints. The Sham acupoints is 4 cm interior to the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints. The sham acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery
215051980|NCT06718504|DEVICE|Virtual Reality Glasses|Virtual reality is a method that can be used to distract and prepare patients for medical procedures. Virtual reality is a computer-generated environment where three-dimensional interaction is possible. It is an advanced technology that allows an individual to move into a virtual environment and focus their attention on other thoughts, allowing them to pay less attention to pain and anxiety. In this study, the virtual reality glasses were put on for the intervention group five minutes before the procedure began and were kept on until the procedure was completed. The virtual reality glasses showed the patient-selected images of a relaxing nature setting or images without any violent content.
215051981|NCT06717984|DIAGNOSTIC_TEST|Biopsy, Mastectomy, Histopathology|"Biopsy:~This intervention involves the collection of breast tissue samples through a biopsy procedure. These samples are obtained from women undergoing investigation for unusual cell growth and are analyzed to detect potential abnormalities, including benign, in situ, or invasive cancerous changes.~Mastectomy:~This intervention refers to the surgical removal of breast tissue, typically performed to treat or prevent the spread of breast cancer. It may involve the removal of part or all of the breast and is considered in cases of invasive breast cancer or high-risk noninvasive breast cancer.~Histopathology:~This intervention focuses on the microscopic examination of breast tissue samples collected through biopsy or mastectomy. Histopathological analysis is conducted to assess cellular abnormalities, determine the presence of cancer, and classify the tissue as benign, in situ, or invasive, providing the basis for diagnosis and treatment decisions."
215051982|NCT06715059|OTHER|Tele-rehabilitation exercise program|A progressive core stability exercise program will be performed based on motor control principles via an online platform.
215051983|NCT06715059|OTHER|Home-based exercise program|A core stability exercise program will be performed at home.
215051984|NCT06710925|BIOLOGICAL|TNM001|single dose intramuscular injection
215051985|NCT06710925|BIOLOGICAL|placebo|single dose intramuscular injection
215051986|NCT06718556|BEHAVIORAL|Virtual reality|"The virtual reality intervention program was carried out in a 30-meter2 area covered with soft ground to prevent injuries. The Microsoft Kinect for Xbox 360 was used for the virtual reality intervention. For the current study, a team of experts was formed to select the games to be used within the virtual reality intervention program. This team determined which skills were required for the games to be run successfully, which skills could be developed, which games were purposeful, and independently observed each game. As a result, 9 different games were chosen. Since all games involve similarly intense visual, cognitive and motor skill requirements, game selection was left to the participants' preference during the intervention process to encourage motivation and participation. The virtual reality intervention procedure was created by utilizing the literature"
215051987|NCT06718556|BEHAVIORAL|Client-centered|"The client-centered (CC) intervention procedure for individuals with schizophrenia was created using literature and the intervention procedure is presented below:~1. Active Communication and Evaluation~2. Daily Routine, Roles, and Occupational Performance~3. Strengths and Barriers~4. Intervention Program Development~5. Implementation of the intervention program~6. Feedback and Revision:"
215051988|NCT06712680|DRUG|Test Product HYP-6589|HYP-6589 should be administered orally at the recommended dosage
215051989|NCT06717542|DIAGNOSTIC_TEST|histochemical and immunohistochemical analysis|2 µm sections will be cut from the paraffin blocks for histochemical and immunohistochemical (IHC) investigations. IHC will be performed with an automated stainer (Ventana/Roche®, Ventana Medical Systems, USA) for the endothelial markers CD34, ERG, Nestin and Caveolin-1
215051990|NCT06717542|DIAGNOSTIC_TEST|RT-PCR|Custom RT-PCR analyses will be performed manually for the transcripts (mRNA) of the ERG, Nestin, VEGFR and other genes, at the Pathology Anatomy lab hall. 18 (Prof. D'Errico). Total RNA will be extracted from the paraffin blocks with the RecoverAll™ Total Nucleic Acid Isolation kit (Invitrogen). Reverse Transcriptase will be performed with the High Capacity Reverse Transcription kit (Life Technologies), using the specific primers. Real-Time PCR will be performed with the CFX Connect Real-Time PCR Identification System (BioRad).
215051991|NCT06714838|DRUG|Rituximab (Mabthera)|Rituximab will be administered in a hospital setting in the course of one day. It will be given intravenously, at time points baseline, week 2 and week 26.
215051992|NCT04676906|DRUG|NNC0113-6861|Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
214297620|NCT04170257|DIAGNOSTIC_TEST|Endoscopic examination using white light, NBI and iodine staining|Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
214297621|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
214297622|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
214297623|NCT01614054|OTHER|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
214297624|NCT05283057|DRUG|Empagliflozin 25 MG|single dose of the SGLT inhibitor Empagliflozin was given
214297625|NCT05283057|DRUG|placebo|single dose of placebo that is similar to Empagliflozin in physical appearance
214297626|NCT05142865|DRUG|Camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
214297627|NCT05142865|DRUG|Etoposide|100mg/m2 IV continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
214297628|NCT05142865|DRUG|Carboplatin|AUC 5 mg/mL/min IV on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6)
214297629|NCT05142865|DRUG|Cisplatin|25mg/m2，continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
214297630|NCT05142865|DRUG|Apatinib|250 mg given orally, once daily in 21-day cycle
214297631|NCT00204607|BIOLOGICAL|mRNA|
214297632|NCT00204607|DRUG|GM-CSF s.c.|
214297633|NCT03954951|OTHER|Multimodality behavioral strategy|"* On-line course on hypertension management based on the new ACC/AHA and ESC/ESH guidelines on hypertension management.~* Weekly performance feedback reports: will include percent of patients with uncontrolled hypertension and among this group percent of visits where no change in medication was made. It will also include a comparative assessment of the performance of the physicians compared with their colleagues in the province."
214297634|NCT03586856|DEVICE|Nasal mask interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
214297635|NCT03586856|DEVICE|Nasal prongs interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
214297636|NCT02168179|PROCEDURE|dermatologic complications management/prevention|Apply KeraStat Skin Therapy topically
214896382|NCT05820126|BIOLOGICAL|Cold-stored platelet concentrate|Patients will be transfused a unit of pooled, pathogen reduced platelets that have been stored for \>24 hours at 1-6˚C
214297637|NCT02168179|OTHER|questionnaire administration|Ancillary studies
214297638|NCT01341964|DRUG|Clopidogrel|600mg (2 pills)
214297639|NCT01341964|DRUG|Aspirin|325mg (1 pill)
214297640|NCT01341964|DRUG|Aspirin|81mg (1 pill)
214297641|NCT02184689|DRUG|fexinidazole|
214297642|NCT00909389|DRUG|Vytorin (R) (Ezetimibe + Simvastatin)|Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
214297643|NCT03505944|DRUG|Venetoclax|venetoclax + lenalidomide + rituximab
214297644|NCT02630433|PROCEDURE|Index cholecystectomy|Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
214297645|NCT02630433|PROCEDURE|Scheduled cholecystectomy|Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
214478373|NCT06421376|DRUG|Cardonilizumab|Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles
214896383|NCT06849271|PROCEDURE|Radical Nephrectomy (RN)|"Complete remove of the kidney. In addition as part of the intervention, a procedure termed Lysis of abdominal adhesions may be performed according to patient medical condition and/or surgeon criteria."
214896384|NCT06849271|PROCEDURE|Partial nephrectomy (PN)|"Partial remove of a section in the kidney. In addition, as part of the intervention, a procedure termed Lysis of abdominal adhesions may be performed according to patient medical condition and/or surgeon criteria."
214896385|NCT06849271|PROCEDURE|Radical Prostatectomy (RP)|"Complete remove of the prostate gland. In addition as part of the intervention, two procedures termed Lysis of abdominal adhesions and/or Lymphadenectomy  (removal of regional lymph nodes) may be performed according to patient medical condition and/or surgeon criteria."
214896386|NCT04179318|DIAGNOSTIC_TEST|Geneswell BCT|Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.
214896387|NCT02631486|OTHER|Physiotherapy|Passive exercises, active exercises, strengthening, stretching
214896388|NCT00934024|DRUG|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
214896389|NCT00300690|DEVICE|6 mm Uni-graft® (B-Braun)|
215051993|NCT04676906|DRUG|NNC0113-6860|Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860
215051994|NCT04676906|DRUG|NNC0113-6891|Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
214297646|NCT00003492|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214297647|NCT04471012|OTHER|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet was given during their first counseling session."
214478374|NCT06421376|RADIATION|Chemoradiotherapy ±immunotherapy|"Chemoradiotherapy ± immunotherapy：~* PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles"
214478375|NCT06421376|PROCEDURE|Radical surgery|Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.
214478376|NCT03907020|DIETARY_SUPPLEMENT|Barley|Assessing the metabolic availability of lysine in barley.
215051995|NCT00664313|DRUG|Linezolid|600 mg po daily for 112 doses (16 weeks)
215051996|NCT00664313|DRUG|Placebo|Placebo given daily for 112 doses (16 weeks)
214896390|NCT00300690|DEVICE|6 mm Gore-Tex® (WL Gore)|
214896391|NCT02185079|BEHAVIORAL|Training to proficiency|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.
214896392|NCT02185079|BEHAVIORAL|Conventional training|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
214896393|NCT03877679|DRUG|Triamcinolone|Triamcenolone +napolycarboxylate
215051997|NCT05121025|DIAGNOSTIC_TEST|Analysis of gut microbiome and immune signatures|The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.
215051998|NCT02904174|BEHAVIORAL|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 \& 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 \& 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 \& 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question \& answer session were included in the group education.
215051999|NCT01415583|DRUG|Dexamethasone|0.5mg/kg (max dose 20mg)
215052000|NCT04600726|OTHER|no intervention|no interventioni
215052001|NCT00003421|BIOLOGICAL|bleomycin sulfate|
215052002|NCT00003421|DRUG|ABVD regimen|
215052003|NCT00003421|DRUG|chlorambucil|
215052004|NCT00003421|DRUG|dacarbazine|
215052005|NCT00003421|DRUG|doxorubicin hydrochloride|
215052006|NCT00003421|DRUG|etoposide|
215052007|NCT00003421|DRUG|prednisolone|
215052008|NCT00003421|DRUG|procarbazine hydrochloride|
215052009|NCT00003421|DRUG|vinblastine sulfate|
215052010|NCT00003421|DRUG|vincristine sulfate|
215052011|NCT00003421|RADIATION|radiation therapy|
215052012|NCT00428181|BEHAVIORAL|Brief alcohol intervention|Brief alcohol intervention
215052013|NCT00428181|BEHAVIORAL|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
215052014|NCT00236288|DRUG|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
215052015|NCT03680833|PROCEDURE|Sentinel node detection in cervical cancer|The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
215052016|NCT04504539|BIOLOGICAL|mOPV|mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
215052017|NCT04504539|BIOLOGICAL|bOPV|bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3
215052018|NCT04504539|BIOLOGICAL|Full dose IPV|FIPV (full dose injectable polio vaccine)
215052019|NCT04504539|BIOLOGICAL|fractional IPV|fIPV (fractional dose injectable polio vaccine)
215052020|NCT03611881|BEHAVIORAL|Counseling|4 or 8 weeks of behavioral counseling support to promote smoking cessation.
215052021|NCT03611881|DRUG|Nicotine patch|2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
215052022|NCT03611881|BEHAVIORAL|Community Resource|Counselor-facilitated referral to a community-based program to address social needs.
215052023|NCT03130907|DEVICE|Placement of ureteral stent|will randomize groups to either receive a postoperative ureteral stent or not.
215052024|NCT01506635|DRUG|Timolol|
215052025|NCT01506635|DRUG|Placebo|artificial tear twice a day
214896394|NCT03877679|DRUG|Turmeric paste|Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University
214896395|NCT06515119|BEHAVIORAL|Resources-Oriented Salutogenic (ROS) intervention|Participants in intervention group will receive an online ROS course via Zoom meeting, post daily salutogenic recordings and comments on Facebook. A closed Facebook group will be created to deliver resources booklet, zoom meeting links, as well as encourage participants share their daily salutogenic recording, give comments and thumps-up by group members.
214896396|NCT04443972|OTHER|PD VitalOs cement®|PD VitalOs cement®\* is a synthetic bone grafting cement designed for bone void filling and bone regeneration in dental surgery
214896397|NCT04443972|OTHER|Hydroxyapatite bone graft|a bioceramic bone substitute, providing a scaffold for bone deposition
214896398|NCT04443972|OTHER|biodegardable collagen membrane|provide efficacious barriers that were interposed between the flap and root surface.
214896399|NCT03098212|OTHER|Aromatherapy|On the day of admission for labor. Pregnant women select type of essential oil. Aroma diffuser is used during labor. Pain score was record during latent, early active and late active phase.
215052026|NCT00292071|DRUG|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
215052027|NCT02494973|DRUG|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
214896400|NCT01553357|DRUG|Lenalidomide, dexamethasone|"Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.~Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study."
214896401|NCT05943717|DEVICE|lung ultrasound and electrical cardiometry|: B-lines of lung ultrasound and the parameters of cardiometry will be measured at the mid-week HD session before starting the session by 30 min then every 30min during HD session for 180 min and then after the end of the session of HD by 30 min and then The specificity and sensitivity of both techniques will be compared to each other
214896402|NCT02938143|PROCEDURE|Exercise|The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
214478377|NCT03525639|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
214896403|NCT02938143|PROCEDURE|Exercise (usual care)|The control treatment is a painful heavy-load eccentric exercise program performed twice daily with 3 sets of 15 repetitions for 12 weeks on a 25° decline board. The downward component (eccentric component) will be performed with the symptomatic leg and the upward component (concentric phase) on the asymptomatic leg.
214896404|NCT05583695|BEHAVIORAL|mindfulness-based music therapy|eight weekly sessions with a combination of both mindfulness and music therapy
214896405|NCT05583695|BEHAVIORAL|mindfulness-based therapy|eight weekly sessions of mindfulness
214896406|NCT05583695|BEHAVIORAL|routine care|eight weekly sessions of routine care
214896407|NCT02736552|DRUG|S-1 for 6 months|6 months S-1 after D2 resection
214896408|NCT02736552|DRUG|S-1 for 1 year|1 year S-1 after D2 resection
214896409|NCT00725491|DRUG|ganirelix|On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
214896410|NCT00725491|DRUG|triptorelin|a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 \<= 50 pg/ml (\<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
215052028|NCT02494973|DRUG|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
215052029|NCT02494973|DRUG|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
215052030|NCT02494973|DRUG|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
215052031|NCT04799002|DRUG|Topotecan|Topotecan intraocular injection for chemotherapy in retinoblastoma
215052032|NCT04799002|DRUG|Melphalan|Melphalan intraocular injection for chemotherapy in retinoblastoma
215052033|NCT00552071|DRUG|Octreotide LAR 30 MG Injection|Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
215052034|NCT01503814|OTHER|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
214907224|NCT02747108|BEHAVIORAL|Blood Test Group Intervention|Patients randomly assigned to the Blood Test Group will complete an HbA1c blood test around the time of their next primary care appointment. Following the HbA1c test, their VA primary care provider will be notified of the test result and will be provided with a detailed interpretation of the result. Trained study staff will then provide brief counseling by phone and written information by mail about their test result. The brief counseling and written information will be based on the American Diabetes Association and National Diabetes Prevention Program guidelines and will emphasize the risk of progression to type 2 diabetes mellitus and the rationale for preventive strategies, encourage aerobic exercise and a calorie-restricted diet to promote and maintain weight loss, and set a goal of achieving and sustaining a weight loss of at least 5% of body weight.
214297648|NCT04565301|DRUG|Dexamethasone|adductor canal block
214669087|NCT06672328|PROCEDURE|Training without Action Observation Therapy|"Cerebral Palsy patients will receive balance and mobility training without action observation in various stances of sitting, standing and turning.~Activities are fun based and include reaching for objects, tower building and taking turns in different positions."
214669088|NCT02032524|DRUG|Avalglucosidase Alfa|Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
214669089|NCT06859528|BEHAVIORAL|Community Walking Program|This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to drive behavioral change (increased physical and social engagement in their communities) throughout the week.
215052035|NCT04305626|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms with flow diversion.
215052036|NCT03180112|GENETIC|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
215052037|NCT04357184|OTHER|Blood flow restriction training|BFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum
214297649|NCT04565301|DRUG|neostigmine|adductor canal block
214297650|NCT04565301|OTHER|NaCl solutions|adductor canal block
214297651|NCT01516424|DRUG|Blonanserin|Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
214297652|NCT01516424|DRUG|Risperidone|Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
214896411|NCT06187428|OTHER|PainSMART-strategy|"Be PainSMART:er is a seven minute long film developed by the research group based on modern pain science and previous qualitative studies.~The film is divided into three sections:~Section 1- Educates that MSKP is a complex protective system that does not reflect the anatomical state of the body and provides reassurance that MSKP is rarely caused by serious pathology.~Section 2- Provides advice on active MSKP coping, such as encouraging work despite some pain, in an attempt to reconceptualise the belief that a painful body part needs to be rested.~Section 3- Aims to prepare patients for a biopsychosocial physiotherapy consultation by encouraging them to reflect on the film's messages.~In addition to the film, the questions posed to the participant at the initial consultation aim to facilitate the discussion around the film and MSKP reflections. Management subsequent to the initial consultation will follow usual management."
214896412|NCT06187428|OTHER|Usual physiotherapy management|Patients randomised to the control group follow usual MSKP physiotherapy management. Specifically, patients first contact their physiotherapy department online or via telephone and are triaged by a certified physiotherapist and are booked for an initial physiotherapy consultation. After triage, study information and the consent to participate, patients in the control group receive online data collection questionnaires identical to those of the intervention group at baseline and prior to the consultation, excluding the film and the questions linked to the film. The initial consultation will take place as usual according to the preferences of the physiotherapist. The physiotherapist will pose one question at start of the consultation to acknowledge the completion of control group questionnaires. Management subsequent to the initial consultation will follow usual management.
214896413|NCT01495000|DRUG|denosumab|60mg subcutaneous injection, single dose
214896414|NCT01495000|DRUG|placebo|placebo subcutaneous injection, single dose
214896415|NCT06194968|DRUG|Urokinase|administered intravenously
214896416|NCT06194968|DRUG|Alteplase|administered intravenously
215052038|NCT02505373|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
215052039|NCT02505373|BEHAVIORAL|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
215052040|NCT03076281|DRUG|Metformin Hydrochloride|Given orally
215052041|NCT03076281|DRUG|Doxycycline|Given orally
215052042|NCT03076281|DRUG|Metformin +Doxycycline|Given orally
215052043|NCT01427218|OTHER|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
215052044|NCT01427218|BEHAVIORAL|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
215052045|NCT01427218|BEHAVIORAL|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
215052046|NCT01427218|OTHER|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
215052047|NCT03370211|OTHER|resistance training|Participants from TG performed program, executed in 3 sets of 10-15RM, 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was composed of 8 exercises comprising one exercise with free weights and seven with machines performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. All participants were personally supervised by physical education professionals with substantial RT experience to help ensure consistent and safe exercise performance. Participants were instructed to inhale during the eccentric phase and exhale during the concentric phase while maintaining a constant velocity of movement at a ratio of approximately 1:2 seconds (concentric and eccentric phases, respectively). Participants were afforded 1 to 2 min of rest between sets and 2 to 3 min between each exercise. The average duration of each session lasted approximately 50-60 minutes.
214297653|NCT04993989|DRUG|Iberogast (STW5, BAY98-7411)|Survey without any intervention assigned in the study.
214297654|NCT01314833|DRUG|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC\*6"
214297655|NCT01314833|DRUG|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF\*3-T\*3"
214297656|NCT01314833|DRUG|Epirubicin Cyclophosphamide Paclitaxel|"1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC\*4-P\*4"
214669090|NCT06616415|DRUG|Belumosudil|Pharmaceutical form: Tablet Route of administration: Oral
215052048|NCT00102986|DRUG|Lopinavir/ritonavir|
214297657|NCT01045642|DRUG|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
214896417|NCT04131088|OTHER|Follow up of midlines|The follow-up data to be collected will be recorded on a monitoring logbook that will follow the patient (Appendix 4). The latter will be involved in the follow-up of his data insofar as he will be able to solicit the various professionals performing care on his midline in order to aim at the exhaustiveness of the filling of the book.
214896418|NCT01200446|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|8 docosahexaenoic acid (4.0 grams) capsules per day for 3 weeks.
214896419|NCT01200446|DIETARY_SUPPLEMENT|Placebo Docosahexaenoic Acid|8 placebo docosahexaenoic acid (corn and soy oil blend) capsules per day for 3 weeks.
214896420|NCT02943837|PROCEDURE|Device: 22G FNA needle|
214896421|NCT02943837|PROCEDURE|Device: 20G FNB needle|
214896422|NCT01295749|DEVICE|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
214896423|NCT01295749|DEVICE|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
214896424|NCT01514461|DRUG|LCQ908|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
214896425|NCT01514461|DRUG|Placebo|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
214896426|NCT00241670|DRUG|5-aminolevulinic acid (5-ALA)|1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
214896427|NCT03499067|DEVICE|Test lens|Contact lens
214896428|NCT03499067|DEVICE|Control lens|Contact lens
214907225|NCT02747108|BEHAVIORAL|Brochure Group Intervention|Participants will be asked to review a handout from the National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations on or around the same date as their next primary care appointment.
214907226|NCT06015529|DIAGNOSTIC_TEST|4PEPS strategy|"Physicians of the participating centers in the intervention group will have the recommendation to apply the 4PEPS strategy. Using 12 variables, 4PEPS defines four levels of CP that rule out a PE, namely~1. based only on clinical data (very low CP: PEPS \< 0),~2. based on a D-dimer level \< 1000 μg/L (low CP: PEPS ≥ 0 and \< 5),~3. based on a D-dimer level with an age-adjusted cut-off value (moderate CP: PEPS ≥ 5 and \<12), or~4. the diagnosis cannot reliably be ruled out based on a D-dimer test (high CP: PEPS ≥ 12)"
214907227|NCT05881759|BEHAVIORAL|Revised ESBA|Four intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols. Two of the four intervention sites will also participate in the Food Rx program. The control group sites will receive the existing ESBA curriculum. All program materials will be available in English and Spanish. Study participation will be maintained via weekly phone calls/text messaging by the Extension staff. For the online feeding practices content, participants will receive messages to visit the project website and watch the videos, participate in online activities, and engage in facilitated online discussions. For the Food Rx arm, participants will receive a 'Food Rx' card for bi-weekly redemption of \~30 lbs of fresh produce, plus whole grains, lean protein and low-fat dairy at a co-located Houston Food Bank food pantry. The prescription will be eligible for redemption every two weeks for 3 months, for a total of 6 redemptions.
214907228|NCT01176578|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
214907229|NCT06528353|DIAGNOSTIC_TEST|HPV16-E6 serology and HPV ctDNA|"In the event of a malignant lesion identified on clinical examination and/or imaging, treatment will be performed according to the standard of care. In the absence of any suspicious lesion, but in the event of HPV ctDNA positivity, prophylactic surgery of the tonsils and base of the tongue (the vast majority of HPV-related OPC develop in these regions) will be proposed to the patient, given the high risk of OPC. In case of refusal of this prophylactic surgery, close clinical and imaging monitoring will be performed.~Surgical specimens will be analyzed to confirm or not the presence of HPV-driven OPC and HPV ctDNA will be measured post-operatively to ensure disease clearance."
214907230|NCT04971980|DRUG|hUC-MSC infusion (BC-U001)|The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10\^6 cells/kg body weight, 1.0x10\^6 cells/kg body weight, 1.5x10\^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
214907231|NCT05282394|PROCEDURE|Abdominal massage|abdominal massage
214907232|NCT05282394|OTHER|Reading|guidance given to parents about reading with baby
214907237|NCT03357536|PROCEDURE|Human biological samples|"* Blood sample~* Skin biopsy~* Saliva"
214907238|NCT06963710|DRUG|ALG-000184|300 mg tablet
214907239|NCT06963710|DRUG|TDF|300 mg tablet
214907240|NCT06388733|DRUG|Niraparib|Participants will receive niraparib 200 mg orally once daily starting on Day 1 of RT. Following completion of RT, participants will continue niraparib adjuvant therapy orally once daily on Days 1 to 28 of each 28-day cycle until progression by BICR
214907241|NCT06388733|DRUG|Temozolomide|Participants randomized to the comparator arm (Arm B) will receive SOC TMZ 75 mg/m2 orally once daily with RT starting on Day 1 of RT. Following completion of RT, participants will complete a 4-week rest period, and then receive adjuvant TMZ 150 to 200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle until progression by BICR or for a maximum of 6 cycles.
214907242|NCT05680805|DRUG|Metformin Hydrochloride|Metformin 1500 mg/day in 3 divided dose for 24 weeks
214907243|NCT05590988|OTHER|Tablet-based training|"Each task is performed for one minute, followed by a 2-minute break. After the task has been performed three times, there is a 5-minute break. The training block is then carried out twice more. This means that three blocks are carried out for each therapy unit."
214907244|NCT05590988|OTHER|ergotherapeutic training|A task is performed for one minute at a time, followed by a 2-minute break. Once three rounds have been completed, there is a 5-minute break. As in the intervention group, there are a total of three training blocks.
214907245|NCT00437021|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax® Vaccinia Vaccine (\~10\^5 \[plaque forming units (pfu)/dose\] given via scarification, titer 10\^8 pfu per mL after reconstitution).
214907246|NCT00437021|BIOLOGICAL|MVA Smallpox Vaccine|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10\^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
214896429|NCT05576090|BEHAVIORAL|Mindfulness Meditation|The mindful awareness practices (MAPS) for Sleep intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA. This intervention includes educational and behavioral content related to sleep, including the importance of regularity of sleep schedules, minimizing noise and light, and reducing caffeine use later in the day. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for questions and group discussion. Home practice is a key component of MAPs and is particularly important for addressing sleep disturbance. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes, with practice prior to bedtime, and to practice at night if they awake and cannot return to sleep.
214896430|NCT05576090|BEHAVIORAL|Sleep Education|The Sleep Education intervention provides education and behavioral content based on the National Institutes of Health and National Sleep Foundation tips for better sleep (e.g., changing poor sleep habits and establishing a bedtime routine). Each session provides didactic instruction, review of behavioral techniques, and opportunity for questions. Homework includes practicing sleep hygiene and weekly reading. Key components of the intervention include information about sleep biology, characteristics of healthy and unhealthy sleep, sleep problems, stress biology and stress reduction, self-monitoring of sleep behavior, relaxation methods for improving sleep, and weekly behavioral sleep hygiene strategies.
214669091|NCT02509338|DEVICE|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
214669092|NCT01013727|RADIATION|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
214896431|NCT06203613|RADIATION|[18F]F-H3RESCA-3A12及[68Ga]Ga-NOTA-3A12|The dose of \[18F\]RCCB6 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 MCi\]/kg, and the method of administration was intravenous push, with a single visualization administered once.
214896432|NCT03658044|OTHER|Participation in the internet forum|Active participation in the forum with encouragement to participate on a weekly basis
214896433|NCT03658044|OTHER|Placebo|No intervention performed. Patients are offered to read the open pages on the website
214896434|NCT01934439|DEVICE|30 PAAD treatments|Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
214896435|NCT02754050|DEVICE|Tandem Snare|
214896436|NCT02380339|BEHAVIORAL|Psych-Educational session and virtual reality|Psych-Educational session and virtual reality
214896437|NCT02380339|BEHAVIORAL|Psych-Educational and BF sessions|Psych-Educational and BF sessions
214896438|NCT04413513|OTHER|Integrated Attention Training Program (IATP)|Integrated attention training program (IATP) is a newly developed cognitive training programs that combined relaxation technique with integrated attentional training into daily life activity.
214896439|NCT04413513|OTHER|Health Education|Health educational sessions on health concerns and physical diseases commonly found in old age
214896440|NCT04122521|DIAGNOSTIC_TEST|MRI|MRI
214896441|NCT02234908|BEHAVIORAL|Contacts|Household contacts who come to the study clinic, present a referral card, and complete TB symptom screening will receive a shopping voucher of $5-10 value.
214896442|NCT02234908|BEHAVIORAL|Index|Index subjects will be entered in a prize lottery if any of their contacts complete TB symptom screening at the study clinic.
214896443|NCT02548832|DRUG|Berberine|"Berberine 1500 mg, each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner."
214896444|NCT02548832|DRUG|Bezafibrate|"Bezafibrate capsule 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
214896445|NCT02548832|DRUG|Berberine plus Bezafibrate|"Berberine 1500 mg each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.~Bezafibrate 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
214907247|NCT00437021|OTHER|Placebo|0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia \[Sterile Saline Placebo (SSP)\].
214907248|NCT00437021|OTHER|Placebo|Physiologic normal saline for injection.
214907249|NCT03589261|DEVICE|MRI (magnetic resonance imaging)|Fluid challenge will be performed with 500 ml of intra venous NaCl (0.9%). Hepatic blood flow measurement will be performed using MRI.
214907250|NCT02194842|DRUG|Ra223|
214907251|NCT02194842|DRUG|Enzalutamide|
214907252|NCT04975152|DRUG|Cemiplimab-Rwlc|Flat dose of cemiplimab-rwlc 350 mg IV every 3 weeks, up to 9 cycles.
214907253|NCT04597359|DRUG|Placebo Administration|Given PO
214907254|NCT04597359|OTHER|Quality-of-Life Assessment|Ancillary studies
214907255|NCT04597359|OTHER|Questionnaire Administration|Ancillary studies
214907256|NCT04597359|DRUG|Sinecatechins|Given PO
214907257|NCT04433234|DRUG|DS-5141b|Administered via subcutaneous injection once weekly
214907258|NCT05381532|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.
214907259|NCT05791812|DEVICE|home-based transcranial direct current stimulation (tDCS)|2mA of tDCS for 20 min every weekday for six weeks
215052049|NCT04714866|BEHAVIORAL|Cognitive behavioral therapy for ADHD|CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
215052050|NCT00638300|DEVICE|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
215052051|NCT00638300|OTHER|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
215052052|NCT00638300|OTHER|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
215052053|NCT04169646|OTHER|Multi-component intervention|Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
214896446|NCT04256915|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Bright Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes. Participants will receive constant blue-green light (500 nm, 506 lux)."
214896447|NCT04256915|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Placebo Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes.Participants will receive red-filtered dim light (\<50 lux)."
214896448|NCT03345420|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214896449|NCT02058069|DEVICE|Robotic Arm Assisted Total Knee Arthroplasty|The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
214896450|NCT01880866|DRUG|(-)-Epicatechin|A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
214896451|NCT01299103|DEVICE|Pelleve Wrinkle Treatment System|comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
214896452|NCT00991393|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
214896453|NCT01689051|OTHER|human glucagon-like peptide 1 (7-36)amide|
214896454|NCT01689051|OTHER|human glucagon-like peptide 1 (9-36)amide|
214896455|NCT04810208|DRUG|Docetaxel|Docetaxel in NanoZolid formulation, for intratumoural injection
214896456|NCT01841684|DRUG|Anacetrapib|100 mg tablet orally, once daily for 12 weeks
214896457|NCT01841684|DRUG|Placebo|Placebo for anacetrapib orally, once daily for 12 weeks
214896458|NCT03014154|OTHER|Training|
214896459|NCT00002578|DRUG|cytarabine|
214896460|NCT00002578|DRUG|gallium nitrate|
214896461|NCT00002578|DRUG|leucovorin calcium|
214896462|NCT00002578|DRUG|methotrexate|
214896463|NCT04241588|DEVICE|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging the structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post-manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion. The device will be given to participants so that they may practice using the device at home.
214896464|NCT04241588|OTHER|Control|A 3D printed hand with be fitted to simulate a prosthesis.
214896465|NCT01629511|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
214896466|NCT01629511|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214896467|NCT01629511|DRUG|Busulfan|Given IV
214896468|NCT01629511|DRUG|Clofarabine|Given IV
214896469|NCT01629511|BIOLOGICAL|Filgrastim|Given SC
214896470|NCT01629511|DRUG|Gemcitabine|Given IV
214896471|NCT01629511|DRUG|Methotrexate|Given IV
214896472|NCT01629511|DRUG|Tacrolimus|Given PO
214896473|NCT00256178|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
214896474|NCT00256178|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
214297658|NCT05347550|OTHER|Graduated Compression Stockings - Thromboembolic deterrent stockings|Centres randomised to the intervention arm will consist of participants receiving GCS.
214896475|NCT00256178|DRUG|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
214896476|NCT03290378|DRUG|Tramadol|IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
214896477|NCT03290378|OTHER|Placebo|IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
214896478|NCT04949217|PROCEDURE|Inlay Bristow|A modified Bristow procedure
214896479|NCT04949217|PROCEDURE|Bristow|Traditional Bristow procedure
214669093|NCT03885765|DIAGNOSTIC_TEST|Predictive data|"The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration \[I\] of the section to be excised / \[I\] total."
214896480|NCT00316732|PROCEDURE|IPSS Questionnaire|
214896481|NCT00316732|PROCEDURE|EQ-5D Questionnaire|
214896482|NCT03982732|BIOLOGICAL|Boostrix-IPV|Receipt of Boostrix IPV at three different gestational time periods
214896483|NCT01380561|DRUG|asimadoline|10mg \[14\]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
214896484|NCT04464174|DRUG|Ipatasertib|Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
214896485|NCT04464174|DRUG|Capecitabine|Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
214896486|NCT04464174|DRUG|Eribulin|Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle
214896487|NCT04464174|DRUG|Carboplatin|Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle
214896488|NCT04464174|DRUG|Gemcitabine|Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
214896489|NCT03405831|DRUG|Ivabradine|Ivabradine, oral tablets, 5 mg, coated in gelatine capsules to ensure blinding, 1 capsule twice a day, for a period of 12 weeks
214896490|NCT03405831|DRUG|Placebo|Placebo, gelatine capsules to ensure blinding, 1 capsule twice daily, for a period of 12 weeks
214896491|NCT00155311|PROCEDURE|orthodontic treatment|
215052054|NCT04169646|OTHER|Control|No intervention takes place during the control phase.
215052055|NCT03856736|OTHER|MIAT|Moderated aerobic exercise
215052056|NCT03856736|OTHER|Control|Weekly body relaxation and sham group
215052057|NCT00532129|DRUG|Rituximab|375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
215052058|NCT00532129|DRUG|Chlorambucil|10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
215052059|NCT03040739|OTHER|use of O'ARM imaging system|use of O'ARM imaging system
215052060|NCT02237001|DEVICE|Suture-based meniscal repair|Suture-based meniscal repair
215052061|NCT00342628|BIOLOGICAL|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
215052062|NCT00342628|BIOLOGICAL|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
215052063|NCT00342628|BIOLOGICAL|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
215052064|NCT06416150|BEHAVIORAL|Stage 1 SOC|Participants will receive high Standard Care, consisting of a telephone call approximately one month before the appointment to confirm the appointment date for the baseline colposcopy appointment, followed by a notification letter including scheduled appointment date and clinic contact information should the clinic be unable to reach the patient by telephone.
215052065|NCT06416150|BEHAVIORAL|Stage 1 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
215052066|NCT06416150|BEHAVIORAL|Stage 2 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
215052067|NCT06416150|BEHAVIORAL|Stage 2 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as health coaching (HC) after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
215052068|NCT06416150|BEHAVIORAL|Stage 3 SOC|Participants will receive a telephone call before their 12-month follow-up appointments to remind participants about their upcoming appointment and schedule/reschedule if needed.
215052069|NCT06416150|BEHAVIORAL|Stage 3 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
215052070|NCT06416150|BEHAVIORAL|Stage 3 HERS+HC|Participants will receive text message barriers counseling as well as HC after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
215052071|NCT06416150|BEHAVIORAL|Stage 4 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
214297659|NCT02100059|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
214297660|NCT00597766|DRUG|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
214896492|NCT02023983|OTHER|Early discharge|Early discharge (within 72 hours) of selected patients with low risk of complications after myocardial infarction with ST segment elevation, treated with successful percutaneous coronary intervention
214896493|NCT02023983|OTHER|Standard discharge|Discharge after myocardial infarction with ST segment elevation in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day)
214896494|NCT01900769|DRUG|Blood Volume Dilution|
214896495|NCT01087918|DEVICE|RAGT|16 sessions / 4 times/week / 45 minutes Lokomat training
214896496|NCT01087918|OTHER|Strength Training|16 sessions / 4 times/week / 45 minutes lower extremity strength training
214896497|NCT05368324|BEHAVIORAL|CogFun-RV|CogFun-RV intervention combines training in daily living skills, organization, task planning, time organization, emotional regulation, self-esteem and mindfulness in children and the parents. It consists of 12 sessions, each lasting 75 minutes. Parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child. As it is a program of a simultaneous nature, excessive impact on the daily life of families is avoided. All sessions will be carried out individually.
214896498|NCT01004354|DRUG|Ergocalciferols|2000 international units by mouth daily for 8 weeks.
214896499|NCT00397462|DEVICE|calf muscle pump stimulation|Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
214896500|NCT03271801|BEHAVIORAL|child health education|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of education about a child health topic.
214896501|NCT03271801|BEHAVIORAL|skills training|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of experiential learning about stimulus control strategies (portion size, energy density, variety).
215052072|NCT06416150|BEHAVIORAL|Stage 4 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as HC. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
215052073|NCT03427814|DRUG|Pamiparib|60 mg orally twice daily
215052074|NCT03427814|DRUG|Placebo|60 mg orally twice daily
215052075|NCT03145064|DRUG|Zanubrutinib|Administered at a dose of 160 mg BID orally.
215052076|NCT03846427|DRUG|Zanubrutinib|Zanubrutinib at a dose of 160 mg orally twice a day (BID)
214297661|NCT00597766|DRUG|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
214669094|NCT03885765|PROCEDURE|Lung resection|Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
214669095|NCT06870994|DEVICE|Targeted Hyperthermia Therapy|Intra-tumoral gold nanorods (SivaRods) exposed to Near Infrared Light (860 +/- 10nm) mediated targeted hyperthermia therapy
214896502|NCT03773523|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
214896503|NCT01288807|DRUG|Milnacipram|Titration to 200mg PO daily
214896504|NCT02913911|OTHER|feedback|Sit to stand training with external feedback
215052077|NCT04651764|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
215052078|NCT01693250|BEHAVIORAL|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
215052079|NCT01693250|BEHAVIORAL|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
215052080|NCT03530150|DRUG|Pirfenidone Oral Product|A pill containing 600 mg of pirfenidone
215052081|NCT06375525|DEVICE|Janssen's icon Application (App)|
215052082|NCT01761513|DRUG|YH4808|"Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks"
215052083|NCT01761513|DRUG|YH4808|"Group2~1. adminitration of YH4808 dose2, qd for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose1, bid for 2weeks"
214297662|NCT00597766|DRUG|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
214297663|NCT00597766|DRUG|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
214297664|NCT02908048|OTHER|Blood samples|Blood samples collected at varying intervals over a two to three year period.
214297665|NCT05528796|DIAGNOSTIC_TEST|Whole genome sequencing|"The investigators will study the genes in a fetus' or child's DNA using a test called genome sequencing. Genes are the instructions passed from individuals to a child, and genes determine how bodies are built and grow. Some medical conditions are caused by differences in genes, and the genome sequencing test looks for changes in genes and other parts of a person's genetic sequence (the genome).~Genetic material will be extracted from bio-specimens. Genome sequencing for this study will be performed at the UCSF Genomic Medicine Laboratory at UCSF. When the genome sequencing results are available, the investigators will arrange an in person or telehealth meeting to explain the test results and what the results mean for the fetus, pregnancy, and family."
214297666|NCT05340374|DRUG|Cabazitaxel|Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.
214297667|NCT05340374|DRUG|177Lu-PSMA-617|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.
214297668|NCT05414279|DIAGNOSTIC_TEST|Sodium determination|Through a single finger prick 10 drops of capillary blood will be drawn. The venous blood sample will be taken through a standard venipuncture. Both samples will be send to the lab for indirect sodium determination
214297669|NCT01463319|OTHER|air insufflation|air insufflation during insertion phase colonoscopy
214297670|NCT01463319|OTHER|warm water irrigation|warm water irrigation during insertion phase colonoscopy
214297671|NCT02771158|DRUG|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
214297672|NCT02771158|DRUG|placebo|placebo will be administered to double blind the study
214297673|NCT02671279|DIETARY_SUPPLEMENT|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
214297674|NCT02250755|OTHER|MRI T1 T2 sequences|MRI
214297675|NCT00134160|DRUG|Olmesartan medoxomil|Olmesartan medoxomil 40mg/Day
214297676|NCT00134160|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
214297677|NCT03030690|OTHER|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
214478378|NCT04389957|OTHER|Veterans Affairs Endoscopy Quality Improvement Program (VA-EQuIP)|We created an innovative informatics framework for centralized reporting of colonoscopy quality across the VA, facilitating the implementation of the VA Endoscopy Quality Improvement Program (VA-EQuIP). The VA-EQuIP quality dashboard (updated at 6 month intervals) provided adenoma detection rates (ADR), bowel preparation quality, and cecal intubation rate to every facility.This initiative directly addressed the OIG's recommendations and the VA's urgent need for evidence-based colonoscopy quality measurement and reporting. Through VA-EQuIP, we provided bi-annual audits and feedback on colonoscopy quality for VA sites and endoscopists, along with individual provider benchmarking against local and national performance standards. Additionally, we organized collaborative learning sessions led by national experts in colonoscopy training and quality. These sessions focused on shared learning, featuring lectures, discussions, skill-building activities, and work on quality improvement projects.
214297678|NCT03030690|OTHER|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
214297679|NCT03030690|OTHER|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
214478379|NCT05079269|OTHER|Crystalloid Solutions|As above
214297680|NCT03822247|PROCEDURE|Multidisciplinary Recovery Program|"Preoperative care:~* Patient's education~* Providing respiratory training~* Assessment of nutritional status~* Application of compression stockings~* Thromboembolism prophylaxis by low molecular weighted heparin~* Induction of hemodynamic support 12 hours before the surgery~* Oral carbohydrate solution loading until 2 hours before the surgery~Intraoperative care:~* Maintaining normothermia~* Multimodal prevention of postoperative nausea and vomiting~* Use of spinal anesthesia~* Prevention of excessive blood loss~* Local anesthetic infiltration~Postoperative care:~* Active pain control~* Early mobilization~* Early onset of oral nutrition~* Early delirium detection~* Application of compression stockings"
214297681|NCT01608659|DRUG|botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
214297682|NCT04958005|DIAGNOSTIC_TEST|ELISA|Enzim linked immunoabsorbant assay
214297683|NCT03398291|PROCEDURE|Synchronous resection of primary pancreatic cancer and liver oligometastasis|Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.
214297684|NCT03398291|DRUG|Standard chemotherapy|Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1
214297685|NCT04566224|DEVICE|Macintosh size 2 blade|intubate with Macintosh size 2 blade
214478380|NCT05972577|OTHER|Health Promotion and Education|Undergo GO!
214478381|NCT05972577|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
214297686|NCT04566224|DEVICE|Macintosh size 3 blade|intubate with Macintosh size 3 blade
214297687|NCT05850572|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
214297688|NCT05850572|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
214297689|NCT05065177|BIOLOGICAL|Investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
214297690|NCT05065177|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
214297691|NCT00240253|DRUG|pramlintide acetate|Clear, colorless, sterile solution for SC injection
214297692|NCT00376350|PROCEDURE|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
214297693|NCT00376350|PROCEDURE|Light Massage|light pressure massage of the low back.
214297694|NCT00376350|PROCEDURE|Pulsed Ultrasound|5 minutes pulsed ultrasound
214297695|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
214896505|NCT00183547|BEHAVIORAL|"Living in Harmony depression prevention program"|Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support
214896506|NCT00183547|BEHAVIORAL|Depression-prevention education and support|Weekly therapy sessions offering general depression-prevention education and support
214297696|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
214896507|NCT00004310|DRUG|Clomipramine|
214896508|NCT01571323|DRUG|Misoprostol|The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
214896509|NCT01571323|DRUG|Oxytocin|The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
214896510|NCT01571323|DRUG|Oxytocin and Misoprostol|The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
214297697|NCT00102102|DRUG|[18F]SPA-RQ|
214297698|NCT06232811|BEHAVIORAL|Assessment|Sensory processing skills of children in the preterm and term groups will be evaluated. Additionally, the attachment between mother and baby will be evaluated.
214297699|NCT01574040|BEHAVIORAL|Promotion of stair climbing|"Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories."
214297700|NCT01574040|BEHAVIORAL|Promotion of a low-salt soup alternative for the 'soup of the day'|"Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure."
214297701|NCT01574040|BEHAVIORAL|Promotion of a low-fat alternative for the butter croissants|"Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids."
214478382|NCT05972577|OTHER|Quality-of-Life Assessment|Complete quality of life assessments and diary entries
214478383|NCT05972577|OTHER|Questionnaire Administration|Complete questionnaires
214478384|NCT06651840|PROCEDURE|"bipolar diathermy Standard technique."|"The bipolar technique for group A:~A bipolar with straight blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
214896511|NCT04882813|DRUG|Dapagliflozin|Dapagliflozin dispensing claim is used as the exposure group.
214896512|NCT04882813|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the reference group.
214896513|NCT05638464|DEVICE|multisite HD-tDCS EMG-driven robot hand|Multisite HD-tDCS will individual stimulation montages with robot hand training will be applied on chronic stroke survivors. In the multisite HD-tDCS group, 5-8 sintered Ag/AgCl ring electrodes will be placed based on the neuroimaging and computation modelling. The location of the electrodes will be identified by the individual brain activity in the primary motor cortex derived from tasked-based fMRI. The Finite Element Model (FEM) will be used to simulate the electric field distribution on individual brain. Optimization of stimulation montages will be based on the derived activation pattern of the brain. After 20-minute multisite HD-tDCS, EMG-driven robot hand training will be conducted.
214896514|NCT05638464|DEVICE|Sham HD-tDCS EMG-driven robot hand|"Sham stimulation with robot hand training will be applied on chronic stroke survivors.~After the sham stimulation, EMG-driven robot hand training will be conducted."
214896515|NCT04127279|BIOLOGICAL|Cream|"The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.~The placebo cream is devoid of the essential oils"
214896516|NCT03142477|OTHER|Questionnaires|Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.
215052084|NCT01761513|DRUG|YH4808|"Group3~1. adminitration of YH4808 dose2, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of Nexium tab 40mg, bid for 2weeks"
214896517|NCT03142477|OTHER|Placebo therapeutic touch|Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.
214896518|NCT03142477|OTHER|Therapeutic touch|Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
214896519|NCT04812444|DEVICE|Zylox Peripheral Venous Stent|Self-expanding stent implantation during the index procedure.
214896520|NCT04812444|DEVICE|Zilver Vena Venous Stent|Self-expanding stent implantation during the index procedure.
214297702|NCT01574040|BEHAVIORAL|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
214669096|NCT06869434|PROCEDURE|Group VBL (Thoracolumbal vertebral body length) received 0.2 mg x VBL cm of %0.5 hyperbaric bupivacaine|intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight. A dosage was derived using Harten's dose chart formulated for Caucasian parturients
214896521|NCT03497741|DIAGNOSTIC_TEST|procalcitonin measurement|For each patient were blood cultures were taken, a procalcitonin level was determined
215052085|NCT01761513|DRUG|YH4808|"Group 4~1. adminitration of Nexium tab 40mg, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, bid for 2weeks"
215052086|NCT06003439|BEHAVIORAL|Virtual Reality Program|Behavioral: Virtual Reality Program The VR Program will be pre-installed on Meta Quest 2 headsets, which will be donned by students as a class to experience the intervention for approximately the length of one school class period (approximately 30-40 minutes). Each participant will experience the program once a week for 3 weeks. Participants who missed a week will complete the program by the 4th or 5th week.
215052087|NCT06003439|BEHAVIORAL|VR Program|VR program participants will be able to download a mobile app that complements and reinforces the school-based VR session.
215052088|NCT04450030|DRUG|Methyl Prednisolonate|2000mg intravenous methyl prednisolone per day for five consecutive days
215052089|NCT04450030|PROCEDURE|Immunoadsorption|6 courses of tryptophane-based immunoadsorption within up to 12 days
215052090|NCT02113774|OTHER|antimicrobial treatment according to in-vitro susceptibility|
215052091|NCT06474520|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
215052092|NCT04764240|PROCEDURE|R0 resection with lymphadenectomy|Patients received a surgical R0 resection; patients who received an R1 or R2 resection were excluded.
215052093|NCT03048435|OTHER|EORTC QLQ CX-24|Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
214297703|NCT04339127|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
214297704|NCT03352622|OTHER|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
214896522|NCT02042508|OTHER|strengthening|
214896523|NCT02042508|OTHER|hybrid training programme|
214896524|NCT05221541|PROCEDURE|vibration|whole-body vibration and soleus tendon vibration will be applied to participants
214896525|NCT03501823|OTHER|Photoacoustic tomography|A non-invasive, safe modality that relies on light and sound to generate images.
215052094|NCT03048435|OTHER|Physician Feedback Form|This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
215052095|NCT06243614|DRUG|Buagafuran capsules, 15mg/ capsule|Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
215052096|NCT06243614|DRUG|Buspirone tablets, 5mg/ tablet|Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
215052097|NCT06243614|DRUG|Buagafuran capsules mimic, 0mg/ capsule|Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
215052098|NCT06243614|DRUG|Buspirone tablets mimic, 0mg/ tablet|Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
215052099|NCT02782585|OTHER|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
214896526|NCT01723800|DRUG|PI3K inhibitor BKM120|Given PO
215052100|NCT02782585|OTHER|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
215052101|NCT02782585|OTHER|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
215052102|NCT06543459|DRUG|MY008211A tablets|Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
215052103|NCT06543459|DRUG|Placebo|Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
215052104|NCT03939767|DRUG|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
215052105|NCT01470222|OTHER|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
215052106|NCT02948764|DEVICE|Vacuum-Assisted Biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
215052107|NCT02655718|OTHER|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
215052108|NCT02655718|DEVICE|MRI|
215052109|NCT02060929|DRUG|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
214896527|NCT01723800|DRUG|pemetrexed disodium|Given IV
214896528|NCT01723800|DRUG|carboplatin|Given IV
214896529|NCT01723800|OTHER|laboratory biomarker analysis|Correlative studies
214896530|NCT01723800|OTHER|pharmacological study|Correlative studies
214896531|NCT01723800|PROCEDURE|quality-of-life assessment|Ancillary studies
214896532|NCT04113161|OTHER|Standard Care|Standard care will consist of 1) community-based screening and referral conducted by HomeGrown St. Louis (HomeGrown StL) network members and supported by HomeGrown StL coordinator; and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
214896533|NCT04113161|OTHER|Child Behavioral Health Navigator (cbhN)|CbhNs will engage in a series of contacts in person and by phone/text to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
214896534|NCT04395456|DRUG|AMY-101|C3 complement inhibitor
214896535|NCT04395456|OTHER|WFI 5% glucose|Placebo
214896536|NCT00383318|PROCEDURE|Gene mutation sample|
214896537|NCT01422200|BIOLOGICAL|2011-2012 seasonal flu vaccine Subcutaneous|
214896538|NCT01422200|BIOLOGICAL|2011-2012 seasonal flu vaccine Intramuscular|
215052110|NCT04288856|DRUG|BIIB078|Administered as specified in the treatment arm.
215052111|NCT00941525|DRUG|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
215052112|NCT02576548|BIOLOGICAL|MEDI4276|MEDI4276 is an investigational product
215052113|NCT05120583|OTHER|Pilates exercises|Side kick internal/ external rotation with Pilate's band
215052114|NCT05120583|OTHER|Traditional physical therapy program|strength, flexibility
215052115|NCT06497751|BEHAVIORAL|Couple-based Dyadic Coping Group|"Session one: We-disease appraisal (30 minutes). Couples will work toward a congruent perception of HIV as a shared disease, enhancing illness control.~Session two: Couple communication (30 minutes). Couples will learn basic knowledge of effective communication and undertake skill-building exercises focusing on effective communication techniques.~Session three: Dyadic coping (60 minutes). Couples will learn basic knowledge of dyadic coping and work on skill-building exercises (e.g., three-phase dyadic coping exercise) to enhance support mobilization."
215052116|NCT03126643|BIOLOGICAL|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
215052117|NCT01396187|DRUG|PF-05231023|5 mg IV twice a week for 4 weeks
214896539|NCT00711087|DRUG|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
214896540|NCT00711087|OTHER|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
214896541|NCT02720718|DEVICE|Stratafix|
214896542|NCT02720718|DEVICE|Vicryl|
214896543|NCT00494637|DRUG|sodium bicarbonate|isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
214896544|NCT00793962|RADIATION|hypofractionation radiotherapy|radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
214896545|NCT00793962|RADIATION|conventional fractionation radiotherapy|50Gy/25/f/5w
215052118|NCT01396187|DRUG|PF-05231023|25 mg IV twice a week for 4 weeks
215052119|NCT01396187|DRUG|PF-05231023|100 mg IV twice a week for 4 weeks
215052120|NCT01396187|DRUG|PF-05231023|200 mg IV twice a week for 4 weeks
214896546|NCT04712344|BIOLOGICAL|COVID-19 convalescent plasma|Infusion of a total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 in Addition to standard treatment.
214896547|NCT00856193|DRUG|Placebo|Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
215052121|NCT01396187|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
215052122|NCT03323138|PROCEDURE|Ex-PRESS and phacoemulsification|
215052123|NCT00660972|DRUG|Raltegravir|400 mg tablet taken orally twice daily
215052124|NCT00660972|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
215052125|NCT05386147|DEVICE|Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)|see arm description
215052126|NCT04564235|GENETIC|genome-wide analyses|genome-wide analyses will be done in patients and parents (father, mother)
215052127|NCT04564235|GENETIC|Search for de novo mutations in paternal sperm samples|Sperm analysis will be done in paternal samples
215052128|NCT03310359|DIETARY_SUPPLEMENT|Astaxanthin|The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
215052129|NCT03310359|OTHER|Placebo|Matching placebo pill
215052130|NCT05323604|OTHER|Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
215052131|NCT01504295|DRUG|Metadoxine|Improve Liver Function and Reduce ALcohol Use
215052132|NCT01405404|BEHAVIORAL|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
214896548|NCT00856193|DRUG|NVA237|NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
214896549|NCT00794690|DRUG|Cimicifuga racemosa extract for the group|40 mg of Cimicifuga racemosa extract daily dor 12 months
214896550|NCT02569801|DRUG|Fulvestrant|Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
215052133|NCT01405404|OTHER|Parent Training|12-session group on parenting skills and child behavior management
215052134|NCT01274598|BIOLOGICAL|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10\^10 CFU by mouth twice daily for 28 days
215052135|NCT06167967|DIAGNOSTIC_TEST|ctDNA methylation|A blood-based circulating tumor DNA methylation assay that uses 6 different methylation markers, SEPT9 region1, SEPT9 region2, BCAT1, IKZF1, BCAN and VAV3.
215052136|NCT06167967|DIAGNOSTIC_TEST|standard treatment|This group was treated according to standard procedure
214297705|NCT03352622|OTHER|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
214896551|NCT02569801|DRUG|GDC-0810|GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
214896552|NCT00428246|DRUG|paricalcitol|1 mcg or 2 mcg for 4 weeks.
214896553|NCT00428246|DRUG|Placebo|Placebo
214896554|NCT01614496|OTHER|Algorithm for insulin administration|
214896555|NCT03863535|DRUG|Conbercept|Participants were randomized (1:1) to receive IVC+PRP or PRP monotherapy. Patients in IVC+PRP group with diabetic macular edema (DME) received 3 monthly IVC injections along with standard PRP within 1 week after the first injection. Those without DME received 1 lVC injection and standard PRP within 1 week after the injection . Re-treatments in both groups were at the investigators'discretion.
214896556|NCT03863535|PROCEDURE|Panretinal coagulation|The PRP monotherapy group received standard PRP between day 1 and month 2; thereafter, re-treatments in both groups were at the investigators'discretion.
214896557|NCT06966492|DRUG|Stannous Fluoride Toothpaste (SnF)|stannous fluoride toothpaste
214896558|NCT02877225|DRUG|Ibrutinib|Ibrutinib (test treatment) 140 milligram (mg), tablet.
214896559|NCT02877225|DRUG|IMBRUVICA|IMBRUVICA (reference treatment), 140-mg capsule
214896560|NCT02741726|DEVICE|acupoint stimulation|Electric stimulation was given through electrode attached to acupoints
214896561|NCT02741726|DEVICE|no stimulation|patients were only attached electrodes without electric current
215052137|NCT02185261|DRUG|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
215052138|NCT06252844|BEHAVIORAL|Resistance exercise training|Supervised PRT will consist of leg extension, leg curl, leg press, and calf raises. Initially participants will start with a 4 weeks adaptation with low loads at 15 (repetition maximum, RM) conducting for 1-3 sets. Further on subjects will continue with a 5 month of PRT with intensity increasing every 2 weeks from 12 to 6 RM. Each exercise will be done for 3 sets with 2 min rest periods between sets. After the 2 weeks at 6 RM, 1 week of rest will be applied. After the rest week, the same cycle starting from 12 RM will be repeated until the end of intervention.
214297706|NCT06023420|DRUG|4 Herbs Formula|4 herbs formula dose: 5g/day
214297707|NCT03149185|BEHAVIORAL|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
214297708|NCT03149185|BEHAVIORAL|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
214297709|NCT01772706|PROCEDURE|low level laser therapy|
214297710|NCT01772706|PROCEDURE|placebo (laser low level energy nonfunctional)|
214297711|NCT01654731|DRUG|Bezafibrate|
214297712|NCT01654731|DRUG|placebo|
214297713|NCT01183897|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
214297714|NCT03229161|BEHAVIORAL|IWT-group|
214669097|NCT06869434|PROCEDURE|Group FD (fixed dose) received a volume of 0.5% hyperbaric bupivacaine based on a dose calculated according to the patient's height 0.065 mg/cm|Group FD (fixed dose) received a volume of 0.5% hyperbaric bupivacaine based on a dose calculated according to the patient's height 0.065 mg/cm
214896562|NCT05330182|DRUG|LMN-201|"LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism"
214896563|NCT05330182|DRUG|Placebo|Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.
214896564|NCT05119257|BIOLOGICAL|Bispecific antibodies (bsAB)|BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.
214896565|NCT05481710|DIAGNOSTIC_TEST|Nociplastic Pain Criteria|All participants will be assessed with the specific nociplastic pain criteria
214896566|NCT02396511|BIOLOGICAL|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
214297715|NCT00847704|DEVICE|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
214297716|NCT05127473|DRUG|Mim8 B, 10 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
214297717|NCT05127473|DRUG|Mim8 B, 100 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
214297718|NCT05127473|DRUG|Mim8 B, placebo|Placebo will be used to dilute the IMP to different Mim8 concentrations
214297719|NCT05325450|PROCEDURE|Program A|Presentation of the sentence to the implant alone
214297720|NCT05325450|PROCEDURE|Program B|Presentation of the sentence to the implanted ear, associated for the non-implanted ear
214297721|NCT05325450|PROCEDURE|Control|Presentation of the sentences alternately to the most recently implanted ear and both implanted ears at the same time
214297722|NCT05908370|PROCEDURE|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
214297723|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Hyoid Bone(DSHB)|Hyoid bone-skin distance Other Name: DSHB
214297724|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Vocal Cord Anterior Commissura(DSAC)|Vocal cord anterior commissura-skin distance Other Name: DSAC
214297725|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Epiglottic(DSE)|Skin-epiglottic distance Other Name: DSE
214669098|NCT06869434|PROCEDURE|Group AD (adjusted dosage) got intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight.|Group AD (adjusted dosage) got intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight.
214669099|NCT05073692|DRUG|SU|Exposure to the class of drugs known as Sulfonylureas (SU)
214669100|NCT05073692|DRUG|DPP4|Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
214669101|NCT05073692|DRUG|SGLT2i|Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
214297726|NCT02269345|OTHER|Battlefield Acupuncture|Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
214297727|NCT02269345|OTHER|Standard Treatment|Standard Treatment alone.
214297728|NCT00775645|DIETARY_SUPPLEMENT|acetyl-L-carnitine hydrochloride|Given orally
214297729|NCT00775645|OTHER|placebo|Given orally
214297730|NCT03163550|DRUG|ACHN-383|Oral dose
214297731|NCT03163550|DRUG|ACHN-789|Oral dose
214297732|NCT03163550|DRUG|Placebo|Oral dose
214669102|NCT05073692|DRUG|GLP-1RA|Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
214669103|NCT05073692|DRUG|SGLT2i or GLP-1RA|Exposure to either SGLT2i or GLP-1RA
214896567|NCT02396511|BIOLOGICAL|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
214896568|NCT01007669|BEHAVIORAL|Physical activity and Health check|Strength training, aerobic capacity training.
214896569|NCT01007669|BEHAVIORAL|Health check only|Health check
214896570|NCT02336321|DEVICE|BNCI controlled hand exoskeleton|The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
214896571|NCT01012895|DRUG|BMS-790052|Tablets, Oral, 60 mg, once daily, 24 weeks
214896572|NCT01012895|DRUG|BMS-650032|Tablets, Oral, 600 mg, twice daily, 24 weeks
214896573|NCT01012895|DRUG|BMS-650032|Tablets, Oral, 200mg, twice daily, 24 weeks
214896574|NCT01012895|DRUG|BMS-650032|Tablets, Oral, 200 mg, once daily, 24 weeks
214297733|NCT03036072|OTHER|Strict normothermia|
214297734|NCT03036072|DEVICE|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
214297735|NCT02922608|OTHER|simulation practice|simulation session
214297736|NCT04108533|BEHAVIORAL|Text-Based Support|Text-based breastfeeding support as described in arm/group descriptions
214297737|NCT04768231|DRUG|Rifampin|The target dose of 35mg/kg will be reached supplementing fixed-dose combination tablets (standard dose) with rifampin-only tablets.
214896575|NCT01012895|DRUG|Pegylated-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly
214896576|NCT01012895|DRUG|Ribavirin|"Tablets, Oral~For subjects weighing \< 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (\< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks"
214896577|NCT01153828|DRUG|Retapamulin|Prescription for retapamulin
214896578|NCT01153828|DRUG|Co-prescription of retapamulin and topical mupirocin|Same day prescriptions for retapamulin and topical mupirocin
214896579|NCT01153828|DRUG|Co-prescription of retapamulin and topical fusidic acid|Same day prescription for retapamulin and fusidic acid.
214896580|NCT01834534|BEHAVIORAL|CarePartners for depression|Automated telephone calls for depression monitoring and self-management support.
214297738|NCT04532957|DRUG|KBP-7072|QD oral capsules
214297739|NCT04532957|DRUG|Placebo|matching placebo capsules
214297740|NCT03444519|DRUG|Mannitol|This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
214297741|NCT02111850|BIOLOGICAL|Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
214297742|NCT02111850|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
214669104|NCT05073692|DRUG|Linagliptin (DPP4)|Exposure to agent Linagliptin (DPP4)
214669105|NCT05073692|DRUG|Exenatide (GLP-1RA)|Exposure to agent Exenatide (GLP1-RA)
214669106|NCT05073692|DRUG|Liraglutide (GLP-1RA)|Exposure to agent Liraglutide (GLP-1RA)
214669107|NCT05073692|DRUG|Empagliflozin (SGLT2i)|Exposure to agent Empagliflozin (SGLT2i)
214669108|NCT05073692|DRUG|Glimepiride (SU)|Exposure to agent Glimepiride (SU)
214669109|NCT05073692|DRUG|Glipizide (SU)|Exposure to Glimepiride (SU)
214896581|NCT05140044|DEVICE|Balance Exercises - Smartphone Delivery|1st week: standing balance tasks; 2nd week: standing with arm manipulation tasks; 3rd week: gait balance tasks; 4th week: gait with arm manipulation tasks.
214896582|NCT05140044|OTHER|Balance Exercises - Traditional Paper Delivery|1st week: standing balance tasks; 2nd week: standing with arm manipulation tasks; 3rd week: gait balance tasks; 4th week: gait with arm manipulation tasks.
214896583|NCT01971528|DEVICE|Electronic muscle stimulator|Participants will perform 8 weeks of electrical stimulation for Quadriceps muscle belly(30 minutes/time, 3 times/week).
214896584|NCT01971528|OTHER|Muscle strength training|Participants will perform 8 weeks of isotonic contraction muscle strength training for lower extremities.
214896585|NCT01125917|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
214896586|NCT01125917|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
214896587|NCT01125917|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
215052139|NCT06252844|BEHAVIORAL|Active control|Supervised static stretching exercises will be performed without causing an unpleasant feeling of stretching, up to pain, maintaining the stretching position for at least 30 s. Exercises will be performed slowly so that heart rate (HR) does not exceed 50% maximum. Subjects will calculate their HR before training, in the middle and after the training measuring the pulse for 10 s. Exercises will be repeated 3-5 times for each side of the body. The duration of the training will be match to PRT group and will take around 40 min. In order to keep the subjects interested and motivated, two of the stretching exercises will be changed every two weeks.
215052140|NCT00014274|DRUG|carboplatin|
215052141|NCT00014274|DRUG|gemcitabine hydrochloride|
214478385|NCT06651840|PROCEDURE|coblation technique.|"The coblation technique for group B:~An coblator with tonsillar blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
214669110|NCT05073692|DRUG|Glimepiride (SU) or Glipizide (SU)|Exposure to agent Glimepiride (SU) or Glipizide (SU)
214896588|NCT02919189|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
214896589|NCT04469595|DRUG|Iluvien 0.19 MG Drug Implant|0.19 mg Fluocinolone Acetonide Intravitreal Implant
214896590|NCT04469595|DRUG|Aflibercept|2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
214896591|NCT03599817|BEHAVIORAL|Healthy lifestyle promotion program|Before implementing the healthy lifestyle program, it will be adapted according to the characteristics of the Yaqui community, their type of food and the activities they carry out, so that the intervention program is culturally accepted by the community. The intervention will consist of two stages, an intensive phase and a maintenance phase. In the intensive phase, 16 weekly group sessions will be given with the aim of achieving a 5% body weight loss and ensuring that the participants do at least 150 minutes of physical activity per week. In the maintenance phase, 6 monthly group sessions will be given in order to maintain the results achieved in the first stage. In the same maintenance phase, but from 12 to 18 months, the lifestyle trainers will make home visits to the participants. Lifestile trainers will record body weight, physical activity and food consumption. In this period there will be no sessions, only monthly visits.
214896592|NCT05548114|PROCEDURE|EUS-guided gastrojejunostomy|AXIOS lumen-apposing metal stent will be used to create a gastrojejunostomy under EUS guidance.
214896593|NCT05548114|PROCEDURE|Surgical gastrojejunostomy|A surgical gastrojejunostomy will be created via laparoscopic or robotic techniques (preferred) or open technique (if these methods fail), as clinically appropriate.
214896594|NCT06557642|DRUG|Entonox|30 minute inhalation using demand valve and mouthpiece
214896595|NCT06557642|DRUG|Medical Air|30 minute inhalation using demand valve and mouthpiece
214896596|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
214896597|NCT05153811|BEHAVIORAL|mHealth|Participants will engage with an application designed to gamify drinking reduction.
214896598|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
214896599|NCT04655547|OTHER|Dietary guidance|Dietary guidance with focus on texture and energy intake, preformed by certified dietitians.
214896600|NCT02015611|DIETARY_SUPPLEMENT|Vitamin D|2,000 IU/ day of Vitamin D3
215052142|NCT00014274|DRUG|methotrexate|
214297743|NCT02111850|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.
214297744|NCT02111850|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
214297745|NCT02389933|DRUG|LCZ696|immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
214669111|NCT05073692|DRUG|SU or DPP4 (excluding saxagliptin and alogliptin)|Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
214669112|NCT05073692|DRUG|Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)|Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
214669113|NCT02874911|OTHER|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
214669114|NCT00538642|DRUG|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
214896601|NCT02015611|DIETARY_SUPPLEMENT|Placebo|Placebo
214896602|NCT06141083|DIETARY_SUPPLEMENT|TCI188 Probiotic|take two tablets per day
214896603|NCT06141083|DIETARY_SUPPLEMENT|Placebo|take two tablets per day
214896604|NCT03435471|OTHER|Prophylactic Swallowing Home Exercise Program|The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
214896605|NCT03435471|OTHER|Clinician-Directed Prophylactic Swallowing Exercises|Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
214896606|NCT05122169|DRUG|Povidone-Iodine|Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
214896607|NCT05122169|DRUG|Chlorhexidine|Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
214896608|NCT00556868|OTHER|Breakfast/no breakfast|"A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention"
215052143|NCT00014274|DRUG|vinblastine sulfate|
215052144|NCT01350674|PROCEDURE|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
215052145|NCT04470882|BEHAVIORAL|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
214297746|NCT03855098|OTHER|Biomarkers of Fruit and Vegetable Intake|"Cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). The following definition of portion sizes will be used; green beans (120g), lettuce (20g), spinach (90g), strawberries (96g) and blueberries (75g).~For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption."
214896609|NCT00428272|DRUG|Lexatumumab alone|Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
214896610|NCT00428272|DRUG|Lexatumumab in combination|Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
214896611|NCT00428272|DRUG|Interferon gamma 1b in combination|Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
214896612|NCT00428272|DRUG|Gamma 1b potential expansion|Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
214896613|NCT05354037|PROCEDURE|Enamel matrix derivative application for treatment of intrabony defects|EMD application will be associated to M-MIST approach in control group and flapless approach in test group.
214896614|NCT03737357|DEVICE|SLActive® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
214896615|NCT03737357|DEVICE|SLA® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
214896616|NCT03442556|DRUG|Carboplatin|Given IV
214896617|NCT03442556|DRUG|Docetaxel|Given IV
214896618|NCT03442556|OTHER|Laboratory Biomarker Analysis|Correlative studies
214896619|NCT03442556|DRUG|Rucaparib Camsylate|Given PO
214896620|NCT03442556|DRUG|Rucaparib|Given PO
214896621|NCT06484556|DRUG|NW-301V|TCR-T cell targeting KRAS G12V mutation
214896622|NCT06484556|DRUG|NW-301D|TCR-T cell targeting KRAS G12D mutation
214896623|NCT04941131|DRUG|Chlorhexidine digluconate, povidone iodine|This is a mouth wash that can be used over the counter.
214896624|NCT06586827|OTHER|VCU-RRTC Online Course|"Approved by ACRE as its accrediting body and has been offered virtually through the VCU RRTC for over 15 years. The course currently entails:~i. Six modules ii. Six online discussion boards iii. Assignments in each module iv. One quiz per module v. Final assignment"
214896625|NCT06586827|OTHER|Zoom Technical Assistance Sessions (6 total)|Technical Assistance sessions will be provided to small groups of participants of 5-7 via Zoom technology. There will be one virtual TA session for each of the six modules that will last for 1 hour. The TA sessions will be provided by a trained SE expert/ mentor. The TA sessions will have instructional plans so that they are delivered consistently and will align with the associated module's content and will entail application and discussion that facilitates implementation and reflection of the material.
214896626|NCT06983925|DRUG|GS1-144 Tablet with new preparation (T)|GS1-144 Tablet with new preparation (T)
214896627|NCT06983925|DRUG|GS1-144 Tablet with present preparation (R)|A single oral dose of GS1-144 Tablet with present preparation
214896628|NCT05531812|OTHER|G2R with individual coaching|"1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Individual coaching at home from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; Water, Sanitation and Hygiene (WASH) practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
214896629|NCT05531812|OTHER|G2R with group coaching|"1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Group coaching in a community setting from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; WASH practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
214896630|NCT05276050|DEVICE|active F8-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
214896631|NCT05276050|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
214896632|NCT06983821|DRUG|Cyclophosphamide|IV Cyclophosphamide 15mg/kg/dose (age and eGFR adjusted), 2 doses 2 weeks apart
214896633|NCT06983821|DRUG|Standard of Care (SOC)|Participants will receive standard of care induction agent and glucocorticoid taper, at investigator discretion
215052146|NCT04470882|BEHAVIORAL|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
215052147|NCT04470882|BEHAVIORAL|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
215052148|NCT03216720|PROCEDURE|CABG|"* Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~* Grafting: pedicled left internal mammary artery, and no-touch~* saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~* Target activated coagulation time of \>400 seconds"
215052149|NCT03216720|PROCEDURE|Miniaturized extracorporeal circulation|"* Centrifugal pump to reduce mechanical stress~* Circuit coated with biosurface to increase haemocompatibilty.~* Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution~* Collapsible soft-shell reservoir for blood volume management~* Cell-saving device~* Venous air removing device and electric clamp system to air embolism"
215052150|NCT03216720|PROCEDURE|Conventional extracorporeal circulation|"* Roller pump~* Circuit uncoated~* Hard-shell venous reservoir~* Intermittend cold blood Harefield cardioplegia"
215052151|NCT03069040|PROCEDURE|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
215052152|NCT03069040|PROCEDURE|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
215052153|NCT01597648|DRUG|Maraviroc|300 mg
215052154|NCT01597648|DRUG|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
215052155|NCT01597648|DRUG|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
215052156|NCT05722834|BEHAVIORAL|SOAR intervention|"This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients."
215052157|NCT05830318|OTHER|P-STEP Mobile Application|A mobile application that allows you track your walking habits while keeping you up to date with air quality information.
215052158|NCT00633763|DRUG|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
215052159|NCT00633763|DRUG|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
215052160|NCT02948699|DIETARY_SUPPLEMENT|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
215052161|NCT02955888|DRUG|PBI4050|Investigational Medicinal Product
215052162|NCT02955888|DRUG|Placebo|Comparator
215052163|NCT00106041|BEHAVIORAL|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
214896634|NCT06983821|DRUG|Prednisone|4 weeks prednisone taper
214896635|NCT06983821|DRUG|Rituximab (R)|Rituximab infusions, dosing and schedule at clinician/investigator discretion
214896636|NCT06200831|PROCEDURE|Staged resection|Patients randomized to staged resection will be operated according to the decision made by the tumor board meeting (liver or colorectal cancer first, based on tumor burden and symptoms), but both resections have to be done within a time period of 4-12 weeks.
214896637|NCT06200831|PROCEDURE|Simultaneous resection|In cases with simultaneous surgery, the liver resection is performed prior to colon resection in order to keep a low central venous pressure during the first part of the surgical procedure and to avoid congestion of the anastomosis line owing to possible Pringle manoeuvre.
215052164|NCT04532125|BIOLOGICAL|ARGX-117|Subjects treated with ARGX-117
215052165|NCT04532125|OTHER|Placebo|Subjects treated with placebo
215052166|NCT04532125|BIOLOGICAL|ARGX-117 + rHuPH20|Subjects treated with ARGX-117 + rHuPH20
215052167|NCT04532125|OTHER|placebo + rHuPH20|Subjects treated with placebo + rHuPH20
215052168|NCT04532125|BIOLOGICAL|ARGX-117 PH20 SC|Subjects treated with ARGX-117 PH20 SC
215052169|NCT04532125|OTHER|Placebo PH20 SC|Subjects treated with placebo PH20 SC
215052170|NCT02871817|OTHER|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
215052171|NCT00196690|DRUG|Donepezil|
215052172|NCT03460652|DRUG|KP415 oral capsule|Once-daily oral dose
215052173|NCT03394781|DRUG|DUR-928|oral suspension daily for 28 days
214297747|NCT02484742|BEHAVIORAL|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
214297748|NCT02447549|RADIATION|WBRT|One RT plan with whole bladder treated to standard dose.
214297749|NCT02447549|RADIATION|SART|Three plans (small, medium \& large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
214297750|NCT02447549|RADIATION|DART|Three plans (small, medium \& large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
214297751|NCT03128333|OTHER|RunKeeper app + physiotherapy coaching|RunKeeper app for half a year to self-monitor leisure-time PA.
214297752|NCT03128333|OTHER|Usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
214297753|NCT02966587|BIOLOGICAL|Durvalumab|Given IV
214297754|NCT02966587|OTHER|Laboratory Biomarker Analysis|Correlative studies
214896638|NCT06340997|DEVICE|Transesophageal echocardiography|"* D.Echocardiography(Transthoracic and transesophageal):~* 2D echocardiography (to detect LA function, severity of MS and Wilkins score).~The following conventional parameters were measured :~* left atrial volume index (LAVi), and left ventricular ejection fraction (LVEF) by modified biplane Simpson's rule , left atrial emptying fraction calculated as (LAVi max-LAVi min)/LAVi max × 100 ,\]degree of concomitant mitral regurgitation. The maximum and minimum LAA areas were measured by planimetry. LAA area change (%) was calculated using the following formula: LAA area change = \[(maximal LAA area-minimal LAA area)/maximal LAA area\] × 100.~* Transesophageal echocardiogram (TEE) (to detect LAA function) .~* LAA flow velocity patterns by pulsed-wave Doppler~* Early diastolic emptying velocity~* Late diastolic emptying velocity or LAA contraction flow~* LAA filling velocity~* Systolic reflection waves~* Two-Dimensional- LAA fractional area change (LAAAC%)"
214297755|NCT05756374|BEHAVIORAL|OUT to IN|OUT to IN comprises 20 body-oriented biweekly 40-minute sessions facilitated by a psychomotor therapist in a pedagogical partnership with the preschool teacher. Sessions are implemented outdoors. All sessions are framed in a context of freedom and self and mutual bodily resonance, according to the following structure: First, children are invited to engage in exercise play activities. Second, children engage in ludic relaxation proposals. Finally, children are asked to reflect on their bodily experiences and express themselves through different expressive mediators. Preschool teachers also participate in a 25-hour training focused on the underlying principles of OUT to In and participate in 20 body-oriented biweekly 20-minute relaxation sessions, facilitated by a psychomotor therapist.
214896639|NCT01306266|DRUG|Rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache
214896640|NCT01306266|DRUG|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
214896641|NCT02810925|PROCEDURE|PENS T6|Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
214896642|NCT02810925|PROCEDURE|TENS T11/T12|Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.
214297756|NCT00513474|DRUG|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
214297757|NCT00513474|DRUG|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
214297758|NCT00513474|DRUG|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
214297759|NCT00513474|DRUG|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
214297760|NCT00513474|DRUG|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
214297761|NCT00513474|DRUG|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
214297762|NCT00513474|DRUG|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
214297763|NCT00513474|DRUG|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
214478386|NCT03709966|DEVICE|Portable monitoring device|similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status
214896643|NCT02810925|DIETARY_SUPPLEMENT|Hypocaloric 1200 Kcal/day diet|Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
214896644|NCT02810925|DIETARY_SUPPLEMENT|Normocaloric 2000 Kcal/day diet|Patients follow a Normocaloric 2000 Kcal/day diet during 12 weeks.
214896645|NCT00838526|DRUG|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
214896646|NCT00838526|DRUG|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
214896647|NCT02287181|DRUG|Remifentanil|short acting opiate
214896648|NCT02287181|DRUG|Propofol|hypnotic drug
214896649|NCT02287181|OTHER|Bispectral index|electroencephalograph
214896650|NCT00972790|PROCEDURE|Bilateral Scalp Nerve Blocks|Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
214896651|NCT03455088|BEHAVIORAL|Dialectical Behavioral Group Therapy|DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.
214896652|NCT03455088|DRUG|Drug: fluoxetine|Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
214896653|NCT05698433|OTHER|No intervention|No intervention
214297764|NCT00513474|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214297765|NCT00513474|PROCEDURE|peripheral blood stem cell transplantation|
214297766|NCT00513474|RADIATION|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
214297767|NCT00513474|DRUG|fludarabine|Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
214297768|NCT00513474|DRUG|allopurinol|Allopurinol per institutional guidelines
214297769|NCT04573907|DRUG|Drug Levothyroxine 100 mcg|Administration of a 600 mcg levothyroxine dose
214297770|NCT04573907|DRUG|Drug Eutirox 100 mcg|Administration of a 600 mcg levothyroxine dose
214669115|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
214896654|NCT02680951|DRUG|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
214896655|NCT02680951|DRUG|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
214896656|NCT02680951|DRUG|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
214896657|NCT02680951|DRUG|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
214896658|NCT02680951|DRUG|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~* 30 mg for patients age 1 - 1.99~* 50 mg for patients age 2 - 2.99~* 70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
214896659|NCT00348829|PROCEDURE|mitral valve repair|surgical mitral valve repair
214896660|NCT02412917|DRUG|FV-100|antiviral nucleoside analog
214896661|NCT02412917|DRUG|valacyclovir|antiviral nucleoside analog
214896662|NCT06328465|DIAGNOSTIC_TEST|Diffusion whole body MRI|Diffusion whole body MRI protocol, consisting of sagittal T1-weighted and T2-weighted sequences on the whole spine, axial T1 weighted, T2-weighted and diffusion-weighted images from head to mid-thigh, performed on a 1.5 T scanner.
214896663|NCT06390709|OTHER|Lab Collection Only|2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study.
214896664|NCT01160328|DRUG|Leuprolide|7.5 mg - 1 month depot, 2 doses over 7 weeks
214297771|NCT05941923|OTHER|respiratory critical care support|Patients in the intervention group will be received respiratory critical care support
214297772|NCT01325389|DIETARY_SUPPLEMENT|Myo-Mel|
214297773|NCT01325389|DIETARY_SUPPLEMENT|Placebo|
214896665|NCT01160328|DRUG|Testosterone|7.5g - 1% testosterone gel, daily x 7 weeks
214896666|NCT01320293|DRUG|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
214896667|NCT03376334|OTHER|Mental Motor Imagery|
214896668|NCT02541968|BEHAVIORAL|Cognitive-behavioral therapy (face-to-face)|
214896669|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy|With therapist support
214896670|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy without therapist support|
214297774|NCT00005972|DRUG|gemcitabine hydrochloride|
214297775|NCT00005972|DRUG|irinotecan hydrochloride|
214297776|NCT03287505|DRUG|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
214297777|NCT02867787|DRUG|Botox arm|
214297778|NCT00051402|DRUG|Isoflavones|
214297779|NCT01506427|RADIATION|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
214297780|NCT00703989|DIETARY_SUPPLEMENT|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
214896671|NCT02475928|DIETARY_SUPPLEMENT|zinc gluconate|Zinc supplementation plus nutritional education
214896672|NCT02475928|DIETARY_SUPPLEMENT|Placebo|
214896673|NCT02475928|BEHAVIORAL|Nutritional education|
215052174|NCT04971967|COMBINATION_PRODUCT|Crowdsourced partner services intervention|The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
214297781|NCT02970409|DEVICE|saline|catheter lock using saline
214297782|NCT02970409|DEVICE|Heparin|catheter lock using Heparin
214297783|NCT05212012|DRUG|Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)|Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)
214297784|NCT04018950|DRUG|ETX2514|intravenous infusion
214297785|NCT04018950|DRUG|14C-ETX2514|intravenous infusion
214297786|NCT00805311|PROCEDURE|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
214297787|NCT00805311|DRUG|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
214297788|NCT05168410|OTHER|Alvarado Score|The Alvarado Score assesses patient symptoms to enable optimal triage and management of cases with suspected acute appendicitis.a
214297789|NCT04481633|DIAGNOSTIC_TEST|COVID 19 serology|Diagnosis of Covid-19 past infection will be made by serology
214896674|NCT04563936|DRUG|LY01005 3.6 mg|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
214896675|NCT04563936|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
214896676|NCT04061239|DRUG|CPX-351|CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
214896677|NCT04061239|DRUG|Daunorubicin|Daunorubicin is commercially available as a powder for reconstitution in 20 mg vials. In this trial, daunorubicin should be administered as an IV infusion over 60 min.
214896678|NCT04061239|DRUG|Cytarabine|Cytarabine is commercially available as vials/bottles for preparation of diluted infusion solution. Cytarabine will be administrated intravenously. In this trial, cytarabine is administered as a continuous infusion.
214896679|NCT04061239|DRUG|Azacitidine|Azacitidine at 75mg/m² for 7 days. Patients should receive a minimum of 2 and up to 6 cycles.
214896680|NCT02907060|DEVICE|Mechanical cervical ripening|"The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon.~It will be used in accordance with user manual"
214896681|NCT02907060|DRUG|Pharmacological cervical ripening|"The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).~It will be used in accordance with Summary of Product Characteristics"
215052175|NCT02353858|OTHER|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
215052176|NCT02353858|RADIATION|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
215052177|NCT02353858|DRUG|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
215052178|NCT01078792|OTHER|CT pulmonary angio, blood tests|
215052179|NCT00720694|DEVICE|Duolith SD1|
215052180|NCT00720694|DEVICE|Sham Duolith SD1|
215052181|NCT05136222|OTHER|Intervention polysomnography|Please refer to 'Arms: Intervention' section.
215052182|NCT05136222|OTHER|Sham polysomnography|Please refer to 'Arms: Control' section.
215052183|NCT03584048|OTHER|Alert to provider|Providers receive alerts of sub-optimal patient attendance using 4 rules.
215052184|NCT00876863|DRUG|CERE-110: Adeno-Associated Virus injection Surgery|Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure.
215052185|NCT00876863|PROCEDURE|Placebo Surgery|Placebo Surgery
215052186|NCT04645992|DEVICE|active TENS|study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
215052187|NCT04645992|DEVICE|sham TENS|control group will be treated with the same protocol as the study group but with the TENS unit is off .
215052188|NCT02337894|DIETARY_SUPPLEMENT|Essential amino acids plus arginine|Flavored drink containing essential amino acids plus arginine.
215052189|NCT02337894|DIETARY_SUPPLEMENT|Placebo|Flavored drink without essential amino acids plus arginine.
215052190|NCT03134391|DRUG|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
215052191|NCT00725686|DRUG|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
215052192|NCT01456793|BEHAVIORAL|Teen Options to Prevent Pregnancy (T.O.P.P.)|Telephone-based care coordination and mobile contraceptive services
215052193|NCT05026151|OTHER|Nutrition therapy according to ICU protocol|The study aims a verifying adherence to the ICU nutrition protocol
215052194|NCT00535769|DEVICE|Electronic + no text message|Electronic monitor is attached but no text-messages are sent through cellular phones
215052195|NCT00535769|DEVICE|Electronic monitor + text messages|Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
214297790|NCT04481633|OTHER|COVID 19 Self-Questionnaire|COVID 19 Self-Questionnaire
215052196|NCT00682929|DRUG|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
215052197|NCT00682929|DRUG|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
215052198|NCT00682929|DRUG|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
215052199|NCT00682929|DRUG|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
215052200|NCT06149923|GENETIC|quantitative Real-time PCR|: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems
215052201|NCT06513611|DIAGNOSTIC_TEST|Serum cortisol.|Serum cortisol levels obtained on admission.
215052202|NCT03040518|BEHAVIORAL|Narrative SMS|Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.
215052203|NCT03040518|BEHAVIORAL|Endowment Incentive|All participants will be 'endowed' with an incentive at the start of the trial. It will be placed into a hypothetical personal account which is theirs for a year (no withdrawals). Participants will be able to secure money for verified weight loss at 3, 6, and 12 months.
215052204|NCT04311112|DRUG|Placebos|Placebo
215052205|NCT04311112|DRUG|ZA Low dose|ZA low dose
214297791|NCT01710254|DRUG|Regadenoson MRI|AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
214297792|NCT01710254|DRUG|Gadobenate dimeglumine|Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.
214297793|NCT03164200|OTHER|High fat breakfast|High fat breakfast
214297794|NCT03164200|OTHER|Higher carbohydrate breakfast|Higher carbohydrate breakfast
214297795|NCT03645655|DIAGNOSTIC_TEST|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II, AFP, and biochemical tests.
214297796|NCT03342976|OTHER|My-AHA platform|ICT strategy for early detection of frailties
214297797|NCT00733044|BEHAVIORAL|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
214297798|NCT00733044|OTHER|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
214297799|NCT05174910|DEVICE|Obsidian ASG|Application of an autologous platelet-rich fibrin matrix
214297800|NCT02958839|PROCEDURE|Catheter ablation|Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
214297801|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
214297802|NCT05767632|DRUG|Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)|1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg \& Mirabegron 50 mg orally administrated followed by 240 ml of water
214896682|NCT02757755|BIOLOGICAL|AB-SA01 (10^8 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
214896683|NCT02757755|BIOLOGICAL|AB-SA01 (10^9 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
214896684|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^8)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
214896685|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^9)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
214896686|NCT00138008|DRUG|endocrine therapy|Drug: endocrine therapy
214896687|NCT00138008|PROCEDURE|radiotherapy|Procedure/Surgery: radiotherapy
214896688|NCT02680236|OTHER|Art Therapy Group|"Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use~At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post."
215052206|NCT04311112|DRUG|ZA high dose|ZA high dose
215052207|NCT06425653|OTHER|Exercise Program|"In the intervention group in addition to the standard protocol, an exercise program intervention was applied and after the initial interview the Exercise Program DVD was provided through mobile phone. All patients were evaluated 4 times: at baseline, at the 4th week (first visit), at the 8th week (second visit) and at the 12th week (final visit) after randomization"
215052208|NCT02988544|PROCEDURE|Artificial shrinkage|Artificial shrinkage of blastocyst
215052209|NCT00094926|DRUG|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
214297803|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
214896689|NCT00425321|DRUG|RWJ-445380 100 mg|RWJ-445380 100 mg once daily for up to 12 weeks
214896690|NCT00425321|DRUG|RWJ-445380 200 mg|RWJ-445380 200 mg once daily for up to 12 weeks
214896691|NCT00425321|DRUG|RWJ-445380 300 mg|RWJ-445380 300 mg once daily for up to 12 weeks
214896692|NCT00425321|DRUG|Placebo|Placebo once daily for up to 12 weeks
214896693|NCT02294214|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
215052210|NCT00094926|DRUG|placebo|matching placebo IM injections every 2wks for 52wks
215052211|NCT06164522|OTHER|Abdominal ultrasound|Abdominal ultrasound to detect sliding sign
215052212|NCT00737724|DRUG|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
215052213|NCT00737724|DRUG|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
215052214|NCT01232439|DRUG|opioid receptor kappa antagonist|"Starting dose of 2 mg, administered orally, once.~The potential dose range for this study is 0.2 mg to 30 mg"
215052215|NCT04716686|DRUG|Niraparib|Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.
215052216|NCT04242628|OTHER|Facebook course|The intervention consists of the attendance to a course on Facebook and Social Networking Sites use
214896694|NCT02294214|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
214896695|NCT02294214|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
214896696|NCT02689583|BIOLOGICAL|Antibiotic selection based on the antibiotic susceptibility testing|The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.
214896697|NCT02689583|GENETIC|PPI selection based on the CYP2C19 gene polymorphism|PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
214896698|NCT02689583|DIETARY_SUPPLEMENT|Probiotics usage based on the 16SrRNA sequencing|Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
214896699|NCT03839420|DEVICE|CZM IOL|implantation of CZM IOL
214896700|NCT03839420|DEVICE|Competitor IOL|implantation of Competitor IOL
214896701|NCT00811967|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
214896702|NCT00811967|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
214297804|NCT04454372|OTHER|demographic and clinical data obtained from hospital's electronic medical record.|This retrospective observational study. . Demographic and severity data will include age, sex, SAPS 3 and SOFA scores at admission, nutritional risk determined by NRS-2002 and commodities. Clinical and laboratory data on arrival at the ICU including PaO2 / FIO2, blood count and PCR D-dimer, ferritin, fibrinogen, DHL. Drug interventions including use of hydroxychloroquine, corticosteroids, heparin, tocilizumab. Characteristics of invasive and non-invasive respiratory support, use of prone position and ECMO and vasoactive drugs. The main complications, acute kidney injury requiring renal replacement therapy, secondary infectious complications will be documented as well as the outcomes.
214896703|NCT02630576|DEVICE|Neuromuscular stimulation|Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
214896704|NCT02336945|DEVICE|Abbott Sensor Based Glucose Monitoring System-Professional|Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
214896705|NCT01152073|DIETARY_SUPPLEMENT|Placebo|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
214896706|NCT01152073|DIETARY_SUPPLEMENT|Second Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
214896707|NCT01152073|DIETARY_SUPPLEMENT|Third Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
214896708|NCT00470470|DRUG|imatinib mesylate|Given orally
214896709|NCT00470470|OTHER|laboratory biomarker analysis|Correlative studies
214896710|NCT00221455|BEHAVIORAL|Patient diabetic self-management using the diabetic patient portal tools|
214896711|NCT00221455|BEHAVIORAL|A variety of educational interventions for non-adopters of the technology, and for non-compliant patients.|
214896712|NCT03110237|OTHER|Control Balance Training (BT) class|Circuit training class with 11 stations, including: step-ups, ball kicking, balance beam, sit to stand, walk and carry, tandem walking, walking over a mat, walking up a ramp, walking at different speeds, speed walk, dual task walking.
215052217|NCT04242628|OTHER|Lifestyle Course|The intervention consists of the attendance to a course on lifestyle education and brain functioning in older people
215052218|NCT02942888|DIETARY_SUPPLEMENT|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
215052219|NCT02942888|DIETARY_SUPPLEMENT|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
215052220|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
215052221|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
215052222|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula A|
215052223|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets|
215052224|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula B|
215052225|NCT03580538|OTHER|resistive exercise with elastic tube|performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
215052226|NCT05914077|DRUG|Secretin|Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.
215052227|NCT05914077|PROCEDURE|Endoscopic aspiration|Endoscopic aspiration of duodenopancreatic juice after secretin stimulation
215052228|NCT05914077|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).
215052229|NCT05310123|DIETARY_SUPPLEMENT|AC-11|6-months of treatment with AC-11
215052230|NCT00066612|DRUG|irinotecan hydrochloride|Irinotecan will be given 250 mg/m\^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
215052231|NCT03621072|DRUG|Fluconazole 150mg Capsule Originator|150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
215052232|NCT03621072|DRUG|Fluconazole 150mg Capsule Localized Originator|150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
214896713|NCT03110237|OTHER|Fallproof Balance Training (BT) class|There are four categories of exercises in this approach including: center of gravity control training (e.g. multi-directional weight shifts in standing, standing with altered base of support), multisensory training (e.g. standing on compliant surfaces, eyes open/closed), postural strategy training (e.g. resisted perturbation to facilitate ankle, hip or step strategy), and gait pattern variation training (e.g. walking with altered base of support , walking over and around obstacles). Each training category will be allocated 5 minutes with two exercises in each category. An additional 5 minutes will be allotted for games to challenge balance (balloon volleyball, pass the potato, circle soccer).There will be opportunity for group discussion and observational learning.
214297805|NCT01829750|GENETIC|Cardiac progenitor cell infusion|"(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1."
214297806|NCT00074087|DRUG|pegylated liposomal doxorubicin hydrochloride|
214297807|NCT00555750|DRUG|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
214297808|NCT00555750|DRUG|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
214297809|NCT04407000|DRUG|Test: Favipiravir 200 mg (LOQULAR)|Test Drug
214297810|NCT04407000|DRUG|Reference: Favipiravir 200 mg (Avigan)|Reference Drug
214297811|NCT00605813|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
215052233|NCT01462929|DRUG|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
215052234|NCT01462929|DRUG|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
214297812|NCT03195114|DIAGNOSTIC_TEST|Multimodality Imaging and Biomarkers|Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
214297813|NCT05243368|DIETARY_SUPPLEMENT|Personalized Nutritional Intervention|Those with malnutrition criteria will also receive a nutritional supplement (e.g. fortimel cubitan, advanced or extra, Nutricia) or another of similar composition, in case of intolerance to the first option. The aim will be to provide at least 50% of the recommended intakes for the main nutrients related to wound healing.
214896714|NCT03458611|BEHAVIORAL|Active Intervention|An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent \& Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.
214896715|NCT03458611|BEHAVIORAL|Placebo Intervention|The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.
214896716|NCT00749450|DRUG|capecitabine|Given orally
214896717|NCT00749450|DRUG|fluorouracil|Given IV
214896718|NCT00749450|DRUG|oxaliplatin|Given IV
214896719|NCT01101113|DRUG|cinacalcet|cinacalcet 25mg qd or 50 mg qd
214896720|NCT01101113|DRUG|control|vit D + P binder
214896721|NCT06601465|DRUG|Vericiguat|Tablet - 2.5 mg, 5 mg, 10 mg
214896722|NCT06841445|DRUG|HRS9531 Tablet|HRS9531 Tablet dose 1
214896723|NCT06841445|DRUG|HRS9531 Tablet|HRS9531 Tablet dose 2
215052235|NCT01462929|DRUG|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
215052236|NCT02453698|DRUG|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, \& Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
215052237|NCT02453698|OTHER|Placebo|Lactose Placebo
214297814|NCT01127308|DRUG|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of \[14C\]ertugliflozin
214297815|NCT01988142|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
214297816|NCT03634787|DIAGNOSTIC_TEST|CT Scan Day 5-7|Computed Tomography on Day 5-7 according to a clinical protocol.
214297817|NCT06340438|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
214297818|NCT06340438|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
214297819|NCT05648370|GENETIC|ctDNA testing and whole exome sequencing|Blood samples will be obtained for ctDNA testing and tumor tissue for whole exome sequencing.
214297820|NCT03678532|DRUG|Midazolam|
214297821|NCT00573755|DRUG|anastrozole|given orally
214297822|NCT00573755|DRUG|exemestane|given orally
214297823|NCT00573755|DRUG|letrozole|given orally
214896724|NCT06841445|DRUG|HRS9531 Tablet|HRS9531 Tablet dose 3
214297824|NCT00573755|DRUG|sorafenib tosylate|given orally
214297825|NCT00573755|OTHER|placebo|given orally
214896725|NCT06841445|DRUG|HRS9531 Tablet placebo|HRS9531 Tablet placebo
214896726|NCT05273151|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
214896727|NCT03483012|DRUG|Atezolizumab|Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway
215052238|NCT03240562|PROCEDURE|serratus anterior plane block|before surgery :ultrasound-guided serratus anterior plane block
215052239|NCT03240562|DRUG|patient controlled analgesia|two groups have same intravenous patient controlled analgesia
215052240|NCT03882437|BIOLOGICAL|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
215052241|NCT05863390|BEHAVIORAL|McKenzie exercise|routine simple McKenzie exercise
215052242|NCT05863390|DIAGNOSTIC_TEST|Trochanteric belt|Trochanteric belt with conventional physical therapy
215052243|NCT05814718|DRUG|modified BEAM|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
215052244|NCT05814718|DRUG|BEAM|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
214297826|NCT00000999|DRUG|Zidovudine|
214896728|NCT03483012|PROCEDURE|Stereotactic radiosurgery (SRS)|Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
214297827|NCT05245708|DRUG|Intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
214478387|NCT03709966|BEHAVIORAL|Routine|Physical activity promotion supported by a kinesiologist
214478388|NCT05988918|DRUG|ESK981|160 mg, PO, Once daily 5 days on and 2 days off
214896729|NCT06609408|OTHER|Nature and Game Based Activities|Individuals in experimental group will participate nature and game activities such as terrarium making, planting flowers, making puzzles in intervention.
214896730|NCT02063568|DRUG|Oxytocin|
214896731|NCT06209099|PROCEDURE|Nonoperative Management (NOM)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)
214896732|NCT06209099|PROCEDURE|Local Excision (LE)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
214896733|NCT06209099|PROCEDURE|Total Mesorectal Excision (TME)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
214896734|NCT00794768|DRUG|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
214896735|NCT00794768|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
214896736|NCT00673699|PROCEDURE|Gastric mucosal biopsy|Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
214896737|NCT05061589|PROCEDURE|permanent colostomy|An operation that creates an opening for the colon through the abdomen
214896738|NCT00578201|DRUG|radiochemotherapy,combination Cetuximab-FOLFOX|objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
214896739|NCT05422001|DRUG|low dose ketamine|"Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml"
214896740|NCT05422001|DRUG|Placebo (saline)|Isotonic Saline
214896741|NCT00793455|BEHAVIORAL|Educational outreach|Participants will get a letter from their physician that explains that their records show the test has not been completed. The letter will be mailed along with an educational brochure and a DVD about colorectal cancer and colorectal cancer screening.
214896742|NCT00318890|DRUG|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
214896743|NCT00318890|DRUG|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
214896744|NCT00318890|PROCEDURE|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
214896745|NCT00318890|DRUG|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
215052245|NCT05448729|DIAGNOSTIC_TEST|Elastography EUS|Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
215052246|NCT02407743|BEHAVIORAL|Surgical patients' clinical progression|Study the dynamic nature of pain
215052247|NCT02407743|GENETIC|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
215052248|NCT01303952|DRUG|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
215052249|NCT03377595|DRUG|Exparel|TAP (Transversus Abdominis Plane) block
214297828|NCT05245708|DRUG|intranasal placebo|Each subject will be assigned to intranasal placebo.
214297829|NCT00000278|DRUG|Disulfiram|
214297830|NCT03345667|DRUG|lucentis|Use of lucentis and other anti-vegf in patients with diabetic retinopathy
214297831|NCT01978665|DRUG|prednisone|similar size tablets
214297832|NCT01995084|DRUG|[F-18]HX4|400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
214896746|NCT04355078|OTHER|Neuromuscular Training|Muscular and neural training by complex exercises
214896747|NCT04355078|OTHER|Strength Training|Strength Training
214896748|NCT01809353|DRUG|JNJ-54452840|Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg
214896749|NCT01809353|OTHER|Placebo|Single matching intravenous dose
214896750|NCT04809532|PROCEDURE|Transverse abdominis plane (TAP) block|Ultrasound guide bilateral TAP block at end of cesarean section
214896751|NCT04809532|DRUG|Bupivacain|20ml 0.25% bupvicaine
214896752|NCT04809532|DRUG|Tramadol|intravenous tramadol
214896753|NCT01785082|DRUG|13-C-Methacetin|intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
214297833|NCT03733288|BEHAVIORAL|Education and training sessions|Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
214297834|NCT03733288|BEHAVIORAL|Support emails|Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.
214896754|NCT02566772|DRUG|TAS3681|TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
214896755|NCT06990711|DRUG|Siltuximab|Interleukin-6 blockade
214896756|NCT06990711|DRUG|Placebo|Siltuximab placebo IV
214896757|NCT04417621|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
214896758|NCT04417621|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
214896759|NCT04417621|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
214896760|NCT04417621|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
214896761|NCT06994754|DEVICE|clear aligners|aligners made with 1mm thickness sheet and covering the whole palate
214896762|NCT06995391|BEHAVIORAL|Contemporary Guideline-Adherence|Participants randomized to Contemporary Guideline-Adherence will receive weekly app and text-based messaging encouraging them not to exceed guideline-directed amounts of alcohol, as well as messaging explaining that abstinence is acceptable and may be the best way to avoid AF and that, if a participant decides to consume alcohol, a Mediterranean drinking pattern may be the most healthy.
214896763|NCT06995391|BEHAVIORAL|Alcohol Abstinence|Participants randomized to Alcohol Abstinence will receive weekly app and text-based messaging encouraging avoiding all alcohol consumption.
214896764|NCT03390803|OTHER|effect of hemifacial spasm on intraocular pressure|To evaluate the effect of Hemifacial spasm on Intraocular pressure measurement.
214896765|NCT03345680|OTHER|Referred to a specific hospital for treatment|To King Saud University Dental College, treatment will be provided free of charge to the referred participants.
214896766|NCT03104517|BIOLOGICAL|AMDC-USR (iltamiocel)|Autologous Muscle Derived Cells for Urinary Sphincter Repair (generic name: iltamiocel)
214896767|NCT03104517|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
214896768|NCT06863311|DRUG|XL092|100 mg orally
214896769|NCT06863311|DRUG|Nivolumab|480 mg intravenously.
214896770|NCT06671873|DRUG|100 µCi [14C] HMPL-306|D1: 250 mg/100 µCi \[14C\] HMPL-306 Single dose
214896771|NCT06538415|OTHER|Pulse Diet|Participants will consume cooked pulse (112 calories -lentils, red kidney beans, black beans, and pinto beans) during 14 weeks.
214896772|NCT06538415|OTHER|Control Rice Diet|Participants will consume cooked rice (112 calories) during 14 weeks.
214896773|NCT06996795|BEHAVIORAL|music therapy|Music therapy will be applied with drums, maracas, cymbals and orf instruments. It will consist of body rhythms, breathing exercises and rhythm studies.
214896774|NCT06996795|BEHAVIORAL|sensory integration|Sensory integration will include sensory modulation activities, vestibular, proprioceptive, tactile, visual and auditory sensory studies.
214896775|NCT04278456|BEHAVIORAL|postpartum depression|melatonin levels in c-sections with different anesthesia modalities.
214896776|NCT05323708|BIOLOGICAL|Bmab 1000|60mg/ml Prefilled syringe single dose
214896777|NCT05323708|BIOLOGICAL|Prolia®|60mg/ml Prefilled syringe single dose
214896778|NCT02574598|DRUG|MK-3475|The dosing interval of pembrolizumab can be increased in case of toxicity.
214896779|NCT02574598|DRUG|Docetaxel|Use on both arms as standard of care.
214896780|NCT02749617|DRUG|apixaban|2.5 mg PO BID
214896781|NCT04782076|DRUG|Dabigatran|Administered orally.
214896782|NCT04782076|DRUG|Selpercatinib|Administered orally.
214896785|NCT03466450|DRUG|PF-04449913|"Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration."
214896786|NCT03466450|DRUG|Temozolomide Oral Capsule|"During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
214896787|NCT04910100|DRUG|Nebivolol Ophthalmic Suspension 1 Percent|1 drop instilled into each eye twice daily
214896788|NCT04910100|DRUG|Nebivolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
214896789|NCT04910100|DRUG|Timolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
215052250|NCT03377595|DRUG|Exparel|Wound infiltration
215052251|NCT04206631|DRUG|Doxycycline Capsule|Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
215052252|NCT04206631|PROCEDURE|Comedone extraction|Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
215052253|NCT00670566|DRUG|irbesartan/hydrochlorothiazide|50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
214896790|NCT04910100|DRUG|Timolol Ophthalmic Solution 0.5 Percent|1 drop instilled into each eye twice daily
214896791|NCT02179762|BEHAVIORAL|moderate exercise intervention|Perform moderate exercise therapy
214896792|NCT02179762|BEHAVIORAL|vigorous exercise intervention - standard|Perform HIIT exercise therapy on a standard stationary bike
214297835|NCT03733288|BEHAVIORAL|Team leader training|Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.
214896793|NCT02179762|OTHER|questionnaire administration|Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)
214896794|NCT02179762|OTHER|laboratory biomarker analysis|Correlative studies
214896795|NCT02179762|BEHAVIORAL|vigorous exercise intervention - cybercycling|perform HIIT exercise on cybercycles aided by electronic racing and other games
214896796|NCT02179762|BEHAVIORAL|Exercise Logs|The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.
214896797|NCT02179762|BEHAVIORAL|Adherence|We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
214896798|NCT02179762|BEHAVIORAL|Exercise and body composition test|Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
214896799|NCT05401981|OTHER|Story checklist|The story checklist consists of a couple of questions that gives the physician something to keep in mind while visiting the patients.
214896800|NCT04267796|OTHER|Aerobic Exercise|Complete aerobic training
214896801|NCT04267796|OTHER|Dietary Intervention|Receive diet recommendations from health coach or registered dietitian
214896802|NCT04267796|OTHER|Quality-of-Life Assessment|Ancillary studies
214896803|NCT04267796|OTHER|Questionnaire Administration|Ancillary studies
214896804|NCT04267796|OTHER|Resistance Training|Complete high-resistance circuit training sessions
214896805|NCT06601764|OTHER|Circuit Training|"1. Warm-up, balance~2. Aerobic, balance~3. Muscle strength Upper Limbs~4. Muscle strength Lower Limbs~5. Stretching both Upper Limb and Lower Limb"
214297836|NCT03733288|DEVICE|Height-adjustable workstation|After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
214297837|NCT04674046|DEVICE|Nonoperative treatment|Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
214297838|NCT04674046|PROCEDURE|Operative treatment|Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
214297839|NCT04674046|BEHAVIORAL|Standardized education|All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
214297840|NCT05348382|PROCEDURE|Intradermal acupuncture|In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.
214297841|NCT05348382|PROCEDURE|Sham intradermal acupuncture|In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
214297842|NCT05778396|PROCEDURE|Active spinal manual therapy protocol|The chiropractor will start by (1) placing one hand over L4-L5 or L5-S1 and then will apply a high-velocity, low-amplitude (HVLA) thrust with a therapeutic line of drive. Side-lying lumbar manipulation will be performed bilaterally, with the treating clinician choosing any suitable technique and with or without occurrence of the characteristic audible joint cavitation associated with spine manipulation. The chiropractor will then perform (2) prone lumbar mobilisation by placing the contact hand and applying downward pressure over L4-L5 or L5-S1 with the other hand guiding a manual flexion-distraction piece to apply therapeutic mobilization of the lumbar spine. The chiropractor will deliver (3) a prone thoracic manipulation by placing two hands over the transverse processes of T5-T6 or T6-T7 and applying a HVLA thrust in a posterior-to-anterior direction.
214297843|NCT05778396|PROCEDURE|Control spinal manual therapy protocol|(1) Control side-lying lumbar manipulation will be operationalised as the application of a low-velocity broad push manoeuvre to the gluteal region following a non-therapeutic line of drive. The chiropractor will then perform (2) control prone lumbar mobilisation, consisting of a non-therapeutic manual manoeuvre involving minimal oscillations (0 to ±2°) of the flexion-distraction piece with light touch over the lumbar spine region, and (3) control prone thoracic mobilisation consisting of two-handed left and right scapula pushes with a nontherapeutic line of drive.
214669116|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 25 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
214669117|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
214896806|NCT06601764|OTHER|Progressive Resistance|"1. Muscle habituation exercises~2. Hypertrophic phase 1 exercises~3. Hypertrophic phase 2 exercises"
214896807|NCT06999460|PROCEDURE|Infraspinatus teres minor block group|Patients in this group will receive a unilateral ultrasound-guided Infraspinatus-teres minor (ITM) block with injection of local anesthetics (20 mL of bupivacaine 0.25% (50 mg), 50 mcg dexmedetomidine (0.5 ml) and 8 mg dexamethasone (2 ml)) before induction of general anesthesia
214896808|NCT06999460|PROCEDURE|Control group|Patients in this group will receive general anesthesia
214896809|NCT07001735|BEHAVIORAL|Talking for Change Group Psychotherapy|Talking for Change (TFC) is a secondary prevention program that targets dynamic risk factors for child sexual abuse, including (1) atypical sexual interests and sexual self-regulation problems; (2) problems in relationships; (3) offense-supportive attitudes; and (4) general self-regulation deficits and related traits (e.g., impulsivity, emotion regulation deficits). Participants will complete 20 weekly, 120-minute sessions delivered via WebEx.
214896810|NCT07001735|BEHAVIORAL|Healthier Me: Managing Risk and Stress in Everyday Life|The active therapeutic control is a non-directive supportive psychotherapy that targets general mental health concerns. It consists of psychoeducation about human sexuality and common mental health concerns, as well as instruction and practice in applied relaxation and stress management, and group discussions that will facilitate sharing and problem-solving current stressors. This active control intervention is equivalent in length to Talking for Change (TFC), consisting of 120-minute long occurring weekly over the course of 20 weeks.
214297844|NCT01020279|DRUG|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d."
214297845|NCT01020279|DRUG|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
214297846|NCT03674918|DIAGNOSTIC_TEST|24 h ambulatory blood pressure measurements|24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
214297847|NCT05048121|OTHER|Cosmetic Active Ingredient CLS02021|Topical, face application of the cream base with the CLS02021, two times a day in a period of 30 days
214297848|NCT05048121|OTHER|Placebo PLC01021|Topical, face application of the cream base, two times a day in a period of 30 days
214297849|NCT02629341|DIETARY_SUPPLEMENT|Functional yogurt powder|"Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10"
214297850|NCT02629341|DIETARY_SUPPLEMENT|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
214297851|NCT02990208|BEHAVIORAL|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens \& Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
214297852|NCT02990208|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger \& Pauli, 2011)
214297853|NCT04384510|PROCEDURE|Planned Cesarean hysterectomy|This procedure refers to planned delivery of the fetus through Cesarean incision, leaving the placenta in situ and proceeding with hysterectomy
214297854|NCT04384510|PROCEDURE|Conservative management|This term describes a single or combined intervention of uterine artery ligation, internal iliac artery ligation, prophylactic balloon placement in the aorta or internal iliac artery, uterine artery embolization, compression sutures, or excision and reconstruction of uterine wall
214297855|NCT04830527|BEHAVIORAL|EMA prompting for patients|"EMA prompting will consist of the delivery of the PHQ-4 and PANAS questionnaires, as well as basic identification, therapy motivations and expectations, location, current activity and social interactions.~These prompts will be presented to patients during a 7 day period, 5 times per day."
214297856|NCT04830527|BEHAVIORAL|PDF Reports for therapists|After the patients' EMA data is collected, a previously designed R script will summarize and transform the data into a brief and graphic report for therapists in the experimental arm of the study. These reports are intended to provide detailed information about the patients' mood, anxiety levels, positive and negative affects, as well as crossed data such as mood according to location, anxiety according to activity, etc.
214297857|NCT06353880|OTHER|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition.|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition. Sperm quality parameters, including count, motility, and morphology, will be assessed through semen analysis. Additionally, hormonal profiles related to reproductive health will be evaluated.
214478389|NCT03778801|DIAGNOSTIC_TEST|kinesiophobia|The investigators assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
214478390|NCT06356285|BEHAVIORAL|Presentation of Antimicrobial Resistance|Participants will be presented with a poster containing information about antibiotics, each intervention poster will have a different name at the top, representing a new way to frame antimicrobial resistance.
214896811|NCT06018467|DRUG|Dasatinib 100 Mg Oral Tablet|"Dasatinib tablets in blister packs of 10 tablets, from either: Sandoz, STADA Nordic, Zentiva or Bristol-Myers Squibb"
214896812|NCT06018467|DIETARY_SUPPLEMENT|Quercetin 1.250 mg (oral)|five 200mg Quercetin Phytosome capsules, from Thorne
214896813|NCT06018467|DIETARY_SUPPLEMENT|Nicotinamide Riboside 1g (oral)|four 250mg Nicotinamide Riboside Capsules, from Elysium Health
214896814|NCT06997848|PROCEDURE|colonic stent|colonic stent deployment
214896815|NCT02051556|BEHAVIORAL|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
214896816|NCT02051556|BEHAVIORAL|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
214896817|NCT02051556|BEHAVIORAL|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
214896818|NCT07005726|BIOLOGICAL|BCG Vaccine|The WHO-prequalified BCG-Japan or BCG-Denmark
214896819|NCT05712395|BEHAVIORAL|Exercise|Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.
214896820|NCT01949662|DRUG|Lorazepam|3 mg by vein one time only.
214896821|NCT01949662|DRUG|Placebo|Placebo consisting of preservative free 0.9% normal saline given one time by vein.
214669118|NCT02975349|DRUG|Placebo|Placebo were administered for 24 weeks in active treatment period.
214896822|NCT01949662|DRUG|Haloperidol decanoate|8 mg/day by vein.
214896823|NCT01949662|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
214896824|NCT07010562|DEVICE|Data collection|A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization. No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital. A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation.
214896825|NCT04891510|DEVICE|REVOLVE Advanced Adipose System|The REVOLVE system is an all-in-one fat processing device that harvests, filters, actively washes, and removes strands from lipoaspirate and allows for reinjection without any additional manipulation (REVOLVE 2020).
214896826|NCT04891510|DEVICE|LipoGrafter|The LipoGrafter system is designed to be a start-to-finish closed system with minimal processing of the lipoaspirate, minimizing the risk of contamination and fat cell damage (LipoGrafter 2020).
214896827|NCT04891510|PROCEDURE|Viality|The Viality system uses the AuraClens solution that acts as a surfactant to bring impurities like blood, free oil, and cellular debris into solution, where they can be flushed out through suction.
214896828|NCT05609981|OTHER|Clinical medication review focused on deprescribing|"A pharmacist-led intervention consisting of a clinical medication review with the focus on deprescribing in older patients using multidose drug dispensing (MDD) systems.~Pharmacist are trained in deprescribing and a developed toolbox to support the intervention is provided"
214896829|NCT07017777|BIOLOGICAL|PCV13i|3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)
214896830|NCT07017777|BIOLOGICAL|Prevnar 13|3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)
214896831|NCT05743257|BEHAVIORAL|Questionnaire|Each participant completes a questionnaire (online or paper version) about socio-demographic characteristics, health outcomes (general health, respiratory health, and weight status), physical activity and sedentary behaviors, perception of neighborhood characteristics, air quality, and noise exposure.
214896832|NCT05743257|BEHAVIORAL|Food diary supply|Sample of participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops. For each food purchase, participants provided details of date, place of purchase and foods purchased (name, quantity and expense incurred). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary.
214896833|NCT05743257|BEHAVIORAL|Interviews (semi-structured)|Sample of participants was interviewed about their food provisioning practice and living conditions.
214896834|NCT05743257|BEHAVIORAL|air and noise|Sample of participant were instructed to wear air and noise sensors to record their daily environmental exposure for 7 consecutive days, except for sleeping, bathing and performing activities in the water. Particulate matter concentrations, the temperature, and the relative humidity were measured - the nitrogen dioxide (NO2) and ozone (O3) concentrations were determined with data loggers that integrate reliable electrochemical gas sensors. Noise levels was measured using noise dosimeters. Sensors were accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
214896835|NCT07017140|DEVICE|Immersive Functional Virtual Reality Intervention using a Head-Mounted Display System for Spatial Neglect Rehabilitation|Participants receive 12 sessions (30 minutes each, 3 per week over 4 weeks) of immersive functional virtual reality (IFVR) using the KINESIX system, a CE-certified Class I head-mounted display device. The intervention targets visuospatial attention and upper limb function through progressively challenging, gamified exercises. All sessions are supervised by a physiotherapist or occupational therapist and delivered in a safe, controlled rehabilitation setting. Participants continue receiving usual care.
214896836|NCT07017244|DIETARY_SUPPLEMENT|Verum|1st cycle - 30 days continuous use Cycle 2 - 30-day washout
214896837|NCT07017244|DIETARY_SUPPLEMENT|Active comparator|1st cycle - 30 days continuous use Cycle 2 - 30-day washout
214896838|NCT07017322|DEVICE|Alpha-Stim AID|Subjects will receive non-invasive cranial electrotherapy stimulation (CES) treatment in 20-minute group sessions taking place immediately prior to breakfast, lunch, and dinner. This study uses the Alpha-Stim AID® CES device which will be set to the highest amplitude that is tolerated by the participant (with a minimum of 200 microampere (µA) and a maximum of 500 µA stimulation) at 0.5 hertz for a duration of 20 minutes per session, 3 sessions per day, for 3 separate days of stimulation (180 minutes of stimulation total).
214896841|NCT07017231|OTHER|histamine dihydrochloride|A small drop of histamine dihydrochloride (1%, in saline) will be applied to two previously determined areas followed by a prick through the drop.
214896842|NCT07017231|OTHER|Cowhage|Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.
214896843|NCT07017907|DEVICE|Heart rate-based AI software for detecting thyrotoxicosis|A software-based investigational medical device that uses artificial intelligence to detect the thyrotoxic state in patients with hyperthyroidism. The device analyzes resting heart rate data collected from wearable devices along with thyroid function test results (free T4 and TSH). The device is not FDA-approved and will be used solely for observational performance evaluation without influencing clinical care.
214896844|NCT07018128|OTHER|Study 2: deep breathing|Participants in the deep breathing group will be randomized to receive a diaphragmatic deep breathing program. They will be instructed to practice deep breathing at a rate of 6-10 breaths per minute for 15 minutes, twice daily, every day for a duration of 3 months.
214896845|NCT07018128|OTHER|Study 2: 4-7-8 breathing|Participants in the 4-7-8 breathing group will be randomized to receive a 4-7-8 breathing program. They will follow the 4-7-8 breathing training program, which involves inhaling for 4 seconds, holding the breath for 7 seconds, and exhaling for 8 seconds, counted as one cycle. This pattern is to be repeated for 6 cycles to complete one set. They will perform 12 sets per day-6 sets in the morning and 6 sets in the evening-with normal breathing between each set. This routine will be carried out daily for a duration of 3 months.
214896846|NCT07018128|OTHER|Study 2: slow breathing with device|Participants in the slow breathing with device group will be randomized to receive a slow breathing with device. They will undergo deep breathing training using a resistance-based breathing device called BreathMax, set at 25% of their maximal inspiratory pressure. The breathing rate will be 6 breaths per minute, continuously for 15 minutes, twice a day. This routine will be performed daily for a duration of 3 months.
214896847|NCT07017218|DIETARY_SUPPLEMENT|IMPACT|immune enhanced formula enriched in arginine, n-3 PUFA and nucleotide
215052254|NCT03653234|DEVICE|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
214896848|NCT07018349|DRUG|2.5% Oral minoxidil|AGA patients will be randomly allocated in both groups using the envelopes method to reduce the biasness. For 3-months, patients in Group-A will get 2.5mg of minoxidil once daily, while those in Group-B will receive 1mg of minoxidil once daily orally. After starting therapy, patients will be asked to come back for evaluations 3 months later. Safety, satisfaction, and the effects of the treatment will be reported. Final outcomes will be evaluated at 3 months post treatment.
214896849|NCT07018349|DRUG|1% Oral Minoxidil|Group-B will receive 1mg of minoxidil once daily orally
215052255|NCT06164964|DIAGNOSTIC_TEST|study of higher cognitive functions|"General objective: increase knowledge about neural correlates:~of the cognitive processing of stimuli of a social nature; of decision-making processes in the context of individual choice; of the influence of the social context on individual decision-making processes."
215052256|NCT01266278|OTHER|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
215052257|NCT01266278|OTHER|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
215052258|NCT01266278|OTHER|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
215052259|NCT04781556|OTHER|No intervention|All patients treated between 01/01/2017 and 12/31/2018 in the Fracture sector will be screened through the computerized medical file. For patients who meet all the eligibility criteria, the information note, study questionnaire and a stamped envelope will be sent to them by post. Without feedback from him within 30 days of this submission, the patient is considered not to have objected to the study. The patient's information as well as his non-objection will be recorded in his medical file.
215052260|NCT02334072|DEVICE|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
215052261|NCT02334072|DEVICE|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
215052262|NCT02334072|DEVICE|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
215052263|NCT02334072|DEVICE|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
215052264|NCT02334072|DEVICE|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
215052265|NCT05330936|COMBINATION_PRODUCT|Potent topical steroid|Cyanocobalamin in Avocado Oil Cream
215052266|NCT04072835|DRUG|Etripamil NS|Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
215052267|NCT04723355|DEVICE|An innovative 3-lead wireless water resistant Holter device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
215052268|NCT04723355|DEVICE|A conventional device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
215052269|NCT02786212|DRUG|Dexmedetomidine|
215052270|NCT02786212|DRUG|Normal Saline|
215052271|NCT03461562|OTHER|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
214896850|NCT07018141|OTHER|Bioactive Sealant with Etching: Participants in this group received a fluoride-releasing bioactive pit and fissure sealant (BeautiSealant, Shofu) applied after etching the tooth surface with 37% phosp|This group received BeautiSealant (a bioactive giomer-based sealant) applied after etching the enamel surface with 37% phosphoric acid for 15 seconds. The etching process creates micro-retentive patterns in the enamel to enhance micromechanical bonding, potentially improving the sealant's retention and wear resistance while also benefiting from the bioactive material's fluoride release and enamel remineralization properties.
214896851|NCT07018141|OTHER|Bioactive Sealant without Etching: In this group, the same bioactive sealant (BeautiSealant, Shofu) was applied directly without acid etching. This simplified technique evaluates the sealant's effecti|In this group, BeautiSealant was applied directly to the tooth surface without prior etching. The goal was to simplify the procedure by eliminating the etching step, relying instead on the sealant's chemical bonding and bioactive properties (such as fluoride release and S-PRG technology) to maintain retention and resist wear, while reducing the risk of enamel alteration and improving clinical efficiency.
214297858|NCT06012045|BEHAVIORAL|Enhanced Cue Exposure Therapy|The E-CET will consist of six weekly sessions and will be delivered by a clinical psychology trainee in person. Session #1 will be used to introduce to the participant the rationale and procedures of E-CET to establish therapeutic alliance, agreement on treatment goals and tasks, and to collect information on idiosyncratic CS-US expectancies to be targeted in exposures. Sessions #2 to #5 will be in vivo exposures. The interventionist will prompt the participant to evaluate the CS-US expectancy to facilitate the violation of the CS-US expectancy maintaining NEE. Between-session homework exposures will be planned and conducted by the participant in their naturalistic environment. They will also be reviewed at the beginning of the following session to consolidate learning. The final session will consist of consolidation of treatment gains and relapse prevention.
214478391|NCT04877444|DEVICE|Duck Duck Punch|"Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. The goal 'dose' of DDP will be 200 repetitions."
214478392|NCT04877444|BEHAVIORAL|Aerobic exercise|Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. The target intensity of aerobic exercise is 70% heart rate reserve. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
214478393|NCT04877444|BEHAVIORAL|Lower extremity stretching|Subjects will perform 15 minutes of lower extremity stretching. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
214478394|NCT05672368|DEVICE|Robot-Assisted Surgery|Undergo surgery using the da Vinci SP device
214669119|NCT02975349|DRUG|Tecfidera|Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period received Tecfidera 120 mg BID orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
214669120|NCT00165737|DRUG|Donepezil Hydrochloride|
214896852|NCT07018141|OTHER|Conventional Resin-Based Sealant with Etching (Control): This group received a conventional resin-based sealant (Fisseal, Promedica) following standard acid etching. This technique represents the trad|This group served as the control and received Fisseal (a conventional resin-based sealant) applied following standard etching with 37% phosphoric acid. This method is considered the gold standard for fissure sealing, offering strong micromechanical adhesion and proven wear resistance, making it a reliable benchmark for evaluating the performance of newer bioactive materials.
214896853|NCT07017894|COMBINATION_PRODUCT|Experimental: breast mask containing cabbage leaves extract group|apply breast mask to the breasts, avoiding the nipples, for 20 minutes, 2 times a day, for 3 days
214896854|NCT07017894|COMBINATION_PRODUCT|Sham Comparator|Apply a breast mask without cabbage leaves extract to the breasts, avoiding the nipples, for 20 minutes, 2 times a day, for 3 days.
214896855|NCT07017465|OTHER|Water melon (sugar baby)|Participants will consume a portion of watermelon Type A containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.
214896856|NCT07017465|OTHER|watermelon (Charleston gray)|Participants will consume a portion of watermelon Type B containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.
214896857|NCT07017465|OTHER|watermelon (Crimson sweet)|Participants will consume a portion of watermelon Type C containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.
214896858|NCT07017764|OTHER|Core stability exercises|Core stability exercises will be performed for 8 weeks, 3 times per week, 30 minutes per session. The program includes bed, wedge, and Swiss ball exercises. Bed exercises involve bridges, curl-ups, bird dog, and side bridges. Wedge exercises include curl-ups in various arm positions. Ball exercises involve bridges, curl-ups, bird dog, and push-ups. Each position is held for 7 seconds with 10 seconds of rest, repeated 10 times per set, for 2 sets per session with 60 seconds rest between sets.
214896859|NCT07017764|OTHER|Theraband resisted exercises|TheraBand resisted exercises will be performed for 8 weeks, 3 times per week, 30 minutes per session. Each session includes a 5-minute warm-up (stretching and joint mobilization), 30 minutes of resistance training for lower limbs (ankle, knee, hip), and a 5-minute cool-down with deep breathing and self-massage. Exercises include ankle flexion/extension, knee flexion/extension, and hip flexion/extension, abduction/adduction using elastic bands. Movements are done alternately on both sides, 10 reps each, 3 sets per session, with 1-2 min rest between sets. Yellow bands are used in weeks 1-4; green bands in weeks 5-8.
214896860|NCT07017764|OTHER|Traditional physical therapy program|All patients will receive a traditional physical therapy program consisting of ambulation training, stretching exercises for lower limb muscles, and range of motion exercises.
214896861|NCT07018648|DEVICE|Medical device|Adding Kardi Ai medical device for detection of heart rythm disorders
214896862|NCT07018206|DRUG|Upadacitinib 15 MG [Rinvoq]|15mg tablet once per day
214896863|NCT07017868|DIAGNOSTIC_TEST|interleukin- 17|focused on the importance of IL-17 in SLE, and its relation to different disease activity
215052272|NCT02342860|OTHER|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~* Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~* Software: operations and maintenance (O\&M) training for teachers, hygiene training, and basic hygiene package."
215052273|NCT04415294|DIAGNOSTIC_TEST|Critical flicker frequency|Measure the critical flicker frequency as a screening test for hepatic encephalopathy using a portable self administered device
215052274|NCT00841776|DRUG|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
215052275|NCT00841776|DRUG|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
214297859|NCT06012045|BEHAVIORAL|Behavioral Lifestyle Intervention|The BLI will consist of six weekly sessions of behavioral counselling integrating behavioral strategies for participants to make dietary changes. These behavioral strategies will include education about healthy and balanced diets, goal-setting, problem-solving, and relaxation. A manualized protocol developed by the PI's team for previous studies in the local community will be used.
214297860|NCT05681585|OTHER|Implementation support program|"The intervention consists of:~I Implementation strategies:~1.1 Ensuring leadership commitment 1.2 Responsive evaluation 1.3 Whole ward approach 1.4 Train the trainer model 1.5 Sustainability after the study~II Implementation interventions 2.1 Implementation team 2.2 ACP coordinator 2.3 Training and supervision: Kick-off, training of resource persons and health care personnel including practical exercises, network conferences 2.4 Toolkit and shared resources: ACP guideline, teaching material, information leaflets, documentation templates etc. 2.5 Structured fidelity measurements of the implementation level of a) the implementation interventions and b) the clinical intervention, with tailored feedback and supervision~III Clinical intervention: Advance Care Planning 3.1 Routine information and invitation to Advance Care Planning to all eligible patients 3.2 Written information to patients and relatives 3.3 Documentation and collaboration with other health care levels"
214297861|NCT02684760|DRUG|PF-06651600|PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
214297862|NCT06366321|OTHER|relining technique|construction of complete denture by flasking and casting the relining impression
214297863|NCT06366321|OTHER|CAD/CAM milling technique|construction of complete denture by milling of the scanned relining impression
214896864|NCT07018596|DEVICE|CellFX nsPFA Endocardial Ablation Catheter System|The CellFX nsPFA Endocardial Ablation Catheter System includes the nsPFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures to treat arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nanosecond pulses of electrical energy. nsPFA is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the cell's and internal organelles' ability to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).
214896865|NCT07016906|OTHER|MRI|Knee MRI at different degrees of flexion
214297864|NCT01812824|BEHAVIORAL|Intervention (Virtual Patient Advocate)|"Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week."
214297865|NCT02988921|DEVICE|MRI and CT|
214297866|NCT02988921|RADIATION|Ratiotherapy|
214297867|NCT02988921|DRUG|Paclitaxel, platinum-based drug|
214297868|NCT00705081|DRUG|ezetimibe|10 mg once daily
214297869|NCT00705081|DRUG|statin|
214297870|NCT01988792|DIETARY_SUPPLEMENT|Human milk fortifiers|
214297871|NCT01730157|BIOLOGICAL|ipilimumab|Given IV
214896866|NCT07017153|OTHER|Questionnaire B|Questionnaire regarding patient decision aid: How Do I Control My Blood Pressure? Lifestyle Options and Choices of Medicines.
214896867|NCT07017153|OTHER|Questionnaire A|Questionnaire regarding patient decision aid: Hypertension - How to Prevent Cardiovascular Diseases
214896868|NCT01622829|PROCEDURE|"Prescription for Activity and individual instructions"|"Structured education. Prescription for Activity. This contains an exercise programme which consists of a 30 minutes muscle strengthening exercises to be performed at home at least three times per week and an endurance sports, chosen by the patient, to be performed at least 2 times per week. Additional the physiotherapists advise them in being more active during their individual daily life ( e.g. using a bike for short distances, regular walking, abandon the lift/escalator)."
214896869|NCT01622829|OTHER|"Prescription for Activity, without instructions"|"Prescription with exercise programme. Prescription for activity. This contains an exercise program consisting of 30 minutes of muscle strengthening exercises to be performed at home at least three times per week, the patient also needs to perform in an endurance sport at least two times per week."
214896870|NCT01622829|OTHER|usual physiotherapy|physiotherapy, treatment as usual
214297872|NCT01730157|RADIATION|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
214297873|NCT01730157|OTHER|laboratory biomarker analysis|Correlative studies
214896871|NCT07018310|OTHER|blood sampling|Additional blood sampling as part of routine care
214297874|NCT00075140|GENETIC|Mutation in the gene|
214297875|NCT02456142|DRUG|caudal bupivacaine|
214297876|NCT02456142|DRUG|intravenous morphine|
214669121|NCT01497171|PROCEDURE|Elevate Mesh|Transvaginal mesh repair of anterior vaginal prolapse
214297877|NCT01382017|DRUG|Lacosamide|Lacosamide 200 or 400 mg
214297878|NCT01382017|DRUG|Placebo|Placebo
214297879|NCT01382017|DRUG|Carbamazepine|Carbamazepine 600 mg
214297880|NCT01879241|DRUG|Rasagiline|
214297881|NCT01879241|DRUG|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
214297882|NCT01369576|DRUG|Placebo|3.75-7.5mg 14 doses 4 weeks
214297883|NCT01369576|DRUG|Zopiclone|3.75-7.5mg 14 doses 4 weeks
214297884|NCT00009854|DRUG|carmustine in ethanol|
214297885|NCT00009854|PROCEDURE|conventional surgery|
214297886|NCT01375907|DRUG|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
214297887|NCT05284669|OTHER|Experimental e-learning|Interactive lecture based on the guidelines for the management of LBP with a focus on self-management and patient's reassurance
214297888|NCT05284669|OTHER|Traditional e-learning|Traditional lecture based on the guidelines for the management of LBP with a focus on diagnostic triage and specific cause of LBP
214297889|NCT04049968|DEVICE|Mobile health application (APP)|The mobile health application (APP) was applied to patients with oral cancer.
214297890|NCT04049968|OTHER|Routine health care and instruction|Traditional routine health care and instruction was applied to patients with oral cancer.
214297891|NCT03155074|BEHAVIORAL|High-intensity training|The exercise program will include a cardiovascular warm-up, high intensity interval training and progressive resistance training (PRT). The intervention will focus on high-intensity training, mainly by uphill walking on a treadmill at 80-95 % of the maximal heart rate and PRT in three series at 6-12 RM by leg press, chest press, back extension, seat row, and front raises. During the first four weeks, the patients will be introduced to the program while focusing on safety, techniques and familiarization. The endurance intensity and strength load will then continuously increase based on the patients' improvement, tolerance of dyspnea, and feelings of well-being or fatigue on each exercise day.
214297892|NCT00918658|OTHER|biologic sample preservation procedure|All specimens will be collected using the Pathology Residual Tissue Procurement.
214297893|NCT00918658|OTHER|immunologic technique|Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
214297894|NCT00918658|OTHER|laboratory biomarker analysis|Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
214297895|NCT06094673|OTHER|No intervention|No intervention
214297896|NCT02132767|DRUG|Amiodarone|"Amiodarone Initial Dose~* Oral: 400 mg po TID for 3 days is recommended~* For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~* Oral: at least 200 mg/day to be continued until 60 days after randomization~* If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
214478395|NCT05908409|DRUG|IDP-121|IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
214896872|NCT07016763|DIETARY_SUPPLEMENT|Oral fatty acid|Intervention therapy (treatment group) daily treated for 90 consecutive days by INCs (mometasone furoate; 1 puff in each nostril, twice a day) and oral supplementation of FAs (550 mg/tablet), vitamin B6 (0.21 mg/tablet), perilla frutescens (20 mg/tablet) and liquorice (200/mg/tablet) (2 tablets a day with meals)
214896873|NCT07016763|DRUG|Mometasone Furoate Nasal Spray (MFNS)|Standard therapy (control group) daily treated for 90 consecutive days by INCs (mometasone furoate; 1 puff in each nostril, twice a day) only
214896874|NCT06265389|DRUG|Pentoxifylline Oral Tablet|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
214896875|NCT01171729|BIOLOGICAL|Autologous dendritic cell|Autologous dendritic cells pulsed with prostate cancer antigen and KLH
214896876|NCT07034820|DIETARY_SUPPLEMENT|Nimsai Herbal|Oral Nimsai Herbal is a novel botanical formulation, administered as one 600 mg capsule per day for a duration of 10 consecutive days. It is specifically designed to target the underlying venous congestion hypothesized by the War-Drill Model, aiming to promote hemorrhoid regression and symptom resolution.
214896877|NCT07034820|DIETARY_SUPPLEMENT|Placebo|This intervention consisted of an oral placebo, formulated to be identical in appearance, taste, and packaging to Nimsai Herbal. It was administered as one capsule per day for 10 consecutive days to ensure blinding and serve as a control for comparison.
214896878|NCT07032402|BEHAVIORAL|Education and Counseling|Mothers who consent will have the ABÖS-M App installed on their smartphones and will create a personal login. Researchers will provide brief training on how to use the app. The intervention consists of four educational modules designed with individualized and gamified content. Mothers are expected to complete all modules within two weeks. The app monitors their progress and provides automated feedback based on their performance, encouraging mothers to review topics if needed. Weekly WhatsApp reminders will be sent to promote app engagement, and researchers will track login frequency and usage time. Mothers who fail to complete the modules within the specified timeframe will be excluded from the study. Participants will also be asked to fill out a daily care diary throughout the intervention period.
214896879|NCT07032402|OTHER|Standard Care|"After obtaining written and verbal consent, the ABÖS-M App will be installed on their smartphones, and researchers will provide face-to-face instructions on its basic use. Mothers in the control group will receive routine newborn care education provided by clinical nurses, which includes non-standardized safe sleep information typically given before hospital discharge. No structured or individualized training will be provided by the researchers during the study period. For one month, control group participants will have limited access to certain app features, including the About Us section, care diary, and assessment tools. Mothers will be asked to complete the care diary daily, and researchers will send regular reminders."
214896880|NCT07030907|BIOLOGICAL|OPB-101|An autologous mesothelin (MSLN) CAR T cell therapy with antigen-dependent expression of OUTSMART designed IL-2 cytokine
214896881|NCT00295425|DRUG|Cyclosporine A versus mycophenolate mofetil for psoriasis|
214297897|NCT02132767|PROCEDURE|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
214297898|NCT02132767|DRUG|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
214297899|NCT01431560|DEVICE|fixation of the ankle fracture (Solco )|fixation with metallic implant
214297900|NCT01431560|DEVICE|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
214297901|NCT05798429|OTHER|compassion education|6 weeks of compassion training
214478396|NCT06854029|DRUG|Cabotegravir Injection|Long-acting injection (LAI) Prep + X-RB treatment initiated in jail or prison.
214478397|NCT06854029|DRUG|Cabotegravir Pill|Oral PrEP + SL-B treatment initiated in jail or prison.
214478398|NCT06854029|DRUG|Buprenorphine injection|Long-acting injection (LAI) Prep + X-RB treatment initiated in jail or prison.
214478399|NCT06854029|DRUG|Buprenorphine Pill|Oral PrEP + SL-B treatment initiated in jail or prison.
214478400|NCT06810804|DRUG|NBQ72S|Patients will receive the study drug every 28 days
214478401|NCT06655818|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered.
214478402|NCT06655818|DRUG|Dostarlimab|Dostarlimab will be administered.
214297902|NCT02074631|DRUG|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
214297903|NCT02074631|DRUG|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
214297904|NCT00778700|OTHER|Placebo Cream|Cream with no active drug
214297905|NCT00778700|DRUG|Ruxolitinib Phosphate|Ruxolitinib phosphate cream
214297906|NCT03895281|DIAGNOSTIC_TEST|FilmArray Meningitis/Encephalitis (ME) Panel|The FilmArray ME pouch is a closed system disposable that houses all the chemistry required to isolate, amplify and detect nucleic acid from multiple meningitis and encephalitis pathogens within a single CSF specimen obtained from a lumbar puncture. The rigid plastic component (fitment) of the FilmArray ME pouch contains reagents in freeze-dried form. The flexible plastic portion of the pouch is divided into discrete segments (blisters) where the required chemical processes are carried out. The user of the FilmArray ME Panel loads the sample into the FilmArray ME pouch, places the pouch into the FilmArray instrument/Module, and starts the run. All other operations are automated.
214297907|NCT00816075|DRUG|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
214896882|NCT05850117|DRUG|esomeprazole, tripotassium dicitrate bismuthate, tetracycline and levofloxacin|Tetracycline combined with levofloxacin quadruple therapy
214896883|NCT05850117|DRUG|esomeprazole , tripotassium dicitrate bismuthate, tetracycline 500mg and metronidazole|standard tincture quadruple therapy
214896884|NCT05850117|DRUG|esomeprazole, tripotassium dicitrate bismuthate , amoxicillin and levofloxacin|amoxicillin combined with levofloxacin quadruple therapy
214896885|NCT06721871|DRUG|Crofelemer Powder for Oral Solution|Crofelemer Powder for Oral Solution
214896886|NCT06721871|DRUG|Placebo Powder for Oral Solution|Matching Placebo Powder for Oral Solution
214896887|NCT02665156|PROCEDURE|Intracorporeal stapled neobladder using robotic staplers|"Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana."
214896888|NCT04631354|DRUG|Radio-labelled S-770108|99mTc radio-labelled S-770108 supplied as a capsule containing 6 mg active pirfenidone for inhalation
214896889|NCT04631354|DEVICE|S-770108 Inhaler A1|Dry powder inhaler
214896890|NCT00729937|DRUG|Cephalexin|500 mg, four times per day.
214896891|NCT00729937|DRUG|Clindamycin|300 mg, four times per day.
214896892|NCT00729937|OTHER|Placebo|Placebo tablet administered orally.
214896893|NCT00729937|DRUG|Trimethoprim-sulfamethoxazole|4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
214896894|NCT04215237|DRUG|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg oral once a day
214669122|NCT01497171|PROCEDURE|Anterior Colporrhaphy|Traditional suture repair of anterior vaginal prolapse
214478403|NCT06811519|DIAGNOSTIC_TEST|Body Composition Analyzer (ACCUNIQ BC720)|Body Composition Analyzer (ACCUNIQ BC720)
214896895|NCT02287155|BEHAVIORAL|occupation based health promotion|"The description of the intervention is provided in the detailed description of the study."
214896896|NCT06121882|DEVICE|Microfragmented Adipose Tissue derived using the Lipogems® System|Intra-articular knee injection of Microfragmented Adipose Tissue (MFat) derived using the Lipogems® System.
214896897|NCT06121882|DRUG|Saline Injection|Intra-articular knee injection of saline
214896898|NCT04614753|OTHER|Dealcoholized Muscadine Wine|300 ml of Dealcoholized Muscadine Wine
214896899|NCT04614753|OTHER|Control Beverage|300ml of Sugar Water and Acid Content
214669123|NCT07026383|BEHAVIORAL|performance test|Injury risk was evaluated using the Lower Extremity Functional Test (LEFT), which involves eight agility drills performed consecutively on a diamond-shaped course without rest intervals. The test includes eight components-forward run, backward run, side shuffle, carioca, figure-eight run, 45-degree cuts, 90-degree cuts, and a counter vertical jump-along with the single-leg hop for distance, following a standardized testing protocol known to predict injury risk. Participants who took longer to complete the test were categorized into the high injury risk group, while those with shorter completion times were classified into the low injury risk group.
214896900|NCT05333731|DRUG|Oxytocin|In the two groups, if spontaneous labor does not occur after PROM, they all receive the oxytocin for up to 24h.
214896901|NCT03207386|BEHAVIORAL|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
214896902|NCT03939663|DRUG|misoprostol|misoprostol 2 tablets
214896903|NCT03939663|DRUG|Placebo|starch pills manufactured to mimic misoprostol 200 mg tablets
214896904|NCT05227963|OTHER|soft tissue mobilization|In this group, each participants received 45-minutes long session that includes 25-minutes of soft tissue mobilization and 20-minutes of neck isometric strengthening exercises. In each session, patient was seated on chair and sustained pressure, direct oscillation, perpendicular mobilization, parallel mobilization, and friction massage was applied on the neck musculature for a minute followed by a release for 30 seconds. This protocol was repeated three times in each session. Each session was repeated four-times a week for two-weeks (a total eight sessions).
214896905|NCT05227963|OTHER|neck isometric strengthening exercises|In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
214297908|NCT04152720|DEVICE|Foley catheter|"If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured."
214297909|NCT03716921|OTHER|Short antibiotics treatment|Patients randomized in this arm will pursue antibiotic administration until visit 3 weeks after D0
214297910|NCT04933942|DRUG|Lomustine|Oral administration of Lomustine
214297911|NCT04933942|DRUG|Romiplostim|Subcutaneous administration of Romiplostim
214297912|NCT05153044|OTHER|severe acute respiratory syndrome CoV-2 serology|diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.
214297913|NCT02573727|DRUG|Nor adrenaline + albumin|
214297914|NCT02573727|DRUG|Terlipressin + albumin|
214297915|NCT03863223|DRUG|Pyrotinib, Trastuzumab, Docetaxel|Pyrotinib 400mg orally daily until progressive disease
214297916|NCT03863223|DRUG|Placebo, Trastuzumab, Docetaxel|Placebo 400mg orally daily until progressive disease
214297917|NCT01230801|BIOLOGICAL|BMN 701|GILT-tagged recombinant human GAA
214297918|NCT01494480|PROCEDURE|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
214896906|NCT00243412|DRUG|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
214297919|NCT00789451|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
214297920|NCT03375801|OTHER|Decision Aid|This will be an online tool giving evidence based information and explanation on their options.
214297921|NCT05826886|BEHAVIORAL|Emotional Writing|Participants complete four 20-minute sessions of emotional writing (at home) on four consecutive days. Instructions are provided online before each writing session.
214297922|NCT03241355|DIETARY_SUPPLEMENT|prebiotic inulin-type fructan|
214297923|NCT03241355|DIETARY_SUPPLEMENT|Placebo maltodextrin|
214297924|NCT01570374|BEHAVIORAL|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
214297925|NCT04057014|DRUG|Amoxicillin|Antibiotic given at different dosages and durations.
214896907|NCT00243412|DRUG|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
214896908|NCT00243412|DRUG|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
214896909|NCT00243412|DRUG|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
214896910|NCT00243412|DRUG|Rituximab|500 mg or 1000 mg IV\*2.
214297926|NCT04057014|PROCEDURE|Tooth extraction|Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
214297927|NCT06146426|DIETARY_SUPPLEMENT|Early diet resumption|Resuming oral diet at pace started from 2 hours after extubation from ventilator.
214297928|NCT05081401|COMBINATION_PRODUCT|Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z|A-SOC: 4Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z/5Lfx(Mfx)+Cfz(Cs)+E+Z During the intensive phase: Bedaquiline(Linezolid);Levofloxacin(Moxifloxacin) All treatment is taken orally
214297929|NCT05081401|COMBINATION_PRODUCT|A1|9Bdq(6m)+Fq+Lzd+Cs+Cfz
214669124|NCT07032012|OTHER|control - anxiety evaluation before Pre-anesthetic|If allocated to the group control, the anxiety questionnaire will be applied, and then the pre-anesthetic evaluation will be conducted.
214896911|NCT06724718|OTHER|smartwatch|Patients in the smartwatch group will undergo rhythm monitoring with a smartwatch
214896912|NCT06724718|OTHER|ECG|Detected POAF episodes will be confirmed via a 12-lead ECG
214896913|NCT01673230|PROCEDURE|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
214297930|NCT05081401|COMBINATION_PRODUCT|A2a|9Bdq(6m)+Fq+Lzd(600mg)+Cs+Z
214297931|NCT05081401|COMBINATION_PRODUCT|A2b|9Bdq(6m)+Fq+Lzd(2m)+Cs+Z
214297932|NCT05081401|COMBINATION_PRODUCT|A2c|9Bdq(6m)+Fq+Lzd(600mg-300mg)+Cs+Z
214297933|NCT05081401|COMBINATION_PRODUCT|A3|9Bdq(6m)+Fq+Lzd+Cfz+Z
214297934|NCT05081401|COMBINATION_PRODUCT|A4|9Bdq(6m)+Fq+Cfz+Cs+Z
214297935|NCT05081401|COMBINATION_PRODUCT|A5|9Fq+Lzd+Cfz+Cs+Z
214297936|NCT05081401|COMBINATION_PRODUCT|B-SOC|6Bdq+Lzd+Cs+Cfz/14Lzd+Cfz+Cs
214297937|NCT05081401|COMBINATION_PRODUCT|B1|9Bdq(6m)+Lzd+Cs+Cfz+Z
214297938|NCT04195685|PROCEDURE|Neurofeedback (NFB)|Participants are seated in a comfortable chair and have common EEG electrodes with a pre-application of EEG adhesion conductive paste placed on scalp. The participant will receive coaching as they look at the game training screen and focus on the image. The game training screen provides almost instantaneous feedback (within 200 milliseconds) to participants about brain functioning. Twenty, one-hour, NFB training sessions will be provided by a trained NFB specialist over an 8-10-week period with up to 5-sessions but usually 3 sessions a week. The specific NFB special use system that will be used is the Cygnet NFB System from Bee Medic Corporation. The latest technological advances in this system has enabled training frequencies in the infra-low frequency range as well as in all other relevant frequency ranges which is a breakthrough capacity not available on any other NFB system. This will enable the individualized training to the person's brain training preference.
214297939|NCT03918590|DRUG|nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)|NSAID
214297940|NCT03918590|DRUG|Theratears tear drop, (Akron, Ann 111 Arbor, MI)|preservative-free Artificial Tears
214297941|NCT03918590|OTHER|patching|no drug/ patching
214896914|NCT06069167|OTHER|Collection of data related to bowel urgency|Data will be extracted from the patient's medical record and patients will be interviewed to collect data specific to the research
214896915|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
214896916|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.
214896917|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
214896918|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
214896919|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
214896920|NCT05256719|BIOLOGICAL|Placebo-1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
214896921|NCT05256719|BIOLOGICAL|Placebo-2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
214896922|NCT05256719|BIOLOGICAL|Placebo-5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
214896923|NCT05256719|BIOLOGICAL|Placebo-7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
214896924|NCT05256719|BIOLOGICAL|Placebo-10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
214896925|NCT06418516|DEVICE|Capsule-sponge|The capsule-sponge is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus.
214896926|NCT05597319|PROCEDURE|Liver resection|Liver resection, different kind of according to pathology
214896927|NCT03787134|BEHAVIORAL|working memory and attention|Behavioral tests of working memory and attention
214896928|NCT04065360|BEHAVIORAL|Group Cognitive behavioural family intervention (CBFI)|four-week, four-session CBT-based family intervention programme
214896929|NCT04065360|BEHAVIORAL|Usual group psychoeducation|Treatment as usual in the institution studied
214896930|NCT01082497|BEHAVIORAL|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
214896931|NCT05295576|PROCEDURE|non surgical periodontal therapy|Scaling and root planing
214896932|NCT01431365|BEHAVIORAL|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
214896933|NCT01431365|BEHAVIORAL|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
214896934|NCT01756430|DRUG|Carvedilol SR 32mg, QD|"* Carvedilol SR 32mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
214896935|NCT01756430|DRUG|Carvedilol SR 64mg, QD|"* Carvedilol SR 64mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
214896936|NCT01756430|DRUG|Carvedilol IR 25mg, QD|"* Carvedilol IR 25mg QD for 4 weeks~* With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks."
214896937|NCT01756430|DRUG|Carvedilol IR 25mg, BID|"* Carvedilol IR 25mg BID for 4 weeks~* With the others investigation product placebo 2 capsules QD for 4 weeks."
214896938|NCT00202930|DRUG|anti-CD20 (Rituximab)|4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
214896939|NCT03810040|DEVICE|140 microns denuding pipette|the degranulated needle size was 140 microns
214896940|NCT03810040|DEVICE|150 microns denuding pipette|the degranulated needle size was 150 microns
214297942|NCT05769543|PROCEDURE|WATSU application|20-minute application of WATSU
214896941|NCT00494962|DRUG|lecozotan SR|
214896942|NCT05101668|DEVICE|Intracranial Thrombosis Aspiration Catheter|Direct Aspiration
214896943|NCT05706584|OTHER|control grup (skills lab.) and experimental group (mateverse skill lab.)|The universe of the study consists of students (N: 190) who took a pediatric nursing course in the 3rd year of the Teaching Department at Istanbul Medipol University. The sample of the study will consist of the students who took the 3rd year child health and diseases nursing course in the nursing department, accepted the study, and met the study criteria. It will try to reach the universe where the sample selection of the research will not be made. With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group
214896944|NCT02586155|DRUG|Apabetalone|100 mg capsule
214896945|NCT02586155|DRUG|Placebo|Capsule manufactured to mimic RVX000222 100 mg capsule
214896946|NCT02586155|DRUG|Atorvastatin|High-Intensity Statin
214896947|NCT02586155|DRUG|Rosuvastatin|High-Intensity Statin
214896948|NCT00378144|DRUG|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime \[Paracetamol (500 mg) and Pseudoephedrine (30 mg)\]
214896949|NCT04779879|BIOLOGICAL|Sotrovimab (Gen1)|Participants will be randomized to receive an IV infusion of Sotrovimab Gen 1 material
214896950|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion or by IM injection
214896951|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion
214297943|NCT05769543|OTHER|Lecture|20-minute lecture on WATSU technique
214896952|NCT02716545|DEVICE|balloon assisted enteroscopy|Patients with recurrent bleeding (\>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
214297944|NCT02278198|DRUG|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
214297945|NCT06234007|DRUG|Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine|"Safety run-in phase: Fruquintinib 4mg/d, oral, once daily, continuous treatment for 2 weeks, 1 week off, q3w, 6 cycles; If the number of patients experiencing dose-limiting toxicity (DLT) was ≤1, the study would continue at that dose level. If the number of patients with DLTs was \>1, the dose of fruquintinib was decreased to 3mg/d, qd po, d1-14, q3w, and the dose expansion phase was continued；Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;~Dose expansion phase: Fruquintinib RP2D, qd po, d1-14, q3w, 6 cycles; Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;"
214297946|NCT00508625|DRUG|AMG 951 (rhApo2L/TRAIL)|AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
214297947|NCT00508625|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
214297948|NCT00508625|DRUG|Carboplatin|Standard platinum based chemotherapy
214297949|NCT00508625|DRUG|Paclitaxel|Standard taxane chemotherapy
214297950|NCT05443932|DRUG|Dapagliflozin|10mg Dapagliflozin daily for 8 weeks
214297951|NCT05443932|DRUG|Hydrochlorothiazide|50mg Hydrochlorothiazide daily for 8 weeks
214297952|NCT02348541|DEVICE|CollaGUARD|
214297953|NCT01744990|OTHER|Oral food challenges to multiple nuts|
214297954|NCT03121547|DRUG|Tapentadol 50 mg Oral Tablet|1 tablet administered
214297955|NCT03121547|DRUG|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|1 tablet administered
214297956|NCT03121547|DRUG|Placebo Oral Tablet|calcium tablet
214297957|NCT02614430|OTHER|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
214297958|NCT03129243|DIAGNOSTIC_TEST|Sperm DNA integrity by flow cytometry|flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.
214297959|NCT05589233|BIOLOGICAL|Vaccionation eighter started or full course|Vaccination against SARS-CoV-2 at any number of doses
214297960|NCT01270711|DRUG|Study Drug|non interventional study - usage as per usual care
214478404|NCT06813287|DIAGNOSTIC_TEST|Electroencephalography (EEG)|Recording of electrical activity in the brain
214478405|NCT06813287|DEVICE|Upper extremity robot|Used for training and objective assessment (kinematics)
214896953|NCT04296591|DIAGNOSTIC_TEST|fetal heart doppler findings|Doppler data of main pulmonary artery and right pulmonary artery, mitral valve e/a wave ratio and lamellar body count were determined as the main research parameters. In both groups, fetal thorax and heart circumference ratio, mitral e/a wave ratio, right pulmonary artery and main pulmonary doppler indexes (PI, RI, S / D, AT / ET) were evaluated before cesarean section.
214896954|NCT02072980|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses
214896955|NCT04253665|BEHAVIORAL|Nursing discharge teaching|Nurses will provide multimorbid seniors inpatients with teaching related to self-management to prepare them to be discharged home. The teaching delivery will be tailored to patients' activation level and priorities. The intervention begins by determining the level of activation at which patients are and identifying priorities to address related to patients' life situation. A Discharge Teaching Guide will be used by nurses to deliver the teaching and includes six domains of self-management. For each domain, nurses first report whether a priority has been identified and what intervention they have proposed to address it. Then for each domain, teaching objectives are described and differ according to the level of patient activation. These six domains of self-management are found in the patient-oriented discharge summary, which is a document for the patient that summarizes what has been addressed in discharge teaching.
214297961|NCT04463095|PROCEDURE|PER ORAL ENDOSCOPY MYOTOMY (POEM)|Peroral endoscopic myotomy (POEM)combines thelong-term efficacy of a myotomy with the benefits of an endoscopic, minimally invasive procedure.Other therapeutic options include endoscopic balloon dilatation and surgical myotomy. Endoscopic balloon dilatation is still widely performed because of its relative non-invasiveness and simplicity, but it has a relatively lower success rate and often requires multiple treatment sessions. Surgical myotomy has been thought to be the curative therapeutic choice for symptomatic achalasia. However, it requires skin incisions and additional anti-reflux surgical intervention.Unlike surgical myotomy, POEM preserves the anatomical integrity of the LES and possibly minimizes postoperative reflux.
214297962|NCT01166724|DRUG|Sirolimus|Tacrolimus to Sirolimus
214297963|NCT01166724|DRUG|Tacrolimus|dosage per trough level
214297964|NCT00383149|DRUG|Ixabepilone|Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.
214297965|NCT00383149|DRUG|Cetuximab|Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.
214297966|NCT04997785|PROCEDURE|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
214478406|NCT06811077|OTHER|individual coaching|in addition to group therapeutic education, the patient participates to individual coaching session and answers several Patient Reported Outcome to assess his wellbeing
214297967|NCT06020365|OTHER|sequential fecal microbiota transplant combined with small intestinal fluid transplant|for eligible patients, the investigator use rifaximin, three times daily, 0.4 g each time, lasting 6 days followed by fecal microbiota transplant combined with small intestinal fluid transplant for 6 days. These procedures were repeated every 28 days.
214669125|NCT07032012|OTHER|group intervention - anxiety evaluation after Pre-anesthetic|If allocated to the group intervention, the first contact of the participant with the interviewer will be on the eve of surgery, in the ward. At that moment, the pre-anesthetic evaluation will be conducted. The next day, upon admission to the preoperative room, the anxiety questionnaire will be applied.
214669126|NCT07031479|DRUG|Itopride HCI 50 mg|Enteral Itopride 50 mg enterally tid ac
214669127|NCT07031479|DRUG|Metoclopramide 10 mg ampoule|"Intravenous Metoclopramide (10 mg IV q 6 hours)~CrCl 15-60 ml/min: Metoclopramide 5 mg IV q 6 hours CrCl \<15 ml/min: Metoclopramide 5 mg IV q 12 hours Hepatic impairment/ cirrhosis: Metoclopramide 5 mg IV q 6 hours"
214669128|NCT07031713|BIOLOGICAL|CAR-T Therapy|CT1192 cells infusion
214896956|NCT04712279|DRUG|Ivermectin 0.6mg/kg/day|Use of ivermectin 0.6m/kg/day q.d.for 05 days
214669129|NCT07031466|OTHER|Retrospective analysis of assigned treatment|Retrospective analysis of assigned treatment will be performed
214896957|NCT04712279|DRUG|Ivermectin 1.0mg/kg/day|Ivermectin 1.0mg/kg/day q.d. for 05 days
214896958|NCT04712279|DRUG|Placebo|Placebo q.d.for 05 days
214896959|NCT04712279|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg/day q.d. for 05 days
214896960|NCT01313052|BEHAVIORAL|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
214896961|NCT01313052|BEHAVIORAL|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
214896962|NCT06077474|OTHER|Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)|Administer the DSM-5 PTSD-RI-5 scale in 155 patients with exposed to traumatic events.
214896963|NCT03000062|BEHAVIORAL|Intervention group|Please see the preceding section
214896964|NCT03833687|DEVICE|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride.
214896965|NCT04665986|DRUG|Navelbine|Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
214896966|NCT04665986|DRUG|Docetaxel|Docetaxel 90mg/m2 on day 1, every 3 weeks
214896967|NCT02624180|DRUG|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
214896968|NCT02624180|DRUG|Placebo|A substance containing no medication
214896969|NCT00266279|DRUG|Oxaliplatin, Capecitabine|"Agent, DOSE AND SCHEDULE (28-days cycle):~Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21"
214896970|NCT00664079|OTHER|Blood draws|17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
214896971|NCT02005380|OTHER|Text-based task|Participants are required to take text-based exercise.
214896972|NCT02005380|OTHER|Graphic-based Task|Participants are required to take the graphic-based exercise.
214896973|NCT01869933|DRUG|OC-10X|
214896974|NCT00542633|DRUG|VIAject™|Dosage as individually required
214896975|NCT00542633|DRUG|Regular Human Insulin|Dosage as individually required
214896976|NCT00238017|DRUG|amodiaquine-artesunate versus amodiaquine|
214896977|NCT00821743|DEVICE|Deep brain stimulation electrode|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
214896978|NCT01573585|BEHAVIORAL|Usual Care|The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.
214896979|NCT01573585|BEHAVIORAL|FAST protocol|The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
214896980|NCT03248115|DIETARY_SUPPLEMENT|Green tea and green coffee extract tablets|"1. Tablets: participants were required to take 6 green tea and 3 green coffee extract tablets daily for a period of 8 weeks. No tablets were taken during the last 4 weeks of the study. Randomly chosen tablets were analysed to quantify their polyphenol content.~2. Urine collections: Several urine collections were required during the supplementation period in order have sufficient time points to estimate the plateau of the concentration of green tea and coffee polyphenols excreted in the urine to then be able to determine their bioavailability. There was a total of five 24-hour urine collections (at week 0 -before supplementation-, 2, 4, 8, and 12 -4 weeks after finishing the supplementation period).~3. Completion of study documents: Participants were provided with urine collection sheets, polyphenol questionnaires, checklists to record polyphenol tablet intake, and detailed instructions."
214896981|NCT04873947|DEVICE|Pulse Oximeter|The investigational device will be placed on the finger of the left or right hand per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter.
214297968|NCT04251819|DRUG|Placebos|Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
214297969|NCT04251819|DRUG|Baclofen 5 mg|Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
214297970|NCT04251819|DRUG|Baclofen 10mg|Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
214297971|NCT03272490|PROCEDURE|Medartis|Surgery using the medartis implant
214669130|NCT07031466|OTHER|Quality of Life (SF-36)|The quality of life will be assessed using the SF-36 (Short-Form Health Subject Questionnaire).
214669131|NCT07031466|OTHER|Quality of Life (EQ-5D)|The quality of life will be assessed using the EQ-5D (European Quality of Life Questionnaire)
214669132|NCT07031466|OTHER|Hospital Anxiety and Depression (HADS)|Hospital Anxiety and Depression will be assessed using the HADS (Hospital Anxiety and Depression Scale)
214297972|NCT03272490|PROCEDURE|Synthes|Surgery using the Synthes implant
214297973|NCT04453033|DEVICE|Celeste Specialized Phototherapy Device|Ocular phototherapy light panel
214297974|NCT01979484|DRUG|PPI-668 capsule|
214297975|NCT01979484|DRUG|PPI-668 tablet|
214297976|NCT00453544|OTHER|Enhanced Consent Procedure|This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
214297977|NCT00453544|OTHER|Routine Consent Procedure|This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
214297978|NCT02457910|OTHER|Biomarker Analysis|Correlative studies
214297979|NCT02457910|DRUG|Enzalutamide|Given PO
214297980|NCT02457910|OTHER|Pharmacological Study|Correlative studies
214297981|NCT02457910|DRUG|Taselisib|Given PO
214297982|NCT05683054|BIOLOGICAL|Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels|In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).
214297983|NCT05683054|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
214297984|NCT05683054|OTHER|Dermatology Life Quality Index (DLQI)|The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
214297985|NCT05683054|OTHER|EQ-5D-5L questionnaire|The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
214297986|NCT05683054|PROCEDURE|Dried blood spot sampling|A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
214297987|NCT06477458|OTHER|Single inspiratory phase computed tomography.|Utilizing deep learning technology in conjunction with single inspiratory phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
214478407|NCT06811961|BEHAVIORAL|Exercise|Patients with lipedema will perform group exercises consisting of warm-up, loading and cool-down periods of 40-50 minutes, 2 days a week for 6 weeks, and strengthening exercises applied to the muscles around the hips and knee extensors with elastic resistance bands, determined according to the effort level perceived by the patient, 3 sets of 10 repetitions, 2 days a week for 6 weeks.
214896982|NCT01333592|DRUG|KAD-1229|
214297988|NCT06477458|OTHER|Respiratory dual-phase computed tomography.|Utilizing deep learning technology in conjunction with respiratory dual-phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
214297989|NCT03434054|DRUG|Losartan|blood pressure medication
214297990|NCT03434054|OTHER|Placebo|non-active sham intervention
214297991|NCT01331954|DEVICE|Ultrasonic ablation device|One or two HIFU procedures
214297992|NCT05076474|DRUG|Orlistat 60mg Cap|Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
214297993|NCT04304807|DRUG|Melatonin 20 mg|Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
214297994|NCT04304807|DRUG|Traditional antibiotic treatment|Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
214297995|NCT02223273|BEHAVIORAL|Multifaceted Strategy|"1. Simulation Based Team Training~2. Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~3. Reminders -~4. Check lists - decision support algorithm~5. Distribution of educational materials: guidelines and recommendations for best practices"
214297996|NCT03630003|DEVICE|MOCS|"The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform."
214297997|NCT03630003|OTHER|Post-use interview|The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
214896983|NCT00653627|BIOLOGICAL|BCG|Mycobacterium bovis Bacille Calmette-Guerin
214896984|NCT01296776|OTHER|wellness control group.|Light physical exercise and relaxation program once a week in blocks of 10 weeks with breaks of 10 weeks between the blocks. The low-intensity, low-volume program was designed to avoid impact on our endpoints.
214896985|NCT01296776|DEVICE|whole-body electromyostimulation|3 sessions of 18 min/14 (1,5 x week)days over 12 months. 10 low-intensity/low amplitude exercises with electromyostimulation equipment with 85 Hz with periods of 6 sec of current and 4 sec of rest.
214896986|NCT07084025|OTHER|Perceive, Recall, Plan and Perform-Intervention protocol (PRPP-I)|"delivered over a 4-week period, in 12 sessions (45/60 min, 3 days a week for 4 weeks) for all patients according to the PRPP-I protocol. The intervention will be carried out by a PRPP-certified occupational therapist working on a Master's degree.~It will consist of :~* Implementation of training in functional cognitive strategies and meta-prompts through performance in home activities,~* Repeated measurement of performance judgment criteria ;~* Assessment of cognitive strategies~* personalized implementation of the PRPP-I cognitive strategy training protocol.~* Collection of feasibility modalities when tracking the intervention (e.g., time, transport, etc.)."
214896987|NCT07086105|DRUG|Adze1.C|Conditionally replicative oncolytic adenovirus expressing CD40L, administered by intratumoural injection in dose escalation cohorts.
214896988|NCT01654692|DRUG|Ipilimumab and Fotemustine|Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
214896989|NCT01380600|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
214896990|NCT06904872|DRUG|Crofelemer Powder for Oral Solution|Crofelemer Powder for Oral Solution
214896991|NCT06904872|DRUG|Matched Placebo Powder for Oral Solution|Matched Placebo Powder for Oral Solution
214297998|NCT01096264|OTHER|SSI and SphygmoCor® evaluations|"* SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~* SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived."
214669133|NCT07031947|OTHER|Core stabilization exercise with telerehabilitation|In addition to a brochure containing patient education, showing the application method of core stabilization exercises, the number of sets and repetitions, the intervention group (G1) will receive a back school program in a total of 2 sessions of videoconference interviews, and the exercises will be explained to them, supported by visuals and videos. In addition, patients will be provided with the application that will be provided with your support, and will be provided with core stabilization exercises 3 times a week for 8 weeks.
214669134|NCT07031947|OTHER|Face-to-face core stabilization exercise|The control group (G2) will receive a brochure that includes patient education, showing the application method of core stabilization exercises, the number of sets and repetitions, as well as a face-to-face back school program in our hospital for a total of 2 sessions. The exercise program will be carried out face to face, 3 sessions per week for 8 weeks, at the Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, under the supervision of a physician, with each exercise session being in groups of 8 people.
214896992|NCT07096336|DIETARY_SUPPLEMENT|vitamin D3 capsule|Administration of vitamin D3 capsule 50,000 IU/week for 8 weeks
214896993|NCT07096284|DIAGNOSTIC_TEST|PvCO2-PaCO2/CaO2-CvO2 ratio|"Patients diagnosed with septic shock will undergo serial measurements of arterial and venous blood gas analyses, arterial lactate levels, and calculation of the Pv-aCO₂/Ca-vO₂ ratio at predefined time points: H0 (baseline), H2, H6, H12, and H24.~Calculation Formulas:~1. Arterial Oxygen Content (CaO₂):CaO2 = SaO2 × Hb × 1,34 + PaO2 × 0,0031~2. Venous Oxygen Content (CvO₂):CvO2 = SvO2 × Hb × 1,34 + PvO2 × 0,0031~3. Pv-aCO₂/Ca-vO₂ Ratio: P(v-a) CO2/C(a-v)O2=(PcvCO2-PaCO2)/(CaO2 -CcvO2)."
214669135|NCT07031128|DIETARY_SUPPLEMENT|Alpha-ketoglutarate|Alpha-ketoglutarate supplements
214896994|NCT07097675|BEHAVIORAL|Art Therapy|"Art Therapy Session Plan The sessions are designed to stimulate positive feelings, satisfaction, and calmness while reducing social isolation and fostering group connections. The focus will be on pleasant experiences and positive life moments, with an emphasis on identifying current strengths and capabilities. Every session begins with a sharing activity: Name three good things that happened this morning or Name three things you are grateful for today.~Session Structure:~Mood check-in → Warm-up task → Main task → Reflection → Mood check-out."
214896995|NCT07097207|COMBINATION_PRODUCT|CAR-T cell|Participants will receive lymphodepleting chemotherapy (FC regimen: Fludarabine + Cyclophosphamide) on Days -5, -4, and -3 relative to the planned CD19/CD20-CAR.p40-T or CD19-CAR.p40-T cell infusion. The CAR-T cell infusion will be administered 72 hours after the completion of the FC chemotherapy.
214896996|NCT07096778|DRUG|Inobrodib|40 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.
214896997|NCT07096778|DRUG|Pomalidomide|4 mg orally once daily on Day 1 to 21 of each 28-day cycle
214896998|NCT07096778|DRUG|Dexamethasone|40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle
214896999|NCT07097883|PROCEDURE|Percutaneous Nephrolithotomy|Patients underwent percutaneous nephrolithotomy (PCNL) for renal calculi \>2 cm.
214897000|NCT07097844|DRUG|0.8 mL/kg of 0.25% bupivacaine|0.8 mL/kg of 0.25% bupivacaine
214897001|NCT07095556|OTHER|Low-level laser therapy|"The low-level laser applications will be made on the same day as the standard of care treatment (day 1), and then day 3, and day 7 by a study team member who is trained in the use of the laser device.~The laser photobiostimulation will be applied using LightWalker® laser (FOTONA), with following settings, Nd:YAG laser 1064 nm, MSP modality (pulse duration), 0.5 W (power), 10 Hz (frequency), 1 min/ 1 cm2 spot using Genova handpiece from buccal, lingual, and occlusal aspects. The Genova handpiece will be placed 1 cm away from gingival tissue.~Participants and operators will wear glasses to protect their eyes from laser beam in all sessions."
214897002|NCT07095439|RADIATION|Total Neoadjuvant Treatment|Participants in this arm receive 4 cycles of induction chemotherapy CAPEOX (or 5 cycles of FOLFOX6), followed by short course radiotherapy (25 Gy in 5 fractions) delivered via IMRT technique ,then consolidation chemotherapy in the form of : 2 cycles of CAPOX (or, 4 cycles of FOLFOX6). Total mesorectal excision (TME) will be performed for non-metastatic patients within 8-12 weeks of the short course radiotherapy.
214897003|NCT07096466|OTHER|DHA stain|On day 1, the volar forearm test area will undergo DHA staining (250μl of 10% DHA solution applied under occlusion with Finn Chambers for 8 hours)
214897004|NCT07096466|OTHER|No DHA stain|On day 1, the volar forearm test area will not undergo DHA staining.
214897005|NCT07096466|OTHER|Cosmetic product application - forearm|The cosmetic product will be applied twice daily for two weeks to the volar forearm test area.
214897006|NCT07096466|OTHER|No cosmetic product application - forearm|The cosmetic product will not be applied for two weeks to the volar forearm test area.
214297999|NCT00438087|DRUG|methylprednisolone|methylprednisolone administrated intra and post operatively
214298000|NCT02315170|DEVICE|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
214298001|NCT02315170|DEVICE|standard lid speculum|standard wire lid speculum
214298002|NCT03721276|BEHAVIORAL|EQuIP (Empowering Queer Identities in Psychotherapy)|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
214897007|NCT07096466|OTHER|Cosmetic products application - face|For two weeks on the face (excluding eye area), a cleansing cosmetic product containing Mitopure will be applied twice daily, and the cosmetic test product (that is used on forearms) will be applied once daily.
214897008|NCT07097766|BEHAVIORAL|"HBM-Based Education and Motivational Interviewing"|This intervention consists of a structured 3-session educational program and motivational interviews based on the Health Belief Model (HBM). It aims to increase knowledge about HPV infection and improve HPV vaccination awareness among women aged 18-45.
214897009|NCT07096089|PROCEDURE|Conventional physical therapy program and Sling exercise therapy|The control group received a conventional physical therapy program in addition to sling exercise therapy (SET) for 60 minutes.
214897010|NCT07096089|PROCEDURE|Whole body vibration|The study group received the same selected conventional physical therapy program in addition to sling exercise therapy (SET) given to the control group (for 30 minutes) besides whole body vibration (WBV) (for 30 minutes).
214897011|NCT07096596|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
214897012|NCT07095335|OTHER|education intervention A-CHARM|Didactic education plus virtual simulation regarding discrimination in the hospital setting
214897013|NCT07094945|DRUG|Remimazolam|Remimazolam 0.3 mg/kg is slowly injected intravenously until loss of consciousness. Remimazolam 0.6-1.0 mg/kg·h is used for anesthesia maintenance.
214298003|NCT05604131|DRUG|Deferiprone Tablets|Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
214669136|NCT07031128|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
214897014|NCT07094945|DRUG|Propofol|Propofol 2 mg/kg is slowly injected intravenously until loss of consciousness. Remimazolam 4-12 mg/kg·h is used for anesthesia maintenance
214897015|NCT07095153|BEHAVIORAL|Neuroathletic Training (NAT)|The intervention group will undergo an 8-week Neuroathletic Training program, conducted three times a week. The program consists of exercises designed to enhance visual-motor coordination, reaction time, balance, and proprioception, integrated with classical judo training. Each session lasts approximately 20-25 minutes and includes 6 to 8 different exercises targeting cognitive and neuromotor skills.
214897016|NCT07095153|BEHAVIORAL|Routine Judo Training|The control group will continue with their usual judo training program, which follows the training plans and technical development programs set by the Turkish Judo Federation for athletes aged 10-18. This program focuses on maintaining and improving existing technical, tactical skills, physical conditioning, and sports culture without any additional neuroathletic training interventions.
214669137|NCT07031375|BEHAVIORAL|Social prescribing|This two-day family-centered forest therapy program incorporates the six core elements of Forest Therapy-plants, water, diet, psychology, climate, and exercise therapy-while integrating multi-sensory experiences and group interaction.
214669138|NCT07031323|BEHAVIORAL|OnTrackCF|OnTrackCF is a mHealth application co-developed with Upstream Dream. It is designed specifically to track and support adherence to CFTR modulator therapy. The app allows users to track their modulator intake and disease symptoms while supporting their adherence goals using Behavioral Change Techniques (BCTs) with empirical evidence of efficacy. The BCTs are administered primarily in the form of messages designed to deliver specific BCTs. The app sends up to 3 adherence support messages per day and provides detailed data to the user about their adherence levels, adherence goals, and disease symptoms. This process will continue until we reach an N=60 AWCF enrolled OR demonstrate that we have achieved 12 weeks of sustained user engagement with the app.
214669139|NCT07030790|DRUG|KLA480 injection|Subcutaneous injection，Single dose
214897017|NCT07097181|BEHAVIORAL|web-based sensory awareness training|"The girl in the intervention group of the study 4 weeks to inform students, raise awareness and provide sensory education. Sensory awareness training will be provided throughout. Presentations to inform during training will be done, then Graded Sensory Discrimination, Graded Motor Imagery (DMI) and a home exercise program, as well as a body awareness training program.~protocol will be applied."
214897018|NCT07095686|DRUG|nL-CHCHD-001|Personalized antisense oligonucleotide
214897019|NCT03065192|DRUG|VY-AADC01|Single dose, neurosurgically infused, bilaterally into the striatum.
214298004|NCT05604131|DRUG|Placebo|Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
214298005|NCT00450333|DRUG|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
214897020|NCT00955617|OTHER|Contrast-enhanced MRA - Imaging examination|Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
214298006|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
214298007|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
214298008|NCT00450333|DRUG|Dynepo|subcutaneous, Q2W for 24 weeks
214298009|NCT00616681|DRUG|Oxcarbazepine|
214298010|NCT00230230|DRUG|SCH 486757|
214298011|NCT03659305|BIOLOGICAL|RPH-001|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
214298012|NCT03659305|BIOLOGICAL|Avastin|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
214298013|NCT02469454|DRUG|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
214298014|NCT02469454|DRUG|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
214298015|NCT06296758|PROCEDURE|Regional anesthesia|ultrasound-guided suprainguinal fascia iliaca block with 40ml of ropivacaine local or ultrasound-guided femoral nerve block with 20ml of ropivacaine local anesthetic
214298016|NCT05429762|DRUG|Tusamitamab ravtansine|Pharmaceutical form: Concentrated solution for intravenous (IV) administration; Route of administration: IV infusion
214669140|NCT07030790|DRUG|Placebo|Subcutaneous injection，Single dose
214897021|NCT07097740|DEVICE|Polymer Prosthetic Heart Valve|Surgical implantation of polymer prosthetic valve.
214669141|NCT07030439|DRUG|Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd.|A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) in second intervention period (after washout period: at least 7 days)
214897022|NCT07095816|DRUG|Acetaminophen|A prospective randomized controlled trial was conducted involving pediatric patients with solid tumors. Participants who met the inclusion criteria were randomly assigned using a computer-generated random number table. The APAP group was administered acetaminophen orally at a dose of 10 mg/kg body weight 2 hours before the surgical procedure.
214897023|NCT07095816|DRUG|Sterilized water|The placebo group was administered 10 mg/kg of sterile water orally two hours before the surgical procedure.
214897024|NCT07095608|BEHAVIORAL|Pressure and stretch sensitivity testing|"We will measure pressure sensitivity by applying gradual pressure (50 kPa/s) at the site of testing using a digital pressure algometer. In healthy subjects, we will perform these measurements on the lateral tongue on the left and the right side. In cancer patients, we will first test on the unaffected contralateral matched site and then at the site of the cancer. We will define pressure sensitivity as the mean of three threshold measurements.~For measuring stretch sensitivity, we will use a visual analog scale (VAS) recording of pain scores associated with tongue stretching. Participants will be asked to perform tongue range of motions (ROM): protrusion, elevation, right and left lateralization, and rate sensitivity score on the VAS scale after holding the tongue in position for five seconds. We will define stretch sensitivity as the sum of VAS scores for protrusion, elevation, right and left lateralization."
214897025|NCT07097077|OTHER|Effect of targeted neuromotor training in patients undergoing ACL reconstruction on the volumetric activation of cerebral cortex regions during fMRI.|The effect of targeted neuromotor training in patients undergoing ACL reconstruction on the volumetric activation of cerebral cortex regions during fMRI. Differences in brain activation will be assessed between timepoint t0 (after ACL reconstruction surgery and before the start of training) and timepoint t1 (after completion of the training).
214897026|NCT07097051|OTHER|real tACS|Those who randomized into real tACS arm will receive ten-session of individually tailored tACS targeting peak alpha power for 20-minutes
214897027|NCT07097051|OTHER|sham tACS|Those who randomized into sham tACS arm will receive ten-session of active sham tACS intervention for 20-minutes
214897028|NCT06076733|DEVICE|high definition-transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
214897029|NCT06076733|DEVICE|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
214897030|NCT00003405|BIOLOGICAL|recombinant interferon alfa|
214897031|NCT00003405|DRUG|amifostine trihydrate|
214897032|NCT00003405|DRUG|bromodeoxyuridine|
214897033|NCT00003405|DRUG|cytarabine|
214897034|NCT00003405|DRUG|idarubicin|
214897035|NCT00003405|DRUG|idoxuridine|
214897036|NCT00003405|DRUG|isotretinoin|
214897037|NCT00003405|DRUG|mitoxantrone hydrochloride|
214897038|NCT03847857|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
214897039|NCT03847857|PROCEDURE|McKeown esophagectomy|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
214897040|NCT01110590|DRUG|BAY60-4552 + Vardenafil|Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil
214897041|NCT01110590|DRUG|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
214897042|NCT01110590|DRUG|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
214298017|NCT02941445|DRUG|sitagliptin and metformin|
214298018|NCT02941445|DRUG|Metformin|
214897043|NCT01110590|DRUG|Placebo|Placebo
214897044|NCT05718024|DRUG|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
214897045|NCT05718024|DRUG|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
214897046|NCT05971940|DRUG|Orforglipron|Administered orally.
214897047|NCT05971940|DRUG|Placebo|Administered orally
214897048|NCT05230862|DIETARY_SUPPLEMENT|Ladder Supplement|Caffeine 200mg L-Theanine 200mg L-Citrulline 6g Creatine 5g Beta-Alanine 1.6g Phosphatidylserine 100mg
214897049|NCT05230862|DIETARY_SUPPLEMENT|Placebo|Placebo
214897050|NCT05627193|OTHER|Teleclinic|Instead of visiting surgeon after travelling from far flung areas for a post surgery follow up appointment, the follow up visit will be done using telephone.
214897051|NCT05627193|OTHER|Physical Clinic|Patients will have to travel to come physically to hospital to meet the operating surgeon.
214897052|NCT03266640|DRUG|viral specific cytotoxic t-lymphocytes|CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.
214897053|NCT04571749|BEHAVIORAL|Customized handoff|A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
214897054|NCT06241729|OTHER|Algorithms to predict the probability of a primary refractory state|Follow-up of a cohort of patients with diffuse large-cell B lymphoma from 2024 using algorithms to predict the probability of a primary refractory state
214897055|NCT04462302|BEHAVIORAL|Internet-based pain coping skills program|The purpose of this study is to determine if an 8-session Internet-based pain management program can help you better manage your cancer-related pain.
214897056|NCT05721261|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.
214897057|NCT05721261|DEVICE|Sham Temporary Peripheral Nerve Stimulation System|Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
214897058|NCT04042753|DRUG|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks,
214897059|NCT04042753|DRUG|Nivolumab|Nivolumab 1 mg/kg every 3 weeks for 4 cycles
214897060|NCT04042753|DRUG|Nivolumab|Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first
214897061|NCT06754501|DRUG|Atezolizumab|Given by vein
214897062|NCT06754501|DRUG|Tiragolumab|Given by vein
214897063|NCT05775913|DEVICE|Tubal Selective Delivery System (TSDS)|A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.
214897064|NCT05996419|OTHER|DSB-I|Participant will receive text message every other day during active phase (30days) via ANNIE text messaging app related to the safety behaviors they identified prior to start.
214897065|NCT05030038|BIOLOGICAL|Fecal swab collection|Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab
214897066|NCT05030038|BIOLOGICAL|Blood samples|Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.
214897067|NCT06443164|BEHAVIORAL|Empowered Relief|Pain Management Course that has been used to treat pain in patients with different pain conditions.
214897068|NCT06443164|OTHER|Standard of Care|Gender Affirming surgery without any attention to pain conditions prior to surgery.
214897069|NCT06102590|OTHER|Individualized red blood cell transfusion strategy|Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%.
214897070|NCT06102590|OTHER|European guidelines red blood cell transfusion strategy|RBCT according to ESICM guidelines
214897071|NCT06197802|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 45 day and 6 month.
214897072|NCT06197802|BIOLOGICAL|Gardasil®9|Three doses administered intramuscularly at 0, 45 day and 6 month.
214897073|NCT06014086|DRUG|PH-762|PH-762 is a potent RNAi molecule targeting PD-1.
214897074|NCT05613985|OTHER|Usual Care alone|"Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) \[If, during the study, PEDIS is \< 2, the ulcer will be covered with nonadherent paraffin gauze\].~Treatment 2 times a week (4 treatment weeks, 8 treatments)."
214897075|NCT05613985|DEVICE|System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|"System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®)."
214897076|NCT03886584|OTHER|Monitoring source test|Internal- and external-monitoring correct responses and inversions
214298019|NCT01689701|DIETARY_SUPPLEMENT|Hizikia Fusiformis extract|Hizikia Fusiformis extract(1.3g/d)
214897077|NCT00070564|BIOLOGICAL|pegfilgrastim|Given IV
214897078|NCT00070564|DRUG|AC regimen|Given IV
214897079|NCT00070564|DRUG|cyclophosphamide|Given IV
214897080|NCT00070564|DRUG|doxorubicin hydrochloride|Given IV
214298020|NCT01689701|DIETARY_SUPPLEMENT|Placebo|Placebo(1.3g/d)
214298021|NCT05360576|DRUG|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|To prevent pregnancy
214298022|NCT05360576|DRUG|NuvaRing Vaginal Ring|To prevent pregnancy
214897081|NCT00070564|DRUG|paclitaxel|Given IV
214897082|NCT04515875|BEHAVIORAL|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
214897083|NCT04515875|BEHAVIORAL|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
214897084|NCT03175302|BEHAVIORAL|digital cognitive testing|The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
214298023|NCT06560762|DRUG|STM01|Neonatal mesenchymal stem cells (nMSCs),
214298024|NCT04925037|BEHAVIORAL|self-questionnaire to patients undergoing SpAax follow-up|On the occasion of a single visit in consultation or hospitalization, an anonymous self-questionnaire will be distributed to patients undergoing SpAax follow-up
214298025|NCT04235231|DEVICE|Bed tilting|15° lateral tilt, original product brand name LINET Eleganza 5
214298026|NCT04235231|OTHER|Body positioning|Manual positioning of body by nurse: left side, back, right side, using positioning pillows
214478408|NCT06811961|BEHAVIORAL|Physical activity|The control group will be given recommendations regarding lipedema and physical activity level.
214897085|NCT05689736|BEHAVIORAL|Motivational Enhancement|"Motivational Enhancements (ME) will include three features:~1. Personalized change plan. Parents will describe their intervention goals, motivation for participation, steps they are willing to take to meet those goals, as well as potential barriers to engagement and strategies to try to overcome such barriers. We will display the change plan to remind parents of their personalized responses. ME will also integrate participants' change plan responses into intervention content.~2. Assessment feedback. We will provide norm-referenced feedback for each selected parenting measure after the week 1 assessment. For simplicity, feedback will graphically categorize the parent or child in 3 categories per outcome: red (≥90th %ile), yellow (70-89th %ile), and green (\<70th %ile).~3. Modified, personalized SMS text nudges. Parents will receive 2 weekly personalized SMS messages based on their change plan responses."
214897086|NCT05689736|BEHAVIORAL|Simplification|We will follow recommendations of research on improving the readability of patient-directed text (e.g., fewer, shorter, less complex words, minimizing colons, semicolons, and decimal points). We will employ the Dale-Chall Readability (DCRI) score, which was developed for health education materials and, compared to other readability metrics, has higher correlations with comprehension. The target DCR score is 7 (8th grade reading level). We will avoid lower DCR scores because moderate levels of complexity enhance, attention, absorption, satisfaction, and ultimately engagement.
214897087|NCT05689736|BEHAVIORAL|Gamification|"Gamification will include four features:~1. Game-like graphical environment (e.g., avatars to represent the participant).~2. Digital rewards. Parents will receive points and badges for completing intervention activities.~3. Leaderboard. A leaderboard will be used to activate competitive motives and social referencing. The leaderboard will display the points/badges of the participant relative to 4 other actual or simulated anonymized parents who are at a similar point in the intervention; their number of points and badges will be determined by those of the participant.~4. Modified, personalized SMS text nudges. SMS text nudges will alternate between Core content (e.g., reminder to complete a module) and reminders about game features such as badges and standings."
214897088|NCT05689736|BEHAVIORAL|Low Engagement Nudges|SMS text nudges will be sent to participants who have fallen behind in completing specific intervention tasks within a given time window; e.g., failing to log-in to the next module by a predetermined date, timed to program enrollment or in a prespecified number of days since completing the previous module.
214897089|NCT05689736|BEHAVIORAL|Essentials for Parenting Toddlers and Pre-schoolers (EFP)|"All parents will receive the Core intervention content, including text, demonstrations (videos and vignettes), and interactive activities (e.g., skill-building), and comprising five modules: Communicating with Your Child; (2) Giving Directions; (3) Creating Structure; (4) Using Discipline and Consequences; and (5) Using Time-out. The Core intervention will be augmented with more prescriptive behavioral skills practice exercises and SMS text nudges to remind participants to complete intervention modules.~All conditions will be housed on Westat servers accessible through any device that can use the Internet, including computers, tablets, and smartphones. Westat has extensive technical capacities for web programming/hosting."
214897090|NCT03983512|DEVICE|PULSTA TPV System|PULSTA transcatheter pulmonary valve replacement.
214897091|NCT04812912|DIAGNOSTIC_TEST|Hormone biomarker analysis|For female patients, hormone biomarker analysis will be performed to measure: anti-Mullerian hormone (AMH), estradiol and FSH in the blood. In male patients, hormone biomarkers of testicular function and spermatogenesis will be monitored: testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH. Sperm analysis will also be performed in male patients to monitor changes in sperm count.
214897092|NCT04812912|BEHAVIORAL|QoL Questionnaires|All participants will respond to protocol questionnaires, which will include both validated questionnaires as well as non-validated ones. This design will allow for basic demographic, psychosocial and sexual-health-related data to be obtained.
214298027|NCT05116930|DRUG|Neostigmine|IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
214298028|NCT05116930|DRUG|Glycopyrrolate|IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
214298029|NCT03253250|DRUG|ETV；TDF；ADV|NAs
214298030|NCT03253250|DRUG|Peginterferon Alfa-2a|peginterferon
214478409|NCT06368947|BEHAVIORAL|Therapeutic Play|Therapeutic play sessions will be organized twice a week for 4 weeks during chemotherapy treatment for children diagnosed with acute lymphoblastic leukemia in the intervention group.
214478410|NCT05327647|DRUG|Bicalutamide|Induction intravesical BCG with bicalutamide 150 mg for 90 days
214478411|NCT05327647|BIOLOGICAL|Control Arm|Induction BCG
214478412|NCT06826053|OTHER|Therapeutic position|each newborn was given four different therapeutic positions in sequence.
214478413|NCT06826053|OTHER|Therapeutic position + smell breast milk|each newborn will be given four different therapeutic positions in sequence and will be made to smell the scent of breast milk.
214478414|NCT03492424|DEVICE|cryotherapy|Subjects will receive focal cryotherapy for treatment of prostate cancer
214478415|NCT05839509|DRUG|GH001|GH001 administered via inhalation
214478416|NCT06006585|DRUG|BI 771716|BI 771716
214478417|NCT04105114|DRUG|Buspirone|Oral Buspirone 7.5mg - 10mg daily during the treatment phase.
214478418|NCT04105114|DEVICE|Non-invasive Spinal Cord Stimulation|A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.
214478419|NCT04105114|DEVICE|Ekso Bionics Exoskeleton|This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.
214298031|NCT02375113|DIETARY_SUPPLEMENT|soy supplementation|"Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone."
214298032|NCT01948453|DIETARY_SUPPLEMENT|Garlic|Garlic tablet in adjunct to medical treatment
214298033|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
214897093|NCT05284721|BEHAVIORAL|Family Peer Navigator for Early Psychosis|The Family Peer Navigator model is theoretical underpinning by the Social-Ecological Model and the Social Cognitive Theory, that incorporates a mixture of evidence- and research-based strategies, to include three key components: 1) Introduction and Assessment; 2) Individual Psychoeducation; 3) Six Brief Check-In
214897094|NCT05284721|BEHAVIORAL|Care Coordination|active control, treatment as usual including services provided by the coordinated specialty care program for first-episode psychosis.
214897095|NCT05113316|BEHAVIORAL|Messy Memories App|"The Messy Memories mobile app is an intervention targeting stress-related problems based on practices with proven effectiveness, to overcome barriers and provide access to evidence-informed intervention strategies aimed to improve mental health in frontline healthcare workers.~The app allows the user to self-administer exposure therapy techniques outside of the traditional psychotherapy context. The Messy Memories app was initially released in a written form for self-help, but with widespread use of smartphones, a mobile application has the potential to further reduce barriers and increase access to care among frontline healthcare workers. The current study proposes to examine this newly developed application for usability and feasibility in a small sample of frontline healthcare workers (Phase I) and then test efficacy of the application in a larger-scale RCT (Phase II) where the application will be compared to a TAU condition."
215052276|NCT01921556|BEHAVIORAL|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
215052277|NCT03836872|DEVICE|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
215052278|NCT01453452|BEHAVIORAL|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be \< 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
215052279|NCT01453452|BEHAVIORAL|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
215052280|NCT01453452|OTHER|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
215052281|NCT01453452|PROCEDURE|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
215052282|NCT05369377|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
215052283|NCT05369377|DRUG|Eltrombopag|eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
215052284|NCT00003923|DRUG|porfimer sodium|
215052285|NCT04583436|DEVICE|Endovascular recanalization|Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
215052286|NCT04583436|OTHER|Open surgery|Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
215052287|NCT03281031|PROCEDURE|Additional MRI Examination|MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
215052288|NCT06154616|DIETARY_SUPPLEMENT|Control Product|Lactose-free skimmed milk
214298034|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
214298035|NCT00388271|DRUG|Alfuzosin (Xatral)|standard treatment plus alfuzosin
214298036|NCT00388271|DRUG|standard treatment|standard treatment
214298037|NCT04756791|PROCEDURE|SAPB|local anesthetic is injected between the serratus anterior and latissimus dorsi muscles.
214298038|NCT04756791|PROCEDURE|Local Injection Anesthesia|Anesthesia is injected directly into the tissue that is will be numbing.
214897096|NCT03159897|DRUG|Doxorubicin|Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
214298039|NCT03107754|DRUG|Lidocaine|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
214298040|NCT03107754|DRUG|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
214298041|NCT04918264|DRUG|Fluoropyrimidine treatment (5-FU or capecitabine) and dosage|In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
214298042|NCT04918264|OTHER|Uracil dosage|For each patient, uracil concentration will be evaluate and patients will be compared based on 16 ng/mL as threshold.
214298043|NCT04918264|BEHAVIORAL|Overall survival|For each group of patient, on 16 ng/mL as threshold for uracil concentration, overall survival will be compared betwen the two groups of patients (Uracil \<16 vs Uracil ≥16).
214669142|NCT07030439|DRUG|Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd.|A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) in second intervention period (after washout period: at least 7 days)
214897097|NCT03159897|DRUG|Bleomycin|Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
214897098|NCT03159897|DRUG|Vinblastine|Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
214897099|NCT03159897|DRUG|Dacarbazine|Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
214897100|NCT06504134|DIAGNOSTIC_TEST|the Novel Esophageal Cell Collection Device|Using the novel cell collection device and the deep learning method to collect and classify esophogeal cell to identify if the participants are GERD patients
214897101|NCT01977105|BEHAVIORAL|Grow Together peer group|"Participants in this intervention will:~* Participate in Facebook group of 6-10 peers for about 8 weeks, led by a professional group mentor.~* Complete an intervention video activity approximately weekly:~  * 1\. View educational videos addressing topics related to healthy infant growth~ * 2\. Create photos/videos modeling healthy behaviors and post them to the group~ * 3\. Provide and receive feedback on posts~ * 4\. Be encouraged to share information with key caregivers of their child~* Attend group party soon after enrollment, to meet peers and group leader in person.~* Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network.~* Have basic program information provided to pediatrician to enhance conversation during office visits."
214897102|NCT01491568|DEVICE|rhBMP-2/CRM/CD HORIZON® Spinal System|rhBMP-2/CRM with the CD HORIZON® SpinalSystem
214897103|NCT05231811|OTHER|massage|Pregnant women by the researcher; Foot massage consisting of classical massage techniques will be applied in a room in the clinic reserved for this application. During the massage; A pillow will be placed under the patient's leg and a disposable cover will be placed on the pillow. During the massage, pregnant women will be massaged with baby oil or vaseline cream. The soles of the pregnant women will be rubbed by the practitioner's fingers. The practitioner will make circular movements by applying pressure to the sole of the pregnant woman's feet with her thumb, and will apply pressure to the foot with up and down movements, using the joint protrusions on the upper surface of the hand that she has made into a fist. The heel and ankle will be squeezed between the thumb and forefinger of the researcher and kneaded and the massage will be terminated. During the application, the researcher who performs the massage will pay attention to the precautions applied in the hospital.
214897104|NCT03320343|OTHER|MRI|3D morphological MRI and diffusion tensor imaging
214897105|NCT03883997|OTHER|No intervention|Cross-sectional
214298044|NCT01721382|DRUG|Sitagliptin|
214298045|NCT02766725|DRUG|preparation F12 sildenafil in situ gel|in situ vaginal gel
214478420|NCT04105114|DEVICE|Gravity Neutral Device|This device is used to train and assess non-weight bearing stepping movements. When using the device, participants will be lying on their side with their legs suspended off the end of a table supported by small slings that are anchored securely to the apparatus.
214897106|NCT02064998|BEHAVIORAL|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
214897107|NCT02064998|BEHAVIORAL|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
214897108|NCT02064998|BEHAVIORAL|TeleCoach|Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
214897109|NCT02059512|PROCEDURE|Group 1|Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.
214897110|NCT02059512|PROCEDURE|Group 0|Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.
214298046|NCT02766725|DRUG|preparation F2 sildenafil in situ gel|in situ vaginal gel
214298047|NCT02766725|DRUG|placebo gel|vaginal gel
214298048|NCT00734903|BEHAVIORAL|A Woman's Path to Recovery|WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.
214669143|NCT07031622|OTHER|Yoga Exercises|The control and intervention groups received birth preparation training for 45 minutes one day a week for 5 weeks. The experimental group additionally received a total of 10 sessions of a yoga program for 45 minutes, 2 days a week. The content of each yoga session included 10 minutes of mindful breathing, 20 minutes of yoga asanas, and 15 minutes of meditation.
214897111|NCT02059512|PROCEDURE|Group 2|Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.
214897112|NCT01247584|GENETIC|DNA analysis|
214897113|NCT01247584|GENETIC|mutation analysis|
214897114|NCT01247584|GENETIC|polymerase chain reaction|
214897115|NCT01247584|OTHER|laboratory biomarker analysis|
214897116|NCT02581579|DIETARY_SUPPLEMENT|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14
214897117|NCT02581579|OTHER|Placebo|Placebo, 1 capsule per day during 14
215052289|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250|Lactose-free skimmed milk enriched with 250 mg aswaghanda
215052290|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250 + TRP|Lactose-free skimmed milk enriched with 250 mg aswaghanda and tryptophan
215052291|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 600|Lactose-free skimmed milk enriched with 600 mg aswaghanda
215052292|NCT02682459|DRUG|Lisinopril|
215052293|NCT04116593|BEHAVIORAL|Nutrition education|Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
215052294|NCT02402595|DRUG|AVP-923|
215052295|NCT02402595|DRUG|AVP-786|
215052296|NCT02402595|DRUG|Itraconazole|
215052297|NCT04982991|DRUG|RIPK1 inhibitor|Capsule Oral
215052298|NCT00977483|DRUG|Thioctic Acid|600mg tablet once daily 4 years double-blind treatment period
215052299|NCT00977483|DRUG|Placebo|1 tablet once daily 4 years double-blind treatment period
215052300|NCT00034021|DRUG|Ginkgo Biloba|
215052301|NCT00034021|BEHAVIORAL|Sex Therapy (genital focus)|
215052302|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
215052303|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
215052304|NCT00672594|DRUG|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
215052305|NCT04317235|DRUG|Ropivacaine 0.5% Injectable Solution|Is to put 3 ml or 5 ml and show the difference
215052306|NCT01306643|DRUG|Idelalisib|Tablet(s) administered orally twice daily
215052307|NCT05385211|OTHER|Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency|Blood samplings; Glucose monitoring; CFTR variants
215052308|NCT02981056|OTHER|Johnson's Baby Top-To-Toe Wash|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
215052309|NCT02981056|OTHER|Johnson's Baby Lotion|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
215052310|NCT02981056|OTHER|Water (in lieu of bathing products)|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
215052311|NCT01149330|DRUG|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
215052312|NCT03039387|DEVICE|anodal transcranial direct current stimulation|
214897118|NCT01114802|BEHAVIORAL|Project Onward website + social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
214897119|NCT01114802|BEHAVIORAL|Project Onward website|Access to an interactive website that provides 8 weeks of Internet-based cognitive behavioral therapy.
214897120|NCT02696668|OTHER|modified FaME|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.
215052313|NCT03039387|DEVICE|transcranial direct current stimulation (sham)|for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
215052314|NCT02071771|DEVICE|Nelfilcon A toric contact lenses|
215052315|NCT02071771|DEVICE|Etafilcon A toric contact lenses|
215052316|NCT04868383|BEHAVIORAL|Use of smart phone technology to support medication adherence and uptake|Use of smart phone technology to support medication adherence and uptake
215052317|NCT04523584|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will undergo MR imaging of the liver. Liver PDFF will be measured.
215052318|NCT04523584|DEVICE|Ultrasound Imaging|Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.
215052319|NCT02746406|DEVICE|Peritron+|Peritron+ device to measure intravesical pressure
215052320|NCT01450644|OTHER|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
215052321|NCT06133881|DRUG|prilocaine|intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
215052322|NCT06133881|DRUG|bupivacaine|intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
214298049|NCT00734903|BEHAVIORAL|12-Step Facilitation|12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
214298050|NCT03259204|DEVICE|Adjuvant IPC|This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
214669144|NCT06723561|DRUG|4.5mg daily dose of naltrexone|Study subjects will take a daily 4.5mg dose of naltrexone.
214669145|NCT06718751|DRUG|Tranexamic Acid 650 MG|PO administration of TXA tablet
214669146|NCT06718751|DRUG|Placebo|PO administration of placebo tablet
214669147|NCT06725290|DIAGNOSTIC_TEST|Ocular Surface Disease Index (OSDI) questionnaire|The OSDI is a validated, self-administered questionnaire for assessing the presence and severity of ocular surface disease symptoms. The OSDI questionnaire includes 12 questions about the respondent's past week experience with the ocular symptoms, vision-related function, and environmental triggers
214897121|NCT02696668|OTHER|Multisensory|"Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:~1. Limits of stability training with eyes open / eyes closed~2. Self induced movement strategies with eyes open / eyes closed~3. Gaze stability exercises in sitting / standing / walking~4. Sensory integration~5. Habituation exercises"
214897122|NCT03605121|PROCEDURE|cardiac surgery|The relationship between body mass index or waist circumference and clinical outcome in patients undergoing cardiac surgery will be assessed
214897123|NCT04576507|DRUG|Active Cannabis|2.98% THC:4.91% CBD cannabis.
214897124|NCT04576507|DRUG|Placebo Cannabis|\<0.01% THC:CBD cannabis.
214897125|NCT06155656|OTHER|Pea protein concentrate|Ingestion of a soup containing 25 g of protein from pea protein concentrate
214897126|NCT06155656|OTHER|Pea protein isolate|Ingestion of a soup containing 25 g of protein from pea protein isolate
214897127|NCT06155656|OTHER|Pea protein extrudate|Ingestion of a soup containing 25 g of protein from pea protein extrudate
214897128|NCT06155656|OTHER|Whey protein|Ingestion of a soup containing 25 g of protein from whey protein
215052323|NCT01516632|BEHAVIORAL|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
215052324|NCT02479880|DRUG|Tenofovir DF|300 mg tablet administered orally once daily for up to 96 weeks
215052325|NCT02479880|RADIATION|DEXA Scan|Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
215052326|NCT00700648|DRUG|insulin aspart|Intravenous NovoRapid dose \& frequency as decided by treating physician
215052327|NCT00355368|DRUG|Succinylcholine|1mg/kg iv
215052328|NCT00355368|DRUG|Rocuronium|0.6mg/kg iv
215052329|NCT01889108|BEHAVIORAL|SPEEDI|Behavior intervention combining parent education and physical therapy intervention for preterm infants
215052330|NCT03824951|BIOLOGICAL|Anti-CD19 iCAR NK Cells|Anti-CD19 iCAR NK Cells injection
215052331|NCT05066126|BEHAVIORAL|Mixed-Presentation of Content|Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
215052332|NCT06227533|PROCEDURE|Endodontic regeneration using concentrated growth factor compared with Platelet rich fibrin|regeneration of mature necrotic teeth with periapical abscess using concentrated growth factor compared with Platelet rich fibrin to allow healing of periapical lesion and regaining sensibility
215052333|NCT01323985|DRUG|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
215052334|NCT01323985|DRUG|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
215052335|NCT03091387|DIAGNOSTIC_TEST|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
215052336|NCT00843336|BEHAVIORAL|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
215052337|NCT00843336|BEHAVIORAL|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
215052338|NCT05801848|DIAGNOSTIC_TEST|[18F]NaF PET/CT scan|Patients will have their lower back scanned using \[18F\]NaF PET/CT
215052339|NCT02680340|PROCEDURE|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
215052340|NCT02897687|BEHAVIORAL|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
215052341|NCT02897687|BEHAVIORAL|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
215052342|NCT02307240|DRUG|CUDC-907|CUDC-907 oral with meals.
215052343|NCT02345616|DRUG|Nitric oxide|
215052344|NCT02471053|OTHER|Moderate Intensity Exercise|Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
215052345|NCT06524271|DIETARY_SUPPLEMENT|Fermented Soybean|Same as described earlier
215052346|NCT06524271|DIETARY_SUPPLEMENT|Supplement without fermented soybean|Same as described earlier
214298051|NCT06391151|OTHER|exposure: OSA resulting from chronic tonsillitis|exposure: OSA resulting from chronic tonsillitis
214298052|NCT01953120|DRUG|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
214298053|NCT04300114|DRUG|Fluzoparib|Fluzoparib capsules po. 150 mg twice daily
214298054|NCT04300114|DRUG|Placebo|Placebo capsules po. twice daily
214669148|NCT02258412|DRUG|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
214897129|NCT06637358|BEHAVIORAL|Extended Scheduled Gradual Reduction (SGR)|The extended SGR program will allow participants additional time to reduce smokeless tobacco use until they reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
214897130|NCT06637358|BEHAVIORAL|Quit Coach|Weekly check-ins and support will be given to this group via the quit coach interactions. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
214897131|NCT04470518|OTHER|diagnostic algorithm|"Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).~The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache \& Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor))."
214897132|NCT03848715|BIOLOGICAL|Endotoxin|Endotoxin
214897133|NCT03848715|BIOLOGICAL|Placebo|Placebo
214897134|NCT00338377|BIOLOGICAL|Dendritic Cell Immunization|1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
215052347|NCT05901571|OTHER|acupuncture|"The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation."
215052348|NCT05901571|OTHER|escitalopram|Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
215052349|NCT05901571|OTHER|sham-acupuncure|In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
215052350|NCT05901571|OTHER|escitalopram placebo|Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
214298055|NCT03760211|BEHAVIORAL|Multilevel Gaming Adherence Intervention|Combination of electronic medication monitoring device with Information-Motivation-Behavior based mobile gaming application tailored for those living with HIV and adherence-based text messages
214298056|NCT03760211|BEHAVIORAL|Treatment as Usual +|Combination of electronic medication monitoring device and non-HIV related mobile gaming application
214298057|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class II-IV|"New york Heart Association Class II-IV  study of markers"
214298058|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class I|New york Heart Association Class I
214298059|NCT03196934|DRUG|Cannabidiol oral solution|Cannabidiol; Pharmacological class of drug
214298060|NCT06095453|OTHER|Pain control regimens|Narcotics in cholecystectomy and hernia repairs
214298061|NCT04253145|DRUG|PM 01183|Lyophilisate for solution for infusion
214298062|NCT04253145|DRUG|Atezolizumab|Concentrate for solution for infusion
214298063|NCT01868685|DRUG|BYM338|BYM338
214298064|NCT01868685|DRUG|Placebo|Placebo
214298065|NCT05609240|DRUG|Cefuroxime|See arm/group description
214298066|NCT03403595|DRUG|177Lu-EB-PSMA-617|accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
214669149|NCT02258412|DRUG|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
214897135|NCT00338377|DRUG|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
214897136|NCT00338377|DRUG|Fludarabine|25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
214897137|NCT00338377|BIOLOGICAL|T-Cells|On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.
214897138|NCT00338377|BIOLOGICAL|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
214897139|NCT00338377|DRUG|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
214897140|NCT00338377|BIOLOGICAL|Intrathecal T-Cells|5.0x10\^9 T-cells administered on Day 1, and 10x10\^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
214897141|NCT00338377|BIOLOGICAL|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
214897142|NCT06109493|BEHAVIORAL|ACT|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
214897143|NCT05310747|BEHAVIORAL|Artwork present|A virtual museum exhibit with a curated selection of artworks
214897144|NCT05310747|BEHAVIORAL|Artwork absent|The same virtual museum exhibit space as the 'Artwork present' condition but with all of the artworks removed from the walls
214897145|NCT05310747|BEHAVIORAL|Social connection high|Participants will identify a person from their life that makes them feel socially connected and then write (1) about that person and (2) an experience they had with that person that made them feel socially connected.
214897146|NCT05310747|BEHAVIORAL|Social connection low|Participants will identify a person from their life that makes them feel socially disconnected and then write (1) about that person and (2) an experience they had with that person that made them feel socially disconnected.
214897147|NCT06166576|PROCEDURE|Ablative radioembolization|The interventional radiologist utilizes a pre-test with 99mTc-MAA SPECT-CT and cone-beam CT for procedural planning. For tumors confined to a single segment, the treatment area is planned to receive a radiation dose of over 400 Gy using the single-compartment MIRD technique. For tumors extending beyond a single segment, the multi-compartment MIRD technique is used to plan a radiation dose of 700 Gy (± 20%) to the tumor. The upper limit for the estimated lung dose is set at 25 Gy, and the upper limit for the perfused non-tumoral liver dose is 250 Gy. In cases where tumors extending beyond a single segment cannot receive the planned dose of 700 Gy (± 20%) due to limits on lung or normal liver dose, the plan is adjusted to deliver the maximum dose to the tumor within the permissible range for lung and normal liver doses. Radioembolization is typically performed in a single session, and any methods not mentioned here should follow the instructions for use of TheraSphere.
215052351|NCT06009822|OTHER|Postoperative outcome measurements|"Kinesiophobia; It will be assessed on the Tampa Kinesiophobia Scale. Function; Lysholm knee score, kujala knee score, single-leg hop test, Y balance test and single leg sway index will be evaluated.~Biodex Bio-balance system device will be used for single leg sway index."
215052352|NCT01195818|DRUG|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
214298067|NCT01347008|DRUG|Sildenafil citrate|Oral sildenafil citratre, 50mg b.i.d., 8 weeks
214298068|NCT01347008|DRUG|Placebo (Sugar pill)|Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
214669150|NCT06741111|OTHER|No treatment given|No treatment given
214897148|NCT03249831|DRUG|Cyclophosphamide|Orally daily
214897149|NCT03249831|DRUG|Pentostatin|Intravenous
214897150|NCT03249831|DRUG|Rabbit anti-thymocyte globulin|Intravenous
214897151|NCT03249831|DRUG|Tacrolimus|Initially IV. If patient tolerates, convert to oral.
214897152|NCT03249831|DRUG|Mycophenolate mofetil|IV or oral
214897153|NCT03249831|BIOLOGICAL|CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Infusion
214897154|NCT06102174|DRUG|Placebo|Placebo
214897155|NCT06102174|DRUG|Active|Sisunatovir
214897156|NCT06836440|DEVICE|Free Prescription Glasses|Participants can choose from a variety of frames, and the research team will customize the glasses according to their pupillary distance and prescription. Once the glasses are ready, they will be provided to the participants following standard usage instructions. In case of loss or damage, participants should report it to the project team and will be provided with replacement glasses as needed. Each year, participants in the intervention group will undergo an eye exam to assess changes in vision, and their glasses prescription will be updated if necessary.
214897157|NCT04982640|BEHAVIORAL|Iyengar yoga|60 minute group-classes of Iyengar yoga delivered twice weekly for 12 weeks
214897158|NCT04982640|BEHAVIORAL|Standard Exercise|60 minutes, twice weekly for 12 weeks, group-based walking program
214897159|NCT04982640|BEHAVIORAL|Nutrition Counseling|One, 30-minute session with registered dietitian
214298069|NCT00776958|OTHER|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
214298070|NCT05102799|OTHER|No intervention|No intervention
214298071|NCT05901168|OTHER|Active Video Games Intervention|Participants will complete active video games in the same order until they fill 20 minutes after the first 5 minutes of warm-up. In addition, during the change between games (lasting approximately 20 seconds), patients will be instructed by a therapist to perform combined exercises to minimize immobility time. These exercises are: elbow flexion and foot flexion, shoulder flexion and unilateral hip extension, and arm abduction and squat exercises that will prevent the patient from cooling down.
214298072|NCT05901168|OTHER|Traditional Exercise Intervention|"Active exercises for the upper extremities (without support): Shoulder flexion, Shoulder abduction, Elbow flexion at shoulder 90° flexion.~Active exercises for the lower extremities: Ankle-foot movements (ankle pumping exercise), heel raise, Knee extension in sitting high, Hip-knee flexion while lying supine~Body: Bridging, Trunk rotations in sitting~These exercises will be done in 1 set of 8-10 repetitions.~It will take about 20 minutes."
214298073|NCT03234192|PROCEDURE|Therapeutic ultra sound|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.
214298074|NCT03234192|PROCEDURE|Astym Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.
214298075|NCT03234192|PROCEDURE|Graston Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
214298076|NCT00277290|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
214298077|NCT00874965|DEVICE|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
214298078|NCT00874965|DEVICE|Sham stimulation|30 min; 5 times / week
214669151|NCT04015557|DRUG|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
214669152|NCT04015557|DRUG|N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
214298081|NCT02083952|OTHER|Swaddle Blanket|Two arms involve varying time spent in blanket
214298082|NCT05430737|RADIATION|stereotactic body radiotherapy|The radiation dose to the primary tumor was 40 or 45 Gy in five fractions according to the clinical determination of the radiologist. The dose to the positive lymph nodes and the prostate and seminal vesicles was 37.5Gy in five fraction. And internal iliac, external iliac, obturator, and presacral pelvic drainage regions received 25 Gy/5f, simultaneously. The treatment was delivered every other day. The volumetric modulated arc radiotherapy (VMAT) or intensity-modulated radiotherapy (IMRT) was used to complete treatment. Image-guided radiotherapy(IGRT) was performed for every treatment.
214298083|NCT01857232|DRUG|Ondansetron|5HT3-antagonist
214298084|NCT01857232|DRUG|Placebo|Comparator
214298085|NCT01857232|DRUG|Dexamethasone|Corticosteroid
214298086|NCT01857232|DRUG|Fosaprepitant|NK1 antagonist
214298087|NCT01857232|DRUG|APD403 IV|Amisulpride IV 20 mg
214298088|NCT01857232|DRUG|APD403 oral|Amisulpride oral 10, 20 or 40 mg
214298089|NCT00165347|DRUG|PTK787/ZK222584|
214298090|NCT02297074|OTHER|Ordinary white bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
214298091|NCT02297074|OTHER|Precooked-Frozen White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
214478421|NCT04105114|DEVICE|Body Weight Supported Treadmill Training|Participants will be supported by a special harness while they are stepping on a treadmill. Trained technicians or therapists will be assist the trunk and legs during stepping as needed.
214478422|NCT04105114|DEVICE|Rolling Walker|A standard rolling walker will be used for balance support and stability during stepping overground.
214478423|NCT04640779|DRUG|Choline Salicylate|Given PO
214478424|NCT04640779|DRUG|Selinexor|Given PO
214478425|NCT02800512|PROCEDURE|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
214478426|NCT02800512|PROCEDURE|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
214897160|NCT05505565|DEVICE|Abbott Freestyle Libre 2|Subjects will be educated on use of Abbott Freestyle Libre 2 and educated on how daily activities impact glucose.
214298092|NCT02297074|OTHER|Candeal-flour White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
214298093|NCT02297074|OTHER|Alfacar White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
214298094|NCT02297074|OTHER|Wholemeal Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
214298095|NCT02297074|OTHER|Glucose|50 g of glucose were administered as a reference
214298096|NCT01784640|DRUG|Hsp90 inhibitor AUY922|Given IV
214669153|NCT03497689|DRUG|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)
214669154|NCT00813228|DRUG|Sitagliptin (Januvia)|
214669155|NCT05911022|DRUG|Colchicine 0.5 MG|three times per day for three days and subsequently twice per day for four days
214669156|NCT05911022|DIETARY_SUPPLEMENT|Probiotic Formula|oral sachets once daily for two weeks
214897161|NCT05505565|OTHER|Standard physical activity and nutritional counseling for prediabetes management|Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.
214897162|NCT05453578|OTHER|Placebo|0.9 percent sodium chloride
214897163|NCT05453578|BIOLOGICAL|WRAIR-PAM-CF1|Bacteriophage combination composed of the following phages: PaWRA01Phi11, PaWRA01Phi39, PaWRA02Phi83, and PaWRA02Phi87.
214897164|NCT05209620|DRUG|ICP-022|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
214897165|NCT05209620|DRUG|Pemetrexed|Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
214298097|NCT01784640|DRUG|pemetrexed disodium|Given IV
214298098|NCT01784640|OTHER|pharmacological study|Correlative studies
214298099|NCT01784640|OTHER|laboratory biomarker analysis|Correlative studies
214298100|NCT04489329|DEVICE|Ingestible Capsule|Participants will swallow capsule and undergo X-rays to establish transit
214298101|NCT04489329|DIETARY_SUPPLEMENT|Probiotic|Participants will swallow a probiotic capsule and the sample collection capsule at the same time to establish concentration of strain in small intestine.
214298102|NCT02323477|BIOLOGICAL|stem cell transplantation|Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
214478427|NCT05003245|DRUG|HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL solution at a 4-week interval for intravitreal injection
214478428|NCT05003245|DRUG|Lucentis|0.05mL solution at a 4-week interval for intravitreal injection
214478429|NCT05597267|DEVICE|MIRIA Laser|4-6 experimental treatments at 4-6 weeks intervals
214669157|NCT05911022|OTHER|Standard protocol|the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks
214669158|NCT03191786|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered via IV infusion once every three weeks (QW3).
214669159|NCT03191786|DRUG|Vinorelbine|Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
214669160|NCT03191786|DRUG|Gemcitabine|Gemcitabine will be administered per relevant local guidelines and SmPC management.
214669161|NCT05706129|DRUG|[68Ga]Ga-DPI-4452|\[68Ga\]Ga-DPI-4452, administered as IV injection.
214669162|NCT05706129|DRUG|[177Lu]Lu-DPI-4452|\[177Lu\]Lu-DPI-4452, administered as IV infusion.
214669163|NCT00528229|RADIATION|Computer Tomography|
214669164|NCT00001269|DRUG|IL-3|
214669165|NCT00830830|DRUG|Hyalgan (sodium hyaluronate)|
214669166|NCT00803088|DEVICE|The Alair System|Treatment of airways with the Alair System
214897166|NCT04569318|DEVICE|Treatment Beam|One of the subject's eyes will be treated with the treatment beam (20mW) up to 8 times for 15 minutes.
214897167|NCT04825834|OTHER|Blood Sample Collection|Subjects enrolled in the DELFI-L101 will have blood specimens collected (\~40 mL) at enrollment.
214897168|NCT06773910|DRUG|BMS-986489|BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.
214897169|NCT06773910|DRUG|Durvalumab|Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.
214897170|NCT05201287|OTHER|VIA Disc NP|VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
215052353|NCT02257749|OTHER|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
215052354|NCT02257749|OTHER|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
215052355|NCT03202433|DEVICE|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
215052356|NCT06266026|DIAGNOSTIC_TEST|ThermoBreast - AI-based evaluation of dynamic breast thermography imaging|"Index test: AI-based evaluation of dynamic breast thermography imaging (ThermoBreast). The ThermoBreast evaluation will be performed independently of the routine breast cancer diagnostic evaluation. Some baseline risk variables (e.g. patient age, hormonal status) may be included in the ThermoBreast evaluation.~Reference test: Routine breast diagnostics will serve as a reference test against which the ThermoBreast outcome will be compared. Depending on national guidelines and clinical scenarios, routine breast cancer diagnostics can consist of several routine procedures, including clinical examination, ultrasound, mammography, tomosynthesis, MRI, follow-up imaging, biopsy, surgical excision, and histopathologic evaluation. All procedures will be performed as indicated and specified by the respective, current national guidelines."
215052357|NCT01861561|DRUG|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
215052358|NCT01861561|DRUG|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
215052359|NCT04384471|OTHER|Online survey|Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
215052360|NCT00355355|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
215052361|NCT00355355|DEVICE|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
215052362|NCT00355355|PROCEDURE|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
215052363|NCT00355355|PROCEDURE|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
215052364|NCT03578107|BEHAVIORAL|improvement of quality of stroke care|"1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams"
215052365|NCT00034671|DRUG|Posaconazole oral suspension|
215052366|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess myofibrillar protein synthesis rates|Amino acid dose = 0.25g/kg bodyweight
215052367|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance|Amino acid dose = 0.25g/kg bodyweight
215052368|NCT01864265|DRUG|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
215052369|NCT01864265|DRUG|Placebo|Placebo will be administered according to the label of the biological
215052370|NCT03263325|OTHER|Discarded urine sample|Collection of discarded urine during surgery and following surgery
215052371|NCT01411423|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
215052372|NCT05276128|DIETARY_SUPPLEMENT|lipids|Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
214478430|NCT06167655|DEVICE|Neurostimulator|Neurostimulation system that applies stimulation to nerve pathways in the head associated with migraine symptoms.
215052373|NCT04455828|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.
215052374|NCT04293276|DRUG|Pyrotinib|Pyrotinib Tablets
215052375|NCT04293276|DRUG|SHR6390|SHR6390 Tablets
215052376|NCT01349673|DRUG|Budesonide Foam|Topical
215052377|NCT02479958|PROCEDURE|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
215052378|NCT02479958|PROCEDURE|Tooth drying|The tooth was dried with air jet.
215052379|NCT02479958|PROCEDURE|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
214298103|NCT01286181|BEHAVIORAL|Twice daily practice of device-guided slow breathing.|Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
214897171|NCT01749826|DRUG|Morphine Sulfate|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
214897172|NCT05631717|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (1 × 10 \^6 cells / kg body weight, suspended in 30ml saline), intravenous drip once.
215052380|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
215052381|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
214298104|NCT04334720|OTHER|Comprehensive treatment of tumor|According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
214478431|NCT05586308|BEHAVIORAL|Text-massaging suport|Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
214897173|NCT05631717|DRUG|Interleukin-2|IL-2 (1×10\^6IU) will be injected subcutaneously every other day for 2 weeks (7 times), with an interval of 2 weeks. 4 weeks is a cycle, and three cycles were continuously treated for 12 weeks.
214897174|NCT03261778|DEVICE|Acromion 2.0 Brace|Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
214897175|NCT03699618|DRUG|Anti-VEGF|Standard of care treatment with anti-VEGF only
214897176|NCT03699618|OTHER|Hemorrhage displacement + Anti-VEGF|Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections
214897177|NCT00386451|DEVICE|Catheter locking systems|
215052382|NCT03234647|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in AHF patients.
215052383|NCT04507048|OTHER|Active educational intervention|an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.
215052384|NCT04507048|OTHER|Passive educational intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
215052385|NCT00094562|DRUG|Fish oil supplement|
214669167|NCT02896140|OTHER|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
214897178|NCT05659563|DRUG|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
214897179|NCT05659563|DRUG|Tamoxifen|Tamoxifen is a selective estrogen receptor (ER) modulator
215052386|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
214897180|NCT05494502|PROCEDURE|Erector spinae plane block|Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
214897181|NCT05494502|PROCEDURE|Control group|General anesthesia alone.
214897182|NCT06406439|DEVICE|Smart Insulin Pen|During the 12-week, for basal insulin, the treatment group will input and inject the dosage using the DIA:CONN P8, using only the insulin injection and injection recording functions, same as the blind CGM period. For bolus insulin, when the carbohydrate counting is entered or the type of meal is selected into the DIA:CONN P8 application, the insulin dosage is automatically calculated and set using the entered information and other indicators. Subjects inject the insulin at that calculated dosage using the DIA:CONN P8.
214897183|NCT06406439|DEVICE|Injection of bolus insulin via conventional therapy using insulin pen|During the 12-week, the control group will use DIA:CONN P8 to manually input and inject the dosage of both basal and bolus insulin, only using the insulin injection and injection recording functions, same as the blind CGM period.
214478432|NCT05586308|BEHAVIORAL|Financial incentive|"1. Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~2. Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~3. A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample"
214669168|NCT04050748|PROCEDURE|Achilles tendon repair|Patients will be undergoing achilles tendon repair
214669169|NCT03177252|DRUG|Lidocaine|-2% lidocaine will be given
214669170|NCT03177252|DRUG|Sodium chloride|-Normal saline will be given
215052387|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
215052388|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
215052389|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
215052390|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
215052391|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
215052392|NCT04190680|BEHAVIORAL|Kokkerelli Learning Street|"The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~1. An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~2. A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~3. A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~4. An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher."
215052393|NCT01810900|DEVICE|Protescal|
215052394|NCT03067402|OTHER|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
215052395|NCT03067402|DIAGNOSTIC_TEST|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
215052396|NCT00447798|BEHAVIORAL|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building \& strengths based case management
215052397|NCT00412191|DRUG|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
215052398|NCT01590368|DEVICE|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
215052399|NCT01590368|DEVICE|"Modified test electrode"|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
215052400|NCT00268281|DEVICE|Left Ventricular Capture Management Software|
215052401|NCT00348946|DRUG|androgen oxandrolone|Oxandrolone ,06 \>mg/kg/day, orally, for 2 years
215052402|NCT00348946|OTHER|placebo|an inactive substance
215052403|NCT06301646|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
215052404|NCT06301646|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
215052405|NCT06301646|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214669171|NCT03177252|DRUG|Bupivacaine|-0.5% bupivacaine will be given
214669172|NCT02082184|DEVICE|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
214669173|NCT02082184|DEVICE|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
214669174|NCT05879939|PROCEDURE|Transcutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
214897184|NCT04482348|OTHER|Explanation|Explanation provided to patients for more pain than expected
214897185|NCT02721732|OTHER|Laboratory Biomarker Analysis|Correlative studies
214897186|NCT02721732|BIOLOGICAL|Pembrolizumab|Given IV
214897187|NCT02721732|OTHER|Questionnaire Administration|Ancillary studies
214897188|NCT05953766|DRUG|Ropivacaine injection|Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml
214897189|NCT05953766|DRUG|Normal saline injection|Sham block using 20 mL of normal saline (0.9% sodium chloride)
215052406|NCT03688919|BEHAVIORAL|Self-Regulation Intervention|The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
215052407|NCT01533441|DIETARY_SUPPLEMENT|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
215052408|NCT02943317|DRUG|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
215052409|NCT02943317|DRUG|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
215052410|NCT04873440|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg/d twice a week
215052411|NCT04873440|RADIATION|Radiotherapy|Measurable lesions were targeted for radiotherapy at the discretion of the treating physician.Standard-of-care radiotherapy or SBRT were both allowed.
215052412|NCT04873440|DRUG|Chemo-immunotherapy|The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
215052413|NCT05862974|DRUG|LPM3480392|Intravenous infusion of 30min duration
215052414|NCT05862974|DRUG|Placebo|Intravenous infusion of 30min duration
215052415|NCT03922464|DEVICE|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV-associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
215052416|NCT00143559|DRUG|Systematic chemotherapy and antibodies|"Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD"
215052417|NCT00143559|PROCEDURE|Allogeneic stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
214897190|NCT04964206|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed according to the routine practice of each study center.
214897191|NCT04964206|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
214897192|NCT05280184|BEHAVIORAL|Coin2Dose|Behavioral Economics incentive intervention that also combines automated text message reminders to dose for insulin
214897193|NCT06583655|RADIATION|SLND(clinical low risk)|treated with whole breast irradiation(WBI)alone 50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx or no PMRT
214298105|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
214298106|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
214298107|NCT00895323|OTHER|enzyme-linked immunosorbent assay|
214298108|NCT00895323|OTHER|pharmacological study|
214298109|NCT00895323|PROCEDURE|whole-body scintigraphy|
214298110|NCT00895323|RADIATION|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
214298111|NCT02055690|DRUG|Pazopanib|Tyrosine Kinase Inhibitor
214298112|NCT02055690|DRUG|Fosbretabulin|Vascular Disrupting Agent
214897194|NCT06583655|RADIATION|SLND(clinical high risk, genomic low risk)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
215052418|NCT00143559|DEVICE|Miltenyi CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
215052419|NCT04588636|BEHAVIORAL|behavioral and self-care therapy|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
215052420|NCT04588636|DEVICE|rigid occlusal splint (ROS)|Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
215052421|NCT04588636|DEVICE|soft occlusal splint (SOS)|Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
215052422|NCT04588636|DEVICE|non-occlusive splint (NOS)|non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
215052423|NCT03975153|BIOLOGICAL|guselkumab|Treatment at the FDA-approved psoriasis dosing for 20 weeks
215052424|NCT01285024|DEVICE|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
215052425|NCT06004297|PROCEDURE|ACL reconstruction|performed arthroscopically
215052426|NCT03417583|OTHER|Protocol Intervention Group|For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
214298113|NCT02670564|GENETIC|Pharmacogenomics|"Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples."
214298114|NCT02670564|OTHER|Busulfan plasma level measurements|"Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).~Blood sampling:~-\>For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion~-\>For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.~For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:~-\> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below"
214298115|NCT05699798|OTHER|Conservative Treatment (CT)|Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
214897195|NCT06583655|RADIATION|SLND alone ,clinical high risk and genomic high risk group|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node Irradiation+ axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
215052427|NCT02776605|DRUG|Prednisone|Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
215052428|NCT02776605|DRUG|Vincristine|Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
215052429|NCT02776605|DRUG|Daunorubicin|Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
215052430|NCT02776605|DRUG|Prednisone|Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
215052431|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg, PO from day 1 to consolidation
215052432|NCT02776605|DRUG|Mercaptopurine|Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
215052433|NCT02776605|DRUG|Methotrexate|MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
215052434|NCT02776605|DRUG|VP-16|VP-16: 100 mg/m2/12 h, IV, days 14 and 42
215052435|NCT02776605|DRUG|ARA-C:|ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
215052436|NCT02776605|DRUG|TIT|TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
215052437|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
214897196|NCT06583655|RADIATION|Sentinel Lymph Node Dissection(SLND) + axillary lymph node dissection(ALND)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
214897197|NCT04715581|DIETARY_SUPPLEMENT|Preoperative nutritional optimization|"1. Indication for oral nutritional supplementation: Patients at risk of malnutrition (MNA-SF 8-11) or with malnutrition (MNA-SF 0-7).~2. Protocol of nutritional optimization: Enteral nutritional powder (Ensure for patients without diabetes and Glucerna for patients with diabetes) twice a day. The target protein intake is 1.5-1.8 g/kg/d. Patients with iron deficient anemia (hemoglobin \<130 g/L for men and \<120 g/L for women) will be given oral iron therapy.~3. The duration of nutritional optimization: The day admitted to the hospital to the surgery to one day prior to the surgery."
215052438|NCT02776605|PROCEDURE|Autologous transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation
215052439|NCT02776605|PROCEDURE|Allo transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
215052440|NCT03771040|DRUG|Masitinib|
215052441|NCT03771040|DRUG|Placebo|
215052442|NCT01786681|PROCEDURE|Positive pressure|
215052443|NCT00506779|DRUG|Imatinib Mesylate|Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily
215052444|NCT00506779|DRUG|Paclitaxel|175 mg/m\^2 by vein over 3 Hours every 21 Days
214669175|NCT05829577|OTHER|Executive Function Strategies and Training|will be conducted by primary investigator and trained therapist ,EF strategies will be implemented during DLS and SI training and these strategies will target following area which proved by evidences within the context of functional training: Using monitoring system for each child , Improving sense of time, Externalize important information , Externalize Motivation, Provide consequences: Immediately, more frequently, Higher magnitude and more powerful, Richer degree of incentive, Rotated or changed more frequently, Personalize the command, praise, instruction, reprimanding, Process training, remediation and training on executive function skill
214669176|NCT05829577|OTHER|Daily Life skill training|each child will receive 25 minute of DLS training which will focus on training children on Grooming, feeding, dressing undressing, toileting and community reintegration tasks aligned with facilitation fine motor skills for children and Using several techniques for ADL training including : prompting, shaping, forward and backward chaining, and modeling ,training children based on level of independency identified by WeeFIM score
215052445|NCT05529251|RADIATION|Radiotherapy boost|"Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~* 20 Gy if no more disease is visible (node \< 1 cm in large diameter)~* 24 Gy for nodes \<= 2 cm~* 30 Gy for nodes \> 2 cm"
215052446|NCT05529251|DRUG|Carboplatin AUC7|Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
215052447|NCT05529251|DRUG|3 cycles of EP|3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
215052448|NCT02215057|DRUG|topical anesthesia|topical anesthetic drops and Group 2
215052449|NCT02215057|DRUG|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
215052450|NCT02153437|DRUG|BMS-919373|
215052451|NCT02153437|DRUG|Sotalol|
215052452|NCT02153437|DRUG|Placebo for BMS-919373|
215052453|NCT03128489|BIOLOGICAL|Infanrix-IPV/Hib|Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
215052454|NCT02924259|DEVICE|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
214897198|NCT04715581|BEHAVIORAL|Preoperative exercise training|"1. The respiratory training will be performed for at least 2-3 times per day. Respiratory training include thoracic breathing exercise and cough training.~2. Aerobic exercise will be performed for at least 1-2 times per day. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Every training should be last for 45 minutes to 1 hour. If the patient can not tolerate, the training time should be reduce to 30 minutes.~4. The duration of exercise training: The day admitted to the hospital to the surgery to one day prior to the surgery."
214897199|NCT04715581|BEHAVIORAL|Postoperative exercise training|"1. Muscle strength training in the bedside and walking in the ward.~2. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Exercise training is performed under the supervision of physiotherpists durign hospital stay, and is reminded by regular telephone calls and phone messages after hospital discharge."
214897200|NCT03370263|DRUG|Benlysta|Benlysta will be administered intravenously or subcutaneously.
214897201|NCT04940000|OTHER|Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).|"Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center.~At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire."
214897202|NCT04861714|DEVICE|Regeneten|Augmentation of standard subscapularis repair with regeneten patch
214897203|NCT04861714|PROCEDURE|Standard repair|Standard subscapularis repair
214897204|NCT06284382|OTHER|High score at Childhood Trauma Questionnaire.|"In the presence of early trauma arm, 15 participants are recruited based on a high Childhood Trauma Questionnaire total score."
215052455|NCT05313763|OTHER|conventional physical therapy|A hotpack will be applied to the neck area for 15 minutes in the prone position of the patients. Conventional type Tens with a frequency of 50 Hz and a pulse duration of \<150 microseconds will be applied for 20 minutes, taking the painful area to the center. Ultrasound will be applied to the patients for 5 minutes with a dosage of 1-1.5 watts/cm2. Cervical joint range of motion exercises, stretching exercises for trapezius, scalenia, rhomboid, levator scapulae, pectoral and suboccipital muscles will be applied, then cervical isometric strengthening exercises and stabilization exercises will be carried out in a controlled manner. Conventional physical therapy will be applied by the same physiotherapist 5 days a week for 3 weeks.
215052456|NCT05313763|OTHER|Active Kinesiotaping|For kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, and the application will be started from the midline of the upper thoracic vertebrae. Initially, 4-5 cm stretching will be applied, and the arms of the Y strip will be adhered to the cervical paravertebral muscles without stretching. I strip will be applied to the painful area with the area correction technique, with maximum stretching in the middle and without stretching the ends. The applications will be made by the same physiatrist with 7 years of clinical experience.
215052457|NCT05313763|OTHER|Sham Kinesiotaping|For Sham kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, the application will be started from the midline of the upper thoracic vertebrae, and the Y and I bands will be applied without stretching. The applications will be made by the same physiatrist with 7 years of clinical experience.
215052458|NCT04149496|COMBINATION_PRODUCT|in vitro maturation of oocytes|Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
215052459|NCT04149483|DRUG|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
215052460|NCT04149483|DRUG|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
215052461|NCT03112291|PROCEDURE|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
215052462|NCT00335309|PROCEDURE|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
215052463|NCT00335309|DRUG|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
215052464|NCT03678051|BEHAVIORAL|Treatment as Usual (TAU)|Standard of care residential treatment
215052465|NCT03678051|BEHAVIORAL|TAU+CBT4CBT|45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
215052466|NCT03685058|DEVICE|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
214298116|NCT05699798|OTHER|Instrument-assisted Soft Tissue Mobilization (IASTM)|"IASTM was performed only on the neck and upper back muscles on the aching side using the sweep technique on the origo and insertion lines. A total of 6 sessions were applied, two sessions per week for 3 weeks.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
214897205|NCT06284382|OTHER|Low score at Childhood Trauma Questionnaire.|"In the absence of early trauma arm, 15 participants are recruited based on a low Childhood Trauma Questionnaire total score."
214897206|NCT01568567|DIETARY_SUPPLEMENT|Lactobacillus Reuteri DSM 17938|One stick pack in the morning and one stick pack afternoon/evening for 28 days.
214897207|NCT00961857|DRUG|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
214298117|NCT05699798|OTHER|Extracorporeal Shock Wave Therapy (ESWT)|"ESWT therapy was applied on the muscle with active trigger point, at 1.5-2.0 bar pressure, at 10 Hz frequency, 2000 beats in each session, twice a week, in total 6 sessions.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
214298118|NCT00416078|BEHAVIORAL|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
214298119|NCT00416078|BEHAVIORAL|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
214298120|NCT06073353|BEHAVIORAL|THRIVE-M|"THRIVE-M is a self-administered psychosocial mobile application for patients living with multiple myeloma that includes the following five modules:~1. Health module - teaching patients about physical symptoms and strategies to cope with physical symptoms~2. Relationships module - helping patients articulate different support needs and communication styles in navigating relationships~3. emotions module - helping patients identify connections between thoughts, feelings, and behaviors, as well as helpful states of mind and gratitude~4. Lifestyle module - helping patients practice skills for saving up energy and using self-care strategies~5. Reflection module - teaching patients to reflect on their lives, meaningful relationships, and sense of purpose.~Each module takes about 15-20 minutes to complete and participants will be instructed to complete all modules within an eight-week period."
214298121|NCT06340828|OTHER|Washing Microbiota Transplantation|Fecal samples from healthy adults were collected and underwent multiple centrifugations and filtrations to obtain a bacterial solution, which was then transplanted into the duodenum of patients via a nasogastric tube.
214298122|NCT00243581|BEHAVIORAL|Dean Ornish Heart Disease Reversing Program|
214298123|NCT05977582|BEHAVIORAL|Spanish version eBodyProject|"The Spanish adaptation of the eBodyProject program will be modified (Stice et al., 2012b). This program consists of 4 modules adapted from the most recent version of the original program The Body Project, presented by the original authors who have given their consent and suggestions for the realization of the Spanish version.~The activities proposed through the different modules will be in written format or behavioral activities aimed at criticizing the ideal of feminine beauty imposed by today's society and promoting self-acceptance."
214298124|NCT05977582|BEHAVIORAL|Psychoeducationa Prevention Program|Participants in this group will receive a weekly newsletter with information about the beauty ideal, the costs of pursuing it, and tips for resisting the pressure to pursue this ideal, as well as tips for managing the emotions associated with it. However, they will not have to perform exercises related to this information, a psychoeducational intervention. Once the study is finished, these participants will receive an email again in case they are interested in taking part in the eBodyProject prevention program.
214669177|NCT05829577|OTHER|Sensory Integration /Processing training|each patient will receive 20 min of SI/SP training Manualized SI/SP intervention which will be used is based on the principles of sensory integration as outlined by Ayres ,such as deep pressure, brushing, weighted vests, and swinging will used , individually-tailored treatment activities might include activities such as using a carpeted scooter board while in the prone position to pull oneself up a ramp, then working to turn the scooter board around to ride down the ramp and land in a cushioned area of mats and pillows that are covered with various textures. Intervention is contextualized in play with active involvement of the child will be conducted in a large gym equipped with mats, a variety of suspended swings, large balls, a climbing wall, carpeted barrels, large inner tubes and foam blocks with opportunities for active, guided, sensory motor play.
214298125|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed QD
214298126|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed BID
214298127|NCT01190878|DRUG|DuraSite Vehicle|Vehicle dosed BID
214298128|NCT01190878|DRUG|Xibrom™|0.09% bromfenac dosed BID
214298129|NCT02520401|OTHER|Probiotic - BioGaia|Use of a probiotic tablet
214897208|NCT00961857|DRUG|Comparator: metformin 500 mg|A single dose of metformin 500 mg tablets
214897209|NCT00961857|DRUG|Comparator: sitagliptin|A single 50 mg tablet of sitagliptin
214897210|NCT00961857|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
214897211|NCT00961857|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
214897212|NCT00961857|DRUG|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablets
214298130|NCT02520401|OTHER|Placebo|Use of a placebo tablet
214298131|NCT02060604|DRUG|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
214298132|NCT02060604|DRUG|Ranibizumab|3 monthly ranibizumab, then as needed
214298133|NCT01829230|DEVICE|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
214298134|NCT02733588|DRUG|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
214298135|NCT00233103|DRUG|Sertraline|Sertraline arm
214298136|NCT00233103|DRUG|Placebo|Placebo
214298137|NCT00045123|DRUG|tarenflurbil|
214298138|NCT00045123|PROCEDURE|adjuvant therapy|
214298139|NCT01907204|DRUG|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
214298140|NCT01907204|DRUG|Budesonide|Budesonide by metered dose inhaler
214298141|NCT01907204|DRUG|Budesonide|Budesonide by nebulization
214897213|NCT04823325|PROCEDURE|Orthognathic Surgery|The duration for presurgical orthodontic treatment was; 7,7 ± 1,7 months.
214897214|NCT04781426|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg|PrEP regimens of Tenofovir Disoproxil Fumarate (TDF) 300 mg/Lamivudine (3TC) 300mg per oral (PO) daily
214897215|NCT04566666|DRUG|Placebo|Placebo of SCD-044 product
214897216|NCT04566666|DRUG|SCD-044_Dose 1|SCD-044 tablets in Dose 1.
214897217|NCT04566666|DRUG|SCD-044_Dose 2|SCD-044 tablets in Dose 2
214897218|NCT04566666|DRUG|SCD-044_Dose 3|SCD-044 in Dose 3
214897219|NCT00652054|DRUG|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
214897220|NCT00908570|DRUG|estriol|4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
214897221|NCT00908570|DRUG|Placebo|Placebo cream
214897222|NCT01290549|DRUG|Polatuzumab Vedotin|Participants will receive escalating intravenous dose of polatuzumab vedotin.
214298142|NCT04969120|DRUG|Metoclopramide 10mg|this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
214298143|NCT04969120|DRUG|Placebo (0.9 sodium chloride)|this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
214298144|NCT03807063|BIOLOGICAL|Rivogenlecleucel|Given IV
214298145|NCT03807063|DRUG|Rimiducid|Given IV
214298146|NCT01272414|DRUG|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
214478433|NCT05586308|BEHAVIORAL|Media literacy|Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
214478434|NCT06815276|OTHER|Exercise|core muscle training
214897223|NCT01290549|DRUG|Rituximab|Rituximab will be administered by an IV infusion at 375 mg/m\^2 body surface area dose q3w.
214897224|NCT02416063|DRUG|Caudal Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Caudal dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~sevoflurane Induction and maintenance of anesthesia"
214897225|NCT02416063|DRUG|Intravenous dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg.~Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml~sevoflurane Induction and maintenance of anesthesia"
214897226|NCT02416063|DRUG|Placebo|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Intravenous: Normal saline 10 ml~sevoflurane Induction and maintenance of anesthesia"
214897227|NCT06544200|DEVICE|Polymeric Hydrogel Matrix|application of Polymeric Hydrogel Matrix along the suture line at the completion of lung resection
214897228|NCT00000914|DRUG|Indinavir sulfate|
214897229|NCT00000914|DRUG|Ritonavir|
214897230|NCT00000914|DRUG|Nelfinavir mesylate|
214897231|NCT00000914|DRUG|Efavirenz|
214298147|NCT01272414|DRUG|Saline injection|Injection of 0.4cc 0.9% normal saline
214478435|NCT06813573|BIOLOGICAL|blood sampling|A maximum of 4 tubes of 10ml will be collected: at baseline (before cycle 1), before each cycle (from 2 to 6 included), at the end of the treatment, and in case of relapse during follow-up period
214478436|NCT06813001|OTHER|ACT-based nursing intervention|ACT-based nursing intervention is a 1:1 single online session with a nurse, which takes about 60 minutes followed by a daily self-monitoring survey for one week, which encourages patients to practice ACT.
214478437|NCT06813989|OTHER|carotid ultrasound|The investigator will perform a carotid ultrasound just 2 cm before the carotid bulb and measure the corrected flow time and flow using Doppler and pulse wave analysis. The corrected carotid flow time will be calculated according to Bazett's equation.
214897232|NCT05906108|BEHAVIORAL|Self-initiated learning|A WeChat Subscription will be created for delivering the intervention. The educational materials involving introduction to internet addiction, the impact of internet addiction and strategies in coping with IA will be posted to the account at the beginning of the intervention. The materials will be prepared in different format including text and video followed by 3 to 5 multiple choice questions (MCQs), and one post for one topic. Relevant materials can be found by typing the keywords in the account or searching under the content list. Participants will be required to follow the account to study the materials at their own pace and complete the MCQs. There will be no limited access to the materials and attempts for MCQs.
214897233|NCT05906108|BEHAVIORAL|Personalized and interactive behavioural support|The intervention group will receive 3-month personalized and interactive behavioural support via WeChat, which including regular messages and real-time conversation. The regular messages will cover the generic information about abstinence support, health warnings, benefits of reducing internet time, knowledge reinforcement, goal setting, encouragement and reminders for self-initiated online learning. The messages will be personalised according to baseline demographic characteristics and internet addiction level, and continually adapted to any change in internet behaviours change reported by subjects during the conversations. A total of 19 messages with a tapering schedule. Personalized real-time conversation via WeChat will be available based on participants' demand.
214897234|NCT05906108|BEHAVIORAL|General health information|Participants in control group will receive WeChat messages on general health information (similar frequency as the intervention group) and reminders on follow-up surveys via WeChat. Various topics will be involved in the general health information such as healthy diet, sleep management, exercise and mood management.
214897235|NCT05294978|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Data of macular optical coherence tomography (OCT)
214897236|NCT01051310|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve
214298148|NCT04387435|OTHER|A change or titration in the current or frequency settings of the VNS therapy system.|The study treatment involves changing the output current or frequency of the default device settings in a FDA approved device for VNS therapy. The proposed frequency changes in this study are within the FDA approved output current and frequency levels.
214298149|NCT03144362|PROCEDURE|Bilateral Sliding Techniques|Bilateral Sliding Techniques
214298150|NCT03144362|PROCEDURE|Unilateral Sliding Techniques|Unilateral Sliding Techniques
214298151|NCT00757744|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
214298152|NCT00757744|BEHAVIORAL|Drug counseling|individual drug counseling
214298153|NCT04993456|PROCEDURE|Caridac surgery|Cardiac surgery
214298154|NCT05205733|OTHER|Mail-in semen analysis kit|Presumably an easier, convenient, and more comfortable way to provide a semen analysis with an in-home mail-in semen analysis kit
214298155|NCT03855280|DRUG|APVO101|Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
214298156|NCT00783250|DRUG|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
214298157|NCT00783250|DRUG|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
214298158|NCT01508858|DRUG|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
214298159|NCT01508858|DRUG|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
214298160|NCT01508858|DRUG|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
214669178|NCT01887444|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
214669179|NCT01887444|OTHER|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
214897237|NCT05825638|OTHER|Continuous training session|Continuous training consists of a 5 minute warm up, 5 minute cool down and 20 minutes of moderate intensity work. The workload is set at 60% of the patient's maximum power
214897238|NCT05825638|OTHER|Interval training session|Interval training consists of a 5-minute warm-up, a 5-minute cool-down and 20 minutes of alternating 60 seconds of high-intensity work (100% of the maximum power recorded in the incremental test that was carried out when the patient was admitted to the pulmonary rehabilitation department) and 60 seconds of unloaded pedalling or rest.
214897239|NCT01144702|DRUG|artesunate & mefloquine combination|A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
214897240|NCT05360810|DEVICE|Wei Nasal Jet Tube|"comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures~airway devices which can use for gastrointestinal procedures"
214897241|NCT05360810|DEVICE|Gastro Laryngeal Tube|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
214897242|NCT02839538|PROCEDURE|Local Infiltration|Injection at perianal region with ropivacaine 0.75%(20ml)
214897243|NCT02839538|PROCEDURE|Subarachnoidal block|Injection at subarachnoidal space with bupivacaine 0.5% ( 2ml)
214669180|NCT01488981|OTHER|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
214897244|NCT03458585|OTHER|Self-administered questionnaire|Self-administered questionnaire
214897245|NCT01038336|BEHAVIORAL|Multimedia Hearing Loss Prevention Program|Interactive, multimedia, computer-based HLPP that provides hands-on education and training about hearing loss, tinnitus, hearing protection, and general hearing health care for Veterans.
214897246|NCT01038336|BEHAVIORAL|Hearing Conservation Brochure|Hearing Conservation brochure provides knowledge-based information similar to that of the multimedia HLPP, but in written form.
214669181|NCT01488981|DEVICE|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
214897247|NCT03077737|BEHAVIORAL|Choose to Change|Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).
214897248|NCT03077737|BEHAVIORAL|Enhanced usual care|Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.
214897249|NCT02572570|DEVICE|Filtek Bulk Fill Posterior|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Bulk Fill Posterior). Procedures done using local anesthesia and following ordinary restorative techniques.
214298161|NCT00004182|DRUG|irinotecan hydrochloride|
214298162|NCT01243879|OTHER|Stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
214298163|NCT01243879|OTHER|No stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
214298164|NCT01014650|DRUG|GLYX-13|single IV or SC dose
214298165|NCT01014650|DRUG|IV normal saline|Single IV dose of normal saline
214298166|NCT03818828|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
214298167|NCT03818828|OTHER|Profore Compression Therapy|Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
214897250|NCT02572570|DEVICE|Filtek Supreme Ultra|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Supreme Ultra). Procedures done using local anesthesia and following ordinary restorative techniques.
214298168|NCT03818828|OTHER|Cadexomer Iodine dressing|During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
214298169|NCT04404751|COMBINATION_PRODUCT|Iodised salt with Iron, Folic acid and Vitamin B12|Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt
214298170|NCT06327451|DRUG|Atorvastatin 20mg|Liptor is a capsule in the form of 20 mg, once daily.
214298171|NCT01122836|OTHER|Massage|Therapeutic Massage
214298172|NCT03594292|DEVICE|FASTFORWARDTM Bunion|The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.
214298173|NCT03594292|PROCEDURE|Conventional surgery|The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
214298174|NCT04156425|DRUG|Escitalopram+golimumab|Escitalopram will be administered at 10-20 mg/d during the acute phase. Golimumab will be administered at the dose of 50mg every month during the acute phase.
214298175|NCT04156425|DIETARY_SUPPLEMENT|Escitalopram+Calcium Tablet|Escitalopram will be administered at 10-20 mg/d during the acute phase. Calcium tablet will be administered at 2000mg/d during the acute phase.
214669182|NCT04762355|DRUG|Palovarotene|ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3
214669183|NCT04762355|DRUG|Vehicle|Placebo-to-match palovarotene ophthalmic solution vials
214669184|NCT05927909|DIAGNOSTIC_TEST|Low Back Activity Confidence Scale (Lobacs)|Confidence Scale (LOBACS) is a self-report questionnaire designed to assess an individual's level of confidence in performing various physical activities involving the lower back region, to evaluate their perceived functional ability, and to assess the impact of low back pain on their daily life and functional performance.
214298176|NCT04156425|DRUG|Escitalopram|Escitalopram will be administered at 10-20 mg/d during the acute phase.
214298177|NCT03352206|DRUG|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
214298178|NCT03352206|DRUG|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
214298179|NCT05918692|DRUG|BMF-500|Investigational Product
214298180|NCT00989014|DRUG|CD07805/47|0.5% Topical Gel
214298181|NCT00989014|DRUG|CD07805/47|0.18% Topical Gel
214298182|NCT00989014|DRUG|CD07805/47|0.07% Topical Gel
214669185|NCT01425866|BEHAVIORAL|Structured self-management group education during 2 years|After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
214669186|NCT05488301|OTHER|chest physiotherapy|"chest physiotherapy session including:~* nasal ventilation~* decrease of respiratory rate without increasement of Tidal volume~* abdomino-diaphragmatic ventilation"
214298183|NCT00989014|DRUG|CD07805/47 placebo|Vehicle Topical Gel
214298184|NCT00643032|PROCEDURE|Transcutaneous iliohypogastric|
214298185|NCT00643032|PROCEDURE|Perioperative administration near the nerve|
214298186|NCT00120770|DRUG|Cellulose Sulfate Vaginal Gel (Microbicide)|
214298187|NCT01949168|DRUG|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)|
214298188|NCT01949168|DRUG|Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection|
214298189|NCT01949168|DRUG|Rebetol® (ribavirin), 1000/1200mg by mouth daily|
214897251|NCT02763046|DRUG|Secukinumab (AIN457) 150 mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 4 x 150 mg secukinumab s.c. every 4 weeks Delayed NSAID tapering (tapering following 4 weeks of secukinumab treatment).
214298190|NCT00969150|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
214298191|NCT00969150|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
214298192|NCT03059498|PROCEDURE|Unilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
214298193|NCT03059498|PROCEDURE|Bilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.
214298194|NCT03059498|DRUG|Bupivacaine|Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
214298195|NCT02525341|OTHER|Hatha yoga|A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
214298196|NCT02525341|OTHER|Aerobic and strengthening exercises|A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
214298197|NCT02525341|OTHER|General education|One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
214298198|NCT01879332|DRUG|Placebo|Matching placebo tablets for oral administration
214298199|NCT01879332|DRUG|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
214669187|NCT03851341|COMBINATION_PRODUCT|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
214669188|NCT03851341|COMBINATION_PRODUCT|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
214298200|NCT01879332|DRUG|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
214298201|NCT01847157|DEVICE|tDCS|"Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current."
214298202|NCT01847157|DRUG|Epidermis anesthesia|"15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
214298203|NCT01847157|DRUG|sham anesthesia|"15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
214298204|NCT01847157|OTHER|Repeated passive movement|"Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes."
214298205|NCT01847157|DEVICE|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
214298206|NCT05464069|DEVICE|Nerivio|Nerivio is a Remote Electrical Neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
214298207|NCT02872467|DRUG|Syntocinon treatment|24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
214298208|NCT02872467|OTHER|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
214298209|NCT04490538|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional transthoracic echocardiographic examination at the intensive care unit.
214298210|NCT04825418|DEVICE|Artic Sun|"1. Induction phase A. Temperature using by esophageal or bladder thermometer. B. Application of a surface cooling device (Arctic Sun) C. Target temperature: 35 ± 0.5 °C D. Induction should be initiated as soon as possible after surgery (less than 6 hours)~2. Maintain phase A. Maintain duration : at least 72 hours and duration can be prolonged according to patient's clinical status B. Use the bedside shivering assessment scale (BSAS) and anti-shivering protocol C. Neuromuscular blocker can be used according to the discretion of the attending physician D. Lung-protective ventilation strategies including low-tidal volume are recommended E. Prophylactic antibiotics can be used to prevent pneumonia during hypothermia~3. Rewarming phase A. Rewarming rate: 0.05 - 0.1 ℃/hr (about 20 - 40 hours) to 37 ℃"
214478438|NCT06814834|DRUG|Oral dissolution therapy|Patients received guidance for oral potassium-sodium-hydrogen-citrate (6:6:3:5) at a dosage of twenty milliequivalents three times every day, along with a daily fluid intake of two to three liters and a food plan to restrict protein and sodium consumption for a maximum of three months.
214669189|NCT00147771|DRUG|Imiquimod 5% cream|Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
214897252|NCT02763046|DRUG|Secukinumab (AIN457) 150 mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 3 x 150 mg secukinumab s.c. every 4 weeks Early NSAID tapering (tapering at the start of secukinumab treatment).
214897253|NCT02763046|DRUG|Placebo - Secukinumab (AIN457) 150 mg s.c.|Placebo for 15 weeks. From Week 16 on, 5 x 150 mg secukinumab s.c. weekly.
214669190|NCT02832271|DRUG|SUNPHENON EGCg|SUNPHENON EGCg Oral, 400mg, twice per day
214897254|NCT02884050|DRUG|Topiramate|antiepilepsy drug
214897255|NCT02884050|DRUG|Placebo|non-active placebo
214897256|NCT05029154|BEHAVIORAL|High intensity interval exercise|Patients in the exercise group will perform interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Patients will undergo 2 initial training sessions at the exercise physiology core lab. All exercise will consist of stationary cycling to avoid discomfort associated with abdominal surgery as well as stress to the incision and help reduce fall risk. Study investigators will check in weekly with participants and remotely track exercise data and compliance via the Fitbit app.
215052467|NCT03685058|OTHER|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
215052468|NCT02261207|DRUG|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
215052469|NCT02639247|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
215052470|NCT02639247|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
214298211|NCT05781607|COMBINATION_PRODUCT|Patient education combined with drug therapy|Receive a health education by a specialist therapist, including explaining the anatomy and function of TMJ; Explain the etiology, prognosis, treatment plan and prognosis of TMD; Correct the patients' daily oral habits, such as unilateral chewing, habitual clenching, eating too much hard food, etc; Instruct the patient to understand the rest position of the temporomandibular joint and correct the bad posture of the neck and shoulder. At the same time, corresponding medication should be given, and NSAIDS should be taken orally or externally for patients with pain.
214298212|NCT05781607|COMBINATION_PRODUCT|Individualized comprehensive physical therapy|Physical factor therapy and/or manual therapy
214298213|NCT00006344|RADIATION|radiation therapy|
214298214|NCT02406482|BEHAVIORAL|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
214478439|NCT06814834|PROCEDURE|Extracorporeal shock wave lithotripsy|Patients received extracorporeal shock wave lithotripsy utilizing a Dornier lithotripter equipped with an integrated ultrasound for stone localization. If the patient required additional sessions, up to a maximum of four sessions, at a rate of 60-90 shocks per minute, the period between sessions was three weeks.
214897257|NCT05029154|BEHAVIORAL|Attention control|Patients in the control group (physical activity education and physical activity monitoring) will receive counseling regarding the benefits of physical activity during chemotherapy treatment. During the intervention, participants will receive a weekly phone call to discuss their physical activity and remind them to engage in physical activity. Patients will be given a goal of working up to 30 minutes of exercise daily. Subjects will be urged to increase daily step counts by 250-500 steps/day. Physical activity will be objectively assessed and made available to the participant using a Fitbit.
214897258|NCT02123004|DRUG|Ticagrelor|180mg loading dose for one day ,and then 90mg per day for 4 weeks
214897259|NCT02123004|DRUG|Clopidogrel|300mg loading dose for one day ,and then 75mg per day for 4 weeks
214897260|NCT01697072|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
215052471|NCT02955238|BEHAVIORAL|Special Intervention|"Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum."
214669191|NCT02832271|DRUG|Placebo|Placebo
214669192|NCT04352660|DRUG|Mitomycin-C injection|MMC delivered by preoperative subconjunctival injection
214669193|NCT04352660|DRUG|Mitomycin-C sponge|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
215052472|NCT02982655|PROCEDURE|Individualized BP lowering|
215052473|NCT02737319|DRUG|Rosuvastatin|40 mg of rosuvastatin before angioplasty
215052474|NCT03462758|DEVICE|IUD|Postpartum IUD placement
215052475|NCT05985707|DRUG|KN026|KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.
214669194|NCT01009112|BEHAVIORAL|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
214669195|NCT01009112|BEHAVIORAL|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
214669196|NCT02066090|DEVICE|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
214897261|NCT01697072|OTHER|Placebo|Placebo
214897262|NCT01697072|DRUG|Epirubicin|Epirubicin is an anthracycline cytotoxic agent.
214897263|NCT01697072|DRUG|Cisplatin|Cisplatin is a non-cell cycle specific chemotherapeutic agent.
214897264|NCT01697072|DRUG|Capecitabine|Capecitabine is an oral fluoropyrimidine.
214897265|NCT04562168|DIAGNOSTIC_TEST|Autoderm® dermatology search engine (ML model) testing|GP using a smartphone camera will take an image of the skin problem and will use the Autoderm ML interface to upload the anonymized image. The obtained predicted diagnosis will be recorded in case report form.
214897266|NCT04750395|DRUG|Haloperidol Solution|Oral transmucosal haloperidol solution 2.5mg
215052476|NCT05985707|DRUG|KN046|KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
215052477|NCT05985707|DRUG|XELOX|XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
215052478|NCT02820844|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
215052479|NCT02820844|DRUG|Placebo|Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
214897267|NCT04750395|DRUG|Olanzapine Tablets|Oral transmucosal olanzapine tablet 5.0mg
214669197|NCT02066090|DEVICE|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
214669198|NCT00863733|DRUG|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
214669199|NCT02964104|DRUG|Insulin icodec|Administered once weekly subcutaneously (s.c., under the skin) for 35 days
214669200|NCT02964104|DRUG|placebo|Administered once daily subcutaneously for 35 days
214669201|NCT02964104|DRUG|insulin degludec|Administered once daily subcutaneously for 35 days
214669202|NCT02964104|DRUG|placebo|Administered once weekly subcutaneously for 35 days
214669203|NCT03406195|DEVICE|Transcranial magnetic stimulation (TMS)|TMS paradigm called theta burst stimulation
214669204|NCT01197573|DRUG|rTPA Treatment|Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
214897268|NCT06278740|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|Upper extremity pathologies of participants with ultrasound
214897269|NCT04562350|OTHER|XatJove Anoia Aplication|All students (age 12-16 years) from middle school and high school in the sanitary region of Anoia, province of Barcelona, will access a Platform ( ABH Health), where the users will enter specific registration data ( age, sex..etc), after every visit the users will be provided with a 6 multiple choice questionary and asked to punctuate in a scale from 1 to 10, the satisfaction of the service provided. Appart from this data, researchers will use a software to register specific Health-related words and classify them as Health-problems. While Osona students will attend face-to-face consultations as usual, apart from this data,Registrations will be reviewed later and specific search techniques and strategies will be coded. A qualitative review will be performed too.
214897270|NCT01272050|RADIATION|radiation therapy|"RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.~Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration."
215052480|NCT02820844|DRUG|Antibiotic therapy|Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
215052481|NCT02820844|OTHER|Bladder diary|The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
215052482|NCT02820844|OTHER|King's Health Questionnaire (KHQ)|The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
214669205|NCT01197573|OTHER|No TPA Treatment|Standard of Care
214298215|NCT02406482|BEHAVIORAL|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
214298216|NCT00461682|DRUG|SB-705498|
214298217|NCT03457129|DRUG|Perampanel Oral Tablet|Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
214298218|NCT04081311|DEVICE|comparing interdental floss to water flosser around dental implants|to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
214298219|NCT00883116|DRUG|Ixabepilone|
214478440|NCT06814834|PROCEDURE|Oral dissolution therapy + extracorporeal shock wave lithotripsy|Patients received a combination of oral dissolution therapy and extracorporeal shock wave lithotripsy.
214478441|NCT06815406|PROCEDURE|Endoscopic Mucosal Resection (EMR)|atients assigned to this arm will undergo Endoscopic Mucosal Resection (EMR), a standard endoscopic technique that involves the resection of colorectal Laterally Spreading Tumors - Granular type (LST-G) using a diathermic snare with submucosal injection. The procedure may be performed en bloc or in a piecemeal fashion, depending on lesion size and characteristics. EMR is widely accepted for lesions with low submucosal invasion risk but has a higher recurrence rate than ESD.
214669206|NCT05744986|DEVICE|SYMPICITY Spyral RENAL DENERVATION (RDN) SYSTEMTM|The second generation SYMPLICITY RDN catheterTM has 4 times electrodes that are arranged in spirally in 90-degree intervals. Theoretically, the newer generation catheter can provide more efficient and extensive denervation in a shorter period of time16. Its efficacy was confirmed in SYMPLICITY HTN ON-MED and OFF-MED trial, which confirmed a consistent and durable BP reduction that lasted into 36 months with or without adjuvant anti-hypertensive drugs
214669207|NCT03456765|DIAGNOSTIC_TEST|Ultrasound|US will be made to assess kidneys
214897271|NCT06070519|DIAGNOSTIC_TEST|CPET and related variables evaluation|"At the baseline visit ,CPET-related variables, echocardiographic, ECG, therapy and blood chemistry data will be collected. The baseline CPET will be repeated within 2 weeks. Patients will perform 4 follow up visits at 6, 12, 18 and 24 months after the baseline visit. At every study step, it will be performed:~* Echocardiography (LVEF)~* Blood sample (Na+, MDRD, Hb)~* Maximal ramp protocol CPET (peakVO2, VE/VCO2 slope)"
214897272|NCT05634421|OTHER|E-learning|The E-learning is under development at the department of Dermatology from MUMC+.
214897273|NCT04544241|BEHAVIORAL|Cancer Survivorship Leadership Training for Clergy Wives and Widows|We will meet with Clergy Wives and Widows monthly for 2-3 hours over 10 months. These sessions will be delivered using innovative online format through Zoom over the ten months. During each meeting session, experienced community and academic leaders will present their expertise with relationship to cancer survivorship and caregiving. These individuals will have extensive experience in the particular area they are presenting in. In addition, allotted time will be given for discussion and group activities that can be performed virtually. To receive credit for completion of the training program, each participant must complete the training and deliver a group workshop. All clergy wives and widows will complete a demographic questionnaire, in addition to pre- and post- intervention questionnaires
215052483|NCT02820844|OTHER|Overactive Bladder Symptom Score (OABSS)|The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
214298220|NCT00883116|DRUG|Doxorubicin|
214298221|NCT00883116|DRUG|Paclitaxel|
214669208|NCT04889677|DRUG|Danicopan|
214897274|NCT04332900|DEVICE|Elastic hip strap|The SERF Strap consist of a thin, elastic material that is secured to the proximal aspect of the leg, wraps in a spiral fashion around the thigh, and is anchored around the pelvis. The line of action of the SERF Strap pulls the hip into abdcution and external rotation.
215052484|NCT02820844|OTHER|Treatment Benefit Scale (TBS)|"The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820."
215052485|NCT02266147|DRUG|SD-101|
215052486|NCT02266147|RADIATION|Radiation therapy|
214669209|NCT04889677|DRUG|Placebo|
214669210|NCT05453253|BIOLOGICAL|Delayed second dose of oral cholera vaccine, Euvichol-Plus|The intervention arms (6 and 12 months) will modify the recommended interval for administration of the second vaccine dose, which will be extended to 6 and 12 months according to the intervention arm.
215052487|NCT04298294|OTHER|injectable platelet rich fibrin|biologic activator
214298222|NCT05562076|DEVICE|the spot stent(ZENFLEX ® Pinto) system|the spot stent(ZENFLEX ® Pinto) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
214669211|NCT05453253|BIOLOGICAL|Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice|"Euvichol-Plus, a WHO prequalified oral cholera vaccine, contains modified killed whole cell vaccine of formalin killed Vibrio cholerae strains of O1 Inaba, O1 Ogawa and O139.~In the control arm, participants will receive the Euvichol-Plus following the manufacturer recommendations: two doses administered orally 14 days apart for individuals aged ≥1 year."
215052488|NCT02177630|OTHER|Endomyocardial Biopsy|
214669212|NCT05835258|DIETARY_SUPPLEMENT|Melatonin with phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement with phenyl capsaicin
214669213|NCT05835258|DIETARY_SUPPLEMENT|Melatonin without phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement without phenyl capsaicin
214669214|NCT01362322|BIOLOGICAL|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
214298223|NCT05562076|DEVICE|the bare stent( Everflex) system|the bare stent( Everflex) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
214298224|NCT00432107|DRUG|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
214298225|NCT02859675|OTHER|triangular test|metabolic state, impedance measurement, potential flavours evoked by sucrose,
214298226|NCT02859675|BIOLOGICAL|blood sampling|sampling of 2 mL
214298227|NCT02859675|OTHER|Questionnaires|Stunkard, PrefQuest
214298228|NCT01326689|DRUG|KW-2246|Rescue medication at an optimal dose, which is determined by dose titration
214298229|NCT01326689|DRUG|Placebo|
214298230|NCT02707874|DRUG|CI 0.2% ropivacaine|Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
214298231|NCT02707874|DRUG|PIB 0.2% ropivacaine|Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
214298232|NCT01852578|DRUG|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
214298233|NCT02703584|DRUG|Buseralin|
214298234|NCT02703584|OTHER|Placebo|
214298235|NCT02703584|DRUG|pregnyl|
214669215|NCT01362322|BIOLOGICAL|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
214669216|NCT02447107|OTHER|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
214669217|NCT02447107|OTHER|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
214669218|NCT02097836|DEVICE|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
214669219|NCT01009463|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
214669220|NCT01009463|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
214669221|NCT05857956|OTHER|Proper Wild energy shot|100% plant-based energy shot containing natural caffeine, L-Theanine, purified water, pineapple juice concentrate, natural flavors, kiwi juice concentrate, organic lemon juice concentrate, organic strawberry juice concentrate, monk fruit juice concentrate, pink himalayan sea salt.
214669222|NCT02690896|BEHAVIORAL|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
214669223|NCT02690896|BEHAVIORAL|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
214669224|NCT03187379|DRUG|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
214669225|NCT03187379|DRUG|Bupivacaine|60cc Bupivacaine
214669226|NCT04359953|DRUG|Hydroxychloroquine|Hydroxychloroquine 2 x per day during 14 days
214669227|NCT04359953|DRUG|Azithromycin|Azithromycin 2 x per day during 14 days
214669228|NCT04359953|DRUG|Telmisartan|Telmisartan 2 x per day during 14 days
214669229|NCT03271827|DEVICE|Apnoeic oxygenation|3 L/min of oxygen by nasal cannula during as apnoeic oxygenation during airway management.
214669230|NCT01742221|BIOLOGICAL|HemaMax|single subcutaneous 12 microgram dose of HemaMax
214669231|NCT01742221|DRUG|Placebo|single subcutaneous dose
214897275|NCT04332900|DEVICE|Insole|Foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each that is made from a block of ethyl vinyl acetate with a thermo-moldable polymer (shore hardness of 45 A) and is manufactured through an automated computer numeric control machine (CNC routers).
214897276|NCT04751552|PROCEDURE|Erector Spinae Plane Block (for postoperative pain relief)|A ultrasound guided single bolus injection of 20 ml of levobupivacaine or placebo between the erector spinae muscle and process transversus of vertebra T5.
214897277|NCT04247113|BEHAVIORAL|Parent-based prevention following bariatric surgery|PBP-B is an adapted version of Parent-Based Prevention (PBP), an innovative approach with demonstrated efficacy in targeting the familial effects of parents with eating disorders on their young children's healthy behaviors. PBP-B addresses the parental cognitions and behaviors that putatively increase the risk for maladaptive outcomes in their children.
214897278|NCT06574659|PROCEDURE|Noninvasive ventilation breathing test guiding sequential invasive Ventilation and noninvasive ventilation weaing protocol|Noninvasive ventilation breathing test guiding sequential invasive Ventilation and noninvasive ventilation weaing protocol
214897279|NCT06574659|PROCEDURE|The standard SBT guiding weaning group|The standard SBT guiding weaning protocol
214897280|NCT00311948|BEHAVIORAL|Telephone counseling + interactive website = more abstinence|
214897281|NCT00311948|BEHAVIORAL|Behavioral: interactive website|
214897282|NCT01839890|DEVICE|Bare metal Stent plus Paclitaxel Balloon|After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
214298236|NCT03138395|DIAGNOSTIC_TEST|droplet digital PCR|This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
214478442|NCT06815406|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Patients assigned to this arm will undergo Endoscopic Submucosal Dissection (ESD), an advanced endoscopic technique that allows for en bloc resection of large colorectal Laterally Spreading Tumors - Granular type (LST-G). The procedure involves the use of specialized knives to dissect the submucosal layer, ensuring complete resection with histologically clear margins (R0 resection). ESD has been associated with lower recurrence rates but requires a high level of expertise, longer procedural times, and carries a higher risk of complications.
214478443|NCT06815016|OTHER|Reflexology ,mulligan mobilization and conventional|Reflexology is a systematic practice in which applying some pressure to any particular points on the feet and hands give impacts on the health of related parts of the body as (Knee reflex point, Pituitary reflex point, Entire spine, Liver reflex area, Thyroid reflex area ) Mulligan's Mobilization with Movement (MWM) apply accessory gliding force combined with active movement as (Lateral glide MWM for flexion / extension, Medial glide MWM for flexion / extension, Self-medial glide MWM for knee flexion/extension: home exercise)
214478444|NCT06815016|OTHER|reflexology and conventional|Reflexology as (Knee reflex point, Pituitary reflex point, Entire spine, Liver reflex area, Thyroid reflex area ) and conventional methods as (Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound Therapy and exercises) treatment.
214478445|NCT06815016|OTHER|mulligan mobilization and conventional|Mulligan mobilization as (Lateral glide MWM for flexion / extension, Medial glide MWM for flexion / extension, Self-medial glide MWM for knee flexion/extension: home exercise) and conventional methods as (Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound Therapy and exercises) treatment.
214478446|NCT06815016|OTHER|Conventional treatment|Conventional methods as (Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound Therapy and exercises) treatment.
214298237|NCT06136754|DRUG|Varnishes, Fluoride|Fluoride varnish containing 5.0% NaF
214478447|NCT06813534|DEVICE|Intravascular Ultrasound guided PCI|Intra-coronary ultrasound
214478448|NCT06813937|DEVICE|Procedure: Peripheral Magnetic Stimulation (PMS)|PMS is a non-invasive neuromodulation technique used to treat chronic pain. Procedure starts with sensory mapping, localisation of the hotspot and detection of sensory threshold. Then two protocols of PMS are implemented: 5 blocks of PMS of varying frequency and 1 block of rPMS.
214478449|NCT06813937|OTHER|Electroencephalography (EEG)|EEG is a technique commonly used for the registration of brain activity. The procedure is non-invasive, electrodes are placed on the scalp of the participants. The recording is made simultaneously with the PMS.
214478450|NCT06841302|OTHER|Fibromyalgia Agents|All study participants were enrolled in a combined treatment program consisting of both a structured aerobic exercise program (swimming, cycling, or brisk walking for at least three days a week, with each session lasting two hours) and a pharmacological treatment regimen. Patients who did not adhere to the prescribed treatment regimen or who discontinued follow-up were excluded from the study.
214478451|NCT06813222|DRUG|Dapagliflozin (DAPA)|Dapagliflozin 10 mg
214897283|NCT01839890|DEVICE|Bare metal Stent|After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
214897284|NCT03411031|DRUG|Elotuzumab|Elotuzumab according to dosing schedule outlined in treatment arms.
214897285|NCT03411031|DRUG|Lenalidomide|Lenalidomide according to dosing schedule outlined in treatment arms.
214897286|NCT03411031|DRUG|Dexamethasone|"Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert."
214897287|NCT03710967|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the primary motor cortex
214897288|NCT00126828|PROCEDURE|External beam radiotherapy|
214897289|NCT04985292|DIETARY_SUPPLEMENT|Probiotic, Lactobacillus|10\^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily
214897290|NCT04985292|DIETARY_SUPPLEMENT|Placebo|Inactive substance packaged to be identical to active treatment
214897291|NCT03052751|DRUG|UCB7665|UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)
214669232|NCT06507020|BEHAVIORAL|Fall prevention knowledge education|"Frequency of Intervention: 4 sessions, 60 mins each, weeks 1, 3, 5, 8.~Intervention format：group intervention, 12-15 participants in one group.~Intervention content: Elderly fall risks, home safety improvements, community hazard identification, behavior modification.~Intervention tools: digital teaching PPTs.~Intervention deliverers: 2 members per community, one as leader for organizing health ed. activities (lectures, discussions, exercises, Q\&A), the other as assistant for support and participant safety during exercises."
214478452|NCT06813950|OTHER|Physical activity|The intervention group will participate in a 10-week structured physical activity program consisting of 120 minutes of supervised exercise per week, led by a team of physiotherapists and physical activity professionals. Meanwhile, the control group will not participate in any organized physical activity program but will continue with their usual activities.
214478453|NCT06842186|DRUG|WVE-007|Stereopure siRNA oligonucleotide
214478454|NCT06841380|OTHER|sesame-based oil|15min of oil pulling with 15ml sesame-based oil for 8 weeks
214478455|NCT06841380|OTHER|distilled water|15min rinsing with 15ml distilled water for 8 weeks
214478456|NCT04802876|DRUG|Spartalizumab|Spartalizumab (PDR001) 400mg will be given intravenously every 28 days
214669233|NCT06507020|BEHAVIORAL|Exercise education|"Frequency of intervention: 4 sessions Duration of intervention: 30 minutes/session, once in each of the 1st, 3rd, 5th and 8th weeks of the intervention period.~Intervention format: group intervention, 12 people in a group (in principle, no more than 15 people).~Intervention content: The content of health education included (1) basic knowledge of exercise safety, 4 methods of balance function exercise (2) review 4 methods of balance function exercise(3) methods of exercising muscle strength (4) 2 methods of endurance exercise.~Intervention tools: accompanying teaching materials Intervention deliverers: same as before."
214897292|NCT03052751|OTHER|Placebo|Placebo will be administered in period 1 of dosage regimen 2.
214897293|NCT06447194|DRUG|Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail|Please refer to description for interventional group.
214897294|NCT06447194|OTHER|Placebo|100mL paraspinal normal saline injection intraoperatively, once.
214897295|NCT06532292|DEVICE|Biofeedback|To facilitate PFM function, electromyography biofeedback and electrical stimulation will be employed using an intravaginal probe, tailored to individual needs.
214897296|NCT06532292|DEVICE|HIFEM|The HIFEM device (i.e. BTL EMSELLA) is FDA approved and its indications are to provide entirely non-invasive electromagnetic stimulation of pelvic floor muscle for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.
214897297|NCT06962514|OTHER|Blood flow restriction cuff|Use of blood flow restriction cuff during resistance training. The cuff pressure is set at 50% of the participant's arterial occlusion pressure.
214897298|NCT06962514|OTHER|Exercise without BFR cuff|Resistance exercise performed without blood flow restriction. Same protocol as BFR group but without cuff application.
214897299|NCT06096662|BEHAVIORAL|Verb Network Strenghtening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, to drive) orally and in writing. The participants are first asked to name someone who may perform a given activity (an agent/subject, for example a chauffeur), then to name an object which the named activity can pe performed with (a patient/object, for example a limousine). Several types of semantic cues and assistance are given if the participant has difficulties finding adequate nouns). This procedure is repeated for three different agents and objects related to the given verb. The participants is then asked to choose one of the three sentences participants have created and expand on it by telling where, when and why the agents are performing the activity. After this, the participants are given sentences (with several foils) including the activity as well as agents and objects/patients, and are asked to indicate whether the sentences are plausible or not.
214897300|NCT06292221|OTHER|A mobile Health (mHealth) tool called 'DepWatch'|The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants
214897301|NCT05417789|DRUG|Emactuzumab|Emactuzumab administered once every 2 weeks (q2w)
214897302|NCT05417789|DRUG|Placebo|Matching placebo administered once every 2 weeks (q2w)
214897303|NCT05017246|DRUG|Bupivacaine|-Epidural bupivacaine 0.1% 2-6ml/hr based on MAP within 10% of patient's baseline MAP
214897304|NCT05017246|DRUG|Morphine|-Preservative-free intrathecal morphine (duramorph) 150mcg injection (0.15ml or a 0.5mg/0.5ml prepared solution)
214897305|NCT05017246|DRUG|Lidocaine|-Lidocaine infusion 1 mg/kg ideal body weight (IBW)
214897306|NCT04208152|DRUG|anle138b|capsule containing excipient and anle138b
214897307|NCT04208152|DRUG|Placebo|matching placebo capsule containing excipient
214897308|NCT04205565|DRUG|Test group: L-oxiracetam Injection|L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
214897309|NCT04205565|DRUG|Control group: Oxiracetam Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.
214897310|NCT04205565|DRUG|Placebo group: Placebo Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
214897311|NCT04459234|DRUG|Ketamine use in CLCC sites (indication and administration protocol)|"Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription):~1. Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain~2. Administration protocol: route, posology, duration, administration sequence, premedication~3. Antalgic efficacy~4. Tolerance profile~5. Quality of life, anxiety and depression evaluations"
214897312|NCT04172935|DEVICE|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance, astigmatism is corrected.
214897313|NCT04647903|DRUG|ADAIR 10 mg IR tablets|manipulated ADAIR 3x10mg
214897314|NCT04647903|DRUG|d-amphetamine sulfate|crushed d-amphetamine sulfate 3x10mg
214897315|NCT04647903|DRUG|Placebo|placebo for oral and intranasal administration
215052489|NCT01916486|BEHAVIORAL|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
214298238|NCT06204718|OTHER|Standard pelvic floor exercises|Pelvic floor muscle exercises will be given as 2 separate exercises including fast and slow contractions. For fast contractions, participants will be asked to contract their pelvic floor muscles strongly, hold them contracted for 5 seconds, and then relax them. For slow contractions, participants will be asked to gradually contract the pelvic floor muscles, hold them at maximum contraction for 5 seconds, and relax them gradually. Participants will be asked to perform 10 slow contractions after every 10 fast contractions. The aim is to train strength, coordination, endurance, and symmetry of pelvic floor muscles, motor learning and control, dynamic lumbopelvic stability, pelvic floor, and abdominal co-contraction. Every day, 10 fast, and 10 slow contractions with a total of 20 repetitions will be applied without changing the number by modifying the exercises every week. It will be applied for a total of 12 weeks.
214298239|NCT06204718|OTHER|Involuntary reflexive pelvic floor exercises|Reflexive exercises (jump, squat jump, etc.) with 20 repetitions per day will be applied to the participants for 12 weeks with modifications every week.
214298240|NCT03939884|DRUG|MuscleCare Topical Product|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
214298241|NCT03939884|DRUG|Voltaren Topical|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
214298242|NCT03939884|DRUG|Nivea, Topical Cream|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
214298243|NCT03387839|OTHER|Stress X-Ray|Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion
214478457|NCT04802876|DRUG|Tislelizumab|Tislelizumab 300mg will be given intravenously every 28 days
214478458|NCT06756191|DRUG|Combination therapy group|Liposomal amphotericin B (AmBisome®) combination with Isavuconazole
214478459|NCT06756191|DRUG|Liposomal Amphotericin B|Liposomal amphotericin B (AmBisome®) alone
214897316|NCT04634006|DEVICE|Home-based transcranial direct current (tDCS) device|tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
214897317|NCT03659214|BEHAVIORAL|Questionnaires|Answering 4 questionnaires : anxiety, depression, quality of life and adherence
214897318|NCT02439216|DRUG|Edasalonexent|
214897319|NCT02439216|DRUG|Placebo|
214897320|NCT01804179|OTHER|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
214897321|NCT01804179|OTHER|Standard Intervention (SI) Educational Materials|"Screen for Life brochure"
214897322|NCT01804179|OTHER|CARES Intervention Educational Materials|Newly developed digital video disc (DVD) and booklet
215052490|NCT01916486|BEHAVIORAL|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
215052491|NCT01916486|BEHAVIORAL|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
215052492|NCT00507585|DRUG|Fluorouracil|300 mg/m\^2 IV over 10 Minutes, then 600 mg/m\^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
215052493|NCT00507585|DRUG|Avastin|10 mg/m\^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
215052494|NCT00507585|DRUG|Leucovorin|200 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
215052495|NCT00507585|DRUG|Oxaliplatin|60 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
215052496|NCT05480735|BEHAVIORAL|Prehabilitation|Multimodal prehabilitation program
215052497|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
214478460|NCT06587516|BEHAVIORAL|Neuromuscular Warmup Program|This intervention consists of a structured warm-up routine specifically designed to enhance neuromuscular function and balance. The program includes exercises such as two way forward lunge, single-leg balance, multidirectional lunges, single-leg hops forward and backward, and single-leg calf raises. Each exercise is aimed at improving proprioception, dynamic stability, and lower limb strength.
214478461|NCT06587516|BEHAVIORAL|Traditional Warmup Program|This intervention involves a conventional warm-up program. It includes general stretching exercises and light jogging intended to prepare the body for physical activity.
215052498|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
215052499|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
215052500|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
215052501|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
215052502|NCT00413660|DRUG|CP-690,550|Oral tablets
215052503|NCT00413660|OTHER|placebo|Placebo
215052504|NCT01896687|DEVICE|Scrambler|Electrotherapy
215052505|NCT04377503|DRUG|Tocilizumab 180 MG/ML|Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.
215052506|NCT04377503|DRUG|Methylprednisolone Sodium Succinate|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
215052507|NCT05292690|DEVICE|Powered Wheelchair Obstacle Alerting System|Evaluation of an Obstacle Alerting System
215052508|NCT05439551|DIAGNOSTIC_TEST|MeMed BV®|Patients Serum and Whole blood samples will be examined using the MeMed BV® test. Test results will have no impact on patient management.
214897323|NCT01804179|OTHER|Baseline Visit Survey|In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
215052509|NCT02021786|BEHAVIORAL|Mobile phone based intervention|Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
215052510|NCT02831855|DRUG|CP-690,550|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
215052511|NCT02831855|DRUG|Methotrexate|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
215052512|NCT02831855|DRUG|Placebo|During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
215052513|NCT02785783|DEVICE|Standard colonoscopy|
215052514|NCT02785783|DEVICE|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
215052515|NCT05794737|BIOLOGICAL|Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.
215052516|NCT01722994|DEVICE|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
215052517|NCT01722994|DEVICE|Chromic Gut Sterile absorbable Suture (Ethicon)|
214897324|NCT01804179|OTHER|Follow-up Questionnaire|12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
214897325|NCT02636478|OTHER|questionnaire for travel habits|questionnaire has been used to collect information about travelling
214897326|NCT01897428|DRUG|Test-Bepotastine salicylate 9.64 mg|
214897327|NCT01897428|DRUG|Reference-bepotastine besilate 10 mg|
214897328|NCT05941312|PROCEDURE|autologous products|After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.
215052518|NCT04858841|DRUG|Levetiracetam Oral Product|Administer levetiracetam powder once a day in eligible patients
215052519|NCT04858841|DRUG|Perampanel Oral Product|Administer perampanel powder once a day in eligible patients
214298244|NCT04472624|OTHER|Fasting|Acute fasting for 72 hours
214897329|NCT01927575|DEVICE|Standard X-Ray + CT|Standard of Care X-Ray Imaging + CT
214897330|NCT01927575|DEVICE|Standard X-Ray + MRI|Standard of Care X-Ray Imaging + MRI
214897331|NCT01927575|DEVICE|TOMO|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
214897332|NCT02378129|DRUG|Resin-modified glass ionomer cement Clinpro XT|Clinpro XT (3M ESPE, Minnesota, USA)
214897333|NCT02378129|DRUG|Glass Ionomer cement Vidrion R|Vidrion R (SS White, Gloucester, UK)
214897334|NCT00413101|DRUG|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/L
214897335|NCT05241340|DRUG|Sasanlimab|Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1). Manufactured by Pfizer, Inc.
215052520|NCT04858841|DRUG|Placebo|Administer placebo powder once a day in eligible patients
215052521|NCT00858325|DRUG|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
215052522|NCT05317650|OTHER|Multi-gravitational suspension-based therapy (M-Gravity)|Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
215052523|NCT06503822|DEVICE|Long peripheral venous catheter|In this study, patients eligible for admission were subjected to peripheral vein long catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data were collected.
215052524|NCT06503822|OTHER|Control group (Short peripheral venous catheter)|In this study, the patients eligible for admission will undergo peripheral venous short catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data will be collected.
215052525|NCT03012191|DRUG|Gentamicin Sulfate|Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
215052526|NCT02485509|DRUG|VM-1500/Placebo|VM-1500 or Placebo
215052527|NCT01803880|DEVICE|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
215052528|NCT01803880|DEVICE|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
214298245|NCT04472624|OTHER|Ketogenic diet|Intake of a ketogenic diet for 14 days
214298246|NCT01361464|DRUG|Tipifarnib|Given PO
214897336|NCT05241340|RADIATION|Stereotactic Body Radiation Therapy|This current study is designed to deliver a biologically equivalent dose of 43.2Gy using a strategy of HD hypo-fractionated radiation therapy 8Gy x 3 in combination with Sasanlimab
215052529|NCT03685981|OTHER|Incentives mailer|Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
215052530|NCT02063685|DRUG|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
214897337|NCT05241340|PROCEDURE|Radical Cystectomy + pelvic lymph node dissection + urinary diversion|"This will include a cysto-prostatectomy in males or a radical cystectomy with anterior exenteration in females, bilateral pelvic lymph node dissection, and creation of a urinary diversion (ileal conduit, Indiana pouch or orthotopic neo-bladder). Robotic assisted or open surgery will be permitted.~Because there is currently equipoise regarding standard or extended template pelvic lymph node dissection, the limits of node dissection will not be protocol mandated. In the standard template, nodal packets will include the common iliac, external iliac, internal iliac (or hypogastric) and obturator nodes. Patients receiving an extended template will have the standard nodes with the addition of the para-aortic, para-caval, pre-sacral, and pre-sciatic node packets. The decision for urinary diversion is multifactorial involving patient factors (e.g., adequate renal function) and preference; thus, it will be made on a case-by-case basis."
214897338|NCT06378515|OTHER|Physical activity, postural changes and cognitive tasks|"1. Measuring while patients are sitting in rest for 5 minutes.~2. Supine to stand test: lying down (5 min) standing up (5 min)~3. Repeated sit stand test: sitting (10 sec) ↔ standing (10 sec), changing position every 10 seconds for 5 minutes.~4. Paced breathing in sitting position: letting patients breath 6 breaths/minute (0.1Hz) for 5 minutes.~5. Breath hold manoeuvre in sitting position: 60s normal breathing, then 32s breath hold + 88s normal breathing repeated 3 times.~6. Arithmetic stress test by giving the subject single digit addition. To give the pressure, subject needs to do as many as possible calculation within 1 minute with 1 minute break. This is repeated 3 times."
214897339|NCT03359850|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
215052531|NCT02063685|DRUG|Observation|not maintenance therapy and followed-up with MRD monitoring.
215052532|NCT02063685|DRUG|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
215052533|NCT02063685|DRUG|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
215052534|NCT02063685|DRUG|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
215052535|NCT00964951|BIOLOGICAL|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
215052536|NCT00964951|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
215052537|NCT00723151|BEHAVIORAL|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
215052538|NCT01487486|DRUG|IVF Antagonist Protocol|"1. Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~2. Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle \>14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~3. hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
215052539|NCT05421676|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
214897340|NCT03963193|DRUG|Etoposide|Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.
214897341|NCT03963193|DRUG|Irinotecan|Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days.
214897342|NCT02492373|DRUG|topical 0.05% Clobetasol propionate ointment|Apply only on the treated area twice a day as mentions
214897343|NCT02492373|DEVICE|Q switched Nd:YAG laser 532 nm|Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
214897344|NCT05638776|DRUG|REGEND001 cell therapy|Transplantation of the cell product
214897345|NCT05638776|DRUG|Placebo|Transplantation of Placebo
214897346|NCT05280392|OTHER|Self-administered questionnaires|4 self-questionnaires given to EHVA T02 participants: at inclusion (Q1, week 0), at the beginning of the ATI period (Q2, week 18), at the end of the ATI period (Q3, date depending on the participant) and at the end of the follow-up period of the clinical trial (Q4, week 54 at the latest)
214897347|NCT05280392|OTHER|Semi-directive individual interviews|With EHVA T02 participants (n=10 to 15): at the end of the follow-up period of the clinical trial.
215052540|NCT00541112|BIOLOGICAL|cetuximab|
215052541|NCT00541112|DRUG|capecitabine|
214298247|NCT01361464|OTHER|Laboratory Biomarker Analysis|Correlative studies
214298248|NCT01269424|BIOLOGICAL|MGMTP140K-encoding retroviral vector|
214298249|NCT01269424|DRUG|O6-benzylguanine|
214298250|NCT01269424|DRUG|temozolomide|
214298251|NCT01269424|OTHER|laboratory biomarker analysis|
214298252|NCT01269424|PROCEDURE|autologous hematopoietic stem cell transplantation|
214298253|NCT01269424|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214298254|NCT01269424|RADIATION|radiation therapy|
214298255|NCT06320028|DEVICE|Non-Invasive Transcranial Focused Ultrasound|The ultrasound will be delivered for 10 minutes per treatment session targeting to the participant's amPFC.
214298256|NCT02667574|DRUG|ERIVEDGE|
214298257|NCT04617444|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214298258|NCT04617444|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
214298259|NCT03566251|OTHER|Balance|Balance was assessed by Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Postural Stability (PS), Limits of Stability (LOS) and Modified Sensory Organization Tests (MSOT) were evaluated with this system. PS test assesses static balance during standing up by the ability to hold the center of gravity on the support surface. The test was performed on both feet and on the left and right foot separately. LOS test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces.
214298260|NCT03566251|OTHER|Functional mobility|Timed Up and Go (TUG) tests were used to evaluate functional mobility. The TUG measures the time it takes a subject to stand up from an armchair, walk a distance of 3 m, turn, walk back to the chair and sit down. Time was recorded in seconds with a stopwatch.
214298261|NCT03566251|OTHER|Core stability|Core endurance and core strength, which are two specific components of core stability, were evaluated separately. Trunk flexor, trunk extensor, right and left side bridge and prone bridge tests were applied to assess the endurance of the core muscles. Tests were terminated when the subjects said they could not continue the test or when the test position was broken. A stopwatch was used for the measurements and the results were recorded in seconds. The power of core muscles was evaluated with sit-ups and modified push-ups tests. It was recorded how many times the subject could do each test for 30 seconds. The tests were repeated twice and the best measurement score was recorded for use in the statistical analyses.
214298262|NCT03566251|OTHER|Trunk position sense|Trunk position sense was evaluated by the trunk reposition test with Dualer IQ digital inclinometer (J-TECH medical, Salt Lake City, UK, USA). Measurements were made in two levels: lumbosacral (LS) and thoracosacral (TS) regions. The testing took place while standing under three visual-surface conditions. Participants flexed the trunk approximately 30° in the sagittal plane, holding the position for a count of 3 seconds (position 1) and then participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position for a count of 3 seconds (position 2). The absolute difference in degrees between positions 1 and 2 was defined as the trunk reposition error (TRE) degree. Participants generated five scores for each visual-surface condition. For each condition, the highest and lowest scores were discarded and the mean of the remaining three scores represented the TRE score
214298263|NCT03087760|DRUG|Pembrolizumab|Concurrent Pembrolizumab after proton reirradiation
214669234|NCT06507020|BEHAVIORAL|Home hazard reduction education|"Intervention Time:~One home fall risk assessment and modification instruction at week 6 of health education.~Frequency of Intervention:~Single session.~Intervention Format:~Project staff conduct in-home fall risk assessments by appointment.~Intervention Content:~1. Evaluate fall risks in elderly living areas.~2. Provide personal guidance, complete two written forms-one for records, one for the participants.~3. Supply night lights, anti-slip mats, warning signs, and carpet mats; more services encouraged where possible.~Intervention Tools:~Utilize Elderly Home Fall Risk and Retrofitting Guide for detailed assessments and suggestions. Include tools like night lights, mats, and signs.~Intervention Deliverers:~Skilled community social workers or community health center staff."
214669235|NCT01566344|OTHER|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
214669236|NCT00003995|BIOLOGICAL|trastuzumab|
214298264|NCT04666584|DEVICE|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon
214669237|NCT00003995|DRUG|irinotecan hydrochloride|
214298265|NCT04666584|DEVICE|Device: standard non-compliant balloon|Pre-dilatation with a standard non-compliant balloon
214669238|NCT05170945|OTHER|Early bowel preparation for colonoscopy|Early (\<24 hours) bowel cleansing prior to colonoscopy.
214669239|NCT00643045|DRUG|Safinamide|
214669240|NCT00643045|DRUG|Safinamide|
214669241|NCT00643045|DRUG|Placebo|
214669242|NCT01688648|DRUG|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
214669243|NCT01688648|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery
215052542|NCT00541112|DRUG|fluorouracil|
215052543|NCT00541112|DRUG|leucovorin calcium|
215052544|NCT00541112|DRUG|oxaliplatin|
215052545|NCT00541112|PROCEDURE|adjuvant therapy|
215052546|NCT00541112|PROCEDURE|conventional surgery|
215052547|NCT00541112|PROCEDURE|neoadjuvant therapy|
215052548|NCT00541112|RADIATION|radiation therapy|
215052549|NCT00001034|DRUG|Ganciclovir|
214298266|NCT04588792|DRUG|Nebulized Furosemide|Furosemide administered by nebulization through the ventilator circuit
214298267|NCT04588792|DRUG|Nebulized Saline|Saline administered by nebulization through the ventilator circuit
214298268|NCT05336955|OTHER|Intake and quarterly assessment:|The START Plan is designed to evaluate the mental health needs of persons with IDD and measure the capacity of the formal and natural support systems. Family caregivers, or the person primarily responsible for day-to-day care of the person, participate in a formatted interview conducted by START coordinators. The START coordinator completes the initial START Plan during intake and quarterly thereafter. Based on informant responses, an intensity rating is assigned to determine the type, frequency, and duration of services to be provided. Quarterly assessment is conducted to inform development or modification of the Cross-Systems Crisis Prevention and Intervention Plan (D.2.b.2.). Hypothesized causal pathway: Family caregiver engagement in assessment enables the START team to efficiently and effectively identify needs and socially valid solutions that strategically reduce use of emergency services and increase mental health stability.
214298269|NCT05336955|OTHER|Consultation & coping skills coaching:|Mental health service consultation is provided by START clinical and medical directors in order to prevent and de-escalate crises. Coping skills coaching, provided by START coordinators, helps to determine with the person, their family, and the system of care how to promote well-being and stability. Successful coping skills for the person are incorporated into the Cross-Systems Crisis Prevention and Intervention Plan. All methods are manualized and reported to meet model fidelity. Hypothesized causal pathway: Providing consultation and coping skills coaching to youth and young adults with IDD, their families, and their system of care increases capacity for crisis prevention and stabilization, reduces emergency service use, and increases quality of care, leading to long-term stability.
214478462|NCT06336772|DEVICE|Restylane Shaype|Half (50%) of study participants will receive Restylane Shaype for the treatment of mild to severe chin retrusion
214478463|NCT06336772|DEVICE|Juvéderm Volux|Half (50%) of study participants will receive Juvéderm Volux for the treatment of mild to severe chin retrusion
214478464|NCT04468672|BEHAVIORAL|Portion size|The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
214478465|NCT06668792|DRUG|BCD-248|subcutaneously
214478466|NCT05819502|DRUG|Restylane line of injectables|Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
214478467|NCT05147584|DEVICE|Dual fetal oxygen sensors|Placement of both internal and external fetal oxygen sensors
214478468|NCT06571812|DEVICE|TSX|Treatment of tooth loss with TSX dental implants
214478469|NCT05460871|DRUG|Pregabalin 75mg|participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, then 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days, then stop.
214478470|NCT03967379|BEHAVIORAL|Mobile App + enhanced standard care|An intervention to help address sexual dysfunction among HCT survivors
214478471|NCT03967379|OTHER|Enhanced Standard Care|Standard of care administered by the institution
215052550|NCT00353080|DRUG|risedronate (HMR4003)|
215052551|NCT03225248|DRUG|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
215052552|NCT03225248|DRUG|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
215052553|NCT00675831|DEVICE|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
214897348|NCT05280392|OTHER|Semi-directive individual interviews|With patients who refused to participate to EHVA T02 or patients not included because of negative screening results (n=10 to 15): within 21 days after the refusal or the results of the screening
214897349|NCT03525704|DEVICE|Saline Solution Enriched|Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution
214897350|NCT03525704|DEVICE|Saline Rinse Solution|sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i
214897351|NCT01690117|BEHAVIORAL|GE-REACH-program|"The intervention program Resources to Enhance Alzheimer's Caregivers Health -second step (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers"
214897352|NCT05933018|DIAGNOSTIC_TEST|liver elastography|the imaging of the liver will perform in the fasting state, in the morning hours by one specialist, dedicated to this procedure,
214897353|NCT04879992|DRUG|Esomeprazole|Proton pump inhibitor
214897354|NCT04879992|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214897355|NCT04879992|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
214897356|NCT04879992|DRUG|amoxicillin rifabutin|Antibiotics for H. pylori eradication
214897357|NCT01371604|DRUG|IDX184|IDX184 50 mg tablet administered orally
215052554|NCT02012036|DRUG|Hexvix|"As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required."
215052555|NCT01453491|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
215052556|NCT01942824|BEHAVIORAL|Text Messages|
215052557|NCT02223052|DRUG|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
215052558|NCT02223052|DRUG|Vidaza|75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
215052559|NCT02954887|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
214298270|NCT05336955|OTHER|24-hour urgent crisis response and intervention:|START teams have 24-hour, in-person mobile crisis intervention services. Emergency calls come from a variety of sources; clients, emergency rooms, service providers, families, and law enforcement. START provides immediate telephonic response and in-person evaluation within two hours of the initial contact. Hypothesized causal pathway: Real-time, immediate support enables the successful enactment of crisis evaluation and stabilization. This reduces severity of the crises and allows for diversion from emergency service use.
214298271|NCT05336955|OTHER|Service linkages, referrals, outreach, & training:|START teams work with stakeholders to develop and maintain linkage agreements. The purpose of these agreements is to enhance the capacity of the system as a whole and develop partnerships to reduce disparities and gaps in the service array. START coordinators conduct crisis prevention-focused outreach visits with the person and/or their system of care. Examples include training during home- and school-based visits, family caregiver coaching to implement new plans or strategies, and checking in with the person to monitor their level of stability. Hypothesized causal pathway: Increased person-centered collaboration and dialogue across systems of care promotes patient perceived quality of care, the identification of more effective strategies that support their mental health needs, and results in reduced use of emergency services.
214298272|NCT04489212|OTHER|Medical Chart Review|Review of medical chart
214669244|NCT02102061|OTHER|multidisciplinary intervention|"a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size."
214669245|NCT02494908|BEHAVIORAL|Playing a computer game simulating a car race|Playing a computer game simulating a car race
214478472|NCT03329937|DRUG|Niraparib|Niraparib is a potent, orally active, highly selective poly adenosine diphosphate (\[ADP\]-ribose) polymerase 1 (PARP1) and PARP2 inhibitor. It will be supplied as 100 mg capsules and will be administered at starting dose of 200 mg PO daily throughout 28 days for 2 cycles (each cycle is 28 days), with the potential for an additional 4 cycles (maximum total of 6 cycles) at the assigned dose and schedule.
214478473|NCT04664959|DRUG|SB16 (Proposed Denosumab Biosimilar)|"Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously."
214669246|NCT04555213|DRUG|NOX66|NOX66 Suppository
214669247|NCT04804124|BEHAVIORAL|Regularized Sleep Schedule|Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
214669248|NCT02974075|PROCEDURE|Salvage lymph node dissection|Open pelvic surgery to dissect pelvic lymph nodes. The landmarks for dissection are: 1. Inferior mesenteric artery 2. Ilioinguinal nerve 3. Inguinal ligament 4. Dorsal pelvic floor 5. Urinary bladder
214669249|NCT00634543|DRUG|Tramadol hydrochloride/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
214897358|NCT01371604|BIOLOGICAL|Peginterferon alfa-2a (Peg-IFN)|Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
214897359|NCT01371604|DRUG|Ribavirin (RBV)|Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
214897360|NCT01371604|DRUG|Placebo|Matching placebo to IDX184 50 mg tablet administered orally
214897361|NCT05709418|BEHAVIORAL|Intensiv support for first graders in Norway|Intervention targeting early numeracy skills that are known to be important for mathematical development, focusing on counting skills, counting strategies, number knowledge, word problem solving and basic understanding of addition and subtraction
214897362|NCT00665405|RADIATION|CT scan|Thoracic CT scan
214897363|NCT01164293|DEVICE|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
214897364|NCT04298398|BEHAVIORAL|Mindfulness Based-Cognitive Therapy (MBCT)|MBCT is a program developed by Zindel Segal, Mark Williams and John Teasdale. During MBCT patients learn to decenter their negative thoughts and feelings, allowing the mind to move from an automatic thought pattern to conscious emotional processing. Mindfulness practices included in this program are breath awareness, body scan, sitting and walking meditation, and mindful yoga. The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
214907260|NCT05926661|OTHER|NCC Support Toolkit|"Pre-discharge intervention-~* Set expectations for parents/caregivers to spend time bedside and attend rounds~* iPad for the families to use the Nemours App, download education materials and Facetime communication with medical personnel.~* Download Nemours App and teach them how to use it~* Education materials- to ease the use of medications, Oxygen and feeding~* Assistance with transportation, child care, parental work schedule for discharge teaching~Post Discharge intervention (Day 1-2):~• Video/Facetime call with the family to check equipment, home environment and answer questions about medications and formula~Post discharge intervention (Day 3-7):~• Phone call to the family to ensure transportation for their first follow-up appointment, answer questions about medications, Oxygen and feeding."
214298273|NCT04489212|OTHER|Patient Observation|Undergo observation
214298274|NCT04489212|OTHER|Quality-of-Life Assessment|Ancillary studies
214298275|NCT04489212|OTHER|Questionnaire Administration|Ancillary studies
214897365|NCT04298398|BEHAVIORAL|Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|EFT-CR is an evidence-based approach to psychotherapy, which combines aspects of person-centered, gestalt and existential therapies with contemporary emotion theory and dialectical constructivism (Elliott et al, 2004, Rice \& Greenberg, 1984). On EFT-CR, therapist follows the client experience and guides the process, proposing therapeutic tasks when specific client behaviors occur. EFT-CR uses a set of emotion change principles which guide a process of emotional deepening process, from undifferentiated distress to secondary reactive emotions to primary maladaptive emotions to core pain and thence to primary adaptive emotions and emotional transformation (Elliott \& Greenberg 2016). The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
214897366|NCT04298398|OTHER|Treatment as usual (no intervention)|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
214897367|NCT05194826|PROCEDURE|Test|immediate implant and VST with fascia lata membrane + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
214897368|NCT05194826|PROCEDURE|Control|immediate implant and VST with connective tissue graft + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
214897369|NCT03472014|BIOLOGICAL|IMVAMUNE®|IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose
214897370|NCT02792517|DRUG|Erenumab|A single dose of erenumab administered in the abdomen.
214897371|NCT02792517|DRUG|Ethynil Estradiol/Norgestimate Oral Contraceptive|Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.
214897372|NCT02931864|OTHER|Online mindfulness training|5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
214897373|NCT02931864|OTHER|Online symptom management|5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
214897374|NCT00663793|DRUG|Acyline|300 mcg/kg
214897375|NCT00663793|DRUG|Testosterone|"24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
214897376|NCT00663793|DRUG|Finasteride|1 mg PO once daily \[day -2 to day 12) 14 days total
214298276|NCT01131923|DRUG|Amlodipine|Amlodipine Tablets, 10 mg
214897377|NCT01803698|BEHAVIORAL|Training in the use of IOM charts|
214897378|NCT00001042|BIOLOGICAL|Aluminum hydroxide|
214897379|NCT00001042|BIOLOGICAL|Lipid A, Monophosphoryl|
214897380|NCT00001042|BIOLOGICAL|Lipid A, Liposome-encapsulated monophosphoryl|
215052560|NCT04476667|BEHAVIORAL|e-Psychotherapy|Module Content: The first 3 sessions will be designed to address the symptoms caused by fear of illness or concerns about personal safety in the context of pandemic. Electronic-CBT (e-CBT) modules will focus on problem solving techniques, with mindfulness practices included, to help build healthy coping skills to address the uncertainties surrounding the COVID-19 pandemic. e-CBT modules will involve guiding participants to develop constructive and balanced coping strategies through 5 focuses: stimulus control, cognitive therapy, sleep hygiene, relaxation therapy, and sleep restriction. Additional focus will be placed on the connection between thoughts, behaviours, emotions, physical reaction and one's environment.
215052561|NCT02388880|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
215052562|NCT03396887|OTHER|U Control Drink Smartphone Application|The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.
215052563|NCT03396887|OTHER|Control group|The control group will receive treatment as usual.
215052564|NCT01459666|DRUG|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
214897381|NCT00001042|BIOLOGICAL|Syntex adjuvant formulation|
214897382|NCT00001042|BIOLOGICAL|MF59|
214897383|NCT00001042|BIOLOGICAL|Threonyl Muramyl Dipeptide|
214897384|NCT00001042|BIOLOGICAL|rgp120/HIV-1 SF-2|
215052565|NCT01459666|DRUG|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
215052566|NCT01404650|DRUG|AUY922|AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
214298277|NCT02511366|OTHER|Ileal infusion of casein|Intraileal infusion of casein
214298278|NCT02511366|OTHER|Ileal infusion of tap water|Intraileal infusion of tap water
214298279|NCT04520737|BEHAVIORAL|Physical Prehabilitation|The prehabilitation program consists of the following interventions: in-hospital high-moderate intensive exercise training, nutritional assessment and high-protein supplementation, smoking cessation, psychological support and Comprehensive Geriatric Assessment.
214298280|NCT02573857|DRUG|DSM265|Oral suspension from bulk powder
214298281|NCT02573857|DRUG|OZ439|Oral suspension from powder in a bottle
215052567|NCT01152788|DRUG|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
214897385|NCT00001042|BIOLOGICAL|MTP-PE/MF59|
214897386|NCT02493153|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
214897387|NCT06351891|DRUG|14-day bismuth quadruple regimen containing cefuroxime and tetracycline|14-day bismuth quadruple regimen containing cefuroxime and tetracycline:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Tetracycline 500mg tid,14 days.Evaluating the efficacy and safety of 14-Day bismuth quadruple therapy containing cefuroxime and tetracycline for Helicobacter pylori eradication.
214897388|NCT06351891|DRUG|14-day bismuth quadruple regimen containing cefuroxime and levofloxacin|14-day bismuth quadruple regimen containing cefuroxime and levofloxacin:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Levofloxacin 500mg qd,14 days.
214897389|NCT04842331|DRUG|RESP301 (a nitric oxide generating solution)|Administration is simple and convenient; each dose of RESP301 is administered 3 times daily (at least 4 hours apart) via inhalation using a portable handheld vibrating mesh nebuliser for approximately 8-10 minutes.
214897390|NCT04842331|DRUG|Standard of Care (SOC)|Participants will receive institutional SOC for the treatment.
214897391|NCT04784091|DRUG|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
214897392|NCT04784091|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
214897393|NCT02479620|DRUG|Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL|Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
214897394|NCT01739465|PROCEDURE|Self expanding metallic stent (SEMS)|Self expanding metallic stent
214897395|NCT01739465|PROCEDURE|Endoscopic radiofrequency ablation (ERFA)|Endoscopic radiofrequency ablation
214897396|NCT01739465|PROCEDURE|Photodynamic therapy (PDT)|Photodynamic therapy
214897397|NCT05596110|BEHAVIORAL|TENS and KT|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
214897398|NCT05596110|BEHAVIORAL|TENS and sham taping|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
214897399|NCT05596110|BEHAVIORAL|KT and sham TENS|KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.
214897400|NCT05596110|BEHAVIORAL|Sham TENS and sham taping|Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
214897401|NCT05861518|BEHAVIORAL|Hypnosis|In the hypnosis group, patients were given hypnosis sessions of approximately 30 minutes each, in groups of three, once a week. In this way, session standardization was achieved. Arm catalepsy was suggested in all patients. The first session was used as hypnosis induction, progressive muscular relaxation and introduction to hypnosis. In the second session, in addition to the first session, self-hypnosis training was given. The second session was applied as the same 3rd session. In these patients, in addition to analgesia suggestions, the feeling of worthlessness was especially studied with the recommendation of a psychiatrist.
214897402|NCT03243110|DIAGNOSTIC_TEST|breathing test|Spirometry is a non-invasive means of measuring lung function: The participant is asked to take a deep breath and then exhale into the sensor as hard and as long as possible. Soft nose clips may be used to prevent air escaping through the nose. If the participant does not show a definitive diagnosis of asthma, a methacholine challenge test will be performed to elicit bronchoconstriction in participants. In methacholine challenge test, the participant breaths in standardized dose of nebulized methacholine again. Methacholine challenge test is widely accepted and standardized method for assisting the diagnosis of asthma and there will be no experimental altercation in the method methacholine challenge is performed.
214897403|NCT00659308|PROCEDURE|amniotic membrane transplantation|patients are submitted to amniotic membrane transplantation
214897404|NCT00659308|PROCEDURE|anterior stromal puncture|the other group is submitted to anterior stromal puncture
214897405|NCT03198442|PROCEDURE|F-18 FDG breast PET scan|
214897406|NCT05418842|OTHER|Prehabilitation|In addition to usual care, the prehabilitation group will exercise 3 times a week, starting immediately after diagnosis and throughout the pre-treatment period. Each exercise session will encompass 5-min warm-up and 45-min conditioning exercises. Aerobic training will be performed using low-volume high intensity interval training (HIIT). The HIIT duration is 16-20 minutes and it will be performed with 8-10 intervals of high intensity (1 minute) and 8-10 intervals of low intensity (1 minute). High intensity intervals will be set to an external load that represents 85-90% of estimated VO2Peak. In addition, patients will do resistance training at moderate intensity. Patients will complete 2 sets of 12 repetitions of 5 upper and lower body exercises.
214897407|NCT04229693|OTHER|no intervention|no intervention, only observational.
214897408|NCT06205771|OTHER|H2S content|H2S content
214897409|NCT00777387|PROCEDURE|slow-freeze|Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures
214897410|NCT00777387|PROCEDURE|vitrification|Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
214669250|NCT00634543|DRUG|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
214897411|NCT04861753|OTHER|Reiki and back massage|In the current study, at the beginning of the treatment, the researcher held his hands 2-3 cm above the patient sand adjusted the aura of the patient by making circular movements from the head to the feet. After this process of aura attunement, the researcher placed his hands directly on the patient's body. In the areas where the practitioner had placed his hands for an average of three minutes, starting from between the eyes, the researcher felt various degrees of warmth and tingling in his palms. Only the back was left exposed to prevent the patient becoming cold. The researcher took a little non-aromatic baby oil in hand and heated it, then began a 20-minute-long massage. The massage consisted of 6.5 minutes of effleurage (stroking), 3.5 minutes of petrissage (kneading), 13 minutes of effleurage and seven minutes of petrissage.
214897412|NCT04871360|DIETARY_SUPPLEMENT|L-Citrulline supplement|The intervention will consist of oral supplementation of six grams of pure l-citrulline for eight weeks.
214897413|NCT04871360|DIETARY_SUPPLEMENT|Carboxymethyl cellulose supplement|The intervention will consist of oral carboxymethyl cellulose supplementation as a placebo.
214897414|NCT03743051|DRUG|Anamorelin Hydrochloride|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
214897415|NCT03743051|DRUG|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
214897416|NCT03830489|DRUG|polyethylene glycol|The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet
214897417|NCT03830489|DRUG|polyethylene glycol plus ascorbic acid|The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet
215052568|NCT01152788|DRUG|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
215052569|NCT02957513|BEHAVIORAL|Text Messaging (TM)|As specified in the arm description above
215052570|NCT02957513|BEHAVIORAL|Health Coaching (HC)|As specified in the arm description above
215052571|NCT02957513|BEHAVIORAL|Enhanced Usual Care (EC)|As specified in the arm description above
215052572|NCT00314821|DRUG|ropinirole|
215052573|NCT04038294|DIETARY_SUPPLEMENT|ISOlution protein supplement|EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
215052574|NCT04038294|DIETARY_SUPPLEMENT|Placebo Supplement|PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
215052575|NCT01749527|BEHAVIORAL|minimal activity|Pad test with minimal activity
215052576|NCT00005579|DRUG|dolastatin 10|
215052577|NCT01746290|OTHER|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
215052578|NCT02950103|DRUG|Phosphoethanolamine|Phosphoethanolamine PO daily
215052579|NCT04904107|DIAGNOSTIC_TEST|modified HEART score (including POC hs cTnI analysis)|"The modified HEART score was developed in 2007 and has been validated to stratify the risk of short-term adverse cardiac events in patients with chest pain at the ED. Negative predictive value (NPV) of the modified HEART score for ACS as well as positive predictive value (PPV) for major adverse cardiac events (MACE) within 6 weeks after presentation is high.~The modified HEART score is an acronym for history, ECG, age, risk factors and troponin at arrival.The components can be rated 0,1 or 2 points each and result in a total score between 0 and 10."
215052580|NCT04904107|OTHER|Standard care and triage according to the local (EMT)protocol.|Standard care and triage of chest pain patients according to the local (EMT)protocol.
215052581|NCT02516501|DIETARY_SUPPLEMENT|MyAmino|MyAmino is a supplement containing the eight essential amino acids. MyAmino has a theoretical net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.
214298282|NCT05020990|DEVICE|Lens A (delefilcon A)|Daily disposable for one week
214897418|NCT02768818|DIETARY_SUPPLEMENT|Probiotic VIVOMIXX™|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
214669251|NCT02401256|DRUG|Efavirenz|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
215052582|NCT02516501|DIETARY_SUPPLEMENT|betaquik|betaquik is a medium chain triglyceride (MCT) emulsion. One bottle is 225ml corresponding to 45g MCT fats.
215052583|NCT02516501|RADIATION|Radio(chemo)therapy|Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
215052584|NCT02251496|OTHER|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
214298283|NCT05020990|DEVICE|Lens B (stenfilcon A)|Daily disposable for one week
214298284|NCT00671502|DRUG|Carisoprodol SR|700 mg twice daily
214298285|NCT00671502|DRUG|Carisoprodol SR|500 mg twice daily
214298286|NCT00671502|DRUG|Placebo|Placebo tablet
214298287|NCT01537744|DRUG|oral 5-azacitidine in combination with romidepsin|"DOSING REGIMEN(S):~Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)~Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15~Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15~Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15~Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15~Level 4d MTD 8mg/m2 days 8, 15, and 22~1. Each cycle will last 28 days.~2. Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.~3. On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.~4. Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene."
214298288|NCT05047510|DRUG|Anti-GPC3-IRDye800CW|Drug Injection: Anti-GPC3-IRDye800CW
214298289|NCT04128267|DEVICE|IPC-1000|Delivers pressure to thumbnail for five seconds at a time
214298290|NCT04128267|DEVICE|Magnetic resonance imaging|Scan of brain using Magnetic resonance imaging
214298291|NCT04128267|OTHER|Correlative Studies|Administration of questionnaires via computer
214298292|NCT04501666|DRUG|Nemolizumab 30 mg|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
214298293|NCT04501666|DRUG|Placebo|Participants received matching placebo as SC injection.
214298294|NCT00894049|DRUG|reduced intensity conditionings|comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
214298295|NCT03007381|DRUG|Ketorolac Tromethamine|Intravenous analgesic
214298296|NCT03007381|DRUG|Normal Saline|Sham comparator
214298297|NCT02651727|DRUG|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
214298298|NCT02651727|DRUG|Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine|IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
214897419|NCT02768818|DIETARY_SUPPLEMENT|Placebo|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
214897420|NCT00811733|BIOLOGICAL|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
214897421|NCT00793871|DRUG|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
214298299|NCT02651727|DRUG|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
214298300|NCT03249298|DRUG|Sterofundin (Bolus of crystalloids)|Bolus of 250 ml crystaloids infused regarding the measures
214298301|NCT03249298|DRUG|Voluven (Bolus of colloids)|Bolus of 250 ml colloids infused regarding the measures
214298302|NCT05821114|OTHER|Head elevation_H|High flow\_Head-elevation
214298303|NCT05821114|OTHER|Supine_H|High flow\_Supine
214298304|NCT05821114|OTHER|Head elevation_L|Low flow\_head elevation
214298305|NCT05821114|OTHER|Supine_L|Low flow\_supine
214298306|NCT04855825|DEVICE|Robotic Exoskeleton Rehabilitation|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
214298307|NCT04855825|OTHER|Conventional Gait Therapy|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
214298308|NCT02747901|OTHER|KINESIOTAPING|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
214298309|NCT02747901|OTHER|COLD THERAPY|Cold therapy group received cold packs immediately after operation and following postoperative days
214298310|NCT03736291|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
214298311|NCT03021265|DRUG|T80/A5/H12.5 FDC|Drug
214478474|NCT04664959|DRUG|Prolia® (Denosumab)|Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
214897422|NCT05642871|RADIATION|DKI and APT|DKI and APT in patients with ovarian malignancy before and after treatment
214298312|NCT01722071|DRUG|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
214298313|NCT01722071|DRUG|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
214298314|NCT01266512|DRUG|DOCETAXEL|Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
214298315|NCT01266512|RADIATION|Intensity Modulated Radiotherapy (IMRT)|2 Gy per fraction
214298316|NCT01266512|DRUG|CISPLATIN|Pharmaceutical form: solution for infusion Route of administration: intravenous
214298317|NCT00642941|DRUG|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
214298318|NCT05072574|OTHER|Specific dietary treatment and follow-up using coaching techniques|Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
214478475|NCT06291207|DRUG|AD-224A|PO, Once daily, 8weeks
214478476|NCT06291207|DRUG|AD-224B|PO, Once daily, 8weeks
214478477|NCT06291207|DRUG|AD-224C|PO, Once daily, 8weeks
214478478|NCT06291207|DRUG|Placebo of AD-224A|PO, Once daily, 8weeks
214907261|NCT03936361|DRUG|Statins|Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
214907262|NCT01815541|DRUG|teicoplanin|
214907263|NCT04594551|BIOLOGICAL|Purified vero rabies vaccine - serum free|Pharmaceutical form:freeze-dried - Route of administration: intramuscular
214298319|NCT03834701|DEVICE|EUS guided radiofrequency ablation|The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
214298320|NCT04881708|DEVICE|Remote Monitoring|Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
214298321|NCT01698047|BEHAVIORAL|Resiliency Class|See Arm Description
214298322|NCT01698047|OTHER|Case Management|See Case Management description
214298323|NCT02632539|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
214298324|NCT02632539|PROCEDURE|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
214298325|NCT02416440|OTHER|blood sample|blood sample
214897423|NCT03426111|DEVICE|Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)|This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
214298326|NCT02649907|DIETARY_SUPPLEMENT|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
214298327|NCT02649907|OTHER|Nutritional counseling|nutritional counseling for healthy eating behaviour
214298328|NCT02649907|DIETARY_SUPPLEMENT|formula diet|formula diet to help weight loss
214298329|NCT00941473|DRUG|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
214298330|NCT00815581|DEVICE|photorefraction,cycloautorefraction,cycloretinoscopy|
214298331|NCT04343599|OTHER|Hypopressive exercises|The first two sessions will have as objective the correct and effective learning of the hypopressive technique. The rest of the sessions will be dedicated to the realization of an exercise protocol based on a progression of postures from standing to supine. Diaphragmatic apneas of approximately 7 seconds will be performed, alternating each apnea with three breaths.
214298332|NCT00447161|DRUG|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10\^9 of Bacillus clausii spores, orally suspension in water
214897424|NCT03426111|BEHAVIORAL|Lifestyle modification|Hypocaloric diet and moderate physical exercise
214897425|NCT02720328|BIOLOGICAL|Blood samples for DOAC measurement|
214897426|NCT01874028|DRUG|trientine dihydrochloride|Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
214897427|NCT02066844|DRUG|Celestone|2cc
214897428|NCT02066844|DRUG|Lidocaine|5cc
215052585|NCT02251496|OTHER|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
214298333|NCT00447161|DRUG|Placebo|Matched placebo
214298334|NCT06376799|OTHER|Self-questionnaire|Provision of a self-questionnaire in digital or paper format for the patient. The patient will be asked to indicate their preferences regarding the primary and secondary objectives of the study.
214298335|NCT02152839|BEHAVIORAL|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
214298336|NCT04506489|OTHER|Psychological investigation|Psychological tests, psychological interviews.
214298337|NCT01614067|DRUG|Ganirelix acetate|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
214298338|NCT05695690|DEVICE|Ultrasonography|Comparing between value of ultrasound vs MRI in uterine fibroids
214298339|NCT03838822|DIETARY_SUPPLEMENT|Cofactors|Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
214298340|NCT02392741|OTHER|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
214478479|NCT06291207|DRUG|Placebo of AD-224B|PO, Once daily, 8weeks
214298341|NCT00002667|OTHER|cytology specimen collection procedure|
214298342|NCT00002667|OTHER|immunoenzyme technique|
214478480|NCT06291207|DRUG|Placebo of AD-224C|PO, Once daily, 8weeks
214897429|NCT04465669|DEVICE|Orsiro stents|"Percutaneous coronary intervention with implantation of either:~a Orsiro® biolimus a9 eluting coronary stent"
214897430|NCT04465669|DEVICE|Resolute Integrity® stents|"Percutaneous coronary intervention with implantation of either:~a Resolute Integrity® zotarolimus eluting coronary stent"
214897431|NCT00725868|OTHER|Data private hospitals, angioplasty, sampling of blood|"* Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency~* coronary angioplasty~* Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made"
214897432|NCT03036826|DRUG|Piperacillin/tazobactam|antiinfective therapy with Piperacillin/Tazobactam within routine care
214897433|NCT03036826|DRUG|Meropenem|antiinfective therapy with Meropenem within routine care
214298343|NCT00002667|PROCEDURE|study of high risk factors|
214298344|NCT01505868|DRUG|Cabazitaxel|Given IV
214298345|NCT01505868|DRUG|Carboplatin|Given IV
214298346|NCT01505868|OTHER|Laboratory Biomarker Analysis|Correlative studies
214298347|NCT03627754|DRUG|Glasdegib 100 mg single oral dose|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.
214298348|NCT01382979|BEHAVIORAL|AlcoholEdu for College|Online course for college freshmen.
214298349|NCT01692327|DIETARY_SUPPLEMENT|High fat meal|
214298350|NCT01410045|PROCEDURE|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
214298351|NCT04892888|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
214298352|NCT02289079|DRUG|Bupivacaine|
214298353|NCT02289079|DRUG|liposomal bupivacaine|
214298354|NCT04203953|OTHER|Early mobilization program|Early mobilization will be defined as any active exercise where the patients could assist with the activity using their own muscle strength and control that occurred within the first 7 days of trauma ICU admission and will be intended to maintain or restore overall function as well as being scored using the ICU mobility scale.15 The ICU mobility scale includes rolling, bridging, sitting, standing and walking, and upper and lower limb flexion and extension. In-bed therapies will include active or active-assist range of motion, bridge exercise, quadriceps setting, straight leg raising, rolling exercises and facilitation.
214478481|NCT05840237|OTHER|"Anhydrous Enol-Oxaloacetate, a Medical Food"|"Treatment with the medical food Oxaloacetate CFS, 2 - 500 mg capsules BID with food"
214478482|NCT05840237|OTHER|White Rice Flour|"Treatment with the food White Rice Flour, 2- 500 mg capsules BID with food"
214478483|NCT01223352|DRUG|bosentan|32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
214478484|NCT05269888|OTHER|Blood Test 1|"Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
214478485|NCT05269888|OTHER|Blood Test 2|"Blood test 2 - At 18 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
214478486|NCT04632433|DRUG|Cemiplimab|350 mg every 3 weeks
214897434|NCT02500589|BEHAVIORAL|Behavioral mood management|The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
214897435|NCT02500589|OTHER|Health education|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information."
214897436|NCT04336280|OTHER|Symptom questionnaire|Arabic version of the International Prostate Symptom Score: Known and validated questionnaire to quantify and qualify the severity of symptoms of the lower urinary tract
214897437|NCT04336280|DIAGNOSTIC_TEST|Urodynamics|Urodynamics: the standard diagnostic tool, it includes invasive recording of the pressure that is produced when the bladder muscle contracts via pressure sensors introduced in the urinary bladder through special types of urethral catheters.
214907264|NCT04594551|BIOLOGICAL|Purified inactivated rabies vaccine|Pharmaceutical form:freeze-dried - Route of administration: intramuscular
214907265|NCT04594551|BIOLOGICAL|Human rabies immunoglobulins|Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular
214907266|NCT06585774|DRUG|INCA034176|IV infusion
214298355|NCT04741061|BIOLOGICAL|Sputnik Light|"Sputnik-Light vector vaccine:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose."
214298356|NCT04741061|OTHER|Placebo|Placebo
214298357|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
214298358|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
214298359|NCT00680043|DRUG|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
214298360|NCT00563511|PROCEDURE|adherence intervention|
214298361|NCT00563511|PROCEDURE|intervention without adherence advice|
214298362|NCT00563511|PROCEDURE|control|
214298363|NCT01105195|OTHER|DuraPrep|DuraPrep is used for skin preparation prior to surgery.
214298364|NCT01105195|OTHER|ChloraPrep|ChloraPrep is used for skin preparation prior to surgery.
214298365|NCT02867033|PROCEDURE|biopsy|pre-therapeutic or post-therapeutic biopsy or resected tissues
214298366|NCT02867033|OTHER|biobank constitution|Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues
214298367|NCT02867033|PROCEDURE|Coloscopy|For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed
214478487|NCT04965766|DRUG|U3-1402|U3-1402 is uniquely designed to target HER3-a receptor that contributes to treatment resistance and poor prognosis in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients. This drug is distinct from other interventions due to its composition as an antibody-drug conjugate (ADC): a monoclonal antibody against HER3 conjugated to a topoisomerase I inhibitor, which specifically targets HER3-overexpressing tumor cells. The drug is delivered via a cleavable linker that allows for controlled release of the chemotherapeutic agent within the cancer cells, minimizing systemic side effects.
214669252|NCT02401256|DRUG|Bupropion|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
214669253|NCT02401256|DRUG|Rosuvastatin|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
214669254|NCT02401256|DRUG|Montelukast|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
214897438|NCT01984320|PROCEDURE|ICSI|Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
214897439|NCT03901794|DEVICE|Non-invasive hemodynamic monitor|MAP, HR, CO, SVI, from Non-invasive hemodynamic monitor
214897440|NCT03665220|OTHER|Ergonomic adjustments|The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form .
214897441|NCT03665220|OTHER|Kinesiotherapy plus ergonomic adjustments|This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
214897442|NCT03665220|OTHER|Healthcare education|This group received health education information, based on an illustrated manual with advice for patients with chronic stroke.
214897443|NCT04191525|DIETARY_SUPPLEMENT|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
214897444|NCT04191525|DIETARY_SUPPLEMENT|Placebo|Placebo masked with the same presentation as the experimental product 1 capsule/day
214897445|NCT02869243|DRUG|hrBMP4|"Patients will undergo a resection or biopsy of the tumour, confirmation of viable malignant glioma tumour cells and intratumour/interstitial placement under neuronavigational guidance of 2 or 3 catheters.~Catheters will be placed during a second procedure a few days later based upon the patient's condition.~Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66ml over up to 4-6 days. Gd-DTPA will be co-infused with BMP4 to determine the extent of intra-tumour and interstitial drug delivery. HrBMP4 will be delivered as a continuous infusion via the intracranial catheters."
214907267|NCT06585774|DRUG|Placebo|IV infusion
214907268|NCT06585774|DRUG|Corticosteroids|Oral/IV Infusion
214907269|NCT06835387|DRUG|Nanoliposomal irinotecan|Nanoliposomal Irinotecan 50 mg/m2 will be administered over 90 minutes (± 10 minutes) IV. All subjects must be pre-medicated prior to nanoliposomal irinotecan infusion with standard doses of dexamethasone and a 5-HT3 antagonist, or equivalent other anti-emetics (according to standard institutional practices).
214907270|NCT06835387|DRUG|Oxaliplatin|Oxaliplatin 60 mg/m2 will be administered over 120 minutes (± 10 minutes) IV. Institutional standards may be used for all aspects of oxaliplatin administration including premedication administration.
214907271|NCT06835387|DRUG|5 fluorouracil|5-FU will be administered as a continuous infusion over 46 hours. Subjects will go home with an infusion pump and return to clinic at the end of infusion for removal of the pump or, if possible, the pump may be removed at the subject's home (except on Cycle 1 Day 3).
214907272|NCT06835387|DRUG|Leucovorin|Leucovorin 400 mg/m2 will be administered over 30 minutes IV.
214478488|NCT04217603|DEVICE|Continuous positive airway pressure (CPAP) device|Use of a CPAP during a 6 minute walk test to maintain the airways open during the respiratory cycle
214669255|NCT03279237|DRUG|Irinotecan|May help shrink tumor before surgery.
214897446|NCT04647084|DRUG|Lidocaine 2% Injectable Solution|An elastic band will be placed around the subject's arm, and the elastic band will be removed once the IV is inserted. After the elastic band is placed on the subject's arm, the arm will be cleaned, and then a small skin wheel will be created with the lidocaine that will be injected very close to where the IV will be placed. The IV will be placed within about a minute from the time when the lidocaine was injected.
214897447|NCT04647084|DEVICE|Buzzy|The Buzzy vibrating ice pack will be placed on the subject's arm with an elastic band around it, and it will remain there as the arm is cleaned and prepped and the IV inserted. The Buzzy device will be removed once the IV is inserted.
214897448|NCT00073203|DRUG|R228060|
214669256|NCT03279237|DRUG|Oxaliplatin|May help shrink tumor before surgery.
214897449|NCT00073203|DRUG|Placebo and Paroxetine|
214897450|NCT02542007|DEVICE|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
214897451|NCT02542007|DEVICE|sirolimus-eluting stent system|
214897452|NCT05300815|OTHER|Delphi Questionaire|"This study involves the use of questionnaires across 3 rounds as follows:~The objectives of round 1 are to collect participant demographic information and generate a list of adverse events. Round 1 will be open for 3 weeks with email reminders being provided at weeks 1 and 2.~The objectives of round 2 will be to share a list of adverse events generated from round 1 (with the addition of adverse events identified in literature if not generated in round 1) and allow participants to rate from 1-4 how important each item is for inclusion on informed consent. As per round 1, the round 2 questionnaire will remain active for 3 weeks with email reminders sent at weeks 1 and 2.~The objective of round 3 is to further gain consensus on adverse events from the results of round 2 where agreement was not reached. Round 3 remains active for 3 weeks with email reminders sent at weeks 1 and 2."
214897453|NCT02996409|DRUG|HVIGI|High Volume Image-Guided Injection with a saline/lidocain solution
214897454|NCT02996409|DRUG|LVIGI|Placebo control with injection of a saline/lidocain solution (low volume)
214897455|NCT02996409|OTHER|Progressive exercise program|A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.
214897456|NCT00015964|DRUG|ZD1839|
214897457|NCT04731805|BEHAVIORAL|Moving On After Breast Cancer|Patient education intervention that is evidence-based, physical therapy, patient \& family centered through the use of face to face instruction, a booklet, and therapeutic exercise DVD. The education materials are designed to deliver information on short term, long term, and late physical and functional effects of breast cancer treatment and given to breast cancer survivors before beginning cancer treatment. The education materials are designed to be used before, during, and after breast cancer treatment.
215052586|NCT00889707|DRUG|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
215052587|NCT00889707|DRUG|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
215052588|NCT02345655|PROCEDURE|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
215052589|NCT02345655|OTHER|no test|normal procedure decided by the general practitioner
215052590|NCT03729843|RADIATION|CBCT and intraoral digital radiography|Simulated periodontal bone defects will be measured by 2 techniques: group I detected and measured using CBCT and group II intraoral digital radiography and all the measurements will be compared with the gold standard real measurements on the dry jaws
215052591|NCT04118725|DIAGNOSTIC_TEST|Pulmonary function test|Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
215052592|NCT00625534|PROCEDURE|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
214669257|NCT03279237|DRUG|Leucovorin|May help shrink tumor before surgery.
214669258|NCT03279237|DRUG|5-Fluorouracil|May help shrink tumor before surgery.
214669259|NCT03279237|DRUG|Paclitaxel|Paclitaxel may stop cancer cells from growing and spreading.
214897458|NCT04220515|BIOLOGICAL|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Type I D antigen 30DU;Type II D antigen 32DU;Type III D antigen 45 DU
214897459|NCT06550856|PROCEDURE|SUTURE-CLOSURE OMENTOPEXY IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired using full thickness suture closure using 3/0 vicryl suture then omental patch laied over the sutures.
215052593|NCT00625534|PROCEDURE|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
215052594|NCT03849664|DRUG|Cytoflavin® solution|Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
215052595|NCT03849664|DRUG|Cytoflavin® enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
215052596|NCT03849664|DRUG|Placebo solution|Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
215052597|NCT03849664|DRUG|Placebo enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
215052598|NCT00898170|PROCEDURE|myoma removal|surgical removal of myoma by hysterectomy
215052599|NCT00235183|OTHER|plasma|transfusion of more than 15 mL/Kg of plasma
215052600|NCT02213068|DRUG|belatacept|Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
215052601|NCT02213068|DRUG|Tacrolimus|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
214298368|NCT02867033|PROCEDURE|Blood sampling (facultative)|Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)
214298369|NCT02867033|OTHER|Pain evaluation|Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)
214298370|NCT02867033|PROCEDURE|Tumor biobank realization|Realization of a tumor biobank is part of classical procedure of participating centers
214298371|NCT05001074|DRUG|Extended release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
214669260|NCT03279237|RADIATION|Radiation Therapy|May help shrink tumor.
214897460|NCT06550856|PROCEDURE|OMENTOPEXY ALONE IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired by using omental patch without any attempt for primary closure of perforation.
214897461|NCT00637845|DRUG|Esomeprazole Magnesium|40mg once daily
214897462|NCT00637845|DRUG|Lansoprazole|30mg twice daily
214897463|NCT06409845|DRUG|Eptinezumab 100 or 300 mg ev|Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention
214897464|NCT00520377|DRUG|MD05|recombinant human GDF-5 coated onto beta-tricalcium phosphate
215052602|NCT02213068|DRUG|MPA|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
215052603|NCT01263457|DEVICE|Easypod|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod
215052604|NCT03762161|DRUG|TAS 102|Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
214897465|NCT00520377|DEVICE|Beta-TCP and autologous bone|beta-tricalcium phosphate and autologous bone
214897466|NCT02140151|DRUG|Ranibizumab 0.5mg|
214897467|NCT03652051|DRUG|AZR-MD-001 Low Dose|AZR-MD-001 is an ophthalmic ointment
214298372|NCT05001074|DRUG|Immediate release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
214298373|NCT04108520|OTHER|Exercise|Exercise with respiratory training
214669261|NCT03279237|DRUG|Carboplatin|Carboplatin may stop cancer cells from growing.
214298374|NCT00023543|BEHAVIORAL|Diet, fat-restricted|Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
214298375|NCT00023543|BEHAVIORAL|Exercise|Rigorous, stepped care approach to reach 150 min/week of physical activity.
214669262|NCT00430781|DRUG|pazopanib (GW786034)|
214669263|NCT00430781|DRUG|lapatinib (GW572016)|
214897468|NCT03652051|DRUG|AZR-MD-001 Mid Dose|AZR-MD-001 is an ophthalmic ointment
214897469|NCT03652051|DRUG|AZR-MD-001 High Dose|AZR-MD-001 is an ophthalmic ointment
214897470|NCT03652051|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
214669264|NCT01435993|DRUG|GSK1223249|Intravenous infusion
214897471|NCT00004008|DRUG|bryostatin 1|
214897472|NCT00124189|DRUG|GRN163L|Weekly intravenous infusion
214897473|NCT06080269|DEVICE|technology based intervention along with conventional therapy|Technology based intervention are training session given to the participants through devices which has software installed to train cognitive functions for patients with cognitive deficit.
214897474|NCT06080269|OTHER|conventional therapy alone|Participants in the control group will receive only conventional therapy
214897475|NCT03778346|BIOLOGICAL|CAR-T therapy in Relapsed/Refractory multiple myeloma|Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells to treat Relapsed/Refractory multiple myeloma
214897476|NCT05224739|PROCEDURE|Minimally Invasive Liver Resection|laparoscopic and robotic liver resections
214897477|NCT05545722|BEHAVIORAL|life coaching group with diabetes|Each patient was interviewed once a week. Coaching interviews were conducted one-on-one and in accordance with coaching principles.
214897478|NCT04800484|DEVICE|Tall Soft|Tall heel wedge made of soft foam
214897479|NCT04800484|DEVICE|Tall Firm|Tall heel wedge made of firm foam
214897480|NCT04800484|DEVICE|Short Soft|Short heel wedge made of soft foam
214897481|NCT04800484|DEVICE|Short Firm|Short heel wedge made of firm foam
215052605|NCT02797912|OTHER|No intervention|
215052606|NCT02008994|OTHER|Genomic and Proteomic Profiling|Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
215052607|NCT02034643|PROCEDURE|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
215052608|NCT05214430|OTHER|3 months exclusive enteral nutrition after surgery|patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.
214298376|NCT01757054|DIETARY_SUPPLEMENT|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
214298377|NCT06136923|DEVICE|CT-100-D-004-A|Attention Biases App CT-100-D-004-A Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
214298378|NCT06136923|DEVICE|CT-100-D-004-B|Attention Biases App CT-100-D-004-B Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
214669265|NCT01435993|OTHER|Saline placebo|placebo intravenous infusion
214669266|NCT01616615|DRUG|Aspirin|150 mg/day oral use
214669267|NCT01616615|DRUG|placebo|1 capsule / day oral use
214669268|NCT03663244|BEHAVIORAL|MBSR|Standardised stress reduction programme with established efficacy
214298379|NCT03402789|DRUG|Docosahexaenoic Acid|Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily
214298380|NCT03402789|DRUG|Placebo Oral Tablet|Placebo tablet daily plus 2 hours of eye patching daily
214298381|NCT00553150|DRUG|everolimus|
214298382|NCT00553150|DRUG|temozolomide|
214298383|NCT00553150|RADIATION|radiation|
214298384|NCT05107687|BEHAVIORAL|Smoking cessation|"Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention."
214298385|NCT03061331|DRUG|LUM/IVA|LUM 400 mg/IVA 250 mg every 12 hours (q12h)
214298386|NCT03061331|DRUG|Placebo|No Active Drug
214298387|NCT05491954|DEVICE|Dexcom G6|Continuous glucose monitoring
214298388|NCT05181423|OTHER|Biomarkers|Different serum and radiological biomarkers neonates undergoing abdominal surgery.
214298389|NCT02143869|DEVICE|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
214298390|NCT03195088|DRUG|BI 473494|Solution for injection
214298391|NCT03195088|DRUG|Placebo|Solution for injection
214298392|NCT05114785|DIAGNOSTIC_TEST|Multi Parametric Cardiac Magnetic Resonance|Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics
214298393|NCT02998840|BIOLOGICAL|B244|odorless suspension
214478489|NCT04217603|DEVICE|Sham-continuous positive airway pressure (CPAP) device|An enlarged air leak incorporated into the exhalation valve will be positioned between the mask and the CPAP tubing, allowing airflow resistance of the exhalation port to be almost eliminated by increasing its area, thereby virtually cancelling positive pressure. Also an orifice restrictor in the CPAP circuit will be connected between the CPAP unit and the tubing in order to load the blower with the same airflow resistance as in true CPAP.
214669269|NCT03663244|BEHAVIORAL|LSR|Existing stress reduction programme in a Danish municipality
214669270|NCT05491642|DRUG|BAY3283142|Oral administration
214298394|NCT02998840|BIOLOGICAL|Vehicle|odorless suspension
214298395|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
214298396|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
214298397|NCT01686633|DRUG|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
214298398|NCT02192814|DRUG|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion"
214298399|NCT04771507|DRUG|Ibrutinib|Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.
214298400|NCT03228589|DIETARY_SUPPLEMENT|probiotic strain|8 weeks of treatment with probiotic strain
214298401|NCT03228589|DIETARY_SUPPLEMENT|Placebo|8 weeks of treatment
214298402|NCT01082406|DRUG|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
214298403|NCT01082406|DRUG|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
214298404|NCT00437554|DRUG|Glimepiride|
214298405|NCT04646798|OTHER|Hemiarthroplasty|standard surgical approaches to repair of fractured elbows
214298406|NCT04646798|OTHER|Total elbow arthroplasty|standard surgical approaches to repair of fractured elbows
215052609|NCT01059747|OTHER|no intervention applied|no intervention applied
214298407|NCT02890446|BEHAVIORAL|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks"
214298408|NCT05328791|BEHAVIORAL|Dietary and mindfulness intervention|"Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program"
214298409|NCT06459908|OTHER|Robot Glove Hand Training|Robot Assisted group will perform hand exercises with the help of robotic glove assistance for 3 times per day/ 4 times per week, 45 minutes per session for 6 consecutive weeks. Total Number of Sessions will be 72 Hours.
214298410|NCT06459908|OTHER|Conventional Hand Rehabilitation Exercises|Conventional therapy group will perform hand exercises without the help of robotic gloves 3 times per day/ 4 times per week, 45 minute session for 6 consecutive weeks.Total number of sessions will be 72.
214298411|NCT02138760|PROCEDURE|MRI UroNav fusion biopsy|
214298412|NCT04915833|DIAGNOSTIC_TEST|Standard high-definition colonoscopy|"Evaluation of the colonic mucosa with a high definition colonoscope (EPKi7010 video processor).~The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) only by one expert endoscopist, randomly assigned.~The number, location and polyps' features (Paris classification) will be recorded by the operator. If a polyp is detected, the endoscopist will remove the polyp endoscopically with a cold snare and forceps biopsy."
214478490|NCT03754465|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer
214478491|NCT03754465|PROCEDURE|Hydrogel SHEET(Vehicle control)|Application of Hydrogel SHEET to diabetic foot ulcer
214669271|NCT05491642|DRUG|Placebo to BAY3283142|Oral administration
214669272|NCT02734732|DRUG|Trimethoprim/Sulfamethoxazole|
214298413|NCT04915833|DIAGNOSTIC_TEST|Colonoscopy with real-time AI assisted automated polyp detection|The same patient will be submitted to a second, same session, computed aided real-time colonoscopy using the DISCOVERY, AI assisted polyp detector. Colonoscopy will be performed by a same-level-of-expertise operator in comparison to the initial procedure. Any polyp or lesion detected with the AI system will be recorded and endoscopically removed and considered as a missed lesion from standard colonoscopy.
214298414|NCT01792674|OTHER|In situ simulation|
214298415|NCT01792674|OTHER|Off site simulation|
214298416|NCT00195676|DRUG|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
214298417|NCT06395974|OTHER|fetal ultrasound|2D, 3D , Doppler ultrasound
214298418|NCT01189812|DRUG|Lithium Carbonate|300 mg one time per day for 4 weeks
214298419|NCT01189812|DRUG|Placebo|Take one time daily for 4 weeks
214298420|NCT01189812|DRUG|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
214298421|NCT01031940|DEVICE|macintosh laryngoscope|intubate with the macintosh laryngoscope
214298422|NCT01031940|DEVICE|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
214298423|NCT01031940|DEVICE|Airtraq device|intubate with the Airtraq device
214298424|NCT01806753|PROCEDURE|Intermittent midazolam/propofol injection controlled by endoscopist|"In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.~First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.~When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).~If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected."
214298425|NCT01806753|PROCEDURE|Continuous propofol infusion with opioid administration|"In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.~First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.~Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.~When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.~If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min."
214298426|NCT02891460|DEVICE|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
214298427|NCT02891460|DEVICE|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
214298428|NCT02022098|DRUG|Cisplatin|A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
214897482|NCT02549781|OTHER|Go-Nogo test|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
214897483|NCT00573690|DRUG|carboplatin|Given IV
214897484|NCT00573690|DRUG|cisplatin|Given IV
215052610|NCT00640003|DRUG|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
215052611|NCT00640003|DRUG|Placebo|placebo drug
215052612|NCT03288844|PROCEDURE|Ophthalmologic examinations|epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
214298429|NCT02022098|RADIATION|Radiotherapy|Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
214298430|NCT02022098|DRUG|Debio 1143|Debio 1143 solution
214298431|NCT02022098|DRUG|Placebo|Matching placebo solution
214298432|NCT03447756|DRUG|ABX-1431|Capsules of either 2mg, 10mg, or 50mg
214298433|NCT03447756|DRUG|Placebo oral capsule|placebo to match
214298434|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
214298435|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
214298436|NCT00616655|DRUG|Placebo|Placebo total daily dose 0.9 mg
214298437|NCT02181439|DEVICE|(LLLT Low Level Laser Therapy) SiroLaser advance|Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
215052613|NCT03288844|OTHER|Digital pictures|Digital pictures 2D to be taken at each visit
214298438|NCT00003150|BIOLOGICAL|rituximab|
214298439|NCT00003150|DRUG|CHOP regimen|
214298440|NCT00003150|DRUG|cyclophosphamide|
214298441|NCT00003150|DRUG|doxorubicin hydrochloride|
214298442|NCT00003150|DRUG|prednisone|
214298443|NCT00003150|DRUG|vincristine sulfate|
214298444|NCT03552146|DRUG|Propofol|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
214298445|NCT03552146|DRUG|Dexmedetomidine|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
214298446|NCT00867425|BEHAVIORAL|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
214298447|NCT03761147|OTHER|Paula exercises|structured exercises aimed to stimulate ring muscles
214298448|NCT01863225|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
214298449|NCT01863225|DRUG|Rosuvastatin|20 mg daily, 28-42 days
214298450|NCT01863225|DRUG|Atorvastatin|40 mg daily, 28-42 days
214298451|NCT01863225|DRUG|Rosuvastatin|40 mg daily, 28-42 days
214298452|NCT01863225|DRUG|Atorvastatin|80 mg daily, 28-42 days
214298453|NCT05184920|OTHER|P1012919 nicotine pouch|P1012919, a nicotine pouch with 12 mg of nicotine
214298454|NCT05184920|OTHER|P1012915 nicotine pouch|P1012915, a nicotine pouch with 8 mg of nicotine
214298455|NCT05184920|OTHER|P1012914 nicotine pouch|P1012914, a nicotine pouch with 4 mg of nicotine
214298456|NCT05184920|OTHER|P1013315 nicotine pouch|P1013315, a nicotine pouch with 8 mg of nicotine
214298457|NCT05184920|OTHER|P1013119 nicotine pouch|P1013119, a nicotine pouch with 12 mg of nicotine
214298458|NCT05184920|OTHER|P1013218 nicotine pouch|P1013218, a nicotine pouch with 10 mg of nicotine
214298459|NCT05184920|OTHER|P1012818 nicotine pouch|P1012818, a nicotine pouch with 10 mg of nicotine
214298460|NCT05184920|OTHER|P1312915 nicotine pouch|P1312915, a nicotine pouch with 8 mg of nicotine
214478492|NCT04623775|BIOLOGICAL|Nivolumab|Specified dose on specified days
214897485|NCT00573690|DRUG|etoposide|Given IV
214897486|NCT00573690|DRUG|pemetrexed disodium|Given IV
214897487|NCT00573690|DRUG|sorafenib tosylate|Given orally
214897488|NCT03238664|PROCEDURE|Biopsy|Undergo biopsy of bladder tumor
214897489|NCT03238664|DEVICE|High-Intensity Focused Ultrasound Ablation|Undergo laparoscopic HIFU
214897490|NCT03238664|OTHER|Laboratory Biomarker Analysis|Correlative studies
214897491|NCT03238664|PROCEDURE|Radical Cystectomy|Undergo RARC
214897492|NCT03238664|DEVICE|Ultrasonography|Undergo CEUS
214897493|NCT00997841|PROCEDURE|Point-of-Care versus conventional coagulation management|Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
214298461|NCT05184920|OTHER|P1312914 nicotine pouch|P1312914, a nicotine pouch with 4 mg of nicotine
214298462|NCT05184920|OTHER|P1313015 nicotine pouch|P1313015, a nicotine pouch with 8 mg of nicotine
214298463|NCT05184920|OTHER|P1313314 nicotine pouch|P1313314, a nicotine pouch with 4 mg of nicotine
214298464|NCT05184920|OTHER|P1312815 nicotine pouch|P1312815, a nicotine pouch with 8 mg of nicotine
214478493|NCT04623775|BIOLOGICAL|Relatlimab|Specified dose on specified days
214478494|NCT04623775|DRUG|Carboplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
214298465|NCT03038633|OTHER|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
214298466|NCT06242314|PROCEDURE|L_PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after L-PRF placing on palatal wounds
214298467|NCT06242314|PROCEDURE|A-PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after A-PRF placing on palatal wounds
214298468|NCT06242314|PROCEDURE|Palatal stent|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after palatal stent placing on palatal wounds
214298469|NCT00099385|BEHAVIORAL|Social Development Instruction|Weekly instruction during regular classroom time by classroom teacher using PATHS (Greenberg \& Kusche) curriculum.
214298470|NCT05598775|OTHER|Non Interventional long term safety follow up|Non Interventional long term safety follow up
214478495|NCT04623775|DRUG|Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
214669273|NCT02734732|DRUG|Ciprofloxacin|
214897494|NCT02600936|DEVICE|vein stent placement|Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
214897495|NCT05680519|OTHER|theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention|The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.
214897496|NCT05680519|OTHER|Control group|The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. In addition, the research assistant will send regular SMS messages to the participants at a similar frequency to the intervention group, but these messages will contain only general health advice.
214897497|NCT02446041|OTHER|Non-Interventional Study|Non-Interventional Study
215052614|NCT03288844|OTHER|QoL Questionnaires|Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
214298471|NCT03670550|DEVICE|Ossur Rebound ACL Brace|ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
214298472|NCT02955485|OTHER|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
214298473|NCT01460420|DRUG|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
214298474|NCT01460420|DRUG|Len (lenalidomide)|"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified."
214298475|NCT03437525|BEHAVIORAL|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will provide education and support for insulin therapy to help reduce barriers around insulin use. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
214298476|NCT05482763|DRUG|Terbinafine Topical Gel|Topical application of terbinafine
214298477|NCT05482763|DRUG|Itraconazole 200 mg|systemic itraconazole pulse therapy
214298478|NCT05482763|DRUG|Terbinafine 250 mg|systemic terbinafine
214298479|NCT05482763|DRUG|Ciclopirox Topical Gel|Topical application of ciclopirox
214298480|NCT05482763|DRUG|Amorolfine 50 MG/ML|Topical application of amorolfine
214298481|NCT05931939|PROCEDURE|Ileal Interposition|Bariatric surgery by laparoscopic Ileal Interposition
214298482|NCT05931939|PROCEDURE|Traditional surgical technique|Bariatric surgery by laparoscopic traditional technique
214298483|NCT02059057|DEVICE|LVRC System|
214298484|NCT02689401|DRUG|Ferumoxytol|
214298485|NCT02689401|DEVICE|MRI 3T scanner|
214298486|NCT05153512|PROCEDURE|MRI|Pelvic MRI without injection of contrast product and WITHOUT rectal or vaginal opacification
214298487|NCT04212260|BEHAVIORAL|Oropharyngeal exercises|Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.
214478496|NCT04623775|DRUG|Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
214298488|NCT04212260|BEHAVIORAL|Sham control|Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
214669274|NCT04889703|DRUG|15% Trichloroacetic acid peel|Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments at 4 week intervals.
214669275|NCT04889703|DRUG|30% Salicylic acid peel|Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
214669276|NCT05099991|DEVICE|Single Foley Balloon|Foley Balloon will be placed through the cervix and inflated with 30mL of saline or water on the day prior to the procedure
214669277|NCT05099991|DEVICE|Dilapan-S|Dilapan S will be placed through the cervix on the day prior to the procedure
214298489|NCT05278247|DIAGNOSTIC_TEST|NIRS|Performance of a NIRS to monitor abdominal tissue oxygen saturation in preterm infants
214298490|NCT03443284|BEHAVIORAL|Health Partner|Health Partner is a combination of an iPhone or iPod Touch Operating System mobile application and a health care provider portal.
214298491|NCT03443284|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health \& Services.
214298492|NCT03984604|DRUG|CHI-921|a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
214298493|NCT03984604|DRUG|Placebo|Placebo is a vehicle oil will match CHI-921
214298494|NCT02242409|DRUG|Gemcitabine and Abraxane|Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
214298495|NCT00902369|DRUG|AK106-001616|Part1: Dose escalation Part2: Dose expansion
214669278|NCT03540121|BEHAVIORAL|Video education + adherence contract|Participants will receive standard education along with the home-based video education plus an adherence contract. Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home. The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life. Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed. The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed. At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
214298496|NCT00902369|DRUG|Placebo|
214298497|NCT00902369|DRUG|Active comparator|
214298498|NCT00309842|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days.
214298499|NCT00309842|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW \> 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
214478497|NCT04623775|DRUG|Nab-Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
214478498|NCT04623775|DRUG|Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
214897498|NCT03412136|DIETARY_SUPPLEMENT|Control|Participants were given 5 minutes to ingest the non-caloric beverage which contained 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water and sweetened with 0.2g sucralose (Tate \& Lyle, Stoney Creek, Ontario, Canada) in order to match sweetness with the glucose beverage.
214298500|NCT00309842|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \> 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
214298501|NCT00309842|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
214298502|NCT00309842|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day."
214298503|NCT00309842|PROCEDURE|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
214298504|NCT00309842|RADIATION|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
214478499|NCT06808139|PROCEDURE|Plasma-Rich Platelet Graft|The clot was extracted from the tube, separated from red blood cells, and gently compressed between two surgical swabs to obtain a soft and resistant membrane. The Snodgrass technique was carried out for all patients, with a suitable size catheter (8-12-Fr), repair was carried out by a continuous layer of polyglycolic suture (Vicryl) size 6/0, covered by an interrupted second layer. In group A, after finishing the Snodgrass TIPU, a PRP sheet coverage was applied over urethroplasty and secured by Vicryl 7/0, and finally the skin sutured directly without any covering layers
214478500|NCT06808139|PROCEDURE|Dartos Flap|preputial dartos flap will be used
214669279|NCT00215501|DRUG|Capecitabine|Orally twice a day for 14 days (dosage will vary)
215052615|NCT01653444|DRUG|GC1119|biweekly, IV infusion
215052616|NCT04966234|DRUG|Posaconazole 100 MG [Noxafil]|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
214897499|NCT03412136|DIETARY_SUPPLEMENT|Glucose|Participants were given 5 minutes to ingest the beverage which contained either 1g of protein (plain whey-protein isolate; BiPro USA., Eden Prairie, Minnesota, U.S.A) per kg of bodyweight and was flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
214897500|NCT03412136|DIETARY_SUPPLEMENT|Protein|Participants were given 5 minutes to ingest the beverage which contained 1g of glucose monohydrate (BioShop Canada Inc., Burlington, Ontario, Canada) per kg of bodyweight and flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
214298505|NCT04859881|OTHER|No intervention|No intervention
214298506|NCT01026792|DRUG|Temsirolimus|Given IV
214298507|NCT01026792|OTHER|Laboratory Biomarker Analysis|Correlative studies
214298508|NCT00423150|DRUG|Temozolomide|Temozolomide capsules 150 mg/m\^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
214298509|NCT04082325|DRUG|Lu AF88434|Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
214298510|NCT04082325|DRUG|Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
214298511|NCT04082325|DRUG|Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
214669280|NCT00215501|DRUG|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
215052617|NCT04966234|DRUG|Posaconazole 40 MG/ML|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
214478501|NCT06810388|OTHER|Health education intervention program based on a family-centered empowerment model|Three sessions of approximately 15-30 min each are conducted within 3 d of the child's admission to the hospital, from the fourth day to the day before discharge, and on the day before discharge. The researcher or charge nurse assesses the caregivers' mastery every week using uniform evaluation criteria and adjusts the topic or number of interventions within each phase based on mastery, with the final intervention content and timeline remaining unchanged.Health education includes: providing family caregivers of children with malignant tumors with knowledge of the disease, guidance on dietary care, instruction on how to recognize symptoms, guidance on medication, post-implantation precautions at the port of infusion, knowledge of blood markers, monitoring of the disease, and emergency treatment.
215052618|NCT02789085|DEVICE|ULF TENS stimulation|
215052619|NCT00374517|DRUG|Pimonidazole hydrochloride|
214298512|NCT04082325|DRUG|Placebo|Placebo to Lu AF88434 oral solution, single dose
214298513|NCT02316041|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
214298514|NCT02316041|DEVICE|ReLEx® (SMILE)|
214298515|NCT03510520|DEVICE|Medium Cut-Off Haemodialysis|Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months
215052620|NCT00741169|DRUG|TMC435350|200 mg taken by mouth once daily for 7 days
215052621|NCT00741169|DRUG|Rifampin|600 mg taken by mouth once daily for 7 days
215052622|NCT00741169|DRUG|TMC435350+rifampin|The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
215052623|NCT02977338|OTHER|Retrospective review|
215052624|NCT05853588|OTHER|training|On-the-job (toolbox) training given to the experimental group and containing brief information, lasting at most 10 minutes
215052625|NCT04487197|PROCEDURE|blood sample for seroepidemiological investigation|blood sample for seroepidemiological investigation
214669281|NCT00215501|DRUG|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
215052626|NCT01514721|DRUG|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
215052627|NCT00123825|DRUG|Gemcitabine|
214669282|NCT00215501|DRUG|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
214669283|NCT00599586|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
214897501|NCT04683861|PROCEDURE|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565; Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
214897502|NCT04319471|DRUG|Capecitabine/S-1|Drug: Capecitabine/S-1
214897503|NCT04319471|DRUG|Chemotherapy|Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
214897504|NCT04319471|RADIATION|Head and neck radiotherapy|IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma；
214897505|NCT04319471|OTHER|Local Consolidative Therapy|radiotherapy，surgery or interventional therapy for all metastatic sites.
214897506|NCT00639756|DRUG|Allopurinol|Allopurinol 300 mg
214897507|NCT00639756|DRUG|Placebo|Placebo given for 2 weeks
214897508|NCT05606640|DIAGNOSTIC_TEST|Biopsychological pain assessment|At baseline (T0) patients underwent the somatosensory pain assessment, joint structure and function assessment and filled in all questionnaires. During one month after baseline (T1) patients wore an activity tracker and filled in the Illness Perceptions Questionnaire and the International Physical Activity questionnaire. During one year after the baseline assessment (T2) patients filled in every month The Brief Pain Inventory, Illness Perceptions Questionnaire and the EQ-5D-5L quality of life questionnaire.
214897509|NCT00192582|BEHAVIORAL|Motivational Interview with care plan and education|
214897510|NCT01936844|DRUG|Anakinra (high dose)|Anakinra 100 mg daily twice daily for days 1, 2, and 3
214897511|NCT01936844|DRUG|Anakinra (standard dose)|Anakinra 100 mg daily for days 4-14
214897512|NCT01936844|DRUG|Placebo|Placebo twice daily for days 1, 2, and 3
214897513|NCT01936844|DRUG|Placebo|Placebo daily for days 4-14
215052628|NCT00123825|DRUG|Cisplatin|
215052629|NCT05634330|OTHER|exercise treatment|core stabilization exercise
215052630|NCT04023942|BEHAVIORAL|Weight maintenance intervention|Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
214298516|NCT03510520|DEVICE|On-Line Haemodiafiltration|Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)
214298517|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.1 μg|solution for intradermal injection, 0.1 µg / 0.1 mL
214298518|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.2 μg|solution for intradermal injection, 0.2 µg / 0.1 mL
214298519|NCT05398562|DIAGNOSTIC_TEST|Placebo|solution for intradermal injection
214298520|NCT00743327|DRUG|Pioglitazone|45mg capsule, once daily for 1 year
214298521|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics|pharmacogenomics
214298522|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics & therapeutic drug monitoring|pharmacogenomics \& therapeutic drug monitoring
214298523|NCT04207385|DRUG|Venlafaxine|Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
214298524|NCT04963933|DEVICE|Nautilus endovascular device|Patients will be treated with the Nautilus Endovascular device followed by treatment follow up for up to 6 months
214298525|NCT05105061|DRUG|Ketamine (Ketalar)|0.5 mg/kg of body weight
214298526|NCT05105061|DRUG|Placebo|IM injection of matching placebo
214298527|NCT05200533|OTHER|Task-sharing and shifting model between family physicians and physiotherapists|Medical consultations for acute low back pain patients are shifted from family physicians to physiotherapists.
214298528|NCT05200533|OTHER|Usual care|Medical consultations for acute low back pain patients are performed by family physicians
214298529|NCT03204305|DRUG|11C-OMAR|11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
214478502|NCT06810388|OTHER|Implementation of routine care measures|"Routine nursing care and current health education content will be provided, including the following: introduction to the department's environment, rules, and regulations; admission counselling; examination guidance; distribution of health education brochures; ongoing education on daily care, medication management, and health practices during hospitalisation; guidance on daily care, medication management, and health education by the nurse in charge; proactive support and communication by medical staff, including resolving questions and sharing caregiver experience; and discharge instructions with follow-up schedules for chemotherapy.~Participants in the control group are offered an FCEM-based intervention regimen on their second admission (at the beginning of the second course of treatment), which is appropriately adapted to the control group's second chemotherapy treatment."
214298530|NCT03204305|DRUG|Cannabis|Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
215052631|NCT05525741|OTHER|Non segmental vitiligo|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
214298531|NCT02025244|PROCEDURE|Key Hole Biopsy ( KHB)|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
214298532|NCT02025244|PROCEDURE|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
214298533|NCT01297140|BEHAVIORAL|questioning|Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
214298534|NCT03793582|DIAGNOSTIC_TEST|ApneaLink Type III portable sleep study|Type III portable sleep study
214298535|NCT05054959|OTHER|consolidation chemotherapy|6 cycles CAPOX after chemoradiotherapy
214298536|NCT05054959|OTHER|induction chemotherapy|4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
214298537|NCT01571414|DRUG|PA-824|200-mg tablets once a day
214669284|NCT02227212|DRUG|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214897514|NCT04082026|BEHAVIORAL|Early Adolescent Skills for Emotions EASE)|"EASE is conducted in 7 weekly group sessions with adolescents. EASE sessions help adolescents:~* Identify their feelings and body reactions~* Practice breathing exercises~* Get active: Make a plan to positively change their actions~* Manage their problems"
214897515|NCT00989482|BEHAVIORAL|Computer kiosk Education|computerized patient education; guidelines for physicians
214897516|NCT01585974|OTHER|No intervention|All dosage, frequency and duration for drugs will be under the decision of the treating physician
214897517|NCT01186068|DRUG|V-101|Cream QD
214897518|NCT01186068|OTHER|vehicle|Cream QD
214897519|NCT04936763|DEVICE|Janesse 20 (Cross-linked Hyaluronic Acid)|Janesse 20 will be administered at baseline (visit 2, day 0) and, if the Investigator will evaluate necessary, also at day 30 (visit 3). The Investigational device will be injected with retrograde technique (moving backward) with homogeneous amount on the length of each side of Labia Majora. The Janesse 20 dosage administered will be 1 ml in left labia and 1 ml in right labia for each session.
214897520|NCT03693131|DRUG|Icosapent (MND-2119)|Icosapent (MND-2119) capsules.
214897521|NCT03693131|DRUG|Icosapent (EPADEL CAPSULES 300)|Icosapent (EPADEL CAPSULES 300) capsules.
214897522|NCT04760080|OTHER|pre-treatment data|"We will evaluate in all patients pre-treatment data :~* Melanoma staging at treatment initiation~* Melanoma characteristics at initial diagnosis~* Number and location of metastasis~* Performans status~* Demographic information"
214897523|NCT04760080|OTHER|during study treatment|"We will evaluate in all patients during study treatment :~* Rate of adverse events~* Type of adverse events~* Radiological response to treatment by CTscans that are routinely performed every three months."
214897524|NCT01227473|BEHAVIORAL|Mindfulness-based diabetes prevention education group|The mindfulness-based diabetes prevention group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, this group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with a modified mindfulness meditation training designed to support the behavioral-change programming.
214298538|NCT01571414|DRUG|Efavirenz (EFV)|600-mg tablets once a day
214298539|NCT01571414|DRUG|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
214298540|NCT01571414|DRUG|Rifampin (RIF)|300-mg capsules once a day
214298541|NCT04178499|DIAGNOSTIC_TEST|cytokine analysis|analysis of intraocular cytokines
214298542|NCT01947920|DRUG|Tramadol HCl, 50 mg|50-mg overencapsulated tablet for oral administration
214298543|NCT01947920|DRUG|Placebo|Size-matching capsules containing an appropriate inactive excipient
214478503|NCT06302933|BIOLOGICAL|Blood sampling|Blood samples collected from children followed in the Pediacam III ANRS12225 cohort
214669285|NCT00310245|PROCEDURE|STI (structured Treatment Interruption)|
214298544|NCT03282942|OTHER|Strength training group|"Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~* Squatting~* Leg press~* Knee Extension~* Knee Flexion~* Supine Challenge~* High Pull~* Elbow flexion~* Extension of elbows~* Development~* Abdominal"
214298545|NCT03282942|OTHER|Aerobic Training Group|Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
214298546|NCT01392976|DRUG|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
214298547|NCT01392976|DRUG|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
214298548|NCT05196009|BEHAVIORAL|mHealth peer navigation and social support|Peer navigation, asynchronous support via SMS, Motivational Interviewing, virtual social support group focused on mental health and substance use, linkage and follow-up
214298549|NCT05589207|DIAGNOSTIC_TEST|Vascular wall invaded|Inferior vena cava vascular wall is invaded according to pathologic examination on the postoperative tumor thrombus/ vascular wall specimen.
214298550|NCT02716103|OTHER|blood collection|
214298551|NCT02716103|OTHER|bone marrow collection|
214298552|NCT00502177|BEHAVIORAL|Questionnaire|QOL Questionnaires taking a total of 10 minutes to complete.
214298553|NCT05969873|OTHER|Pilates exercise|Patients in this group will be treated with pilates exercise and conventional physical therapy as baseline treatment.
214298554|NCT05969873|OTHER|Balance training|Patients in this group will be treated with balance training and conventional physical therapy as baseline treatment.
214298555|NCT00535223|BEHAVIORAL|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
214298556|NCT00535223|BEHAVIORAL|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus."
214298557|NCT02953314|DRUG|TEZ|
214298558|NCT02953314|DRUG|TEZ/IVA|
214298559|NCT02953314|DRUG|IVA|
214478504|NCT03419260|OTHER|Clinically indicated EEG monitoring.|Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.
214897525|NCT01227473|BEHAVIORAL|Conventional diabetes prevention education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
214897526|NCT03468517|OTHER|Bathe method:|BATHE technique, on the other hand, is one of the short therapeutic consultation techniques that strengthen the doctor-patient relationship. BATHE stands for the initials of the questions that include the titles for Background, Affect, Trouble, Handling and Empathy. It allows evaluating the physiological stress of the patients quickly. BATHE method necessitates an empathetic expression that includes the view of the patient in addition to asking the key questions by the doctor doing the interview
214897527|NCT00762255|DRUG|Vorinostat|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
214298560|NCT04183920|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
214298561|NCT04183920|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
214298562|NCT04888156|OTHER|Unchanged treatment|Treatment is the same pre- and post self-tonometry
214298563|NCT04888156|OTHER|Changed treatment|Treatment is changed post self-tonometry
214298564|NCT02335099|DRUG|ticagrelor|ticagrelor 90 mg twice a day for 6 months
214298565|NCT02335099|DRUG|Placebo|1 pill twice a day for 6 months
214298566|NCT01312688|OTHER|Early Goal Directed Hemodynamic Therapy in Sepsis|Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
214298567|NCT03249233|DEVICE|ZenLens™|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
214478505|NCT06065280|DRUG|Empagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
214478506|NCT06065280|DRUG|Dapagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
214478507|NCT05493280|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.
214298568|NCT03249233|DEVICE|Zen™ RC|The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
214298569|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
214298570|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
214298571|NCT04269980|OTHER|MAP|MAP
214298572|NCT02045797|DRUG|GSK2140944 Lyophile|GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
214897528|NCT00762255|DRUG|Bevacizumab|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
214669286|NCT06119698|BEHAVIORAL|GetActive+|This is a 10-week group mind body program focused on improving self-reported physical activity, performance-based physical activity, and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increase in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
214897529|NCT00762255|DRUG|Irinotecan|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
214897530|NCT02200055|DEVICE|Bodystat Quadscan 4000|"Each patient involved in the study will be evaluated with a bioimpedance monitor to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
214897531|NCT01114035|GENETIC|blood samples and skin biopsies|to detect mutations
214897532|NCT01114035|GENETIC|Skin biopsies|to detect mutations
214897533|NCT01700062|DIETARY_SUPPLEMENT|Total Parenteral Nutrition (TPN)|Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
214897534|NCT05469737|DRUG|Oral Azacitidine|Specified dose on specified days
214897535|NCT05469737|DRUG|Placebo for Oral Azacitidine|Specified dose on specified days
214897536|NCT02528877|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
214897537|NCT02528877|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoeitic stem cell transplant
214897538|NCT02528877|DRUG|Fludarabine Phosphate|Given IV
214897539|NCT02528877|OTHER|Laboratory Biomarker Analysis|Correlative studies
214897540|NCT02528877|DRUG|Melphalan|Given IV
214897541|NCT02528877|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo hematopoietic stem cell transplant
214897542|NCT02528877|OTHER|Pharmacological Study|Correlative studies
214897543|NCT02528877|DRUG|Ruxolitinib Phosphate|Given PO
214897544|NCT02528877|DRUG|Sirolimus|Given PO
214897545|NCT02528877|DRUG|Tacrolimus|Given IV or PO
215052632|NCT05525741|OTHER|Health Volunteers|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
214669287|NCT04303390|DRUG|Cefuroxime|second generation cephalosporin
214669288|NCT04303390|DRUG|Cefazolin|First generation cephalosporin
214897546|NCT01871623|PROCEDURE|Segmental Le Fort I osteotomy|comparison the stability of segmental Le Fort I osteotomy with conventional approach of one-piece Le Fort I osteotomy
214897547|NCT01871623|PROCEDURE|One-piece Le Fort I Osteotomy|conventional approach
214897548|NCT03442751|DRUG|Test Article A|Riboflavin Ophthalmic Solution A
214897549|NCT03442751|DRUG|Test Article B|Riboflavin Ophthalmic Solution B
215052633|NCT03333356|RADIATION|pelvic radiotherapy|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
214298573|NCT02045797|DRUG|GSK2140944 Capsules|GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
214298574|NCT01455337|DRUG|pentoxifylline|400mg tid
214298575|NCT01455337|DRUG|Prednisolone|40mg qd
214298576|NCT02024620|BEHAVIORAL|Behavioral activation plus mobile app|
214298577|NCT02024620|BEHAVIORAL|Standard behavioral activation|
214298578|NCT02032966|PROCEDURE|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
214897550|NCT03442751|DRUG|Placebo|Placebo Vehicle of Test Article
214897551|NCT03442751|DEVICE|KXL medical device system|Mock UVA light source
214897552|NCT03442751|DEVICE|KXL medical device system|Cross-linking UVA light source
214897553|NCT04997252|DRUG|Apalutamide|apalutamide as neoadjuvant therapy
214897554|NCT01315392|PROCEDURE|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for a second debridement and definitive closure.
214897555|NCT01315392|PROCEDURE|immediate wound closure|traumatic and surgical wounds closed at the initial surgical intervention
214897556|NCT00498394|BEHAVIORAL|Clinical diet trial|
214897557|NCT04311866|DEVICE|Synthetic pants|The use of synthetic materials is preferred (glass fiber), resistance, durability and low weight makes them optimal. To give some extra strenght to the cast, fiber strips are placed anterior and posterior at the level of the groin, this can facilitate the transportation of the patient avoiding the use of a bar.
214897558|NCT04311866|DEVICE|Spica cast|The use of the spica cast is a standard practice for the management of the femoral shaft fractures, however its use, under some circumstances has been related to a wrong management of the cast, auto-retrieval, patient discomfort, and a difficult situation trying to maintain personal hygiene for the patient.
214298579|NCT02032966|PROCEDURE|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
214298580|NCT01421758|BEHAVIORAL|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
214298581|NCT01421758|BEHAVIORAL|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
214897559|NCT05421819|DIETARY_SUPPLEMENT|Calcium and vitamin D supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 plus flavonoids once per day.
214897560|NCT05421819|DIETARY_SUPPLEMENT|Calcium, vitamin D and prebiotic supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
214897561|NCT05421819|DIETARY_SUPPLEMENT|Calcium, vitamin D and flavonoid supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
214897562|NCT06577961|DRUG|Vorolanib|stage Ⅰ：Vorolanib 200mg QD stage Ⅱ：Vorolanib RP2D QD
214897563|NCT06577961|DRUG|cadonilimab|stageⅠ：cadonilimab 10mg/kg Q3W stageⅡ：cadonilimab 10mg/kg Q3W
214897564|NCT04291287|DRUG|Antithrombotic Agent|"Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~* Clopidogrel (Plavix®)~* Prasugrel (Efient®)~* Ticagrelor (Brilique®)~DOACs therapy include:~* Apixaban (Eliquis®)~* Dabigatran (Pradaxa®)~* Edoxaban (Lixiana®)~* Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~* Warfarin (Counmadin®)~* Acenocumarol (Sintrom®)"
214897565|NCT01946620|DRUG|Flutiform|
214897566|NCT01946620|DRUG|Formoterol|
214897567|NCT06445738|RADIATION|Arm A: Radiotherapy Omission|Omission of radiotherapy based on pre-surgical MRI and pathology findings at surgery.
214897568|NCT06445738|OTHER|Arm B: Standard Treatment|Ineligible for RT omission on study; includes management of MRI-detected lesions.
215052634|NCT03495934|DRUG|pracinostat|\[14C\]-pracinostat
215052635|NCT05829837|OTHER|Ultrasonographic evaluation|Ultrasonographic evaluation for the thickness of piriformis muscle
215052636|NCT02136784|DRUG|morphine sulfate|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
215052637|NCT02136784|DRUG|hydrocodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
214298582|NCT05192551|OTHER|Bowel-prep (Plenvu as experimental arm)|In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
214478508|NCT06656676|BEHAVIORAL|WePrEP: A shared decision-making tool|WePrEP will be bilingual, both patient- and provider-facing, stored on the provider's electronic device (and will have the capability to integrate with electronic health records in the future to enable scalability), and easily accessible during in-person or virtual patient-provider encounters. WePrEP is designed to present pertinent PrEP information to transgender women and their PrEP service providers to stimulate discussions about PrEP choice and support adherence (once a PrEP strategy has been chosen). We hypothesize that this will ensure selection of the ideal PrEP method and improve subsequent adherence.
214478509|NCT06656676|BEHAVIORAL|Active comparator: CDC recommendations for discussing PrEP|Standard of care recommendations to discuss PrEP with potential end-users, endorsed by the CDC.
214478510|NCT06581029|OTHER|The multidimensional peer victimization scale (PVS)|The multidimensional peer victimization scale (PVS), a self-report scale for children and adolescents, was used to assess the victimization
214478511|NCT00964392|PROCEDURE|Atrial fibrillation ablation|Radiofrequency ablation
214478512|NCT06657196|OTHER|No Intervention: Observational Cohort|No intervention.
214478513|NCT05378373|BEHAVIORAL|Garmin, Pattern Health App|Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
214897569|NCT02596204|OTHER|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. Fitbit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (CDE, NP and/or MD) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
214897570|NCT02596204|DEVICE|FitBit|All subjects will wear a FitBit activity monitor.
214897571|NCT05183139|DRUG|Ixazomib|Ixazomib capsules
214897572|NCT05183139|DRUG|Pomalidomide|Pomalidomide capsules
214897573|NCT05183139|DRUG|Lenalidomide|Lenalidomide capsules
214897574|NCT05183139|DRUG|Dexamethasone|Dexamethasone tablets
214897575|NCT00435669|DRUG|Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME
214478514|NCT06002100|OTHER|fNIRS measurement|Kernel Flow2 measurements.
214478515|NCT05458908|DIAGNOSTIC_TEST|Non-contrast cranial MDCT head scan|Non-contrast cranial MDCT imaging for visualization of the brain parenchyma (the choice of the device is up to the investigator)
214478516|NCT05458908|DIAGNOSTIC_TEST|Non-contrast syngo DynaCT Sine Spin head scan and application software|Non-contrast syngo DynaCT Sine Spin imaging for visualization of the brain parenchyma with ARTIS icono biplane angiography system and syngo application software with syngo DynaCT Sine Spin 3-D head imaging protocol.
214478517|NCT06806306|PROCEDURE|LASIK|Laser-assisted in situ keratomileusis is one of the most widely performed refractive surgeries for correcting myopia, hyperopia, and astigmatism
214897576|NCT00435669|DRUG|Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression
214298583|NCT04974710|DIAGNOSTIC_TEST|Outpatient MRI|All participants will undergo a standardised imaging protocol in a MRI scanner. This will take place during the same visit or following the transvaginal ultrasound (TVUS) and in advance of any surgical procedure (laparoscopy).
214478518|NCT06807502|DEVICE|The DM/DIV ScreenCell is the experimental product studied during this research|The product is not used directly on the subject, but on a blood sample taken from the participant.
214669289|NCT04303390|OTHER|24 hours|Duration of antibiotic therapy
214669290|NCT04303390|OTHER|48 hours|Duration of antibiotic therapy
214669291|NCT05405543|DRUG|MYK-224|Specified dose on specified days
214669292|NCT05405543|OTHER|Placebo|Specified dose on specified days
214669293|NCT06480929|OTHER|Contrast TTE procedure, the SonoVue ultrasound agent|The intervention involved using contrast-enhanced transthoracic echocardiography (TTE) to improve the detection of left ventricular thrombus in patients with anterior ST-elevation myocardial infarction (STEMI).
214897577|NCT02896634|BIOLOGICAL|clinical biology analyzes spectrometry mass|clinical biology analyzes spectrometry mass
214897578|NCT03651154|PROCEDURE|Hypovolemic Phlebotomy|Removal of 7-10ml/kg of blood from participant, as tolerated after patient is under anesthesia, before liver resection start time
214897579|NCT06058572|DRUG|Rifaximin 200Mg Tab|Drug rifaximin 200 mg tablet form orally twice daily (with or without food) from day-8 of transplant to day + 60 of transplant
214897580|NCT06058572|PROCEDURE|allogenic hematopoietic stem cell transplantation|Control arm will undergo allogenic hematopoietic stem cell transplantation as standard of care
214897581|NCT06402110|OTHER|Femoral Triangle Block|Patients will receive femoral triangle block (FTB) at the end of surgery. The probe will be positioned at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle, a block needle advanced in an in-plane technique into femoral triangle. After negative aspiration, 2ml of saline will be injected to confirm the needle tip position close to the femoral artery then injection of 15ml of bupivacaine 0.25% will be performed.
214907277|NCT06587035|DRUG|Somatrogon|Long-acting growth hormone for pediatric growth hormone deficiency.
214907278|NCT05933200|DRUG|Triheptanoin|Liquid for oral (PO) or enteral feeding tube administration
214907279|NCT05933200|DIETARY_SUPPLEMENT|MCT Oil|Liquid for oral (PO) or enteral feeding tube administration
214298584|NCT01279551|DRUG|0.4% nitroglycerin ointment|Local endoanal application 2 times a day
214298585|NCT01279551|DRUG|lidocaine cloridrato 2.5% ointment|Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
214298586|NCT01764009|BIOLOGICAL|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
214907280|NCT06341998|DRUG|sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children|The planned treatment protocol comprised four cycles of the S-TIC regimen, which included sirolimus administered orally at a dose of 1 mg/m² from day 1 to day 21-28, nab-paclitaxel at a dose of 200 mg/m² on day 1, ifosfamide at a dose of 1200 mg/m² from day 2 to day 5, and carboplatin at a dose of 400 mg/m² on day 2. Additionally, mesna and sulfamethoxazole were prescribed to prevent hemorrhagic cystitis and Pneumocystis Jirovecii Pneumonia (PJP), respectively. Each cycle spanned a duration of three to four weeks. AFP levels were evaluated at the end of each cycle, and radiological assessments were conducted every two cycles. Surgical intervention decisions were made based on the results of these assessments.
214907281|NCT06424769|OTHER|Enhanced Digital Care|Participants will receive brief check-in surveys about their IBD symptoms once a month, via text messaging. If the survey response indicates significant symptoms, an alert will be sent to the participant's IBD care team and participant will receive more frequent surveys (weekly) over the next month. Participants and their IBD clinical team will be able to communicate by text for non-emergency IBD-related questions.
214907282|NCT06424769|OTHER|Education|Participants will receive education texts about IBD from trusted sources approximately twice a week. Topics will include: diet, medication adherence, fatigue, preventative care and other relevant issues.
214298587|NCT01749579|DRUG|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
214298588|NCT01749579|DRUG|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
214298589|NCT01749579|DRUG|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
214298590|NCT05067582|DRUG|L1-79|tyrosine hydroxylase inhibitor
214298591|NCT01765153|BEHAVIORAL|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
214298592|NCT01765153|BEHAVIORAL|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
214298593|NCT03578081|DRUG|Palonosetron Hydrochloride|Given IV
214298594|NCT03578081|DRUG|Ondansetron Hydrochloride|Given IV or PO
214298595|NCT03578081|DRUG|Dexamethasone|Given PO
214298596|NCT03578081|DRUG|Fosaprepitant Dimeglumine|Given IV
214298597|NCT03578081|DRUG|Olanzapine|Given PO
214478519|NCT06638203|OTHER|The 2-hour Exemplary Leadership Course (ELC)|"This two-hour course, based on the Five Exemplary Leadership Model, aims to refresh participants' theoretical understanding of leadership while providing insights into effective leader-follower interactions through practical scenarios. The session will begin with an exploration of the nature of leadership, including its philosophical and historical context. The significance of leadership in nursing will be emphasized, highlighting its impact on education, clinical practice, and the profession overall. Participants will examine the key roles of nurse leaders, focusing on modeling the way, inspiring a shared vision, challenging the process, enabling others to act, and encouraging the heart. Content Outline:~1. The Nature and Definition of Leadership (5 minutes)~2. Leadership and Its Importance in Nursing (15 minutes)~3. Transformational Leadership and Its Components (40 minutes)~4. Positive Leader-Follower Interactions (15 minutes)~5. Case Study Discussions (45 minutes)"
214669294|NCT01447056|BIOLOGICAL|LMP specific T cells|"Three dose levels will be evaluated:~Dose Level 1: 2×10\^7 cells/m2; Dose Level 2: 1×10\^8 cells/m2; Dose Level 3: 2×10\^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."
214897582|NCT06402110|OTHER|Adductor Canal Block|Patients will receive adductor canal block (ACB) at the end of surgery. The probe will be positioned at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the Sartorius muscle and a block needle advanced in an in-plane technique toward the target nerve after negative aspiration, 2ml of saline will be injected into adductor canal to confirm the block needle tip within it, the block needle will be advanced with the guidance of ultrasound in an in-plane technique and 15ml bupivacaine 0.25% will be injected.
214897583|NCT04009278|OTHER|Self compression arm|The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
214897584|NCT02051348|BIOLOGICAL|Pylopass|Pylopass
214897585|NCT02051348|BIOLOGICAL|Placebo|Placebo
214897586|NCT04488341|OTHER|aerobic exercises in addition to diet recommendations|aerobic exercises time of session 40-50 min initial 10 min warm up exercises on treadmill in low intensity and active phase 20- 30 min intensity will increase until patient reach to target heart rate then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks
214897587|NCT04488341|OTHER|diet recommendations|control group will receive diet recommendations for 12 weeks
214897588|NCT06966817|DRUG|control group(chlorhexidine)|The sponge swab is dipped in 0.25% chlorhexidine solution and used once for each part of the mouth, 4 times a day to provide oral care.
214897589|NCT06966817|DRUG|Experimental Group(cetylpyridinium chloride)|The mouth is cleaned by dipping a sponge swab into 0.05% cetylpyridinium chloride solution and using it once for each part of the mouth, 4 times a day.
214669295|NCT03938662|DIETARY_SUPPLEMENT|formulation containing S-Adenosyl methionine and choline|Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.
214897590|NCT06519357|DRUG|Lamivudine 300 MG|Participants receive 300 mg of Lamivudine daily for 24 weeks
214897591|NCT05966506|BEHAVIORAL|Dyad-based Zoom health coaching|This will be delivered by a certified nurse coach, certified in holistic nursing who will provide 6 sessions of Zoom health coaching over 12 weeks to dyads, biweekly (weeks 1, 3, 5,7, 9 \&11) for 45 minutes
214907283|NCT06514261|DRUG|Azacitidine|Given IV or SC
214298598|NCT03578081|OTHER|Placebo|Given IV
214298599|NCT05936996|DEVICE|MANTA Vascular Closure Device|The MANTA® Vascular Closure Device consists of a 14F or 18F MANTA® Closure Device, a 14F or 18F Sheath with Introducer, and an 8F Depth Locator. In the U.S. and Canada, the MANTA® Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.
214298600|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(non freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
214298601|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
214298602|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
214298603|NCT04274426|DRUG|Carboplatin|Carboplatin will administered by intravenous route
214298604|NCT04274426|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered by intravenous route
214298605|NCT04274426|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous route
214298606|NCT04274426|DRUG|Paclitaxel|Paclitaxel will be administered by intravenous route
214298607|NCT04274426|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered by intravenous route
214298608|NCT00319644|DEVICE|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
214298609|NCT05646797|DRUG|ASP2074|intravenous (IV) infusion
214298610|NCT06032000|BIOLOGICAL|LEM-mR203|mRNA vaccine using Lemonex's Drug Delivery System (DDS), DegradaBALL
214298611|NCT06032000|BIOLOGICAL|Placebo|0.9% Sodium Chloride Solution
214478520|NCT06638203|OTHER|The NurseLead in Progress Game|Developed collaboratively by the author and a company, this unpublished game focuses on role-playing leader-follower interactions to navigate scenarios effectively. Designed for five students per session, the game consists of five sections, lasting approximately one hour, with each section corresponding to one of the Five Practices of Exemplary Leadership. In each section, one student takes on the role of leader while the other four act as followers. The main objective is to guide a newly appointed charge nurse in making sound decisions when facing challenges to achieve key goals. Following the game, a debriefing session will allow participants to analyze responses with experts. Performance will not be formally evaluated, as the game serves as a learning experience, enabling students to lead and engage as followers. This activity aims to activate the experiential learning phase of Kolb's Learning Model.
214669296|NCT03938662|DIETARY_SUPPLEMENT|Placebo|Placebo of same appearance, colour and taste,
214669297|NCT00431860|PROCEDURE|Coronary computed tomographic angiography|
214897592|NCT05966506|BEHAVIORAL|Fitbit activity monitor|"Participants will be instructed to use the Fitbit to monitor their partners' PA in addition to their own. All participants will be instructed to friend their health coach to enable real-time monitoring of PA to inform coaching zoom calls. The Fitbit will provide feedback on steps, active minutes, and calories burned. Participants will be asked to wear the device on most days and while they sleep."
214897593|NCT05966506|OTHER|Electronic newsletters|Newsletters will be sent twice monthly during months 1-3 via email or text with an online link. Newsletters will be designed to share educational PA-related information from publicly available resources. Newsletters will also contain tips for overcoming barriers to PA ,finding time to exercise, low-cost ways to be active and being active with kids.Newsletters will also contain links to brief exercise routines that participants can do in their homes and information on low cost/free exercise classes in the community, which may help to overcome perceived access barriers
214897594|NCT03994172|DRUG|Teriparatide or human parathyroid hormone (PTH) 1-34|Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone. It is given by subcutaneous injection in the dosage of 20 micrograms per day in the trial in both treatment arms for the 48 weeks or 11 months of the trial.
214897595|NCT03994172|DRUG|Cinacalcet|This drug is an orally active calcimimetic (drug that activates Ca-sensing receptors on target cells) that will be given daily orally to the men randomized to the Experimental Treatment Arm (#1). Cinacalcet tablets will be given simultaneously with the injection of PTH(1-34) or teriparatide. Cinacalcet will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
215052638|NCT02136784|DRUG|hydromorphone HCI|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
214298612|NCT06007560|OTHER|Exercise|Aerobe cycling training consisting of 12-weeks of HR-controlled training at 50-60% of VO2max (maximal oxygen uptake) for 1 hour, for 2 times (week: 1-6) to 3 times (week: 7-12) per week
214298613|NCT05448066|DIAGNOSTIC_TEST|Component resolved diagnosis|Physicians in this group will have access to allergen molecular component sensitization profile, using ImmunoCAP ISAC E112i and to all standard diagnostic tolls
214298614|NCT05448066|DIAGNOSTIC_TEST|Standard diagnosis|Physicians will only have access to standard diagnostic tools namely skin prick tests and sIgE sensitization (not molecular IgE) and clinical history.
214298615|NCT05257681|PROCEDURE|Interlobar fissure completion and pleural adhesiolysis|A video-assisted thoracic surgery or robotic approach will be used to perform pleural adhesiolysis and the lobar fissure adjacent to the previously targeted lobe during bronchoscopic lung volume reduction will be completed using a surgical stapler.
214298616|NCT02176330|OTHER|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
214298617|NCT02176330|OTHER|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
214298618|NCT05151146|DRUG|ANJ900|Metformin hydrochloride delayed-release tablets
214298619|NCT05151146|DRUG|Metformin IR|metformin hydrochloride
214298620|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
214298621|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
214298622|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
214669298|NCT01382589|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
214669299|NCT01382589|DEVICE|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
214897596|NCT03994172|DRUG|placebo tablet|The placebo tablet in the trial will be purchased from Consolidated Midland Corporation in Brewster, NY. Each white tablet contains Lactose, Stearic Acid and Magnesium Stearate (330 mg total). Subjects randomized to the placebo arm or Placebo - Arm #2 - will take one tablet orally at the same time as he injects the teriparatide each day. Placebo tablets will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
214907284|NCT06514261|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214907285|NCT06514261|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214907286|NCT06514261|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214907287|NCT06514261|PROCEDURE|Buccal Swab|Undergo buccal swab
214907288|NCT06514261|DRUG|Iadademstat|Given PO
214907289|NCT06514261|DRUG|Venetoclax|Given PO
214907290|NCT06065748|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
214907291|NCT06065748|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
214907292|NCT06065748|DRUG|Abemaciclib|If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
214907293|NCT06065748|DRUG|Palbociclib|If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
214907294|NCT06065748|DRUG|Ribociclib|If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
214907295|NCT06065748|DRUG|LHRH Agonist|Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
214907296|NCT06065748|DIAGNOSTIC_TEST|FoundationOne Liquid CDx Assay (F1LCDx)|F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
214907297|NCT06414590|DRUG|Tebentafusp-Tebn|Tebentafusp will be administered as follows: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter.
214907298|NCT05557292|DRUG|RMC-5552|Given IV
214907299|NCT05433064|DEVICE|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
214907300|NCT06951477|PROCEDURE|Revision Total Knee Arthroplasty|Study participants must be scheduled to receive a revision TKA.
214907301|NCT05391841|DRUG|NOVOCART Inject|Autologous Chondrocyte Implantation
214907302|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 6 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 8 stimuli (the Fully Learned stimuli). Each of the 8 Fully Learned stimuli will be produced 60 times over the 6 training sessions.
214907303|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 1 training session|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During the training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 60 times.
214907304|NCT05437159|BEHAVIORAL|Learning of novel multisyllabic nonwords|Each trial of the training sessions (total of 6 training sessions over 2 days) will follow a simple reaction time protocol in which a nonword stimulus formed by 2 or 3 syllables that are legal in American English is presented auditorily to the participant, who then produces the stimulus as quickly and accurately as possible. During training, each participant will repeatedly produce 6 nonwords, with each nonword produced a total of 60 times over the 6 training sessions.
214907305|NCT05437159|DEVICE|Anodal tDCS|Continuous anodal tDCS is delivered to a speech processing area of the brain during a 19-minute speech training session. The tDCS stimulation will ramp up to its maximum value (2 milliamperes) in the minute prior to the training session and maintained at that level throughout the session.
214907306|NCT05437159|DEVICE|Sham tDCS|Sham tDCS stimulation is delivered to a speech processing area of the brain during a 19-minute speech training session. During the minute prior to training onset, the tDCS stimulator is ramped up to 2 milliamperes and then back down to 0.
214907307|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 8 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 120 times over the 8 training sessions.
214907308|NCT05952726|OTHER|Expiratory cycling change at different levels of pressure support ventilation|"Four different levels of expiratory cycling will be randomly applied at 3 different degrees of pressure support.~Three end-inspiratory and three end-expiratory occlusion manoeuvres will be carried out at the end of 10 minute steps of ventilation during each set value expiratory cycling and pressure support level.~Total study time will be about 120 minutes. Levels of pressure support wil be clinical pressure support ± 4 cmH2O; expiratory cycling percentages applied for each pressure support step will be 15%, 30%, 45% and 60% of peak inspiratory flow."
214907309|NCT04898634|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
214907310|NCT05721755|DRUG|Carboplatin|Given IV
214907311|NCT05721755|DRUG|Cisplatin|Given IV
214478521|NCT05088759|BEHAVIORAL|Alert|The alert-based CDS will consist of an on-screen electronic dialogue box that will notify the clinician that the patient is at increased risk for cardiovascular events and is not at LDL-C goal according to current evidence-based clinical practice guidelines. The clinician will have the opportunity to proceed to an order template through which ezetimibe or a PCSK9 inhibitor can be prescribed. The clinician could also elect to learn more about current evidence-based clinical practice guideline recommendations for LDL targets. Finally, the clinician could elect to proceed without ordering more intensive lipid-lowering therapy or reading the guidelines but would have to provide a rationale for not prescribing ezetimibe or a PCSK9 inhibitor.
214897597|NCT03994172|DIETARY_SUPPLEMENT|Calcium citrate tablet|Ca citrate supplements (forms 200 or 250 mg elemental Ca/oral tablet) will be used in the study. Each subject will have average dietary Ca intake quantified by a Food Frequency Questionaire. Each subject will take sufficient Ca citrate supplements to make the total Ca intake equal \~1000 mg per day (diet+supplements). Ca supplements will be spread out during the day so that any amount of supplements over 500 mg will be taken at 2 different time-points. Ca citrate supplements will be sourced by our research pharmacist will be of high-quality and consistency. Ca supplements will be started at Screening Visit 2 and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily Ca supplements at the same dose and times as during the run-in period. That daily dosing will continue from day of Randomization through the end of 48 weeks or 11 months of the trial.
214897598|NCT03994172|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be given 1000 IU vitamin D3 in tablet form to be taken orally once a day at any time during the day. Vitamin D3 supplements will be sourced by our research pharmacist and supplements selected for use in the trial will be of high quality and consistency. Vitamin D3 supplements will be started at Screening Visit 2 in the trial and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily vitamin D3 supplements at the same dose and timing as during the run-in period. That daily dosing will continue from the day of Randomization Visit through to the end of the 48 weeks or 11 months of the trial.
214897599|NCT06163040|DRUG|Elotuzumab in combination with pomalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
214897600|NCT06163040|DRUG|Elotuzumab in combination with lenalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
214897601|NCT03674697|DEVICE|Green LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
215052639|NCT02136784|DRUG|oxycodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
215052640|NCT02136784|DRUG|buprenorphine|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
215052641|NCT02136784|DRUG|oral tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
215052642|NCT02136784|DRUG|sublingual tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
215052643|NCT02025790|PROCEDURE|Per Oral Endoscopic Myotomy (POEM)|"* Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).~* Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~* Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~* Long endoscopic myotomy is performed 10 cm proximal to GEJ extending~* Closure of mucosal entry: the mucosal incision is closed using hemostatic clips"
215052644|NCT02025790|PROCEDURE|Pneumatic Dilatation|Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
215052645|NCT03198156|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
215052646|NCT03198156|DEVICE|Sham stimulation|Sham stimulation
215052647|NCT05424601|BEHAVIORAL|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
215052648|NCT05424601|BEHAVIORAL|PsyPills|PsyPills is a mobile app designed to provide personalized psychological pills
215052649|NCT04743713|OTHER|UWRI-Tr|Questionnaire
215052650|NCT05111288|DEVICE|Pulsed electromagnetic field therapy (PEMF)|Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields.
214478522|NCT05818475|OTHER|Angiography-guided PCI|Non-culprit lesion treatment will be based on visual estimation by angiography. The evaluation of PCI result will be also based only on angiography.
214478523|NCT05818475|OTHER|Angiography-derived FFR PCI indication and planning|Non-culprit lesion treatment will be based on angiography-derived FFR result. In case of positive assessment, PCI will be planned according to the virtual PCI plan based on the physiology pullback curve.
214298623|NCT01152086|OTHER|Mountain hiking in the Austrian and Bavarian Alps|"Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~* Endurance training (performed within 70-85% of the maximum heart rate)~* Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~* Stretching after hiking (ca. 5 min)~* Short break at half-time (ca. 15 min)"
214298624|NCT04700618|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
214298625|NCT01851564|DEVICE|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
214897602|NCT03674697|DEVICE|White LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
214897603|NCT02766335|DRUG|Docetaxel|Given IV
214897604|NCT02766335|BIOLOGICAL|Durvalumab|Given IV
214897605|NCT02766335|OTHER|Laboratory Biomarker Analysis|Correlative studies
214897606|NCT04859452|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
214897607|NCT04859452|DRUG|Metformin hydrochloride tablets|Drug: Metformin hydrochloride, tablet, oral
214897608|NCT04859452|DRUG|Glibenclamide tablets|Drug: Glibenclamide, tablet, oral
214897609|NCT04859452|DRUG|Valsartan Capsules|Drug: Valsartan, capsule, oral
214897610|NCT04859452|DRUG|Simvastatin tablets|Drug: Simvastatin, tablet, oral
214897611|NCT00501995|DRUG|IV Cyclophosphamide|Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
214897612|NCT02905604|DEVICE|dmPFC iTBS|2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
214897613|NCT02905604|DEVICE|dmPFC Sham iTBS|Sham iTBS
214298626|NCT01851564|OTHER|Standard Therapy|Standard Medical and Endoscopic Therapy
214298627|NCT01401868|DRUG|ME-143|"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
214897614|NCT01223378|DRUG|BOL-303259-X|ophthalmic solution, various concentrations, once daily (QD) 28 days
214897615|NCT01223378|DRUG|Latanoprost|0.005% ophthalmic solution, QD 28 days
214897616|NCT03903302|DRUG|CS1-Sodium Valproate|Single and multiple dose evaluation of CS1
214897617|NCT04765930|OTHER|Q-switched nd:YAG laser toning|Q-switched nd:YAG laser toning for melasma.
214897618|NCT01515423|DRUG|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
214897619|NCT01515423|DRUG|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
214897620|NCT01515423|DRUG|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
214897621|NCT01515423|DRUG|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
214897622|NCT01515423|DRUG|Placebo (20% Intralipid)|Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
214897623|NCT01515423|DRUG|PP1M 50 mg eq.|Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
214897624|NCT01515423|DRUG|PP1M 75 mg eq.|Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
214897625|NCT01515423|DRUG|PP1M 100 mg eq.|Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
214907312|NCT05721755|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
214907313|NCT05721755|DRUG|Fluorouracil|Given IV
214907314|NCT05721755|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214907315|NCT05721755|DRUG|Paclitaxel|Given IV
214907316|NCT05721755|BIOLOGICAL|Pembrolizumab|Given IV
214907317|NCT05721755|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214907318|NCT05721755|OTHER|Quality-of-Life Assessment|Ancillary studies
214907319|NCT05721755|RADIATION|Radiation Therapy|Undergo radiation therapy
214907320|NCT05579314|DRUG|XW014|Oral tablets
214907321|NCT05579314|DRUG|Placebo|Matched oral placebo tablets
214907322|NCT05579314|DRUG|XW014|Oral capsules
214907323|NCT05579314|DRUG|Placebo|Matched oral placebo capsules
214907324|NCT06370143|BEHAVIORAL|Questionnaire|The questionnaire on clinical, environmental, lifestyle, and dietary risk factors will be administered
214907325|NCT06328608|DRUG|PRX-102 1 mg/kg every two weeks|Drug: PRX-102 1 mg/kg every two weeks
214907326|NCT05573464|DRUG|BGF MDI HFO 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
214907327|NCT05573464|DRUG|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
214907328|NCT06557876|PROCEDURE|Pulmonary vein isolation by pulse field ablation|Pulse Field Ablation (PFA) is a non-thermal energy based on high voltage, ultra-short energy pulses applied selectively to cardiomyocytes.
214907329|NCT06557876|PROCEDURE|Pulmonary vein isolation by cryoablation|Cryoablation is a conventional thermal energy, also delivered with a single-shot cryoballoon device.
214907330|NCT04671667|DRUG|Carboplatin|Given IV
214907331|NCT04671667|DRUG|Cisplatin|Given IV
214907332|NCT04671667|PROCEDURE|Computed Tomography|Undergo CT
214897626|NCT01515423|DRUG|PP1M 150 mg eq.|Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
214897627|NCT01015534|DRUG|Temozolomide|
214897628|NCT01015534|RADIATION|Whole brain irradiation|
214897629|NCT04786002|DRUG|Busulfan|The BU administration regimen was four times a day (Q6h), continuous intravenous infusion for 2 hours, 3 or 4 days in a row.
214897630|NCT04421131|DEVICE|Pocket colposcope/Mobile phone camera|The Pocket colposcope or mobile phone camera will be used to capture magnified digital images of the cervix
214897631|NCT04421131|OTHER|mIVAA|A mobile-phone-based telemedicine platform that enables remote consultation with an expert colposcopist
214897632|NCT00347984|OTHER|Systane Lubricant eye drops|
214897633|NCT03926351|DIETARY_SUPPLEMENT|Omega-3 capsules|BASF AS is the developer of the gelatine capsules containing Omega-3 ethyl ester from fish oil concentrate, as the dietary (nutritional) ingredient. The additional capsule fill ingredients are food additives permitted in food supplements according to Regulation (EC) No 1333/2008 on Food additives.
214897634|NCT03926351|DIETARY_SUPPLEMENT|Olive oil|Soft gelatine capsule containing 1000 mg olive oil, refined.
214897635|NCT03680677|PROCEDURE|Bone Marrow or Peripheral Blood Graft (BMT)|Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
215052651|NCT05111288|DEVICE|Inactive Pulsed electromagnetic field therapy (PEMF)|PEMF device that turns on but does not provide any electromagnetic stimulation
215052652|NCT06315192|DEVICE|Stroke Alarm|Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.
215052653|NCT03841942|OTHER|clinically-based spacing strategy|All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.
215052654|NCT03841942|OTHER|Trough level-based strategy|"patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level \< 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study."
215052655|NCT05827705|OTHER|need for Ephedrine hydrochloride|ephedrine dose in hypotension
215052656|NCT01547156|DEVICE|Intervention group|
215052657|NCT05985837|DEVICE|KalobaGOLA spray (1)|Oral spray, 2-4 spray, till 8 times per day
215052658|NCT05985837|DEVICE|KalobaGOLA spray (2)|Oral spray, 2-4 spray, till 4 times per day
215052659|NCT05985837|DEVICE|KalobaGOLA tablets|1 tablets, 6 times per day
214298628|NCT02894931|DIETARY_SUPPLEMENT|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
214298629|NCT02894931|DIETARY_SUPPLEMENT|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
214298630|NCT02894931|DIETARY_SUPPLEMENT|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
214298631|NCT02894931|DIETARY_SUPPLEMENT|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
214298632|NCT02894931|OTHER|Control- water|Chilled water flavored with lemon juice as control
214298633|NCT05563896|OTHER|No intervention|No intervention
214298634|NCT03202797|OTHER|audiometric tests|tone and speech audiometry
214298635|NCT03202797|OTHER|Questionnaires|APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire
214298636|NCT03202797|OTHER|Settings of cochlear implants|pitch matching, evolutionary algorithm setting
214298637|NCT00221598|PROCEDURE|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
214298638|NCT05343975|PROCEDURE|biopsy with audio-guided Meditation|biopsy with audio-guided Meditation
214298639|NCT03635710|DEVICE|The patient will undergo no intervention|Night coughs will be monitored using smartphone a app and interpreted using machine learning algorithm.
214298640|NCT03849859|DEVICE|Single plastic stent|Deployment of single plastic stent
214298641|NCT03849859|DEVICE|Multiple plastic stents|Deployment of multiple plastic stents
214298642|NCT01725334|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
214298643|NCT01058109|OTHER|calcium-rich diet|dietary calcium intake of 1500 mg/d
214298644|NCT01058109|OTHER|Calcium rich diet|dietary intake of 1500 mg/d from food
214298645|NCT01239706|DRUG|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
214298646|NCT04366453|PROCEDURE|echocardiography|Four measurements in echocardiography performed in addition to standard care
214298647|NCT02554812|DRUG|Avelumab|Anti-PD-L1 antibody
214298648|NCT02554812|DRUG|Utomilumab|Anti-4-1BB antibody
214298649|NCT02554812|DRUG|PF-04518600|OX40 Agonist
214298650|NCT02554812|DRUG|PD 0360324|Anti-M-CSF
214298651|NCT02554812|DRUG|CMP-001|TLR9 agonist
214897636|NCT03680677|OTHER|Cancer-directed Therapy or Best Supportive Care|"Cancer-directed therapy with intensive regimens (7+3, Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care."
214897637|NCT03680677|DIAGNOSTIC_TEST|Frailty Assessment|Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
214897638|NCT02501928|DRUG|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
214897639|NCT02501928|DRUG|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
214897640|NCT02501928|DRUG|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 28 weeks
214897641|NCT02501928|DRUG|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 28 weeks
214897642|NCT06243276|PROCEDURE|One stage implant surgery|It is a technique in which the healing cap is connected to the implant at the stage of implant placement.
214897643|NCT06243276|PROCEDURE|Two stage implant surgery|It is a technique in which the healing cap is connected to the implant three months after the implant is placed.
214897644|NCT05392868|DEVICE|SDF|38% silver diamine fluoride solution
214298652|NCT03229668|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
214298653|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
214298654|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
214298655|NCT00290914|DRUG|Vilazodone|
214298656|NCT01448278|PROCEDURE|"All-inside"|"The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation."
214897645|NCT05392868|DEVICE|KNO3|5% potassium nitrate solution
214897646|NCT01059656|DRUG|Pazopanib|Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
214897647|NCT00189124|DRUG|Dehydroepiandrosterone (DHEA)|
214897648|NCT04937140|DIAGNOSTIC_TEST|14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients|assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)
214897649|NCT00858494|DRUG|Hyland's Cold 'n Cough 4 Kids|Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
214897650|NCT06979102|OTHER|Real Patient Interactive Stoma Care Management Teaching|"The real patient interactive stoma care management teaching will be carried out with ileostomy patients who have recently undergone ileostomy surgery and their caregivers in the intervention group. The 2nd month after discharge, the newly ileostomy patients and their caregivers will be asked one open-ended question to elicit their thoughts and suggestions regarding the real patient interactive stoma care management teaching. The question is: A real patient with a previous ileostomy participated in the stoma care management teaching. He demonstrated how to perform ileostomy care on himself and shared his experiences and suggestions regarding adapting to life with an ileostomy. What are your thoughts and suggestions regarding this teaching?"
214897651|NCT06979102|OTHER|Standard Stoma Care Management Teaching|The standard stoma care management teaching will be carried out with ileostomy patients who have recently had their ileostomy opened and their caregivers in the control group.
214907333|NCT04671667|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214907334|NCT04671667|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214907335|NCT04671667|BIOLOGICAL|Pembrolizumab|Given IV
214907336|NCT04671667|RADIATION|Proton Beam Radiation Therapy|Undergo PBRT
214907337|NCT06639451|DEVICE|RANGER™ Paclitaxel Coated Balloon Catheter|A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon coated with paclitaxel at the end of it. When the tube is in place, it inflates to open the blood vessel, so that normal blood flow is restored. The tube is then removed.
214907338|NCT06644417|DRUG|TQA3605 tablets plus NAs|TQA3605 tablets is core protein regulator
214907339|NCT06644417|DRUG|TQA3605 Placebo plus NAs|Placebo without drug substance
214907340|NCT05763290|OTHER|Affective Response to Exercise|Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.
214907341|NCT02512497|DRUG|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
214907342|NCT02512497|DRUG|Busulfan|Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI \>4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
214907343|NCT02512497|DRUG|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
214907344|NCT02512497|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
214298657|NCT01448278|PROCEDURE|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
214897652|NCT03427736|DRUG|Ketorolac Tromethamine|IV ketorolac will be given per standard of care, not prescribed for this study
214897653|NCT03427736|DRUG|Hydromorphone|IV Hydromorphone will be given per standard of care, not prescribed for this study
214897654|NCT03427736|DRUG|Ketamine|IV Ketamine will be given per standard of care, not prescribed for this study
214897655|NCT03427736|DRUG|Oxycodone|PO Oxycodone(solution or tablet) will be given per standard of care, not prescribed for this study
214897656|NCT03427736|DRUG|Morphine|IV Morphine will be given per standard of care, not prescribed for this study
214897657|NCT02782663|DRUG|ABT-494|Tablet: Oral
214897658|NCT06247410|DRUG|Rotigotine 8Mg/24Hrs Patch|Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days
214897659|NCT06568224|DRUG|Mesalazine|oral mesalazine 1g qid
214897660|NCT00520897|DRUG|Raltegravir (MK0518)|400mg BID; 48 weeks
214897661|NCT00520897|DRUG|Placebo|400mg QD
214897662|NCT00520897|PROCEDURE|Leukopheresis|pack of cells as per protocol
214897663|NCT00520897|PROCEDURE|Sigmoid Biopsy|gut samples as per protocol
214897664|NCT05643872|DRUG|PTX-022|QTORIN rapamycin 3.9% anhydrous gel
214897665|NCT01823367|BEHAVIORAL|Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
214897666|NCT01963741|DRUG|leukotriene D4|Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was \<30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.
214897667|NCT01963741|DRUG|histamine|Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was \<30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
215052660|NCT05221645|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications because of its mechanism of action to bind the PD-1 receptor on the T cell.
214897668|NCT06455813|DRUG|Bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
214897669|NCT06455813|DRUG|Macrogol 3350 and electrolytes|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
214897670|NCT06455813|DRUG|A combination of macrogol 3350 and electrolytes and bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
214907345|NCT02512497|DRUG|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
214907346|NCT04137757|OTHER|Lower Body Negative Pressure|Lower body negative pressure will be applied.
214907347|NCT04137757|OTHER|Sham Pressure|Noise will be turned on but no pressure will be applied.
214907348|NCT02899819|OTHER|meconium|The meconium will be sampled in the first 2 days of life
214907349|NCT04877691|DRUG|Medi-546|Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
214907350|NCT04877691|DRUG|Placebo|Solution for injection in aPFS
214907351|NCT03492372|OTHER|Waste tissues are collected at the time of spinal surgery.|This is a single visit study. Waste tissues are collected at the time of spinal surgery.
214907352|NCT05734157|DEVICE|Peripheral PTA with a drug coated balloon|Peripheral artery angioplasty
214907353|NCT00979238|GENETIC|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
214907354|NCT00979238|DRUG|scAAV2/8-LP1-hFIXco|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
214907355|NCT06044454|OTHER|qXR|a software product that uses artificial intelligence to triage, prioritise, and (for tuberculosis only) diagnose based upon identified abnormalities within the CXR.
214907356|NCT06377852|DRUG|Palbociclib 125mg|Arm 1: Indicated dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle)
214907357|NCT06377852|DRUG|Ribociclib 600mg|Arm 1: Indicated dosing of ribociclib (600 mg orally daily on days 1-21 of 28-day cycle)
214907358|NCT06377852|DRUG|Ribociclib|Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
214907359|NCT06377852|DRUG|Palbociclib|Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
214907360|NCT05918835|DEVICE|High-frequency repetitive transcranial magnetic stimulation (active rTMS)|HF-rTMS is applied with a figure-of-8 coil using the Magstim TMS System. Participants receive one administration of HF-rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). HF-rTMS is delivered at a frequency of 10 Hz for approximately 37 minutes (3000 total pulses).
214907361|NCT05918835|DEVICE|Sham repetitive transcranial magnetic stimulation (sham rTMS)|Sham rTMS is applied with a figure-of-8 sham coil using the Magstim TMS System, which is identical to the active coil, replicates the sounds of HF-rTMS, and is designed to mimic sensations of HF-rTMS. Participants receive one administration of sham rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). Sham rTMS is delivered for approximately 37 minutes (3000 total pulses).
214907362|NCT04874454|DIAGNOSTIC_TEST|ultrasound|evaluate the vocal cord movement among the stroke patients
214907363|NCT03298893|DRUG|Nivolumab Injection|2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks
214907364|NCT03298893|DRUG|Cisplatin|40 mg/m2, once a week during radiotherapy
214907365|NCT03298893|RADIATION|radiotherapy|"Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.~An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.~An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center."
214907366|NCT06634524|DRUG|Dexmeditomidine|Patients who will receive IV infusion of (0.2 µg/kg/hr dexmeditomidine).
214907367|NCT06634524|DRUG|Normal saline|Patients who will receive IV infusion of normal saline, at the same rate of dexmedetomidine infusion.
214907368|NCT06636435|DRUG|CBA-1205 Part 1|CBA-1205: 0.1, 0.3, 1, 3, 10, 20, 30 mg/kg (Intravenous solution)
214907369|NCT06636435|DRUG|CBA-1205 Part 2|CBA-1205: 20 mg/kg and 30 mg/kg (Intravenous solution)
214907370|NCT06636435|DRUG|CBA-1205 Part 3|CBA-1205: 30 mg/kg (Intravenous solution)
214907371|NCT06636435|DRUG|CBA-1205 Part 4|CBA-1205: 20 mg/kg (Intravenous solution)
214907372|NCT06636435|DRUG|CBA-1205 Part 5|CBA-1205: 10 mg/kg (The initial cohort, Intravenous solution)
214907373|NCT06026046|OTHER|Adapted sport program based on fencing|"This adapted sport program includes 3 to 5 sessions per week of adapted fencing (excluding weekends and public holidays), carried out either by a fencing master trained in adapted sport, or by an APA teacher trained in adapted fencing by the fencing master.~Sessions can last from 10 to 30 minutes. The course of the session is validated by the fencing master and adapted to each patient. The limiting factors are taken into account, in order to direct towards a specific practice.~The sessions are progressive with very short and varied sequences calling on the imagination and experience of the fencing masters."
214897671|NCT01268462|OTHER|Heliox+PEP|For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
214897672|NCT01268462|OTHER|Oxygen+PEP|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
214897673|NCT01268462|OTHER|Heliox|For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
214897674|NCT01268462|OTHER|Oxygen|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
214897675|NCT06497907|DIETARY_SUPPLEMENT|polymeric formula|Patients with growth faltering received nutritional rehabilitation with polymeric formula and were reassessed after 12 weeks by anthropometric measurements
214897676|NCT06497907|DIETARY_SUPPLEMENT|peptide based formula|patients who were defined as non responders and underwent upper gastrointestinal endoscopy and diagnosed as environmental enteropathy, received nutritional rehabilitation with peptide based formula
214897677|NCT06996886|DRUG|AZD5004|Participants will be receiving three different formulations (F1, F3, and F4) as single dose of AZD5004 orally in fasted and fed state.
214897678|NCT05426369|BIOLOGICAL|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein for injection (Strength: 1 mg/ml, 0.5ml/vial)
214897679|NCT06072859|OTHER|Humidified Forest Oils|60mls Limonene in 200mls water humidified with a diffuser.
214897680|NCT06072859|OTHER|Forest oils and audio-visual forest exposure|60mls Limonene in 200mls water humidified with a diffuser and audiovisual Forest sights and sounds on Surface Pro tablet.
214897681|NCT07010276|DEVICE|DBS Arm|Patients in the DBS treatment arm will undergo surgical DBS implantation.
214897682|NCT07010276|DEVICE|VNS arm|Patients in the VNS treatment arm will undergo surgical VNS implantation.
214897683|NCT06756035|DRUG|CT-95|Weekly IV dosing
214907374|NCT05443490|DIETARY_SUPPLEMENT|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.|Sachets containing a probiotic mixture at concentrations equal to or greater than 1x10\^9 colony forming unit (CFU) per dose, with maltodextrin as excipient.
214907375|NCT05443490|OTHER|Placebo comparator with maltodextrin as a carrier.|Sachets containing maltodextrin
214907376|NCT03413384|DRUG|Ceftriaxone|1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
214907377|NCT03413384|OTHER|Placebo|Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
215052661|NCT05221645|DRUG|Rituximab|Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
215052662|NCT05221645|DRUG|Ifosfamide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
215052663|NCT05221645|DRUG|Carboplatin|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
215052664|NCT05221645|DRUG|Etoposide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
215052665|NCT04881682|DEVICE|Immunoadsorption|see arm/group description
215052666|NCT04881682|BIOLOGICAL|Immunoglobulins|see arm/group description
215052667|NCT06567002|DRUG|MK-6552|Oral Administration
215052668|NCT02157909|DEVICE|Lotrafilcon B sphere modified design contact lenses|
215052669|NCT02157909|DEVICE|Lotrafilcon B sphere contact lenses|
215052670|NCT00287781|DRUG|Lidocaine|
215052671|NCT02268383|DRUG|Luspatercept|Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.
215052672|NCT01911468|DRUG|metformin|
215052673|NCT01911468|DRUG|liraglutide|
215052674|NCT01911468|DRUG|metformin and liraglutide|
215052675|NCT04355650|OTHER|Clinical decision support tool|Adults (aged 18-64 years) who meet DSM-5 diagnostic criteria for non-psychotic unipolar major depressive disorder (MDD) and meet study eligibility criteria will receive 8 weeks of open-label treatment with an SSRI or SNRI antidepressant. Depressive symptoms will be assessed using the subject- and clinician-rated versions of the 16-items QIDS scale (QIDS-SR and QIDS-CR) and the 17-item HAMD at baseline, week 2 (via telephone), week 4, and week 8; with an additional phone contact at week 24. The QIDS scale scores at 2- and 4-weeks will be entered into the AHI-based clinical decision support tool, and the outcome predicted by the tool (e.g., the predicted eventual treatment outcome at 8 weeks) will be recorded. Clinicians and patients will be blinded to the clinical decision support tool prediction of outcome provided at the 2- and 4 weeks.
214897684|NCT07017569|BEHAVIORAL|Mobile health application|"This group will receive the mHELP mobile and watch application with full functionality which provides weekly self-assessment and self-reported events PLUS self-management functionality. The self- management functionality includes additional on-demand features (see the attached list of features). These include~* a breath functionality that provides a times breathing exercise similar to the one provided by the Apple iWatch; users can see changes in their heart rate during the breathing exercise and will see a summary of heart rate changes~* a calendar features that allows students to upload their class schedule and see different activities such as self-assessments~* a journaling feature that allows participants to write a journal~* a task list to take note of major tasks and add them to calendar~* a set of relaxation media including videos and audios that participants can use on demand"
214897685|NCT07017634|DEVICE|Novosis Putty|Single Level TLIF surgery with Novosis Putty
214897686|NCT07017634|OTHER|Standard of Care|Single Level TLIF surgery with standard of care bone graft
214897687|NCT07017413|PROCEDURE|Transosseous Maxillary Sinus Lift using Osseodensification|A surgical procedure utilizing the Versah® osseodensification technique for transcrestal sinus floor elevation. The approach involves the use of specialized Densah® burs to prepare the osteotomy and elevate the sinus membrane through a transosseous (crestal) access, avoiding the lateral window technique. No grafting materials will be used in this procedure.
214897688|NCT07017582|DIETARY_SUPPLEMENT|Soidum Bicarbonate|Supplementation with 0.03 g/kg of sodium bicarbonate
214897689|NCT07017582|DIETARY_SUPPLEMENT|Placebo|0.03 g·kg-1 body mass sodium chloride
214897690|NCT07018557|DRUG|Eszopiclone 3 mg|Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).
214897691|NCT07018557|DRUG|Placebo|Placebo pills identical to the active comparator.
214897692|NCT07018804|PROCEDURE|Bronchoscopic brushing|The collected samples are digested with tissue collagenase for the culture of airway basal cells (BCs).
215052676|NCT02708680|DRUG|Entinostat|An orally available histone deacetylases inhibitor (HDAC).
215052677|NCT02708680|DRUG|Atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
215052678|NCT02708680|DRUG|Placebo|A pill containing no active drug ingredient
215052679|NCT05110326|OTHER|ERGON Technique|"* Hot pack for 15 minutes.~* Patient position: Prone with knee flexion approximately 45◦.~* Position of therapist: Standing at the affected side of patient.~* Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~* Strengthening exercises for quadriceps and hamstring will then be performed.~* Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Wall sits: For 10 seconds, 5 sets."
215052680|NCT05110326|OTHER|Proprioceptive Neuromuscular Facilitation (PNF) stretching|"* The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~* Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~* Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~* The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~* Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~* The procedure will be repeated 3 times in every session.~Strengthening Exercises:~* Same as ERGON Group"
214478524|NCT06876298|DIAGNOSTIC_TEST|- Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.|\- Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.
214897693|NCT07018804|GENETIC|Single - cell cloning|After primary BCs are expanded in the P1 passage, single-cell cloning libraries are established by planting them into 384-well cell culture plates in a single-cell per well format using a flow chamber cell sorter. Ten samples are selected from the expandable clones for the identification of differentiation and proliferation capabilities, while the remaining clones are cryopreserved.
214897694|NCT07018804|GENETIC|Cell function identification|For single-cell samples of each patient, in vitro expansion culture is performed to observe the morphology of cells at each passage and calculate the clonogenic rate. Immunofluorescence technique is used to detect the expression of the cell proliferation marker Ki67, and the proliferation capacity is evaluated by combining with the CCK8 assay. Cells at passages P3-P5 are seeded on the permeable membrane of cell culture inserts at a density of \\(10\^6\\) cells/cm², and after 21 days of culture, the differentiated structures are collected. The expression of ciliated cell marker Ace-Tubulin and goblet cell marker MUC5AC is detected to assess the differentiation capacity. Meanwhile, cells are injected subcutaneously into NSG mice at \\(10\^6\\) cells/injection site for in vivo differentiation for 28 days, and the differentiated structures are collected for pathological analysis.
215052681|NCT04162470|DRUG|REGN3918|Subcutaneous (SC) every week (QW) over the treatment period
215052682|NCT00002593|DRUG|fluorouracil|Given IV as described in Arm Description
214298658|NCT05713032|PROCEDURE|Pulsed radiofrequency on lumbar dorsal root ganglion|voltage of pulsed radiofrequency on DRG
214298659|NCT02872636|DEVICE|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
214298660|NCT03900481|PROCEDURE|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive.
214298661|NCT05257499|BEHAVIORAL|On line debriefing|Online Debriefing in the Simulation Sessions of the Helping Babies Breathe Course
214298662|NCT01119014|DRUG|Aripiprazole|pill, 2,5-20 mg/day, maximum 16 weeks
214298663|NCT01119014|DRUG|Quetiapine|pill, 50-600mg/day, maximum 16 weeks
214298664|NCT05919329|DRUG|Piflufolastat|Given IV
214298665|NCT05919329|PROCEDURE|PSMA PET/CT Scan|Undergo PSMA PET/CT
214298666|NCT05919329|PROCEDURE|PSMA PET/MRI scan|Undergo PET/MRI
214298667|NCT05919329|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214298668|NCT05919329|OTHER|Electronic Health Record Review|Ancillary studies
214298669|NCT04114851|DEVICE|NoL|NoL active
214897695|NCT07018804|GENETIC|Identification of local microenvironmental changes|The air-liquid interface (ALI) differentiation culture medium is collected, and cell debris is removed by high-speed centrifugation. The supernatant is then collected to extract proteins. Target proteins are purified via immunoprecipitation or affinity chromatography, followed by desalting and concentration for mass spectrometry analysis to detect inflammatory cytokines and extracellular matrix (ECM). Real-time PCR and Western blot techniques are used to measure the expression levels of epithelial markers, mesenchymal markers, and ECM in cells across all groups, thereby evaluating changes in the local microenvironment around small airways.
214897696|NCT07018804|GENETIC|Gene editing|After plasmid construction, based on gene function, the CRISPR-Cas9-sgRNA (all-in-one) plasmid is transiently transfected into expanded single-cell strains via Nucleofection to knockout the target gene, or the CRISPR-dCas9 fusion-sgRNA plasmid is transiently transfected to activate or inhibit the target gene. After 3-5 days of culture, viable cells are sorted by FACS, and single cells are seeded into 96-well plates for two additional passages of expansion. Samples are collected for Sanger sequencing to screen successfully constructed cell lines.
214897697|NCT07018804|PROCEDURE|Prevention of ferret airway basal cell transplantation|Before surgery, basal cells (BCs) of recipient ferrets are collected by bronchoscopic brushing, followed by in vitro culture and identification. Prior to the onset of BOS, the cells are injected into recipient ferrets via bronchoscopy. Outcomes including ferret survival rate, body weight, CT imaging, and lung tissue pathology are collected to evaluate the preventive effect of BCs on BOS.
215052683|NCT00002593|DRUG|leucovorin calcium|Given IV as described in Arm description.
215052684|NCT00002593|DRUG|levamisole hydrochloride|Given as described in arm description
214298670|NCT06426108|DRUG|Fluoride Varnishes|the investigators will utilize a fluoride varnish with a concentration of 22,600 ppm F. The application will be facilitated using a microbrush, ensuring thorough coverage over the entire length of the lesion for a duration of 30 seconds. Following application, the varnish will be finished with water to create a film on the tooth surface. After completing the interventions, patients will receive instructions to refrain from consuming hard foods and to postpone tooth brushing for at least four hours, adhering to the manufacturer's recommendations.
214298671|NCT06426108|DRUG|Varnishes placebo|the investigators will apply a placebo varnish without the active ingredient (fluoride), ensuring that it is packaged identically to the fluoride varnish and has the same taste and texture, thus maintaining consistency in application. The varnish will be applied using a microbrush, spreading it evenly over the entire length of the lesion for a duration of 30 seconds. Following the interventions, patients will receive instructions to avoid consuming hard foods and to delay tooth brushing for at least four hours after applying the varnish.
214298672|NCT06426108|RADIATION|Low-Intensity Laser 1J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 1 Joule, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
214298673|NCT06426108|RADIATION|Low-Intensity Laser 2J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 2 Joules, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
214298674|NCT04365855|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Combines MRI imaging with sound waves to create a visual map (elastogram) showing the stiffness of body tissues.
214298675|NCT04365855|OTHER|Blood draw|Clinical blood tests with a focus on liver function parameters and diabetes
214298676|NCT04365855|PROCEDURE|Liver biopsy|If indicated per MRE results a biopsy will be taken of the liver.
214478525|NCT06351761|DEVICE|Investigational Device (Withings SCT02) 30 second Electrocardiogram recording|30 second ECG recording with investigational device (Withings SCT02)
214478526|NCT06351761|DEVICE|Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording|30 second ECG recording with reference device (Schiller Cardiovit FT-1)
214478527|NCT06308445|DRUG|Rapamycin|This is a 2-dose rapamycin safety study, with a target through level of 3 to \<5 ng/ml for the first 3 months and 5-8 ng/ml for the next 3 months for each of the included patients. To avoid the possible cumulative effect, the two treatment phases will be separated by a 3-weeks wash-out period.
215052685|NCT01384851|DRUG|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
215052686|NCT01384851|DRUG|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
215052687|NCT01384851|DRUG|Refresh Contacts|One drop both eyes four times daily for two weeks
215052688|NCT02568722|OTHER|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI \> 72 hours following the time of randomization."
214298677|NCT04365855|PROCEDURE|Fibro Scan|If indicated per MRE results a fibroscan will be performed of the liver.
214298678|NCT05698446|PROCEDURE|Modified Broström + Suture tape augmentation operation|Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation
214298679|NCT05698446|PROCEDURE|Anatomic reconstruction operation|Anatomic reconstruction operation
214298680|NCT05698446|PROCEDURE|Open Modified Broström procedure|Open Modified Broström-Gould surgery
214298681|NCT02893072|BEHAVIORAL|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
214298682|NCT03055000|BIOLOGICAL|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
214298683|NCT03055000|BIOLOGICAL|AGS-v + adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
214298684|NCT03055000|OTHER|Placebo|WFI (0.5mL) on Day 0 and Day 21
214298685|NCT03566667|DRUG|Metoprolol|Betablocker
214298686|NCT03566667|DRUG|Standard care|Standard care
214298687|NCT00211445|PROCEDURE|Photodynamic Therapy with Verteporfin|
214298688|NCT00211445|DRUG|verteporfin|
214298689|NCT06178328|BEHAVIORAL|Things You Do Course|Participants receiving the brief psychological intervention ('Things You Do' Course) will have access to a single online lesson that includes course materials and printable materials (i.e., an activity guide and planner) that can be retained for longer-term use. The course materials include an introduction to the purpose and content of the course, education about factors that impact mental health, and information about the 'Big Five' things participants can do to improve their mental health. Participants will also receive automated no-reply emails (5 days/week) through the intervention platform to remind them to practice the skills from the course.
214298690|NCT00087581|DRUG|Mycophenolate mofetil|Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m\^2 in pediatrics. In Groups A and B, subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. In Group C, subsequent doses are not to be adjusted, except in the case of unacceptable toxicity.
214298691|NCT00087581|DRUG|Cyclosporine|Cyclosporine will be given as 100-mg soft gelatin capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 125-165 ng/mL (reduced) or 250-270 ng/mL (full); Days 90 through end of study, 95-145 ng/mL (reduced) or 190-220 ng/mL (full).
214298692|NCT00087581|DRUG|Tacrolimus|Tacrolimus will be given as 1-mg and 5-mg capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL (reduced), 8-10 ng/mL (full); Days 90 through end of study, 3-5 ng/mL (reduced), 6-8 ng/mL (full).
214298693|NCT02809690|DEVICE|CAT|Undergo 18F-FMAU PET/CT
214897698|NCT07018804|PROCEDURE|Transplantation treatment of ferret airway basal cells|Stable cell lines with target gene knockdown are established in ferret basal cells (BCs). After ferrets develop bronchiolitis obliterans syndrome (BOS), the constructed cell lines are transplanted into recipient ferrets to validate the therapeutic effect of gene-corrected BCs on the disease.
215052689|NCT02568722|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
214298694|NCT02809690|DRUG|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
214298695|NCT02809690|OTHER|Laboratory Biomarker Analysis|Correlative studies
214298696|NCT02809690|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
214298697|NCT02809690|DEVICE|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
214298698|NCT02809690|DEVICE|Ultrasound|Undergo TRUS-guided biopsy
214897699|NCT07018284|PROCEDURE|AH Plus (Dentsply Sirona, Charlotte, NC, USA)|Root canal obturation using AH Plus (Dentsply Sirona, Charlotte, NC, USA), a resin-based sealer with low solubility and shrinkage. Used in combination with gutta-percha for root canal filling
214897700|NCT07018284|PROCEDURE|NeoSealer Flo|Root canal obturation using NeoSealer Flo (Avalon Biomed, Houston, TX, USA), a premixed bioceramic sealer based on calcium silicate. Used in combination with gutta-percha to enhance apical healing and biocompatibility.
214897701|NCT07018284|PROCEDURE|Continuous Wave Condensation|A warm vertical compaction technique using heat-softened gutta-percha to obturate the canal in three dimensions. Considered the gold standard for achieving dense and homogenous root canal fillings.
214298699|NCT00813085|OTHER|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
214298700|NCT03341832|DRUG|NVP-1203|oral dose for 7 days
214298701|NCT03341832|DRUG|NVP-1203-R|oral dose for 7 days
214298702|NCT03341832|DRUG|NVP-1203 placebo|oral dose for 7 days
214298703|NCT03341832|DRUG|NVP-1203-R placebo|oral dose for 7 days
214298704|NCT01930851|PROCEDURE|Gastric bypass operation|
214298705|NCT05885074|DRUG|Empagliflozin Arm|The subject will be randomized, in a double-blind manner to Empagliflozin 25mg once daily for a period of 12 months
214298706|NCT05885074|OTHER|Control Arm|The subject will be randomized, in a double-blind manner to receive placebo once daily for a period of 12 months
214298707|NCT05885074|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
214298708|NCT05885074|OTHER|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
214298709|NCT00415909|DRUG|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
215052690|NCT01086696|DRUG|FPAC|Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
215052691|NCT01062698|DRUG|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
215052692|NCT01062698|PROCEDURE|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
214897702|NCT07018284|PROCEDURE|Single Cone Technique|A cold hydraulic condensation technique using a single gutta-percha cone matched to the last rotary file, combined with a high-flow sealer. Designed for simplified obturation with minimal operator variability
214897703|NCT04748822|OTHER|questionnaires|The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
214897704|NCT07018063|DRUG|nab-paclitaxel|Nab-paclitaxel is administered as an intravenous (IV) infusion at a dose of 125 mg/m² on day 1 of each 3-week cycle, for a total of 3 cycles in the neoadjuvant (preoperative) setting.
214897705|NCT07018063|DRUG|oxaliplatin|Oxaliplatin is administered as an intravenous (IV) infusion at a dose of 85 mg/m² on day 1 of each 3-week cycle, for a total of 3 cycles in the neoadjuvant (preoperative) setting.
214897706|NCT07018063|DRUG|S-1|"S-1 is administered orally twice daily (BID) on days 2 to 15 of each 3-week cycle, for a total of 3 cycles. The dose is based on body surface area (BSA) as follows:~BSA \< 1.25 m²: 40 mg BID (total 80 mg/day); BSA 1.25-1.5 m²: 50 mg BID (total 100 mg/day); BSA \> 1.5 m²: 60 mg BID (total 120 mg/day)"
214897707|NCT07018063|DRUG|sintilimab|Sintilimab is administered as an intravenous (IV) infusion at a fixed dose of 200 mg on day 1 of each 3-week cycle, for a total of 3 cycles in the neoadjuvant (preoperative) setting.
214897708|NCT07018063|PROCEDURE|D2 Gastrectomy|Curative-intent D2 radical gastrectomy is performed 3 to 6 weeks after completion of neoadjuvant therapy. The procedure includes either proximal, distal or total gastrectomy depending on tumor location, with en bloc resection of the stomach and systematic D2 lymphadenectomy according to Japanese Gastric Cancer Association (JGCA) guidelines. D2 lymph node dissection involves removal of both perigastric (N1) and second-tier (N2) lymph nodes.
214897709|NCT07017725|DRUG|CID-103|Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of six months.
214897710|NCT01870089|DEVICE|SmartCare/PS-NIV Drägerwerk Lübeck Germany|
214897711|NCT05975073|DRUG|AMG 193|Administered PO
214897712|NCT05975073|DRUG|IDE397|Administered PO
214897713|NCT06708338|PROCEDURE|Needle bevel orientation for arteriovenous fistula puncture|"For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.~Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:~* Bevel-up group~* Bevel-down group"
214897714|NCT06705816|OTHER|None interventional|This is an observational study
214897715|NCT05845983|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
214897716|NCT05845983|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
214897717|NCT01001754|DRUG|PEG-rIL-29|Weekly SC injections in combination with ribavirin for up to 48 weeks
215052693|NCT01102920|BEHAVIORAL|Behavioural strategies to promote physical activity and weight loss|"8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.~Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.~Treatments are provided by a physical therapist and a dietician."
215052694|NCT01102920|DEVICE|CPAP|CPAP-treatment as usual (during nights)
215052695|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
215052696|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
214897718|NCT01001754|DRUG|Peginterferon alfa-2a|Weekly SC injections in combination with ribavirin for up to 48 weeks
214897719|NCT01001754|DRUG|Ribavirin|Daily oral administration (400-600 mg BID)
214897720|NCT07042334|BEHAVIORAL|Serious game for transition readiness|The serious game is an interactive narrative fiction game in which players guide a character through a hospital setting, making choices that simulate real-life healthcare scenarios. The game is designed to improve skills such as communication with healthcare providers, understanding medical information, and managing appointments and medications. No drugs or medical devices are used in this intervention.
214897721|NCT07045818|BEHAVIORAL|Emotional provocation task involving multisensory aversive stimuli|To elicit hemodynamic responses in the dorsolateral prefrontal cortex (DLPFC) and activate the sympathetic nervous system, we used a standardized multisensory aversive stimulation protocol comprising: (i) Visual stimuli: 72 high-arousal images from the GAPED database (moral violations, legal violations, fear-related) shown in 12 blocks (6 images/block, 5 s each) with 20 s baseline and 30 s stimulation; (ii) Auditory stimuli: each block paired with 30 s of calibrated 90 dB(A) high-frequency narrowband white noise (4 kHz center frequency), shown to increase heart rate; (iii) Cold-pain stimuli: during each block, participants placed both hands on 0 °C ice-filled bottles for pain-induced sympathetic activation. This tri-modal task reliably provokes DLPFC engagement and autonomic responses.
214897722|NCT06731270|BIOLOGICAL|Atezolizumab|Given atezolizumab
214897723|NCT06731270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215052697|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
215052698|NCT05588440|BIOLOGICAL|ONCT-808|"A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts."
215052699|NCT05588440|DRUG|Bridging Therapy|Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
214298710|NCT00415909|DRUG|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
214298711|NCT03226431|DRUG|Ascorbic Acid|ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
214298712|NCT03981081|DRUG|Prednisone|Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
215052700|NCT01818843|OTHER|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
214298713|NCT05657665|OTHER|Observational measurements of skin tone|Objective and subjective skin tone measurements will be performed.
214298714|NCT01862887|DRUG|PH-797804|Tablet, 24 mg, single dose
214298715|NCT01862887|DRUG|Moxifloxacin|Tablet, 400 mg, single dose
214298716|NCT01862887|DRUG|Placebo|Tablet, PH-797804 matched placebo, single dose
214897724|NCT06731270|BIOLOGICAL|Cemiplimab|Given cemiplimab
214897725|NCT06731270|PROCEDURE|Computed Tomography|Undergo CT
214897726|NCT06731270|DRUG|Diclofenac Potassium|Given PO
214897727|NCT06731270|OTHER|Electronic Health Record Review|Ancillary studies
214897728|NCT06731270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214897729|NCT06731270|BIOLOGICAL|Nivolumab|Given nivolumab
215052701|NCT04475107|DRUG|Pyronaridine-Artesunate|Pyramax
214298717|NCT04526483|DEVICE|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System
214298718|NCT04792632|DEVICE|Veye Lung nodules|Veye Lung Nodules
214298719|NCT00366145|BIOLOGICAL|Prochymal®|2 infusions of 2 million cells/kg per week for 4 weeks
214298720|NCT00366145|DRUG|Placebo|2 infusions per week for 4 weeks
214298721|NCT00366145|DRUG|Standard of Care for GVHD|Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)
214298722|NCT03577743|DRUG|Bevacizumab|-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
214298723|NCT03232281|DRUG|Triptorelin Pamoate PR 3-month|15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
214897730|NCT06731270|BIOLOGICAL|Pembrolizumab|Given pembrolizumab
214298724|NCT03232281|DRUG|Triptorelin Acetate PR 1-month|3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
214298725|NCT03210870|BEHAVIORAL|nutritional education classes|The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
214298726|NCT01403246|DRUG|Lenalidomide; Chlorambucil|MTD of lenalidomide given in combination with chlorambucil
214298727|NCT01472250|DRUG|Clinical chemo-drugs|"Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel"
214298728|NCT06146933|DIAGNOSTIC_TEST|Glucometer Test|blood glucose measurement using finger tip capillary blood using BGM
214897731|NCT06731270|PROCEDURE|Positron Emission Tomography|Undergo PET
214897732|NCT06718439|PROCEDURE|Restrictive Transfusion|Red blood cell transfusion when the participant's hemoglobin level is measured below 70 g/L or to maintain a hemoglobin target range of 70-80 g/L. This strategy will be adhered to during surgery and up to 6 hours in the post-operative anesthesia care unit.
214897733|NCT06718439|PROCEDURE|Liberal transfusion|Red blood cell transfusion when the participant's hemoglobin level is measured below 90 g/L or to maintain a hemoglobin target range of 90-100 g/L. This strategy will be adhered to during surgery and up to 6 hours in the post-operative anesthesia care unit.
215052702|NCT04475107|DRUG|Placebo|Placebo
215052703|NCT05000372|DRUG|68Ga-grazytracer|68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.
215052704|NCT05508126|DIAGNOSTIC_TEST|DECT examination|DECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).
215052705|NCT05508126|DIAGNOSTIC_TEST|mpMRI examination|The examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).
215052706|NCT06173505|COMBINATION_PRODUCT|Vudalimab + Carboplatin + Pemetrexed|Vudalimab intravenous + carboplatin intravenous + pemetrexed intravenous
215052707|NCT06173505|COMBINATION_PRODUCT|Pembrolizumab + Carboplatin + Pemetrexed|Pembrolizumab intravenous + carboplatin intravenous + pemetrexed intravenous
215052708|NCT03552016|DRUG|Oral Riboflavin|The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
215052709|NCT00066053|PROCEDURE|Periodontal Treatment: SRP|Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
214298729|NCT06146933|DIAGNOSTIC_TEST|Refernce Measurement|blood glucose measurement using finger tip capillary blood using reference method
214897734|NCT06924853|OTHER|Platelet lysate|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist into 8 yellow top tubes and 1 purple top tube and processed into 5cc PL of which 4cc will be used for treatment and the remaining 1cc will be frozen and used for QC. A lavender top blood tube will be collected and used for quantitative CBC analysis (Beckman Coulter DxH 500 Series). Patient will lie on table prone with a pillow under their abdomen to flatten their L-spine, sterilely prepped and draped. Provider to put patient in conscious sedation to maintain study blinding. The physician will then use a 25-gauge needle under intermittent x-ray visualization to access the TF space. The physician will inject the TF space with x-ray contrast (0.5mL of OMNIPAQUE) to confirm epidural flow. Once flow is confirmed, the physician will inject 4mL of the PL, and 0.5mL of 0.5% ropivacaine into the epidural space at each level of interest. A 0.22 micron filter will be used.
215052710|NCT00066053|PROCEDURE|Referral|
214298730|NCT05383560|BIOLOGICAL|mRNA-1273.214 Vaccine|Omicron Variant-Matched Vaccine
214897735|NCT06924853|OTHER|Saline control|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist into 8 yellow top tubes and 1 purple top tube and processed into 5cc PL of which 4cc will be used for treatment and the remaining 1cc will be frozen and used for QC. A lavender top blood tube will be collected and used for quantitative CBC analysis; same as active treatment to maintain blinding. Patient will lie on table prone with a pillow under their abdomen to flatten their L-spine, sterilely prepped and draped. Provider to put patient in conscious sedation to maintain study blinding. The physician will then use a 25-gauge needle under intermittent x-ray visualization to access the TF space. The physician will inject the TF space with x-ray contrast (0.5mL of OMNIPAQUE) to confirm epidural flow. (6) Once flow is confirmed, the physician will inject 4mL of sterile saline (0.9%), and 0.5mL of 0.5% ropivacaine into the epidural space at each level of interest.
214897736|NCT06889350|DRUG|HD-P023|Single dose administration of HD-P023
214897737|NCT06889350|DRUG|Teneligliptin|Single does administration of Teneligliptin and Empagliflozin High
214897738|NCT06889350|DRUG|Empagliflozin High|Single does administration of Teneligliptin and Empagliflozin High
214897739|NCT07045116|DEVICE|Electronic anesthesia|The child will receive electronic anesthesia to the right side of the upper jaw; the pain and anxiety level will be assessed.
214897740|NCT07045116|DEVICE|Conventional anesthesia|The child will receive conventional anesthesia to the maxillary left side
214897741|NCT04229667|OTHER|Improved Community Health Volunteer (CHV) program|"Multi-modal intervention targeting intensive household monitoring of high-needs patients using monthly visits to measure blood pressure and blood sugar, adherence to treatments and compliance with clinics visits, and motivational interviewing to facilitate behavior change and psychosocial support."
214897742|NCT06741345|DRUG|BIO 300 Oral Suspension|Suspension of genistein nanoparticles for oral administration
214897743|NCT03245112|DRUG|Eribulin Mesylate|The patients received intravenous eribulin 1.4 mg/m2 over 2-5 minutes on days 1 and 8 of every 21 days.
214897744|NCT01872286|DEVICE|AKE-1|
214897745|NCT01872286|DEVICE|Pillcam SB2|
214897746|NCT05372965|OTHER|experimental-periodontitis-mirna-223-gingival tissue-saliva samples|Non-surgical periodontal treatment will be applied to individuals with periodontitis, gingival samples will be collected during the treatment, clinical measurements and saliva collection will be repeated 6 weeks after the treatment. MiRNA-223 gene expression analysis will be performed by real-time PCR (Polymerase Chain Reaction) method in saliva and gingival samples of individuals. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
214897747|NCT05372965|OTHER|control-clinical healthy mirna-223-gingival tissue-saliva samples|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample will be collected from the clinically healthy group. A tissue sample will be collected during the clinical crown lengthening operation.
215052711|NCT06473051|OTHER|Original set|The original set of implementation strategies will include the same strategies as applied in the INTERCARE study by the research group but will be updated to fit the current practice field.
215052712|NCT06473051|OTHER|Adapted set|The adapted set of implementation strategies will contain similar implementation strategies that are expected to achieve the same outcomes as the first set, but with less resources required (for instance, by providing group coaching sessions rather than single sessions).
215052713|NCT05575466|DIAGNOSTIC_TEST|Blood samples|Hemostatic biomarkers
215052714|NCT05575466|DIAGNOSTIC_TEST|Questionnaires|Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
215052715|NCT04519931|OTHER|Stress ball|The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
215052716|NCT03934866|RADIATION|Low Dose CT scan|Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.
214298731|NCT05383560|BIOLOGICAL|MRNA-1273 Vaccine|Moderna's commercial COVID-19 Vaccine
214298732|NCT05383560|BIOLOGICAL|Placebo|Normal Saline for injection
214298733|NCT05383560|BIOLOGICAL|MRNA-1273.222 Vaccine|Moderna's commercial COVID-19 Vaccine
214298734|NCT02522286|BEHAVIORAL|Ask 3 Questions|"Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare."
214298735|NCT02522286|BEHAVIORAL|Open Communication|"Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2\) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3\) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow."
214298736|NCT02848014|BEHAVIORAL|Writing task|
214298737|NCT01175733|DRUG|Panitumumab|During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
214298738|NCT04952142|OTHER|minimal water exchange|Use a new technique, minimal water exchange colonoscopy, which adds the infusion of modest amounts of water by constant pressure on the air-water valve button of the endoscope to achieve intubation.
214298739|NCT01700855|PROCEDURE|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
214298740|NCT01700855|PROCEDURE|Electroacupuncture|"Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3\~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate."
214298741|NCT00774228|DEVICE|I-ZIP Ocular Bandage|
214298742|NCT00774228|DEVICE|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
214298743|NCT04922983|DRUG|Botulinum toxin type A|A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).
214298744|NCT04922983|BEHAVIORAL|Isometric Yoga-like exercise|Extended torso and legs held diagonally by one straight arm, back against wall if necessary
214298745|NCT04922983|BEHAVIORAL|Placebo|Used as placebo
214298746|NCT05771142|DEVICE|Smart t-shirt|24h ECG Monitoring with the smart t-shirt under study
214298747|NCT05771142|DEVICE|ECG Holter|24h ECG Monitoring with ECG Holter
215052717|NCT06293937|BEHAVIORAL|Numerical label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
215052718|NCT06293937|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
215052719|NCT06293937|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
215052720|NCT06293937|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
214298748|NCT05771142|DEVICE|Smartwatch|24h ECG Monitoring with a smartwatch
214298749|NCT01924312|BEHAVIORAL|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
214298750|NCT06021015|DEVICE|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
214298751|NCT06021015|DEVICE|Irinotecan and HepaSphere Microspheres|Irinotecan and HepaSphere Microspheres
214298752|NCT03445819|PROCEDURE|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon
214298753|NCT03445819|OTHER|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery.
214298754|NCT00174915|DRUG|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
214298755|NCT00174915|DRUG|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
214298756|NCT00174915|DRUG|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
214298757|NCT00174915|DRUG|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
215052721|NCT01643460|PROCEDURE|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size \& amount of fluid aspirated from the cyst.
214298758|NCT00174915|DRUG|Placebo|Placebo, orally, once daily for up to 28 weeks.
214478528|NCT06652672|PROCEDURE|Organ-sparing surgery|Endoscopy-assisted laparoscopic/robotic wedge resection and sentinel lymph node biopsy using submucosal injection of ICG.
214298759|NCT03632278|BEHAVIORAL|Mindfulness psychoeducation Programme|"A MBPP will be conducted for 2 hours for each session, one a week for eight weeks. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien \& Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).~The programme will be integration of mindfulness and psychoeducation to cultivate the client's mindfulness attitude. The clients will learn to apply the mindfulness in illness management and daily difficulties."
214298760|NCT01837992|DRUG|Primaquine|
214298761|NCT01837992|DRUG|delayed primaquine|
214298762|NCT00183092|DRUG|Quinacrine|100mg by mouth three times a day
214298763|NCT00183092|DRUG|Placebo|100mg by mouth three times a day
214897748|NCT01799044|DEVICE|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
214897749|NCT03653884|DIAGNOSTIC_TEST|Ultrasound monitoring|Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.
214897750|NCT02845700|BEHAVIORAL|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
214897751|NCT02845700|BEHAVIORAL|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
214897752|NCT03068039|OTHER|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
214897753|NCT03068039|OTHER|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
214897754|NCT01022697|OTHER|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
214897755|NCT05641844|DEVICE|RD2 Ver.02|Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.
214897756|NCT05641844|OTHER|Saline|Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.
214897757|NCT02452476|DRUG|CHF5633|Rescue treatment (if needed)
214897758|NCT02452476|DRUG|Poractant alfa|Rescue treatment (if needed)
214897759|NCT02033031|DRUG|Lucentis intravitreal injection|Lucentis intravitreal injection
214897760|NCT02033031|DRUG|Avastin intravitreal injection|Avastin intravitreal injection
214897761|NCT04874831|DRUG|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
214897762|NCT02068612|BEHAVIORAL|Moderate Intensity Continuous Training+Interval Training|
214897763|NCT02068612|BEHAVIORAL|Low Intensity Continuous Training|
214897764|NCT02201784|DRUG|Levobupivacaine|Comparison of Equipotent doses
214897765|NCT02201784|DRUG|Ropivacaine|Comparison of equipotent doses
214897766|NCT03161977|OTHER|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
214897767|NCT04200027|PROCEDURE|total mesorectal excision|Total Mesorectal Excision Total Mesorectal Excision is currently the standard technique for surgical treatment of RC. It was first described in 1982 by Bill Heald, and relies on the excision of the whole mesorectum within an intact mesorectal fascia, with the contained lymphatic system along with the tumour bearing bowel segment Total mesorectal excision
214897768|NCT01231776|OTHER|electronic acupuncture|applying a stimula on neiguang and shenmen through electronic acupuncture
214897769|NCT00165763|DRUG|donepezil hydrochloride (Aricept)|5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
214897770|NCT01729949|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry and Blackcurrent extract
214897771|NCT01729949|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|without active components
214897772|NCT03561129|OTHER|Embryo transfer|all the fresh embryo transfers, performed between January 1997 and December 2016 at Humanitas Fertility Center after IVF-ICSI cycles, divided per operator
214897773|NCT05066880|OTHER|Exercise training|Exercise training for 8 weeks
214897774|NCT03419689|PROCEDURE|Tumour tissue collection|"Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
214897775|NCT03419689|PROCEDURE|Blood sample collection|"Blood samples will be taken:~* At the time of first diagnosis~* About 1 week after starting any treatment~* At each radiological response assessment~* At each subsequent relapse or disease progression"
214298764|NCT03889821|BEHAVIORAL|Parent-implemented Early Start Denver Model|The Parent-implemented Early Start Denver Model (P-ESDM; Rogers et al., 2012) consists of 12 consecutive sessions, each session approximately 1 hour long, that promote parental ability to support and interact with their young children with autism spectrum disorder (ASD). Intervention sessions are conducted in the clinic setting by therapists trained to fidelity by ESDM-certified parent trainers. The manualized intervention has a detailed parent-training curriculum, a specific coaching intervention method, and a therapist fidelity measure. Therapists introduce skills through descriptions, interaction, modeling, coaching, and feedback.
214298765|NCT03889821|BEHAVIORAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) protocol is derived from the work by Dykens et al. (2014), which is based on the stress reduction and relaxation program (Kabat-Zinn, 1982, 1990). In this study, it is offered as 6 weekly sessions that run concurrent with the P-ESDM intervention. Participants work one-on-one with a therapist for instruction and practice in mindfulness skills as well as discussions of stress, coping, and homework assignments.
214298766|NCT03459378|OTHER|no intervention - retrospective analyses|retrospective data examination, there are no study related interventions
214298767|NCT05791045|PROCEDURE|single vs double|we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade
214298768|NCT02451410|OTHER|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
214298769|NCT04345575|DEVICE|PainCare VR|Didactic content delivered in virtual reality to support participants in learning cognitive and behavioral self-management skills based on cognitive-based therapy, biofeedback, and mindfulness strategies for pain management.
214298770|NCT04345575|OTHER|Audio content|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the VR program could not be included in the audio. Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
214298771|NCT00115856|PROCEDURE|Intravascular MRI|Arterial imaging of atherosclerosis
214298772|NCT04375488|OTHER|Resistance Exercise Training|60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week
214298773|NCT04375488|OTHER|Inspiratory Muscle Training|with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
214298774|NCT03454074|BEHAVIORAL|Problem-solving|Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
214298775|NCT03454074|BEHAVIORAL|Education|Education about healthy brain aging behaviors provided.
214298776|NCT05665790|RADIATION|radiotherapy|radiotherapy
214298777|NCT05665790|PROCEDURE|palliative surgery|palliative surgery
214298778|NCT00539578|DRUG|MK0777|Duration of Treatment: 4 weeks
214298779|NCT00539578|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
214298780|NCT04976842|DEVICE|OFA|Anesthesiology technique based on Mulier protocol. Before induction, loading dose of dexmedetomidine 0,25mcg/kg (max 20mcg). Induction with dexmedetomidine 0,1mcg/kg, lidocaine 1mg/kg, ketamine 0,1mg/kg plus propofol 2mg/kg plus rocuronium1mg/kg IBW (if required). Maintenance with dexmedetomidine 0,1mcg/kg/h, lidocaine 1mg/kg/h, ketamine 0,1mg/kg/h and propofol infusion adjusted according to bispectral index indication ( BIS maintained 40-60). 15 minutes prior to end of surgery, the dose of drugs is reduced to dexmedetomidine 0,05mcg/kg/h, lidocaine 0,5mg/kg/h, ketamine 0,05mg/kg/h.
214298781|NCT04976842|DRUG|OBA|Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
214478529|NCT06652672|PROCEDURE|Standard of care segmental resection|Standard of care segmental resection of the affected part of the colon including removal of regional lymph nodes.
215057462|NCT05043181|BIOLOGICAL|Low Density Lipoprotein Receptor mRNA Exosomes|"The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase."
214298782|NCT02052232|OTHER|Experimental protein powder sachet|mixed with 8 oz. water
214298783|NCT02052232|OTHER|Control protein powder sachet|mixed with 8 oz. water
214298784|NCT01734330|BEHAVIORAL|Cognitive behavioral therapy in group|
214298785|NCT01734330|DRUG|Nicotine replacement|
214298786|NCT00138944|DRUG|placebo|od
214298787|NCT00138944|DRUG|eplerenone|50mg od
214298788|NCT03927612|DEVICE|Virtual reality perspective taking training|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.
214478530|NCT06652425|OTHER|Low temperature (15°C) group|The exposure group will be exposed to low temperature (15°C) in a chamber for about 2 hours, resting during the whole periods.
214478531|NCT06652425|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
214478532|NCT05960032|DRUG|Zavegepant|Participants receiving single dose of Zavegepant 10 mg
214298789|NCT03927612|DEVICE|Virtual reality control perspective|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
214298790|NCT00679185|BEHAVIORAL|expressive writing|four non-emotional writing assignments
214298791|NCT05868070|DEVICE|Conventional rehabilitation plus multimodal exercise|Depending on the patient's condition, the intervention gradually progressed to passive, active assistive, active, and resistive exercise modes and the frequency of exercise interventions is gradually increased, and the application time of cycling/stepping is 20 minutes per session, and up to 3 times if there is no serious problem corresponding to the safety standards.
214298792|NCT01870583|DRUG|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
214298793|NCT01870583|DRUG|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
214298794|NCT01870583|DRUG|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
214298795|NCT05011864|BEHAVIORAL|Behavioral Activation|In BA, depressive symptoms are viewed as depressive behaviors. Compared to those without depression, people with depression engage in fewer overt behaviors that provide positive reinforcement and pleasure/enjoyment and in more behaviors that function to escape or avoid aversive stimuli (e.g., staying in bed all day).55-59 Thus, BA is aimed at increasing and reinforcing meaningful, healthy, and enjoyable behaviors while decreasing depressive behaviors and is well-suited to help depressed, disabled older adults increase mood-enhancing activities, self-care management skills, and social connectedness.
214298796|NCT05011864|BEHAVIORAL|Fall Prevention|Following FP psychoeducation based on the Centers for Disease Control and Prevention (CDC)'s STEADI tool kits, lay coaches will assist clients in implementing evidence-based FP strategies that have been adapted for low-income homebound seniors. These include referrals to healthcare providers as needed, home safety checks, practice of safe ambulation/transfer and mobility aid use, medication review, and in-home exercise routines with an innovative, gamified tablet-based exercise app for balance and strength building.
214298797|NCT05011864|OTHER|Telephone support|Subjects in this arm will receive 9 weekly support calls last 30 minutes each. These calls are intended to provide an opportunity for social support and check safety.
214298798|NCT02508493|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~* Digit Symbol Substitution Test (DSST)~* Choice Reaction Time (CRT)~* One-back working memory tool~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
214298799|NCT02508493|OTHER|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:~* Digit Symbol Substitution Test (DSST)~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~* Variant of Choice Reaction Time (CRT)~* Variant of the One-back working memory tool"
214298800|NCT03963791|OTHER|Eggshell powder gel|Eggshell powder gel produced from chicken eggs.
214298801|NCT03963791|OTHER|CPP-ACP crème|A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
214298802|NCT00379626|DRUG|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
214298803|NCT00301444|DEVICE|mirror-box treatment|
214298804|NCT00301444|BEHAVIORAL|Mental visualization|
214298805|NCT04518514|DEVICE|TAPE-Software|Telemedical Risk Assessment and Preoperative Evaluation prior to anaesthesia via personal computer
214298806|NCT05038527|DEVICE|ABM/P-15 bone graft|RCT (single blinded) where the patients will be randomized into two groups. One group receiving the standard bone graft which is a mix of locally autologous harvested bone and a morselized femoral head (allogenic) and the other group will receive bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15).
214298807|NCT02834104|DEVICE|RMI|
214298808|NCT02834104|OTHER|myocardial biopsy|
214298809|NCT02834104|BIOLOGICAL|blood sample|
214897776|NCT03419689|PROCEDURE|Ascites Collection|"Ascites will be collected if paracentesis is required during any of the following time points:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
214478533|NCT04375891|RADIATION|Radiation Therapy|30 Gy in 10 fractions of 3 Gy each
214478534|NCT04375891|RADIATION|Radiofrequency Ablation (RFA)|Radiofrequency Ablation (RFA) / Vertebral Augmentation
214298810|NCT00245206|DRUG|Aripiprazole|Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
214298811|NCT00245206|DRUG|Olanzapine|Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
214298812|NCT00245206|DRUG|Risperidone|Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
214478535|NCT06631092|BIOLOGICAL|Oral DNA Vaccine|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
214897777|NCT03419689|PROCEDURE|Fluid Collection|Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
214897778|NCT06498843|OTHER|administration of an isotonic seawater solution (9g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis, and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
215057463|NCT05270018|DRUG|Bacterial Lysates|14mg once a day
215057464|NCT05270018|OTHER|normal saline|14.0ml once a day
214478536|NCT03969563|BEHAVIORAL|Mindfulness-based Stress Reduction|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
215057465|NCT03870373|DEVICE|Pulse Oximeter|Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
215057466|NCT00149539|DRUG|Buprenorphine/naloxone|
215057467|NCT00110786|BIOLOGICAL|Ragweed MATAMPL|
215057468|NCT00271856|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
215057469|NCT00271856|BEHAVIORAL|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
214298813|NCT04248608|PROCEDURE|serratus plane block|ultrasound guided block
214298814|NCT04248608|PROCEDURE|erector spinae block|ultrasound guided block
214298815|NCT04248608|DRUG|Morphine Sulfate|intravenous morphine sulfate 0.1 mg/kg
214298816|NCT02430675|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
214298817|NCT02430675|DEVICE|NanoKnife|
214298818|NCT06115811|BEHAVIORAL|Radiation Treatment Plan Evaluation Learning Tool|Web-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org.
214298819|NCT00746993|OTHER|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
214298820|NCT01122706|OTHER|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
214298821|NCT05766644|OTHER|Education|An 8-week program providing educational materials via a mobile app for chronic kidney disease management. Materials consist of videos, card news, and live online seminars with a Q\&A session. Topics are on general disease information, nutrition, and exercise.
214298822|NCT04208204|OTHER|somatocognitive physiotherapy|Somatocognitive physiotherapy (SCT) is a multimodal physical therapy approach that has been developed in an attempt at alleviating the burden of longstanding pain. The main foci of SCT include: (1) bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension in different situations; (2) education about the vulvodynia and factors influencing pain experience; (3) coping with emotions and thoughts related to bodily experiences; and (4) structured homework assignments promoting application of the learned techniques in daily situation and gradual exposure to activities associated with pain. An important goal of SCT is to facilitate integration of new bodily habits into the patient's daily activities. The most important learning process thus occurs in the space between the treatment sessions. The therapeutic techniques are to be rehearsed in everyday situations.
214298823|NCT02988271|OTHER|Interview|Participate in interview
214298824|NCT02988271|PROCEDURE|Meditation Therapy|Complete meditation therapy
214298825|NCT02988271|PROCEDURE|Quality-of-Life Assessment|Complete questionnaires
214298826|NCT02988271|PROCEDURE|Supportive Care|Receive supportive care
214298827|NCT01358591|DIETARY_SUPPLEMENT|High calcium milk|High calcium milk (9 mg/kgBM)
214298828|NCT01358591|DIETARY_SUPPLEMENT|Control|Regular Milk
214298829|NCT05291247|DEVICE|Peripheral lithotripsy system (Shockwave Medical)|The combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device for calcified femoropopliteal disease.
214298830|NCT06054230|DEVICE|Genomic Sequencer|Genomic Sequencing Device
214298831|NCT00937157|DRUG|Copaxone|12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
214298832|NCT03562104|OTHER|videofluoroscopy|Swallowing description in Minimally consciousness Patient
214298833|NCT03562104|OTHER|Wessex Head Injury Matrix scale|Wessex Head Injury Matrix scale in Minimally consciousness Patient
214298834|NCT01404845|DIETARY_SUPPLEMENT|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
214298835|NCT01404845|DIETARY_SUPPLEMENT|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
214298836|NCT03892590|BIOLOGICAL|Gut microbiota|Status of microbiota
214298837|NCT00469092|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
214298838|NCT00469092|DRUG|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
214478537|NCT03969563|BEHAVIORAL|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
214478538|NCT06806345|DEVICE|Hyperbaric oxygen therapy|Hyperbaric Oxygen Therapy (HBOT):(Haux, Starmed 2300, Germany). A multichamper Double-lock, divided into Main chamber and Antichamber, with omega Ω-shape and all safety and CE-Certificate,
214298839|NCT00469092|DRUG|metformin|Tablets, 2550 mcg. Administered once daily.
214298840|NCT00469092|DRUG|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
214298841|NCT00002546|DRUG|cisplatin|
214298842|NCT00002546|DRUG|ifosfamide|
214298843|NCT00002546|PROCEDURE|adjuvant therapy|
214298844|NCT00002546|RADIATION|radiation therapy|
214478539|NCT06806345|DRUG|Hypoglycemic Drug|"Metformin reduces serum glucose level by several different mechanisms without increasing insulin secretion.it increases the effects of insulin so it is termed insulin sensitizer ,metformin also suppresses the endogenous glucose production by the liver ,which is mainly due to a reduction in the rate of gluconeogenesis and asmall effect on glycogenolysis. Moreover, metformin activates the enzyme adenosine monophosphate kinase (AMPK) resulting in the inhibition of key enzymes involved in gluconeogenesis and glycogen synthesis in the liver while stimulating insulin signaling and glucose transport in muscles"
214298845|NCT05317533|PROCEDURE|cardiac catheterization via distal radial artery|cardiac catheterization via distal radial artery
214478540|NCT05259943|DRUG|Psilocybin first|Participants will receive 8 doses of 2mg psilocybin.
214478541|NCT05259943|DRUG|Placebo first|Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin
214298846|NCT06219447|DEVICE|VRRS Home Tablet or Medico Amico Kids APP|Tele-rehabilitation (TR) permits intensive and personalized intervention monitored by clinicians in an ecological friendly, home setting. The VRRS Home Kit, comprising a tablet and peripheral devices, permits TR of cognitive, speech and motor functions. These peripherals such as sensors and balances allow motor rehabilitation across different body districts involved (upper and lower limbs, trunk). Touch screen activities, enables neuropsychological and speech therapy sessions. Medico Amico APP, offers a wide library of cognitive, language and motor exercises, stratified by difficulty levels, targeting specific functions. An avatar guides real-time movements, offering visual references. Adjustable parameters include duration, repetitions, difficulty, speed, movement amplitude. Both technologies facilitate TR sessions via a dedicated platform, that can occur in real-time, involving interaction with patients, or independently with continuous monitoring by clinical staff.
214298847|NCT00344227|DRUG|Lucentis (Ranibizumab)|
214298848|NCT02962804|DRUG|Nivolumab|240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study
214298849|NCT02962804|RADIATION|Radiation|Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
214298850|NCT05969288|OTHER|Behavioral survey|"Behavioral survey by administering a short self-administered questionnaire (read more in the Detailed description section)."
214298851|NCT05342259|PROCEDURE|Caudal nerve block /neuroaxial|"Technique of the caudal block The patient was placed in lateral decubitus position for blind caudal epidural block. A line was drawn to connect the bilateral posterior superior iliac crests and used as one side of an equilateral triangle; then the location of the sacral hiatus was approximated by palpating the sacral cornua as 2 bony prominences, the sacral hiatus was identified as a dimple in between. A needle was inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone was contacted.~A subjective feeling of loss of resistance suggests piercing the sacral ligament.The whoosh test, performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of air, Palpating for subcutaneous bulging on rapid injection of 5 mL air or saline had a positive predictive value of 83% and a negative predictive value of 44%."
214897779|NCT06498843|OTHER|administration of a hypertonic seawater solution (21g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
214897780|NCT04771559|OTHER|COVID-19 antibody test|5 cc blood sample from each participant will be taken 4 weeks after the second dose of the COVID-19 vaccine . After blood samples are centrifuged at 2500 rpm for 10 minutes, the separated serum will be backed up in two different ependorphs and stored at -80 or -20 degrees. The samples will be delivered to the working center in a manner suitable for cold chain transport. COVID-19 antibody test will be performed on the blood samples
214897781|NCT04132687|PROCEDURE|autologous blood patch therapy|use autologous blood as blood patch therapy in persistent air leak
214897782|NCT05462197|BEHAVIORAL|Qigong Wuqinxi|Wuqinxi is an exercise method developed by the ancient Chinese physician Hua Tuo by combining the ancient guide, breathing, and imitating the shapes of five animals, such as tiger, deer, bear, ape, and bird, combined with the zang-fu and meridian theory of traditional Chinese medicine. There have been studies in the past proven that this exercise can achieve health-promoting effects
214897783|NCT04319354|DIAGNOSTIC_TEST|Analysis of cfDNA|Analysis of cfDNA through liquid biopsy
214897784|NCT07057167|OTHER|Diagnostic Laparoscopy videos|"Diagnostic laparoscopy videos will be collected and stored on internal hard drives.~Pseudo-anonymized laparoscopic videos will be annotated by expert clinicians. Artificial intelligence (AI)-based solutions will be developed, trained, and validated."
214897785|NCT06338579|OTHER|Questionnaire|"A questionnaire is distributed and self-administered 4 weeks before the start of an embarked mission on a surface ship at the Toulon naval base, during an embarked mission of at least 4 weeks.~The questionnaire consists of 2 parts:~* A section on socio-demographic characteristics~* A section on self-medication practices during this deployment"
214897786|NCT01757275|DRUG|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
214298852|NCT05342259|PROCEDURE|Dorsal penile nerve block|"Technique of Dorsal penile nerve block:~Under aseptic technique and under ultrasound guidance. A 'hockey-stick' probe was used, covered by transparent sterile dressing. The probe was placed vertically over the pubic symphysis and the base of the penile shaft. With adjustment of the probe, a sagittal view of the penile shaft was produced. Scarpa's fascia was seen as a hyperechoic line superficial to the penile shaft. Under real-time guidance, the needle was inserted and advanced until its tip laid deep to Scarpa's fascia (i.e., within the subpubic space), where local anesthetic was deposited. The local anesthetic solution injected was 0.5% bupivacaine in a recommended volume. (2 ml up to 3 years and an additional 1 ml for each3 years up to maximum 6 ml)."
214897787|NCT01757275|DRUG|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
214897788|NCT01757275|DRUG|Esomeprazole Mg|40 mg tablet once daily for 27 days
214897789|NCT01848600|BEHAVIORAL|interpretation of the abstract|the intervention consist to interpret the results of the meta-analysis after reading the abstract.
214478542|NCT01474122|DRUG|Macitentan 3 mg|Macitentan 3-mg tablet once daily
214897790|NCT02139137|OTHER|Computerized Cognitive Training - active|Cognitive training using working memory span task
214897791|NCT02139137|OTHER|Computerized cognitive training - sham|Sham training condition
214897792|NCT00233233|BEHAVIORAL|Standardized Asthma Education Program|
214897793|NCT00795652|BEHAVIORAL|Distance Treatment for postpartum depression|Evidence-based, cognitive behavioural intervention for women with postpartum depression
214298853|NCT05342259|PROCEDURE|Combined caudal and dorsal penile nerve block|Combined techniques of caudal and dorsal penile nerve block
214298854|NCT02116400|OTHER|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
214298855|NCT02116400|OTHER|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
214298856|NCT02116400|BIOLOGICAL|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
214298857|NCT02024867|DRUG|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
214298858|NCT05070065|DEVICE|Cognitive remedy intervention with virtual reality (CEREBRUM)|Cognitive Remedial method Virtual Reality (CEREBRUM)
214298859|NCT05331287|OTHER|Head position|Influence of different head position on nasal endotracheal intubation
214298860|NCT00047840|DRUG|ZD6474|
214298861|NCT00047840|DRUG|Placebo|
214298862|NCT00047840|DRUG|Docetaxel|
214298863|NCT00003010|DRUG|marimastat|
214478543|NCT01474122|DRUG|Macitentan 10 mg|Macitentan 10-mg tablet once daily
214897794|NCT01488773|DRUG|first prescription of montelukast|The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
214897795|NCT01488773|DRUG|first prescription of salmeterol|The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
214298864|NCT04267133|DIAGNOSTIC_TEST|Facial video of detection of cardiac disease|This project proposes to evaluate a non-contact video recording technology to detect the presence of AF. The technology extracts a pulsatile signal by measuring the subtle variations in skin color of a patient's face (flushing) due to the variations of blood volume underneath the skin. The technology uses a standard web camera. This technique is videoplethysmography (VPG).
214478544|NCT01474122|DRUG|Placebo|Placebo tablet matching macitentan tablet, once daily
214478545|NCT06587945|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Oral Nicotinamide Riboside, 2g daily for 4 weeks followed by 1g daily for 16 weeks
214298865|NCT01571258|BEHAVIORAL|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
214298866|NCT02282670|DRUG|DA-5204|
214298867|NCT02282670|DRUG|Stillen tab.|
214298868|NCT04535960|DRUG|Empagliflozin 25 MG + Liraglutide 1.8 MG|Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.
214298869|NCT04535960|DRUG|Liraglutide 1.8 MG + Empagliflozin 25 MG|Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.
214298870|NCT01225575|DRUG|co.don chondrosphere®|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect"
214478546|NCT06587945|OTHER|Placebo|Matched placebo
214478547|NCT06587945|PROCEDURE|Vitrectomy and Gas tamponade|Standard of care Vitrectomy surgery for retinal reattachment
214478548|NCT06813300|PROCEDURE|Electrophysiological recordings|Addition of electrophysiological recordings performed during cognitive tasks passation in patients undergoing DBS: in pre-op, per-op, peri-op and post-op setting
214897796|NCT01298232|OTHER|Cardiophonogram|Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure
214897797|NCT06757647|DRUG|Acalabrutinib|Given PO
214897798|NCT06757647|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214897799|NCT06757647|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214897800|NCT06757647|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214897801|NCT06757647|PROCEDURE|Computed Tomography|Undergo CT
214298871|NCT04067557|DIAGNOSTIC_TEST|molecuar test of BV|diagnosis of BV
214298872|NCT05700981|DIAGNOSTIC_TEST|colon capsule endoscopy|Patient allocated for the intervention arm will have a CCE using the PillCam Colon 2 (Medtronic, Minneapolis, Minnesota, USA). Upon inclusion and allocation to the intervention arm patients are contacted by a dedicated CCE nurse. The course of the CCE procedure and preparations are explained thoroughly. In case of additional questions patients can contact the nurses by telephone during office hours (Monday-Friday, 8am-3pm). Before the CCE participants will have to undergo a bowel preparation procedure. The bowel preparation kit will be distributed by mail and is to be completed at home, beginning 72 hours before the CCE. The kit contains polyethylene glycol (PEG) sachets (Movicol, Norgine Danmark A/S, Herlev, Denmark), PEG solutions (MoviPrep, Norgine Danmark A/S, Herlev Denmark) and instructions on how to properly perform the preparation procedures.
214298873|NCT06413797|BEHAVIORAL|FDA warnings + Image|For six days (days 2-7) participants will be contacted and asked to complete a daily survey. As part of the survey, participants will view FDA-proposed LCC warnings with images at 30% size on a cigarillo package. Participants will be contacted each day to be invited to complete the survey for that day of the study protocol.
214298874|NCT06413797|BEHAVIORAL|FDA Warnings Text-Only|Participants will receive messages including images in 30% size.
214897802|NCT06757647|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo CMR
214897803|NCT06328621|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214897804|NCT06328621|PROCEDURE|Computed Tomography|Undergo low-dose CT
214897805|NCT06328621|OTHER|Electronic Health Record Review|Review of medical records
214897806|NCT06328621|OTHER|Survey Administration|Complete survey
214298875|NCT06413797|BEHAVIORAL|Surgeon General Text-Only Warnings|Participants will receive messages including Surgeon General Text-only Warnings.
214298876|NCT03348345|BEHAVIORAL|Eat Breathe Thrive|Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
214298877|NCT01998633|BIOLOGICAL|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~* Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~* Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~* Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~* Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~* Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
214298878|NCT00825747|DEVICE|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
214478549|NCT06811259|OTHER|Virtual reality (in experimental group)|Virtual reality application is performed with virtual reality glasses. Virtual reality glasses are a simulation model that provides participants with the opportunity to communicate with a dynamic environment created by computers and gives them a sense of reality. Virtual reality glasses, which have a mechanism compatible with smart phones, allow videos downloaded to mobile phones or watched directly via the internet to be viewed at a 360-degree angle. The two lenses on the device provide panoramic viewing by dividing the image into two equal parts. The bands on the front of the device that fits the face are flexible and prevent the device from slipping from the face. The buckles on the back are adjustable and provide ease of use. Thanks to the proximity sensor on the device, images can be zoomed in and out to obtain a clearer image. Thanks to the device holder on the sides, the phone can be easily placed and removed from the device. Again, videos can be advanced or changed with the tou
214897807|NCT03097627|DRUG|ICG Intervention|The intervention to be administered is the drug indocyanine green.
214298879|NCT02913547|DEVICE|Silk'n HST|Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
214298880|NCT03914040|OTHER|IPSE program|"1. Pre-immersion preparation. A self-study course will be offered about lifestyle modification. Some readings will be suggested to introduce students to the concepts of health promotion and prevention of metabolic syndrome.~2. Immersion. Four different learning methods will be provided: I) four hours of didactic lectures followed by group discussion, II) four hours per student of role playing, III) 30' per students of standardized patient experiences and IV) 30' per students of a new immersive advanced simulation learning environment (e-REAL). Four case-studies will be used to create scenarious, including woman with menopause weight gain, obese young adult, obese child and adult with unhealthy behaviours."
214298881|NCT03755986|DEVICE|ATOMO Diagnostic Test|The ATOMO diagnostic test device is the only intervention used in this study.
214298882|NCT02773927|DRUG|Metformin|Metformin in tablet presentation of 500 mg
214298883|NCT02773927|DIETARY_SUPPLEMENT|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
214298884|NCT02773927|OTHER|Placebo of agave inulin|Calcinated magnesia powder
214298885|NCT02773927|OTHER|Metformin placebo|Calcinated magnesia tablet
214298886|NCT01860755|OTHER|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
214298887|NCT01860755|OTHER|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
214298888|NCT06245291|DRUG|Imdusiran|subcutaneous injection
214478550|NCT06811259|OTHER|Standart care|Women in the control group will receive only standard care during colposcopy
214897808|NCT03097627|DEVICE|Near Infrared Camera|The intervention to detect the administered drug, indocyanine green.
214897809|NCT03989882|OTHER|Wheat germ energy ball|wheat germ mixed other ingredients to make an energy ball
214897810|NCT03989882|OTHER|Control|corresponding control without wheat germ
214298889|NCT06245291|DRUG|Durvalumab|intravenous injection
214298890|NCT05435079|DEVICE|high-flow oxygen therapy device for tracheotomized patients|From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher \& Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
214897811|NCT02519374|DRUG|Placebo (including Maltodextrin)|
214897812|NCT02519374|DRUG|PROMITOR® (including Maltodextrin)|Investigational product dose 1
214897813|NCT02519374|DRUG|PROMITOR® (including Maltodextrin)|Investigational product dose 2
214897814|NCT02519374|DRUG|PROMITOR® (including Maltodextrin)|Investigational product dose 3
214897815|NCT03577080|OTHER|ET+RT+ NMES|Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
214897816|NCT06212531|PROCEDURE|Medical male circumcision using standard surgical technique.|Medical male circumcision using the WHO standard technique followed by examination of wound healing and behavioral risk assessment.
214897817|NCT01987440|DRUG|lubricating gel|
215052722|NCT06358521|OTHER|Physiotherapist-led primary care model for hip and knee pain|"1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral.~4. Additional PT care: Patients who require community PT but do not have the appropriate coverage for community-based services will be managed by the PT who provided the assessment in the primary care setting."
215052723|NCT06358521|OTHER|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
215052724|NCT05580614|DEVICE|Sham|MRI (Magnetic Resonance Imaging) paired ERP/Sham YBOCs(Yale-Brown Obsessive Compulsive Scale) (4,8,12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
215052725|NCT05580614|DEVICE|tVNS|MRI (Magnetic Resonance Imaging) paired ERP/tVNS YBOC's (Yale-Brown Obsessive Compulsive Scale) (4, 8, 12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
215052726|NCT04372875|BEHAVIORAL|SHS-derived CDS|This intervention will provide electronic clinical decision support for adolescents who screen at risk or at high risk of an STI.
215052727|NCT05196308|DRUG|Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)|"Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator."
215052728|NCT05196308|DRUG|Placebo administration|"For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator."
215052729|NCT06073704|PROCEDURE|antimicrobial photodynamic therapy (aPDT)|Scaling and root planing followed by antimicrobial photodynamic therapy
215052730|NCT06073704|PROCEDURE|Control|Treatment of scaling and root planing
215052731|NCT05195203|DRUG|HS-10353|Single or multiple dose(s) of HS-10353
215052732|NCT05195203|DRUG|Placebo|Single or multiple dose(s) of placebo
214478551|NCT06290895|OTHER|women having had a second IVF cycle with AOA|The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.
214478552|NCT06603025|OTHER|chewing gum|Preoperative intervention group patients will chew sugarless gum for at least 30 minutes 30-60 minutes before surgery. The gum will be removed before going to the operating room.
215052733|NCT03338985|GENETIC|Genetic analysis|Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
215052734|NCT00788814|BEHAVIORAL|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
215052735|NCT04185350|DRUG|68Ga-NOTA-MAL-Cys39-exendin-4|After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.
214897818|NCT03247569|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
214897819|NCT03177525|BEHAVIORAL|Social SUCCESS|"Social SUCCESS will run for 12 weeks, with up to 5 children with ASD per group. Parents will attend didactic group sessions focused on motivating children with ASD to initiate to peers (90 min weekly) and will attend a portion of the existing 90 min social group to practice applying these strategies with their children and peer volunteers. Parent training will utilize the manual Improving Socialization in Individuals with Autism."
214897820|NCT03177525|BEHAVIORAL|Wait List|Participants assigned to the Wait List will continue stable community treatments for 12 weeks and will be provided an intervention similar to Social SUCCESS upon completion of all post measures.
214897821|NCT05961696|DRUG|Mosunetuzumab|Subcutaneous (SQ or Sub-Q) injection under the skin
215052736|NCT00962871|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc/week for 2 weeks
215052737|NCT00962871|DRUG|tenofovir|300mg po daily for 2 weeks
215052738|NCT04035343|BEHAVIORAL|Face down positioning|See description of the face down positioning group
215052739|NCT04035343|BEHAVIORAL|Supine positioning|See description of the supine positioning group
215052740|NCT02991339|DRUG|Dexamethasone|Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day
215052741|NCT02270281|DRUG|Dexmedetomidine 0.7 Mcg/kg/h|CIF 0.7mcg/kg/h
215052742|NCT02705092|OTHER|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
215052743|NCT02705092|OTHER|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
214298891|NCT04999150|PROCEDURE|Micro-Osteoperforations|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced \~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)"
214298892|NCT04999150|PROCEDURE|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed. The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex, until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)"
214298893|NCT06508593|DIAGNOSTIC_TEST|Serum metabolic profile|Venous serum samples were analyzed for serum metabolic profiles using liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) non targeted metabolomics techniques
214298894|NCT05171283|OTHER|Oats or Oat Fibre|Interventions that contain whole grain oats or oat beta-glucan.
214298895|NCT05673044|PROCEDURE|modified Studer ileal neobladder|orthotopic ileal neobladders
214298896|NCT01077947|PROCEDURE|Functional anesthetic discography|Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
214298897|NCT01077947|PROCEDURE|Provocative Discography|Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
214298898|NCT00372931|DRUG|AL-37807|
214298899|NCT01001507|PROCEDURE|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
214298900|NCT01354847|DEVICE|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
214298901|NCT00343200|DRUG|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
214478553|NCT06594900|BEHAVIORAL|resistance training intervention|"The RT intervention focuses on knee extensor muscles, following current guidelines. Children will attend two supervised 1-hour sessions per week, proven sufficient for adaptations. Trained coaches and a scientific assistant, supported by master students, will document the sessions. Sessions are spaced 48 hours apart, totaling 40 over 20 weeks, with eight sessions between PRE and MID.~Each session has three phases: warm-up, strength, and coordination. Warm-up involves whole-body games to increase heart rate and prepare for strength training. The strength phase, documented for effort and adjustments, includes squats, lunges, and step-ups, with intensity changes over time. Four sets of 8-12 repetitions per exercise are performed, aiming for strength increase and hypertrophy. Movements are done with great effort but not until voluntary failure.~The coordination phase focuses on age-appropriate strength and motor skills through a circuit of challenges."
214478554|NCT06767644|OTHER|music|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
214478555|NCT06767644|OTHER|no music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
214897822|NCT04207658|BEHAVIORAL|Valsalva's Style Pushing|The second stage of labour is defined as the time passed after the cervical dilatation reaches 10cm. The expulsion stage is the time between the sight of baby's head in the vulva and the end of labour. the participants are given information about the study after self introduction of each gravid is done for completing baseline obstetric data forms by midwives. Also, blood samples for pre and postpartum haemoglobin level changes are collected. The perineal area is examined for postpartum tears through pad checks. Vital findings (respiration, pulse and TA) are evaluated prior to their transfer to the delivery room. Just after the birth, mothers are tested for pH, pO2, pCO2 and lactate levels in blood while the newborns are tested for pH, pO2 (mmHg) and pCO2 levels through umbilical artery along with 1st min and 5 min APGAR analysis. The visual scale is utilized for determination of first 24-hour fatigue and they are recorded in follow-up forms.
215052744|NCT01544348|OTHER|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
215052745|NCT01544348|BIOLOGICAL|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
215052746|NCT01544348|BIOLOGICAL|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
215052747|NCT01544348|BIOLOGICAL|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
215052748|NCT01544348|BIOLOGICAL|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
215052749|NCT01544348|BIOLOGICAL|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
215052750|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
214298902|NCT00343200|DRUG|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
214298903|NCT03667560|PROCEDURE|Dermacell ADM without basement membrane|Patient will be implanted with Dermacell ADM.
214298904|NCT03667560|PROCEDURE|FlexHD|Patient will be implanted with FlexHD.
214298905|NCT06135233|OTHER|No intervention|all patients undergoing minimally invasive pancreatic surgery, no intervention, no randomization
215052751|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
214478556|NCT06769204|DRUG|EMLA SPRAY|2 puffs of lidocaine-prilocaine spray into the cervix and cervical canal 5 minutes before the procedure
214298906|NCT02350881|DEVICE|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
214298907|NCT00755157|DRUG|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
214298908|NCT00755157|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
214298909|NCT04344314|DEVICE|Peripheral Intravenous Catheter|Randomised controlled
214298910|NCT01243970|DRUG|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg \*~\* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
214478557|NCT06769204|DRUG|Placebo|2 puffs of saline into the cervix and cervical canal 5 minutes before the procedure
214478558|NCT06605417|GENETIC|Methylomics|Methylomics analysis of FFPE blocks and frozen tissues
214478559|NCT06605417|GENETIC|RNA sequencing|RNA sequencing of FFPE blocks and frozen tissues
214478560|NCT06605417|GENETIC|Spatial transcriptomics|Spatial transcriptomics of FFPE blocks and frozen tissues
214478561|NCT06605417|GENETIC|Liquid biopsy|cfDNA characterization extracted from blood/saliva
214897823|NCT02445716|DRUG|Testosterone|"It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit."
214897824|NCT02445716|DRUG|Placebo|It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
214897825|NCT01872312|DEVICE|treatment with valves (The Spiration® IBV Valve System)|treat BPF
214897826|NCT02620995|DRUG|sildenafil citrate|the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
214897827|NCT02620995|OTHER|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
214897828|NCT04537884|DRUG|UBX1325|Investigational drug intravitreal injection
214897829|NCT06464484|DIETARY_SUPPLEMENT|Probiotics (Lactobacillus rhamnosus GG (ATCC 53103)|Already mentioned in arm/group descriptions
214897830|NCT01987778|OTHER|Resistance training|Resistance training supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
214897831|NCT01941615|DRUG|faldaprevir|oral doses for 10 days (period B)
214897832|NCT01941615|DRUG|Microgynon®|oral doses for 23 days (period A+B)
214478562|NCT03652272|BEHAVIORAL|EMC2|"1. Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~2. Patients will receive a Medication Guide + Summary with their After Visit Summary~3. Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~4. Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
214478563|NCT06698250|DRUG|Zanzalintinib|Next generation tyrosine kinase inhibitor (TKI) with the target inhibition proﬁle identical to cabozantinib but with a superior pharmacokinetic proﬁle.
214478564|NCT06698250|DRUG|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)
214478565|NCT06698250|DRUG|Tremelimumab|Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells
214478566|NCT06810063|OTHER|Assessment only, no intervention|Participants in this study complete two visits to test the agreement of telehealth and in person assessments of arm and hand movement.
214478567|NCT06798636|DRUG|Psilocybin 5 mg with cognitive behavioural therapy intervention|This is an oral 5mg psilocybin dose preceding a mental imagery rescripting procedure
214478568|NCT06798636|DRUG|Placebo with cognitive behavioural therapy intervention|This is an oral placebo comparator preceding a mental imagery rescripting procedure
214897833|NCT01941615|DRUG|BI 207127|oral doses for 10 days (period B)
214897834|NCT02769507|DEVICE|DC Stimulator PLUS (NeuroConn)|
214897835|NCT02654054|DRUG|Elagolix|Film-coated tablets
214897836|NCT02654054|DRUG|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
214897837|NCT02654054|DRUG|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
214897838|NCT02654054|DRUG|Placebo for Elagolix|Film-coated placebo tablets
215052752|NCT04196725|OTHER|Physical therapy treatment|Two weeks rehabilitation programme focusing on physical therapy treatment, e.g. manual lymphatic drainage and compression bandaging
215052753|NCT04196725|BEHAVIORAL|Lifestyle treatment|Two weeks rehabilitation programme focusing on physical activity
214298911|NCT01243970|DRUG|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. \*~\* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
214298912|NCT02140788|DRUG|Metformin|
214298913|NCT02140788|DRUG|Fish Oil|
214298914|NCT02968563|DRUG|Tirabrutinib|Tablets administered orally
214298915|NCT02968563|DRUG|Idelalisib|Tablets administered orally
214478569|NCT06816030|DRUG|MK-4482|Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.
214478570|NCT06820918|DEVICE|Bottle PEP|Home respiratory physiotherapy using the PEP bottle for a minimum of 10 minutes to a maximum of 30 minutes, twice a day (morning and evening), every day for 30 days
214478571|NCT04173247|DEVICE|KeraStat Cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions.
214897839|NCT03289091|BEHAVIORAL|water-based continuous aerobic training|Participants who will be randomized for the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
214897840|NCT03289091|BEHAVIORAL|water-based interval aerobic training|Participants who will be randomized for interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
214897841|NCT00420420|DRUG|MK0249|MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
214897842|NCT00420420|DRUG|Comparator: Placebo (unspecified)|MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
214897843|NCT00273182|DEVICE|InSync Model 8040|Subjects with sucessful implants of InSync Model 8040.
214897844|NCT00273182|DEVICE|InSync III Model 8042|Subjects with successful implants of InSync III Model 8042
214897845|NCT02626091|PROCEDURE|Left-sided colonic resection|"During interventions, anastomosis perfusion will be estimated (outcomes: visual appreciation of the surgeon, ICG fluorescence-based enhanced reality and series of peri-operative samplings) in order to validate the accuracy of ICG fluorescence-based enhanced reality technique.~In any case, the resection will be performed according to the surgeon's appreciation."
214897846|NCT04821076|OTHER|Diet intervention - caloric restriction|Energy restriction is set to 25 kcal / kg fat-free mass
214897847|NCT04821076|OTHER|Exercise intervention|Exercise will consist of supervised resistance training, interval training and moderate intensity cycling
214298916|NCT02968563|DRUG|Obinutuzumab|Administered intravenously
214298917|NCT05350033|DEVICE|tDCS - tDCS|active-tDCS administered during 10 sessions, in Phase 1 and Phase 2
214298918|NCT05350033|DEVICE|tDCS - Sham|active-tDCS administered during 5 sessions, in Phase 1
214298919|NCT05350033|DEVICE|Sham - tDCS|active-tDCS administered during 5 sessions, in Phase 2
214298920|NCT05350033|DEVICE|Sham - Sham|sham-tDCS administered during 10 sessions, in Phase 1 and Phase 2
214298921|NCT04990414|OTHER|Cognitive Behavioural Therapy|Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.
214298922|NCT06058767|DIAGNOSTIC_TEST|Otoacoustic Emissions Testing|An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.
214478572|NCT04173247|OTHER|Routine Skin Care - Commercially Available Agents|Commercially available skin moisturizers from an approved list that do not interfere with radiation.
214478573|NCT06818318|OTHER|Temporomandibular disorder|Fonseca's Anamnestic Index was used for TMJ dysfunction. The diagnostic accuracy of the Fonseca's Anamnestic Index was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
214298923|NCT06058767|DIAGNOSTIC_TEST|Pure Tone Audiometry|The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
214897848|NCT04821076|OTHER|Diet intervention - Energy balance|Energy balance is set to 50 kcal / kg fat-free mass
214897849|NCT02364765|DRUG|Remifentanil|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
214897850|NCT06118476|BEHAVIORAL|3D animation|Education with 3D animation videos
214897851|NCT05475314|DIETARY_SUPPLEMENT|ReFerm(R)|Enemas of approx 250 mL twice daily
214897852|NCT00949637|BEHAVIORAL|Scouting Nutrition and Activity Program|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
214298924|NCT05338892|OTHER|Non-Interventional|No study treatment will be administered on this study.
214298925|NCT01631877|DRUG|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
214298926|NCT01631877|OTHER|placebo|injection placebo will be given for 5 days along with placebo tablets
214298927|NCT00295347|DRUG|Spironolactone|
214298928|NCT00295347|DRUG|fludrocortisone|
214298929|NCT00295347|DRUG|escitalopram|
214897853|NCT00949637|BEHAVIORAL|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
215052754|NCT03911297|OTHER|Women with polycystic ovary syndrome|Prospective cohort study in women with polycystic ovary syndrome to identify the risk of developing metabolic disease
215052755|NCT05200559|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
215052756|NCT05200559|DRUG|E7777|E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
215052757|NCT06128057|OTHER|Blood products|Massive blood transfusion
215052758|NCT02257320|DEVICE|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
215052759|NCT01647854|PROCEDURE|Teleconsultation|Teleconsultation in prehospital emergencies
215052760|NCT04079660|DIAGNOSTIC_TEST|Capillary blood glucose blood draw|Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
215052761|NCT03424395|OTHER|Personalized dietary and wellness program|Single arm intervention containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only
215052762|NCT03790748|PROCEDURE|Standard Lumbar Epidural Technique|Standard Lumbar Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
215052763|NCT03790748|PROCEDURE|25G Dural Puncture Epidural Technique|25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
215052764|NCT03790748|PROCEDURE|27G Dural Puncture Epidural Technique|27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
215052765|NCT03649802|DIETARY_SUPPLEMENT|Low dose vitamin D3|Low dose arm-800 IU given daily
215052766|NCT03649802|DIETARY_SUPPLEMENT|High dose vitamin D3|High dose arm-5000 IU given daily
215052767|NCT01445847|DRUG|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
215052768|NCT01445847|OTHER|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
215052769|NCT00626041|OTHER|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
214298930|NCT03495830|PROCEDURE|Carotid endarterectomy|Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.
214298931|NCT03287804|BIOLOGICAL|AUTO2|"AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.~Following Phase 2 dose determination patients will be treated with selected dose of APRIL CAR T Cells"
214298932|NCT02661542|DRUG|FF-10502-01|
214298933|NCT02937649|PROCEDURE|Laparoscopic sleeve gastrectomy using 48-Fr bougie|After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
214298934|NCT02937649|PROCEDURE|Laparoscopic sleeve gastrectomy using standard care bougie|After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
215052770|NCT02314442|DRUG|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
215052771|NCT02314442|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
214298935|NCT02044744|BEHAVIORAL|Physical activity referral|Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
214897854|NCT03870815|PROCEDURE|CABG|Patients who undergoing CABG
214897855|NCT03870815|PROCEDURE|PCI|Patients who undergoing PCI with DES
214897856|NCT05702333|DRUG|Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan|Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.
215052772|NCT03332147|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
215052773|NCT03332147|DEVICE|reference group-Earlysense system|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
215052774|NCT03834896|OTHER|AYMES MADRID|AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
215052775|NCT03768323|OTHER|1X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey
215052776|NCT03768323|OTHER|2X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey
214897857|NCT03411161|DRUG|Combination therapy (S81694 + paclitaxel) phase I|Dose escalation S 81694 (IV); paclitaxel started at 80 mg/m²,(IV)
214298936|NCT00385996|DRUG|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
214478574|NCT06818318|OTHER|Smartphone Addiction Scale-Short Form|In our study, the Smartphone Addiction Scale-Short Form will be filled out in order to evaluate the intensity of smartphone use of students, and the daily duration of smartphone use will be recorded. The Smartphone Addiction Scale-Short Form is a 6-point Likert-type scale consisting of 10 items used to measure the risk of smartphone addiction. Scores obtained from the scale vary between 10-60, and an increase in the score indicates an increased risk for smartphone addiction. Although the scale does not have a cut-off score in our country, it was determined as 31 for men and 33 for women in the Korean sample.
214897858|NCT03411161|DRUG|Paclitaxel|Paclitaxel (IV) at 80 mg/m²/week
214897859|NCT03411161|DRUG|Combination therapy (S81694 + paclitaxel) phase II|S 81694 (IV) at RP2D; paclitaxel (IV) at 80 mg/m²/week
214897860|NCT04114682|OTHER|Multi parametric MRI scan|There will be no intervention to the standard of care these patients receive. However, consented participants will be asked to make two study visits where a multiparametric MRI scan will be performed - these visits will be defined as visit 2 and visit 3. An optional echocardiogram may be included at Visit 2.
214897861|NCT00856492|BIOLOGICAL|bevacizumab|Given IV
214897862|NCT00856492|BIOLOGICAL|pegfilgrastim|Given subcutaneously
214897863|NCT00856492|DRUG|cyclophosphamide|Given IV
214897864|NCT00856492|DRUG|doxorubicin hydrochloride|Given IV
214897865|NCT00856492|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214897866|NCT00818350|DRUG|SUNITINIB|50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
214298937|NCT05270655|OTHER|Cognitive-behavioural intervention|Participants in the experimental group will receive five sessions of cognitive-behavioural intervention. Each session will be conducted face-to-face for 30-35 minutes a week and supplemented by home-based practices. The first session is an introductory to cognitive-behavioural intervention, the second session includes identifying, evaluating and challenging maladaptive thoughts, beliefs and behaviour, the third session includes behavioural activation, the fourth session is deep breathing, and the last session includes treatment evaluation and relapse prevention. The interventions will be delivered before chemotherapy sessions to avoid fatigue and to increase the patient's engagement with the interventions. To establish a strong therapeutic alliance and enhance intervention delivery and family support, parents will be invited to attend the introduction of the first session and the summary of each session (the last five minutes).
214897867|NCT04069273|DRUG|Pembrolizumab Monotherapy|Pembrolizumab 200 mg IV
214897868|NCT04069273|DRUG|Ramucirumab|Ramucirumab 10 mg/kg IV
214897869|NCT04069273|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV
214897870|NCT03852953|OTHER|Under- or overdiagnosed cancer|Diagnosed with a cancer that was visible on prior mammograms
214897871|NCT03852953|OTHER|Screening|Invited or attended BreastScreen Norway
214897872|NCT06024408|DRUG|ALN-PNP|Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
214897873|NCT06024408|DRUG|Placebo|Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
214897874|NCT07073586|PROCEDURE|Lymphovenous Anastomosis|Microsurgical creation of multiple lymphatic-venous connections in the most affected limb under general anaesthesia.
214897875|NCT07073586|OTHER|Complete Decongestive Therapy|Complete Decongestive Therapy, comprising bandaging, skin care and exercise, followed by compression garments.
214897876|NCT04239755|DRUG|Doxycycline 100 MG Oral Tablet|doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day
214897877|NCT04239755|OTHER|placebo|placebo in addition to the standard treatment.
214897878|NCT05012618|DRUG|LUNA18|LUNA18 Capsule
214298938|NCT01900327|RADIATION|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
214298939|NCT01900327|DRUG|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
214298940|NCT01900327|PROCEDURE|Surgery|Upfront pancreato-duodenectomy
214298941|NCT01900327|DRUG|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
214298942|NCT06214429|DIAGNOSTIC_TEST|Vascular Ultrasound|Complete vascular ultrasound routine in B mode, color mode and Doppler.
214298943|NCT06214429|DIAGNOSTIC_TEST|Shear Wave Elastography|Vascular ultrasound assisted shear wave elastography of the atherosclerotic plaque.
214298944|NCT06214429|DIAGNOSTIC_TEST|Greyscale Median|Vascular ultrasound assisted assessment of the plaque in B mode. The plaque image will be post-processed for the histogram median value for the plaque area.
214298945|NCT06214429|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Assessment of the plaque and carotid residual lumen by magnetic resonance.
214298946|NCT06214429|DIAGNOSTIC_TEST|Histopathology|Histopathology findings for patients that undergo carotid endarterectomy.
214478575|NCT06818318|OTHER|Neck Disability Index|The Neck Disability Index was used to assess the disability caused by neck pain. This questionnaire consists of ten items, four of which are related to subjective symptoms (pain intensity, headache, concentration, sleep) and six of which are related to activities of daily living (self-care, lifting, reading, work, driving and leisure activities). Scale scoring ranges from 0-40.
214478576|NCT06818318|OTHER|Temporomandibular Joint Pain|Numeric Pain Scale is a simple, reliable and short-term method commonly used in the clinic to measure pain intensity. It is a very reliable method in the evaluation of pharmacological and nonpharmacological treatments that reduce pain. The patient is told that the most severe pain he/she experiences is 10, and if he/she has no pain, the pain intensity is 0. The participant was asked to say a number between 0 and 10 corresponding to the intensity of pain felt in the TMJ region.
214897879|NCT05012618|DRUG|Cetuximab|Cetuximab as a IV infusion
214897880|NCT06814756|BIOLOGICAL|phage therapy|Single anti-Morganella morganii bacteriophage drug product
214897881|NCT02290444|DRUG|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
214897882|NCT05797974|OTHER|MyChart enabled virtual weight loss coach|MyChart-enabled virtual coach utilized to aid in preoperative weight loss.
214897883|NCT05797974|OTHER|Standard preoperative weight loss tools|Participants will utilize current standard preoperative weight loss tools.
214897884|NCT06903728|DEVICE|continous glucose monitoring|Pregnant women with type 2 diabetes are given a sensor \< week 14 of their pregnancy and will use it until 4-6 post partum. They will receive training in how to use the sensor, and support when needed.
214897885|NCT07087080|OTHER|Blood sampling|Single blood sampling (16 ml) after study inclusion before undergoing the PET-CT scan
214897886|NCT07091513|PROCEDURE|group ESP|. In the ESP group, a high frequency linear transducer (HFL50XP, SonoSite Inc., Bothell, WA, USA ) was located vertically approximately 3 cm lateral to the projection point with identification of the spinous process, lamina, transverse process, and the erector spinae muscle. The skin and subcutaneous tissues were infiltrated using 5 mL of 1% Lidocaine Hydrochloride. A 22-G peripheral nerve block needle (50 mm) (SonoTAP, Pajunk, Geisingen, Germany) was inserted in-plane from caudal to cranial between the fascia of the erector spinae muscle and the transverse process under the ultrasound guidance. After hydro-localization using 1 ml of with normal saline, this plane was opened. The same 20 mL mixture of LA was injected after negative aspiration of blood.
214897887|NCT05170503|DRUG|Sintilimab|Sintilimab 200mg iv drip. Qd D1 + Oxaliplatin 130/m2 iv drip. Qd D1 + Tegafur (Gimeracil and Oteracil Potassium Capsules) \[40mg/m2 if BSA \<1.25m2, 50mg/m2 if BSA ≥1.25m2 \& \<1.5m2, 60mg/m2 if BSA ≥1.5m2\] po. Bid D1-14 for three cycles
214897888|NCT07097649|DEVICE|Textured lateral wedge insole|Participants in the experimental group will wear custom-designed textured lateral wedge insoles made from EVA material. These insoles incorporate lateral wedging to offload the medial knee compartment and a textured surface to enhance plantar sensory input. Participants will use the insoles during daily activities for a period of 8 weeks, with no additional intervention or exercise protocol.
214897889|NCT07097649|DEVICE|Use of lateral wedge flat insole|Participants in this arm will use a customized lateral wedge flat insole with the same lateral inclination as the experimental insole but without any textured surface. This design allows for controlling the mechanical effect of the wedge while eliminating additional sensory stimulation.
214897890|NCT07095530|PROCEDURE|titanium membrane|surgical treatment for horizontal ridge augmentation by titanium mesh and PVDF membrane
214897891|NCT07097389|DIETARY_SUPPLEMENT|Cellobiose|Cellobiose powder (Savanna Ingredients GmbH), 5 g per day and 10 g per day, mixed into \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.
215052777|NCT02004301|DRUG|Radiolabelled T4 Tablet|
215052778|NCT02004301|DRUG|Radiolabelled T6 Tablet|
215052779|NCT00251992|DRUG|Esomeprazole|
215052780|NCT02962921|DRUG|Insulin LISPRO intravenous loading|intravenous infusion of insulin Lispro.
215052781|NCT04052165|PROCEDURE|Glaucoma Implant|
214298947|NCT03028831|DIETARY_SUPPLEMENT|70g of fully digestible starch amylopectin corn starch|Fully digestible amylopectin corn starch
214298948|NCT03028831|DIETARY_SUPPLEMENT|Resistant starch|70g high-amylose maize starch
214298949|NCT00775970|BEHAVIORAL|walking activity|
214298950|NCT00002490|BIOLOGICAL|BCG vaccine|
214298951|NCT00002490|DRUG|mitomycin C|
214298952|NCT00002490|RADIATION|radiation therapy|
214298953|NCT06003348|DIETARY_SUPPLEMENT|OHCit- standard dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
214298954|NCT06003348|DRUG|Potassium Citrate|10 mEq Extended-release tablets for oral use
214298955|NCT06003348|DRUG|Placebo|Placebo
214298956|NCT06003348|DIETARY_SUPPLEMENT|OHCit- low dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
214298957|NCT00981955|DIETARY_SUPPLEMENT|Caffeine and L-theanine|Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
214298958|NCT01662518|DEVICE|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
214298959|NCT03193931|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
214298960|NCT03193931|DRUG|Methotrexate Injectable Solution|Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
214298961|NCT05626595|BEHAVIORAL|Project Group - PRO-ECO Project|The PRO-ECO project will be tailored to individual sites. Through collection of focus group and baseline data, the project will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective projects outlined in the literature have informed the development of the project foundation and potential tailoring.
214298962|NCT05626595|BEHAVIORAL|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO project.
214298963|NCT00410553|DRUG|Eribulin Mesylate|Given IV
214298964|NCT00410553|DRUG|Gemcitabine Hydrochloride|Given IV
214298965|NCT02977988|BEHAVIORAL|Mindfulness Meditation|MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
214298966|NCT02977988|BEHAVIORAL|Brain and Recovery (B&R)|B\&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B\&R group will receive didactic education on the neurobiology of addiction. B\&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
214298967|NCT05028439|DEVICE|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
214298968|NCT05028439|DRUG|Chemotherapy drug|Gemcitabine 1 000 mg/m2 intravenously on day 1，8; S-1 80 mg/m2 was taken orally twice for two weeks. The curative effect was evaluated comprehensively for each 2 cycles of chemotherapy
214298969|NCT03872219|COMBINATION_PRODUCT|Nature-based materials|In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
214298970|NCT02015650|DRUG|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
214298971|NCT02015650|DRUG|Mitomycin-C/ 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
214298972|NCT00003644|DRUG|carboplatin|
214298973|NCT00003644|DRUG|paclitaxel|
214897892|NCT07097389|DIETARY_SUPPLEMENT|Oligofructose P95|Oligofructose (Orafti® P95, Beneo GmbH), 5 g per day and 10 g per day, dissolved in \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.
214897893|NCT07097389|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin powder (Special Ingredients Limited), 5 g per day and 10 g per day, dissolved in \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.
214298974|NCT03296254|BEHAVIORAL|Sitting Mindfulness Exercises.|5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
214298975|NCT03296254|BEHAVIORAL|Body Mindfulness Exercises|5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
214298976|NCT00590447|DRUG|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
214298977|NCT00590447|DRUG|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
214298978|NCT04877470|OTHER|Consultation at spine-centre|All patients who visited the spine-centre for the first time in 2019 are included in this group.
214897894|NCT07097155|OTHER|Daily Avocado Consumption|Participants follow their usual diet and consume one avocado per day for 4 months
215057470|NCT02235792|DEVICE|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
215057471|NCT04599803|DEVICE|Verily Sleep Apnea (VSA) Program/App|The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
214298979|NCT06505577|OTHER|No additional intervention|All patients are scheduled to undergo standard breast surgery as part of their routine clinical care. No additional interventions are administered specifically for this study.
214298980|NCT05587400|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
214298981|NCT05587400|DRUG|dobutamine test|infusion dobutamine
214298982|NCT05587400|DRUG|inhaled nitric oxide|nitric oxide inhalation
214478577|NCT06818318|OTHER|Anterior posture of the head|The anterior posture of the head was assessed with the Craniovertebral angle using a goniometer. The Craniovertebral angle was measured in degrees as the angle between the horizontal plane and the 7th cervical vertebra and the ear hole.
214478578|NCT06818318|OTHER|Pressure Pain Threshold Assessment|In our study, the pressure pain threshold measurement of the dominant and non-dominant side masseter and tenar muscles was evaluated with Baseline manual algometer.
214478579|NCT06795555|BEHAVIORAL|Virtual reality food exposure|Patients in this condition are exposed to a virtual kitchen environment once/day, for 5 consecutive days (from Monday, day 1, to Friday, day 5). Each session lasts 5 minutes. The VR environment was specifically developed by the study team (Natali et al, 2024) and it consists of a kitchen with foods of different calorie contents. Patients are invited to explore the environment; they can freely move, open the cupboards and the fridge, and grab and hold the foods. Participants can choose to interact with one of three versions of the virtual kitchen environment: a) a kitchen alone, b) a kitchen with a virtual pet which participants can interact with (and aimed at inducing positive mood) and c) a kitchen with a compassionate avatar which motivates the participant to face food-related fears.
214897895|NCT07097103|BEHAVIORAL|Mediterranean Diet Intervention|Participants will follow a personalized diet plan over 24 weeks, based on the guidelines of the Mediterranean diet and defined according to their needs and the state of the disease; no food category will be excluded a priori. Individualized nutritional counseling and support materials (weekly meal plans, sample recipes, portion guides) will be provided by a qualified nutritionist. Adherence to the Mediterranean diet will be monitored periodically. Participants will maintain their usual diet during a pre-baseline period of at least 4 weeks, then switch to the Mediterranean plan under the supervision of a nutritionist.
214897896|NCT07097103|BEHAVIORAL|Intensive Physical Activity Intervention|Participants will perform exercise, over 24 weeks, according to WHO recommendations for adults, including those aged ≥ 64 years, to achieve at least 150-300 minutes of moderate-intensity aerobic physical activity, or at least 75-100 minutes of vigorous-intensity aerobic physical activity, or an equivalent combination of moderate and vigorous activity during the week. The WHO 2020 also recommend moderate-intensity or greater muscle-strengthening exercises involving alla major muscle groups for 2 or more days per week. Adherence will be monitored during in-person sessions and through wearable devices for activity tracking.
214897897|NCT07097103|OTHER|Control|Participants will continue their usual medical management for early Parkinson's disease according to current clinical guidelines, without any additional dietary or exercise interventions provided by the study, and will be monitored through standard follow-up visits but will not receive any study-specific dietary or physical activity programs.
214298983|NCT06560970|BEHAVIORAL|COPPEhR Intervention|Participants will receive access to the COPPEhR system which will provide social support and engagement among older adults diagnosed with HIV.
214897898|NCT07090317|DRUG|Iparomlimab and Tuvonralimab|The administration regimen of Iparomlimab and Tuvonralimab is: the recommended dose of Iparomlimab and Tuvonralimab is 5mg/kg, intravenous infusion, with a treatment cycle of 21 days. The subjects will continue to receive treatment with Iparomlimab and Tuvonralimab until the termination criteria are met.
214897899|NCT07090005|DEVICE|EndoZip System|The EndoZip System is a single-use automated suturing device, designed to create multiple internal gastric segmentations in the stomach using an endoscopic approach.
214897900|NCT07090005|DEVICE|OverStitch Endoscopic Suturing System (ESG)|The OverStitch ESG is suturing device, designed to create manual suturing in the stomach using an endoscopic approach.
214298984|NCT06560970|BEHAVIORAL|Device-only Control Condition|Participants will have access to a device only without the COPPEhR system.
214298985|NCT02316067|OTHER|Rehabilitation|The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
214298986|NCT03806959|OTHER|Pan Capsule and colonoscopy in patients with IBS|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only Usual biological tests (CBC, CRP, TSH, anti-transglutaminase antibodies) and measurement of fecal calprotectin.
214298987|NCT03461835|DIAGNOSTIC_TEST|Risk classification of PUL by M4|High or low risk of being an ectopic pregnancy
214298988|NCT03461835|DIAGNOSTIC_TEST|Risk classification of PUL by NICE|High or low risk of being an ectopic pregnancy
214298989|NCT06163846|DIAGNOSTIC_TEST|Assess the role of baseline image mining, ctDNA data and their combination in patient staging and risk stratification|Assess the combination of baseline and follow-up image mining, together with ctDNA, in predicting disease relapse and progression.
214298990|NCT01838993|DRUG|Lidocaine inhalation|Lidocaine inhalation before intubation
214298991|NCT01838993|DRUG|Placebo|
214897901|NCT07096310|DRUG|Meropenem I.V. 2g as a 3 hour infusion every 8 hours|Non C group will receive non Carbapenems (Tazocin) 4.5 gm IV slow infusion over 20 minutes every 8 hours per day
215057472|NCT04293224|OTHER|DGA Mediterranean diet pattern, energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations.
214298992|NCT03904433|OTHER|Coconut oil|Coconut oil given in coffee with cream
214298993|NCT03904433|DIETARY_SUPPLEMENT|Caprylic acid|Caprylic acid given in coffee with cream
214298994|NCT03904433|OTHER|Sunflower oil|Sunflower oil given in coffee with cream
214298995|NCT03904433|OTHER|Glucose|Glucose dissolved in water
214298996|NCT05092685|GENETIC|AAVLK03hOTC|Peripheral intravenous infusion of AAVLK03hOTC.
214298997|NCT00010075|DRUG|fluorouracil|
214298998|NCT00010075|DRUG|leucovorin calcium|
214298999|NCT00010075|DRUG|mitoxantrone hydrochloride|
214299000|NCT03456674|DEVICE|LaseMD System|A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
214299001|NCT02987400|DRUG|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
214299002|NCT02987400|DRUG|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
214299003|NCT04215380|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic dissolved in 200 ml of water to be consumed early morning in daily basis for 12 weeks
214299004|NCT04215380|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
214299005|NCT05217329|OTHER|smart phone App rehabilitation|stroke subjects use smart phone to complete therapeutic tasks 5 min/session total 8 sessions/day with affected arm or bilateral arm movement for 6 weeks
214299006|NCT05217329|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program for 6 weeks(30min/day)
214299007|NCT01054781|DRUG|Rituximab|1st cycle R+R-CHOP 2-8th cycle R-CHOP
214478580|NCT06795555|BEHAVIORAL|Virtual Reality Nature Exposure|"Patients in this condition complete a session of VR exposure to a natural scenario (from the NatureTreksVR app) for 5 consecutive days (from Monday to Friday), one session/day. Each session lasts 5 minutes. Participants can choose exposure to one of three different natural environments, at the start of each session: a white sand beach (Blue Ocean), a snowy mountain (White Winter), or a forest in autumn foliage (Red Fall)."
214478581|NCT06820632|BEHAVIORAL|Enhanced physical education|"The Enhanced physical education is based on the Health and Physical Education (HPE) Curriculum Framework developed by the Bhutanese Ministry of Education and well-document in the 2022 edition, www.education.gov.bt. The enhanced PE group will follow closely the description of the HPE curriculum and receive two 90-minute sessions weekly for 5 months. According to the HEP curriculum, the enhanced PE program incorporate both PE with socio-emotional competencies, such as self-regulation, self- and social-awareness, empathy-building exercises, and cooperation activities."
214478582|NCT06820632|BEHAVIORAL|HPE Standard curriculum|Health and physical education (HPE) standard curriculum includes roughly one hour per week of general physical education, typically involving activities like football and basketball.
214478583|NCT06821308|DEVICE|Implant placement|Each patient received 4 implants to support a bar supported overdenture. One implant is commercially available, 3 implants were experimentally made by the manufacturer for this study. The implants were similar in macro-desing, surface and platform shift but differ in microthread design and implant-abutment connection.
214897902|NCT07096310|DRUG|Tazocin (pipercillin/tazobactam)|Non C group will receive non Carbapenems (Tazocin) 4.5 gm IV slow infusion over 20 minutes every 8 hours per day
214897903|NCT07095179|BEHAVIORAL|Eupnea|Participants will breathe normally.
214897904|NCT07095179|BEHAVIORAL|Intermittent inspiratory muscle training (IIMT)|Intermittent inspiratory muscle training (IIMT) will be conducted throughout the trial
214897905|NCT07097246|OTHER||We do not intervene with the subjects; we only observe their body composition data.
214897906|NCT07097012|BIOLOGICAL|Tdap Vaccine Administration|The Tdap vaccine will be administered according to the Product Monograph. Participants will be asked to look away during vaccine administration to maintain blinding.
214897907|NCT07097012|BIOLOGICAL|RSV Vaccine|The RSVpreF vaccine will be administered according to the Product Monograph. Participants will be asked to look away during vaccine administration to maintain blinding.
214299008|NCT04778189|DRUG|Placebo|while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia
214299009|NCT04778189|DRUG|i.v dexmethasone|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia
214299010|NCT05426226|DEVICE|laser acupuncture|using laser acupuncture device on sleep acupoints during sleep
214299011|NCT05426226|DEVICE|sham device|using sham device on sleep acupoints during sleep
214299012|NCT00017992|DRUG|Lopinavir/Ritonavir|
214299013|NCT00017992|DRUG|Emtricitabine|
214299014|NCT00017992|DRUG|Stavudine|
214299015|NCT02808026|DRUG|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast
214299016|NCT01275833|DEVICE|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
214299017|NCT04923087|DEVICE|Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements|"Validate the evaluation criteria Do you hear the biscuit crunch? and Is it a pleasure?"
214299018|NCT03307720|DRUG|Gonadotropin Releasing Hormone Agonists (GNRH-A)|Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
214299019|NCT03307720|DRUG|Human chorionic gonadotropin|Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
214299020|NCT00304564|BEHAVIORAL|Music Listening|subjects listen to music
214299021|NCT01002469|OTHER|sodium [1-13C] acetate|
214299022|NCT01411709|DRUG|Vitano|two 200mg tablets per day for 14 days
214299023|NCT05133947|OTHER|Non interventional|Non interventional
214299024|NCT05098860|OTHER|Home Exercise Program|Educational training program includes active stretching, strengthening, and stabilization exercises of head and neck muscles as well as relaxation and breathing exercises.
214299025|NCT05098860|OTHER|Manual Therapy Combined with Home Exercise Program|Manual Therapy program includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae.
214299026|NCT05098860|OTHER|Tele-rehabilitation Assisted Program|Tele-rehabilitation assisted program will be given in the on-line environment. Patients will apply active cervical and thoracic region mobilizations called self-mobilization.
214299027|NCT02870660|OTHER|Registry|
214897908|NCT07097012|OTHER|Saline (as a placebo)|Normal saline (0.5mL) will be administered as a placebo according to the Product Monograph. Participants will be asked to look away during vaccine administration to maintain blinding.
214897909|NCT07095426|DIETARY_SUPPLEMENT|inulin|6g inulin from chicory root per day for one week and 12g inulin per day for eight weeks dissolved into cool or room temperature liquid
214897910|NCT07095322|BEHAVIORAL|Strength Education Session|Strength education session given at the first 4 weeks of intervention to educate women on muscle-strengthening exercises
214299028|NCT06399588|BEHAVIORAL|Intervention for Adolescent Tobacco Initiation Prevention (IATIP)|The IATIP is an evidence-based tobacco prevention program tailored for Bangladeshi adolescents, integrating Behavior Change Techniques, the Behavior Change Wheel, and the Theoretical Domains Framework. Utilizing the Arena Blended Connected (ABC) model ensures effective delivery. Six key learning types are integrated to optimize knowledge acquisition, concept exploration, collaboration, discussions, practical application, and skill development. The curriculum comprises three core components addressing adolescents' challenges: the information curriculum cultivates factual awareness, the social competence curriculum strengthens refusal skills and social competencies, and the social influence curriculum builds resilience against tobacco-promoting social influences.
214299029|NCT00374725|BEHAVIORAL|Administration of probiotic (L. rhamnosus and L. acidophilus)|
214299030|NCT00879281|BEHAVIORAL|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
214299031|NCT01747941|DRUG|PF-06305591|single dose, solution
214299032|NCT01747941|DRUG|Placebo|matching placebo
214299033|NCT01747941|DRUG|PF-06305591|single dose, solution
214299034|NCT01747941|DRUG|Placebo|matching placebo
214299035|NCT01747941|DRUG|PF-06305591|single dose, solution
214299036|NCT01747941|DRUG|Placebo|matching placebo
214299037|NCT04400786|PROCEDURE|intermittent treatment|According to the feeling of pain, the on-demand treatment group is prescribed with or without Imrecoxib (100mg/tablet, 100mg.prn.po), but the maximal dose does not exceed 100 mg per time, twice (morning and evening) per day. The duration lasted for 24 weeks.
214299038|NCT04400786|PROCEDURE|continuous treatment|The continuous treatment group is prescribed Imrecoxib (100mg.bid.po) regardless of the pain in the treatment course for 24 weeks.
214299039|NCT02087475|DRUG|Irinotecan|
214299040|NCT02087475|DRUG|5-fluorouracil|
214299041|NCT02087475|RADIATION|Local radiotherapy|
214299042|NCT02087475|PROCEDURE|R0 resection|
214299043|NCT03830060|DIAGNOSTIC_TEST|Measurement of cortisol|Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
214299044|NCT00321282|PROCEDURE|Atrial Fibrillation|
214299045|NCT04861155|DEVICE|SIVA-P3|Digital cough recording: Participants receive a small, wearable data recorder, wear it during waking hours and keep it on the nightstand during sleep for 7x24 hours. The data is sent to a smartphone application, where a cough detection algorithm converts it into time-stamped cough events. Participants respond to questions on their smartphone once a day for additional context data. The cough events and context data are sent to a secure online database for further evaluation. For the first 24 hours, segments of audio data are sent to be able to validate the performance of the cough detection algorithm. Afterwards, only cough events and context data are sent from the participant's smartphone.
214299046|NCT04941248|DEVICE|total-body PET/CT(uEXPLORER , United Imaging Healthcare, China)|This prospective study will enroll twenty-five patients, including nine healthy volunteers, sixteen patients with decreased cardiac function . All of them will have a whole-body PET/CT(uEXPLORER , United Imaging Healthcare, China) in our department, Renji Hospital.
214299047|NCT03134482|PROCEDURE|IVM|No gonadotropin is used, but hCG priming is utilized 36 hour before oocyte maturation.
214299048|NCT03134482|PROCEDURE|Minimal stimulation IVF|IVF with minimal use of gonadotropin, i.e. 150 or less IU of recombinant FSH, followed by hCG triggering in GnRH antagonist protocol.
214299049|NCT03720496|BIOLOGICAL|CD19-TriCAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10\^6 CAR+ T cells/kg body weight.
214299050|NCT03486795|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
214299051|NCT03486795|DEVICE|PMC stimulation|stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
214299052|NCT03486795|DEVICE|Sham stimulation|sham stimulation over both primary motor cortex and premotor cortex
214299053|NCT00262808|BIOLOGICAL|sargramostim|
214299054|NCT00262808|DRUG|fluorouracil|
214299055|NCT00262808|DRUG|leucovorin calcium|
214299056|NCT00262808|DRUG|oxaliplatin|
214299057|NCT00262808|PROCEDURE|adjuvant therapy|
214299058|NCT00262808|PROCEDURE|conventional surgery|
214299059|NCT00262808|PROCEDURE|neoadjuvant therapy|
214299060|NCT02741882|OTHER|Questionary|Questionary with clinical, demographic and behavior outcomes at the pregnancy period
214299061|NCT00329654|PROCEDURE|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
214299062|NCT03190161|BEHAVIORAL|Music session|Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level \<6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
214299063|NCT05756946|PROCEDURE|periodontal dressing (coe-pak)|Guided tissue regeneration and periodontal dressing
214299064|NCT05756946|PROCEDURE|Guided Tissue Regeneration|Regeneration of lost periodontal tissues
214299065|NCT00442975|BIOLOGICAL|Fluarix|
214897911|NCT07095322|BEHAVIORAL|Gym Membership|12 weeks gym membership to allow participant to go to the gym on their own
214897912|NCT07095322|BEHAVIORAL|Group Exercise Session|Optional exercise sessions from week 4 to week 12 of the intervention if the participants want to join
214897913|NCT07095322|BEHAVIORAL|Training Log|To record the exercise done for 24 weeks duration. Consist of date, day, exercise, set, repetitions, load, RPE
214897914|NCT07095322|BEHAVIORAL|Support group|For reminders and support for the participant for the first 12 weeks of intervention
214897915|NCT07095088|OTHER|Mind-body therapy|In addition to the 1-week birth preparation training at the Kayseri City Education and Research Hospital Pregnancy School, the intervention group received Mindfulness-Based Parenting and Birth Preparation Training. This training aimed to teach participants how to monitor their thoughts and emotional states, how to deepen their sensory awareness of their bodies, how to be more careful about how their minds work, and how to deepen their sensory self-awareness, so that they would be more sensitive during the birth and parenting processes. A total of 9 separate sessions were implemented. Mindfulness-Based Parenting and Birth Preparation Training was held once a week for 9 weeks, with the duration of each session varying according to the parents' compliance and needs in the program, and each session lasted an average of 150 minutes.
214897916|NCT07097467|OTHER|Buteyko Breathing Technique|The buteyko breathing technique is a breath holding technique mostly used in Asthma patients
214897917|NCT06926894|DRUG|Rapidly generated virus specific T (R-MVST) cells|"Group A dose escalation schedule:~* Cohort (-1A): 0.25x10\^6 R-MVST TNC/kg~* Cohort (1A): 0.5x10\^6 R-MVST TNC/kg~* Cohort (2A): 1x10\^6 R-MVST TNC/kg~Groups B \& C dose escalation schedule:~* Cohort (-1B) + (-1C): 1x10\^6 R-MVST TNC/kg~* Cohort (1B) + (1C): 2x10\^6 R-MVST TNC/kg~* Cohort (2B) + (2C): 4x10\^6 R-MVST TNC/kg"
215052782|NCT01166035|DRUG|Lenalidomide|"Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.~Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
214897918|NCT07096869|DRUG|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|IV infusion, 260 mg/m\^2
214897919|NCT07096869|DRUG|Abraxane®|IV infusion, 260 mg/m\^2
214897920|NCT07096934|OTHER|Standard of Care (SOC)|The participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded.
214897921|NCT07096934|BIOLOGICAL|SoC + Low dose CYWC628|The participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded. Low dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks
214897922|NCT07096934|BIOLOGICAL|SoC + High dose CYWC628|The participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded. High dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks
214897923|NCT07096323|PROCEDURE|Nanofat only|"Fat was collected from either the lower abdomen or lateral upper thigh. A blunt-tipped infiltration cannula (Luer Lock Mercedes Gold Liposuction Cannula 4mm x 30 cm, Pakistan) was used for injection of Klein solution for tumescent anesthesia. Liposuction cannula was then used, connected to a 50 ml syringe mounted with a stopper to generate negative pressure for liposuction. The lipoaspirate was washed to obtain pure adipose tissue, and mechanical emulsification was achieved by transferring the fat through progressively smaller sieves (2.2 mm, 1.5 mm, 1.2 mm) between two 10 ml syringes connected with Luer-Lock connectors, with at least 30 passages each. The emulsion was not filtered and is referred to as Nanofat 2.0."
215052783|NCT01166035|DRUG|Cetuximab|"Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.~Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
215052784|NCT04527835|DIAGNOSTIC_TEST|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
215052785|NCT00222820|DRUG|escitalopram|
215052786|NCT00222820|BEHAVIORAL|Interpersonal Psychotherapy|
215052787|NCT02060981|BEHAVIORAL|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
215052788|NCT02060981|BEHAVIORAL|Interview Only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
215052789|NCT02060981|BEHAVIORAL|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
214299066|NCT02733991|DEVICE|MiniMed™640G and Suspend before low|"All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.~Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase."
214299067|NCT02733991|DEVICE|MiniMed™640G|Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
214299068|NCT01128257|DRUG|alendronate|As prescribed by physician
214299069|NCT01128257|DRUG|ibandronate [Bonviva/Boniva]|As prescribed by physician
214299070|NCT04240925|DEVICE|NIMV with sigh breaths|Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol
214299071|NCT04240925|DEVICE|Standard NIMV|Will be treated by standard NIMV with no sigh
214299072|NCT02902640|DRUG|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
214299073|NCT02902640|DRUG|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
214299074|NCT02902640|DRUG|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
214299075|NCT04404075|OTHER|SkinTracker Mobile App|a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
214299076|NCT01862562|PROCEDURE|Open surgery|Conventional technique
214299077|NCT01862562|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
214299078|NCT05533450|DEVICE|Multi-focal rigid scleral contact lens|True scleral lenses rest on the sclera and do not touch the cornea and limbus, leaving a clear area between the contact lens and the cornea.
214299079|NCT05533450|DEVICE|Rigid gas permeable contact lens|"RGP contact lens is designed from a special rigid hydrophobic material. Patients wear RGP contact lens to form a contact lens-tear-cornea system to correct irregular astigmatism, reduce aberrations, provide good visual quality, and control the development of the disease through mild shaping effect."
214299080|NCT00061698|BEHAVIORAL|Cognitive Behavior Therapy Child Only|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
214299081|NCT00061698|BEHAVIORAL|CBT plus Parent Training|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
214299082|NCT03189758|OTHER|Observational Control Diet|Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
214299083|NCT03189758|OTHER|Controlled Dietary Sodium Restriction|Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
214299084|NCT05273138|OTHER|Blood sampling and skin biopsy|Blood sampling and skin biopsy
214299085|NCT00775151|DRUG|amlodipine 10 mg tablet|
214897924|NCT07096323|PROCEDURE|Nanofat mixed with PRP|Nanofat is prepared the same way as arm 1. PRP was prepared as follows: Ten milliliters of venous autologous whole blood were collected with tri-sodium citrate as an anticoagulant, then centrifuged at 112g (1000 rpm) for 10 minutes. The plasma was transferred to new tubes without tri-sodium citrate and centrifuged again at 448g (2000 rpm) for 10 minutes to separate the platelet pellet and platelet-poor plasma (PPP). PRP was kept for mixing it with nanofat while PPP was discarded
214897925|NCT07096505|BEHAVIORAL|Early time restricted eating with calorie restriction|Participants followed a diet with 25% energy restriction and an 8-hour eating window from 08:00 to 16:00. Dietary compliance was monitored by dietitian through food consumption records.
214897926|NCT07096505|BEHAVIORAL|Delayed Time Restricted Eating with calorie restriction|Participants followed a diet with 25% energy restriction and an 8-hour eating window from 12:00 to 20:00. Dietary compliance was monitored by dietitian through food consumption records.
214897927|NCT07096505|BEHAVIORAL|Control group with calorie restriction|Participants followed a diet with 25% energy restriction and a usual eating window from 08:00 to 20:00. Dietary compliance was monitored by dietitian through food consumption records.
214897928|NCT03476616|DRUG|Eplerenone (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
215052790|NCT04443114|OTHER|Organ Donation Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators
214299086|NCT01523574|DRUG|Vitamin E|Vitamin E 400mg PO orally
214299087|NCT01523574|DRUG|Placebo|Placebo, given orally
214299088|NCT04231539|DRUG|Nicotine|Vape different flavor nicotine products
214299089|NCT04231539|DEVICE|Vaporizer Device|Take puffs from vaporizer filled with different flavors
214299090|NCT03680950|DEVICE|Upper Gastrointestinal Monitoring System|Participants will wear a monitoring system consisting of a tiny endoscopy and a mobile device. The endoscopy is inserted to upper gastrointestinal tract via nasal cavity and the mobile device is set to take and send images from the endoscopy to a server for analyzing if the abnormal condition occurs.
214299091|NCT03627689|OTHER|Active air purifier in respiratory allergies/asthma|Continuous use of air purifier to improve allergies and asthma control
214299092|NCT03627689|OTHER|Sham air purifier|control arm
214299093|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the upper arm
214299094|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the lower abdomen
214299095|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the thigh
214299096|NCT03366402|DIAGNOSTIC_TEST|RT-PCR H1N1|At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
214897929|NCT03476616|DRUG|Valsartan (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
214897930|NCT04823897|DRUG|CCI-001|"Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase."
214897931|NCT01893307|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214897932|NCT01893307|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMPT
214897933|NCT01893307|OTHER|Laboratory Biomarker Analysis|Correlative studies
214897934|NCT01893307|RADIATION|Photon Beam Radiation Therapy|Undergo IMRT
214897935|NCT01893307|RADIATION|Proton Beam Radiation Therapy|Undergo IMPT
214897936|NCT01893307|OTHER|Quality-of-Life Assessment|Ancillary studies
214897937|NCT05303662|DIAGNOSTIC_TEST|Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs|Pooled throat/nose sample and a rectal sample is taken prior to the ERCP
214897938|NCT05303662|DIAGNOSTIC_TEST|MDRO-testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted. Then cultured for presence of MDRO's
214897939|NCT05303662|DIAGNOSTIC_TEST|Microbiome through rectal swab|An rectal swab is collected for microbiome purposes
214897940|NCT05303662|DIAGNOSTIC_TEST|Microbiome testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted for microbiome analysis
214897941|NCT06002711|DIAGNOSTIC_TEST|MR scanning; Clinical data collection|Multi-dimensional spatial heterogeneity analysis of MRI
214897942|NCT06633900|DRUG|IM naltrexone|The study drug is an intramuscular injection of naltrexone (380mg), administered every 4 weeks via an injection in the ventrogluteal region.
215052791|NCT04443114|OTHER|End of Life Care Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
214299097|NCT02049307|DRUG|Losartan 100mg daily|
214897943|NCT06633900|BEHAVIORAL|Usual Care|Participants assigned to usual care will receive a harm reduction bundle in clinic. It will include the following components: 1) intranasal naloxone 4mg x 2, 2) participant choice of safer consumption kits based on substances and route used (specific materials for inhaled use vs. injecting, based on common use practices in the region), 3) fentanyl test kits with 2 lateral flow assays per package along with instructions to minimize false positive results, and 4) information about universal overdose precautions (behavioral modifications to optimize safety like using in the presence of others, use a test dose of new substances, etc.)
214897944|NCT05411991|DIAGNOSTIC_TEST|UNa measurement after intravenous loop diuretic bolus|Sodium concentration is measured on a urine spot sample, collected 30-120 min after administration of every protocol-specified intravenous bumetanide dose.
214897945|NCT05411991|DRUG|Intravenous acetazolamide 500 mg OD|Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (\>145 mmol/L) or metabolic acidosis (bicarbonate \<22 mmol/L) is present at the moment of the scheduled administration.
214897946|NCT05411991|DRUG|Intravenous bumetanide TID|An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR \>45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR \<30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), a dose of 4 mg TID is used.
215052792|NCT00125788|DRUG|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
215052793|NCT00125788|DRUG|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
215052794|NCT00128999|PROCEDURE|Intensity-Modulated Radiation Therapy|
215052795|NCT01987466|BIOLOGICAL|Serum NGAL level|Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
215052796|NCT05805163|BEHAVIORAL|FABI tailored COVID-19 testing pamphlet|FABI adapted COVID-19 educational pamphlet
215052797|NCT05805163|BEHAVIORAL|Standard COVID-19 home-based test kit|Standard COVID-19 home-based test kit
215052798|NCT05843331|PROCEDURE|implants|Four implants in the maxilla with locator attachments
214299098|NCT02049307|DRUG|Matching placebo|
214299099|NCT02550366|DRUG|MRI Contrast|MRI Contrast
214299100|NCT03063658|DRUG|Paracetamol|The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
214299101|NCT03063658|DRUG|Ibuprofen 800 mg|The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
214299102|NCT05357274|DIAGNOSTIC_TEST|Diagnostic testing|Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
214299103|NCT02289976|PROCEDURE|core decompression|Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
214299104|NCT00197730|DRUG|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
214299105|NCT00197730|DRUG|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
214299106|NCT02249533|OTHER|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
214299107|NCT05276245|BEHAVIORAL|Structured Protocol of Nature Contact|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
214299108|NCT00336713|DRUG|Saredutant (SR48968C)|oral administration (capsules)
214299109|NCT00336713|DRUG|Placebo|oral administration (capsules)
214299110|NCT04245384|OTHER|Internet-based dietetic treatment with video calls|The dietitian meets the patient through video calls, no physical meetings
214299111|NCT04245384|OTHER|Traditional dietetic treatment|The dietitian meets the patient through physical meetings
214299112|NCT04523233|DIAGNOSTIC_TEST|Amniocentesis|Amniocentesis is a procedure in which amniotic fluid is removed from the uterus for testing or treatment.
214299113|NCT02794662|PROCEDURE|Oxygen Environment|FiO2 delivered by servo-controlled incubator
214299114|NCT02794662|PROCEDURE|Nasal Cannula Oxygen|FiO2 delivered by nasal cannula
214299115|NCT03420651|OTHER|Peak Expiratory Flow Rate (PEFR)|PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
214299116|NCT03420651|OTHER|Standard Clinical Judgement|Providers will use physical exam and standard clinical judgement to guide management.
214299117|NCT01869296|PROCEDURE|higher flow rates|higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
214299118|NCT01869296|PROCEDURE|lower flow rates|lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
214299119|NCT04702477|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a well-documented approach to reduce participants' stress level \[19\], with the existing group-based peer support, self-empowerment, and lifestyle counseling intervention. MBSR is a type of meditation therapy with the goal of actively cultivating conscious attention and awareness to enhance health benefits. This included 10 hours of intervention with groups of 3-5 people.
214299120|NCT00579956|DRUG|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
214478584|NCT06819345|OTHER|Survey form|PPE15 (Picker Patient Experience Questionnaire) at all visit of the study KDQOL-SF (Kidney Disease Quality Of Life -short form) at inclusion and 3 months after initiation of RRT ou 24 months after inclusion SDMQ9 (Shared Decision Making Questionnaire): at inclusion and 3 months after receiving information related to RRT SDRS (Score Decision Regret Scale) : 3 months after initiation of RRT ou 24 months after inclusion HLS EU 16 (Health Literacy Survey) : at inclusion or 3 months after information on RRT
214897947|NCT05411991|DRUG|Oral chlorthalidone OD|In case of hypernatremia (\>145 mmol/L) or low eGFR (\<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L.
215052799|NCT01677871|DRUG|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
215052800|NCT01677871|DRUG|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
214299121|NCT00579956|DRUG|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
214299122|NCT00857220|DRUG|eszopiclone|One 2 mg tablet per day for 12 months
214299123|NCT00857220|DRUG|eszopiclone|one 3mg tablet per day for 12 months
214299124|NCT03246113|DRUG|Cannabis|Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.
214299125|NCT03246113|DRUG|Temozolomide|Oral alkylating agent with demonstrated antitumor activity.
214299126|NCT03246113|RADIATION|Radiation Therapy|standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
214299127|NCT05048446|OTHER|observational|Non intervention
214299128|NCT01787084|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
214299129|NCT02612935|DEVICE|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
214299130|NCT00680745|DRUG|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
214299131|NCT00680745|DRUG|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
214299132|NCT00680745|DRUG|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
214299133|NCT00680745|DRUG|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
214299134|NCT00680745|DRUG|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
214299135|NCT05874076|BEHAVIORAL|Physiotherapy|Physiotherapy
214299136|NCT03704961|BEHAVIORAL|music and audiobook listening|
214299137|NCT02612428|BIOLOGICAL|ELAD System|An extracorporeal human hepatic cell-based liver treatment
214299138|NCT02612428|OTHER|Standard of Care (Control)|Standard medical treatment as defined by the protocol
214299139|NCT04846621|DRUG|Potassium Channel Opener|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
214299140|NCT04846621|DRUG|Calcium channel blocker|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
214299141|NCT00330941|DRUG|lidocaine|
214299142|NCT00829881|DRUG|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
214299143|NCT00829881|DRUG|Placebo Capsule|A single placebo capsule
214897948|NCT05411991|DRUG|Intravenous canrenoate 200 mg OD|At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), intravenous canrenoate 200 mg OD is provided. Canrenoate is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L or if serum potassium levels are \>5.5 mmol/L. If canrenoate is administered, oral mineralocorticoid receptor drugs are temporarily withhold until switch to oral diuretic treatment.
214897949|NCT05411991|OTHER|Maintenance infusion|A maintenance infusion with 500 mL dextrose 5% and 3 g MgSO4 is started at an infusion rate of 20 mL/h upon the moment of first protocol-specified administration of intravenous diuretics and continued until switch to oral diuretic therapy. 40 mmol KCl is added if serum potassium levels are \<4 mmol/L. In case of hypotonic hyponatremia with serum sodium concentration \<130 mmol/L, dextrose 5% will not be provided and MgSO4 will be administered in 50 mL of normal saline (NaCl 0.9%).
214897950|NCT05411991|DRUG|Oral potassium supplements|If serum potassium levels are \<3.5 mmol/L at any time during the administration of intravenous diuretics, oral potassium supplements are provided as needed to keep serum potassium levels \>4 mmol/L
214897951|NCT05411991|OTHER|Intravenous hypertonic saline|In case of hypotonic hyponatremia with serum sodium concentration \<125 mmol/L, a bolus of 150 mL hypertonic saline 3% is administered and repeated OD if necessary, until sodium levels are ≥135 mmol/L.
214299144|NCT02465801|DRUG|HSA-GCSF 1.2 mg|Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
215052801|NCT01677871|DRUG|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
215052802|NCT01677871|DRUG|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
214299145|NCT02465801|DRUG|HSA-GCSF 1.5 mg|Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
214299146|NCT02465801|DRUG|GCSF|GCSF 5 mcg/kg/day
214299147|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B test|Swab Samples for Diagnostic test
214299148|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & RSV test|Swab Samples for Diagnostic test
214299149|NCT04532866|BEHAVIORAL|Isolation and Confinement|Eight months of isolation and confinement in the spaceflight analog NEK in Moscow
214299150|NCT04573816|OTHER|Use of an internet plateform|Use of an internet platform for remote monitoring of patients.
214299151|NCT04290689|DRUG|Botulinum Toxin-A injection|Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.
214299152|NCT04290689|PROCEDURE|Serial casting stretching|Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
214299153|NCT00137423|DRUG|SU011248 (sunitinib)|37.5 mg/day, oral, continuous daily dosing
214299154|NCT00003443|DRUG|bryostatin 1|
214299155|NCT03084874|BEHAVIORAL|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
214299156|NCT03219489|OTHER|Electronic medical record alert|"An electronic medical record alert will be inserted into the clinic's electronic medical records. The alert reads: Consider Progesterone 100-200 mg pv qhs \> or =16 weeks, if previous spontaneous PTB or current short cervix, and no allergies to peanuts or progesterone.~This alert will appear on the Ministry of Health-mandated Perinatal Records."
214299157|NCT03388333|PROCEDURE|Catheter Ablation|
214299158|NCT03611790|DEVICE|NeVa VS|mechanical dilatation
214299159|NCT00819351|DRUG|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
214299160|NCT00819351|DRUG|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
214299161|NCT00807807|DIETARY_SUPPLEMENT|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
214299162|NCT00807807|DRUG|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
214299163|NCT02423538|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
214299164|NCT02423538|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
214299165|NCT05542264|DRUG|SEP-363856|SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.
214299166|NCT05542264|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
214299167|NCT01613625|PROCEDURE|Elastography|
214897952|NCT05411991|OTHER|Switch to oral diuretic therapy|"Upon complete resolution of clinical signs of fluid overload with UNa \<80 mmol/L, intravenous diuretics are switched to an oral schedule including:~* Loop diuretics with dose \& frequency at the discretion of the treating physician~* Chlorthalidone 50 mg if added for diuretic resistance at any time during the intravenous diuretic phase~* Spironolactone 25 mg or another equivalent mineralocorticoid receptor antagonist"
214897953|NCT05411991|OTHER|Usual AHF care|It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines.
214897954|NCT05584826|DRUG|MDMA|On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (\~84 mg MDMA) + 40 mg MDMA HCl (\~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
214897955|NCT04740736|PROCEDURE|Saline Infusion|Patient with hypovolemia on day 1 will be randomized to a saline or sham infusion prior to the Day 2 exercise test.
214897956|NCT06614725|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly on Day 1 to participants in OA-RSV and Adults-AIR-RSV groups.
214897957|NCT06614725|COMBINATION_PRODUCT|Placebo|1 dose of placebo (saline solution) administered intramuscularly on Day 1 to participants in OA-Placebo and Adults-AIR-Placebo groups.
214897958|NCT03639753|BEHAVIORAL|Parent-Teen Intervention|Parent health coaching and resources + teen on-road driver experience + safe driving eLearning Modules
214897959|NCT03639753|OTHER|Usual Practice|Standard care for teens who get licensed in the state of PA
215052803|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]
215052804|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]
215052805|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]
215052806|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
215052807|NCT03172754|DRUG|Nivolumab|PD-1 inhibitor
215052808|NCT03172754|DRUG|Axitinib|Tyrosine kinase inhibitor
215052809|NCT04790279|DRUG|Amlodipine|Initiation of amlodipine 2.5 mg
215052810|NCT04790279|DRUG|NIFEdipine ER|Initiation of nifedipine ER 30 mg
215052811|NCT03851887|COMBINATION_PRODUCT|TAI combine SBRT|TAI combine SBRT
214478585|NCT06817954|PROCEDURE|endoscopic-assisted mastectomy and immediate breast reconstruction|endoscopic-assisted mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer
214897960|NCT05842967|BIOLOGICAL|RSVpreF|120-µg
215052812|NCT00211796|DRUG|Divalproex Sodium ER|
215052813|NCT04874883|DIETARY_SUPPLEMENT|Simbyotic|6 grams of the symbiotic will be administered twice a day
214299168|NCT01893073|BEHAVIORAL|Mindful walking program|
215052814|NCT04874883|DEVICE|Control Group|6 grams of the maltodextrin will be administered twice a day
215052815|NCT05972421|OTHER|High Intensity Proactive Outreach|phone calls + mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
215052816|NCT05972421|OTHER|Low Intensity Proactive Outreach|mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
215052817|NCT04206397|BEHAVIORAL|affective touch|Various types of touch such as brushing, pressure, and tapping, as well as heat pain
215052818|NCT03400358|OTHER|uterocervical angle|the angle between cervical canal and anterior uterine wall is measured sonographically.
215052819|NCT03930771|DRUG|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
215052820|NCT03930771|DRUG|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
215052821|NCT00589706|DRUG|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
214299169|NCT02141997|BIOLOGICAL|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
214299170|NCT02141997|BIOLOGICAL|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
215052822|NCT01779336|DRUG|PL225B|"* Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
215052823|NCT00778076|DEVICE|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
215052824|NCT00778076|DEVICE|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
214299171|NCT02158338|OTHER|Asthma|mothers who have children that have been diagnosed with respiratory issues
214299172|NCT02158338|OTHER|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
214299173|NCT03124914|OTHER|Neuromuscular tests|Neuromuscular tests
214897961|NCT05842967|OTHER|Placebo|Placebo
214897962|NCT05988996|BEHAVIORAL|Participant guided peer support gathering|This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.
214897963|NCT05831085|PROCEDURE|State-of-the-Art Percutaneous Coronary Intervention|supported by intracoronary imaging (e.g., intravascular ultrasound \[IVUS\] or optical coherence tomography \[OCT\]), intracoronary physiology (e.g., fractional flow reserve \[FFR\] or instantaneous wave-free ratio \[iFR\]), contemporary metallic drug-eluting stents (DES), guideline-directed optimal medical therapy \[GDMT\] with advanced cardiovascular and anti-diabetic medications \[e.g., a sodium-glucose cotransporter \[SGLT\]-2 inhibitors\]) in patients with type 2 diabetes and three-vessel coronary artery disease (CAD) (not involving left main)
214897964|NCT05831085|PROCEDURE|standard CABG|Coronary-Artery Bypass Grafting
214897965|NCT01692041|DRUG|ivy leaves dry extract|5 ml twice daily po
214897966|NCT01692041|DRUG|Placebo|5 ml per os twice daily
214897967|NCT06577142|OTHER|Burn 2 Learn|"The 'Burn 2 Learn' group encompassed the following components and implementations. A brief introductory seminar will be conducted with the principle, school event coordinator, school sports teacher and students from grade 8 to 10. The aim of this seminar is to provide a better understanding of the rationale and presenting evidence of the beneficial effects of high intensity interval training on overall wellbeing of students. The sessions will be conducted thrice a week for 10 to 15 minutes by the research team members for a period of 10 weeks. The sessions will consist of high intensity interval training activities such as lunges, jumping jacks, boxing, dancing and sports activities. The intervals ranging between 8-16, 30 second work out followed by 30 seconds rest, maintaining a 1:1 work rest ratio.~51 participants will be in the experimental group A giving them Burn 2 Learn exercise protocol along with the normal sports training plan for ten weeks."
214897968|NCT06577142|OTHER|Control Group|51 participants will be in control group B and will perform their routine school physical activities, sports games or any exercise routines.
214897969|NCT01406379|PROCEDURE|Prophylactic clip|Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group
214897970|NCT01406379|PROCEDURE|Detachable snare|In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
214897971|NCT01103180|DRUG|Escitalopram|10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
214897972|NCT01173523|DRUG|STA-9090|
214897973|NCT05362916|DRUG|Letermovir|Participants in the treatment arm will take either 1 tablet of 480mg PO once daily or 2 tablets of 240mg PO once daily.
215052825|NCT06017960|OTHER|Dry needling + usual care|"Participants assigned to the dry needling group will receive a weekly session for four weeks of ultrasound-guided dry needling in the inner gastrocnemius muscle with disposable stainless-steel needles, according to the depth of the muscle to be treated. For the realization of the technique, the diagnostic criteria of the Dry Needling in Hypertonia and Spasticity technique (DNHS®) developed by Herrero et al. will be applied adapted to the characteristics of the study, as well as the procedure for its application.~The ultrasound guidance will be the same ultrasound device than in the assessments. This ultrasound-guided intervention allows to guarantee the safety of the approach, to have the certainty in the location of the target structure and to see the responses of local spasm. During the application of the technique, patient will not look at the ultrasound screen to ensure the blindness of the patient to the group allocated."
215052826|NCT06017960|OTHER|Sham dry needling + usual care|"Participants assigned to this group will receive the same assessments, the same number of sessions, and the sham dry needling at the same site as the dry needling group, but with a sham intervention, where the needle is dropped through the guide tube and touch the skin. The patient will not feel anything, or at most that the needle touches the skin, since it does not get into the subcutaneous cell tissue, as placebo interventions were performed in similar studies. The context will be simulated in its entirety, using the same ultrasound and disposable needles for the intervention.~Both groups will continue their daily motor rehabilitation treatment during the 4 weeks, which consists of strength training, balance, motor control, gait training, and mass practice oriented to tasks of intensity and duration appropriate to each patient, allowing the fastest possible clinical improvement, as recommended by clinical practice guidelines."
215052827|NCT04832789|DEVICE|Venovenous ECMO|Venovenous ECMO
215052828|NCT01222117|BIOLOGICAL|Plasmin|Plasmin prepared in 0.9% saline for injection
215052829|NCT01222117|BIOLOGICAL|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
215052830|NCT01222117|OTHER|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
215052831|NCT01904396|DRUG|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
215052832|NCT05337982|OTHER|Downhill Eccentric Treadmill Training with Electrical Stimulation|Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
215052833|NCT02026674|DEVICE|FloRite|Disposable home use urine flow meter.
215052834|NCT03914430|OTHER|Food|The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
215052835|NCT05089552|OTHER|1-WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale|WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale The WHOQOL-BREF is composed of 26 self-administered items. Using a 5-point Likert response scale ranging from 1 (very dissatisfied/very poor) to 5 (very satisfied/very good), family caregivers were asked to rank each item accordingly. Caregivers were asked to respond to the items indicating their assessment of QOL during the preceding 2 weeks, Ohaeri and Awadalla developed and tested the Arabic version of the WHOQOL-BREF among an Arab population in Kuwait. The translated Arabic WHOQOL-BREF has considerable reliability and validity indices . As reported in the Kuwaiti study, a satisfactory (≥0.7) Cronbach's alpha was reported for the full questionnaire and the domains
214897976|NCT06192589|DRUG|Cannabidiol|Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.
215052836|NCT05089552|OTHER|SCL-90-R(Symptoms Checklist-90-Revised) Arabic version scale|"developed by Derogatis et al. and El-Behairy. established the validity and reliability of the Arabic version.SCL-90-R is a 90-item self-report symptom inventory, and reflect the psychologic symptom pattern of psychiatric and medical patients. Each item of the 90 is rated on a five-point scale of distress (0-4), ranging from not at all to extremely.Under usual circumstances, SCL-90-R requires between 12 and 15 minutes to be completed.SCL-90-R is a measure of the current psychologic symptom status. It is not a measure of personality, except indirectly, in that certain personality disorders may manifest a characteristic profile on the primary symptom dimensions."
215052837|NCT05089552|OTHER|addiction severity index|a semi-structured interview that takes approximately 45 minute. developed to evaluate treatment outcome in substance abusers. The instrument focuses on seven areas that are typically affected in the lives of substance abusers: medical status, employment, drug use, alcohol use, legal status, family/social status, and psychiatric status. Information regarding frequency, duration, and severity of problems in these seven areas is collected for both lifetime and recent (past 30 days) history. The ASI provides two types of scores: severity and subjective ratings of the client's need for treatment, and composite scores of problem severity during the prior 30 days. Specific alcohol-related questions include total lifetime years of use, money spent on alcohol, and number of days that alcohol problems are experienced.
215052838|NCT06035172|BEHAVIORAL|guided imagery|The guided imagery technique, which is one of these methods, is used in the method of pain by establishing a connection between mind and body. In the technique, a peaceful scene is depicted in which positive energy is reflected in the person to ensure complete relaxation and relaxation.
215052839|NCT06035172|BEHAVIORAL|music recital|It is stated that the acemasiran tune (instrumental music) has a reducing effect on the duration of labor, as well as having labor pain and muscle relaxant properties.
215052840|NCT04631198|OTHER|Thoracoabdominal rebalancing|the patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
215052841|NCT06306911|DIETARY_SUPPLEMENT|Aronia Melanocarpa extract|Aronia Melanocarpa extract (AME) consisting of a mixture of anthocyanins and other polyphenols
215052842|NCT00810277|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
215052843|NCT01536028|DRUG|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
215052844|NCT01536028|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
215052845|NCT01536028|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
215052846|NCT01536028|DRUG|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
214299174|NCT04061096|DIAGNOSTIC_TEST|Evaluation of cold test|Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
214897977|NCT06192589|DRUG|Placebo|Placebo will be administered orally twice daily for 28 days in Part 1
214897978|NCT06192589|DRUG|Citalopram|Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13.
214299175|NCT04061096|DIAGNOSTIC_TEST|Evaluation of electrical pulp test|Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
214299176|NCT04061096|DIAGNOSTIC_TEST|Evaluation of pain during the treatment|Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
214897979|NCT06192589|DRUG|Morphine|Morphine will be administered once at 15 mg on days 1, 4, and 11.
214897980|NCT01867918|PROCEDURE|Radiofrequency ablation, microwave, radiation therapy|Radiofrequency ablation Microwave ablation Radiation therapy
214897981|NCT01867918|DRUG|Standard Chemotherapy|
214897982|NCT04627792|BEHAVIORAL|IUSECAMH Parent Intervention (Waitlist)|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
214897983|NCT05552820|DEVICE|Verum Electroacupuncture|Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.
215052847|NCT02899455|DRUG|HGP0904|
215052848|NCT02899455|DRUG|HGP0608|
215052849|NCT02899455|DRUG|HGP0816|
214299177|NCT00631527|DRUG|Leuprolide|Injections given through a needle in the muscle every 3 months.
214299178|NCT00631527|DRUG|Goserelin|Subcutaneous injections given once every 3 months.
214299179|NCT00631527|DRUG|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
214299180|NCT00631527|DRUG|Casodex|Once a day by mouth for 2 weeks.
214299181|NCT00631527|RADIATION|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
214897984|NCT05552820|DEVICE|Sham Electroacupuncture|Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23)，SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.
215052850|NCT02899455|DRUG|HGP0904 Placebo|
214897985|NCT01439802|DEVICE|Copper IUD placement at time Cesarean Delivery (Copper T 380A)|Placement of Paragard IUD at time of Cesarean Delivery
214897986|NCT01727752|PROCEDURE|Decompression|
214897987|NCT02201537|DEVICE|renal echography|"Renal biopsy will be performed at 3 and 12 months.~The functional imaging examinations will be held as follows:~Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS"
214897988|NCT05729737|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in pancreatic tumors, it is safe and widely used in liver and pancreatic disease.
214897989|NCT00696215|DRUG|placebo|Placebo 1 mg once a day
214897990|NCT00696215|DRUG|rasagiline|1mg
214897991|NCT04468685|DRUG|Ondansetron|Interperitoneal administration in the gall bladder bed
214897992|NCT04468685|DRUG|Normal saline|Interperitoneal administration in the gall bladder bed
214897993|NCT01722578|DRUG|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
214897994|NCT01722578|DRUG|Placebo|Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
214897995|NCT01570478|DRUG|Foster® NEXThaler® 100/6 µg/unit dose|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
214897996|NCT01570478|DRUG|Seretide® Accuhaler® 250/50 µg/actuation|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
214897997|NCT04581993|DIETARY_SUPPLEMENT|Super Cereal - wheat soya blend with sugar|Pregnant and lactating women will received Super Cereal during pregnancy and first six months of lactation.
214897998|NCT04581993|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement-medium quantity (LNS-MQ)|Children will receive LNS during 6-23 months of age.
214897999|NCT04581993|BEHAVIORAL|Social and behavior change communication (SBCC)|SBCC will be provided to improve care-givers knowledge, attitudes and practices related to infant and young child feeding.
214898000|NCT05396898|DRUG|LCP-tacrolimus|Prophylaxis of transplant rejection in liver and kidney allograft recipients
214898001|NCT05396898|DRUG|twice-daily tacrolimus|Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients
215052851|NCT02899455|DRUG|HGP0816 Placebo|
214898002|NCT05855200|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
214898003|NCT05855200|DRUG|CAPEOX|CAPEOX will be administered.
214478586|NCT06817954|PROCEDURE|mastectomy and immediate breast reconstruction|conventional mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer
214478587|NCT05985382|OTHER|Lower Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
214898004|NCT05855200|DRUG|FOLFOX|FOLFOX will be administered.
215052852|NCT00318318|DRUG|Premarin|
215052853|NCT02644213|OTHER|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~* simulated road march using a virtual reality environment without additional load~* simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~* without physical or cognitive load (without march, waiting between performance evaluations) as control."
215052854|NCT02836470|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
214898005|NCT06165887|OTHER|No intervention|This is an observational study, no intervention will be implemented.
214898006|NCT06165887|OTHER|No intervention|This is an observational study, no intervention will be implemented.
214898007|NCT01008358|BIOLOGICAL|CP 675,206|
214898008|NCT05925465|PROCEDURE|Maxillary and mandibular nerve block|receive bilateral combined maxillary and mandibular nerve block
214898009|NCT05925465|OTHER|Control|not receive any nerve block
214898010|NCT05965375|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
214898011|NCT06487793|BEHAVIORAL|Enhanced Insomnia Coach|The intervention combines the Insomnia Coach app with additional brief alcohol intervention to facilitate behavior change for both drinking behavior and insomnia symptoms. Insomnia Coach contains multiple components of CBT-I (e.g., stimulus control, cognitive restructuring, relaxation training, sleep hygiene/psychoeducation, monitoring of sleep via journals). The brief alcohol intervention content added to the CBT-I app is based on CBT skills for moderate drinking, delivered in a motivational enhancement style, and has demonstrated efficacy among young adults and veterans (e.g., correcting perceived norms, use of protective behavioral strategies, challenging expectancies).
215052855|NCT02836470|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
215052856|NCT05804487|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
215052857|NCT06405438|OTHER|No intervention|No intervention.
214898012|NCT06487793|BEHAVIORAL|Sleep hygiene comparator|Content is based on sleep hygiene practices, but without additional CBT-I content featured in the experimental condition. There is also not brief alcohol intervention content in the control condition.
214898013|NCT02690831|OTHER|Inspiratory Muscle training (IMT)|Inspiratory Muscle training This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
214898014|NCT02690831|OTHER|IMT + Manual Therapy and Motor Control Exercise|IMT + Manual Therapy and Motor Control Exercise The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
214898015|NCT02690831|DEVICE|Powerbreathe|
214898016|NCT05229094|DEVICE|Eva Nexus|Eva Nexus vitrectomy device
215052858|NCT00005903|DRUG|GDNF & Synchro Med Infusion System|
215052859|NCT02342769|DRUG|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
215052860|NCT04289558|DRUG|Sodium Nitrite|Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
214898017|NCT03321682|OTHER|Functional Training|Exercises performed in circuit, using weights, elastic bands, suspension tapes, cones and on unstable surfaces.
214898018|NCT03321682|OTHER|Strength Training|Exercises carried out using weights and involving the main muscle groups.
214898019|NCT04621344|DIAGNOSTIC_TEST|Guided bronchoscopy and/or endosonography|Endoscopic procedures aimed at sampling of intrathoracic lymph nodes or pulmonary lesions
214898020|NCT02561429|PROCEDURE|SPT|SPT of histamine concentration 1, 5 and 10 mg/ml
214898021|NCT00000929|DRUG|Nonoxynol-9|
215052861|NCT01433406|DRUG|TAK-875|
215052862|NCT01433406|DRUG|TAK-875|
215052863|NCT03402932|OTHER|Auditory amplified|The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
215052864|NCT03402932|OTHER|Visual|The cognitive test will be administered visually by using timed computer slides.
215052865|NCT03402932|OTHER|Auditory unamplified|The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
215052866|NCT01698203|DRUG|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
215052867|NCT01698203|DRUG|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
215052868|NCT01698203|DRUG|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
214299182|NCT03063476|DRUG|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
214898022|NCT01207180|OTHER|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
214898023|NCT01207180|OTHER|Satisfaction survey|Patients will be given a satisfaction survey.
214898024|NCT01207180|OTHER|Control group --- no intervention|Control group
214898025|NCT01866826|DRUG|Rifaximin|subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)
214898026|NCT01866826|OTHER|Placebo|subject will receive three capsules of placebo by mouth twice daily.
214898027|NCT04384094|DEVICE|Esthesiometer measurement|Measuring the corneal sensitivity using rebound technology.
214898028|NCT02493660|DEVICE|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
214898029|NCT02493660|PROCEDURE|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
214898030|NCT01687894|DRUG|Vasopressins|Vasopressins propofol vasopressins sevoflurane
214898031|NCT01687894|DRUG|Placebo|Placebo propofol \& placebo sevoflurane
214898032|NCT01687894|DRUG|propofol|vasopressin propofol \& placebo propofol
214898033|NCT01687894|DRUG|sevoflurane|vasopressins sevoflurane placebo sevoflurane
214898034|NCT03073876|DRUG|Donepezil Hydrochloride|5mg of Donepezil Hydrochloride by mouth
215052869|NCT02526303|DRUG|Nadroparin Calcium and Warfarin|Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
215052870|NCT03884153|DEVICE|CRP apheresis|"selective CRP apheresis by use of the PentraSorb-CRP"
215052871|NCT06184685|DRUG|Sahasthara Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
215052872|NCT06184685|DRUG|Diclofenac Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
215052873|NCT05128071|DRUG|Progesterone|Randomized to 400 mg (200 mg twice daily) oral micronized progesterone daily
214478588|NCT05985382|OTHER|Upper Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
214478589|NCT06817694|BEHAVIORAL|Cognitive-behavioral group therapy|The intervention consists of a 4-week cognitive-behavioral group therapy. Each session is given online and will last 90-minutes. The intervention has been adapted to the population of women with a cancer and a BRCA1/2 mutation from a behavioral-cognitive therapy for fear of cancer recurrence that already exists and has already been proven effective.
214898035|NCT03073876|DRUG|Placebo|prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
214898036|NCT01980030|DRUG|Romiplostim|
214898037|NCT04513392|PROCEDURE|Laser treatment|A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
214898038|NCT05074368|BIOLOGICAL|ChAdOx1-nCov-19 (Astra-Zeneca)|vaccine inoculation and mixed inoculation
214898039|NCT05074368|BIOLOGICAL|SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine|vaccine inoculation and mixed inoculation
214898040|NCT05181046|DEVICE|Nanodropper adaptor|The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
214898041|NCT05181046|OTHER|Original eyedrop bottle/No Nanodropper|The original eyedrop bottle dispenses standard eyedrops.
214898042|NCT01847404|DRUG|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
214898043|NCT01847404|DRUG|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
214898044|NCT01847404|DRUG|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
214898045|NCT01847404|DRUG|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
214898046|NCT05147935|BEHAVIORAL|Palliative Care Consultation|In person or telehealth clinic visit with palliative care physician or nurse practitioner
214898047|NCT01521650|DIETARY_SUPPLEMENT|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
214898048|NCT04552795|DRUG|3TC|12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.
214898049|NCT05718934|DRUG|Neostigmine and glycopyrrolate|See arm descriptions
214898050|NCT05718934|DRUG|Sugammadex|See arm descriptions
214898051|NCT05731518|DRUG|SC0245|SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
214898052|NCT05731518|DRUG|Irinotecan|Irinotecan 80mg/m\^2 via IV administered for every 4 weeks (fixed dosing) in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
214898053|NCT04435834|DRUG|Propofol or Sevoflurane|Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.
214898054|NCT05624918|DRUG|Nab paclitaxel|125 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
214898055|NCT05624918|DRUG|Gemcitabine|1000 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
214898056|NCT05624918|DEVICE|NovoTTF-200T(P)|Worn \> 18 hr /day starting C1D1 until completion of cycle 3
214898057|NCT05627843|DIETARY_SUPPLEMENT|Curcumin capsules 1 gm|Dietary supplement
214898058|NCT05627843|DIETARY_SUPPLEMENT|Placebo capsule|placebo corn starch
214898059|NCT02347059|DRUG|L-dopa|Antiparkinsonian medication
214898060|NCT02347059|DRUG|Dopamine Agonists (pramipexole, ropirinole)|Antiparkinsonian medication
214898061|NCT05832632|BEHAVIORAL|Headspace Basics Program|30-day smartphone-based mindfulness intervention consisting of 10 minutes per day. The program consist of generic mindfulness techniques such as breath awareness, body scans, mindful noting of thoughts and emotions.
214898062|NCT05832632|BEHAVIORAL|Headspace Breathing Exercises|30-day smartphone-based breathing exercises. Each exercise consists of box breathing for 1 minute and participants are instructed to complete 10 sessions corresponding to 10 minutes per day.
214898063|NCT05832632|BEHAVIORAL|Headspace Stress Program|20-day smartphone-based mindfulness intervention consisting of 15 minutes per day. The Stress program content is based on well-established concepts and practices within stress management, and mindfulness, and is targeted to people with elevated stress.
214898064|NCT05832632|BEHAVIORAL|Active Control (Audiobook)|30-day smartphone-based Audiobook book consisting of 10 minutes per day.
214898065|NCT06453499|OTHER|Physical therapy|ultrasound for 5 minutes,Tens and hot packs for 20 minutes, back exercise
214898066|NCT05108974|DRUG|Choline Bitartrate|Powdered drink mix for daily consumption
214898067|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
214898068|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
214898069|NCT02083068|BIOLOGICAL|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
214898070|NCT00994812|DRUG|metformin|The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
214898071|NCT01736592|DRUG|Long term follow up in all patients who received SAR422459 in previous study TDU13583|Blood draw for the laboratory assessment
214898072|NCT02476019|DRUG|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
214898073|NCT02476019|DRUG|Placebo|Placebo administered subcutaneously
214898074|NCT02502149|BIOLOGICAL|rFVIIIFc|As per arm description
214898075|NCT04333160|DRUG|JTA-004|Patients will undergo a single intra-articular injection of JTA-004 into the knee joint
215052874|NCT05128071|DRUG|Placebo|Randomized to placebo twice daily
215052875|NCT06174155|OTHER|physical therapy treatment|The control group will receive the physical therapy program and conduct five times per week over four consecutive weeks under the supervision of a physical rehabilitation specialist. The primary focus of the program was to improve scar malleability, lengthen muscles and tendons, enhance joint mobility, and to restore functionality. Each session lasted almost for 45 minutes and consisted of therapeutic paraffin application; deep tissue massaging (5 minutes); stretching exercises; active ROM exercises.
215052876|NCT06174155|OTHER|Botulinum toxin-A injection in addition to physical therapy program|Two injection procedures will be used. The first is an EMG-guided BTX-A administration (Botox®, Allergan PLC, Dublin, Ireland) that will be localized to the motor endplate zone of the wrist flexors, radial and ulnar deviators. The second is a meso-injection procedure, where the BTX-A will be injected subdermal, intradermal, and into the scar (around the periphery and into the center).
215052877|NCT06174155|OTHER|shock wave therapy in addition to physical therapy program|After wound and skin graft healing (\~ 90 days post-surgery), the unfocused shockwave will be applied to the site of burn injury on the volar aspect of the hand of the subjects and will allocate to the shock wave therapy intervention arm. The treatment will be delivered using a portable shockwave device (Zimmer enPuls, EMS physio Ltd, Germany).
215052878|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
215052879|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
215052880|NCT02533544|DRUG|tenofovir disoproxil fumarate|
215052881|NCT01032187|DRUG|Meglumine antimoniate|20mg/kg/day IV for 20 days
215052882|NCT01032187|DRUG|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
215052883|NCT03447405|DEVICE|Dino Egg|DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
215052884|NCT05909033|PROCEDURE|Kasai procedure|All KPs were performed by a medical team. This technique involved creation of a 35-40 cm Roux loop to facilitate biliary drainage. After dissection of the hepatic vasculature at the hilum and excision of the hilar plate, hepaticojejunostomy was performed as an anastomosis extending from the bifurcation of the right hepatic artery into anterior and posterior branches to the Rex confluence of the left portal vein with the obliterated umbilical vein.
214898076|NCT04333160|DEVICE|Hylan G-F 20|Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint
214898077|NCT04333160|OTHER|placebo|Patients will undergo a single intra-articular injection of placebo into the knee joint
214898078|NCT02968576|DRUG|TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA]|
214898079|NCT02968576|DEVICE|Proteus Sensor System|
214898080|NCT03855774|GENETIC|Polymorphisms|Classification of sleep disorders using 22 genetic polymorphisms
214898081|NCT02222922|DRUG|PF-06647020 Q3W|"Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
214898082|NCT02222922|DRUG|fluconazole|combination drug used for drug-drug interaction sub-study
214898083|NCT02222922|DRUG|PF-06647020 Q2W|"Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
214898084|NCT02222922|DRUG|PF-06647020 combined with Avelumab|Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
215052885|NCT04509570|PROCEDURE|Biopsy|5\~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
215052886|NCT02549989|DRUG|LY3023414|Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
215052887|NCT02478112|DEVICE|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
214299183|NCT03063476|DRUG|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
214299184|NCT03987061|DEVICE|MOTIV BVS|MOTIVS BVS in below-the-knee artery disease
215052888|NCT06295380|BEHAVIORAL|Virtual environment practiced on the Caren|The virtual environment practised on the Caren will make the scenario totally immersive and allow the subject to perform the motor task by recruiting muscles according to a motor coordination scheme different from the traditional one.
215052889|NCT06295380|BEHAVIORAL|Conventional physiotherapy|Conventional physiotherapy
215052890|NCT00288548|DRUG|Metoprolol|
214299185|NCT04105998|DRUG|Oxytocin|Oxytocin 10 IU
214299186|NCT04105998|DRUG|Placebo|Placebo
214299187|NCT05776654|DEVICE|Biometric wearable devices|Passive data collection using biometric wearable devices.
214299188|NCT01271920|DRUG|AUY922|
214898085|NCT03010228|BIOLOGICAL|VLA15 with Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
214898086|NCT03010228|BIOLOGICAL|VLA15 without Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
214898087|NCT06160609|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered.
214898088|NCT06160609|DRUG|GSK3174998|GSK3174998 will be administered.
214898089|NCT02761668|PROCEDURE|ParS+Ortho 4W|Orthodontics 4 weeks post surgical
214898090|NCT02761668|PROCEDURE|ParS+Ortho 6M|Orthodontics 6 months post surgical
214898091|NCT02783924|DRUG|Cholecalciferol|Vitamin D preparation
214898092|NCT02783924|DRUG|Placebo|placebo
215052891|NCT02904369|DRUG|Emtricitabine|
215052892|NCT02904369|DRUG|Tenofovir alafenamide|
214299189|NCT01271920|DRUG|Trastuzumab|
214299190|NCT01510379|DEVICE|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
214299191|NCT01510379|DRUG|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
214299192|NCT01510379|DRUG|IV promethazine 25 mg q 6 hours prn|
214299193|NCT01510379|DRUG|Elixir promethazine 25 mg q 6 hours prn after discharge|
214299194|NCT03536403|RADIATION|EOS X-rays|EOS X-rays is done with et without a kyphosis induced corset
214299195|NCT03536403|OTHER|8-meters walk test|8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
214299196|NCT03024723|DEVICE|nasal mask CPAP|CPAP and ventilation administered via nasal mask
214299197|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
214299198|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate|nutritional iron (14 mg) supplement in form of ferrous sulphate
214898093|NCT03623503|OTHER|Observational study|
214898094|NCT03721120|DIAGNOSTIC_TEST|InvisionFirst® molecular panel|"During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:~* regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.~* regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS-,LKB1-, NTRK and/or RET mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.~* for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis."
214898095|NCT02090088|DRUG|Not applicable- observational study|
214898096|NCT02265393|DRUG|OTO-104|
214898097|NCT02265393|DRUG|Placebo|
215052893|NCT02904369|DRUG|Tenofovir disoproxil|
215052894|NCT01621984|OTHER|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
215052895|NCT00972023|DRUG|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
215052896|NCT00972023|PROCEDURE|Surgical resection|Surgical procedure of the invasive breast cancer
215052897|NCT05225077|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
215052898|NCT03412110|OTHER|active surveillance: electronic platform|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
215052899|NCT05605730|OTHER|Maitland mobilization for thoracic spine|The thoracic spine mobilization will be consisting of oscillations to the thoracic vertebrae from the prone positions for repeated 30 times with 1 min interval between each 4 sets for 15 minutes. For central posterio-anterior mobilization, a grade III large amplitude rhythmic oscillation in the postero-anterior direction will be applied to the joint sign segment which is defined as the patient's most painful or hardest to move segment. It will be detected through a passive accessory intervertebral motion (PAIVM) test. T6,7 will be used as a site for application if the joint sign can't be detected. The frequency of treatment sessions will be 3 sessions per week for 4 weeks.
214299199|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate|nutritional iron (14 mg) supplement in form of ferric pyrophosphate
214299200|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 3.5 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)
214299201|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)
214299202|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)
214299203|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C
214478590|NCT06219369|PROCEDURE|Group T|"SPSIPB Technique:~The SPSIPB block, which follows the guidelines we routinely use, will be performed after the completion of the surgical procedure and before the patient wakes up.~TPVB Technique:~The US probe (11-12 MHz, Vivid Q) will be placed 2-3 cm lateral to the T5 spinous process. After visualizing the transverse process, the paravertebral area, internal intercostal membrane, paravertebral space, and pleura, the needle will be advanced to the paravertebral space using an in-plane technique."
214478591|NCT06819462|DRUG|Inhaled Placebo|Inhalation of drugs was started within 24 hours after the screening of patients. Both groups inhaled with vibrating mesh spray twice a day for 3 days. The NS group inhaled with normal saline .
214898098|NCT03952637|BIOLOGICAL|AAV9-GLB1|The risks of administering this treatment in a subject with GM1 gangliosidosis are not completely known. The major risk associated with intravenous infusion is from the subject s immunological response to the viral capsid and/or the beta-gal protein. To reduce this possibility, immune modulation therapy is being started prior to vector delivery and maintained for six months afterward. There is a theoretical risk that the integration of a small percentage of the rAAV vector DNA into the host cell genome could cause cellular transformation to cancer cells and lead to a malignancy. This has never been seen in subjects receiving intravenous AAV9 gene therapy so the risk of this complication, is likely very low.
214478592|NCT06819462|DRUG|inhaled corticosteroids and other asthma drugs|Inhalation of drugs was started within 24 hours after the screening of patients. Both groups used vibrating mesh spray twice a day for 3 days. The Polymyxin E group inhaled polymyxin， 75 mg bid.
214669300|NCT03855072|PROCEDURE|customized fixation plate|"* All cases will undergo one surgery under general anesthesia.~* Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~* Amucoperiosteal flap was reflected to expose the lateral mandibular ramus to the posterior border and the sigmoid notch~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* 3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~* The customized fixation plate is positioned to fix the proximal and distal segment together after setback"
214898099|NCT03952637|PROCEDURE|Abdominal ultrasound|Abdominal ultrasound will be performed as part of screening and safety follow- up studies. The ultrasound will be performed in a radiology department and will take approximately 20-30 minutes.
214898100|NCT03952637|DRUG|Rituximab|We are proposing the use of immune modulation to transiently deplete B-cells using rituximab. It will be infused at -21 days and -14 days before gene transfer.
214898101|NCT03952637|DRUG|Sirolimus|Sirolimus is a macrocytic lactone that inhibits T lymphocyte activation and proliferation by inhibiting activation of mammalian Target of Rapamycin (mTOR) kinase that suppresses cytokinedriven T-cell proliferation. We plan to give sirolimus from day -21 to Day 90 with option to extend to day 365 if clinically indicated.
214898102|NCT03952637|DRUG|Methylprednisolone|Subjects will receive IV methylprednisolone 1 mg/kg or a maximum dose of 50 mg, 60-120 minutes prior to vector administration on day 0 to mitigate potential acute innate immune response against the vector.
214898103|NCT03952637|DRUG|Prednisone|Prednisone (oral solution, dose 0.5 mg/kg) will be taken daily on Days 1-3.
214898104|NCT03952637|DIAGNOSTIC_TEST|Audiology assessment with ABR|The audiology assessment will be performed in the Audiology Clinic using a standard audiogram to measure thresholds for pure tones and speech, word recognition, tympanometry, and otoacoustic emissions if the subject is capable and tolerant of these measures. The assessment will take approximately 30 minutes. The ABR is a noninvasive neurophysiologic test to evaluate electrical signal transmission from the 8th cranial nerve to the brainstem and the cortex in response to specific tones. Electrodes are placed on the scalp and on each earlobe. An earphone gives off a brief click or tone and the electrodes pick up the brain's responses to these sounds and record them. This will be performed by a trained neurophysiology technician to monitor possible change in hearing during treatment. The procedure will be performed in the Interventional Radiology suite while the subject is sedated following the MRI, fMRI, and MRS of the brain.
214299204|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)
214299205|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
214478593|NCT06818448|DEVICE|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
214478594|NCT06818448|DEVICE|Rotator cuff repair with comparator device|Treatment of rotator cuff lesions with the conventional surgical technique (comparator device)
214299206|NCT00242957|BEHAVIORAL|Intervention with Microfinance for AIDS and Gender Equity|
214299207|NCT02548520|OTHER|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
214478595|NCT06818292|BIOLOGICAL|Liraglutide|0.6 mg of the pre-filled solutions from pen-injector Liraglutide (GLP-1 Agonist)
214478596|NCT06818292|BIOLOGICAL|Placebo|0.1 mL NaCl
214478597|NCT06817486|OTHER|RUNNİNG TRAİNİNG|Running training It was performed between 08:00 and 10:00 for morning running and between 18:00 and 20:00 for evening running (Bessot et al., 2014). The exercise intensity of each child in the running group was determined as the 50% heart rate (HR) according to the Karvonen formula (target pulse: (220-age-basal pulse) × intensity) + basal pulse). HR was determined via a telemetric heart rate monitor (PolarM400, Finland) during the first week of running training. Environmental conditions are known to influence the degree of airway epithelial disruption during high-intensity exercise (Boukelia et al., 2017). Therefore, all the participants performed continuous running exercise on a football field in Kelkit/Gümüşhane/Turkey (altitude: 1373 m). It was performed for 50 minutes (including 10 min warm-up and cool-down), 3 days a week, for 8 weeks at the set target heart rate. Each session was supervised by trainers. Running included approximately 10 minutes of warm-up and cool-down with stati
214478598|NCT06817486|PROCEDURE|TRAİNİNG|RUNNING TRAINING WAS DONE
214898105|NCT03952637|DIAGNOSTIC_TEST|Bone density scan (DEXA)|Type II subjects - This is a noninvasive enhanced form of X-ray that is used to measure bone loss. Loss of bone density is a known complication with GM1 gangliosidosis due to decrease in weight-bearing activities with disease progression. The procedure will be performed in the Nuclear Medicine Department. The subject s femur, spine, and whole body will be scanned at baseline and then yearly for 3 years. The procedure will take approximately 10 minutes and may be limited due to the subject s cooperation.
214898106|NCT03952637|DIAGNOSTIC_TEST|Electrocardiogram (EKG)|Performed as part of screening and for safety before sedated procedures. The ECG will take approximately 10 minutes and may be limited due to the subject s cooperation.
214898107|NCT03952637|DIAGNOSTIC_TEST|Echocardiogram|Performed as part of screening. The Echo will be done in the Echo Lab and may take approximately 20-30 minutes. The exam may be limited due to the subject s cooperation level.
214898108|NCT03952637|OTHER|Electroencephalogram (EEG) awake and extended overnight|Completed at baseline. The subject will also have an EEG if clinically indicated (for example encephalopathy, seizures, or other change in neurological status or if changes on the previous study are deemed to warrant a follow up study) during post treatment follow up. The procedures will be conducted in the Neurology Testing Department. The total time for an awake EEG, including lead placement, is approximately 40 minutes. An extended overnight EEG will take approximately 12 hours. The exam may be limited due to the subject s cooperation level.
214898109|NCT03952637|DIAGNOSTIC_TEST|Laboratory tests|Performed on blood and urine include safety labs, clinically indicated labs and research collections. Additional specimens may be collected for the PI s biorepository or as clinically indicated. Blood volumes for clinical diagnostic testing and research will be consistent with Clinical Center laboratory guidelines.
214898110|NCT03952637|PROCEDURE|Lumbar puncture|Performed to obtain cerebrospinal fluid (CSF) to measure GM1 ganglioside, beta-gal enzyme, AAV antibodies, Pentasaccharide biomarkers and other research tests. CSF will also be sent for cell count and differential, glucose, protein, and culture as well as CSF neurotransmitters. The amount of CSF obtained will be less than or equal to 0.75 mL/kg body weight. The procedure will be performed while under sedation following MRI imaging. If a sedated MRI is not being performed, then the LP will be performed in consultation with the pediatric consult service using conscious sedation and local anesthesia. The procedure will take approximately 15 minutes.
214898111|NCT03952637|PROCEDURE|Brain MRI/MRS/fMRI|Magnetic resonance imaging (MRI), functional MRI (fMRI) and spectroscopy (MRS) Procedure/Surgery - The subject will undergo noncontrast MRI, including DTI sequences, fMRI, and MRS in the 3T scanner using the same image acquisition sequences and the same MRS voxels to capture the same metabolites as prior sequencing under natural history protocol 02-HG0107. The MRI, fMRI, and MRS will be interpreted for signs of disease progression or stabilization and any signs of treatment toxicity by two board-certified radiologists with specialty training in neuroradiology. The scan will require anesthesia. Sedation will be administered by the anesthesia service after a preanesthesia consultation to assess risk. The type of sedation and whether the subject will be intubated for the procedure will be at the discretion of the anesthesia service.
214898112|NCT03952637|BEHAVIORAL|Neurocognitive testing|Type II Subjects - The Vineland-3 will be administered under the supervision of a psychologist. The Vineland-3 provides several types of scores, measure of personal and social independence designed to examine the domains of communication, daily living skills, social skills and motor development. Other standard neurocognitive instruments may be used depending on the subject s ability, and some visits will (may) include a measure of intelligence /cognitive development if the child is able to achieve a basal score. Neurocognitive testing will take approximately 2-3 hours depending on subject cooperation. The assessments will not address sensitive topics. Type I Subjects - Bayley Scales of Infant and Toddler Development (BSID-III), a well-normed and validated, examiner-administered evaluation of cognition, language, and motor skills for children from birth to 42 months of age.
214898113|NCT03952637|OTHER|Neurology exam|Neurology exam will be performed by a neurologist in the screening and followup appointments to monitor for any adverse reactions and to assess for clinical response to the treatment. The exam will be scripted for consistency within subject visits and between subjects and will take approximately 30 minutes to one hour. The exam will be videotaped. The exam may be limited due to the subject s cooperation level.
214898114|NCT03952637|BEHAVIORAL|PICC or other Central line placement|PICC line or other central line placement will be done under sedation in Interventional Radiology. The procedure will be done under sedation and may take 20 minutes. A chest Xray will be done after placement to confirm correct positioning of the catheter.
214478599|NCT06818916|DRUG|Hetrombopag|Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.
214299208|NCT01540656|DEVICE|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|"A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
214898115|NCT03952637|PROCEDURE|Skeletal survey|A skeletal survey will be performed to assess the degree of skeletal involvement of the disease. This will include X-rays of the a/p lateral spine, chest, and pelvis. The exam will take approximately 30 minutes. The exam may be limited due to the subject s cooperation level.
214898116|NCT03952637|PROCEDURE|Skin biopsy|Skin biopsy will be performed on subjects who have not already had a skin biopsy under the 02-HG-0107 protocol. The procedure will be done under sedation using local anesthetic. After washing the skin with chlorhexidine and numbing the skin with injectable lidocaine, a 3mm circle of skin is removed under sterile conditions and the wound is dressed. The entire procedure takes approximately 5 minutes.
214898117|NCT03952637|PROCEDURE|Speech and modified barium swallow study|Performed as a marker of response to treatment and safety. The swallow assessments will include a parental swallowing questionnaire and cranial nerve assessment. The NIH Swallowing Questionnaire from the Speech Language Pathology Section is designed to identify the presence and or absence of functional swallowing dysfunction as perceived by the subject and or caregiver. This 4point scale assists with further identification of clinical/research assessments of oral pharyngeal swallowing function if indicated in the form of a modified barium swallow. In addition to swallow assessments, tape recording of speech will also be included with diadochokinetic tasks and sustained phonations as well as speech if able. Recordings will be stored on a shared drive accessible only by the study team. The assessment may take approximately 30 minutes to 1 hour.
214299209|NCT03994692|DEVICE|PEEK eminoplasty|making obstacle at eminence using patient specefic PEEK device
214669301|NCT03855072|PROCEDURE|maxillomandibular fixation|"* All cases will undergo one surgery under general anesthesia.~* incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint to assure accuracy of the mandibular position."
214898118|NCT03952637|PROCEDURE|Ophthalmology exam|The ophthalmology exam will be performed by an ophthalmologist in the screening and follow-up appointments to support subtype diagnosis and assess efficacy. Pictures of bilateral macula will be taken and saved to a secure database. OCT will also be performed. These exams will only be administered to Type I subjects.
214898119|NCT02976857|BIOLOGICAL|C-CAR-011|lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.
214898120|NCT04413019|OTHER|Clinical follow up|"Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~* Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~* Penicillin may be used in patients who can't tolerate erythromycin~* In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection."
214898121|NCT00479999|DRUG|VRC-HIVADV027-00-VP|
214898122|NCT00479999|DRUG|VRC-HIVADV038-00-VP|
214898123|NCT00247715|DRUG|algeldrate/magnesium oxide|
214898124|NCT00247715|DRUG|ranitidine|
214898125|NCT00247715|DRUG|pantoprazole|
214898126|NCT04842071|DIAGNOSTIC_TEST|18F-sodium fluoride|Intravenous injection of 4 MBq/kg for pediatric patients, or 5 MBq/kg for adult patients (maximum of 555 MBq), followed by a 45 minutes waiting time. Patients is then placed in supine position in a PET/CT scanner for a duration of no more than 30 minutes.
214898127|NCT00199420|DRUG|Istradefylline (KW-6002)|
214898128|NCT02246751|DEVICE|Targeted Training for trunk control|Orthotics Research and Locomotor Research Unit (ORLAU) standers will be custom fit to help the child train at the segmental level of the trunk where they begin to lose control of posture. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body. The researchers evaluate children every 8 weeks and adjust the stander to lower levels of support as the child gains control.
214898129|NCT03182231|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
214898130|NCT06187129|DEVICE|nerve ultrasound|nerve ultrasound
214898131|NCT03359148|DEVICE|Disposable ventilator system|
214898132|NCT03359148|DEVICE|Conventional reused ventilator system|
215052900|NCT05605730|OTHER|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Verbal instructions will be provided for the patient to move into thoracic extension and do over-pressure at the end of ROM while a transverse glide is maintained by the therapist for a set of 10 repetitions. The significance of performing a pain-free movement will be emphasized to the patient all the time. There will be 3 sets of 10 repetitions with one minute rest between each set.
214299210|NCT03994692|PROCEDURE|autogenous onlay grafting eminoplasty|making obstacle at eminence using chin graft
214669302|NCT06127212|DRUG|Dapagliflozin 10 mg film-coated tablet|One tablet of the test drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
214898133|NCT06377774|OTHER|No intervention in this study|No intervention in this study
215057473|NCT04293224|OTHER|DGA Mediterranean diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations
215057474|NCT04293224|OTHER|TAD diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends.
214898134|NCT00517504|DRUG|Methylphenidate|"* 1-week single blind placebo lead-in phase.~* step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.~Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.~After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control."
214898135|NCT03981172|BEHAVIORAL|Daily snack food intake|participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.
214898136|NCT01487967|OTHER|Preference and Goal Instrument|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
214898137|NCT01974622|DRUG|Visudyne|Half fluence verteporfin
214898138|NCT03280810|OTHER|Movement group|Experimental group : patients with schizophrenia who realise psycho-corporal training once a week, during 1 hour and a half for a period of two months
214898139|NCT05898724|PROCEDURE|Blank group|include six orthodontic patients, which have a surgical procedure to install two orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed orthodontic titanium miniscrews.
214898140|NCT05898724|PROCEDURE|Silver hydroxyapatite|include six orthodontic patients, which have a surgical procedure to install two silver hydroxyapatite nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed silver hydroxyapatite nano-coated orthodontic titanium miniscrews.
214898141|NCT05898724|PROCEDURE|Zinc oxide|include six orthodontic patients, which have a surgical procedure to install two zinc oxide nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed zinc oxide nano-coated orthodontic titanium miniscrews.
214898142|NCT06431724|OTHER|Patient Survey|A simple data intake collection from the patients regarding their medical history that will allow the researchers to assess if recommended guidelines were followed.
214898143|NCT06431724|OTHER|Provider Survey|A survey will be used to evaluate providers' practices, knowledge and adherence to guidelines, and decision making related to current practice for cervical screening in women \>65.
214898144|NCT00853008|DRUG|Vincristine|Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)
214898145|NCT00853008|DRUG|Daunorubicin|Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22
214898146|NCT00853008|DRUG|Prednisone|Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28
215052901|NCT05605730|OTHER|Traditional exercise management|"Prone back extension. Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
215052902|NCT05460897|BEHAVIORAL|Health behaviour change|weekly sessions addressing strategies to tackle behavioural risk factors for chronic disease
215052903|NCT00002798|DRUG|asparaginase|
215052904|NCT00002798|DRUG|daunorubicin hydrochloride|
215052905|NCT00002798|DRUG|fludarabine phosphate|
214299211|NCT00584558|PROCEDURE|Catheter Ablation|Catheter Ablation of arrhythmias
214299212|NCT00002130|DRUG|Vesnarinone|
214898147|NCT00853008|DRUG|Mitoxantrone|Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation
214898148|NCT00853008|DRUG|Cytosine Arabinoside|ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
214898149|NCT00853008|DRUG|Dexamethasone|Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
214898150|NCT00853008|DRUG|Methotrexate (MTX)|Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
214898151|NCT00853008|DRUG|Cytarabine|Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
214898152|NCT00853008|DRUG|ASP|ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
214898153|NCT00853008|DRUG|Mercaptopurine|Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
214898154|NCT00853008|DRUG|Teniposide|Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
214898155|NCT00853008|DRUG|Hydrocortisone|Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
214898156|NCT00116779|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
214898157|NCT02105467|DRUG|Grazoprevir 100mg / Elbasvir 50 mg FDC|
214898158|NCT02105467|DRUG|Placebo to Grazoprevir / Elbasvir 50 mg FDC|
214898159|NCT03665740|DRUG|Resveratrol|resveratrol is an OTC supplement
215052906|NCT00002798|DRUG|therapeutic hydrocortisone|
214669303|NCT06127212|DRUG|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|One tablet of the reference drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
215052907|NCT00002798|PROCEDURE|allogeneic bone marrow transplantation|
215052908|NCT00002798|RADIATION|3-dimensional conformal radiation therapy|
215052909|NCT00002798|BIOLOGICAL|filgrastim|Given SC
215052910|NCT00002798|DRUG|cytarabine|Given IV or IT
215052911|NCT00002798|DRUG|idarubicin|Given IV
214299213|NCT01236937|DEVICE|Bellows-based breath hold device|"Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed."
214299214|NCT02115711|BEHAVIORAL|Community health worker|The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
214299215|NCT00278109|DRUG|cyclophosphamide|chemotherapy
214299216|NCT00278109|DRUG|Doxorubicin|doxorubicin
214299217|NCT00278109|RADIATION|radiation|radiation
214299218|NCT04849806|DIAGNOSTIC_TEST|Assessments of the sympathetic nerve activity axis|"For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed."
214299219|NCT04849806|DIAGNOSTIC_TEST|OSA severity|OSA is defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h) and sleep architecture
214299220|NCT04849806|DIAGNOSTIC_TEST|Determination of PH and right HF severity|(defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography
214299221|NCT04849806|DIAGNOSTIC_TEST|Comprehensive lung function and inspiratory muscle function testing.|Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis.
214299222|NCT04849806|DIAGNOSTIC_TEST|Assessment of systemic inflammation|Based on blood samples taken.
214299223|NCT02090517|DEVICE|Pulsed Dye Laser|Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
214478600|NCT06816316|PROCEDURE|external angular dermoid cysts surgical removal|"Skin incision was done below the eyebrow, subcutaneous and orbicularis dissection was done to remove the cysts. Upon accidental opening of the cyst then removal of the cyst walls and its contents from the surgical field as much as possible was done.~At this step, in group (A) only saline was used to wash the surgical field from any remnants. In group (B) the surgical field was cleaned with a gauze soaked with ethyl alcohol 70%. Then closure of the wound in both groups."
214478601|NCT06816719|DRUG|Treatment A: JW0106 1 tablet + C2101 1 tablet|"* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101~* Administration orally with 150 mL of water under fasting conditions"
214478602|NCT06816719|DRUG|Treatment B: JW0107 1 tablet|"* Administration alone of 1 tablet of JW0107~* Administration orally with 150 mL of water under fasting conditions"
214478603|NCT04576741|BEHAVIORAL|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
214478604|NCT04576741|BEHAVIORAL|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
214478605|NCT06820684|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|"The OMT protocol will be delivered as follows:~1. Touching and applying gentle pressure to the participant's upper shoulder area (this is called Thoracic inlet direct myofascial release)~2. Touching and applying gentle pressure to the participant's midsection and abdomen (this is called Abdominal diaphragm direct myofascial release)~3. Touching and applying gentle pressure to the participant's pelvis and sacrum (this is called Muscle Energy or Counterstrain, if indicated).~4. Touching and applying gentle pressure to the participant's hips and hamstrings (this is called muscle energy) and will be done in 3 repeated rounds of 5 seconds each.~5. Touching and applying gentle pressure to the backs of the participant's knees (this is called open popliteal fossa with direct myofascial release)~6. Touching and applying gentle pressure to the participant's feet, moving them back and forth in 10 rhythmic pulses (this is called Pedal Pump)"
214478606|NCT06818279|DRUG|Dabigatran|Dabigatran 150 mg BD fixed dose to be given for duration of 6 months.
214478607|NCT06818279|DRUG|Enoxaparin|Enoxaparin . Treatment would be given with 1 mg /Kg (100IU/Kg) dose s/c twice daily for 6 months.
214478608|NCT06820502|PROCEDURE|Transurethral Resection of Prostate (TURP)|"TURP:~Transurethral resection of the prostate remains the criterion standard therapy for obstructive prostatic hypertrophy and is both the surgical treatment of choice and the standard of care when medication fails. It improves obstructive voiding symptoms and urinary flow rate with success rates ranging from 85 to 90% ."
214478609|NCT06820502|PROCEDURE|Transurethral Resection Of Bladder Tumor|"TURBT:~Trans-urethral resection of bladder tumor (TURBT), performed endoscopically, is the firstline procedure for diagnosis, staging, and treatment of visible bladder tumors,"
214478610|NCT06819982|OTHER|BCM2.0|The BCM2.0 programme provides occupational therapy sessions and assistive devices to support older people who want to age in place.
214669304|NCT04942639|DEVICE|JOE|Audiovisual support by the robot when taking maintenance treatments at home.
215052912|NCT00002798|DRUG|dexamethasone|Given PO
214299224|NCT02090517|DEVICE|Long Pulsed Alexandrite Laser|Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
214478611|NCT06816485|DEVICE|PTV (Percutaneous Transcatheter Valvuloplasty) Balloon|Minimally invasive medical procedure used to replace a diseased aortic valve without the need for open-heart surgery. It is commonly used to treat severe aortic stenosis, a condition in which the aortic valve becomes narrowed and restricts blood flow from the heart to the rest of the body.
214478612|NCT05536245|OTHER|Questionnaire|To prevalence of psychological, physical and sexual violence suffered or committed in a population of patients suffering from one or more addictions
214898160|NCT06575634|BEHAVIORAL|Supervised exercise training|Participants perform Intradialytic cycling exercise training in the hospital for 6 months (24 weeks) and 3 months (12 weeks) at home. Exercise prescription: 50-60% maximal workload for 20-30 minutes, including low intensity warm-up and cool down (30% of maximal workload).
214898161|NCT01358435|BIOLOGICAL|30% Regular Insulin Human Neutral and 70%Isophane Insulin|Total Dose per subject is 0.4 IU/Kg given subcutaneously.
214898162|NCT01358435|BIOLOGICAL|Novolin 70/30|Total Dose per subject is 0.4IU/Kg given Subcutaneously.
214898163|NCT01502319|BEHAVIORAL|Cognitive therapy|Interventional studies conducted by the consortium focus on a range of cognitive and cognitive-behavioral techniques including cognitive therapy.
214898164|NCT00731835|PROCEDURE|Endovascular Revascularization|"* angioplasty, also called percutaneous transluminal angioplasty (PTA) and/or~* stent placement~* atherectomy"
214898165|NCT06262763|DEVICE|Laser Therapy|High-intensity
214898166|NCT06262763|OTHER|Traditional exercises|Hamstring and piriformis stretch, plank exercises and bird dog exercise
214898167|NCT06262763|OTHER|Placebo laser|Not directed radiation to participant
214898168|NCT03866213|DIAGNOSTIC_TEST|BiliSpec|BiliSpec will quantitatively measure the bilirubin content of a neonatal blood sample.
214898169|NCT01037218|DRUG|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
214898170|NCT01037218|DRUG|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
214898171|NCT05356871|OTHER|VO2max validity and reliability assesment|Reliability assessment of VO2max determination with three repeated measures for two methods.
214898172|NCT01475799|DEVICE|Replacement of the Aortic Stenotic Valve|Treatment for patients with Severe Aortic Stenosis.
214898173|NCT02676882|DIETARY_SUPPLEMENT|EnBrace HR|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study
214299225|NCT02090517|DEVICE|Pulsed Dye Laser Plus Nd:YAG Laser|The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
214478613|NCT06657677|DIETARY_SUPPLEMENT|40mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
214898174|NCT04249960|BEHAVIORAL|Managed transition|Young people, their family and clinicians will receive transition guidelines and will be asked to follow them as much as possible.
214898175|NCT00400374|DRUG|Erlotinib|Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.
214898176|NCT00400374|DRUG|Celecoxib|Celecoxib, 400 mg, daily for 6 months.
214898177|NCT03035591|DRUG|ODM-207|
214898178|NCT02084862|DEVICE|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
214898179|NCT02084862|DEVICE|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
214898180|NCT04504968|OTHER|Multimodal intervention|"1. Optimal control: HbA1c between 7.6-8.5% (60-69 mmol/mol) and Blood Pressure\<150/90 mmHg~2. The physical exercise program that will be used will be the Vivifrail program (Erasmus + UE). Vivifrail includes: Strength for arms and legs, balance and gait, flexibility and resistance. The duration will be 16 weeks. (3 weeks to explain the program in the Trial site and the rest of weeks, it will be carried out at home).~3. Nutritional and educational program to increase diabetes knowledge, develop practical self-care skills for diabetes and increase the likelihood of improving glycemic control safely. The intervention aims to minimize the risk of hypoglycemia, ensure optimal nutritional status and help to maintain functional status. Seven separate sessions of 45 minutes each one twice a week for a period of 3-4 weeks in small groups. They will be moderated by a physician or diabetes educator and focused on behavioral changes and key points."
214898181|NCT04504968|OTHER|Usual care group|The level of usual health care that a patient with diabetes receives from their local national health system
215052913|NCT00002798|DRUG|thioguanine|Given PO
214299226|NCT02090517|PROCEDURE|Electrodesiccation|A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
214478614|NCT06657677|DIETARY_SUPPLEMENT|100mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
214478615|NCT06657677|DIETARY_SUPPLEMENT|180mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
214898182|NCT02675036|PROCEDURE|Tooth extraction|
214898183|NCT00776841|DRUG|Aramchol|1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
214898184|NCT00776841|DRUG|Aramchol|Oral Aramchol at dose 30 mg to 900 mg
214898185|NCT00776841|DRUG|Aramchol|Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
214898186|NCT03024502|DRUG|EPP-AF Gel 1%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
215052914|NCT00002798|DRUG|etoposide|Given IV
215052915|NCT00002798|DRUG|methotrexate|Given IT
215052916|NCT00002798|DRUG|cyclophosphamide|Given IV
215052917|NCT00002798|BIOLOGICAL|aldesleukin|
215052918|NCT00002798|DRUG|busulfan|
215057475|NCT02200926|OTHER|Loaded breathing training|7 days/weeks, for 8 weeks
215057476|NCT02200926|OTHER|Unloaded breathing training|7 days/week, for 8 weeks
214478616|NCT06656078|OTHER|1. WORKING MEMORY TASK:|Arithmetic task: backward counting with serial 3 subtractions out loud. Group 1 and Group 2 participants will be asked to count backwards with serial 3 subtractions out loud while walking 10 meters. There is considerable disruption of performance because of simultaneous articulatory suppression. However, when errors were observed they were calculated to be numerically close to the correct figure which suggests that performance was not completely disrupted by suppression of articulation.
214898187|NCT03024502|DRUG|EPP-AF Gel 2%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
214898188|NCT03024502|DRUG|Clotrimazole|Administration intravaginal of clotrimazol, 1x/day, 7 days
214898189|NCT01483703|DEVICE|Laser Speckle Imaging|Laser Speckle Imaging of Critical Care Neonates
214478617|NCT06656078|OTHER|2. VISUAL AND VERBAL FLUENCY TASK|Modified Stroop test or Stroop colour word test: Participants are asked to name the colour of ink that each word is printed. It is the most frequent test used to show attention bias in anxiety patients. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
214898190|NCT01302743|DRUG|Group 1: Metformin|Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
214898191|NCT01302743|DIETARY_SUPPLEMENT|Group 2: Cinnamon Bark|Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days
214898192|NCT01302743|DIETARY_SUPPLEMENT|Group 3: Cinnulin PF|Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
214898193|NCT01321879|DRUG|Telavancin|10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
214898194|NCT05762250|OTHER|Auricular Acupuncture|Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
214898195|NCT01676207|PROCEDURE|Coronary Angiography with collateral flow measurements|"* Diagnostic coronary angiography and LV angiography~* Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~* Right and left IMA CFI during a 1-minute ostial vessel occlusion~* Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~* IMA angiography (left and right) during distal IMA and coronary occlusion."
214898196|NCT01676207|PROCEDURE|Coronary Angiography with collateral flow measurements|"* Diagnostic coronary angiography and LV angiography~* Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~* Right and left IMA CFI during a 1-minute ostial vessel occlusion~* Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~* IMA angiography (left and right) during distal IMA and coronary occlusion."
215052919|NCT03183765|DRUG|Measles-Mumps-Rubella Vaccine|"MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
215052920|NCT03183765|PROCEDURE|cryotherapy|"patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison.~The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
215052921|NCT05687981|DRUG|Bupivacaine|the use of higher concentration of bupivacaine in ilioinguinal and iliohypogastric nerve block (IINB) might increase the efficacy of postoperative analgesia
215052922|NCT05687981|DRUG|Dexamethasone|2 mg dexamethasone
214478618|NCT06656078|OTHER|3. MOTOR TASK:|Carrying a tray with four glasses filled with water. Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
214478619|NCT05754515|PROCEDURE|target controlled infusion (TCI) group|"Patients in the TCI group will be anesthetized with propofol and remifentanil throughout the operation.~Patients included in the inhalation anesthesia group will be anesthetized with desflurane and remifentanil with a bispectral index of 40-60 throughout the operation."
214478620|NCT00364637|DRUG|Sevoflurane (Volatile Anesthetic)|
214478621|NCT00364637|DRUG|Total intravenous anesthesia|
214898197|NCT00837837|DRUG|Chlorpheniramine|
214898198|NCT00593515|BEHAVIORAL|Family cognitive behavioral therapy|12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
214898199|NCT00593515|BEHAVIORAL|Child-focused cognitive behavioral therapy|12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
214898200|NCT03492515|DRUG|recombinant human thrombopoietin|If platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,the patients began to receive subcutaneous injection of TPO with the dose of 300 Unit/kg qd,duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qod;If platlet count ≥100×109/L, stop this treatment;After delivery, if platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,subcutaneous injection of TPO with the dose of 300 Unit/kg qd or qod will be given at a duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qw;If platlet count ≥100×109/L, stop the treatment.
214898201|NCT03492515|DRUG|Platelet Concentrate|according to the their conditions, use if necessary
215052923|NCT02628444|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
215052924|NCT02628444|BIOLOGICAL|Placebo (Sodium chloride 0.9%)|0.5 mL, Subcutaneous
215057477|NCT02200926|OTHER|Placebo|7 days/week, for 8 weeks
214898202|NCT00402909|DRUG|Nateglinide|
214898203|NCT00004115|RADIATION|yttrium Y 90 monoclonal antibody HMFG1|
214299227|NCT00149123|DRUG|hydrocortisone 200 mg/day|
214299228|NCT01966965|DRUG|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
214478622|NCT01855633|DEVICE|Traditional Theta burst stimulation (TBS)|
214478623|NCT01855633|DEVICE|Modified TBS rTMS|
214478624|NCT01855633|DEVICE|Sham rTMS|
214478625|NCT06811597|PROCEDURE|Voco Meron Conventional Glass Ionomer|The right molars were bonded with Meron
214478626|NCT06811597|PROCEDURE|High-Q-Bond Band™ self-adhesive resin cement.|The left mandibular first molars were bonded with FSM High-Q-Bond Band™ self-adhesive resin cement.
214478627|NCT06478693|DRUG|MT-303|MT-303
214478628|NCT06653556|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
214478629|NCT06807879|BEHAVIORAL|Modified Otago Exercise with Routine care Physical therapy|"To improve the efficacy of the balance improvement intervention, we modified the OEP by incorporating the additional walking, recommended by the OEP guidelines, into a single exercise session and conducting it as a group exercise program in accordance with a previous meta-analysis (Chiu et al., 2021) . As shown in Figure 1, the modified-OEP group intervention consisted of 15 min of walking followed by a 30 min Otago Exercise Program consisting of balance and strength training, followed by another 15 min of walking. The 15 min walking was accomplished through continuous walking at an individual pace in the \~15m training room. Participants were asked to walk 15 m, make a U-turn towards the left side, walk 15 m, then make a U-turn towards the right side at the next turning point, in order to achieve an equivalent effect on the promoted benefit of symmetry when turning left and right.~This was repeated until the session was complete."
214898204|NCT06391307|OTHER|Crystallized phenol|Crystallized phenol + Exosome + Stem Cell
214898205|NCT06391307|BIOLOGICAL|Crystallized phenol + Exosome|Crystallized phenol + Exosome will be applied to wound area.
214898206|NCT06391307|BIOLOGICAL|Crystallized phenol + Stem Cell|Crystallized phenol + Stem cell will be applied to wound area.
214898207|NCT06391307|BIOLOGICAL|Crystallized phenol + Exosome + Stem Cell|Crystallized phenol + Exosome + Stem Cell will be applied to wound area.
214898208|NCT00897715|DRUG|Rilonacept|160 mg of rilonacept administered subcutaneously once a week for 12 weeks
214898209|NCT00897715|DRUG|Placebo|160 mg of placebo administered subcutaneously once a week for 12 weeks
214898210|NCT00554385|DRUG|ABT-089|Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
214898211|NCT00958828|DEVICE|Nelfilcon A contact lens|Spherical, soft contact lens for daily disposable wear
214898212|NCT00958828|DEVICE|Narafilcon A contact lens|Spherical, soft contact lens for daily disposable wear
214898213|NCT03711097|DRUG|Vanish XT Dental Varnish|Varnish will be applied to the front surface of the intervention upper central and lateral incisors
214898214|NCT05628597|DEVICE|Fos Biomedical patch product|Participants will apply a Fos Biomedical patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
214898215|NCT05628597|DEVICE|Fos Biomedical patch product:placebo|Participants will apply a placebo patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
215052925|NCT01084577|DEVICE|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
215052926|NCT01084577|DEVICE|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
215052927|NCT00174850|DRUG|Gaitril|
215052928|NCT02386462|DRUG|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
215052929|NCT02386462|DRUG|Propofol|
215052930|NCT05115370|OTHER|Semi-structured qualitative interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
214299229|NCT01966965|DRUG|NEDAX|AS SPECIFIED AT THE LEAFLET
214299230|NCT02580357|PROCEDURE|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
215052931|NCT03259243|DRUG|Bupivacaine Hydrochloride|0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
215052932|NCT05071612|DRUG|AD109|Oral administration at bedtime
215052933|NCT05071612|DRUG|AD504|Oral administration at bedtime
214299231|NCT02580357|DEVICE|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
214299232|NCT04563741|BEHAVIORAL|MOVE!+UP|behavioral weight management intervention developed for Veterans with PTSD
214299233|NCT04563741|BEHAVIORAL|MOVE!|standard VA weight management intervention
214299234|NCT03935633|DRUG|CN128 Tablets|Iron chelator， oral tablets
214299235|NCT02064166|DRUG|Intranasal Insulin|"1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~2. placebo arm: normal saline, daily, intranasally, for 4 weeks."
214478630|NCT06807879|BEHAVIORAL|Routine Care Physical Therapy|The routine care physical therapy session typically involves a variety of exercises aimed at general strengthening, stretching, and basic gait training. 1 hour of standard physiotherapy exercises focusing on general strengthening, stretching, and basic gait training. The session included a combination of exercises aimed at general strengthening, such as core stability exercises, muscle-strengthening exercises with weights or resistance bands and functional movements like squats and lunges. Stretching exercises targeting key muscle groups like hamstrings will be incorporated to improve flexibility and range of motion. Gait training will focus on activities like side lunges, step-ups, and balance exercises to enhance walking ability and postural control. Additionally, the plan emphasized progressive challenges incorporating a mix of static and dynamic balance exercises using tools like foam pads or balance boards.
214898216|NCT02765997|BIOLOGICAL|Unmanipulated UCB|Unmanipulated UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
215052934|NCT05071612|DRUG|Atomoxetine Hydrochloride|Oral administration at bedtime
215052935|NCT05071612|DRUG|Placebo|Oral administration at bedtime
215052936|NCT04276194|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo intensity modulated proton therapy
214299236|NCT05173649|OTHER|Calisthenic Training|"Calisthenic Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Abductor-Adductor leg raise~2. Alternate toe touch~3. Knee Bend~4. Prone leg extension~5. Forward Lunges~6. Toe Raise/ Calf raise Progressive training include following exercises.~1\. Leg Lifts 2. Jack Twists 3. Side Lunges 4. Short bridge 5. Calf Raise with weight."
214299237|NCT05173649|OTHER|Neuromuscular Training|"Neuromuscular Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Up and down step exercise in posterior and lateral directions.~2. Walking in anterior and posterior~3. Directions with eyes opened and eyes closed.~4. Walking in lateral direction with eyes opened and eyes closed.~5. Standing on one extremity~6. Inclination in anterior and lateral direction with eyes opened and closed. Progressive training includes following exercises.~1\. Up and down on Bosu exercise. 2. Plantar flexion on minitrampoline. 3. Standing on one extremity on Bosu. 4. Standing on one extremity on minitrampoline"
214299238|NCT01909037|DIETARY_SUPPLEMENT|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
214299239|NCT02258100|OTHER|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
214299240|NCT00934739|DRUG|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
214478631|NCT05302219|OTHER|Respiratory rate|The participant alternates respiratory rates of 30, 15 and 7.5 breaths/min. Breathe each frequency for 2 minutes with a one-minute break.
214898217|NCT02765997|BIOLOGICAL|SR-1 UCB|SR-1 UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
214898218|NCT04977011|OTHER|relaxing music|30 minutes relaxing music for continuity 3 days since admission
214898219|NCT01268553|DRUG|Treprostinil|Transition to inhaled treprostinil
214898220|NCT01942577|DEVICE|NoSting|Each participant with get both interventions. The infant's NoSting treated thigh will be sprayed with NoSting following delivery and again at 7 days of age. A quarter 1.5 x 3 inch silicon patch that is applied to the infant's thighs will be used for data sampling.
215052937|NCT04276194|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215052938|NCT00003846|BIOLOGICAL|filgrastim|
215052939|NCT00003846|DRUG|carboplatin|
215052940|NCT00003846|DRUG|cyclophosphamide|
215052941|NCT00003846|DRUG|thiotepa|
215052942|NCT00003846|DRUG|vincristine sulfate|
214299241|NCT00934739|DRUG|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
214299242|NCT03362281|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
214299243|NCT03362281|DRUG|Omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
214299244|NCT03362281|DRUG|Ilaprazole tablet|Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
214898221|NCT05268653|BEHAVIORAL|Motivatıonal İnterviewing (Treatment Group)|Obese adolescents will be given a 6-session motivational interview.
214898222|NCT02687451|DRUG|Oxymorphone HCl|Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).
214898223|NCT02687451|DRUG|Placebo|Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
214898224|NCT02265094|OTHER|Electroencephalography|EEG recordings during memory tests
214898225|NCT02265094|BEHAVIORAL|Neuropsychological assessment|patterns of eye gaze during cognitive tests
214898226|NCT00149682|BEHAVIORAL|6-month educational program|
214898227|NCT00149682|BEHAVIORAL|6-month standard care program|
215052943|NCT00003846|PROCEDURE|bone marrow ablation with stem cell support|
214478632|NCT05302219|OTHER|Tidal volume|The participant alternates tidal volumes of approx. 2, 1 and 0.5 litres. Breathe each tidal volume for 2 minutes with a one-minute break.
214478633|NCT05302219|OTHER|Apnea|The participant simulates three apneic pauses lasting 1 minute with a two-minute break.
214898228|NCT02321111|DRUG|Eritoran|Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
214898229|NCT02321111|DRUG|D5W (5% Dextrose in water)|D5W = 5% Dextrose Water Vehicle
214898230|NCT03760692|DEVICE|i-gel|Evaluation of clinical performance in terms of insertion, ventilation and complications
214898231|NCT03760692|DEVICE|Ambu AuroGain|Evaluation of clinical performance in terms of insertion, ventilation and complications
214898232|NCT04304989|OTHER|mHealth program|mobile health applications
214898233|NCT04304989|OTHER|usual care|usual care
215052944|NCT00003846|PROCEDURE|peripheral blood stem cell transplantation|
215052945|NCT00003846|RADIATION|radiation therapy|
215052946|NCT04709679|PROCEDURE|MicroPulse TransScleral CycloPhotoCoagulation|A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
215052947|NCT00784368|DRUG|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
215052948|NCT00784368|DRUG|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
215052949|NCT01596855|DRUG|FG-4592|TIW dosing, capsule
215052950|NCT01596855|DRUG|Epoetin Alfa|TIW
215052951|NCT05625295|OTHER|data collection protocol in clinical history|collection of data from the clinical history according to the established protocol
215052952|NCT03696550|DRUG|Eravacycline (TP-434)|"Subjects will be stratified by age into 2 cohorts, as follows:~* Cohort 1: from 12 to \<18 years of age (N=8)~* Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)"
215052953|NCT00200707|PROCEDURE|Intracoronary injection of autologous bone marrow mononuclear cells|
215052954|NCT04194892|BIOLOGICAL|Pegilodecakin|Administered SQ
214299245|NCT03362281|DRUG|amoxicillin and clarithromycin|The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
214299246|NCT04309305|DEVICE|EksoGT™, Ekso Bionics, Berkley, CA, USA|The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking.
214299247|NCT04309305|OTHER|Standard of Care|Standard gait therapy provided by licensed physical therapists post stroke.
214478634|NCT04813172|BEHAVIORAL|Symptom Assessment|"Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H\&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit."
214478635|NCT06819501|DEVICE|hyperbaric oxygenation treatment|Administration of 100% oxygen at a pressure of 2.0ATA once daily for 60-90 minutes for a total of 30-40 times.
214669305|NCT01389128|OTHER|Non-pharmacological resources|"A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~* Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~* Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm."
214898234|NCT01799629|DRUG|Glycerin suppositories|
214898235|NCT02478944|DEVICE|Manometry|Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
214898236|NCT01125189|DRUG|Daclatasvir|Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
214898237|NCT01125189|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
215052955|NCT03254628|OTHER|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
215052956|NCT03254628|OTHER|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.
215052957|NCT03254628|BEHAVIORAL|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
215052958|NCT03254628|BEHAVIORAL|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
214299248|NCT04309305|OTHER|No Intervention|Testing Only
214299249|NCT06320132|OTHER|Treatment of spontaneous intracranial hemorrhage|Data collection of therapeutic approach, including radiological, medical, surgical therapies.
214898238|NCT01125189|DRUG|Placebo|Tablets, oral, 0 mg, once daily, 24 weeks
214898239|NCT01125189|DRUG|peg-interferon alfa-2a|Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
214898240|NCT01125189|DRUG|ribavirin|Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
214898241|NCT01396668|DRUG|gemcitabine, cisplatin, capecitabine|Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)
214898242|NCT00927589|DRUG|carboplatin|Intravenous repeating dose
214898243|NCT00927589|DRUG|docetaxel|Intravenous repeating dose
215052959|NCT03254628|DRUG|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
215052960|NCT03254628|DEVICE|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
214299250|NCT04625205|BIOLOGICAL|NEO-PTC-01|Administered via intravenous infusion.
214299251|NCT04625205|DRUG|IL-2|Administered via intravenous infusion.
214299252|NCT04625205|DRUG|PD-1 Inhibitors|Administered via intravenous infusion.
214299253|NCT06335810|BEHAVIORAL|Social Network Intervention|Social Network interventions are an intentional effort to modify or use the characteristics of social networks to improve, generate, and maintain healthy behaviors among individuals and populations. This study will focus on implementing a behavioral social-network intervention to promote changes in weight loss behaviors.
215052961|NCT03170570|DEVICE|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
215052962|NCT04729153|DRUG|DAAD Compound|Sofosbuvir , Daclatasvir and ribavirin
215052963|NCT04452747|PROCEDURE|Vaginal Dinoprostone system (Propess®)|Labour will be induced using the vaginal Dinoprostone system (Propess®) as a first strategy
215052964|NCT04452747|PROCEDURE|Dilatation balloon|Labour will be induced using a cervix dilatation balloon as a first strategy
215052965|NCT02079909|DRUG|T-817MA-H|224 mg or 448 mg T-817 MA once daily
215052966|NCT02079909|DRUG|T-817MA-L|224 mg T-817 MA once daily
215052967|NCT02079909|DRUG|Placebo|Placebo
214299254|NCT06335810|BEHAVIORAL|Individual Lifestyle Intervention|The individual lifestyle intervention will serve as the control group and will implement the use of DPP based health coaching sessions to promote individual level changes in weight loss behaviors.
214299255|NCT06335810|OTHER|Social Network Member|The social network member will serve as the friend, family member, or co-worker nominated to participate in the social network intervention by the social network intervention participant.
214299256|NCT03971188|PROCEDURE|Trapeziectomy with Internal Brace|Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
214299257|NCT02252198|OTHER|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2\*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
214299258|NCT05356494|OTHER|Postural drainage|(Group A will be treated with postural drainage)
214299259|NCT05356494|OTHER|Positive expiratory pressure|(Group B will be treated with positive expiratory pressure technique).
214299260|NCT03053076|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation
214299261|NCT03053076|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
214299262|NCT00315198|DEVICE|Eye Patch|2 hours daily patching
214478636|NCT06819501|BEHAVIORAL|routine care|Administration of pressurised ice gloves 30 minutes before, during, and 30 minutes after administering paclitaxel chemotherapy drugs.
214478637|NCT06819163|DIETARY_SUPPLEMENT|Berry leaf extract|The study foresees the intake of 2 capsules per day during 12 weeks
214478638|NCT06819163|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 12 weeks
214299263|NCT00315198|PROCEDURE|Near activities|near visual activities while patching
214478639|NCT03239613|OTHER|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
214478640|NCT06857292|DRUG|Telpegfilgrastim|"Experimental group: Patients were subcutaneously injected with Telpegfilgrastim 33μg/kg (maximum dose ≤2mg) 24h after chemotherapy, 21 days for one chemotherapy cycle, and only one chemotherapy cycle was observed.~Pharmacokinetic determination: Among them, 8 patients underwent pharmacokinetic determination. The pharmacokinetic sampling time points were blood samples taken before administration, 12 h, 24 h, 48 h, 120h, 168 h, 336 h, 480h after administration. A total of 8 blood samples were collected, and the pharmacokinetic characteristics of the experimental drugs were analyzed by ELISA."
214299264|NCT00315198|PROCEDURE|Distance activities|distance visual activities while patching
214299265|NCT01569490|BEHAVIORAL|Incentives for abstinence and treatment engagement|Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
214299266|NCT01569490|BEHAVIORAL|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
214299267|NCT03999450|BEHAVIORAL|brief motivational intervention (BMI)|The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
214478641|NCT06857721|DEVICE|Intraoral Scanners|Intraoral scanners for pediatric patients
214478642|NCT04532177|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
214478643|NCT06410157|BEHAVIORAL|Daily practice|Participants will be asked to undergo daily mindfulness practice while regulating (either increase or decrease) heart rate oscillation.
214898244|NCT00927589|DRUG|trastuzumab|Intravenous repeating dose
214898245|NCT04135092|BIOLOGICAL|Individual Patient TCR Transduced PBL|Day 0: Cells will be infused at a dose not to exceed .5e11 in 400 mL IV on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
214898246|NCT04135092|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
214898247|NCT04135092|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2 /day IVPB daily over 30 minutes for 5 days.
214898248|NCT04135092|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
214898249|NCT04135092|DRUG|Pembrolizumab|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Day -2 and then every 3 weeks until time of disease progression.
214898250|NCT04062669|BIOLOGICAL|Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the low dose (Ld-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) low dose formulation, administered intramuscularlyat Days 1 and 61.
214898251|NCT04062669|BIOLOGICAL|Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the medium dose (Md-) RG SAM (CNE) group will receive 1 doses of RG SAM (CNE) medium dose formulation, administered intramuscularly at Day 1.
214898252|NCT04062669|BIOLOGICAL|Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lower dose (Lrd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lower dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
214898253|NCT04062669|BIOLOGICAL|Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lowest dose (Ltd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lowest dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
214898254|NCT04062669|DRUG|Saline Placebo|Subjects in the Saline Placebo group will receive 2 doses of saline Placebo, administered intramuscularly Day 1 and 61.
214898255|NCT04062669|BIOLOGICAL|RabAvert|Subjects in the RabAvert Group will receive 2 doses of RabAvert vaccine, administered intramuscularly, at Days 1 and 61.
214898256|NCT05669404|BEHAVIORAL|Salt Restriction Group (SRG)|Patients assigned to the SRG continued to consume their usual diet, but they had to restrict their sodium intake to 2,000 mg/ day. They were given a detailed booklet containing information about table salt, foods rich in sodium, and practical ways to decrease salt consumption. During each 45-min individual session, they received intensive counselling and training to increase adherence to salt restriction. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
214299268|NCT03999450|BEHAVIORAL|cognitive behavioral therapy|This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
214299269|NCT02859207|DRUG|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
214299270|NCT04264598|BIOLOGICAL|sIPV|The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
214299271|NCT04264598|BIOLOGICAL|Commercialized sIPV|The commercialized sIPV was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.The antigen contents of type I, type II and type III polioviruses in the commercialized sIPV were 30 DU, 32 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
215052968|NCT02277249|DRUG|Digoxin (transvaginal administration)|"Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
215052969|NCT02277249|DRUG|Digoxin (transabdominal administration)|"Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
215052970|NCT05233501|PROCEDURE|low level laser therapy|adjunctive application of low level laser therapy to non-surgical periodontal treatment
215052971|NCT05233501|PROCEDURE|non-surgical periodontal treatment|standart periodontal therapy
214299272|NCT04264598|BIOLOGICAL|Commercialized IPV|The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.The antigen contents of type I, type II and type III polioviruses in the commercialized IPV were 40 DU, 8 DU and 32 DU. The vaccine was in liquid form, 0.5 ml per dose.
214299273|NCT03350633|DRUG|Tocilizumab Injection|Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.
214299274|NCT03350633|DRUG|Azathioprine|Azathioprine will be orally given at a dose of 2-3 mg/kg/d
214299275|NCT00778089|DEVICE|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
214299276|NCT06296108|OTHER|acute kidney injury|The incidence of acute kidney injury was determined in patients included to the study
214299277|NCT04680442|DRUG|Trastuzumab|Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
214299278|NCT04680442|DRUG|Pertuzumab|Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
214299279|NCT04680442|DRUG|Trastuzumab emtansine|Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
214478644|NCT06855979|OTHER|Food with high antioxidant potential|The dietary intervention using fruit and nut bars with high antioxidant activity will last 1 month. Before and after the procedure, oxidative-antioxidant markers in the blood and intestinal microflora in the stool will be determined.
214898257|NCT05669404|BEHAVIORAL|DASH Diet combined with salt restriction Group (DDG)|Patients assigned to the DDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the DASH diet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the DASH diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
215052972|NCT06517368|DEVICE|MRI, Ultrasound|The patients will undergo both B-mode and sonoelastographic examinations in the supine and lateral decubitus position and will perform during breath-holding after deep inspiration. The elastogram was displayed over the B-mode image in a color scale: red (greatest strain, softest tissue component), green (average strain, intermediate tissue component), and blue (no strain, hardest tissue component) Patients will be examined by MRI with diffusion images and ADC values.
215057478|NCT01116388|OTHER|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
215057479|NCT01116388|OTHER|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
215057480|NCT04677543|DRUG|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes.
215057481|NCT04677543|DRUG|Azithromycin|Oral tablet
215057482|NCT04677543|DRUG|Ethambutol|Oral tablet
214669306|NCT01389128|OTHER|Routine care|Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
214669307|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose under fasted conditions
214669308|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
214898258|NCT05669404|BEHAVIORAL|Mediterranean Diet combined with salt restriction Group (MDG)|Patients assigned to the MDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the MedDiet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the MedDiet diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
214898259|NCT03559972|OTHER|on-label facial injection|Assessing if adding SkinMedica's cosmetic topical skincare regimens improves the appearance of the skin and the subject's experience, when used after pre-elected on-label facial injection
214898260|NCT05832268|OTHER|Obstetric Anal Sphincter Injury|We will investigate if a new vaginal delivery in those with a previous obstetric anal sphincter injury affects the function of anal musculature negatively
214898261|NCT00920868|DRUG|dasatinib|dasatinib at 50 mg PO BID)
214898262|NCT00920868|DRUG|bevacizumab|7.5 mg/kg IV day 1
214898263|NCT00920868|DRUG|Oxaliplatin|130 mg/m2 IV day 1
214898264|NCT00920868|DRUG|Capecitabine|850 mg/m2 PO BID on days 1-14
214898265|NCT05927012|DRUG|KER-047|Oral tablet, daily (or every other day) administration
214898266|NCT02264769|DRUG|Carbetocin|
214898267|NCT02501122|OTHER|Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database|Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
214898268|NCT03942757|OTHER|bilirubin serum level determination|bilirubin serum level before and after phototherapy treatment will be measured
214898269|NCT03942757|OTHER|Phototherapy|Preterm infant \< 35 weeks of gestation with a jaundice requiring phototherapy according to NICE guidelines can be included for the duration of the phototherapy treatment.
214898270|NCT00707239|DRUG|tigecycline|An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
214898271|NCT00707239|DRUG|tigecycline|An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
214898272|NCT00707239|DRUG|imipenem/cilastatin|Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
214898273|NCT03295838|BEHAVIORAL|Mentalization-based treatment|See Arm description
214898274|NCT02593695|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
214898275|NCT02593695|OTHER|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
214898276|NCT02961595|BIOLOGICAL|Oral Polio Vaccine (OPV)|Serial Oral Polio Vaccine (OPV) was given to intervention group instead of inactivated poliovirus vaccine (IPV).
214898277|NCT04711538|DEVICE|MRI|imaging inner ear and petrous bone of the candidate by MRI and CT
214898278|NCT01651117|BEHAVIORAL|Peer Mentoring|Patients will receive peer mentoring.
214898279|NCT02386319|DRUG|Melatonin|Gelatin capsules
214898280|NCT02386319|DRUG|Placebo|Placebo capsules
214898281|NCT02714218|BIOLOGICAL|Nivolumab 3 mg/kg IV|Followed by Nivolumab monotherapy
214898282|NCT02714218|BIOLOGICAL|Ipilimumab 1 mg/kg IV|Followed by Nivolumab monotherapy
214898283|NCT02714218|BIOLOGICAL|Nivolumab 1 mg/kg IV|
214898284|NCT02714218|BIOLOGICAL|Ipilimumab 3 mg/kg IV|
214898285|NCT02714218|BIOLOGICAL|Nivolumab 6 mg/kg IV|A dose of 240mg is identical to a dose of 3mg/kg, therefore 6mg/kg is approximately equal to \~ 480mg.
214898286|NCT04670328|DIAGNOSTIC_TEST|not required|Diagnostic tests( hematological parameters) were assessed.
214898287|NCT06327139|DEVICE|Conventional 5 point closed face immobilisation mask.|The conventional closed face mask is a standard of care immobilization device for head and neck cancer patients which covers and immobilizes the entire anterior portion of the patients head, neck and shoulders using a semi rigid thermoplastic material.
214898288|NCT06327139|DEVICE|5 point open face immobilization mask|The 5 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face or chest. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the level of their clavicle.
214898289|NCT06327139|DEVICE|3 point open face immobilization mask|The 3 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the below the patients chin. The three point mask does not cover the patients shoulders and does not extend inferiorly to the level of the clavicle.
214898290|NCT05587010|DEVICE|AFO|ankle foot orthosis
214898291|NCT05587010|DEVICE|lycra sock|custom fitted lycra sock
214898292|NCT05587010|DEVICE|OrthPed splint|novel compression splint
214898293|NCT03494712|DRUG|S 95010|Single administration of S 95010 in healthy volunteers
214898294|NCT03494712|OTHER|Placebo|Single administration of placebo in healthy volunteers
214898295|NCT05303610|OTHER|Observational|This is a cross sectional study. The aim of the study is to evaluate the myofascial chain lines in addition to the general evaluation parameters in patients with patellofemoral pain syndrome (PFPS) and to determine whether deviations from normal in the myofascial structure have an effect on the development of PFPS.
215057483|NCT04677543|DRUG|ELC|Inhalation via nebulization over approximately 6 to 15 minutes.
214299280|NCT03505983|DEVICE|ESR Prosthetic Foot First|Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
214669309|NCT01059812|DRUG|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
214669310|NCT01059812|DRUG|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
214898296|NCT06261424|PROCEDURE|IMPACT - rehabIlitation prograM for sPAstiC aTaxias|The rehabilitation program will last 12 weeks and consists of three training sessions of 60 minutes per week (2 sessions in a therapy room and 1 session in an adapted pool with multiple levels of water) for a total of 36 sessions. Participants will be divided into 7 subgroups of 6 participants and each sub-group will be supervised by one physiotherapist (PT) and one physiotherapy technologist for safety considerations. It will focus on these three domains: 1) postural control; balance, trunk-limbs and multi-joints control and coordination and 3) functional mobility. Each domain contains a standardized list of exercises with different difficulty levels and specific times allocation. All exercises will be executed by the participants at each session at the appropriate difficulty level. The initial level of difficulty for each exercise will be determined by the PT based on individual results of the pre-intervention assessment and on individual performance, fatigue level and safety.
214898297|NCT05379413|DRUG|Botulinum toxin type A|Botulinum neurotoxin (BoNT) Type A injection with either OnaBoNT-A, AboBoNT-A, IncoBoNT-A
214898298|NCT05417841|DRUG|Insulin Degludec and Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp BID in T2DM
214898299|NCT05417841|DRUG|Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM
214898300|NCT02862236|DRUG|Hypericum perforatum extract|250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.
215052973|NCT01784367|DEVICE|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
215052974|NCT00470002|DRUG|Somatropin|
215052975|NCT00727545|OTHER|iron bisglycine chelate|
215052976|NCT00727545|OTHER|placebo|
215052977|NCT04579406|PROCEDURE|non-cardiac surgery|All the patients are undergoing non-cardiac surgery.
215052978|NCT02457650|DRUG|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
215052979|NCT02457650|DRUG|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
215052980|NCT02457650|BIOLOGICAL|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
215052981|NCT03798639|BIOLOGICAL|Ipilimumab|Given IV
215052982|NCT03798639|BIOLOGICAL|Nivolumab|Given IV
215052983|NCT03798639|RADIATION|Radiation Therapy|Receive radiation therapy
215052984|NCT00720356|DRUG|bevacizumab|10mg/kg administered intravenously every 2 weeks
215052985|NCT00720356|DRUG|erlotinib hydrochloride|150 mg/daily orally
215052986|NCT01869634|DRUG|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
215052987|NCT00290992|DRUG|rasburicase (SR29142)|
215052988|NCT03474263|BIOLOGICAL|Biologic: IC14 (monoclonal antibody against human CD14)|IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
215052989|NCT03045614|OTHER|No intervention|No intervention
215052990|NCT01244230|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
215052991|NCT04059081|DRUG|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
215052992|NCT02075294|DRUG|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
215052993|NCT01713582|DRUG|OTX015/Birabresib|OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
215052994|NCT05221996|BEHAVIORAL|Resistance training|Resistance circuit training
215052995|NCT04426175|DEVICE|2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting|2D and 3D cutting methods were randomly used in same subjects
214299281|NCT03505983|DEVICE|Articulating ESR Prosthetic Foot First|Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
214299282|NCT03505983|DEVICE|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
214669311|NCT03433066|PROCEDURE|Advanced platelet-rich fibrin mixed with biphasic alloplast|mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.
214299283|NCT06407518|DRUG|Midazolam oral solution|Each individual administers the midazolam oral solution nightly from enrollment to the surgry.
214299284|NCT06407518|OTHER|Placebo|Each individual administers placebo solution nightly from enrollment to the surgry.
214299285|NCT04124289|OTHER|Pain measurement using 3 scales|Patients will assess their pain after surgery using three different pain scales.
214299286|NCT00503087|PROCEDURE|Saline Injection|
214299287|NCT00503087|DEVICE|Pneumatic Skin Flattening (PSF)|
214299288|NCT02496832|DRUG|18F-Fluoroazomycin arabinoside|
214299289|NCT00991055|DRUG|Pioglitazone|"A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)"
214299290|NCT00604331|DRUG|Pyruvate|sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
214299291|NCT04294511|DRUG|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
214299292|NCT05982626|RADIATION|68Ga/131I-SGMIB-ZT-199|68Ga-SGMIB-ZT-199: PET imaging; 131I-SGMIB-ZT-199: SPECT imaging.
214299293|NCT00619801|DRUG|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
214299294|NCT00619801|DRUG|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
214299295|NCT05931354|OTHER|HPV test and Pap Smear|HPV test and Pap Smear
214299296|NCT02516215|OTHER|No intervention|
214299297|NCT05729659|DIETARY_SUPPLEMENT|Sideritis Scardica (SidTea+) extract supplementation|1500 mg of Sideritis Scardica (SidTea+) extract per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
214299298|NCT05729659|DIETARY_SUPPLEMENT|Placebo supplementation|1500 mg of placebo per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
214299299|NCT05815472|DEVICE|Fitbit charge|Internet of Things Technologies Device
214299300|NCT05625672|OTHER|Training|Hemovigilance module training
214299301|NCT02066974|GENETIC|hepatoma requiring radiotherapy|hepatoma requiring radiotherapy
214299302|NCT03352830|BEHAVIORAL|RANAS Behavior Change Intervention|The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.
214299303|NCT03352830|OTHER|Infrastructural Intervention - Direct Delivery|Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
214299304|NCT03750812|BEHAVIORAL|Aerobic Exercise|Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes
214299305|NCT03750812|BEHAVIORAL|Watching television|Sitting and watching television for 30 minutes
214299306|NCT01901198|BIOLOGICAL|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
214299307|NCT01901198|BIOLOGICAL|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
214299308|NCT02548494|DRUG|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
214299309|NCT02548494|DRUG|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
214299310|NCT02548494|OTHER|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
214299311|NCT02548494|OTHER|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~* Administer 1-3 L during the first hour.~* Administer 1 L during the second hour.~* Administer 1 L during the following 2 hours~* Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
214299312|NCT00000210|DRUG|Buprenorphine|
214299313|NCT03732001|DRUG|Anlotinib combined Docetaxel|Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
214299314|NCT03732001|DRUG|Docetaxel|Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
214299315|NCT03867305|DEVICE|MOBIDERM|Use of a MOBIDERM mobilizing band after total knee prosthesis
214299316|NCT05062681|DRUG|Dexamethasone|Patients will receive dexamethasone 8 mg q12hours
214299317|NCT05062681|DRUG|Methylprednisolone|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
214299318|NCT06391723|DEVICE|Active rTMS|rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session)
214299319|NCT06391723|DEVICE|Sham rTMS|Sham rTMS will be administered over the left dorsolateral prefrontal cortex
214669312|NCT03433066|PROCEDURE|Biphasic alloplast mixed with saline|mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.
214299320|NCT06385223|DEVICE|Beam F3 targeted accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
214299321|NCT06385223|DEVICE|Individualized connectome-guided accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
214898301|NCT03164018|DRUG|Fampridine|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments and management of the disease will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behavior.
215052996|NCT03567967|BEHAVIORAL|Fruit and vegetable voucher|Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
215052997|NCT02193009|BEHAVIORAL|SipSmarter|6-month behavioral trial
215052998|NCT02193009|BEHAVIORAL|MoveMore|6 month behavioral trial
214299322|NCT01106898|DRUG|cyclophosphamide|Given IV
215052999|NCT03085459|BEHAVIORAL|work Time|nurse got qualification certificate and the working time
215053000|NCT04930835|PROCEDURE|Implant supported dentures|Placement of dental implants with different loading protocols for supporting full arch dentures.
215053001|NCT02210988|OTHER|acupuncture|Intervention with acupuncture
215053002|NCT04725045|DEVICE|Boston Scientific: Study tool computer|compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
215053003|NCT01887730|BEHAVIORAL|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
215053004|NCT01887730|BEHAVIORAL|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
215053005|NCT01887730|BEHAVIORAL|Control|
215053006|NCT05230446|DEVICE|PCI with OCT guidance|Procedure will be optimize using pre-and post-stent OCT imaging, to improve the accuracy of stent placement and reduce geographic miss, but also to prevent malapposition of the stent and to discover dissections.
214299323|NCT01106898|DRUG|paclitaxel|Given IV
215053007|NCT04737434|DEVICE|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
214299324|NCT01106898|BIOLOGICAL|trastuzumab|Given IV
214299325|NCT01106898|OTHER|laboratory biomarker analysis|Correlative studies
214299326|NCT00999791|DRUG|Bevacizumab|
214299327|NCT00999791|DRUG|Diclofenac|
214299328|NCT03864250|DRUG|Tacrolimus|The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.
214898302|NCT05951803|BEHAVIORAL|Brief Behavioral Intervention in Insomnia|Weekly intervention of 4 sessions where behavior therapy techniques are administered, such as stimulus control, sleep hygiene, sleep restriction and progressive muscle relaxation. Each session lasts 60 minutes.
214898303|NCT00372684|GENETIC|with severe malaria hospitalized in ICU|with severe malaria hospitalized in ICU
214898304|NCT00372684|GENETIC|with uncomplicated malaria|with uncomplicated malaria
214898305|NCT03984864|OTHER|Exercise therapy|3-4 items from a list of 10 general exercises - intended for treatment of low back pain
215053008|NCT04737434|DEVICE|electromagnetic field with no wave|electromagnetic field with no wave
214299329|NCT03864250|DRUG|Prednisone|The initial dose of prednisone is 0.5 mg/kg/d orally (maximum dose 40 mg/d), and after 8-12 weeks, the dose was gradually reduced until discontinuation. TAC treatment is given at the same time (the treatment plan is the same as the experimental group).
214299330|NCT06179797|DEVICE|remote ischemic conditioning|suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.
214299331|NCT02968927|DRUG|Everolimus 0.5 MG|
214299332|NCT02968927|DRUG|Auranofin 6 MG|
214299333|NCT02968927|DRUG|Vitamin D3|
214299334|NCT02968927|DRUG|CC-11050|
214299335|NCT02968927|DRUG|2HRbZE/4HRb|
214299336|NCT03176329|OTHER|Nursing 1 : INTELLIVENT-ASV|
214299337|NCT03176329|OTHER|Nursing 2 : INTELLIVENT-ASV|
214299338|NCT03176329|OTHER|Nursing 1 : Conventional mode|
214299339|NCT03176329|OTHER|Nursing 2 : Conventional mode|
214299340|NCT00090311|DRUG|quetiapine fumarate|
214299341|NCT03689803|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy.
214299342|NCT03689803|PROCEDURE|gastric bypass|gastric bypass
214299343|NCT04728061|DRUG|Gen1E-1124|Intravenously-infused Gen1E-1124 in vehicle.
215053009|NCT00062855|PROCEDURE|Skin Biopsy|
214299344|NCT04728061|DRUG|Placebo|Intravenously-infused vehicle.
214299345|NCT06371118|DEVICE|Directly mailed self-sampling kit to collect a vaginal sample|"The HPV self-sampling test will be sent by post directly to the woman's address. If the woman does not return the sample within 20 days, she will be sent a SMS reminder.~The returned samples will be analysed. If high-risk HPV is present, women will be invited to be screened for cervical cancer in a clinical setting by their family doctors.~Self-samples in which high-risk HPV is present will also be subjected to HPV DNA methylation test. If an abnormal HPV DNA methylation is detected and the woman has not attended the screening in a clinical setting yet, she will be informed by her family doctor that a new test has indicated the need to attend a medical appointment."
214299346|NCT06371118|DEVICE|Mailed self-sampling kit to collect a vaginal sample after opt-in prodecure|"Women will initially receive an invitation letter in their home addresses to receive the self-sampling kit, as well as a pre-paid envelope to return the answer to this invitation. If the woman does not return the answer within 10 days, she will be sent a SMS reminder. Only those who respond affirmatively to the question will receive the self-sampling kit.~The steps that follow will be the same as in intervention 1."
214299347|NCT06371118|DIAGNOSTIC_TEST|Standard of care - screening in a clinical setting|Corresponds to the standard of care. An invitation to attend the conventional cervical cancer screening (clinician-collected cervical sample for HPV test and reflex cytology) will be sent by post to the woman's address.
214299348|NCT01255657|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
215053010|NCT00062855|GENETIC|Gene Modified Neuroblastoma Cells|"The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.~A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).~At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received."
215053011|NCT00025571|DRUG|HPPH|
215053012|NCT04254692|DRUG|Liposomal bupivacaine|Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
214299349|NCT01351844|BEHAVIORAL|Education and exercise intervention|An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
214669313|NCT01878565|DRUG|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
214669314|NCT01878565|DRUG|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
215053013|NCT04254692|OTHER|Standard of care|Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
215053014|NCT03629665|BEHAVIORAL|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
215053015|NCT03629665|DEVICE|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
215053016|NCT05410925|DRUG|Recombinant staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
214299350|NCT01351844|BEHAVIORAL|Education and General Exercise|A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
214299351|NCT00622479|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib will be administered at 400mg BID for a 28 day cycle.
214299352|NCT01698801|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
214299353|NCT01698801|DRUG|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
214299354|NCT04080817|DEVICE|Neolexon|Application (Neolexon) on Tablet. Same frequency \& intensity as in the other interventions
214299355|NCT04080817|OTHER|Speech therapy|standard logopedic speech therapy. Same frequency \& intensity as in the other interventions
214299356|NCT04080817|OTHER|Self training|Same frequency \& intensity as in the other interventions
214478645|NCT06855901|DEVICE|Ultra-longterm EEG monitoring at home by means of a scubscalp electrode implant.|"Subjects with uncontrolled seizures previously investigated in outpatients epilepsy clinics and for whom an admission to the Epilepsy Monitoring Unit is indicated by clinical practice, will be screened for eligibility.~Implantation of subcutaneous EEG electrodes will be done at each Research Unit by a neurosurgeon/surgeon. The implantation procedure will consist of placing subcutaneously the electrode contacts over the site of the suspected seizure focus as defined by a previous Video-EEG and neuroimaging evaluations. Surgical procedures will be performed under local anesthesia. If the device is well-tolerated, all the subjects will proceed to the extended home monitoring study, which is the core of the study protocol. The aim of the extended study is to assess sensitivity of seizure detection of sqEEG in comparison to subject's home diary, and the tolerability and safety of sqEEG in a period of 6 months."
214478646|NCT06856876|OTHER|Multidisciplinary Care Team (MDCT) Approach|A personalized breast cancer treatment plan developed through regular case discussions by a team of radiologists, oncologists, and surgeons. The MDCT coordinates patient support services and tracks treatment progress according to evidence-based guidelines.
214299357|NCT02467010|DRUG|Bortezomib|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
214669315|NCT01521845|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
214669316|NCT00298532|PROCEDURE|Advanced Life Support|
214898306|NCT04956744|BIOLOGICAL|IMS001|IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).
214898307|NCT04377204|DRUG|marcaine bupivacaine|This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
214898308|NCT04377204|DRUG|Lidocaine|This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
214898309|NCT02545569|DEVICE|hearing aid (MD class IIa) - ITE, BTE, RIC|Hearing aid means any wearable instrument or device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing.
214898310|NCT02738918|DRUG|Nulojix (Belatacept)|Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12
214898311|NCT04316338|DEVICE|Intermittent theta-burst stimulation (iTBS)|Non-invasive brain stimulation technique
214898312|NCT01113892|DEVICE|vascular grafts|All devices will be used to treat patients with peripheral arterial occlusive disease
214898313|NCT01307865|DRUG|injectable poly-L-lactic acid|Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
214898314|NCT01656460|RADIATION|Stereotactic radiation Arm 1|"Dose Levels Dose per Fraction Total Dose~1 8 Gy 16 Gy"
214898315|NCT01656460|RADIATION|Stereotactic radiation Arm 2|Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
214898316|NCT01656460|RADIATION|Stereotactic radiation Arm 3|Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
214898317|NCT01656460|RADIATION|Stereotactic radiation Arm 4|Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
214898318|NCT03359616|PROCEDURE|Transanally curable surgical resection|Transanally, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
214898319|NCT03359616|PROCEDURE|Laparoscopic total mesorectal excision|Conventionally by laparoscopic surgery, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
214898320|NCT03822091|DRUG|Terlipressin|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, and randomised into group A and B. Group A patients will receive further higher doses of Terlipressin. The dose of Terlipressin will be increased by 1mg after 24 hrs if:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours.~Maximum terlipressin dose will be given upto 12 mg/day.Albumin will be administered in both arms according to standard protocol at the following dose :~1. 1st day - Albumin at 1 gram/kg - a maximum dose of 100grams can be given.~2. A dose of 20gram/day to 60gram/day in the following days."
214898321|NCT03822091|DRUG|Terlipressin and Noradrenaline|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, will be randomised into group A and B. Group B patients will be treated with~Terlipressin(2mg/24hr infusion- fixed dose) and Noradrenaline, which would be given as a continuous infusion at a starting dose of 0.5 mg/hr. The dose od noradrenaline will be increased every 24 hours in steps of 0.5 mg/hr, the maximum dose being 3 mg/hr IF:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours."
214898322|NCT00656656|DRUG|Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine|"Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks~Rituximab: 1000 mg i.v. given twice at a 2-week interval~Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks~Azathioprine: 2.5 mg/kg body weight daily p.o."
215053017|NCT05410925|DRUG|Placebo|Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
215053018|NCT04551898|DRUG|BGB-DXP593|Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
215053019|NCT04551898|DRUG|Placebo|Placebo to match BGB-DXP593 administered as specified in the treatment arm
215053020|NCT01393483|OTHER|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
214898323|NCT05516680|DEVICE|electro-acupuncture|Acupoints consist of Neiguan (PC6, bilateral), Shuigou (GV26), Sanyinjiao (SP6, affected side), Yintang (EX-HN3), Shangxing (GV23), Baihui (GV20), and Sishencong (EX-HN1). Disposable stainless-steel needles (0.25mm× 40 mm）will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensation of achiness, heaviness, and numbness (known as de qi) at all acupoints. Following needle manipulations, electroacupuncture instruments(SDZ-V) will be used to attached the needle handles at EX-HN3, GV23, GV20 and EX-HN1 with a dilatational wave of 5 \~ 10 Hz and a current intensity of 1 \~ 3 mA depending on the patient's tolerance. The needles will be removed after 30 minutes except for GV26 without needle retention. Participants will receive 12-20 electroacupuncture sessions over four weeks at a frequency of 3-5 times per week.
214898324|NCT05516680|DEVICE|MRI-navigated rTMS|MRI:All MRI scans were taken to acquire high-resolution T1-weighted anatomical images on the 3T MRI Scanner. Electromyography(EMG):Surface EMG was used to record MEPs from the abductor pollicis brevis for determining RMT of the non-lesioned motor cortex.A single TMS pulse was delivered to the location to identify the RMT,defined as the minimum intensity capable of evoking at least 5 MEPs of \>50 μV in 10 consecutive trials.MRI-navigated rTMS:Using BrainSight system,left DLPFC targeting was individualized by reconstructing MRI data into a 3-dimensional brain image for neuro-navigation. Left DLPFC localization was central middle frontal gyrus,between superior frontal sulcus and middle frontal sulcus based on T1-weighted anatomical images.Focal rTMS was administered using a Magstim Rapid 2 connected to Y125-round coil that was identical.rTMS was applied at 110% RMT to the left DLPFC.At each session,3000 pulses were applied at 10 Hz with a total of 12-20 rTMS sessions over a 4-week period.
214898325|NCT03527069|DRUG|Cipros 10 association|oral, once a day.
214898326|NCT03527069|DRUG|Crestor 10 mg|oral, once a day.
214898327|NCT02923778|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214898328|NCT02923778|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214898329|NCT02923778|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214898330|NCT02923778|RADIATION|Radiation Therapy|Undergo radiation therapy
214898331|NCT02923778|BIOLOGICAL|Talimogene Laherparepvec|Given IT or via intralesional injection
214898332|NCT05968261|PROCEDURE|Real time 'near remote' guidance of regional blocks|Trainees who are to perform regional blocks will do so under expert guidance via tele-mentoring. This will be done using a novel technology consisting of a wirelessly linked iPad which will display the ultrasound image to the block operator/trainee. This image will be concurrently visualized by an expert mentor through their smartphone, who will then provide feedback/guidance in real-time to the operator/trainee.
214898333|NCT06399185|DRUG|Normal saline|20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
214898334|NCT06399185|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.
214898335|NCT06399185|DRUG|Esketamine|Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
214898336|NCT06399185|DRUG|Combined dexmedetomidine-esketamine|Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
214898337|NCT02603887|OTHER|Laboratory Biomarker Analysis|Correlative studies
214898338|NCT02603887|BIOLOGICAL|Pembrolizumab|Given IV
214898339|NCT05334641|OTHER|Listening Music|The patients in the experimental group were listened to music.
214898340|NCT05334641|OTHER|Not Listening Music|The control group was not listened to music.
214898341|NCT03935698|OTHER|Physiotherapy|
214898342|NCT04539002|BEHAVIORAL|Aerobic exercise|Aerobic exercise performed on a stationary ergometer for 30 minutes, thrice weekly, with graded supervision. Participants will participate in the intervention over 24 weeks.
214898343|NCT04539002|BEHAVIORAL|Education Group Control|A monthly, hour-long, class over various MS topics and symptoms, led by a trained facilitator.
214898344|NCT04629040|OTHER|Lateral wedge insole|Lateral wedge insole for knee osteoarthritis patient
214898345|NCT04629040|OTHER|Ordinary insole|Ordinary insole
214898346|NCT00137150|PROCEDURE|Placement of implants|
214898347|NCT05611983|BEHAVIORAL|sensory relearning|feasibility of early sensory relearning
214898348|NCT04390919|OTHER|elevated monocyte count|The monocyte count at admission was higher than 0.445×10\*9 cells/L
214898349|NCT05236114|OTHER|Observation|No intervention
214898350|NCT06668168|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|25g ketone ester 3x/day. The ketone ester will be a beta-hydroxybutyrate monoester \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate\].
215053021|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
214898351|NCT06668168|BEHAVIORAL|Ketogenic diet|Ketogenic diet (\<50 g carbohydrate per day)
214898352|NCT06547086|DEVICE|Transcranial electrical stimulation with Temporal Interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
214898353|NCT06976723|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
214898354|NCT05017025|DRUG|Aurora A Kinase Inhibitor LY3295668|Given PO
214898355|NCT05017025|DRUG|Osimertinib|Given PO
214898356|NCT05264025|DRUG|Fexofenadine|tablet
214898357|NCT05264025|DRUG|Placebo|tablet
215057484|NCT03074201|PROCEDURE|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
215057485|NCT03074201|DEVICE|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
214898358|NCT05326230|DEVICE|Paradise™ (PRDS-001) Renal Denervation Ultrasound System|Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control
214299358|NCT02467010|DRUG|Cyclophosphamide|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
214299359|NCT02467010|DRUG|Dexamethasone|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
214299360|NCT04667767|OTHER|WASH kit|WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.
214478647|NCT06856876|OTHER|Standard Breast Cancer Therapy|Breast cancer treatment provided according to the institutional protocols at Hayatabad Medical Complex, including standard surgery, chemotherapy, and/or radiotherapy as clinically indicated.
214478648|NCT06856980|PROCEDURE|Suture button fixation|Patients undergoing suture button fixation of syndesmosis injury.
214478649|NCT06856980|PROCEDURE|Syndesmotic screw fixation|Patients undergoing syndesmotic screw fixation of syndesmosis injury.
214478650|NCT06856603|RADIATION|stereotactic radiation therapy in ablative doses to each metastatic site|Stereotactic ablative radiation therapy will be utilized for each metastatic site in patients with 6 to 10 sites of metastasis (persistent or progressive disease).
214478651|NCT06855823|DRUG|Golicitinib combined with Pomadomide|golidoctinib 150 mgqd, pomalidomide 2mg/3mg/4mgqd
215053022|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
215053023|NCT02112643|DRUG|Sodium selenate|A 100 microgram pill will be orally administered twice a day for 6 months.
215053024|NCT02112643|DIETARY_SUPPLEMENT|Sugar pill|The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
215053025|NCT02824393|BIOLOGICAL|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
215053026|NCT01741493|DRUG|ABT-494|Oral administration of ABT-494 capsules
215053027|NCT01741493|DRUG|Placebo|Oral administration of placebo capsules
215053028|NCT01741493|DRUG|Tofacitinib|Oral administration
214478652|NCT06818981|DRUG|8mg dexamethasone|Minimal research exists on how to treat pain, odynophagia, and dysphagia in sleep surgery patients. One study by Williams et al. evaluated the use of a one-time dose of intravenous or intramuscular dose of steroids versus placebo after uvulopalatopharyngoplasty but did not find a clinically significant difference between the two groups postoperatively. However this study mentioned that their current intervention was too short and that a longer-term steroid intervention could be beneficial. This is the goal of this intervention.
214478653|NCT06816888|OTHER|No Prompt|Presence and type of message included in the prompt will be randomized
214898359|NCT05326230|DEVICE|Renal Angiogram|Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure
214898360|NCT04025398|BEHAVIORAL|Cognitive remediation program|Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
214898361|NCT04025398|BEHAVIORAL|Control group|"Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)"
214299361|NCT04667767|OTHER|Standard treatment|National standard outpatient treatment for uncomplicated severe acute malnutrition
214299362|NCT03326258|DRUG|Glembatumumab Vedotin|Given IV
214898362|NCT03627988|OTHER|Patients with invasive breast cancer will receive:|"* Mastectomy with Immediate prosthetic breast reconstruction~* Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy)."
214898363|NCT04028557|OTHER|Decision Support Systems, Clinical|Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
215053029|NCT02155101|DRUG|Darunavir|Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.
215053030|NCT02155101|DRUG|ART with 2 NRTIs plus LPV/r (or ATV/r)|Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
215053031|NCT04649216|DRUG|PCO371|PCO371 Capsule
214299363|NCT03326258|BIOLOGICAL|Ipilimumab|Given IV
214299364|NCT03326258|OTHER|Laboratory Biomarker Analysis|Correlative studies
214299365|NCT03326258|BIOLOGICAL|Nivolumab|Given IV
214299366|NCT03326258|OTHER|Pharmacological Study|Correlative studies
214299367|NCT01778829|PROCEDURE|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
215053032|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Oral solution
215053033|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Solution for infusion
215053034|NCT01424358|OTHER|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
215057486|NCT05287776|DEVICE|Narrow band UVB|Narrow band UVB emitting UVB at wavelength 311nm
214299368|NCT01778829|PROCEDURE|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
214299369|NCT01991457|DRUG|Fludarabine|
214299370|NCT01991457|PROCEDURE|Total Body Irradiation|
214299371|NCT03852641|OTHER|Length of feeding|Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
214299372|NCT03642236|DRUG|Ibrutinib|Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
214299373|NCT01306357|DRUG|Somatropin|4 mg or 10 mg delivered by needle-free device
214299374|NCT01988857|BIOLOGICAL|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
214299375|NCT02567942|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation
214299376|NCT02567942|DRUG|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
214299377|NCT04366076|DIAGNOSTIC_TEST|Fetal heart rate (FHR) monitoring through computerized cardiotocography (cCTG) analysis antepartum|The investigator conducted antepartum surveillance through computerized cardiotocography (cCTG) analysis antepartum. This is a non-invasive method to study fetal well being. For each patient, a cCTG was attended using a computerized cardiotocography machine. External cCTG was practised for no less than 20 min (max 60 min), two transducers were fixed on the maternal abdomen: one above the fetal heart level and the other at the uterine fundus
214299378|NCT05058300|DEVICE|CT Thorax|CT Thorax (GE Revolution with chest pain algorithm)
214299379|NCT03946384|OTHER|data collection|data collection on the history of the disease, hemophilia
214299380|NCT00751244|BEHAVIORAL|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
214898364|NCT03825224|PROCEDURE|Diagnostic Test: Myostrain|This test measures the contraction of the heart muscle in one to three heartbeats per plane. It's a pulse sequence that produces images that reveal the underlying contraction fo the muscle of a healthy heart and associated weaknesses in case of disease.
214898365|NCT03348618|BIOLOGICAL|IVIG|Intravenous immunoglobulin
214898366|NCT06062550|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative intravenous analgesia.
214299381|NCT00751244|BEHAVIORAL|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
214898367|NCT05115695|OTHER|traditional physiotherapy approach|Traditional upper extremity strengthening and tonus regulation (weight shifting, weight bearing, active reaching in sitting exercises) exercises consisting of Neurodevelopmental Therapy (NDT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
214898368|NCT05115695|OTHER|muscle strengthening exercise/Proprioceptive Neuromuscular Facilitation (PNF)|Muscle strengthening with scapular and upper extremity patterns of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
214898369|NCT02776943|BIOLOGICAL|umbilical cord mesenchymal stem cells|
214898370|NCT02776943|DEVICE|Hyaluronic acid|
214898371|NCT01903798|DRUG|Mycophenolate mofetil|Immunosuppressive agent
214898372|NCT01903798|DRUG|Prednisolone|Corticosteroid
214898373|NCT01903798|DRUG|Rilonacept|
214898374|NCT00356226|DRUG|clonidine|
214898375|NCT01123057|PROCEDURE|riboflavin-induced collagen cross-linking treatment|"The principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment.~The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application."
214299382|NCT00751244|OTHER|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
214299383|NCT01655550|OTHER|Withhold oral contrast|The intervention is to withhold oral contrast
214299384|NCT03643640|BEHAVIORAL|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
214299385|NCT03643640|OTHER|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
214299386|NCT04379882|DEVICE|Digital Sedation (Silva)|Use of Digital Sedation (virtual reality associated with psychological interventions) for preoperative anxiety management
214299387|NCT02415751|BEHAVIORAL|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
214478654|NCT06816888|OTHER|Prompt 1|Presence and type of message included in the prompt will be randomized
214478655|NCT06816888|OTHER|Prompt 2|Presence and type of message included in the prompt will be randomized
214478656|NCT06820112|OTHER|mechanical ventilation|patients who received mechanical ventilation
214478657|NCT06856811|PROCEDURE|tmj lavage with ringer lactate solution|tmj lavage using 150ml ringer lactate in symptomatic side of unilateral anterior disc displacement with reduction
215057487|NCT02902445|BIOLOGICAL|rotavirus rapid screen test|According to routine care
214299388|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with fish oil capsules (3 capsules daily. Containing EPA+DHA: 1.8 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: EPA+DHA: 1.8 g.
214299389|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with chia/linseed oil capsules (3 capsules daily. Containing ALA 1.6 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: ALA 1.6 g).
214299390|NCT01929850|PROCEDURE|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
214898376|NCT01123057|DEVICE|Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia|Use of riboflavin eyedrops during the procedure Use of UVA device (Peschke Meditrade)
214898377|NCT03618017|BEHAVIORAL|CCC website|ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
214299391|NCT01929850|BEHAVIORAL|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
214299392|NCT02188212|DEVICE|NobelProcera Crown Shaded Zirconia|
214299393|NCT02062879|DRUG|Ketamine|Ketamine administered as patient-controlled analgesia.
214299394|NCT02062879|DRUG|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
214299395|NCT00647790|PROCEDURE|PET scan with injection of 5-8 mCi of 18FES|Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
214299396|NCT01109654|DRUG|Cetrorelix acetate and Follitropin alfa|Cetrorelix acetate given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection.Ovarian stimulation therapy with Follitropin alfa generally starts on cycle Day 2 or 3. The starting dose of Follitropin alfa is based on the Investigators' discretion
214299397|NCT00035620|DRUG|pegfilgrastim|pegfilgrastim
214299398|NCT00035620|DRUG|filgrastim|filgrastim
214299399|NCT01114321|BEHAVIORAL|Protein and calorie controlled diet|Protein and calorie controlled diet Self-hypnotic relaxation
214299400|NCT03181204|PROCEDURE|Bronchial biopsy|The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
214299401|NCT03181204|PROCEDURE|Skin biopsy|The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
214299402|NCT03181204|PROCEDURE|Blood sample|The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
214299403|NCT02344160|OTHER|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
214299404|NCT04053192|PROCEDURE|BAV|BAV
214299405|NCT04053192|PROCEDURE|BAV + TAVR|BAV + TAVR
214299406|NCT04053192|PROCEDURE|SAVR|Surgical aortic valve replacement (SAVR)
214299407|NCT03487757|OTHER|Core Stabilization Exercises|Jeffrey's core stabilization exercise training protocol will be performed to the training group. This protocol includes exercises progressing gradually from level 1 to level 3. Level 1; static contraction training on a stable surface, level 2; dynamic training on a stable surface, level 3; dynamic and resistant training on an unstable surface.
214299408|NCT03487757|OTHER|No Intervention|Since no training is given to the control group during the study period, it is ethically necessary to give the same training to the control group if the benefit is achieved when the study is completed.
214299409|NCT01073982|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
214478658|NCT06659536|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device|Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar URO device using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling.
214478659|NCT06658197|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg) plus mechanical thrombectomy
214478660|NCT06658197|DRUG|Alteplase|Alteplase 0.9 mg/kg administered as 10% bolus +90% infusion/1 hour (maximum dose 90mg) plus mechanical thrombectomy
214478661|NCT04214834|DRUG|Morphine|The dose interval for morphine will be either every 3 or 4 hours, per hospital practice. Clinical teams are asked to wean study drug at least every 24 hours.
214898378|NCT03618017|BEHAVIORAL|Static care plan|"The control is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
214898379|NCT03143790|PROCEDURE|Extracorporeal Shockwave Terapy|Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
214299410|NCT06018259|PROCEDURE|healthy volunteers blood sampling|One blood sample will be taken from healthy volunteers in order to isolate PBMC and to assess the effect of the lipid of interest on them PBMC will be activated in vitro (e.g. using LPS or PHA) in the presence or absence of the lipid of interest.
214299411|NCT03256539|BEHAVIORAL|Sleep intervention|Behavioral sleep intervention program
214898380|NCT04331613|BIOLOGICAL|CAStem|CAStem will be administered intravenously.
214898381|NCT00423878|DRUG|Risperidone|Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
214898382|NCT00423878|DRUG|Olanzapine|Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
214898383|NCT00423878|DRUG|Quetiapine|Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
214898384|NCT00423878|DRUG|Aripiprazole|Switching medication to aripiprazole for schizophrenia for up to 6 months in study
214898385|NCT00681343|DRUG|Thymoglobulin|Induction
214898386|NCT00681343|DRUG|Campath-1H|Induction
214898387|NCT00681343|DRUG|Daclizumab|Induction
214898388|NCT03438838|PROCEDURE|Laparoscopic Heller's myotomy|"Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach"
214898389|NCT03438838|PROCEDURE|Anterior Fundoplication|The Fundus was sutured with 3 stitches on either side of the esophagus to right and left crus of diaphragm using ethibond(1-0) beside intervening stitch over esophagus. Width of fundoplication is kept approximately at 2cm. The proximal short gastric vessels were divided only if the fundus is insufficiently mobile
214898390|NCT05161338|DIAGNOSTIC_TEST|MICROBIOME GENETIC ANALYSIS|Vaginal samples will be taken. A floxed nylon swab will be rotated against the posterior vaginal wall, Nucleic acid extraction and genetic analisys will be performed
214898391|NCT05161338|DIAGNOSTIC_TEST|VAGINAL PH VALUE|Intravaginal Ph value meassurement.
214898392|NCT05161338|DIAGNOSTIC_TEST|SERUM PROGESTERONE LEVELS|Determination of serum P4 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day-.
214898393|NCT05161338|DIAGNOSTIC_TEST|SERUM OESTRADIOL LEVELS|Determination of serum E2 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day.
215053035|NCT03166852|OTHER|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
215053036|NCT03690401|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.
215053037|NCT03690401|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
215053038|NCT01647698|BEHAVIORAL|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
215053039|NCT01647698|BEHAVIORAL|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
214299412|NCT03256539|BEHAVIORAL|Placebo intervention|Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
215053040|NCT01647698|BEHAVIORAL|No training|No training during the experiment.
215053041|NCT05840835|DRUG|IMX-110 combined with Tislelizumab|Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
215053042|NCT01898286|DRUG|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
215053043|NCT01201928|DRUG|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
215053044|NCT01201928|DRUG|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
215053045|NCT03245346|DRUG|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
214898394|NCT00850811|DRUG|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
214898395|NCT05716126|DRUG|[14C]Iruplinalkib (WX-0593)|Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) as a solution on Day 1
214898396|NCT05758870|PROCEDURE|surgical stabilization of low rib fratures|surgical stabiliazation of rib fractures by internal fixation
214898397|NCT05758870|OTHER|converstive treatment of low rib fratures|chest wall fixation band
214898398|NCT00235755|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
214898399|NCT00235755|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
214898400|NCT00235755|DRUG|Placebo|Oral tablet.
214898401|NCT01105897|PROCEDURE|Endometriosis surgery|Complete surgical excision of all visible endometriosis by multidisciplinary approach
215053046|NCT03245346|DRUG|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
215053047|NCT03245346|DRUG|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
215053048|NCT03245346|DRUG|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
215053049|NCT02257242|DRUG|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
215053050|NCT02257242|DRUG|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
215053051|NCT02257242|DRUG|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
215053052|NCT04968392|DRUG|Dexmedetomidine Hydrochloride|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
215053053|NCT04968392|DRUG|Levobupivacaine|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
215053054|NCT02433496|OTHER|Physician coaching|"The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice."
215053055|NCT02714491|OTHER|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
215053056|NCT02714491|OTHER|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
215053057|NCT02714491|OTHER|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
215053058|NCT03225391|BEHAVIORAL|nap from 0:00 to 3:00 hours|A nap from 0:00 to 3:00 hours during a night shift.
215053059|NCT03225391|BEHAVIORAL|nap from 3:00 to 6:00 hours|A nap from 3:00 to 6:00 hours during a night shift.
215053060|NCT00153413|BEHAVIORAL|Cookin' Up Health|A brief nutrition intervention designed to improve dietary habits
215053061|NCT02659813|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
215053062|NCT03495726|BEHAVIORAL|Headspace app|Headspace is a Contemplative Application (App) for Well-being (CAW). Participants will be provided initial instructions for downloading and using the Headspace app. The Headspace app includes guided meditations, articles and videos. Participants will be asked to engage in meditation practice for an average of 10 minutes a day during the 6-week training period.
215053063|NCT06090123|DRUG|TPN171H|"Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10."
215053064|NCT06090123|DRUG|Itraconazole|Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
215053065|NCT06090123|DRUG|Rifampicin|Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
215053066|NCT04014699|PROCEDURE|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
215053067|NCT04014699|PROCEDURE|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
215053068|NCT00548197|DRUG|Bevacizumab|one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
215053069|NCT01602263|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
215053070|NCT05673824|DRUG|Huaier Granule|"Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher."
215053071|NCT05673824|DRUG|VEGFR-TKIs|Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib. Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
215053072|NCT00245388|DRUG|Muraglitazar|
215053073|NCT01650831|DEVICE|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
215053074|NCT00598923|DRUG|topiramate|100 mg twice per day for 3 months
215053075|NCT00598923|DRUG|topiramate|100 twice per day for 6 days after loading dose of phenytoin
215053076|NCT00598923|DRUG|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
215053077|NCT02614339|DRUG|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
215053078|NCT02614339|DRUG|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
215053079|NCT01876303|OTHER|laboratory biomarker analysis|Correlative studies
215053080|NCT01876303|OTHER|questionnaire administration|Ancillary studies
215053081|NCT05156944|OTHER|physiotherapeutic intervention|"The intervention consists of a brief physiotherapeutic assessment, the short physical performance battery, a brief information on the expected course of the condition, a check of fall hazards at home using the Bundesamt für Unfallverhütung (bfu) checklist, and instructions on self-management (eg. staying active, adaptation of behavior and surrounding at home). Additionally, two exercises for daily self-guided therapy will be instructed, namely, sit-to-stand and balance performance exercises."
215053082|NCT03810547|DRUG|Propofol 10 Mg/mL Intravenous Emulsion|when spinal anesthesia is not satisfactory intervention drugs are used
215057488|NCT02902445|GENETIC|polymorphism exploration|from an oral swab collected after parents consent
214898402|NCT04421599|OTHER|The Necessity of Aspiration|"The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same Intramuscular Injection Application Protocol was applied while all the injections were administered."
214898403|NCT03164551|DEVICE|GERI+ incubator|The embryo culture of consented participants were carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos were reviewed firstly by GERI Assess software, using bright-field imaging. Finally the embryo(s) with the highest EEVA grade are transferred were followed up until the achievement of implantation and confirmation of pregnancy.
214898404|NCT03164551|DEVICE|Conventional incubator|The embryo culture of consented participants were carried out in conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade were transferred and were followed up until the achievement of implantation and confirmation of pregnancy.
214898405|NCT03197623|DRUG|LLP2A-ALENDRONATE|A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
214898406|NCT03197623|DRUG|Placebo|Placebo, one time single administration given intravenously over 120 minutes.
214898407|NCT01722708|DRUG|Clindamycin|Oral clindamycin 300 Milligrams\*2/Day for a week
214898408|NCT01722708|DRUG|Metronidazole|Oral metronidazole 500 Milligrams\*2/Day for a week
214898409|NCT03490110|BEHAVIORAL|State regulation skill training|Participants complete seven supervised training sessions. Training sessions last 2 hours, and participants are requested to complete approximately 2.5 hours of additional skill practice over the course of each week outside of session (total \~4.5 hours per week).
214898410|NCT03490110|OTHER|Treatment-as-usual|Participants receive clinical care as usual over a matched time period.
214898411|NCT05059613|OTHER|probiotics|one times a day during the whole treatment
214898412|NCT02314026|DEVICE|Suspected NASH BreathID test with 13C-Octanoate|Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
214898413|NCT02314026|DEVICE|Suspected NASH Breath test with 13C Methacetin|Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water
214898414|NCT02056223|DRUG|Intravenous paracetamol|15 mg/Kg every 6 hours for three days
214898415|NCT02056223|DRUG|Intravenous ibuprofen|10 -5-5 mg/Kg once a day for three days
214898416|NCT03974867|DRUG|Prednisone 5Mg Tab|"Glucocorticoids:~d1-d7: Oral Pred. 1mg/kg/d a (maximum daily dosage is no more than 60mg); d8-d9: Oral Pred. 10mg less than d7; d10-d11: Oral Pred. 10mg less than d9; d12: Oral Pred. 10mg less than d11; d13: Oral Pred. 10mg less than d12; d14: Oral Pred. 10mg less than d13;"
214898417|NCT03974867|DRUG|Methylprednisolone 40 mg|"Glucocorticoids:~7 intratympanic injections of 40mg/ml Met. in 14 days, one injection every other day;"
214898418|NCT05824754|OTHER|Just-In-Time-Adaptive-Intervention (JITAI)|"Behavioral: MiWaves behavioral messages~Participants will be using the MiWaves mobile app for 30 days. When a participant is assigned to receive a message, a message will be randomly selected from a pool of intervention message sets. Messages are based in motivational interviewing and include affect management and behavioral economic strategies."
214898419|NCT05586100|DRUG|Toripalimab+cetuximab|"Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing \<50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
214898420|NCT05286736|DIAGNOSTIC_TEST|Neuroimaging|This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.
214898421|NCT05286736|DIAGNOSTIC_TEST|Quantitative assessments|Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function
214898422|NCT05610215|PROCEDURE|hybrid ablation|simultaneous thoracoscopic epicardial and catheter endocardial ablation
214898423|NCT05610215|PROCEDURE|catheter ablation|catheter endocardial ablation
214898424|NCT06344091|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
214898425|NCT02174003|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
214898426|NCT06429722|DRUG|NMRA-335140 80 mg|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.
214898427|NCT06429722|DRUG|Placebo|Placebo will be administered orally
214898428|NCT06855225|DRUG|Tremelimumab|Tremelimumab is administered at 300mg intravenously once at Cycle 1.
214898429|NCT06855225|DRUG|Durvalumab|Durvalumab is administered at 1500mg intravenously every 3 weeks for Cycles 1-8, then every 4 weeks for Cycles 9+.
214898430|NCT06855225|DRUG|Gemcitabine|Gemcitabine is administered at 1000mg/m\^2 intravenously on Day 1 and Day 8 of Cycles 1-8 only.
214898431|NCT06855225|DRUG|Cisplatin|Cisplatin is administered at 25mg/m\^2 intravenously on Day 1 and Day 8 of Cycles 1-8 only.
214478662|NCT04214834|DRUG|Methadone|The dose interval for methadone will be every 8 or 12 hours, per hospital practice. Clinical teams are asked to wean study drug at least every 24 hours.
214898432|NCT04257214|BEHAVIORAL|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
215053083|NCT01479244|BIOLOGICAL|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
215053084|NCT01479244|BIOLOGICAL|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
215053085|NCT01741298|BEHAVIORAL|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
215053086|NCT03774771|DRUG|Cinacalcet|Capsule for oral administration
215053087|NCT03774771|DRUG|Placebo|Capsules for oral administration
215053088|NCT01495039|DRUG|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
215053089|NCT05892497|OTHER|Tecartherapy|The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
214299413|NCT06387745|DEVICE|Hepatoscope|The Hepatoscope is a non-invasive external ultrasound imaging device, intended for general purpose pulse echo ultrasound imaging, and soft tissue elasticity imaging of the human body. In addition, the Hepatoscope provides measurements of shear wave speed and tissue stiffness, ultrasound beam attenuation and estimates of speed of sound, in internal structures of the body.
214299414|NCT01679977|DEVICE|Vibrational-proprioceptive Resistance Exercise Training|
214299415|NCT01679977|DEVICE|Neuromuscular Electrical Stimulation Training|
214299416|NCT06502626|OTHER|Regular training|performed their routine programs
214299417|NCT06502626|OTHER|Sprint Interval Training|Sprint interval training will be given for 4 weeks. Each week consisted of three training sessions, separated by at least one resting day. Participants will complete a 15-minutes warm up before training session. The Sprint interval training group consisted of 30 s sprints at near maximal effort, with three minutes of rest between each sprint. The training intensity of Sprint interval training sessions was evaluated subjectively during sessions. During the first week, the Sprint interval training group performed five sprints per session. The number of sprints then increased gradually, until a total of 10 sprints per session. When the number of sprints reached seven, subjects were given six minutes of rest midway through the training session
214898433|NCT00477737|DRUG|Sevoflurane|
214898434|NCT00477737|DRUG|propofol|
214898435|NCT06856629|OTHER|Eccentric blood-flow restriction training|Eccentric blood-flow restriction training
214898436|NCT06856629|OTHER|Eccentric free-flow training|Eccentric free-flow training
214898437|NCT06676878|DEVICE|Incremental exercise|A graded exercise test will be performed on a treadmill. After 3 minutes of standing on the treadmill, participants will walk at a speed of 4 km/h for the first 3 minutes, then the speed will be increased to 8 km/h. After this point, the treadmill speed will be increased by 2 km/h every 3 minutes until voluntary exhaustion.
215053090|NCT05077839|DRUG|Trifluridine/Tipiracil|Trifluridine/tipiracil was approved in the third-line treatment of advanced colorectal cancer. Its efficacy in the first-line treatment was unknown.
215053091|NCT03449849|OTHER|Base Diet|Base Diet
215053092|NCT03449849|OTHER|Kale Treatment|Base Diet plus Kale
215057489|NCT03087604|PROCEDURE|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
215057490|NCT03087604|PROCEDURE|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
215057491|NCT03087604|DRUG|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
215057492|NCT00181818|DRUG|bupropion SR (sustained-release)|
215057493|NCT04300660|OTHER|neuropathic pain after thoracic surgery|analysis of perioperative factors implicated in the onset of postoperative pain after chest surgery and the incidence of neuropathic pain
215057494|NCT00100958|DRUG|indole-3-carbinol|
215057495|NCT05767788|OTHER|Movement with Mobilization (MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
215057496|NCT05767788|OTHER|Sham Movement with Mobilization (Sham MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior light-touch glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
215057497|NCT05748301|OTHER|AI Clinician|N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.
215057498|NCT05075733|OTHER|Survey|Survey was sent to all the Americas Hepato-Pancreato-Biliary Association's members
214898438|NCT07013422|OTHER|Psychoeducational support|Study Intervention: psychoeducational sessions, 5 sessions were given to the participants allocated to the intervention arm (60-90 minutes each) covering health education, stress management, coping strategies, and communication with children
214898439|NCT06688461|OTHER|Experimental group: Exercise training|HIIT program, 3 times per week for 12 weeks
214478663|NCT04947137|DRUG|Tc99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
214898440|NCT07017790|OTHER|Amino-acid PET|Patients received 18-fluoroDopa then a PET exam
214898441|NCT07017439|DRUG|Beta-3 agonists (Mirabegron/Myrbetriq)|Patients in this arm will receive the medication in pill form following their procedure
214898442|NCT07017439|OTHER|Placebo group post rezum|Patients in this arm will receive the placebo pill following their procedure.
214898443|NCT06443788|DIAGNOSTIC_TEST|transperineal ultrasound|"The following measurement will be recorded:~1. Amniotic fluid pooling assessment will be performed in sagittal and transverse planes. ,~   * Images will be evaluated for appearance of accumulated hypoechogenic fluid around cervix. Whenever collection is spotted, three largest dimensions of fluid will be measured (length, width, depth).~  * Fluid accumulations around the cervix that are clearly demarcated from surrounding tissues will be considered positive.~2. Cervical length: it will be measured between the internal os point to the external os point below. Cervical dilatation will be measured in a transverse plane from inner to inner.~3. Presence of fetal part prolapse and/or cord prolapse"
214898444|NCT07017270|DRUG|Semaglutide Pen|Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.
214898445|NCT00946738|OTHER|Biofeedback|Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
214898446|NCT00946738|OTHER|Deep oscillation|Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
215053093|NCT02515344|OTHER|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
214898447|NCT01851044|PROCEDURE|Platelet Rich Plasma|
215053094|NCT02515344|OTHER|Providing general information about CRC sreening|
215053095|NCT00632775|DRUG|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
215053096|NCT00632775|DRUG|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
215053097|NCT01007188|OTHER|1.5PD almonds|average American diet plus 1.5 oz per day almonds
215053098|NCT01007188|OTHER|3.0PD almonds|average American diet plus 3.0 oz per day almonds
215053099|NCT01007188|OTHER|Base (without almonds)|average American diet without almonds
215053100|NCT03475069|OTHER|Custom Designed Exercises|
215053101|NCT03475069|OTHER|Plates Exercises|
215053102|NCT03475069|OTHER|Calisthenics Exercises|
215053103|NCT01834599|DEVICE|cerebral oximetry|tissue saturation measurement in pregnant women
215053104|NCT06072625|DIETARY_SUPPLEMENT|Extra virgin organic olive oil (ULTRA PREMIUM)|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
215053105|NCT02315040|DEVICE|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
215053106|NCT02315040|OTHER|Standard Intrauterine Insemination|standard intrauterine insemination procedure
215053107|NCT00074139|DRUG|cyclophosphamide|
215053108|NCT00074139|DRUG|docetaxel|
215053109|NCT00074139|DRUG|doxorubicin hydrochloride|
215053110|NCT04377958|DIAGNOSTIC_TEST|Serum biomarker testing|Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
215053111|NCT05604144|DEVICE|Cryoanalgesia (iovera°®)|iovera°® treatment will be administered via ultrasound guidance to 1-2 branches of the dorsal/digital/proper nerve/s that innervate the Morton's neuroma. The treatment will be completed one time per subject.
215053112|NCT01393210|DIETARY_SUPPLEMENT|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
215053113|NCT01393210|OTHER|low-calorie diet|low-calorie diet only for 12 weeks.
215053114|NCT03336190|BEHAVIORAL|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
215053115|NCT02089932|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
215053116|NCT02089932|DRUG|Placebo|
214299418|NCT03251079|DEVICE|Continuous glucose monitoring system|Implanted continuous glucose monitoring system
214478664|NCT01692366|DRUG|SAR302503|"Pharmaceutical form:Capsule~Route of administration: oral"
215053117|NCT02448355|DEVICE|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
215053118|NCT02259725|DRUG|regorafenib|Given PO
215053119|NCT02259725|OTHER|laboratory biomarker analysis|Correlative studies
215053120|NCT00610792|DRUG|bortezomib|1.3 mg/m2 on Days 1, 4, 8 \& 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
215053121|NCT00610792|DRUG|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
215053122|NCT03417310|DEVICE|"H joystick"|A joystick that corrects lateral displacement and angulation for multi-direction reduction
215053123|NCT03417310|PROCEDURE|Common reduction methods|Manual reduction methods without the assistance of any devices
215057499|NCT04432922|OTHER|Hospitalized Patients for COVID-19 Infection|Face to face semi-directed interviews about perceptions, representations and experiences of septic isolation, including nine opened-questions.
215057500|NCT02001324|OTHER|Web-based data collection|
214299419|NCT03729856|BEHAVIORAL|intervention|The adapted physical activity (APA) intervention is a theory-based physical activity (PA) promotion intervention. The APA model is comprised of 4 steps: 1) pre-participation evaluation of physiological, personal and environmental factors that influence PA adoption and maintenance; 2) application of individualised, evidence based strategies associated with increased PA participation tailored to the participant's motivational readiness; 3) development of structured exercise and/or lifestyle PA program; and 4) tailored relapse prevention strategies to maintain physical activity beyond the duration of the program. The intervention will be conducted in the participant's home environment.
214299420|NCT03729856|OTHER|B|Participants will undertake their usual activities during the baseline period. An extended pre-intervention time frame is needed to establish a stable control phase and enhance internal validity.
214299421|NCT03729856|OTHER|Follow-up|Participants will have no contact with intervention personnel during the 5 week follow-up, withdrawal period. The withdrawal phase enables initial assessment of physical activity behavior change.
214299422|NCT02675413|DRUG|Dimethyl Fumarate|Open-label
214299423|NCT03968302|DRUG|ARM A Triple therapy for helicobacter pylori|The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
214299424|NCT03968302|DRUG|ARM B Quadruple therapy for helicobacter pylori|Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
214299425|NCT03031977|OTHER|visceral mobilization|
214299426|NCT02051946|DEVICE|Retroject Device|
214299427|NCT02051946|DRUG|ethacrynic acid injection|
214299428|NCT02051946|DRUG|balanced salt solution|
214299429|NCT02919501|DRUG|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
214299430|NCT02919501|OTHER|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
214299431|NCT02919501|DRUG|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
214299432|NCT00222196|PROCEDURE|lifestyle, PTA|
214299433|NCT00954902|DIETARY_SUPPLEMENT|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
214299434|NCT00954902|BEHAVIORAL|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
214299435|NCT00954902|OTHER|Placebo antioxidant concentrate|Placebo capsules
214299436|NCT01979809|BEHAVIORAL|MENU GenY|Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
214299437|NCT01402674|DRUG|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
214898448|NCT01851044|PROCEDURE|Whole Blood Injection|
214898449|NCT01851044|PROCEDURE|Saline Injection|
214299438|NCT00717340|DRUG|tivozanib (AV-951) + paclitaxel|"Tivozanib (AV-951):~Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.~Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.~Paclitaxel: Phase 1b study and Phase 2a study:~All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks)."
214299439|NCT03613051|BEHAVIORAL|Movement Assessment Battery for children|this test measures manual dexterity , balance , aiming and catching
214299440|NCT04233554|BEHAVIORAL|Patient Priorities Care|Patients will participate in a structured conversation in which the facilitator (i.e. social worker) helps patients identify their health goals, measurable, actionable, realistic outcomes (e.g. walk ½ mile daily). Both practice and patient level data will be collected.
214299441|NCT06860477|DRUG|Tislelizumab|Tislelizumab will be administered by IV, 200 mg on day 1 of each 21 day cycle.
214299442|NCT06860477|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily
214299443|NCT06860477|PROCEDURE|cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. Lenvatinib plus Tislelizumab will be administered 1-3 days after cryoablation.
214299444|NCT06860477|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|FOLFOX chemotherapy was administered intravenously every 2 weeks for a maximum of 12 cycles (oxaliplatin 85 mg/m², leucovorin, 400 mg/m2, fluorouracil 400 mg/m² \[bolus\], and fluorouracil 2400 mg/m² as a 46-h continuous intravenous infusion
214898450|NCT01406574|DRUG|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
214898451|NCT01406574|DRUG|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
214299445|NCT06740526|DRUG|Sibeprenlimab|"Sibeprelimab SC (Period 1)~Sibeprelimab SC (Period 2)"
214898452|NCT04052620|DRUG|Diclofenac diethylamine 2.32% gel|Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
214898453|NCT04052620|DRUG|Diclofenac diethylamine 1.16% gel|Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.
215057501|NCT02001324|OTHER|Paper-based data collection|
214299446|NCT04087798|BEHAVIORAL|Control-EDI|Patients in the control group will receive Control-EDI from their primary care provider during clinic visit. Subsequent patient CKD education and follow-up will be provider dependent. Patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
214299447|NCT04087798|BEHAVIORAL|Intervention-EDI and health coaching|"Patients in the intervention group will receive a personalized Intervention-EDI from their primary care provider during visit, which will include their most recent BP, their urine protein level and most recent eGFR. There is also a space for their provider to type in a sentence about specific goals for the patient.~Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over an 11-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only)."
214299448|NCT05689320|OTHER|Behavioral: EMA-based intervention|This study will compare the effect of fixed and incremental incentive strategies on compliance rates. All participants will be promised a basic incentive. An additional gift voucher will be given to intervention group participants who comply with the intervention at least 85% of the time, whereas a basic incentive will only be given to control group participants.
214299449|NCT06648382|BEHAVIORAL|Self-directed psychotherapy program for premenstrual disorders|The intervention consists of receiving 11 videos that are 10-15 minutes in length along with a workbook containing homework exercises. Participants are instructed to watch the videos over the course of two menstrual cycles: the first 6 during the first cycle and the last 5 during the second cycle. Each module focuses on a different skill inspired by cognitive behavioral therapy and dialectical behavior therapy.
214299450|NCT04735666|DEVICE|TauroPace™|TauroPace™ is intended to be used as a disinfecting solution during any CIED related surgery procedure or handling of any uncoated or silicon-, epoxy- or polyurethane-coated CIED (including its components, e.g., leads) made of titan or stainless steel in any adult patient requiring or carrying a CIED.
214299451|NCT04219891|DEVICE|WaveLight EX500 excimer laser system with InnovEyes sightmap|FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the WaveLight EX500 software will be upgraded to include the InnovEyes treatment.
214299452|NCT04219891|PROCEDURE|LASIK|Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system and data obtained from the InnovEyes sightmap.
214898454|NCT04052620|OTHER|Placebo|Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
214299453|NCT04219891|DEVICE|InnovEyes sightmap|Non-contact ophthalmic diagnostic device that captures images of the eye and collects ocular data preoperatively to generate a patient-specific ablation profile for refractive correction surgery
214478665|NCT04472013|OTHER|Data collection from lumbar puncture|Cerebro spinal fluid (CSF) will be acquired by lumbar puncture and sent for routine analysis including CSF chemistry, cytology and microbiology. Targeted CSF proteomics using OLINK Proximity Extension Assay (PEA) technology to assess a potential CNS-contribution of the disease will be performed.
214478666|NCT04472013|OTHER|Data collection from blood draw|Plasma samples will be acquired for plasma cytokine proteomics using CyTOF (mass cytometry analysis) technology.
214478667|NCT04472013|OTHER|CNS magnetic resonance imaging (MRI) imaging|3Tesla magnetic resonance imaging (MRI) will be performed to document early/manifest encephalitic changes in COVID-19 patients.
214898455|NCT03552380|DRUG|Entinostat|RP2D will be determined with a 6 patient safety lead-in. Entinostat will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
214898456|NCT03552380|DRUG|Nivolumab|Nivolumab will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
214898457|NCT03552380|DRUG|Ipilimumab|Ipilimumab will be administered in combination with entinostat and nivolumab for Cycles 1-4 only.
214898458|NCT01801904|DRUG|Panitumumab|6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
214898459|NCT03093701|DRUG|TLC399 (ProDex)|2-vial system: TLC399-DSP and TLC399-Lipid
214898460|NCT00168779|DRUG|telmisartan 80 mg / hydrochlorothiazide 25 mg|
214898461|NCT00168779|DRUG|valsartan 160 mg / hydrochlorothiazide 25 mg|
214898462|NCT00168779|DRUG|placebo|
214898463|NCT02494661|BEHAVIORAL|Healthy Cart and Stress Management Videos|Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.
214898464|NCT02494661|BEHAVIORAL|Healthy Cart Video|Healthy Cart Video: educational video on healthy food shopping
214898465|NCT06833437|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|Patients in the 68Ga-Pentixafor PET/CT group will first undergo 68Ga-Pentixafor PET/CT, followed by adrenal venous sampling (AVS). The subsequent treatment will be guided based on the diagnostic results.
214898466|NCT06833437|DIAGNOSTIC_TEST|AVS|Patients in the adrenal venous sampling (AVS) group will first undergo adrenal venous sampling (AVS), followed by 68Ga-Pentixafor PET/CT. The subsequent treatment will be guided based on the diagnostic results.
214898467|NCT02841982|PROCEDURE|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
214898468|NCT02841982|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
214898469|NCT02841982|DEVICE|PAJUNK StimuLong|
214898470|NCT02841982|DRUG|single dose ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~* given immediately after the correct position of the tip of the needle has been verified."
214898471|NCT02841982|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg
214898472|NCT00150280|DRUG|celecoxib and ibuprofen SR|
214898473|NCT00059592|DRUG|Valacyclovir|
214898474|NCT00367302|DRUG|buprenorphine|maintenance
214898475|NCT00367302|DRUG|methadone|maintenance
214299454|NCT06910046|DIAGNOSTIC_TEST|CLE and ssRAB-guided cryobiopsy|All procedures are performed under general anesthesia with endotracheal intubation and mechanical ventilation. A conventional flexible bronchoscope is used to examine the subject's airway and clear the secretion. After the registration procedure is completed, the catheter of the ssRAB system is navigated to the target lesion. Cone beam computed tomography (CBCT) is used to confirm whether the target lesion has been reached. After that, an appropriate CLE probe is inserted. Right before CLE imaging, 2.5 ml of 10% fluorescein sodium is administered intravenously. CLE is then used to examine the target lesion. Based on real-time CLE imaging, the optimal biopsy location is identified and localized on the fluoroscopy. After CLE imaging, the CLE probe is retracted, followed by cryobiopsy at the same location under fluoroscopy guidance. Rapid on-site evaluation is available during the procedure to assess sample adequacy.
214299455|NCT05636098|DEVICE|Masimo Rainbow Sensors|Noninvasive pulse oximeter sensor
214299456|NCT00436254|BIOLOGICAL|pNGVL3-hICD vaccine|Plasmid-based DNA vaccine, given intradermally
214299457|NCT00436254|BIOLOGICAL|sargramostim|Given intradermally
214299458|NCT00436254|OTHER|flow cytometry|Correlative studies
215053124|NCT02559635|PROCEDURE|Bowel stimulation|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
215053125|NCT02559635|DRUG|Nestle Resource|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
215053126|NCT03344783|OTHER|PUFA and R-TFA|PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
215053127|NCT04005391|OTHER|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
215053128|NCT00002081|DRUG|Zidovudine|
215053129|NCT00002081|DRUG|Zalcitabine|
214299459|NCT00436254|OTHER|immunologic technique|Correlative studies
215053130|NCT00289172|BIOLOGICAL|Live attenuated human rotavirus vaccine|
215053131|NCT01034501|DEVICE|sham procedure|non activated laser tip
215053132|NCT01034501|DEVICE|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
214299460|NCT00436254|OTHER|immunoenzyme technique|Undergo ELIspot (correlative studies)
214299461|NCT00436254|GENETIC|protein expression analysis|Undergo ELISA (correlative studies)
214299462|NCT00436254|PROCEDURE|biopsy|Undergo punch biopsy (correlative studies)
214299463|NCT04889352|OTHER|Access to colonoscopy web app|There is a very high utilization of colonoscopy at both shorter and longer time intervals than the recommended guidelines. Investigators have developed a clinical support tool in which the characteristics of the patients can be inputted and the guideline recommended time interval for surveillance colonoscopy is then provided. This tool uses the recommendations from the current North American national guidelines. The tool has been developed as a web-based application as well as a smart phone application.
215053133|NCT02236325|BEHAVIORAL|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
215053134|NCT02236325|BEHAVIORAL|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
215053135|NCT01999244|BEHAVIORAL|Self-monitoring skills|
215053136|NCT01999244|BEHAVIORAL|Technology|
215053137|NCT01999244|BEHAVIORAL|Interventionist Contact|
214299464|NCT05933629|BEHAVIORAL|Online EmReg|A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
214299465|NCT05933629|BEHAVIORAL|Consultation Sessions|3 months of bi-weekly consultation sessions
214299466|NCT06913023|DRUG|Semaglutide 3 MG [Rybelsus]|Semaglutide 3mg for 4 weeks.
214299467|NCT06913023|DRUG|Semaglutide 7 MG [Rybelsus]|Semaglutide 7mg for 4 weeks.
214299468|NCT06913023|DRUG|Semaglutide 14 MG [Rybelsus]|Semaglutide 14mg for 16 weeks.
214299469|NCT06913023|DRUG|Placebo Oral Tablet|Placebo tablet
214299470|NCT06914323|PROCEDURE|Acupressure|improvements in pain, limb swelling, and comfort
214669317|NCT04923373|OTHER|telerehabilitation|"Procedure for both groups:~I pre surgery evaluation~1. initial training in hospital~2. physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation"
214669318|NCT04923373|PROCEDURE|standard physiotherapy|standard physiotherapy
214669319|NCT01532453|DEVICE|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
214669320|NCT01532453|OTHER|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
215053138|NCT04068077|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
214898476|NCT03442439|BEHAVIORAL|Nutrition and Play Intervention|Mothers and children in the Nutrition and Play group will play educational and nutrition-focused games.
214299471|NCT06914739|BEHAVIORAL|The Health Empowerment Theory (HET) program|The intervention group received the HET-based intervention program for 12 weeks. From the first week to the fourth week, community nurses interacted with the participants face-to-face to analyze and establish their problems and needs in health management (usual community health services utilization, such as medicine purchases and vaccinations) and helped clarify the importance of health management and their strengths (such as existing health knowledge). From the fifth to twelfth weeks, participants attended health knowledge lectures led by community nurses, covering topics such as: a) healthy lifestyle, primarily diet, exercise, and disease prevention and management for older adults; and b) community health services, which included recent or long-term community health services (such as health examinations for older adults and family doctor contracts). WeChat groups and offline gatherings at community health centers (with groups of eight to ten peers) were organized to interact and comm
214898477|NCT03442439|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state though sustained physical contact; comfort touch, soothing words, and eye contact.
214898478|NCT03078686|PROCEDURE|tSVF by lipoaspiration|Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system
214898479|NCT03078686|PROCEDURE|PRP Concentration|Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System
214898480|NCT03078686|PROCEDURE|Emulsification tSVF|Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen
214898481|NCT03078686|PROCEDURE|cSVF isolation and concentration|Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates
214898482|NCT03078686|PROCEDURE|cSVF in Normal Saline IV|cSVF + NS for IV Placement
214898483|NCT01833650|DIETARY_SUPPLEMENT|thymus honey mouthwash|
214898484|NCT05668702|OTHER|crossover design|The researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
214898485|NCT02431364|DRUG|Verdinexor|Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
214898486|NCT02431364|OTHER|Placebo|Participants received placebo matched to verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
214898487|NCT02715011|DRUG|JNJ-63709178|Participants will receive JNJ-63709178 in Part 1 and Part 2.
214898488|NCT00916383|DRUG|350 mg Donepezil Transdermal Patch|Active and placebo patches will be applied to opposite sides for 7 days.
214898489|NCT00916383|DRUG|Placebo Patch|Active and placebo patches will be applied to opposite sides for 7 days.
214898490|NCT03548727|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT Imaging of tumor hypoxia and proliferation
214898491|NCT03878927|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.
214898492|NCT03878927|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab ozogamicin is a CD-33 directed antibody drug conjugated to calicheamicin. CD 33 is expressed on myeloid leukemic blast cells and on normal hematopoietic cells. The drug is approved for the treatment of newly diagnosed CD 33 positive AML in adults and the treatment of relapsed and refractory CD 33 positive AML in adults. The drug is available for injection 4.5 mg as a lyophilized cake or powder in a single use vial for reconstitution and dilution.
214898493|NCT00258960|DRUG|Liposomal Doxorubicin|
214898494|NCT00258960|DRUG|Cyclophosphamide|
214898495|NCT00258960|DRUG|Trastuzumab|
214898496|NCT06551480|DEVICE|Biometry|Only one eye from each patient will be included in the study. All subjects and patients included in the study will undergo biometric measurements with both devices (IOL master 500 and VCSEL based swept source optical biometry).
214898497|NCT03355612|DRUG|Apatinib|Apatinib: 500 mg, qd, po, last 180 days
214898498|NCT03355612|DRUG|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
214898499|NCT00473590|DRUG|Bevacizumab|15 mg/kg administered by intravenous infusion
214898500|NCT00473590|DRUG|Bortezomib|1.3 mg/m\^2 administered by intravenous bolus injection
214898501|NCT00473590|DRUG|placebo|Intravenous repeating dose
214898502|NCT01112059|DRUG|Doxycycline|100 mg twice a day for 8 days
214898503|NCT01112059|OTHER|placebo|placebo
214898504|NCT03781687|PROCEDURE|Bilateral ESP Block|Bilateral ESP Block will be performed at T8
214898505|NCT03781687|PROCEDURE|Unilateral ESP Block|Unilateral ESP Block will be performed at T8 (right side)
214898506|NCT03781687|DEVICE|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
214898507|NCT04778475|OTHER|Intensive therapy|PT services twice a day for 3-5 days and then daily for the remainder of hospital stay
214898508|NCT04778475|OTHER|Standard of care therapy|PT services 3-5 times a week for 15 to 30 minutes
214898509|NCT06499675|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy / bariatric surgery
214898510|NCT06499675|PROCEDURE|Liver Biopsy|intraoperative liver biopsy
214299472|NCT06914739|BEHAVIORAL|routine community care|The control group received routine community care, including notifications of community- related activities and lectures through WeChat group chats or telephone calls, and had questions answered by researchers and community nurses.
214898511|NCT03636178|PROCEDURE|Classic alar base suture technique|An index finger will be used to apply extraoral pressure on the alar base region, and a dentate forceps will grasp this tissue through the intraoral incision. A suture bite will be taken at this point through the tissue previously held by the forceps. The same procedure will be applied on the opposite side. After passing the suture on both sides, it will be tightened with attention to the alar base response. If the alar base suture will be judged to be adequate, the vestibular incision will then be closed in a routine fashion, with or without performing a V-Y lip closure
214669321|NCT04954846|DIETARY_SUPPLEMENT|OMNi-BiOTiC SR-9|"The Probiotic contains the following ingredients:~Maize Starch, Maltodextrin, Inulin, Potassium Chloride, Hydrolysed rice protein, Magnesium Sulphate, Fructooligosaccharides, Amylase, Manganese Sulphate~Additionally, the following bacterial strains are included:~Lactobacillus Casei W56, Lactobacillus Acidophilus W22, Lactobacillus Paracasei W20, Bifidobacterium lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium lactis W52, Lactobacillus plantarum, Bifidobacterium bifidum W23"
214898512|NCT03636178|PROCEDURE|Modified alar base suture technique|The alar base will be marked with 3 landmarks: left alar base (point LAB), columella (point C), and right alar base (point RAB). A needle will be inserted through the skin at the nasofacial skin fold and exited through the fibroareolar tissue. A nonabsorbable suture without a needle will be inserted through the needle from the oral cavity to the outside. The needle will be retracted through point RAB without leaving the skin point, then returned to the oral cavity in a medial position. Finally the needle will be retracted from point RAB, leaving the suture through the soft tissue. The same procedure will be repeated on the other side. The 2 free ends of the sutures will be then tied together after passing through a hole made in the nasal spine.
214898513|NCT01444261|DIETARY_SUPPLEMENT|Fer-in-Sol|Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
214299473|NCT06914232|COMBINATION_PRODUCT|Warm Compress|The intervention involves perioperative Warm compress therapy administered to the participants in the intervention group before and after cataract surgery for 3 seesions per week for 6 weeks. The therapy aims to enhance tear film stability and alleviate symptoms of dry eye by delivering warm compress to the meibomian glands to restore their function. Participants will undergo a session of warm compress therapy prior to surgery and another one following the surgery.
214299474|NCT06914232|DIAGNOSTIC_TEST|Standard Care|The control group will receive standard care, which includes artificial tears or other conventional methods for dry eye management for 3 sessions per week for 6 weeks. , but they will not receive Warm Compress therapy.
214299475|NCT06914531|OTHER|Questionnaire comprehension test|Participants will complete a standardized questionnaire assessing social cognition, adapted for cochlear-implanted children aged 3 to 6 years. The assessment includes the Item Scale and the Test of Emotions Comprehension adapted and mixed together. The questionnaire evaluates children's ability to understand emotions, social interactions, and cognitive perspective-taking. Each child will complete the test in a single session lasting approximately 20 minutes, under the supervision of a trained investigator, with an orthophonist and a parent present
214299476|NCT06913179|BIOLOGICAL|All enrolled patients will first receive CAR-T cell therapy. Patients who achieve complete remission following CAR-T infusion will subsequently undergo allo-HSCT|All enrolled patients will first receive CAR-T cell therapy. Patients who achieve complete remission (CR) following CAR-T infusion will subsequently undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) based on clinical assessment. The entire treatment process will be standardized and closely monitored, with follow-up evaluations focusing on adverse events, engraftment success, relapse risk, and overall survival.
214299477|NCT06913413|COMBINATION_PRODUCT|core stabilization exercise|Will receive 8 week core stabilization exercise 3 session per week which include 10 min warm up and 10 min cool down (walking ) 6 sets of movements co contraction of abdominal muscles (Abdominal hollowing) ,bridging ,dead bug ,plank with 50,000 IU of vitamin D weekly
214299478|NCT06913413|DIAGNOSTIC_TEST|stabilization exercise|stabilization exercise 3 session per week which include 10 min warm and 10 min cool down (walking ) sham medicine, 6 sets of movements co contraction of abdominal muscles (Abdominal hollowing) ,bridging ,dead bug and plank
214299479|NCT06912620|DIETARY_SUPPLEMENT|Soy-based RUTF|This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free formula that includes dairy (milk powder) with added crystalline amino acids
214299480|NCT06912620|DIETARY_SUPPLEMENT|Soy-maize-sorghum-based RUTF|This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free and dairy-free formula with added crystalline amino acids
214299481|NCT06912620|DIETARY_SUPPLEMENT|Standard RUTF|This is the control, the standard, currently used formulation of ready-to-use therapeutic foods (RUTFs), which contains dairy and peanut ingredients
214299482|NCT06914804|DEVICE|Stomasense|A smart device worn alongside stoma pouch systems which detects onset of a leak.
214898514|NCT01444261|OTHER|control|No dietary supplements
214898515|NCT01922505|DRUG|PPI triple therapy|
214669322|NCT04954846|DIETARY_SUPPLEMENT|Placebo|The Placebo contains no bacterial strains, only the prebiotic ingredients found in OMNi-BiOTiC SR-9.
214898516|NCT00395161|DRUG|Metoclopramide|0.2 mg/kg/dose IV every 12 hours
214898517|NCT00395161|DRUG|Zinc|one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)
214669323|NCT05117801|DEVICE|Petale|The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
214898518|NCT00395161|DIETARY_SUPPLEMENT|Glutamine|one enteral dose daily of glutamine 0.3 gm/kg/day
214898519|NCT00395161|DRUG|Selenium|one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children \> 13 years)
214898520|NCT00395161|OTHER|saline|equivalent volume of intravenous saline
214898521|NCT00395161|OTHER|sterile water|equivalent volume of sterile water
214898522|NCT00395161|OTHER|selenium|equivalent volume of sterile water
214898523|NCT00395161|DIETARY_SUPPLEMENT|whey-protein|one enteral dose daily of whey-protein
214299483|NCT06914583|DEVICE|Sodium Hyaluronate|Sodium Hyaluronate 32 mg/ml
214299484|NCT06913634|DRUG|Luspatercept (ACE-536)|Luspatercept (ACE-536)
214299485|NCT06912854|OTHER|Sensory Adapted Dental Environment|"The SADE condition consists of physical adaptations (visual, auditory, tactile modifications) to the dental environment meant to create a less anxiety-provoking sensory experience. Direct overhead fluorescent lighting and the regular dental overhead lamp will be turned off and darkening curtains will cover the windows. Adapted lighting will include slow moving visual color effects (Snoezelen) shining on the ceiling in the child's visual field. The dentist will wear a surgical dental headlamp directed into the patient's mouth, reducing bright lights shining in the child's eyes. Auditory stimuli will be calming rhythmic music (Dan Gibson's Exploring Nature) projected via portable speakers. The tactile deep pressure stimulus will be a commercially available weighted blanket (10-15% of the child's weight) placed on the child to provide deep hugging pressure, which produces a calming effect."
214299486|NCT06912854|OTHER|Video-based Modeling|Participants will watch an approximately 5-minute video depicting a dental cleaning being performed on a sex and age-matched cooperative child, designed to expose the participant to the activities of the dental cleaning and thereby create a less anxiety-provoking dental experience.
214299487|NCT02697695|OTHER|Laboratory Examination|Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
214669324|NCT01507194|DRUG|Ondansetron|Single IV dose
214669325|NCT01507194|DRUG|Vestipitant|Single IV dose
214898524|NCT03774355|DRUG|CG1801|Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
214898525|NCT03774355|DRUG|CGL1802|Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
214898526|NCT04115215|BEHAVIORAL|Physical exercise (PE)|This arm includes 10 sessions of multi-component exercise sessions (including aerobic, resistance, flexibility, dual-tasking) of 1 hour/week of functional group exercise, directed to foster empowerment for subsequent continuation of exercise in community-dwelling older adults referred by primary care to a geriatrician and an expert physical therapist. Participants will receive a leaflet with instructions to perform five strength-based exercises and instructors will recommend participants to perform the exercises and walk at least 15 minutes daily.
214898527|NCT04115215|DEVICE|Transcranial current stimulation (tCS)|This arm includes 1 application/week for 10 weeks during PE, through an adapted commercial helmet. Transcranial current stimulation (tCS) is a neural stimulation technique based on electrical stimulation of selected parts of the brain with direct or alternated electrical current (tDCS or tACS) of very low intensity of 1,5 milliamps (mA), using one or more electrodes placed on the skull. tCS is non-invasive (no surgical procedures) and it is painless, as applied in the proposed protocols.
214299488|NCT00433849|DRUG|R744|100μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
214299489|NCT00433849|DRUG|R744|150μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
214299490|NCT01064791|DRUG|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
214299491|NCT01064791|DRUG|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
214669326|NCT04277702|DRUG|Montelukast 10mg|Oral administration of 10mg of montelukast daily for 12 months
214669327|NCT04277702|PROCEDURE|Endovascular treatment|Percutaneous transluminal angioplasty combined with bare-metal stenting of lower limbs arteries
214669328|NCT04277702|DRUG|Standard anti-platelet treatment|Standard antithrombotic treatment for patients undergoing endovascular procedures
214669329|NCT06247540|PROCEDURE|Biopsy|Undergo tissue biopsy
214299492|NCT01064791|DRUG|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
214299493|NCT01064791|DRUG|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
214299494|NCT06175793|BEHAVIORAL|ASPIRE Intervention|In addition to usual care and a free blood pressure cuff, participants in the intervention arm will receive the ASPIRE components: (1) ASPIRE Tool Kit, (2) ASPIRE Coach, (3) SMBP EHR Documentation, and (4) screening and addressing SDOHs.
214299495|NCT06114992|DEVICE|Servo-n HFOV modes|Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care
214669330|NCT06247540|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214669331|NCT06247540|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214669332|NCT06247540|PROCEDURE|Computed Tomography|Undergo PET/CT, CT
214669333|NCT06247540|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214669334|NCT06247540|BIOLOGICAL|Nivolumab|Receive IV
214669335|NCT06247540|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214669336|NCT06247540|BIOLOGICAL|Rituximab|Receive IV
214669337|NCT06247540|DRUG|Venetoclax|Receive PO
214669338|NCT05847972|PROCEDURE|MWM (Mobilization with movement)|This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.
214669339|NCT05847972|DEVICE|Plantar orthoses|"Procedure: MWM All participants will undergo MWM. This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.~Procedure: Plantar orthoses The moulds will be taken immediately after the manipulation. The PO will be made of resin (0.8mm +1.2mm), 2mm hard EVA heel stabiliser, 3mm semi-hard EVA cover. The PO should be worn for 3 months to obtain the results of the study."
214669340|NCT02237053|DRUG|Glucagon|
214669341|NCT02237053|DRUG|Octreotide|
214669342|NCT02237053|BEHAVIORAL|Placebo|
214669343|NCT02237053|DRUG|Insulin|
214299496|NCT02960776|BEHAVIORAL|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
214299497|NCT06833086|PROCEDURE|Paravertebral block (ropivacaine) left|Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
214299498|NCT06833086|PROCEDURE|Paravertebral block (ropivacaine) right|Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
214299499|NCT03425617|DRUG|Tiotropium + Olodaterol|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose
214299500|NCT03425617|OTHER|PLACEBO|PLACEBO via Respimat® single dose
214299501|NCT04742101|DRUG|S65487 and azacitidine|Treatment cycle of combination of S65487 and azacitidine during 4 weeks. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.
214299502|NCT02150655|BIOLOGICAL|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
214299503|NCT02150655|BIOLOGICAL|Placebo|
214669344|NCT00524095|DRUG|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
214898528|NCT04115215|OTHER|Control|Participants of similar profile, randomized to the control group, will undergo weekly 30 minutes educational sessions on healthy aging, including relevant aspects of nutrition, self-care, physical activity, plus measurement of blood pressure, heart rate and peripheral oxygen Hb saturation. These participants will be offered to join the PE program after the 6-months follow-up (end of the study).
214898529|NCT02039193|BEHAVIORAL|Cognitive behavioral therapy|CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, \& Brown, 1992; Borkovec \& Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
214898530|NCT04791137|BEHAVIORAL|Imagery cognitive bias modification|The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell \& Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. It is hypothesised that via repeatedly practising imagining positive resolutions for ambiguous situations in the training sessions, a bias is trained to automatically imagine positive resolutions for ambiguous situations encountered in daily life.
214898531|NCT02920671|OTHER|Tracer-enhanced oral glucose tolerance test (OGTT*)|Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.
214299504|NCT01357265|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
214299505|NCT02071355|DRUG|TMC435 100 mg|Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
214299506|NCT02071355|DRUG|TMC435 150 mg|Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
214299507|NCT00312494|DRUG|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
214299508|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
214299509|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
214299510|NCT05047328|BIOLOGICAL|inolimomab|"1 or 2 Induction Phases at 0.3 mg/kg/day for adults or 0.4 mg/kd/day for children over 8 consecutive days If no complete response (CR) occurs after 8 days, a second induction phase is conducted until day 16 (even if CR is obtained before completion of the second induction phase).~Maintenance Phase: 0.4 mg/kg administered 3 times a week until Day 28 In case of a CR at day 9, the maintenance phase will start after day 9 and will be sustained until day 28.~In case of a CR, partial response (PR) or mixed response (MR) at day 17, the maintenance phase will start after day 17 and will be sustained until day 28.~Total duration of treatment is 28 ±2 days."
214299511|NCT03077802|OTHER|Modified Seldinger technique, Experienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
214299512|NCT03077802|OTHER|Seldinger technique, Experienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
214669345|NCT00524095|DRUG|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
214669346|NCT03471754|DEVICE|TESA-HB Transcranial Electronic Stimulation Device|Duration of treatment: 50 Minute Therapy sessions administered one time each day, for two 5-day cycles
214669347|NCT04144062|OTHER|CAD/CAM crowns|CAD/CAM crowns
214669348|NCT00480961|PROCEDURE|intramiocardiac autograft of autologous stem cells|
214299513|NCT03077802|OTHER|Modified Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
214299514|NCT03077802|OTHER|Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
214299515|NCT03077802|OTHER|Long-axis technique|Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.
214299516|NCT03077802|OTHER|Short-axis technique|Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.
214299517|NCT05783115|PROCEDURE|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion|transverse bone transport with bone marrow cell transplantation
214299518|NCT05783115|PROCEDURE|Tibial Transportation|transverse bone transport
214299519|NCT03674242|DRUG|eryaspase (L-asparaginase encapsulated in red blood cells)|IV infusion 100 U/kg
214299520|NCT03674242|DRUG|Gemcitabine|IV infusion 1000 mg/m2
214299521|NCT03674242|DRUG|Carboplatin|IV infusion AUC2
214299522|NCT06053138|DIETARY_SUPPLEMENT|Ketone monoester|Supraphysiological levels of ketosis acutely, part 1, and intermittently and longer lasting, part 2, as obtained by ingestion of a ketone monoester dietary supplement
214299523|NCT06053138|DIETARY_SUPPLEMENT|Placebo|The placebo vehicle is matched to the ketosis intervention in the experimental arm with regards to taste, volume, viscosity, appearence, and packaging
214299524|NCT01329640|DEVICE|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|"1. Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~2. Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks"
214478668|NCT04472013|OTHER|Microscopy of defined brain regions on autopsy specimens|High dimensional, microglia-centric CODEX fluorescent microscopy of defined brain regions on autopsy specimens will be acquired from medulla oblongata, cortex, cerebellum, and olfactory bulb. A brain-specific CODEX panel for the assessment of the immune microenvironment was implemented, with inclusion of a wide array of myeloid/microglia markers, T-cell markers, and a few neuronal markers. All the antibodies have been validated and tested in formalin-fixed tissues of different zones of glioblastoma tumors including invading tumor periphery. The Panel will be modified to include the viral entry receptors, CD147, ACE2 and TMPRSS2. Presence of SARS-CoV-2 virus particles will be assessed by qPCR, andMultiplexed Ion Beam Imaging (MIBI) technology will be used to visualize tropism of virus to specific cellular brain compartments.
214669349|NCT04880811|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 21 day cycle.
214669350|NCT04880811|DRUG|Toripalimab|Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
214898532|NCT02920671|OTHER|Muscle MRI|Non-invasive muscle MRI will be performed to evaluated metabolic capacity.
214898533|NCT02920671|OTHER|Dual energy x-ray absorptiometry (DXA)|DXA will be performed to evaluate body composition.
214898534|NCT02920671|OTHER|Questionnaires|Questionnaires will be used to evaluate participants' health and habits.
214898535|NCT06328933|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214299525|NCT00488163|DRUG|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
214299526|NCT03394092|DIAGNOSTIC_TEST|Quantitative measurements the changes of IgG glycosylation|Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
214299527|NCT01577147|OTHER|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
214299528|NCT05888246|DIAGNOSTIC_TEST|Magnetocardiogram|Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
214299529|NCT00413192|DRUG|E7389|1.4 mg/m\^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
214299530|NCT01769833|DRUG|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
214299531|NCT01769833|DRUG|Nucleosides|
214299532|NCT03988192|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
214299533|NCT02589782|DRUG|Bedaquiline|
214299534|NCT02589782|DRUG|Pretomanid|
214299535|NCT02589782|DRUG|Moxifloxacin|
214299536|NCT02589782|DRUG|Linezolid|
214299537|NCT02589782|DRUG|Clofazimine|
214299538|NCT02589782|DRUG|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
214299539|NCT00939276|DRUG|Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
214299540|NCT00939276|DRUG|Nepafenac ophthalmic suspension vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
214299541|NCT05009940|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
214299542|NCT04516590|OTHER||There was no intervention in this observational study
214299543|NCT00159250|DRUG|AVI-4658 (PMO)|morpholino antisense oligonucleotide
214299544|NCT01829555|BEHAVIORAL|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
214299545|NCT04117425|BIOLOGICAL|biological collection|"Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption."
214299546|NCT04730830|OTHER|Questionnaire|Patients completing emergence assessment questionnaires at the time of the first dressing placement, as well as at the scheduled weekly placement. As part of a planned repair, the emergence will be assessed at most once a week, preferably at the beginning of the week by the patient. In any other case of dressing change, an emergence assessment will be requested.
214299547|NCT01882374|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
214299548|NCT03573947|DRUG|Nivolumab|360 mg intravenously every 3 weeks
214299549|NCT03573947|DRUG|Ipilimumab|1 mg/kg intravenously over 30 minutes
214299550|NCT03573947|DRUG|Paclitaxel|80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
214299551|NCT02588170|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
214299552|NCT02588170|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
214299553|NCT00842283|OTHER|skin tissue sample|skin tissue sample
214299554|NCT03008083|DRUG|3 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
214299555|NCT03008083|DRUG|12 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
214299556|NCT02335164|BIOLOGICAL|recombinant influenza hemagglutinin|recombinant influenza hemagglutinin
214299557|NCT02335164|BIOLOGICAL|Advax1|Delta inulin adjuvant formulation 1
214299558|NCT02335164|BIOLOGICAL|Advax2|Delta inulin adjuvant formulation 2
214299559|NCT05303207|DIETARY_SUPPLEMENT|YOUR SUPER Detox Bundle|During days 1-5, participants will complete the 5-day Your Super Detox, consuming 2 smoothies daily (breakfast and dinner) containing Your Super Detox superfood powders.
214299560|NCT00000381|DRUG|Fluoxetine|
214299561|NCT05393141|BEHAVIORAL|diet and biopsychosocial exercise intervention|dietary intervention: biopsychosocial exercise intervention:
214299562|NCT01304966|PROCEDURE|biopsy|excisional biopsy
214299563|NCT04467879|DEVICE|Zona Plus Device|Zona Plus 3.0 Individualized Isometric Handgrip Therapy Device
214299564|NCT04467879|DEVICE|Control Device|Zona Plus control sham device, with a nominal weaker grip
214299565|NCT00870896|DRUG|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
214299566|NCT05891483|DRUG|SHR-1905 Injection|SHR-1905 Injection
214299567|NCT05891483|DRUG|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
214299568|NCT04164615|DRUG|GB221|"GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
214299569|NCT04164615|DRUG|Placebo control|"Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
214299570|NCT00003901|OTHER|immunohistochemistry staining method|
214669351|NCT04230577|DEVICE|Real LED Intervention|A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
214299571|NCT00003901|PROCEDURE|biopsy|
214299572|NCT00003901|PROCEDURE|surgery|
214299573|NCT00144209|DRUG|pramipexole|
214299574|NCT00144209|DRUG|levodopa in combination with benserazide|
214299575|NCT05319795|BEHAVIORAL|Effortful Swallow Maneuver|Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
214299576|NCT02813564|BEHAVIORAL|Cognitive Assessment & Video-game INtervention Solutions (CAVINS)|"This is a computerized video-game like intervention. The participants will exercise/strengthen the cognitive (mental) deficits that may be responsible for symptom profiles such as socialization impairments, academic disabilities, and repetitive behaviour for several weeks. This program will stimulate communication between brain regions that make up an information processing neural network in order to promote proper network development."
214299577|NCT02637752|BEHAVIORAL|Lifestyle counseling or nutrition/physical counselling|A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
214478669|NCT06299683|BEHAVIORAL|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population and tested in a prior study. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
214478670|NCT06299683|OTHER|Pelvic Floor Physical Therapy|The pelvic floor physical therapy condition consists of 10 weekly 45-minute individual visits with an assigned trained physical therapist. In IC/BPS, pelvic floor physical therapy (PT) uses manual manipulation to release localized muscle tension, trigger points, and correct other scars and restrictions to reduce pain and urgency symptoms. Specific techniques will include external connective tissue manipulation to the abdominal wall, back, buttocks and thighs, myofascial trigger point release, and internal transvaginal/transrectal treatment of the soft tissues of the pelvic floor with connective tissue and myofascial manipulation to pelvic floor musculature
214898536|NCT06328933|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214898537|NCT06328933|BEHAVIORAL|comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214898538|NCT01756183|DRUG|S-1 + Paclitaxel Chemotherapy|"Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1"
214898539|NCT05919277|DIAGNOSTIC_TEST|Dengue Immunoglobulin G antibodies performed with ELISA|All participants who agree to participate by signing an informed consent form will undergo a finger prick for the determination of Immunoglobulin G antibodies measured by ELISA. In a subgroup of persons who test positive, they will be invited to have blood drawn for neutralization determination in order to study serotypes and the presence of other flaviviruses.
214898540|NCT02647697|DRUG|Radiprodil oral|"* Active Substance: Radiprodil~* Pharmaceutical Form: dry granules for oral suspension~* Concentration: 30 mg~* Route of Administration: oral use"
214898541|NCT06460805|DIETARY_SUPPLEMENT|Partial enteral nutrition|70% caloric intake from enteral nutrition formula and 30% caloric intake from a limited range of solid foods
214898542|NCT00795327|DEVICE|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
214898543|NCT04505527|BEHAVIORAL|Lateral stepping|Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.
214898544|NCT04505527|BEHAVIORAL|Forward walking|Subjects will have a typical forward walking
214898545|NCT01656980|DRUG|Carmustine|As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
214898546|NCT01656980|PROCEDURE|tumor resection surgery|For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
214299578|NCT03119194|DRUG|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
214299579|NCT05615012|DRUG|BMS-986322|Specified dose on specified days
214299580|NCT05615012|DRUG|Rosuvastatin|Specified dose on specified days
214299581|NCT05615012|DRUG|Metformin|Specified dose on specified days
214478671|NCT03901534|DEVICE|Continuous positive airway pressure (CPAP) therapy|Standard, clinically used CPAP therapy. CPAP will be prescribed by the participants' clinician provider and not by the study investigators.
214898547|NCT00297076|DRUG|GW873140|
214898548|NCT03716362|DEVICE|Otoacoustic emissions device|as a screening tool for Auditory brainstem response
214898549|NCT03700762|DIAGNOSTIC_TEST|ultrasound gray-scale ratio|RADinfo radiograph reading system was used to measure the gray-scales of PTMC, NG, and thyroid tissues at the same gain level, the UGSR values of the PTMC, NG, and thyroid tissue were calculated.
214299582|NCT05615012|DIETARY_SUPPLEMENT|Glucose|Specified dose on specified days
214299583|NCT05615012|DRUG|Methotrexate|Specified dose on specified days
214299584|NCT05615012|DRUG|Leucovorin|Specified dose on specified days
214898550|NCT02486874|DEVICE|PoreSkin|a human acellular dermal matrix
214299585|NCT00774618|DEVICE|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
214299586|NCT01078012|BEHAVIORAL|Trained counselling|
214299587|NCT02417688|DEVICE|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
214299588|NCT04197089|DRUG|Vitamin D|First dose of 10.000 IU Vitamin D at baseline visit for all patients; stratification of treatment (10.000 or 50.000 IU Vitamin D) depending base 25(OH)Vitamin D levels. Treatment weekly during 4 weeks before scheduled cystectomy
214299589|NCT06377228|BIOLOGICAL|TAK-007|TAK-007 IV infusion.
214299590|NCT06377228|DRUG|Chemotherapy Agents|Fludarabine and cyclophosphamide IV infusion.
214299591|NCT02464345|BEHAVIORAL|HAPIFED|HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
214299592|NCT02464345|BEHAVIORAL|CBT-E|CBT-E therapy
214299593|NCT06378541|BEHAVIORAL|Virtual Hope Box Enhanced Facilitation|The VHB-EF intervention has two phases: (1) The in-person inpatient phase involves a single, one-on-one, 60-minute session delivered by the study interventionist prior to hospital discharge. During this session, the interventionist will obtain access to the participant's personal phone and assist them in downloading the VHB app. The interventionist will provide education about the app and personalized behavioral practice for each component of the app. They will also address strategies to enhance app use. In addition, participants will receive a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. (2) The remote-delivery phase builds on the work begun in the hospital via 2 follow-up phone contacts within 14 days following discharge, during which the study interventionist will monitor risk, review/revise VHB content, and support app use and outpatient treatment engagement.
214299594|NCT06378541|BEHAVIORAL|Enhanced Usual Care|The EUC condition will involve a one-on-one, 30-minute session delivered prior to hospital discharge, during which the study interventionist will review a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. The EUC session will remain focused only on reviewing the standardized list of Veteran and community services; no counseling will be provided, and the list provided by the study interventionist does not include non-services (i.e., does not list any smartphone applications, including the VHB app).
214299595|NCT06108791|DRUG|FIO2=0.8|the concentration of intraoperative inspired fraction of oxygen is 80% oxygen + 20% air
214299596|NCT06108791|DRUG|FIO2=0.33|the concentration of intraoperative inspired fraction of oxygen is 33% oxygen + 66% air
214299597|NCT02268864|DRUG|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
214299598|NCT02268864|DRUG|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
214299599|NCT00006337|DRUG|KW-6002|
214299600|NCT00006337|DRUG|IV Levodopa|
214299601|NCT00003147|BIOLOGICAL|Ad5CMV-p53 gene|
214299602|NCT03737747|PROCEDURE|induced hypothermia|
214299603|NCT02499250|DEVICE|remote ischemic conditioning (TDFT-12-A2)|"The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd."
214299604|NCT02499250|DRUG|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
214299605|NCT04072211|BIOLOGICAL|Engerix-B|Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
214299606|NCT00003573|BIOLOGICAL|filgrastim|
214299607|NCT00003573|DRUG|cisplatin|
214299608|NCT00003573|DRUG|cyclophosphamide|
214299609|NCT00003573|DRUG|etoposide|
214299610|NCT00003573|DRUG|vincristine sulfate|
214299611|NCT00003573|RADIATION|radiation therapy|
214478672|NCT03901534|DEVICE|Nox A1 Recorder|Non-invasive, body-worn, sleep recording device for nocturnal polysomnography.
214299612|NCT06084546|DEVICE|geko™ X-W3|The geko™ X-W3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ W3 device and the new geko™ XW-3 device is the adhesive used to attach each device to the skin.
214299613|NCT03371628|DEVICE|Non invasive ventilation|Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
214478673|NCT06583213|PROCEDURE|Fractional Spinal Anaesthesia.|An intrathecal catheter 20 G will be then inserted 4-5 cm into the intrathecal space.This technique of SA will be performed on all patients , the needle should be inserted between L3 and L4 space or L4 and L5 space in order to avoid injury to the spinal cord. An intrathecal mixture (5mL) containing 3 mg/ml hyperbaric bupivacaine and 1 μg/ml dexmedetomidine will be prepared. Intrathecal anaesthesia will be induced by giving 2 mL (6 mg of hyperbaric bupivacaine and 2 μg of dexmedetomidine ) of the mixture, followed by a second 2 mL injection after 25 min. (i.e., a total intrathecal dose (4mL) of 12 mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ).
214898551|NCT01107691|OTHER|Amount of resistance offered in training|to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
214299614|NCT06493396|DRUG|Opioid-free Analgesics|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
214299615|NCT06493396|DRUG|Opioid group|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
214299616|NCT03731520|DIAGNOSTIC_TEST|Assessing exercise behavior|11-point Numeric Analogue Scale (NRS) for satisfaction of exercising, Exercise Stages of Change Scale-Short Form (ESCS), Exercise Self-Efficacy Scale (ESES), and Decisional Balance Scale (DBS) for exercise behaviour will be inquired for the patients with JIA.
214299617|NCT04729569|PROCEDURE|Feather edge finish line preparation|Tooth preparation with feather edge finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
214299618|NCT04729569|PROCEDURE|Deep chamfer finish line preparation|Tooth preparation with deep chamfer finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
214299619|NCT04184531|OTHER|Medical Data Collect|It is a retrospective clinical study and we will collect only the medical data registered in our hospital software
214299620|NCT01524848|DRUG|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
214299621|NCT00073359|BEHAVIORAL|Cognitive Behavioral Therapy|
214299622|NCT00204854|BEHAVIORAL|telephone counseling|
214299623|NCT02937519|DEVICE|Chrono-chemotherapy pump:Melodie|
214299624|NCT02937519|DEVICE|Routine intravenous drip|
214299625|NCT02937519|DRUG|induction Chrono-chemotherapy|
214299626|NCT02937519|DRUG|induction Routine-chemotherapy|
214299627|NCT02937519|DRUG|cisplatin chrono-chemotherapy|
214299628|NCT02937519|DRUG|cisplatin routine-chemotherapy|
214299629|NCT02937519|RADIATION|intensity-modulated radiation therapy|
214299630|NCT03888872|DEVICE|High tone power therapy|"1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week."
214299631|NCT03888872|OTHER|Selected Physical Therapy Program|"Selected physical therapy program: (For both groups).~1. Wobble board training:~2. Active range of motion exercises (AROM):~3. Gentle manual stretching exercises for both UL \& LL:~4. Graduated gait training:"
214669352|NCT04230577|DEVICE|Sham LED Intervention|A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
214669353|NCT05058872|DRUG|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg
214669354|NCT05058872|DRUG|Placebo|Placebo comparator
214299632|NCT00527943|DRUG|Vorapaxar|oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
214299633|NCT00527943|DRUG|Placebo|oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
214299634|NCT05954624|DRUG|Digoxin|oral
214299635|NCT05954624|DRUG|Rosuvastatin|oral
214299636|NCT05954624|DRUG|ZSP1273|oral
214299637|NCT05954624|DRUG|Itraconazole|oral
214299638|NCT05954624|DRUG|Probenecid|oral
214299639|NCT01447810|OTHER|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
214299640|NCT02345967|DEVICE|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
214299641|NCT03096327|DRUG|Montelukast|Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
214299642|NCT03096327|DRUG|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
214299643|NCT00177528|DRUG|venlafaxine-XR|
214299644|NCT00035464|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
214669355|NCT05463601|DRUG|Mecapegfilgrastim|Mecapegfilgrastim
214669356|NCT05463601|DRUG|dalpiciclib|dalpiciclib
214669357|NCT05463601|DRUG|exemestane, fulvestrant, letrozole, tamoxifen|endocrine therapy
214669358|NCT03056287|BEHAVIORAL|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
214669359|NCT03056287|OTHER|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
214669360|NCT06506279|DEVICE|CorTec Brain Interchange (BIC) System|Surgical implantation of the BIC System. This study's main objective is to implement and evaluate neuroplasticity-inducing stimulation. The stimulation methods for inducing neuroplasticity have been selected based on prior preclinical and intraoperative work that has shown promise in providing rehabilitative benefits for stroke patients.
214669361|NCT00015249|DRUG|Amantadine|
214299645|NCT00035464|DRUG|Placebo|placebo tablets, twice a day for 6 months
214299646|NCT01908361|BEHAVIORAL|Unilateral Hybrid (InMotion3 plus CIT) Intervention|"During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.~During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions."
214299647|NCT01908361|BEHAVIORAL|Bilateral Hybrid (BMT plus BAT) Intervention|"During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.~During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands."
214299648|NCT01908361|BEHAVIORAL|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
214299649|NCT03016962|DEVICE|cap-assisted colonoscopy|cap-assisted colonoscopy
214299650|NCT03016962|DEVICE|Standard colonoscopy|Standard colonoscopy
214299651|NCT00441311|BEHAVIORAL|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
214299652|NCT00352521|DRUG|bevacizumab|
214299653|NCT00352521|DRUG|irinotecan|
214299654|NCT00352521|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214299655|NCT02211521|BIOLOGICAL|PRP|3ml of PRP
214299656|NCT02211521|DRUG|Hyaluronic acid|3ml hyaluronic acid
214299657|NCT00742001|BIOLOGICAL|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
214299658|NCT02617511|DIETARY_SUPPLEMENT|Omega-3 Supplementation|
214299659|NCT02617511|DIETARY_SUPPLEMENT|Placebo|
214299660|NCT05592782|BEHAVIORAL|Virtual Reality Based Mindfulness meditation|Participants will undergo a guided VR meditation using a commercial VR application. The meditation will last approximately 15 minutes. Prior to starting and on upon completion of each VR meditation session, participants' state pain, anxiety, depression, and stress will be assessed. For each participant enrolled, baseline and monthly assessments using the DASS-21 and PPI-SFI3a will be performed for three consecutive months.
214299661|NCT02373020|OTHER|colonoscopic biopsies|
214299662|NCT03646682|PROCEDURE|vitrectomy with membrane peeling|during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
214478674|NCT06583213|PROCEDURE|Conventional Spinal Anaesthesia|"Intrathecal anaesthesia will be induced by giving 12.5 mg Hyperbaric bupivacaine (2.5mL) and 4 μg of dexmedetomidine (1mL) (i.e., a total intrathecal dose (3.5 mL) of 12.5mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ). (Mohamed T et al., 2017).~Sensory level will be monitored by cold spray. Haemodynamic recordings will be documented every five minutes up until 45 minutes."
214478675|NCT03327714|BEHAVIORAL|Mindfulness and compassion|
214478676|NCT05161819|DEVICE|Repetitive transcranial magnetic stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses
214478677|NCT05161819|DEVICE|Sham stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses (with sham coil)
214898552|NCT04718831|DIETARY_SUPPLEMENT|Spirulina|Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.
214898553|NCT00026065|BEHAVIORAL|Biofeedback|
214898554|NCT05988580|OTHER|Pasta dish with resistant starch|Pasta dish with 20-22% of resistant starch
214898555|NCT05988580|OTHER|Original version of pasta dish|Original pasta dish, not reinforced with resistant starch
214898556|NCT00896974|OTHER|Laboratory Biomarker Analysis|Correlative studies
214898557|NCT00896974|OTHER|Pharmacological Study|Correlative studies
214898558|NCT00896974|DRUG|Retinoid 9cUAB30|Given orally
214898559|NCT00556244|PROCEDURE|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
214898560|NCT02214992|DRUG|Telmisartan/Ramipril|Fixed dose combination tablet
214898561|NCT02214992|DRUG|Telmisartan|
214898562|NCT02214992|DRUG|Ramipril capsule|
214898563|NCT02214992|DRUG|Ramipril tablet|
214299663|NCT05023746|DIAGNOSTIC_TEST|Genetron lung cancer panel|Follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with Genetron lung cancer panel and comparison methods. The detection results are compared, and the samples that are inconsistent with the detection results of similar products on the market are reviewed by the the Sanger sequencing method, when the site detection results compared with Sanger sequencing method are inconsistent, Sanger's detection results are recognized. The results were determined independently according to the cutoff values or interpretation requirements provided by each method, and relevant statistics were used to evaluate clinical application performance of Genetron lung cancer panel.
214478678|NCT06407739|OTHER|Three-Phase Physical Therapy Intervention|Phase 1: It include subtalar and talocrural joint mobilization in the supine position along with stretching and home education Stage 2: It include subtalar and talocrural joint mobilization in the supine position along with Kinesiotaping and functional exercises Phase 3: this phase include balance and propioceptive training aling with along with strengthening exercises of peroneal and tibialis anterior
214478679|NCT06814769|DEVICE|hyaluronic acid|intra-articular administration
214898564|NCT05256186|OTHER|Basketball Pre-injury Attack program|The intervention had a total duration of 24 weeks, with 3 sessions per week (before starting training) with a total duration of 12 to 15 minutes per session. Each session consisted of 8 exercises with a load of 2 to 3 series between 6 and 12 repetitions; and with a rest at the end of each series of \<60 seconds.
214898565|NCT02371434|BIOLOGICAL|autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)|autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 10\^6, 1 x 10\^6, and 2.5-3 x 10\^6 cells/kg body weight in cohorts of three patients each.
214898566|NCT04805112|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing. Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
214898567|NCT03367819|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214898568|NCT03367819|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214898569|NCT01835041|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
214898570|NCT01835041|DRUG|oxaliplatin|Given IV
214898571|NCT01835041|DRUG|leucovorin calcium|Given IV
214898572|NCT01835041|DRUG|irinotecan hydrochloride|Given IV
214898573|NCT01835041|DRUG|fluorouracil|Given IV
214898574|NCT01835041|OTHER|laboratory biomarker analysis|Correlative studies
214898575|NCT00835302|PROCEDURE|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
214898576|NCT00102752|DRUG|Glufosfamide|
214898577|NCT00102752|DRUG|Gemcitabine|
214898578|NCT02833987|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
214898579|NCT02833987|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
215053139|NCT04660695|DEVICE|EUS-guided gastroenterostomy|Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
215053140|NCT01048242|DRUG|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
214478680|NCT05659147|DIAGNOSTIC_TEST|Research MRI without administration of intravenous secretin|Participants will undergo a research MRI examination. MRI images will be quantitatively analyzed and will be compared to / used to predict diabetes.
214898580|NCT02833987|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
214898581|NCT02833987|DRUG|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
214898582|NCT05387187|DRUG|Pu Yang Wan Wu Tang plus Pentoxifylline|Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
214898583|NCT05387187|DRUG|Pentoxifylline|Pentoxifylline 100mg TID
214898584|NCT00584454|BIOLOGICAL|Q Fever Vaccine (NDBR 105|Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
214898585|NCT02176954|DEVICE|Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
214898586|NCT02176954|DEVICE|Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
214898587|NCT02176954|DEVICE|Comparator|"Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed."
214898588|NCT00033397|PROCEDURE|biopsy|
214898589|NCT00033397|PROCEDURE|magnetic resonance imaging|
214898590|NCT00033397|PROCEDURE|radiomammography|
214898591|NCT00033397|PROCEDURE|ultrasound imaging|
214898592|NCT00033397|RADIATION|gadopentetate dimeglumine|
214898593|NCT00033397|DRUG|chemotherapy|
214898594|NCT01889147|BIOLOGICAL|hRESCAP|one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
214898595|NCT01889147|BIOLOGICAL|Placebo|
214898596|NCT03075020|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
215053141|NCT01048242|DRUG|Placebo|placebo
215053142|NCT05351177|OTHER|Exercise Training|Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
215053143|NCT02964273|DRUG|Tolvaptan|Tolvaptan spray-dried, immediate release tablets
215053144|NCT02964273|DRUG|Tolvaptan Matching-placebo|Tolvaptan matching-placebo tablets
215053145|NCT03358355|DRUG|unacelyated ghrelin|We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
215053146|NCT03333928|DRUG|HTD1801|HTD1801 tablets, 250 mg
215053147|NCT03333928|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
214299664|NCT01050257|DRUG|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
214299665|NCT01050257|DRUG|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
214299666|NCT00171223|DRUG|STI571|STI571 oral capsules or tablets.
214299667|NCT01618552|BEHAVIORAL|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
214299668|NCT01618552|OTHER|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
214299669|NCT00116051|DEVICE|Acetabular implant, Monoblock cup|
214299670|NCT04238351|DEVICE|Transnasal humidified rapid insufflation ventilator exchange|applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.
214299671|NCT04238351|DEVICE|Conventional face mask|applying oxygen using usual face mask
214299672|NCT03770650|PROCEDURE|Stenting|DK crush technique with SYNERGY (Boston Scientific) drug-eluting stent implantation.
214299673|NCT03786757|DRUG|Rivaroxaban|Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
214898597|NCT03075020|OTHER|AIR|Room air will be administered as placebo
214898598|NCT05582798|DRUG|Alpha 1-Proteinase Inhibitor 180mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
214898599|NCT05582798|DRUG|Alpha 1-Proteinase Inhibitor 120mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
214898600|NCT05582798|DRUG|Sodium chloride|Sodium chloride 09.% intravenous infusion
214898601|NCT05579457|OTHER|Short Physical Performance Battery|The SPPB was applied to determine the physical performance levels of the elderly. This test is a valid and reliable test that measures the performance of the lower extremities and can be applied for elderly. The SPPB included three sections: getting up from a chair, standing balance, and walking speed. At the end of these tests, the scores of the three sections were calculated and higher scores were evaluated as reflecting higher levels of physical performance
214898602|NCT05416840|DRUG|Clonidine controlled-release patch|"Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
214898603|NCT05416840|DRUG|Amlodipine|"Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
214898604|NCT01907230|DRUG|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
214898605|NCT05260294|PROCEDURE|Epidural space identification with cervical epidural steroid injection employing CST and LORT.|Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.
214898606|NCT05667376|OTHER|Local drug delivery|Local application of curcumin gel into the periodontal pocket
214898607|NCT05667376|DRUG|curcumin gel|curcumin gel
214898608|NCT01254773|DRUG|Experimental Bapineuzumab|Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
214299674|NCT05093296|DRUG|Oxytocin nasal spray|24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.
214299675|NCT05093296|DRUG|Naltrexone Pill|All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
214299676|NCT05093296|DRUG|Placebo|Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
214478681|NCT05659147|DIAGNOSTIC_TEST|Research MRI with administration of intravenous secretin|Participants will undergo a research MRI examination with intravenous administration of secretin. MRI images will be quantitatively analyzed and will be compared to / used to predict exocrine and endocrine pancreatic insufficiency based on the reference standards of ePFTs or fecal elastase and blood hemoglobin A1c (HbA1c) and fasting glucose, respectively.
214299677|NCT03171987|DRUG|Lidocaine patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
214299678|NCT03171987|DRUG|Flurbiprofen patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
214299679|NCT04229004|DRUG|Gemcitabine combined with nab-paclitaxel|"Arm is closed to recruitment.~Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle.~If one of the chemotherapy medications is held, the other study medications may be given.~Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
214299680|NCT04229004|DRUG|Dose -mFOLFIRINOX|"Arm is closed to recruitment.~The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
214299681|NCT04229004|DRUG|Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel|"Arm is closed to recruitment.~Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15)~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle"
214299682|NCT04229004|DRUG|Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine|"Arm is closed to recruitment.~Canakinumab 250mg SC- Day 1 of every 28 day cycle~Spartalizumab 400 mg IV - Day 1 of every 28 day cycle~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle"
214299683|NCT04229004|DRUG|Drug: Dose -SM-88|"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus."
214299684|NCT01627821|DEVICE|Jarvik 2000 VAS|Jarvik 2000 LVAD
214299685|NCT01627821|DEVICE|HeartMate II|HeartMate II LVAD
214299686|NCT03625921|BEHAVIORAL|Powered device with physical therapy|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.
214299687|NCT03625921|BEHAVIORAL|Powered device with standard of practice|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
214299688|NCT00006101|DRUG|eflornithine|Take 500mg of DFMO per day for 12 months
214299689|NCT00006101|DRUG|Placebo|Take placebo per day for 12 months
214299690|NCT04949165|DIETARY_SUPPLEMENT|Iron Supplementation|low dose ferrous sulphate (65mg elemental iron) supplements
214299691|NCT02167607|DIETARY_SUPPLEMENT|Active Comparator|Purple Potato
214299692|NCT02167607|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Comparator
214299693|NCT06007599|PROCEDURE|Skin closure using skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures with skin adhesive
214299694|NCT06007599|PROCEDURE|Skin closure without skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures without skin adhesive
214299695|NCT04999462|OTHER|Full-fat fermented dairy|Subjects assigned to the full-fat fermented dairy condition will consume 1 serving/d each of full-fat yogurt (plain or reduced sugar varieties) and full-fat fermented cheese.
214299696|NCT04999462|OTHER|Low-fat fermented dairy|Subjects assigned to the low-fat fermented dairy condition will consume 1 serving/d each of low-fat yogurt (plain or reduced sugar varieties) and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
214299697|NCT04999462|OTHER|Non-dairy, non-fermented foods|Subjects assigned to the control condition will consume 2 servings/d of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
214299698|NCT04245423|BEHAVIORAL|Collaborative Care for Opioid Use Disorders and Mental Health Conditions|CC is delivered using the investigators' Foundations for Integrated Care model. The first line pharmacotherapy is buprenorphine-naloxone. The second line pharmacotherapy included is extended-release injectable naltrexone. Pharmacotherapy is accompanied by brief problem-solving therapy, cognitive-behavioral therapy, and/or motivational interviewing. The primary care physician, in consultation with the addictions psychiatrist and care manager, also will provide psychotropic medications for psychiatric disorders. In-person and telephone visits consist of the care manager carrying out intervention activities over 6 months. Visits are at baseline (90-minute intake appointment), home or office induction when in moderate opiate withdrawal if buprenorphine is prescribed, twice a week for two weeks with telephone calls in between visits, then weekly, and when stable once a month. There will be a final visit at 6 months. The intervention includes routine collection of urine drug screens.
214898609|NCT03564392|BEHAVIORAL|Acceptance Based Behavioral Intervention|This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
214898610|NCT05870384|BEHAVIORAL|Group Interpersonal Psychotherapy|Ten sessions of IPT-G, which focuses on the common problem area of patient relatives, will be applied.
214898611|NCT04504994|BEHAVIORAL|inclusion condition|cyberball game: ex- versus over-inclusion condition
214898612|NCT00676702|DIETARY_SUPPLEMENT|Ensure Plus|A high-fat liquid meal of 500 ml of Ensure Plus
215053148|NCT05023785|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
214898613|NCT00676702|DRUG|Pancrelipase in combination with Ensure Plus|3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
215053149|NCT05606848|OTHER|Nutrition Emulsion (TPF-T)|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake control product with recommended energy.~* 1-8 days after surgery: Patients gradually increase control product intake to reach the recommended energy."
215053150|NCT05606848|OTHER|Foods for special medical purposes [FSMP] for patients with tumors|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake FSMP with recommended energy.~* 1-8 days after surgery: Patients gradually increase FSMP intake to reach the recommended energy."
214299699|NCT04245423|BEHAVIORAL|Augmented Usual Care|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. All practices will have mental health clinicians to treat mild psychiatric disorders. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD.
214299700|NCT04245423|BEHAVIORAL|Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists|This intervention includes the Collaborative Care Intervention plus Certified Recovery Specialist to assist with treatment engagement and retention.
214299701|NCT04784052|DRUG|JSP191|Participants will receive a single IV dose at start of conditioning
214299702|NCT04784052|DEVICE|CliniMACS Prodigy System|The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
214299703|NCT04784052|BIOLOGICAL|Depleted Stem Cell Transplant|TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
214299704|NCT04784052|BIOLOGICAL|Rabbit Anti-Thymoglobulin (rATG)|3 consecutive daily doses of rATG will be given by IV during conditioning
214299705|NCT04784052|DRUG|Cyclophosphamide|4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
214299706|NCT04784052|DRUG|Fludarabine|4 consecutive daily doses of fludarabine will be given by IV during conditioning
214898614|NCT05589077|BEHAVIORAL|Education on Female Athlete Nutritional Concerns|Visual and audio information presented within the Qualtrics system will cover topics on the Female Athlete Triad, Relative Energy Deficiency in Sport, and eating disorders.
214898615|NCT00725920|DRUG|Topiramate|patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day
214299707|NCT04784052|DRUG|Rituximab|1 dose of rituximab will be given at the end of conditioning
214299708|NCT04849351|DRUG|HMPL-689|All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
214898616|NCT00725920|DRUG|placebo control group|initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
214898617|NCT01057680|DIETARY_SUPPLEMENT|creatine monohydrate|Powder, 0.1 g per day, 12 months
214898618|NCT01057680|DIETARY_SUPPLEMENT|sugar placebo|powder, 0.1 g/day, 12 months
214478682|NCT05659147|GENETIC|Genetic Sequencing|Blood will be drawn to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
214299709|NCT05791383|DEVICE|transcutaneous auricular neurostimulation|All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
214299710|NCT01321515|DRUG|famciclovir|500 mg tablet
214299711|NCT03523754|DRUG|Isosorbide Mononitrate 40 MG to study group|Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening \& induction of labor in study group
214299712|NCT03996954|DEVICE|Alivecor recording|Alivecor recording and ECG recording from the same patient in very close temporal proximity
214299713|NCT03940066|DEVICE|Biomonitor-2 and Kardia mobile|Implantable cardiac monitor and Smart-phone based electrocardiogram recording
214299714|NCT03940066|OTHER|No Intervention|No intervention
214299715|NCT05414331|OTHER|Discontinuing all beta-blocker|All beta-blockers will be stopped 2 months after CABG
214299716|NCT02981498|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214898619|NCT03918629|BIOLOGICAL|Clostridium difficile|Toxoid-based Clostridium difficile vaccine
214898620|NCT03918629|BIOLOGICAL|Placebo|Normal saline solution (0.9% sodium chloride)
215053151|NCT01282255|DRUG|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
214478683|NCT05659147|DIAGNOSTIC_TEST|Blood Tests|Research blood draw (for markers of pancreatic endocrine insufficiency)
214299717|NCT02981498|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
214299718|NCT00612924|DEVICE|Anaconda Stent Graft System|Endovascular device
214299719|NCT00612924|DEVICE|Anaconda ONE-LOK Stent Graft System|Endovascular device
214478684|NCT05659147|DIAGNOSTIC_TEST|Stool Tests|Research stool collection (for fecal elastase as a marker of exocrine insufficiency)
214478685|NCT05659147|OTHER|Survey Completion|Participants will be contacted to complete a survey and their charts will be reviewed annually after research MRI to identify any evidence of subsequent development of pancreatic endocrine insufficiency or progression of pancreatitis. Survey and chart review will occur within +/- 14 days of the anniversary date.
214478686|NCT05659147|DIAGNOSTIC_TEST|Endoscopic pancreatic function tests (ePFTs)|At least two duodenal fluid aspirates will be collected over 15 minutes following secretin administration. Aspirates will be immediately pH tested and will be submitted for analysis of bicarbonate, enzyme (trypsin, amylase, lipase, chymotrypsin) activity, and total protein.
214478687|NCT05659147|DRUG|Secretin|"Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg).~Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI.~Participants in Aim 4 will receive two doses (1 during each MRI).~Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study."
214478688|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Test Arm|Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia
214299720|NCT04324554|DIAGNOSTIC_TEST|MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
214299721|NCT03033511|DRUG|Placebo for dexamethasone|Placebo for dexamethasone PO twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
214299722|NCT03033511|DRUG|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
214299723|NCT03033511|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
214299724|NCT03033511|DRUG|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
214299725|NCT00730912|DRUG|loratadine|Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
214898621|NCT05215444|DIAGNOSTIC_TEST|some prognostic factors|cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count
214898622|NCT03752814|DEVICE|SYNOSTE Nitinail System|Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
214898623|NCT04935541|DRUG|Dexmedetomidine infusion|After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
215053152|NCT01282255|DRUG|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
215053153|NCT04818307|OTHER|Macquarie Injury Management group|Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.
215053154|NCT04818307|OTHER|Mulligan Mobilization with Movement|Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
215053155|NCT03380637|OTHER|ultrasound|Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
215053156|NCT03372720|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
215053157|NCT03372720|OTHER|Questionnaire Administration|Ancillary studies
215053158|NCT03372720|PROCEDURE|Sham Intervention|Undergo sham laser therapy
214299726|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
214299727|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
214299728|NCT00987077|DEVICE|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
214299729|NCT05608746|OTHER|Physical Exercise|Home-based individualized training, consisting of unsupervised aerobic exercise and resistance exercise, with moderate intensity. The pt. receives an exercise manual and exercise videos online, through an APP.
214299730|NCT05608746|OTHER|Pelvic Floor exercise|Patients will be assessed by a physiotherapist and instructed in a pelvic floor exercise program, accessed through the APP. Furthermore, the pt. is provided with general information about pelvic floor anatomy and muscle function.
214299731|NCT05608746|OTHER|Sexual counseling|Patients will be provided with 1 video-consultation with a clinical sexologist, during the prehabilitation period. The patients will be instructed in strategies to improve postoperative communication regarding, sex, realistic expectations, erectile dysfunction and the use of aids.
215053159|NCT06176781|DRUG|Edaravone Dexborneol Sequential Therapy|Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).
215053160|NCT06176781|DRUG|Placebo|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
215053161|NCT01095081|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
215053162|NCT01453036|PROCEDURE|23S rRNA point mutation test of Helicobacter pylori|mutation test group\>\> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group \>\> no intervention
215053163|NCT01453036|PROCEDURE|UBT test & Gastroenterology with biopsy c silver stain|UBT test \& Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group \>\> intervention
214299732|NCT05608746|DIETARY_SUPPLEMENT|Nutritional supplement|Patients are systematically screened for malnutrition to assess the nutritional status. Patients are given recommendations with dietary advice online, through the APP. If the patient is at nutritional risk, the patient is provided with a nutritional supplement.
214299733|NCT05608746|OTHER|Stress management|Patients are systematically screened for anxiety and depression. If patients are at risk of anxiety or depression, they are referred to a consultation with a nurse, who will provide information and strategies to handle the uncertainties they may experience.
214299734|NCT05608746|OTHER|Standard pre-surgical preparation and pt. information.|One week preoperatively the usual regime for the presurgical preparation and information will be followed.
215053164|NCT00559104|DRUG|carmustine|Unique to the Carmustine in Conditioning arm
215053165|NCT00559104|DRUG|cyclophosphamide|Used in Both Arms
214299735|NCT06235788|BEHAVIORAL|Experimental Group ICEMS verbal feedback with pause group|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down and reflecting for 22 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
214299736|NCT06235788|BEHAVIORAL|Experimental Group ICEMS audio feedback with pause and expert video|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down, turning their attention to a 9-second expert-level demonstration video, and reflecting for 13 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
214299737|NCT03467841|DEVICE|CMV IgM, IgG in blood real time PCR for serum CMV DNA .|Colonoscopic examination will be done for all studied patients after standardbowel preparation using a Pentax videoscope to= Assess the endoscopic lesions using Mayo endoscopic subscore
214299738|NCT04656145|DEVICE|3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing|On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
214299739|NCT01457066|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
214299740|NCT02409459|DRUG|Injectafer|
214299741|NCT02409459|DRUG|Placebo|Normal saline solution
214299742|NCT01317745|OTHER|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
214299743|NCT01317745|DRUG|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
214299744|NCT01317745|BIOLOGICAL|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
214299745|NCT04147455|BEHAVIORAL|Adapted RealConsent|The program is a novel, theory-driven, evidence-based serial drama and educational program tailored to young men and delivered in six episodes via the web. Participants will view six 30-minute modules designed to prevent sexual violence in young men
214299746|NCT04147455|BEHAVIORAL|Health Education Control Condition|Participants will view six 30-minute web-based serial drama modules designed to promote health.
214299747|NCT03311659|BIOLOGICAL|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
214299748|NCT05241522|DIAGNOSTIC_TEST|Tc-99m-Tilmanocept|Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.
214299749|NCT06363656|DEVICE|Wears the smartwatch during the sleep time to capture sleep characteristics and answer questionaires|"* Synchronization of smartwatch with smartphone (internet connection) to send sleep characteristics captured by the application~* Weight~* Height~* Body measurements (circumferences)~* Questionnaires about overall health status~* Pittsburgh Sleep Quality Index questionnaire~* Insomnia Severity Index~* Sleep Hygiene Index~* Epworth Sleepiness Scale~* NoSAS score (Neck, Obesity, Snoring, Age, Sex)"
214299750|NCT05747092|PROCEDURE|gingival graft|"investigators:~Donor site:~* tissue graft harvesting from the palate behind the palatal rugae .~* placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~* Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~* Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope"
214898624|NCT04935541|DRUG|Remifentanil infusion|After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
214898625|NCT03288064|DIETARY_SUPPLEMENT|Corinthian currant|Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise
214898626|NCT03288064|DIETARY_SUPPLEMENT|Glucose drink|Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise
214898627|NCT03288064|DIETARY_SUPPLEMENT|Water ingestion|Supplementation of 7ml/kg BW prior to exercise
214898628|NCT01891864|DRUG|GP2015 Etanercept|Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
215053166|NCT00559104|DRUG|etoposide|Used in Both Arms
215053167|NCT00559104|PROCEDURE|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
214299751|NCT04053023|DRUG|GSK2330672 (linerixibat)|GSK2330672 is available as a tablet with unit dose strength of 45 mg.
214299752|NCT04053023|DRUG|Obeticholic acid|Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
214299753|NCT02972489|DEVICE|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
214299754|NCT02972489|DEVICE|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
214299755|NCT02577211|DIETARY_SUPPLEMENT|Hipocaloric enteral nutrition|15 kcal/Kg of body weight
214898629|NCT01891864|DRUG|Enbrel|Enbrel is used as reference product to GP2015.
214898630|NCT05491902|DIAGNOSTIC_TEST|[C11] Leucine PET scan|Each participant will receive an i.v. bolus of the PET radioligand, \[11C\]-Leucine (\<100 μg), for each scan. \[11C\]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (\<100 μg) with no adverse effects.
214898631|NCT05491902|DIAGNOSTIC_TEST|[18F] Flutemetamol PET scan|Each participant will receive an i.v. bolus of the PET radioligand, \[18F\]-Flutemetamol (\< 10 μg), for each scan.
214898632|NCT05491902|DIAGNOSTIC_TEST|MRI scan|Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.
214898633|NCT03793764|PROCEDURE|TAP block|USG guided TAP block
214898634|NCT03793764|PROCEDURE|QL block|USG guided QL block
214898635|NCT04480684|DIAGNOSTIC_TEST|Three-dimensional Endoanal Ultrasound|"Three-dimensional endoanal ultrasound is the gold standard diagnostic tool in the assessment of obstetric anal sphincter injury. The anorectal transducer is inserted directly into the anal canal which allows assessment of the anal sphincter complex.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
214898636|NCT04480684|DIAGNOSTIC_TEST|Transperineal Ultrasound(multiplanar)|"If endoanal ultrasound is declined or not tolerated, the anal sphincter will also be assessed using three-/four-dimensional (3D/4D) transperineal ultrasound with the probe placed externally on the area of the fourchette.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
214898637|NCT04480684|DIAGNOSTIC_TEST|The MolecuLight i:X: Bacterial autofluorescence camera|"The bacterial load of the perineal wound will be measured every week using the MolecuLight i:X. This is a system, which uses fluorescent illumination to capture and document the presence of bacteria.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed.~These findings will be supported by microbiological analysis of the wound fluid with swab culture and sensitivity."
214898638|NCT04480684|DEVICE|Silhouette® 3D camera: Three-dimensional wound measuring camera|For wound that have superficially dehisced, the wound surface area, depth, volume and healing progress will be precisely measured using the Silhouette® 3D camera. This is a system that uses 3D laser technology to track wound healing progression.
214898639|NCT02571699|OTHER|Subgluteal Nerve Block|ultrasound-guided subgluteal sciatic nerve block.
214898640|NCT03906799|DRUG|OMT-28|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
215053168|NCT00559104|PROCEDURE|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
215053169|NCT00559104|RADIATION|total-body irradiation|Unique to the Radiation in Conditioning Arm
215053170|NCT00559104|DRUG|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
215053171|NCT04879108|OTHER|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
215053172|NCT04879108|OTHER|Physiotherapy Rehabilitation|"Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
215053173|NCT01957293|DRUG|Salbutamol|single oral administration, 4 mg
215053174|NCT01957293|DRUG|Placebo|single oral administration
214299756|NCT02577211|DIETARY_SUPPLEMENT|Normocaloric enteral nutrition|25 kcal/kg of body weight
214898641|NCT03906799|DRUG|Placebo|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
214898642|NCT01959633|DRUG|Vemurafenib|Vemurafenib 960 mg b.i.d. for each course of treatment lasting 28 days
214898643|NCT01959633|DRUG|Peg-interferon|"In the Phase I are included 3 cohorts. Cohort 1) Peg-interferon 1 µg/Kg one time per week s.c. Cohort 2) Peg-interferon 2 µg/Kg one time per week s.c. Cohort 3) Peg-interferon 3 µg/Kg one time per week s.c. Interferon treatment should start after 15 days of Vemurafenib only~In the Phase II is included the cohort selected by phase I due to MTD and expanded at RD."
214898644|NCT01959633|DRUG|Cobimetinib|Cobimetinib 60 mg o.d. (21 days on followed by 7 days off)
214898645|NCT00000947|DRUG|Azithromycin|
214898646|NCT02771977|OTHER|Drug-specific alert|A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired.
214898647|NCT04785547|DRUG|Blinatumomab|15 mcg/m2/day for 28 days
214299757|NCT03604185|BEHAVIORAL|Choir Singing|A weekly 2-hour group choral session over fourteen weeks. Plus an optional weekly 1-hour online musical and vocal training session.
214299758|NCT03604185|BEHAVIORAL|Music Appreciation|A fourteen week course which will emphasize analytic listening to musical excerpts, and will match the choir class in terms of duration, homework demands, and instructor.
214299759|NCT04718467|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.
214299760|NCT04718467|BIOLOGICAL|Placebo|Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.
214898648|NCT01026753|BEHAVIORAL|Refrigerator Magnet|The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
214299761|NCT01019642|DRUG|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
214898649|NCT04720105|DRUG|Duobrii®|Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
215053175|NCT05544201|DEVICE|High-definition transcranial current stimulation|High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
214299762|NCT01019642|DRUG|placebo|no active principles given.
214299763|NCT03429179|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
214898650|NCT05978401|DRUG|GLS-012+GLS-010|Two dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
214898651|NCT05978401|DRUG|GLS-012+GLS-010|Target dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
214898652|NCT05978401|DRUG|GLS-012+GLS-010+pemetrexed+carboplatin|GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with pemetrexed and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
214898653|NCT05978401|DRUG|GLS-012+GLS-010+paclitaxel+carboplatin|GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with paclitaxel and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
214898654|NCT04252027|OTHER|Sample collection|Plasma and urine sample collection
214898655|NCT06165276|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
214898656|NCT06165276|BIOLOGICAL|Meningococcal Group C-CRM197 Conjugate Vaccine|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
214898657|NCT03358927|BEHAVIORAL|Immediate Fast-Track Care|Eligible for fast-track care at enrollment
214898658|NCT03358927|BEHAVIORAL|Deferred Fast-Track Care|Eligible for fast-track care after 6 months on ART
215053176|NCT06417827|DIAGNOSTIC_TEST|SP patients-actors|SP Actors employed by MesserMSR, the Israeli Center for Medical Simulation, trained to simulate symptoms of psychiatric illnesses.
215053177|NCT06417827|DIAGNOSTIC_TEST|Patients|Patients (n=150) examined in the psychiatric division and emergency room (ER) of Sheba Medical center. Or people who applied following an advertisement on social networks.
215053178|NCT06417827|DIAGNOSTIC_TEST|Control group- patients|Control group (n=50) Patients who came to the ER at the hospital due to physical complaints, and no psychiatric history.
215053179|NCT05294497|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
215053180|NCT05294497|OTHER|Product B|Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine
215053181|NCT05294497|OTHER|Product C|Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine
214299764|NCT03429179|OTHER|Physiological saline|intravenous infusion of the same volume of 0.9% saline
214299765|NCT00060931|DRUG|carvedilol|
214299766|NCT00060931|DRUG|metoprolol|
214898659|NCT03987789|OTHER|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers.
214898660|NCT03987789|OTHER|Low PEEP|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
214898661|NCT00882752|PROCEDURE|molecular analysis|bowel disease
214898662|NCT04705792|PROCEDURE|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
214898663|NCT02483676|DEVICE|Treadmill plus anklebot|This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.
214898664|NCT02483676|BEHAVIORAL|Treadmill only|This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period
214898665|NCT03926429|OTHER|Standardised data collection|The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).
215053182|NCT05294497|OTHER|Product D|Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine
215053183|NCT05294497|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
215053184|NCT05294497|OTHER|Product E|Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
215053185|NCT04740086|PROCEDURE|Calcium alginate hydrogel|"1. The external and internal fistulous orifice and fistulous tract were explored without applying any product, including hydrogen peroxide or povidone-iodine.~2. The seton was removed and FT cannulation was performed using a needle for cleaning with a gauze impregnated with saline.~3. Calcium chloride was applied through the EFO until it exits through the IFO, and then the IFO was obturated.~4. Alginate was applied, and the pressure at the IFO was stopped, until the alginate solution partial exits through the IFO.~5. The IFO was closed with a 3/0 braided resorbable suture.~6. The EFO was removed with an electric scalpel and closed with a 3/0 braided resorbable suture."
215053186|NCT00512850|DIETARY_SUPPLEMENT|Folic acid|Intervention group 1g folic acid per day
215053187|NCT00512850|OTHER|Placebo|One placebo pill per day
214898666|NCT02350465|BEHAVIORAL|Eccentric Exercise|Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
215053188|NCT04216849|BIOLOGICAL|human umbilical cord mesenchymal stem cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
215053189|NCT04216849|OTHER|saline|Saline solution containing human serum albumin will be infused to the control group
215053190|NCT05044650|DIETARY_SUPPLEMENT|KOVIR capsule combined with background treatment|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
215053191|NCT02396108|DRUG|Paclitaxel + Carboplatin + ASLAN001|"Phase I~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~* PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~* PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
214299767|NCT03948256|PROCEDURE|Control intervention|Prompt closure of EVD with subsequent observation period
214299768|NCT03948256|PROCEDURE|Experimental intervention|Gradual weaning of EVD with 5 cmH2O increase in drainage resistance daily until complete closure with subsequent observation period
214299769|NCT06376110|DRUG|Topical Antioxidant Serum|An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.
214299770|NCT06376110|DEVICE|AviClear Laser|The AviClear (1726nm) laser is FDA-cleared for use on mild to severe inflammatory acne, with a recommended treatment course comprised of 3 laser procedures each one month apart.
214299771|NCT01899794|PROCEDURE|TVT-O/Oxytrol|
214299772|NCT01899794|DEVICE|TVT-O|
215053192|NCT00111449|DRUG|Etanercept|
215053193|NCT03355950|PROCEDURE|Lichtenstein Repair|Well defined Lichtenstein Repair for inguinal hernias
215053194|NCT03355950|PROCEDURE|TEP Repair|Laparoscopic totally extraperitoneal repair for inguianal hernias
214299773|NCT01899794|DRUG|Oxytrol|
214299774|NCT02386904|DRUG|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
214299775|NCT00071760|DRUG|GW433908|Fosamprenavir suspension bid
214299776|NCT00071760|DRUG|ritonavir|Ritonavir solution bid
214299777|NCT00375739|DRUG|PEP005|
214478689|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Control Arm|Single vision, impact-resistant spectacle lenses
214898667|NCT02350465|BEHAVIORAL|Concentric Exercise|Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
214898668|NCT02477644|DRUG|Olaparib|Tablets, per os, 300 mg twice daily;
214898669|NCT02477644|DRUG|Placebo|Tablets, per os, 300 mg twice daily.
214898670|NCT03717155|DRUG|Avelumab|Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
214299778|NCT04144556|OTHER|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
214299779|NCT04144556|OTHER|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
214299780|NCT05568147|DRUG|Aspirin tablet|When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.
214299781|NCT05568147|DRUG|Placebo|When patients are randomized into the placebo group, they will receive placebo orally once a day.
214299782|NCT05052385|DRUG|Ruxolitinib|As per treating physician's decision - non interventional study
214299783|NCT05052385|DEVICE|Extracorporeal photopheresis|As per treating physician's decision - non interventional study
214299784|NCT05052385|DRUG|Ibrutinib|As per treating physician's decision - non interventional study
214299785|NCT02614950|OTHER|Treatment interruption|
214299786|NCT03488654|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance|CMR including cine, late gadolinium enhancement (LGE) and stress perfusion sequences
214299787|NCT06344754|OTHER|Gamified education|Training will be provided with gamification method. Data will be collected with \&#34;Introductory Information Form\&#34; and \&#34;Family Planning Attitude Scale\&#34;. The family planning attitude scale will be administered as both pre and post test.
214299788|NCT04651634|DRUG|MIT-001 plus CCRT|MIT-001 IV-infusion plus CCRT
214299789|NCT02202642|PROCEDURE|collagenase|Cultured limbal stem cells transplantation
214299790|NCT01994629|BIOLOGICAL|MenACWY-CRM|MenACWY-CRM
214299791|NCT01994629|BIOLOGICAL|MenACWY-TT|MenACWY-TT
214299792|NCT03945396|DRUG|Homeopathic Medication|A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
214299793|NCT03945396|OTHER|Multidisciplinary intervention (Exercise program, diet, motivational support)|"Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight."
214299794|NCT03945396|DRUG|Homeopathic placebo|A 30 ml bottle of 30% alcohol-distilled water.
214299795|NCT04364308|OTHER|Fetal Echography|Fetal ultrasound and its parameters
214299796|NCT00412022|DRUG|tamoxifen|20 mg daily for 5 years
214299797|NCT00412022|DRUG|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
214299798|NCT00412022|DRUG|letrozole|2.5 mg daily for 5 years
214299799|NCT00412022|DRUG|zoledronic acid|4 mg every 6 months
214299800|NCT06829953|BEHAVIORAL|GET ActivE|The GET ActivE health coach will review data from the Vira app and send nudges to the participant with insights encouraging them to engage in activities that bring enjoyment or pleasure.
214299801|NCT06829953|BEHAVIORAL|Treatment As Usual|Participants randomized to Treatment As Usual may have access to activity data from an app and receive summary information about activity patterns at the end of their participation.
214299802|NCT04566614|OTHER|ctDNA blood sampling|Screening/baseline blood sample to be analysed for ctDNA
214299803|NCT05193656|DIAGNOSTIC_TEST|Al_bladder|Detection of bladder tumor with help of Artificial intelligence
214299804|NCT02625155|OTHER|Urine diagnostic testing as SOC, drug regimen changes per SOC|
214299805|NCT02625155|OTHER|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
214299806|NCT05483179|DIAGNOSTIC_TEST|CPET|Cardiopulmonary exercise test
214299807|NCT04759209|DIAGNOSTIC_TEST|Biopsies|
214299808|NCT03424265|DIETARY_SUPPLEMENT|EAA mixture|Dietary supplement intervention for 12-weeks
214299809|NCT03424265|DIETARY_SUPPLEMENT|Placebo (whey protein)|Dietary supplement intervention for 12-weeks
214299810|NCT01558752|DEVICE|Total hip replacement with titanium shell and CORAIL stem|Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
214299811|NCT01558752|DEVICE|Total hip replacement with Modular Titanium Femoral Stem|Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
214299812|NCT01716598|DEVICE|IPS System|TLD Therapy will be achieved bronchoscopically.
214299813|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
214299814|NCT02160158|DRUG|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
214299815|NCT02160158|DRUG|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
214299816|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
214299817|NCT02160158|DRUG|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
214299818|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
214299819|NCT02160158|DRUG|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
214299820|NCT02160158|DRUG|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
214299821|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
214299822|NCT02160158|DRUG|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
214299823|NCT04964154|BEHAVIORAL|Protect Your Elders Campaign|This is a behavioral intervention where participants will receive cultural appropriate educational information about COVID-19 testing and vaccination.
214299824|NCT02172742|DRUG|BIA 2-093|BIA 2-093 1200 mg once-daily
214299825|NCT02172742|DRUG|Placebo|matching placebo
214299826|NCT02172742|DRUG|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
214299827|NCT01927666|DIETARY_SUPPLEMENT|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
214299828|NCT01471106|DRUG|Dasatinib|"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."
214299829|NCT05077709|DRUG|IO102-IO103 in combination with pembrolizumab|The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
214299830|NCT01601782|PROCEDURE|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
214299831|NCT01601782|DEVICE|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
214299832|NCT04100304|DIAGNOSTIC_TEST|resection|CT volumetry,liver function,biopsy before resection
214299833|NCT02401594|DRUG|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
214299834|NCT02401594|DRUG|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
214299835|NCT00387439|BEHAVIORAL|standard medical treatment + anoperineal physiotherapy.|
214299836|NCT00387439|BEHAVIORAL|Standard medical treatment|
214299837|NCT02883153|DRUG|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
214299838|NCT00726804|DRUG|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
214299839|NCT01132131|OTHER|Delegation form|The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
214299840|NCT03337074|OTHER|Questionnaire, semen sample, fasting blood sample|Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
214299841|NCT03337074|OTHER|Questionnaire|Participants are asked to complete a questionnaire.
214299842|NCT03337074|OTHER|Questionnaire, fasting blood sample|Participants are asked to complete a questionnaire and provide a fasting blood sample.
214299843|NCT05058443|DRUG|Denosumab 60 mg/ml [Prolia]|denosumab subcutaneously every 6 months (Q6M)
214299844|NCT05058443|DRUG|Placebo|placebo subcutaneously every 6 months (Q6M)
214299845|NCT03064360|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
214299846|NCT03064360|DEVICE|Patient Activity|Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
214299847|NCT03064360|BEHAVIORAL|Questionnaires|Symptom and quality of life questionnaire at baseline, and every week following to study completion
214299848|NCT00210041|DRUG|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
214299849|NCT00210041|DRUG|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
214299850|NCT01797601|DRUG|Human Insulin|160 U of insulin
214299851|NCT01797601|DRUG|Placebo|Insulin dilution medium without insulin
214299852|NCT03792867|DRUG|Doxorubicin|Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
214299853|NCT05079295|PROCEDURE|CSDH evacuation|Burr hole for chronic subdural hematomas
214299854|NCT06027853|DRUG|CLL1 CAR-NK cell injection|"Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent"
214669362|NCT06472570|RADIATION|Stereotactic radiotherapy boost|"A stereotactic radiosurgery boost is given in two cases:~* Upfront boost-on the first day of overall treatment time (OTT) (to 6 days before beginning conventional radiotherapy).~* Direct boost-on Days 43-49 of OTT in relation to conventional radiotherapy to total dose (TD) 70 Gy, i.e., up to 6 days after a dose of 60 Gy.~Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin 100 mg/m2 or 40 mg/m2 in a 21-day or 7-day cycle, respectively~Patients who start the treatment from induction chemotherapy may have a chance to qualify for an upfront or direct boost, depending the evaluation of the response to systemic treatment~Prescribed doses of stereotactic boost are in the range of 10-18 Gy"
214669363|NCT02963467|PROCEDURE|cigarette|smoking 4 conventional cigarettes
214898671|NCT03717155|DRUG|Cetuximab|Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m\^2) body surface area on Day 1 and 500 mg/m\^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m\^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.
215053195|NCT03766464|DIAGNOSTIC_TEST|Evaluation of TMD and pain sensitivity|Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
215053196|NCT03766464|DIAGNOSTIC_TEST|Evaluation of SB|The presence or absence of SB will be diagnosed by Polysomnography
215053197|NCT03766464|DIAGNOSTIC_TEST|Evaluation of AB|A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
215053198|NCT04463563|OTHER|Physiological|Changes to carbon dioxide, oxygen flow, cardiac output, blood pressure, haemoglobin, surgical surveillance, depth of anaesthesia, patient position.
214669364|NCT02963467|PROCEDURE|"dummy cigarette"|"smoking a dummy cigarette"
214898672|NCT03717155|DRUG|Gemcitabine|Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m\^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
214898673|NCT03717155|DRUG|Cisplatin|Participants received cisplatin intravenous infusions at a dose of 75 mg/m\^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
215053199|NCT01618058|DRUG|No Investigational Product|"This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants"
215053200|NCT01448889|DRUG|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
215053201|NCT01448889|DRUG|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
215053202|NCT05018195|PROCEDURE|Excise adipose tissue|Perform partial omentectomy to obtain one 5\*5 cm omental fat and excise one 3\*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
215053203|NCT01336712|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m\^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
215053204|NCT01713647|DRUG|Amlodipin, losartan, HCTZ|
215053205|NCT00001901|DRUG|Etanercept|
215053206|NCT06368414|DRUG|Asciminib|that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
215053207|NCT05487690|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries. to help to reduce intra-operative radiation.
215053208|NCT05487690|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
215053209|NCT02469701|DRUG|nivolumab and ablation|
215053210|NCT04300504|OTHER|observational study|observational study
215053211|NCT03520296|OTHER|Questionnaire|Questionnaire evaluating well-being in relation to diet and nutrition
215053212|NCT05580263|BEHAVIORAL|aerobic exercise|The main AE program will be designed and controlled for at least moderate intensity of heart rate reserve (HRR) lasting 30 minutes. The goal of intensity will be set at least 40% of HRR during the first two weeks, and then progressively increase the targeted intensity at the end of 16 weeks with 60% HRR. The motions will design by involving core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).
214669365|NCT03987217|DIETARY_SUPPLEMENT|Creatine Monohydrate|Given orally
214299855|NCT01941641|DRUG|neoadjuvant FOLFOXIRI|
214299856|NCT01941641|DRUG|Capecitabine|
214299857|NCT03935191|DEVICE|Dexcom CGM System|Dexcom CGM System
214299858|NCT00110825|BEHAVIORAL|Cognitive Behavior Therapy|extended treatment with cognitive behavior therapy
214299859|NCT00002433|DRUG|Interferon gamma-1b|
214299860|NCT04608851|DRUG|E. coli Nissle|1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain
214299861|NCT04608851|OTHER|Placebo control|1 ml oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g.
214898674|NCT03717155|DRUG|Carboplatin|In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.
214299862|NCT03263494|DEVICE|Continuous Glucose Monitor (CGM)|Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
214299863|NCT00531817|DRUG|Tocilizumab|Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
214299864|NCT00531817|DRUG|Placebo|Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
214898675|NCT01257269|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
214299865|NCT00531817|DRUG|Permitted DMARDs|As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
214898676|NCT04135937|DRUG|Bupropion|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
214898677|NCT04135937|DRUG|Varenicline|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
214898678|NCT04135937|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral intervention; modules include identifying reasons for quitting, setting a quit date, breathing relaxation technique, identifying smoking triggers, identifying social support, and education about relapse prevention
214898679|NCT04135937|DRUG|Nicotine Replacement Therapy|Participants may be prescribed single-formulation NRT (i.e., nicotine patch) or dual NRT (patch + rescue method such as nicotine gum, inhaler, or lozenges).
214898680|NCT04135937|BEHAVIORAL|Relapse Prevention Text Messaging|Participants will be invited to utilize SmokefreeVET, a mobile text messaging service for military Veterans trying to quit smoking. The 6- to 8-week program provides 24/7 encouragement, advice, and tips to help smokers quit smoking and stay quit.
214898681|NCT03081832|DRUG|Oxytocin|Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
214898682|NCT03081832|OTHER|Control|Not treated.
214898683|NCT01710787|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
214898684|NCT01710787|DRUG|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
214898685|NCT01710787|DRUG|Placebo|3 unilateral intranasal sprays per dose
214898686|NCT07097714|PROCEDURE|Piezocision with ribose cross-linked collagen matrix (Ossix® Volumax)|A full-thickness mucoperiosteal flap will be elevated to expose the alveolar bone. Vertical corticotomy grooves (piezocision) will be created in strategic locations to accelerate orthodontic tooth movement. The Ossix® Volumax collagen matrix will be trimmed and applied directly onto the decorticated bone surface to support bone regeneration and soft tissue augmentation.
214898687|NCT07097714|PROCEDURE|control|A minimally invasive full thickness flap will be raised to expose the alveolar bone. Vertical corticotomy grooves will be performed in strategic locations to accelerate orthodontic tooth movement. The Deepitelized Free Gingival Graft (DFGG) will be placed and secured over the areas of decortication to promote soft tissue healing and augmentation.
214898688|NCT07094503|BEHAVIORAL|Wysa Digital Chatbot Program|Wysa is a digital rules-based chatbot program platform offering cognitive-behavioral therapy-based guided self-help modules, including five modules for eating and body image developed by our team. Participants in this arm will engage with the digital chatbot program daily for three months to complete all five modules.
214898689|NCT07097571|PROCEDURE|Glenohumeral Joint Injection and Suprascapular Nerve Block|An intra-articular injection into the glenohumeral joint will be performed using 4 cc of normal saline and 1 cc of betamethasone. Additionally, a suprascapular nerve block will be administered with 5 cc of lidocaine(%2).
214898690|NCT07097610|OTHER|Mosaic Puzzle Intervention|This study aims to investigate the effect of mosaic puzzle application on nomophobia in adolescents. The data for the study will be collected over a 5-week period. The experimental group children will be asked to play mosaic puzzle games for 1 hour, 2 days a week for 5 weeks at a time deemed appropriate by the school under the supervision of the researcher. The control group children will not be given any application; they will only be observed, and a final test will be administered at the end of the 5 weeks. The study is planned as a single-center study, and a total of 30 children aged 12-14 with a nomophobia scale score of 60 or higher who meet the inclusion criteria will be included in the study.
214898691|NCT07097480|PROCEDURE|Blood samples collection|Blood samples of 40 ml will be taken.
214898692|NCT07097480|PROCEDURE|Saliva samples collection|Saliva samples will be collected
214898693|NCT07097623|OTHER|respond to 3 rounds of online Delphi surveys|In the first round, the responses of the participants will be collected, coded, and categorised into several themes/factors anonymously. In the second round, the participants will obtain the controlled feedback of all other participants and rate the level of agreement of the factors using a 5-point Likert scale ('strongly agree', 'agree', 'neither agree or disagree', 'disagree', and 'strongly disagree'; or 'essential', 'important', 'don't know/depends', 'unimportant', and 'should not be considered'). In the third round, the participants will rank the importance of the factors. In each round, the participants will be expected to complete the survey within one month.
214299866|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
214299867|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
214299868|NCT00894322|OTHER|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
214299869|NCT04776499|DRUG|Propylthiouracil, Riociguat, Perphenazine|"Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg"
214299870|NCT01196923|DEVICE|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
214299871|NCT00737620|PROCEDURE|Prosthetic AV graft implantation|Surgical arteriovenous fistula creation with standard or propaten graft
214299872|NCT00231725|DRUG|insulin lispro injection [rDNA origin] Low Mix|
214299873|NCT03522974|DIETARY_SUPPLEMENT|Strawberry powder|Freeze dried strawberry powder
214299874|NCT03522974|DIETARY_SUPPLEMENT|Placebo powder|40 g/d placebo powder matched for taste and appearance
214299875|NCT00753558|DRUG|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel."
214299876|NCT03773705|PROCEDURE|Electrocautery versus scalpel|Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
214299877|NCT01302587|DRUG|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
214898694|NCT07097623|OTHER|attend an individual semi-structured interview|The individual semi-structured interview will be audio-recorded, last for 45 minutes at maximum, and carried out by a trained and independent research assistant in a meeting room of PolyU or a room affiliated with the respective acute wards of the participating hospitals.
214299878|NCT04170114|OTHER|Comprehensive Respiratory Physiotherapy|"All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control."
214299879|NCT04177342|DRUG|Fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
214299880|NCT04177342|DRUG|Oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
214299881|NCT03195543|DIAGNOSTIC_TEST|Platelet function analyzer-100|The PFA-100 system evaluates primary hemostasis in whole blood samples.
214299882|NCT03195543|DIAGNOSTIC_TEST|Light transmission aggregometry|Light transmission aggregometry is the gold standard method for assessing platelet function.
215053213|NCT05580263|BEHAVIORAL|resistance exercise|"In the process, the participants will be instructed by resisting the weight smoothly, and peaking at hold. RE prescription consist of 2-4 sets with 10-15 repetitions per set with a rest interval of 1-2 minutes between sets to improve muscular fitness.~The first two weeks will start with two sets of 10-15 repetitions and then gradually progress on four sets of 15 repetitions at the end of 16 weeks. The total duration of RE will lasting around 15 minutes."
214299883|NCT03195543|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.
214299884|NCT03195543|DIAGNOSTIC_TEST|Endogenous thrombin potential|The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
214299885|NCT02945033|DRUG|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
214299886|NCT02945033|DRUG|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
214478690|NCT06825767|DEVICE|Conventional Treatment|Conventional treatment including hotpack therapy, Transcutaneous Electrical Nerve Stimulation (TENS), joint range of motion exercises, straight leg lifting exercises, quadriceps strengthening exercises, pillow squeezing exercises, balance exercises on one leg for 4 weeks, 3 days a week for 4 weeks in 24 patients
214478691|NCT06825767|DEVICE|conventional treatment and high-intensity laser therapy(HILT)|Conventional treatment and HILT including hotpack therapy, Transcutaneous Electrical Nerve Stimulation (TENS), joint range of motion exercises, straight leg lifting exercises, quadriceps strengthening exercises, pillow squeezing exercises, balance exercises on one leg and HILT for 4 weeks, 3 days a week for 4 weeks in 24 patients .
214478692|NCT06825767|DEVICE|conventional treatment and low-intensity laser therapy (LLLT)|Conventional treatment and LLLT including hotpack therapy, Transcutaneous Electrical Nerve Stimulation (TENS), joint range of motion exercises, straight leg lifting exercises, quadriceps strengthening exercises, pillow squeezing exercises, balance exercises on one leg and LLLT for 4 weeks, 3 days a week for 4 weeks in 24 patients.
214669366|NCT03987217|BEHAVIORAL|Exercise Intervention|Complete POWER resistance training program
214669367|NCT03987217|OTHER|Questionnaire Administration|Ancillary studies
214669368|NCT05953662|PROCEDURE|Reduced-port laparoscopic surgery|compare different operational styles of colon and upper rectal cancer
214898695|NCT07095374|OTHER|Rapid palatal expansion|Patients undergone orthopedic treatment with rapid palatal expander
214299887|NCT02945033|PROCEDURE|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
214299888|NCT02945033|BIOLOGICAL|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
214299889|NCT02945033|BIOLOGICAL|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
214299890|NCT03659591|BEHAVIORAL|Cognitive Behaviour Therapy|CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
214299891|NCT03659591|BEHAVIORAL|Adaptive Psychological Training|APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
214299892|NCT03338855|DRUG|Dapagliflozin|"The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2."
214299893|NCT01170455|DEVICE|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
214299894|NCT01170455|DEVICE|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
214299895|NCT05863910|DRUG|Medical Cannabis|Any cannabis product that is available to participants through the Medical Cannabis Access Program is eligible to be included in this study.
214898696|NCT07095478|DRUG|Artesunate|Patients with HPV positive CIN2/3 will receive 3 cycles of oral artesunate 200mg OD prior to standard of care therapeutic LLETZ. Each 21 day treatment cycle will comprise oral artesunate 200mg OD for 14 days followed by a 7 day treatment break.
215053214|NCT03545308|DRUG|Rocuronium|Dose: 1 mg/kg
214898697|NCT07095491|OTHER|Experimental|A structured hybrid training program based on self-care and self-efficacy will be implemented for the intervention group. The training will be conducted in two sessions, one day per week, over a total of two weeks.
214898698|NCT07095491|OTHER|Control|The control group will not receive any different intervention and will continue the process with routine nursing care (standard treatment).
215053215|NCT00620373|DEVICE|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
215053216|NCT00620373|DEVICE|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
215053217|NCT00620373|DRUG|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
214299896|NCT04857515|DEVICE|Clickotine®|Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
214299897|NCT00681655|OTHER|Alcohol|Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).
214299898|NCT00681655|OTHER|Placebo|Placebo (saline vehicle) infused for 2.8 hour long session.
214898699|NCT07096726|DEVICE|Five-point ultrasound|In-person study visits will be done on initial evaluation and then at least every 48 hours, during which serial five-point ultrasound will be performed to assess venous congestion. Each visit will not be at strict intervals; a reasonable time window is every 48 hours +/- 12 hours. Ultrasound may be performed more frequently if clinically indicated. During these visits or between them, ultrasound of the heart may additionally be performed. Each visit will last between 10 and 60 minutes.
214898700|NCT07096726|OTHER|Standard of care|Standard of care will most likely include radiographic investigations (chest X-ray, chest CT), laboratory evaluation (complete blood counts, metabolic panel, B-type natriuretic peptide, high-sensitivity troponin, electrolytes, renal function, urine testing), volume status, and cardiopulmonary physical exam.
214898701|NCT07097038|DRUG|Oliceridine|Intraoperative analgesia should be administered with Oliceridine
214898702|NCT07097038|DRUG|Oxycodone|Oxycodone is used for intraoperative analgesia
214898703|NCT07095712|DRUG|nL-TARD-001|Personalized antisense oligonucleotide
214898704|NCT07097116|OTHER|Hiking Bench Exercise Program|The training is performed 2 times per week over 8 weeks. It includes 4 progressive phases using a hiking bench, simulating hiking posture exercises targeting endurance, trunk control, and leg strength.
214299899|NCT03183375|DRUG|Hydroxyurea|Hydroxyurea (starting from 10mg/kg/day with increasing dose by 2mg/kg/day until the desired response is achieved. The maximum dose given will be 20mg/kg/day)
214299900|NCT05544331|BEHAVIORAL|Exercise group (written form)|The exercise program will be structUred with core stabilization exercises. Patients will be given the written form of exercises and will be applied as home exercises. Exercise progression will be provided by position changes.
214299901|NCT05544331|BEHAVIORAL|Exercise group (video based)|The exercise program will be structUred with core stabilization exercises. Patients will be given the exercise videos, which provide visual and auditory feedback, and will be applied as home exercises. Exercise progression will be provided by position changes.
214299902|NCT00151099|DRUG|high caloric drink with protein|
214299903|NCT00511667|DRUG|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
214299904|NCT00511667|DRUG|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
214299905|NCT00056407|DRUG|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
214299906|NCT00056407|DRUG|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
214299907|NCT04394104|OTHER|Survey|No intervention is being administered.
214299908|NCT02369003|PROCEDURE|Autologous Peripheral Nerve Graft|Implantation of Autologous Peripheral Nerve Graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with PD undergoing deep brain stimulation (DBS) surgery.
214299909|NCT00197041|BIOLOGICAL|RTS,S/AS02A|
214478693|NCT06819540|BEHAVIORAL|Mindfulness-Based Stress Reduction Programme|Mindfulness involves paying attention to what is occurring in the present moment, noticing the particularity of that attention, and accepting without judgement all states of awareness. Mindfulness is important in moving individuals away from automatic thoughts, habits and unhealthy patterns of behaviour, and therefore can play an important role in promoting conscious and self-affirmed behavioural regulation, which has long been associated with enhancing well-being. Mindfulness is a way of regulating one's self, thoughts and awareness. It has been demonstrated to enhance the ability to remain present in the moment, arising through purposeful, momentary, non-judgemental attention to experience. Recently mindfulness appears to have a positive impact on helping people overcome addiction and psychological problems and providing effective techniques to manage them
214299910|NCT02543645|DRUG|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg."
214299911|NCT01230268|OTHER|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
214669369|NCT05953662|PROCEDURE|conventional laparoscopic surgery|conventional laparoscopic surgery
215053218|NCT02869126|PROCEDURE|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"* During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~* Stress conventional acquisition with D.SPECT camera 20 min after injection~* 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~* double isotope acquisition 5 min after thallium-201 injection~* injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~* rest conventional acquisition 20 min later"
214299912|NCT05230225|BEHAVIORAL|Physician Notification Letter|Receiving the electronic Physician Notification Letter to highlight echocardiography results that are consistent with or may be consistent with severe AS and to be reminded of ACC/AHA Clinical Practice Guideline recommendations regarding the management of severe AS.
214299913|NCT02042248|BIOLOGICAL|AGS-004|All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
215053219|NCT02869126|DRUG|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
214299914|NCT05748977|DRUG|SABA SAMA ICS Vs LABA LAMA ICs|Short acting agents,long acting agents ,ics
214299915|NCT00324324|DRUG|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
214299916|NCT00324324|DRUG|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
214299917|NCT05372328|OTHER|Position of arm while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
214299918|NCT00816231|BEHAVIORAL|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
214299919|NCT00816231|OTHER|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
214299920|NCT00816231|OTHER|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
215053220|NCT02869126|DRUG|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
214669370|NCT00980083|DRUG|Saline|
214669371|NCT00980083|DRUG|Exendin(9-39)amide|
214299921|NCT02158104|PROCEDURE|Deep dry needling|
214299922|NCT03666845|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
214299923|NCT06120920|OTHER|Assigned Interventions|Conventional physical therapy consists of hot pack application and transcutaneous electric stimulation (TENS) and routine knee strengthening exercises in addition with core stability exercises in three sessions per week for 4 weeks. Core stability exercises include bent knee hollow hold, bridging, supine toe tap and knee strengthening exercises include knee flexion strengthening exercises and knee extension isometric exercises.
214299924|NCT06120920|OTHER|Conventional Physical Therapy and Routine Knee Exercises with Hip Strengthening Exercises.|Conventional physical therapy consists of hot pack application, Tens and routine knee exercise program same as group A and in addition with hip strengthening exercises. Hip strengthening exercises include hip flexion and extension strengthening exercises and hip internal rotation and external rotation and hip adduction and abduction strengthening exercises.C
214299925|NCT00129493|BEHAVIORAL|Group medical visits|Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
215053221|NCT03109743|BEHAVIORAL|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
214299926|NCT05821868|DEVICE|Dosivent|Dosivent® inhalation chamber is designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
214299927|NCT05821868|DEVICE|Aerochamber Plus Flow Vu|Aerochamber Plus Flow Vu® inhalation chamber is also designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
214299928|NCT06046456|OTHER|Prenatal Affective CogntiiveTraining|A psychological intervention using computer- and virtual reality based exercises to modify negative cognitive bias and improve emotion regulation
214478694|NCT06819267|OTHER|Horizontal Plyometric Group|"Group A~* Duration: A 30-minute treatment session for four weeks.~* Frequency: Two to three sessions per week.~* Warm-up: 5 minutes following the FITT principle (Frequency, Intensity, Time, Type).~* Warm-up Components:~* 5 minutes of moderate to high-intensity cardiovascular warm-up.~* Exercise Components (30 minutes per session):~* Horizontal ankle jumps\| Long jumps \| Diagonal obstacle jumps~* Intensity: Moderate to high."
214898705|NCT07097116|OTHER|Structured Land-Based Exercise Program|This protocol adds aerobic warm-up, dynamic stretching, foundational strength (glutes, core), and cool-down flexibility work. Exercises are adapted to sailing-specific demands and performed 2 times per week alongside hiking bench work.
214299929|NCT02967497|DRUG|YQ1|Oral administered powder
214669372|NCT00981435|DRUG|Prednisolone 1%|Prednisolone 1% to lasered eye 4 times/day for 4.5 days
214898706|NCT03816475|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance.
214898707|NCT07097233|PROCEDURE|Virtual Reality Haptic Simulator|Students will use a virtual reality haptic simulator as an adjunct educational tool before treating real patients in the clinical setting.
214898708|NCT07097233|PROCEDURE|Mobile app|Students will use a mobile app as an adjunct educational tool before treating real patients in the clinical setting.
214898709|NCT07097233|PROCEDURE|Control|Students will directly treat real patients without using virtual reality haptic simulator or mobile app.
214898710|NCT06915038|DIAGNOSTIC_TEST|NavDx|NavDx is a clinically validated blood test to detect circulating tumor HPV DNA (ctHPVDNA). In this study, ctHPVDNA results, in conjuction with specimen analysis, will be used to assign post-surgical adjuvant treatment.
215053222|NCT03109743|BEHAVIORAL|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
214898711|NCT06915038|RADIATION|Adjuvant Radiation 30 Gray|If undetectable postoperative ctHPVDNA levels and five or more positive nodes, or confirmed extranodal extension (ENE) (greater than 2 mm) deintensified radiation treatment of 30 gray.
214898712|NCT06915038|RADIATION|Adjuvant Radiation 40 Gray|If detectable postoperative ctHPVDNA, then reimage to evaluate for potentially operable disease, followed by appropriate surgery as indicated. If surgery is performed, repeat ctHPVDNA levels will be checked, and if then negative, subject will be placed in observation if N0 or N1 disease, and 30 Gy of radiation if N2 disease on final pathologic staging. If repeat ctHPVDNA level is positive, or shows no obvious operable disease, then subject will undergo 40 Gy of radiation.
215053223|NCT00869492|DRUG|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
215053224|NCT00869492|DRUG|nadifloxacine|Nadifloxacine 1% cream twice dailly
215053225|NCT04120246|DRUG|Alpha-tocopheryloxyacetic Acid|Given PO
215053226|NCT04120246|BIOLOGICAL|Trastuzumab|Given IV
214299930|NCT01665066|OTHER|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
214299931|NCT01665066|OTHER|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
214299932|NCT01665066|OTHER|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
214299933|NCT01665066|OTHER|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
214299934|NCT01665066|OTHER|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
214299935|NCT05517889|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography is a non-invasive scanner which generates real-time in-vivo images of the skin and its adnexal structures. Images are generated by light-interferometry.
214299936|NCT01338831|DRUG|LFA102|
214299937|NCT02793102|OTHER|Olfactory workshop|Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
214299938|NCT02793102|OTHER|Somesthesia workshop|Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
214478695|NCT06819267|OTHER|Vertical Plyometric Group|"Group B~* Duration: A 30-minute treatment session for four weeks.~* Frequency: Two to three sessions per week.~* Warm-up: 5 minutes following the FITT principle (Frequency, Intensity, Time, Type).~* Warm-up Components:~* 5 minutes of moderate to high-intensity cardiovascular warm-up.~* Exercise Components (30 minutes per session):~* Vertical ankle jumps~* Counter movement jump~* Front obstacle jumps"
214478696|NCT06825104|DEVICE|Volta AF-Xplorer|Dispersion ablation strategy guided by Volta Medical AI-software targeting areas of spatiotemporal dispersed electrograms
214898713|NCT05993273|PROCEDURE|Epidural|The epidural catheter is placed while the patient is awake, before the induction of general anesthesia. The intervertebral spaces used for catheter insertion are alternatively T4-T5, T5-6 or T6-T7. After locating the epidural space through the technique of the loss of resistance, a catheter is introduced for about 5 cm and left in place for the administration of drugs into the epidural space. Once the correct functioning of the epidural catheter has been verified with a negative test for cerebrospinal fluid aspiration and a negative bolus test for the onset of signs and symptoms from intrathecal infusion, the catheter is used intraoperatively for administration of local anesthetics in refracted boluses (Lidocaine and Ropivacaine ) at anesthetic dosage and postoperatively for continuous infusion of Ropivacaine 0.15% at 5 mL/h.
214478697|NCT06825104|PROCEDURE|Dispersion ablation + PVI|TAILORED-AF index procedure: Dispersion ablation + PVI
215053227|NCT01144169|DRUG|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
215053228|NCT04247893|DEVICE|blood flow restriction|Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
215053229|NCT04247893|DEVICE|Photobiomodulation|Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
215053230|NCT04247893|DEVICE|Placebo photobiomodulation|Placebo photobiomodulation - photobiomodulation device turned off.
214299939|NCT02793102|OTHER|Auditory workshop|Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
214299940|NCT05814887|DEVICE|ReLink|Medical device
214299941|NCT01857388|BEHAVIORAL|ParentCorps|
214299942|NCT06209645|DEVICE|tDCS (Transcranial Direct Current Stimulation)|The tDCS group will be treated with non-invasive motor cortex stimulation. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region. If pain is bilateral, the most painful region will be chosen to be treated.
214299943|NCT06209645|DEVICE|tACS (Transcranial Alternating Current Stimulation)|The tACS group will be treated with non-invasive motor cortex stimulation. The stimulation series comprises six sessions spaced 2 weeks apart, the first session being placebo. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Stimulation frequency will be set according to the dominant frequency recorded over the motor area. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region.
214299944|NCT03556189|DEVICE|Case management|Case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
214478698|NCT06825104|PROCEDURE|PVI|TAILORED-AF index procedure: PVI only
214478699|NCT06662435|BEHAVIORAL|GYNCOG|"Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ. Participants will be instructed to use the Brain HQ app for approximately 2.5 hours per week. Patients will be provided with a calendar to help keep track of daily BrainHQ use, including the number of exercises completed and the amount of time spent on the app per day.~Patients will be asked to undergo the exercises that target the speed and accuracy of information processing. Examples of the exercises include:~Double Decision: This exercise tests your ability to quickly identify and choose between two options.~Eye for Detail: It challenges participants to spot small differences between two similar images.~Participants will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week (i.e., 2.5 hours per week) for 10 weeks, for a total of approximately 25 hours."
214478700|NCT06824116|BEHAVIORAL|Exercise|Training on a bicycle ergometer was performed four times a week for 3 weeks for 45 min. The exercise intensity corresponded to 50%-60% of maximal oxygen uptake (VO2max).
214478701|NCT06824116|BEHAVIORAL|Exercise|Training on a bicycle ergometer was performed four times a week for 3 weeks for 45 min. The exercise intensity corresponded to 70 - 80% of maximal oxygen uptake (VO2max).
214669373|NCT00981435|DRUG|Ketorolac|Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
214669374|NCT00981435|DRUG|Artificial Tears|Artificial saline tears to lasered eye 4 times/day for 4.5 days
214299945|NCT04891783|DEVICE|ultrasonography|The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus\[26\]. Plaque is defined as a focal protrusion in the lumen at least cIMT\>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching \>0.5 mm \[26\]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
214299946|NCT05126784|BIOLOGICAL|AVT03|AVT03 (biosimilar to denosumab) will be given as single subcutaneous injection
214299947|NCT05126784|BIOLOGICAL|Prolia|Prolia (denosumab) will be given as single subcutaneous injection
214299948|NCT06431854|BEHAVIORAL|ED-MINERVA Program|ED-MINERVA Program aims to improve ED symptoms and related difficulties of the patient and provide tools to enhance the family's management (nutritionally, emotionally, and behaviorally) in their natural environment. The treatment consists of four phases with a gradually decreasing therapeutic intensity, ranging from total hospitalization, family treatment apartment, to home treatment and subsequent linkage with specialized local facilities. The ED-MINERVA program uses various aspects of family-based treatment, cognitive behavioral therapy, dialectical behavioral therapy, and systemic family therapy.
214299949|NCT02738450|BIOLOGICAL|ACI-24 low dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
214299950|NCT02738450|BIOLOGICAL|ACI-24 high dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
214299951|NCT02738450|BIOLOGICAL|Placebo|Placebo is a standard PBS sterile solution administrated via s.c. injection.
214299952|NCT01375985|DRUG|AVI-7100|Single intravenous administration
214299953|NCT01375985|DRUG|Placebo|Single intravenous administration
214478702|NCT03617237|OTHER|Retrospective Populations|"All patients who are currently treated by any physician at the University of Texas Southwestern campus Aston Clinic, Seay Clinic, PHHS Clinic, Moncrief Radiation Oncology, St. Paul West Campus Radiation Oncology, East Radiation Oncology Clinic will be included in the registry. The data from the charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number.~1. The research involves no more than minimal risk to the subjects.~2. The waiver will not adversely affect the rights and welfare of the subjects.~3. The research could not practicably be carried out without the waiver.~4. Whenever appropriate, the subjects will be provided with additional pertinent information after participation."
214478703|NCT06825936|OTHER|Diet intervention|For participants assigned to the intervention arm, the dietary intervention consists of: a) pre-cooked Asian-Mediterranean meals: participants will receive free meals, two meals a day, five days a week, and b) pre-packed nuts, 30g a day, five days a week, during the intervention period. Additionally, participants will receive a dietary consultation session at baseline and every four weeks.
214478704|NCT06825936|OTHER|Control|For participants assigned to the control arm, they will receive a leaflet with dietary advice based on national guidelines at baseline.
214478705|NCT06825949|DEVICE|Hyperbaric oxygen treatment|Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
215053231|NCT04266392|DRUG|[18F]-DCFPyl Ligand|To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
215053232|NCT00475592|DEVICE|Esophageal Capsule Endoscopy|
215053233|NCT00475592|DEVICE|Upper Gastrointestinal Endoscopy|
215053234|NCT02151916|OTHER|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
215053235|NCT02151916|OTHER|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
214478706|NCT06824779|DRUG|Flu Vaccine|Vaccination against FLU by one of FLU vaccines in the french market
214478707|NCT06824779|BIOLOGICAL|Biological samples|"Before and after the FLU vaccination, according the french recommendations, the following samples will be collected :~Nasal fluid sampling Saliva sampling Blood samples Nasal cell sampling"
214478708|NCT03884101|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
214478709|NCT03884101|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
214478710|NCT03884101|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
214478711|NCT03884101|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
214478712|NCT06665724|DRUG|5-Aminolevulinic acid Hydrochloride (Gliolan®)|Patients will receive 5-Aminolevulinic acid hydrochloride via oral administration (20 mg/kg) 6-8 hours before CV01 treatment.
214669375|NCT00402350|DRUG|Inhaled Placebo|Inhaled Staccato Placebo, same number of doses as active comparator in that arm
214669376|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg|Inhaled Staccato Fentanyl, 25 mcg x 1 dose
214299954|NCT00706407|DEVICE|Fully integrated Uro-NIRS:UDS|As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
214299955|NCT03043989|DRUG|Docetaxel|6 infusions of Docetaxel with 18 doses clarithromycin
214299956|NCT03043989|DRUG|Cabazitaxel|6 infusions of Cabazitaxel with 18 doses clarithromycin
214299957|NCT03043989|DRUG|Clarithromycin|18 doses of clarithromycin with either Docetaxel or Cabazitaxel
214299958|NCT05713045|DIETARY_SUPPLEMENT|Konakion|Comparing 4 different regimen of Vitamin K administration in newborn
214299959|NCT04566354|OTHER|Repeated 30-s sprint exercise|Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
214299960|NCT00951808|BIOLOGICAL|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
214299961|NCT00951808|BEHAVIORAL|Standard care|Participants will receive standard care for ACS while in the hospital.
214299962|NCT04554329|PROCEDURE|bandage contact lens|bandage contact lens
214299963|NCT02120729|OTHER|Genotype-guided care|Pharmacogenetic alerts are furnished to the clinician within 2 days of admission. Buccal cell DNA is analyzed for 21 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
214299964|NCT02654483|DRUG|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
214299965|NCT02654483|OTHER|Placebo|Matching tablets to VPD-737 tablets without active drug
214299966|NCT00768807|DEVICE|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
214299967|NCT02314650|OTHER|acupoint stimulation|stimulation was given at acupoints
214299968|NCT02314650|OTHER|non-acupoint stimulation|stimulation was given at non-acupoints
214299969|NCT02314650|OTHER|electrodes attached|electrode were attached to skin
214299970|NCT01643811|PROCEDURE|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
214299971|NCT01643811|PROCEDURE|Endoscopic submucosal dissection|endoscopic submucosal dissection
214299972|NCT03913884|PROCEDURE|Concentrated growth factor|CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
214299973|NCT03913884|OTHER|Non-Concentrated growth factor Group|To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
214299974|NCT05691296|BEHAVIORAL|Home training|Letter Chart Accomodative Rock Training for 2 minutes each time
214299975|NCT05691296|BEHAVIORAL|School training|Letter Chart Accomodative Rock Training for 2 minutes each time
214299976|NCT04940650|DIAGNOSTIC_TEST|exercise testing|To define the strenuous physical exercise in this study, each participant will be asked to perform two hours of high intensity (HIT)-effort during the endurance exercise of at least 6 to 7 hours. Therefore all participants will have exercise testing approximately 1 week before the physical exercise to set aerobic and anaerobic gas exchange thresholds, as well as VO2max.
214299977|NCT04940650|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles at rest enabling comparisons with cardiac MRI and traditional echo measures.
214299978|NCT03946904|DEVICE|Er,Cr:YSGG Laser|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
214299979|NCT00140569|PROCEDURE|CHVP + interferon|
214478713|NCT06665724|DEVICE|CV01|Ultrasound will be delivered 6-8 hours after administration of 5-aminolevulinic acid hydrochloride. A total of 12 fields will be treated (10 treatment sites across the hemisphere with 2 additional treatments over areas of increased enhancement).
214898714|NCT05993273|PROCEDURE|ESP block|Erector spinae plane (ESP) block is performed after induction of general anesthesia, with the patient in a lateral decubitus position. With the aid of the ultrasound guide with linear probe, the transverse process of T5 ipsilateral to the site of the operation is identified. With the in-plane technique, the lower fascia of the ESP muscle is hydrodissected through the administration of Ropivacaine 0.5% 3 mg/Kg lean body weight. Subsequently, a catheter is introduced and left in place for continuous postoperative infusion of Ropivacaine 0.2% at 12 mL/h.
214898715|NCT05993273|PROCEDURE|Cryoanalgesia|Cryoanalgesia is performed after the induction of general anesthesia, single lung ventilation and after performing the first thoracoscopic surgical access. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access. The active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8 and kept resting for 4 ½ minutes on each nerve at a temperature of -70°C, under direct thoracoscopic vision, generating an interruption of the sensory functions.
214299980|NCT00140569|DRUG|fludarabine|
214299981|NCT00140569|PROCEDURE|CHOP + TBI and autotransplant|
214299982|NCT01114165|OTHER|Detection of microbial DNA in blood by SeptiFast Test|The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
214299983|NCT01114165|OTHER|Pathogen detection by blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
214299984|NCT04955522|DIAGNOSTIC_TEST|radiomics|Differential diagnosis of spinal myeloma and metastases by radiomics
214299985|NCT02045576|DEVICE|sleep position trainer|
214299986|NCT02045576|DEVICE|Oral Appliance Therapy|
214299987|NCT00999557|DRUG|bimatoprost ophthalmic solution|Applied topically
214299988|NCT00999557|DRUG|placebo|Applied topically
214299989|NCT00004489|DRUG|alendronate sodium|
214299990|NCT00004489|DRUG|calcium carbonate|
214299991|NCT00004489|DRUG|cholecalciferol|
214299992|NCT00494988|DRUG|insulin aspart|
214299993|NCT00494988|DRUG|insulin NPH|
214299994|NCT00050843|DRUG|thalidomide|
214299995|NCT05381467|PROCEDURE|immediate implant placement with The Dual-Zone Therapeutic Concept|After tooth removal, implant placement, bone grafting, and screw retained provisional restoration, the contour of the ridge can change. Using dual zone grafting was claimed to minimize contour change associated with immediate anterior implants. In this technique. The implant should be placed in an optimal 3 dimensional mode . Xenograft, will be used in the gap to graft the bone and tissue zones, . The graft material helps serve as a scaffold to maintain hard- and soft-tissue volume as well as blood clot for initial healing.
214299996|NCT05381467|PROCEDURE|Immediate implant placement with the bone shielding concept|After atraumatic tooth extraction using periotomes and luxators , socket curettage and cleaning simultaneously using an irrigation curette will be performed. Sulcular dissection of the attached tissue close to the socket orifice incisal and apically will be done using periotome to create a tunnel via the socket orifice. Dental implant will be placed. complete access of the labial plate of bone where all the regenerative materials will be performed to have the bone sheild delivered. A membrane will be inserted to the labial tunnel and tacked using 2 membrane tacks.
214299997|NCT03106220|BEHAVIORAL|exercise|home exercise program
214299998|NCT03106220|OTHER|placebo|encourage walking and physical therapy per standard care.
214299999|NCT03258190|DRUG|Lime Powder Regimen|LPR and placebo were randomly given to subjects for 6 months
214898716|NCT05546021|PROCEDURE|NOL monitor|"NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuous monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics and avoiding overdose or underuse of these drugs.~The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation). The nociception level is a composite score derived from a set of physiologic variables (i.e., peripheral effectors of the autonomous nervous system): heart rate, heart rate variability, the amplitude of the photoplethysmogram, skin conductance, skin conductance variability, and the time derivatives of these variables."
214898717|NCT04433182|DRUG|Copanlisib|"Induction phase: 6 cycles of Copa-RB every 28 days according to the following schedule~* Copanlisib (Copa): 60 mg/day i.v. on days 1,8,15~* Rituximab (R): 375 mg/sqm i.v. day 1\*~* Bendamustine (B): 90 mg/sqm i.v. days 1-2\*~note: during cycle 1 rituximab can be administered on day 2: in this case bendamustine will be administered on days 2-3; in the case of a frail patient or a patient with high tumor burden copanlisib could be administered on day 1, rituximab on day 2 and bendamustine on days 3-4, at physician discretion.~Maintenance phase: patients who reach at least SD after induction will receive a maintenance with copanlisib in monotherapy according to the following schedule:~• Copanlisib: 60 mg/day i.v. on days 1 and 15 in 28-day cycles for 1 year"
214300000|NCT00455429|DRUG|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
214300001|NCT00455429|DRUG|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
214300002|NCT00455429|DRUG|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
214300003|NCT00455429|DRUG|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
214478714|NCT06823999|DRUG|Ascorbic acid (Vitamin C)|In the study, acute ischemic stroke patients will receiving vitamin C 4 gram perday for 4 days.
214300004|NCT00455429|DRUG|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
214300005|NCT06069960|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
214300006|NCT01165554|DRUG|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
214300007|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for the duration of the study.
214300008|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
214300009|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
214300010|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for the duration of the study.
214300011|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
214300012|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
214300013|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for 20 weeks.
214300014|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for 20 weeks.
214300015|NCT06072950|OTHER|Usual care|Patients received usual care
214300016|NCT00431210|BIOLOGICAL|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
214300017|NCT04291391|OTHER|North American-type diet|All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)
214478715|NCT06823999|OTHER|Normal Saline (Placebo)|Particiapnts receiving normal saline 20 ml perday for 4 days
214300018|NCT02951156|BIOLOGICAL|Avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
214300019|NCT02951156|BIOLOGICAL|Utomilumab|Investigational, fully human IgG2 CD 137/4-1BB agonist
214300020|NCT02951156|BIOLOGICAL|Rituximab|CD20-directed cytolytic antibody
214300021|NCT02951156|OTHER|Azacitidine|Antimetabolite antineoplastic agent and demethylation agent.
214300022|NCT02951156|DRUG|Bendamustine|Alkylating drug
214300023|NCT02951156|DRUG|Gemcitabine|Nucleoside analogue
214300024|NCT02951156|DRUG|Oxaliplatin|Platinum-based drug
214300025|NCT01427894|OTHER|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
214898718|NCT06828471|BEHAVIORAL|Social Cognition Training|Neuroplasticity-based social cognition training that targets a range of social cognition skills, including visual and vocal affect perception, social cue perception, theory of mind, self-referential style, and empathy
215053236|NCT05253937|DRUG|Epinephrin|The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
215053237|NCT03051464|PROCEDURE|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
215053238|NCT03051464|RADIATION|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
215053239|NCT03051464|RADIATION|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
215053240|NCT02319460|BIOLOGICAL|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
215053241|NCT02319460|BIOLOGICAL|Plasma|
215053242|NCT02225704|DRUG|Radium-223 and enzalutamide|
215053243|NCT00159679|DRUG|Pregabalin|
215053244|NCT06374927|DEVICE|Rehabilitation Gaming System (VR-based mobile application)|The study intervention includes using the mobile phone technology RGSapp. This application integrates sensor data for delivering patient-tailored VR and AR-based training via gamified exercises for cognitive training.
214300026|NCT01735643|DEVICE|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
214300027|NCT01735643|OTHER|waiting|waiting for 12 weeks
214300028|NCT06192186|DRUG|Adebrelimab combined with SOX regimen|Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
214300029|NCT06192186|DRUG|Placebo combined with SOX (S-1/oxaliplatin) regimen|Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles (stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging) → radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
214898719|NCT07104604|DRUG|Liposomal Irinotecan|In this study, the novel drug liposomal irinotecan was added, replacing the conventional formulation of irinotecan, and used as an intensified chemotherapy regimen (liposomal irinotecan + capecitabine) combined with immunotherapy and radiotherapy for neoadjuvant treatment of mid-lower rectal cancer.
214898720|NCT06222931|DEVICE|Triplanar vibrating platform|Mechanical vibration emitted by triplanar vibrating platforms
214898721|NCT06222931|DEVICE|Side-alternating vibrating platform|Mechanical vibration emitted by side-alternating vibrating platforms
215053245|NCT04930861|DRUG|Covidir injections|administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
215053246|NCT04930861|DIAGNOSTIC_TEST|One Step Test|rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
215053247|NCT04930861|DIAGNOSTIC_TEST|IgM and IgG dosage|blood collection for dosage of Anti SARS-CoV-2 antibodies.
215053248|NCT04930861|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
215053249|NCT04930861|DIAGNOSTIC_TEST|Screening blood test|complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
214300030|NCT04954612|OTHER|Questionnaire study (Cross-sectional analytical clinical research)|Questionnaire study (Cross-sectional analytical clinical research)
214300031|NCT04669392|DRUG|70% Ethanol Alcohol|"Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time."
214300032|NCT03571074|OTHER|Oxygenation|Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
214669377|NCT00402350|DRUG|Intravenous Fentanyl 25 mcg|Intravenous Fentanyl 25 mcg, single dose
214300033|NCT05635240|OTHER|Interview / questionnaires|At each of the 4 visits, the participant will have to answer several questions regarding trauma-related data, employment and sport practice.
214300034|NCT03386942|DRUG|Farletuzumab Ecteribulin|Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
214300035|NCT03849833|DIETARY_SUPPLEMENT|cholecalciferol, Vitamin D3|Vitamin D3 as dietary supplement
214300036|NCT04351087|DEVICE|Platelet Rich Plasma|"Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance."
214300037|NCT00130416|BEHAVIORAL|E-mail coaching to improve patient communication with doctor|
214300038|NCT01066247|DRUG|Morphine hydrochloride; Midazolam|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
214300039|NCT01066247|DRUG|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
214300040|NCT02260479|PROCEDURE|Preheated|Skin disinfection solution is preheated in a warming cupboard
214300041|NCT05202509|DRUG|Obicetrapib|10mg obicetrapib tablet
214300042|NCT05202509|DRUG|Placebo|Placebo tablet to resemble obicetrapib
214300043|NCT05992597|DRUG|ZR2 RDHAP|ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.
214300044|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Infusion|Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
214300045|NCT02240199|DRUG|Perioperative Pregabalin|Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
214300046|NCT02240199|DRUG|Perioperative Pregabalin Placebo|Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
214478716|NCT06664827|DEVICE|Delfi PTS Blood Flow Restriction Tourniquet System|In Houston Methodist rehabilitation clinics these devices are used as standard of care for BFR therapy in many post-operative treatments. General guidelines suggest using ranges between 30% - 80% of limb occlusion pressure (LOP). In our previous research efforts involving BFR the investigators have adhered to these guidelines and experienced no adverse events while observing these ranges to be well tolerated by subjects.
214898722|NCT06222931|OTHER|Sham vibration|Simulated vibration
214898723|NCT07097727|DRUG|acetyl cysteine 600 mg|patients received acetyl cysteine 600 mg/ 12h IV in addition to antibiotics
214300047|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Placebo Infusion|Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
214300048|NCT01593423|BEHAVIORAL|plant-based Homestead Food Production|The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
214300049|NCT01593423|BEHAVIORAL|Homestead Food Production plus small pond aquaculture|In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.
214300050|NCT01593423|BEHAVIORAL|a comparison group|No intervention.
214300051|NCT05212714|DEVICE|taVNS|The non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) device that will be used in this study is a wearable TENS unit called the Vorso STIM100 System. The Vorso system consists of a wearable, external stimulator, a neural interface ear piece, and an arm band designed to be safe for human contact. The external stimulator generates electrical pulses that are transcutaneously delivered to the auricular branch of the vagus nerve through the ear canal. The ear piece contains 4 electrodes that carry current from the external stimulator to the auricular branch of vagus nerve. The external stimulator connects to a flexible arm band that attaches to the upper arm for ease of use during each stimulation session. The type of stimulation (including shape, frequency, pulse width, amplitude, total charge, and energy delivered) is comparable to the levels applied by commercially available TENS stimulators. The sham control group will not receive any stimulation.
214300052|NCT02014844|DRUG|250 mg/m2 aldoxorubicin|
214300053|NCT02014844|DRUG|350 mg/m2 aldoxorubicin|
214300054|NCT05585151|DRUG|Evolocumab 140 MG/ML|Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times
214478717|NCT06825221|DIETARY_SUPPLEMENT|Oral Nutrition supplement|Participants received normal diet and in the interventional group received package of immune formula 2 meals per day for 10-14 days prior surgery.
214898724|NCT07097727|DRUG|antibiotics and saline.|patients received only antibiotics and saline
214898725|NCT00868530|BIOLOGICAL|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
214898726|NCT02841501|GENETIC|Analysis of genetic polymorphisms|An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
214898727|NCT03309501|DRUG|Tong-Luo-Qu-Tong Plaster|for 14 days as two period of treatment, daily 1 time.
214898728|NCT03309501|DRUG|Qi-Zheng-Xiao-Tong Plaster|for 14 days as two period of treatment, daily 1 time
214898729|NCT03311204|DEVICE|BlephEx|BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.
214898730|NCT03311204|OTHER|Lid Hygenix|Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
214898731|NCT07110948|PROCEDURE|Tongue tie release|surgical release of tongue tie
214898732|NCT07113366|DRUG|FAE cream|Ficus awkeotsang Makino extract (FAE)
215053250|NCT04930861|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram with report.
215053251|NCT04930861|DIAGNOSTIC_TEST|Medical evaluation|evaluation by the principal investigator or assistant physician with a complete physical examination.
215053252|NCT04930861|DIAGNOSTIC_TEST|NEWS-2 score|assessment of the participant by the NEWS-2 score.
214300055|NCT05585151|DRUG|Intensive statin treatment|Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
214898733|NCT07113366|DRUG|Placebo|Placebo
215053253|NCT04930861|DIAGNOSTIC_TEST|WHO score|assessment of the participant by the score of the World Health Organization.
215053254|NCT00000870|DRUG|Indinavir sulfate|
215053255|NCT00000870|DRUG|Lamivudine|
215053256|NCT00000870|DRUG|Stavudine|
215053257|NCT00000870|DRUG|Zidovudine|
214300056|NCT04602182|PROCEDURE|music therapy intervention|Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
214300057|NCT03519347|OTHER|Potassium Removal Maximization|This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
214898734|NCT07113457|OTHER|Acute Intermittent Hypoxia (AIH)|This intervention involves breathing lowered levels of oxygen (similar to those experienced on a tall mountain) for 60 seconds at a time. This is immediately followed by 60 seconds of breathing normal room air. These bouts are repeated approximately 15 times. For the intervention, the participant is fitted with a non-rebreathing mask which supplies the two different air levels
214898735|NCT07111572|DIAGNOSTIC_TEST|fecal calprotectin|patients will accpet test of FC combine FIT
215053258|NCT00000870|DRUG|Didanosine|
215053259|NCT00000870|DRUG|Aldesleukin|
215053260|NCT04069949|DRUG|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
215053261|NCT04514627|DEVICE|Auricular percutaneous neurostimulation|The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.
215053262|NCT00399568|DRUG|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
215053263|NCT00399568|DRUG|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
215053264|NCT03166462|OTHER|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
215053265|NCT02704624|DIETARY_SUPPLEMENT|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
215053266|NCT02704624|OTHER|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
215053267|NCT02330354|BEHAVIORAL|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
215053268|NCT05711875|OTHER|Virtual Reality (VR) glasses|During the Non Stress Test (NST), the pregnant women in the experimental group watched a video of nature scenery with Virtual Reality (VR) glasses for 10 minutes
215053269|NCT06199908|DRUG|AMT-562|Administered AMT-562 for injection intravenously
214300058|NCT03519347|OTHER|Potassium Gradient Minimization|This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
215053270|NCT04169503|DRUG|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
215053271|NCT02657694|DRUG|Sofosbuvir+Ledipasvir|DAA medication treatment
215053272|NCT02657694|DRUG|Sofosbuvir+Daclatasvir|DAA medication treatment
215053273|NCT02657694|DRUG|Sofosbuvir+Velpatasvir|DAA medication treatment
215053274|NCT00551434|DIETARY_SUPPLEMENT|Creatine|Creatine 21 g daily
215053275|NCT00551434|DIETARY_SUPPLEMENT|L-arginine and creatine|L-arginine
215053276|NCT00551434|DIETARY_SUPPLEMENT|l-arginine|l-arginine 9 g daily
215053277|NCT00551434|DIETARY_SUPPLEMENT|placebo, double|placebo
215053278|NCT01037335|DRUG|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
215053279|NCT02695017|DEVICE|Iso inertial|
215053280|NCT02695017|DEVICE|Conventional machine|
215053281|NCT04257968|DIAGNOSTIC_TEST|Ultrasonography|carotid ultrasonography (IMT and elastography)
215053282|NCT04257968|DIAGNOSTIC_TEST|MRI|MRI of carotid artery and brain
215053283|NCT04257968|DIAGNOSTIC_TEST|Neuro Psychological Assessment Battery|Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV
214478718|NCT05189236|PROCEDURE|Control Group (Only Algorithm of Febrile Neutropenia Management)|"Common Procedure Steps~1. The child is admitted to the unit and evaluated.~2. The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.~3. The inclusion and exclusion criteria are evaluated.~4. The group of the child to be included in the study is determined in accordance with the randomization order.~5. The first section of the patient information and follow-up form is filled out.~6. The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.~Procedure Steps for Control Group:~1. Common procedure steps are followed.~2. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
214300059|NCT03519347|OTHER|Alkalosis Avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.
214300060|NCT03519347|OTHER|Acidosis avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.
214300061|NCT03519347|DIAGNOSTIC_TEST|Point of Care Testing|POC testing will use the Abbott BLUE I-STAT CHEM8+ , a portable, handheld device that provides lab quality analysis within 2-3 minutes using a few drops of whole blood (≤100uL).
214300062|NCT03519347|DEVICE|Cardiac Monitor|Device is one-third of the size of a triple-A battery and is placed subcutaneously in the left chest during a brief procedure that can be done in-office under local anesthesia.
214300063|NCT02078609|DRUG|LGH447|LGH447 in patients with AML or MDS
214300064|NCT02078609|DRUG|LGH447 + midostaurin|LGH447 + midostaurin in patients with AML
214300065|NCT04890366|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
214300066|NCT05517382|OTHER|supportED|suicide prevention videogame
214300067|NCT05517382|OTHER|Control|non-health related videogame
214300068|NCT01871116|BEHAVIORAL|POWER-remote|Web-based weight loss program.
214300069|NCT01871116|BEHAVIORAL|Self-directed|"Pamphlet entitled Aim for a Healthy Weight will be given."
214300070|NCT01641692|DRUG|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
214300071|NCT01641692|PROCEDURE|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
214669378|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 2|Inhaled Staccato Fentanyl, 25 mcg x 2 doses
214669379|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 4|Inhaled Staccato Fentanyl, 25 mcg x 4 doses
214669380|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 6|Inhaled Staccato Fentanyl, 25 mcg x 6 doses
214669381|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 12|Inhaled Staccato Fentanyl, 25 mcg x 12 doses
214300072|NCT01641692|DRUG|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
214300073|NCT03164096|DRUG|Bupivacaine Hydrochloride|intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
214300074|NCT01685996|DRUG|zonisamide|In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
214300075|NCT01685996|DRUG|placebo|
214300076|NCT05523661|DRUG|Dasatinib plus anti-CD19/CD22 CAR-T cells|Dasatinib plus VP chemotherapy was administrated to newly diagnosed Ph-positive patients aged 55-70 years old,if hCR was achieved,autolymphocyte was collected,and anti-CD19/CD22 CAR-T cells infusion was administrated to patients followed by Fludarabine and Cyclophosphamide therapy
214300077|NCT00762242|PROCEDURE|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
214300078|NCT00841087|DRUG|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
214300079|NCT00841087|DRUG|insulin detemir|Injection subcutaneously at bedtime
214300080|NCT00841087|DRUG|insulin aspart|Injection subcutaneously immediately before each meal.
214300081|NCT02278588|DRUG|Rasagiline|
214300082|NCT03249311|DRUG|Levomilnacipran|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
214300083|NCT03249311|DRUG|Duloxetine|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
214300084|NCT03249311|DRUG|Placebos|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
214300085|NCT02254928|DRUG|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
214300086|NCT01264978|DEVICE|Repetitive magnetic stimulation of the quadriceps muscle|"During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions."
214300087|NCT01761838|OTHER|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
214300088|NCT01761838|OTHER|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
214300089|NCT01761838|OTHER|Low back pain participants without SMT|No treatment
214300090|NCT02913079|BEHAVIORAL|Sit-stand desk|
214300091|NCT02913079|BEHAVIORAL|Sitting desk|
214478719|NCT05189236|PROCEDURE|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|"Procedure Steps for Experiment Group:~1. Common procedure steps are followed.~2. Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).~3. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
214478720|NCT06665737|DRUG|Early receiving G-CSF group|Early receiving G-CSF group will be given within 72 hours post chemotherapy
214478721|NCT06665737|DRUG|Late receiving G-CSF group|Late receiving G-CSF group will be given after 72 hours post chemotherapy
214478722|NCT06824636|OTHER|a personalized diet plan was prepared according to the calculated requirements of each patient by two expert dietitians|Oral enteral nutrition products were added to the diet if the daily calorie and/or protein requirements could not be met by the diet. All of the patients underwent follow-up visits (4th and 8th weeks) after the initial assessment on admission. Each visit (0, 4th and 8th weeks) included screening of the nutritional status and food consumption, and measurements of body mass index (BMI), muscle mass, muscle strength, gait speed, serum albumin and serum C-reactive protein (CRP). Anthropometric measurements, muscle strength, physical performance, and the physical exercise plan were assessed.
214300092|NCT06144346|RADIATION|Stereotactic Ablative Radiation Therapy|SABR to all metastatic lesions
214300093|NCT06144346|PROCEDURE|Locoregional treatment|mastectomy or BCS for the primary tumor
214898736|NCT07111260|DEVICE|pHA130 Hemoadsorption + High-Flux Hemodialysis|A combination blood-purification procedure in which a pHA130 hemoperfusion cartridge is connected in series with a high-flux hemodialyzer. Blood first passes through the HP cartridge to adsorb protein-bound uremic toxins and is then dialyzed. In the 4-hour arm the HP cartridge remains online for the entire 4-hour session; in the 2-hour arm the cartridge is removed after 2 hours and dialysis continues alone for the remaining 2 hours. Blood-flow rates are 250-350 mL/min (4-hour arm) or 200-250 mL/min (2-hour arm).
214898737|NCT07113522|DRUG|MT-501|MT-501 Tablets
214300094|NCT06144346|OTHER|Standard of Care|Systemic treatment and palliative treatment
214300095|NCT04023448|PROCEDURE|transverse coloplasty pouch|a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
214300096|NCT00000609|DRUG|amiodarone|
214300097|NCT00000609|DEVICE|defibrillators, implantable|
214300098|NCT03051321|DEVICE|Wellness toilet system|Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
214300099|NCT01134978|BEHAVIORAL|Practice Order|"Blocked order - predictable~Random order - unpredictable"
214898738|NCT07113535|OTHER|RAM cannula|RAM cannula as an interface for non invasive ventilation in preterm newborns
214898739|NCT07113535|OTHER|Short binasal prong|Short binasal prong as an interface for non invasive ventilation in preterm newborns
214898740|NCT07111195|DEVICE|The ONCOhabitats software for MRI-based habitat segmentation|"ONCOhabitats is an MRI-based software platform designed to segment IDH-wildtype glioblastomas into four biologically distinct habitats (HAT, LAT, IPE, and VPE) based on vascular heterogeneity.~In this study, the software is applied preoperatively to generate imaging biomarkers that guide surgical sampling and are assessed for their ability to predict overall survival and stratify patients accordingly.~The intervention includes advanced perfusion imaging processing using the HTS methodology, non-invasive tumor characterization, and integration with molecular and histopathological data."
214300100|NCT03945487|BIOLOGICAL|umbilical cord-derived mesenchymal stem cell|Taken a dose of 1.0\*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment.
214478723|NCT06825611|DEVICE|Momentum Application|A mobile application to scan and predict spinal curvature. The application monitors curvature and track changes over time.
214478724|NCT06826183|DEVICE|REVEAL Linq device|Implantable loop recorder
214898741|NCT07112534|OTHER|Static stretching|Static stretching: 3 sets of 1 minute and 30 seconds of rest between sets
214898742|NCT07112534|OTHER|Foam rolling|Foam rolling: 3 sets of 1 minute and 30 seconds of rest between sets
215053284|NCT04257968|DIAGNOSTIC_TEST|Questionaires|Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
215053285|NCT05850819|DRUG|Colloidal silver gelatin sponge|Augment the extraction socket with Gelatamp
215053286|NCT05850819|DRUG|Sterile gauze pack|Extraction socket allowed to heal without augmentation with any material
214300101|NCT03945487|OTHER|Comprehensive treatment|"1. All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)).~2. Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers)."
214300102|NCT01897012|DRUG|Alisertib|Given PO
214300103|NCT01897012|OTHER|Laboratory Biomarker Analysis|Correlative studies
214300104|NCT01897012|DRUG|Romidepsin|Given IV
214300105|NCT06526637|OTHER|Paper Package|Paper based (as per current practice at Central and North West London (CNWL) NHS Foundation Trust) version of Palliate.
214300106|NCT06526637|OTHER|V1 + Preparation Sheet|Paper based version of Palliate plus a preparation sheet, that provides visual cues as to what equipment is required for the preparation and administration of the medications.
214300107|NCT06526637|OTHER|V2 + Video Training|Hybrid - paper based materials, preparation sheet, and video instructions available via an interactive portable document format (PDF) version of the training materials.
214300108|NCT04615663|BEHAVIORAL|Score SMI|the investigator will complete the SMI score
214300109|NCT05855668|BEHAVIORAL|CBT|12 weeks of group CBT for AUD or CUD
214300110|NCT05666258|DIAGNOSTIC_TEST|GEP|GEP before surgery to determine need for neoadjuvant chemotherapy
214300111|NCT05943145|OTHER|Group Dance and Movement Training|Dance movement-based sessions including personalized tasks and imagery, mirroring, and inscription, plus warm-up and cool down practices to ensure physical safety
214300112|NCT02775734|DRUG|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
214300113|NCT02775734|DRUG|Clomiphene citrate|Clomiphene citrate + Laparoscopic ovarian drilling
214300114|NCT03021239|PROCEDURE|Echo Guided Testing|
214300115|NCT03021239|PROCEDURE|Hemodynamic-Echo Ramp Testing -|
214300116|NCT02563795|DRUG|Bupivacaine|To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
214300117|NCT02563795|DRUG|Fentanyl|To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
214300118|NCT01801644|DRUG|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
214300119|NCT00656409|DRUG|Conjugated pneumococcal vaccine (Prevenar)|
214898743|NCT07111910|DEVICE|Virtual Reality Infection Control Training|This study evaluates a VR training program designed specifically to improve infection control skills among healthcare workers during the Hajj pilgrimage, one of the world's largest mass gatherings. Unlike traditional training, this VR intervention offers immersive, realistic simulations tailored to the unique cultural and environmental challenges of Hajj. It focuses on practical skill-building and clinical readiness in crowded, high-risk settings. Using a rigorous randomized controlled trial design, the study aims to show that VR training is more effective than conventional methods, potentially setting a new standard for infection control education in mass gathering healthcare.
214898744|NCT07111325|BIOLOGICAL|iEV|induced pluripotent stem cell-derived extracellular vesicles
214898745|NCT07111325|BIOLOGICAL|PRP|PRP injection
214898746|NCT07111325|OTHER|immobilization|immobilization
214898747|NCT07111611|PROCEDURE|Non-Traumatic Nasopharyngeal Suction Procedure|A modified suctioning technique that avoids deep catheter insertion and minimizes mucosal contact. Sterile saline (0.9%) is instilled into one nostril, and secretions are aspirated using external suction via the opposite nostril or mouth. This approach is designed to reduce pain and physiological stress compared to standard suction methods in preterm infants undergoing non-invasive ventilation.
214898748|NCT07112859|PROCEDURE|Complete Pulpotomy with Biodentine|"Administration of local anesthesia followed by rubber dam isolation.~Removal of coronal pulp tissue to perform a complete pulpotomy.~Hemostasis achieved with saline-soaked cotton pellet.~Placement of Biodentine as the pulp-capping agent on the radicular pulp.~Temporary restoration placed immediately after Biodentine placement.~Permanent composite restoration placed after 1 week.~Follow-up visits at 7 days, 1 month, and 3 months for clinical and radiographic evaluation."
214898749|NCT07112209|COMBINATION_PRODUCT|Rezvilutamide combined with docetaxel|"Intervention Description:~Drug:Rivarestatine Description: 240mg, po, qd Drug:Docetaxel Description:75mg/m2，ivgtt q3w Drug:Prednisone Description:5mg,po,bid"
214300120|NCT03563417|PROCEDURE|Percuteneous Coronary Intervention|PCI of Chronic Total Occlusions
214300121|NCT03563417|OTHER|Optimal Medical Therapy|Initiation and titration of optimal medical therapy in the control arm.
214300122|NCT01326767|DRUG|Paclitaxel dosing according to SmPC|Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
215053287|NCT04931914|OTHER|Clinical pharmacy sharing in the patient care regimen|antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
214300123|NCT01326767|DRUG|Individualized pharmacokinetically driven paclitaxel dosing|Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
214300124|NCT00206414|DRUG|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
214300125|NCT00206414|DRUG|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
214300126|NCT00199927|DRUG|Fluvastatin|Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
214300127|NCT00199927|DRUG|standard therapy|standard therapy
214300128|NCT02461225|DEVICE|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
214300129|NCT02461225|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
214478725|NCT06825728|DRUG|Different doses of Metoprolol.|The control group received 23.75mg/d of metoprolol, and the experimental group received the maximum tolerable dose of metoprolol.
214300130|NCT05482009|OTHER|Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment|The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
214300131|NCT04321148|PROCEDURE|standard of care PCI|optimal medical care PCI
214300132|NCT04321148|PROCEDURE|Impella-protected PCI|Impella-protected PCI
214300133|NCT06447727|DRUG|SIRT with Yttrium-90 Microspheres|Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection
214300134|NCT06447727|DRUG|FOLFIRI and Bevacizumab|FOLFIRI and Bevacizumab
214300135|NCT04432051|BEHAVIORAL|mechanical ventilator settings and position|Mechanical ventilation settings and patient position will be re-evaluated
214300136|NCT04368286|BEHAVIORAL|pulmonary rehabilitation|Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
214300137|NCT00484939|DRUG|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
214300138|NCT00484939|DRUG|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
214300139|NCT00897247|GENETIC|microarray analysis|
214300140|NCT00897247|GENETIC|protein expression analysis|
214300141|NCT00897247|GENETIC|proteomic profiling|
214300142|NCT00897247|OTHER|laboratory biomarker analysis|
214300143|NCT00358566|BIOLOGICAL|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
214300144|NCT00358566|DRUG|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
214898750|NCT07111286|OTHER|Assessment|"Before and after the programme :~* Self-questionnaires: assessment of pain (visual analogue scale), functional disability (Oswestry), kinesiophobia (Tampa scale of Kinesiophobia), mood (Hospital Anxiety Depression Scale), quality of life (SF12), level of physical activity (Simple Physical Activity Questionnaire), and level of motor imagery (Kinesthesic and Visual Imagery Questionnaire-10)~* Functional tests: Sorensen test, Shirado test, Time Up and Go test (TUG), 6-minute walk test, 200-metre fast walk test, measurement of maximum isometric strength of back extensors/flexors, 3D analysis of locomotion, posture and trunk flexion.~* Evaluation of excitability and inhibition mechanisms within the primary motor cortex at rest and during motor imagery using single and double pulse TMS. Excitability between the brain and the erector spinae muscles and inhibition of the primary motor cortex will be measured at rest and during imagery of back flexion and extension movements"
214898751|NCT07111286|OTHER|Motor imagery task sessions|3 sessions of 30 minutes per week
214300145|NCT03099876|PROCEDURE|treatment period|7 days treatment or 10 days treatment
214300146|NCT04948450|BEHAVIORAL|Physical activity intervention|"Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home for 45 minutes twice a week. The sessions will be organized in groups (6-10 patients/ group) and supervised by 2 physiotherapists. Within each small group (maximum 10), participants will follow the program tailored to their individual functioning level, with constant oversight by trainers.~People with dementia and care staff will be instructed to follow the prescribed PRT exercises for the rest of the week. Subjects will be encouraged to exercise daily."
214300147|NCT04948450|BEHAVIORAL|Cognitive stimulation intervention|"The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts. The intervention involves 14 sessions of themed activities, which typically run twice weekly. The sessions will be organized in groups (6-10 patients/ group).~People with dementia and their care staff will be instructed on how to practice the various activities at their nursing home for the rest of the week."
214300148|NCT04948450|BEHAVIORAL|Social intervention|Social intervention will be combined with physical and cognitive interventions through doing these in a group, playing games during exercises (dancing, throwing ball to each other) or doing cognitive stimulation therapy in a group.
214300149|NCT04948450|OTHER|Management of metabolic and vascular risk factors|"Study physicians will assess the risk of developing new chronic diseases, change in blood pressure, weight and BMI, and hip and waist circumference, blood test (glucose, lipid parameters, fasting glucose, and HbA1C if the person with dementia has diabetes) at 3 and 6 months.~Participants in the intervention group will be provided with information on the importance of reducing risk factors, guidance on lifestyle changes and prescribing treatment if necessary by cardiologists and endocrinologists. The target for blood pressure is less than 120/90 mmHg and the target for HbA1c is less than 8 %."
214300150|NCT00776347|DRUG|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
214300151|NCT00776347|DRUG|Donepezil|
214898752|NCT07111286|OTHER|Cognitive task sessions|3 sessions of 30 minutes per week
214898753|NCT07111286|OTHER|Assessment of satisfaction and tolerance|During the final assessment, which will take place after the programme. Satisfaction and tolerance will be assessed using a visual analogue scale.
214898754|NCT07113171|DEVICE|Conventional Direct Laryngoscope|The Macintosh laryngoscope blade was used for intubation. The technique involved neck extension to create a direct line of sight to the vocal cords for successful tracheal tube placement.
214898755|NCT07113171|DEVICE|Video Laryngoscope|The video laryngoscope allowed visualization of the glottis on a monitor without the need for cervical extension, facilitating intubation in anticipated difficult airway cases.
214898756|NCT07113444|OTHER|Tai Chi|Yang style of Tai Chi (24 form)
215053288|NCT00699946|DRUG|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
215053289|NCT00699946|DRUG|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
215053290|NCT03346421|BEHAVIORAL|diet and physical activity|
214300152|NCT00735787|BIOLOGICAL|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
214300153|NCT00735787|BIOLOGICAL|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
214300154|NCT01352988|DRUG|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
214300155|NCT02493673|DEVICE|Continuous positive airway pressure device|(ResMed Spirit S8)
214478726|NCT05008172|PROCEDURE|Splenic Artery Embolization|The decision for proximal or distal (selective) embolization is at the discretion of the Interventional Radiologist. For patients with angiographically evident injury, the choice of embolization site will be left to the discretion of the operator. For patients without angiographically evident injury, proximal splenic embolization will be performed with approved materials (coils or plugs for most patients) within the main splenic artery. The embolization endpoint will be hemostasis in the main splenic artery.
214478727|NCT06817525|DRUG|6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group A： Albumin-bound paclitaxe (260 mg/m²,d 1)+Carboplatin (AUC=5, d 1)+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;"
214478728|NCT06817525|DRUG|6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group B: Albumin-bound paclitaxe (125 mg/m²,d 1,8,15)+Carboplatin (AUC=5, d 1 )+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;"
214478729|NCT06817525|DRUG|6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group C： Albumin-bound paclitaxe (260 mg/m²,d 1, 6 cycles)+Carboplatin (AUC=5,d 1, 6 cycles)+Camrelizumab (200 mg, , d 1, 6 cycles)+Bevacizumab (15mg/kg, d 1,5 cycles), 21 days as one cycle;"
214898757|NCT07113444|OTHER|Moderate-Intensity Combined Exercise (MICE)|start from warm up (5 minute )repetitions in circuit in the exercises bent row with elastic band, bodyweight squats, adapted push-ups (on the wall or on the counter), deadlifts with an elastic band, presses with an elastic band and an abdominal band on the floor or adapted on the chair and cool down in the end
214898758|NCT07113444|OTHER|Control ( No Exercise )|The CON session will last 60 minutes and will be conducted only sitting. Participants will be told not to sleep and will not be allowed to use reading materials or any electrical gadgets during the CON session.
214300156|NCT01566461|DEVICE|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
214300157|NCT01566461|DEVICE|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
214300158|NCT05711225|BEHAVIORAL|smoking cessation intervention given according to the web-based transtheoretic model during pregnancy on postpartum smoking relapse.|Smoking cessation videos prepared according to the Web-Based Transtheoretic model A module was created on the web, with 5 sections, prepared by the researcher according to the Web-Based Transtheoretic model, for quitting smoking or for pregnant women who quit smoking to maintain this behavior. The modules are prepared in the form of animated videos in which the researcher is educational. Each module is arranged for an average of 5-10 minutes. Theoretical information about the content has been added under each video.
214300159|NCT00623064|DRUG|cisplatin|
214300160|NCT00623064|DRUG|gemcitabine hydrochloride|
214300161|NCT00623064|DRUG|lapatinib ditosylate|
214300162|NCT00623064|OTHER|pharmacological study|
214300163|NCT02444572|DRUG|Enoxaparin 4000 IU|
214300164|NCT00847457|BEHAVIORAL|Aerobic exercise|Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
214300165|NCT00847457|BEHAVIORAL|Stretching|Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
214300166|NCT00437593|PROCEDURE|ppVE, MP, ICG|surgery with ILM staining
214300167|NCT00437593|PROCEDURE|ppVE, MP, MB|Surgery with ERM staining
214300168|NCT05289011|OTHER|Interviews and questionnaires|"* Evaluation of inflammatory rheumatism~* Dietary survey~* International Physical Activity Questionnaire IPAQ~* BASDAI self-questionnaire~* Assessment of quality of life by ASQol questionnaire~* Assessment of fatigue by FACIT questionnaire~* Assessment of digestive symptoms~* Collection of demographic and general data~* Collection of treatment"
214300169|NCT04733365|OTHER|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
214898759|NCT07113392|DRUG|Suraxavir Marboxil|Suraxavir Marboxil will be administered as oral suspension: 40 mg (if weight ≥ 32 kg), or 20 mg (if weight \<32 kg).
214898760|NCT07113392|DRUG|Oseltamivir|Oseltamivir will be administered as oral granules: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≤ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.
215053291|NCT00129090|DRUG|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
214300170|NCT03849742|OTHER|Quality-of-Life Assessment|Ancillary studies
214300171|NCT03849742|OTHER|Questionnaire Administration|Ancillary studies
214300172|NCT03849742|PROCEDURE|Supportive Care|Receive Uber rides
214300173|NCT02221375|DRUG|BHT low|
214300174|NCT02221375|DRUG|BHT medium|
214300175|NCT02221375|DRUG|BHT high|
214300176|NCT02221375|DRUG|BI 54903 XX low|
214300177|NCT02221375|DRUG|BI 54903 XX medium 1|
214300178|NCT02221375|DRUG|BI 54903 XX medium 2|
214300179|NCT02221375|DRUG|BI 54903 XX high|
214300180|NCT02221375|DRUG|Ciclesonide|
214478730|NCT06817525|DRUG|6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group D: Albumin-bound paclitaxe (125 mg/m²,d 1,8,15,6 cycles)+Carboplatin (AUC=5, d 1, 6 cycles)+Camrelizumab (200 mg, d 1, 6 cycles)+Bevacizumab (15mg/kg, d 1,5 cycles), 21 days as one cycle;"
214300181|NCT01946997|OTHER|OCT Imaging both Normal and diabetic groups|Images taken to determine thickness values in the retina
214300182|NCT00631566|DRUG|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
214300183|NCT00631566|DRUG|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
214300184|NCT01976234|OTHER|Fresh RBC|Patients will receive fresh blood only
214300185|NCT01976234|OTHER|Old RBC|
214300186|NCT01481142|DEVICE|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
214300187|NCT04637542|OTHER|Mobile Learning|"The necessary interviews and correspondences were carried out in order to conduct the research. Permission was obtained from Health Sciences University Istanbul Training and Research Hospital Clinical Research Ethics Committee. The purpose of the study was explained to the students as per the sample criteria and their consents were obtained. All of the students participating in the study attended four hours of theoretical lessons in the classroom related to anatomy of the genital system. Following the theoretical training, students were divided into experiment (mobile application) and control (genital organ model) groups. Both groups where then given the Structured Student Presentation Form, Status and trait anxiety inventory and Knowledge Examination (pre-test) on paper.~The didactic content prepared for the institution's standard curriculum (control group) or mobile learning is similar for both training methods."
214300188|NCT01038024|DIETARY_SUPPLEMENT|1 tablet composed of antioxidants and minerals|1 tablet daily
214300189|NCT03616899|DRUG|KPI-121 Ophthalmic Suspension|KPI-121 Ophthalmic Suspension
214300190|NCT03616899|DRUG|Vehicle|Vehicle for KPI-121 0.25% ophthalmic suspension
214300191|NCT05339503|OTHER|enamel microabrasion|It is a non-restorative, conservative treatment that works both chemically and mechanically to remove up to 0.2 mm of affected enamel per application. Pumice either mixed with 18% hydrochloric acid or 5.25% sodium hypochlorite was used to remove fluorosis stains.
214300192|NCT02863133|DEVICE|Liquid Embolic|The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
214300193|NCT00060476|DRUG|rofecoxib|
214300194|NCT00060476|DRUG|Comparator: placebo (unspecified)|
214300195|NCT03448185|BEHAVIORAL|High intensity exercise|Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
214300196|NCT03448185|DIETARY_SUPPLEMENT|Omega-3 fish oil|Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
214300197|NCT03448185|BEHAVIORAL|Yoga|Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
214300198|NCT03448185|DIETARY_SUPPLEMENT|olive oil capsules|Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
214300199|NCT04528745|DIAGNOSTIC_TEST|Bio Impedance Spectroscopy (BIS)|Determination of fat free mass by BIS
214478731|NCT06818942|OTHER|Observations on preoperative and intraoperative factors influencing the difficulty of surgery|Age, body mass index, gender, inflammatory indicators, previous history of abdominal surgery, underlying disease
215053292|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
214300200|NCT00177892|PROCEDURE|sleep disruption|experimentally-induced Sleep Fragmentation
214300201|NCT00177892|PROCEDURE|sleep with and without positive pressure|OSAH patients with and without chronic positive airway pressure therapy
214300202|NCT01799616|DRUG|Pamidronate|
214300203|NCT01799616|OTHER|Placebo|
214300204|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 400|dose 400 UNT/day for 12 months
214300205|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 800|dose 800 UNT/day for 12 months
214300206|NCT03691896|DRUG|Cholecalciferol 1200|dose 1200 UNT/day for 12 months
214300207|NCT04640519|OTHER|Usual care|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
214300208|NCT04640519|OTHER|TASC intervention|TASC patients will receive a BP monitoring kit and electronic tablet with patient tailored BP infographics. They will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
214300209|NCT00862446|DRUG|Omegaven|1 gram/kg/day daily until on feeds
214300210|NCT00982475|PROCEDURE|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
214478732|NCT06818500|OTHER|high-fat meal|Participants will report fasted and consume two Jimmy Dean breakfast bowls (sausage).
214478733|NCT06818500|OTHER|Stress|Participants will report fasted and undergo a mental stress task.
214478734|NCT06267716|PROCEDURE|PENG block|preoperative ultrasound-guided pericapsular nerve group block
214478735|NCT06267716|PROCEDURE|IPB|preoperative ultrasound-guided iliopsoas plane block
214478736|NCT04616924|DRUG|RHB-204|RHB-204
214898761|NCT07111585|OTHER|Personalized health coaching program|"Clinical: Pre-discharge education on HF management (e.g., symptoms, treatment, diet, medication, lifestyle) is provided with a booklet and website link. A digital scale is given. After discharge, 12-week phone coaching monitors medication adherence, weight, and sodium intake.~Functional: Patients are referred to cardiac rehab for tailored exercise plans. Education on home exercise and oxygen monitoring is provided, with QR-linked videos. Coaching supports exercise adherence.~Psycho-cognitive: Emotional support is based on the PERMA model. Patients with severe issues are referred to psychiatry. Post-discharge, coaching includes psychiatric appointment support and use of the 100-Day Diary for self-care and gratitude journaling.~Social: Nurses foster trust and social reintegration. Referrals to community services are made as needed. Weekly calls ensure service connection and address unmet needs via social workers."
214898762|NCT07111585|OTHER|standard care|Participants in the control group will receive standard care, including guideline-directed medical therapy, based on the latest clinical guidelines currently provided to patients with HF at the hospital, as well as HF education. HF education will be provided using a booklet that includes information on HF (definition, causes, symptoms, diagnosis, treatment, medications, and self-management), an exercise poster, a symptom log, a symptom checklist, fall prevention tips, and a dietary guide. Additionally, nutritionist consultations on HF-related diets, cardiac rehabilitation exercises, and financial support available through the social work department, if necessary, will be provided.
214898763|NCT07112352|COMBINATION_PRODUCT|Smart devices with Personalised data feedback and habit coaching|Smart devices (smartwatch and sleep mat) with a bespoke 'Healthy Habits' application with three healthy habit coaching and data feedback modules, focused on active minutes, steps and sedentary time, viewable on a tablet.
214898764|NCT07112352|DEVICE|Smart devices with data feedback|"Smart devices (smartwatch and sleep mat) with a standard off-the-shelf data feedback application (WithingsTM App) providing generalised data feedback from the participant's smartwatch and sleep mat, viewable on a tablet for 6 months."
214898765|NCT07112352|OTHER|Control|Standard care where they will be signposted to National Health Service (NHS) guidance on Healthy Ageing for older adults.
214898766|NCT07113093|OTHER|Augmented Reality|Gait training will be conducted using the AR applications Stepping Stones, Reactive Stones, Obstacles, Speed Adjustment, Slalom, Tandem, and Monster Game for 45 minutes.
214898767|NCT07113093|OTHER|Virtual Reality|Gait training will be conducted using the VR applications Nature Island, Italian Apps, and Soccer for 45 minutes.
214898768|NCT07113093|OTHER|Self Directed Exercises|"Patients will be taught exercises including walking on a flat surface, walking with varying step lengths, walking over obstacles, and walking at different speeds. They will be instructed to perform these exercises for 45 minutes per day."
214898769|NCT07113093|OTHER|Others|The treatment duration is 60 minutes. Based on the patient's needs, the following exercises will be performed: scapular and thoracolumbar mobilization; upper and lower extremity exercises (range of motion, stretching, and strengthening); bed mobility and transitional movements such as rolling, coming to a sitting position, and standing up; core activation exercises such as bridging and functional reaching; weight shifting and balance training; gait training (e.g., walking between parallel bars, walking in different directions, and walking over obstacles); and cycling on a bicycle ergometer.
214898770|NCT07111949|OTHER|SSC Group 1 (Operation room)|"Salivary cortisol sampling from mothers, pain assessment (VAS), and measurement of physiological findings will be done at the following 3 measurement times. (1)Before transfer to the operating room (OR) (2)1 hour (h) after admission to the post-op room (PR) (3)at least 1 h after admission to the maternity ward (MW) The stress levels of the newborns will be assessed using the Neonatal Stress Scale at the following 4 measurement times, the heart rate and O2 saturation will be measured and recorded.~1. At least 5 min after the initiation of SSC in the OR~2. During the Hep-B vaccination in the PR~3. At least 30 min after SSC after admission to the MW~4. At least 24 h after birth in the MW, at least 30 min after SSC. The success of the newborn sucking will be assessed using the LATCH at the following 3 measurement times.~(1) At least 5 min after the initiation of SSC in the OR (2)At least 1 h after admission to the MW, during SSC (3)At least 24 h after birth in the MW during SSC."
214898771|NCT07111949|OTHER|SSC Group 2 (Post-operation room)|"SC sampling from mothers, pain assessment (VAS), and measurement of physiological findings will be done at the following 3 measurement times. (1)Before transfer to the OR (2)1 hour (h) after admission to the PR (3)At least 1 h after admission to the MW.~The stress levels of newborns will be assessed using the Neonatal Stress Scale at the following 4 measurement times, and heart rate and oxygen saturation will be measured and recorded.~(1)At least 5 min after birth under radiant heater in the baby care room (BCR) (2)At least 10 min after being taken to the BCR during Hep-B vaccination under radiant heater (3)At least 5 min after being admitted to the maternity ward after SSC (4)5 min after being held in the mother's arms Newborn sucking success will be assessed using LATCH at the following 3 measurement times.~(1)At least 5 min after starting SSC in the post-op care unit (2)During SSC after being admitted to the MW (3)At least 24 h after being held in the mother's arms in the MW."
214898772|NCT07111338|DRUG|Telitacicept 160mg|Telitacicept (RC18) is a recombinant TACI-Fc fusion protein that simultaneously neutralizes B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby inhibiting B-cell differentiation and plasma-cell survival. In this study, it is supplied as a sterile, preservative-free, lyophilized powder (160 mg/vial) that is reconstituted with 1 mL water for injection and administered subcutaneously into the abdomen or thigh at a fixed dose of 160 mg once weekly for 24 weeks. Each injection is performed by trained study personnel, and pre-filled backup syringes are available to ensure exact dosing. No dose escalation or tapering is planned; dose reductions or temporary discontinuation are allowed only for predefined safety criteria.
214898773|NCT06918574|OTHER|Breastfeeding Education with Breastfeeding Roadmap|"Information about the Breastfeeding Roadmap prepared by the researchers will be explained to the mothers in the intervention group and hung in poster rooms."
215053293|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
215053294|NCT01999842|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
214478737|NCT04616924|DRUG|Placebo|Matching placebo to RHB-204
214300211|NCT06328153|DEVICE|Fu's Subcutaneous Needling|Operation of the FSN will follow the KOA's Fu's Subcutaneous Needling Treatment Code of Practice24. After routine disinfection, a disposable Fu's subcutaneous needle ( Nanjing-Paifu Medical Technology Co., Ltd., Jiangsu, China ) is inserted parallel into the subcutaneous loose connective tissue of the pathological tight muscles ( gastrocnemius muscle, tibial anterior muscle and quadriceps femoris muscle ). The FSN needle is operated in a swaying movement. The fan angle is approximately 60°; perform a total of 45 round trips in 30 seconds. Swaying is accompanied by reperfusion approach: 20 sweeps with 10 seconds of reperfusion approach as a group, 3 groups for each pathological tight muscle. The reperfusion approach requires active, short and sharp contractions of the pathological tight muscle. The muscle alternates contraction and relaxation. The FSN group is treated 3 times a week for 2 weeks.
214300212|NCT06328153|DRUG|Celecoxib|Participants in the drug group will receive celecoxib (capsule) 200mg every day continuously for 2 weeks.
214300213|NCT03727412|DRUG|Drugs, Generic (Naprosyn)|naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
214898774|NCT06917963|DRUG|Intensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM)|This intervention consists of intensified intravenous omeprazole therapy specifically designed to reduce high-output ileostomy after surgery. It includes an initial loading dose of 80 mg omeprazole administered intravenously on the day before surgery (or on the day of surgery in emergency cases), followed by a continuous treatment of 40 mg intravenously twice daily (at 6:00 AM and 6:00 PM) during hospitalization and after discharge to complete 10 day therapy, distinguishing it from standard once-daily omeprazole dosing protocols typically used for gastrointestinal ulcer prophylaxis.
214898775|NCT06917963|DRUG|Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM).|The control group will receive standard intravenous omeprazole therapy as per routine clinical practice for gastrointestinal prophylaxis. Participants will receive a single daily dose of 40 mg omeprazole intravenously administered at 6:00 AM during hospitalization. This standard dosing regimen serves as the comparator for assessing the efficacy of the intensified dosing regimen used in the experimental group.
214300214|NCT03727412|DRUG|Placebo Oral Tablet|placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
214300215|NCT03022760|BEHAVIORAL|Work-related measures|After mapping the patient's psychosocial work situation using tools provided at the one-day training, the patient's employer will be contacted and involved in the rehabilitation planning.
214300216|NCT00668486|DRUG|Lactic acid (Dermacid)|
214300217|NCT05220579|DEVICE|"Exposure to TOR device"|"Specific wave spectrum is directed by the TOR device to human tissues affected by the SARS-CoV-2 virus in order to disrupt its activity."
214300218|NCT05220579|DEVICE|"Exposure to switched off TOR device"|"The TOR device has screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators."
214300219|NCT02478554|OTHER|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
214300220|NCT05459103|OTHER|Bidirectional remote interaction intervention|Intervention group participants engaged in a 12-week bidirectional remote interaction. All interactions were conducted through the same group on Line. A one-hour interactive online group intervention was held every Monday to Friday from 14:30 to 15:30, for a total of 60 hours. The online interactive interventions were conducted in a structured course format, with a facilitator conducting live classes and alternating between static and dynamic classes.
214898776|NCT06282965|DRUG|Angiotensin (1-7)|The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.
214300221|NCT05459103|OTHER|Unidirectional remote interaction intervention|Control group participants engaged in a 12-week unidirectional remote interaction. All interactions were conducted through the same group on Line. Research assistants posted a YouTube video on the Line group at 14:30 every day, Monday through Friday, covering art, music, senior sports, long-term care resources, travel, and food preparation.
214898777|NCT06282965|DRUG|Sterile saline|Sterile solution of 0.9% NaCl in water.
214898778|NCT06216899|OTHER|Whole-food based smoothie|The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
214898779|NCT06216899|OTHER|Formula|Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
214898780|NCT05442801|DRUG|Cyclopentolate|Well known eye drop used for cycloplegic refraction among children.
214300222|NCT01631058|DRUG|Everolimus|"This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.~Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
214300223|NCT00657241|DRUG|Carvedilol CR|
214300224|NCT00657241|DRUG|Valsartan|
214300225|NCT01173718|DEVICE|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
214300226|NCT03384979|DRUG|Iopamidol|Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
214898781|NCT05442801|DRUG|Tropicamide|Well known eye drop used for cycloplegic refraction among children.
214898782|NCT04745221|OTHER|autologous fecal bacteria|autologous fecal bacteria transplantation
214898783|NCT07110987|PROCEDURE|Phototherapy|Triple continuous phototherapy per AAP Guudelines
214898784|NCT07110987|DRUG|ursodeoxycholic acid (UDCA)|10mg/kg/day orally divided in two doses (URSORASHA) . Given with feeds untill the bilirubin level drop down to limits that don't need therapy due to AAP guidelines.
215053295|NCT03788642|PROCEDURE|Control LED shoe arm|Patients with DFU will wear LED shoe 30 minutes once daily
215053296|NCT03788642|PROCEDURE|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes once daily
214300227|NCT02325336|DEVICE|BCMA (bar-code-assisted medication administration)|"Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.~In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification."
214300228|NCT05384067|BEHAVIORAL|Mindfulness-based intervention|Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
214898785|NCT07112469|BEHAVIORAL|Health promotion communication|"1. Students (Research subjects):~   * All students: Students perform plays during flag-raising ceremonies for all grades. These plays emphasize the importance of increasing physical activity for better health.~  * Selected students from Phase 1: Students selected in Phase 1 are guided to play games that help them identify healthy behaviors. They also receive flyers with messages about the benefits of physical activity.~2. Parents:~   Parents receive flyers with messages about the benefits of physical activity.~3. Schools:~Research team advises school principals and discusses ways to adjust factors that affect students' physical activity time. These factors are assessed based on cross-sectional study results, literature reviews, and the evaluation of the current situation at each school."
215053297|NCT02882061|PROCEDURE|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
215053298|NCT00331994|DRUG|Bacillus clausii|3 bacillus clausii vials/day for one month
215053299|NCT00331994|DRUG|Metronidazole|3 Metronidazole tablets/day for one week
215053300|NCT00601692|DRUG|cisplatin|Given IV
215053301|NCT00601692|DRUG|docetaxel|Given IV
215053302|NCT00601692|DRUG|irinotecan hydrochloride|Given IV
215053303|NCT00601692|RADIATION|radiation therapy|Given 5 days a week for 3 weeks
215053304|NCT04081662|BEHAVIORAL|compACT Intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of distress, depressive symptoms, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
215053305|NCT05770297|DIETARY_SUPPLEMENT|Propolis|intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group
215053306|NCT05770297|OTHER|placebo|intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group
215053307|NCT02295631|DEVICE|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
214300229|NCT04356131|OTHER|progressive relaxation exercises and massage|Progressive relaxation exercises included 30 minute rhythmic breathing and muscle relaxation exercises were demonstrated in the second part of the CD with river sounds and verbal instructions. Massage techniques were performed on the site between upper symphysis pubis and umbilicus with 15 minute effleurage demonstrated in the third part of the CD with nature sound.
214300230|NCT01525043|DRUG|Naproxen|Naproxen 500mg BID for the first 2 weeks
214300231|NCT01525043|DRUG|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
214300232|NCT01525043|DRUG|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
214300233|NCT01525043|DRUG|Naproxen|500mg bid
214300234|NCT01525043|DRUG|Synera|Topical appication of single patch to elbow for 12hrs/day
214478738|NCT03370913|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
215053308|NCT02295631|DEVICE|ETView VivaSight SL|ETI with ETView VivaSight SL
215053309|NCT06407453|OTHER|control|There will be no interference ergonomics training
215053310|NCT06407453|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
215053311|NCT03073525|BIOLOGICAL|Vigil|The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
215053312|NCT03073525|DRUG|Atezolizumab|"Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters."
215053313|NCT03569124|OTHER|Teaching tool for identification of colorectal polyps|This is a teaching session on how to identify the colorectal polyps shot in blue light imaging.
214300235|NCT01525043|DRUG|Synera|Single patch applied to elbow for 4hrs/twice daily
214300236|NCT03906903|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
214300237|NCT03906903|BEHAVIORAL|Cognitive Stimulation|Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.
214300238|NCT06477614|BIOLOGICAL|DC cell Vaccine|Deliver DC cell vaccine into patients for anti-ancer therapy.
214300239|NCT04078061|BEHAVIORAL|MABA|Adaptive, modular, behavioral intervention.
214300240|NCT04078061|BEHAVIORAL|EIBI|Early Intensive Behavioral Intervention
214898786|NCT07112469|BEHAVIORAL|Guidance and practice in developing physical activity plans|"The intervention is exclusively implemented for students who participated in the Phase 1 survey. These students are being guided to create weekly physical activity plans by keeping a journal. They are also encouraged to self-monitor their progress. A Facebook page has been created to launch the Active Moments with Family challenge and provide regular health-related updates. Teachers are sharing this page with parents to promote participation in the challenge and enhance their health knowledge."
214898787|NCT07112768|DIAGNOSTIC_TEST|Serum levels of LH, FSH, testosterone, prolactin, and ferritin|Measurement of both hormonal and biochemical markers in Jordanian PCOs females, including Serum levels of LH, FSH, testosterone, prolactin, and ferritin)
214898788|NCT06463028|DRUG|Sapanisertib|Oral
214898789|NCT06463028|DRUG|Serabelisib|Oral
215053314|NCT03263403|BIOLOGICAL|Ingovax ACWY|The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
215053315|NCT03263403|BIOLOGICAL|Quadri Meningo|Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited. Quadri Meningo \[Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined\] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
215053316|NCT04140617|BEHAVIORAL|Exposure to aerosol of electronic cigarette|Exposure to aerosol of electronic cigarette (30 min)
215053317|NCT06097403|DIAGNOSTIC_TEST|Covid 19 swap|diagnostic tool
215053318|NCT06100757|DEVICE|Micra Transcatheter Pacing System (TPS°|Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months
215053319|NCT06100757|DEVICE|Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR|Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months
215053320|NCT03692403|DRUG|Quinagolide 360 µg|Vaginal ring containing quinagolide 360 µg for daily releases
215053321|NCT03692403|DRUG|Quinagolide 720 µg|Vaginal ring containing quinagolide 720 µg for daily releases
215053322|NCT03692403|DRUG|Quinagolide 1080 µg|Vaginal ring containing quinagolide 1080 µg for daily releases
214300241|NCT01367158|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
214300242|NCT01367158|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
214300243|NCT01367158|BIOLOGICAL|Tdap|Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
214300244|NCT02850315|DEVICE|optimal coherence tomography|
214898790|NCT06463028|DRUG|Paclitaxel|Infusion
214898791|NCT06932484|PROCEDURE|parameters|during surgery hemodynamic will be optimized based on percentage variation of different variables
215053323|NCT03692403|DRUG|Placebo|Matching placebo
214300245|NCT04595513|DRUG|TAVT-18 (sirolimus)|The investigational drug product to be used in this study is TAVT-18, a proprietary formulation of sirolimus in clinical development, by Tavanta Therapeutics, Inc. It is provided in a powder formulation in pre-measured vials.
214898792|NCT05517330|BIOLOGICAL|Tislelizumab|200mg IV Q3W
214300246|NCT05772936|BEHAVIORAL|Balance training|perturbation induce step training to improve reactive stepping with paretic leg.
214300247|NCT04854811|DRUG|Roflumilast Oral Tablet|Once daily for 12 weeks
214300248|NCT04428996|BEHAVIORAL|Social Cognition and Interaction Training (SCIT)|The social cognition and interaction training (SCIT) is a manual-guide group intervention that can apply to people with serious mental illness. There have been evidences showing that the SCIT could improve emotional perception, theory of mind, attribution bias, and social relationship.
214300249|NCT00161993|DRUG|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
214300250|NCT00161993|DRUG|Gammagard S/D (Solvent/Detergent)|
214300251|NCT05921019|DEVICE|laser acupuncture|This study will use the Handylaser Trion laser manufactured by RJ Laser, Germany.
214898793|NCT05517330|DRUG|Afatinib|30mg PO QD
214898794|NCT06950983|BEHAVIORAL|AYA-NAV|Support for AYA and vocational navigation sessions from clinical team
214898795|NCT06949436|PROCEDURE|GK SRS|Under local anaesthesia, a Leksell stereotactic head frame is fixed to the patient's head to allow for complete cranial immobilization during treatment. The retrogasserian (i.e., mid-cisternal) target will be utilized at a single 4 mm isocenter, and 40 Gy will be administered to the 50% isodose line while limiting the brainstem to 12 Gy.
214898796|NCT00858273|DIETARY_SUPPLEMENT|Antioxidant supplement|1 capsule daily with dinner
214300252|NCT05921019|DEVICE|sham laser acupuncture|This study will use the sham Handylaser Trion laser manufactured by RJ Laser, Germany,and without any laser beam delivering
214300253|NCT00275951|DRUG|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
214300254|NCT02226003|DRUG|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
214300255|NCT02226003|DRUG|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
214300256|NCT02226003|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
214300257|NCT02226003|DRUG|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
214300258|NCT02226003|DRUG|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
214300259|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_4000_20|application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz
214300260|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_500_2|application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz
214300261|NCT05308641|PROCEDURE|standard multimodal pain therapy|standard multimodal pain therapy
214300262|NCT05751239|OTHER|Questionaire|All participants answered an online questionaire. Out of the 837 participants 641 were included
214300263|NCT02467465|OTHER|Physical therapy modalities|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
214300264|NCT02467465|DEVICE|Invasive Physical therapy modalities|Dry needling added to massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
214300265|NCT05139563|OTHER|Placebo injection: Intralipid 20% fat emulsion|placebo intralipid 20% intramuscular (IM) injection
214300266|NCT05139563|OTHER|Placebo implant|placebo subdermal implant rod
214300267|NCT03242174|OTHER|Health Behavior Questionnaire Packet|Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
214300268|NCT03293381|DEVICE|additional biopsies|additional biopsies
214300269|NCT02795442|OTHER|Even protein|5 day intake of even protein 3 day rotating menu.
214669382|NCT02659345|BEHAVIORAL|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
214300270|NCT02795442|OTHER|Skewed protein|5 day intake of skewed protein 3 day rotating menu.
214300271|NCT01572194|BIOLOGICAL|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
214669383|NCT02659345|BEHAVIORAL|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
214669384|NCT00602407|DRUG|Cilostazol|
214898797|NCT00858273|OTHER|Diabetes treatment|Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator
214669385|NCT05306678|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
214669386|NCT05306678|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
214898798|NCT00858273|DRUG|Regular Insulin|Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
214300272|NCT01689584|GENETIC|salivary kit|The saliva samples will be made of selected related (DNA).
214300273|NCT04167683|OTHER|No intervention|No intervention
214300274|NCT06596148|OTHER|Access to Shingrix dashboard|The investigators will build and grant access to a clinical dashboard that exists behind the VA firewall. The dashboard will identify Veterans from each VA facility who are receiving immunosuppressants (prescribed via the VA). The dashboard will also provide information about the number of Shingrix vaccines each patient has received (which have been documented within the VA electronic health record). VA clinicians will have access to view information about patients based on their VA electronic health record permissions.
214300275|NCT06449469|DRUG|Rivaroxaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
214300276|NCT06449469|DRUG|Acetylsalicylic acid|Antiplatelets decrease platelet aggregation and inhibit thrombus formation. In NOTION-4 acetylsalicylic acid (75 mg once a day) is used as first line choice. For participants who are allergic to acetylsalicylic acid, clopidogrel (75 mg once a day) will be used. If the patient has already been prescribed Clopidogrel before the aortic valve intervention e.g. due to apoplexia, the patient will continue this medication following the procedure as an antiplatelet treatment, which is administered according to current guidelines.
214300277|NCT06449469|DRUG|Clopidogrel|Antiplatelets decrease platelet aggregation and inhibit thrombus formation. In NOTION-4 acetylsalicylic acid (75 mg once a day) is used as first line choice. For participants who are allergic to acetylsalicylic acid, clopidogrel (75 mg once a day) will be used. If the patient has already been prescribed Clopidogrel before the aortic valve intervention e.g. due to apoplexia, the patient will continue this medication following the procedure as an antiplatelet treatment, which is administered according to current guidelines.
214300278|NCT06449469|DRUG|Edoxaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
214300279|NCT06449469|DRUG|Dabigatran|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
214300280|NCT06449469|DRUG|Apixaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
214300281|NCT06449469|DRUG|Warfarin|If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
214300282|NCT05986019|DEVICE|transcranial focused ultrasound (tFUS)|Transcranial focused ultrasound (tFUS) is a promising new technology that is both noninvasive and may be focally applied to deep brain targets. tFUS utilizes transducers which contain piezoelectric elements to produce pulses of ultrasonic waves that summate deep in the brain. Transcranial focused ultrasound (tFUS) uses a single transducer fixed in a head-worn apparatus on the scalp to produce ultrasonic waves deep into the brain.
214300283|NCT05776667|RADIATION|Hypofractionated Radiation Therapy|"Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by standard of care wide local excision 2-6 weeks later."
214478739|NCT06816277|PROCEDURE|Desbridamiento de periimplantitis|"The implant with the most severe involvement was selected, although the treatment was performed on all implants, to prevent patients with more affected implants from having greater statistical relevance.~The peri-implant surgical treatment was performed under local infiltrative anesthesia with 4% articaine with 1:100,000 adrenaline. Debridement was performed using ultrasound with irrigation, complemented using curettes. Treatment with melatonin or placebo was applied through computer block randomization. To achieve blinding, a different code was assigned to the group applying 1.9 mg of melatonin (A) and to the control group (B) applying placebo (dextrinomaltose 2 mg) powder and the samples and records were coded. It was sutured with 4/0 monofilament in a pre-assembled 3/8 s"
214478740|NCT06816277|DRUG|Aplicación de melatonina|Treatment with melatonin or placebo was applied through computer block randomization. To achieve blinding, a different code was assigned to the group applying 1.9 mg of melatonin (A) and to the control group (B) applying placebo (dextrinomaltose 2 mg) powder and the samples and records were coded.
214478741|NCT06816277|OTHER|Placebo application|Treatment with melatonin or placebo was applied through computer block randomization. To achieve blinding, a different code was assigned to the group applying 1.9 mg of melatonin (A) and to the control group (B) applying placebo (dextrinomaltose 2 mg) powder and the samples and records were coded.
214478742|NCT05521477|DIETARY_SUPPLEMENT|SLAB51|One dose of probiotic consists of a bag of probiotic powder to dissolve in a glass of water according to the manufacturer instructions. Each bag contains 100 billion bacteria of the following strains: streptococcus thermophilus DSM 32245, 2 Bifidobacteria lactis DSM 32246 and DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244 and Lactobacillus brevis DSM 27961.
214478743|NCT06825676|BEHAVIORAL|CKD Patient Management Based on Guidelines|"1. Lifestyle Education: smoking cessation, physical activity, healthy eating, and weight management.~2. Pharmacological Treatment: Implement targeted and guideline-based pharmacological treatment plans for patients with different comorbidities, such as the use of RAAS inhibitors (RASi), SGLT2 inhibitors, statins, and other medications.~3. Risk Factor Management: Effectively manage risk factors such as hypertension, diabetes, and dyslipidemia, and regularly reassess these factors.~4. Risk Assessment: Perform risk assessments for CKD patients based on eGFR and UACR, and implement graded management according to the results.~4、Referral Management: Refer patients with eGFR \< 30 ml/min/1.73m² or severe proteinuria.~5、CKD Patient Management Checklist: Community doctors should complete the CKD patient management checklist in a standardized manner, including records of risk factors, dynamic kidney function, and follow-up plans."
214478744|NCT06825962|OTHER|Water intake|Water ingested to fully replace sweat losses during exercise.
214478745|NCT06825962|OTHER|Water restriction|Water restriction to induce hypohydration of \~3% body mass through sweat losses during exercise.
214478746|NCT06824220|DEVICE|High-Flow Tracheal Oxygen|High-Flow Tracheal Oxygen is the use of high oxygen flows in tracheostomized patients. Unlike conventional oxygen therapy which is performed through siliconized nasal prongs, this is done through a connector directly on the tracheostomy tube.
214478747|NCT06825286|DRUG|Bupivacaine|Patients received general anesthesia and bilateral ultrasound guided transmuscular quadratus lumborum block wilh (20 ml bupivacaine 0.25%).
214300284|NCT05436951|BEHAVIORAL|Brief on-shift nap|The brief nap opportunity will allow for a 45-minute nap between the hours of 0200 and 0300 during the in-lab 12-hour simulated night shift.
214300285|NCT05612581|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
214300286|NCT05612581|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
214300287|NCT05612581|DRUG|TDF|TDF given orally
214300288|NCT05612581|DRUG|PEG-IFNα|PEG-IFNα given by subcutaneous injection
214300289|NCT05459116|DEVICE|Placement of nasogastric balloon|A nasogastric balloon catheter will be inserted after inclusion. This will be a NutriVent (Sidam S.R.L., Mirandola, Italy) for patients \>40kg, and a SmartCath Esophageal pressure catheter (Vyaire/Carefusion) for patients \<40kg. This placement is similar to a standard nasogastric tube placement, which is a common procedure in an ICU. Potential minor side effects include a nosebleed, sore throat and erosion of the nose where the tube is anchored. All patients will receive this intervention. When the esophageal catheter becomes displaced or is accidentally removed during the study period, it will be replaced.
214300290|NCT05785000|OTHER|Physical exercise programme as an add-on|Consists of an individually tailored bike exercise program guided by symptoms, pulse rate and patient specific judgement of exertion monitored also by BORG RPE and VAS and progressively increasing time and level of resistance below symptom provocation
214300291|NCT05785000|OTHER|Control patients receiving usual care|No exercise intervention
214300292|NCT01896440|DRUG|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
214478748|NCT06825286|DRUG|Bupivacaine and Dexmedetomidinc) group|Patients received general anesthesia and bilateral ultrasound guided transmuscular quadratus lumborum block with (20ml Bupivacaine 0.25%) + (Dexmedetomidine Imic/kg)
214478749|NCT06826339|OTHER|ACApatch™|Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214898799|NCT06756503|DIAGNOSTIC_TEST|fecal elastase|To investigate exocrine pancreatic insufficiency (EPI), all patients will be asked to provide a stool sample for fecal elastase (Fel-1) analysis. Participants will be instructed to collect their stool sample in a sterile, disposable plastic container and submit it to the Gastroenterology Chemistry Laboratory (Litwin Laboratory) for processing and analysis. Based on previously published reports, samples will be refrigerated at 4-8 °C for no more than 48 hours. The concentration of Fel-1 in all samples will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (ScheBo-Pancreatic Elastase 1™, Giessen, Germany), with fecal elastase extracted and analyzed according to the manufacturer's instructions.
214898800|NCT06756503|DIAGNOSTIC_TEST|Serum cytokines|Cytokines will be quantified using the Bio-Plex Pro™ Human Cytokine 27-plex commercial kit (Bio-Rad Laboratories, USA) following the kit instructions.
214898801|NCT05502341|DRUG|Bictegravir|Tablets administered orally without regard to food
214898802|NCT05502341|DRUG|Lenacapavir|Tablets administered orally without regard to food
214898803|NCT05502341|DRUG|BIC/LEN FDC|Tablets administered orally without regard to food
215053324|NCT05783895|DIAGNOSTIC_TEST|Post screening diagnostic test|1\) anti-PF4/heparin antibody test (ELISA) and 2) in vitro platelet aggregation tests. The diagnosis of HIT is made when both tests are positive or when a platelet aggregation test is positive.
215053325|NCT01057537|DRUG|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
214300293|NCT06112782|DEVICE|Keravive by Hydrafacial Treatments|Scalp hydradermabrasion
214300294|NCT01384968|DIETARY_SUPPLEMENT|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
214300295|NCT06151795|DIAGNOSTIC_TEST|XTR006|Single dose intravenous injection of XTR006. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
214300296|NCT05982392|DRUG|Tramadol|Tramadol 100mg will be given 60 minutes before start of procedure.
215053326|NCT01057537|DRUG|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
215053327|NCT02056444|DRUG|Tranexamic Acid|
215053328|NCT03032419|BIOLOGICAL|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
215053329|NCT03032419|BIOLOGICAL|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
215053330|NCT02065323|DRUG|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
215053331|NCT02065323|DRUG|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
215053332|NCT04058015|OTHER|Stress-induced hyperglycemia|Stress-induced hyperglycemia (SIH)was defined as a serum glucose ≥ 200 mg/dL in the patients without Diabetes mellitus.
215053333|NCT04058015|OTHER|Diabetic hyperglycemia|Diabetic hyperglycemia (DH) which indicated a serum glucose ≥ 200 mg/dL in patients with Diabetes mellitus.
215053334|NCT04058015|OTHER|Diabetic normoglycemia|Diabetic normoglycemia (DN), which was defined when there was a serum glucose \< 200 mg/dL in the patients with Diabetes mellitus.
214300297|NCT05982392|DRUG|Naproxen Sodium|Naproxen sodium 550mg will be given 60 minutes before start of procedure.
214478750|NCT06826339|OTHER|caregraFT™|Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215053335|NCT04058015|OTHER|Non-diabetic normoglycemia|Non-diabetic normoglycemia (NDN) indicating a serum glucose \< 200 mg/dL in patients who were absent of Diabetes mellitus.
214300298|NCT05982392|DRUG|Placebo|Placebo will be given 60 minutes before start of procedure.
214300299|NCT00437099|DRUG|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
214300300|NCT00437099|DRUG|Placebo|Placebo
214300301|NCT02104700|DRUG|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
214300302|NCT03847454|COMBINATION_PRODUCT|REACH|The intervention consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity.
214300303|NCT03847454|OTHER|Standard of care|Standard of care for rehabilitation treatment for musculoskeletal patients.
214300304|NCT01017614|DRUG|Monofer|"* administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~* administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained"
214300305|NCT01017614|DRUG|Iron Sulphate|200 mg daily
214300306|NCT00000901|DRUG|Indinavir sulfate|
214300307|NCT00000901|DRUG|Lamivudine|
214300308|NCT00000901|DRUG|Stavudine|
214300309|NCT03284164|DRUG|Tenofovir Exalidex (TXL)|Drug: Tenofovir Exalidex (TXL)
214300310|NCT04262232|BEHAVIORAL|Adapted Ca-HELP for Geriatric Cancer Patients|Intervention group: This intervention will be informed by social-cognitive theory10-13 and modeled after the tailored education and coaching intervention (TEC) used for Ca-HELP previously and consists of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
214300311|NCT01975909|DEVICE|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
214300312|NCT00457600|PROCEDURE|patient-driven health IT product|
214300313|NCT05634551|BEHAVIORAL|Questionnaires|Participants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires
214300314|NCT05634551|BEHAVIORAL|Interview|The interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)
214300315|NCT05048810|RADIATION|68Ga-DOTA-NT-20.3|In this study, all patients will receive one injection of 68Ga-DOTA-NT-20.3, a PET radiopharmaceutical selective for neurotensin receptor 1 (NTR-1). For the injection, subjects will receive a target dose of 2-4 MBq per kg of body weight as a bolus injection. 68Ga-DOTA-NT-20.3 injection will be followed by a 10 ml saline flush.
214300316|NCT05431933|BIOLOGICAL|Eupolio|Inactivated Polio vaccine (Sabin strains)
214300317|NCT05677815|PROCEDURE|Underwent Surgery from 2019 to 2022|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia
214300318|NCT04709341|DEVICE|TR Band 60MIN|TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals
214300319|NCT04709341|DEVICE|TR Band 120MIN|TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals
214300320|NCT03534154|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging
214300321|NCT03534154|DIAGNOSTIC_TEST|Blood Sampling|Sampling of serum
214300322|NCT03534154|DIAGNOSTIC_TEST|Microdialysis|Monitoring of cerebral fluid protein levels
214478751|NCT06826339|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214478752|NCT06817824|OTHER|Su-jok therapy|"Su Jok therapy was developed by South Korean scientist Professor Woo Jae Woo (1942-2010) in 1986. In Korean language, 'Su' means hand and 'Jok' means foot (Friman \& Chelala, 2016; Ivanov 2018; Woo 1987, 1991, 2000, 2002, 2007; Sharma \& Sharma, 2015). In Su Jok therapy, it is argued that there are reflection points of the body in the hands and feet and that these points activate every organ and part of the body like a remote control (Woo 1987, 1991, 2000, 2002, 2007; Şimşek \& Alpar, 2020).~Holistic approaches, energy flow and meridians form the basis of Su Jok therapy (Ivanov, 2018; Seth, 2013). Su Jok is an integrated therapy method that includes many tried and trusted methods of oriental medicine (Ponni, 2011; Rodríguez et al., 2018; Seth, 2013). In particular, it is similar in content to practices such as acupuncture and acupressure, which are approaches expressed by the same philosophy (Ivanov 2018; Ponni, 2011; Rodríguez et al., 2018)."
214478753|NCT06824441|BEHAVIORAL|Age- and Role-Specific Questionnaire Administration|"Participants will be assigned a sequence number upon eligibility confirmation. The intervention consists of completing a series of questionnaires, as follows:~Child/AYA/Caregiver Group:~Pre-clinic Visit: 3 questionnaires (approximately 15-20 minutes total). Post-clinic Visit: 2 questionnaires (approximately 5-10 minutes total).~Clinician Group:~Post-clinic Visit: 2 questionnaires (approximately 5 minutes total)."
215053336|NCT02887157|DEVICE|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
214300323|NCT03534154|DIAGNOSTIC_TEST|Neuropsychological tests|Battery of tests to assess cognitive function, patient outcomes
214300324|NCT03534154|DIAGNOSTIC_TEST|MRI (advanced)|Advanced MRI
214300325|NCT04768465|DRUG|Pyridostigmine, Prednisone, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
214300326|NCT04768465|DRUG|Pyridostigmine, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
214300327|NCT00050596|DRUG|MDX-010 / MDX-010 + Docetaxel|
214478754|NCT06825117|DIETARY_SUPPLEMENT|OMNi-BiOTiC® 41167|The probiotic OMNi-BiOTiC® 41167 consists of 3g of 3 x 10\^9 CFU total L. gasseri W15, L. plantarum W1, L. plantarum W21, B. lactis W51, L. acidophilus W70 and L. reuteri W192 per sachet of which two are to be taken each day. Additional non-probiotic components are cranberry-extract (0.01g), D-mannose (0,4 g), vitamin D (2,25µg), maize starch and hydrolyzed rice protein. All the strains in OMNi-BiOTiC® 41167 are specifically tested and selected for their inhibition potential against the known most common uropathogens like the uropathogenic Escherichia coli (UPEC), Klebsiella pneumonia, Proteus mirabilis and Entercoccus faecalis.
214300328|NCT06367543|DIAGNOSTIC_TEST|Time in therapeutic range of vital parameters|"Treatment adherence on NICU to the following vital parameters:~1. Temperature (T\<37,5°C) (every 4 hours during the first 96 h after admission to neurocritical care unit)~2. systolic blood pressure ICD-10 (International Statistical Classification of Diseases 10th Revision) (I60, 161 \& 162): 100-140 mmHg ICD-10 (I63): 120-180 mmHg (every 4 hours during the first 96 h after admission to neurocritical care unit)~3. Mean arterial blood pressure (MAP: 60-90 mmHg) (every 4 hours during the first 96 h after admission to neurocritical care unit)~4. Arterial oxygen partial pressure (paO2: 75 - 100 mmHg) (every 4 hours during the first 96 h after admission to neurocritical care unit)~5. Arterial carbon dioxide partial pressure (paCO2: 35 - 45 mmHg). (every 4 hours during the first 96 h after admission to neurocritical care unit)~6. Blood glucose (BG: 80-180 mg/dL). (every 4 hours during the first 96 h after admission to neurocritical care unit)"
214300329|NCT06914817|DEVICE|Brillouin optical scanning system (Intelon Optics) (BOSS)|Brillouin microscopy is a non-invasive optical imaging technique that measures the mechanical properties of tissues, such as stiffness and elasticity, by analyzing light scattering caused by natural acoustic waves within the tissue.
214300330|NCT00296374|DRUG|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
214300331|NCT00296374|DRUG|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
214300332|NCT00296374|DRUG|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
214669387|NCT00947154|DRUG|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
215053337|NCT02887157|OTHER|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
214300335|NCT03730948|BIOLOGICAL|DC vaccine|DC vaccine for colorectal cancer
214478755|NCT06825117|DIETARY_SUPPLEMENT|Placebo|The placebo consists of all components of OMNi-BiOTiC® 41167, except the probiotic bacteria, cranberry-extract, D-mannose and vitamin D. It has the same smell, taste and texture as the OMNi-BiOTiC® 41167.
215053338|NCT02887157|OTHER|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
215053339|NCT05214937|BEHAVIORAL|Intervention|During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action \& coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.
214300336|NCT00330291|DRUG|Xyrem|
214300337|NCT06081543|DIETARY_SUPPLEMENT|Ketogenic diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
214300338|NCT06081543|DIETARY_SUPPLEMENT|Low-fat Mixed diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
214300339|NCT05283252|DEVICE|3-D printed Guide|Guided Endodontic micro-surgery
214300340|NCT05283252|OTHER|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
214478756|NCT06826300|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension
214478757|NCT06826300|OTHER|Placebo|Performing manipulations without a two-second preliminary tension of the joint capsule in the shoulder and elbow joints.
214300341|NCT00670800|DRUG|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
214300342|NCT01786629|DRUG|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
214478758|NCT06825078|DEVICE|multiparametric MRI|"An MRI scan will be performed within 2 weeks of the discovery of a solid lung nodule ≥ 5mm on the screening scan.~When a follow-up scan is indicated, an MRI will be repeated on the same day as the follow-up scan.~The MRI sequences that will be performed are: SpiraleVibe UTE, T1map, T2 map and Diffusion.~A synthetic scanner image will be generated from the UTE morphological MRI image using a generative artificial intelligence (GAN) model."
214478759|NCT06825975|DEVICE|Hyperbaric oxygen treatment|Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
214478760|NCT00160732|DRUG|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
214478761|NCT00160732|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
214478762|NCT03169634|PROCEDURE|short or long stemmed rTKR cemented|An evaluation of the outcomes of different ways of performing revision total knee replacement surgery
214478763|NCT03169634|PROCEDURE|Cone with short stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with short stems is cemented in to it
214898804|NCT05502341|DRUG|Stable Baseline Regimen|"SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~* Nucleos(t)ide Reverse Transcriptase Inhibitors:~  * Abacavir~ * Emtricitabine~ * Lamivudine~ * Tenofovir alafenamide~ * Tenofovir disoproxil fumarate~ * Zidovudine~* Non-Nucleosite Reverse Transcriptase Inhibitors:~  * Delavirdine~ * Efavirenz~ * Nevirapine~ * Rilpivirine~ * Doravirine~* Integrase Inhibitors:~  * Bictegravir~ * Cabotegravir~ * Dolutegravir~ * Elvitegravir~ * Raltegravir~* Protease Inhibitors:~  * Atazanavir~ * Darunavir~ * Fosamprenavir~ * Indinavir~ * Lopinavir~ * Nelfinavir~ * Saquinavir~ * Tipranavir~* Chemokine Co-receptor 5 (CCR5) Antagonist:~  * Maraviroc~* Fusion Inhibitors:~  * Enfuvirtide~* gp120 Attachment Inhibitor:~  * Fostemsavir~* Anti-CD4 Monoclonal Antibodies:~  * Ibalizumab-uiyk"
214898805|NCT06235086|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
214898806|NCT06235086|DRUG|Dulaglutide|Dulaglutide, SC, once a week
214898807|NCT05242393|OTHER|No intervention is planned|No intervention is planned
214898808|NCT02257502|DRUG|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
214898809|NCT04199104|DRUG|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
214898810|NCT04199104|BIOLOGICAL|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
214898811|NCT04199104|DRUG|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
214898812|NCT06074016|DRUG|Zolmitriptan intranasal.|Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
214300343|NCT01786629|DRUG|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
214300344|NCT06293846|BEHAVIORAL|What I Learned at Home|What I Learned at Home is a self-efficacy intervention intended to build home repair and management skills while improving performance self-efficacy.
214300345|NCT05514067|PROCEDURE|Electro-Acupuncture|A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
214300346|NCT06450470|DEVICE|Therapeutic lens alone|Therapeutic lens will be apposed on the patient's eye after crosslinking. Therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.
214478764|NCT03169634|PROCEDURE|Cone with long stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with long stems is cemented in to it
214478765|NCT06507072|BEHAVIORAL|Adaptive Rock Climbing Program|Twelve week rock climbing program. The program will take place once per week over the course of twelve weeks.
214478766|NCT06825507|BEHAVIORAL|Lifestyle-based mental health care|Participants in the LSC will access a stepped care treatment consisting of 3 steps, including self-help multicomponent LM treatment (Step 1), guided self-help based on the LM approach and low-intensity cognitive behavioural therapy for depression (Step 2), and specialist mental health services (Step 3).
214669388|NCT01247233|RADIATION|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50 Gy + Boost 16 Gy or Whole breast, either 40 Gy in 15 fractions in 3 weeks or 42.5 Gy in 16 fractions in 3 weeks
214669389|NCT01247233|RADIATION|Accelerated partial breast irradiation|Tumor bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5 to 7 days.
214669390|NCT02260011|DRUG|Ipratropium bromide HFA-134a inhalation aerosol|
214300347|NCT06450470|COMBINATION_PRODUCT|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on the patient's eye after crosslinking. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.
214300348|NCT05591027|DRUG|Centella asiatica product|A sachet of powdered product containing 4 g of a dried hot water extract of Centella asiatica as the active ingredient, combined with inactive ingredients (excipients) for color and taste dissolved in 10 oz of warm or room temperature water and consumed orally.
214300349|NCT05591027|DRUG|Placebo|A sachet of powdered inactive ingredients (excipients) for color and taste identical in volume to those found in the active arm (CAP) dissolved in 10 oz of warm or room temperature water and consumed orally.
214300350|NCT05927376|BEHAVIORAL|Mediterranean diet|All foods, meal plans and instructions provided.
214300351|NCT05927376|BEHAVIORAL|Western diet|All foods, meal plans and instructions provided.
214300352|NCT06247345|DRUG|ADEL-Y01 - healty participants|In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
214300353|NCT06247345|DRUG|Placebo - Healthy Participants|In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
214300354|NCT06247345|DRUG|ADEL-Y01 - MCI/AD|"In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy."
214300355|NCT06247345|DRUG|Placebo - MCI/AD|"In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions."
214478767|NCT06825507|OTHER|Care-as-usual|Participants in the CAU will receive their baseline depressive symptom severity via text message following randomisation, and they will have unrestricted access to mental health services based on their needs and preferences, such as pharmacological treatments, psychological treatments, and complementary and alternative medicine.
214478768|NCT04906824|DEVICE|great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing|VascuCel implantation in order to perform great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
214478769|NCT06824909|DEVICE|ROSE-AI diagnostic system|"All samples were obtained due to the necessity for disease treatment and in accordance with routine clinical workflows. After the pathological diagnoses were confirmed by the pathology departments of the hospitals affiliated with the respective endoscopic centers, the eligible pancreatic puncture Diff-Quik stained smears were borrowed and transferred to Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University. There, the self-developed Zhiying Shunxi system was used to capture corresponding traditional light microscope RGB images. After the imaging was completed, all specimens were returned to the endoscopic centers from which they originated. Using the RGB images as input, an artificial intelligence algorithm was developed to assist in differentiating solid pancreatic lesions."
214478770|NCT06241495|OTHER|Placebo|Placebo oil will be applied to the individuals included in the study. During the semen sample giving process, coconut oil (placebo) will be applied with a diffuser.
214478771|NCT06241495|OTHER|Aromatherapy|Aromatherapy will be applied to the individuals included in the study. During the semen sample giving process, lavender oil will be applied with a diffuser.
214669391|NCT02260011|DRUG|Atrovent® CFC inhalation aerosol|
214669392|NCT02260011|DRUG|Placebo|
214898813|NCT06074016|DRUG|Zolmitriptan oral.|Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
214898814|NCT05319132|OTHER|Adult subjects with ROSAH syndrome|The main objective is to evaluate the ex vivo inhibitory potential of DF-003 on alpha-1 kinase activity.
214898815|NCT03414502|DRUG|Methotrexate|Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg daily.
214898816|NCT03414502|DRUG|Abatacept|Starting dose may be adjusted as needed at investigator's discretion.
214898817|NCT03414502|DRUG|Adalimumab|Starting dose may be adjusted as needed at investigator's discretion.
214898818|NCT03414502|DRUG|Azathioprine|Starting dose may be adjusted as needed at investigator's discretion.
214898819|NCT03414502|DRUG|Baricitinib|Starting dose may be adjusted as needed at investigator's discretion.
214300356|NCT06244784|BEHAVIORAL|effectiveness of a training course on a healthy work environment for nurses and nursing assistants in a hospital|"Once the participants have been included in the study, they will be assigned to each group; control group and intervention group by convenience sampling. Baseline data will be collected in both groups. At this time, questionnaires will be collected in both populations and focus groups will be conducted in the professionals assigned to both groups. Once the data have been obtained, the intervention group will conduct the training course.~After the training, data will be collected again at three different times: 1) Right after the training: questionnaires and focus group will be collected from intervention group professionals; 2) 6 months after the training: questionnaires will be collected from control group and intervention group; 3) 12 months after the training: questionnaires will be collected and focus groups will be conducted in both groups."
214300357|NCT02926924|DEVICE|Wound Vac|a therapeutic technique using a vacuum dressing to promote healing in acute or chronic wounds and enhance healing of first and second degree burns.
214300358|NCT02926924|OTHER|Standard Dressing|standard dressing with drain tube and bandage
214300359|NCT05695248|DRUG|STAR-0215|STAR-0215 will be administered as a subcutaneous bolus injection.
214300360|NCT05544513|DRUG|Ferrous sulfate 3 days week|Participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
214300361|NCT05544513|DRUG|Ferrous sulfate daily|Participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
214300362|NCT05544513|DRUG|Ferrous sulfate higher concentration|Participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
214300363|NCT05907057|DRUG|Ivosidenib 500mg Oral Tablet|Provided as tablets, taken orally as two 250mg tablets once daily.
214300364|NCT05907057|DRUG|Azacitidine|Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
214478772|NCT06420830|PROCEDURE|SAPIEN 3 Ultra RESILIA Valve|Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.
214478773|NCT06608303|DRUG|Topical Human Granulocyte Macrophage Stimulating Factor Gel|Human granulocyte macrophage colony-stimulating factor (rhGM-CSF), as a multifunctional haematopoietic factor, stimulates the proliferation and differentiation of haematopoietic precursor cells to granulocyte macrophages and promotes their peripheral translocation, as well as enhances phagocytosis and secretion of granulocytes and macrophages \[11\]. Since macrophages are key players in regulating the inflammatory response of wounds and promoting wound repair, rhGM-CSF is thought to potentially play a positive role in the treatment of acute and chronic wounds.
214478774|NCT06608303|DRUG|Saline (NaCl 0,9 %) (placebo)|placebo
214478775|NCT04499638|DEVICE|Peripheral vascular catheters|Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
214669393|NCT00645242|DRUG|fluconazole|Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
214669394|NCT04265534|DRUG|Telaglenastat|Oral Glutaminase Inhibitor
214669395|NCT04265534|DRUG|Carboplatin Chemotherapy|IV infusion
214898820|NCT03414502|DRUG|Certolizumab|Starting dose may be adjusted as needed at investigator's discretion.
214898821|NCT03414502|DRUG|Etanercept|Starting dose may be adjusted as needed at investigator's discretion.
214898822|NCT03414502|DRUG|Golimumab|Starting dose may be adjusted as needed at investigator's discretion.
214898823|NCT03414502|DRUG|Hydroxychloroquine|Starting dose may be adjusted as needed at investigator's discretion.
214669396|NCT04265534|DRUG|Pemetrexed Chemotherapy|IV infusion
214669397|NCT04265534|BIOLOGICAL|Pembrolizumab Immunotherapy|IV infusion
214669398|NCT04265534|DRUG|Placebo|Oral placebo
214669399|NCT04265534|DIETARY_SUPPLEMENT|Folic acid 400 -1000 μg|Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.
214898824|NCT03414502|DRUG|Infliximab|Starting dose may be adjusted as needed at investigator's discretion.
214898825|NCT03414502|DRUG|Leflunomide|Starting dose may be adjusted as needed at investigator's discretion.
214898826|NCT03414502|DRUG|Minocycline|Starting dose may be adjusted as needed at investigator's discretion.
214898827|NCT03414502|DRUG|Rituximab|Starting dose may be adjusted as needed at investigator's discretion.
214898828|NCT03414502|DRUG|Sarilumab|Starting dose may be adjusted as needed at investigator's discretion.
214898829|NCT03414502|DRUG|Sulfasalazine|Starting dose may be adjusted as needed at investigator's discretion.
214898830|NCT03414502|DRUG|Tofacitinib|Starting dose may be adjusted as needed at investigator's discretion.
214898831|NCT04021043|DRUG|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Given IV
214898832|NCT04021043|BIOLOGICAL|Ipilimumab|Given IV
214898833|NCT04021043|BIOLOGICAL|Nivolumab|Given IV
214898834|NCT04021043|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215053340|NCT05214937|BEHAVIORAL|FitBit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
214300365|NCT04624373|OTHER|Molecular analysis of surnatant|"The interventional pulmonologist selects the most suspect node. The corresponding TBNA is placed in Cytolyt and tagged using a sticker to indicate the specimen from which supernatant must be saved after the initial spin.~The supernatant is transferred to the Laboratoire de Biologie Médicale Oncologique where it undergoes a further hard spin. The remaining supernatant is stored at -80°C before to send it to Foundation One for DNA extraction from 3 ml of supernatant and genotyping.~Two 7,5 mL blood tubes are transferred to the laboratory to extract plasma. Plasma was stored at -80°C and then sent to Foundation One for DNA extraction from 2 mL of plasma and genotyping.~10 slides from the cell block are shipped to Foundation One. These specimens are tested by FoundationOne®CDX (tissue), and FoundationOne®Liquid (supernatant and plasma) for genomic and TMB analyses (hybrid-capture based next generation sequencing)."
214898835|NCT05120193|DEVICE|Mapping and Ablation|Minimally invasive catheter mapping and ablation procedure
214898836|NCT06404112|DRUG|Melatonin|Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
214300366|NCT05449054|PROCEDURE|Anterior colporrhaphy|All patients will be operated by the vaginal route. They are prepared under strict aseptic conditions in the dorsal lithotomy position. The bladder is emptied preoperatively with a thin disposable catheter and antibiotic prophylaxis (cefazolin) is administered before incision. A vasoconstricting solution (combination of vasopression and NaCl) is administered and a vertical anterior vaginal incision is made from the apex to two centimeters short of the external urethral meatus using an electric cautery or a scalpel. The vaginal epithelium is grasped on both sides and the fibromuscular layer of the anterior vaginal wall is sharply dissected laterally to the inferior pubic ramus. The bladder is completely dissected from the apex and up to 4 to 6 cm from the pubic ramus. The anterior colporrhaphy is defined as a native tissue repair and rows of absorbable sutures (2/0 vicryl) are used.
214300367|NCT00000533|BEHAVIORAL|social support|
214300368|NCT02742012|OTHER|the study is observational|the study is observational
214300369|NCT02346253|RADIATION|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
214300370|NCT02346253|DRUG|Bicalutamide|Given PO
214300371|NCT02346253|DRUG|Leuprolide Acetate|Given IM or SC
214300372|NCT02346253|DRUG|Goserelin Acetate|Given SC
214300373|NCT02346253|DRUG|Triptorelin Pamoate|Given IM
214300374|NCT02346253|DRUG|Degarelix|Given SC
214300375|NCT02346253|OTHER|Laboratory Biomarker Analysis|Correlative studies
214300376|NCT02346253|OTHER|Quality-of-Life Assessment|Ancillary studies
214300377|NCT04629287|DRUG|KPCXM18|KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
214300378|NCT04629287|DRUG|Placebo|Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
214300379|NCT02519920|DRUG|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
214300380|NCT02519920|DRUG|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
214300381|NCT02519920|DRUG|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
214300382|NCT02519920|DRUG|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
214300383|NCT04221685|OTHER|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg
214300384|NCT04221685|OTHER|Artinibsa|"Powerful local anaesthetic with a short latency time.~Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains:~Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg"
214300385|NCT04408846|DEVICE|Lumbar fusion|Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
214300386|NCT05300490|DRUG|Prednisolone|In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
214300387|NCT03048396|PROCEDURE|Uterus transplantation|
214300388|NCT04884711|OTHER|No Interventions. Participants will be using their everyday digital health technologies.|The investigators will be involving older people to understand the barriers \& facilitators of digital health technology adoption for homebound older people. In this process no interventions will be given by us.
214300389|NCT04884711|OTHER|In depth Interviews|In-depth interviews will be conducted to gather lived experiences of homebound older people.
214300390|NCT04884711|OTHER|Focus Group Discussions|Focus Group Discussions will be used to create avenues to enhance dignity and human perspectives in digital designs for older people.
214300391|NCT05601310|DEVICE|liquid chromatography-mass spectrometry (LC/MS) analysis|To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
214300392|NCT05132621|DIAGNOSTIC_TEST|Smear|A smear of the posterior vaginal fornix collected with a gynecological speculum.
214300393|NCT01234545|DRUG|activated recombinant human factor VII|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
214300394|NCT04924829|DRUG|Tocilizumab|Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.
214300395|NCT05064956|BIOLOGICAL|Ad26.ZEBOV|"Ad26.ZEBOV is a non-replicating, monovalent vaccine expressing the full-length Mayinga glycoprotein (GP) of the Ebola virus (formerly known as Zaire ebolavirus), and is produced in human cell line.~Participants will receive a 0.5mL intramuscular injection of Ad26.ZEBOV, at a concentration of 1x10\^11 vp/mL, into the anterolateral deltoid muscle."
214300396|NCT03491618|OTHER|PAIN REDUCTION ON VAS/NRS|Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
214669400|NCT04265534|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
214669401|NCT04265534|DRUG|Dexamethasone 4 mg|For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
214898837|NCT06404112|DRUG|Melantonin Placebo|Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
215053341|NCT00002186|DRUG|Crofelemer|
215053342|NCT00002186|DRUG|Acyclovir|
214300397|NCT05023226|PROCEDURE|RM|RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.
214300398|NCT05023226|PROCEDURE|LPVS|LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight \[PBW\]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
214300399|NCT02504567|DEVICE|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
214300400|NCT02504567|DEVICE|RF ablation|Pulmonary vein isolation using the RF ablation catheter
214300401|NCT01811927|DEVICE|PRO-Kinetic Energy Stent|Bare-metal stent
214300402|NCT03474887|OTHER|Physical Consultation|Regular physician consultation at the primary care clinic.
214669402|NCT02616653|PROCEDURE|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
214669403|NCT05021614|DEVICE|Valveclip® Transcatheter mitral valve repair|Transcatheter mitral valve repair system
214898838|NCT06404112|DEVICE|Tailored lighting (TL) Active|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
214898839|NCT06404112|DEVICE|Tailored lighting (TL) Placebo|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
214898840|NCT04151134|DIAGNOSTIC_TEST|Step serial sectioning histological processing|Step serial sectioning histological processing
214898841|NCT05979688|BEHAVIORAL|yogic breathing exercise|A typical session will begin with the yoga instructor demonstrating a breathing exercise technique. The participants will learn and practice each technique.
214898842|NCT03325062|BEHAVIORAL|Control|The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.
214898843|NCT03325062|BEHAVIORAL|Experimental: MOVE|The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
214898844|NCT03285412|DRUG|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
214898845|NCT03285412|OTHER|Endocrine therapy|Hormone therapy
214898846|NCT04797000|DRUG|Eltrombopag|Eltrombopag comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
214898847|NCT04797000|DRUG|Placebo|Placebo comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
214898848|NCT06144450|OTHER|Web-Based Monitoring Program|"The research will be carried out in three stages; (1) creating the content of the follow-up program, (2) designing the web page, (3) implementing the program with mothers. The topics to be included in the monitoring program will be prepared within the framework of the Empowerment Model. Knowledge and attitude-self-efficacy will be tried to be increased with the modules to be prepared. Accordingly, the program is planned to consist of 3 modules. These are Preparation for Hospital Discharge Module, Transitional Care Module and Home Care Module. The presented modules will be made accessible to mothers in the experimental group through a website. The modules will be completed in order and the necessary forms and follow-ups will be completed at the end of each module."
214898849|NCT06543212|OTHER|physiotherapy exercises|physiotherapy exercises to improve eye alignment and eye control post strabismus surgery
214898850|NCT06184061|COMBINATION_PRODUCT|Herbal Supplement|Herbal supplement will be the mixture of strawberry, black mulberry, blueberry, raspberry, ginseng, ashwagandha, honey, water
214898851|NCT05229770|DIETARY_SUPPLEMENT|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
214300403|NCT03474887|OTHER|Online Consultation|An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
214300404|NCT01892930|RADIATION|stereotactic body radiation therapy|Undergo SBRT
214300405|NCT01892930|PROCEDURE|therapeutic conventional surgery|Undergo partial or radical nephrectomy
214300406|NCT01892930|OTHER|laboratory biomarker analysis|Correlative studies
214300407|NCT03411473|BIOLOGICAL|AGEN1884 in combination with pembrolizumab|AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
214300408|NCT04095507|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
214300409|NCT04433468|DEVICE|RIPC|The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.
214300410|NCT05564936|DEVICE|ME&MG mobile application|ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
214300411|NCT03026712|DEVICE|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
214300412|NCT03026712|DEVICE|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
214300413|NCT04551846|DIETARY_SUPPLEMENT|Oligomeric enteral feeding|Oligomeric enteral feeding will be administered to the PICU patients
214300414|NCT04551846|DIETARY_SUPPLEMENT|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
214300415|NCT01024296|DEVICE|Port Close|Device for applying loop suture to close surgical site
214300416|NCT05096416|DEVICE|The three-dimensional (3D) printed hemodialysis vascular model|The three-dimensional (3D) printed hemodialysis vascular model will be used as a guide map to cannulate the patients for hemodialysis and to minimize the risk of vascular access complications
214300417|NCT04992572|DRUG|Propofol Injection|25mg Propofol administered by injection
214300418|NCT04992572|DRUG|Lidocaine Hydrochloride, Injectable|Licocaine administered locally via injection.
214300419|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|single dose of 1 × 10(7) cells intrathecally
214300420|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart
214300421|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|2 doses of 1 × 10(8) cells intrathecally each 1 month apart
214300422|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
214300423|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
214478776|NCT06608693|OTHER|PNF stretching|Subjects lay supine on a treatment table, holding one knee to the chest and letting the other leg extend freely toward the floor at the end of the table. This protocol was adapted from previous studies. The hip joint was carefully and gradually lowered towards the floor, with the knee flexing at a 90-degree angle until the individual experienced a mild stretching sensation (Visual analog scale:4-6). Then, the subject performed a sub-maximal voluntary isometric contraction by utilizing the flexor muscles for 20 seconds while resisting the applied force exerted by an examiner through the utilization of a hand-held dynamometer (K-Force Muscle Control). The examiner proceeded to passively manipulate the leg to achieve the desired range of motion (ROM), maintaining it for 20 seconds. This process was repeated six times for each limb. The patient rested for 2 minutes before applying the same technique to the other side.
214478777|NCT06608693|OTHER|Static stretching group|While the patient was lying supine, the hip and knee joints on the non-stretch side were kept in 90⸰ flexion. A sandbag was positioned on the side to be stretched, specifically proximal to the patella, in order to induce a moderate sensation of stretching in the patient. Subsequently, a force was exerted in the direction of hip extension for a duration of 30 seconds. Afterward, the patient was instructed to relax. This process was repeated a total of six times, with a designated 20-second rest period between each repetition. The patient took a two-minute rest before the same technique was applied to the other side. There was no specific order on which side to apply the technique.
214478778|NCT06606327|DRUG|Diazoxide, 3 mg/kg per dose|Insulin anti-secretagogue taken for 8 doses over 4 days
214478779|NCT06608030|DRUG|Esketamine|A single dose of 0.3mg / kg esketamine during induction of anesthesia.
214478780|NCT06608030|DRUG|normal saline|Receiving the same volume of normal saline during induction of anesthesia.
214478781|NCT06608641|DRUG|Endoxifen enteric-coated tablet (8 mg)|Patients will continue treatment with their initial randomized medication for 3 weeks
214478782|NCT06608641|DRUG|Placebo Tablets|Patients will be treated with Endoxifen Placebo Tablets for 21 days
214300424|NCT06710145|BEHAVIORAL|Combat Attention Training|The Combat Attention App is a response-time based mechanized preventive intervention designed to train combat soldiers' attention toward threats before combat exposure in order to reduce the risk for combat-related post-trauma symptoms. In light of the results of controlled studies that proved the efficacy of this preventive intervention, the Israel Defense Forces (IDF) decided at the beginning of the Iron Swords War (October 7th, 2023) to implement an internet-based App of the intervention, and soldiers and combat reservists were invited to train on the Combat Attention App.
214300425|NCT01365780|PROCEDURE|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
214300426|NCT03879707|DRUG|Melatonin 5 mg|Melatonin is known to induce sleep
214300427|NCT03879707|DRUG|Placebo Oral Tablet|Placebo
214300428|NCT03879707|DRUG|Magnesium 500Mg Oral Tablet|Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
214300429|NCT03271879|DRUG|Empagliflozin at a dose of 10 mg/day|Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
214300430|NCT03492255|DRUG|Cyclophosphamide|Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
214300431|NCT03492255|DRUG|Methylprednisolone|"Patients in EUROLUPUS group will receive Methylprednisolone \[750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)."
214300432|NCT03492255|DRUG|Prednisone|Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.
214300433|NCT03492255|DRUG|Mycophenolate Mofetil|From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
214300434|NCT00804518|OTHER|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at \~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
214300435|NCT03407742|BEHAVIORAL|CAPAS Youth|9-week parenting intervention
214300436|NCT05174182|OTHER|A novel treatment approach|A novel treatment approach, as described before.
214300437|NCT05174182|OTHER|Usual care|Usual care, as described before.
214300438|NCT05027438|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
214300439|NCT05027438|BEHAVIORAL|Deprescribing|The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
214300440|NCT05882110|PROCEDURE|Cultured autologous epidermal cell membrane|The cultured autologous epidermal cell membrane is made from the patient's autologous epidermal cells by in vitro rapid expansion and culture technology, which has good biocompatibility, non-toxic, non-teratogenic, can reduce the skin area cut by traditional autologous skin grafting methods, and has high proliferative activity to promote wound repair and regeneration.
214300441|NCT06005922|OTHER|physiotherapy|ultrasound hotpack electrotherapy joint range of motion exercises isometric neck exercises stretching exercises
214300442|NCT06005922|OTHER|TMJ exercises|tongue relaxation position TMJ isometric strengthening exercises Posture exercises Isometric neck extension in neutral position back extension Strengthening the abdominal muscles Supine dorsal stretch pectoral stretch
214300443|NCT05325879|OTHER|VAGUS-NDT|Neurodynamic test for vagus nerve
214300444|NCT06523751|DIAGNOSTIC_TEST|Trabeculopuncture|Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.
214300445|NCT03094845|BIOLOGICAL|Placebo solution|15 injections over 7 weeks
214300446|NCT03094845|BIOLOGICAL|hdmASIT+TM|15 injections over 7 weeks
214300447|NCT05830487|BEHAVIORAL|Low AGE diet with reduced energy and fat|This group will be given a low AGE diet with reduced energy and fat,.
214300448|NCT05830487|BEHAVIORAL|Energy and fat-reduced normal diet|This group will be given a diet with reduced energy and fat, and AGE levels will not be interfered with
214300449|NCT01477060|DRUG|Lapatinib|1250 mg/ die, os
214300450|NCT01477060|DRUG|Metformin|1500 mg/die, os
214300451|NCT04075565|BEHAVIORAL|Terrestrial altitude|Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.
214300452|NCT04075565|BEHAVIORAL|Cloud 9|"Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined."
214300453|NCT01984008|DRUG|Picosulfate sodium, magnesium oxide, citric acid|
214300454|NCT00485407|DRUG|Atomoxetine Hydrochloride|
215053343|NCT00511758|PROCEDURE|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
214300455|NCT03001388|PROCEDURE|Transient Elastography (TE)|Participants enrolled in Cystic Fibrosis Liver Disease Network (CFLD NET)Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) study in longitudinal follow up at centers with Fibroscan available (currently 8/11 centers)
214300456|NCT06367309|PROCEDURE|Extended totally extraperitoneal repair|The anterior rectus sheath is incised and the retromuscular space is entered through the rectus muscle fibres. The capnopreperitoneum is established and blunt dissection of the retromuscular space is performed. Two additional laparoscopic ports are established 8-10cm lateral to the linea alba caudally to the initial port. The medial border of the rectus sheath is incised and the preperitoneal space below the linea alba is dissected. The hernia orifice is also dissected from peritoneum and preperitoneal fatty tissue. The medial border of the right retromuscular space is then incised and blunt dissection is performed. The hernia orifice is closed with barbed suture and a synthetic mesh is placed on the posterior sheath of the dissected space (intended Mesh-defect ratio 16). The mesh is fixed non-traumatically using glubran glue or no fixation at all.
214478783|NCT06608186|DRUG|Cetrorelix drug|a drug injection daily sc. from day 5 of stimulation till hCG trigger day
214478784|NCT06608186|DRUG|Drospirenone drug|A drug drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day
214478785|NCT06608407|BIOLOGICAL|PRP group|After the completion of hysteroscopic adhesiolysis, recruited participants will be randomized to one of the two treatment groups by computer-generated numbers: Immediately administer uterine perfusion with PRP after surgery, and administered PRP perfusion during hysteroscopy at 4 and 8 weeks after hysteroscopic adhesiolysis, A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery. Control group without PRP treatment.
214478786|NCT06606886|DRUG|Tablet Metformin (Group A)|Tablet Metformin 500 mg/dose orally twice a day with meal for 1 year
214478787|NCT06606886|DRUG|Tablet Hydroxyurea (Group B)|Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
214478788|NCT06607939|DRUG|ORB-021|ORB-021 is dosed via IV infusion
215053344|NCT03729635|PROCEDURE|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
215053345|NCT05816746|DRUG|Low-Dose Decitabine plus anti-PD-1|Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
214300457|NCT06367309|PROCEDURE|Intraperitoneal onlay mesh|Capnoperitoneum is established through left sided subcostal Veress-Needle punction. Three laparoscopic ports are placed 8-10cm lateral to the linea alba usually on the patient's left side. The peritoneum is incised and detached from the umbilical and supraumbilical linea alba. The peritoneum including the hernia sac and preperitoneal fat is resected. The hernia orifice is then closed using a barbed suture. A coated mesh is than placed to the ventral abdominal wall covering the closed hernia orifices (intended mesh-defect-ratio: 16). The mesh is fixed with two transfacial absorbable sutures and several absorbable tackers placed in double crown technique around the hernia orifice. The capnoperitoneum is released, the trocars removed and the fascia closed with an absorbable suture. The skin is sutured with absorbable sutures.
214300458|NCT05434650|DEVICE|electrophysiology study and ablation with an Abbott Ablation Catheter|During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat
214300459|NCT01799499|DEVICE|TC-3 hydrogel|
214300460|NCT01799499|DEVICE|TC-3 hydrogel|
214300461|NCT01799499|DEVICE|TC-3 hydrogel|
214300462|NCT01927406|DRUG|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
214300463|NCT01927406|DRUG|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
214300464|NCT05782751|PROCEDURE|GROUPI|10 sites treated with Free connective tissue graft (FCTG) + growth factors enhanced matrix 21 s GEM 21S + coronally advanced flap (CAF)
214300465|NCT05782751|PROCEDURE|GROUP II|10 sites treated withCollagen membrane + GEM 21S + coronally advanced flap (CAF)
214300466|NCT00988507|DRUG|Ferroquine (SSR97193)|"Pharmaceutical form: capsule~Route of administration: oral"
214300467|NCT00988507|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
214300468|NCT00988507|DRUG|artesunate|"Pharmaceutical form: tablets~Route of administration: oral"
214898852|NCT05724043|DEVICE|SmartJournal|SmartJournal is a tablet application with three modules: Module 1 offers a system for simple check-box registration of daily oral hygiene routines. This module also includes an open text field where the caregiver can give a brief description of strategies used if the patient shows resistant behaviors. Module 2 offers a system for monitoring the patient's oral health through monthly check-ups. This module is an image-based, interactive learning- and assessment tool. Upon completion of the monthly oral health assessment health personnel receive a summary report with suggestions for tailored preventive and/or curative measures to be initiated. Module 3 offers an easily accessible knowledge base which includes information on geriatric oral health, standard equipment and procedures for daily oral hygiene routines for patients with various care needs. It also includes scientifically documented strategies that may be used to approach patients with dementia refusing oral care assistance.
214898853|NCT06009107|BIOLOGICAL|HY004|A single infusion of Autologous 2nd generation CD19/CD22-directed CAR-T cells administered intravenously.
214898854|NCT06009107|DRUG|Cyclophosphamide|Administered intravenously.
214898855|NCT06009107|DRUG|Fludarabine Phosphate|Administered intravenously.
214898856|NCT05097287|DRUG|Dupilumab|solution for injection subcutaneous
214898857|NCT05097287|DRUG|Placebo|solution for injection subcutaneous
214300469|NCT00846755|DRUG|Levothyroxine, Propylthiouracile|Drugs were titrated to render euthyroid pregnant patients with thyroid disease
214300470|NCT00000751|DRUG|Anti-HIV Immune Serum Globulin (Human)|
214300471|NCT00000751|DRUG|Globulin, Immune|
214300472|NCT00000751|DRUG|Zidovudine|
214898860|NCT02874040|PROCEDURE|Endoresection|Endoresection of the tumor scar
214898861|NCT02874040|PROCEDURE|Laser diode|Transpupillary thermotherapy by laser diode on the tumor scar
214898862|NCT06956664|OTHER|Conventional Physiotherapy|Standard physical-agent package delivered three times weekly for 6 weeks: 20 min moist hot-pack (≈70 °C hydrocollator packs); 5 min continuous therapeutic ultrasound (1 MHz, 1 W cm-²); 20 min biphasic TENS (100 Hz, 100 µs). Initiated 2 weeks after the caudal epidural steroid injection (CESI).
215053346|NCT01486355|BIOLOGICAL|Measles vaccine|Edmonston-Zagreb measles vaccine
214300473|NCT03455660|OTHER|no intervention|no intervention
214300474|NCT02093598|DRUG|Temsirolimus|
214300475|NCT04176900|OTHER|Ingeo Biopolymer (PLA)|Biopolymer used for 3D-printing of rigid bolus
214300476|NCT04176900|OTHER|Ecoflex 030|Polymer used for the 3D-printed flexible bolus
214300477|NCT05759442|DRUG|Metformin Hydrochloride (HCL)|Tab Metformin HCL 500mg twice per day aimed at improving glycemic indices in Prediabetics
214898863|NCT06956664|BEHAVIORAL|Aerobic Exercise Programme|Supervised treadmill walking three times weekly for 6 weeks: 5 min warm-up at \~40 % HR\<sub\>max\</sub\>; 10-25 min load at 55-80 % HR\<sub\>max\</sub\> (5 % weekly progression); 5 min cool-down. Heart-rate telemetry and Borg CR-10 used to titrate intensity. Starts 2 weeks post-CESI.
214898864|NCT06956664|BEHAVIORAL|Core-Stabilization Exercise Programme|Phased lumbopelvic motor-control regimen three times weekly for 6 weeks: Phase I isolated transversus abdominis/multifidus activation with pressure biofeedback; Phase II functional co-contraction with limb movements in quadruped, sitting, standing; Phase III dynamic tasks on Swiss-ball/BOSU with resistance. Progression requires pain ≤ 3/10 VAS and flawless technique. Begins 2 weeks post-CESI.
215053347|NCT05650463|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
215053348|NCT02776683|DRUG|BI 695502|
215053349|NCT02776683|DRUG|Avastin|
215053350|NCT02973139|OTHER|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
214300478|NCT05759442|DIETARY_SUPPLEMENT|Apple cider vinegar|Apple cider vinegar aimed at improving glycemic indices in Prediabetics
214300479|NCT04718220|DIAGNOSTIC_TEST|Antibody testing for SARS-CoV-2 IgG|Women enrolled into the unexposed (SARS-CoV-2 negative) cohort will undergo testing for SARS-CoV-2 IgG antibodies at enrollment, every trimester of pregnancy, and during delivery hospitalization.
214300480|NCT04718220|DIAGNOSTIC_TEST|Testing for SARS-CoV-2 RNA|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of placental tissue, umbilical cord blood, amniotic tissue, and neonates for SARS-CoV-2 RNA, as available.
214300481|NCT04718220|DIAGNOSTIC_TEST|Testing for SARS-CoV-2 IgM/IgG|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of umbilical cord blood for SARS-CoV-2 IgG and IgM antibodies, as available.
214300482|NCT03099044|OTHER|Placebo comparator|Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.
214300483|NCT03099044|OTHER|Single Active dose|Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
214300484|NCT03099044|OTHER|Double Active dose|Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
214898865|NCT03244384|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214898866|NCT03244384|OTHER|Clinical Observation|Undergo observation
214898867|NCT03244384|PROCEDURE|Computed Tomography|Undergo a CT scan
214898868|NCT03244384|PROCEDURE|CT Urography|Undergo a CT urography
214898869|NCT03244384|PROCEDURE|Cystoscopy|Undergo a cystoscopy
214898870|NCT03244384|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
214898871|NCT03244384|BIOLOGICAL|Pembrolizumab|Given IV
214300485|NCT04355325|DEVICE|modified monolithic zirconia crowns|outcomes and complications of implant restoration
214300486|NCT04355325|DEVICE|Metal Ceramic crowns|outcomes and complications of implant restoration
214300487|NCT01433679|BEHAVIORAL|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
214300488|NCT03346499|BIOLOGICAL|NK cells and IL-2|Natural Killer Cells
214300489|NCT01852942|DRUG|Losartan|Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
214300490|NCT01852942|DRUG|Placebo|one tablet by mouth daily
214300491|NCT00624494|DEVICE|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
214300492|NCT00624494|DEVICE|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
214478789|NCT04803604|BEHAVIORAL|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, lay coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training as well as monthly follow-up.
214478790|NCT05016856|BEHAVIORAL|Adherence Promotion With Person-centered Technology (APPT) System|A personalized and adaptive text message reminder system.
214898872|NCT03244384|OTHER|Pharmacological Study|Correlative studies
214898873|NCT03244384|OTHER|Quality-of-Life Assessment|Ancillary studies
214300493|NCT00002304|DRUG|Ketoconazole|
214898874|NCT03244384|OTHER|Questionnaire Administration|Ancillary studies
214898875|NCT06467435|DRUG|Kamuvudine-9|96 mg tablets taken twice a day for 24 weeks
214898876|NCT06467435|DRUG|Kamuvudine-9|96 mg tablets taken once
214898877|NCT04945460|DRUG|Sotatercept 0.3 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
214898878|NCT04945460|DRUG|Placebo|Administered by subcutaneous injection
214898879|NCT04945460|DRUG|Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
214898880|NCT05797870|COMBINATION_PRODUCT|Selective Internal Radiation Therapy with 188Re-SSS lipiodol|"The treatment with 188Re-SSS lipiodol SIRT requires two steps during the patient's hospitalization: the pre-treatment simulation step and the treatment step itself.~Pre-therapeutic simulation is performed during the screening phase, before definite patient inclusion, and is composed of two procedures: a diagnostic liver angiography and a liver perfusion scintigraphy (MAA scan and SPECT/CT).~The therapeutic stage is also composed of two procedures a therapeutic liver angiography with 188Re-SSS lipiodol and a 188Re-SSS lipiodol SPECT/CT."
214898881|NCT06377020|BEHAVIORAL|PACT2|Behavioral lifestyle intervention
214300494|NCT00002304|DRUG|Fluconazole|
214300495|NCT01921179|BEHAVIORAL|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
214300496|NCT01921179|BEHAVIORAL|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
214300497|NCT05371574|DRUG|clonidine group|Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision
214478791|NCT05016856|BEHAVIORAL|Standard Reminder System (Active Control)|A typical text message reminder system.
214898882|NCT02894710|DRUG|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
214478792|NCT04866641|DRUG|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
214669404|NCT05089305|DRUG|Ozone plasma|Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).
214898883|NCT02894710|DRUG|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
214898884|NCT06167291|RADIATION|Arm 1- Ipsilateral|Given by I-RT
214898885|NCT04124497|DRUG|Daratumumab|"* Daratumumab 16 mg/kg intravenously at following schedule:~* cycle 1 and 2: days 1, 8, 15, and 22~* cycle 3 through 6: days 1, and 15~* from cycle 7 until disease progression: day 1."
214898886|NCT04124497|DRUG|Pomalidomide|4 mg once daily on days 1-21
214898887|NCT04124497|DRUG|Dexamethasone|Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (\>75 years old) on days 1, 8, 15 and 22
214898888|NCT03968900|BEHAVIORAL|Sleep restriction condition|On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep restriction condition (4 hours, TIB \[Time in Bed\]; 1:00 a.m. to 5:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham (UAB) Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
215053351|NCT02973139|OTHER|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
214300498|NCT04568590|BEHAVIORAL|educational intervention|If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average \> 3), they will be given the informational handout along with a brief script.
214300499|NCT04267003|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
214300500|NCT00874354|DRUG|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
214300501|NCT05279820|PROCEDURE|Partial pulpotomy|Partial pulp tissue amputation
215053352|NCT05232214|DEVICE|Biometry|Only one eye from each patient will be included in the study. All patients included in the study will undergo biometric measurements in a random fashion with the three devices (IOLMaster 700, Argos and Anterion Heildelberg). Each patient will be measured three times with each device
215053353|NCT03700164|OTHER|Temperature|Water-perfused suit.
215053354|NCT05575544|PROCEDURE|Acupuncture plus morphine|The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure
215053355|NCT02869542|OTHER|Data collection|
215053356|NCT03350451|DRUG|Lumasiran|Multiple doses of lumasiran by SC injection
215053357|NCT04798222|DRUG|Treatment A|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
214300502|NCT05279820|PROCEDURE|Full Pulpotomy|Full Pulpotomy
215053358|NCT04798222|DRUG|Treatment B|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
215053359|NCT04798222|DRUG|Treatment C|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition
215053360|NCT04798222|DRUG|Treatment D|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.
215053361|NCT04798222|DRUG|Treatment E|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.
215053362|NCT04798222|DRUG|Treatment F|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.
215053363|NCT04798222|DRUG|Treatment G|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
215053364|NCT04798222|DRUG|Treatment H|Participants will receive oral dose of dapagliflozin capsule in fasted condition.
215053365|NCT01751672|BEHAVIORAL|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
215053366|NCT01751672|BEHAVIORAL|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
215053367|NCT03553537|DRUG|Decitabine|10mg/m² iv on day 1-5
215053368|NCT03553537|DRUG|Cyclophosphamide|750mg/m² iv on day 6
215053369|NCT03553537|DRUG|Doxorubicin|DOX
215053370|NCT03553537|DRUG|Vincristine|1.4mg/m² iv on day 6
214300503|NCT01640483|OTHER|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
214300504|NCT02053181|DRUG|Cadazolid|Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
214300505|NCT02050282|OTHER|Supplementary NT-proBNP measurement|In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
214300506|NCT03631901|DRUG|oral melatonin|Both melatonin and diazepam were given only during the febrile illness.
214300507|NCT03631901|DRUG|oral diazepam|Both melatonin and diazepam were given only during the febrile illness.
214300508|NCT00253474|BIOLOGICAL|PEG-interferon alfa-2a|
214898889|NCT03968900|BEHAVIORAL|Sleep extension condition|sleep extension On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep extension condition (10 hours, (TIB); 10:00 p.m. to 8:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
214898890|NCT05277714|OTHER|Sham|The sham protocol will last 15 minutes per session, and during each session, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy that the participant tries to implement is not correlated with the visual feedback provided by the gauge.
214898891|NCT05277714|OTHER|NF|"The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the patient will have to increase the brain activity of her dlPFC using a visual gauge representing the activity level of her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
214898892|NCT05317728|DEVICE|BAL-FAIOL IOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
214898893|NCT05317728|DEVICE|Monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
214898894|NCT05317728|PROCEDURE|Cataract surgery|Phacoemulsification with a clear cornea incision
214898895|NCT05180825|DRUG|Trametinib|Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
214898896|NCT05180825|DRUG|Vinblastine|weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
214898897|NCT05556798|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg
214898898|NCT05556798|DRUG|Nirogacestat|1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.
214898899|NCT05556798|DRUG|Pomalidomide|After the 4-day run-in period, all patients will receive nirogacestat in combination with belantamab, mafodotin and pomalidomide. Pomalidomide was added for day 1-14 for cycle 1-3 and day 1-14 and day 21-35 for C4+.
214300509|NCT02540460|DRUG|LCB01-0371 800mg|LCB01-0371 800mg
214300510|NCT02540460|DRUG|LCB01-0371 800mg BID|LCB01-0371 800mg BID
214898900|NCT06799650|DRUG|Gammora®|Gammora® SC + Tenofovir/3TC + darunavir+ritonavir
214300511|NCT02540460|DRUG|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
214300512|NCT02540460|DRUG|Placebo|Placebo
214898901|NCT06377930|DRUG|RAP-219|RAP-219 oral tablet
214898902|NCT04269265|BIOLOGICAL|Yellow Fever Vaccine|YF-VAX®, Yellow Fever Vaccine, for subcutaneous use
215053371|NCT03553537|DRUG|Prednisone|100mg/m² po on day6-10
214300513|NCT06787508|DEVICE|TMS|Continuous high-frequency transcranial magnetic stimulation therapy Targeting the left M1 area, continuous high-frequency stimulation was performed at a frequency of 10Hz with 80-100% TEP for 5 minutes each time, twice a day for a total of 5 days
214300514|NCT06787508|DEVICE|TMS|Consistent with the experimental group protocol, the magnetic stimulation probe is a false stimulation probe that only produces sound but does not actually produce stimulation
214300515|NCT06488482|DRUG|nivolumab or pembrolizumab|See above
214300516|NCT02599155|DRUG|Crystalloid|normal saline administration for volume expansion in hypovolemic status
214300517|NCT02599155|DRUG|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
214300518|NCT00049439|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
214300519|NCT00049439|DRUG|cyclophosphamide|Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
214300520|NCT00049439|DRUG|etoposide|Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
214300521|NCT00049439|DRUG|lomustine|Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
214300522|NCT00049439|DRUG|procarbazine hydrochloride|Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
215053372|NCT02638714|BIOLOGICAL|Stem Cells|Intervention: Transplantation of autologous purified stem cells
214300523|NCT01089088|DRUG|cisplatin|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
214300524|NCT01089088|DRUG|gemcitabine hydrochloride|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
214300525|NCT01089088|DRUG|sunitinib malate|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
214300526|NCT00533533|DRUG|docetaxel, oxaliplatin|"Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.~Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1"
214300527|NCT04693507|DRUG|teverelix TFA 120 mg|Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24
214300528|NCT04693507|DRUG|teverelix TFA 180 mg|Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24
214300529|NCT04991181|DRUG|400 mg BIA 5-1058|Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
214300530|NCT04377360|RADIATION|Diffusing Alpha-emitter Radiation Therapy|Diffusing Alpha-emitter Radiation Therapy (DaRT) is a method of delivering interstitial brachytherapy, based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life). These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. As the radioisotope has a short half-life, the majority of radiation absorption happens in the tumor.
214300531|NCT05310045|BEHAVIORAL|Personalised primary prevention intervention|"Personalised primary prevention intervention~1. Consultation 1~   * Assess caregiver's situation regarding their cancer risk factors~  * Explain the causal links between risk factors and cancer~  * Inform about national recommendations to prevent and limit cancer risk~  * Clarify informal caregiver situation with respect to national screening programs~  * Define a personalised primary prevention program~2. Implementation: personalised primary prevention program~   * Carried out by the informal caregiver~  * Supervised by the coordinating nurse~3. Consultation 2~   * Assess prevention actions realised by informal caregiver in relation to actions defined in the personalised primary prevention program~  * Identify barriers and facilitators to their implementation whether actions or no actions have been done.~  * Adapt the personalised primary prevention program to informal caregiver needs."
214300532|NCT00486694|DRUG|Sulfadoxine-pyrimethamine + artesunate|
214669405|NCT01570725|BEHAVIORAL|Virtual reality exposure|"The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation."
214669406|NCT01570725|BEHAVIORAL|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
214669407|NCT02943551|OTHER|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
214898903|NCT06544525|OTHER|Physical therapy|The intervention will be physical therapy standard of care.
214898904|NCT06375564|DRUG|177Lu-AB-3PRGD2 radioligand therapy|Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
214898905|NCT03696654|PROCEDURE|adenotonsillar surgery|when indicated, adenotonsillar surgery for SDB treatment
214300533|NCT00486694|DRUG|Chloroquine|
214300534|NCT01002755|DRUG|Lenalidomide|Given PO
214300535|NCT01002755|BIOLOGICAL|Ofatumumab|Given IV
214300536|NCT04295421|PROCEDURE|adductor canal block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
214300537|NCT04295421|PROCEDURE|IPACK block|IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
214300538|NCT03251573|OTHER|cognitive impairment|one are of patients were exposed to cognitive impairment
214300539|NCT03046199|OTHER|Questionnaire|Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
214300540|NCT03046199|OTHER|Coordination|Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
214898906|NCT05589181|DRUG|High Dose Buprenorphine|32mg of BUP split as 16mg at 0 minutes and 16mg at 30-60 min as an induction dose
214898907|NCT05589181|DRUG|Standard Buprenorphine Dose|12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose
214898908|NCT05731128|DRUG|Dupilumab|injection solution subcutaneous
214898909|NCT05731128|DRUG|Placebo|injection solution subcutaneous
215053373|NCT04803513|DRUG|Galcanezumab|Galcanezumab according to clinical indication in real life
215053374|NCT02964806|DIETARY_SUPPLEMENT|Ordinary Diet|
214898910|NCT04827862|DRUG|Pembrolizumab|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
214898911|NCT05918861|DRUG|Dalcetrapib|Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
214898912|NCT05918861|DRUG|Placebo|matching placebo tablets
214898913|NCT05925023|DRUG|Sirolimus|Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
214300541|NCT04930679|DRUG|Andiabet|Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
214300542|NCT03348085|OTHER|No intervention|No intervention.
214300543|NCT04272528|OTHER|uniform care|The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
214300544|NCT04272528|OTHER|conventional care|Nurses carry out the routine care procedures.
214300545|NCT01388075|DRUG|Rifampicin|oral, 450 mg/day , 7 days
214300546|NCT01769040|DRUG|Rifaximin|550 mg two times daily for 28 days
214300547|NCT01769040|DRUG|placebo|
214300548|NCT01299623|BEHAVIORAL|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
214300549|NCT02629692|DRUG|Vodobatinib (K0706) capsules|"Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily."
214300550|NCT00858442|PROCEDURE|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width \& length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width \& length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
214300551|NCT02710890|DRUG|Lacosamide|"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
214300552|NCT00484237|DRUG|etanercept|
214300553|NCT06065761|OTHER|Comprehensive ED heart failure management tool|The investigators plan a regional implementation of an electronic health record-based heart failure decision support tool across 21 EDs of Kaiser Permanente Northern California (KPNC).
214300554|NCT04298996|DIAGNOSTIC_TEST|taking saliva samples to determine oxidative stress markers TAS and TOS|
214300555|NCT03669120|OTHER|Informational Intervention|Receive advice to quit smoking and materials to promote smoking cessation
214300556|NCT03669120|BEHAVIORAL|Telephone-Based Intervention|Receive individualized text based messages
214300557|NCT01150929|DEVICE|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
214300558|NCT04092166|OTHER|Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
214300559|NCT03250546|PROCEDURE|transplant from a haplo-identical donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
214300560|NCT03250546|PROCEDURE|transplant from a non related donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
214669408|NCT02943551|OTHER|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
214898914|NCT03719105|DRUG|Methotrexate|Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
214898915|NCT03719105|DRUG|pralatraxate,|Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
214898916|NCT03719105|DRUG|Ifosfamide|Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
214300561|NCT03051542|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
214300562|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
214300563|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
214300564|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
214300565|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
214300566|NCT01520116|DRUG|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
214300567|NCT01520116|DRUG|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
214300568|NCT01520116|DRUG|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
214898917|NCT03719105|DRUG|Dexamethasone|Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
214300569|NCT01520116|DRUG|Timoptic|0.5%
214300570|NCT00056030|BIOLOGICAL|cetuximab|
214300571|NCT00056030|DRUG|fluorouracil|
214300572|NCT00056030|DRUG|leucovorin calcium|
214898918|NCT03719105|DRUG|Etoposide|Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
215053375|NCT02964806|DIETARY_SUPPLEMENT|Modified Atkin's Diet|
215053376|NCT02964806|DIETARY_SUPPLEMENT|Ketogenic Diet|
214300573|NCT00056030|DRUG|oxaliplatin|
214300574|NCT05351346|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
214300575|NCT05351346|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
214300576|NCT05351346|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
214300577|NCT05351346|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
214300578|NCT05351346|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
214300579|NCT05351346|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
214300580|NCT05351346|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
214300581|NCT05351346|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
214478793|NCT05148117|DIAGNOSTIC_TEST|Suspected Sepsis Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
214669409|NCT02943551|OTHER|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
214669410|NCT02943551|OTHER|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~* The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~* The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
214898919|NCT03719105|DRUG|calaspargase pegol|Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
214898920|NCT03719105|DRUG|cyclophosphamide|Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
214898921|NCT03719105|DRUG|Doxorubicin|Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
214898922|NCT03719105|DRUG|Prednisone|Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
214898923|NCT03719105|DRUG|Brentuximab Vedotin|Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
214300582|NCT04968899|DRUG|Neofordex®|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
214300583|NCT04968899|DRUG|Intravenous immunoglobulins|IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
214300584|NCT01028508|DRUG|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
214300585|NCT01028508|PROCEDURE|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
214300586|NCT00817167|DEVICE|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
214300587|NCT00817167|DEVICE|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
214898924|NCT05120934|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
214898925|NCT05120934|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
214898926|NCT05120934|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
214300588|NCT01908569|OTHER|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
214300589|NCT01908569|OTHER|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
214300590|NCT02126540|DEVICE|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
214300591|NCT06225089|DRUG|pericapsuler nerve block|-Ultrasound Guided pericapsuler nerve block: will be externally rotated and abducted to 45 degrees. The shoulder area will be sterilized with povidone-iodine. High-frequency linear ultrasound perpendicularly between the coracoid and the humeral head probe. The deltoid muscle, subscapular muscle and tendon, and humeral head will be identified on the ultrasound screen. With the in-plane technique, a 22 gauge, 50 millimeter (mm) simplex A peripheral nerve block needle will be used. After passing the deltoid muscle, the needle will contact the tendon of the subscapularis muscle. The needle will be slightly withdrawn and directed between the deltoid muscle and the tendon of the subscapularis muscle and a local injection consisting of will be applied.
214300592|NCT03443440|OTHER|Neurocognitive Testing|neurocognitive testing, computerized
214300593|NCT01829516|DRUG|Oxytocin|Intranasal oxytocin
214300594|NCT01829516|DRUG|Placebo|Intranasal placebo
214300595|NCT02418923|OTHER|Procedure: Blood specimen collection|Blood specimen collection
214300596|NCT04322253|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
214898927|NCT05120934|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
214300597|NCT01859533|DEVICE|Neopuff|"* Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).~* Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010)."
214300598|NCT02989740|PROCEDURE|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
214300599|NCT01053364|DEVICE|NL-Prow interspinous spacer implant|Interspinous spacer implant
214300600|NCT05351242|OTHER|Thermotherapy/sauna bath|Thermotherapy/sauna bath
214300601|NCT02498457|OTHER|low calcium dialysis|patients in this group will receive low calcium dialysis for 1 year.
214300602|NCT00202644|DRUG|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
214300603|NCT00202644|DRUG|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
214300604|NCT00712829|DRUG|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
214300605|NCT00712829|DRUG|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
214300606|NCT00602576|DRUG|sorafenib tosylate|Given orally
214300607|NCT00602576|DRUG|temozolomide|Given orally
214478794|NCT05148117|DIAGNOSTIC_TEST|Control Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
214478795|NCT04902872|DRUG|CBX-12|CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
214478796|NCT01582867|DEVICE|ARTIS hemodialysis system|"Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B\_HC01"
214478797|NCT05883345|DIAGNOSTIC_TEST|Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin-17 levels|Endoscopic biopsy
214669411|NCT02943551|OTHER|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
214300608|NCT02760446|BEHAVIORAL|CAM-ICU.fr|Neuropsychological testing
214300609|NCT00898157|OTHER|laboratory biomarker analysis|
214300610|NCT04171687|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg tablet
214478798|NCT05904691|DRUG|OCU-10-C-110 for Injection|OCU-10-C-110 for Injection in one of 3 doses
214478799|NCT05057572|DRUG|Carvedilol|\- Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP\>90, HR \>55.
214478800|NCT05057572|DRUG|Standard Medical Treatment|"* Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)"
214669412|NCT01726777|DIETARY_SUPPLEMENT|Control|Normal cheddar cheese
214300611|NCT04171687|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
214300612|NCT04171687|DRUG|RAPA113|RAPA113 tablet
214300613|NCT00772772|DRUG|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
214300614|NCT02570906|DEVICE|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
214300615|NCT02750592|DRUG|Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.|Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
214300616|NCT05364723|OTHER||no intervention
214300617|NCT05118451|PROCEDURE|3 d visualization technology|3D visualization technology refers to the conversion of 2d imaging data such as CT and MR into 3D stereoscopic images through computer calculation, analysis and reconstruction, visually separating the shapes and spatial distribution features of targets such as liver, blood vessels and tumors directly, accurately and quickly to present three-dimensional views. Combined with transparency, rotation, scaling and measurement techniques, real-time and interactive 3D dynamic analysis of 3d visual model is carried out. In addition, the computer was used to simulate the operation, and the feasible surgical plan was discussed. The best surgical plan was selected based on the patient's individual data.
214300618|NCT04611750|DRUG|AD036|AD036 will be given for 14 days
214300619|NCT04611750|DRUG|Placebo|Placebo will be given for 14 days
214300620|NCT05283187|BEHAVIORAL|Mindfulness Based Cognitive Therapy Group|Mindfulness Based Cognitive Therapy
214300621|NCT03642392|OTHER|Identification and treatment of early tendinopathy|Participants receive initial guidance about load reduction when tendinopathy
214669413|NCT01726777|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 supplemented cheddar cheese
214669414|NCT04097288|DRUG|Citalopram 40mg|Single dose
214669415|NCT04097288|DRUG|Reboxetine 8 mg|Single dose
214669416|NCT04097288|DRUG|Placebo oral tablet|Single dose
214669417|NCT04097288|DRUG|Placebo oral tablet|Single dose
214669418|NCT04628871|BIOLOGICAL|SB-318|No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
214898928|NCT05120934|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
214300622|NCT06112951|PROCEDURE|Extracorporeal Photopheresis|Patients randomized into the interventional group will receive ECP. ECP will be started within one week after randomization. Initially a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
214300623|NCT00302874|BEHAVIORAL|Implementation of a protocol for treatment of hyperglycemia|
214300624|NCT00861146|BEHAVIORAL|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
214478801|NCT05614206|BEHAVIORAL|Behavioral intervention based on Applied Behavior Analysis principles|"Intervention sessions are conducted by licensed therapists with a training in applied behavior analysis or behavior analysts. One-to-one interventions for 3 h/week are carried out over a period of 5 months.~The intervention focused on two target symptoms, imitation and joint attention, as two of the pivotal skills in early development. Behavior analytic techniques are used, including discrete trial, shaping for positive reinforcement, systematic prompting and fading procedures, and reinforcement procedures, according to the published manual.~Imitation sessions start with imitation recognition and imitation of familiar actions (gestural and object imitation) and end with the imitation of novel actions. Joint attention evolvs from initiating requests (starting with gaze shift with the child looking away from an interesting object to the adult and back) to coordination of gaze shift, vocalization and gestures through reaching, and pointing and showing behaviors."
214300625|NCT00671307|DRUG|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
214300626|NCT00671307|DRUG|Placebo|Vehicle control given as IV infusion over 1 hour
214300627|NCT02981342|DRUG|Abemaciclib|Administered orally
214300628|NCT02981342|DRUG|LY3023414|Administered orally
214300629|NCT02981342|DRUG|Gemcitabine|Administered IV
214669419|NCT04628871|BIOLOGICAL|SB-913|No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
214669420|NCT04628871|BIOLOGICAL|SB-FIX|No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
214669421|NCT00884507|DRUG|Placebo|po daily for 24 weeks
214669422|NCT00884507|DRUG|RO5313534|1mg po daily for 24 weeks
214669423|NCT00884507|DRUG|RO5313534|5mg po daily for 24 weeks
214898929|NCT05120934|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
214898930|NCT06346132|DEVICE|Virtual reality application|In this group, virtual reality will be added to usual care
214898931|NCT05954559|DRUG|Elucirem (Gadopiclenol)|Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.
214898932|NCT05708768|OTHER|Receiving physician manned rapid response car services|All patients receiving services from the physician manned rapid response car will be included
214300630|NCT02981342|DRUG|Capecitabine|Administered orally
214300631|NCT01629368|DRUG|Carbamazepine|Multiple doses of carbamazepine
214300632|NCT01629368|DRUG|RO4917523|Single dose of RO4917523
214300633|NCT02392962|PROCEDURE|Static Stretching|To analyze the immediate effects of static stretching on performance of sprinters
214300634|NCT02392962|PROCEDURE|Dynamic Stretching|To analyze the immediate effects of dynamic stretching on performance of sprinters
214300635|NCT04430777|DRUG|Tranexamic acid|Administration of tranexamic acid 1 gr either intravenously or subcutaneously
214300636|NCT04622839|OTHER|Tylenol and NSAIDS (Ibuprofen, diclofenac)|"This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~* Agents used in nerve block (lidocaine vs ropivacaine)~* Location of injection for analgesic~* Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~* Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~* Number of pills in the initial opioid prescription~* Instructions for sling wear (duration of use or type of sling)~* Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage."
215053377|NCT01891396|DEVICE|Hyaluronic Acid and TH (Cingal®)|Injection into knee
215053378|NCT01891396|DEVICE|Hyaluronic Acid (Monovisc®)|Injection into knee
214300637|NCT02468869|BEHAVIORAL|"Communication skills training empathy skills"|
214300638|NCT02468869|BEHAVIORAL|"Communication skills training information structuring skills"|
214300639|NCT04510779|DEVICE|Apple Watch|Apple Watch is a smartwatch developed by Apple Inc. The heart rate variability function will be used.
214300640|NCT04258345|OTHER|ASB Feeding Study|Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
214300641|NCT03238404|PROCEDURE|NAC group|NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
214300642|NCT03238404|PROCEDURE|Surgery alone group|Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
214669424|NCT00884507|DRUG|RO5313534|15mg po daily for 24 weeks
215053379|NCT01891396|DEVICE|Saline|Saline placebo packaged to look identical to comparator syringes. Injection into knee.
215053380|NCT06090058|DIAGNOSTIC_TEST|Measurement of neurofilament light chain|Serum samples will be collected into a serum gel with clotting activator tube (Sarstedt). After delivery to the laboratory, the serum samples were centrifuged at 2500 × g for 6 min at 4 Celsius degree, then aliquoted into at least three vials (0.3 mL per vial) and stored at -70 Celsius degree until the analysis.
214898933|NCT04748510|PROCEDURE|Functionally Aligned Total Knee Arthroplasty|Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
214898934|NCT04748510|PROCEDURE|Mechanically Aligned Total Knee Arthroplasty|Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
214898935|NCT06049134|BIOLOGICAL|PCV20|Given by Injection into the muscle
214898936|NCT02325973|DEVICE|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
214898937|NCT05437965|OTHER|Treatment made by experienced clinicians|Treatment made by experienced clinicians
214898938|NCT06308588|DRUG|Blinatumomab|Given by Infusion
214898939|NCT06308588|DRUG|Asciminib|Given by PO
214898940|NCT06484790|DRUG|NW-301V|TCR-T T cell targeting KRAS G12V mutation
214898941|NCT06484790|DRUG|NW-301D|TCR-T T cell targeting KRAS G12D mutation
214898942|NCT05655546|OTHER|Access to Cue Health COVID-19 Remote testing and treatment for COVID-19|Participants will receive at home COVID-19 test for themselves and others in their household.
214898943|NCT05888779|OTHER|Beverage One (Milk)|Participant will consume beverage one (milk) and complete novel cognitive assessment questionnaire on paper.
214898944|NCT05888779|OTHER|Beverage Two (Juice)|Participant will consume beverage two (fruit drink) and complete novel cognitive assessment questionnaire on paper.
214898945|NCT06072612|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
214898946|NCT06072612|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
214898947|NCT06072612|DRUG|Interferon infiltration of the inoculation site|Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
214898948|NCT06072612|DRUG|Retifanlimab|Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
214898949|NCT06072612|DRUG|Treatment of Physician's Choice|Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
214898950|NCT06494111|DRUG|Pravastatin|Given by PO
214898951|NCT06494111|DRUG|Pentoxifylline|Given by PO
214898952|NCT06494111|DRUG|Tocopherol|Given by PO
214898953|NCT06162468|PROCEDURE|Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel|EUS-PCA using gemcitabine and paclitaxel
214898954|NCT05334381|BEHAVIORAL|Adapted-STAT ED|Patient navigator assigned to provide culturally informed motivational interviews, brief case management, psychoeducation and telephone contacts
214898955|NCT05334381|BEHAVIORAL|Standard Enhanced Treatment|Follow up phone calls following discharge from the emergency department to confirm mental health treatment referral recommendations
214898956|NCT05678647|DRUG|Sucrosomial Iron|20 capsules of Sucrosomial Iron 30 mg is given after blood donation
214898957|NCT05678647|DRUG|Iron Sulfate|20 tablets of oral iron sulphate (Duroferon®) 100 mg is given after blood donation
214898958|NCT05308758|OTHER|Game-based High-Intensity Interval Training|There will be two training sessions each week. In each training session, there will be four sets of training programs separated by 3 minutes of passive recovery in accordance with a previous study.Each set of activities will last for around 5 minutes; therefore, the total duration of each training session will be approximately 30 minutes. A small group size (4-6 children per group) will be adopted to facilitate individual supervision and adaption of the exercise program.
214300643|NCT04608786|DRUG|ZKAB001 5mg/kg|ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
214300644|NCT04608786|DRUG|Capecitabine|Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
214898959|NCT05308758|OTHER|GameSAE|Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week. Six to eight stations of multidimensional exercises will be set up for each session. Adopting the train-the-trainer (TTT) model, training will be provided by front-line healthcare providers or trained helpers. Children will be instructed to finish the exercises in all stations one after another in a predetermined order.
214300645|NCT01372501|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
214478802|NCT06346171|BEHAVIORAL|Virtual Reality Integrative Psychotherapy|"Music therapy: Weightless by Marconi Union plays continuously, bridging VR distraction and psychotherapy.~Before: Patients pick a VR scene (-13 to -10 min), learn VR navigation, and practice 4-7-8 breathing with a VR flower for grounding and resilience (-10 to -9 min). They continue 4-7-8 doing Progressive Muscle Relaxation (4+7 contraction, 8 relaxation), moving from lower body to facial muscles (-8 to -5 min). Values and commitment to action are discussed (-4 to -2 min), emphasizing present-focused thoughts and acceptance (-1 min).~During: Mindfulness and relaxation are encouraged, with PMR during intense moments. Empowerment and procedural feedback are provided (0 to 30/45 min).~After: Debriefing normalizes the experience, reinforcing proactive health actions (35 to 50 min)."
214478803|NCT06346171|DEVICE|Virtual Reality Distraction|"Software: Nature Treks VR nature environments. Hardware: dedicated head-mounted VR display (Oculus Rift S.) powered by a high-end computer (Laptop with at least GTX 1080 graphics card, both with processing units that lower the bottleneck chances); minimum specifications should facilitate presence while limiting cybersickness by ensuring refresh rates beyound 85 frames/second.~Music therapy: Weightless by Marconi Union plays continuously, facilitating sensorial distraction while also allowing blinding.~Although the psychotherapist will interact with the patient, the dialogue will exclude psychotherapic approaches. The dialogue is designed to be neutral, resembling a comprehensive tutorial for the VR experience. This serves as a comparator to assess the added value of integrating psychotherapeutic techniques within the VR experience."
214478804|NCT02050906|BEHAVIORAL|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
214478805|NCT02050906|BEHAVIORAL|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
214300646|NCT01466348|DRUG|Paracetamol and Caffeine|Paracetamol 1000 mg and caffeine 130 mg
214300647|NCT01466348|DRUG|Paracetamol|Paracetamol 1000 mg
214300648|NCT04139967|RADIATION|Short course radiation therapy|25 Gray in 5 fractions over 5-7 days
214300649|NCT05334901|DEVICE|High intensity light cure|Bulk fill resin composite restoration cured with high intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
214300650|NCT05362747|BEHAVIORAL|Behavioral weight loss and produce vouchers|Participants will receive weekly 30-minute, individual, in-person lifestyle counseling delivered by trained interventionists (e.g., registered dietitians) that consists of behavioral, dietary, and physical activity counseling. ProduceRx vouchers will be in the form of Food Bucks and will be provided at each session.
214300651|NCT04599374|OTHER|no intervention|This study collected data only without any intervention.
214300652|NCT05405192|DRUG|Dostarlimab|First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.
214300653|NCT03989440|DRUG|AXER-204|human NoGo Trap fusion protein
214300654|NCT03989440|DRUG|Placebo|Phosphate buffered saline formulation
214478806|NCT02050906|OTHER|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
214478807|NCT02050906|BEHAVIORAL|telephone based counseling|Undergo behavioral activity and nutritional counseling
214478808|NCT02050906|PROCEDURE|quality-of-life assessment|Ancillary studies
214478809|NCT02050906|OTHER|questionnaire administration|Ancillary studies
214478810|NCT06589687|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under neuraxial anesthetic.
214478811|NCT04807751|DRUG|Delgocitinib cream|Cream for topical application
214669425|NCT03607734|DRUG|Amoxicillin|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~* 50mg amoxicillin (10% total dose)~* 250mg amoxicillin (50% total dose)~* 200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
214300655|NCT04136054|BEHAVIORAL|Adjusted group CBT-i for Depression, Anxiety and PTSD|Adjusted group CBT-i for Depression, Anxiety and PTSD. CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. Adjustments include the relationship between sleep and the psychiatric conditions at hand and and working with motivational enhancement techniques to increase adherence to treatment.
214300656|NCT04136054|OTHER|Care as usual wait-list control group|Usual care at the clinic. This entails managing pharmacological treatment for the psychiatric problems and/or sleep problems. The clinic also provides different group treatments, such as mindfulness groups and CBT groups for symptoms of worry and depression, and individual therapy.
214300657|NCT01312090|BIOLOGICAL|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (-30°Cand-60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
214300658|NCT01312090|BEHAVIORAL|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
214300659|NCT05725954|BEHAVIORAL|GUT LINK SmartPath|A virtual care delivery and referral support tool for primary healthcare providers.
214300660|NCT02974296|DEVICE|transcranial magnetic stimulation|non invasive brain stimulation approach
214300661|NCT03679780|DRUG|BQ-788|This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
214300662|NCT03679780|DRUG|BQ-123|This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
214300663|NCT03679780|DRUG|L-Arginine|A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
214300664|NCT03679780|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
214300665|NCT03679780|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
214300666|NCT03679780|DRUG|Lactated Ringer's|Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
214300667|NCT03704272|BEHAVIORAL|SunBrite|SunBrite is a family-empowered injury risk mitigation intervention with 3 core components: screening for the risk of supervisory neglect associated with traumatic injury in very young children; a brief behavioral intervention using motivational interviewing designed to provide feedback to the caregiver on supervisory risk and traumatic injury; and a referral to treatment for ongoing risks such as substance abuse, trauma or mental illness, requiring specific clinical interventions.
214300668|NCT06536777|OTHER|Plyometric Exercises|This include Plyometric Training for 8 weeks
214669426|NCT03161418|DRUG|KSP-910638G, 0.4 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
214669427|NCT03161418|DRUG|KSP-910638G, 1.2 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
214669428|NCT03778255|PROCEDURE|Sentinel Lymph Node Biopsy|"1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining."
214669429|NCT00609271|BEHAVIORAL|low carbohydrate diet|\<40 grams carbohydrate/day
214300669|NCT06536777|OTHER|Blood Flow Restriction Training|This include Blood Flow Restriction Training for 8 weeks
214300670|NCT02207790|DRUG|E2609|
214300671|NCT02207790|DRUG|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
214300672|NCT03970733|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
214300673|NCT03970733|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
214300674|NCT03693079|PROCEDURE|Wet cupping therapy|"CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~1. Primary suction; cups are left attached to the skin for 5 minutes.~2. Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~3. Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~4. Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~5. Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied"
214300675|NCT02341807|BIOLOGICAL|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
214300676|NCT04834479|DEVICE|Ankle US and Ankle MRI|Ankle US and Ankle MRI
214300677|NCT03322488|PROCEDURE|Fistulodesis|"Fistulodesis comprises the following treatment steps:~* Curettage and/or brushing of the fistula tract~* Mini-excision of the inner (endoanal) fistula opening~* Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~* Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~* Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~* Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~* Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline)."
214300678|NCT02189473|RADIATION|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
214300679|NCT00822068|DEVICE|anodal tDCS|anodal transcranial direct current stimulation
214300680|NCT00822068|DEVICE|cathodal tDCS|cathodal transcranial direct current stimulation
214300681|NCT00822068|DEVICE|sham stimulation|sham stimulation
214300682|NCT03664947|OTHER|exercise|After the initial evaluations, a video-based gaming console exercise program will be implemented for 8 weeks, taking into account the possibility of accepting and participating in treatment with children. Exercises applied by a Nintendo Wii Fit Plus System. Evaluations will be repeated at the end of treatment.
214300683|NCT06423144|PROCEDURE|TACE/HAIC|TACE/HAIC were performed within 1 month prior/after the first PD-1/PD-L 1 inhibitor/antiangiogenic drug treatment;
214669430|NCT00609271|BEHAVIORAL|low fat diet|\<30% fat, \<7% saturated fat
214898960|NCT06090890|DRUG|Colchicine|Add 0.5mg QD orally and start using it within 48 hours after intervention.
214898961|NCT06090890|DRUG|Prednisone|0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.
214898962|NCT06090890|DRUG|Aspirin|Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.
214300684|NCT06423144|DRUG|PD-1/PD-L1 inhibits and anti-angiogenic agents|Agents were administrated based on the instructions recommended
214300685|NCT01818076|DRUG|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
214300686|NCT01955161|DRUG|Placebo|Once daily, matching placebo capsules, orally
214898963|NCT06090890|DRUG|P2Y12 Receptor Antagonist|Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.
214898964|NCT06090890|DRUG|Lipid-lowering drug|Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
214898965|NCT06172088|OTHER|Fasting|Sieben days of online supervised prolonged therapeutic fasting (max. 350 kcal/d).
214898966|NCT04168125|DEVICE|Tilapia skin|Application tilapia skin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
214898967|NCT04168125|DEVICE|Surgical Wound Dressing|Application surgical wound dressing as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
214898968|NCT05683145|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|This is a computerized version of cognitive behavioral therapy for insomnia that is augmented by support from a licensed mental health professional. The intervention consists of 6 modules designed to provide education regarding sleep and insomnia, establish behavioral modifications to reduce insomnia symptoms, and monitor progress. Participants will be able to complete these intervention at their own pace, which will take between 6-9 weeks.
214898969|NCT05745480|OTHER|Opioid Misuse Screening with an Addiction Consult Service|Opioid Misuse Screening with an addiction consult service for brief intervention/motivational interviewing (MI), medication assisted treatment (MAT), or referral to substance use treatment as an outpatient.
214898970|NCT06459284|OTHER|retrospective data analysis|Surgical video-documentation including continous iOCT will ne reviewed for Instrument tissue interactions at the grasp site of the starting point of Membrane peeling
214300687|NCT01955161|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
214300688|NCT01227772|BIOLOGICAL|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
214300689|NCT01059474|DRUG|transdermal DMPS|"12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS."
214300690|NCT04136392|DEVICE|ABIOMED, Inc. hemodynamic support devices|ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
214300691|NCT01011517|DIETARY_SUPPLEMENT|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
214300692|NCT00565968|DRUG|melphalan|
214898971|NCT05062239|DRUG|Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative|Discontinuance of prior statin therapy
214898972|NCT05062239|DRUG|No-intervention.|Continuance of prior statin therapy
214300693|NCT00565968|DRUG|sorafenib tosylate|
214300694|NCT00565968|GENETIC|gene expression analysis|
214300695|NCT00565968|GENETIC|protein expression analysis|
214478812|NCT04807751|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
214898973|NCT05507671|BIOLOGICAL|BCG (Bacillus Calmette-Guérin) vaccine|Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
214898974|NCT05507671|OTHER|Placebo|Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion
214898975|NCT04496674|DRUG|CC-1 and Toczilizumab|Adminsitration of CC-1 and Toczilizumab
214898976|NCT03974113|DRUG|Fitusiran|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous
214898977|NCT06793696|OTHER|Nurse prompt|Nurse prompt to complete COWS
214898978|NCT06793696|OTHER|Provider prompt|Provider prompt to use EMBED CDS
214898979|NCT06793696|OTHER|Patient facing materials|Patient materials provided at discharge from ED
214898980|NCT06793696|OTHER|EMBED|Original EMBED CDS
214898981|NCT06645327|OTHER|a change in operating room table position, which will mimic an IV fluid bolus|"Cardiac Output (CO) measurements will be obtained at two separate time points: prior to sternotomy (opening of the chest) and after separation from cardiopulmonary bypass.~Intervention~1. the participant will be placed in the reverse Trendelenburg position (head up) to 15 degrees for 60-90 seconds. CO measurement will be obtained~2. the participant will be transitioned to the Trendelenburg position (head down) to 15 degrees for 60-90 seconds. CO measurement will be obtained"
214898982|NCT06558409|BEHAVIORAL|" Safer Still  Interactive Intervention"|An interactive intervention will be developed to help promote safe storage of firearms during the critical period immediately following high-risk care transitions.
214300696|NCT00565968|GENETIC|western blotting|
214300697|NCT00565968|OTHER|pharmacological study|
214300698|NCT06024044|BEHAVIORAL|Mobilization Training|"The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients."
214300699|NCT05440279|DEVICE|digital patient support|"Intervention takes place through a regular electronic therapy support in addition to standard care that is defined as follows:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~1. electronic questionnaires (web-based) on possible problems during therapy and subjective therapy success,~2. possibility to set personal adherence goals every week,~3. links to explanations and videos on therapy and the handling of therapy equipment and accessories,~4. provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring."
214300700|NCT00873509|DRUG|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
214300701|NCT00873509|DRUG|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
214300702|NCT00873509|DRUG|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
214300703|NCT01245270|DIETARY_SUPPLEMENT|Bilberry capsule first, then control cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
214300704|NCT01245270|DIETARY_SUPPLEMENT|Control capsule first then bilberry cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
214300705|NCT03852303|DRUG|ivermectin|evaluate effect of ivermectin on frequency of seizures
214300706|NCT01321125|BIOLOGICAL|Bacterial culture of the prepared skin's areas|Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
214478813|NCT06588803|OTHER|No intervention, only for observational studies|No intervention, only for observational studies
214898983|NCT06558409|OTHER|Enhanced Usual Care (EUC):|Families randomly assigned to the control condition will receive a psychological placebo that will feature an education only website developed by NCH's web design team. This website will cover warning signs for suicide, the leading methods of suicide - so that both conditions have content that features information about firearms - and locating professional help. The control website will NOT feature these three behavioral economic strategies--namely (a) multiple suggested alternatives for means restriction, (b) requests to justify inaction regarding means restriction, and (c) normative feedback about means restriction.
214898984|NCT04510090|DRUG|EP547|EP547
214898985|NCT04510090|DRUG|Placebo|Placebo
215053381|NCT04231097|OTHER|MBCT intervention for ACS patients|The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants involved in the intervention will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
214898986|NCT05825404|DEVICE|Smart Ambient Bright Light (SABL)|The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers. The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night
215053382|NCT05744856|BEHAVIORAL|Self-care with informal support|"The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
214898987|NCT05825404|OTHER|Control|Usual light.
214300707|NCT01321125|OTHER|Preparing skin's areas to be tested|Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
214300708|NCT01321125|BIOLOGICAL|Antiseptic substantivity|Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
214300709|NCT04572607|DIETARY_SUPPLEMENT|The consumption of avocado honey was analyzed|The subjects of honey group consumed 25 g of honey each day for 4 weeks.
214300710|NCT02784821|DRUG|Antibiotic|Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.
214300711|NCT02784821|OTHER|Gastric fluid|Microbiome evaluated using gastric aspirate.
214300712|NCT02784821|OTHER|Breast milk|Microbiome will be evaluated using mother's breast milk.
214300713|NCT02784821|OTHER|Stool samples|Microbiome will be evaluated using infant's stool.
214300714|NCT02784821|DRUG|Antibiotics|Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
214300715|NCT02157142|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
214300716|NCT04122859|DEVICE|Zip Skin Closure Device|The device is a CE-marked, single use, sterile medical device that is designed to provide closure speed superior to sutures, while resulting in a suture-like cosmetic outcome. It adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives.
214300717|NCT05333900|BEHAVIORAL|Plant-Based Diet then animal-based diet|Participants started with plant based diet: high in fiber, low in animal products for 7 days, with 14 day washout period between interventions. Following that, participants were switched to animal-based diet: high in animal products, low in fiber for 7 days.
214300718|NCT05333900|BEHAVIORAL|Animal-based diet then plant-based diet|Participants were started with animal-based diet: high in animal products, low in fiber for 7 days, with 14 days washout period between interventions. Following that, participants were switched to plant-based diet: high in fiber, low in animal products for 7 days
214300719|NCT04877938|BEHAVIORAL|Echolgical physical activity Intervention|'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV).
214300720|NCT00302042|BEHAVIORAL|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
214300721|NCT00302042|BEHAVIORAL|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
214300722|NCT03662984|DRUG|Ciprofibrate 100Mg Tablet|Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
214300723|NCT03662984|DRUG|Placebo Oral Tablet|To compare ciprofibrate
214300724|NCT00829543|PROCEDURE|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
214898988|NCT06181656|BIOLOGICAL|Pneumonia vaccine|Given by SC
214898989|NCT05728151|DRUG|Articaine and Epinephrine Only Product|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
214300725|NCT03561623|OTHER|magnetic resonance (MR) Imaging|MRI of spinal cord and brain
214300726|NCT03561623|OTHER|quantitative muscle force assessment|quantitative assessment of muscle force
214478814|NCT06030076|DRUG|Tildrakizumab|As provided in real-world clinical practice.
214898990|NCT05728151|DRUG|levobupivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
214898991|NCT05728151|DRUG|mepivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and in peribulbar block on postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
214898992|NCT05736666|BEHAVIORAL|Treadmill-based perturbation training|The intervention consists of disturbances delivered on a treadmill that simulates tripping over an obstacle or being perturbed to the side. These disturbances require a compensatory step to respond. Through this task-specific training, participants should learn to control their trunk motion in a way that will cause them to avoid a trip or fall to the side.
214898993|NCT05736666|BEHAVIORAL|Education Control|Fall prevention educational material
215053383|NCT04676893|DRUG|D418 Tab.|1T
215053384|NCT04676893|DRUG|CKD-388 Tab.|1T
215053385|NCT04363242|BIOLOGICAL|SYN125|Administered by IV infusion
215053386|NCT04363242|BIOLOGICAL|SYN004|Administered by IV infusion
214300727|NCT06482476|DIAGNOSTIC_TEST|Measurement of Lp(a) levels|Collection of a venous blood sample for the measurement of Lp(a) levels using standardized laboratory methods
214300728|NCT03666923|DRUG|THR-687 dose level 1|single intravitreal injection of THR-687 dose level 1
214898994|NCT06183944|OTHER|Hierarchical clustering methods|Hierarchical clustering methods will be used to form homogeneous groups of patients based on their data at diagnosis: presence or absence of symptoms, clinical and biological data, and presence or absence of favouring factors. Patient evolution at 6 months can fall into categories: stable, aggravation or progress, which are determined by events such as recurrence, hemorrhage, functional sequelae or death.
214898995|NCT06172517|OTHER|Orthosis intervention|Clinical feasibility trial with one group using a custom-made foot orthotics prescribed by podiatrists (foot impression, polypropylene orthotics and covering at podiatrists' discretion).
214898996|NCT06396871|DIAGNOSTIC_TEST|Oral glucose tolerance test|75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min
214898997|NCT06396871|DIAGNOSTIC_TEST|Liver Ultrasound|A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.
215053387|NCT06133556|DRUG|MCBC regimen|using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
215053388|NCT06133556|DRUG|Bu/Cy regimen|control group, the standard conditioning regimen Busulfan/Cyclophosphamide
215053389|NCT01645774|PROCEDURE|10s injections duration|10s injections duration
215053390|NCT01645774|PROCEDURE|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
215053391|NCT01645774|PROCEDURE|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
214300729|NCT03666923|DRUG|THR-687 dose level 2|single intravitreal injection of THR-687 dose level 2
214300730|NCT03666923|DRUG|THR-687 dose level 3|single intravitreal injection of THR-687 dose level 3
214300731|NCT04148950|OTHER|Kinesio Tape|
214300732|NCT04148950|OTHER|Compression Stockings|
214300733|NCT04148950|OTHER|Exercise Program|
214898998|NCT06396871|DIAGNOSTIC_TEST|Fibroscan of the Liver|FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).
214898999|NCT06396871|DIAGNOSTIC_TEST|Magentic Resonance Imaging (MRI) of the liver|The exact calculation of liver fat with proton density fat fraction will take place with MRI.
214300734|NCT01763424|DRUG|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
214300735|NCT01763424|DRUG|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
214300736|NCT04283162|DRUG|Calcium Dobesilate|use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months
214899000|NCT01240681|PROCEDURE|FLT PET and BOLD MRI scan|Eligible consenting patients with LABC receiving neoadjuvant chemotherapy (NA CT) will undergo FLT PET, BOLD MRI, and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy (CT). The imaging studies will be performed at baseline and after the first cycle of NA CT.
214899001|NCT04434339|PROCEDURE|erector spinae block|A volume of 20 ml for each side of erector spinae plane with 0.25% plain bupivacaine
214899002|NCT04434339|PROCEDURE|transversus abdominis block|A volume of 20 ml for each side of transversus abdominis plane with 0.25% plain bupivacaine
214899003|NCT01415518|DRUG|Drug: Budesonide/formoterol (Symbicort Turbuhaler|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
214899004|NCT01415518|DRUG|Drug: ipratropium (AtroventTM)|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
215053392|NCT01645774|PROCEDURE|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
215053393|NCT02584712|OTHER|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
214300737|NCT04283162|OTHER|conventional treatment|maintain lifestyle habits and the usual treatment
214300738|NCT06069973|OTHER|No intervention, observational study|No intervention
214300739|NCT00817895|DRUG|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
214300740|NCT00817895|DRUG|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
214300741|NCT00817895|PROCEDURE|TACE|All patients will accept TACE one month after tumor was resected.
214300742|NCT04695860|DRUG|Burosumab|Q4w, 1mg/kg Body weight, s.c.
214899005|NCT01415518|DRUG|theophylline SR|theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
214899006|NCT00679211|DRUG|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
214899007|NCT01473823|DIETARY_SUPPLEMENT|Omega-3 LCPUFA|Dosage is 5 ml daily until age 3 years.
214899008|NCT05531123|DRUG|Tislelizumab|Tislelizumab 200 mg I.V. Q3W on the day 1
214899009|NCT05531123|DRUG|gemcitabine and cisplatin|Cisplatin 70mg/m2 I.V. Q3W on the day 1, dose fractionation is allowed ;Gemcitabine 1000mg/m2 I.V. Q3W on the day 1 and day 8
214899010|NCT05531123|RADIATION|Modified hypofractionation|"* Whole bladder 44Gy / 16fractionation (If N1: Whole bladder + Pelvic nodes 44Gy / 16fractionation) (Positive lymph nodes can be dosed to the maximum tolerable dose)~* Tumor boost 11Gy / 4fractionation~* Radiosensitizing chemotherapy: DDP 75-80 mg/m2 weekly Q3W"
214300743|NCT06129721|PROCEDURE|Emergent Stenting|Emergent Stenting In Acute Vertebrobasilar Occlusions
214300744|NCT03011255|BIOLOGICAL|peptide specific CTL|Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
214300745|NCT01893554|BIOLOGICAL|RSV ΔNS2 Δ1313 I1314L Vaccine|"For participants in Groups 1, 3, and 4: 10\^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10\^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL)."
214899011|NCT05890924|OTHER|WAST questionnaire|"WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence.~(ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)"
214300746|NCT01893554|BIOLOGICAL|Placebo|Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
214899012|NCT04295083|BEHAVIORAL|clay based group study|"Clay based group work sessions were applied to the experimental group for 60-90 minutes once a week for 6 weeks. The sessions are composed of structured or semi-structured activities prepared for the purpose of the literature by the researcher for the purposes such as acquiring new solutions and life skills to reduce loneliness and hopelessness of individuals aged 65 and over, and sharing their feelings, thoughts, and memories with other individuals. Clay Study Activity Booklet . Four expert opinions were obtained for the booklet created. Methods such as narration, sharing experiences, group practice, question-answer, learning by doing, imagining were used in the activity program. The physical, psychological, social and mental characteristics of the elderly were taken into consideration in the selection of these methods."
215053394|NCT01396356|PROCEDURE|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
215053395|NCT03762460|OTHER|Online eHealth tool|Mobile-optimized online eHealth tool to support MBC.
214300747|NCT05028179|DIAGNOSTIC_TEST|EchoGo|EchoGo Pro is an software Medical Device which is able to assess Stress Echocardiograms and provide a binary classification of risk of CAD
214300748|NCT04001881|OTHER|Transthoracic echocardiography|A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
214300749|NCT04001881|DRUG|Spinal anesthesia|Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
214300750|NCT04022720|PROCEDURE|Platelet Rich Fibrin Application|Platelet Rich Fibrin application at first post-op visit.
214300751|NCT06164470|BEHAVIORAL|Support Group|monthly virtual patient support with multidisciplinary education for 12 sessions
214300752|NCT01962129|BIOLOGICAL|Sampling of blood|
214300753|NCT03147547|OTHER|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
214300754|NCT03147547|OTHER|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
214300755|NCT03147547|OTHER|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
214300756|NCT03147547|OTHER|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
214300757|NCT05542303|DRUG|ZB001 for injection|Dose Cohort1 (3mg/kg) ZB001 of single IV injection
214300758|NCT05542303|DRUG|ZB001 for injection|Dose Cohort2 (10mg/kg) ZB001 of single IV injection
214300759|NCT05542303|DRUG|ZB001 for injection|Dose Cohort3 (20mg/kg) ZB001 of single IV injection
215053396|NCT03762460|OTHER|Informational website|Participants randomized to this group will receive information about online resources for mental health
215053397|NCT00400517|BIOLOGICAL|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
215053398|NCT00400517|DRUG|thalidomide|doses up to 400 mg/day
215053399|NCT00400517|PROCEDURE|conventional surgery|SOC care surgery
214300760|NCT01061242|BEHAVIORAL|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
214899013|NCT01042353|PROCEDURE|E test|At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
214899014|NCT01042353|PROCEDURE|standard culture method|BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
214899015|NCT01730053|DRUG|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
214899016|NCT01730053|DRUG|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
214899017|NCT01730053|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablets orally.
214899018|NCT01730053|DRUG|Placebo|Placebo for alirocumab and ezetimibe.
214899019|NCT05460013|DIETARY_SUPPLEMENT|Traditional Control|Placebo control is a compounded made-up shake that is traditionally used by the Haematology ward to supplement patients receiving HSCT. The control provides an equivalent of 500kcals and 20.6g protein, 3.4g fiber per day. The participants will be randomly assigned to consume the control twice daily for the duration of 7 days prior to the admission to the day of discharge.
214899020|NCT05460013|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|The product to be studied is a standard polymeric formula. It is intended to provide 500cals, 18.4g protein, and 5g fiber per day. The fiber contained is mostly presented in the form of soluble fiber (inulin, fructo-oligosaccharide). The participants will be randomly assigned to consume the intervention twice a day for the duration of 7 days prior to the admission to the day of discharge.
214899021|NCT01805518|DIETARY_SUPPLEMENT|Scelectium Tortuosum|"One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.~The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d."
214899022|NCT03727919|BEHAVIORAL|Exoskeleton-assisted gait training|In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.
214899023|NCT01470248|DRUG|Arsenic Trioxide|Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects
214899024|NCT06426342|BEHAVIORAL|metaverse-based blended online intervention|A new metaverse-based blended online intervention was developed using an online program and coaching via metaverse to prevent depression among Generation MZ Employees in South Korea.
214899025|NCT05085834|DRUG|Zinc Gluconate|Two 45 mg capsules once daily
214899026|NCT05085834|DRUG|Placebo|Two placebo capsules once daily
214899027|NCT01876771|DRUG|[177]Lu-DOTA-TATE|Peptide receptor radionuclide therapy (PPRT)
214899028|NCT05708235|DRUG|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
214300761|NCT00745992|OTHER|Blood drawn (lab data)|"1. Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~2. Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
214478815|NCT06592053|PROCEDURE|Breast Cancer Surgery Pain|Factors affecting the occurrence of chronic pain in patients undergoing elective mastectomy surgery will be investigated.
214478816|NCT06587295|DRUG|Intramuscular ACM-CpG Monotherapy (Escalation)|Dose escalation for ACM-CpG monotherapy administered via intramuscular injection will similarly be conducted using traditional 3+3 dose escalation. Three dose levels have been planned. If the patient experiences a DLT or two Grade ≥ 2 drug-related toxicity, the dose level will be expanded according to a 3+3 design. The safety and tolerability of each dose level will be assessed by the study team after all patients enrolled in the dose level have been followed for at least 21 days after the first dose of the ACM-CpG (DLT observation period). Once the MTD is reached, the RP2D will be determined.
214478817|NCT06587295|DRUG|Intramuscular ACM-CpG Monotherapy (Expansion)|Patients will be administered ACM-CpG monotherapy at a dose determined in the dose escalation phase.
214478818|NCT06593210|BIOLOGICAL|Adjuvant, non-live RSV vaccine|One dose of arexvy vaccine to transplant recipients.
214478819|NCT06470022|DEVICE|Medtronic Evolut FX|TAVI performed with Medtronic Evolut FX
214478820|NCT06470022|DEVICE|Edwards Sapien 3 Ultra Resilia|TAVI performed with Edwards Sapien 3 Ultra Resilia
214899029|NCT05708235|DRUG|Abemaciclib|Abemaciclib is an orally administered CDK4/6 inhibitor
214899030|NCT05708235|DRUG|Inavolisib|Inavolisib is a potent, selective inhibitor of the Class I phosphatidylinositol 3-kinase α (PI3K-alpha isoform (p110-alpha)
214899031|NCT05815628|DIAGNOSTIC_TEST|DISQVER|NGS based infection diagnosis
214300762|NCT01559896|DIETARY_SUPPLEMENT|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
214300763|NCT04052269|DRUG|Sildenafil 100mg|study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
214300764|NCT00112658|DRUG|fluorouracil|
214300765|NCT00112658|DRUG|gemcitabine hydrochloride|
214300766|NCT00112658|DRUG|irinotecan hydrochloride|
214300767|NCT00112658|DRUG|leucovorin calcium|
214300768|NCT00112658|DRUG|oxaliplatin|
214300769|NCT01950533|PROCEDURE|Oral food challenge|Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
214478821|NCT06824571|DIETARY_SUPPLEMENT|High-Dose Taurine Supplementation (6g)|Participants will receive taurine supplementation at a high dose of 6g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of high-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
214478822|NCT06824571|DIETARY_SUPPLEMENT|Medium-Dose Taurine Supplementation (4g)|Participants will receive taurine supplementation at a medium dose of 4g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of medium-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
214300770|NCT05777915|OTHER|Usability testing|Usability testing
214899032|NCT02243605|DRUG|Cabozantinib S-malate|Given PO
214899033|NCT02243605|OTHER|Laboratory Biomarker Analysis|Correlative studies
214899034|NCT05047926|BEHAVIORAL|Behavioral Counseling|Undergo behavioral counseling
214899035|NCT05047926|DIETARY_SUPPLEMENT|Nutritional Supplement Drink|Given Boost or Ensure
214899036|NCT05047926|OTHER|Physical Activity|Complete physical activity assignments
214899037|NCT05047926|OTHER|Survey Administration|Complete surveys
214899038|NCT05047926|PROCEDURE|Computed Tomography|Undergo CT scans
214300771|NCT01571206|BIOLOGICAL|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
214300772|NCT03724812|DEVICE|Portico Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach
214300773|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
214300774|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
214899039|NCT05047926|PROCEDURE|Biospecimen Collection|Undergo blood collection
214899040|NCT05047926|BEHAVIORAL|Health Education|Complete Resilient Living program
214899041|NCT05047926|OTHER|Medical Device Usage and Evaluation|Wear a FitBit
214899042|NCT05974176|BEHAVIORAL|Trauma Focused CBT (TF-CBT)|TF-CBT is an evidence-based treatment for children and adolescents impacted by trauma and their parents or caregivers. It is a components-based treatment model that incorporates trauma-sensitive interventions with cognitive behavioral, family, and humanistic principles and techniques.
214899043|NCT05974176|BEHAVIORAL|Trauma Systems therapy (TST)|Trauma Systems Therapy (TST) is focused on the factors that contribute to children and adolescents who experience traumatic stress through the lens of the social context, vulnerabilities, and strengths of the person undergoing treatment.
214300775|NCT01851720|DRUG|Low dose fentanyl PCA|
214899044|NCT06462989|OTHER|ECHONEXT|ECHONEXT Artificial intelligence algorithm
214899045|NCT03831230|GENETIC|collection of blood, urine, tumor and ascite samples|collection of blood, urine, tumor and ascite samples during ovarian surgery
214300776|NCT01851720|DRUG|Standard IV fentanyl bolus|
214300777|NCT01434238|OTHER|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
214899046|NCT04833335|OTHER|MRI perfusion sequence|Quantitative analysis
214899047|NCT04932863|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.
214300778|NCT02954510|DRUG|ferumoxytol|ferumoxytol will assess patency of coronary arteries
214300779|NCT03276689|DRUG|Duloxetine|The patients will take duloxetine for 8 weeks.
214300780|NCT03276689|DRUG|Pregabaline|The patients will take pregabaline for 8 weeks.
214300781|NCT03276689|OTHER|Placebo|The patients will take placebo for 8 weeks.
214300782|NCT03862274|OTHER|CLN2 Treatment|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
214478823|NCT06824571|DIETARY_SUPPLEMENT|Low-Dose Taurine Supplementation (1g)|Participants will receive taurine supplementation at a low dose of 1g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of low-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
214478824|NCT06824571|DIETARY_SUPPLEMENT|Placebo (0g Taurine)|Participants will receive a placebo, consisting of an inactive substance (0g taurine). The placebo will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention serves as a control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
214478825|NCT05869487|RADIATION|Dual-energy X-ray absorptiometry|Whole body x-ray absorptiometry
214478826|NCT06598631|DRUG|Volenrelaxin|Administered SC
214478827|NCT06598631|DRUG|Placebo|Administered SC
214478828|NCT06820983|OTHER|adult questionnary for parents of children aged 8 to 13|Quality of life questionnaire for parents of children aged 8 to 13
214669431|NCT01332032|BEHAVIORAL|Reminder Letter|A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
214669432|NCT01332032|BEHAVIORAL|Reminder Call|A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
214669433|NCT01332032|BEHAVIORAL|Counselor Call|Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
214669434|NCT04764032|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be undertaken by a range of appropriately competent practitioners including; intensive care clinicians, cardiologists and specialist echocardiographers. Imaging obtained will be in keeping with the protocol required for a Focused Intensive Care Echo (FICE) scan and should include ECG monitoring at all times. A focused dataset will be used to answer the primary outcome. If available and the echocardiographers competency and experience permit, further measures of RV function will be obtained at this time.
214669435|NCT03196050|DEVICE|Handheld Device (Smart Phone)|"Handheld device will be used for 3 tasks:~1x per day: status update (how are you today?)~1x per week: 10 questions on general health status~1x per month: EORTC QLQ-C30 questionnaire"
214669436|NCT03650439|DIAGNOSTIC_TEST|culture on Sabouraud's Dextrose Agar (SDA)|• Clinical samples will be cultured onto Sabouraud's Dextrose Agar (SDA) plates supplemented with chloramphenicol. the culture was incubated at 25 C° and at 37° C (for yeasts and moulds isolation )
214669437|NCT06477159|DRUG|Pancrelipase Capsules|Treatment with Pancreatic Enzyme Replacement Therapy
214899048|NCT06277310|OTHER|3 Wishes Project|palliative care initiative in which clinicians elicits and implements small acts of kindness for dying patients and their families
215053400|NCT00400517|PROCEDURE|neoadjuvant therapy|post radical prostatectomy
214669438|NCT03601026|BEHAVIORAL|Genetic counselling|Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
214669439|NCT02734121|BEHAVIORAL|pre-consultation educational group intervention|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (40 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (20 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteers (30 mins) questions and answers about their personal experience"
214478829|NCT06820983|OTHER|Quality of life questionnaire for children aged 8 to 13|Quality of life questionnaire for children aged 8 to 13
214478830|NCT06820983|OTHER|Quality of life questionnaire for adolescents aged 14 to 17|Quality of life questionnaire for adolescents aged 14 to 17
214478831|NCT06820983|OTHER|Quality of life questionnaire for adults|Quality of life questionnaire for adults
214478832|NCT06820983|OTHER|A satisfaction adherence questionnaire|A satisfaction adherence questionnaire will also be distributed to patients after several months' use of oscillating PEP
214478833|NCT06274853|DRUG|GS-441524|Oral GS-441524 capsules
214478834|NCT06274853|DRUG|Placebo|Placebo capsules
215053401|NCT00104338|DRUG|FK778|
215053402|NCT00353301|DRUG|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
214300783|NCT03842384|BEHAVIORAL|iENDURE|The proposed intervention will initially target motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance.
214300784|NCT05349149|DRUG|Tocilizumab/Actemra® (Roche)|The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
214478835|NCT06816589|BEHAVIORAL|ChatGPT-based job coaching|Using ChatGPT for creating job resumes, discussing job types, preparing and practicing for job interviews, writing job descriptions for individuals with Asperger's syndrome, and discussing workplace social interactions
214899049|NCT06266182|BEHAVIORAL|Acceptance and Commitment Therapy|ACT intervention will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive a web-based intervention consisting of educational and practical tasks/activities. Participants will learn to recognize moments of choice (actions that lead towards values or away from them) and to use attention flexibly to free themselves from the power of thoughts, to open up and accept emotions, and to be able to determine what is important and take action in line with values. All of the tasks will be available in written form and audio. The ACT intervention is built from standard ACT exercises.
214300785|NCT05349149|DRUG|Saline 9%|The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
214300786|NCT04160364|OTHER|qualitative study|qualitative research via guided interview
214899050|NCT06266182|BEHAVIORAL|Education|Education will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive information about post-transplant prescriptions along with exercises to support the implementation. Participants will learn about nutrition, personal hygiene, preventing infections, coping with fatigue, resuming activity, rest and sleep, engaging in social interactions, and sexual health. The content is prepared based on available guides for HCT recipients.
214300787|NCT04382131|OTHER|NaCl Solution|NaCl Solution prepared by participants at home using water and salt
214478836|NCT05271097|OTHER|MyLink2Care app full functionality|Participants will be shown how to download the app and use the assessment tool.
214478837|NCT05271097|OTHER|MyLink2Care app major intervention features inactivated|Participants will be shown how to download the app and use the assessment tool.
214478838|NCT06585917|DEVICE|7F Thin-Walled Sheath|The 7F Thin-Walled Sheath is used during coronary intervention procedures via distal radial artery access. This device has a smaller outer diameter compared to traditional 7F sheaths, designed to reduce the risk of vascular complications while allowing for the performance of complex coronary interventions.
214478839|NCT06585917|DEVICE|6F Thin-Walled Sheath|The 6F Thin-Walled Sheath is the standard device used in coronary intervention procedures via distal radial artery access. It is employed as a control in this study to compare its efficacy and safety against the 7F Thin-Walled Sheath.
214899051|NCT00751699|DRUG|Asacol|Asacol tablets, 6 tablets per day at 7 am for 7 days
214899052|NCT00751699|DRUG|Asacol|Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days
214899053|NCT00751699|DRUG|Lialda|Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
214899054|NCT06367231|OTHER|VibrantMinds|We are exploring the potential of computer games to reveal insights into the cognitive abilities of older adults. We developed the VibrantMinds (https://vibrant-minds.org/vibrantminds2/start) platform, featuring five games: Whack-a-Mole, Bejeweled, Mahjong Solitaire, Word Search, and Memory Game. Our evaluation focused on the usability of these games, their appeal to users, and their effectiveness in enhancing cognitive functions. The next phase of our study aims to determine whether these games can offer meaningful data on the cognitive skills of older adults.
214899055|NCT05286229|DRUG|Etentamig|Intravenous (IV) Infusion
214899056|NCT04540809|OTHER|Assessment of strength, proprioception, skill and coordination of the hand|Disease Activity Score 28 was used to determine the disease activity of patients with PsA. Grip strength was measured with the help of Baseline Digital Hand Dynamometer®. Pinch strength was measured with Baseline Hydraulic Pinch Gauge®. Wrist proprioception was assessed by measuring the joint position sensation using a goniometer by actively repeating the target angle predetermined by the researcher (30 ° for flexion and extension, 15 ° for ulnar deviation, 10 ° for radial deviation. Finger skills were assessed using a mobile application called Ball Tap©. The application included the fastest contact of the participants to the balls coming from different parts of the screen for 30 seconds. Two hand coordination and skills were evaluated using the Purdue Pegboard test. The Michigan Hand Outcomes Questionnaire was used for functional evaluation of the hand, and the Health Assessment Questionnaire was used to assess the general functional condition and health-related quality of life.
214899057|NCT03869320|DRUG|ACT-1004-1239|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg. For the ADME subpart, a single oral dose of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given simultaneously with the ACT-1004-1239 capsule. For the absolute bioavailability subpart, a single intravenous dose of a maximum of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given at the expected tmax after the administration of the ACT-1004-1239 capsule.
214899058|NCT03869320|OTHER|Placebo|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
214899059|NCT03869320|DRUG|ACT-1004-1239 (Food-effect subpart)|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg.
214899060|NCT03869320|OTHER|Placebo (Food-effect subpart)|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
214899061|NCT04173507|DRUG|Avelumab|Given IV
214899062|NCT04173507|DRUG|Talazoparib|Given PO
214899063|NCT04173507|DRUG|Talazoparib Tosylate|Given PO
214899064|NCT01823328|DRUG|Ketamine|Subjects will receive ketamine for sedation prior to rapid sequence intubation.
214899065|NCT01823328|DRUG|Etomidate|Subjects will receive etomidate for sedation prior to rapid sequence intubation.
214899066|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
215053403|NCT00353301|DRUG|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
215053404|NCT03378544|BEHAVIORAL|mhGAP|The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity
215053405|NCT03058198|DIAGNOSTIC_TEST|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
215053406|NCT03974126|OTHER|40 grams of starch|40 grams of starch in form of white bread to be consumed within 15 minutes
215053407|NCT03974126|OTHER|80 grams of starch|80 grams of starch in form of white bread to be consumed within 15 minutes
215053408|NCT04535102|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin is an ADC designed for the targeted delivery of MMAE(mono-methyl auristatin E), a potent microtubule inhibitor to lymphoma cells expressing CD79b. MMAE has a mechanism of action that is similar to that of vincristine.
215053409|NCT00091663|DRUG|Tarceva (erlotinib HCl)|
215053410|NCT02381314|BIOLOGICAL|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
215053411|NCT04237181|DEVICE|Filmarray PCR multiplex-PCT assay|Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
214300788|NCT02210936|OTHER|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
214669440|NCT05611463|DRUG|Camrelizumab Plus Docetaxel and Cisplatin|Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
214899067|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
214899068|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
214899069|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
215053412|NCT03924219|OTHER|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
215053413|NCT04264520|BEHAVIORAL|PTSD Psychoeducation + Skills Intervention|A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
215053414|NCT02326727|DRUG|Ropivacaine|Epidural analgesia
215053415|NCT02326727|DRUG|Fentanyl|General Anesthesia
215053416|NCT02326727|DRUG|Propofol|General Anesthesia
215053417|NCT02326727|DRUG|Isoflurane|General Anesthesia
215053418|NCT02326727|DRUG|Nitrous Oxide|General Anesthesia
215053419|NCT04541485|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
214300789|NCT03510156|BEHAVIORAL|Behavior analytic treatment|Function-based treatment
214300790|NCT00424138|RADIATION|FDG|
215053420|NCT04541485|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
215053421|NCT03586271|PROCEDURE|trifocal lens|phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation
215053422|NCT03586271|PROCEDURE|bifocal lens 1|phacoemusification +bifocal lens(Diff-aay) implantation
215053423|NCT03586271|PROCEDURE|bifocal lens 2|phacoemusification +bifocal lens (ReSTOR +3.0D) implantation
215053424|NCT03586271|PROCEDURE|bifocal lens 3|phacoemusification +bifocal lens (ReSTOR +2.5D) implantation
215053425|NCT01881789|DRUG|Oprozomib|Extended release (ER) tablets administered orally
215053426|NCT01881789|DRUG|Lenalidomide|Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.
215053427|NCT01881789|DRUG|Dexamethasone|Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.
215053428|NCT01881789|DRUG|Cyclophosphamide|Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
214899070|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
215053429|NCT02512380|DRUG|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
215053430|NCT02512380|DRUG|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
215053431|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
215053432|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
215053433|NCT04229888|DEVICE|LipiFlow|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
215053434|NCT04229888|DEVICE|Light Based (Sham) Treatment|A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.
215053435|NCT02592421|DRUG|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
215053436|NCT02592421|DRUG|Placebo|Placebo Comparator
215053437|NCT05156411|OTHER|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied
215053438|NCT00005989|DRUG|tipifarnib|
215053439|NCT00841061|DIETARY_SUPPLEMENT|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
215053440|NCT00841061|DIETARY_SUPPLEMENT|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
215053441|NCT01305187|DEVICE|Hyaluronic Acid Filler|The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
215053442|NCT00403143|PROCEDURE|cataract surgery|
215053443|NCT05973708|OTHER|Clamshell Exercise|Clamshell Exercise: The clamshell exercise keeps the hips moving, it strengthens both the gluteus medius AND gluteus maximus. The gluteus medius is the main abductor (movement away from the midline of the body) and external rotator of the hip.
214899071|NCT06092814|DEVICE|Active transcranial alternating current stimulation (tACS)|Transcranial Alternating Current Stimulation (tACS) is a device that applies a low-intensity electrical current to the brain through electrodes on the scalp.
214899072|NCT05796219|RADIATION|Low dose mammogram|Low dose mammogram
214899073|NCT04030442|DRUG|Immediate-release Oral Morphine Sulfate Tablets|0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions
214899074|NCT04030442|OTHER|Thermal and Pressure Nociceptive Sensitivity|Primary outcome measures of pain threshold and tolerance.
214899075|NCT00745862|BEHAVIORAL|questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided|This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
214899076|NCT02157935|DRUG|Symbicort|Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
214899077|NCT02157935|DRUG|Formoterol turbohaler|Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
214899078|NCT02157935|OTHER|Placebo for Symbicort pMDI|pMDI, aerosol for oral inhalation, placebo, 120 doses
214899079|NCT02157935|OTHER|Placebo for Formoterol Turbohaler|PLacebo powder for oral inhalation, 60 doses
214899080|NCT03176303|DEVICE|SpinalStim|PEMF osteogenesis stimulator
214899081|NCT00389311|DRUG|Normosol-R|
214899082|NCT00389311|DRUG|Nonoxynol-9|
214899083|NCT00389311|PROCEDURE|Gastrointestinal instrumentation|
215053444|NCT05973708|OTHER|Frog pump exercise|Frog pump exercise: The frog hip thrust mainly targets the gluteal muscles responsible for thigh extension and abduction. The exercise also works the hamstrings on the back of the thighs which helps in hip extension.
215053445|NCT00872274|DRUG|sumatriptan 100mg|
215053446|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
215053447|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
215053448|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
215053449|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
215053450|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
215053451|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
215053452|NCT01296750|OTHER|Early Physiotherapy start|Physiotherapy starting at one day post op
214899084|NCT04276961|OTHER|Acupuncture|Acupuncture will be given for a total of 12 session over 4 weeks. Acupuncture at acupoints Tianshu (ST25), Shangjuxu (ST37), Zusanli (ST36), and Neiguan (PC6) bilaterally will be given.
214899085|NCT02178657|DRUG|Autologous bone marrow mononuclear cell intra-arterial injection|
214899086|NCT00751920|PROCEDURE|Enhanced MRI Scan|Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
214899087|NCT02764762|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
214899088|NCT02764762|DRUG|Adalimumab|Adalimumab injection for subcutaneous use.
214899089|NCT02764762|DRUG|Methotrexate|Methotrexate oral tablets.
214899090|NCT00000594|DRUG|cholestyramine|
214899091|NCT03182504|DRUG|nacubactam|Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
214899092|NCT03182504|DRUG|meropenem|Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
214899093|NCT02194283|DRUG|Ambroxol - in single rising doses|
214899094|NCT02194283|DRUG|Placebo|
214899095|NCT00944931|DEVICE|DC Brain Polarization|
214899096|NCT02739789|DEVICE|tDCS|tDCS
214899097|NCT02739789|DEVICE|Sham tDCS|Sham tDCS
214899098|NCT00172172|DRUG|PTH/Calcium|PTH(1-84) subcutaneous injection and calcium 700 mg oral
214899099|NCT00172172|DRUG|PTH/placebo|PTH (1-84) injected subcutaneously and placebo provided orally
214899100|NCT00172172|DRUG|placebo|Placebo injected subcutaneously and 700 mg calcium orally
214899101|NCT05979103|BEHAVIORAL|Listening to Reggae Music and told the stereotype|Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks. Each day, we will send them a playlist to listen to.
214899102|NCT05979103|BEHAVIORAL|Listening to Preferred Music|Participants in this group will NOT be told the stereotype for the audio they are listening to. They will listen to preferred music over the 4 weeks. Each day, we will remind them to listen to preferred music.
214899103|NCT01957514|OTHER|Cytology Specimen Collection Procedure|Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection
214899104|NCT01957514|OTHER|Laboratory Biomarker Analysis|Correlative studies
214899105|NCT01957514|OTHER|Quality-of-Life Assessment|Ancillary studies
214899106|NCT01957514|OTHER|Questionnaire Administration|Ancillary studies
214899107|NCT02717507|DRUG|Carvedilol|Given PO
214899108|NCT02717507|OTHER|Laboratory Biomarker Analysis|Correlative studies
214899109|NCT02717507|OTHER|Pharmacogenomic Study|Correlative studies
214899110|NCT02717507|OTHER|Pharmacological Study|Correlative studies
214899111|NCT02717507|OTHER|Placebo Administration|Given PO
214899112|NCT02717507|OTHER|Quality-of-Life Assessment|Ancillary studies
214899113|NCT02717507|OTHER|Questionnaire Administration|Ancillary studies
214899114|NCT05894707|DRUG|SCT650C|Recombinant anti-IL-17A antibody
214899115|NCT05592171|PROCEDURE|Microwave ablation + Occlusafe + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
214899116|NCT05592171|PROCEDURE|Microwave ablation + Occlusafe|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time."
214899117|NCT05592171|PROCEDURE|Microwave ablation + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
214899118|NCT03145415|PROCEDURE|Caudal block|1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.
214899119|NCT03145415|PROCEDURE|Bilateral Pudendal block|0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
214899120|NCT02489188|PROCEDURE|arthroplasty|patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery
214899121|NCT02489188|OTHER|manual therapy|patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
214899122|NCT02489188|PROCEDURE|lumbar spinal stenosis decompression|patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
214899123|NCT02710721|OTHER|Fasting|Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.
214899124|NCT02710721|OTHER|Control|Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
214899125|NCT01662778|DRUG|1.5 microns at 50mg|STAG generated monodisperse 1.5micron particles
214899126|NCT01662778|DRUG|6 microns at 50mg|STAG generated monodisperse 6 micron particles
214899127|NCT01662778|DRUG|Placebo Comparator|No drug just solvent
214899128|NCT01662778|DRUG|MDI FP|
214899129|NCT00742209|DRUG|GSK1838262|Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
214899130|NCT00742209|DRUG|Placebo|Placebo-control
214899131|NCT01061593|DIETARY_SUPPLEMENT|Immunoxel|1 lozenge once per day
214899132|NCT01061593|OTHER|Placebo|1 lozenge once per day
214899133|NCT02207205|DRUG|Blood drawn from indwelling catheters versus direct venipuncture|Evaluation of the source of blood samples on whole blood clotting time
214899134|NCT02862015|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
214899135|NCT02862015|DRUG|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
214899136|NCT01138787|DIETARY_SUPPLEMENT|Reference spread|Single dose (30 gr) of spread, containing 2250 mg PS
214899137|NCT01138787|DIETARY_SUPPLEMENT|Placebo spread|Single dose (30 gr) of regular light margarine
214899138|NCT01138787|DIETARY_SUPPLEMENT|Test spread|Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
214899139|NCT03524651|DRUG|Ferrous Sulfate|Blisters of 10 capsules containing 150 mg of ferrous sulfate.
214899140|NCT03524651|DRUG|Fe-ASP|Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.
214899141|NCT03524651|DRUG|Ferrous Sulfate|Boxes of 10 vials of 15 ml containing inactive ingredients of Omalin.
214899142|NCT03524651|DRUG|Fe-ASP|Blisters of 10 capsules containing inactive ingredients of Microfer.
214899143|NCT02562066|DRUG|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
214899144|NCT02562066|DRUG|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
214899145|NCT03679689|DIETARY_SUPPLEMENT|artificially sweetened beverages|artificially sweetened beverages restriction
214899146|NCT02003209|DRUG|Aromatase Inhibition Therapy|Given at the investigator's discretion
214899147|NCT02003209|DRUG|Carboplatin|Given IV
214899148|NCT02003209|OTHER|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
214899149|NCT02003209|DRUG|Docetaxel|Given IV
214899150|NCT02003209|DRUG|Goserelin Acetate|Given SC
214899151|NCT02003209|OTHER|Laboratory Biomarker Analysis|Correlative studies
214899152|NCT02003209|BIOLOGICAL|Pertuzumab|Given IV
214899153|NCT02003209|OTHER|Quality-of-Life Assessment|Ancillary studies
214899154|NCT02003209|PROCEDURE|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
214899155|NCT02003209|BIOLOGICAL|Trastuzumab|Given IV
214669441|NCT02250040|OTHER|Conventional physiotherapy|Physiotherapy techniques that included muscle training, stretching and endurance.
214899156|NCT02003209|RADIATION|Whole Breast Irradiation|Undergo whole breast irradiation
214899157|NCT06145841|DIAGNOSTIC_TEST|Pathogen metagenomic next-generation sequencing|In diagnosing patients with AIDS combined with severe pneumonia and/or sepsis, use pathogen metagenomics technology to detect peripheral blood specimens
214899158|NCT05839314|DRUG|Huaier granule|Huaier granule, oral administration, 10g each time, 3 times a day, continuous medication for 24 weeks. After 24 weeks of treatment, the dosage should be adjusted according to efficacy.
214899159|NCT05839314|DRUG|Renin-angiotensin-aldosterone system inhibitors (RASI)|"Run-in period: All the patients should be treated with RASI for at least 4 weeks, and stop using any medicine containing Huaier or similar ingredients for at least 2 weeks before enrollment. If the patient is receiving RASI, the RASI can be continued until the end of the study. RASI can be adjusted once a week until the maximum tolerable dose based on albuminuria and blood pressure. If the patient is not receiving RASI therapy, then RASI is recommended.~Treatment period: RASI therapy is continued throughout the trial. Check blood pressure twice daily: morning and evening."
214899160|NCT05839314|DRUG|Ciclosporin soft capsules|"The initial dose of Ciclosporin soft capsules is an oral dose of 3.5mg/kg/d, divided into two equal doses, given every 12 hours. Assess the plasma concentration of CsA (valley value) every 2 weeks in the first 8 weeks. If the plasma concentration of CsA reaches 100-150ug/L, continue to maintain the dose. If the plasma concentration of CsA is below the target concentration, increase the dose of CsA. If the plasma concentration of CsA is higher than the upper limit of the target concentration, appropriate dose reduction. A single dose adjustment is 25mg/d. After increasing/decreasing the dose, CsA concentration is remeasured at intervals of 2 weeks ±3 days until the target concentration is reached.~CsA at target concentration followed by 24 weeks of treatment, then the dosage shall be adjusted according to efficacy."
214899161|NCT00638508|DRUG|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
214899162|NCT00638508|DRUG|Ketorolac and Ropivacaine|Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
214899163|NCT05911334|BEHAVIORAL|ROADE Program|Outpatient Behavioral Intervention for Eating Disorder
214899164|NCT06269458|BEHAVIORAL|Baby Massage|In the baby massage application, mothers were trained on baby massage and the massage applied by the mother to her baby was observed once. The baby massage video prepared by the researchers was shared with mothers. Mothers were informed about the importan
214899165|NCT06269458|BEHAVIORAL|Monther-Baby Yoga|"Mothers were asked to choose the most suitable time of day for themselves and the baby, to ensure that the baby was fed at least 45 minutes before yoga, and to practice yoga in a calm and dimly lit environment, listening to music or white noise of their choice. One yoga session lasted approximately 20 minutes. Mothers and their babies did mother-baby yoga three times a week for four weeks. Mothers were informed about the importance of having the same treatment room for each treatment. All mothers were called once a week by a researcher to provide counseling and follow-up of the process.~At the end of four weeks, measurement tools were applied to all mothers and the groups were changed, massage was applied to the yoga group, and yoga intervention was applied to the massage group, as in the beginning of the research. At the end of four weeks, all mothers were evaluated for mother-infant attachment and the infant's sleep diary."
214899166|NCT00739713|DIETARY_SUPPLEMENT|Sea buckthorn (Hippophaë rhamnoides) oil|Dosage 2 g/d, frequency twice/d, duration 3 months
214899167|NCT00739713|DIETARY_SUPPLEMENT|Placebo comparison|Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
214899168|NCT03606616|PROCEDURE|no further ALND arm|Patients meeting the Z0011 inclusion criteria to receive no additional ALND
215053453|NCT03512574|DRUG|Pregabalin|One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
215053454|NCT03512574|DRUG|Dexmedetomidine|One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
215053455|NCT03512574|OTHER|Placebo|One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
215053456|NCT03512574|DRUG|Pregabalin and dexmedetomidine|One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
214899169|NCT01030419|BEHAVIORAL|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
214669442|NCT02250040|OTHER|Techniques based on patients' functional level were added.|The added techniques aimed to improve balance and movement dissociation.
214899170|NCT01030419|BEHAVIORAL|Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
214300791|NCT00379496|PROCEDURE|Antidepressants|
214300792|NCT00379496|PROCEDURE|acupuncture|
214899171|NCT05972902|DRUG|Dydrogesterone|Dydrogesterone molecular structure and pharmacologic effects are closely related to endogenous progesterone
214899172|NCT05972902|DRUG|Cetrorelix acetate|GnRH antagonist
214899173|NCT05972902|DRUG|Triptorelin|GnRH agonist
214300793|NCT05150535|RADIATION|Hypofractionation Radiotherapy.|Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.
214300794|NCT05150535|RADIATION|Ultra-hypofractionation radiotherapy|Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.
214300795|NCT05423821|OTHER|Anesthesia efficacy in patients undergoing MRI|atropine will be administered when bradycardia develops, oxygen will be given if hypoxia develops
214300796|NCT04287504|DIAGNOSTIC_TEST|SavvyCheck Vaginal Yeast Test|Point-of-care test for the detection of vaginal candidosis
214300797|NCT04287504|DIAGNOSTIC_TEST|OSOM BVBLUE Test|Point-of-care test for the detection of bacterial vaginosis
214899174|NCT02486237|OTHER|None, observational study|None, it is an observational study
214899175|NCT04092309|DRUG|ACE inhibitor, Sacubitril-Valsartan|Search for Protective effect after chemotherapy and bone marrow transplantation
214899176|NCT00017693|BIOLOGICAL|Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)
214899177|NCT00017693|BIOLOGICAL|Placebo for Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
214899178|NCT04789993|OTHER|No intervention.|There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient.
214899179|NCT00003744|DRUG|gemcitabine|
214899180|NCT01152372|PROCEDURE|Insulin, glucose and staple isotopes|
215053457|NCT01964378|DRUG|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
215053458|NCT01964378|DRUG|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
215053459|NCT03686878|DRUG|Lifitegrast|Lifitegrast used twice a day
215053460|NCT03400410|BEHAVIORAL|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
215053461|NCT02655276|OTHER|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
215053462|NCT02655276|OTHER|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
214300798|NCT03061110|BIOLOGICAL|Stromal Vascular Fraction|Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.
214300799|NCT03061110|OTHER|Usual Care|Usual care will include over-the-counter and prescription methods to treat xerostomia.
214300800|NCT05408416|PROCEDURE|preoperative group and intraoperative group|ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
214300801|NCT05256121|OTHER|AD Risk factors balance|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants by phone every 3-4 weeks to inquire about risk factors data. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
214300802|NCT06050694|DRUG|glofitamab|Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
214300803|NCT01394523|DRUG|Bupivacaine|0.25% or 0.5%
214300804|NCT03573479|OTHER|PICU Liber8 Bundle|Bundle of elements for quality improvement
214300805|NCT04937296|BEHAVIORAL|Physical activity|Participants will be asked to perform resistance exercises 3-times a week on alternating days for 12 weeks. Exercises will be performed with a TheraBand and will include the squat, lunge, press-up, cross body reach, reverse fly, lateral raise, biceps curl, triceps extension, frontal raise and bridge. In addition to the resistance exercises, the participants will perform aerobic exercise. They will be asked to download a specific exercise app to record the number of steps on day 1 of the intervention and participants who do not possess the required phone technology will be provided with a pedometer. They then will be asked to add 2000 steps on to their daily steps; this amount will then become their daily step goal. Once they have reached this goal on 4 out of 5 days, they will be asked to increase their new step step goal by an extra 500 per day.
214300806|NCT04937296|OTHER|Usual care|Usual care.
214300807|NCT00225160|DRUG|acetyl L-carnitine|
214300808|NCT01829581|OTHER|no intervention, only descriptive data analysis|
214300809|NCT06209229|BIOLOGICAL|sodium nucleinate|"* Calcitriol- 5000 units in the morning before meals every other day 21 days and the next 3 weeks after the end of therapy.~* Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally 3 tablets per meter square of body surface area, in the evening 2 hours before bedtime, 21 days and the next 3 weeks after the end of therapy.~* Quercetin from onion juice - take orally 1000 mg in the morning before meals, 21 days, as well as the next 3 weeks after the end of therapy.~* sodium oligodinucleatide orally at the rate of 2 tablets under the tongue per meter square of body surface, in the morning 15 minutes before meals every other day, a total of 5 times (1, 3, 5, 7 , 9 day from the beginning of therapy), then after 21 days to repeat the course for 3 months.~* Spray natirium nucleonate 4 doses in the morning on the hyoid, suck, do not swallow for 3-5 minutes, once every 4 days for 21 days."
214478840|NCT06586541|OTHER|Participation in attending team rounds|Family members can participate both in-person and virtually, which can vary daily if desired. If the family member wishes to participate in-person, they will be invited to be present when the team rounds in the ICU. If the family member wishes to participate virtually, they will be provided with a personalized link by email to attend rounds.
214478841|NCT06602375|OTHER|Standard care|The standard care (control) group will follow the plan of care determined by their treating dental provider. These decisions will be based on the clinical judgment of the dental provider and subject desires. Intervention may include, but is not limited to typical patient education, pharmacotherapy, oral splinting or occlusal device, cryo/thermotherapy recommendations, and exercise handouts.
214478842|NCT06602375|OTHER|Physical Therapy (PT)|Participants randomized to this group will receive individualized, tailored courses of physical therapy care. Interventions may be directed at the temporomandibular, cervical, and/or scapulothoracic regions based on subject clinical presentation and impairments. Manual therapy joint and soft tissue mobilizations may be used to address pain, mobility, and motor control. Motor control exercises may be used to promote relaxation, improve range of motion, and appropriate postures. Strengthening exercise, primarily directed to the cervical and scapulothoracic regions, may be implemented as appropriate. Stretching exercise may be used to address pain and mobility deficits. The interventions are intentionally pragmatic; study participants will receive treatment as they are comfortable and as recommended by the treating therapist.
214899181|NCT00495807|BEHAVIORAL|No Words|Without any words was given during pain management
214899182|NCT00495807|BEHAVIORAL|Positive words|Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
214899183|NCT00495807|BEHAVIORAL|Partially Negative Words|Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
214899184|NCT00495807|BEHAVIORAL|Totally Negative Words|Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
214899185|NCT00962897|PROCEDURE|Femoral-popliteal bypass|Surgical bypass of blockage in the thigh
214899186|NCT00962897|PROCEDURE|Stent-graft placement|Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
214899187|NCT03500198|DEVICE|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL|Intraocular lens replaces the natural lens removed during cataract surgery.
214899188|NCT03500198|DEVICE|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL|Intraocular lens replaces the natural lens removed during cataract surgery.
214899189|NCT06424548|DRUG|Administration of Sarpogrelate|Aspirin 100mg plus Sarpogrelate 100mg
214899190|NCT06424548|DRUG|Traditional administration of Clopidogrel|Aspirin 100mg plus Clopidogrel 75mg
214300810|NCT03794557|DRUG|Sterile Water Injection|Inhaled Sterile Water Injection
214300811|NCT03794557|DRUG|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution
214899191|NCT00531167|DRUG|combination of lamivudine+adefovir vs entecavir|Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
214899192|NCT05845801|OTHER|Register|Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.
214899193|NCT02904772|DRUG|alipogene tiparvovec|A dose of 1x10(\*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
214899194|NCT02904772|DRUG|Prednisolone|IV bolus methylprednisolone 1mg/kg half hour prior to administration
214899195|NCT02904772|DRUG|Cyclosporins|Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
214899196|NCT02904772|DRUG|Mycophenolate mofetil|Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
214300812|NCT06018714|DRUG|Fruquintinib|"Drug:~Maintenance treatment regimen:~Fruquintinib 5 mg, qd, po, with three weeks of continuous treatment followed by one week of drug discontinuation. Each treatment cycle lasts four weeks. The treatment will be continued for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~Adverse drug reactions that occur during the trial will be graded according to the NCI CTCAE version 5.0 and dose adjustments will be made according to the corresponding rules."
214300813|NCT00905554|PROCEDURE|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
214300814|NCT00905554|PROCEDURE|air insufflation|air insufflation during the insertion phase of colonoscopy
214478843|NCT06824935|PROCEDURE|Anesthesia|The study planned to investigate the anesthesia requirements and frequency and the risk factors that play a role in the anesthesia of patients who had completed preoperative anesthesia evaluation and were going to undergo outpatient cataract surgery.
214899197|NCT01126242|DEVICE|Tape|Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
214899198|NCT01126242|DEVICE|Semi rigid brace|Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
214899199|NCT01126242|DEVICE|Lace-up brace|Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
214899200|NCT00755742|OTHER|Lifestyle intervention|"The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided."
214899201|NCT02165449|DRUG|Ketamine|Approved FDA indications for ketamine include use as an adjunct in the induction and maintenance of general anesthesia and for procedural sedation. For general anesthesia, ketamine is given at dosages ranging from 1-2mg/kg and given either as bolus injection or run continuously (0.1 to 0.3mg/kg/min) in conjunction with another anesthetic or sedation agent. In this study, ketamine at a subanesthetic dose of 0.5mg/kg will be diluted in 60cc of normal saline and administered via a slow IV infusion over 40 minutes at each treatment session in patients while undergoing hemodynamic monitoring. When used in this manner, ketamine infusion does not induce general anesthesia or states of unconsciousness, and patients remain fully awake, responsive to commands, and do not lose respiratory drive.
214899202|NCT01167478|DIETARY_SUPPLEMENT|Caffeine|After ingestion of 6 mg.kg-1 of body mass of caffeine, subjects will perform the one exercise trial.
214899203|NCT01167478|DIETARY_SUPPLEMENT|Caffeine|6 mg/kg of body mass of caffeine will be ingested by subjects before exercise.
214899204|NCT01551771|DRUG|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
214899205|NCT01551771|DRUG|GW824575 matched-placebo|Placebo
214899206|NCT02287792|PROCEDURE|18-FDG PET/CT scan|Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
214899207|NCT04347720|DRUG|Indomethacin|Intravenous formulation
214899208|NCT04347720|DRUG|Ibuprofen|Intravenous and oral formulations
214899209|NCT04347720|DRUG|Acetaminophen|Intravenous and oral formulations
215053463|NCT03542266|DRUG|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
214300815|NCT05429190|RADIATION|Short MRI surveillance (SMS) protocol|Bi-annual, non-contrast agents, MRI screening consisting of Diffusion Weighted Imaging (b-values of 50 and 800 s/mm2), T2-weighted imaging and T1-weighted in- and out-of-phase imaging
214300816|NCT05429190|RADIATION|Bi-annual ultrasonography screening|Bi-annual ultrasonography for screening of HCC in high-risk patients
214300817|NCT00373867|BEHAVIORAL|Standard physical therapy|Treatment-based classification physical therapy
214300818|NCT00373867|BEHAVIORAL|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
214300819|NCT00373867|OTHER|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
214300820|NCT04741074|DRUG|Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution|Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.
214478844|NCT06604637|OTHER|Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS)|taVNS will be applied for a total of 12 sessions, 20 minutes each session, 3 days/week.
214300821|NCT04741074|DRUG|Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution|Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
214300822|NCT00364884|DRUG|ketoaminoacid|
214300823|NCT01684631|DEVICE|Total Hip arthroplasty|
214300824|NCT02432846|BIOLOGICAL|Intuvax (INN: ilixadencel)|Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.
214300825|NCT02432846|DRUG|Sunitinib|Cytostatic/cytotoxic drug: protein kinase inhibitor .
214300826|NCT01770379|BIOLOGICAL|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
214300827|NCT01770379|BIOLOGICAL|Placebo|
214478845|NCT06824844|DRUG|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
214478846|NCT06824844|DRUG|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
214478847|NCT06597071|OTHER|NeuraLight PD|NeuraLight software-based platform for PD patients
214478848|NCT06597071|OTHER|NeuraLight PSP|NeuraLight software-based platform for PSP patients
214478849|NCT06597071|OTHER|NeuraLight MSA|NeuraLight software-based platform for MSA patients
214478850|NCT06597071|OTHER|NeuraLight|NeuraLight software-based platform
214478851|NCT06589297|DIAGNOSTIC_TEST|Modified Rankin scale|Acute stroke patients will undergo modified rankin scale
214478852|NCT06817681|DIETARY_SUPPLEMENT|Sodium Bicarbonate (NaHCO3)|Ingestion of gelatin capsules containing 0.4 g/kg body weight of sodium bicarbonate (NaHCO3) followed by 90 minutes of rest. Continuous high intensity cycling to be performed following 90-minute resting measures.
214478853|NCT06817681|OTHER|Placebo (Sodium Chloride)|Ingestion of gelatin capsules containing 0.4 g/kg body weight of sodium chloride (NaCl) followed by 90 minutes of rest. Continuous high intensity cycling to be performed following 90-minute resting measures.
214478854|NCT06825429|PROCEDURE|exercise programme for group with ECOG 0-1|exercise programme for group with ECOG 2
214478855|NCT06825429|PROCEDURE|exercise programme for ECOG 2 group|this intervention shall be proportionated to the ECOG status of the group
214899210|NCT04544774|DRUG|AIT|AIT for airborn allergens (SCIT/SLIT)
214899211|NCT04544774|DIAGNOSTIC_TEST|NAPT|NAPT test with airborn allergens ( HDM, Threes, Grasses)
214899212|NCT00595621|DEVICE|Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)|Multi-Channel Phased Gastric Pacemaker (MGP-1)
214899213|NCT04305743|DRUG|OnabotulinumtoxinA 100 UNT|Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
214899214|NCT00087815|DRUG|dexamethasone|
214899215|NCT00087815|DRUG|hyperbaric oxygen|
214899216|NCT00087815|PROCEDURE|cognitive assessment|
214899217|NCT00087815|PROCEDURE|magnetic resonance imaging|
214899218|NCT00087815|PROCEDURE|positron emission tomography|
214899219|NCT00087815|PROCEDURE|quality-of-life assessment|
214899220|NCT00324987|BIOLOGICAL|Bevacizumab|Given IV
214899221|NCT00324987|DRUG|Imatinib Mesylate|Given PO
214899222|NCT00324987|OTHER|Laboratory Biomarker Analysis|Correlative studies
214899223|NCT00324987|OTHER|Pharmacological Study|Correlative studies
214899224|NCT04551456|BIOLOGICAL|Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS|Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease
214899225|NCT04610905|BEHAVIORAL|Reducing sedentary behaviour|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours. The participants will receive a diary to write down whether they stand up.
214899226|NCT04610905|BEHAVIORAL|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. It can include walking, to ride a bike, jogging, tennis, football,... Additionnaly they need to be active in periods of at least 10 minutes. The participants will receive a diary to write down which activity they did and also for how long.
214899227|NCT04904211|OTHER|Home-based chemotherapy|To investigate the feasibility and safety of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Furthermore, we examined the quality of life (QOL) and psychological wellbeing while receiving induction and consolidation chemotherapy at home.
214899228|NCT00348127|DEVICE|Neurovision|
214899229|NCT02138877|PROCEDURE|After coming stent after dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.
214899230|NCT02138877|PROCEDURE|Stentless dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. No stents are inserted
214899231|NCT04699929|DRUG|YH001|YH001 will be administered intravenously over 60minutes every three weeks (Q3W) for up to 1 years .
214899232|NCT03295292|BIOLOGICAL|Stem cells|Mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in fibrin sealant
214899233|NCT03295292|OTHER|Vehicle|50uL of commercially available fibrin sealant (Baxter, TISEEL)
214899234|NCT04982289|DRUG|ALXN1830|Administered as an SC infusion.
214899235|NCT04982289|OTHER|Placebo|Administered as an SC infusion.
214300828|NCT03045887|DRUG|GSK2292767 50 μg|GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
214300829|NCT03045887|DRUG|GSK2292767 500 μg|GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
214300830|NCT03045887|DRUG|Placebo|Lactose as powder for inhalation
214300831|NCT03689998|DEVICE|immediate implant placement|immediate implant placement in freshly extraction socket
214899236|NCT05116501|DIAGNOSTIC_TEST|Whole-exome sequencing|Whole Exome Sequencing (WES), as a comprehensive genetic test, will be used to identify changes in a patient's DNA that are causative or related to patient's low VWF levels.
214899237|NCT05158673|DIETARY_SUPPLEMENT|Placebo of Cocoa flavonoids|Dietary supplement: The administration of two capsules of 500 mg orally of placebo (excipient q.s. starch capsule) 1 every 12 hours, for 12 weeks
214899238|NCT05158673|DIETARY_SUPPLEMENT|Cocoa flavonoids|Dietary supplement: Two 500 mg capsules of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours (one in the morning and one at night) for 12 weeks
215053464|NCT03542266|DRUG|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
215053465|NCT01015755|BEHAVIORAL|combined therapy treatment|mouth care
214899239|NCT00935116|DRUG|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
214899240|NCT02480517|DEVICE|Ultrasound|
214899241|NCT02480517|DEVICE|Sham Ultrasound|
215053466|NCT00135616|DEVICE|surgical placement of a suburethral sling tvt or tvt-o|
215053467|NCT02252640|BIOLOGICAL|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
215053468|NCT02252640|BIOLOGICAL|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
215053469|NCT02252640|BIOLOGICAL|ChAd63 ME-TRAP (5 x 10^10 vp)|
214899242|NCT01480323|DRUG|Interleukin-2|intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases
214899243|NCT01480323|DRUG|Ipilimumab|IV infusion, 3 mg/kg, day 2, 23, 44, 65
215053470|NCT02252640|BIOLOGICAL|MVA ME-TRAP (2 x 10^8 pfu)|
214478856|NCT06825988|DEVICE|Grasp|Grasp system (hardware and mobile application) during first 6 postsurgical weeks of rehabilitation. Subjects are instructed to report pain through squeezing the hardware in 3 different levels regulaly during the day, and, in addition enter answers to questions on patient reported outcome meassures (sleep quality, overall well-being, use of medication, appetit, physical activity) and register exercise time into the mobile application.
214899244|NCT02392481|PROCEDURE|Biofluid sampling|
214899245|NCT04365010|DRUG|Sodium Bicarbonate Ringer's Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
215053471|NCT04767672|DIETARY_SUPPLEMENT|Non digestible carbohydrates|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
215053472|NCT04767672|DIETARY_SUPPLEMENT|Placebo|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
215053473|NCT00838812|DRUG|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
215053474|NCT04914156|OTHER|Genetic based dietary advice|Genetic test results for 70 genes relating to nutrition and physical activity will be used in conjunction with participants current dietary intake to create nutrition advice tailored to each individual.
215053475|NCT04914156|OTHER|Personalised population based dietary advice|Current dietary intake will be compared with current best practice population-based sports nutrition dietary advice to create tailored nutrition advice for each of the participants
214300832|NCT03689998|DRUG|Melatonin|topical application of melatonin
214300833|NCT02400879|DRUG|Remifentanil|administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
214300834|NCT02400879|DRUG|sevoflurane and sufentanil|administering sevoflurane and sufentanil for anesthesia maintenance
214478857|NCT06819358|DEVICE|Transcranial Magnetic Stimulation|Patients in Group A will receive 2 weeks (10800 Hz daily, 5 days×2) of TMS treatment, while patients in Group B will receive sham stimulation with the same frequency. After a 4-week washout period, the two groups cross over. Patients in Group A will receive sham stimulation, and patients in Group B will receive TMS treatment for 2 weeks (10800 Hz daily, 5 days×2).
214478858|NCT06097494|OTHER|No intervention|Observational analysis of usual care only.
214899246|NCT04365010|DRUG|0.9% Sodium Chloride Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
214899247|NCT01410214|DRUG|Erlotinib|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
214300835|NCT04219982|DRUG|DPI-386 Nasal Gel|Nasal gel
214300836|NCT04219982|DRUG|DPI-386 Placebo Nasal Gel|DPI-386 Placebo Nasal Gel
214300837|NCT04219982|DRUG|Transderm Scop®|Transderm Scop®
214300838|NCT05353127|DIAGNOSTIC_TEST|CPET/Cardiopulmonary Exercise Test|During CPET, a patient exercises against a progressively increasing work rate until volitional exhaustion, while breath-by-breath respiratory gasses are analyzed.
214899248|NCT01410214|DRUG|vinorelbine/cisplatin|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
214300839|NCT03839511|PROCEDURE|Hyperinsulinemic-hypoglycemic clamp|Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.
214300840|NCT03145025|DEVICE|Retisert|Intravitreal Implant
214300841|NCT03145025|DRUG|Fluocinolone Acetonide Intravitreal Implant|Intravitreal Implant
214300842|NCT05413707|PROCEDURE|Fixation of the posterior malleolus fractures|Fixation of the posterior malleolus fracture with screws and or plating.
214300843|NCT05413707|PROCEDURE|Fixation of lateral and/or medial malleolus fractures|Fixation with screws and/or plating
214300844|NCT05413707|PROCEDURE|Syndesmotic fixation|Fixation of unstable syndesmosis with one or two 3.5 mm tricortical screws, or with a suture button.
214478859|NCT06594757|PROCEDURE|Toothbrushing with triple-headed manual toothbrush|Toothbrushing with triple-headed manual toothbrush
214478860|NCT06594757|PROCEDURE|Toothbrushing with standard manual toothbrush|Toothbrushing with tstandard manual toothbrush
214899249|NCT03690050|PROCEDURE|Diode 577 nm subthreshold micropulse laser|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The DSML surgery will be performed by an Ophthamologist
214478861|NCT06444594|DRUG|TRPM8 Agonist|menthol gel 4-10%
214478862|NCT06444594|DRUG|TRPV1 Agonist|camphor gel 5-20%
214478863|NCT06444594|DRUG|TRPV4 Agonist|capsaicin gel 0.05-1%%
214478864|NCT06444594|DRUG|TRPM8, TRPV4, TRPV1 Agonists|menthol (4-10%), capsaicin (0.05-1%), camphor (5-20%)
214478865|NCT06444594|OTHER|Vehicle gel|Inactive vehicle gel
214478866|NCT06597344|DRUG|Gepotidacin|Gepotidacin will be administered.
214478867|NCT06589765|DRUG|HRS-7535 tablet|HRS-7535 tablet
214478868|NCT06589765|DRUG|dapagliflozin tablet|dapagliflozin tablet
214899250|NCT03690050|PROCEDURE|Standard threshold laser (532 nm laser)|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The standard laser surgery will be performed by an Ophthamologist
214899251|NCT00268450|BIOLOGICAL|bevacizumab|"Before surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 4 cycles~After surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 3 cycles"
214899252|NCT00268450|DRUG|cisplatin|Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
214899253|NCT00268450|DRUG|gemcitabine hydrochloride|Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
214899254|NCT00268450|DRUG|paclitaxel|After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles
214899255|NCT00268450|PROCEDURE|cysectomy|
214899256|NCT01068639|BEHAVIORAL|No treatment given|No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
214899257|NCT02780258|DEVICE|Restylane Silk|
214300845|NCT04434690|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeons bilateral TKA group
214300846|NCT04434690|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
214300847|NCT01912287|BEHAVIORAL|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
214300848|NCT01912287|BEHAVIORAL|Stress Education|Active control group (12 sessions)
214300849|NCT01912287|BEHAVIORAL|Yoga|12 sessions, mindfulness components
214300850|NCT04094922|BEHAVIORAL|Swedish PTSD Coach smartphone app|Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
214300851|NCT02287558|DRUG|Pomalidomide|
214478869|NCT06587464|OTHER|No Intervention|This is a non-interventional study.
214478870|NCT06603441|DIAGNOSTIC_TEST|Samsung Galaxy Watch|Samsung Galaxy Watch technology to monitor sleep patterns, oxygen saturation, PPG, and heart rate variability amongst other physiologic parameters.
214478873|NCT06599359|BEHAVIORAL|BLISS Questionnaire|"After extensive literature review and review from the IRB of the Lebanese University. A questionnaire was developed to assess the Intention to leave, job stress, burnout, and job satisfaction among pharmacists in Lebanon~The following sections will be considered:~* Socio-economic characteristics~* Work-related characteristics~* Job stress assessment (Likert scale)~* Burnout assessment (Likert scale)~* Intention to Leave assessment (Likert scale)"
214478874|NCT06857305|DRUG|Eribulin biweekly regimen|Eribulin biweekly regimen
214899258|NCT05370625|DIETARY_SUPPLEMENT|Totum-854|To compare Totum-854 with Placebo on blood pressure
214899259|NCT05370625|DIETARY_SUPPLEMENT|Placebo|Five capsules per day to consume orally in two intakes
214899260|NCT06067841|DRUG|BMS-986460|Specified dose on specified days.
214899261|NCT05464979|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation.
214899262|NCT05464979|DRUG|midazolam, fentanyl|Midazolam at 0.1mg/kg BW, fentanyl at 1ug/kg BW, rocuronium bromide at 0.6mg/kg BW was given intravenously for induction intubation; After the intubation was completed, sufentanil at 0.1 μg/kg/h was administered for analgesia, and remazolam tosylate at an initial dose of 0.075 mg/kg/h was administered for sedation, and the dose of remazolam tosylate was adjusted according to the RASS score.
214899263|NCT00005575|DRUG|Imipramine|
214899264|NCT00005575|BEHAVIORAL|Cognitive-behavior therapy|
214899265|NCT01644656|DEVICE|ARFI ultrasound|ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
214899266|NCT02766270|DRUG|Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).
214899267|NCT02766270|RADIATION|Radiotherapy|
214899268|NCT02545582|DEVICE|VITARIA System|Implantable vagus nerve stimulator
214300852|NCT06201117|BEHAVIORAL|Preparatory information for ICU stay|Preparatory information for ICU stay after cardiac surgery via 12-minute digital media
214300853|NCT06201117|BEHAVIORAL|Usual information|Preoperative information that is given to patients before having cardiac surgery
214300854|NCT03294395|DRUG|Ertapenem 1000 MG|single dose 1000mg intramuscular injection
214300855|NCT03294395|DRUG|Fosfomycin Oral Suspension|single dose 6g oral suspension
214300856|NCT03294395|DRUG|Gentamicin Sulfate, Injectable|single dose 5mg/kg (maximum 400mg) intramuscular injection
214478875|NCT06857305|DRUG|Eribulin standard regimen|Eribulin standard regimen
214899269|NCT05755880|PROCEDURE|Intrathecal dexamethason|After general anesthesia intrathecal dexamthasone will be added
214899270|NCT01254643|BIOLOGICAL|V503|V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
214899271|NCT01200693|DEVICE|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
214899272|NCT01200693|DEVICE|Everolimus eluting stent|Implantation of Everolimus eluting stent
214899273|NCT01200693|DEVICE|Zotarolimus eluting stent|Implantation of Zotarolimus eluting stent
214899274|NCT01598961|OTHER|TOF count-guided partial NMB|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
214899275|NCT01598961|OTHER|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
214899276|NCT01598961|OTHER|No NMB|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
214899277|NCT03485144|BIOLOGICAL|TV003|Live attenuated virus vaccine-TetraVax-DV
214899278|NCT03485144|BIOLOGICAL|Placebo for TV003|Placebo
214899279|NCT03998267|DEVICE|Droobi|A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.
214899280|NCT03998267|OTHER|Standard of care|Standard of care including physicians, dietetics and diabetes educators support
214300857|NCT03294395|DRUG|Ceftriaxone|single dose 500mg intramuscular injection
214300858|NCT02763852|DRUG|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
214300859|NCT02763852|DRUG|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
214300860|NCT02763852|DRUG|Madopar® 125|Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
214300861|NCT00000296|DRUG|Cotinine fumarate|
214899281|NCT03253614|DIAGNOSTIC_TEST|Audiometry|Extended high-frequency (EHF; 9-16 kHz) audiometry
214899282|NCT03253614|DIAGNOSTIC_TEST|Urine biomarkers for renal tubular function|Kidney Injury Molecule-1
214899283|NCT03253614|DIAGNOSTIC_TEST|Blood pressure|Blood pressure right arm, measured With standard Methods 3 times
214899284|NCT03817125|DRUG|Placebo for antibiotic|Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.
214899285|NCT03817125|DRUG|Vancomycin pretreatment|Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.
214899286|NCT03817125|DRUG|Nivolumab|Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.
214899287|NCT03817125|DRUG|Matching Placebo for SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
214300862|NCT06117384|GENETIC|Biomolecular profiling|Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.
214899288|NCT03817125|DRUG|SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
214899289|NCT03979391|DIAGNOSTIC_TEST|Tear collection and lumbar punction|Tear collection and lumbar punction will be performed in order to detect supernumerary oligoclonal bands
214899290|NCT01797874|DRUG|Pazopanib|Experimental
214899291|NCT01797874|DRUG|Placebo|placebo arm
214899292|NCT01998919|DRUG|erlotinib [Tarceva]|150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
214899293|NCT01998919|DRUG|placebo|orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
214899294|NCT01998919|DRUG|gemcitabine|1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
214899295|NCT01998919|DRUG|cisplatin|75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
214899296|NCT01998919|DRUG|carboplatin|5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
214899297|NCT04455867|BEHAVIORAL|Diabetes Exercise and Healthy Lifestyle Program|The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.
214899298|NCT04455867|OTHER|Outpatient care|Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education
215053476|NCT01183429|DRUG|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. \*High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
214478876|NCT05106036|OTHER|Clinical Support Decision Tool|Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
214300863|NCT02929823|DRUG|High Dose SJP-0035 Ophthalmic Solution|0.001% SJP-0035 Ophthalmic Solution
214300864|NCT02929823|DRUG|Low Dose SJP-0035 Ophthalmic Solution|0.0002% SJP-0035 Ophthalmic Solution
215053477|NCT05807152|DEVICE|RenalGuard device|Patients will be given an intravenous loading dose of 40 mg of furosemide and continuous infusion of furosemide based on baseline eGFR. An additional bolus of 40 mg of furosemide will be administered and the infusion rate increased according to the same protocol of the control group (Figure 1). The venous peripheral cannula will be connected with the extracorporeal circuit of the RenalGuard System (PLC Medical Systems Inc., MA) for fluid infusion. The RenalGuard System is capable of delivering sterile replacement solution to a patient in an amount matched, or higher or lower, to the volume of urine produced by the patient. Thus, in the RenalGuard group, estimated daily targeted negative fluid balance will be utilized to define, for each patient, hourly negative fluid balance to be set in the RenalGuard system display.
214300865|NCT02929823|DRUG|Vehicle of SJP-0035 Ophthalmic solution|0% SJP-0035 Ophthalmic Solution
214300866|NCT03758144|DRUG|Rifaximin 200 MG|patients with type 2 diabetes and gut dysbiosis will be given rifaximin
214300867|NCT05137743|BEHAVIORAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
214300868|NCT05137743|BEHAVIORAL|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
214300869|NCT06181097|DEVICE|negative pressure wound therapy|The intervention group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The Smith \& Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility.
214478877|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 48-hour course of antibiotics.
214478878|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 7 day course of antibiotics.
214478879|NCT06589128|DIETARY_SUPPLEMENT|Astaxanthin Oral Capsule|Once daily supplementation of oral astaxanthin capsule for 24 weeks
214478880|NCT06589128|DIETARY_SUPPLEMENT|Placebo|Once daily supplementation of olive oil capsule for 24 weeks
214899299|NCT00150735|DRUG|LEVETIRACETAM|
215053478|NCT05009576|OTHER|silver alginate|silver alginate hydrofiber dressing
215053479|NCT05009576|OTHER|VAC dressing without silver alginate|vaccum assisted dressing
215053480|NCT05789498|OTHER|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
215053481|NCT04832529|PROCEDURE|No packing of perianal abscess cavity|introducing new method to no packing of abscess cavity.
214300870|NCT06181097|OTHER|standard dressing|The standard dressing group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The same PICO dressing will be applied, but without the suction.
214300871|NCT00758082|DEVICE|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
214300872|NCT00758082|DEVICE|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
214300873|NCT03226392|DRUG|QAW039|QAW039 once daily
214300874|NCT03226392|DRUG|Placebo|Placebo once daily
214478881|NCT04861636|BEHAVIORAL|HealthTRAC|Behavioral weight management intervention targeting emotion regulation skill building. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
214478882|NCT04861636|BEHAVIORAL|SBWC|Behavioral intervention focused on behavioral weight control. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
214478883|NCT06597500|DRUG|GSK3923868|GSK3923868 will be administered.
214478884|NCT06597500|DRUG|Itraconazole|Itraconazole will be administered.
214899300|NCT03359993|PROCEDURE|Premedication of intubation|The umbilical vein is punctured to inject drugs efficiently. The access is simple, the umbilical vein is clearly visible, and a blood reflux can be found easily. We used the same equipment required for a peripheral venous injection: 24 gauge cannula, antisepsis, compress, and a syringe with the prepared anesthetic drugs. We report 5 cases of intubations in the delivery room using this method to administer the premedication.
215053482|NCT05789459|DEVICE|Stapler|Stapler
215053483|NCT05789459|OTHER|Suture|Suture
215053484|NCT05324592|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously."
215053485|NCT05324592|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~One dose(2mg) of the drug will be injected intravitreously."
215053486|NCT06184230|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine
215053487|NCT05881681|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
215053488|NCT00149799|DRUG|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
215053489|NCT00149799|DRUG|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
214300875|NCT02357901|DRUG|SUBOXONE|SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
214300876|NCT02357901|DRUG|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
214300877|NCT02357901|DRUG|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
214300878|NCT02547467|OTHER|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
214300879|NCT02963207|OTHER|Modified Sano's classification|Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
214300880|NCT02963207|OTHER|NICE classification|Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
214300881|NCT02834533|DEVICE|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
214300882|NCT05616156|DEVICE|Cre8™ BTK|Implant of Cre8™ BTK stent the treatment of infrapopliteal peripheral artery disease
214899301|NCT00987532|BEHAVIORAL|parent-focused intervention|The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
214300883|NCT02856633|DEVICE|Vitaliti|
214300884|NCT03808051|PROCEDURE|Physiological-based cord clamping|See Arm description.
214300885|NCT03808051|PROCEDURE|Time-based cord clamping|See Arm description.
214300886|NCT03643094|DIETARY_SUPPLEMENT|Golden Black Seed|1 capsule per day for 8 weeks.
214300887|NCT04246294|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care."
214300888|NCT00838058|DRUG|CE-224,535|one 250mg tablet, once in the morning in fasted state
214300889|NCT00838058|DRUG|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
214899302|NCT00987532|BEHAVIORAL|twice weekly gym lessons|twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
214899303|NCT04412356|PROCEDURE|Tracheotomy|Surgical procedure to secure airway
214899304|NCT01059838|BEHAVIORAL|sentence recognition|testing the ability for sentence recognition in quiet and in noise.
215053490|NCT00969163|DRUG|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
214300890|NCT00838058|DRUG|CE-224,535|4x250mg tablets, once in the morning, in fasted state
214300891|NCT00838058|DRUG|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
214300892|NCT00838058|DRUG|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
214300893|NCT00838058|DRUG|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
215053491|NCT00969163|DRUG|Comparator: placebo|transdermal placebo gel for 6 weeks
215053492|NCT00452075|DRUG|erlotinib|150mg daily
215053493|NCT01495533|DEVICE|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
215053494|NCT01495533|COMBINATION_PRODUCT|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
214300894|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
214899305|NCT00576719|BEHAVIORAL|Intensive panic control treatment without parent involvement|Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
214899306|NCT00576719|BEHAVIORAL|Intensive panic control treatment with parent involvement|Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
214899307|NCT00576719|OTHER|Waitlist control|Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
214899308|NCT05962385|DEVICE|Brain state while receiving TMS|Brain state whilst receiving TMS - cognitive control or perceptual. Repeated measures design, so all participants receive the same procedures.
214899309|NCT01157793|DRUG|r-hGH|r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route
214899310|NCT01157793|DRUG|r-hGH|Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route
214899311|NCT04086056|OTHER|NIRS monitoring|Regional cerebral oxygen saturation (rScO₂) will be collected by NIRS monitoring before anesthesia induction, during surgery and after extubation, in children with craniosynostosis.
214899312|NCT04478383|PROCEDURE|a new transosseous suture technique|a new technique using the spur base on the insertional site to drill the suture tunnel to repair Achilles sleeve avulsion.
214899313|NCT01242293|OTHER|0.9% Saline with glucose 5%|intravenous hydration at a rate of 125 ml per hour during labor
214899314|NCT01242293|OTHER|Ringer lactate|intravenous hydration at a rate of 250 ml per hour during labor
214899315|NCT01242293|OTHER|Ringer lactate - Controls|intravenous hydration at a rate of 125 ml per hour during labor
214899316|NCT01342471|BEHAVIORAL|TV commercial stepping|"Participants were instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
214899317|NCT01342471|BEHAVIORAL|30-min walk|"Participants were instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
214899318|NCT03295071|OTHER|Patient-reported outcomes (PROs)|Patient-reported outcomes (PROs)
214899319|NCT03655171|DIAGNOSTIC_TEST|Video-based quantitative methods|The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.
214899320|NCT02088177|DRUG|Long-acting injectable naltrexone|Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
214899321|NCT01910493|BEHAVIORAL|SMS reminders|Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
214899322|NCT02534051|OTHER|Clinical Care Pathway|The clinical care pathway guides aspects of care specific to obese pregnant women:1st trimester: offer of testing for pre-existing diabetes with either 75g OGTT or 50g GCT, nuchal translucency ultrasound (u/s), calculation of body mass index, counselling about weight gain, advising about medical complications, screening for obstructive sleep apnea, and referral to Maternal-Fetal Medicine if history of bariatric surgery, 2nd trimester: offer of maternal-serum alpha fetal protein (spina bifida), anatomy u/s, and 50g GCT and 75g OGTT, 3rd trimester: offer of consultation with anesthesiology, u/s for growth \& well-being, counselling about birth risks, and discussion of breastfeeding.
214899323|NCT06206304|OTHER|Root canal therapy|Traditional root canal therapy was performed with rubber-dam isolation.
214899324|NCT05234801|DEVICE|DARCO™ Headed Cannulated Screw|The DARCO™ Headed Cannulated Screw is a multi-size screw system designed to be used over a guide pin or wire with instrumentation to provide interfragmentary compression and stability for bone fracture/fragment fixation.
214300895|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
214300896|NCT02943720|DRUG|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
214300897|NCT02943720|DRUG|placebo|placebo
214899325|NCT05234801|DEVICE|ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System|A multi-indication foot reconstruction solution providing indication specific implants and instruments designed to address the unique demands of the forefoot and midfoot.
214899326|NCT05234801|DEVICE|ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module|A comprehensive fixation system consisting of a wide variety of plate options, created with the purpose of stabilization and fixation of fractures, revision procedures, joint fusion and reconstruction of small bones of the feet.
214899327|NCT00596531|DRUG|Acamprosate|Oral administration, 666 mg, tid, for 4 months
214899328|NCT00596531|DRUG|Placebo|Oral administration of 2 pills, tid, for 4 months
214300898|NCT05266755|OTHER|Fracture Territorial Liaison Service afert a Hip fracture|Give a diferent than the current one way of follow up to the patients with hip fracture
214300899|NCT05040854|GENETIC|HLA-DQA1*05 and DRB1|All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1
214300900|NCT05766475|BEHAVIORAL|ROSE Program: In Person|In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
214300901|NCT05766475|BEHAVIORAL|ROSE Program: Virtual|Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
214899329|NCT06205862|PROCEDURE|fecal microbiota transplantation|We will use fecal suspensions and capsules prepared from the feces of healthy donors for fecal microbiota transplantation. Participants are required to complete one colonoscopy and infuse 150ml of fecal suspension into the terminal ileum under endoscopy, performing the first fecal microbiota transplantation (FMT) on day 0. Subsequently, for 2 days continuously (day 1-2), the participants will undergo microbiota transplantation in the form of oral capsules, taking 40 FMT capsules within one day (20 capsules bid). Subsequently, participants will receive a maintenance treatment with oral FMT capsules (20 capsules bid) at 3, 6, and 9 months (approximately every 75 to 90 days). Participants will undergo their first follow-up colonoscopy between 6 to 12 months(the high-risk adenoma group will receive colonoscopy at 6 months, and the low-risk adenoma group will receive colonoscopy at 12 months).
214899330|NCT01774760|DRUG|18F-EF5|
214899331|NCT01774760|PROCEDURE|Pretreatment PET/CT-scan (performed two times)|
214899332|NCT05714592|OTHER|Blood sample|The referring haematologist will suggest that the patient participate in the study during the consultation. In these patients, the investigators will perform OGM on the cytogenetic sample
214899333|NCT01730989|DIETARY_SUPPLEMENT|Estromineral Serena Plus|
214300902|NCT04699708|DEVICE|Carbon dioxide monitoring|Blinded recording of CO2 during preterm resuscitation.
214300903|NCT05160831|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.
214899334|NCT01730989|DIETARY_SUPPLEMENT|Estromineral|
214899335|NCT05582889|BEHAVIORAL|Fitbit Intervention|Participants receive a Fitbit activity tracker and the free Fitbit smartphone app. A trained health coach provides technical support to set up and use the Fitbit and app. The health coach also provides motivational counseling to help participants to gradually increase the number of steps per day during the 12-weeks.
214899336|NCT05733429|OTHER|eye cervical re-education|patients will receive eye-cervical re-education in the form of 10 exercises at three phases; the first phase will include stimulation of ocular mobility, the second phase will consist of Cervical mobility exercise with restricted eye movement and the third phase will include stimulation of eye and neck movement co-ordination
214899337|NCT05733429|OTHER|motor imagery therapy|the patients will receive motor imagery therapy for four weeks; the first week will receive kinesthetic imagery, the second week will receive visual imagery, the third week will receive action observation exercises with motor imagery and the fourth week will receive motor control exercises in front of a mirror.
214899338|NCT05733429|OTHER|conventional physical therapy|the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
214899339|NCT03801135|DRUG|Fibrinogen concentrate|Haemocomplettan will be infused after plasma exchange procedure
214899340|NCT03801135|OTHER|Fresh Frozen Plasma|Fresh frozen plasma will be part of replacement fluid
214899341|NCT01268631|DRUG|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
214300904|NCT02237859|DRUG|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
214300905|NCT02237859|DIETARY_SUPPLEMENT|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
214300906|NCT06037720|DEVICE|Coaguchek testing|Patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.
214300907|NCT00491387|DRUG|Metoprolol Succinate|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
214300908|NCT03592147|OTHER|Guided Imagery Relaxation Tape|The meditation is approximately 7 minutes in duration.
214300909|NCT03592147|OTHER|Music Listening|Participants have the option of selecting one of the following music categories: New age, classical, and oriental. The songs were selected based on criteria established in a previous study to induce relaxation. All songs were also modified in length to be approximately 7 minutes in duration.
214300910|NCT03592147|OTHER|Relaxation Lighting|The participants were asked to select either orange or blue lighting settings using the Philips Hue lighting. The intensity of the light will be fixed to control for that measure. They were asked to sit for approximately 7 minutes in duration.
214300911|NCT03592147|OTHER|Meditation and Relaxation Light|The guided imagery meditation and relaxation lighting were combined.
214300912|NCT03592147|OTHER|Music and Relaxation Light|The music and relaxation lighting were combined.
214300913|NCT03592147|OTHER|Control/Silence|The participants were asked to relax for a duration of 7 minutes, with no explicit advice given. Lighting was adjusted to a specific intensity and colour (basic yellow light) as was used in the music and guided imagery interventions.
214300914|NCT02621242|PROCEDURE|Upper endoscopy|Upper endoscopy with biopsies
214300915|NCT02621242|PROCEDURE|Anoscopy|Anoscopy with biopsies
214300916|NCT02621242|DRUG|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
214300917|NCT02276729|OTHER|Mirror Box Therapy|Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
214300918|NCT06228040|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
214300919|NCT06228040|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
214300920|NCT02631850|BEHAVIORAL|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
214669443|NCT01588197|BEHAVIORAL|Attention/Distraction Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
214669444|NCT01588197|BEHAVIORAL|Stimulus Quality/Severity Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
214669445|NCT01588197|BEHAVIORAL|Control Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
214669446|NCT05891743|DIAGNOSTIC_TEST|Patch Test|The Patch Test will include the European baseline series, as well as the epoxy and isocyanate series. Additionally, specific products commonly used in the workplace, such as glues, resins, and paints, will be prepared and included in the testing.
214300921|NCT02631850|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
214300922|NCT02631850|BEHAVIORAL|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
214300923|NCT02631850|BEHAVIORAL|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
214899342|NCT01268631|DRUG|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
214899343|NCT01976026|DEVICE|Flow Diversion|
214899344|NCT01976026|DEVICE|Best Standard Therapy|
214899345|NCT02651701|PROCEDURE|MR-PET|whole body MR-PET with dedicated liver+rectal protocol
214899346|NCT01681446|DRUG|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
214899347|NCT05603169|OTHER|High intensity resistance Exercise Training|The resistance training will consist of five resistance exercises (thrice a week on non-consecutive days): squat, leg press, knee extension, lunges, and abdominal crunches. Every participant will be assessed pre and post intervention for hormonal change, BMI/anthropometric measures, fasting glucose and quality of life.The plan will be followed for 12 weeks
214899348|NCT05603169|OTHER|High intensity aerobic Exercise Training|The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
214899349|NCT01228201|BEHAVIORAL|Moderate continuous training|Three training sessions per week in a total of 12 weeks
214899350|NCT01228201|BEHAVIORAL|Aerobic interval training|Three training sessions per week in a total of 12 weeks
214899351|NCT01352572|DRUG|antidepressant response|Antidepressants administration for 6 weeks under therapeutic dose responders
214899352|NCT01352572|DRUG|antidepressant non-response|Antidepressants administration for 6 weeks under therapeutic dose nonresponders
214899353|NCT04435912|DRUG|Hydrocortisone 200mg IV|single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine
214899354|NCT01778530|DRUG|TRC105|Intravenous infusion.
214899355|NCT02420925|PROCEDURE|Celiac Plexus Block|Patients will undergo celiac plexus block via upper endoscopy with endoscopic ultrasound guidance. Injections will be performed using 0.75% bupivicaine and 40mg/ml of triamcinolone, ideally 1ml each directly into the celiac ganglia. If no ganglia is identifiable, then the injection will be performed into the celiac space, located at the take off of the celiac artery from the aorta.
214899356|NCT01199939|DRUG|Etravirine|400mg once daily orally for 48 weeks
214899357|NCT01199939|DRUG|Ritonavir|100mg once daily orally for 48 weeks
214899358|NCT01199939|DRUG|Darunavir|800mg once daily orally for 48 weeks
214899359|NCT01962610|OTHER|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit.
214899360|NCT00535210|BEHAVIORAL|Cardiovascular training|The cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. This program will last for 6 weeks while the participant is in the hospital. The cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital.
214899361|NCT00535210|BEHAVIORAL|Balance training|The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital. The balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.
215053495|NCT05453071|OTHER|Cognitive Exercise Therapy Approach (BETY)|BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
214669447|NCT04969393|DEVICE|High intensity laser therapy|"Fifteen treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 5 weeks in succession via EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. Patients in group (A) received HILT along with the conventional physical therapy program. The session involved 3 subphases: (1) The Initial phase Analgesic phase, (2) In the intermediate phase Trigger point phaseand (3)The final phase Bio-stimulation phase was applied for 6 minutes with a slow scanning in several parallel longitudinal lines."
214899362|NCT04952181|DEVICE|optical biometry|optical biometry is a fast, noncontact method it uses the method of partial coherence interferometry (PCI) to measure the axial length (AXL), based on reflection of the interference signal of the retinal pigment epithelium.
214899363|NCT04952181|DEVICE|ultrasonic biometry|ultrasonic biometry is contact method depends on ultrasonic transducer producing thin sound beam travelling through different media of the eye when it faces interface of substance dissimilar from that it is travelling through part is reflecting and the other travel through the different substance
214899364|NCT04868695|PROCEDURE|1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3|1\) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
214899365|NCT04696224|DRUG|Tranexamic acid|The surgical technique consists in patient in supina position with previous reduction with lower limb traction (on a traction table or manual) associated or not with the use of percutaneous reduction clamps. Longitudinal lateral incision of 3-5 cm proximal to the greater trochanter, approximately 5 cm long, will be performed. After the skin and subcutaneous incision, the fascia lata will be incised in the same direction, with exposure of the gluteal muscles and the proximal femur. The awl will be introduced at the tip of the greater trochanter and then, at the same location, an intramedullary guidewire, towards the proximal shaft, crossing the fracture. A 3 cm incision to the thigh and inferior to the initial incision with template to introduce the screw in the center of the femoral head. Then, a 2cm incision will be made at the distal end of the nail, and a hole in the femur for the distal lock in dynamic nail hole with a 4.5mm drill where a cortical screw will be inserted.
214899366|NCT04696224|OTHER|Saline solution|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2
214899367|NCT01894919|BIOLOGICAL|Bexsero® vaccine (1 dose at study month zero)|
214899368|NCT01894919|BIOLOGICAL|Bexsero® vaccine (2 doses 1 month apart)|
214899369|NCT04291313|DIETARY_SUPPLEMENT|Vitamin D3 (90µg)|The intervention is a higher dose of vitamin D than what is currently recommended to Danish pregnant women
214899370|NCT04291313|DIETARY_SUPPLEMENT|Vitamin D3 (10µg)|This intervention serves as a control as they get the current recommended vitamin D dose
214899371|NCT01255488|BEHAVIORAL|Access to EBN-Search (without full-text manuscripts)|Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
214899372|NCT01433471|DRUG|Trichuris suis ova|2,500 eggs by mouth every two weeks for 12 weeks
214899373|NCT01823861|BEHAVIORAL|Mobile phone-based intervention|Automated voice message to support post-abortion contraception use every two weeks for total of three months. Direct follow up phone call by family planning counsellor depending on response to voice message.
214899374|NCT03711188|DRUG|Nivolumab|Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.
214899375|NCT03711188|DRUG|Ipilimumab|Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.
215053496|NCT02821156|DRUG||Inhaled Nitric Oxide with monitoring by EZ-KINOX device
215053497|NCT01191515|DEVICE|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
215053498|NCT06120686|OTHER|Biofeedback method|Study group - implementing a conventional therapy program supplemented additionally with visual and auditory biofeedback training on a dynamic balance platform
214300924|NCT05501184|OTHER|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
214300925|NCT05501184|OTHER|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
214300926|NCT04098107|DEVICE|Throwing Device|The Innovative Design Labs ( IDL) PhySens will be used to monitor the physical motions of subjects during standard sports-related actions (e.g. throwing a baseball). For this test, the PhySens Carrier will be attached via clothing rivets to a fabric sleeve or strap made of compliant materials commonly used in clothing and wearable products (e.g. nylon, spandex, neoprene).
214300927|NCT01415063|PROCEDURE|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
214300928|NCT01415063|PROCEDURE|TACE-RFA|TACE first, then RFA within 2 weeks
214300929|NCT03022344|RADIATION|Cardiac CT|
214300930|NCT03013439|DRUG|Iron Isomaltoside|The trial is a dose escalating trial.
214300931|NCT06133192|DRUG|Uvadex|Uvadex use for ECP
214300932|NCT06133192|DRUG|Steroids|steroids 2 mg/kg/d
214300933|NCT05240560|DRUG|BP1.3656|Histamine H3 receptor antagonist/inverse agonist
214899376|NCT03711188|DRUG|IMM-101|A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
214300934|NCT05972499|OTHER|task-oriented training with pretend play|"Pretend play: Children engage in pretend play by acting out themes, taking on roles, assigning attributes to inanimate objects, and using objects as if they were something else Props will be added to hold the child interest. Role play costumes, or occupation props (police officer's suit), stimulate pretending elements.~Task-oriented training: It is involving the active, repetitive practice of functional activities to learn or relearn a motor skill. Training implies that the behavioral experiences are not just repetition of the same sensorimotor skill but involves progressive challenges to a participant's capabilities and involves tasks that are meaningful to the participant. It is based on the following principles: functional goal-directed training focus on practicing specific activities of importance to the child during daily activities; planning activity-focused interventions by adapting knowledge of motor learning ; and allowing for the interest and participation of the children."
214300935|NCT03331146|DRUG|Saline|A placebo (saline infusion) will be administered after induction of general anesthesia.
214899377|NCT03521388|BEHAVIORAL|Take care of your mood (CUIDA TU ANIMO in Spanish)|The adolescents will be registered in the Website www.cuidatuanimo.org
214899378|NCT03521388|OTHER|Control|The adolescents will visit the Website www.cuidatuanimo.org, but they can not register
214899379|NCT03726697|OTHER|Tahneek|A single dose of soft date containing glucose equivalent to 200mg/kg at 1 h after birth will be massaged into the buccal mucosa of the palate and cheek from right to left side, until the date paste is fully absorbed
214899380|NCT03196583|DEVICE|Velo-Lingual Bite (BVL)|The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
214899381|NCT03700983|DIETARY_SUPPLEMENT|Nutri-PEITC jelly|an edible, easily to swallow nutritious gel containing a bioactive compound PEITC
214899382|NCT04780893|DEVICE|Modius Sleep|The device utilizes a technology called vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
214899383|NCT03238651|DRUG|TAK-659|TAK-659 Tablets.
214899384|NCT00000876|DRUG|CD4-IgG2|
214899385|NCT05580874|OTHER|Massage|The babies in the massage group were given a massage once a day.
214899386|NCT05580874|OTHER|Swaddling|Control group
214899387|NCT00483444|BEHAVIORAL|Scheduled telephone follow-up|Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
214899388|NCT03875508|DRUG|Risankizumab|Risankizumab to be injected subcutaneously (SC)
214899389|NCT03875508|DEVICE|Autoinjector|Single dose pre-filled autoinjector containing risankizumab for SC injection
214899390|NCT06000150|DIAGNOSTIC_TEST|Corneal topography|AS-OCT,PENTACAM
214899391|NCT03048708|PROCEDURE|Bariatric surgery|patients who had received treatment with bariatric surgery for medical reasons
214899392|NCT01400477|DRUG|DMXB-A-SR|Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
214899393|NCT01400477|OTHER|Placebo|Placebo Comparator
214899394|NCT00401648|DRUG|Brivaracetam|
214899395|NCT00316511|DRUG|Aroplatin|
214899396|NCT05947383|DRUG|Psilocybin|Psilocybin 25 mg oral capsule
214899397|NCT05947383|DRUG|Placebo|Niacin 100 mg oral capsule
214899398|NCT01270438|DRUG|FOLFOX regimen|Given IV
214899399|NCT01270438|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
214899400|NCT01270438|BIOLOGICAL|bevacizumab|Given IV
214899401|NCT01270438|DRUG|oxaliplatin|Given IV
214300936|NCT03331146|DRUG|Sodium Nitrite|Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
214300937|NCT00217139|DRUG|Celgosivir|
214300938|NCT04727229|DRUG|Bupivacaine Hydrochloride|Injection of Bupivacaine near the stellate ganglion
214300939|NCT04727229|DRUG|Normal Saline|Injection of Normal Saline near the stellate ganglion
214300940|NCT02982850|DRUG|Dabigatran|
214899402|NCT01270438|DRUG|leucovorin calcium|Given IV
214899403|NCT01270438|DRUG|fluorouracil|Given IV
214899404|NCT05773105|DRUG|Cadonilimab+regorafenib|cadonilimab(10mg/kg, iv,Q3W,D1) + regorafenib(80mg,PO,QD,everyday)
214899405|NCT00518271|DRUG|Rapamune® (Sirolimus)|
214899406|NCT00518271|DRUG|Tacrolimus|
214899407|NCT00518271|DRUG|Corticosteroids|Perioperative
214899408|NCT03154983|DRUG|docetaxel|Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA\<1.25 40mg Po bid(twice a day), BSA \>=1.25-\<1.5 50mg Po bid, BSA \>=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
214899409|NCT03101956|PROCEDURE|Lumbar Spine Manipulation|• The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position the subject's superior thigh in flexion and rotate the subject's upper trunk to the opposite side. The therapist will place his cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
214899410|NCT03101956|PROCEDURE|Lumbar Spine Manipulation Placebo|The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position both hips and knees in approximately 45° of flexion. The therapist will place his or her cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
214300941|NCT02982850|DRUG|Acetylsalicylic acid|
214300942|NCT02982850|DRUG|Warfarin|
214300943|NCT04860791|OTHER|questionnaires|Patients will complete the MSWDQ-23 in French, as well as the DEX, questionnaire for the evaluation of executive dysfunction in daily life, to evaluate their cognitive complaints and the SF36 questionnaire to evaluate their quality of life
214300944|NCT00751647|OTHER|Physical Therapy|Treatment
214300945|NCT04657614|OTHER|Neutral Alignment|Alignment that is a neutral replicate of the participants prescribed prosthesis.
214899411|NCT02954484|DRUG|pregabalin|see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.
214300946|NCT04657614|OTHER|Anterior Alignment|Alignment that is anterior displaced pylon.
214300947|NCT04657614|OTHER|Posterior Alignment|Alignment that is posteriorly displaced pylon.
214899412|NCT02954484|DRUG|Placebo|Placebo capsule containing lactose and MCC (no active ingredients).
214899413|NCT02954484|DRUG|Etoricoxib|Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
214899414|NCT02954484|DRUG|paracetamol|Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia
214300948|NCT04699409|OTHER|stroke educational campaign: FAST|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
214300949|NCT04699409|OTHER|stroke educational campaign: STROKE 112|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
214300950|NCT02444260|DRUG|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
214478885|NCT04571736|OTHER|access to the internet information platform|This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.
214899415|NCT02954484|DRUG|Morphine|"patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany"
214300951|NCT02444260|DRUG|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
214478886|NCT06203327|OTHER|Esophagogastroscopy (OLGA 0-Ⅰ)|Surveillance endoscopies at years 3-5.
214478887|NCT06203327|OTHER|Esophagogastroscopy (OLGA II)|Surveillance endoscopies at years 2-3.
214899416|NCT02954484|DRUG|Ropivacaine|Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
214899417|NCT00240721|DRUG|topiramate|
214899418|NCT03973606|OTHER|Heath literacy assessment in Arab women in East Jerusalem|A 4-sessions intervention to increase the participant's self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
214899419|NCT01424007|BEHAVIORAL|Weight loss|Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
214899420|NCT05410249|DIAGNOSTIC_TEST|Serum IL10 By ELISA|measurement Of IL10 by ELISA
214899421|NCT05410249|DIAGNOSTIC_TEST|SNP -3279 A/C of FOXP3|Genotyping of -6054 del/ATT will be performed using the real-time polymerase chain reaction.
214899422|NCT05410249|DIAGNOSTIC_TEST|SNP-924 A/G Of FOXP3|Genotyping of -924 A/G polymorphisms was performed using the real-time polymerase chain reaction.
214899423|NCT06076993|BEHAVIORAL|BodyKind programme|"BodyKind is a four-session, teacher-led, school-based programme for adolescents aged 15-17 years. This programme was developed by a team of international experts in body image and incorporates empirically supported principles of cognitive dissonance (which involves publicly criticising body ideals) and self-compassion (which involves reappraising self-critical evaluations). BodyKind also contains a social activism component that aims to tackle appearance biases, discrimination and racism and promote greater inclusivity and compassion for others.~Programme Outline Lesson 1. Appearance Bias Lesson 2. Self-compassion \& social media Lesson 3. Compassion for others Lesson 4. Becoming agents of change Learning Objectives~* To cultivate skills in awareness, mindfulness, non-judgement, reflection, conscientiousness, compassion~* To decrease levels of body dissatisfaction and self-criticism~* To improve levels of self-compassion, positive body image, psychological wellbeing"
214899424|NCT04280692|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites
214899425|NCT04280692|DRUG|Sulfadoxine-Pyrimethamine|Sub-curative 500mg/25mg single dose regimen
214899426|NCT04280692|DRUG|Piperaquine|Sub-curative 480mg single dose regimen
214899427|NCT04280692|DRUG|Artemether lumefantrine|Three day curative regimen 20mg/120mg
214300952|NCT02444260|DRUG|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
214300953|NCT02444260|DRUG|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
214300954|NCT03104114|BEHAVIORAL|pharmacist-intervention|A clinical pharmacist provides patients with motivational counseling regarding their cancer treatments. Patients will be asked to complete three different surveys throughout the study; surveys focus on social support systems and both provider- and pharmacist-patient relationships
214300955|NCT03104114|BEHAVIORAL|Historical control|Patients that did not receive in-person motivational counseling support from a clinical pharmacist prior and during treatment
214300956|NCT05757661|OTHER|Focal Vibration|"A single 30-minute focal vibration procedure will be performed on both quadriceps with the V-Plus Wintecare® machine.~Three channels will be used on the muscle bellies of the rectus anterior, vastus internus and vastus externus. The positioning of the vibration heads will be done with straps designed by the manufacturer to keep the vibration focus stable on the muscle belly.~The configuration of the vibration program will be in an automatic mode of 10 seconds of vibration and 3 seconds of rest to avoid the coupling of the mechanoreceptors. The frequency used will be between 60 Hz to 150 Hz with a power of 80%."
214899428|NCT04280692|DRUG|Primaquine|Single low dose regimen 0.25 mg base/kg
214899429|NCT02385773|DIETARY_SUPPLEMENT|PTM202|Administration of study nutritional product once per day for 3 days starting immediately after enrollment
215053499|NCT06120686|OTHER|Conventional therapy program|Control group - rehabilitation management aimed at improving cognitive and motor functions in children with mild intellectual disabilities.
215053500|NCT01162473|DIETARY_SUPPLEMENT|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
214899430|NCT02385773|DIETARY_SUPPLEMENT|Enfamil Puramino|Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
214899431|NCT04425057|OTHER|Interval training|
214899432|NCT01110018|DRUG|GSK573719 (SOLUTION)|20μg /mL solution for IV and Oral dosing
214899433|NCT01110018|DRUG|GSK573719 (INHALATION POWDER)|500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
214899434|NCT03757819|DEVICE|tDCS|Brain Stimulation
214899435|NCT03757819|DEVICE|SHAM|Placebo device
215053501|NCT01162473|DRUG|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
214899436|NCT01459133|DRUG|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
214899437|NCT06010953|DRUG|SS109|on-demand treatment with SS109 at the time of a new hemorrhage event
214899438|NCT01332344|DRUG|Fluticasone propionate/salmeterol combination|Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
214899439|NCT01332344|DRUG|Inhaled corticosteroids|asthma subjects newly prescribed inhaled corticosteroids in clinical practice
214899440|NCT06976307|BEHAVIORAL|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
215053502|NCT01162473|OTHER|Food Challenge|
215053503|NCT05582148|DEVICE|Hearing aids fitting|Fitting hearing aids and evaluating the results at 6 months
215053504|NCT05329337|DIAGNOSTIC_TEST|Blood test|Sixteen mL of blood will be collected on EDTA for the purpose of this study
215053505|NCT03747796|OTHER|Supine position|The children will be placed in the supine position after ingestion of a standard volume of clear fluid
215053506|NCT03747796|OTHER|Semi-sitting position|The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
215053507|NCT00440492|DRUG|PLA-695|
215053508|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
215053509|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
215053510|NCT04770558|OTHER|Interactive Exergame|The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
215053511|NCT01478932|BEHAVIORAL|diaphragmatic breathing retraining|In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.
215053512|NCT01478932|BEHAVIORAL|Health Promotion|n-person instructions will be given about what the intervention includes. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, health promotion topics will be discussed (lipid profile, healthy eating to improve lipid profile, importance of regular doctor visits, cancer screening, and so forth).
215053513|NCT03456219|OTHER|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
215053514|NCT03456219|OTHER|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
215053515|NCT05568563|DRUG|Ethyl chloride|Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
215053516|NCT05568563|OTHER|Honey|Honey is a natural dietary product
215053517|NCT01072136|OTHER|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
215053518|NCT01072136|DRUG|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
215053519|NCT01072136|DRUG|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
215053520|NCT03983720|OTHER|Evaluation of degree chronic fatigue.|Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
215053521|NCT03983720|OTHER|Questionnaires|"* Fatigue Severity Scale (FSS)~* Modified Fatigue Impact Scale (MFIS)~* Godin Leisure-Time Exercise Questionnaire (GLTEQ)~* Scale of life quality of multiple sclerosis (SEP-59)~* Center for Epidemiologic Studies Depression (CES-D)~* Pittsburgh Sleep Quality Index (PSQ-I)"
215053522|NCT03983720|BIOLOGICAL|Blood sample|Blood sample will be realized to evaluate anemia and inflammations.
215053523|NCT03983720|OTHER|Cardiopulmonary evaluation|Cardiopulmonary evaluation will be realized with a cycle ergometer.
215053524|NCT03983720|DEVICE|Capacity of muscular oxygen extraction|Measure the capacity of muscular oxygen extraction with a cycle ergometer.
215053525|NCT03983720|DEVICE|Sleep assessment|Sleep assessment will be measured by actigraphy during 15 days.
215053526|NCT03983720|DEVICE|Metabolic fatigue|Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
215053527|NCT03983720|OTHER|Neuromuscular evaluation|"Neuromuscular evaluation will be measured by the composite of the results of:~* Fatigue test~* Measure of voluntary isometric force~* Surface electromyography~* Peripheral nerve stimulation~* Transcranial Magnetic Stimulation (TMS)~* Perceived fatigue~* Cognitive fatigue~* Thermoregulation"
214300957|NCT05757661|OTHER|Sham Group|The same procedure of the intervention group will be performed but without the focal vibration head contacting the skin (sham). A sufficient space will be left between the head and the headgear so that the vibration does not touch the skin.
214300958|NCT05710809|OTHER|Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement|Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions
214899441|NCT06976307|BEHAVIORAL|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
214899442|NCT01075789|DRUG|Lignocaine|Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
214899443|NCT01075789|DRUG|Placebo|Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
214899444|NCT04993131|PROCEDURE|Liver transplant|Liver transplant.
214899445|NCT06655805|DEVICE|Non-invasive ventilation, Invasive mechanical ventilation, high-flow nasal oxygen|No intervention is intended by the nature of this observational study.
214899446|NCT02902523|DRUG|Viread® tablet 300mg|Single dose administration(PO) in the fasted state
214899447|NCT02902523|DRUG|HUG116 tablet 245mg|Single dose administration(PO) in the fasted state
214899448|NCT05836207|BEHAVIORAL|Abstinence-focused Contingency Management (CM) - stand alone|Outpatient abstinence-focused contingency management (CM) as stand-alone treatment (12 weeks). Monetary incentives (vouchers) are provided for cannabis abstinence, based on twice-weekly rapid test urinalysis and an escalating reward scheme with bonuses. Urine samples are collected at the treatment centre during 15-minute sessions by a trained CM-practitioner. For each cannabis-negative urine, patients receive a monetary voucher starting at €5 and escalating to max. €35 after eight consecutive weeks of cannabis abstinence, with an additional €10 bonus after two consecutive cannabis-negative urines. The voucher-value is reset to €5 after a cannabis-positive urine test. Total earnings can be max. €675 for 12 weeks of consecutive cannabis abstinence (average: €8 p/day). Youths sign an agreement stating that vouchers must be spent on recovery-oriented goals.
214899449|NCT05836207|BEHAVIORAL|Standard Outpatient Cognitive Behavioural Therapy (CBT)|"CBT is the usual care first line treatment for CUD in youth, in the Netherlands. CBT for CUD is focused on learning cognitive, emotional, motivational and behavioral skills to reduce or cease cannabis use, and generally consists of 12 once-weekly 60-minute sessions and 'homework' exercise assignments, provided by a psychologist.~Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist. CBT-youths receive the same cannabis urine-testing procedures as CM-youths, but test results will not be disclosed to treatment staff or patient, and no rewards will be given for cannabis abstinence."
214899450|NCT03851237|DRUG|64Cu-DOTA-ECLIi|-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
214899451|NCT03851237|DEVICE|PET/CT|-Standard of care
214899452|NCT06594926|DRUG|Testosterone Enanthate|Testosterone enanthate is a depot formulation used in Australia typically for androgen replacement in people with confirmed testosterone deficiency.
214899453|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon
214899454|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
214899455|NCT05247229|BEHAVIORAL|Middle school education program|The intervention assesses the impact of a middle school education program (implemented as an after school program in Sitka, AK and Juneau, AK and during school hours as an elective in Hoonah, AK) on shellfish and toxin knowledge and clam harvesting planned behaviors. The intervention takes place weekly during the school year. The curriculum centers around teaching children about local traditional ecological knowledge and traditional harvesting and gathering practices.
214899456|NCT03329339|PROCEDURE|1 L PEG with ascorbic acid with prepackaged, low residue diet|Participants who were allocated to the 2 L PEG with ascorbic acid (PEGA) group took 250 ml of PEG with ascorbic acid at 15-min intervals, completing 1 L of the PEG with ascorbic acid protocol at 8:00 PM on the day prior to the procedure. The remaining 1 L of the PEG with ascorbic acid solution was administered in the same manner at 6:00 AM on the day of the procedure. Participants assigned to the 1 L PEG with ascorbic acid with PLD (PLD) group consumed a prepackaged, low residue diet (ZeroCol, Korea Medical Food Inc., Seoul, Korea) which consisted of a breakfast, lunch and dinner, the day prior to colonoscopy. The Participants took 1 L PEG with ascorbic acid solution at 6:00 AM on the day of the colonoscopy in the same way as described above. All of the subjects ingested 500 mL of water for every 1 L of 1 L PEG with ascorbic acid solution consumed. The Participants completed all of the administrations at least 2 hours before the colonoscopy.
214300959|NCT05792631|DEVICE|Near infra red imaging|"The iTero Element 5D is an intra-oral scanner that incorporates near-infrared illumination capabilities used to provide a near-infrared image of the teeth enabling the detection of both occlusal and proximal caries, at the various stages, ranging from initial enamel caries to established caries reaching the DEJ.~Near-infrared Imaging (NIRI) is a nonionizing imaging technology that leverages differences in scattering and absorption of near-infrared light depending on the degree of tooth mineralization."
214300960|NCT02556268|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg, Oral (fasted conditions), 1 single dose
214478888|NCT06203327|OTHER|Esophagogastroscopy (OLGA III-IV)|Surveillance endoscopies every year.
214669448|NCT04969393|OTHER|Conventional Physical Therapy|Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
214300961|NCT02556268|DRUG|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
214300962|NCT02556268|DRUG|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
214300963|NCT02556268|DRUG|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
214300964|NCT02556268|DRUG|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
214300965|NCT02556268|DRUG|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
214300966|NCT03949205|OTHER|Leg Extension Isometric Training|The leg extension isometric exercise will be performed tree times a week , in four 2 min bouts of isometric contraction, at a intensity of 30% of maximal voluntary contraction and an interval of two minutes between bouts.
214300967|NCT02109120|PROCEDURE|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
214899457|NCT00931086|DRUG|belimumab|IV 10mg/kg q28days
214899458|NCT03447639|DRUG|Povidone-iodine irrigation|Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique
214899459|NCT03401463|OTHER|traning seminar|There will be provided 30 min training seminar on the function of endotracheal cuff and cuff pressure.
214899460|NCT06252571|COMBINATION_PRODUCT|- Melatonin - Active light ttherapy|1 tablet per day, in the evening + morning light therapy over 6 weeks
214899461|NCT06252571|COMBINATION_PRODUCT|- Placebo drug - Placebo light therapy|1 tablet per day in the evening + morning placebo light therapy
214899462|NCT04251247|DIAGNOSTIC_TEST|D-dimer/fibrinogen ratio|The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
214899463|NCT02354729|OTHER|Behavioral Economics|Use financial incentives to promote epinephrine-carrying.
214899464|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single administration by anterior juxtascleral depot
214899465|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single administration by anterior juxtascleral depot
214899466|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 75 mg/mL|Single administration by anterior juxtascleral depot
214899467|NCT00691717|OTHER|Anecortave Acetate Vehicle|Single administration by anterior juxtascleral depot
214899468|NCT02573961|DEVICE|Laser acupuncture|GaAlAs semiconductor diode Laser Phototherapy Device
214899469|NCT02573961|BEHAVIORAL|high protein low carbohydrate diet|A tailored high protein/low carbohydrate/low caloric diet
214899470|NCT02573961|BEHAVIORAL|low caloric diet|Tailored balanced low caloric diet
214899471|NCT05590611|OTHER|Dietary Intervention with Brown Bread|The participants in this group will be asked to replace all their habitual bread intake by standard brown bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
214899472|NCT05590611|OTHER|Dietary Intervention with Sourdough Bread|The participants in thisgroup will be asked to replace all their habitual bread intake by wholemeal sourdough bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
214899473|NCT01117896|OTHER|Chest compression on adult and pedi manikins|Each participant will be required to perform chest compressions on all 2 manikins, one on each of 2 assigned days. Participants will be randomized to one of 2 groups differing only in the order of manikins compressed, i.e. pediatric-adult; adult-pediatric, etc.
214899474|NCT01117896|OTHER|Use of stepstool during chest compressions|In the additional arm of the study, a new cohort of participants will use only the adult manikin on two separate sessions. Participants will be randomized to one of two groups differing only in the use of a stepstool.
214899475|NCT04507295|DEVICE|cerebral oximetry ( INVOS 5100 )|"in case of critical cerebra desaturation occurred which is defined as decrease in cerebral saturation by 20% from the base line the following will be done~1. Increase FIO2 up to 100%~2. Increase PEEP up to 5 cmH2O~3. Decrease insufflation pressure"
214899476|NCT05123313|BEHAVIORAL|Deprescribing intervention|"The intervention is comprised of a minimum of three consultations with a general practitioner (GP), where adjustment of the patient's medication is made according to the patient's preference, goals and needs~Consultation 1: Patient and GP discuss how the patient feels about their medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation.~Consultation 2: A clinical pharmacist have beforehand examined the patient's medication list and provided suggestions to the GP on which drugs can be deprescribed. The patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities.~Consultation 3: Patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal."
214300968|NCT05799807|PROCEDURE|Conservative treatment|Patients with negativ weight-bearing CT will be treated conservative
214300969|NCT05799807|PROCEDURE|Minimally invasive stabilization|Patients with positive weight-bearing CT will be operated by minimally invasive stabilization (eg, isolated homerun screw)
214300970|NCT03411681|OTHER|Resistance Exercise|Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
214300971|NCT06238635|DRUG|Dostarlimab|Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.
214300972|NCT06238635|DRUG|Cobolimab|Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.
214300973|NCT06411691|DRUG|KRAS Vaccine with Poly-ICLC adjuvant|"SLP mKRASvax with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22 in Cycle 1 (Prime Phase) and on day 1 in cycle 4 and every other cycle and beyond (Boost Phase). Up to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
214899477|NCT01532934|BEHAVIORAL|motivational enhancement therapy|Four 45-minute MET sessions
214899478|NCT01532934|OTHER|standard care|
214300974|NCT06411691|DRUG|Balstilimab|"240 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on day 1 and day 15 during Cycle 1 in Prime Phase and on day 1 and day 15 of every cycle in the Boost Phase beginning on Cycle 2 (for a maximum of 2 years from initial vaccination).~Drug: 240 mg IV"
214300975|NCT06411691|DRUG|Botensilimab|"75 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on Cycle 1 day 1 in Prime Phase and on Cycle 2 day 15 in the Boost Phase.~Drug: 75 mg IV"
214300976|NCT02881242|OTHER|Laboratory Biomarker Analysis|Correlative studies
214300977|NCT02881242|OTHER|Quality-of-Life Assessment|Ancillary studies
214300978|NCT02881242|DRUG|Trametinib|Given PO
214478889|NCT06826235|OTHER|3 dates at the breakfast meal in the diet program|Participants in the intervention group will consume 3 dates at the breakfast meal in the diet program.
214478890|NCT06173349|DRUG|PLZ4-coated paclitaxel loaded micelles (PPM)|Given PLZ4-coated paclitaxel loaded micelles intravesically
214478891|NCT06855953|DIETARY_SUPPLEMENT|Vitamin K|Participants receive 0.5 mg/day phylloquinone orally for 12 weeks
214899479|NCT05699941|DEVICE|Ectoin® Inhalation Solution|Ectoin Inhalation Solution (Class-IIa Medical Device Directive (MDD) legacy medical device) is an isotonic, aqueous solution containing Ectoin 1.3 % and sea salt 0.6%. It is used for moistening the lung epithelium by the Ectoin hydro complex and supports the barrier function of the lung epithelium. The inhalation solution can be administered with jet, mesh, and ultrasound nebulizers.
214899480|NCT06439251|COMBINATION_PRODUCT|Group 1|The treatment included TENS therapy, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques. Participants in Group A also received Phonophoresis as an experimental technique.
214899481|NCT06439251|COMBINATION_PRODUCT|Group 2|The treatment included routine physiotherapy with TENS, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques.
214899482|NCT05608681|DRUG|EP-104GI|Extended-release fluticasone propionate \[FP\] for injectable suspension for gastrointestinal administration, Powder suspended in vehicle
214899483|NCT05608681|OTHER|Matching vehicle control|A sterile liquid containing sterile water and excipients necessary to prepare a uniform suspension of the powder.
214899484|NCT06984302|OTHER|proactive therapy|drugs and fluids will be given based on the hypotension prediction index
214899485|NCT05821075|DRUG|Prednisolone|prednisolone 60mg tablet once daily for 5 days then tapering dose
214899486|NCT05821075|DRUG|Cerebrolysin|intramuscular Cerebrolysin 10 mg daily for 3 weeks
214899487|NCT06596759|BEHAVIORAL|Diaphragmatic Breathing|REDCap will be used to administer the Mayo Bloating Questionnaire (MBQ) and collect self-reported compliance to diaphragmatic breathing (DB) exercises over a 4 week follow up period. After completion of the MBQ, the patient will be taught DB techniques by an individual physical therapist face to face over a 30-minute session. The patient will be instructed to complete 5-10 minutes of diaphragmatic breathing twice a day for a period of 4 weeks. Patients will receive a telephone call and electronic health record portal message to check progress and answer any questions. At the end of the 4-week follow up period, patients will repeat the MBQ and self-report their adherence to daily diaphragmatic breathing. The questionnaire will include prompts investigating perceived side effects and attitudes towards therapy, willingness to perform DB therapy, likelihood to attempt self-guided DB in the future, and if the participant would recommend the therapy to a friend.
214899488|NCT06603883|BIOLOGICAL|Fecal microbiota transplantation (FMT) by nasal jejunal tube|FMT was administered via a naso-jejunal tube to inject 50ml commercial intestinal bacterial suspension into the jejunum.
214899489|NCT06858761|PROCEDURE|Robot-assisted surgical strategy|Primary or revision bariatric surgery (for complications or side effects of a previous surgery), using a robotic approach. The robot used will be the Da Vinci X or Xi model (depending on the center) from the company Intuitive Surgical.
214899490|NCT06858761|PROCEDURE|Conventional laparoscopic surgical strategy|Primary or revision bariatric surgery (for complications or side effects of a previous surgery), using a conventional laparoscopic approach
214899491|NCT06858761|OTHER|Visual analog scale|All patients will have pain evaluation with visual analog scale
214899492|NCT06858761|OTHER|EQ-5D-5L questionnaire|All patients will have quality of life assessment with EQ-5D-5L questionnaire
214899493|NCT06858761|OTHER|Impact of Weight on Quality of Life (IWQOL) questionnaire|All patients will have Quality of life assessment with IWQOL questionnaire
214899494|NCT06670222|DRUG|Arsenic Trioxide (ATO)|"Study treatment: oral Arsenic 5d/7 for 21 days over a 28-day cycle, three doses tested (0.10 mg/kg, 0.15 mg/kg and 0.20 mg/kg).~Dose escalation cohort to determine the dose limiting toxicity according to a BOIN (Bayesian optimal interval) scheme, 9 patients will be treated at each dose.~An expansion cohort at the selected dose will be conducted with 6 patients.~Tolerability will be assessed after one treatment cycle. Response will be assessed after 3 cycles of treatment. Responders may continue study treatment until progression or limiting toxicity. Limiting toxicity is defined as any grade III/IV extra-hematological toxicity or grade IV hematological toxicity lasting more than 25 days."
215053528|NCT04836611|PROCEDURE|1 blood sample|2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
215053529|NCT03555877|DRUG|Ribociclib|Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.
215053530|NCT03555877|DRUG|Anastrozole|1mg once daily as indicated in the SmPC
215053531|NCT03555877|DRUG|Letrozole|2,5mg once daily as indicated in the SmPC
215053532|NCT03555877|DRUG|Exemestane|25mg once daily as indicated in the SmPC
215053533|NCT03555877|DRUG|Fulvestrant|(prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
215053534|NCT02797314|OTHER|Bone biopsies|Bone biopsies
214300979|NCT06067542|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
215053535|NCT03503396|BEHAVIORAL|BAC Driving Feedback/Warning|Participants will receive a warning at a set BAC limit, indicating they are too impaired to drive.
214300980|NCT06540209|DRUG|Bacillus clausii|Children will be give Bacillus clausii for 5 days
214300981|NCT06540209|DRUG|Saccharomyces boulardii|Children will be give Saccharomyces boulardii for 5 days
214300982|NCT06540209|DRUG|Zinc|Zinc will be given to all children for 5 days
214300983|NCT06540209|DRUG|ORS|ORS will be given to all children for 5 days
214300984|NCT01849627|BEHAVIORAL|Low-ED|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.
214300985|NCT01849627|BEHAVIORAL|Energy Balance|Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
214300986|NCT01220947|DRUG|Copegus|Copegus 1000 mg or 1200 mg po daily for 24 weeks.
214300987|NCT01220947|DRUG|Danoprevir|Danoprevir 50 mg BID
214300988|NCT01220947|DRUG|Danoprevir|Danoprevir 100 mg BID
214300989|NCT01220947|DRUG|Danoprevir|Danoprevir 200 mg BID
214300990|NCT01220947|DRUG|Pegasys|Pegasys 180 microgram sc qw
214300991|NCT01220947|DRUG|Ritonavir|Ritonavir 100 mg
214300992|NCT03222596|BEHAVIORAL|Exercise training|Exercise programme includes breathing and upper limbs exercises.
214300993|NCT00531024|DRUG|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
214300994|NCT00531024|DRUG|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
214300995|NCT03964155|BIOLOGICAL|Sample|After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
214300996|NCT01086540|BIOLOGICAL|Rituximab|"Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions."
214300997|NCT01086540|OTHER|Placebo|"Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions."
214669449|NCT05772689|OTHER|Usual Care|Caregivers assigned to the usual care group will be enrolled in the course at the 3-month mark after consenting. All caregivers will then participate in quantitative interviews at post- 6months of their baseline
215053536|NCT03503396|BEHAVIORAL|No Feedback|Participants will receive no information about BAC, but will still complete study assessments and provide breath samples during drinking sessions.
215053537|NCT01930604|DRUG|Botox (onabotulinumtoxinA)|
215053538|NCT01930604|DRUG|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
215053539|NCT01930604|DRUG|NaCl (placebo)|
215053540|NCT05519111|DRUG|Dronabinol|Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)
215053541|NCT05519111|DRUG|Placebo|placebo equivalent
215053542|NCT01591408|DEVICE|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
215053543|NCT03662282|DRUG|Omegaven|Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
215053544|NCT04444739|OTHER|radiographic data collection|From existing radiological Images (upright standing X-ray and supine MRI of the lumbar spine), specific radiographic parameters will be extracted
215053545|NCT02108756|DRUG|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
215053546|NCT02108756|DRUG|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
215053547|NCT05419752|DRUG|bioceramic sealer|bioceramic based obturating sealer
214899495|NCT06613074|DEVICE|Ali Pay intelligent navigation applet|"The intelligent navigation applet comprises of three function modules:~1. Stroke knowledge public education: information regarding prevention and emergency treatment of stroke would be push to users\&#39; mobile phones regularly;~2. Stroke recognition: questionaires, voice interaction, and facial recognition are employed to identify patients with AIS and large vessel occlusion;~3. Hospital recommendation: this module combines real-time traffic and average in-hopital delay of each stroke center nearby, recommending the stroke center in which patients are mostly likely to receive reperfusion therapy"
214899496|NCT04988919|DIETARY_SUPPLEMENT|4D|multi-ingredient supplement mixed with 24 ounces of water
214899497|NCT04988919|DIETARY_SUPPLEMENT|placebo|taste-matched placebo mixed with 24 ounces of water
214899498|NCT02154867|BIOLOGICAL|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
214899499|NCT02154867|OTHER|Placebo fecal transplant|Fecal transplantation with own feces
214899500|NCT01147068|BIOLOGICAL|0.5mL Intramuscular Injection|0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
214899501|NCT05385653|BEHAVIORAL|"experimentation of the virtual reality RevBED"|"ReVBED is a VR-based exposure scenario for CBT for the induction of food craving in patients with bulimia nervosa and binge eating disorder.~The use of ReVBED requires no VR experience and only generic and commonly used virtual reality tools (a computer with VR software, a wireless virtual reality headset, two controllers and headphones), all with a CE mark, allowing its users to move in and interact with a specially designed virtual environment.~This exhibit scenario takes place in a VR environment built to represent a standard apartment consisting of four exhibit rooms (a bedroom, a teenager's bedroom, a living room and a kitchen) in which the ReVBED user moves sequentially through the scenario. In each room, specific cues of craving are displayed. These cues are not only visual, but also audio, emotional and socio-environmental. A central hall connects the other rooms and serves as a safe place for debriefing, where measures such as craving are assessed."
214899502|NCT03746132|DEVICE|EPIFLO|EPIFLO is a 3 ounce oxygen generator that continuously delivers 3 ml/hr of pure oxygen to the wound site, to enable tissue regenerative processes, thus driving closure of delayed-healing acute or chronic wounds.
214300998|NCT01086540|DIAGNOSTIC_TEST|CMRI|Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
214300999|NCT01086540|DRUG|prednisone|Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
214301000|NCT01086540|DRUG|methylprednisolone|Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
214301001|NCT01086540|DRUG|diphenhydramine|"Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
214301002|NCT01086540|DRUG|acetaminophen|"Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
214899503|NCT04327544|BEHAVIORAL|Frailty Intervention|In overall, participants will attend one session of frailty talk, 22 sessions of low to moderate intensity of multi-components exercise course and 6 session of nutrition education interventions. Both nutritional education and exercise intervention will be conducted concurrently for a 12-week (3-month) of intervention period. Noted that every session will be held in PPR flats' facility area or hall around 60 minutes that will be conducted by the dietitian or nutritionist and physiotherapist from the research team.
214301003|NCT02201186|OTHER|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
215053548|NCT05419752|DRUG|MTA|MTA based obturating sealer
215053549|NCT05419752|DRUG|resin sealer|resin based obturating sealer
215053550|NCT00405730|DRUG|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
215053551|NCT00405730|DRUG|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
215053552|NCT00405730|OTHER|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
215053553|NCT01983007|PROCEDURE|High-intensity exercise|Performance of high-intensity exercise
215053554|NCT01983007|PROCEDURE|Low-intensity exercise|Performance of low-intensity exercise
215053555|NCT05554276|COMBINATION_PRODUCT|neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy|All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
215053556|NCT01176877|BEHAVIORAL|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
215053557|NCT00394264|PROCEDURE|Soft Tissue|
215053558|NCT00394264|PROCEDURE|Myofascial release|
215053559|NCT00394264|PROCEDURE|Counterstrain|
215053560|NCT00394264|PROCEDURE|Muscle energy|
215053561|NCT00394264|PROCEDURE|Sacro-iliac articulation|
215053562|NCT00394264|PROCEDURE|High-velocity, low amplitude|
215053563|NCT05871580|RADIATION|Low frequency laser activated photobiomodulation|"Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients.~* apex tongue: 3 points~* lateral edge of the tongue: 4 points~* tongue dorsum: 10 points~* jugal mucosa: 8 points~* labial mucosa: 5 points~* hard palate: 8 stitches~* soft palate: 3 stitches~* gingiva or alveolar mucosa: 3 stitches per sextant.~Time of 30 seconds in each application point, with dosage: 3 J/point."
215053564|NCT05871580|OTHER|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
215053565|NCT00777348|DRUG|Combination DSCG and Reproterol|1:
215053566|NCT06337981|DRUG|(AJU-S56 5% and placebo)|(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
215053567|NCT06337981|DRUG|AJU-S56 5%|(AJU-S56 5%), 1drop/1times, 6times in a day
215053568|NCT06337981|DRUG|Placebo(Vehicle)|Placebo(Vehicle), 1drop/1times, 6times in a day
215053569|NCT01237431|DIETARY_SUPPLEMENT|500ml water intake|subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
215053570|NCT00752414|DRUG|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
214899504|NCT05719935|DEVICE|KinematX total wrist arthroplasty system|The KinematX total wrist implant is a joint metal/polymer semi-constrained cemented prosthesis that utilizes an articulation that mimics the midcarpal joint instead of the radiocarpal joint.
214899505|NCT01867528|PROCEDURE|Laparoscopic adhesiolysis|
214899506|NCT01867528|PROCEDURE|Open adhesiolysis|
214899507|NCT05711420|BEHAVIORAL|Gamification method group|Gamification method group
214899508|NCT05711420|BEHAVIORAL|Flipped learning group|Flipped learning group
214899509|NCT07015463|OTHER|Multi-component intervention in health literacy|Multi-component intervention aiming at increasing the health literacy of patients suffering from hypertension, in achieving the target blood pressure goal three months after the start of the intervention in poorly controlled hypertensive patients
214899510|NCT06624410|OTHER|Educational Intervention|"Pre-operative anxiety levels will be assessed with the mYPAS-SF6-12 (below). Subjects will be observed for behaviors and then given a score out of possible 5 across 5 domains that corresponds with demonstrated behaviors, specified in the figure below. The 5 domains include Activity, Vocalization, Emotional Expressivity, State of Arousal, and Use of Parent. Note that the Vocalization domain differs in that It's possible scores range from 1-7. Pilot data collection will involve mYPAS scoring in isolation to demonstrate existing anxiety burden at Doernbecher Children's Hospital."
214899511|NCT02291237|DRUG|Eleclazine|Tablet (s) administered orally once daily
214899512|NCT02291237|DRUG|Placebo|Placebo to match eleclazine administered orally once daily
214899513|NCT05430646|DEVICE|Covered metal ureteral stents|The CMUS is a fully covered, self-expanding, large caliber metal stent. The stent is made of super-elastic nickel-titanium alloy, which maintain lumen patency via providing long-term direct wall support.
214899514|NCT05430646|DEVICE|Tandem DJ stents|Tandem DJ stents represents for two stents side-by-side, which improves the urine flow by better withstanding the compressive tumoral forces and allowing urine to flow between the stents.
214899515|NCT03903432|OTHER|MRI|candidates for ESS will be referred to conventional CT scans of the sinuses. If surgery is to be performed, the patients will sign an informed consent and be referred for a sinus MRI.
214899516|NCT01149863|DRUG|Plerixafor|Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
215053571|NCT00752414|DRUG|Placebo|same frequency as MP-376
215053572|NCT03695887|DRUG|Nitrous Oxide Inhalant Product|Nitrous Oxide Inhalant Product
214301004|NCT00914355|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
214301005|NCT01068119|PROCEDURE|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
214301006|NCT00746642|DEVICE|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
214478892|NCT06855953|DIETARY_SUPPLEMENT|Placebo|Participants receive daily placebo for 12 weeks
214899517|NCT06732921|DEVICE|Alertwatch - Recovery Control Tower|Decision-support software, customized for the PACU environment, Interaction between the telemedicine center and the PACU
214899518|NCT02112851|OTHER|Orange flavored beverage|Intervention involves consumption of one beverage of 240ml following baseline measurements
214899519|NCT01306305|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
214899520|NCT06301542|DEVICE|Functional electrical stimulation|The FES system will be placed on the plantar flexors, dorsiflexion, and quadriceps muscles and be paired with the machine learning directed inertial measurement units.
214899521|NCT06745128|DRUG|Tirzepatide|Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 32-week period. Following the instructions of the FDA-approved prescribing label, participants or a licensed study clinician will administer the tirzepatide injection subcutaneously in either the abdomen, thigh, or upper arm once weekly for 32 weeks total. Following the instructions of the FDA-approved prescribing label, the dosing schedule will include a 4-week titration at a starting dosage of 2.5mg/week. After four weeks, dosage will be increased in 2.5mg increments. The recommended maintenance dosages per prescribing label are 5mg/week, 10mg/week, or 15mg/week injected subcutaneously. Maximum dosage (up to 15mg/week) will be optimized for each individual. We will use commercially available tirzepatide, primarily dispensed as ZEPBOUND® for this study, but in the event of medication shortage or other pharmacy-related issue, MOUNJARO® may be dispensed as an alternative.
214899522|NCT03326193|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (\>=) 77 kg and Baseline platelet count of \>=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (\<) 77 kg and/or Baseline platelet count of \<150,000/μL will take 200 mg (2X100 mg) at each dose administration.
214899523|NCT03326193|BIOLOGICAL|Bevacizumab|Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
214899524|NCT07052864|DRUG|Dexamethasone|8 mg of Intravenous Dexamethasone in 100 ml Normal saline given 1 hour before anesthesia induction
214899525|NCT07052864|DRUG|Placebo|100ml of Normal saline administration 1 hour before anesthesia induction
214899526|NCT06736223|DRUG|ITF2357|ITF2357 (INNM Givinostat hydrochloride Monohydrate), single dose
214899527|NCT00978874|RADIATION|fludeoxyglucose F 18|
215053573|NCT03695887|DRUG|Placebo|Inactive comparator
214899528|NCT00978874|RADIATION|fluorine F 18 EF5|
215053574|NCT01204957|DIETARY_SUPPLEMENT|Seaweed and Soy Protein|5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
214669450|NCT05772689|OTHER|Caring While Black|Caregivers assigned to this group will receive a schedule for their completion of the course over the next 2 months and supplemental course materials through the mail. The Canvas platform will enable the course to monitor everyone's movement in the cohort through the asynchronous part of the course. Nudges and reminders will be sent twice a week via text or email with the participant's consent.
214669451|NCT06430892|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Patients presented with acute myocardial infarction undergoing primary percutaneous coronary intervention with stent deployment
214899529|NCT04691427|DEVICE|Virtual Eye Rotation Vision Exercises (VERVE)|A video game designed with elements of vision therapy will be delivered to participants utilizing consumer-available virtual reality headsets (VIVE Pro Eye).
214899530|NCT04420494|OTHER|Umbilical Cord Blood|The diagnosis is definitely immune cytopenia (IRC), including autoimmune hemolytic anemia (AIHA, Hgb \<100g / L, acquired pure red aplastic anemia (PRCA, Hgb \<100g / L, EVANS syndrome , Hgb \<100g / L and / or platelet count \<30 × 109 / L, or blood cell reduction secondary to immune diseases (the same as the treatment indications, or neutrophils \<0.5 × 109 / L), at least after hormone therapy Patients who are ineffective (did not reach PR after 4 weeks of hormone therapy) or who have not achieved PR after 3-5 mg / kg / d of cyclosporine. These patients would be treated with umbilical cord blood.
214899531|NCT02886780|BEHAVIORAL|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
214899532|NCT02886780|BEHAVIORAL|Self-help|
214899533|NCT05771389|DIAGNOSTIC_TEST|serum raftlin-1 protein levels|Lipid raft linker 1 (Raftlin-1) is a protein which enables double-stranded RNA binding activity. It is involved in T cell receptor signaling pathway; membrane raft assembly; and positive regulation of growth rate. It acts upstream of or within dsRNA transport; response to exogenous dsRNA; and toll-like receptor signaling pathway. Located in endosome; membrane raft; and plasma membrane.
214899534|NCT03302676|DIETARY_SUPPLEMENT|Chewing gum|
214899535|NCT01932866|OTHER|diabetic risk score|
214899536|NCT02272257|BEHAVIORAL|Early Direct Access Physical Therapy|Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
214899537|NCT02272257|BEHAVIORAL|Physician management|Physician management including advice, medication, and referral to physical therapy or other provider.
214899538|NCT01688557|DEVICE|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
214899539|NCT01688557|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
214899540|NCT00703872|DRUG|Oral HDV-Interferon + ribavarin|Naive pateints
214899541|NCT00703872|DRUG|Injectable HDV-Interferon + ribavarin|Nonresponders
214899542|NCT01122186|BEHAVIORAL|Motivational Interviewing + Cognitive Behavioral Skills Training|The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
215053575|NCT01204957|DIETARY_SUPPLEMENT|Placebo and Soy Protein|5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
215053576|NCT05006066|OTHER|Temporal Summation|4 type of stimulations applied on the right arm
215053577|NCT03695445|DRUG|Peripheral administration of Norepinephrine|Systematic follow-up of complications from peripheral administration of Norepinephrine
215053578|NCT01710566|DRUG|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
215053579|NCT01710566|DRUG|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
214669452|NCT01023282|DRUG|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
215053580|NCT03532022|DRUG|Chronocort®|Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
215053581|NCT03532022|DRUG|Standard Care|The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
214669453|NCT01023282|DRUG|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
214669454|NCT04939155|BIOLOGICAL|SARS-CoV-2 mRNA vaccine|mRNA vaccine for COVID
215053582|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
214301007|NCT05959538|BEHAVIORAL|Building Regulation in Dual Generations (BRIDGE)|The BRIDGE intervention includes 16 weeks of 20-30 minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use). The clinical team will consist of two Master's or PhD level clinical psychology trainees and a parent peer coach. Mood tracking will be completed using a brief weekly survey, including questions on depression, parenting stress, positive mood, and recent stressful experiences.
215053583|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
215053584|NCT03093714|DRUG|FDL169|CFTR corrector
215053585|NCT03093714|DRUG|Placebo|Placebo for FDL169
215053586|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
214669455|NCT01627145|DRUG|Solifenacin|Solifenacin 5 mg qd,
215053587|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire"
215053588|NCT03098095|BEHAVIORAL|Physical Activity|Moderate physical activity
215053589|NCT05353413|DEVICE|Neuroimaging|Magnetic resonance diffusion tensor imaging of the brain
215053590|NCT05353413|DIAGNOSTIC_TEST|VEP - visual evoked potential|Electrophysiology of the visual pathway.
215053591|NCT05353413|DIAGNOSTIC_TEST|Ophthalmology examination.|Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
215053592|NCT01392573|DRUG|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
215053593|NCT01392573|DRUG|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
215053594|NCT02374229|PROCEDURE|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
215053595|NCT02374229|PROCEDURE|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
215053596|NCT05807126|PROCEDURE|Biopsy|Undergo biopsies
215053597|NCT05807126|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214669456|NCT04945382|DEVICE|Scotchbond Universal 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Scotchbond universal 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
215053598|NCT05807126|PROCEDURE|Computed Tomography|Undergo CT
215053599|NCT05807126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215053600|NCT05807126|BIOLOGICAL|Magrolimab|Given IV
215053601|NCT05807126|DRUG|Olaparib|Given PO
215053602|NCT01027429|DRUG|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
215053603|NCT01027429|DRUG|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
215053604|NCT01027429|DRUG|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
215053605|NCT02789852|DEVICE|Orthosis|use orthosis
215053606|NCT02636647|BIOLOGICAL|Fecal transplant|
215053607|NCT00100737|DRUG|interleukin-2|
215053608|NCT00100737|DRUG|rituximab|
215053609|NCT01545596|BEHAVIORAL|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
215053610|NCT05006105|DEVICE|seven-day ECG Holter|Participants receive a seven-day ECG Holter after hospital discharge.
215053611|NCT05006105|DEVICE|24-hour blood pressure monitor|Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.
215053612|NCT05006105|OTHER|Questionnaire: vision of mHealth|Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.
215053613|NCT05006105|OTHER|Questionnaire: user experience & feeling of safety|Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.
215053614|NCT05006105|DEVICE|Insertable loop recorder|Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
215053615|NCT03670849|DEVICE|LapAR|LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
215053616|NCT03008070|DRUG|IVA337|1200mg
215053617|NCT03008070|DRUG|IVA337|800mg
215053618|NCT03008070|DRUG|Placebo|Placebo to match
215053619|NCT04631809|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
215053620|NCT04631809|PROCEDURE|CT-Coronary Angiography + Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
215053621|NCT00841412|BEHAVIORAL|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
215053622|NCT00841412|BEHAVIORAL|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
215053623|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered transdiagnostic emotion regulation treatment|Please see description of experimental arm (arm one)
214478893|NCT06856486|DIETARY_SUPPLEMENT|Sulforaphan Smart®|Fasting volunteers will intake the Sulforaphan Smart® pill, and blood and urine samples will be taken at the beginning of the intervention (Time 0 hours, before intake the pill), and 6 and 24 hours after its intake the pills (Time 6 hours and Time 24 hours) to measure the biomarkers related to the bioavailability of GSL/ITCs.
214899543|NCT01122186|BEHAVIORAL|Education Attention Control|"During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery."
214899544|NCT02713412|OTHER|Glucose|75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
214899545|NCT02713412|OTHER|Water|300ml water
215053624|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered supportive treatment|Please see description of active comparator arm (arm two)
215053625|NCT04409834|DRUG|Unfractionated Heparin IV|Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE
215053626|NCT04409834|DRUG|Enoxaparin 1 mg/kg|Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours
215053627|NCT04409834|DRUG|Clopidogrel|Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days
215053628|NCT04409834|DRUG|Unfractionated heparin SC|Heparin 5,000 units administered subcutaneous three times daily
215053629|NCT04409834|DRUG|Enoxaparin 40 mg SC|Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)
215053630|NCT00668759|DRUG|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
214478894|NCT06353529|DRUG|Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution|2mL injection bilateral (4mL total) of 0.5% bupivacaine with 1:200,000 epinephrine solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
214899546|NCT03933566|PROCEDURE|Ultrasound-Guided Superficial Cervical Plexus Block|Ultrasound-Guided Superficial Cervical Plexus Block
214899547|NCT03933566|PROCEDURE|Landmark-Based Superficial Cervical Plexus Block|Landmark-Based Superficial Cervical Plexus Block
215053631|NCT00668759|DRUG|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
215053632|NCT05419245|OTHER|Guided Health History for Freeman-Burian Syndrome Questionnaire|Completed during the interview. The Guided Health History for Freeman-Burian Syndrome Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
215053633|NCT05419245|OTHER|Freeman-Burian syndrome Semi-Structured Quality of Life Interview|Completed during the interview. Freeman-Burian syndrome Semi-Structured Quality of Life Interview is a quality of life interview for Freeman-Burian syndrome, taking into consideration individual's total health.
215053634|NCT05419245|OTHER|Medical Records Review|Review of medical records will be used, along with Guided Health History for Freeman-Burian Syndrome Questionnaire to assess patient histories and outcomes.
215053635|NCT05419245|OTHER|PTSD Checklist for DSM-5|"Completed by patients before the interview. The PTSD Checklist for DSM-5 is a 20-item questionnaire. Each item is rated 0-4, with 0 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms."
214899548|NCT06035978|DRUG|Nebivolol|Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
214899549|NCT06035978|DRUG|Valsartan and Sacubitril|Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
215053636|NCT05419245|OTHER|Modified Flanagan Quality of Life Scale|"Completed by patients before the interview. The Modified Flanagan Quality of Life Scale is a 16-item survey designed for use in persons with chronic illness. Each item is rated 1-7, with 1 being Terrible and 7 being Delighted. Higher scores suggest the person may be experiencing a better quality of life."
215053637|NCT05419245|OTHER|Center for Epidemiologic Studies Depression Scale|"Completed by patients before the interview. The Center for Epidemiologic Studies Depression Scale is a 20-item survey that asks about depressive feelings and behaviours in the past week. Each item is rated 0-3, with 0 being Rarely or none of the time (less than 1 day) and 3 being Most or all of the time (5-7 days). Lower scores suggest the person may be experiencing fewer symptoms."
215053638|NCT05419245|OTHER|Review of Systems|Completed during the interview. A review of systems is a checklist of medical problems.
215053639|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance of the Face"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face."
215053640|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance Distress"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face."
215053641|NCT05419245|OTHER|"FACE-Q | Craniofacial - Facial Function"|"Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning."
215053642|NCT06607263|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
215053643|NCT06607263|DRUG|Essential oils mouthrinse|Essential oils mouthrinse
215053644|NCT06607263|DEVICE|Dental floss|Dental floss
214301008|NCT05959538|BEHAVIORAL|Dialectical Behavioural Therapy Skill Training|Participants in the DBT arm will participate in 16 weeks of DBT skills training only led by two Master's or PhD level clinical psychology trainees. Participants in the DBT Skills condition will participate in a skills group which follows the DBT Skills Training Manual 2nd Edition (Linehan, 2015) through weekly, synchronous 1.5-hour virtual group therapy sessions. Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness skill domains will be covered. Participants will be asked to complete worksheets between sessions to practice using skills, and will be asked to complete a Diary Card to track DBT skills use each week (Linehan, 2015). Mood tracking will be completed using a brief weekly survey including questions on depression, parenting stress, positive mood, and recent stressful experiences.
214301009|NCT01518777|OTHER|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
214301010|NCT04679792|DIAGNOSTIC_TEST|Dynamic posturography|Balance evaluation
214301011|NCT05153031|OTHER|lithiasic|Cholelithiasis is the presence of one or more calculi (gallstones) in the gallbladder.
214301012|NCT05153031|PROCEDURE|Emergency surgery|Emergency cholecystectomy
214301013|NCT05153031|PROCEDURE|cholecystectomy|cholecystectomy
214899550|NCT06035978|DRUG|Carvedilol|Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
214899551|NCT06035978|DRUG|Bisoprolol|Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
214899552|NCT06035978|DRUG|Metoprolol|Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
214899553|NCT06035978|DRUG|Spironolactone|Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
214899554|NCT03237338|PROCEDURE|ture acupuncture|"ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
214899555|NCT03237338|PROCEDURE|sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
214899556|NCT03088761|DEVICE|cuffed tracheal tube|the changes in cuff pressure will be determined using a cuff manometer
215053645|NCT06607263|DRUG|Toothpaste|A commercially available fluoride toothpaste
215053646|NCT06607263|DEVICE|Toothbrush|A commercially available adult toothbrush
214301014|NCT04991155|DRUG|BIA 5-1058|BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
214301015|NCT05962970|DRUG|continuous adductor canal block (CACB) ropivacaine|The CACB group will receive an infusion of 0.2% ropivacaine 5mL/h
214478895|NCT06353529|DRUG|Placebo|2mL injection bilateral (4mL total) 0.9% saline solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
214899557|NCT00699998|DRUG|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
214899558|NCT00699998|DRUG|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
214899559|NCT00699998|DRUG|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
214899560|NCT02826629|DEVICE|Manual dexterity|Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)
214899561|NCT02826629|DEVICE|Oculomotor movements|Oculomotor movements during behavioral task will be recorded using a video-oculography device
214301016|NCT05962970|DRUG|sham continuous adductor canal block - ShACB NaCl|sham continuous adductor canal block - ShACB and ShACB group will receive an infusion of NaCl 0.9% 5mL/h.
214301017|NCT06149507|DRUG|Acetaminophen|Prescribe the drug to the child
214301018|NCT06149507|DRUG|Ibuprofen|Prescribe the drug to the child
214301019|NCT02278263|DRUG|Tranexamic Acid|Given intravenously or topically
214301020|NCT02278263|DRUG|Normal saline (0.9% NaCl)|Administered in all 3 groups
214301021|NCT03164928|DRUG|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
214301022|NCT03164928|OTHER|Placebo|SC Q6M placebo
214478896|NCT06353529|DRUG|Sham Comparator|Participants receive no additional study injections
214478897|NCT04628585|OTHER|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
214669457|NCT04945382|DEVICE|Single Bond 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Single Bond 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
214899562|NCT02826629|DEVICE|TMS coupled to EMG recording|The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording
214899563|NCT02826629|OTHER|Psychopathological evaluations|
214899564|NCT02826629|OTHER|Neuropsychological evaluations|
214899565|NCT03782168|OTHER|There is no other intervention, only clinical treatment.|The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in PA.
214899566|NCT04825392|DRUG|HX008|Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
214899567|NCT00128440|DRUG|BEA 2180 BR|
214899568|NCT00128440|DRUG|tiotropium|
214899569|NCT06468592|PROCEDURE|Tilted insertion of implants|Using osteotomes, implants are inserted and tilted from 30° to 45° into the palatal direction from the maxillary sinus.
214899570|NCT06468592|PROCEDURE|Straight insertion of implants|The implants are inserted in an axial direction into the maxillary sinus according to Summers' traditional technique.
214899571|NCT00270244|BEHAVIORAL|Group interpersonal psychotherapy for depressed adolescents (IPT-AG)|Participants assigned to IPT-AG will attend two to three, 40-minute individual pre-group sessions, followed by 12, 90-minute group therapy sessions and two additional individual sessions-one midway through the group sessions and another upon completion of group therapy. Sessions will focus on problems in interpersonal relationships.
214899572|NCT00270244|BEHAVIORAL|Treatment as usual (TAU)|TAU will consist of counseling sessions as regularly conducted by the school clinic social worker and/or referral to another agency.
214899573|NCT02698163|DEVICE|Nanodiamond reinforced Gutta Percha|Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
214899574|NCT02698163|DEVICE|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
214899575|NCT00772863|DRUG|docetaxel and cisplatin|4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
214899576|NCT05361863|DEVICE|Orthodontic brackets|Interventions involving orthodontic brackets of different slot sizes
214899577|NCT02142790|DRUG|paclitaxel liposome injection|
215053647|NCT06712017|DEVICE|Yttrium-90 (Y-90) resin microspheres|selective internal radiation therapy
214899578|NCT06509802|BEHAVIORAL|Web-based Single-session Intervention of Mindset on Intelligence, Failure, and Emotion (We-SMILE)|This study will be a two-arm randomised controlled trial to examine the efficacy of the We-SMILE for pre-practicum social work and/or counselling students by comparing to the We-SMILE intervention group and the no-intervention training-as-usual group.
214899579|NCT03207984|PROCEDURE|Root coverage surgery|Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM
214899580|NCT00452764|BEHAVIORAL|Withdrawal of medication|
214899581|NCT03234543|PROCEDURE|Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity in order to induce temporary and reversible ischemia.
214899582|NCT03234543|PROCEDURE|No Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity with minimal inflation without inducing ischemia.
214899583|NCT05373108|DRUG|Macitentan|Macitentan is a nonselective endothelin-receptor antagonist (ERA) that is approved for use in pulmonary arterial hypertension (PAH); the use of Macitentan in post-heart transplant patients is considered investigational.
214899584|NCT04245254|DIETARY_SUPPLEMENT|Collagen Protien Powder|Collegen Protein Powser
215053648|NCT06716164|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
214669458|NCT02622932|DRUG|Anlotinib and 14C-labeled Anlotinib|oral
214899585|NCT06213077|DIETARY_SUPPLEMENT|Nitric Oxide|Naturally produced and found in many different kinds of cells and organ systems, NO is an integral molecule in regulating blood pressure and maintaining a healthy cardiovascular system. NO produced or generated in the vasculature then diffuses into the underlying smooth muscle causing these muscles to relax. This results in vasodilation, causing a reduction in systemic blood pressure and an increase in blood flow and oxygen delivery to specific vascular beds.
214899586|NCT06213077|DRUG|Tadalafil|Vasodilator which treats erectile dysfunction and enlarged prostate (benign prostatic hyperplasia). It can also treat high blood pressure in the lungs (pulmonary arterial hypertension).
214899587|NCT06213077|OTHER|Placebo|Nitric Oxide Placebo Compound
214899588|NCT05579028|DIETARY_SUPPLEMENT|Nutridrink ONS 200 ml|Nutridrink is a high-protein, high-calorie formula for the specialized nutrition of patients with or at risk of malnutrition. The product can be used as an additional or sole source of nutrition
214899589|NCT06265454|DRUG|low dose atropine eye drops|Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.
214899590|NCT06265454|DRUG|Placebo|placebo
214899591|NCT06079372|DRUG|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
214899592|NCT06079372|DRUG|asfotase alfa|Asfotase alfa will be administered via SC injection.
215053649|NCT06716073|PROCEDURE|Surgery|comparison of 2 surgical procedures
215053650|NCT06715657|DRUG|Morphine intrathecal|patients intrathecal anaesthesia with morphine
214899593|NCT03058627|PROCEDURE|PCI|FFR guided PCI
215053651|NCT06715657|DRUG|propofol|patients will receive 0.5 mg/kg propofol diluted in 10 ml saline 0.9% IV injection 15 min before the end of surgery
214301023|NCT05545566|PROCEDURE|Thoracic ultrasound versus chest X-ray|"Perform un ultrasound test, in addition to Chest X-Ray (usual practice), few hours after the surgery (D0), the next day (D1) and 4 to 6 hours after drain removal.~The data are collected in the standardized protocol for the two type of imaging.~The thoracic ultrasound and the Chest X-Ray are performed, blindly each other, in the same position for the patient and the same suction level of drain."
214301024|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
214899594|NCT01185327|BEHAVIORAL|Breastfeeding|Breastfeeding
214899595|NCT03854760|BEHAVIORAL|anesthesiologist with limited experiment|Using the simulate device, the trainees are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
214899596|NCT01312376|BIOLOGICAL|OC-DC vaccine|All subjects will receive a dose of 5-10 million cells of OC-DC intradermally
214899597|NCT01312376|DRUG|Bevacizumab|Patients will start receiving Bevacizumab at 15 mg/kg starting Day 30 and every 4 weeks thereafter until end of study.
214899598|NCT01312376|DRUG|cyclophosphamide 300 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous cyclophosphamide for 300 mg/m2/d for 3 days.
214899599|NCT01312376|DRUG|fludarabine 30 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous fludarabine 30 mg/m2/d for 3 days
214899600|NCT01312376|DRUG|ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells|All subjects will receive a single intravenous infusion of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T-cells at the starting dose of 10-15 x 109 (10-15 billion) T-cells with escalating doses in cohort 2 and 3.
214899601|NCT01313065|DRUG|VX15/2503|Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
214899602|NCT02689765|DIETARY_SUPPLEMENT|Anthocyanins|Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
214899603|NCT02689765|DIETARY_SUPPLEMENT|Placebo|Placebo capsules is identically packaged.
214899604|NCT02892331|BEHAVIORAL|Moderate intensity exercise training (MOD-INT)|Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
214899605|NCT02892331|BEHAVIORAL|High Intensity exercise training (HI-INT)|Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
215053652|NCT06715657|DRUG|propofol|patients will receive 0.5 mg/kg propofol diluted in 10 ml saline 0.9% IV injection just before intrathecal anaesthesia
214899606|NCT01116167|DRUG|Letrozole -Berberine|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine~1.5g daily for 6 month."
214899607|NCT01116167|DRUG|Letrozole|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine Placebo~5 tablet tds for 6 months"
214899608|NCT01116167|DRUG|Berberine|"Berberine~1.5g daily for 6 month.~Letrozole placebo~1 tablet daily from day 5 of the menses for 5 days for month 1 to 3, 2 tablets daily from day 5 of the menses for 5 days for month 4 to 6."
214899609|NCT01480869|DRUG|calcium and cholecalciferol|Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
214899610|NCT01480869|DRUG|calcium and cholecalciferol|"Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level \< 30 ng/mL"
215053653|NCT03070990|DRUG|Enfortumab vedotin|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
214301025|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
214669459|NCT02688413|DEVICE|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
214899611|NCT01950455|DRUG|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
214899612|NCT05138861|DRUG|TP-03 (Lotilaner Ophthalmic Solution), 0.25%|A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
214899613|NCT00610428|DRUG|Staccato Placebo|Inhaled Staccato Placebo
214899614|NCT00610428|DRUG|Staccato Prochlorperazine 5 mg|Inhaled Prochlorperazine 5 mg
214899615|NCT00610428|DRUG|Staccato Prochlorperazine 10 mg|Inhaled Prochlorperazine10 mg
215053654|NCT02856022|DEVICE|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1\~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
215053655|NCT02856022|PROCEDURE|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
215053656|NCT01365455|DRUG|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
215053657|NCT01365455|DRUG|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
215053658|NCT04632017|DIAGNOSTIC_TEST|Computerized cardiotocography|To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing
215053659|NCT04858113|OTHER|Blephaclean|Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.
215053660|NCT04858113|OTHER|Baby Shampoo|Conventional baby shampoo
215053661|NCT00928187|DRUG|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening
215053662|NCT00928187|DRUG|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)|Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight \< 60 kg, 400 mg if weight \> 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening
215053663|NCT00928187|DRUG|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
215053664|NCT05729906|OTHER|psychological and physical tests|"Once included (T0), participants will be reviewed at 6 (T1), and 12 (T2) months. At the three measurement times, research professionals (belonging to the PAVeA laboratory) will carry out, within the nursing home the physical and psychological measurements (classic standardized tests for the population). These measurements will be carried out in parallel with the routine biological explorations performed in the institution.~At each visit, the remaining blood sampled in routine will be frozen in 2 aliquots for metabolomic and spectrometric analyses at the end of the study by the iBrain and Research Center for Respiratory Diseases laboratories."
215053665|NCT02895178|BEHAVIORAL|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
215053666|NCT01682356|DIETARY_SUPPLEMENT|Beetroot juice|double-blind placebo-controlled cross-over study
215053667|NCT05393245|DRUG|Tiotropium+Olodaterol|Tiotropium+Olodaterol
215053668|NCT05393245|DEVICE|Spiolto Respimat|Spiolto Respimat Inhaler device
215053669|NCT05393245|DRUG|Long-acting muscarinic antagonists (LAMAs)|Long-acting muscarinic antagonists (LAMAs)
215053670|NCT05393245|DRUG|Long-acting β2-agonists (LABAs)|Long-acting β2-agonists (LABAs)
215053671|NCT04062747|DEVICE|I-gel|After standard anesthesia i-Gel was placed into the patient
215053672|NCT04062747|DEVICE|Ambu aura i|After standard anesthesia ambu aura was placed into the patient
214301026|NCT04260542|BEHAVIORAL|Ketogenic diet/ fasting|1 month of fasting-mimicking ketogenic diet and subsequent 2-days of refeeding. The subjects will be instructed by nutritional specialist to follow isocaloric ketogenic diet consisting of 6% carbohydrates, 17 % of proteins and 77% fat to cover individual energy demand. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
214301027|NCT02227589|BEHAVIORAL|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
214301028|NCT02227589|BEHAVIORAL|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
214301029|NCT02227589|OTHER|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
214301030|NCT06068933|BEHAVIORAL|K-HEARS Intervention|Tailored aural rehabilitation for participant and care partner
214301031|NCT06068933|DEVICE|K-HEARS Sound Amplifier Intervention|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
214301032|NCT06242249|BIOLOGICAL|Anti-BCMA CAR-NK|"Ten eligible patients with relapsed refractory multiple myeloma will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of BCMA CAR NK cells with close monitoring using one of the following dose levels:~* Dose Level 1: 1×10\^7/Kg~* Dose Level 2: 5×10\^7/Kg~* Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow IMWG guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease."
214301033|NCT00598247|DRUG|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
214301034|NCT00777647|OTHER|Sugar-sweetened soft drink|One litre a day for six months.
214301035|NCT00777647|OTHER|Aspartame-sweetened soft drink|One litre a day for six months.
215053673|NCT06513741|BEHAVIORAL|Mentoring Workshop|"Faculty mentoring workshop with the title Faculty Mentoring; building stronger by digging deeper was designed as a two-day workshop of three hours each for the faculty members of the two institutions at separate times"
215053674|NCT02944721|GENETIC|Genetical analyses|
215053675|NCT02944721|OTHER|Chronic pain identification questionnaires|
215053676|NCT02944721|OTHER|Neurophysiological and psychophysical evaluations|
214301036|NCT00777647|OTHER|Semi-skimmed milk|One litre a day for six months
214301037|NCT00777647|OTHER|Water|One litre a day for six months.
214301038|NCT03711487|DRUG|Foeniculum Vulgare Seed Ironing|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
214669460|NCT02688413|OTHER|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
214899616|NCT05163483|DRUG|Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab|"Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years"
214899617|NCT01522209|PROCEDURE|Liver Surgery|R0 Resection of Liver Metastases after Planning with preoperative imaging data and comparison with intraoperative contrast enhanced ultrasound
214899618|NCT01522209|DEVICE|Contrast Enhanced Ultrasound|The contrast enhanced Ultrasound imaging is performed before and during the operation using Sonovue contrast agent (2.5ml iv preop, 4.5ml iv intraop)
214899619|NCT01522209|RADIATION|CT Scan (standard)|A staging CT of the liver/abdomen with the minimal possible dosage for aquiring sufficent triphasic data in a 64-line helical scan
214899620|NCT01522209|RADIATION|Primovist MRI (3 Tesla)|an MRI scan of the liver with Primovist contrast agent including late phase as addition to the preop staging according to the protocol
214899621|NCT06132061|OTHER|universal prevention|Health education related to depression to strengthen the participants' self-care skills to reduce sub-health risk factors.
215053677|NCT02944721|OTHER|Quality of life questionnaires|
215053678|NCT06547697|OTHER|Dialysate sodium concentration|
215053679|NCT00862368|BEHAVIORAL|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
215053680|NCT00862368|BEHAVIORAL|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
215053681|NCT00862368|BEHAVIORAL|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
215053682|NCT04111796|OTHER|nature based solution for stress reduction|participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
214301039|NCT00530933|PROCEDURE|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
214301040|NCT00530933|PROCEDURE|Transcutaneous tibial nerve stimulation|30 minutes once weekly
214301041|NCT00530933|PROCEDURE|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
214899622|NCT06132061|OTHER|selective prevention|Psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) aimed at risk factors to prevent more severe depressive symptoms.
214899623|NCT06132061|OTHER|targeted prevention|Therapeutic psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) to reduce patients' depressive symptoms.
214899624|NCT06132061|OTHER|Waiting treatment.|Waiting treatment.
214899625|NCT07056920|PROCEDURE|Zirconia shell technique|Customized Zirconia membrane will be printed as a porous shell and will be used as a non resorbable membrane for horizontal ridge augmentation of deficient posterior mandibular region.
214899626|NCT06839170|OTHER|FM-IRDs assisted|A Foundation Model for Assisting the precision Diagnosis of Inherited Retinal Diseases: FM-IRDs
215053683|NCT03962907|DRUG|Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
215053684|NCT03962907|DRUG|BACTROBAN® Nasal ong|Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
215053685|NCT04910386|DRUG|Envafolimab plus Gemcitabine&Cisplatin|Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision
215053686|NCT04910386|DRUG|Gemcitabine&Cisplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
215053687|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
214899627|NCT06839170|OTHER|without FM-IRDs|without FM-IRDs
214301042|NCT03975855|DEVICE|NeoNavia® Biopsy System|Biopsy of axillary lymph node using the NeoNavia Biopsy System. The investigator shall obtain as many/large samples as judged adequate and sufficient for diagnosis.
214301043|NCT02318511|PROCEDURE|Knee injection|Injection into knee for the treatment of Osteoarthritis
214899628|NCT00349973|DRUG|Dipyridamole|Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm
214899629|NCT00349973|OTHER|Olanzapine|Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm
214899630|NCT01458665|PROCEDURE|Conventional arthroscopic rotator cuff repair|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
214899631|NCT01458665|PROCEDURE|Arthroscopic rotator cuff repair with PRP|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
214899632|NCT03348540|BEHAVIORAL|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
214899633|NCT03348540|BEHAVIORAL|Comparison Task|Neutral- neutral stimuli prior to response task
214899634|NCT00695344|DRUG|everolimus|Everolimus 2 times per day, v.o., 2 years treatment.
214899635|NCT00695344|DRUG|azathioprine or mycophenolate mofetil|2 times per day during 2 years
214899636|NCT03754010|PROCEDURE|Scaling and root planning|Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.
215053688|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
214301044|NCT02318511|OTHER|ReNu amniotic allograft|
214899637|NCT03754010|DRUG|Hyaluronic acid gel (HA) and SRP|In Group 2, after SRP will be performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA will be applied intrasulcular.
214899638|NCT03754010|DRUG|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse will be used as an irrigator after SRP.
215053689|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
215053690|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
214301045|NCT02318511|DEVICE|placebo saline|
214301046|NCT02318511|DEVICE|Hyaluronic Acid|
214301047|NCT03023969|DRUG|ozone oxygen mixture|receive 10 ml of ozone oxygen mixture under variable dosing
214301048|NCT01053819|DRUG|etanercept|Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
214301049|NCT05003453|DRUG|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
214301050|NCT05003453|DRUG|Placebo Comparator|A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
215053691|NCT06403553|DIAGNOSTIC_TEST|Fecal Calprotectin|Fecal Calprotectin measurement on days 1and 3
215053692|NCT06464731|PROCEDURE|EVT|Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
214899639|NCT03754010|DRUG|HA mouthrinse+gel and SRP|In Group 4, after SRP will be performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel will be applied.
214899640|NCT00006186|PROCEDURE|Autologous fresh whole blood|
214899641|NCT04904250|DEVICE|Emboshield|a distall occlusion Emboshield NAV6 will be used as the embolism protection device during CAS
214899642|NCT04904250|DEVICE|Spider|a distal SpiderFX will be used as the embolism protection device during CAS
214899643|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers
214899644|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers
214899645|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers
214899646|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers
214899647|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers
214899648|NCT01161069|DRUG|Placebo|Placebo in oral solution, given once daily for 14 days
214899649|NCT00073164|DRUG|Divalproex Sodium Extended-Release Tablets|
214899650|NCT00073164|DRUG|Olanzapine|
215053693|NCT04777006|BEHAVIORAL|Problem Management Plus|"PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4"
215057502|NCT01555996|BEHAVIORAL|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
214301051|NCT03251508|DRUG|Peanut OIT|Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
214301052|NCT00101907|DRUG|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
214301053|NCT00101907|BIOLOGICAL|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
214301054|NCT00101907|DRUG|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
214301055|NCT00101907|DRUG|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
214301056|NCT02496455|PROCEDURE|cesarean section|Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
214301057|NCT02496455|DRUG|Opioid Tramadol|Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
214301058|NCT04062838|DRUG|Dextrose 50|As above
214478898|NCT03989089|DRUG|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
214478899|NCT06234410|RADIATION|Computed tomography coronary angiography (CTCA)|Single CTCA scan prior to kidney transplantation
214899651|NCT00073164|DRUG|Risperidone|
214899652|NCT02508623|DRUG|Rifaximin|Rifaximin 550 mg tablet BID for 60 days
214899653|NCT02508623|DRUG|Placebo|Placebo 1 tablet BID for 60 days
214899654|NCT03509064|OTHER|Collection sheet|Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet
214899655|NCT01388959|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
214899656|NCT00425243|DRUG|zolpidem-MR (SL800750)|
214899657|NCT05993364|DEVICE|Free Aspire with Expiratory Flow Accelerator (EFA) technology|Treatment sessions during which the EFA technology is used. Depending on the patient's clinical conditions, an oxygen additional support can be provided, while using the device. If present, during the sessions the tracheal cannula must be cuffed. Tracheal cannula aspiration must be provided when necessary. Sessions take place three times a day and take 20 minutes each time, from Monday to Saturday.
214899658|NCT05993364|DEVICE|In-Exufflator Machine|Sessions using the In-Exufflator machine to improve the cough function, when the oxygen saturation decreases and the bronchial secretions increases.
214899659|NCT05993364|OTHER|Traditional respiratory treatment|"Standard rehabilitative treatment to improve the secretions management, that includes:~* A change of the patient posture every three hours;~* Airways humidification depending on the secretions features;~* Aspiration in the tracheal cannula whenever necessary."
214899660|NCT05993364|OTHER|Traditional swallowing treatment|"Traditional rehabilitative treatment carried out by the speech and language pathologist in order to:~* Obtain decannulation (when a tracheal cannula is applied) following the Bargellesi Protocol steps;~* Improve oral structures strength and motility;~* Improve oral and perioral sensitivity with thermal or gustative or tactile stimulations;~* Improve the swallowing function with food trials of different consistencies, volume and temperature;~* Improve swallow efficacy and safety through the prescription of compensatory postures;"
214478900|NCT06609655|OTHER|no intervention studied, it&#39;s a databank|"The AgeTeQ database Arts, health and new information and communication technologies has three objectives.~The first is to preserve the data collected as part of the research projects carried out by the AgeTeQ laboratory.~The second objective of the database is to use the information provided by the recorded data to fuel reflection, test new research hypotheses and thus open up new avenues of research for the Arts, Health and New Information and Communication Technologies research team.~The third objective is to share the AgeTeQ database with the scientific community on a non-commercial basis, to improve access to data on the themes of arts, health and new technologies, and to increase knowledge and enable the development of research in these fields."
214899661|NCT02510443|DEVICE|ESS305 (Essure, BAY1454032)|Bilateral insert placement
214899662|NCT04314037|DRUG|Cesol (Test)|Participant will receive coated cesol tablet in sequence 1 (Day 1 and Day 15) and in sequence 2 (Day 8 and Day 22). A washout period of 7 days will be maintained between 4 treatment periods.
214899663|NCT04314037|DRUG|Biltricide (Reference)|Participant will receive biltricide tablet in Sequence 1 (Day 8 and Day 22) and in sequence 2 (Day 1 and Day 15). A washout period of 7 days will be maintained between 4 treatment periods.
214899664|NCT03645473|DEVICE|Monarch Airway Clearance System|HFCWO Airway Clearance Device
214899665|NCT02490631|DRUG|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
214899666|NCT00356382|DRUG|Lactobacillus (L.) casei|
214899667|NCT06151873|DIAGNOSTIC_TEST|Adapted sport|control group sample, healthy subjects without musculoskeletal, neurological or vestibular alterations can participate.
214899668|NCT06151873|DIAGNOSTIC_TEST|Adapted sport|Subjects with cerebral palsy/acquired brain damage belonging to the Spanish National Soccer Team with cerebral palsy and acquired brain damage may participate as an experimental group.
214899669|NCT03818113|OTHER|cardioplegia with HTK-Bretschneider cardioplegic solution|cardioplegia with HTK-Bretschneider cardioplegic solution
214899670|NCT03818113|OTHER|cardioplegia with St. Thomas cardioplegic solution|cardioplegia with St. Thomas cardioplegic solution
214899671|NCT05670808|DRUG|Epinephrine injection|Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
214899672|NCT06034106|BEHAVIORAL|Pomegranate (Punica granatum) peel compress|Pomegranate (Punica granatum) peel compress was applied 3 days a week for 3 weeks by turning the powder into porridge check.
214899673|NCT06034106|BEHAVIORAL|Hot compress|Hot compress was applied 3 days a week for 3 weeks.
214899674|NCT01370447|DRUG|EPI-743|EPI-743 (oral solution \[100 mg/mL\] or liquid-filled capsules \[100 mg or 200 mg\]) will be administered per dose and schedule specified in the arm.
214899675|NCT06902233|DEVICE|High-definition transcranial infraslow grey noise stimulation|HD-tIGNS will be administered three times a week (30 minutes/ session) for a total of 4 weeks (i.e., 12 sessions in total) using a 32-channel transcranial current stimulator. The HD-tIGNS will be used to alter the functional connectivity strength between the three cortical networks \[namely the salience network (SN), the default mode network (DMN) and the somatomotor network (SMN)\] in the infraslow frequency spectrum (0.1 Hz). A total of fifteen circular Ag/AgCl electrodes \[eleven stimulation electrodes (C1, C2, C3, C4, F7, F8, FC3, FT7, FPz, Fz, and O2) and four electrodes with zero current (FC1, FC2, FC4, and FCz)\] will be placed on a neoprene head cap following the International 10-10 EEG system. The optimal montages has been created using the Stimweaver optimization software by the Neuroelectrics company, to specifically decrease the functional connectivity i.e., phase synchronization of the brain regions of the SN with the SMN and the DMN.
214899676|NCT06902233|DEVICE|Sham Comparator|The Actisham protocol (with FC2 as the itchy electrode) created by the Neuroelectrics will be used for the sham stimulation group. Similar to the active treatment group, the actisham will be administered three times a week (30 minutes/ session) for a total of 4 weeks (i.e., 12 sessions in total) using a 32-channel transcranial current stimulator.Similar to active group, a total of fifteen circular Ag/AgCl electrodes will be placed on a neoprene head cap following the International 10-10 EEG system to appropriately blind the participant. The electrodes would comprise of four stimulation electrodes (FC1, FC2, FC4, and FCz) and eleven electrodes (C1, C2, C3, C4, F7, F8, FC3, FT7, FPz, Fz, and O2) with zero current.
214899677|NCT07090278|DRUG|ulinastatin|Ulinastatin for the treatment of sepsis patients during ICU stay
214899678|NCT07097857|OTHER|SFDI|SFDI imaging is performed on both treated and untreated limb.
214899679|NCT07096765|DRUG|Group O|"Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg ,~%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
215053694|NCT04777006|DRUG|Antidepressant Therapy|"Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care."
215053695|NCT01948219|DEVICE|ENTegral Artificial Larynx implant|
215053696|NCT03870464|DIAGNOSTIC_TEST|CT-scans extended|CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
215053697|NCT03870464|DIAGNOSTIC_TEST|MRI scan of the brain|MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
214301059|NCT05883930|OTHER|'Let's Move' program|"Students will complete data collection forms as part of the program. According to International Physical Activity Questionnaire (IPAQ), those who are low in activity and inactive will be assigned to the appropriate intervention program based on their sedentary lifestyle stage.~Students will enter the module system prepared according to the five different stages of change \[not thinking (1), thinking (2), preparing (3), acting (4), continuing (5)\] of sedentary living.~There are 12 different initiatives for each phase/module of the program. Summary and reinforcing questions are asked at the end of each trial. If participants do not answer the questions, they cannot continue with the next week's initiative.~Participants' daily step counts with the smart wristband are recorded in the program.~Daily alerts/reinforcement messages related to that week's initiative will be sent during all phases."
214669461|NCT03968965|DEVICE|3D MvIGS Spine Navigation|The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.
215053698|NCT03870464|OTHER|Prospective registration of irAEs|irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
215053699|NCT03870464|BEHAVIORAL|Quality of Life questionnaires|Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
215053700|NCT01273038|DEVICE|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
215053701|NCT01273038|DEVICE|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
215053702|NCT03248388|DEVICE|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
215053703|NCT03248388|DEVICE|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
215053704|NCT05865951|OTHER|Isometric Exercises|Isometric (same length) strengthening exercises of the neck muscles will be performed.
215053705|NCT05865951|OTHER|Isotonic Exercises|Isotonic strengthening exercises for the neck muscles will be performed.
215053706|NCT01976299|DEVICE|AVERT|
215053707|NCT00649350|DRUG|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fed
215053708|NCT00649350|DRUG|Glucophage XR 750 mg|750mg, single dose fed
215053709|NCT02722213|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
215053710|NCT02735603|DRUG|Naltrexone HCl/bupropion HCl|Naltrexone HCl/bupropion HCl extended-release tablet.
215053711|NCT02735603|OTHER|Placebo|Naltrexone/bupropion placebo-matching tablets.
215053712|NCT02735603|DRUG|Moxifloxacin|Moxifloxacin tablet.
215053713|NCT00614419|DEVICE|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
214301060|NCT05883930|OTHER|no intervention|No intervention will be applied to the control group.
214301061|NCT00245674|DRUG|amisulpride|
214301062|NCT02500784|DRUG|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
214301063|NCT02500784|OTHER|Formoterol B (placebo)|2mL, BID inhaler for 12 months
214301064|NCT00230464|DRUG|LAF 237|
214301065|NCT04111679|OTHER|Music|Participant selected music, applied using noise cancelling headphones
214301066|NCT00941044|DEVICE|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
214301067|NCT04734509|DEVICE|Silhouette breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
214301068|NCT02883634|OTHER|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
214301069|NCT02883634|OTHER|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
214301070|NCT01103609|DRUG|Warfarin|Oral tablet od on Day 4
214899680|NCT07096765|DRUG|Group T|"Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg ,~%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
214899681|NCT07096765|DRUG|Group C|"Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg ,~%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
214899682|NCT07096557|DRUG|Coenzyme Q10|Coenzyme Q10 100 mg capsule once daily for 3 months
214899683|NCT07097402|BEHAVIORAL|Self-compassion intervention (Self-Compassion for Healthcare Communities course)|An online 6-week mindful self-compassion course with weekly sessions.
214899684|NCT05296148|DEVICE|Transcatheter Tricuspid Valve Implantation|Implantation of a tricuspid coaptation valve through a transcatheter approach.
214899685|NCT05390086|OTHER|Standard of care|The study is being implemented among children who are seeking care at collaborating hospitals for signs and symptoms suggestive of TDD. All children will be treated by the hospital physicians following the usual hospital procedures. The study will not interfere in any with the administration of required treatments and interventions.
214899686|NCT03058159|OTHER|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
214301071|NCT01103609|DRUG|Placebo|Oral tablet bd, stepwise increased
214669462|NCT03968965|OTHER|2D Fluoroscopy|Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
214899687|NCT05110144|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
214899688|NCT05110144|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
214301072|NCT01103609|DRUG|AZD1656|Oral tablet bd, stepwise increased
214301073|NCT04052984|PROCEDURE|Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section|Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
214301074|NCT04882228|DRUG|Entelon Tab.150mg|twice daily for 8 weeks
214301075|NCT04882228|DRUG|Venitol Tab.|twice daily for 8 weeks
214301076|NCT04882228|DRUG|Placebo of Venitol Tab.|twice daily for 8 weeks (with Entelon Tab.150mg. It is for the masking.)
214301077|NCT04882228|DRUG|Placebo of Entelon Tab.150mg|twice daily for 8 weeks(with Venitol Tab. It is for the masking.)
214301078|NCT01997515|DRUG|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
214301079|NCT01997515|DRUG|placebo|Group P (placebo) will receive the same amount of saline.
214301080|NCT05270954|BIOLOGICAL|Betuvax-CoV-2|Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)
214301081|NCT05270954|DRUG|Placebo|Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
214301082|NCT03527199|DIAGNOSTIC_TEST|Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)|Standard of care-Pelvic CT or MRI and MDP bone scan + or - 18F-NaF PET/CT
214899689|NCT05110144|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
214899690|NCT05110144|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
214899691|NCT05110144|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
214899692|NCT05110144|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
214899693|NCT02543788|PROCEDURE|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
215053714|NCT00614419|DEVICE|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
214301083|NCT00110409|BEHAVIORAL|Asthma Education in Adults|The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.
215053715|NCT05922995|DRUG|Tasimelteon|20 mg capsules taken on a nightly basis
215053716|NCT03895294|OTHER|Health care under the strategic purchase-Clinical pathway|1\) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
214478901|NCT06331065|OTHER|Information session on mindfulness meditation and questionnaires|"The information session on mindfulness meditation is an information meeting on the PROMIND study opened to all hospital professionals from the 8 participating departments, i.e. the intervention and control groups.~During this information session, it is specified that it is desirable for the non-intervention groups to maintain their usual practice (or non-practice) during the study, without starting a new practice of mindfulness meditation.~Before this meeting, the baseline questionnaires are administered. Immediately after this time, the questionnaire on representations of mindfulness meditation is administered."
214899694|NCT02546986|DRUG|CC-486|CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
214899695|NCT02546986|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
214899696|NCT02546986|DRUG|Placebo|Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
214899697|NCT04874207|DRUG|Regorafenib|Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15
214899698|NCT03800407|OTHER|Observational study|Outcome of EFV-based ART in children with TB/HIV coinfection compared to those with HIV only on EFV-based ART
215053717|NCT03895294|OTHER|Usual care process prior strategic purchase-clinical pathway|1\) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
215053718|NCT03852784|OTHER|Bone and joint infection with Streptococcus peumoniae|description of the osteoarticular infection with Streptococcus peumoniae
215053719|NCT03985280|DEVICE|Cooled radiofrequency|Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.
215053720|NCT03985280|DRUG|Intraaticular steroids and local anesthetic injections|Intraaticular steroids and local anesthetic injections
215053721|NCT01958255|BEHAVIORAL|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
214301084|NCT00110409|BEHAVIORAL|Standard Emergency Room Asthma Education|Participants will receive standard emergency room education about asthma.
214899699|NCT03598426|DRUG|Dexamethasone|Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
214899700|NCT00947362|OTHER|Electro-thermo-coagulation|
214899701|NCT00947362|DRUG|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
214899702|NCT00947362|DRUG|saline|physiological saline
215053722|NCT01947335|DEVICE|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
215053723|NCT03972618|BEHAVIORAL|Installation of water filtration system for filtering existing water source|Installation of water filtration system and education on hand washing.
215053724|NCT00540592|BIOLOGICAL|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
215053725|NCT00540592|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
215053726|NCT01927263|BIOLOGICAL|NI-071|100mg/vial
215053727|NCT01927263|BIOLOGICAL|Infliximab|100mg/vial
215053728|NCT01456130|DRUG|Alogliptin|Alogliptin tablets
215053729|NCT01456130|DRUG|Rapid-acting insulin secretagogue|Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
215053730|NCT02748252|OTHER|stroke center referral|
215053731|NCT03931499|DIAGNOSTIC_TEST|Metabolomic analysis|Blood will be collected in all patients blood before surgery and after surgery (postoperative day 1). Our study is based on a polar metabolomics profiling of plasma and/or serum using hybrid triple quadrupole mass spectrometer coupled with chromatographic system.
215053732|NCT04863053|OTHER|Blood samples will be taken to assess platelet function. There is no change in treatment.|
214301085|NCT05237479|PROCEDURE|Suprainguinal fascia ilica block|Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory \& motor distribution of the LFCN, FN, \& ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory \& motor distribution of LFCN, FN, \& ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory \& motor distribution of LFCN, FN, \& ON \& adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
214301086|NCT05237479|OTHER|Placebo|The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
214301087|NCT06181890|OTHER|Motivational Interview|The data of the research will be collected between October 2023 and June 2024. Each meeting will last approximately 15-30 minutes.
214301088|NCT05705986|OTHER|Blood Draw|Single blood draw
214669463|NCT05212129|DEVICE|Percutaneous vagal nerve stimulation (pVNS) device|Subjects in Treatment Arm B will enter a six-week, prospective open label treatment trial with the FDA-approved and commercially available device IB-Stim. This is an ambulatory, neurostimulation device which consists of a battery powered, externally affixed generator with 4 wire leads attached to electrode/needle arrays affixed to the outer ear. The device delivers low voltage (3.2V) stimulation in alternating frequencies for a total of 5 days (around the clock).
214669464|NCT05212129|OTHER|Acoustic vagal nerve stimulation (aVNS) treatment|All subjects receiving acoustic therapy via active VNS (aVNS; n=30) or sham VNS (sVNS; n=30) will enter a four-week, randomized, double-blind clinical trial during which they will listen to either computer altered/filtered vocal music (active treatment) that has been designed to stimulate vagal calming vs. regular non-filtered music (sham treatment). The stimuli will mirror the acoustic intervention known as the Safe and Sound Protocol. This protocol has been found to reduce auditory hypersensitivities and calming the autonomic nervous system by increasing vagal regulation of the heart via brainstem ventral vagal complex. The acoustic intervention may be played by an electronic device (i.e. smartphone, tablet, laptop, mp3) and delivered virtually with the help of trained coaches.
215053733|NCT03689569|DIETARY_SUPPLEMENT|Resistant starch|Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
215053734|NCT03689569|BEHAVIORAL|Exercise|Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
214669465|NCT02495337|OTHER|Tissue Collection|
214669466|NCT03898934|DRUG|Vitamin D|receive 6000iu daily for 8 weeks
214899703|NCT06526949|BEHAVIORAL|Reiki|Reiki application was performed by a responsible researcher who has a Level 3 (Reiki Master) certificate. To prevent contamination between patients and to provide a suitable environment during the intervention, a curtain-screen system was used in the intensive care unit, and patients were fitted with earplugs to provide a quiet environment during the procedure. During the treatment (total time 30 minutes) the Reiki practitioner gently placed his/her hands on or above the patient's head and eyes, upper body from neck to pelvic area, arms and legs (standard Reiki hand positions). The application was limited and performed once due to the rapid changes in intubation time, intensive care unit stay and hemodynamic stability.
214899704|NCT06526949|OTHER|(Sham Reiki)|n the placebo (sham Reiki) group, treatments were performed by sham practitioners (not involved in the study) who had no experience with energy work and did not believe in energy therapy. In order to ensure blinding during the sham application, the patients were given the same hand movements as the experimental group for the same duration. In order not to distract the patients during the application, the area was separated with a curtain and screen system and earplugs were used. The sham practitioner gently placed his hands on or above the patient's head and eyes, upper body from the neck to the pelvic area, arms and legs for 30 minutes. The application was simulated in a manner similar to standard Reiki hand positions.
214899705|NCT02210078|BIOLOGICAL|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given IV
214899706|NCT04791839|DRUG|Zimberelimab|Zimberelimab will be supplied by Arcus Biosciences.
214301089|NCT04521465|DEVICE|NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)|Eye drops
214669467|NCT03898934|DRUG|Placebo Oral Tablet|placebo for the same period
214899707|NCT04791839|DRUG|Domvanalimab|Domvanalimab will be supplied by Arcus Biosciences.
214669468|NCT01939379|DRUG|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
214669469|NCT01939379|DRUG|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
214899708|NCT04791839|DRUG|Etrumadenant|Etrumadenant will be supplied by Arcus Biosciences.
214899709|NCT04259788|OTHER|AHEI diet|Main intervention is the consumption of an AHEI diet for 12 weeks.
215053735|NCT03689569|BEHAVIORAL|Starch|Patients will be given 30 grams of corn starch
215053736|NCT06281977|DRUG|Dexmedetomidine|Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
215053737|NCT06281977|DRUG|Normal saline|Programed as dexmedetomidine on infusion pump.
215053738|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
215053739|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
215053740|NCT04404673|PROCEDURE|Evaluation of urinary and sexual dysfunction after rectal resection|Comparison among the 4 different surgical approaches for urinary and sexual function
215053741|NCT02692963|BIOLOGICAL|BCG vaccination|BCG vaccine InterVax
215053742|NCT02688192|BEHAVIORAL|Exercise Intervention|Participate in fitness program
214899710|NCT06844214|BIOLOGICAL|SAR446268|Pharmaceutical form: Solution for infusion; Route of administration: IV infusion
214899711|NCT05956340|BEHAVIORAL|Research interview|Research interview to capture speech data with high quality cardioid headset microphone
214899712|NCT05743036|DRUG|ZN-c3|ZN-c3 tablet by mouth, in combination with encorafenib
214899713|NCT05743036|DRUG|Encorafenib|Encorafenib capsule by mouth, in combination with ZN-c3
214899714|NCT05743036|DRUG|Cetuximab|Infusion
214899715|NCT04640987|BIOLOGICAL|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
214899716|NCT04640987|DEVICE|CliniMACS Prodigy System|Device used for production of T-allo10 cells.
214899717|NCT04640987|DRUG|T-allo10 cells addback|T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.
214899718|NCT06092892|PROCEDURE|Breast Surgery (BCS or mastectomy) with TAD/SNB|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
214899719|NCT06092892|RADIATION|Adjuvant Radiation Therapy|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
214899720|NCT05569486|DEVICE|Green Light|This is a low-energy device. It produces almost no heat because it uses an LED source for light. The device does not store energy or electrical power that can be discharged later.
214899721|NCT06270589|BEHAVIORAL|MF-HIIT|A single bout of 20-min MF-HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s mindful intervals), and finally a 2-min cool-down.
214899722|NCT06270589|BEHAVIORAL|MF-only|A single bout of 20-min intervention mindfulness intervention that includes 5 x 90s mindful intervals separated by sitting rest
214899723|NCT06270589|BEHAVIORAL|HIIT-only|A single bout of 20-min HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s rest intervals), and finally a 2-min cool-down.
214899724|NCT06270589|BEHAVIORAL|Sitting rest|Participants will sit in a comfortable chair, placed on the treadmill, while watching a HIIT video without mindfulness instructions for 20 minutes.
214899725|NCT05609253|DRUG|Itraconazole in capsule form|Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
214899726|NCT05609253|DRUG|Itraconazole in solution form|Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
214899727|NCT03623646|DRUG|Chemoradiotherapy arm|Radiation Therapy in combination with Chemotherapy (Cisplatin)
214899728|NCT03623646|DRUG|Immunotherapy + Radiotherapy arm|Radiation Therapy in combination with Immunotherapy drug (Durvalumab)
214899729|NCT04064138|PROCEDURE|Peritoneal block|At the beginning of surgery, immediately after insertion of the first port 2 mg/kg lidocaine and 25mg/kg magnesium sulfate and 1/200 000 epinephrine in a total volume 50 ml (completed with saline .9%) will be given intra-peritoneal 10 min before the surgeon proceeds . At the end of the surgery another similar lidocaine-magnesium-epinephrine injection will be instillated before removal of the last port and the drain will be kept closed for 30 min.
214899730|NCT04064138|PROCEDURE|Ultrasound guided erector spinae plane block|Before general anesthesia, ESPB will be performed under ultrasound guidance. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. The patient's skin will be anesthetized with 3 mL of 2% lidocaine. A 21 gauge 10cm needle will be inserted using an in plane superior to inferior. The tip of the needle will be placed into the facial plane on the deep aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process on ultrasonographical imaging. The calculated dose of lidocaine (2mg/kg) with 150 mg MgSo4 and 1/200 000 epinephrine will be injected on each side.
214899731|NCT04064138|OTHER|General anesthesia|General anesthesia
214899732|NCT04446169|DIAGNOSTIC_TEST|SARS-CoV 2 RNA PCR Urine|Search for SARS-CoV 2 RNA in urine through PCR
214899733|NCT04446169|DIAGNOSTIC_TEST|SARS-CoV 2 RNA PCR Semen|Search for SARS-CoV 2 RNA in Semen through PCR
214899734|NCT04446169|DIAGNOSTIC_TEST|Semen Qualitative Analysis|Search for Semen Alterations in patients with past SARS-CoV 2 infection
214899735|NCT04446169|DIAGNOSTIC_TEST|IIEF-5 questionnaire|IIEF-5 assessment in patients with past SARS-CoV 2 infection
214899736|NCT04446169|DIAGNOSTIC_TEST|Male Sexual Health Questionnaire (MSHQ)|Male Sexual Health Questionnaire (MSHQ) assessment in patients with past SARS-CoV 2 infection
214899737|NCT04446169|DIAGNOSTIC_TEST|IPSS questionnaire|IPSS assessment in patients with past SARS-CoV 2 infection
214899738|NCT04446169|DIAGNOSTIC_TEST|SECRET questionnaire|SECRET questionnaire assessment in patients with past SARS-CoV 2 infection
214899739|NCT04446169|DIAGNOSTIC_TEST|Interleukin assessment in semen|Assessment of Interleukin presence and quantitative analysis in semen, to study if a previous inflammation/infection due to SARS-CoV 2 in testis was present
214899740|NCT01168232|DRUG|Ixabepilone|Given IV
214899741|NCT01168232|OTHER|Laboratory Biomarker Analysis|Correlative studies
215053743|NCT02688192|BEHAVIORAL|Internet-Based Intervention|Engage in private social support messaging and Use the mobile app
215053744|NCT02688192|DEVICE|Monitoring Device|Wear an electronic accelerometer
215053745|NCT02688192|OTHER|Quality-of-Life Assessment|Ancillary studies
215053746|NCT03805854|DEVICE|10 Hz tACS of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
215053747|NCT03805854|DEVICE|10 Hz tACS of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
215053748|NCT03805854|DEVICE|80 Hz tACS of the bilateral somatosensory cortex|80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
214301090|NCT05879406|DIETARY_SUPPLEMENT|VitaMedica® Clear Skin Formula capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Vitamin A (from Betatene® Carotenoid Blend) (7,500 IU/2,250 mcg RAE) Vitamin A (from Retinyl Palmitate) (5,000 IU/1,500 mcg RAE) Vitamin C (as Ascorbic Acid) (60 mg) Vitamin E (from d-alpha-Tocopheryl Acid Succinate) (30 IU/20 mg) Zinc (from Zinc Bisglycinate Chelate) (24 mg) Selenium (from Selenium Glycinate) (48 mcg) Chromium (from Chromium Nicotinate Glycinate Chelate) (150 mcg) MSM (Methylsulfonylmethane) (200 mg) Bromelain (200 mg) Burdock (Arctium lappa) root (50 mg) Oregon Grape (Mahonia aquifolium) root (25 mg) Dandelion (Taraxacum officinale) root (50 mg) Yellow Dock Extract (Rumex crispus) root (50 mg) Hypromellose Microcrystalline cellulose Magnesium Stearate Silicon Dioxide"
214669470|NCT02065089|OTHER|playing the ipad quiz game|Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.
215053749|NCT03805854|DEVICE|80 Hz tACS of the prefrontal cortex|80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
215053750|NCT03805854|DEVICE|Sham stimulation of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
215053751|NCT03805854|DEVICE|Sham stimulation of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
214899742|NCT05236205|PROCEDURE|Caries removal with a lowspeed drill|"1. Initial periapical and interproximal radiographs;~2. Prophylaxis with toothbrush and fluoride toothpaste;~3. Relative isolation with lip bumper, cotton roll, and aspirator;~4. Microbiological sampling with ear curette for standardization of volume of carious tissue;~5. Removal of carious dentin with carbide burs and manual instruments;~6. Additional microbiological sampling;~7. Clinical inspection of texture of remaining dentin with an exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar Easy Mix - 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months."
214899743|NCT05236205|PROCEDURE|Partial removal of carious tissue with the administration of Papacarie™|"1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ for 5 m inutes, removal of carious tissue around lateral walls of the cavity with noncutting curette and no removal of carious tissue on pulp floor;~5. Second microbiological sample of remaining dentin with curette;~6. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~7. Restoration with glass ionomer cement;~8. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
215053752|NCT05695040|BEHAVIORAL|"dietary workshop proteins"|"The workshop will have 2 objectives:~* Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~* Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety."
215053753|NCT05384834|BEHAVIORAL|#HerHeart tool|An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
215053754|NCT02490397|OTHER|Day Light|Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.
215053755|NCT02490397|OTHER|Room Light|Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
215053756|NCT03898271|OTHER|Virtual World|Participants will complete a synchronous PTSD training in an immersive virtual world environment.
215053757|NCT00515528|BIOLOGICAL|4-peptide melanoma vaccine|Experimental cancer vaccine given as a shot under the skin once every two weeks
215053758|NCT00515528|DRUG|Ontak|A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
215053759|NCT01341535|RADIATION|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
215053760|NCT01341535|RADIATION|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
215053761|NCT00681395|DRUG|ABT-143|once daily for 6 days
215053762|NCT00681395|DRUG|ABT-335|once daily for six days
214301091|NCT05879406|OTHER|Placebo Capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Magnesium Stearate (VEG) (NON-GMO) Silica (As Silicon Dioxide) Micro Cellulose (MCG) (NON-GMO)"
214301092|NCT04780854|DRUG|Metformin|Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration
214301093|NCT04780854|DRUG|Placebo|Participants in the placebo group will be administered metformin free tablet as placebo twice daily
214301094|NCT00990496|DRUG|Fludarabine|30 mg/m2
214301095|NCT00990496|DRUG|Cyclophosphamide|600 mg/m2
215053763|NCT00681395|DRUG|Rosuvastatin|Once daily for 6 days
215053764|NCT03940079|DEVICE|computer-based cognitive game (including 3 training tasks)|"First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor."
215053765|NCT02112305|DRUG|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval
214301096|NCT00990496|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
214301097|NCT03583138|DRUG|buprenorphine|To provide buprenorphine for 12 months for those who are interested in receiving it.
214301098|NCT02420054|BEHAVIORAL|Intermittent fasting|Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
214301099|NCT02420054|OTHER|Time control|Time control period with no change in eating habits.
214301100|NCT01523886|DRUG|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
214301101|NCT01523886|DRUG|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
214301102|NCT05266092|OTHER|Observational study|Observational study
214301103|NCT00000806|DRUG|Telinavir|
214301104|NCT06469112|DEVICE|Vibration|The device was used to provide vibration with the participants in this group. This device, designed as a combination of cold application and local vibration to reduce pain experienced during invasive procedures, is frequently chosen for all age groups.
214669471|NCT02060734|PROCEDURE|Lidocaine|Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
214899744|NCT05236205|PROCEDURE|Partial removal of carious tissue with the administration of Papacarie™ and application of Bixa Orellana extract (20%)|"1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes, removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement;~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
214899745|NCT05236205|PROCEDURE|Partial removal of carious tissue with the administration of Papacarie™, application of Bixa Orellana extract (20%) and LED (aPDT)|"1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes and the blue light-emitting diode (LED) irradiation with 440-480 nm. Removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
214899746|NCT01279317|DIETARY_SUPPLEMENT|placebo co-ingestion|25 ml water co-ingested with a glucose-containing beverage
214899747|NCT01279317|DIETARY_SUPPLEMENT|vinegar co-ingestion|25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
214899748|NCT05070793|BEHAVIORAL|Culturally adapted interpersonal psychotherapy|Individual psychotherapy based on Brief Interpersonal Psychotherapy, culturally adapted for transgender and nonbinary individuals.
215053766|NCT02112305|DRUG|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
215053767|NCT01984047|DRUG|GSK3050002|GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
215053768|NCT01984047|DRUG|Placebo|Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
215053769|NCT00473109|PROCEDURE|Dialysis without systemic heparinization|Dialysis without systemic heparinization
215053770|NCT05089292|BEHAVIORAL|Narrative breast health education|Health education program utilizing narrative messages to promote breast cancer screening in Chinese immigrant women will be delivered in a group format in the community
215053771|NCT06121648|OTHER|hydrotherapy|30 degrees temperature pool balance and breathing therapy
215053772|NCT06121648|OTHER|neurological physiotherapy|Balance and neurological physiotherapy on land
215053773|NCT00042237|BEHAVIORAL|Schema Therapy|
215053774|NCT03925987|BEHAVIORAL|Exposure therapy|10 weekly sessions of group-based exposure therapy
215053775|NCT04651205|DIETARY_SUPPLEMENT|vitamin B1 and magnesium supplements|vitamin B1 - 100 mg/day magnesium - 400 mg/day
215053776|NCT06113757|DEVICE|Signal Therapy provided by Dr.Biolyse device|Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. Electrical signal will be applied to the lung and upper leg area for 90 minutes in the morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on the 4th and 5th days, to the lung and upper leg area. During your first hospitalization, blood will be drawn from you daily for 5 days and evaluated in terms of various biochemical parameters and detailed molecular analyzes.
215053777|NCT06113757|OTHER|Liquid Support Treatment|The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
214301105|NCT06469112|OTHER|Placebo|The device was used with participants in this group. The device, at room temperature, was placed by the researcher 5cm proximal to the injection site before the injection was performed. With participants in this group, the device was placed on the procedure site, but no vibration was made. The device was held on the participants for one minute before the injection and throughout the procedure, with the vibration switched off.
214301106|NCT06913556|DIAGNOSTIC_TEST|Preoperative dry eyes|In group 1 we access preoperative dry eyes condition and postoperatively we access the condition in 2nd and 4th week with the use of Hylorunic acid lubricant.
214301107|NCT06913556|COMBINATION_PRODUCT|Lipid coated carbomer gel eye drops|In group 2 we prescribe the lipid coated carbomer gel eye drops and access dry eyes condition preoperative and postoperative on 2nd and 4th week and check the curative effect of drop.
214301108|NCT06912737|BEHAVIORAL|Group Emotion Focused Behavioral Intervention (G-EFBI)|Group EFBI (G-EFBI) is aimed at assisting people with T2D to gain knowledge about emotions and improve their ability to regulate and manage their emotions.
214301109|NCT06912737|BEHAVIORAL|Group - With Every Heartbeat is Life (G-WEHL)|G-WEHL is an educational intervention designed to increase awareness and prevention of cardiovascular disease.
214301110|NCT06914375|OTHER|Goya Foods - Canned Chickpeas|Whole-cooked, canned chickpeas supplied by Goya Foods. Provided to participants on a weekly basis in amounts specific to DGAs 2020-2025 and the participant's gender.
214899749|NCT04938310|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
214899750|NCT04938310|DEVICE|support garment|A custom made support garment
214899751|NCT02841618|OTHER|High Linoleic Acid Healthy Cookies|
214899752|NCT02841618|OTHER|High Oleic Acid Healthy Cookies|
214899753|NCT06452355|DEVICE|KOKO Device|The intrauterine drain is extended into the uterus, where low pressure vacuum is applied to the uterus through the fabric intrauterine drain. The KOKO™ device utilizes this vacuum to remove excess blood and compress the uterus reducing further blood loss.
214899754|NCT05316116|DRUG|Siltuximab|Siltuximab will be given on day 1 of each cycle. The dose will be 11 mg/kg given over 1 hour by intravenous infusion. Each cycle is three weeks (+-3 days).
214899755|NCT06217159|DIETARY_SUPPLEMENT|Poikilocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will wear a specialized face mask and breathe room air for 60 min. The face mask will be attached to an automated gas-blender system; however, only room air will be delivered.
214899756|NCT06217159|DIETARY_SUPPLEMENT|Normocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will be outfitted with a specialized face mask and breathe air with a slightly higher concentration of CO2 to maintain PetCO2 to resting baseline values for 60 min. Gas will be continuously delivered by an automated gas-blender system.
214899757|NCT03510858|OTHER|Multilevel training intervention (intervention group)|QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act). The QC will then repeat one PDCA cycle. The control group will receive the same intervention one year later.
214899758|NCT03510858|OTHER|Multilevel training intervention (control group with crossover)|The control group will undergo a crossover and receive the same intervention one year after the intervention group. QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act).
214899759|NCT05167565|OTHER|MRI/DTI|High resolution MRI scans will be acquired from each infant at three time points (\~3, 6, and 12 months), while they are naturally asleep to measure the progressive myelination of the major brain fiber tracks, grey matter maturation, and to create generative models for source reconstruction of EEG sensor data.
214301111|NCT06914375|OTHER|Goya Foods - Canned Lentils|Whole-cooked, canned lentils supplied by Goya Foods. Provided to participants on a weekly basis in amounts specific to DGAs 2020-2025 and the participant's gender.
214301112|NCT06914375|OTHER|Control|Participants in the Control condition (CTL) will be asked to consume their standard diet while avoiding any and all pulse intake.
214301113|NCT06914791|PROCEDURE|Kegel arm|in this group participants will be followed up for 8 weeks with kegel exercises
214301114|NCT06914791|PROCEDURE|De Gasquet arm|in this group participants will be followed up for 8 weeks with de gasquet exercises
214301115|NCT06913244|BEHAVIORAL|Multidisciplinary Physiotherapy Program (MD Physio)|"A comprehensive program that integrates:~Specific Exercise Therapy: Supervised stretching and strengthening sessions (30-60 minutes/session, 3× per week for 8 weeks) followed by a prescribed home-based maintenance regimen.~Manual Therapy: Targeted soft-tissue mobilization and myofascial release (20-30 minutes/session, twice per week for 4 weeks).~Education Sessions: Three sessions (both in-person and online) covering pain neuroscience and self-management techniques.~Mind-Body Interventions: Weekly 40-minute sessions of yoga or tai chi for 6 weeks."
214301116|NCT06913244|BEHAVIORAL|Standard Physiotherapy Care|Routine care involves standard follow-up with basic physiotherapy advice as currently provided to breast cancer survivors. This serves as the active comparator in the trial.
214301117|NCT06337864|OTHER|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU.
214301118|NCT06913192|BIOLOGICAL|CAR-T|All enrolled patients will receive three cycles of induction therapy using either the DVRd regimen (Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone) or the DKRd regimen (Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone). Following induction, patients will undergo high-dose melphalan conditioning followed by autologous hematopoietic stem cell transplantation. On Day 5 after stem cell reinfusion, patients will receive anti-BCMA CAR-T cell infusion. After CAR-T therapy, patients will enter the maintenance phase with lenalidomide monotherapy or lenalidomide in combination with bortezomib until disease progression or intolerable toxicity occurs.
214301119|NCT06913101|DRUG|Trelagliptin 100 mg|Trelagliptin 100 mg was administered orally once weekly before breakfast on the same day of the week.
214301120|NCT06913101|DRUG|Vildagliptin 50 mg|Vildagliptin 50 mg was administered orally once daily.
214301121|NCT01721330|DRUG|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
214301122|NCT01721330|DRUG|Placebo|Placebo twice a day for 6 weeks
214669472|NCT02060734|OTHER|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
214669473|NCT03185676|OTHER|Bilberry|A bilberry based probiotic beverage
214899760|NCT05167565|OTHER|EEG|EEG will be used to record infant brain activity during reaching and grasping actions to analyze beta activity
214899761|NCT05167565|OTHER|Eye Tracking|Infants will be presented with the experimental stimuli, which will consist of images of adults displaying different facial expressions and non-social images (e.g. a cross, a geometric pattern). This procedure is based on commonly used eye tracking paradigms designed to assess attention biases in infancy. Infant eye movement and position will be measured during stimuli presentation.
214899762|NCT05167565|OTHER|Ages and Stages Questionnaire (ASQ)|"The parents will be asked to complete the ASQ questionnaire (Developmental questionnaire).~ASQ-3 has 5 aspects: Communication, Gross motor, Fine motor, Problem solving and Personal-Social Each aspect has 6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. ASQ-3 average = average score of 5 aspects."
214899763|NCT05167565|OTHER|Infant Behavior Questionnaire Revised (IBQ-R)|"The parents will be asked to complete the IBQ-R questionnaire (Developmental questionnaire).~The 191-item instrument provides scores on 14 temperament scales which in turn cluster into 3 overarching factors: Positive Affectivity/Surgency, Negative Emotionality, and Orienting/Regulatory Capacity. Items are rated on a 7-point scale."
214899764|NCT05167565|OTHER|Beck Depression Inventory (BDI)|"The parents will be asked to complete the BDI questionnaire (Mental health questionnaire).~Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression."
214899765|NCT05167565|OTHER|The Brief Fear of Negative Evaluation Scale (BFNE)|"The parents will be asked to complete the BFNE questionnaire (Mental health questionnaire).~The BFNE measures anxiety associated with perceived negative evaluation. This scale is composed of 12 items describing fearful or worrying cognition. Scores from for each item are added up to obtain the total score."
214899766|NCT05167565|OTHER|Edinburgh Postnatal Depression Scale|"The parents will be asked to complete the Edinburgh Postnatal Depression Scale (Mental health questionnaire).~This is a set of 10 screening questions that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child. The total score is calculated by adding the numbers selected for each of the 10 items. If the parent's score is 10 points or above, they should speak to a health professional about those symptoms."
214899767|NCT02904577|OTHER|Any treatment, watch and wait policy included|"Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes."
214899768|NCT05012098|DRUG|Bintrafusp alfa/M7824|Participants will be treated with bintrafusp alfa 1200 mg every 2 weeks for 26 doses.
214899769|NCT05012098|DRUG|Ibuprofen|400 mg or comparable non-steroidal anti-inflammatory drugs (NSAIDs) dose up to 2 hours before and 8 hours after the start of each dose for prophylaxis of flu-like symptoms.
214899770|NCT05012098|DIAGNOSTIC_TEST|PET scan|Screening
214899771|NCT05012098|DIAGNOSTIC_TEST|CT scan|Screening
215053778|NCT01282866|DEVICE|LightSheer Duet|LightSheer Duet HS handpiece
215053779|NCT02118948|BEHAVIORAL|Abuse-focused intervention|
215053780|NCT02118948|BEHAVIORAL|Sexual behavior-focused intervention|
215053781|NCT05285228|BEHAVIORAL|effect of choice on cooperation (pseudoalternative)|For the test group, before the standard check-up starts, the participant is given the choice of selecting the taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint), which will be applied at the end of the visit. Post-placement instructions provided by the manufacturer will be given to the caregiver and the child and questionnaires will be handed out.
214301125|NCT02530034|DRUG|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Given IV
214301126|NCT02530034|OTHER|Laboratory Biomarker Analysis|Correlative studies
214301127|NCT02530034|OTHER|Pharmacological Study|Correlative studies
214301128|NCT04544449|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
214301129|NCT04544449|DRUG|Ocrelizumab|Participants will receive ocrelizumab.
214301130|NCT04544449|DRUG|Placebo matched to ocrelizumab|Participants will receive ocrelizumab-matching placebo.
214301131|NCT04544449|DRUG|Placebo matched to fenebrutinib|Participants will receive fenebrutinib-matching placebo
214301132|NCT05826912|DRUG|Atorvastatin Calcium|Capsule, 80 mg/day, with no loading dose, for 28 days
214301133|NCT05826912|DRUG|Minocycline Hydrochloride|Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
214301134|NCT05826912|DRUG|Candesartan Cilexetil|Capsule, 8 mg once on Day 1, then 16 mg daily for 27 days
214301135|NCT05826912|DRUG|Placebo|Capsule, 2x/day for 28 days
214301136|NCT04726982|DRUG|Acetazolamide|250 mg once daily
214301137|NCT04726982|DRUG|Acetazolamide|500 mg once daily
214301138|NCT04726982|OTHER|Placebo|Once daily
214301139|NCT06026592|GENETIC|determination of circulating biomarkers of renal origin circulating biomarkers of renal origin|The extracted circulating DNA will be extracted and converted using the methylation kit. Finally, circulating DNA will be analyzed using the PCR mix developed by CGenetix, quantifying tubular and glomerular biomarkers (patented technology).
214301140|NCT05571059|DRUG|Ifetroban Sodium|Once daily oral ifetroban
214301141|NCT05571059|DRUG|Placebo|Matching oral placebo
214669474|NCT03185676|OTHER|beverage without bilberries or probiotics|A control beverage without bilberries or probiotics
214301142|NCT06781619|DIETARY_SUPPLEMENT|Test Product: Plant based high energy high protein ONS|Plant based high energy high protein ONS 2 servings/day for a period of 8 weeks.
214301143|NCT06781619|DIETARY_SUPPLEMENT|Control Product: Dairy based high energy high protein ONS|Dairy based high energy high protein ONS 2 servings equivalent in energy \& protein for a period of 8 weeks.
214899772|NCT05012098|PROCEDURE|Tumor tissue biopsy|Baseline, and subsequent weeks as stipulated in the study calendar.
214899773|NCT05012098|DIAGNOSTIC_TEST|Brain MRI|Baseline
214899774|NCT05012098|DIAGNOSTIC_TEST|Dotate scan|Baseline
215053782|NCT05285228|BEHAVIORAL|given fluoride varnish (control)|For the control group the participant is provided with a given taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint) according to the randomization list.
214899775|NCT05012098|DIAGNOSTIC_TEST|PET FDG scan|Baseline
214899776|NCT05012098|DIAGNOSTIC_TEST|Nuclear bone scan|Baseline
214899777|NCT05012098|DIAGNOSTIC_TEST|EKG|Baseline
214899778|NCT05258773|DRUG|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.
214899779|NCT05534269|BIOLOGICAL|autologous muscle precursor cells|Patients own Muscle Precursor Cells are isolated and injected into the rhabdomyosphincter
214899780|NCT04814693|DEVICE|EndoRotor® System (Interscope, Inc., Northbridge, MA USA),|The EndoRotor System is intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. DEN with the EndoRotor System (study device) is considered to be standard of care therapy for patients with WON and not investigational.
214899781|NCT04814693|PROCEDURE|Conventional endoscopic devices (according to standards of care)|Endoscopic devices used to perform conventional DEN will be chosen according to standard of care and Investigator preference.
214899782|NCT05678218|PROCEDURE|Endoscopic Ultrasound registration|Registration of all findings during Endoscopic Ultrasound
214899783|NCT04104438|DRUG|Basiliximab 20 MG|Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30
214899784|NCT05980767|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation.
214899785|NCT05277922|DRUG|C21|C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
215053783|NCT04240431|DIAGNOSTIC_TEST|Probing /irrigation of lacrimal passages|Probing of the lacrimal passage was done using #00 Bowman's lacrimal probe which can reveal any narrowing (resistance) or obstruction (soft stop) of the canaliculi during its advancement from punctum towards the lacrimal sac.
215053784|NCT02143349|DIETARY_SUPPLEMENT|Coleus forskohlii extract|Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
215053785|NCT02143349|OTHER|Placebo|Ingestion of 250 mg placebo capsule twice a day for 12 weeks
215053786|NCT02560727|DEVICE|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
215053787|NCT02560727|DEVICE|colonoscope|FMT via colonoscope is the most common approach.
215053788|NCT03960879|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
214301144|NCT05723198|DRUG|Baricitinib|Administered orally
214301145|NCT05723198|DRUG|Placebo|Administered orally
214301146|NCT05099003|PROCEDURE|Biopsy Procedure|Undergo a biopsy
214301147|NCT05099003|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
214301148|NCT05099003|RADIATION|Radiation Therapy|Undergo radiation therapy
214301149|NCT05099003|DRUG|Selinexor|Given orally
214301150|NCT05260307|OTHER|hearing aid condition|The intervention will be a hearing aid or a modification to the sound stimulus that simulates a hearing aid configuration, style, or processing strategy.
214301151|NCT06701656|DRUG|Cohort C: bevacizumab|Administered as a single IV dose of 500 mg on Day 1
214301152|NCT06701656|DRUG|Cohort C: placebo|Administered as a single IV dose of placebo on Day 1
214899786|NCT05277922|DRUG|Sodium Nitroprusside|Ascending doses of 4, 8 and 16 µg sodium nitroprusside Positive control
214899787|NCT02344121|RADIATION|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
214899788|NCT03018288|DRUG|Pembrolizumab|Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
214899789|NCT03018288|BIOLOGICAL|HSPPC-96|One week post RT, patients will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
214899790|NCT03018288|DRUG|Temozolomide|Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
215053789|NCT03960879|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cervical cytology
215053790|NCT03960879|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
215053791|NCT03533088|OTHER|Hospitalized rehabilitation|Patients will recive a rehabilitation prgram at the clinic twice in a week until the post-operative 12. weeks
214301153|NCT04736199|DRUG|Darolutamide (Nubeqa, BAY1841788)|Coated tablet, oral administration
214301154|NCT04736199|DRUG|Placebo|Coated tablet matching Darolutamide in appearance, oral administration
214301155|NCT04736199|OTHER|Androgen deprivation therapy (ADT)|Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
214301156|NCT06552000|DEVICE|NovoTTF-200T System|Exposure/Frequency: 150 kHz Route: Transdermal through patented microarray system to the hemithorax affected with cancer, 2-4 week duration, target 18 hours/day (on average)
214301157|NCT04449549|DRUG|Nilotinib and Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
214301158|NCT06150118|OTHER|CBT+VR (Cognitive behavioral therapy and virtual reality)|The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
214899791|NCT03018288|OTHER|Placebo|One week post radiation therapy (RT), participants will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of Temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
214669475|NCT05252689|OTHER|monolithic zirconia single posterior crowns with deep chamfer finish line|deep chamfer of 1 mm average thickness for cervical finish line, a convergence angle of 6-12° on each side and up to 20° total, in some studies, is acceptable and occlusal reduction of 1,5-2 mm
214899792|NCT03018288|PROCEDURE|Surgery|Tissue for vaccine production and neo-epitope monitoring.
214899793|NCT03076008|OTHER|Observational|No intervention
214899794|NCT05681481|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
214899795|NCT05681481|DRUG|Prednisone|Oral Prednisone
214899796|NCT06961708|DRUG|Oral Fosmanogepix|Oral Tablet
214899797|NCT06961708|DRUG|IV Fosmanogepix|IV infusion
214899798|NCT06961708|DRUG|IV placebo|Matching IV placebo
214899799|NCT06961708|DRUG|oral placebo|Matching oral placebo
214899800|NCT03593473|DRUG|Intranasal Oxytocin|Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
214899801|NCT03593473|DRUG|Placebo|Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
214899802|NCT04867954|OTHER|Ensure Plus®|In-between two MRI exams, patients will ingest a standardized meal of two cans (16oz) of Ensure Plus® (Abbott Laboratories), providing a 700cal meal (13g protein, 11g fat, 50g carbohydrates), proven to elicit a strong hyperemic splanchnic response.
214899803|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
214899804|NCT04867954|OTHER|Clinical validation MRI|"Participants will be screened for any previous reactions to Ferumoxytol or GBCAs and dosing will be consistent with standard of care.~Participants will then undergo a research MRI lasting approximately 1.5 hours.~* All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which a 1/2 or 3/4 of the full dose of gadolinium based contrast agent (GBCA) or the total dose of Ferumoxytol will be administered.~* The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing).~* All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 minutes) during which, the remaining 1/4 or 1/2 dose of GBCA will be administered, if required."
214899805|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI + fasting|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1.5 hours. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
214899806|NCT04971096|DIETARY_SUPPLEMENT|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 30 billion CFU (colony forming units) of PS23
214899807|NCT04971096|DIETARY_SUPPLEMENT|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 30 billion of PS23 cells.
214669476|NCT05252689|OTHER|monolithic zirconia single posterior crowns with vertical finish line|using special round-ended 2 degrees tapered diamond burs a non-working tip (batt bur). It has coronal diameter of 1.2 mm, apical diameter of 0.7 mm, and non- cutting end of 1 mm, which reduces or avoids damage to the connective attachment and allows a tooth-guided preparation procedure
214899808|NCT04971096|DIETARY_SUPPLEMENT|Placebo|The placebo capsule contains microcrystalline cellulose.
214899809|NCT06796868|DRUG|GW117 Tablets|GW117 Tablets 20mg orally once a day
214899810|NCT06796868|DRUG|GW117 Tablets|GW117 Tablets 20mg\*2 orally once a day
214301159|NCT06150118|BEHAVIORAL|Control (placebo) group|The investigators are testing whether the placebo control protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
214899811|NCT06796868|DRUG|GW117 Tablets|GW117 Tablets 20mg\*3 orally once a day
214301160|NCT06453642|DEVICE|GPX® Embolic Device|Treatment includes distal embolization in the peripheral vasculature of vascular tumors, renal embolization, and portal vein branches
214899812|NCT06796868|DRUG|Placebo|placebo orally once a day
214899813|NCT04635189|DRUG|Daratumumab|Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
214899814|NCT04635189|DRUG|Lenalidomide|Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
214899815|NCT04635189|DRUG|Dexamethasone|Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab
214899816|NCT05582460|DIAGNOSTIC_TEST|Reporter Gene Assay|Transcription factor reporter gene assay using luciferase
215053792|NCT03533088|OTHER|Home-based rehabilitation|Patients will recive a home program once in a two weeks until the 6. weeks of post-operative period. Then will start to recieve a rehabilitation program ar the clinic once in a week auntil the 12. week of the post-operative period.
214301161|NCT05635175|OTHER|hip abductors physiotherapy self training|hip abductors self training program during 7 to 10 weeks associate with a PFMT
214301162|NCT05635175|OTHER|Standard pelvic floor muscle training|Standard pelvic floor muscle training
214669477|NCT03741361|OTHER|anxiety and depression|Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
214669478|NCT01844076|DRUG|Quinacrine and Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
214669479|NCT02734563|OTHER|Collagen turnover|Type IV and V collagen synthesis and breakdown
215053793|NCT01299389|DRUG|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
215053794|NCT01299389|DRUG|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
214899817|NCT05582460|DIAGNOSTIC_TEST|Flow Cytometry|Flow Cytometry Analysis using the Sysmex UF-4000, analyzing for bacteria, mononuclear and polymorphonuclear cells, and red blood cell and white blood cell count.
214899818|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Active|The patients will be treated with cTBS and usual medical treatment after endovascular treatment
215053795|NCT02573571|OTHER|Development of biomarkers|Blood sampling
215053796|NCT01060787|PROCEDURE|Fluocinolone Acetonide 0.59 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
215053797|NCT01060787|PROCEDURE|Fluocinolone Acetonide 2.1 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
215053798|NCT03363178|BIOLOGICAL|GC3107|BCG Vaccine, 0.1mL
215053799|NCT00006132|DRUG|acyclovir|
215053800|NCT02784392|DRUG|Ulimorelin|Active
215053801|NCT02784392|DRUG|Metoclopramide|Comparator
215053802|NCT01151020|DEVICE|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
215053803|NCT01778959|DEVICE|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
215053804|NCT01778959|DEVICE|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
215053805|NCT01778959|DEVICE|standard OVD|use of a standard cohesive OVD during cataract surgery
215053806|NCT01778959|DEVICE|OVD|use of a highly cohesive OVD during cataract surgery
214899819|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Sham|The patients will be treated with sham-cTBS and usual medical treatment after endovascular treatment
214899820|NCT05878730|DIAGNOSTIC_TEST|urine collection|"* Urine collection will be made on a 12 hours period (20h00-8h00), the night before V2~* at V2 : 2 mL urinal sample for measure of 6-SMT concentration (ng/mL) and creatinin (mg/mL)~* Measure of 6-SMT will be made by a validated radio-immunology assay"
215053807|NCT00610259|BEHAVIORAL|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
215053808|NCT00610259|OTHER|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
215053809|NCT01738633|BEHAVIORAL|nutritional counseling|
215053810|NCT01738633|BEHAVIORAL|respirology counseling|
215053811|NCT01635998|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
215053812|NCT03706768|OTHER|Glycocalyx|Measure Degradation of the Glycocalyx
215053813|NCT06348641|OTHER|baby massage|The infant massage to be applied before the examination will be applied by a single nurse=researcher. Video recordings will be taken before and during the ROP examination and evaluations will be made by two neonatal nurses other than the researcher.
214301163|NCT05635175|OTHER|Standard pelvic floor muscle training self training|Standard pelvic floor muscle training self training
214899821|NCT05878730|DIAGNOSTIC_TEST|Level of Proteins|"* blood sample at V2 (2x3.5mL citrate tubes)~* measured by ELISA"
214899822|NCT05878730|DIAGNOSTIC_TEST|Level of mRNA and miRNA|"* blood sample at V2 (2x2.5mL PAX-gene tube)~* measured by quantitative RT-PCR"
214301164|NCT04318080|DRUG|Tislelizumab|200 milligrams (mg) intravenously every 3 weeks (Q3W)
214899823|NCT05878730|DIAGNOSTIC_TEST|Level of plasmatic and intraerythrocytic lithium|"* blood sample at V2 (mmol/L)~* 4mL EDTA tube"
214899824|NCT03722680|DRUG|Riluzole|Riluzole during chemotherapy (oxaliplatin)
214899825|NCT03722680|DRUG|Placebo Oral Tablet|placebo
215053814|NCT01603173|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
214301165|NCT04537026|DRUG|Amniotic Fluid Allograft|Amniotic Fluid Allograft will be mixed with sterile water and injected using transforaminal approach
215053815|NCT01603173|DRUG|Quetiapine Fumarate|25 mg tablet once a day
215053816|NCT03894696|DRUG|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
215053817|NCT06075875|DIETARY_SUPPLEMENT|mixed animal and vegetable proteins|"mixed animal and vegetable proteins in the standard ratio (2/3:1/3; 60%:40% respectively) present in the nutritional menu over all hospitals in the general organization of teaching hospitals and institutes GOTHI; Egypt= as a control group) and continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm)."
214478902|NCT06331065|DEVICE|Mindfulness meditation experimentation, practice program, questionnaires, individual interview and focus group|"After randomization, a mindfulness meditation trial session is offered to all professionals in the intervention group follow by the questionnaire on representations of mindfulness meditation administration.~Then, interdepartmental focus groups is conducted with leaders. The following mindfulness meditation program consists of 10 1-hour sessions within 15 days, in groups of up to 15 professionals, conducted at the participants' place and time of work, by a certified mindfulness meditation trainer with a recommended daily practice of 10-20 minutes with the possibility of a longer duration, and an audio guidance tool adapted to the study.~After the program, and 3 months later, questionnaires are administered for both groups.~For the intervention group, individual interviews, and inter-departmental focus groups (leaders) are carried out at the end of the intervention, and intra-departmental focus groups are conducted 3 months after the end."
215053818|NCT06075875|DIETARY_SUPPLEMENT|pure vegetable proteins|pure vegetable proteins continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm).
215053819|NCT03235193|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
215053820|NCT03235193|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
214301166|NCT04537026|DRUG|Dexamethasone sodium phosphate|Dexamethasone phosphate mixed with sterile water will be injected by transforaminal approach
215053821|NCT02985177|DRUG|INF2.0 + IBU|Analgesics
215053822|NCT02985177|DRUG|INF1.0 + IBU|Analgesics
214478903|NCT06865326|OTHER|Standardized CTEPH Screening Protocol|Implementation of a standardized screening algorithm for early detection of CTEPH in patients after Acute Pulmonary Embolism (APE) and establishment of optimized referral of patients to specialized centers.
214301167|NCT05417516|RADIATION|Whole Breast Irradiation (WBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
214301168|NCT05417516|RADIATION|Partial Breast Irradiation (PBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
214301169|NCT06458712|DRUG|DSB2455|PARP1 inhibitor
214301170|NCT06611423|BIOLOGICAL|AZD3427|AZD3427 SC injection to be prepared using AZD3427 diluent
214301171|NCT06611423|OTHER|AZD3427 Placebo|AZD3427 Placebo
214301172|NCT06611423|DRUG|Dopamine|Dopamine Hydrochloride 50mg/5mL
214301173|NCT06611423|OTHER|Radiolabelled ligand|Injection of radioligand for PET examinations
214478904|NCT06540768|OTHER|Therapeutic Normothermia Group|Maintenance of a body temperature between 35 and 37 degrees Celsius using conservative and pharmacological interventions for 72 hours.
215053823|NCT03853967|OTHER|Low dose CT scan|low dose CT scan
215053824|NCT03125330|BEHAVIORAL|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
215053825|NCT00958477|BIOLOGICAL|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
215053826|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 single dose + paracetamol|Single dose of ChAdOx1nCOV19 vaccine, 5x10\^10 vp + paracetamol
215053827|NCT04536051|BIOLOGICAL|MenACWY single dose + paracetamol|Single dose of MenACWY + paracetamol
215053828|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 two dose + paracetamol|Two dose of ChAdOx1 nCoV-19 vaccine, 5x10\^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10\^10 vp), 4-12 weeks apart + paracetamol
215053829|NCT04536051|BIOLOGICAL|MenACWY prime & saline placebo boost + paracetamol|MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
215053830|NCT03765580|DIETARY_SUPPLEMENT|Fish|Lunch containing fish
215053831|NCT03765580|OTHER|Control|Lunch containing no fish
215053832|NCT01918865|DRUG|ISIS-PTP1BRx|
215053833|NCT01918865|DRUG|Placebo|
215053834|NCT01918865|DRUG|daily OAD (metformin and/or sulfonylurea)|
214301174|NCT06611423|OTHER|Saline|Saline solution
214899826|NCT06271564|DRUG|Magnetite ZnO Composite Nanoparticles|Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell
214899827|NCT06271564|DRUG|Topical Placebo Gel|Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
215053835|NCT03011112|PROCEDURE|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
215053836|NCT06089031|DIAGNOSTIC_TEST|Coronary Function Test|Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
215053837|NCT01934907|OTHER|Washing of packed RBC by normal saline|
215053838|NCT01144325|PROCEDURE|thoracoscopic esophagectomy|"In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.~In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position."
215053839|NCT03774797|OTHER|Implementation Toolkit|Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
215053840|NCT03464513|DEVICE|Multislice CT Angiography|Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
215053841|NCT04003844|DRUG|Immunoglobulin G|single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
215053842|NCT04003844|DRUG|Acetylsalicylic acid|Coadministration
215053843|NCT06156852|OTHER|Mindfulness-based stress reduction group|Mindfulness-based stress reduction (MBSR) group interventions were implemented for eight weeks.
215053844|NCT06156852|OTHER|Cognitive behavioral-based stress reduction group|Cognitive behavioral-based stress reduction group interventions were implemented for eight weeks.
215053845|NCT03502915|DRUG|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
215053846|NCT03502915|OTHER|Placebo|100% oxygen via Nitronox delivery device
215053847|NCT01769950|OTHER|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
214899828|NCT05653518|DEVICE|Tandem t:slim X2 with Control-IQ Technology|FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
214899829|NCT05653518|DEVICE|Sensor augmented pump (SAP) therapy|Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump
214301177|NCT05367440|DRUG|AZD5305|Patients will receive an oral dose of AZD5305 once daily
214301178|NCT05367440|DRUG|Enzalutamide|Patients will receive an oral dose of Enzalutamide once daily
214301179|NCT05367440|DRUG|Abiraterone Acetate|Patients will receive an oral dose of Abiraterone Acetate once daily
214301180|NCT05367440|DRUG|Darolutamide|Patients will receive an oral dose of Darolutamide twice daily
214301181|NCT05367440|DRUG|Apalutamide|Patients will receive an oral dose of Apalutamide once daily
214301182|NCT06814795|OTHER|Medically tailored meals|"The intervention will be 12-weeks in duration, with doses (meal deliveries) of up to 10 healthy, frozen meals per week for household use as needed, plus selected condiments for personalization"
214301183|NCT00410761|DRUG|ZD6474 (Vandetanib)|once daily oral tablet
214301184|NCT00446953|DRUG|betamethasone|2x12 mg betamethazone c-section at 38 weeks
214301185|NCT00446953|OTHER|placebo|c-section at 39 weeks
215053848|NCT02638467|DRUG|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
215053849|NCT02638467|PROCEDURE|Bone Marrow Transplant|"Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.~The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.~The goal is to transplant \> 3 x 106 CD34+ cells/kg BW recipient from bone marrow or \> 3 x 108 nucleated cells/kg BW recipient from bone marrow"
215053850|NCT02638467|DRUG|Bone Marrow cells|
215053851|NCT00610844|PROCEDURE|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
214301186|NCT06308822|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214301187|NCT06308822|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214301188|NCT06308822|PROCEDURE|Computed Tomography|Undergo CT
214301189|NCT06308822|DRUG|Erdafitinib|Given PO
214301190|NCT06308822|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214301191|NCT06124378|DRUG|Tislelizumab|200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.
214301192|NCT06124378|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
214301193|NCT06124378|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
214899830|NCT05293366|DIAGNOSTIC_TEST|Assessments of endocrinological phenotypes of LO-COCO patients|Assessment of:thyroid-stimulating hormone(TSH),free triiodothyronine (FT3), free thyroxine (FT4),calcitonin,antibodies against thyroglobulin (AbTG) and against thyroperoxidase (AbTPO),adrenocorticotropic hormone (ACTH),cortisol, luteinizing hormone (LH),follicle-stimulating hormone(FSH),Testosterone,17-beta estradiol,sex hormone binding globulin (SHBG),progesterone, prolactin (PRL), growth hormone (GH), insulin growth factor-1 (IGF-1), dehydroepiandrosterone sulphate (DHEAS),delta 4-androstenedione,aldosterone,renin,glycemia, insulinemia, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, HbA1c, vitamin D, adiponectin, irisin, IL-6.Thyroid and ovarian ultrasounds, pituitary and adrenal MRI will be performed as well. Body composition will be assessed with bioimpedance analysis and DXA scans.Female sexual dysfunctions will be evaluated with Female Sexual Function Index (FSFI), Sexual Inhibition and Sexual Excitation Scale (SIS/SES),Body Uneasiness Test (BUT).
214899831|NCT05293366|DIAGNOSTIC_TEST|Assessment of muscular phenotypes of LO-COCO patients|Questions will be collected regarding the tolerance to physical activity and modifications after diagnosis of Covid. Muscular strength will be assessed by means of tests (Medical Research Council Scale) and dynamometers. Balance will be assessed with a Romberg test, tolerance to stress will be assessed by means of cyclometer.
215053852|NCT01671553|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
215053853|NCT04615624|DRUG|Furosemide|Furosemide, a loop diuretic
215053854|NCT04615624|OTHER|Placebo|Normal saline
215053855|NCT03384459|DEVICE|the 308-nm excimer laser|For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
215053856|NCT05247684|DRUG|AK112|IV infusion
215053857|NCT05247684|DRUG|Carboplatin|IV infusion
215053858|NCT05247684|DRUG|Cisplatin|IV infusion
215053859|NCT05247684|DRUG|Paclitaxel|IV infusion
215053860|NCT03920241|BEHAVIORAL|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
214301194|NCT06124378|PROCEDURE|Colectomy|The specific surgical approach is laparoscopic. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
214301195|NCT05693909|DRUG|SP-420|Capsules for oral intake
214301196|NCT06703073|DRUG|Cohort A: vilobelimab|Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
214301197|NCT06703073|DRUG|Cohort A: placebo|Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
214301198|NCT06703073|DRUG|Cohort B: paridiprubart|Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
214301199|NCT06703073|DRUG|Cohort B: placebo|Administered as a single IV dose of placebo on Day 1
214301200|NCT06703073|DRUG|Cohort C: bevacizumab|Administered as a single IV dose of 500 mg on Day 1
214301201|NCT06703073|DRUG|Cohort C: placebo|Administered as a single IV dose of placebo on Day 1
215053861|NCT03920241|BEHAVIORAL|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
214301202|NCT06829329|DRUG|AHB-137|AHB-137 will be administered .
214301203|NCT06829329|DRUG|NAs|NAs will be administered.
214301204|NCT06829329|DRUG|Placebo|Placebo will be administered .
214301205|NCT05554380|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
215053862|NCT03920241|OTHER|Control Group|A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
214301206|NCT05554380|PROCEDURE|Biospecimen Collection|Undergo blood collection
214301207|NCT05554380|PROCEDURE|Computed Tomography|Undergo CT scan
214301208|NCT05554380|DRUG|Ipatasertib|Given PO
214301209|NCT05554380|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214301210|NCT05554380|DRUG|Paclitaxel|Given IV
214301212|NCT05828069|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
214301213|NCT05828069|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214301214|NCT05828069|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214301215|NCT05828069|PROCEDURE|Computed Tomography|Undergo CT
214478905|NCT06862063|DIAGNOSTIC_TEST|Genetic testing|Each eligible patient will undergo a blood sample to perform a genetic analysis through Next Generation Sequencing (NGS) technique in order to analyze a high number of genes involved in the structure/function of connective tissue
214301216|NCT05828069|PROCEDURE|Echocardiography Test|Undergo ECHO
214301217|NCT05828069|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG-PET imaging
214478906|NCT03717623|DRUG|Posaconazole pharmacokinetics|Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
214899832|NCT05293366|DIAGNOSTIC_TEST|Assessment of neuropsychiatric phenotypes of LO-COCO patients|Validated questionnaires will be collected to investigate depression (Beck Depression Inventory-II, BDI-II), apathy (Apathy Evaluation Scale, AES), anxiety (Test Anxiety Inventory, TAI), attention and cognitive functions (Montreal Cognitive Assessment and Quick Mild Cognitive Impairment). Fatigue will be assessed by Fatigue Rating Scale (FRS) and Fatigue Severity Scale (FSS). Muscle power will be assessed by six-minute walking test and sit and stand up test. The presence of myopathy will be evaluated by mean electrophysiological study.
214899833|NCT05293366|PROCEDURE|Muscle biopsy|Muscle biopsy will be performed upon need.
214899834|NCT05293366|DIAGNOSTIC_TEST|Assessment of pulmonary phenotypes of LO-COCO patients|Modified Medical Research council questionnaire will be administered for evaluating of the dyspnoea level. Complete respiratory status assessment, including global spirometry, CO lung diffusion capacity and arterial gases analysis will be run. HRCT - high resolution CT scan of the chest - will be performed in selected cases to rule out the eventual sequelae of SARS-Cov2 related pneumonia.
214899835|NCT05293366|DIAGNOSTIC_TEST|Assessment of cardiological phenotypes of LO-COCO patients|Cardiological assessment will be run upon data collected from: Short Form-36 Health Survey (SF36), echocardiogram at rest and during stress tests, six-minute walking test, N-terminal fragment brain natriuretic peptides (NT-proBNP)
214899836|NCT05293366|DIAGNOSTIC_TEST|Assessment of vascular phenotypes of LO-COCO patients|The assessment of the potential post-thrombotic vascular damage will comprise the investigation of prevalence of previously unknown deep venous thrombosis by ultrasonography.
214899837|NCT05293366|DIAGNOSTIC_TEST|Assessment of dermatological phenotypes of LO-COCO patients|Dermatology evaluation will account on: thrichoscopy, dermoscopy, onychoscopy and capillaroscopy, confocal microscopy, skin ultrasonography
214899838|NCT05293366|PROCEDURE|Tissue biopsy|Tissue biopsy will be performed upon need.
214899839|NCT05975333|BEHAVIORAL|Writing|Participants will be asked to write about their experiences with cancer, guided by several specific open-ended writing prompts to spark ideas.
214899840|NCT05975333|BEHAVIORAL|Interview|Following completion of the writing exercise, participants will reflect on their experiences with the writing intervention in a semi-structured private interview with a member of the research team.
214899841|NCT05086419|OTHER|Sub-symptom threshold aerobic exercise|For the first three weeks, participants will be offered guided sub-symptom threshold aerobic exercise on a treadmill or exercise bike once a week. The remaining 2-4 sub-symptom threshold aerobic exercise workouts per. week will be on their own. Location and mode of exercise (treadmill, walking, jogging, exercise bike / bicycle, swimming, or elliptical machine) will be individually adapted to the patients experience, preferences and opportunities. The intensity of the sub-symptom threshold aerobic exercise will always be monitored using a heart rate monitor and/or ratings of perceived exertion (Borg RPE). If there still is a need for closer follow-up after the first three weeks, a physiotherapist in primary health care service will be involved under supervision from a physiotherapist (research fellow) in the project.
214899842|NCT06700512|DEVICE|Hearing Aid Signia Pure C&G 7IX|Receiver in Canal (RIC) hearing aid, M Receiver
214899843|NCT06700512|DEVICE|Own Hearing Aid|subjects' own hearing aids, any brand, any model
214899844|NCT01490086|DRUG|RP5063|daily
214899845|NCT01490086|DRUG|placebo|daily
214899846|NCT01490086|DRUG|aripiprazole|daily
214899847|NCT06018285|BEHAVIORAL|Stepped Approach to Reducing Risk of Suicide in Primary Care|Intervention consists of implementation of clinical pathway for youth suicide risk
214899848|NCT05598320|DRUG|TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
214899849|NCT05598320|DRUG|Placebo for TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
215053863|NCT04763889|BEHAVIORAL|CBT|CBT for those with an allergy and anxiety
215053864|NCT06187779|OTHER|Lower segment measurment|Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
215053865|NCT06424821|DRUG|Cadonilimab|Cadonilimab + chemotherapy
215053866|NCT00755963|DRUG|estradiol valerate|Progynova® 21; 2mg/d
215053867|NCT00755963|DRUG|micronized progesterone|Utrogestan®; 200mg/d
215053868|NCT00755963|DRUG|placebo|maltodextrin
215053869|NCT01107964|DRUG|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
215053870|NCT01107964|DRUG|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
215053871|NCT01153204|BEHAVIORAL|Group Psychotherapy|
215053872|NCT01153204|OTHER|Group Psychotherapy plus Sildenafil citrate|
215053873|NCT01153204|DRUG|Sildenafil citrate|
215053874|NCT03504891|DIAGNOSTIC_TEST|MRI prior to CRT Upgrade|We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
215053875|NCT03504891|DIAGNOSTIC_TEST|MRI prior to de novo CRT|We will perform MRI prior to de novo CRT implants as the comparison group.
215053876|NCT02822742|DRUG|DE-117 ophthalmic solution|
215053877|NCT02822742|DRUG|Latanoprost ophthalmic solution 0.005%|
214301218|NCT05828069|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214301219|NCT05828069|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214301220|NCT05828069|DRUG|Tovorafenib|Given PO
214301221|NCT06701669|DRUG|Cohort B: paridiprubart|Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
214301222|NCT06701669|DRUG|Cohort B: placebo|Administered as a single IV dose of placebo on Day 1
214301223|NCT06787235|DIETARY_SUPPLEMENT|Modified ketogenic diet|The modified Atkins KD is defined as \<20g carbohydrate per day with freely allowed protein consumption. Recommended protein and fat intake will be calculated for each participant based on their energy needs.
214301224|NCT06787235|OTHER|Individual nutritional consultation|The nutritional consultation will be provided by a dietician to improve individual health
214301225|NCT06605599|DRUG|ABBV-932|Oral Capsule
214301226|NCT06605599|DRUG|Placebo for ABBV-932|Oral Capsule
215053878|NCT02794896|DRUG|High dose propofol, fentanyl and sevoflurane|Deep Anesthesia
215053879|NCT02794896|DRUG|Low dose propofol, fentanyl and sevoflurane|Shallow Anesthesia
215053880|NCT04224922|DRUG|Paclitaxel|
214301227|NCT04345757|BEHAVIORAL|Structured exercise|The exercise program will be designed by a physical therapist (Ms. Patricia Ladis) who specializes in postnatal rehabilitation and will be supervised by sports medicine physicians from the Hospital For Special Surgery (HSS). The structured program will include approximately 10 minutes of core muscle group exercises. They will begin this program 2 weeks after their cesarean section. The study group will perform these exercises 5 times per week.
214301228|NCT04996849|OTHER|Data Capture|Data collected
214899850|NCT05899985|COMBINATION_PRODUCT|FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System|"FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy, with an MRI conducted 12h to 28 days after injection. The MRI will be blinded to the clinical team and will assess the location of the primary draining lymph nodes (sentinel lymph nodes or SLNs).~Patients will proceed to standard of care neoadjuvant therapy and/or surgery. During surgery, indocyanine green (ICG) will be used to identify draining lymph nodes. Following surgery, pathologists will use FerroMag to identify SLNs which will undergo standard H\&E assessment, and if negative ultras-staging (fine serial slice and immunochemistry)."
214899851|NCT06005649|BIOLOGICAL|HY004|"Autologous 2nd generation bispecific CAR-T cells targeting both CD22 and CD19, single infusion intravenously.~Start Dose level: 2.00 x 10\^6/kg CAR+T-cells"
214899852|NCT06025721|BEHAVIORAL|Cardiovascular Risk Homeless Support|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular health behaviors. The coach will encourage a focus on smoking\>medication\>sleep\>physical activity\>healthy eating to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed in participants' preferred format (handout, video, audio, etc.).
215053881|NCT04224922|DRUG|Carboplatinum|
214899853|NCT06228053|DRUG|SX-682|Specified dose twice daily
214899854|NCT06228053|DRUG|Enzalutamide|Specified dose once daily
214478907|NCT06607029|DRUG|the opioid-based control group|Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.
214899855|NCT05895747|DRUG|Low Dose 5-hydroxytryptophan|5-hydroxytryptophan 100mg PO BID
214899856|NCT05895747|DRUG|High Dose 5-hydroxytryptophan|5-hydroxytryptophan 200mg PO BID
214899857|NCT05895747|DRUG|Low Dose Creatine Monohydrate|Creatine monohydrate 5g PO qday
214899858|NCT05895747|DRUG|High Dose Creatine Monohydrate|Creatine monohydrate 10g PO qday
214899859|NCT05895747|DRUG|Placebo|Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
214899860|NCT06630104|PROCEDURE|Biospecimen Collection|Undergo hair, buccal, and saliva sample collection
215053882|NCT04224922|DRUG|Epirubicin|
215053883|NCT04224922|DRUG|Cyclophosphamide|
215053884|NCT02945163|DRUG|Tenofovir|Tenofovir Disoproxil Fumarate
215053885|NCT02945163|DRUG|Lamivudine|Lamivudine
215053886|NCT02945163|DRUG|Efavirenz|Efavirenz
215053887|NCT01220401|BEHAVIORAL|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
215053888|NCT05723744|DEVICE|ECG Holter and investigational device recordings for the purpose of developing Continuous Measurement of Heart Arrythmias|"For Candidates for pacemaker implantation: ECG Holter and investigational device recordings (of PPG, ECG, and motion sensors tracings non-invasively) will be recorded before procedure, during patient's hospitalization at cardiology division. Blood pressure values that are collected by an automated cuff will be collected including any notes attached to the values.~All collected data will be analyzed offline"
215053889|NCT00362882|DRUG|docetaxel|Given IV
215053890|NCT00362882|DRUG|bortezomib|Given IV
214301229|NCT04996849|OTHER|Questionnaire Administration|Ancillary studies
214301230|NCT05316662|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
214301231|NCT04940052|DRUG|Dabrafenib|Dabrafenib will be administered orally twice daily
214301232|NCT04940052|DRUG|Trametinib|Trametinib will be administered orally once daily
215053891|NCT00362882|OTHER|laboratory biomarker analysis|correlative study
215053892|NCT00362882|OTHER|immunoenzyme technique|correlative study
214301233|NCT04940052|DRUG|Trametinib placebo|Trametinib will be administered orally once daily
214301234|NCT04940052|DRUG|Dabrafenib placebo|Dabrafenib placebo will be administered orally twice daily
214301235|NCT06957418|DRUG|AADvac1|AADvac1 tau directed therapy
214899861|NCT06630104|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214899862|NCT06630104|OTHER|Electronic Health Record Review|Ancillary studies
215053893|NCT00362882|OTHER|immunohistochemistry staining method|correlative study
215053894|NCT00362882|OTHER|pharmacological study|correlative study
215053895|NCT03073863|DRUG|Atorvastatin|Analysis
215053896|NCT05339399|OTHER|oxytocin augmentation|Only observation of the outcome
215053897|NCT05764252|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
215053898|NCT00562822|PROCEDURE|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
215053899|NCT00562822|OTHER|Physical and medical therapy|Treatment with physical and medical therapy alone
215053900|NCT00956722|DRUG|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
215053901|NCT00093262|DRUG|clevidipine|
215053902|NCT00093262|DRUG|placebo|
215053903|NCT06293716|DRUG|CVL237 tablets|CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
215053904|NCT06293716|DRUG|CVL237 placebo tablets|CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
215053905|NCT03204877|DRUG|Melatonin|Oral capsules
215053906|NCT03204877|OTHER|Placebo|Oral capsules
215053907|NCT00839280|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
215053908|NCT00839280|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
215053909|NCT03969745|BEHAVIORAL|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
215053910|NCT03969745|BEHAVIORAL|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
215053911|NCT01279876|DRUG|Melatonin|3mg oral, daily, one hour before sleep
215053912|NCT03413033|OTHER|Resonance tube|Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
215053913|NCT03413033|OTHER|Tongue trill|Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
214301236|NCT06957418|DRUG|Tau2|Tau2 directed therapy
214301237|NCT06745791|DEVICE|BoneMRI|BoneMRI is a quantitative 3D MRI technique,capable of generating CT-like, quantitative radiodensity bone MRI images to visualize cortical and trabecular bone, allowing to assess bone structure and morphology, in addition to regular clinical MRI images.
214301238|NCT03712904|RADIATION|Stereotactic Body Radiation Therapy|Undergo radiation
214301239|NCT03712904|BIOLOGICAL|Ziv-Aflibercept|Given IV
214301240|NCT04674683|DRUG|HBI-8000 in combination with nivolumab|Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight \< 40 kg, nivolumab will be dosed at specific doses on specific days.
215053914|NCT01504516|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
215053915|NCT01504516|DRUG|Aricept|Aricept 10 mg Tablets
215053916|NCT05730946|DIAGNOSTIC_TEST|Interview- based questionnaire|Interview-based questionnaire by the use of an interview guide to explore and understand the Challenges faced in the past and the concerns for the future experienced by parents of CLP patients.
215053917|NCT00005739|BEHAVIORAL|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
215053918|NCT00005739|BEHAVIORAL|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
215053919|NCT02574039|DIETARY_SUPPLEMENT|Oat bran|66g oat bran made up in 350ml skimmed milk
215053920|NCT02574039|DIETARY_SUPPLEMENT|refined grain|refined grain product and 350ml skimmed milk
215053921|NCT06493175|DIAGNOSTIC_TEST|Application of large language model in emergency chest pain triage.|The large language model MedGuide-V5 is able to quickly extract key information from a patients description, and by analyzing these descriptions, it provides physicians with a possible initial diagnosis to help them quickly prioritize the treatment of patients.
215053922|NCT06493175|DIAGNOSTIC_TEST|According to the normal procedures to receive medical treatment|After the artificial intelligence system evaluation, the patients will receive the diagnosis and treatment according to the normal procedure. The overall time of artificial triage, the triage of patients, and other data will be recorded. Patient visits should not be delayed by the use of artificial intelligence systems for evaluation.
215053923|NCT03386435|PROCEDURE|remote ischemic preconditioning|Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
214478908|NCT06607029|DRUG|the opioid-free anesthesia group|The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
214899863|NCT06630104|PROCEDURE|Follow-Up|Undergo CFU
214899864|NCT06630104|OTHER|Genetic Counseling|Receive genetic counselor consultation
214899865|NCT06630104|OTHER|Genetic Testing|Undergo sequencing analysis
214899866|NCT04755335|DIAGNOSTIC_TEST|Ultrasound|In this project, The investigators will use Alpinion ECUBE-12R (Alpinion, Bothell, WA) US platform. This state-of-the-art research US machine provides beam formed as well as Plane-Wave imaging options that allow high frame rate imaging. The investigators have characterized the acoustic output of this system for safe human studies and obtained the IRB approval for human studies. It should be noted that our technique is not limited to the Alpinion system; the investigators can also use other US systems, such as Verasonics, Vantage, (Redmond, WA). This technique can be adapted to other modern US machines in the future.
215053924|NCT01611740|PROCEDURE|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :~* the variability of the cardiac cycle duration ;~* the variability of respiratory cycle amplitude and duration ;~* and their relationships."
215053925|NCT01738685|BEHAVIORAL|Behavioral Intervention.|
214899867|NCT05873777|DIAGNOSTIC_TEST|18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-LM3, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
214899868|NCT01127256|DRUG|zonisamide|Initial dose was 100mg/day, increased by 100mg. The maximum dose was 600mg/day.
214899869|NCT01127256|DRUG|carbamazepine|Initial dose was 100mg/day, increased by 200mg every 1 week to 600mg/day. The maximum dose was 1200mg/day.
214899870|NCT03938883|DEVICE|Ocular Bandage Gel (OBG)|A modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries including surgical trauma.
214899871|NCT03938883|DEVICE|Bandage Contact Lens (BCL)|A bandage contact lens protects an injured or diseased cornea from the mechanical rubbing of the blinking eyelids, therefore allowing it to heal. It is a normal (usually soft, but not always) contact lens has no power. It is not intended to improve your vision.
215053926|NCT01738685|OTHER|Nutritional Education.|
214478909|NCT06864663|DRUG|nerve block with bupivacaine 0.25%|ultrasound guided adductor canal block and interspace between the popliteal artery and the knee capsule using bupivacaine 0.25%
214899872|NCT05252325|DEVICE|hyaluronic acid plus lidocaine|local injection for correction of nasolabials fold
214899873|NCT05252325|DEVICE|hyaluronic acid without lidocaine|local injection for correction of nasolabial folds
214899874|NCT00240448|DRUG|telmisartan 80 mg/hydrochlorothiazide 25 mg|
215053927|NCT00384215|DRUG|insulin glargine [rDNA origin] injection|
215053928|NCT00625586|BIOLOGICAL|RAV12|RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.
215053929|NCT00625586|DRUG|Gemcitabine|1000 mg/m2 weekly, intravenously
215053930|NCT00751712|DEVICE|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
215053931|NCT05792163|DRUG|SNP318 (A)|Capsule for oral administration
215053932|NCT05792163|DRUG|Placebo (B)|Placebo capsules matching the SNP318 capsules
214478910|NCT06864663|DRUG|Nerve Block with bupivacaine 0.25%|ultrasound guided combined adductor canal block and genicular nerve block using bupivacaine 0.25%
214899875|NCT00240448|DRUG|valsartan 160 mg/hydrochlorothiazide 25 mg|
214899876|NCT00240448|DRUG|placebo|
214899877|NCT03944668|BEHAVIORAL|Exercise|36 sessions of comprehensive cardiac rehabilitation over 12 weeks
214899878|NCT05501418|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion with 12 months of follow up after treatment.
214899879|NCT05501418|BIOLOGICAL|Controlled normal saline|Normal saline will be IV infusion with 12 months of follow up after treatment.
215053933|NCT06235918|DRUG|Tislelizumab|Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
215053934|NCT06235918|DRUG|Nab-paclitaxel|260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
215053935|NCT06235918|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles
215053936|NCT03995095|OTHER|Therapeutic interview: kibo protocol|The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
215053937|NCT00906178|BEHAVIORAL|CyberSenga|Internet-based HIV prevention program
215053938|NCT01178476|DEVICE|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
215053939|NCT01681667|DRUG|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
215053940|NCT02402530|DRUG|Placebo|Matching placebo administered as intravenous infusion.
215053941|NCT02402530|DRUG|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
215053942|NCT01971671|OTHER|no intervention.|
215053943|NCT00643890|GENETIC|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10\^12 vector genomes in 35 uL.
215053944|NCT02946177|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
215053945|NCT02946177|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
215053946|NCT01125475|DEVICE|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
215053947|NCT03123900|BEHAVIORAL|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
214899880|NCT04904497|BEHAVIORAL|Early Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: trained family members and health staff about the intervention process"
215053948|NCT03123900|BEHAVIORAL|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
214301241|NCT04674683|DRUG|Placebo in combination with nivolumab|Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
214899881|NCT02068508|DRUG|Pioglitazone|Pioglitazone Tablets
214899882|NCT00004789|DRUG|heme arginate|
214899883|NCT00004789|DRUG|tin mesoporphyrin|
214899884|NCT02549404|DRUG|KHK7580|Oral administration
214899885|NCT01011751|DRUG|Cyproterone acetate|Cyproterone acetate tablet-in-capsule.
214899886|NCT01011751|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate tablet-in-capsule.
214899887|NCT01011751|DRUG|Venlafaxine|Venlafaxine capsule.
214899888|NCT01011751|DRUG|Leuprorelin|Leuprorelin injection.
214899889|NCT01011751|DRUG|Flutamide|Flutamide tablet
214899890|NCT01011751|DRUG|Placebo|Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
214899891|NCT06309160|BEHAVIORAL|COMPASS Across Settings (CAST)|CAST will begin with an initial joint session with the student, caregiver, special education teacher, and pre-employment transition specialist that allows for discussion on the student's postsecondary goals, preferences, frustrations, challenges, and strengths related to social skills, adaptive/self-management, communication, problem behaviors, learning skills, and sensory sensitivities and preferences. This discussion will pinpoint critical social, communication, and work behavior/learning goals related to postsecondary goals and inform the intervention plans that are generated for each goal. Following this initial consultation, there will be four additional 1-hour sessions that incorporate evidence-based coaching, provided by the investigators, including performance feedback monitoring and instructional support. Each session is standardized and allows for assessment of student progress and intervention modification/self-reflection on the implementation of the intervention plans.
214899892|NCT00464958|DRUG|sublingual tizanidine 12 mg|Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
214899893|NCT06576414|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|the first hour of ACT intervention followed by 1 hour of back exercise class, which led by a trained ACT counsellor and a trained exercise trainer
214899894|NCT06576414|BEHAVIORAL|back exercise|1 hour of back exercise class led by a trained exercise trainer
214899895|NCT06576414|BEHAVIORAL|back care education|1 hour long interactive lesson to participants about LBP-related pathology, disability, psychology, and pain management skills.
214899896|NCT04158258|DRUG|Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
214899897|NCT04158258|DRUG|Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
214899898|NCT04158258|DRUG|Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
214899899|NCT04158258|DRUG|Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
214899900|NCT04158258|DRUG|Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
214899901|NCT04158258|DRUG|Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
214899902|NCT04469075|DRUG|Clindamycin Phosphate|phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
214899903|NCT04469075|DRUG|Triamcinolone Acetonide|triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
214899904|NCT04680026|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
214899905|NCT04680026|DRUG|Placebo|Normal saline
214899906|NCT06578546|DRUG|Venetoclax|100mg d1, 200mg d2, 400mg d2-21, oral (Adjusted according to the plasma concentration of venetoclax on day 4)，every 28 days for a treatment cycle.
214899907|NCT06578546|DRUG|Azacitidine|75mg/m2 qd, d1-d7, subcutaneous injection, every 28 days for a treatment cycle.
215053949|NCT03123900|BEHAVIORAL|Combined training|Subjects included in this group receive both types of intervention.
214899908|NCT06578546|DRUG|Orebatinib|20mg qod, d4-d21, oral, every 28 days for a treatment cycle.
214899909|NCT05648773|BEHAVIORAL|Messaging|Booster reminder message
214301242|NCT05485974|DRUG|HBI-2438|KRAS G12C Inhibitor
214301243|NCT04536298|DIETARY_SUPPLEMENT|vitamin D|Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
214301244|NCT04536298|DIETARY_SUPPLEMENT|Placebo|Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28
214899910|NCT05648773|BEHAVIORAL|Financial Incentive|Financial Incentive for getting boosted within 2-weeks of the message
214899911|NCT05648773|OTHER|Placebo|Treatment as usual; no additional message and no incentive.
215053950|NCT05620056|DRUG|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs|medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
215053951|NCT00124072|DRUG|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
214301245|NCT05775341|OTHER|No Intervention|This is purely an observational study.
214301246|NCT00097474|DRUG|Hydrocortisone|Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated
214301247|NCT00097474|DRUG|Melatonin|Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated
214301248|NCT00097474|DRUG|Placebo|Placebo
214301249|NCT05111886|BEHAVIORAL|Communication Skills Training|The training will focus on communication skills based on key constructs in the Health Belief Model and motivation/resistance research (described in section A3), the training will focus on: (1) conveying the benefits of parenting programs, (2) knowledge of and responses to common perceived barriers to attending parenting programs, and (3) skills and strategies to effectively motivate and refer parents in ways that are least likely to elicit resistance. The in-person training will last 60-90 minutes. It will include a theoretical background and experiential learning; each step of the referral process will be demonstrated and role-played. The investigators will work to ensure that personnel receive continuing education credits for the training.
214478911|NCT04856384|OTHER|synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations
214478912|NCT06250855|DEVICE|Mini Toric IOL|Adults (males and females) ≥18 years with cataract and pre-existing corneal astigmatism who have undergone monocular or binocular Mini Toric Ready implantation after cataract surgery in which the cataract lens was removed by phacoemulsification, with circular capsulorhexis, leaving the posterior capsule intact.
214478913|NCT06876792|DEVICE|electrical impedance tomography|Respiratory drive assessed by flow index measured by electrical impedance tomography.
214899912|NCT00200447|DRUG|carbidopa/l-dopa|
214899913|NCT00200447|DRUG|carbidopa/l-dopa/entacapone|
214899914|NCT00200447|DRUG|Stalevo|
214899915|NCT00200447|PROCEDURE|[123I]-IBZM imaging|
215053952|NCT00124072|DIETARY_SUPPLEMENT|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
215053953|NCT00124072|DRUG|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
215053954|NCT00124072|DRUG|Placebo|Placebo vitamin B12/folic acid tablet once daily
215053955|NCT03118336|DRUG|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
215053956|NCT05204095|DEVICE|Portable slit-lamp photography|The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.
215053957|NCT02869672|BIOLOGICAL|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
214301250|NCT05111886|BEHAVIORAL|eHealth GenPMTO|The GenPMTO is delivered over the phone (not online). This version is up to 6 sessions in length. This brief eHealth version of GenPMTO will be delivered through community therapists. The program will be delivered one-on-one (i.e., between a therapist and a parent or couple).
214301251|NCT05111886|BEHAVIORAL|Written Referral Process|"A written summary and process map of the referral process, modeled on the Institute for Healthcare Improvement (IHI) 9-step process for closing the loop on referrals."
214301252|NCT05111886|BEHAVIORAL|One Session Education about Resources|"One online or phone conversation with the therapist in which the therapist guides the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) a website, behaviorchecker.org, which includes behavioral prescriptions for common behavior issues; and (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools."
214301253|NCT05111886|DIAGNOSTIC_TEST|Survey of Experience|Satisfaction with referral process
214899916|NCT01056783|DRUG|OC000459|OC000459 100mg, twice daily, tablet
214899917|NCT01056783|DRUG|Placebo|Placebo tablets to match OC000459 tablets, twice daily
214899918|NCT00726856|DRUG|Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate|Ezetimibe 10 mg taken daily for 3 months
214899919|NCT02806908|DRUG|JZP-110|
214899920|NCT02806908|DRUG|Placebo|
215053958|NCT02869672|BIOLOGICAL|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
215053959|NCT00092820|DRUG|MK0653, ezetimibe|
215053960|NCT00092820|DRUG|Comparator: placebo|
215053961|NCT03402191|DRUG|L-arginine|l-arginine for thalassemia with pulmonary hypertension
215053962|NCT03402191|DRUG|Sildenafil|Sildenafil for thalassemia with pulmonary hypertension
215053963|NCT01736033|DRUG|Tamsulosin|1 tablet(0.2mg) orally q.d.
214301254|NCT06349070|BEHAVIORAL|Low Touch - Text Messaging Implementation Strategy|The low touch strategy is designed as a tool to distill and organize the most important information from the Starting Early Program (StEP) original evidenced-based intervention curriculum. Video links are sent to pregnant subjects via automated SMS messaging. Subjects will receive videos (20 videos total) at least weekly lasting 17 to 31 weeks and the duration is based upon the gestational age at enrollment into the study. Subjects will also receive SMS messages in between videos at least weekly to keep them engaged and reinforce the video content delivered. The StEP curriculum is guideline concordant and includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management, enhance prenatal breastfeeding support, and build social support. The StEP curriculum was adapted into brief videos (\<5 minutes), and an additional module on Sleep Health was added.
214899921|NCT05319925|OTHER|Patient reported outcome measure|Newly developed patient-reported instrument to measure financial effects of a cancer diagnosis and therapy of cancer patients in Germany
214899922|NCT04404543|DRUG|SYHA1807|Escalation Cohort Administration: Orally
214899923|NCT04404543|DRUG|SYHA1807|Dose Expansion Cohort Administration: Orally
214899924|NCT04931030|OTHER|Dietary advice|Subjects are provided dietary advice by the dietitians as part of the research team/ investigators
214899925|NCT06152562|DIAGNOSTIC_TEST|VerifyNow antiplatelet therapy response test|VerifyNow testing after minimum of 2 hours and at latest 24 hours after the first four dosis of ASA
214899926|NCT00381082|DRUG|1) MOOV Head Lice Treatment (Ego Pharmaceutical).|
214899927|NCT00381082|DRUG|Banlice Mousse Aerosol (Pfizer, Australia)|
214899928|NCT00381082|DRUG|3) KP24 Medicated Foam (Nelson Laboratories)|
214899929|NCT04961385|BIOLOGICAL|Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine|Blood samples were taken from the vaccinated participants for antibody testing against SARS-CoV-2
214899930|NCT04445272|DRUG|Tocilizumab|Treatment with Tocilizumab
214899931|NCT01760304|DRUG|Budesonide / Formoterol|"Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
214899932|NCT01760304|DRUG|Placebo|"Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
214899933|NCT05923801|DEVICE|switch to BT electrode position|use of different electrode positions of ECT device
214899934|NCT05923801|DEVICE|continue with RUL electrode position|use of different electrode positions of ECT device
214899935|NCT04070001|DRUG|400 Mg Ibuprofen|1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
214899936|NCT04070001|DEVICE|laser application|A single irradiation of laser after elastomeric separator placement
214899937|NCT04070001|OTHER|placebo tablets|Placebo lactose tablets 1-hour before elastomeric separator placement
214899938|NCT05149625|DEVICE|Dexcom G6|continuous glucose monitoring device
214899939|NCT02790567|OTHER|HEP score|"The HEP score is a clinicobiological score evaluating the probability of the HIT diagnosis.~The HEP score is based on the blood platelet count, the timing of the platelet decrease, the existence of clinical manifestations of HIT (thrombosis, haemorrhage, skin necrosis) and the existence of an other cause of thrombocytopenia."
214899940|NCT02790567|OTHER|4Ts score|The 4Ts score is a clinicobiological score evaluating the probability of the HIT diagnosis. The 4Ts score is based on the change in blood platelet count during heparin therapy, the timing of platelet decrease, the existence of a thrombosis, and the existence of an other cause of thrombocytopenia.
215053964|NCT01736033|DRUG|Finasteride|1 tablet(5mg) orally q.d.
215053965|NCT01736033|DRUG|Placebo|1 tablet(0.2mg) orally q.d.
215053966|NCT03040128|DRUG|Minocycline|high-dose, intravenous minocycline
214899941|NCT02790567|OTHER|ID-PaGIA test|The ID-PaGIA test is a particle gel immunoassay that detects immunoglobulins (Ig) G, A and M specific to the heparin/PF4 complexes.
215053967|NCT03040128|OTHER|normal saline infusion|
215053968|NCT02534883|DRUG|Misoprostol|To be place vaginally
215053969|NCT02534883|DRUG|Placebo|To be placed vaginally
215053970|NCT04981964|PROCEDURE|Exercise training|both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
215053971|NCT05474456|OTHER|SNAGs|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
215053972|NCT05474456|OTHER|Manipulation|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
215053973|NCT06043180|PROCEDURE|Transcatheter aortic valve implantation|Intervention on aortic valve for severe aortic stenosis
215053974|NCT00886769|DRUG|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
215053975|NCT00886769|DRUG|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
215053976|NCT00198679|DRUG|Chlorhexidine|
215053977|NCT05231759|DEVICE|L'DISQ|
214301255|NCT06349070|BEHAVIORAL|High Touch - Community Health Worker (CHW) Implementation Strategy|The curriculum will be delivered by CHWs. Each subject will be asked to participate in 1-hour live sessions with a CHW. During the sessions, videos are interspersed with open-ended questions and pauses to discuss these open-ended questions. This results in an interactive session that employs principles of active learning. The curriculum includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management during pregnancy, enhance prenatal breastfeeding support, and build social support and are anchored by the same brief videos developed for the low touch strategy.
214301256|NCT06019325|PROCEDURE|RIB|After endotracheal intubation, patients will be positioned in lateral decubitus position. A RIB will be performed at the level of T5-T6 by ultrasound guidance. A single shot block will be performed by injecting 30 ml of 0.25% bupivacaine to the interfacial plane between rhomboid major muscle and intercostal muscle.
214301257|NCT05816187|BEHAVIORAL|Education program on healthy habits|6-week supervised educational program.
214478914|NCT00640822|DRUG|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
214899942|NCT02790567|OTHER|HIT-Ab(PF4-H) test|The HIT-Ab(PF4-H) test consist in the incubation of plasma samples with latex beads coated PF4/polyvinylsulfate complexes. After binding of the plasma antibodies a monoclonal antibody recognizing PF4/heparin complexes is added. In the presence of human anti-PF4/heparin antibodies, binding of the monoclonal antibody and subsequent agglutination of latex beads is inhibited. Inhibition of agglutination is quantified and reported in arbitrary units (U/ml). A value equal or higher than 1.0 u/ml may indicate the presence of HIT antibodies.
214899943|NCT04429503|DRUG|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
214899944|NCT04429503|DRUG|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
214899945|NCT06094699|OTHER|Sleep friendly order set|"Every evening, the following orders (which comprise the sleep-friendly order set) will be input into the EMR:~Hold vital signs and neurological checks overnight Retime applicable medications outside of the nighttime window of 10pm-6am Retime daily lab draws outside of the nighttime window of 10pm-6am Order melatonin if no clinical contraindications Discontinue finger stick glucose measurements for patients with a stable blood glucose values Change DVT prophylaxis to enoxaparin for all clinically eligible patients"
214899946|NCT06094699|OTHER|Patient sleep menu|Patients will be given a menu of non-pharmacological options that support sleep by improving comfort and reducing anxiety.
215053978|NCT03980392|OTHER|Multidomain intervention program|Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
215053979|NCT03019523|DIETARY_SUPPLEMENT|Caffeine Blend|Taken orally in capsule form
215053980|NCT03019523|OTHER|Sugar Pill|Taken orally in capsule form
215053981|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
215053982|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
215053983|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
215053984|NCT03328832|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
215053985|NCT03328832|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
214301258|NCT05816187|BEHAVIORAL|Habitual|The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking
214478915|NCT00640822|DRUG|Tacalcitol Ointment|Once daily application for up to 8 weeks
214478916|NCT00640822|DRUG|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
214478917|NCT03248479|DRUG|Magrolimab|Administered intravenously
215053986|NCT03328832|DRUG|rivaroxaban (10mg)|Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
215053987|NCT00873821|DRUG|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
215053988|NCT00873821|DRUG|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
215053989|NCT00414076|DRUG|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
215053990|NCT00049257|DRUG|carboplatin|Administered Day 1 of each cycle. AUC=6.
215053991|NCT00049257|DRUG|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
215053992|NCT03816722|DEVICE|Airvo2|Treatment with HighFlow through the Airvo2 device, 8 hours per day
215053993|NCT03816722|OTHER|Usual care|"High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients"
214478918|NCT03248479|DRUG|Azacitidine|Administered according to region-specific drug labeling either subcutaneously or intravenously
214899947|NCT06550128|DRUG|AHB-137 injection|AHB-137 injection will be administered subcutaneously.
214899948|NCT06550128|DRUG|Placebo|Placebo will be administered subcutaneously.
214899949|NCT06161194|OTHER|Supervised group exercise therapy|Participants will participate in a 90 minutes supervised group exercise therapy program 2 times a week for 8 consecutive weeks.
214301259|NCT05791734|OTHER|assessing preoperative skin cleanliness|2 skin swabs on surgical incision sites and direct skin visual observation by a nurse
214301260|NCT06148272|DRUG|LY3971297|Administered SC
215053994|NCT06118424|BEHAVIORAL|deepfake video|The combination of the words deep and fake is called deepfake in the literature as deep learning. Deepfakes, which have recently become more widely known as a result of the shocking images and sound recordings of many people, from politicians to famous movie stars, are generally hyperrealistic videos in which people's faces and voices are used by other faces and voices without permission and manipulated digitally. Deepfakes rely on neural networks that analyze large data samples to learn to mimic a person's facial expressions, mannerisms, voice and tone. The process involves feeding a deep learning algorithm to exchange images of two people or faces.
215053995|NCT06555341|BEHAVIORAL|Experimental: Six Thinking Hats Group|"2\. Subcutaneous insulin administration was explained with the traditional training model.~3\. The Six Thinking Hats technique and how it is used was then explained in detail to the students. Any points that were not fully understood were explained again so that the technique was thoroughly reinforced.~4\. The researchers had made hats from different coloured card. All the students wore all the hats in turn and were asked the questions related to that colour hat as stated above (semi-structured questionnaire 1-6).~5\. The responses given by the students to the questions were audio-recorded. Each interview lasted 30 mins."
214301261|NCT06148272|DRUG|Placebo|Administered SC
214301262|NCT06148272|DRUG|LY3971297 IV|Administered IV
214301263|NCT05508971|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
215053996|NCT06555341|BEHAVIORAL|Other: Video Group|"2\. Subcutaneous insulin administration was explained with the traditional training model.~3\. Then by scanning the QR code from the nursing practice skills textbook(Aylaz \&amp; Yakıncı, 2024), the researchers provided the link for the students to watch the insulin application video.~4\. Without mentioning hat colours or the Six Thinking Hats method to this group, the questions on the semi-structured questionnaire were asked, and the interviews, each lasting 30 mins, were audio-recorded.~5\. After completing the video training, the mid-test data were collected by applying the Subcutaneous Insulin Application Skill Level Observation Form during administration of insulin to a dummy."
215053997|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 150mg at 0 Day 1, Day 8, Day 15
214301264|NCT05508971|PROCEDURE|Adenotonsillectomy|Tonsil and adenoid removal
214301265|NCT04875182|DIAGNOSTIC_TEST|Evaluation of Delirium development|Postoperative pain scores of the patients will recorded by using a numerical rating scale.
214301266|NCT06570681|DIAGNOSTIC_TEST|Video call assisted assessment of acute stroke|If the patient is eligible for study inclusion, eight symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. Afterwards, the EMS personnel will contact the on-call neurologist and if the vehicle is in the intervention arm a live video stream is initiated. The on-call neurologist then examines the patient via via the video-call and triages the patient.
214301267|NCT06081868|BEHAVIORAL|Use of toothbrush/toothpaste/fluoride varnish|Children receive information about the use of toothbrush/toothpaste/fluoride varnish.
214301268|NCT06081868|BEHAVIORAL|Education on nutrition/oral hygiene|Children receive education on nutrition/oral hygiene.
214301269|NCT05443334|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
214301270|NCT06701682|DRUG|Cohort A: vilobelimab|Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
214301271|NCT06701682|DRUG|Cohort A: placebo|Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
215053998|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 300mg at 0 Day 1, Day 8, Day 15
215053999|NCT05980065|DRUG|Placebo|Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
215054000|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 600mg at 0 Day 1, Day 8, Day 15
215054001|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 900mg at 0 Day 1, Day 8, Day 15
215054002|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 1200mg at 0 Day 1, Day 8, Day 15
215054003|NCT04721158|DEVICE|Continuous glucose monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
215054004|NCT03842774|DIETARY_SUPPLEMENT|Exract of Gelidium elegans|Exract of Gelidium elegans will be given to the test group.
215054005|NCT03842774|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be given to the test group.
215054006|NCT01587248|DEVICE|Harmonic|Dissection with harmonic scalpel
215054007|NCT01587248|PROCEDURE|electrocautery|Dissection in modified radical mastectomy
215054008|NCT06287255|BEHAVIORAL|EIM+|The Exercise is Medicine (EIM) program involves a personalized exercise prescription and wellness coaching component. At the first 1:1 session, participants are provided with a Fitbit and onboarded with Fitabase, allowing for documentation of baseline health behaviors. Over the course of the program, the EIM fitness specialist reviews Fitbit data and progress towards goals, sending push notifications for encouragement and reminders. A personal training session is conducted, followed by sixteen group sessions including up to eight participants. The final session includes updating goals, incorporating Fitbits, and providing an updated exercise prescription. Upon program completion, participants will attend monthly webinars and health coaching sessions at 6- and 12-months post-program. The program aims to help individuals overcome barriers and maintain long-term exercise self-efficacy.
215054009|NCT02867228|OTHER|changes in ventilator settings|Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
215054010|NCT03242226|DEVICE|two spectacles|single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
215054011|NCT03242226|DEVICE|single vision spectacles|Wear single vision spectacle only
215054012|NCT04625400|DIAGNOSTIC_TEST|bronchoscope|Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
215054013|NCT03271216|DEVICE|No intervention|no intervention
214899950|NCT05516108|BEHAVIORAL|Mindfulness|The mindfulness intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific meditation techniques through didactic explanation and guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention on the intended target, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts build on the skills trained in each lesson, encouraging participants to practice brief moments of mindful awareness, mindfulness while doing daily tasks, or formal meditation.
214899951|NCT05516108|BEHAVIORAL|Coping|The coping intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific coping techniques through didactic explanation and guided practice. Lessons train coping skills (reflection, reappraisal, and problem solving) without encouraging focus on or acceptance of present experience (i.e., mindfulness skills). Participants are instructed to: (1) reflect and let their minds drift, (2) reframe or reappraise past and anticipated events, and (3) analyze and solve personal problems. Practice prompts build on the skills trained in each lesson, encouraging participants to take brief reflection breaks or to practice reappraisal or problem-solving skills.
215054014|NCT02542059|RADIATION|68Ga-exendin PET/CT|68Ga-exendin PET/CT
215054015|NCT03440554|DIAGNOSTIC_TEST|Whole Body Non-Contrast MRI|Whole Body Non-Contrast MRI in Prostate Cancer Patients
215054016|NCT04877678|DRUG|Bepotastine|10 mg Bepotastine, twice a day
215054017|NCT04877678|DRUG|Placebo|Identical looking placebo, twice a day
215054018|NCT01060254|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
215054019|NCT01060254|DRUG|JNJ-42160443|Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
215054020|NCT04113889|DRUG|Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)|72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.
214301272|NCT04216342|BIOLOGICAL|Fx-5A peptide complex|subject will receive a slow I.V. infusion of the Fx-5A peptide complex as described in Table 1. Five to 10 mL of blood will be collected at 30min (+/- 5min\*), 1h (+/- 10min\*), 2h (+/- 10min\*), 4h (+/- 15min\*), 8h (+/- 30min\*), 12h (+/- 30min\*), and 24h (+/- 30min\*) for laboratory tests and to be stored for research tests. The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.
214301273|NCT06153771|OTHER|Collection of brain and kidney NIRS measurements|(recorded continuously) by a person not involved in the study 30 minutes before echocardiography was performed
214301274|NCT06153771|OTHER|echocardiography|on day 2, day 4 and day 7 of life
215054021|NCT04113889|DRUG|Metformin, pioglitazone and placebo|72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
215054022|NCT01830348|DRUG|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
215054023|NCT01830348|DRUG|placebo vehicle gel|
215054024|NCT05655975|PROCEDURE|upper gi endoscopy|In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
215054025|NCT02321605|BEHAVIORAL|e-BPS|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
215054026|NCT02321605|BEHAVIORAL|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
215054027|NCT00622921|BEHAVIORAL|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
215054028|NCT06014307|BEHAVIORAL|Diet order: PBMA, Animal|Participants will follow the PBMA, and Animal diets (in this order) for 4-6 weeks each.
215054029|NCT06014307|BEHAVIORAL|Diet order: Animal, PBMA|Participants will follow the Animal, and PBMA diets (in this order) for 4-6 weeks each.
215054030|NCT01630317|PROCEDURE|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
215054031|NCT01630317|PROCEDURE|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
215054032|NCT04480229|BEHAVIORAL|Telenursing and Counseling|After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment. In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
214301275|NCT05838404|BEHAVIORAL|M-O-M-S on the Bayou|Peer and mentor support and meetings across pregnancy
214301276|NCT05608005|BIOLOGICAL|Panblok + MF59 Dose 1|Pharmaceutical form: suspension for injection Route of administration: intramuscular
214301277|NCT05608005|BIOLOGICAL|Panblok + MF59 Dose 2|Pharmaceutical form: suspension for injection Route of administration: intramuscular
214478919|NCT06170814|OTHER|Exercise|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. One group will be given external focus stimuli, the other group will be given internal focus stimuli.
215054033|NCT01949129|DRUG|VP16|60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
215054034|NCT01949129|RADIATION|TBI|2 x 2Gy/day , 3 days (total 12Gy)
215054035|NCT01949129|DRUG|Thiotepa|2x5 mg/kg BW, 1 day
215054036|NCT01949129|DRUG|Treosulfan|14g/m² BS, 3 days
215054037|NCT01949129|DRUG|Fludarabine|30 mg/m² BS, 5 days
215054038|NCT01949129|DRUG|Busulfan|iV, dosage according therapeutic drug monitoring, 4 days
215054039|NCT01949129|DRUG|ATG Thymoglobulin|MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
215054040|NCT01949129|DRUG|Cyclophosphamide|as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
215054041|NCT01949129|DRUG|Grafalon|MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
215054042|NCT03388541|DRUG|Dexmedetomidine|Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
215054043|NCT03388541|DRUG|Placebo|A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
215054044|NCT00921388|OTHER|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
215054045|NCT00921388|BEHAVIORAL|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
215054046|NCT04512118|DIAGNOSTIC_TEST|PET-CT of 18F-FDG|Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)
215054047|NCT01796288|RADIATION|simultaneous radiotherapy|
215054048|NCT01796288|DRUG|Erlotinib|
215054049|NCT04590053|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
215054050|NCT02102243|DRUG|DEFINITY® infusion|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
215054051|NCT02102243|DRUG|Human Recombinant Regular Insulin infusion|The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
215054052|NCT02102243|DRUG|Dextrose infusion|The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
214301278|NCT05608005|BIOLOGICAL|Unadjuvanted Panblok Dose 3|Pharmaceutical form: liquid for injection Route of administration: intramuscular
214301279|NCT04708886|DRUG|Romosozumab|Year 1 study drug
214301280|NCT04708886|DRUG|Alendronate|Year 2 study drug
215054053|NCT02102243|PROCEDURE|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
215054054|NCT02102243|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
214301284|NCT06845774|BEHAVIORAL|CDC PrEP with active referral|The single session SOC utilizes structured risk assessments and educational materials recommended by the CDC, based on the CDC PrEP 101 information, and delivered one-on-one by trained study staff in about 15 minutes. This will be followed by active referral to a local provider; local providers have been identified to receive study referrals in each community. This session will occur the same day or within one week of study enrollment.
215054055|NCT02102243|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
215054056|NCT02102243|PROCEDURE|Microneurography|Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
215054057|NCT05035459|DIAGNOSTIC_TEST|lung ultrasound|drug adjustment based on lung ultrasound results
214301285|NCT06845774|BEHAVIORAL|TelePrEP|The TelePrEP intervention includes an initial one-on-one in person intervention session with trained study staff that: 1) engages in provides basic education on PrEP care tailored for PWID; 2) encourages participation in a telehealth clinical evaluation for PrEP; and, 3) offers the opportunity to participate in point of care baseline testing for PrEP. At the conclusion of session 1, for those who express readiness to link with PrEP care, study staff will immediately facilitate access to the telehealth platform onsite. Four telehealth visits will be offered to access initial and follow-up clinical care for PrEP.
214301286|NCT06843590|DRUG|ALKS 2680|Oral tablet containing ALKS 2680 for once daily administration
214301287|NCT06843590|DRUG|Placebo|Oral placebo tablet for once daily administration
214301288|NCT04925349|DIAGNOSTIC_TEST|Blood sample collection|blood sample collection
214478920|NCT01999361|DRUG|Myfortic|treatment with myfortic
214478921|NCT04980924|OTHER|no intervention|no intervention
215054058|NCT05035459|DIAGNOSTIC_TEST|Lung ultrasound|drug adjustment independent on lung ultrasound results
215054059|NCT05593705|OTHER|observation|photograph for maxillary labial frenum and measurements with a periodontal probe
215054060|NCT04042454|OTHER|milk based anti-regurgitation infant formula|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
215054061|NCT04042454|OTHER|Milk based infant formula|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
215054062|NCT04872569|BEHAVIORAL|Decision-making tool|"Participants will be directed to use the decision tool for 3 months using it at their own pace.~The tool covers topics relevant to women with disabilities in considering or planning a pregnancy and reflects core elements of decision making tools based on the Ottawa Framework for Decision Support."
215054063|NCT02382991|DEVICE|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
214899952|NCT05413343|DRUG|Ceftazidime-avibactam|Patients with severe sepsis and treatment with CAZ-AVI will be enrolled. Blood samples at 0 hour, 2 hours, 4 hours, 6 hours, and 8 hours after the first time and the steady state concentration(more than 4 times drug administration) of drug administration will be collected to detect plasma drug concentrations of CAZ-AVI
214899953|NCT06853184|DRUG|Artesunate|Low Dose Artesunate: 2.4 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices High Dose Artesunate: 4.8 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices
214899954|NCT06853184|DRUG|Ganciclovir (GCV)|Standard Treatment Ganciclovir: GCV or VGCV and SOC per local institutional practices
215054064|NCT02382991|DEVICE|NMPK-3C60|1 month with NMPK - 3 months with 3C60
215054065|NCT05211089|OTHER|Optical Coherence Tomography imaging of choroid|A single expert retinal specialists used a Topcon DRI-1 SS-OCT to do the Choroidal Thickness measurements. A 12, 9-mm radial line scan procedure was performed. Each radial line was automatically scanned 32 times in the same spot, followed by the creation of 12 high-resolution average B-scan images. Each scan was double-checked to confirm that it was centred on the fovea. Only scans of good quality were included. The perpendicular distance between the outer border of the RPE and the junction of the choroid and sclera was used to calculate CT. It was calculated automatically using the mapping software incorporated into the device and displayed as a colourful topographic map with nine subfields defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) style grid.
215054066|NCT02288000|DRUG|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
214301289|NCT05856695|DRUG|Carboplatin + Paclitaxel + Durvalumab|Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
214478922|NCT06253871|DRUG|IAM1363|Oral, immediate release capsules of IAM1363
214478923|NCT06316882|DIAGNOSTIC_TEST|Screening endoscopy|We perform upper endoscopy, when the patient authorizes it, during their screening colonoscopy
214478924|NCT05650996|BEHAVIORAL|ADL/Cast Care instruction|Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated in a cast and cast care. Participants in the experimental group will also receive a handout on ADL participation and cast care.
214899955|NCT06332807|GENETIC|NGGT002|adeno-associated viral vector with human phenylalanine hydroxylase gene
214899956|NCT06852807|DRUG|18F-MFBG|Patients with neuroblastoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
214899957|NCT05309278|BEHAVIORAL|Physical training|Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
214301290|NCT00372268|DEVICE|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.
214301291|NCT00372268|DEVICE|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
214301292|NCT05440929|BEHAVIORAL|Clinician Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
214301293|NCT05402072|PROCEDURE|Autologous matrix-induced chondrogenesis (AMIC)|AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.
214669480|NCT03641300|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
214301295|NCT06573658|BEHAVIORAL|Perturbation-based balance training (PBT)|It will be a two-session training with each session lasting for approximately an hour. Perturbations will be induced during treadmill walking. Participants will be instructed to recover their balance and continue walking after the perturbations.
214899958|NCT05309278|BEHAVIORAL|Cognitive training|These participants will also perform a weekly remote and supervised cognitive training session with neurobic exercises for 1 hour. In addition to the supervised cognitive training session, participants will also be prescribed asynchronous neurobic exercises to be performed on the remaining days of the week (without supervision). The intervention will last for 12 weeks, and all asynchronous neurobic exercises will be recorded in the following synchronous sessions by the supervisor. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
214301296|NCT06573658|BEHAVIORAL|Walking exercise (control)|It will be a two-session training with each session lasting for approximately an hour. The same training duration and format will be used as the PBT group, except that no perturbations will be induced during the treadmill walking.
214899959|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
214899960|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
214899961|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
214899962|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg,q3w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, intravenous injection for 60 to 90 minutes. Every 3 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
214899963|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q3w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, intravenous injection for 60 to 90 minutes. Every 3 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
214899964|NCT01315431|DRUG|Tesetaxel plus capecitabine|"Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol."
214899965|NCT04618731|DIAGNOSTIC_TEST|caries prevalence def ,DMF|the examination will carried out on dental chair using diagnostic set
214301301|NCT05621252|DRUG|PLN-74809|160 mg PLN-74809
214301302|NCT05621252|DRUG|Placebo|Matching placebo
214301303|NCT05864469|OTHER|12-week psychosocial dyadic intervention|Comprising six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
214899966|NCT03197441|OTHER|Platelet-rich plasma|Intraoperative platelet-rich plasma injection during arthroscopic knee surgery
214899967|NCT00709995|DRUG|Enzastaurin|Administered orally
214899968|NCT00709995|DRUG|Sunitinib|Administered orally
215054067|NCT02288000|DRUG|Placebo|the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
215054068|NCT00945373|DRUG|calcium dobesilate|2.5% gel
214478925|NCT05650996|BEHAVIORAL|Cast Care Instruction|Participants in the control group will watch a video instructing them on cast care. Participants in the control group will receive a handout on cast care.
214899969|NCT00709995|DRUG|Placebo|Administered orally
214899970|NCT03650699|DEVICE|Electropalatography Biofeedback Training|The study agent is electropalatography (EPG). The LinguaGraph EPG device is a biofeedback technology that creates a digital visualization of tongue function during speech. The visualization is accomplished by a custom made mouthpiece that fits over the hard palate with 62 sensors that capture tongue position. The information from the sensors in the mouthpiece, as well as the audio output, is processed in an EPG Unit that converts the information from mouthpiece to a visual representation on a computer screen. The visual information with respect to tongue position can be used to provide biofeedback training.The computer can be used in the clinic during a patient visit or it can be seen over the internet with the patient at home and the speech and language pathologist at the clinic.
214899971|NCT05637216|DRUG|Losartan 25 milligram capsule|Losartan 25 milligram oral capsule
214899972|NCT05637216|DRUG|Placebo|Placebo 25 milligram oral capsule
215054069|NCT00945373|PROCEDURE|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
215054070|NCT00432068|DRUG|Octreotide pamoate|
215054071|NCT00770627|DIETARY_SUPPLEMENT|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
215054072|NCT03027518|OTHER|WILD 5 Wellness|Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
214301304|NCT03525574|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
214301305|NCT03525574|DRUG|IVA|Tablet for oral administration.
214478926|NCT05211050|DRUG|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
214899973|NCT05045287|RADIATION|hypofractionated radiotherapy|Undergo hypofractionated RT，obeserve reconstruction failure，cosmetic result and recurrence rate
214899974|NCT02386137|DEVICE|Contrast-enhancement ultrasound with Sonovue|
214899975|NCT00326391|DRUG|methylphenidate hydrochloride extended-release tablets|
214899976|NCT03827265|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
214899977|NCT03252405|DEVICE|mask ventilation|before intravenous induction, mask application is made. then intravenous cannulation and induction
214899978|NCT03252405|DEVICE|intravenous cannulation|induction is applied by using intravenous cannulation
214899979|NCT01983267|DRUG|cannabis|use of cannabis oil or cigarets
214899980|NCT03388151|DRUG|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
214899981|NCT03388151|DRUG|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
215054073|NCT03376139|DRUG|Zonisamide|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
215054074|NCT03376139|DRUG|Placebo Comparator|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
215054075|NCT04896801|RADIATION|MR-guided RT|The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy \< 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT
215054076|NCT05788601|DRUG|Dapiglutide|GLP-1/GLP-2 receptor agonism
215054077|NCT05788601|DRUG|Placebo|Placebo
215054078|NCT04095052|DIETARY_SUPPLEMENT|Methyl Folate|1,000 mcg methyl folate and Microcrystalline Cellulose in a capsule
214301306|NCT04155632|DRUG|N-acetylcysteine|N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
214301307|NCT04155632|DEVICE|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
214301308|NCT04850846|DRUG|Metformin XR|Orally by mouth
214301309|NCT04850846|OTHER|Placebo|Orally by mouth
214478927|NCT05211050|DRUG|Sumatriptan|10 min infusion of 4 mg sumatriptan.
214899982|NCT05111327|OTHER|Structured guideline|Students in the intervention group will receive more learning materials before study. The structured guideline will be used to facilitate students' learning in simulation by the facilitator.
215054079|NCT04095052|DIETARY_SUPPLEMENT|Placebo|Microcrystalline Cellulose capsule
214478928|NCT05211050|DRUG|Saline|10 min infusion of isotonic saline (placebo).
214478929|NCT04679389|DRUG|Placebo|administered orally or enterally
214899983|NCT01428596|BIOLOGICAL|HIVAX|Vaccine 1.0 ml SQ lower dose (10\^8 TU) at weeks 0, 8 and 16.
214899984|NCT01428596|BIOLOGICAL|saline solution|Saline solution 1.0 ml SQ at weeks 0, 8 and 16.
214899985|NCT01428596|BIOLOGICAL|HIVAX|Vaccine 1.0 ml SQ higher dose (10\^9 TU) at weeks 0, 8 and 16.
214899986|NCT04341363|DEVICE|Tattoo machine|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
214899987|NCT01219816|DRUG|Epratuzumab|Combination of chemotherapy + Epratuzumab
214899988|NCT01219816|DRUG|Epratuzumab|Vincristine + Dexamethasone + Epratuzumab
214899989|NCT03618693|PROCEDURE|Spinal anesthesia|Injection of a single shot of local anesthetic bupivacaine 0.5% combined with 20 mcg fentanyl intrathecally.
214899990|NCT03618693|DEVICE|TAP Block|TAP block with a single shot of 20ml ropivacaine 0.375% combined with 75 mcg clonidine bilaterally
214899991|NCT03618693|OTHER|Standard|Concomitant systemic administration of lidocaine (as an adjuvant) to the standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.
214899992|NCT00063934|BIOLOGICAL|oblimersen sodium|Given IV
214899993|NCT00063934|DRUG|doxorubicin hydrochloride|Given IV
214899994|NCT00063934|DRUG|docetaxel|Given IV
214899995|NCT00063934|BIOLOGICAL|filgrastim|Given SC
214899996|NCT00063934|BIOLOGICAL|pegfilgrastim|Given SC
214899997|NCT00063934|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
214899998|NCT00063934|OTHER|pharmacological study|Optional correlative studies
215054080|NCT04635202|BEHAVIORAL|exercise training on elliptical device|This group (n=30) will receive aerobic training on an elliptical trainer for 16 weeks (3 sessions per week). The session will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
215054081|NCT04635202|BEHAVIORAL|group B (control group)|this group will receive general advises on maintaining physical activities for 16 weeks without any additional supervised training
215054082|NCT04176393|DRUG|ivosidenib|subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
215054083|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior frontal gyrus (IFG)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
215054084|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior parietal lobule (IPL)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
215054085|NCT04466384|DEVICE|BIS|Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
215054086|NCT05598905|DRUG|Pregabalin 150mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
215054087|NCT05598905|DRUG|Oxycodone 10mg|one 10mg tablet
214478930|NCT04679389|DRUG|Acetazolamide|administered orally or enterally
214478931|NCT06864572|DIAGNOSTIC_TEST|P17-079, P16-093, or P15-041 PET/CT|P17-079, P16-093, or P15-041 PET/CT
214478932|NCT06859619|OTHER|Peripheral venous blood sample|Peripheral venous blood sampling for IgG serology against leishmaniasis, leptospirosis, brucellosis, Q fever, rickettsiosis, tularemia, psittacosis, Lyme disease, tick-borne encephalitis, hantavirus, hepatitis E virus, dengue virus, Zika virus, Chikungunya virus, West Nile virus, Usutu virus, Toscana virus, Crimean-Congo hemorrhagic fever virus.
214478933|NCT06858215|BEHAVIORAL|Y-MIND Intervention|All participants in the intervention arm will receive the the Y-Mind intervention. Y-Mind intervention will be delivered by trained and supervised lay counsellors in primary health care clinics. The six sessions will include a) psychoeducation on depression, b) behavioural activation (helping the participant see the connection between their behaviour, daily activities, and low mood and activity scheduling) and c) problem-solving therapy (the counsellor helps the participant identify and define a specific problem to work on, evaluate the potential solutions to the problem, and carry out the selected solution(s)).
214478934|NCT06671106|OTHER|toothbrushing|manual toothbrush (meridol)
214478935|NCT06671106|OTHER|flossing|dental floss (meridol)
214478936|NCT06671106|DEVICE|Toothpaste Product|amine and zinc lactate - containing toothpaste (meridol Gum Protection)
214478937|NCT06671106|DEVICE|Mouthrinse|amine and zinc lactate - containing mouthrinse (meridol Gum Protection)
214899999|NCT00063934|OTHER|laboratory biomarker analysis|Optional correlative studies
214900000|NCT02009553|OTHER|Information sheet|
214900001|NCT02009553|OTHER|No information sheet|
215054088|NCT05598905|DRUG|Lacosamide 150 mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
215054089|NCT05496361|DEVICE|Tianyi Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
215054090|NCT05496361|DEVICE|Solitaire FR Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
215054091|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
215054092|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
215054093|NCT01014806|BIOLOGICAL|Influenza VLP Vaccine|Single dose; 0.5mL
215054094|NCT01014806|BIOLOGICAL|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
215054095|NCT00876252|BIOLOGICAL|IC43|
215054096|NCT00876252|DRUG|Placebo|NaCl
215054097|NCT00451061|DRUG|Alfuzosin|
215054098|NCT00451061|DRUG|Tamsulosin|
215054099|NCT04902430|PROCEDURE|Power chain and Crimpable hook for En-Masse Retraction|"Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew"
214478938|NCT06671340|DRUG|Dorzagliatin|chronic treatment with dorzagliatin for 4 weeks (50mg twice daily or 75mg twice daily, oral)
214478939|NCT06606665|OTHER|Cognitive skills test|Cognitive skills; It will be evaluated with the Montreal Cognitive Assessment Scale.
214900002|NCT04223336|BEHAVIORAL|Brief physical activity and diet intervention|The intervention is an integrated care pathway that provides a computerized prompts for practitioners in the STOP program via their online portal. For a participant who is in the intervention group, the online portal will screen the participant for their physical activity and fruit/vegetable consumption and provide the practitioner (who is seeing this participant for their visit) with computerized alerts for physical activity and fruits/vegetable consumption. Specifically, the portal will prompt practitioners to provide a brief intervention for these two behaviours using risk communication and will also suggest brief intervention language designed based on the Elicit-Provide-Elicit framework. The portal will also have available a self-monitoring resource for physical activity and fruits/vegetable consumption and will prompt practitioners to provide this self-monitoring resource to the participant during their visit.
214900003|NCT03627117|DRUG|Verum|Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
214900004|NCT03627117|DRUG|Placebo|Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
214900005|NCT03941808|DRUG|Glisodin tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
214900006|NCT03941808|DRUG|Placebo tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
214900007|NCT02863094|DEVICE|transcranial magnetic stimulation|
214900008|NCT04078594|OTHER|sepsis e-alert|At 2-each month interval, the e-alert will be activated in five new randomly selected wards, until all wards eventually will have active alert
214900009|NCT04181294|BEHAVIORAL|Family meetings using time limited trials as default ICU communication and care planning approach|Providers will be trained using didactics, focus groups, and simulations using actors as family members. A TLT protocol and checklist will be used to facilitate family meetings. A coordinator will schedule family meetings. Routine feedback sessions will be held with the local champions.
214900010|NCT04181294|BEHAVIORAL|Usual practice|Baseline practice of ICU communication and care planning
215054100|NCT04902430|PROCEDURE|T- Loop|Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
215054101|NCT00560300|DRUG|1 alpha D2|Vitamin D sterol
215054102|NCT00560300|DRUG|1,25 dihydroxy vitamin D3|Active vitamin D sterol
215054103|NCT00560300|DRUG|Sevelamer HCl|Phosphate binder
215054104|NCT00560300|DRUG|Calcium Carbonate|Phosphate binder
214478940|NCT06606665|OTHER|Reaction time test|Reaction time; It will be evaluated with the 12-Red Square Test on the App-coo test application via tablet.
214478941|NCT06606665|OTHER|Quality of life assessment|Quality of life assessment; It will be evaluated with the Nottingham Health Profile.
214900011|NCT05068180|DRUG|low-dose neuroleptanalgesia|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
214900012|NCT05068180|DRUG|Placebo|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
214900013|NCT05348460|DIETARY_SUPPLEMENT|Ketone ester drink (DeltaG®, 500 mg/kg body weight)|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
214900014|NCT05348460|DIETARY_SUPPLEMENT|Taste-matched, isovolumic placebo drink|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
215054105|NCT01166347|DEVICE|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
215054106|NCT01166347|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
215054107|NCT02469220|DIETARY_SUPPLEMENT|Low FODMAP|Blinded food supplements containing only items with a low content of FODMAPs
215054108|NCT02469220|DIETARY_SUPPLEMENT|Standardized FODMAP|Blinded food supplements containing FODMAPs
215054109|NCT05364710|DIETARY_SUPPLEMENT|Transfer factor from colostrum ultrafiltrate|Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
215054110|NCT05325203|BIOLOGICAL|Ongericimab|Administered by subcutaneous injection
215054111|NCT05325203|DRUG|Placebo|Administered by subcutaneous injection
215054112|NCT03566472|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
215054113|NCT02822053|PROCEDURE|US-guided laser ablation for refractory neoplasms|
215054114|NCT03949868|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt."
215054115|NCT03949868|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes."
215054116|NCT03949868|BEHAVIORAL|Active control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in."
214478942|NCT06606665|OTHER|Lower extremity muscle strength assessment|Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.
214478943|NCT06606665|OTHER|Hand grip strength measurement test|Hand grip strength measurement test; It will be evaluated with a dynamometer.
214478944|NCT06606665|OTHER|Pulmonary function assessment|Pulmonary function assessment; It will be evaluated by spirometry.
214478945|NCT06606665|OTHER|Balance assessment|Balance assessment will be done with the Wii Fit Balance Board.
214478946|NCT06593847|BEHAVIORAL|Single-session VR exposure intervention|VR exposure is the only intervention, but the VR intervention is conducted following either positive or negative mood induction.
215054117|NCT05807373|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)
215054118|NCT05000307|DIAGNOSTIC_TEST|Blood sample|Analysing blood samples for the presence of antibody against SARS-CoV2. When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.
215054119|NCT03558646|OTHER|There is no intervention planned (observational)|There is no intervention planned (observational)
214478947|NCT06598644|OTHER|Cervical SNAGS (C3-C7) + Conventional PT|Cervical SNAGS at C3-C7 with active movements of lateral flexion and rotation with overpressure at the end range. .Frequency: 10 reps 3 times/week for 3 consecutive weeks Intensity: starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-hot pack for 10 minutes 2-Cervical Stretchings for levator scapulae and sternocleidomastoid 3-cervical isometric exercises, 4. Cervical Range of motion exercises
214478948|NCT06598644|OTHER|IASTM (ergon) + Conventional PT|IASTM, ergon applied at levator scapulae and sternocleidomastoid muscle, with 30 strokes at an angle. After that icing done at the levator scapulae and sternocleidomastoid muscle for 5-10 minutes using cold pack.
214478949|NCT06679153|DRUG|VVN461 Ophthalmic Solution 1.0%|VVN461 Ophthalmic Solution, 1.0%, for up to 28 days
214478950|NCT06679153|DRUG|VVN461 Ophthalmic Solution 0.5%|VVN461 Ophthalmic Solution, 0.5%, for up to 28 days
214478951|NCT06679153|DRUG|Prednisolone acetate|Prednisolone acetate, 1%, for up to 28 days
214478952|NCT06678542|DRUG|GP681 tablet|GP681 tablet, 20 mg, single oral dose in each Group.
214478953|NCT06678542|DRUG|GP681 Powder for Oral Suspension|GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.
214478954|NCT06866392|DIAGNOSTIC_TEST|photoelectric detection|Methylation test and colposcopic biopsy was performed in the conventional group, and clinical follow-up was performed according to the methylation results; in the experimental group, methylation test and colposcopic biopsy and OITS was performed, and clinical follow-up was performed according to the methylation results and OITS results.
214900015|NCT05219760|DEVICE|LIVIA|"The study aim to compare the efficacy of an IBI targeting complicated grief symptoms (LIVIA 2.0) compared to an already investigated IBI (LIVIA 1) using a guidance on demand design in a randomised controlled trial.~Both programs are composed of 10 weekly sessions proposing educational material, questionnaires and exercises. They are based on current scientific theories of grief but present their content differently. Compared to LIVIA 1, LIVIA 2.0 is less based on academic readings and participants can choose more freely which topics and exercises they want to do. LIVIA 2.0 also offers a system of reminder messages to maximize adherence as well as more elaborate automated guidance."
214900016|NCT01963104|PROCEDURE|Automated hearing test|Subjects will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
214900017|NCT01963104|PROCEDURE|Pure-tone Screener test|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
214900018|NCT01963104|PROCEDURE|Digits-in-noise test|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
215054120|NCT02351011|BIOLOGICAL|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
215054121|NCT02351011|BIOLOGICAL|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
215054122|NCT02351011|BIOLOGICAL|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
215054123|NCT00327925|PROCEDURE|Find Cancer Associated Antibodies|
215054124|NCT01718899|BIOLOGICAL|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
215054125|NCT05468645|DRUG|[14C]Hemay005|Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
215054126|NCT05859646|DIETARY_SUPPLEMENT|Probiotic use|Probiotics were used for 3 months and all participated patients were followed for 6 months.
215054127|NCT03554018|DRUG|Acetaminophen|Acetaminophen 500-1000mg every 6 hours
214478955|NCT06866327|BEHAVIORAL|Piano lessons|The program consists of 12-weekly piano lessons, alternating small group lessons and individual lessons each week. Individual lessons reinforce and help personalize what is instructed during group lessons. Lessons are tailored to help older adults with memory challenges learn note reading, finger positioning, and song playing. Participants are asked to practice at home in between lessons for 10 minutes per day, 5 times per week, with a keyboard and bench provided.
214900019|NCT01963104|PROCEDURE|No screening test|This group of subjects will not receive a screening test. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
214900020|NCT01963104|PROCEDURE|Automated hearing test/Motivation video|Subjects will take an automated hearing test that presents tones at different pitches and volumes.Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
214301310|NCT03914326|DRUG|Semaglutide|Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
214301311|NCT03914326|DRUG|Placebo (semaglutide)|Placebo tablets to be taken with water at the same time every morning in a fasting state
214478956|NCT06866327|BEHAVIORAL|Music Lessons|The program consists of 12-weekly music lessons, alternating small group lessons and individual lessons each week. Individual lessons reinforce and help personalize what is instructed during group lessons. Lessons are tailored to help older adults with memory challenges learn various instruments, engage in group playing during group lessons, and engage in music appreciation activities. Participants are asked to practice at home in between lessons for 10 minutes per day, 5 times per week, with instruments provided.
214478957|NCT06619093|OTHER|blood sampling|3 additional citrate tubes (2.7mL)
215054128|NCT03554018|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg every 6 hours
215054129|NCT03554018|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health\_Info/Back\_Pain/default.asp)
215054130|NCT03554018|DRUG|Placebo oral capsule|To match acetaminophen, patients will take one or two capsules every 6 hours
215054131|NCT00900497|BIOLOGICAL|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
215054132|NCT05362292|DRUG|Tolterodine Tartrate ER|Anticholinergic
215054133|NCT05362292|DRUG|Mirabegron|Beta-3-adrenergic agonist
215054134|NCT05362292|DRUG|Placebo|matching placebo pill
214900021|NCT01963104|PROCEDURE|Pure-tone Screener/Motivation video|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
214900022|NCT01963104|PROCEDURE|Digits-in-noise test/Motivational video|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
214900023|NCT01963104|PROCEDURE|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
214900024|NCT01963104|PROCEDURE|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
215054135|NCT04010097|OTHER|chewing gum|The test involves chewing a chewing gum for 4 minutes
215054136|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
215054137|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
215054138|NCT06340230|DRUG|SHR-A1811 Injection|Drug: SHR-A1811 Injection
215054139|NCT05223998|PROCEDURE|Full-thickness skin microcolumns implantation|Surgical harvest and implantation of FTSM on an open wound requiring coverage.
215054140|NCT05171166|PROCEDURE|HAIC|Hepatic arterial infusion chemotherapy is consist of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 would be intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
214301312|NCT04017585|DIETARY_SUPPLEMENT|diet containing gluten|gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days
214301313|NCT04017585|DIETARY_SUPPLEMENT|Diet containing placebo|Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
214478958|NCT05112900|BEHAVIORAL|Text Messaging (TM)|\[see arm/group descriptions\]
215054141|NCT05171166|PROCEDURE|TACE|A standard hepatic artery catheter would be introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery would be performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply, the proportion of the liver supplied by each artery would be estimated by the arteriography. After optimal positioning of the catheter, cTACE or DEB-TACE protocol would be performed to embolize the tumor supplying artery blood flow until the stasis of the supplying artery.
215054142|NCT05171166|DRUG|FOLFOX|oxaliplatin,leucovorin, and 5-FU
215054143|NCT05171166|DRUG|cTACE or DEB-TACE|lipiodol or microspheres that mixed with EPI
214900025|NCT01963104|PROCEDURE|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss.~Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care."
214900026|NCT00774501|PROCEDURE|image guidance with general anesthesia and suspended ventilation during treatment delivery|"All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.~Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.~The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery."
214900027|NCT00210769|DRUG|paliperidone ER Oros|
214900028|NCT03560401|DEVICE|Knight-Taylor [chairback] brace|Knight-Taylor \[chairback\] brace, is one kind of rigid lumbosacral orthosis. The manufacturer was Rehabilitation and Technical Aid Center, Taipei Veterans General Hospital.
214900029|NCT05961046|DEVICE|Vivity IOL|Vivity IOL
214900030|NCT01837901|DEVICE|Transcorneal electrostimulation|
214900031|NCT02257346|DRUG|Lidocaine|Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.
214900032|NCT02257346|DRUG|Normal Saline|Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
214900033|NCT02865304|DRUG|endostar|
214900034|NCT06053346|BEHAVIORAL|Pay For Performance (PFP)|Wraparound mental health, psychosocial, and addiction treatment services provided by contractor under an schedule of rewards or penalties that was agreed to with Santa Clara County.
214900035|NCT06053346|BEHAVIORAL|Usual Care (UC)|Outpatient and inpatient mental health and psychosocial services delivered by Santa Clara County services and systems.
214900036|NCT05863884|BEHAVIORAL|Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake|CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
214900037|NCT02850146|DRUG|18F-AV-1451|
215054144|NCT05171166|DRUG|Donafenib|200 mg of donafenib (consisting of two 100-mg tablets) twice daily.
215054145|NCT06016075|DEVICE|Hyperpolarised MRI|Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.
215054146|NCT06016075|DEVICE|Sodium MRI|MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium.
214301314|NCT05971108|DIAGNOSTIC_TEST|Elecsys® GAAD|Elecsys® GAAD is a CE marked in vitro diagnostic (IVD) multivariate index assay, intended as an aid in the diagnosis of early-stage HCC. It provides a semi quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP (alpha-fetoprotein) and Elecsys® PIVKA-II (protein induced by vitamin K absence II) levels in serum and plasma, with gender and age. Clinical evidence showed that Elecsys® GAAD had high performance in detecting HCC (sensitivity 86.5%), particularly early stage (sensitivity 78.9%), with 91.4% specificity for both early and all stages, out-performing current standard of care (Chan et al. 2021). Elecsys® GAAD may be integrated into current surveillance practice to increase early-stage HCC detection rate, reduce unnecessary onward investigations and patient anxiety.
214301315|NCT05268133|DIETARY_SUPPLEMENT|Aronia|As described in experimental arm
214301316|NCT05268133|DIETARY_SUPPLEMENT|Control|As described in placebo comparator arm
214301317|NCT03695562|PROCEDURE|sequential drilling technique|Patient with vitamin D deficiency using sequential drilling technique
214301318|NCT05276570|DRUG|ARO-RAGE|single or multiple doses of ARO-RAGE by inhalation of nebulized solution
214301319|NCT05276570|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
214301320|NCT05855005|DEVICE|DTC Hearing Aids|DTC hearing aid programmed to the individual participant.
214301321|NCT04482842|DEVICE|Gene detection (CYP2C9*3, VKORC1)|Warfarin is administered at the recommended dose by detecting CYP2C9\*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.
214301322|NCT04482842|DRUG|Warfarin Sodium|Warfarin is administered at a gene-guided dose or at a regular dose.
214301323|NCT06441175|OTHER|Intubation device order|"D-V group: the group that performs direct laryngoscopy first and then videolaryngoscopy.~V-D group: the group that performs video laryngoscopy first and then directlaryngoscopy."
214301324|NCT06459648|OTHER|Headache record|The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication.
214301325|NCT06459648|OTHER|Scales|Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia.
214301326|NCT06459648|DRUG|Monoclonal antibody anti-CGRP|Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab
215054147|NCT06016075|DEVICE|Deuterium metabolic imaging (DMI) MRI|Drink of a sugar drink 90min before the MRI scan. Non-radioactive, no risk, approved for use in humans.
215054148|NCT04792190|DRUG|dapagliflozin|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
215054149|NCT04792190|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
215054150|NCT04740151|PROCEDURE|Best PEEP|In OLV, the investigator will perform a PEEP decremental titration trial, decreasing PEEP from 16 to 4 cmH2O (steps of 2-cmH2O, lasting 1 minute). At the end of every step driving pressure (Pplat-PEEP) will be calculated, and the PEEP corresponding to the lowest driving pressure + 2cmH2O will be set.
215054151|NCT04740151|PROCEDURE|Standard PEEP|In OLV, a PEEP of 5 cm H2O will be set.
215054152|NCT06551350|OTHER|Data Collection|Collection of medical data from MICU intervention file and the medical records of patients at the destination hospital
214301327|NCT06427603|BEHAVIORAL|physical activity|workshops and mobile apps: break sedentary behavior by activity breaks
214301328|NCT01447524|BEHAVIORAL|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
214301329|NCT04172246|DRUG|Zanubrutinib|Zanubrutinib at 160 mg orally twice daily
214900038|NCT04534530|OTHER|Systematic screening for ischemic heart disease in type 2 diabetic patients|Systematic screening for ischemic heart disease in type 2 diabetic patients at very high cardiovascular risk, without known coronary heart disease.
214900039|NCT01229995|DEVICE|dental implants - zirconia abutmetns - prefabricated abutments|
214900040|NCT06080035|OTHER|Topical Cetyl Tranexamate Mesylate|Topical product will be applied onto clean skin morning and night.
214900041|NCT00840749|RADIATION|CyberKnife Stereotactic Radiotherapy|Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy
214900042|NCT00840749|PROCEDURE|Surgery|Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
214900043|NCT00004919|DRUG|cisplatin|Given IV
214900044|NCT00004919|DRUG|irinotecan hydrochloride|Given IV
214900045|NCT00004919|DRUG|amifostine trihydrate|Given IV
214900046|NCT00004919|OTHER|pharmacological study|Correlative studies
214900047|NCT03808649|DRUG|1500ml of 2.5% mannitol|1500ml of 2.5% mannitol was used in experimental group
214900048|NCT03808649|DRUG|different volume of 2.5% mannitol|different volume of 2.5% mannitol based on BMI was used in active comparator group
214900049|NCT00677664|DRUG|Glatiramer acetate (Copaxone)|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
214900050|NCT00677664|DRUG|Mannitol|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
214900051|NCT04259164|DRUG|QVM149|Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol
214900052|NCT04259164|DRUG|QMF149|Mometasone / Indacaterol
214900053|NCT04310202|OTHER|Abbreviated Profile of Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on two occasions.
214900054|NCT04310202|OTHER|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on two occasions.
214900055|NCT04310202|OTHER|Additional follow-up visits after surgery|There are 1-2 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
214900056|NCT02836002|DRUG|Sulfadoxine-pyrimethamine (low dose)|\- subcurative regimen (500mg/25mg)
214900057|NCT02836002|DRUG|Piperaquine (low dose)|\- subcurative regimen (480 mg)
214900058|NCT02836002|DRUG|Sulfadoxine-pyrimethamine (high dose)|\- curative regimen (1000mg/50mg)
214900059|NCT02836002|DRUG|Piperaquine (high dose)|\- curative regimen (960 mg)
214900060|NCT02836002|BIOLOGICAL|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
214900061|NCT02836002|DRUG|Atovaquone-proguanil|\- curative regimen: 1000/400 mg, for 3 days
214900062|NCT06189664|DIAGNOSTIC_TEST|Frozen section|Frozen section analysis
214900063|NCT00155064|DRUG|captopril, Losartan (drug)|
214900064|NCT03458442|OTHER|Simulation-based surgical training|"Those in the intervention group will be introduced to a variety of simulation-based surgical training techniques. Specifically, this will involve breaking down the SICS cataract surgery procedure into stages, and practicing each stage repeatedly using simulation. This sustained deliberate practice will be integrated into the six-week course, as an enhancement to the course, and not as a replacement of any part of the educational content. Within the last three weeks of the course, 'intervention' arm participants will be introduced to the artificial eyes, the Simulation-OSSCAR rubric, and be provided with ongoing feedback.~All participants in both intervention and control arms will undertake the six-week Orbis-COS training course."
214900065|NCT03458442|OTHER|Standard surgical training|Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
214478959|NCT05112900|BEHAVIORAL|Text Messaging + Health Navigation (TM+HN)|\[see arm/group descriptions\]
214478960|NCT06866587|OTHER|exercise therapy|Priorities of the treatment included care and interventions to avoid inappropriate neck positions and to provide a regular exercise program for neck muscles and ergonomics training (ergonomic arrangements for desk setup, reading position, computer and mobile phone use, handcrafts, television watching, and pillow height). Of note, patients were advised to avoid cold exposure, particularly in the neck area (air-conditioned environments, wet hair, and holding the hair dryer too close to the scalp). Patients that did not show improvement after training and regular exercise were initiated on medical treatment after the second week and were given myorelaxant gel and oral tablets (diclofenac sodium) for the neck area.
215054153|NCT02894398|DRUG|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
214301330|NCT05443191|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
214301331|NCT04387851|BEHAVIORAL|Placebo induction|The placebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce placebo effects on somatosensory sensations.
214478961|NCT04956549|BEHAVIORAL|Physical activity program|Supervised group sessions will be held twice per week for approximately 52 weeks. Each physical activity session will last slightly approximately 80 minutes and will consist of aerobic, strength, flexibility, and balance training. The 80 minutes of activity consists of a 5 minute warm-up, 45 minutes of aerobic training, 15 minutes of strength training, 10 minutes of balance training, and a 5 minute cool-down. The physical activity group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations.
214478962|NCT04956549|BEHAVIORAL|Successful Aging|The successful aging group will be based on a low-intensity activity program and a healthy aging educational component. Sessions will be approximately 60 minutes in duration and will occur once per week for the first 6 months and then every other week for the remainder 6 months of the study. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
214478963|NCT05849610|DRUG|Daratumumab|Daratumumab will be administered by SC injection.
214478964|NCT05849610|DRUG|Bortezomib|Bortezomib dose will be calculated using the patient's actual body surface area (BSA) at baseline and will be administered by subcutaneous (SC) injection.
214478965|NCT05849610|DRUG|Lenalidomide|Lenalidomide will be administered by oral route.
214478966|NCT05849610|DRUG|Teclistamab|Teclistamab will be administered by SC injection.
214478967|NCT05849610|DRUG|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
214478968|NCT04745962|DEVICE|Slimscope|Slimscope thin EBUS endoscope is inserted and used to visualize lung nodules.
214478969|NCT05687344|DRUG|Nifedipine ER|Postpartum BP treatment to \<140/90 mmHg
215054154|NCT02894398|DRUG|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
214478970|NCT06854068|DEVICE|laser treatment|In the laser treatment groups, the Fotona LightWalker® Erbium laser (2,940 nm) will be used, with each session lasting five minutes. During treatment, the energy density will be set to 20 J/cm², and the laser tip will be held perpendicular to the target area, applied in continuous and contact modes.
214478971|NCT06854068|DEVICE|application of desensitizing agent|"Mix the product for 15 s. Apply in a thin layer on treatment area(s) with aid of a microbrush, with no rinsing or removal"
214478972|NCT06854068|OTHER|Placebo|"Simulation of a single layer application (15s) , with the aid of a microbrush, on the surface of the tooth and with no rinsing or removal."
214900066|NCT04785378|DEVICE|Medical mask|Participants will carry out field tests one day wearing a medical mask and the other day without a mask.
214900067|NCT04785378|OTHER|Field tests|Participants will perform 6 MWT and ISWT tests to determine their exercise capacity, and a 30-second sit and stand test to determine lower extremity endurance.
214900068|NCT03507361|OTHER|HRV-BASED MUSIC|Music is produced by Sound-of-Soul technology that translates HRV power frequency spectrum real-time into music. The intervals between the heartbeats are detected in milliseconds and then transferred into a frequency spectrum. Sound of Soul system gets wired into different band pass filters which are linked to the frequencies of the heart (i.e. low frequency and high frequency). Once the signal is detected and computed, the Sound of Soul system links it through a musical instrument digital interface (MIDI). This interface transforms ECG data into music and sounds. The audio production is performed using a virtual instrumentation technology with different music libraries. For the puropose of this study, all patients will ear the same instrument (arp). Once the instrument have been selected, the ECG gets recorded and in real-time the patient can hear a music obtained from his/her own HRV. The investigator will control the volume and the different settings of the music.
215054155|NCT02894398|DRUG|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
215054156|NCT02894398|DRUG|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
214301332|NCT04387851|BEHAVIORAL|Control|Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).
214478973|NCT03350516|DIETARY_SUPPLEMENT|Daily 500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
214478974|NCT03350516|DIETARY_SUPPLEMENT|Daily1500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
214478975|NCT06225232|DRUG|Psilocybin combined with Psychotherapy|The intervention consists of a 9-week treatment protocol that is based on supportive psychotherapy and Motivational Enhancement Therapy. Overall, the therapy course includes 8 motivational enhancement therapy sessions and two experimental drug sessions.
214301333|NCT04387851|BEHAVIORAL|Nocebo|The nocebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce nocebo effects on somatosensory sensations.
214478976|NCT03581071|DRUG|TS-143|
214900069|NCT02550561|DEVICE|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
214900070|NCT04526028|DRUG|Fulvestrant Injectable Product|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
214900071|NCT04526028|DRUG|Palbociclib|Palbociclib is in the form of oral capsules, which are divided into three specifications: 75 mg, 100 mg and 125 mg. The recommended dose is 125 mg once daily for 21 days, followed by 7 days (3/1 dosage regimen), 28 Day is a treatment cycle.
214900072|NCT02083744|BEHAVIORAL|PsychoEducational Support|
214900073|NCT02083744|BEHAVIORAL|Usual Care|Standard Heart Failure Care
214900074|NCT04237376|DRUG|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
214900075|NCT04237376|DRUG|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Tenofovir Disoproxil Fumarate 300 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
214900076|NCT00086229|DRUG|Glucosamine|
214900077|NCT00086229|DRUG|Chondroitin|
214900078|NCT05021393|OTHER|Clinical Pharmacist Intervention|Medication review, patient education, counseling, and corresponding written recommendation will be performed by clinical pharmacists for all randomized patients.
214900079|NCT05352620|OTHER|Implant assisted maxillary overdenture|For each patient, an implant assisted maxillary overdenture will be fabricated using a minimally invasive flapless surgical technique with OT-Equator and Smart Box attachment
214900080|NCT02757001|OTHER|Inferior vena cava filter placement and retrieval|"There are really no interventions in this study. This is an prospective observational study of patients that have been implanted a inferior vena cava filter with intention to be retrieved.~Patients are recruited when the filter is implanted, and the investigators observe when is it finally retrieved, and if there is any complication at the retrieval of the filter."
214900081|NCT03495557|PROCEDURE|Control|Fascial closure with simple polydioxanone suture 2/0 stitches
214900082|NCT03495557|DEVICE|Experimental|Onlay polypropylene mesh placement (MN mesh)
214900083|NCT02742662|DEVICE|Wearable technology, smartscale|
214900084|NCT02742662|BEHAVIORAL|Smartphone applications|
214900085|NCT02742662|BEHAVIORAL|Standard Weight Management Visits|
214900086|NCT01434095|PROCEDURE|half-dose photodynamic therapy|photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
214301334|NCT04259762|OTHER|Aim 8 (INT, Pilot Test): Breast, Colorectal, and Cervical Cancer Screening Cognitive-Behavioral Interventions|Adult men and women will receive age- and gender-specific INTs. Women age 45-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 45-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The cognitive-behavioral INTs on age-gender specific cancers will range from 1-2 hours. The study team will utilize a digital flipchart that will cover each cancer's specific risk/protective factors, incidence, mortality, screening methods, and resources. The study team member delivering the INTs will function as a facilitator linking information with practical skills.
214301335|NCT01203046|DRUG|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
214478977|NCT05447338|PROCEDURE|Specific joint mobilization post muscle inhibition on C1|Grasp the hand with the thumb or forefinger at the spinous process of C1. The contratoma hand is placed in forceps with the thumb and forefinger on the patient's temple, one on each side. Resisting with the hand on the temple, the therapist asks the patient to perform a 6-second isometric contraction of the cervical spine flexor muscles. The therapist then instructs the patient to relax the musculature and simultaneously performs posteroanterior pressure on the spinous process of C2 and passive extension of the head (with the hand on the temple). The maneuver is repeated until the therapist notices the release in the flexion-extension movement of the head.
214900087|NCT01621334|BEHAVIORAL|Motivational Enhancement Therapy|Two personal feedback sessions with counselor using motivational interviewing strategies.
214900088|NCT01621334|BEHAVIORAL|Educational information|Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
214301336|NCT02769247|DRUG|Naproxen|Oral naproxen vs placebo
214301337|NCT02769247|DRUG|Lidocaine|Intrauterine lidocaine vs normal saline
215054157|NCT02894398|DRUG|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
215054158|NCT06351826|OTHER|ELLASI|A structured intervention for polytrauma patients
215054159|NCT06351826|OTHER|Standard|Unstructured interventions that are given in everyday practice (standard intervention)
215054160|NCT04841993|DRUG|Cannabis decoction|A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
215054161|NCT04841993|DRUG|Cannabis oil|A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
215054162|NCT04841993|DRUG|Vaporized cannabis|100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
215054163|NCT01881282|DRUG|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
215054164|NCT01881282|DRUG|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
215054165|NCT04393662|DIAGNOSTIC_TEST|Measurement of Muscle strength using a dynamometer|"Muscle strength will be measured in the elbow bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). Supination tests will be performed with the forearm in neutral position, 60° pronation and 60° supination. The elbow will be in 90° flexion, and the shoulder in 45° flexion. Constant pressure is applied to lever of device for 3 to 5 seconds. Maximum torque will be recorded automatically. For each position, three repetitions of 3s (to 5s) contractions will be performed with a break of 15 (or 30s) between the repetitions. There will be an additional break of 2 minutes between measurements of the supination strength in the different positions. This parameter will be analysed regarding asymmetry between both limbs.~Isometric endurance of forearm supination will be measured in neutral forearm. Flexion tests will be carried in the same setting as for supination. Flexion tests will be performed with the elbow in 90, 45 and 0° of flexion."
215054166|NCT04393662|DIAGNOSTIC_TEST|Range of motion clinical measurement (shoulder and elbow)|The range of motion parameters (degree) of both shoulders and elbows will be documented. The circumference of the arm will be measured on the line between the medial acromion and the cubital fossa at 1/3 from the cubital fossa
215054167|NCT04393662|DIAGNOSTIC_TEST|Electromyography (EMG)|Electromyographic (EMG) data will be collected using a wireless EMG system (myon AG, Schwarzenberg, Switzerland). Surface electrodes will be placed bilaterally on biceps and triceps following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles)
215054168|NCT03345355|DIAGNOSTIC_TEST|Imaging|Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
215054169|NCT00659841|DRUG|Ciclesonide|200µg Ciclesonide versus placebo
215054170|NCT00659841|DRUG|Placebo|placebo
215054171|NCT05096637|OTHER|PreventiPlaque App|PreventiPlaque is an app that supports patients with atherosclerotic plaque by strengthening their adherence.
215054172|NCT05237583|BEHAVIORAL|Prehabilitation|All participants will be offered a multimodal prehabilitation program. This program will include an individualized and supervised aerobic and resistance exercise training program, nutritional optimization, and psychological support. The program will last 6 months or until liver transplantation, whichever comes first.
214900089|NCT01683435|OTHER|HBA binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
214900090|NCT00160303|DRUG|Prolotherapy|
214900091|NCT00160303|DRUG|Local Corticosteroid Therapy|
214900092|NCT04969679|DRUG|E. coli Nissle 1917 (Mutaflor®)|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
214900093|NCT04969679|DRUG|Placebo|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
214900094|NCT00395629|DRUG|Deferasirox (ICL670)|
214900095|NCT03534687|BEHAVIORAL|Aerobic Exercise|12-week supervised aerobic exercise
214900096|NCT01051960|DRUG|Ambrisentan|Ambrisentan 5mg or 10mg once daily
214900097|NCT03481673|BEHAVIORAL|COPE for Asthma|The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression.
214900098|NCT02110082|BIOLOGICAL|Urelumab|
214900099|NCT02110082|BIOLOGICAL|Cetuximab|
214900100|NCT02394600|DRUG|Grastek®|one tablet daily for four months
214900101|NCT02394600|DRUG|Placebo|one tablet daily for four months
214301338|NCT02769247|DRUG|placebo|either normal saline or empty oral capsule
214301339|NCT06238479|DRUG|LY4101174|Intravenous
214900102|NCT02125682|DRUG|atovastatin 10 mg/day|patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
214900103|NCT02125682|DRUG|Atorvastatin 80 mg/day|patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
214301340|NCT05216731|PROCEDURE|Femoro-popliteal bypass|Under general or local anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
214900104|NCT02094274|DRUG|LAS40468|
214900105|NCT02094274|DRUG|Salmeterol/fluticasone propionate|
214900106|NCT02094274|DRUG|Placebo|
214900107|NCT00333320|PROCEDURE|postconditioning|patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
215054173|NCT04990583|BEHAVIORAL|Face-to-Face PrEP Adherence Intervention Based on LifeSteps|This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.
215054174|NCT04990583|BEHAVIORAL|Adherence Coaching Facilitated by Carium Adherence App|The Carium app will be used to deliver medication reminders to participants, track medication adherence, engage in two-way secure messaging with participants, and connect with participants through a secure video feature. The adherence coach will use the secure messaging feature to support the participant with their adherence
215054175|NCT05121961|PROCEDURE|Sacroiliac intra-articular injection|CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
215054176|NCT05004415|DRUG|AT-527 (R07496998)|Study participants will receive a single radiolabeled dose of 550 mg AT-527.
215054177|NCT02891226|DRUG|Mirikizumab|
215054178|NCT02891226|DRUG|Placebo|
215054179|NCT02977078|BEHAVIORAL|Active feedback on monitored inhaler use|Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback
214301341|NCT05216731|PROCEDURE|Endovascular procedure|Under general anesthesia, local anesthesia or sedation: Performing a balloon angioplasty completed by preferred stent deployment or drug-coated balloon angioplasty.
214301342|NCT04101981|PROCEDURE|oocytes retrieval|The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.
214900108|NCT00333320|PROCEDURE|Control group|Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
214900109|NCT01080482|DRUG|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
214900110|NCT01686373|DEVICE|Activa Dose II Real tDCS|20 minutes of 1 milliamp active tDCS per treatment day (15 total sessions)
214900111|NCT01686373|DEVICE|Activa Dose II Sham tDCS|20 minutes of sham stimulation per treatment day (15 total sessions)
214900112|NCT05220982|BEHAVIORAL|Conversation Training Therapy|Training clear speech in conversation with new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
214900113|NCT05220982|BEHAVIORAL|Global Voice Prevention and Therapy Model|Training of four new voices (i.e., resonant voice in connected speech, falsetto for quiet talking, oral twang for talking over noise, and belt for healthy yelling) defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with new vs other or old voice at each step. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
214900114|NCT05220982|BEHAVIORAL|Modified Conversation Training Therapy|Training clear speech in conversation with no use of new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
214900115|NCT05220982|BEHAVIORAL|Modified Global Voice Prevention and Therapy Model|Training of a new resonant voice in connected speech defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with no use of new vs old voice. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
214900116|NCT04232865|DEVICE|Biop System|"Stage 1 - Training:~Up to 320 women in whom a complete procedure with the Biop System will be performed. Biopsies will be taken solely based on colposcopy examination. Enrolled participants will include at least 80 participants Histopathology identified with a high-grade lesion and at least 80 participants Histopathology identified as normal or with a low-grade lesion.~Stage 2 - Validation:~Up to 330 HIV negative women in whom a complete procedure with the Biop System will be performed.~Validation stage will also include up to 165 HIV positive participants. All participants will be enrolled in up to 3 sites in South Africa."
215054180|NCT02977078|DEVICE|Inhaler casing|Monitors inhaler use
215054181|NCT02977078|DEVICE|Mobile application|Mobile application software linked to inhaler casing
215054182|NCT01928433|DRUG|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
215054183|NCT01928433|DRUG|Finafloxacin placebo i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
215054184|NCT01928433|DRUG|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
215054185|NCT01928433|DRUG|Finafloxacin placebo tablets once daily|Administered as four tablets
215054186|NCT01928433|DRUG|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
215054187|NCT01928433|DRUG|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
215054188|NCT01928433|DRUG|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
214301343|NCT04788953|DRUG|Solriamfetol Oral Tablet|The administered drug is SUNOSI (solriamfetol) tablets for oral use. Initial U.S. Approval: 2019
214301344|NCT04788953|DRUG|Placebo|Control subjects will receive placebo tablets for oral use.
214478978|NCT05447338|PROCEDURE|Maitland C2|Maitland central posterior-anterior passive joint mobilization at C2: The patient will lie prone, the therapist behind the patient's head, with both thumbs will apply a central force on the spinous process of C2. The duration of the application will be up to five applications of 10 to 30 seconds in duration, depending on clinical judgment.
214900117|NCT00707148|DRUG|Placebo|Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
214900118|NCT00707148|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
214900119|NCT00754130|DRUG|Placebo|Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
214900120|NCT00754130|DRUG|MK-0941|MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
214900121|NCT00661557|BIOLOGICAL|Meningococcal vaccine GSK134612 (Nimenrix)|one dose, as intramuscular injection
214900122|NCT04735510|DRUG|cyclosporine ophthalmic emulsion 0.05%|All subjects will receive restasis
214900123|NCT06477198|OTHER|QLB|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the convex probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the quadratus lumborum muscle, the needle will be punctured and 5 ml of saline will be injected into the posterior border of the quadratus lumborum muscle between QLM and latissimus dorsi muscle.. After the block location is confirmed, 30 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (60 ml totally).
214900124|NCT06477198|OTHER|ESPB|ESP block will be performed. Convex probe will be placed longitudinally 4 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle, 2 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for the block in each side (total 60 mL).
214900125|NCT06477198|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
214900126|NCT01376999|DRUG|FSH-r (Follicule stimulate hormone)|Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
214900127|NCT01607515|OTHER|Impedance cardiography|noninvasive measure of cardiac index by impedance cardiography.
214900128|NCT03831009|PROCEDURE|Open reduction internal fixation (ORIF)|Open fracture reduction followed by internal fixation using a plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
214900129|NCT03831009|OTHER|Conservative treatment|Conservative treatment involves ankle protection with a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
214900130|NCT01436513|DRUG|Premarin reference tablet (fasted)|Premarin reference tablet, single dose, fasted conditions
215054189|NCT01928433|DRUG|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
215054190|NCT05271942|PROCEDURE|Tilt and Tumble|The Tilt and Tumble technique is used to remove the human lens.
215054191|NCT05271942|PROCEDURE|Divide and Conquer|The Divide and Conquer technique is used to remove the human lens.
215054192|NCT00145626|DRUG|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
215054193|NCT00145626|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
215054194|NCT00145626|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
215054195|NCT00220506|DRUG|Provigil|
215054196|NCT05535114|OTHER|Yoga-resistance exercise|Breathing exercise (5 minutes), flexibility (5 minutes), resistance exercise (20 minutes), relaxation \& meditation (10 minutes).
214900131|NCT01436513|DRUG|Premarin new tablet (fasted)|Premarin new tablet, single dose, fasted conditions
214900132|NCT01436513|DRUG|Premarin reference tablet (fed)|Premarin reference tablet, single dose, fed conditions
214900133|NCT01436513|DRUG|Premarin new tablet (fed)|Premarin new tablet, single dose, fed conditions
214900134|NCT03696212|DRUG|grapiprant and pembrolizumab|Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab
214900135|NCT00774163|BIOLOGICAL|Lactobacillus reuteri|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
214900136|NCT00774163|OTHER|Placebo|5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
214900137|NCT03775616|OTHER|Educational Intervention|Receive financial navigation program intervention
214900138|NCT03775616|OTHER|Questionnaire Administration|Ancillary studies
214900139|NCT03775616|OTHER|Quality-of-Life Assessment|Ancillary studies
214900140|NCT06121323|OTHER|Sodium lactate infusion|Dosage of sodium-lactate: 0.5 mol/L; 3 mL/kg/time; maximal 300 mL/hour.
214900141|NCT06121323|OTHER|Sodium lactate ingestion|Oral dose is equal to the i.v. dose.
215054197|NCT05592301|DIAGNOSTIC_TEST|Diffusion-weighted Magnetic Resonance Imaging (DW-MRI)|The Diffusion-weighted Magnetic Resonance Imaging (DW-MRI) is used to diagnose perioperative stroke.
215054198|NCT05592301|DIAGNOSTIC_TEST|Transcranial Doppler (TCD)|Used to diagnose PFO
215054199|NCT05592301|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|Used to diagnose PFO.
214900142|NCT03266653|DRUG|cytotoxic t-lymphocytes|EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
214900143|NCT06507410|DRUG|Propofol|Continuous propofol infusion will be given with syringe pump for maintenance, with the initial rate set at 25-75 mic/kg/min IV during the first 10-15 min. To avoid administering sedatives at rates greater than clinically necessary, infusion rates will be gradually titrated to 25-50 mic/kg/min and regulated with the clinical response, with an onset of peak drug action expected to occur within 2 min.
214900144|NCT06507410|DRUG|Propofol combined with clonidine|Patients will receive 2 μg/kg of clonidine for injection intravenously 30 min before induction of sedation, administered over 10 min.
214900145|NCT03068234|DRUG|Pirfenidone|A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.
214900146|NCT03068234|DRUG|Placebo oral capsule|Placebo for pirfenidone capsule
214900147|NCT03068234|DRUG|Steroids|Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
214900148|NCT04747158|BIOLOGICAL|Convalescent plasma|COVID-19 convalescent plasma at admission, after confirmation of eligibility, 200 ml on day 1 and 2
214900149|NCT01960413|DRUG|Montelukast added to Hydroxyurea|
214900150|NCT01960413|DRUG|Placebo added to Hydroxyurea|
214900151|NCT01057706|OTHER|chiropractic|spinal manipulation and mobilization
214900152|NCT01057706|BEHAVIORAL|exercise|strengthening, stretching, balance
214900153|NCT03486808|DEVICE|IFG stimulation|stimulating left inferior frontal cortex with transcranial direct current stimulation for 30 minutes
214900154|NCT03486808|DEVICE|DLPFC stimulation|stimulating left dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
214900155|NCT03486808|DEVICE|Sham stimulation|sham stimulation over both left inferior frontal cortex and dorsolateral prefrontal cortex
214900156|NCT03859596|PROCEDURE|MGB/OAGB|BARIATRIC PROCEDURE INVOLVED CREATION OF SLENDER GASTRIC POUCH OF 12-15CM IN LENGTH AND BILIO-PANCREATIC LIMB OF 150-200 CM
214900157|NCT02307942|PROCEDURE|Gastric banding|The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
214900158|NCT02780037|BEHAVIORAL|Regulatory frame: prevention|Exercise program presented as preventing deterioration.
214900159|NCT02780037|BEHAVIORAL|Regulatory frame: promotion|Exercise program presented as promoting improvement.
214900160|NCT02780037|BEHAVIORAL|Regulatory frame: not implied|Exercise program presented without implied consequences.
214900161|NCT03995485|DRUG|KW-136 capsule|KW-136 60 mg was provided in a single capsule of 60 mg.
214900162|NCT03995485|DRUG|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
214900163|NCT06123091|OTHER|Questionnaires with patient reported outcome measures|Questionnaires to gain insight of the prevalence of extracutaneous manifestations and the impact of the disease on the quality of life.
214900164|NCT00776035|PROCEDURE|PET (Positron Emission Tomography)|This is a diagnostic scan that requires the injection of radioactive tracer compounds intravenously using an IV placed in the arm.
214900165|NCT00776035|PROCEDURE|Echocardiogram|An echocardiogram is an ultrasound of the heart. Participants received a complete 2D- and Doppler echocardiographic examination on the day of the PET scan.
214900166|NCT00776035|RADIATION|^15O-water|This is a radioactive tracer used to study blood flow in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.
214900167|NCT00776035|RADIATION|1-^11C-palmitate|This is a radioactive tracer used to study fatty acid usage in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.
214900168|NCT00776035|RADIATION|1-^11C-glucose|This is a radioactive tracer used to study glucose usage in the heart during the PET scan. It was administered intravenously at a dose of 20 Mci..
214900169|NCT06280911|OTHER|Date Fruit group|Consumption of Date Fruit
214900170|NCT06280911|OTHER|Nipple group|Nipple Stimulation
214900171|NCT00791778|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.
215054200|NCT04883255|DRUG|10 mg Δ9-tetrahydrocannabinol (THC)|5-day course of orally-administered THC (dronabinol), 10 mg
214900172|NCT00791778|DRUG|Placebo|Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
214900173|NCT05973188|DRUG|Warfarin|Anticoagulant
214900174|NCT05973188|DRUG|Rivaroxaban 20 MG Oral Tablet|Anticoagulant
214900175|NCT05973188|DRUG|Apixaban 5mg or 2.5mg oral tablet|Anticoagulant
214900176|NCT02445261|RADIATION|mobile phone|Each woman was subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound was done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone.
214900177|NCT01082328|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
214900178|NCT02285361|DRUG|GIOTRIF 20mg|NSCLC with GIOTRIF 20mg
214900179|NCT02285361|DRUG|GIOTRIF 40mg|NSCLC with GIOTRIF 40mg
214900180|NCT02285361|DRUG|GIOTRIF 30mg|NSCLC with GIOTRIF 30mg
214900181|NCT02435693|OTHER|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
214900182|NCT02435693|OTHER|Without PHARMACEUTICAL CARE programe|
215054201|NCT04883255|DRUG|600 mg cannabidiol (CBD)|5-day course of orally-administered CBD, 600 mg
215054202|NCT04883255|DRUG|Placebo|5-day course of orally-administered placebo
215054203|NCT01058252|COMBINATION_PRODUCT|INVOCell, Letrozole 2.5 mg, recFSH 75 IU|"OVARIAN STIMULATION:~In previous cycles, cycle length and ovulatory status must be assessed and documented.~STEP 1: ANOVULATION by ORAL CONTRACEPTION~* Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.~* Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst \> 10 mm).~* Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.~STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).~* On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.~* Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder."
215054204|NCT01058252|PROCEDURE|STEP-3: LH Suppression & Monitoring|"Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.~• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.~The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)~No need of LH testing, or E2 testsing during the stimulated cycle."
214301345|NCT04063020|BEHAVIORAL|Psychological monitoring|"Discussions with the psychologist PhD student before and after every surgery times : 3 discussions.~* Before the first surgery (about 1 month before) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)~* Before the second surgery (3 months later the first surgery) Clinical interview Drawing a person~* After the second surgery (15 months later the first surgery) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)"
214301346|NCT05719116|BEHAVIORAL|Physical exercise|The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.
214900183|NCT04677777|BIOLOGICAL|PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)|PP-007 is PEGylated carboxyhemoglobin. Eligible patients will receive two doses of PP-007 (at least 24 hours apart) to evaluate extended drug exposure along with MT and/or IVT (individually or together) as SOC to evaluate safety in AIS patients.
214900184|NCT03306745|DIETARY_SUPPLEMENT|Profertil female|"For micronutrient ingredients please see details above. PROfertil ® female is approved in Austria by the Austrian Ministry of Health and has a Free Sales Certificate."
214900185|NCT03306745|DIETARY_SUPPLEMENT|Folic acid 400 mg|Folic acid 400 mg
214900186|NCT05306002|COMBINATION_PRODUCT|Antioxidant therapy|Antioxidant therapy based in the following dietary components: Zinc, Selenium, Magnesium, carotenoids, indole-3-carbinol, curcumin, epigalactocatechin, caffeine, resveratrol, lycopene, genistein, phytoestrogens
214900187|NCT02462590|DRUG|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
214900188|NCT02462590|DRUG|Placebo - Microcrystalline Cellulose|Microcrystalline Cellulose
214900189|NCT05529927|DRUG|Sustained-release Dexamphetamine|"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."
214900190|NCT05529927|DRUG|Placebo|"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."
214301347|NCT05897073|BEHAVIORAL|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
214301348|NCT05897073|BEHAVIORAL|Exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
214478979|NCT05447338|PROCEDURE|SNAG C1|Sustained natural apophyseal slippage (SNAG) will be applied e.g. in the case of wanting to improve the left rotation. The therapist performs a sustained anterior glide to the C1 transverse process on the left. The participant will be seated, simultaneously rotating their head to the left while holding the SNAG. The glide of C1 will be maintained by the therapist until the participant's head returns to the neutral starting position. The same will be done, but in the opposite direction to improve the right rotation.
214900191|NCT02224651|DRUG|PF-06650833|Subjects will receive sequential single escalating doses of 1-1000 mg of Immediate Release of PF-06650833 (as solution/suspension) under fed and / or fasted conditions.
214900192|NCT02224651|DRUG|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.
214900193|NCT02224651|DRUG|PF-06650833|Subjects will receive sequential single escalating doses of 10-500 mg of Modified Release of PF-06650833 (as capsule) under fed and / or fasted conditions.
214478980|NCT05447338|PROCEDURE|Specific joint mobilization post muscle inhibition on C2|The therapist rotates the head to the right side until the final sensation of the movement is noted, either due to pain or muscular tension. From this position, the therapist asks the patient to rotate the head to the left side while offering resistance with both hands in the opposite direction, in such a way as to generate an isometric contraction of the rotator muscles of the head to the left. The therapist then asks the patient to hold the position for 6 seconds. Subsequently, the therapist with the finger in the transverse process of C1, pushes it in the postero-anterior direction and simultaneously (with the contratome hand) rotates the patient's head to the right. The technique is repeated until the ROM improves, always taking into account the patient's tolerance.
214900194|NCT02224651|DRUG|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
214900195|NCT00874575|DIETARY_SUPPLEMENT|Placebo|
214900196|NCT00874575|DIETARY_SUPPLEMENT|Vitamin D|
214900197|NCT00874575|DIETARY_SUPPLEMENT|Beta-hydroxy-Beta-methylbutyrate|
214900198|NCT00874575|DRUG|Beta-hydroxy-Beta-methylbutyrate and Vitamin D|
214900199|NCT00234975|DRUG|Lopinavir/Ritonavir|400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
214900200|NCT05835440|OTHER|no intervention|interviews
214900201|NCT05370950|DRUG|SHR-1209|SHR-1209，single subcutaneous injection of 450mg
214900202|NCT00490750|PROCEDURE|Dor fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Dor fundoplication
214900203|NCT00490750|PROCEDURE|Toupet fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Toupet fundoplication
214900204|NCT02059135|BIOLOGICAL|Recombinant human antithrombin (ATryn)|Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
214900205|NCT02059135|OTHER|Normal Saline 0.9%|Placebo Comparator: Normal Saline 0.9%
214900206|NCT01498796|DRUG|Ketorolac|
214900207|NCT01498796|DRUG|Normal Saline|
214900208|NCT00381862|DRUG|aprepitant|Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
214900209|NCT00381862|DRUG|dexamethasone|Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
214900210|NCT00381862|DRUG|fluorouracil|as per institutional standard of care
214900211|NCT00381862|DRUG|irinotecan hydrochloride|as per institutional standard of care
214900212|NCT00381862|DRUG|leucovorin calcium|as per institutional standard of care
214900213|NCT00381862|DRUG|oxaliplatin|as per institutional standard of care
214900214|NCT00381862|DRUG|palonosetron hydrochloride|Palonosetron 0.25 mg IV push on day 1 only.
214900215|NCT00381862|PROCEDURE|quality-of-life assessment|baseline
214900216|NCT05855135|DEVICE|OPTIMIZER® Integra CCM-D System (Treatment Arm)|"The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a Cardiac Contractility Modulation - Defibrillator. All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years."
214900217|NCT02173691|DRUG|Tiotropium inhalation powder capsules|
214900218|NCT02173691|DRUG|Salmeterol inhalation aerosol|
214900219|NCT02173691|DRUG|Placebo inhalation aerosol|
214900220|NCT02173691|DRUG|Placebo inhalation powder capsules|
214900221|NCT02773901|DEVICE|HS-1000|
214900222|NCT00292734|DRUG|Zolpidem|
214900223|NCT05176821|DRUG|esomeprazole plus amoxicillin|amoxicillin 750mg QID + esomeprazole 20mg QID for 14 days
214900224|NCT05176821|DRUG|amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole|amoxicillin 1000mg BID + furazolidone 100mg BID + bismuth potassium citrate 600mg BID + esomeprazole 20mg BID for 14 days
214900225|NCT04508257|DIETARY_SUPPLEMENT|Oral feeding of Investigational Formula (Stage 1&2)|Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
214900226|NCT04508257|DIETARY_SUPPLEMENT|Oral feeding of Control formula (Stage 1&2)|Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
214900227|NCT04508257|DIETARY_SUPPLEMENT|Breast feeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
214900228|NCT04900259|BEHAVIORAL|COVID-19 pandemic|Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
214900229|NCT06578611|COMBINATION_PRODUCT|Enhanced recovery after surgery|Recommended pre-, intra-, and post-operative care interventions in the enhanced recovery after surgery.
214900230|NCT01367678|DEVICE|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
214900231|NCT01367678|DEVICE|i-Gel extraglottic airway device|Directly measured mucosal pressures
214900232|NCT06295874|OTHER|Effect of aromatherapy massage on vital signs, pain, anxiety and comfort level|The study applied a mixture of lavender, thyme and eucalyptus oil (5 drops of lavender oil, 4 drops of thyme oil, 3 drops of eucalyptus oil and 20 ml of almond oil in 20 ml) to patients who were monitored in intensive care on high-flow and oxygen, for three days. It was conducted as a randomized controlled single-blind study to evaluate the effects of aromatherapy massage applied twice a day for a total of 30 minutes on some physiological parameters, pain, anxiety and comfort levels.
214900233|NCT03335475|BEHAVIORAL|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
214900234|NCT03335475|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
214900235|NCT00232297|DRUG|SSR149744C|
214900236|NCT05944913|DEVICE|Prevena|PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
214301349|NCT05897073|BEHAVIORAL|Time-restricted eating plus exercise intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
214301350|NCT02595931|DRUG|Berzosertib|Given IV
214301351|NCT02595931|PROCEDURE|Biopsy Specimen|Undergo biopsy
214900237|NCT05308134|OTHER|Standard fortification|Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
214900238|NCT05308134|OTHER|Target fortification|Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
214900239|NCT05308134|OTHER|BUN adjustable fortification|BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
214900240|NCT02755103|BEHAVIORAL|Mindfulness Based Relapse Prevention (MBRP)|MBRP integrates coping skills from cognitive-behavioral relapse prevention therapy with Mindfulness Meditation (MM) practices, raising awareness of substance use triggers and reactive behavioral patterns, and teaching skillful coping responses.
214900241|NCT01285362|DRUG|Fish Oil Supplementation|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
214900242|NCT01285362|DRUG|Placebo Supplementation|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
214900243|NCT03142139|BIOLOGICAL|RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 1st dose within the month of scheduled vaccination:~* timely vaccinated: received 1st dose of DTaP-IPV-Hib before 4 months of age~* delayed vaccinated: did not receive the first dose of DTaP-IPV-Hib before 4 months of age."
215054205|NCT01058252|PROCEDURE|STEP-4: HCG Timing|"IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:~* E2 level is over 150 pg/ml/per mature follicle (\> 15 mm)~* Domminent follicle is greater than 18 mm in mean diameter~* LH Remains as Baseline, OR~* The day when Urinary LH Surge is positive"
215054206|NCT01058252|PROCEDURE|STEP-5: OPU, ET, Cancellation|"Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.~Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.~Maximum of 2 embryos are transferred, using ultrasound guided transfer.~Cancellation Criteria:~* Poor patient compliance~* Premature Ovulation~* Premature LH Surge~* Endometrium \< 7 mm~* Poor Follicular Development~* E2 Level \> 2,500 pg/ml"
215054207|NCT01058252|PROCEDURE|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 100000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
215054208|NCT00436436|DRUG|O6-benzylguanine|
215054209|NCT00436436|DRUG|temozolomide|
214900244|NCT03142139|BIOLOGICAL|RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 2nd dose within the month of scheduled vaccination:~* timely vaccinated: received 2nd dose of DTaP-IPV-Hib before 6 months of age~* delayed vaccinated: did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age."
215054210|NCT05254756|DEVICE|Bouquet speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
215054211|NCT05254756|DEVICE|Traditional plastic 2-blade disposable speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
215054212|NCT01326299|OTHER|Carbohydrate placebo|dissolve in water and consume with meal
215054213|NCT01326299|OTHER|Nutritional ingredient|Dissolve in water and consume with meals
215054214|NCT01326299|OTHER|#1 Nutritional ingredient +Fiber|Dissolve in water and consume with meal
215054215|NCT01326299|OTHER|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
215054216|NCT01326299|OTHER|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
215054217|NCT04803474|DIAGNOSTIC_TEST|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
215057503|NCT01555996|BEHAVIORAL|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
214301352|NCT02595931|PROCEDURE|Biospecimen Collection|Correlative studies
214301353|NCT02595931|PROCEDURE|Computed Tomography|Undergo CT
214301354|NCT02595931|DRUG|Irinotecan Hydrochloride|Given IV
214669481|NCT03641300|DEVICE|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
214900245|NCT03142139|BIOLOGICAL|RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated|"• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as unvaccinated until date of vaccination where they will shift exposure group to vaccinated."
214900246|NCT05955937|OTHER|Enhanced HF Clinical Care (Core-HF)|All clinical care providers involved in HF care at participating RRHs will be trained in a HF service bundle including a care protocol (treatment algorithm based on global guidelines), self-care training for patients and providers, and medication stock management to ensure supply of HF medications to patients in need.
214900247|NCT05955937|OTHER|Digital health intervention (Medly Uganda) plus enhanced HF clinical care (Core-HF)|A patient-facing mobile health application designed to improve self-care will be provided to the study participant, which will operate on all mobile devices. This will be introduced after the Core-HF intervention has been delivered.
214900248|NCT03578432|DRUG|Everolimus|Given PO
214900249|NCT03578432|OTHER|Laboratory Biomarker Analysis|Correlative studies
214900250|NCT03578432|OTHER|Survey Administration|Ancillary studies
214900251|NCT03574285|DRUG|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
214900252|NCT03574285|DRUG|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
214900253|NCT04736849|DEVICE|Percutaneous epidural and dorsal root stimulation|"Abbott percutaneous trial lead for dorsal root ganglion neurostimulation (Model MN10350)~Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
214900254|NCT02090348|DRUG|dimethyl fumarate|Administered as specified in the treatment arm
214900255|NCT06539507|DRUG|BCX17725|BCX17725 for injection
214900256|NCT06539507|DRUG|Placebo|Placebo for injection
214900257|NCT00658723|DRUG|Fibrin Pad|Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
214900258|NCT00658723|DEVICE|SURGICEL™|Absorbable hemostat
214900259|NCT02411656|OTHER|Laboratory Biomarker Analysis|Correlative studies
214900260|NCT02411656|BIOLOGICAL|Pembrolizumab|Given IV
214900261|NCT06546449|DRUG|LH-001|LH-001 will be administered oral
214900262|NCT06546449|DRUG|Placebo|Placebo will be administered oral
214900263|NCT02017158|OTHER|Virtual Sprouts|The Virtual Sprouts intervention group will play Virtual Sprouts in a school-based implementation of the game.
214900264|NCT06481709|DRUG|RLF-OD032|100 mg/mL oral suspension
214900265|NCT06481709|DRUG|Kuvan|100 mg powder for oral solution
214900266|NCT06968104|DEVICE|transcutaneous vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation (taVNS) delivered using the CE-certified tVNS® device (tVNS Technologies GmbH). Stimulation parameters include a pulse width of 250-500 μs, frequency of 10-25 Hz, and an individually titrated intensity (typically up to 5 mA). The device operates with a 20-50% duty cycle and is used at home.
214900267|NCT06968104|DEVICE|transcutaneous vagus nerve stimulation|Sham stimulation using the same CE-certified tVNS® device. Electrode placement is on the earlobe, which lacks vagus nerve innervation. Stimulation parameters (pulse width, frequency, intensity, duty cycle) mirror those of the active condition, with intensity adjusted to perceptual threshold to mimic the sensation of real stimulation and preserve blinding.
214900268|NCT05303064|DRUG|OLZ/SAM|OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
214900269|NCT05303064|DRUG|Olanzapine|The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
214900270|NCT06967805|BIOLOGICAL|MTX-463|MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.
214900271|NCT06967805|OTHER|Placebo|Placebo
214900272|NCT06968026|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|The eligible participants will undergo an intensity sweep consisting of six stimulation trains over the right dorsolateral prefrontal cortex (DLPFC), with stimulation intensities ranging from 100% to 150% of the individual resting motor threshold (RMT), increasing in 10% increments. Each train will last 60 seconds, comprising 40 seconds of active rTMS at 1 Hz and a 20-second intertrain interval (ITI). Synchronous electrocardiogram (ECG) data will be continuously recorded throughout the entire procedure.
214900273|NCT06968286|PROCEDURE|SRP|participants with periodontitis treated with scaling and root planning
215057504|NCT04884880|DRUG|Luo-Fu-Shan Plaster|Luo-Fu-Shan Plaster 10g，once daily，4 weeks
215057505|NCT04884880|DRUG|The placebo 10g|Placebo 10g，once daily，4 weeks
215057506|NCT00843440|DRUG|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
215057507|NCT02110485|OTHER|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
215057508|NCT01145963|OTHER|Control pasta|control pasta
215057509|NCT01145963|OTHER|Experimental pasta B|experimental pasta
215057510|NCT01145963|OTHER|Experimental pasta C|experimental pasta
215057511|NCT02149355|OTHER|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
214301355|NCT05623748|PROCEDURE|CTCs isolation/purification and cell number expansion|In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
214301356|NCT04940026|DRUG|amcenestrant|Tablet Oral
214301357|NCT04940026|DRUG|[14C]-SAR439859 microtracer|Solution for infusion Intravenous
214301358|NCT04940026|DRUG|[14C]-SAR439859|Powder for oral solution Oral
214478981|NCT05447338|PROCEDURE|Myofascial inductions; Suboccipital induction|The therapist places his hands under the patient's head in such a way that he can palpate the spinous processes of the cervical vertebrae with his fingers. Next, slowly bring your fingers up until they contact the occipital condyles. At this time he should gently move his fingers downward, thus finding the space between the condyles and the spinous process of the axis. Next, flexing the metacarpophalangeal joints to 90°, slowly elevate the skull. The therapist's hands should remain together and the base of the skull should rest on their palms. The therapist should apply pressure with the index, middle and ring fingers of each hand. This pressure should be maintained for a few minutes until a release of the fascia is noted. In the last phase of the technique, the therapist, without releasing the pressure, opens his hands and slowly brings his head back.
214669482|NCT03982667|DIAGNOSTIC_TEST|PCT-guided group|In the PCT-guided group, the study protocol encourages to stop the prescribed antibiotics if PCT concentration decrease by 80% or more of its peak value (or if PCT concentration is ≥0·25 and \<0·5 μg/L), and strongly encourage to stop the prescribed antibiotics when it reaches a value of \< 0·25 μg/L. The attending physician is free to decide whether to continue antibiotic treatment in patients who reach these thresholds. Reasons for non-adherence will be recorded. Antibiotics in the standard-of-care group will be stopped according to local or national guidelines and according to the discretion of attending physicians. Patients will be followed-up until hospital discharge.
214900274|NCT06968286|PROCEDURE|SRP+Injectable platelet rich fibrin|The iPRF will be prepared by the same operator according to the protocol developed by Miron and Choukron in 2017. It involves collecting 10 mL of intravenous blood from the participant using venipuncture of the antecubital vein under sterile conditions. The collected blood is transferred to a plain sterile test tube without anticoagulant and immediately subjected to centrifugation at 70-g force at 700 rpm for 3 minutes. After centrifugation, the blood separates into two parts: the bottom layer consists of a red blood cell compartment, and the top layer is platelet-rich fibrin plasma, which is still in liquid consistency. The top platelet-rich fibrin layer is aspirated into a 2-mL syringe and locally delivered in to the periodontal pocket
214900275|NCT06968286|PROCEDURE|SRP+ciprofloxacine loaded iPRF|"The concentration of the ciprofloxacin drug to be loaded in iPRF will be decided based on the study of Murugan et al., 2024. According to their study, 1 mg/mL of the drug concentration will be found to be biocompatible with maximum efficacy and showed a sustained release of 59% of the loaded drug at the end of the 14-day observation. 1 mg of the drug will be weighed and mixed with 100 μL of deionized water and shaken for 30 seconds to make the drug completely soluble, which will be done just before the blood collection from the participants. Then, 900 μL of the obtained i-PRF will be dispensed in a vial containing a 1-mg/100 μL solution of ciprofloxacin and shaken gently for 10 seconds to obtain a homogenous mix with a final concentration of 1 mg/mL.~This mixture will further immediately loaded in a 1-mL insulin syringe and injected into the periodontal pocket until it filled the pocket"
214900276|NCT05702931|DRUG|Semaglutide 14 MG [Rybelsus]|At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.
214900277|NCT05702931|DRUG|Placebo|Saline
214900278|NCT06546254|DRUG|Lidocaine 1% Injectable Solution|10 cc 1% lidocaine paracervical injection
214900279|NCT06546254|OTHER|Capped needle|Tapping the cervicovaginal junction with a capped needle
214900280|NCT05584735|BIOLOGICAL|Influenza vaccine|Observe effects of flu vaccine on microbiome
214900281|NCT05584735|BIOLOGICAL|COVID-19 vaccine|Observe effects of COVID-19 vaccine on microbiome
214900282|NCT06476990|BEHAVIORAL|Healthy food box|All participants received 12 weekly deliveries of food containing approximately $8 worth of shelf-stable food items purchased from a local food bank (beans, canned vegetables and no-sugar added fruit, shelf-stable dairy products, canned tuna, and whole grains) and $25 of fresh produce (5-7 items including leafy greens, peppers, potatoes, broccoli, carrots, zucchini, cauliflower, celery, cabbage, asparagus, apples, or strawberries). When seasonably available, fresh vegetables and fruit were sourced from local farmers via a local food hub. In addition to food, participants in the Food + CHW group also received 7 weekly virtual sessions with a CHW (four 90-minute ZOOM counseling sessions and three 30 to 60-minute check-in phone calls). CHW sessions included diabetes-appropriate cooking and nutrition education and personalized benefit enrollment and linkage to existing food access resources (for example SNAP, Double up Food Bucks, and Kansas Senior Farmers Market Vouchers).
214900283|NCT04684147|BIOLOGICAL|single dose of CNCT19|Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
214900284|NCT06089408|OTHER|Best Practice|Use a regular blanket
214900285|NCT06089408|OTHER|Supportive Care|Use a weighted blanket
214900286|NCT06089408|OTHER|Survey Administration|Ancillary studies
214900287|NCT04512378|BEHAVIORAL|Behavioural Experiments for Intolerance of Uncertainty|Cognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique
215054218|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - OptiMA|"All children randomized to this arm will be treated with a RUTF, with weekly ration determined according to MUAC, weight and presence of nutritional edema. Ration will be adjusted weekly according to the change in MUAC and weight throughout the outpatient follow-up until the child achieves nutritional recovery.~RUTF dosage will 170 kcal/kg/d for the most severely wasted (MUAC \< 115 mm or edema) and reduced to 125 kcal/kg/d for children with MUAC 115-119mm and 75 kcal/kg/d for children with MUAC 120-124 mm.~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet nutritional recovery criteria, and then a monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition). Referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected)."
214669483|NCT06346275|PROCEDURE|Acupuncture|Acupoints: Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), Taixi (KI3), Zusanli (ST36), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7).
214669484|NCT06023914|OTHER|STRENGTH EVALUATION WITH ELECTROSTIMULATOR|Evaluation of isometric strength using an electrostimulator.
214669485|NCT06023914|OTHER|STRENGTH EVALUATION WITHOUT ELECTROSTIMULATOR|Evaluation of isometric strength not using an electrostimulator.
214669486|NCT05483127|DEVICE|Verofilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
214669487|NCT05483127|DEVICE|Stenfilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
214900288|NCT06620562|DRUG|Naltrexone/Bupropion|Patient randomized in the Neltrexone/Bupropion group will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release 8mg/90mg, up to 2 tabs twice a day (32mg/360mg) adjusted according to tolerance and side-effects to improve long-term use. Duration of therapy will be 24 months.
214900289|NCT06620562|DRUG|Placebo|Patient randomized in the placebo group will be started one month after surgery on a progressive numbers of matched placebo tablets up to 2 tabs twice a day. Duration of therapy will be 24 months.
214900290|NCT06190808|DIAGNOSTIC_TEST|Dexcom G7 Continuous Glucose Monitor|Continuous glucose monitor
214900291|NCT05365451|DRUG|MetFORMIN Oral Solution|liquid
214900292|NCT05365451|DRUG|Cimetidine 400 MG|tablet
214900293|NCT05365451|DRUG|Furosemide Oral Liquid Product|oral solution
214900294|NCT05365451|DRUG|Probenecid 500 MG|tablet
214900295|NCT05873816|DEVICE|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
214900296|NCT05873816|DEVICE|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
214900297|NCT04985435|DRUG|Filgotinib|200 mg tablet once daily or 100 mg once daily
214900298|NCT04985435|DRUG|Anti-Tumor Necrosis Factor Alpha Drug (Product)|Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
214900299|NCT04985435|BEHAVIORAL|50 patients will have a Free Choice between Filgotinib and anti TNF|50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.
214900300|NCT03933904|DRUG|Sirolimus|Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.
214900301|NCT05366010|DEVICE|Oscillation and Lung Expansion (OLE) therapy|Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
214900302|NCT02224157|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
214900303|NCT02224157|DRUG|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
214900304|NCT01639157|DRUG|Buspirone|Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
214900305|NCT01639157|DRUG|Placebo|Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
214900306|NCT00002346|DRUG|Adefovir dipivoxil|
214900307|NCT06582472|PROCEDURE|Ophthalmological examination including imaging assessments|Ophthalmological examination including imaging assessments (SD-OCT, Spectral Domain Optical Coherence Tomography, a procedure to study and quantify possible retinal neurodegeneration and OCT-A, Optical coherence tomography angiography, a procedure to study and quantify possible retinal vascular abnormalities)
214900308|NCT06582472|PROCEDURE|confocal analysis of cornea|Confocal analysis of cornea: a procedure to study and quantify possible corneal nerve degeneration as a marker of involvement of diabetic neuropathy
214900309|NCT06582472|PROCEDURE|Dynamic Vessel Analyzer (DVA)|Dynamic Vessel Analyzer (DVA), a device that measures the response of retinal arteries and veins to a standardized stimulus (flickering light) allowing direct quantification of the inflammatory status of the retinal vasculature
214900310|NCT06582472|PROCEDURE|tear sampling collection|Collect and analyze tear samples to identify biomarkers in tears and at the endothelium of the ocular surface through impression conjunctival cytology and the quantitative/qualitative analysis of pro-inflammatory cytokines
214900311|NCT06582472|PROCEDURE|blood sampling collection|collection and analysis of blood samples to identify diabetic retinopathy biomarkers and early abnormalities of the vascular retinal system.
214900312|NCT04160624|PROCEDURE|transcatheter aortic valve replacement|Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS
214900313|NCT05867615|DRUG|[177Lu]Lu-PSMA I&T|177Lu activity to be administered to single patient (range 5.5-7.4 GBq), every 8 weeks (±2 weeks) will be measured in a dose calibrator, properly calibrated for the radionuclide. The radiopharmaceutical will be slowly infused intravenously over 15-30' in a dedicated room using a dedicated pump system.
215054219|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - ComPAS|All children randomized to this arm will be treated with RUTF, with weekly ration determined according to MUAC and presence of nutritional edema. Children enrolled with MUAC \< 115 mm or edema will receive 1000 kcal/d (2 sachets/day) RUTF until MUAC has surpassed 115 mm and/or edema is resolved for 2 weeks at which time ration will be reduced to 500 kcal/d (1 sachet/day) until MUAC \> or = to 125 mm is achieved for 2 consecutive weeks. Children enrolled with MUAC 115-124 mm will receive 1 sachet/day until MUAC \> or = 125 mm is achieved for 2 consecutive weeks and clinically well. Following nutritional recovery, a study nurse will conduct monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition) with referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected) for the remainder of the 6 month period following inclusion.
215054220|NCT04698070|OTHER|National nutritional Strategy (Niger)|"Different protocols for SAM and MAM comprise the Niger National Nutrition Protocol:~1. SAM: Children with MUAC\<115 or WHZ\<-3 or nutritional edema, will be treated with RUTF, according to a dosage table based on weight at each visit.~2. MAM: Children aged between 6-24 months with MUAC between 115 -124 mm and WHZ\>-3 will be treated with RUSF. Children with the same anthropometry but age 24-59 m will only receive supplementation if they develop criteria for SAM during the 6 month study period. They will be monitored via monthly home visits by a study nurse.~All children will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
214900314|NCT05906628|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214900315|NCT05906628|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
214900316|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
214900317|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
214900318|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
214900319|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
214900320|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
214900321|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
214900322|NCT01191034|DRUG|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|"The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.~This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod."
214900323|NCT06432803|OTHER|PET-Scan analysis|Investigate and determine the clinical value of different cortex/striatal metabolic ratio patterns in each antibody-specific subtype of autoimmune encephalitis
214900324|NCT06513481|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
214900325|NCT06513481|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
214900326|NCT00461942|DRUG|Green Tea Polyphenols (EGCG/ECG)|
214900327|NCT02926066|DRUG|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10\^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10\^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
214900328|NCT00416611|BEHAVIORAL|Implementation of guidelines|
214900329|NCT03487471|DIAGNOSTIC_TEST|Real-time elastography|Breast ultrasound with real-time elastography
214900330|NCT03487471|DIAGNOSTIC_TEST|Shear wave elastography|Breast ultrasound with shear wave elastography
214900331|NCT00399061|DRUG|Systane, Optive, Restasis|Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
214900332|NCT05317312|DRUG|MR-107A-02|MR-107A-02 oral tablet
214900333|NCT05317312|DRUG|Placebo|Placebo oral tablet
214900334|NCT01060072|DRUG|Loteprednol etabonate|Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.
214900335|NCT01060072|DRUG|Vehicle of Loteprednol Etabonate|Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.
214900336|NCT00837148|DRUG|Sorafenib and Dacarbazine|"Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance."
215054221|NCT01983592|OTHER|Homeopathic medicine|Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
215054222|NCT01983592|OTHER|Unmedicated lactose/sucrose globule|
215054223|NCT00006261|BIOLOGICAL|therapeutic allogeneic lymphocytes|Beginning on day 120 after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion (DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence of grade III or IV graft versus host disease or marrow aplasia.
215054224|NCT00006261|DRUG|cyclophosphamide|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
215054225|NCT00006261|DRUG|docetaxel|Docetaxel IV over 1 hour. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
214669488|NCT06104683|DRUG|Placebo|Administered orally
214900337|NCT05374655|OTHER|Preoperative blood glucose control|Patients included in this group, under the guidance of endocrinologists, develop hypoglycemic strategies for patients, follow up and guide patients to take medication, review HbA1c levels after 6 weeks, perform surgical treatment if they meet preoperative HbA1c\<7.5%, continue hypoglycemic therapy if still above standards, and administer drugs according to the corresponding type of heart disease during this period.
214900338|NCT01291355|OTHER|Specific maternal position during the labor|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts."
214900339|NCT03526068|DEVICE|SafeZoneUVC|SafeZoneUVC® uses a Krypton Chloride (Kr-Cl) excimer lamp as its light source. The Kr-Cl excimer lamp emits UVC light having a main wavelength of 222 nm when the Kr-Cl exciplex is deactivated to non-excited state molecule in the lamp. This 222 nm UVC light can inactivate bacteria, while the Kr-Cl excimer lamp also emits UVC light having a wavelength of 230 nm or more. SafeZoneUVC® effectively eliminates UVC light with a wavelength of 230 nm or more by incorporating an appropriate optical filter inside the unit and also utilizing an opaque guide to ensure that light is not dispersed beyond the target area.
214900340|NCT01509339|DRUG|Vancomycin|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
215054226|NCT00006261|DRUG|doxorubicin hydrochloride|Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
215054227|NCT00006261|DRUG|fludarabine phosphate|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of fludarabine IV over 30 minutes on days -8 to -4.
214669489|NCT06104683|DRUG|Pirtobrutinib|Administered orally
214478982|NCT05447338|PROCEDURE|Myofascial inductions; Synchronization of the temporal bones PHASE 1|The therapist rests his two forearms on the table, in such a way that he can contact the external auditory canal with his middle fingers. Place the ring fingers on the mastoid processes and the index fingers on the zygomatic arches. Subsequently, a rotary movement is made on the axis marked by the line that joins the middle fingers. With one of the hands, the movement is in the direction of movement clockwise, and with the other hand, simultaneously, in the opposite direction. By obtaining a symmetry in the movement in opposite directions, the movement is made in the same direction with both hands, first forwards and then backwards. Note how the ring fingers rotate first backwards and then upwards. Symmetry in movements should also be sought
214900341|NCT01494675|OTHER|procalcitonin measurement|"The patients assigned to the procalcitonin group had procalcitonin and C reactive protein levels measured at day 0 (bacteremia), 5 or 7 (if positive blood culture) and then every 48 hours until hosptital discharge, death or until the antibiotics were stopped. A predefined procalcitonin protocol was used together with the clinical outcome, to guide the physician´s decision to discontinue antibiotics.~The procalcitonin protocol encouraged the physician to discontinue the antibiotics when: 1)procalcitonin dropped more than 90% from the baseline peak level or 2)an absolute value below 0,5ng/mL was reached. Cases in which the antibiotic treatment was continued against what the PCT values indicated were categorized as  antibiotic discontinuation overruling"
214900342|NCT04128930|DEVICE|PAP titration at home|Fixed CPAP or APAP titration at home
215054228|NCT00006261|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim (G-CSF) and sargramostim (GM-CSF) mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0.
215054229|NCT01906268|OTHER|Attentional Bias Modification Treatment (ABMT) - Active|"The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
215054230|NCT01906268|OTHER|Attentional Bias Modification Treatment - Placebo|"The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
215054231|NCT00947219|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
215054232|NCT00947219|DEVICE|Control device|Device is used 3 times a week on non-consecutive days
214900343|NCT04271228|DEVICE|DreaMed Advisor Pro|Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
214900344|NCT04982861|DRUG|Cefixime Trihydrate 100 mg/5 mL Dry Syrup|Participants received a single dose of 5 mL of cefixime dry syrup with 240 mL of water
214900345|NCT04982861|DRUG|Suprax 100 MG in 5 mL Oral Suspension|Participants received a single dose of 5 mL of Suprax with 240 mL of water
214900346|NCT00818077|OTHER|Continuous Glucose Monitoring of Carbohydrate Intake|Subjects eat standard breakfast and lunch and keep food records.
215054233|NCT00766116|DRUG|5-Azacitidine|Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.
215054234|NCT00766116|DRUG|Gemtuzumab ozogamicin|Mylotarg given 2 times over 2 weeks
215054235|NCT06332586|BEHAVIORAL|Diversified teaching|Diversified teaching (read and jointly mark the key points of the triage diagnosis teaching manual and read the TMS online course at any time, 1 triage diagnosis seminar/quarter, interactive teaching) for triage diagnosis nurses
214669490|NCT06052462|DRUG|[14C]-LY3556050|Administered orally
214900347|NCT03453775|DEVICE|Ultrasound guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
214900348|NCT03453775|DEVICE|Fluoroscopy guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
214900349|NCT03126773|DRUG|BAY86-4891|Drospirenone 0.25 mg + estradiol hemihydrate 0.5 mg (Angeliq Micro, G03FA17).Dosage form is one tablet a day.
214900350|NCT00380874|DRUG|Pregabalin|150- 600 mg/day (double blind in divided doses)
214900351|NCT00380874|DRUG|Placebo|Placebo
214900352|NCT04159389|OTHER|Mental visualization|Instruction in mental visualization by theoretical lessons and support of practice by audio guide and session of experience sharing.
214900353|NCT03839628|OTHER|Reduced Physical Activity|Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
215054236|NCT03309982|DIETARY_SUPPLEMENT|Plant polyphenol blend|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
215054237|NCT03309982|OTHER|Placebo|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
215054238|NCT00466180|BEHAVIORAL|Nevirapine from twice-a-day to once-a-day|
215054239|NCT03261921|DRUG|Dexamethasone|Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
215054240|NCT03261921|DRUG|Dexmedetomidine|Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
215054241|NCT03261921|DRUG|Bupivacaine|local anesthetic agent
215054242|NCT05809427|DEVICE|Periodontal probing|"Imaging/Scanning and recording : Ultrasonic periodontal probing per operator (10 teeth X 6 sites/teeth = 60 probing sites per operator). In addition, 2 teeth per patient will be probed with the ultrasonic probe a second time (2 teeth x 6 sites per tooth = 12 sites per patient) for intra-operator reproducibility purpose.~Manual probing per operator with the OMS probe (part of the routine of care)"
214301359|NCT06136871|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
215054243|NCT06460870|OTHER|Mojzisova method|The home based regular exercises stretching and strengthning exercises twice daily along with hot pack. Manual therapy was applied in the first half of the menstrual cycle, once a month, for one hour. It includes mobilization of ribs, lumbar spine, and sacroiliac joints as well as coccygeal treatment, and internal rectal work. The patient was received 2 sessions per month for 3 months, for 45 minutes.
214301360|NCT06136871|BEHAVIORAL|Inactive Control Group|An inactive control group will be used to control for maturation and testing effects. Weekly contact will be made via teleconferencing to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce PCS symptoms. The content of each of these meetings will be tracked in intervention notes. Each contact will be recorded for fidelity monitoring to ensure all active ingredients of the CO-OP intervention are avoided.
214301361|NCT05537402|DRUG|Atezolizumab and bevacizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle and Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
214301362|NCT05537402|RADIATION|transarterial chemoembolization (TACE) or transarterial radioembolization (TARE|TACE cycles occur every 8 weeks +/- 7 days OR TARE cycles occur every 12 weeks +/- 7 days
214301363|NCT04478747|PROCEDURE|TVM|Transvaginal mesh operation using BSC mesh (A.M.I., Feldkirch, Austria)
214478983|NCT05447338|PROCEDURE|Myofascial inductions; Horizontal induction of the TMJ.|The therapist places the middle fingers of both hands on the lingual aspect of the lower molar teeth and then gently presses towards the table. This pressure must be maintained for a minimum of 90 to 120 seconds. Afterwards, the therapist, very attentive to the changes in the direction of the fascial restriction, follows the release movement.
214478984|NCT05447338|PROCEDURE|Myofascial inductions; Posterior elongation of the cervical fascia in the supine position|Position of the patient, lying on the stretcher in the supine position. Therapist position: Sitting at the head of the table. Technique: With one of his hands, the therapist supports the patient's head on the occipital area and slowly brings it to flexo-elevation. With the other hand, he contacts the mass of the paravertebral muscles, placing the thumb on one side of the spine and the proximal interphalangeal joint of the index finger in flexion on the other. While one hand holds the head position, the other performs a downward vertical slide. The maneuver is repeated between 3 and 7 times in a slow and progressive manner.
215054244|NCT06460870|OTHER|Stretching exercises|Stretching exercises was performed such as cobra pose, cat/cow pose and baby pose along with hotpack for 2 sessions per month for 45 min for 3 months.
215054245|NCT04063917|DEVICE|ZENS|ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
215054246|NCT02398201|DRUG|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
215054247|NCT05406128|OTHER|preoperative erector spina plane block|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
215054248|NCT05406128|OTHER|intraoperative erector spina plane block|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
215054249|NCT03654274|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
215054250|NCT03654274|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
215054251|NCT01152801|DRUG|Everolimus (RAD001)|
215054252|NCT02752490|DRUG|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
215054253|NCT02752490|DRUG|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
215054254|NCT00539123|BEHAVIORAL|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
215054255|NCT00539123|BEHAVIORAL|abstinence-contingent buprenorphine (ACB)|Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.
215054256|NCT05005273|DRUG|Nivolumab|Specified dose on specified days
215054257|NCT05005273|DRUG|Ipilimumab|Specified dose on specified days
215054258|NCT05005273|DRUG|BMS-986207|Specified dose on specified days
215054259|NCT05005273|OTHER|Placebo|Specified dose on specified days
215054260|NCT06199765|OTHER|Needlestick Injury Prevention|this intervention will be using needlestick injury prevention module which will involve lecture, demonstration, and role play
215054261|NCT06598072|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
215054262|NCT06598072|DRUG|Essential oils mouthwash|Essential oils mouthwash
215054263|NCT06598072|DEVICE|Dental floss|Dental Floss
215054264|NCT05951647|DRUG|Chamomile extract mouthwash|5% chamomile extract mouthwash in a dose of 15 ml twice daily.
215054265|NCT05951647|DRUG|Pomegranate peel extract mouth wash|5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.
215054266|NCT05951647|DRUG|Combination of 5% chamomile extract and pomegranate peel extract mouthwash|Use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.
215054267|NCT05951647|PROCEDURE|Scaling|Patients will be managed by scaling
215054268|NCT05951647|DRUG|Scaling and Chlorohexidine mouthwash|scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.
215054269|NCT05125146|BEHAVIORAL|e-CBTi|See arm/group description
215054270|NCT05125146|DRUG|Trazodone|See arm/group edescription
214301364|NCT04478747|PROCEDURE|Colposacropexy|Colposacropexy using EndoGYNious mesh (A.M.I., Feldkirch, Austria)
214900354|NCT04959721|COMBINATION_PRODUCT|Injection with triamcinolone acetonide, bupivacaine, and normal saline|"Triamcinolone acetonide is a synthetic corticosteroid medication used intra-articularly to treat various joint conditions. Bupivacaine is a medication used to decrease feeling in a specific area. In nerve blocks, it is injected around a nerve that supplies the area, or into the spinal canal's epidural space. Saline is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.~The procedure will be performed with the patient in a prone position under a C-arm fluoroscopy scanner, with the thorax rests on 2 pillows, flexing the neck maximally, and the head turns 60-90° away from the side of injection. The C-arm tube will be angled cephalad, until it was at a tangent to the cervical facet joint space. A 26-gauge, 90 mm spinal needle will be inserted parallel to the C-arm beam. To confirm intra-articular placement of the needle tip, an arthrogram of the cervical facet joint will be performed by injecting 0.3 mL of contrast."
214900355|NCT02912702|DRUG|Pegaspargase|2000U/m2 day5
214900356|NCT02912702|DRUG|doxorubicin hydrochloride liposome injection|25 mg/m2 day 1
215054271|NCT03289754|DEVICE|iPoly XE tibial insert with ConforMIS iTotal KRS|The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
215054272|NCT06613880|DRUG|standard IST combined with Romiplostim N01|Romiplostim N01 is a class of TPO receptor agonists. Its TPO peptide can bind to TPO receptors on megakaryocyte precursors in the bone marrow and activate them, triggering a series of intracellular signalling pathways, including JAK2/STAT5, PI3K/Akt, MEK/ERK, and p38, which ultimately lead to gene transcription and increased megakaryocyte proliferation and differentiation.
215054273|NCT02151786|DRUG|Lansoprazole|Lansoprazole intravenous 30 mg
214900357|NCT02912702|DRUG|etoposide|100 mg/m2 was administered once on the first day of every week
215054274|NCT04814953|OTHER|questionnaires|EQ-5D-5L questionnaire questioning their overall health on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). In addition patients will have to fill in the generic 15D questioning 15 specific dimensions on 5 levels as well as the BaSQoL, which is a disease specific questionnaire for patients with KC. The Time-trade off task is the final question.
214900358|NCT02912702|DRUG|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
215054275|NCT02909088|DRUG|Ecopipam 50mg|
215054276|NCT02909088|DRUG|Ecopipam 100mg|
214301365|NCT04561206|DRUG|Brentuximab Vedotin|Given IV
214301366|NCT04561206|BIOLOGICAL|Nivolumab|Given IV
214301367|NCT04695899|DEVICE|Dental Implant|"See Section Procedures."
214301368|NCT06581406|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
214301369|NCT06581406|BIOLOGICAL|Ipilimumab|Ipilimumab: human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
214301370|NCT06581406|BIOLOGICAL|Nivolumab|Nivolumab: Anti-PD-1 Monoclonal antibody
214301371|NCT02293655|DRUG|OROS-Methylphenidate (MPH)|OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
214478985|NCT05447338|PROCEDURE|Myofascial induction; Angle of the scapula|Position of the patient, supine position, with the arm resting along the trunk. Position of the therapist, standing or sitting at the head of the table. The therapist places one of his hands under the shoulder blade, embracing the lower angle with the fingertips and bringing it slightly cranially. This maneuver frees access to the superior angle of the scapula, which makes it easier for the index and middle fingers of the other hand to contact the insertion of the angle. More sustained pressure is applied to this point, while the hand placed on the scapula moves in the direction of release.
215054277|NCT01607125|DRUG|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
215054278|NCT01607125|DRUG|Placebo|capsules, orally, once daily for 13 to 14 days
215054279|NCT03533660|BEHAVIORAL|Feedback|Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources
215054280|NCT03533660|BEHAVIORAL|Enhanced Usual Care|Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources
214301372|NCT02150954|DRUG|pitocin|
214301373|NCT04902924|BEHAVIORAL|repeated cold water therapy|This information can be found the description of the experimental arm.
214301374|NCT04902924|BEHAVIORAL|repeated warm water therapy|This information can be found the description of the experimental arm.
214301375|NCT04902924|OTHER|control|This information can be found the description of the experimental arm.
214301376|NCT04167917|DRUG|NTX-301|oral hypomethylating agent
214301377|NCT01206647|DRUG|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
214301378|NCT03814746|DRUG|Crizanlizumab (SEG101)|"Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV."
215054281|NCT04544735|BEHAVIORAL|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will provide pelvic health physical therapy interventions including: education about vaginal moisturizers and lubricants, low back and hip assessment and instruction in accommodations (e.g., strategies for accommodating sexual position of choice), instruction in vulvar massage, instruction and facilitation of vaginal dilator use, and pelvic floor muscle training (PFMT) and exercises. Women will be given a set of vaginal dilators. Cognitive behavioral techniques that have been successfully used by physical therapists in prior intervention studies will be integrated into the PT intervention including breathing and relaxation techniques, guided imagery, systematic desensitization, cognitive restructuring techniques and coping thoughts, and problem solving
214301379|NCT03814746|DRUG|Placebo|Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
214301380|NCT04892043|BIOLOGICAL|SQZ-AAC-HPV|Activating antigen carriers (AACs) cell therapy; therapeutic vaccine engineered from red blood cells manufactured with immunogenic epitopes of HPV16
214301381|NCT04892043|DRUG|Ipilimumab|Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
214301382|NCT04892043|DRUG|Nivolumab|Programmed cell death 1 (PD-1) blocking antibody
214301383|NCT03642210|COMBINATION_PRODUCT|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system
214301384|NCT06007586|DRUG|Aprepitant Injection|Two antiemetic groups use placebo,Dexamethasone and Ondansetron, Three antiemetic groups use Aprepitant,Dexamethasone and Ondansetron.
214301385|NCT04084041|DEVICE|Simeox|Airway clearance device
215054282|NCT06183489|DRUG|Elranatamab|Elranatamab will be administered via a subcutaneous injection (SC)
214900359|NCT02912702|DRUG|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
214900360|NCT02912702|DRUG|dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
214301386|NCT04084041|OTHER|CCPT|Conventional chest physiotherapy
214301387|NCT04473937|RADIATION|Radiotherapy|Radiotherapy at pre-determined dose and schedule
214900361|NCT02700217|PROCEDURE|Bupivacaine and Diamorphine|
214301388|NCT05126342|DRUG|Niraparib|Niraparib starting dose of study treatment will be based upon the patient's baseline body weight and baseline platelet count. Patients with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 10\^9/L may start with niraparib 300 mg (3 x 100 mg capsules) daily unless the dose has not already been reduced to 200 mg in a prior treatment line. Patients with a baseline body weight \<77 kg or a baseline platelet count \<150 x 10\^9/L will be administered niraparib 200 mg (2 x 100 mg capsules) daily.
214900362|NCT02700217|PROCEDURE|Remifentanil, Propofol and Cistracurium|
214900363|NCT02700217|PROCEDURE|Bupivacaine and Rectus Sheath injection|
214900364|NCT03699332|DRUG|Indium-111-DOTA-Labetuzumab-IRDye800CW injection|Tracer injection
214900365|NCT03699332|RADIATION|SPECT/CT scan|Abdominal and thoracic SPECT/CT scan.
214900366|NCT03699332|PROCEDURE|CRS extended with dual-modality imaging|cytoreductive surgery will be performed extended with the use of dual-modality imaging.
214900367|NCT03816423|OTHER|video|Participants randomized to the intervention group, will wacth a pre-appointment video, followed by a routine prenatal care visit.
214900368|NCT01707290|DRUG|Ivacaftor|150 mg tablet, oral use, every 12 hours (q12h)
214301389|NCT05126342|DRUG|Dostarlimab|Dostarlimab (TSR-042) is administered 500 mg iv Q3W for the first 12 weeks. For the remainder of the study dostarlimab (TSR-042) is administered 1000 mg iv Q6W.
214301390|NCT05773144|BEHAVIORAL|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
214301391|NCT05773144|BEHAVIORAL|Progressive stretching|Static stretching of eight major muscle groups
214301392|NCT06260709|DRUG|NNC6019-0001|Intravenous NNC6019-0001 every 4 weeks added to the standard of care until Week 140.
214301393|NCT05325632|BIOLOGICAL|HER-2 pulsed DC1|Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.
214301394|NCT05325632|DRUG|Trastuzumab|8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks
214301395|NCT05325632|DRUG|Pertuzumab|840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.
214301396|NCT05325632|DRUG|Paclitaxel|80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18
214301397|NCT05325632|PROCEDURE|Resection surgery|After week 18, participants will undergo standard of care resection surgery.
214301398|NCT05637112|OTHER|None (Observational study)|Not Applicable since Observational Study
214900369|NCT00474084|DEVICE|Intravascular Coronary Stent|
214900370|NCT02588898|DEVICE|Blood collection and electrophysiological tests|Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
214900371|NCT00671112|DRUG|Bortezomib|"Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.~The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line."
214900372|NCT00671112|DRUG|Everolimus|Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
214900373|NCT05715411|OTHER|Placebo with light therapy glasses|Placebo
214900374|NCT05715411|OTHER|light therapy with light therapy glasses|light therapy
214900375|NCT07018180|DEVICE|Use of COVER patchs for continuous glucose monitoring sensor|"The intervention consists of wearing a patch over the continuous glucose monitoring (CGM) sensor typically used by the participant.~The COVER patch is compatible with a wide range of CGM devices on the market, including Freestyle 2 or 3, Dexcom G6/One or G7/One+, and Guardian Sensor 4 or Simplera.~At each sensor change, the participant is required to apply a new COVER PATCH over the CGM sensor. This is done throughout the entire duration of their participation in the study, which lasts for 4 months."
214900376|NCT04306211|DEVICE|SuperNO2VA|SUPERNO2VA is nasal PAP device for oxygen delivery
214900377|NCT06353347|DRUG|HTD1801|HTD1801 1000 mg administered orally BID as four capsules
214900378|NCT06353347|DRUG|Placebo|Matching placebo administered orally BID as four capsules
214900379|NCT03048227|DEVICE|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
214900380|NCT03681249|DRUG|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml twice a day for 24 weeks 150ml twice a day for 24 weeks
214900381|NCT03681249|DRUG|ShenqiDihuang Decoction placebo|traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
215054283|NCT00633178|BEHAVIORAL|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
215054284|NCT00633178|BEHAVIORAL|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
215054285|NCT06630533|OTHER|Baduanjin Exercise Group|Baduanjin exercises (Eight-Part Exercises or Eight-Part Brocades), an important part of Qigong, consist of eight postures (1-holding the hands high with palms up, 2- posing as an archer shooting, 3- holding one arm aloft, 4- looking backwards, 5- swinging the head and lowering the body, 6- moving the hands down the back and legs and touching the feet, 7- thrusting the fists and making the eyes glare, and 8- raising and lowering the heels).
215054286|NCT05570708|DRUG|MDMA, LSD, psilocybin|"* MDMA per os (2 x 100mg) in a group setting~* LSD per os (75 and 150 mcg) in a 1:1 setting~* Psilocybin per os (15 mg and 25 mg) in a group setting~* Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting"
215054287|NCT03586375|OTHER|Intensive Support Team Care|Intensive Support Teams (ISTs) are specialist teams which have been advocated for many years as the right services to help people with intellectual disabilities (ID) and challenging behaviour stay in their local communities. They may be staffed by one or more professions, e.g. psychology, nursing, psychiatry, and usually deliver interventions such as positive behaviour support and accept people with ID who are in a crisis when challenging behaviour emerges or provide support when a person is admitted to a local inpatient facility.
215054288|NCT04666974|BEHAVIORAL|iCBT|Online CBT modules will be completed weekly with content mirroring in-person CBT for their diagnosis. Homework will be submitted weekly through the OPTT platform which will be reviewed by a trained professional who will provide personalized feedback.
215054289|NCT04666974|BEHAVIORAL|In-Person CBT|Participants will be assigned to in-person CBT that will mirror the content and homework covered in the iCBT group. It will be delivered by professionals and attended weekly.
215054290|NCT06692894|OTHER|Observational|Blood will be collected from one cohort to identify potential blood biomarkers.
215054291|NCT00996658|DRUG|Placebo|Placebo matching linagliptin tablets once daily
215054292|NCT00996658|DRUG|Linagliptin|Linagliptin tablets once daily
215054293|NCT06704100|DRUG|Fosamprenavir Calcium & Sodium Alginate|1400 mg FOS-SA BID: 15 ml oral solution containing 1400 mg fosamprenavir calcium and 24.5 mg sodium alginate administered BID
215054294|NCT06704100|OTHER|Placebo|15 ml oral solution containing 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate
214900382|NCT05593809|RADIATION|SPECT with pentavalent 99mTc DMSA|"A dose of 555-740 MBq 99mTc (V) DMSA is injected into a peripheral vein. Delayed brain SPECT/CT images will be obtained at 2-3 h after injection. Imaging will be performed on a hybrid dual head SPECT/CT machine (Symbia T, Siemens, Erlangen, Germany) fitted with a low energy high-resolution collimator, using 15% energy window set at 140 keV.~SPECT images are acquired in a noncircular 360° arc for a total of 64 frames, 25-s/frame, using a 128 × 128 matrix size. Following SPECT acquisition, low-dose CT is acquired for anatomical localization and attenuation correction. The used CT parameters are: tube voltage 130 kV, tube current 80 mA, and slice thickness 1 mm. Images will be reconstructed using manufacturer's iterative protocol (four iterations, four subsets, and Gaussian filter 8 mm). The reconstructed images will be reviewed on a viewing workstation running OsiriX MD version 6.5.2 (Pixmeo, Bernex, Switzerland)."
214900383|NCT05107947|OTHER|Biocentric light|Light that changes in intensity and spectral distribution during the day to mimick daylight. High in intensity and high circadian stimulus during daytime and low intensity and low circadian stimulus during late afternoon and night.
214900384|NCT03062709|BEHAVIORAL|Breathe Easy Coalition written materials|written materials about secondhand and thirdhand environmental smoke exposure in children
214900385|NCT03062709|BEHAVIORAL|Maine Tobacco Helpline|referral to tobacco cessation counselor, helpline calls adult referred to provide counseling over the phone.
214900386|NCT03062709|DIAGNOSTIC_TEST|Urine cotinine testing|the child's urine is tested for cotinine, which is produced when the body absorbs nicotine. These results are communicated to the child's parent/guardian.
215054295|NCT06716944|DEVICE|Acupuncture|self-acupuncture
215054296|NCT06719401|OTHER|Foot Chest Compression|Foot chest compression is an alternative cardiopulmonary resuscitation (CPR) technique where the rescuer uses one foot to perform compressions on the chest instead of their hands. The heel of the foot is placed on the lower half of the sternum, with the foot parallel to the sternum to ensure effective pressure. The opposite foot provides stability by being positioned beside the patient.
214900387|NCT00199394|DRUG|Istradefylline (KW-6002)|
215054297|NCT06719401|OTHER|Hand Chest Compression|Hand chest compression is the conventional method of performing chest compressions during CPR. It involves the use of both hands, with one hand placed over the other on the lower half of the sternum. The rescuer positions their body directly over the patient, using the weight of their upper body to deliver compressions of 50-60 mm depth at a rate of 100-120 compressions per minute. Proper technique includes full chest recoil between compressions, maintaining a straight arm posture, and avoiding pressure on the xiphoid process to minimize injury risks. This method adheres to the 2020 AHA guidelines for high-quality CPR.
215054298|NCT06718023|BEHAVIORAL|Nordic walking|NW training sessions are conducted by a certified NW instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. Participants used professional Nordic Pole.
215054299|NCT06718023|BEHAVIORAL|Strength training|Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
215054300|NCT06718023|BEHAVIORAL|Bungy Pump Exercises|Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, , a total of 12 weeks. Participants used professional Bungy Pump Pole.
215054301|NCT06717529|OTHER|Sodium hyaluronate (hyaluronic acid)|The patient will receive one 3mL Sodium Hyaluronate injection containing 75 mg of active substance in one knee joint.
215054302|NCT06717529|DRUG|Methylprednisolone Acetate Injection|The patient will receive 2mL of methylprednisolone acetate solution containing 80 mg of the medicine in other knee joint.
214900388|NCT05655130|DRUG|Dexamethasone|Intraoperative 10 mg IV Dose
214900389|NCT05655130|DRUG|Methylprednisolone|"The oral methylprednisolone taper course will begin on the day of surgery and will taper as noted below:~Day 1: 24 mg orally (8 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 2: 20 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 3: 16 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 4 mg at bedtime) Day 4: 12 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg at bedtime) Day 5: 8 mg orally (4 mg before breakfast; 4 mg at bedtime) Day 6: 4 mg orally (4 mg before breakfast)"
214900390|NCT05655130|OTHER|Standard of Care|standard of care surgery
214900391|NCT01597310|DRUG|Warfarin|single doses at specified time periods
214900392|NCT01597310|DRUG|Dexpramipexole|multiple doses
214900393|NCT03971786|BEHAVIORAL|Quality of life|Assessment of quality of life through measuring scales
214900394|NCT00981487|DRUG|Ondansetron|24 mg one time
214900395|NCT00981487|DRUG|Ondansetron|24 mg, on time in the am
214900396|NCT01007305|PROCEDURE|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy
214900397|NCT01007305|PROCEDURE|Ovarian conservation|Both ovaries and fallopian tubes not removed at the time of hysterectomy
215054303|NCT06717620|BEHAVIORAL|Body composition before and after exams|Measurement of body composition, eating habits, physical exercise in the same group of students before and after the exams
215054304|NCT06718829|OTHER|Core Stability Exercises|Patients will perform core stability exercises three times weekly for eight weeks. The exercises include abdominal hollowing, bridge, right-angle leg lifts with thigh press, seated twist, knee-to-chest with elbow flexion, prone abdominal hollowing, prone arm and leg lift, quadruped abdominal hollowing, quadruped arm or arm-leg lifts, and various plank positions: forearm plank, side plank, forearm plank with hip raise, and forearm plank with straight legs.
214301399|NCT05665530|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion once weekly.
214900398|NCT05756582|DIAGNOSTIC_TEST|Prevalence of Latent Tuberculosis Infection|The prevalence of Latent Tuberculosis Infection \[LTBI\] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed \[higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)\], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.
214900399|NCT04395482|OTHER|Lung CT scan analysis in COVID-19 patients|This research project will evaluate the morphological characteristics of the lung by CT scan analysis in COVID-19 patients which will be identified as specific patterns using artificial intelligence technology and their impact on outcome.
214900400|NCT01364376|DRUG|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|"FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy"
214900401|NCT03806673|DRUG|marcaine|epidural block
214900402|NCT01926431|OTHER|Exercise|
214900403|NCT01926431|OTHER|Rest|
214900404|NCT04800640|OTHER|Experimental: Electroanalgesia|The sample will consist of 66 individuals, of both men and women, where they will be randomly included in two groups: Intervention group composed of 33 patients who will effectively receive the treatment through electroanalgesia via TENS;
214900405|NCT03334929|DEVICE|Virtual Reality headset|The participants in this group would wear Virtual Reality headset called Oculus Gear VR during their trigger point injections.
214900406|NCT01565889|DRUG|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
214900407|NCT01565889|DRUG|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
214900408|NCT01565889|DRUG|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
214900409|NCT01565889|DRUG|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
214900410|NCT01565889|DRUG|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
214900411|NCT01565889|DRUG|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
215054305|NCT06718829|OTHER|Sensorimotor Training Exercises|Patients will perform sensorimotor training exercises three times weekly for eight weeks, progressing through three phases: static (weeks 1-2), dynamic (weeks 3-4), and functional (weeks 5-8). Exercises, repeated 3-5 times per session with rest intervals, advance from simple to complex as patients master each level. Static exercises include standing on firm/soft surfaces and single-leg balances. Dynamic exercises add forward lunges and T-band kicks. Functional training incorporates walking on various surfaces, toe and heel skipping, squats, balance drills on wobble boards, and multidirectional rolling movements with visual and single-leg variations. This progression enhances coordination, balance, and functional stability.
215054306|NCT06718829|OTHER|Traditional physical therapy program|All patients will undergo a traditional physical therapy program consisting of stretching exercises, strengthening exercises, and scar management techniques, three times weekly for eight weeks.
214301400|NCT05665530|DRUG|Zanubrutinib|Zanubrutinib will be provided in capsules for oral administration once or twice daily.
214301401|NCT05665530|DRUG|Venetoclax|Venetoclax will be provided in tablet for oral administration once daily
214301402|NCT06150976|BEHAVIORAL|MAAT-YS|MAAT is an evidence-based cognitive-behavioral therapy composed of eight 45-minute telehealth appointments and an accompanying workbook.
214301403|NCT05144724|PROCEDURE|Volume targeted ventilation|Positive pressure ventilation will be provided using a set tidal volume
214301404|NCT05144724|PROCEDURE|Pressure targeted ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
214900412|NCT01565889|DRUG|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
214900413|NCT01565889|DRUG|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
214900414|NCT01565889|DRUG|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
214900415|NCT01565889|DRUG|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
214900416|NCT01565889|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214900417|NCT03564457|OTHER|No interventions will take place (observational)|No interventions will take place (observational)
214900418|NCT01390025|BIOLOGICAL|TCN-032|TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.
214900419|NCT01390025|BIOLOGICAL|Placebo|Placebo - 0.9% Sodium Chloride for Injection, USP
214900420|NCT05190939|DIAGNOSTIC_TEST|water as bladder distending media|water will be used for bladder dissension during cystoscopy
214900421|NCT05190939|DIAGNOSTIC_TEST|intravenous dye|intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
214900422|NCT05190939|DIAGNOSTIC_TEST|No intervention|Saline only, no dye
215054307|NCT06719310|DRUG|ACC017+FTC/TAF|ACC017+FTC/TAF
215054308|NCT06719310|DRUG|Placebo|Placebo
215054309|NCT06719388|BEHAVIORAL|combination of exercise therapy and a jaw-mobilizing device|Participants in the experimental group will receive a combination of exercise therapy and a jaw-mobilizing device. The intervention includes structured exercise therapy sessions and the use of the jaw-mobilizing device for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.
215054310|NCT06719388|BEHAVIORAL|exercise therapy only|Participants in the control group will receive exercise therapy only. This intervention involves the same structured exercise therapy sessions as the experimental group for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.
215054311|NCT06717568|DIAGNOSTIC_TEST|no intervention|This is a diagnostic test with no intervention.
215054312|NCT06718842|BEHAVIORAL|walking free online supervised program|this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)
214900423|NCT02737774|DRUG|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
214900424|NCT02737774|DRUG|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
214900425|NCT00263822|DRUG|erlotinib hydrochloride|
214900426|NCT04190992|OTHER|E-based & personalized breast reconstruction surgery decision aid|This decision aid contains information regarding surgical options, including breast reconstruction and mastectomy, such as the advantages and disadvantages, the complication probabilities of each option, a value clarification exercise for the patient's self-evaluation, and a summary of the participant's decision-making process.
214900427|NCT04190992|OTHER|Usual care|A pamphlet introduce the introduction of types of surgery
214900428|NCT05123430|PROCEDURE|Monitoring of the pressure of the middle left atrium|During the MitraClip surgery, additional catheter is installed in order to monitoring the ppressure of the middle left atrium
214900429|NCT03457181|OTHER|music|effect of music on anxiety scores
214900430|NCT03457181|OTHER|operating room noise|effect of operating room noise on anxiety scores
214900431|NCT01508884|BIOLOGICAL|influenza vaccine|single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
214900432|NCT01508884|DRUG|Imiquimod|pretreatment with topical imiquimod cream to the injection site before vaccination
214900433|NCT01508884|BIOLOGICAL|influenza vaccine|single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
214900434|NCT01508884|DRUG|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
214900435|NCT01508884|BIOLOGICAL|influenza vaccine|single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
214900436|NCT01508884|DRUG|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
214900437|NCT03793608|DRUG|Dupilumab|Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)
214900438|NCT00285064|PROCEDURE|CT|
214900439|NCT02060305|DRUG|Bevacizumab intra-articular injection|Bevacizumab, 20\~40mg, intra-articular injection every 28 days for 4 times
214900440|NCT04877847|DEVICE|Low-frequency therapeutic ultrasound (LOTUS)|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on per normal operating instructions.
214900441|NCT04877847|DEVICE|LOTUS System with Ultrasound Disabled|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on and set to Control Setting.
215054313|NCT06719193|COMBINATION_PRODUCT|Enhanced community-wide TB intervention|"Interventions in the intervention arms consist of the following key components:~1. an optimized national recommended set of interventions; such as the implementation of all types of contact investigation, targeted TB screening and diagnosis at key affected population, and optimized HIV screening and TPT for PLHIV;~2. intensive, active, and community-based HH screening and diagnosis of TB using combined TB screening (clinical and X-ray) and X-pert MTB/RIF, as indicated;~3. community-based enhanced TPT; and~4. community-based awareness creation and health education using the community social associations."
214900442|NCT01326845|DRUG|Deferasirox|
214900443|NCT04166201|PROCEDURE|double mesh hernioplasty with modified chevrel's technique|hernioplasty done by modification of the chevrel's technique , no dissection further than 1 cm of the midline laterally, the medial flaps of the anterior rectus sheath is dissected of the anterior surface of the rectus abdominis muscle and sutured together reforming the posterior rectus sheath , one polypropylene mesh was fixed over the posterior rectus sheath and the other was tailored to raw area of the rectis abdominis muscle and sutured to the lateral free edges of the anterior rectus sheath
214900444|NCT04400162|BEHAVIORAL|Usability of the CCT|Evaluation of the usability of the provided training.
214900445|NCT04400162|BEHAVIORAL|Changes in regards to the depressive disorder|Evaluation of depressive symptoms and whether they change in regards to the provided training.
214900446|NCT00051948|DRUG|TLK286|
214900447|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
214900448|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
214900449|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
214900450|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
214900451|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
214900452|NCT00982657|DRUG|Sunitinib|50 mg sunitinib daily (4 out of 6 weeks)
214900453|NCT02000791|OTHER|Comparison of fibreoptic view|
215054314|NCT06719193|COMBINATION_PRODUCT|Routine TB program activities|In the control arm, the standard of care will continue per the national guideline.
215054315|NCT06719297|OTHER|Personalized cognitive-sensorimotor VR/MR training|Thinking task integrated walking and balance training program
215054316|NCT06719297|OTHER|Standard of Care|Standard walking and balance training
215054317|NCT06715176|OTHER|Clinical periodontal measurements at baseline (T0)|Full-mouth clinical periodontal measurements, including PD, CAL, GI, and PI were recorded at 6 sites per tooth, except the third molars, at baseline (T0). A manual periodontal probe was used for PD (millimeters) and CAL (millimeters) measurements; the cemento-enamel junction was used as a reference point for the measurement of CAL.
214900454|NCT04558073|BEHAVIORAL|Body Project (BP)|"The BP intervention offers discussions and exercises to make participants realize the cost of pursuing social ideals valuing thinness. This produces cognitive dissonance, a cognitive discomfort due to a contradiction between speech and beliefs, which motivates to modify one's beliefs. The curriculum includes discussions on techniques of the advertising industry and the unique ideal of beauty promoted worldwide, as well as on the costs of pursuing the thin-ideal. Participants are also challenged to try behaviours they avoid because their appearance bother them. Societal activism actions are also discussed."
214900455|NCT04558073|BEHAVIORAL|Healthy Weight Program (HW)|The HW intervention allows participants to make personalized changes in their diet and physical activity each week gradually, to aim for a health-ideal rather than a thin-ideal. The intervention is based on small changes, based on behavioural change techniques. Advice is given on what types of changes introduce to promote health, and how to implement changes sustainably. Difficulties are discussed in the group with a problem-solving approach. The last session introduces a long-term view of lifestyle change.
214900456|NCT00748592|DRUG|Placebo|Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
214900457|NCT00748592|DRUG|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
214301405|NCT03043625|OTHER|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
214301406|NCT03043625|OTHER|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
214301407|NCT05566990|BIOLOGICAL|LIV-GAMMA SN Inj.10%|LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.
214301408|NCT04204135|PROCEDURE|LLIF or ALIF procedures|LLIF or ALIF procedures
214301409|NCT04916470|DRUG|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.
214301410|NCT04916470|DRUG|Placebo (Semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
214301411|NCT06960967|OTHER|Chestnut meal|Participants will receive an isocaloric baked meal with chestnut flour.
214301412|NCT06960967|OTHER|Control meal|Participants will receive an isocaloric baked meal without chestnut flour.
214900458|NCT00748592|DRUG|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
214900459|NCT00748592|DRUG|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
214900460|NCT00475267|DEVICE|Trifecta aortic heart valve|Intended as a replacement for a diseased, damaged, or malfunctioning aortic heart valve.
214900461|NCT01615367|OTHER|Nutrition, Exercise, and Wellness (NEW) psychotherapy|NEW Tx is a flexible modular treatment such that modules are selected based on the needs of the individual to increase its generalizability across patients, settings, and providers as well as its acceptability to patients.
214900462|NCT01615367|DRUG|Typically consists of at least one FDA-approved mood stabilizer|Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
214900463|NCT04748484|DEVICE|KCC Active or inactive|Depending of the randomization, the KCC will be active or inactive, and will provide heat when active, but the patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
214900464|NCT04105673|OTHER|Clinical examination and survey|Children will be seen during an one consultation. A clinical examination and survey are realized.
214900465|NCT03511027|DEVICE|SME + Karie Device|For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.
214900466|NCT03511027|OTHER|SME only|At discharge, participants will be provided with self-medication education.
214900467|NCT04015973|DIETARY_SUPPLEMENT|High energy diet|An overfeeding regime of 135% required energy intake per day, set from baseline energy requirements consisting of high (saturated) fat snacks, added to the usual diet, supervised by a dietitian.
214900468|NCT01317628|BEHAVIORAL|Tobacco smoke reduction trial intervention program|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
214900469|NCT00752128|DEVICE|Endeavor Resolute Zotarolimus-Eluting Coronary Stent System|Stent implantation
215054318|NCT06715176|OTHER|Saliva collection at baseline (T0)|Unstimulated whole saliva was collected from all participants at baseline (T0). The participants were instructed to refrain from mechanical or chemical oral hygiene practices, eating, drinking, and chewing gum for 2 hours prior to sample collection. Every participant rinsed the mouth with tap water for 2 minutes. Ten minutes after rinsing, they were told to allow the accumulation of the saliva in their mouths and then to drain passively the saliva pool from the lower lip into a steril container for 5 minutes.
215054319|NCT06715176|OTHER|Scaling and root planing|Periodontitis patients (grade B and C) underwent a program of non-surgical periodontal therapy consisting of conventional quadrant-based scaling and root planing using ultrasonic instruments and manual periodontal curette over four visits at 1-week intervals. All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Patients who did not respond to treatment at baseline (T0) received a further round of scaling and root planing at three (T3) months post-therapy in order to eliminate residual pockets.
214900470|NCT06579209|DIETARY_SUPPLEMENT|Nicotinamide adenine dinucleotide|Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo
215054320|NCT06715176|OTHER|Clinical periodontal measurements at T1, T3, and T6.|Full-mouth clinical periodontal measurements were performed for all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.
215054321|NCT06715176|OTHER|Saliva collection at T1, T3, and T6.|Unstimulated whole saliva were collected from all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.
215054322|NCT06714695|DRUG|Chitosan|chitosan mouthwash
215054323|NCT06719206|BEHAVIORAL|Digital self-management program|The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention.
215054324|NCT06714903|OTHER|treatment option-sintilimab plus fruquintinib|sintilimab plus fruquintinib
215054325|NCT06714903|OTHER|treatment option-fruquintinib alone|fruquintinib alone
215054326|NCT06714994|DEVICE|free spectacles|Children will receive free spectacles
215054327|NCT06717204|DRUG|Vericiguat Oral Tablet [Verquvo]|Vericiguat in addition to conventional treatment
214900471|NCT02286713|BEHAVIORAL|Patient Decision Aid|Participants will receive study materials including a video to watch about lung cancer screening
214900472|NCT02286713|BEHAVIORAL|Standard Educational Information|Participants will receive study materials including a booklet to read about lung cancer screening.
215054328|NCT06717204|DRUG|Prescription Drugs|Conventional treatment only
215054329|NCT06716476|DRUG|Vitamin D|Supplemental with Vitamin D 4000 IU
214900473|NCT02286713|BEHAVIORAL|Follow-Up Assessments: Questionnaires|Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
214900474|NCT04787471|COMBINATION_PRODUCT|30 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
214900475|NCT04787471|COMBINATION_PRODUCT|10 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
214900476|NCT07079930|DRUG|Psilocybin and D-Serine|"A single administration of the drug, with dosage divided as follows:~Cohort 1: 15 mg of Psilocybin and 5 gr of D-Serine Cohort 2: 25 mg of Psilocybin and 7 gr of D-Serine"
214301413|NCT06838273|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214301414|NCT06838273|DRUG|Osimertinib|Oral administration, 80mg daily for a cycle of 3 weeks.
214301415|NCT06838273|DRUG|Osimertinib|Oral administration, 80mg daily for a cycle of 3 weeks.
214301416|NCT06961006|BIOLOGICAL|V940|IM injection
215054330|NCT06715189|DIAGNOSTIC_TEST|serum Adiponectine and Resistin|corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
215054331|NCT06715189|DIAGNOSTIC_TEST|fibroscan|hepatic fibrosis detection in type 2 diabetes mellutis
215054332|NCT06716554|DIETARY_SUPPLEMENT|Shatavari extract|Shatavari is scientifically known as Asparagus racemosus. One capsule containing Shatavari 300mg should be taken once daily.
215054333|NCT06716554|DIETARY_SUPPLEMENT|Shatavari + Ashwagandha extract|Shatavari is scientifically known as Asparagus racemosus along with Ashwagandha root extract scientifically known as Withania somnifera. One capsule containing Shatavari 300mg + Ashwagandha root extract 250mg should be taken once daily.
215054334|NCT06716554|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
215054335|NCT06717737|BEHAVIORAL|Control group： Maintaining old exercise habits|The control group will maintain their original daily habits without any intervention behaviors for them
215054336|NCT06717737|BEHAVIORAL|Intervention group：Conducted a 6-month team training intervention|"Spanning six months, the program incorporated aerobic training, resistance training, and functional exercises essential for rescue operations. Each training session was led by certified professionals who emphasized adherence to safety protocols and provided real-time feedback.~Central to the training process was the significance of teamwork and mutual support, with sessions conducted in small groups focused on shared objectives. This framework fostered a collaborative environment that promoted peer support and motivated participants to actively engage in their fitness regimen. The group setting enabled firefighters to encourage one another and share individual progress, thereby enhancing their sense of responsibility and belonging."
215054337|NCT06717724|DRUG|Periarticular Procaine Injection (PAPI)|Participants will receive periarticular 5 ml procaine injections targeting painful joints for 10 consecutive days alternating between knee- and/or hip joints
214669491|NCT05299710|PROCEDURE|Laparoscopic surgery|Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
214900477|NCT07079930|DIAGNOSTIC_TEST|Physical Examination|The physical examination will include diagnosis and documentation of any significant clinical abnormalities or diseases. It will be performed during the baseline rating visit (preparation phase).
214900478|NCT07079930|DIAGNOSTIC_TEST|Vital signs|"Vital sign measurements (blood pressure, pulse, and oxygen saturation) will be taken at screening, preparation, baseline rating, administration day, day 2, day 28, and day 84.~Vital signs will be assessed at the following time points on the administration day and on day 2: pre-administration, and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours post-administration."
215054338|NCT06717724|OTHER|Kinesiotherapy|Kinesiotherapy
215054339|NCT06715202|PROCEDURE|Patient Education Booklet|Before the surgery, a personal information form and the SF-36 Quality of Life Scale will be filled out. The educational content regarding the problems that these patients may encounter with the DJ stent after the surgery until they are discharged will be explained in sections and the patients' questions will be answered. When the patient comes to the hospital for DJ stent removal 4 weeks after discharge, the Ureteral Stent Symptom 1st Questionnaire and the SF-36 Quality of Life Scale will be filled out while the DJ stent is in place. The Ureteral Stent Symptom 2nd Questionnaire and the SF-36 Quality of Life Scale will be applied 4 weeks after the stent is removed. The education booklet will be prepared by the researchers in accordance with the recommendations of the European Association of Urology and the relevant literature.
215054340|NCT06717633|DEVICE|extracorporeal shock wave therapy|The ESWT will be administered using an ESWT device (Modus ESWT Compact Model-Portable) once weekly over three consecutive weeks, resulting in a total of three sessions. A radial shockwave mode was chosen for the therapy. During each session, participants will receive 3000 pulses at an 12-Hz frequency and pneumatic pressure of 2.5 bars
215054341|NCT06717633|DEVICE|low-level laser therapy|The MLS (Multiwave Locked System) laser is a specific type of low-level laser therapy (LLLT) that combines two different wavelengths of light-typically 808 nm (near-infrared) and 905 nm (mid-infrared)-to produce therapeutic effects. These wavelengths are delivered simultaneously in a synchronized manner, which is intended to enhance the overall effectiveness of the treatment. LLLT will be conducted with the laser device (MLS Laser M6 Robotic Multiwave Lock System, Asalaser, Italy) with the use of protective goggles, and the treatment parameters were set as follows: 100% power, 3 Joules per treatment spot with 904 nm wavelength, and a treatment area of 20 cm². The LLLT will be applied to five points on the anterior part of the joint space, with each point treated for 3 minutes, totaling 15 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.
215054342|NCT06717633|DEVICE|pulsed electromagnetic field therapy|For PEMF, the applicator of the device (Easy QS Magnetotherapy Portable Magnetotherapy Medical Device, Asalaser, Italy) will be positioned to target the medial and lateral aspects of the knee. The treatment parameters were defined as follows: rectangular field shape, 30 Hz frequency, 10 mT intensity, and a duration of 20 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.
214301417|NCT06961006|BIOLOGICAL|Pembrolizumab|IV infusion
214301418|NCT06961006|OTHER|Placebo|IM injection
214301419|NCT06838208|DRUG|Tislelizumab, Carboplatin /Cisplatin, Etoposide|Induction therapy stage LDRT: lung lesions, 15Gy/5f; Maintenance therapy phase SBRT: The main residual lesions evaluated by the investigators, 30Gy/5f；
214301420|NCT04780763|OTHER|Milk product fermented by lactic bacteria or not fermented|2 bottles of 100g consumed daily during 28 days
214900479|NCT07079930|DIAGNOSTIC_TEST|ECG test|A 12-lead ECG will be performed to rule out underlying cardiac abnormalities. An ECG will be conducted for each patient during the screening and Day 2 visits.
214301421|NCT01319903|BIOLOGICAL|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
214301422|NCT01463644|DRUG|Mepolizumab|This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.
214301423|NCT01463644|DRUG|placebo|The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
214900480|NCT07079930|DIAGNOSTIC_TEST|Comprehensive Blood Panel|"A comprehensive blood panel will be performed to assess kidney and liver function, electrolyte balance, and glucose levels.~It will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84."
214900481|NCT07079930|DIAGNOSTIC_TEST|Complete Blood Count|"Complete Blood Count will be performed to check for hematological abnormalities.~It will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84."
214900482|NCT07079930|DIAGNOSTIC_TEST|Urinalysis|Urinalysis will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84.
214900483|NCT07079930|DIAGNOSTIC_TEST|Urine Toxicology Screen|Urine Toxicology Screen will be performed to rule out illicit drug use. It will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84.
215054343|NCT06719115|DIETARY_SUPPLEMENT|UClear|Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).
215054344|NCT06719115|OTHER|Placebo|Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).
215054345|NCT06718660|BEHAVIORAL|Tailored Educational Nursing program|The intervention is a structured educational program designed to enhance nursing competence in biomedical waste management at El-Minia University Hospital. It was developed based on evidence-based guidelines, national and international standards, and a detailed assessment of baseline knowledge and practices among the participating nurses.
215054346|NCT06719154|DEVICE|Profhilo Structura|2 injections (30 days apart) of investigated medical device into superficial fat compartments of zygomatic arch and preauricular area
215054347|NCT06719154|OTHER|Sham (No Treatment)|Sham (No Treatment)
215054348|NCT06715826|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-NOTA-T4 injection.
215054349|NCT06715826|DRUG|[18F]F-RESCA-T4|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-T4 injection.
215054350|NCT06715826|DRUG|[68Ga]Ga-DOTA-H2D3|Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-DOTA-H2D3. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-DOTA-H2D3 injection.
214669492|NCT06035523|DEVICE|Endoform™ Antibacterial|Application of Endoform™ Antibacterial
214900484|NCT07079930|DIAGNOSTIC_TEST|A pregnancy Urine test|A urine pregnancy test will be performed for women of childbearing potential only. It will be conducted during the screening and baseline rating visits. If the urine test is positive, a serum β-hCG test will be performed for confirmation.
214900485|NCT07079930|DIAGNOSTIC_TEST|Electroencephalogram|EEG will be performed during the baseline rating scale and Day 7 visits to evaluate brain activity
214900486|NCT07079930|DIAGNOSTIC_TEST|Plasma Amino Acid Levels|The following blood test parameters - D-Serine, L-Serine, and Glycine - will be assessed during the Screening and Day 28 visits.
214900487|NCT07079930|DIAGNOSTIC_TEST|Plasma Inflammation Markers|The following blood test parameters - Tumor Necrosis Factor Alpha (TNF-α), Interleukin-6 (IL-6), and C-Reactive Protein (CRP) - will be assessed during the Screening and Day 28 visits.
214900488|NCT07079930|DIAGNOSTIC_TEST|Plasma Brain-Derived Neurotrophic Facto|Plasma BDNF (Brain-Derived Neurotrophic Factor) levels will be measured during the screening and Day 28 visits.
214900489|NCT07079930|OTHER|Mini International Neuropsychiatric Interview|The Mini International Neuropsychiatric Interview (MINI) will be administered during the screening visit to rule out any current or past major psychiatric disorders.
215054351|NCT06715826|DRUG|[18F]F-RESCA-RB14|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.
215054352|NCT06715449|DRUG|Empagliflozin 10 MG|Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day in addition to their usual stroke care.
215054353|NCT06715215|DIAGNOSTIC_TEST|Acute phase proteins|Assessment of acute phase proteins levels in patients diagnosed with immune thrombocytopenia
215054354|NCT06718985|OTHER|No intervention|No intervention
215054355|NCT06718400|PROCEDURE|Sentinel Skin Flap|Willing participants who will be receiving an intestinal transplantation will receive a sentinel skin flap on their forearm from the same donor
215054356|NCT06715293|DEVICE|Hemopill|Hemopill will be swallowed to detect the presence of active bleeding in the upper GI tract
215054357|NCT06715293|PROCEDURE|OGD|OGD will be performed to compare the results of the hemopill
215054358|NCT06718153|DIAGNOSTIC_TEST|Immunohistochemistry and in situ hybridisation analysis|immunohistochemistry and in situ hybridisation analysis for several markers, including p53, beta-Catenin and albumin, but also markers considered diagnostic for HCC such as Glutamin Synthetase, Glypican-3 and HSP70, to identify a more rational diagnostic-prognostic algorithm for primary liver lesions.
215054359|NCT04584398|DEVICE|Respiratory muscle training with steam inhalation|
214669493|NCT06035523|DEVICE|Endoform™ Natural|Application of Endoform™ Natural
215054360|NCT06716398|OTHER|Test product|Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.
215054361|NCT06716398|OTHER|Comparator product|Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.
214900490|NCT07079930|OTHER|Family Psychiatric History Assessment|The Family Psychiatric History Assessment (FPHA) will be administered during the screening visit to help rule out any current or past major psychiatric disorders.
215054362|NCT00790049|DRUG|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
215054363|NCT00790049|DRUG|Placebo; oral|matching placebo
215054364|NCT06715332|DEVICE|Colorectal ESD with SpydrBlade Flex|"The allocated intervention would be performed under sedation or monitored anaesthesia by experienced endoscopists with at least 50 case experience of colon ESD.~Colon ESD procedure would be performed as per described in the literature. After submucosal injection of solution to create a cushion, mucosal incision and submucosal dissection would be performed with the SydrBlade Flex. Submucosal plane dissection will be performed using the SpydrBlade Flex (BRF, cutting frequency 400kHz, power setting 35W). The exact resection strategy would be according to the endoscopists' preference, including different adjunctive techniques such as countertraction, tunnelling or pocket creation method. Upon completion of ESD, the resultant mucosal defect would be examined for any perforation or bleeding."
214301424|NCT05931302|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET scan|"68Ga-FAPI-46 is a radiotracer for the detection of Fibroblast Activation Protein (FAP) in cancer patients.~68Ga-FAPI-46 will be administered intravenously at a dose of 2MBq/kg. Patients will be scanned 60 minutes after administration of 68Ga-FAPI-46."
214478986|NCT05447338|PROCEDURE|Myofascial induction sternocleidomastoid muscles|Objective, release the myofascial restrictions of the fascia of the SCM muscle. Position of the patient, supine position with the head near the upper edge of the stretcher. Therapist position. sitting at the head of the stretcher. Technique: The therapist, with one hand placed on the occipital region, gently rotates the patient's head. The other hand places it on the mass of the SCM muscle with the thumb at the point of insertion on the mastoid process. While one hand applies the rotational movement and a slight extension of the head, the other performs a transverse slide over the zone of restriction in the SCM muscle. A longitudinal sliding movement of the SCM muscle can be made between the thumb and forefinger of the executing hand.
214478987|NCT05447338|PROCEDURE|Myofascial induction of pectoralis major and minor|Objective, release the fascia of the pectoralis major and minor muscle. Position of the patient, supine position, with the arm abducted to about 120 degrees. Position of the therapist, standing next to the patient, at head height. Technique: with his cranial hand, the therapist holds the patient's arm, and with the caudal hand, placed in a prone position, contacts the space between pectoralis major and ribs. This contact is made with the fingertips. The pressure should be maintained for about 5 minutes. As the release occurs, both of the therapist's hands must adjust to the direction of the changes. When detecting the restriction in the pectoralis minor, the penetration should be deepened with the hand, sliding it over the ribs. Contact and restraints with the pectoralis minor and major are often particularly painful, forcing the therapist to apply controlled force.
214669494|NCT06035523|DEVICE|Symphony™|Application of Symphony™
214900491|NCT07079930|OTHER|Beck Depression Inventory|The Beck Depression Inventory (BDI) will be administered at the following visits: screening, baseline, day 7, day 28, and day 84. It will be used to assess baseline mood and to rule out depressive symptoms.
214900492|NCT07079930|OTHER|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory (STAI) will be administered at the following visits: screening, baseline, day 7, day 28, and day 84. It will be used to screen for anxiety disorders.
215054365|NCT06718777|OTHER|0.1% polyhexanide Care|After the patient was randomized for pressure ulcer care, data were recorded at the first follow-up before care and pressure ulcer care was performed with 0.1% polyhexanide solution. Then, 2 treatments were performed at 48-hour intervals and PUSH scores were recorded before each care. A total of three pressure ulcer care and four follow-ups were performed.
214669495|NCT05839561|DRUG|Letrozole as monotherapy|Letrozole 5 mg daily orally for 10 days from day 0
214900493|NCT07079930|BEHAVIORAL|Profile of Mood States|"The Profile of Mood States (POMS) will be administered to assess baseline mood and emotional state.~It will be administered at the following visits: screening, baseline, administration day, day 2, day 7, day 28, and day 84.~On the administration day and on day 2, it will be administered at the following time points: pre-administration, and 8 and 20 hours post-administration."
214900494|NCT07079930|BEHAVIORAL|Subjective Units of Distress Scale|"Subjective Units of Distress Scale (SUDS) will be administered to assess anxiety and stress levels.~It will be administered at the following visits: screening, baseline, administration day, day 2, day 7, day 28, and day 84.~On the administration day and on day 2, it will be administered at the following time points: pre-administration, and 8 and 20 hours post-administration."
215054366|NCT06718777|OTHER|0.9 % NaCl Care|After the patient was randomized for pressure ulcer care, data were recorded at the first follow-up before care and pressure ulcer care was performed with 0.9% sodium chloride. Then, 2 care sessions were performed at 48-hour intervals and PUSH scores were recorded before each care. A total of three pressure ulcer care sessions and four follow-ups were performed.
215054367|NCT06716892|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of muscle and subcutaneos regions.
215054368|NCT06714877|OTHER|prism treatment group|wearing prism glasses
215054369|NCT06714877|PROCEDURE|botulinum toxin group|botulinum toxin injection
214301425|NCT05813964|DRUG|TDF/FTC 300mg/200mg fixed-dose combination tablets|Event-driven dosing regimen
214301426|NCT05813964|DRUG|TAF/FTC 25mg/200mg fixed-dose combination tablets|Event-driven dosing regimen.
214301427|NCT03997383|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
214301428|NCT03997383|DRUG|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
215054370|NCT06716268|OTHER|phonation and respiratory tasks|"Participants performed various tasks to evaluate pelvic floor muscle activity and displacement. These included a maximum voluntary contraction (cutting off the flow of urine mid-stream), a pelvic floor strain (bearing down for a bowel movement), and the Valsalva maneuver to clear the Eustachian tubes. Additionally, phonation and respiratory exercises were conducted, such as producing the ah sound at different pitches, open-mouth exhalation, coughing, and semi-occluded vocal tract (SOVT) exercises using a small coffee straw, commonly used in singing warm-ups to enhance vocal efficiency. Each task lasted 3 seconds, with 1-minute rest intervals to assess their impact on pelvic floor displacement"
214900495|NCT07079930|OTHER|Five-Dimensional Altered States of Consciousness questionnaire|"The Five-Dimensional Altered States of Consciousness questionnaire (5D-ASC) will be used to assess the acute subjective psychedelic experience. It will be administered after the acute effects have subsided - at 6.0 hours post-administration on the administration day, and again on day 2 - to evaluate five key experiential dimensions: visual restructuralization, oceanic boundlessness, reduction of vigilance, anxious ego dissolution, and auditory alterations. Each item will be rated using a Visual Analogue Scale (VAS) ranging from NO, not more than usually (0 mm) to YES, much more than usually (100 mm)."
214900496|NCT07079930|BEHAVIORAL|Integration|The integration process is conducted to support participants in processing and incorporating their therapeutic experience into daily life, with the aim of enhancing emotional insight and psychological well-being. Integration will take place at the following visits: 8.0 hours post-treatment on the administration day, day 2, day 7, day 28, and day 84.
214900497|NCT07079631|BIOLOGICAL|BNT314|Intravenous (IV) infusion
214900498|NCT07079631|DRUG|BNT327|IV infusion
214900499|NCT07079631|DRUG|SoC chemotherapy treatment 1|IV infusion / IV bolus
215054371|NCT06715969|OTHER|Myofascial Release Techniques|Separate techniques will be applied to the parts of the thoracolumbal fascia that surround the erector spina, quadratus lumborum, latissimus dorsi muscles and extend in that direction to patients in the MFR group. Techniques will continue for 180 seconds, tissue shift will be carried further as relaxation is achieved. Applications Total 8 sessions will be applied twice a week by an experienced physiotherapist.
215054372|NCT06715969|OTHER|Myofascial Induction Techniques|"MIT will be applied to the lumbal region by a physiotherapist trained and experienced in fascial treatments to patients in the MIT group. Applications 2 sessions per week, a total of 8 sessions will be applied, with an average of 20-25 minutes. The application principles of this technique will be as follows.~* Induction of the lumbal interfacial triangle region (stroke application) (3 min)~* Induction of the lumbal interfacial triangle region (deep induction application) (3 min)~* Cross-hands myofascial induction (3 min)"
215054373|NCT06715969|OTHER|classıcal phsyotherapy|15 sessions of mictowave diathermy (MDD), Vacuum Interference, Infraruj and Classic waist exercise program will be applied to patients in this group.
215054374|NCT06719518|DEVICE|ViTrack device|In the operating room the ViTrack™ device will be applied the wrist. Monitoring will start in the operating room and will continue throughout the surgery. The device can be worn on either wrist. It will be connected to a power unit that will capture blood pressure data and stream the data to a secure laptop
215054375|NCT06718478|DEVICE|SakuraBead Resorbable Microspheres|Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres
215054376|NCT06716775|DEVICE|Tumor treating felds (TTF)|Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day.
215054377|NCT06716775|OTHER|Best Standard of Care|Patients will be treated with the best known standard of care for NSCLC brain metastasis and undergo SRS alone.
215054378|NCT06716515|DEVICE|digital inclinometer|Digital inclinometer to assess gender difference in knee repositioning error
214669496|NCT05839561|DRUG|MTX as monotherapy|MTX in a single dose of 100 mg intravenously on day 0
214669497|NCT04887311|DRUG|MBM-01|Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
214900500|NCT07079631|DRUG|SoC chemotherapy treatment 2|IV infusion / IV bolus / oral
214900501|NCT07079631|DRUG|Bevacizumab|IV infusion
214900502|NCT06885619|OTHER|Diagnostic Test: echocardiography and blood collection|Blood samples were collected from all patients at the time of myocardial infarction (MI) diagnosis. For those with acute ST-elevation myocardial infarction, blood samples were taken on the day of diagnosis(T0), as well as two days (T1), one week (T2) and one month (T3) after percutaneous coronary intervention (PCI). Echocardiography was performed at the time of STEMI diagnosis, and then again at one week, one month, and six months post-onset.
214900503|NCT05204927|DRUG|177Lu-PSMA-I&T|Radioligand therapy
214900504|NCT05204927|DRUG|Abiraterone with Prednisone or Enzalutamide|Hormone Therapy
215054379|NCT06717048|DEVICE|Repeated Low-level Red-light|In addition to single vision spectacle lenses (SVS) with power for correcting distance refraction, the subjects used the prescribed power low-intensity red light treatment instrument for the prescribed number of treatments from Monday to Friday, with a 3-minute interval of 4 hours.
215054380|NCT06717048|DEVICE|Red LED|In addition to SVS with power for correcting distance refraction, red LED will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
215054381|NCT06717945|DRUG|remimazolam besylate|Patients received an initial dose of remimazolam (0.3mg/kg) for induction and a continuous infusion rate of 1 mg/kg/h for anesthesia maintenance. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
215054382|NCT06717945|DRUG|propofol|Patients received an initial dose of propofol (1.0 mg/kg) and a continuous infusion rate of 1-1.5 mg/kg/h. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
215054383|NCT06715956|OTHER|Observational Cohort Classification of Inflammatory Subtypes in Bronchiectasis|This observational study classifies patients with non-cystic fibrosis bronchiectasis into inflammatory subtypes based on sputum analysis. No active treatment or intervention is administered during this observational phase. Participants will later be considered for treatment with HSK31858 as part of an independent clinical trial.
215054384|NCT06719336|RADIATION|High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy|Twice-daily thoracic radiotherapy at a dose of 54 Gy in 30 fractions with IMRT and VMAT
214900505|NCT07082608|DEVICE|Endoscopic Sleeve Gastropathy|"Weight loss through diet, exercise, and behavioural changes positively impacts sleep quality. Reduction in body weight can alleviate OSA symptoms and improve overall sleep architecture1,2,3 Surgical weight loss procedures play a crucial role in managing obesity-related health issues, including OSA.4 Endobariatric procedures, including Endoscopic Sleeve Gastroplasty (ESG), have gained attention as a weight loss solution with the potential for improving obesity-related health issues.~ESG involves suturing the stomach to reduce its size, limiting food intake. Unlike traditional bariatric surgeries, ESG doesn't require incisions. ESG has shown promise in achieving clinically significant weight loss, up to 20% of TBWL. By reducing stomach capacity, it promotes satiety and calorie restriction. ESG is generally safe, with fewer complications compared to more invasive procedures"
214900506|NCT07082608|OTHER|Lifestyle Modification alone|Participants will follow a structured program involving a low-calorie diet (typically 1200-1500 kcal/day), regular physical activity (150 minutes of moderate-intensity exercise per week), and behavioural therapy sessions.
214900507|NCT07112807|OTHER|Strengthening Exercises|Strengthening exercises targeting the middle and lower trapezius and serratus anterior muscles will be performed. The program will progress by increasing the number of exercises and the amount of resistance.
214900508|NCT07112807|OTHER|ShoulderSphere Exercises and Resistive Exercises|In addition to strengthening exercises, exercises will be performed using the ShoulderSphere in the frontal, sagittal and transverse planes with the shoulders in 90° flexion and the elbows in extension.
214900509|NCT07112807|OTHER|Bodyblade Exercises and Resistive Exercises|In addition to strengthening exercises, 15 minutes of exercises using the Bodyblade will be performed. Individuals will perform oscillation exercises in the frontal, sagittal, and transverse planes while holding the Bodyblade bar firmly with their shoulders in 90° flexion and elbows in extension.
214900510|NCT01804790|DRUG|mFolfirinox|Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles: oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-FU: 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800 mg/m² twice a day 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on the center's choice.
214900511|NCT01804790|RADIATION|Radiotherapy 50 Gy|5 radiations per week of 2 Gy for 5 weeks
214900512|NCT01804790|DRUG|Capecitabine|1600 mg/m² (800 mg/m² twice daily) for 5 weeks
214900513|NCT01804790|PROCEDURE|TME surgery|
214900514|NCT01804790|DRUG|mFolfox6 or capecitabine|oxaliplatine 85 mg/m² (day 1 of cycle; perfusion in 2h), folinic acid 400 mg/m² (day 1 of cycle perfusion in 2h), 5-FU (bolus 400 mg/m² in 10 min and 2400 mg/m² perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500 mg/m²/day (Each cycle consists of 1250 mg/m² twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
215054385|NCT06719336|DRUG|atezolizumab or durvalumab|atezolizumab 1200 mg Q3W or durvalumab 1500 mg Q4W
215054386|NCT04685213|DEVICE|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
215054387|NCT04685213|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
215054388|NCT06717087|OTHER|Acupuncture+lifestyle intervention|8 weeks Acupuncture treatment for 2-3 times/week, 30min each time and lifestyle intervention((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)
215054389|NCT06717087|OTHER|Metformin+lifestyle intervention|8 weeks Metformin 500 mg three times a day with meals and lifestyle intervention ((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)
215054390|NCT06716047|OTHER|Oral administration|Take it directly
214900515|NCT07085273|DRUG|Irinotecan Liposomal|FOLFIRINOX + Karelizumab Irinotecan liposomal: 60 mg/m2, IV infusion, d1; 5-FU: 400 mg/m2, IV infusion, d1, followed by 1200 mg/m2/d x 2 days of continuous IV infusion (total 2400 mg/m2, 46-48h infusion); Calcium folinate: 400 mg/m2, IV infusion, d1; Oxaliplatin: 85 mg/m2, IV infusion, d1; Karelizumab: 200 mg, IV infusion, d1; Repeat every 2 weeks.
214900516|NCT05160532|DRUG|Placebo|5ml of normal saline (NS)
214900517|NCT05160532|DRUG|Dextrose prolotherapy (DPT)|25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.
214900518|NCT07079449|PROCEDURE|Dry Needling|Dry needling applied to bilateral active trigger points in the masseter and temporalis muscles once per week for three weeks.
214900519|NCT07079449|PROCEDURE|Lidocaine Hydrochloride|Lidocaine (20 mg/mL) injected into each active trigger point in the masseter and temporalis muscles once per week for three weeks.
214900520|NCT07079449|PROCEDURE|Mepivacaine Hydrochloride|Mepivacaine (30 mg/mL) injected into each active trigger point in the masseter and temporalis muscles once per week for three weeks.
214900521|NCT07079813|DEVICE|EasyStars™ High Density Mapping Catheter|All patients underwent treatment for complex arrhythmias using EasyStars™ High Density Mapping Catheter.
215054391|NCT06716697|BEHAVIORAL|physical and mental fatigue|physical and mental fatigue as a result of exposed to exams
215054392|NCT06716411|DEVICE|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
214669498|NCT02195830|OTHER|Ultrasound of the inferior vena cava|B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
214669499|NCT01217775|DRUG|PH80|PH80 intranasal spray 800 nanograms
214669500|NCT01217775|DRUG|Placebo intranasal spray|Placebo intranasal spray
214900522|NCT03323398|BIOLOGICAL|mRNA-2416|mRNA encoding human OX40L
214900523|NCT03323398|BIOLOGICAL|Durvalumab|PD-L1 inhibitor
214900524|NCT02235454|DEVICE|SDOCT-GMPE software|Noninvasive imaging of the optic nerve in patients with existing glaucoma
214900525|NCT07087184|BEHAVIORAL|Whole Milk-Skim Milk|If randomized to the whole milk-skim milk treatment sequence, participants will be instructed to restrict their liquid milk consumption to only whole milk for the first 2 months and to only skim milk for the last 2 months of the enrollment period. Participants will receive weekly app and text-based message reminders of their randomization assignments.
214900526|NCT07087184|BEHAVIORAL|Skim Milk-Whole Milk|If randomized to the skim milk-whole milk treatment sequence, participants will be instructed to restrict their liquid milk consumption to only skim milk for the first 2 months and to only whole milk for the last 2 months of the enrollment period. Participants will receive weekly app and text-based message reminders of their randomization assignments.
214900527|NCT06866574|BIOLOGICAL|Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli)|Participants received 3 doses of 9-valent HPV vaccine according to a 0, 1, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle of the upper arm)
214900528|NCT06866574|BIOLOGICAL|Aluminum Adjuvant|Participants received 3 doses of Aluminum Adjuvant according to a 0, 1, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle the upper arm).
214900529|NCT06782360|DEVICE|Active Neurostimulation|The stimulation frequency, pulse width, and amplitude will be varied in order to determine the optimal stimulation conditions for elongating the period of peak subject performance during the experimental tasks. Amplitude, pulse width, and frequency meet or exceed International Electrotechnical Commission (IEC) 60601-2-10:2016 requirements. The amplitude range specified is selectable for either channel with any frequency and pulse width combination. We will test an amplitude range of 0 mA - 5.0 mA. We will test a frequency range of 1 Hz - 150 Hz. We will test a pulse width range of 50 μs - 750 μs. The study coordinator should apply neurostimulation when the reported cognitive state metric corresponding to the performance task reaches different thresholds. These thresholds will be determined before execution of the study and will be chosen to maximize the likelihood of discovering an optimal trigger for neurostimulation based on reported cognitive state.
214900530|NCT06782360|DEVICE|Sham Stimulation|Modulation of stimulation frequency and amplitudes outside of the known physiological effective ranges during intervention periods.
215054393|NCT06714890|DEVICE|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation Combined with Accommodation-related Visual Training
215054394|NCT06714890|OTHER|Visual Training|Accommodation-related Visual Training
215054395|NCT06716489|BEHAVIORAL|Aerobic exercise|Participants will undergo an aerobic exercise training program on a motorized treadmill at an intensity corresponding to 60-70% of their heart rate reserve (calculated by adding baseline heart rate to 60-70% of reserve heart rate). The program will last 16 weeks and will consist of three 1-hour, 10-minute sessions per week, divided into four phases: a 5-minute warm-up at an intensity below the target exercise heart rate (baseline + 30-40% of the reserve heart rate); a 50-minute main exercise session at the target exercise heart rate intensity; a 5-minute cool-down at an intensity below the target exercise heart rate; and a 10-minute relaxation and general stretching phase. This structured exercise protocol was designed to evaluate the effects of aerobic exercise on sensory perception, musculoskeletal alterations, and psychosocial factors in patients with migraine.
215054396|NCT06713031|PROCEDURE|cannulated compression screws + iliac bone graft|"Using cannulated compression screws + iliac bone graft technique to treat old femoral neck fractures"
215054397|NCT06713031|PROCEDURE|DCS + medial support plate + iliac bone graft|"Using DCS + medial support plate + iliac bone graft technique to treat old femoral neck fractures"
214301429|NCT05521412|DRUG|[ 161 Tb]Tb PSMA I&T|During dose escalation, doses of \[161 Tb\]Tb PSMA I\&T will range between 4.4 GBq to 9.5 GBq. The recommended phase 2 dose of \[161 Tb\]Tb PSMA I\&T will be used during dose expansion. \[161Tb\]Tb-PSMA-I\&T dose will be reduced by 0.4 GBq for each subsequent cycles (2 to 6).
214301430|NCT06064097|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214900531|NCT03641469|DEVICE|Green Sun Dynamic Brace|Change from standard-of-care TLSO to GSM brace
214900532|NCT06178016|OTHER|Bystander Intervention Program for Dating Violence|"The Bystander Intervention Program for Dating Violence includes the following topics: Dating violence and its types (Session 1), risk factors and consequences of dating violence (Session 2), bystander intervention in dating violence and barriers to intervention (Session 3), bystander intervention strategies for dating violence (Session 4), self-care for bystanders witnessing dating violence (Session 5).~Each session is planned to last 60-90 minutes. Materials will be used in the Bystander Intervention Program for Dating Violence are PPT (PowerPoint Presentations) slides, videos, interactive scenarios, and group discussions. The Bystander Intervention Program for Dating Violence is planned to be applied face-to-face in 4 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group."
214900533|NCT07089667|BEHAVIORAL|virtual reality exergame|virtual reality exergame using Nintendo RingFit
214900534|NCT07089667|BEHAVIORAL|Conventional|Conventional-based aerobic exercise using video aerobic exercise of the Ministry of Health (KEMENKES) protocol
214900535|NCT04052217|DEVICE|Penile Ring|Penile Ring at base of penis
214900536|NCT06906874|DRUG|Activated Charcoal|oral activated charcoal capsules
215054398|NCT02161536|DEVICE|Motus Cleansing System|
215054399|NCT02906410|OTHER|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
215054400|NCT02906410|OTHER|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
215054401|NCT03898284|DIAGNOSTIC_TEST|Impulse Oscillometry|Impulse Oscillometry will be performed in addition to usual care
214301431|NCT06064097|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
214301432|NCT06064097|PROCEDURE|Chest Radiography|Undergo chest x-ray
214301433|NCT06064097|DRUG|Cisplatin|Given IV
214301434|NCT06064097|PROCEDURE|Computed Tomography|Undergo CT
214301435|NCT06064097|PROCEDURE|Echocardiography Test|Undergo ECHO
214301436|NCT06064097|OTHER|Electronic Health Record Review|Ancillary studies
214301437|NCT06064097|OTHER|Fluciclovine F18|Given IV
215054402|NCT00752921|DRUG|etoricoxib|120 mg
214900537|NCT06906874|DRUG|Phosphate Binders|calcium-based or non-calcium based (sevelamer) binders
215054403|NCT00752921|DRUG|placebo|placebo
214900538|NCT07092046|DRUG|Sevoflurane (Volatile Anesthetic)|An inhalational anesthetic agent will be used for the maintenance of anesthesia, administered at a concentration of 2-3% in a gas mixture consisting of 40% oxygen and air.
214900539|NCT07092046|DRUG|Propofol 1%|An intravenous hypnotic agent will be used for anesthesia induction at a dose of 2-3 mg/kg.
214900540|NCT07092046|DRUG|Remifentanil 2 MG|A short-acting opioid will be administered intravenously for maintenance of anesthesia at a dose of 0.02-0.2 micrograms per kilogram per minute (μg/kg/min).
215054404|NCT00775255|DRUG|clarithromycin 250 mg/5 mL powder for oral suspension|
215054405|NCT04999735|BEHAVIORAL|CHDR Monitoring Remotely (MORE)|CHDR MORE is a highly customizable platform which allows remote monitoring of patients and trial subjects, data ingestion, and data management. The current infrastructure includes an Android app to unobtrusively collect data from smartphone sensors, and a connection to the Withings Health online platform to collect wearable data. Data is stored on a secure server in a structured data scheme ensuring clear data management processes, forming a prerequisite for comprehensive data analysis. The Android app enables data collection from multiple smartphone sensors (e.g. location data, accelerometer and ambient light) as well as phone usage logs (e.g. app usage, calls and texts).
215054406|NCT04999735|BEHAVIORAL|Withings Steel HR|The Withings Steel HR is a commercially available smartwatch that combines various sensors to measure activity (steps, sleep, etc.) and heart rate (HR). HR is measured using a PPG (photoplethysmogram, i.e. optically obtained volumetric measurement) based on a commercially available sensor (AS7000) incorporating low-noise and high-sensitivity analogue circuitry. The manufacturer supplies the algorithm for converting the PPG signal into HR values. Data is transferred from the watch to the smartphone using the Withings Health Mate app from where it will be uploaded to the output server.
215054407|NCT04999735|BEHAVIORAL|Withings Body+ scale|Body composition (weight, BMI and Skeletal Muscle Mass) can be assessed with the Withings Body+ smart scale at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging.
215054408|NCT04999735|BEHAVIORAL|Withings Blood Pressure Monitor|Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
215054409|NCT05246202|BEHAVIORAL|Alcohol-Anxiety Personalized Feedback Intervention 2.0|AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.
215054410|NCT05246202|BEHAVIORAL|Control Personalized Feedback Intervention|C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
215054411|NCT04486690|DRUG|Ketofol (propofol to ketamine ratio 1:1)|"* Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min"
215054412|NCT04486690|DRUG|propofol|"Propofol infusion, 25-150 mcg/kg/min.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min."
215054413|NCT00971282|DRUG|adapalen 0.1%|"Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
215054414|NCT00971282|OTHER|Cetaphil®|"Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
215054415|NCT01101529|DRUG|Aprepitant (Emend)|Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
215054416|NCT01101529|DRUG|Placebo|Placebo will be administered instead of Emend
215054417|NCT01852643|PROCEDURE|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
215054418|NCT01852643|PROCEDURE|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
215054419|NCT02348190|OTHER|Lipid/heparin|"32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs."
214301438|NCT06064097|DRUG|Gemcitabine|Given IV
214900541|NCT07092046|DRUG|Rocuronium 50 mg/5 ml|A neuromuscular blocking agent will be administered intravenously at a dose of 0.6-1.2 mg/kg for induction, and 0.15 mg/kg for maintenance of muscle relaxation during surgery.
214900542|NCT07092046|DRUG|Lidocaine %2 ampoule|This agent will be administered intravenously at a dose of 1-1.5 mg/kg prior to anesthesia induction to reduce injection pain and facilitate smooth induction.
214900543|NCT07092046|DRUG|Ephedrine Hydrochloride 0,05 mg/ml ampoule|This agent will be administered intravenously at a dose of 0.1 mg/kg to treat intraoperative hypotension that does not respond to fluid replacement or adjustment of anesthetic depth.
214900544|NCT07092046|DRUG|Sugammadex 200 MG in 2 ML Injection|Sugammadex will be administered intravenously at a dose of 2 mg/kg or 4 mg/kg, depending on the degree of neuromuscular blockade.
214900545|NCT07092046|DRUG|Fentanyl (IV)|Fentanyl will be administered intravenously as part of the anesthesia induction regimen, at a dose ranging from 1 to 2 micrograms per kilogram (µg/kg).
215054420|NCT03440866|DRUG|Administration of drugs concomitantly.|Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.
215054421|NCT01085526|BIOLOGICAL|Alutard phleum pratense subcutaneous immunotherapy|standard regimen of SCIT
215054422|NCT01085526|DRUG|Alutard phl prat|
214301439|NCT06064097|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214900546|NCT07092046|DRUG|Atropine Sulphate 0.5mg/ml ampoule|In cases of intraoperative bradycardia, defined as a heart rate (HR) below 45 beats per minute (bpm), 0.5 mg of the agent will be administered intravenously.
214900547|NCT07092046|PROCEDURE|Peripheral Intravenous Cannulation|All participants received peripheral intravenous cannulation using 18-20 G IV cannulas placed on the dorsum of the hand before anesthesia induction.
214900548|NCT07092046|PROCEDURE|Mechanical Ventilation|Following endotracheal intubation, mechanical ventilation will be initiated using volume-controlled settings, with a tidal volume (TV) of 6-8 mL/kg, respiratory rate (RR) of 12 breaths per minute, and fraction of inspired oxygen (FiO₂) set at 50%. Ventilator parameters will be adjusted to maintain end-tidal carbon dioxide (ETCO₂) between 30 and 36 mmHg.
214900549|NCT07092046|PROCEDURE|Peripheral Intravenous Cannulation|All participants will undergo peripheral intravenous cannulation with 18-20 gauge (G) IV (intravenous) cannulas placed on the dorsum of the hand prior to anesthesia induction.
214900550|NCT07092046|DRUG|Crystalloid solutions|Participants will receive calculated maintenance fluid therapy with crystalloids administered via intravenous infusion, both prior to and throughout the surgical procedure.
214900551|NCT07092046|PROCEDURE|Endotracheal Intubation|Following induction of anesthesia and establishment of neuromuscular blockade, endotracheal intubation will be performed using a standard technique in all participants.
214900552|NCT07092046|PROCEDURE|American Society of Anesthesiologists (ASA) Standard Monitors|Routine monitoring in accordance with American Society of Anesthesiologists (ASA) guidelines, including noninvasive blood pressure, electrocardiogram (ECG, D2 lead), end-tidal carbon dioxide (ETCO₂), and peripheral oxygen saturation (SpO₂), will be performed in all patients starting from the preoperative period and continuing throughout the surgery.
214900553|NCT07092046|PROCEDURE|Minimal-Flow Anesthesia|In the minimal-flow anesthesia group, after induction and once a minimum alveolar concentration (MAC) of 1 is achieved, the fresh gas flow will be reduced to 0.5 L/min with a mixture of 45% oxygen (O₂) and 55% air, and maintained throughout the surgical procedure. At the end of surgery, the flow will be increased to 3 L/min to facilitate emergence. Disposable anesthesia circuits, bacterial filters, and face masks will be used for each patient, and carbon dioxide (CO₂) absorbers will be replaced daily.
214900554|NCT07092046|PROCEDURE|Normal-Flow Anesthesia|In the normal-flow anesthesia group, after induction and once a minimum alveolar concentration (MAC) of 1 is achieved, the fresh gas flow will be adjusted to 2 L/min and maintained during the surgical procedure. For emergence, the flow will be increased to 3 L/min. Disposable anesthesia circuits will be used, and daily maintenance protocols, including replacement of carbon dioxide (CO₂) absorbers, will be applied in the same manner as in the minimal-flow group.
214900555|NCT07092046|DIAGNOSTIC_TEST|Anesthesia Circuit Sampling|Sterile swab samples will be collected from both the inspiratory and expiratory limbs of the anesthesia circuit-once prior to circuit connection and again immediately after disconnection at the end of the surgical procedure. All samples will be processed for microbial culture and species-level identification.
214900556|NCT07092046|PROCEDURE|Body Temperature Monitoring|In addition to routine monitoring-including electrocardiogram (ECG), non-invasive blood pressure, peripheral oxygen saturation (SpO₂), and end-tidal carbon dioxide (ETCO₂)-body temperature will be continuously monitored in both study groups throughout the surgical procedure using appropriate thermal sensors. Temperature measurements will be recorded at 5-minute intervals and used to assess the impact of different fresh gas flow rates on intraoperative thermoregulation.
214900557|NCT07092046|DIAGNOSTIC_TEST|Nasopharyngeal Swab Collection|A sterile nasopharyngeal swab (Dry SWAB) will be collected from each patient upon arrival in the operating room, prior to anesthesia induction. Each sample will be labeled with the patient's identification number, date, time, and collection site, and will be transferred in appropriate transport medium to the microbiology laboratory for culture and microbiological analysis.
215054423|NCT03874767|BEHAVIORAL|Patient Mobility|A team of two mobility technicians will switch between two units on a monthly basis. The unit staffed by the mobility technician will be referred to as the intervention unit, while the other will be referred to as the control unit. One unit will start as the control unit and will switch to being the intervention unit after one month. Similarly, the other unit will start as the intervention unit and will switch to becoming the control unit after one month. All patients present on a unit during the intervention period will be provided mobility technician support according to standardized clinical guidelines that have been developed by the care team and described below. Patients who are present on a unit at the time of cross-over will not be included in the analysis, but will either no longer receive mobility technician support (if crossing from intervention to control) or will start to receive mobility technician support (if switching from control to intervention).
215054424|NCT03199833|DEVICE|RETRAINER-S2|"It consists of the execution of different exercises with the affected forearm-hand supported by the RETRAINER-S2 device. The subject is actively involved in the exercises and the system provides two types of support: wrist-fingers motion constraining and FES. The following exercises can be performed: controlled wrist flexion and wrist extension; controlled fingers flexion and extension; repeated grasping of an object; anterior reaching and grasping of an object; moving of objects on a plane or in space.~A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
214669501|NCT01386671|DRUG|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
214301440|NCT06064097|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214669502|NCT01386671|DRUG|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
214669503|NCT00396396|DRUG|Acetylcysteine|
214669504|NCT00315302|DRUG|Atropine|Atropine 1% once each weekend day
214669505|NCT00315302|DEVICE|Plano Lens|Plano lens for the sound eye
214900558|NCT07092046|DIAGNOSTIC_TEST|Microbiological Culture and Identification|All collected swab samples-including both nasopharyngeal and anesthesia circuit specimens-will be cultured using the serial dilution method on 5% sheep blood agar within 15 minutes of arrival at the microbiology laboratory. Cultures will be incubated at 35-37°C for 48 hours. Colony growth will be evaluated by a clinical microbiologist, and microorganisms will be identified to the species level using an automated MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry) system.
214900559|NCT03082534|DRUG|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
214900560|NCT07088211|DRUG|Sacituzumab Tirumotecan and Toripalimab|The dosing regimen for the combination of Sacituzumab Tirumotecan and Toripalimab is as follows: the recommended dose of Sacituzumab Tirumotecan is 5mg/kg, administered intravenously every 2 weeks, and Toripalimab is administered intravenously (without prophylactic medication), with a fixed dose of 240mg, and 3mg/kg is used for subjects with baseline body weight\<50kg. Each infusion lasts for 30 minutes (not less than 20 minutes, not more than 60 minutes), administered once every 2 weeks. The subjects will continue to receive combination therapy with Sacituzumab Tirumotecan and Toripalimab until the termination criteria are met.
214900561|NCT07090629|OTHER|Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring|Epicardial adipose tissue measurement
214900562|NCT07095127|DRUG|NVG-2089|Study Treatment
214900563|NCT07096414|DIETARY_SUPPLEMENT|Vitamin D3|Administration of vitamin D3 capsule 50,000 IU/week for 8 weeks
214900564|NCT05479435|BEHAVIORAL|Blue Prescription Exercise Program|"After the evaluation, participants will receive feedback and physical activity training, along with an explanation of the benefits of exercise, provided in the form of a brochure. They will then be enrolled in the Blue Prescription program, which includes weekly follow-ups for 12 weeks and a re-evaluation at the end of the 12th week. Motivation and support will be offered in accordance with the Blue Prescription philosophy, addressing home exercise programs, physical activity selection, and overcoming obstacles. Participants will be encouraged to determine the most suitable program for themselves and maintain an activity diary.~Throughout the study, participants will have the opportunity to communicate with the physiotherapist via various methods such as phone, SMS, or email."
214900565|NCT05479435|BEHAVIORAL|Video Based Home Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
214900566|NCT05479435|BEHAVIORAL|Supervised Group Exercise Program|DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Participants will engage in exercises with a physiotherapist three days a week for 12 weeks, and the effectiveness of the program will be re-evaluated at the end of the 12th week.
214900567|NCT07094958|BIOLOGICAL|stromal vascular fraction (SVF)|Autologous stromal vascular fraction (SVF) isolated from adipose tissue was injected intradermally into one side of the face to evaluate its efficacy in treating atrophic acne scars. SVF was freshly prepared on the same day of injection using enzymatic digestion and centrifugation.
214900568|NCT07094958|OTHER|Normal Saline (NS)|Normal saline (NS) was injected intradermally into the contralateral side of the face and served as a placebo comparator to SVF in this split-face study on atrophic acne scars.
214900569|NCT06911684|COMBINATION_PRODUCT|lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy|"Group A patients received two cycles of QL1706, regorafenib, and CAPOX induction therapy, followed by sequential short-course radiotherapy, and then continued with four cycles of QL1706, regorafenib, and CAPOX consolidation therapy.~lparomlimab and Tuvonralimab Injection(QL1706): 5 mg/kg, intravenous (IV), on Day 1, every 3 weeks (q3w) during the neoadjuvant treatment phase.~Regorafenib:80 mg, oral (PO), once daily (qd), Days 1-14, every 3 weeks (q3w) during the neoadjuvant treatment phase.~CAPOX: Oxaliplatin( 130 mg/m², IV over 2 hours, Day 1, every 3 weeks (q3w))+ Capecitabine( 1000 mg/m², PO, twice daily (bid), Days 1-14, every 3 weeks (q3w)).~Short-course radiotherapy:The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose."
214900570|NCT06911684|COMBINATION_PRODUCT|lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy|"Group B patients received short-course radiotherapy followed by six cycles of QL1706, regorafenib, and CAPOX consolidation therapy.~lparomlimab and Tuvonralimab Injection(QL1706): 5 mg/kg, intravenous (IV), on Day 1, every 3 weeks (q3w) during the neoadjuvant treatment phase. Regorafenib:80 mg, oral (PO), once daily (qd), Days 1-14, every 3 weeks (q3w) during the neoadjuvant treatment phase. CAPOX: Oxaliplatin( 130 mg/m², IV over 2 hours, Day 1, every 3 weeks (q3w))+ Capecitabine( 1000 mg/m², PO, twice daily (bid), Days 1-14, every 3 weeks (q3w)). Short-course radiotherapy:The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose."
214900571|NCT07095192|OTHER|Preimplementation of HCV Point of care testing|Exploring the pre-implementation of HCV Point of care antibody and RNA tests
215054425|NCT03199833|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy"
214301441|NCT06064097|BIOLOGICAL|Nivolumab|Given IV
214301442|NCT06064097|PROCEDURE|Positron Emission Tomography|Undergo PET
214301443|NCT06064097|OTHER|Quality-of-Life Assessment|Ancillary studies
214900572|NCT07096817|BEHAVIORAL|Highly intensive individualized balance therapy|"In the form of a camp with total therapy hours of 40 hours with a central theme of Circus, children will receive individualized (1 therapist per child) intensive therapy. The intervention is functional, and divided in six activity categories: jumping, sitting balance, walking and running, circus, individual goals and group activities with focus on social interaction. Each category should: 1. partially or fully cover the multisystemic balance framework of Horak, with the overall program covering the entire framework, 2. be fun and focusing on collaboration rather than competition."
214900573|NCT07096115|DRUG|Taiglididine|The first patient receives an intravenous injection of 1 mg taiglididine for anesthesia induction, followed by 1-2 mg/kg propofol. When the patient's bispectral index (BIS) drops below 60, eyelash reflex disappears, and MOAA/S score is 0, intravenous rocuronium 0.6 mg/kg is given, and a laryngeal mask is inserted by a senior anesthesiologist using a unified method 1 min later. From the second patient onward, the taiglididine dose is dynamically adjusted based on the previous patient's response to laryngeal mask insertion using BCD-UDM: if the previous patient shows a positive insertion response (positive response or MOAA/S ≥2 within 2 min after induction), the next patient's dose increases by 0.1 mg; if negative, a random number (1-95) generated by computer determines the dose: doses remain unchanged when the number is 6-95 (89% probability) and decrease by 0.1 mg when the number is 1-5 (11% probability). A collaborator not involved in result evaluation provides a sealed envelope with
214900574|NCT07096219|PROCEDURE|Catheter Ablation|A minimally invasive procedure that delivers energy through catheters to destroy abnormal cardiac tissue causing arrhythmias.
214900575|NCT07096219|DIAGNOSTIC_TEST|ultrasonic cardiography (UCG)|Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surfa
214900576|NCT07095517|DRUG|Tirzepatide|Study drug injected subcutaneously once a week
214900577|NCT07096141|BEHAVIORAL|DBT-informed Group Psychotherapy for Emotion Regulation|An 8-session Dialectical Behaviour Therapy informed emotion regulation psychotherapy group.
214900578|NCT07096856|DEVICE|Robotic assisted cholecystectomy|Robotic assisted cholecystectomy
214900579|NCT07097415|DEVICE|Continuous blood glucose monitoring assisted blood glucose management|(1) individualized health education sessions conducted by endocrinology healthcare providers covering CGM concepts, usage methods, advantages, risks, and precautions, along with hands-on device demonstration and provision of written materials and user manuals; (2) development of an integrated CGM data management platform that connects with community healthcare information systems for real-time data transmission, storage, and analysis; (3) establishment of standardized CGM response protocols for healthcare providers, including glucose target setting, dietary and exercise recommendations, personalized medication adjustments based on glucose fluctuations, and management procedures for hypoglycemic and hyperglycemic alerts; and (4) mobile application setup and data transmission configuration for patients.
214900580|NCT07096700|OTHER|VR and walking brace-based gait rehabilitation|The study implements the use of VR and wearable sensors to enhance gait analysis in clinical practice. Participants will take part in two outpatient sessions (T1 and T2) involving the use of VR and wearable sensors, during which they will be asked to complete standardized gait tests and questionnaires. These two sessions will be separated by a one-week home phase (Th), during which participants will wear the walking brace in their daily activities and their gait and physiological data will be recorded by wearable sensors. A final session (T3), conducted without VR, will be scheduled two months later to assess the long-term retention of the intervention effects.
214900581|NCT07095244|DIETARY_SUPPLEMENT|Iron Supplement|FeraMAX Pd powder 15: NPN 80109337 FeraMAX Pd Therapeutic 150 capsules: NPN 80075623 (for an adolescent that can swallow capsules)
214900582|NCT07095244|DIETARY_SUPPLEMENT|Comprehensive Nutrition Management|Standard nutrition care will depend on the results of the nutrition assessment, as well as underlying conditions, and will be performed regardless of iron supplementation. The intervention will be at the discretion of the dietician but may include; diet education, recommendations for vitamin and mineral supplements, optimization of tube feeds (if the child is tube fed), high protein or high energy diet education if the child is underweight, dddition of oral nutrition supplements (i.e., Pediasure or Ensure) to promote weight gain in orally fed children, discussion surrounding enteral feeding (for children who are orally fed, but severely malnourished and cannot meet their nutritional needs by mouth).
214900583|NCT07096050|OTHER|HyaleXo|Treatment of HyaleXo 3 times
215054426|NCT00769054|DRUG|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
215054427|NCT00769054|DRUG|Isotonic NaCl|Local Infiltration with NaCl
215054428|NCT03005340|DRUG|Treatment B|Bazedoxifene 20 mg
215054429|NCT03005340|DRUG|Treatment C|Cholecalciferol granule 10 mg
215054430|NCT03005340|DRUG|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
215054431|NCT04446312|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
215054432|NCT01207206|DRUG|oral ketamine|"The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).~The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception"
215054433|NCT03931187|BEHAVIORAL|Cognitive progressive muscular relaxation therapy|This therapy combines cognitive psychotherapy and progressive muscular relaxation, intervened 6 times with 1-1.5 hour each time. The whole therapy will last round 28-30 days during IVF-ET.
215054434|NCT02224170|DRUG|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
215054435|NCT02224170|DRUG|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
215054436|NCT05379699|OTHER|TOR-BSST© eLearning Training|An online self-directed training program for TOR-BSST© dysphagia screeners.
215054437|NCT05379699|OTHER|Standard TOR-BSST© Training|Standard 4-hour in-person TOR-BSST© screener training conducted by a Speech-Language Pathologist.
214900584|NCT07095062|DEVICE|HD-EEG recordings, combined with cognitive and motor assessment|Participants will undergo high-density EEG (HD-EEG) recordings under two conditions: at rest and while performing an upper limb motor task. The data obtained will be used to reconstruct source cortical activity and derive patterns of functional connectivity, using advanced neurophysiological analysis techniques, including the Avalanche Transition Matrix (ATM). In addition, patients will complete a neuropsychological assessment and participate in an intensive multidisciplinary rehabilitation program lasting 3 to 4 weeks, depending on age. The intervention aims to assess changes in the functional organization of the brain before and after treatment, as well as one year later, in order to explore potential biomarkers of disease progression.
214900585|NCT07097350|DEVICE|computer-aided detection alone|colonoscopy with computer-aided detection
215054438|NCT00655837|DRUG|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
215054439|NCT00655837|DRUG|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
215054440|NCT00655837|DRUG|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
214669506|NCT04252417|DRUG|MD1003|Single oral dose administration of MD1003 at Day 1
214301444|NCT06064097|OTHER|Questionnaire Administration|Ancillary studies
214301445|NCT06064097|RADIATION|Radiation Therapy|Receive radiation therapy
214900586|NCT07097350|DEVICE|transparent cap-assisted colonoscopy combined with computer-aided detection|transparent cap-assisted colonoscopy combined with computer-aided detection
214900587|NCT07096479|DRUG|Telpegfilgrastim Injection|Within 48 ± 12 hours after the end of each chemotherapy cycle, a single subcutaneous injection of a fixed dose of 2mg of Telpegfilgrastim is administered. Use once per chemotherapy cycle and enroll in 1-4 cycles based on the patient's actual condition.
214900588|NCT07095166|BEHAVIORAL|Meal Location|The location at which the child will eat the experimental meal - home or lab
214900589|NCT07097831|DRUG|HRS-1301 Tablets|HRS-1301 tablets.
214900590|NCT07097831|DRUG|Rosuvastatin Calcium Tablets|Rosuvastatin calcium tablets.
214301446|NCT06064097|PROCEDURE|X-Ray Imaging|Undergo dental x-ray
214301447|NCT04327232|DRUG|Spironolactone 25mg|Mineralocorticoid Receptor Antagonists
214301448|NCT04327232|DRUG|Placebo oral tablet|Placebo
214301449|NCT05006716|DRUG|BGB-16673|Orally administered
215054441|NCT00192543|BEHAVIORAL|diet of fish and fruit|fish and fruit in specified quantities
215054442|NCT00192543|BEHAVIORAL|fruit and fish|no drugs
215054443|NCT00192543|BEHAVIORAL|diet only|Fish and fruit
215054444|NCT00192543|BEHAVIORAL|regular diet|no change in regular diet
214301450|NCT00002631|DRUG|chemotherapy|
214301451|NCT00002631|DRUG|cisplatin|
214301452|NCT00002631|DRUG|fluorouracil|
214301453|NCT00002631|RADIATION|low-LET electron therapy|
214301454|NCT00002631|RADIATION|low-LET photon therapy|
214301455|NCT02596581|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
214669507|NCT00217438|DRUG|melphalan|Given IV
214669508|NCT00217438|DRUG|amifostine trihydrate|Given IV
214669509|NCT00217438|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
214669510|NCT00217438|GENETIC|fluorescence in situ hybridization|Correlative study
214669511|NCT00217438|PROCEDURE|bone marrow ablation with stem cell support|Undergo transplant
215054445|NCT02175186|DRUG|ALBIS|
215054446|NCT02175186|DRUG|Placebo|
215054447|NCT03154476|DRUG|Sildenafil|Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
215054448|NCT03154476|DRUG|Placebo|Placebo capsules matching study drug
215054449|NCT04734158|OTHER|corneal imaging|corneal imaging using AS-OCT
215054450|NCT02685826|DRUG|Durvalumab|single use vials administered via intravenous infusion
215054451|NCT02685826|DRUG|Lenalidomide|capsules for oral administration
215054452|NCT02685826|DRUG|Dexamethasone|tablets for oral administration
215054453|NCT02610972|DEVICE|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
215057512|NCT04808713|BEHAVIORAL|Treatment|The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
215054454|NCT04317144|BEHAVIORAL|Web-based follow-up programme.|Participants who are randomized to the intervention-group will have access to web-based follow-up for one year. The programme includes short films of equipment used in intensive care e.g. ventilator, suction-device. Continous renal replacement therapy , central vein catheter among other things. About 15 short films with icu-staff talking and show how the equipment works and alarm sounds. The intervention also includes lectures about how the ICU works and what problems a critically ill patient can suffer from post-icu. There is a built-in conversation tool in the programme that can be used both by the participant and the staff who works with the follow-up programme. Questionnaires is sent out 2,6 and 12 month post-icu. The questions include PTSD, Depression, QoL and physical activity. At the end of the study, participants are sent a questionnaire asking for their experience using the web-based follow up programme.
215054455|NCT04317144|BEHAVIORAL|No follow-up|"Participants randomized to no follow-up receive e-questionnaires 2, 6 and 12 months post-ICU care. The questions are the same as in web-based follow-up intervention group and include PTSD, Depression, QoL and physical activity."
215054456|NCT06091358|DEVICE|PrO2|"The intervention arm will receive a handheld PrO2 device and will participate in two unsupervised sessions and one supervised via Microsoft teams sessions per week.~Participants will complete 3 sessions per week, for 4 weeks. Each session will include 6 x 6 inspirations at 80% of MIP. MIP will be measured on the supervised session day each week."
215054457|NCT05095298|DRUG|Vaccine, COVID19|It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
214900591|NCT07095309|DRUG|Artesunate|Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
214900592|NCT07095309|DRUG|Artesunate matching Placebo|Matched placebo PO OD for 14 days prior to colorectal resection surgery
215054458|NCT03919565|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
215054459|NCT03919565|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
215054460|NCT03919565|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
215054461|NCT00200967|DRUG|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
215054462|NCT00200967|DRUG|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
215054463|NCT02108886|DRUG|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
215054464|NCT02108886|DRUG|Placebo|empty capsule filled with sugar
215054465|NCT02108886|OTHER|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
214478988|NCT05447338|PROCEDURE|Myofascial induction; upper trapezius|Objective, release the myofascial restrictions of the upper trapezius. Position of the patient, supine, with the elbow flexed and the hand resting on the abdomen, and the arm in a slight abduction. Therapist position, sitting at the head of the table. Technique: The therapist places his hand on the patient's shoulder so that he can grasp the fibers of the upper trapezius between the index, middle, and ring fingers above and the thumb below. Subsequently, he exerts gentle and sustained pressure overcoming three restraining barriers.
215054466|NCT01950728|DEVICE|Interferential current|Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 100 Hz.
215054467|NCT01950728|DEVICE|Aussie Current|Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 100 Hz.
215054468|NCT01950728|DEVICE|TENS|TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 100 Hz.
215054469|NCT02751944|DIETARY_SUPPLEMENT|NEM|Dietary supplement for the support of joint health.
215054470|NCT02751944|DIETARY_SUPPLEMENT|Placebo|Placebo
215054471|NCT04892706|DRUG|IDP-126 Gel|Gel applied to face once daily in the evening.
214669512|NCT05635565|OTHER|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
214900593|NCT04941092|OTHER|no intervention|no intervention, retrospective comparison
215054472|NCT04892706|DRUG|IDP-126 Vehicle Gel|Gel applied to face once daily in the evening.
215054473|NCT04892706|DRUG|Epiduo® Forte Gel|Gel applied to face once daily in the evening.
215054474|NCT00936663|DRUG|Placebo|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
215054475|NCT00936663|DRUG|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
215054476|NCT00894777|OTHER|Clinical record review|
215054477|NCT06012630|DIAGNOSTIC_TEST|Ultarsound|Median nerve evaluation of participants with ultrasound
215054478|NCT01444430|DRUG|Symbicort pMDI|Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
214900594|NCT06817330|OTHER|Intervention group, listening to recorded music|Participants in the group receiving music will be offered a tablet with several pre-created playlists. When the patient has made a selection, they will listen to music via headphones for 30 minutes before each ECT treatment session. The headphones will be removed and the music stopped after the 30 minutes. After active ECT treatment, the headphones will be put back on the patient and the music played for another 12 minutes while the patient is recovering and moved to the recovery room. If patients protest against the music and/or headphones, the researcher will ask them to put the headphones back on. If the patient still protests after asking to put the headphones back on, this will be written down by the researcher, with the amount of time without the (control) intervention noted. No coercion will be used during the whole study process.
214900595|NCT06817330|OTHER|Control group, headphones with no music|The control group will wear headphones without music for the same duration as the music group (30 minutes before ECT and 12 minutes after ECT) to reduce bias and achieve a similar level of background-noise dampening.
214900596|NCT07103343|BEHAVIORAL|MOVI-OLE intervention|"In the MOVI-OLE! classrooms, traditional desks and chairs will be replaced by three dynamic learning zones:~A) Dynamic seating: an area with traditional wheeled desks combined with dynamic seats such as fitballs, stools, pedal desks, etc.; B) Standing desks: an area with manually adjustable high desks to allow standing work. Students will also have stools with small backrests and footrests for when they need to sit; C) Vertical boards: vertical boards (vinyl, paper, chalkboard paint, etc.) installed on walls for standing work.~To facilitate use and adapt to classroom routines, teachers will decide how to distribute students among the different zones, with the requirement that all students spend at least 20 minutes per school day in zone B.~In addition to the workstations, teachers will receive training and didactic support materials focused on student-centered methodologies and the use of open learning spaces."
214900597|NCT06394739|DEVICE|Thrombectomy|RevCore Thrombectomy to treat in-stent thrombosis
214900598|NCT01236716|DRUG|Albumin paclitaxel plus carboplatin|Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
214900599|NCT01236716|DRUG|Gemcitabine plus carboplatin|Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
214900600|NCT07111741|DEVICE|Total contact cast|Arm with 51 patients was given total contact cast for offloading DFU
214900601|NCT07111741|DEVICE|Posterior slab cast|Arm with 48 patients were given posterior slab cast for offloading DFU
214900602|NCT07112300|PROCEDURE|cervical nerve radiofrequency|Pulsed radiofrequency treatment is applied to the cervical 5-6-7 nerve roots defined under ultrasound guidance in the intertubercular or interscalene space by approaching the cervical 5-6-7 nerve roots with an inplane technique via a cannula electrode.
214900603|NCT07112625|OTHER|education and coaching|education associated to coaching
214900604|NCT07112625|OTHER|education|education without coaching
215054479|NCT01444430|DRUG|budesonide pMDI|Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
215054480|NCT02560220|BIOLOGICAL|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
215054481|NCT03280368|OTHER|Bloodtest|
214900605|NCT07111104|DRUG|Immunotherapy|"The immunotherapy intervention consists of treatment with immune checkpoint inhibitors, specifically Nivolumab (OPDIVO), Atezolizumab (TECENTRIQ), Pembrolizumab (KEYTRUDA).~These drugs are monoclonal antibodies that block PD-1 or PD-L1 pathways, aiming to enhance the immune system's ability to recognize and destroy cancer cells. The treatment is administered intravenously according to standard dosing schedules."
215054482|NCT03280368|OTHER|Questionnaires|
215054483|NCT03273686|PROCEDURE|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
215054484|NCT05360251|DEVICE|PDL(595nm)|One subject was treated with pulsed dye laser (Vbeam platinum, 595 nm, Candela Corporation): energy dosages of 9-11 J/cm2, pulse durations of 10/20 ms, and spot size of 7 mm.
215054485|NCT05360251|DEVICE|IPL(DPL)|One subject was treated with IPL(delicate Pulsed Light, Dye-VL, Alma Lasers Corporation): energy dosages of 8.4-10.6 J/cm2, pulse durations of 10/12 ms, and spot size of 10×30 mm.
214669513|NCT05635565|OTHER|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
214669514|NCT03939208|BEHAVIORAL|BRISC|
214669515|NCT03939208|BEHAVIORAL|SAU|
214669516|NCT00000249|DRUG|20% N2O|20% inhaled N2O
214669517|NCT00000249|DRUG|30% N2O|30% inhaled N2O
214669518|NCT00000249|DRUG|40% N2O|40% inhaled N2O
214669519|NCT02082691|DRUG|G-202|Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
214669520|NCT05736315|OTHER|Placebo dairy beverage|Placebo dairy beverage (placebo) is a sweetened dairy beverage.
215054486|NCT05360251|DEVICE|IPL(M22 590)|One subject was treated with IPL(M22 590, 590-1200nm, Lumenis Limited): energy dosages of 15-18 J/cm2, pulse durations of 3-4 ms, pulse delay of 30-40 ms, and spot size of 15×35 mm.
215054487|NCT05360251|DEVICE|IPL(M22 vascular)|One subject was treated with IPL(M22 vascular, 530-650nm and 900-1200nm, Lumenis Limited): energy dosages of 9-17 J/cm2, pulse durations of 4-6 ms, pulse delay of 20-40 ms, and spot size of 15×35 mm.
215054488|NCT01144624|DRUG|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
215054489|NCT01144624|DRUG|Placebo|Intravenous infusion of a saline solution
215054490|NCT05812339|DEVICE|Gastric Alimetry System|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
214900606|NCT07111104|RADIATION|Radiotherapy|The radiotherapy intervention involves targeted delivery of ionizing radiation to metastatic lesions. Radiotherapy may be given either concurrently with immunotherapy or sequentially afterward, depending on the patient's treatment plan. The purpose is to achieve local tumor control and potentially enhance the systemic immune response through immunogenic cell death. Different radiation techniques and dose regimens may be employed based on lesion size, location, and clinical considerations.
214900607|NCT06034080|OTHER|Changes to the electronic health record (EHR)|"EHR changes will include minor changes to prescription fields to make it easier for clinicians to order wait and see antibiotics to be filled only if the child worsens or does not improve rather than antibiotics to take immediately."
214900608|NCT06034080|OTHER|Individualized audit and feedback reporting for clinicians|Automated audit and feedback reports detailing participating clinicians' antibiotic prescribing habits for AOM both individually and in comparison to their peers will be shared with clinicians on a quarterly basis throughout the intervention period.
214900609|NCT06034080|OTHER|Clinician education sessions|Virtual education sessions will be held for clinicians to learn more about national guidelines for antibiotic prescribing for AOM, etc. The sessions will be recorded and distributed to clinicians who were unable to attend. Attendance of these sessions will apply toward continuing medical education credits for participants.
214900610|NCT06034080|OTHER|Use of a shared decision-making (SDM) aide|A previously validated SDM aide for AOM will be used by clinicians during visits with children with AOM. The aide will be available online and in paper form.
214900611|NCT06034080|OTHER|Shared decision-making (SDM) education|Clinicians will receive education on SDM and how to use the aid via virtual, recorded sessions.
214900612|NCT04566900|BEHAVIORAL|Neurofeedback|Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
214900613|NCT04566900|OTHER|Placebo|Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
214900614|NCT04821622|DRUG|talazoparib plus enzalutamide|experimental arm
214900615|NCT04821622|DRUG|Placebo plus enzalutamide|Active comparator arm
214900616|NCT06581965|OTHER|Short duration prophylaxis|"Only during hospitalization: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guideline Antitrombotisch beleid. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use (same type as used for control group)."
215054491|NCT04405440|BEHAVIORAL|Behavioral avoidance task|Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
215054492|NCT03572231|DRUG|mirabegron|oral
215054493|NCT03572231|DEVICE|solifenacin|oral
215054494|NCT03572231|DRUG|darifenacin|oral
215054495|NCT03572231|DRUG|imidafenacin|oral
215054496|NCT03572231|DRUG|tolterodine|oral
215054497|NCT03572231|DRUG|oxybutynin|oral
215054498|NCT03572231|DRUG|trospium|oral
214301456|NCT03318250|DEVICE|Dorsal Root Ganglion Stimulation|During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
215054499|NCT03572231|DRUG|fesoterodine|oral
215054500|NCT03572231|DEVICE|propiverine|oral
215054501|NCT05977816|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
215054502|NCT05977816|OTHER|Standard wound dressing|Application of a standard wound dressing to the wound post laparotomy
215054503|NCT01986894|DRUG|Placebo|Single oral dose of Placebo
215054504|NCT01986894|DRUG|Pomalidomide|Single oral dose of 4 mg pomalidomide
215054505|NCT01986894|DRUG|Pomalidomide|Single oral dose of 20 mg pomalidomide
215054506|NCT01986894|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
215054507|NCT05965076|PROCEDURE|Glycine Perio Flow|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss and glycine perio-flow.
215054508|NCT05965076|BEHAVIORAL|Angled Toothbrush|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and an angled toothbrush.
214301457|NCT01127412|BEHAVIORAL|Physical activity stimulating program|
214301458|NCT05539391|OTHER|Data patient|Medical History and characteristic of patient
214301459|NCT05539391|OTHER|Physical examination|Arterial pressure, arterial oxygen saturation, heart rate
214301460|NCT05539391|PROCEDURE|Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB|Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.
215054509|NCT05965076|PROCEDURE|Standard Professional Oral Hygiene|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss.
215054510|NCT05965076|BEHAVIORAL|Standard Domiciliary Oral Hygiene|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and a standard toothbrush.
215054511|NCT00662831|DRUG|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
215054512|NCT00662831|DRUG|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
215054513|NCT02678962|DEVICE|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
215054514|NCT02678962|DEVICE|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
214900617|NCT06581965|OTHER|Higher intensity and longer duration prophylaxis|"The use of any thrombocyte aggregation inhibitors should be discontinued 5 days prior to surgery. Day 0-2: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.~Day 3: Apixaban 5mg b.i.d., continued until 6 weeks after surgery, conditional on the fact that no active bleeding of the surgical wound can be observed. In case of active bleeding, the prophylactic dose of thrombosis prophylaxis is continued. Thereafter, in case no active bleeding has been observed for 24 hours, the 5mg b.i.d. apixaban treatment will be started.~The 5mg b.i.d. apixaban dose will be adjusted to 2.5mg b.i.d. in case of an impaired kidney function (defined as eGFR 10-30ml/min)."
214900618|NCT06581965|OTHER|Control|4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.
214900619|NCT02562235|DRUG|Riociguat (Adempas, BAY63-2521)|For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
214900620|NCT02695251|OTHER|low AGE meal|Patients will receive a low AGE (eggs) meal
214900621|NCT02695251|OTHER|High AGE meal|Patients will receive a high (mixed nuggets) AGE (eggs) meal
214900622|NCT06807970|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Patients in intervention group will have GLP-1RA semaglutide for 48 weeks and then stops for one month before and after TKR following the latest anesthesia guideline for GLP-1RA. Followed by TKR They will continue semaglutide for 48 weeks during the post-operative follow-up period. This is decided based on balancing treatment effect of semaglutide, waiting time for TKR, and TKR follow-up requirement. In Hong Kong, waiting time for TKR would be \~4 years and so a period of 12 months treatment of semaglutide is reasonable. And in the STEP 6 trial, weight loss at week 52 (-12%) is similar to that in study end at week 68(-13·2%), and STEP5 trial showed maintaining semaglutide to week 104 could maintain weight loss of similar degree as in week 52. And the consensus of assessing TKR Patient-Reported Outcome Measures (PROMs) is one year follow up.
215054515|NCT02678962|DEVICE|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
215054516|NCT02678962|DEVICE|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
214669521|NCT06447012|DIAGNOSTIC_TEST|Colonoscopy|No intervention required from this study, however images will be obtained from patient presenting for colonoscopy
214669522|NCT02437669|DRUG|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
214669523|NCT03976089|BEHAVIORAL|Recipe 4 Success|"The Recipe 4 Success intervention consisted of 10 weekly lessons in which parents and toddlers prepared simple snacks or meals.~All Recipe 4 Success lessons started and ended with some evidence-based information for the parents about children's self-regulation skills or healthy eating habits. Most of each lesson in Recipe 4 Success was devoted to the snack or meal preparation activities. Each week, home visitors coached the parents as they worked with their toddlers to make increasingly challenging snacks and meals. During these activities, home visitors pointed out opportunities for parents to practice sensitive scaffolding strategies. At the same time, these meal and snack preparation activities allowed children to practice multiple age-appropriate self-regulation skills."
214669524|NCT03976089|BEHAVIORAL|Treatment as Usual Early Head Start|Treatment as Usual Early Head Start consisted of an evidence-based curriculum (usually Parents as Teachers) in which home visitors and parents worked with children on activities to support their physical, cognitive, and social-emotional development.
214900623|NCT06807970|OTHER|Control (Standard treatment)|If patients are randomized to the control group, they will receive routine follow-up with general advice on diet and physical activity but will not receive semaglutide, and will not be offered a specific management program for their weight. This is in line with current practice.
214900624|NCT03030378|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
214900625|NCT03030378|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214669525|NCT00704106|DRUG|Entecavir|0.5 or 1 mg dose qd
214900626|NCT03030378|PROCEDURE|Computed Tomography|Undergo a CT scan
214900627|NCT03030378|BIOLOGICAL|Edodekin alfa|Given SC
214900628|NCT03030378|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
215054517|NCT02678962|DEVICE|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
215054518|NCT02678962|DEVICE|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
215054519|NCT01470131|DRUG|Masitinib|Masitinib 6 mg/kg/day
215054520|NCT01470131|DRUG|Placebo|Matching placebo
215054521|NCT01470131|DRUG|Bortezomib|Standard therapy (cycles of bortezomib)
215054522|NCT01470131|DRUG|Dexamethasone|Standard therapy (cycles of dexamethasone)
215054523|NCT04213469|BIOLOGICAL|PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells|Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1
215054524|NCT05274412|OTHER|hypotension prediction index(HPI)|Implementing hypotension prediction index (HPI) in perioperative goal-directed hemodynamic therapy. Keep HPI \< 85; pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
215054525|NCT05274412|OTHER|ordinary goal-directed hemodynamic therapy|Keep pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
214900629|NCT03030378|BIOLOGICAL|Pembrolizumab|Given IV
214900630|NCT03030378|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
214900631|NCT05445830|PROCEDURE|High-Intensity-Interval-Exercise|Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
214900632|NCT05445830|PROCEDURE|Moderate-Intensity-Continuous-Exercise|Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
214900633|NCT05445830|PROCEDURE|Strength training|Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
214900634|NCT05445830|PROCEDURE|Baseline assessment|Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
214900635|NCT05445830|PROCEDURE|1 year follow-up|Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
214900636|NCT04291612|OTHER|Physical exam|Part 2 participants will be prospectively followed clinically for relapse for 30 months from the date of surgery for physical examination at post-ops visits.
214900637|NCT05878769|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W
214900638|NCT04214535|DEVICE|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Anterior Cage for one or two-levels
214900639|NCT05039801|BIOLOGICAL|Bevacizumab|Given IV
215054526|NCT02449811|DRUG|Perindopril|
215054527|NCT02449811|DRUG|Olmesartan|
215054528|NCT02449811|DRUG|Amlodipine|
215054529|NCT02449811|DRUG|Hydrochlorothiazide|
214900640|NCT05039801|DRUG|Glutaminase-1 Inhibitor IACS-6274|Given by PO
214900641|NCT05039801|DRUG|Paclitaxel|Given by IV (vein)
214900642|NCT05039801|DRUG|Capivasertib|Given by PO
214900643|NCT06369012|DRUG|Mefenamic acid 500 mg|To compare the effectiveness of mefenamic acid versus tranexamic acid in the management of abnormal uterine bleeding.
214900644|NCT06465316|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214900645|NCT06465316|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214900646|NCT06465316|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214900647|NCT06465316|PROCEDURE|Computed Tomography|Undergo PET/CT
214900648|NCT06465316|DRUG|Iberdomide|Given PO
215054530|NCT01819207|OTHER|blood test by thromboelastography|
215054531|NCT00192920|BEHAVIORAL|Transfusion practice|
215054532|NCT00115271|DRUG|Nutritional supplements|
215054533|NCT04496908|PROCEDURE|amniotomy|Artificially rupturing membranes
215054534|NCT04496908|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline.
215054535|NCT04496908|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
214900649|NCT06465316|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR
214900650|NCT06465316|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MR
214900651|NCT06465316|DRUG|Teclistamab|Given SC
215054536|NCT01798901|DRUG|HDAC inhibitor AR-42|Given PO
215054537|NCT01798901|DRUG|decitabine|Given IV
215054538|NCT01798901|OTHER|laboratory biomarker analysis|Correlative studies
215054539|NCT01798901|OTHER|pharmacological study|Correlative studies
215054540|NCT05667883|DRUG|glucocorticoid + cytoxan|The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
215054541|NCT06345261|DRUG|DiphenhydrAMINE 50 Mg/mL Injectable Solution|injection of Diphenhydramine 50 Mg/mL
215054542|NCT06345261|DRUG|Saline|injection of saline
215054543|NCT00816491|DEVICE|conventional white light colonoscopy|conventional white light colonoscopy
215054544|NCT00816491|DEVICE|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
214301461|NCT05539391|PROCEDURE|Rapid sequence intubation (RSI) : Recommendations for emergency intubation|Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
214301462|NCT04390204|OTHER|intervenions|"* Motor control exercises~* A supervised home self-rehabilitation program"
214301463|NCT03880019|PROCEDURE|Computed Tomography|Undergo CT
214301464|NCT03880019|PROCEDURE|Core Biopsy|Undergo tumor biopsy
214301465|NCT03880019|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214301466|NCT03880019|DRUG|Olaparib|Given PO
214301467|NCT03880019|DRUG|Temozolomide|Given PO
214301468|NCT03752112|DRUG|Cefixime|Cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection
214900652|NCT05016960|BEHAVIORAL|Sleep-SMART|Sleep-SMART is a telehealth delivered treatment for insomnia that follows the standard 6 session 50-minute Cognitive Behavioral Therapy for Insomnia (CBT-I) format. Sleep-SMART delivers CBT-I treatment along with training in select cognitive strategies from CogSMART to enhance intervention learning and adherence.
214900653|NCT06846203|OTHER|Core stabilization Exercise Group|"This group will be subjected to following core stabilization exercises:~1: Sit-up-1, 2: Sit-up-2, 3: Back extention-1, 4: Back extention-2 , 5: Front plank, 6: Back bridge , 7: Quadruped , 8:Side bridge A combination of activities will be administered and alterations will be made every session.~Session will be held 3 times per week for 8 consecutive weeks."
214900654|NCT06846203|OTHER|Neuromuscular Fascilitation Exercise Group|"This group will be subjected to neuromuscular facilitation exercises :~Week 1: McGill curl up, Week 2: Bird dog stretch, Week 3: Side bridge or mermaid side bridge with bent knees, Week 4: Single leg stretching, Week 5: Shoulder bridge Week 6: Tai chi Warrior stance, Week 7 \& 8: Cat - cow - downward facing dog, Hip circumduction, hamstring stretching, starting position Session will be held 3 times per week for 8 consecutive weeks"
214900655|NCT04796961|OTHER|Implementation Intervention|The implementation intervention involves training, coaching, expert consultation, organizational strategy meetings.
214900656|NCT02361528|DRUG|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
215054545|NCT03120663|DRUG|amoxicillin-clavulanic acid|"During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.~Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² ."
215054546|NCT00154817|PROCEDURE|radiotherapy|
215054547|NCT04850924|OTHER|evaluation psychological trauma|9 classes of symptoms to be evaluated
215054548|NCT01903772|OTHER|Inspiratory Muscle Training|
215054549|NCT05103553|OTHER|Outpatient Clinic|Follow-up in outpatient clinic
215054550|NCT05434793|DEVICE|RJ-LASER, LASERPEN®; Reimers & Janssen, Germany|The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
214301469|NCT03752112|DRUG|Benzathine penicillin 2.4 million units|Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
214478989|NCT05447338|PROCEDURE|Myofascial induction, of the fascia of the subscapularis muscle|Position of the patient, supine, with the arm raised about 90-160 degrees, depending on the degree of movement restriction. Therapist position, standing at the head of the table. Phase A With his cranial hand, the therapist holds the patient's arm and performs very gentle traction. The palm of the caudal hand, thumb up, is placed on the outer edge of the scapula, as close as possible to the glenohumeral joint. A slight traction is performed with both hands in opposite directions, subsequently following the direction of release. Phase B, The thumb of the caudal hand slightly invades the space between the inner aspect of the scapula and the thorax. The rest of the application is performed as in phase A. Phase C, the therapist places his caudal hand in a prone position and slowly penetrates the aforementioned space with the tips of the fingers. sustained for a time ranging between 90 seconds and 5 minutes, following the release stages.
214900657|NCT02361528|DRUG|Placebo|placebo subcutaneously, for 5 days
214900658|NCT05289193|DIAGNOSTIC_TEST|PET Scan|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
214900659|NCT05289193|DRUG|Nivolumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
214900660|NCT05289193|DRUG|Ipilimumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
215054551|NCT00600275|DRUG|BGT226|
215054552|NCT00125814|DRUG|Interferon alfa-2b|
215054553|NCT00125814|PROCEDURE|Structured treatment interruptions|
215054554|NCT01747343|BEHAVIORAL|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
214301470|NCT02432534|DRUG|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
214301471|NCT02432534|OTHER|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
215054555|NCT06179810|OTHER|Baduanjin exercise|Baduanjin exercise
215054556|NCT01061723|DRUG|Sarilumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
215054557|NCT01061723|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
215054558|NCT02078050|OTHER|Phrenic nerves magnetic stimulations|
215054559|NCT01811069|PROCEDURE|Head up|30˚ reverse trendelenburg body position
215054560|NCT02795624|PROCEDURE|Spirometry|Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
215054561|NCT02795624|PROCEDURE|Pulse Wave Analysis|It is a non-invasive assessment of the pulse character
214900661|NCT05289193|PROCEDURE|Surgical Resection of Melanoma|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
214900662|NCT05986630|DEVICE|TEOSYAL® TPVM|"Injection of TEOSYAL® TPVM at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
214900663|NCT05986630|DEVICE|COMPARATOR|"Injection of a COMPARATOR at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
214900664|NCT01376752|PROCEDURE|Maximal cytoreductive surgery|Maximal cytoreductive surgery
214900665|NCT01376752|DRUG|HIPEC|HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
214900666|NCT05096273|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations
214900667|NCT06570759|PROCEDURE|Early intervention for OMI|Early PCI for OMI (+) STEMI (-) patients
214900668|NCT06570759|PROCEDURE|Standard early intervention for STEMI|Early PCI for OMI (+) and STEMI (+) patients
214900669|NCT06570759|PROCEDURE|Standard delayed intervention for NSTEMI|Medical stabilization and then PCI for OMI (-) and STEMI (-) patients
214900670|NCT06041958|DEVICE|Extracorporeal shock wave therapy|2 times/week for 12 weeks
214900671|NCT06041958|DEVICE|Pulse electromagnetic field therapy|2 times/week for 12 weeks
214900672|NCT06041958|OTHER|Rehabilitation|2 times/week for 12 weeks
214900673|NCT01534819|DEVICE|EndoAnchor™|Use of the EndoAnchor™ in conjunction with endograft
214900674|NCT01534819|PROCEDURE|endovascular treament|implantation of a device inserted through an artery
214900675|NCT06207942|DEVICE|Feed back controlled temperature device|If core temperature exceeds 37.7 degrees celsius a feedback controlled-device will be used at set to 37.5 degrees celsius
214900676|NCT06207942|OTHER|High MAP|A mean arterial blood pressure (MAP) of \>85mmHg will be used. Vasopressors will be titrated to this target during 36 hours
214900677|NCT06207942|OTHER|Deep sedation|Deep sedation for at least 36 hours
214900678|NCT06207942|OTHER|Fever control without a device|Management of fever in the intensive care unit without a device
214900679|NCT06207942|OTHER|Low MAP|A mean arterial blood pressure (MAP) of \>65mmHG will be used. Vasopressors will be titrated to this target during 36 hours
215054562|NCT02795624|PROCEDURE|Peripheral arterial tonometry|It is a non-invasive method to measure endothelial dysfunction.
215054563|NCT03935789|BEHAVIORAL|BLAST|12-week self-guided intervention using a web-based platform
214900680|NCT06207942|OTHER|Minimal sedation|A strategy of minimal sedation in the intensive care unit, used only as needed to facilitate transport, imaging and invasive procedures
215054564|NCT05197933|PROCEDURE|Laparoscopic resection|Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
215054565|NCT02152475|DRUG|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
215054566|NCT02152475|DEVICE|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
215054567|NCT01631201|DRUG|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
215054568|NCT01631201|DRUG|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
215054569|NCT02476032|DEVICE|Prof applied oxalate|Crest Sensi-Stop strips (Procter \& Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
215054570|NCT02476032|DEVICE|Self applied oxalate|Subjects will apply the strips (Procter \& Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
215054571|NCT02476032|DEVICE|Prof applied placebo|Crest Sensi-Stop strips (Procter \& Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
215054572|NCT05077540|DRUG|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
215054573|NCT05077540|DRUG|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
214301472|NCT04906551|DEVICE|laser Doppler|A direct measure of blood flow
214301473|NCT03744533|OTHER|head-down position treatment|the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.
214301474|NCT03744533|OTHER|guideline-based treatment|guideline-based treatment
214301475|NCT00957073|DEVICE|Rheos® system|Implant procedure
214301476|NCT00326950|DRUG|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
214301477|NCT06114147|DEVICE|trans thoracic echocardiography measure|The trans thoracic echography would be carried out with cardiac classic sections to ensure the structural cardiac and valvular normality and then sections repeated 3 times over 10 minutes will be carried out to calculate the cardiac output.
214301478|NCT06114147|DEVICE|ICON measure|The ICON will be placed at the beginning of the consultation and the measurements will be taken at the same time as the trans thoracic ultrasound in the left lateral decubitus position.
214301479|NCT06114147|DEVICE|USCOM|Afterwards, measurements will be made with USCOM in left lateral position and 3 of the best spectra archived according to the Fremantle score.
214301480|NCT02607891|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
214301481|NCT02607891|DRUG|Placebo|Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
214900681|NCT03685448|DRUG|Cabozantinib|The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
214900682|NCT04496479|BIOLOGICAL|LYG-LIV0001|Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.
214900683|NCT02218463|DRUG|Estradiol cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
214900684|NCT02218463|DRUG|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
214900685|NCT05738187|PROCEDURE|local cryotherapy treatment|cryotherapy
214900686|NCT05136820|DEVICE|Atrial Flow Regulator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
214900687|NCT05136820|DEVICE|Sham Comparator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
214900688|NCT05730257|PROCEDURE|Robot-Assisted Kidney Transplantation|Robot-Assisted Kidney Transplantation takes place with the patient under general anaesthesia. Several ports are placed in the lower abdomen, for the entry of the camera, surgical instruments and manuel access. The DaVinci robot is placed between the patient's legs and docked to the ports. The iliac vascular bed is prepared and a peritoneal cavity created laterally. The kidney is introduced through the handport, regional hypothermia obtained via iceslush in the cavity and the vessel lumens flushed with heparin. The vessels are blocked during suturing with the kidney graft vessels anastomosed end-to-side to the external iliac vessels. The kidney graft is placed in the retroperitoneal cavity and a ureterovesical anastomosis performed ad modem Woodruff over double J stent. The ureter is placed extra peritoneally, fascia closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
214900689|NCT05730257|PROCEDURE|Open Kidney Transplantation|Open Kidney Transplantation takes place with the patient under general anaesthesia. A jockey-stick (Gibson) incision is made in the left or right iliac fossa and the peritoneum is displaced. With the kidney under hypothermia, the iliac vascular bed is prepared, the vessel lumens flushed with heparin and a vascular clamp instrument is used to block the vessels during suturing. The kidney graft vessels are anastomosed end-to-side to the external iliac vessels and the ureterovesical anastomosis performed ad modem Woodruff over a double J stent. The kidney graft is placed in the cavity and the fascia is closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
214900690|NCT03700125|PROCEDURE|ECMO resuscitation|Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
214900691|NCT06384417|BEHAVIORAL|Hello for Cancer game|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~The questions used in Hello for Cancer were modified from the original Hello game based on the results of phase 1 of testing this game in cancer populations. The modifications made to the game will be assessed for acceptability during this study."
214900692|NCT06384417|OTHER|Table Topics game|To play Table Topics, players are provided a deck of cards that have a variety of general conversation starter questions. The group takes turns selecting a card and reading it to the group for the group to answer. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
214900693|NCT05965518|BEHAVIORAL|High-Intensity Interval Training|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
214900694|NCT05965518|BEHAVIORAL|Continuous Moderate Exercise|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
214900695|NCT06067230|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
214900696|NCT05696301|DEVICE|Winback® on|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is activated."
214900697|NCT05696301|DEVICE|Winback® off|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is not activated."
214669526|NCT04297007|OTHER|PECS block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
214900698|NCT05696301|BEHAVIORAL|self-massage of the scar|The women in both groups will have the standard recommended treatment: manual self-massage of the scar. Women's instruction in this self-massage will be structured and identical for both groups, including the provision of an informational document describing how to perform the massage. This training will be provided immediately after randomization and before the intervention or control measures.
214900699|NCT02513160|DRUG|Beclomethasone Dipropionate 640|Beclomethasone Dipropionate 640 mcg BAI
214900700|NCT02513160|DRUG|Placebo|"Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug."
214900701|NCT02513160|DRUG|Beclomethasone dipropionate via 320 mcg BAI|Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
214900702|NCT02513160|DRUG|albuterol/salbutamol|Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
214900703|NCT02513160|DRUG|Beclomethasone dipropionate via 320 mcg MDI|Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
214900704|NCT00070031|DRUG|edotecarin|
214900705|NCT06575803|OTHER|clinical measurements and evaluation|clinical performance of single restorations fabricated for the patients from pressed and repressed ceramics
214900706|NCT05902884|DEVICE|MSOT Acuity Echo|Imaging of muscles applying Multi-spectral optoacoustic tomography (MSOT)
214900707|NCT02844543|DEVICE|EYE-SYNC eye-tracking device|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
214900708|NCT02844543|OTHER|SCAT-3|The Symptom subtest of SCAT-3 assessment tool will be administered to participants.
214900709|NCT02844543|DEVICE|Desktop Eye-Tracker|Eye movements are recorded with an eye tracking system (Desktop Eye-Tracker, Eyelink CR, SR Research) with up to 1000 Hz temporal resolution. The target stimulus is presented on a computer screen approximately 50 cm from the participant. Participants are asked to follow a dot with their eyes, as the dot moves on the monitor screen of the desk-top eye-tracking device.
214900710|NCT05147415|OTHER|Placebo|Inactive comparator
214900711|NCT05147415|DRUG|Tesomet|Fixed-dose combination
214900712|NCT02133560|BEHAVIORAL|Video recording|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
214900713|NCT02133560|BEHAVIORAL|Medication Administration Log|Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
214900714|NCT02133560|BEHAVIORAL|Education|"During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.~Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation."
214900715|NCT03220204|BEHAVIORAL|PP-based health behavior intervention|The positive psychology exercises include 3 modules: gratitude-based activities, strength-based activities, and meaning-based activities. The goal-setting portion of the program focuses primarily on physical activity (8 weeks) but also includes 4 weeks focusing on diet and medication adherence.
214900716|NCT03220204|BEHAVIORAL|MI-based educational control condition|The MI-based educational program includes information on five topics: (1) information about heart disease and risk factors for worsening heart disease, (2) physical activity, (3) a heart-healthy diet, (4) medication adherence, and (5) stress management.
214900717|NCT01921868|DRUG|Acetyl-L-Carnitine|Acetyl-L-Carnitine, 2 g/day, up to 24 months.
214900718|NCT03241862|DEVICE|Restylane® Silk|Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
214669527|NCT04297007|OTHER|Rhomboid intercostal block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
214900719|NCT04071210|DIETARY_SUPPLEMENT|Probiotic tablet|Probiotic tablet twice a day for 12 weeks
214900720|NCT04071210|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet twice a day for 12 weeks
214900721|NCT01028547|DRUG|dexamethasone|single Bolus dose of dexamethasone 8mg
214900722|NCT01028547|OTHER|normal saline|2 ml 0.9% saline
214900723|NCT03588754|DRUG|Propranolol|Propranolol Extended Release (160mg/day).
214900724|NCT03588754|DRUG|Placebo|Placebo pill administered orally.
214900725|NCT00728260|BIOLOGICAL|None administered in this study|N/A in this study
214900726|NCT05483023|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
214900727|NCT05414500|DRUG|Mogamulizumab|Administered IV
214900728|NCT05414500|DRUG|Brentuximab vedotin|Administered IV
214900729|NCT06167499|OTHER|Diabetes Therapeutic Education conducted by nurses|"Individual consultations with the therapeutic education IDE, who will help the patient to achieve the therapeutic objectives set before the medical consultation.~Once the objectives have been set, the IDE will set up individual workshops and subsequently assess the patient's learning and its impact on his or her care. These workshops can include equipment demonstrations and practical exercises, explanations of treatment adaptation protocols, and dietary or sexual advice."
214478990|NCT05447338|PROCEDURE|Intraoral myofascial induction of the masseter|Position of the patient, supine position, on the stretcher without the pillow. Position of the therapist, sitting at the head of the table. Technique: The therapist, with the index of his hand, contacts the masseter just below the zygomatic arch and inside the mouth. To ensure proper contact on the masseter, the patient is asked to attempt to close the mouth. Once the muscle is correctly located, the patient should immediately relax the masseter. Next, the therapist compresses the masseter between his index finger and thumb. You have to wait long enough for the release to occur. Sometimes both hands are used by placing the forefinger of the other hand on the outer surface.
214900730|NCT04710576|DRUG|Axatilimab|Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.
214900731|NCT05726981|PROCEDURE|Fine needle aspiration biopsy (FNAB)|"Thyroid FNAB is a minimally invasive procedure performed routinely by an experienced sonographer.~It is a safe and brief procedure, performed with a 27G or 25G (very fine) needle (3 needles, i.e. 1 needle per pass)"
214900732|NCT03779854|RADIATION|Total-Body Irradiation|Undergo TBI
214900733|NCT03779854|DRUG|Thiotepa|Given IV
214900734|NCT03779854|DRUG|Fludarabine|Given IV
214900735|NCT03779854|DRUG|Cyclophosphamide|Given IV
214900736|NCT03779854|DRUG|Busulfan|Given IV
214900737|NCT03779854|PROCEDURE|Allogeneic Bone Marrow Transplantation|Receive unmanipulated T cell replete BM
214900738|NCT03779854|DRUG|Tacrolimus|Given IV
214900739|NCT03779854|DRUG|Methotrexate|Given IV
214900740|NCT03779854|PROCEDURE|Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation|Receive naive T-cell depleted PBSCs
214900741|NCT03779854|PROCEDURE|Echocardiography|Undergo ECHO
214900742|NCT03779854|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
214900743|NCT03779854|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214900744|NCT03779854|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214900745|NCT01188525|DRUG|10 parents drugs adminstration|A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
214900746|NCT03581500|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
214900747|NCT03581500|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
214900748|NCT06153836|PROCEDURE|Neurotization Procedure|Undergo placement of nerve graft
214900749|NCT06153836|OTHER|Questionnaire Administration|Ancillary studies
214900750|NCT06153836|PROCEDURE|Subcutaneous Mastectomy|Undergo standard of care NSM
214900751|NCT05682066|DEVICE|Innovalve MR system|Innovalve MR system
214900752|NCT03428958|DRUG|NUC-3373 + leucovorin|NUC-3373 + leucovorin
214900753|NCT03428958|DRUG|NUC-3373|NUC-3373
214900754|NCT03428958|DRUG|NUFOX|NUC-3373 + oxaliplatin
214900755|NCT03428958|DRUG|NUFOX + VEGF pathway inhibitor|NUC-3373 + oxaliplatin + bevacizumab
214900756|NCT03428958|DRUG|NUFOX + EGFR inhibitor|NUC-3373 + oxaliplatin + cetuximab/panitumumab
214900757|NCT03428958|DRUG|NUFIRI|NUC-3373 + irinotecan
214669528|NCT04754373|DIETARY_SUPPLEMENT|GFA-918|Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.
214669529|NCT04754373|OTHER|Placebo|Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
214900758|NCT03428958|DRUG|NUFIRI + VEGF pathway inhibitor|NUC-3373 + irinotecan + bevacizumab
214900759|NCT03428958|DRUG|NUFIRI + EGFR inhibitor|NUC-3373 + irinotecan + cetuximab/panitumumab
214900760|NCT03428958|DRUG|NUC-3373 + bevacizumab|NUC-3373 + bevacizumab
214900761|NCT06167434|DEVICE|Future Cardia™ Insertable Cardiac Monitoring (ICM) System|The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.
214900762|NCT02971501|BIOLOGICAL|Bevacizumab|Given IV
214900763|NCT02971501|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214900764|NCT02971501|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214900765|NCT02971501|PROCEDURE|Computed Tomography|Undergo CT scan
214900766|NCT02971501|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214900767|NCT02971501|DRUG|Osimertinib|Given PO
214900768|NCT05660109|DRUG|TPM502|TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
214900769|NCT05660109|OTHER|Placebo|Placebo
214900770|NCT06513728|OTHER|MPACT Intervention|MPACT has 4 components: accredited training about patient centered, trauma informed methadone treatment, staff education about trauma symptoms with navigation to self screening and treatment or stress management, clinic self assessment tools for trauma informed, patient centered care, and reflective supervision for counselors, case managers and peer staff.
214900771|NCT04969133|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|To compare TAP block versus local infiltration of the trocar wounds with levobupivacaine 2.5 mg/ml for post operative pain relief after laparoscopic appendicectomy in children
214900772|NCT05382442|DRUG|AK112|AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity
214900773|NCT05382442|DRUG|AK117|AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity
214900774|NCT05382442|DRUG|Oxaliplatin|Oxaliplatin via IV infusion
214900775|NCT05382442|DRUG|Capecitabine|Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
214900776|NCT05382442|DRUG|Irinotecan|Irinotecan via IV infusion
214900777|NCT05382442|DRUG|Leucovorin|Leucovorin via IV infusion
214900778|NCT05382442|DRUG|5-fluorouracil|5-fluorouracil via IV infusion
215054574|NCT04245449|BEHAVIORAL|TEAACH|"TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required \~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities."
215054575|NCT04346186|DIAGNOSTIC_TEST|IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2
215054576|NCT04346186|DIAGNOSTIC_TEST|Elisa-test for IgM and IgG to SARS-CoV-2|Elisa-test for IgM and IgG to SARS-CoV-2
215054577|NCT01135888|DEVICE|Skin cooling devices|Cooling vest and cooling bandana
215054578|NCT05508542|BEHAVIORAL|Progressive relaxation exercises|Personal information form, Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be applied to the pregnant women at the first interview. Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. Afterwards, the Relaxation Exercises CD will be played and the exercises will be performed with the patient along with the CD. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.
215054579|NCT00164840|DRUG|Esomeprazole|
215054580|NCT03812341|OTHER|Experimental|KeraKlear Non-Penetrating Keratoprosthesis The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity
214900779|NCT05757700|BIOLOGICAL|19(T2)28z1xx TRAC T cell|"Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6"
215054581|NCT06028152|OTHER|"End-of-life conversation game called Hello"|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~Other Name: Previously named My Gift of Grace"
214900780|NCT05721937|DRUG|Abrocitinib|taken by mouth
214900781|NCT06031194|OTHER|Non-Interventional Study|Non-interventional study
215054582|NCT05203211|PROCEDURE|Testicular sperm extraction (TESE)|During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
215054583|NCT00286624|BIOLOGICAL|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
215054584|NCT00286624|DRUG|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
215054585|NCT00286624|DRUG|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
215054586|NCT00286624|DRUG|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
215054587|NCT00615225|PROCEDURE|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
214301482|NCT02002923|PROCEDURE|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
214669530|NCT01400828|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
214669531|NCT01400828|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
214900782|NCT05595642|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W
214900783|NCT05595642|DRUG|Placebo|Participants will receive SC placebo Q2W
214900784|NCT04859296|DRUG|Placebo|Vaporized placebo
214900785|NCT04859296|DRUG|Low CBG|Vaporized CBG (5 mg)
214900786|NCT04859296|DRUG|High CBG|Vaporized CBG (15 mg)
214900787|NCT04859296|DRUG|Low THC|Vaporized THC (5 mg)
214900788|NCT04859296|DRUG|High THC|Vaporized THC (15 mg)
214900789|NCT05226507|DRUG|NXP800|NXP800 is an anti-neoplastic, oral small molecule.
214900790|NCT06271850|OTHER|Ergonomics breastfeeding training|The ergonomics training includes the most ergonomically appropriate methods to breastfeed and ergonomic guidelines, including how to cuddle and breastfeed the baby correctly.
214301483|NCT02002923|DRUG|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
214301484|NCT05185128|BEHAVIORAL|PEERS social skills intervention|The PEERS treatment program consists of 90-minute sessions, delivered once a week over the course of 16- weeks. Parents and children/adolescents attend separate concurrent sessions that instruct them on key elements about making and keeping friends. Among others, this parent-assisted, social skills intervention provides explicit instruction to target verbal and nonverbal communication skills, appropriate use of humor and resolving peer conflict, as well as expanding and developing friendship networks38. The candidate, Dr. Nair, has been trained on the PEERS social skills intervention extensively for the past five years, and is a certified provider for the adolescent program. The PEERS program will be provided by Dr. Nair's research team (consisting of Dr. Nair, lab co-ordinators, and clinical psychology doctoral students) through the LLU Department of Psychology.
214301485|NCT00519818|DRUG|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
214301486|NCT00519818|DRUG|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
214478991|NCT05447338|PROCEDURE|Deep myofascial induction of the external pterygoid|"Objective, release the myofascial restrictions and recover the functional coordination of the external pterygoid muscles.~Position of the patient, supine position, on the stretcher without the pillow. Therapist position, sitting at the head of the table. Technique: The therapist palpates the temporomandibular joint with the index or middle finger of one hand. With the index finger of the other hand, he contacts the pterygoid inside the mouth and maintains pressure until release occurs."
214669532|NCT01400828|DRUG|Placebo|(encapsulated) Tablets QD/14 days
214669533|NCT02286960|DRUG|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
214669534|NCT02286960|DIETARY_SUPPLEMENT|Lactose Pills|4 day course 2 x 20mg per da
214301487|NCT03718767|DRUG|Nivolumab|IV Nivolumab
214669535|NCT00440401|DRUG|fibrinogen (human) + thrombin (human)|
214669536|NCT00440401|DRUG|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
214669537|NCT05064241|OTHER|Access to Genetic Counselor for answering questions|A genetic counselor answers questions posed by participants in the intervention arm on how to access genetic medicine. At the end of the study, the number of participants who were able to access genetic medicine will be assessed
215054588|NCT06084000|DEVICE|Drug-coated balloon (Bingo© [Paclitaxel-coated Balloon], Yinyi Ltd., China)|"* Patients treated with DCB will receive dual antiplatelet therapy (DAPT, aspirin plus P2Y12 inhibitor) for 1-3 months, followed by long-term single antiplatelet therapy (SAPT, aspirin or P2Y12 inhibitor).~* Patients with bailout stenting will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration in Drug-eluting stent Arm), and then followed by long-term SAPT."
215054589|NCT06084000|DEVICE|Drug-eluting stent|"* Patients treated with DES will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration below), and then followed by long-term SAPT.~* Special consideration:~  1. Patients will take additional assessment (both DAPT score and PRECISE-DAPT score) to determine their personalized duration of DAPT.~ 2. The duration of DAPT is extended to 12 months for patients diagnosed as acute coronary syndrome within 12 months.~ 3. If anticoagulation is indicated, patient will receive a short-term triple antithrombotic therapy (generally 1 to 4 weeks), followed by a variable length of dual antithrombotic therapy (oral anticoagulation (OAC) plus a single antiplatelet agent, preferably clopidogrel) and subsequent long-term OAC mono-therapy. The duration of dual antithrombotic therapy is determined by bleeding risks (HAS-BLED score) according to current guidelines."
215054590|NCT00395473|DRUG|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
215054591|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate venous blood sampling
214301488|NCT06698510|DRUG|Arpraziquantel 150mg dispersible tablet|Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics.
214301489|NCT06555783|DRUG|ALKS 2680|Oral tablet containing ALKS 2680
214301490|NCT06555783|DRUG|Placebo|Oral tablet containing placebo for once daily administration
214301491|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
214669538|NCT01288183|PROCEDURE|sham tDCS|"sham condition as delivered by the stimulator study mode (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day"
214669539|NCT01288183|PROCEDURE|active tDCS|anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
214669540|NCT02420886|OTHER|Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media|
214669541|NCT04616586|DRUG|Siltuximab|11 mg/kg IV administered over 1 hour
214669542|NCT04616586|OTHER|Normal Saline|IV administered over 1 hour
214669543|NCT02337842|BIOLOGICAL|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units.
214669544|NCT02337842|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
214669545|NCT02886104|PROCEDURE|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
214669546|NCT02886104|DEVICE|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
214669547|NCT01937312|DRUG|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
214669548|NCT01937312|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
214669549|NCT01937312|DRUG|Prostaglandin analogue|
214669550|NCT04269408|DRUG|Nicardipine|10 NicaPlant® implants releasing 4 mg nicardipine each.
214669551|NCT04269408|OTHER|Standard of care|Both arms receive the usual standard of care.
214669552|NCT06370247|DIAGNOSTIC_TEST|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K will measure
214669553|NCT01940718|DRUG|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (\~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
214669554|NCT05929534|DEVICE|active intermittent Theta Burst Stimulation|Each patient will receive two 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
214669555|NCT05929534|DEVICE|sham intermittent Theta Burst Stimulation|Each patient will receive two sham 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
214669556|NCT00474253|DRUG|Sugammadex|Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
214900791|NCT06271850|OTHER|Pilates exercises|Pilates exercises, 3 times per week, for 8 weeks, in the form of neck extensor stretching, neck extensor and rotation stretching, pectoral muscle stretching, strengthening of deep neck flexors and scapular retractor, and core strengthening exercises ( pelvic bridging, plank, cat and camel, curl up, single leg abdominal press and double leg abdominal press).
214301492|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
214301493|NCT04824170|OTHER|Neural Glide|hot pack and cervical traction is applied for 10-15 min.Group A received Neural mobilization of median nerve which includes gliding and sliding was given,therapist stood on the patient \& affected side besides the patient, patient'S shoulder was depressed with one hand and elbow was moved in 90 degree flexion, forearm supination, extend the wrist and fingers with other hand. Then patient arm was moved into 90 degree abduction and then sliding or gliding of nerve was applied. Sliding was applied with elbow extension and wrist flexion and elbow flexion with wrist extension. 6 sets were performed. Each set was performed for 60 seconds, for alternative days in week for 4 weeks and then progressed to gliding/tensioning technique when symptoms improved
214669557|NCT00474253|DRUG|Succinylcholine|Single bolus IV dose of 1.0 mg/kg succinylcholine
214669558|NCT00474253|DRUG|Rocuronium|Single bolus IV dose of 1.2 mg/kg rocuronium
214669559|NCT06338449|BEHAVIORAL|Aerobic training (AT)|An exercise program was developed by a full-time physical education teacher, with all group exercises conducted at the outdoor track and field facility of Xuzhou Medical University. Participants in the aerobic training group, after completing a warm-up, were required to perform moderate-intensity aerobic running for 60 minutes per session, 4-5 times a week. The exercise intensity was set to reach 50%-70% of the maximum heart rate (Maximum heart rate = 220 - age). The exercise sessions were scheduled in the evening after dinner, from 17:30 to 19:00.All participants were continuously intervened for 8 weeks.
214669560|NCT06338449|BEHAVIORAL|Resistance training (RT)|Participants in the resistance training group were required to complete moderate-intensity resistance exercises 4-5 times per week. Each session included a warm-up, followed by exercises such as knee lifts with torso twists, knee-to-hand taps under the hips, jumping jacks, burpees, sit-ups, planks, and squats. The routine was structured to perform 5-6 exercises per session, with 6-8 repetitions for each set. There was a 30-second rest interval between sets, and the total exercise time was 60 minutes. The timing for these exercise sessions was the same as for the AT group, conducted in the evening after dinner.All participants were continuously intervened for 8 weeks.
214900792|NCT06420349|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214900793|NCT06420349|PROCEDURE|Computed Tomography|Undergo CT
214900794|NCT06420349|BIOLOGICAL|Heat Shock Factor 1 Pathway Inhibitor NXP800|Given PO
214669561|NCT06338449|BEHAVIORAL|Combined aerobic and resistance training (AT + RT)|Participants in the combined aerobic and resistance training (AT+RT) group started their sessions with a warm-up, followed by 30 minutes of aerobic running. After the aerobic training, they engaged in resistance training. The resistance training regimen was the same as that for the RT group, except that the duration of the resistance training was shorter. The total duration of the exercise session was 60 minutes.All participants were continuously intervened for 8 weeks.
214900795|NCT06420349|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214900796|NCT06420349|PROCEDURE|Positron Emission Tomography|Undergo PET
214669562|NCT04442529|BEHAVIORAL|Mothers and Babies (MB)|Mothers and Babies is an evidence-based postpartum depression prevention intervention. It consists of 12 sessions which each last between 15-20 minutes. Intervention sessions are to be delivered either in person or by phone. The intervention is based on principles of cognitive-behavioral therapy (CBT).
214900797|NCT06420349|PROCEDURE|Ultrasound-Guided Biopsy|Undergo ultrasound-guided tumor biopsy
214900798|NCT01922037|DRUG|Omalizumab|Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
214900799|NCT03242850|BEHAVIORAL|Intervention Group|This group will view a video on shared reading upon enrollment, receive standard guidance on shared reading, and receive a series of text messages for a period of 6 months.
214900800|NCT05110417|DRUG|Pyridostigmine Bromide 60 Milligrams (mg)|One tablet will be provided to patients during the second visit.
215054592|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
215054593|NCT00057564|DRUG|A (Thalidomide + Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
215054594|NCT00057564|DRUG|B (Placebo + Dexamethasone)|Placebo + Dexamethasone 40mg
215054595|NCT01537315|DRUG|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
215054596|NCT01537315|OTHER|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
214478992|NCT05447338|PROCEDURE|Intraoral mifascial induction of the internal pterygoid|Objective, release the restrictions of the internal pterygoid fascia. Position of the patient, supine position on the stretcher. Therapist position, sitting laterally at the head of the stretcher and looking at the patient. Technique: Therapist palpates the TMJ with the index or middle finger of one hand. With the index of the other hand, he contacts the pterygoid inside the mouth and maintains pressure until release occurs. You have to wait three consecutive releases.
214669563|NCT05182736|BEHAVIORAL|TRAIL intervention|The TRAIL program is comprised of a multi-tier system of strategies: Universal strategies impact the entire school via a school-wide social norms marketing campaign and school-climate change activities. School staff trainings and professional development activities focus on enhancing protective factors for students to reduce the effects of stressful life events and trauma, improving classroom management, linking students to resources, and improving the overall school climate for students and staff. Targeted strategies include an in-school curriculum and service learning component, which impact all ninth grade students at the intervention high schools and all eighth grade students at the intervention middle schools. Intensive strategies are intended for a subset of youth and their caregivers with identified increased risk-factors, and they include peer mentoring, after-school running/positive youth development programming, summer programming, and parent workshop support.
214669564|NCT01480986|DRUG|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m\^2，ivgtt，90min，D1 Cisplatin 50 mg/m\^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
214669565|NCT00030576|DRUG|cisplatin|
214669566|NCT00030576|DRUG|erlotinib hydrochloride|
214669567|NCT04227691|DEVICE|Long-pulsed Nd Yag laser treatment|One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients
214669568|NCT04227691|DEVICE|IPL treatment|One treatment of the assigned axilla with IPL treatment in ten patients
214669569|NCT02273115|DRUG|Oxytocin|
214669570|NCT02273115|DEVICE|Transcervical Foley catheter|
214669571|NCT04348903|BEHAVIORAL|Virtual Reality Distraction|The researchers will prepare the VR device. The researches will explain the aim of using VR and adopt tell-show-do technique in introducing VR Glasses. Once VR device headset will be adapted to the child's head size and adjusted in front of his/her eyes, the selected 3D cartoon movie will be played in the waiting room and throughout the procedure of dental LA injection. After ensuring that the child is fully immersed in the cartoon movie, a needle of local anesthetic agent will be prepared and injected after explanation of the procedure.
214900801|NCT05502939|BEHAVIORAL|Music Program|"The cohort of students entering the program at the Colburn school in Los Angeles will be a part of a traditional strings curriculum. Students will join the program on a full scholarship and will be provided all materials necessary for instruction, including an instrument. Students will attend Colburn twice a week in a group setting and will receive private instruction once a week.~The program will last 2, 15-week semesters (fall, spring) for 2-years. There will be 2 groups of 10 students. Students will undergo group instruction for 1 hour, 2 times a week and private instruction for 45 minutes, once a week."
214900802|NCT05502939|BEHAVIORAL|After School Enrichment Program|The afterschool program will be led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members.
214900803|NCT03424005|DRUG|Capecitabine|Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.
214900804|NCT03424005|DRUG|Atezolizumab|"For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle."
214900805|NCT03424005|DRUG|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
214900806|NCT03424005|DRUG|SGN-LIV1A|SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
214900807|NCT03424005|DRUG|Bevacizumab|Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
214900808|NCT03424005|DRUG|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.~Or~Eribulin will be administered by IV, 1.4 mg/m\^2 on days 1 and 8 of each 21 day cycle."
214900809|NCT03424005|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
214900810|NCT03424005|DRUG|Tocilizumab|Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
214900811|NCT03424005|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.
214900812|NCT03424005|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
214900813|NCT03424005|DRUG|Abemaciclib|Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
214900814|NCT03424005|DRUG|Fulvestrant|Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
214900815|NCT03424005|DRUG|Ribociclib (dose #1)|Ribociclib tablets will be administered by mouth once daily.
214900816|NCT03424005|DRUG|Inavolisib (dose #2)|Inavolisib tablets will be administered by mouth once daily.
214900817|NCT03424005|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
214900818|NCT03424005|DRUG|Ribociclib (dose #2)|Ribociclib tablets will be administered by mouth once daily.
214900819|NCT03424005|DRUG|Letrozole|Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).
214900820|NCT03424005|DRUG|Inavolisib (dose #1)|Inavolisib tablets will be administered by mouth once daily.
215054597|NCT06069830|DRUG|4 cycles of ESA regimen with sandwiched radiotherapy|Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
215054598|NCT06069830|DRUG|2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
215054599|NCT06069830|DRUG|2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|PD-1 monoclonal antibody, 200mg, i.v. d1
215054600|NCT01971684|DRUG|Second Line ITP agents|The treating physicians will select the second line agent and clinical data will be collected.
215054601|NCT03938051|OTHER|Experimental group|Multicomponent intervention for twice weekly 55-60 minutes 6 weeks
215054602|NCT03938051|OTHER|Control group|20 minutes treadmill walk thrice weekly, 5-7 /10 subjective rate of perceived exertion
215054603|NCT04310696|OTHER|Buteyko Breathing exercises|Buteyko breathing technique was performed by asking the patient to take a small breath in and then out and hold his/her breath and count the time in seconds, as long as he or she can, until first signs of air hunger start to appear, followed by normal breathing once again. This procedure was repeated 15 times, three sets of 15 repetitions were given to the patient per day, 3 days per week and the treatment was continued for 4 weeks.
215054604|NCT04310696|OTHER|Pursed lip breathing|Pursed lip breathing was performed as nasal inspiration followed by expiratory blowing against partially closed lips. Participants received a total of 3 sets of 15 repetitions per day, 3 times a week and the treatment was continued for 4 weeks.
215054605|NCT02529111|DEVICE|"Echonavigator software"|
215054606|NCT01147393|DRUG|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over \~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
215054607|NCT01147393|BIOLOGICAL|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
215054608|NCT00329823|DRUG|Etanercept sc 50mg per week for 12 weeks|
215054609|NCT00852579|DRUG|Azithromycin|Daily dose 250mg
215054610|NCT00852579|DRUG|Placebo|Placebo
215054611|NCT01065675|OTHER|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
215054612|NCT00752492|OTHER|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
214900821|NCT03424005|DRUG|Inavolisib|Inavolisib tablets will be administered by mouth once daily.
214900822|NCT06356571|DRUG|Isatuximab SC-OBDS|Pharmaceutical form:Solution for SC-OBDS administration-Route of administration:SC-OBDS
214900823|NCT06356571|DRUG|Montelukast|Pharmaceutical form:As per local commercial product-Route of administration:Oral
214900824|NCT06356571|DRUG|Dexamethasone|Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV
214900825|NCT06356571|DRUG|Acetaminophen|Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV
214900826|NCT06356571|DRUG|Diphenhydramine|Pharmaceutical form:As per local commercial product-Route of administration:Oral (as premedication) or IV/oral equivalent (for management of infusion reaction)
214900827|NCT06356571|DRUG|Methylprednisolone|Pharmaceutical form:As per local commercial product-Route of administration:IV
215054613|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
215054614|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
215054615|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
215054616|NCT03644810|DIAGNOSTIC_TEST|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
215054617|NCT03644810|DIAGNOSTIC_TEST|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
215054618|NCT03644810|PROCEDURE|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
215054619|NCT03457610|BEHAVIORAL|Speech and language intervention|Speech therapy includes education about cough and vocal hygiene, teaching strategies to reduce cough, breathing and vocal exercises. The whole therapy consists of eight sessions once a week.
215054620|NCT06326008|DRUG|Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy|Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors and haematopoietic stem cells are collected from donors.
215054621|NCT01563900|DEVICE|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
215054622|NCT01563900|DEVICE|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
215054623|NCT02859831|OTHER|water samples|
215054624|NCT00844142|DRUG|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
215054625|NCT00844142|DRUG|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
215054626|NCT01344486|PROCEDURE|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
215054627|NCT01344486|PROCEDURE|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
215054628|NCT02975804|DEVICE|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
215054629|NCT03263065|DIETARY_SUPPLEMENT|Bran|220g rice pudding meal with raspberry jam with added bran flakes
215054630|NCT03263065|DIETARY_SUPPLEMENT|Nopal|220g rice pudding meal with raspberry jam with added nopal flakes
215054631|NCT03263065|DIETARY_SUPPLEMENT|Psyllium|220g rice pudding meal with raspberry jam with added psyllium flakes
215054632|NCT05495880|PROCEDURE|Laryngoscopy with forearm-support|forearm-supported head extension during direct laryngoscopy
215054633|NCT05495880|PROCEDURE|Laryngoscopy without forearm-support|without forearm-support for head extension during direct laryngoscopy
215054634|NCT00901225|DRUG|G-CSF plus Plerixafor|"On Day 5 of G-CSF mobilization,~1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."
214900828|NCT06356571|DRUG|Carfilzomib|Pharmaceutical form:As per local commercial product-Route of administration:IV
214900829|NCT04577014|DRUG|Retifanlimab|"Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)"
214900830|NCT04577014|DRUG|Gemcitabine|"Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
214900831|NCT04577014|DRUG|Docetaxel|"Phase I:~Dose Level 1 - 75 mg/m2 Dose Level 0 - 75 mg/m2 Dose Level -1 - 60 mg/m2 Dose Level -2 - 50 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
214900832|NCT05838690|OTHER|Personalized Intubation Safety (PINS) Bundle|The Personalized Intubation Safety (PINS) Bundle addresses 5 core domains that are individualized to the patient to develop a prospective, personalized and comprehensive multidisciplinary intubation plan: (1) patient risk assessment; (2) treatment threshold for intubation; (3) premedication (promoting paralytic premedication); (4) equipment (promoting video laryngoscope); (5) provider selection and escalation plan
215054635|NCT02588417|DRUG|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
215054636|NCT02588417|DRUG|Levobupivacaine|levobupivacaine 2.5 mg
215054637|NCT01408277|BIOLOGICAL|Santyl|2 mm Santyl applied once daily
214900833|NCT06330025|OTHER|Children between 2 and 8 years, without medical treatments or pathologies impacting food intake and his parents|The group comprises 102 children aged between 2 and 8 years, hospitalized for at least 48 hours and their parents. The children's pathologies and medical treatments should not influence their food intake.
215054638|NCT01408277|PROCEDURE|Control|Standard Care
215054639|NCT03355248|OTHER|Oxycodone Acetaminophen|Decrease in opioid prescribing for post-operative cesarean pain management
214900834|NCT03874923|OTHER|Fluid challenge|After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.
215054640|NCT00000792|DRUG|Hypericin|
215054641|NCT02039011|DRUG|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
215054642|NCT02039011|DRUG|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
215054643|NCT05802277|DIAGNOSTIC_TEST|Hamstring muscles function assessment|Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.
214900835|NCT04778449|OTHER|Medical Chart Review|Medical charts are reviewed
214900836|NCT04778449|OTHER|Questionnaire Administration|Complete questionnaires
215054644|NCT02620475|DEVICE|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
215054645|NCT05045859|BEHAVIORAL|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning. It assumes that PTSD exists within the couple's relationship and that partners can join together to reduce the presence of PTSD in their relationship. Sessions are organized into three phases of treatment: (1) psychoeducation about PTSD and relationships; (2) behavioral interventions to enhance relationship functioning; and (3) dyadic cognitive intervention designed to contextualize trauma memories and address trauma-relevant cognitions held by either partner that keep the PTSD and/or relationship distress alive. Out-of-session assignments are designed to assist the couple in reinforcing skills learned in the sessions.
215054646|NCT00682175|OTHER|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
215054647|NCT05285579|BIOLOGICAL|Blood collection|Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer
215054648|NCT05285579|OTHER|Tumour samples|reuse of tumour tissue collect in usual patient care
214301494|NCT04824170|OTHER|Rhythmic stabilization technique|"This group was receiving (PNF) Rhythmic stabilization technique with base line treatment.~Subject was lying in spine position on the treatment table and therapist resist an isometric contraction of agonist muscle group.pt maintain this position for 10 sec without trying to move and 12-15 repetitions were performed with 30 sec rest. Each therapeutic session treatment was focused on facilitation of neck stabilizers, improving neck stability, coordination, decreasing pain and improving postural control"
214900837|NCT05765643|OTHER|Nurse parental support in symptom management using a mobile health App|Parents in this group will receive a mobile App that includes health assessment, monitoring, health education and nurse support using phone calls over a 3-month period
214900838|NCT01442480|DIETARY_SUPPLEMENT|Fish oil|Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
214900839|NCT01442480|DIETARY_SUPPLEMENT|Olive oil|Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
214900840|NCT04136171|DRUG|Eplontersen|Eplontersen by subcutaneous injection
214900841|NCT04136171|DRUG|Placebo|Eplontersen-matching placebo by subcutaneous injection
215054649|NCT01239771|DRUG|TC-5214|Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
215054650|NCT01239771|DRUG|Placebo|Two subjects in each cohort will be given placebo.
214301495|NCT06216613|BEHAVIORAL|Sensory Enhanced Aquatics|Sensory Enhanced Aquatics (SEA) utilizes the Sensory Profile to individualize lessons based on children's sensory preferences. The program incorporates evidence-based approaches for autistic children, including: 1) visual supports, 2) sensory supports, 3) communication strategies, 4) behavioral strategies, and 5) modeling to maximize skill acquisition. Lessons will be 1:1 with social opportunities at the beginning and end of each lesson. Like standard swim lessons, skills are taught in progression from water orientation (e.g., blowing bubbles, submerging different body parts) to advanced swimming (e.g., swimming 15 or more yards of different swim strokes). All lessons include instruction of water safety skills. Each skill has been task analyzed by therapists so instruction can be graded according to children's ability. A social story is provided to transition children to lessons. SEA curriculum was reviewed by USA Swimming Foundation and is included as a Swim Lesson Network Provider.
215054651|NCT03699566|OTHER|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
214301496|NCT06216613|BEHAVIORAL|Standard Swim Lessons|Standard swim lessons will adhere to USA Swimming Foundation Swim Network Provider requirements ensuring lessons meet or exceed industry best practices. Lessons have up to a 1:5 instructor to child ratio and will focus on stroke development and water-safety with skills advancing from water-orientation to stroke technique and endurance.
214301497|NCT03913637|BEHAVIORAL|Strategy Training|Occupational therapists deliver Strategy Training to older adults virtually. Strategy training optimizes engagement in meaningful daily activities through generating self-selected goals, monitoring daily activities, scheduling activities, and problem-solving solutions to barriers experienced when engaging in activities.
214301498|NCT03913637|OTHER|Enhanced Usual Care|In this comparison condition, usual care will be enhanced by connecting older adults with MCI to resources available to meet their needs, and notify appropriate physicians when required. Enhanced Usual Care provides a usual care comparison while providing the participants with close monitoring of changes in symptoms.
214900842|NCT04892472|DEVICE|NovoTTF-200T|All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.
214900843|NCT04892472|DRUG|Pembrolizumab (MK-3475) 200 mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
214900844|NCT06258148|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
214900845|NCT06258148|DRUG|Placebo|Placebo, SC, once a week
214900846|NCT05857488|DEVICE|Transnasal introduction tube|Imaging of the GI tract using the transnasal introduction tube and system. Optional gut microbiome sample collection using the microbiome brush and/or intestinal potential difference measurement using the intestinal potential difference probe.
214900847|NCT03851406|DEVICE|5% Hypertonic Saline|Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.
214900848|NCT03851406|OTHER|No treatment|No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
215054652|NCT03699566|OTHER|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
215054653|NCT03699566|OTHER|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
215054654|NCT04378101|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
214301499|NCT02863380|PROCEDURE|Functional magnetic resonance imaging used to individualize rTMS protocol|Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
214900849|NCT04013802|BIOLOGICAL|HLA-matched VSTs|"An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3)."
214900850|NCT04521764|BIOLOGICAL|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Given IT
214900851|NCT04521764|PROCEDURE|Computed Tomography|Undergo CT scan
214900852|NCT04521764|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214900853|NCT04521764|PROCEDURE|Biopsy|Undergo tumor biopsy
214900854|NCT04521764|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214301500|NCT02863380|DEVICE|Individualized rTMS (transcranial magnetic stimulation)|
214301501|NCT02863380|DEVICE|Classical rTMS (transcranial magnetic stimulation)|
214301502|NCT02863380|DEVICE|Classical tDCS (transcranial direct current stimulation)|
214301503|NCT05587309|DRUG|BLI5100|Orally via tablet
214900855|NCT06583577|DEVICE|3D Ostomy simulator|The ostomy simulator is 3D printed model created in collaboration with Earl E. Bakken Medical Devices Center at the University of Minnesota. The anatomically accurate model is created by analyzing de-identified segmental imaging after bowel diversion surgeries. The Stratasys J750 Polyjet 3D Printer is utilized to create the simulator using usual synthetic material.
214900856|NCT05346276|DIAGNOSTIC_TEST|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
214900857|NCT06005623|DEVICE|SENS Motion + Motivational Feedback|"To weeks prior to surgery and in a 12-week period following discharge after TKA/UKA patients will be equipped with a discrete patch and built-in accelerometer (SENS Motion, Denmark, Copenhagen) attached on the thigh of the leg not undergoing surgery.~Following discharge after TKA/UKA patients randomized to the intervention-group will receive the app (SENS motion). On their provided app, patients will be able to choose between two tabs. Tab 1 will allow patients to view predefined goals, all of which are locations in a self-selected city. The sensor will measure the physical activity and daily rhythm of the patient, and accelerometer counts will be converted into daily steps, which will be visible to the patients. In Tab 2, patients will be able to see graphical representations of their daily activity as well as their history during the period in which they have worn the accelerometer. The graphical representations include: Daily steps, physical active minutes, and type of activity."
214900858|NCT06400147|BEHAVIORAL|Strategy Training|This intervention will use an adapted form of strategy training for people with neglect.
214900859|NCT06400147|BEHAVIORAL|Attention Control|This intervention will use a reflective listening protocol.
214900860|NCT02177461|DRUG|Telmisartan|
214900861|NCT02177461|DRUG|Enalapril|
214900862|NCT02177461|DRUG|Clonidine|
214900863|NCT00375986|PROCEDURE|Manual placental removal at Cesarean delivery|
214900864|NCT00375986|PROCEDURE|Spontaneous placental removal at Cesarean delivery|
214900865|NCT03224312|OTHER|no intervention|no intervention
214900866|NCT00413699|DRUG|CP-690,550|5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
214301504|NCT05587309|DRUG|PPI Control|Orally via tablet
214301505|NCT02972554|DRUG|Propanolol hydrochloride|One-time dose of 40mg of propranolol
214301506|NCT02972554|OTHER|Placebo|Outside casing matching that of active drug
214301507|NCT06287333|DIAGNOSTIC_TEST|Polysomnography in routine care|Children performed a polysomnography in routine clinical care
214900867|NCT00413699|DRUG|CP-690,550|10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
214301508|NCT02280772|DIETARY_SUPPLEMENT|Glucomannan|
214301509|NCT02280772|DIETARY_SUPPLEMENT|Maltodextrin|
214301510|NCT02518555|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
214301511|NCT02518555|DRUG|Ibrutinib|Given PO
214301512|NCT02518555|OTHER|Laboratory Biomarker Analysis|Correlative studies
214301513|NCT02518555|OTHER|Pharmacological Study|Correlative studies
214301514|NCT02518555|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
214301515|NCT02518555|OTHER|Quality-of-Life Assessment|Ancillary studies
214301516|NCT02518555|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
214301517|NCT05926908|BEHAVIORAL|A Mobilisation Initiative|The Mobilisation Initiative consists of physiotherapists assisting nursing staff in mobilising patients to sit in a chair for breakfast and lunch. This intervention follows the interventions of focus group interviews, formal education, observations of patients and the environment, and awareness of mobilisation survey
214301518|NCT05926908|BEHAVIORAL|Focus Group Interviews|Focus group interviews using a semi-structured interview guide are conducted with health care professionals at the wards to explore the acceptability and demand for the contents of the Mobilisation Initiative, including the identification of facilitators and barriers to mobilisation
215054655|NCT03346083|DRUG|Betrixaban|Factor Xa inhibitor.
215054656|NCT04356300|BIOLOGICAL|Exosome of MSC|Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
215054657|NCT06133855|RADIATION|Pulsed electromagnetic field|The experimental group will be treated with an ASA magnetic field device (Automatic PMT Quattro Pro) at a frequency of 50 Hz in addition to the traditional physical therapy program. Each session will consist of 20 minutes of the patient lying prone and exposed to low-intensity 20-gauss PEMF.
214669572|NCT04348903|BEHAVIORAL|Positive Pre-Visit Imagery Intervention|Short narrative visual information regarding the dental chair, environment and equipment will be provided. It will be done through showing children an interactive book that contained photographs of A4 size, depicting three children model aged 4 - 6 years who are smiling while sitting in the dental chair and cooperative with the dentist. Benefit of LA in alleviating pain will be explained. The researchers also will explore the children's reflection of the children model and allow them ask questions relevant to LA injection.
214669573|NCT03614390|BEHAVIORAL|mindfulness based cognitive therapy (MBCT)|a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
214669574|NCT01409889|BEHAVIORAL|Diabetes Prevention Program|
214669575|NCT01409889|BEHAVIORAL|Healthy Living Program|
214669576|NCT05841849|DRUG|Aprepitant|oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3
214900868|NCT05524389|RADIATION|Vaginal brachytherapy|"High-dose rate vaginal brachytherapy (VBT) was delivered with a vaginal cylinder.For VBT administered alone, the dose is recommended: 3 fractions of 7 Gy or 5 fractions of 6 Gy or 6 fractions of 5 Gy.~For VBT administered after completion of EBRT: 2-3 fractions of 4-6 Gy."
214900869|NCT05524389|RADIATION|Pelvic external beam radiotherapy|EBRT was delivered to the pelvic area using a total dose of 45-50.4Gy in 25-28 fractions over 5-6 weeks with the intensity-modulated radiotherapy (IMRT) technique, three-dimensional conformal radiotherapy (3D-CRT) modality
214900870|NCT05524389|OTHER|Observation|No radiotherapy is administrated, but active follow-up and quality of life questionnaires is needed after surgery.
214900871|NCT05524389|DRUG|Chemotherapy|Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.
214900872|NCT02800460|PROCEDURE|fMRI-3T|fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
214900873|NCT03644641|PROCEDURE|Desflurane Group|General anesthesia will be held using desflurane in end- tidal concentration according to target value of entropy levels (between 40 and 60).
214900874|NCT03644641|PROCEDURE|Propofol Group|General anesthesia will be held using Schnider effect model for propofol (target control anesthesia). Titration will be done according to target value of entropy levels (between 40 and 60).
214900875|NCT03945305|DEVICE|Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.
214900876|NCT03945305|OTHER|Previous antihypertensive treatment|Patients are only treated with previous antihypertensive treatment.
214900877|NCT03511105|DRUG|GSK2798745|GSK2798745 will be available as white to slightly colored, round biconvex tablets to be administered via the oral route.
214900878|NCT03511105|DRUG|Placebo|Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.
214900879|NCT03511105|DRUG|Lipoplysaccharide from Escherichia Coli|LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
214900880|NCT03511105|DRUG|Saline|Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
214900881|NCT04992078|DEVICE|NAVIO/CORI Surgical System|Unicompartmental knee replacement with robotic assistance
214900882|NCT04992078|PROCEDURE|Non-robotic conventional instrumentation|Unicompartmental knee replacement with non-robotic conventional instrumentation
214900883|NCT05823285|DRUG|QLS31903|0.01μg/kg-2.16 μg/kg QLS31903 for injection
214900884|NCT03903289|PROCEDURE|Automated red cell exchange|Erythrocytapheresis is an automated red cell exchange procedure that removes blood that contains HbS from the patient while simultaneously replacing that same volume with packed red cells free of HbS.
214900885|NCT03903289|PROCEDURE|Manual red cell exchange|Active Comparator: Manual red cell exchange
214900886|NCT03903289|PROCEDURE|Simple red cell transfusion|Active Comparator: Simple red cell transfusion
214900887|NCT02810457|DRUG|FKB238 (bevacizumab)|
214900888|NCT02810457|DRUG|Avastin (bevacizumab)|
214900889|NCT02810457|DRUG|Paclitaxel|
214900890|NCT02810457|DRUG|Carboplatin|
214900891|NCT02943980|DEVICE|CMAC Videolaryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the CMAC
214900892|NCT02943980|DEVICE|Macintosh Laryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the conventional Macintosh Laryngoscope
214900893|NCT03215680|OTHER|Climate|Hot and temperate climate
214900894|NCT01566188|DIETARY_SUPPLEMENT|omega-3 from vegetal origin|6 months of supplementation with omega-3 from vegetal origin
214900895|NCT01566188|DIETARY_SUPPLEMENT|Placebo|6 months of supplementation with placebo
214900896|NCT06303804|BEHAVIORAL|Educational videos|Participants will be delivered a link to complete demographic information and the initial assessment. Upon completing the (initial) pre-test knowledge assessment, participants will be sent links to the three educational videos staggered across 7 days. Educational videos will determine gaps in knowledge related to opioid use and overdose based on questionnaire responses. Upon the completion of the 7 days, participants will be sent a link to the (final) post-test knowledge assessment to complete.
214669577|NCT05841849|DRUG|Palonosetron|oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
214669578|NCT05841849|DRUG|Fosaprepitant|intravenous fosaprepitant 150mg for D1 before chemotherapy
214669579|NCT02823912|DRUG|Capsaicin|
214669580|NCT02823912|DRUG|Magnesia calcinada|
214900897|NCT00497068|BEHAVIORAL|tobacco abstinent contingent|Participants receive vouchers wiht monetary rewards for providing breath samples that show tobacco smoking abstinence
214900898|NCT00497068|BEHAVIORAL|non-contingent|Participants receive vouchers regardless of tobacco use status
214900899|NCT00497068|BEHAVIORAL|control|this group receives no vouchers
214900900|NCT02215655|BEHAVIORAL|Motivational interviewing|Motivational interviewing counselling sessions will be administered to the subjects.
214900901|NCT06106581|BIOLOGICAL|VLA1553 full dose|Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate
214900902|NCT06106581|BIOLOGICAL|VLA1553 half dose|Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate
214900903|NCT06106581|BIOLOGICAL|Control|Nimenrix
214900904|NCT00451373|DEVICE|CVVH and SLED|
215054658|NCT06133855|OTHER|traditional physical therapy program|"A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles."
215054659|NCT02366676|DRUG|hyaluronic acid and chondroitin sulphate|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd\~5th month:once a month)
215054660|NCT01047917|BEHAVIORAL|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
215054661|NCT04712123|OTHER|relapse due to S. aureus|to find out if it is the same S. aureus in both infections
215054662|NCT02228044|BEHAVIORAL|Prevention program|
214478993|NCT05447338|PROCEDURE|Myofascial inductions; Synchronization of the temporal bones PHASE 2|The therapist rests his two forearms on the table, in such a way that he can contact the external auditory canal with his middle fingers. Place the ring fingers on the mastoid processes and the index fingers on the zygomatic arches. Subsequently, a rotary movement is made on the axis marked by the line that joins the middle fingers. With one of the hands, the movement is in the direction of movement clockwise, and with the other hand, simultaneously, in the opposite direction. By obtaining a symmetry in the movement in opposite directions, the movement is made in the same direction with both hands, first forwards and then backwards. Note how the ring fingers rotate first backwards and then upwards. Symmetry in movements should also be sought.
215054663|NCT03011749|OTHER|FLT PET/CT|FLT PET/CT before first series of Radium-223 and after 2 series
215054664|NCT03801928|DRUG|Inflectra|The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.
215054665|NCT05706207|DRUG|HB0030 injection|0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
214478994|NCT01601808|DRUG|Placebo|Orally once a day, continuously throughout the study
214478995|NCT01601808|DRUG|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
214478996|NCT06858254|BIOLOGICAL|Autologous mesenchymal stem cells|"1. Participant's blood is drawn at the start of each visit.~2. Bone marrow aspirate is drawn from the posterior aspect of the pelvis and is subsequently harvested and processed.~3. The following procedures are administered in a crossover design (Day 0 and 6 months):~   * Intranasal bone marrow aspirate administration (INA BMAC) OR Sham INA~  * Intravenous bone marrow aspirate administration (IV BMA) OR Sham IVA~4. At 12 months, all participants receive IV BMA + INA BMAC"
214478997|NCT04031209|DEVICE|G7 Acetabular System|All patients will receive G7 Acetabular System
215054666|NCT05706207|DRUG|HB0030 injection|0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
215054667|NCT05706207|DRUG|HB0030 injection|1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
214478998|NCT06189170|DRUG|KP405|Experimental drug
214478999|NCT06189170|DRUG|Placebo|Placebo
214479000|NCT05473637|DIAGNOSTIC_TEST|MRI|Patients will repeat study-protocol MRI at baseline (enrollment) and at least once in 1 year or 2 years follow-up (depends on availability).
214900905|NCT00451373|DRUG|Vancomycin|
214900906|NCT00451373|DRUG|Daptomycin|
214900907|NCT00451373|DEVICE|FX60, AV600 (dialyzer)|
214900908|NCT03004274|OTHER|Running sutures|
214900909|NCT03004274|OTHER|Interrupted sutures|
214900910|NCT05486039|BEHAVIORAL|Changing behaviour|Changing the lying position and mattress system
214900911|NCT04115319|DRUG|SEP363856|SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
214900912|NCT04115319|DRUG|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
215054668|NCT05706207|DRUG|HB0030 injection|3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
214900913|NCT03587402|OTHER|Transcutaneous perineal stimulation|Surface stimulation
214900914|NCT03587402|OTHER|Anal stimulation|Intra-cavitary stimulation
214900915|NCT05673980|DRUG|Vitamin D2|Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
214900916|NCT05673980|OTHER|placebo|This group will not do any intervention
214900917|NCT00632268|DRUG|RAD001; Cisplatin; 5-FU; Leucovorin|RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
214900918|NCT00663936|DRUG|T-817MA|224 mg T-817 MA once daily
215054669|NCT05706207|DRUG|HB0030 injection|10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
214900919|NCT00663936|DRUG|Placebo|Placebo once daily
214900920|NCT02832687|DRUG|Acetaminophen|patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. \<50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
214900921|NCT02832687|DRUG|normal saline|100mL of normal saline every 4 hours to a maximum administration of 400mL
214900922|NCT03751033|DEVICE|BSS|Intraoperative aberrometry measurements for BSS will be performed.
214900923|NCT03751033|DEVICE|DiscoVisc|Intraoperative aberrometry measurements for DiscoVisc will be performed.
214900924|NCT05304130|BIOLOGICAL|Otilimab|Otilimab will be administered via pre-filled syringe.
214301519|NCT05926908|BEHAVIORAL|Formal Education|Formal education for all nursing staff employed at the two wards includes information on the consequences of immobilisation, with the purpose of enhancing confidence, competencies, and awareness of mobilisation
214301520|NCT05926908|BEHAVIORAL|Self-reported Level of Mobilisation|Patient's self-reported mealtime mobilisation level reported through interview-based surveys, including structured follow-up questions
214301521|NCT05926908|BEHAVIORAL|Observations of Patients and the Environment|During breakfast and lunch, the mobilisation status of all patients in the wards is observed using an observation checklist
215054670|NCT05706207|DRUG|HB0030 injection|20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
214301522|NCT05926908|BEHAVIORAL|Awareness of Mobilisation Survey|To assess the nursing staff's awareness of and confidence in the mobilisation of the patients, a short survey on mobilisation awareness is distributed to the nursing staff at both wards
214479001|NCT05693337|DEVICE|Forward Looking Infrared Radar (FLIR) thermal imaging|The FLIR camera will collect temperature recordings pre-procedure and 5 minutes post-procedure, which will be used to calculate a delta T to assess achievement of a successful sympathetic block.
214301523|NCT03071978|DEVICE|CRT with LV-only pacing / bi-ventricular pacing|LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.
214301524|NCT00749918|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
214479002|NCT04711759|DEVICE|High flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
214479003|NCT04711759|DEVICE|Standard oxygen therapy|Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.
214479004|NCT05541484|DRUG|SGLT2 inhibitor|See above.
214479005|NCT05541484|DEVICE|Biosense Breath Ketone Analyzer|The hand-held device tests ketones in exhaled breath
214479006|NCT05386589|DRUG|Molnupiravir|Four 200 mg capsules administered orally as a single dose
214479007|NCT06868069|DIAGNOSTIC_TEST|Diagnostic tests and questionnaires|Assessment of office blood pressure, orthostatic hypotension, 24-hour ambulatory blood pressure, frailty
214479008|NCT03233646|DEVICE|Retinal and Choroidal Imaging|Non-invasive OCT, OCTA, and UWF fundus photography of retina
214479009|NCT06753487|PROCEDURE|Myofacial Release|"Manual Myofascial Release:~Control group will receive 3- 5 repetitions of Manual Myofascial Release in Piriformis muscle i.e giving ischemic pressure on muscle directly for 90 secs and then release."
214479010|NCT06753487|PROCEDURE|Facilitated positional release technique|"FPRT:~Treatment group will receive 5 repetitions of FACILITATED POSITIONAL RELEASE technique i.e applying pressure over tender area of muscle while maintaining specific postion"
214479011|NCT06752512|DEVICE|Remote Patient Monitoring|24/7 remote patient monitoring with a wearable thermometer
214479012|NCT06691490|DEVICE|Transcranial Magnetic Stimulation Sham|cTBS over SMA and cTBS over precuneus (control site)
214900925|NCT04231825|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
214301525|NCT03628755|BEHAVIORAL|Digital Manipulation of Thyroid cartilage|"Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60."
214301526|NCT03628755|BEHAVIORAL|Fluency Shaping Therapy|FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
214669581|NCT00986778|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
214669582|NCT00986778|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
214669583|NCT00986778|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
214900926|NCT05958043|DEVICE|3D- printed Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
215054671|NCT05706207|DRUG|HB0030 injection|30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
215054672|NCT05706207|DRUG|HB0030 injection|40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
215054673|NCT00465608|DRUG|propranolol|propranolol by mouth (per os)
215054674|NCT05130684|DRUG|Nivolumab|adding nivolumab to conventional neoadjuvant CRT
215054675|NCT05116397|OTHER|Inspired gas|Inspired gas content
215054676|NCT02520492|DEVICE|noninvasive method of ICP measurements (Elios)|
214301527|NCT03628755|BEHAVIORAL|combination Group|combination group intervention of DMT + FST
214301528|NCT05298332|DRUG|ATI-2173 50 mg|ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
214301529|NCT04263207|OTHER|No intervention|No intervention
214479013|NCT06688227|OTHER|Isolated Core Stability Program|The control group consists of basic core exercises which include the activation of transversusabdominins and multifidus muscles and progressive strengethening of these muscles in all positions using swiss balls and floor mats. All exercises were done for at least 3 sets of 15 repetitions to build proper core stability.
214669584|NCT01329757|DRUG|GH|Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
214669585|NCT01329757|DRUG|Placebo|Administration of a subcutaneously injected daily dose of placebo for 1 year
214669586|NCT04336176|DEVICE|PulseFlow DF boot|Offloading boot
214900927|NCT05958043|DEVICE|CAD/CAM-milled Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
214900928|NCT06492135|DRUG|survodutide|survodutide
214900929|NCT03665831|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
214900930|NCT06356714|DRUG|Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens|"Nocardia Rubra Cell Wall Skeleton 200 mcg-400 mcg, 0.3 ml diluted in water for injection or lidocaine, was injected subcutaneously every 2 or 3 weeks.~Efficacy was evaluated every 2 cycles according to RECIST 1.1 criteria. Patients are enrolled and given this study regimen of drugs on top of their prior second- or third-line regimen until disease progression or intolerable toxicities occur; or the patient requests to be discharged."
214900931|NCT01034202|DRUG|NNC126-0083|One of five dose levels administered subcutaneously (under the skin)
214900932|NCT01034202|DRUG|Norditropin® SimpleXx®|One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
214900933|NCT01034202|DRUG|placebo|Placebo comparator
214900934|NCT01034202|DRUG|NNC126-0083|One of three dose levels administered subcutaneously (under the skin)
214900935|NCT01034202|DRUG|Norditropin® SimpleXx®|One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
214900936|NCT04553731|BEHAVIORAL|empowerment program with mHealth|empowerment program with mHealth
214900937|NCT04606212|DRUG|Losartan|administration of losartan (50 mg) (oral)
214900938|NCT04606212|DRUG|Placebo Oral Tablet|administration of placebo (oral)
214900939|NCT02019472|BIOLOGICAL|adalimumab 40 mg|SC injections
214900940|NCT02019472|BIOLOGICAL|sirukumab 100 mg|SC injections
214900941|NCT02019472|BIOLOGICAL|sirukumab 50 mg|SC injections
214900942|NCT02019472|DRUG|Placebo|SC injections
214900943|NCT01543438|OTHER|Video Prescription (additional education)|receives video prescriptions
214900944|NCT01441024|DRUG|DAS181|20 mg per day of DAS181-FO3 for 5 days
214900945|NCT01441024|OTHER|Placebo|20 mg per day of Lactose for 5 days
214900946|NCT02813655|DRUG|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
214900947|NCT02813655|DRUG|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
215054677|NCT03154255|BEHAVIORAL|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
215054678|NCT04122989|OTHER|MS-SUPPORT|MS-SUPPORT is a shared decision making tool designed to be used by patients and providers.
215054679|NCT04808791|DRUG|Irinotecan|"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."
215054680|NCT04808791|DRUG|Oxaliplatin|"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."
215054681|NCT04808791|DRUG|TAS 102 (Trifluridine/Tipiracil)|"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"
214900948|NCT05418881|DEVICE|Mobile Tracking Device (one spot)|Patients will be fitted with 4 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, FitBit Sense®, Withings ScanWatch®).
214900949|NCT05418881|DEVICE|Mobile Tracking Device + Activity Sensor (longitudinal)|Patients will be fitted with 1 of 3 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, Withings ScanWatch®). The type of tracking device will be randomized. Additionally an Activity Tracker and one-channel ECG (Movesense®) will be worn by the patients.
214900950|NCT03861390|DRUG|60 mg Prednisone|Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
215054682|NCT02821065|DEVICE|Remote Patient Monitoring|
215054683|NCT02936518|PROCEDURE|Lingual frenotomy and/or maxillary labial frenectomy|
215054684|NCT05708573|DRUG|Rosuvastatin|In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
214900951|NCT03861390|DRUG|Placebo|Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
214900952|NCT02818452|OTHER|Oatmeal + OatWell28XF|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
214900953|NCT02818452|OTHER|Oatmeal|
214900954|NCT02818452|OTHER|Hot cereal|
214900955|NCT06251973|BIOLOGICAL|AgenT-797|AgenT-797 is an investigational product, composed of allogeneic human unmodified iNKT cells, isolated from mononuclear cell aphaeresis units from healthy donors
214900956|NCT06251973|BIOLOGICAL|Botensilimab|Botensilimab is a novel, human, Fc-engineered IgG1 anti-CTLA-4 antibody
214900957|NCT06251973|DRUG|Balstilimab|Botensilimab is supplied as a sterile, single-use solution for IV administration
214900958|NCT06251973|DRUG|Ramucirumab|Ramucirumab is a fully human anti-VEGFR2 monoclonal IgG1 antibody (IgG1) that binds with high affinity to the extracellular domain of VEGFR2. Ramucirumab is a part of standard of care treatment for advanced gastric cancer or GEJ adenocarcinoma, after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
214900959|NCT06251973|DRUG|Paclitaxel|Paclitaxel is widely used across multiple cancer types and is a part of standard of care treatment for advanced EG adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
214900960|NCT01217112|DRUG|GWP42003|100 mg capsules, PO, BD, 91 days
214900961|NCT01217112|DRUG|GWP42003|5 mg capsules, PO, BD, 91 days
214900962|NCT01217112|DRUG|GWP42004|5 mg capsules, PO, BD, 91 days
214900963|NCT01217112|DRUG|Placebo|0 mg capsules, QDS, PO, 91 days
214900964|NCT03192488|DRUG|Cetirizine|Cetirizine tablet 10 mg
214900965|NCT03192488|DRUG|Placebo oral capsule|Gelatin placebo
214900966|NCT03192488|OTHER|Hypoxia|Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft
214900967|NCT03669211|DIAGNOSTIC_TEST|Cardiac stress test|In order to assess the evolution of their cardiorespiratory function, patients will benefit from two cardiac stress test combined with VO2 study, one at inclusion in the study, and the other one 6 months later.
214900968|NCT01401361|DEVICE|Treatment Arm|The investigational parts of the system consists of Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement .
214900969|NCT01637428|DEVICE|ActiveCare+S.F.T 3rd generation|Intermittent Pneumatic Compression Device
214900970|NCT02213172|DIETARY_SUPPLEMENT|Bifidobacterium longum R0175|
214900971|NCT02213172|DIETARY_SUPPLEMENT|Lactobacillus paracasei HA-196|
215054685|NCT05708573|DRUG|ALXN2040|In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
215054686|NCT02014506|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -2
215054687|NCT02014506|DRUG|Cyclophosphamide|50 mg/kg IV on day -3 and -2
215054688|NCT02014506|BIOLOGICAL|anti-thymocyte globulin|
215054689|NCT02014506|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
215054690|NCT02014506|RADIATION|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 \& -4 (severe aplastic anemia)
215054691|NCT02014506|PROCEDURE|TCRαβ-depleted hematopoietic cell transplantation|
215054692|NCT02014506|DEVICE|CliniMACS|Immunogenetic depletion of TCRαβ cells
214669587|NCT04336176|DEVICE|Usual standard of care|Usual standard of care (offloading device)
214900972|NCT02213172|OTHER|Placebo|
214900973|NCT00867529|BIOLOGICAL|rituximab|Given IV
214900974|NCT00867529|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
214900975|NCT00867529|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
214900976|NCT00867529|OTHER|pharmacological study|Correlative studies
214900977|NCT00867529|OTHER|laboratory biomarker analysis|Correlative studies
214900978|NCT01660750|DRUG|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
214900979|NCT01660750|DRUG|Cyclophosphamide|PO on days 1, 8, and 15 every 28 days
214900980|NCT01660750|DRUG|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
214900981|NCT04903015|DIAGNOSTIC_TEST|MRI|"The following sequences of the MRI will be acquired during the inclusion visit:~* 3D T1 gradient echo (GRE): anatomy; registration; cerebral, white matter, and grey matter volumetry; and cortical thickness;~* multiecho 3D T2 GRE: quantitative susceptibility mapping (QSM), iron overload quantification;~* continuous arterial spin labeling (ASL) 3D: cerebral perfusion;~* resting-state fMRI: functional connectivity;~* 64-direction DTI (b=1000 and 2500): alterations in white matter and its microstructure, anatomic connectivity;~* monovoxel spectroscopy of the mesencephalus with short echo time (TE)."
214900982|NCT00198718|DRUG|Vitamin A (retinyl palmitate)|
214900983|NCT04310670|OTHER|Psychotherapy|The patient will be treated according to Lacanian psychoanalytic ethics, which allows to adequately respond to the patient's request for healing but who at the same time does not ignore the progress of scientific research in the neurological field
214900984|NCT04310670|BEHAVIORAL|Physiotherapy|Physiotherapy treatment will be articulated through the use of techniques designed to qualify the functionality of the subject divided by symptom: weakness, dystonic attitudes of the limbs, walking disorders, tremor.
214900985|NCT04310670|OTHER|Non-Invasive Brain Stimulation (NIBS)|"Diversified transcranial electrical maneuver protocols with an on-line or off-line approach may be applied for therapeutic purposes. This will include: transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), random noise stimulation (tRNS)."
214900986|NCT00841386|DRUG|Riboflavin-5-phosphate|Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
215054693|NCT04420832|PROCEDURE|Surgical treatment|Se above
215054694|NCT04420832|OTHER|Non-surgical treatment|See above
214900987|NCT00841386|DRUG|Sham cross-linking|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
214900988|NCT02332226|BEHAVIORAL|Representational approach|Representational approach to patient education
214301530|NCT01393340|DRUG|Omalizumab|"Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab."
214669588|NCT04336176|DEVICE|Sham|Sham shoe (closest to barefoot or baseline pressures)
214900989|NCT01288677|DRUG|TMC649128|Escalated doses
214900990|NCT00304798|BEHAVIORAL|Hospital admission|
214900991|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
214900992|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection
214900993|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection
214900994|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
214900995|NCT04528667|DRUG|STI-5656|STI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.
214900996|NCT04528667|DRUG|Placebo|Placebo capsules
214900997|NCT00118339|DRUG|chemoprotection|
214900998|NCT00118339|PROCEDURE|complementary or alternative medicine procedure|
214900999|NCT00118339|PROCEDURE|management of therapy complications|
215054695|NCT04952662|GENETIC|Genetic variants|COL1A1 rs1800012, COL1A2 rs412777, COL5A1 rs12722, ACTN3 rs1815739, ACE rs1799752, ESR1 rs2234693, MMP3 rs679620, VDR rs2228570 and GDF5 rs143383
215054696|NCT04036201|DRUG|Bupivacaine|peribulbar block
215054697|NCT00584818|DRUG|PB127 for Injectable Suspension|"Stages 1 \& 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 \& 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
215054698|NCT00864175|DRUG|INCB007839|100 mg BID
215054699|NCT00864175|DRUG|INCB007839|200 mg BID
215054700|NCT00864175|DRUG|INCB007839|300 mg BID
215054701|NCT00864175|DRUG|INCB007839|300 mg BID
215054702|NCT00864175|DRUG|trastuzumab|trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.
215054703|NCT00864175|DRUG|Docetaxel|
215054704|NCT02940899|OTHER|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
214301531|NCT01393340|DRUG|Placebo|Placebo
214301532|NCT06104358|DRUG|HU6|HU6 is being evaluated for its effect on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function
214301533|NCT01902342|DRUG|Oseltamivir 75 mg 1 cap|
214901000|NCT02512302|DRUG|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
214901001|NCT02512302|DRUG|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
214901002|NCT02512302|DRUG|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
214901003|NCT02512302|DRUG|Seebri® Breezhaler® with activated charcoal|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
214901004|NCT02512302|DRUG|Glycopyrrolate Injection|50 mcg glycopyrrolate via IV
214901005|NCT03426306|DIAGNOSTIC_TEST|4DCT-Ventilation|4DCT-ventilation is an imaging modality that provides superior image quality, reduced cost, and a faster imaging procedure compared to nuclear medicine VQ scans.
214901006|NCT04144413|DRUG|Open-label Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
214901007|NCT04144413|DRUG|Masked Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
214901008|NCT04144413|OTHER|Vehicle Comparator: Masked Vehicle|Vehicle of IKERVIS® - sterile, ophthalmic cationic oil-in-water emulsion containing no active substance.
214901009|NCT00827008|DRUG|Neramexane mesylate|Up-titration treatment period of 5 weeks up to 75mg Neramexane mesylate oral per day followed by 49 weeks treatment maintenance
214901010|NCT06270381|OTHER|EMPOWER|The EMPOWER intervention (Enhancing and Mobilizing the POtential for Wellness and Emotional Resilience) is a cognitive-behavioral and acceptance-based intervention divided into six modules.In the current application, this intervention is conducted in 6 in-presence or online 50-minute sessions and 2 booster sessions 2 and 4 weeks after the final intervention. It is a manualized treatment in which each session has a specific goal: 1st) Welcome, initial assessment and adherence to the intervention; 2nd) Psychoeducation and transmission of resources for stabilization; 3rd) Psychoeducation on Trauma, Grief and Cognitive-Behavioral Model; 4th)Promoting Experiential Acceptance; 5th) Imagined dialogue; 6th) Coping Training; and two final boosting sessions. In every session, the impact of the previous consultation and evolution is evaluated. This intervention was developed by Lichtenthal et al., 2022.
214901011|NCT06270381|OTHER|Treatment as usual (TAU)|The treatment as usual (TAU) consists of supportive psychotherapy based on a non-structured and integrative method that focuses on the development of more adaptive coping strategies, understanding and working on the patient's internal models of self, others, and the world. The TAU will be considered during the same period as the EMPOWER intervention.
214901012|NCT01969149|DRUG|Exenatide|
214901013|NCT01969149|DRUG|Insulin|
214901014|NCT04126980|BEHAVIORAL|Rates of readmission and reoperation|All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.
214901015|NCT00438581|DRUG|Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )|
214901016|NCT01434160|DRUG|Skyla (Levonorgestrel, BAY86-5028)|Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.
214901017|NCT01002989|DEVICE|Doppler Ankle-Brachial Index measurement|Measurement of the Ankle-Brachial Index by Doppler.
214901018|NCT01002989|DEVICE|WatchBP Office Ankle-Brachial Index measurement.|Measurement of Ankle-Brachial Index by WatchBP Office device.
214901019|NCT06576180|DRUG|Carboplatin（ neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214901020|NCT06576180|DRUG|Paclitaxel （neoadjuvant）|Paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214901021|NCT06576180|DRUG|Anti-PD-1 Drugs|Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214301534|NCT01266460|BIOLOGICAL|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
214301535|NCT01266460|OTHER|Laboratory Biomarker Analysis|Correlative studies
214301536|NCT03756688|DEVICE|RestoreX PTT - 6 months|Penile traction therapy in straight position for all 6 months.
214301537|NCT03756688|DEVICE|RestoreX PTT - 3 months|Penile traction therapy in straight position for first phase (3 months)
214479014|NCT06688227|OTHER|Integrated Core Stability Program|"An individualized protocol was designed for these cricketers targeting static and dynamic core stability, with integration of balance, endurance and power component.~Tranversusabdominis and multifidus strengthening is combined with upper extremity motions to work on the fast bowling action i.e throwing of the players.~At the same time lower extremity balance and strengthening is also included to ensure the high speed of sprint."
214301538|NCT04923867|DEVICE|Suturable DuraGen™|Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
214301539|NCT05436925|DEVICE|Dexcom G6 sensor Continuous Glucose Monitor (CGM)|The device used as part of the study is to obtain results for glucose testing for research only and not for diagnostic purposes.
214901022|NCT06576180|PROCEDURE|Surgical resection|Standard of care
214901023|NCT06230926|OTHER|Validity, Reliability and Adaptation|The Hoehn \& Yahr Scale (HDS) and the Unified Parkinson's Disease Rating Scale (UPDRS) will be used for the clinical evaluation and disease staging of the individuals included in the study. In addition to the PDQoL-7 questionnaire, the 'Short Form-36' and 'Parkinson's Disease Questionnaire-39' questionnaires will be administered to patients to assess concurrent validity. Since at least 5-10 times the number of items in the questionnaire (7 items) must include at least 5-10 times the number of participants in order to perform factor analysis, a pretest of the questionnaire will be applied to individuals with PD with at least 35-70 participants. To determine the test-retest reliability, the PDQoL7 questionnaire will be administered again to the same patients after 2 weeks.
214301540|NCT00859235|DRUG|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
214301541|NCT00859235|OTHER|Plain water|Mouth wash prior to procedure
214301542|NCT01132547|DRUG|cyproheptadine hydrochloride|Given orally
214301543|NCT01132547|OTHER|placebo|Given orally
214301544|NCT03407573|BIOLOGICAL|Administration of Red Cell|Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.
214301545|NCT01897142|BIOLOGICAL|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
214301546|NCT01897142|DRUG|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
214901024|NCT01269216|DRUG|5-FU with leucovorin|5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29
214901025|NCT01269216|DRUG|TS-1 with Irinotecan|Irinotecan 40mg/m2/day IV on day 1,8,15,22 and 29 with TS-1 70mg/m2/day PO for 25 days
214901026|NCT06648395|BEHAVIORAL|CBT Text Messages|CBT text messages will be sent 3 times per week for 4 weeks
214901027|NCT06648395|BEHAVIORAL|Supportive Messages|Supportive text messages will be sent 3 times per week for 4 weeks
214901028|NCT04648969|DRUG|kisspeptin 112-121|20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
214901029|NCT04648969|DRUG|GnRH|1 intravenous dose of GnRH
214901030|NCT06147999|DEVICE|Biophotonizer - a Biophoton Generator|A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.
214901031|NCT01024504|DRUG|Oxaliplatin|Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
214901032|NCT01024504|DRUG|Capecitabine|Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
214901033|NCT01024504|DRUG|Bevacizumab|Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
215054705|NCT05210088|DRUG|Hypoxia, intermittent|"The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored."
215054706|NCT05210088|OTHER|Normoxia|The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
215054707|NCT04097275|OTHER|Skin biopsy|The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.
214479015|NCT06689540|BIOLOGICAL|MTS105|"MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg."
214479016|NCT06868394|RADIATION|radiotherapy|The impact of previous radiotherapy exposure was studied on developing second primary malignancies.
215054708|NCT04097275|OTHER|Withdraw of blood|"Blood will be collected in:~* 1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~* 1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~* 1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing"
215054709|NCT02590276|BEHAVIORAL|characterization|
215054710|NCT03612128|OTHER|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
215054711|NCT03612128|OTHER|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
215054712|NCT04983693|BEHAVIORAL|Dementia-friendly Worship Service|Key elements of dementia-friendly worship services include familiar hymns, prayers and bible stories and short sermons. Participants can attend the worship services either in person or through online video streaming. Participant dyads should watch the six worship services together, over a span of 6 to 8 weeks.
215054713|NCT02468687|DRUG|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
214301547|NCT01897142|BIOLOGICAL|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
214301548|NCT01897142|DRUG|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
214301549|NCT01897142|BIOLOGICAL|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
214301550|NCT01897142|DRUG|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
214301551|NCT01897142|BIOLOGICAL|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
214301552|NCT01897142|DRUG|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
214301553|NCT01897142|BIOLOGICAL|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
214301554|NCT01897142|DRUG|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
214901034|NCT01237171|RADIATION|Cesium-131 Brachytherapy Seed|85 Gray Dose
214901035|NCT05532111|DRUG|Rituximab combined with tacrolimus induction + rituximab maintenance|RT-R group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml). At the end of 24 weeks, tacrolimus was stopped, and rituximab was given 1 g/time × 1 time.
214901036|NCT05532111|DRUG|Rituximab combined with tacrolimus induction + tacrolimus maintenance|RT-T group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml).
214901037|NCT05532111|DRUG|Glucocorticoid combined with cyclophosphamide induction + maintenance|PC-C group: The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d), and the dose was gradually reduced after 4-8 weeks, and then stopped within 6-9 months. Cyclophosphamide 750mg/m2 (adjusted according to eGFR and other conditions), once a month, intravenous pulse therapy. CTX maintenance therapy.
214901038|NCT05348772|DRUG|AmnioPul-02|Mesenchymal stem / stromal cells, MSC
214901039|NCT00572936|DRUG|Latanoprost|prostaglandin
214901040|NCT00572936|DRUG|Dorzolamide|carbonic anhydrase inhibitor
214901041|NCT00572936|DRUG|Timolol|beta blocker
214901042|NCT05737524|OTHER|Telerehabilitation (VAST 2)|The telehealth platform will be available by a web secure link accessible on a home computer or loaded on user friendly tablets that are customized for the patient's impairments. Telerehabilitation services will include 2 out of 3 disciplines: Occupational Therapy, Speech Therapy, Physical Therapy. All therapy interventions will be delivered by licensed therapists and will be based on patients' specific impairments and goals. Therapy intervention will be provided 3x/wk. for each of 2 disciplines. The intervention will be going on for 4 weeks which will total to 24 sessions. Self-management support with trained health coach will be integrated into 1 therapy session each week. An additional individual 30 minute session will occur with the health coach each week.
214901043|NCT02547428|DRUG|CTN SR|CTN SR tablets, daily, Orally.
214901044|NCT02547428|DRUG|Matching placebo|Matching-placebo tablets daily, orally.
214901045|NCT05138588|DEVICE|rTMS|For each subject, a verum condition and a control condition will be programmed. We will use the QPS-5 method (4 pulses, Inter-Stimulation Interval; ISI: 5 seconds).
214901046|NCT04399616|OTHER|Risk Map|The tool we test in this project (the visual hazard map) aims to enable the practitioner to quickly identify critical areas for systematically implementing relevant safe practices (appropriate for each situation).
214901047|NCT04572503|PROCEDURE|Barbed Suture Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
214901048|NCT01479465|BIOLOGICAL|Simtuzumab|SIM administered via intravenous infusion over 30 minutes
214901049|NCT01479465|DRUG|Placebo to match SIM|Placebo to match SIM administered via intravenous infusion over 30 minutes
214901050|NCT01479465|DRUG|Leucovorin|l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours
214901051|NCT01479465|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 administered via intravenous infusion over 90 minutes
214901052|NCT01479465|DRUG|Fluorouracil|Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours
214901053|NCT02807038|PROCEDURE|Lung function test|Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
214901054|NCT04820465|OTHER|Non available due to cross-sectional study design|Non available since this study (survey) has a cross-sectional design
214901055|NCT01791673|DEVICE|Ultrasound glaucoma treatment|Ultrasound glaucoma treatment with EYEOP1 device
214901056|NCT03043326|DRUG|Tenofovir Disoproxil Fumarate and Emtricitabine|This is an observational study. Pre-exposure Prophylaxis with TDF/3TC will be distributed to all participants elegible to receive PrEP.
214901057|NCT02162251|DRUG|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
214901058|NCT04527718|DRUG|Placebo|placebo as a single SC injection on Day 1;
214901059|NCT04527718|DRUG|611|611 as a single SC injection on Day 1;
214901060|NCT03364725|DRUG|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.
214901061|NCT05688566|DEVICE|pinnacle trainer|The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.
214901062|NCT05023447|BEHAVIORAL|BRIDGE Intervention|Intensive clinical assessment; \>16 sessions of Cognitive Analytic Therapy (CAT); Development of a shared formulation
215054714|NCT01360814|PROCEDURE|quality-of-life assessment|Ancillary studies
214301555|NCT01897142|BIOLOGICAL|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
214301556|NCT01897142|DRUG|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
214301557|NCT05811234|DRUG|CAL/BDP PAD Cream|As provided in real-world clinical practice.
214301558|NCT00259077|DRUG|Omeprazole|
214301559|NCT06961344|DRUG|zagociguat 15mg|once daily oral tablets
214901063|NCT05023447|BEHAVIORAL|Service as Usual|Likely to range from social services, mental-health services, forensic services to no intervention
214901064|NCT03014583|DEVICE|Precision Spectra™ system|Neurostimulation procedures
214901065|NCT01449656|DEVICE|LMA Proseal: control device|LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization
214901066|NCT01449656|DEVICE|LMA Supreme: comparison device|LMA Supreme will be placed in children weighing 10-20kg based on a computer generated randomization
214901067|NCT04886583|DEVICE|Gabi Baby Band|Every enrolled patient must wear the Gaby Baby Band on the left arm in the aim to perform data analytics after the test has been performed
214901068|NCT04651855|DRUG|Mesenchymal stem cells isolated from Wharton's jelly|Intrathecal administration of mesenchymal stem cells
214901069|NCT04150939|PROCEDURE|Core Biopsy|Undergo core biospy
214901070|NCT04150939|PROCEDURE|Cryosurgery|Undergo cryoablation
214901071|NCT04150939|DRUG|Immunotherapeutic Agent|Receive standard of care immunotherapy
214901072|NCT05051735|DRUG|Paracetamol|Paracetamol 500 mg
214901073|NCT05051735|DRUG|Placebo|Placebo
215054715|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive multidisciplinary structured intervention
215054716|NCT01360814|OTHER|questionnaire administration|Ancillary studies
215054717|NCT01360814|OTHER|counseling intervention|Receive multidisciplinary structured intervention
215054718|NCT01360814|BEHAVIORAL|exercise intervention|Receive multidisciplinary structured intervention
215054719|NCT01360814|OTHER|educational intervention|Receive multidisciplinary structured intervention
215054720|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive standard care
215054721|NCT01360814|PROCEDURE|standard follow-up care|Receive standard care
214301560|NCT04310020|DRUG|Atezolizumab|Given IV
214301561|NCT04310020|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214301562|NCT04310020|PROCEDURE|Computed Tomography|Undergo CT scan
215054722|NCT04192045|OTHER|Survey|A survey will be used at 24 hours and 30 days to assess the quality of recovery
215054723|NCT06367660|DRUG|Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine|In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
215054724|NCT02775630|PROCEDURE|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
215054725|NCT05634824|DRUG|intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO)|rhTPO at an initial does of 150U/kg qd subcutaneously for 28 days and IVIg 400mg/kg qd for 5 days. The maintenance treatment consisted rhTPO 150U/kg qd.
214901074|NCT00370552|DRUG|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m\^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
215054726|NCT05634824|DRUG|intravenous immunoglobulin|intravenous immunoglobulin
215054727|NCT01819363|PROCEDURE|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
215054728|NCT06312163|DEVICE|The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design). A CE (UKCA) marked class 2 medical devices.|The participants will be fitted with (i) the optimal lens design as specified by the virtual fitting module, in addition to (ii) lenses that are one clinically significant step (0.12 mm) flatter and (iii) steeper in axial edge lift (AEL).
215054729|NCT04263766|OTHER|Transcranial magnetic stimulation|TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
215054730|NCT02678754|OTHER|No intervention required, purely observational|
215054731|NCT00302172|DRUG|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
215054732|NCT04163653|DIAGNOSTIC_TEST|Non-contrast MRI|Classification and characterization of the lymphatic vasculature using non-contrast MRI.
215054733|NCT04163653|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Cardiopulmonary exercise test, measurement of VO2 and heart rate.
215054734|NCT06413147|DEVICE|PFO closure|Surgery of PFO closure
215054735|NCT00581048|DRUG|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
214301563|NCT04310020|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214901075|NCT00370552|DRUG|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m\^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
215054736|NCT02088099|OTHER|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
215054737|NCT02088099|OTHER|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
215054738|NCT02186782|DRUG|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
214301564|NCT04310020|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214301565|NCT02166554|OTHER|Saline|On the day of initial surgery
214301566|NCT02166554|DEVICE|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
214301567|NCT01874847|DIETARY_SUPPLEMENT|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
214301568|NCT01874847|DIETARY_SUPPLEMENT|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
214301569|NCT04267991|DRUG|Tacrolimus ointment|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
214901076|NCT00370552|DRUG|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m\^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
214901077|NCT04262648|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|Lactobacillus Reuteri NCIMB 30351
214901078|NCT04262648|DIETARY_SUPPLEMENT|Placebo|Sunflower oil
214901079|NCT04650217|DRUG|Carbidopa/levodopa|"L-DOPA is the immediate precursor of dopamine, is converted to dopamine in presynaptic dopaminergic nerve terminals, and enhances dopaminergic transmission in multiple brain regions. Subjects assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, or 1.5 25mg carbidopa/100mg levodopa tablets at 9am and placebo tablets at~1pm and 5pm. In Week 2 the L-DOPA daily dose will increase to 300mg (1.5 25mg carbidopa/100mg levodopa tablets at 9am and 5pm, with placebo at 1pm), followed by a Week 3 to 8 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets three times daily). Subjects assigned to placebo will take 1.5 placebo tablets three times daily for three weeks. Individuals will be instructed to maintain the same timing of doses throughout the study. Individuals unable to tolerate an increased dose will have their dosage reduced to the maximum previously tolerated dose."
215054739|NCT02186782|DRUG|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
214901080|NCT04650217|DRUG|Placebo|Carbidopa/levodopa matched placebo
214901081|NCT04650217|BEHAVIORAL|Exercise training|Subjects assigned t Exercise will exercise individually at their home on a program set each week by Dr. Sloan and the research assistant (RA) coach, who will work with the patient to ensure they train according to the program at the appropriate level of intensity. Subjects will select from a series of aerobic activities and for Weeks 1-2 will train at 55-65 percent of maximum HR as established during their qualifying CPET. In Weeks 3-4, they will increase exercise intensity to 65-75 percent of maximum HR, and in Weeks 5-12 they will train at 75 percent of maximum HR.
214901082|NCT04650217|BEHAVIORAL|Control|Control will engage in a series of stretches and toning exercises designed to promote flexibility and improve core strength.
214901083|NCT01088477|OTHER|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.
214479017|NCT06868394|OTHER|No intervention|This group received no radiotherapy
214901084|NCT05204992|PROCEDURE|ultrasound guided hydrodissection|Injection of steroids, saline and bupivicaine ultrasound guided
214901085|NCT02883972|OTHER|Intervention letter|Behavioural-insight informed letter template
214901086|NCT02883972|OTHER|Control letter|Invitation letter used by local area last year (updated as required)
214901087|NCT02883972|OTHER|Reminder|Behavioural-insight informed SMS/email reminder message to return consent form
215054740|NCT06554600|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
215054741|NCT06554600|DRUG|Polatuzumab Vedotin|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.
215054742|NCT06554600|DRUG|Bendamustine|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.
215054743|NCT06554600|DRUG|Rituximab|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.
215054744|NCT03371199|DRUG|Sodium chloride|Sodium chloride tablets, 250 mg
215054745|NCT03371199|DRUG|Placebo Oral Tablet|Starch tablets
215054746|NCT05356988|BEHAVIORAL|Physical activity experiment|The Physical Activity (PA) group will have access for one year to the PA website to help increase aerobic and strength training activities.
214479018|NCT06868472|PROCEDURE|Prehabilitation|"The waiting time until the operation is about 6 weeks. The intervention is carried out during this time:~The intervention group receives a brochure with an evidence-based exercise program for the shoulder and shoulder girdle. The brochure contains pages in which the patient documents how the exercises are carried out. The exercise program is supplemented by information in the form of a video/Power Point presentation on: Anatomy/function, pain management, hospitalization and subsequent rehabilitation.~After 2 and after 4 weeks, the physiotherapist who has explained the exercise program will contact you by telephone/zoom."
214479019|NCT06868472|PROCEDURE|Control|The control group receives a leaflet with general information for the period up to the operation (e.g. buy water-resistant plasters, arrange post-op physiotherapy appointments).
214901088|NCT00857155|OTHER|Clopidogrel withdraw prior to CABG|Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
214901089|NCT04333316|PROCEDURE|large head|implantation of large head total hip
214901090|NCT04333316|PROCEDURE|dual mobility cup|implantation of dual mobility total hip
214901091|NCT00839358|DRUG|albumin|albumine 40 g every 15 days
214901092|NCT00839358|DRUG|Midodrine|Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
214901093|NCT00839358|DRUG|Placebo|saline solution
214901094|NCT02070250|BEHAVIORAL|From Cancer to Health (C2H-D)|From Cancer to Health gives people with cancer the information and tools they need to manage their stress to improve their health throughout the cancer journey. Each institution involved in this study will implement the core techniques of the C2H-D Intervention but may alter the format somewhat to meet their patient population needs (e.g., shorten hourly 18 week intervention into 2-hour 9 week intervention).
214901095|NCT04897854|DRUG|Folfirinox|In both arms the intervention will be FOLRINIOX or nab paclitaxel in combination with gemcitabine per investigator's choice
215054747|NCT05356988|BEHAVIORAL|Balance and flexibility control|The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure around stretching and balance exercises.
215054748|NCT03961243|BIOLOGICAL|YUVA-GT-F901|Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
215054749|NCT01179308|OTHER|General-epidural anesthesia|General anesthesia combined with epidural anesthesia
215054750|NCT01179308|OTHER|Balanced general anesthesia and postoperative opioids|General anesthesia alone
214479020|NCT03279978|DRUG|BI 730357|BI 730357 film-coated tablet
215054751|NCT03369665|DRUG|Mavenclad®|Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
215054752|NCT05461599|DEVICE|SparkRx Mobile App|The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
214301570|NCT04267991|PROCEDURE|phototherapeutic keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
214301571|NCT00121420|DRUG|Motexafin gadolinium|
214301572|NCT05875155|DIAGNOSTIC_TEST|Infectious Disease Labwork|Infectious disease labs will be drawn and resulted.
214301573|NCT05875155|DIAGNOSTIC_TEST|Fertility-Based Labwork|Other labwork to understand fertility may be drawn.
214301574|NCT04499781|BEHAVIORAL|ACCESS II mHealth Intervention|Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
214479021|NCT03279978|DRUG|Placebo|Placebo
214901096|NCT02035111|DRUG|Tianshu capsule|
214901097|NCT02035111|DRUG|Sugar pill|
214901098|NCT03413462|DRUG|HS-25|HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.
214901099|NCT03413462|DRUG|Placebo of HS-25|Placebo HS-25 10mg/tablet, 20mg,once daily,for 12 weeks,and then HS-25 20mg once daily for 40 weeks.
214901100|NCT05264662|DRUG|Adacel (Tdap)|Administer Adacel to hiv infected and hiv uninfected pregnant mothers
214301575|NCT04499781|BEHAVIORAL|ACCESS II control condition|Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
214901101|NCT05635591|BIOLOGICAL|Autologous monocyte - derived DCs pulsed with EBV antigen|Patients will receive approximately （5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
215054753|NCT02553928|DRUG|Memantine (once daily)|
215054754|NCT02553928|DRUG|Memantine (twice daily)|
215054755|NCT05959317|OTHER|Pilates Exercises|Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.
215054756|NCT05959317|OTHER|Neural dynamic mobilization|Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
215054757|NCT05238350|PROCEDURE|Acupressure|Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
215054758|NCT03366363|OTHER|acupuncture|acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
215054759|NCT01316458|DRUG|STI571 (Glivec®)|
215054760|NCT00689897|PROCEDURE|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
215054761|NCT00689897|PROCEDURE|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
215054762|NCT03369015|DRUG|10 mg d-amphetamine|10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
215054763|NCT03369015|DRUG|20mg d-amphetamine|20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
215054764|NCT03369015|DRUG|Placebo|Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
215054765|NCT03926910|DIAGNOSTIC_TEST|Detection of hypovolemia using a ventricular stimulation without atrial pacing|"Upon the return in intensive care:~* Baseline measurements: 1) Three measurements of blood pressure during inspiration and 3 during expiration will be collected for averaging systolic blood pressure, diastolic blood pressure, mean arterial pressure and ΔPP. Data from a pulmonary artery catheter will be also collected.~* Realization of VESAP pacing with adjustment of the pacemaker (PM) at a heart rate 5 bpm higher than the heart rate of the patient. After 20 seconds of stimulation, recording of the blood pressure curve as done at baseline during at least 3 respiratory cycles,~* Then vascular filling with 500 ml of physiologic saline solution over 10 minutes and new set of measurement (same than at baseline)~* Second realization of VESAP pacing, and new set of measurement (same than at Baseline)~* Then, if the ΔPP is \>10%, new vascular filling with 500 ml of physiologic saline solution over 10 min and new set of measurements as previously performed."
215054766|NCT00976638|OTHER|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
215054767|NCT00976638|OTHER|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
215054768|NCT05879731|OTHER|EEG-hd (high density electroencephalogram)|"Once in the operating room, the investigators will place a 128-channel Hd-EEG (high density electroencephalogram) saline net referenced to Cz on the patient's head. Impedances will be verified and maintained \<50 kΩ for the duration of the study. The patient will be positioned supine and all routine monitors will be installed. A 5 minutes baseline resting-state Hd-EEG with eyes closed will be performed before induction. Once under general anesthesia and intubated, a no pain period of 5 minutes will take place. During this 5-min period, resting-state Hd-EEG recording will be recorded. A standardized tetanic stimulation to the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator (100 Hz, 70 mA) for a duration of 30 seconds will then be applied. Hd-EEG recording will take place during this 30 seconds and will continue during the 5 minutes after. Once this period will be over, the Hd-EEG net will be removed and the investigators will exit the operating room."
214479022|NCT03279978|DRUG|Midazolam|Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed
214479023|NCT04998422|DRUG|HG381|HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
214479024|NCT06874101|DEVICE|Activated ROAM System with User Feedback|The activated ROAM device will provide the user with daily information about their oxygen therapy usage and pulse oximetry.
214479025|NCT06874101|DEVICE|Sham Comparator|The sham comparator is a ROAM device that monitors oxygen usage, but keeps the usage details blind to the user.
214479026|NCT06877806|OTHER|Core exercise|The experimental treatment had a total of 18 introductory courses lasting 30 minutes each. The treatment included exercises to increase the mobility and strength of the neck, shoulders, pelvis and hips, and anti-flexion, anti-extension and rotation exercises were used to stabilize the spine. McGill curl-up was performed during each treatment for all 6 weeks. In the first two weeks, the subjects did general and introductory exercises (all positioned planks, plank walking, forearm cranes, plank pad forearms, etc.). Week 3 and 4 with additional movements and rotations (alternating hand and foot board holding, superman posture, faceplate switches, etc.). During the fifth and sixth weeks, the exercises were performed on unstable surfaces (one-handed board, ball stirring pot, feet raised sideboard, etc.). The intensity of those training courses was individual, but each one started at submaximal.
214479027|NCT06877507|DEVICE|Gastroscopy|Gastroscopy for all included patients
214479028|NCT06877507|DIAGNOSTIC_TEST|Gas Chromatography - Mass Spectrometry|Using a patient's exhaled breath test with Gas Chromatography - Mass Spectrometry
214479029|NCT05525104|DEVICE|Narcotrend Monitor (MT MonitorTechnik, Hannover, Germany)|"This trial is designed to investigate the additional value of Density Spectral Array monitoring, on the speed of emergence after general anaesthesia. We will compare traditional general anaesthesia with sevoflurane using a MAC value and subjective clinical parameters to the objective and continuous approach using DSA depth of hypnosis. The investigational product is the validated Narcotrend monitor, an electroencephalographic monitor, that is regularly used in anaesthesia practice in the Sophia children's hospital and will be used according to intended purpose. The extended version as used in the operating room in the Sophia Children's hospital offers a diversity of diagrams including Density Spectral Array.~The electroencephalographic Narcotrend monitor records frontal EEG-activity. Standard paediatric ECG electrodes are used for EEG registration"
214901102|NCT03975894|BIOLOGICAL|Serial prophylactic exchange blood transfusion (SPEBT).|"Serial prophylactic exchange blood transfusion (SPEBT) will be given via automated apheresis technology. SPEBT will be carried out on the haematology day unit or on the antenatal day unit/ward in accordance with local policies in participating units. The procedure will be carried out using standard operating procedures, by the clinical or research nurse/midwife, haematology day unit staff or specialist sickle nursing staff. Venous access will be via peripheral access if possible or by femoral line access if not.~SPEBT will be commenced between 6 and 18+0 weeks gestation. It will be repeated at 6-10 weekly intervals aiming to maintain HbS% \<30%. It will continue throughout pregnancy and be stopped at the end of pregnancy.~Number of red cell units used per transfusion will depend on patient weight and pre-transfusion HbS%, but will usually be between 6 and 8 units of red cells on each occasion of exchange transfusion."
214901103|NCT02496182|DRUG|Placebo|Placebo tablet only with the excipients of the Pirfenidone tablet
214901104|NCT02496182|DRUG|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg
214901105|NCT02496182|DRUG|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
214901106|NCT01644240|DRUG|TD-8954|Intravenous infusion
214901107|NCT01644240|DRUG|Placebo - saline|Intravenous infusion
214901108|NCT03036657|DEVICE|MAC acupuncture needles|"Sterile single-use MAC acupuncture needles (0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea. Used for Manual Acupuncture~Used for: Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
214901109|NCT03036657|DEVICE|Electrostimulator 6c.Pro, Pantheon Research, Venice, CA|"Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture~Used for Interventions:~Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min"
214901110|NCT03095664|BEHAVIORAL|Intervention group|A behavior change program with 4 monthly 90-min sessions about healthy eating and physical activity.
214901111|NCT00942084|DRUG|Acyclovir|"Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days)."
215054769|NCT04463537|PROCEDURE|Body Temperature Measurements|"measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form."
215054770|NCT04858542|BEHAVIORAL|Educational Vocal Health Modules|We have developed four educational health modules (total duration of approximately 30 minutes). First, these modules explain how masks impact communication and voice, then they describe health strategies to improve communication and voice, and finally, they give real-life examples of how the strategies can be implemented into the work setting.
214479030|NCT04479514|OTHER|Warm Baths or Showers|Daily warm baths or showers
214479031|NCT04479514|OTHER|Moisturizer|moisturizers applied daily immediately after bathing
214901112|NCT04348552|OTHER|Primary care professionals reports of potential patient safety incidents, non-COVID-19 related|Primary care professionals reports of potential patient safety incidents, non-COVID-19 related
214901113|NCT00940628|BEHAVIORAL|Diet and Exercise|mildly hypocaloric diet and physical exercise
214901114|NCT00940628|DRUG|orlistat [Xenical]|120mg po tid
214901115|NCT04885309|PROCEDURE|Nerve Stimulator-guided Obturator Nerve Block|Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.
214901116|NCT00234637|DRUG|Rivastigmine, memantine|
214901117|NCT01381965|PROCEDURE|Vitreous surgery for macular hole|Vitreous surgery for macular hole
214901118|NCT04540991|PROCEDURE|implant placement|The implants are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
214901119|NCT04540991|PROCEDURE|gingiva former placement|Gingiva former are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures of oppeninf implant cower and gingiva former placement on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
215054771|NCT04981847|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for 3 months.
215054772|NCT03782623|DIAGNOSTIC_TEST|Analysis of eicosanoid profile prior to and after PRBC transfusion|Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
214479032|NCT04479514|DRUG|SPF 30 or Higher Suncreen|Mineral based sunscreen of SPF 30 or higher applied on a daily basis on all sun exposed areas.
214479033|NCT04479514|OTHER|Sun Protective Clothing|Sun protective clothing worn when outdoors
214479034|NCT04479514|BEHAVIORAL|Limited Sun Exposure|Limit sun exposure during peak hours of 10am-4pm
214479035|NCT04479514|OTHER|Dilute bleach baths|Warm 10-15 minute dilute bleach baths every other day
214479036|NCT01504789|BEHAVIORAL|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
214301576|NCT03935373|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of Sjögren's syndrome patients and health subjects will take to do the DNA Exome sequencing.
214301577|NCT03935373|DIAGNOSTIC_TEST|Oral microbiome|The saliva of Sjögren's syndrome patients and health subjects will take to do the oral microbiome.
214479037|NCT01504789|BEHAVIORAL|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
214901120|NCT04540991|DIAGNOSTIC_TEST|Collecting gingival epithelial cellsusing the swab technique|Samples of gingival epithelial cells are collected from each participant's implementation site using the swab technique at three different time points: a control swab is taken just before the placement of the dental implant (T0); the second swab is taken 90 days after implantation meaning immediately before placement of the gingiva former (T1); and the third swab is taken 21 days after placement of the gingiva former (T2).
214901121|NCT01276340|DEVICE|KEAT stimulator|electrical stimulation with KEAT stimulator : 4 times per week during 2 months
214301578|NCT03935373|DIAGNOSTIC_TEST|Proteomics|The protein of Sjögren's syndrome patients and health subjects will take to do the proteomics.
214901122|NCT01772589|PROCEDURE|New saw blade|
214901123|NCT01772589|PROCEDURE|Reprocessed saw blade|
214901124|NCT00789048|OTHER|radiograph|One radiograph with the patient lying on his contralateral side
214901125|NCT04369391|DRUG|SEP363856 150 mg|SEP363856 tablet 150 mg
214901126|NCT04369391|DRUG|Placebo|Placebo tablet
214901127|NCT04369391|DRUG|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
214901128|NCT05382273|BEHAVIORAL|T-Break Guide|"The T-Break Guide was designed to help people complete a 21-day break from cannabis. For each day of the break, the Guide offers inspiration in the form of a quote, reflections based on likely experiences occurring at that point during the break, advice on ways to overcome challenges, alternative activities in which to engage, and encouragement.~* The first week focuses on physical symptoms of cannabis withdrawal (e.g., sleep, appetite).~* The second week focuses on the emotional experience (e.g., anxiety, boredom).~* The third week focuses on behavioral aspects (e.g., examining patterns, connections).~The T-Break Guide follows the Motivational Interviewing principles of affirmation and autonomy."
214901129|NCT06359990|BEHAVIORAL|BrotherlyACT|BrotherlyACT is a digital intervention to prevent youth violence and substance use among trauma-exposed young Black males, ages 125-24. This intervention combines life skills coaching, safety planning tools, and an AI-driven chatbot to reduce the risk and effects of violence and early substance use.
214301579|NCT03935373|DIAGNOSTIC_TEST|RNA sequencing|The RNA of Sjögren's syndrome patients and health subjects will store to do the RNA sequencing.
214301580|NCT03935373|DIAGNOSTIC_TEST|Cytokine|The serum of Sjögren's syndrome patients and health subjects will store to do the cytokine detection in the future.
214479038|NCT01504789|BEHAVIORAL|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
214479039|NCT01504789|BEHAVIORAL|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
214479040|NCT06048250|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214901130|NCT06359990|OTHER|BrotherlyACT Waitlist Control Group (WCG)|During the waiting period, participants in the control group do not receive the BrotherlyACT intervention but may continue with their usual activities or interventions.
214901131|NCT01468714|DRUG|PF-04937319 / ketoconazole|Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
214301581|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pattern.
214479041|NCT06048250|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214901132|NCT05862623|DRUG|AER-01|AER-01 solution for inhalation delivered via nebulizer
214901133|NCT05862623|DRUG|Placebo|Placebo for solution for inhalation delivered via nebulizer
214901134|NCT04807010|PROCEDURE|Prostate Artery Embolization|Prostate artery embolization reduces symptoms from benign prostatic hyperplasia by delivering embolic materials to the prostate through the prostatic arteries.
214901135|NCT04807010|PROCEDURE|Sham Prostate Artery Embolization|Angiogram without embolization initially. At 6 months patients will be allowed to crossover to prostate artery embolization.
214901136|NCT01451450|DRUG|QGE031|QGE031 liquid for subcutaneous injection.
214301582|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine tongue diagnosis.
214301583|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pulse diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pulse diagnosis.
214901137|NCT01451450|DRUG|Placebo|Placebo liquid for subcutaneous injection.
214901138|NCT00656422|DRUG|insulin Levemir|The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
214901139|NCT00656422|DRUG|insulin Lantus|The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
214901140|NCT06266325|OTHER|There is no intervention. Exposures are predictor variables of mortality.|Predictor variables of mortality will be in following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information.
214901141|NCT01366417|DRUG|ChloraPrep One-Step|1.5 ml applicator patient preoperative skin preparation
214901142|NCT01366417|DRUG|70% isopropyl alcohol|Curity Alcohol Prep Pads
214901143|NCT03979625|OTHER|Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies|Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.
214901144|NCT01151124|BIOLOGICAL|CTX0E03 neural stem cells|Single administration by surgical delivery to the damaged area of the brain
214901145|NCT06313541|RADIATION|SBRT or LDRT|Radiotherapy: (1) Low dose radiotherapy (LDRT) : a dose of 2 Gy/1 Fx was given to all visible lesions in the whole body within 1 week before the first course of PD-1/PD-L1 inhibitor combined with chemotherapy (different parts of the lesion could be irradiated separately, but it was required to be completed within 1 week); (2) SBRT: patients received first-line immunotherapy combined with chemotherapy, and their response was evaluated every 6 weeks. Individualized SBRT was planned based on the treatment responses.
215054773|NCT05671523|PROCEDURE|Dry needling|Firstly the skin is cleaned with a piece of cotton immersed in alcohol. Then sterilized disposable thin, stainless steel needles (25 × 0.30 mm) will be inserted into the skin over the nodule in A1 pulley anatomic location. The duration of needling will be 1 minute. The needle will be inserted deeply at 45° to the level of metacarpophalangeal level to the nodule. The needle may be inserted into the tendon. This is confirmed by needle movement when the patient ﬂexes and extends the distal phalanx. The needle is withdrawn slowly until this motion ceases, and the needle tip is in the A1 pulley. This will be repeated 2 times per week for 5 weeks.
215054774|NCT05671523|OTHER|conventional treatment|"Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing."
215054775|NCT03230318|DRUG|derazantinib|Derazantinib was administered orally at 300 mg once daily
215054776|NCT00377897|PROCEDURE|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
215054777|NCT01053533|DRUG|Chinese herbal medicines plus western therapy|injections of Chinese herbal medicines and Chinese herbal medicines decoction\& supportive therapy and antivirus therapy when necessary
215054778|NCT01053533|DRUG|western therapy|supportive therapy and antivirus therapy when necessary
215054779|NCT02253082|DRUG|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
215054780|NCT02253082|BIOLOGICAL|Fresh frozen plasma|Standard FFP from the Blood Bank
214901146|NCT06313541|DRUG|PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy|The control group received standard PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy as first-line treatment, and the experimental group received extra treatment response adapted hybrid radiotherapy.
214901147|NCT03604224|DRUG|Canagliflozin 300 mg|Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
214901148|NCT03627975|PROCEDURE|Conservative treatment|"1. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment.~2. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima.~3. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved."
214901149|NCT06520618|DRUG|Qing Re He Ji|Oral administration of Qing Re He Ji
214901150|NCT06520618|DRUG|Shuanghuanglian Oral Liquid|Oral administration of Shuanghuanglian Oral Liquid
214901151|NCT01641640|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
214901152|NCT01641640|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214901153|NCT01641640|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
214901154|NCT03076892|DEVICE|Aktilite® Galderma|preparation of the lesions, Metvixia application + occlusive dressing during 3 hours + illumination: 7 to 10 minutes
215054781|NCT02705482|BIOLOGICAL|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
214479042|NCT06048250|PROCEDURE|Computed Tomography|Undergo CT
214479043|NCT06048250|BIOLOGICAL|Mezigdomide|Receive PO
214479044|NCT06048250|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214901155|NCT03076892|DEVICE|PHOS ISTOS PDT|preparation of the lesions, Metvixia application + occlusive dressing during 30 minutes + illumination: 2.5 hours
214901156|NCT02308969|DRUG|LSD|100ug per os, single dose
214901157|NCT02308969|DRUG|Placebo|Capsules containing mannitol looking identical to LSD
215054782|NCT02705482|BIOLOGICAL|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
214901158|NCT06360172|BEHAVIORAL|Motivational Interviewing|Motivational interviewing, or MI, is a collaborative, person-centered counseling technique to uncover and enhance a person\&#39;s motivation for behavior change
215054783|NCT02705482|BIOLOGICAL|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
215054784|NCT04475159|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)|Pressurized Intraperitoneal Aerosol Chemotherapy will be delivered to the abdominal cavity by means of laparoscopy.
215054785|NCT00209144|DRUG|Intensive insulin therapy|
215054786|NCT03925103|PROCEDURE|3D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system
215054787|NCT03925103|PROCEDURE|2D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
215054788|NCT03569878|BEHAVIORAL|Peer-Integrated Multidisciplinary Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
215054789|NCT03569878|BEHAVIORAL|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
215054790|NCT03194308|BEHAVIORAL|PrEP for Safer Conception|Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.
214301584|NCT03935373|DIAGNOSTIC_TEST|Heart rate variability|Sjögren's syndrome patients and health subjects will take the heart rate variability.
214301585|NCT03935373|DIAGNOSTIC_TEST|Schirmer's test|Sjögren's syndrome patients will take the Schirmer's test.
214301586|NCT03935373|DIAGNOSTIC_TEST|Blood function test, liver function test, kidney function test, and immune function test|Sjögren's syndrome patients and health subjects will take the blood function test (WBC, RBC, Hb, HCT, Platelet, MCV, MCH, and MCHC), liver function test (AST and ALT), kidney function test (BUN and Cre), and immune function test (RF, Anti-SSA, Anti-SSB Ab, ESR, and CRP)
214901159|NCT01839708|BEHAVIORAL|Lifestyle Counseling|The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
214901160|NCT00180843|DRUG|salbutamol + ipratropium bromide nebules|
214901161|NCT00180843|DRUG|nebulized saline|
215054791|NCT04065698|DRUG|RV521|Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
214479045|NCT05131347|BEHAVIORAL|motor intervention|Children in the motor intervention group will receive motor skills training based on motor learning theory. Movement activities include playing on trampoline and tilt board, walking on knees, toes and heels, creeping and crawling under different obstacles, jumping forward and backward, driving scooter board, playing balance devices, hopping, and visual motor coordinated movement. These activities are designed from easy to complex.
215054792|NCT05858476|OTHER|21-Day Detox and Green Drink supplement|"Detox plan description:~7AM Water 16oz. 8AM Green Drink 16oz. 9AM Ultra Shake 16oz. 9-12PM Water 24 - 48oz. 12PM Green Drink 16oz. 12:30 - 2PM Water 24 - 48oz. 2PM Green Drink 16oz. 3PM Ultra Shake 16oz. 3:30- 6PM Water 24 - 48oz. 6PM Green Drink 16oz. 7PM Detox Soup 16oz. 7:30 - 10PM Water 24 - 48oz. This 21-day period will be followed by 7 days of consuming the Green Drink Supplement."
215054793|NCT00004049|DRUG|apomine|
214301587|NCT03301142|PROCEDURE|Laser|The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.
214479046|NCT05131347|BEHAVIORAL|cognitive intervention|Children in the cognitive intervention group will receive cognitive training. The activities consist of 12 exercises with progressive cognitive demands at 10 levels to improve cognitive functions such as attention, cognitive flexibility, inhibitory control, and working memory.
214901162|NCT03540888|OTHER|Deep transverse Friction Massage|The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur
214901163|NCT03540888|OTHER|Dynamic stretching intervention|Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
214901164|NCT03540888|OTHER|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
214901165|NCT03849924|BEHAVIORAL|Self-affirmation|Self-affirmation implementation intentions in the form of a questionnaire.
215054794|NCT06015360|PROCEDURE|Fat Graft|Fat grafting
215054795|NCT05849350|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
215054796|NCT05849350|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
214301588|NCT03301142|PROCEDURE|kinesiotherapy|"Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions."
214901166|NCT00422916|BEHAVIORAL|behavioral intervention|
214901167|NCT02127151|DRUG|BMN 673|Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
214301589|NCT04275791|OTHER|Triage|Experimental : Trauma patient orientation in a structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
214901168|NCT01836471|DRUG|QAW039|QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
214901169|NCT01836471|DRUG|Placebo QAW039|Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
214901170|NCT01836471|DRUG|Fluticasone 250 mcg|Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
214901171|NCT01836471|DRUG|Fluticasone 100 mcg|Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
214901172|NCT02637882|OTHER|Ear plug|The patients will receive the first intervention (ear plug) in the third night (N3) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale.
214901173|NCT02637882|OTHER|Eye mask|The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
214901174|NCT02637882|OTHER|Mixed intervention (ear plug and eye mask)|The patients will receive the intervention (eye mask and ear plug) in the first night (N1) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
214301590|NCT03419000|GENETIC|blood sample|Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
214301591|NCT05147766|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214901175|NCT04556682|DEVICE|Rotational atherectomy|Device used for severely calcified coronary lesion preparation before stent implantation.
214901176|NCT04556682|DEVICE|Intravascular lithotripsy|Device used for severely calcified coronary lesion preparation before stent implantation.
214901177|NCT02564601|BEHAVIORAL|Piano Training|The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
214901178|NCT02564601|BEHAVIORAL|Computer Cognitive Training|The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
214901179|NCT00128882|DRUG|Anti-D|Subcutaneous injection
214901180|NCT06453668|BIOLOGICAL|TCD601|Investigational Product
214901181|NCT00958958|OTHER|multifaceted strategy|"There are multifaceted Interventions Including~1. Distribution of educational materials: distribution of published or printed recommendations for clinical care.~2. Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used~3. Reminders~4. Practical training"
214901182|NCT05183841|DRUG|Bronchodilator (Ipratropium and Fenoterol)|8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
214901183|NCT05183841|OTHER|Placebo|8 puffs of placebo via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
215054797|NCT02440139|DEVICE|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
215054798|NCT02933879|DRUG|NVXT topical|topical treatment
215054799|NCT02933879|DRUG|Placebo (Vehicle) Topical|Placebo (Vehicle) Topical
215054800|NCT01352208|DRUG|ASP9521|oral
215054801|NCT02882191|DRUG|LevoCept|placement of LevoCept IUD
215054802|NCT00220155|DRUG|Gemcitabine|
215054803|NCT05820841|DRUG|R-miniCHOP + Acalabrutinib|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5)~* Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks"
215054804|NCT05820841|DRUG|R-miniCHOP|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks"
215054805|NCT00534768|PROCEDURE|active debridement|debridement on 1st, 3-5th and 7th postoperative days
215054806|NCT00534768|PROCEDURE|control group|Postoperative debridement on 7th postoperative day
215054807|NCT05711160|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
214301592|NCT04659967|BEHAVIORAL|Virtual Training|Participants will receive a virtual training that is tailored to age-related hearing loss, use of non-custom personal amplification devices, and communication strategies.
214301593|NCT04422054|PROCEDURE|Open Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent open surgical repair.
214301594|NCT04422054|PROCEDURE|Endovascular Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent endovascular repair.
214901184|NCT05720741|BEHAVIORAL|Project THINK|Project THINK is a 30-minute self-guided digital intervention designed to teach children and adolescents how to change the way that they think. Specifically, Project THINK is based on the principles of cognitive restructuring, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project THINK uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for assessing the presence of unhelpful thoughts and replacing them with more helpful ones. Although never formally tested in a randomized trial, Project Think has been used by hundreds of students, and feedback has been very positive.
214901185|NCT05720741|BEHAVIORAL|Project SHARE|Intervention delivered in a web browser that focuses on encouraging feelings disclosure to trusted others using facts about the brain, testimonials from peers, and writing exercises (also referred to as Sharing Feelings Intervention; Schleider et al., 2021).
214901186|NCT00128635|RADIATION|iodine I 131 monoclonal antibody TNT-1/B|
214901187|NCT01580124|PROCEDURE|PVI alone|PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation
214901188|NCT01580124|PROCEDURE|PVI + Defragmentation + linear lesions|PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
214901189|NCT06121817|OTHER|Food/meal intervention|2 types of exotic fruits, durian and banana, are the study test meals. Both isocaloric test meals are performed at breakfast. All subjects are required to consume the entire meal within 10 minutes.
214901190|NCT02945241|DRUG|Vancomycin|Intravenous
214901191|NCT02945241|OTHER|Cystatin C dosing algorithm|Expressed in milliliters per minute
214901192|NCT02945241|OTHER|Creatine clearance dosing algorithm|Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
214901193|NCT05506046|BEHAVIORAL|Reduced nicotine message exposure|Participants will be shown two messages about harms of reduced nicotine cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that reduced nicotine cigarettes will still have the rest of the harmful chemicals and cause diseases as the regular cigarettes, but they would make it easier to quit.
214901194|NCT05506046|BEHAVIORAL|Modified risk message exposure|Participants will be shown two messages about electronic cigarettes as an alternative to regular cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that electronic cigarettes are less likely than regular cigarettes to cause severe diseases such as lung cancer.
214301595|NCT05487326|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound guidance
214301596|NCT05487326|PROCEDURE|cervical epidural injection|cervical epidural injection by fluoroscopy
214301597|NCT04216654|DIAGNOSTIC_TEST|ELISA (enzyme-linked immunosorbent assay)|ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.
214901195|NCT05506046|BEHAVIORAL|Combined message exposure (reduced nicotine + modified risk)|Participants will be shown two messages, one from the reduced nicotine message set and one modified risk message set.
215054808|NCT05711160|DIAGNOSTIC_TEST|CBCT images|All patients have been undergoing CBCT scans for both jaws
215054809|NCT05711160|DIAGNOSTIC_TEST|IOS images|The patient's teeth have been dried with air syringe and scanned with the Intraoral scanner
215054810|NCT00804895|DRUG|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
214301598|NCT00117247|DRUG|darbepoetin alfa|
214301599|NCT01832870|DRUG|sipuleucel-T|
214301600|NCT01832870|DRUG|ipilimumab|
214901196|NCT05506046|BEHAVIORAL|Control message exposure|Participants will be shown two messages about drinking bottled water. These will be selected from a pool of five message. The messages display specific water products and describe hydration as a healthy activity.
214901197|NCT03124368|DRUG|Danicopan|Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).
214901198|NCT02892669|OTHER|non interventional study|non interventional study
215054811|NCT00804895|DRUG|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
215054812|NCT00804895|DRUG|Verapamil|standard prophylactic treatment
215054813|NCT03409081|DRUG|gilteritinib|oral
215054814|NCT03586024|DRUG|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
214301601|NCT04723940|DRUG|Bactrim|Bactrim will be given for 6 weeks to treat joint infection
214301602|NCT04723940|DRUG|Cefadroxil|Cefadroxil will be given for 6 weeks to treat joint infection
214301603|NCT04723940|DRUG|Doxycycline Hcl|Doxycycline HCl will given for 6 weeks to treat joint infection
214301604|NCT04723940|DRUG|Clindamycin|Clindamycin will given for 6 weeks to treat joint infection
214301605|NCT00487851|PROCEDURE|surgery|hepaticojejunostomy and gastroenterostomy
214301606|NCT00487851|PROCEDURE|endoscopic strategy|Stent insertion
214301607|NCT00280956|DRUG|natalizumab|
214301608|NCT00157703|DRUG|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
214901199|NCT03121846|DRUG|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
214901200|NCT05587322|DRUG|BLI5100|Orally via tablet
214901201|NCT05587322|DRUG|Placebo|Orally via tablet
214901202|NCT05046912|BEHAVIORAL|Yoga|8 weeks of online weekly yoga or chair yoga class
214901203|NCT05046912|BEHAVIORAL|Mindfulness|8 weeks of online weekly mindfulness class
214901204|NCT01109212|DRUG|Bindarit|dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks
214901205|NCT01109212|DRUG|Placebo|dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
214301609|NCT03019107|DEVICE|Breath synchronized abdominal NMES|VentFree prototype (VF03) that delivers electrical stimulation pulses to the abdominal muscles during exhalation with a frequency of 30 Hz, a pulse width of 350 µs and 90% of the maximum current that the participant can tolerate. These stimulation parameters were selected to cause a tetanic (continuous) contraction of the abdominal muscles, without pain for the patient. Stimulation will be administered for 30 minutes 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
214901206|NCT03102346|OTHER|home-based cardiac rehabilitation|The exercise training includes aerobic exercise (fast walking or cycling ,30-40 minutes per day,5-6 times a week), stretching exercise (15 minutes every time, 5-6 times a week), and resistance and balance training (each of 15 minutes every time, twice to 3 times a week).
214901207|NCT04212325|PROCEDURE|Group C (Continuous sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
214901208|NCT04212325|PROCEDURE|Group S (sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After single injection sciatic nerve block, outcome measures will be assessed.
214901209|NCT00766012|DRUG|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
214901210|NCT00766012|DRUG|Placebo|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
214901211|NCT03666130|PROCEDURE|endoscopic septoplasty|endoscopic septoplasty is the use of nasal endoscopy in the septoplasty surgery for treatment of deviated nasal septum . we aim to compare the outcome of using this method versus conventional septoplasty
214901212|NCT00519857|DRUG|Tibolone|1.25 mg p.o, once daily for 3 years
214901213|NCT00519857|DRUG|Placebo|Tablet p.o, once daily for 3 years
215054815|NCT05111197|RADIATION|SRT|"Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface)."
215054816|NCT05111197|DRUG|Immunotherapy|Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
215054817|NCT00075764|DRUG|anastrozole|Given orally
215054818|NCT00075764|DRUG|fulvestrant|Given intramuscularly
215054819|NCT04965298|DRUG|Lansoprazole|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
215054820|NCT04965298|OTHER|Matched placebo|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
215054821|NCT05922228|OTHER|neural flossing with proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week contract relax technique of proprioceptive neuromuscular facilitation for 5 minutes, 10 repetitions ×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 10 minutes
215054822|NCT05922228|OTHER|Neural flossing without proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 5 minutes
214301610|NCT03019107|DEVICE|Sham breath synchronized abdominal NMES|Modified VentFree prototype (VF03) that delivers stimulation pulses to the abdominal muscles during exhalation with a frequency of 10 Hz, a pulse width of 100 µs and current set to 10 milliamp. These stimulation parameters were chosen to cause a twitch contraction of the abdominal wall muscles. Stimulation will be administered for 30 minutes, 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
214901214|NCT00683722|DRUG|Prochymal™|IV infusion of ex- vivo cultured adult human mesenchymal stem cells.
214901215|NCT00683722|DRUG|Placebo|IV infusion of excipient of Prochymal™.
215054823|NCT01119196|OTHER|Icodextrin dialysate|use of alternate SOC dialysate
215054824|NCT02010593|DRUG|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-\[\[4-\[(2,4,6-trimethylphenyl)amino\]-2- pyrimidinyl\]amino\]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
215054825|NCT02010593|DRUG|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
215054826|NCT00088270|DRUG|OSI-7904L|
215054827|NCT00088270|DRUG|5-Fluorouracil/Leucovorin|
215054828|NCT03497468|OTHER|Combined exercise training|Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
215054829|NCT03497468|OTHER|Task-oriented training|Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
215054830|NCT01773967|DRUG|LGG|LGG 10\^10 cfu PO BID X 5 days
215054831|NCT01773967|DRUG|micro-crystalline cellulose|1 capsule PO bid x 5 days
215054832|NCT02623777|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
215054833|NCT02623777|DIETARY_SUPPLEMENT|Short chain fatty acids|Short chain fatty acids administered
215054834|NCT04311970|DEVICE|EsoCheck|All patients with known diagnosis of EoE will be administered the EsoCheck device prior to standard of care endoscopy
215054835|NCT05760027|OTHER|Plyometric exercise|The group of athletes will perform plyometric stability exercises and their usual exercise for 30 days.
215054836|NCT05760027|OTHER|Regular exercise|The group of athletes will perform their usual exercise for 30 days.
215054837|NCT01640015|OTHER|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
215054838|NCT01135459|DRUG|CEP-33457|CEP-33457 will be administered per dose and schedule specified in the arm description.
215054839|NCT01135459|DRUG|Placebo|Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
215054840|NCT01703052|DRUG|CHF 6001 SD or placebo|Dry Powder Inhaler
214901216|NCT06323681|DRUG|Peginterferon α-2b based treatment group|Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks. If the baseline HBV DNA is higher than the minimum detection limit (using high-sensitivity kit), combined with nucleos(t)ide analogs (NAs) is recommended.
214901217|NCT06323681|DRUG|NAs monotherapy group|First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally, for 48 weeks.
214901218|NCT00485719|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally
215054841|NCT01703052|DRUG|CHF 6001 MD or placebo|Dry Powder Inhaler
215054842|NCT04177615|PROCEDURE|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
215054843|NCT05351840|DRUG|LivaloV|Treatment A, Tablet, Oral, QD for 7 Days
215054844|NCT05351840|DRUG|A|Treatment B, Tablet, Oral, QD for 10 Days
215054845|NCT05351840|DRUG|LivaloVA|Treatment C, Tablet, Oral, QD for 7 Days
215054846|NCT05912595|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms."
214479047|NCT05163639|PROCEDURE|Non-invasive pairing of cortical and spinal stimulation|Transcranial magnetic stimulation (TMS) threshold, Transcutaneous spinal cord stimulation (TSCS) threshold, and peripheral and central motor conduction times will be determined. In the active intervention, two TMS pulse intensities will be tested: 90% and 120% of motor threshold. Two conditioning TSCS pulse intensities will be tested: 50% and 90% of response threshold. Single TSCS pulses will be delivered timed to arrive in the cervical spinal cord at a range of intervals from 30ms before to 30ms after the TMS pulse. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
214301611|NCT05643365|RADIATION|Radioactive Iodine therapy|All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.
214301612|NCT03953573|OTHER|Survey|Survey completed at 1 day, 8 days 1 or 3 months post delivery
214901219|NCT00516841|DRUG|Volociximab|15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
214901220|NCT03144908|OTHER|Standard Operating Procedures|Observational on Standard Operating Procedures
214901221|NCT01120808|PROCEDURE|Paper tape|Paper tape assigned to each participant's randomly selected foot.
215054847|NCT02226588|DRUG|Misoprostol|
215054848|NCT03472820|OTHER|Diet Recommendations|Specific dietary guidelines will be outlined for participants.
215054849|NCT03472820|OTHER|Lifestyle Recommendations|Participants are encouraged to average a minimum of 7 hours of sleep per night.
215054850|NCT03472820|OTHER|Exercise Recommendations|Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
215054851|NCT03472820|OTHER|Stress Management Recommendations|Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
215054852|NCT03472820|OTHER|PhytoGanix (tropical fruit flavor)|Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
215054853|NCT03472820|OTHER|UltraFlora Intensive Care|Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
215054854|NCT02089009|OTHER|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
215054855|NCT02089009|OTHER|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
215054856|NCT02089009|OTHER|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
215054857|NCT01324960|DRUG|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
215054858|NCT01324960|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
215054859|NCT01766037|DEVICE|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
214901222|NCT03051100|DRUG|Bempedoic acid 180mg|bempedoic acid 180 mg
214901223|NCT03051100|DRUG|Ezetimibe 10mg|ezetimibe 10 mg
215054860|NCT01766037|BEHAVIORAL|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
214479048|NCT05163639|PROCEDURE|Intraoperative pairing of cortical and spinal stimulation|The surgeon will position spinal cord electrodes on the epidural surface one level rostral (typically C4/C5) to the site of myelopathy. Spinal and cortical thresholds will be determined. Investigator will then test the immediate effects of paired stimulation by stimulating the cortex at 120% of threshold and the spinal cord at 90% of threshold at various latencies relative to the time of synchronous convergence. The control intervention will include cortical only (120%) spinal only (90%) and non-convergent latency pairing stimulation.
214901224|NCT03051100|DRUG|Atorvastatin 20mg|atorvastatin 20 mg
214901225|NCT03051100|OTHER|Placebo|placebo
214901226|NCT04754932|OTHER|Cognitive Stimulation Therapy|Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.
214901227|NCT01160692|DIETARY_SUPPLEMENT|Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months
214901228|NCT01160692|OTHER|Placebo|Daily oral intake of matching placebo tablets for 3 months
214901229|NCT04967820|OTHER|resilience and institutional support|psychological inherent resilience and institutional support during COVID-19 outbreak
214901230|NCT06012344|OTHER|post facilitation stretch|PFS Post-Facilitation Stretch Participants in this arm received the intervention of post-facilitation stretch technique. Post-facilitation stretch involves the application of manual stretching techniques to the targeted muscles after a facilitation phase, which aims to enhance muscle extensibility. The participants underwent a standardized post-facilitation stretch protocol focusing on the hamstring muscles.
214901231|NCT06012344|OTHER|post isometric relaxation|Participants in this arm of the study received the intervention of post-isometric relaxation technique. Post-isometric relaxation involves the application of isometric contraction followed by a relaxation phase to promote muscle lengthening and improve flexibility. The participants underwent a standardized post-isometric relaxation protocol targeting the hamstring muscles.
214901232|NCT06012344|OTHER|hamstring nordic lower|Participants in this arm received the intervention of hamstring Nordic lower exercise. The hamstring Nordic lower exercise is a challenging eccentric exercise that specifically targets the hamstring muscles. Participants performed the exercise under supervision and followed a standardized protocol for the number of repetitions, sets, and rest intervals.
214901233|NCT00450099|DRUG|bupivacaine|0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
214901234|NCT05576142|DIAGNOSTIC_TEST|Oral examination|Patients underwent oral examination with the recording of DMFT, PSR, PI and presence/absence of mouth breathing.
214901235|NCT06578377|OTHER|descriptive study|It is a descriptive study
214901236|NCT05037201|BEHAVIORAL|Text message|The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
214901237|NCT01664663|RADIATION|Standard radiochemotherapy to 68 Gy|
214901238|NCT01664663|RADIATION|Dose escalated radiochemotherapy up to 84 Gy|
214901239|NCT03776357|DEVICE|VERA clinic|A software system used with the Microsoft Kinect intended to support the physical rehabilitation of adults in the clinic and at home.
214901240|NCT00004656|PROCEDURE|Metabolic assessment with body composition evaluation|
214901241|NCT04055701|OTHER|assesment of thymus volume|assesment of thymus volume
214901242|NCT05071209|DRUG|Elimusertib|Given PO
214901243|NCT06576531|OTHER|Therapeutic exercise|A stepped training intervention designed ad hoc based on a combination of aerobic and strength exercises.
214901244|NCT05921903|BIOLOGICAL|RSVPreF3 OA Investigational Vaccine|0.5 mililiter dose was administered intramuscularly as 1 dose to RSV\_IC\_1 and RSV\_HA groups, and 2 doses to RSV\_IC\_2 group.
214901245|NCT06441994|DRUG|PSW-1025|PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)
215054861|NCT05712265|DRUG|Miricorilant|Miricorilant 6 x 100 mg coated tablets
215054862|NCT05712265|DRUG|Fluvoxamine|Fluvoxamine 50 mg tablet
214901246|NCT01471483|BEHAVIORAL|geriatric assessment and telephone call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.
214901247|NCT01471483|OTHER|geriatric assessment and no call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
215054863|NCT01084291|BIOLOGICAL|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
215054864|NCT01084291|OTHER|Placebo injection|Subcutaneous injection of placebo
215054865|NCT04544644|DRUG|AK104+anlotinib|AK 104 is given by intravenous infusion and anlotinib is given by oral.
215054866|NCT04626284|PROCEDURE|Heart Transplantation|Heart Transplantation
215054867|NCT00847899|DRUG|AR9281|AR9281 taken in BID dosing regimen for 28 days
215054868|NCT00847899|DRUG|AR9281|AR9281 taken in TID dosing regimen for 28 days
215054869|NCT00847899|DRUG|Placebo|Placebo taken in BID dosing regimen for 28 days
215054870|NCT00847899|DRUG|Placebo|Placebo taken in TID dosing regimen for 28 days
215054871|NCT05957458|DEVICE|Airdoc device of red light for Myopia|This light is Narrow-Band, Long-Wavelength Lighting with three different illumination (400lux, 800lux, 1200lux) or irridiance (1.2mW, 0.6mW, 0.37mW) respectively. And the wavelength is 650nm. It allows biocular therapy.
214301613|NCT05305534|DEVICE|QIAstat-Dx® BCID GN and GPF Plus AMR Panels|The performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested
214301614|NCT00684476|DRUG|venom immunotherapy|
214479049|NCT05163639|PROCEDURE|Non-invasive repeated pairing of cortical and spinal stimulation (SCAP)|Thresholds will be determined as above. Immediately prior to repetitive pairing, a set of 12 TMS pulses will be delivered at 120% threshold to measure the baseline cortical MEP. Likewise, a set of 12 TSCS pulses will be delivered at 120% of threshold to establish the baseline spinal MEP. For each session, baseline maximal pinch dynamometry will be determined. Immediately after the SCAP protocol is completed, response to TMS, TSCS, and maximal pinch dynamometry will be measured again every 10 minutes over the subsequent hour. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
214901248|NCT05704166|DRUG|Pirfenidone/Placebo|Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
214901249|NCT04099966|DRUG|alpha beta depletion|donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
214901250|NCT03305848|DRUG|Nitrostat 0.4Mg Sublingual Tablet|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure \> 100 mmHg.
214901251|NCT03648229|PROCEDURE|Selective laser trabeculoplasty (SLT)|Delivery of laser energy to the trabecular meshwork of the eye with the goal of reducing intraocular pressure
214901252|NCT03648229|DRUG|Latanoprost ophthalmic solution|Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure
214901253|NCT03648229|DRUG|Timolol ophthalmic solution|Timolol ophthalmic solution 0.5% for reduction of intraocular pressure
214901254|NCT00631592|DRUG|GSK1349572|
214901255|NCT00489866|DRUG|Aripiprazole|Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
214901256|NCT00489866|DRUG|Placebo|Same as active drug.
214901257|NCT06488586|DRUG|Low dose IV Ketamine vs. IN Esketamine|For IV ketamine treatment, ketamine is administered at 0.5mg/kg over 40 minutes. For IN esketamine treatment, esketamine is administered as a nasal spray, two sprays per nostril (56mg total) for the first treatment and three sprays per nostril (84mg) for the rest of the acute series. All treatments are administered at the academic center under the supervision of a mental health care professional. Patients are asked to come fasting at least two hours prior to treatment and to remain resting in the treatment room throughout the dosing session. Throughout each dosing session, blood pressure, oxygen levels, and onset, duration and severity of common side effects are recorded by nursing staff and/or physicians. Patients are discharged after a minimum of 30 minutes post administration, provided that the vital signs return to baseline and that the patient is calm, alert, and oriented.
214901258|NCT05745818|DRUG|Colchicine Pill|oral pills
214901259|NCT06320340|OTHER|Exercise|the patients were performed following five exercises for 20 minutes of treatment session two days a week for the 8 weeks.: (1) the swan-dive vol. I, (2) the swan-dive vol II., (3) breast stroke preparation vol. I, (4) breast stroke preparation vol. II, and (5) swimming vol. II. All the exercises were repeated for the 10 times in a session. Before the exercises, patients were taught and instructed about the five key elements (lateral expansion, centralization, positioning the chest, the shoulder girdle, and the head) of clinical pilates that they should pay attention to while performing the exercises. In addition, verbal and tactile feedbacks were given to patients during all the treatment sessions to maintain the good posture and to perform exercises properly.
214901260|NCT06320340|OTHER|Electrotherapy|Two channels of four-channelled Compex SP Fit-3 (MediCompex SA in Geneva, Switzerland) was used to apply NMES (120 mA, 400 μs, 150 Hz) on lower trapezius and serratus anterior muscles for 20 minutes during exercise.
214901261|NCT03548818|DRUG|Interferon Gamma-1B|Study function and biochemistry of neutrophils off the drug for one week and then 12 hours after first dose and fourth dose.
214901262|NCT03516695|DEVICE|TheraSphere®|Intra-arterial Yttrium-90 glass microspheres
214901263|NCT03837054|BIOLOGICAL|Blood collection and Micronuclei assay on binucleate lymphocytes in culture|"The activity of the oncology Department of the North Hospital ensures the quick and easy recruitment of 30 patients over the 10-month inclusion period. The collection of samples will be done in a forward-looking manner during chemotherapy and at different times. The patients will have 4 blood samples of 10 mL carried out during their chemotherapy with a sampling at T0 (before the initiation of chemotherapy), then to T1 (after the first 3 cures), to T2 (after the 6th cure) and to T3 is 5 weeks after the end of the chemo And before the onset of radiation therapy. The samples will be carried out within the Medical Oncology Department of the hospital Nord of Marseille.~We will also perform micronuclei testing on Binucleate lymphocytes in culture. The lymphocyte Micronuclei test reveals structure and number chromosomal damage and allows to reveal clastogenic or eugènes exposures."
214301615|NCT05567055|DRUG|Capmatinib|Capmatinib is a medication for the treatment of metastatic non-small cell lung cancer tumors that have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR
214301616|NCT03394287|DRUG|SHR-1210|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
214301617|NCT03394287|DRUG|Apatinib|Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
214301618|NCT00644280|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
214301619|NCT03185728|OTHER|iLook Out for Child Abuse|"Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting."
214901264|NCT05511870|DRUG|Etripamil Nasal Spray 70mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
215054872|NCT02963363|OTHER|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
215054873|NCT02994485|DRUG|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
215054874|NCT01109615|DRUG|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
215054875|NCT01109615|DRUG|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
215054876|NCT05401344|DIAGNOSTIC_TEST|test strips,sponges and cold dry air test|Test strips were used to evaluated the degree of dry nose, sponges were used to obtain the nasal secretion and cold dry air test was used to making diagnosis of vasomotor rihinitis.
215054877|NCT03388801|OTHER|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
215054878|NCT02118454|BEHAVIORAL|Daily IVR Calls Intervention|
214301620|NCT02173912|DRUG|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
215054879|NCT02118454|BEHAVIORAL|Weekly IVR Survey Only|
215054880|NCT02725450|BEHAVIORAL|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
215054881|NCT02725450|BEHAVIORAL|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
215054882|NCT00587808|PROCEDURE|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
215054883|NCT06093958|DIAGNOSTIC_TEST|Manual loading of the chest wall|The chest wall will be loaded by either compression of the abdominal wall, compression of the lumbar spine, or compression of the sternum.
215054884|NCT00725946|DRUG|Iodine-124|
214901265|NCT05511870|DRUG|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
214901266|NCT01047384|PROCEDURE|acupuncture-moxibustion therapy|
214901267|NCT01047384|PROCEDURE|Regular therapy|
215054885|NCT00725946|RADIATION|PET/CT with Iodine-124|
215054886|NCT05101733|DIAGNOSTIC_TEST|Nasal provocation|Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device
215054887|NCT05101733|DIAGNOSTIC_TEST|Skin-Prick Test|Skin-Prick-Test is administered to determine an allergy against Alternaria
215054888|NCT05101733|DIAGNOSTIC_TEST|Blood draw|For further analysis
215054889|NCT05101733|DIAGNOSTIC_TEST|Collection of nasal secretion|Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray
215054890|NCT01481350|DRUG|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
215054891|NCT06495320|OTHER|Rational drug use education|Rational Drug Use Education Program for Parents: The training program consists of 30 minutes. The training program will be delivered to parents in the form of a 30-minute training session with a powerpoint presentation, using the face-to-face education model. Interactive education methods that enable parents' participation will be used. In addition, in order to increase the permanence of education, the educational content will be given to parents in the form of an educational booklet.
214301621|NCT02173912|DRUG|CJ-30059 (Test)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
214301622|NCT02065960|RADIATION|Stereotactic body radiotherapy (SBRT)|
214301623|NCT03102931|OTHER|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
214301624|NCT03102931|OTHER|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
214301625|NCT04739631|OTHER|acupuncture|use disposable sterile needles to insert to the acupuncture point
214901268|NCT00789854|DRUG|Quetiapine XR|300 mg once daily (od)
214901269|NCT00789854|DRUG|Lithium carbonate|900 mg once daily (od)
214901270|NCT00789854|DRUG|SSRI/Venlafaxine|SSRI - doses within label, Venlafaxine dose up to 225 mg/day
214901271|NCT03972904|DIETARY_SUPPLEMENT|Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance|Subjects will be given the Light-Fat Rice® combined with Active Peptide® with a lifestyle guidance to assist diabetes management. The method of taking the product has two parts: 1.Light-Fat Rice®: 80g (1 pack) per day as a staple meal replacement, used as a separate staple food or mixed with other staple foods, taking 4 weeks; 2.Active Peptide®: 20g (2 packs) per day (1 pack each morning and evening), served with 300ml of 40°C warm water each time before meals and take it for 4 weeks.
214901272|NCT03972904|DIETARY_SUPPLEMENT|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin (both produced by the same manufacturer) with a lifestyle guidance will be given by the professional to assist in diabetes management. The product is taken as follows: 1.equal-energy staple food containing a small amount of dietary fiber: 80g (1 pack) per day, used as an independent staple food or mixed with other staple foods, taking for 4 weeks; 2.equal-energy maltodextrin: 20g(2 packs) per day(1 pack each morning and evening),take it with 300ml of 40°C warm water for 4 weeks.
214901273|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
215054892|NCT04981106|OTHER|Elastic Band Exercise|"The participants were asked to do exercise 4 times a day with a minimum of 2 hours interval between the sessions. The participants were instructed to avoid elastic band exercise 1 hour before or after the meals in order to prevent a physical impairment and to adopt a moderately progressive approach in order to prevent lower extremity pain after exercise and to increase the sense of success and confidence.~Through phone calls, researchers asked the participants in intervention group if they do the elastic band exercises at home and if they had any difficulty while doing these exercises, as well as the reasons if they haven't done the exercises. When the participants in control and intervention groups returned to hospital after 4 weeks, the knee joint movement, lower extremity strength, knee joint pain, quality of life, kinesiophobia, and depression levels and physical functions of these groups were compared."
214901274|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
214901275|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
215054893|NCT06322550|BEHAVIORAL|cover story|After agreeing to participate, migraine patients were randomly given the briefing information and therefore their group allocation. Patients received the cover stories via the allocated flyer with study information and also by the physician from the outpatient clinic. Fifty percent of patients (Migraine as Patients \[MP\]) received the information that they will take part in a migraine study (compared to healthy controls) and that this study would investigates migraine associated dizziness by watching a visual stimulus (roller coaster video). The protocol for the intervention was standardized and identical for all participants. The other 50% (Migraine as Healthy \[MH\]) received the information that this study was in cooperation with the University's vertigo Department and that they will take part as controls since they were healthy apart from their migraine.
215054894|NCT02673099|PROCEDURE|HDF online|Hemodialysis by the HDF online method
215054895|NCT02144571|BEHAVIORAL|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
215054896|NCT00318240|DEVICE|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
215054897|NCT05976568|DRUG|QL1706|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
215054898|NCT05976568|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
215054899|NCT05976568|DRUG|Oxaliplatin injection|85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
214901276|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
214301626|NCT04739631|OTHER|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture(superficial needling) at non- acupoints.
214301627|NCT00822458|DRUG|vismodegib|Given orally
214301628|NCT00822458|OTHER|laboratory biomarker analysis|
214301629|NCT00822458|OTHER|pharmacological study|
214901277|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
214901278|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
214901279|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
214301630|NCT00227305|DRUG|quetiapine fumarate|Oral dosing, flexible dosing
214301631|NCT06637995|DEVICE|Intraoperative Nerve Monitoring|Observational data collection from Locating, Stimulating, and Monitoring target nerves during a surgical procedure (clinician standard of care)
214301632|NCT00002161|DRUG|Adefovir dipivoxil|
214301633|NCT01028339|DRUG|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
214301634|NCT01028339|DRUG|Mannitol|Mannitol
214901280|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
214901281|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
214901282|NCT06560151|BIOLOGICAL|3.75 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
214901283|NCT06560151|BIOLOGICAL|7.5 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
214901284|NCT06560151|BIOLOGICAL|15 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
214901285|NCT05952804|BIOLOGICAL|Immune Globulin Infusion (Human), 10% Solution|Given IV
214901286|NCT05952804|BIOLOGICAL|Anti-CD19 CAR T Cells Preparation|Given CAR-T treatment
214901287|NCT05952804|OTHER|Saline|Given IV
214901288|NCT05952804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214901289|NCT05952804|OTHER|Survey Administration|Ancillary studies
214901290|NCT05952804|OTHER|Electronic Health Record Review|Ancillary studies
215054900|NCT05976568|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
215054901|NCT05976568|DRUG|Sintilimab|200 mg administered as IV infusion on Day 1 of each 21-day cycle
215054902|NCT04234347|PROCEDURE|Intravenous access method|Comparing long and short axis approach to USGPIV access.
215054903|NCT02499913|BEHAVIORAL|breath alcohol monitoring|Daily breath alcohol monitoring
215054904|NCT02499913|BEHAVIORAL|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
215054905|NCT03443089|DRUG|Test formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
214901291|NCT05122052|OTHER|Psychological session|Just before the oncology visit, each patient is invited to undergo a psychological session of 20-30 minutes. During the session with a psycho-oncologist the following tasks are addressed: 1) favor emotional expression identifying the most difficult issues to promote mechanisms of elaboration of living experiences; 2) offer a containment of intense emotions; 3) assess awareness of diagnosis and prognosis; 4) favor expression of fears of treatment expectancy; 5) favor expression of difficulties on the inability to cope with prior commitments after the disease; 6) assess family and friend network; 7) improve the patient medic communication and relationship. At the end of the session, the distress thermometer and ESAS-r scale are compiled together with the demographic characteristics. All outstanding issues that are relevant to the therapeutic plan are then discussed between the psychotherapist and the medic before the oncology visit together with delivery of the DT and ESASr scale result.
214301635|NCT06045195|DRUG|Pembrolizumab|"As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and BrECADD (P-BrECADD). Response to induction therapy will be measured after 1x P (PET-1) and after 1x P + 2x P-BrECADD (PET-3).~Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two further cycles of P-BrECADD while participants with a positive PET-3 will receive four further cycles of P-BrECADD. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care."
214301636|NCT02627430|DRUG|Hsp90 Inhibitor AT13387|Given IV
214901292|NCT03181633|DRUG|ACH-0144471|ACH-0144471 will be administered to all participants enrolled in the study.
214901293|NCT06668883|PROCEDURE|Sputum collection for molecular analysis|Sputum collection to be used with syndromic multiplex PCR testing
215054906|NCT03443089|DRUG|Reference formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
215054907|NCT04574180|OTHER|Dental Crown|Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
215054908|NCT02413996|DEVICE|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
215054909|NCT02413996|BEHAVIORAL|Functional activities|Stairs, walking
215054910|NCT02413996|OTHER|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
215054911|NCT02413996|OTHER|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
215054912|NCT02653586|OTHER|"program In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
215054913|NCT00002124|DRUG|Delavirdine mesylate|
215054914|NCT00002124|DRUG|Lamivudine|
215054915|NCT00002124|DRUG|Zidovudine|
214301637|NCT02627430|OTHER|Laboratory Biomarker Analysis|Correlative studies
214301638|NCT02627430|OTHER|Pharmacological Study|Correlative studies
214301639|NCT02627430|DRUG|Talazoparib|Given PO
214301640|NCT02940288|OTHER|Auricular Acupuncture|Participants will receive bilateral auricular acupuncture using the Battlefield Acupuncture (BFA) protocol while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. Acupuncture needles will be left in place for 30 minutes.
214301641|NCT02940288|OTHER|Sham Acupuncture|Participants will receive sham acupuncture while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. During the sham procedure, needles will be inserted bilaterally in five nonspecific ear acupoints. Acupuncture needles will be left in place for 30 minutes.
214901294|NCT06668883|DEVICE|Breath and cough collection for molecular analysis|Breath and cough collection with two proprietary devices to be used with syndromic multiplex PCR testing
214901295|NCT06995651|DRUG|Dorzagliatin|Randomized, double-blind, cross-over study of Dorzagliatin 75 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.
215054916|NCT05263180|BIOLOGICAL|EMB-09|EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
214301642|NCT01867827|OTHER|Neurofeedback and Physical Exercise|
214301643|NCT01867827|OTHER|Physical Exercise|
214901296|NCT06995651|DRUG|Placebo|Randomized, double-blind, cross-over study of Dorzagliatin 75 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.
214901297|NCT00665782|OTHER|laboratory biomarker analysis|
214901298|NCT00665782|OTHER|questionnaire administration|
214901299|NCT00665782|OTHER|study of socioeconomic and demographic variables|
215054917|NCT03280199|OTHER|simulation types|Different types of simulation interfaces and image acquisitions
215054918|NCT03529838|OTHER|Combined exercise|The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
215054919|NCT02374281|DRUG|Glucose sucking|
215054920|NCT02374281|DRUG|Water sucking|
215054921|NCT02374281|OTHER|No sucking|
215054922|NCT04894539|DEVICE|DS5 electrical stimulator|TENS
215054923|NCT01457664|DRUG|Placebo|Placebo to RO4995819 once daily for 14 days
215054924|NCT01457664|DRUG|RO4995819|RO4995819 doses once daily for 14 days
215054925|NCT01527240|DRUG|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
215054926|NCT01527240|DRUG|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
214901300|NCT00665782|PROCEDURE|assessment of therapy complications|
214901301|NCT00665782|PROCEDURE|psychosocial assessment and care|
215054927|NCT05151510|PROCEDURE|Trigger point injection with 1% lidocaine|Previously discussed in prior section.
215054928|NCT05151510|DRUG|Lidocaine patch 5%|Will place lidocaine patch onto skin overlaying point of maximal tenderness
215054929|NCT00521209|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program (SCSDPP)|"The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling"
215054930|NCT00521209|OTHER|Stand procedures, no intervention|
215054931|NCT01672879|BIOLOGICAL|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
214301644|NCT02591355|DEVICE|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
214479050|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)|Intraoperative: Spinal and cortical thresholds will be determined. Immediately prior to repetitive pairing, a set of 12 baseline cortical pulses and 12 baseline spinal pulses will be delivered at 120% threshold. SCAP protocol will be applied, both of which have been successful at inducing lasting effects in the rat. After pairing, cortical stimulation at 120% of threshold and spinal cord stimulation at 120% threshold will be repeated every 10 minutes for the duration of surgery. In a subset of patients repeated pairing will be conducted with a latency that investigator does not expect will induce SCAP, or with electrodes placed over the ventral epidural surface. The control intervention will include repeated pairing at a non-convergent latency, as well as pairing of cortical stimulation with ventral epidural stimulation.
215054932|NCT01672879|BIOLOGICAL|SIM|Intravenous infusion over 30 minutes every 2 weeks
215054933|NCT01476540|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
214479051|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region|As per the intervention 'Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)' targeted at or below myelopathic region.
214479052|NCT03636490|BEHAVIORAL|Psychological Stress Intervention|All enrolled participants who attended the laboratory visit underwent stress-inducing tasks (psychological stress) using validated research tools. Participants performed a 5-minute computer Stroop Color Test and a 5-minute verbal Mental Arithmetic Task. The research assistant asked the participant to work as quickly and accurately as possible for both tasks.
214479053|NCT06385106|DEVICE|Real repetitive transcranial magnetic stimulation|The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session.
215054934|NCT00888914|DRUG|RT001|RT001
214901302|NCT00665782|PROCEDURE|therapeutic conventional surgery|
214901303|NCT01838369|DRUG|BI-505|
214301645|NCT02591355|DEVICE|Saline solution injection|Placebo is a saline solution
214301646|NCT05498038|BEHAVIORAL|Aerobic Exercise|Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
214301647|NCT00099554|DRUG|Etanercept|
214901304|NCT03211676|DEVICE|Theranova-500 dialyzer|hemodialysis with Theranova-500 dialyzer.
214901305|NCT03211676|DEVICE|Elisio-21H|hemodialysis with Elisio-21H dialyzer
214901306|NCT05866835|OTHER|Manufacture of custom-made IOP|"Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~* digital recording of the maxillary and mandibular dental arches~* mandibular wedging performed with an inter-arch piece~* digital recording of the inter-arch position"
214901307|NCT05866835|OTHER|Ventilation tests|"Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~* At rest, standing still.~* During a 4 minute run on a treadmill at 50% of MAS.~* During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS"
215054935|NCT00888914|DRUG|RT001|RT001
215054936|NCT00888914|DRUG|RT001|RT001
215054937|NCT00888914|DRUG|RT001|RT001
215054938|NCT00888914|OTHER|Vehicle Comparator|Vehicle Comparator
214301648|NCT06200207|DRUG|Ziltivekimab|Zilitivekimab will be administered subcutaneously once-monthly.
214301649|NCT06200207|DRUG|Placebo|Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
214301650|NCT03930043|DIAGNOSTIC_TEST|Metagenomic shotgun sequencing|preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen
214301651|NCT05892042|DRUG|Rivaroxaban 15 MG [Xarelto]|Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
214301652|NCT03832582|DRUG|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
214301653|NCT05630209|DEVICE|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
214301654|NCT05630209|DRUG|Doxorubicin|Doxorubicin infusion
215054939|NCT06307249|GENETIC|SNP|Diagnostics of patients' carriers or not of the risk allele(s)
215054940|NCT06307249|DRUG|Palbociclib 125mg|Palbociclib 125mg/day/os over 21 days every 28 days
215054941|NCT06307249|DRUG|Bevacizumab|10mg/kg every 21 days
214901308|NCT05866835|OTHER|Evaluation of comfort level:|Collection from participants (self-questionnaire)
214901309|NCT06676917|DRUG|Datopotamab deruxtecan|Trophoblast cell surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) consisting of a humanized anti-TROP2 monoclonal antibody (MAAP-9001a), a GGFG tetra-peptide linker, and a Topo I inhibitor (MAAA-1181a, derived from exatecan). Upon binding to TROP2 on the cell surface, Dato-DXd internalizes into the cells and releases MAAA-1181a in the cytoplasm which inhibits cell replication and promotes cell apoptosis.
214901310|NCT04555317|COMBINATION_PRODUCT|Musculoskeletal health package|3 month prehabilitation exercise program during radiotherapy with assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
214901311|NCT06919536|OTHER|No intervention (observational study)|There is no intervention, this is a observational study,
214901312|NCT07005817|BEHAVIORAL|Experimental Health Communication|"Participants view a brief psychoeducational video about the value of connecting in-person with others and receive guided instructions for creating if-then behavioral plans for increasing moments of high-quality social connection. Over the next four weeks, they view messages on a simulated social media platform to encourage in-person, connections with strangers and acquaintances on a platform called Invibe. The Invibe feed will also have approximately 15 background posts each day from users' about their lives, including food, fitness, pets, and travel, common on social media platforms.~During the 4-week Invibe phase, after participants complete each Day Report, they will view the Invibe simulated social media feed. Participant exposure to each target message will be both passive, via that day's feed, and forced, via inclusion on the Day Report. Participants will see 12 social media messages during this 4-week phase, shown in random order within the first 3 daily posts."
214901313|NCT07005817|BEHAVIORAL|Simulated Social Media Platform Only|To rule out placebo and nonspecific effects, the Keep Social RCT engenders positive expectations in all participants by promoting the use of Invibe as a beta social media platform to build and maintain social ties, a framing that mirrors information-as-usual for wellness through social media connections. Those in the Placebo Control condition receive no further health communication (view no psychoeducational video) and encounter all background content on Invibe (all target messages excluded) with control posts that feature unrelated content.
214901314|NCT07006636|OTHER|Watermelon Juice + liquid meal test at baseline|WMJ will be purchased from a commercially available brand. The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available.
214901315|NCT07006636|OTHER|Sweetened placebo beverage +liquid meal test at baseline|The placebo beverage made of water and sugar will match the sugar content provided in 355 ml of WMJ (approximately 10-20 g). The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available.
214901316|NCT06141655|DRUG|Influenza vaccine|Participants will be individually randomized 1:1 to receive either QIV-HD or QIV-SD, one dose, the day of the inclusion in the trial
214901317|NCT05421221|DEVICE|Sniffin' sticks Duftquartett|"4-odor training set over 12 weeks with Sniffin' sticks Duftquartett"
215054942|NCT04388007|OTHER|Thoracic spinal manipulation|High velocity, low amplitude force manipulation
214301655|NCT06140147|OTHER|Protocolised reduction of non-resuscitation fluids|Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)
214901318|NCT06616636|DRUG|Azacitidine|Given by IV
214901319|NCT06616636|DRUG|Rezatapopt|Given orally with food
214901320|NCT02816372|OTHER|Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)|Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial
214901321|NCT04671940|OTHER|DNA Analysis|Molecular analysis includes DNA analysis on the blood/saliva and on the cancer specimens from the biopsies \& subsequent resections
214901322|NCT04029623|OTHER|Partnered Rhythmic Rehabilitation (PRR)|Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
214301656|NCT06140147|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.~Medications: concentrated per local protocol"
215054943|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
215054944|NCT00938613|DRUG|Placebo|nasal spray, one spray per nostril at time 0
215054945|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
215054946|NCT02370992|RADIATION|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
215054947|NCT04340388|DRUG|Dolutegravir 50 MG|15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
215054948|NCT04340388|DRUG|Antiretroviral/Anti HIV|15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
214901323|NCT04029623|OTHER|Group walking (WALK)|WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
214901324|NCT06207318|BEHAVIORAL|Acceptance and commitment therapy|The intervention will be based on Acceptance and Commitment Therapy (ACT). ACT is an empirically-based therapeutic approach that focuses on psychological flexibility, acceptance, and the reduction of experiential avoidance. It encourages individuals to change their relating to thoughts and experiences and act in accordance with their values.
214901325|NCT02236039|PROCEDURE|Bronchoscopy|Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
214901326|NCT05303194|BEHAVIORAL|Patient Priorities Care (PPC) Approach|First, identify patient priorities, and second align care received with those priorities.
214901327|NCT05303194|BEHAVIORAL|Adapted PPC|First, identify patient priorities, and second align care received with those priorities.
214901328|NCT06615921|OTHER|No Intervention|This is a non-interventional study.
214901329|NCT01210560|DRUG|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
214901330|NCT01210560|DRUG|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
214901331|NCT01210560|DRUG|Tolvaptan MR|60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
214901332|NCT01210560|DRUG|Tolvaptan IR|90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
214901333|NCT01210560|DRUG|Tolvaptan MR|120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
214901334|NCT04837196|DRUG|ASP7517|Intravenous (IV)
214901335|NCT04837196|DRUG|Pembrolizumab|Intravenous (IV)
214901336|NCT05271175|DEVICE|Active intermittent theta burst stimulation|An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.
214901337|NCT05271175|DEVICE|Sham intermittent theta burst stimulation|"An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil. The MagVenture Cool-B65 Active/Placebo (A/P) coil is designed to support true double blinded clinical trials as it can produce active and placebo stimulation by flipping the coil and can mimic tapping sensation during placebo condition During the sham condition, the coil produced the same sound as the real active condition but did not deliver any stimulation on the side of the participant's skull."
214901338|NCT00991887|RADIATION|Radiation Therapy (XRT)|The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
214901339|NCT06130566|DRUG|Amlitelimab|Injection solution SC injection
214901340|NCT06130566|DRUG|Placebo|Injection solution SC injection
214901341|NCT07023588|DRUG|Venetoclax|Patients identified with a suboptimal response to chemotherapy based on minimal residual disease (MRD) levels in peripheral blood on Day 6 will initiate venetoclax therapy added on Day 8, administered for 7 days.
214901342|NCT06872450|OTHER|informational intervention|informational intervention
214901343|NCT02070705|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
214901344|NCT02070705|DRUG|Ferumoxytol|Given IV
214901345|NCT03640338|DEVICE|Cold-Therapy System|After surgery, participants assigned to this group will receive the cold-therapy system to use at the hospital and during the first 2 weeks following discharge.
214901346|NCT06880419|DRUG|Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection|"Model-predicted patients at high risk (HR): Recombinant humanized anti-CD25 monoclonal antibody: 50 mg/day when the post-transplant model predicts high risk in the second week post-prediction and 25 mg/day in the fourth and sixth weeks post-prediction. Administered in combination with conventional aGVHD prevention regimen.~Model-predicted patients at moderate risk (MR): Recombinant anti-CD25 humanized monoclonal antibody: 25 mg/day when the model predicts intermediate risk post-transplantation and at the 2nd, 4th, and 6th weeks post-prediction. Administered in combination with conventional aGVHD prevention regimen.~Model-predicted patients at low-risk (LR): A conventional aGVHD prevention regimen only was used."
215054949|NCT06361966|DEVICE|3d printed prosthetic socket|3d printed prosthetic socket produced through multi-jet fusion (MJF)
215054950|NCT02445729|OTHER|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
215054951|NCT02445729|OTHER|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
215054952|NCT04961281|DRUG|Dexmedetomidine|injection of Dexmedetomidine ( 10 microgram/kg) + 10 cc saline injection nearby median nerve as hydro-dissection
215054953|NCT04961281|DRUG|Triamcinolone|injection of triamcinolone ( 40 mg) + 10 cc saline injection nearby median nerve as hydro-dissection
215054954|NCT01037998|DRUG|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
215054955|NCT00221546|DRUG|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
215054956|NCT06353048|PROCEDURE|fixation of tibial plateau fractures|fixation of tibial plateau fractures by screws only versus plate and screws
214901347|NCT06876363|GENETIC|EN-374|Single dose of EN-374 administered by intravenous infusion after mobilization and followed by enrichment
214901348|NCT06691425|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT (5 x 8 Gy)
214901349|NCT06691425|DRUG|Chemotherapy|Standard of care: mFOLFIRINOX or gemcitabine/nab-paclitaxel
215054957|NCT00222755|BEHAVIORAL|Disease Management|Self-management, care management, guidelines
214301657|NCT06043102|DEVICE|TheraClearX|TheraClear®X combines vacuum pressure with a broadband light source (500 nm to 1,200 nm) to treat facial acne.
214901350|NCT07113314|DIETARY_SUPPLEMENT|Lactoferrin Bovine|In addition to standard treatment, a gold-soluble formulation of bovine lactoferrin or bLF (Mosiac®) at the standard dose of 200 mg/day, in single administration, from the start of chemo/radiotherapy treatment and throughout the risk period.
214901351|NCT07112456|DRUG|Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare|\*\*Intervention Description:\*\* Nebulized ketamine is administered as a single dose of 0.5 mg/kg of ketamine hydrochloride diluted in 0.9% normal saline to a total volume of 5ml. The solution is delivered via a standard jet nebulizer over approximately 15-20minutes. This intervention is given once at the time of enrollment in the emergency department, in addition to standard asthma care. The ketamine used is in injectable solution form (typically 50 mg/mL concentration), drawn and diluted immediately prior to nebulization. Participants are monitored continuously for 60 minutes after administration to assess changes in peak expiratory flow rate (PEFR), symptom relief, and adverse events. The goal is to evaluate the bronchodilatory effect and safety of nebulized ketamine in adults with moderate to severe asthma exacerbation who present to the emergency department.
214901352|NCT07112456|DRUG|Placebo nebulization (5 mL normal saline) plus standard asthma care|\*\*Intervention Description (Control Group):\*\* Participants in the control group will receive a single nebulized dose of 5 mL of 0.9% normal saline, delivered using a standard jet nebulizer over approximately 10-15 minutes. This placebo intervention is administered once at the time of enrollment in the emergency department, after standard asthma care. Standard care includes repeated doses of nebulized salbutamol and ipratropium, systemic corticosteroids (oral or intravenous), and supplemental oxygen as needed. The placebo solution is identical in appearance and volume to the active ketamine solution used in the intervention group to maintain blinding. All participants will be monitored for 60 minutes after nebulization to assess changes in peak expiratory flow rate (PEFR), symptom relief using a visual analog scale (VAS), and the occurrence of any adverse events.
215054958|NCT05050292|OTHER|Personalized cognitive stimulation|"Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity."
214901353|NCT07113015|DRUG|propranolol|40 mg orally twice daily, titrated up to a maximum of 80 mg/day.
214901354|NCT07113015|DRUG|Amantadine|100 mg orally twice daily, titrated up to a maximum of 200 mg/day.
214901355|NCT07112495|OTHER|pregnant women with|pregnant women with
214901356|NCT07111377|BEHAVIORAL|Brief Cognitive Behavioral Therapy|Participants received an 8-session culturally adapted Brief Cognitive Behavioral Therapy intervention targeting suicidal ideation, psychological distress, and financial stress. Therapy included crisis stabilization, cognitive restructuring of maladaptive thoughts related to economic hardship, behavioral activation, problem-solving skills for financial and psychosocial stressors, and emotion-regulation training. It concluded with relapse prevention planning and connection to supportive community resources. Sessions were delivered weekly, either individually (60 minutes) or in groups (90 minutes), based on participant preference.
214901357|NCT07035769|DRUG|Debio 1453P|Powder for oral solution
214901358|NCT07035769|DRUG|Placebo|Oral solution
214901359|NCT07037498|DIETARY_SUPPLEMENT|Moringa Oleifera|Participants receive MRJ capsules containing 490 mg of Moringa oleifera leaf extract and 10 mg of royal jelly, taken orally twice per week for 12 months. The capsules are plant-based, produced using locally sourced ingredients, and are part of a food-based supplementation strategy developed as an alternative to iron-folic acid tablets. The intervention is combined with standardized nutrition education via TikTok videos. Adherence is monitored weekly through teacher log sheets and WhatsApp documentation. and Participants receive iron-folic acid (IFA) tablets containing 60 mg of elemental iron and 400 µg of folic acid, taken orally once per week for 12 months in accordance with Indonesia's national supplementation guidelines for adolescent girls. This control intervention is combined with the same standardized nutrition education via TikTok videos. Compliance is tracked weekly through teacher-supervised control sheets and WhatsApp photo submissions.
214901360|NCT02988960|DRUG|ABBV-927|Intravenous
214901361|NCT02988960|DRUG|ABBV-927|Intratumoral
214901362|NCT02988960|DRUG|ABBV-181|Intravenous
214901363|NCT03274193|BEHAVIORAL|Yoga training program|The hatha yoga program will be led by an experienced yoga instructor. Each 60 minutes session will consist of 10 minutes of breathing exercises (pranayama), 40 minutes of yoga pose practice (asana), and 10 minutes of supine meditation/relaxation (savasana). Yoga props, such as blocks and belts, will be used in accordance to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably. The yoga poses are chosen for providing a restorative session and based on their purported relationship to restorative effects. Participants will be instructed to maintain their concentration and breath control at all times during the yoga session.
214901364|NCT06722651|DEVICE|Netrod™ six-electrode radiofrequency renal denervation system|"Netrod™ renal denervation (RDN) system, which is indicated for the treatment of uncontrolled hypertension. It consists of the following two components:~* Netrod™ Six-Electrode Basket Radiofrequency Renal Denervation Catheter and~* Netrod™ Renal Denervation Radiofrequency Generator The catheter's electrodes deploy into a self-adaptive basket structure, optimizing contact with the vessel wall for effective ablation."
215054959|NCT05050292|OTHER|Sham cognitive stimulation|"Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game."
215054960|NCT00056173|DRUG|GTI-2040|
215054961|NCT06287242|OTHER|spinal manipulation|High velocity, low amplitude (HVLA) manipulation of the cervical or thoracic spine
215054962|NCT01871545|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
214301658|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
214301659|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
214301660|NCT03495323|DRUG|LY3300054|LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
215054963|NCT02831127|OTHER|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
215054964|NCT02831127|OTHER|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
215054965|NCT00698438|DEVICE|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
215054966|NCT00698438|PROCEDURE|Trabeculectomy|standard trabeculectomy
215054967|NCT00001040|DRUG|Saquinavir|
215054968|NCT00001040|DRUG|Zidovudine|
215054969|NCT00001040|DRUG|Zalcitabine|
215054970|NCT01506557|DIETARY_SUPPLEMENT|cholecalciferol|dose 800 IU/day for 6 month
215054971|NCT01506557|DIETARY_SUPPLEMENT|placebo|oil capsules
214901365|NCT06722651|DEVICE|Sham Procedure|Patients will be remained on the catheterization table for at least 20 min prior to sheath removal.
214901366|NCT00002100|DRUG|Curdlan sulfate|
214901367|NCT02843984|DRUG|Lactoferrin|
214901368|NCT03271684|OTHER|self-management|one session of up to one-hour per week over a six-week period in addition to their usual rehabilitation. During each session strategies will be used to promote specific behaviors that exemplify the hallmarks of self-management. These behaviors include enabling patients to work out ways of taking control of their daily lives by setting small targets, recording their progress and problem-solving. The content of the sessions is determined by the patient and their personal goals rather than being professionally directed
214901369|NCT03271684|OTHER|Control|Participants will receive usual rehabilitation treatment, they will also be given a booklet with education program and exercises they can perform at home.
214901370|NCT01522456|DRUG|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
215054972|NCT00060671|DRUG|rituximab|
215054973|NCT00060671|DRUG|Pixantrone (BBR 2778)|
215054974|NCT00202696|DRUG|nalmefene|Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
214901371|NCT01522456|DRUG|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
215054975|NCT00202696|OTHER|Placebo|Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
215054976|NCT03930589|PROCEDURE|Remote Ischemic conditioning|BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles
215054977|NCT03930589|OTHER|Standard of care|Standard of care
214301661|NCT03495323|DRUG|Prexasertib|Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
214901372|NCT04910594|DRUG|recombinant human erythropoietin|To determine the efficacy and safety of recombinant human erythropoietin in improving anemia in patients with lymphoma, and to improve the quality of life and the efficacy of chemotherapy in patients with lymphoma.
214901373|NCT03856801|OTHER|Exercise|Whole-body vibration training in hypoxia and normoxia condition
214901374|NCT04455165|PROCEDURE|Aortic valve replacement|Aortic valve replacement with or without associated cardiac surgery (coronary bypass, mitral valve surgery,...)
214901375|NCT02975947|DEVICE|Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher \& Paykel's HUMIGARD system (Fisher \& Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.
214901376|NCT02975947|DEVICE|Standard heating|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
214901377|NCT06717776|BEHAVIORAL|Compensation Based Problem Solving Therapy|"Compensation-Based Problem Solving Therapy (CB-PST) is a therapeutic approach based on the occupational adaptation model. It entails the implementation of compensatory strategies with the objective of enhancing the performance of both extremities in daily life activities. The therapy encompasses the implementation of problem-solving training.~The occupational problem is defined.~The development of compensation-focused strategies is based on the personal factors and occupational environment identified as relevant to the problematic occupation, as determined according to the principles of the occupational adaptation model.~Once a compensatory strategy has been selected, the next step is to apply it and evaluate its efficacy, with the expectation that an adaptive response will be observed, and that the resulting adaptation will be reflected in improved occupational performance, as guided by the occupational adaptation model."
215054978|NCT04532515|DEVICE|Seal-G Surgical Sealant|"Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
215054979|NCT04532515|DEVICE|Seal-G MIST System|"Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
215054980|NCT01567033|BEHAVIORAL|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
215054981|NCT04828135|DRUG|Hyperpolarized 129Xenon gas|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
215054982|NCT02058979|DRUG|BOLUS INFUSION (Ancef)|Bolus Infusion of antibiotics
215054983|NCT02058979|DRUG|CONTINUOUS INFUSION (Ancef)|Continuous Infusion of ANCEF with infusion pump
215054984|NCT02972229|RADIATION|10x(3-5) Gy IMRT|10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
215054985|NCT02972229|RADIATION|10x3 Gy IMRT|10x3 Gy IMRT on whole vertebral body for spinal metastases
215054986|NCT03694951|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (i.e., action planning and coping planning) to reduce sedentary behaviour.
215054987|NCT02553187|DRUG|Kanglaite Injection|"200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks)."
214479054|NCT06385106|DEVICE|Sham repetitive transcranial magnetic stimulation|The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session. The patients were applied with the coil angled away from the head to reproduce the noise of the stimulation as well as some local sensation
214479055|NCT06563713|DRUG|STSP-0902 injection|Subjects will receive the administration dose on Day 0 following protocol requirements
214479056|NCT06563713|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements
214479057|NCT04919629|BIOLOGICAL|Bevacizumab|Given IV
214479058|NCT04919629|PROCEDURE|Biopsy|Undergo tumor biopsy
215054988|NCT00598507|DRUG|ZK-EPO|Participants were treated with 16 mg/m\^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
215054989|NCT00300378|DRUG|desvenlafaxine 50 mg|
215054990|NCT00300378|DRUG|desvenlafaxine 100 mg|
215054991|NCT00719992|PROCEDURE|coronary angiography|effect of level of HS-CRP
215054992|NCT00934583|BEHAVIORAL|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
215054993|NCT04834726|BEHAVIORAL|Opt-In (Call-Back)|Messaging will include a prompt to agree to scheduling. If patient agrees, the access center will call these patients back to schedule, calling up to 3 times.
215054994|NCT04834726|BEHAVIORAL|Opt-in (In-Bound)|Messaging will include a prompt to agree to scheduling followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
215054995|NCT04834726|BEHAVIORAL|Standard Message|The message describes that the patient is eligible for the COVID vaccine.
215054996|NCT04834726|BEHAVIORAL|Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination.
215054997|NCT04834726|BEHAVIORAL|Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine.
214479059|NCT04919629|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214901378|NCT06717776|BEHAVIORAL|standard rehabilitation|The standard rehabilitation program is provided to all individuals in the inpatient service on an equal basis. The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays. These units are staffed by physiotherapists and occupational therapists. All individuals included in the study received the same service from the same therapists at the same times in a homogeneous manner. All individuals received physiotherapy, electrotherapy, and hydrotherapy as part of this service. In the physiotherapy unit, the first intervention was 25 minutes of electrotherapy for the upper extremity. This was followed by 40 minutes of physiotherapy exercises, conducted with the assistance of a physiotherapist. The final component of the physiotherapy unit programme was 15 minutes of hydrotherapy. In the occupational therapy unit, a standard 40-minute occupa
214479060|NCT04919629|DRUG|Pegcetacoplan|Given IV and SC
214901379|NCT03859544|OTHER|Retrospective study|Retrospective study to search mutations associated with Central nervous system lymphoma and study of the prognostic impact (overall survival and progression-free survival) of these mutations.
214901380|NCT00298727|BEHAVIORAL|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
214901381|NCT00298727|BEHAVIORAL|ePBL|Online Problem-Based Course
214901382|NCT01406587|DRUG|PP4001|50 mg, 1 dose every 12 hours x 4 doses
214901383|NCT01406587|DRUG|PP4001|100 mg, 1 dose every 12 hours x 4 doses
214901384|NCT01406587|DRUG|PP4001|200 mg, 1 dose every 12 hours x 4 doses
214901385|NCT01406587|DRUG|Placebo|Placebo, 1 dose every 12 hours x 4 doses
214901386|NCT00114660|DRUG|Cocoa butter application|
214901387|NCT03290963|DRUG|Lithium|Lithium will be dosed in units (LI level \> or = 0.4 milliequivalents (mEq)/L)
214901388|NCT03290963|DRUG|Placebo|Placebo tablets, dosed in units
214901389|NCT03290963|DRUG|Ketamine|All subjects will receive 3 IV ketamine infusions of 0.5mg/kg, over 100 min. over 7 days.
214901390|NCT07074145|BEHAVIORAL|Heart Health and Nutrition for Life (HHNL)|The CHW-led educational intervention will draw on two evidence-based programs, Healthy for Life (American Heart Association) and Your Heart, Your Life (NHLBI). Both curricula are designed to be facilitated by community health workers/promotores de salud and have been tested in both English and Spanish. Study-adapted curricular elements will include 12 core educational activities, delivered in six, two-hour, in-person sessions. In the context of expected family and work obligations alongside limited resources of FNCH patients, the investigators anticipate structuring sessions over, at most, 2 months with a class size of approximately 5-15 patients. In the CHW-led educational intervention, participants will learn about topics such as understanding risk for heart disease, the importance of physical activity, affordable healthy eating, and how family members can support health.
214901391|NCT07074145|BEHAVIORAL|Self-Measured Blood Pressure|Self-measured blood pressure (SMBP) is a proven, cost-effective strategy to improve blood pressure control by promoting patient engagement and medication adherence. All study participants will receive the same validated BP monitor, with cuff sizes adjusted as needed, selected from the US Blood Pressure Validated Device Listing. Patients will be trained using the AMA's 7-Step SMBP Quick Guide, consistent with FNCH clinical education practices. They will be asked to record baseline BP readings and complete at least one SMBP cycle per month during the 12-month study. Each cycle includes at least three consecutive days of morning and evening BP measurements.
214901392|NCT06736158|GENETIC|Genetic testing for inherited bleeding disorders|Gene panel for bleeding: This analysis will look at a list of genes known to be associated with rare coagulation, platelet, connective tissue, and bleeding disorders. There are currently 318 genes on the panel however this list may be updated throughout the study. Genes of study include those on the the International Society of Thrombosis and Haemostasis (ISTH) TIER-1 (the first group of genes are the diagnostic-grade) and TIER-2 gene list, as well as additional genes identified in published research.
214901393|NCT07081438|BEHAVIORAL|icbt|12-Week Therapist-Based iCBT for OCD (Adapted Version of OCD Net: https://therapistguide.webcbt.se/index.html)
214901394|NCT06861231|DEVICE|Transcraneal Direct Current Stimulation (tDCS)- Active|The stimulation will use a neoprene cap with carbon rubber electrodes and sponges soaked in saline solution (5x5 cm). The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC), and the cathode over the right supraorbital area (rSO). Constant current intensity of 2mA and a stimulation time of 20 minutes per day for 12 days will be applied, with an initial and final ramp of 30 seconds.
214901395|NCT06861231|DEVICE|Transcranial Direct Current Stimulation (tDCS)- Sham|Participants assigned to the sham tDCS group will also receive 12 home-based sessions of 20 minutes each. However, to mimic the sensation of active stimulation without delivering therapeutic current, the stimulator will only apply current during the initial and final 30-second ramp periods. The device will remain on for 20 minutes, but no current will be applied after the first ramp, simulating an active procedure without physiological effect.
214901396|NCT06861231|BEHAVIORAL|Cognitive Training (CT)|All participants will complete 12 home-based cognitive training sessions, each lasting 50 minutes. The training will include structured tasks focused on executive function and memory, such as categorization, problem-solving, autobiographical recall, planning, and schedule analysis. Instructions will be provided at the start of each session, and participants will work independently or with caregiver support.
214901397|NCT07094243|BEHAVIORAL|Motivational Psychotherapy|A structured short-term intervention based on motivational psychotherapy, delivered in individual sessions over 8 weeks to improve adolescent depression and academic self-concept.
215054998|NCT04834726|BEHAVIORAL|Opt-Out Framing|This will highlight that a vaccine is reserved for the patient, implying that they need to opt-out.
215054999|NCT04834726|BEHAVIORAL|Phone Call|The access center will call these patients to schedule their vaccine appointment. These patients will not receive text messaging.
214301662|NCT06001554|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
214301663|NCT00961844|BIOLOGICAL|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
214301664|NCT00961844|DRUG|Temozolomide|
214301665|NCT05135520|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo Transvaginal NOSE
214301666|NCT05135520|PROCEDURE|Transabdominal specimen extraction|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo transabdominal specimen extraction with incision elongation
214301667|NCT00070187|BIOLOGICAL|aldesleukin|Given IV
214901399|NCT07096180|DRUG|Chemotherapy drug|Participants in the standard care group receive conventional chemotherapy for breast cancer according to clinical guidelines. Treatment includes 8 cycles of chemotherapy administered every 3 weeks. No Traditional Chinese Medicine (TCM) is provided in this group.
214901400|NCT07096180|OTHER|Integrative Treatment (Chemotherapy + TCM)|Participants in the integrative care group receive conventional chemotherapy combined with Traditional Chinese Medicine (TCM) treatment. Herbal formulas are prescribed by licensed TCM physicians based on syndrome differentiation and are aimed at strengthening vital qi and harmonizing stomach function. Treatment is conducted under Taiwan's National Health Insurance coverage.
214901401|NCT07097129|PROCEDURE|Mask Ventilation|Mask ventilation with mechanical ventilator set to pressure controlled ventilation, 15 cmH20 peak pressure, 10 respiratory rates per minute
214901402|NCT07096791|DRUG|KH607 tablet|oral，once daily for 14 days
214901403|NCT07096791|DRUG|placebo|oral，once daily for 14 days
214901404|NCT07094919|DEVICE|Corheart 6 left ventricular assist system|Corheart 6 left ventricular assist system provides circulatory support for patients with advanced left heart failure.
214901405|NCT07096713|DRUG|Intervention 1: Brolucizumab|Intravitreal injection of Brolucizumab (6 mg/0.05 mL) for the treatment of center-involving diabetic macular edema.
214901406|NCT07096713|DRUG|Intervention 2: Aflibercept|Intravitreal injection of Aflibercept (2 mg/0.05 mL) for the treatment of center-involving diabetic macular edema.
214901407|NCT07095218|DEVICE|Application of Tacs|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at various gamma frequencies (40 Hz, 80 Hz, individual gamma frequency) and in a theta-gamma coupling range (6-80 Hz). A sham stimulation group will also be included. The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4). Pre- and post-stimulation cognitive performance will be assessed using neuropsychological tests, while EEG will be used to evaluate theta-gamma phase-amplitude coupling and oscillatory changes.
214301668|NCT00070187|BIOLOGICAL|filgrastim|Given IV
214301669|NCT00070187|BIOLOGICAL|recombinant interferon gamma|Given IV
214901408|NCT07097636|OTHER|Video education|A video demonstrating the steps of the urodynamic procedure was shown, and afterward, participants' questions were answered by an experienced nurse who performed the procedure.
215055000|NCT02647476|DIETARY_SUPPLEMENT|Immunomodulating nutrition (Reconvan)|protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
215055001|NCT02647476|DIETARY_SUPPLEMENT|Standard nutrition (Peptisorb)|oligopeptide, low-fat, isocaloric, non-residue diet
215055002|NCT00833443|DRUG|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
215055003|NCT03111212|DRUG|Iloprost|Iloprost nebulized
215055004|NCT03111212|DRUG|control|sodium chloride 0,9% nebulized
215055005|NCT02739958|DRUG|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
215055006|NCT02739958|DRUG|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
215055007|NCT00426803|DRUG|activated recombinant human factor VII|
215055008|NCT04061109|DRUG|Recombinant Human Coagulation FVIII|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
215055009|NCT02176629|OTHER|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
215055010|NCT02176629|OTHER|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
214301670|NCT00070187|DRUG|carmustine|Given IV
214301671|NCT00070187|DRUG|cyclosporine|Given IV
214301672|NCT00070187|DRUG|cytarabine|Given IV
214301673|NCT00070187|DRUG|etoposide|Given IV
214301674|NCT00070187|DRUG|melphalan|Given IV
214301675|NCT00070187|PROCEDURE|autologous bone marrow transplantation|
214301676|NCT00070187|PROCEDURE|bone marrow ablation with stem cell support|
214301677|NCT00070187|PROCEDURE|peripheral blood stem cell transplantation|
214301678|NCT00803868|DRUG|varenicline|up to 1mg po bid for 9 weeks
214301679|NCT00803868|DRUG|placebo|placebo matching study drug up to 1mg po bid
214301680|NCT04322747|DIAGNOSTIC_TEST|Distortion product otoacoustic emissions (DPOAE)|Audiometry for extended high frequencies, DPOAE, and, ECochG measurements will be collected before and after skull-based surgeries.
214301681|NCT04754737|OTHER|No antibiotic|No antibiotics will be given prior to intravesical injection of onabotulinumtoxinA
214301682|NCT04754737|OTHER|Prophylactic antibiotic|This is the current standard of care, this group of patients will be given a single dose of prophylactic antibiotic prior to the injection of onabotulinumtoxinA via cystoscopy
214901409|NCT07097636|OTHER|No intervention|Children scheduled to undergo urodynamic testing for any reason received the procedure without any prior video-based education being provided to their parents
214901410|NCT07094906|DEVICE|Isometric handgrip exercise training|Maximum voluntary contraction (MVC) will be assessed first in both hands using a hand dynamometer with a digital display (Handexer HFEH20); the participant squeezes the hand dynamometer as hard as they can for 3 to 5 attempts to obtain the MVC. The intervention is an 8- week training protocol that consists of handgrip exercises performed by the participant at home. Each cycle of sustained handgrip exercise consists of sustained squeezing of the hand dynamometer at 30% of MVC for 2 minutes (i.e. isometric) followed by 1 minute of rest.
214901411|NCT07094906|DEVICE|Sham Training|Each cycle of sustained handgrip exercise consists of sustained squeezing of the hand dynamometer at 3 - 5% of MVC rather than 30%.
214901412|NCT07095036|OTHER|Spinal cord stimulation (SCS)|After implantation of SCS trial leads - which is standard of care for evaluating whether SCS improves chronic pain - patients will visit clinic before the trial leads are explanted. During these visits, stimulation will be turned off and the leads will be disconnected from the clinical external pulse generator and reconnected to an external research stimulator. Patients will be seated in a chair and will interface with a touch-screen display where they will participate in a psychophysical task (a two-alternative forced-choice task). More specifically, the task will involve selecting between two options on a screen while spinal stimulation is delivered through the leads. As the patients perform the tasks, audio or video recordings will be made for future research analysis, education, or scientific communication. The research stimulator will also collect epidural signals through the stimulation leads.
214901413|NCT07095413|DIAGNOSTIC_TEST|Wesper Lab Home Sleep Apnea Test|Subjects will wear the Wesper Lab home sleep apnea tests, which includes 2 wireless sensors and a pulse oximeter.
215055011|NCT06443333|OTHER|Data collection and follow-up observation|At the time of enrollment, the patient's biological samples are collected to obtain genetic information. Following enrollment, trained investigators carry out a 2-year follow-up observation through face-to-face, telephone call or online visits. During the follow-up, basic clinical information, laboratory tests, imaging examinations, neurophysiology, clinical classification, medication use, and scale assessments are collected.
215055012|NCT06443333|OTHER|Data collection|Collect demographic and genetic information from healthy volunteers upon enrollment.
215055013|NCT04143581|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg/die for 28 days
215055014|NCT02663336|OTHER|Comparison ABPM with OBPM|No interventions
215055015|NCT04734262|DRUG|Sitravatinib|Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
215055016|NCT04734262|DRUG|Tislelizumab|Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody
215055017|NCT04734262|DRUG|Nab-paclitaxel|Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
215055018|NCT03161210|OTHER|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
214301683|NCT04754737|PROCEDURE|cystoscopic injection of onabotulinumtoxinA|cystoscopic injection of onabotulinumtoxinA
215055019|NCT03161210|OTHER|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
214301684|NCT02118012|DRUG|Chlorcyclizine HCl|Chlorcyclizine HCl (75 mg twice daily)
214301685|NCT02118012|DRUG|Ribavirin|RBV was dosed via a weight-based regimen of 1000 mg daily\<75 kg and 1200 mg daily ≥75 kg.
214301686|NCT03130842|DRUG|Sublingual alprazolam|Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
214479061|NCT04919629|BIOLOGICAL|Pembrolizumab|Given IV
214901414|NCT07095699|DEVICE|EndoSCell System|EndoSCell Scaner (ES) is a new type of intraoperative cell-level fluorescence-guided imaging technology that can be used for direct and rapid intraoperative tissue cell interpretation. This technology uses a handheld cell microscope system to magnify local tissue by about 1280 times, and can perform rapid real-time scanning and imaging of in vivo or excised ex vivo tissue.
215055020|NCT03161210|OTHER|Saline|Saline is a control group
215055021|NCT00208065|DRUG|almotriptan or pseudoephedrine|
215055022|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
215055023|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
215055024|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
215055025|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
215055026|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
215055027|NCT02948582|DRUG|Placebo 0.5mL|Placebo 0.5mL via eFlow, once daily
215055028|NCT03271164|DEVICE|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
215055029|NCT03271164|OTHER|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
215055030|NCT03810014|OTHER|Conditional ACT subsidy, Arm 1 levels|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
215055031|NCT03810014|OTHER|Conditional ACT subsidy, Arm 2 levels|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
215055032|NCT03810014|OTHER|Conditional ACT subsidy, Arm 3 levels|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
214301687|NCT03130842|DRUG|Oral midazolam|Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
214301688|NCT00649623|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fasting
214479062|NCT04919629|OTHER|Questionnaire Administration|Ancillary studies
214479063|NCT05191823|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
214301689|NCT00649623|DRUG|Benicar® Tablets 40 mg|40mg, single dose fasting
214479064|NCT05191823|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
214479065|NCT05989269|OTHER|Modified lab reporting|If appropriateness of culturing i.e., clinical criteria for pneumonia testing does not meet the algorithm AND there is growth of one or more organism(s) that are not considered normal upper respiratory flora, during the intervention period, the result will be modified to reflect the likelihood of asymptomatic colonization.
214901415|NCT07097519|OTHER|Immersive Virtual Reality (IVR)|This intervention involves the use of a high-end immersive virtual reality (IVR) application through the Oculus Quest 2 headset. Nurses participate in a rhythm-based exergame, Beat Saber, for at least 10 minutes per session, during 8-16 clinical shifts over an 8-week period. The game engages users in physical movement to music, requiring whole-body coordination and providing visual, auditory, and haptic feedback. The intervention aims to reduce stress and anxiety and enhance job performance among ICU nurses by providing an immersive, engaging, and therapeutic experience within the clinical environment.
214901416|NCT07096999|OTHER|Non-Interventional Study|Non-interventional study
214479066|NCT03489122|BEHAVIORAL|yoga|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
214669589|NCT06375850|OTHER|Sesame oil|"A peripheral venous catheter will be channeled to the patient admitted to the unit and who requires it. The indications included in the guide for channeling venous access of the Marqués de Valdecilla hospital will be followed.~Once the venous access has been channeled, it will be fixed with, leaving the puncture point visible for future monitoring.~The sesame oil chosen for the project is Sesame bio - 100% pure vegetable oil from the Naissance brand.~To perform the procedure, two drops of sesame oil will be applied daily by the nurse in charge of the patient during the morning shift in the area about 2 cm above the insertion point and coinciding with the course of the vein channeled for intravenous therapy. A small massage of the area of application will be performed, with an approximate extension of 3x3cm, until its absorption. It will be left to dry in the air."
215055033|NCT03810014|OTHER|Conditional ACT subsidy, Arm 4 levels|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
215055034|NCT02137447|DEVICE|Negative Pressure treatment|
214901417|NCT07097688|BIOLOGICAL|Sodium Hexametaphosphate (SHMP) Inorganic polyphosphates (poly[P]) are linear polymers of orthophosphate (Pi) residues linked by energy-rich phosphoranhydride bonds, Ithas multiple physiological funct|The study will be with two parallel arms (1:1 allocation ratio). The sample size per group will be calculated according to the following equation for binary outcomes; N = (Zα/2 + Zβ) 2 ×p1(1 - p1) + p2(1 - p2)/δ 2 so the minimal sample size for an equal size clinical trial is 27teeth in each group. We will recruit 30 teeth in each group for possible attrition
214901418|NCT07097142|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214901419|NCT07097142|DRUG|Cisplatin|Given IV
214901420|NCT07097142|DRUG|Gemcitabine|Given IV
214901421|NCT07097142|DRUG|Mitomycin|Given IV
215055035|NCT04483258|PROCEDURE|Sedation with sevoflurane insufflation|Induction with %8sevoflurane after adequate sedation reducing %3
215055036|NCT04483258|PROCEDURE|intravenous sedation|midazolam +ketamine + atropine
214479067|NCT03489122|BEHAVIORAL|walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
214901422|NCT07097142|DRUG|Fluorouracil|Given IV
214901423|NCT07097142|PROCEDURE|Computed Tomography|Undergo CT scan
214901424|NCT07097142|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214901425|NCT07097142|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214901426|NCT07097142|PROCEDURE|Biospecimen Collection|Undergo blood, tissue, and urine sample collection
214901427|NCT07097142|OTHER|Survey Administration|Ancillary studies
215055037|NCT04422691|DIAGNOSTIC_TEST|Lung ultrasound|After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
215055038|NCT02091635|DRUG|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
215055039|NCT02091635|DRUG|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
215055040|NCT04684576|DEVICE|Permobil Explorer Mini|The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
215055041|NCT04684576|DEVICE|Modified Ride-On Car|Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
214479068|NCT04510740|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
214479069|NCT05679232|DEVICE|Hydrogel coating|hydrogel coating applied to implant's surfaces during cementless hip revision arthroplasty
214479070|NCT05679232|PROCEDURE|Control|standard cementless hip revision arthroplasty
214901428|NCT07096570|BEHAVIORAL|Selected Multisensory Training (SMST)|A 12-week supervised exercise program involving two 40-minute sessions weekly. The program includes proprioceptive challenges on progressively firmer surfaces, vestibular activation with gait drills and head movements, and visual tracking tasks. Intensity progresses every three weeks by increasing surface instability, adding handheld weights, and reducing visual input (eyes open to eyes closed). The intervention aims to improve neuromuscular activation, balance, and sensory integration in older women with diabetic peripheral neuropathy.
214901429|NCT06438575|DIAGNOSTIC_TEST|Xpert® Xpress MVP test|The Xpert® Xpress MVP is an FDA-cleared point-of-care test for vaginitis diagnosis
214901430|NCT06438575|DIAGNOSTIC_TEST|Usual Care|Usual methods used by the healthcare provider for vaginitis diagnosis
214901431|NCT04563715|DIAGNOSTIC_TEST|HIV counseling and testing|Receive HIV testing risk assessment and advice about risk reduction and future testing.
214301690|NCT03899376|RADIATION|Volumetric modulated arc therapy|VMAT therapy focuses on reducing the dose radiation in adjacent organs at risk
214901432|NCT04563715|BEHAVIORAL|Network intervention|Key individuals are trained to provide advice about regular testing and risk reduction.
214901433|NCT03362372|BEHAVIORAL|Mediterranean diet counseling|"The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~1. Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~2. Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~3. Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog."
214901434|NCT07097441|DRUG|Placebo drug ( normal saline )|At the end of surgery patients will be given placebo ( normal saline ) instead of neostigmine ( reversal agent of atracurium ) , to observe Heart rate, blood pressure , respiratory rate and oxygen saturation on extubation and post operative airway reflexes and residual paralysis
214901435|NCT07097441|DRUG|neostigmine (reversal agent)|At the end of surgery patients will be given neostigmine ( reversal agenr ) , to observe Heart rate, blood pressure , respiratory rate and oxygen saturation on extubation and post operative airway reflexes and residual paralysis
214901436|NCT07097220|DRUG|General Anesthesia (GA) group|In the General Anesthesia (GA) group (n = 59), patients received combined intravenous-inhalation general anesthesia. Anesthesia induction was performed using propofol and remifentanil, followed by maintenance with sevoflurane to ensure adequate anesthetic depth and hemodynamic stability throughout the procedure.
214901437|NCT07097220|DRUG|General-Epidural Anesthesia (GEA) group|In the General-Epidural Anesthesia (GEA) group (n = 47), patients received the same general anesthesia protocol as the GA group, in addition to epidural anesthesia. An epidural catheter was placed preoperatively at the T7-T9 vertebral level using a midline approach under strict aseptic conditions. Following successful catheterization and confirmation of proper placement, a continuous intraoperative infusion of 0.25% ropivacaine was administered via the epidural route to provide segmental analgesia and reduce intraoperative opioid requirements.
214901438|NCT07095790|DRUG|Tirofiban+Oral Dual Antiplatelet Therapy|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 47.5 hours; sequential Oral Dual Antiplatelet Therapy (Aspirin 100mg qd; Clopidogrel 75mg qd)
214901439|NCT07095790|DRUG|Oral Dual Antiplatelet Therapy|Aspirin 100mg qd; Clopidogrel 75mg qd (after first dose of 300mg)
214901440|NCT07089771|PROCEDURE|Virtual Chromoendoscopy|"High-Definition Virtual Chromoendoscopy (HD-VCE):~Surveillance colonoscopy using high-definition virtual chromoendoscopy enhances mucosal visualization through advanced imaging filters integrated into the colonoscope. This dye-free technique improves detection of dysplasia by increasing contrast and highlighting subtle mucosal patterns during withdrawal. HD-VCE reduces procedure time and eliminates risks related to dye application, offering a practical alternative to dye-based methods. Its efficacy in IBD surveillance requires further validation."
214901441|NCT07089771|PROCEDURE|Dye-Based Chromoendoscopy|"High-Definition Dye-Based Chromoendoscopy (HD-DCE):~Surveillance colonoscopy using high-definition dye-based chromoendoscopy involves segmental application of indigo carmine dye via a spray catheter. The dye enhances mucosal surface patterns, aiding dysplasia detection. HD-DCE is currently considered a gold standard in IBD surveillance due to superior dysplasia detection rates."
215055042|NCT00002343|DRUG|Ethambutol hydrochloride|
215055043|NCT00002343|DRUG|Rifabutin|
215055044|NCT05358626|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody testing|IgG Antibody testing for previous exposure to SARS-CoV-2
215055045|NCT05860907|DRUG|Huaier Granule|10g each time, three times a day
215055046|NCT04887194|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
215055047|NCT04887194|DRUG|Warfarin|CYP2C9 probe substrate
214301691|NCT03899376|RADIATION|conventional radiotherapy|Radiotherapy focus on pelvis area
214301692|NCT00483379|BIOLOGICAL|alglucosidase alfa|intravenous infusion
214669590|NCT06375850|OTHER|Saline solution|After cannulation of the vein following the same procedure as explained in the intervention arm, patients belonging to the control arm will be administered two drops of saline solution.
214901442|NCT07094932|DRUG|TBD09|TBD09 will be administered orally
215055048|NCT04887194|DRUG|Dextromethorphan|CYP2D6 probe substrate
215055049|NCT04887194|DRUG|Midazolam|CYP3A4 probe substrate
215055050|NCT04887194|DRUG|Digoxin|P-gp probe substrate
215055051|NCT04887194|DRUG|Rosuvastatin|BCRP probe substrate
215055052|NCT04887194|DRUG|Nivolumab|Nivolumab is a programmed death receptor (PD-1) blocking antibody
215055053|NCT01672086|DEVICE|Stelkast Surpass Acetabular System implant|
215055054|NCT06451367|OTHER|neuromuscular programm|neuromuscular programm during 12 weeks (3 times a week, 10 minutes each time)
215055055|NCT01853462|OTHER|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
214479071|NCT04464564|DRUG|AVP-786|oral capsules
214479072|NCT04464564|DRUG|Placebo|oral capsules
214479073|NCT06965166|PROCEDURE|PCD-CT|Participants undergo PCD-CT scan on study
214479074|NCT03021395|DRUG|Decitabine|Decitabine at a dose of 20mg/㎡/d on day 1-5.
215055056|NCT01853462|OTHER|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
215055057|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
215055058|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
215055059|NCT04005495|BEHAVIORAL|Teaching kitchen program|The teaching kitchen program will include five 4-hour Saturday classes every other weekend over the course of 10 weeks (5 sessions totaling 20 hours of instruction). It will be taught by subject matter experts from the Emory University faculty and staff as well as potentially from the community. The classes will include the scientific rationale, practical applications, and recommendations for implementing self-care components into participants' daily lives. Experiential learning will include hands-on cooking demonstrations, mindfulness-based lunches, a yoga session, and a group exercise session. Rather than being prescriptive, the lectures and demonstrations are geared to inspire self-designed and personalized alterations in dietary patterns and behaviors that will match participants' culture, preferences, and health conditions. Biometrics and survey instruments will be assessed at 4 times: at baseline, after the 10-week program, and at 6 and 12 months after the program.
215055060|NCT02460068|DRUG|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
215055061|NCT02460068|DRUG|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
214479075|NCT06236503|BEHAVIORAL|Real Stimulation|"Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). · Time B:~Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 20 minutes with the anode placed on the international electrode position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Rest Period: 2 months."
214479076|NCT06236503|BEHAVIORAL|Placebo Stimulation|Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 5 seconds with the anode placed on the electrode 10-20 position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma recovery Scale-R (CRS-R). Time D. Behavioral assessment using the Coma Recovery Scale-R (CRS-R).
214479077|NCT06134258|OTHER|mixed meal test|mixed meal test after fasting
214479078|NCT04950894|DEVICE|Hypoglossal Nerve Stimulation|Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)
214479079|NCT03868826|PROCEDURE|Orthopaedic surgery and/or rehabilitation|The avulsion is repaired and hereafter the patient follows rehabilitation. Some are treated conservatively and only follow rehabilitation.
214479080|NCT03596801|BIOLOGICAL|RSV 6120/∆NS1|Delivered as nose drops
214901443|NCT07094932|DRUG|Placebo|Placebo will be administered orally
214901444|NCT07095569|DEVICE|(Shoulder individual nerves TRF (thermal radio frequency): Patients will receive shoulder individual nerves Thermal RF.|Shoulder individual nerves thermal RF technique: The patient will be put in the sitting position, monitored with electrocardiography, pulse oximetry, and non-invasive blood pressure. after disinfection A high-frequency linear transducer (10-15 Hz) will be placed parallel and cephalad to the spine of the scapula. The probe will be moved from cephalad to caudad until the trapezius and supraspinatus muscles were identified. The suprascapular nerve will be identified as a hyperechogenic structure in the suprascapular fossa deep to the superior transverse scapular ligament. A 10 cm radiofrequency needle, with a 10 mm active tip, will be inserted in plane with the ultrasound beam and advanced to reach the proximity to the nerve. A nerve stimulator was used as an additional nerve-finding modality.
215055062|NCT02460068|DRUG|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
215055063|NCT04620616|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
215055064|NCT04620616|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
215055065|NCT04620616|OTHER|Subject Usual Brand ENDS|Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
214479081|NCT03596801|BIOLOGICAL|RSV 6120/F1/G2/∆NS1|Delivered as nose drops
214901445|NCT07095569|DRUG|conservative treatment|Patients will receive conservative treatment Acetaminophen (paracetamol 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.
214479082|NCT03596801|BIOLOGICAL|Placebo|Delivered as nose drops
214479083|NCT05374538|DRUG|VIC-1911|VIC-1911 tablets for oral administration
214479084|NCT05374538|DRUG|sotorasib|Sotorasib tablets for oral administration
214479085|NCT06809322|DRUG|Vorasidenib|Vorasidinib will be administered orally once daily at a dose of 40 mg in continuous 28-day cycles
214479086|NCT06809322|DRUG|Vorasidenib Placebo|Matched oral vorasidenib placebo will be administered once daily in continuous 28-day cycles
214901446|NCT07096895|PROCEDURE|EDEE (EUS-directed transenteric ERCP)|Technical aspects of EUS-guided anastomosis and ERCP via LAMS (Lumen apposing metal stent)
215055066|NCT05325229|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion，75 mg/m\^2 or 100 mg/m\^2 once every 3 weeks.
215055067|NCT05325229|DRUG|Bevacizumab|Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
214901447|NCT07107646|BEHAVIORAL|vision training system, VTS|Participants in this group will receive individualized visual perceptual learning using the Vision Training System (VTS). The training involves blurred Gabor stimuli presented via a computer-based application. Each participant will complete approximately 20 training sessions over 3 months, with each session lasting 15 to 30 minutes, conducted twice per week. The program is designed to enhance uncorrected visual acuity, contrast sensitivity, and other visual functions by engaging neural mechanisms related to perceptual learning. Training progression is adaptive based on individual performance. The VTS software was developed in collaboration with Bar Ilan University.
214901448|NCT07110935|DRUG|intravenous iron|intravenous iron dextran
214901449|NCT07110935|DRUG|oral iron|oral iron(ferrous Sulphate)
214901450|NCT07105514|DIETARY_SUPPLEMENT|Indole-3-propionic acid (IPA)|Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Active capsules are taken orally and contain 250 mg of IPA each.
214901451|NCT07105514|DIETARY_SUPPLEMENT|Placebo|Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Placebo capsules are taken orally and contain maltodextrin.
214901452|NCT07113158|DRUG|Aspirin + Acid folic|Aspirin 100 mg/day and Acid Folic 5 mg/day + gold standard treatment
214901453|NCT07113158|DRUG|Placebo Aspirin + Placebo Acid folic|The Placebo Aspirin 100 mg/j + Placebo folic acid 5 mg/j + reference treatment
214901454|NCT07112716|PROCEDURE|Empirical superior vena cava isolation|Empirical superior vena cava isolation with radiofrequency ablation
214901455|NCT07112716|PROCEDURE|Ablation without empirical superior vena cava isolation|No ablation or ablation of other arrhythmic foci wuthout empirical superior vena cava isolation
214901456|NCT07113288|DEVICE|Inspire® UAS System|Participants will be implanted with a commercially available Inspire® UAS System. In addition, participants will receive a patient remote which is used to initiate therapy each night.
214901457|NCT07113301|PROCEDURE|incisional or core-needle biopsy for tumor diagnosis|incisional or core-needle biopsy for tumor diagnosis
214901458|NCT07111715|DEVICE|Small bowel Video Capsule Endoscopy (VCE) using an Capsule System equipped with a Deep Neural Network based system called SmartScan (SC),|Small bowel Video Capsule Endoscopy (VCE) will be performed using the an Capsule System equipped with a Deep Neural Network based system called SmartScan (SC), which is able to automatically select suspected lesions thus creating a very short video constituted only by selected images.
214901459|NCT07111247|DRUG|Gonadotropin Releasing Hormone Antagonists Relugolix|Gonadotropin releasing hormone antagonist (gnRH) taken for 10 days starting during the midluteal phase.
215055068|NCT00786305|DRUG|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
215055069|NCT00786305|DRUG|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
215055070|NCT02148263|DEVICE|senofilcon A|
215055071|NCT05563662|PROCEDURE|Cardiac surgery|Patients with infective endocarditis undergoing open heart surgery
215055072|NCT02594007|DEVICE|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
214901460|NCT07112144|BIOLOGICAL|DTacP|Vaccinate 1 dose at 2 months, 4 months, 6 months, 18-24 months and 6 years of age respectively, with each injection dose being 0.5 ml；Injection；
214901461|NCT07112144|BIOLOGICAL|DTaP|Vaccinate 1 dose at 2 months, 4 months, 6 months, 18-24 months and 6 years of age respectively, with each injection dose being 0.5 ml.Injection
214901462|NCT07112144|BIOLOGICAL|DTacP-IPV/Hib|Administer 1 dose at 2 months, 4 months, 6 months and 18 months of age respectively, with each injection dose being 0.5 ml.Injection
214301693|NCT04318990|PROCEDURE|Distal radial artery access|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
214301694|NCT04318990|PROCEDURE|Proximal radial artery surgery|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
214901463|NCT07111767|DIETARY_SUPPLEMENT|Low-Cost Post-Bariatric Diet|"Low-Cost Post-Bariatric Diet (Experimental):~Based on the American Society for Metabolic and Bariatric Surgery (ASMBS) guidelines.~Uses affordable, locally available foods (e.g., eggs, lentils, local dairy products) to meet protein and micronutrient needs.~Designed to be cost-effective and accessible for patients from low-income or rural areas."
214901464|NCT07111767|DIETARY_SUPPLEMENT|Standard High-cost Post-Bariatric Diet|"Standard Post-Bariatric Diet (Active Comparator):~The conventional high-cost diet currently followed at the study hospital. Includes imported or expensive protein supplements such as whey protein and cottage cheese, along with nutritional products not easily accessible in rural or low-resource settings."
214901465|NCT07111832|DRUG|SHR-A1811 for Injection|SHR-A1811 for injection.
214901466|NCT07111832|DRUG|SHR-1316 Injection|SHR-1316 injection.
215055073|NCT02594007|DEVICE|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
215055074|NCT02594007|DEVICE|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
215055075|NCT02310737|PROCEDURE|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
215055076|NCT02310737|PROCEDURE|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
215055077|NCT02988726|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
214901467|NCT07111832|DRUG|Toripalimab Injection|Toripalimab injection.
214901468|NCT07111832|DRUG|Paclitaxel for Injection|Paclitaxel for injection.
214901469|NCT07111156|OTHER|Topical Cream containing 0.1% Pinorox®|"Mode of Usage: Apply a coin size (approximately 1g) amount of the test treatment to the face and gently massage it until fully absorbed.~Frequency: Apply the treatment twice daily Route of administration: Topical Dosage Form: Semisolid (Cream) Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
214901470|NCT07111156|OTHER|Topical Cream containing 1% Pinorox®|"Mode of Usage: Apply a coin sized (approximately 1 g) amount of the test treatment to the face and gently massage it until fully absorbed.~Frequency: Apply the treatment twice daily Route of administration: Topical Dosage Form: Semisolid (Cream) Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
214901471|NCT07111156|OTHER|Placebo (Base Cream)|"Mode of Usage: Apply a coin sized (approximately 1 g) amount of the test treatment to the face and gently massage it until fully absorbed.~Frequency: Apply the treatment twice daily Route of administration: Topical Dosage Form: Semisolid (Cream) Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
214901472|NCT07111793|OTHER|Extended phenotyping|Extended phenotyping (analysis performed at Nantes University Hospital, MANDATORY DELIVERY WITHIN 24 HOURS) = 1 EDTA 3 mL tube for patients included in Nantes.
214901473|NCT07111793|OTHER|Blood sample for WES|Blood sample for WES : 1 x 3 mL EDTA tube (if not included in DIABACT IV biocollection)
214901474|NCT07111793|OTHER|Blood sample for PBMC freezing|Blood sample for PBMC freezing integrated into the biocollection: 1 EDTA tube = 3 mL
214901475|NCT07111793|OTHER|POPC score evaluation|Assessment of POPC score (Pediatric Overall Performance Category)
214901476|NCT07111793|OTHER|Questionnaire completion|"Questionnaires completed by parents or children:~* SDQ~* PedSQL4.0"
214901477|NCT07112729|OTHER|Active SMS Invitation|Participants in this group will receive a text message inviting them to participate in the free FOBT program. The SMS message will include a brief explanation of the program, instructions on how to obtain a screening kit, and a contact number for inquiries. A reminder SMS message will be sent one week after the initial message.
214901478|NCT07113262|DRUG|IBI311|Teprotumumab N01 injection (code name IBI311)
214901479|NCT07113262|DRUG|Placebo|Placebo
214901480|NCT07112586|DRUG|Plasma derived exosomes|Exosomes derived from patients' plasma, centrifuged at high speeds multiple times
215055078|NCT02663427|DEVICE|serological examination and gastroscope|
215055079|NCT03536325|DRUG|Guselkumab Dose 1|Participants will receive Dose 1 of guselkumab on Day 1.
215055080|NCT03536325|DRUG|Guselkumab Dose 2|Participants will receive Dose 2 of guselkumab on Day 1.
214301695|NCT06793488|DRUG|Disulfiram 250 mg|Disulfiram will be used in Participants with Alcohol Use Disorder only to facilitate abstinence.
214301696|NCT06793488|DIAGNOSTIC_TEST|functional MRI|Participants will undergo fMRI scanning. Participants with alcohol use disorder will undergo scanning after 1 week and 3 months of disulfiram maintenance. Healthy volunteer participants will undergo scanning once.
214901481|NCT07113223|DEVICE|Willem™ platform ECG assessment|AI-assisted ECG analysis via the Willem™ platform
214901482|NCT00741507|BEHAVIORAL|Alcohol drinking|Never drinking of alcohol
214901483|NCT00741507|BEHAVIORAL|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
214901484|NCT00741507|BEHAVIORAL|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
214901485|NCT00741507|BEHAVIORAL|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
214901486|NCT00741507|BEHAVIORAL|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
214901487|NCT06932107|DRUG|Aprepitant Injection|Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
214901488|NCT06932107|DRUG|Aprepitant Injection Placebo|Before anesthesia induction, 4.4ml was given by a single intravenous injection, which was completed within 30 seconds
214901489|NCT06933355|DRUG|JARDIANCE 25mg|"The intervention will be SGLT2i compared with placebo. The trial include a total of 8 non-diabetic kidney transplant recipients.~4 patients will randomly be assigned to start in the active arm, and treated with a single dose SGLT2i at intervention day 1 and a single dose placebo at intervention day 2.~4 patients will randomly be assigned to start in the non-active arm, each participant will be treated with a single dose placebo at intervention day 1 and a single dose SGLT2i at intervention day 2."
215055081|NCT03536325|DRUG|Guselkumab Dose 3|Participants will receive Dose 3 of guselkumab on Day 1.
214301697|NCT05958407|DRUG|Tralokinumab|After a loading dose of 600 mg under the skin (s.c.) at baseline, trial participants are administered a dose of 300 mg every two weeks for 32 weeks
215055082|NCT03536325|DRUG|Placebo|Participants will receive matching placebo on Day 1.
215055083|NCT04313777|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
215055084|NCT04313777|DEVICE|Virtual therapeutic support|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.
215055085|NCT04313777|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
215055086|NCT03483792|BIOLOGICAL|Plasma dosage|4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
215055087|NCT03483792|GENETIC|placental biopsy|Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
214901490|NCT06933355|DRUG|Placebo|The intervention will be SGLT2i compared with placebo. The trial include a total of 8 non-diabetic kidney transplant recipients. 4 patients will randomly be assigned to start in the active arm, and treated with a single dose SGLT2i at intervention day 1 and a single dose placebo at intervention day 2. 4 patients will randomly be assigned to start in the non-active arm, each participant will be treated with a single dose placebo at intervention day 1 and a single dose SGLT2i at intervention day 2.
214901491|NCT06940063|PROCEDURE|Active music-based intervention|Musical experience includes playing an instrument, singing, or songwriting.
214901492|NCT06936436|OTHER|Implanon (Etonogestrel)|implanon is a long acting ,reversible contraceptive implants used to prevent pregnancy
214901493|NCT02107924|PROCEDURE|APPI of TKR-Stimulan|
214901494|NCT04388852|BIOLOGICAL|Ipilimumab|Given IV
214901495|NCT04388852|DRUG|Valemetostat|Given PO
214301698|NCT05958407|DRUG|Placebo|After a loading dose under the skin (s.c.) at baseline, trial participants are administered a placebo dose every two weeks for 16 weeks
214301699|NCT05880927|DRUG|Pyrotinib|Patients receive pyrotinib 400mg/day for half or one year
214301700|NCT04760366|OTHER|fascial- muscular lengthening therapy|"Patients in this group will receive interventional therapy~To perform this technique:~1. Have the patient in side lying position~2. Hip is maximally flexed to shorten the iliopsoas muscle.~3. Therapist fingers should be on to the targeted area.~4. Apply gentle pressure in upward direction.~5. While maintain the pressure, stretch the muscle by moving the hip in extension through full ROM.~6. Therapist will maintain the pressure in opposing direction. This is considered as one pass. This technique is performed bilaterally. Patients in this group will also receive the conventional therapy which will include:~   * Hot pack for 15 minutes.~  * Myofascial release of iliopsoas.~  * TENS for 15 minutes."
214301701|NCT04760366|OTHER|Stretching's of iliopsoas muscle|"Patients in this group will receive the interventional therapy which will include:~Stretching's of iliopsoas muscle which can be done in two positions:~1. modified lunge position.~2. The prone stretch.~Patients in this group will also receive the conventional therapy which will include:~* Hot pack for 15 minutes.~* Myofascial release of iliopsoas~* TENS for 15 minutes."
214301702|NCT04760366|OTHER|the conventional therapy|the conventional therapy
214901496|NCT03460002|BIOLOGICAL|Measles vaccine|A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.
214901497|NCT03460002|BIOLOGICAL|Oral polio vaccine|A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.
214901498|NCT04941820|OTHER|clinical pharmacist intervention|clinical pharmacist intervention
214901499|NCT05671588|PROCEDURE|Controlled combined exercise group|Patients will undergo protocol-defined combined aerobic-resistant therapy on a cycling ergometer and multifunctional fitness device
214901500|NCT05671588|PROCEDURE|Conventional rehabilitation|Patients will undergo conventional rehabilitation.
214901501|NCT06949228|DRUG|tenecteplase|Patients treated with standard of care mechanical thrombectomy (MT) that achieved mTICI 2b or higher revascularization. Patients will be randomized into one of two arms: IA TNK or control.
214901502|NCT03859921|DRUG|Dydrogesterone|Progesterone
214901503|NCT03859921|DRUG|Placebo|Placebo with appearance similar to Dydrogesterone
214901504|NCT03862430|DRUG|NanO2TM|0.1 mL/kg NanO2 infusion
214301703|NCT04506853|DEVICE|MED-EL Cochlear Implant System|Cochlear implant and audio processor
214301704|NCT00001437|DRUG|pentoxifylline|
214301705|NCT04621188|DRUG|Lorlatinib|100 mg once daily
214301706|NCT03849885|DRUG|Benzoyl peroxide gel|Skin prep with Chlorohexidine wipes and BPO.
214301707|NCT05952024|DRUG|Acalabrutinib|Patients will receive acalabrutinib orally with dosing schedule of X.
214901505|NCT03862430|DRUG|Placebo Saline Infusion|Saline Infusion
214901506|NCT01136902|DIETARY_SUPPLEMENT|Oral Glucose Tolerance Test (OGTT)|75 g of glucose dissolved in 250 mL water.
214301708|NCT05952024|BIOLOGICAL|Rituximab|Patients will receive rituximab via IV infusion on Cycle 1 Day 15 and via SC injection on Day 1 of Cycle 2 through Cycle 8.
214901507|NCT01924832|DRUG|dimethyl fumarate|tablet
214901508|NCT02246140|OTHER|Cerebral MRI and MRA|
214901509|NCT03312387|OTHER|Exercise|Aerobic exercise performed 3/d per week during intervention
214901510|NCT03312387|DIETARY_SUPPLEMENT|Essential Amino Acids|Mixture of 10g of essential amino acids ingested throughout intervention
214901511|NCT03312387|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrin ingested throughout intervention
214901512|NCT02220556|PROCEDURE|Blood sampling|
214901513|NCT04581824|DRUG|Dostarlimab|Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
214901514|NCT04581824|DRUG|Pembrolizumab|Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
214901515|NCT04581824|DRUG|Chemotherapy|"Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision."
214907378|NCT06351800|BEHAVIORAL|Predictplusprevent intervention|The intervention is based on validated risk algorithms to predict depression and anxiety and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps participants to develop their own personalized plans to prevent (PPP) depression and/or anxiety; 3) eight intervention modules (the core of the system) including activities to prevent depression and anxiety, to be proposed and monitoring by the DSS. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6, 9 and 12 months.
214901516|NCT04796909|BEHAVIORAL|Occupational Performance coaching|The OPC intervention comprises three components: (1) connect - building parents' trust in the coach by using verbal and nonverbal strategies; (2) structure - building parents' competence by adopting a problem-solving framework of setting goals, exploring options, planning action, carrying out plans, checking performance, and generalizing; and (3) share - building parents' autonomy by reciprocally exchanging information between the coach and parents with an emphasis on eliciting parents existing knowledge. During the exploration of the options for a particular goal, collaborative performance analysis is used. The coach follows the four steps to (a) identify parents' perception of what currently happens, (b) identify what they would like to happen, (c) explore barriers and bridges to the desired performance, and (d) identify their needs for taking actions to achieve goals. Parents are guided to find strategies to facilitate their child's performance to support goal achievement.
214901517|NCT04796909|BEHAVIORAL|Parent consultation|The parent consultation consists of the use of the toolbox to provide parents with available environmental resources and strategies to enhance community participation of their child with developmental disability, followed by the understanding of current situation and the identification of problems encountered by parents. Direct informing approach will be used to instruct parents about the availability of environmental resources close to their living areas and what they can plan to do by using possible supportive strategies. In addition, information about child disability and/or developmental milestone may be provided if needed.
214901518|NCT05633667|DRUG|Zimberelimab (ZIM)|Administered intravenously
214901519|NCT05633667|DRUG|Domvanalimab (DOM)|Administered intravenously
214901520|NCT05633667|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
214901521|NCT05633667|DRUG|Etrumadenant (ETRUMA)|Administered orally
214901522|NCT05633667|DRUG|Carboplatin|Administered intravenously
214901523|NCT05633667|DRUG|Cisplatin|Administered intravenously
214901524|NCT05633667|DRUG|Pemetrexed|Administered intravenously
214901525|NCT05633667|DRUG|Paclitaxel|Administered intravenously
214901526|NCT05633667|DRUG|Nab-paclitaxel|Administered intravenously
214901527|NCT05633667|DRUG|Docetaxel|Administered intravenously
214901528|NCT05633667|DRUG|Nivolumab|Administered intravenously
214901529|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))|"Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
214901530|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)|"Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2 and 3~or~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 100 mg, Days 2 and 3~* Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
214901531|NCT03700138|DRUG|Privigen® 100mg/ml at the dose of 2g/kg of body weight|The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
214901532|NCT03700138|DRUG|NaCl 0,9%|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
214901533|NCT06117150|DEVICE|Drug-eluting Coronary Spur Stent System|All subjects enrolled will be treated with the Drug-eluting Coronary Spur Stent System.
214901534|NCT03879135|BIOLOGICAL|rVWF|Recombinant von Willebrand factor
214901535|NCT03879135|BIOLOGICAL|rFVIII|Recombinant Factor VIII
214901536|NCT04162847|DEVICE|SilverCloud Health Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
214901537|NCT06557733|PROCEDURE|Biopsy Procedure|Undergo biopsy
214901538|NCT06557733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214901539|NCT06557733|DRUG|EP2/EP4 Antagonist TPST-1495|Given PO
214901540|NCT06557733|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
214901541|NCT06557733|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
214301709|NCT05911399|DRUG|Tiratricol|Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.
214301710|NCT00213915|DRUG|12 g of L-arginine glutamate during 6 weeks twice a day|
214301711|NCT05095597|PROCEDURE|Injection of hUC-PRP by hysteroscopy|PRP previously frozen at -80ºC (6±2 mL) will be defrozen after checking donor-receptor compatibility and viral safety study. PRP (4±2 mL) will be activated with 5% CaCl2 and immediately injected (4±2 mL) in the sub-endometrial wall via hysteroscopy.
214301712|NCT05095597|DRUG|Oestraclin|Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).
214301713|NCT05095597|PROCEDURE|Umbilical cord blood collection|The SCU will be collected using a blood collection bag containing anticoagulant. This step will be performed by the medical and nursing staff of the obstetrics service of the HUP La Fe. The blood collection bags will be the following, or similar: Cord Blood Collection Bags from MACOPHARMA; CPD Umbilical Cord Bag from GRIFOLS.
214479087|NCT06614270|DRUG|anti-CD19 CAR-NK cells|Patients will receive Fludarabine and Cyclophosphamide for conditioning. Multiple doses of anti-CD19 CAR-NK cells will be infused on Day 0, 3, and 6.
214479088|NCT06094621|OTHER|Survey|For the patients who underwent a pre-operative virtual visit, data will be collected through semi-structured interviews conducted by trained research personnel. The interviews will be conducted in a one-on-one format, either in-person or via telephone, according to the participant's preference.
214901542|NCT06557733|OTHER|Questionnaire Administration|Ancillary studies
214901543|NCT05653687|DEVICE|Intraoperative fluoroscopy|Fluoroscopy is a medical procedure that makes a real-time video of the movements inside a part of the body by passing x-rays through the body over a period of time.
214901544|NCT06581874|OTHER|Clinical assessment by emergency psychiatrist|After a clinical assessment by the emergency department psychiatrist which does not lead to hospitalization, the patient will be given a psychiatric interview and sent home.
214901545|NCT06581874|OTHER|Psychiatric consultation booked through Med@Psy platform|The patient will be seen within 48 hours after the consultation with his or her general practitioner by a psychiatrist taking part in the study.
214901546|NCT06375083|BEHAVIORAL|Cognitive Behavioral Therapy|The computerized Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) course is comprised of 12 online sessions and is augmented by use of a companion workbook. The computerized Cognitive Behavioral Therapy for Depression (cCBT-D) course is comprised of 12 online sessions.
214901547|NCT05252949|DIETARY_SUPPLEMENT|Oleoylethanolamide (OEA)|Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.
214901548|NCT05252949|DIETARY_SUPPLEMENT|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.
214901549|NCT03874117|OTHER|Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis|Twice weekly hemodialysis for 4 weeks, then thrice weekly hemodialysis for 4 weeks.
214901550|NCT03874117|OTHER|Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis|Thrice weekly hemodialysis for 4 weeks, then twice weekly hemodialysis for 4 weeks.
214479089|NCT06815510|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|Patients will be followed up to find out any of these complications: pulmonary, hemodynamic complications, temperature disturbances, or pain
214479090|NCT02095691|DEVICE|Celsius® ThermoCool® Renal Denervation|The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
214901551|NCT06282029|BEHAVIORAL|Group Therapy|Acceptance and Commitment Therapy based group therapy
214901552|NCT04487470|OTHER|Flavored filtered cigars|Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase
214301714|NCT05095597|PROCEDURE|Endometrial biopsy|Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.
214301715|NCT06406621|PROCEDURE|Laser hair depilation|"Laser hair depilation treatment with Nd:YAG laser every 4-6 weeks to obtain a total of 5 treatments. Similar to the control group, they will also receive the best recommended standard care including teaching on hair removal techniques and asked to perform either chemical or mechanical depilation as needed between treatments."
214479091|NCT03476369|DRUG|Fentanyl|Premedicated with Fentanyl (at least 25mcg by IV)
214901553|NCT04487470|OTHER|Unflavored filtered cigars|Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase
214901554|NCT05512143|DEVICE|Transcranial magnetic stimulation|Participants will undergo a standard course of TMS treatment (30 sessions/6 weeks).
214901555|NCT05493904|PROCEDURE|OCT-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using OCT.~OCT Reference site: Most normal looking segment, No Lipidic plaque. Operator can decide 1 of 2 methods for stent sizing.~1. By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane \[EEL\] can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25mm (Ex\> mean external elastic membrane reference diameter 3.35mm, 3.25mm stent diameter will be chosen).~2. By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25mm (Ex\> mean distal reference lumen diameter 2.55mm, 2.75mm stent diameter will be chosen)."
214907379|NCT06351800|OTHER|Psychoeducational intervention|To know the level of risk of experiencing depression and/or anxiety in the next 12 months. In addition, participants assigned to this intervention will have free access to the 24 self-help pamphlets for preventing depression and anxiety.
214907380|NCT05486637|BEHAVIORAL|Perception of acoustic cues to emotion|Using novel methodologies and stimuli comprising both controlled laboratory recordings and materials culled from databases of ecologically valid speech emotions (e.g., from publicly available podcasts), the team aims to collect perceptual data to build a statistical model to test the hypothesis that experience-based changes in emotion identification by pediatric and adult CI recipients is mediated by improvements in cue-optimization.
214907381|NCT05486637|BEHAVIORAL|Production of acoustic cues to emotion|The team will acoustically analyze vocal emotion productions by participants, quantify acoustic features of spoken emotions, and obtain behavioral measures of how well normally hearing listeners can identify those emotions.
214907382|NCT01734135|OTHER|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
214907383|NCT02895750|DRUG|Metformin|Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)
214907384|NCT04462406|BIOLOGICAL|Ipilimumab|Given IV
214907385|NCT04462406|BIOLOGICAL|Nivolumab|Given IV
214907386|NCT04462406|OTHER|Patient Observation|Undergo active surveillance
214907387|NCT04462406|BIOLOGICAL|Pembrolizumab|Given IV
214907388|NCT03026062|BIOLOGICAL|Durvalumab|Given IV
214907389|NCT03026062|BIOLOGICAL|Tremelimumab|Given IV
214907390|NCT06454240|DRUG|lunsekimig|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
214901556|NCT05493904|PROCEDURE|Angiography-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using angiography only.~The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 30% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended."
214901557|NCT05493904|DEVICE|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
214901558|NCT06522607|DEVICE|rapid palatal expander|Clinical evaluation of the patients who will be treated with rapid palatal expander for about 6 month.
214901559|NCT04790344|DEVICE|Investigational LUX-Dx ICM Implant|All subject will receive an investigational version of the LUX-Dx ICM device.
214901560|NCT00899301|OTHER|biologic sample preservation procedure|Tissue, urine and blood collection.
214901561|NCT05022667|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements.
214901562|NCT06962488|BEHAVIORAL|Regular Care|Educational brochures and lifestyle guidance on blood pressure control, medication adherence, physical activity, and healthy diet, provided at baseline only. No additional counseling or genetic risk disclosure will occur during the 12-month intervention period.
214901563|NCT06962488|BEHAVIORAL|SBP PRS Dissemination|Participants receive individualized SBP PRS reports and structured genomic counseling sessions delivered by trained genetic counselors. Counseling addresses key constructs of the Health Belief Model, including perceived susceptibility, severity, and benefits of behavior change, with an emphasis on lifestyle modification and medication adherence.
214901564|NCT06961747|DRUG|Zilucoplan|Dose formulation: Solution for injection. Route of administration: Subcutaneous injection.
214901565|NCT06257108|OTHER|Class II Cavity Restorations|The study involved a split-mouth design in which Ultradent PQ1 Bond (standard bond) and Ultradent Peak Universal Bond (chlorhexidine-containing bond) were used as the bonding agents, and Tetric N Ceram Bulk Fill composite was used as the restorative material for the restoration of primary molars with class II cavity.
214901566|NCT01817517|DEVICE|Medtronic Activa Deep Brain Stimulation System|
214901567|NCT04519216|BEHAVIORAL|Telesimulation|Telesimulation educational intervention
214901568|NCT05785494|OTHER|Narstaende.se|Web-site with supportive information, videos and chat forum targeting family caregivers of patients with life-threatening illness.
214901569|NCT05912010|DIAGNOSTIC_TEST|NP/OP swab|NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.
214901570|NCT06434909|DRUG|Cytalux™ (pafolacianine) for fluorescent imaging|"Cytalux™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye for real-time cancer margin status.~This is used in conjunction with appropriate imaging system."
214901571|NCT06434909|PROCEDURE|Image Guided Surgery|prostatectomy using appropriate imaging system
214907391|NCT06454240|DRUG|placebo|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
214907392|NCT04721769|PROCEDURE|Endoscopic strip craniectomy (with lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
214907393|NCT04721769|PROCEDURE|Endoscopic strip craniectomy (without lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
214907394|NCT06335966|DEVICE|Screening with swallowable esophageal cell-collection devices (SECD)|All participants who enroll in this study and provide their consent will undergo screening with an FDA approved swallowable esophageal cell-collection device (SECD)
214907395|NCT05743595|BIOLOGICAL|Personalized Neoantigen DNA vaccine|The sites of immunization may be rotated for each of the immunizations.
214901572|NCT06293183|OTHER|Mobile app|Participants in the intervention group will be expected to watch the training video in the mobile application installed on their phones or tablets and then regularly enter all the food and liquid amounts they consume during the day into this application. In the mobile application data entry area, visuals that will be included in the application showing the amount and types of foods consumed by the participants during the day (1 soup bowl, 1 vegetable dish plate, 1 meat dish plate, 1 water glass, 1 tea glass, tablespoon, dessert spoon, teaspoon, ladle). etc.) will choose through. The mobile application will calculate the total amount of liquid consumed by the participants in 24 hours, and will give a yellow warning when the amount of liquid consumed is 2-2.5 liters, an orange warning when it is 2.5-3 liters, and a red warning when it is 3 liters and above. This will contribute to reducing the amount of fluid intake of participants between two dialysis sessions.
215055088|NCT03480984|OTHER|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
215055089|NCT03480984|OTHER|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
214901573|NCT05242848|BEHAVIORAL|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
214901574|NCT00134680|DRUG|Letrozole|Letrozole tablets 2.5 mg by mouth daily
214901575|NCT00134680|DRUG|Trastuzumab|Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.
214901576|NCT01332669|PROCEDURE|DebDox TACE|HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
214901577|NCT00295581|DRUG|PpPfs25/ISA51 & ScPvs25/ISA51|
214901578|NCT00637312|DEVICE|Cervical Artificial Disc (Advent™ Cervical Disc)|Advent™ Cervical Disc
214901579|NCT00637312|DEVICE|Hallmark™ Anterior Cervical Plate System|Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
214901580|NCT05267379|DIAGNOSTIC_TEST|Take blood samples|Blood samples are used to check for polymorphisms in NSAID metabolization genes and to determine the diclofenac levels.
214901581|NCT05270577|OTHER|Prehabilitation|prehabilitation
214901582|NCT05270577|OTHER|Standard care|No intervention
214901583|NCT00813150|DRUG|Dexamethasone|Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
214901584|NCT00813150|DRUG|Bortezomib|Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
214901585|NCT00813150|DRUG|Cyclophosphamide|Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
214901586|NCT03368092|DRUG|Dornase Alfa Inhalant Solution [Pulmozyme]|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
214901587|NCT03368092|DRUG|Placebos|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
214901588|NCT03033368|DRUG|Rilpivirine|Rilpivirine 25 mg tablet
214901589|NCT06617208|DEVICE|Neuropixel probe recording|Neuropixel recordings captures neuronal activity at the single-neuron level across the layers of the cortex.
214901590|NCT05159375|DIETARY_SUPPLEMENT|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
214901591|NCT05159375|OTHER|SMCC|Placebo comparator
215055090|NCT05687227|BEHAVIORAL|Online education and counseling|Online education and counseling regarding gynecological examination
215055091|NCT02165943|DEVICE|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
215055092|NCT00166127|DRUG|Levosimendan|
215055093|NCT03159910|BEHAVIORAL|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
215055094|NCT03159910|BEHAVIORAL|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
215055095|NCT00375466|DRUG|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
215055096|NCT00375466|DRUG|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
215055097|NCT00439101|DRUG|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
215055098|NCT00439101|OTHER|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
215055099|NCT04858607|DIAGNOSTIC_TEST|Blood sample|Serology, immune status, T cell immunity, and T cell aging.
215055100|NCT04858607|DIAGNOSTIC_TEST|Saliva sample|Antibody tests
214669591|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
214901592|NCT00100607|DRUG|AAE581|
214901593|NCT02024607|DRUG|BBI608|
214901594|NCT02024607|DRUG|Fluorouracil|
214901595|NCT02024607|DRUG|Oxaliplatin|
214901596|NCT02024607|DRUG|Leucovorin|
214901597|NCT02024607|DRUG|Irinotecan|
214901598|NCT02024607|DRUG|Bevacizumab|
214901599|NCT02024607|DRUG|Capecitabine|
214901600|NCT02024607|DRUG|Regorafenib|
214901601|NCT05354388|PROCEDURE|Resection surgery of gastrointestinal stromal tumor|oral administration of Ripretinib 150 mg QD. Resection of gastrointestinal stromal tumors was performed in patients who achieved PR or SD
214901602|NCT06682741|OTHER|Exercise|supervised exercise training; twice a week for 12 months
214901603|NCT06759753|DRUG|Aleeto|According to the groups, patients would be treated with Aleeto via intravenous injection, and the specific dosage of Aleeto will depend on the grouping.
214901604|NCT06759753|DRUG|Placebo|Placebo with the same dosage form, odor and color as Aleeto was administered in the same way and course of treatment.
214901605|NCT05803551|DRUG|Ketamine Hydrochloride|Intravenous 0.5 mg/kg infusions of ketamine for three consecutive days, 24 hours apart, with no more than 1mg/kg or 60 mg/day regardless of body weight
214901606|NCT05803551|DRUG|Placebo|Intravenous 0.9% saline infusions for three consecutive days.
214901607|NCT04514692|DRUG|GCSF|Granulocyte Colony Stimulating Factor (GCSF)
214901608|NCT03811964|OTHER|Specific light exposures|Specific light exposures using light in a wide range of intensities or different light/dark regimens
214901609|NCT04721106|DRUG|Vizimpro|treatment group
214901610|NCT01741311|BEHAVIORAL|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
214901611|NCT01741311|BEHAVIORAL|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
214901612|NCT06247956|DRUG|SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection|SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Oxaliplatin: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
214901613|NCT06247956|DRUG|Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection|Adebrelimab: Specified dose on specified days. Oxaliplatin Injection: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
214901614|NCT06408545|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
214901615|NCT06417099|DRUG|Dihydroartemisinin|dihydroartemisinin 40mg tid po for 90 consecutive days
214901616|NCT03593525|OTHER|SPARK|see above
214301716|NCT03698994|OTHER|Pharmacokinetic Study|Ancillary studies
214301717|NCT03698994|DRUG|Ulixertinib|Given PO
214901617|NCT04543253|OTHER|MUSE biofeedback|biofeedback through a headband
214901618|NCT04440189|DEVICE|GID SVF-2 Device System|The GID SVF-2 Device System is used for harvesting, filtering, separating and concentrating autologous stromal vascular fraction from adipose tissue.
214901619|NCT06645860|PROCEDURE|SDF+KI+LED Light 20s|After the silver diamine fluoride (SDF) and potassiım iodide (KI) application, 20-second LED light will be applied to the cavity.
214301718|NCT01572506|DRUG|Biotin RBC survival|
214301719|NCT06453044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214901620|NCT06645860|PROCEDURE|SDF+KI|Silver diamine fluoride (SDF) and potassium iodide(KI) will be applied.
214901621|NCT04214626|DRUG|Rituximab|"Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles (Total 8 cycles)."
214901622|NCT04214626|DRUG|Lenalidomide|Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214901623|NCT04214626|DRUG|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214907396|NCT05743595|BIOLOGICAL|Retifanlimab|Retifanlimab will be supplied by Incyte.
215055101|NCT00224965|BEHAVIORAL|Behavior Therapy|
215055102|NCT05002348|DEVICE|Laser acupoint stimulation(Laser pen)|Select 5-7 acupuncture points according to physical fitness. Each acupoint is performed once a day. The acupuncture point stimulation process takes about 3-5 minutes. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat and blood oxygen) with a physiological monitor. , If the patient has any discomfort, the procedure will be stopped for a maximum of 10 days.
215055103|NCT02358408|DEVICE|Blood glucose monitoring systems for self-testing|
214301720|NCT06453044|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214301721|NCT06453044|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214301722|NCT06453044|BIOLOGICAL|Mosunetuzumab|Given SC
214301723|NCT06453044|DRUG|Polatuzumab Vedotin|Given IV
214301724|NCT06453044|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215055104|NCT00132301|DRUG|Docetaxel|Chemotherapy agent
215055105|NCT00132301|DRUG|Prednisone|steroid in combination with chemotherapy agent
214901624|NCT04214626|DRUG|Epirubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214901625|NCT04214626|DRUG|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214901626|NCT04214626|DRUG|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
214901627|NCT04214626|DRUG|Methotrexate|Induction Chemotherapy: 1g/m2, Intravenous administration on day 3 of each 3-week cycle from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
214901628|NCT04585984|DIETARY_SUPPLEMENT|Experimental - Probiotic|Patients in the experimental group will take one compound (pill) a day for 21 days, containing a 50% combination of two probiotics: Lactobacillus rhamnosus and Bifidobacterium longum, at a dose of 10\^9 cfu/day. The carrier of lyophilized probiotics is maltodextrin and the mixture is encapsulated in hypromellose capsules.
214901629|NCT04585984|DIETARY_SUPPLEMENT|Placebo|Patients in the control group will take one unit of placebo a day for 21 days.
214901630|NCT06022016|GENETIC|For each person (index case or related) included in this study:|"* an health questionnaire will be completed in order to gather information on the participant's medical history and lifestyle.~* a saliva sample will be taken (if applicable) so that a genetic analysis can be performed."
214901631|NCT05639946|DRUG|brivaracetam|Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.
214901632|NCT05639946|DRUG|Placebo|Participants will receive placebo drug
215055106|NCT05710250|BEHAVIORAL|6-week MBSR program|"Participants will follow a 6-week program of mindfulness meditation. MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 6 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
215055107|NCT05710250|BEHAVIORAL|6-week muscular relaxation program|"Control group : This group will follow a 6-week program of progressive muscle relaxation training in order to learn achieving a deep relaxation of the body through voluntary tensing and relaxing muscles. It proceeds by the individual sequentially tensing and then releasing specific groups of muscles throughout the body, and noticing how tension feels relative to relaxation.~The accomplishment of physical relaxation promotes mental calmness in a parallel manner. This program is based on the work of Bernstein and Borkovec and Jacobson, and will be structured in 6-week group with weekly two and half hours sessions and out-of-session assignments for at-home practice (30-min daily)."
215055108|NCT06170567|OTHER|The effect of puzzles on students' course success|The effect of puzzles on students' course success
215055109|NCT02012218|DRUG|ADT|
215055110|NCT02012218|DRUG|Brexpiprazole|
214301725|NCT06453044|OTHER|Questionnaire Administration|Ancillary Studies
214301726|NCT04663607|BEHAVIORAL|Use of PretermConnect App|Participants will receive health education via a mobile app, PretermConnect, in addition to the standard of care, and complete additional surveys on the social determinants of health
214301727|NCT05379829|DRUG|Ziltivekimab|Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).
214301728|NCT05379829|DRUG|Placebo|Participants will be administered 3 doses s.c. Q4W.
214301729|NCT05206227|BEHAVIORAL|Aerobic Exercise|Subjects will complete a single bout of aerobic exercise.
214301730|NCT05206227|DRUG|alpha-FMH|Subjects will undergo either local heating with diathermy or whole body heating with far-infrared sauna.
214301731|NCT05206227|BEHAVIORAL|Resistance and Aerobic Exercise|Subjects will complete bouts of resistance and aerobic exercise.
214301732|NCT05206227|DRUG|Antihistamine|Subjects will complete a single bout of aerobic exercise under placebo vs antihistamine conditions.
214301733|NCT04959968|DEVICE|eye patch and earplug|The use of eye patch and ear plugs in post-operative intensive care in craniotomy cases.
214301734|NCT06368102|DRUG|Ampicillin|Total 2g vs 3g
214301735|NCT02067299|DRUG|JNJ-42847922|Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.
214901633|NCT05725681|OTHER|High protein ramen|Participants will be served one portion of high-protein instant ramen noodles \[CHEF WOO Roasted Chicken Flavor Ramen Cup Noodles, Borealis Foods; 71 g\]
214301736|NCT02067299|OTHER|Placebo|Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
214301737|NCT05882565|BEHAVIORAL|A brief (14-day) online mindfulness intervention|The content of the online mindfulness intervention is based on studies by Cavanagh et al. (2013, 2018). There is an approximately 10-minute audio tutorial that participants will listen to daily for 14 days. In the first week, participants will be instructed to apply their learned mindfulness skills to their daily activities. In the second week, they will continue practicing by learning to walk in a mindful manner.
214901634|NCT05725681|OTHER|Standard ramen|Participants will be served one portion of standard instant ramen noodles \[RAMEN EXPRESS Chicken Flavor Ramen Cup Noodle Chef Woo, Borealis Foods; 71 g\]
214901635|NCT06049849|DEVICE|Biophoton Energizing Brain and Whole Body|The patient is to be energized within a strong biophoton field which is constantly generated by active biophoton generators.
215055111|NCT01043718|BEHAVIORAL|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
214901636|NCT03568656|DRUG|CCS1477|Capsules, oral
214901637|NCT03568656|DRUG|Abiraterone acetate|Abiraterone acetate 500mg tablets plus prednisone/prednisolone
214901638|NCT03568656|DRUG|Enzalutamide|Enzalutamide 40mg capsules/tablets
214901639|NCT03568656|DRUG|Darolutamide|300mg tablets
214901640|NCT03568656|DRUG|Olaparib|150mg tablets
214901641|NCT03568656|DRUG|Atezolizumab|840mg/14ml concentrate for solution for infusion vials
214901642|NCT03103087|DRUG|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
214901643|NCT03103087|DRUG|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
214901644|NCT03103087|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
214901645|NCT03103087|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
214901646|NCT03472300|OTHER|Survey about knee pain and treatment|All citizens are surveyed to describe the prevalence of knee pain in a danish community.
214901647|NCT00075816|BIOLOGICAL|Allogeneic bone marrow transplantation|Bone marrow transplant from HLA compatible unrelated donors.
215055112|NCT01043718|BEHAVIORAL|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
215055113|NCT02253043|DEVICE|Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)|PINS Stimulator System
214479092|NCT03476369|DRUG|Ticagrelor 90Mg Tablet|Ticagrelor administered crushed vs non-crushed
214479093|NCT02724540|DEVICE|Bland Embolization|Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
214479094|NCT02724540|COMBINATION_PRODUCT|Transarterial chemoembolization|Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
214901648|NCT00075816|BIOLOGICAL|Peripheral blood stem cell transplantation|Peripheral blood transplant from HLA compatible unrelated donors.
214901649|NCT05678322|DRUG|18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent|Under development for the diagnosis of prostate cancer by Blue Earth Diagnostics. rhPSMA-7.3 (18F) will be administered intravenously as a single-dose injection. The molecular structure of the drug substance comprises a prostate-specific membrane antigen (PSMA) binding motif, a peptide spacer, an 18F-radiolabeled silicon fluoride acceptor moiety and a gallium chelator complex.
214901650|NCT05678322|DEVICE|PET MRI Imaging|rhPSMA-7.3 (18F) PET MRI imaging will be conducted once at baseline and a second time within one year of the initial scan.
214901651|NCT00161226|DEVICE|Levonorgestrel intrauterine system|
214901652|NCT00026988|DRUG|Creatine|
214901653|NCT02950415|BEHAVIORAL|virtual|Parent is present via an internet pad (iPad)
215055114|NCT02193997|OTHER|Fiber|
214301738|NCT05882565|BEHAVIORAL|Psychoeducation online|"The online psychoeducation was modified from the study by Harrer et al (2019, 2021).~This intervention consists of 14 audio tutorials about stress for 14 days, each lasting approximately 10 minutes. Additionally, there is a text version of each audio tutorial, which can be accessed by participants after listening to the audio."
214301739|NCT05020340|PROCEDURE|External cephalic version|In the intervention group, ECV will be performed by two operators with one of them having experience of ≥ 5 successful ECV. The procedure will be performed by the first operator under real time continuous ultrasonographic guidance. The fetal head and buttock will be grasped by both hands and attempt to rotate the fetus to a longitudinal lie either in a clockwise or anti-clockwise fashion. The second operator will perform the ECV if the first operator fails the procedure.
214301740|NCT04930848|OTHER|Euphorbia hirta (Dudhiya)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
215055115|NCT02193997|OTHER|Fiber|
215055116|NCT02193997|OTHER|Placebo|
215055117|NCT02903693|OTHER|cross sectional|
215055118|NCT03186625|DRUG|Compound Panax Notoginseng Granule|"Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months."
215055119|NCT03186625|DRUG|Placebo Granule|Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
214901654|NCT02950415|BEHAVIORAL|coaching|Parent learns what to say verbally to soothe child
214901655|NCT02950415|BEHAVIORAL|physical|Parent is present in the operating room
214901656|NCT02950415|BEHAVIORAL|no coaching|Parent does not learn what to say verbally to soothe child
214901657|NCT06048744|PROCEDURE|external oblique intercostal block|U S guided external oblique intercostal block after induction.
214901658|NCT06048744|PROCEDURE|Erector Spine block|US guided erector spine block after induction
214901659|NCT01683318|PROCEDURE|Thermal Pulsation therapy|
214901660|NCT00474890|DRUG|cetericine and pseudoephedrine|
214901661|NCT01864993|DIETARY_SUPPLEMENT|gluten|The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme
214901662|NCT01864993|DIETARY_SUPPLEMENT|Placebo|Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
214901663|NCT03924726|PROCEDURE|Micro-osteoperforation (MOP)|Micro-osteoperforation technique is used to accelerate orthodontic tooth movement.
214901664|NCT05998187|DRUG|intra-rectal botulinum toxin injections|Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.
214901665|NCT03742661|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
214901666|NCT00111605|BIOLOGICAL|HIV-1 gag DNA|A 0.75 mL intramuscular injection of HIV gag DNA vaccine into the deltoid
214901667|NCT00111605|BIOLOGICAL|HIV-1 gag DNA plus IL-12 DNA adjuvant|Injection IL-12 DNA adjuvant intramuscularly into the deltoid
214901668|NCT00111605|BIOLOGICAL|CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)|A 1 mL intramuscular injection in the deltoid
214901669|NCT00111605|BIOLOGICAL|Sodium chloride injection (0.9%)|"All placebo groups will receive an intramuscular injection of sodium chloride (0.9%) in the deltoid.~Group 1 will receive a 0.75 mL injection on Days 0, 28, and 84. Group 2 will receive a 0.8 mL injection on Days 0, 28, and 84. Group 3 will receive a 1.0 mL injection on Days 0, 28, and 84. Group 4 will receive a 1.5 mL injection on Days 0, 28, and 84. Group 5 will receive a 0.75 mL injection on Days 0, 28, 84, 168, and 273. Group 6 will receive a 1.5 mL injection on Days 0, 28, 84, 168, and 273. Group 7 will receive a 1.5 mL injection on Days 0, 28, and 84 and a 1 mL injection into the deltoid on Days 168 and 273."
214901670|NCT00976001|OTHER|Information, further rehabilitation, additional drugs to prevent recurrent stroke|
214901671|NCT00976001|OTHER|As the general practitioner wants to do|
214301741|NCT04930848|OTHER|PBO(Combined powder of Terminalia arjuna and Terminalia bellerica)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
214301742|NCT04743505|DRUG|APL-101|-Provided by Apollomics
214901672|NCT06575855|OTHER|IASTM|Group A received IASTM by using Graston Tool
214901673|NCT06575855|OTHER|METS|Group B received METs
214901674|NCT02594033|DRUG|insulin aspart|All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
214901675|NCT01892501|PROCEDURE|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
214901676|NCT01892501|DEVICE|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
214901677|NCT06188078|OTHER|Control|Babies in the control group will be fed only breast milk or formula, and a urine bag will be inserted after 25 minutes and they will be expected to urinate. The success of the transaction and the processing time will be recorded.
214901678|NCT06188078|OTHER|The bladder stimulation technique|"Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. A urine bag will be inserted 25 minutes after the feeding.~The newborn will be held under the armpit by the nurse, male infants will be held with their legs hanging down, and female infants will be held in the hip flexion position.~Newborns with spontaneous voiding during the period from the beginning of the investigation procedure to positioning the newborn will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until voiding begins.The success of the transaction and the processing time will be recorded."
214901679|NCT06188078|OTHER|Bath|Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. Babies will be bathed under running water 20 minutes after feeding.The bathing process will take 4 minutes in total. After bath, a urine bag will be inserted at the 25th minute of feeding. The success of the transaction and the processing time will be recorded.
215055120|NCT00714662|DEVICE|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
215055121|NCT02880228|DRUG|Dexamethasone|Given PO
215055122|NCT02880228|OTHER|Laboratory Biomarker Analysis|Correlative studies
215055123|NCT02880228|DRUG|Lenalidomide|Given PO
214301743|NCT04743505|DRUG|Osimertinib|-Given standard of care
214301744|NCT05640102|DRUG|Zanubrutinib|Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling
214301745|NCT06501196|DRUG|BH-30236|BH-30236 will be provided as either a 5 mg, 15 mg or 30 mg tablet. Participants will take BH-30236 tablets orally depending on their dose level assignment.
215055124|NCT02880228|BIOLOGICAL|Pembrolizumab|Given IV
214901680|NCT05994872|PROCEDURE|Reverse drilling technique|A standard hamstring autograft procedure was performed using reverse drilling technique to prepare bone tunnel.
215055125|NCT02765048|BEHAVIORAL|GAIN Program|Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
214901681|NCT05994872|PROCEDURE|Traditional extraction drilling|A standard hamstring autograft procedure was performed using traditional extraction drilling to prepare bone tunnel.
214901682|NCT02549859|DEVICE|Deep Brain Stimulation (DBS) at 60 Hz|Bilateral subthalamic nucleus deep brain stimulation at 60 Hz
214901683|NCT02549859|DEVICE|Deep Brain Stimulation (DBS) at 130 Hz|Bilateral subthalamic nucleus deep brain stimulation at 130 Hz
214901684|NCT02549859|DEVICE|Deep Brain Stimulation (DBS) Off (Sham)|Deep Brain Stimulation (DBS) Off (Sham)
214901685|NCT01399775|PROCEDURE|immediate implantation|Immediately after tooth extraction, a dental implant is inserted
214901686|NCT01399775|PROCEDURE|Delayed implantation|Four months after extraction, a dental implant is inserted and measurements are recorded.
214901687|NCT04775082|DRUG|Liraglutide|"The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.~The dose will increase each week over 4 or 5 weeks until the final dose is reached."
214901688|NCT04775082|DRUG|Placebo|The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
214901689|NCT03070236|OTHER|Survey|Select questions will be ask in the survey
214901690|NCT01710865|OTHER|Ultraseal Sealant|This is a newly developed hydrophilic sealant material.
214901691|NCT01710865|OTHER|Ultraseal Sealant|This is a previously existing hydrophobic sealant material.
214901692|NCT05685147|GENETIC|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
214901693|NCT03173898|PROCEDURE|PDL anesthesia versus local infiltration|Every patient received the recommended volumes of 2% lidocaine with 1:100.000 epinephrine for PDL injection on the experimental side, and for local infiltration on the control side. A Visual Analogue Scale (VAS) was used to describe the pain felt during injection.
215055126|NCT01830985|DRUG|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
215055127|NCT00738569|DRUG|Raltegravir|Raltegravir 400 mg PO BID for 12 months
215055128|NCT03406403|DEVICE|Laryngeal mask airway|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
215055129|NCT03406403|DRUG|Magensium sulphate|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
215055130|NCT03406403|OTHER|Control group (closure of anesthetics)|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
215055131|NCT01265017|DRUG|Estradiol, medroxyprogesterone, hydrocortisone, GH|"* Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection,"
215055132|NCT01265017|DRUG|Matching placebo|matching placebo
215055133|NCT00836771|DIETARY_SUPPLEMENT|Infant Formula|
215055134|NCT01143909|OTHER|omitting FFP transfusion before an intervention|In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
214301746|NCT06501196|DRUG|Venetoclax|Venetoclax will be provided as 10 mg, 50 mg or 100 mg tablets. Participants will take venetoclax orally per label instructions.
215055135|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
215055136|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
214301747|NCT05986292|DRUG|LY3016859 ISA|Administered intravenously (IV)
214301748|NCT05986292|DRUG|LY3556050 ISA|Administered orally
214301749|NCT05986292|DRUG|LY3526318 ISA|Administered orally
214901694|NCT02962583|OTHER|Weight loss|
214901695|NCT02962583|DRUG|Probiotic Formula|
214901696|NCT02962583|DRUG|Placebos|
214901697|NCT03552068|DRUG|placebo|"Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening)."
214901698|NCT03552068|DRUG|Clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).
214301750|NCT05986292|DRUG|LY3857210 ISA|Administered orally
214301751|NCT05986292|DRUG|Placebo Oral|Placebo administered orally
214301752|NCT05986292|DRUG|Placebo|Placebo administered IV
214901699|NCT06338488|OTHER|Real dry needling|dry needling into the muscle under ultrasound guidance.
214901700|NCT06338488|OTHER|Sham dry needling|dry needling into the subcutaneous fatty tissue under ultrasound guidance.
214901701|NCT05492136|PROCEDURE|Additional margin coagulation|After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
214901702|NCT05816239|PROCEDURE|Dual Energy CT|Patient will receive Dual Energy CT
214901703|NCT05249868|OTHER|Exposure SARS-CoV-2 Infection|"The exposure variable is confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.~Positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for \<5 days is positive on a PRAg test."
214901704|NCT04733079|OTHER|Cleanweb electronic messaging ePro|Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
215055137|NCT02593058|BEHAVIORAL|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
215055138|NCT02593058|BEHAVIORAL|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
215055139|NCT01642446|PROCEDURE|Precise hepatectomy|Precise hepatectomy
214301753|NCT03560050|BEHAVIORAL|Nutrition assistance|Participating family child care home providers in and around the Oklahoma City (OKC) area will be randomized to either the Nutrition (n=26), or an environmental health comparison group (n=26). Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
214901705|NCT04733079|OTHER|Usual follow-up|Adaptation and follow-up of ULT according to referring physician's habits
214901706|NCT06265051|DRUG|Tirofiban|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
214901707|NCT06265051|DRUG|Saline placebo|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
215055140|NCT01642446|OTHER|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
215055141|NCT03475342|DRUG|Tranexamic Acid|Ampoules and packaging for both arms will be identical in appearance.
215055142|NCT03475342|OTHER|Placebo|Ampoules and packaging for both arms will be identical in appearance.
214901708|NCT05615818|DRUG|Futibatinib|Dose 20 mg once a day (QD)
214901709|NCT05615818|DRUG|Ivosidenib|Dose 500 mg QD
214901710|NCT05615818|DRUG|Zanidatamab|Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
214901711|NCT05615818|DRUG|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
214901712|NCT05615818|DRUG|Neratinib|Dose: 240 mg QD (combination with trastuzumab)
214901713|NCT05615818|DRUG|Encorafenib|Dose: 450 mg QD (Combination with binimetinib)
214901714|NCT05615818|DRUG|Binimetinib|Dose: 45 mg twice a day (BID) (Combination with encorafenib)
214901715|NCT05615818|DRUG|Niraparib|Dose: 200 mg QD or 300 mg QD
214901716|NCT05615818|DRUG|Cisplatin|Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
214901717|NCT05615818|DRUG|Gemcitabine|Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
214901718|NCT06255223|RADIATION|High-dose Radiotherapy (HDRT)|SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).
214901719|NCT06255223|RADIATION|Low-dose Radiotherapy (LDRT)|Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.
214901720|NCT06255223|DRUG|Anti-PD-1 monoclonal antibody|At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.
215055143|NCT00584532|DRUG|Placebo|10 Placebo Capsules taken orally every day.
214479095|NCT02724540|COMBINATION_PRODUCT|Drug Eluting Beads Embolization|CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
214479096|NCT06040840|PROCEDURE|BAX|Injection of 30 mL of lidocaine (10 mg/ml) around the median, radial, ulnar and musculocutaneous nerves.
214479097|NCT06040840|PROCEDURE|Tourniquet|Inflation pressure 75 to 100 mmHg above the patient's systolic blood pressure.
214901721|NCT06642181|DRUG|Guanfacine pharmacotherapy|It is a pharmacotherapy
214901722|NCT06642181|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement (MORE)|It is a mindfulness intervention
214901723|NCT03448042|DRUG|Runimotamab|Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
214901724|NCT03448042|DRUG|Trastuzumab|Trastuzumab will be administered via IV infusion
215055144|NCT00584532|DRUG|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
215055145|NCT00746525|OTHER|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
214479098|NCT06040840|DRUG|Lidocaine|Axillary block with Lidocaine (10 mg/ml).
214901725|NCT03448042|DRUG|Tocilizumab|Participants will receive IV tocilizumab if needed
214901726|NCT03664232|DRUG|JNJ-42165279|Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
215055146|NCT00746525|OTHER|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
215055147|NCT00746525|OTHER|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
215055148|NCT02579434|DRUG|Midazolam I.V.|Midazolam I.V. 1mg/ml
215055149|NCT01569815|DRUG|LCZ696|LCZ696 400 mg once daily
214479099|NCT06040840|PROCEDURE|WALANT|"Preparation of a mixture of 20 ml of lidocaine (10 mg/ml) with epinephrine (0.005 mg/ml) + 3 ml Na bicarbonate (84 mg/ml) + 17 ml sterile normal saline.~The ultrasound probe will be placed to obtain a transverse image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 5 ml of the solution posterior and then anterior to the median nerve under the annular carpal ligament.~Then the ultrasound probe will be placed to obtain a longitudinal image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 15 ml of the solution anterior to the median nerve towards the carpal tunnel.~At last, a local infiltration with 5 ml of the solution will be performed around the surgical incision."
214479100|NCT06040840|DRUG|Lidocaine + Epinephrine|WALANT technique with lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine.
215055150|NCT04831437|RADIATION|Hypofractionated EBRT|EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2
214479101|NCT06050915|DRUG|DISC-3405|DISC-3405 is administered as a single dose IV infusion or subcutaneous injection
214479102|NCT06050915|DRUG|DISC-3405|DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection
214479103|NCT06050915|DRUG|Placebo|Placebo is administered as a single dose IV infusion or subcutaneous injection
214901727|NCT03664232|DRUG|Placebo|Participants will receive a matching placebo orally twice daily for 12 weeks.
214901728|NCT02820857|DRUG|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
215055151|NCT04831437|RADIATION|Standard EBRT|EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2
214901729|NCT02820857|DRUG|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
214901730|NCT03904173|DIAGNOSTIC_TEST|Multi-parameter tests|Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
214901731|NCT05753618|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
214479104|NCT06050915|DRUG|Placebo|Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
214901732|NCT05753618|DRUG|Omission of Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
214901733|NCT02759419|DRUG|Adempas (Riociguat, BAY63-2521)|0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
214901734|NCT06315205|DRUG|Letrozole LEBE 75 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg
214901735|NCT06315205|DRUG|Letrozole LEBE 150 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg
214901736|NCT06315205|DRUG|Letrozole LEBE 225 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg
214901737|NCT01034878|DRUG|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
214901738|NCT00271193|BEHAVIORAL|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
214901739|NCT00353158|DRUG|Doxycycline|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
215055152|NCT05407207|DEVICE|Tennant Biomodulator ®|Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.
215055153|NCT02746328|DRUG|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
214901740|NCT00353158|DRUG|Voriconazole|After taking voriconazole for (Bullet)7 days to achieve a steady state of voriconazole for subjects, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
214901741|NCT05687123|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
215055154|NCT04987827|OTHER|No intervention|No intervention
215055155|NCT05940389|DEVICE|Naso Alveolar Mold|The NAM appliance is constructed according to the Grayson technique \[8\] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed.
215055156|NCT05940389|DEVICE|Taping with nasal elevator:|For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.
215055157|NCT02720523|DRUG|Placebo|Tablet; Oral
214901742|NCT05687123|PROCEDURE|Computed Tomography|Undergo a CT scan
214901743|NCT05687123|DRUG|Lutetium Lu 177 Dotatate|Given IV
214901744|NCT05687123|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214479105|NCT06602141|PROCEDURE|Muscle Biopsy|This procedure is used to sample muscle cells from the leg Vastus Lateralis (thigh) muscle.
214479106|NCT06602141|PROCEDURE|Adipose Biopsy|This procedure is used to sample fat tissue from the abdomen (belly).
214901745|NCT05687123|PROCEDURE|Positron Emission Tomography|Undergo a SSR PET/CT scan
214901746|NCT05687123|DRUG|Sunitinib Malate|Given PO
214901747|NCT05187390|PROCEDURE|VATS application|The chronic pain findings of the patients who underwent VATS will be questioned at the postoperative 1st and 3rd months.
214901748|NCT03515512|DRUG|Enasidenib|Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells
214901749|NCT03346096|DRUG|Thiotepa|fixed dose 5mg/kg on days -7-6
214901750|NCT01668615|DRUG|all-trans-retinoid acid|10 mg three times a day oral administration for 4 months
214901751|NCT02399137|DRUG|MM-141|
215055158|NCT02720523|DRUG|Upadacitinib|Tablet; Oral
215055159|NCT04118543|OTHER|Intervention Group|Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
214901752|NCT02399137|DRUG|Placebo|
215055160|NCT04118543|OTHER|Sham-Exercise Group|Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
214901753|NCT02399137|DRUG|Gemcitabine|
214901754|NCT02399137|DRUG|Nab-Paclitaxel|
214901755|NCT02485093|DEVICE|Septal ventricular pacing|Ventricular pacing must be at least 90%, from the septum and with optimized AV delay
214901756|NCT02485093|DEVICE|VIP|Ventricular pacing must be less than 10%.
214901757|NCT01733550|DEVICE|Home iCare (study nurse)|the intraocular pressure is measured by iCare performed by the study nurse
214901758|NCT01733550|DEVICE|goldmann applanation tonometry|the intraocular pressure is measured by goldmann applanation tonometry
214901759|NCT01733550|DEVICE|home iCare (by patient)|the intraocular pressure is measured by the iCare performed by the patient him self
214901760|NCT00012792|BEHAVIORAL|Exercise Training|
214901761|NCT03503604|BIOLOGICAL|hPV19 mAb|Intravenous (IV) infusions, 4 and 6 milligrams per kilogram (mg/kg) every 2 weeks
214901762|NCT03503604|BIOLOGICAL|hPV19 mAb|Intravenous (IV) infusions, 6 milligrams per kilogram (mg/kg) every 3 weeks
214901763|NCT03503604|DRUG|5-Fluorouracil|400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks
214901764|NCT03503604|DRUG|Oxaliplatin|IV Infusion, 85 milligrams per square meter (mg/m2) every 2 weeks
214901765|NCT03503604|DRUG|Leucovorin|IV infusion, 400 mg/m2 every 2 weeks
214901766|NCT03503604|DRUG|Paclitaxel|IV infusion, 175 mg/m2 every 3 weeks
214901767|NCT03503604|DRUG|Carboplatin|IV infusion, AUC=6 every 3 weeks
214901768|NCT03503604|DRUG|Gemcitabine|IV infusion, 1000 mg/m2 at day1 and day 8 every 3 weeks
214901769|NCT03503604|DRUG|Carboplatin|IV infusion, AUC=4 every 3 weeks
214901770|NCT03503604|DRUG|Irinotecan|IV Infusion,180 milligrams per square meter (mg/m2) every 2 weeks
214901771|NCT04278781|DRUG|AG-120|AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
214901772|NCT00690911|DRUG|adalimumab|40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
214901773|NCT05083026|DIAGNOSTIC_TEST|COVID-19 neutralizing antibody|"This study enrolled persons already who received COVID-19 vaccination under government policy.~1. We collect 5mL blood at 2, 4, 6, 9, 12 months after COVID-19 vaccination~2. isolate serum and store in -80 degree deep freezer~3. measure neutralizing Antibody"
214901774|NCT02353286|DEVICE|Endoscopic insertion of biodegradable biliary stent|Endoscopic insertion of biodegradable biliary stent
215055161|NCT02340169|DRUG|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
215055162|NCT06028698|OTHER|Inducing positive emotion music|listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.
215055163|NCT00742170|DEVICE|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
214901775|NCT04107324|PROCEDURE|ARAPS|In a previous experimental study on rats, the investigators have shown that PVE combined with radiofrequency ablation (RFA), hereafter called Associated Radiofrequency Ablation and Portal Vein Ligation for Staged Hepatectomy (ARAPS), can induce accelerated growth of the FLR
214901776|NCT04107324|PROCEDURE|PVE|Portal vein embolisation
214901777|NCT02636218|DRUG|Ketamine|500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
214901778|NCT02636218|DRUG|0.9% NaCl|500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
214901779|NCT06417190|DRUG|Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)|Single-arm, open-label
215055164|NCT05961683|DEVICE|NIV plus software|interventions received by infants studied after placing them on ventilator using NIV plus software
215055165|NCT00572598|DRUG|4- [F-18] fluoropaclitaxel|4- \[F-18\] fluoropaclitaxel, \<84 micrograms, \<10 mCi, IV followed by PET/CT imaging
215055166|NCT05918978|DRUG|Efgartigimod|Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
214479107|NCT06602141|OTHER|Glucose Clamp|In this test, we will measure the effect of insulin by giving you insulin and glucose (sugar) intravenously through an IV line in your arm.
214479108|NCT06602141|OTHER|Accelerometer|The tri-axial accelerometer measure activity and uses those values to estimate the number of calories burned based on your height, weight, age, and gender. The monitor also evaluates physical effort and the body's response to different activities.
214901780|NCT03238521|PROCEDURE|Spinal osteosynthesis with classical pedicle finder|Posterior thoracic and lumbar osteosynthesis with classical pedicle finder
214901781|NCT03238521|PROCEDURE|Spinal osteosynthesis with pedicle finder with impedancemetry|Posterior thoracic and lumbar osteosynthesis with pedicle finder with impedancemetry
214901782|NCT02597764|BEHAVIORAL|Diaphragmatic Breathing|
214479109|NCT06602141|OTHER|Endurance Exercise|Visit the study site 3 times a week to engage in endurance exercise training for approximately 12 weeks. Each session will last approximately 75 minutes, and exercise group can choose to use either a stationary bike or a treadmill to complete the training.
214479110|NCT06602141|OTHER|Physical activity/ dietary habits|Visit the study site bi-weekly to get weight measurements and speak to the study team about weight maintenance and participant physical activity/dietary habits.
214479111|NCT06602141|OTHER|Heavy Water Labeling Period|Participants in both control groups will be required to drink heavy water, which is ordinary water that is enriched with deuterium (stable, non-radioactive isotope) and called deuterium-labeled water, for 12 weeks.
214669592|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
214669593|NCT02102230|BEHAVIORAL|Desensitization Treatment for Insomnia|"This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing."
215055167|NCT01224886|BEHAVIORAL|Physical activity|Supervised exercise intervention
215055168|NCT06324474|DRUG|Hyaluronic acid|Gengigel syringe containing 1ml of 0.8% HA
214901783|NCT02597764|BEHAVIORAL|Standard Urotherapy|
214901784|NCT03505970|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate in powder form ingested in gelatine capsules. This leads to an increase bicarbonate concentration in blood, increasing buffering capacity which may lead to improvements in exercise
215055169|NCT06324474|BEHAVIORAL|scaling and root planning|scaling and root planning using ultrasonic scaler
215055170|NCT06290388|DRUG|23ME-01473|23Me-01473 given by intravenous infusion
215055171|NCT03929913|DEVICE|Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)|The Transcatheter Mitral Cerclage Annuloplasty implant has two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and right ventricular outflow track limbs. Procedure is performed from a trans-jugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein to the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. After desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.
215055172|NCT02294032|DRUG|Immunosuppressive Agents|standard of care for patients post-transplant
215055173|NCT03961802|OTHER|sessions of shoulder rehabilitation|3 sessions of shoulder rehabilitation per week for 3 months (36 sessions)
215055174|NCT01154452|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214479112|NCT04782752|RADIATION|Radiation: Varying Doses of RT|3+3 radiation dose escalation model to see the maximum tolerated dose
214479113|NCT06810986|BEHAVIORAL|16-week digital intervention|"Participants will be enrolled in a 16-week programme with the aim to manage T2DM through lifestyle adjustments. Participants will be given online support by their personal health coach with additional support from a dietitian or clinician in the study if required.~Each participant will receive personalised recommendations for blood glucose monitoring schedule, diet and physical activity. Participants are required to log their blood glucose, diet and physical activity in the BruHealth application. Participants will review their progress with their health coach via video consultation on a regular basis. Additionally, participants will also participate in a structured diabetes self-management education course."
214901785|NCT03505970|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be used as a placebo as it will not lead to any increases in circulating bicarbonate and, at this dose, will not likely have any physiological effect.
214901786|NCT00210028|DRUG|Tamoxifen|
214901787|NCT00210028|DRUG|Zarnestra|
214901788|NCT04364893|OTHER|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
214901789|NCT03707210|BEHAVIORAL|VR training program|Use VR software to make a training education program.
214901790|NCT04506034|DRUG|lidocaine patches|for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
214901791|NCT04506034|DRUG|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
214901792|NCT04506034|DRUG|IV saline infusion|received i.v. saline infusion.
214901793|NCT02267681|DRUG|Fentanyl|Intravenous fentanyl for sedation/analgesia
215055175|NCT01154452|OTHER|Laboratory Biomarker Analysis|Correlative studies
215055176|NCT01154452|OTHER|Pharmacological Study|Correlative studies
215055177|NCT01154452|DRUG|Vismodegib|Given PO
215055178|NCT05949918|BEHAVIORAL|Stage-matched interventions|"The study intervention will be designed based on each Stage of Change of the Transtheoretical Model of Change in that participants in each Stage of Change will receive the intervention that matches the Stage of Change they would be in.~A 12-week interval would be considered between administering the intervention and posttest 1 and the same interval would be used between posttest 1 and posttest 2."
214669594|NCT00736229|DRUG|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
214901794|NCT02267681|DRUG|Alfentanil|Intravenous alfentanyl for sedation/analgesia
214901795|NCT02267681|DRUG|Propofol|Intravenous propofol for sedation
214901796|NCT02790164|DRUG|Esmeron|Neuromuscular Blockade
214901797|NCT02790164|DRUG|Saline|Normal Saline
214901798|NCT04740450|DEVICE|Kinesio taping|skin colored Kinesio-Tex Gold tape, 50 mm \_ 5 m (Kinesio Holding Corp, Albuquerque, NM) tapped in technique described by Gozluklu et al in 2020
214901799|NCT04740450|DEVICE|Wound Tape|skin colored wound tape tapped in technique described by Gozluklu et al in 2020
214901800|NCT01075438|BIOLOGICAL|Prevenar® (7-valent pneumococcal conjugate vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
214901801|NCT01075438|BIOLOGICAL|Pneumovax® (pneumococcal polysaccharide vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
214901802|NCT00685217|PROCEDURE|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
214901803|NCT00685217|PROCEDURE|TVT (Gynecare)|Sling procedure for stress urinary incontinence
215055179|NCT04892719|DIAGNOSTIC_TEST|Fluoroscopic chest imaging with 4Dx technology software analysis|4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
215055180|NCT04073901|OTHER|Endocrowns|Adhesive monoblock restoration for pulpotomized primary molars
215055181|NCT02932826|BIOLOGICAL|Umbilical Cord Blood Regulatory T cells Therapy|Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml NS
215055182|NCT02932826|DRUG|Insulin|Treated according to routine clinical practice at the discretion of the treating physician
215055183|NCT03381287|DRUG|HTD1801 Tablets, 500 mg|500 mg/day (250 mg BID)
215055184|NCT03381287|DRUG|HTD1801 Tablets, 1000 mg|1000 mg/day (500 mg BID)
215055185|NCT03381287|DRUG|HTD1801 Tablets, 2000 mg|2000 mg/day (1000 mg BID)
215055186|NCT03381287|DRUG|Placebo to match 500 mg HTD1801|2 tablets/day (1 tablet BID)
215055187|NCT03381287|DRUG|Placebo to match 1000 mg HTD1801|4 tablets/day (2 tablet BID)
215055188|NCT03381287|DRUG|Placebo to match 2000 mg HTD1801|8 tablets/day (4 tablet BID)
215055189|NCT00572104|OTHER|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
215055190|NCT00572104|OTHER|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
215055191|NCT01904929|OTHER|Walk-tests|"Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2."
215055192|NCT03455894|DEVICE|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
215055193|NCT01102491|DRUG|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
215055194|NCT03359369|DIAGNOSTIC_TEST|level of serum cholesterol and triglyceride|other
215055195|NCT04524221|DRUG|PTG-100|PTG-100, 600mg taken twice daily in capsule form for 42 days
215055196|NCT04524221|DRUG|Placebo|Placebo taken twice daily in capsule form for 42 days
215055197|NCT02847169|DEVICE|filcon IV1 toric lens|toric contact lens
215055198|NCT02847169|DEVICE|ocufilcon D toric lens|toric contact lens
215055199|NCT01771874|DRUG|MDMA|125 mg per os, single dose
215055200|NCT01771874|DRUG|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
215055201|NCT01771874|DRUG|Placebo|per os
214901804|NCT03334435|DRUG|Baricitinib|Administered orally
214901805|NCT03334435|DRUG|Placebo|Administered orally
214901806|NCT03922321|DRUG|RVT-1401|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
214901807|NCT01387659|PROCEDURE|Gastric emptying test|Gastric emptying tests will be performed at baseline, 6 months and 12 months
214901808|NCT02832232|OTHER|translational dorsal glide mobilization technique grade III|"Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
214901809|NCT02832232|OTHER|pressure maintained suboccipital Inhibition technique|"Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
214901810|NCT02832232|OTHER|Control Group|Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
214301754|NCT03560050|BEHAVIORAL|Children's environmental health|Participating family child care home providers in and around the OKC area will be randomized to either the Nutrition (n=26), or an environmental health intervention (n=26) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Intervention will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
214901811|NCT02249975|DEVICE|C2 CryoBalloon Focal Ablation System|"The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.~Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.~Evaluations include, but are not limited to the following:~* Device malfunctions~* Adverse events~* Patient Pain~* Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus."
214901812|NCT03632499|OTHER|rehabilitation|rehabilitation
214901813|NCT05169190|PROCEDURE|Stellate Ganglion Block|After procedure informed consent, the procedure will be done using an ultrasound guided technique with a high frequency (6 to 13 MHz) linear transducer and confirmation of placement by fluoroscopy at sites who do this in clinical practice. The subject will be prepped and draped and placed in supine position in a suite with continuous vital sign monitoring and advanced cardiac life support equipment and IV placement. Local anesthesia with 1% buffered lidocaine will be achieved. After visualization of Chassaignac's tubercle of C6 is identified along with the carotid artery, internal jugular vein and longus colli and capitus muscles, a 25-gauge echo-enhanced needle will be inserted to inject anesthetic over 2 minutes anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle. The needle will be withdrawn and the subject will be monitored for a minimum of 30 minutes.
214901814|NCT05169190|PROCEDURE|Sham Stellate Ganglion Block|"The Sham protocol is identical to the SGB protocol except After needle tip confirmation and negative aspiration, normal saline (0.9%) + contrast (unlabeled to keep treater blinded) will be slowly injected over 2 minutes while closely monitoring the subject."
214901815|NCT02828293|OTHER|Dynamic videofluoroscopic analysis|Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.
214901816|NCT02508337|DRUG|XG-102|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
215055202|NCT05086965|OTHER|Playing the virtual game simulation|The virtual game simulation developed by the researchers and designed by the researchers will be played on the computer for the students of the intervention group. Virtual game simulations are virtual games developed by researchers, specific to a clinical scenario, and prepared by transferring the videos taken with an action camera to the computer environment and displaying them in two dimensions.
215055203|NCT01837680|DRUG|Insulin|
215055204|NCT00788060|DRUG|Everolimus (RAD001)|5mg per day, continuously
214901817|NCT02508337|DRUG|Placebo|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
214901818|NCT04966871|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
214901819|NCT04966871|BIOLOGICAL|PfSPZ Challenge (7G8) for CHMI|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
214901820|NCT04966871|OTHER|Normal Saline|normal saline placebo control
214901821|NCT03275493|BIOLOGICAL|CD19 CAR-T cells|Express a Second Generation 4-1BB: CD19 CAR-T cells
215055205|NCT00788060|DRUG|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
215055206|NCT02544347|OTHER|gingival crevicular fluid|gingival crevicular fluid was collected
215055207|NCT02544347|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
215055208|NCT02276742|BEHAVIORAL|Social Cognitive Theory|focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
215055209|NCT02276742|OTHER|Monitoring|Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
215055210|NCT02612493|OTHER|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
215055211|NCT03128983|DEVICE|Participants wear a sensor bracelet for collecting physiological data and conducted urine tests to estimate the day of ovulation|
215055212|NCT05011175|OTHER|Survey|Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
215055213|NCT01412125|OTHER|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
215055214|NCT01412125|OTHER|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
214301755|NCT06287983|DEVICE|Inspiratory Muscle Trainer (IMT) (POWERbreathe Medic Classic)|Inspiratory muscle training will be started at an intensity of 50% of the patient's measured PIMAX value and will be increased by 2 cm/H20 per day according to patient tolerance, and will be applied for a total of 6 weeks / 5 days per week / 3 sessions per day / 10 breaths per session.
214301756|NCT06287983|OTHER|The Sample Spondylitis Exercise Program|The Sample Spondylitis Exercise Program recommended by the Spondylitis Association of America will be translated into Turkish and each exercise will be applied in 3\*10 sets. The exercise program will be applied to both groups, 3 sessions a week for 60 minutes for 6 weeks.
214901822|NCT03275493|BIOLOGICAL|CD19 CAR-T cells with CRS suppression technology|Express a Second Generation 4-1BB:CD19 CAR-T cells with CRS suppression technology
214901823|NCT00618111|DRUG|Granisetron|
214901824|NCT01022840|DRUG|S-Ketamine|drug
214901825|NCT01022840|OTHER|Placebo Comparison|saline control
214901826|NCT05221944|OTHER|Patients had a history of antithrombotic therapy|Patients with antithrombotic drugs were identified and grouped and their medical records were reviewed.
214901827|NCT05221944|OTHER|Patients had no history of antithrombotic therapy|Patients had no history of antithrombotic therapy
214669595|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 2mg, Once daily, 6 weeks.
214901828|NCT04246086|DRUG|Mosunetuzumab (IV)|Participants will receive IV mosunetuzumab as defined by the study protocol
214901829|NCT04246086|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
214901830|NCT04246086|DRUG|Lenalidomide|Participants will receive oral lenalidomide as defined by the study protocol
214901831|NCT04246086|DRUG|Mosunetuzumab (SC)|Participants will receive SC mosunetuzumab as defined by the study protocol
214901832|NCT02308150|DEVICE|transcatheter aortic valve replacement|
214901833|NCT05293704|DRUG|Mizoribine|Orally administered at 3-4 mg/kg/d, once every 12 hours; When body weight ≤50 kg, each dose of 75 mg; Weight \& gt At 50 kg, the dosage was 100 mg each time.
214901834|NCT04261946|OTHER|Quality of life survey|Unilateral patulous eustachian tube surgically treated were interviewed about our life's quality by a survey
214901835|NCT01607450|DRUG|GLP-1 Low Dose|0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study
214901836|NCT01607450|DRUG|GLP-1 Mid-Range Dose|1.5mmol/kg/min for 12 hours prior to PET study
214901837|NCT01607450|DRUG|GLP-1 High Dose|4.0mmol/kg/min GLP-1 for 12 hours prior to PET study
214901838|NCT01607450|DRUG|Saline|Normal saline placebo infusion for 12 hours prior to PET study
214901839|NCT01961050|BEHAVIORAL|Dual-Focused Brief Physician Intervention (DFBPI)|The DFBPI is incorporated in OB/GYN clinic visit. The intervention consists of two brief (5 to 10 minutes) manualized counseling segments delivered face-to-face by an OB/GYN in the context of two clinic visits.
214901840|NCT01961050|OTHER|Services as usual|Active Comparator: Standard OB/GYN clinic visits that include OB/GYN services as usual.
214901841|NCT00224367|BEHAVIORAL|time to first ambulation|
214901842|NCT05807295|OTHER|Relaxation Program|The relaxation program will include progressive muscle relaxation exercises and videos for relaxation. Videos will be sent to caregivers' social media accounts. Initial applications will be implemented with caregivers. The relaxation program is planned to last 6 weeks. The program is planned to last 8 weeks in total, with pre-test and post-test applications.
214901843|NCT04067050|DEVICE|comfilcon A asphere|Contact Lens
214669596|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 5mg, Once daily, 6 weeks.
214669597|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 10mg, Once daily, 6 weeks.
214901844|NCT04067050|DEVICE|Spectacles|Habitual spectacles
214901845|NCT01446341|PROCEDURE|Below knee plaster casting|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
214901846|NCT01446341|PROCEDURE|Functional rehabilitation|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
214907397|NCT05743595|DEVICE|TDS-IM v 2.0 electroporation device|Each DNA vaccination will be 1 mL vaccine administered intramuscularly using an integrated electroporation administration system
214907398|NCT00236340|DEVICE|Syringe aspiration|It consists of performing successive aspirations using a 50ml syringe connected to the needle by a flexible tube.
214907399|NCT00236340|DEVICE|Wall suction|The tubing is connected to the centralized suction system by continuous vacuum, the value of the applied vacuum is 250mmHg
214907400|NCT06205706|DRUG|BI-1910|BI-1910 administered as a flat-dose IV infusion once every 3 weeks
214907401|NCT06205706|DRUG|Pembrolizumab|Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion
214907402|NCT04670068|DRUG|CAR.B7-H3|Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.
214907403|NCT04670068|DRUG|Fludarabine|30 mg/m\^2 IV for 3 consecutive days
214907404|NCT04670068|DRUG|Cyclophosphamide|300 mg/m\^2 IV for 3 consecutive days
214907405|NCT06515145|PROCEDURE|High Volume Therapeutic Plasma Exchange|Experimental- High Volume Therapeutic Plasma Exchange at (8 - 9 litres of plasma would be exchanged in each patient over 6 - 8 hours)
214907406|NCT06515145|PROCEDURE|Standard volume therapeutic plasma exchange|Active Comparator - The standard volume strategy would be performed centrifugation technique with Plasma volume varying from 1.5 - 2.5 times the plasma - volume along with Standard Medical Treatment.
214901847|NCT05294679|DRUG|Propofol|All patients completed pre-anaesthesia assessment, signed informed consent, and completed vital signs on the day before surgery, with values as baseline vital signs. On the day of surgery, after routine preparation before colonoscopy (fasting for at least 6h and water restriction for at least 2h before surgery), venous access was established in the left hand. 0.5μg/kg fentanyl was administered intravenously after oxygen inhalation through a nasal catheter (4-6 L/min). About 3 minutes after fentanyl administration, sedation induction was performed with ciprofol or propofol immediately.
214901848|NCT05294679|DRUG|Ciprofol|Ciprofol
214901849|NCT03379337|DIAGNOSTIC_TEST|Dental imaging|The target teeth positions for imaging included 4 incisors and all 4 canines. Only the vestibular and interproximal regions were of interest. Images were taken of these target teeth positions regardless of whether or not they exhibited plaque, consisted of full or partial restorations, contained major cracks/fractures, chips, or were missing. Other captured images included any abnormality of the tooth or gum exhibiting red fluorescence physically accessible by the devices.
214901850|NCT01588288|PROCEDURE|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
214901851|NCT03160378|BEHAVIORAL|Organizational skills training|10 sessions of parent and child training in a group format.
214901852|NCT03160378|OTHER|Treatment as usual|Treatment as usual in the outpatient clinic
214901853|NCT00659711|DRUG|Januvia (Sitagliptin) 100 mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
214901854|NCT00659711|DRUG|Placebo|will be placed on a placebo for 12 weeks.
215055215|NCT04972266|DEVICE|AcumenTM Hypotension Prediction Index software|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
215055216|NCT00002348|DRUG|Mitoguazone|
215055217|NCT05409703|BEHAVIORAL|reiki therapy|reiki therapy for nurses
215055218|NCT01471821|DRUG|antiretroviral treatment|antiretroviral treatment
214301757|NCT05805787|OTHER|Acupressure|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
214301758|NCT05144984|DRUG|NNC0480-0389|A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
214669598|NCT00080327|DRUG|Placebo|Tablets, Oral, 0mg, Once daily, 6 weeks.
214669599|NCT05073289|BEHAVIORAL|Sandplay activity|The sandplay in psychiatric care, with a creative and fun approach, makes it easier for patients to verbally express their personal life stories and feelings in a safe environment, individually or as a group.
214901855|NCT02677753|RADIATION|Fluoroscopy|
214901856|NCT00498043|DRUG|R-CHOP14 induction regimen|R-CHOP14 induction regimen
214901857|NCT00498043|DRUG|R-ACVBP14 induction regimen|R-ACVBP14 induction regimen
214901858|NCT02933164|DEVICE|Continuous Glucose Monitoring System|Effectiveness and safety of a Continuous Glucose Monitoring System
214901859|NCT03390608|DRUG|Endocrine therapy|Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
214901860|NCT03390608|RADIATION|Radiotherapy|Radiotherapy versus no radiotherapy.
214901861|NCT03390608|DRUG|Herceptin|Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
215055219|NCT06376864|BEHAVIORAL|Activity Breaks|The Activity Breaks intervention is a 5-minute Activity Breaks programme that allows classroom teachers of all ages and ability levels to lead simple movement activities within their classrooms, negating the need for additional personnel or space.
215055220|NCT02990715|DEVICE|C-Scan System|"1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
215055221|NCT02075086|DRUG|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
215055222|NCT06007027|DEVICE|SmartXIDE2V2LR, Monalisa Touch, DEKA, Florence, Italy|The laser probe is gently inserted up to the top of the vagina, and subsequently withdrawn and rotated in order to deliver a complete treatment of the vaginal wall.
215055223|NCT00297739|DRUG|Risperidone|
215055224|NCT06619899|OTHER|PAP exercise with 0% body mass|The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass.
215055225|NCT06619899|OTHER|PAP exercise with 20% body mass|Description: The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass
215055226|NCT06619899|OTHER|No PAP exercise|No PAP exercise will be performed. The participants will perform only 6 x 30m sprints.
214901862|NCT03390608|DRUG|Chemotherapy|Chemotherapy versus no chemotherapy.
214901863|NCT03390608|PROCEDURE|Type of breast cancer surgery|Type of surgery (partial mastectomy, mastectomy, other).
214901864|NCT03390608|OTHER|Age at diagnosis|Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).
214901865|NCT03390608|OTHER|Screen detected tumor|Screening detected tumor (yes, no).
214901866|NCT03390608|OTHER|Menopausal status at diagnosis|Menopausal status (premenopausal, postmenopausal).
214901867|NCT03390608|OTHER|Tumor size|Tumor size (≤5 mm, 6-≤10 mm).
214901868|NCT03390608|OTHER|Estrogen receptor (ER) status|ER-status (positive, negative).
214901869|NCT03390608|OTHER|Tumor grade|Tumor grade (1, 2, 3).
214901870|NCT03390608|OTHER|HER2-status|HER2-status (positive, negative).
214901871|NCT03390608|OTHER|Intrinsic subgroups of breast cancer|Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
215055227|NCT05750108|DEVICE|Parasym device (active, current (mA) < discomfort threshold)|Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
215055228|NCT05750108|DEVICE|Parasym device (sham, current (mA) = 0)|Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
214901872|NCT03390608|OTHER|Nodal status|N-status (N0, N1).
214901873|NCT00151879|DRUG|SPM 927|
214901874|NCT02436928|BIOLOGICAL|AT-501 High Dose vaccine|Comparison of each dose of vaccine
214901875|NCT02436928|BIOLOGICAL|AT-501 High Dose vaccine with Adjuvant|Comparison of each dose of vaccine
214901876|NCT02436928|BIOLOGICAL|AT-501 Low Dose vaccine|Comparison of each dose of vaccine
214901877|NCT02436928|BIOLOGICAL|AT-501 Low Dose vaccine with Adjuvant|Comparison of each dose of vaccine
214901878|NCT02342678|BEHAVIORAL|Yoga Therapy|
215055229|NCT06709079|DRUG|Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals)|Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the evening, for a period of 20 days.
215055230|NCT06116981|OTHER|High Induction Magnetic Field Therapy|High Induction Magnetic Field Therapy is a method that has no side effects, is non-invasive and easy to apply, and is used to increase circulation in tissues.
215055231|NCT06116981|OTHER|Conservative Treatment|Shoulder exercises, transcutaneous electrical nerve stimulation, stretching.
215055232|NCT06718764|DEVICE|Neurosteer's single-channel EEG monitoring device|"Neurosteer device will be attached to participants forehead and readings will be collected for the duration of their NSICU stay.~Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters."
215055233|NCT06714942|DIETARY_SUPPLEMENT|Proprietary Blend of Ashwagandha|One capsule (300mg) is taken twice daily with water
215055234|NCT06714942|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha root extract|One capsule (300mg) is taken twice daily with water
214301759|NCT05144984|DRUG|Semaglutide|A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.
214901879|NCT02342678|BEHAVIORAL|Physical Conditioning|
214901880|NCT02015728|DEVICE|Tumor biology testing|"Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the best available combination of low-dose oral cytotoxic agents, including temozolomide and etoposide."
215055235|NCT06714942|DIETARY_SUPPLEMENT|Placebo|One capsule (300mg) is taken twice daily with water
215055236|NCT06719466|OTHER|low linoleic acid (LA)|diet guidance with low linoleic acid (LA) diet
214301760|NCT05144984|DRUG|Placebo (NNC080-0389)|A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
214901881|NCT02015728|DRUG|Temozolomide|"Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
214901882|NCT02015728|DRUG|Etoposide|"Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
215055237|NCT06718582|DEVICE|Delfi Training Device|Delfi (Vancouver, Canada) training devices will be used for exercise and testing sessions. Cuffs will be placed around the right and left proximal thigh. The LOP will be set at 60% immediately before exercise and will be applied during the entire exercise set (approximately 30-60 seconds in duration) following manufacturer specifications. In the supine LOP session, the BFR cuffs will be pressurized to 60% of the supine LOP. In the seated LOP session, the BFR cuffs will be pressurized to 60% of the seated LOP. And, in the standing LOP session, the BFR cuffs will be pressurized to 60% of the standing LOP. The cuffs will maintain pressure during training and rest periods. The LOP will be reduced to 0% immediately after completing the last set.
214301761|NCT05144984|DRUG|Placebo (semaglutide)|A weekly dose of placebo (semaglutide). The study will last for about 41weeks.
214301762|NCT04582110|DIAGNOSTIC_TEST|Optical coherence tomography angiography|Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
214669600|NCT05073289|OTHER|Routine Care|Routine care is the care given to the control group by the nurse to the patients in the psychiatry clinic.
214901883|NCT02015728|DRUG|Sorafenib|Sorafenib is a broad-spectrum kinase inhibitor.
214901884|NCT02015728|DRUG|Everolimus|Everolimus is an mTOR pathway inhibitor.
214901885|NCT02015728|DRUG|Erlotinib|Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
214901886|NCT02015728|DRUG|Dasatinib|Dasatinib is a broad spectrum SRC inhibitor.
214901887|NCT05726201|DIAGNOSTIC_TEST|ultrasound|Point-Of-Care Ultrasound (POCUS) As an Early Screening Tool for Diagnosing Skull Fractures In Children With Mild Closed Head Injuries
214901888|NCT05628610|DRUG|Tislelizumab|200mg d1, Q3W
214901889|NCT05628610|RADIATION|Radiation|Radiotherapy dose: 5,000 c G y / 30f
214901890|NCT05628610|DRUG|Paclitaxel|Paclitaxel: 150mg / m2 ,d1, q3w
214901891|NCT05628610|DRUG|Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs|cisplatin, carboplatin, naidaplatin and other platinum drugs
214901892|NCT01742312|RADIATION|DEXA scan|all patients will undertake a full body DEXA scan before and after chemotherapy
214901893|NCT01742312|PROCEDURE|Muscle biopsy|All patients will have a muscle biopsy before and after chemotherapy
214901894|NCT01742312|OTHER|cardio-pulmonary exercise testing (CPEX)|patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
214901895|NCT02383017|DIETARY_SUPPLEMENT|Shroom Tech Sport|STS will be given every day in accordance to company guidelines for 12 weeks.
214901896|NCT02383017|DIETARY_SUPPLEMENT|Placebo|Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
214669601|NCT05690321|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
214901897|NCT02029118|DRUG|Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)|Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
214901898|NCT02029118|DEVICE|acupoint|select acupoint according to traditional Chinese medicine
214901899|NCT02029118|DRUG|Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.|foundation treatment
214669602|NCT05690321|DRUG|Placebo|Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
214901900|NCT03334513|DRUG|Bevacizumab|intravitreal injection of bevacizumab
214901901|NCT03334513|DRUG|Ranibizumab|intravitreal injection of ranibizumab
214901902|NCT02004418|RADIATION|11C-Choline|
214901903|NCT02333942|DEVICE|Nautilus NeuroWaveTM System|A noninvasive device to detect dementia utilizing headset and sensors
214901904|NCT01795963|BEHAVIORAL|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress. Specifically, it teaches communication techniques and problem-solving skills that help couples to effectively deal with conflict. It also teaches couples how to enhance positive aspects of their relationship by fostering fun and friendship.
214901905|NCT01795963|BEHAVIORAL|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz \& Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite \& Fincham, 2007; Braithwaite \& Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
214901906|NCT04981418|DEVICE|customised pelvic support shorts|"These apply targeted compressive forces to the pelvic girdle through selective precisely positioned reinforced lycra panels that aim to stabilize and align body segments to improve function and reduce unwanted movements. The construction material (Nylon and Elastane) is durable and breathable, and its mechanical properties enable it to provide dynamic stability and support (rather than the rigid support provided by off-the-shelf belts) during movement/functional activities. This aims to optimise comfort and movement to increase wear compliance, which is crucial as any benefits gained rely upon this."
214901907|NCT04981418|OTHER|Exercise|Women will be provided with up to a maximum of 4 exercises from a pre-defined list of exercises. Suggested dosages are referred to in the protocol. The exercise programme contains a range of exercise focused around the pelvic girdle and hips (including movement control and strengthening
214901908|NCT04981418|OTHER|advice|standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat\_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource.
214901909|NCT04505670|DRUG|Donepezil|donepezil orally 5mg
214901910|NCT04505670|DRUG|Placebo oral tablet|Placebo
214901911|NCT04505670|DRUG|Topical Zinc Oxide|Topical Zinc Oxide 20%
214901912|NCT01109693|DRUG|Sertraline|Sertraline 50 mg/d or 100 mg/d for 6 more weeks
214901913|NCT01109693|DRUG|Mirtazapine|Augment with or switch to mirtazapine 15-45 mg/d
214901914|NCT06461806|DIETARY_SUPPLEMENT|Protein supplement - Plant protein|Pea/lupine protein powder mix
214901915|NCT06461806|DIETARY_SUPPLEMENT|Protein supplement - Animal protein|Whey protein powder
214901916|NCT05848193|OTHER|MyHeadHealth online application|MyHeadHealth is an online application to be accessed through the patients smartphone. The goal of MyHeadHealth is to improve treatment compliance by providing patients with free and convenient access to resources and activities that align with their treatment plan
214901917|NCT05848193|OTHER|Standard of Care|Patients will receive Standard of Care from our concussion clinic as necessary as per the consultation with the physician
214901918|NCT03458078|DRUG|Saline Solution|Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.
214901919|NCT03458078|DRUG|Magnesium Sulfate|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).
214901920|NCT03458078|DRUG|Midazolam 5 MG/ML Injection|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
215055238|NCT06717100|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.
214901921|NCT00498147|OTHER|ADEC Program|Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
214901922|NCT03084653|OTHER|Survey|Close-ended survey will be performed to the participants. The survey consisted of 18 questions (Appendix). The first six questions (#1-6) were related with respondent's demographical and educational data and experiences of surgical and laparoscopic practices. There were five questions to determine preferred technique for first entry (#7-11), three questions for complications (#12-14), and remaining four questions for safety maneuvers (#15-18).
214901923|NCT05405751|DRUG|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.
214901924|NCT00648791|DRUG|Finasteride Tablets 5 mg|5mg, single dose fasting
214901925|NCT00648791|DRUG|Proscar Tablets 5 mg|5mg, single dose fasting
214901926|NCT04056260|PROCEDURE|ICG-NIR guided surgery|ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy
214901927|NCT01068860|DRUG|Canakinumab 150 mg|Single subcutaneous injection of Canakinumab 150 mg.
214901928|NCT01068860|DRUG|Placebo to Canakinumab|Single subcutaneous injection of Placebo to Canakinumab.
214901929|NCT01441648|OTHER|contact lens wear|tinted contact lens wear
214901930|NCT01615458|BEHAVIORAL|Chronic Care Model for Mood Disorders|CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
214901931|NCT01928264|BEHAVIORAL|Physical activity|
215055239|NCT06715930|PROCEDURE|Interventional treatment|The procedure was performed via the traditional transfemoral arterial approach, under general anesthesia and complete heparin anticoagulation. PEDs were introduced using Marksman or Phenom-27 microcatheters (Medtronic, Irvine, USA), while coils were introduced via Echelon-10 microcatheters (Medtronic, Dublin, Ireland). An appropriate working projection was used to generate three-dimensional rotational angiography. Un-subtracted images were used to verify whether PED was completely deployed and attached to the parent artery. Wall apposition was enhanced using balloon angioplasty if post-deployment imaging indicated inadequate apposition. Overlapping devices were used when a single PED was not enough to cover the aneurysm neck and reconstruct blood flow. Neurointerventionalists with more than 15 years of experience conducted all endovascular procedures. The same dual-antiplatelet therapy was used for 6 months post-procedure, followed by aspirin monotherapy for a minimum of 12 months.
215055240|NCT06716762|PROCEDURE|Open Surgery|Open cyst excision and Roux-en-Y hepaticojejunostomy performed through a 10 cm incision
215055241|NCT06716762|PROCEDURE|Laparoscopic Surgery|Laparoscopic cyst excision and Roux-en-Y hepaticojejunostomy performed through small incisions with a laparoscope
214669603|NCT00736281|OTHER|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
214669604|NCT03611140|DIETARY_SUPPLEMENT|DP|a package containing a mix of functional foods
214901932|NCT00460603|DRUG|bevacizumab|bevacizumab 5 mg/kg every 2 weeks
214901933|NCT00460603|DRUG|AG-013726|AG-013726 5 mg bid every 2 weeks
214901934|NCT00460603|DRUG|AG-013736 (axitinib)|AG-013736 5 mg bid starting dose
214901935|NCT02843321|BIOLOGICAL|T-cell infusion, influenza vaccination|Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)
214901936|NCT00317343|DRUG|Bivalirudin (thrombin specific anticoagulant)|Percutaneous Coronary Intervention
214901937|NCT01156779|DRUG|SR-exenatide|Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
214901938|NCT00722228|BIOLOGICAL|Autologous or Allogeneic tumor cells|Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
214901939|NCT01956578|OTHER|Breathing Exercise Cohort|All patients enrolled will be asked to wear a respiration band and perform a series of breathing exercises.
214901940|NCT03176069|OTHER|Evaluation and Comparison of women pelvic floor with and without sexual dysfunction|Pelvic floor muscles will also be evaluated by electromyographic biofeedback.
215055242|NCT06716853|GENETIC|Temferon|Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
215055243|NCT06716853|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400mg IV every 6 weeks commencing at D+30
215055244|NCT06716853|DRUG|Cabozantinib|40mg QD once PD occurs as assessed at D+30 or at subsequent visits
215055245|NCT06719323|BEHAVIORAL|Family Walking Instruction with Support by Heart (Family WISH) program|Researchers will compare the 12-week Family WISH program, based on self-efficacy theory, to a comparison group receiving a family walking health education sheet to evaluate the long-term effectiveness of the Family WISH program.
215055246|NCT06719323|BEHAVIORAL|Comparison group|a family walking health education sheet received
214901941|NCT03176069|OTHER|The physiotherapeutic treatment|"The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~* Kinesiotherapy~* Manual therapy~* Electrotherapy (electric electrostimulation, ultrasound)~* Behavioral therapy"
214901942|NCT00513240|DRUG|Erythropoetin|Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
214901943|NCT00513240|DRUG|Normal saline|"Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~."
214901944|NCT00469430|DRUG|cefotaxim and metronidazol|iv administration for at least 24 h
214901945|NCT02647710|BEHAVIORAL|PHAT Life Intervention|HIV Prevention behavioral health intervention
214901946|NCT02647710|BEHAVIORAL|Health Promotion Control|Behavioral health intervention control
214901947|NCT05263908|DRUG|nirmatrelvir / ritonavir|The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.
214901948|NCT00316238|DRUG|olanzapine-RAIM|
214901949|NCT00316238|DRUG|placebo|
214901950|NCT04962295|OTHER|No intervention|No intervention
215055247|NCT03672214|PROCEDURE|Without placement of indwelling catheter|No placement of indwelling catheter prior to Caesarean section
215055248|NCT03672214|PROCEDURE|With placement of indwelling catheter|Placement of indwelling catheter prior to Caesarean section
214669605|NCT03611140|DIETARY_SUPPLEMENT|Placebo|a package containing maltodextrins and caseinate calcium to mimic the DP
214901951|NCT05973539|OTHER|Diet|Eucaloric diet enriched in either carbohydrates or fat (both contributing to 65% total energy intake)
215055249|NCT04991493|DRUG|Tramadol hydrochloride|"pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured."
215055250|NCT04991493|OTHER|Normal Saline|"pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia."
215055251|NCT05989568|BEHAVIORAL|BASIS-T|BASIS-T is designed to address the behavioral components often missing from standard EBPP training and consultation that relate to motivation prior to receiving EBPP training, and volition after EBPP training. It is an EBPP-agnostic implementation strategy designed to be delivered within the Preparation/Adoption phase, immediately prior to Active Implementation (CITE EPIS). BASIS-T targets behavioral intentions via improvement in attitudes, subjective norms, and self-efficacy.
214901952|NCT00279435|DRUG|visilizumab|
214901953|NCT01921608|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
214901954|NCT04711993|OTHER|Aerobic exercise|"Patients will do aerobic exercise three days a week for 40 minutes during 8 weeks. Aerobic exercise protocol will consist of warm up, loading and cooling periods. . Exercise prescription will be prepared in line with the recommendations of The American College of Sports Medicine."
214901955|NCT04711993|OTHER|Stretchin exercise|Patients will do stretching exercise three days a week for 40 minutes during 8 weeks. Stretching exercises will start with active warm-up activities. Static stretching method will be used.
214901956|NCT05564156|BEHAVIORAL|Intervention groups|The drugs used by the participants within 24-48 hours after hospitalization were recorded. In the case of new prescribing, the recommendations made by the investigators to the physician are recorded in intervention group. The medication reconciliation report will be evaluated before the discharge of the participants and possible omissions discussed with the physician in charge. A detailed medication review will be accomplished by the investigators during the hospitalization of the participants.
214901957|NCT04588701|PROCEDURE|surgical procedures commonly done for anal fistula|Surgical procedures performed, including fistulotomy; fistulotomy with sphincter repair; seton; advancement flap; fistula plug;
214901958|NCT02340429|DEVICE|DE500 Digital Video Otoscope|
214901959|NCT00278057|DRUG|dialysisis with and without glucose in the dialysis|
214901960|NCT02129231|DRUG|calcined magnesia|We ensured the patient took the drug at night before meals
214901961|NCT02129231|DRUG|Ezetimibe/simvastatin|We ensured the patient took the drug at night before meals
214901962|NCT02129231|DRUG|Rosuvastatin|We ensured the patient took the drug at night before meals
214901963|NCT00289848|DRUG|sitagliptin phosphate|Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
214901964|NCT00289848|DRUG|Comparator: placebo|placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
214901965|NCT05867030|DRUG|lenalidomide|lenalidomide is administered orally
214901966|NCT05867030|DRUG|rituximab|rituximab is administered intravenously
214901967|NCT05867030|DRUG|parsaclisib|parsaclisib is administered orally
215055252|NCT05989568|BEHAVIORAL|Attention Control (ACC)|Teachers assigned to the ACC will receive pre- and post-training experiences designed to mirror those received in the BASIS-T condition. These training experiences will be virtual, delivered by the same interventionist, and be approximately the same length as the BASIS-T experiences, but will not contain any of the BASIS-T content or mechanisms of change. The ACC pre-training experience will define, describe, and advocate for EBP implementation in schools. Content will be didactic, as is typical in professional development training for teachers.
214669606|NCT00262704|BEHAVIORAL|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
214669607|NCT00262704|BEHAVIORAL|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
214669608|NCT00543647|DRUG|Fenofibrate 160 mg tablet|
214901968|NCT01545648|DRUG|Denosumab|"Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
214901969|NCT00894972|OTHER|Rehabilitation following lumbar disc surgery (discectomy)|Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
214901970|NCT01121614|DEVICE|LOTUS|Device used to seal blood vessel
214901971|NCT01121614|DEVICE|Ethicon Harmonic Scalpel|
214901972|NCT01121614|DEVICE|LigaSure bipolar vessel sealing device|
214901973|NCT05265286|DRUG|FRSW117|"Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117.~Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117."
214901974|NCT03785522|DRUG|Insulin degludec|Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter.
214901975|NCT00860795|BIOLOGICAL|Echinacea purpurea|Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
214901976|NCT00860795|DRUG|placebo|placebo 25 ml daily in 2 divided doses for 10 days
214901977|NCT05650112|BIOLOGICAL|FB-001|FB-001 is formulated as a powder in capsule intended for oral administration
214901978|NCT05650112|BIOLOGICAL|Placebo|In order to maintain study blinding, matching placebo in identical packaging is manufactured using an inactive powder in capsule
214901979|NCT01316081|DIETARY_SUPPLEMENT|Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine|"Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets"
214901980|NCT05799638|OTHER|Guideline-Directed Medication Treatment (GDMT)|GDMT contains ACEIs/ARBs/ARNI, β blockers, SGLT2is, MRAs. ACEI/ARB/ARNI and β blocker will gradually be titrated up to the maximum tolerable dose
214901981|NCT03871543|DEVICE|AquaComfort Plus|Test Lens 1
214901982|NCT03871543|DEVICE|Acuvue Oasys 1-Day|Test Lens 2
214901983|NCT00194441|OTHER|Bedside display of cerebral perfusion pressure information|Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
215055253|NCT03994016|BEHAVIORAL|WiseGuyz|"The WiseGuyz program was developed by the Centre for Sexuality (Calgary, AB), and aims to reduce male-perpetrated adolescent dating violence, improve mental and sexual health, and support youth to build healthier, more inclusive relationships in their peer groups, schools and communities, by helping participants identify and deconstruct gender role norms.~WiseGuyz is offered during instructional time by community-based facilitators from the Centre for Sexuality. WiseGuyz is comprised of 20 sessions across four modules. These sessions typically take the full school year (September-May) to implement."
214669609|NCT00543647|DRUG|Placebo|
214901984|NCT02598635|DRUG|Cholecalciferol|Patients on peritoneal dialysis and 25-(OH) levels \<20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
214901985|NCT02598635|DRUG|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
214901986|NCT04777942|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
214901987|NCT04777942|PROCEDURE|Surgery alone|hepatic resection remove the liver tumors
214901988|NCT04294407|OTHER|No intervention|no intervention in this study
215055254|NCT05040698|DRUG|Fostamatinib|Open label Fostamatinib
215055255|NCT05910567|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST) Examination|A bedside Focused Assessment with Sonography for Trauma (FAST) Examination will be conducted on those participants who are randomized to the FAST arm.
214669610|NCT06487949|DRUG|valsartan-amlodipine 80/5 mg FDC|fix dose combination of valsartan 80 mg and Amlodipine 5 mg given as single pill
214669611|NCT06487949|DRUG|valsartan 80 mg and amlodipine 5 mg as free combination|Free combination of valsartan 80 mg and amlodipine 5 mg given separately
214669612|NCT00184990|DRUG|Aminoguanidine|
214669613|NCT00184990|DRUG|endotoxin|
214901989|NCT02383979|DEVICE|Sham (Comparator) Plasma Ball|"will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
214901990|NCT02383979|DEVICE|Mirror|will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb
214901991|NCT01279824|BEHAVIORAL|swallowing therapy|Standardized behavioral swallowing intervention
214901992|NCT00454337|DRUG|FTC/TDF + EFV or LPV/R +T20|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
214901993|NCT00454337|DRUG|FTC/TDF + EFV or LPV/R|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
214901994|NCT04790903|DRUG|Venetoclax|Participants will self-administer Venetoclax, as described in the Arm Descriptions.
214901995|NCT04790903|DRUG|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.
214901996|NCT04790903|DRUG|Rituximab|Participants will receive Rituximab at a dose of 375 mg/m\^2 by IV infusion on Day 1 of Cycles 1-6.
214901997|NCT04790903|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide at a dose of 750 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
214901998|NCT04790903|DRUG|Doxorubicin|Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
214901999|NCT04790903|DRUG|Prednisone|Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.
214902000|NCT02028897|OTHER|Conventional embryo culture|
215055256|NCT05910567|OTHER|No Intervention: Standard of Care - Without the FAST Examination|Participants randomized to usual care will be evaluated per the standard operating procedures of the institution/site for the condition under study without the FAST exam.
215055257|NCT01224327|BIOLOGICAL|umbilical cord Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
215055258|NCT01224327|DRUG|Conserved therapy|Oral or intravenous administration
215055259|NCT00643942|OTHER|No intervention required|
215055260|NCT03300206|DEVICE|Breast Biopsy|A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
214902001|NCT02028897|OTHER|Enclosed embryo culture|
214902002|NCT03920124|OTHER|Step and walk-based high intensity interval exercise|"Four hospital-based trials will include two step-based (3 x 20 sec with 120 sec rest, or 3 x 60 sec with 60 sec rest) and two walking-based (e.g. 3 x 60 sec with 60 sec rest or 3 x 180 sec with 180 sec rest) interval exercise protocols, in a randomised and counterbalanced order.~Unsupervised (At home) exercise intervention will incorporate patients' preferred stair and/or walking-based interval exercise (from those completed during hospital trials). Initially patients will complete their chosen protocol three days per week, and then gradually progress exercise load (i.e. reps, work-to-rest ratio, and/or sessions per week) as appropriate, to a maximum of 6 x 60 sec stepping / 5 x 180 sec walking, five times per week (i.e. maximum of \~30 min daily or \~150 min weekly)."
215055261|NCT06525480|PROCEDURE|Percutaneous pulmonary thrombectomy|Pulmonary thrombus extraction
215055262|NCT06321445|OTHER|providing ASA score|ASA scoring, or the American Society of Anesthesiologists (ASA) Physical Status Classification System, is a framework used by anesthesiologists to assess the preoperative physical fitness of a patient before surgery. It categorizes patients into six classes based on their overall health status, ranging from ASA I (a healthy patient) to ASA VI (a declared brain-dead patient whose organs are being removed for donor purposes). The ASA score helps in predicting perioperative risks and assists healthcare professionals in making informed decisions about anesthesia management and the need for special precautions during and after surgery.
215055263|NCT01491061|DRUG|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
215055264|NCT01491061|DRUG|Placebo|os, two doses 12 hours apart prior to PCI
215055265|NCT00008411|DRUG|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
214902003|NCT05496205|DRUG|iN1011-N17|"This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached."
215055266|NCT00008411|DRUG|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
215055267|NCT01239277|OTHER|protein|20g protein
214902004|NCT05496205|DRUG|Placebo|Matching Placebo for each formulations
214902005|NCT00890383|DRUG|tetrastarch (Voluven)|Goals directed volume therapy for severe trauma resuscitation
214902006|NCT01313897|DRUG|Bortezomib|bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
214902007|NCT01930162|DRUG|HSC835|HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
214902008|NCT02814604|OTHER|Nutrition Rating Systems|Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
214902009|NCT00695461|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v in oatmeal drink|Bacteria in a concentration of 10(9) CFU/ml
214902010|NCT00695461|DIETARY_SUPPLEMENT|Oatmeal drink|Oatmeal drink as in arm 1 but without bacteria added.
214902011|NCT01253629|DRUG|AFQ056|AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
214902012|NCT01253629|DRUG|Placebo|Placebo medication identical in appearance to active medication was provided
214902013|NCT02635594|DIETARY_SUPPLEMENT|L-Carnitine|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
214902014|NCT02635594|OTHER|Placebo|1000mg cellulose + 475mg L-tartaric acid
214902015|NCT02805153|DRUG|PEG-rhG-CSF|
214902016|NCT02805153|DRUG|rhG-CSF|
214902017|NCT06068062|OTHER|modification of OSCE using TBL format|Modification of Team-based learning format and implementing OSCE using that modified format to teach clinical skills to medical students.To teach clinical skills this structure of TBL was modified and with use of OSCE following strategy was planned as intervention. First of all, the students were provided with the resource material regarding the skills to be taught. Then a formative OSCE session was organized where students were divided into groups each with 5 students. They were rotated in two OSCE stations. First each student one by one was supposed to perform the task that was clearly documented and was evaluated by peers and facilitator. Immediate feedback from peers and facilitators was given to each student. Students were also instructed to discuss among themselves and designate roles also to make a plan and act like team in performing task on OSCE station 2.
214902018|NCT02309320|BIOLOGICAL|ALX-0171|
214902019|NCT02309320|OTHER|Placebo|
214902020|NCT02584101|BEHAVIORAL|ACT|ACT therapy administered in 3 sessions over a 4 week period
214902021|NCT02584101|BEHAVIORAL|Enhanced Treatment as Usual|2 group discussion sessions over a 4 week period
214902022|NCT01293916|OTHER|Spica casting|single versus double leg spica casting
214902023|NCT00606112|DRUG|Trodusquemine (MSI-1436)|A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
214902024|NCT00105118|DEVICE|Magstim Super Rapid Magnetic Stimulator|
215055268|NCT01239277|OTHER|protein and carbohydrate|20g protein and 20g carbohydrate
214902025|NCT03113864|DIETARY_SUPPLEMENT|Placebo|Daily supplementation for 9 months
214902026|NCT03113864|DIETARY_SUPPLEMENT|Lutein|Daily Supplementation for 9 months
214902027|NCT01967862|PROCEDURE|computed tomography|Undergo CT
214902028|NCT01967862|PROCEDURE|bone scan|Undergo bone scan
215055269|NCT01239277|OTHER|protein and leucine|20g protein, 2.5g leucine
215055270|NCT00276406|DRUG|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
214902029|NCT01967862|PROCEDURE|3-Tesla magnetic resonance imaging|Undergo axial MRI
214902030|NCT01967862|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo WB MRI
214902031|NCT01967862|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT
214902032|NCT01967862|PROCEDURE|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT
214902033|NCT01967862|PROCEDURE|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT
214902034|NCT01967862|OTHER|laboratory biomarker analysis|Correlative studies
214902035|NCT02271334|DRUG|A006 DPI|Single dose 110 mcg, 1 inhalation
214902036|NCT02271334|DRUG|A006 DPI|Single dose 220 mcg, 1 inhalation
214902037|NCT02271334|DRUG|Proventil® MDI|Single dose 90 mcg, 1 inhalation
214902038|NCT02271334|DRUG|Proventil® MDI|Single dose 90 mcg, 2 inhalations
214902039|NCT00031590|DRUG|Cisplatin|Given at a dose of 70mg/m2 by intravenous (IV) infusion over 8 hours on day 0 of each cycle (Regimen A only).
214902040|NCT00031590|DRUG|Cyclophosphamide|Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).
214902041|NCT00031590|DRUG|Etoposide|Given at a dose of 150mg/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Given orally at a dose of 50mg/m2 as a single daily dose for 21 days beginning on day 14 of a cycle (Regimen B only).
214902042|NCT00031590|DRUG|Lomustine|Given at a dose of 75mg/m2 taken orally on days 0 of each 6-week cycle with vincristine and cisplatin (Regimen A only).
215055271|NCT00276406|DRUG|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
215055272|NCT02141230|DRUG|Alli® 60 mg|Participants purchasing Alli®
214902043|NCT00031590|DRUG|Vincristine|Given at a dose of 1.5mg/m2 given by IV infusion once a week for the first six weeks of treatment during radiation therapy. During maintenance therapy, it will be given as an IV push on days 0, 7 and 14 of each 6-week cycle (Regimen A only).
214902044|NCT00031590|RADIATION|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (vincristine).
215055273|NCT02297815|DRUG|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
215055274|NCT02297815|DRUG|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
215055275|NCT04713410|DRUG|Prednisolone|Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
215055276|NCT01356862|DRUG|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
215055277|NCT01356862|DRUG|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
215055278|NCT01422941|DEVICE|CAVU Attune Device|The CAVU Attune device is used with LAGB.
214902045|NCT05302401|BEHAVIORAL|intrapartum uninterrupted midwife support|Prenatal women will be trained about the birth process and psychological and physical support will be provided to women during childbirth. Among these supports, healthy women will be exercised during the labor action, given positions that facilitate childbirth, their hands will be held when they need them, their oral intake will not be restricted, and warm showers will be applied according to their wishes. (These applications can be increased.)
214902046|NCT01650480|OTHER|HELP-COPD action plan|The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
214902047|NCT01780012|BEHAVIORAL|Osteoporosis prevention program|Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD
214902048|NCT01714830|DEVICE|standars electromagnetic DUOLITH SD1|In the first group patients will be treated by ESWT once a week for 4 weeks. (Each time 3000 impulses, with 0.25 mJouls/M2 and 3 Hertz of frequency. After each 500 pulses, the probe position will be corrected, using trans-perineal ultrasound.
214902049|NCT01714830|DEVICE|turn off standars electromagnetic DUOLITH SD1|In the control group, the same protocol is applied but with the probe being turned off.
214902050|NCT00299325|DRUG|Rimonabant|Tablet, oral administration
215055279|NCT04013269|DEVICE|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
215055280|NCT03033680|DRUG|[F-18]PBR06|PET radiopharmaceutical
215055281|NCT01780844|DRUG|ASKP1240|intravenous infusion
215055282|NCT01780844|DRUG|Tacrolimus|intravenous or oral
215055283|NCT01780844|DRUG|Mycophenolate Mofetil (MMF)|intravenous or oral
215055284|NCT01780844|DRUG|Basiliximab|intravenous
215055285|NCT01780844|DRUG|Methylprednisone|Intravenous
215055286|NCT01780844|DRUG|Prednisone|Oral
214669614|NCT05585372|OTHER|CT guided opening mobilization of cervical intervertebral foreman|"1. the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~2. cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~3. Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~4. Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
214902051|NCT00299325|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
214902052|NCT00299325|OTHER|Mild hypocaloric diet|Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
214902053|NCT04248114|DIAGNOSTIC_TEST|Ultrasound of the Neck|Anatomical measurements were performed on participants during an ultrasound exam
214902054|NCT01622218|BEHAVIORAL|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
214902055|NCT05882019|DEVICE|Breast Exam with Bexa|Breast exam with Bexa uses pressure elastography to produce a map of the breast tissue's elasticity.
214902056|NCT01026519|DRUG|REGN88|Single dose of REGN88 and 43 day follow up.
215055287|NCT05291546|DRUG|REGN9035|Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
215055288|NCT05291546|DRUG|REGN5381|Part B: Selected doses administered by IV infusion on day 1.
215055289|NCT05291546|OTHER|Placebo|Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
215055290|NCT00566982|DRUG|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
215055291|NCT00566982|DRUG|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
215055292|NCT04994028|OTHER|Conventional treatment|Behavioral and life style modification and dyspnea prevention education i.e. Sitting: Sit upright with back against chair, feet wide apart, leaning forward with arms on bedside table or on knees. Standing: Lean back against wall with feet slightly apart with head and shoulder relaxed. In Bed: Elevate head of the bed, support and elevate arms with pillow. Stairs: Lean forward with on banister when climbing stairs.
214902057|NCT01026519|OTHER|Placebo|Placebo to match REGN88 administration
214902058|NCT00505219|BIOLOGICAL|Ixmyelocel-T|Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.
214902059|NCT00505219|OTHER|Standard of Care Only|Core decompression of the femoral head to remove necrotic tissue
214902060|NCT00165464|DRUG|Taxotere|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
214902061|NCT00165464|DRUG|Cisplatin|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
214902062|NCT00165464|DRUG|Irinotecan|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
214902063|NCT01282684|DRUG|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
214902064|NCT01282684|DRUG|Placebo|Matching placebo for PLX5622.
214902065|NCT00907543|OTHER|Preoperative treatment of chemotherapy and radiation|Cisplatin + 5FU with concurrent radiation followed by surgery
214902066|NCT00907543|OTHER|Postoperative treatment of chemotherapy and radiation|Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation
214902067|NCT00706459|DEVICE|Magnetic Resonance Imaging|All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
214902068|NCT04746287|DRUG|CKD-510 single dose|Investigational drug
214902069|NCT04746287|DRUG|CKD-510 food effect|Investigational drug
214902070|NCT04746287|DRUG|CKD-510 multiple dose|Investigational drug
214902071|NCT04746287|DRUG|Placebo|Matching placebo
214902072|NCT05071599|DEVICE|Twin Arch Brackets|Twin Arch Brackets characterized by double horizontal slots which make it capable to accept two arch wire at the same time which in turn can achieve a better control over orthodontic tooth movement
214902073|NCT05408299|BIOLOGICAL|Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)|Vaccination
214902074|NCT05986604|BEHAVIORAL|Memory Support Intervention|The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
214902075|NCT05986604|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|TranS-C aims to provide one protocol to treat a range of sleep and circadian problems because sleep and circadian problems are often not so neatly categorized and because the existing research provides few guidelines to treat more complex patients.
214907407|NCT02972060|DRUG|ODM-201|ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
214301763|NCT03987893|DRUG|PEG-3350 with Electolytes|experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.
214301764|NCT03987893|DRUG|Lactulose|Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
214301765|NCT03199300|DRUG|Anthracyclines|Chemotherapy regimen containing anthracyclines.
214301766|NCT03199300|DRUG|Trastuzumab|Systemic treatment including trastuzumab.
214301767|NCT03199300|DRUG|Cisplatin|Chemotherapy including cisplatin.
214301768|NCT03199300|DRUG|Bleomycin|Chemotherapy including bleomycin.
214902076|NCT03105908|BEHAVIORAL|Internet delivered Acceptance and Commitment therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
214902077|NCT03105908|BEHAVIORAL|Waiting list control condition|After a ten week wait list period, the control condition receive same treatment as the intervention group, but without therapist support.
214301769|NCT06545370|OTHER|Intervention 1 / Nurse-led patients' education|nurse-led education through oral sessions, educational materials, and regular phone calls
214301770|NCT06545370|OTHER|Intervention 2 / Nurse-led patients' & caregivers' education|nurse-led education while caregivers also undergo training through oral sessions, phone calls, and appropriately designed educational materials
214301771|NCT04969224|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablet for oral administration.
214301772|NCT04969224|DRUG|IVA|Tablet for oral administration.
214301773|NCT01958775|DRUG|GLP-2|single subcutaneous dose of 1500mcg
214301774|NCT01958775|DRUG|Placebo|
214902078|NCT03115437|OTHER|Hard cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by hard cushioning.
214902079|NCT03115437|OTHER|Soft cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by soft cushioning.
214902080|NCT01185678|DRUG|Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)|One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
214301775|NCT03165110|DEVICE|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
214301776|NCT05544565|DRUG|IV Antibacterial Agents|Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .
214301777|NCT05544565|DRUG|Orally antibacterial agents|Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days
214301778|NCT05544565|PROCEDURE|Fecal/Rectal Swab|Collected by the nurse or the physician (D0,D3,D10 or 17 and D31 or D38), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.
214301779|NCT05544565|PROCEDURE|PCT assay|Dosage of procalcitonin (if not performed in standard care) at D0
214669615|NCT00593112|DRUG|OROS methylphenidate|Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
214902081|NCT05743829|PROCEDURE|Tissue excision as part of routine clinical care|Tissue excision
214301780|NCT05700825|BEHAVIORAL|Expiratory Muscle Strength Training + Cough Skill Training|"Expiratory Muscle Strength Training (EMST). EMST is a widely used and efficacious treatment approach that uses a calibrated device with a one-way, spring-loaded pressure relief valve to mechanically overload the expiratory and submental muscles.~Cough Skill Training (CST) involves a digital peak flow meter device which measures PEFR (peak expiratory flow rate) in liters/second and allows patients to receive immediate biofeedback."
214301781|NCT04540770|DRUG|HuL001|Anti-ENO1 monoclonal antibody
214301782|NCT05533632|DRUG|Semaglutide|Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.
214301783|NCT02236429|BIOLOGICAL|vaginal flora transplant|
214301784|NCT05784246|DRUG|Mirikizumab IV|Administered IV
214301785|NCT05784246|DRUG|Mirikizumab SC|Administered SC
214301786|NCT06520865|OTHER|Acoustic paradigms|Acoustic oddball Gap detection
214669616|NCT00593112|OTHER|No intervention|No intervention
214669617|NCT05217862|DIAGNOSTIC_TEST|PCR for COVID-19 testing|PCR for asymptomatic adult undergoing elective cataract surgery
214669618|NCT04610307|PROCEDURE|buffered anesthesia|patients will undergo surgery under buffered local anesthesia
214669619|NCT00950027|DRUG|povidone iodine|oropharyngeal decontamination every 4 hours
214669620|NCT00950027|DRUG|Placebo|oropharyngeal decontamination every 4 hours
214902082|NCT00598741|OTHER|DCE-MRI|"Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.~MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner."
214902083|NCT01169064|DEVICE|Silver-containing surgical dressing|Dressing placed over surgical incision and remain for 3-5 days
214902084|NCT01169064|DEVICE|Cloth adhesive dressing|Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
214301787|NCT00213837|DEVICE|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
214301788|NCT05041842|DRUG|Tucatinib|300 mg orally twice daily
214301789|NCT05041842|DRUG|Pertuzumab|Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
214301790|NCT05041842|DRUG|Trastuzumab|"Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly"
214669621|NCT03446547|DRUG|Durvalumab|durvalumab 1500 mg i.v. every fourth week for 12 months
214669622|NCT02328716|PROCEDURE|Cytoreduction|Cytoreduction
214902085|NCT01750775|DRUG|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
214902086|NCT01750775|DRUG|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
214902087|NCT06965465|BIOLOGICAL|PF-07999415|Participants will receive single doses of PF-07999415.
214902088|NCT06965465|DRUG|Placebo|Participants will receive matching placebo.
214902089|NCT04189978|DIAGNOSTIC_TEST|Clinical evaluation|The assessment is based on a comprehensive questionnaire, a simple clinical examination, an spirometry test, allergic skin tests, measurement of the exhaled fraction of NO (FeNO) and blood serum analysis.
214902090|NCT06575478|DRUG|Fuling Yunhua Granules|Fuling Yunhua Granules
214301791|NCT05041842|DRUG|Hormone therapy|Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
214902091|NCT06575478|DRUG|Fuling Yunhua Granules matched placebo|Fuling Yunhua Granules placebo
214902092|NCT06575478|DRUG|Dihuang Baoyuan Granules|Dihuang Baoyuan Granules
214301792|NCT05041842|DRUG|Pertuzumab/ Trastuzumab|"Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly"
214301793|NCT03968315|PROCEDURE|Diaphragm Fluoroscopy|Undergo diaphragm fluoroscopy
214301794|NCT03968315|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214301795|NCT06335069|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI|All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
214669623|NCT02328716|DRUG|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
214669624|NCT01258439|DRUG|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
214669625|NCT01258439|DRUG|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
214669626|NCT03619122|PROCEDURE|Second Examination|The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
214902093|NCT06575478|DRUG|Dihuang Baoyuan Granules matched placebo|Dihuang Baoyuan Granules placebo
214902094|NCT05509907|OTHER|Pedi@ctivity Analysis and Tracking Mobile Applications and Web Platform|"Pedi@ctivity Analysis Mobile Application and than Pedi@ctivity Analysis and Tracking Web Platform synchronized with the Pedi@ctivity Tracking Mobile Application, will be developed. The collected data will be analyzed with statistical methods and models using artificial intelligence algorithms will be created. According to the evaluations, physical activity and exercise videos and programs will be prepared and uploaded to web platform. Programs will include stretching, strengthening, balance, aerobic, calisthenic exercises and aerobic dance. The exercise and physical activity program will also be synchronized with the Pedi@ctivity Tracking Mobile Application and the smart watch. Pedi@ctivity Mobile Applications will provide health parameters from the smart watch, suggestions suitable for the exercise and physical activity program, and motivational feedback. Each adolescent will be included in a 3-month program. After the 3-month all evaluations at the beginning will be repeated."
214902095|NCT06574685|DIETARY_SUPPLEMENT|Twinkle Eyez Supplementation|The intervention supplement consisted of marigold extract, zeaxanthin, elderberry extract, bilberry extract, lycopene extract, multivitamin, silicon dioxide, inulin, and dextrose monohydrate, all in powder form and packaged in individual sachets (Twinkle Eyez™; Xmegami, Selangor, Malaysia). Each sachet contained 4.6 mg of lutein and zeaxanthin and 15.4 mg of elderberry extract.
215055293|NCT04994028|OTHER|conventional treatment with volume Spirometry and deep breathing|Group B or interventional group was received conventional treatment along with volume Spirometry and deep breathing exercise, total 5 breaths with 3sec inhalational breath hold for each breath at one session per day for volume Spirometry and for deep breathing exercise 10 times with breath hold 2sec at every session for 5 minutes 3 times per week for total duration of two weeks.
214902096|NCT06574685|DIETARY_SUPPLEMENT|Placebo|The placebo supplement was identical in composition but excluded the active ingredients.
215055294|NCT05336734|BEHAVIORAL|Psychotherapy|see group description
215055295|NCT00003420|PROCEDURE|computed tomography|
215055296|NCT03889340|DEVICE|IQool|Subjects will undergo hypothermia therapy with the IQool system
215055297|NCT04106258|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
215055298|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
214301796|NCT04878393|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214669627|NCT01501344|DIETARY_SUPPLEMENT|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
214902097|NCT05754892|OTHER|Blood sample|For patients with ACC : blood (30ml) sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : blood (30ml) sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking
215055299|NCT02507661|DRUG|no-preservation of alveolar ridge - 2 months|
215055300|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
215055301|NCT02507661|DRUG|no-preservation of alveolar ridge - 4 months|
215055302|NCT02507661|PROCEDURE|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
215055303|NCT02507661|DRUG|no-preservation of alveolar ridge - 9 months|
214669628|NCT02163408|OTHER|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
214669629|NCT02873546|DEVICE|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
214669630|NCT00482001|DRUG|donepezil|
214669631|NCT00482001|DRUG|Placebo (cornstarch)|
214669632|NCT01426048|OTHER|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
214669633|NCT02119208|BEHAVIORAL|Intensity and timing of exercise|
214669634|NCT00258154|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
214669635|NCT00258154|BIOLOGICAL|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
214669636|NCT00258154|BIOLOGICAL|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
214902098|NCT05754892|OTHER|Urine sample|For patients with ACC : urine sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : urine sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking
214902099|NCT05754892|OTHER|Tumor sample|For patients with ACC and patients with MPP : tumor sample during surgery
215055304|NCT03811392|PROCEDURE|Hernioraphy/Caudal block|30 patients will receive a caudal block after induction of general anaesthesia
215055305|NCT03811392|PROCEDURE|Hernioraphy/Quadratus Lumborum block|30 patients will receive ultrasound guided quadrates lumborum block
215055306|NCT01487174|DRUG|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
215055307|NCT01487174|DRUG|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
215055308|NCT02482662|PROCEDURE|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
215055309|NCT01067118|DRUG|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
215055310|NCT01067118|DRUG|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
215055311|NCT03323853|BEHAVIORAL|Computerized Assessment and Referral System (CARS) Self-Assessment Screener|Subjects will take the CARS-SA Screener.
214301797|NCT06545331|DRUG|XB010|IV administration of XB010
214301798|NCT06545331|DRUG|Pembrolizumab|IV administration of Pembrolizumab
215055312|NCT03323853|BEHAVIORAL|CARS-SA Summary Results|Subjects will be evaluated by emergency care providers using the CARS-SA Summary Results Report.
215055313|NCT02197572|DRUG|Sapanisertib|Sapanisertib capsules.
215055314|NCT02769429|DEVICE|Ultrasound-guided CISB|This group will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
215055315|NCT02769429|DEVICE|nerve stimulator-guided CCPVB|This group will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
215055316|NCT02027727|OTHER|No Intervention|no intervention- tihs is an observational study
215055317|NCT04015011|COMBINATION_PRODUCT|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
215055318|NCT02661204|DEVICE|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
214902100|NCT06411158|OTHER|Interventionist-guided training|Interventionist-guided training at baseline (i.e., approximately 6 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session approximately 4 weeks later, and then continued HEP. Two exercise sets per day are encouraged between baseline and 6 months postpartum (i.e., time of the primary outcome), followed by at least 3 times-per-week exercise sets until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
214902101|NCT06411158|DEVICE|Home pelvic floor exercises guided by the leva® device|Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. Between baseline and 6 months postpartum, twice-daily exercise sets will be encouraged, followed by at least 3 times-per-week exercises from 6 to 12 months postpartum. As in Arm 1, the PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
214902102|NCT06411158|OTHER|Education|Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.
214902103|NCT04024969|DIAGNOSTIC_TEST|T2* MRI|Research T2\* weighted MRI sequence
214902104|NCT04024969|DIAGNOSTIC_TEST|Lumbar puncture to test for presence of unmatched oligoclonal bands|Current clinical standard practice
214902105|NCT05480072|DRUG|Palmitoylethanolamide|Palmitoyethanolamide (PEA) s a dietary supplement with anti-inflammatory and analgesic properties. Subjects will receive PEA (Levagen+) 600 capsules mg twice daily (BID) orally from Day 1 to Day 21
214902106|NCT05480072|OTHER|Placebo|Participants will receive placebo matched to 600 mg PEA (Levagen+) capsules BID orally from Day 1 to Day 21
214902107|NCT04903639|DIAGNOSTIC_TEST|sleep study|The polysomnography consists of electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), electromyogram (EMG), pulse oximetry, thoracic and abdominal straps, body posture sensor, nasal thermistor and nasal cannula to assess respiratory flow and pressure and bipolar channel limb movements (tibialis anterior). Electrodes and sensors were attached to patients by sleep physiologist. Data collection was obtained following signal perception by preprocessed computer (DOMINO Software, ver. 2.6.0; SOMNO Medics GmbH).
214902108|NCT05089513|PROCEDURE|Robotic surgery|Robotoc surgery (Da Vinci) in both donor and recipient
214902109|NCT05938647|OTHER|Risk factor: group 3|Severe dengue, no shock. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
214902110|NCT05938647|OTHER|Risk factor: group 4|Dengue shock syndrome. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes
214902111|NCT05644054|DRUG|THC|Patients will be administered a one-time dosage of 0.2 mg/kg THC oil (AXIBAN, T10/C2, manufactured by Panaxia Pharmaceuticals, Lod, Israel)
214902112|NCT05644054|DRUG|Placebo|Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.
215055319|NCT00703742|DRUG|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
215055320|NCT03943576|DRUG|GXCPC1|The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)
215055321|NCT03943576|DEVICE|HA|Hya Joint Plus synovial fluid supplement 3mL
214902113|NCT06578832|DIAGNOSTIC_TEST|physical and chemical methods|Salivary flow rate, pH, buffering capacity
214902114|NCT06578832|DIAGNOSTIC_TEST|biochemical methods|Total oxidant and antioxidant capacities
214902115|NCT06578832|DIAGNOSTIC_TEST|biochemical tests|urea, calcium, potassium, phosphorus
214902116|NCT06578832|DIAGNOSTIC_TEST|Oral Health Habits|Tooth brushing frequency Dental floss usage Annual dentist visits
214902117|NCT06578832|DIAGNOSTIC_TEST|Oral Findings|"DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries.~DDE Index: Developmental Defects of Enamel index. BAKH Index: Basic Anatomic Keratinization Hierarchy, typically used in specific studies.~DI (Debris Index): Assesses oral hygiene based on the amount of debris on the teeth.~CI (Calculus Index): Measures the amount of calculus (tartar) on the teeth. OHI-S (Simplified Oral Hygiene Index): Assesses oral hygiene based on the presence of debris and calculus.~MGI (Modified Gingival Index): Assesses the severity of gingivitis based on inflammation."
214902118|NCT06578832|DIAGNOSTIC_TEST|Quality of Life Assessment|KINDLR Scale: Used to assess disease-related quality of life from both the child's and the parent's perspectives.
214902119|NCT03971136|DIAGNOSTIC_TEST|pulmonary ultrasound|The subjects will have an ultrasound on admission and on day 1, 2 and 3
214902120|NCT01833481|RADIATION|Fluoroscopy surveillance of patients while walking|While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
214902121|NCT04795648|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
215055322|NCT00370266|DRUG|Triamcinolone|
215055323|NCT01087983|DRUG|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
215055324|NCT01087983|DRUG|Sirolimus|Starting oral dose 1 mg daily.
215055325|NCT01087983|DRUG|Metformin|Starting oral dose 1000 mg daily.
215055326|NCT00854789|BIOLOGICAL|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
215055327|NCT03942198|DRUG|Taodan Granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
215055328|NCT03942198|DRUG|Taodan Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
215055329|NCT05350215|DRUG|Placebo oral capsule|Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
215055330|NCT05350215|DRUG|Atomoxetine Oral Capsule [Strattera]|Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
215055331|NCT02840253|DEVICE|NIRS|
215055332|NCT00473889|DRUG|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
215055333|NCT00473889|DRUG|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
215055334|NCT00473889|DRUG|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
215055335|NCT00473889|DRUG|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
214902122|NCT04795648|DEVICE|Placebo|Passive emanator with formulated inert ingredients
214902123|NCT03314792|DRUG|Tapentadol|"* Palexia depot 50 mg® (tapentadol depot 50 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. Palexia depot is repeated once after 12 hours.~* Palexia 50 mg® (tapentadol 50 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 tablets/24-hour study period. Minimum 1 hour 15 minutes between tablets. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
214902124|NCT03314792|DRUG|Oxycodone|"* OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. OxyContin is repeated once after 12 hours.~* OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 capsules/24-hour study period. Minimum 1 hour 15 minutes between capsules. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
214902125|NCT02874625|PROCEDURE|Dental restoration|Teeth with caries will be restored
214902126|NCT05383911|BEHAVIORAL|SCD Shared Decision-Making Toolkit for AYAs - including VR|The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including virtual reality, online (videos, animations, articles), and print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
214902127|NCT05383911|BEHAVIORAL|SCD Shared Decision-Making Toolkit for AYAs - without VR|The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including online videos, animations, and articles as well as print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
215055336|NCT06221410|OTHER|Alternative teaching method: Funny Scenario-Based Education|"A humorous scenario is written and performed by students as part of this alternative educational intervention. The engaging approach facilitates both a deeper understanding of complex medical terminology and adds a sense of humor and fun to the learning process.~Approximately 5 to 10 students will participate in each small group. A group size will be determined based on the voluntary interest and willingness of the students. These dynamic teams will provide students with opportunities to collaborate, enhance peer interaction, and cultivate soft skills such as communication and teamwork, all while having fun together."
215055337|NCT06221410|OTHER|Alternative teaching method: Mind-mapping Education|As part of an alternative educational intervention, Mind-mapping Education encourages students to visually map out information, creating a graphic representation of their ideas and knowledge. Using such mind maps, students can see the connections and hierarchies in the information they are learning because they have a central idea with branches that denote related concepts, facts, and details.
215055338|NCT05433701|RADIATION|Stereotactic Body Radiotherapy|"* Verify the setup position and respiration of patients as in the simulation CT image.~* To precisely align the tumor prior to each treatment, cone-beam CT and gated fluoroscopy using the On-board Imager mounted on the linear accelerator are performed.~* The Real-time Position Management system is used to monitor the accuracy of breathing phase during treatment."
215055339|NCT05433701|PROCEDURE|Radiofrequency Ablation|\- RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.
214301799|NCT05380401|DIETARY_SUPPLEMENT|Enfamil® DHA & ARA Supplement for Special Dietary Use|Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe
214902128|NCT06966622|PROCEDURE|3D visualization system with coaxial illumination|operation through 3D visualization system with coaxial illumination
215055340|NCT03153501|DIAGNOSTIC_TEST|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
215055341|NCT00868829|DEVICE|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
214902129|NCT06966622|PROCEDURE|microscope with standard illumination|operation through microscope with standard illumination
214902130|NCT02651662|DRUG|cemiplimab|Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.
215055342|NCT03783962|BEHAVIORAL|Active Intervention - Cooking|"Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings."
214301800|NCT02233868|OTHER|connectivity|Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.
214902131|NCT02651662|DRUG|odronextamab|Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
214902132|NCT00864630|BEHAVIORAL|Computer-based problem solving therapy|Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
214902133|NCT04584801|DEVICE|Structured Light Plethysmography|"Development Phase (Original Part A): Participants will have two 5-minute SLP measurements (Pre and Post bronchodilator).~Participants will also undergo standard of care spirometry assessment"
214902134|NCT03939702|DRUG|BMS-986177|An orally administered anticoagulant to prevent and treat thromboembolic events
215055343|NCT03783962|BEHAVIORAL|Demonstrations - Cooking|The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
215055344|NCT03458325|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
214301801|NCT02233868|DRUG|neuroinflammation|The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
214301802|NCT02233868|OTHER|neurofunction|To assess regional brain glucose metabolism.
214301803|NCT06273124|DEVICE|SteadiSet Extended Wear Infusion Set|Each participant will be given 12 Extended Wear Infusion Sets to wear over 12 wear periods up to 168 hours each.
214301804|NCT05230589|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214301805|NCT03903016|DRUG|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214301806|NCT03903016|DRUG|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214479114|NCT06807476|OTHER|Validity and reliability|"The scale consists of 40 items and four sub-dimensions, and is scored according to a 5-point Likert rating scale (ranging from Strongly Disagree (Score = 1 point) to Strongly Agree (Score = 5 points)). The scale evaluates the healthy/patient individual's readiness attitude level towards acupuncture, personal beliefs, preferences and experiences. The score received per sub-dimension varies between a minimum of 10 and a maximum of 50 points. The average cut-off score per sub-dimension is 25. The higher the score (above the average cut-off score), the more open the healthy/patient individual is to acupuncture. Sub-dimensions:~Sub-Dimension 1 (Items 1-10): Willingness to Try Acupuncture Sub-Dimension 2 (Items 11-20): Belief in the Effectiveness of Acupuncture Sub-Dimension 3 (Items 21-30): Comfort in the Acupuncture Sub-Dimension 4 (Items 31-40): Concerns and Preferences"
214902135|NCT05578261|DEVICE|intermittent theta burst stimulation|stimulatory protocol
214902136|NCT00167011|PROCEDURE|CT|
214902137|NCT05067556|BEHAVIORAL|Acceptance and Commitment Therapy for chronic pain (ACT-CP)|Delivered virtually via Zoom or via telephone on an individual level; 30-minute sessions led by a trained psychologist and occur weekly for 6 weeks.
214902138|NCT06585176|OTHER|No intervention|This concerns a natural history study. No interventions will be used.
214902139|NCT00923013|DRUG|Cladribine|Cladribine 0.15 mg/Kg/day by 2-hour intravenous (i.v.) infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the principal investigator (PI).
214902140|NCT00923013|DRUG|Rituximab|Rituximab 375 mg/m\^2 intravenous (i.v.) infusion every week x8, begin day 1 in half of randomized patients and in all hairy cell leukemia variant (HCLv) patients, and then again in all patients at least 6 months later when hairy cell leukemia (HCL) is detected by blood fluorescence-activated cell sorting (FACS).
214902141|NCT00923013|PROCEDURE|BMbx|Baseline and week 5.
214902142|NCT00923013|DIAGNOSTIC_TEST|MRI|Baseline and week 5.
215055345|NCT05761288|BEHAVIORAL|Intraoperative microbreaks and exercises|"Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. Intervention exercises include: chest and shoulder opener elbows in pockets, chin tuck, neck rotation, squat with truncal rotation (chair pose with prayer), and forward bend."
214301807|NCT05090865|DIETARY_SUPPLEMENT|Liberalized dietary potassium via fruits and vegetables|On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
214902143|NCT00923013|DIAGNOSTIC_TEST|EKG|Baseline and week 5.
214902144|NCT00923013|DIAGNOSTIC_TEST|Echocardiogram|Baseline.
214902145|NCT00923013|DIAGNOSTIC_TEST|Abdominal/splenic ultrasound|Baseline and week 5.
214902146|NCT00923013|PROCEDURE|Stress test|Baseline.
214902147|NCT06524739|BIOLOGICAL|IgPro20|IgPro20 is a 20% ready-to-use liquid formulation of polyvalent human immunoglobulin G (IgG) for subcutaneous (SC) administration
214902148|NCT06524739|BIOLOGICAL|Placebo|2% human albumin solution administered subcutaneously as a volume-matched dose to the experimental IMP.
214902149|NCT06585254|DEVICE|Transcutaneous vagus nerve stimulator|A device attached to the tragus of the ear which when activated stimulates an ascending branch of the vagus nerve
214902150|NCT05768854|DRUG|Bisphosphonate|Administered per investigator discretion via intravenous (IV) infusion
214902151|NCT05768854|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
214902152|NCT06188520|DRUG|AZD8421|CDK2 inhibitor
214902153|NCT06188520|DRUG|Camizestrant|SERD
214902154|NCT06188520|DRUG|Ribociclib|CDK4/6 inhibitor
214902155|NCT06188520|DRUG|Palbociclib|CDK4/6 inhibitor
214902156|NCT06188520|DRUG|Abemaciclib|CDK4/6 inhibitor
214902157|NCT06621953|DEVICE|BFR|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to either 80% or 40% of limb occlusion pressure during lower limb strengthening exercises, as determined by Phase One (2318/MODREC/24a). These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum in Week 1, 25% in Week 2 and 30% in Week 3.
214902158|NCT06621953|OTHER|control group|Standard residential rehabilitation consists of; (1) exercise-based therapy delivered in group settings and individually to address a variety of physical components relating to their pathology (e.g., balance and co-ordination, cardiovascular endurance, mobility and flexibility, motor control and dynamic stability, and muscular strength), (2) patient education sessions (e.g., activity modification, behavioural change, and focusing on pain management), and (3) one-on-one support sessions (e.g., dietetics, occupational therapy, physiotherapy, podiatry, prosthesis/orthosis specialists, social workers, and speech and language therapists).
214902159|NCT06503588|OTHER|Guidelines promoting surgical abstention|Guidelines promoting surgical abstention
214902160|NCT04333017|DEVICE|Percutaneous radiofrequency ablation of parietal endometriosis|Treatment is carried out under local anaesthesia after surgical asepsis, in interventional radiology room. Radiofrequency needles are inserted percutaneously under ultrasound guidance. Number of needles depends on the size of lesion (1 or 2 or 3 needles). In case of proximity between lesion and peritoneum, artificial ascites can be performed. Treatment is carried out in accordance with device's instructions for use (thyroid nodules treatment algorithm), with a gradual increase in power every 5 minutes, without exceeding the maximum authorised power (depending on number and length of needles). State of coagulation is monitored under visual ultrasound control of ablation area (diffusion of Co bubbles), until a decrease in effective power is obtained. Several ablation zones are performed on the same nodule with overlapping of the different impacts. An ice pack is applied to the treated area. An analgesic PO treatment of step 1 and/or 2 is prescribed for 5 days.
214902161|NCT06651372|BIOLOGICAL|The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons|Serological tests detecting IgM and IgG
214902162|NCT05685472|BIOLOGICAL|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
214902163|NCT02484716|DRUG|Timolol nasal spray|Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
215055346|NCT01460810|OTHER|1000CsK Silicon Oil Tamponade|Details covered in arm description
215055347|NCT04199065|OTHER|Good Practice Guidelines implementation|Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
215055348|NCT00337831|PROCEDURE|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.
215055349|NCT02204423|PROCEDURE|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
214902164|NCT02484716|DRUG|Placebo nasal spray|Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
214902165|NCT05125809|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
214902166|NCT05125809|OTHER|Placebo|A 5% dextrose/glucose solution administered QM via IV infusion
214902167|NCT05458440|OTHER|Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors|The investigators aim to demonstrate that it is possible to implement a biobank of leucocytes from convalescent donors that could be used as raw material to generate anti-SARS COV-2 viral specific T cells. The protocol will be explained during hospitalisation for each donor. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
214902168|NCT02409316|DRUG|[18F]FES|\[18F\]FES PET/CT scan
215055350|NCT05370274|PROCEDURE|Strength training intervention|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb (the wrist extensors and the elbow and shoulder flexors). In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Training will start at 50% of 1RM and progress by 10% each week to reach 80% of 1RM by week 4. The same gradation of intensity will be applied to the grip muscles. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
214902169|NCT06460285|BEHAVIORAL|EmRes|There will be six, one hour, treatment sessions across nine weeks of emotional resolution therapy, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a licensed therapist.
214902170|NCT06460285|BEHAVIORAL|Mindfulness|There will be six, one hour, treatment sessions across nine weeks of a mindfulness intervention program, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a trained member of the study staff.
214902171|NCT05694260|DRUG|Bempedoic acid|Once daily oral dosing with oral tablets.
214902172|NCT06551181|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.
214902173|NCT06551181|DRUG|Placebo|One dose of placebo is administered intramuscularly at Day 1.
214902174|NCT06427538|OTHER|Saline Flush|sterile saline 20 mL flushed into their catheter by trained nurses or study team members every 6 ± 2 hours
214902175|NCT05385549|DRUG|Imatinib Mesylate|Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)
214902176|NCT05901974|DRUG|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28);
214902177|NCT05901974|DRUG|azactidine|azacitidine 75 mg/m2 subcutaneously once daily on days 1-7
214902178|NCT03135717|DIETARY_SUPPLEMENT|Nutritional care|"* Diagnosis of protein energy wasting : anthropometry, calculation of the nutrient intakes, evaluation of appetite, evaluation of gastrointestinal syndromes, hand grip test and bioimpedancemetry~* Treatment of protein energy wasting : estimation of nutritional requirements, prescription of oral nutritional supplement or artificial nutrition, physical rehabilitation~* Multidisciplinary approach (nephrologists, dieticians, physiotherapists, nurses)~* Evaluation of the nutritional treatment (plasma albumin and prealbumin, weight evolution, muscle strength and body composition)"
214902179|NCT06581354|PROCEDURE|PROVISIONALIZATION|glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
214902180|NCT04459936|OTHER|URICORI|Treatment for cardiovascular risk factors according to national guideline administered at the department of Rheumatology
214902181|NCT04459936|OTHER|CONTROL|Treatment for cardiovascular risk factors according to national guideline administered at the General Practitioner
214902182|NCT01693016|DEVICE|non-invasive measurement of Hb|
214902183|NCT01693016|PROCEDURE|taking blood samples|
214902184|NCT03733769|PROCEDURE|transmuscular quadratus lumborum block|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
214902185|NCT00447174|BEHAVIORAL|Dyadic treatment for parental bereavement|
214902186|NCT01416636|DRUG|Treprostinil sodium|
214902187|NCT01193777|DRUG|L-Carnitine|4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.
214902188|NCT01193777|DRUG|Normal Saline|Bolus followed by 1 L NS infusion over 12 hours.
214902189|NCT02301169|BEHAVIORAL|Heat pain stimuli A|
214902190|NCT02301169|BEHAVIORAL|Video A|
214902191|NCT02301169|DRUG|Administration of T4P1001 capsules|This treatment is given as add on therapy to patients' regular analgesic
214902192|NCT02301169|BEHAVIORAL|Heat pain stimuli B|
214902193|NCT02301169|BEHAVIORAL|Video B|
214902194|NCT02301169|DRUG|Administration of placebo capsules|This treatment is given as add on therapy to patients' regular analgesic
214902195|NCT04553159|BIOLOGICAL|Autologous adipose derived stem cells|Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
214902196|NCT00218023|DRUG|Modafinil|The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase I.
214902197|NCT00218023|DRUG|Levodopa/Carbidopa|Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase I.
214902198|NCT00218023|DRUG|Naltrexone HCl|Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase I.
214902199|NCT00218023|DRUG|Placebo|Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
214902200|NCT00218023|BEHAVIORAL|Motivational Interviewing (MI)|The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.
215055351|NCT05370274|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each strength training session, the CN-NINM will be applied, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants for 20 minutes. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 μsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
214902201|NCT00218023|BEHAVIORAL|Contingency management (CM)|Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).
214902202|NCT00218023|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.
214902203|NCT03389503|PROCEDURE|Radial approach|Approach site for coronary angiography and coronary intervention
214902204|NCT01105364|DRUG|antiangiogenesis therapy|
214902205|NCT01105364|DRUG|stabilized sulphur hexafluoride microbubble-based contrast agent|
214902206|NCT01105364|OTHER|imaging biomarker analysis|
214902207|NCT01105364|OTHER|pharmacological study|
214902208|NCT01105364|PROCEDURE|computed tomography|
214902209|NCT01105364|PROCEDURE|magnetic resonance imaging|
214902210|NCT01198470|DEVICE|TRIUMPH® Lumbar Artificial Disc|The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
214902211|NCT04924387|PROCEDURE|Exercise|All patients will start learning how to activate the abdominal muscles in the first training session. The exercise progression will be adapted according to the capacity of each patient, considering their pain levels. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rests between series will be of 30 seconds, and between exercises of 2-3 minutes.
214301808|NCT05090865|DIETARY_SUPPLEMENT|Standard dietary potassium restriction|Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake \< 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
214301809|NCT05578495|OTHER|Accelerometer data|Patients will wear an accelerometer 3 times a year for 5 days (3 weekdays and 2 weekend days), the data will be collected
214301810|NCT03771469|OTHER|Sleep study|Sleep study
214902212|NCT00578045|PROCEDURE|Transfusion|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
214902213|NCT02452606|DRUG|Stalevo®|"* Sleep disorders in Parkinson's disease~* Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~* If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective."
214301811|NCT04410965|DRUG|TERIFLUNOMIDE|Pharmaceutical form:tablet Route of administration: oral
214902214|NCT02670226|OTHER|Samples|Blood samples, muscle biopsy
214902215|NCT04944043|DRUG|TQ05105 Tablet|TQ05105 tablet is a Janus Kinase (JAK) inhibitor, which can inhibit the abnormal activation of JAK 2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK / STAT pathway.
214902216|NCT01477346|OTHER|Nurse intervention|Complex package of care involving patient information and advice concerning lifestyle modification and recommended drug therapy.
214902217|NCT01477346|OTHER|Standard care|Continuing standard General Practitioner led care.
214902218|NCT05375357|PROCEDURE|Application of L-PRF on the donor area|After implant uncovering procedure with apically positioned flap, the donor area is covered with a layer of L-PRF
214902219|NCT05375357|PROCEDURE|Secondary intention healing of the donor area|After implant uncovering procedure with apically positioned flap, the donor area is left to heal by secondary intention
214902220|NCT02949973|DRUG|voclosporin|
214902221|NCT00716599|DEVICE|training in use of rapid diagnostic tests (RDTs) for malaria|training program and introduction of RDTs for use in case management of patients presenting for routine care at government health centers
214902222|NCT06525350|DRUG|Glumetinib tablets|An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
214902223|NCT06525350|DRUG|HB1801 (docetaxel, albumin-bound）|An improved new formulations of docetaxel
214902224|NCT06525350|DRUG|Docetaxel|A chemotherapy drug
214902225|NCT01422213|DRUG|Placebo|capsules; daily; orally
214902226|NCT01422213|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
214902227|NCT01422213|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
215055352|NCT04614012|OTHER|treated with hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
215055353|NCT03339310|DEVICE|Optimizer Smart System with 2-leads|The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
214479119|NCT06656325|DEVICE|Erchonia® FX405|"Procedure administrations with the Erchonia® FX-405 will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Erchonia FX405 takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing prior to the administration of the first procedure with the Erchonia FX405, and a second time at the 3-month study midpoint assessment visit."
214902228|NCT00144820|DRUG|Injection of Hyaluronan or Saline|
214902229|NCT03197389|DRUG|Pembrolizumab|Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
214902230|NCT01325363|DEVICE|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
214902231|NCT02054429|DRUG|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
214902232|NCT04129125|DEVICE|Zoom Reperfusion System|Thrombectomy
214902233|NCT04484142|DRUG|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
214902234|NCT06809543|DEVICE|Polynucleotides (Tropho Tend)|"Tropho Tend is administered by injecting the solution at level of muscular-tendineal (MJT) or osteo-tendineal junctions (OTJ) using a fine-gauge needle (usually 25-30G).~Before injecting the product, the target area will be disinfected with alcohol or another antiseptic, with the antiseptic removed with physiologic sterile solution.~Total number of treatments will consist in 3 Tropho Tend administrations: at T0 - basal visit;~* T1 - after 2 weeks;~* T3 - after 4 weeks."
214902235|NCT06809543|PROCEDURE|Rehabilitation physiotherapy|Rehabilitation physiotherapy (standard of care)
214902236|NCT03314636|DRUG|Carfilzomib|See in arm description
214902237|NCT03314636|DRUG|Lenalidomide|See in arm description
214902238|NCT03314636|DEVICE|PET-CT|See in arm description
214902239|NCT03314636|DRUG|Dexamethasone|See in arm description
214902240|NCT06973356|DRUG|Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.|Description: A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）.
214902241|NCT06126055|DEVICE|Band Ligation|Placing bands in distal esophagus
214902242|NCT05507125|BEHAVIORAL|Mental health|Early life exposure to abuse and development of hidradenitis suppurativa
214902243|NCT06502379|DRUG|AZD8965|AZD8965 will be administered orally.
214902244|NCT06502379|OTHER|Placebo|Placebo will be administered orally.
214902245|NCT06813703|DEVICE|Using an electrical stimulation device to relieve pain during colonoscopy|In the electrical stimulation group, the device's current intensity will be adjusted to the maximum tolerance below the participant's pain threshold, while in the control group, the current intensity will be set to the minimum.
214902246|NCT01261728|DRUG|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
214902247|NCT06587893|OTHER|echography|performance of ultrasound of the scapular regions to identify and measure the suprascapular notch in our group of healthy adult volunteers.
214902248|NCT06655207|DEVICE|Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding|Oli is a non-invasive wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding, including postpartum haemorrhage.
214902249|NCT06052813|DRUG|BN104 monotherapy|Phase I(adults): Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
214902250|NCT06052813|DRUG|BN104 monotherapy|Phase I(adolescent): Will be administered orally twice daily (approximately every 12 hours)
214902251|NCT06052813|DRUG|BN104 monotherapy - rp2d|receiving oral BN104 treatment at a dose of 600 mg BID (300 mg BID when co-administered with strong CYP3A4 inhibitors)
214902252|NCT06824974|BEHAVIORAL|Time-restricted eating plus healthy diet|Subjects will restrict calorie consumption to 8-10 hours during the day plus will follow a healthy plant-based diet.
214902253|NCT05986149|BEHAVIORAL|Conversation about arts and culture|intergenerational conversation about arts and culture between older adults and international students who native language is not English.
214301821|NCT05699343|PROCEDURE|InterOss Collagen (Bone xenograft) and InterOss Collagen Guide (Collagen membrane)|Group will receive InterOss Collagen and InterOss Collagen Guide during surgical intervention visit.
214301822|NCT05699343|PROCEDURE|InterOss Collagen (Bone xenograft)|Group will only receive InterOss Collagen during surgical intervention visit.
214301823|NCT05782283|DEVICE|ACE (AI-Cirrhosis-ECG) 2.0|An electrocardiogram (ECG) based artificial intelligence (AI) powered tool for detection of undiagnosed cirrhosis in primary care practices. And email alert is sent to providers which will display whether the ACE 2.0 result is positive or negative for the likelihood of advanced liver disease.
214301824|NCT06803485|DRUG|Venlafaxine|Venlafaxine will be started at a dose of 37.5 mg/day in first week and increased to a stable dose of 75 mg/day from second week and will be continued till 8 weeks.
214902254|NCT06699212|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)
214301825|NCT06803485|DRUG|Dosulepin|Dosulepin will be started at a dose of 25 mg/day in first week and increased to a stable dose of 50 mg/day from second week and will be continued till 8 weeeks.
214301826|NCT02954874|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214301827|NCT02954874|OTHER|Laboratory Biomarker Analysis|Correlative studies
214902255|NCT06699212|BIOLOGICAL|Pembrolizumab|200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)
214902256|NCT06699212|DRUG|Carboplatin|Area under the curve (AUC) 5 mg/mL/min IV infusion, Q3W up to 6 cycles
214902257|NCT06699212|DRUG|Cisplatin|100 mg/m\^2 IV infusion, Q3W up to 6 cycles
215055354|NCT02584062|PROCEDURE|no-touch fluid-air exchange|
215055355|NCT02584062|PROCEDURE|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
215055356|NCT01142076|DRUG|Xinju Xiaogao Prescription|treatment group
215055357|NCT01142076|DRUG|placebo|Therapeutic dose of 10%
214301828|NCT02954874|OTHER|Patient Observation|Undergo standard monitoring
214301829|NCT02954874|BIOLOGICAL|Pembrolizumab|Given IV
214902258|NCT06699212|DRUG|5-fluorouracil|1000 mg/m\^2 per day from Days 1-4 of each cycle, IV infusion, Q3W up to 6 cycles
215055358|NCT02956746|BIOLOGICAL|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
215055359|NCT02956746|BIOLOGICAL|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
214479120|NCT06656325|DEVICE|Placebo Laser|"Procedure administration with the Placebo Laser (emitting non therapeutic light) will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Placebo Laser takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing prior to the administration of the first procedure with the Placebo Laser, and a second time at the 3-month study midpoint assessment visit."
214301830|NCT02954874|OTHER|Quality-of-Life Assessment|Ancillary studies
214301831|NCT02954874|OTHER|Questionnaire Administration|Ancillary studies
214301832|NCT02954874|RADIATION|Radiation Therapy|Undergo radiation therapy
214301833|NCT05614739|DRUG|LOXO-435|Oral
214301834|NCT05614739|DRUG|Pembrolizumab|IV
214301835|NCT05614739|DRUG|enfortumab vedotin|IV
214479121|NCT06656026|DRUG|ZSP1273 granules|Oral
214902259|NCT06699212|DRUG|Paclitaxel|100 mg/m\^2 IV infusion given on Days 1 and 8, Q3W up to 6 cycles or 175 mg/m\^2 IV infusion given on Day 1, Q3W up to 6 cycles
214301836|NCT03706053|DRUG|Midodrine Hydrochloride|Midodrine Hydrochloride, enteral, 10 or 20 mg
214301837|NCT03706053|OTHER|placebo|investigational pharmacy formulated placebo comparator
214301838|NCT05191212|PROCEDURE|indocyanine green|Cervical indocyanine green injection for the detection of sentinel lymph node
214301839|NCT05142592|DRUG|IPG7236|The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
214301840|NCT05456425|DRUG|CBT-001|CBT-001 eye drop
214301841|NCT05456425|DRUG|Vehicle|Formulation without drug
214301842|NCT04232670|PROCEDURE|EUS + SHAM|Endoscopic Ultrasound
214902260|NCT06699212|DRUG|Docetaxel|75 mg/m\^2 IV Infusion, Q3W up to 6 cycles
215055360|NCT02956746|BIOLOGICAL|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
215055361|NCT02956746|BIOLOGICAL|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
215055362|NCT02327585|BEHAVIORAL|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
215055363|NCT02039765|DRUG|Brimonidine tartrate|
215055364|NCT00820989|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
215055365|NCT03663309|DIAGNOSTIC_TEST|detecting Gluten peptides in faecal and urine samples|"At each visit patient will:~* Bring 4-day food diary (attached)~* Fill symptoms and complaints questionnaire (attached)~* Provide 24 h diet recall in case a food diary absents~* Fill Biagi score questionnaire (attached)~* Perform blood test of TTG~* Provide stool and urine samples"
215055366|NCT01634230|DRUG|OCR-002|daily dose: 10 g infused over 24 hours
215055367|NCT02100254|BEHAVIORAL|behavioral intervention|View personal narrative informational video
215055368|NCT02100254|BEHAVIORAL|behavioral intervention|View fact-based informational video
214301843|NCT04232670|PROCEDURE|EUS + Pancreatic Endotherapy|Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement.
214301844|NCT01584687|BIOLOGICAL|Omalizumab|The patients will receive Omalizumab according to their age and weight for 4 months.
214301845|NCT05644249|DRUG|Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy|Each course of combined treatment will start with PIPAC (a pressurized aerosol containing cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 diluted in NaCl 0.9% applied through the nebulizer inside the abdominal cavity during laparoscopy). Fourteen days afterward 2 cycles of systemic FOLFOX chemotherapy will be applied within 28 days. The interval between combined treatment courses will be 14 days.
214479122|NCT06368050|BEHAVIORAL|practice structure intervention|practice structure intervention
214479123|NCT03498521|DRUG|Alectinib|Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
214902261|NCT05813886|OTHER|biodex balance system|The balance tests of the patients were performed 2 to24 WEEKS after their recovery from the disease, which was confirmed by the evaluations of the Covid-19 staff and negative polymerase chain reaction test.
214902262|NCT04967573|DRUG|Rivaroxaban|Rivaroxaban 20 mg or 10 mg for 3 months
214902263|NCT02723344|DIETARY_SUPPLEMENT|of Lactobacillus reuteri (L. reuteri; DSM 17938)|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
214902264|NCT02723344|OTHER|Sunflower and medium chain triglyceride oils|Placebo
214902265|NCT00524940|BIOLOGICAL|Inactivated, Split-Virion Influenza Virus|0.5 mL, Intramuscular
214902266|NCT03473184|DRUG|Diacerein 1% ointment|Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.
214902267|NCT01410903|DEVICE|TheraSorb Ig|1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
214902268|NCT02964247|DRUG|liraglutide|Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
214902269|NCT02964247|DRUG|placebo|Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
214902270|NCT04851847|DEVICE|Guided Tissue Regeneration (GTR)|Use of resorbable collagen membrane to treat periodontal intrabony defects.
214902271|NCT06239727|DRUG|PD-1 blocking antibody|"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1."
214902272|NCT06239727|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
214902273|NCT06239727|DRUG|Cisplatin (80 mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
214902274|NCT06239727|RADIATION|Reduced-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F."
214902275|NCT06239727|RADIATION|Conventional-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F."
214902276|NCT06239727|DRUG|Cisplatin (100 mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
215055369|NCT02877576|PROCEDURE|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
215055370|NCT02877576|BEHAVIORAL|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter…). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
215055371|NCT02877576|BEHAVIORAL|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
214479124|NCT03498521|DRUG|Vismodegib|Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
214669637|NCT06963853|DIAGNOSTIC_TEST|Blood cultures will be obtained from three sources: 1. The central venous catheter (CVC), 2. The dialysis machine circuit, and 3. A peripheral vein|PTH levels during sepsis and compare them to baseline pre-infection levels, with serial follow-up of PTH values post-recovery.
214301846|NCT03632655|PROCEDURE|prostate biopsy|Men will be randomized to receiving either TPM or TRUS targeted biopsy
214301847|NCT05163028|DRUG|HBI-2376|SHP2 Inhibitor
214301848|NCT02860364|PROCEDURE|Hypothermic circulatory arrest|During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
214902277|NCT06239727|DRUG|Capecitabine|Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
214902278|NCT00607321|DEVICE|Medtronic Bifurcation Stent System|Percutaneous Coronary Stenting
214902279|NCT03631589|BIOLOGICAL|MSCs|mesenchymal stem cells therapy
214902280|NCT04127773|DEVICE|oro gastric tube|According to clinical need, an orogastric tube will be inserted at birth using the group method in VLBW infants in whom an umbilical catheter has been placed. An X-ray chest will be performed according to routine clinical practice to assess the position of the umbilical catheter. On the same X-ray the position of the gastric tube will be assessed by a radiologist blinded to the method used for orogastric tube placement.
214902281|NCT02535403|BEHAVIORAL|ICBT|
214902282|NCT01689883|DEVICE|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
214902283|NCT01354405|DRUG|Lanreotide|120 mg every 28 days intramuscular
214902284|NCT02162277|DEVICE|diagnostic osteoporotic kit ( including 7 genes and 4 life styles)|Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
214902285|NCT03143283|BEHAVIORAL|Safety Study Lethal Means Counseling|Clinicians provide applicable families with locking devices and handouts on safe storage of firearms and medications.
214902286|NCT01756027|DEVICE|Ulthera System providing one treatment per cheek|Focused ultrasound energy delivered below the surface of the skin per cheek.
214902287|NCT01756027|DEVICE|Ulthera System providing two treatments per cheek|Focused ultrasound energy delivered below the surface of the skin
214902288|NCT04731727|DRUG|Riboflavin|Corneal cross linking achieved by combination of Riboflavin and ultraviolet light
214902289|NCT04118491|DEVICE|hyperbaric oxygen and sham hyperbaric oxygen|see arm descriptions
214902290|NCT02044380|DRUG|Afatinib|40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
214902291|NCT01654640|DRUG|Metformin|metformin 500mg p.o. bid for 24 weeks
214902292|NCT01654640|DRUG|Placebo (for metformin)|placebo 1T bid
214902293|NCT04680169|DEVICE|Bronchoscopic intubation through AuraGain LMA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
214902294|NCT04680169|DEVICE|Bronchoscopic intubation through I-gel SGA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
214902295|NCT00740636|DRUG|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.
214902296|NCT00740636|DRUG|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
214301849|NCT04327388|DRUG|Sarilumab SAR153191|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
214301850|NCT04327388|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
214301851|NCT06132178|DRUG|Psilocybin|A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).
214301852|NCT06132178|DEVICE|Accelerated intermittent theta burst (aiTBS) rTMS treatment|A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.
214301853|NCT06132178|DRUG|Low-dose psilocybin|A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).
214301854|NCT06132178|DEVICE|Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment|The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.
214301855|NCT05737940|DRUG|AZD3427|The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
214301856|NCT05737940|DRUG|Placebo|The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
214301857|NCT04305834|DRUG|Abemaciclib|Given PO
214301858|NCT04305834|OTHER|Questionnaire Administration|Ancillary studies
214301859|NCT01934660|DRUG|13N-amonia|PET/Scan
214301860|NCT01934660|DRUG|Fludeoxyglucose F18|PET/Scan
214301861|NCT06561958|DRUG|REKOVELLE|Individualised dosing regiment of REKOVELLE in routine clinical practice.
214301862|NCT05996874|DRUG|Semaglutide|Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.
214301863|NCT06639087|DRUG|AZD5462|Participants will receive AZD5462 on top of dapagliflozin once daily.
214301864|NCT06639087|DRUG|Dapagliflozin|Participants will receive dapagliflozin once daily with AZD5462 or placebo.
214301865|NCT06639087|OTHER|Placebo|Participants will receive placebo on top of dapagliflozin once daily.
214669638|NCT05700747|BEHAVIORAL|Health Through Activity|Six, weekly, customized sessions with licensed physical and occupational therapists.
214902297|NCT02125500|DRUG|Sofosbuvir/Ledipasvir fixed dose|SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
214902298|NCT04456140|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214902299|NCT04456140|OTHER|Genetic Counseling|Watch pre-test genetic counseling video
214301866|NCT06440538|DEVICE|PCMS + Contralateral Motor Training|PCMS + Contralateral Motor Training will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2 Hz) to the weaker first dorsal interosseous (FDI) muscle immediately before a session of ballistic index finger abduction training at the opposite, stronger FDI muscle.
214479125|NCT03498521|DRUG|Ipatasertib|Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
214902300|NCT04456140|OTHER|Genetic Testing|Undergo genetic testing
214902301|NCT04456140|OTHER|Survey Administration|Ancillary studies
214301867|NCT06440538|DEVICE|PCMS + Rest|PCMS + Rest will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2Hz) to the weaker FDI followed by a 30-min rest.
214669639|NCT05920213|DRUG|Polyethylene Glycols|280g/ 24 hours for 5 days
214669640|NCT05920213|DRUG|Lactulose oral solution|60-120 ml per day for 5 days
214902302|NCT03667040|BEHAVIORAL|JOOL app|Participants will use the JOOL app for 30 days
214669641|NCT05920213|DRUG|L-ornithine L-aspartate|30g/24 hours in 3 divided doses for 5 days
214902303|NCT05810532|OTHER|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water
214902304|NCT05810532|OTHER|1 hour of fasting time|Oral intake is not allowed for 4 hours before sedation, while water is allowed to intake before 1 hour of sedation
214902305|NCT06147882|BEHAVIORAL|The group will include patients with fibromyalgia syndrome who will receive positive psychotherapy.|The group will include patients with fibromyalgia syndrome who will receive positive psychotherapy.
214902306|NCT06059287|DRUG|Henagliflozin|Henagliflozin 10mg qd po
214902307|NCT06059287|DRUG|Metformin|Metformin 1000mg bid po
214902308|NCT05982470|DRUG|Estradiol Gel|Estradiol gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application) for 12 months
214902309|NCT05982470|DRUG|Estradiol Placebo Gel|Estradiol placebo gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application) for 12 months
214902310|NCT05982470|DRUG|Progesterone Soft Capsule|Progesterone soft capsules 100mg once daily (oral) for 12 months
214902311|NCT05982470|DRUG|Progesterone Placebo Soft Capsule|Progesterone placebo soft capsules 100mg once daily (oral) for 12 months
214902312|NCT04773340|BEHAVIORAL|Dialectical Behavior Therapy|Behaviorally-focused intervention for individuals with personality disorder and a history of significant behavioral problems.
214301868|NCT06440538|DEVICE|Sham PCMS + Contralateral Motor Training|360 TMS pulses will be delivered at a location 10-cm posterior to the participant's head (into the air, 0.2Hz) and no PNS pulses will be generated, followed by a session of 30-min ballistic index finger abduction training at the opposite, stronger FDI muscle.
214301869|NCT06497465|DRUG|Dolutegravir 50mg Tab|Participants will receive Dolutegravir 50mg
214479126|NCT03498521|DRUG|Olaparib|Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
214479127|NCT03498521|DRUG|Erlotinib|Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
214669642|NCT01661322|DRUG|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
214669643|NCT05641649|DRUG|Sodium valproate and valproic acid extended release tablet|Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
214902313|NCT06792955|DRUG|HRS9531 injection|Multi-dose pen of HRS9531 injection solution.
214902314|NCT06792955|DRUG|HRS9531 injection|Single-dose pen of HRS9531 injection solution.
214902315|NCT06370676|DIAGNOSTIC_TEST|Oesophageal temperature measurement|Oesophageal temperature measurement
214902316|NCT05639465|BEHAVIORAL|JoH-C19|Journey of Hope- COVID 19 (JoH-C19) includes eight, 1-hour consecutive sessions delivered in groups of 8 children during the school day and in after school settings. The 1.5 hour JoH-C19 caregiver workshop is delivered with groups of 8 parents prior to the child JoH-C19 curriculum
214902317|NCT05639465|BEHAVIORAL|Switch off Get Active|Switch off Get Active covers 4 topics, and its eight, 1- hour sessions are delivered in groups of 8 children. The 1.5 hour Switch Off Get Active caregiver workshop is delivered with groups of 8 parents prior to the Switch off Get Active child curriculum
214902318|NCT03832686|OTHER|Virtual Coach|The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.
214902319|NCT04052555|DRUG|Berzosertib|Given IV
214902320|NCT04052555|PROCEDURE|Biospecimen Collection|Correlative studies
214902321|NCT04052555|OTHER|Quality-of-Life Assessment|Ancillary studies
214902322|NCT04052555|OTHER|Questionnaire Administration|Ancillary studies
214902323|NCT04052555|RADIATION|Radiation Therapy|Undergo RT
214902324|NCT07078175|PROCEDURE|Xingnao Kaiqiao Acupuncture|"Acupuncture procedure developed by Prof. Shi Xuemin. Key acupoints include DU26, PC6, SP6, LI4, and GV20, applied with rapid and penetrating stimulation.~Arm(s): Xingnao Kaiqiao Acupuncture"
215055372|NCT04570306|DRUG|Belimumab|The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
215055373|NCT01607762|DRUG|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
215055374|NCT01607762|DRUG|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
215055375|NCT01607762|DRUG|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
215055376|NCT01607762|DRUG|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
214301870|NCT06497465|DRUG|Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]|Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]
214301871|NCT06497465|DRUG|Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)|Participants will receive Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
214301872|NCT05615649|DEVICE|MED-EL BONEBRIDGE Bone Conduction Implant|Subjects will be implanted with the MED-EL BONEBRIDGE Bone Conduction Implant System. Subjects will be fit with the appropriate external audio sound processor.
215055377|NCT01607762|DRUG|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
215055378|NCT00454740|DRUG|solifenacin succinate|Oral
214301873|NCT04906460|DRUG|WVE-N531|WVE-N531 is an antisense oligonucleotide (ASO)
214301874|NCT06853067|OTHER|Monitoring of body temperature|Body temperature is monitored in the forehead using the Temperature Monitoring Patient Sensors in patients sedated with dexmedetomidine or remimazolam during spinal anesthesia.
214301875|NCT06014242|DIAGNOSTIC_TEST|Peripheral vascular flow reserve measurement|Peripheral arterial (below knee popliteal and above the level of ankle distal tibial) thermodilution curves will be obtained. One of the distal tibial arteries (anterior tibial, posterior tibial or peroneal artery, whichever reaches the most distal part of the foot in the run off) will be picked for measurements. At room temperature, 3 ml of saline will be injected brisk manually to determine the peak arterial flow, presented as mean transit time (Tmn). Resting Tmn will be performed and averaged by triplicate measurements at baseline. Then maximal hyperemia will be induced by intra-arterial injection of 30 mg papaverine through the guiding catheter, then 3 ml of saline will be injected to get hyperemic Tmn averaged by triplicate measurements. The guidewire will be kept in a fixed position during the series of measurements. Peripheral vascular flow reserve was calculated as resting Tmn divided by hyperemic Tmn (Fukunaga 2015).
214301876|NCT04828785|OTHER|MTM|weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
214301877|NCT04828785|OTHER|Food Subsidy|$40/month food subsidy
214479128|NCT03498521|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
215055379|NCT02536144|PROCEDURE|magnetic-controlled capsule endoscopy system|"1. A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~2. The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~3. While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~4. The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
215055380|NCT02536144|PROCEDURE|Colonoscopy|"1. Bowel preparation should be well done before the examination.~2. A tube with illumination and camera system would insert into colon from anus.~3. From the pictures captured by the camera ,the doctor would see the mucous of the colon."
215055381|NCT05253742|OTHER|No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner|The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
215055382|NCT03749928|DEVICE|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
215055383|NCT03749928|DEVICE|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
214479129|NCT03498521|DRUG|Vemurafenib|Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
214479130|NCT03498521|DRUG|Cobimetinib|Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
215055384|NCT00594607|DEVICE|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
215055385|NCT00594607|DEVICE|Fx8 (Fresenius)|Polysulphone dialysis membrane
214479131|NCT03498521|DRUG|Trastuzumab Subcutaneous (SC)|Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
214902325|NCT07078175|PROCEDURE|Electroacupuncture|Routine electroacupuncture using standard acupoints for hemiplegic upper limb rehabilitation, including LI15, LI11, SJ5, and LI4, with low-frequency electrical stimulation.
214902326|NCT07078136|DIAGNOSTIC_TEST|Multimodal AI Model|Patients' endoscopic images, EUS images, and clinical data will be analyzed by a multimodal AI model for lesion classification and GIST risk stratification.
214902327|NCT07078136|DIAGNOSTIC_TEST|Expert Endoscopist Assessment|Endoscopic ultrasound images will be interpreted by experienced endoscopists for comparison with the AI model.
214902328|NCT07081100|DIETARY_SUPPLEMENT|Probiotic group|Participants took a freeze-dried probiotic powder every day, half an hour after a meal.
214902329|NCT07076329|DIETARY_SUPPLEMENT|Ambrosia bar|"The experimental intervention involves the AMBROSIA bar alongside healthy dietary counseling.~The AMBROSIA bar is a novel chocolate bar designed for older Heart Failure (HF) and Atrial Fibrillation (AF) patients to prevent undernutrition. Its distinguishing features are:~* Unique Composition: It contains a unique and specific blend of probiotic strains and a cocktail of micro/macronutrients.~* Patented Probiotic Efficacy: The SYNBIO® blend is patented (RM2004A000166, EP1743042) for its exceptional intestinal mucosal adhesion, ensuring effective colonization and persistence.~* Optimal Delivery Matrix: The chocolate bar serves as a palatable and effective vehicle for probiotic delivery, confirmed to maintain probiotic viability.~* Targeted Nutritional Strategy: The bar aims to modulate gut microbiota and address undernutrition, inflammation, and cachexia in the target."
214902330|NCT06930495|DRUG|Weight loss SOC Treatment with second generation anti-diabetic medications|To determine the best incretin-based drug for the treatment \[done as part of regular standard of care (SOC) treatment\], participants will go to UTSW weight wellness clinic and undergo a comprehensive history and physical exam to evaluate their overall health. This information is used to create an individualized approach to the participants weight loss regimen. As part of the regimen, participants will receive guidance on initiating lifestyle modifications including diet and exercise and may be referred to a clinical psychologist for evaluation and management of factors like stress, anxiety and depression, and exercise which may influence their health behaviors and body weight.
214902331|NCT07112066|DIAGNOSTIC_TEST|FAPI tracer|18F-FAPI-74 PET/CT, cardiac MRI, echocardiography and blood sample for BMP5 serum concetration is performed at baseline and 12-month follow-up.
214902332|NCT06581107|PROCEDURE|CT-fluoroscopy guided master-slave intervetional robot-assisted lung Cryoablation|During the procedure, the participants first undergo a CT scan. The radiologist plans the trajectories based on the registered preoperative CECT (contrast-enhanced computed tomography) and intraoperative CT. All participants then undergo navigation, localization, and establishment of cryoprobe trajectories using the interventional master-slave system. On the day of the procedure, the number of needle adjustments, number of cryoprobes used, puncture time, ablation time, and procedure time are recorded. The performance of the research device is evaluated by the radiologists. Postoperative complications of the participants are recorded 7±1 days postoperatively/on the day of discharge based on the postoperative CT scan (whichever comes first).
214902333|NCT06932562|DRUG|Linvoseltamab|Administered per the protocol
214902334|NCT06932562|DRUG|Daratumumab|Administered per the protocol
214479132|NCT03498521|DRUG|Pertuzumab|Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
214479133|NCT03498521|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
214479134|NCT03498521|DRUG|Carboplatin|Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
214479135|NCT03498521|DRUG|Paclitaxel|Paclitaxel will be administered intravenously, 175 mg/m\^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
214902335|NCT06932562|DRUG|Lenalidomide|Administered per the protocol
214902336|NCT06932562|DRUG|Dexamethasone|Administered per the protocol
215055386|NCT03723798|DRUG|SA001 Low dose|3 tablets b.i.d for 12 weeks
215055387|NCT03723798|DRUG|SA001 Mid dose|3 tablets b.i.d for 12 weeks
215055388|NCT03723798|DRUG|SA001 High dose|3 tablets b.i.d for 12 weeks
215055389|NCT03723798|DRUG|Placebo|3 tablets b.i.d for 12 weeks
215055390|NCT01527422|DRUG|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
214669644|NCT01941225|DRUG|Inhaled iloprost 5.0 mcg|Single administration
214669645|NCT01941225|DRUG|Placebo|Single administration
214669646|NCT04276558|DRUG|Udonitrectag|Eye drop solution in single dose unit.
214902337|NCT06925932|BEHAVIORAL|Dietary advice - Sweet taste|Asked to reduce their free sugar intakes to \< 5%TEI and replace sweet foods and drinks that are high in free sugars with foods and drinks that are sweet but have no or low amounts of free sugars, e.g., sweet no- or low-free sugar foods, fruit, and no- or low-calorie sweeteners.
214902338|NCT06925932|BEHAVIORAL|Dietary advice - Taste|Asked to reduce their free sugar intakes to \< 5%TEI and replace sweet foods and drinks that are high in free sugars with foods and drinks that are non-sweet but are full of tasty flavours, e.g., non-sweet foods and drinks with nuts, herbs or spices.
214479136|NCT03498521|DRUG|Cisplatin|Cisplatin will be administered intravenously, 60-75 mg/m\^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
214902339|NCT06925932|BEHAVIORAL|Dietary advice - No taste|Asked to reduce their free sugar intakes to \< 5%TEI and replace sweet foods and drinks that are high in free sugars with foods and drinks that are non-sweet and have no strong flavours, e.g., non-sweet plain foods and drinks.
214902340|NCT06932094|DRUG|QLS5132|antibody drug conjugate (ADC).
214902341|NCT05696444|DEVICE|RAS Prostatectomy|Subjects indicated for Robotic Assisted Surgery (RAS) for prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system.
214902342|NCT05696444|DEVICE|RAS Cystectomy|Subjects indicated for Robotic Assisted Surgery (RAS) for cystectomy will have the RAS surgery using the Medtronic Hugo RAS system.
214902343|NCT05696444|DEVICE|RAS Nephrectomy|Subjects indicated for Robotic Assisted Surgery (RAS) for nephrectomy (Radical/Partial) will have the RAS surgery using the Medtronic Hugo RAS system.
214902344|NCT06933459|DRUG|Test Drug|AJU-C714
214902345|NCT06933459|DRUG|Reference Drug|C714R
214902346|NCT01609790|BIOLOGICAL|Bevacizumab|Given IV
214902347|NCT01609790|OTHER|Laboratory Biomarker Analysis|Correlative studies
214902348|NCT01609790|OTHER|Pharmacological Study|Correlative studies
214902349|NCT01609790|OTHER|Placebo Administration|Given IV
214902350|NCT01609790|BIOLOGICAL|Trebananib|Given IV
214902351|NCT06361927|DRUG|SSGJ-707|bispecific antibody
214902352|NCT06940999|OTHER|Traditional physical therapy|Application of laser three times per week in addition to applying deep friction massage, stretching exercises along with the uses of pressure garment.
214902353|NCT06945107|DRUG|Picankibart|"The participants in picankibart treatment group will receive picankibart 200mg SC at Weeks 0, 4, 8, 20 and 32.~The participants in IL-17 mAb continued treatment group will receive picankibart 200mg SC at Weeks 16, 20, 24 and 36."
214902354|NCT06945107|DRUG|Secukinumab|The participants in IL-17 mAb continued treatment group who have received secukinumab before enrollment, will receive secukinumab 300mg SC at Weeks 0, 4, 8 and 12.
214902355|NCT06945107|DRUG|Placebo|"The participants in picankibart treatment group will receive placebo SC at Weeks 12, 16, 24 and 36.~The participants in IL-17 mAb continued treatment group will receive placebo SC at Week 32."
214479137|NCT03498521|DRUG|Gemcitabine|Gemcitabine will be administered intravenously, 1000 mg/m\^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
214479138|NCT03498521|DRUG|Entrectinib|Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
214902356|NCT06945107|DRUG|Ixekizumab|The participants in IL-17 mAb continued treatment group who have received ixekizumab before enrollment, will receive ixekizumab 80mg SC at Weeks 0, 4, 8 and 12.
214902357|NCT06941298|BEHAVIORAL|Neuroimaging Investigation|Participants will undergo fMRI neuroimaging at two timepoints, at the start of the study and at the 1 year follow up. The fMRI is one hour in duration. During the fMRI, participants will complete two tasks investigating diverse aspects of reward circuitry activity. After this is completed, participants will be followed up for another year clinically.
214902358|NCT03886025|OTHER|Anodal transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
214902359|NCT03886025|BEHAVIORAL|Cognitive training|Iowa Gambling Task will be used for cognitive training
214902360|NCT03886025|OTHER|Sham transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
214479139|NCT03498521|DRUG|Ivosidenib|Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
214902361|NCT06946641|DRUG|QLS12010|QLS12010 oral capsule(s)
214902362|NCT06946641|DRUG|Placebo|Matching placebo oral capsule(s)
214902363|NCT00518700|OTHER|new MPS|
214902364|NCT00518700|OTHER|RepleniSH|
214902365|NCT06950957|DEVICE|Video Laryngeal Mask Airway (VLMA)|A second-generation supraglottic airway device with an integrated video camera, used for airway management in adult patients undergoing elective septoplasty. The device allows real-time visualization of the glottic inlet to identify blood infiltration or anatomical challenges. Prior to removal, a fiberoptic bronchoscope will be introduced through the device's lumen to assess the distal trachea for blood contamination. Parameters such as airway insertion time, ventilation mechanics, hemodynamic data, analgesic requirements, and postoperative recovery scores (e.g., Aldrete score, sore throat incidence) will be recorded and analyzed.
214902366|NCT06950957|DEVICE|Endotracheal Tube (ETT)|A standard cuffed endotracheal tube inserted using direct laryngoscopy, employed for airway management during elective septoplasty. At the end of surgery, a fiberoptic bronchoscope will be passed through the ETT to evaluate the distal trachea for blood contamination. Airway insertion time, ventilation parameters, intraoperative hemodynamics, analgesic use, and postoperative outcomes (including sore throat and recovery scores) will be documented and compared with the VLMA group to assess differences in airway safety and clinical performance.
214902367|NCT06955520|DRUG|Vonoprazan|a potassium-competitive acid blocker (P-CAB), offers superior acid suppression and may provide enhanced healing in post-POEM reflux esophagitis.
214902368|NCT06955520|DRUG|Esomeprazole 40mg|It is a proton pump inhibitor which reduces the excessive acid secretion in the stomach and it heals grade B esophagitis (\>5mm ulcer between two mucosal folds in esophagus)
214902369|NCT06951581|DIETARY_SUPPLEMENT|Short Chain Fatty Acid|Participants in this arm will receive an oral formulation of short-chain fatty acids (SCFAs) daily for 12 weeks. SCFAs are administered as a dietary supplement to investigate their potential impact on the systemic and urinary metabolome in kidney transplant recipients.
214902370|NCT06951581|DIETARY_SUPPLEMENT|Placebo Capsule(s)|Oral capsules with sacharosa (200 mg) matching SCFA appearance, administered once a day.
215055391|NCT03351868|GENETIC|Gene-modified autologous stem cells|Infusion for 5x10\^6\~1x10\^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
215055392|NCT03618667|DRUG|GC1118|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
214479140|NCT03498521|DRUG|Pemigatinib|Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
214479141|NCT06061575|DRUG|Acetaminophen|fever will be managed with acetaminophen
214479142|NCT06061575|DRUG|Ibuprofen|fever will be managed with ibuprofen
214479143|NCT06876688|DRUG|Relma-cel Followed by Tislelizumab|Enrolled patients with relapsed/refractory (R/R) CNSL will receive Relma-cel infusion, followed by treatment with Tislelizumab (200mg, IV, q4w, for 12 months) starting at 35 days post-infusion. BTK inhibitors will be used in combination as needed.
214902371|NCT06459102|OTHER|Motor Learning|In addition to the conventional physiotherapy program .... per week for 4 weeks Sessions of motor learning exercise will be performed. For the exercise, the participant will sit in a chair with back support, in front of a table, with arms on the table. The participant will wear a glove with an IMU sensor on the upper surface and a pressure sensor on the palm, and a cylinder will be placed in the palm. The participant will be asked to bring the wrist into extension and then back into flexion while grasping the cylinder with maximum force. The participant will be asked to maintain maximum strength during the entire movement. The participant will be given visual feedback on muscle strength and range of motion of the wrist on the monitor in front of them throughout the movement. The same protocol will be applied by keeping the size of the cylinder in the participant's palm the same and changing the weight.
215055393|NCT02869165|DRUG|Conjugated equine estrogen topical cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
215055394|NCT02869165|DRUG|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
215055395|NCT02807220|DRUG|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
215055396|NCT05147753|DRUG|Moxonidine|0.6 mg moxonidine daily
214669647|NCT04276558|OTHER|Vehicle|Eye drop solution with no active substance in single dose unit.
215055397|NCT04847440|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
215055398|NCT04847440|DRUG|Viread|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
215055399|NCT04847440|DRUG|AB-729|AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
215055400|NCT01009905|DRUG|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
215055401|NCT00792090|OTHER|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
214479144|NCT06652815|BEHAVIORAL|Suicide ideation or suicide attempt|Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study. socio- demographics details will also be gathered. Following this Depression, Anxiety and Stress Scale (DASS-21), Wisconsin Card Sorting Test (WCST), Metacognitions Scale (MCQ-30) and Stigma of Suicide Scale (SOSS) will be administered.
214479145|NCT06653127|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients. Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence.
214669648|NCT05797129|DEVICE|CEDM|Women underwent CEDM screening
214669649|NCT04454814|OTHER|Protaper Universal instruments|Root canal treatment using Protaper Universal instruments
214669650|NCT04454814|OTHER|Reciproc Blue instruments|Root canal treatment using Reciproc Blue instruments
214669651|NCT02129764|DRUG|Prednisone|
214669652|NCT02129764|DRUG|Allopurinol|
215055402|NCT00792090|OTHER|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
215055403|NCT04105686|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
215055404|NCT04105686|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
215055405|NCT04094324|BEHAVIORAL|Questionnaires|4 questionnaires will be answered via iPads
214669653|NCT00212914|BEHAVIORAL|Reminder letter|
214669654|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, Low phytate Diet|Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
214902372|NCT06459102|OTHER|Control|The control group will receive a conventional physiotherapy program for 4 weeks, 5 days a week. Eccentric training for the extensor carpi radialis brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercises for the ECRB muscle will be given. For eccentric training, the weight that the patients can lift in 10 maximal repetitions will be calculated and they will be asked to work with this weight. The best stretching position for the ECRB tendon is extension of the elbow joint, pronation of the forearm and flexion of the wrist with ulnar deviation. Each participant will be taught to perform each exercise for 10 repetitions and 10 seconds. Patients will perform these exercises in a sitting position. In the control group, daily exercises will be performed under the supervision of a physiotherapist
214902373|NCT05776953|DRUG|Ketorolac|IV Ketorolac for pain
214902374|NCT05858996|BEHAVIORAL|Pain-CPG-EIT|"Following randomization champions and stakeholder team members from the communities will be identified. The investigators will recommend the following individuals to be members of the stakeholder team: a nurse in a leadership position (e.g., director of nursing); the designated champion(s); nursing home administrator; physician/medical director, nurse practitioner and/or physician assistant; unit nurse; nursing assistant; activity staff; social worker; pharmacist; and rehabilitation therapists.~Following the first stakeholder team meeting, treatment communities will be provided with a research nurse facilitator to work 8 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to provide the four components of the PAIN-CPG-EIT."
214902375|NCT05858996|OTHER|Pain-CPG-Education Only|The Pain-CPG-Education only group will be provided with the same education as used in Component II of the Pain-CPG-EIT intervention. The education will be provided based on the preferences of the community (this may be face-to-face; online; or via handouts).
214902376|NCT03758417|BIOLOGICAL|LCAR-B38M CAR-T Cell|Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
214902377|NCT06047080|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab
214902378|NCT06047080|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin in combination with R-CHP
214902379|NCT06047080|DRUG|Rituximab|Participants will receive IV rituximab
214902380|NCT06047080|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide as part of CHP chemotherapy
214902381|NCT06047080|DRUG|Doxorubicin|Participants will receive IV doxorubicin
214902382|NCT06047080|DRUG|Prednisone|Participants will receive oral prednisone as part of CHP chemotherapy
214902383|NCT06142565|DEVICE|Nose plug|Participants will complete olfactory training with scented nose plugs.
214902384|NCT06142565|OTHER|Regular olfactory training|Participants will complete olfactory training with regular odors found in their home.
214902385|NCT05422794|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214902386|NCT05422794|PROCEDURE|Biopsy Procedure|Undergo biopsy
214902387|NCT05422794|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214902388|NCT05422794|PROCEDURE|Computed Tomography|Undergo CT
214902389|NCT05422794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214479146|NCT06810401|PROCEDURE|Debridement of implant surface with titanium curettes and irrigation with sterile saline solution|All patients in both groups received non-surgical treatment of peri-implantitis involving the debridement of hard- and soft accumulations on implant surfaces using titanium curettes (Titanium Implant Scaler 204SD, Hu-Friedy) for 15 minutes, followed by irrigation with sterile saline solution
214902390|NCT05422794|DRUG|Nab-paclitaxel|Given IV
214902391|NCT05422794|BIOLOGICAL|Pembrolizumab|Given IV
214902392|NCT03717311|OTHER|Nutritional Intervention|The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
214902393|NCT02862275|DRUG|Atezolizumab|Given IV
214902394|NCT02862275|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214902395|NCT02862275|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
214902396|NCT02862275|PROCEDURE|Computed Tomography|Undergo CT scan
214902397|NCT02862275|OTHER|Laboratory Biomarker Analysis|Correlative studies
214902398|NCT02862275|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214902399|NCT06293456|OTHER|Dignity Therapy|A trained research staff member will conduct the DT interview virtually. The interview will occur or by phone only if the participant lacks access to technology for videoconferencing. The interviewer asks a series of open-ended questions that encourages patients to talk about their lives and what matters most to them.
214902400|NCT06336044|DEVICE|Karisma|Intradermal injection
214479147|NCT03188692|BIOLOGICAL|DPT-IPV-Hib (Combined Vaccine)|0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
214907408|NCT02972060|DRUG|ADT|"ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
214907409|NCT05523544|BEHAVIORAL|schematherapy|psychotherapy
214907410|NCT03682081|DEVICE|Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)|An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
214301878|NCT05074693|OTHER|EASE app|EASE is a mobile intervention designed to reduce ongoing mental health concerns among BLAI individuals with elevated anxiety and/or depressive symptoms by targeting anxiety sensitivity. The EASE app employs a variety of features to educate its users on how to deal with increased levels of stress, anxiety, and depression, and train users on how to better cope with the negative feelings of stress. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos designed to teach participants how to better deal with stress. EASE also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time. Finally, EASE is outfitted with COVID-19 related elements, including a symptoms tracker (which participants can use to report symptoms of COVID-19 they may be experiencing), and a collection of COVID-19 related food, housing, and job placement resources.
214301879|NCT05074693|OTHER|INSIGHT (Control) App|"A standard of care control intervention was developed using the INSIGHT platform. This app contains a library of educational videos that cover topics such as meditation and mindfulness, as well as general stress reduction techniques. Additionally, participants have access to a Report Distress feature that enables them to report moments when they are feeling high levels of stress. Finally, participants will be able to report any COVID-19 related symptoms they experience using a COVID-19 symptom tracker feature. Participants assigned to this condition will received 2 daily EMAs, during which they will be prompted to watch one of the aforementioned educational videos."
214301880|NCT04957719|COMBINATION_PRODUCT|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer 16 mg of selatogrel subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
214301881|NCT04957719|COMBINATION_PRODUCT|Placebo|"Placebo will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer placebo subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
214301882|NCT04601753|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214301883|NCT04080440|PROCEDURE|Extubation readiness clinical score|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated.~If the score is \> 9, extubation has to be completed."
214301884|NCT04080440|PROCEDURE|Usual Care|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to usual care."
214301885|NCT05171231|DEVICE|HEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD|"HEMOCOLLAGENE® is an absorbable, sterile and hemostatic sponge, composed of type I undenatured, native and lyophilized bovine collagen (0.027 g per sponge).~HEMOCOLLAGENE® will be inserted into oral sites (mainly the alveoli dental) after post-extraction or post-invasive dental surgical procedure, in case of bleeding not controled by usual hemostatic method. HEMOCOLLAGENE® will be let in place and will undergo a complete and natural absorption after several weeks."
214301886|NCT05941897|DRUG|Ceralasertib|Participants will receive ceralasertib oral tablets.
214301887|NCT05941897|DRUG|Durvalumab|Participants will receive durvalumab as an intravenous infusion
214301888|NCT05564377|DRUG|Alpelisib|Given PO
214301889|NCT05564377|DRUG|Binimetinib|Given PO
214301890|NCT05564377|PROCEDURE|Biopsy Procedure|Undergo biopsy
214479148|NCT06589635|DRUG|ADC-189 and Itraconazole|"Part 1:~Day 1, fasting condition, 45 mg ADC189, administered orally~Part 2:~Day 22, 200 mg itraconazole bid, taken orally after meals. Day 23-Day 25, 200 mg itraconazole was taken orally after meals. Day 26, 45 mg ADC-189 and 200 mg itraconazole was taken orally after meals. Day 27-Day 39, 200 mg itraconazole was taken orally after meals."
214479149|NCT06817434|DRUG|Revascularization/Conservative management|Revascularization/Conservative management
214907411|NCT03682081|DEVICE|Biotene Oral Balance Gel|Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.
214907412|NCT06334705|OTHER|blood test, food collection, hair collection, calcium scan, etc.|everything is specified during the phone call and in the consent form to be signed
214907413|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Erector Spinae block|Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
214902401|NCT04958265|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing =\> 40 to \<100 kg) or 1500 mg IV (for participants weighing \>=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing =\> 40 to \<100 kg) or 1020 mg SC (for participants weighing \>=100 kg). Enrollment of participants weighing \<40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing \>=20 kg to \<40 kg, followed by Group 2 participants weighing \>=5 kg to \<20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.
214902402|NCT03150329|OTHER|Laboratory Biomarker Analysis|Correlative studies
215055406|NCT00118274|BIOLOGICAL|incomplete Freund's adjuvant|Given intradermally and subcutaneously
215055407|NCT00118274|BIOLOGICAL|melanoma helper peptide vaccine|Given intradermally and subcutaneously
215055408|NCT00118274|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
215055409|NCT00118274|BIOLOGICAL|tetanus toxoid helper peptide|Given intradermally and subcutaneously
215055410|NCT00118274|DRUG|cyclophosphamide|Given IV
215055411|NCT00855777|DRUG|etoricoxib|etoricoxib 120 mg/day for 3 days
215055412|NCT00855777|DRUG|ibuprofen|ibuprofen 1,800 mg/day for 3 days
214902403|NCT03150329|BIOLOGICAL|Pembrolizumab|Given IV
214902404|NCT03150329|DRUG|Vorinostat|Given PO
214907414|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Paravertebral block|Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
214301891|NCT05564377|PROCEDURE|Biospecimen Collection|Undergo blood collection
214301892|NCT05564377|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214301893|NCT05564377|PROCEDURE|Bone Scan|Undergo bone scan
214907415|NCT02563327|DRUG|Rifapentine|A rifamycin with activity against Mycobacterium tuberculosis
214907416|NCT02563327|DRUG|Moxifloxacin|A fluoroquinolone
214907417|NCT02563327|DRUG|Rifampin|A rifamycin with activity against Mycobacterium tuberculosis
214907418|NCT02563327|DRUG|Isoniazid|An anti-tuberculosis agent
214907419|NCT02563327|DRUG|Pyrazinamide|An anti-tuberculosis agent
214907420|NCT02563327|DRUG|Ethambutol|An anti-tuberculosis agent
214907421|NCT02563327|DIETARY_SUPPLEMENT|Pyridoxine|An essential vitamin
214907422|NCT01368094|PROCEDURE|Drain removal at D4|If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.
214907423|NCT01368094|PROCEDURE|Standard drain removal|If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
214907424|NCT05794906|DRUG|Darolutamide (BAY1841788, Nubeqa)|Coated tablet, 300 mg / tablet, oral.
214907425|NCT05794906|OTHER|Placebo matching darolutamide|Coated tablet, oral
214907426|NCT05794906|OTHER|ADT|Luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonists
214907427|NCT06647069|DRUG|DR-0201|DR-0201 is a bispecific antibody
214907428|NCT02770235|OTHER|DE assessment|by a validated self-administered questionnaire: Index International erectile function (IIEF-15)
214907429|NCT02770235|OTHER|AGE measurement|By AGE-ReaderTM
214907430|NCT05172284|OTHER|Questionnaires|This is a collection of data from normal clinical routine: patients will be asked to record the assessments they undergo during their course of treatment, without changing clinical practice in any way. Data inherent to the following procedures will be collected: examinations, laboratory tests, imaging tests, questionnaires and rating scales.
214907431|NCT03215290|PROCEDURE|TCS|"The cutting surface recognized as not good cutting surface was further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
215055413|NCT05810909|DIETARY_SUPPLEMENT|amorphous calcium carbonate/ Placebo|The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
215055414|NCT01160393|DEVICE|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
215055415|NCT01724216|DEVICE|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
215055416|NCT02770066|DEVICE|Percutaneous transluminal renal angioplasty|"Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia)~Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician~* Antiplatelet therapy (usually standard)~* Cholesterol-lowering drugs (usually standard)~* Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated)~* Smoking cessation, diet and physical activity (usually standard)"
215055417|NCT00175916|DRUG|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
215055418|NCT02463084|OTHER|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
215055419|NCT02463084|OTHER|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
214902405|NCT03286387|OTHER|Functional brain imaging without any contrast agent|"During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
214902406|NCT06848075|DRUG|Elismetrep (K-304) Dose Level 1|Administered orally
214902407|NCT06848075|DRUG|Elismetrep (K-304) Dose level 2|Administered orally
214902408|NCT06848075|DRUG|Elismetrep (K-304) Dose level 3|Administered orally
214902409|NCT06848075|DRUG|Elismetrep (K-304) Dose level 4|Administered orally
214902410|NCT06848075|DRUG|Placebo|Administered orally
214902411|NCT05295290|DIAGNOSTIC_TEST|Cardiac Imaging|ECG, echocardiogram, ambulatory monitor, exercise stress test
214902412|NCT04663347|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|6 cycles (21-day cycles)
214902413|NCT04663347|DRUG|rituximab and lenalidomide|rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles)
214902414|NCT04663347|DRUG|rituximab and bendamustine|6 cycles (28-day cycles)
214902415|NCT04663347|DRUG|rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin|3 cycles (21-day cycles)
214902416|NCT04663347|DRUG|gemcitabine and oxaliplatin|4 cycles (28-day cycles)
214902417|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
214902418|NCT04663347|DRUG|rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone|6 cycles (21-day cycles)
214902419|NCT04663347|DRUG|Lenalidomide|12 cycles (28-day cycles)
214902420|NCT04663347|DRUG|rituximab, ifosfamide, carboplatin, and etoposide phosphate|3 cycles (21-day cycles)
214902421|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
214902422|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
214902423|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and then every 8 weeks for a total of 2 years.
215055420|NCT01817842|BEHAVIORAL|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
214301894|NCT05564377|PROCEDURE|Computed Tomography|Undergo CT
214301895|NCT05564377|PROCEDURE|Echocardiography Test|Undergo ECHO
214902424|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
214902425|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
214902426|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
214902427|NCT04663347|BIOLOGICAL|Epcoritamab|"Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules.~Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years.~In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years."
214902428|NCT04663347|DRUG|Rituximab and Lenalidomide|Rituximab 375 milligrams per meter squared (mg/m\^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles.
214902429|NCT04663347|BIOLOGICAL|Epcoritamab|Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
214902430|NCT04716452|DRUG|Ceramide NanoLiposome (Ceraxa)|Ceramide NanoLiposome will be given by IV twice a week. The dose, which is based on body size, will be increased for the next group of patients if the first group of patients tolerates that dose and it will decrease for the next group if they do not tolerate the dose.
214902431|NCT06222853|BIOLOGICAL|anti-CD19-CAR-T cells|Three dose groups (0.3×10\^5/kg, 1×10\^5/kg, 3×10\^5/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
214902432|NCT02853214|GENETIC|Genetic analysis of peripheral blood samples|M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
215055421|NCT01817842|BEHAVIORAL|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
215055422|NCT01817842|BEHAVIORAL|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
214301896|NCT05564377|DRUG|Fluorouracil|Given IV
214301897|NCT05564377|DRUG|Fulvestrant|Given IM
214301898|NCT05564377|DRUG|Ipatasertib|Given PO
214301899|NCT05564377|DRUG|Leucovorin|Given IV
214301900|NCT05564377|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214902433|NCT06140836|DRUG|Repotrectinib|Specified dose on specified days
214902434|NCT06140836|DRUG|Crizotinib|Specified dose on specified days
214902435|NCT03284385|DRUG|Adavosertib|Given PO
214902436|NCT04860453|GENETIC|WES via Illumina NextSeq 550 sequencing system|Sequencing will be performed on an Illumina sequencing system
214902437|NCT04860453|DIAGNOSTIC_TEST|Blood Draw|Blood draw will be via any University Hospitals Laboratory site and sent at room temperature via courier to the Center for Human Genetics (CHG) Laboratory
214902438|NCT04860453|DIAGNOSTIC_TEST|Skin biopsy|Skin samples obtained via 3mm punch biopsy will be suspended in cell culture media prepared per CHG routine and sent via courier to the Center for Human Genetics Laboratory
214902439|NCT04860453|DIAGNOSTIC_TEST|Saliva Sample|Participant will provide a saliva sample which be shipped to University Hospitals Laborator site at room temperature
214902440|NCT06565195|DRUG|LY3962681|IT injection
214902441|NCT06565195|OTHER|Placebo (aCSF)|IT injection
214902442|NCT06565260|OTHER|Exercise Intervention|Participate in exercise program
214902443|NCT06565260|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
214902444|NCT06565260|OTHER|Nutritional Intervention|Participate in nutrition program
214902445|NCT06565260|OTHER|Physical Performance Testing|Ancillary studies
214902446|NCT06565260|OTHER|Questionnaire Administration|Ancillary studies
214902447|NCT03375307|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214902448|NCT03375307|PROCEDURE|Biospecimen Collection|Undergo blood collection
214902449|NCT03375307|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214902450|NCT03375307|PROCEDURE|Bone Scan|Undergo bone scan
214902451|NCT03375307|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214902452|NCT03375307|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214902453|NCT03375307|DRUG|Olaparib|Given PO
214902454|NCT03375307|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214902455|NCT06807268|DRUG|Abrocitinib|Abrocitinib administered as liquid oral suspension.
214301901|NCT05564377|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214902456|NCT06807268|OTHER|Placebo|Placebo administered as liquid oral suspension.
214902457|NCT05703685|RADIATION|Lung scan|Immediately after the brain scan
214902458|NCT05703685|DRUG|Apremilast|Oral administration of apremilast
214902459|NCT05703685|DRUG|18F-PF-06445974|Injected IV followed by PET scanning
214902460|NCT05702229|DRUG|Rilvegostomig|an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion
214301902|NCT05564377|PROCEDURE|Mutation Carrier Screening|Undergo tumor mutational screening
214902461|NCT05702229|DRUG|Volrustomig|an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion
214902462|NCT05702229|DRUG|FOLFOX|5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2
214902463|NCT05702229|DRUG|XELOX|capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1
214902464|NCT05702229|DRUG|AZD7789|an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion
214902465|NCT05702229|DRUG|AZD0901|an anti Claudin18.2 ADC; IV infusion
214902466|NCT05702229|DRUG|5-Fluorouracil|5-FU, IV infusion, Q3W
214902467|NCT05702229|DRUG|Capecitabine|Oral take, Q3W
214902468|NCT05838768|DRUG|HRO761|Tablet
214902469|NCT05838768|BIOLOGICAL|pembrolizumab|Concentrate for solution for infusion
214301903|NCT05564377|DRUG|Neratinib Maleate|Given PO
214301904|NCT05564377|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO
214301905|NCT05564377|DRUG|Olaparib|Given PO
214301906|NCT05564377|DRUG|Oxaliplatin|Given IV
214301907|NCT05564377|DRUG|Paclitaxel|Given PO or IV
214301908|NCT05564377|DRUG|Palbociclib|Given PO
214301909|NCT05564377|BIOLOGICAL|Panitumumab|Given IV
214902470|NCT05838768|DRUG|irinotecan|Concentrate for solution for infusion
214902471|NCT05580666|DRUG|Azithromycin Oral Tablet|Antimicrobial therapy
214902472|NCT05580666|DRUG|Placebo oral tablet|Inert ingredients
214902473|NCT03321643|DRUG|Atezolizumab|Given IV
214902474|NCT03321643|PROCEDURE|Biopsy Procedure|Undergo biopsy
214902475|NCT03321643|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214902476|NCT03321643|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214902477|NCT03321643|PROCEDURE|Computed Tomography|Undergo CT or PET-CT
214902478|NCT03321643|DRUG|Gemcitabine|Given IV
214902479|NCT03321643|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214902480|NCT03321643|DRUG|Oxaliplatin|Given IV
214902481|NCT03321643|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
214902482|NCT03321643|BIOLOGICAL|Rituximab|Given IV
214902483|NCT06452225|OTHER|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block.
214902484|NCT06452225|OTHER|Transversus Abdominis Plane Block|Patients will receive ultrasound guided transversus abdominis plane block.
214902485|NCT04438824|DRUG|INCMGA00012|INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
214902486|NCT04438824|DRUG|Palbociclib|Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days
214907432|NCT01822639|DRUG|GSK2944404 FDC|Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
214907433|NCT01822639|DRUG|Amlodipine 5 mg|Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.
214907434|NCT01822639|DRUG|Enalapril Maleate 20 mg|Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
214301910|NCT05564377|PROCEDURE|Positron Emission Tomography|Undergo PET
214301911|NCT05564377|DRUG|Selumetinib Sulfate|Given PO
214301912|NCT05564377|DRUG|Sotorasib|Given PO
214669655|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, High Phytate Diet|Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
214902487|NCT00739882|DRUG|Efalizumab - anti CD11a recombinant human monoclonal antibody|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week. The treatment period will be 24 weeks divided into two phases: 1) double-blind for 12 weeks, and 2) open-label for 12 additional weeks, in which all subjects from the placebo group and those subjects from the Raptiva ® group with ≥ 50% of improvement will be allocated to extended treatment with Raptiva ® for 12 additional weeks while non-responders to Raptiva ® (improvement ≤ 50%) will be followed in an observational manner for 12 additional weeks without treatment.
214902488|NCT00739882|DRUG|Placebo|Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
214902489|NCT02593279|GENETIC|asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
214902490|NCT02593279|GENETIC|asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
214902491|NCT06360198|OTHER|No intervention|No intervention was applied to the group.
214902492|NCT03995537|BIOLOGICAL|blood sample|"Samples will be collected at the inclusion and repeated if necessary before LT, including one 4 mL EDTA sample and one 4 mL Heparin sample and one 2.5 mL PAXgene® sample, allowing the HLA-DR assay to be performed with also plasma aliquots and messenger RNAs.~Same samples will also be collected :~* between inclusion and LT in case of major clinical change~* During the pre-transplant follow-up 3 months after inclusion, for patients who have not been transplanted within 3 months after inclusion~* at day 1 after LT~* 2 times a week after the LT for a maximum of 1 month~Biological data will be collected at those different times."
214902493|NCT04033861|DRUG|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
214902494|NCT04033861|DRUG|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
214902495|NCT05045443|DRUG|Curcumin|Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement
214902496|NCT05045443|DIETARY_SUPPLEMENT|Standard of Care|As per institution protocol for Standard of nutritional Care
214902497|NCT00804310|DRUG|ixabepilone|This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
214301914|NCT00412763|DRUG|Silymarin (Silybum marianum)|
214301915|NCT00941018|DRUG|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
214301916|NCT02384707|OTHER|allegic food|"Reintroduction procedure for small doses :~* Administration of the first dose~* Clinical monitoring for 45 minutes~* Administration of the second dose"
214301917|NCT02384707|OTHER|Placebo|
214301918|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
214301919|NCT01359657|BIOLOGICAL|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
214301920|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
214301921|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
214301922|NCT01359657|BIOLOGICAL|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
214301923|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
214902498|NCT00804310|DRUG|lapatinib ditosylate|Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
214301924|NCT01980355|DRUG|Tranexamic Acid|
214301925|NCT01980355|OTHER|Placebo|
214301926|NCT02419053|OTHER|Surgical Safety Checklist|An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
214301927|NCT06466135|DRUG|WAL0921|Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.
214301928|NCT06466135|DRUG|Placebo|Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
214301929|NCT00326456|DRUG|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
214301930|NCT00326456|DRUG|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
214301931|NCT00326456|DRUG|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
214479150|NCT06820255|DRUG|Platinum + Gemcitabine|Eligible patients will be treated with platinum-based chemotherapy (i.e. cisplatin + gemcitabine or carboplatin + gemcitabine).
214669656|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, Low Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
214301932|NCT04062331|DEVICE|Transcranial Magnetic Stimulation (TMS)|"By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months."
214301933|NCT04062331|DRUG|Placebos|Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
214902499|NCT05549843|OTHER|Manual therapy|Each session will last approximately 50-60 minutes, with 1 physiotherapy session per week over a period of 3 weeks. Each session is made up of 10 steps, of which 9 correspond to manual interventions commonly used in the field of manual therapy.
214902500|NCT04111289|DRUG|-Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)|"* After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~* Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~* Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
214902501|NCT05736757|DRUG|Tissue Plasminogen Activator|Injection of 50 ug tissue plasminogen activator into the suprachoroidal cavity or subretinal space to assist in bleeding liquefaction
214902502|NCT01038986|BIOLOGICAL|CureXcell|The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.
214902503|NCT02646995|DIETARY_SUPPLEMENT|modified lipid formulation|Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.
214902504|NCT02646995|DIETARY_SUPPLEMENT|Fish oil|Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
214902505|NCT05682456|DIETARY_SUPPLEMENT|High-fat shake|The high-fat shake consisted of 53% (w/v) fresh cream, 3% (w/v) sugar and 44% (w/v) water
214902506|NCT05682456|DIETARY_SUPPLEMENT|Reference shake|The reference shake consisted of 43% (w/v) full cream milk, 48% (w/v) full cream yoghurt, 4% (w/v) lemonade, 4% (w/v) fantomalt (Nutricia B.V., the Netherlands) and 1% (w/v) wheat fiber
215055423|NCT00548626|PROCEDURE|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
215055424|NCT00548626|PROCEDURE|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
214902507|NCT03444181|BEHAVIORAL|Music lessons|Also described as neurocognitive music therapy. Singing lessons will be provided once a week for a period of 12 months by a person with a qualification in music therapy, or by a person with a different relevant qualification (e.g. psychology and music teaching) under the supervision of a music therapist. Additionally, participants will have the opportunity to meet regularly (1-2 times per month) as a choir to sing the song they have learned together in a group.
214902508|NCT03444181|BEHAVIORAL|Training intervention|Cognitive training that is comparable in scope and extent to the music lessons, but not using music. Group training sessions will be provided once a week for a period of 12 months by a person with a qualification in physiotherapy or occupational therapy. Group activities may include group tours such as mountain hikes and the like (about 2 times per month) and will follow an established program for the elderly.
214902509|NCT02408835|DEVICE|PICO™|Negative pressure wound therapy device for closed surgical wounds.
214902510|NCT01820143|DRUG|Ilaprazole|
214902511|NCT01820143|DRUG|Esomeprazole|
214902512|NCT02445248|BIOLOGICAL|Tisagenlecleucel|The target dose of CTL019 transduced cells for adult patients consisted of a single infusion of 5 x 10\^8 viable CTL019 transduced cells, which was administered via intravenous infusion. The acceptable dose range was 1 - 5x10\^8 viable CTL019 transduced cells.
215055425|NCT04381416|DEVICE|SEAD treatment|up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
215055426|NCT01005641|DRUG|exemestane|25 mg daily
214301934|NCT01147029|DRUG|angiogenesis inhibitor GSAO|
214301935|NCT01147029|OTHER|laboratory biomarker analysis|
214301936|NCT01147029|OTHER|pharmacological study|
214479151|NCT06820255|DRUG|Avelumab first-line maintenance|Patients with stable disease or tumor response after treatment with platinum-based chemotherapy will start treatment with avelumab 800 mg fat dose Q2 weeks until progression of disease or unacceptable toxicity
214902513|NCT02445248|DRUG|Lymphodepleting chemotherapy|Prior to CTL019 cell infusion, an additional lymphodepleting chemotherapy cycle was planned. The use of any additional bridging therapy prior to the recommended lymphodepleting chemotherapy was at the discretion of the investigator and dependent on the patient's disease burden. Lymphodepleting chemotherapy was started 14 to 5 days before CTL019 infusion (D1) to allow for at least 48 hours from last dose of lymphodepleting chemotherapy to CTL019 infusion. The lymphodepleting regimen was: Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) and cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).
215055427|NCT01005641|DRUG|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
215055428|NCT01014767|DRUG|Carboplatin|"Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3"
215055429|NCT01014767|DRUG|Cisplatin|Cycles 1 \& 2: 70 mg/m²/d IV over 6 hours on day 4
215055430|NCT01014767|DRUG|Cyclophosphamide|"Standard Arm, Cycle 1: 1 g/m\^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 \& 5: 1 g/m\^2 IV over 1 hour on day 2 and 3"
215055431|NCT01014767|DRUG|Dactinomycin|Cycles 1 \& 2: 45 µg/kg/day (max. 2 mg), IV on day 1
214902514|NCT01554670|PROCEDURE|RF micro-tenotomy|an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
214902515|NCT01563042|DRUG|Intravenous (IV) single dose|GSK2434735 administered as a single intervenous dose at the beginning of the study
214902516|NCT01563042|DRUG|Subcutaneous (SC) single dose|GSK2434735 administered as a single subcutaneous dose at the beginning of the study
214902517|NCT04320225|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
214902518|NCT04968535|DEVICE|StimaWELL|mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed
214902519|NCT02779920|PROCEDURE|per oral pylorotomy|The procedure is endoscopic pylorotomy. The standard procedure consists in the realization of a longitudinal incision of 2 cm at the anterior surface of the gastric antrum at 5 cm from the pylorus after a submucosal injection of a solution containing 85% saline 10% glycerol and 5% fructose. This longitudinal incision serve as an input for producing a submucosal tunnel dissected fibers gastric submucosa step. The internal circular of the pyloric muscle is then severed fiber after fiber over its entire length and its entire thickness. Once the pyloric section completed, the tunnel inlet will be closed by means of hemostatic clips.
214902520|NCT01899482|OTHER|Manual Lymphatic Drainage|
214902521|NCT01899482|BEHAVIORAL|Education|Behavioral education.
215055432|NCT01014767|DRUG|Doxorubicin|Cycles 1 \& 2: 25 mg/m²/day IV over 12 hrs on days 1-3
215055433|NCT01014767|DRUG|Etoposide|"Standard Arm (1), Cycles 1 \& 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5"
214902522|NCT00351468|DRUG|eltrombopag olamine (SB-497115-GR)|Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
214902523|NCT03088072|DRUG|Edoxaban|"Edoxaban 60mg once daily in patients with CrCl \>50- ≤95 mL/min, or 30mg once daily in patients with CrCL 15-50 mL/min.~If at 6 week TEE LAA closure is deemed acceptable by the operator (i.e., peri-device flow \<5mm), edoxaban will be discontinued. Aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up, then clopidogrel will be discontinued.~If LAA unacceptable on 6-week TEE due to peri-device flow ≥5mm, edoxaban will be continued for an additional 6 weeks, and LAA reassessed by TEE If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference."
214301937|NCT01147029|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214902524|NCT03088072|DEVICE|WATCHMAN LAA Closure|Per Inclusion Criteria, enrolled subjects must have a successful Left Atrial Appendage (LAA) Closure using the WATCHMAN Device
214902525|NCT03088072|DRUG|Aspirin and Clopidogrel|"If at 6 week TEE LAA closure is deemed acceptable by the operator edoxaban will be discontinued, and aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up. Then clopidogrel will be discontinued.~Aspirin 325mg daily rather than 81mg daily can be administered according to operator preference after the 6-week follow-up visit."
214902526|NCT03088072|DRUG|Aspirin and Warfarin|If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference.
214902527|NCT05260567|BEHAVIORAL|Exercise and Lifestyle Change|"Patients will undergo to weekly phone call/videoconference for 12 weeks and discuss the behaviour change.~They also will undergo to home-based exercise training will be performed twice a week for 12 weeks via Zoom (up to 5 patients per session). Each session will be comprised of warm-up (10 min), the main part (15 to 20 min), and cooldown (5 to 10 min). The training aims to develop resistance, aerobic and functional capacity such as getting up, walking, pulling, pushing, throwing, transferring body weight or external loads. In addition, patients will be encouraged to increase their physical activity. Patients will be provided with a Fitbit device to monitor their step count and will be recommended to increase their previous week's average step count by 10%."
214902528|NCT06040515|DRUG|Probiotic Formula|Capsule with 25 billion live strains of Escherichia coli Nissle 1917
214902529|NCT00838903|BIOLOGICAL|albiglutide|albiglutide
215055434|NCT01014767|DRUG|Irinotecan|"Temozolomide Irinotecan arm (4), Cycles 1 \& 2:~50 mg/m2/day x 5 days as 1 hour IV infusions"
215055435|NCT01014767|DRUG|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
215055436|NCT01014767|DRUG|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
215055437|NCT01014767|DRUG|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
215055438|NCT01014767|DRUG|Vincristine|"Standard Arm (1), Cycles 1 \& 2 : 1.5 mg/m\^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 \& 2: 1.5 mg/m\^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5"
215055439|NCT00564733|DRUG|carboplatin|Given IV
215055440|NCT00564733|DRUG|docetaxel|Given IV
214301938|NCT04430114|DEVICE|branched prosthesis for surgical treatment of thoraco-abdominal aortic aneurysms|"Jotec TAAA spinal loop graft custom made CE equivalent branched prosthesis, compared with the cohort of patients already treated with standard prostheses and / or Gelweave ™ Coselli Thoracoabdominal Grafts."
215055441|NCT00564733|DRUG|gemcitabine hydrochloride|Given IV
215055442|NCT00564733|DRUG|paclitaxel|Given IV
215055443|NCT00564733|PROCEDURE|computed tomography|Undergo FDG PET/CT
215055444|NCT00564733|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
215055445|NCT00564733|RADIATION|fludeoxyglucose F 18|Given IV
215055446|NCT00564733|OTHER|imaging biomarker analysis|Correlative studies
214301939|NCT04837157|DEVICE|Exoskeleton rehabilitation|The participants will perform physical therapy with the ATLSA2030 device, for 90 minutes per session.
214301940|NCT03051607|DRUG|Tozadenant|1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
214902530|NCT00838903|DRUG|sitagliptin|sitagliptin
214902531|NCT00838903|DRUG|glimepiride|Glimepiride
214902532|NCT00838903|DRUG|metformin|Metformin
214902533|NCT00838903|BIOLOGICAL|placebo albiglutide|placebo to match albiglutide
214902534|NCT00838903|DRUG|placebo sitagliptin|placebo to match sitagliptin
214902535|NCT00838903|DRUG|placebo glimepiride|placebo to match glimepiride
214902536|NCT02154451|DEVICE|Infrared Imaging Device- ALIAS|Infrared Camera
214902537|NCT02734966|DRUG|Magnesium Isoglycyrrhizinate Injection 100mg OD|Magnesium Isoglycyrrhizinate Injection 100mg OD
214902538|NCT02734966|DRUG|Magnesium Isoglycyrrhizinate Injection 200mg OD|Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
214902539|NCT02734966|DRUG|Tiopronin Injection|Tiopronin Injection 200mg OD
214902540|NCT04565145|DRUG|Kava Dietary Supplement|Participants will be given three 75mg kava capsules per day for one week
214902541|NCT04565145|DRUG|Placebo|Participants will be given three placebo capsules per day for one week
214902542|NCT04122963|PROCEDURE|High power CLOSE-guided PVI ablation|CLOSE-guided PVI ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds)
214902543|NCT04122963|PROCEDURE|Standard CLOSE-guided PVI ablation|Standard AF ablation according to the CLOSE-protocol
214902544|NCT04293939|DIAGNOSTIC_TEST|Functional Magnetic Risonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. MRI Protocol: T1 weighted image structural, T2 weighted image structural, fMRI task. Task fMRI: experiment will be implemented using the block design is as follow: 1.Rest (control condition): no touch; 2.Soft touch (stimulus condition): gentle strokes on infant's right leg (\~15 cm area) with a soft brush at a velocity of \~5 cm/s Stimulus blocks will last for \~15s, allowing the blood-oxygen-level-dependen (BOLD) signal to reach the steady state. Control blocks duration will be randomized (10-18s) to avoid foresee activation phenomena. Condition will be administered multiple times (\~10 times). Two run will be administered. The stimulus will be administered using a soft brush. A regular audio signal will help the operator to keep a constant stroke velocity. Audio commands will also be used to direct the operator. Infant must be asleep (natural sleep) during the fMRI acquisition.
214902545|NCT03096314|DRUG|Vitamin D3|540,000 IU vitamin D3 delivered as a single, liquid enteral dose administered either orally or via naso/orogastric tube
214902546|NCT03096314|DRUG|Placebo|A single, liquid enteral dose identical in appearance and consistency to cholecalciferol administered either orally or via naso/orogastric tube.
214902547|NCT05661539|DEVICE|Transvaginal Ultrasonography|The amount of resistance and blood flow in the main arteries that provide uterine perfusion will be determined by uterine artery Doppler velocimetry performed on the patients.
214902548|NCT01535417|DRUG|Shinbaro Capsule|Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)
214902549|NCT01535417|DRUG|Celebrex|
214902550|NCT04380935|BIOLOGICAL|Convalescent plasma|Convalescent plasma of recovered COVID-19 patients (donor)
214902551|NCT04380935|DRUG|Standard of care|"According to national or hospital guidelines COVID-19 Management Protocol"
214902552|NCT00002234|DRUG|Efavirenz|
214902553|NCT00002234|DRUG|Adefovir dipivoxil|
214902554|NCT00002234|DRUG|Lamivudine|
214902555|NCT00002234|DRUG|Didanosine|
214902556|NCT01735825|DEVICE|paclitaxel-coated balloon catheter with Iopromide coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
214301941|NCT05160454|DEVICE|near infrared spectroscopy|evaluate cerebral blood flow with and without breatholding
214902557|NCT01735825|DEVICE|drug eluting stent with everolimus|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
214902558|NCT01735825|DEVICE|seal-wing paclitaxel-eluting balloon catheter|Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
214301942|NCT05872711|OTHER|Low carbohydrate diet|"In order to maintain equal intensity of treatment, each patient will get a cooking workshop and received a personalized diet regime at baseline, based on the randomly assigned diet. Format and quality of the materials are similar.~All diet plans are individualized and matched for energy intake personally . Participants will meet individually with the dietitian for diet instruction and support at week 1,2,4,7,10,12 and thereafter at 24 weeks for a total of seven frontal meetings. Twice during the first 12 weeks the dietician will conduct 10-15-minute motivational telephone calls with all the participants."
214902559|NCT00516022|DRUG|Mistletoe extract|The drug will be administered 3 times a week at home.
214902560|NCT04632186|DEVICE|EXOPULSE Mollii suit|"All sessions start with rated perceived pain with the NRS and the ShoulderQ questionnaire and assessed body function with the Fugl-Meyer UE scale, Ashworth scale and the Neuroflexor, before the start of the intervention.~Session 1. Stimulation with TENS according to best clinical practice. Session 2. Stimulation with the Mollii suit according to current best experienced practice with selective stimulation directed to the shoulder region Session 3. Stimulation using the full body Mollii suit according to current best experienced practice.~Outcome of each session is assessed with a pain drawing, the NRS (during and after treatment) and the Fugl-Meyer UE, Ashworth scale and the Neuroflexor (after treatment)."
214902561|NCT01850238|BIOLOGICAL|AADvac1|AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
214902562|NCT01850238|OTHER|Placebo|The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
214301943|NCT04045340|DEVICE|Philips QLAB Ultrasound Quantification Software|Offline processing of intraoperative transesophageal echocardiography would be performed with Global Longitudinal Strain on apical 4 chamber, apical 2 chamber and long axis views in order to analyze left ventricle and left atrium contractility and right ventricle free wall motion
214301944|NCT03965533|DRUG|GSK2831781|GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
214301945|NCT03965533|DRUG|Placebo|Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
214301946|NCT01074957|DEVICE|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
214301947|NCT01074957|DEVICE|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
214301948|NCT01074957|OTHER|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
214301949|NCT02144389|DRUG|Praziquantel (PZQ)|"40 mg/kg, a single dose, administered orally~1 g of corn/soybean oil (50%/50%), administered orally"
214301950|NCT02144389|DIETARY_SUPPLEMENT|Arachidonic acid (ARA)|ARA (40% of total fatty acid)
214301951|NCT02144389|DIETARY_SUPPLEMENT|PZQ+ARA|A single dose of PZQ administered seven days in advance of initial treatment with ARA.
214902563|NCT01447550|DRUG|Bosentan|Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
214902564|NCT04976010|OTHER|No intervention|There will be no intervention in the separate goups, as this is an observational study
214902565|NCT04167319|OTHER|QST and PRO measurements during treatment|We will observe the natural course of CIPN using multiple measurements
214902566|NCT04323410|PROCEDURE|Cast immobilization|Cast immobilisation is done using finger trap traction. The fractured forearm is splinted above elbow with dorsal cast without attempted reduction.
215055447|NCT02641756|OTHER|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
215055448|NCT06280768|DRUG|SHR-2004 injection|dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6
214669657|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, High Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
214902567|NCT04323410|PROCEDURE|Percutaneus pinning|Reduction under fluoroscopic guidance and fixation using two crossing 1.6mm K-wires.
214902568|NCT00683618|DRUG|Rosuvastatin|Capsule/Tablet, oral, qd, 6 or 12 weeks
214902569|NCT00683618|DRUG|Atorvastatin|Capsule/Tablet, 10mg, oral, qd, 6 weeks
214301952|NCT03169582|DRUG|Avanafil|Drug administration (Avanafil)
214902570|NCT06396117|OTHER|mTESE (microscopic testicular sperm extraction)|"Microdissection Testicular Sperm Extraction (mTESE) is a surgical procedure used to retrieve sperm from the testicles of men with non-obstructive azoospermia (NOA). It involves:~1. Testicular biopsy: Removing a small sample of testicular tissue.~2. Microscopic examination: Examining the tissue under a microscope to identify areas with sperm production.~3. Sperm extraction: Dissecting out individual sperm cells from the testicular tissue.~This technique allows for:~* More accurate identification of sperm-containing areas~* Lower risk of damage to surrounding testicular tissue~* Potential for higher sperm retrieval rates compared to conventional method"
214902571|NCT03726970|RADIATION|CBCT radiation|CBCT scanning
215055449|NCT01489709|DRUG|Vesicare|oral
215055450|NCT00276939|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|
215055451|NCT01579058|DRUG|bisoprolol|bisoprolol 5mg qd for 4 years
215055452|NCT01579058|DRUG|placebo|placebo for 4 years
215055453|NCT02142335|DRUG|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 \& 3 (days 1 \& 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
214301953|NCT03169582|DRUG|Sildenafil|Drug administration (Sildenafil)
214301954|NCT02297269|DEVICE|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
214301955|NCT02297269|DEVICE|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
214301956|NCT01865539|DEVICE|Custom Foot Orthotic|Custom foot orthotic with custom design pads
215055454|NCT00000763|DRUG|TNP-470|
214301957|NCT01865539|DEVICE|Sham Orthotic|Leather insert without the custom design pads
214301958|NCT04660448|DIAGNOSTIC_TEST|Bedside lung ultrasound examination|Lung ultrasound exploring 12 areas (6 in each lung) at 12 +/- 6 hours and at 48-72 hours from PICU admission. Clinical and analytical data collection coinciding with ultrasound imaging and during follow-up while admitted to PICU.
214479152|NCT06820255|DIAGNOSTIC_TEST|NGS test for DDR alterations|All patients will be tested for DDR alterations on tumor tissue.
214479153|NCT06821165|OTHER|Dr. Goniometer Application|The Dr. Goniometer application is a digital tool used for measuring elbow flexion range of motion (ROM). In this study, participants' elbow flexion ROM will be assessed using both the Dr. Goniometer application and a manual goniometer. Measurements will be taken twice by two different raters to evaluate the validity and reliability of the digital application compared to the manual goniometer.
214479154|NCT06820762|DRUG|irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity|"Drug: ivonescimab 20mg/kg, IV, D1, Q3W~Other Names:~AK112 Drug: irinotecan liposome(II) 70mg/m\^2, IV, D1, Q3W"
214301959|NCT03420469|DRUG|Bupropion|Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
214301960|NCT06547008|BEHAVIORAL|Army-SPRING|Army-SPRING includes a package of implementation options to support implementation of ASIST.
214902572|NCT01092234|OTHER|Traditional ward|provision of care in a traditional unit/ward.
214902573|NCT01092234|OTHER|Organizational change|Observational unit (new organizational unit) for organizing in-hospital care
214301961|NCT06547008|BEHAVIORAL|Risk Reduction Group (Control)|Risk Reduction Group is a mandated training from National Guard Service members
214301962|NCT01946373|DRUG|Cyclophosphamide|
214301963|NCT01946373|DRUG|Fludarabine|
214301964|NCT01946373|BIOLOGICAL|T cells|
214301965|NCT01946373|BIOLOGICAL|Interleukin-2|
214301966|NCT01946373|BIOLOGICAL|Dendritic cell vaccine|
214902574|NCT04570670|DRUG|monomethyl fumarate 190 mg|
214902575|NCT04570670|DRUG|dimethyl fumarate 240 mg|
214902576|NCT02746718|OTHER|Blood sample|A blood sample for CPK dosage and pompe disease test
214902577|NCT06536361|OTHER|Virtual Reality-Based Learning Tool|The intervention involves the use of a virtual reality-based learning tool to teach thorax and lung physical examination skills. The tool uses Oculus Meta Quest 3 VR headset to provide immersive simulation experiences. The VR tool includes high-quality graphics and interactive scenarios to facilitate skill development.
214301967|NCT01603459|DRUG|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
214301968|NCT06430203|BEHAVIORAL|Peer mentoring|Indigenous young adult peer mentors who will develop and deliver the program based on needs and wants of our participants. The program will be built on their experience and ideas. They will be empowered to guide the program in the direction they see best for their communities.
214301969|NCT00196716|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
214301970|NCT00233896|DRUG|Oral beclomethasone dipropionate (drug)|
214301971|NCT00399360|DRUG|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
214301972|NCT00399360|DRUG|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
214907435|NCT02004366|DRUG|Linagliptin|Linagliptin once daily + correction doses of rapid acting insulin if needed
214907436|NCT02004366|DRUG|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
214907437|NCT02004366|DRUG|Linagliptin|Patients with admission A1C \< 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
214907438|NCT02004366|DRUG|Linagliptin + 50% Glargine dose on discharge|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
214907439|NCT02004366|DRUG|Linagliptin + 80% Glargine|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
214907440|NCT03476889|OTHER|Infant formula|Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
214907441|NCT03158038|BIOLOGICAL|Monovalent Influenza Vaccine|A single dose of monovalent influenza vaccine \[10\^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain\] will be administered as intranasal spray on Day 1.
214907442|NCT03158038|OTHER|Placebo|A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.
214907443|NCT01130376|BIOLOGICAL|GTU-MultiHIV B clade vaccine1mg|Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
214907444|NCT01130376|DRUG|Interleukin-2|5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
214907445|NCT01130376|DRUG|GM-CSF|150 ug administered subcutaneously once daily 4 hours from IL-2 injections
214907446|NCT01130376|DRUG|Growth Hormone|4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
214907447|NCT02467738|RADIATION|Brachytherapy|Undergo brachytherapy with Cesium-131
214907448|NCT02467738|DRUG|Cesium-131|Undergo brachytherapy with Cesium-131
214907449|NCT02467738|PROCEDURE|Conventional surgery|Undergo surgical resection
214907450|NCT02863055|DRUG|Nintedanib|Nintedanib 200 mg administered twice daily
214907451|NCT02863055|DRUG|Placebo|Matching placebo administered twice daily
214907452|NCT05980624|DIETARY_SUPPLEMENT|oral nutrition supplement|patients receive ONS 300kcal in daily basis
214907453|NCT01219426|OTHER|Filling of three questionnaires|The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
214907454|NCT02527746|DRUG|F-627|F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
214907455|NCT02527746|DRUG|EC regimen|Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.
214907456|NCT02275546|DRUG|Placebo vaginal ring|Drug-free placebo vaginal ring
214907457|NCT02275546|DEVICE|Single-use, non-sterile applicator|Single-use, non-sterile, plastic applicator for insertion of vaginal ring.
214907458|NCT01962012|DEVICE|AcceleDent Aura|
214907459|NCT01962012|DEVICE|Sham Device|
214907460|NCT02955355|BIOLOGICAL|HYQVIA|Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
214907461|NCT02612623|DRUG|Gefapixant|Gefapixant tablets administered by mouth twice daily for 8 weeks
214907462|NCT02612623|DRUG|Placebo (for gefapixant)|Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
215055455|NCT00596557|DRUG|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
214301973|NCT00399360|BEHAVIORAL|Lifestyle Modification|Lifestyle Modification
214301974|NCT02144441|DRUG|glargine and aspart|Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
214301975|NCT02442960|DRUG|Herbal treatment (SA100)|This treatment has been used extensively in traditional medicine practices for hundreds of years.
214301976|NCT06237595|DEVICE|Vagus nerve stimulation|Electrical stimulation of the vagus nerve.
214301977|NCT06237595|DRUG|Medical treatment|Medical treatment for fibromyalgia patients
214479155|NCT06820294|OTHER|No intervention|As per widely adopted clinical research practice for case reviews of de-identified, anonymised data, no explicit consent of participants (or their legal guardians) would be required for this study other than the consent they provided at biopsy (from which the whole genome sequencing data is derived) for researchers to access their notes (as documented on hospital consent form).
214902578|NCT06536361|OTHER|Traditional Small Group Training|The intervention involves traditional small group training conducted in the Nursing Principles Skills Laboratory. This training includes hands-on practice with physical examination techniques using simulation mannequins and feedback from instructors. The approach is designed to provide practical experience without the use of virtual reality technology.
214902579|NCT02062060|DRUG|Abametapir Lotion 0.74% w/w|
214902580|NCT02062060|DRUG|Vehicle Lotion|
214902581|NCT05770141|PROCEDURE|laser hemorrhoidoplasty|A skin incision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
214902582|NCT05770141|PROCEDURE|open surgical hemorrhoidectomy|The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
214902583|NCT03557619|DRUG|Venetoclax|tablet; oral
214902584|NCT03557619|DRUG|ethinyl estradiol/levonorgestrel|tablet; oral
214902585|NCT04405492|DEVICE|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Evaluated point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Clinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different clinical samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
214902586|NCT04405492|DEVICE|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken (D0). A follow-up at D15, M1, M3, M6, M9 will be done. At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.~Cinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
214902587|NCT04405492|DEVICE|Capillary and salivary sampling|Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.
214902588|NCT05331131|DRUG|Ketamine Topical|Ketamine hydrochloride in mouthwash form
214907463|NCT00980239|DRUG|Irinotecan|Starting dose of 35 mg/m\^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).
214907464|NCT00980239|DRUG|Bevacizumab|10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.
214907465|NCT00980239|DRUG|Oxaliplatin|Starting dose 60 mg/m\^2 by vein over 2 hours on Days 1 and 15 of every cycle.
214907466|NCT00980239|DRUG|Cetuximab|500 mg/m\^2 by vein on Days 1 and 15 of every cycle. The first time given over 2 hours, all other cycles over 1 hour.
214907467|NCT05891093|DRUG|Fluzoparib|Fluzoparib 50mg bid orally for 1 year.
214907468|NCT05891093|DRUG|Anastrozole|1mg, qd orally
214907469|NCT05891093|DRUG|Letrozole|2.5mg, qd orally
214301978|NCT06237595|COMBINATION_PRODUCT|Combined vagus nerve stimulation and medical treatment|Combination of the two interventions
214301979|NCT05321615|DEVICE|Palpator|Palpator for tumor localization
214301980|NCT05321615|DEVICE|Grasper|Atraumatic lung grasper
214907470|NCT05891093|DRUG|Exemestane|25mg, qd orally
214907471|NCT05891093|DRUG|Tamoxifen|10mg, bid orally
214907472|NCT05891093|DRUG|Toremifene|60mg, qd orally
214907473|NCT05891093|DRUG|Abemaciclib|150mg/100mg/50mg, bid orally for 2 years
214907474|NCT05891093|DRUG|LHRH agonist|Leuprorelin acetate, goserelin acetate
214301981|NCT05321615|DEVICE|Ultrasound|VATS ultrasound
214301982|NCT05321615|OTHER|Finger palpation|Palpation of the lung/tumour using the surgeon's finger
214301983|NCT06187610|BEHAVIORAL|Digital education|Patients assigned to the experimental group will learn about symptom self-management in a digital learning environment.
214479156|NCT06815991|DRUG|MIB-725|MIB-725 is a modified precursor of the NAD+ biosynthetic pathway.
214902589|NCT06574074|BEHAVIORAL|Gain-Life (Give informAtIoN to transform Life)|The Gain Life intervention comprises four components: (i) information about depression, (ii) awareness of available services, (iii) stigma reduction through dispelling myths and facts about depression, and (iv) a life transformation story. The first module aims to raise awareness about depression, with a particular focus on its causes, manifestations, and the potential negative consequences of untreated depression. The second component includes the types of services offered, costs, distance to service providers, and operating hours. The third component address stigma and misconceptions surrounding depression by addressing the root causes of stigma, dispelling myths, and providing accurate information about depression. The final module of the Gain Life intervention features recovery stories of individuals who have overcome depression. This module includes two 8-minute video stories of individuals who successfully recovered from depression.
214902590|NCT02606916|RADIATION|SMART|Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
214902591|NCT02606916|DRUG|DDP|DDP(25 mg/m2.qw) for six weeks.
214902592|NCT02606916|DRUG|S-1|S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
214902593|NCT00760916|DRUG|UT-15C 1 mg|UT-15C 1 mg
214902594|NCT00760916|DRUG|UT-15C 0.25 mg|UT-15C 0.25 mg
214902595|NCT00760916|DRUG|UT-15C 5 mg|UT-15C 5 mg
214902596|NCT00760916|DRUG|Placebo|Placebo
214902597|NCT04751643|OTHER|Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|"Therapeutic plasma exchange (TPE) ; 3 sessions in 3 consecutive days (Day 1 to Day 3) in intensive care unit in addition to usual treatments.~Plasma removed is replaced by thawed fresh frozen plasma. Plasma blood volume exchanged : 1.2 Apheresis type: centrifugation"
214902598|NCT04751643|OTHER|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
214902599|NCT06648681|DRUG|Lemborexant 5 mg|"The intervention is the oral administration of a study drug containing lemborexant 5 mg daily between 2000h and 0000h for the first 7 days following extubating/initiation criteria is met or until their hospital discharge or until the first diagnosis of delirium, whichever occurs first.~Initiation criteria:~I. The participant has been extubated for at least 2 hours II. all other sedative medications have been discontinued for \>1 hour III. the participant has a Richmond Agitation and Sedation Scale (RASS) score of \>-1 or a Pasero Opioid-induced Sedation Scale (POSS) score \<3.~If satisfactory sleep is not achieved with the 5 mg dose of the study drug, as defined by a Richards Campbell Sleep Score \<50 within 1 hour, another insomnia medication may be administered on participant request and clinician judgement.~If participants develop delirium, the study drug will be discontinued."
215055456|NCT04365426|DEVICE|Mechanical stimulus|Electrical dynamometer to measure mechanical pressure
215055457|NCT04365426|PROCEDURE|Thermal (cold) stimulus|Water cold bath
215055458|NCT04365426|OTHER|Oral contraceptive (OC)|Oral contraceptive (OC)
214902600|NCT06648681|DRUG|Control (placebo) group|"The control group will receive an oral placebo tablet daily between 2000h and 0000h for the first 7 days following when initiation criteria is met or until their hospital discharge, whichever occurs first.~Initiation criteria:~I. The participant has been extubated for at least 2 hours II. all other sedative medications have been discontinued for \>1 hour III. the participant has a Richmond Agitation and Sedation Scale (RASS) score of \>-1 or a Pasero Opioid-induced Sedation Scale (POSS) score \<3.~If satisfactory sleep is not achieved with the 5 mg dose of the study drug, as defined by a Richards Campbell Sleep Score \<50 within 1 hour, another insomnia medication may be administered on participant request and clinician judgement.~If participants develop delirium, the study drug will be discontinued."
214902601|NCT02129166|DRUG|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
215055459|NCT04365426|OTHER|No oral contraceptive (No OC)|No oral contraceptive (No OC)
215055460|NCT02406521|DRUG|Pazopanib|
215055461|NCT02406521|DRUG|Sorafenib|
215055462|NCT02406521|DRUG|Radium-223|
214479157|NCT06816134|DRUG|TmBU conditioning Regimen|TmBU conditioning Regimen and GVHD Prophylaxis of Haploid transplantation (Haplo-HSCT) and unrelated donor transplantation (UDT) : Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG) or GVHD Prophylaxis of Matched Sibling Donor Hematopoietic Stem Cell Transplantation (MSD-HSCT)：Cyclosporine A (CsA) + short-term low-dose methotrexate (MTX), then stem cells are infused into patient's blood.
215055463|NCT06554561|DRUG|Pomalidomide|3-5mg d1-d14 for 4-6 cycles, every 21 days as induction/consolidation chemotherapy, Then 3-5mg d1-d14 for 12 cycles, every 28 days as maintenance treatment.
215055464|NCT06554561|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 4-6 cycles will be prescribed.
215055465|NCT06554561|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.
215055466|NCT02621476|BEHAVIORAL|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
215055467|NCT02621476|BEHAVIORAL|Usual care|Usual care
215055468|NCT01890096|RADIATION|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
215055469|NCT01890096|RADIATION|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
215055470|NCT04795115|OTHER|Auditory rhythmical cueing|Auditory rhythmical cueing intervention targeting balance and gait for 30 minutes x5 per week for 3 weeks.
215055471|NCT05342324|DIAGNOSTIC_TEST|Optical coherence tomography angiography|To evaluate the vessel density in choriocapillary vascular networks, using optical coherence tomography angiography
214669658|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
214301984|NCT04989400|DRUG|Ulipristal Acetate|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
215055472|NCT03151122|BEHAVIORAL|Nurse-led Continuous Support|"The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age."
214902602|NCT02129166|DRUG|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
214902603|NCT00002772|BIOLOGICAL|filgrastim|
214902604|NCT00002772|DRUG|carboplatin|
214902605|NCT00002772|DRUG|carmustine|
214902606|NCT00002772|DRUG|cisplatin|
214902607|NCT00002772|DRUG|cyclophosphamide|
214902608|NCT00002772|DRUG|doxorubicin hydrochloride|
214902609|NCT00002772|DRUG|paclitaxel|
214902610|NCT00002772|DRUG|tamoxifen citrate|
214479158|NCT06816134|DRUG|mBUCY conditioning regimen|mBUCY conditioning Regimen and GVHD Prophylaxis of Haploid transplantation (Haplo-HSCT) and unrelated donor transplantation (UDT): Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG) or GVHD Prophylaxis of Matched Sibling Donor Hematopoietic Stem Cell Transplantation (MSD-HSCT)：Cyclosporine A (CsA) + short-term low-dose methotrexate (MTX), then stem cells are infused into patient's blood.
214479159|NCT06817096|DRUG|Nitazoxanide 600Mg Oral Tablet / placebo oral tablet|1 tablet every 12 hours
214902611|NCT00002772|DRUG|thiotepa|
214902612|NCT00002772|PROCEDURE|autologous bone marrow transplantation|
214902613|NCT00002772|PROCEDURE|peripheral blood stem cell transplantation|
214902614|NCT00002772|RADIATION|radiation therapy|
215055473|NCT03151122|PROCEDURE|routine follow-up care|after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
215055474|NCT00344175|DRUG|pitavastatin|
214902615|NCT05138705|BIOLOGICAL|Quadrivalent Influenza Virus Split Vaccine|0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains
214902616|NCT01113437|DRUG|Omalizumab|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
214902617|NCT01113437|DRUG|Placebo|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
214902618|NCT05795543|PROCEDURE|Subtalar Arthrodesis by Screws|Instruments: cannulated screws Steps: supine position , tournique over the thigh, using a extended lateral approach or sinus tarsi approach with joint debridement and preparation. Single-screw fixation was most often placed from posterior to anterior and double screws fixation was placed triangular pattern
214902619|NCT05080075|BIOLOGICAL|Platelet Rich Plasma Injection|Research participants own blood will be used to prepare the platelet rich plasma injectate, which will be injected into the affected knee using ultrasound guidance.
214902620|NCT06574581|BIOLOGICAL|ADSC01|The initial 3 subjects will receive low-dose AD-MSC (1x10E6 cells/kg) infusion therapy only once; if no adverse events after 4 weeks, the next 4-7 subjects will receive medium-dose AD-MSC (1x10E6 cells/kg) infusion therapy twice; if no adverse events after 4 weeks of the last infusion, the next 8-10 subjects will receive high-dose AD-MSC (1x10E6 cells/kg) infusion therapy three times.
214902621|NCT03444428|OTHER|Non Invasive Ventilation|Assessments for those participants who are being set up onto NIV
214902622|NCT03444428|OTHER|Without Non Invasive Ventilation|Assessments for those participants who are not being set up onto NIV
214902623|NCT05035407|DRUG|IL-2 (Aldesleukin)|dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period beginning within 24 hours of cell infusion and continuing for up to four days (maximum 12 doses).
214902624|NCT05035407|DRUG|Cyclophosphamide|30 mg/kg IV infusion over 1 hour (+ 10 min) Once daily x 2 doses (Days -6 and -5)
214902625|NCT05035407|BIOLOGICAL|KK-LC-1 TCR|1 x 108 transduced KK-LC-1 TCR T cells
214479160|NCT06817369|OTHER|Exercises given with internal focus instructions|Both groups of girl volleyball players will be given 5 exercises. Exercise 1: Hands-free vertical jump (the movement of an individual jumping from a certain point and then jumping back to the same point) Exercise 2: Training in catching and throwing the ball thrown by the physiotherapist while the individual remains stationary for 30 seconds in the lunge position Exercise 3: Weight transfer on balance beam Exercise 4: Stretching the hamstring and trunk muscles / Bending the trunk while standing upright and touching the toes to the ground exercise Exercise 5: Exercise used in Wall Catch Coordination test Each exercise will be 3 sets of 10 repetitions / 1-2 minutes of rest between each set.
215055475|NCT00344175|DRUG|simvastatin|
215055476|NCT04165551|BIOLOGICAL|Probiotic|Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.
214902626|NCT05035407|DRUG|Fludarabine|25 mg/m2 IV infusion over 30 minutes (+ 10 min) To be administered following completion of cyclophosphamide. Once daily x 5 doses (Days -6, -5, -4, -3, -2)
214902627|NCT06140524|DRUG|Linvoseltamab|Administered per the protocol
214902628|NCT01062425|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiotherapy
214902629|NCT01062425|DRUG|Cediranib Maleate|Given PO
214902630|NCT01062425|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
214902631|NCT01062425|OTHER|Laboratory Biomarker Analysis|Correlative studies
214902632|NCT01062425|OTHER|Placebo Administration|Given PO
214902633|NCT01062425|DRUG|Temozolomide|Given PO
214669659|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
214902634|NCT03003962|DRUG|Durvalumab (MEDI4736)|Anti-PD-L1 monoclonal Antibody monotherapy
214902635|NCT03003962|DRUG|Paclitaxel + carboplatin|Chemotherapy Agents
214902636|NCT03003962|DRUG|Gemcitabine + cisplatin|Chemotherapy Agents
214902637|NCT03003962|DRUG|Gemcitabine + carboplatin|Chemotherapy Agents
214902638|NCT03003962|DRUG|Pemetrexed + cisplatin|Chemotherapy Agent
215055477|NCT04165551|BIOLOGICAL|Placebo|Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.
215055478|NCT03178825|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
215055479|NCT00122876|PROCEDURE|Photodynamic therapy|
215055480|NCT00122876|DRUG|Talaporfin Sodium|
215055481|NCT00310375|DRUG|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
214902639|NCT03003962|DRUG|Pemetrexed + carboplatin|Chemotherapy Agent
214902640|NCT02695446|DRUG|Minocycline|Oral extended release minocycline
214902641|NCT04614519|PROCEDURE|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
214902642|NCT04614519|PROCEDURE|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
214902643|NCT04302415|DRUG|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
214902644|NCT00179907|PROCEDURE|Photon Radiosurgery System (Intrabeam)|In this study we had intended to perform a similar dose escalation study with doses ranging from 10-19 Gy, 10-16 Gy and 10 - 14 Gy for tumors \< 20 mm, 21-25 mm and 26-40 mm respectively
214902645|NCT00850057|BIOLOGICAL|Intranodal injection of Ad-ISF35|Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).
215055482|NCT01905189|PROCEDURE|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
214669660|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
215055483|NCT01719848|OTHER|Measurements of parameters related with physical examinations for difficult airway prediction|
214902646|NCT00861640|DRUG|Intravenous Omeprazole|Intravenous Omeprazole 1amp qd (every day)
214902647|NCT00861640|DRUG|Oral Rabeprazole|Oral Rabeprazole 1 bid
214902648|NCT02162134|OTHER|sugar free chewing gum|Sugar free chewing gum (orbit) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
214902649|NCT02162134|OTHER|sugared chewing gum|Sugared chewing gum (singsong bubble gum) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
214902650|NCT02162134|DRUG|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
214902651|NCT02162134|DRUG|Inj. Midazolam 0.7mg/kg 45 min before surgery|Inj . Midazolam 0.7 mg/kg given as premedication.
214902652|NCT02162134|DRUG|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
214902653|NCT02162134|DRUG|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia.
214902654|NCT02162134|DRUG|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
214902655|NCT02162134|DRUG|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
214902656|NCT02162134|DRUG|Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
214902657|NCT02162134|DRUG|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
214902658|NCT01474174|BIOLOGICAL|trivalent influenza vaccine|Given IM
214902659|NCT01474174|OTHER|laboratory biomarker analysis|Correlative studies
214902660|NCT02300064|OTHER|Knee-extensor exercise test|Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes
215055484|NCT03526094|OTHER|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
214902661|NCT02300064|OTHER|Exercise test with restricting/releasing blood flow|10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.
214902662|NCT02300064|OTHER|Exercise test with variable oxygen concentration and MRI|Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine
214902663|NCT02300064|OTHER|Exercise test with oral antioxidant or placebo cocktail|Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort
214902664|NCT03904251|DRUG|Gemtuzumab Ozogamicin|Given IV
214902665|NCT03904251|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214902666|NCT02256618|OTHER|Autologous umbilical cord blood cells|Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused
215055485|NCT03526094|OTHER|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
215055486|NCT03526094|OTHER|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
215055487|NCT03526094|OTHER|Flavanol-berry blend|Flavanol-berry blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
214902667|NCT02069015|BEHAVIORAL|Patient education|Patient education on hypertension delivered through a touchscreen kiosk.
214902668|NCT06292845|DRUG|Topical application of a fluorescent imaging agent|"The fluorescent imaging agent will be topically applied only onto the resection planes of the freshly resected tumor specimen.~During incubation and after each washing steps, visible light and fluorescent overlay images will be acquired using a fluorescence sensitive camera system."
214902669|NCT04636775|DIAGNOSTIC_TEST|Microbiome|Nasal and buccal swabs, and stool sample, as well as the extracted DNAs
214902670|NCT05198830|DRUG|Carboplatin|Given IV
214902671|NCT05198830|DRUG|Cisplatin|Given IV
214902672|NCT05198830|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
214902673|NCT05198830|BIOLOGICAL|Durvalumab|Given IV
214902674|NCT05198830|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
214902675|NCT05198830|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214902676|NCT05198830|DRUG|Methoxyamine|Given PO
214902677|NCT05198830|DRUG|Pemetrexed|Given IV
214902678|NCT05198830|RADIATION|Radiation Therapy|Undergo thoracic radiation
214902679|NCT02095548|DRUG|SM04690, 0.03mg/2mL|
214902680|NCT02095548|DRUG|SM04690, 0.07mg/2mL|
214902681|NCT02095548|DRUG|SM04690, 0.23mg/2mL|
214902682|NCT02095548|DRUG|Placebo|
214902683|NCT01182012|BEHAVIORAL|Lifestyle counseling|Depending on the results of cardiovascular risk factor indexes, the treatment (including drugs, if needed) may be modified or adjusted. A nurse visit will be programmed to explain the lifestyle behaviour the patient should have.
214902684|NCT00779935|BIOLOGICAL|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
214902685|NCT03055455|DIAGNOSTIC_TEST|MR imaging|Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
214902686|NCT05651321|OTHER|Samples materials of basic taste stimuli and enteral nutrition preparations|Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.
214902687|NCT02599285|DEVICE|Fixation|Fixation of the posterior malleolus with lag-screws or plate-fixation. If syndesmosis is intra-operatively stable, no syndesmotic positioning screws will be placed.
214902688|NCT02599285|DEVICE|NO Fixation|Posterior malleolus will not be fixated. Syndesmotic positioning screws will be placed.
214902689|NCT02179892|DRUG|Bupivacaine Extended-Release Liposome Injection (Exparel)|266mg/30mL of Exparel will be injected via unilateral TAP block
214902690|NCT02179892|DRUG|Bupivacaine and Dexamethasone Injection|As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.
214902691|NCT02179892|DRUG|IV Acetaminophen|Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.
214902692|NCT02179892|DRUG|Oral Acetaminophen|Oral acetaminophen 650 mg every 6 hours.
215055488|NCT03526094|OTHER|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
215055489|NCT03526094|OTHER|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
214902693|NCT05976321|DRUG|TAK-279|TAK-279 capsules.
214902694|NCT06576232|DEVICE|Median LCS|End-to-end processing of chest LDCT DICOM images by an AI/ML tech-based SaMD to detect, localize, and characterize (assign a malignancy score) each detected pulmonary nodule. The output of the device is a DICOM File (Median LCS result report) summarizing results per patient.
214902695|NCT06975267|BEHAVIORAL|Norwegian version of Second Step Early Learning|"The interventions is a 28 weeks program divided into five themes. The themes are 1. Skills that promotes learning, 2. Empathy, 3. Managing emotions, 4. Friendship skills and problem solving, and 5. Transitioning to school.~The intervention consists of daily activities. The guidebook is a central part of the program and provides the kindergarten teachers with practical tools and activities to implement the program in everyday settings. The guidebook includes:~28 weekly themes: Each week introduces a new theme with related activities and discussion topics.~Brain-building games: Activities designed to strengthen children's cognitive skills and self-regulation.~Songs and music: Songs that reinforce the learning of social skills. Parent connections: Information sheets and activities to involve parents in their children's social-emotional development.~Puppet theatre: The use of hand puppets Dog and Snail to illustrate and discuss feelings and social situations."
214902696|NCT06975267|BEHAVIORAL|Free play|"Control kindergartens will have additional designated playtime consisting of free play for 28 weeks. The checklist for play conditions is defined as when: Time is set aside in the daily kindergarten routine where (1) it is clearly announced or signaled to the children that it is now free play, (2) it is an absence of requirements for sedentary sitting (unless it is part of the children's play), (3) it is not a situation where children are required to follow instructions (unless it is part of the children's play or general rules in the kindergarten (?)), (4) it is an absence of a pronounced learning outcome or goal with the activities available for the children (beyond what is defined by the children themselves), (5) the children can start and finish activities themselves, and choose what they want to participate in, and (6) adults can join in the game/initiate, but on the children's terms, and the children can choose to leave this game whenever they want."
214902697|NCT02861417|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
214902698|NCT02861417|DRUG|Busulfan|Given IV
214902699|NCT02861417|DRUG|Cyclophosphamide|Given IV
215055490|NCT03526094|OTHER|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
215055491|NCT03526094|OTHER|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
215055492|NCT03526094|OTHER|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
215055493|NCT03526094|OTHER|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
215055494|NCT01387750|OTHER|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
215055495|NCT01387750|OTHER|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
214479161|NCT06817369|OTHER|Exercises given with external focus instructions|Both groups of girl volleyball players will be given 5 exercises. Exercise 1: Hands-free vertical jump (the movement of an individual jumping from a certain point and then jumping back to the same point) Exercise 2: Training in catching and throwing the ball thrown by the physiotherapist while the individual remains stationary for 30 seconds in the lunge position Exercise 3: Weight transfer on balance beam Exercise 4: Stretching the hamstring and trunk muscles / Bending the trunk while standing upright and touching the toes to the ground exercise Exercise 5: Exercise used in Wall Catch Coordination test Each exercise will be 3 sets of 10 repetitions / 1-2 minutes of rest between each set.
214479162|NCT06818188|OTHER|Turning based specific training with rhythmic auditory stimulation (RAS)|"The study involved an experimental group that underwent a 6-week turning-based training with rhythmic auditory stimulation (TBST-RAS), performed three times a week on alternate days. The purpose was to improve motor control and walking abilities through rhythmic auditory cues, specifically adjusting the metronome's beat to the patient's cadence.~Week 1: Patients performed turning exercises around a cone and walking with visual cues at 5% rhythmic auditory cue intensity, with rest periods.~Weeks 2-3: The intensity of rhythmic auditory cues increased to 10%, and patients engaged in cone turning, figure-of-eight walking, and walking with visual cues, with rest breaks in between.~Weeks 4-5: Rhythmic auditory cue intensity increased to 15%. Exercises included cone turning, figure-of-eight walking, walking with visual cues, multidirectional stepping, and rest periods.~Week 6: The final week involved exercises with a further increase in rhythmic auditory cue intensity to 20%. The exercise"
214669661|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
214669662|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
215055496|NCT03513913|PROCEDURE|ICSI|Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
215055497|NCT00573391|DRUG|Velcade, Thalidomide, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
215055498|NCT00573391|DRUG|Velcade, Melphalan, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
214669663|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
214902700|NCT02861417|DRUG|Fludarabine|Given IV
214902701|NCT02861417|DRUG|Fludarabine Phosphate|Given IV
214902702|NCT02861417|OTHER|Laboratory Biomarker Analysis|Correlative studies
214902703|NCT02861417|DRUG|Mycophenolate Mofetil|Given PO
214902704|NCT02861417|OTHER|Pharmacological Study|Correlative studies
214902705|NCT02861417|DRUG|Tacrolimus|Given IV or PO
214902706|NCT02861417|DRUG|Thiotepa|Given IV
214902707|NCT06425549|DRUG|bimekizumab|Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.
214902708|NCT06425549|DRUG|ustekinumab|Study participants receive ustekinumab (USTE) administered as subcutaneous injection at pre-specified timepoints during the study.
214902709|NCT06425549|DRUG|placebo|Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.
214902710|NCT06485622|PROCEDURE|open bypass group|After heparinization, the target artery is clamped above and below the anastomosis. The target artery is dissected along the anterior wall, calcium portions or mural thrombus are removed. Graft (autologous or prosthetic graft) is cut obliquely and anastomosis suturing starts with distal angle. Next stage is tunnel creating for graft conduction.
214902711|NCT06485622|PROCEDURE|bare metal stent group|Bare metal stent implantation during the index procedure.
214902712|NCT06485622|PROCEDURE|plain old balloon angioplasty group|Only plain old balloon was used during the index procedure.
214902713|NCT06485622|PROCEDURE|drug-coated balloon group|Drug-coated balloon was used during the index procedure.
214902714|NCT06485622|PROCEDURE|directional atherectomy group|Directional atherectomy (with or without drug-coated balloon) during the index procedure.
214902715|NCT06485622|PROCEDURE|hybrid repair group|Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery. Arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological). Endovascular revascularization followed.
214902716|NCT04453436|DRUG|Tenofovir Disoproxil|Genotipic resistance test
214902717|NCT01108718|OTHER|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
214902718|NCT01108718|OTHER|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
214902719|NCT05095844|BIOLOGICAL|vaccinated|Pfizer-BioNTech COVID-19 Vaccine, Moderna or J\&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)
214902720|NCT02162056|DEVICE|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffolds for coronary artery disease.
214902721|NCT03360383|PROCEDURE|percutaneous vertebroplasty|Undertake Percutaneous vertebroplasty with polymethylmetacrylate bone cement.
214902722|NCT03360383|PROCEDURE|conservative treatment|complete on bed with prevention of complications
214902723|NCT02500095|OTHER|Fasting|72 hours of fasting
214902724|NCT02500095|DRUG|Saline|Concomitant saline during fasting
214902725|NCT02500095|DRUG|Pegvisomant|Concomitant Growth hormone receptor blockade with Pegvisomant during fasting
215055499|NCT03045588|OTHER|Combined exercise and diet intervention|Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
215055500|NCT02516397|DIETARY_SUPPLEMENT|Omnia|12weeks of treatment
215055501|NCT02516397|DIETARY_SUPPLEMENT|Placebo|12weeks of treatment
215055502|NCT04796558|OTHER|AVAS Classification|Validation of AVAS classification
215055503|NCT04211285|DIAGNOSTIC_TEST|e-GAB|android application for comprehensive geriatric assessment
215055504|NCT04211285|DIAGNOSTIC_TEST|standard physician performed CGA|CGA by an experienced geriatrician blinded to the result of e-GAB
215055505|NCT00579969|DRUG|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
215055506|NCT00579969|DRUG|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
215055507|NCT03117114|DEVICE|Endocuff Vision assisted polypectomy|EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy
215055508|NCT03117114|OTHER|Standard polypectomy|Absence of an EVD, standard polypectomy
215055509|NCT04826783|DEVICE|Lasers|The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
215055510|NCT04570878|PROCEDURE|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
215055511|NCT04570878|PROCEDURE|Control|No regional block is provided at the end of surgery.
215055512|NCT00004846|DRUG|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
215055513|NCT01127932|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
215055514|NCT01127932|BEHAVIORAL|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
215055515|NCT02209935|OTHER|Early Rehabilitation Protocol|
215055516|NCT02209935|OTHER|Usual care|
215055517|NCT00807183|OTHER|woodstove|installation of new EPA-certified woodstove
215055518|NCT00807183|OTHER|inactive air filter|air filter units without filter in place
215055519|NCT00807183|OTHER|Active air filter|air filter units correctly operating
214669664|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
215055520|NCT01458301|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
215055521|NCT01458301|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
215055522|NCT01458301|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
215055523|NCT01458301|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
215055524|NCT01458301|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
215055525|NCT06107543|DRUG|Nebulized Lidocaine|Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.
215055526|NCT06107543|DRUG|Iv Lidocaine|Intravenous %2 lidocaine was administered before induction of anesthesia.
215055527|NCT02589197|DEVICE|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
215055528|NCT02589197|DEVICE|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
215055529|NCT04679961|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
215055530|NCT05807399|DRUG|BTZ-043|BTZ-043 1,000mg once daily.
215055531|NCT05807399|DRUG|Rifampicin|Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.
215055532|NCT05807399|DRUG|Isoniazid|Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.
215055533|NCT05807399|DRUG|Pyrazinamide|Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.
215055534|NCT05807399|DRUG|Moxifloxacin|Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2:.
215055535|NCT03247582|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
215055536|NCT04388215|DRUG|CKD-828|orally, 1 tablet once a day for 8 weeks
215055537|NCT04388215|DRUG|CKD-828(placebo)|orally, 1 tablet once a day for 8 weeks
215055538|NCT04388215|DRUG|D326|orally, 1 tablet once a day for 8 weeks
215055539|NCT04388215|DRUG|D326(placebo)|orally, 1 tablet once a day for 8 weeks
215055540|NCT04388215|DRUG|D337|orally, 1 tablet once a day for 8 weeks
215055541|NCT04388215|DRUG|D337(placebo)|orally, 1 tablet once a day for 8 weeks
215055542|NCT04388215|DRUG|D013|orally, 1 tablet once a day for 8 weeks
215055543|NCT04388215|DRUG|D013(placebo)|orally, 1 tablet once a day for 8 weeks
215055544|NCT01802099|OTHER|Enteral nutrition|
214479163|NCT06818188|OTHER|Turning based specific training without rhythmic auditory stimulation (RAS)|"The control group underwent 6 weeks of turning-based specific training without rhythmic auditory stimulation (TBST), performed three times a week on alternate days. The training followed this pattern:~Week 1: Patients began with cone turning for 5 minutes, followed by 2 minutes of rest. Then, they walked with visual cues for 5 minutes, also without rhythmic auditory stimulation.~Weeks 2-3: The exercises continued with cone turning and figure-of-eight walking for 5 minutes each, with 2-minute rest periods in between. Patients also walked with visual cues for 5 minutes without RAS.~Weeks 4-5: The exercises included cone turning, figure-of-eight walking, walking with visual cues, and multidirectional stepping (forward, backward, laterally), all for 5 minutes each, with rest periods between exercises.~Week 6: In the final week, the duration of cone turning and figure-of-eight walking was reduced to 3 minutes, but the exercises still had 2-minute rest periods in between. Patients also p"
214902726|NCT03710408|OTHER|Intravenous hydration|"Participants assigned to the intravenous hydration arm will receive their hydration therapy through an intravenous access. This access will be achieved by inserting a BD VenflonTM Pro Safety - 22G in a vein in the dorsal side of the hand or further up the forearm. If the participants is suspected of becoming delirious and at risk of removing the cannula from the hand/forearm, it may be inserted at the dorsal side of the foot. The clinical staff judge this risk and decide site of placement.~Furthermore, a sham subcutaneous access device BD Saf-T-Intima™ Integrated Safety Catheter System will be placed on the abdomen without piercing the skin."
214902727|NCT03710408|OTHER|Subcutaneous hydration|"Participants assigned to the subcutaneous hydration arm will receive their hydration therapy through a subcutaneous access. This access will be achieved by placing a BD Saf-T-Intima™ Integrated Safety Catheter System on the abdomen or, alternatively if the participants is suspected of becoming delirious and at risk of removing the needle, it will be placed on the back at the scapular region.~Furthermore, a sham IV access device BD VenflonTM Pro Safety - 22G will be placed on the dorsal side of the hand without piercing the skin."
214902728|NCT00432926|BEHAVIORAL|EDGE counseling, no maintenance|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
214902729|NCT00432926|BEHAVIORAL|EDGE counseling, plus maintenance|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
214902730|NCT00432926|BEHAVIORAL|Attention control|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
214902731|NCT04535141|DRUG|Olanzapine 5 MG|It will be a de-identified pill created by investigational drug services at University of North Carolina
214902732|NCT04535141|DRUG|Placebo|It will be a de-identified pill created by investigational drug services at University of North Carolina
214902733|NCT01014546|DRUG|Arsenic Trioxide|Given PO
214902734|NCT01014546|DIETARY_SUPPLEMENT|Ascorbic Acid|Given PO
214902735|NCT01014546|OTHER|Laboratory Biomarker Analysis|Correlative studies
214902736|NCT01014546|OTHER|Pharmacological Study|Correlative studies
214902737|NCT06258538|DEVICE|Robots can aid in distal UE rehabilitation through exoskeleton (EXO)|Exoskeleton robot-assisted therapy Each EXO robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Hand of Hope (HOH) robotic hand system . HOH is an exoskeleton type of robot that is worn on the dorsal side of the impaired hand with 2 surface EMG sensors attached to the extensor digitorum and flexor digitorum superficialis.
215055545|NCT01802099|OTHER|Parenteral nutrition|
214479164|NCT06813599|OTHER|Neurodevelopmental Technique on Gait Pattern in Children With Spastic Diplegic Cerebral Palsy|"Each child of group A received a designed NDT program, attending three sessions per week for two consecutive months. The internationally recognized neurodevelopmental therapy (NDT) intervention will be used, consisting chiefly of three components:~1\. Exercise training: the therapist is goal-oriented and works with the child to make a family exercise plan. The plan is developed based on specific activities of the children in the family. The plan is designed step by step, and all tasks allow the child to reach a functional goal. Having set an exercise target, the child is able to achieve the goal as his/her exercise ability increases. Subsequently, the difficulty level of the task is increased or the environment altered, so the infant continues to face challenges to exercise ability. In the process of implementing the training plan, the therapist should pay attention to the degree of completion and quality of child movements, making corrections and offering guidance twice weekly."
214669665|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
214669666|NCT02509962|DIETARY_SUPPLEMENT|Slow sodium tablets|6 g sodium chloride per day over 14 days
215055546|NCT00131352|DEVICE|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
215055547|NCT00131352|OTHER|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
215055548|NCT04762082|DRUG|Tadalafil 10 MG|comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
215055549|NCT03110211|PROCEDURE|Physical Therapist Evaluation|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.
215055550|NCT03110211|PROCEDURE|Primary Care Physician|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
215055551|NCT04098653|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
215055552|NCT04098653|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
215055553|NCT04098653|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
215055554|NCT02872870|BEHAVIORAL|auditory lexical decision task|
215055555|NCT02872870|DEVICE|electroencephalogram|
215055556|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
214479165|NCT06813599|OTHER|Motor Planning Exercises on Gait Pattern in Children With Spastic Diplegic Cerebral Palsy|"Each child of group B will receive a designed motor planning program, attending three sessions per week for two consecutive months. Practicing skills will help children with poor motor planning ability become more confident. There are many things we can do to help children improve their motor planning. Using simple language, Thinking about all the different steps to complete a sequence of steps can be difficult for children with motor planning difficulties so we should keep language simple to help them better understand what they need to do to complete a task.~Breaking new skills down into smaller steps, Guiding the child through a task by providing one instruction at a time. This will help them to better follow instructions and reduce anxiety over learning a new skill. Starting with the simplest movement first, Practice the individual movements that make up a task, gradually increasing the degree of difficulty as your child gains confidence in the simpler movements."
215055557|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
215055558|NCT01530529|DRUG|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
215055559|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
215055560|NCT04859348|OTHER|routine physical therapy|G- A 36 participants received only routine treatment for GDM which includes insulin therapy and diet control guided by gynecologist and routine physical therapy which includes walk for 1 hr with proper warm up and cool down periods, three times in a week from 20-24 weeks of gestation to till delivery.
215055561|NCT04859348|OTHER|routine physical therapy and antenatal exercises|G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises for 3 days a week, for 2 weeks 6 sessions under the supervision of physiotherapist and remaining was performed at home. Exercise was started from 15 min and reach to 30 mins gradually.10-15-minute warm-up, cool-down period was included by using ACOG Guideline. Aerobic exercise includes a brisk walk and strengthening exercise were performed with hold for 5 seconds and 10 repetitions. Exercise should stop if they experience any signs of dizziness, dyspnea, amniotic fluid leaking or vaginal bleeding. Confidentiality and blindness ensure by random allocation.
215055562|NCT03138551|BEHAVIORAL|Mealtime PREP (Promoting Routines of Exploration and Play)|
215055563|NCT06156878|COMBINATION_PRODUCT|Anti-EGFR and PD-1 inhibitor arm|Drug: PD-1 inhibitor and anti-EGFR monoclonal antibody The patients will receive radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week). The specific treatment description is included in arm description.
214479166|NCT06817798|OTHER|Specific foot mobility|Specific mobility of the foot, performed bilaterally.
215055564|NCT04073511|DRUG|Eungyosan|This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
215055565|NCT04073511|DRUG|Samsoeum|This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
214479167|NCT03818178|DIETARY_SUPPLEMENT|Intralipid|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
214902738|NCT06258538|DEVICE|End-effector robot-assisted therapy (EE)|Each EE robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Amadeo robotic system. Amadeo is an end-effector robot with 5 finger slides, which are attached to the fingertips and the thumb via magnetic finger pads. The integrated sensor for each finger allows the robot system to provide patients with real-time visual feedback of finger strengths and range of motion
214902739|NCT06258538|BEHAVIORAL|Unilateral task-oriented therapy|The therapy will focus on task-oriented therapy with the affected UE and the training tasks involve proximal or distal UE movement, such as ringing a bell, picking up coins, grasping and releasing various cups, and other functional movements involved in daily activities. The level of challenge will be adapted according to patient ability and improvement during training.
214902740|NCT06258538|BEHAVIORAL|Bilateral task-oriented therapy|The functional training tasks emphasize UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously, such as opening 2 closet doors, grasping and releasing 2 towels, wiping the table with 2 hands, and so on. The activities can also be graded in terms of difficulty and task requirements, according to the impairment level and the progression of the UE of each participant.
214902741|NCT00063726|DRUG|bortezomib|
215055566|NCT04073511|DRUG|Placebo|It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
215055567|NCT03653806|OTHER|computerized algorithm for automated analysis|"First: to develop a computerized algorithm for automated analysis of the electrical impedance tomography (EIT) data. The algorithm calculates the optimal positive end-expiratory pressure (PEEP) and inspiratory pressure defined as the optimal balance between stretch, ventilation distribution and collapse.~Second: to compare the results of the algorithm with the current standard of care clinical judgement of experienced EIT users"
215055568|NCT03183752|DRUG|Metformin|500 mg metformin three times daily
215055569|NCT03183752|DRUG|Placebo|500 mg placebo three times daily
215055570|NCT05536882|DRUG|Benzoyl peroxide|See arm description
215055571|NCT05536882|DRUG|Adapalene Gel|See arm description
215055572|NCT04583124|OTHER|ATENTO-B|Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.
214902742|NCT02847949|BIOLOGICAL|IGN002|IGN002 is a monoclonal antibody fusion protein
215055573|NCT04583124|OTHER|ATENTO-T|Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
214902743|NCT01861743|OTHER|Multimodal Analgesia|Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.
214902744|NCT01861743|OTHER|Patient controlled analgesia|Subjects will be treated with patient controlled narcotic analgesia for pain management.
214902745|NCT03691519|DRUG|Omega-3 treatment|"Patient in the treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day)."
214902746|NCT03691519|DIETARY_SUPPLEMENT|Placebo|"The appearance and taste of the placebo will be similar to those of the active ingredient. Placebo capsules contained a 1:1 ratio of corn oil and soy oil.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment. Active treatment consists of 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day).~For the 18 months placebo-controlled period (n=200/arm): 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day) or placebo (3 similar pills /day)."
214902747|NCT04468425|DRUG|Tofacitinib Citrate|Period 1: Xelijanz® 5 mg tablet (tofacitinib citrate) for single oral dosing. Period 2: Tofacitinib Citrate Topical Gel 3.2% for repeat topical dosing BID for 14 days.
214902748|NCT00586703|DEVICE|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
214902749|NCT04146441|COMBINATION_PRODUCT|SonoVue|1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only
214902750|NCT04146441|DRUG|Chemotherapy|FOLFIRINOX Regime according to Norwegian national guidelines
214902751|NCT05526677|DEVICE|x-guide dynamic navigation system|One implant placement is assisted with x-guide dynamic navigation system. The other implant placement is assisted with static surgical guide
214902752|NCT04851977|BIOLOGICAL|Respiratory Syncytial Vaccine|BARS13 low dose (one dose of 10 μg rRSV-G protein/10 μg CsA by IM injection to the deltoid region of one arm, and one dose of placebo \[saline/mannitol\] by IM injection to the deltoid region of the other arm, given sequentially).
214902753|NCT04851977|BIOLOGICAL|Respiratory Syncytial Vaccine|BARS13 high dose (IM injection of 10 μg rRSV-G protein/10 μg CsA administered to the deltoid region of each arm \[one injection of 10 μg rRSV-G protein/10 μg CsA per arm\], given sequentially). The high dose is twice the strength of the low dose.
214902754|NCT04851977|BIOLOGICAL|Placebo|Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm \[one injection per arm\], given sequentially).
214902755|NCT01860365|OTHER|Complementary medicine consultation and treatment|Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.
215055574|NCT03190499|OTHER|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
215055575|NCT02439307|DRUG|Rifaximin|1200 mg of rifaximin for 2 weeks.
214902756|NCT01860365|OTHER|Patients receiving conventional supportive care|Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
214902757|NCT02452944|DEVICE|nerve stimulator (stimuplex HNS12)|whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
215055576|NCT02439307|DRUG|Placebo|Placebo for 2 weeks
214902758|NCT02452944|DEVICE|ultrasound|we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
215055577|NCT05740631|DRUG|Ocaliva|Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
215055578|NCT05740631|DRUG|Placebo|Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
215055579|NCT01166789|DRUG|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
215055580|NCT01166789|DRUG|Placebo|2 capsules daily, taken in morning and evening
215055581|NCT01194219|DRUG|Apremilast|
215055582|NCT01194219|DRUG|Placebo|Identical matching placebo
215055583|NCT01194219|DRUG|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
215055584|NCT03743545|OTHER|low speed drilling without irrigation|comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
215055585|NCT01039324|OTHER|Reports|Primary care event reports and patient letters
215055586|NCT01039324|OTHER|Reports and Notices|Primary care event reports, patient letters and care manager notices
215055587|NCT01039324|OTHER|Usual care|This is the study's control group
215055588|NCT00781443|DRUG|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
215055589|NCT00781443|DRUG|placebo|Repeating subcutaneous injection
214902759|NCT01805089|DRUG|Melatonin 3 mg|Melatonin vs. Placebo
215055590|NCT05523830|OTHER|No Intervention|No intervention
215055591|NCT03576014|BIOLOGICAL|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2\~4 weeks after the transplant.
214902760|NCT03762265|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
214902761|NCT03762265|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
214902762|NCT00197782|BIOLOGICAL|Hib conjugate vaccine|
214902763|NCT04423991|DEVICE|COViage|Machine learning intervention
214902764|NCT00688350|BEHAVIORAL|Behavioral feedback|The medication adherence intervention consists of five components: medication feedback, hypertension feedback, medication-taking skills, habit adjustment, and succinct medication and disease information delivered over an 8-week period.
214902765|NCT00806403|DRUG|reteplase 10+10 U|comparison to primary PCI
214902766|NCT00806403|PROCEDURE|primary PCI|comparison to thrombolysis
214902767|NCT01882985|DRUG|Docetaxel|Given IV
214902768|NCT01882985|DIETARY_SUPPLEMENT|Lycopene|Given PO
214902769|NCT06337149|OTHER|neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)|neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)
214902770|NCT00765102|DRUG|Bortezomib|"Bortezomib was administered at a dose of 1.0 mg/m\^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
214902771|NCT00765102|DRUG|Romidepsin|Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.
214902772|NCT02857816|DEVICE|NURO System PTNM Therapy|
215055592|NCT04886102|OTHER|An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital|Research protocol involving the human person (Category 3 - Non-interventional research\_ not related to a health product) Serology, molecular biology, phylogenetic and phylodynamic analyzes of hepatitis B and D
214902773|NCT05220852|COMBINATION_PRODUCT|Dry needling with exercise|"At the initial session, dry needling will be given to their upper trapezius muscles' hyperactive trigger sites, and EX will continue for a minimum of three times per week.~1. Cranio-cervical spine flexion is the exercise.~2. Extension of the cranio-cervical spine Exercice 3 Shoulder Elevation 4-Retraining of the scapular muscles Every exercise should be done for 30 se"
214902774|NCT05220852|OTHER|Exercise|"patients in this group are going to have onley neck exercise for 2 weeks minimum 3 times a week.~1. Cranio-cervical spine flexion is the exercise.~2. Extension of the cranio-cervical spine Exercice 3 Shoulder Elevation 4-Retraining of the scapular muscles Every exercise should be done for 30 se"
214902775|NCT01155856|OTHER|Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital|For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
214902776|NCT05669625|BIOLOGICAL|Investigational live attenuated varicella vaccine|0.5 ml/vial
214902777|NCT05669625|BIOLOGICAL|Placebo of live attenuated varicella vaccine|0.5 ml/vial
214902778|NCT06345859|BEHAVIORAL|Heart rate variability biofeedback|This is a Phase 2 parallel intervention design with random assignment. We will randomly assign participants to one of two biofeedback conditions. Both conditions involve completing breathing exercises at home, 30 minutes per day for 10 days, while receiving continuous feedback about parasympathetic activity from the computer.
214902779|NCT02940756|DRUG|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
214902780|NCT02940756|DRUG|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to \<15 kg, two tablets twice daily for those weighing 15 to \<25 kg and three tablets twice daily for those weighing 25 to \< 35 kg, for three days."
214479168|NCT03818178|DIETARY_SUPPLEMENT|Palm Oil Emulsion|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
215055593|NCT02413944|PROCEDURE|ACTH stimulation test|ACTH stimulation test
214669667|NCT01609283|BIOLOGICAL|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~* Group 1: single intrathecal dose of 1 x 107 cells~* Group 2: single intrathecal dose of 5 x 107 cells~* Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~* Group 4: single intrathecal dose of 1 x 108 cells~* Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
214902781|NCT02940756|DRUG|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to \<7 kg, one tablet once daily for those weighing 7 to \<13 kg, and two tablets once daily for those weighing 13 to \<24 kg, for three days.
214902782|NCT06471049|PROCEDURE|Benign Hysterectomy|removal of the uterus
215055594|NCT03377816|BEHAVIORAL|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
215055595|NCT03377816|BEHAVIORAL|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
215055596|NCT02003976|PROCEDURE|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
214669668|NCT00862602|BEHAVIORAL|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet \& nutrition and prevention.
214902783|NCT00053716|DRUG|Liprostin [liposomal Prostaglandin E1]|
214902784|NCT05636696|BEHAVIORAL|Samen Minder Moe (Dutch intervention name)|'Samen Minder Moe' is a mindfulness-based cognitive behavioral therapy for cancer-related fatigue directed at couples.
214902785|NCT00602251|DRUG|Terbinafine|
215055597|NCT02003976|OTHER|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
215055598|NCT05386342|DEVICE|TufTex Over-the-Wire Embolectomy Catheter|The OTW Catheter can be used for the removal of emboli and thrombi. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
214669669|NCT00322114|DIETARY_SUPPLEMENT|lycopene|Given orally
214669670|NCT00322114|OTHER|placebo|Given orally
214669671|NCT00396578|DRUG|aerosolized vancomycin or gentamicin|
214902786|NCT03399045|PROCEDURE|9-minute withdrawal|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw
214902787|NCT03399045|PROCEDURE|6-minute withdrawal|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
214902788|NCT01932333|DRUG|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
214902789|NCT01932333|DRUG|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
214479169|NCT03818178|OTHER|Saline|All participants will serve as their own controls with a saline infusion study day.
214669672|NCT02039154|BEHAVIORAL|Aerobic and strength training group|A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
214669673|NCT02039154|BEHAVIORAL|Balance and flexibility group|For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
214902790|NCT01932333|DRUG|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
215055599|NCT03666520|OTHER|Clinical Decision Support prompted to the clinician to convert drug.|This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.
214902791|NCT02547012|DRUG|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
214902792|NCT02547012|DRUG|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
214902793|NCT06258928|DIAGNOSTIC_TEST|Functional examination|Compared to nonoperated limb, after 6 months of early rehabilitation.
214902794|NCT06194838|DEVICE|Ossur Power Knee|Newest version of the commercially-available powered knee developed by Ossur.
215055600|NCT00292045|BIOLOGICAL|NY-ESO-1 protein/CpG 7909|Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).
214902795|NCT06194838|DEVICE|Reboocon Intuy Knee|Commercially-available powered knee developed by Reboocon.
214902796|NCT03929523|DEVICE|End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)|"In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the back-table phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified)."
214902797|NCT03929523|DEVICE|classic static cold storage|The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation
214902798|NCT03502733|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
215055601|NCT00758940|DEVICE|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
215055602|NCT06302803|BEHAVIORAL|Intermittent fasting plus time-restricted eating|Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.
215055603|NCT06302803|BEHAVIORAL|Calorie restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
215055604|NCT05371834|DEVICE|Microwave Treatment (Swift System)|"Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise."
215055605|NCT05371834|DEVICE|Cryotherapy|Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
215055606|NCT04295837|OTHER|ABLE|Home-based occupational therapy compensatory programme addressing activities of daily living
214669674|NCT03633331|DRUG|Palbociclib|Given PO
214669675|NCT03633331|DRUG|Letrozole|Given PO
214669676|NCT03633331|DRUG|Fulvestrant|Given IM
214669677|NCT03633331|OTHER|Questionnaire Administration|Ancillary studies
215055607|NCT04295837|OTHER|Usual Care|Standard occupational therapy
215055608|NCT04474197|DRUG|VX-864|Tablets for oral administration.
215055609|NCT04474197|DRUG|Placebo|Placebo matched to VX-864 for oral administration.
214669678|NCT03633331|OTHER|Quality-of-Life Assessment|Ancillary studies
214669679|NCT04935944|RADIATION|CBCT radiation|CBCT scanning
214902799|NCT03502733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214902800|NCT03502733|PROCEDURE|Computed Tomography|Undergo CT scan
214902801|NCT03502733|DRUG|Copanlisib|Given IV
214902802|NCT03502733|PROCEDURE|Echocardiography Test|Undergo ECHO
214902803|NCT03502733|BIOLOGICAL|Ipilimumab|Given IV
215055610|NCT04482972|PROCEDURE|DCB|Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.
215055611|NCT04482972|PROCEDURE|DES|Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
215055612|NCT04281420|DRUG|ATG-019|ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
215055613|NCT04281420|COMBINATION_PRODUCT|ATG-019 + Niacin ER|ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
215055614|NCT05655533|DIAGNOSTIC_TEST|Magnetic resonance Imaging scanners of sacroiliac joints.|"Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not"
215055615|NCT05231850|DRUG|Tislelizumab|All eligible patients receive received 200 mg Tislelizumab intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
214301985|NCT04989400|DRUG|Misoprostol|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
214301986|NCT00384722|DEVICE|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
214301987|NCT05966168|DEVICE|Medtronic Micra AV Device|Participants will already be planned to have a Micra AV 2.0 device implanted. Participants will then undergo treadmill exercise testing and wear a Holter monitor to determine the effectiveness of the Micra AV 2.0 device during exercise or elevated heart rates.
214301988|NCT04123288|DRUG|ACT-709478|1 film-coated minitablet contains 2 mg of ACT-709478
214301989|NCT04123288|DRUG|ACT-709478|1 hard capsule contains 10 mg of ACT-709478.
214301990|NCT01166178|DRUG|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
214301991|NCT01166178|DRUG|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
214301992|NCT01166178|DIETARY_SUPPLEMENT|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
214301993|NCT03797833|PROCEDURE|Spinal Anaesthesia|Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
214301994|NCT01967251|DRUG|Udenafil|Udenafil tablets
214902804|NCT03502733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214902805|NCT03502733|BIOLOGICAL|Nivolumab|Given IV
214902806|NCT02816632|OTHER|mRI|Neural bases of feedbacks' influence on decision making processes
214902807|NCT02816632|OTHER|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
214902808|NCT05292001|DRUG|Iron-Dextran Complex Injection [InFed]|single 1000mg dose
214902809|NCT05292001|OTHER|Saline Placebo|Normal saline
214902810|NCT07135115|BEHAVIORAL|Digikost report baseline only|The Digikost report will be made available for the participant immediately after completing of the Digikost questionnaire at baseline.
214902811|NCT07135115|BEHAVIORAL|Digikost report intensive with individual counselling and webinars|The Digikost report will be made available for the participant each time after completion of the Digikost questionnaire every 6 months. Additionally, the participant is offered an individual lifestyle counselling meeting by telephone at baseline and invited to inspirational webinars on cancer preventive lifestyle every 6 months.
214902812|NCT07135115|BEHAVIORAL|Digikost report intensive|The Digikost report will be made available for the participant each time after completion of the Digikost questionnaire every 6 months.
214902813|NCT05881863|OTHER|No intervention|This is an observational study
214902814|NCT06267469|DEVICE|Thermoplastic orthosis|The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.
214902815|NCT06979505|DRUG|GV101|GV101 suspension
214902816|NCT06979505|DRUG|GV101 placebo|GV101 placebo suspension
214902817|NCT03155620|PROCEDURE|Biopsy Procedure|Undergo biopsy
214902818|NCT03155620|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214902819|NCT03155620|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow and/or biopsy
214902820|NCT03155620|PROCEDURE|Bone Scan|Undergo a bone scan
214301995|NCT01967251|DRUG|Placebo|Udenafil placebo-matching tablets
214902821|NCT03155620|PROCEDURE|Computed Tomography|Undergo CT, PET/Ct, and/or CT/MRI
214902822|NCT03155620|DRUG|Ensartinib|Given PO
214902823|NCT03155620|DRUG|Erdafitinib|Given PO
214902824|NCT03155620|OTHER|Laboratory Biomarker Analysis|Undergo molecular analysis
214902825|NCT03155620|DRUG|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
214902826|NCT03155620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
214902827|NCT03155620|PROCEDURE|Mutation Carrier Screening|Undergo tumor tissue mutation screening
214902828|NCT03155620|DRUG|Olaparib|Given PO
214902829|NCT03155620|DRUG|Palbociclib|Given PO
214902830|NCT03155620|OTHER|Pharmacological Study|Correlative studies
214902831|NCT03155620|PROCEDURE|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
214902832|NCT03155620|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
214902833|NCT03155620|DRUG|Samotolisib|Given PO
214301996|NCT01730755|DRUG|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
214301997|NCT01178593|OTHER|Gut-focused hypnotherapy in group sessions|weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
214902834|NCT03155620|DRUG|Selpercatinib|Given PO
214902835|NCT03155620|DRUG|Selumetinib Sulfate|Given PO
214902836|NCT03155620|DRUG|Tazemetostat|Given PO
214902837|NCT03155620|DRUG|Tipifarnib|Given PO or via nasogastric or gastric tube
214902838|NCT03155620|DRUG|Ulixertinib|Receive PO
214902839|NCT03155620|DRUG|Vemurafenib|Given PO
214902840|NCT03155620|PROCEDURE|X-Ray Imaging|Undergo an x-ray
214902841|NCT06692192|DRUG|Psilocybin|25mg of psilocybin
214902842|NCT06692192|DRUG|Psilocybin|1mg of psilocybin
214902843|NCT06692192|DRUG|Midazolam|The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.
214301998|NCT00471848|DRUG|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
215055616|NCT04396548|DRUG|Midodrine Oral Product|Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.
215055617|NCT04396548|DRUG|Inert tablet containing sugar (placebo)|: Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
215055618|NCT02334020|OTHER|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
215055619|NCT02147210|OTHER|biological analysis|
214301999|NCT00264355|DRUG|cyclosporine A|
214669680|NCT02090543|DRUG|Phenprocoumon (Marcumar)|common use, no requirements (real life situation)
214669681|NCT02090543|DRUG|Rivaroxaban (Xarelto, BAY-59 7939)|common use, no requirements (real life situation)
214902844|NCT06692192|DRUG|Saline|Saline will be administered as a placebo for midazolam
214902845|NCT06984328|BIOLOGICAL|Acasunlimab|Intravenous (IV) infusion
214902846|NCT06984328|BIOLOGICAL|Pembrolizumab|IV infusion
214902847|NCT05211882|OTHER|Immediate ENABLE nurse coaching, on top of usual care|Participants in the intervention arm will start on the ENABLE program at point of randomization
214902848|NCT05211882|OTHER|Usual Care|Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
214902849|NCT06980038|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
214902850|NCT06980038|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214902851|NCT06980038|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214902852|NCT06980038|BIOLOGICAL|Cemiplimab|Given IV
214902853|NCT06980038|PROCEDURE|Computed Tomography|Undergo CT scan
214902854|NCT06980038|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214902855|NCT06980038|PROCEDURE|Tumor Resection|Undergo resection surgery
214902856|NCT02092870|DRUG|Adipose derived stem cells|ASCs harvested from autologous lipoaspirate
214902857|NCT01787292|BEHAVIORAL|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
214902858|NCT01787292|BEHAVIORAL|Aerobic Exercise Intervention|Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
214902859|NCT01787292|BEHAVIORAL|Self Monitoring|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
214902860|NCT01827111|DRUG|ABI-007|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
214902861|NCT01827111|DRUG|Ipilimumab|3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
214902862|NCT01827111|BEHAVIORAL|Phone Call|Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
214902863|NCT03016884|BIOLOGICAL|Zostavax vaccine|After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
214902864|NCT06595563|DRUG|Trastuzumab emtansine|T-DM1 will be administered IV at a dose of 3.6 mg/kg every 3 weeks. (21 days +/- 3 days) until disease progression, unacceptable toxicity or request of the subject to withdraw from the study. The total dose will depend on the subject's weight on day 1 of each T-DM1 cycle.
214902865|NCT06609096|BEHAVIORAL|Sexual counseling based on the PLISSIT model|Four sessions of sexual counseling based on the PLISSIT model will be provided. The intervention consisted of four consecutive sessions, with one session per week. Each session is 30 minutes on average.
214902866|NCT06609096|BEHAVIORAL|Sexual counseling based on the BETTER model|A total of four sessions of sexual counseling based on the BETTER model will be provided. The intervention consists of four consecutive sessions, one session per week. Each session is 30 minutes on average.
214902867|NCT05541016|PROCEDURE|Biospecimen Collection|Undergo blood and saliva specimen collection for NavDx testing
214902868|NCT05541016|DRUG|Cisplatin|Given IV
214902869|NCT05541016|PROCEDURE|Computed Tomography|Undergo CT scan
214902870|NCT05541016|RADIATION|Diffusing Alpha-emitter Radiation Therapy|Undergo DART
214902871|NCT05541016|DRUG|Docetaxel|Given IV
214902872|NCT05541016|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
214902873|NCT05541016|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214902874|NCT05541016|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214902875|NCT05541016|PROCEDURE|Modified Barium Swallow Study|Undergo MBSS
214902876|NCT05541016|OTHER|Observation|Undergo observation
214902877|NCT05541016|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214902878|NCT05541016|OTHER|Quality-of-Life Assessment|Ancillary studies
214902879|NCT05541016|OTHER|Questionnaire|Ancillary studies
214902880|NCT06661720|BIOLOGICAL|Pembrolizumab|Given intravenously
214902881|NCT06661720|DRUG|Tivozanib|Given orally
214902882|NCT06661720|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214902883|NCT06661720|PROCEDURE|MRI|Undergo MRI
214902884|NCT06661720|PROCEDURE|Computed Tomography|Undergo CT scan
214902885|NCT06661720|PROCEDURE|Biopsy|Undergo biopsy
214902886|NCT06661720|OTHER|Questionnaire Administration|Ancillary studies
214902887|NCT06858319|DRUG|zigakibart|solution for subcutaneous injection
215055620|NCT03169868|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
215055621|NCT05503979|DRUG|Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]|1 tab every 24 hrs for 12 weeks
215055622|NCT02289196|DRUG|Vx-006: 0,5mg|
215055623|NCT02289196|DRUG|Vx-006: 1mg|
215055624|NCT02289196|DRUG|Vx-006: 5mg|
214302000|NCT03515772|DRUG|Co-administration of darunavir with a cardiovascular drug|Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
215055625|NCT02289196|DRUG|Vx-006: 10mg|
214902888|NCT06986434|GENETIC|CAR19BCMA-T cells|"CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 1×10\^6 /kg, the medium dose is 2×10\^6 /kg, and the high dose is 3×10\^6 /kg."
214302001|NCT01536314|DRUG|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
214902889|NCT06986434|DRUG|fludarabine and cyclophosphamide|"Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells.~Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells."
214902890|NCT06984094|BIOLOGICAL|SCB-1019T|SCB-1019T (bivalent recombinant RSV vaccine candidate) consists of two recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)) and RSV B strain (SCB-1019T(B)).
214902891|NCT06984094|BIOLOGICAL|SCB-1022|SCB-1022 (combination recombinant RSV-hMPV vaccine candidate) consists of three recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), and hMPV (SCB-1021).
214902892|NCT06984094|BIOLOGICAL|SCB-1033|SCB-1033 (combination recombinant RSV-hMPV-PIV3 vaccine candidate) consists of four recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), hMPV (SCB-1021) and PIV3 (SCB-1020).
214902893|NCT06860178|OTHER|Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months|in the intenvention arm, the children will get the vaccine R21 Matrix M together with the CPS
214902894|NCT06990321|DRUG|Intermediate-dose Cytarabine in Combination with Venetoclax|Elderly patients with Middle- and High-risk Acute Myeloid Leukemia who received the Intermediate-dose Cytarabine in Combination with Venetoclax at the First Hospital of Jilin University from March 1, 2024 to December 31, 2026.
214902895|NCT04252651|OTHER|Blood Draw|This study will involve blood draws to test for specific cytokines
214902896|NCT02641093|DRUG|Pembrolizumab|Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
215055626|NCT02443337|DRUG|LY3023414|Administered orally
215055627|NCT02443337|DRUG|Necitumumab|Administered IV
215055628|NCT00659386|DRUG|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
215055629|NCT04169529|DEVICE|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
215055630|NCT00635349|DRUG|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
214669682|NCT01715025|DRUG|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
214669683|NCT05572099|DIAGNOSTIC_TEST|ExoDx Prostate|Observational only.
214902897|NCT02641093|PROCEDURE|Surgery|gross total surgical resection
214902898|NCT02641093|RADIATION|Radiation Therapy|60-66 Gy over 6 weeks
215055631|NCT00635349|DRUG|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
215055632|NCT00635349|DRUG|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
215055633|NCT02011230|OTHER|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
215055634|NCT00533728|DRUG|Soluble beta-glucan (SBG)|
215055635|NCT01564823|DRUG|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
215055636|NCT01564823|DRUG|Metronidazole|Metronidazole 250 mg/8h 3 months
215055637|NCT01564823|DRUG|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
215055638|NCT01564823|DRUG|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
215055639|NCT01017042|DRUG|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
215055640|NCT04345900|DRUG|Plinabulin|a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
215055641|NCT04345900|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
215055642|NCT00162591|DRUG|remifentanyl|
215055643|NCT00276055|DRUG|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
214669684|NCT01009294|DRUG|Ataluren|Oral powder
214669685|NCT01009294|DRUG|Chronic Corticosteroid Therapy|Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
214669686|NCT00228371|DEVICE|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
214669687|NCT03469310|DRUG|Acetaminophen 500Mg Cap|non-narcotic medication first with narcotic as second choice
214669688|NCT03469310|DRUG|Tylenol #3 Oral Tablet|Narcotic medication first
214669689|NCT03469310|DRUG|Tramadol|non-narcotic medication first with narcotic as second choice
214902899|NCT02641093|DRUG|Cisplatin|Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
214902900|NCT04805905|OTHER|FACE-Q patient reported outcome|"As both interventions of treatment are gold standards and clinical equipoise exists if one intervention is superior to the other, there is no true control group. However, for the purpose of the application, the local flap group will be chosen as the control group.~Skin graft (Experimental): Participants in the experimental group will receive a skin graft and receive the FACE-Q skin cancer questionnaire pre- and post-treatment. There will also be photos taken of the patient's face along with the distributed questionnaires.~Local flap (Control): Participants in the experimental group will receive a local flap and receive the FACE-Q questionnaire pre- and post-treatment."
214902901|NCT06576973|DRUG|Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib|Adbelimumab 1200mg Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Apatinib 250mg Po Day 2-4. Preoperative neoadjuvant therapy for 4 cycles, one cycle every 21 days.
215055644|NCT01059045|PROCEDURE|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
215055645|NCT01059045|OTHER|Control|No intervention
214902902|NCT06576973|PROCEDURE|Esophagectomy|Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive IvorLewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy. The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon.
214902903|NCT06576973|OTHER|Collecting samples from participant|Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use. 20 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery. Tumour sample will be collected before neoadjuvant therapy and after surgery.
214902904|NCT00659191|DRUG|GSK1265744|
214902905|NCT02962648|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion."
214902906|NCT05708248|DRUG|pentoxifylline|400 mg pentoxifylline tablets twice daily with meals for 6 months
215055646|NCT04193449|DIAGNOSTIC_TEST|colonoscopy|colonoscopy procedure
215055647|NCT04148066|DIAGNOSTIC_TEST|ctDNA blood sample|every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
215055648|NCT03823586|DIAGNOSTIC_TEST|Questionnaire AQUA©, pediatric version|A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
215055649|NCT02838043|DIETARY_SUPPLEMENT|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
215055650|NCT03951766|BEHAVIORAL|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
215055651|NCT04198883|COMBINATION_PRODUCT|Protheracytes|Intramyocardiac (LV) injection of stem cells with a dedicated catheter
215055652|NCT02328521|DRUG|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
215055653|NCT02328521|DRUG|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
215055654|NCT00283543|DRUG|Gliadel Wafer|
215055655|NCT00283543|DRUG|Temozolomide|
215055656|NCT00283543|PROCEDURE|Limited field radiation|
215055657|NCT01288625|DRUG|Amifostine|500 mg sc, qod, 3 times per week
215055658|NCT01288625|RADIATION|Amifostine|500mg rinsing wash, qod, 3 times per week
214902907|NCT02852174|BEHAVIORAL|Mindfulness meditation training|Mindfulness meditation training
214902908|NCT02702830|OTHER|Cardiopulmonary Exercise Testing|Undergo CPET
214902909|NCT02702830|DEVICE|Magnetic Resonance Imaging|Undergo MRI
214902910|NCT06223672|OTHER|Walnuts|56g of walnuts consumed each day for 7 days
214902911|NCT06223672|OTHER|Simply White Diary-free chocolate bar|68g of the white chocolate style-bar each day for 7 days
214902912|NCT04576156|DRUG|Imetelstat|Imetelstat sodium will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.
214902913|NCT04576156|DRUG|Best Available Therapy (BAT)|Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.
214902914|NCT06596434|DRUG|Drug: 4-Aminopyridine|Active study drug
214902915|NCT06596434|OTHER|Placebo|Placebo comparator
215055659|NCT03819257|DIAGNOSTIC_TEST|Endoanal ultrasound|For the assessment of the internal and external anal sphincter integrity. To evaluate fistulas/perianal abscess and seton placement.
215055660|NCT03819257|DIAGNOSTIC_TEST|High-resolution anorectal manometry|"1. rest - basal anal pressures at rest over 60 s~2. squeeze - anal pressure during voluntary effort; long squeeze - anal pressure during sustained voluntary effort~3. cough - anorectal pressure changes during cough~4. push - anorectal pressure changes during simulated defecation~5. rectoanal inhibitory reflex - reflex anal response to rectal distension~6. rectal sensation - assessment of rectal sensitivity to distension."
215055661|NCT03819257|DIAGNOSTIC_TEST|Balloon expulsion test|A non-latex balloon will be inserted in the rectum after applying lubricating gel. This balloon is then filled with 50ml of warm water. The patient is ask to sit on a commode and to try to expel the device in privacy, while the time is being recorded. The test ends when the patient expelled the balloon or when 3 minutes are reach.
215055662|NCT00514930|DEVICE|Hexablate|
215055663|NCT05350540|OTHER|ICG dye|Patients assigned to the intervention group will undergo surgery guided by tissue perfusion as directed by the ICG imaging
215055664|NCT01757301|OTHER|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
215055665|NCT01757301|OTHER|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
215055666|NCT06393777|DIETARY_SUPPLEMENT|honey|analgesic effect of honey
214902916|NCT06989645|DRUG|SYN321|Intra-articular
214902917|NCT06989645|DRUG|Placebo|Intra-articular
214902918|NCT06989853|DRUG|Placebo|The effects of placebo will be determined.
214302002|NCT01536314|DRUG|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
214302003|NCT03424174|DEVICE|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
214902919|NCT06989853|DRUG|Methamphetamine|Placebo and methamphetamine will be administered intravenously during experimental sessions.
214902920|NCT01597778|BIOLOGICAL|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
215055667|NCT04830943|DRUG|Cerebrolysin|Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
215055668|NCT03467256|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|anti-CD19 chimeric antigen receptor - transduced T-cell given IV
215055669|NCT03467256|DRUG|Fludarabine|given IV
214302004|NCT03424174|DEVICE|Standard Total Knee Arthroplasty|Implantation StandardTotal Knee Arthroplasty
214302005|NCT03160742|DEVICE|Mespere VENUS 200CVP system|Non-invasive sensor placed on the neck
214302006|NCT03036761|PROCEDURE|Auriculotherapy|3 sessions of auriculotherapy at one month intervals.
214302007|NCT01556581|PROCEDURE|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
214907475|NCT04831411|PROCEDURE|Total Knee Arthroplasty|The extremities of patients admitted to the operating room to be applied TKA will be determined using a safe surgical Fast-Track recovery protocol. Patients will be operated by the same surgical team using the same technique. Spinal anaesthesia or general anaesthesia will be applied to the patients according to the evaluations of the anesthesiologists.
214907476|NCT04831411|OTHER|Whole Body Vibration|Whole Body Vibration
214907477|NCT04831411|OTHER|Progressive Resistance Training|Progressive Resistance Training
214907478|NCT05177484|DRUG|oral ferric maltol|The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.
214907479|NCT04446013|OTHER|Optic Nerve Sheath Diameter Measurement|The change in intracranial pressure via optic nerve sheath diameter measurement
214907480|NCT04947384|DIAGNOSTIC_TEST|To discern micro-RNA specific for right and left heart induced PH|While undergoing other procedures, the investigators will be collecting a total of three blood samples. The first sample will be obtained on arterial cannulation before the initiation of the intervention, the second sample will be collected upon the end of the procedure prior to leaving the procedure room, and the third sample will be collected on the day of discharge from the hospital.
214907481|NCT03426124|DEVICE|EkoSonic Endovascular System with thrombolytic|The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.
214907482|NCT03132935|PROCEDURE|Telemedical support|Telemedical support by a physician in a telemedicine centre
214907483|NCT01129440|DEVICE|Fluoride Varnish|Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
215055670|NCT03467256|DRUG|Cyclophosphamide|given IV
215055671|NCT03467256|DRUG|Tocilizumab|given IV
215055672|NCT03467256|DRUG|Cytarabine|given IV
215055673|NCT03467256|DRUG|Etoposide|given IV
215055674|NCT03467256|DRUG|Dexamethasone|given IV
215055675|NCT00700908|BEHAVIORAL|automated telephone intervention vs. usual care|
215055676|NCT03606486|OTHER|Biospecimen Collection|Undergo collection of tumor sample and blood draw
215055677|NCT03606486|OTHER|Laboratory Biomarker Analysis|Correlative studies
215055678|NCT03606486|DEVICE|Lavage|Undergo uterine lavage
215055679|NCT03606486|OTHER|Pap Smear|Undergo pap smear
215055680|NCT00903422|DRUG|eltrombopag olamine|thrombopoietin receptor agonist
215055681|NCT00903422|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
215055682|NCT01266226|DEVICE|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
215055683|NCT01266226|DEVICE|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
215055684|NCT03806530|DRUG|Gabapentin|100 mg capsule
215055685|NCT03806530|DRUG|Ropinirole|0.50 mg capsule
214302008|NCT01556581|PROCEDURE|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
214302009|NCT03319355|BEHAVIORAL|cognitive behavioral therapy|exercise therapy
214302010|NCT04424017|BIOLOGICAL|Specific anti-SARS-CoV-2 antibodies|"A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA)."
214902921|NCT01597778|BIOLOGICAL|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
214902922|NCT02755285|DEVICE|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
214902923|NCT00422604|DRUG|salmeterol|
214902924|NCT00422604|DRUG|tiotropium|
214902925|NCT00422604|DRUG|GSK233705|
214902926|NCT00004883|BIOLOGICAL|trastuzumab|Given IV
214902927|NCT00004883|OTHER|laboratory biomarker analysis|Correlative studies
214902928|NCT06581978|PROCEDURE|Whole-Body Vibration Intervention|Whole-Body Vibration Intervention
214902929|NCT06581978|PROCEDURE|Exercise Intervention Group|Traditional Chinese medical exercises training
214902930|NCT01417793|BEHAVIORAL|Smoking Cessation Program|Comparison of smoking cessation rate among different smoking cessation program
214902931|NCT04831021|PROCEDURE|Dialysis without physical exercise|Hemodialysis control condition
214902932|NCT04831021|PROCEDURE|Dialysis with pre-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will be performed 60 minutes before connection to hemodialysis.
214902933|NCT04831021|PROCEDURE|Dialysis with per-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will start 30 minutes after the start of dialysis.
215055686|NCT03806530|DRUG|Placebo Gabapentin|Placebo capsule
215055687|NCT03806530|DRUG|Placebo Ropinirole|Placebo capsule
215055688|NCT01405703|OTHER|xrays|xrays from 2 week postop to 5 year postop
215055689|NCT03888378|DRUG|0.3% Topical Minocycline Ointment|0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
215055690|NCT03888378|DRUG|1% Topical Minocycline Ointment|1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
215055691|NCT03888378|OTHER|Topical Vehicle Ointment|Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction
214302011|NCT05463510|DIAGNOSTIC_TEST|Videodermoscopy|Patients who had records for at least twice with videodermoscopy every 3 months were included.
214302012|NCT00529542|DRUG|Lipitor|40mg caplets per day for six weeks
214302013|NCT00529542|DRUG|Placebo|1 placebo caplet per day for six weeks.
214302014|NCT00868075|PROCEDURE|Chest physiotherapy|Twice daily for 8 weeks
215055692|NCT03499860|DIAGNOSTIC_TEST|Passive Leg Raising Test|A passive leg raising test is performed in all patients included in the study
215055693|NCT00049322|BIOLOGICAL|bevacizumab|"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
215055694|NCT05663008|PROCEDURE|128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)|128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
215055695|NCT04538599|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
215055696|NCT03534505|OTHER|Ketorolac group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
215055697|NCT03534505|OTHER|Bupivacaine group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
215055698|NCT00453869|OTHER|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
215055699|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
215055700|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
214902934|NCT04383327|BEHAVIORAL|ParentCorps-Professional Development (PD)|Multi-component school-based intervention that promotes early childhood mental health and development. Teachers (pre-primary to 4th grade) will participate in a 3-day ParentCorps-PD training during the school term. They will also receive 8 sessions (8 hours) of face-to-face group-based coaching during after the training. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
214902935|NCT04383327|BEHAVIORAL|T-Wellness|A brief teacher stress management psychoeducation package, adapted from EBIs including one-day workshop for common stress management and stress management, and three follow-up group support sessions (3 additional monthly 1-hr wellness sessions for teachers as a group that were integrated into the 3 of the 8 PD coaching sessions. A total 3 hours of coaching were included.
214902936|NCT07011446|DEVICE|Safer Seat Usability Trial|"Participants will be asked to transfer onto/off of the vehicle seat using their normal method of transfer and then to trial transferring onto/off of a vehicle seat with the Safer Seat 1 one or more times with study personnel. Demographic data will be recorded for all participants to include age, sex, and type of mobility disability. Transfers will be observed by the research personnel and success in transfers will be recorded according to the Physical Mobility Scale.~Usefulness and usability of the Safer Seat transfer experience will be reported by participants via Technology Acceptance Model Surveys; and participants will engage in a brief semi structured interview that will be audio recorded and transcribed via Microsoft Teams."
214902937|NCT06103292|DIAGNOSTIC_TEST|ionized calcium levels|measuring calcium level in trauma patients
214902938|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles); Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
214907484|NCT01129440|DEVICE|Glass Ionomer Sealant|"Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.~After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar."
215055701|NCT05511506|OTHER|aqueous humor collection|Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.
215055702|NCT06283277|DEVICE|Obstetric Ultrasound|Measuring fetal clavicular length and estimated fetal weight using Hadlock IV formula and Youssef's formula.
215055703|NCT02552095|DEVICE|Triathlon PKR|
215055704|NCT04051749|PROCEDURE|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
215055705|NCT03873727|BIOLOGICAL|Prevenar13 (PCV13) and Pneumovax (PPS23)|One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
215055706|NCT03873727|BIOLOGICAL|Placebo / Pneumovax (PPS23)|One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
215055707|NCT03873727|BIOLOGICAL|Blood sample|an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
215055708|NCT05836558|PROCEDURE|mitral valve repair in right minithoracotomy|reparative surgery of the mitral valve accessing heart via an incision in the right 3rd or 4th intercostal space.
215055709|NCT03475446|DEVICE|real anodal tDCS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
215055710|NCT03475446|DEVICE|real tACS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
215055711|NCT03475446|DEVICE|sham tES healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
215055712|NCT03475446|DEVICE|real anodal tDCS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
215055713|NCT03475446|DEVICE|real tACS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
215055714|NCT03475446|DEVICE|sham tES MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
215055715|NCT03475446|DEVICE|real anodal tDCS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
215055716|NCT03475446|DEVICE|real tACS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
215055717|NCT03475446|DEVICE|sham tES AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
215055718|NCT00415870|BEHAVIORAL|Printed Material|Printed Material
215055719|NCT00415870|BEHAVIORAL|Weekly Weighing|Weekly Weighing
215055720|NCT00415870|BEHAVIORAL|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
215055721|NCT00415870|DEVICE|Text Message|Text Message
215055722|NCT00415870|BEHAVIORAL|Diet Goals via Cell Phone|Diet Goals via Cell Phone
215055723|NCT00415870|BEHAVIORAL|Food Monitoring|Food Monitoring
214302015|NCT00868075|PROCEDURE|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
214669690|NCT04537442|DRUG|IM21 CAR-T cells|"IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide"
214902939|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles);~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
214902940|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-CHOP Q21 + 2 cycles Q21 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis planned by the study."
215055724|NCT05401539|DEVICE|Cardboard VR|Google Cardboard is a discontinued virtual reality (VR) platform developed by Google. Named for its fold-out cardboard viewer into which a smartphone is inserted, the platform was intended as a low-cost system to encourage interest and development in VR applications. To use the platform, users run Cardboard-compatible mobile apps on their phone, place it into the back of the viewer, and view content through the lenses. The parts that make up a Cardboard viewer are a piece of cardboard cut into a precise shape, magnets or capacitive tape, a hook and loop fastener, a rubber band, and an optional near field communication tag. Smartphone is inserted in the back of the device and held in place by the selected fastening device. A Google Cardboard-compatible app splits the smartphone display image into two, one for each eye, while also applying barrel distortion to each image to counter pincushion distortion from the lenses.The result is a stereoscopic image with a wide field of view.
215055725|NCT00583674|DRUG|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
215055726|NCT00583674|DRUG|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
215055727|NCT00583674|DRUG|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
215055728|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
215055729|NCT00583674|DRUG|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
215055730|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
215055731|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
215055732|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
215055733|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
215055734|NCT04013776|DIETARY_SUPPLEMENT|Phosphate supplemented diet|Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
215055735|NCT04311268|DEVICE|F2D armband|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
215055736|NCT03943290|DRUG|ACE-083|Recombinant fusion protein
215055737|NCT02750046|PROCEDURE|total hip arthroplasty or proximal femoral nails|Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
215055738|NCT04787731|DRUG|Bupivacaine Local Anesthetic|Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment
215055739|NCT03579693|DIETARY_SUPPLEMENT|CoQ10|CoQ10 tablet
215055740|NCT03579693|DIETARY_SUPPLEMENT|Nicotinamide riboside|NR tablet
215055741|NCT03579693|DIETARY_SUPPLEMENT|Placebo|Sugar pill designed to mimic coQ10 and NR
215055742|NCT00295646|DRUG|tamoxifen|20 mg/d
215055743|NCT00295646|DRUG|anastrozole|1 mg/d
215055744|NCT00295646|DRUG|zoledronic acid|4 mg q6m
215055745|NCT00295646|OTHER|goserelin|3.6 mg goserelin subcutaneously every 28 days
215055746|NCT02626156|DEVICE|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
215055747|NCT02626156|DEVICE|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
215055748|NCT03390517|DEVICE|Fluorescence angiography with indocianyne green|The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
214902941|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm B)|"Arm B (Experimental arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging: induction therapy shall be completed based on the response achieved and on the treatment chosen:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-CHOP Q21+ 2 cycles Q21of rituximab~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis."
215055749|NCT04972188|DRUG|ZYIL1 Capsule|NLRP3 inflammasome inhibitor
215055750|NCT02289365|DRUG|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
215055751|NCT02289365|DRUG|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
215055752|NCT02289365|DRUG|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
215055753|NCT01119144|DEVICE|Polycaprolactone / Tri-Calcium Phosphate|Orbital implant for reconstruction of the orbital walls
215055754|NCT01119144|DEVICE|Titanium Mesh|Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
215055755|NCT04430361|DRUG|Megestrol|160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
215055756|NCT04430361|DRUG|5-HT3 receptor antagonist|5-HT3 receptor antagonist 2.5mg/iv
215055757|NCT04430361|DRUG|dexamethasone|dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
214669691|NCT05776537|DEVICE|Fibreoptic bronchoscopy|different endoscopies used for confirmation of diagnosis
215055758|NCT02441101|DEVICE|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
215055759|NCT02441101|DEVICE|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
215055760|NCT00794846|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
215055761|NCT00794846|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
215055762|NCT04754971|OTHER|psycho-education program|Psychoeducation Practice 1 day per week, 60-90 min. sessions will take 8 weeks. At the end of the training, the final test will be applied to the experimental and control group. 3rd and 6th month follow-up measurements are planned to be carried out intermittently at the end of the month.
215055763|NCT02676947|DRUG|Tocilizumab|
214902942|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-bendamustine Q28 (28-days cycles);~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in Stable Disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
214902943|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case 2 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-bendamustine Q28;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
214479170|NCT06592443|BEHAVIORAL|LvL UP|"The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant."
214669692|NCT01122355|DRUG|lipid modification|1\) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
214902944|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
214902945|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm B)|"4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion."
214902946|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 4 cycles of G-CVP Q21;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
214902947|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm B)|"Arm B (Experimental arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 4 cycles of G-CVP Q21~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
214902948|NCT06303141|OTHER|Closed Chain exercises|"Open eyes and closed eyes across arm (3 sets x 60 sec) Lateral step down (3 sets x 6-12 reps) Semi-Squat Exercise (3sets x 6-12 reps) Thera-band isometric (3 sets x 10 -15sec each)"
214902949|NCT06303141|OTHER|Neuromuscular Training|"Neuromuscular Training Exercise:~* Single Leg Raise (3 sec x 30sec each)~* Ankle eversion/inversion (3 sets x 25 reps)~* Double Hopping in place then out of place (3 sets 30 sec)~* Reach with feet (3 sets x 30-60 sec each)~* Reach with hands (3 sets x 30-60 sec each)~* Wobble board Exercise (3sets x 30-60sec each"
215055764|NCT04749043|DEVICE|Oculus Quest 2 Virtual Reality Device|30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects
214669693|NCT02716376|DEVICE|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
214902950|NCT06303141|OTHER|Mobilization with Movement|"Joint mobilization with movement (by Mulligan) refers to manual therapy techniques that are used to modulate pain and treat joint dysfunctions that limit the range of motion (ROM).~(3 sets x 6 oscillation/glide each)"
214902951|NCT00491868|DRUG|R744|100μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
214902952|NCT00491868|DRUG|R744|150μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
214902953|NCT00491868|DRUG|rHuEPO|2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
214902954|NCT00491868|DRUG|rHuEPO|4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
214902955|NCT00491868|DRUG|R744 placebo|0 μg/4week for 24 weeks
214902956|NCT00491868|DRUG|rHuEPO placebo|0 IU 2 or 3 times/week for 8 weeks, then 1\~3 times/week for 16 weeks
215055765|NCT04749043|DRUG|Nitrous oxide|30 min exposure for labor analgesia
215055766|NCT02472587|OTHER|Questionnaire|
215055767|NCT04868305|PROCEDURE|Intramedullary nail|"Intertan nail (Smith \& Nephew)\* or Gamma 3 nail (Stryker)\*~\* All of the above-mentioned products are subjects to change into an equivalent product"
215055768|NCT04868305|PROCEDURE|Hip arthroplasty|"Total hip arthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~* Cup: Cemented Avantage dual mobility cup (Zimmer Biomet)\*~Hemiarthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~  * All of the above-mentioned products are subjects to change into an equivalent product"
215055769|NCT01295307|DRUG|Clofarabine|Induction and consolidation therapy / conditioning therapy with Clofarabine
215055770|NCT02517255|DEVICE|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
214902957|NCT07027072|DRUG|KDS2010|KDS2010 will be administered orally once daily, two tablets per day, for 24 weeks. Dosage will be either 60 mg or 120 mg depending on the assigned group.
214902958|NCT07027072|DRUG|Placebo|Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, two tablets per day, for 24 weeks.
214902959|NCT01289678|DRUG|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
214669694|NCT00198705|BEHAVIORAL|Improved management of severe neonatal infections|
214669695|NCT04155879|DRUG|Colchicine Tablets|Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
214669696|NCT04155879|PROCEDURE|Cardioversion|Electrical or pharmacologic restoration of sinus rhythm
214902960|NCT06137235|OTHER|cows milk infant formula and follow-on formula with bioactive ingredients|infant formula and follow-on formula with bioactive ingredients
214902961|NCT06137235|OTHER|standard cows milk infant formula and follow-on formula|standard cows milk infant formula and follow-on formula
214902962|NCT06878170|BIOLOGICAL|RBM-001|To evaluate the safety and tolerability of the RBM-001 vaccination in healthy adults.
214902963|NCT07036081|DIETARY_SUPPLEMENT|Wilbo's Blends+|"A new feeding plan will be developed by the study dietitians. Participants will be transitioned from their current enteral feeding plan to incorporate Wilbo's Blends+. In this new plan Wilbo's Blends+ can provide up to 100% but not lower than 30% of their total daily calorie requirements depending on participant's individual clinical needs, as assessed by the study dietitian.~All participants will be on at least 30% Wilbo's Blends+ for at least 7 days.~If required clinically there is the option to transition participants onto Wilbo's Blends+ over 1-6 days, for children who are deemed particularly sensitive to change in their feeding plan.~Participants or their families/carers will complete an electronic workbook consisting of:~* GI tolerance records for 7 days whilst receiving Wilbo's Blends+~* Compliance records for 7 days whilst receiving Wilbo's Blends+~* Ease of use and palatability questionnaire at the end of the study intervention (after last administration of Wilbo's Blends+"
215055771|NCT06182098|OTHER|1/2 maintenance fluids|Patients will receive 1/2 maintenance normal saline (with a maximum of 50 mL/hr), over one hour.
215055772|NCT06182098|DRUG|Ketorolac|0.5mg/kg, with a maximum of 30mg
215055773|NCT06182098|DRUG|Diphenhydramine|0.5mg/kg, with a maximum of 25mg
215055774|NCT06182098|DRUG|Prochlorperazine|0.15mg/kg, with a maximum of 10mg
215055775|NCT06182098|OTHER|bolus|20mL/kg normal saline bolus, with a maximum of 1L, given over one hour
215055776|NCT05365789|DEVICE|Blocked Nose Baby nasal spray|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.
215055777|NCT05365789|OTHER|Standard of care|Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
215055778|NCT00161915|DRUG|Fibrin Sealant|
214902964|NCT07038473|PROCEDURE|Investigational Procedure|"It consists of prospective blood sample collection from children, adolescents and first-degree relatives of T1D probands.~Study without any Investigational Medicinal Product (IMP) administration."
214902965|NCT02996656|DRUG|Cefazolin|Antibiotic that will be give before a Trauma or elective open shoulder surgery
214902966|NCT02996656|DRUG|Ceftriaxone|Antibiotic that will be give before a Trauma or elective open shoulder surgery
214902967|NCT01132729|DRUG|Valacyclovir Hydrochloride|1000 mg caplet
214902968|NCT00468819|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
214902969|NCT07040319|DRUG|Glecaprevir/pibrentasvir|100 mg glecaprevir and 40 mg pibrentasvir for a total daily dose of glecaprevir 300 mg/pibrentasvir 120 mg
215055779|NCT06485726|DRUG|Valproic Acid 500 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
215055780|NCT06485726|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
215055781|NCT03271320|OTHER|appearance scales|appearance scales : AVS; ASWAP; DAS 59
215055782|NCT00955474|DRUG|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
215055783|NCT00955474|DRUG|escitalopram|"Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
215055784|NCT00955474|DRUG|Sertraline|"Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
215055785|NCT00955474|DRUG|Citalopram|"Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
214902970|NCT06705829|BIOLOGICAL|Prothrombin|"Comparison of prothrombin time results obtained with the different thromboplastins reagent for subgroup (extrinsic pathway factor and for those with hepatocellular insufficiency) by a regression line and a Bland-Altman representation.~Comparison of extrinsic pathway factor assays obtained with the different thromboplastins reagent for each subgroup by a regression line and a Bland-Altman representation.~Evaluation and determination of the sensitivity of the prothrombin time according to the activity rate obtained for each factor (for each reagent)."
214902971|NCT06724549|DRUG|BN104|This study adopts two-treatment (fasting or following a high-fat meal), two-period, two-sequence crossover design. The subjects will be randomly assigned into one of two treatment sequences in a 1:1 ratio. A single 600 mg dose of BN104 tablets administered under fasting conditions or after a standard high-fat breakfast in period 1 and 2.
214902972|NCT07042529|PROCEDURE|OptEx-TAVI|"During TAVI with either self-expanding or balloon-expandable TAVs:~* Pre-dilatation: systematic pre-dilatation with an optimally-sized balloon.~* Post-dilatation: systematic TAV post-dilatation with an optimally-sized balloon.~Optimally-sized balloon:~1. The recommended balloon size used for pre- and post-dilatation is the perimeter-derived mean diameter of the native aortic annulus minus 1 mm and should never exceed the perimeter-derived mean diameter of the native aortic annulus. A smaller-sized balloon should be considered in case of severe left ventricular outflow tract calcium and/or severely calcified leaflets in combination with a shallow sinus of Valsalva.~2. In case of post-dilatation of the Evolut TAV (Medtronic, USA), the instructions for use (IFU) for post-dilatation of the Evolut valve should be respected.~3. Also, a balloon-expandable TAV has to be post-dilated with an optimally-sized balloon in case of randomization to the OptEx-TAVI arm."
215055786|NCT00933439|DRUG|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
214669697|NCT00201799|DRUG|Infliximab|"A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42"
214669698|NCT06297304|BEHAVIORAL|Sedentary and physical activity behaviors|The intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: Week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to sedentary behaviors and the physical activity levels will be recorded to assess the progress of each student.
214669699|NCT01856673|BEHAVIORAL|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
214669700|NCT01856673|BEHAVIORAL|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
214669701|NCT01856673|OTHER|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
214669702|NCT04803812|OTHER|"Remote SMS (short message service, also known as text message) delivery"|Assessing the comparative effects of SMS types (storytelling; resources/strategies; and a combination of both) on physician wellbeing.
214669703|NCT05279378|RADIATION|lung ultrasonography versus CT|"chest CT will be done before admission and LUS within first 24 h from admission into the quarantine sector. In addition to 2 weeks after admission.~CT images will be reviewed by chest radiologist expert, who will calculate a CT severity score based on extension and distribution of GGOs and consolidations.~All CT scans will be performed in supine position at end inspiration without intravenous administration of contrast media.~Within 24 h from admission and CT scanning, bedside LUS will be performed by clinician who will be blind to chest CT findings.~Examinations will be performed with the patient in the sitting position, systematically scanning the front and the back side of each hemithorax.~Blood sample will be collected into 4 mL Vacuette containing EDTA. Samples will be stored on ice, processed within 30 min and plasma will be isolated by centrifugation at 2000g for 20 min at 4 °C. Plasma will be immediately frozen at - 80 °C in several aliquots."
214669704|NCT01310738|DRUG|Antimoniate of N-methylglucamine|Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
214669705|NCT01310738|DRUG|amphotericin B deoxycholate|1mg/kg/d, I.V. for 14 consecutive days.
214669706|NCT01310738|DRUG|Liposomal amphotericin B|3mg/kg/d, I.V. for 7 consecutive days.
214669707|NCT01310738|DRUG|Liposomal amphotericin B|10mg/kg/d, I.V. single dose.
214669708|NCT01310738|DRUG|Antimoniate of N-methylglucamine|20mg/kg/d of pentavalent antimonial I.V. for 10 days
214669709|NCT04332419|DEVICE|PET/CT|Standard Imaging
214669710|NCT04332419|DEVICE|PET/MR|Additional Imaging
214669711|NCT04332419|RADIATION|SIRT with Y-90|SIRT with Y-90 for palliative treatment of the liver malignancy.
214669712|NCT00073944|DRUG|forodesine hydrochloride|
214669713|NCT02472483|BEHAVIORAL|Cognitive and Behavior Therapy (CBT)|20-weeks CBT
214669714|NCT02472483|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|8-weeks MBCT
214669715|NCT05372705|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
214669716|NCT00172380|DRUG|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
214669717|NCT06198257|DEVICE|spider cage|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
214669718|NCT06198257|DEVICE|modified suits therapy|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
215055787|NCT02691416|DRUG|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
215055788|NCT02691416|DRUG|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
215055789|NCT02263872|DRUG|Minocycline|Minocycline 200mg perday
214669719|NCT03020693|PROCEDURE|Invasive electrostimulation combined with exercises|Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
214902973|NCT07042529|PROCEDURE|SoC-TAVI|During TAVI with either self-expanding or balloon-expandable TAVs: Pre-dilatation: optional, as per operator preference and post-dilatation: optional, as per operator preference. Operators are only encouraged to post-dilate the implanted TAV in case of ≥ moderate paravalvular regurgitation or a suboptimal transvalvular gradient. The balloon size used for pre- or post-dilatation is left at the operator's discretion.
214902974|NCT07044323|BEHAVIORAL|Active Virtual Reality Treatment|The self-administered active VR treatment will consist of 8 twice-weekly sessions, each approximately 1 hour in duration, during which subjects will participate in a variety of Virtual Reality active games that require leg movements while receiving high-quality visual feedback of the missing lower leg.
214902975|NCT05247125|COMBINATION_PRODUCT|Blue light exposure + Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
214902976|NCT05247125|DRUG|Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed.
215055790|NCT03678337|OTHER|observational cohort with plasma samples|plasma samples
215055791|NCT05496985|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
214669720|NCT03020693|PROCEDURE|Placebo electrostimulation and exercises|First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
214669721|NCT01429649|PROCEDURE|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
214669722|NCT04953455|OTHER|no intervention|no intervention
214669723|NCT02892097|DEVICE|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
214669724|NCT02892097|DEVICE|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
214669725|NCT02892097|BEHAVIORAL|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
214669726|NCT05798975|OTHER|Aerobic Exercise. 1 session of acute exercise|40 minutes on cycle ergometer, 60% of heart rate reserve
214669727|NCT05798975|OTHER|Resistance Exercise. 1 session of acute exercise|2 exercises for lower limbs and 2 for upper limbs with 4 sets of 12 repetitions at 60% 1-RM. 40 minutes
214669728|NCT05798975|OTHER|no exercise|Rest
214669729|NCT04341571|DIETARY_SUPPLEMENT|Probiotics|Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
214669730|NCT04341571|DRUG|Metformin|"Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks.~Homologated to the other intervention."
214669731|NCT00658333|DRUG|Enteric-coated Mycophenolate Acid (EC-MPA)|
214669732|NCT00658333|DRUG|Mycophenolate Mofetil (MMF)|
214902977|NCT05247125|DEVICE|Blue light exposure|Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
214902978|NCT05247125|COMBINATION_PRODUCT|Placebo|Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening
214902979|NCT04952961|BEHAVIORAL|Training in Vulval Self-Examination|Face-to-face training in vulval self-examination Supplemented with use of aids ( hand mirror, mobile phone with selfie-stick), patient information leaflet, reminders to self-examine
215055792|NCT02569463|DRUG|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
215055793|NCT06125184|DRUG|Vasopressor test|Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.
215055794|NCT02408172|DRUG|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
215055795|NCT02408172|DRUG|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
215055796|NCT00403013|PROCEDURE|Positioning and anesthesia|Positioning during axillary plexus block
214669733|NCT00658333|DRUG|Placebo MMF|
214669734|NCT00658333|DRUG|Placebo EC-MPA|
215055797|NCT05254951|DIAGNOSTIC_TEST|Tidal Volume Challenge|Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
214669735|NCT04210492|RADIATION|45 Gray (Gy) regimen|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
215055798|NCT05046873|DRUG|Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
214669736|NCT04977544|DEVICE|vert|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
215055799|NCT05046873|DRUG|semaglutide 1.34 mg/mL (placebo)|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
215055800|NCT05046873|DRUG|Semaglutide 1.34 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
215055801|NCT05046873|DRUG|NNC0480-0389 A 10 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
215055802|NCT03815630|DRUG|pd-1 and dc-cik cells|Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
215055803|NCT04603469|OTHER|Non invasive blood pressure|measurement of blood pressure during induction of general anesthesia
214669737|NCT04977544|DRUG|Sertraline|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
214669738|NCT04687917|BEHAVIORAL|The facilitation, training, feedback, and consultation (FTFC) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, and consultation
215055804|NCT01737762|BIOLOGICAL|HP802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
215055805|NCT01737762|BIOLOGICAL|Vehicle|
215055806|NCT05934110|DRUG|EMP16-120/40|"EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID)."
215055807|NCT05934110|DRUG|MR orlistat 120 mg|"MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID)."
215055808|NCT05934110|DRUG|Conventional orlistat 120 mg,|"Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID)."
214669739|NCT04687917|BEHAVIORAL|The facilitation, training, feedback, consultation, and incentivization (FTFCI) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, consultation, and incentivization.
214669740|NCT06971692|BEHAVIORAL|Metacognitive therapy (MCT)|MCT is delivered in weekly face-to-face sessions
214669741|NCT06971692|BEHAVIORAL|Unified protocol (UP)|UP is delivered in weekly face-to-face sessions
214669742|NCT06971172|DEVICE|Low energy diode Laser|Diode Laser
214669743|NCT06971172|DRUG|Medication|pulse steriod therapy and immunosuppressive drugs
214669744|NCT06971315|DIETARY_SUPPLEMENT|Vitamin C|Three doses of 900 mg vitamin C taken orally (baseline, 12 hours and 24 hours)
214669745|NCT06971315|OTHER|Placebo|Three doses of 900 mg placebo taken orally (baseline, 12 hours and 24 hours)
214669746|NCT06970561|PROCEDURE|enlarged resection|patients underwent secondary enlarged resection within 1 month after the diagnosis of IDP combined with ADH,
214669747|NCT06970951|BIOLOGICAL|UTAA91 injection|Infusion of UTAA91 injection in subjects screened after signing informed consent.
214669748|NCT06970457|BEHAVIORAL|Resistance Exercise Training|12-week progressive and individualized resistance exercise training program
214669749|NCT06970457|BEHAVIORAL|Aerobic Exercise Training|12-week progressive and individualized aerobic exercise training program
215055809|NCT05934110|DRUG|EMP16-60/20|"Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)"
215055810|NCT05934110|DRUG|Placebo|"Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)"
215055811|NCT01525823|DRUG|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
215055812|NCT01525823|DRUG|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
215055813|NCT06041022|OTHER|Exposure factors|Including demographical data, laboratory features and liver histological indicators.
215055814|NCT00517010|DRUG|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
214302016|NCT03369054|BEHAVIORAL|Minority Stress Treatment|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
215055815|NCT03301337|DIETARY_SUPPLEMENT|Meat protein absorption|Meat protein absorption when digested together with a full meal.
215055816|NCT02843438|OTHER|Fluorescein angiography|
215055817|NCT02843438|OTHER|Dilated fundus examination|
215055818|NCT02843438|BIOLOGICAL|Toxoplasmosis serology|
215055819|NCT02843438|DRUG|Anti-toxoplasmosis treatment|
215055820|NCT02843438|DRUG|Anti-inflammatory treatments|
215055821|NCT02843438|OTHER|Puncture in anterior chamber|
215055822|NCT00148031|DRUG|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
215055823|NCT00148031|BEHAVIORAL|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
214669750|NCT06970392|BEHAVIORAL|Bedtime Pass|The Bedtime Pass is a small paper card that children will be allowed to exchange for a trip out of their bedroom after bedtime. Once the card has been exchanged, participants will be instructed to ignore any additional pleas from their child. Participants will also be provided with general information about good sleep hygiene.
214669751|NCT06972186|DIAGNOSTIC_TEST|Fatigue Protocol + Joint Position Sense Testing|Groups will undergo an isokinetic fatigue protocol at 180°/s using a Biodex dynamometer. Passive and active joint position sense tests will be performed before and after fatigue.
215055824|NCT00148031|BEHAVIORAL|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
214669752|NCT06972199|BEHAVIORAL|Reflexology|Reflexology application
214669753|NCT06972199|BEHAVIORAL|Hot water foot bath|Hot water foot bath application
214669754|NCT06971081|OTHER|LED light|(Dental Light Cure), LED light at wavelengths of 420-480nm and will be applied for 30 seconds at a distance of 1cm from the extraction site
214669755|NCT06970210|BEHAVIORAL|Group-Based Education|The group-based education will consist of group sessions led by research staff, covering topics such as physical activity, sedentary behavior, balance and fall prevention, and activities of daily living. Social interactions amongst group members will be facilitated through group activities and discussions regarding the topics being discussed.
214669756|NCT06970210|BEHAVIORAL|Individualized Coaching|Individualized coaching aims to increase the participants daily step count. Participants will be encouraged to achieve step count increases of 2%, 5%, or 10% per week or visit, depending on their readiness and willingness to progress. SMART goal-setting strategies will be employed to assist with the goal setting. Participants may also receive coaching related to reducing sedentary behavior and engaging in physical activities.
214669757|NCT06971003|BEHAVIORAL|Ho'ouna Pono|An efficacious culturally grounded substance use prevention intervention developed and tested with Hawaii Island students. Teachers deliver the 11 lesson program through 30-45 minute weekly sessions. The modular intervention can be customized to students by teachers.
214669758|NCT06970964|DIETARY_SUPPLEMENT|Intervention Name: Fermented milk containing Lacticaseibacillus paracasei strain Shirota. Intervention Name: Non-fermented milk (placebo)|Participants will ingest 80 mL per day of fermented milk containing 40 billion colony-forming units (CFU) of Lacticaseibacillus paracasei strain Shirota (LcS), starting 30 days before a triathlon competition and continuing until 14 days post-race. The fermented milk is stored refrigerated and consumed once daily.
215055825|NCT00148031|BEHAVIORAL|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
215055826|NCT03083665|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use"
215055827|NCT03083665|DRUG|Brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 25 mg tablets and 50 mg tablets~* Route of administration: Oral use"
215055828|NCT00890435|OTHER|questionnaire administration|
215055829|NCT00890435|PROCEDURE|psychosocial assessment and care|
215055830|NCT00399607|PROCEDURE|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
215055831|NCT00399607|PROCEDURE|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
215055832|NCT00399607|PROCEDURE|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
215055833|NCT00399607|PROCEDURE|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
215055834|NCT00399607|PROCEDURE|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
215055835|NCT04383028|PROCEDURE|MELD algorithm use to aid in the planning of SEEG electrode trajectories|"During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations."
215055836|NCT04352543|BEHAVIORAL|Active Video Game Exercise|Play during 30 minutes in the easy level
215055837|NCT04352543|BEHAVIORAL|Treadmill walking exercise|30 minutes (65 - 75% heart rate maximal)
214669759|NCT06970964|DIETARY_SUPPLEMENT|Non-fermented milk (placebo)|Participants will ingest 80 mL per day of non-fermented milk identical in taste, appearance, and packaging to the probiotic drink, but without Lacticaseibacillus paracasei strain Shirota. Administration follows the same schedule as the probiotic group.
214669760|NCT06971302|OTHER|Mindfullnes Based Breastfeeding Education|Pregnant women in the intervention group will receive mindfulness-based breastfeeding training, conducted face-to-face and online by the researcher at designated days and times. The intervention group will undergo a total of 12 sessions of mindfulness-based breastfeeding training over a six-week period. The training will be made memorable and easy to understand through the support of visual presentations, videos, and models prepared by the researcher.
214669761|NCT06971653|PROCEDURE|conventional surgery|This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with conventional surgery
214669762|NCT06971653|PROCEDURE|piezoelectric surgery|This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with piezoelectric surgery
214669763|NCT01994187|PROCEDURE|Carotid endarterectomy|
214669764|NCT01994187|PROCEDURE|carotid angioplasty|
214669765|NCT04400500|DIAGNOSTIC_TEST|Approaches to differential diagnosis and risk stratification|Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
214669766|NCT03542188|BEHAVIORAL|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
214669767|NCT03542188|BEHAVIORAL|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
214669768|NCT04721314|DEVICE|Adjustment of lower rate limit|Patients with preserved ejection fraction (EF \>50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.
214669769|NCT04721314|DEVICE|Maintenance of lower rate limit|Lower rate limit will be maintained at 60 beats-per-minute
214669770|NCT04615871|DRUG|semaglutide|semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
214669771|NCT03940885|PROCEDURE|Erector spinea plane block group|Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
214669772|NCT03940885|PROCEDURE|Transversus abdominis plane block|Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
214669773|NCT03940885|PROCEDURE|Control group|this group will receive only standard general anesthesia
214302017|NCT03369054|BEHAVIORAL|Treatment As usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
214669774|NCT03008512|DRUG|Genexol-PM|
214669775|NCT04045912|OTHER|AGYW-Friendly Services|"Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW."
214902980|NCT04030299|DEVICE|Over-the-counter fitting|In this group, pre-configured hearing aids, which simulate over-the-counter hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
214902981|NCT06715592|DRUG|Bleomicina|Colposcopically guided ECT following intralesional administration / intravenous Bleomycin or intralesional Cisplatin according to ESOPE recommendations. Reassessment after 30 days by colposcopy and conization with acquisition of histological examination.
214902982|NCT07049536|OTHER|Assessment Group|Allogeneic Stem Cell Transplant recipients will be evaluated with a supervisor physiotherapist for 2 days between the time they are admitted to the stem cell transplantation unit.
214669776|NCT04045912|OTHER|HIVST|Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
214669777|NCT02054832|DIETARY_SUPPLEMENT|Glycosade|
214902983|NCT07049536|OTHER|Control Group|Adult healthy group with similar sociodemographic characteristics to the evaluation group.
214902984|NCT03765983|DRUG|Trastuzumab|"Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system"
215055838|NCT04352543|BEHAVIORAL|Sedentary Behavior|Quiet Rest: 30 minutes
215055839|NCT02501148|DEVICE|carotid artery stenting|Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
214902985|NCT03765983|DRUG|GDC-0084|GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
214902986|NCT00218595|BEHAVIORAL|DBT|Dialectical behavior therapy plus opiate replacement medication.
214902987|NCT00218595|BEHAVIORAL|I/GDC|Individual and group drug counseling plus opiate replacement medication.
214902988|NCT05771077|DRUG|Poly(Amidoamine) dendrimer|to evaluate the Remineralizing effect of Poly Amido Amine Dendrimer, Nanohydroxy apatite \& Their Combination on demineralized enamel \& Their Clinical Efficacy on White Spot lesion
215055840|NCT04532840|DEVICE|cryotherapy (Gymna Cryoflow ICE-CT)|Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
215055841|NCT04532840|OTHER|Exercising, Positioning and splinting, Pressure Therapy and Massage|Exercising, Positioning and splinting, Pressure Therapy and Massage
214902989|NCT06891794|COMBINATION_PRODUCT|Menstrual disc with EMLA cream|Eutectic mixture of local anesthetics (EMLA) cream self-administered using a menstrual disc
214902990|NCT06891794|COMBINATION_PRODUCT|Cervical cap with EMLA cream|Eutectic mixture of local anesthetics (EMLA) cream self-administered using a menstrual disc
214902991|NCT06169176|OTHER|RAPA-501 Autologous T stem cells|Experimental: Intermediate size expanded access cohort. Single-agent RAPA-501 T stem cells, (80 x 10EE6 cells per infusion; acceptable dose range of RAPA-501 T stem cells is 20-to-80 x 10EE6 cells per infusion.
214902992|NCT06736795|OTHER|Exercise|All participants will be instructed in a progressive Achilles tendon loading exercise program.
215055842|NCT00897780|BEHAVIORAL|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
215055843|NCT01467466|DRUG|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
214669778|NCT00519532|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
214669779|NCT02984475|DRUG|Metformin|
214669780|NCT03554590|BEHAVIORAL|carbohydrate counting|patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods
214669781|NCT03554590|BEHAVIORAL|insulin therapy according to standard care|patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme
214669782|NCT05859958|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups
214669783|NCT01179763|OTHER|Optical coherence tomography|Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
214669784|NCT06971523|DRUG|CTS3497|CTS3497: Orally via capsules
214902993|NCT06736795|OTHER|Education|All participants will receive education on Achilles tendinopathy terminology, common symptoms, diagnosis, expected recovery timeline, importance of physical activity, self-management strategies, multiple factors influencing pain, alternative and adjunct treatment options.
214902994|NCT06743009|OTHER|N-lactoyl-phenylalanine|Intravenous infusion of N-lactoyl-phenylalanine (Lac-Phe)
214902995|NCT06743009|OTHER|NaCl|0.9% isotonic NaCl infusion
214902996|NCT06893965|DIAGNOSTIC_TEST|Intra ocular pressure Measure|Measurement of IOP before injection (T0), just after the injection (T1) then 15 (T15), 30 (T30) and 45 (T45) minutes after the injection. Measurement are done with Perkins Tonometer
214902997|NCT06836141|DIAGNOSTIC_TEST|MRI|MRI during hospitalization and at 12 months post sICH
214902998|NCT06836141|DIAGNOSTIC_TEST|Blood Draw|Will occur during hospitalization and at 3, 6 and 12 months post sICH
214902999|NCT06836141|DIAGNOSTIC_TEST|Cognitive Test|Cognitive testing will occur during hospitalization and at 3, 6 and 12 months post sICH
214903000|NCT00830973|OTHER|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
214903001|NCT00830973|OTHER|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
214903002|NCT03204682|DEVICE|Repetitive transcranial magnetic stimulation|Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
214903003|NCT06737653|DEVICE|Gel containing postbiotics, lactoferrin, aloe barbadensis leaf juice powder and sodium hyaluronate|The gel will be applied until the wound is filled with the gel, which will be left undisturbed for 5 min.
214903004|NCT06737653|DEVICE|Placebo gel|The gel will be applied until the wound is filled with the gel, which will be left undisturbed for 5 min.
214903005|NCT05451628|DEVICE|Default CI fitting|Programming of cochlear implant speech processor according to standard clinical care
214903006|NCT05451628|DEVICE|Anatomy-based CI fitting|Programming of cochlear implant speech processor with anatomy-based fitting
214903007|NCT05134311|DEVICE|PIUR tUS Imaging System|PIUR imaging has developed PIUR Infinity tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging.
214903008|NCT03481582|DRUG|Nitroglycerin|(nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle.
214903009|NCT03481582|DEVICE|Three dimensional power doppler|Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow
215055844|NCT01467466|DRUG|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
214903010|NCT03817827|OTHER|Acupuncture|this group will receive Acupuncture for 30 minutes three times per week
214903011|NCT03817827|DIETARY_SUPPLEMENT|Diet supplementary|Diet supplementary with soy product
214903012|NCT02922127|DRUG|Ulipristal Acetate|Daily use of Ulipristal Acetate
214903013|NCT02922127|DRUG|Combined Oral Contraceptive Pill|Daily use of Oral Contraceptive Pill
214903014|NCT03196336|OTHER|Pharmacotherapy follow-up care|The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
215055845|NCT01467466|DRUG|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
215055846|NCT01467466|DRUG|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
215055847|NCT06554106|OTHER|Neuromuscular Electrical Stimulation Group|All patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises. In addition to the study group, NMES will be applied to the upper trapezius muscle for 30 minutes 5 days a week for 4 weeks. Neuromuscular Electrical Stimulation (NMES) applications will be performed with a Compex 3 (Compex Medical SA, Ecublens, Switzerland) model, portable and programmable electrostimulator unit in rehabilitation mode and under the supervision of an expert physiotherapist experienced in the device and application. The NMES program will be applied with a 4-channel device with a functional stimulation capacity of 120 mA, pulse duration 400 μs and pulse frequency 150 Hz.
215055848|NCT06554106|OTHER|Control Group|Patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises.
214903015|NCT05446779|DIAGNOSTIC_TEST|Adrenal aldosterone synthase (CYP11B2) staining|Immunoshistochemical diagnosis of primary aldosteronism
214903016|NCT05446779|DIAGNOSTIC_TEST|Adrenal cortisol synthase (CYP11B1) staining|Immunoshistochemical diagnosis of adrenal hypercortisolism
214903017|NCT05446779|DIAGNOSTIC_TEST|Histopathological analysis|Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
214903018|NCT00577603|PROCEDURE|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
214903019|NCT00577603|OTHER|no intervention|
214903020|NCT01595347|DRUG|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
214903021|NCT01595347|OTHER|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
214903022|NCT06007235|DEVICE|CACIPLIQ20|CACIPLIQ20 contains RGTA heparan sulphate mimetics
214903023|NCT06007235|DRUG|Placebo|Saline solution in identical spray bottles
214903024|NCT04740918|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
214903025|NCT04740918|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion
214903026|NCT04740918|OTHER|Placebo|Placebo matched to atezolizumab
214903027|NCT03626038|DEVICE|A.L.P.S. Proximal Humerus Plating System|Anatomically contoured, locking plates that can be customized intra-operatively, multidirectional screws allow for stable fixation for a wide variety of patients.
214903028|NCT07061899|DIAGNOSTIC_TEST|Anal swap for Chlamydia and Gonorrhoea|"If inflammation is observed on endoscopy up to 35 cm from the anal opening, a swab will be taken during the procedure to test for Chlamydia and Gonorrhoea using standard PCR techniques. If the swab is not taken during the endoscopy, it will be collected during a follow-up outpatient visit. The tests will be analysed immediately at the Department of Microbiology, Aarhus University Hospital.~If positve, the patient will be offered treatment at the department of Venerological diseases."
215055849|NCT00178971|DRUG|adjunctive treatment with buspirone|buspirone 15-30 mg qd
215055850|NCT00178971|DRUG|placebo|placebo
215055851|NCT04149171|DRUG|with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.|The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
215055852|NCT04149171|DRUG|conventional treatment|standard treatment based on crystalloid fluid and tranexamic acid (TXA)
215055853|NCT04062084|DEVICE|Multifunctional Cataract-assisted Retractor|Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
215055854|NCT01789359|OTHER|Blueberry Juice|Dietary intervention
214903029|NCT06275438|OTHER|The delivery being performed via cesarean section surgery rather than natural childbirth|At Kars Harakani State Hospital and Kafkas University, 16 placentas were collected, with 8 obtained from induced deliveries and 8 from spontaneous deliveries, between 09:00-21:00. Nulliparity and multiparity were not distinguished among the expectant mothers. Placentas were obtained hours before delivery from mothers admitted to the gynecology service, whose eligibility was determined based on exclusion criteria, after obtaining signed informed consent forms, with assurances given that no interventional procedures would be performed on the mother or the baby. The method of cesarean section (spinal or general anesthesia) in the case group was recorded, ensuring that the anesthetic agents used contained the same active ingredients. Placentas from births involving different anesthetic drugs were not included in the study, aiming to standardize the procedure.
214903030|NCT02524847|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
214903031|NCT02524847|PROCEDURE|Extracorporeal Photopheresis (ECP)|
214903032|NCT04784611|BEHAVIORAL|Our Peers - Empowerment and Navigational Support (OP-ENS) Peer Health Navigator Intervention|Disability peer health navigator mentored and manualized process of barriers identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
214903033|NCT00254709|DRUG|Sirolimus|
214903034|NCT04352101|DRUG|Bupropion XL|Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.
214903035|NCT04352101|DRUG|Escitalopram|Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.
214903036|NCT01943383|GENETIC|iPSC|Single blood draw for the production of induced pluripotent stem cells.
214903037|NCT05148091|BIOLOGICAL|SCTV01C|A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants
214903038|NCT05148091|OTHER|Adjuvant|SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial
214903039|NCT05148091|OTHER|Saline|Saline is used as the other control in the trial
214903040|NCT00870844|DRUG|Lu AA24493 (CEPO)|0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
214903041|NCT00870844|DRUG|Placebo|Vials with solution for IV infusion
214903042|NCT02205463|DRUG|KD019|
214903043|NCT05484492|BIOLOGICAL|demineralized and mineralized combination putty bone allograft|Subjects in this group will receive an intrasocket demineralized and mineralized combination putty bone allograft following tooth extraction
214903044|NCT05484492|BIOLOGICAL|calcium phosphosilicate putty alloplast graft|Subjects in this group will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft following tooth extraction
214903045|NCT03992521|GENETIC|Nucleosome positioning|Stratification of patients based on nucleosome positioning from plasma DNA.
214903046|NCT02279966|DRUG|Vortioxetine 10 mg|
215055855|NCT02626936|OTHER|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
215055856|NCT02626936|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
214903047|NCT02279966|DRUG|Paroxetine 20 mg|
214903048|NCT02279966|DRUG|Placebo|
214903049|NCT00815464|DEVICE|Liquid Acupuncture (Herb Acupoint Injection)|Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
214903050|NCT03696290|DRUG|Aztreonam lysine|Nebulised aztreonam lysine 75mg
214903051|NCT03696290|OTHER|Placebo|Nebulised lactose monohydrate 5mg
214903052|NCT01709500|DRUG|LMT (atorvastatin, simvastatin, or rosuvastatin)|
214903053|NCT01709500|DRUG|alirocumab|Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
214903054|NCT01709500|DRUG|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
214903055|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally|Volunteers take 1 capsule (200 mg) of NIOCH-14 as a single oral dose.
214903056|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 as a single oral dose. (Total 600 mg NIOCH-14 per day)
215055857|NCT02626936|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
215055858|NCT02626936|DEVICE|Dexcom G4 Platinum glucose sensor|
215055859|NCT02626936|DEVICE|Accu Chek Combo insulin pump|
215055860|NCT00714506|BEHAVIORAL|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
214903057|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)|Single 1200-mg oral dose. (1200-mg dose of the drug is administered by 600 mg twice a day at 8-00 and 20-00 in the hospital and presence of a clinical investigator or a nurse).
214903058|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days|Volunteers take 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days.
214903059|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days.
214903060|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days.
215055861|NCT00714506|OTHER|Physical activity control|physical activity plus successful aging health education
215055862|NCT05429580|DRUG|Tranexamic acid|given intravenous tranexamic acid
215055863|NCT05429580|OTHER|5% Dextrose|given placebo.
215055864|NCT02622295|BEHAVIORAL|Single-session electrically induced exercise|A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.
215055865|NCT02622295|BEHAVIORAL|Electrically-induced exercise training|Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
214903061|NCT02749500|OTHER|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
214903062|NCT02749500|DEVICE|m2 BAT|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
214903063|NCT00197171|BIOLOGICAL|Combined Hepatitis A and B vaccine|
214903064|NCT01036854|DRUG|EUR-1025|orally, 24 mg, daily for 6 days
214903065|NCT01036854|DRUG|EUR-1025|orally, 8 mg, twice daily over 6 consecutive days
215055866|NCT01027559|DRUG|Sertraline|Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
214903066|NCT01036854|DRUG|EUR-1025|orally, 8 mg, three times a day over 6 consecutive days
214903067|NCT01036854|DRUG|EUR-1025|orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
214903068|NCT01132833|OTHER|enzyme-linked immunosorbent assay|Measurement of markers of coagulation and endothelial activation
214903069|NCT01132833|OTHER|laboratory biomarker analysis|The PPP will be used for in vitro assays to measure TF activity, coagulation markers and markers of endothelial cell damage
214903070|NCT01132833|OTHER|medical chart review|The patient's clinical course with respect to development of venous thromboembolism and response to treatment will be monitored for a total of 3 months from enrollment.
214903071|NCT04579354|OTHER|virtual reality tour|Patients will be guided via VR on their way through the hospital to the operating theater
214903072|NCT00499005|DRUG|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100microgram
214903073|NCT00499005|DRUG|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100micgrams
214903074|NCT06575582|BEHAVIORAL|Support from Digital Navigators to Treatment Team|The trained professionals (the Digital Navigators) support the treatment teams in the study centers in the selection and integration of suitable apps and digital health applications (DiGAs).
214903075|NCT06575582|BEHAVIORAL|Support from Digital Navigators to Patients|The trained professionals (the Digital Navigators) accompany and support the selected patients to find a suitable app for them and integrate it into their treatment.
214903076|NCT06575582|BEHAVIORAL|Training for Digital Navigators|The training takes place in the six study centers and is preferably aimed at medical assistants.
214903077|NCT02205073|DRUG|Placebo RD + AVP SD|Placebo (matching to study drug) repeat doses + intranasal AVP single dose
214903078|NCT02205073|DRUG|Placebo RD + Placebo SD|Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
215055867|NCT01027559|BEHAVIORAL|Cognitive Behavioral Therapy|Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
215055868|NCT02409641|DRUG|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
215055869|NCT03343340|OTHER|Early CRRT|Continous Renal Replacement Therapy
215055870|NCT03343340|OTHER|Late CRRT|Continous Renal Replacement Therapy
215055871|NCT03343340|OTHER|Standard Medical Therapy|Standard Medical Therapy
215055872|NCT01841021|DRUG|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
215055873|NCT00393991|DRUG|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
215055874|NCT00393991|DRUG|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
215055875|NCT00393991|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
215055876|NCT00393991|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
214903079|NCT02205073|DRUG|RG7314 RD + AVP SD|RG7314 repeat doses + intranasal AVP single dose
215055877|NCT04189302|PROCEDURE|connective tissue graft harvest using KPM blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using KPM blade.
215055878|NCT04189302|PROCEDURE|connective tissue graft harvest using 15 C blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using 15C blade.
215055879|NCT01144416|BIOLOGICAL|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
214903080|NCT04492982|BEHAVIORAL|Yoga|1 hour of group format, guided yoga practice
214903081|NCT04492982|BEHAVIORAL|Distress Tolerance|1 hour didactic group format, to develop distress tolerance skills
214903082|NCT02806882|DRUG|Ceftaroline fosamil|600mg IV infusion
214903083|NCT04808674|BEHAVIORAL|Cognitive remediation program|Evaluation of REmediation programs for patients suffering from mild cognitive deficits after Cancer
214903084|NCT03687320|DEVICE|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
214903085|NCT03687320|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
214903086|NCT02603289|DEVICE|Invisalign|
214903087|NCT06275373|DRUG|Teprotumumab Injection [Tepezza]|IGF1 monoclonal antibody
214903088|NCT02387840|DEVICE|Magnetic Resonance Imaging|Patients will have a scan of soft tissue using magnetic field and radio frequency pulses.
214903089|NCT02387840|DEVICE|Magnetic Resonance Fingerprinting|Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2).
214903090|NCT00437567|DIETARY_SUPPLEMENT|Galacto-oligosaccharide (GOS)|Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
214903091|NCT00437567|OTHER|Placebo|Similar quantity of sterile water to be added to milk
214903092|NCT00908544|OTHER|PHI-patients|Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
214903093|NCT00908544|OTHER|CHI-patients|Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
215055880|NCT01144416|BIOLOGICAL|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
215055881|NCT01144416|DRUG|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
214479171|NCT06592443|BEHAVIORAL|LvL UP + MI|"After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle)."
214903094|NCT03170544|DRUG|MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
214903095|NCT03170544|DRUG|MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
214903096|NCT03170544|DRUG|MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
214903097|NCT03170544|DRUG|MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
214903098|NCT03170544|DRUG|MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
214903099|NCT03170544|DRUG|Glargine 3.0 nmol/kg|Glargine 3.0 nmol/kg, SC, as a single dose
214903100|NCT03170544|DRUG|Lispro 1.2 nmol/kg|Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting \~12 hours after MK-1092 administration.
214903101|NCT03170544|DRUG|Placebo to glargine|Placebo to glargine, SC, as a single dose
214903102|NCT03170544|DRUG|Placebo to MK-1092|Placebo to MK-1092, SC, as a single dose
214903103|NCT03170544|OTHER|Dextrose|20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.
214903104|NCT03170544|BIOLOGICAL|Insulin|Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.
214903105|NCT03745079|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
214903106|NCT03745079|OTHER|Spoton Temporal|Mesuring temperature on skin near to temporal artery using Spoton
214903107|NCT03745079|OTHER|Spoton Carotid|Mesuring temperature on skin near to carotidl artery using Spoton
214903108|NCT03280238|DIAGNOSTIC_TEST|Measurement of pupil dilation and analgesia nociception index|painful electrical stimuli of various intensities were administered to the subjects after which changes in pupil diameter and analgesia nociception index were measured
214903109|NCT04192643|DRUG|Tranexamic Acid 100 MG/ML|1 GR TRANEXAMİC ACİD İN 100 ML SALİNE SOLUTİON GİVEN İN 15 MİNUTES
214903110|NCT04192643|DRUG|Placebos|100 ML SALİNE SOLUTİON
214903111|NCT01593397|DRUG|Propofol and Fentanyl administration|Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
214903112|NCT00226577|DRUG|Gemcitabine|Gemcitabine (GemzarR) 1500 mg/m2
214903113|NCT00226577|DRUG|Pemetrexed|Pemetrexed (AlimtaR) 500 mg/m2
214903114|NCT00226577|PROCEDURE|Surgery|When the chemotherapy treatment is completed, the patient's tumor response will be evaluated by a CT scan, pulmonary function test, and another PET scan between days 50 and 63 (during weeks 8 and 9). If there is no growth or spread of the cancer on any of these tests, patients will then proceed to have surgery by week 10 to remove the cancer.
214903115|NCT01156545|DRUG|BIBW 2992|BIBW 2992 40mg, once a day, oral intake, every day
214903116|NCT01156545|DRUG|simvastatin|simvastatin 40mg, once a day, oral intake, every day.
214903117|NCT04600947|DRUG|LP002|10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.
214903118|NCT01003873|BIOLOGICAL|Evaluation of the endocannabinoid system|The evaluation of the endocannabinoid system consist in the determination of plasma concentration of the 2 main endocannabinoids (2AG and AEA) before (5 blood samples) and after (5 blood samples) after consumption of a calibrated food. As a comparator, ghrelin will be measured at the same time.
214903119|NCT01003873|PROCEDURE|Biopsy of visceral and peripheral adipose tissue|The endocannabinoids will be also determined in adipose tissue. Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral adipose tissue will be done 6 months after surgery.
214903120|NCT01003873|BIOLOGICAL|Evaluation of metabolic parameters|The evaluation of the metabolic status consist in evaluation of body composition (DEXA), determination of visceral adiposity (CT scan) and measurement of plasma lipids, glucose, insulin, leptin, adiponectin.
214903121|NCT01003873|BEHAVIORAL|Evolution of behavioral parameters|The behavioral evaluation will de done with different questionnaires: ORWELL 97, HAD scale, Three Factor Eating Questionnaire, Beck Depression inventory, Questionnaire of personality TCI.
214903122|NCT01003873|BEHAVIORAL|Dietician consultation|The evaluation of the metabolic status will also be seen by a dietician.
214903123|NCT01003873|BEHAVIORAL|Psychologist consultation|The behavioural evaluation will de done with a psychologist consultation
214903124|NCT04435873|OTHER|"Survey using Your Home Dialysis Care Experience tool."|Validation of a new survey instrument to capture the experience of care by home dialysis patients.
214903125|NCT03202082|BEHAVIORAL|Neuropsychological testing|Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.
214903126|NCT04143373|PROCEDURE|warm saline irrigation|The objective of this research was to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.
214903127|NCT01772329|OTHER|Cognitive Therapy|CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.
214903128|NCT01772329|OTHER|Routine Care|Routine Care. No Cognitive Therapy Intervention
214903129|NCT01436240|BEHAVIORAL|questionnaire administration followed by cognitive interviews|Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
214903130|NCT03655730|OTHER|weekly psychotherapeutic individual sessions|weekly psychotherapeutic individual sessions following the IPT method during one year
215055882|NCT01144416|DRUG|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
215055883|NCT04821934|OTHER|TR|"TR is a specific remote tele rehabilitation program on exercise activity managed by the physiotherapist (PT) at home, this is the experimental group. PT will explain the rehabilitation program at hospital discharge by the use of a brochure and videos. TR will include an early exercise re-conditioning program \[aerobic exercise at the free body (with or without tools), cyclette and walking with a pedometer\] comprising 20 sessions of 60 minutes/day, 6 out of 7 days to be performed at home, for one month after discharge. The sessions will be self-managed by the patients 4 times a week and an expert PT will remotely supervise 2 times a week through a dedicated platform. The program will be progressively incremental and divided into 4 different levels of intensity (0- 3).~In addition to this specific rehabilitation program, the patients will be followed by a nurse tutor once a day for two weeks and once a week for a further two weeks in a program of Telesurveillance."
215055884|NCT04821934|OTHER|TSu|"The patients of this group will perform a usual Telesurveillance and will be considered as control group.~All patients, at discharge from the hospital, will be provided with a finger pulse oximeter and a dedicated application (app) on their personal smartphone and will be advised on free physical activity to be performed at home. The nurse will check through scheduled calls (once a day for two weeks and once a week for a further two weeks) the patient's health condition, vital parameters and drugs administration. Patients will be able to contact the nurse at each time, in case of specific need, out of the scheduled call, 7/7 days.~A follow up by phone will be planned by nurse tutor at 2 months from the end of the study."
215055885|NCT00003935|DRUG|etoposide|
214302018|NCT01136096|BEHAVIORAL|Physical activity promoting intervention|"1. An interview with a physiotherapist~2. An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home~3. An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model~4. The daily record to check their body weight, exercise mode and duration~5. Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details~6. Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule"
214302019|NCT01136096|BEHAVIORAL|General instruction and education|"1. Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic~2. Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule~3. Without individualized exercise program and interview with a physiotherapist"
214302020|NCT00022828|DEVICE|3-D Laser Imaging Device|
214903131|NCT03655730|OTHER|Usual care|the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
214903132|NCT00999986|DRUG|cyclophosphamide|50 mg oral per day for 7 days
214903133|NCT04947592|DRUG|Fluconazole 150 mg|fluconazole 150 MG once daily for 14 days
214903134|NCT04845867|DEVICE|ISAR-M THYRO|A diagnostic device for early detection of haemorrhage following thyroid surgery
214903135|NCT04993001|OTHER|Open lung extubation|Before starting emergence from anesthesia, the patient will be transferred to their hospital bed or stretcher and seated at 30 degrees. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be maintained at the same level or increased to 50% (minimum FiO2) with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilation mode will be changed to pressure support. The level of pressure support will be modified by the anesthesiologist to generate the same volumes as with controlled ventilation. The PEEP will be maintained at the same level. The minimum respiratory rate will be reduced by 4 min-1. The inspiratory flow for triggering will be 2 L.min-1.
215055886|NCT00003935|DRUG|vincristine sulfate|
215055887|NCT00003935|RADIATION|radiation therapy|
215055888|NCT00860626|DRUG|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
215055889|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
215055890|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
214903136|NCT04993001|OTHER|Conventional extubation|Before starting emergence from anesthesia, the patient will be transferred to his hospital bed or stretcher and kept in the supine position. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be increased to 100% with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilator will be stopped with the APL valve open to atmosphere. The patient will be manually ventilated with the reservoir bag until spontaneous ventilation resumes. Then, the patient may be manually assisted if the treating anesthesiologist deems it necessary.
214903137|NCT00452244|DRUG|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
215055891|NCT05925348|DIAGNOSTIC_TEST|Patients with cardiopulmonary bypass|"Due to the observational design of the study, no study-specific interventions are performed.~Blood samples are measured to analyze blood-levels of endotoxin"
215055892|NCT01654939|DRUG|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
215055893|NCT05522283|DIAGNOSTIC_TEST|Stool and blood CMV PCR|Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
215055894|NCT05088044|OTHER|training porogram|training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
214479172|NCT06592443|BEHAVIORAL|Comparison|Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
214903138|NCT00452244|DRUG|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
214903139|NCT03888469|DEVICE|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
214903140|NCT03888469|DEVICE|Etafilcon A contact lenses|Commercially available daily disposable soft contact lenses
214903141|NCT04108286|DEVICE|1-DAY ACUVUE MOIST|TEST
215055895|NCT05982912|DIAGNOSTIC_TEST|breath sampling|We collect a breath sample of exhaled air and analyse the VOC profile in this sample
215055896|NCT03541499|BIOLOGICAL|BPZE1|Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.
214903142|NCT04108286|DEVICE|DAILIES AQUA COMFORT PLUS|CONTROL
214903143|NCT02983019|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
215055897|NCT03541499|OTHER|Placebo|The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
215055898|NCT04545879|DIETARY_SUPPLEMENT|Raw garlic juice containing allicin|Fresh garlic juice containing around 48mg allicin for 7 days
215055899|NCT02131662|DRUG|BAY1002670|Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
215055900|NCT02131662|DRUG|BAY1002670|Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
215055901|NCT02131662|DRUG|BAY1002670|Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
215055902|NCT02131662|DRUG|BAY1002670|Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
215055903|NCT02131662|DRUG|Placebo|Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
214903144|NCT04133012|OTHER|Samplings|"* blood samples~* rectal biopsies~* nodes biopsies~* cutaneous fat tissues biopsies~* semen sample"
214903145|NCT04098341|DIAGNOSTIC_TEST|IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection|All eligible pregnant migrants will be offered an opt-out screening IGRA blood test for latent Tuberculosis infection
214479173|NCT06365684|DRUG|Sodium zirconium cyclosilicate|In the case of hyperkalemia patients will be treated with Sodium zirconium cyclosilicate to allow the continuation of potassium enriched diet. In case hyperkalemia arises in the control group, patients will be treated with Sodium zirconium cyclosilicate as well.
214903146|NCT02735902|DRUG|Vitamin K antagonist or direct oral anticoagulant treatment|"The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg"
214903147|NCT02735902|DRUG|Aspirin|"Daily dose is between 75 mg and 100 mg.~Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped."
214903148|NCT00054795|DRUG|Motexafin Gadolinium|
214903149|NCT05405816|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy for obesity
214903150|NCT02135523|RADIATION|involved-field radiation therapy|Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
214903151|NCT05623423|OTHER|(Admira Fusion, Voco GmbH, Germany)|cavity margins will be extended to the proximal area, incisal edge, facial and lingual surfaces All enamel margins will be beveled at a 45° angle to the external cavosurface.(approximately 0.5-2.0 mm) An impression for the upper anterior teeth will be taken to produce a silicon palatal index The proximal margins of the restorations will be achieved using the Unica anterior matrix teeth will be etched using 37% phosphoric acid gel for 30 s then rinsed with air water for 20 s A single coat of universal bond cured using and LED light curing unit for 10 s Using the chosen enamel shade of the ORMOCER Resin Composite a thin layer (0.5-1 mm) Unica matrix will used to produce the proximal margins of the restorations Contouring, finishing and polishing of the restoration will be done Dental floss and finishing strips will be used Rubber dam will then be removed and occlusion will be checked using an articulating paper
214903152|NCT05623423|OTHER|Methacrylate Based Composite|The exact same steps as in the intervention will be done but using the chosen shades of Methacrylate Based Composite Resin. (Ceram.X Spectra ST, Dentsply Sirona, UK)
214903153|NCT03784638|PROCEDURE|lingually-based triangle flap design|A mucoperiosteal lingually-based triangle flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
214903154|NCT03784638|OTHER|buccally based triangular flap design|A mucoperiosteal buccally based triangular flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
214903155|NCT03398564|PROCEDURE|Erector Spinae Plan Block|The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.
214903156|NCT03398564|PROCEDURE|Oblique subcostal TAP|ultrasound-guided bilateral oblique subcostal TAP block with bupivacaine 0.25% (20ml on each side)
214903157|NCT06582238|OTHER|Dentists in Clinical Practice|Experience in managing Dentine Hypersensitivity
214903158|NCT01585090|OTHER|doing strengthening exercises of pelvic floor muscles|
214903159|NCT03539302|DRUG|Flecainide Acetate|Oral inhalation form using a nebulizer
214903160|NCT05533619|DRUG|Proton pump inhibitor|Inpatients using proton pump inhibitor
214903161|NCT00993538|PROCEDURE|Blood sampling|
214903162|NCT00993538|PROCEDURE|Bone marrow aspiration|
214903163|NCT02585908|BIOLOGICAL|CIK|CIK cells will be used against tumor cells.
214903164|NCT02585908|BIOLOGICAL|γδ T|γδ T cells will be used against tumor cells.
214903165|NCT02585908|BIOLOGICAL|CIK and γδ T|CIK and γδ T cells will be used against tumor cells.
214903166|NCT02172443|DRUG|tiotropium inhalation powder capsules|
214903167|NCT02172443|DRUG|Atrovent|
214903168|NCT02172443|DRUG|placebo to Atrovent|
214903169|NCT02172443|DRUG|placebo to tiotropium inhalation capsules|
214903170|NCT03883321|OTHER|Cognitive behavioral stress management|Management of patients in 10 group sessions with cognitive and behavioral therapies associated with relaxation in order to learn how to manage stress
214903171|NCT00203333|DEVICE|Medtronic REVEAL|
214903172|NCT03477006|BIOLOGICAL|Whole blood|Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood
214903173|NCT01506505|DRUG|Cardiovascular Agents|Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
214903174|NCT06357897|DRUG|Local PEG4000|PEG-Chula is developed from PEG 4000 used at King Chulalongkorn Memorial Hospital with added sweetener and flavours. Children will be given PEG-Chula at a dose of 0.5 - 1 g/kg/day.
214903175|NCT06357897|DRUG|Commercial PEG4000|For commercial PEG, We use Forlax as the control group. Children will be given Forlax at a dose of 0.5 - 1 g/kg/day.
215055904|NCT00858351|BEHAVIORAL|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
215055905|NCT00858351|BEHAVIORAL|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
214302021|NCT00229255|OTHER|high frequency of meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
214903176|NCT05683704|DRUG|AK105，Anrotinib hydrochloride|AK105 administered IV at day 1 every 3 weeks for 8-12 cycles Anrotinib administered PO at day 1-14 every 3 weeks for 8-12 cycles
214903177|NCT06797505|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
214903178|NCT06797505|DRUG|PEG-rhGH with present preparation (T)|A single subcutaneous injection of PEG-rhGH with present preparation
214903179|NCT02298127|OTHER|Auricular acupressure|For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
214302022|NCT00229255|OTHER|twice a day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
214903180|NCT05579431|DRUG|VX-634|Suspension for oral administration.
214903181|NCT05579431|DRUG|Placebo|Suspension for oral administration.
214903182|NCT02174627|DRUG|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
214903183|NCT02174627|DRUG|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
214903184|NCT00512681|DRUG|Irinotecan, Oxaliplatin, TS-1|"* S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~* Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1~* Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1"
214903185|NCT00071110|PROCEDURE|Electroacupuncture|For subjects randomized to EA, needles were placed at points GV-20-on the crown of the head and yin tang-on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
214903186|NCT00071110|PROCEDURE|Sham|For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
214903187|NCT03213808|OTHER|No intervention: analysis of health data from patients with|No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
214903188|NCT00944060|OTHER|lifestyle intervention|
214903189|NCT05761314|DIAGNOSTIC_TEST|Molecular characterization of solid tumor in RASopathies|NGS analysis on tumor sample
214903190|NCT02350023|DRUG|Topical latanoprost 0.005%|Local application of the drug on affected skin/scalp
214903191|NCT02350023|DRUG|Topical betamethasone 0.05%|Local application of the drug on affected skin/scalp
214903192|NCT04707573|DRUG|Vadadustat|oral capsules
214903193|NCT01025882|DRUG|gemcitabine hydrochloride|Given IV
214903194|NCT01025882|RADIATION|stereotactic body radiation therapy|Given as a single fraction
214903195|NCT05255731|RADIATION|Low frequency laser activated photobiomodulation|"Protocol description Infrared: analgesia, biostimulation of tissues, edema and hyperemia (hard and soft tissues). There will be 11 laser application points, 3 intra-oral and 8 extra-oral, with a total dose of 33J.~Intraoral: one point in the region of the mandibular lingula (point of submersion of the mandibular nerve), one vestibular point and one lingual point in relation to the alveolus of the extracted wisdom tooth.~Extraoral: for muscle relaxation, five points on the masseter muscle; for oedema drainage, one point in each lymph node region: parotid, submandibular and buccal."
214903196|NCT05255731|OTHER|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
214903197|NCT06452017|OTHER|Telerehabilitation exercise program|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased.
214903198|NCT06452017|OTHER|Routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
214903199|NCT01138202|DRUG|LPV/r|LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
215055906|NCT04103476|COMBINATION_PRODUCT|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
215055907|NCT04103476|OTHER|Placebo|Placebo
215055908|NCT05920174|DEVICE|NEO|Subjects will be implanted with the NEO device.
215055909|NCT01708044|DRUG|Pramlintide acetate|
215055910|NCT01708044|OTHER|Placebo|Placebo Comparator
215055911|NCT01402869|DRUG|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
215055912|NCT01402869|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
214302023|NCT01328860|BIOLOGICAL|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
214302024|NCT05132959|DIAGNOSTIC_TEST|magnetic resonance imaging|The MRI images of patients who had undergone to shoulder magnetic resonance imaging because of shoulder pain or another pathology were studied
214302025|NCT04990752|DRUG|ulinastatin|In the ulinastatin group, early application of ulinastatin was performed for inflammation management and organ protection before ECMO initiation.The recommended clinical routine dosage of ulinastatin is 300,000 IU, q8h (continuous administration for more than 5 days).
215055913|NCT01740687|DEVICE|ESS305 (Essure, BAY1454032)|Essure Permanent Birth Control
215055914|NCT01740687|PROCEDURE|NovaSure|Nova Sure Endometrial Ablation
215055915|NCT03139461|OTHER|PT-REFER Capacity-building Toolkit|"1. Written guidelines for building partnerships with physical therapists. Information includes information on who to contact, how to contact them, and how to present information about the program (e.g., evidence base, program structure)~2. Support from Change Agent~3. Technical Assistance Calls"
215055916|NCT05452252|DIAGNOSTIC_TEST|functional mandibular evaluation|Active mandibular movements including depression, protrusion, and left-right deviation, facial anthropometry was measured on facial shape on photograph, and phenotype and asymmetry
215055917|NCT04217018|DIAGNOSTIC_TEST|Prediction of molecular pathology|Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
215055918|NCT05125744|DIAGNOSTIC_TEST|Assisted Ventilation|patients will be invasively ventilated in assisted mode. In all enrolled patients ventilated in assisted mode. Diaphragmatic activity will be evaluated through ultrasound (primary end point) and electrical activity of the diaphragm (optional) at stepwise decreasing of PEEP level. Also, the activity of remaining respiratory muscles will be assessed through sonography at the same levels of PEEP (secondary end point).
215055919|NCT02588157|DEVICE|Macintosh|Direct laryngoscopy
215055920|NCT02588157|DEVICE|Glidescope|Glidescope videolaryngoscope
215055921|NCT02588157|DEVICE|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
215055922|NCT00827814|DRUG|Dutasteride|Dutasteride 0.5 mg od.
215055923|NCT04294355|DEVICE|Artificial intelligence-Assisted colonoscopy|Artificial intelligence-Assisted colonoscopy for detection of colonic polyp
215055924|NCT04294355|PROCEDURE|Conventional colonoscopy|Conventional colonoscopy
215055925|NCT02171689|DRUG|[14C]- BIBW 2992 MA2|
215055926|NCT05004844|DIAGNOSTIC_TEST|Viscoelastic assays and aggregometry tests|Viscoelastic assays and aggregometry tests performed with ROTEM will allow us to characterize the clot forming abilities and platelet functions of our patients. ROTEM is used routinely for aiding clinicians in choosing the appropriate blood products for patients ROTEM requires samples of whole blood in an amount that does not entail additional burden or risk for patients. In our study, viscoelastic assays and aggregometry will be performed upon arrival, and 24-,48-,72-hours post-admission.
215055927|NCT00611390|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.
215055928|NCT00611390|DIETARY_SUPPLEMENT|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
215055929|NCT01226303|DRUG|ATRA|see the protocol
215055930|NCT01226303|DRUG|ATRA + IDA|see the protocol
215055931|NCT02529683|DRUG|Nuvaring|contraceptive vaginal ring with ethinyl estradiol and etonogestrel
215055932|NCT03914989|OTHER|olfactory enrichment (essential oils)|Participants will be exposed to either a higher or lower concentration of essential oils nightly for two hours as they are going to sleep, using a nebulizing fragrance diffuser, rotating through seven different scents, one per night.
215055933|NCT01562886|DRUG|Rilpivirine|Rilpivirine 26mg
215055934|NCT00196209|PROCEDURE|catheter ablation|catheter ablation to treat persistent atrial fibrillation
214302026|NCT00001877|DRUG|Pentoxifylline|
214302027|NCT01048021|PROCEDURE|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
214302028|NCT01813084|DRUG|RV1729 single dose|Safety and tolerability of single escalating doses
214302029|NCT01813084|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
214302030|NCT01813084|DRUG|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
215055935|NCT00196209|PROCEDURE|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
215055936|NCT02006186|BEHAVIORAL|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
214302031|NCT01813084|DRUG|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
214302032|NCT05778786|DEVICE|Acuvue Oasys 1 Day for Astigmatism|CONTROL
214302033|NCT05778786|DEVICE|TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore|TEST
215055937|NCT02151656|DRUG|F17464|
215055938|NCT02151656|DRUG|Placebo|
215055939|NCT06160323|PROCEDURE|EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis|"The EUS scope was first inserted into the stomach, and the coeliac trunk was visualized by scanning from the lesser curve of the gastric body. After visualization, the scope was rotated clockwise, enabling visualization and identification of the left adrenal gland. The coeliac ganglia are often seen to the left of the coeliac artery, between the aorta and the left adrenal gland, at the level between the coeliac artery and the left adrenal artery. They are also visualized cephalad to the coeliac artery in some cases. Hypoechoic nodular structures linked by hypoechoic threads residing in the periphery of this region were defined as the coeliac ganglia . A 19G or 22G needle was used for puncture of the CGN. After confirming the lack of backflow of blood with aspiration, a mixture of 5ml of 0.25-0.5% bupivacaine and 5ml absolute alcohol was injected.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed."
215055940|NCT03390725|BEHAVIORAL|A Healthy School Start Plus intervention|Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting
214302034|NCT05762146|DRUG|Riociguat|Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.
215055941|NCT05964179|BEHAVIORAL|time extended feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 14 hours per day.
215055942|NCT05964179|BEHAVIORAL|time restricted feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 8 hours per day.
214302035|NCT05762146|DRUG|Propylthiouracil|Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors
215055943|NCT00741065|PROCEDURE|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
215055944|NCT03420144|DRUG|Standard Medical Therapy|Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
215055945|NCT03420144|DRUG|Growth Hormone|GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
214302036|NCT05762146|DRUG|Perphenazine|Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
214302037|NCT03280290|BIOLOGICAL|blood|assessment pre-donation of hematopoietic stem cells (blood sample)
214302038|NCT03322254|OTHER|respiratory pathogen panel|lab testing for respiratory pathogens
214302039|NCT02270827|DRUG|Aminophylline|intravenous medication
214302040|NCT02270827|DRUG|Hydrocortisone|Intravenous medication
214302041|NCT00620438|DRUG|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
215055946|NCT06286332|OTHER|Music Therapy|30 minutes of self-selected music playback every day.
215055947|NCT03333694|DRUG|Cutaneous Cream application|Cutaneous Cream application twice daily with experimental (CLL442)
215055948|NCT03333694|DRUG|Placebo Cutaneous Cream application|Cutaneous Cream application twice daily with placebo
215055949|NCT03100266|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamonosus GG
215055950|NCT03100266|OTHER|Inactive capsules|Placebo
215055951|NCT05340530|DRUG|The injectable TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibatam.
215055952|NCT05340530|DRUG|meropenem|Meropenem is a carbapenem antibiotic
214903200|NCT03961737|PROCEDURE|prostate biopsies|"Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment.~Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients."
214903201|NCT03521011|DEVICE|MSCT|Non enhanced MSCT Abdomen
214903202|NCT06778551|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|A therapeutic exercise protocol will be carried out, consisting of 2 sessions per week for 8 weeks, supervised and guided by a physiotherapist. The objective is to improve thoracic mobility, as well as the strength and motor control of the scapular retractor and protractor muscles (middle and lower trapezius, rhomboids, and serratus anterior) and the rotator cuff.
214903203|NCT06778551|OTHER|Control (Standard treatment)|The protocol will include the application of therapeutic ultrasound. For this application, ultrasound gel will be used to reduce friction and improve the transmission of waves. Using a 5 cm² transducer, pulsed ultrasound will be applied at a frequency of 3 MHz and an intensity of 1 W/cm² for 10 minutes. Patients will be informed that they should not feel any sensation during the procedure, and if they do, the intensity will be reduced. Finally, kinesitherapy will be applied through classic shoulder mobility exercises.
214903204|NCT02389829|DRUG|Hydromorphone|
214903205|NCT02389829|DRUG|Prochlorperazine|
214903206|NCT02389829|DRUG|Diphenhydramine|
214903207|NCT00246194|DRUG|risperidone (RISPERDAL CONSTA)|Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
214903208|NCT01950468|DRUG|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
215055953|NCT05340530|DRUG|Avibactam Sodium|Avibactam is beta-lactamase inhibitor.
215055954|NCT05340530|DRUG|Placebo|It is a placebo.
214302042|NCT00620438|DRUG|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
214903209|NCT01950468|DRUG|DaTscan|A single intravenous dose of 3 to 5 mCi
214903210|NCT02165163|OTHER|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
214903211|NCT04527133|DRUG|Aprotinin|Intravenous or inhalation
214903212|NCT02362360|DEVICE|Coloplast Test Product|A new 2-piece ostomy appliance developed by Coloplast A/S
214903213|NCT02362360|DEVICE|Comparator (Hollister)|Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.
215055955|NCT01103856|BEHAVIORAL|Patient Mentor Intervention|The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
215055956|NCT01103856|BEHAVIORAL|HIV transmission risk reduction|The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
214302043|NCT00620438|DRUG|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
214302044|NCT03004066|DRUG|Daptomycin|standard care
214302045|NCT05699603|PROCEDURE|Biopsy|Undergo skin biopsy
214302046|NCT05699603|DRUG|Calcipotriene|Applied topically
214302047|NCT05699603|DRUG|Fluorouracil|Applied topically
215055957|NCT03215381|DRUG|[11C]AZD1390|\[11C\]AZD1390
215055958|NCT04679038|BIOLOGICAL|SHR-1701|Intravenous (IV) on Day 1 of each cycle
214302048|NCT03745326|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
214302049|NCT03745326|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 5 days.
214302050|NCT03745326|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
214302051|NCT03745326|BIOLOGICAL|anti-KRAS G12D mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
214302052|NCT03174197|DRUG|Atezolizumab|Given IV
214302053|NCT03174197|RADIATION|Radiation Therapy|Undergo RT
215055959|NCT04679038|DRUG|Famitinib|Famitinib, po, qd
215055960|NCT01310010|DRUG|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
215055961|NCT05697653|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
215055962|NCT05112848|BIOLOGICAL|NVX-CoV2373|"Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70)."
214903214|NCT06789523|BEHAVIORAL|Friendship Bench|"The Friendship Bench model comprises 6 weekly, individual sessions with trained peer workers in addition to the usual care. Peer workers will help participants identify problems, outline potential solutions, and implement selected solutions.~The adaptation of Friendship Bench for Vietnamese methadone patients made revisions, such as removing the 'Belief in supernatural powers' section, replacing the Shona Symptom Questionnaire with DASS-21, and adding meth use. But this adaptation removed women-focused content on pregnancy and postpartum depression that we plan to include."
214903215|NCT06789523|BEHAVIORAL|Usual psychiatric care|Usual care includes monthly check-ups by peer workers, referral to hospital-based psychiatric services or other available mental health services if needed. This usual care might surpass standard psychiatric care in other provinces given that peer workers in Haiphong have been well trained on case management skills.
214903216|NCT07067827|OTHER|Self-administered questionnaire|The self-administered questionnaire was previously prepared by the research team for another project. It includes 14 questions addressing the dentition, fractures, joint hypermobility, height, and eye abnormalities present in the participants or their relatives. This questionnaire covers the clinical manifestations of rare bone diseases such as osteogenesis imperfecta, pycnodysostosis, hypophosphatasia, and osteopetrosis. This self-administered questionnaire will be filled online by participant. Average completion time of 20 minutes.
214903217|NCT07067827|OTHER|Family tree|For the family tree, this step is done by a telephone interview lasting a maximum of 45 minutes, depending on the size of the participant's family. The researcher will be able to reconstruct the family history with the index case. The family tree will then contain the family history up to the second degree of kinship with respect to the index cases. The information collected through the index cases when creating the family tree must include, for each relative, biological sex, as well as information on the presence or absence of a rare or genetic bone disease and clinical signs associated with these diseases, such as short stature, bone deformities, deafness, eye problems, etc.
214903218|NCT00133016|PROCEDURE|Amniotomy|
214903219|NCT04748562|DRUG|Progesterone|Taking prontogest vaginally
214903220|NCT02084225|PROCEDURE|ultrasound guided regional nerve block|participants were the physicians performing the procedure
214903221|NCT06582654|DEVICE|Sampling|"Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study)."
214903222|NCT01738347|DRUG|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
214903223|NCT06655493|OTHER|No treatment given|Participants will continue their normal care and will not get any treatment as part of this study.
214903224|NCT03746431|DRUG|[111In]-FPI-1547 Injection|\[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
214903225|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection multi-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.
214903226|NCT03746431|BIOLOGICAL|FPI-1175 Infusion|FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.
214903227|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection single-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of \[225\]-FPI-1434 Injection. Dose is per cohort assignment.
214903228|NCT07089706|BIOLOGICAL|mRNA-1283 Variant-containing Formulation|Sterile liquid for injection
214903229|NCT04960592|DEVICE|Spinal Cord Stimulation|Temporary implantation of a clinical available neurostimulator.
215055963|NCT01543919|DRUG|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
215055964|NCT01543919|DRUG|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
215055965|NCT01543919|DRUG|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
215055966|NCT01543919|DRUG|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
215055967|NCT01543919|DRUG|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
215055968|NCT01543919|DRUG|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
215055969|NCT03780751|BEHAVIORAL|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
215055970|NCT03780751|BEHAVIORAL|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
215055971|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using bupivacaine: xylocaine|Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
215055972|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using normal saline|Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
215055973|NCT02656394|DRUG|GL101|Topical Gel
215055974|NCT02656394|DRUG|Placebo|Placebo topical gel
214302054|NCT03174197|DRUG|Temozolomide|Given PO
214302055|NCT06846671|DRUG|BGB-16673|Administered orally
214302056|NCT06846671|DRUG|Bendamustine|Administered intravenously
214302057|NCT06846671|DRUG|Idelalisib|Administered orally
214302058|NCT06846671|DRUG|Rituximab|Administered intravenously
214903230|NCT07095946|DEVICE|Electronic Syringe Intraligament Technique|Use of an electronic syringe device to deliver local anesthesia using the periodontal ligament (PDL) technique in pediatric dental patients
214903231|NCT07095946|DEVICE|Electronic syringe IANB Technique|Use of an electronic syringe device to deliver local anesthesia via the Inferior Alveolar Nerve Block Technique in pediatric dental patients
214903232|NCT05303233|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anaesthetics around the nerve.
214903233|NCT05303233|PROCEDURE|IPACK|The IPACK will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where twenty mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anaesthetics will be observed above the posterior capsule.
214903234|NCT06643637|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
214903235|NCT06643637|DRUG|Placebo|Capsule with no active ingredients
214903236|NCT07104721|DRUG|YTS109 cell|Subjects will receive a single infusion of YTS109 cells. The dose groups are set to commence at 3×10⁶ STAR-T cells/kg, employing a 3+3 escalation principle for dose titration.
214903237|NCT07103070|DEVICE|Arch supports|Set of 3 arch supports supplied by Good Feet
214903238|NCT07101900|DIAGNOSTIC_TEST|68Ga-NYM096 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator. The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration.
214903239|NCT07100249|DRUG|HDM2012|HDM2012 will be administered via IV infusion.
214903240|NCT02970487|DEVICE|Intraocular implant of the Precisight|Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.
214903241|NCT07104695|BEHAVIORAL|Solomiya App - CBT-based self-help intervention|"Solomiya App - CBT-based self-help intervention~The Solomiya app is a mobile-based self-help intervention designed to reduce and cope with depressive symptoms and improve sleep in individuals exposed to chronic stress. It has been created within the Solomiya project and is based on preliminary work in other international health settings (Böge 2022) where it has shown to improve depressive symptoms as part of a Stepped Care and Collaborative Model (SCCM). It includes psychoeducational multimedia modules on stress management and sleep problems, along with cognitive behavioral therapy (CBT)-based tools such as guided relaxation exercises, mindfulness practices, and behavioral activation strategies. The app also offers symptom tracking using the PHQ-9 to support user self-monitoring. Participants are instructed to engage with the app regularly over a 4 week period. The intervention is entirely self-guided and does not involve therapist support. App usage and adherence data will be collect"
215055975|NCT02556281|BIOLOGICAL|Blood sampling|Blood sampling is done for patient with colorectal cancer
215055976|NCT06511687|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered in a single dose at birth for newborn cohort and at the beginning of the campaign for the other cohorts under study
215055977|NCT00104728|DRUG|ZD1839|
215055978|NCT04204850|DRUG|Cabozantinib|Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.
215055979|NCT00126152|BEHAVIORAL|Exercise, education and medical management|
214302059|NCT06846671|DRUG|Venetoclax|Administered orally
214302060|NCT05425056|DRUG|Sirolimus|SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
214302061|NCT05459571|BIOLOGICAL|Axicabtagene Ciloleucel|Administered intravenously
214302062|NCT05459571|DRUG|Cyclophosphamide|Administered intravenously
214302063|NCT05459571|DRUG|Fludarabine|Administered intravenously
214302064|NCT05459571|DRUG|Dexamethasone|Administered orally or intravenously
214302065|NCT05091437|DIAGNOSTIC_TEST|Observational study|Incidental lung nodules identification
214302066|NCT06801626|COMBINATION_PRODUCT|Famotidine and 4% topical cromolyn sodium|Patients will be instructed to take a 20mg famotidine capsule twice daily, and to use the lotion (4% cromolyn sodium) twice daily.
214302067|NCT06801626|OTHER|Placebo|Treatment with active H1 antihistamine plus administration of placebo famotidine and placebo cromolyn sodium.
214302068|NCT06119581|DRUG|LY3537982|Administered orally.
214302069|NCT06119581|DRUG|Pembrolizumab|Administered IV.
214302070|NCT06119581|DRUG|Placebo|Administered orally.
214302071|NCT06119581|DRUG|Cisplatin|Administered IV.
214302072|NCT06119581|DRUG|Carboplatin|Administered IV.
214302073|NCT06119581|DRUG|Pemetrexed|Administered IV.
214302074|NCT06493019|DRUG|Pembrolizumab|Chemoradiation Pembrolizumab 200mg IV
214302075|NCT06493019|DRUG|Paclitaxel|Paclitaxel 50 mg/m\^2 IV
214302076|NCT06493019|DRUG|Carboplatin|Carboplatin AUC 2 IV
214302077|NCT06493019|RADIATION|Radiation|Delivered as per institutional standards
214903242|NCT07104929|DIETARY_SUPPLEMENT|Beta Glucan|12 weeks of supplementation with two capsules daily of BWH Labs Beta Glucan 500
214903243|NCT03578367|DRUG|Asciminib add-on|Asciminib 60 mg or 40 mg taken orally once daily.
214903244|NCT03578367|DRUG|Imatinib|Imatinib 400 mg taken orally once daily
214903245|NCT03578367|DRUG|Nilotinib|Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
214903246|NCT04685512|DRUG|tenofovir disoproxil and emtricitabine|Experimental drugs administration of 7-day short course TDF/FTC
214903247|NCT05043480|DEVICE|PEMF|Participants will receive pulsed electromagnetic fields (PEMF) exposure to alternate lower limbs weekly for 16 weeks. Participants will place alternate lower limb into the PEMF machine. Each lower limb will be exposed to 1.5mT magnetic field exposure for 10 mins once a week (total 10 min each week) for 16 weeks.
214903248|NCT03304301|BEHAVIORAL|sunlight exposure|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
214903249|NCT02562573|DRUG|PBI4050|
214903250|NCT01956201|DRUG|Atorvastatin 20mg|\[Atorvastatin Run-in Period\] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) \[Treatment Period\] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) \[Extension Period\] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)
215055980|NCT01963767|DRUG|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries\* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract\*~* Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
215055981|NCT01963767|DIETARY_SUPPLEMENT|Placebo|
215055982|NCT03520309|PROCEDURE|Dental treatment|Treatment of all dental restorations of the children according to the diagnosis criteria
215055983|NCT00190333|DRUG|escitalopram|escitalopram
215055984|NCT04451200|DRUG|Busulfan Injection|injections doses will be personalized by PK at days -7 and -4
214903251|NCT01956201|DRUG|Fenofibrate 160mg|Refer to Intervention Description of Atorvastatin 20mg
214903252|NCT01956201|OTHER|Placebo (Fenofibrate 160 mg)|Refer to Intervention Description of Atorvastatin 20mg
214903253|NCT01267019|BEHAVIORAL|social cognitive training with in vivo augmentation|24 sessions of social cognitive training plus 6 sessions of in vivo exercises
214903254|NCT01267019|BEHAVIORAL|social cognitive training|30 sessions of social cognitive training without in vivo exercises
214903255|NCT01267019|BEHAVIORAL|non-social skills training|30 sessions of skills training that has no specific social content
215055985|NCT01723969|GENETIC|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
214903256|NCT02729025|DRUG|Evolocumab|Administered subcutaneously once a month using an autoinjector/pen.
214903257|NCT02729025|DRUG|Placebo|Administered subcutaneously once a month using an autoinjector/pen.
215055986|NCT06006871|BEHAVIORAL|The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game|Patients are pharmacologically stable and receive a cognitive intervention with our videogame twice a week in the hospital (10 sessions) and twice a week in their home with a computer video game (other 10 sessions).
215055987|NCT06006871|DRUG|Usual treatment for ADHD|All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.
215055988|NCT04277624|DRUG|fezolinetant - test formulation|Administered orally
215055989|NCT04277624|DRUG|fezolinetant - reference formulation|Administered orally
215055990|NCT03960684|DEVICE|Levita Magnetic Surgical System|Levita Magnetic Surgical System
215055991|NCT06452732|OTHER|MFC for the determination of leukemia stem cell|MFC for the determination of leukemia stem cell
215055992|NCT06617286|BIOLOGICAL|CD30 CAR T-cell|After MAC and AutoHSCT patients will receive CD30+ CAR T-cells (Phase 1B dose level 1 - 1x108/m2 (max 2.5x108) or dose level 2 - 2x108/m2 (max 5.0 x108) 21-42 days after the AutoHSCT and the RP2D dose level obtained in the Phase IB part administered in the Phase II portion.
215055993|NCT02524249|DRUG|Caffeine|
215055994|NCT02524249|DRUG|Placebo (dextrose)|
215055995|NCT02043145|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
215055996|NCT04894019|DEVICE|Continuous invasive blood pressure monitoring|Continuous invasive blood pressure monitoring using an arterial catheter
215055997|NCT04894019|DEVICE|Intermittent non-invasive blood pressure monitoring|Intermittent non-invasive blood pressure monitoring using upper-arm cuff oscillometry
214302078|NCT06493019|DRUG|Pembrolizumab|Maintenance Pembrolizumab 400mg IV
214903258|NCT07112326|BEHAVIORAL|Community Gardening Program|Participants will take part in a 26-week community gardening program with Ecosource, which involves cooking classes, as well as nutrition and type 2 diabetes education. These weekly sessions will be led by Ecosource and take place in community gardens across different sites in Mississauga and at Ecosource's teaching kitchens. Diabetes education sessions will take place once per month (6 times/program) and will be led by subject matter experts including dietitians/diabetes educators. The delivery format for these sessions may be virtual or in-person depending on the topic covered and participant availability. Participants will be invited to a WhatsApp Community Chat to stay motivated and engaged with the study over the 26-week period.
214903260|NCT07113431|DIETARY_SUPPLEMENT|IBD-AID diet combined with Kate Farms Peptide 1.5|Combining standardized-IBD diet developed by the University of Minnesota (IBD-AID) with commercially available pea protein plant-based enteral nutrition formula (Kate Farms Peptide 1.5)
214903261|NCT07113431|OTHER|IBD-AID diet|Standardized IBD diet developed by the University of Massachusetts Medical School (IBD-AID)
214903262|NCT07112248|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214302079|NCT06317662|DRUG|Asparaginase Erwinia chrysanthemi|Given recombinant crisantaspase IM or crisantaspase IM or IV
214903263|NCT07112248|DIETARY_SUPPLEMENT|inulin|Inulin is a kind of soluble dietary fiber.
214903264|NCT07111026|BEHAVIORAL|Sisters of Heart|"The intervention consists of ten weekly, 60-75-minute in-person peer support group sessions led by trained community health workers/promotoras (CHWs/Ps), with 6-10 participants per group. Sessions will be semi-structured, covering AHA Life's Essential 8 (LE8), stress management, and individualized topics based on participant priorities and social needs identified through surveys or group discussions. Each session includes stress management, core educational content, and time for addressing participant-driven issues. CHWs/Ps will also provide individualized support outside the sessions through direct community resource navigation, including phone or in-person warm handoffs to needed services."
214903265|NCT07111026|BEHAVIORAL|Basic intervention|The Basic intervention will include assessment of AHA LE8, provision to participants of results of 1) their baseline AHA LE8 assessments, including lab results, 2) written/online information with pertinent AHA LE8 health education content, 3) stress management educational materials, and 4) written information about the Ellenton Migrant Farm Worker Clinic and a community resource list
214903266|NCT07112430|DRUG|Fentanyl Citrate (Intranasal)|Fentanyl citrate will be administered intranasally at a dose of 2 mcg/kg via a mucosal atomization device, 5 minutes prior to ROP screening. Used in conjunction with standard non-pharmacologic comfort strategies.
214903267|NCT07112430|DRUG|Normal Saline (Placebo, Intranasal)|An equivalent volume of intranasal normal saline will be administered using a mucosal atomization device, 5 minutes prior to ROP screening.
215055998|NCT03015285|BEHAVIORAL|Cognitive Behavioural Therapy|A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.
215055999|NCT06619821|BEHAVIORAL|Emotiaonl skill enhancement|This intervention combines online material with practical, emotion-focused activities. Participants will receive training on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
215056000|NCT06619821|BEHAVIORAL|PCE promotion|The intervention requires parents to complete a weekly parent-child interaction task designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
215056001|NCT06619821|BEHAVIORAL|Psychoeducation|Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
215056002|NCT06709287|OTHER|clear aligners|The investigators measured pain and chewing performance at 8 time points during the first 6 months.
215056003|NCT06709287|OTHER|orthodontic metal bracket|Conventional metal bracket.
215056004|NCT00954161|OTHER|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
215056005|NCT00954161|OTHER|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
215056006|NCT06716723|PROCEDURE|Nephrectomy|Receipt of a laparoscopic nephrectomy for kidney donation
214302080|NCT06317662|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214302081|NCT06317662|BIOLOGICAL|Blinatumomab|Given IV
214302082|NCT06317662|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214302083|NCT06317662|DRUG|Calaspargase Pegol|Given IV
214302084|NCT06317662|PROCEDURE|Computed Tomography|Undergo CT
214302085|NCT06317662|DRUG|Cyclophosphamide|Given IV
214302086|NCT06317662|DRUG|Cytarabine|Given IT or IV
214302087|NCT06317662|DRUG|Daunorubicin|Given IV
214302088|NCT06317662|DRUG|Dexamethasone|Given PO or NG or IV
214302089|NCT06317662|DRUG|Doxorubicin|Given IV
214302090|NCT06317662|PROCEDURE|Echocardiography Test|Undergo ECHO
215056007|NCT06715566|BEHAVIORAL|ActForStroke|ActForStroke is a combination of 10 sessions high-intensity gait training and subsequent with up 7 coaching sessions until 1 year after stroke.
214302091|NCT06317662|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
214903268|NCT07110857|PROCEDURE|Cervical plexus block with 0.2 % Naropeine|Under ultrasound guidance, a superficial cervical plexus block is performed immediately after induction and before skin incision by injecting 15-25 mL of 0.2 % ropivacaine (Naropeine) uni- or bilateral depending on the surgical incision
214903269|NCT07110857|PROCEDURE|Cervical plexus block with saline placebo|Under ultrasound guidance, a superficial cervical plexus block is performed immediately after induction and before skin incision by injecting 15-25 mL of 0.9 % saline uni- or bilateral depending on the surgical incision
214903270|NCT07110766|DRUG|MDR-001|Oral administration of small molecule MDR-001 tablets
214903271|NCT07110766|DRUG|Placebo|Administered orally placebo
214903272|NCT07111312|DIETARY_SUPPLEMENT|Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.|Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, plant extracts, amino acids, and other bioactive compounds designed to support hair growth and scalp health in women.
214903273|NCT07111312|OTHER|Placebo control|Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.
214903274|NCT07112963|DRUG|Fluoride Varnish|"Application of fluoride varnish to proximal surfaces of primary molars following standard clinical protocols to promote remineralization and arrest early carious lesions.~Application of resin infiltrant material to proximal non-cavitated carious lesions in primary molars, performed according to manufacturer instructions to arrest lesion progression.~Sequential application of resin infiltration followed by fluoride varnish on proximal surfaces of primary molars to maximize caries arrest and remineralization effects."
214903275|NCT07113119|OTHER|Exercise intervention|Patients that will be randomly assigned in the group A will be invited to attent 1-year exercise sessions, with frequency 3 sessions per week. The program included 30 minutes of Pilates exercises, strengthening, balance and flexibility exercises, which are performed with rubber bands, mobility sticks and balls.
214903276|NCT07111819|BEHAVIORAL|Self-sampling acceptance|Cervical self-sampling devices will be distributed among the study participants followed by survey on the devices acceptance
214903277|NCT07111000|PROCEDURE|Epley Maneuver|The patient's head is turned 45 degrees towards the side that caused the most nystagmus or reproduced their initial symptoms. The patient is then laid down with their head hanging over the edge of the bed. After that, the head will be rotated 90 degrees in the opposite direction, with the head remaining in a dependent position. The patient is then asked to roll onto their side with their head facing downward. They are then brought back to a sitting position and the head is moved forward 45 degrees. Each position is held until the vertigo and/or nystagmus subsides or for at least 30 seconds
214903278|NCT07111000|PROCEDURE|Sham maneuver|This control maneuver will involve coordinated movements of the hands and legs, while excluding any head movement. Patients will be at first in a sitting position with both feet on the ground and both hands placed on the thighs and then they will be asked to lift both hands off the thighs, keeping the arms extended. They will then be asked to return to their initial upright sitting position. Patients will then raise their right foot off the ground while keeping the left one planted on the ground. It will be an alternating movement between lifting the right and left feet while maintaining a smooth and well- controlled rhythm for 90 seconds.
214903279|NCT07113418|DIAGNOSTIC_TEST|ELISA|Enzyme-Linked Immunosorbent Assay. It's a lab technique used to detect and measure specific proteins like antibodies or antigens in a biological sample using enzyme-linked antibodies. When a substrate is added, the enzyme causes a color change, which makes it easy to measure the result accurately.
214903280|NCT07113353|DEVICE|Brain4Care|Non-invasive intracranial pressure monitor
214903281|NCT07112560|DIAGNOSTIC_TEST|Standard screening procedure for amblyopia|"The standard examination for amblyopia screening consists of three steps:~A monocular visual acuity assessment using optotypes from the LEA scale, presented from the simplest to the most complex in front of each eye via an alternating occlusion mask.~A cover/uncover test, during which the child is required to fixate on an image A Lang I stereopsis test performed under binocular vision."
214903282|NCT07112560|DIAGNOSTIC_TEST|New amblyopia screening method using a virtual reality headset.|The examination with the virtual reality headset consists of three main steps: A monocular visual acuity assessment using optotypes from the LEA scale, presented from the simplest to the most complex in front of each eye via an alternating occlusion mask. The eye-tracking system analyzes fixation and the visual response of the stimulated eye. A cover/uncover test, during which the child is required to fixate on an image projected inside the headset. Eye movements are tracked to detect any deviations or abnormalities in ocular coordination. A Lang I stereopsis test performed under binocular vision, in which the child must identify three-dimensional images hidden within a virtual board. The eye-tracking system detects fixation on the images and allows evaluation of depth perception
215056008|NCT06715566|BEHAVIORAL|Standard care|Usual rehabilitation services
215056009|NCT06718114|PROCEDURE|immediate urinary catheter removal|Immediate urinary catheter removal indicates that the urinary catheter will be removed immediately after surgery.
214302092|NCT06317662|DRUG|Leucovorin|Given PO or NG or IV
214302093|NCT06317662|DRUG|Levoleucovorin|Given IV
214302094|NCT06317662|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214302095|NCT06317662|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214302096|NCT06317662|DRUG|Mercaptopurine|Given PO or NG
214302097|NCT06317662|DRUG|Methotrexate|Given IT or IV or PO or NG
214302098|NCT06317662|DRUG|Methylprednisolone|Given IV
214302099|NCT06317662|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214302100|NCT06317662|DRUG|Prednisolone|Given PO or NG
214302101|NCT06317662|DRUG|Prednisone|Given PO or NG
214302102|NCT06317662|DRUG|Therapeutic Hydrocortisone|Given IT
214302103|NCT06317662|DRUG|Thioguanine|Given PO or NG
214302104|NCT06317662|DRUG|Venetoclax|Given PO or NG
214302105|NCT06317662|DRUG|Vincristine|Given IV
214302106|NCT05696288|PROCEDURE|Respiratory Gas Delivery System|Oxygen therapy during general anesthesia for ENT panendoscopy
215056010|NCT06718114|PROCEDURE|early removal of urinary catheter|The urinary catheter will be kept after surgery and be removed within 48 hours after surgery.
215056011|NCT06718062|DRUG|Aliskiren|Participants in this group will receive Aliskiren (240 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Shenzhen Xinlitai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20138002. The primary objective is to evaluate the non-inferiority of Aliskiren in lowering serum uric acid levels, and its effects on blood pressure and kidney function.
215056012|NCT06718062|DRUG|Losartan|Participants in this group will receive Losartan (100 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Zhejiang Huahai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20143030. The goal is to compare the efficacy of Losartan in reducing serum uric acid levels with Aliskiren and evaluate its impact on blood pressure and kidney function.
215056013|NCT06714760|PROCEDURE|Reconstruction following parcellar resections of the mandibular gingival region|"In our surgical approach, we have used periosteum, galea, or pericranium flaps for reconstruction of bone and tissue defects in the cervicofacial region, with excellent results. To treat mandibular osteoradionecrosis, we harvested periosteum flaps from the radius, demonstrating efficacy in bone regeneration. For minor defects, such as those of the nose, we used flaps from the medial femoral condyle, despite the complexity of harvesting.~The cranial region, particularly the temporo-parietal area, offered excellent vascularization, allowing the use of revascularized flaps for reconstruction of the oral mucosa after removal of carcinomas. These flaps have also been effective in the treatment of pharyngeal fistulas, proving to be a functionally reliable solution for oral cavity and cervicofacial defects."
214903283|NCT07110831|DRUG|Fluoxetine|Participants in the intervention arm will receive oral fluoxetine capsules starting with 20mg daily for 12 weeks. The dose of the fluoxetine may be adjusted during follow-up by titrating the dose against the participants' response..
214903284|NCT07110831|BEHAVIORAL|Cognitive-behavioral therapy|Participants with HAM-D score of between 8 and 13 (mild depression) will receive sessions of Cognitive Behavioural Therapy (CBT) as per standard routine care. Participants in the intervention arm will also receive sessions of CBT as per standard routine care.
215056014|NCT06718881|OTHER|simulation application in a virtual reality environment|In the project, theoretical lessons were given on preeclampsia, postpartum care, and condom counseling, each in a separate week. After each theoretical lesson, an application was made in the laboratory on the subject explained in the same week. The applications were made in the form of a simulation application in a virtual reality environment for the students in the experimental group.
215056015|NCT06718894|OTHER|Biologic fluid sampling|The only interventions in addition to standard clinical practice will be blood sampling, the collection of morning spot urine and the collection of the discarded effluent of the plasmapheresis procedure (when performed according to clinical indication).
215056016|NCT05913544|OTHER|SINTYA|10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session
215056017|NCT06716996|DEVICE|repeated transcranial magnetic stimulation|20 sessions of repeated transcranial magnetic stimulation
215056018|NCT06716996|DEVICE|sham treatment|20 sessions of sham treatment
215056019|NCT06716918|DRUG|Corticosteroid Injection|Participants who have received antenatal corticosteroids (betamethasone or dexamethasone) prior to cesarean section as part of their prenatal care.
215056020|NCT06716385|DEVICE|MSiHy Silicone Hydrogel Soft Contact Lens|The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
215056021|NCT06716385|DEVICE|Monthly Silicone Hydrogel Contact Lenses (oA)|The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
215056022|NCT06717464|DRUG|Capecitabine|1250mg/m2, D1-D14, q3w, for 24 weeks (8 cycles)
214903285|NCT07112235|BIOLOGICAL|Rhinovirus-A16|Nasal inoculation with a dose equivalent to 100 TCID50 of rhinovirus-A16 inoculum will be administered to all participants in the study
214903286|NCT07103369|DRUG|SM17 for injection|SM17 monoclonal antibody for intravenous infusion use
214903287|NCT07103369|OTHER|SM17 placebo for injection|placebo to be compared with SM17, excipient solution of SM17 monoclonal antibody without protein
215056023|NCT06717464|DRUG|Toripalimab|240mg intravenous injection, q3w, for 54 weeks (18 cycles)
215056024|NCT06714825|BIOLOGICAL|HS235|Up to 4 Single and 3 Multiple Ascending Doses
215056025|NCT06714825|DRUG|Placebo|Subcutaneous Injection
215056026|NCT06719167|BEHAVIORAL|Psychoterapy|During 11 weeks admission the programme will include group sessions using different modalities (psychoeducation videos, live psychoeducation groups, expressive arts therapy, equine facilitated therapy, mindfulness and discussion groups) all using TIST methodology. Parallell individual therapy with therapist (psychologist or psychiatrist) and milieu therapist. All therapists will be trained minimum in TIST level 1 and recieve supervision from an expert TIST therapist.
215056027|NCT03687775|OTHER|Stability assessment|Qualitative and quantitative stability assessment
215056028|NCT06713278|OTHER|masseter muscle thickness measurement|masseter muscle thickness measurement with ultrasonography
215056029|NCT06713278|OTHER|scales|headache impact scale (HIT-6) Short SF-36 fibromyalgia total score widespread pain index symptom severity scale fibromyalgia impact questionnaire (FIQ)
215056030|NCT03941483|DRUG|ASP1128|Intravenous Infusion
215056031|NCT03941483|DRUG|Placebo|Intravenous Infusion
215056032|NCT01211392|OTHER|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
215056033|NCT01586689|BEHAVIORAL|Oxford House|community-based recovery home for participants recovering from substance dependency
215056034|NCT01586689|BEHAVIORAL|Safe Haven|professionally-staffed treatment facility
215056035|NCT01586689|BEHAVIORAL|Usual aftercare|control group - participants may or may not seek treatment on their own
215056036|NCT01252589|OTHER|HRQOL questionnaire|
215056037|NCT02835144|OTHER|TIQAAM_therapy|The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
214302107|NCT05732194|DRUG|ITI-333|ITI-333 oral solution
214302108|NCT05732194|OTHER|Placebo|Matching placebo
214302112|NCT03447808|BIOLOGICAL|Daratumumab|Given IV
214302113|NCT03447808|DRUG|Ibrutinib|Given PO
215056038|NCT02835144|OTHER|Psychoeducation|This intervention is a psychoeducation module pertaining to substance use disorders.
214669785|NCT03138564|BEHAVIORAL|SPIRIT|"SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.~During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.~Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record."
214903288|NCT07109453|OTHER|18 Test Products along with positive and negative control|1\. Deep Hydration Gel 2. Anti-Wrinkle Gel 3. Anti-Aging Gel 4. Under Eye Cream 5. Brightening Cream 6. Moisturizing Cream 7. Anti-Acne Serum 8. Face Toner 9. Anti-Aging Toner 10. Clear Glow Toner 11. Super Anti-Aging Serum 12. Sun Screen SPF50 13. Anti-Pigmentation Serum 14. Super Cleansing Cream 15. Root Revive Hair Serum 16. Root Nourishment Hair Oil 17. Anti-Acne Face Wash 18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
214903289|NCT07110779|BEHAVIORAL|Telenursing consultation|Telenursing consultations, which will be carried out via telephone calls, video calls, or messaging platforms, will be held between one, three, and five months after the first consultation. The North American Nursing Diagnosis Association (NANDA-I), the Nursing Outcomes Classification (NOC), and the Nursing Interventions Classification (NIC) taxonomies will be used to structure these consultations.
214903290|NCT07113379|BIOLOGICAL|Evaluate the effectiveness of current Human Papillomavirus (HPV) vaccination and screening programs in reducing cervical cancer incidence in Spain.|Data will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.
215056039|NCT04283188|BEHAVIORAL|Dialectical behavioral therapy|Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
215056040|NCT00529672|PROCEDURE|crossectomy and short stripping|under spinal or complete anaesthesia
215056041|NCT00529672|PROCEDURE|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein\>
215056042|NCT00529672|PROCEDURE|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
214302114|NCT03447808|OTHER|Laboratory Biomarker Analysis|Correlative studies
214302115|NCT03447808|OTHER|Pharmacological Study|Correlative studies
214302116|NCT00678821|OTHER|Aerobic exercise|Supervised aerobic exercise and educational lectures for 10 weeks
214302117|NCT06639607|BIOLOGICAL|PEP-CMV vaccine|Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.
214302118|NCT06639607|BIOLOGICAL|Tetanus booster|Td 5 flocculation units, Lf
214302119|NCT06639607|BIOLOGICAL|Nivolumab|Administered intravenously
214302120|NCT06639607|DRUG|Temozolomide|Administered orally
214302121|NCT06807632|DRUG|Valemetostat|"Dose level -1 100 mg po once daily~Dose level 1 150 mg po once daily~Dose level 2 200 mg po once daily"
214302122|NCT06807632|DRUG|Atezolizumab|1680 mg IV q4weeks
214302123|NCT00099437|DRUG|Fulvestrant|intramuscular injection
214302124|NCT03366155|DEVICE|Codman 3000 constant flow pump catheter|implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter
214302125|NCT03366155|DRUG|Panitumumab|6 mg/kg, IV
214302126|NCT03366155|DRUG|FUDR-Dex|HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
214302127|NCT03366155|DRUG|Oxaliplatin|85 mg/m2, IV
214302128|NCT03366155|DRUG|5FU|2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin
214302129|NCT03366155|DRUG|Irinotecan|150 mg/m2, IV
214302130|NCT03366155|PROCEDURE|HAIP installation|HAI pump installation
214302131|NCT03366155|DRUG|cetuximab|500 mg/m2, IV
214302132|NCT03366155|DEVICE|Medtronic SynchroMed II Pump|implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
214302133|NCT04674748|DRUG|INCB086550|Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
214302134|NCT05521256|DRUG|NNC0113-6856|Participants will receive NN0113-6856 orally or intravenously.
214302135|NCT05521256|DRUG|Placebo|Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.
214903291|NCT07110961|PROCEDURE|A suggested immobilization test (SIT)|The Suggested Immobilization Test (SIT) is a provocative test. RLS symptoms (urge to move the leg and leg paresthesia) are primarily observed during wakefulness, especially at rest, in the evening, and/or during the night. During the test, the patient remains in a bed (or a reclining chair), at a 45° angle with legs outstretched. Originally, the SIT only quantified leg motor activity. Since 2002, it also includes the assessment of leg discomfort, which is estimated by the patient every 5 min, on a 100-mm horizontal visual analogue scale. Leg movements are quantified using surface electromyography (EMG) from bilateral anterior tibialis muscles. Using these pathological thresholds, the clinical RLS/WED diagnosis is correctly predicted in 88% of subjects with a sensitivity of 82% and a specificity of 100%.
214302136|NCT05821699|BEHAVIORAL|LCS (Life Care Specialist)|"The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~* Opioid Risk Education~* Therapeutic Intervention~* Clinical Pain Coordination"
214479174|NCT06657729|OTHER|Succiometry|Assessement of sucking performance by measuring pressures (suction, crushing) with a succiometer every 10 days. This instrument consists of a standard silicone teat for premature newborns, which is connected via two silicone tubes to pressure micro-sensors. These pressure sensors measure the child's sucking activity on the teat. This activity is characterised by suction and crushing movements. It is a non-nutritive sucking activity (no fluid is delivered). Sucking performance is recorded during a period of calm awakening of the infant and over a period of 5 minutes, and is part of routine care since non-nutritive sucking is a common practice in neonatal unit. The first measurement will be taken in the first week of life and then every 7-10 days until discharge from the neonatal unit.
214479175|NCT06656507|PROCEDURE|Quadro Iliac Plane Block (QIPB)|The Quadro Iliac Plane Block (QIPB) will be performed pre-awakening in patients undergoing lumbar vertebra surgeries. Using a low-frequency convex ultrasound transducer (2-6 MHz), the spinal process will be identified at the L3 level in a prone-positioned patient. The transducer will be moved laterally to locate the transverse process within the erector spinae muscle and then rotated to the parasagittal plane to identify the Quadratus Lumborum Muscle (QLM) attachment to the iliac crest. A 22G x 100 mm block needle will be advanced under ultrasound guidance, and 50 mg (0.25%) bupivacaine will be injected bilaterally into the fascia beneath the QLM. This technique is designed to provide effective postoperative pain control by blocking the nerves in the quadratus lumborum plane.
214669786|NCT03138564|BEHAVIORAL|Comparison Condition|As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
214669787|NCT06315114|BEHAVIORAL|Lighthouse MBT Parenting Program (LPP)|The experimental group is a manualized transdiagnostic mentalization-based parenting intervention (Lighthouse MBT Parenting Program). This is a 12-week parenting group intervention (weekly session of 2 hours) with one preperatory initial individual session (1 hour) before the group commence.
215056043|NCT04416243|BEHAVIORAL|Recumbent Stepping, High-Intensity Interval Training|"The intervention will involve 12 weeks of supervised, progressive (i.e., intensity increases after midpoint testing based on reassessment of aerobic fitness) HIIT sessions two to three times per week. HIIT exercise sessions will be manualized and led by exercise leaders. Secondary outcomes testing will occur at baseline (week 0), midpoint (following week 6 of training), and post-intervention (following week 12 of training).~The individual HIIT sessions will involve 10 cycles of 60s intervals at the wattage associated with 90% VO2peak followed by 60s of active recovery intervals at 15 watts, totaling 20 min in length. All exercise sessions will begin and end with a 5-minute warm-up and cool-down, respectively. Required power output for each interval of the exercise session will be individualized and completely automated. VO2peak from baseline and midpoint testing will be used to determine exercise intensity for weeks 1-6 and weeks 7-12, respectively."
215056044|NCT04624100|PROCEDURE|Hernia repair|Primary or mesh repair of primary ventral or incisional hernia
215056045|NCT00570843|DRUG|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
215056046|NCT00570843|DRUG|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
215056047|NCT02668341|OTHER|non-interventional|non-interventional survey study
215056048|NCT02345733|OTHER|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
215056049|NCT02345733|DRUG|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
214302137|NCT05821699|BEHAVIORAL|Standard of Care|Patients will receive the current standard-of-care for pain management in the aftermath of surgery: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
214302138|NCT06007638|DRUG|LY3876602|Administered IV.
214302139|NCT06007638|DRUG|Placebo|Administered IV.
215056050|NCT04698239|DEVICE|LASER MILESMAN 445 NM|Laser application
215056051|NCT00928343|DRUG|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
215056052|NCT00928343|DRUG|Placebo|Matching subcutaneous or oral placebo
214302140|NCT03312972|RADIATION|HDR Brachytherapy|HDR Brachytherapy implant, deliver 1 to 2 fractions, Up to 30 Gray (Gy) to target lesion
214302141|NCT06646276|BIOLOGICAL|BMS-986489 (BMS-986012+Nivolumab)|Specified dose on specified days
214302142|NCT06646276|BIOLOGICAL|Atezolizumab|Specified dose on specified days
214302143|NCT06646276|DRUG|Carboplatin|Specified dose on specified days
214302144|NCT06646276|DRUG|Etoposide|Specified dose on specified days
214302145|NCT05413369|DRUG|Insulin glargine/Lixisenatide|solution, by subcutaneous injection
214903294|NCT07105254|DRUG|Roflumilast topical 0.3% foam|Roflumilast 0.3% topical foam
215056053|NCT00054743|PROCEDURE|Blood draw|
214903295|NCT07112508|BEHAVIORAL|PRISM dashboard is a data report|The PRISM dashboard captures a clinicians activity relative to their peers. It provides social norms feedback on an array of clinical interventions that an FCP makes.
214903296|NCT07112508|OTHER|THe usual care intervention is a first contact physiotherapy service.|usual care
214903297|NCT07111143|OTHER|nursing intervention|medication only
214903298|NCT07111169|DEVICE|intermittent theta burst stimulation (iTBS) intervention|iTBS protocol: Intervention with an 80-120% resting threshold was used. In the active group, the left dlPFC was selected as the stimulation site and a stimulation protocol with iTBS parameters was given. This was a neuro-modulation protocol of excitatory sequences, with theta burst stimulation at 50 Hz, repeated at 5 Hz, stimulation for 2 s with an interval of 8 s, for a total of 1,800 pulses, with a treatment time of about 20 min/session, two sessions per day, with a15-30 min rest between sessions, and five consecutive days of treatment per week, with a rest of 2 days, and two weeks of treatment.
214903299|NCT07110753|BEHAVIORAL|combined lifestyle intervention focusing on various lifestyle components, delivered by a lifestyle coach and oncology nurse|The combined lifestyle intervention focuses on various lifestyle components, including nutrition, physical activity, sleep, stress and sense of purpose, and is structured around the process of behaviour change. It is delivered by a lifestyle coach in collaboration with an oncology nurse.
214903300|NCT07110753|BEHAVIORAL|short online lifestyle intervention by lifestyle coach and educational materials after 6 months|The control group receives 4 online group sessions from a lifestyle coach and all educational materials after 6 months of intervention
214903301|NCT07111845|BEHAVIORAL|Medical Consultation|Participants will be randomly assigned to receive medical consultation about urinary stone disease from one of five sources: a real urologist (in-person) or one of four AI chatbots (ChatGPT, Gemini, Perplexity, or Microsoft Copilot). Each participant will be instructed to ask all their questions related to urinary stone disease and continue the consultation until they feel adequately informed. The consultation format (human vs. AI) will depend on group assignment. After the session, participants will complete a validated satisfaction questionnaire (CSQ-8) to assess their experience.
214903302|NCT04240626|DRUG|Neurontin|600 mg on-call prior to surgery, post surgery 100 mg liquid q 8-12 hours post surgery with Tylenol every 6 hours
215056054|NCT03714438|DRUG|Medicago Sativa|Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.
214903303|NCT04240626|DRUG|Dilaudid Injectable Product|.5-1 mg IV Q3 hours and IV Tylenol 1000mg every 6 hours post surgery transitioning to oral pain control medications (Hycet 7.5/325mg/5 ml, 5-10 ml every 4 hours
214903304|NCT04240626|DRUG|Marcaine Injectable Product|0.25% local injectable anesthetic agent infiltrated at all laparoscopic incision sites for both groups.
214903305|NCT04240626|DRUG|Oxycodone Hydrochloride|1 mg/ml oral solution, dosage 5-10mg q4h prn for pain control
214903306|NCT04240626|DRUG|Hycet 7.5Mg-325Mg/15Ml Solution|Dosage: 10-15ml q4h prn for pain control
214903307|NCT04240626|DRUG|Zofran Injection|4 mg IV for nausea control while inpatient, prn
215056055|NCT03714438|DIETARY_SUPPLEMENT|Placebo|Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.
215056056|NCT00537537|DRUG|Telbivudine|
215056057|NCT01082081|DRUG|Paracetamol 1000 mg|Paracetamol 1000 mg
215056058|NCT01082081|DRUG|Paracetamol 500 mg|Paracetamol 500 mg
214903308|NCT04240626|DRUG|Scopolamine patch|Topical application patch for nausea control, used with/without Ativan.
214903309|NCT04240626|DRUG|Ativan|0.5mg IV as needed in conjunction with/without Scopolamine and Zofran for Nausea control
214903310|NCT04240626|DRUG|Flexeril Oral Product|5 mg orally q8h prn for muscle spasms.
214903311|NCT04240626|DRUG|Tylenol Suspension|1000 mg q6h PRN for pain control.
214903312|NCT05673577|DRUG|Camrelizumab+cetuximab+chemotherapy|"Camrelizumab: 200mg vgtt q3w, 3 weeks as a cycle; Cetuximab first dose 400mg/m2, vgtt, following by 250 mg/m2 after first dose, qw, 3 weeks as a cycle; albumin paclitaxel: 125mg/m2, vgtt, d1, 8, q3w，for up to 6 cycles; cisplatin: 75mg/m2, vgtt，d1，q3w, for up to 6 cycles;~Then, in maintenance therapy, Camrelizumab: 200mg vgtt q2w; Cetuximab 500mg/m2, vgtt q2w until intolerable toxicity or disease progression"
215056059|NCT01082081|DRUG|Placebo|Placebo
215056060|NCT01980199|DRUG|Fexinidazole|"600 mg tablets given orally, after the main daily meal~* at the daily dose of 1800 mg (3 tablets) once a day for 4 days~* continued by 1200mg (2 tablets)once a day for 6 days"
215056061|NCT04152954|DEVICE|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
215056062|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
215056063|NCT00932035|DRUG|isosulfan blue based lymphatic mapping|
215056064|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo standard axillary lymph node dissection
215056065|NCT00932035|PROCEDURE|quality-of-life assessment|Ancillary studies
215056066|NCT00932035|OTHER|Questionnaire administration|Ancillary studies
215056067|NCT00670930|DRUG|omalizumab at a dose of 0.016mg/kg/IU/mL|
215056068|NCT00670930|DRUG|Placebo|
215056069|NCT04949945|BEHAVIORAL|Self Help Culturally Cognitive Behavioral Therapy|Experimental group (CHF patients)will be screened on PHQ9 questionnaire for depression after receiving guided self help culturally adapted cognitive therapy they will be reassessed for their depression,improvement in functional disability ,improvement in classification of NYHA,reduction in hospital admission as compare to control group.
215056070|NCT01464749|BEHAVIORAL|Task-oriented circuit class training|5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
215056071|NCT01464749|BEHAVIORAL|usual care|no specific rehabilitation
214302146|NCT05413369|DRUG|IDegAsp|solution, by subcutaneous injection
215056072|NCT04592471|DEVICE|kneeMID500-STRONG700|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (2 device types: Knee MID 500 and Knee STRONG 700) totalling 60 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
215056073|NCT04584047|PROCEDURE|Cell-based non-invasive prenatal testing|Blood sampling.
215056074|NCT03199677|DRUG|Apatinib|Apatinib is an oral tyrosine kinase inhibitor.
215056075|NCT01539447|DRUG|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
214302147|NCT05413369|DRUG|Metformin|Tablet, orally
214302148|NCT05413369|DRUG|SGLT2 inhibitor|Tablet, orally
214903313|NCT06940973|GENETIC|Parental samples|"On fertilization, following the conventional ICSI/IVF procedure, samples from cumulus cells (obtained during the routine oocyte denudation process) and surplus sperm cells present in seminal plasma will be retrieved. These samples will be stored frozen at -20°C until they are sent to Igenomix. There, they will be used to perform the genetic analysis required to achieve the study's objectives, provided the patient consents to participate. If the patient ultimately chooses not to participate, these samples will be destroyed.~Parents may be asked to provide a saliva sample for the same purpose in cases where obtaining the samples during fertilization was not possible or if the collected samples were unsuitable for processing in the laboratory. The saliva sample may be collected at the clinic during one of the scheduled visits for reproductive treatment or, alternatively, by the parents at home using a kit provided by the clinic."
214903314|NCT06940973|DIAGNOSTIC_TEST|PGT-A|On day 3 of development, assisted hatching will be performed to facilitate biopsy at the blastocyst stage. Each embryo will be biopsied in the laboratory using conventional trophectoderm (TE) biopsy techniques on day +5, +6, or +7 of development, depending on when they reach the appropriate blastocyst stage. After biopsy, blastocyst will be vitrified following the clinical routine protocol and store until the genetic results are available. The biopsy samples will be placed in a PCR tube labeled with its corresponding study-specific code and stored in a cold rack at 4°C before being transferred to a freezer at -20°C. Finally, the samples will be sent to the Igenomix for preimplantation genetic testing for aneuploidy.
214903315|NCT06940973|GENETIC|TE rebiopsies and spent blastocyst media collection|"After obtaining the PGT-A results, any embryo not genetically confirmed as euploid and without ploidy abnormalities will be thawed, washed, and cultured for rebiopsy. A complementary analysis using next-generation sequencing (NGS) techniques will be performed to confirm the diagnosis and determine the origin of the abnormalities. For this additional analysis, in addition to the new biopsies, the individual culture medium of each embryo will be aspirated after an incubation period of 8 to 24 hours. The collected medium will be placed in PCR tubes and stored in a freezer at -20°C before being sent to the laboratory.~Regardless the result of these complementary analysis, no rebiopsied blastocyst will be considered for clinical purposes."
214903316|NCT06940011|DIETARY_SUPPLEMENT|Endocalyx Pro|4 capsules once daily OR 2 capsules twice daily
214903317|NCT06940011|OTHER|Placebo|4 capsules once daily OR 2 capsules twice daily
215056076|NCT01539447|DRUG|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
215056077|NCT01274234|DEVICE|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
215056078|NCT01235663|BEHAVIORAL|advisory support|regular advisory support to the prolong breast-feeding period
215056079|NCT02587832|DEVICE|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
215056080|NCT02587832|DEVICE|NCPAP|Bubble CPAP System.
215056081|NCT04593368|OTHER|FMT|oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
214302149|NCT02809677|OTHER|Non-Interventional|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
214479176|NCT06656507|PROCEDURE|Erector Spinae Plane Block (ESP)|The Erector Spinae Plane Block (ESP) will also be performed pre-awakening. A linear ultrasound probe will be placed transversely at the level of the L3 vertebra to visualize the transverse process. A block needle will be advanced under ultrasound guidance until it touches the transverse process, after which the needle will be withdrawn 1 mm. Fifty milligrams (0.25%) bupivacaine will then be administered bilaterally. The ESP block aims to provide postoperative analgesia by blocking sensory nerves in the erector spinae plane.
214669788|NCT06315114|BEHAVIORAL|Care as usual (CAU)|"1-2 next of kin sessions (called 'Familiesamtale') is considered the care as usual offered to parents in adult mental health service in the Capital Region of Denmark.~Parents are offered the possibility of bringing their spouse or offspring to one of the sessions."
215056082|NCT00187304|DEVICE|Aortic valve replacement|
215056083|NCT05874505|DRUG|Adalimumab|Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
215056084|NCT05874505|DRUG|Tocilizumab|Tocilizumab 162 mg subcutaneous each week for 15 weeks
215056085|NCT03368781|DEVICE|AcQMap Imaging and Mapping System|3D Cardiac Imaging and Mapping during ablation procedures
215056086|NCT01107639|BIOLOGICAL|cetuximab|Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion
215056087|NCT01107639|DRUG|cisplatin|"* Cisplatin 75 mg/m2 1h infusion d1, 22~* Cisplatin 25 mg/m2 1h infusion weekly x5"
214302150|NCT01471808|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
215056088|NCT01107639|DRUG|docetaxel|"* Docetaxel 75 mg/m2 1h infusion d1, 22~* Docetaxel 20 mg/m2 1/2h infusion weekly x5"
214302151|NCT01471808|DRUG|CSII, Metformin, Pioglitazone|CSII for 2\~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
214302152|NCT01471808|DRUG|CSII, Sitagliptin|CSII for 2\~4 weeks combined with sitagliptin 100mg/d for 3 months
214302153|NCT06077760|BIOLOGICAL|Intismeran autogene|IM injection
215056089|NCT01107639|PROCEDURE|adjuvant therapy|During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².
214302154|NCT06077760|BIOLOGICAL|Pembrolizumab|IV infusion
214302155|NCT06077760|OTHER|Placebo|IM injection
214669789|NCT02670304|DRUG|letrozole|letrozole from the day of oocyte retrieval for 5 days
214669790|NCT02670304|DRUG|Aspirin|aspirin from the day of oocyte retrieval for 5 days
214903318|NCT06941233|BEHAVIORAL|Our Peers - Empowerment and Navigational Support - Community Living (OP-ENS - CL)|Op-ENS - CL is a 12-month, remote delivered peer navigator intervention. Participants will meet with a trained peer navigator who mentors nad supports them through a manualized process of collaborative conversations, barrier identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
214903319|NCT06940128|PROCEDURE|Direct Ischemic Conditioning A|Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 5 cycles of 30-s balloon inflations and 30-s deflations.
214903320|NCT06940128|PROCEDURE|Direct Ischemic Conditioning B|Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 4 cycles of 60-s balloon inflations and 60-s deflations.
214903321|NCT06940128|PROCEDURE|Direct Ischemic Conditioning C|Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 3 cycles of 120-s balloon inflations and 120-s deflations.
215056090|NCT01107639|PROCEDURE|neoadjuvant therapy|During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
215056091|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
215056092|NCT04750343|BIOLOGICAL|GBP510 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.
215056093|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
215056094|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
215056095|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
215056096|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
215056097|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
215056098|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
215056099|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
215056100|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
214302156|NCT05636176|DRUG|Ziltivekimab|Ziltivekimab subcutaneous (s.c.) injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
214302157|NCT05636176|DRUG|Placebo|Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
214302158|NCT04933539|DRUG|Dexamethasone|Dexamethasone PO/IV (for Cycles 1-4: Dexamethasone 40 mg IV/PO on days 1, 8, 15, 22; for Cycles =5: Dexamethasone 20 mg IV/PO on days 1, 8, 15, 22); for up to 12 cycles
214302159|NCT04933539|DRUG|Carfilzomib|Carfilzomib IV (for Cycles 1-2: 20 mg/m2 IV on day 1, 56 mg/m2 IV on days 8, 15; Cycles =2: 56/m2 IV on days 1, 8, 15); for up to 12 cycles
214302160|NCT04933539|BIOLOGICAL|Daratumumab|Daratumumab SC 1800 mg (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); up to 36 cycles total
214302161|NCT04402788|DRUG|Atezolizumab|Given IV
214302162|NCT04402788|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
214302163|NCT04402788|PROCEDURE|Computed Tomography|Undergo CT
214302164|NCT04402788|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214302165|NCT04402788|PROCEDURE|Positron Emission Tomography|Undergo PET
214302166|NCT04402788|RADIATION|Radiation Therapy|Undergo radiation therapy
214302167|NCT04103892|DRUG|CLE-100|1 tablet of CLE-100 administered once daily
214302168|NCT04103892|DRUG|placebo|1 tablet of placebo administered once daily
214302169|NCT03288025|BEHAVIORAL|Nutrition and Exercise|5 times a week exercise training and biweekly diet counseling for 12 weeks.
214302170|NCT05933577|BIOLOGICAL|Intismeran autogene|IM injection
214903322|NCT06795035|DIAGNOSTIC_TEST|Continuous Saline Thermodilution|Continuous saline thermodilution for determination of microvascular resistance reserve (MRR) is a novel operator-independent method to assess coronary microvascular function. CST has been studied in the setting of angina with nonobstructive coronary arteries (ANOCA), but not in the setting of acute MI. In contrast, bolus thermodilution, used to determine the index of microcirculatory resistance (IMR), has been shown in the setting of STEMI to predict extent of myocardial injury and long-term clinical outcomes (e.g., heart failure, mortality, nonfatal MI, and ischemic stroke). In contrast to bolus thermodilution techniques, CST does not require the use of active medications (e.g., papaverine or adenosine) -- only a small volume of normal saline.
214903323|NCT03212235|RADIATION|Hypofractionated radiation therapy|Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
214903324|NCT03376724|OTHER|Functional Exercise Protocol|Functional exercise protocol. This protocol started with corporal conscience exercise, breathing, abdominal activation, activities such as sitting, getting up, climbing stairs, reaching with arms, moving forward, bodyweight exercises, bridges and boards. This protocol will be performed during 12 weeks, two sessions per week.
214903325|NCT03376724|OTHER|Minimal|Analgesic use when necessary and a single back scholl class
214903326|NCT03427242|DRUG|Apatinib|oral apatinib 750mg qd
214903327|NCT00980694|DIETARY_SUPPLEMENT|ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
214903328|NCT07112001|BEHAVIORAL|PositiveLinks with Counseling|A community health worker delivered, specialized counseling intervention through video call on the PositiveLinks app
215056101|NCT05962281|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS), a form of non-invasive brain stimulation which involves the use of low intensity currents propagated via the scalp, is widely implemented as both a fundamental and clinical neuroscientific tool. Over the last decades, tDCS showed significant therapeutic promise, as numerous studies revealed that it can result in improved attention and executive functions in patients with neurological disorders, through modification of neuronal excitability.
215056102|NCT05923697|BEHAVIORAL|AF-EMDR|"Investigational treatment~All participants receive four 90 min. AF-EMDR sessions within a timeframe of two weeks following the baseline phase. The AF-EMDR treatment will be provided by the principal investigators, a level II EMDR therapist (RvdH) and an EMDR consultant in training who developed the AF-EMDR protocol. The EMDR therapist (RvdH) will be trained by the EMDR consultant (WM), who is available for consultation. Additionally, both participate monthly in peer-supervision whereby videotaped sessions are discussed. See appendix 1 for a detailed understanding of the AF-EMDR protocol."
215056103|NCT06552845|DIAGNOSTIC_TEST|LGE-MRI Scan|Participants will receive LGE-MRI scan before catheter ablation and 3 months after catheter ablation
214302171|NCT05933577|BIOLOGICAL|Pembrolizumab|IV infusion
215056104|NCT05304442|DRUG|Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]|Single Dose of IV Iron
215056105|NCT05304442|DRUG|Ferrous Sulfate 65 mg elemental iron (325 mg tablets)|Once daily by mouth for 42 days
215056106|NCT03431454|PROCEDURE|trained to do the pencil push-ups procedure|15 minutes per day, five days a week
215056107|NCT03431454|PROCEDURE|using a major amblyoscope twice weekly with additional home orthoptic therapy|60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
215056108|NCT03431454|PROCEDURE|using three diopter over-minus lenses and a base out prism|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
215056109|NCT01949766|DRUG|Glycerol phenylbutyrate|
215056110|NCT03493451|DRUG|Tislelizumab|Administered intravenously
215056111|NCT05097560|DEVICE|high flow nasal cannula|HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.
215056112|NCT05097560|DEVICE|Venturi mask|VM is commonly used by COPD patients during exercise training.
215056113|NCT05262777|DEVICE|GP0112|Injectable gel
215056114|NCT05262777|DEVICE|Restylane Lyft Lidocaine|Injectable gel
215056115|NCT02248441|OTHER|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
214302172|NCT05933577|OTHER|Placebo|IM injection
214302173|NCT05442957|BEHAVIORAL|BRIGHT|BRIGHT is a manualized theory-based tele-CBT intervention consisting of 6 weekly 60-minute sessions. BRIGHT is delivered one-on-one by a licensed clinical psychologist at each site via standard video tele-CBT platform. BRIGHT session topics include (1) psychoeducation about the cognitive model of body image, (2) self-monitoring about thoughts, feelings, and body image behaviors, (3) cognitive restructuring to identify and challenge unhelpful automatic HNC body image thoughts, (4) positive body image coping strategies, (5) social support and identifying personal value, and (6) thinking ahead and planning for setbacks.
215056116|NCT06046183|BEHAVIORAL|Process group|The medical student process group serves as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
215056117|NCT05641584|OTHER|retrospective data review study|Patient information will be scanned retrospectively from the computer environment and patient cards. No intervention will be made to the patients.
215056118|NCT05084079|DRUG|CSII with formula-based initial insulin regimen|Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
215056119|NCT05084079|DRUG|CSII with weight-based initial insulin regimen|TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
215056120|NCT01746355|PROCEDURE|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
215056121|NCT05871424|DRUG|buprenorphine patch group|5 mcg/h buprenorphine patch will be applied preoperatively
215056122|NCT05871424|DRUG|placebo group|simple dressing tape only will be applied
214903329|NCT07112001|BEHAVIORAL|Standard of Care (SOC)|This intervention includes the use of the unmodified PositiveLinks app and the standard of care for addressing anxiety and depression in the HIV clinic
214903330|NCT06106269|DEVICE|Rectal Artery Embolization|Subjects will undergo planned rectal artery embolization (RAE) in Vascular and Interventional Radiology per standard clinical protocol.
214903331|NCT03072420|OTHER|Compression of the fingertip under MRI.|Compression of the fingertip by a static loading on the phalanx distal of the index of the subjects; Then also a shear stress in the transverse direction of the finger. The data provided by the MRI images will be geometric information such as the thickness of the skin and its possible variation as a function of the area of the finger, the total thickness of soft tissues in compression as a function of the variation in l The angle between the axis of the phalanx and the plane of contact; Mechanical type information relating to the displacements and reaction forces, to the internal deformations of the different areas of the finger.
214903332|NCT05372614|PROCEDURE|Biopsy Procedure|Undergo biopsy
214903333|NCT05372614|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215056124|NCT05773807|OTHER|Bispectral index|In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
214302174|NCT05442957|BEHAVIORAL|Attention Control|AC is a manualized video-tele-supportive care intervention that addresses non-body image aspects of HNC survivorship. Identical to BRIGHT, AC consists of 6 weekly 60-minute sessions delivered by a trained empathic interventionist via standard video-telemedicine platform. AC session topics include (1) Introduction to HNC survivorship, (2) Post-Treatment Side Effects (3) Psychosocial Aspects of HNC, (4) Health Promotion and Nutritional Challenges, (5) Financial Distress and Return to Work, and (6) Cancer Recurrence. AC controls for professional attention (i.e., ensuring that findings are not driven by simply interacting with an empathic interventionist), common factors, dose, and delivery method while not providing the active, behavior change mechanism in BRIGHT.
214302175|NCT05941507|DRUG|LCB84|TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug
214903334|NCT05372614|PROCEDURE|Computed Tomography|Undergo CT scan
214903335|NCT05372614|PROCEDURE|Echocardiography Test|Undergo echocardiography
214903336|NCT05372614|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
215056125|NCT05773807|OTHER|Observer's assessment alert Sedation|In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
215056126|NCT05773807|PROCEDURE|Gastroscopy|Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
215056127|NCT05773807|DRUG|Propofol|Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
215056128|NCT00145210|DRUG|Nebivolol and Atenolol|
215056129|NCT00711048|DRUG|AZD1386|oral, single dose
214302176|NCT05941507|DRUG|Anti-PD-1 monoclonal antibody|anti-PD-1 Ab
214903337|NCT05372614|DRUG|Neratinib Maleate|Given PO
214903338|NCT05372614|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
214903339|NCT01744444|DRUG|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
215056130|NCT00711048|DRUG|Placebo|Oral solution, single dose
214903340|NCT01744444|DRUG|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
214903341|NCT05063981|DRUG|Mepolizumab|Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control
214903342|NCT03737695|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
215056131|NCT04178525|DEVICE|ChitoCare gel|ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
215056132|NCT04178525|DEVICE|Placebo gel|Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
215056133|NCT00349011|PROCEDURE|Personalized risk assessment|
215056134|NCT00349011|PROCEDURE|genetic counseling intervention|
215056135|NCT05984758|DIAGNOSTIC_TEST|AS-OCT imaging|Image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines
214903343|NCT03737695|OTHER|Medical Chart Review|Undergo clinical information collection
214903344|NCT05916313|DRUG|BI 764532|BI 764532
214903345|NCT05224102|DRUG|Faricimab|Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.
215056136|NCT05984758|DIAGNOSTIC_TEST|Slit lamp examination|SLE of anterior chamber
215056137|NCT06846086|DRUG|Melatonin 10 MG|Melatonin
215056138|NCT06846086|DRUG|Placebo|placebo
215056139|NCT04245306|OTHER|computerized test for pragmatic inferences|Computerized tests
215056140|NCT05028348|DRUG|Selinexor|Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.
215056141|NCT05028348|DRUG|Elotuzumab|Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.
215056142|NCT05028348|DRUG|Pomalidomide|Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
215056143|NCT05028348|DRUG|Dexamethasone Oral|Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for \>75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.
215056144|NCT03245242|OTHER|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
215056145|NCT03245242|OTHER|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
215056146|NCT05306665|BEHAVIORAL|ACT intervention|One day in person workshop + telephone booster
215056147|NCT06284460|DRUG|ASTX029|Given by PO
215056148|NCT06284460|DRUG|ASTX727|Given by PO
215056149|NCT06262048|DRUG|Tamsulosin Hydrochloride|2 days pre-op, day of surgery, 2 days post-op
215056150|NCT06262048|OTHER|Placebo|2 days pre-op, day of surgery, 2 days post-op
215056151|NCT06260631|DEVICE|high-intensity laser acupuncture and Exercise therapy program|"The experimental group will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program~The patients will perform an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
215056152|NCT06260631|OTHER|Sham laser acupuncture|"Sham laser acupuncture and exercise therapy program~The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
215056153|NCT05999630|DRUG|Artificial Tears Methylcellulose|Participants will self-administer the artificial tears according to the schedule.
215056154|NCT05740527|DEVICE|Noninvasive electrical stimulation of genital nerves|A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
215056155|NCT03722420|DRUG|Radotinib|Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
215056156|NCT03722420|DRUG|Imatinib|Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
215056157|NCT02709512|DRUG|ADI-PEG 20 plus Pem Platinum|Investigational Drug in combination approved standard of care treatment for this indication
215056158|NCT02709512|OTHER|Placebo plus Pem Platinum|Placebo in combination approved standard of care treatment for this indication
215056159|NCT04115514|DRUG|Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.|"Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway."
214302177|NCT06229366|DRUG|[Ac-225]-PSMA-62 (mCRPC)|"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week cycle for up to 4 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week or 4-week cycle, for a total of 4 cycles."
214302178|NCT06229366|DRUG|[Ac-225]-PSMA-62 (OmHSPC)|"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles."
214302179|NCT04340362|DRUG|VX-147|Tablets for oral administration.
215056160|NCT04115514|OTHER|Non-intervention|Standard of Care (SOC)
214302180|NCT00102544|DEVICE|EM Tracking|Utilizing electromagnetic tracking technology as a fusion and navigation tool for minimally invasive interventional procedures.
215056161|NCT03610854|DEVICE|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
215056162|NCT05318300|DIETARY_SUPPLEMENT|tested formula with fiber|formula containing fibers
215056163|NCT05318300|DIETARY_SUPPLEMENT|Control|formula without fiber
215056164|NCT03609502|BEHAVIORAL|behavioral training|the participants will be trained to perceive a non-native speech contrast
215056165|NCT05497739|DRUG|Intraperitoneal chemotherapy|5-Fu 1 g/m\^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m\^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
215056166|NCT05497739|DRUG|Adjuvant systemic chemotherapy|Oxaliplatin 85 mg/m\^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2).
215056167|NCT05354492|OTHER|Program to Support Well-Being after Adversity|You will be asked to meet on Zoom weekly for 6 weeks with our trained program facilitators along with the other 6-10 members of the intervention group. Meetings will last approximately 75-90 minutes each, and will involve a variety of discussions and activities related to navigating the changes you may face after experiencing a difficult life event. These sessions will be audio-recorded for research purposes and to ensure that facilitators are doing a good job delivering the program.
214302181|NCT06305767|BIOLOGICAL|Pembrolizumab|Administered via intravenous (IV) infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every cycle for up to four 3-week neoadjuvant cycles and up to thirteen 3-week adjuvant cycles for Perioperative Cohort participants.
214302182|NCT06305767|BIOLOGICAL|Intismeran autogene|Administered via intramuscular (IM) injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.
214479177|NCT06656377|BEHAVIORAL|exercise intervention|A total of 25 prediabetic adults of either gender will participate in the study they will engage in exercise at intensities of 50%, 60%, 70%, or 80% of their predicted maximum heart rate (PMHR). In duration they will exercise for 15, 30, 45 and 60 minutes, and in timing protocol they will exercise at various time points after having breakfast. Blood samples were collected at four time points i.e. at fasting, pre-exercise and post-exercise at 30 and 60 minutes to measure glucose, insulin, and C-peptide levels.
214903346|NCT04774718|DRUG|Alectinib|Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle
214903347|NCT06792175|DIAGNOSTIC_TEST|Solicue Machine Learning Models|"A comprehensive machine-learning tool aimed at providing probability estimates for several compatible disorders, including Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Bipolar Affective Disorder (BPAD), Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), and Schizophrenia Spectrum Disorders (SSD). By offering a multi-diagnostic assessment based on speech analysis, Solicue aims to assist clinicians in navigating this complexity and potentially identifying conditions that might otherwise be overlooked in initial assessments.~Solicue leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features."
215056168|NCT05567445|DIAGNOSTIC_TEST|Echocardiography, CBC, Liver function, kideny function|Echocardiography, AST, ALT, UREA,CREAT. , CBC,may blood cultures.
215056169|NCT05415553|PROCEDURE|IOBT|Surgery of inferior oblique muscle belly transposition for treatment of primary position hypertropia with inferior oblique overaction
214479178|NCT06657690|DRUG|Irinotecan liposome|Irinotecan liposome injection, 50mg/m2, D1、D15, ivgtt, Q4w.
215056170|NCT05415553|PROCEDURE|IO-Rec|Surgery of inferior oblique muscle recession for treatment of primary position hypertropia with inferior oblique overaction
215056171|NCT00348478|BEHAVIORAL|water and health education program to improve hygiene|
215056172|NCT05327660|COMBINATION_PRODUCT|Quitline Treatment as Usual (TAU)|Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content).
215056173|NCT05327660|COMBINATION_PRODUCT|Remote Carbon Monoxide (CO) Monitoring|Remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor.
215056174|NCT05327660|COMBINATION_PRODUCT|Incentivized Remote CO Monitoring|Incentivized remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor and delivers small monetary incentives for each use of the CO monitor.
215056175|NCT05176340|OTHER|Specific Thematic Nursing Care Action Modules (STNC-AM)|"The STNC-AM platform that investigators present here is an educational program that integrates education and coaching.~The nurse coaching component was based on the STNC-AM platform. This online platform can guide nurses' health education for the comprehensive care of stroke patients. Nurses can use an iPad and enter the STNC-AM platform website, where they can directly access the Care Action Module."
215056176|NCT00240812|DRUG|ibuprofen; pseudoephedrine HCl|
215056177|NCT04599491|DEVICE|Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'|Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
214302183|NCT06305767|OTHER|Placebo|Intismeran autogene diluent only (saline and/or dextrose) administered via IM injection Q3W for up to 9 doses.
214479179|NCT06657690|DRUG|S-1|S-1, D1-D14, BID, p.o., Q4w (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose).
215056178|NCT04599491|DEVICE|Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'|Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
215056179|NCT01177085|BEHAVIORAL|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
214903348|NCT06792175|DIAGNOSTIC_TEST|Mercuria Machine Learning Models|"Mercuria is designed to stratify the risk of bipolar disorder in individuals presenting with depressive symptoms. This is a critical clinical need, as misdiagnosis of bipolar disorder as unipolar depression is common and can lead to inappropriate treatment, potentially worsening outcomes. By analyzing speech patterns characteristic of bipolar disorder, Mercuria aims to provide an additional tool for clinicians to differentiate between these conditions more accurately, guiding appropriate treatment decisions.~Mercuria leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features."
214903349|NCT02444741|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214903350|NCT02444741|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214903351|NCT02444741|OTHER|Laboratory Biomarker Analysis|Correlative studies
214903352|NCT02444741|BIOLOGICAL|Pembrolizumab|Given IV
214903353|NCT02444741|RADIATION|Proton Beam Radiation Therapy|Undergo PBRT
215056180|NCT03902015|DEVICE|Nuance Phone case|"participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues."
215056181|NCT02499627|DRUG|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
215056182|NCT02499627|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
215056183|NCT05153603|DRUG|Olaparib mono-maintenance therapy|Olaparib mono-maintenance therapy in patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer is defined as drug exposure. At least one dose of olaparib tablets monotherapy as maintenance therapy will be required.
215056184|NCT00600106|DRUG|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
215056185|NCT00600106|DRUG|Placebo|1 mg placebo
215056186|NCT02678403|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
214302184|NCT06305767|BIOLOGICAL|Enfortumab Vedotin|Administered via IV infusion at a dose of 1.25 mg/kg on Day 1 and Day 8 of every cycle for up to four 3-week neoadjuvant cycles and up to five 3-week adjuvant cycles for Perioperative Cohort participants.
214302185|NCT06305767|PROCEDURE|Surgery (RC plus PLND)|Curative intent surgery (RC plus PLND) will be administered to all participants in the Perioperative Cohort and will be done in accordance with the American Urological Association/American Society for Radiation Oncology/American Society of Clinical Oncology/Society of Urologic Oncology guidelines. RC plus PLND will be performed within 6 weeks of the last dose of neoadjuvant intismeran autogene plus pembrolizumab plus EV treatment. Adjuvant intismeran autogene plus pembrolizumab plus EV treatment will begin within 8 weeks of completing RC plus PLND.
214302186|NCT05841563|DRUG|PM54|"PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54.~Route of administration: Intravenous infusion"
214302187|NCT05735483|DRUG|Lebrikizumab|Administered SC
214903354|NCT02444741|RADIATION|Radiation Therapy|Undergo low dose radiation therapy
214903355|NCT02444741|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214903356|NCT05796752|DRUG|Memantine|Cognition-enhancing medication
214903357|NCT05796752|BEHAVIORAL|ComB Behavioral Therapy|Therapy for BFRBs
214903358|NCT05065047|DRUG|Belantamab mafodotin|Given by IV
214903359|NCT04068194|DRUG|Avelumab|Given IV
214903360|NCT04068194|PROCEDURE|Biopsy Procedure|Undergo biopsy of tumor
214903361|NCT04068194|PROCEDURE|Biospecimen Collection|Correlative studies
214903362|NCT04068194|PROCEDURE|Computed Tomography|Undergo CT scan
214302188|NCT05735483|DRUG|Placebo|Administered SC
214903363|NCT04068194|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
214903364|NCT04068194|DRUG|Peposertib|Given PO
214903365|NCT05399498|DRUG|Psilocybin|Psilocybin 25mg capsule
214903366|NCT04198350|PROCEDURE|Islet implantation|Transplantation of allogeneic pancreatic human islets will be performed into the anterior chamber of a single eye with the poorest visual acuity (see inclusion/exclusion criteria below). Up to 40 000 IEQ of islets in a maximum volume of 350µl will be transplanted.
214903367|NCT05753748|PROCEDURE|Endoscopic Eradication Therapy|Endoscopic eradication therapy is a procedure performed to destroy the precancerous cells at the bottom of your esophagus, so that healthy cells can grow in their place. It involves procedures to either remove precancerous tissue or burn it. These procedures are performed through the endoscope.
214903368|NCT06345495|DRUG|Ruxolitinib|Given by PO
214903369|NCT06345495|PROCEDURE|Allogeneic Stem Cell Transplantation|Given by Transplant
214903370|NCT06345495|DRUG|Levetiracetam|Given by PO
214903371|NCT06345495|DRUG|Eltrombopag|Given by PO
214903372|NCT06345495|DRUG|Busulfan|Given by IV
214903373|NCT06345495|DRUG|Romiplostim|Given by IV
214903374|NCT06345495|DRUG|Fludarabine phosphate|Given by IV
214903375|NCT06345495|DRUG|Cyclophosphamide|Given by IV
214903376|NCT06345495|DRUG|Mesna|Given by IV
214903377|NCT06345495|DRUG|Tacrolimus|Given by IV or PO
214903378|NCT05199077|DRUG|GM-XANTHO|a topical applied ointment
214479180|NCT06657105|DRUG|EE/LNG|EE/LNG tablet will be administered orally.
214479181|NCT06657105|DRUG|Baxdrostat|Baxdrostat tablet will be administered orally.
214903379|NCT06485141|BEHAVIORAL|Safe Storage Intervention|Firearm storage information and secure storage device.
214903380|NCT06485141|BEHAVIORAL|Safe Kids Medication|The Control participants will view a brief medication storage safety video produced by Safe Kids. A Frequently Asked Questions handout on medication safety created by Safe Kids will be available for parents as well.
214903381|NCT05862103|OTHER|Treatment Strategies|AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion
214903382|NCT03606967|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214903383|NCT03606967|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214903384|NCT03606967|DRUG|Carboplatin|Given IV
214903385|NCT03606967|PROCEDURE|Computed Tomography|Undergo CT scan
215056187|NCT02678403|DEVICE|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
215056188|NCT00252512|BEHAVIORAL|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
215056189|NCT00252512|OTHER|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
215056190|NCT01184703|OTHER|Low GI food|Comparison of carbohydrates in diabetic patients
215056191|NCT03631771|DRUG|Iohexol|Iohexol administered intravascularly
214302192|NCT06253507|BIOLOGICAL|Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47|"Cryopreserved autologous CD34+ cells transduced ex vivo with the pCCLCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use.~The minimum cell dose for infusion is 3 x 10\^6 CD34+/kg."
214479182|NCT06286800|DEVICE|Transcranial direct current stimulation (tDCS) with OT|Weak direct current (0.5-2 mA) will be delivered for up to 20 minutes through surface electrodes which will be positioned using the ptDCS montage. The current will be increased and decreased ramp-like at the beginning and end of the 20-minute stimulation to lessen the itchy/numb skin sensation and decrease the likelihood of an innocuous phosphene-like visual phenomenon. The stimulation will be delivered during the first 20 minutes of occupational therapy targeted to the more affected upper extremity.
215056192|NCT03631771|DRUG|Iodixanol|Iodixanol administered intravascularly
215056193|NCT03631771|DRUG|Iopromide|Iopromide administered intravascularly
215056194|NCT03631771|DRUG|Ioversol|Ioversol administered intravascularly
214903386|NCT03606967|BIOLOGICAL|Durvalumab|Given IV
214903387|NCT03606967|DRUG|Gemcitabine Hydrochloride|Given IV
214903388|NCT03606967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903389|NCT03606967|DRUG|Nab-paclitaxel|Given IV
214302193|NCT04339764|DRUG|iPSC-derived RPE/PLGA transplantation|iPSC-derived RPE/PLGA transplantation
214302194|NCT04299490|BEHAVIORAL|Sleep Fragmentation|Subjects are provided an 8-hour sleep opportunity. Two speakers are placed 12 inches from the head of the bed and four remote-activated mechanical vibrators are placed underneath the mattress. EEG microarousals (\>3 s), as defined according to standard criteria, are elicited at a frequency of 30 or more events per hour.
214479183|NCT06286800|DEVICE|Sham tDCS with OT|Same procedure and montage as with the active stimulation but the current will be increased then decreased ramp-like and switched off after 20 seconds instead of the 20 minutes to elicit the same cutaneous sensation as the other stimulation conditions. \[69\] This short length of stimulation is documented to elicit sensations comparable to those of real stimulation. With this procedure, subjects were unable to differentiate between tDCS and sham stimulation in our and other previous studies.
214903390|NCT03606967|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Given SC
214903391|NCT03606967|DRUG|Poly ICLC|Given SC
214903392|NCT03606967|BIOLOGICAL|Sacituzumab Govitecan|Given IV
214903393|NCT03606967|BIOLOGICAL|Tremelimumab|Given IV
214903394|NCT02298959|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214903395|NCT02298959|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214903396|NCT02298959|PROCEDURE|Computed Tomography|Undergo CT scan
214903397|NCT02298959|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
214903398|NCT02298959|BIOLOGICAL|Pembrolizumab|Given IV
214903399|NCT02298959|BIOLOGICAL|Ziv-Aflibercept|Given IV
214903400|NCT03570827|DRUG|Androgen Suppression|Given androgen suppression therapy
214903401|NCT03570827|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214903402|NCT03570827|OTHER|Quality-of-Life Assessment|Ancillary studies
214903403|NCT03570827|OTHER|Questionnaire Administration|Ancillary studies
215056195|NCT00137488|DEVICE|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
215056196|NCT04098887|RADIATION|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV\_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV\_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV\_2000 and PTV\_6670, respectively).
215056197|NCT02322580|DRUG|etanercept|
215056198|NCT05124028|DRUG|Orelabrutinib|50mg po qd 6 weeks
215056199|NCT01895400|DRUG|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
215056200|NCT01895400|DRUG|Placebo|Take placebo drug 1T bid po medication for 8 weeks
214903404|NCT05768906|OTHER|observational|Observation of disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians
214903405|NCT06956157|DRUG|N-Acetylcysteine Tablets|In addition to participants' existing medication regimens, NAC will be added.
215056201|NCT05464238|OTHER|Exercise rehabilitation|The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.
215056202|NCT05464238|OTHER|Standard treatment|Standard treatment during study duration
214903406|NCT06956157|DRUG|Placebo Oral Tablet|Placebo oral tablets are identical in appearance (size, shape, color), packaging, taste, and administration schedule to the N-Acetylcysteine tablets to maintain blinding. The tablets contain inert excipients and no active pharmacological ingredients.
215056203|NCT05254990|DRUG|Reparixin|Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
215056204|NCT05254990|OTHER|Placebo|"Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion."
215056205|NCT04644588|DIAGNOSTIC_TEST|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
215056206|NCT04015817|OTHER|paramedical and non-pharmacological services|Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
215056207|NCT05881486|DRUG|Ondansetron 8mg|8 mg Ondansetron+100 ml normal saline
215056208|NCT05881486|DRUG|Fosaprepitant 150 mg|150 mg fosaprepitant +100 ml normal saline
215056209|NCT05148936|OTHER|COVID-19 Testing Home-based (Aim 1)|Implementation of Antigen and PCR testing at participant homes
215056210|NCT05148936|OTHER|COVID-19 Testing Mobile (Aim 1)|Implementation of Antigen and PCR testing at mobile test sites
215056211|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 1 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - active outreach
215056212|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 2 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
215056213|NCT06253455|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
215056214|NCT01391689|DIETARY_SUPPLEMENT|diindolylmethane|Given PO
215056215|NCT01391689|DIETARY_SUPPLEMENT|placebo|Given PO
215056216|NCT02424500|DEVICE|d-Nav|Insulin dosage is adjusted as required
214302195|NCT04299490|DRUG|Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)|On the third day of the in-patient visit participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter pain medications, or placebo (saline).
214302196|NCT04299490|BEHAVIORAL|Sleep Continuity Disruption|An 8-hour sleep opportunity period starting from lights out is divided into eight, one-hour intervals. One of the intervals is randomly determined to be a 60 minute forced awakening, during which no sleep is permitted. Each of the remaining seven, 60-minute intervals are subdivided into tertiles (20 min. blocks). A 20-min forced awakening (FA) is randomly scheduled to occur in either the 1st, 2nd, or 3rd tertile of each hour. During FAs, staff keep subjects awake, either by voice or gentle shaking.
214302197|NCT04299490|BEHAVIORAL|Undisturbed Sleep|Subjects sleep normally for an 8 hour period.
215056217|NCT02424500|DEVICE|Blood Glucose Monitoring System|Insulin dosage is adjusted as required
214903407|NCT06954714|PROCEDURE|Drug-eluting stent implantation|"IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups.~In DES group, latest second-generation DES will be used in accordance with standard practice guideline."
214903408|NCT06954714|PROCEDURE|Drug-coated balloon angioplasty|"IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups.~In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds."
214903409|NCT05207865|DRUG|Rimegepant|rimegepant ODT 75mg daily
214903410|NCT02813291|DEVICE|tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~\- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex."
214903411|NCT02813291|DEVICE|sham tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~\- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex."
214903412|NCT03861117|PROCEDURE|Assisted strategy|Daily spontaneous breathing trial (SBT) with 7 cmH2O pressure support and 5 cmH2O positive end-expiratory pressure are performed to assess weanability. In case of success, a SBT with T-piece is performed to determine if the patients is at high risk of extubation failure. In this case and/or in the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
214903413|NCT03861117|PROCEDURE|Non assisted strategy|Daily spontaneous breathing trials (SBT) with T-piece are performed to assess weanability. In the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
214903414|NCT04861259|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (\>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and every 4 weeks (Q4W) thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight \>= 40kg to \<100kg) or 1020 mg SC (for participants with body weight \>=100kg).
214903415|NCT06004661|DRUG|AAA617|Administered intravenously once every cycles (1 cycle = 6 weeks)
214903416|NCT06004661|DRUG|68Ga-PSMA-11|Single intravenous dose of approximately 150 MBq
214302198|NCT05848258|DRUG|LY3871801|Administered orally
214903417|NCT05618834|BEHAVIORAL|Promoting Positive Care Interactions (PPCI)|"The PPCI consists of four steps: (1) stakeholder engagement in developing facility specific goals; (2) environment and policy assessments; (3) flexible staff education; and (4) ongoing mentorship, motivation, and support (in-person visits and text messages) for staff to optimize care interactions.~A research nurse facilitator (RNF), a registered nurse (RN) with prior experience in long-term care will work with an identified internal champion monthly to implement the four steps of PPCI. The PPCI intervention comprehensively focuses on intrapersonal, interpersonal, organizational, and environmental/policy factors to bring together evidence and key stakeholders to optimize daily care interactions in assisted living."
215056218|NCT06474000|BEHAVIORAL|Oxytocin induction group|"Participants in the oxytocin induction group filled out the Information Form at the time of application to the delivery room. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
215056219|NCT06474000|BEHAVIORAL|Control group|"Participants in the control group filled in the Information Form when they applied to the birth centre. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
215056220|NCT00212875|DRUG|epoetin alfa|
215056221|NCT02200757|DRUG|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
215056222|NCT02200757|DRUG|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
215056223|NCT03127917|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline capsules given at 6 g/day
215056224|NCT03127917|OTHER|Placebo|Maltodextrin capsules given as placebo
215056225|NCT04875468|OTHER|TheraCem self-adhesive resin cement|MDP, calcium and fluoride releasing cement for dental zirconia crowns
215056226|NCT04875468|OTHER|Multilink adhesive resin cement|(non MDP, non-calcium and fluoride releasing cement)
215056227|NCT00141648|DRUG|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
215056228|NCT00141648|RADIATION|Radiotherapy|Total 45 Gy in 25 fractions
215056229|NCT02468531|OTHER|oxygen|50% oxygen inhalation
215056230|NCT02468531|DRUG|Xenon|50% Xenon inhalation
214302199|NCT05848258|DRUG|Placebo|Administered orally
214302200|NCT05559359|DRUG|Lebrikizumab|Administered SC
214302201|NCT05559359|DRUG|Placebo|Placebo given SC
214903418|NCT05618834|BEHAVIORAL|PPCI-Staff Education Only (EO)|The EO will include a 30-45 min in-service session and monthly f/u visits for booster education. The education content and process will be the same as outlined in Step 3 of the PPCI for treatment sites.
214903419|NCT01882660|DRUG|Decitabine|
214903420|NCT03793114|DIAGNOSTIC_TEST|Cosyntropin stimulation test|Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.
214903421|NCT03793114|DIAGNOSTIC_TEST|Baseline blood tests|Medication-fasting morning levels of adrenocortical hormones.
214903422|NCT03793114|DEVICE|30-hour ambulatory sampling of intestinal fluid|30-hour ambulatory sampling of intestinal fluid for analysis of adrenocortical hormones.
214903423|NCT03793114|OTHER|Blood test|Cardiovascular and inflammatory biomarker profiles
214903424|NCT03808155|DRUG|Tamsulosin|The drug ist taken once a day per os five days prior to the operation and two days after the operation.
214903425|NCT03808155|DRUG|Placebo Oral Tablet|The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
214903426|NCT06734156|OTHER|No intervention: observational study|No intervention: observational study
214903427|NCT06843226|OTHER|No Intervention|This is a non-interventional study.
214903428|NCT05632484|BIOLOGICAL|Cord blood sampling|Collection of 2 milliliters (mL) of cord blood on an Ethylenediaminetetraacetic acid (EDTA) tube, on the day of delivery and after cutting the umbilical cord, for genetic testing
214903429|NCT05632484|BIOLOGICAL|Cord blood sampling|Collection of 50 to 100 mL of cord blood from the cord blood collection bag
214903430|NCT05632484|BIOLOGICAL|Cord sampling|Collection of 20 centimeters (cm) of umbilical cord
214903431|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19
214903432|NCT04324606|BIOLOGICAL|MenACWY|Standard single dose of MenACWY vaccine delivered intramuscularly
214903433|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 full boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19
214903434|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 half boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 2.5x10\^10vp of ChAdOx1 nCoV-19
214903435|NCT04324606|BIOLOGICAL|MenACWY boost|A standard dose of MenACWY followed by a boost dose of MenACWY
214903436|NCT04324606|DRUG|Paracetamol|1g every 6 hours for 24 hours
214903437|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp)
214903438|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of 5x10\^10vp of ChAdOx1 nCoV-19
214903439|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of MenACWY, then a boost 4-12 weeks later
214903440|NCT06154915|OTHER|medical treatments|All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding) according to the best standard of care
214903441|NCT06205056|BIOLOGICAL|Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a]|Participants in Arm 1a will receive dose consistent injections (5x10\^10 vp/0.5 mL) of Ad26.Mos4.HIV in a 0.5 mL injection volume and dose consistent injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS-21) in a 1.1 mL injection volume on Study Days 1 and 57
214903442|NCT06205056|BIOLOGICAL|CH505 TF chTrimer + ALFQ [Arm 1a]|Participants in Arm 1a will receive a dose-consistent injection of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Day 169.
214903443|NCT06205056|BIOLOGICAL|Placebo [Arm 1a]|Participants in Arm 1a will receive dose-consistent 0.5 mL injection and a 1.1 mL injection of Placebo on Study Days 1 and 57, followed by a 1.1 mL injection of Placebo on Study Day 169.
214903444|NCT06205056|BIOLOGICAL|Ad26.Mos4.HIV in CH505 TF chTrimer +ALFQ [Arm 2a]|"Participants in Arm 2a will receive a lower dose of Ad26.Mos4.HIV (2.5x10\^10 vp/0.25 mL) in a 0.25 mL injection volume and a lower dose of CH505 TF chTrimer (30 µg)+ALFQ (50 µg MPLA/25 µg QS-21) in a 0.5 mL injection volume on Study Day 1.~Participants in Arm 2a will receive an injection Ad26.Mos4.HIV (5x10\^10 vp/0.5 mL) in a 0.5 mL injection volume and CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Day 57."
214903445|NCT06205056|BIOLOGICAL|CH505 TF chTrimer +ALFQ [Arm 2a]|"Participants in Arm 2a will receive a rapid, dose escalating injections of CH505 TF chTrimer (100 µg, 150 µg, and 300 µg)+ALFQ (50 µg MPLA/ 25 µg QS-21) on Study Days 4 (0.5 mL injection volume), 8 (0.5 mL injection volume), and 15 (0.9 mL injection volume).~Participants in Arm 2a will receive a injection of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Day 169."
214903446|NCT06205056|BIOLOGICAL|Placebo [Arm 2a]|Participants in Arm 2a will receive a 0.25 mL injection and a 0.5 mL injection of Placebo on Study Day 1; followed by 0.5 mL, 0.5 mL, and 0.9 mL injections of Placebo on Study Days 4, 8, and 15, respectively; followed by a 0.5 mL injection and a 1.1 mL injection of Placebo on Study Day 57; followed by a 1.1 mL injection of Placebo on Study Day 169.
214903447|NCT06205056|BIOLOGICAL|CH505 TF chTrimer + ALFQ [Arm 1b]|Participants in Arm 1b will receive dose consistent injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS-21) in a 1.1 mL injection volume on Study Days 1, 57, and 169.
214903448|NCT06205056|BIOLOGICAL|Placebo [Arm 1b]|Participants in Arm 1b will receive a 1.1 mL injection of Placebo on Study Days 1, 57, and 169.
214903449|NCT06205056|BIOLOGICAL|CH505 TF chTrimer + ALFQ [Arm 2b]|"Participants in Arm 2b will receive a lower dose of CH505 TF chTrimer (30 µg)+ALFQ (50 µg MPLA/25 µg QS 21) in a 0.5 mL injection volume on Study Day 1.~Participants in Arm 2b will receive a rapid, dose escalating injections of CH505 TF chTrimer (100 µg, 150 µg, and 300 µg)+ALFQ (50 µg MPLA/ 25 µg QS-21) on Study Days 4 (0.5 mL injection volume), 8 (0.5 mL injection volume), and 15 (0.9 mL injection volume).~Participants in Arm 2b will receive a injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Days 57 and 169."
214669791|NCT02279316|DRUG|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
214903450|NCT06205056|BIOLOGICAL|Placebo [Arm 2b]|Participants in Arm 2b will receive a 0.5 mL injection of Placebo on Study Days 1, 4, and 8; followed by a 0.9 mL injection of Placebo on Study Day 15; followed by a 1.1 mL injection of Placebo on Study Days 57 and 169.
214903451|NCT05469009|DRUG|Aducanumab|Standard aducanumab therapy will be given by intravenous infusion every 4 weeks for 6 cycles with blood brain barrier opening
214903452|NCT05469009|DEVICE|Exablate Model 4000 Type 2|The Exablate Model 4000 will be utilized for the BBBO (blood-brain barrier opening) after each cycle of Aducanumab or Lecanemab administered per label.
215056231|NCT05672641|OTHER|Inertial training|Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
214903453|NCT05469009|DRUG|Lecanemab|Standard lecanemab therapy will be given by intravenous infusion every 2 weeks for up to 6 cycles with blood brain barrier opening
214903454|NCT06320938|OTHER|Neuroscience-Based Pain Education Combined with Home Exercise Program|Neuroscience-Based Pain Education and Home Exercises will be applied.
214903455|NCT06320938|OTHER|Myofascial Induction Techniques Combined with Home Exercise Program|Myofascial Induction Techniques and Home Exercises will be applied.
214903456|NCT06320938|OTHER|Home Exercises Group|Home Exercises wiil be applied
214302202|NCT05559359|DRUG|Topical Corticosteroid (TCS)|TCS administered
214302203|NCT06220669|DRUG|LY3541860|Administered IV
214302204|NCT06220669|DRUG|Placebo|Administered IV
214302205|NCT05999994|DRUG|Ramucirumab|Administered IV
214302206|NCT05999994|DRUG|Cyclophosphamide|Administered orally
214302207|NCT05999994|DRUG|Vinorelbine|Administered IV
214302208|NCT05999994|DRUG|Gemcitabine|Administered IV
214302209|NCT05999994|DRUG|Docetaxel|Administered IV
214302210|NCT05999994|DRUG|Abemaciclib|Administered orally
214302211|NCT05999994|DRUG|Irinotecan|Administered IV
214302212|NCT05999994|DRUG|Temozolomide|Administered orally
214302213|NCT06965751|DRUG|PDI204|PDI204 is a fully human, immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein
214302214|NCT06965751|OTHER|0.9 % saline|0.9% saline used as placebo
215056232|NCT05672641|OTHER|Body building training|Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
214479184|NCT06812598|DRUG|Letermovir (0-24w）|Patients will begin receiving prophylactic treatment with domestically produced letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg, administered orally once daily. If used in combination with cyclosporine, the dose should be reduced to 240 mg once daily. The treatment will continue until 24 weeks post-transplant (approximately 170 days).
214479185|NCT06812598|DRUG|Letermovir (0-14w）|Patients will begin receiving prophylactic treatment with domestically produced letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg, administered orally once daily. If used in combination with cyclosporine, the dose should be reduced to 240 mg once daily. The treatment will continue until 14 weeks post-transplant (approximately 100 days).
214479186|NCT06988215|OTHER|Kinesiology Taping with Exercise|Real kinesiology taping is applied to the suprahyoid region in three directions (from the hyoid bone to the clavicle, to the sternum, and horizontally). Taping is renewed every three days. Participants also perform effortful swallowing and oromotor exercises daily (5 sets of 10 repetitions) for 6 weeks.
214479187|NCT06988215|OTHER|Placebo Taping with Exercise|Non-therapeutic kinesiology taping with no tension is applied to the suprahyoid region to mimic the appearance of the therapeutic tape. Participants perform the same daily swallowing and oromotor exercises as the intervention group for 6 weeks
214479188|NCT04966637|OTHER|COPD cohort|as this a retrospective descriptive study no intervention will be administered to study participants
214479189|NCT06817109|DEVICE|interactive technological intervention for improvement of mental health symptoms in Primary Care users Health|Intervention based on cognitive and behavioral techniques, such as psychoeducation on anxiety, depression and insomnia; muscle relaxation and breathing techniques; sleep hygiene techniques, behavioral activation and mindfulness techniques
214479190|NCT06857201|PROCEDURE|Left Bundle Branch Area Pacing|LBBAP is performed during permanent pacemaker implantation post-TAVR.
214479191|NCT06857201|PROCEDURE|Right Ventricular Pacing|RVP is performed during permanent pacemaker implantation post-TAVR.
214479192|NCT06818890|DEVICE|Definitive abutment base|Definite abutment base, this is a two-piece definitive abutment where the base is connected to the implant as soon as it is placed.This abutment will allow the tissues around the implant to heal undisturbed, thus, establishing a good and healthy periimplant soft and hard tissue with long-term stability.
214903457|NCT05721222|BIOLOGICAL|GEN1160|IV infusion of GEN1160
214903458|NCT06962852|GENETIC|BI 3720931|BI 3720931
214903459|NCT05692180|DRUG|Benralizumab|Benralizumab active solution will be administered SC to the patients.
214903460|NCT05692180|DRUG|Placebo|Placebo solution will be administered SC to the patients.
214903461|NCT03753490|OTHER|ABC score guided therapy|In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.
214903462|NCT03753490|OTHER|Standard care|In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
214903463|NCT04643015|DIAGNOSTIC_TEST|MRI|"Briefly, new MRI sequences will be used on a patient who is undergoing a scheduled, clinically necessary MRI exam. Any new research sequence will be scanned in addition to the clinically required sequences and will not interfere with the clinical scan other than requiring five to ten minutes of additional table time. There will be no invasive measures under this protocol."
214903464|NCT03907254|OTHER|Service Dog Training Program|Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
215056233|NCT02525484|DRUG|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
215056234|NCT02853396|OTHER|Cognitive Behaviour Therapy|
215056235|NCT02853396|OTHER|Psychoeducation|
214479193|NCT06818890|DEVICE|Conventional Healing Abutment|A healing abutment of different diameters (4.3, 5, 6 mm) and heights (1.5, 3 mm) is placed on the day of the surgery, and the flaps are sutured around them to allow for tissue healing around the abutment to create an optimum emergence profile and tissue cuff around the implant and definitive abutment.
214479194|NCT06818578|PROCEDURE|Lesion Sterilization and Tissue Repair Therapy|LSTR treatment is a minimally invasive, cost-effective, and easy-to-apply procedure for necrotic primary teeth, with a focus on disinfection with an antibiotic mixture without the need for root canal instrumentation.
215056236|NCT02841007|DEVICE|geko neuromuscular electrostimulation device|
214479195|NCT06818578|DRUG|Different Antibiotic Combinations|Clinical and Radiographic Success of Different Antibiotic Combinations (evaluating whether the alternative 3Mix-MP combination of clindamycin instead of minocycline is as effective as the standard 3Mix-MP formulation) in Lesion Sterilization and Tissue Repair Therapy
214479196|NCT06855615|DRUG|Mixtard® 30 TDS|The clinical use of TDS premixed human insulin (PHI) is unclear. In contrast, biphasic insulin analogue given thrice daily is a well-proven, safe and suitable alternative to an intensified insulin regimen.
214479197|NCT06855615|DRUG|Insulatard® once daily and thrice daily prandial Actrapid®|Basal bolus regimen is considered a physiological form of treatment and the standard of care in clinical practice but the multiple daily injections often lead to poor compliance.
214903465|NCT04441307|BEHAVIORAL|Healthy Foundations|Healthy Foundations combines elements of a community-based parent education program with additional information about infant and child development, good parenting practices, parent health behavior, and couple support.
214302215|NCT06967545|BEHAVIORAL|Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S)|Therapeutic Evaluative Conditioning for Suicide (active TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair suicidal behavior stimuli (pictures, words) with other negative stimuli and self-related stimuli with positive stimuli.
214903466|NCT04441307|BEHAVIORAL|Family Foundations|A modified version of Family Foundations, an evidence-based preventive intervention for couples during the transition to parenthood, will be implemented to address several aspects of parent and family adjustment, including parent health behavior, particularly alcohol use, and couple relationship dynamics, to promote a healthy parenting environment.
214903467|NCT03262259|BEHAVIORAL|GSDG multi-component intervention|Multi-component intervention, including screening and brief intervention, other evidence-based interventions, and novel or partially tested interventions that warrant further evaluation.
214903468|NCT06023069|OTHER|Number of steps recorded by mobile phone as a proxy for physical activity|This cohort is likely to have patients with many steps/day (high activity) and few steps/day (low activity)
214903469|NCT04090398|PROCEDURE|Biospecimen Collection|Correlative studies
214903470|NCT04090398|PROCEDURE|Bone Scan|Undergo bone scan
214903471|NCT04090398|PROCEDURE|Computed Tomography|Undergo CT scan
214903472|NCT04090398|OTHER|Electronic Health Record Review|Ancillary studies
214903473|NCT04090398|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903474|NCT04090398|DRUG|Paclitaxel|Given IV
214903475|NCT04090398|RADIATION|Radium Ra 223 Dichloride|Given IV
214903476|NCT04090398|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
214903477|NCT05618028|DRUG|ABBV-525|Oral; Tablet
214903478|NCT02084810|DRUG|activated recombinant human factor VII|"All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.~Each subject will be allocated to two treatment periods separated by a wash-out period of a week."
214903479|NCT02084810|DRUG|eptacog alfa (activated)|All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
214302216|NCT06971874|OTHER|No intervention|No intervention
214479198|NCT06664203|PROCEDURE|Selective turuncus block with 25 ml bupivacain|A high-frequency linear ultrasound (USG) probe will be used to locate the C7 transverse process, which will serve as a sonoanatomic landmark. Once the C5 ventral ramus is identified at the C7 transverse process level, the linear probe will be slightly caudally angled to visualize the C6 ventral ramus. The area where the superior trunk is formed by C5 and C6 will be examined with the USG probe until the superior trunk is visualized. Below the superior trunk, the middle trunk and the C8 ventral ramus will be visible. In Group 1, a total of 23 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used as the local anesthetic mixture, totaling 25ml. 7ml of the local anesthetic mixture will be injected into the superior trunk, the middle trunk for an additional 8 ml. The probe will then be directed caudally to obtain an optimal view of the lower trunk, where 10 ml of the same mixture will be injected close to the lower trunk.
214479199|NCT06664203|PROCEDURE|Selective turuncus block with 15 ml bupivacain|In Group 2, 13 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used, totaling 15 ml. In Group 2, 5 ml of the local anesthetic mixture will be injected into the superior trunk, followed by 5 ml into the middle trunk and 5 ml into the lower trunk, as in Group II.
214479200|NCT06660875|DRUG|Serratus posterior superior intercostal plane block|Serratus posterior superior intercostal plane block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
214479201|NCT06660875|DRUG|Interscalene brachial plexus block and superficial cervical plexus block|İnterscalene brachial plexus block and superficial cervical plexus block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
214669792|NCT02279316|OTHER|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
214669793|NCT02279316|OTHER|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
214669794|NCT04960358|PROCEDURE|Surface Electromyography|will be applied Surface Electromyography to assess Flexion Relaxation Response
214903480|NCT06072274|OTHER|The virtual reality educational modules|The experimental group will participate in a dementia education program combining VR lasting approximately 2-3 hours. The virtual reality educational modules predominantly offer first-person narratives that delineate various symptoms associated with dementia.
214669795|NCT01816087|OTHER|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
214903481|NCT04596774|PROCEDURE|Traditional Approach|Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
214903482|NCT04596774|PROCEDURE|Enhanced Recovery After Surgery (ERAS) Approach|Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
214907485|NCT06056037|BEHAVIORAL|Experimental: Making ART Work|A culturally tailored, theoretically grounded provider-facilitated group-based social support intervention (4 sessions) that emphasizes a collective approach to ART adherence and includes establishing a common understanding of ART, identifying potential barriers to ART adherence with a focus on social and structural barriers (e.g., stigma, relationship influences, family support, economic stressors), developing practical strategies to increase self-esteem and self-efficacy to enhance ART adherence, and generating and maintaining peer norms and support for ART adherence within one's social group. These sessions will include SGM youth-specific video vignettes that address the social/contextual realities faced by SGM YLWH in Brazil. Lastly, the intervention includes daily SMS text messaging that serve as both reminders and cognitive cues to take medication as prescribed.
214903483|NCT04151186|BIOLOGICAL|TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy|"Specification: 30 mL-100 mL, cell density of about (1-10) x10\^6 cells/ml in each bag, number of T-cells about (1-10) x10\^8 cells.) 300 ml for each infusion.~Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 5-10 min."
214903484|NCT01236508|RADIATION|PET/CT imaging with F-18 fluorodeoxyglucose|Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
214903485|NCT02611895|BIOLOGICAL|HIV DNA|Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
214903486|NCT06578208|OTHER|Spinal Manipulation|The patient was placed in the lateral decubitus position by the therapist. The foot was placed on the popliteal fossa of the lower leg while the upper knee was flexed. Once the patient was in this position, the therapist performed high velocity and low amplitude thrusts (HVLA; high velocity - low amplitude) on the vertebra with dysfunction (Fagundes Loss et al., 2020).
214903487|NCT04406181|BEHAVIORAL|HADS|Hospital Anxiety and Depression Scale
214903488|NCT04406181|BEHAVIORAL|a survey|made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak
214903489|NCT05092958|DRUG|Avelumab|Given IV
214903490|NCT05092958|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
215056237|NCT02985918|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
215056238|NCT02985918|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
215056239|NCT02318017|DRUG|Methylphenidate|Before neurocognitive testing, Methylphenidate/Placebo will be given
215056240|NCT02318017|DRUG|Placebo|
214479202|NCT06659861|OTHER|RV3278B-OS0386|Cosmetic product to be applied twice a day on the face during the whole study
214479203|NCT06659861|OTHER|RV4632A-RY1845|Cosmetic product to be applied in the event of facial skin discomfort only
215056241|NCT02003443|BEHAVIORAL|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
215056242|NCT05409469|PROCEDURE|surgery|surgery on patients with aortic dissection
215056243|NCT03284983|OTHER|Suture spacing for wound closure|The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
215056244|NCT04739111|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)|In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
215056245|NCT05836831|DRUG|Tranexamic acid injection|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.
215056246|NCT01108328|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
215056247|NCT03577834|DIETARY_SUPPLEMENT|liquid vinegar|6% red wine vinegar (2 tablespoons providing 1.7 g acetic acid)
214669796|NCT04515719|BIOLOGICAL|Belimumab|Belimumab 2mg/kg intravenously
214669797|NCT04515719|BIOLOGICAL|Placebo|Placebo intravenously
214903491|NCT05092958|PROCEDURE|Bone Scan|Undergo bone scan
214903492|NCT05092958|DRUG|Cabozantinib S-malate|Given PO
214903493|NCT05092958|PROCEDURE|Computed Tomography|Undergo CT
215056248|NCT03577834|DIETARY_SUPPLEMENT|vinegar pill|Apple Cider Vinegar Tablets (1 tablet providing 0.0225 g acetic acid)
214669798|NCT04652934|OTHER|Neurodynamic|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
214903494|NCT05092958|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903495|NCT05092958|OTHER|Quality-of-Life Assessment|Ancillary studies
214903496|NCT05092958|OTHER|Questionnaire Administration|Ancillary studies
214903497|NCT06508658|DRUG|Epcoritamab|Subcutaneous Injection
214903498|NCT06508658|DRUG|Rituximab|Intravenous (IV) Infusion
215056249|NCT02432781|DIETARY_SUPPLEMENT|Carbohydrate-rich drink|
215056250|NCT02432781|DIETARY_SUPPLEMENT|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
214903499|NCT06508658|DRUG|Lenalidomide|Oral Capsule
214903500|NCT06508658|DRUG|Oxaliplatin|IV Infusion
214903501|NCT06508658|DRUG|Gemcitabine|IV Infusion
214903502|NCT06807281|DRUG|Abrocitinib|Abrocitinib administered as liquid oral suspension.
214903503|NCT05356013|DRUG|Caplyta|Atypical antipsychotic
214903504|NCT05356013|DRUG|Placebo|Pill that contains no medicine.
214903505|NCT05541835|DIAGNOSTIC_TEST|sampling|venous sampling of patient
214903506|NCT06581224|OTHER|Primary Hospital Provider Team|The PHP team aims to enhance continuity during hospital readmissions with a consistent cohort of seven hospital medicine physicians and two advanced practice providers (APPs). To improve care transitions, the team will have an integrated case manager who will continue following PHP patients during subsequent hospitalizations. Physicians will follow a standard seven-day service schedule, with the two APPs alternating five-to-seven-day periods. Daily huddles between physicians and APPs will further promote continuity. During the index admission, the PHP team will create a care plan in consultation with the patient to improve standardization of inpatient care and transition to outpatient settings. Communication will be a core tenet of the team, with scheduled monthly team meetings of physicians, APPs, case manager, dyad partner, and representatives from nursing and therapy services to revise individualized care plans for PHP patients and brainstorm solutions for complex challenges.
214903507|NCT06066580|DRUG|Sevasemten|Sevasemten is administered orally once per day
214903508|NCT01517945|BEHAVIORAL|AIM materials and assessments|"Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~* Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~* Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~* Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~* Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~* Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~* Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over \< 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session."
214903509|NCT05423093|BEHAVIORAL|Single-Session Virtual Group Psychoeducational Session about Postpartum Depression|Session contents include (1) Introduction to clinic staff, contacts, and resources (2) A video-recorded testimonial of a patient with a history of perinatal depression followed by a group discussion about/reflection on the video; (3) Review of prevalence and signs of PPD; (4) Discussion of clinic PPD screening procedures and rationale for screening; (5) Discussion of self-care and mood monitoring; (6) Discussion of relevant local resources, including information about availability of primary care resources for parents (including uninsured parents) and information about resources addressing social needs.
214903510|NCT03112408|BEHAVIORAL|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
214903511|NCT03112408|BEHAVIORAL|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
214903512|NCT03112408|BEHAVIORAL|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
214903513|NCT03112408|BEHAVIORAL|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
214903514|NCT05364931|DRUG|Cotadutide|Cotadutide administered subcutaneously once daily
214903515|NCT05364931|DRUG|Placebo|Placebo administered subcutaneously once daily
214903516|NCT02833961|DEVICE|Magnetic resonance imaging|
214903517|NCT06800144|BEHAVIORAL|Heart rate synchronized motor imagery music therapy|Participants included in this group will listen a metronome sound in a rhythm synchronized with their heart rate.
214903518|NCT06800144|BEHAVIORAL|Heart rate synchronized music therapy|Participants included in this group will listen to soothing/relaxing music without lyrics in a rhythm synchronized with their heart rate.
214903519|NCT05551000|OTHER|Experimental, comparator and control|"To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group."
214903520|NCT04550494|PROCEDURE|Biopsy Procedure|Undergo biopsy
214903521|NCT04550494|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214903522|NCT04550494|PROCEDURE|Computed Tomography|Undergo CT scan
214903523|NCT04550494|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903524|NCT04550494|DRUG|Talazoparib|Given PO
214903525|NCT06325566|DRUG|Rexlemestrocel-L + HA mixture|Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.
214903526|NCT06325566|DRUG|Saline|Saline solution injection adjacent to the index disc.
214903527|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume with bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
214903528|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume without bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
214903529|NCT04929223|DRUG|Inavolisib|Inavolisib will be administered orally as per schedule specified in the respective arms.
214903530|NCT04929223|DRUG|Bevacizumab|Bevacizumab IV will be administered as per schedule specified in the respective arm.
214903531|NCT04929223|DRUG|Cetuximab|Cetuximab IV will be administered as per schedule specified in the respective arm.
214302217|NCT06969547|DIAGNOSTIC_TEST|dynamic SPECT (two-day rest/stress protocol)|"All nuclear examinations will be performed using a hybrid specialized SPECT/CT Discovery NM/CT570C. At the first stage the passage of the bolus of the radiopharmaceutical through the chambers and the LV myocardium will be recorded at rest. Through a pre-installed intravenous catheter, a bolus of the radiopharmaceutical in a volume of 5 ml (370 MBq) will be injected at a rate of 0,5 ml/sec, after which 30 ml of saline will be injected at a rate of 2 ml/sec. Data acquisition will begin immediately before the introduction of the radiopharmaceutical. Registration of dynamic images will be performed in the List Mode.~At the second day stress test study will be performed (ATP at a dosage of 160 mcg/kg/min over 4 minutes). The bolus volume of the radiopharmaceutical, saline and the rate are equal to the study at rest. The time of data collection at each stage of the study will be 12 minutes. The introduction of the radiopharmaceutical will be performed at 2 minutes of the stress test."
214903532|NCT04929223|DRUG|Atezolizumab|Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
214903533|NCT04929223|DRUG|Tiragolumab|Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
214903534|NCT04929223|DRUG|SY-5609|SY-5609 will be administered by mouth as per schedule specified in the respective arm.
214903535|NCT04929223|DRUG|Divarasib|Divarasib will be administered orally as per schedule specified in the respective arms.
214903536|NCT04929223|DRUG|FOLFOX|FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
214903537|NCT04929223|DRUG|FOLFIRI|FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
214903538|NCT04514484|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214903539|NCT04514484|DRUG|Cabozantinib S-malate|Given PO
214903540|NCT04514484|PROCEDURE|Computed Tomography|Undergo CT
214903541|NCT04514484|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903542|NCT04514484|BIOLOGICAL|Nivolumab|Given IV
214903543|NCT05036109|DRUG|Aspirin|by mouth every day for up to 90 days
214903544|NCT05036109|DRUG|Vitamin D|by mouth every day for up to 90 days
214903545|NCT05036109|DIETARY_SUPPLEMENT|Diet|Patients will receive counseling promoting a plant-based diet and avoidance of Western dietary patterns in a one on one session with a licensed dietitian prior to day 1.
214903546|NCT05036109|OTHER|Physical Activity|The exercise goal is to increase recreational physical activity from baseline by at least 10 MET hours per week, which is equivalent to 150 minutes of moderate activity weekly
214903547|NCT05036109|BEHAVIORAL|Behavioral Support Counseling Sessions|Patients will undergo a one-on-one counseling session prior to day 1
214903548|NCT06489834|OTHER|Group Drumming|Weekly group drumming for 8 weeks
214903549|NCT04396873|DRUG|11C-MC1|Injected IV followed by PET scanning
214903550|NCT04396873|DRUG|11C-PS13|Injected IV followed by PET scanning
214903551|NCT04396873|DRUG|18f-florbetaben|Injected IV followed by PET scanning
214903552|NCT05537233|DRUG|Semaglutide|Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
214903553|NCT05537233|DRUG|Placebo|Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
214903554|NCT02160015|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214903555|NCT02160015|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215056251|NCT01679938|BEHAVIORAL|primary obesity prevention|"1. Training of child care providers.~2. Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~3. Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~4. Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
214903556|NCT02160015|PROCEDURE|Computed Tomography|Undergo CT
214903557|NCT02160015|PROCEDURE|Electrocardiogram|Undergo ECG
214903558|NCT02160015|DRUG|Ibrutinib|Given PO
214903559|NCT02160015|DRUG|Lenalidomide|Given PO
214903560|NCT02160015|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903561|NCT02160015|BIOLOGICAL|Rituximab|Given IV
214903562|NCT04164082|PROCEDURE|Biopsy Procedure|Undergo bladder biopsy
214903563|NCT04164082|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
214903564|NCT04164082|PROCEDURE|Computed Tomography|Undergo CT
214903565|NCT04164082|PROCEDURE|Cystoscopy|Undergo cystoscopy
214903566|NCT04164082|DRUG|Gemcitabine Hydrochloride|Given intravesically
214903567|NCT04164082|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903568|NCT04164082|BIOLOGICAL|Pembrolizumab|Given IV
214903569|NCT04164082|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
214903570|NCT05302583|OTHER|Aromatherapy Inhaler|Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler
214903571|NCT03505801|DEVICE|Confirm Rx ICM insertion procedure|Insertion of Confirm Rx ICM device
214903572|NCT05828082|PROCEDURE|Biopsy Procedure|Undergo biopsy
214903573|NCT05828082|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214903574|NCT05828082|PROCEDURE|Computed Tomography|Undergo CT
214903575|NCT05828082|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903576|NCT05828082|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI or PET/CT
214903577|NCT05828082|DRUG|Tuvusertib|Given PO
214903578|NCT05828082|PROCEDURE|Ultrasound Imaging|Undergo U/S
214903579|NCT03504397|DRUG|zolbetuximab|Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Each cycle was approximately 42 days.
214903580|NCT03504397|DRUG|placebo|Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C1D22 until participant met study treatment discontinuation criteria. Each cycle was approximately 42 days.
214903581|NCT03504397|DRUG|oxaliplatin|Participants received up to 12 treatments of oxaliplatin administered 85 mg/m\^2 IV infusion over 2 hours) on Days 1, 15 and 29 of each cycle.. A maximum of 12 doses of oxaliplatin was permitted. Each cycle was approximately 42 days.
214903582|NCT03504397|DRUG|folinic acid|Participants received up to 12 treatments of folinic acid administered 400 mg/m\^2 IV infusion over 2 hours 4 or more cycles on Days 1, 15 and 29 of each cycle. participants could continue to receive folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
215056252|NCT05703724|DEVICE|AI algorithm for the detection of glaucoma|The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
214903583|NCT03504397|DRUG|fluorouracil|Participants received up to 12 treatments of 5-fluorouracil over 4 or more cycles administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Participants could continue to receive 5-fluorouracil on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
214903584|NCT03190993|OTHER|Sugar Sweetened Solid Treatment|Consume Sugar Sweetened Solid Treatment (product) daily.
215056253|NCT05382741|DRUG|Durvalumab Injection for intravenous use 500 mg vial solution for infusion|MEDI4736
214302218|NCT06969547|DIAGNOSTIC_TEST|gated myocardial perfusion imaging|"Gated MPI will be performed according to a two-day rest-stress protocol. For both stress and rest studies, the acquisition will be performed 60 minutes after the dynamic SPECT. The recording time will be 5 minutes. To correct the attenuation, a low-dose CT scan of the chest, obtained earlier with dynamic recording, will be used. The voltage on the X-ray tube will be 120 kV, the current strength will be 20 mA; tube rotation time 0.8 s; pitch 0.969:1. Radiopharmaceutical administration will be performed only once a day during dynamic SPECT.~Immediately after recording the gMPI at rest, the patient will undergo a series of sequential injections of dobutamine at doses of 5 and 10 µg/kg/min with simultaneous recording. The duration of data collection on each dose of dobutamine will be 5 minutes."
214903585|NCT03190993|OTHER|Sugar Sweetened Beverage Treatment|Consume Sugar Sweetened Beverage Treatment (product) daily.
214903586|NCT02596971|DRUG|Atezolizumab|Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
215056254|NCT05382741|DRUG|Regorafenib 30 mg capsules|BAY73-4506
215056255|NCT00585988|DEVICE|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
215056256|NCT00585988|DEVICE|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
215056257|NCT00833469|DRUG|Escitalopram|Once daily by mouth
215056258|NCT05042401|DRUG|SHR-1703|SHR-1703 low dose
215056259|NCT05042401|DRUG|placebo|placebo low dose
215056260|NCT05042401|DRUG|SHR-1703|SHR-1703 high dose
215056261|NCT05042401|DRUG|placebo|placebo high dose
215056262|NCT04406103|BEHAVIORAL|Sleepwell|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
215056263|NCT04406103|BEHAVIORAL|Empower|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
214302219|NCT06969547|OTHER|blood sampling|"Indicators of:~* endothelial dysfunction (specific endothelial cell molecule 1 (endocan, ESM1), endotelin-1)~* severity of inflammatory response (tumor necrosis factor (TNF-α), interleukin-6 (IL-6))~* myocardial fibrosis (matrix metalloproteinase (MMP-9)~* myocardial dysfunction (NT-proBNP)"
214903587|NCT02596971|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
214903588|NCT02596971|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
214903589|NCT02596971|DRUG|Doxorubicin|Doxorubicin will be administered at a dose of 50 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
214903590|NCT02596971|DRUG|Obinutuzumab|Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
214903591|NCT02596971|DRUG|Prednisone|Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m\^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).
214903592|NCT02596971|DRUG|Vincristine|Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
214903593|NCT02596971|DRUG|Rituximab|Atezo-R-CHOP: Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.
214903594|NCT00595920|BIOLOGICAL|Tovaxin|2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
214903595|NCT05594992|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
214903596|NCT00508014|OTHER|Usual Care|Usual Care with primary care provider during time period
214903597|NCT00508014|BEHAVIORAL|Concurrent Peer Review visit|Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
214903598|NCT04457908|DIAGNOSTIC_TEST|intelligent assessment|intelligent neurological function assessment
214903599|NCT03588910|DRUG|Acetaminophen|50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
214903600|NCT03588910|DRUG|Ibuprofen 600 mg|25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
214903601|NCT03588910|DRUG|Oxycodone|The number of tablets of oxycodone prescribed is the only difference between the two arms.
214903602|NCT00611923|DRUG|Flutamide|Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
214903603|NCT00611923|DRUG|Placebo|Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
214903604|NCT04740710|BEHAVIORAL|Breathing and Attention Training|A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.
214903605|NCT03162250|DRUG|DSTA4637S|DSTA4637S will be administered as an IV infusion at 3 dose levels.
214903606|NCT03162250|DRUG|Placebo|Placebo matched to DSTA4637S IV infusion will be administered as specified.
214903607|NCT03162250|DRUG|SOC|Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
214903608|NCT02242812|DRUG|Telmisartan|
214903609|NCT02242812|DRUG|Metoprolol succinate|
214903610|NCT02242812|DRUG|Placebo|
214903611|NCT03103438|BIOLOGICAL|BCD-089|
214903612|NCT04261803|BIOLOGICAL|salivary sample|spit of saliva in a tube
214903613|NCT04261803|BIOLOGICAL|blood test|2millilitter blood test
214903614|NCT01570790|DRUG|Combretastatin A-4 phosphate|27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
215056264|NCT01665911|DRUG|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
215056265|NCT01665911|DRUG|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
214302220|NCT06969547|DIAGNOSTIC_TEST|Low Dose CT-scan|Scanning parameters: tube voltage 120 kV; current 435 mA; tube rotation time 0.4 s; slice thickness 2.5 mm; interslice interval 2.5 mm.
214903615|NCT01570790|DRUG|Combretastatin A-4 Phosphate|36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
215056266|NCT01665911|DRUG|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
214302221|NCT06969547|DIAGNOSTIC_TEST|CT-coronary angiography|The study will be performed on a 64-slice GE Discovery NM/CT 570С (GE Healthcare, Milwaukee, WI, USA) from the level of the tracheal bifurcation to the diaphragm during breath holding (6-8 s) in the prospective (for HR≤55) or retrospective (for HR\>55) ECG-synchronized mode. To contrast coronary arteries, it is planned to use an intravenous infusion of 85-90 ml (at a rate of 5 ml/s) of an iodine-containing (370 mg iodine/ml) radiopaque substance.Scan will be performed with the following parameters: current strength 120 kV; voltage 300-600 mA with ECG modulation; tube rotation speed 0.4 s; pitch: 0.18-0.22 (depending on heart rate).
214903616|NCT01570790|DRUG|Combretastatin A-4 Phosphate|45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
214903617|NCT05273528|BIOLOGICAL|Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
214903618|NCT02521883|DEVICE|Sooma tDCS|2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
214903619|NCT02521883|DEVICE|Sham tDCS|sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
214302222|NCT02422745|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
214903620|NCT04243889|DEVICE|NEOX Cord 1K|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
214903621|NCT03802825|BEHAVIORAL|Diabetes Self-Management Training|The Decision-making Education for Choices in Diabetes Everyday (DECIDE) program is a nine-module, literacy adapted diabetes and cardiovascular disease education and problem-solving training program. Participants are taught the five steps of problem solving with each module going in depth on a single step: 1) identify the problem; 2) brainstorm possible strategies for problem resolution; 3) select the most appropriate strategy; 4) apply the strategy; 5) evaluate the effectiveness of the strategy. During the six months, CHWs will have weekly or bi-weekly contact with participants in-person or by phone to deliver the DECIDE modules and address social and economic needs.
214903622|NCT03802825|OTHER|Standard Patient Navigation|Once the participant has completed the YCLS assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 months by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention.
214903623|NCT01699009|OTHER|Plant based diet|
214903624|NCT01699009|OTHER|an unrestricted diet|
214903625|NCT03673969|PROCEDURE|Gastric bypass|Surgical method of gastric bypass
214903626|NCT05809869|DRUG|Durvalumab|Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles
214903627|NCT05809869|DRUG|Tremelimumab|Tremelimumab 300mg intravenous infusion on week 1 only.
214903628|NCT05809869|RADIATION|Yttrium-90 radioembolisation|Yttrium-90 radioembolisation on week 2 only.
214903629|NCT06575322|DRUG|Carboplatin（ neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214903630|NCT06575322|DRUG|Paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214903631|NCT06575322|DRUG|Anti-PD-1 Drugs|Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214903632|NCT06575322|PROCEDURE|Surgical resection|Standard of care
214903633|NCT00407134|PROCEDURE|Different abdominal volumes and different glucose-concentrations during peritoneal dialysis|
214903634|NCT05875402|DRUG|Chimeric antigen receptor T cell preparation targeting GCC|Chimeric antigen receptor T cell preparation targeting GCC
214903635|NCT02926443|OTHER|Upper Extremity Neuromuscular Training Program|Neuromuscular and strengthening shoulder exercises in a group setting.
214903636|NCT02926443|OTHER|Usual Physiotherapy Care|One-on-one physiotherapy care in a clinical setting.
214903637|NCT04383561|OTHER|Non-surgical periodontal treatment|Scaling and root planing (SRP), in four clinical visits
214903638|NCT04383561|OTHER|Oral hygiene instructions|Oral hygiene instructions includes brushing with the modified Bass technique, interdental cleaning with dental floss and interdental brushes.
214903639|NCT01468337|DRUG|Interferon gamma-1b|"Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg~Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.~Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.~Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.~If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes)."
214903640|NCT00000468|DRUG|tissue plasminogen activator|
214903641|NCT06349525|DEVICE|telescopic overdenture|Maxillary implant supported telescopic overdenture
214903642|NCT06349525|DEVICE|Locator overdenture|Maxillary implant supported locator overdenture
215056267|NCT01665911|DRUG|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
214302223|NCT02422745|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
214302224|NCT02422745|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
214302225|NCT02422745|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
214302226|NCT06073821|DRUG|Sonrotoclax|Administered orally
214302227|NCT06073821|DRUG|Zanubrutinib|Administered orally
214302228|NCT06073821|DRUG|Venetoclax|Administered orally
214302229|NCT06073821|DRUG|Obinutuzumab|Administered intravenously
214302230|NCT06612437|DEVICE|continuous theta burst stimulation (cTBS)|Standard 600-pulse continuous theta burst stimulation (cTBS) can inhibit the corticomotor excitability. The cTBS will be delivered with an intensity of 70% individual resting motor threshold (RMT) of the hand knob over the contralesional M1.
214903643|NCT02034734|DRUG|ASP3652|oral
214903644|NCT01675934|PROCEDURE|Retroflexion with the adult colonoscope.|
214903645|NCT01675934|PROCEDURE|Retroflexion with the pediatric colonoscope.|
214903646|NCT03775525|DRUG|GZ17-6.02|Super enhancer Inhibition
214903647|NCT03775525|DRUG|Capecitabine|antimetabolite
214903648|NCT05339373|DRUG|Aceclofenac film-coated tablet 100 mg|Aceclofenac is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 100 mg of aceclofenac.
214903649|NCT05339373|DRUG|Airtal® film-coated tablet 100 mg|"Airtal ® is manufactured by Gedeon Richter- RUS, Russia / Gedeon Richter, Hungary. Each tablet contains 100 mg of aceclofenac."
215056268|NCT01665911|OTHER|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
215056269|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor|Arm A
215056270|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor with chemotherapy|Arm B
215056271|NCT02872597|DRUG|Ipratropium|
215056272|NCT02872597|DRUG|0.9% Sodium Chloride|
215056273|NCT02872597|DRUG|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
214903650|NCT03662087|COMBINATION_PRODUCT|HMA+DLI|HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days. DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
214903651|NCT03662087|BIOLOGICAL|DLI|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
215056274|NCT02872597|DRUG|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
215056275|NCT03650413|DRUG|UTTR1147A|UTTR1147A will be administered based on disease status, as described in the protocol.
215056276|NCT03073083|PROCEDURE|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
215056277|NCT03073083|PROCEDURE|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
215056278|NCT03073083|PROCEDURE|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
214903652|NCT03428152|PROCEDURE|superior hypogastric block|superior hypogastric blockade during surgery
214302231|NCT06612437|DEVICE|intermittent theta burst stimulation (iTBS)|Standard 600-pulse intermittent theta burst stimulation (iTBS) can increase the corticomotor excitability. The iTBS will be delivered with an intensity of 70% individual resting motor threshold (RMT) of the hand knob over the contralesional M1.
214302232|NCT06612437|DEVICE|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device.
214903653|NCT03908996|BEHAVIORAL|Profile by Sanford weight management plan|The purpose of this study is to observe weight changes in patients who completed endometrial cancer treatment, are clinically overweight, and who participate in the Profile by Sanford weight management program. An exploratory purpose is to examine the bacterial content of the patient's gut by examining stool specimens before starting the Profile by Sanford weight management program and after 6 months of participation in the Profile by Sanford weight management program.
215056279|NCT01963182|DRUG|Irinotecan|
215056280|NCT06331039|OTHER|PFMT|PFM exercises were done. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
215056281|NCT06331039|OTHER|PFMT+Otago|It were done by combining Otago exercises and PFM exercises. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
215056282|NCT04755998|OTHER|Use of virtual reality glasses during vaccination applications in children|"To the experimental group:~Before the vaccine administration;~* Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.~* Cartoons and virtual reality glasses that the student wanted to watch were prepared.~* While the nurse was preparing the vaccines, the student was put on virtual reality glasses and the distance settings of the lenses were adjusted and the cartoons he chose to watch during the vaccination applications started to be shown. Since virtual reality glasses can cause anxiety attacks manifested by nausea in some children, this was also tested beforehand. It took about two minutes to administer the vaccine and watch cartoons.~Those applied after the vaccine administration;~\- Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student."
215056283|NCT03032211|DEVICE|Alfapump|Implant Alfapump® System
215056284|NCT05828615|OTHER|Group A|"Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
214903654|NCT00486746|BEHAVIORAL|Lifestyle intervention (physical activity and dietary counseling)|One-year intervention
214903655|NCT00486746|BEHAVIORAL|General information on healthy lifestyle habits|A single session
214903656|NCT05002634|DIETARY_SUPPLEMENT|undenatured collagen type II (UCII) supplement|The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
214302233|NCT04559815|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214479204|NCT06661031|BEHAVIORAL|Motivational Enhancement Therapy plus Ecological Momentary Intervention|Two Motivational Enhancement Therapy (MET) sessions (1st, \~45 minutes; 2nd, \~30 minutes) between counselor and participant occur one week apart. MET sessions are personalized, interactive, face-to-face, and delivered according to a manual. MET session discussion topics include triggers for cannabis use, life goals/values, and development of a change plan. Participants then complete a 2-week Ecological Momentary Intervention (EMI) period. Survey prompts are sent 4x/day (3x/day at quasi-randomized times, 1x/day at fixed time; \~2 mins each) that ask about the participant's recent cannabis use. Depending on answers reported, the participant can receive tailored messages that support their self-efficacy and prompt use of coping strategies.
214903657|NCT06127342|BEHAVIORAL|Moderate Intensity Exercise|Participants will wear a heartrate monitor and cycle on a stationary bike at a slow speed for 5 minutes, then slowly cycle on a stationary bike for 30 minutes, then cycle on the stationary bike at a slow speed for 5 minutes.
214903658|NCT06127342|BEHAVIORAL|Low Intensity Exercise|Participants will wear a heartrate monitor and cycle on a stationary bike at a slow speed for 40 minutes.
214903659|NCT03749876|OTHER|Unfiltered Cigarettes|Participants will be given unfiltered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
214903660|NCT03749876|OTHER|Filtered Cigarettes|Participants will be given filtered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
214903661|NCT00941135|OTHER|Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab|"Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks~Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43"
214903662|NCT03915132|DRUG|Nimotuzumab|Nimotuzumab 200mg/m2 IV on d1 of a week before radiotherapy , and 100mg/m2 IV on d1 weekly for 7 cycles
214903663|NCT03915132|RADIATION|VMAT|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume.
214903664|NCT04269369|DRUG|5-Fluorouracil|"The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature."
214903665|NCT02154568|DRUG|hyperpolarized helium MRI of the chest|Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
214903666|NCT01146639|RADIATION|DynaCT|One extra set of images with DynaCT including one extra injection of contrast medium.
214903667|NCT01146639|DRUG|Iodixanol|One extra set of images with DynaCT including one extra injection of 50 ml contrast medium.
214903668|NCT05008744|PROCEDURE|Fetoscopic laser ablation|"Under ultrasound guidance, a 2 mm skin incision will be made and a 10Fr Cook Check Flow valve cannula and trocar will be introduced into the amniotic cavity.~The communicating vessels will be located endoscopically using a Storz straight or curved semirigid fetoscopes in a fetoscopic sheath, a Humanitarian Use Device, used with permission of the Federal Drug Administration under a Humanitarian Device Exemption agreement with Karl Storz, Inc, and will be ablated with a diode laser fiber that is passed through the operating channel of the endoscope."
214903669|NCT06008652|DRUG|DR-0201|DR-0201 is a bi-specific antibody
214479205|NCT06661031|BEHAVIORAL|Enhanced Usual Care|Participants meet with a study counselor 1-on-1 via videoconference to review a brochure containing cannabis information and treatment resources.
214903670|NCT06008652|DRUG|Placebo|Placebo
214903671|NCT04287660|DRUG|clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells|"* clarithromycin: 500mg, PO, twice daily, on days 1\~21 for a 28-day cycle.~* lenalidomide: 25mg, PO, on days 1\~21 for a 28-day cycle. dexamethasone: 40mg, PO on days 1,8,15 and 22 for a 28-day cycle. BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.~* Doses should be adjusted according to renal function."
214903672|NCT00917748|DRUG|DOCETAXEL(XRP6976) + MODAFINIL|arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
214903673|NCT00917748|DRUG|Modafinil|best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
214903674|NCT00917748|DRUG|Placebo of Modafinil|Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
214903675|NCT01454323|OTHER|Bone marrow mononuclear cells|Intracoronary infusion of autologous bone marrow-derived mononuclear cells
214903676|NCT02415101|PROCEDURE|Resective surgery|
214302234|NCT04626635|DRUG|REGN7075|Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
214302235|NCT04626635|DRUG|Cemiplimab|Administered concomitantly Q3W by IV infusion or SC injection
214302236|NCT04626635|DRUG|Platinum-based doublet chemotherapy|Administered IV Q3W
214903677|NCT04426006|OTHER|PRO-SERO-COV|"At inclusion, 3 months and 12 months :~* blood sample (2 x 5ml)~* self-administered questionnaire"
214669799|NCT04652934|OTHER|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
215056285|NCT05828615|OTHER|Group B|"The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
215056286|NCT05921591|DRUG|IRL201104|Lyophilised powder for reconstitution for IV dosing
214903678|NCT06778330|DRUG|Dapagliflozin (DAPA)|Control group: receive dapagliflozin in addition to standard therapy
214903679|NCT06778330|DRUG|Sildenafil|Test group: receive combination therapy of dapagliflozin and a small dose of sildenafil(25mg/day) in addition to standard therapy
214903680|NCT06041204|DRUG|Letrozole 2.5mg|Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.
214903681|NCT06041204|DRUG|Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet|Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
215056287|NCT05921591|DRUG|Placebo|Matching placebo for IRL201104
215056288|NCT02031003|DIETARY_SUPPLEMENT|Infant formula|Infant formula
214302237|NCT04626635|DRUG|Bevacizumab|Administered per protocol
214903682|NCT05280470|DRUG|Ifinatamab Deruxtecan (I-DXd)|I-DXd will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (every Q3W).
214903683|NCT05548062|OTHER|Hydroxyurea|Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.
214302238|NCT04626635|DRUG|Trifluridine-tipiracil|Administered per protocol
214302239|NCT02784210|DRUG|Methylprednisolone|3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day
214302240|NCT02784210|DRUG|Prednisone|3 days of corticosteroids (oral prednisone at 1250 mg/day
214302241|NCT04170348|DRUG|Daily oral vitamin D3, 3,333 IU|Oral vitamin D3, 3,333 IU, will be administered daily.
215056289|NCT01206140|OTHER|Laboratory Biomarker Analysis|Correlative studies
214302242|NCT04170348|DRUG|Monthly oral vitamin D3, 100,000 IU|Oral vitamin D3, 100,000 IU, will be administered monthly.
214302243|NCT04170348|DRUG|Placebo oral tablet|Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.
214302244|NCT06969443|PROCEDURE|Rehabilitation Procedure|"Rehabilitation procedure list :~1. Passive limb mobilization~2. Active (or active-assisted) limb mobilization~3. Passive transfer to chair~4. Active transfer to chair~5. Sitting on edge of bed~6. Standing table (or similar)~7. Standing on legs~8. Walking~9. Cyclo-ergometer (bed or chair)~10. Electrostimulation"
214302245|NCT06965426|OTHER|Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation|Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation
214669800|NCT06971068|PROCEDURE|Procedure: EVLA|Great or small saphenous vein occlusion with endovenous laser ablation using ELVeS Radial 2ring fiber
215056290|NCT01206140|DRUG|Selumetinib|Given PO
215056291|NCT01206140|DRUG|Temsirolimus|Given IV
215056292|NCT05388604|DEVICE|RF device|The entire defined treatment area will then be treated by delivering adjacent pulses with minimal overlap of 10% or less. Parameters may be adjusted throughout the treatment in order to increase subject comfort.
214302246|NCT06970743|DRUG|BGB-16673|Administered orally
214302247|NCT06970743|DRUG|Bendamustine|Administered intravenously
214302248|NCT06970743|DRUG|Rituximab|Administered intravenously
214302249|NCT06970743|DRUG|Methylprednisolone|Administered intravenously
214302250|NCT05104567|DRUG|THOR-707|Solution for infusion: intravenous infusion
214302251|NCT05104567|DRUG|Pembrolizumab|Solution for infusion: intravenous infusion
214302252|NCT05104567|DRUG|Cetuximab|Solution for infusion: intravenous infusion
214302253|NCT05853458|DRUG|Hydroxyurea|Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment
214302254|NCT06212076|DRUG|IPG1094|IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg
214302255|NCT04230512|OTHER|Pump prototype|Effects of pump function on gait
214903684|NCT05548062|OTHER|Ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.
214903685|NCT06180122|DIAGNOSTIC_TEST|Duplex ultrasound|Vascular ultrasound scan of the left common iliac vein
214903686|NCT03266627|DRUG|cytotoxic t-lymphocytes|adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
214903687|NCT05352750|BIOLOGICAL|SON-1010|SON-1010 multiple ascending dose
214903688|NCT05671341|DIAGNOSTIC_TEST|Assessment|Tandem walking test, Tandem Stance test, Activity-specific Balance Confidence Parkinson's Disease Quality of Life-8 N/L ratio Tinetti Balance Test UPDRS
214302256|NCT05619718|BEHAVIORAL|Awareness, Courage, and Love Groups|Groups based on the Awareness, Courage, and Love framework from functional analytic psychotherapy
214302257|NCT05619718|OTHER|Mutual Help Meetings|Groups based on treatment as usual where patients gather to discuss how they can help others on the ward, and make requests for how others can help them.
214302258|NCT06073951|OTHER|Best Practice|Receive usual care
214302259|NCT06073951|OTHER|Exercise Counseling|Receive walking step goals
214302260|NCT06073951|OTHER|Exercise Intervention|Participate in Mates in Motion program
214302261|NCT06073951|OTHER|Medical Device Usage and Evaluation|Wear Actigraph
214903689|NCT03028428|BIOLOGICAL|Placenta Derived Mesenchymal Stem Cell|1ml 1\*10\^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
214903690|NCT03028428|DRUG|Sodium Hyaluronate|Sodium hyaluronate administered into the knee joint once
214302262|NCT06073951|OTHER|Medical Device Usage and Evaluation|Wear Garmin activity tracker
214302263|NCT06073951|OTHER|Physical Performance Testing|Undergo walk-test
214302264|NCT06073951|OTHER|Questionnaire Administration|Complete questionnaires
214669801|NCT06971068|PROCEDURE|Procedure: VALA|Great or small saphenous vein occlusion with endovenous laser ablation using ELVeS Radial 2ring Pro fiber
214903691|NCT03380429|DRUG|RELVAR/BREO|RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
214903692|NCT03380429|DRUG|Salbutamol|Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
214903693|NCT03380429|DEVICE|Smart phone app|Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.
214903694|NCT03380429|DEVICE|HCP Dashboard|The information from sensors will be reviewed by the HCP via an online dashboard.
214903695|NCT03380429|DEVICE|Sensors|Clip-on sensors will be fitted to electronically record the actuation data.
214903696|NCT02828579|PROCEDURE|Bariatric surgery|Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
214903697|NCT03982290|OTHER|Probiotic, Lactobacillus plantarum PS128|PS128 capsules, 2 capsules per day
214903698|NCT03982290|OTHER|Placebo, microcrystalline cellulose|Placebo capsules, 2 capsules per day
214903699|NCT06194448|DRUG|Osimertinib|80 mg daily (or 40 mg daily for dose reduction)
214903700|NCT06194448|DRUG|Cisplatin or Carboplatin; Pemetrexed or Paclitaxel|Pemetrexed (500 mg/m2 to be administered on Day 1 of every 3-week cycle for 2 cycles) or Paclitaxel (175 mg/m2 on Day 1 of every 3-week cycle for 2 cycles) PLUS Cisplatin (75 mg/m2) or Carboplatin (AUC5) to be administered on Day 1 of every 3--week cycle for 2 cycles
214669802|NCT06532617|DRUG|Cadonilimab+S-1or Capecitabine|Eligible patients will receive Cadonilimab (6mg/k, iv, D1,Q3W)combined with S-1 (40-60mg po BID Q3W D1-14）or Capecitabine (1250mg/m2, po BID Q3W D1-14）until disease progression or unacceptable toxicity. Patients who had used S-1 in the first line should choose capecitabine; patients who had used capecitabine in the first line should choose S-1; otherwise decided by investigator's choice.
214669803|NCT05059197|DIETARY_SUPPLEMENT|AP collagen peptide|Health functional food
214903701|NCT06194448|DRUG|Radiation|"Patients must have received a total dose of radiation of 60 Gy ± 10% (54 to 66 Gy) as part of the chemoradiation therapy. It is recommended but not required that patients have a:~* Mean lung dose \< 20 Gy and/or V20 \< 35%~* Mean oesophagus dose \< 34 Gy~* Heart V50 \< 25%, V30 \< 50%, and V45 \< 35%"
214903702|NCT04750954|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214903703|NCT04750954|PROCEDURE|Computed Tomography|Undergo CT
214903704|NCT04750954|DRUG|Lutetium Lu 177 Dotatate|Given IV
214903705|NCT04750954|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903706|NCT04750954|DRUG|Peposertib|Given PO
214903707|NCT01175993|OTHER|Elliptical exercise|Each participant with TBI will participate in an exercise intervention which will be done in the home. The exercise device in this protocol will be an elliptical trainer that requires coordinated reciprocal movements of both the legs and the arms. Primary emphasis will be placed on maintaining a near maximal speed of movement and to progressively increase this over time. Mild resistance to the leg motion will be provided initially and will be progressively increased once speed and coordination are optimized. The device will be loaned to them to use in the home, and will be delivered to the home fully assembled. Participants will be monitored by phone the first week and thereafter every two weeks and progressed as indicated. The exercise program will be performed 5 days a week for 30 minutes per session, for a total duration of 12 weeks. All will record the length, speed and resistance of each session on a paper-based log sheet.
214903708|NCT06982222|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
214302265|NCT05734443|BEHAVIORAL|step training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.
214669804|NCT05059197|DIETARY_SUPPLEMENT|Placebo|placebo
214903709|NCT06982222|PROCEDURE|Bone Scan|Undergo technetium TC-99m bone scan
214903710|NCT06982222|PROCEDURE|Computed Tomography|Undergo PET/CT, SPECT/CT and PSMA PET/CT
214903711|NCT06982222|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214903712|NCT06982222|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT
214669805|NCT02772783|OTHER|high GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of \~90 is achieved by using corn syrup as a carbohydrate source.
214903713|NCT06982222|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214903714|NCT06982222|RADIATION|Technetium TC-99m|Undergo technetium TC-99m bone scan
214903715|NCT06982222|RADIATION|Tin Sn 117m Pentetate|Given IV
214903716|NCT02043457|OTHER|phenotyping|
214903717|NCT06574906|OTHER|Parameters of Early Warning Scores|Parameters of Early Warning Scores
214903718|NCT06656143|OTHER|Traditional Physical therapy|"The exercise program included the strengthening of the deep cervical flexor and shoulder retractor muscles and also stretching of the pectoralis and cervical extensor muscles.~(3 sets of 12 repetitions) Strengthening Deep Cervical Flexors Lying chin tuck Lying chin tuck with head lift. Strengthening Shoulder Retractors Standing shoulder pull back with elastic Shoulder pull back with weight Stretch Cervical Extensors Chin drop Stretch Pectoralis Muscle Bilateral Pectoral stretch"
214903719|NCT06656143|OTHER|Diaphragmatic Myofascial Release|To release the diaphragm, the patient was positioned in the supine position. The therapist stood at the head of the patient. The therapist made manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th) with hypothenar regions of the hands and last three fingers. During the patient's inspiration, the therapist was gently pulling the points of hands contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist deepened hand contacts towards the inner costal margins Exercise Program (3 sets of 12 reps) Strengthening deep cervical flexors Strengthening shoulder retractors Stretching Cervical Extensors Stretching Pectoralis Muscle
214903720|NCT04542824|BIOLOGICAL|Epcoritamab (monotherapy)|Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
214903721|NCT04542824|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
214903722|NCT04542824|DRUG|Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
214479206|NCT06662682|OTHER|Whole-Body Vibration|The intervention (IC) will be specified as a five-minute Whole-Body Vibration session. The WBV take place on a side alternating vibration plate (Wellengang, Germany). The patients stand barefoot on the vibration plate on a prescribed position. In this position the amplitude will be 6-7mm. The WBV protocol contains mobilizing sequences with lower frequencies and activating sequences with higher frequencies
214479207|NCT06662682|OTHER|Control Condition|Non-intervention control condition
214479208|NCT06662019|DRUG|N-IP-00001 inhalation solution|Multiple ascending dose (MAD) study. Over the 2 dosing days participants will receive a total of 6 inhaled doses of 5 ml of N-IP-00001 at increasing concentrations, ranging from 0.5mg/ml to 16mg/ml (total volume loaded in the nebuliser is 6 ml per dose).
214903723|NCT04542824|DRUG|Gemcitabine and oxaliplatin|28-day cycles
214903724|NCT04542824|BIOLOGICAL|Epcoritamab (maintenance)|28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
214903725|NCT04542824|DRUG|Rituximab and lenalidomide|28-day cycles.
214903726|NCT06818045|PROCEDURE|Non Surgical Periodontal Treatment|This procedure will be applied to all patients. All patients received nonsurgical periodontal treatment. Scaling root planing and subgingival debridement were performed.
214903727|NCT06818045|OTHER|Periodontal measurements will be performed|Periodontal measurements will be performed on all patients (plaque index, gingival index, bleeding on probing, periodontal pocket depth, clinical attachment loss).
214903728|NCT06818045|OTHER|biochemical measurements|Serum and gingival crevicular fluid (GCF) samples will be collected from patients for biochemical evaluations.
214903729|NCT06818045|OTHER|No medication will be administered to patients.|No medication will be administered to patients.
214903730|NCT05562466|DRUG|QMF149|QMF149 75/40 μg o.d via Breezhaler
214903731|NCT05562466|DRUG|Budesonide|Budesonide 200 μg o.d via Breezhaler
214903732|NCT01041924|OTHER|Carbon dioxide|2% inhaled CO2 for up to 8 hours.
214903733|NCT01041924|OTHER|Carbon dioxide|Up to a maximum of 2% CO2, only delivered for a maximum of up to 20 seconds per 60 seconds for 8 hours
214903734|NCT04010565|DIETARY_SUPPLEMENT|Aged black garlic extract|"Participants will intake a tablet with 250 mg of a aged black garlic extract with higher concentration of bioactive compounds S-allyl cysteine and alliin, and minor unwanted compounds such as simple sugars and furfural derivatives.~In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias."
214903735|NCT04010565|DIETARY_SUPPLEMENT|Placebo|Participants will intake a tablet with 250 mg of microcrystalline cellulose. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias.
214903736|NCT06490224|BEHAVIORAL|Relevant Patient Reported Outcome Measures (PROMs)|Depending on the participant's complaint: Hip disability and osteoarthritis outcome score JR (HOOS JR), Knee disability and osteoarthritis outcome score JR (KOOS JR), Quick Disabilities of the Arm, Shoulder, and Hand, Quick Disabilities of the Arm, Shoulder, and Hand (QUICKDASH), Patient Health Questionnaire 9 (PHQ-9), General Anxiety Disorder-7 (GAD7), Patient Self-Efficacy Questionnaire (PSEQ-2), Patient-Reported Outcomes Measurement Information System (PROMIS Global 10)
214903737|NCT06490224|OTHER|My Whole Health Map|Short visual map of responses to 10 questions of subjective measures.
215056293|NCT05388604|DEVICE|Microneedling device|"Test spots may be performed prior to the first treatment. Test spots may be performed prior to the first treatment. It will follow a similar procedure to treatment but only in an inconspicuous place, such as behind the ear, in an area no larger than 2in x 2in.~The tip will be placed in contact with the skin, and parameters may be adjusted throughout the treatment and will determined by the Clinician."
214903738|NCT04272788|DRUG|Infliximab|The CD patients at initial active stage without treatment of glucocorticoids, immunosuppressants and biological agents are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
214903739|NCT05975008|BEHAVIORAL|RECLAIM - Reconnecting to Civilian Life using Activities that Improve Mindfulness|Brief virtual mindfulness-based intervention
214903740|NCT04449874|DRUG|GDC-6036|The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
215056294|NCT03896854|BIOLOGICAL|CART-19|CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19 cells/kg).
215056295|NCT05504187|DRUG|KP104|KP104 will be administered.
215056296|NCT02994082|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
214903741|NCT04449874|DRUG|Atezolizumab|A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
214903742|NCT04449874|DRUG|Cetuximab|Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.
214903743|NCT04449874|DRUG|Bevacizumab|A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
214903744|NCT04449874|DRUG|Erlotinib|150 mg of erlotinib will be administered PO QD in 21 day cycles.
214903745|NCT04449874|DRUG|GDC-1971|The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
214903746|NCT04449874|DRUG|Inavolisib|The starting dose of inavolisib will be determined from its single-agent dose escalation.
214903747|NCT06594068|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE (Furie 2017). Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo (Furie 2019; Morand 2020). Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo (Furie 2017). These data resulted with applications to the FDA and the EMA, leading to approval by them in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
214903748|NCT04846400|DEVICE|ssNPA|The ssNPA is a self-supporting nasopharyngeal airway, a stent that is a non-surgical alternative to treat severe OSA
214903749|NCT03142737|OTHER|Red kidney bean intake|Each participant will consume 1/2 cup of cooked red kidney bean
214903750|NCT03142737|OTHER|Eggs intake|Each participant will consume 2 cooked large eggs.
214903751|NCT03142737|OTHER|Peanut butter intake|Each participant will consume 2 tablespoons of peanut butter.
214903752|NCT03142737|OTHER|Ground beef intake|Each participant will consume 2 ounces of 90% lean ground beef.
214903753|NCT03142737|OTHER|Intact beef intake|Each participant will consume 2 ounces of intact beef.
214903754|NCT06988553|DRUG|AZD5004|AZD5004 will be administered as an oral tablet once daily.
214903755|NCT06988553|DRUG|Placebo|Placebo will be administered as an oral tablet once daily.
214903756|NCT01924689|BIOLOGICAL|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
214903757|NCT05326750|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
214903758|NCT06517602|DIETARY_SUPPLEMENT|Supplementation of Moringa oleifera leaf powder|Women in the experimental group were asked to consistently take the prescribed oral hypoglycemic therapy and to maintain their lifestyle and eating habits. In addition, for the duration of the study (3 months), the experimental group was provided with 10 g of Moringa oleifera leaf powder daily to be consumed with main meals.
214903759|NCT05793164|OTHER|no intervention|no intervention
214903760|NCT01790074|OTHER|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
214903761|NCT01790074|OTHER|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
214903762|NCT03267212|DEVICE|Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
214903763|NCT03267212|DEVICE|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
215056297|NCT02994082|BEHAVIORAL|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
214903764|NCT03267212|OTHER|Functional Electrical Stimulation Row Training (FESRT)|FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
214903765|NCT00063011|BEHAVIORAL|Calcium rich diet|
214903766|NCT00063011|BEHAVIORAL|Weight bearing exercise|
214903767|NCT01560975|DEVICE|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
214479209|NCT06662019|DRUG|0.9% NaCl isotonic saline solution|Nebulized treatment consisting of 0.9% saline solution.
214903768|NCT05481632|OTHER|Endoangel assisted the process of colonoscopy|Endoangel assisted doctors to detect polyps
214903769|NCT05481632|OTHER|Colonoscopy was performed without endoangel assistance|Polyps were detected without ENDOANGEL assistance
214903770|NCT04106427|DEVICE|continuous theta burst stimulation (cTBS)|"cTBS stimulation of 17 mins over right inferior parietal lobe (IPL) with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 100% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
214302266|NCT05734443|BEHAVIORAL|treadmill training|Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
214903771|NCT04106427|DEVICE|placebo cTBS|"Placebo stimulation of 17 mins over right IPL with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 0% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
214903772|NCT04106427|BEHAVIORAL|social cognitive remediation therapy (SCRT)|16 sessions of group SCRT will be scheduled within 8 weeks, comprising 6-8 participants per group with 2 therapists. Duration of group sessions will be 60-90 mins. The content will follow the manual of SCRT and we will add a short intervention to practice the use of co-speech gestures at each session
214903773|NCT04106427|BEHAVIORAL|Sham group therapy|Group activities in closed groups of 6 participants. Schedule of two sessions per week for 8 weeks. Two therapists are guiding different leisure activities, e.g. group walks, going to museums/movies, games.
214903774|NCT03139851|DRUG|Cyclophosphamide 50mg|One tablet per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
214903775|NCT03139851|DRUG|Pembrolizumab 100 MG in 4 ML Injection|IV infusion every 3 weeks. Pembrolizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
214903776|NCT04208100|DEVICE|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery. The 595nm and 660nm wavelengths of the Lutronic PicoPlus Laser system are used for the treatment of benign pigmented lesions.
215056298|NCT02994082|BEHAVIORAL|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
215056299|NCT02994082|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
215056300|NCT02994082|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
214903777|NCT04132973|BEHAVIORAL|Compassion for Skin Conditions|Online guided self-help intervention derived from Compassion Focused Therapy (Gilbert, 2010).
214903778|NCT05575973|DRUG|Mitoxantrone Hydrochloride Liposome|Drug: Mitoxantrone hydrochloride liposome (20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.
214903779|NCT05575973|DRUG|Rituximab|Drug: Rituximab (375 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.
215056301|NCT02994082|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
215056302|NCT02994082|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
215056303|NCT02994082|DRUG|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
215056304|NCT02994082|DRUG|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
215056305|NCT02994082|DRUG|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
215056306|NCT02994082|DRUG|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
215056307|NCT02994082|BEHAVIORAL|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
215056308|NCT02994082|BEHAVIORAL|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
215056309|NCT06436014|OTHER|Providing VR experience|Participants undergoing VR intervention will experience a VR program of their choice based on personal preferences. Among these programs are videos offering natural visual experiences. For instance, participants can opt for videos featuring seaside views, forest tours, or lake landscapes.
214302267|NCT01602380|DRUG|faslodex 500mg|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
214302268|NCT01602380|DRUG|arimidex 1mg|oral tablet 1 daily
215056310|NCT06368843|DRUG|Gargle with ketamine|The patients asked to gargling with ketamine solution in the preoperative waiting area after explain the whole procedure and the goals of the study.
214479210|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Synergy ZFR00).
214479211|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Symfony ZXR00).
214479212|NCT06663813|BEHAVIORAL|Educational Intervention|Utilizing the Health Belief model, educational materials detailing diabetes risk factors to address perceived susceptibility, diabetes severity and complications to address perceived severity, and PCP follow-up information and medication assistance programs to address perceived barriers will be provided.
214903780|NCT05575973|DRUG|Lenalidomide|Drug: Lenalidomide (25 mg) will be taken orally from day 1 to day 8 of each 28-day cycle.
214903781|NCT02537561|DRUG|Cisplatin|
214903782|NCT02537561|DRUG|Gemcitabine|
214903783|NCT02537561|DRUG|Talazoparib|
214903784|NCT02841137|DRUG|Progesterone|comparison of different dosages of drug towards the active comparator
214302269|NCT01602380|DRUG|faslodex dummy|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
214479213|NCT06661733|DRUG|AZD5462|Participants will receive AZD5462 orally.
214479214|NCT06663098|DRUG|Atezolizumab|1200 mg IV on day 1 of every 21 days, during induction phase and maintenance phase
214479215|NCT06663098|DRUG|Carboplatin|AUC 4 or 5, depending on patient's characteristics, on day 1 every 21 days during induction phase
214479216|NCT06663098|DRUG|Etoposide|80 mg/sqm or 100 mg/sqm, depending on patient's characteristics, on days 1-2-3 of every 21 days
214479217|NCT06777745|OTHER|Model-assisted breast examination application|Designed for the development of self-examination skills, this model is in the shape of a female upper body with medium-sized breasts. Thanks to its ergonomic design, it can be worn easily and offers a comfortable use. Made of high quality, dermatologically tested and tactile silicone material. This model, which reflects all the details of the skin realistically, has a structure suitable for standing and lying examination. For educational use, there are 2 benign tumours, 4 malignant tumours and 2 typical anomalies. This model allows for practical explanation of all stages of breast examination such as determining the area to be examined, manual examination of the area, examination method, nipple examination and detection of malignant formations in the breast.
214903785|NCT06675929|DRUG|BI 770371|BI 770371
214903786|NCT06675929|DRUG|Placebo for BI 770371|Placebo for BI 770371
214903787|NCT07008599|OTHER|Pulpal Blood Sample|Biochemical markers were measured in blood samples using enzyme-linked immunosorbent assay (ELISA).
214903788|NCT05913336|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg , Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
214903789|NCT07005960|OTHER|Art Therapy for Anxiety in Hemodialysis Patients|"Patients in the experimental group will be administered the Volunteer Information and Consent Form, the Patient Information Form, and the State-Trait Anxiety Inventory prior to the intervention.~Then, for four weeks, the experimental group will participate in art therapy sessions involving drawing and painting for approximately 30 minutes, twice a week. In the first week, patients will be asked to paint a given picture. In the second week, they will be given a different picture to paint. In the third week, they will be asked to draw and paint a picture of their choice. In the fourth week, they will again be asked to draw and paint a picture of their choice. At the end of the fourth week, the scales will be completed again.~After this, there will be a one-month break from art therapy, during which no intervention will be conducted. At the end of this month, the same scales will be administered again to the experimental group."
214907486|NCT06056037|BEHAVIORAL|Standard of Care|Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.
215056311|NCT01413711|DRUG|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
214302270|NCT01602380|DRUG|arimidex dummy|oral tablet 1 daily
214302271|NCT06448910|DRUG|Cadonilimab (AK104)|Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatin/cisplatin plus etoposide, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy + carboplatin/cisplatin plus etoposide), and finally consolidation therapy with cadonilimab (AK104) for 1 year.
214302272|NCT06059638|DEVICE|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated|Antihypertensive therapy utilizing atrioventricular interval modulation.
214302273|NCT06059638|DEVICE|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated|AVIM therapy is deactivated
214302274|NCT03658538|DEVICE|Active HEPA Air Cleaner|The active treatment arm will receive two active air cleaners with HEPA and carbon filters to support a home smoking ban and SHS reduction.
214302275|NCT03658538|BEHAVIORAL|Motivational interviewing|"The active treatment arm will receive 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).~The Control arm will receive only continued counseling for smoking cessation."
214302276|NCT03658538|DEVICE|Sham Air Cleaner|The Control arm will receive sham air cleaners
214302277|NCT05554289|DEVICE|Depression Auxiliary Intervention Treatment Software (WL-iCBT)|The Depression Auxiliary Intervention Treatment Software (WL-iCBT) is a mobile application for smartphones that delivers cognitive behavioral therapy (CBT) and cognitive bias modification (CBM) through structured interactive multimedia methods, including animations, videos, audio, and interactive exercises.
214479218|NCT03349801|OTHER|No intervention|According to clinical practice.
214669806|NCT02772783|OTHER|low GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of \~40 is achieved by using uncooked corn starch as a carbohydrate source.
214669807|NCT02772783|DRUG|euglycemic insulin clamp|Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
214669808|NCT02772783|DRUG|primed-variable insulin infusion|A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are \> 400 mg/dl or \< 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
214669809|NCT02830165|OTHER|Laboratory Biomarker Analysis|Correlative studies
214669810|NCT02830165|OTHER|Quality-of-Life Assessment|Ancillary studies
214669811|NCT02830165|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214669812|NCT04723030|DRUG|carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)|"Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week."
214669813|NCT00443521|DRUG|Triamcinolone Acetonide 4 mg intravitreal injection|
214669814|NCT00443521|PROCEDURE|Panretinal photocoagulation|
214669815|NCT01440725|BIOLOGICAL|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
214669816|NCT01440725|PROCEDURE|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
214669817|NCT05091138|DRUG|Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
214669818|NCT05091138|DRUG|Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
214669819|NCT01374698|DRUG|Aspirin|Aspirin 325 mg
214669820|NCT03443024|BIOLOGICAL|Lebrikizumab|Sterile liquid solution administered subcutaneously.
214669821|NCT03443024|DRUG|Placebo|Solution administered subcutaneously.
214669822|NCT04801914|PROCEDURE|Percutaneous biliary drainage|Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).
214669823|NCT04422587|OTHER|RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
214669824|NCT02456623|BEHAVIORAL|Intervention|Home-based session targeting the parent
214669825|NCT02456623|BEHAVIORAL|Attention Control|Attention condition with newsletters and support phone calls
214669826|NCT00820105|DRUG|ADX10059|oral administration
214669827|NCT00820105|DRUG|ADX10059|Oral administration
214669828|NCT00820105|DRUG|ADX10059|Oral administration
214669829|NCT00820105|DRUG|ADX10059 Matching Placebo|Oral administration
214669830|NCT06459752|OTHER|visceral manipulation and noble technique|"First, the patient will lie face-up on a massage or exam table. Physiotherapists feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles. Physiotherapist manual poking, pressing, and massage actions do three things:~1. Reveals visceral adhesions.~2. Find tender spots.~3. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that makeup fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Minor adhesions may resolve after one session. Tough, stubborn adhesions may require several sessions plus self-manipulation between sessions"
214669831|NCT06459752|OTHER|noble technique|The patient is positioned in supine with both knees bent and feet flat on a firm surface. The patient then places her crossed hands over her abdomen to support and pull the rectus abdominis muscles towards the midline. Finally, the patient is asked to slowly raise her head until a slight contraction is felt in the abdomen, holding for 20 seconds and repeating the exercise up to 20 times a day
214903790|NCT07005960|OTHER|Art Therapy for Resilience in Hemodialysis Patients|"Patients in the experimental group will be administered the Volunteer Information and Consent Form, the Patient Information Form, the Brief Resilience Scale, prior to the intervention.~Then, for four weeks, the experimental group will participate in art therapy sessions involving drawing and painting for approximately 30 minutes, twice a week. In the first week, patients will be asked to paint a given picture. In the second week, they will be given a different picture to paint. In the third week, they will be asked to draw and paint a picture of their choice. In the fourth week, they will again be asked to draw and paint a picture of their choice. At the end of the fourth week, the scales will be completed again.~After this, there will be a one-month break from art therapy, during which no intervention will be conducted. At the end of this month, the same scales will be administered again to the experimental group."
215056312|NCT03813875|DRUG|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0\~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
214302278|NCT05554289|DEVICE|Placebo Control Software (WL-iHE)|The placebo control software (WL-iHE) is a mobile application that mimics the appearance and usage pattern of the active intervention software but lacks the therapeutic cognitive behavioral therapy components. The software has a similar user interface and time requirements, with participants using it once daily for 10-15 minutes, completing a total of 56 sessions over the 8-week treatment period. Unlike the active intervention, the placebo software does not deliver structured cognitive behavioral therapy content or cognitive bias modification training, instead providing general health education information without specific depression treatment techniques.
214302279|NCT06143956|DRUG|LY3305677|Administered SC. ISA specific interventions will be listed in the ISA.
214302280|NCT06143956|DRUG|LY3841136|Administered SC. ISA specific interventions will be listed in the ISA.
214302281|NCT06143956|DRUG|Tirzepatide|Administered SC. ISA specific interventions will be listed in the ISA.
214669832|NCT00624338|DRUG|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
214669833|NCT00624338|DRUG|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
214669834|NCT00624338|OTHER|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
214903791|NCT06550947|GENETIC|Immunohistochemistry|Immunohistochemical expression of ALDOA in bladder urothelial carcinoma
214903792|NCT04444440|DRUG|Ciprofloxacin|Fluoroquinolone antibiotic.
214903793|NCT04444440|OTHER|Placebo Pill|Placebo Pill
214903794|NCT06870344|DRUG|Dihydroartemisinin piperaquine|Taken orally. 11 kg to less than 17 kg 1 tablet per day for 3 days 40 mg 320 mg 17 kg to less than 25 kg 1½ tablets per day for 3 days 60 mg 480 mg 25 kg to less than 36 kg 2 tablets per day for 3 days 80 mg 640 mg 36 kg to less than 60 kg 3 tablets per day for 3 days 120 mg 960 mg 60 kg to less than 80 kg 4 tablets per day for 3 days 160 mg 1280 mg 80 kg or more 5 tablets per day for 3 days 200 mg 1600 mg For patients weighing less than 11 kg, alternative formulations supplying lower amounts of active substance should be preferred
214903795|NCT06870344|COMBINATION_PRODUCT|Dihydroartemisinin piperaquine + Bacillus thuringiensis israelensis|Study staff will provide adult participant with LLIN(s), DP and with an 8-oz packet of Bti, a pair of latex gloves, a teaspoon, and a tracking form. A staff member will then survey an area (50 m radius) around the house and demonstrate appropriate application in up to 5 potential breeding sites.
214903796|NCT06870344|OTHER|Long-lasting Insecticidal Net|Distribution of Long-lasting Insecticidal Net to all households on the study.
214903797|NCT06873009|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) for Smoking Cessation|"A structured three-session group intervention (1.5 hours per session over three weeks) using cognitive-behavioral and motivational strategies to enhance motivation, manage cravings, and prevent relapse.~Associated Arm: CBT Group"
214903798|NCT06873009|OTHER|Health Education Session on Tobacco Use|"A single-session group intervention (1 hour) providing information on the health risks of tobacco use, addiction mechanisms, and the long-term benefits of quitting smoking.~Associated Arm: Health Education Group"
214903799|NCT06625775|DRUG|BBO-10203|Participants will receive assigned dose of BBO-10203 orally once daily
214903800|NCT06625775|DRUG|Trastuzumab|Participants will receive trastuzumab as infusion or subcutaneous injection every 21 days
214302282|NCT06143956|DRUG|Placebo|Administered SC. ISA specific interventions will be listed in the ISA.
214903801|NCT06625775|DRUG|Fulvestrant|Patients will receive Fulvestrant as an intramuscular injection every 28 days (additional dose on C1D15)
214903802|NCT06625775|DRUG|Ribociclib|Patients will receive Ribociclib orally once a day (21 days on treatment, 7 days off)
214903803|NCT06625775|DRUG|FOLFOX|Patients will receive FOLFOX as infusion every 14 days
214302283|NCT06143956|DRUG|LY3549492|Administered orally. ISA specific interventions will be listed in the ISA.
214903804|NCT06625775|DRUG|Bevacizumab|Patients will receive bevacizumab as infusion every 28 days
214903805|NCT07013539|DIETARY_SUPPLEMENT|plant extract|hard shell capsule containing plant extract
214903806|NCT07013539|DIETARY_SUPPLEMENT|Placebo|hard shell capsule containing maltodextrine
214903807|NCT06689852|DEVICE|Enriched|To be used twice a day
214903808|NCT06689852|DRUG|Loceryl 5%|To be used once a week
214903809|NCT00156403|DRUG|amlodipine (drug)|
214903810|NCT01904695|DRUG|Herbs|Herbs 180ml by mouth every 12 hours for 8 weeks
214903811|NCT01904695|DRUG|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
214903812|NCT03212274|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214903813|NCT03212274|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214903814|NCT03212274|PROCEDURE|Computed Tomography|Undergo a CT scan
214903815|NCT03212274|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
214903816|NCT03212274|DRUG|Olaparib|Given PO
214903817|NCT05691712|DRUG|Tirzepatide|Administered SC
214903818|NCT05691712|DRUG|Placebo|Administered SC
214903819|NCT00226499|BIOLOGICAL|Priorix-tetra™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group
214903820|NCT00226499|BIOLOGICAL|Priorix™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group
214903821|NCT00226499|BIOLOGICAL|Varilrix™|1 dose administered subcutaneously at Day 42 to subjects in OKAH Group
214903822|NCT03479580|OTHER|Patients with a cardiomyopathy|Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.
214903823|NCT06632977|OTHER|Genetic testing|undergo genetic testing
214903824|NCT06632977|DRUG|Valemetostat Tosylate|Given PO
214903825|NCT06632977|PROCEDURE|Magnetic Resonance Imaging|undergo Magnetic Resonance Imaging
215056313|NCT03813875|OTHER|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
214302284|NCT05559749|BEHAVIORAL|collaborative care|a 24-week neurology based collaborative care program consisting of: 1. a series of every 2 weeks care management calls by the care manager to evaluate anxiety, depression, seizures and side effects and deliver brief therapy interventions to the participant, and 2. collaborative care conferences including a psychiatrist to generate expert recommendations for anxiety and depression management and communication of recommendations between the care manger, psychiatrist and neurologist.
214302285|NCT05559749|BEHAVIORAL|usual neurology care|ongoing usual neurology care, without the addition of the collaborative care program
214302286|NCT03372733|DRUG|control olive oil (COO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
214302287|NCT03372733|DRUG|palmitoleate-rich oil (PLO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
214903826|NCT06632977|PROCEDURE|Computed Tomography|undergo Computed Tomography
214903827|NCT06632977|PROCEDURE|Bone scan|undergo Bone scan
214903828|NCT06632977|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET
214903829|NCT06632977|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
214903830|NCT06632977|PROCEDURE|Biospecimen Collection|undergo blood collection
214903831|NCT06632977|DRUG|Carboplatin|Given IV
214903832|NCT06632977|DRUG|Cabazitaxel|Given IV
214302288|NCT05997615|DRUG|VIR-5500|Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
214903833|NCT06632977|DRUG|Abiraterone Acetate|Given PO
214903834|NCT06632977|DRUG|Enzalutamide|Given PO
214903835|NCT06632977|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
214903836|NCT07028294|COMBINATION_PRODUCT|Combined exercise and nutrition intervention|Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks). Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol. Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
214903837|NCT07028749|DRUG|MAR001|Subcutaneous Injection
214903838|NCT07028749|DRUG|Placebo|Subcutaneous injection
214903839|NCT00352742|DRUG|ATN-224 + bortezomib|ATN-224 and bortezomib dose to be determined in Phase I portion of study
214903840|NCT05584618|OTHER|Education|education
214903841|NCT05828498|DIETARY_SUPPLEMENT|THE Mediterranean diet|The Mediterranean diet was applied to the patients with bacterial vaginitis selected randomly. diet content and application techniques were explained to the patient.
214903842|NCT03161353|DRUG|Perjeta|All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
214903843|NCT03161353|DRUG|Herceptin|All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
214903844|NCT03161353|DRUG|Docetaxel|Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
214903845|NCT03161353|DRUG|Carboplatin|Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
214903846|NCT03161353|DRUG|Letrozole|Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
214903847|NCT03161353|DRUG|Tamoxifen|"Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.~Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy."
214903848|NCT00583765|DRUG|Regional citrate anticoagulation|Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
214903849|NCT02851017|OTHER|Exercise|This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
214903850|NCT05327400|OTHER|Pathological|The pancreatic cancer cohort and the healthy cancer-free patient cohort were divided according to pathology reports
214903851|NCT06694805|DRUG|CAB LA + RPV LA|Intramuscular injection administered monthly for first 2 initiation doses then every 2 months.
214903852|NCT06694805|DRUG|Oral ART|Oral medication provided to participants by the site/their regular healthcare professional (HCP) as part of their standard of care (SOC) treatment.
214903853|NCT06686342|OTHER|No intervention|The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
214903854|NCT06686342|OTHER|No Intervention: Observational Cohort|The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
214903855|NCT06444399|DRUG|Deucravacitinib|6 mg administered orally twice daily for 24 weeks.
214903856|NCT07032467|OTHER|Psychosocial and Behavioral Assessment|Participants completed validated self-report questionnaires to assess levels of social media addiction and compulsive exercise behaviors. No therapeutic or experimental intervention was administered. Data were collected through surveys for observational analysis.
214903857|NCT07035158|DIAGNOSTIC_TEST|Libra Oral Solution|EVOC Probe
214903858|NCT07032935|BEHAVIORAL|Virtual Reality Glasses will be used DURING CORONARY ANGIOGRAPHY APPLICATION|Virtual Reality Glasses will be used DURING CORONARY ANGIOGRAPHY APPLICATION
214903859|NCT07135687|DRUG|Losartan|Two types of losartan capsules will be compounded by combining a broken-up 25mg or 50mg losartan tablet and microcrystalline cellulose placebo filler to eliminate rattling of the broken tablet inside of the capsule. The 25mg losartan capsules will be yellow and the 50 mg losartan capsules will be blue.
214903860|NCT07135687|OTHER|Placebo|The placebo capsules will consist of microcrystal cellulose and will come in yellow and blue to appear identical to the losartan capsules.
214903861|NCT06707844|OTHER|Conventional treatment|"Conventional treatment will include:~* Stretching exercises (5Reps with 15sec hold): Gastrocnemius-soleus stretch, TA stretch.~* Strengthening exercises (5Sets, 5Reps, 5sec hold): Weight-bearing lunges, Short-foot exercise.~* Maitland mobilization Grade 2 \& 3 (3 Sets, 20Reps) at Talonavicular joint."
215056314|NCT03813875|DRUG|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
215056315|NCT03813875|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0\~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
215056316|NCT03813875|DRUG|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0\~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
214302289|NCT05997615|COMBINATION_PRODUCT|Enzalutamide|Oral administration
214302290|NCT05997615|COMBINATION_PRODUCT|Darolutamide|Oral administration
214302291|NCT06632054|BEHAVIORAL|Text Message Reminders|Text message reminders (instead of usual care - phone call reminders) to complete FIT for colon cancer screening.
214302292|NCT04596631|DRUG|Oral semaglutide|Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
214302293|NCT04596631|DRUG|Placebo (semaglutide)|Placebo treatment for 52 weeks.
214903862|NCT06707844|OTHER|Myofascial release|"* Myofascial release is a manual therapy applying sustained pressure on the calf muscles to release fascial restrictions.~* Protocol: 3 sets of 2-minute pressure applications with a 1-minute break between sets~* Performed twice weekly for 3 weeks"
214903863|NCT06707844|OTHER|Tissue flossing|"Tissue flossing involves wrapping a latex band around the calf muscles with 50-75% elongation, followed by active ankle movements (dorsiflexion, plantarflexion, circles, heel raises).~Protocol: 4 sets of 8 repetitions, 10-second rest between sets Performed twice weekly for 3 weeks."
214903864|NCT07137117|OTHER|Behavioral Treatment|"Patients in the experimental group will be administered a Patient Information Form on the morning of surgery. Standard discharge education will be provided within 72 hours after surgery. After discharge, patients will be contacted at 1, 2, 3 weeks, and 2, 4, and 5 months for informational purposes only; no assessment will be administered. During this period, regular follow-up and support will be provided to enhance patient compliance with post-surgical care. The Interview Information Collection Form will be used during telephone interviews with patients to collect and evaluate current health data. This practice will ensure systematic and accurate recording of patients' current conditions. Patients will be contacted at 1, 3, and 6 months to complete the Medication Adherence Scale and the Nutrition and Exercise Attitude Scale, collecting data on medication adherence and behavioral attitudes. These assessments will be used as a systematic approach to monitoring patient adherence t"
214903865|NCT07137572|OTHER|Art Prescription|Any of the art interventions (theatre, dance, visual arts, music or cinema)
214903866|NCT07047183|DRUG|VEN (Venetoclax)|Enrolled patients will receive: Venetoclax: 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Days 3-14. Azacitidine: 75 mg/m² on Days 1-7. Cycle duration: 28 days Total cycles: 1 to 2 cycles
214903867|NCT05369754|BIOLOGICAL|YBSW015 injection|Prepared YBSW015 injection is intravenously injected by an infusion pump or gravity infusion with intravenous infusion of 250 mL for 60 min±10 min.
214903870|NCT07052084|DRUG|Vasopressin administration|Low dose of vasopressin (0.02ui /min), maximum 5 days
214903871|NCT07052084|DRUG|Sodium chloride administration|NaCl 0.9 %, maximum 5 days
214903872|NCT07051798|OTHER|It is a qualitative type of study that will be conducted through face-to-face interviews.|It is a qualitative type of study that will be conducted through face-to-face interviews.
214903873|NCT07054515|DRUG|AZ-3102|Oral dispersible tablets
214903874|NCT07054515|DRUG|Placebo|A matching placebo will be administered in the same regimen as the intervention
214903875|NCT07053800|BIOLOGICAL|Obecabtagene autoleucel|Obecabtagene autoleucel (obe-cel) given as a single infusion
214903876|NCT06896578|PROCEDURE|Lateral lymph node dissection|Removal of lateral lymph nodes in the obturator and internal iliac compartment including fatty tissue, but excluding vascular and nervous tissue
214903877|NCT02225431|DRUG|sodium chloride infusion|
214903878|NCT06793800|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|TAVSS is an application system that uses an electrical transcutaneous stimulation device placed on the concha or tragus of the ear. Functional Magnetic Resonance Imaging studies have shown that stimulation of these areas activates the ipsilateral nucleus tractus solitarius (NTS) via vagal projections to the brainstem and forebrain. Unlike cervical vagus nerve stimulation, TAVSS utilizes a physiological pathway to activate the NTS and the dorsal motor nucleus, which subsequently sends impulses bilaterally to the heart surface via efferent cervical vagus nerves. Therefore, this technique eliminates the possibility of directly and asymmetrically stimulating cardiac motor efferent fibers, which could lead to adverse cardiac events. TAVSS combines advantageous qualities such as being non-invasive, cost-effective, convenient, and efficient.
214903879|NCT05063552|BIOLOGICAL|Atezolizumab|Given IV
214903880|NCT05063552|BIOLOGICAL|Bevacizumab|Given IV
214903881|NCT05063552|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214903882|NCT05063552|DRUG|Carboplatin|Given IV
214903883|NCT05063552|BIOLOGICAL|Cetuximab|Given IV
214903884|NCT05063552|DRUG|Cisplatin|Given IV
214903885|NCT05063552|PROCEDURE|Computed Tomography|Undergo CT scan
214903886|NCT05063552|DRUG|Docetaxel|Given IV
214903887|NCT05063552|PROCEDURE|Echocardiography Test|Undergo ECHO
214903888|NCT05063552|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214903889|NCT05063552|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214903890|NCT03640494|DEVICE|Optical Coherence Tomography|This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.
214903891|NCT03719027|DIAGNOSTIC_TEST|Study population|Dyspnea assessment (NYHA functional class) EKG Echocardiography
214903892|NCT01422980|OTHER|1- Test dairy product containing specific ingredients|
214903893|NCT01422980|OTHER|2- Control dairy product without specific ingredients|
214903894|NCT05142280|OTHER|Decision-aid for cardiovascular disease risk|The active choice intervention aims to promote an active choice regarding coping with an increased risk of cardiovascular disease. This means that individuals should (a) become aware of a discrepancy between the current and desired situation; (b) understand what the CVD risk means, and what its causes and consequences are; (c) evaluate the pros and cons of the different options to cope with the risk; and (d) are clear about their values regarding the choice.
214903895|NCT05142280|OTHER|Control|The control condition contains information that resembles usual care by a GP regarding CVD prevention
214903896|NCT00946920|DRUG|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
214903897|NCT00946920|DRUG|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
214302294|NCT05615233|BEHAVIORAL|TACAD|"Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of PLAD (TACAD). It includes four components in three languages (English, MandarinChinese, and Korean):~1. 2 sub-ethnic specific social media sites;~2. interactive online educational modules;~3. online resources; and~4. a VR component based on A Walk Through Dementia (WTD)"
214302295|NCT05615233|BEHAVIORAL|Alzheimer's Association website|The webpage on caregiving includes information on caregiving, care option, financial/legal planning, caregiver health, daily care, stages and behaviors, and safety. The content will be available in the three languages at the project website.
214302296|NCT06422884|DRUG|ENV-101|oral tablet, dosed once a day
214302297|NCT06422884|DRUG|Placebo|oral tablet, dosed once a day
214302298|NCT06975618|DRUG|CYH33|CYH33: Participants will receive oral CYH33 once daily. The starting dose for adults in Phase I is 10 mg QD; adolescents begin at 5 mg QD. In Phase II, patients will receive RP2D determined in the Phase I study.
214302299|NCT06975618|DRUG|Placebo|Placebo: Matching placebo tablets will be administered once daily during the double-blind period of the Phase II PRVM cohort. Patients randomized to placebo will switch to CYH33 at the end of the blinded phase.
214302300|NCT05270707|RADIATION|Stereotactic radiosurgery|HyperArc is a radiotherapy treatment with a structured workflow to plan and deliver stereotactic radiosurgery (SRS).
214903898|NCT03482973|DRUG|Bupivacaine Group|20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).
214903899|NCT03482973|OTHER|Placebo|20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).
214903900|NCT01223391|OTHER|Abdominal binder|External abdominal compression sequentially applied at 20 mmHg for 3 minutes, maximal tolerable level for 1.5 minutes and comfortable level for 2 minutes.
214903901|NCT01223391|OTHER|No abdominal binder|Standing without abdominal binder for 3 minutes
214903902|NCT05008874|OTHER|Natural History Observation|Data collection on progression of disease
214302301|NCT03671889|DEVICE|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
214302302|NCT05219435|DRUG|Nivolumab|Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle. Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
214302303|NCT05219435|DRUG|Ipilimumab|Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.
214302304|NCT05094037|DEVICE|Removable cam walker boot|Standard of care device given to diabetic foot ulcer patients.
214302305|NCT05094037|OTHER|Counseling|Additional education, counseling and encouragement of use of the orthosis beyond the current standard of care.
214302306|NCT00213850|PROCEDURE|EFR|
214903903|NCT03666273|DRUG|Bapotulimab (BAY1905254)|Intravenous administration of escalating doses of Bapotulimab
214903904|NCT03666273|DRUG|Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)|Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab
214903905|NCT01553669|BEHAVIORAL|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
214903906|NCT02452437|DRUG|Oxycodone|Controlled release oxycodone 40 mg twice daily
214903907|NCT04433754|OTHER|biochemical analysis|cRP, d-dimer levels and lymphocyte counts will be compared
214903908|NCT01005147|DRUG|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
214903909|NCT01005147|OTHER|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
214903910|NCT05333705|BIOLOGICAL|infusion of natural killer cells|Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were sorted and cultured. NK cell production will be infused after chemotherapy
214907487|NCT05085548|DRUG|ProAgio Dose Levels (DL) 1,2,3|ProAgio is administered to study participants by intravenous injections once every 14 days.
214907488|NCT05085548|DRUG|ProAgio Dose Levels (DL) 4,5,6|ProAgio is administered to study participants by intravenous injections once every 7 days.
214907489|NCT05085548|DRUG|ProAgio Dose Levels 4a,5a,6a|ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations. Optional co-administration of gemcitabine (Gem) during dose expansion beginning with Cycle 2.
214907490|NCT05079035|BIOLOGICAL|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
214907491|NCT05079035|BIOLOGICAL|Saline|2 mL Sterile, preservative free 0.9% NaCl
214907492|NCT00001258|DRUG|Oxygen-15 Water|
214907493|NCT06234384|OTHER|Sarcoidosis diagnosis|Participants have been diagnosed with sarcoidosis.
214907494|NCT02849145|BIOLOGICAL|Blood sampling|7,5 ml of patient peripherical blood will be collected at each blood sample.
214907495|NCT05216861|OTHER|Demand and ability protocol|"The intervention consists of a structured conversation between the patient and his immediate manager under the guidance of licensed medical staff (in this case REKO) with knowledge of the requirements of the patient's work and his/her current functional ability. The intervention takes about 90 minutes excluding preparation time for REKO.~DAP consider the following domains; 1) mental and cognitive ability, 2) basic skills and social ability, 3) tolerance for physical conditions, 4) ability to work dynamically, 5) ability to work statically and 6) to be able to work certain times.~Based on the above domains, a structured review is made of the balance between requirements and function in current work in order to identify possible adaptations and measures at the workplace. During the intervention, the work requirements and the patient's function/ability are identified on a three-point scale and in domains where there is thus an imbalance adjustments or changed tasks are identified."
215056317|NCT03813875|DRUG|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0\~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
215056318|NCT03238703|DRUG|Anastrozole|Given PO
215056319|NCT03238703|DRUG|Exemestane|Given PO
214302307|NCT04173416|BEHAVIORAL|Youth Opioid Recovery Support (YORS)|The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
214302308|NCT06574789|DRUG|Standard dosing of IV ganciclovir|IV ganciclovir at standard dosing
214903911|NCT06859645|BEHAVIORAL|Motor imagey training|In addition to the prescribed exercise training, participants in the intervention group will follow a pre-designed motor imagery program for eight weeks, practicing daily. This program will include pre-recorded exercise videos specifically targeting the lumbar region, along with synchronized audio recordings providing detailed explanations of the exercises.
214903912|NCT06859645|BEHAVIORAL|Exercise training|All participants will receive telerehabilitation-based exercise training under the supervision of a physiotherapist for eight weeks. The exercise program will be delivered via videoconferencing as part of a telerehabilitation-based approach. The exercises, conducted under the physiotherapist's supervision, will consist of flexibility and stabilization exercises targeting the lumbar region and will last approximately 25 minutes per session.
214903913|NCT06877546|DEVICE|Lumoral treatment|"Lumoral® Treatment devices are handed over to study participants on the first visit. The treatment is performed first at the clinic under supervision by the researchers. Treatment is then repeated at home twice a week for 12 weeks.~The treatment is started by dissolving one 7 mg Lumorinse® oral tablet in 30 ml amount of pure water. The tablet dissolves in water in one minute, after which the mouthwash is poured into the mouth and swished for 60 seconds. The indocyanine green in the mouthwash adheres to the plaque surface in the teeth and gum line. The mouthwash is then spat out and the mouthpiece of the Lumoral® Treatment device is inserted into the mouth and a light is activated. After 10 minutes, the device turns itself off, after which the mouthpiece is removed from the mouth. Normal oral hygiene routines will then be performed."
214903914|NCT02690038|DRUG|Intravenous immunoglobulin (IVIG)|"Baseline Ig \< 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization"
214903915|NCT02690038|DRUG|Normal Saline|"Baseline Ig \< 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization"
214903916|NCT01414673|DRUG|HCG|5000 IU
214903917|NCT02166567|PROCEDURE|Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS|
214903918|NCT02166567|PROCEDURE|Swim-up|Semen processing will be carried out with the conventional swim-up method.
214907496|NCT05216861|OTHER|Collaborative interventions as usual|The rehabilitation coordinator conduct collaborative interventions as usual with patient and employer. This might be through phone calls are unstructured meetings.
215056320|NCT03238703|OTHER|Laboratory Biomarker Analysis|Correlative studies
214302309|NCT06574789|DRUG|Personalised dosing of IV ganciclovir|IV ganciclovir at a personalised dosing calculated using a ganciclovir dosing web app
214302313|NCT05519085|DRUG|mezigdomide|Specified dose on specified days
214302314|NCT05519085|DRUG|Pomalidomide|Specified dose on specified days
214907497|NCT04213885|COMBINATION_PRODUCT|PXL 330 Platinum device/Riboflavin|30mW, 5 sec, 5 sec off, 10 minutes of illumination
214907498|NCT05486091|BEHAVIORAL|App-Enhanced Brief Cognitive-Behavioral Therapy|BCBT is a cognitive-behavioral intervention designed to target core skills deficits among suicidal individuals. App-enhanced BCBT incorporates the use of a SmartPhone app during the therapy sessions.
215056321|NCT03238703|DRUG|Letrozole|Given PO
215056322|NCT03238703|OTHER|Quality-of-Life Assessment|Ancillary studies
215056323|NCT03238703|OTHER|Questionnaire Administration|Ancillary studies
215056324|NCT03238703|DRUG|Tamoxifen Citrate|Given PO
215056325|NCT03238703|DRUG|Toremifene Citrate|Given PO
215056326|NCT01735383|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
215056327|NCT01735383|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
215056328|NCT00022295|DRUG|idronoxil|
215056329|NCT01440114|DRUG|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
215056330|NCT01440114|DRUG|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
215056331|NCT01378650|DRUG|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
214302315|NCT05519085|DRUG|Bortezomib|Specified dose on specified days
215056332|NCT01378650|DRUG|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
214903919|NCT06410482|PROCEDURE|US guided caudal block|"After placing the patient in the left lateral position (hips and knees flexed) following monitoring and induction of anaesthesia, the field will be sterilized with 70% alcohol in 2% chlorhexidine.~Initial scanning in the transverse plane allows for visualization of the midline and identification of the sacrococcygeal ligament between the 2 sacral cornua. The 2 cornua resemble the 2 eyes of a frog and thus are collectively called the frog-eye sign. The US probe is then rotated 90 degrees to acquire a longitudinal view. The needle is then advanced at a 20-degree angle with needle tip and length visualization Once the needle is confirmed to be in the caudal space on the screen, carefully aspirate to confirm absence of CSF or blood.~A slow injection of the local anaesthetic can then be performed, dose of (0.2 mL/kg 0.25% bupivacaine and 1 μg/kg of dexmedetomidine"
214302316|NCT05519085|DRUG|Dexamethasone|Specified dose on specified days
215056333|NCT05930847|DEVICE|Digital Game Application|The digital game contains brief information about the respiratory system adapted to children, and it is a game whose duration can be adjusted manually to follow the treatment process of the patient, taking into account the ½ ratio in the inhalation and exhalation process in the clinic.
215056334|NCT05930847|DRUG|Use of medication for asthma|The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
214903920|NCT06410482|PROCEDURE|Dorsal penile nerve block|"after general anesthesia induction. With the patient in the supine position. After skin sterilization the US linear probe will be transversely placed on the root of the penis. After placing the penis in gentle traction, a50 mm block needle will be inserted from the lateral part of the penis root towards the dorsal section of the penis with the in-plane technique, It will be advanced through Dartos fascia until resistance to the needle disappeared.~Once the superficial sheath will be passed, the tip of the needle will be advanced into Buck's fascia and then positioned between Buck's fascia and tunica albuginea, lateral to the dorsal artery. After making sure there will be no blood with negative aspiration, half of the total 0.2 mL/kg dose of 0.25% bupivacaine will be administered while observing its distribution with US. The same procedure will be then repeated on the other side of the penis."
214903921|NCT01573182|BIOLOGICAL|Zostavax|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.
214903922|NCT00782054|OTHER|Provase|NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
214903923|NCT00782054|OTHER|Control moisturizer|Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
214903924|NCT04016454|PROCEDURE|Intervention|There will be one complete handover
214903925|NCT02692859|BIOLOGICAL|Hib conjugate vaccine|Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
214903926|NCT03952182|OTHER|Spinal Orthosis (LSO, TLSO)|spinal orthosis prescribed for specific spinal fracture (TLSO for thoracic or high lumbar fracture, LSO for lumbar fracture)
215056335|NCT05257421|DEVICE|shockwave machine|shockwave therapy. 2000 impulses will be applied, 1000 on the TrPs and 1000 surrounding it, with Energy level up to 2,5 bars and frequency of 10Hz
214302317|NCT05924802|DIETARY_SUPPLEMENT|Ketone Ester|Added to water or lemonade 3 times per day.
214302318|NCT05924802|DIETARY_SUPPLEMENT|Placebo|Added to water or lemonade 3 times per day.
214903927|NCT03952182|OTHER|No orthosis|no orthotic given for spinal fracture. These patient's will be given a bending restriction
214903928|NCT00842673|DRUG|ST101|30 mg; administered once/day
214903929|NCT00842673|DRUG|ST101|90 mg; administered once/day
215056336|NCT05257421|OTHER|leg and back exercises|"the exercise program will include 5 exercises that focuses on the back and lower limbs. These exercises are:~* Bridge~* Plank~* Squat~* Push-ups~* Back extension Each exercise will be done for 3-5 sets."
215056337|NCT05257421|COMBINATION_PRODUCT|shockwave and exercises|both types of interventions will be applied for the patient
215056338|NCT02967549|DEVICE|NAVA|NAVA delivered by the Servo-n ventilator (Maquet)
215056339|NCT02967549|DEVICE|PAV|PAV delivered by the Stephanie ventilator (Stephan)
215056340|NCT00211172|BEHAVIORAL|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
215056341|NCT02509936|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
214302319|NCT06424288|DRUG|vicadrostat|vicadrostat
215056342|NCT02509936|DIETARY_SUPPLEMENT|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
215056343|NCT04434430|DRUG|Gabapentin|Oral Gabapentin 600 mg
215056344|NCT04434430|OTHER|Placebo|Oral NaCl 500 mg
215056345|NCT01692496|DRUG|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
214302320|NCT06424288|DRUG|empagliflozin|empagliflozin
214302321|NCT06424288|DRUG|Placebo|Placebo matching vicadrostat
214302322|NCT02133196|DRUG|Aldesleukin|Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.
214302323|NCT02133196|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
214302324|NCT02133196|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
214302325|NCT02133196|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
214302326|NCT05363774|DRUG|NNC0519-0130|"SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels."
214302327|NCT05363774|DRUG|Placebo (NNC0519-0130)|"SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels."
214302328|NCT05450692|DRUG|Ceralasertib|Participants will receive ceralasertib oral tablets.
214302329|NCT05450692|DRUG|Durvalumab|Participants will receive durvalumab as an intravenous infusion.
214903930|NCT00842673|DRUG|ST101|180 mg; administered once/day
214903931|NCT00842673|DRUG|Placebo|placebo to match ST101 tablets
214903932|NCT02794727|DEVICE|Blinded Fitbit|Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
214903933|NCT02794727|DEVICE|Unblinded Fitbit|Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
214903934|NCT01268527|DRUG|0.03% E6201|Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
214903935|NCT01268527|DRUG|0.1% E6201|Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
214903936|NCT01268527|DRUG|0.2% E6201|Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
214903937|NCT01268527|DRUG|0.005% E6201|Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
214903938|NCT01268527|DRUG|0.01% E6201|Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
214903939|NCT01268527|DRUG|0.05% E6201|Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
214903940|NCT01268527|OTHER|Placebo - 0.03% gel vehicle|Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
214903941|NCT01268527|OTHER|Placebo - 0.1% gel vehicle|Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
214903942|NCT01268527|OTHER|Placebo - 0.2% gel vehicle|Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
214903943|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
214903944|NCT01268527|OTHER|Placebo - 0.01% gel vehicle|Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
214903945|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
214903946|NCT01268527|DRUG|Calcipotriene|Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
214302330|NCT05450692|DRUG|Docetaxel|Participants will received docetaxel as an intravenous infusion.
214903947|NCT05744167|BEHAVIORAL|BFRT|Following a warm-up of 10 min, subjects in the experimental group will undergo BFRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). BFRT will be at 40% of 1 repetition maximum (1RM); The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
214903948|NCT05744167|BEHAVIORAL|MDRT|Following a warm-up of 10 min, subjects in the experimental group will undergo MDRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). The exercise will be at 80% of 1RM concentric-only or 120% of 1RM eccentric-only in a 3:1 ratio. The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
214903949|NCT01930682|DRUG|Alteplase|Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
214903950|NCT01930682|PROCEDURE|Early post-fibrinolytic catheterisation|Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
214903951|NCT01930682|PROCEDURE|Primary PCI|For STEMI Patients,primary PCI is performed within 12 hours after the onset.
214903952|NCT03676218|OTHER|Elderly cancer patients|No intervention: consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
214903953|NCT01288079|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
214903954|NCT01288079|DRUG|Duloxetine|Capsule, oral, once daily
214903955|NCT01288079|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
214903956|NCT01530464|DRUG|Aminophylline|Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.
214903957|NCT01530464|DRUG|Ambrisentan|Drug will be administered as a single dose of 5mg, followed by a 48h washout period
215056346|NCT06215365|BEHAVIORAL|Adult cancer survivors who have completed their heavy treatments|"The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.~Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected."
215056347|NCT00770562|DRUG|rituximab|
214903958|NCT01530464|DRUG|Aminophylline plus ambrisentan|Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period
214903959|NCT05981690|BEHAVIORAL|Therapist guided, parent-led CBT for preadolescent children with OCD|This treatment was adapted from an existing evidence based therapist guided parent-led CBT intervention for preadolescent children with anxiety difficulties. It consists of 6 to 8 treatment individual treatment sessions where parents learn CBT techniques to apply at home with their child
214903960|NCT04273308|DEVICE|whole-body vibration training|The experimental group participated in a 12-week whole-body vibration training that was conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time. The control group were provided home DVDs on resistance exercise and manuals for preventing frailty
214903961|NCT06528379|BEHAVIORAL|Physical Activity|"The exercise programme is a 6-month progressive tailored-based exercise regime comprising~* aerobic exercises (40-60%)~* resistance exercises (20-40%)~* balance with resistance exercises (20%) .~This is peformed 3 times weekly, it is tailored to each individual but delivered in a small group-based manner. Two sessions are supervised by physiotherapist /exercise scientist and one session is unsupervised, home-based."
214903962|NCT00043303|DRUG|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
214903963|NCT00753038|BIOLOGICAL|REOLYSIN®|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
214903964|NCT00753038|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
214903965|NCT00753038|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
214903966|NCT02164045|DRUG|BMS-663068|BMS-663068
214903967|NCT03479398|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is an evidence-based psychotherapy that treats a variety of disorders. In this study, clinicians will be enrolled who use types of CBT for anxiety disorders, depression and PTSD in their routine clinical practice. CBT is usually a 12-16 session treatment that focuses on intervening on disorders cognitively and behaviorally through the use of worksheets during session and outside of session.
214903968|NCT01755533|OTHER|Rural curriculum|Students in schools randomly assigned to this condition receive the rural version of the curriculum.
214903969|NCT01755533|OTHER|Classic curriculum|Students in schools randomly assigned to this condition receive the classic version of the curriculum.
214903970|NCT01189162|DEVICE|NIMV with SLE ventilator vs HFNC via Vapotherm|Nasal respiratory support for RDS
214903971|NCT04777227|DRUG|Lidocaine injection|2% (20mg/ml) lidocaine solution
214903972|NCT04777227|DRUG|Physiological water injection|0.9% sterile sodium chloride water
214903973|NCT04777227|PROCEDURE|Debridement|A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.
214903974|NCT04777227|PROCEDURE|Needle insertion|A 27-gauge needle on a 3 mL syringe was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side
214903975|NCT02353182|DRUG|Dexmedetomidine|Loading dose:1 mcg/kg over 10 minutes. Infusion: Start 1-1.5 mcg/kg/hr. Titrate up or down within 50% of starting doses as needed.
214903976|NCT02353182|DRUG|Remifentanil|Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2-0.5 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
214903977|NCT02353182|DRUG|Bupivacaine|Administered in caudal/epidural/field block: 0.175%-0.25% (dose at discretion of anaesthetist)
214903978|NCT02353182|DRUG|Ropivacaine|Administered in caudal/epidural/field block: 0.2% (dose at discretion of anaesthetist)
214903979|NCT04382729|OTHER|Neuromuscular Electrical Stimulation|The intervention group, in addition to the daily routine physical therapy, receives NMES for 15 days (5 days per week for 3 weeks). NMES is applied bilaterally using an electrical stimulator with pairs of electrodes placed transversally on the quadriceps muscles and on the gastrocnemius muscles. The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 µs). Stimulation intensity is adjusted daily by the physical therapist to elicit a visible twitch in each muscle. The total duration of the NMES session is 30 min for the first week and 45 min for the second and third week. Stimulation (on) time is 5 s and relaxation (off) time is 15 s, thus eliciting a total of 90 evoked contractions per day during the first week and 135 contractions per day during the second and third week.
214903980|NCT04382729|OTHER|Physical Therapy Exercise|The control group is subjected to a protocol of physical therapy exercises, applied once a day for 30 minutes (5 days per week for 3 weeks) by the staff physical therapists. It starts with global passive range of motion exercises, followed by active and resistive exercises (including controlled breathing exercises and respiratory muscle training), transfer to the edge of the bed or to a chair, standing and walking.
214903981|NCT00537173|PROCEDURE|Core Biopsy|biopsy
214903982|NCT00537173|PROCEDURE|Blood Collection|Blood/serum sample
215056348|NCT00770562|DRUG|Dexamethasone|
215056349|NCT00306839|PROCEDURE|standardized Lichtenstein technique|
215056350|NCT01816776|DEVICE|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
214903983|NCT00537173|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
214903984|NCT00537173|DRUG|Avastin|Avastin 10 mg/kg IV, day 1 and 15
214903985|NCT00185289|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
215056351|NCT01816776|DEVICE|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
215056352|NCT03493672|DIAGNOSTIC_TEST|Objective measurement of physical activity and fitness|Physical activity and fitness will be assessed objectively with a smartphone
215056353|NCT04934696|DRUG|BMS-986166|Specified dose on specified days
214903986|NCT03678246|PROCEDURE|Ramped position|LSFOI glottis view
214903987|NCT03678246|PROCEDURE|Supine position|LSFOI glottis view
214903988|NCT05129774|PROCEDURE|Radical surgery with PALND|sufficient resection margins of the tumor, D3 dissection of the regional lymph nodes and para-aortic lymph node dissection from the bifurcation of iliac artery to the left renal vein via laparoscopic approach
214903989|NCT05129774|PROCEDURE|Radical surgery without PALND|surgery includes sufficient resection margins of the tumor and D3 dissection of the regional lymph nodes without PALND
214903990|NCT04113473|OTHER|Yoga Therapy|"An hour of yoga therapy included loosening exercise (sukshma vyayama), yoga postures (asana), yoga breathing (pranayama), relaxation (shavasana) and meditation.~Each participant were given handouts to follow home practice sessions everyday for twice a day for at least 15 minutes."
214903991|NCT03403673|OTHER|Frailty assessment tools|There is evidence to suggest that patients who are frail have a higher risk of developing complications after major surgery. Our aim is to ask you simple questions about your physical ability to perform daily life activities, assess your general health condition and ask you to do simple tasks such as drawing a clock or walking for a short distance to assess your speed of walking. Our main aim is to identify a tool that will assist us to identify patients who are at risk of frailty
214903992|NCT02047474|DRUG|oxaliplatin|Given IV
214903993|NCT02047474|DRUG|leucovorin calcium|Given IV
214903994|NCT02047474|DRUG|irinotecan hydrochloride|Given IV
214903995|NCT02047474|DRUG|fluorouracil|Given IV
214903996|NCT02047474|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
215056354|NCT04934696|DRUG|Oral contraceptive|Specified dose on specified days
215056355|NCT01643408|DRUG|asparaginase Erwinia chrysanthemi|
214903997|NCT02047474|OTHER|laboratory biomarker analysis|Correlative studies
214903998|NCT05192239|DRUG|THC 5|5 milligrams of THC in gummy form
214903999|NCT05192239|DRUG|Placebo|Commercially available non-THC fruit snack
215056356|NCT03915444|DRUG|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL\* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
214904000|NCT03402295|DRUG|Bortezomib, cyclophosphamide, thalidomide, dexamethasone|Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
214904001|NCT03223350|DRUG|Capsaicin 0.1% Cream|Topical application
214904002|NCT03223350|DRUG|Placebos|placebo cream
214904003|NCT05117216|BEHAVIORAL|Parental Vigilant Care (Parental training)|
214904004|NCT05117216|BEHAVIORAL|Technological Parental Monitoring|
214904005|NCT02627690|OTHER|islet transplanted|islet transplantation
214904006|NCT02627690|OTHER|non islet transplanted|no islet transplantation (for a non nephrologic reason)
214904007|NCT05802628|DRUG|Cetylpyridinium Chloride Buccal Tablets|Subjects administrated single dose of Cetylpyridinium Chloride Buccal Tablet
214904008|NCT02251483|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|
214904009|NCT02251483|OTHER|Placebo|
214904010|NCT01927120|DRUG|IL-2|A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
214904011|NCT01927120|DRUG|Tacrolimus|Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
215056357|NCT04263116|PROCEDURE|Balloon Assisted Maturation|Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
214479219|NCT05763901|DIAGNOSTIC_TEST|Clinical tests and motor control evaluation using Inertial Measurement Units|Each patient is evaluated using clinical tests (Movement ABC2, Test of Motor Competence), a screening questionnaire (DCD-Q), and wearable Inertial Measurement Units to assess balance and motor control during a Natural Walking and Tandem Walking test.
214904012|NCT01927120|DRUG|Sirolimus|Orally on day -1. The dose for loading is 12 mg by mouth (PO)
214904013|NCT00107627|OTHER|Caprosyn subcuticular sutures.|Caprosyn subcuticular sutures.
214904014|NCT00107627|OTHER|Monocryl subcuticular sutures.|Monocryl subcuticular sutures.
214904015|NCT00107627|OTHER|Skin staples;|Skin staples;
214904016|NCT04127227|DRUG|sintilimab,pegaspargase,gemcitabine,oxaliplatin|"All patients enrolled in the study will accept sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimens their first-line therapy.~Patients with CR or PR will receive sintilimab maintenance therapy"
214904017|NCT04542473|DRUG|Pancreatic Enzyme|CREON micro 5000
214904018|NCT04542473|DRUG|Ursodeoxycholic acid|Ursodiol C24H40O4 suspension
214904019|NCT04542473|OTHER|Pancreatic Enzyme placebo|Microcrystalline Cellulose,Macrogel 4000, Iron Oxide Yellow, Iron Oxide Red, Activated Charcoal.
214904020|NCT04542473|OTHER|Ursodeoxycholic acid placebo|Sodium Citrate Dihydrate, Aspartame, Carboxymethylcellulose Sodium, Citric Acid Monohydrate, Dispersible Cellulose, Glycerol, Polysorbate-80, Saccharin Sodium,Sodium Benzoate, Sodium Methylparaben, Sodium Propylparaben
215056358|NCT01696799|DRUG|Econazole Nitrate|
215056359|NCT01696799|DRUG|placebo|
215056360|NCT03398941|DRUG|Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide|Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
215056361|NCT02236572|DRUG|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~* Anastrozole 1 mg~* Letrozole 2.5 mg~* Exemestane 25 mg"
214302331|NCT03681054|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
214302332|NCT03681054|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
214302333|NCT03695796|DIAGNOSTIC_TEST|biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank|To evaluate and improve the non-invasive diagnosis of liver fibrosis in NAFLD and to develop the non-invasive diagnosis of NASH
214302334|NCT05877599|BIOLOGICAL|Autologous, engineered T Cells targeting TP53 R175H|"* Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion TCR T cells~* Post-infusion recombinant interleukin-2 (rIL-2)"
214904021|NCT01614873|DEVICE|Servo-i® ventilator, MAQUET,Critical Care, Sweden|Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
214904022|NCT00392691|DRUG|ibritumomab tiuxetan|185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients \> 80kg) for imaging.
214302335|NCT05012930|OTHER|Baby Foods - Meat|Commercially available baby foods
214904023|NCT00392691|DRUG|rituximab|250 mg/m2
214904024|NCT00392691|DRUG|melphalan|"* Dose level 1: 100 mg/m2~* Dose level 2: 140 mg/m2~* Dose level 3: 170 mg/m2~* Dose level 4: 200 mg/m2"
214904025|NCT00392691|DRUG|vinorelbine tartrate / G-CSF|on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days
214302336|NCT05012930|OTHER|Baby Foods - Dairy|Commercially available baby foods
214904026|NCT00392691|PROCEDURE|autologous hematopoietic stem cell harvesting and transplantation|"Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.~Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils \> 0.5x109/l for at least 2 consecutive days."
214904027|NCT03493191|DRUG|0.5μg/kg SHR0410|a single dose of 0.5μg/kg SHR0410
214904028|NCT03493191|DRUG|1μg/kg SHR0410|a single dose of 2μg/kg SHR0410
214904029|NCT03493191|DRUG|2μg/kg SHR0410|a single dose of 2μg/kg SHR0410
214904030|NCT03493191|DRUG|5μg/kg SHR0410|a single dose of 5μg/kg SHR0410
214904031|NCT03493191|DRUG|10μg/kg SHR0410|a single dose of 10μg/kg SHR0410
214904032|NCT03493191|DRUG|20μg/kg SHR0410|a single dose of 20μg/kg SHR0410
214904033|NCT05050565|BEHAVIORAL|Experiences of stigma and psychological flexibility in chronic pain participants|Chronic pain participants will answer questionnaires at two points in time, two weeks apart. These questionnaires ask about stigma and psychological flexibility, as well as depression, catastrophizing, pain interference, and social adjustment. The data collected is only observational and does not include any intervention.
214904034|NCT06564818|DRUG|CYB003|CYB003 is a Deuterated Psilocin Analog.
214904035|NCT06564818|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
214904036|NCT06564818|DRUG|Placebo|Placebo
214904037|NCT04564092|DRUG|DaTSCAN™ Ioflupane (123I) Injection|Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
214904038|NCT02026050|PROCEDURE|intraarticular dexamethasone|2ml 8 mg dexamethasone administration for intraarticular
214302337|NCT05012930|OTHER|Baby Foods - Plant|Commercially available baby foods
214302338|NCT05012930|OTHER|Foods from the home|Caregiver will provide participant with usual foods from the home
214904039|NCT02026050|PROCEDURE|interscalene dexamethasone|2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine
214904040|NCT02026050|PROCEDURE|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
214904041|NCT05344495|DRUG|hyalase group|bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.
214904042|NCT05344495|DRUG|midazolam group|2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%
215056362|NCT01057693|DRUG|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
215056363|NCT01057693|DRUG|Placebo|Placebo is supplied as capsules and given 3 times daily.
215056364|NCT01570517|DEVICE|IASD System|Implantation of the DC Devices Inc. IASD System
214904043|NCT03165812|PROCEDURE|SADJB-SG group|Patients will undergo bariatric surgery. A clear liquid high protein diet will be started in the first two postoperative days. If no complications were detected by physical examination, patients will be stimulated to walk and will be dismissed from the hospital on postoperative day 3. Patients will be subjected to a strict adherence to diet and close monitoring of their blood glucose and HbA1c levels during the study period. Standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Glycaemic control at home will be maintained as in the preoperative period and patients will need to inform the results of their blood glucose levels to the doctor during each follow-up visits.
215056365|NCT03200431|OTHER|New adhesive strip|This is a newly developed strip.
214302339|NCT04122313|OTHER|Evaluation of Dupuytren's Disease Treatment|There are no study interventions. The study interaction will be asking the patients to complete an additional outcome questionnaire and allow a medical record review.
214302340|NCT06479876|OTHER|HBCR|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
214302341|NCT06732804|BIOLOGICAL|AVT80|Single subcutaneous injection of AVT80 (108mg)
214302342|NCT06732804|BIOLOGICAL|Geographical region 1 Entyvio|Single subcutaneous injection of Geographical region 1 Entyvio (108mg)
214302343|NCT06732804|BIOLOGICAL|Geographical region 2 Entyvio|Single subcutaneous injection of Geographical region 2 Entyvio (108mg)
214302344|NCT04862923|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to treat the participant with a given product is independent of the decision to include him/her in the study.
214904044|NCT03165812|PROCEDURE|IMT group|Patients will be subjected to strict adherence to their diet, optimisation of their diabetic medications and close monitoring of their blood glucose and HbA1c levels at 0, 6, 12, 24 months. The endocrinologist will be monitoring the patients in this group. Detailed individualized lifestyle and dietary counseling will be given by a dietitian emphasizing on nutrition knowledge, the timing of meal with medication, portion control, and increasing daily physical activity level.
214904045|NCT00127114|DRUG|Amantadine|
214904046|NCT00127114|DRUG|Placebo|
214904047|NCT04507464|BEHAVIORAL|Ecological Momentary Intervention|Participants will wear a Fitbit that has been programmed to deliver a notification (a buzz) when activity has ceased for more than 10 minutes. They will receive suggestions on their Illumivu mEMA smartphone app on how to replace sitting time with PA such as standing up 5 times or taking 20 steps, or even performing a short (20 seconds) preferred dance routine. Fitbit data will be captured in real-time via the iCardia platform. Participants will receive reminders from their smartphones to enter real-time feedback on activity options selected and how successful they were in adopting the option. These data will allow tracking of underlying preferences for behaviors and to tailor the program accordingly.
214904048|NCT00146302|BIOLOGICAL|Bacille Calmette Guerin (BCG)|
214904049|NCT00200564|DRUG|ketamine|
214904050|NCT01759602|DRUG|C1-esterase inhibitor (Cinryze)|
214904051|NCT05579964|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|Priming dose of 0.5 mcg/kg in a 5 ml syringe mixed in priming fluid and 0.25 mcg/kg/hour DEX infusion diluted in 0.9% NaCl 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
214904052|NCT05579964|DRUG|Placebo|Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
214904053|NCT03447587|OTHER|Electroacupuncture|Each subject will be treated with predefined acupoints including bilateral Ear-Shenmen, Touwei (ST8), Sishencong (EX-HN1), and unilateral Yintang (EXHN3) and Baihui (GV20) on the head (total 8 needles). Subject's current symptoms will be ascertained using a Traditional Chinese Medicine symptom checklist and eight additional acupoints will therefore be selected and needled based on their clinical judgements. The acupuncture treatment will consistent of two sessions per week (30 minutes) for 4 consecutive weeks.
214904054|NCT03447587|OTHER|Sham acupuncture|Subjects will be treated at 1 cm posteriorly and laterally adjacent to the same acupoints as the traditional acupuncture group using validated non-invasive sham needles. Subjects will also be assessed with Traditional Chinese Medicine checklist. The acupuncturist, setting, treatment frequency, and duration of the treatment course will be the same as in the traditional acupuncture group.
214904055|NCT01473264|DRUG|recombinant human CC10 (rhCC10)|5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
214904056|NCT01473264|DRUG|recombinant human CC10 (rhCC10)|1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
214904057|NCT01473264|DRUG|placebo|Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
214904058|NCT02686307|PROCEDURE|ICD Implant|Implantation of an implantable cardioverter/defibrillator
214904059|NCT00480337|PROCEDURE|In Vitro Maturation of immature oocytes|
214904060|NCT04073537|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
214904061|NCT04073537|DRUG|Placebos|Anlotinib blank analog capsule.
214904062|NCT04073537|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV on Day 1 of each 21-day cycle.
214904063|NCT04073537|DRUG|Carboplatin|Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
215056366|NCT00237666|DRUG|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
215056367|NCT00579553|DRUG|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
215056368|NCT00579553|DRUG|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
214904064|NCT02433132|OTHER|Nasal brushing|The CCBN test is to evaluate the ion transport in the nasal epithelial cells taken from a subject by brushing the inferior turbinate with a mini-brush after local anesthesia. Analysis of ion transport is carried out ex vivo on the primary culture of nasal epithelial cells after brushing
214904065|NCT01796678|DRUG|Arginine|
214904066|NCT01796678|DRUG|Placebo|Saline or Sugar pill was given as placebo
214904067|NCT03896698|DEVICE|Transcranial Ultrasound Stimulation|TUS activate the brain cells
214904068|NCT00503698|DRUG|somatropin|20 mcg/kg/day, injected s.c. (under the skin)
214904069|NCT00503698|DRUG|placebo|Placebo injected s.c (under the skin)
214904070|NCT06808516|DRUG|Oxytocin nasal spray|24 IU
214904071|NCT06808516|DRUG|Placebo|0.9% NaCl
214904072|NCT04430062|PROCEDURE|Surgical procedures performed under general anesthesia|Surgical procedures performed under general anesthesia in patients with perioperative SARS-CoV-2 infection
215056369|NCT02435459|PROCEDURE|No lining|No lining material placed under amalgam dental restorations
215056370|NCT02435459|PROCEDURE|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
214904073|NCT00856882|DIETARY_SUPPLEMENT|soy protein|
214904074|NCT00856882|DIETARY_SUPPLEMENT|isoflavones|
214904075|NCT00856882|DIETARY_SUPPLEMENT|milk protein|
214904076|NCT02696291|DRUG|UV-4B 30 mg oral solution|UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
214904077|NCT02696291|DRUG|UV-4B 75 mg oral solution|UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
214904078|NCT02696291|DRUG|UV-4B 150 mg oral solution|UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
214904079|NCT02696291|DRUG|UV-4B X mg (dose to be determined) oral solution|UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
214904080|NCT02696291|DRUG|UV-4B Y mg (dose to be determined) oral solution|UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
214904081|NCT02696291|DRUG|Placebo|Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
214904082|NCT03257540|DEVICE|Small Bone Intramedullary Nail|Patients undergoing a Lapidus Arthrodesis procedure for hallux valgus correction who are receiving a Phantom Small Bone Intramedullary nail will begin weight-bearing at 2 weeks and follow a pre-determined post-operative protocol.
214904083|NCT02107131|DRUG|Intravitreal ranibizumab 0.3mg|
214904084|NCT02312167|DEVICE|confocal laser endomicroscopy|probe-based and needle-based confocal laser endomicroscopy
214904085|NCT06358768|OTHER|teamwork job improvement overall|increase of teamwork capacities and skills improvement
214904086|NCT06358768|OTHER|teamwork job improvement in actor scenario vs mannequin scenario|increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning
214904087|NCT00218712|BEHAVIORAL|Cognitive behavioral intervention|Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
214904088|NCT00218712|BEHAVIORAL|Standard counseling|Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
214904089|NCT02252835|DRUG|Arhalofenate|800 mg once daily orally for four weeks
214904090|NCT02252835|DRUG|Febuxostat|40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
214904091|NCT02252835|DRUG|Arhalofenate|600 mg once daily orally for four weeks
214904092|NCT02252835|DRUG|Febuxostat|80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
214904093|NCT02252835|DRUG|Colchicine|0.6 mg daily
214904094|NCT06871254|OTHER|Therapeutic Intermittent Hypoxia (TIH) + Exercise Training (ET)|TIH in combination with upper limb and respiratory ET. The intervention is predominantly home-based and will be delivered three times per week for six weeks.
214904095|NCT02773147|DRUG|Cyanocobalamin|
214904096|NCT02773147|DRUG|Folate|
214904097|NCT02773147|DRUG|Pyridoxine|
215056371|NCT02435459|PROCEDURE|RMGI cement|placement of lining material under amalgam dental restorations
215056372|NCT02435459|PROCEDURE|Resin Bonding Agent|placement of lining material under amalgam dental restorations
215056373|NCT04453358|DEVICE|InCourage-Connect|This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.
215056374|NCT04453358|DEVICE|InCourage|This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
215056375|NCT00203736|DRUG|Sulfadoxine-pyrimethamine|
215056376|NCT00203736|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
215056377|NCT04779450|OTHER|Kinesiotherapy protocol|The kinesiotherapy protocol is an exercise-based treatment designed to gain upper limb range of motion and muscle strengthening.
215056378|NCT04779450|OTHER|Usual orientations|Usual orientations for post-breast cancer women, such as skin care, return to activities, upper limb functionality, self-care, lymphedema, and physical activity practice.
215056379|NCT04157153|DEVICE|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
215056380|NCT00305903|DRUG|Rivastigmine, memantine|
215056381|NCT01206634|PROCEDURE|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
214302345|NCT03333044|BEHAVIORAL|Community Health Worker (CHW)-Led Health Coaching|CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to manage diabetes.
214302346|NCT03333044|OTHER|EHR-Embedded Alerts|An electronic health record (EHR) intervention for primary care providers (PCPs) utilizing embedded alerts to identify South Asian patients with uncontrolled diabetes.
215056382|NCT01206634|BEHAVIORAL|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
215056383|NCT00253513|DRUG|fludarabine|30 mg/m2, IV for 5 days
215056384|NCT00253513|DRUG|treosulfan|12 or 14 g/m2, IV for 5 days
215056385|NCT00253513|PROCEDURE|allogeneic blood or bone marrow transplantation|bone marrow or peripheral blood stem cells
214302347|NCT06359691|BEHAVIORAL|Patient-focused strategies|"Patient-focused strategies to increase HTN management practices:~1. Hypertension registry: notify patients of their status, target education and resources to patients~2. Home BP monitoring: provide BP monitors, encourage reporting of home BP readings~3. Enhance standardization of home and office BP readings: patients trained by care staff, posters in clinics on how to measure BP correctly~4. Nurse-directed BP medication titration with CHW/Health Educator reinforcement: self-directed referrals to nurse-directed clinics and CHW/health educators~5. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: tailored educational materials offered to patients in clinic, via text and the patient portal.~6. Social needs screening and linkage to community resources: awareness of and self-referrals to community resources~7. Behavioral science intervention messaging: posters in clinic waiting rooms, scripts for RN/PCP, texts to patients"
214302348|NCT06359691|BEHAVIORAL|Provider-focused strategies|"Provider-focused strategies to increase HTN management practices:~1. Hypertension registry: identify patients with uncontrolled BP, notify care team~2. Home BP monitoring: provide home BP monitors, encourage reporting of BP readings~3. Enhance standardization of home/office BP readings: staff training, posters in clinic~4. Simplify treatment protocols using fixed-dose combo meds: education on fixed-dose combo meds~5. Nurse-directed BP med titration w/ CHW/Health Educator support: system for team-based care, referral to nurse-directed clinics \& CHWs/health educators~6. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: Increased availability of tailored materials~7. Social needs screening and linkage to community resources: referral system to resources~8. CHW assigned to patients with complex medical and social needs: referral of complex patients to CHWs~9. Behavioral science messaging: posters in charting rooms, scripts for RNs"
214302349|NCT06359691|BEHAVIORAL|Patient- and provider-focused strategies|A combination of the 7 patient-focused strategies (see patient-focused strategies outlined above) and 9 provider-focused strategies (see provider-focused strategies outlined above) implemented simultaneously.
214302350|NCT04820075|BEHAVIORAL|improvement of preoperative shower|Process about preoperative shower
214302351|NCT06258837|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
214302352|NCT06258837|PROCEDURE|Adenotonsillectomy|Tonsil and/or adenoid removal
214904098|NCT02673177|PROCEDURE|robot-assisted total mesorectal excision|The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery. This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
214904099|NCT02673177|PROCEDURE|laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
214904100|NCT06751238|BIOLOGICAL|Secukinumab|Intravenous secukinumab
215056386|NCT04224233|OTHER|Home-based physical activity programme|iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
215056387|NCT04224233|OTHER|Usual care|Participants will receive a leaflet with exercises and PA recommendations.
214904101|NCT03845660|BEHAVIORAL|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
214904102|NCT01611727|DRUG|Cisplatin|Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
214904103|NCT03123744|DRUG|Palbociclib 125mg|Palbociclib 125 mg is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study evaluations include physical exams, performance status, vital signs, laboratory blood tests, and radiographic or MRI imaging.
214904104|NCT01452880|DRUG|Remifentanil|Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
214302353|NCT06401668|BEHAVIORAL|Community health worker (CHW) strategy|CHWs will offer participants personalized support to assist in overcoming barriers and leveraging facilitators to PRx uptake. CHWs are trained lay members of the communities they serve. The CHW strategy is an evidence-based.
214904105|NCT01452880|DRUG|Remifentanil|GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
214904106|NCT00180531|DEVICE|Renewal TR2|
214904107|NCT05227391|PROCEDURE|Oral Letrozole|Oral Letrozole at a dose of 2.5mg daily will be started on days 3-5 of the menstrual cycle and will be continued for 5 days.
214904108|NCT05227391|PROCEDURE|Oral estradiol valerate|Oral estradiol valerate at a dose of 3mg twice daily will be started on days 3-5 of the menstrual cycle.
214904109|NCT05460767|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
214904110|NCT03026634|BEHAVIORAL|Sleep-disordered breathing|Prevalence and dynamic of sleep-disordered breathing after heart transplantation
214904111|NCT05718414|DEVICE|Ultrasound via artifical intelligence|"The peripheral nerve and plan block regions (adductor canal, axillary brachial plexus, PECS, popliteal, rectus sheath, ESP, femoral, and superficial cervical plexus regions) and related anatomical landmarks are practised by 3 anesthesiology residents who were in the training program of regional anesthesia and qualified to perform ultrasound guided techniques . Then, scans of 8 block types for all 40 volunteers; when the scan success gauge on the AI software was 100% at the time the images were saved. Using this procedure, 960 ultrasound images were acquired in both raw and AI-processed forms for expert assessment ."
214904112|NCT02259010|DRUG|Alisertib|Alisertib tablets
214904113|NCT02259010|DRUG|Itraconazole|Itraconazole oral solution
214904114|NCT06582576|DIAGNOSTIC_TEST|Effect of different gastric electrical stimulator stimulation paragdimes on brain, heart, and stomach.|Measuring EEG, ECG, and ultrasound in both groups during different stimulation intensities provided by the previously implanted gastric electrical stimulator.
215056388|NCT03278795|PROCEDURE|pressure support ventilation mode|PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
215056389|NCT03278795|PROCEDURE|volume support ventilation mode|"VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated."
214904115|NCT06634420|BIOLOGICAL|NTLA-2002|CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration
214904116|NCT06634420|BIOLOGICAL|Normal Saline IV Administration|The administration of intravenous (IV) normal saline
214904117|NCT07065149|OTHER|1)0.1% Pinorox® Cream 2)1% Pinorox® Cream 3)Base cream 4)Positive control 5)Negative control|0.04 gm of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through finn chamber patch.
214904118|NCT01626001|PROCEDURE|4D CT scans|4 (or 5 for Cohort 2) 4DCT scans performed. 1 scan performed while breath held for less than 20 seconds. CT scans take about 5 minutes each to complete.
214904119|NCT05774067|DRUG|Saline|patient received normal saline 4ml/kg/hr with deflation of tourniquet
214904120|NCT05774067|DRUG|Norepinephrine|patient received noradrenaline infusion at rate 0.1 mcg/kg/min. with deflation of tourniquet
214904121|NCT05774067|DRUG|glypressin|patient receive glypressin infusion at rate 2 mcg/kg/hr.
214904122|NCT00463372|DRUG|PF-02545920|
214904123|NCT01805063|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
214302354|NCT06401668|BEHAVIORAL|PRx Program|The PRx Program provides free fruit and vegetables and nutrition education to patients with T2D and food insecurity.
214302355|NCT07113743|DRUG|Busulfan|Conditioning drug
214302356|NCT07113743|DRUG|Tocilizumab|Monoclonal Antibody
214302357|NCT07113743|DRUG|Eltrombopag|Thrombopoietin Receptor Agonist
214904124|NCT01805063|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
214904125|NCT06031090|DRUG|Clonidine Injection|intravenous Clonidine 0.5 µg/kg diluted in 10ml normal saline 20 minutes before spinal anesthesia
214904126|NCT06031090|DRUG|Granisetron Injection|intravenous 1mg of granisetron diluted in 10ml normal saline 20 minutes before spinal anesthesia.
214904127|NCT06031090|DRUG|Normal Saline 10 mL Injection|intravenous 10 ml normal saline 20 minutes before spinal anesthesia
214904128|NCT02433184|DRUG|Etanercept|Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
214904129|NCT02433184|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
215056390|NCT03110718|DEVICE|ArmeoP+real MV|All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
215056391|NCT04169464|DRUG|Sofosbuvir Oral Product|to investigate the drug effect on renal function and insulin resistance
214302358|NCT07113743|DRUG|Sirolimus|Post transplant immunosuppressant drug
214302359|NCT07113743|OTHER|pCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene|Intervention Infusion on Day 0
214302360|NCT06978582|BEHAVIORAL|Therapeutic conscious movement|The program will last for 12 weeks and will consist of one weekly 45-minute session, with an additional 5 minutes of exercise added each month: • 15 minutes of health education, covering topics such as self-management and physical activity planning, mechanisms through which exercise and awareness training can improve health status, guidance on how to detect and work with bodily awareness, key concepts in proprioception and interoception, and strategies for autonomous symptom regulation. • 30 minutes of conscious movement practice, increasing by 5 minutes each month and guided by pacing recommendations. Additionally, participants will be encouraged to engage in at least 15 minutes of daily practice with the support of recorded material.
214302361|NCT06978582|BEHAVIORAL|Conventional exercise|"The program will last for 12 weeks and will consist of one weekly 45-minute session, with an additional 5 minutes of exercise added each month:~* 15 minutes of health education, addressing topics such as self-management, physical activity planning, mechanisms through which exercise can benefit health, and strategies for autonomous symptom regulation.~* 30 minutes of strength and aerobic exercise practice, with session duration progressively increased by increasing by 5 minutes each month and guided by pacing recommendations.~Additionally, participants will be encouraged to engage in at least 15 minutes of daily practice with the support of recorded material."
214904130|NCT02433184|DRUG|Sulfasalazine|Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
214904131|NCT02433184|DRUG|Hydroxychloroquine|Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
215056392|NCT00318929|DRUG|Divalproex Sodium Extended-Release Tablets|Once a day dosing
215056393|NCT00127881|DRUG|HuMax-CD4 (zanolimumab)|Monoclonal Antibody, 12 weekly infusions.
215056394|NCT00352859|DRUG|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
215056395|NCT00352859|DRUG|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
215056396|NCT05595343|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups
215056397|NCT06319209|OTHER|Preoperative resolved COVID-19|We observed postoperative outcomes only in patients who had or did not have COVID-19 before surgery, without any additional intervention.
215056398|NCT03487016|DRUG|Gemcitabine|Arm A
214904132|NCT02433184|DRUG|Etanercept|Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
215056399|NCT03487016|DRUG|Nab-paclitaxel|Arm A
215056400|NCT03487016|DRUG|5-FU|Arm B Arm C
215056401|NCT03487016|DRUG|Irinotecan Liposomal Injection|Arm B Arm C
215056402|NCT03487016|DRUG|Oxaliplatin|Arm C
215056403|NCT02613195|DRUG|Hydrogen-Rich Celsior Solution|Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
215056404|NCT05842525|DRUG|intensive treatment|Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off Irinotecan 150 mg/m2 LV 400 mg/m2 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 on day 1, q2w （intensive treatment up to 8 cycels）
215056405|NCT05842525|DRUG|Maintenance treatment|Fruquintinib 5mg, orally, once daily, 3 weeks on/ 1 week off
215056406|NCT00363142|DRUG|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
215056407|NCT00363142|DRUG|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
214479220|NCT05464251|OTHER|Prospective chart review of subjects diagnosed with spinal epidural abscess|Collection and assessment of available clinical, pathological, radiological, and socioeconomic data on subjects presenting with spinal epidural abscess. Standard of care treatment and outcomes for each group will be analyzed.
214479221|NCT06777771|OTHER|Reformer pilates exercises|The reformer pilates exercises session will start with 5 minutes of warm-up exercises, continue with resistance exercises for 20 minutes, and end with 5 minutes of cool-down exercises. The springs of the reformer pilates device will be adjusted to create mild fatigue in the first week and will be gradually increased to create moderate fatigue in the following weeks. Reformer pilates sessions will consist of 15-20 different exercises with 12-15 repetitions, including all major muscle groups. These sessions will also include exercises that strengthen the pelvic floor muscles. Reformer pilates sessions will be applied twice a week for 6 weeks, a total of 12 sessions. Apart from this, they will be asked to walk for at least 30 minutes a day, at least 3 days a week.
214479222|NCT06498388|OTHER|Stiffness measurement by visco-elastography|Participant will be asked to put on the study's bra with the help of a female member of the team if necessary and to complete the examination process.
214904133|NCT02433184|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
214904134|NCT01801943|BEHAVIORAL|Cognitive Remediation Therapy Group|30 min Cognitive Remediation Therapy + 60 Min Healthy Living class 3x week
214904135|NCT01801943|BEHAVIORAL|Walking Intervention (WI) Group|60 min Walking Intervention + 30 min low interface reading 3x week
214904136|NCT01801943|BEHAVIORAL|Combination Group|30 min Cognitive Remediation Therapy + 60 min Walking Intervention 3x week
214904137|NCT01801943|BEHAVIORAL|Healthy Living Group|60 Min Healthy Living class + 30 min low interface reading 3x week
214904138|NCT03690700|OTHER|BFRE|BFR will be performed in the aBFRE group by use of pneumatic occlusion cuffs placed proximally on the thigh close to the inguinal fold, using an occlusion pressure corresponding to 40 % of seated arterial occlusion pressure (AOP). The individual AOP will be documented at baseline using doppler ultrasound (Siemens ACUSON S2000TM). Previous studies have shown that this pressure level can promote significant muscle adaptations to a similar degree and are associated with significantly less discomfort than higher occlusion pressures. The occlusion pressure of the participants in sham BFRE group will be 10mmHg.
214904139|NCT01238159|RADIATION|CCRT+MIDLE chemotherapy|Patients are planned to be treated with CCRT plus MIDLE chemotherapy
215056408|NCT02701309|DEVICE|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
215056409|NCT03396302|OTHER|Educational intervention|The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
215056410|NCT01541865|DEVICE|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
215056411|NCT04771689|DRUG|Buprenorphine/Naloxone|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for the length of their hospital stay, at least 6 days.
215056412|NCT06341361|DIAGNOSTIC_TEST|OCT-based machine learning FFR|OCT-based machine learning FFR and wire-based FFR
214904140|NCT03830333|DRUG|Ceftolozane/Tazobactam|Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive ceftolozane 500 mg / tazobactam 250 mg.
214904141|NCT03830333|DRUG|Metronidazole|Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.
214904142|NCT03830333|DRUG|Meropenem|Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.
214904143|NCT03830333|DRUG|Placebo|Saline by IV infusion every 8 hours for 4 to 14 days.
214904144|NCT04968730|OTHER|Postoperative rehabilitation nursing|Make postoperative rehabilitation plan according to nursing experience for group A Develop rehabilitation process according to the activity plan for group B
215056413|NCT05715658|DRUG|Dabigatran etexilate capsule|Adult healthy subjects and elderly healthy subjects only take one 110 mg dabigatran etexilate capsule (low-dose specification in the instruction manual) orally. Elderly patients with atrial fibrillation take dabigatran etexilate according to routine medical treatment.
215056414|NCT04254146|OTHER|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
215056415|NCT01313910|DIETARY_SUPPLEMENT|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
215056416|NCT03775317|PROCEDURE|Video Laryngoscopy|The direct, or conventional, laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Macintosh or Miller laryngoscope for direct visualization of the larynx.
215056417|NCT03775317|PROCEDURE|Direct Laryngoscopy|The video-assisted laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Storz C-MAC S Video Laryngoscope to allow for indirect visualization of the larynx.
215056418|NCT00004891|DRUG|chemotherapy|
215056419|NCT00004891|PROCEDURE|computed tomography|
215056420|NCT00004891|PROCEDURE|conventional surgery|
215056421|NCT00004891|PROCEDURE|neoadjuvant therapy|
215056422|NCT00004891|PROCEDURE|positron emission tomography|
215056423|NCT00004891|PROCEDURE|radionuclide imaging|
215056424|NCT00004891|RADIATION|fludeoxyglucose F 18|
215056425|NCT00004891|RADIATION|radiation therapy|
214904145|NCT02817763|PROCEDURE|Connective tissue graft (CTG)|Periodontal surgical technique to treat gingival recessions
214302363|NCT05765058|OTHER|Group A|Application of SDF (silver diamine fluoride) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
214302364|NCT05765058|OTHER|Group B|Application of Sodium Fluoride varnish on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
215056426|NCT03107728|DEVICE|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
214904146|NCT02817763|PROCEDURE|CTG plus resin composite restoration|Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss
214904147|NCT02817763|DRUG|sodium dipyrone|sodium dipyrone was recommended for all participants after the surgical procedures.
214904148|NCT00131612|DRUG|FEC 100|5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
214904149|NCT02816346|BIOLOGICAL|Shigella sonnei 53G|"Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)"
214904150|NCT02724319|DEVICE|SpartanRX|A buccal swap genetic sample will be collected from eligible patients who provide written informed consent for CYP2C19 testing. Genotyping will be performed by the SpartanRX system as a clinical test at the UF Health Pathology Laboratory in Jacksonville.
214302365|NCT05765058|OTHER|Group C|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Biosmalto tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
214302366|NCT05765058|OTHER|Group D|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
214302367|NCT05497349|OTHER|Leukocyte Rich- PRP injection|Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
214302368|NCT05497349|OTHER|Leukocyte Poor- PRP injection|Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
214904151|NCT05454319|DEVICE|Biofeedback|Home-based biofeedback with medical device
214904152|NCT00496717|DEVICE|Helicoidal fast scann|Each patient will have an computed aortic tomodensitometric scan without contrast injection. This procedure lasts few minutes and irradiation is low. The aortic calcium scoring is calculated using a specific program included in the scan machine
214904153|NCT00824200|BEHAVIORAL|Behavioral|Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene \& non-pharmacological management of peripheral edema.
214904154|NCT00824200|DRUG|tamsulosin (alpha-adrenergic antagonist medication)|0.4 mg given daily
214904155|NCT00824200|DRUG|placebo|tamsulosin placebo
215056427|NCT03107728|DEVICE|Conventional orthotic brace|Participants will use the standard of care orthosis
215056428|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
215056429|NCT00693069|DRUG|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
215056430|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
214302369|NCT07131358|DEVICE|Glass ionomer pit and fissure sealant plus fluoride varnish|Application of glass ionomer pit and fissure sealant plus fluoride varnish
214302370|NCT07131358|DEVICE|Pit and fissure sealant with Giomer® technology|Application of pit and fissure sealant with Giomer® technology
214302371|NCT07131358|DEVICE|Fluoride varnish|Biannual application of fluoride varnish
214904156|NCT00824200|BEHAVIORAL|placebo|placebo behavioral intervention
214904157|NCT05232383|DEVICE|polychromatic light|Application of polychromatic light at different times of day
214904158|NCT05232383|DEVICE|polychromatic light|Application of polychromatic light for 2h30 at different times of day with sleep
214904159|NCT05232383|DEVICE|red light|Application of red light at different times of day
214904160|NCT05232383|DEVICE|red light|Application of red light at different times of day with sleep
214904161|NCT05232383|DEVICE|green light|Application of green light at different times of day
215056431|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
214302372|NCT06855264|DRUG|varegacestat|Single oral dose of varegacestat
214302373|NCT06855264|DRUG|Placebo|Single oral dose of placebo
214302374|NCT06855264|DRUG|Moxifloxacin 400 mg|Single oral dose of moxifloxacin
214302375|NCT02849496|DRUG|Atezolizumab|Given IV
214302376|NCT02849496|PROCEDURE|Biopsy Procedure|Undergo a biopsy
214302377|NCT02849496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214302378|NCT02849496|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214302379|NCT02849496|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214302380|NCT02849496|PROCEDURE|Bone Scan|Undergo a bone scan
214302381|NCT02849496|PROCEDURE|Computed Tomography|Undergo a CT scan
214302382|NCT02849496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904162|NCT05232383|DEVICE|green light|Application of green light at different times of day with sleep
215056432|NCT00730353|DRUG|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
215056433|NCT00730353|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
215056434|NCT04847570|OTHER|Music session|Non-clinical intervention only, and no change to clinical care or treatment. Participants will have 10 minutes of undisturbed rest, followed by a supervised music-listening session of up to 40 minutes, ending with another 10-minute rest period.
215056435|NCT06273566|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the AdT-Physio, Brief Cope and GSES questionnaires in random order.
214904163|NCT07067736|OTHER|Cefazolin antibiotic prophylaxis|Determination of cerebrospinal fluid concentration
214904164|NCT07068139|OTHER|AI-Based Predictive Modeling|This is not a therapeutic or diagnostic intervention. The study uses a retrospective dataset of radiologic and pathological records to train and validate a deep learning model designed to predict tumor stage and survival in patients with non-small cell lung cancer (NSCLC). No experimental procedure is applied to participants.
214904165|NCT01992627|DEVICE|HILTERAPIA HIRO 3.0|High-intensity laser therapy (HILT), which involves higher-intensity laser radiation and which causes minor and slow light absorption by chromophores. This absorption is obtained not with concentrated light but with diffuse light in all directions (the scattering phenomenon), increasing the mitochondrial oxidative reaction and adenosine triphosphate, RNA, or DNA production (photochemistry effects) and resulting in the phenomenon of tissue stimulation called photobiology.
214904166|NCT05402189|DRUG|Ketodex, Fentanyl|"The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group.~Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively .~Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline."
214904167|NCT02413905|BIOLOGICAL|Stool samples|Stool samples
214904168|NCT00181727|DRUG|divalproex sodium extended release|
214904169|NCT03764774|DRUG|LY3463251|Administered SC
214904170|NCT03764774|DRUG|Placebo|Administered SC
214904171|NCT07071441|DRUG|Indomethacin 100 MG|All patients without contraindications should receive 100mg rectal indomethacin within 30mins before ERCP procedure
214904172|NCT07071441|DRUG|Diclofenac 100mg|All patients without contraindications should receive 100mg rectal diclofenac within 30mins before ERCP procedure
214904173|NCT01188031|DRUG|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions
214904174|NCT01188031|DRUG|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
214904175|NCT01467297|DRUG|ceftidoren|ceftidoren 200 mg bid for 5 days
214904176|NCT01467297|DRUG|levofloxacin|levofloxacin 500 mg once daily for 7 days
214904177|NCT06701591|OTHER|Kinesiotaping|Participants will be seated on a chair, KT will be applied bilaterally at the end of the expiration on the fifth to sixth and ninth to tenth intercostal muscles transversally and on the anterior and posterior axillary line longitudinally with 50% tension. In order to stimulate the muscle and support the function, the stimulation technique is usually applied from the origin to the insertion of the muscle with the recommended stretching of 25 to 50%.
214904178|NCT06701591|OTHER|chest physical therapy|The chest physical therapy program is consisted of deep breathing exercises, postural drainage, and cough.
214904179|NCT06650150|DIAGNOSTIC_TEST|maximal inspiratory pressure|maximal inspiratory pressure (mip) will be measured with a specific device
215056436|NCT03072043|DRUG|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
214904180|NCT06650150|DIAGNOSTIC_TEST|maximal expiratory pressure|MEP will be measured with a specific device
215056437|NCT03072043|DRUG|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.
214904181|NCT06650150|DIAGNOSTIC_TEST|6 minute walk test|6mwt will be done by a phsyotherapist
214904182|NCT07071714|DRUG|SHR-8068 Injection|SHR-8068 injection.
214904183|NCT07071714|DRUG|Adebrelimab Injection|Adebrelimab injection.
214904184|NCT07071714|DRUG|Bevacizumab Injection|Bevacizumab injection.
214904185|NCT04517409|PROCEDURE|Goal-directed hemodynamic therapy|Eligible patients were equally randomized into two study groups: 1) Standard perioperative (Control group ) and 2) hemodinamic management based using radial artery pulse contour analysis (GDHT group). Randomization was performed the day before surgery by the study member responsable for anesthesia delivery using sealed opaque envelope technique stored in non-transparent containers with group allocation in a 1:1 ratio. Only patients were blinded to group allocation. Care providers and investigators could not be blinded due to the presence of the cardiac index trending monitor
215056438|NCT01340664|DRUG|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
215056439|NCT01340664|DRUG|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
215056440|NCT01340664|DRUG|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
215056441|NCT01340664|DRUG|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
215056442|NCT03748589|DEVICE|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
215056443|NCT05206214|PROCEDURE|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. . Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
215056444|NCT05206214|PROCEDURE|Mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
215056445|NCT02186483|DRUG|Metformin|Metformin,1000mg, once daily
215056446|NCT02186483|DRUG|Rosuvastatin|Rosuvastatin, 20 mg, once daily
215056447|NCT02186483|DRUG|Metformin and Rosuvastatin|Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
214302383|NCT02849496|DRUG|Olaparib|Given PO
214302384|NCT02849496|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
214904186|NCT04517409|PROCEDURE|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment."
214904187|NCT05615727|DRUG|Dexmedetomidine|2 mcg/kg of undiluted dexmedetomidine \[= 0.02 ml/kg\] and oral placebo tablet
214904188|NCT05615727|DRUG|Zolpidem|zolpidem 10 mg and intranasal saline 0.02 ml/kg
214904189|NCT05615727|OTHER|Placebo|a placebo oral tablet and intranasal saline at 0.02 ml/kg
214904190|NCT02298777|PROCEDURE|- Skin biopsy - Urine sample - Blood sample|
214904191|NCT06046066|DRUG|NM6603|NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
214904192|NCT05319574|RADIATION|SBRT|Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy
214904193|NCT05319574|DRUG|Tislelizumab|200mg q3w for two cycles administrated concurrently with chemotherapy
214904194|NCT05505591|DRUG|Cangrelor|Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes
214904195|NCT07079826|DEVICE|Sparrow Link (Active tAN)|Participants will receive the Sparrow Link device with active transcutaneous auricular neurostimulation (tAN) in addition to standard hospital-based opioid withdrawal management. Standard care may include pharmacologic treatments such as methadone, buprenorphine, full agonist opioids (e.g., oxycodone), and non-opioid medications, as clinically indicated.
214904196|NCT07079826|DEVICE|Sparrow Link (Sham tAN)|Participants will receive the Sparrow Link device with sham (non-active) stimulation in addition to standard hospital-based opioid withdrawal management. Standard care may include pharmacologic treatments such as methadone, buprenorphine, full agonist opioids (e.g., oxycodone), and non-opioid medications, as clinically indicated.
214904197|NCT06889168|DRUG|Imatimib Mesylate|Participants will take Imatinib mesylate (imatinib), an FDA approved drug for leukemia, orally 400 mg (twice daily)
214904198|NCT06889168|DRUG|Placebo|Placebo will be administered in the same dosage and manner as the study drug. The placebo looks like the study drug but contains no active ingredients.
214904199|NCT06929312|OTHER|Tabletop simulation based teaching|a pre tested and validated questionnaire was used as a tabletop simulation method on Cholera outbreak.
214904200|NCT06929312|OTHER|conventional class room teaching|conventional class room lecture using power point was delivered on Cholera outbreak.
214904201|NCT01546025|BEHAVIORAL|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
214904202|NCT01546025|BEHAVIORAL|Relaxation training|One hour training in relaxation techniques
214904203|NCT06850662|OTHER|Backward walking observation training|Backward treadmill training after watching a video of backward walking.
214904204|NCT06850662|OTHER|Non-motor observational backward walking training|Backward treadmill training after watching a video of landscape without any movements.
214904205|NCT06618222|DEVICE|Wingspan stent system|All patients had received Percutaneous transluminal angioplasty and stenting with Wingspan stent system.
214904206|NCT07079683|OTHER|Toothpaste Product|BioFresh toothpaste containing a blend of alpha-amylase and gluco-amylase enzymes to be used twice a day, morning and evening, (one minute) at a dose of approximately 1.5 g/toothbrushing (full ribbon of toothpaste) for the 28-day study duration.
214904207|NCT07079683|OTHER|Toothpaste Product|Placebo toothpaste containing no enzymes to be used twice a day, morning and evening, (one minute) at a dose of approximately 1.5 g/toothbrushing (full ribbon of toothpaste) for the 28-day study duration.
214302385|NCT02849496|OTHER|Questionnaire Administration|Ancillary studies
214302386|NCT02849496|PROCEDURE|X-Ray Imaging|Undergo an x-ray
214302387|NCT04537637|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214302388|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) with a goal inventory|Goal Attainment Scaling (GAS) with a goal inventory (list of common goals) as a behavioral interventional tool
214302389|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) without inventory|Goal Attainment Scaling (GAS) without a goal inventory (list of common goals) as a behavioral interventional tool
214302390|NCT03076554|DRUG|Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
214302391|NCT06799364|OTHER|28-days consumption of Product A in 45 to 60-year-old healthy subjects.|48 healthy volunteers will consume Product A twice per day during 28 consecutive days.
214302392|NCT06799364|OTHER|28-days consumption of Product B in 45 to 60-year-old healthy subjects.|48 healthy volunteers will consume Product B twice per day during 28 consecutive days.
214302393|NCT06799364|OTHER|28-days consumption of Control product in 45 to 60-year-old healthy subjects.|48 healthy volunteers will consume Control product twice per day during 28 consecutive days.
214302394|NCT06149897|DEVICE|tDCS|Non invasive brain stimulation with sham and active comparators
214904208|NCT03798028|BIOLOGICAL|UC-MSCs|The UC-MSCs will be administrated by intravenous injection at the dose of 1×10\^6 cells/kg.
214302395|NCT06349915|BEHAVIORAL|Supporting Wellbeing with Everyday Experiences of Peers (SWEEP)|Each day during a 14-day trial period, participants will receive one narrative featuring lived experience with and recovery from suicidal thoughts and behaviors. These narratives will be presented in audio and text format via a smartphone app. Participants will also complete self-report surveys assessing study outcomes using the same smartphone app five times per day.
214302396|NCT06812780|DRUG|AZD2389|Single oral dose of AZD2389 in participants from all cohorts
214904209|NCT06181630|DIAGNOSTIC_TEST|Breast milk, plasma, and blood samples|Although this study is non- interventional regarding treatment with ozanimod, the study is considered interventional due to the collection of breast milk and plasma from the lactating women and blood samples from their breastfed infants and the additional diagnostic and monitoring procedures required for the study.
214904210|NCT04423627|DRUG|Clonidine|Clonidine 0.2 mg/day oral tablet
214904211|NCT04423627|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 37.5 mg/day oral tablet
214904212|NCT04423627|DRUG|Placebo|Placebo
214904213|NCT07084389|BEHAVIORAL|FinSoc|Financial Social Work intervention (FinSoc) The FinSoc intervention is a structured financial social work program designed for families experiencing complex financial difficulties. It consists of five modules, each delivered in a one-on-one session with a trained social worker. The modules focus on key areas such as budgeting, emotional and relational aspects of money, financial decision making, building long-term financial capability. The intervention aims to reduce financial anxiety, strengthen economic self-efficacy, and support overall wellbeing. Motivational interviewing techniques and client-centred approaches are used throughout to encourage active participation and goal-setting.
214904214|NCT07091669|DRUG|Tamsulosin (0.4 mg/j)|Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain)
214904215|NCT07091669|DRUG|Tamsulosin (0.4 mg/j)|Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands
214904216|NCT06905093|OTHER|Standard care|Standard care including rehabilitation sessions three times per week.
214904217|NCT06905093|OTHER|Eccentric training of the non-immobilized arm|The training protocol involves 3 sessions per week, separated by 24-48 hours. Each session includes 4-6 sets of 10 repetitions of elbow flexion/extension exercises on the non-immobilized arm at 60-90% of 1-RM, depending on the week. Eccentric actions are performed with controlled contraction duration (4 seconds) using a metronome. Rest periods of 2 seconds between repetitions and 2 minutes between sets are provided.
214904218|NCT06905093|OTHER|Concentric training of the non-immobilized arm|The training protocol involves 3 sessions per week, separated by 24-48 hours. Each session includes 4-6 sets of 10 repetitions of elbow flexion/extension exercises on the non-immobilized arm at 60-90% of 1-RM, depending on the week. Concentric actions are performed with controlled contraction duration (4 seconds) using a metronome. Rest periods of 2 seconds between repetitions and 2 minutes between sets are provided.
214904219|NCT06909006|DRUG|Semaglutide 2.4mg|The active comparator of the intervention is s.c. Semaglutide injection once a week in increasing doses every month from 0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg and the placebo comparator is s.c. injection with a visually identical and same label pen as described for the active comparator
214904220|NCT06909006|DRUG|Semaglutide placebo|Visually identical and same label as the active comparator intervention
214904221|NCT05223400|DRUG|Clindamycin Injection|it is a clindamycin use evaluation study
214904222|NCT06480240|DRUG|OBI-992|OBI-992 is an antibody-drug conjugate
214904223|NCT05081063|COMBINATION_PRODUCT|Routine labs|Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.
214904224|NCT05359822|OTHER|Image-Based Report|Participants will receive the new coronary artery calcium score risk report plus the old report
214904225|NCT07095595|OTHER|Patient Safety Educational Program based on WHO Curriculum|This study involves a structured 5-day educational program targeting nursing leaders and educators, with each day comprising 2 to 3 hours of instructional sessions. it will will include a combination of lectures, videos, group discussions, and case study analyses to enhance engagement and practical learning
214904226|NCT06876415|OTHER|P0.1 and delta Poeso integration into the decanulation decision|P0.1 and delta Poeso integration into the decanulation decision
214904227|NCT06926205|DRUG|Mosunetuzumab (IV)|6 cycle of Mosunetuzumab+CHOP and then 11 cycles more of mosunetuzumab on mnotherapy
214904228|NCT02836691|DEVICE|EKG (electrocardiogram)|Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
214904229|NCT01047254|DRUG|Elontril|flexible dose of Bupropion 150-300 mg
214904230|NCT01047254|DRUG|placebo|
214302397|NCT06800313|DRUG|HLD-0915|A treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
214904231|NCT00346983|DRUG|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
214302399|NCT06980649|DRUG|BHV-1300|BHV-1300 is delivered subcutaneously (SC)
214904232|NCT00346983|DRUG|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
214904233|NCT02996227|PROCEDURE|TAP block|Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
214904234|NCT02996227|PROCEDURE|Epidural analgesia|Epidural catheters will be inserted preoperatively.
214904235|NCT02996227|DRUG|EXPAREL|Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
214904236|NCT02996227|DRUG|Bupivacaine|Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
214904237|NCT07098234|DRUG|Vitamin D3|Neonates were given vitamin D3 (cholecalciferol) in an oral drops formulation (400 IU/drop), at a dose of 400 IU once a day until the serum bilirubin level was out of phototherapy range or a maximum of 72 hours as an adjuvant therapy to phototherapy.
214904238|NCT07098234|PROCEDURE|Phototherapy|Neonates received only phototherapy until the serum bilirubin level was out of phototherapy range or a maximum of 72 hours.
214904239|NCT06865053|OTHER|Heart failure screening pathway|Heart failure screening pathway in general medicine consultations (questionnaire, NT-proBNP level, echocardiographic examination)
214904240|NCT07101263|DIETARY_SUPPLEMENT|Standard whey|A typical whey protein is given that differs in chemical structure from the atypical whey protein used in the experimental group
214302400|NCT03188094|BEHAVIORAL|CHW-Led Health Coaching|The CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to prevent diabetes.
214904241|NCT07101263|DIETARY_SUPPLEMENT|Hydrolyzed whey|This type of whey has different chemical structure from typical wheys such as that used in this nstudy's control group
214904242|NCT06208306|DRUG|Itepekimab (SAR440340)|Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
214904243|NCT06208306|DRUG|Placebo|Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
214904244|NCT07111923|OTHER|Balance Assesment|The study design was a single-group repeated measures design. Nineteen individuals meeting the inclusion criteria were included. The assessments were conducted individually in a quiet environment, isolated from other athletes and external factors. Athletes were instructed to refrain from intense exercise and training, avoid caffeine consumption, and attend the assessment in sportswear within the last 24 hours. Upon arrival for the assessments, athletes were seated to rest while demographic information was collected. Each test was explained verbally and visually, and participants were allowed to perform a trial. A crossover design method was used in the study, with the order of tests (hands on hips or hands free) determined randomly. Retest measurements were conducted 24 hours after the initial test at the same time of day. The tests performed are described below.
214904245|NCT07110740|DRUG|UI009|inhale UI009 twice a day on Day 1 and Day 8.
214904246|NCT07110740|DRUG|UIC202005|inhale UIC202005 twice a day on Day 1 and Day 8.
214904247|NCT07113041|DEVICE|Combined (Robotic balance training and high-definition transcranial direct current stimulation)|The robotic platform will train the participants to maintain dynamic balance in the sagittal and transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.
214904248|NCT07113041|OTHER|Standard of Care Balance Training|Participants in this group will receive a standard-of-care balance training (dose matched to the experimental group) administered by the Physical therapist.
214904249|NCT07112417|DEVICE|Augmented Reality|Participants in this group will undergo mini-screw placement assisted by augmented reality (AR) technology. A customized AR system will guide the clinician in real-time to ensure optimal screw positioning, improve accuracy, and minimize placement errors.
214904250|NCT07112417|PROCEDURE|Conventional screw placement|Participants in this group will receive mini-screw placement using the conventional freehand method without augmented reality assistance. The screws will be placed according to standard clinical protocols based on anatomical landmarks and clinician experience
214904251|NCT07111676|BEHAVIORAL|The Solution-focused Intervention for Mental health (SIM)|SIM is a manual-based program delivered to upper secondary school students in mentor groups by a specially trained teacher. It consists of group-based, solution-focused coaching set within a normative frame of mental well-being. By co-creating perceptions and meaning through language and dialogue, focusing on resources for approaching a preferred future, students increase their solution-building capability, thereby acquiring skills to become agents in their own life, more aware of and prone to invest in mental health. For a detailed description, see Söderqvist et al. https://doi.org/10.1016/j.ssmmh.2025.100493.
214904252|NCT07112027|OTHER|Behavioral and MR scanning|After enrollment, participants will be screened on the basis of the inclusion and exclusion criteria. Subsequently, during the single study, participants will be administered a series of questionnaires (Edinburgh Handedness Inventory - Short Form; Evaluation of social related abilities, competences, and traits: Autism Quotient Test, DASS-21, SIAS, DERS, Ekman test; SET; I-TIPI, and conceptual ratings on semantic dimensions (moral, social, political). Then, an MR acquisition without contrast will be performed. Specifically, we will acquire structural, resting state and functional (BOLD) sequences, in the latter case during the administration of a semantic categorization task. The task is aimed to ascertain participants' responses time and accuracy in processing abstract concepts. Participants will be required to indicate the category of each of the visually presented words by means of button press. The study visit will last 3 hours in total.
215056448|NCT03286192|BEHAVIORAL|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
215056449|NCT02015949|DRUG|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
215056450|NCT02015949|DRUG|Placebo|Twice daily placebo tablet for two weeks
214302401|NCT03188094|OTHER|EHR Alerts|Primary care providers (PCP) treating patients in the intervention group will receive embedded EHR alerts to increase screening and identification of South Asian patients at-risk for T2DM with BMI \>23 kg/m2 and registries to track outcomes.
215056451|NCT02146053|DIETARY_SUPPLEMENT|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
215056452|NCT02146053|DIETARY_SUPPLEMENT|Placebo|placebo capsules: methyl cellulose
215056453|NCT00633087|DRUG|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
215056454|NCT02997865|BEHAVIORAL|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
215056455|NCT00048945|DRUG|PEGASYS|
215056456|NCT02977364|DRUG|HS-10241|
215056457|NCT05730868|PROCEDURE|myofascial release|Soft tissue release will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
215056458|NCT05730868|PROCEDURE|muscle energy technique|Muscle energy Technique will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
214302402|NCT06599879|OTHER|Neuropsychological assessments:|"Several neuropsychological assessments were carried out during the study (at inclusion and 2 years after inclusion), consisting of :~* parental questionnaires (standard questionnaires and questionnaires specifically drawn up for the trial). The aim of these questionnaires will be to assess the patient's neurocognitive level at different times (before and after radiotherapy treatment).~* patient cognitive tests (½ day face-to-face consultation/assessment with a neuropsychologist specialising in paediatrics, followed by a 30-minute telephone call).~Only for patients having received their radiotherapy treatment at the IUCT-O: a multimodal MRI specific to the study (without injection of contrast product) may be performed at inclusion and 2 years after inclusion."
214479223|NCT02163694|DRUG|Veliparib Placebo|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
214479224|NCT02163694|DRUG|Veliparib|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
214479225|NCT02163694|DRUG|Carboplatin|Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.
214479226|NCT02163694|DRUG|Paclitaxel|Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
214479227|NCT06258707|DEVICE|LuxBoost IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
214479228|NCT06258707|DEVICE|LuxGood IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
214479229|NCT04074733|DIAGNOSTIC_TEST|Patient undergoes a ULD scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
214904253|NCT07110974|BEHAVIORAL|Diabetes Distress scale 17 and Quality Of Life Instrument|questionnaire that assesses the distress resulting from being diabetic patient type 1 and another questionnaire that assesses the quality of life among type 1 diabetic Sohag University students
214904254|NCT07113340|DEVICE|Carina™ Surgical Platform, developed by Ronovo Surgical, Inc|A modular surgical robot that offers greater flexibility in the number of instrument arms and surgical layout options.
214904255|NCT07112183|DRUG|Oral treprostinil (UT-15C) sustained release tablets|30 patients with symptomatic primary or secondary Raynaud's phenomenon (RP) resistant to standard vasodilatory therapy will be enrolled. Prior to treatment, subjects will record each day for 42 days the number of RP attacks as well as the duration of each RP attack, considered to be baseline data. After the 6-week baseline run in, all subjects will receive oral treprostinil sustained release tablets. Dose escalations can occur every 48 hours in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 3mg three times daily over a 6-week period. Titration can be done as quickly as tolerated. Once at goal dose subjects will enter the 26-week treatment phase. Throughout the study (6-week titration - 26-week treatment phase) subjects will record each day the number of RP attacks.
215056459|NCT05730868|PROCEDURE|MFR & MET|combination of myofascial release and muscle energy technique will be performed on the trapezius, suboccipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
215056460|NCT05730868|PROCEDURE|conventional therapy|traditional physical therapy devices are used to relieve pain and spam. this will include a hot pack, ultrasound, and TENS (Transcutaneous electrical nerve stimulation)
215056461|NCT01926444|DRUG|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
215056462|NCT00742131|DRUG|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
214479230|NCT04074733|DIAGNOSTIC_TEST|Patient undergoes a standard X-ray|"The following doses will be applied:~For the pelvis : front view and profile for the hip. For the dorsal spine : front and profile. For the lumbar spine : front and profile For the extremities : front and profile"
214479231|NCT04074733|DIAGNOSTIC_TEST|Patient undergoes a classic-dose scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
214904256|NCT07112950|DEVICE|Press Needle Acupuncture and standart therapy|The patient will have a press needle applied, which will be removed on the seventh day.
215056463|NCT05918965|DEVICE|transcutaneous electrical vagal neurostimulation|daily for 12 weeks
215056464|NCT00043745|DIETARY_SUPPLEMENT|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
215056465|NCT00043745|DIETARY_SUPPLEMENT|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
215056466|NCT05393999|BIOLOGICAL|BMS-986414|Broadly neutralising antibodies BMS-986414
215056467|NCT05393999|BIOLOGICAL|BMS-986413|Broadly neutralising antibodies BMS-986413
214904257|NCT07112664|DEVICE|Fully Guided Dental Implant Placement Using Surgical Guide|All participants will undergo fully guided dental implant placement using a 3D-printed surgical guide (tooth-supported or mucosa-supported). The surgical guide is designed and fabricated based on preoperative CBCT and intraoral scan data. Implant site preparation and fixture insertion are performed entirely through the guide using manufacturer-specific guided surgery kits.
214479232|NCT06823154|DRUG|Amoxicillin|Prospective cohort study of patients presenting to the ED with a reported BLA. (1) Allergy history and risk assessment, (2) Oral provocation challenge (if eligible), and (3) Post-discharge follow-up (if received OPC or referred to allergy).
214904258|NCT07111299|DIETARY_SUPPLEMENT|Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.|Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, plant extracts, amino acids, and other bioactive compounds designed to support hair growth and scalp health in women.
214904259|NCT07111299|OTHER|Placebo Control|Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.
214904260|NCT07110792|OTHER|Mindfulness-based Cognitive Therapy for Life (MBCT-L)|"The MBCT-L (Bernard, Cullen \& Kuyken, 2017) intervention is an 8-week group intervention, comprising a pre-course orientation session, eight 2-hour sessions, and a half-day silent session.~MBCT-L was delivered synchronously online. MBCT-L group were led by one MBCT-L instructor"
214904261|NCT07112092|BEHAVIORAL|Tell-Show-Do|Standard behavioral management technique where the dental procedure is explained to the child, demonstrated, and then performed.
215056468|NCT02628041|RADIATION|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure."
215056469|NCT02628041|RADIATION|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
214904262|NCT07112092|BEHAVIORAL|Music Therapy|Participants listen to calming music during the dental extraction procedure to reduce anxiety and pain perception.
215056470|NCT04970173|OTHER|use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy|Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
215056471|NCT01724229|DRUG|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
215056472|NCT01999686|DRUG|DLBS3233|
215056473|NCT01999686|DRUG|Metformin XR|
215056474|NCT01999686|DRUG|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
215056475|NCT01999686|DRUG|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
215056476|NCT02528942|RADIATION|Radiation therapy|Radiation therapy will be given to study patients.
215056477|NCT03595735|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
215056478|NCT00881530|DRUG|BI 10773|BI 10773 high dose once daily
215056479|NCT00881530|DRUG|Metformin|open label comparator
215056480|NCT00881530|DRUG|BI 10773|BI 10773 low dose once daily
215056481|NCT00881530|DRUG|Sitagliptin|open label comparator
215056482|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^8 vp/mL administered on Day 0
215056483|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^9 vp/mL administered on Days 0, 28, and 56
215056484|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^10 vp/mL administered on Days 0, 28, and 56
214904263|NCT07112092|BEHAVIORAL|Therapeutic Play Therapy|Use of structured play activities designed to reduce dental anxiety and improve cooperation during tooth extraction.
214904264|NCT07111221|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt performed prior to liver transplantation in patients with increased risk of intraoperative blood loss
214904265|NCT07111221|DRUG|Non-selective beta-blockers|Non-selective beta-blockers for lowering portal hypertension
214904266|NCT07113002|BEHAVIORAL|Emotional Freedom Technique (EFT)|Emotional Freedom Technique (EFT) is a psychological intervention that uses tapping on acupuncture points combined with cognitive techniques to reduce stress and anxiety. Participants received EFT sessions for 4 weeks.
214904267|NCT07112105|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 30 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
215056485|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^11 vp/mL administered on Days 0, 28, and 56
215056486|NCT01509846|BIOLOGICAL|Placebo: 1-3 doses|Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
214904268|NCT07112105|DEVICE|Sham rTMS|Subjects randomized to sham rTMS will undergo the same procedures on the same equipment as subjects assigned to active rTMS, but no active magnetic stimulation will be delivered.
215056487|NCT01687881|OTHER|Chiropractic|Chiropractic Spinal Manipulative Therapy
215056488|NCT01687881|OTHER|Sham Chiropractic|Sham manipulation
215056489|NCT02194946|DRUG|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
215056490|NCT02194946|DRUG|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
215056491|NCT03836846|BEHAVIORAL|CBT Mobile App|TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.
215056492|NCT03836846|BEHAVIORAL|Treatment as usual|TAU as per standard of care
215056493|NCT05833412|DIAGNOSTIC_TEST|Septicyte Rapid ®|SeptiCyte RAPID is based on the measurement of two gene expression biomarkers in peripheral blood (PLAC8 and PLA2G7) using quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Based on the results obtained in 1 hour from whole blood (100 mcl), the device issues a report with a sepsis probability scale according to 4 bands (1 low probability, 2-3 intermediate probability and 4 high probability).
215056494|NCT05833412|DIAGNOSTIC_TEST|FilmArray® blood culture identification (BCID2®)|After 6 to 8 hours of blood culture incubation, BCID2 will be performed on each of the 4 bottles. The BCID2 assay is an approved molecular test for the direct identification of pathogens causing bloodstream infections from blood cultures. The BCID2 Panel analyzes 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeasts and 10 antimicrobial resistance genes, all with a single test and with results available in approximately one hour from the blood culture. In addition, the BCID2® Panel menu includes seven additional resistance genes, including carbapenemases, colistin resistance genes and a MREJ assay that enables more speciﬁc MRSA identiﬁcation.
215056495|NCT04017780|DEVICE|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
215056496|NCT04017780|DEVICE|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
215056497|NCT04017780|DEVICE|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
215056498|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
215056499|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant
215056500|NCT05508178|DRUG|Placebo|Norovirus vaccine (rNV-2v) vehicle without antigen
215056501|NCT06227312|DEVICE|LADY 1 Pro, New Life Balance|whole-body vibration training on the platform
215056502|NCT06227312|OTHER|exercises|calf raises and modified drop jumps
215056503|NCT01743612|PROCEDURE|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
215056504|NCT01743612|PROCEDURE|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
215056505|NCT00373646|DRUG|Thalidomide, Pharmion|200 mg p.o. daily
215056506|NCT01552512|DIETARY_SUPPLEMENT|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
214904269|NCT07111897|PROCEDURE|percutaneous cannulated screw fixation|fixation of calcaneal fractures by cannulated screws inserted percutaneously
214904270|NCT07111897|PROCEDURE|Plate fixation|Fixation of calcaneal fracture by plate.
214302403|NCT06712745|RADIATION|Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)|Radiation Therapy Prescription Dose: A dose of 40-50 Gy in 5 fractions prescribed to the PTV will be used for all cases
214302404|NCT04343950|BEHAVIORAL|SMS reminders to enhance colorectal cancer screening|Individual randomization will be used. Individuals assigned to the experimental arm with a wrong phone number will get a reminder letter (protocol analysis).
214302405|NCT04343950|BEHAVIORAL|SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|Individual randomization will be used. Individuals with a wrong phone number assigned to the experimental arm will not get any reminder (protocol analysis).
214302406|NCT04343950|BEHAVIORAL|Invitation by SMS to previous participants in breast cancer screening:|Individual randomization. Women assigned to the experimental arm and with a wrong phone number will get an invitation letter (protocol analysis).
214904271|NCT07111728|DIAGNOSTIC_TEST|Spectra-BREAST system in Invasive Breast Cancer|"Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities~Hyperspectral imaging (HSI):~HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma.~Point-wise Raman spectroscopy (RS):~RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected hotspots flagged by HSI as at risk. RS will be acquired on the surface of the specimens confirming the possible presence of positive margins~Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed."
214904272|NCT07111728|DIAGNOSTIC_TEST|Spectra-BREAST system in DCIS Breast Cancer|"Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities Hyperspectral imaging (HSI): HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma. Point-wise Raman spectroscopy (RS): RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected hotspots flagged by HSI as at risk. RS will be acquired on the surface of the specimens and using a special needle probe 2 mm below the tissue surface thus confirming the possible presence of positive margins.~Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed"
214302407|NCT03975829|DRUG|dabrafenib|dabrafenib oral, twice daily
214302408|NCT03975829|DRUG|trametinib|trametinib oral, once daily
214302409|NCT06824506|OTHER|No-intervention|No interventions will be performed by the research team.
214302410|NCT05230615|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214302411|NCT06982599|DIETARY_SUPPLEMENT|postbiotics|3 capsules/day postbiotics (20 × 10\^9 CFU/day) for 8 weeks
214904273|NCT07112261|OTHER|Avatar Therapy|The Avatar Intervention will take place over 10 consecutive weeks, with one session per week. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars. The goal of the therapy is to develop strategies to improve mood and promote the fulfillment of social functioning.
214904274|NCT07112287|DEVICE|MyeloGen Gene Panel|The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.
214904275|NCT07111442|DIAGNOSTIC_TEST|renal artery fractional flow reserve measurement|Eligible participants who meet all inclusion and exclusion criteria will undergo renal angiography. On the day of angiography, a functional assessment of renal artery stenosis will be performed according to the Standard Operating Procedure (SOP) using a pressure wire under dopamine-induced maximal hyperemia to measure the Fractional Flow Reserve (FFR).
214904276|NCT07111442|DRUG|dopamine|Administer dopamine at 50 µg/kg via the renal artery to induce hyperemic.
214302412|NCT06982599|DIETARY_SUPPLEMENT|placebo|3 capsules/day placebo for 8 weeks
214302413|NCT06606899|DRUG|Melatonin 3 MG|Oral syrup melatonin 3 mg
214904277|NCT07111442|DEVICE|renal artery stent|Stent will be treated for the stenotic renal artery for patients randomized to stenting group
214904278|NCT07111442|OTHER|sham stenting|For participants randomized to the sham procedure, the procedure will last at least 15 minutes to simulate actual intervention according to SOP guidelines.
214904279|NCT07111806|DRUG|Tirofiban|Tirofiban is administered as a loading dose and continuous intravenous infusion as soon as possible after the randomization.
214904280|NCT07111806|DRUG|Placebo|Matched placebo will be infused in a similar fashion.
214302414|NCT06606899|DRUG|Chloral Hydrate|Oral chloral hydrate (50 mg/kg, maximum 2 g)
214302415|NCT06606899|DRUG|Sevoflurane|Inhalational Sevoflurane
214302416|NCT06987058|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
214302417|NCT06409767|OTHER|Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.|The calculation of NEWS requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. Each parameter used to calculate the NEWS will be collected least three times a day by the attending nurse.
214302418|NCT06589804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214302419|NCT06589804|BIOLOGICAL|Cetuximab|Given IV
214302420|NCT06589804|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214302421|NCT06589804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214302422|NCT06589804|BIOLOGICAL|Pembrolizumab|Given IV
214302423|NCT06589804|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214904283|NCT07110870|PROCEDURE|Cognitive Physical Dual task training|"Randomized Control Group (A)/ Cognitive Physical Dual Task Training Participants in control group will perform cognitive physical dual task training to improve working memory, attention and executive function in elderly with mild cognitive impairment. Dual-task training involved eight programs consist from simple dual-task to more complex dual-task tasks.~Cognitive task involves verbal fluency, attention, Forward digit span task, backward digit span task, calculation tasks and memory, aerobic exercise including performing actions like dragging the foot and placing it on floor markers (Marked from 1 to 5), Drawing any letters with their feet while seated, range of motion exercise while standing, forward walking, backward walking, tandem walking and stair climbing and strengthening exercise consisting of Thera-band with low intensity training by arms and by legs and passing/throwing a ball (0.1kg, 0.4kg) will be used for physical tasks. Eight programs will be repeated thrice, resultin"
214904284|NCT07110870|PROCEDURE|Binaural Beats and Cognitive physical dual task training|"In experimental group, Binaural beats will be given 03 min before performing a dual task.~Participants will be in a quiet room and two tones of different frequencies will be generated through the Audacity Program (Version 3.4.2) via stereo headphones presenting a different tone to each ear.~Phase-I: A warm-up at the beginning of each session (05 min) with supervised walking exercises on a flat surface.~Phase II: Binaural beats will be induced thrice a week, for 08 weeks. Alpha, and gamma waves, over 30 min, split into two sub-sessions lasting 12 min each. Participants will be allowed to take a 6-minute rest between sub-sessions. Alpha BB (10 Hz), (R: 410 Hz, L: 400 Hz) and gamma BB (30 Hz) (R: 430 Hz, L: 400 Hz) will be provided.~Phase-III: Return to calm (05 min) with relaxation and breathing exercises, lying on the floor.~The stimulus volume, played through stereo headphones will be set by the participants at the start of the session to a comfortably loud level."
214904285|NCT07112157|DRUG|Oliceridine|After entering the room, the patient was intravenously injected with oselidine at a dose of 0.08mg/kg during anesthesia induction
214904286|NCT07112157|DRUG|Sulfentanil|After the patient entered the room, sufentanil was injected intravenously during anesthesia induction with a dose of 0.4 μ g/kg
214904287|NCT07113275|RADIATION|Short-course radiotherapy|Eligible subjects will receive short-course radiotherapy (SCRT). One week after the end of treatment, subjects continued to receive neoadjuvant chemotherapy.
214904288|NCT07113275|RADIATION|Long-course radiotherapy|Long-course radiotherapy (LCRT, 50.4 Gy administered in 28 fractions) will be delivered concurrently with oral capecitabine.
214904289|NCT07113275|DRUG|Capecitabine|1000mg/m2, bid, po, d1-14,q3w
214904290|NCT07113275|DRUG|Oxaliplatin|130mg/m2, ivgtt, d1,q3w
214904291|NCT07113275|DRUG|Camrelizumab|200mg, ivgtt, q3w
214904292|NCT07113275|PROCEDURE|TME surgery|The surgery was performed 1 week after the end of neoadjuvant therapy.
214904293|NCT07113106|BIOLOGICAL|CD40.Pan.CoV Low dose(0.25mg)|SC Injection in deltoid of Low dose (LD; 0.25 mg) CD40.Pan.CoV vaccine non adjuvanted at Day 0.
214904294|NCT07113106|BIOLOGICAL|CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol®|SC injection in deltoid of LD (0.25 mg) CD40.Pan.CoV vaccine Hiltonol® adjuvanted at Day 0.
214904295|NCT07113106|BIOLOGICAL|CD40.Pan.CoV High dose (1mg)|SC injectionin deltoid of High dose (HD; 1mg) CD40.Pan.CoV vaccine non adjuvanted at Day 0.
214904296|NCT07113106|BIOLOGICAL|CD40.Pan.CoV High dose (1mg) adjuvanted with Hiltonol®|SC injection in deltoid of HD (1mg) CD40.Pan.CoV vaccine Hiltonol® adjuvanted at Day 0.
214904297|NCT07112677|DIAGNOSTIC_TEST|Brucella Antibody Testing (ELISA)|Serological testing for Brucella antibodies using the SERION ELISA classic Brucella IgG/IgM/IgA kit (Institut Virion\\Serion GmbH, Würzburg, Germany). The test detects Brucella-specific IgG, IgM, and IgA antibodies in serum samples to assess current or past exposure. All samples were processed and interpreted according to the manufacturer's instructions. This diagnostic intervention was used for both the low back pain group and the control group.
214904298|NCT03257280|OTHER|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
214904299|NCT01276860|DEVICE|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
214904300|NCT07111754|BEHAVIORAL|Behavioural Message|"Participants are presented with an image of an antibiotic packet, that contains information about the behaviour take antibiotics exactly as prescribed. This can be delivered to participants via a QR code, or a warning message on the packet."
214904301|NCT07111754|BEHAVIORAL|Behavioural message + positive framing|"Participants are presented with an image of an antibiotic packet, that contains information about the behaviour take antibiotics exactly as prescribed and information about AMR, framed in a positive manner. This can be delivered to participants via a QR code, or a warning message on the packet."
214904302|NCT07111754|BEHAVIORAL|Behavioural message + negative framing|"Participants are presented with an image of an antibiotic packet, that contains information about the behaviour take antibiotics exactly as prescribed and information about AMR, framed in a negative manner. This can be delivered to participants via a QR code, or a warning message on the packet."
214904303|NCT06921382|BEHAVIORAL|Peer counseling|Participants in the intervention condition will be matched with Spanish-speaking peer counselors who will visit mothers at home regularly (weekly at the beginning of the study, monthly at the end of the study).
215056507|NCT01552512|OTHER|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
215056508|NCT02250131|PROCEDURE|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery \> 280 mL/min/m2
214302424|NCT06591533|OTHER|Music therapy + standard care|In the pre-extubation and extubation phase, the musical characteristics will be based on a slow to medium tempo, simple harmonic structures (e.g., tonic-subdominant movements), fluid melodies, and avoiding large intervals or abrupt changes of tonalities. The musical instruments used will be a classical guitar with nylon strings (Yamaha C-40) and the voice of the music therapist without lyrics or words. In the post-extubation phase, the musical characteristics will be based on a moderate tempo, introducing chord progressions aiming at tension-resolution (e.g., dominant-tonic), and a more rhythmic application of melodic or harmonic material.
214904304|NCT06921382|BEHAVIORAL|Additional funds|In Month 1, mothers can choose to receive a $150 gift card or an electric breast pump. In Months 2-5, if infants are signed up for the WIC exclusive breastfeeding package, infants will receive $100 and mothers will receive $50. If infants are signed up for the WIC partial breastfeeding package, infants will receive $50 and mothers will receive $30.
214904305|NCT07112131|BEHAVIORAL|Non-Diet Nutrition Education Program|The intervention is an 8-week online nutrition education program based on non-diet approaches, including intuitive eating, rejecting diet mentality, honoring hunger, body acceptance, and well-being. Each weekly session is 60 minutes long and involves interactive discussions and home practices.
214904306|NCT07110727|BEHAVIORAL|Two days, role play, adult interactive capacity building sessions of healthcare workers on PTSD screening and management. Pre/posttest and change in practice in screening will be used for evaluation|"Intervention~1\. Capacity Building of Healthcare workers on PTSD Management For training, the three purposefully selected health facilities selected for the study were written on small pieces of paper. The papers were twisted and thrown on a table. Then, a child was asked to pick up any paper. The one picked was the intervention health facility (Buea Regional Hospital). Healthcare workers at the BRH who provide care to RTI survivors at risk of PTSD 1 month after RTI from our health units of interest in the BRH, will be selected for training (mostly unit heads and front-line staff in trauma/injury will be trained) in two role-play, adult training, interactive sessions on the screening of PTSD using the DSM-5 tool and on timely management of RTI patients with regard to PTSD, linkage to care to psychotherapists, and referrals. Pre/post knowledge evaluation on the use of the DSM-5 tool and management of PTSD will be done, and results compared."
214904307|NCT07112196|DRUG|Visugromab (CTL-002)|IV infusion
214904308|NCT07112196|DRUG|Placebo|IV infusion
214904309|NCT06933342|BEHAVIORAL|Habituation to dental examination|"The habituation will be performed by dental hygenists working in the public dental service in Rogaland or Vestland counties. The dental hygenists have completed a 2-day educational course consisting of both theoretical and practical information specifically adressing dental examination of children with autism spectrum disorder. The habituation will be done at the dental office.~The intervention consists of five structured habituation sessions with the trained dental hygienist where the different elements of a clinical dental examination will be introduced stepwise in a controlled manner. Parents/guardians will also receive a toolbox with visual aids and a dental examination mirror with instructions for use during home preparations prior to the habituation sessions."
214904310|NCT06933342|BEHAVIORAL|Preparations at home|"Participants in the augmented control group will receive a toolbox with visual aids and a dental examination mirror. The parents/guardians of these participants will receive written information on how to use these tools at home to prepare for a clinical dental examination."
215056509|NCT03686930|DRUG|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
215056510|NCT03686930|DRUG|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
214302425|NCT06591533|OTHER|Standard Care (in control arm)|Standard care during the extubation process involves providing usual the medical care provided for patients according to each hospital's guidelines.
214302426|NCT05938361|OTHER|Psoriasis clinical assessments|Global evaluation of psoriasis and specific evaluation by areas
214302427|NCT05938361|OTHER|Quality of life evaluation|DLQI questionnaire at each visit
214302428|NCT05938361|OTHER|Satisfaction assessment|Visual analogic scale at W16, W28, W52
214302429|NCT05938361|OTHER|Pruritus evaluation|Visual analogic scale at each visit
214302430|NCT06609343|DRUG|Bupropion Hydrochloride 150 MG|Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks
214302431|NCT06013176|OTHER|Encounter-based PRO monitoring|This arm consists of usual practice plus the addition of patient reminders to complete PRO questionnaires and triage nurse alerts for severe symptoms. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
214479233|NCT06823154|OTHER|Study questionnaire|"In the first component of the study, research staff will survey patients for history pertinent to their BLA label. This includes questions regarding any prior evaluations, patients' perception of their allergy label, and clinical details of allergy history. The latter involves an allergy history risk assessment, which will screen patient for high-risk features (eg, new maculopapular rash within 2 hours of administering antibiotic). Presence of any high-risk features will disqualify the patient from subsequent study components.~Finally, the questionnaire will screen for presence of any clinical confounders that would preclude administration of the OPC (eg, use of antihistamines within prior 72 hours)."
214904311|NCT06853353|OTHER|Heart Failure Specialist Nurses consultations|Heart Failure Specialist Nurses consultations
214904312|NCT06954493|DRUG|Ibrexafungerp|Ibrexafungerp Oral Tablet
214302432|NCT06013176|OTHER|Remote PRO monitoring|This arm will consist of weekly PRO questionnaires administered via the patient portal, de-linked from clinical encounters. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
214302433|NCT04960722|DEVICE|OIF/β-TCP|bone graft implantation
214302434|NCT06326021|DRUG|autologous FL-33 CAR T therapy|Autologous FL-33 CAR T cells are infused intravenously.
214302435|NCT06326021|DRUG|prior-HSCT donor-derived FL-33 CAR T therapy|Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.
214302436|NCT06326021|DRUG|Newly matched donor-derived FL-33 CAR T therapy|Newly matched donor-derived FL-33 CAR T cells are infused intravenously
214302437|NCT06992297|OTHER|Questionnaire|a standardised, structured questionnaire, validated by the department's clinicians, to assess the physical, cognitive and psychological after-effects.
214302438|NCT06854042|DRUG|E1018|Specified dose on specified days.
214302439|NCT06854042|DRUG|Placebo|E1018 matching placebo on specified days.
214302440|NCT06672250|PROCEDURE|CTCs/CTMs culture|Collect the thrombosis from participants underwent catheter-based thrombectomy.To characterized by cancer-specific surface markers successfully and identify within the culture
214302441|NCT06671613|DIETARY_SUPPLEMENT|FMD|Plant-based diet program
214479234|NCT06826040|DRUG|SKB445 for injection|SKB445 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
214904313|NCT06953934|DRUG|ABBV-932|Oral Capsule
214904314|NCT05966584|DRUG|Benralizumab|Benralizumab 30mg subcutaneously on day -1.
214904315|NCT05966584|DRUG|fulvestrant or AIs) and PI3K inhibition (alpelisib)|SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)
214907499|NCT06686485|DEVICE|FARAPULSE™ PFA system and WATCHMAN LAAC Delivery Systems|"The FARAPULSE™ PFA System consists of the FARAWAVE™ Pulsed Field Ablation Catheter, the FARASTAR™ Pulsed Field Ablation Generator, and the FARADRIVE™ Steerable Sheath.~The WATCHMAN LAA Closure Technology consists of the WATCHMAN Access System (which consists of the Access Sheath and Dilator and the WATCHMAN Delivery System (which consists of the delivery catheter and the pre-loaded closure device). The WATCHMAN Access System and WATCHMAN Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium."
214907500|NCT05929664|BIOLOGICAL|Cemiplimab|Given IV
214907501|NCT05929664|PROCEDURE|Computed Tomography|Undergo CT scan
214907502|NCT05929664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214907503|NCT05929664|OTHER|Quality-of-Life Assessment|Ancillary studies
214907504|NCT05929664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214907505|NCT05929664|PROCEDURE|Biopsy|Undergo biopsy
214907506|NCT06112860|DEVICE|Over the counter hearing aid|An over the counter hearing aid is a device that provides amplification appropriate for individuals with mild to moderate hearing loss. Participants will receive the devices with typical directions and have one scheduled remote visit one week after receiving devices with an audiologist.
214907507|NCT06112860|BEHAVIORAL|Communication Strategies Information/Counseling|Communication Strategies provide information meant to help an individual compensate for hearing loss. The information provides tips both for the individual with hearing loss and for those communicating. People who choose not to pursue hearing aids will typically be given communication strategies information to help them manage their hearing loss. Participants will receive the counseling information in the mail and then have a 1 week follow-up appointment with an audiologist.
214302442|NCT06671613|COMBINATION_PRODUCT|Regular Diet Plus FMD|Patients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6
214302443|NCT06862128|DIAGNOSTIC_TEST|OGTT at home using CGM|OGTT at home using CGM
214302444|NCT06862128|DIAGNOSTIC_TEST|OGTT at the clinic|OGTT at the clinic
214302445|NCT06037785|BEHAVIORAL|Self-Paced Self-Management (SPSM)|(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.
214302446|NCT06994442|DRUG|Acetaminophen|"Intravenous (IV) dose, 15 mg/kg\* (maximum 600 mg) every 6 h for 5 days.~\*Note: For children \<28 days old, dose will be 12.5 mg/kg every 6 hours, as per U.S. Food and Drug Administration (FDA) recommendations. The dosing of acetaminophen for intravenous infusion will follow the current Acetaminophen for injection labeling based on the participant's age and weight."
214479235|NCT06306898|OTHER|Endotracheal Intubation|Ventilation with an endotracheal tube
214907508|NCT04423211|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
214907509|NCT04423211|DRUG|Apalutamide|Given PO
214907510|NCT04423211|PROCEDURE|Computed Tomography|Undergo PET/CT
214907511|NCT04423211|DRUG|Degarelix|Given SC
214479236|NCT06306898|OTHER|Laryngeal tube|Ventilation with an laryngeal tube
214479237|NCT06306898|OTHER|Laryngeal mask|Ventilation with an laryngeal mask
214479238|NCT06306898|OTHER|I-Gel-Laryngeal Mask|Ventilation with an I-Gel-laryngeal mask
214479239|NCT06825858|DRUG|KH658|KH658: AAV vector containing a coding sequence for an anti-VEGF protein
214907512|NCT04423211|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214907513|NCT04423211|OTHER|Fluciclovine F18|Given IV
214907514|NCT04423211|DRUG|Goserelin Acetate|Given SC
214907515|NCT04423211|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
214907516|NCT04423211|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214907517|NCT04423211|DRUG|Leuprolide Acetate|Given IM
214907518|NCT04423211|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR
214907519|NCT04423211|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MR
214907520|NCT04423211|OTHER|Quality-of-Life Assessment|Ancillary studies
214907521|NCT04423211|OTHER|Questionnaire Administration|Ancillary studies
214907522|NCT04423211|DRUG|Relugolix|Given PO
214904316|NCT04760990|OTHER|data collection|clinical data collection regarding COVID-19 suggestive symptoms or confirmed SARS-CoV-2-infections (medical events), recorded comorbidities (concomitant diseases relevant to MS and COVID-19) and recorded vaccinations (other treatments). This information is systematically collected during the routine clinical visits of the patient within the SMSC every 6-12 months.
214904317|NCT04760990|OTHER|analysis of blood samples|analysis of archived serum samples collected every 6-12 months within the SMSC for measurement of anti-SARS-CoV-2 antibodies in pre-pandemic reference samples and prospectively determine the anti-SARS-CoV-2-serostatus during the study period.
214479240|NCT06663072|DRUG|Fulvestrant|"Safety-Run In: Starting Dose: 500 mg IM on Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.~Dose Expansion: 500 mg IM: Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses."
214904318|NCT03796988|DEVICE|Autologous Regeneration of Tissue (ART) device|This device will harvest hundreds of full-thickness columns of skin tissue (500 micrometer diameter) using single-needle, fluid-assisted harvesting technology.
214904319|NCT06068101|DIAGNOSTIC_TEST|Secreening test for primary aldosteronism and Confirmatory Testing|Serum aldosterone and plasma direct renin concentrations were measured by a chemiluminescent immunoassay. A positive PA screening was defined by aldosterone \> or = 10 ng/dL and aldosterone to renin ratio \> or = 2 ng/dL/uUI/mL
214904320|NCT06299592|COMBINATION_PRODUCT|PET/MRI using [18F]FEPPA tracer|PET/MRI scans with \[18F\]FEPPA radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia
214904321|NCT06067828|DRUG|Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
214904322|NCT06067828|DRUG|Treatment B: Budesonide and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
214904323|NCT06067828|DRUG|Treatment C : Placebo|Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
214904324|NCT06705205|OTHER|SAS video|The intervention is a short, animated storytelling video, with soundtrack, aimed at reducing addiction stigma.
214904325|NCT01611844|DEVICE|Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
214907523|NCT04423211|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214907524|NCT04423211|DRUG|Triptorelin|Given IM
214907525|NCT04423211|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
214907526|NCT04884815|GENETIC|UX701|Nonreplicating, recombinant gene transfer vector
214907527|NCT04884815|DRUG|Standard of Care (SOC)|SOC treatment (i.e., copper chelators and/or zinc) administered according to standard regimens.
214907528|NCT02909777|DRUG|CUDC-907|
214907529|NCT06343090|DRUG|CD19 CAR T-cell|Murine-derived CD19 CAR T cells
214907530|NCT06343090|DRUG|CD22 CAR T cells|humanized CD22 CAR T cells
214907531|NCT06343090|PROCEDURE|hematopoietic stem-cell transplantation|allo-HSCT
214907532|NCT04290988|DEVICE|EEG Neurofeedback|Active EEG neurofeedback
214907533|NCT04290988|DEVICE|Sham Feedback|Sham EEG feedback sessions identical to active sessions except that the feedback given to the participant will not be based on the individual's live EEG activity.
214907534|NCT05971693|DEVICE|OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator|Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping \[stimulating and recording\] and, when used with a Generator, for cardiac ablation).
214907537|NCT03971071|DRUG|Erenumab 70 mg|Erenumab once every 4 weeks. Subcutaneous injection.
214907538|NCT03971071|DRUG|Erenumab 140 mg|Erenumab once every 4 weeks. Subcutaneous injection.
214907539|NCT03971071|DRUG|Placebo|Placebo once every 4 weeks. Subcutaneous injection.
214907540|NCT03697148|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
214907542|NCT04977804|OTHER|Exercise|The interventions are a form or exercise, specifically resistance exercise.
215056511|NCT03686930|DRUG|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
214302447|NCT06994442|DRUG|Ketorolac|IV dose; 0.5mg/kg (maximum 30 mg) every 6 h for 5 days 4.1.d. \*Note: Ketorolac for intravenous bolus administration is currently labeled for multiple-dose treatment in adults. For patients under 65 years of age, the recommended dose is 30 mg every 6 hours, with a maximum daily dose of 120 mg. For patients 65 years or older, renally impaired patients, and those weighting less than 50 kg, the recommended dose is 15 mg every 6 hours, with a maximum daily dose of 60 mg. In this study, we will be limiting ketorolac to \<15 mg per dose, with a maximum of 60 mg per day.
214904326|NCT01611844|DEVICE|medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
214904327|NCT06335017|DIETARY_SUPPLEMENT|Induction of labor|In both groups the balloon catheter will be removed at nearly 12 hours after insertion. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
214904328|NCT06957249|DRUG|Optic White 5%HP ActivShine Toothpaste|0.76% MFP toothpaste
214904329|NCT06957249|DRUG|Crest3DWhite Advanced Radiant Mint Toothpaste|0.243% NaF toothpaste
214904330|NCT06524544|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214904331|NCT06524544|PROCEDURE|Computed Tomography|Undergo CT
214904332|NCT06524544|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904333|NCT06524544|BIOLOGICAL|Pembrolizumab|Given IV
214904334|NCT06524544|OTHER|Questionnaire Administration|Ancillary studies
214904335|NCT06524544|BIOLOGICAL|Sacituzumab Govitecan|Given IV
214904336|NCT05930106|OTHER|Intraoperative fluid ratio|This ratio is calculated by dividing the sum of procedure subcutaneous infiltration and intravenous fluid by the total aspirate volume during surgery
214904337|NCT05930106|DEVICE|Carotid Artery Doppler Peak Velocity Variation|Patients will be given a fluid maintenance rate of 1.5 ml/kg/h. To determine fluid responsiveness, the carotid artery peak velocity variation (ΔVPeak-CA) will be measured before, during, and after the procedure. If the ΔVPeak-CA goes above 15%, the patient will receive a fluid bolus of lactated ringer solution at a rate of 4-6 ml/kg over 10-15 minutes, and the team will re-measure fluid responsiveness 10 minutes after each ΔVPeaK-CA.
214904338|NCT05060939|DIAGNOSTIC_TEST|COVID-19 vaccinated people|Patients with at least one dose of COVID-19 vaccine tested for SARS-CoV-2 infection with RT-PCR on respiratory specimen. RT-PCR, serological testing and viral sequencing will be applied on patient's samples
214904339|NCT05688514|DEVICE|Innovalve MR system|Innovalve MR system
214904340|NCT02369718|OTHER|Listening to 12 Fournier's lists of words|Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
214904341|NCT02369718|OTHER|Listening to 48 Fournier's lists of words|48 disyllable Fournier's lists of words are presented to the subjects (6 SNR\*2 coding strategies\*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
214302448|NCT06994442|DRUG|Placebo|Placebos will be normal saline solution, i.e., 0.9% NaCl. In order to maintain blinding, the investigational pharmacy will dispense placebo in a volume to match the corresponding study drug.
214904342|NCT04242446|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
214904343|NCT04242446|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
214904344|NCT06790563|DEVICE|Neuromodulation|Neuromodulation by UCon
214904345|NCT05826808|DIAGNOSTIC_TEST|Polysomnography|The polysomnographic recordings include electroencephalogram (EEG), electrooculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), pulse oximetry, transcutaneous capnography, nasal airflow and thoracic and abdominal respiratory effort.
214904346|NCT04708418|PROCEDURE|Biopsy Procedure|Undergo biopsy
214302449|NCT04104178|DRUG|Clindamycin|Investigating whether a significantly higher number of MRSA throat carriers succeed in becoming MRSA free, when using Clindamycin on top of our general recommended topical treatment of Mupirocin nasal ointment + chorhexidin baths
214904347|NCT04708418|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214904348|NCT04708418|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214904349|NCT04708418|BIOLOGICAL|Pembrolizumab|Given IV
214904350|NCT04708418|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214302450|NCT04104178|DRUG|Placebo|Placebo
214904351|NCT04708418|PROCEDURE|Surgical Procedure|Undergo surgery
214904352|NCT04708418|DRUG|VLP-encapsulated TLR9 Agonist CMP-001|Given SC or intratumorally
214904353|NCT04821856|DRUG|Cannabidiol Oil|Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma
214904354|NCT04821856|DRUG|Placebo|MCT oil and flavoring solution, also manufactured by THC Pharma
214904355|NCT01947023|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214904356|NCT01947023|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214904357|NCT01947023|PROCEDURE|Computed Tomography|Undergo CT
215056512|NCT03686930|DRUG|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
215056513|NCT01899131|DEVICE|platform-switch tapered internal implants|Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
214904358|NCT01947023|DRUG|Dabrafenib|Given PO
214904359|NCT01947023|DRUG|Dabrafenib Mesylate|Given PO
214904360|NCT01947023|PROCEDURE|Echocardiography Test|Undergo ECHO
214904361|NCT01947023|DRUG|Lapatinib|Given PO
214904362|NCT01947023|DRUG|Lapatinib Ditosylate|Given PO
214904363|NCT01947023|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904364|NCT01947023|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214904365|NCT01947023|PROCEDURE|Positron Emission Tomography|Undergo PET
214904366|NCT05420064|BEHAVIORAL|Intervention Arm At-risk Relative/ARR Contacts|Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
214904367|NCT05420064|BEHAVIORAL|MyGene Portal|Through the MyGene Portal, participants will be able to continually access their genetic test results, personalized medical management recommendations from the MSK CGS care team, an interactive pedigree for personal/family history updates, and tailored educational materials for patients with a VUS in an effort to promote sustained engagement and transparency.
214904368|NCT05420064|BEHAVIORAL|Standard of Care|Participants will received appropriate clinical care as outline by standard of care guidelines
214904369|NCT04257578|DRUG|Acalabrutinib|Given PO
214904370|NCT04257578|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
214904371|NCT05457790|BEHAVIORAL|ACT Intervention|1-week baseline data collection period followed by an 8-week ACT intervention period focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
214904372|NCT05457790|BEHAVIORAL|Waitlist|1-week baseline data collection period followed by 8 weeks of maintaining usual routine followed by an 8-week intervention focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
214904373|NCT04692103|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
214904374|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
214904375|NCT04692103|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
215056514|NCT03565822|OTHER|Interview|individual interview and/or focus group Grounded theory qualitative analysis of data related to socio-demographic and child characteristics data First, data will be prepared for qualitative analysis. Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel/word data file. Second, focus group data will be qualitatively analyzed using the constant comparative process. A qualitative data analysis program, NVivo11 (Victoria, Australia/ QSR International)) will be used to assist with this coding process.
215056515|NCT04901806|DRUG|PBI-200|PBI-200 will be administered orally over continuous 28-day cycles
215056516|NCT05557994|OTHER|Method|treatment of mature teeth with apical periodontitis
215056517|NCT05729555|DRUG|Compound ibuprofen polyrelease tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
215056518|NCT05729555|DRUG|reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time"
214302451|NCT04537234|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
214302452|NCT04537234|BIOLOGICAL|Standard-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
214904376|NCT04692103|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
214904377|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
214904378|NCT04692103|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214904379|NCT04692103|OTHER|Laboratory Biomarker Analysis|Correlative studies
214904380|NCT06104488|DRUG|Avutometinib|Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
215056519|NCT04556357|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
215056520|NCT04556357|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
214904381|NCT06087445|DEVICE|NeuroLife EMG-FES Sleeve System|Participants will complete a 12-week training protocol (3x/week, 1-2 hours/session) which includes an activity-based upper extremity training paradigm where participants will complete multiple repetitions attempting functional tasks in different categories (grip, grip with rotation, pinch, and pinch with rotation) while using the closed-loop EMG-FES system on one forearm/hand. Each category includes \~10 functional tasks (e.g., grip - open a jar; pinch with rotation - nuts and bolts) that progressively increase in difficulty. Each session will include massed practice of 3 functional tasks (20-minute blocks for each task) with rest breaks as needed to avoid fatigue. Sessions will include \~60 minutes of task practice, but they may last 1-2 hours to account for setup time and rest breaks.
214904382|NCT06794177|OTHER|Variable priority dual task training|Variable priority dual task training with balance and walking exercises performed simultaneously with cognitive tasks, twice a week for six weeks
214904383|NCT06794177|OTHER|Fixed priority dual task training|Fixed priority dual task training with balance and walking exercises performed simultaneously with cognitive tasks, twice a week for six weeks
214904384|NCT06794177|OTHER|Single task training|Single task training with balance and walking exercises, twice a week for six weeks
214904385|NCT05633511|PROCEDURE|Split Mouth Design|PRF on one side of mouth and CTG on the other side of participant's mouth.
214904386|NCT04665765|DRUG|Carboplatin|Given IV
214904387|NCT04665765|DRUG|Etoposide|Given IV
214904388|NCT04665765|DRUG|Ifosfamide|Given IV
214904389|NCT04665765|DRUG|Polatuzumab Vedotin|Given IV
214904390|NCT04665765|BIOLOGICAL|Rituximab|Given IV
214904391|NCT04563754|DIAGNOSTIC_TEST|mHRME (Mobile High resolution microendoscope)|"Standard of care (SOC) high-resolution anoscopy (HRA) with Lugol's iodine will be performed. The unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis:~1. contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)),~2. the mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.~This is a single-arm study where all subjects will receive both SOC HRA and experimental mHRME imaging."
214904392|NCT04563754|DRUG|Proflavine Hemisulfate|Contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)) to use with the mHRME
214904393|NCT04563754|DIAGNOSTIC_TEST|High resolution anoscopy|Standard of care (SOC) HRA with Lugol's iodine will be performed.
214904394|NCT06313970|DRUG|QL1706|QL1706 5mg/kg，IV，D1, Q3W
214904395|NCT06313970|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1、8, Q3W
214904396|NCT06313970|DRUG|Gemcitabine|gemcitabine，1000mg/m2，IV，D1、8；Q3W.
214904397|NCT06313970|DRUG|Bevacizumab|bevacizumab, 7.5mg/kg，IV，D1；Q3W.
214904398|NCT04023396|DRUG|ABX464|"ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks."
214302453|NCT06359171|OTHER|Application ARTH-e|"The ARTH-e application must be downloaded via the PlayStore or Applestore platform on phone and/or tablet. Once the application has been downloaded, the patient must scan a QRcode sent by the CHU to anonymize the data.~Participants will have 6 months to use the application at their convenience."
214904399|NCT06452940|OTHER|Exercise|A 16-week clinical pilates exercise program will be applied 3 days a week for 60 minutes each session. It will consist of a warm-up, main exercise and a cool-down period.Exercises will start with 10 repetitions and will be gradually increased in 3-week periods.
214904400|NCT06029309|DRUG|Zanubrutinib|"Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~* Phase 1 Dose Level 1: 320 mg~* Phase 1 Dose Level -1: 240 mg~* Phase 2: Recommended dose determined in Phase 1."
214904401|NCT06029309|DRUG|Tafasitamab|"Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~* Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~* Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~* Late Induction - Cycles 4 through 12: Days 1 and 15"
214904402|NCT04075825|OTHER|Placebo|Darvadstrocel placebo-matching eASCs intralesional injection received in previous ADMIRE-CD II study. No drug administration in this study.
214904403|NCT04075825|BIOLOGICAL|Darvadstrocel|Allogenic expanded adipose-derived stem cells (eASCs) 5 million cells/ml - suspension for injection darvadstrocel received in previous ADMIRE-CD II study. No drug administration in this study.
214904404|NCT04428554|RADIATION|Experimental arm|Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
214904405|NCT05972018|DRUG|Liposomal bupivacaine|Rectus Sheath Block: Total 60mL: (20mL 1.3% Liposomal bupivacaine + 30mL 0.25% bupivacaine + 10mL NS).(30mL per side)
214302454|NCT06998433|BIOLOGICAL|Platelet-Rich Plasma (PRP) Injections|PRP will be injected into the affected scalp.
214302455|NCT06998433|DRUG|Saline|Placebo saline solution will be injected into affected scalp.
214302456|NCT03860584|DIETARY_SUPPLEMENT|MFGM-enriched full-fat dairy milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content). This delivers MFGM at \~10-times that in full-fat dairy milk, which reflects that consumers obtain MFGM from dairy foods other than whole milk.
214904406|NCT05972018|DRUG|Ropivacaine|Total 60mLof 0.2% ropivacaine: (60mL of 0.2% ropivacaine (3 vials)
214904407|NCT05972018|DRUG|Bupivacain|Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)
214904408|NCT04907097|DIETARY_SUPPLEMENT|Monomeric and oligomeric flavanols|Monomeric and oligomeric flavanols will be derived from Vitis vinifera seeds extract.
214904409|NCT04907097|OTHER|Placebo|Placebo capsuled will be used as a comparator.
214904410|NCT00780377|DRUG|Bradykinin|Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
214904411|NCT05325177|DRUG|Standard Dose Ibuprofen|(10-5-5 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
214904412|NCT05325177|DRUG|High Dose Ibuprofen|(20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
214904413|NCT01820117|OTHER|Neurocognitive Evaluation|The neurocognitive evaluation will include measures of academic achievement, intelligence, sustained attention, memory, processing speed, executive functions, functional behavior, and emotional functioning.
214904414|NCT01820117|OTHER|Quantitative Brain Imaging|Imaging will include raw images to both quantify white matter hyperintensities and hemosiderin deposits, as well as cortical thickness and tissue segmentation. Brain imaging will be repeated on participants who are concurrently enrolled on BRIGHT and MIND protocols at St. Jude and who completed prior brain imaging during the BRIGHT clinic visit. The repeat MRI will be done at their 6 month MIND clinic visit.
214907543|NCT04977804|OTHER|Eccentric plus blood-flow restriction|Eccentric plus blood-flow restriction
214907544|NCT05053633|PROCEDURE|Combined spinal epidural anesthesia|The Anxiety (Visual Analogue Scale for Anxiety), pain (Visual Analogue Scale), and the Analgesia Nociception Index (ANI) assessments are conducted at four specific time points: lateral position, local anesthesia, epidural needle puncture and 2 minutes after puncture.
214907545|NCT04830631|DEVICE|Cathodal transcranial direct current stimulation (tDCS) over the contralesional motor cortex|Cathodal tDCS will be applied to the contralesional motor cortex with 2mA intesntisy for 30 mins/day. Total 10 sessions will be applied.
214907546|NCT04656821|DRUG|Control Rx|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed
214904415|NCT01820117|OTHER|Neurologic Evaluation|Evaluation includes a complete review of neurologic symptoms, and interview and examination by the neurologist, assessment of neurologic symptoms and determination of their impact on day-to-day living, and quantified neurologic examination by the neurologist.
214904416|NCT01820117|OTHER|Health Questionnaire|Participants will be asked to complete an approximately 450-item survey to assess health history and status, social and demographic factors, health behaviors, and psychosocial constructs.
214904417|NCT01820117|OTHER|Vascular Testing|Digital assessment of endothelial function will be studied, and central blood and pulse pressure and carotid-femoral pulse wave velocity will be non-invasively measured.
214904418|NCT01820117|OTHER|Cardiopulmonary Exercise Testing|Study participants will undergo cardiopulmonary exercise testing by treadmill. Those participants whose physical performance does not permit walking safely on the treadmill (extreme deconditioning, lower extremity paralysis, balance disorder, acute lower extremity injury) will perform cardiopulmonary exercise testing on a bicycle or upper extremity ergometer using a comparable testing protocol.
214904419|NCT01820117|OTHER|Echocardiography|A complete 3D as well as 2D echocardiogram with Doppler and M-mode will be performed.
214904420|NCT01820117|OTHER|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volume measurements by body plethysmography, and single-breath carbon monoxide-diffusion capacity (DLCO).
214904421|NCT01820117|PROCEDURE|Serum Biomarkers|Blood for serum biomarkers associated with cardiovascular morbidity will be drawn, including high-sensitivity C-reactive protein, serum homocysteine.
214904422|NCT01820117|OTHER|Ophthalmology Examination|Ophthalmology examination will include a review of symptoms, examination, and fundus imaging. The examination will consist of visual acuity testing, refraction testing, retinoscopy, ocular pressure, and examination under mydriasis. Fundus photography will be used to capture an image of the retina for examination of potential hypertensive retinopathy.
214904423|NCT00351624|BEHAVIORAL|DHA|
214904424|NCT00351624|BEHAVIORAL|placebo|
214904425|NCT04021914|DEVICE|EnChroma glasses|Each participant will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life. They will be encouraged to wear the glasses for at least 10 hours over 1-2 weeks prior to wearing them in a clinical setting to adjust to their use, and for 10 minutes before beginning patient care as per manufacturer instructions. They will be encouraged to take specific note of clinical scenarios that require the use of color vision (e.g., - rashes, tympanic membrane erythema, stool guaiac testing, etc.).
214904426|NCT01506037|DRUG|Desloratadine|Desloratadine ODT 5 mg
214904427|NCT05299177|DEVICE|InControl|Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
214904428|NCT04969406|OTHER|Brillouin Spectroscopy via BOSS System|Biomechanical Imaging of the Cornea and Lens
214904429|NCT04941651|BEHAVIORAL|OBE-COACH program|"OBE-COACH works through private exchanges between the user and an automatic generator of recommendations, advice and messages of encouragement. Web focus groups are propoposed by specialist to respond to the questions of the participants and a tele-interview at 6 months with a dietetician to encourage and assist the patient to make the best use of the program.~The program is divided into missions to perform. These missions are grouped into 10 families. The completion of each mission and the correct answers to the quiz offer points and bonuses.~To promote better adherence to the program, missions are not repetitive. They are proposed to surprise the user and constantly renew his desire to connect to the program and achieve goals.~The intensity level of the program is selected by the user at any time."
214907547|NCT04656821|PROCEDURE|Erector Spinae Block|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
214302457|NCT03860584|DIETARY_SUPPLEMENT|Soy phospholipid/lecithin milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content).
214904430|NCT04941651|DEVICE|Connected devices|"Connected devices provide to patient are auto-tensiometer and balance. These devices will not be connected to the OBE-COACH program.~The auto-tensiometer (Tensio-screen, Terraillon) is a connected tensiometer allowing the patient to measure by himself with an armband his systolic and diastolic blood pressure and his heart rate.~The balance (Web coach premium, Terraillon) is a connected scale to collect body weight."
214904431|NCT04941651|DEVICE|Connected Activity Tracer|The Activity Tracer (activi-T band, Terraillon) is a a wristband connected activity tracer worn on the wrist that tracks the patient's physical activity and calculates the number of steps, distance traveled and calories burned. The Activity Tracer will not be connected to the OBE-COACH program.
214904432|NCT04941651|BEHAVIORAL|e-learning program|e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health)
214904433|NCT03349060|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
214904434|NCT03349060|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
214904435|NCT03349060|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
214904436|NCT04137081|BEHAVIORAL|App-based mindfulness training|Unwinding Anxiety is an app-based mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time.
214904437|NCT00183404|DRUG|Olanzapine|Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
214904438|NCT02861586|BIOLOGICAL|MV-CHIK low dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
214904439|NCT02861586|BIOLOGICAL|MV-CHIK high dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
214904440|NCT02861586|BIOLOGICAL|Priorix®|lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
215056521|NCT01637584|DRUG|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
215056522|NCT01637584|DRUG|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
215056523|NCT02967419|OTHER|No Intervention|
214302458|NCT07001462|BEHAVIORAL|Inspiratory Muscle Training / Positive Expiratory Pressure (IMT/PEP) Therapy|IMT/PEP therapy was administered using a dual-function device (BİO Breathe, Korea) designed to provide both inspiratory muscle resistance and positive expiratory pressure. Patients performed the therapy for 15 minutes, twice daily, over a 12-week period, in addition to standard pharmacological treatment. Pressure levels were individually adjusted between 5-40 cmH₂O based on patient capacity.
214302459|NCT06997198|DRUG|Deutetrabenazine Oral Capsule|Open-label twenty-four-week treatment with Deutetrabenazine oral tablets (up to 24 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
214302460|NCT03204721|OTHER|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
214302464|NCT07128615|BIOLOGICAL|AZD4117|Intramuscular (IM) injection
214302465|NCT07128615|BIOLOGICAL|AZD5315|IM injection
214302466|NCT07128615|OTHER|Placebo|IM injection
214302467|NCT07005102|DRUG|Standard of Care|Standard of Care
214302468|NCT07005102|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
214302469|NCT07005102|DRUG|Osimertinib (Osi)|Oral Tablet
214302470|NCT07129993|DRUG|Dato-DXd|Dato-DXd will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 4 mg/kg or 6 mg/kg in Part A or RP3D in Part B
214302471|NCT07129993|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of AUC 4.5 or 5.0 mg•min/mL
214904441|NCT02861586|BIOLOGICAL|physiological saline solution|sterile physiological saline solution 0.9% used as placebo
214904442|NCT00955409|BIOLOGICAL|ACC-001(3µg) + QS21|Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
214904443|NCT00955409|BIOLOGICAL|ACC-001(10µg) + QS21|Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
214904444|NCT00955409|BIOLOGICAL|ACC-001(30µg) + QS21|Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
214904445|NCT01894308|DRUG|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
214904446|NCT01894308|DEVICE|Pump Sprayer|A dose of product solution is delivered by means of a metered pump spray.
214904447|NCT06577389|OTHER|Enhanced recovery after surgery|The ERAS program for lumbar fusion surgery will be implemented.
214904448|NCT03356938|BEHAVIORAL|Sleep restriction|Restricted sleep to 5 hours / night for 5 days prior to sleep laboratory examination
214904449|NCT03356938|BEHAVIORAL|Sleep deprivation|Sleep deprivation during first night of sleep laboratory examination
214904450|NCT00485732|BIOLOGICAL|HPV-16/18 VLP/AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
214904451|NCT00485732|BIOLOGICAL|Placebo|Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
214904452|NCT00803790|DRUG|alendronate sodium+vitamin D combination|A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
214904453|NCT00803790|DRUG|Comparator: alendronate|A single dose tablet of 70mg alendronate in one treatment period of each sequence.
214904454|NCT00803790|DIETARY_SUPPLEMENT|Comparator: Vitamin D|Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
214904455|NCT06552416|DRUG|MT-401-OTS|MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.
214904456|NCT03109067|OTHER|Standardized meal|Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
214904457|NCT06554652|PROCEDURE|Lymph node tracer navigated selective neck dissection|Selective lateral lymph node dissection (after injection of tracer, lymph nodes in compartment III-IV are dissected; if there is dyed lymph node in compartment IIA, then IIA is dissected).
214904458|NCT06554652|PROCEDURE|Modified neck dissection|Lymph nodes in compartment IIA, IIB, III, IV, VB are dissected.
214904459|NCT06219148|BEHAVIORAL|Music Therapy Telehealth|Music Therapy: delivered via Zoom by a board-certified music therapist (MT-BC) 30-min 2x/week for 4 weeks (8 sessions total); follows the Clinical Practice Model, which guides customizations of various music experiences (e.g., singing, songwriting, movement, relaxation, lyric discussion, improvisation, instrument play, etc.) per participants' strengths, interests, preferences, culture, and momentary responses. Each participant works with the same MT-BC throughout the study.
214904460|NCT06219148|BEHAVIORAL|Non-Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed social worker (SW) or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. SWs operate independently from MT-BCs to identify possible participant service referral needs using the Aging and Memory Quality of Life Survey (AMQoL), baseline data, SW session interactions, and SW Referral Worksheet. Each participant works with the same SW throughout the study.
214904461|NCT06219148|BEHAVIORAL|Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed SW or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. In addition to the AMQoL, baseline data, SW session interactions, and the SW Referral Worksheet, SWs collaborate fully with MT-BCs, have full access MT session notes, and can discuss participants' needs with MT-BC to identify possible participant service referral needs. Each participant works with the same SW throughout the study.
214904462|NCT03457948|PROCEDURE|Arterial Embolization|Undergo TAE
214904463|NCT03457948|BIOLOGICAL|Pembrolizumab|Given IV
214904464|NCT03457948|BIOLOGICAL|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate|Given IV
214904465|NCT03457948|DEVICE|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere RE
214904466|NCT04183348|BEHAVIORAL|Training Protocol n°1 first at Visit 1, then, Training Protocol n°2 at Visit 2|"During Protocol 1 (visit 1), participants of Group A will perform auditory spatial localization tasks with sensory feedback and during Protocol 2 (visit 2), they will perform auditory tasks without any notion of spatial localization. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
214904467|NCT04183348|BEHAVIORAL|Training Protocol n°2 first at Visit 1, then, Training Protocol n°1 at Visit 2|"During Protocol 2 (visit 1), participants of Group B will perform auditory tasks without any notion of spatial localization and during Protocol 1 (visit 2), they will perform auditory spatial localization tasks with sensory feedback. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
214904468|NCT06801002|DRUG|JBZ-001|JBZ-001 Oral Capsule
214904469|NCT06342700|DRUG|Rilzabrutinib crystalline form|Pharmaceutical form:Film coated tablet Route of administration:Oral
214904470|NCT06342700|DRUG|Rilzabrutinib amorphous form|Pharmaceutical form:Film coated tablet Route of administration:Oral
214904471|NCT05773092|DRUG|Oral S-1 + Oral Osimertinib|S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.
214904472|NCT01857037|OTHER|Histoscanning™ and multiparametric MRI|Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
214904473|NCT05775900|DRUG|Cetuximab|Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.
215056524|NCT01518725|DIETARY_SUPPLEMENT|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
214904474|NCT05775900|DRUG|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)
214904475|NCT03125421|PROCEDURE|standard preventive methods of pressure sores|"During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage."
214904476|NCT03125421|PROCEDURE|experimental multifaceted preventive methods of pressure sores|"During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected."
214904477|NCT06358326|OTHER|Dry needling|In addition to stretching, nerve mobilization and tendon gliding exercises, a total of 5 sessions of dry needling will be performed for fascial mobilization, 2 days a week for 3 weeks.
214904478|NCT06358326|OTHER|Control group|The physiotherapist will teach stretching, neuromobilization and tendon shifting exercises and will be asked to do them regularly for 3 weeks.
215056525|NCT01518725|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
215056526|NCT00097929|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
215056527|NCT02484443|BIOLOGICAL|Dinutuximab|Given IV
215056528|NCT02484443|OTHER|Laboratory Biomarker Analysis|Correlative studies
215056529|NCT02484443|OTHER|Pharmacological Study|Correlative studies
215056530|NCT02484443|BIOLOGICAL|Sargramostim|Given SC
215056531|NCT03147378|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
215056532|NCT02870062|OTHER|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
215056533|NCT02870062|OTHER|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
215056534|NCT03298698|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
215056535|NCT03298698|DRUG|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
215056536|NCT03823105|DEVICE|OHR Tracker and PulseWatch|Category A (ClinO). Medical study with CE-marked medical devices to photoplethysmographic measure heart rate, heart rate variability, and pulse wave and accelerometric data
214302472|NCT07129993|DRUG|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 70 mg/m2
214302473|NCT07129993|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion at a dose of 1000 mg/m2 on Day 1 and 8 of every 3 week cycle.
214904479|NCT02466191|DRUG|Memantine|
214904480|NCT02466191|DRUG|Gabapentin|
214904481|NCT01880554|DEVICE|Contrast-enhanced intraoperative ultrasound|"Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:~Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages"
214302474|NCT05356741|DRUG|VIR-5818|Administered as IV infusion
214904482|NCT03315390|OTHER|"Narrative Exposure Therapy-oriented intervention"|Narrative Exposure Therapy (NET) in an Primary-care adapted Version in 3 sessions (S) 6 weeks (S1), 8 weeks (S2) and 12 weeks (S3) after baseline data collection at T0.
214904483|NCT03315390|OTHER|improved treatment as usual (iTAU)|improved standard primary care for PTSD according to Guidelines, customized to patients' needs and symptoms during 3 consultations between T0 and T1
214904484|NCT03981796|BIOLOGICAL|Dostarlimab|Participants will be administered dostarlimab
214904485|NCT03981796|DRUG|Placebo matching dostarlimab|Participants will be administered placebo matching dostarlimab
215056537|NCT05841719|OTHER|Screening test|Capillary blood sampling by finger-prick devices and second confirmatory venous sampling when needed.
215056538|NCT03215628|DIAGNOSTIC_TEST|TCEUS|Intravenous sulphur hexafluoride microbubbles
215056539|NCT03987711|DRUG|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
215056540|NCT03987711|DRUG|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
215056541|NCT03987711|OTHER|No oral anticoagulation|No oral anticoagulation
215056542|NCT04619667|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
214302475|NCT05356741|DRUG|pembrolizumab|Administered as IV infusion
214904486|NCT03981796|DRUG|Carboplatin|Participants will be administered carboplatin
214904487|NCT03981796|DRUG|Paclitaxel|Participants will be administered paclitaxel
214904488|NCT03981796|DRUG|Niraparib|Participants will be administered niraparib
214904489|NCT03981796|DRUG|Placebo matching Niraparib|Participants will be administered placebo matching Niraparib
214904490|NCT05454735|PROCEDURE|coronary artery bypass surgery|coronary artery bypass surgery
214904491|NCT05454735|PROCEDURE|aortic valve replacement surgery|aortic valve replacement surgery
214904492|NCT05679570|DRUG|Satralizumab (Genetical Recombination)|"Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period\[1\]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period\[2\]:~Subjects completed continuation dosing period\[1\], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period."
214904493|NCT05161481|DRUG|Avenciguat (BI 685509)|Participants received Avenciguat twice daily (BID) throughout the study. Up-titration depended on the assigned dose group. At Visit 2 (Week 1), each dose included one 1 mg Avenciguat tablet. At Visit 3 (Week 2), the dose was increased to one 2 mg Avenciguat tablet per dose. From Visit 4 onward (Week 3+), participants received one 3 mg Avenciguat tablet per dose. This regimen continued for 24 weeks, with all doses taken with water, with or without food.
214904494|NCT05161481|DRUG|Placebo matching Avenciguat (BI 685509)|Participants received matching placebo twice daily (BID) throughout the study. At Visit 2 (Week 1), each dose included one 1 mg and one 2 mg placebo tablet (four tablets daily). A pseudo up-titration was applied at Visit 3 (Week 2), maintaining the same tablet composition to preserve blinding. From Visit 4 (Week 3) onward, a second pseudo up-titration adjusted each dose to one 2 mg and one 3 mg placebo tablet (four tablets daily). All doses were taken with water, with or without food.
214904495|NCT06096246|PROCEDURE|Pulmonary vein isolation|The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
214904496|NCT06096246|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
214904497|NCT06096246|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
214904498|NCT06096246|PROCEDURE|Femoral sheath insertion|Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
214904499|NCT03629977|DEVICE|CRRT|Continuous Renal Replacement Therapy
214904500|NCT04557956|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214904501|NCT04557956|PROCEDURE|Computed Tomography|Undergo CT scan
214904502|NCT04557956|DRUG|Dabrafenib Mesylate|Given PO
214904503|NCT04557956|PROCEDURE|Echocardiography Test|Undergo ECHO
214904504|NCT04557956|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904505|NCT04557956|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214904506|NCT04557956|DRUG|Tazemetostat Hydrobromide|Given PO
214904507|NCT04557956|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214904516|NCT06033547|DRUG|Cabotegravir Formulation F|Cabotegravir Formulation F will be administered
214904517|NCT06033547|DRUG|Cabotegravir Formulation G|Cabotegravir Formulation G will be administered
214904518|NCT01251874|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214904519|NCT01251874|DRUG|Carboplatin|Given IV
214904520|NCT01251874|PROCEDURE|Computed Tomography|Undergo PET/CT
214904521|NCT01251874|OTHER|Fluorothymidine F-18|Given FLT
214904522|NCT01251874|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214904523|NCT01251874|DRUG|Veliparib|Given PO
214904524|NCT03600701|DRUG|Atezolizumab|Given IV
214904525|NCT03600701|PROCEDURE|Biopsy Procedure|Undergo biopsy
214904526|NCT03600701|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214904527|NCT03600701|DRUG|Cobimetinib|Given PO
214904528|NCT03600701|PROCEDURE|Computed Tomography|Undergo CT scan
214904529|NCT03600701|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904530|NCT06801665|COMBINATION_PRODUCT|FMT+QL1706+Bevacizumab+XELOX|Participants will receive FMT combined with QL1706+Bevacizumab+XELOX for 6 cycles. If there is no progression of the disease after 6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. The therapy of maintenance treatment stage was at the discretion of the investigator.
214904531|NCT06382168|DRUG|DFP-10917|DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.
214904532|NCT06382168|DRUG|Venetoclax|Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.
214904533|NCT05674812|DIAGNOSTIC_TEST|Multimodal pre-extubation risk assessment in elderly surgical patients|This observational cohort study evaluates risk factors for extubation failure in elderly surgical patients. All participants receive standard pre-extubation clinical assessments per institutional protocol, including LUS、DE and oxygenation index (PaO₂/FiO₂), arterial blood gas analysis, and the patients'laboratory results before and after surgery. The association between these parameters and extubation failure will be analyzed.
214904534|NCT05230628|DEVICE|Active TENS|Active TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
214904535|NCT05230628|DEVICE|Sham TENS|Sham TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
214904536|NCT05172245|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214904537|NCT05172245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214904538|NCT05172245|DRUG|Cisplatin|Given IV
214904539|NCT05172245|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214904540|NCT05172245|DRUG|Ipatasertib|Given PO
214479241|NCT06663072|DRUG|177Lu-DOTATATE|"Safety-Run In: Starting Dose: 7.4 GBq (200 mCi) IV every 8 weeks for a total of 4 Cycles~Dose Expansion:177Lu-DOTATATE7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV: IV dose every 8 weeks for a total of 4 Cycles."
214479242|NCT06824324|DRUG|intramuscular Botulinum Toxin|A thirty units of Botulinum toxin A was injected intramuscularly in Triger zone of patient with myofascial pain syndrome
215056543|NCT04619667|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
215056544|NCT04465604|OTHER|Wearing surgical face mask sprayed with hypertonic saline|The inner surface of a standard surgical face mask will sprayed by 10 to 15 ml of HTS (6% w/v Saline solution prepared by adding 6 gram NaCl to 100 ml of water if not commercially available) and allowed to air dry. The participant will wear the face mask for 20-30 minutes every 6 hours until discharge, intubation for mechanical ventilation or death. A new HTS sprayed mask will be worn by the participant every 24 hours. The data items will be collected on daily basis
215056545|NCT03549494|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|Ocoxin-Viusid group (Experimental). Oral solution of Ocoxin-Viusid (vials of 30 ml), at a rate of 60 ml daily (1 vial every 12 hours), administrado preferably administered after breakfast and dinner. The product will dilute in water, milk or juice. The treatment will have a period of 19 weeks, starting 2 weeks before the onco-specific treatment with FOLFOX chemotherapy and will end 3 weeks after the end of the sixth cycle of chemotherapy. QT FOLFOX will be prescribed intravenously every 14 days for 6 cycles as follows: Oxaliplatin (85 mg x m2) on day 1 Folinic acid (200 mg x m2) on day 1 and 2 5 Fluoracil (400 mg x m2, bolus) on day 1 and 2 5 Fluoracil (600 mg x m2, continuous infusion) on day 1 and 2
214904541|NCT05172245|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214479243|NCT06825819|BIOLOGICAL|Subjects with and without Long COVID|To collect biospecimens (matched stool \& blood) samples from 400 people with and without long COVID (200 participants/group) to understand how COVID-induced dysbiosis impacts symptom severity, immune suppression, and gut barrier dysfunction both ex vivo and in vitro.
214479244|NCT06666179|BIOLOGICAL|low dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
214479245|NCT06666179|BIOLOGICAL|adjuvanted low dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
214904542|NCT05172245|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214904543|NCT05172245|RADIATION|Radiation Therapy|Undergo radiation therapy
214904544|NCT03985800|OTHER|TEAM|TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.
214904545|NCT03985800|OTHER|TECH|TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
214904546|NCT05733312|DEVICE|InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system|Focused ultrasound which targets energy to a specific area in the brain based on imaging and disrupts the blood brain barrier which keeps certain drugs and other molecules out of the brain.
214904547|NCT03422822|DRUG|Abrocitinib 100 mg|In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
214904548|NCT03422822|DRUG|Abrocitinib 200 mg|In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
214904549|NCT03422822|DRUG|Placebo|For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
214904550|NCT03422822|DRUG|Abrocitinib 100 mg|For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
214904551|NCT03422822|DRUG|Abrocitinib 100 mg|In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
214904552|NCT03422822|DRUG|Abrocitinib 200 mg|In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
214904553|NCT05799378|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg capsules. Administered orally.
214904554|NCT05799378|DRUG|Placebo|Hydroxychloroquine-matching placebo capsule. Administered orally.
214904555|NCT05559580|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
214904556|NCT05559580|DRUG|Placebo|Placebo
214904557|NCT06039358|DIETARY_SUPPLEMENT|Caffeine.|Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
214904558|NCT06039358|DRUG|Cellulose.|Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
214904559|NCT05867849|DRUG|Cannabidiol|Cannabinoid
214904560|NCT05867849|OTHER|Placebo|Inactive substance
214904561|NCT05904626|DRUG|ELGN-2112|To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
214904562|NCT05904626|DRUG|Placebo|A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
214904563|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg QD hard capsules
214904564|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg BID hard capsules
214904565|NCT03874858|DRUG|Asciminib|Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
214904566|NCT05279651|DRUG|Ivabradine|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
214904567|NCT05279651|DRUG|Placebo|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
214904568|NCT06173024|BIOLOGICAL|TAK-577|TAK-577 as IV injection at dose calculated based on the participant's body weight.
214904569|NCT06308614|DRUG|20 mg estetrol monohydrate|Active treatment
214904570|NCT06308614|OTHER|Placebo|Matching Placebo to E4
214904571|NCT06484660|PROCEDURE|Minimally Invasive Approach In The Mucosal Advancement Flap Technique|Surgical treatment of complex perianal fistula. Less tissue damage. Electrocoagulation source with 75% lower power. Better de-epithelialization of the intra-sphinteric tract. More precise closure of orifice. More consistent mucosal flap
214904572|NCT06253104|DIAGNOSTIC_TEST|BodyMetrix Body Composition Ultrasound|We will use a BodyMetrix Pro A-mode ultrasound device (BodyMetrix Pro, Intelametrix Inc., Livermore, CA) which is a lay imaging tool designed specifically to assess body composition. Images will be taken at two sites; the lateral thigh and bicep on the dominant side if able to identify, or else on the right side. On each visit, five images will be taken at each site (the lateral thigh and bicep). Participants will be measured 2-3 days from initiation in study, then 7 days after, and then weekly from the first measurement until time of advanced therapy, discharge, or death. This measurement sequence will then be repeated following advanced therapy up until discharge or death. Each measurement session will last about 20-30 minutes. This will be performed by the PI or members of the study team who have been trained by the research coordinator.
214904573|NCT03317392|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214904574|NCT03317392|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214904575|NCT03317392|PROCEDURE|Computed Tomography|Undergo CT
214904576|NCT03317392|OTHER|Laboratory Biomarker Analysis|Correlative studies
214904577|NCT03317392|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904578|NCT03317392|DRUG|Olaparib|Given PO
214904579|NCT03317392|OTHER|Quality-of-Life Assessment|Ancillary studies
214904580|NCT03317392|RADIATION|Radium Ra 223 Dichloride|Given IV
214904581|NCT04199676|DIAGNOSTIC_TEST|Glucose tolerance test|Oral administration of a 75g glucose tolerance test during the postpartum hospitalization
214904582|NCT06644924|COMBINATION_PRODUCT|Intervention: AS MDI|Drug Treatment: (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) Randomized participants will receive a single-dose (2 inhalations)
214904583|NCT06644924|COMBINATION_PRODUCT|Intervention: Ventolin Evohaler|Drug: Treatment (Ventolin Evohaler) Randomized participants will receive a single-dose (2 inhalations)
214904584|NCT06644924|COMBINATION_PRODUCT|Intervention: Placebo matching AS MDI|Drug: Treatment (Placebo MDI) Randomized participants will receive a single-dose (2 inhalations to match AS MDI)
214904585|NCT06325020|OTHER|The assessment of patients with possible angina using the ORACLE pathway|"Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms.~Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured.~The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events."
214904586|NCT04815083|DRUG|Aminolevulinic Acid Hydrochloride|PD G 506 A for oral solution (aminolevulinic acid \[ALA\] hydrochloride \[HCl\] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
214904587|NCT04815083|DEVICE|Eagle V1.2 Imaging System|Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.
214904588|NCT04815083|DRUG|Placebo|Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
214904589|NCT06251323|OTHER|iPATH implementation approach|A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy.
214904590|NCT03911700|DEVICE|Phasix™ Mesh|Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).
214904591|NCT06497699|DRUG|Dexycu|single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
214904592|NCT06061913|BEHAVIORAL|Breast Pump suction pattern|Mothers who have reached secretory activation and are pumping \<350 mLs/day will be randomized to one of three breast pump suction patterns.
214904593|NCT04465409|DEVICE|Intrastromal implantation of CorVision bioengineered corneal inlay for correction of presbyopia.|Presbyopia is an age-related progressive loss of crystalline lens accommodation power resulting in the decreased ability to see near objects. CorVision® is a tissue-mimetic device primarily intended to be used as a corneal inlay in the management of presbyopia and low hypermetropia. The inlay is inserted into the patient's cornea via a minimally invasive laser pocket procedure to modify corneal surface topography and corneal optical performance.
214904594|NCT04214067|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214904595|NCT04214067|RADIATION|Brachytherapy|Undergo vaginal brachytherapy
214904596|NCT04214067|PROCEDURE|Computed Tomography|Undergo CT
214904597|NCT04214067|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214904598|NCT04214067|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904599|NCT04214067|BIOLOGICAL|Pembrolizumab|Given IV
214904600|NCT04214067|OTHER|Quality-of-Life Assessment|Ancillary studies
214904601|NCT04214067|OTHER|Questionnaire Administration|Ancillary studies
214904602|NCT04214067|PROCEDURE|X-Ray Imaging|Undergo x-rays
214904603|NCT04645589|DRUG|Myfortic|There is no treatment allocation. Patients administered Myfortic by prescription that have started before inclusion of the patient into the study will be enrolled.
214904604|NCT00003624|DRUG|amifostine trihydrate|
214904605|NCT00003624|DRUG|cisplatin|
214904606|NCT00003624|DRUG|paclitaxel|
214904607|NCT04417010|PROCEDURE|Radiofrequency ablation|Both groups of patients underwent radiofrequency ablation
214904608|NCT02863185|DRUG|Pitavastatin|
214904609|NCT02863185|DRUG|Atorvastatin|
214904610|NCT05679947|OTHER|Mobilization protocol|The mobilization protocol includes six levels. Protocol levels are applied from the day the patient is operated and ends on the day of discharge. The researcher explains the protocol levels to the patient before surgery.The patient is mobilized within the first 24 hours after surgery. Implement mobilization protocol three times during the day and more as tolerated. Mobilization protocol:Level 1: Repositioning should occur every two hours. Level 2: Range of motion (PROM) should occur at least three times a day. Level 3: The head of bed (HOB) \>30 degrees. Duration goal: 5-15 minutes. HOB 65≥ degrees with patient sit in the bed. Duration goal: 5-15 minutes. Progress to level 4. Level 4: HOB 65≥ degrees with legs in dependent position (recliner chair). Duration goal: 5-15 minutes. Progress to level 5. Level 5: Stand/pivot/step to chair. Sitting in chair. Duration goal: 5-15 minutes. Progress to level 6. Level 6: Patient is able to ambulate at least three times a day.
214904611|NCT00612274|DRUG|tacrolimus|Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
214904612|NCT00612274|DRUG|Sirolimus|Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
214904613|NCT00612274|DRUG|Methotrexate|Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
214904614|NCT02772211|DRUG|Ketamine|"Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals."
214904615|NCT02772211|DRUG|D-cycloserine|"Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
214904616|NCT02772211|DRUG|Placebo|"Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
214904617|NCT06496568|DRUG|Inavolisib|Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.
214302476|NCT02070744|DRUG|VX-661|Tablet, oral use
214904618|NCT06496568|DRUG|Atezolizumab|Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.
214904619|NCT05904834|OTHER|Flexibility training|Each session consisted of three or four exercises, of which three were static stretches and if there was a fourth, it was dynamic. The duration of each exercise was 20 seconds with 15 seconds rest between sets and 30 seconds rest between exercises.
214904620|NCT02735681|PROCEDURE|meibomian gland probing|Investigator will do baseline (OSDI) questionnaires prior to probing as well as at 1 week (at home), 1 month, 3months, and 6 months at office visits.
214904621|NCT02735681|PROCEDURE|Left eye Meibomian Gland Probing Control Group|There will be no probing in the left eye. This will be used as a control for the right eye.
214904622|NCT06626477|DEVICE|Intra nasal mechanical stimulation treatment (INMEST)|The treatment is performed with the Walther System manufactured by Abilion Medical Systems AB.
214904623|NCT06626477|DEVICE|Sham (No Treatment)|A modified Walther System not delivering active treatment manufactured by Abilion Medical Systems AB.
214904624|NCT00001247|DRUG|Sirolimus|Drug not used in study.
214904625|NCT06569316|PROCEDURE|Biospecimen Collection|Undergo blood or saliva and leftover tissue sample collection
214904626|NCT06569316|OTHER|Communication Intervention|Receive care plan recommendations
214904627|NCT06569316|OTHER|Genetic Testing|Undergo genetic testing
214904628|NCT06569316|OTHER|Survey Administration|Ancillary studies
214904629|NCT06216366|DRUG|Sodium Chloride 0.9% Inj pre-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately before hyperbaric chamber exposure
214904630|NCT06216366|DRUG|Sodium Chloride 0.9% Inj post-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately after hyperbaric chamber exposure
214904631|NCT06216366|DRUG|Recombinant human plasma gelsolin pre-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately before hyperbaric chamber exposure
214904632|NCT06216366|DRUG|Recombinant human plasma gelsolin post-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately after hyperbaric chamber exposure
214904633|NCT06216366|OTHER|Hyperbaric chamber|High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water
214904634|NCT04673149|BIOLOGICAL|GLS-5310|GLS-5310 DNA plasmid vaccine
214904635|NCT04673149|BIOLOGICAL|Placebo|Placebo
214904636|NCT05388760|DRUG|Tralokinumab|A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.
214904637|NCT03662776|BEHAVIORAL|BASC-3 survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
214904638|NCT03662776|BEHAVIORAL|PROMIS survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
214904639|NCT06346119|OTHER|this arm will received relaxing touch (hands, feet, head) during 30 minutes twice a day|Patients who will be included in this arm will receive massage twice a day of the head (10 minutes), feet (10 minutes) and hands (10 minutes)
214904640|NCT01955499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214904641|NCT01955499|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214904642|NCT01955499|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214904643|NCT01955499|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
214904644|NCT01955499|DRUG|Ibrutinib|Given PO
214904645|NCT01955499|DRUG|Lenalidomide|Given PO
214904646|NCT01955499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904647|NCT01955499|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214904648|NCT05904171|BEHAVIORAL|Tangotherapy|"Learning and practicing a series of moves - both individual and with a partner - taken from Argentine Tango, according to the Riabilitango (R) approach. The training is aimed at improving both physical (e.g., balance, change of direction, coordination, endurance) and cognitive (i.e., learning, divided attention, inhibition, planning) domains, in a pleasant, enjoyable, and inclusive environment.~This group-based training will take place twice a week (1h each session), for 6 weeks."
214904649|NCT05904171|BEHAVIORAL|Physical activity|Walking and stretching in group twice a week (1h each session), for 6 weeks.
214904650|NCT05636748|DIAGNOSTIC_TEST|18F-GP1 PET/CT|Patient will receive 1 18F-GP1 PET/CT
214904651|NCT05636748|DIAGNOSTIC_TEST|Agitated Contrast Echocardiogram|Agitated saline and ultrasound contrast will be performed to assess for intracardiac shunts and left ventricular thrombus.
214904652|NCT05636748|DIAGNOSTIC_TEST|MRI Head|Where necessary, if the CT head is normal or the clinical diagnosis of a stroke is not definite, a research MRI head will be undertaken if this has not already been performed as part of standard care.
215056546|NCT02969915|BEHAVIORAL|Incentives|Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
215056547|NCT02969915|BEHAVIORAL|Integrated Care Centers|ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
214302477|NCT02070744|DRUG|Ivacaftor|Film coated tablet, oral use
214302478|NCT02070744|DRUG|Placebo matched to VX-661|Tablet, oral use
214302479|NCT02070744|DRUG|Placebo matched to Ivacaftor|Film coated tablet, oral use
214302480|NCT06870539|OTHER|Non-Interventional Study|Non-Interventional Study
214302481|NCT05220137|BEHAVIORAL|Modified A-B-C: Working with Events, Thoughts, and Feelings|The Modified A-B-C session teaches the Veteran how to draw connections between events, thoughts, and feelings and incorporates preliminary cognitive restructuring to help challenge stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
214479246|NCT06666179|BIOLOGICAL|high dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
214904653|NCT05636748|DIAGNOSTIC_TEST|ECG Monitoring|All patients who do not have evidence of atrial fibrillation or atrial flutter on their 12-lead ECG will undergo an ECG Holter monitor for up to 7 days. This will be part of their standard care. If this has not been arranged by the usual care team this will be performed as a research procedure.
214904654|NCT03837626|DRUG|Placebo - Cap|6 months of 1 pill a day
214904655|NCT03837626|DRUG|Amiloride Pill|Max dose of 5 mg a day for 6 months
214904656|NCT06345443|DIETARY_SUPPLEMENT|Nicotinamide Riboside Malate|Active supplement.
214904657|NCT06345443|OTHER|Placebo|Placebo
214904658|NCT06274658|BEHAVIORAL|High-intensity interval exercise|Three high-intensity exercise bouts, each at 100% of maximal power output for 20 seconds, interspersed with active recovery periods of 120 seconds at 10% of maximal power output.
214904659|NCT06473779|COMBINATION_PRODUCT|Tezepelumab|IMP. Subcutaneous injection. Unit dose strengths 210 mg.
214904660|NCT06473779|COMBINATION_PRODUCT|Budesonide/formoterol|AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation
214904661|NCT06473779|COMBINATION_PRODUCT|Albuterol/budesonide (AIRSUPRA®)|AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.
214302482|NCT05220137|BEHAVIORAL|Challenging Questions|The Challenging Questions session teaches the Veteran to question and confront maladaptive self-statements and stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
214302483|NCT05220137|BEHAVIORAL|Patterns of Problematic Thinking|The Patterns of Problematic Thinking session teaches the Veteran to identify counterproductive thinking patterns. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
214302484|NCT05220137|BEHAVIORAL|Challenging Beliefs|The Challenging Beliefs session teaches the Veteran to generate alternative thoughts based on the outcome of cognitive restructuring. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
214302485|NCT05220137|BEHAVIORAL|Veteran's choice of Module (Safety/Trust/Power and Control/Esteem/Intimacy)|The therapist will present the Module options to the Veteran and the Veteran will select one Module to work on. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
214479247|NCT06666179|BIOLOGICAL|adjuvanted high dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
214904662|NCT06473779|COMBINATION_PRODUCT|Mannitol|NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules
214904663|NCT06473779|COMBINATION_PRODUCT|Salbutamol|AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation
214904664|NCT05019716|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214904665|NCT05019716|PROCEDURE|Biopsy Procedure|Undergo biopsy
214479248|NCT06666179|OTHER|Placebo|0.9% NaCl saline placebo
214479249|NCT02405221|BIOLOGICAL|TA-CIN (arm)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
214479250|NCT02405221|BIOLOGICAL|TA-CIN (thigh)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
214904666|NCT05019716|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214904667|NCT05019716|PROCEDURE|Chest Radiography|Undergo chest x-ray
214904668|NCT05019716|DRUG|Cisplatin|Given IV
214904669|NCT05019716|PROCEDURE|Computed Tomography|Undergo CT or PET-CT
214904670|NCT05019716|DRUG|Etoposide|Given IV
214904671|NCT05019716|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
214904672|NCT05019716|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904673|NCT05019716|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
214904674|NCT06410196|BEHAVIORAL|Mood modulation|Autobiographical memory recall designed to modulate mood and affective state by reminiscing about personal life events
214904675|NCT05120635|DEVICE|Deep Brain Stimulation|Deep brain stimulation will be used
214904676|NCT00932412|DRUG|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
214904677|NCT00932412|DRUG|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
214904678|NCT01875601|BIOLOGICAL|Recombinant human interleukin-15 (rhIL-15)|Continuous infusion rhIL15 IV
214904679|NCT01875601|BIOLOGICAL|NK Cell Infusion|Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
214904680|NCT05879978|DRUG|Obrixtamig|Obrixtamig
214904681|NCT05879978|DRUG|Ezabenlimab|Ezabenlimab
214904682|NCT05541653|OTHER|Financial Well-being Interventions|Tax preparation; access to public benefits; financial counseling and microgrants
214904683|NCT05541653|OTHER|Place-based Interventions|Vacant lot greening; abandoned house remediation; trash cleanup; and tree planting.
214904684|NCT06202443|OTHER|Early PT|Physical therapy delivered within the first three months after surgery.
214904685|NCT06202443|OTHER|Delayed PT|Physical therapy delivered greater than 3 months after surgery.
214904686|NCT06008782|DEVICE|HEARS-SLP device|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
214904687|NCT06008782|BEHAVIORAL|HEARS-SLP program|Tailored aural rehabilitation for participant and communication partner
214904688|NCT06348238|BEHAVIORAL|Self-Affirmation|Self-affirmation theory contends that integrity of one's self-concept (self integrity) is essential for navigating daily stressors. When individuals encounter information or contexts that pose a threat to one's self-integrity, we can adopt maladaptive coping strategies to alleviate the discomfort. One strategy for strengthening self-integrity is engage in an explicit process of reinforcing sources of self-worth - self-affirmation. Self affirmation interventions have participants engage in an exercise writing about core personal values (a writing induction). In a writing induction, participants review a list of values and are instructed to choose up to two that are important to them. Participants are then asked to write a few sentences about why their chosen values are important to them and identify times in which these values have helped them navigate challenges.
214904689|NCT04316546|DRUG|MK-7075 (miransertib)|MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck Sharp \&amp; Dohme (Merck), that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.
214904690|NCT05437705|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100\* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
214904691|NCT05782400|RADIATION|CT scan|CT scan at baseline and then every three months as per clinical practice. The standardization of the procedure of images' collection through a CT- acquisition's protocol has been planned to control bias.
214904692|NCT05782400|BIOLOGICAL|Plasma collection|● Blood samples will be collected at baseline, at 1 month and at the first PD. Sixteen ml of blood will be collected in EDTA tubes and centrifuged at 1900×g for 10 min at 4 °C within 2 h after drawing to collect plasma, which will be stored at -80°C until analysis. Plasma samples will be sent to the Laboratory of Pharmacogenetics - Unit of Clinical Pharmacology and Pharmacogenetics - University Hospital of Pisa. Plasma samples will be used to isolate cell free DNA (cfDNA) and microvesicles-derived RNA for molecular analysis.
214904693|NCT03431714|DRUG|Artesunate amodiaquine|Drugs were administered under observation of the study nurse for three days
214904694|NCT06386055|BEHAVIORAL|Active exercise|The intervention group will be provided with training courses for 3 months.
214904695|NCT04357769|OTHER|PSS (Perceived Stress Scale)|Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks
214904696|NCT04357769|OTHER|GAD-7 (7-item Generalized Anxiety Disorder)|Self-administered scale for the evaluation of anxiety symptoms in the last weeks
214904697|NCT04357769|OTHER|PHQ-9 (9-item Patient Health Questionnaire)|Self-administered scale for the evaluation of depressive symptoms in the last weeks
214302486|NCT06876077|OTHER|Auricular acupuncture|Auricular acupuncture is administered in each side of the ear for 4 weeks using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Five acupoints are selected on one ear, including the will be performed at Shenmen (TF4), Mu 1 (TG2b), Mu 2 (AT1b), Kidney (CO10), and Liver (CO12). These acupoints are believed to be effective in relieving dry eye symptoms. The patch will be kept on the auricle for 5 days and be replaced 5 times during the experimental period.
214302487|NCT06876077|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is administered in each side of the ear for 4 weeks using patches, each possessing a square shape with a side length of 10 mm, without a needle. Five acupoints are selected on one ear, including the will be performed at Shenmen (TF4), Mu 1 (TG2b), Mu 2 (AT1b), Kidney (CO10), and Liver (CO12). These acupoints are believed to be effective in relieving dry eye symptoms. The patch will be kept on the auricle for 5 days and be replaced 5 times during the experimental period.
214904698|NCT04357769|OTHER|SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks
214904699|NCT04357769|OTHER|Zaritt Burden Interview|Self-administered scale for the evaluation of severe mental disorder patients' caregiver burden
214904700|NCT04629495|DRUG|Rapamycin|RAPA will be administered orally 1mg daily
214302488|NCT06876077|OTHER|Artificial Tears (AT)|Artificial tear drops were applied 5-6 times per day over the 4-week period
214302489|NCT03745235|OTHER|stress reduction program based on mindfulness|a two and a half hour session per week for 8 weeks
214904701|NCT04629495|OTHER|Placebo|Placebo will be administered orally once daily
214904702|NCT02767557|DRUG|Tocilizumab|Intravenous infusion
214904703|NCT02767557|DRUG|Gemcitabine|Intravenous infusion
214904704|NCT02767557|DRUG|nab-Paclitaxel|Intravenous infusion,
215056548|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
215056549|NCT00429871|DRUG|Capecitabine|Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
215056550|NCT00429871|DRUG|Epirubicin|Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
215056551|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
215056552|NCT00124969|DRUG|Amlodipine|10mg
215056553|NCT00124969|DRUG|Placebo|10mg
214904705|NCT00998504|DIETARY_SUPPLEMENT|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
214904706|NCT00998504|DIETARY_SUPPLEMENT|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
214904707|NCT06513078|OTHER|Static cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 10 minutes.
214904708|NCT06513078|OTHER|Static sham cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 10 minutes. A pin hole in the cup allowed pressure to slowly leak out during the treatment.
214904709|NCT06513078|OTHER|Dynamic cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 5 minutes, then did ankle exercises for 3 minutes, and lastly lay prone on the table for the last 3 minutes.
214904710|NCT06513078|OTHER|Dynamic sham cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 5 minutes, then did ankle exercises for 3 minutes, and lastly lay prone on the table for the last 3 minutes. A pin hole in the cup allowed pressure to slowly leak out during the treatment.
214302490|NCT03745235|BIOLOGICAL|venipunctures|1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months
214669835|NCT05088317|DIAGNOSTIC_TEST|Exercise capacity|The incremental shuttle walking test at increasing speed (ISWT) is one of the field tests used to evaluate exercise capacity. It has been shown that ISWT is a valid and reliable assessment tool that can be used to evaluate exercise capacity in obese individuals. This test is an exercise test in which walking between two cones 10 m apart at increasing speed for 12 minutes is counted as one sit-up for each 10-meter walk between the two cones. It is continued until the patient is unable to continue the test due to shortness of breath, the heart rate reaches 85% of the maximum expected heart rate, or completes the 12-minute test. In this test, the primary measure is the distance walked, and the result is calculated based on the number of shuttles completed.
214904711|NCT01989585|PROCEDURE|Biopsy Procedure|Undergo biopsy
214904712|NCT01989585|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214904713|NCT01989585|PROCEDURE|Computed Tomography|Undergo CT
214904714|NCT01989585|DRUG|Dabrafenib|Given PO
214904715|NCT01989585|PROCEDURE|Echocardiography Test|Undergo echocardiography
214904716|NCT01989585|OTHER|Laboratory Biomarker Analysis|Correlative studies
214904717|NCT01989585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904718|NCT01989585|PROCEDURE|Multigated Acquisition Scan|Undergo multigated acquisition scan
214904719|NCT01989585|BIOLOGICAL|Navitoclax|Given PO
214904720|NCT01989585|OTHER|Pharmacological Study|Correlative studies
214904721|NCT01989585|DRUG|Trametinib|Given PO
214904722|NCT01078935|DIETARY_SUPPLEMENT|probiotics|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
214302491|NCT03745235|OTHER|psychometric questionnaires|"* Cohen PSS' perceived stress scale~* Beck's anxiety and depression questionnaires~* Watson's affectivity questionnaire, positive affect and negative affect schedule~* optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~* IN-OUT DASQ dispositional affective style questionnaire"
214302492|NCT07005154|DRUG|ASP5541|Intramuscular Injection
214904723|NCT01078935|DIETARY_SUPPLEMENT|placebo|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
214904724|NCT02653963|DRUG|Adjunctival Triamcinolone|Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
214904725|NCT05627245|DRUG|Belinostat|Given IV
214904726|NCT05627245|PROCEDURE|Biopsy Procedure|Undergo biopsy
214904727|NCT05627245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214904728|NCT05627245|PROCEDURE|Computed Tomography|Undergo CT scan
214904729|NCT05627245|OTHER|Pharmacokinetic Study|Pharmacokinetic study
214904730|NCT05627245|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT
214904731|NCT05627245|DRUG|Tazemetostat|Given PO
214904732|NCT04289441|DIETARY_SUPPLEMENT|Bifiasthm|Subjects will be instructed to take an active or placebo sachet twice daily for eight weeks, and subsequent intake of one dose daily for a further eight weeks.
214904733|NCT04289441|DIETARY_SUPPLEMENT|Placebo|Placebo
214904734|NCT00961675|DRUG|FST201 (dexamethasone 0.1% with povidone-iodine 1%)|4 gtt BID (twice a day)
214904735|NCT00961675|DRUG|Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )|4 gtt BID (twice a day)
214904736|NCT00323375|DRUG|AQ-13|A treatment dose of AQ-13 (1750 mg base) was administered orally to subjects randomized to AQ-13 over 3 days (as two capsules on days 1 and 2, plus one capsule on day 3).
214904737|NCT00323375|DRUG|Chloroquine (CQ) Treatment|A treatment dose of CQ (1500 mg CQ base) was administered orally to subjects randomized to CQ over 3 days (as two capsules on days 1 and 2, and one capsule on day 3).
214904738|NCT04689191|BIOLOGICAL|Experimental Group A and C meningococcal polysaccharide vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
214302493|NCT07005154|DRUG|Prednisone|Oral
214302494|NCT07005154|DRUG|Prednisolone|Oral
214302495|NCT07005154|DRUG|abiraterone acetate|Oral
214302496|NCT06869122|DEVICE|Ablation|Bronchoscopy and microwave ablation of the lung tumour prior to surgical resection.
214302497|NCT06681220|COMBINATION_PRODUCT|Stenoparib/Temozolomide|Stenoparib at the recommended phase 2 dose +Temozolomide 40mg/day daily will be given in combination x21 days each cycle
214302498|NCT06681220|DRUG|Lurbinectedin|Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion x 21 days each cycle
214904739|NCT04689191|BIOLOGICAL|Control Group A and C meningococcal polysaccharide vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
214904740|NCT01239810|DRUG|Hyaluronic Acid|Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
214302499|NCT06681220|COMBINATION_PRODUCT|Stenoparib/Temozolomide|Patients will be assigned to one of three doses of Stenoparib (200mg po qd, 200mg po BID, and 200mg in am and 400mg in pm). The initial starting dose will be the 200 mg po QD orally daily for 21 days.
214302500|NCT07007273|DRUG|Pembrolizumab|Outpatient infusion
214302501|NCT06623422|BIOLOGICAL|Pembrolizumab|IV Infusion
214302502|NCT06623422|DRUG|Cisplatin|IV infusion
214302503|NCT06623422|DRUG|Carboplatin|IV infusion
214302504|NCT06623422|DRUG|Pemetrexed|IV infusion
214904741|NCT06370637|OTHER|Barrier Cream|Patients in the control arm will be treated with a 15% zinc oxide barrier cream. Scotiaderm will supply the control product, such that the formula is identical to the intervention with the only difference being the addition of plant extract in the investigational product.
214904742|NCT06370637|OTHER|Dermategrity Everyday Barrier Cream|Patients randomized to the intervention arm will receive treatment with Scotiaderm's proprietary barrier cream formula. This product contains soy extract for enhanced healing of MASD secondary to fecal incontinence.
214479251|NCT06824298|OTHER|TENS|"Before surgery: The socio-demographic data of the patients will be recorded. During surgery: After patients are taken to the operating room and anesthesia is induced, TENS electrodes will be attached to the paravertebral muscles at the level of Lumbar vertebrae 2, 3 and Sacral Vertebrae 2, 3. After the surgery is completed, TENS will be activated before the patient is woken up.~TENS settings: In modulation type, medium intensity contractions will be given at a frequency ranging from 60-80 Hertz to 1-5 Hertz, with a current rate ranging from 50-100 microseconds to 150-200 microseconds.~After surgery: TENS will continue to be applied to patients in the recovery room for 30 minutes after the surgery. Patients will be evaluated by researchers in terms of pain and comfort associated with bladder tenesmus at 0, 15 and 30 minutes in the recovery room and at 6, 12 and 24 hours in the postoperative ward."
214479252|NCT06824597|BEHAVIORAL|Baby-friendly hospital initiative training program|"The Baby-Friendly Hospital Training Program is a critical intervention to improve maternal and infant health outcomes by promoting and supporting breastfeeding worldwide. It empowers the maternity nurses in this study to create an environment that prioritizes the needs of mothers and babies, ensuring the best possible start to life. It will be conducted for eight sessions (theoretical and practical), each session for about 20-30 minutes. It will include the importance of early initiation of breastfeeding, skin-to-skin contact immediately after birth, the importance of exclusive and continued breastfeeding, positions of breastfeeding, the importance of avoiding pre-lacteal feeds and unnecessary supplementation, advantages of rooming-in, and how to manage common breast and nipple conditions.~The researcher will design an Arabic booklet and distribute it to the nurses at the first session as a guide to reinforce the teaching"
214479253|NCT06823284|DRUG|Esflurbiprofen Topical System|The total of two TK-254RX per day for 5 days (one patch applied to left and right lower leg above ankle)
214904743|NCT02348736|DEVICE|Time for tracheal intubation|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
214479254|NCT06823284|DRUG|Flurbiprofen tablet|3 tablets per day for 4 days
214479255|NCT05983055|DRUG|Dexamethasone 20mg|Periarticular dexamethasone injection
214479256|NCT04298450|BEHAVIORAL|Active SMS Intervention|Welcome message letting participant know they will be contacted to book an appointment, followed by appointment reminders and other clinic information, psychoeducational materials, and a distress check-in with two-way feedback to their care team, all sent by SMS/text message at the participant's preferred time of day. If they indicate that they are in high distress, or they request, their care provider will be notified and asked to reach out to them. They will also receive crisis resources.The intervention will continue until the patient attends the first consultation appointment, or for up to 30 days if the patient does not attend, which reflects the program's practice of closing referrals for non-attending patients.
214904744|NCT03807791|PROCEDURE|Blood sample|"A blood sample will be taken by the nurse of our unit within a week after their consent. It consists as a simple blood sample and it will be taken during the normal analysis planed by the chief of the service in order to avoid to collect two different samples.~The measurement method will use equipment from the Lyon Sud hospital laboratory. The samples need a pre-treatment in the 3 hours after taking the blood to avoid the oxidation of vitamin C and a result lower than expected."
214904745|NCT03558802|OTHER|questionnaire|questionnaire
214904746|NCT03761108|DRUG|Linvoseltamab|Administered per the protocol
214904747|NCT00191581|DRUG|Humalog Mix 50|
214904748|NCT00191581|DRUG|Human Insulin Mix 50:50|
214904749|NCT05961033|DEVICE|Virtual Reality based exercises|Play VR games
214904750|NCT03266861|DIAGNOSTIC_TEST|Exercise oximetry|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
214907548|NCT04656821|PROCEDURE|Thoracic Paravertebral Block|Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography
214907549|NCT00357292|DRUG|Azithromycin (T1225)|
214907550|NCT03068377|DIETARY_SUPPLEMENT|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
214302505|NCT06623422|DRUG|Gemcitabine|IV infusion
214302506|NCT06623422|DRUG|Paclitaxel|IV infusion
214302507|NCT06623422|BIOLOGICAL|Intismeran autogene|IM injection
214302508|NCT06623422|OTHER|Placebo|IM injection
214302509|NCT06870487|DRUG|PF-08046032|PF-08046032 will be administered intravenously (IV) infusion.
214302510|NCT06870487|DRUG|Sasanlimab|Sasanlimab will be administered as subcutaneous (SC) injection.
214302511|NCT07019129|DIETARY_SUPPLEMENT|Beetroot Juice - Active|Nitrate-rich beetroot juice
214904751|NCT03800199|OTHER|Perceptive rehabilitation|The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.
214302512|NCT07019129|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Without Nitrate|Nitrate-poor beetroot juice
214904752|NCT04992650|PROCEDURE|Fat grafting|Fat grafting
214904753|NCT01419756|DEVICE|VentriPoint Medical System|The Knowledge Based Reconstruction (KBR) method generates a 3D reconstruction of the RV based on the Piecwise smooth subdivision surface method but without requiring manual border tracing. Instead KBR reconstructs a new patient's ventricular surface from the placement of anatomic landmark points on a 2D ultrasound image
214302513|NCT03935685|DRUG|Mirtazapine (Remeron)|Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
214302514|NCT07023289|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
214302515|NCT07023289|DRUG|Standard of Care|Standard of care treatment based on investigator's judgement to the active surveillance.
214904754|NCT06071364|DIAGNOSTIC_TEST|Ultrasonography imaging and Hand-held dynamometer (HHD)|"Ultrasound imaging system will be used to evaluate the thickness, cross -sectional area and fat infiltration of lumbar extensors lumbar multifidus , erector spinae and quadratus lumborum muscles.~The hand-held dynamometer assessing isometric lumbar muscles strength"
214904755|NCT04382495|OTHER|survey|online survey
214904756|NCT04370171|OTHER|care modalities|For these patients the consultation has been postponed for 6 months. No specific intervention for this group of patient.
214904757|NCT04370171|OTHER|Teleconsultation either by phone or by computer consultation|Management of diabetic patients by telemedicine with a teleconsultation either by phone or by computer consultation
214904758|NCT01059422|DRUG|Raltegravir; Abacavir/Lamivudine|Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
214904759|NCT03842917|OTHER|Biological samples|Urine and blood samples
214904760|NCT03842917|OTHER|Blood pressure measurement|Home blood pressure self-measurement and hospital blood pressure measurement
214904761|NCT03173118|PROCEDURE|Endoscopic ultrasound elastography|Endoscopic ultrasound elastography performed on both groups of patients as per routine
214904762|NCT04186793|BEHAVIORAL|Guided Grocery Shopping (GGS)|"The GGS group will be scheduled for 4 weekly sessions to co-shop with the study Registered Dietitian (RD) or clinical research coordinator (CRC). The primary shopper for the household will be required to attend all 4 sessions. The study participant will be required to attend at least 1 session and other family/household members will be encouraged to attend. The weekly sessions will take place at the family's primary grocery store. During each session, the RD will facilitate selection of low free sugar foods and guide the primary shopper on menu planning for a low free sugar diet. In the 4th session, the primary shopper will be asked to shop independently while being observed by the RD/CRC. Prior to checking out, the RD/CRC will approve and/or correct their shopping choices.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
214907551|NCT03068377|DIETARY_SUPPLEMENT|Placebo|soft gel capsules without test material
214302516|NCT04199117|DRUG|Varenicline|Participants randomized to intensive treatment who choose to use this intervention will receive one 0.5 mg pill for the first 3 days, starting 7 days prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. This will not be used at the same time as combination nicotine replacement therapy.
214479257|NCT04298450|BEHAVIORAL|Sham SMS|Single welcome message letting participant know they will be contacted to book an appointment.
214479258|NCT06823011|DIAGNOSTIC_TEST|blood collection|Blood was collected from the study group and the control group at 10 am in the morning on an empty stomach.
214479259|NCT04633538|DEVICE|6MWT smartphone app|Use of smartphone app to measure 6 minute walk test (6MWT)
214479260|NCT06231927|BEHAVIORAL|The Skills for Life Adjustment and Resilience (SOLAR) program|The SOLAR program is a 5-session intervention program that aims to introduce participants necessary recovery skills after a traumatic event resulting in a subclinical distress. During the program, participants will be given workbooks including the topics for skill development for recovery and adjustment. At each session, they will discuss these topics with the study coaches.
214907552|NCT03892798|OTHER|No interventions are planned|No interventions are planned
214907553|NCT00121914|PROCEDURE|percutaneous ethanol instillation (PEI)|
214907554|NCT04886843|OTHER|Cold pack|Five minutes cold pack was applied on the affected side dorsiflexor muscle skin, a five-minute break was given and a further 5-minute cold application was repeated
214907555|NCT04886843|DEVICE|NMES|NMES was applied to the nonaffected side ankle dorsiflexors
214907556|NCT01033903|DRUG|misoprostol|800 micrograms intravaginally ONCE
214907557|NCT04298970|DIETARY_SUPPLEMENT|Intervention|Freeze-dried Brassica oleracea var. acephala
214907558|NCT04298970|DIETARY_SUPPLEMENT|Placebo|Placebo product
215056554|NCT06343272|DIETARY_SUPPLEMENT|EAA supplementation|"The experimental group will receive the mixture (Amino-Ther® PRO, Professional Dietetics, Milan) composed of (in mg): L-leucine 1200, l L-isine 900, L-threonine 700, L-isoleucine 600, L-valine 600, L-cystine 150, L histidine 150, L-phenylalanine 100, L-methionine 50, L-tryptophan 50, vitamin B6 0.85, vitamin B1 0.70, citric acid 409, acidomalic 102.5, succinic acid 102.5.~1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days There are: proteins 0.00 g, carbohydrates 2.1 g, fats 0.00 g"
214479261|NCT06610045|OTHER|No intervention|No specific intervention is assess in this study.
214479262|NCT01027728|DRUG|CCX 354-C|"* Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~* Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~* Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days."
214479263|NCT05969223|DRUG|Risankizumab|Subcutaneous injection
214479264|NCT05969223|DRUG|Placebo for Risankizumab|Subcutaneous injection
214479265|NCT02595424|DRUG|Capecitabine|Given PO
214479266|NCT02595424|DRUG|Carboplatin|Given IV
214479267|NCT02595424|DRUG|Cisplatin|Given IV
214479268|NCT02595424|DRUG|Etoposide|Given IV
214904763|NCT04186793|OTHER|Diet Provision Group|"This intervention will be applied to each family and will target foods and beverages that contain free sugars added to food by consumer, cook, or manufacturer, but preserve the family's other food group choices. During the 4 week long intervention, families will be able to choose meals from a list of foods similar to their usual diet. Groceries for each week will be delivered to the family. Each child will be provided with a lunch bag and instructed to bring lunch to school to maintain the study diet.~Families will have the opportunity to choose from a list of pre-prepared evening meals that are similar to what they consumed before study initiation but without free sugars. The families will be instructed to not eat any food outside of the assigned diet.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
214904764|NCT05377463|BEHAVIORAL|Peer support to promote uptake and persistence of medication assisted treatment (MAT)|Participants will be assigned to receive peer support to promote uptake of MAT and persistence. This component will consist of two informational sessions, a tailored recovery plan, and on-going support from a peer for the first 6 months.
214904765|NCT05377463|BEHAVIORAL|Behavioral Activation Treatment (BAT) to reduce depression|Participants will be assigned to receive BAT treatment for depression. This component will consist of 8 sessions where participants will identify short and long-term goals, values, and the activities unrelated to substance use that were previously enjoyed or are likely to increase a feeling of well-being. This intervention component focuses on making a plan to troubleshoot barriers to re-engage in these activities. Sessions are delivered weekly. The content includes psycho-education about what depression is, the intervention rationale, and the activities and monitoring of activities, building social contracts to engage networks, and discussion of potential barriers to following through with activities.
214904766|NCT05377463|BEHAVIORAL|No Intervention Components|Participants not assigned to components 1 and 2
214904767|NCT02620293|DEVICE|Eczema Repair Emollient|An Emollient
214904768|NCT03396653|BEHAVIORAL|Peer-delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
214904769|NCT03396653|BEHAVIORAL|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
214479269|NCT02595424|OTHER|Laboratory Biomarker Analysis|Correlative studies
214479270|NCT02595424|DRUG|Temozolomide|Given PO
214904770|NCT06362746|DRUG|Non-immunogenic recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
214904771|NCT06362746|DRUG|Placebo|15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
214904772|NCT05013710|OTHER|Complete Clinical Interaction|The intervention consists of a completed interaction with the mobile health clinic during the study periods, on which adequate evaluative data was collected on the patient visit (e.g. staff was able to note their visit and reason for visit, the patient met with an healthcare professional, etc)
214904773|NCT02570308|DRUG|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
214904774|NCT01832064|BEHAVIORAL|Mailed Chronic Disease Self-Management Program|materials are mailed to participants
214904775|NCT04046887|DRUG|Lonsurf|Lonsurf will be administered orally twice a day on days 2-6 and 16-20 of every 28-day cycle at a dose of 25 mg/m2, 20 mg/m2 or 30 mg/m2 depending on cohort assignment.
214904776|NCT04046887|DRUG|Gemcitabine|Gemcitabine will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 800 mg/m2, 600 mg/m2 or 1000 mg/m2 depending on cohort assignment.
214904777|NCT04046887|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 100 mg/m2, 75 mg/m2 or 125 mg/m2 depending on cohort assignment.
214904778|NCT00629356|GENETIC|dengue fever|
214904779|NCT00957801|DRUG|Testosterone injection|100 mg single IM injection
214904780|NCT00957801|DRUG|Testosterone gel|Testosterone gel 10 mg. administered topically daily for seven days
214904781|NCT00957801|DRUG|Medrol|Medrol 6 day dose pack with an additional 4mg dose on day 7
214904782|NCT01283464|DRUG|Retinol|1.0% cream
214904783|NCT01283464|DRUG|Tretinoin|0.02% cream
214904784|NCT04289025|OTHER|Exercise|A set of exercises are provided to each patient.
214904785|NCT02450201|DRUG|Pyruvate|
214479271|NCT06745466|DRUG|ganirelix acetate|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration. Women will self-administer subcutaneous injections (0.25 mg/day in 0.5 ml of normal saline) of the GnRH antagonist ganirelix acetate (Antagon, Organon, Inc., West Orange, New Jersey,) every day for \~12-15 days (starting on day \~2-4 of the menstrual cycle). Testing will occur on day 3-4 and day14-15 of using Antagon.
214479272|NCT05061017|DRUG|Pixatimod|Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.
214302517|NCT04199117|DRUG|Combination nicotine patch and nicotine mini-lozenge treatment|Participants randomized to intensive treatment who choose to use this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges for use starting on the target quit date and the following 12 weeks. Participants will be instructed to use 9-20 mini-lozenges per day (one every 1-2 hours) for the first 6 weeks, then reduce to a mini-lozenge every 2-4 hours for 3 weeks, and then a mini-lozenge every 4-8 hours for 3 weeks. Combination nicotine patch and nicotine mini-lozenge treatment will not be used at the same time as varenicline.
214302518|NCT04199117|BEHAVIORAL|Monetary incentives for initiating treatment|Participants randomized to this intervention will earn an incentive each time they complete a first counseling session in an available treatment, up to 2 rounds of counseling per year, and up to 4 rounds of counseling over 2 years of enrollment.
214904786|NCT01778855|OTHER|IV t-PA and normothermia|
214904787|NCT01778855|DEVICE|IV-tPA and hypothermia|
214302519|NCT04199117|BEHAVIORAL|Automated tailored outreach|Participants randomized to this intervention will receive 5 tailored letters delivered every 4-6 months. Letter content will be tailored to participant demographics and use of study treatment, and personalized with references to their primary care teams and tobacco care manager. Letters offer encouragement to quit and information about how to access available treatments.
214302520|NCT04199117|BEHAVIORAL|Care management|Participants randomized to this intervention will receive 5 live, proactive phone calls lasting 10-15 minutes from as assigned Tobacco Care Manager who will provide manualized support and motivational encouragement, discuss available treatment options, and inform the participant how to initiate treatment when ready to quit.
214904788|NCT06578000|DRUG|Magnesium sulfate|Iontophoresis therapy (MgO4 will be applied to the active positive electrode and the treatment will be repeated twice a week for four weeks) + conventional therapy (Splint + Stretch + strength).
214904789|NCT06578000|OTHER|conventional therapy|conventional therapy (Splint + Stretch + strength) twice a week for six weeks
214904790|NCT03563599|DRUG|Telacebec (Q203)|High, Mid, Low dose of telacebec
214904791|NCT03563599|DRUG|Rifafour e-275|RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)
214904792|NCT02525120|DEVICE|Triojection|Triojection is system intended to deliver a specific amount of ozone to a herniated disc.
214904793|NCT02525120|PROCEDURE|Surgical discectomy|Patients will receive surgery to remove the herniated disc material.
214904794|NCT06047730|PROCEDURE|operation ways|nothing
214904795|NCT00916084|DEVICE|Fixed Tongue Appliance|A functional appliance used for maxillary protraction. It has two bands on first molars, expansion screw and long palatal plate in the canine area which cages the tongue and transfers the force of the tongue during physiological activity to the upper arch.
214904796|NCT00916084|DEVICE|Fixed Face Mask|An extra-oral appliance used for treatment of maxillary deficiency in growing patients. It takes anchorage from the chin and forehead, has a fixed intra-oral appliance with an expansion screw and hooks for elastics that exert a force of 300 gr. It should be used 14 hours a day.
214904797|NCT06070467|OTHER|Mixed Methods Research (MMR) using quantitative (QUAN) and qualitative (QUAL) tools|"A Mixed Methods Research (MMR) using quantitative (QUAN) Vision Related-QoL (VR-QoL = FVQ-CYP and VQoL-CYP) tools and psychosocial PEM-CY, and qualitative (QUAL) socio-anthropologic investigations can capture reliably children's and teenagers' Patient-Reported Outcome (PRO).~The QUAN study is a cross-sectional study including short-term re-test repetition (children/teenagers only) using the following PROMs for children/teenagers:~1. Self-reported questionnaires for patients (FVQ-CYP and VQoL-CYP)~2. For caregivers: PEM-CY questionnaires~The QUAL study will rely on the following instruments:~1. Semi-directive interviews,~2. Focus groups,~3. Field observation."
214904798|NCT01427348|PROCEDURE|with assistant|head extension by an assistant during direct laryngoscopy
214904799|NCT01427348|PROCEDURE|without assistant|without head extension by an assistant during direct laryngoscopy
214904800|NCT04503148|DRUG|Propofol|Propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
214904801|NCT04503148|DRUG|Inhaled General Anesthetics|Sevoflurane or desflurane for induction and maintenance of anesthesia
214904802|NCT00873392|DRUG|Transdermal nicotine|Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
214904803|NCT00873392|OTHER|Usual drug treatment of Parkinson's disease|Usual drug treatment of Parkinson's disease
214904804|NCT05505435|DRUG|Depot-Medroxyprogestereone Acetate|subcutaneous depot medroxyprogesterone acetate
214904805|NCT05505435|DRUG|Depot-Medroxyprogestereone Acetate|intramuscular depot medroxyprogesterone acetate
214904806|NCT02182492|DRUG|Clarithromycin|Clarithromycin 250 mg tablet once daily for 3 months
214904807|NCT02182492|DRUG|Glucocorticoid|Fluticasone propionate nasal spray 200 μg/d for 3 months
214904808|NCT03992963|DEVICE|Hearing Aid without frequency lowering enabled|Each participant will be fitted with frequency lowering disabled. Disabled means standard hearing loss compensation without lowering higher frequencies in lower frequency areas. The input frequency is mapped to the same frequency in output.
214904809|NCT03992963|DEVICE|Hearing Aid with frequency lowering enabled|Each participant will be fitted with frequency lowering enabled. The principle of the frequency lowering algorithm is to lower high frequencies to a lower frequency region with the aim of ensuring high frequency audibility to improve auditory emotion recognition.
214904810|NCT03589417|OTHER|Assessments with Biodex Balance System®|Postural Stability, limits of stability and fall risk tests will be applied with the Biodex Balance System®
214904811|NCT02825017|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm\*2 test application.(Formulation-SR15-79\_Y73-161)
214904812|NCT02455206|BEHAVIORAL|physical activity counseling|5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.
214904813|NCT02455206|BEHAVIORAL|Usual care|
214904814|NCT06142604|DRUG|Flecainide|Single 300mg dose of oral flecainide
214907559|NCT05682209|DRUG|Octreotide Injection|100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
214904815|NCT06576804|BEHAVIORAL|Eccentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week"
214904816|NCT06576804|BEHAVIORAL|Concentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week"
214904817|NCT00582101|BEHAVIORAL|Family-Based HIV Prevention for Latinos|7-hour one-day workshop with adolescents and parents in separate and joint sessions
214904818|NCT00582101|BEHAVIORAL|General Health Promotion|7 hour one-day workshop on general health promotion topics
214904819|NCT03005704|DRUG|Antiplatelet treatment|Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
214904820|NCT04268225|PROCEDURE|US guided dynamic needle tip positioning peripheral intravenous cannulation|Catheterizations will be performed by one of three pediatric intensivists with vast experience in both traditional and US guided DNTP techniques for peripheral intravenous access. The operator will be allowed to independently choose which peripheral vein to cannulate. If necessary, patients will be given supplemental dose of sedation and analgesia in addition to the already given continuous infusions for invasive mechanical ventilation. Before puncture, the limb will be taped and maintained in an optimal position. A tourniquet will be placed proximal to the planned cannulation site. The site of puncture will be disinfected with Chlorhexidine gluconate 0.5% w/v, Alcohol 70% v/v. The choice of catheter will be left to the discretion of the operator. Available PIV cannulas include : 14 GA, 2X45 mm; 17 GA, 1.4X45 mm; 18 GA 1.2X45 mm; 20 GA 1X32mm BD Venflon™ and 24 GA, 0.7X19 mm; 26 GA 0.6X19 mm BD Neoflon™ (Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden).
214904821|NCT04268225|PROCEDURE|Traditional peripheral intravenous cannulation|For traditional insertion technique insertion attempt will be blind or tactile.
214904822|NCT00674648|BIOLOGICAL|CMV-Peptide-Specific T cells|"In this phase I trial, five escalating dose levels will be tested. Each dose will be administered to groups of at least 3 and up to 6 patients. Dose escalation will be based on the dose limiting toxicity (DLT) observed in each treatment group (Confer Biostatistics).~The patient groups and donors are outlined as follows: Group I will receive a single dose of 5 x 105 T cells/kg body weight/dose; Group II will receive a single dose of 1 x 106 T cells/kg/dose; and group III will receive a single dose of 2 x 106 T cells/kg/dose; group IV will receive 3 weekly doses of 1 x 106 T cells/kg/dose; group V will receive 3 weekly doses of 2 x 106 T cells/kg/dose."
214904823|NCT01894386|DRUG|FF 400 mcg|100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
214904824|NCT01894386|DRUG|UMEC 500 mcg|125 mcg powder for inhalation delivered by DPI
214904825|NCT01894386|DRUG|UMEC 250 mcg|62.5 mcg powder for inhalation delivered by DPI
214904826|NCT01894386|DRUG|VI 100 mcg|25 mcg powder for inhalation delivered by DPI
214904827|NCT06081842|OTHER|Contraceptive counseling strengthening intervention package|Development of contraceptive counseling strengthening intervention package that strengthens existing family planning services and is effective, safe, sustainable, scalable, and culturally appropriate.
214904828|NCT06354036|PROCEDURE|the Transhiatal Tunnel Valvuloplasty technique|The ThTV esophagogastrostomy procedure involved placing a lengthy gastric tube into the lower mediastinum, firmly bound to the esophagus.
214904829|NCT03489642|BEHAVIORAL|Telehealth Program|Telehealth program delivered remotely to study participants. Program developed by Cambium Technologies.
214904830|NCT01775111|BEHAVIORAL|Cognitive Training|
214904831|NCT01775111|BEHAVIORAL|Strength Training|
214904832|NCT01775111|DIETARY_SUPPLEMENT|FortiFit|
214904833|NCT04261829|PROCEDURE|Autologous Fat Transfer|Female breast cancer patients who were surgically treated with mastectomy could opt for a full breast reconstruction with Autologous Fat Transfer in combination with external expansion.
214904834|NCT04089631|DRUG|Capecitabine|6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
214904835|NCT01286467|DRUG|PF-04449913|Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
214904836|NCT01058642|DRUG|ADL5747|
214904837|NCT01058642|DRUG|Placebo|
214904838|NCT01058642|DRUG|Pregabalin|
214904839|NCT03247231|DEVICE|Endoscopic band ligation without resection|Endoscopic treatment of subepithelial tumors: autoamputation by endoscopic band ligation without resection.
214904840|NCT03247231|PROCEDURE|SINK|To obtain sample tissue biopsies after the endoscopic band ligation without resection, performing a single-incision with a needle-knife.
214904841|NCT01009450|PROCEDURE|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
214907560|NCT05682209|OTHER|Sterile water|1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
214907561|NCT06577311|COMBINATION_PRODUCT|Aminolevulinic acid hydrochloride 10% topical gel with Red Light|Participants will have their facial Cutaneous Squamous Cell Carcinoma in situ (SCCis) prepped then treated with Aminolevulinic acid hydrochloride 10% topical gel (Ameluz ®), followed by red light therapy administered for 13 minutes and 30 seconds to deliver the total desired light dose to the SCCis lesion.
214907562|NCT04940273|DRUG|Remifentanil Injection [Ultiva]|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
214907563|NCT02044120|DRUG|niraparib|
214907564|NCT02044120|DRUG|Temozolomide|
214907565|NCT02044120|DRUG|Irinotecan|
214907566|NCT06097364|DRUG|Odronextamab|Administered by intravenous (IV) infusion
214907567|NCT06097364|DRUG|Rituximab|Administered by IV infusion, or subcutaneous (SC)
214907568|NCT06097364|DRUG|Cyclophosphamide|Administered by IV infusion
214907569|NCT06097364|DRUG|Doxorubicin|Administered by IV infusion
214907570|NCT06097364|DRUG|Vincristine|Administered by IV infusion
214907571|NCT06097364|DRUG|Prednisone/Prenisolone|Administered orally (PO)
214904842|NCT01009450|PROCEDURE|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
214904843|NCT01256450|DRUG|Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
214904844|NCT01256450|DRUG|Placebo|buccal soluble film; applied to the buccal mucosa twice daily
214904845|NCT01994408|OTHER|default intensification|The investigators will determine which blood pressure medications to use. No specific drug will be tested but rather the automatic intensification of medications is the intervention. Examples of drugs used in this study are calcium channel blockers (e.g., amlodipine 2.5 mg to 10 mg) or ACE-inhibitors (e.g., lisinopril 5 mg to 40 mg) or diuretics (HCTZ 25 mg).
214904846|NCT06468085|PROCEDURE|premixed Bioceramic NeoPUTTY®|Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
214904847|NCT06468085|PROCEDURE|Biodentine™|Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic or Biodentine™ according to the corresponding group then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
214904848|NCT06468085|PROCEDURE|Root canal treatment|Root canal treatment will be performed to the control group followed by composite restoration. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
214904849|NCT03866512|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
214904850|NCT04915313|DEVICE|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 200mmHg and 5-min deflation.
214904851|NCT04915313|DEVICE|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
214904852|NCT06255119|DEVICE|3D Therapy Thrive|A novel virtual reality software intervention that utilizes elements of Cognitive Behavioral Therapy to improve outcomes for inpatients with OUD.
214904853|NCT02593838|OTHER|CT-MPI and SPECT-MPI|All patients undergo CT-MPI plus SPECT-MPI
214904854|NCT04787913|BEHAVIORAL|herdimm|In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
214904855|NCT04787913|BEHAVIORAL|guardianmeasles|A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated
214904856|NCT04787913|BEHAVIORAL|theotheredmundmeasles|A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4
214904857|NCT04787913|BEHAVIORAL|sbsnewsgeneric|A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles
214904858|NCT04787913|BEHAVIORAL|publichealthagencycanadaflu|A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html
214904859|NCT04787913|BEHAVIORAL|robertkochgeneric|A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
214904860|NCT01118741|DRUG|Disulfiram|Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
214904861|NCT02137213|DRUG|Naloxone|Naloxone will be added to oral methadone preparation in methadone:naloxone ratio of 50:1
215056555|NCT06343272|OTHER|Isocaloric placebo|The control group will take 25g of maltodextrins daily with the same methods as the treated group: 1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days
215056556|NCT03353662|OTHER|Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
214479273|NCT05061017|DRUG|Nivolumab|Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer
214904862|NCT02137213|DRUG|Placebo|Normal saline will be added to oral methadone preparations as placebo.
214904863|NCT00529503|DRUG|SGN-40|2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
214904864|NCT00529503|DRUG|placebo|Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
214904865|NCT00529503|DRUG|rituximab|375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
214904866|NCT00529503|DRUG|etoposide|100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
214904867|NCT00529503|DRUG|carboplatin|AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
214904868|NCT00529503|DRUG|ifosfamide|5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
214904869|NCT05214690|DRUG|DW1809-T2|pelubiprofen 25mg
214904870|NCT05214690|DRUG|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
214904871|NCT03690128|BEHAVIORAL|I-EWS with incorporated clinical assessment (Trigger Tool)|In relation to systematic measurement of vital parameters the nursing staff will perform an individual clinical assessment of the patient and adjust the I-EWS score accordingly.
214904872|NCT03690128|BEHAVIORAL|Standard EWS - Control (Trigger Tool)|Standard EWS - Based on principles of National Early Warning Score (NEWS)
214904873|NCT00965211|DEVICE|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 1 Hz to the supplementary motor cortex and then a 2 minute recess.each subject would undergo 5 sessions a week for 4 weeks.
214904874|NCT05188261|DRUG|IW-3300|A single dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.
214302521|NCT04199117|OTHER|Wisconsin Tobacco Quit Line referral|This is recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. The Wisconsin Tobacco Quit Line (WTQL) offers a single 20-minute counseling session to all Wisconsin residents ready to set a date to stop smoking in the next month, at no charge, and offers those who meet their medical eligibility criteria a 2-week supply of either nicotine patches, lozenges, or gums, at no charge. The WTQL assumes full clinical responsibility for participants' use of cessation medications dispensed by the WTQL.
214302522|NCT04199117|OTHER|Primary care provider referral|This is a form of recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. Participants who choose to use this intervention will be referred electronically to their primary care provider for counseling and/or medication if they express an interest in quitting in the next 30 days and agree to this referral.
214302523|NCT04199117|BEHAVIORAL|Untailored outreach|Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
214302524|NCT04199117|BEHAVIORAL|Multiple smoking cessation coaching calls|Participants randomized to intensive treatment access who choose to quit will receive three 15-20-minute quit coaching calls from a trained smoking cessation health counselor. Calls will be scheduled for one week pre-quit, one day after the target quit day, and one week after the target quit day.
214302525|NCT07025551|DRUG|MK-8527|Oral administration
214302526|NCT06681207|COMBINATION_PRODUCT|anodal transcranial direct current stimulation (a-tDCS)|Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Stroke participants in the first two groups will receive five sessions of the assigned brain stimulation combined with visuomotor stepping training over five consecutive days. Healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.
214302527|NCT06368141|DRUG|Serplulimab|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
214302528|NCT06368141|DRUG|Capecitabine|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
214302529|NCT06368141|DRUG|Oxaliplatin|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
214904875|NCT05188261|DRUG|Placebo|A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.
214904876|NCT03280524|OTHER|reflexology|
214904877|NCT03280524|OTHER|self-care guidelines with feet|
214904878|NCT00777296|DRUG|ARIKACE™|Study start date is before Jan 18, 2017.
214904879|NCT00777296|DRUG|Placebo|Study start date is before Jan 18, 2017.
214904880|NCT06258941|BEHAVIORAL|MF-HIIT|Two 10-min MF-HIIT sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
214904881|NCT06258941|BEHAVIORAL|HIIT-only|Two 10-min HIIT-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
214904882|NCT06258941|BEHAVIORAL|MF-only|Two 10-min MF-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
214904883|NCT06258941|BEHAVIORAL|Sedentary activity|Two 10-min sedentary sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
214904884|NCT05392946|DRUG|Bortezomib|Given SC
214904885|NCT05392946|BIOLOGICAL|Daratumumab|Given SC
214904886|NCT05392946|DRUG|Dexamethasone|Given PO
214904887|NCT05392946|DRUG|Iberdomide|Given PO
214904888|NCT04973150|BEHAVIORAL|To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children.|To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children. Methods A total of 300 preschool-age children who underwent general anesthesia of selective ophthalmic surgery in a 3A grade hospital from August 2019 to July 2020 were selected as the research object, who were divided into experimental group and control group with 150 cases each by random number table. Children in the control group received regular education on cartoon animation videos before surgery; children in the experimental group received eye-covering pretreatment on the basis of cartoon animation videos. The differences in preoperative anxiety degree score, postoperative acute delirium incidence, delirium degree score, and postoperative nursing care difficulty score were compared between the two groups.
214904889|NCT04665219|BEHAVIORAL|HBM-based text messages|"The intervention in the test group will consist of a set of text messages developed based on the HBM to be sent to the parents regularly in the following 48 weeks.~During the first 24 weeks, parents will receive a text message (and feedback if deemed appropriate) each week. In the next 24 weeks, the parents will receive a text message every 4 weeks, altogether 30 messages will be sent to the parents. All messages will be sent to the parents individually through free mobile App by a research assistant."
214904890|NCT04665219|BEHAVIORAL|Standard text message|Parents in the control group will receive an oral health education pamphlet produced by the Oral Health Education Division in the Department of Health, the Government of Hong Kong SAR. In order to maintain a double-blind design in the present study, the pamphlet will be distributed in an electronic form and sent via a text message.
214302530|NCT07025460|DRUG|darbepoetin alfa|Participants receive darbepoetin alfa administered subcutaneously once every 4 weeks for 12 weeks during the evaluation phase. Dose adjustments are made to maintain hemoglobin levels within 10.0-11.0 g/dL.
214904891|NCT00123760|PROCEDURE|Positron Emission Tomography (PET) scan|
214904892|NCT03437863|DEVICE|Mobile application|Use of a mobile application (on a borrowed device) with following features: 1) strengths reflection and identification, 2) summary of registered strengths, 3) defining goals, and 4) linking strengths to goals.
214904893|NCT01139125|DRUG|(Cystagon) Cysteamine Bitartrate|Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
214904894|NCT04768816|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
214904895|NCT04768816|BIOLOGICAL|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Autism Spectrum Disorder for safety and effect evaluation.
214904896|NCT06364917|DRUG|Pembrolizumab|The dosing regimens for Pembrolizumab (200 mg Q3W), are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
214904897|NCT06364917|DRUG|Carboplatin|The combination therapy dosages for Carboplatin are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
214904898|NCT06364917|DRUG|Paclitaxel|The combination therapy dosages for Paclitaxel are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
214479274|NCT05061017|DRUG|Cyclophosphamide (low dose)|Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
214904899|NCT06364917|DRUG|Pemetrexed|The combination therapy dosages for Pemetrexed are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
214904900|NCT06364917|DRUG|Nivolumab|The dosing regimens for Nivolumab (360 mg Q3W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
214907572|NCT06271785|DIAGNOSTIC_TEST|HR-EEG recording|All participants will have a HR-EEG recordings. It will be made at rest. Nap-like sleep is encouraged, but no sedatives will be given. Recording time will not exceed two hours.
214907573|NCT05946590|PROCEDURE|Frenotomy|Frenotomy in which clipping/incised of the lingual frenulum releases the tongue-tie performed by a health care professional
214907574|NCT05000788|BEHAVIORAL|Qigong|Eight-Section Brocades Practice: The treatment group will undergo an 8-week Eight-Section Brocades intervention program consists of a total of 16 group training sessions with two 1-hour sessions per week. The treatment group participants will be provided with health qigong exercise in a group format led by qualified qigong instructors. All the health qigong instructors will be trained by a certified Traditional Chinese Medicine (TCM) practitioner with an expertise in health qigong and they are required to pass the certification examination before delivering health qigong intervention at the clinical settings. The Eight-Section Brocades protocol will be used in this study because it is easy to learn by the participants and the clinical effects on psychosocial health were evidenced in previous RCTs. A complete cycle of the Eight-Section Brocades took 12 minutes for completion, which consists of eight sequential and simple forms of movements.
214907575|NCT05000788|BEHAVIORAL|Exercise|Exercise Program: Participants in the control group will attend a physical exercise program for 8 weeks (1-hour sessions, 2 times a week). The exercise program will incorporate aerobic fitness, strength training, body weight workouts, balance training, flexibility and stretching into the training plan. The exercise program is provided in a group format, which will be led by qualified physical trainer.
214479275|NCT05057468|DRUG|Cyclosporine|2.5-5 mg orally for 3 months
214479276|NCT05057468|DRUG|Rituximab|375 mg/ m2 weekly dose for a maximum of 4 weeks
214904901|NCT06364917|DRUG|Ipilimumab|The dosing regimens for Ipilimumab (1 mg/kg Q6W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
214904902|NCT04494490|BEHAVIORAL|Clinical Practice Guidelines and Psychologically Informed Physical Therapy training/audit/feedback|The aim of the active training strategy is to improve the knowledge and skills of physical therapists with regard to evidence-based physical therapy with an emphasis on active treatments and PIPT for the treatment of patients with low back pain and to encourage increased adherence with CPGs. This Continuing Education (CE) training session will be offered to all therapists regardless of study participation. During the CE training session, focus will be placed on interventions that have been shown to be effective, such as interactive education and discussion, feedback, and reminders.
214904903|NCT02472106|DEVICE|Post-dilatation|Post-dilatation in self-expanding TAVI device procedures
214904904|NCT05989256|DIAGNOSTIC_TEST|EndoTool|EndoTool is a vendor based glucose management software
214904905|NCT05989256|OTHER|glucose management team|comparison group will be services that have not yet implemented EndoTool
214904906|NCT05989256|OTHER|standard of care glucose management|providers adjusting insulin and consulting the Glucose Management Team at their discretion
214904907|NCT04798911|OTHER|Phase 1 Observational Interviews|Qualitative interviews with patients with SS
214904908|NCT04349228|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200mg/day
214904909|NCT04349228|DRUG|Placebo oral tablet|Placebo of Hydroxychloroquine (HCQ) without any active substance
214904910|NCT03827993|BEHAVIORAL|dedicated sexual health clinic appointment|Intervention will consist of a dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This provider will perform a focused history and physical, and will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
214904911|NCT00061997|DIETARY_SUPPLEMENT|inositol|
214904912|NCT04970147|OTHER|Gastrostomy care bundle|Gastrostomy care bundle
214904913|NCT06089564|BEHAVIORAL|Skit video, Pictorial, Sign language|Three oral health educational intervention groups, group A (skit video), group B (pictorial) and group C (sign language) by using Sequentially Numbered Sealed Opaque Envelopes (SNOSE). Children picked a sealed envelope randomly and assigned to oral health education intervention group A, B and C. Participants in group A were assigned a skit video method of oral hygiene intervention and shown 5 minute video on what to eat and how to brush their teeth. The video included that what is good and bad for teeth, and how to brush which includes method, time and duration of tooth brushing. Participants assigned to group B and C was provided same instructions for tooth brushing and eating habits in the form of pictures and sign language respectively. The children of Group A received instructions in the form of laminated cards and asked to take with them at home. Participants in group C were received instructions in sign language in the presence of teacher.
214904914|NCT06052566|DRUG|Efinopegdutide|Subcutaneous injection administered at a dose of 7 mg
214904915|NCT04908774|BEHAVIORAL|Fasting Mimicking Diet|"The mobile application Salufast provides standardised fasting packages for 5 days of approx. 500 kcal and accompanies the participants during all fasting days."
214904916|NCT03061136|DRUG|Clonazepam|
214904917|NCT03061136|DRUG|Placebo|
214904918|NCT05689151|DRUG|Abrocitinib|Study Drug for Observational Data Collection
214904919|NCT02608216|DRUG|[18F]FLT|\[18F\]FLT PET/CT scan, imaging tracer
214904920|NCT02608216|DEVICE|PET/CT|\[18F\]FLT PET/CT scan
214904921|NCT02608216|DRUG|ribociclib|therapeutic
214904922|NCT02608216|DRUG|paclitaxel|therapeutic
214904923|NCT05538897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214904924|NCT05538897|PROCEDURE|Computed Tomography|Undergo CT scan
214904925|NCT05538897|DRUG|Ipatasertib|Given PO
214904926|NCT05538897|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904927|NCT05538897|DRUG|Megestrol Acetate|Given PO
214479277|NCT06219668|PROCEDURE|Omentopexy group|Omentopexy and Clips on staple line during LSG
214904928|NCT04598009|DRUG|Binimetinib|Taken orally (PO) twice a day (BID)
214904929|NCT04598009|DRUG|Imatinib|Taken orally (PO) once a day (QD)
214904930|NCT06742840|DRUG|HRS-2129|HRS-2129.
214904931|NCT06742840|DRUG|HRS-2129 placebo|HRS-2129 placebo.
214904932|NCT02393157|DRUG|Obinutuzumab|Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
214904933|NCT02393157|DRUG|Liposomal ARA-C|Will be given intrathecally for both prophylaxis and treatment of CNS disease.
214904934|NCT02393157|DRUG|Ifosfamide|Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
214904935|NCT02393157|DRUG|Carboplatin|Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
214904936|NCT02393157|DRUG|Etoposide|Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
214904937|NCT06292065|DIAGNOSTIC_TEST|Point-of-care gastric ultrasound|Using ultrasound to visualise the gastric antrum in supine position and right lateral decubitus.
214904938|NCT04418167|DRUG|JSI-1187|JSI-1187 capsules for oral administration
214904939|NCT04418167|DRUG|Dabrafenib|Dabrafenib capsules for oral administration
214904940|NCT06309251|OTHER|ketogenic diet (as per clinical practice)|Patients recruited receive a ketogenic diet. The prescription, the type of KD protocol and the route of administration will depend, essentially, on the patient's ability and willingness to feed spontaneously and independently, as well as on compliance with the therapies set and the severity of the clinical conditions.
214904941|NCT03045016|DRUG|Prazosin, ALPRESS® LP 2,5 et 5 mg|"Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days."
214904942|NCT05050136|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
214904943|NCT05050136|DRUG|Placebo|Capsules matched to study drug without the active pharmaceutical ingredient
214904944|NCT05697809|DRUG|OXU-001|Suprachoroidal sustained release dexamethasone acetate
214904945|NCT05697809|DEVICE|Semi-automated suprachoroidal illuminated microcatheter|Ophthalmic administration device
214904946|NCT05697809|DRUG|Ozurdex® Ophthalmic Intravitreal Implant|Ophthalmic dexamethasone intravitreal implant
214904947|NCT04381143|DRUG|Aspirin 100 mg Oral Tablet|Aspirin 100 mg tablet daily
214904948|NCT04381143|DRUG|Matching Placebo|Matching Placebo 1 pill daily
214904949|NCT01664637|DRUG|10 mg TZP-102|One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
214904950|NCT01664637|DRUG|Placebo|One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
214904951|NCT06818669|BEHAVIORAL|CVD-FIT|The structured incentive will include monthly supplemental income plus weekly reimbursement for the purchase of healthy food options. Education for CVD risk reduction will include mailed education and telephone calls with a trained health educator.
214904952|NCT06818669|BEHAVIORAL|Enhanced Usual Care|Education for CVD risk reduction will include mailed education and telephone calls with a trained health educator.
214904953|NCT05029037|DRUG|High doses of intravenous vitamin C|Two (2) High doses of intravenous vitamin C for seven (7) days.
214904954|NCT05029037|DRUG|Dextrose 500 mL|"Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.~Twice a day for seven days."
214904955|NCT05821933|DRUG|RC108|RC108 plus Furmonertinib and/or Toripalimab
214904956|NCT02749188|OTHER|Bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
214904957|NCT06965114|PROCEDURE|Biospecimen Collection|Undergo blood sample and buccal swab collection
214904958|NCT06965114|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214904959|NCT06965114|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214904960|NCT06965114|DRUG|Cladribine|Given IV
214904961|NCT06965114|PROCEDURE|Computed Tomography|Undergo CT
214904962|NCT06965114|BIOLOGICAL|Rituximab|Given IV
214904963|NCT06965114|DRUG|Tovorafenib|Given PO
214904964|NCT06643299|DRUG|Probiotic Agent|BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.
214904965|NCT06643299|OTHER|Placebo|Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.
214904967|NCT06105632|DRUG|PF-07220060 CDK4 inhibitor|Experimental
214904968|NCT06105632|DRUG|Fulvestrant|Experimental and Active comparator
214904969|NCT06105632|DRUG|Everolimus|Active Comparator
214479278|NCT02938520|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
214904970|NCT06105632|DRUG|Exemestane|Active Comparator
214904971|NCT06169124|PROCEDURE|Biospecimen Collection|Undergo archived tissue and blood sample collection
214904972|NCT06169124|PROCEDURE|Chest Radiography|Undergo chest x-ray
214904973|NCT06169124|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
214904974|NCT06169124|DRUG|Darolutamide|Given PO
214904975|NCT06169124|DRUG|Exemestane|Given PO
214904976|NCT06169124|DRUG|Leuprolide Acetate|Given IM
214904977|NCT06169124|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214904978|NCT06169124|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214904979|NCT05387473|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I) integrated in best-evidence usual care (CBTi-UC)|In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly CBT-I. This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.
214904980|NCT05387473|BEHAVIORAL|Best-evidence usual care (UC) plus information sessions|In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly general information sessions (general education sessions in line with recommendations from best-practice guidelines and recent evidence). This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.
214904981|NCT05840224|BIOLOGICAL|GS-4528|Administered intravenously
214904982|NCT05840224|DRUG|Zimberelimab|Administered intravenously.
214904983|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260
214904984|NCT04400838|BIOLOGICAL|MenACWY vaccine|Standard single dose of MenACWY vaccine
214904985|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later
214904986|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine|Two standard doses of MenACWY vaccine 4-6 weeks apart
214904987|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (qPCR)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR
214904988|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL prime plus boost|Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)
214904989|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine min. 4 weeks apart|Two standard doses of MenACWY vaccine minimum 4 weeks apart
214904990|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart
214479279|NCT02938520|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose."
214479280|NCT02938520|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
214479281|NCT02938520|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
214479282|NCT02938520|DRUG|ABC/DTG/3TC STR - Tablet|"It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate."
214904991|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
214904992|NCT05574101|DRUG|Cemiplimab|Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.
214904993|NCT05574101|RADIATION|Radiotherapy|Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
214904994|NCT05755438|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).
214904995|NCT05755438|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle controlled period (DBVC).
214904996|NCT06013969|DRUG|Spesolimab|Spesolimab intravenous (i.v.) infusion
214904997|NCT04633252|DRUG|ADT|For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
214904998|NCT04633252|DRUG|Prednisone|For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.
214904999|NCT04633252|DRUG|M7824|M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.
214905000|NCT04633252|DRUG|Docetaxel|Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
214905001|NCT04633252|DRUG|M9241|M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.
214905002|NCT06622850|OTHER|Acupressure|"In acupressure, cun is used as the unit of measurement to determine the points to be applied. In order to find the acupressure points correctly, measurements should be made using the individual\&#39;s own fingers. The thumb widths of the individuals participating in the study will be measured and converted as centimeter 1 cun unit. The points to be used in acupressure will be Shen Men (HT7) located in the transverse wrist crease, in the small depression between the pisiform and ulna bones, (LI11) located at the end of the crease when the elbow is bent, and Hegu (LI4) located in the space between the thumb and index finger will be marked by the certified researcher (GB) with an acetate pen in the patients in the study group. And the application will be performed by the certified researcher (GB)."
214905003|NCT06973603|OTHER|Blood samples|24mL blood sample (3 dry tubes with 8mL)
214905004|NCT05781295|DEVICE|TaurolockTM|The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.
214905005|NCT05781295|DEVICE|Physiological serum|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
214905006|NCT06703996|OTHER|Discussion|Participate in check-in/goal-setting discussions
214905007|NCT06703996|OTHER|Medical Device Usage and Evaluation|Wear the InBody Band 3 fitness tracker
214905008|NCT06703996|OTHER|Questionnaire Administration|Ancillary studies
214905009|NCT06055790|DIAGNOSTIC_TEST|18F-Fluciclovine (Axumin) PET/CT|"PET/CT protocol:~All patients will be instructed to fast for 4 hr. prior to the scan. CT imaging of the head will be performed using GE Discovery MI Digital PET/CT (Boston, Massachusetts) prior to the injection of 18F-fluciclovine. While the patient is in a supine position on the PET table, 5 mCi (185 MBq) of 18F-fluciclovine will be administrated intravenously, followed by a saline flush. At the time of the injection, a continuous dynamic PET images lasting 60 min will be performed using 3D-dynamic and list-mode acquisition: 2.0 mm slice thickness, number of frames(f) x time in seconds(s) and minutes(m) of: 4f x 15s, 4f x 30s, 6f x 2m, 5f x 3m, and 6f x 5m. PET images at 0-5 (flow), 15-25 (early), 25-35 (mid), 45-60 min (delayed) post-injection will be reconstructed using Qclear 500 and OSEM iterative reconstruction with TOF (VPFX): 8 iterations, 5 subsets, 440 image matrix, 4 mm Gaussian filter, TOF. \[24, 27\]."
214905010|NCT06321133|OTHER|High flow nasal cannula immediate ending|High flow is immediately ended
214905011|NCT06321133|OTHER|High flow nasal cannula weaning|High flow is gradually weaned by reducing the flow rate
214905012|NCT06596460|DIAGNOSTIC_TEST|TAVI planning CT (adapted)|TAVI planning CT (adapted) to obtain a standard assessment of the Left Ventricular Outflow Tract (LVOT), valve annulus, aortic root, and ascending aorta up to neck branches. There will be no requirement to scan the ilio-femoral arteries as per standard TAVI planning CT
214905013|NCT02638142|DRUG|Continuous Furosemide Infusion|Intravenous continuous Furosemide infusion
214905014|NCT02638142|DRUG|Intermittent Furosemide Infusion|Intravenous bolus intermittent Furosemide Infusion
214302531|NCT06503354|DEVICE|Neural Sleeve and Zeno walkway|"A standard manual stopwatch will be used to record time. The Zeno pressure gait mat will be laid flat on the ground and used for all walking conditions. Overall, participants will perform four, 5-minute walking bouts while wearing the Neural Sleeve without electrical stimulation. Participants will not receive any intervention or treatment. Simultaneously, the Zeno walkway will be operated according to manufacturers instructions. Condition descriptions are as follows:~Condition 1 (normal walking speed): During this condition, participants will be asked to walk at their normal, comfortable pace for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course.~Condition 2 (fast walking speed): During this condition, participants will be asked to walk, covering as much distance as possible for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course."
214302532|NCT06699836|DRUG|350 mg leronlimab|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
214302533|NCT06699836|DRUG|700 mg leronlimab|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
214302534|NCT05668013|DRUG|TEV-48574 Dose Regimen A|Subcutaneous (sc) administration using a commercial sc infusion system
214302535|NCT05668013|DRUG|TEV-48574 Dose Regiment B|Subcutaneous (sc) administration using a commercial sc infusion system
214302536|NCT07024784|DRUG|IMGN151|Intravenous (IV) infusion
214302537|NCT07024784|DRUG|Carboplatin|Intravenous (IV) infusion
214302538|NCT07024784|DRUG|Bevacizumab|Intravenous (IV) infusion
214302539|NCT07024784|DRUG|Olaparib|Oral Tablet
214302540|NCT06698237|OTHER|immediate cold-water immersion|immediate 10 minute water immersion in 10 degree Celsius
214302541|NCT06698237|OTHER|delayed cold-water immersion|3 hour delayed 10 minute water immersion in 10 degree Celsius
214302542|NCT06698237|OTHER|immediate thermoneutral water immersion|immediate 10 minute water immersion in 35 degree Celsius
214302543|NCT07004972|DRUG|Mavacamten|Specified dose on specified days
214302544|NCT05364203|DEVICE|DEEPSEN virtual reality mask|DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.
214302545|NCT06878326|DEVICE|tDCS|Participant will receive three stimulation conditions: cathodal tDCS of the left DLPFC, anodal tDCS of the left DLPFC and sham-tDCS. The order of the conditions will be randomized and counterbalanced across participants, and the three stimulation conditions will be administered at least a week apart to avoid carry-over effects. The tDCS session will last for 20 minutes.
214479283|NCT02938520|DRUG|DTG Tablet|"It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate."
214479284|NCT04992299|BEHAVIORAL|Mindfulness-Based Intervention|6-week mindfulness-based intervention of 6 weekly 1 hour group sessions
214479285|NCT04992299|BEHAVIORAL|Cognitive-Behavioral Therapy|6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions
214479286|NCT04992299|BEHAVIORAL|Health Education|6-week health education didactic program of 6 weekly 1 hour group sessions
214479287|NCT04101916|DEVICE|Paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 12 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
214905015|NCT06798948|DIETARY_SUPPLEMENT|Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra|Oral combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
214905016|NCT06798948|OTHER|Placebo maltodextrin|The patient takes two tablets of the placebo maltodextrin every day
214905017|NCT06948929|DIETARY_SUPPLEMENT|SCV09|SCV09 consists of a blend of four probiotic species from the Bifidobacterium and Lactobacillus genera (20 billion CFU in 1 sachet per day), prebiotic compounds including galacto-oligosaccharides, xylo-oligosaccharides and inulin, vitamin B6, B9, B12 and vitamin D.
214905018|NCT04577755|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214905019|NCT04577755|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214905020|NCT04577755|PROCEDURE|Computed Tomography|Undergo CT
214905021|NCT04577755|DRUG|Pomalidomide|Given PO
214905022|NCT04577755|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214905023|NCT05816785|DRUG|Cetuximab|Week 1: loading dose of 400mg/m2; Week 2: 250mg/m2
214905024|NCT05816785|DRUG|Imatinib|400 mg orally daily
214905025|NCT04242498|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
214905026|NCT04242498|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
214905027|NCT05836584|BIOLOGICAL|Atezolizumab|Given IV
214905028|NCT05836584|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214905029|NCT05836584|DRUG|Capecitabine|Given PO
214905030|NCT05836584|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214905031|NCT05836584|DRUG|Docetaxel|Given IV
214905032|NCT05836584|PROCEDURE|Echocardiography Test|Undergo ECHO
214905033|NCT05836584|DRUG|Fluorouracil|Given IV
214905034|NCT05836584|DRUG|Leucovorin Calcium|Given IV
214905035|NCT05836584|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
214905036|NCT05836584|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214905037|NCT05836584|DRUG|Oxaliplatin|Given IV
214905038|NCT05836584|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214905039|NCT05836584|PROCEDURE|Surgical Procedure|Undergo surgery
214905040|NCT06133387|DEVICE|Endoscopic submucosal dissection using the ELS System|All subjects will undergo endoscopic submucosal dissection, with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.
214905041|NCT06647654|BIOLOGICAL|ABRYSVO|"Test Negative Design: This is a non-interventional retrospective study; therefore, ABSYRVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.~Ecologic Before-and-After Design: This is an ecologic before-and-after study using aggregated data; as such, the 'exposure' of interest is time before ABRYSVO program implementation (i.e., five historical pre-ABRYSVO RSV seasons) and time after ABRYSVO implementation (i.e., post-ABRYSVO RSV seasons: 2024-2026)."
214905042|NCT06852248|PROCEDURE|Ureteric stenting|The ICE trial is a pilot study involving two methods for identifying the ureters (tubes connecting the kidneys to the bladder) during endometriosis surgery. One group will have conventional ureteric stenting (temporary tubes placed in the ureters)
214905043|NCT06852248|PROCEDURE|Indocyanine green (ICG) dye|The ICE trial is a pilot study involving two methods for identifying the ureters (tubes connecting the kidneys to the bladder) during endometriosis surgery. One group will receive indocyanine green (ICG) dye injected into the ureters to make them visible under a special light.
214905044|NCT06238128|BEHAVIORAL|Opioid Rapid Resonse System (ORRS) training|ORRS is on online system to train citizen responders to administer NARCAN to save the lives of opioid overdose victims. It capitalizes on the innovative PulsePoint technology to connect responders to overdose events. PulsePoint is an app that connects 911 requesting assistance for cardiac arrests to responders with Cardiopulmonary Resuscitation (CPR) training. ORRS allows us to partner with PulsePoint users to expand its reach to opioid overdoses, which share the need for a quick response that emergency responders are often unable to provide. ORRS has the advantage of expanding the population of responders with NARCAN, rescue breathing, and CPR training that can be connected to overdose events, increasing the likelihood of saving overdose victims' lives through a quick, efficient response. ORRS is delivered through an interactive, digital platform containing sequential, multi-media modules.
214905045|NCT06238128|BEHAVIORAL|Non-active opioid overdose response training|"Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training.~Once the project is completed, participants will receive online Naloxone training."
214905046|NCT06573294|DRUG|GEN1057|Intravenous (IV) infusion
214905047|NCT06573294|DRUG|Premedication|IV infusion/orally by mouth.
214905048|NCT06574373|OTHER|Blood Collection Protocol for Patients with Indolent, Invasive, and Pancreatic Cancer-Associated IPMN Based on Clinical Course and Surgical Intervention|Blood will be collected from patients with indolent IPMN, invasive IPMN, and IPMN associated with pancreatic cancer, depending on their clinical course. Patients with indolent IPMN will be monitored by the gastroenterology units of their respective institutions, which will inform the patient. Patients with invasive IPMN and/or associated with cancer will undergo surgical resection as part of their standard clinical care, and blood will be collected after informed consent is obtained by the surgical teams at each institution.
214905049|NCT06079359|DRUG|ALXN1850|Participants will receive a ALXN1850 via subcutaneous (SC) injection.
214905050|NCT06079359|DRUG|Placebo|Participants will receive placebo via SC injection.
214905051|NCT05715281|BIOLOGICAL|Atezolizumab|Given IV
214905052|NCT05715281|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214479288|NCT04101916|DEVICE|Sham paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
214905053|NCT05715281|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214905054|NCT05715281|PROCEDURE|Computed Tomography|Undergo CT scan
215056557|NCT03353662|OTHER|Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
214479289|NCT05500040|BEHAVIORAL|Multimodal Rehabilitation|The rehabilitation measure is based on the biopsychosocial ICF model of the WHO. A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.
214905055|NCT05715281|PROCEDURE|Echocardiography Test|Undergo ECHO
214905056|NCT05715281|DRUG|Tiragolumab|Given IV
214905057|NCT06616584|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214905058|NCT06616584|BIOLOGICAL|Cemiplimab|Given IV
214905059|NCT06616584|PROCEDURE|Computed Tomography|Undergo CT
214905060|NCT06616584|DRUG|Dexamethasone|Given PO
214905061|NCT06616584|DRUG|Docetaxel|Given IV
214905062|NCT06616584|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214479290|NCT04831086|DRUG|Steroid Drug|Steroids doses will be optimized in the intervention group according the risk based on predictive models
214479291|NCT04831086|DRUG|Tocolytic Agents|Tocolysis duration will be optimized in the intervention group according the risk based on predictive models
214905063|NCT06616584|BIOLOGICAL|Ramucirumab|Given IV
214905064|NCT05586321|BIOLOGICAL|GEN1056|GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1.
214907576|NCT03964285|OTHER|rumination induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.
214907577|NCT03964285|OTHER|distraction induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
214907578|NCT06061809|DRUG|Bevacizumab|Participants will receive 10mg/kg of Bevacizumab intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
214907579|NCT06061809|DRUG|PD-L1 t-haNK|Participants will receive PD-L1 t-haNK (\~2 × 109 cells/infusion) intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
214907580|NCT06061809|DRUG|N-803|Participants will receive 1mg subcutaneously (SC) on Day 1 and Day 15 of each repeated cycle of treatment.
214905065|NCT04424719|OTHER|Blood test|"High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule :~(i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines).~(ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.~* M0 : during the first medical oncology visit.~* At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120).~* At the diagnosis of metastasis.~* At each significant event during the metastatic disease (surgery, treatment response or progression)."
214905066|NCT05170204|DRUG|Alectinib|Participants will receive oral alectinib twice daily with food.
214905067|NCT05170204|DRUG|Entrectinib|Participants will receive oral entrectinib once daily, with or without food.
215056558|NCT03353662|OTHER|Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
215056559|NCT03353662|OTHER|Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between the age of 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
215056560|NCT03353662|OTHER|Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
215056561|NCT03353662|OTHER|Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
215056562|NCT03799952|BEHAVIORAL|Zoomers on the Go Exercise Program|60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
215056563|NCT01393899|DRUG|Placebo|oral tablets twice daily
215056564|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
215056565|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
215056566|NCT02503085|DRUG|Nurofen for Children®|
215056567|NCT02503085|DRUG|Algifor Dolo Junior®|
215056568|NCT03017339|OTHER|Functional Exercise|
215056569|NCT03017339|RADIATION|Low Level Laser Therapy|
215056570|NCT03017339|RADIATION|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
215056571|NCT03330678|DIETARY_SUPPLEMENT|Probiotic (VSL#3)|Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
215056572|NCT00175760|PROCEDURE|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
215056573|NCT04372550|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
215056574|NCT04372550|OTHER|Standard of Care|Standard of care rehabilitation
215056575|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
215056576|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
214905068|NCT05170204|DRUG|Durvalumab|Participants will receive IV durvalumab every 4 weeks.
214905069|NCT06048575|PROCEDURE|Cholecystectomy|Early or late surgery, ambulatory, emergency, or differed.
214669836|NCT01548638|DRUG|Galantamine ER|"The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER."
214905070|NCT06513091|DEVICE|OCS Lung|The TransMedics Organ Care System (OCS) Lung is an FDA approved portable extracorporeal lung perfusion and monitoring system.
214905071|NCT05111782|OTHER|Symptom Modulation Approach, Movement Control Approach, Functional Optimization Approach|Based on the patients' symptoms and level of disability, either symptom modulation or movement control or functional optimization exercises will be used. The exercises will be provided on alternate days for a duration of 30 minutes in each session preceded by electrotherapeutic modalities for pain relief and muscle relaxation. These modalities will be given for 15 min in each session. The total no. of sessions will be based on the patient's progress for a maximum of 4 weeks.
214905072|NCT03694080|COMBINATION_PRODUCT|Calcium electroporation|Patients with potentially curable colorectal rectal cancer will be treated preoperatively
214905073|NCT03215212|OTHER|eye mask|eye mask administered from 10 pm to 7 am
214905074|NCT03215212|OTHER|ocean sound|Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
214905075|NCT03215212|OTHER|ear plug|ear plug administered from 10 pm to 7 am
214905076|NCT04633317|DEVICE|A pneumatic nebulizer|Inhaled colistimethate sodium generated by a pneumatic nebulizer
214905077|NCT04633317|DEVICE|A vibrating mesh nebulizer|Inhaled colistimethate sodium generated by a vibrating mesh nebulizer
214905078|NCT05717972|OTHER|Kombucha|"Kombucha is a fermented tea drink that originated in ancient Chinese civilization. It is made by combining tea, juice, and SCOBY (Symbiotic Culture of Bacteria and Yeast).~During the fermentation process, the yeast in the SCOBY breaks down the sugar in the tea releasing friendly probiotic bacteria, giving kombucha its fizzy body and its sweet and tangy taste."
215056577|NCT00749788|DRUG|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
215056578|NCT05976152|DRUG|dl-3-butylphthalide|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
215056579|NCT05976152|DRUG|dl-3-butylphthalide placebo|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
214905079|NCT04760626|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
214905080|NCT04760626|DRUG|Insulin Glargine 100U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
214905081|NCT04760626|DRUG|Insulin Degludec|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
214905082|NCT04760626|DRUG|Insulin Glargine 300U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
214905083|NCT03786848|OTHER|MiniPDX Group|Mini patient derived xenograft (MiniPDX) is a drug sensitivity test model established by transplanting primary human tumor cells into immunodeficient mice by special methods. This test can provide sensitivities of single drug or drug combination within 7 days to screen out the optimal individualized regimens for each patient.
214905084|NCT01753310|BIOLOGICAL|Botulinum toxin type A|Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
214905085|NCT01753310|DRUG|Placebo|Up to 2mL
214905086|NCT02946463|BIOLOGICAL|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
214905087|NCT02946463|BIOLOGICAL|Eculizumab|All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.
214905088|NCT02491840|PROCEDURE|Biopsy|Biopsy of Gastric and cardia adenocarcinomas
215056580|NCT01145781|PROCEDURE|Cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
215056581|NCT04312139|DIAGNOSTIC_TEST|Echocardiography|Baseline and prospective follow-up echocardiography
215056582|NCT04312139|DIAGNOSTIC_TEST|Computerized Tomography Aortic Valve Calcium Score|Baseline and prospective follow-up CT calcium score of aortic valve
215056583|NCT04312139|OTHER|Untargeted LC/MS and LC-MS/MS|Serum samples untargeted proteomics and metabolomics
215056584|NCT04312139|OTHER|Targeted LC/MS and LC-MS/MS|Serum samples targeted proteomics and metabolomics
214479292|NCT06605131|DRUG|GP+Toripalimab+CCRT|"1\. Induction Chemotherapy (GP Regimen combined with Toripalimab):~1. GP Regimen Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing less than 40 kg: 3 mg/kg; every 3 weeks for 3 cycles.~2\. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
214669837|NCT02313480|OTHER|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
214669838|NCT00001542|DRUG|fluconazole|
214905089|NCT07121179|BEHAVIORAL|Beighton Scoring system|The Beighton Scoring system is commonly used to distinguish individuals with generalized joint hypermobility from those without. The Beighton Scoring system includes the following assessments: passive dorsiflexion of the fifth metacarpophalangeal joint, passive hyperextension of the elbow, passive hyperextension of the knee, passive apposition of the thumb to the flexor aspect of the forearm, and forward flexion of the trunk. A Developmental Physiotherapy and Pediatric Rehabilitation specialist will evaluate the joint hypermobility assessment of infants.
214905090|NCT07121179|BEHAVIORAL|Brief Infant Sleep Questionnaire|"Infant sleep problems are among the most common problems presented to pediatricians. The extended version of the Brief Infant Sleep Questionnaire is a questionnaire developed by Sadeh to assess sleep problems and their causes in early childhood."
214905091|NCT06812884|OTHER|Education|The mobile application will be introduced to the group to be trained and the application will be downloaded to their phones, tablets or computers.
214905092|NCT06981832|BEHAVIORAL|Personalised support (advanced practice nurse and adapted physical activity teacher)|Personalised support (advanced practice nurse and adapted physical activity teacher)
214905093|NCT06981832|BEHAVIORAL|Standard support (advanced practice nurse)|Standard support (advanced practice nurse)
214905094|NCT06986174|DRUG|Pacritinib|Kinase inhibitor, capsule, taken orally per protocol.
214302546|NCT07034989|OTHER|Exercise|Teach respiratory exercises and function-focused trunk stabilization exercises to individuals with RA-IAH via online platforms. Subsequently, instructional exercise videos will be delivered to the patients online. The respiratory exercise training will include thoracic expansion and diaphragmatic breathing exercises. The program will consist of a warm-up phase including 10 minutes of trunk stabilization exercises, a 40-minute functional exercise session targeting the upper and lower extremities with trunk stabilization, followed by a cooldown phase including 10 minutes of flexibility exercises involving trunk stabilization. The exercise videos related to these phases will be sent to the participants online. Participants will start the exercises with 6 repetitions and will be encouraged to increase to 8 repetitions as the program progresses. The assigned physiotherapist will contact patients once a week by phone to monitor exercise adherence.
214905095|NCT06467760|DEVICE|InDx CMC Implant|The InDx CMC Implant is a hemiarthroplasty device for the CMC joint which consists of a unified assembly of three components: metacarpal stem, polyethylene liner, and articulating head. Because the device functions as a hemiarthroplasty, it does not link or constrain the CMC joint
214905096|NCT04817124|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 6 sessions with 20 minutes stimulation each (1,5 mA).
214905097|NCT04817124|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 6 sessions for approximately 20 min
214905098|NCT04817124|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 6 sessions with 30 sec stimulation each (1,5 mA) to ensure blinding of participants.
214905099|NCT02621359|DRUG|Nitazoxanide|Nitazoxanide 500 mg twice daily
214905100|NCT02621359|DRUG|Levofloxacin|Levofloxacin 500 mg once daily
214302547|NCT06713343|DEVICE|Laryngeal Mask Airways|The 172 patients who will be admitted for elective surgery will be divided into two groups as Group L and Group R by computer-assisted randomization method. Patients in Group L will be ventilated with a classical laryngeal mask airways (cLMA) stored at 10 °C to 12 °C (low temperatures), while patients in Group R will be ventilated with a classical laryngeal mask airways (cLMA) stored at 22 °C to 25 °C (room temperatures).
214479293|NCT06605131|DRUG|GP+CCRT|"1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
214669839|NCT06970301|DRUG|glovadalen|Study participants will receive doses of glovadalen (UCB0022) at pre-specified time points during the Treatment Period of Part A and Part B.
214669840|NCT06970301|OTHER|Placebo|Study participants will receive matching placebo at pre-specified time points during the Treatment Period of Part A and Part B.
214905101|NCT02621359|DRUG|Doxycyclin|Doxycyclin 100 mg twice daily
214905102|NCT02621359|DRUG|Omeprazole|Omeprazole 40 mg twice daily
214905103|NCT00779896|DRUG|Tazarotene|Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.
214905104|NCT01946750|BIOLOGICAL|Serum|
214905105|NCT01946750|BIOLOGICAL|Stools|
214905106|NCT01946750|BIOLOGICAL|Saliva|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
214905107|NCT01946750|BIOLOGICAL|Whole blood|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
214905108|NCT01383174|BEHAVIORAL|Peer Support Program|"* Work with a trained counselor who is a breast cancer survivor~* Meet 8 times in-person over the 8 week program with the counselor~* Counselor helps participant develop a personalized support program to help her improve her quality of life~* Receives information on breast cancer, its treatments, and stress management"
214905109|NCT04181619|DIETARY_SUPPLEMENT|Coffeeberry beverage|One exposure of 300 mg coffeeberry extract in a 300 ml flavored still beverage prior to exercise session
214905110|NCT04181619|OTHER|Comparator beverage|One 300 ml still beverage, color and flavor matched to experimental beverage prior to exercise session
214905111|NCT05872789|DRUG|Diazepam 1% oral gel|Diazepam 1% used with topic oral gel on tongue and palate twice daily.
214905112|NCT05872789|DRUG|Placebo|Placebo oral gel used on tongue and palate twice daily.
214905113|NCT06129448|DIAGNOSTIC_TEST|transthoracic echocardiography|All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.
214905114|NCT06463990|OTHER|TyG index|association between TyG index and triglyceride to high-density lipoprotein cholesterol ratio with fetal macrosomia
214905115|NCT00828217|OTHER|adapted physical activity|one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
214905116|NCT06149975|OTHER|motor-cognitive training|"The motor-cognitive training in this study will be conducted in form of a step-based dual-task training. A mat (approximately 90 x 90 cm) made from extra non-slip yoga mats is required. The mat is divided into 9 equal squares with a 3 x 3 pattern. Participants will be presented with stepping patterns which they must memorize and then execute on the mat in the pace given by a metronome. All participants will start at the same level. The progression will be adjusted individually according to the fixed criteria of the StepIt concept within the sessions. All sessions will be supervised by at least one physical therapist."
214905117|NCT02250898|OTHER|Myofascial Massage Therapy|Myofascial Massage Therapy is a manual massage therapy consisting of the following techniques: fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage.
214905118|NCT02250898|OTHER|Global Relaxation Massage|Global Relaxation Massage is a manual massage therapy consisting of a full body relaxation massage that includes light kneading and stroking in order to restore a sense of well- being
214905119|NCT02169271|DRUG|Aspirin|Given PO
214905120|NCT02169271|OTHER|Laboratory Biomarker Analysis|Correlative studies
214905121|NCT02169271|OTHER|Placebo|Given PO
214905122|NCT05289739|BEHAVIORAL|Exercise training|Exercise training during intensive cancer treatment. Training mainly consists of age-appropriate and personalized endurance, strength, flexibility, balance/coordination and gait training. Three to five weekly training sessions lasting 30 to 60 minutes each for about eight to ten weeks (depending on the course of the cancer treatment).
214905123|NCT04421560|DRUG|Ibrutinib|Capsule, taken by mouth daily
214905124|NCT04421560|DRUG|Pembrolizumab|Given as an intravenous injection through a vein (IV) every 3 weeks
214905125|NCT04421560|DRUG|Rituximab|Given as infusion into a vein (intravenous, IV)
214905126|NCT06605105|DRUG|CYB003|CYB003 is a deuterated psilocin analog
214905127|NCT06606990|PROCEDURE|Biopsy Procedure|Undergo biopsy
214905128|NCT06606990|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214905129|NCT06606990|PROCEDURE|Computed Tomography|Undergo CT
214905130|NCT06606990|PROCEDURE|Echocardiography Test|Undergo ECHO
214905131|NCT06606990|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214905132|NCT06606990|BIOLOGICAL|Pidnarulex|Given IV
214905133|NCT06409611|DEVICE|neuromuscular electrical stimulation|Application of neuromuscular electrical stimulation using the NeuroDyn III device (IBRAMED, Amparo - SP)
214905134|NCT06602739|DRUG|REGN5713|Administered per protocol
214905135|NCT06602739|DRUG|REGN5715|Administered per protocol
214905136|NCT06602739|DRUG|Placebo|Administered per protocol
214905137|NCT06613438|DEVICE|eGERD device|"The eGERD device is a novel device developed by GerdCare Medical for reducing symptoms of GERD. The device is noninvasive and designed for self-use in the home environment. It is applied on the abdominal skin and generates electrical stimulation pulses.~For optimized effect, the stimulation is synchronized with the breathing phase, such that it is active mainly during inhalation. The stimulation intensity can be adjusted by the user."
214905138|NCT06613438|DEVICE|eGERD_Sham|The eGERD\_Sham is a sham version of the eGERD device. It is capable of inducing sensation of electrical stimulation pulses in the target abdominal muscles without a therapeutic effect. Aside from this difference, the eGERD\_Sham is identical to the eGERD device.
214905139|NCT04585958|PROCEDURE|Biopsy Procedure|Undergo biopsy
214905140|NCT04585958|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
214905141|NCT04585958|PROCEDURE|Computed Tomography|Undergo CT
214905142|NCT04585958|PROCEDURE|Echocardiography Test|Undergo echocardiography
214905143|NCT04585958|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214905144|NCT04585958|DRUG|Olaparib|Given PO
214905145|NCT04585958|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
214905146|NCT03307980|BIOLOGICAL|PF-06838435 (formerly SPK-9001)|Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
214905147|NCT06671834|DRUG|PF-07905428|Topical solution of PF-07905428 0.08% or PF-07905428 0.24%
214905148|NCT06671834|DRUG|Placebo|Topical solution of placebo
214905149|NCT07009080|OTHER|motor imagery|The researcher will explain to the players what MI is and how it works. Following the explanation, players will seated in a comfortable armchair facing the researcher, will ask to minimize distracting thoughts, and to be as mindful as possible without speaking for five minutes, and to imagine themselves executing the correct angles during a landing.
214905150|NCT03141684|DRUG|Atezolizumab|Given IV
214905151|NCT03141684|BIOLOGICAL|Bevacizumab|Given IV
214905152|NCT03141684|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine
214905153|NCT03141684|PROCEDURE|Computed Tomography|Undergo CT
214905154|NCT03446430|DEVICE|PWV measurement by LDV|PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
214905155|NCT06411223|BEHAVIORAL|Collaborative drug therapy management model|CDTM+ is an interdisciplinary approach to patient care in which clinicians collaborate with pharmacists to provide and manage patient drug therapy.
214905156|NCT06411223|DRUG|Cabotegravir/Rilpivirine|Long-acting injectable treatment prescribed to treat HIV-1 infection in people 12 years and older and who weigh at least 77 lbs (35kg), to replace their current HIV-1 medicines when their healthcare provider determines they meet certain requirements.
214905157|NCT07011420|DEVICE|Experimental socket with 4 untargeted channels active|Participants will utilize the experimental socket made with untargeted EMG channels. Untargeted sites will ideally be located by creating a band of electrode pairs at the largest muscular circumference distal to the elbow. Only 4 channels will be active during this condition.
214905158|NCT07011420|DEVICE|Experimental socket with 8 untargeted channels active|Participants will utilize the experimental socket made with untargeted EMG channels. Untargeted sites will ideally be located by creating a band of electrode pairs at the largest muscular circumference distal to the elbow. Only 8 channels will be active during this condition.
214905159|NCT07011420|DEVICE|Experimental socket with up to 16 untargeted channels active|Participants will utilize the experimental socket made with untargeted EMG channels. Untargeted sites will ideally be located by creating a band of electrode pairs at the largest muscular circumference distal to the elbow. All16 channels (or the maximum number of channels based on limb size) will be active during this condition.
214905160|NCT07011420|DEVICE|Experimental socket with 8 targeted channels active|Participants will utilize the experimental socket made with targeted EMG channels. This socket will follow Coapt's clinical instructions for targeted site location to identify and mark locations for 8 targeted EMG channels.
214302548|NCT06880731|BEHAVIORAL|Modeling with Verbal Mediation|Children will watch and listen as a friendly animated character completes shifting task trials while narrating his thoughts and actions, providing a model of verbal mediation.
214905161|NCT07011420|DEVICE|Coapt EMG Cuff|This device is the commercially available Coapt EMG Cuff. This armband cuff with electrodes can be strapped onto the user's arm to connect with the Coapt app and play virtual games with their EMG signals.
214905162|NCT07013630|DIETARY_SUPPLEMENT|Clarity Placebo Control|Participants will use their Clarity Placebo Control as directed for a period of 6 weeks.
214905163|NCT07013630|DIETARY_SUPPLEMENT|Clarity Active Product|Participants will use their Clarity Active Product as directed for a period of 6 weeks.
214905164|NCT04123431|DEVICE|Total Hip Replacement|Primary elective total hip replacement
214905165|NCT06681181|DRUG|GSK4528287|GSK4528287 will be administered.
214905166|NCT06681181|DRUG|Placebo|Placebo will be administered.
214905167|NCT06680258|DRUG|TPST-1120|TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα)
214905168|NCT06680258|BIOLOGICAL|Atezolizumab|Atezolizumab is an IV administered biologic.
214905169|NCT06680258|BIOLOGICAL|Bevacizumab|Bevacizumab is an IV administered biologic.
214905170|NCT06874426|PROCEDURE|Endoscopic endonasal skull base surgery|This intervention will be performed as part of the standard-of-care for patients scheduled for endoscopic endonasal skull base surgery for lesions in the (para)sellar region
214905171|NCT04030338|DRUG|18F-DCFPyL-iPSMA|Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
214905172|NCT04030338|DRUG|68Ga-HBED-iPSMA|Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
214905173|NCT04030338|DIAGNOSTIC_TEST|PET/CT scan|The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
214905174|NCT06874322|OTHER|Voiceitt|Participants will use Voiceitt App
214905175|NCT05199701|DEVICE|Mammography|All subjects who are indicated for a screening or diagnostic mammogram or breast biopsy will undergo an investigational exam in a new mammography device.
214905176|NCT05584449|OTHER|Counseling|Attend online group facilitated by two oncology social workers
214905177|NCT05584449|PROCEDURE|Discussion|Discuss survivorship issues/concerns
214905178|NCT05584449|OTHER|Informational Intervention|Receive young adult cancer survivorship information
214905179|NCT05584449|OTHER|Medical Chart Review|Ancillary studies
214905180|NCT05584449|OTHER|Quality-of-Life Assessment|Ancillary studies
214905181|NCT05584449|OTHER|Questionnaire Administration|Ancillary studies
214905182|NCT02603588|PROCEDURE|active sphenopalatine ganglion acupuncture|"The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
214905183|NCT02603588|PROCEDURE|sham sphenopalatine ganglion acupuncture|The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
214905184|NCT06685068|DRUG|GEN1286|Specified dose on specified days
214905185|NCT06694480|DRUG|FID-022|Advanced solid tumors
214905186|NCT06687421|OTHER|High-risk treatment SOC|radiotherapy (RT) + ADT (3 years) + Abiraterone acetate (2 years), with radical prostatectomy being an option if contraindication for RT exists)
214905187|NCT06687421|OTHER|Active monitoring|Followed with PSA measurements
214905188|NCT06687421|PROCEDURE|Radical prostatectomy|Radical prostatectomy
214302549|NCT06880731|BEHAVIORAL|Modeling Only|Children will watch as a friendly animated character completes shifting task trials.
214302550|NCT06881862|OTHER|The immediate craniocervical flexion and correct posture training|The craniocervical flexion and correct posture training were given immediately during the assessment, with no follow-up sessions or long-term interventions. The focus was solely on providing the training at that moment, without any prolonged or repeated exercises.
214302551|NCT07033494|BIOLOGICAL|MK-2214|IV infusion
214905189|NCT06687421|RADIATION|Radiotherapy|Radiotherapy
214905190|NCT06687421|DRUG|Androgen deprivation therapy|GnRH agonist + abiraterone acetate/enzalutamide and/or docetaxel
214302552|NCT07033494|DRUG|Placebo|IV infusion
214302553|NCT07039526|DRUG|CYTALUX™ (pafolacianine) injection preoperatively|CYTALUX™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye as a solution in vials containing 1.6 mL at 2 mg/mL. Each subject will be administered a single intravenous dose of not less than 1 hours before and not more than 24 hours before initiation of intraoperative NIR fluorescent imaging.
214302554|NCT06057402|DRUG|Elranatamab|Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
214302555|NCT06697184|DRUG|Sonrotoclax|Administered orally
214905191|NCT06689163|DRUG|HRS-1167 tablets|HRS-1167 tablets
214302556|NCT06697184|DRUG|Zanubrutinib|Administered orally
214905192|NCT06689163|DRUG|Abiraterone Acetate tablets（II）|Abiraterone Acetate tablets（II）
214905193|NCT06689163|DRUG|Prednisone Acetate tablets|Prednisone Acetate tablets
214905194|NCT07022717|BEHAVIORAL|Brief youth overdose prevention education|Providers in the intervention group will inform youth participants about: the risk factors for overdose, how to stay safe and prevent overdose, how to recognize an overdose, and how to respond to an overdose.
214905195|NCT07022717|OTHER|Information about Naloxone|Providers in the intervention group will inform youth participants how to use naloxone and offered a kit to take home.
214905196|NCT07022717|OTHER|Usual standard of care|Participants will be provided usual care by providers in the control group.
214905197|NCT06696131|DRUG|TNK|TNK will be delivered into the site of the intracerebral hemorrhage via a brain catheter.
214905198|NCT03958747|DIAGNOSTIC_TEST|Ultrasound - Serial and Tibial Nerve|Participants will undergo a serial and tibial nerve ultrasound
214905199|NCT03958747|PROCEDURE|Skin Biopsy|Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh
214905200|NCT03958747|OTHER|Abbreviated Neurologic Exam|Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.
214905201|NCT03958747|OTHER|Blood draw|12 ml blood sample will be taken
215056585|NCT04312139|DIAGNOSTIC_TEST|multiplex ELISA|Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.
215056586|NCT03730714|DRUG|"Local Anesthetic, Epinephrine and Morphine"|local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
215056587|NCT03730714|DRUG|"Local Anesthetic, Epinephrine, Morphine and Surgicel"|Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
215056588|NCT03730714|DRUG|"Normal Saline"|normal saline 0.9% to soak the surgicel according to the planned technique
215056589|NCT04726930|PROCEDURE|Intercostal nerve blocks|Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.
215056590|NCT04726930|PROCEDURE|Paravertebral block|Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen
215056591|NCT00442377|PROCEDURE|exposure to malaria sporozoites|
215056592|NCT02704949|RADIATION|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
215056593|NCT02704949|RADIATION|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
215056594|NCT01294137|DEVICE|ventilatory polygraphy|
215056595|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy with AI|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. The Eleos Health platform provides real-time data that optimizes this therapy and helps the provider tailor the intervention to the specific client.
215056596|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders.
215056597|NCT02595866|DRUG|Antiretroviral Therapy|Given PO
215056598|NCT02595866|PROCEDURE|Biopsy|Undergo biopsy
215056599|NCT02595866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214302557|NCT07041125|DEVICE|Watchman FLX™ Pro device.|Patients eligible for the main DISRUPT-AF Registry with a planned concomitant LAAC procedure using the Watchman FLX™ Pro device.
214302558|NCT06882824|PROCEDURE|myomectomy with placebo|myomectomy after administration of placebo (control group)
214302559|NCT06882824|PROCEDURE|myomectomy with misoprostol|myomectomiy after administration of misoprostol 400μg PO (experimental group)
214905202|NCT03958747|DIAGNOSTIC_TEST|Nerve Conduction Study|Sural and tibial nerve assessments
214905203|NCT03958747|OTHER|QLQ-CIPN20 Questionnaire Administration|Self-reported neuropathy scoring questionnaire completed same day as blood draw.
214905204|NCT07025824|DRUG|Treosulfan (Treo)|10 g/m2 intravenous
214905205|NCT07025824|DRUG|Melphalan (Mel)|140 mg/m2 intravenous
214905206|NCT07025824|DRUG|Fludarabine (Flud)|30 mg/m2 intravenous
214905207|NCT07026981|DRUG|[Ga-68]MTP220 PET/CT Scan|Participants will undergo PET/CT imaging after they have received an injection of the targeted PET tracer drug, \[Ga-68\]MTP220.
214905208|NCT00697632|DRUG|MGCD265|Oral daily administration without interruption
214905209|NCT03171376|PROCEDURE|Root canal treatment and coronal restoration|After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
214905210|NCT06216275|BEHAVIORAL|Integrated Snoezelen-Aromatherapy-Personal Item Therapy|"Intervention Description:~This unique intervention combines three distinct therapeutic approaches specifically tailored for Arab elderly patients with dementia experiencing agitation.~Snoezelen Therapy: Customized sessions in a Snoezelen environment - a specialized room designed to deliver controlled multi-sensory stimuli. This room features adaptable lighting, colors, sounds, and textures to provide a soothing and stimulating experience. Sessions are personalized based on each patient's response and preference, under the guidance of trained professionals.~Aromatherapy: Carefully selected essential oils known for their calming properties are used in a culturally sensitive manner. These oils are diffused in the environment or used during individual sessions to provide a relaxing olfactory experience. The choice of oils and method of delivery are standardized"
214302560|NCT06717698|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
214302561|NCT06717698|DRUG|Placebo|Placebo matching NNC0519-0130 will be administered subcutaneously.
214302562|NCT06717698|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
214905211|NCT06715735|BEHAVIORAL|Theory-based health behaviour change intervention|The online individual education sessions are related to MetS, CKD, healthy dietary and PA, displayed in the form of texts and pictures, and online instant conversations via WeChat. The online group music-paced brisk walking training includes a 5-minute warm-up, 30-minute music-paced brisk walking, and 5-minute stretching exercises to promote cool-down. The group discussion is related to current health status, recommended dietary regimens, and exercise and personal goals. The telephone follow-up after the group discussion is to reinforce the predetermined goals and the practice of healthy dietary and music-paced brisk walking, and to provide opportunities for answering any questions related to the practice of healthy dietary and music-paced brisk walking. All the education session contents are based on a well-structured health handbook. The self-music-paced brisk walking is required to be performed for 30 minutes/day, 5 days/week.
214905212|NCT07035990|DRUG|SION-451|"* Pharmaceutical form: tablet~* Route of administration: oral"
214905213|NCT07035990|DRUG|SION-2222|"* Pharmaceutical form: capsule~* Route of administration: oral"
214905214|NCT07035990|DRUG|SION-109|"* Pharmaceutical form: tablet~* Route of administration: oral"
214905215|NCT07035990|DRUG|Placebo SION-451|Placebo matched to SION-451
214905216|NCT07035990|DRUG|Placebo SION-2222|Placebo matched to SION-2222
214905217|NCT07035990|DRUG|Placebo SION-109|Placebo matched to SION-109
214905218|NCT01288963|DRUG|IL-2|Observation only
214905219|NCT00450593|GENETIC|gene expression analysis|
214905220|NCT00450593|GENETIC|microarray analysis|
214905221|NCT00450593|GENETIC|molecular genetic technique|
214905222|NCT00450593|GENETIC|mutation analysis|
214905223|NCT00450593|OTHER|laboratory biomarker analysis|
214905224|NCT00450593|PROCEDURE|mutation carrier screening|
214905225|NCT00450593|PROCEDURE|study of high risk factors|
214905226|NCT02556229|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
214905227|NCT07047703|DRUG|Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers|Participants in Part A will receive a single dose of GRWD0715 on Day 1 only.
214905228|NCT07047703|DRUG|Part B - Multiple Ascending Dose (MAD) in participants with axSpA|Participants in Part B will receive GRWD0715 for 28 days
214905229|NCT07047703|DRUG|Part C - Safety expansion cohort in participants with axSpA|Participants in Part C will receive GRWD0715 for 12 weeks
214905230|NCT07047703|DRUG|Part D - Randomised, placebo-controlled, expansion cohort in participants with axSpA|Participants in Part D will receive GRWD0715 or placebo-to-match for 12 weeks
214905231|NCT06725030|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
214905232|NCT07044479|DRUG|Enlicitide|Single dose of enlicitide is administered orally on day 1 of each testing period
214905233|NCT05756595|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|This group will inject once a week. Evaluation of pain score after 30 seconds and 3 hours.
214905234|NCT03910400|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|"After stents were implanted whenever technically possible in the STEMI patients, the investigators created a temporary artificial stenosis inside the stent by partially inflating a balloon catheter during pharmacologic hyperemia.~Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections with the artifical stenosis, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR."
214905235|NCT06891443|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
214905236|NCT06891443|OTHER|Placebo IVT|Placebo with identical appearance to sepofarsen
214905237|NCT06741683|BIOLOGICAL|TDV|TDV SC injection.
214905238|NCT06741683|OTHER|Placebo|Placebo SC injection.
214905239|NCT00651274|DRUG|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
214302563|NCT07038876|DRUG|Placebo|Matched Placebo
214302564|NCT07038876|DRUG|ML-007C-MA BID|ML-007C-MA dosed as 210/3 mg BID
214302565|NCT07038876|DRUG|ML-007C-MA QD|ML-007C-MA dosed as 330/6 mg QD
214905240|NCT00651274|DRUG|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
214302566|NCT07037420|DRUG|ALXN2420|ALXN2420 will be administered via subcutaneous (SC) injection
214302567|NCT07037420|DRUG|Placebo|Placebo will be administered via SC injection.
214302568|NCT06723652|DRUG|SHR-1918|six administration
214302569|NCT06723652|DRUG|SHR-1918 placebo|SHR-1918 placebo three administration+SHR-1918 three administration
214302570|NCT06880848|DRUG|Sonidegib Phosphate Capsules|Sonidegib should be taken 1 hour before or 2 hours after a breakfast
214905241|NCT04616612|BEHAVIORAL|SystemCHANGE (TM)|Participants randomized to the refined SystemCHANGE™ intervention will receive 7 personalized sessions with a nurse-interventionist (session 1 virtual face-to-face, sessions 2-7 via phone) and weekly feedback MMS message reports delivered to mobile phones.
214905242|NCT04616612|OTHER|Attention Control|Participants randomized to attention control will receive nurse-led kidney disease self-care education based on materials developed by The National Institute of Diabetes and Digestive and Kidney Diseases and The National Kidney Foundation. Similar to the intervention, participants will receive one virtual visit from the nurse-interventionist and 6 phone calls (weeks 2, 3, 4, 5, 6 and 7) and weekly educational MMS messages delivered by mobile phone.
214905243|NCT04376931|DRUG|Intravenous Solution|Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg.
214905244|NCT02912182|DRUG|Betamethasone|Betamethasone intravenous
214905245|NCT02912182|DRUG|Placebo|Placebo intravenous NaCl intravenous administration Placebo tablets
214905246|NCT02912182|DRUG|Prednisolone|Oral tablets
214905247|NCT03203200|BEHAVIORAL|ZETRA cognitive behavioral structural|ZETRA cognitive behavioral structural
214905248|NCT06891612|BEHAVIORAL|Cognitive Assessments|Cognitive Assessments
214905249|NCT06891612|DEVICE|Eye-tracking|measurement of the points of gaze
214905250|NCT06891612|DEVICE|Electroencephalography (EEG)|Electrophysiological monitoring method to record electrical activity of the brain
214905251|NCT06891612|DEVICE|Electrocardiography (ECG)|measurement of the electrical activity of the heart
214905252|NCT06741553|DRUG|Lecanemab 10 mg/kg|Lecanemab was administered 10mg/kg every two weeks.
214905253|NCT02988128|DEVICE|Treatment for intracranial aneurysms|Embolization of aneurysms
214905254|NCT02988128|DEVICE|Treatment for Acute Ischemic Stroke|Revascularization of an intracranial blood vessel
214905255|NCT07055594|DRUG|SOA101|Participants will receive SOA101. The RP2D will be determined based on the results of the Phase I study. During the dose expansion phase, participants will receive SOA101 at the RP2D regimen.
214905256|NCT07057999|BEHAVIORAL|MIND Diet (Mediterranean-DASH Intervention for Neurodegenerative Delay)|The MIND diet consists of 15 components. While the first 10 of the components are considered healthy for the brain, the last 5 are considered unhealthy. The MIND diet portion and consumption frequency recommendations are as follows; olive oil consumption ≥ 48 g/day; oil seeds and nuts ≥ 5 servings/week; green leafy vegetables ≥1 serving/day; cooked vegetables ≥1 serving/day; whole grains ≥3 servings/day; legumes 3 servings/week; red fruits such as blueberries and strawberries ≥2 servings/week; poultry ≥2 servings/week; fish and seafood ≥1 serving week; red wine 1 glass/day; red meat ≤4 servings/week; butter ≤10 g/day; bakery products \<5 servings/week; fast food \<1 serving/week. Patients assigned to this group will be given a diet program based on isocaloric, MIND diet principles, which they will be asked to follow for 12 weeks.
214905257|NCT07057999|BEHAVIORAL|Traditional healthy nutrition program specific to Turkey|There are no prohibited foods in the traditional Türkiye-specific nutrition recommendations included in the TÜBER 2022 report, but there are foods that are recommended to be restricted or increased. According to the healthy nutrition program, 3 portions/day from the milk and dairy products (milk, yogurt, kefir, cheese) group; 2.5-3 portions/day from the meat, chicken, fish, eggs, legumes, oilseeds and nuts group; 2.5-4 portions/day from the vegetable group; 2-3 portions/day from the fruit group; 3-7 portions/day from the bread and cereal group; 3-4 portions/day from the fat group and finally, simple sugar consumption is recommended as a maximum of 10% of total energy. An isocaloric diet will be prepared according to the body composition and eating habits of the patients and they will be asked to follow it for 12 weeks.
214479294|NCT06605482|OTHER|Patient Reported Outcome Measures|Participants will complete the following outcome measures American Shoulder and Elbow Surgeons Evaluation Questionnaire - upper limb function score 12-Item Short Form Survey - general health questionnaire
214479295|NCT06605482|OTHER|Range of Motion|Shoulder and Elbow Range of Motion collected at the time of radiographic union
214905258|NCT04401215|BEHAVIORAL|Technology Augmented Treatment for Screening, Brief Intervention, Referral, and Treatment (SBIRT)|This group will answer to questions on the iPad at baseline visit and will receive up to 4 text messages per day asking about their Health and treatment during 30 days.
214905259|NCT06424197|OTHER|Racial group-targeted messages|Colorectal cancer screening messages targeted towards participants racial group.
214905260|NCT06424197|OTHER|Explicit Commitment|Indicate explicit commitment to return at home screening kit.
214905261|NCT06762873|DIAGNOSTIC_TEST|Drug Induced Sleep Endoscopy with PNS|Enrolled subjects will complete an overnight PSG and then undergo a DISE procedure with a 30-minute research period.
214905262|NCT01184430|DEVICE|Pulse contour cardiac output device|Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
215056600|NCT02595866|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214905269|NCT01597973|DRUG|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
215056601|NCT02595866|BIOLOGICAL|Pembrolizumab|Given IV
215056602|NCT02595866|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214479296|NCT06253234|BIOLOGICAL|personalized dendritic cell injection ZSNeo-DC1.1|Sequence A: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 3 weeks as a dosing cycle, a total of 6 dosing cycles Sequence B: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 2 weeks as a dosing cycle, a total of 6 dosing cycles
214905270|NCT01597973|DRUG|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
214905271|NCT00333294|DRUG|Gefitinib|
214905272|NCT00333294|PROCEDURE|Radiation therapy|
214905273|NCT00333294|DRUG|Cisplatin|
214905274|NCT00333294|DRUG|Vinorelbine|
214905275|NCT03499444|DRUG|Rucaparib|Rucaparib will be administered twice daily
214905276|NCT06058819|DIAGNOSTIC_TEST|Newborns suspected of Infections|This study will include NICU newborns of at least 7 days of life with suggestive signs of neonatal sepsis. The results will be extrapolated to this same population.
214905277|NCT07073794|DRUG|Cancer Therapeutic Procedure|Given standard of care cancer treatment in clinic
214905278|NCT07073794|DRUG|Cancer Therapeutic Procedure|Given standard of care cancer treatment in home
215056603|NCT03439644|OTHER|Measurement of the upper eyelid laxity|Measurement using a soft slider of the distance between our 2 marks The difference obtained between the measurement and the initial 10 millimeters corresponds to the tarsal laxity.
215056604|NCT01074476|DIETARY_SUPPLEMENT|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
215056605|NCT01074476|OTHER|Placebo|Placebo tablets, twice per day for 3 months
214905279|NCT07073794|OTHER|Health Care Delivery|Receive in home cancer treatment with CCBW
215056606|NCT00811291|DIETARY_SUPPLEMENT|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
215056607|NCT00811291|DIETARY_SUPPLEMENT|calcium|according to protocol
215056608|NCT04153695|OTHER|Music Therapy|to listen flamenco music during 30 minuts per day during 2 weeks
214302571|NCT06880159|DEVICE|tDCS with computerized cognitive training|Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes.
215056609|NCT05296551|OTHER|Motor Task|A visuomotor task is presented where an individual must match their knee to an ellipse that moves up and down on a screen, resulting in a marching-in-place motion at a specified frequency.
215056610|NCT05296551|OTHER|Cognitive-motor dual-task|"While performing the Motor Task intervention, letters of different colors and orientation randomly appear one at a time on the screen. During the Cognitive-motor dual-task, individuals are instructed to count the number of times that either 1 (simple cognitive task), or 2 (complex cognitive task) characters appear on the screen during the motor task."
214302572|NCT07043400|DRUG|Subcutaneous Tislelizumab|Administered by subcutaneous injection
214302573|NCT07043400|DRUG|Intravenous Tislelizumab|Administered by intravenous infusion
214302574|NCT07043400|DRUG|Cisplatin|Administered by intravenous infusion
214302575|NCT07043400|DRUG|Leucovorin|Administered by intravenous infusion
214302576|NCT07043400|DRUG|5-fluorouracil (5-FU)|Administered by intravenous infusion
214302577|NCT07043400|DRUG|Oxaliplatin|Administered by intravenous infusion
214302578|NCT07043400|DRUG|Capecitabine|Administered orally
214302579|NCT06888024|PROCEDURE|non-contrast enhanced abdomen and pelvis MRI|non-contrast enhanced abdomen and pelvis MRI
214302580|NCT06888453|DRUG|lozenges containing propolis|lozenges containing propolis Participants will be given the test interventions, lozenges containing propolis, and will be asked to chew twice per day and will be instructed to ordinary oral hygiene instruction, No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days
214302581|NCT06926634|DRUG|Zanzalintinib|Provided by Exelixis
214302582|NCT07047885|DRUG|Ropeginterferon alfa-2b|Will be administered via subcutaneous injection once every 2 weeks
214302583|NCT06728254|DEVICE|medication management|"The test system consists of:~* Linked care platform (backend) which provides a new possibility of data exchange for IT systems of caregivers, pharmacies, and GPs~* User interfaces for caregivers as well as for the systems myneva.carecenter and mynevaTOgo~* An extension of the user interface for GPs in their IT system (in the test only for the physician software PCPO by CompoGroup Medical )~* An extension of the user interface for pharmacists in their IT system (in the test only for pharmacies with software from Apothekerverlag)~Functionally, the solution should, coordinate the medication requirements between pharmacies, GPs, and caregivers (subarea medication)."
214302584|NCT06728254|OTHER|Usual Care Group|Usual care.
214302585|NCT03423628|RADIATION|Radiation Therapy|35 Gy of Intensity-modulated radiation therapy (IMRT) administered at daily fractions of 3.5 Gy over 10 fractions (2 weeks)
214302586|NCT03423628|DRUG|AZD1390|"AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0: 1 dose prior to Radiation Therapy. Cycle 1: 2 weeks Intermittent or continuous dosing during Radiation Therapy. Cycle 2: 2 weeks adjuvant treatment after Radiation Therapy. For optional food effect assessment in Arm A, 2 doses prior to RT under both fed and fasted conditions. Note: the food effect assessment is currently open to recruitment.~Arm A includes the Japan part following the same dosing administration."
214302587|NCT03423628|RADIATION|Radiation Therapy|30 Gy of whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT) administered at daily fractions of 3 Gy over 10 fractions (2 weeks).
214302588|NCT03423628|RADIATION|Radiation Therapy|60 Gy of intensity- modulated radiation therapy (IMRT) administered at daily fractions of 2 Gy over 30 fractions (6 weeks)
214302589|NCT03423628|DRUG|AZD1390|AZD1390 administered in 1 Cycle. AZD1390 administration concomitantly with RT (2 weeks). Cycle 1 also contains an additional 5 days (post completion of RT with AZD1390 administration). Arm is Closed.
214302590|NCT03423628|DRUG|AZD1390|"AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0: 1 dose prior to Radiation Therapy. Cycle 1: 6 weeks Intermittent or continuous dosing during Radiation Therapy. Cycle 2: 2 weeks adjuvant treatment after Radiation Therapy. Arm is closed."
214302591|NCT06742385|DEVICE|MedicWise|"* Both arms are equipped with the application, data are collected via the application and telemonitoring with alerts to the care team are activated in the active telemonitoring arm.~* Data are collected in both arms at baseline, M3, M6, M9 and M12~* Each center defines who handles alerts internally (physicians, IBD nurses, others, etc.) according to its internal organization. The application does not impose an internal operation.~* the alert thresholds are identical and fixed for all centers during the study. Within the framework of the study, alerts are defined according to the study's modalities but cannot be modified by the centers.~* Participating sites will have no obligation to respond to alerts.~* Randomization will be stratified by centers and by diseases (Crohn and UC) with unbalanced blocks of randomization"
214479297|NCT06605586|DRUG|Tasquinimod|treatment with tasquinimod capsules once daily
214905280|NCT07073794|OTHER|Questionnaire Administration|Ancillary studies
214905281|NCT06391775|BIOLOGICAL|GEN1055|Intravenous (IV) administration.
214905282|NCT06391775|BIOLOGICAL|Pembrolizumab|IV administration
214905283|NCT06391775|DRUG|Standard Chemotherapy|IV administration
214905284|NCT05491317|BIOLOGICAL|GEN1042|Intravenous
214905285|NCT05491317|DRUG|Pembrolizumab|Intravenous
214905286|NCT05491317|RADIATION|Radiotherapy|Radiotherapy
214905287|NCT05689164|BIOLOGICAL|fordadistrogene movaparvovec|gene therapy administered in a previous study.
214905288|NCT03878095|PROCEDURE|Biopsy Procedure|Undergo tumor biopsies
214905289|NCT03878095|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214905290|NCT03878095|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214905291|NCT03878095|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214905292|NCT03878095|DRUG|Ceralasertib|Given PO
215056611|NCT03964168|DRUG|Biologic Agent|Patients who discontinued a bioloic agent
214905293|NCT03878095|PROCEDURE|Computed Tomography|Undergo CT scans
214905294|NCT03878095|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
214905295|NCT03878095|DRUG|Olaparib|Given PO
214905296|NCT06560463|DEVICE|Access to Dexcom G7 CGM Data|Eligible patients will undergo Continuous Glucose Monitoring using the Dexcom G7
214905297|NCT06065098|BEHAVIORAL|Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension, diabetes, and hypercholesterolemia.
214905298|NCT03854474|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214905299|NCT03854474|PROCEDURE|Computed Tomography|Undergo CT
214905300|NCT03854474|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214905301|NCT03854474|BIOLOGICAL|Pembrolizumab|Given IV
214905302|NCT03854474|DRUG|Tazemetostat|Given PO
214905303|NCT05894239|DRUG|Inavolisib|Participants will receive an inavolisib tablet to be taken orally (PO), once a day (QD), on Days 1-21 of each 21-day cycle, beginning on Day (D) 1 of Cycle (C) 1 of maintenance treatment.
214302592|NCT06894420|PROCEDURE|Surgeon-Initiated Local Anesthetic|In laparoscopic hernia repairs, patients are positioned supine, and the surgical area is cleansed with povidone iodine and covered with sterile green drapes. A 1-centimeter incision will be made 1 centimeter below the umbilical border. A 10-mm trocar will be inserted into the preperitoneal space. The operation was filmed from the front with a 30-degree camera. After observing the preperitoneal space, two five-mm working trocars will be placed midline, two and six centimeters inferior to the symphysis pubis. Next, the cord structures and Cooper ligament will be exposed and the hernia sac freed from surrounding anatomical structures.Prolene mesh will be spread over the preperitoneal area to cover all hernia defects and secured to the Cooper ligament and abdominal wall with an absorbable fixation device. Group 1 patients undergo desufflation via 50 mg of bupivacaine into the preperitoneal space, followed by 10 mg of bupivacaine into each trocar incision and skin closure with sutures.
214905304|NCT05894239|DRUG|Phesgo|Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
214905305|NCT05894239|DRUG|Placebo|Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.
214905306|NCT05894239|DRUG|Taxane-based Chemotherapy|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy will be administered after Phesgo.
214905307|NCT05894239|DRUG|Optional Endocrine Therapy of Investigator's Choice|Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI \[anastrozole, letrozole, or exemestane\]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
214905308|NCT00809562|DRUG|Placebo|po daily for 10 days
214905309|NCT00809562|DRUG|RO4917523|orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
214905310|NCT02208362|BIOLOGICAL|Arm 1: IL13Ra2-specific CAR Tcm cells|Given via intratumoral catheter
214905311|NCT02208362|BIOLOGICAL|Arm 2: IL13Ra2-specific CAR Tcm cells|Given via intratumoral/intracavitary catheter
214905312|NCT02208362|BIOLOGICAL|Arm 3: IL13Ra2-specific CAR Tcm cells|Given via intraventricular catheter
214905313|NCT02208362|BIOLOGICAL|Arm 4: IL13Ra2-specific CAR Tcm cells|Given via intratumoral or intracavitary, and via intraventricular catheter
214905314|NCT02208362|BIOLOGICAL|Arm 5: IL13Ra2-specific CAR Tn/mem cells|Given via intratumoral or intracavitary, and via intraventricular catheter
214905315|NCT02208362|OTHER|Laboratory Biomarker Analysis|Correlative studies
214905316|NCT02208362|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
214905317|NCT02208362|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Correlative studies
214905318|NCT02208362|OTHER|Quality-of-Life Assessment|Ancillary studies
214905319|NCT07077174|OTHER|Permissive lung-protective ventilation|The goal is to achieve the lowest possible respiratory rate (RR) according to a guideline in which the target RR is estimated by combining the baseline RR with the results of arterial blood gas analysis (ABG), determined by the highest acceptable partial pressure of carbon dioxide (PaCO2) of ≤ 8.5 kPa (64 mmHg) but limited by the lowest acceptable arterial pH (pHa) of \> 7.20. The RR is gradually decreased, in steps of 2 breaths every 10 minutes, based on continuous end-tidal CO2 monitoring. To ensure that the pHa does not fall below 7.20, following randomization, ABGs are repeated every hour until the target RR is reached, for at least 6 hours. Thereafter, blood gas analyses are repeated at least every 8 hours (at the start of every nursing shift). Down-titration of RR stops at a rate of 4 breaths per minute. This approach continues until the switch to spontaneous breathing. Of note, when the pHa is \> 7.50, this must first be decreased to ≤ 7.50 based on local protocol.
215056612|NCT00062491|DRUG|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
215056613|NCT03672812|DRUG|Liraglutide|liraglutide 3mg 6/6 hours
215056614|NCT02455102|OTHER|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
215056615|NCT02021890|BEHAVIORAL|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
215056616|NCT02021890|BEHAVIORAL|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
215056617|NCT01744067|DRUG|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
215056618|NCT01744067|DRUG|Placebo|Placebo capsules 3 times a day (oral administration)
215056619|NCT06482775|DRUG|dexmedetomidine|The dosing and administration will be implemented according to an algorithm based on pain scoring results
214905320|NCT07077174|OTHER|Conventional lung-protective ventilation|Following randomization, which should happen within 1 hour after start of ventilation in the ICU, the RR is set according to standard of care, based on continuous end-tidal CO2 monitoring, to target a normal PaCO2 (4.7-6.4 kPa or 35-48 mmHg) combined with a pHa within the range of 7.35 to 7.45. Following randomization, blood gas analyses are repeated every hour for at least 6 hours, and thereafter at least every 8 hours (at the start of every nursing shift). This approach continues until the weaning phase.
214905321|NCT00435331|DRUG|sapropterin dihydrochloride (6R-BH4)|2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
214905322|NCT06903793|OTHER|cervical manipulation|Cervical upglide/rotation manipulation targeted to C5/C6 on the dominant shoulder side
214905323|NCT07111429|DIAGNOSTIC_TEST|Novel severity grading system of stoma-related complication in cancer patients|Over 5000 stoma patients treated at 26 centers between 2022 and 2023 were classified according to SITI-CD Classification.
214905324|NCT07113080|DRUG|lavender essential oil inhaled using face mask|participants will inhale lavender essential oil via nebulizer before local anesthesia administration
214905325|NCT07113080|DRUG|lemongrass essential oil inhaled using face mask|participants will inhale lemongrass essential oil via nebulizer before the local anesthesia administration
214905326|NCT07111780|OTHER|"Coordinative-Based Physical Activity Practices training group"|In the first session, participants were asked to fill in an information form, including demographic information. They were asked to complete the Brunel Mood Scale and the International Physical Activity Questionnaire (IPAQ). participants' height and body weight were measured. Participants' height was measured with a portable statiometer. Body weight was measured with a digital scale witha precision of 0.1 kg. In the second session, Go/No-Go and mental rotation tests, which are used to evaluate the cognitive functions of the participants, were administered to the participants. The KTK3+ motor competence test was used to determine the motor competence of the participants.The tests were administered to the participants in the same order and by the same researchers. Before the assessment of KTK3+ test of 5 minutes of running and 5 minutes of dynamic stretching was performed. Coordination-based physical activity applied to the exercise group continued for 25-30 minutes twice for 8 weeks.
214669841|NCT06970600|DRUG|Artemether-lumefantrine (Coartem)|Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure. Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication. Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. To differentiate recrudescence from new infection by polymerase chain reaction (PCR) analysis.The Molecular markers associated with suboptimal response to ACTs will be investigated.
214905327|NCT07112690|OTHER|Electronic Health Record Review|Ancillary studies
214905328|NCT07112690|PROCEDURE|Fluoroscopy|Undergo fluoroscopy
214905329|NCT07112690|PROCEDURE|Ganglion Impar Neurolysis|Undergo ganglion impar neurolysis
214905330|NCT07112690|OTHER|Questionnaire Administration|Ancillary studies
214905331|NCT07111273|DIAGNOSTIC_TEST|FC and FIT TEST at WEEK0 2 4|FC and FIT TEST at WEEK0 2 4
214905332|NCT07111351|OTHER|Without intervention|Without intervention
214905333|NCT06512935|OTHER|Increase in the PEEP followed by decrease in the PEEP|Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
214905334|NCT06512935|OTHER|Decrease in the PEEP followed by increase in the PEEP|Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
214905335|NCT06002009|RADIATION|MRI|MRI of shoulder
214905336|NCT06002009|OTHER|Nerve conduction study|Nerve conduction study
214905337|NCT06508710|DRUG|Ketamine|Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
214905338|NCT06508710|DRUG|Placebo|Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
214905339|NCT05652153|OTHER|Single-/paired-pulse transcranial magnetic stimulation|Single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) is a technique for noninvasive assessment of brain physiology by delivering single or paired magnetic stimuli to the scalp with an electromagnetic coil. This results in transient induction of cortical electrical activity, which can be measured as evoked potentials by electromyography (EMG) and electroencephalography (EEG). Note that sp/ppTMS is used for neurophysiologic measurements; it is distinct from other TMS applications such as repetitive TMS, which can be used as interventions.
214905340|NCT06939972|DIETARY_SUPPLEMENT|Topical Analgesic with Camphor and Menthol|Participants will apply the product directly to the lower abdomen or back during menstrual cycles, following specific application instructions. The product provides analgesic and cooling effects to reduce discomfort.
214905341|NCT05759182|DEVICE|Powered Exoskeleton Gait Training|A trained medical professional will adjust the exoskeleton to fit each participant and tailor the program(sit to stand, stand to sit, standing balance and weight shift, walk in place, walk forward) according to their physical condition and specific needs. Based on each participant's walking ability, appropriate safety devices (such as crutches, canes, or a harness) will be used during the intervention.
215056620|NCT03150290|OTHER|Indirect Calorimetry.|REE measurement
215056621|NCT03150290|DEVICE|18-FDG-PET|18-FDG-PET
215056622|NCT05645796|OTHER|Adopted contrast media amount by using different approaches|Using different contrast media approaches recommended by literature to explore the impact on the contrast enhancement in chest CT
215056623|NCT02466035|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
215056624|NCT02520388|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
215056625|NCT02520388|DRUG|Placebo|
215056626|NCT04839250|PROCEDURE|heads-up method|3D surgical video system, which includes Alcon NGENUITY 3D visualization system (Alcon, Fort Worth, TX) and Leica M822 and M844 microscopes (Leica Microsystems, Wetzlar, Germany),can be used to perform head-up phacoemulsification combined with intraocular lens implantation surgery.
214905342|NCT03967522|DRUG|Cabozantinib|All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
214905343|NCT03008642|OTHER|CO-Rebreathing technique at diagnosis of polycythemia|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
214905344|NCT04442971|BEHAVIORAL|Music Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to their preferred music.
214905345|NCT04442971|BEHAVIORAL|Alternative Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to an audio book.
214905346|NCT04442971|BEHAVIORAL|No Auditory Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and hear silence.
214669842|NCT05593432|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214905347|NCT06519149|DEVICE|Slow Wave UASD|An oral appliance for the treatment of OSA and snoring
214905348|NCT05597943|BEHAVIORAL|Malama App|The Malama smartphone application is a gestational diabetes management app that syncs directly with commercially-available glucometers via Bluetooth, enabling both automatic blood glucose logging and providing interactive diet management/diet education tools. We aim to perform a pilot study assessing the impact of the Malama smartphone application on perinatal and postpartum outcomes in patients with GDM.
214905349|NCT01536808|OTHER|Cardiac RMI|Cardiac RMI
214905350|NCT01536808|OTHER|Analysis telomere|Analysis telomere
214905351|NCT01536808|OTHER|Stress test|Stress test
214905352|NCT01536808|OTHER|echocardiography|echocardiography
214905353|NCT06527365|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
214905354|NCT02742506|OTHER|Electroencephalography (EEG)|EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
214905355|NCT04214262|DRUG|Atezolizumab|Given IV
214905356|NCT04214262|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214905357|NCT04214262|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214905358|NCT04214262|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
214669843|NCT05593432|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
214905359|NCT04214262|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214905360|NCT04214262|OTHER|Quality-of-Life Assessment|Ancillary studies
214905361|NCT04214262|OTHER|Questionnaire Administration|Ancillary studies
214905362|NCT04214262|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214669844|NCT03476850|PROCEDURE|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
214669845|NCT03476850|PROCEDURE|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
214669846|NCT00152256|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for 6 months
214669847|NCT00152256|DRUG|Asoprisnil|Asoprisnil 25mg Tablet, oral Daily for 6 months
214905363|NCT06514495|OTHER|Therapy|Cognitive behavioral psychotherapy with exposure
214905364|NCT05419375|OTHER|Screening platform|The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing.
214905365|NCT02978625|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214905366|NCT02978625|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214905367|NCT02978625|PROCEDURE|Computed Tomography|Undergo CT
214905368|NCT02978625|OTHER|Laboratory Biomarker Analysis|Correlative studies
214669848|NCT00152256|DRUG|Placebo|Placebo Tablet, oral Daily for 6 months
214905369|NCT02978625|BIOLOGICAL|Nivolumab|Given IV
214905370|NCT02978625|PROCEDURE|Positron Emission Mammography|Undergo PET/CT
214905371|NCT02978625|BIOLOGICAL|Talimogene Laherparepvec|Given IT
214905372|NCT05773404|OTHER|Passive Neurodynamics and Passive axial hip mobilisation/distraction|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles.
214905373|NCT05773404|OTHER|Active therapy|Active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves
214905374|NCT05773404|OTHER|2.5.3. Combined therapy|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles and active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves.
214905375|NCT05579366|DRUG|Rina-S|Intravenous infusion of Rina-S
214905376|NCT05579366|DRUG|Carboplatin|Carboplatin intravenous infusion
214905377|NCT05579366|DRUG|Bevacizumab|Bevacizumab intravenous infusion
214905378|NCT05579366|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion
214905379|NCT06682871|PROCEDURE|Analgesia|Postoperatively, patients will be given analgesia
214905380|NCT03917381|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).
214905381|NCT03917381|BIOLOGICAL|Acasunlimab in combination with docetaxel (in a single expansion cohort)|Acasunlimab and docetaxel will be administered intravenously once every 21 days.
214905382|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)|Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.
215056627|NCT02860234|DRUG|Oxaliplatin|
215056628|NCT02860234|DRUG|Capecitabine|
215056629|NCT02860234|RADIATION|intensity modulated radiotherapy|
215056630|NCT02860234|PROCEDURE|DRE-Endoscopy-MRI-CEA|
215056631|NCT02860234|PROCEDURE|Nonoperative Management|
215056632|NCT02860234|PROCEDURE|Local Excision|
215056633|NCT02860234|PROCEDURE|Total Mesorectal Excision|
214905383|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)|Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.
214302593|NCT06894420|PROCEDURE|Transversus abdominis plane (TAP) block|After the surgery, the anesthesiologist will use a TAP block under ultrasound guidance. Before the patient wakes up, the Hitachi ultrasound probe will be sterilized and positioned between the iliac wing and the costae. An ultrasound shows the skin, fat beneath it, the six abdominal muscle layers, and a support muscle.A thin needle goes through the skin from one side to the other to reach the muscle layers. The location of the block is confirmed by injecting 1-2 ml of 0.09% NaCl followed by negative aspiration. Patients receive 15-20 ml (40-50 mg per quadrant) of bupivacaine 0.5% concentration in a controlled manner with negative aspiration every 5 ml. The block is performed bilaterally.
214302594|NCT07054931|BIOLOGICAL|ChAdOx1.tHIVconsv1|solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
214302595|NCT07054931|BIOLOGICAL|ChAdOx1.HIVconsv62|solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
214905384|NCT05599581|BEHAVIORAL|Tu'Washindi|"Tu'Washindi consists of 3 primary components:~1. PrEP Adherence Support Clubs: Eight 2-hour sessions that occur over the intervention period: twice per month for the first 2 months \& once per month for the remaining 4 months. Sessions will use structured \& unstructured activities designed to improve outcomes expectations, increase self-efficacy to use PrEP safely \& consistently, increase peer support for PrEP use, provide access to community IPV resources \& provide skills for healthy communication \& PrEP disclosure with male partners.~2. Community Male Sensitization conducted weekly over the first 3 months of the intervention period aimed to increase PrEP knowledge, reduce stigma, \& promote healthy relationship communication.~3. Buddy Days, which take place 3 months into the intervention period, designed to bring participants \& their male partners together to learn about PrEP, discuss community attitudes \& concerns regarding PrEP use, \& promote HIV prevention \& family well-being."
214905385|NCT04281485|GENETIC|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 1 for Cohort 1.
215056634|NCT02860234|BEHAVIORAL|Quality of Life Questionnaires|
215056635|NCT01415297|DRUG|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
214302596|NCT07054931|BIOLOGICAL|MVA.tHIVconsv4|suspension for injection two doses of 1 x 10\^8 vpu/ml Arm B and Arm C
215056636|NCT02445105|BEHAVIORAL|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
215056637|NCT02445105|BEHAVIORAL|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
215056638|NCT02919891|OTHER|Questionnaire|Questionnaires
215056639|NCT02592278|DRUG|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
215056640|NCT02592278|DRUG|Control Group|Twice a day brush with fluoride toothpaste.
215056641|NCT04326218|OTHER|Blood sample|"Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~* anti-PLA2R1 and anti-THSD7A antibodies~* anti-PLA2R1 and anti-THSD7A epitopes~* HLA typing"
215056642|NCT01480726|PROCEDURE|Surgery|
214302597|NCT07054931|BIOLOGICAL|GS-5423|Solution for infusion 2550 mg Arm A, Arm B and Arm C
214302598|NCT07054931|BIOLOGICAL|GS-2872|Solution for infusion 850 mg Arm A, Arm B and Arm C
214905386|NCT04281485|OTHER|Placebo|Placebo will be administered as a single IV infusion at Year 1 for Cohort 2.
214905387|NCT04281485|OTHER|Placebo|Placebo will be administered as a single IV infusion at Year 2 for Cohort 1.
214905388|NCT04281485|GENETIC|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 2 for Cohort 2
215056643|NCT06405165|OTHER|student success|The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.
215056644|NCT01288157|DRUG|Golimumab|Single dose of 100 mg subcutaneously
215056645|NCT01288157|DRUG|Golimumab|Single dose of 50 mg subcutaneously
215056646|NCT03345303|DRUG|Bortezomib|Bortezomib Injectable Solution
214302599|NCT07054931|OTHER|Treatment interruption induced viraemia|Participants pause ART before receiving vaccines and/or bNAbs Arm A and Arm C
215056647|NCT05196750|OTHER|Behavioural questionnaires and assessments on mother and child|Questionnaires include, but not limited to, State Trait Anxiety Inventory, Beck Depression Inventory, LYNDON Maternal Health and Well Being, Facial Imitation Task, Deferred Imitation, Habituation, Relational Binding, Behavioural Observation, Mirror Self Recognition, Standardized Assessment and Experimental Task, Snack and Sticker Delay, Implicit Attitude Test
215056648|NCT01232127|DRUG|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
215056649|NCT01232127|DRUG|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
215056650|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
215056651|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
215056652|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
215056653|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
215056654|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
215056655|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
215056656|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
215056657|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
214302600|NCT05964829|DEVICE|Cionic Neural Sleeve NS-100|The Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks.
214669849|NCT03411070|DEVICE|Implanted Medical Device|Undergo SCOUT reflector placement
214905389|NCT06057038|BIOLOGICAL|GEN1042|Intravenous
214905390|NCT06057038|DRUG|Pembrolizumab|Intravenous
214905391|NCT06057038|DRUG|Cisplatin|Intravenous
214905392|NCT06057038|DRUG|Carboplatin|Intravenous
214905393|NCT06057038|DRUG|5-Fluorouracil|Intravenous
214905394|NCT06169449|BEHAVIORAL|Weight management--diet|The diet structure adopts an energy-limited balanced diet. In this structure, the total daily energy intake is reduced by 500\~1000 kcal based on the target energy intake; however, the balance is maintained for the energy supply ratio of the three major nutrients (with carbohydrate, protein, and fat accounting for 55\~60%, 10\~20%, and 15\~30% of the total daily energy, respectively). Combined with the patient's eating habits, the food exchange portion method is used as a guide; each portion providing 90 kcal is considered as one portion. Specific recipes are formulated after calculating the ideal weight and the total daily calorie intake based on activity intensity, determining the number of six food exchange portions and the distribution of three meals according to the total calorie and diet structure, and combining the equivalent food exchange table based on individual tastes and preferences; this ensures patient acceptability and implementation.
214905395|NCT06169449|BEHAVIORAL|Weight management--exercise|Exercise goals are divided into four levels based on individual health conditions and personal preferences; these include: cultivating exercise habits, improving cardiopulmonary function, enhancing muscle strength, and improving flexibility. Individualized exercise prescriptions that specify the exercise type, intensity, time, and frequency are formulated.
214905396|NCT06169449|BEHAVIORAL|Weight management--accompany|This component involves the inclusion of patients in online management. Online groups are established, daily feedback is obtained regarding weight management implementation, self-sharing is encouraged, and peer support is established; a total of 6 sessions of online health education are provided once every 4 weeks for 20-60 minutes at each session. This includes information regarding the risks associated with overweightness and obesity; weight management benefits; knowledge regarding diet and nutrition, exercise and sports, and behavioral styles; and problem exchange and sharing, among others. Professional support is provided by weekly communication with patients one-on one via WeChat or telephonic conversations. The patient's diet and exercise record sheet are checked, patients are asked questions regarding implementation of the current program and any discomfort or difficulties; corresponding guidance is provided as appropriate.
214905397|NCT06169449|BEHAVIORAL|Weight management--refresh|According to the dietary nutrition guidelines for Chinese residents, patients are advised to drink 2500 ml or more of water daily; they are also advised to work and rest regularly to ensure sufficient sleep time, ensure smooth bowel movements, take deep breaths when waking up in the morning, pay attention to the work-rest balance, avoid being sedentary, and stand up and move around at least once every 50 minutes, maintain physical vitality by adjusting daily living habits.
214905398|NCT06169449|BEHAVIORAL|Control group|The relationship between overweightness and obesity and endometrial cancer risk was explained to patients in the control group and their willingness for self-weight management was respected. Communication was maintained with patients from treatment initiation to 3 and 6 months after treatment; patients' questions regarding weight reduction were answered and suggestions were provided regarding nutrition, exercise, and lifestyle management.
215056658|NCT02339805|OTHER|next generation sequencing|DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
214905399|NCT06463782|DRUG|68Ga-LNC1007 Injection|The participant will receive a single intravenous injection with 0.05 mCi/kg (according to the participants' body weight) 68Ga-LNC1007 Injection on the scan bed. The final dose of the drug is allowed to fluctuate within the 20% range, but not below 3 mCi. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
214905400|NCT06355531|DRUG|FNP-223|Oral tablets
214905401|NCT06355531|DRUG|Placebo|Oral tablets
214905402|NCT03984448|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214905403|NCT03984448|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214905404|NCT03984448|PROCEDURE|Computed Tomography|Undergo CT scan
214905405|NCT03984448|DRUG|Cyclophosphamide|Given IV
214905406|NCT03984448|DRUG|Doxorubicin Hydrochloride|Given IV
214905407|NCT03984448|DRUG|Etoposide|Given IV
215056659|NCT02339805|DEVICE|Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|tumor Assessment tool during the study
214905408|NCT03984448|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214905409|NCT03984448|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214669850|NCT03411070|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214905410|NCT03984448|DRUG|Prednisone|Given PO
214905411|NCT03984448|BIOLOGICAL|Rituximab|Given IV
214905412|NCT03984448|DRUG|Venetoclax|Given PO
214905413|NCT03984448|DRUG|Vincristine Sulfate|Given IV
214905414|NCT00152061|DRUG|3TC and FTC|
214669851|NCT06969755|DRUG|aripiprazole|aripiprazole arm (titrated dose)
214669852|NCT06969755|DRUG|risperidone|risperidone arm (titrated dose)
214669853|NCT06969755|DRUG|clozapine|clozapine (titrated dose)
214669854|NCT05574153|DIAGNOSTIC_TEST|Cardiac MRI|Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
214905415|NCT00001298|DRUG|carboxypeptidase-G2|
214905416|NCT00127231|BEHAVIORAL|Brief alcohol intervention based on Project Treat|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
215056660|NCT02171143|DRUG|ASP2409|intravenous (IV)
215056661|NCT02171143|DRUG|Placebo|intravenous (IV)
215056662|NCT03563482|DIAGNOSTIC_TEST|PET scan|Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
215056663|NCT03506412|DRUG|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
215056664|NCT06220877|PROCEDURE|Buccal Pad of Fat|surgical procedure
215056665|NCT06220877|PROCEDURE|A-PRF|blood sample
214302601|NCT05964829|BEHAVIORAL|Walking Program|15 minutes of walking for 5 days per week for 6 weeks
214905417|NCT00127231|BEHAVIORAL|Standard care|Hazardous/binge female drinkers will be identified in the Johns Hopkins Hospital HIV clinic and will be randomized to brief intervention or standard care. Outcome measures will include: alcohol/drug use, engagement in an on-site alcohol support group and other substance abuse treatment services, HIV-risk behaviors, HIV disease markers and treatment compliance, and psychiatric symptoms.
214905418|NCT02284074|OTHER|Nasal LPS spray|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
214905419|NCT02284074|OTHER|Experimental: Nasal LPS spray 1µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
214905420|NCT02284074|OTHER|Experimental: Nasal LPS spray 10 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
214905421|NCT02284074|OTHER|Experimental: Nasal LPS spray 30 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
214905422|NCT02284074|OTHER|Experimental: Nasal LPS spray 100 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
214905423|NCT02029066|DRUG|SR-T100 gel|2g of SR-T100 will topical apply on 100 cm\^2 once for 24 hours.
214905424|NCT01817868|OTHER|Recombinant Factor VIII (Kogenate, BAY14-2222)|All dosage, frequency and duration for drugs will be under the decision of the treating physician.
214905425|NCT05884385|OTHER|Simulated exercises|as detailed in arm description
214905426|NCT05884385|OTHER|Mental Visualisation|as detailed in arm description
214905427|NCT00010335|PROCEDURE|Stem Cell Transplantation|Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.
214905428|NCT00010335|DEVICE|CD34 selection|CD34+ cells are separated from the rest of the peripheral blood stem cells.
214905429|NCT05472025|OTHER||
214905430|NCT01997788|DRUG|The intrathecal morphine injection|A single injection of morphine intrathecally
214905431|NCT01997788|DRUG|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
214905432|NCT01997788|DRUG|Demerol on demand|Demerol 25 mg intravenously when pain scores more than 5.
214905433|NCT05727839|DRUG|JCXH-211 Injection|JCXH-211 administered once every 28 days
214905434|NCT03205722|OTHER|Non-Interventional|Non-Interventional
214905435|NCT00083382|DRUG|Pamidronate|Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
214905436|NCT00083382|DRUG|Thalidomide|"All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.~Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)"
214905437|NCT00083382|DRUG|Zometa|Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
214905438|NCT02852135|DEVICE|LMA Proseal|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium,LMA Proseal was inserted and cuff inflated in each group.
214905439|NCT02852135|DEVICE|LMA Supreme|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium ，LMA Supreme was inserted and cuff inflated in each group.
214905440|NCT05995574|BEHAVIORAL|avatar communication training|Avatar simulates a mother and a daughter for the pediatrician to practice communication about contraception.
214905441|NCT00959114|BIOLOGICAL|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
214905442|NCT00959114|BIOLOGICAL|ALV003 placebo|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
214905443|NCT00578019|PROCEDURE|IM Nailing|Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith \& Nephew supracondylar nail.
214905444|NCT00578019|PROCEDURE|LISS|Group B patients will have their fracture stabilized with the LISS plates (Synthes \[USA\], Paoli, PA, USA).
214905445|NCT05650684|OTHER|data collection|continuation of exclusive breastfeeding until the post-natal visit (6 to 8 weeks after birth)
214905446|NCT03779217|OTHER|screening mammography|As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.
214905447|NCT03779217|PROCEDURE|mastoplasty and breast fat excission|As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.
214905448|NCT00975117|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) twice a day, for 12 weeks.
214905449|NCT00975117|DIETARY_SUPPLEMENT|Spermotrend|One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
214905450|NCT02393950|DRUG|ODM-106|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
214905451|NCT02393950|DRUG|Placebo|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
214905452|NCT03775265|DRUG|Atezolizumab|Given IV
214905453|NCT03775265|PROCEDURE|Biopsy of Bladder|Undergo a bladder biopsy
214905454|NCT03775265|DRUG|Cisplatin|Given IV
214905455|NCT03775265|PROCEDURE|Computed Tomography|Undergo CT or MRI
214905456|NCT03775265|PROCEDURE|Cystoscopy|Undergo a cystoscopy
214905457|NCT03775265|DRUG|Fluorouracil|Given IV
214905458|NCT03775265|DRUG|Gemcitabine|Given IV
214905459|NCT03775265|PROCEDURE|Magnetic Resonance Imaging|Undergo CT or MRI
215056666|NCT06220877|PROCEDURE|fibrin glue|procedure
215056667|NCT06220877|PROCEDURE|oxidized cellulose|procedure
215056668|NCT03680196|DRUG|medication Botulinum A injection.|In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
215056669|NCT05466552|PROCEDURE|PCI procedure|During the PCI procedure, use of ECMO/Impella 5.0 is allowed hemodynamic instability (bail- out).
215056670|NCT01176617|DEVICE|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
215056671|NCT03305952|BEHAVIORAL|CBCT|
215056672|NCT03305952|OTHER|TAU|
215056673|NCT04809493|PROCEDURE|Conventional dialysis treatment|Conventional dialysis treatment
215056674|NCT04809493|PROCEDURE|Isonatremic dialysis treatment|Isonatremic dialysis treatment
214302602|NCT07055282|DRUG|Empagliflozin (Jardiance®)|Empagliflozin (Jardiance®), 10 mg tablet taken orally once daily for 4 weeks. Dispensed at baseline by the Investigational Drug Service. It will be administered at home by participants.
214302603|NCT05478252|DRUG|Semaglutide J|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
214302604|NCT05478252|DRUG|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
214302605|NCT06746805|DIETARY_SUPPLEMENT|CHO+KETONE|Sports drink containing glucose and ketone mono-esters
214302606|NCT06746805|DIETARY_SUPPLEMENT|CHO+PLACEBO|Sports drink containing glucose and placebo
214302607|NCT06892509|BEHAVIORAL|mindfulness-based stress reduction program|In this study, Mindfulness-Based Stress Reduction Programme will be applied to the women to be included in the experimental group as a nursing intervention. For this programme, the researchers participated in the Mindfulness-Based Stress Reduction Programme consisting of eight internationally validated modules consisting of eight sessions given by Tera Consultancy and completed the training. The certificates of the researchers are given in the appendices. The experimental group will receive a mindfulness-based stress reduction programme for a total of eight weeks, 2-1.5 hours per week. The mindfulness programme usually lasts eight weeks because it has been reported that this is an effective period of time to produce noticeable changes in brain structure, stress levels, emotional regulation and general well-being.
214302608|NCT06745661|DEVICE|RLRL device|Each participant in the intervention group will be provided a repeated low-level red-light therapy (RLRL) device, which they are required to use twice daily for 3 minutes per session, with a minimum interval of 4 hours between sessions, 7 days a week for one month.
214302609|NCT06745661|DEVICE|sham device|Each participant in the sham group will be provided a sham therapy device, which they are required to use twice daily for 3 minutes per session, with a minimum interval of 4 hours between sessions, 7 days a week for one month.
214302610|NCT07059962|DEVICE|Bodyport Cardiac Scale|The Bodyport Cardiac Scale captures several physiological signals, which are used to derive multiple biomarkers that reflect a user's hemodynamic and fluid status.
215056675|NCT03035864|DRUG|rhNGF|Eye Drop 20 μg/mL
215056676|NCT03035864|OTHER|Vehicle|Vehicle Eye Drop
215056677|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Screening-2002|Nutritional Risk Screening-2002
214302611|NCT04601740|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
214302612|NCT02928289|DEVICE|VISCO360 ab interno canaloplasty surgery|360 degrees of viscodilation of Schlemm's canal
214302613|NCT02928289|DEVICE|Selective Laser Trabeculoplasty (SLT)|360 degrees of selective laser trabeculoplasty
214302614|NCT05782907|DRUG|Upadacitinib|Oral Solution/ Tablets
214302615|NCT06796907|DRUG|GSK5733584|GSK5733584 will be administered intravenously (IV).
214905460|NCT03775265|DRUG|Mitomycin|Given IV
214905461|NCT03775265|OTHER|Quality-of-Life Assessment|Ancillary studies
214905462|NCT03775265|RADIATION|Radiation Therapy|Undergo 3DCRT or IMRT
214905463|NCT03775265|OTHER|Survey Administration|Ancillary studies
214905464|NCT03775265|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo a TURBT
214905465|NCT04335123|DRUG|Losartan|25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion
214905466|NCT05079945|PROCEDURE|Spinal cord Tractography in order to differentiate spinal tracts.|Spinal cord tractography using DTI MRI sequences of the brain and spinal cord, in order to differentiate tracts at the spinal cord level; and by performing a stitching process between Brain and Spinal cord DTI sequences.
215056678|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Index|Nutritional Risk Index
215056679|NCT05417672|DIAGNOSTIC_TEST|Mini Nutritional Assessment|Mini Nutritional Assessment
215056680|NCT05417672|DIAGNOSTIC_TEST|Glasgow Prognostic Score|Glasgow Prognostic Score
215056681|NCT05417672|DIAGNOSTIC_TEST|Prognostic Nutritional Index|Prognostic Nutritional Index
215056682|NCT05417672|DIAGNOSTIC_TEST|Anthropometric measurements|middle arm circumference
215056683|NCT05417672|DEVICE|Handgrip strength test|Handgrip strength test
214905467|NCT01643577|PROCEDURE|Acupuncture for gastroparesis|A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
214905468|NCT01643577|PROCEDURE|Acupuncture for musculoskeletal pain|Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
214905469|NCT02506868|DRUG|Darbepoetin alfa|Weekly sc administration of darbepoetin alfa
214905470|NCT00076726|DRUG|Infliximab|
214905471|NCT05029791|OTHER|Tumor biopsy|2 cutaneous tumor biopsies before treatment initiation (D-28 to D-1) and under treatment (Month 1)
214302616|NCT06796907|DRUG|Anticancer therapy 1|Anticancer therapy 1 will be administered IV.
214302617|NCT06796907|DRUG|Anticancer therapy 2|Anticancer therapy 2 will be administered IV.
214302618|NCT06796907|DRUG|Anticancer therapy 3|Anticancer therapy 3 will be administered IV.
214302619|NCT06796907|DRUG|Anticancer therapy 4|Anticancer therapy 4 will be administered IV.
214302620|NCT03939897|DRUG|Abemaciclib|Given PO
214302621|NCT03939897|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214302622|NCT03939897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214302623|NCT03939897|DRUG|Copanlisib Hydrochloride|Given IV
214302624|NCT03939897|PROCEDURE|Diagnostic Imaging Testing|Undergo imaging
214905472|NCT05029791|OTHER|Blood sample|1 EDTA blood sample (8mL) before treatment initiation (D-28 to D-1)
214905473|NCT06315231|DRUG|Edaravone dexborneol sublingual tablet|Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks
214905474|NCT06315231|DRUG|Placebo|Patients will receive one placebo twice daily for 24 weeks
214302625|NCT03939897|PROCEDURE|Echocardiography Test|Undergo ECHO
214302626|NCT03939897|DRUG|Fulvestrant|Given IM
214302627|NCT03939897|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214905475|NCT06963996|BEHAVIORAL|Sleep health education|"The intervention consists of three structured sessions delivered over three weeks, with additional online follow-ups. Each session lasts 1.5 hours and takes place in the evening, with a one-week interval between sessions.~Session 1 focuses on providing fundamental knowledge about sleep health. Session 2 introduces behavioral strategies to improve sleep health and asks participants to implement behavior change intentions.~Session 3 reviews the implementation of the intention, the changes made or not, and addresses the relationship between stress and sleep, along with coping strategies."
215056684|NCT03879616|BEHAVIORAL|An Enhanced Reminder|"This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure."
214669855|NCT06159595|DEVICE|Intracranial electrodes|Surgically-implanted intracranial electrodes.
214669856|NCT02809066|OTHER|Sufficient dietary calcium intake in premenstrual syndrome|"Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;~* 50 gr kashkaval cheese,~* 400 ml milk and~* 150 gr yogurt for each day."
214669857|NCT02912364|DRUG|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
214302631|NCT06738355|BEHAVIORAL|PREVENT|The proposed study will assess the feasibility of an RCT for clinic-based outreach to increase vaccination rates for HPV at community clinics in rural counties. The study is a pilot trial that will assign adult parent/caregiver participants to a timeline for receiving the vaccination messaging intervention. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings).
214669858|NCT02912364|DRUG|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
214669859|NCT01525758|DRUG|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
214669860|NCT01525758|DRUG|microcrystalline cellulose|identical number of tablets to active drug groups
215056685|NCT01223339|DRUG|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
215056686|NCT01223339|DRUG|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
215056687|NCT01223339|DRUG|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
215056688|NCT01223339|DRUG|Placebo|Placebo tablets administered once daily in the fed state for 7 days
215056689|NCT05263570|DRUG|Standard Therapy|Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
215056690|NCT05822037|BIOLOGICAL|CT0594CP|Cell injection
214669861|NCT04033289|DEVICE|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
214669862|NCT03542214|COMBINATION_PRODUCT|Calcium electroporation|Patients with inoperable colorectal cancer will be treated with calcium electroporation
214905476|NCT05025358|DRUG|LP-118 tablet|Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
214905477|NCT05660967|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.
214905478|NCT05660967|DRUG|Lenalidomide|Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.
214905479|NCT06305728|DIAGNOSTIC_TEST|89Zr-DFO-HuMab-5B1 immunoPET|Participants who choose to will undergo immunoPET before surgery.
214905480|NCT06305728|DIAGNOSTIC_TEST|HP MRI|Participants who choose to will undergo HP MRI before surgery.
214905481|NCT06305728|COMBINATION_PRODUCT|Blood assay|Will be drawn within 6 weeks of surgery and annually as post operative care
214905482|NCT06317987|BEHAVIORAL|Care Navigation|Care navigation is an intervention that seeks to help patients follow up on substance use treatment plans that are established by care coordinators in the health system by reducing barriers to accessing treatment. This includes advocating for patients to reduce disparities based on language, income or geographical barriers, and cultural preferences (i.e., linkage to available services); and using motivational enhancement techniques to help patients maintain their motivation to obtain substance use treatment while working through these barriers (i.e., motivational intervention). Thus, the care navigator's role is to take the care plan developed between the patient and the mental health care coordinator forward and connect the patient to available services and provide motivational enhancement techniques to help direct the patient toward completion of the care plan.
215056691|NCT02947633|DRUG|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
215056692|NCT02947633|DRUG|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
214302635|NCT07063693|DRUG|ABY-029|"ABY-029 will be administered via single intravenous injection to subjects with high-grade glioma approximately 1-3 hours prior to surgery.~All research procedures will occur during surgery. The research procedures involve image and measurement data collection and biopsy specimen sampling. Research data collection will occur at 3 or 4 time points during surgery using either standard-of-care tools and methods or non-significant risk experimental devices.~No follow-up visit will be required of participants. Participants will be monitored for possible adverse events for approximately 30 days by the operating surgeon involved in the clinical trial procedures and through review of participant medical records."
215056693|NCT04980625|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
214302636|NCT06774742|DIETARY_SUPPLEMENT|HAFS Supplementation|1 capsule of HAFS per day
214302637|NCT06774742|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo per day
214302638|NCT06774573|BEHAVIORAL|CBT-txt-A|8-week automated text-message delivered treatment for Generalized Anxiety Disorder
214302639|NCT07067697|OTHER|Physical exercise|Progressive, supervised multicomponent physical exercise program, including aerobic resistance, strength, and balance training. Strength training for lower limbs (leg press and knee extension) and upper limbs (seated chest press) will be adapted to each individual's functional capacity.
214302640|NCT07067697|OTHER|Usual Care|"* Hospital physiotherapy for preventing nosocomial disability when necessary.~* Hospital diet modifications appropriate to each participant's clinical situation.~* Oral nutritional supplementation aimed at meeting daily nutritional requirements: 30 kcal/kg body weight, 1.5-2 g protein/kg body weight, 25 g daily fiber.~* Approximate free water intake: women 1.5 L/day, men 2 L/day (unless clinically restricted)."
214302641|NCT01352962|DRUG|Gemcitabine|1,000mg/m2 IVPB over 30 min x 1
214302642|NCT01352962|DRUG|Carboplatin|AUC 5\*\* IVPB over 30 min x 1
214302643|NCT01352962|DRUG|Lenalidomide|Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
214302644|NCT02858336|BEHAVIORAL|NEA|Neutral Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 45 kcal/kg LBM day.
214302645|NCT02858336|BEHAVIORAL|DEA|Deficient Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 20 kcal/kg LBM day.
214302646|NCT04929028|PROCEDURE|Anoscopy|Undergo anoscopy
214905483|NCT06381154|PROCEDURE|Biopsy|Undergo biopsy
214302647|NCT04929028|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214302648|NCT04929028|DRUG|Capecitabine|Given PO
214302649|NCT04929028|PROCEDURE|Colonoscopy|Undergo colonoscopy
214302650|NCT04929028|PROCEDURE|Computed Tomography|Undergo CT or FDG PET/CT
214302651|NCT04929028|PROCEDURE|Digital Rectal Examination|Undergo digital rectal exam
214302652|NCT04929028|PROCEDURE|Echocardiography Test|Undergo ECHO
214302653|NCT04929028|OTHER|Fludeoxyglucose F-18|Receive FDG
214302654|NCT04929028|DRUG|Fluorouracil|Given IV
214302655|NCT04929028|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214302656|NCT04929028|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
214302657|NCT04929028|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
215056694|NCT04980625|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
215056695|NCT00496431|DRUG|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
215056696|NCT04067791|DIETARY_SUPPLEMENT|Prolonged-Release Melatonin|4.47 mg melatonin in a bi-layer prolonged-release capsule
215056697|NCT04067791|DIETARY_SUPPLEMENT|Immediate-Release Melatonin|4.47 mg melatonin in a standard release bi-layer capsule
215056698|NCT03153891|OTHER|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
215056699|NCT03153891|OTHER|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
214302658|NCT04929028|DRUG|Mitomycin|Given IV
214302659|NCT04929028|BIOLOGICAL|Nivolumab|Given IV
214302660|NCT04929028|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT or PET/MRI
214302661|NCT04929028|PROCEDURE|Proctoscopy|Undergo proctoscopy
214302662|NCT04929028|OTHER|Questionnaire Administration|Ancillary studies
214302663|NCT04929028|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
214905484|NCT06381154|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214905485|NCT06381154|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214905486|NCT06381154|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
214905487|NCT06381154|DRUG|Fluorouracil|Given IV
214905488|NCT06381154|DRUG|Irinotecan|Given IV
214905489|NCT06381154|DRUG|Leucovorin|Given IV
214905490|NCT06381154|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
214905491|NCT06381154|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214905492|NCT06381154|DRUG|Oxaliplatin|Given IV
214905493|NCT06381154|BIOLOGICAL|Pembrolizumab|Given IV
214905494|NCT06381154|DRUG|Photodynamic Therapy|Undergo intratumoral photoradiation
214905495|NCT06381154|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and PET/MRI
214905496|NCT06381154|OTHER|Questionnaire Administration|Ancillary studies
214905497|NCT06381154|DRUG|Verteporfin|Given IV
214905498|NCT04968184|DRUG|Placebo|Participants will orally receive placebo matching to KBP-5074 tablets QD.
214905499|NCT04968184|DRUG|KBP-5074|Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
214905500|NCT04057729|DRUG|IMP4297|10mg/capsule.
214302664|NCT06784947|PROCEDURE|Pre-Treatment Biopsy|The pre-treatment biopsy should be performed at least 3 days prior to C1D1 of treatment.
214302665|NCT06784947|PROCEDURE|On-Treatment Biopsy|While the acceptable window for the C3D1 biopsy is ±3 days, it is preferred that the biopsy occurs following all treatments on C3D1.
214302666|NCT06784947|DRUG|Tiragolumab|Tiragolumab is a human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. This treatment may help the immune system attack cancer cells.
214905501|NCT01163201|BIOLOGICAL|Treg cells|Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10\^6/kg, 10 x 10\^6/kg, 30 x 10\^6/kg, 100 x 10\^6/kg and 300 x 10\^6/kg)
214905502|NCT01163201|BIOLOGICAL|CD3+ Teff cells|Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10\^6 cells/kg, 6 x 10\^6 cells/kg, 9 x 10\^6 cells/kg, 12 x 10\^6 cells/kg, and 15 x 10\^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
214905503|NCT01163201|DRUG|Fludarabine|Given intravenously on Days -8 through -6, 25 mg/m\^2 over 1 hour
214905504|NCT01163201|DRUG|Cyclophosphamide|Given intravenously on Day -7 and -6, 60 mg/kg
214905505|NCT01163201|RADIATION|Total body irradiation|Given on Days -4 through -2, 165 cGY twice a day.
214905506|NCT01163201|BIOLOGICAL|Umbilical cord blood transplantation|Infusion given on day 0
214905507|NCT00525681|DRUG|cyclosporine A|Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.
214905508|NCT00525681|DRUG|tacrolimus|Dosing of tacrolimus is given twice daily and individualized as per center practice.
214905509|NCT03943693|DEVICE|Double shock|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized. If the first attempt with this approach fails to terminate atrial fibrillation a second attempt will be made using the same approach. If the second attempt fails the dual shock approach will be considered to have failed and further treatment will be determined by the primary team/attending cardiologist.
214905510|NCT03943693|DEVICE|Single shock|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only. A repeat attempt will be made using the same approach if the initial shock fails. If the second attempt fails, the single shock approach will be considered to have failed. Patients will be crossed over to dual shock therapy while under the same sedation episode. For cross-over patients, two near-simultaneous 200-Joule shocks will be delivered through the two sets of pads already in position. If this fails further treatment will be determined by the primary team/attending cardiologist.
214905511|NCT05457023|OTHER|Plasma Neurofilament Light (NF-L)|Plasma NF-L is a biomarker of axonal brain injury following sports-related head impacts.
214905512|NCT05457023|OTHER|Omega-3 Index|Omega-3 Index is the omega-3 fatty acid content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) within the erythrocyte cell membrane. It is expressed as EPA+DHA as a percent of total identified fatty acids.
214905513|NCT05457023|OTHER|HeadCount Questionnaire|HeadCount is a web-based, structured, self-administered questionnaire to assess longer-term heading exposure during competitive play and is administered bi-weekly.
214905514|NCT01293695|BEHAVIORAL|Hypnosis|Hypnosis relaxation in five weekly sessions
214905515|NCT01293695|OTHER|Structured attention|Meets with therapist for five weekly sessions and receives structured attention/supportive counseling, but receives no hypnotic relaxation therapy
214905516|NCT04977375|DRUG|Pembrolizumab|Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks
214905517|NCT04977375|RADIATION|Stereotactic Radiation Therapy|Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7
214905518|NCT04977375|PROCEDURE|Surgical Resection|Standard of care surgical resection of tumor on Day 10-28
214905519|NCT00319137|DRUG|GW274150|
214905520|NCT03669380|OTHER||
214905521|NCT04703972|BEHAVIORAL|clinical assessment (mood relapses identification)|clinical assessment via psychometric scales physiological data acquired automatically via the connected device (wristwatch, wristband)
214905522|NCT04439929|BIOLOGICAL|TUR01|Administered as a single 40 mg, subcutaneous dose
214905523|NCT04439929|BIOLOGICAL|Adalimumab-EU|Administered as a single 40 mg, subcutaneous dose
214905524|NCT05104437|BIOLOGICAL|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
214905525|NCT05104437|BIOLOGICAL|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
214905526|NCT01935609|BEHAVIORAL|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
214905527|NCT00140868|DEVICE|Luminal stents|
214905528|NCT00140868|PROCEDURE|Minimally Invasive Surgical Bowel Diversion|
214905529|NCT03841864|OTHER|IV placement using ultrasound guidance vs traditional method|Ultrasound guided IV placement
214905530|NCT00482768|BEHAVIORAL|Practice Facilitation|Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
214905531|NCT05098522|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
214905532|NCT05098522|DRUG|Placebo|Matching placebo for IRL201104
214905533|NCT00448266|DRUG|Intensified Cyclophophamide, Carboplatin and Thiotepa|2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
214905534|NCT00448266|DRUG|dose dense adriamycine and cyclophosphamide|dose dense adriamycine and cyclophosphamide, Q 2 weeks
214905535|NCT02124655|DRUG|Essential oils|
214905536|NCT02124655|DRUG|0.2% chlorhexidine|
214905537|NCT02124655|DRUG|Sterile water|
214905538|NCT00002303|DRUG|Epoetin alfa|
214905539|NCT00225615|DRUG|sapropterin dihydrochloride|
214905540|NCT04024670|OTHER|Arts Intervention|If selected for the arts activity, an artist in residence will visit you 3 times a week for a total of 3 weeks during your hospital stay. Two visits will focus on the arts activity and one visit will be the administration of the questionnaire. Each visit will be approximately 25 minutes at a time.
214905541|NCT06534762|BIOLOGICAL|Mirabegron|To explore the efficacy and safety of milaberon combined with standard treatment in advanced solid tumors
214302667|NCT06784947|DRUG|Atezolizumab|Atezolizumab is a type of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 (programmed death) on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.
214905542|NCT06122792|PROCEDURE|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
214905543|NCT06122792|PROCEDURE|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic injection of tissue adhesives will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new endoscopic injection of tissue adhesives will be performed."
214905544|NCT01692860|OTHER|Energy Restriction|Subjects consume 750 kcal/d of energy below their need
214302668|NCT06784947|DRUG|Bevacizumab|Bevacizumab works by blocking a protein called Vascular Endothelial Growth Factor (VEGF), which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow, and may help improve the immune response in the tumor. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor.
214302669|NCT06893510|OTHER|Virtual Reality Based Progressive Muscle Relaxation|Participants engage in progressive muscle relaxation exercises using a virtual reality headset that provides immersive visual and auditory relaxation content. Sessions are conducted under researcher supervision, followed by self-guided practice using an audio recording.
214905545|NCT01171144|OTHER|Epidemiologic Surveillance System of the Ministry of Health of Panama|Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
214905546|NCT01171144|OTHER|Mortality database of the Contraloria General de la Republica|Reviewing the Mortality database of the Contraloria General de la Republica
214905547|NCT01171144|OTHER|Hospital discharge records|Reviewing the hospital discharge records
214905548|NCT00256074|PROCEDURE|Enteral feeding formula|
214905549|NCT02626026|DRUG|Tirabrutinib|Capsules administered orally.
215056700|NCT00480740|DRUG|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
215056701|NCT05778994|DEVICE|INTORUS|Exercise protocol with intorus
215056702|NCT05110781|BIOLOGICAL|Atezolizumab|Given IV
214905550|NCT02626026|DRUG|Placebo|Capsules administered orally.
214905551|NCT00687726|BEHAVIORAL|Standing balance exercise|Standing balance and mini squat exercise performed 30 times/day/side, 5 days/week, for 4 weeks.
214905552|NCT00687726|BEHAVIORAL|Isometric knee extension exercise|Isometric knee extension exercise performed 10 repetitions/set, 3 sets/day, 5 days/week for 4 weeks
215056703|NCT05110781|RADIATION|Radiation Therapy|Undergo radiation therapy
215056704|NCT05110781|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
215056705|NCT03667313|COMBINATION_PRODUCT|sirolimus-eluting balloon (SEB) MagicTouch|Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
215056706|NCT03667313|COMBINATION_PRODUCT|paclitaxel-eluting balloon (PEB) Sequent Please|Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
215056707|NCT02375373|OTHER|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
215056708|NCT01626781|DEVICE|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
215056709|NCT01626781|OTHER|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
215056710|NCT01229007|BIOLOGICAL|Biostate|1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
215056711|NCT02148068|PROCEDURE|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
214669863|NCT04980547|DEVICE|ACUMED® Scapholunate Repair System Group|To address the technical difficulties associated with the RASL procedure, Dr. Mel Rosenwasser developed an external over-the-top jig that in theory enables accurate and easy scapholunate-axis screw placement. The Acumed Scapholunate Repair System was designed treat patients with acute or chronic, static or dynamic scapholunate instability in the absence of significant capitolunate osteoarthritis, scapholunate ligament repair, scapholunate reduction, lunotriquetral ligament repair, lunotriquetral reduction, and carpal instability. This new Scapholunate Repair System features a targeting guide designed to enable the surgeon to reproducibly place the implant in optimal position. The implant allows physiologic intercarpal scapholunate rotation by means of a free rotation design. The procedure can forestall progressive osteoarthritis and the need for secondary salvage procedures.
214669864|NCT00934609|BEHAVIORAL|Endurance training|45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
214905553|NCT02079623|PROCEDURE|Electroporation/ Nano knife treatment|
214905554|NCT02079623|DEVICE|NanoKnife|
214905555|NCT06415708|DRUG|Obinutuzumab Combined With Bendamustine|"The treatment is divided into two phases: induction therapy and maintenance therapy Induction therapy: 6 cycles of obinutuzumab (1000 mg, IV) on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6 (28 days/cycle). Bendamustine (90 mg/m2, IV) on Days 1 and 2 of Cycles 1-6.~Maintenance therapy: Patients who achieved at least a partial response after 6 months of induction therapy were eligible to enter the maintenance phase, during which obinutuzumab (1000 mg, IV) was administered every 2 months for 2 years."
214905556|NCT00879307|DRUG|quetiapine|Use of quetiapine for 16 weeks in acute mania and depression
214905557|NCT03491293|BEHAVIORAL|Behavioral Weight Loss + Text|Participants will attend weekly one hour classes on line. They will type their input and responses within the chat room. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide feedback to reinforce or shape new behaviors and to identify high risk situations for problem solving.
214905558|NCT03491293|BEHAVIORAL|Behavioral Weight Loss + Video|Participants will attend weekly one hour classes on line. They will have audio and video within the chat room, and will talk with their facilitator and classmates during their weekly meeting. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide
215056712|NCT00386620|BEHAVIORAL|Questionnaire|45 minute survey about health, pain and relationships
215056713|NCT00386620|BEHAVIORAL|Interview|Feedback on use of handheld computer electronic diaries (ED).
215056714|NCT04665804|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
215056715|NCT04665804|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin sulfate supplementation|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
215056716|NCT04665804|OTHER|Supervised Exercise training|"Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
215056717|NCT04665804|OTHER|Home Exercise Program|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
214302670|NCT06893510|OTHER|Face-to-Face Progressive Muscle Relaxation|Participants practice progressive muscle relaxation exercises in a traditional face-to-face setting, guided by a researcher. Initial supervised sessions are complemented by self-guided practice using an audio recording.
215056718|NCT04665804|PROCEDURE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
215056719|NCT04665804|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
215056720|NCT04940468|OTHER|Diet Intervention|The dietary fiber intake target will be 19 g/d for ages 9-18 and females age 19 and older and 23g/d for males age 19 and older.
214302671|NCT07072988|DRUG|Efgartigimod|Administration of efgartigimod, a neonatal Fc receptor (FcRn) antagonist, given either intravenously (IV) or subcutaneously (SC) to treat patients with generalized Anti-AChR Myasthenia Gravis.
214302672|NCT06767683|DRUG|ALKS 2680, 4mg|Oral tablet containing 4 mg of ALKS 2680 for once daily administration
214302673|NCT06767683|DRUG|ALKS 2680, 6mg|Oral tablet containing 6 mg of ALKS 2680 for once daily administration
214302674|NCT06767683|DRUG|ALKS 2680, 8mg|Oral tablet containing 8 mg of ALKS 2680 for once daily administration
214302675|NCT06767683|DRUG|ALKS 2680, 10mg|Oral tablet containing 10 mg of ALKS 2680 for once daily administration
214302676|NCT06767683|DRUG|ALKS 2680, 14mg|Oral tablet containing 14 mg of ALKS 2680 for once daily administration
214302677|NCT06767683|DRUG|ALKS 2680, 18mg|Oral tablet containing 18 mg of ALKS 2680 for once daily administration
214302678|NCT06901349|DRUG|Bimagrumab|Administered SC
214302679|NCT06901349|DRUG|Tirzepatide|Administered SC
214302680|NCT06901349|DRUG|Bimagrumab Placebo|Administered SC
215056721|NCT04644510|DEVICE|Lung ultrasonography|Standardized eight-point Lung ultrasonography
214302681|NCT06901349|DRUG|Tirzepatide Placebo|Administered SC
214302682|NCT06836752|OTHER|Yoghurt|250 g per day
214302683|NCT06836752|OTHER|Milk|250 g per day
214669865|NCT04377945|DRUG|Part 1, JM-010 component Group A|JM-010 component Group A
214669866|NCT04377945|DRUG|Part 1, JM-010 component Group B|JM-010 component Group B
214669867|NCT04377945|DRUG|Part 1, JM-010 component Group C|JM-010 component Group C
214669868|NCT04377945|DRUG|Part 1, Placebo Group|Placebo Group
214669869|NCT04377945|DRUG|Part 2, JM-010 combination Group A|JM-010 combination Group A
214669870|NCT04377945|DRUG|Part 2, JM-010 combination Group B|JM-010 combination Group B
214669871|NCT04377945|DRUG|Part 2, JM-010 component Group C|JM-010 component Group C
214905559|NCT02479451|DRUG|Theophylline|The study medication will be provided by Foundation Care.
214302684|NCT06400121|DRUG|Apimostinel Infusion, Intravenous|Single injection of Apimostinel (10mg)
214905560|NCT00191477|DRUG|Gemcitabine|2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
214905561|NCT00191477|DRUG|Placebo|intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
214905562|NCT02865967|OTHER|Usual care + a-GPS|Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.
214302685|NCT06400121|BEHAVIORAL|Cognitive Training|8 sessions of digital active training
214302686|NCT06400121|BEHAVIORAL|Sham Training|8 sessions of digital sham training
214302687|NCT06400121|DRUG|Isotonic Solution, Intravenous|Single injection of placebo
214302688|NCT02759744|DEVICE|ultrasound image-guided ablation device|ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
214905563|NCT02865967|OTHER|Usual care|The subjects will be treat for their asthma by their physicians according to usual care.
214905564|NCT02962492|DRUG|Exenatide/Exenatide extended release|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
214905565|NCT02962492|DRUG|Dapagliflozin|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
214905566|NCT02962492|DRUG|Placebo|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
214905567|NCT03027635|DEVICE|PleurX, peritoneal tunnelated catheter|A permanent catheter
214905568|NCT03027635|DEVICE|Large Volume Paracentesis|Short time drainage
214905569|NCT03027635|DRUG|Ciprofloxacin 500Mg Tablet|SBP prophylaxis
214905570|NCT01571219|BIOLOGICAL|Infliximab|CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
214905571|NCT01616836|OTHER|continuous FNB|femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration
214905572|NCT01616836|OTHER|single femoral nerve block|single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration
214905573|NCT01616836|OTHER|local infiltration analgesia|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
214905574|NCT06424613|DRUG|Lithium Carbonate|Participants must have been prescribed lithium for the past year and demonstrate at least 80% adherence to their lithium medication regimen during the first six months of the study period.
214905575|NCT06424613|DRUG|Non-lithium medication|No history of lithium use within the past year
214669872|NCT04377945|DRUG|Part 2, Placebo Group|Placebo Group
214905576|NCT00272077|DRUG|Insuline glargine|
214905577|NCT03549078|BEHAVIORAL|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
214905578|NCT00249301|DRUG|MLN8054|MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
214905579|NCT03638804|DIAGNOSTIC_TEST|89Zr-KN035|Single injection of 89Zr labeled KN035 in subjects to observe KN035 affinity in PD-L1 expressed Solid tumors by using PET imaging.
214905580|NCT03922308|OTHER|Placebo|Participants will receive injection of placebo matched to SHP655.
214905581|NCT03922308|DRUG|SHP655|Participants will receive injection of SHP655.
214905582|NCT03922308|OTHER|Standard of Care|Participants will receive PEX as Standard of Care (SOC).
215056722|NCT01890265|DRUG|Pamrevlumab|Solution for infusion
215056723|NCT01890265|DRUG|Placebo|Solution for infusion
215056724|NCT01890265|DRUG|Sub-Study: Pirfenidone|Pirfenidone concomitant therapy will not be provided by the Sponsor.
214479298|NCT06608173|BEHAVIORAL|radKIDS2.0 Safety and Empowerment Education Program|radKIDS® uses activity-based skill training to help elementary aged children develop personal safety boundaries, critical thinking skills for responding to threats of danger, age-appropriate coping strategies for dealing with current and past victimization, self-assertiveness and physical skills for self-defense, communication skills for reporting incidences to parents/adults, and increasing child self-worth-the program's cornerstone for personal safety and healthy development for elementary students.
214669873|NCT02544776|DRUG|Clomifene citrate ( clomid 50 mg )|
215056725|NCT01890265|DRUG|Sub-Study: Nintedanib|Nintedanib concomitant therapy will not be provided by the Sponsor.
214669874|NCT02544776|DRUG|Amlodipine|
214669875|NCT04946318|DRUG|CSJ117|CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.
214669876|NCT04946318|DRUG|Placebo|Placebo inhaled once daily for 12 or 24 weeks. Delivered via Concept1 device.
214905583|NCT06577324|BEHAVIORAL|Live group music therapy|The intervention will involve the use of live music in a group of patients during their quimiotherapy session. The intervention will last approximately forty minutes and will be organized into three stages: Opening (10 min), Body Awareness and Movement (7-10 minutes), Intervention Development (20 minutes). Genres and songs are performed based on the group's preferences and suggestions. The instruments used for the group intervention are the same as those mentioned earlier; participants are provided with percussion instruments, accompanied by the music therapist's voice and the participants' voices. The intervention encourages active participation, with users playing the instruments, singing, engaging in dialogue, and/or reflecting between songs.
214905584|NCT02538575|OTHER|6-minute walk test|a walk of 6 minutes repeated twice in an interval of 30 minutes
214905585|NCT05428774|OTHER|Test product 1|Participants will receive TP1 during one experimental visit.
214905586|NCT05428774|OTHER|Test product 2|Participants will receive TP2 during one experimental visit.
214905587|NCT05428774|OTHER|Placebo|Participants will receive placebo during one experimental visit.
214905588|NCT03779230|DRUG|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
214905589|NCT05602844|PROCEDURE|PSI Lapidus|Design of PSI: DICOM files will be imported into the Model Intestinal Microflora in Computer Simulation (MIMICS 21.0) 3D image processing software (Materialize, Belgium) for 3D rendering. The segmented bone images will be used for design of the computer-aided modelling (CAM) surgical jigs. 3D printing of PSI jig. PSI-assisted Lapidus Surgery.
214905590|NCT05602844|PROCEDURE|Conventional Lapidus|exposure of the 1TMTJ via a 3-5cm medial longitudinal skin incision and capsulotomy. Freehand creation of the fusion surface with fluoroscopic assistance. Fixation of the Lapidus arthrodesis will be performed with two 3.5mm headless compression screws
214905591|NCT01697748|DEVICE|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
214905592|NCT01697748|DEVICE|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
214905593|NCT02694172|OTHER|Fiber rich cereal bars|Two cereals per day and per subject for 4 weeks
215056726|NCT01445613|DEVICE|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
215056727|NCT00245453|DRUG|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
215056728|NCT00245453|DRUG|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
215056729|NCT00245453|DRUG|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
215056730|NCT02931409|PROCEDURE|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
215056731|NCT02931409|PROCEDURE|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
215056732|NCT05918016|DIAGNOSTIC_TEST|Routine cranial ultrasounds|we will use the routine cranial ultrasounds
215056733|NCT04193904|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
215056734|NCT04193904|RADIATION|Hypofractionated Preoperative Radiation|Radiation will be delivered as 30Gy/10 fractions over two weeks.
215056735|NCT03029039|OTHER|Blood samples|Blood samples will be collected at inclusion.
215056736|NCT01918891|BEHAVIORAL|Nurse Practitioner Only|
215056737|NCT01918891|BEHAVIORAL|Nurse Practitioner + Health Coach|
214479299|NCT06608433|DRUG|semaglutide|semaglutide/Rybelsus will be administered as a single oral dose
214479300|NCT06608433|DRUG|Placebo|Placebo pills will be administered as a single oral dose
214905594|NCT02183324|DRUG|Low dose of BI 1356 BS|
214905595|NCT02183324|DRUG|Medium dose of BI 1356 BS|
214905596|NCT02183324|DRUG|High dose of BI 1356 BS|
214905597|NCT02183324|DRUG|Placebo|
214905598|NCT03825796|DRUG|Enasidenib Mesylate|Given PO
214905599|NCT03825796|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214905600|NCT01136057|BIOLOGICAL|Collection of Anti-Influenza A Immune Plasma|
215056738|NCT05396339|DRUG|IAE0972|IAE0972 is an investigational product
215056739|NCT03569787|DIAGNOSTIC_TEST|MRI Pituitary|Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
215056740|NCT01479751|DRUG|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
215056741|NCT01479751|DRUG|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
215056742|NCT01479751|DRUG|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
215056743|NCT05346744|OTHER|Chairside CAD/CAM ceramic materials for dental restoration|"6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)"
215056744|NCT04373148|OTHER|There is no intervention|There is no intervention
215056745|NCT03789123|DRUG|Estradiol valerate/dienogest|The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
215056746|NCT03593486|DEVICE|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
215056747|NCT03593486|DEVICE|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
215056748|NCT00631280|BEHAVIORAL|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
215056749|NCT00631280|BEHAVIORAL|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
214905601|NCT00323453|DEVICE|Open appendectomy using Alexis Wound Retractor followed by standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
215056750|NCT02725905|BEHAVIORAL|Multi-Modal Education (MME)|"The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese."
215056751|NCT02725905|BEHAVIORAL|Traditional Education (TE)|Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
215056752|NCT00648258|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
214905602|NCT00323453|PROCEDURE|Open appendectomy with standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
214905603|NCT03376789|DRUG|MYL-1501D product using manufacture process V|MYL-1501D product using manufacture process V
214905604|NCT03376789|DRUG|MYL-1501D product using manufacture process VI|MYL-1501D product using manufacture process VI
214302689|NCT06746675|DRUG|Healthy Families PrEP Counselling Intervention|Healthy Families-PrEP intervention with HIV-uninfected women with plans for pregnancy in the next year and concerns about or exposure to HIV. Session 1 focuses on providing information about HIV prevention in the context of reproductive goals (using tools with locally developed images), increasing motivation for behavior change, and developing a safer conception plan (e.g., PrEP uptake, PrEP adherence, couples-based counselling and testing, delaying condomless sex until partner serostatus known and, if living with HIV, virally suppressed). Sessions 2 and 3 (conducted at 1 and 3 months) review the safer conception plan and revise as needed (e.g., changes in readiness to initiate PrEP, partner serostatus knowledge) and engaging in problem-solving barriers (including structural) to plan execution, communication skills training, and motivational strategies for successful plan execution. Participants receive quarterly adherence counseling using tools developed by this team.
214302690|NCT06766214|DEVICE|transcranial direct current stimulation|Simultaneous treatment with tDCS and online-based psychotherapy
214302691|NCT06766214|DEVICE|sham transcranial direct current stimulation|Simultaneous treatment with sham-tDCS and online-based psychotherapy
214905605|NCT03906617|DRUG|Intercostal nerve block and wound infiltration with liposomal bupivacaine|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.
214905606|NCT03906617|DRUG|Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
214905607|NCT01867125|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
214905608|NCT01867125|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
214905609|NCT04812041|OTHER|CAM-ICU 7 score|A 7-point rating scale (0-7) was derived from the CAM-ICU and RASS assessments 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.
214905610|NCT04812041|OTHER|4C Mortality Score|4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters
214905611|NCT04051671|DEVICE|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy. Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 2 weeks. The two experiments will be performed in random order for each subject.
214905612|NCT04501237|BEHAVIORAL|Bruxers with sleep hygiene instructions|the test group will receive instructions of sleep hygiene, limited use of screens and a relaxation audio.
214905613|NCT06575283|OTHER|No intervention will be performed in this cohort study|Deep learning classification models will be used for automatic prediction of cerebral palsy. Machines will be used to assist doctors in cerebral palsy risk evaluation.
214905614|NCT03732937|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography with biometry and TCD measurement
214905615|NCT05966077|OTHER|IMPACT OF SENDING AN SMS|"Each subject of the experimental group will receive, in addition to the usual procedure of the VigilanS Lorraine device, an SMS 48 hours before the telephone call for evaluation at 3 months, warning him of this call.~The time of this SMS has been set at 1:00 p.m. for all the people included in this group.~At the end of this evaluation call, the caller will pass a satisfaction questionnaire to the subject in relation to the sending of the SMS"
214905616|NCT04177095|DIAGNOSTIC_TEST|Allosure|Monthly monitoring of dd-cfDNA levels in blood
214905617|NCT04177095|DRUG|Immunosuppression reduction|Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results
214905618|NCT04177095|DIAGNOSTIC_TEST|Trugraf|Monthly monitoring of Trugraf result
214905619|NCT03693638|DRUG|Bupivacaine-fentanyl|2,5 ml total anesthetic drug dose were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
214905620|NCT03693638|DRUG|Bupivacaine-fentanyl|1,5 ml of total anesthetic drug dose followed by 1 ml remaining dose after 90 s interval were given
215056753|NCT00648258|DRUG|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
215056754|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
215056755|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
214302694|NCT00646022|DRUG|[18F]-DOPA|18F-DOPA PET/CT Scan.
214302695|NCT06444048|BIOLOGICAL|EV68-228-N|EV68-228-N is a recombinant human monoclonal IgG1 antibody which is produced by genetically engineered plasmids in Nicotiana benthamiana. This intervention is directed against enterovirus EV-D68 capsid protein potentially providing treatments for EV-D68 infection and AMF.
214302696|NCT06444048|OTHER|Placebo for EV68-228-N|The placebo is a sterile buffer solution formulated to match the EV68-228-N Drug Product. The formulation is 20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80, with a target pH of 5.5. The placebo will be filled into glass vials at 10 mL per vial. The formulation buffer is a clear colorless liquid.
214302697|NCT06827613|DRUG|STAR0602|solution, intravenous infusion
214302698|NCT06827613|DRUG|Sacituzumab Govitecan (SG)|intravenous infusion, 10mg/kg
214302699|NCT06435429|DRUG|Zanidatamab|Administered by intravenous infusion
214302700|NCT06435429|DRUG|Trastuzumab|Administered by intravenous infusion
214302701|NCT06435429|DRUG|Eribulin|Administered by intravenous infusion
214302702|NCT06435429|DRUG|Vinorelbine|Administered by intravenous infusion
214302703|NCT06435429|DRUG|Gemcitabine|Administered by intravenous infusion
214302704|NCT06435429|DRUG|Capecitabine|Given orally
214302705|NCT07079111|DEVICE|Formlabs 3D printed occlusal splint|In house 3D printed occlusal splint with Formlabs printer
214302706|NCT07079111|DEVICE|Industry made occlusal splint|Industry made occlusal splint
214302707|NCT06318637|OTHER|Baby Wash/Shampoo|Marketed baby wash/shampoo to be used as needed.
214302708|NCT06318637|OTHER|Daily Activities|Participants to follow their typical daily activities with their baby.
214302709|NCT06318637|OTHER|Body Lotion|Marketed body lotion to be used as needed.
214302710|NCT03605927|DRUG|BMS-986004|BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.
214302711|NCT03605927|DRUG|Sirolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
214302712|NCT03605927|DRUG|Tacrolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
214302713|NCT06680830|DRUG|NEU-411|NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity
214302714|NCT06680830|OTHER|Placebo|Orally-administered matched placebo
214302715|NCT06578247|DRUG|Quizartinib|Participants will receive quizartinib at 60 mg/day orally once daily
214905621|NCT02810041|DIETARY_SUPPLEMENT|yoghurts enriched with XXS|
214905622|NCT02810041|DIETARY_SUPPLEMENT|yoghurts non enriched with XXS|
214905623|NCT04171336|BEHAVIORAL|Animal-assisted therapy|Six sessions of animal-assisted intervention for children and adolescents, group format. The sessions will focus on psycho-education on pain, mindfulness, defocusing, getting active, and resources. Additionally, the intervention includes two family visits.
215056756|NCT02321228|PROCEDURE|Salpingectomy with delayed oophorectomy|Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
215056757|NCT02321228|PROCEDURE|Risk-reducing salpingo-oophorectomy|This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
214905624|NCT01731132|DRUG|Levonorgestrel IUD or Copper IUD|Women who initiate the use of an IUD at the time of the study.
214905625|NCT00228436|DRUG|peginesatide|
214905626|NCT04973267|BEHAVIORAL|Game Plan for PrEP|See arm description.
214905627|NCT04973267|BEHAVIORAL|Attention-Matched Control Lifestyle Habits Videos|Web-based videos providing information on sleep hygiene and proper diet.
214905628|NCT04082923|OTHER|Liquid meal|Four-hour liquid mixed meal test
214905629|NCT04082923|OTHER|Solid meal|Four-hour solid mixed meal test
214302716|NCT06578247|DRUG|Placebo|Participants will receive placebo at 60 mg/day orally once daily
214302717|NCT06578247|DRUG|Chemotherapy|Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
214302718|NCT07079397|DEVICE|Restylane Injectables|Participants will receive pan-facial treatment in at least one facial area using a Restylane NASHA product and at least one different facial area using Restylane OBT product. Participants will undergo three (3) scheduled MRI scans thoughout the duration of the study post HA injections.
214302719|NCT06859073|DRUG|NNC4004-0002|NNC4004-0002 will be given as a single ascending dose via subcutaneous route.
214669877|NCT04708912|OTHER|Observation|The study parameters will be obtained at the time of recuirement (Basal)
214905630|NCT03876743|OTHER|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
214905631|NCT03876743|OTHER|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
214905632|NCT03876743|OTHER|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
214905633|NCT03876743|OTHER|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
214905634|NCT05382819|DRUG|FRTX-02 Capsule|DYRK-1A Inhibitor
214905635|NCT05382819|DRUG|Placebo|Matching Placebo
214905636|NCT00590213|DRUG|Casodex 150mg|
214302720|NCT06859073|DRUG|Placebo|Placebo matched to NNC4004-0002 will be given via subcutaneous route.
214302721|NCT06791057|BEHAVIORAL|Dyspnea Intervention|Brief behavioral intervention for dyspnea management that includes three nurse-led sessions focused on psychoeducation, behavioral techniques for managing acute breathlessness, and relaxation training for reducing physiological stress as well as a digital health app to reinforce practice of breathing skills.
214302722|NCT06791057|BEHAVIORAL|Enhanced Usual Care|Patients will receive educational materials on the management of symptoms of lung cancer and its treatment as well as any usual care for dyspnea deemed appropriate by the clinical team.
214302723|NCT05171179|PROCEDURE|Breast Reconstruction (Mammaplasty)|Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander
214905637|NCT00590213|PROCEDURE|Radiotherapy|
214905638|NCT00590213|PROCEDURE|Haematology|
214905639|NCT03889418|BEHAVIORAL|Electronic medical recorded clinical decision support [EMR CDS]|The opioid management tool has quick links to the Opioid Risk Tool (ORT), health maintenance reminders for risk mitigation tasks (pain management agreements; urine drug screening; prescribing naloxone); Pain Scale and depression/anxiety screen. The frequency with which providers are prompted to complete mitigation tasks is based on patients' level of risk for aberrant drug behavior defined by the ORT score. Additionally, the EMR CDS flags patients as high risk if one of the following criteria are met: (1) co-prescriptions for benzodiazepines; (2) active diagnosis of substance abuse in the last 12 months; or (3) MEDD \>=90 mg. The ORT score, morphine equivalent daily dose (MEDD), and hyperlinks to the Louisiana pharmacy drug monitoring program data are visible in the prescription writer. If MEDD \>=90 mg, the calculated MEDD is displayed in red font to alert the prescribing provider of high dosage. An Epic banner appears in charts to alert providers of existing pain management agreements.
214907581|NCT06061809|DEVICE|Tumor Treating Fields (TTFields, 200 kHz)|"TTFields (OPTUNE Gio®), for the treatment of newly diagnosed and/or recurrent GBM, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body/brain. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells. TTFields is comprised of two main components: (1) an Electric Field Generator and (2) INE Insulated Transducer Arrays (the transducer arrays). Patients carry the device in an over-the-shoulder bag or backpack and receive continuous treatment without changing their daily routine."
215056758|NCT06438198|OTHER|Pre-specified switch from controlled to assisted ventilation when PaO2/FiO2-ratio > 200 mmHg|A pre-specified switch from controlled to assisted ventilation will be initiated when PaO2/FiO2-ratio \> 200 mmHg. The moment of switch is pre-specified but patient management and ventilator settings are up to the clinical team. Switch is complete when the patient triggers all breaths spontaneously. Switch success is defined if patient reaches 72 hours on assisted ventilation. Switch failure is defined if patient switches back to controlled ventilation for more than 2 hours before 72 hours.
215056759|NCT03034707|DIETARY_SUPPLEMENT|biotin|
215056760|NCT00137059|DRUG|acetaminophen sustained-release|
214479301|NCT06601673|BEHAVIORAL|Cognitive training|The intervention consists of computer-based cognitive training in the areas of attention, processing speed, memory, emotional intelligence, reasoning and orientation. The training takes place under supervision for 120 minutes a day from the first to the fifth postoperative day.
214669878|NCT04232449|DRUG|PREDNISON Galepharm Tabl. 20 mg|5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone
214669879|NCT04232449|DRUG|placebo tablets|5 daily- doses of placebo (2 tablets)
214479302|NCT06601673|BEHAVIORAL|Listen to audio book|Here, an audio book is listened to for 2h daily for the first five postoperative days (or until discharge from hospital if earlier). The audio book is brought and set up by study staff.
214479303|NCT03409718|DEVICE|Biomet Comprehensive Shoulder System|Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform
214479304|NCT06820567|DRUG|Dapagliflozin (DAPA)|patient will recive dapagliflozin for 24 week to improvement of eGFR on CKD patients
214669880|NCT01346800|DRUG|Prasugrel|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
214669881|NCT01346800|DRUG|Ritonavir|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
214905640|NCT03889418|BEHAVIORAL|Stepped opioid collaborative care model [CCM]|The licensed clinical social worker (LCSW) will provide counseling services as indicated (behavioral activation, psychotherapy, crisis planning, facilitating connection to substance abuse counseling and treatment); meet weekly with the consulting psychiatrist for complex case review and care plan adjustments; and supervise the community health worker (CHW) case management and depression/anxiety care management activities. The CHW will update assets and barriers to recovery and self-management and help patients navigate community resources. The clinical pharmacist will review and reconcile active medication lists, assess medication side effects, drug interactions and adverse events; monitor analgesia; recommend algorithm based anti-depression medication titration as indicated. The consulting psychiatrist will directly co-manage patients with severe mental illness, substance abuse and complex medication regimens.
215056761|NCT03343561|BEHAVIORAL|Nutrition Advice|Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
214669882|NCT04653662|DEVICE|Earol|Treated with Earol on both ears and subsequent removal after 6 days of application
214669883|NCT05191628|BIOLOGICAL|Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane placed by the investigator during macular hole surgery
214669884|NCT05158348|DRUG|Dexmedetomidine Hydrochloride|Group A will receive post-operative nebulised dexametomidine and lidocaine.
214669885|NCT05158348|DRUG|Nebulized lidocaine|Group B will receive post-operative will receive nebulised lidocaine
214669886|NCT05158348|DRUG|Local infiltration of lidocaine|group C will receive intra-operative local infiltration of lidocaine
214905641|NCT00350090|DRUG|Epoetin Alfa|
214905642|NCT00092118|DRUG|Montelukast|one 10 mg tablet, taken once daily at bed time for 6 weeks
214905643|NCT00092118|DRUG|Comparator: Placebo|one placebo tablet, taken once daily at bed time for 6 weeks
214479305|NCT06820567|DRUG|Placebo|type 2 diabetic patients with chronic kidney diseases will recive placebo for 24 weeks
214479306|NCT06587841|DEVICE|Spinal COrd NEuromodulation™ (SCONE™) for transcutaneous spinal cord stimulation (TSCS)|The SCONE™ class II investigational device is a non-invasive central nervous system (CNS) stimulator (electrical continence device) designed to provide transcutaneous spinal cord stimulation for the improvement of symptoms of bladder dysfunction associated with centrally-mediated NLUTD.
214479307|NCT06824038|BEHAVIORAL|nutritional counseling|"Nutritional counseling based on the nutritional assessment of each patient. Each patient will receive a package of:~i. A booklet that contains the whole instructions and dietary records to help in remembering information and record their application of the plan.~ii. A tailored diet menu adjusted according to the required calories of the patient calculated by the Harris Benedict equation, considering the patient preferences, individualized requirements and with choices suitable for different economic classes."
214669887|NCT00121823|BIOLOGICAL|FP9 ME-TRAP|
214669888|NCT00121823|BIOLOGICAL|MVA ME-TRAP|
214905644|NCT00210418|DIETARY_SUPPLEMENT|Fortified food rations|The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ \<-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.
214905645|NCT00210418|BEHAVIORAL|Education and communication to improve feeding practices|The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
215056762|NCT06160596|GENETIC|Long term survival multimodal analysis|"* To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"
215056763|NCT04650295|OTHER|Household Remedy|If the participant experiences a muscle cramp one tablespoon (one sip) of the household product will be taken. The treatment phase of the study will be for 28 days.
215056764|NCT04650295|OTHER|Tap water|If the participant experiences a muscle cramp one tablespoon (one sip) of tap water will be taken. The treatment phase of the study will be for 28 days.
215056765|NCT04787003|DRUG|oncolytic virus (OVV-01) injection|intratumoral injection of OVV-01 with or without immune checkpoint inhibitors
215056766|NCT04335071|DRUG|Tocilizumab (TCZ)|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
214302724|NCT05171179|DEVICE|Pecs blocks|Pectoral nerve (Pecs) blocks I and II function by blocking the pectoral, intercostal, intercostobrachial nerves, and/or long thoracic nerve. These are used primarily for breast surgeries and are gaining momentum as simple administers of local analgesics. Pecs blocks utilize ultrasound to guide injection of local analgesic. It is less invasive and more accurate than most current modes of analgesia administration.
214302725|NCT05171179|DRUG|Exparel|Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel, bupivacaine is released from the multivesicular liposomes over a period of time.
214905646|NCT02967315|PROCEDURE|Cardiac Magnetic Resonance Imaging (CMRI)|"There will be 2 CMRIs. The first one will be patient's routine clinically schedule CMRI after the patient has fasted for 12 hours.This CMRI uses contrast.~The second CMRI will be the research CMRI after the fluid administration. This CMRI does not use contrast."
214905647|NCT02967315|PROCEDURE|Central venous line placement|An ultrasound guided central line catheter will be placed in the internal jugular vein (IJV) under local anesthesia.
214905648|NCT02967315|PROCEDURE|Chest X-ray|A chest X-ray will be performed for safety reasons to rule out pneumothorax (\< 1% risk) after central line placement.
214905649|NCT02967315|PROCEDURE|Fluid administration|Administration of 15cc/kg of normal saline for fluid hydration through peripheral IV that is placed for the MRI contrast administration.
215056767|NCT04335071|DRUG|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
215056768|NCT06159283|DRUG|Immunoglobulins|Dosage is Immunoglobulin 1,000mg/kg IV. It administer over 2\~3 days.
215056769|NCT04115124|BEHAVIORAL|Participatory Action Research|The research will employ a Participatory Action research quasi-experimental pre-post test study design .
214302726|NCT05171179|DRUG|Bupivacaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in both arms.
214302727|NCT06752590|DRUG|ONO-1110|ONO-1110 tablets once a day
214302728|NCT06752590|DRUG|Placebo|Placebo tablets once daily
214302729|NCT07083076|OTHER|Short term (10 day) low residue diet restriction|Patients will have an unrestricted diet (as opposed to a low residue diet restriction) 10 days after surgery.
214302730|NCT07083076|OTHER|6 week low residue diet restriction|Patients will be restricted to a low residue diet for 6 weeks after surgery. After this period, their diet will be unrestricted.
214905650|NCT02967315|PROCEDURE|Blood Draw|One to two teaspoons of blood will be drawn for basic metabolic panel.
214302731|NCT07082270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214302732|NCT07082270|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214302733|NCT07082270|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214302734|NCT07082270|DRUG|Carfilzomib|Given IV
214302735|NCT07082270|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
214302736|NCT07082270|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
214302737|NCT07082270|DRUG|Dexamethasone|Given PO
214302738|NCT07082270|PROCEDURE|Echocardiography Test|Undergo ECHO
214905651|NCT02967315|PROCEDURE|Pregnancy test|A urine pregnancy test will be performed in female subjects.
214905652|NCT02967315|PROCEDURE|Electrocardiogram|12 lead ECG
214905653|NCT01644071|DRUG|cipralex|one time 10 mg, tablet
214905654|NCT00206271|BEHAVIORAL|neck collar; advice to act-as-usual; active mobilisation|
214905655|NCT04459325|BIOLOGICAL|Tigerase® and best available care|Nebulised dornase alfa \[2.5 mg BID\] for 7 days
214905656|NCT04459325|OTHER|Best available care|Patients will receive the usual care in accordance with good practice.
214905657|NCT05984901|DEVICE|The continuous ambulatory vestibular assessment (CAVA) system|"The CAVA trial is a diagnostic accuracy multicentre device trial which aims to quantify the extent to which the CAVA system can differentiate three common inner-ear causes of dizziness: Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV).~The CAVA device is composed of two components: a set of bespoke single-use sensor arrays that adhere to the left and right side of the participant's face; and a small reusable module fitting over the ear that contains a battery, microcomputer data storage facility and connection ports for the arrays. The CAVA device will be worn by all participants for 30 days with the aim of capturing eye movement data during a dizzy attack.~The first objective is to develop an algorithm that can discriminate between the 3 listed dizziness conditions. The second is to quantify the financial and patient benefits of deployment in the NHS. The final objective is to expedite a plan to deploy the system in the NHS."
214905658|NCT04282941|DRUG|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
214905659|NCT04282941|DRUG|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
214905660|NCT05113550|OTHER|Surgical remove|liver hydatid cyst (LHC) treated by total or partial pericystectomy
214905661|NCT00952835|OTHER|regular treatment|regular treatment
214905662|NCT00672724|DRUG|Ramelteon|Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
214905663|NCT00672724|DRUG|Placebo|Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
214905664|NCT03751098|DRUG|Tropicamide/Phenylephrine ophthalmic solution (TR/PE)|Tropicamide 1%/phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
214905665|NCT03751098|DRUG|Placebo|Eyewash administered with the Optejet microdose dispenser
214905666|NCT01908075|DRUG|FP/SAL|
214905667|NCT01908075|DRUG|BDP/FOR|
214905668|NCT02483221|DRUG|Hydromorphone|Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.
214905669|NCT02483221|DRUG|Morphine|Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.
214905670|NCT04889443|PROCEDURE|Surgical cartilage repair procedure requiring harvest procedure or Autologous Stromal Cell Implantation|Any surgical cartilage repair procedure of the knee that requires a harvest biopsy of knee cartilage, which will leave a controlled small cartilage injury
214905671|NCT06005272|OTHER|Questionnaire|Interviewer assisted completion of questionnaire.
214905672|NCT06087848|BIOLOGICAL|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
214905673|NCT06175325|PROCEDURE|Trans-radial embolisation of haemorrhoids|"Once patients have provided informed consent to participate, an assessment of symptom severity will be obtained during the initial visit using the a standardised set of 4 validated scoring systems used in research of haemorrhoidal disease. These include the French bleeding score (FBS), Goligher classification of internal haemorrhoids (GS), quality of life score (QoL) and Visual analogue score for pain (VAS). Routine blood tests will be taken. During the procedure, routine observations will be recorded on the paper CRF. The data collected on the paper CRF will be entered onto the electronic CRF.~The Transarterial fluoroscopically guided superior rectal artery embolization procedure will be performed on all participants. It is a day case procedure performed under local anaesthetic."
214905674|NCT06325085|OTHER|compensatory and restorative rehabilitation techniques|"compensatory and restorative rehabilitation techniques Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week."
214905675|NCT06325085|OTHER|Traditional cognitive rehabilitation training|"Naming words ( ask patient to name food, states, family members) Counting numbers backwards, backward counting of days and months) Spell the word backwards, remembering a piece of information Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week."
214905676|NCT06333171|DRUG|4-Aminopyridine|Active study drug
214905677|NCT06333171|OTHER|Placebo|Placebo comparator
214905678|NCT06974773|DEVICE|NettleEndo|The NettleEndo device is a portable, home-use transcranial direct current stimulation (tDCS) system designed to deliver low-intensity electrical stimulation to targeted brain regions. The device delivers a constant current of 2 mA in the active stimulation group, targeting the left primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC) through pre-set electrode positioning.
214907582|NCT06455137|DEVICE|Epidural Stimulator|Participants will have a 16-electrode epidural array implanted in the C4-C7 and T11-L2 areas of the spinal cord. Following a 2 weeks recovery period, patients will engage in a structured training of physical rehabilitation and electrical stimulation.
214669889|NCT01106755|DEVICE|gait training on ground level using BWS|An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
214905679|NCT06974773|DEVICE|Sham NettleEndo Device|The sham version of the NettleEndo device is visually identical to the active device and is used under the same schedule. The device is pre-programmed to deliver a brief 2 mA current for 20 seconds at the beginning of each session to mimic the initial skin sensations of active stimulation, after which no current is delivered for the remainder of the session. This allows participants to remain blinded to their group assignment. The device is used with the same electrode positioning as the active version.
214905680|NCT06838767|OTHER|Conventional treatment|"10 min moist heat pack Self-assisted anterior capsular stretching Hold for 30 sec and repeat 5 times with 10 sec rest between each stretch Self-assisted posterior capsular stretching Hold for 30 sec and repeat 5 times with 10 sec rest between each stretch Self -assisted inferior capsule stretching Hold for 30 sec and repeat 5 times with 10 sec rest between each stretch Codman's pendular exercises 10 reps Muscle strengthening exercises (after 4 weeks)~* Internal rotators and External rotators isometrics Hold for 5-8 seconds and repeat 10 times~* chair press According to FIIT protocol 10 reps progressing to 20 and 30 repetitions in 5th and 6th week with two session in a day, three days per week for six consecutive weeks"
214302739|NCT07082270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214302740|NCT07082270|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214302741|NCT07082270|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214302742|NCT07082270|OTHER|Questionnaire Administration|Ancillary studies
214302743|NCT07082270|DRUG|Selvigaltin|Given PO
214905681|NCT06838767|OTHER|Kinetic chain approach|Kinetic chain approach Shoulder flexion with ipsilateral anterior step-up, Shoulder-dump exercise Starting position with Body weight is on the contralateral-side leg with trunk flexion and rotation. Finishing position. With Body weight is on the ipsilateral-side leg with thoracic extension. Modified shoulder-dump Exercise Sternal-lift starting position with head and trunk flexed forward. Finishing position with emphasizing thoracic extension. Tubing fencing exercise starting position with body weight on the ipsilateral leg. Elbow is at the hip; thoracic extension and scapular retraction are encouraged, Athletic stance during ball-stabilization exercise. Axially loaded wall-slide exercise. Motion at the hips and trunk complements the sliding pattern of the hand.Perform each exercise for 3 Days (twice a day) a week for 6 weeks. 10 reps ,2 sets According to FITT protocol, 10 reps, two sessions per day, and three days per week for 6 consecutive weeks.
214905682|NCT06572917|DRUG|Indomethacin|Single dose of 0.1 mg/kg dose intravenous indomethacin as a slow infusion over 20 mins
214905683|NCT06572917|DRUG|Placebo|Single dose of intravenous normal saline placebo as a slow infusion over 20 mins
214905684|NCT05432791|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214905685|NCT05432791|PROCEDURE|Bone Scan|Undergo bone scan
214905686|NCT05432791|PROCEDURE|Computed Tomography|Undergo CT scan
214905687|NCT05432791|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214905688|NCT05432791|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214905689|NCT05432791|DRUG|Olaparib|Given PO
214905690|NCT05432791|DRUG|Pazopanib|Given PO
214905691|NCT05432791|DRUG|Temozolomide|Given PO
214905692|NCT05432791|DRUG|Trabectedin|Given IV
214669890|NCT01106755|DEVICE|gait training on ground level using BWS associated to FES|An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
214669891|NCT04387279|OTHER|Interview|Surveys on medical use patterns and patient's perceptions about COVID-19
214905693|NCT05432791|PROCEDURE|Transthoracic Echocardiography Test|Undergo TTE
214905694|NCT02593292|BEHAVIORAL|PROSPERO|"The intervention is carried out in 3 steps:~1. At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~2. During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~3. The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
215056770|NCT00953953|DEVICE|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
215056771|NCT02881775|DEVICE|rTMS and exercise|rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
215056772|NCT02881775|DEVICE|Sham rTMS and exercise|rTMS unit is on and running but mu metal is placed between the coil and the skull
215056773|NCT01849315|BEHAVIORAL|AKIDS II|Physically active intervention
215056774|NCT05101811|DRUG|Vitamin D Levels measurement using chemiluminescent assay|Measurement of serum vitamin D levels
215056775|NCT05101811|DEVICE|Vitamin D level assessment|Using lIAISON DEVICE
215056776|NCT03399942|PROCEDURE|Deep brain Stimulation of cingulum anterior|The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
214302746|NCT06903338|DRUG|Tobevibart|Tobevibart administered by subcutaneous injection
214302747|NCT06903338|DRUG|Elebsiran|Elebsiran administered by subcutaneous injection
214302748|NCT06930560|DEVICE|HEARS-NPS device|Tailored fitting and programming of a personal sound amplifier accompanied by an aural rehabilitation component.
214302749|NCT06930560|BEHAVIORAL|HEARS-NPS program|Tailored aural rehabilitation for participant and care partner.
214302750|NCT06895070|DEVICE|Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)|Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
214302751|NCT05746650|PROCEDURE|Electrical stimulation|Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
214302752|NCT05746650|DRUG|Growth hormone (somatropin)|Daily injection of growth hormone
214905695|NCT02593292|OTHER|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
215056777|NCT01634217|BIOLOGICAL|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
214905696|NCT04666740|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.
215056778|NCT04565912|DRUG|Sage extract mouthwash|Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
215056779|NCT04565912|DRUG|Chlorohexidine based mouthwash|Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
214905697|NCT04666740|DRUG|Olaparib|Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
214905698|NCT01841047|RADIATION|Radiotherapy|Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
215056780|NCT02360852|DRUG|A4250|A4250 once daily
215056781|NCT05698303|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
215056782|NCT06522477|OTHER|Virtual reality gait training|Individuals will walk on a treadmill with overhead harness system in place while viewing 1st-person perspective walking videos on a television placed immediately in front of the treadmill.
215056783|NCT05112614|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
214302753|NCT05746650|OTHER|Control (No electrical stimulation, nor growth hormone)|No electrical stimulation, nor growth hormone
215056784|NCT05112614|OTHER|Electronic Health Record Review|Review of medical records
214302754|NCT06930846|BEHAVIORAL|HOBSCOTCH-CA|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-CA is an adaptation of the HOBSCOTCH program for people who are survivors of brain cancer or a brain tumor that incorporates education about the effects from brain cancer/tumor and its treatment on cognition into the education module and gives them the option of enrolling with a Caregiver. CA Participants receive all sessions of HOBSCOTCH-CA. If they enroll with a Caregiver, the Caregiver participates in the education (introductory) session and sessions 1 and 8. The HOBSCOTCH-CA Participant may invite their Caregiver to attend all sessions.
214302755|NCT06880640|BEHAVIORAL|Stress Induction|Participants will complete the Trier Social Stress Test to induce stress, which includes a public speaking simulation and mental arithmetic.
214669892|NCT01275638|DRUG|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
214669893|NCT04746040|DRUG|Test|2 inhalations of Test and Reference product in each study period
215056785|NCT02054039|DEVICE|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
215056786|NCT02054039|DEVICE|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
215056787|NCT03137953|PROCEDURE|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
215056788|NCT03137953|DIAGNOSTIC_TEST|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
215056789|NCT00809926|DRUG|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
215056790|NCT00809926|DRUG|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
215056791|NCT00642707|DRUG|PRO 140 (humanized monoclonal antibody to CCR5)|
215056792|NCT00642707|DRUG|Placebo Comparator|
215056793|NCT00808522|DRUG|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
215056794|NCT02835703|PROCEDURE|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
215056795|NCT00130039|DRUG|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
215056796|NCT00130039|DRUG|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
215056797|NCT02530476|DRUG|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
214302756|NCT06878859|BEHAVIORAL|Amplification of Positivity - Cannabis Use (AMP-C)|AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.
214302757|NCT06176352|DRUG|Faricimab|Faricimab 6 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
214302758|NCT06176352|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
214302759|NCT06176352|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Participants will undergo the sham procedure at study visits where no study drug is to be administered, in order to maintain masking.
214302760|NCT07085845|OTHER|Inserting a swab 5 cm into the anus during self-sampling|The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 5 cm to collect anal exfoliated cells.
214302761|NCT07085845|OTHER|Self-sampling with a swab by inserting the swab 3 cm into the anus.|The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 3 cm to collect anal exfoliated cells.
214669894|NCT04746040|DRUG|Reference|2 inhalations of Test and Reference product in each study period
214905699|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 1Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 1 Hz ThorS-MagNT, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
214905700|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 10Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 10Hz ThorS-MagNT involves delivering one train of 100 pulses per minute with 50-second rest intervals over twelve minutes on both right and left sides (total 1200 pulses/side).
214905701|NCT05273788|DEVICE|Sham Stimulations|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. Sham stimulations, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
214905702|NCT06332014|DRUG|Prolia|Partcipants will receive subcutaneous (SC) injections of Prolia Q6M.
214905703|NCT03670615|OTHER|tDCS|All study participants randomized to tDCS will receive active tDCS.
214905704|NCT03670615|OTHER|Exercise|Participants will exercise at TRI according to an individualized exercise prescription.
214905705|NCT03670615|OTHER|Exercise Education|Exercise education/ treatment as usual will include routine advice about physical activity for older adults.
214905706|NCT03670615|OTHER|Sham tDCS|The same procedure for tDCS will be used for the sham condition, except without active current.
214905707|NCT03745209|DEVICE|Ultrasound|Use of real-time ultrasound in an attempt to establish intravenous peripheral catheter.
214905708|NCT03268083|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
214905709|NCT03268083|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
214905710|NCT03268083|BIOLOGICAL|EV71 vaccine ([1 μg total protein ] per dose)|Two vaccinations at 28 days apart
214905711|NCT01442597|BEHAVIORAL|Standard Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.
214905712|NCT01442597|BEHAVIORAL|Individual clinician-provided CBT|Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.
214905713|NCT01442597|BEHAVIORAL|CBT4CBT|Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
214905714|NCT06403176|OTHER|No intervention|No intervention
214905715|NCT01739205|BEHAVIORAL|CALM-D Intervention|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
214905716|NCT06317389|OTHER|Questionnaires|Patients will benefit of supervision by the ONCORAL team in the usual way and their intervention will be limited to completing questionnaires.
214905717|NCT00357981|DRUG|ORTHO EVRA, the contraceptive patch|
215056798|NCT02530476|DRUG|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
214905718|NCT06101966|RADIATION|external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)|Radical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age consideration and patients' desires.
214905719|NCT05047692|BIOLOGICAL|AdCLD-CoV19-1|Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein
214905720|NCT05784233|BEHAVIORAL|Relevance (Likelihood Salient Item is Target)|The proportion of trials, when the salient visual item is present in the array, where the salient item is the search target.
214905721|NCT00051051|DRUG|CI-1033|
214905722|NCT03447925|DRUG|Medicinal Plant|Medicinal Plant Extract with vaseline cream
215056799|NCT05875844|DIAGNOSTIC_TEST|Wrist Splint|Wrist Splint to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
215056800|NCT05875844|DIAGNOSTIC_TEST|Occupational Therapy|Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
214302762|NCT05069545|DRUG|Insulin degludec|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
214302763|NCT05069545|DRUG|Fast-acting insulin aspart|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
214302764|NCT07089550|RADIATION|PSMA PET/CT scan|All Patients undergoing PSMA PET for pre-treatment disease staging with different radiotracers (\[68Ga\]Ga-PSMA-11, \[18F\]-DCFPyL, \[18F\]-PSMA-1007).
214302765|NCT07088068|DRUG|Teplizumab|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
214302766|NCT07088068|OTHER|Placebo|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
214302767|NCT07087912|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|A single 0.5 mL dose of the live attenuated tetravalent dengue vaccine (Butantan-DV), administered subcutaneously on Day 1. The vaccine contains attenuated viral strains for DENV-1, DENV-3, DENV-4, and a chimeric DENV-2 component. It is manufactured and formulated by the Instituto Butantan (São Paulo, Brazil).
214905723|NCT03447925|DRUG|Salicylate|Salicylate 10% with vaseline cream
214905724|NCT03447925|DRUG|Vaseline|Vaseline cream
214905725|NCT01770769|DEVICE|Hemi - arthroplasty|modular hemiarthroplasty
214905726|NCT01770769|DEVICE|internal fixation|Two cancellous parallel screws - internal fixation of the femoral neck fracture
214905727|NCT06577246|PROCEDURE|scaling root planing|periodontal treatment in all groups was performed using ultrasonic and hand instruments (#15/30, #6/7) by the same physician (UGE) who was blind to the study groups.
214905728|NCT06577246|BEHAVIORAL|Three-Dimensional Animation (video1-2)|"The video used in the study was created by DentalMaster (MD Stimulation Ltd) by combining their own footage (http://www.mdsimulation.com/). This video is divided into three parts, summarized below:~* i. Overview of the causes and symptoms of periodontal disease (section 1)~* ii. Treatment of periodontal disease and daily oral care practices for individuals (section 2)"
214905729|NCT06577246|BEHAVIORAL|Three-Dimensional Animation (video 3)|iii.Consequences of periodontal disease (such as gingival recession and tooth loss) that individuals may face if periodontal diseases are not treated and if they do not perform regular oral care (section 3). In this group, patients watch the video together with the physician (SG), who is familiar with the randomized patient groups.
214907583|NCT05981989|DEVICE|Epidural electrical stimulation (EES)|Subjects will undergo a surgical procedure to implant a system that provides epidural electrical stimulation (EES) of the cervical spinal cord. After surgery, subjects will undergo a structured physical rehabilitation program and electrical stimulation.
214907584|NCT06972901|BIOLOGICAL|Early faecal calprotectin dosage|An early dosage of faecal calprotectin will be done for the active arm group.
214302768|NCT01446133|DRUG|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
214302769|NCT01446133|DRUG|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
214302770|NCT02311374|OTHER|Brain connectivity and physiology|Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
214302771|NCT02311374|OTHER|Brain Wave|ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
214302772|NCT06880016|DIAGNOSTIC_TEST|Evaluation of serial lung ultrasound data after ENSURE surfactant treatments|Intubating the infant, administering intratracheal surfactant, and then extubating them back to nasal respiratory support (ENSURE method)
214302773|NCT06880016|DIAGNOSTIC_TEST|Evaluation of serial lung ultrasound data after LISA surfactant treatments|Delivering surfactant via a thin catheter (5F) directly into the trachea while the infant remains on existing nasal respiratory support, without disconnecting them from it (LISA method)
214302774|NCT06840834|DRUG|Ivonescimab|Ivonescimab is administered IV Q3W on Day 1 of each cycle. Ivonescimab is given at a dose of 20 mg/kg (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥160 kg). The total duration of ivonescimab treatment is up to 24 months.
214302775|NCT07092514|DRUG|Lenvatinib|Lenvatinib is an oral drug which will be administered on an outpatient basis at a dose of 24 mg daily or 10 mg daily for an unlimited number of cycles.
214907585|NCT00832702|PROCEDURE|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
214907586|NCT03523416|DEVICE|Transcatheter Atrial Shunt System|Transcatheter treatment of symptomatic left heart failure patients
214302776|NCT04194736|OTHER|Ultrasound scan|"First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan."
214905730|NCT06577246|BEHAVIORAL|Periodontal Disease Prediction (PDP)|The patients in the test group viewed sections 1 and 2 videos in the same manner as the 3DA group. However, unlike the 3DA group, they did not view section 3. Instead, they were shown estimates of their current condition and potential future periodontal tissue loss (gingival recession) for 1-5 years, 5-10 years, and 10-20 years. These projections were presented to the patients in three dimensions with PDP visualisation.
214905731|NCT00473317|BEHAVIORAL|Sun Exposure|Each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).
214905732|NCT05488340|DRUG|LBP-EC01 0.1 x IV dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
214905733|NCT05488340|DRUG|LBP-EC01 0.01x IV Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
214905734|NCT05488340|DRUG|LBP-EC01 IV Infusion Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
214302777|NCT05427318|BEHAVIORAL|PATH|The intervention integrates two theoretically-grounded interventions - one with a strong peer navigator component and the other with a scalable mHealth component - into the intervention called Peers plus mobile App for Treatment in HIV (PATH)
214302778|NCT07095738|DIAGNOSTIC_TEST|thermal images (IT)|The IT images were recorded with an OPTRIS PI 450 IRT camera coupled to Optris PI Connect Software (Germany). The IRT camera has a Noise Equivalent Temperature Difference \<40 mK with 38º x 29º FOV, a wide range of temperature from -20°C to +100°C, spectrum range of 7.5-13 μm, focal plane array sensor size of 382 × 288 pixels, emissivity set at 0.98 and a measurement uncertainty of ± 2% of the overall temperature reading. The size of the capture frame will be 55.4 × 40.63 cm (1.5 mm/px).
214302779|NCT04244864|BEHAVIORAL|Cross-sectoral psychosocial intervention|The intervention seeks to integrate working with social stressors alongside treatment for trauma-related mental health problems. This is done in two ways; by a cross-sectoral collaboration with the patient's case counsellor in the municipality including three collaborative meetings and by a systematic focus on social stressors during the treatment.
214302780|NCT04244864|BEHAVIORAL|Treatment as usual (TAU)|"Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy."
214302781|NCT07093528|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR)|Patients will consent to undergo a 50-minute non-invasive stress perfusion CMR.
214302782|NCT06747585|DRUG|ALE.P02|ALE.P02, will be administered by IV infusion according to the assigned arms.
214302783|NCT06542874|DRUG|NNC0487-0111 subcutanous|NNC0487-0111 administered subcutanously (under the skin)
214302784|NCT06542874|DRUG|Placebo (NNC0487-0111 subcutanous)|NNC0487-0111 placebo administered subcutanously (under the skin)
214302785|NCT06542874|DRUG|NNC0487-0111 oral|NNC0487-0111 administered orally (in the mouth)
214302786|NCT06542874|DRUG|Placebo (NNC0487-0111 oral)|NNC0487-0111 placebo administered orally (in the mouth)
214905735|NCT05488340|DRUG|Placebo|Dose regimen selected from Part 1 of placebo (Tris buffer).
214905736|NCT05488340|DRUG|LBP-EC01|Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.
214302789|NCT07104799|DRUG|Momelotinib|Administered orally once per day during each 28-day cycle. This will start on day -7 (7 days before HCT) and continue for up to 13 cycles. Dose cohorts (100 mg daily, 150 mg daily, 200 mg daily) will be investigated in the peri-transplant period. Once participants have achieved hematopoietic recovery and are at least Day 21 after HCT, participants will increase the dose to 200 mg daily.
214479308|NCT06587529|BEHAVIORAL|The Set Me Free Project's (SMFP) READY to Stand (RTS)© Curriculum|Students will receive the Ready to Stand (RTS)© programming over six school days, spread over six weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
214479309|NCT06597682|DRUG|Prednisone|Total 4 weeks of treatment
214479310|NCT06597682|DRUG|Budesonide/Formoterol|Total 8 weeks of treatment
214905737|NCT05488340|DRUG|TMP/SMX|TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
214905738|NCT05169515|DRUG|SC Mosunetuzumab|Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)
214905739|NCT05169515|DRUG|IV Glofitamab|Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
214905740|NCT05169515|DRUG|Iberdomide|Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
214905741|NCT05169515|DRUG|Golcadomide|Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)
214905742|NCT05169515|DRUG|Obinutuzumab|Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
214905743|NCT05169515|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
214905744|NCT06307795|DRUG|ANS014004|Varying doses of ANS014004
214905745|NCT06191744|DRUG|Epcoritamab|Subcutaneous (SC) Injection
214905746|NCT06191744|DRUG|Prednisone|Oral Tablet
214905747|NCT06191744|DRUG|Rituximab|Intravenous (IV) Infusion
214905748|NCT06191744|DRUG|Lenalidomide|Oral Capsule
214905749|NCT06191744|DRUG|Doxorubicin|IV Injection
214905750|NCT06191744|DRUG|Vincristine|IV Injection
214905751|NCT06191744|DRUG|Cyclophosphamide|IV Injection
214905752|NCT06191744|DRUG|Obinutuzumab|IV Infusion
215056801|NCT00901238|PROCEDURE|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
215056802|NCT06396702|OTHER|EASE-SOT|EASE integrates supportive counseling and trauma-focused cognitive behavioral therapy (CBT) (EASE-psy) with systematic physical symptom screening and triggered referral to supportive care to manage moderate to severe physical symptoms (EASE-phys) using electronic patient reported outcome measures (ePROMs). The intervention duration is 8 weeks. Based on individual preference, EASE-psy may be administered in person or virtually via Microsoft Teams. Based on individual preference, participants may receive ePROMs either on tablets or to their personal electronic devices via email, while at the hospital ward and in clinics, ensuring easy access and administration of these tools.
214302790|NCT07108049|BEHAVIORAL|Let us Grow Together: Economic Wellbeing for Families|Married couples in clusters assigned to the intervention receive a structured program of six community-based sessions. Each session lasts between 2.5 and 3 hours and includes participatory activities, discussions, and exercises. All six sessions would be conducted by the same two facilitators - one male and one female. The content integrates financial literacy (e.g., household budgeting, saving practices, joint financial planning) with gender-transformative training (e.g., equitable household roles, communication skills, conflict resolution, and fostering empathy between spouses). Sessions are delivered by trained facilitators in a group setting with fifteen couples, approximately every 2-4 weeks. Some sensitive content to address economic violence context would be done in a gender segregated manner separately to encourage reflections, ensure safety and reduce defensiveness. Between sessions, SMS reminders and tips are sent to participants' mobile phones to reinforce key messages and e
214479311|NCT06597682|DRUG|Vitamin C combined with Coenzyme Q10 oral treatment|Total 4 weeks of treatment
214905753|NCT06191744|DRUG|Bendamustine|IV Infusion
214905754|NCT06022406|BIOLOGICAL|FMT capsules|Formulation: 80-100g of healthy donor stool processed, frozen and encapsulated in gelatin capsules (modified Kao et al, 2017).
214905755|NCT06022406|BIOLOGICAL|Placebo capsules|Formulation: microcrystalline cellulose, for equivalence in weight and color, will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
214905756|NCT04737889|DRUG|Rituximab|Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
214905757|NCT04737889|DRUG|Lenalidomide|"Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles."
214905758|NCT04737889|DRUG|Methotrexate|Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
214905759|NCT04737889|DRUG|Temozolomide|Induction Chemotherapy: 150mg/m2/d oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
214905760|NCT05581641|BIOLOGICAL|BNT165b1|RNA vaccine for active immunization against malaria administered as intramuscular injection.
214905761|NCT05581641|OTHER|Placebo|Placebo matched to RNA vaccine administered as intramuscular injection.
215056803|NCT06207552|GENETIC|BBM-F101 injection|The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
215056804|NCT01706731|BEHAVIORAL|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
215056805|NCT01706731|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
215056806|NCT05812963|DIAGNOSTIC_TEST|IVUS-guided PCI group|In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
215056807|NCT05812963|DIAGNOSTIC_TEST|FFR-guided PCI group|In FFR-guided PCI group, FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.
215056808|NCT00286650|PROCEDURE|3rd molar teeth extraction|
215056809|NCT03586960|DEVICE|Peak Force Measurement|Force will be measured at 5,10, and 30 minutes
215056810|NCT05881707|DRUG|CKD-828, D064, D702|QD, PO
214479312|NCT06597682|DRUG|Montelukast tablets oral treatment|Total 8 weeks of treatment
214479313|NCT06597409|OTHER|Standard PR|(Aerobic exercise, PLB, ACBT, Education)
214905762|NCT06982365|DIETARY_SUPPLEMENT|Enovita® (Grape Seed Extract)|Enovita® is a standardized grape seed extract containing polyphenols, known for their antioxidant and vasodilatory properties. Participants in this group will take 150 mg of Enovita® orally, twice daily (total daily dose: 300 mg) for 8 weeks.
214905763|NCT06982365|OTHER|Placebo Capsule|Participants in this group will receive a matching placebo capsule identical in appearance to the Enovita® capsule, taken orally, twice daily for 8 weeks.
214905764|NCT04064827|DRUG|Paricalcitol|Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser
214302791|NCT02979873|DRUG|Sirolimus|Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).
215056811|NCT03321071|BEHAVIORAL|Healthy Summer Learners|"Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.~Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.~Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.~Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading."
215056812|NCT03321071|BEHAVIORAL|21st Century Summer Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
215056813|NCT05007548|DRUG|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
214905765|NCT03993626|DRUG|CXD101 in Combination With Nivolumab|HDAC inhibitor in combination with anti-PD-1 monoclonal antibody
214905766|NCT05111561|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214905767|NCT05111561|DRUG|Binimetinib|Given PO
214905768|NCT05111561|PROCEDURE|Biopsy Procedure|Undergo biopsy
214905769|NCT05111561|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215056814|NCT06237634|OTHER|splint and exercise and advices|A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.
214905770|NCT05111561|PROCEDURE|Computed Tomography|Undergo CT
215056815|NCT06237634|OTHER|Triamsinolon Asetonid ozone|40 mg (1 ml) of triamcinolone acetonide was injected to the median nerve's around at wrist level under ultrasound guidance.
214302792|NCT06833073|BIOLOGICAL|Intismeran autogene|IM injection
214302793|NCT06833073|BIOLOGICAL|BCG|Intravesicular instillation. BCG is a preparation of Bacillus Calmette-Guerin.
214302794|NCT06823167|BIOLOGICAL|IM-1021|IM-1021 is an antibody-drug conjugate
214302795|NCT06693310|OTHER|de-escalation or discontinuation of therapy|De-escalation of therapy, defined as a step-down from maintenance with advanced therapy (biologic or synthetic small molecule) to oral aminosalicylate-based therapy or complete discontinuation of therapy if they are allergic or intolerant to aminosalicylate-based therapy. If patients are receiving immunomodulator or oral aminosalicylate maintenance therapy, they will be de-escalated to complete discontinuation of therapy.
214302796|NCT06693310|OTHER|continuation of current therapy|continuation of current maintenance medical therapy for ulcerative colitis
214669895|NCT04554576|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish|"The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)"
214905771|NCT05111561|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214905772|NCT06683534|DIETARY_SUPPLEMENT|Quercetin (dietary supplement)|Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.
215056816|NCT06237634|OTHER|ozone|In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
215056817|NCT05715060|PROCEDURE|Median sternotomy closure (sternal closure)|Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire \& Polydioxanone (PDS)
215056818|NCT01296503|DRUG|Thalidomide plus dexamethasone|"D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
214905773|NCT06683534|DRUG|Placebo|Subjects randomized to receive placebo will be administered a standard placebo sugar pill.
214905774|NCT06686979|OTHER|No Intervention: Observational Cohort|The patients with R/M SGC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
214905775|NCT07040033|OTHER|There will be no intervention|There will be no intervention
214479314|NCT06597409|OTHER|Standard PR plus Respiratory Muscle Stretching (RMS)|Standard PR plus Respiratory Muscle Stretching (RMS)
215056819|NCT01296503|DRUG|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
215056820|NCT06093399|DEVICE|System ON|The DBS system will be turned on, and the individual's stutter will be assessed.
215056821|NCT06093399|DEVICE|System OFF|The DBS system will be turned off, and the individual's stutter will be assessed.
215056822|NCT01541488|DRUG|BI 1021958|tablet
215056823|NCT01541488|DRUG|BI 1021958|drinking solution / tablet
215056824|NCT01541488|DRUG|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
215056825|NCT00100802|OTHER|Laboratory Biomarker Analysis|Correlative studies
214669896|NCT04554576|BEHAVIORAL|Remote feedback active group|After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)
214905776|NCT07040033|BEHAVIORAL|There will be no intervention|There will be no intervention
214669897|NCT04554576|BEHAVIORAL|Remote feedback control group|After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.
214302803|NCT06744543|DEVICE|SIGHT Prompted Provider Message|Among patients surpassing a 0.30 probability threshold that have a scheduled visit to pediatric primary care at VUMC, 500 will be randomized to the intervention and a SIGHT-prompted provider message will be generated.
214905777|NCT06719440|RADIATION|Radiotherapy (CTV=10mm)|Radiotherapy with reduced irradiation volume CTV=10mm
214669898|NCT05502588|BEHAVIORAL|Self-Guided Forest Bathing|Participants will participate in two, 60-90 minute self-guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails and be given prompts to consciously use their five senses in the forest.
214479315|NCT06599528|DRUG|T-R (Test-Reference drug)|T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.
214479316|NCT06599528|DRUG|R-T (Reference-Test drug)|R: Ovidrel®(Referecne drug) T: SJ04 (Test drug) 250 μg of SJ04 or Oviderl®, administered subcutaneously once at two week intervals.
214479317|NCT06591728|DIETARY_SUPPLEMENT|Oral PCA|Administration of 1,000 mg BID of oral PCA in individuals with knee prosthetic joint infection prior to revision surgery
214479318|NCT05894096|DEVICE|Cold Atmospheric Plasma Jet Treatment|Application of Colf Atmospheric Plasma Jet on the wound
214905778|NCT06719440|RADIATION|Radiotherapy (CTV=15mm)|Radiotherapy with standard irradiation volume CTV=15mm
214905779|NCT06703437|DRUG|Dehydrated alcohol|Long-acting neuraxial blockade at the time of prostate biopsy by periprostatic injection of Dehydrated alcohol.
214905780|NCT06703437|DRUG|Lidocaine IV|By periprostatic injection, 2mL
214905781|NCT06157008|DRUG|General Anesthetics|General anesthetics used in spinal cord electrical stimulator insertion surgery
214905782|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
214302806|NCT06570798|DRUG|Inebilizumab|Intravenous (IV) Infusion
214302807|NCT06570798|DRUG|Blinatumomab|SC Injection
214302808|NCT07100938|DRUG|BGB-45035|Administered orally
214302809|NCT07100938|DRUG|Placebo|Administered orally
214905783|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions BID over 14 days
214905784|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions daily (QD) over 14 days
214905785|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
214905786|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every QD over 14 days
214905787|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
214905788|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
214905789|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
214905790|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
214905791|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
214905792|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
214905793|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
214302810|NCT07109843|DIETARY_SUPPLEMENT|Boswellia serrata extract|Boswellia Serrata 1x day (600mg)
214302811|NCT07109843|OTHER|Placebo|Placebo 1x/day
214302812|NCT06864208|BEHAVIORAL|Behavioral Weight Management|Prescription of diet and physical activity strategies paired with behavioral strategies for weight management
214479319|NCT05894096|DEVICE|Alginate Patch|Application of Alginate Patches on the wound
214479320|NCT06457958|DRUG|Sevoflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Sevoflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Sevoflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
214905794|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
214905795|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
214905796|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
214905797|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
214905798|NCT05807490|DRUG|PF-07328948|Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition
214905799|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
214905800|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
214905801|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
214905802|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
214905803|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
215056826|NCT00100802|DRUG|Lomustine|Given PO
215056827|NCT00100802|RADIATION|Radiation Therapy|Undergo radiation therapy
215056828|NCT00100802|DRUG|Temozolomide|Given PO
214669899|NCT05502588|BEHAVIORAL|Guided Forest Bathing|Participants will participate in two, 60-90 minute guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails. They will be invited by a certified forest therapy guide to consciously use their five senses in the forest.
214905804|NCT00204490|DIETARY_SUPPLEMENT|isoflavones|soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.
214905805|NCT00204490|DIETARY_SUPPLEMENT|carbohydrate|carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.
214905806|NCT02901938|PROCEDURE|cemented femoral stem|The patients assigned even numbers will undergo implantation of cemented femoral stem.
214905807|NCT02901938|DEVICE|cannulated compression screws|The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
214905808|NCT06551493|OTHER|Observation of postnatal wound assessment|Observation of postnatal wound assessment
214905809|NCT06551493|OTHER|Interview|Interview to elicit individual perspectives of wound assessment
214905810|NCT01497028|PROCEDURE|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
214905811|NCT04214977|PROCEDURE|Spinal Anesthesia for Anorectal Surgeries in Prone Position|Spinal anesthesia in sitting position was done under complete aseptic technique through a standard midline approach. One and a half millilitres of 0.5% bupivacaine (7.5 mg) was injected through a 25 Gauge pencil-point needle into the subarachnoid space at L3-L4 or L4-L5 interspace. All patients were kept in a head-up position for 3 minutes. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
214905812|NCT04214977|PROCEDURE|General Anesthesia Using Laryngeal Mask Airway for Anorectal Surgeries in Prone Position|General anesthesia was induced using fentanyl 2 mcg/kg and Propofol 2-3 mg/kg. Any stomach contents were then suctioned through an oro-gastric tube to reduce the risk of regurgitation. Proper (weight-based) classic laryngeal mask airway was then blindly inserted. laryngeal mask airway was then properly fixed to the face and anesthesia was maintained with isoflurane 1-2% in 50% Oxygen/air mixture.
214905813|NCT01582776|DRUG|Lenalidomide and GA101|1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
214905814|NCT06325826|DIAGNOSTIC_TEST|General Evaluation Score (GES)|According to Evaluation of GES scores Patient will be classified into three groups based on GES score low risk group (score ≤6 points), intermediate risk group (score 6-7.5 points), and high-risk group (score \>7.5 points)
214905815|NCT00238966|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214905816|NCT04145765|OTHER|correlation|the subjects completed the questionnaires
214905817|NCT06704672|DEVICE|Accu-Chek SmartGuide CGM Solution|The Accu-Chek SmartGuide CGM solution is used for real-time continuous glucose monitoring (CGM) in the interstitial fluid. It consists of the Accu-Chek SmartGuide device and two smartphone applications (apps): the Accu-Chek SmartGuide app and the Accu-Chek SmartGuide Predict app. The Accu-Chek SmartGuide device contains a CGM sensor pre-assembled in a sensor applicator. It has connectivity to the smartphone that is running the Accu-Chek apps. The Accu-Chek SmartGuide app is the primary display of the real-time glucose values. The Accu-Chek SmartGuide Predict app is an information management tool that further visualizes and analyzes diabetes data from the Accu-Chek SmartGuide device.
214905818|NCT06704672|DEVICE|Accu-Chek SmartGuide Sensor and Blinded Apps|The participants in the SMBG control group will wear a SmartGuide sensor with blinded SmartGuide apps intermittently, i.e., during the assessment periods. It is not possible to read out the glucose data from the blinded app, hence neither the SmartGuide app nor the SmartGuide Predict functionalities can be accessed by the participants in this group.
214905819|NCT06704672|DEVICE|SMBG Device|With the SmartGuide apps in blinded mode, participants in the SMBG control group will continue using their own SMBG device or they may use the Accu-Chek Instant meter that will be provided for calibration of the SmartGuide device.
214905820|NCT02257710|DEVICE|Orsiro|
214905821|NCT05460338|DRUG|Cholecalciferol|native form of Vitamin D.
214905822|NCT02397512|DRUG|application of lactulose|Subjects will ingest 50g of lactulose once
214905823|NCT02397512|OTHER|application of sucrose|Subjects will ingest 50g of sucrose once
214905824|NCT05952102|DRUG|Nigella Sativa Oil capsule|Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
214905825|NCT02166333|DIETARY_SUPPLEMENT|200 IU/d cholecalciferol|
214905826|NCT02166333|DIETARY_SUPPLEMENT|1000 IU/d cholecalciferol|
214302813|NCT06864208|BEHAVIORAL|Weight Bias Internalization|Addressing weight stigma and improving weight-related self-perception through challenging weight-related stereotypes, practicing self-compassion, reducing self-criticism, and coping with weight stigma
214905827|NCT02166333|DIETARY_SUPPLEMENT|2000 IU/d cholecalciferol|
214905828|NCT02166333|DIETARY_SUPPLEMENT|4000 IU/d cholecalciferol|
214905829|NCT01853215|DEVICE|T.A.L.O.N. Intraosseous System|intraosseous catheter for use in the sternum
214905830|NCT03221647|OTHER|Intestinal biopsies|Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.
214905831|NCT03901677|OTHER|Tai-chi training|Group exercise apply with physiotherapist
214302814|NCT07108114|DRUG|SLV-324 intravenous (IV infusion)|SLV-324 will be administered as an IV infusion
214302815|NCT07115212|DIETARY_SUPPLEMENT|Bromelain|1 tablet daily with water, for 9 days-starting 2 days before surgery and continuing for 7 days after. Record each dose in the provided log, along with any other medications taken and the time they were taken.
214905832|NCT03523520|DRUG|Methylnaltrexone Bromide 150 mg Oral Tablet|Methylnaltrexone Bromide 150 mg Oral Tablet
214905833|NCT03523520|DRUG|Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1|Methylnaltrexone Bromide 12 MG Subcutaneous Solution
215056829|NCT04454060|PROCEDURE|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
215056830|NCT01521598|DRUG|SKL11197|SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
215056831|NCT01521598|DRUG|Placebo|This is the placebo. Patients will be randomized the placebo.
215056832|NCT02709720|DRUG|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
215056833|NCT02709720|DRUG|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
214669900|NCT04752787|OTHER|Online breastfeeding training|Online breastfeeding training will be provided to pregnant women expecting twin babies.
214905834|NCT03523520|DRUG|Naloxegol 25 MG Oral Tablet|Naloxegol 25 MG Oral Tablet
214905835|NCT03083327|DIETARY_SUPPLEMENT|Parenteral nutrition.|Nutrition support will be provides as per usual, but oral and enteral intake will be topped up with a standard parenteral nutrition solution. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L).
214905836|NCT03083327|OTHER|Pragmatic standard care.|Nutrition support will be provided as per usual care.
215056834|NCT02709720|DRUG|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
215056835|NCT02709720|DRUG|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
215056836|NCT02709720|RADIATION|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
214302816|NCT07114198|DRUG|Ibuprofen 10 mg/kg|Ibuprofen was administered orally at a dose of 10 mg/kg body weight, 40 minutes before the start of the dental procedure. This intervention was designed to reduce intraoperative pain and pulse elevation associated with reversible pulpitis.
214302817|NCT06921434|DIETARY_SUPPLEMENT|Monk fruit sweetener mouth rinse|monk fruit mouth rinse 10 grams of sweetener powder and 90 ml of distilled water for 30 participants for 1 minute
214302818|NCT06921434|DIETARY_SUPPLEMENT|Splenda (sucralose) sweetener mouth rinse|10 g of splenda powder with 90 ml of distilled water for 30 participants for 1 minute
214905837|NCT04389229|DRUG|cyclophosphamide|600mg/m2/day for 3 days ( on day -5, -4, -3)
214905838|NCT04389229|DRUG|fludarabine|30mg/m2/day for 3 days ( on day -5, -4, -3)
215056837|NCT03478670|GENETIC|Strimvelis|"Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only.~This is an observational registry that includes all patients who have previously received Strimvelis™ or GSK2696273."
215056838|NCT03744338|OTHER|questionnaire|"The questionnaire is composed of two parts:~The first part let know the characteristics of the patients as age, the BMI, the socio-professional category, the current treatments, the medical-surgical antecedents of interest."
215056839|NCT02615119|DRUG|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
215056840|NCT02615119|DRUG|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
214302819|NCT06921434|DIETARY_SUPPLEMENT|Sucrose mouth rinse|10 g of sucrose powder dissolved in 90 ml of distilled water as a positive control group for 30 participants for 1 minute
214302820|NCT06921785|DRUG|Tremelimumab|IV therapy
214302821|NCT06921785|DRUG|Rilvegostomig|IV therapy
214302822|NCT06921785|DRUG|Bevacizumab|IV therapy
214669901|NCT04752787|OTHER|QR code supported online breastfeeding training|QR code supported online breastfeeding training will be given to pregnant women who are expecting twin babies.
214302823|NCT06921785|DRUG|Atezolizumab|IV therapy
214302824|NCT07116967|DRUG|Deucravacitinib|Specified dose on specified days
214302825|NCT07116967|DRUG|Ustekinumab|Specified dose on specified days
214905839|NCT04389229|DRUG|IL-2 (Proleukin)|Subcutaneous injections at a fixed dose of 18 million units once a day following TIL infusion
214905840|NCT04389229|GENETIC|Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)|Single dose at 5 x 10\^9 - 5 x 10\^10
214905841|NCT04389229|GENETIC|Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)|Single dose at 2 x10\^9 (+/- 20%) (engineered TIL)
214905842|NCT00868920|OTHER|patient control of pump|Patient controls sedation pump during colonoscopy.
214905843|NCT00868920|OTHER|anesthesiologist controlled sedation|Anesthesiologist will control the sedation pump during colonoscopy.
214905844|NCT05895448|DRUG|velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .|Directly active antiviral therapy (velpatasvir 100 mg+sofobuvir 400 mg) once daily
214905845|NCT00495573|DRUG|acyclovir|400 mg acyclovir, orally three times a day for 5 days
214905846|NCT02604095|DIETARY_SUPPLEMENT|melatonin|Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
214905847|NCT00682786|DRUG|5FU|
214905848|NCT00682786|RADIATION|Radiation|
214905849|NCT00682786|PROCEDURE|Surgery of resectable lesions|
215056841|NCT04514731|DRUG|Magnesium sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of isotonic saline over 15 minutes after spinal anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/hour) until the end of surgery.
215056842|NCT04514731|DRUG|Isotonic Saline|Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
215056843|NCT04871828|DRUG|Leukotriene Receptor Antagonist|Zafirlukast
215056844|NCT04871828|OTHER|Placebo|Placebo
215056845|NCT02062515|DRUG|icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
215056846|NCT01484145|DRUG|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
215056847|NCT01198574|DIETARY_SUPPLEMENT|Iron group|Ferrous fumarate, 60 mg, weekly dose
215056848|NCT01198574|DIETARY_SUPPLEMENT|Vitamin A group|Retinol, weekly dose, 15,000 IU
215056849|NCT01198574|DIETARY_SUPPLEMENT|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
215056850|NCT01198574|DIETARY_SUPPLEMENT|Placebo group|folic acid only as placebo group
215056851|NCT02462031|DRUG|KD101|200mg, 400mg, 800mg, 1400mg
215056852|NCT02462031|DRUG|placebo|200mg, 400mg, 800mg
214669902|NCT02852369|BEHAVIORAL|Task Oriented Treatment|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
214669903|NCT06495151|DIAGNOSTIC_TEST|Mannose-binding lectin-associated serine protease-3 (MASP-3) Level|Measurement of venous blood serum and peritoneal fluid levels of MASP-3 level by ELISA method.
214669904|NCT06495151|DIAGNOSTIC_TEST|Adipsin Level|Measurement of venous blood serum and peritoneal fluid levels of adipsin level by ELISA method.
214905850|NCT00682786|DRUG|Irinotecan|
214905851|NCT03551990|PROCEDURE|whole-body electromyostimulation WB-EMS|Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
214905852|NCT05667090|OTHER|Vitamin D|Oral supplementaiton of 576,000 IU once a week of vitamin D3 for 4 weeks
214905853|NCT05667090|OTHER|Placebo|Oral supplementaiton of placebo once a week for 4 weeks
214905854|NCT02381847|PROCEDURE|intraperitoneal chemoperfusion|HIPEC with cisplatin at the time of D2 radical surgery
214905855|NCT05684874|RADIATION|Neoadjuvant RT|"Dosimetric CT scan with contrast injection for treatment planning. Radiation therapy at a dose of 50Gy in 25 fractions, 5 fractions per week. Daily pre-treatment positioning tomographic imaging (either high energy (MVCT) or cone beam computed tomography (CBCT)).~Delineation of the tumor volume and evaluation of its evolution. In case of change of volume and if medically relevant, new dosimetric scan and collection of the tumor volume."
214905856|NCT05684874|OTHER|Pre-radiotherapy mpMRI|"Performed less than 14 days before the dosimetric scan. Conventional morphological T1-weighted, T2-weighted, and T1-weighted imaging sequences after injection of contrast agent.~Quantitative imaging sequences including multiple b-value diffusion imaging. Chemical shift sensitized sequences."
215056853|NCT02060786|DRUG|generic clopidogrel (Plavitor® )|
214669905|NCT06495151|DIAGNOSTIC_TEST|Properdin Level|Measurement of venous blood serum and peritoneal fluid levels of properdin level by ELISA method.
214669906|NCT06495151|DIAGNOSTIC_TEST|Complement Factor H (CFH) Level|Measurement of venous blood serum and peritoneal fluid levels of CFH level by ELISA method.
214669907|NCT06495151|DIAGNOSTIC_TEST|Cancer Antigen 125 (CA-125) Level|Measurement of venous blood serum level of CA-125 level by ELISA method.
214669908|NCT01748383|PROCEDURE|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
214669909|NCT01748383|PROCEDURE|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
214669910|NCT01748383|PROCEDURE|stenting of IRA|The only stent implantation
214905857|NCT05684874|OTHER|Post-radiotherapy mpMRI|"Performed 4 to 6 weeks after the end of the radiotherapy. Conventional morphological T1-weighted, T2-weighted, and T1-weighted imaging sequences after injection of contrast agent.~Quantitative imaging sequences including multiple b-value diffusion imaging. Chemical shift sensitized sequences."
214905858|NCT05684874|PROCEDURE|Tumor resection|Performed 6 to 8 weeks after the end of radiotherapy. An anatomopathological observation of the surgical specimen will be performed.
214905859|NCT05383131|DRUG|HEC585|Mulltiple doses of HEC585 for up to 10 days
214905860|NCT05383131|DRUG|Pirfenidone|Mulltiple doses of Pirfenidone for up to 3 days
214905861|NCT05383131|DRUG|Nintedanib|Mulltiple doses of Nintedanib for up to 7 days
214905862|NCT01294774|DRUG|KRP203 - 1.2mg|
214905863|NCT01294774|DRUG|Placebo to KRP203 - 1.2 mg|
214905864|NCT03099031|DRUG|Tinzaparin|Subcutaneous injection of 175 IU/kg once daily for 6 months
214905865|NCT00396682|DRUG|Cyclophosphamide|150 - 250 - 350 mg
214905866|NCT07062380|PROCEDURE|Curative liver resection|Standard radical hepatectomy performed according to 2024 HCC guidelines. No neoadjuvant or adjuvant therapies administered. Follows institutional surgical protocols for BCLC 0-A HCC.
214905867|NCT07062380|PROCEDURE|Real-world multimodal therapy|Curative resection combined with clinically indicated therapies (e.g., TACE, targeted drugs, immunotherapy) as per treating physician's decision. Treatments recorded but not protocol-mandated.
214905868|NCT00359424|DRUG|IV rt-PA alone|Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
214905869|NCT00359424|OTHER|endovascular therapy|Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
214905870|NCT01210534|OTHER|No intervention|No intervention
215056854|NCT02060786|DRUG|original clopidogrel (Plavix® )|
215056855|NCT00648648|DRUG|adavosertib|adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
215056856|NCT00648648|DRUG|gemcitabine|Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
215056857|NCT00648648|DRUG|cisplatin|Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.
214302826|NCT06924827|DRUG|Epidiolex 100 mg/mL Oral Solution|The participant's 'artisanal' CBD and Epidiolex dose should be taken consistently with food or consistently without food throughout the entire study. The participant's dosing with or without food should be consistent with their method of dosing of 'artisanal' CBD prior to screening. Oral administration is recommended. When necessary, Epidiolex can be enterally administered via silicone feeding tubes, such as nasogastric or gastrostomy tubes.
214905871|NCT00762710|DRUG|Prazosin medication|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
214905872|NCT00762710|DRUG|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
214905873|NCT05828381|DRUG|Envafolimab|300mg,sc,d1,q3w; for a total of 2 cycles.
214905874|NCT05828381|DRUG|Abraxane|100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles
214905875|NCT05828381|DRUG|Cisplatin|75 mg/m2 vigtt D1 , q3w , for a total of 2 cycles
214905876|NCT02569879|OTHER|Pertussis maternal immunization|Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.
214905877|NCT02218138|BEHAVIORAL|Learning 2 BREATHE|Mindfulness-based group program
214905878|NCT02218138|BEHAVIORAL|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
214905879|NCT02462603|DRUG|PTC-589|PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
214905880|NCT00720551|OTHER|alcohol|alcohol 0.05%, 0.08% or 0.11% or placebo
214905881|NCT01235754|DRUG|transdermal testosterone gel 1%|300 mcg once daily transdermal testosterone gel 1%
214905882|NCT01235754|DRUG|placebo gel|once daily transdermal placebo gel
214905883|NCT07063823|DRUG|HB-2121|HB-2121 taken once orally.
214905884|NCT01370629|DRUG|Vernakalant|Prescribed at the discretion of the physician in accordance with their usual practice
214905885|NCT00025025|OTHER|sample testing|
214905886|NCT01461837|DRUG|CD34 selected T-cell depleted allogeneic SCT|Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
214905887|NCT05160922|DRUG|crizotinib|crizotinib oral treatment
214905888|NCT06498648|DRUG|Abemaciclib|Given PO
214905889|NCT06498648|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214905890|NCT06498648|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215056858|NCT00648648|DRUG|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
215056859|NCT00781638|DEVICE|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
215056860|NCT01791621|OTHER|Elimination/Challenge Diet|"An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team."
214302827|NCT06916741|DIAGNOSTIC_TEST|Ultrasound with Sacral lift|Intervention includes using a sacral lift during ultrasound to collect femoral vein measurements.
214302828|NCT06922149|OTHER|Group A Funtional massage therapy and eccentric exercise in lower limb|Functional Massage (FM) on lower limb. FM is a therapeutic technique that incorporates joint motion with massage to treat musculotendinous pain and impairments. Eccentric exercises training for lower limb. It can be useful in strengthening the muscles of the lower limbs, and promoting gait performance.
214669911|NCT03701503|BEHAVIORAL|Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women|
214669912|NCT02936895|DRUG|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
214669913|NCT02936895|DRUG|Placebo|Placebo for 2 days
214905891|NCT06498648|PROCEDURE|Computed Tomography|Undergo PET/CT
214905892|NCT06498648|DRUG|Docetaxel|Given IV
214905893|NCT06498648|OTHER|Fluorothymidine F-18|Given IV
214905894|NCT06498648|DRUG|Gemcitabine|Given IV
214905895|NCT06498648|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214905896|NCT02805920|DRUG|Bupivacaine|comparison of different volumes-dosages of 0.25% Bupivacaine
214905897|NCT02092376|DRUG|Cholecalciferol|
214905898|NCT02092376|DRUG|Placebo|
214905899|NCT03067727|DRUG|Dinoprostone|The DVI contains 10 mg Dinoprostone
214905900|NCT03067727|DRUG|Placebo|The placebo product is identical with the active product except that it does not contain Dinoprostone.
214905901|NCT00004330|DRUG|luteinizing hormone-releasing factor|
214905902|NCT05888220|OTHER|warm salt water bath|Warm water and warm salt water bath were applied to the hands and feet of the patients. It is a non-pharmacological intervention
214905903|NCT03312244|DRUG|Pyridostigmine Bromide|Pyridostigmine 180mg/day p.o.
214905904|NCT03312244|DRUG|Placebo|Placebo
214905905|NCT00304850|BEHAVIORAL|polyamine-free diet|Polyamine-free diet in the 7 days befor surgery
214905906|NCT00304850|DRUG|Ketamine or placebo|Peroperative and post operative (48h) ketamine injection
214905907|NCT02044263|BEHAVIORAL|Internet CBT-i SHUTi|Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
214905908|NCT02044263|BEHAVIORAL|face-to-face CBT-i|
214905909|NCT05479786|OTHER|Expectant management|Follow-up with beta-HCG dosages and transvaginal ultrasound scans
215056861|NCT04368377|DRUG|Tirofiban Injection|Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
215056862|NCT04368377|DRUG|Clopidogrel|Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
214302829|NCT06922149|OTHER|Group B. Eccentric exercises training|Eccentric exercises training and therapeutic exercise is a type of physical activity used to treat or prevent injuries and improve functional outcomes. Eccentric exercises focuses on movements, or phases of a movement, that lengthen the muscles. Some examples of eccentric exercise include lowering into a squat or lowering into a press-up. In contrast, when a person pushes out of a squat or press-up, this shortens the muscles. This is known as concentric movement
214302830|NCT07126483|PROCEDURE|Thoracic paravertebral block|Ultrasound-guided single-injection thoracic paravertebral block using 0.4 mL/kg of 0.25% bupivacaine with epinephrine (1:400,000) before induction of standardized general anesthesia. Postoperative analgesia will be provided with intravenous patient-controlled analgesia morphine, along with scheduled paracetamol and NSAIDs.
214302831|NCT07126483|DRUG|Morphine|Single intrathecal injection of morphine (5 mcg/kg diluted in 3 mL 0.9% saline) at the L3-L4 or L4-L5 interspace before induction of standardized general anesthesia. Postoperative analgesia will be provided with intravenous patient-controlled analgesia morphine, along with scheduled paracetamol and NSAIDs.
214669914|NCT05300529|OTHER|Vestibular Rehabilitation Exercises|The Vestibular Rehabilitation program focuses on stabilizing the gaze and gaining the Vestibular Ocular Reflex (VOR). The general mechanisms of recovery from vestibular injuries are vestibular adaptation and replacement exercises, which are designed to improve gaze stability and the interaction between sight and the vestibular system during head movements. The exercises will be carried out progressively according to the tolerance of the patient, varying the stimulus in intensity and frequency.
214669915|NCT05300529|OTHER|Conventional Rehabilitation exercises|The conventional rehabilitation program in which exercises are performed to improve joint range, flexibility, and gait. It will always be done with the eyes open, on a firm surface and will not include training in sensory strategies
214905910|NCT05479786|PROCEDURE|Salpingectomy|Removal of the affected Fallopian tube by laparoscopy
214905911|NCT05479786|PROCEDURE|Salpingostomy|Removal of the ectopic pregnancy from the Fallopian tube, without removing the whole Fallopian tube, by laparoscopy
214905912|NCT05079672|DRUG|Dexmedetomidine|Dexmedetomidine injectable solution, at the rate of 0,3μg/ kg/h, will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
214905913|NCT05079672|DRUG|0,9% Saline|Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.
214905914|NCT01591096|DRUG|Tissue plasminogen activator (Activase®)|Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
214905915|NCT02227563|DEVICE|Active tDCS|repetitive daily tDCS sessions for a period of one week
214905916|NCT02227563|DEVICE|control|
214905917|NCT01831635|OTHER|Methodological pens|Randomisation of branded pen, non-branded pen and no pen
214905918|NCT01831635|OTHER|Methodological compensation|Randomisation of a £10 monetary reimbursement for expenses on completion of the study
214905919|NCT01831635|OTHER|Methodological trolley tokens|Trolley tokens to be randomly assigned to half of cases and General Practice controls.
214905920|NCT06065163|OTHER|Diuretic de/escalation based on ultrasound findings (VExUS Score)|Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)
214905921|NCT06065163|OTHER|Diuretic de/escalation based on clinical findings (CCS Score)|Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)
214905922|NCT03113812|DRUG|ABvac40|
214905923|NCT03113812|DRUG|Placebo|
215056863|NCT04368377|DRUG|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
214905924|NCT05790395|OTHER|Theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention|The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.
214905925|NCT05790395|OTHER|health-risk behaviors|The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
214905926|NCT02716714|DRUG|ingenol mebutate gel 0.015%|-Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days
214905927|NCT02716714|DRUG|ingenol mebutate gel 0.05%|-Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
215056864|NCT04368377|DRUG|Fondaparinux|Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
214905928|NCT04321746|DRUG|Ketamine|ketamine will be administered at a dose of 0.3 mg/kg in normal saline at 0.9% (250 mL)
214905929|NCT04321746|OTHER|Placebo|the control group will receive only normal saline at 0.9%, with the same physical characteristics of the ketamine solution
214905930|NCT00240708|DRUG|risperidone|
214905931|NCT01875523|DRUG|Serelaxin|
214905932|NCT01163838|BIOLOGICAL|Placebo|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
214905933|NCT01163838|BIOLOGICAL|1 mg/kg every 2 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
215056865|NCT05445258|DEVICE|InnoCath AB® hyper-compliant balloon catheter|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
215056866|NCT02298309|OTHER|Test-and-Treat TB|
215056867|NCT00711152|OTHER|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
215056868|NCT00711152|OTHER|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
215056869|NCT01970644|RADIATION|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
215056870|NCT04220580|OTHER|Blood samples|3 blood samples, two for RNA and one for metabolites are taken 5 minutes before a Cold Pressor Test and again 1 hour after the Cold Pressor Test.
214905934|NCT01163838|BIOLOGICAL|2 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
214302832|NCT07128888|DRUG|GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets|GZR18 injection: 3 mg-36 mg，16 weeks; Warfarin Sodium Tablets:2.5mg，twice; Rosuvastatin Calcium Tablets：10mg，twice; Digoxin Tablets:0.25mg，twice
214302833|NCT07119645|DIETARY_SUPPLEMENT|NT-II™ (240 mg)|A once-daily capsule containing 240 mg of NT-II™, a marine-derived undenatured type II collagen supplement obtained from enzymatically processed salmon cartilage and bone. Taken orally for 12 weeks.
214905935|NCT01163838|BIOLOGICAL|4 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
214905936|NCT01163838|BIOLOGICAL|4 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
215056871|NCT00945568|DRUG|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
214302834|NCT07119645|DIETARY_SUPPLEMENT|NT-II™ 480 mg|Two capsules of NT-II™ (each 240 mg), taken orally once daily for a total of 480 mg/day over 12 weeks. Sourced from salmon bone and cartilage to support joint health via oral tolerance.
215056872|NCT00325130|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
215056873|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
215056874|NCT00325130|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
215056875|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
215056876|NCT00325130|BIOLOGICAL|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
214302835|NCT07119645|DIETARY_SUPPLEMENT|Glucosamine/Chondroitin|A combined dietary supplement containing 1500 mg glucosamine and 1300 mg chondroitin, taken orally once daily for 12 weeks. This supplement serves as the active comparator and is widely used to support joint structure and function.
214302836|NCT06930391|DRUG|Oxytocin|Oxytocin 10-5M will be added to 3 groups of myometrial strips for 2 hours to induce desensitization.
214302837|NCT06930391|DRUG|Carbetocin|Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M
214302838|NCT06930391|DRUG|Calcium|Calcium chloride in the following concentrations:1.25mM, 2.5mM and 5.0mM.
214302839|NCT06934057|DRUG|Nivolumab|Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion.
214302840|NCT06934057|DRUG|Cabozantinib|Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
214302841|NCT06934915|DRUG|Prednisone|Starting dose: 5 mg daily. Maximum dose: 60 mg daily. Dosage forms: 5 mg, 10 mg, and 20 mg capsules.
214302842|NCT06934915|DRUG|Placebo|Capsules identical in size and appearance to those containing prednisone. Placebo capsules contain inactive ingredients.
214302843|NCT06935370|DRUG|vicadrostat|vicadrostat
214905937|NCT01163838|BIOLOGICAL|8 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
214905938|NCT01163838|BIOLOGICAL|12 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
214905939|NCT04417452|OTHER|Basic data collection (online survey or written form)|Basic data collection is carried out by means of a questionnaire that participants can fill in outside the study centre. It contains questions about the current life situation, sleep and activity behaviour.
214905940|NCT04417452|OTHER|Physical examination|The physical examination takes place at the study centre and includes the measurement of height, current weight and body fat, as well as the recording of heart and circulation parameters (e.g. blood pressure measurement or determination of vascular health by means of ultrasound). General metabolic and hormonal parameters are analysed by means of a blood sample. In addition, a sugar test for diabetes diagnosis will be carried out.
214905941|NCT04417452|BEHAVIORAL|Psychometric examination|Psychometric examination is carried out at the study centre with the help of a RIAS (Reynolds Intellectual Assessment Scales and Screening) test.
214905942|NCT04417452|DIAGNOSTIC_TEST|Recording of the adrenergic stress reaction (saliva test)|The adrenergic stress reaction is recorded by a saliva test.
214905943|NCT02772133|PROCEDURE|Primary PCI|
214905944|NCT04302870|DRUG|Memantine Hydrochloride Oral Solution|Memantine hydrocholoride taken once daily
214905945|NCT04302870|DRUG|Trazodone Hydrochloride oral solution|Trazodone Hydrochloride taken once daily
214905946|NCT04302870|DRUG|Placebo oral solution|Placebo taken once daily
214905947|NCT04302870|DRUG|Amantadine Hydrochloride Oral Solution|Amantadine Hydrochloride taken once daily
214905948|NCT04302870|DRUG|Tacrolimus 1Mg Cap|Tacrolimus 1Mg overencapsulated tablet taken once daily
214905949|NCT04302870|DRUG|Placebo capsule|Placebo taken once daily
214905950|NCT03531775|DIAGNOSTIC_TEST|Upright MRI|Participants will be scanned using an upright MRI in sitting/standing position and supine position. They will also be scanned in supine position using a conventional MRI.
214905951|NCT00677937|BEHAVIORAL|Modified DESMOND education and ongoing support|6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
214905952|NCT02206854|DRUG|R-flurbiprofen|200 mg gelatine capsule once orally
214905953|NCT03655405|OTHER|Individual Deprescribing Intervention|The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.
214905954|NCT00000377|DRUG|Nortriptyline|
214905955|NCT03936205|DRUG|Dexmedetomidine|Patients allocated to this group receive a combination of Morphine and Dexmedetomidine
214905956|NCT00019773|DRUG|capecitabine|
214905957|NCT00019773|DRUG|oxaliplatin|
214905958|NCT04988269|DIAGNOSTIC_TEST|Blood sampling|Assessment of circulating levels of plasma ACTH, plasma aldosterone and serum interleukin -6 levels at day 1
214905959|NCT04988269|DIAGNOSTIC_TEST|Saliva sampling|Assessment of diurnal variation of cortisol and DHEA levels in the saliva at 4 different time points during the day (0.800, 12.00, 18.00, 22.00) at day 2.
214905960|NCT01657838|DRUG|Isavuconazole|oral
214905961|NCT01657838|DRUG|Ketoconazole|oral
214905962|NCT02045264|DRUG|Icatibant (30 mg)|On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
214905963|NCT01991743|DRUG|Group 2.5|Administration of bupivacaine 2.5 mg.
214905964|NCT01991743|DRUG|Group 5|Administration of 5 mg bupivacaine
214905965|NCT01991743|DRUG|Group 7.5|Administration of 7.5 mg bupivacaine
214905966|NCT01991743|DRUG|Group 10|Administration of 10mg bupivacaine.
214905967|NCT05969184|DRUG|CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)|CDK4/6 inhibitor (Qilu) have got the cFDA approval and Trastuzumab (Hanquyou) have few data on combination use, this two drugs need clinical treatment data
214905968|NCT05523102|DRUG|Paracetamol|Intravenous paracetamol/acetaminophen
214905969|NCT05523102|DRUG|Ketorolac|Intravenous ketorolac/NSAID
214905970|NCT03218995|DRUG|Eteplirsen|Infusion for intravenous use.
214905971|NCT02641795|DEVICE|Minimally invasive robotic cochlear implantation|
214905972|NCT03601013|OTHER|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy
214905973|NCT00450879|DRUG|Pazopanib Hydrochloride|Given PO
214905974|NCT00450879|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
214905975|NCT00450879|OTHER|Pharmacological Study|Correlative studies
214905976|NCT00450879|OTHER|Laboratory Biomarker Analysis|Correlative studies
214905977|NCT02288403|BEHAVIORAL|Aerobic interval training|
214905978|NCT02288403|BEHAVIORAL|Continuous training|
214905979|NCT03059017|DRUG|Salbutamol Sulphate|salbutamol sulphate packaged as aerosol
214905980|NCT03059017|DRUG|Niosomes|Niosomes
214905981|NCT00310999|DEVICE|Shikani Optical Stylet|
214905982|NCT00147875|DRUG|Prednisone|
214905983|NCT00147875|DRUG|Vinblastine|
214905984|NCT00147875|DRUG|Doxorubicin (Adriamycin)|
214905985|NCT00147875|DRUG|Gemcitabine|
214905986|NCT03440242|DEVICE|JJVC Contact Lens|etafilcon A with PVP DD
214905987|NCT03440242|DEVICE|Marketed Contact Lens|nelfilcon A DD
214905988|NCT00108459|BEHAVIORAL|Low Carbohydrate Diet|
214905989|NCT00039559|OTHER|Early detection|CA125 is measured in blood and the longitudinal results interpreted with a statistical algorithm to determine if there has been a significant increase from baseline.
214905990|NCT00546533|DRUG|Etanercept|
214905991|NCT02859337|DRUG|UPA-ECx1|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
214905992|NCT02859337|DRUG|UPA-ECx2|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
214905993|NCT05794100|OTHER|Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator|One pack of each product (1 to 10) will be consumed on a separate occasion
214905994|NCT00616837|OTHER|Telemedicine consultation|Outpatient consultation by help of telemedicine (video conference)
215056877|NCT04770688|DRUG|Osimertinib|Osimertinib, 80mg, QD, p.o.
215056878|NCT04770688|DRUG|Anlotinib|"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."
215056879|NCT06400628|BEHAVIORAL|Self-management education|The base line data will be taken and used as control, while the final result will be utilized as the case
215056880|NCT00326001|DEVICE|Gold tip catheter|Radiofrquency ablation using gold tip catheter
215056881|NCT00326001|DEVICE|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
215056882|NCT00238082|DRUG|HFA-134A Beclomethasone DIpropionate (QVAR)|
215056883|NCT03626064|BEHAVIORAL|Smoking Cessation Counselling|One on one smoking cessation counselling with a certified mental health nurse
215056884|NCT03626064|DRUG|Nicotine Replacement Therapy|Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
215056885|NCT03015155|PROCEDURE|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
215056886|NCT00965289|DRUG|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
215056887|NCT00550186|OTHER|placebo|
215056888|NCT00550186|DRUG|Ringers Lactate|
215056889|NCT00550186|DRUG|HaemoHES 6%|
215056890|NCT01840813|DRUG|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
214302844|NCT06935370|DRUG|empagliflozin|empagliflozin
214302845|NCT06935370|DRUG|Placebo|Placebo matching vicadrostat
214302846|NCT07137208|PROCEDURE|ESP block|In the ESP group, patients will be positioned in the right lateral position. The ultrasound probe will be placed vertically about 3 cm lateral to the spinous process of T9 to visualize the transverse process, trapezius, and erector spinae muscles. A 22-gauge spinal needle will be inserted in-plane in the cranial-to-caudal direction until the needle tip reaches the fascial plane between the erector spinae muscle and transverse process. Following hydrodissection with 2 mL of sterile saline to confirm needle placement, and negative aspiration to rule out intravascular placement, the local anesthetic will be injected. Likewise, the same block procedure will be performed at the T11 level and on both levels on the other side, 10 mL will be injected at each of the four injection sites.
214302847|NCT07137208|PROCEDURE|TAP Block|In the TAP group, patients will be positioned in the supine position. A posterior approach will be employed, with the ultrasound probe placed transversely on the anterolateral abdominal wall, midway between the costal margin and iliac crest, posterior to the midaxillary line. This will allow visualization of the external oblique, internal oblique, and transversus abdominis muscles. The probe will then be moved posteriorly to identify the tapering of the transversus abdominis muscle toward the quadratus lumborum. A 22-gauge spinal needle will be inserted in-plane from anterior to posterior. Following hydrodissection with 2 mL of sterile saline to confirm needle placement, and negative aspiration to rule out intravascular placement, the local anesthetic will be injected into the plane between the internal oblique and transversus abdominis muscles. Likewise, the same block procedure will be performed on the other side.
214302848|NCT07137208|DRUG|Bupivacaine injection|A total of 20 mL of 0.25 bupivacaine will be administered at each side.
214302849|NCT06949072|DRUG|Test Dentifrice|Dentifrice containing 5 percent (%) weight by weight (w/w) Potassium nitrate (KNO3) and 1150ppm fluoride as sodium fluoride.
214302850|NCT06949072|DRUG|Reference Dentifrice|Dentifrice containing 1100ppm fluoride as stannous fluoride.
214302851|NCT06949072|DRUG|Negative Control Dentifrice|Dentifrice containing 5% KNO3 with no fluoride.
214479321|NCT06457958|DRUG|Desflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Desflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Desflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
214905995|NCT00616837|OTHER|Standard care in orthopaedic outpatient clinic|Standard care in orthopedic outpatient clinic (usual care)
214905996|NCT02822937|DRUG|Methylphenidate|Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
215056891|NCT01840813|DRUG|Normal saline|It is a placebo group
215056892|NCT02489149|OTHER|Multi-sector interventions|"* Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~* For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~* For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~* Helping families to have more knowledge about your citizen rights."
215056893|NCT02489149|OTHER|Control|Placebo Comparator: Conventional approach of current public food and nutrition policies.
215056894|NCT05863403|DIAGNOSTIC_TEST|Neuromuscular Training|Neuromuscular Training on Balance and Fall in Geriatric Population With Fall Risk
215056895|NCT05863403|DIAGNOSTIC_TEST|Traditional Exercise|Traditional Exercise on Balance and Fall in Geriatric Population With Fall Risk
214905997|NCT02822937|DRUG|Triazolam|Triazolam is a benzodiazepine similar to Valium. Triazolam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia). Triazolam is used to treat insomnia (trouble falling or staying asleep).
214905998|NCT02822937|OTHER|Project: EVO|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
214905999|NCT02822937|DRUG|Placebo|Sugar pill
214906000|NCT02871154|OTHER|Delaying oocyte pick up beyond 39 hours post hCG|Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
215056896|NCT05047133|DRUG|Tranexamic acid|TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
214302852|NCT07141901|BEHAVIORAL|Decision Tool|"For patients with life expectancy \<10 years: Active (i.e. interruptive) BPA that will fire when the clinician orders colorectal cancer screening. The BPA will advise that screening is not recommended due to \<10 year life expectancy. An active alert is required to prevent the clinician from ordering a potentially inappropriate test. The BPA will contain a box with suggested language with which to express this to the patient.~For patients with life expectancy ≥10 years: Passive alert on the Storyboard indicating that patient could benefit from screening as their predicted life expectancy is ≥10 years. A passive alert does not interfere with workflow and is available whenever it is convenient for the clinician to address it."
214302853|NCT04519580|DIAGNOSTIC_TEST|PET/CT|FDG-PET/CT at baseline, week 8 and week 10.
214302854|NCT07146503|DRUG|Esketamine (Intranasal Spray)|Esketamine Intranasal Spray at a dosage ranging from 28 to 84 mg weekly, with twice-weekly administration during the first month of treatment, according to the approved labeling
214302855|NCT07144800|BEHAVIORAL|Parent Weekly Individual Telephone Support|Interventionists will deliver a 20-30 minute session via videoconference (e.g. Zoom) using the Family COMIDA Intervention Manual
214302856|NCT07144800|BEHAVIORAL|Child Education|6 weekly diet/PA education sessions ('Child Education')
214302857|NCT07144800|BEHAVIORAL|Parent Initial Counseling|Interventionists will deliver a 20-30 minute session via videoconference (e.g. Zoom) using the Family COMIDA Intervention Manual
214302858|NCT07144800|BEHAVIORAL|Parent Monthly Group Support|Parents will be invited to join a Spanish language (English if preferred) weekly group videoconference (can join by phone if preferred).
214479322|NCT05754658|OTHER|Standard of Care|Drugs routinely administered for breast cancer per local standard.
214906001|NCT03277287|RADIATION|Fractional CO2 laser|Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
214906002|NCT03451253|OTHER|amino acid mixture beverage|commercially available amino acid mixture. Contains 5 amino acids, electrolytes and natural flavoring.
214906003|NCT03451253|OTHER|glucose-based sports drink|Commercially available glucose-based sports drink, contains electrolytes, sugar and artificial flavoring.
214906004|NCT04382547|BIOLOGICAL|Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
214906005|NCT04382547|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
214906006|NCT05563454|DRUG|BAY2395840|Administration of dosage form 1 under diet 1 condition
214906007|NCT03875053|DIAGNOSTIC_TEST|Monitoring Device|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
214906008|NCT03875053|OTHER|Quality-of-Life Assessment|Ancillary studies
214906009|NCT03875053|OTHER|Questionnaire Administration|Ancillary studies
214906010|NCT02573051|DRUG|Misoprostol|800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
214906011|NCT02573051|DRUG|Isosorbide mononitrate|40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
214906012|NCT02573051|OTHER|placebo|
215056897|NCT01196897|DEVICE|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
214906013|NCT03077477|DRUG|AMXT 1501|Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
214906014|NCT03077477|DRUG|Placebo Oral Tablet|"Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered"
214906015|NCT05106140|OTHER|Magnetic Resonance Imaging (MRI)|A research MRI will be performed at 6-weeks post-stroke to document stroke lesion location and size.
214906016|NCT05106140|DEVICE|Kinarm Robotic Exoskeleton Assessment|"The Kinarm Robotic Exoskeleton is a device used to provide therapy and assessment. The device has framework that supports the arms and these supports are adjustable to ensure a comfortable fit. Motors attached to the framework move the arms and record shoulder and elbow movements.~The assessment involves performing a number of tasks using the Kinarm to measure proprioceptive and motor impairment, adaptation to force and visual disturbances, and retention after 24 hours."
214906017|NCT05106140|OTHER|Clinical Assessment|The clinical assessment will be performed by a qualified stroke therapist and include a number of verified measurements to examine: reflexes, strength, apraxia, somatosensation, physical abilities, and cognition.
214906018|NCT00520065|OTHER|enteral nutritional formula|Meal glucose tolerance test
215056898|NCT03814135|DRUG|Hipnos 3|1 tablet, oral, once a day.
215056899|NCT03814135|DRUG|Hipnos 5|1 tablet, oral, once a day.
214906019|NCT00520065|OTHER|Diabetes specific enteral product|Meal Glucose tolerance test
214906020|NCT01445730|DIETARY_SUPPLEMENT|Fructose|3 month fructose diet 75 g/day
214906021|NCT05507073|PROCEDURE|Manual Total Hip Replacement|Implantation of a hip Device to alleviate pain and recover range of movement
214906022|NCT05507073|PROCEDURE|Robot-Assisted Total Hip Replacement|Robot assisted Implantation of a hip Device to alleviate pain and recover range of movement
214906023|NCT01167140|DEVICE|Cryo-Touch II|Percutaneous treatment with the device
215056900|NCT03814135|OTHER|Hipnos 5 Placebo|1 tablet, oral, once a day.
215056901|NCT03814135|OTHER|Hipnos 3 Placebo|1 tablet, oral, once a day.
214906024|NCT02680704|OTHER|PEEP titrated mechanical ventilation|Enrolled patients will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O. Intracranial pressure, transpulmonary pressure, vitals, and mechanical ventilator data will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period.
214906025|NCT03805412|DEVICE|DEXCOM G6 RT-CGM|CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.
214906026|NCT05814263|DEVICE|HIS/LBB pacing|3830 lead to HIS or LBB
215056902|NCT03751826|OTHER|Incentivised network delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the first intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV themselves and in their peers and friends. They will be counselled to receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
215056903|NCT03751826|OTHER|Peer navigator delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the second intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV and then receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
214302859|NCT07151924|OTHER|Questionnaires answers|Patients will be asked to complete the MScoff and QACD questionnaires during interviews with the dietitian at baseline, 3 months and 6 months.
214302860|NCT07151924|OTHER|Biological assessment|Collection of HbA1c level and continuous glucose monitoring data
214302861|NCT07148713|BEHAVIORAL|CGM-Augmented FIM|The intervention arm will receive electronic healthy foods vouchers and unblinded, real-time CGM sensors for 16-weeks, in addition to individualized nutrition counseling with a registered dietician for 5-8 sessions (all participants will attend 5 sessions, with up to three additional sessions scheduled as needed based a set of a-priori decision rules).
214302862|NCT07148713|BEHAVIORAL|FIM only|The comparator arm will receive electronic healthy foods vouchers and healthy eating resources and self-directed nutrition education. This group will not receive unblinded CGM sensors or any nutrition counseling for the first 12 weeks. This group will receive 30-days of unblinded CGM sensors to use in the extension phase only.
214479323|NCT05754658|OTHER|Standard of Care|Drugs routinely administered for prostate cancer per local standard.
214302863|NCT07150806|DRUG|Actinium Ac 225 DOTATATE RYZ101|Given IV
214302864|NCT07150806|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214302865|NCT07150806|PROCEDURE|Computed Tomography|Undergo CT scan
214479324|NCT06827548|DEVICE|vagal nerve stimulation|"Cervical neck electrodes used in this part of the study will include the multi electrode array (MEA). The MEA can be placed on either side of the neck over the area of the vagus nerve to record any electrical activity that might occur during the baseline period.~Two ECG electrodes are placed either one on each arm or on the chest for measurement of the electrocardiogram (ECG).~Three ECG electrodes are placed on the abdomen in a line parallel to the longitudinal axis of the stomach to record the electrogastrogram (EGG).~A onetime baseline recording will be made for 20 minutes after which the subject will be discharged from the study."
214479325|NCT05198648|OTHER|Trigeminal cardiac reflex|Trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
214906027|NCT05814263|DEVICE|LV pacing|LV lead in a CS branch
214302866|NCT07150806|PROCEDURE|Echocardiography Test|Undergo echocardiography
214302867|NCT07150806|RADIATION|Gallium Ga 68-DOTATATE|Given IV
214302868|NCT07150806|DRUG|L-lysine/L-arginine-containing Amino Acid|Given IV
214302869|NCT07150806|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214302870|NCT07150806|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214302871|NCT07150806|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214302872|NCT07150806|PROCEDURE|Somatostatin Receptor Positron Emission Tomography|Undergo SSTR PET scan
214302873|NCT07155889|OTHER|Educational Competition Method|"This study aims to evaluate nursing students' knowledge levels, practical skills, and the effectiveness of the educational competition method regarding medical waste management. The study consisted of three phases. In the first phase, students were informed, their consent was obtained, the Informative Information Form was completed, and the Knowledge Level Test was administered as a pre-test. In the second stage, the researcher gave a two-hour interactive lecture to all students, explaining the waste classification and separation processes. In the third stage, the Educational Competition Method was applied in Section A. In an arrangement prepared with mock waste and color-coded bins, students placed the waste in the appropriate bins within the specified time. The winner was rewarded at the end of the competition. One week later, a final test and satisfaction form were administered to evaluate the effectiveness of the method."
214906028|NCT06301763|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
215056904|NCT03751826|OTHER|standard of care|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the standard of care arm encourage females aged 18-24 to test for HIV, receive sexual and reproductive health services, contraception and condoms, and link to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
214302874|NCT07157787|DRUG|ALXN1920|Participants will receive ALXN1920 SC infusion.
214302875|NCT07157787|DRUG|Placebo|Participants will receive Placebo SC infusion.
214906029|NCT06301763|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
214906030|NCT04494386|BIOLOGICAL|Umbilical Cord Lining Stem Cells (ULSC)|IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection
214906031|NCT04494386|OTHER|Placebo (carrier control)|IV infusion of carrier control consisting of sterile saline for injection
214906032|NCT01465412|DRUG|Preladenant|After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
214906033|NCT00160823|PROCEDURE|Self-administered leaflet|
214906034|NCT03241849|PROCEDURE|Modified surgical technique for placenta accreta|suturing of the myometrium splitted by the placenta in cases presented by placenta accreta
214906035|NCT04231617|DRUG|glibenclamide|Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
214906036|NCT04231617|DRUG|CGRP infusion|CGRP infusion
214906037|NCT04231617|DRUG|Placebo|placebo
214906038|NCT05605418|BEHAVIORAL|CHESS intervention|The multi-faceted CHESS intervention includes: (1) home blood pressure monitoring (HBPM) for patients, and the data will be uploaded to central electronic health records (EHR) automatically; (2) a Smart Reminder and Alert System (SRAS) to send educational messages and reminders to support patients on HBPM, improve blood pressure medication adherence and lifestyle modification; (3) a decision support system (DSS) to provide physicians with antihypertensive medications prescriptions and referral recommendations; (4) regular quality assessment reports will be provided to health care providers automatically to improve the quality of hypertension management at PHC level.
214906039|NCT01974518|DRUG|Rituximab and Cyclophosphamide IV|
214906040|NCT06416943|OTHER|3D printed educational model|Slide-based presention plus 3D printed port-A catheter model
214906041|NCT04390113|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
214906042|NCT04390113|BIOLOGICAL|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
214906043|NCT05951413|DRUG|Sildenafil Citrate|a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5),
214906044|NCT05951413|DRUG|estradiol|estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound.
214906045|NCT02913118|DRUG|Andrographolid Sulfonate Injection (AS Injection)|
214906046|NCT02913118|DRUG|Cephalosporin|
214906047|NCT02913118|DRUG|Azithromycin, Minocycline or Doxycycline|
214906048|NCT02913118|DRUG|Amoxicillin-clavulantic acid|
214906049|NCT02913118|DRUG|Fluoroquinolones|
214906050|NCT02913118|DRUG|Placebo|
214906051|NCT07061951|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214906052|NCT07061951|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214906053|NCT07061951|PROCEDURE|Computed Tomography|Undergo CT
214906054|NCT07061951|PROCEDURE|Echocardiography Test|Undergo echocardiography
214906055|NCT07061951|DRUG|Mirdametinib|Given PO
214302876|NCT07162129|BEHAVIORAL|Cognitive Behavioral Therapy for Postpartum Depression (PPD) and Anxiety|Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). Each session will be two hours in duration. The 1st hour involves teaching and practice of CBT skills followed by one hour of unstructured discussion about topics relevant to PPD and PPA (sleep, supports, transitions). Each group will be delivered online via Zoom and guided by our intervention manual.
214302877|NCT07170189|DRUG|HU6|HU6 tablet or capsule
214302878|NCT07166120|BEHAVIORAL|Usual care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
214302879|NCT07166120|BEHAVIORAL|Precision treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information, adapted for oncology.
215056905|NCT03739151|BEHAVIORAL|Behavioral Obesity Treatment|"Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week."
215056906|NCT01038505|DRUG|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
214302880|NCT07166237|BEHAVIORAL|Cognitive Behavioral Therapy for Paternal Perinatal Depression|Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). The weekly group sessions will be two hours long and take place once a week for 9 consecutive weeks. The first hour of the session will involve teaching and practice of CBT skills, followed by one hour of unstructured discussion around topics relevant to participants with paternal perinatal depression. Each group will be delivered online via Zoom and guided by our intervention manual.
214302881|NCT07167797|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|Group II (Treatment) group: received vitamin D single oral dose 300000 IU for age \< 1 year and dose of 600000IU for age\> 1 year in addition to standard treatment
214302882|NCT07167797|DRUG|Standard treatment for rotavirus|Standard treatment for rotavirus which includes rehydration therapy and antipyretic therapy including sodium chloride fluid and paracetamol infusion
214302883|NCT07172464|DEVICE|Recross P3 Occluder (P3O) System|The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.
214479326|NCT05198648|OTHER|Non-trigeminal cardiac reflex|No trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
214906056|NCT01351649|BEHAVIORAL|middle school physical activity intervention for girls|"Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model."
214479327|NCT06729762|PROCEDURE|ultrasound-guided thermal ablation|radiofrequency ablation, microwave ablation, laser ablation
214906057|NCT00195143|GENETIC|Surgical infusion of AAV-GAD into the subthalamic nucleus|
214906058|NCT05488743|BEHAVIORAL|educational intervention|The program consists of five 50-minutes sessions conducted in person as scheduled during weekly class meetings. Educators will conduct workshops with PowerPoint presentations and worksheets dedicated to in-class activities.
214906059|NCT05607784|BEHAVIORAL|Formative Research- Content Translation|"This formative research includes brainstorming translation of content and reviewing wireframe prototypes generated from this process. It also includes attending to cultural, developmental, and gender considerations.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
214302884|NCT07170969|OTHER|An Enhanced Coping-oriented Supportive Programme (E-COSP) for Community-Dwelling People with Spinal Cord Injury|The intervention group will receive eight weekly online group sessions (6-8 participants per group) with one hour for each session using Zoom videoconferencing software. A detailed intervention manual will be used to guide all intervention delivery. The intervention will be led by a registered rehabilitation nurse (who will be employed as a part-time RA2) who has more than three years of work experience in caring for people with SCI. The nurse who delivers the intervention will receive extensive training from the PI and CI, who are experts in coping interventions and relevant psychosocial intervention skills. The intervention providers will also receive training in group dynamics and group intervention skills, and be supervised by the research team and a psychologist during the whole period of the study. Selected audio-taped intervention sessions will be rated by the PI and CI on the fidelity of the intervention delivery
214302885|NCT07177885|BIOLOGICAL|Blood collection|Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.
214906060|NCT05607784|BEHAVIORAL|Formative Research- Content Feedback and Acceptability|"This formative research includes providing feedback on the proposed content and ensure contextual acceptability in schools.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
214906061|NCT04750499|PROCEDURE|Adipose tissue injection associated with endorectal advancement flap.|"Injection of adipose tissue will be associated with endorectal advancement flap technique. In blind fistulas and special cases, in which the flap is not indicated, alternative techniques will be used. In all cases, autologous, micro-fragmented and minimally manipulated adipose tissue, obtained with a standardized procedure, previously validated and authorized, will be injected. This procedure uses the Lipogems ® device (Lipogems International SpA, Milan, Italy), with which a well-characterized adipose tissue is obtained with the maximum safety guarantees."
214906062|NCT03815500|BEHAVIORAL|Enhanced Education|Enhanced educational curriculum will involve learning modalities including 3D modeling, video, and visual-aid enhanced text for references to improve caregiver and patient understanding of wound packing techniques.
214906063|NCT05164770|DRUG|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX|"Zanubrutinib+R-CHOP Regimen: Zanubrutinib 160mg bid; R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-DA-EPOCH Regimen: Zanubrutinib 160mg bid; R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-HD MTX Regimen: Zanubrutinib 160mg bid; R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
214906064|NCT05164770|DRUG|R-CHOP; R-DA-EPOCH; R-HD MTX|"R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
214906065|NCT00396071|DRUG|vildagliptin|vildagliptin 100 mg
214906066|NCT00396071|DRUG|Placebo|matching placebo
214906067|NCT07067567|DRUG|AK146D1 for injection|AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate
214906068|NCT04125147|DEVICE|Experimental: Montage Bone Hemostat|Use of Montage bone hemostat on the cut surfaces of bone at the osteotomy site
214906069|NCT06469905|DEVICE|Erector Spina Plan Block|ESPB will be applied to the patients in the study group. Stabilization exercises will be applied together with ESPB treatment. The needle will be inserted between the erector spinae muscle and the transverse process structures.The local anesthetic will be monitored to spread along the erector spinae muscle.
214906070|NCT06469905|OTHER|Stabilization exercises|Stabilization exercises will be practiced to control group
214906071|NCT04628247|DEVICE|Spring gravity bar|"1. contain two wooden board length (160 cm) and width (15 cm)~2. contain pair of spring at every end of board~3. two wooden board connect in the middle"
214906072|NCT03695783|OTHER|Online decision aid called IBD&me|Patients randomized to IBD\&me will be directed to go through the website at least 2 days before their clinic appointment, and will be asked to bring their personalized report with them to their upcoming visit.
214906073|NCT03695783|OTHER|Standardized educational material|Patients randomized to the control arm will be sent a PDF file corresponding to the CCFA's online resource at least 2 days before their clinic appointment, and will be asked to bring it with them to their upcoming visit.
214906074|NCT04107545|BEHAVIORAL|athletes|Control of body temperature using the bodyCap temperature monitor that records body temperature for up to 48h (three times)
214906075|NCT01769573|BIOLOGICAL|RG-HRV16|A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin
214906076|NCT01769573|DRUG|Placebo|The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
214906077|NCT04044989|DEVICE|Laser|Diode laser device was used for photobiomodulation
214906078|NCT04044989|DEVICE|light-emitting diode (LED)|LED device was used for photobiomodulation
214906079|NCT04044989|DEVICE|Placebo|Diode laser device was used for placebo effect
214479328|NCT06786962|DEVICE|Virtual reality Hypnosis|"The experimental group of 22 participants consists of a hypnosis intervention using a virtual reality device (HypnoVR®).~Participants are seated in a quiet area of the unit:~They choose a visual scenario from among 3 proposals, guaranteeing the conditions of a restorative environment. During each session, the same script (support mode) is spoken and the same music (serenity program with soothing tones) is associated with the script. Each participant is fitted with a virtual reality mask and a headset with active noise reduction."
215056907|NCT02971371|DEVICE|Lokomat|"Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis"
214302886|NCT07178132|OTHER|tissue floss band|Floss band is wrapped in thigh from distal to proximal for 2 minutes. during this period patient is asked to actively perform movement for 2 minute, after that the band is removed and repeated once more. Immediately followed by flexibility measurements
214906080|NCT03242473|OTHER|Fluid Management|The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.
214906081|NCT01170429|DRUG|Procaterol hydrochloride|25µg BID for 8 weeks
214906082|NCT01170429|DRUG|Meptin placebo|25µg BID for 8 weeks
214906083|NCT03126968|DRUG|Topical epinephrine|Prophylactic topical epinephrine
214906084|NCT03126968|DRUG|Placebos|Topical placebo (normal saline)
214906085|NCT00030901|DRUG|L-selenomethionine|Randomization between active L-selenomethionine and placebo
214906086|NCT00030901|DRUG|L-selenomethionine placebo|Randomization between active L-selenomethionine and placebo
214906087|NCT00052572|DRUG|ixabepilone|
214906088|NCT01598272|DIETARY_SUPPLEMENT|Vitality product AM + Vitality product PM|Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
214906089|NCT01598272|DIETARY_SUPPLEMENT|Placebo|Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
214906090|NCT03441412|DRUG|Ticagrelor 90mg|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
215056908|NCT03565341|DEVICE|PiQo4|PiQo4 Laser System for treatment of Melasma
214906091|NCT03441412|DRUG|Epinephrine|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
214906092|NCT03441412|DRUG|Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
214302887|NCT07178132|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) Stretching using the hold-relax method: participants perform an isometric contraction of the hamstring at the end of its stretch range , followed by relaxation and passive stretch, then flexibility assessed similarly
214302888|NCT07178366|OTHER|Standard medical therapy (SMT)|Standard medical therapy includes nutritional support (25-30 kcal/kg/day), lactulose, bowel wash, albumin, vasopressors (norepinephrine/terlipressin), antibiotics, antivirals for HBV reactivation, renal replacement therapy, and intensive care support as per institutional guidelines.
214479329|NCT06786962|OTHER|Control arm (SEQ):|"Restoration time~Participants are seated in a quiet area of the unit. The control group of 21 participants consists of a break with the following instructions and suggestions:~Take advantage of this break, this time just for you, to recharge your batteries. Sit in this armchair and I suggest you think of something pleasant and comfortable."
214479330|NCT02705859|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
214906093|NCT05897281|PROCEDURE|SHOOT exercise group|In addition to routine training, the experimental group will be done a progressive resistance band exercise program (SHOOT) created for shooters, 3 days a week for 8 weeks, accompanied by a physiotherapist.
214906094|NCT05897281|PROCEDURE|routine training group|The control group will continue their routine training
214906095|NCT00369954|DRUG|carboplatin|
214906096|NCT00369954|DRUG|gemcitabine hydrochloride|
214302889|NCT07178366|DEVICE|Double Plasma Molecular Adsorption System (DPMAS)|DPMAS therapy uses extracorporeal liver support with two sequential hemoadsorption cartridges (BS330 ion exchange resin and HA330-II neutral macroporous adsorption resin). Minimum 2 sessions (3-4 hours each) are performed within the first 7 days, with additional sessions if partial response is observed.
214906097|NCT01886677|BEHAVIORAL|Immediate diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
214906098|NCT01886677|BEHAVIORAL|Delayed diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
214906099|NCT05290883|DIETARY_SUPPLEMENT|Novel yoghurt drink containing Polar Lipids|Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption
214906100|NCT02153177|PROCEDURE|Rotator cuff repair|Arthroscopic procedure
214906101|NCT02153177|DRUG|Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole|In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
214906102|NCT02153177|DRUG|Hydrocodone/Acetaminophen|Hydrocodone/Acetaminophen is given for pain control after the surgery.
214906103|NCT05632861|DRUG|HuHuangLianzonggan capsule|HuHuangLianzonggan capsule, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
214906104|NCT05632861|DRUG|HuHuangLianzonggan capsule placebo|HuHuangLianzonggan capsule placebo, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
214906105|NCT06545851|OTHER|Oxygen therapy - constant oxygen flow|During five exercise training sessions, oxygen therapy is delivered via prescribed constant oxygen flow
214906106|NCT06545851|OTHER|Oxygen therapy - automatic titrating oxygen flow|During five exercise sessions, oxygen therapy is delivered via an automatically titrated oxygen flow rate to maintain an SpO2 target of 90-94%.
214906107|NCT01724697|OTHER|BMSC transplantation|Patients randomized to the intervention arm will be collected for bone marrow stem cells and then infused with these cells via hepatic artery.
214906108|NCT01724697|OTHER|conventional treatment & antivrial treatment|Participants will recieve conventional treatment and antivrial treatment.
214906109|NCT04014205|DRUG|Orelabrutinib (ICP-022)|ICP-022 The drug product is a white, round, uncoated tablet
214906110|NCT03550677|PROCEDURE|general anesthesia|The patient will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10-20 mg rocuronium and proper size Laryngeal mask airway will be placed securely the airway.
214906111|NCT03550677|PROCEDURE|ankle block|ankle nerve block will be performed in group ankle block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5% bupivacaine and same amount placebo (saline) in groups placebo under the guidance of peripheral nerve stimulator the anesthesia will be discontinued and LMA will be removed. The patients will be transferred from postoperative care unit to the ward after they are eligible for discharge according to modified Aldrete scoring system.
214906112|NCT01806051|DRUG|Kuvan|Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
214906113|NCT02576847|DRUG|Omiganan|Topical gel
214906114|NCT04083599|BIOLOGICAL|GEN1042|Intravenous
214906115|NCT04083599|DRUG|Pembrolizumab|Intravenous
214906116|NCT04083599|DRUG|Cisplatin|Intravenous
214906117|NCT04083599|DRUG|Carboplatin|Intravenous
214906118|NCT04083599|DRUG|5-FU|Intravenous
214906119|NCT04083599|DRUG|Gemcitabine|Intravenous
214906120|NCT04083599|DRUG|Nab paclitaxel|Intravenous
214906121|NCT04083599|DRUG|Pemetrexed|Intravenous
214906122|NCT04083599|DRUG|Paclitaxel|Intravenous
214906123|NCT06436976|DRUG|LT-002 (Lactobacillus reuteri ATG-F4|The group that will be consuming probiotics for 12 weeks.
214906124|NCT00964574|DRUG|INSULIN GLULISINE (HMR1964)|"Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day"
214906125|NCT00964574|DRUG|INSULIN GLARGINE|"Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening"
214906126|NCT07068204|DEVICE|2% Calcium Hypophosphite Toothpaste|Oral hygiene instruction and regular application of the 2% Calcium Hypophosphite Toothpaste at home (twice daily over a period of 546 days, i.e., 18 months).
214906127|NCT07068204|DEVICE|Sodium Fluoride Toothpaste (1450 ppm F)|Oral hygiene instruction and regular application of the Sodium Fluoride Toothpaste at home (twice daily over a period of 546 days, i.e., 18 months).
214906128|NCT03989128|OTHER|Medical Chart Review|Undergo medical chart review
214906129|NCT03989128|OTHER|Survey Administration|Complete survey
214906130|NCT02985580|DIETARY_SUPPLEMENT|Blueberry|
214906131|NCT02985580|DIETARY_SUPPLEMENT|Placebo|
214906132|NCT06765733|DRUG|Aleeto|"Aleeto is a nerve repair protein developed by Darwin Start (Beijing) Biopharmaceutical Co., Ltd. It is a group of specific microenvironmental protein polymers secreted under the emergency conditions of stem cells. It has the advantages of selective assembly, targeted delivery, efficient repair of damaged tissues, high safety, chemical stability, easy storage, etc., and has a powerful neural repair function. According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection."
214906133|NCT06897748|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study
214906134|NCT06897748|DRUG|Tozorakimab|Administered subcutaneously tozorakimab and placebo throughout the study
215056909|NCT05859139|OTHER|DA Scaling Strategies|For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.
214906135|NCT06900413|PROCEDURE|Group ESP|"Experienced anesthesiologists with at least five years of expertise in regional anesthesia will perform the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe (Affiniti 50; Philips) will be used. The ESP block will be applied at the T8 level on the right side, using an in-plane approach, while the patient is in a sitting position. The probe will be placed 2-3 cm lateral to the vertebra in a sagittal position to visualize the erector spinae muscle and transverse processes.~A 22G, 100 mm block needle (Stimuplex® Ultra, Braun, Germany) will be advanced in a craniocaudal direction. The correct needle position will be confirmed by injecting 0.5-1 mL of isotonic NaCl and observing the spread via hydrodissection. Finally, 0.3 mL/kg of 0.25% bupivacaine will be administered, ensuring cranial and caudal spread of the local anesthetic."
214906136|NCT06900413|PROCEDURE|Group EXORA|Experienced anesthesiologists with at least five years of expertise in regional anesthesia will administer the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe will be placed laterally to the xiphoid process on the parasternal line in a sagittal position. The probe will be moved craniocaudally to identify the 6th rib and further advanced caudally to locate the 8th rib. Once the rectus abdominis muscle and 8th costal cartilage are identified, a 22G, 100 mm block needle will be used to administer 0.3 mL/kg of 0.25% bupivacaine. The correct spread of the local anesthetic will be confirmed via ultrasound.
214906138|NCT03153163|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
214302890|NCT07177313|PROCEDURE|Ureteroscopy|patients presenting with acute ureteral obstruction who undergo primary ureteroscopy (URS).
214302891|NCT07181135|DRUG|Finerenone (BAY 94-8862)|Finerenone 10 or 20mg in participants with chronic kidney disease not using renin-angiotensin-system inhibitors
214302892|NCT07181135|DRUG|Placebo|Placebo matching finerenone
214302893|NCT07182058|DEVICE|Transcranial Electrical Stimulation Device|The Sphere V3.0 is a non-invasive transcranial electrical stimulation device that delivers amplitude-modulated transcranial pulsed random noise stimulation (am-tPRNS).
214302894|NCT07173803|BIOLOGICAL|AADvac1|Active immunotherapy
214302895|NCT07173803|DRUG|AZP006 (Ezeprogind®)|Lysosomal targeting therapy
214302896|NCT07182929|PROCEDURE|Lateral Sinus Floor Augmentation with Deproteinized Porcine Bone Mineral|Lateral Sinus Floor Augmentation Using Deproteinized Porcine Bone Mineral (DPBM, test) with Simultaneous Implant Placement and 6-Month CBCT Follow-Up
214906139|NCT05057130|DRUG|Doxorubicin, Cisplatin, Methotrexate|IV
214906140|NCT05057130|DRUG|Doxorubicin, Cisplatin|IV
214302899|NCT07179978|DRUG|Lorazepam|The primary exposure of interest will be oral lorazepam at a dose range of \>1-4 mg/day.
214302900|NCT07184047|OTHER|Adjuvant Chemotherapy (Standard of Care)|"Patients aged 65 years and older with non-metastatic or locally advanced gastrointestinal cancers will receive standard adjuvant chemotherapy regimens as part of routine clinical practice. Regimens may include FOLFOX, CAPEOX, FOLFIRI, FOLFOXIRI, FOLFIRINOX, capecitabine, gemcitabine, 5-FU/leucovorin, or oxaliplatin-based combinations, depending on tumor type and physician decision.~No investigational drugs or experimental interventions are administered. The study is observational, and all treatments follow standard of care."
214302901|NCT07180875|BEHAVIORAL|hypoventilation group|"Traditional Aerobic Training Participants will perform supervised aerobic exercise (e.g., cycling or treadmill walking) under controlled intermittent hypoxic conditions.~Hypoxia protocol: alternating cycles of low-oxygen exposure (FiO₂ 12-16%) for 3-5 minutes followed by normoxic recovery for 2-3 minutes, repeated 6-8 times per session.~Frequency: 3 sessions per week for 12 weeks.~Exercise intensity: Moderate (50-70% of heart rate reserve), adjusted individually based on baseline exercise testing"
214302902|NCT07184164|BEHAVIORAL|Educational Program by Using Behavior Change Wheel Model|"The BCW model includes three layers: the behavior system, intervention functions, and policy categories, with the last not being applied in this study. The research was structured into four phases: assessment, planning, implementation, and evaluation.~Phases of the Study Assessment Phase: Researchers introduced themselves to parents and adolescents through personal interviews, explaining the study's significance. They collected demographic data in the forensic and toxicology department, using various tools to assess adolescents' behaviors before the educational program.~Planning Phase: A tailored BCW model encompassed a wide range of educational interventions. The content"
214302903|NCT07184164|BEHAVIORAL|Routine Health Education|Participants in the control group received the routine health education and advice from nurses and healthcare providers working in the study settings
214302904|NCT07183813|DEVICE|Electroacupuncture group|The needles will be inserted to 15-40mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance. The electronic acupuncture apparatus will be connected to the bileteral Taiyang, Anmian and Baihui, with a continuous wave of 2 Hertz (Hz) and an electric current of 1-3 milliampere (mA). Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks.
214479331|NCT02705859|DRUG|Trastuzumab|Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
214906141|NCT06568016|OTHER|Best Practice|Receive clinical care consistent with current practice
214906142|NCT06568016|OTHER|Communication Intervention|Receive standardized communication from FIT QI champion
214906143|NCT06568016|OTHER|Communication Intervention|Receive coordination from GI liaisons
214906144|NCT06568016|OTHER|Coordination|Receive enhanced GI care coordination
214906145|NCT06568016|OTHER|Educational Intervention|Watch pre-colonoscopy educational video
214906146|NCT06568016|OTHER|Electronic Health Record Review|Undergo FIT result review by Primary Care FIT Tracker
214906147|NCT06568016|OTHER|Electronic Health Record Review|Ancillary studies
214906148|NCT06568016|OTHER|Informational Intervention|Undergo generation and review of GI FIT Tracker report
214906149|NCT06568016|OTHER|Informational Intervention|Receive informational sheet
214906150|NCT06568016|OTHER|Interview|Ancillary studies
214906151|NCT06568016|BEHAVIORAL|Patient Navigation|Receive navigation from GI liaisons
214906152|NCT06568016|OTHER|Referral|Receive referral
214906153|NCT06568016|OTHER|Referral|Receive referral per standardized template
214906154|NCT06568016|OTHER|Text Message-Based Navigation Intervention|Receive follow-up text message
214906155|NCT06899282|BEHAVIORAL|Jigsaw method|"Jigsaw/puzzle method is one of the collaborative learning techniques. The Jigsaw technique requires each student to focus on a particular aspect of the topic, become an expert on that topic and teach it to their peers. Once the students have learned the topic in their expert group, they return to the original group and teach what they have learned back to them as if solving a jigsaw puzzle (Geiselman et al., 2024). For the application of the technique, the Jigsaw Technique Application Directive was prepared as a training material to be delivered to the students."
214906156|NCT06899282|BEHAVIORAL|The theoretical training|The theoretical training will be conducted in 2 sessions. The first session will cover the definition, prevalence and importance of pressure ulcers, etiology and classification, risk assessment and pressure ulcers in special patient groups. The second session will cover prevention and treatment of pressure ulcers.
215056910|NCT05694663|DEVICE|Vivistim|After one month of prehabiliatory training, the patient will then undergo surgical placement of the implantable VNS device (Vivistim System) consisting of an implantable neurostimulator and an implantable lead and electrode per standard of care. The device comes with a controller and software system which allows for control of the stimulation settings during the rehabilitation phase. The PMA number for this device is 210007 and the date of FDA notice of approval occurred on August 27, 2021.
215056911|NCT05250921|PROCEDURE|Corticision|Corticision will be performed to enhance teeth alignment.
215056912|NCT05250921|DEVICE|Conventional fixed appliance|No surgical intervention is going to be applied to the patients in this group.
215056913|NCT06715839|DRUG|[68Ga]Ga-DOTA-H2D3|Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[68Ga\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-DOTA-H2D3 injection.
215056914|NCT06715839|DRUG|[18F]F-RESCA-RB14|Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[18F\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RB14 injection.
215056915|NCT06715839|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[68Ga\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
215056916|NCT06715839|DRUG|[18F]F-RESCA-T4|Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[18F\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
215056917|NCT06715839|DRUG|[68Ga]Ga-NOTA-G5|Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[68Ga\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-G5 injection.
215056918|NCT06715839|DRUG|[18F]F-RESCA-G5|Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[18F\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-G5 injection.
214302905|NCT07183813|DEVICE|Sham electroacupuncture|The needle will be inserted to 2-3mm in Bai Hui acupoint. For the remaining acupoints, needles will be inserted into the pad till reaching but without penetrating the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effects of the needle tip penetrating the skin. The electronic acupuncture apparatus will be connected to the Baihui acupoint, Shang Yin Tang acupoint, and bilateral An Mian acupoints, with a continuous wave of 2 Hertz (Hz) and an electric current of 0.1-0.3 mA. In about 3-5 seconds, the electric current will be turned down. Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks.
214302906|NCT07175623|DRUG|Methyl Prednisolone (MP)|"Dose: 1 mg/kg IV~Timing: at the induction of anesthesia"
214302907|NCT07175623|DRUG|Dexamethasone (0.2 mg/kg)|"Dose: 0.2 mg/kg IV (glucocorticoid equivalent to 1 mg/kg methylprednisolone)~Timing: at the induction of anesthesia"
214302908|NCT07175623|DRUG|Saline (0.9% NaCl)|"Dose: 5 ml IV~Timing: at the induction of anesthesia"
214302909|NCT07177326|DRUG|Tadalafil 2.5 mg|patients recived Tadalafil 2.5 mg daily
214302910|NCT07177326|DRUG|Sildenafil 25 mg|patients recived Sildenafil 25 mg daily
214302911|NCT07177326|DRUG|Tadalafil 5 mg|patients recived Tadalafil 5 mg daily
214302912|NCT07184541|BEHAVIORAL|Wake and Weigh|The Wake and Weigh tool includes the patient's dry weight and instructions for daily weight monitoring. Participants in the intervention group will be instructed on the use of the tool. While in the hospital, weight is being managed by the healthcare team, so the goal during hospitalization is to educate the patient on what to do once discharged, and to recognize changes in weight.
214302913|NCT07184541|BEHAVIORAL|Usual care|The usual care group will receive the heart failure handbook that is routinely given to heart failure patients.
214906163|NCT06447662|DRUG|PF-07934040|panKRAS inhibitor
214906164|NCT06447662|COMBINATION_PRODUCT|Gemcitabine|Chemotherapy (antimetabolite)
214906165|NCT06447662|COMBINATION_PRODUCT|Nab-paclitaxel|Taxane-type Chemotherapy
214479332|NCT06003582|OTHER|Infant Parent Support|Therapeutic Intervention
214479333|NCT02934282|DRUG|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
214479334|NCT04736810|BIOLOGICAL|AK105|IV infusion
214479335|NCT04736810|DRUG|Cisplatin|IV infusion
214906166|NCT06447662|COMBINATION_PRODUCT|Cetuximab|Monoclonal Antibody (EGFR Inhibitor)
214906167|NCT06447662|COMBINATION_PRODUCT|Fluorouracil|"Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)"
214906168|NCT06447662|COMBINATION_PRODUCT|Oxaliplatin|"Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)"
214906169|NCT06447662|COMBINATION_PRODUCT|Leucovorin|"Part of FOLFOX chemotherapy regimen~Folic Acid Analog"
214906170|NCT06447662|COMBINATION_PRODUCT|Bevacizumab|VEG-F inhibitor
214906171|NCT06447662|COMBINATION_PRODUCT|Pembrolizumab|immune checkpoint inhibitor (PD-1 inhibitor)
214479336|NCT04736810|DRUG|Gemcitabine|IV infusion
214479337|NCT04736810|DRUG|Anlotinib hydrochloride|Oral administration
214906172|NCT06447662|COMBINATION_PRODUCT|pemetrexed|"Can be used in Platinum-based Chemotherapy regimen~Antimetabolite"
214906173|NCT06447662|COMBINATION_PRODUCT|Cisplatin|"Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)"
214906174|NCT06447662|COMBINATION_PRODUCT|Paclitaxel|"Can be used in Platinum-based chemotherapy regimen~Taxane"
214906175|NCT06447662|COMBINATION_PRODUCT|Carboplatin|"Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)"
214906176|NCT06676943|PROCEDURE|XEOS AURA 10 specimen PET-CT scan of tumour specimens|Participants will be injected with a small amount of radioactive tracer at the beginning of their cancer operation. This tracer will attach itself to the cancer cells. Once the surgical specimen is removed it will be placed into the specimen PET-CT scanner so that the surgeon can see the cancer within the specimen and assess the margin.
214906177|NCT07081087|DIAGNOSTIC_TEST|PERIBLOOD|In the study, peripheral blood will be taken from all patients, shipped and analyzed at the Weizmann Institute of Science to produce a report based on our technology. The report will contain data on the diagnosis, blast counts and karyotype. This information will be compared with the results from the bone marrow scan, taken separately to each patient, to validate the accuracy of our technology
214906178|NCT06830629|DRUG|MZE829|Capsules for oral administration
214906179|NCT07082543|DRUG|AZ-3102|Nizubaglustat
214906180|NCT07082543|DRUG|Placebo|Placebo
214479338|NCT06608914|DRUG|Nandrolone decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
214906181|NCT07122986|DRUG|E coli vaccine 1 Dose A|Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval
214906182|NCT07122986|DRUG|E coli vaccine 1 Dose B|Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval
214906183|NCT07122986|DRUG|E coli vaccine 2|Candidate E coli vaccine 2, administered according to a 0, 6-month interval
214906184|NCT07122986|DRUG|E coli vaccine 3|Candidate E coli vaccine 3, administered according to a 0, 6-month interval
214906185|NCT07122986|DRUG|E coli Vaccine 4 Dose A|Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval
214906186|NCT07122986|DRUG|E coli Vaccine 4 Dose B|Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval
214906187|NCT07122986|DRUG|E coli Vaccine 4 Dose C|Candidate E coli vaccine 4 Dose C, administered according to a 0, 6-month interval
214906188|NCT07122986|DRUG|E coli Vaccine 5 Dose A|Candidate E coli vaccine 5 Dose A, administered according to a 0, 6-month interval
214906189|NCT07122986|DRUG|E coli Vaccine 5 Dose B|Candidate E coli vaccine 5 Dose B, administered according to a 0, 6-month interval
214906190|NCT07122986|DRUG|Placebo|Placebo administered according to a 0, 6-month interval
214906191|NCT07085507|DRUG|VT7208|a small synthetic molecule capsule, oral
214906192|NCT07085507|DRUG|Placebo|capsule, oral
214906193|NCT06902389|BIOLOGICAL|Super Hi-TCR-T cells|"Intravenous infusion of 3.0×10⁶ cells/kg of Super Hi-TCR-T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP.~The expression levels of Nectin4, NKG2DL, TROP2, B7H3, GPC3 and FAP were detected by immunohistochemistry. Meanwhile, 20ml peripheral blood was extracted to evaluate the quality of T cells. Patients with positive expression rates of at least 2 targets (excluding FAP) \>10% and qualified T cell quality could be considered for inclusion.~Peripheral blood lymphocytes were collected and Hi-TCR-T cells targeting three targets (including FAP) were prepared. After pretreatment with fludarabine + cyclophosphamide chemotherapy (FC regimen), the prepared Hi-TCR-T cells were transfused back, in which the dose of Hi-TCR-T cells at each target was 3.0x106 cells/kg body weight (the dose was the extended therapeutic dose obtained in the previous clinical trial), and the drug was administered by peripheral intravenous infusion."
214906194|NCT05467501|DEVICE|Theraputic ultrasound|Therapeutic ultrasound
214906195|NCT00682812|OTHER|2 cervical takings and 2 sampling of blood|"* 2 cervical takings~* 2 sampling of blood before and after the total hysterectomy"
214906196|NCT00682812|OTHER|2 cervical takings and 2 sampling of blood|"* cervical taking during the cervical conization~* 2 sampling of blood before and after the intervention"
214906197|NCT00682812|OTHER|2 cervical takings and 2 sampling of blood|"* cervical taking during the pelvien examination under general anesthetic realized systematically during the balance sheet of pre-therapeutic evaluation~* 2 sampling of blood before and after the intervention"
214906198|NCT01073085|BEHAVIORAL|"Web-based automated coaching by e-mails"|
214906199|NCT01073085|BEHAVIORAL|Self-help guide|
214906200|NCT05044117|DRUG|Capecitabine|Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year
214906202|NCT03817190|DRUG|DS107|DS107 Capsule
214906203|NCT03817190|DRUG|Placebo|Placebo capsule
214906204|NCT05412953|OTHER|Questionnaire Administration|Complete questionnaire
214906205|NCT05412953|BEHAVIORAL|Tonation Breathing Technique|Participate in tonation breathing techniques
214906206|NCT07080476|OTHER|Decongestive lymphatic therapy|"Decongestive lymphatic therapy (DLT) is the current standard of care for lymphoedema management as recommended by the International Society of Lymphology (ISL). It consists of manual lymphatic drainage (MLD), skin care (education), compression therapy using a properly fitted compression bra, and supervised exercise therapy. Sessions last 45 minutes and are delivered two times per week for a period of four weeks.~On non-treatment days, participants are encouraged to perform home exercises and document self-care practices in a diary."
215056919|NCT06715839|DRUG|[68Ga]Ga-NOTA-WWH347|Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[68Ga\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-WWH347 injection.
215056920|NCT06715839|DRUG|[18F]F-RESCA-WWH347|Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[18F\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-WWH347 injection.
214479339|NCT06608914|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
214479340|NCT06860464|BEHAVIORAL|Remote Ischemic Condtioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the baseline assessment visit, and visits 2-6 are RIC plus training visits.
214479341|NCT06860464|BEHAVIORAL|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the baseline assessment visit, and visits 2-6 are Sham plus training visits.
214479342|NCT06860464|BEHAVIORAL|Balance training|All participants will undergo training on a balance board, learning to hold the board level within the 5- degree horizontal range. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
214479343|NCT06860698|OTHER|E-cig use|Based on e-cigarette usage, participants will be divided into those who used e-cigarettes and those who did not use e-cigarettes
214479344|NCT06665477|DEVICE|Restylane Volyme|Subjects in Restylane Volyme treatment group will receive treatment on Day 1 and optiponal treatment 1 month later.
214479345|NCT06860854|PROCEDURE|Epidural Analgesia|"The eligible patients will have their vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery measured directly before the administration of ELA. They will be also asked to rate their level of pain on the visual analogue scale (VAS).~The specific method and drug regimen for ELA will be determined by the attending anesthesiologist. The mode of administration (continuous infusion, intermittent bolus, or patient-controlled epidural analgesia) will be recorded along with the anesthetic agents used for future subgroup analysis.~The vital signs, the Doppler velocities and VAS score will be recorded after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor."
214479346|NCT06856694|OTHER|NLP+AI Report|A NLP model will extract key content from consultations and AI (Chat GPT) will summarize that information. Reports including the top sentences by NLP probability for key content areas will be generated and will be provided to patients and providers within approximately 72 hours after each case. In both arms, a follow up phone call will allow for clarification any concepts that was inadequately communicated during the consultation. This call will be audio recorded and qualitatively assessed to determine whether deficiencies in risk communication observed in the consultation were rectified.
214479347|NCT06858059|OTHER|psychological intervention|All participants of the lighthouse parenting programme will engage in the full program over a period of five weeks, divided into ten sessions. The 5 group interventions will occur once a week for 1.5 hours. During this time, the psychotherapist will disseminate psychological knowledge and skills pertinent to parenting, after which the group members will engage in practice exercises and discourse. Subsequently, one individual session will be conducted each week for one hour.
214479348|NCT06668025|OTHER|MxA tests|Whole blood samples will be collected on Days 1, 4, 7, and 10 for MxA testing. MxA measurements on Days 4, 7, and 10 will be performed only for patients still hospitalized on antiviral thearpy or at the attending physician's discretion.
214479349|NCT06668025|OTHER|MxA feedback|MxA results will be reported to the attending physician within 4 hours, along with MxA-based antiviral treatment guidelines.
214479350|NCT06668025|OTHER|Follow-up at Day 30|A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.
214479351|NCT06861816|OTHER|incentive spirometer and walking with dog|End stage renal diseased adolescents (numbering twenty) will trained by incentive spirometer 30 min during the sessions of dialysis three applications weekly for 12 weeks. they will additionally walked freely with a dog 30 min three times weekly (in opposite days of hemodialysis). The duration of this trial will be 12 weeks.
214479352|NCT06861816|OTHER|training by incentive spirometer only|End stage renal diseased adolescents (numbering twenty) will trained by incentive spirometer 30 min during the sessions of dialysis three applications weekly for 12 weeks.
214479353|NCT06862830|OTHER|Virtual reality video|Virtual reality video: luna park, carousels, space, zoo, safari, dinosaurs, sightseeing, role-play
214906207|NCT07080476|OTHER|Kinesio tape|"Kinesio tape will be applied by trained physiotherapists twice a week. The kinesio tape remains in place for three consecutive days and is replaced once a week. After six days of continuous use, patients will have one rest day without kinesio tape to allow the skin to recover. This cycle will be repeated for the duration of the intervention period.~The kinesio tape will be applied using a standardised fan-cut technique to ensure consistent application across all study sites. Tape length will be individually tailored. Each application will consist of three fan-shaped strips:~1. Breast: Anchored at the ipsilateral axilla and directed vertically over the affected breast.~2. Ventral anastomosis: Originating from the contralateral axilla and applied horizontally over the chest.~3. Dorsal anastomosis: Also anchored at the healthy axilla and applied horizontally over the back.~Patients will be instructed in safe self-application for potential use during follow-up."
214906208|NCT07080476|OTHER|Compression bra (sub-study)|In a subset of participants, different types of commercially available compression bras are tested for pressure and comfort. Each bra is worn for a period of one week without compromising the outcomes of the primary objective. The pressure exerted by the garment is measured using the PicoPress device on the first day of wear. The wearing comfort is evaluated using an adjusted version of the ICC compression questionnaire after one week of wearing the compression bra.
215056921|NCT06715839|DRUG|[68Ga]Ga-NOTA-RND20|Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[68Ga\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RND20 injection.
214479354|NCT01396408|DRUG|Sunitinib|50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
214479355|NCT01396408|DRUG|Temsirolimus|25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
214479356|NCT06862258|PROCEDURE|Shehata technique|For patients whose intra-abdominal testicle cannot easily reach the contralateral internal inguinal ring due to a short testicular pedicle, the Shehata procedure will be performed. This technique involves a two-stage laparoscopic orchidopexy that preserves the testicular vessels. In the first stage, the intra-abdominal testicle is fixed above the contralateral iliac crest using prolene vascular suture. Twelve weeks later, a second procedure is performed to position the testicle lower. This approach ensures the preservation of the testicular vessels, vas deferens, and overall circulation.
214302914|NCT07181655|OTHER|Modified Intermittent Fasting|Participants in Intervention group will follow a structured intermittent fasting protocol, specifically the 16:8 method, where they fast for 16 consecutive hours each day and restrict their eating to an 8-hour window. The fasting period can be personalized to suit individual schedules. During these fasting hours, participants must abstain from all foods and caloric drinks, but are encouraged to stay hydrated with non-caloric beverages and they will follow a structured, calorie-restricted diet, tailored to them, using a developed Food Frequency Questionnaire tool to select their daily calorie intake across sections to identify appropriate foods and beverages for patients with metabolic conditions. They will be prescribed to engage in at least 150 minutes per week of moderate intensity aerobic activities, such as brisk walking will be measured and evaluated using the mobile application of physical activity recommended by the Ministry of Health in Saudi Arabia.
214302915|NCT07181473|DRUG|TJ101|TJ101 is a EGFR/B7H3 directed antibody conjugate with a cleavable linker and a noval topoisomerase I inhibitor.
214479357|NCT04159610|DRUG|WO3970|Application of cream to each axilla
214906209|NCT04545112|DEVICE|CABG|"Elective, coronary artery bypass (CABG) surgery. Each study subject will receive an left internal mammary artery (LIMA) conduit to the left anterior descending (LAD) coronary artery. Patients with uncompromised saphenous veins will receive a SVG to the LCX or RCA and the XABG to the remaining territory. Patients with compromised arterial and/or saphenous veins, (i.e., no-vein patients), will receive one XABG to the LCX or RCA to achieve incomplete revascularization."
214906210|NCT05180474|BIOLOGICAL|GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.|GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
214906211|NCT06128564|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
214906212|NCT06775886|OTHER|myPACE+ algorithm|myPACE+ algorithm with mono-fractional exponent
214906213|NCT05348915|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
214906214|NCT04117074|DRUG|Liposomal bupivacaine|Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
214906215|NCT04117074|OTHER|Thoracic epidural analgesia (bupivacaine)|Perioperative bupivacaine based thoracic epidural placed preoperatively.
214479358|NCT04159610|DRUG|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
214479359|NCT03919032|OTHER|This is an observational study without intervention|This is an observational study without intervention
214479360|NCT06437223|DRUG|Tonabersat|Tonabersat 40mg. Two tablets per day
214479361|NCT06437223|DRUG|Placebo|Placebo 40mg, Two tablets per day
214479362|NCT04791579|DRUG|Ciprofloxacin|Fluoroquinolone antibiotic
214479363|NCT04791579|DRUG|Placebo|Placebo pill
214906216|NCT07087587|DEVICE|CPAP|CPAP will be randomized 2 weeks on 2 weeks off for 12 weeks total
214906217|NCT02321033|DIETARY_SUPPLEMENT|soft drinks|soft drinks with palatinose and maltodextrin
214906218|NCT04521881|DRUG|Tranexamic Acid 500 MG|given once as an intramuscular injection
214906219|NCT02051582|PROCEDURE|Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
214906220|NCT02051582|PROCEDURE|Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
214906221|NCT06338514|OTHER|Real dry needling|dry needling into the muscle under ultrasound guidance.
214906222|NCT06338514|OTHER|Sham dry needling|dry needling into the subcutaneous fatty tissue under ultrasound guidance.
214906223|NCT04751370|PROCEDURE|Computed Tomography|Undergo CT
214906224|NCT04751370|BIOLOGICAL|Ipilimumab|Given IV
214906225|NCT04751370|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214906226|NCT04751370|BIOLOGICAL|Nivolumab|Given IV
214906227|NCT04751370|RADIATION|Radiation Therapy|Undergo short-course radiation therapy
214906228|NCT04751370|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
214906229|NCT04751370|PROCEDURE|Total Mesorectal Excision|Undergo TME
214906230|NCT04524871|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
214906231|NCT04524871|DRUG|Bevacizumab 15 mg/kg|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
214906232|NCT04524871|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
214906233|NCT04524871|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
214906234|NCT04524871|DRUG|TPST-1120|TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
214906235|NCT04524871|DRUG|Tobemstomig 2100 mg|Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
214906236|NCT04524871|DRUG|Bevacizumab 10 mg/kg|Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
214906237|NCT04524871|DRUG|Tobemstomig 600 mg|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
214906238|NCT04524871|DRUG|Tobemstomig 1200 mg|Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.
214906239|NCT04524871|DRUG|ADG126|ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
214906240|NCT04524871|DRUG|IO-108 1800 mg|IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.
214906241|NCT04524871|DRUG|NKT2152|NKT2152 will be administered by mouth.
215056922|NCT06715839|DRUG|[18F]F-RESCA-RND20|Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[18F\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RND20 injection.
215056923|NCT06717828|BEHAVIORAL|Tai Chi Exercise|Tai Chi is a moderate-intensity exercise suitable for middle-aged and elderly individuals. Participants will engage in the practice five times a week (three sessions will be in-person teaching, and two will be online), with each session lasting 60 minutes, continuing until the end of a six-month follow-up. Before the intervention begins, participants will receive a manual or instructional video on Tai Chi to understand its principles, practice techniques, and safety precautions. Each class will start with a warm-up and include a review of Tai Chi principles and movements, breathing techniques, and relaxation methods. Participants will document their Tai Chi practice over 24 weeks by submitting exercise weekly logs, while researchers will monitor their exercise progress weekly via phone using standardized forms to assess frequency, completion status, adverse events, and adherence.
215056924|NCT06717828|BEHAVIORAL|Regular Exercise|The intervention for middle-aged and elderly individuals includes a combination of common activities: 15 minutes of walking, 15 minutes of body coordination activities (including limb movements and balance training), 15 minutes of muscle stretching, and 15 minutes of relaxation. Each exercise session lasts for 60 minutes, conducted five days a week. The heart rate during exercise will be adjusted based on monthly fitness assessments, and the daily activity level will be evaluated through logs and fitness trackers.
215056925|NCT06717828|BEHAVIORAL|Control|All participants will be advised not to change their existing lifestyle habits and will only receive health education related to fatty liver throughout the intervention. The educational methods will include large group sessions, individual education, and telephone follow-ups, conducted every two months. Additionally, dietary and exercise assessments will be carried out during the intervention, with dietary intake recorded using a three-day food diary to track daily calorie consumption.
215056926|NCT06715410|DEVICE|CO2|To collect CO2 data
215056927|NCT04824014|DIAGNOSTIC_TEST|4FMFES-PET|Intravenous 4FMFES injection, followed with PET imaging
214302916|NCT07181226|DEVICE|High-frequency repetitive transcranial magnetic stimulation|High-frequency rTMS was delivered to the left dorsolateral prefrontal cortex using the 5 cm rule to localize the target site. Stimulation intensity was set at 100% of the resting motor threshold, determined by visible motor-evoked potentials in the right abductor pollicis brevis muscle. Each session consisted of 1500 pulses at 10 Hz, organized into 10 trains of 15 seconds (150 pulses per train) with 50-second inter-train intervals. Total stimulation time per session was approximately 12.5 minutes. A figure-of-eight coil (70BFX-LQC, Deymed Diagnostics) connected to a DuoMagXT-100 stimulator was used, with the coil positioned at \~45° from the midline, handle pointing posterolaterally.
214302917|NCT07181226|DEVICE|Intermittent Theta Burst Stimulation|Intermittent theta-burst stimulation (iTBS) was delivered to the left dorsolateral prefrontal cortex using the 5 cm rule for target localization. Stimulation intensity was set at 100% of the resting motor threshold, determined by motor-evoked potentials in the right abductor pollicis brevis muscle. Each session consisted of 600 pulses delivered in bursts of three 50 Hz pulses repeated every 200 ms. Trains of 2 seconds were followed by 8-second inter-train intervals. Total stimulation time per session was approximately 3 minutes and 20 seconds. A figure-of-eight coil (70HF-LQC, Deymed Diagnostics) connected to a DuoMagXT-100 stimulator was used, with coil orientation \~45° from the midline, handle pointing posterolaterally.
214906242|NCT04524871|DRUG|IO-108 1200 mg|IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
214906243|NCT07097818|BEHAVIORAL|T1D team, structured education, peer support , and diabetes technologies|Patients with T1D will use insulin pumps and CGM , while undergoing structured education courses under the management of a specialized T1D team and engaging in peer support activities.
214906244|NCT07097818|BEHAVIORAL|Routine Management|Patients with T1D will be managed according to the routine diagnosis and education model of each hospital.
214906245|NCT03488082|BEHAVIORAL|fMRI|saccadic adaptation (target presentations, with or without target jump) during fMRI exam
214906247|NCT07103356|BEHAVIORAL|Water Pitcher Filtration System|Table-top water pitcher filtration system
214906248|NCT04982848|DRUG|Talzenna|Talzenna treatment under Korea regulatory approval indication/dosage
214906249|NCT07106580|OTHER|lyophilized FMT capsules|A total of 18 capsules made from the initial 80 g of donor stool given through 3 days (three capsules twice daily)
214906250|NCT07106580|OTHER|Placebo capsules|18 capsules of identical appearance and weight given in the same way as FMT capsules
214906251|NCT06873659|DRUG|SON-DP|Solution for IV administration
214906252|NCT04708054|DRUG|Busulfan|Given IV
214906253|NCT04708054|DRUG|Cladribine|Given IV
214906254|NCT04708054|DRUG|Fludarabine Phosphate|Given IV
214906255|NCT04708054|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell transplantation
215056928|NCT00014729|DRUG|isotretinoin|
215056929|NCT04210661|OTHER|prediction software with spell checker|test with prediction software with spell checker
215056930|NCT02662426|DRUG|Lingdancao granules|4 packs per time (3g/pack), three times per day
215056931|NCT02662426|DRUG|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
215056932|NCT02662426|DRUG|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
215056933|NCT02662426|DRUG|analogous Lingdancao granules|4 packs per time, three times per day
214906256|NCT04708054|DRUG|Thiotepa|Given IV
214906257|NCT04708054|DRUG|Venetoclax|Given PO
214906258|NCT07111091|OTHER|GAIT AND BALANCE EVALUATION|"In our study, participants' walking assessments were made with GAITRite electronic walking path (CIR System INC. Clifton. NJ. USA.).~In the postural balance assessments of the participants, the Bertec Balance Check Screener™ BP5050 20x20 inch (Bertec Comporation Columbus, OH, USA) force platform was used. The Bertec force platform is a three-component balance platform that is based on objectively measuring instantaneous changes in vertical force and center of pressure (CoP). Bertec was designed to evaluate the ability to maintain balance while standing.~The assessments were made in all participants without an orthosis, with unilateral AFO and with bilateral AFO. In our study, participants were given a 10-minute rest period between assessments."
214906259|NCT07111520|DRUG|BNT326|intravenous (IV) infusion
214906260|NCT07111520|DRUG|BNT327|IV infusion
214906261|NCT07111520|DRUG|Pembrolizumab|IV infusion
214302918|NCT07182565|RADIATION|hypofractionated radiotherapy|In Phase Ib, hypofractionated radiotherapy (HFRT) will be administered at one of three dose levels: 3 Gy × 5 fractions, 4 Gy × 5 fractions, or 5 Gy × 5 fractions. The recommended dose determined in Phase Ib will be used in Phase II (delivered as 5 fractions).
214302919|NCT07182565|DRUG|PD-1 inhibitor|Serplulimab will be administered concurrently with chemotherapy at a fixed dose of 300 mg via intravenous infusion on Day 1 of each 3-week cycle.
214302920|NCT07182565|DRUG|TS-1|The TS regimen includes paclitaxel at a dose of 175 mg/m² administered via intravenous infusion on Day 1, and oral administration of tegafur-gimeracil-oteracil (S-1) for 14 consecutive days followed by a 7-day rest period (21-day cycle). The S-1 dose is based on body surface area (BSA): 40 mg twice daily (bid) for BSA ≤ 1.5 m²; 50 mg bid for BSA 1.5-1.6 m²; and 60 mg bid for BSA ≥ 1.6 m².
214906262|NCT07111520|DRUG|SoC|IV infusion. Combination chemotherapy (pemetrexed, paclitaxel, or carboplatin). Chemotherapy will be selected according to the indication.
214906263|NCT07112820|OTHER|perfusion ultrasound|"During the examination, the power of the probe will be increased in order to assess myocardial perfusion.~The contrast agent bubbles are destroyed by applying a 'flash', i.e. a temporary increase in the power of the ultrasound beam. Systole after systole, on a recorded loop, the filling velocity of the myocardium, which depends on myocardial blood flow, is analysed. The assessment of perfusion is visual and qualitative."
214906264|NCT07112274|DRUG|Empagliflozin 10 MG|Treatment group will receive empagliflozin 10 mg tablet once daily
214906265|NCT07112274|OTHER|Placebo Tablet|control group will receive placebo tablet.
214906266|NCT07113145|DRUG|Oral intake of medication|● Group A: Received Citalopram hydrobromide, starting with 10 mg once daily for 1 week, followed by 20 mg once daily for 10 weeks, and 10 mg daily during the final week (tapered).
214906267|NCT07113145|DRUG|Oral intake of medication|● Group B: Received Silodosin 4mg, administered orally once daily.
214906268|NCT07113145|DRUG|Oral intake of medication|● Group C: Received Dapoxetine hydrochloride 30 mg, taken 2 hours before intercourse, on-demand, minimum of 8 times/month for 3 months.
214906269|NCT07113145|DRUG|Oral intake of medication|● Group D: Received Dapoxetine hydrochloride 30 mg, administered daily.
214906270|NCT07111208|BEHAVIORAL|Green Space Activity Group - Daily Physical Activity|Participants in this group will be instructed to take a brisk 30-minute walk each day in designated urban green spaces (e.g., parks, forested areas). Physical activity will be monitored using Fitbit Alta wristband sensors to track duration, intensity, and steps.
214906271|NCT07111208|BEHAVIORAL|Mediterranean Diet Group - Dietary Intervention|Participants in this group will follow the principles of the Mediterranean diet, including increased consumption of fruits, vegetables, whole grains, legumes, nuts, and olive oil, and reduced intake of red meat and processed foods. They will receive dietary guidance and support for meal planning throughout the 7-day intervention.
214906272|NCT07112898|PROCEDURE|Platelet-Rich Plasma (PRP)|Autologous PRP (approximately 4-6 mL) will be prepared using a double centrifugation technique and activated with 10% calcium gluconate. It will be administered by injecting 0.1-0.2 mL/cm² subdermally into the recipient bed and intradermally into the graft prior to placement.
214906273|NCT07112898|PROCEDURE|Standard Skin Grafting|Grafts will be placed on a clean, vascularized wound bed, secured with nonabsorbable sutures, and covered with standard postoperative dressings. No PRP will be applied.
214906274|NCT07112703|OTHER|Incentive spirometer exercises|The study group was instructed to use an incentive spirometer, which should be held upright, sealed around the mouthpiece, and taken slowly and deep breaths. They will be motivated to achieve a preset volume through visual feedback. The child will hold their breath for 2-3 seconds at full inspiration and, after each set of 10 breaths, cough to clear mucus from the lungs. The exercise duration is 15 minutes.
214906275|NCT07112703|OTHER|Diaphragmatic breathing|The child will lie on their back, place one hand on their belly and one on their chest, and use a balloon or doll to fill both belly and chest up like a balloon. Inhale deeply, let the hands on the belly rise, then exhale slowly, making the belly down. The exercise will last for 10 minutes.
214906276|NCT07112703|OTHER|Pursed lip breathing:|Sit in a seated position with crossed legs or knees. Inhale slowly through the nose for three seconds, then exhale through pursed lips, similar to blowing out birthday candles.
214906277|NCT07112703|OTHER|Costal breathing exercises|The study involves conducting Costal breathing exercises for children. The exercises involve placing hands on the apical region of the lung, turning the child's head, relaxing the shoulder and neck muscles, taking a deep breath, pushing the hand out, holding, and exhaling slowly. The hands provide pressure and resistance after initiation of inspiration, and the children rest for 2 minutes between exercises. The duration of the exercise varies between the control and study groups.
215056934|NCT01042158|DRUG|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
215056935|NCT04525144|DRUG|Tebonin Forte|Dietary supplement: Gingko biloba EGb 761
214302921|NCT07183839|BEHAVIORAL|Immersive Virtual Reality|While wearing an immersive VR helmet, participants grabbed virtual objects andd put them into a bowl of virtual water, while memorizing a list of words from the real world.
214302922|NCT07183839|BEHAVIORAL|Plausible control condition|Participant passively viewed the laboratory room they saw while wearing Apple Vision Pro goggles, while memorizing a list of words read to them from the real world.
214669916|NCT00404729|DRUG|Citicoline|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
214669917|NCT01983865|OTHER|Exposure to birch pollen|
214302923|NCT07184398|OTHER|Intervention with Consolidated Cysteine (Immunocal) 20 g per day|CRWPI Immunocal® (Immunotec™) was administered at a dose of 20 grams (2 sachets once daily) for 12 consecutive weeks. The research team delivered Immunocal directly to the subjects and instructed them on how to mix and self-administer it.
214302924|NCT07184398|BEHAVIORAL|Cognitive rehabilitation workshops|Neuropsychological rehabilitation consisted of in-person group sessions for 40 adults (18 years or older) to work on cognitive functions such as memory and attention. Each session lasted 45 minutes. These sessions were held three times a week for a period of 12 weeks.
214302925|NCT07191158|DEVICE|Group 1 conventional|Conventional miniscrew-supported distal jet appliance
214906278|NCT07111689|BEHAVIORAL|Conventional Occupational Therapy Interventiın|1-2. Week: Occupation-based interventions for visual skills 3-6. Week: Social Skills Training 7-8. Week: Interventions for participation problems in ADLs
214906279|NCT07111689|BEHAVIORAL|Virtual Reality İntervention|In this study, the Xbox 360 gaming console and Kinect sensor were utilized for the virtual reality (VR) intervention. The Xbox 360 functions as an interactive gaming platform, while the Kinect sensor is a motion-detection device that captures users' positions and movements through an integrated camera and sensors. The selection of games for the VR intervention was conducted in collaboration with experts from various disciplines. The evaluation process considered the cognitive and functional demands required for successful gameplay, the potential skills each game could enhance, and the overall therapeutic purpose of the selected games. Following an independent assessment of each game, nine games were identified as suitable for the intervention. Given that all selected games shared similar functional requirements, participants were provided access to the full set of games to optimize engagement and motivation.
214906280|NCT07113470|DEVICE|The Salvia PRIMUS implantable neurostimulator System|The Salvia PRIMUS implantable neurostimulator System is designed to provide subcutaneous neurostimulation to the V1 branches of the Trigeminal nerves (supra-orbital and supra-trochlear nerves) and the branches of the Greater Occipital Nerves. It is intended to modulate headaches' neural networks by utilizing mild electrical pulses. There are 2 stimulation waveforms options: the Salvia burst waveform providing paresthesia-free stimulation and Tonic waveform, providing paresthesia-provoking stimulation. The PRIMUS System comprises a 25 cm (forehead) and a 17cm (back of the head) subcutaneous implant, a MySalvia device, a programmer, and surgical tooling.
214906281|NCT07112638|OTHER|immersive technology-based intergenerational intervention to improve movement patterns in older adults|Intervention group The intervention consists of 60-minute supervised sessions conducted once per week for 12 weeks. Each session begins with a 10-minute warm-up, followed by 15 minutes of strength training. Four structured session types (A, B, C, and D) were designed and are being rotated throughout the 12-week period. These sessions incorporate upper and lower body exercises performed using body weight and/or resistance bands, adapted to each participant's physical function.
214906282|NCT07113184|DEVICE|dual sr|Dual Stentriever
214906283|NCT07113184|DEVICE|single sr|Single Stentriever
214906284|NCT07110883|DRUG|SYS6023|SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.
214906285|NCT07113197|RADIATION|conventional angiography|"* Peak systolic velocity (PSV)~* Velocity ratios~* Segment visualization quality~* Degree of stenosis"
214906286|NCT07111598|BIOLOGICAL|Blood test at D0|Six extra blood collection tubes (28 mL) will be drawn during the visit (D0), in addition to the routine blood samples, at the blood collection center
214906287|NCT07111598|BIOLOGICAL|Blood test at D+3 months|six extra blood collection tubes (28 mL) will be drawn during the visit (D+3 months) for group 3 patients, in addition to the routine blood samples, at the blood collection center
214906288|NCT07113405|DIETARY_SUPPLEMENT|Protein and Polyphenols|Participants in this group will receive 10 times a recovery drink containing protein and polyphenols.
214906289|NCT07113405|DIETARY_SUPPLEMENT|Protein|Participants of this group will receive ten times a recovery drink containing only protein without polyphenols.
214906290|NCT07113405|DIETARY_SUPPLEMENT|Placebo|Participants of this group will receive 10 times a placebo containing no protein nor polyphenols.
214906291|NCT05668663|DIAGNOSTIC_TEST|Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample|"If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.~The blood sample will be collected up to 3 days after admission"
214906292|NCT07110909|OTHER|HPV Education|HPV Education
214906293|NCT07112833|DRUG|Induction stage：Adebrelimab+TC；Treatment stage: TC/PF+ radiation therapy；Maintenance stage: Adebrelimab|"Induction stage：Adebrelimab+TC： Adebrelimab : 1200mg d1, iv, q3w ； TC : paclitaxel 135mg/m2, or nab-paclitaxel paclitaxel 180mg/m2, d1, iv，carboplatin AUC=5, d1, iv, q3w，2 cycles.~Treatment stage: TC/PF+ radiation therapy:~PET-CT responders (SUV (PETr) reduction ≥35%)：~TC/PF+ radiation therapy:~TC : paclitaxel 50mg/m2, nab-paclitaxel paclitaxel 60mg/m2, d1, iv; carboplatin AUC=2, d1, iv, qw，5 cycles.~PF : fluorouracil 750-1000mg/m2, CIV 96 hours，cisplatin 75mg/m2, d1, iv, q4w，2 cycles.~Radiation therapy: 50.4Gy-60Gy/28-33f.~PET-CT non-responders (SUV (PETr) reduction \<35%)：(switch to a different chemotherapy drug which not used during the earlier induction phase)~PF/TC+ radiation therapy:~dose same as above.~Maintenance stage: Adebrelimab:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs（Up to one year）."
214906294|NCT07111468|DRUG|YHP2401|Total 7 days of treatment and The daily dose is tid.(YHP2401 + Placebo of YHR2402 + Placebo of YHR2403)
214302926|NCT07191158|DEVICE|Group 2 3D printed|New 3D printed miniscrew-supported molar distalizers
214302927|NCT07190976|OTHER|Routine EEG|The study is observational. No intervention is anticipated. Patients will be submitted to EEG recording within the first seven days of stroke
214302928|NCT07190976|OTHER|Routine EEG|The study is observational
214669918|NCT02838030|DRUG|L-arginine|3 gr per day
214669919|NCT02838030|DRUG|Placebo (for L-arginine)|3 gr per day
214302929|NCT07190508|OTHER|No Intervention (Observational)|Participants undergo routine diagnostic upper gastrointestinal endoscopy with standard institutional care. No additional intervention is applied beyond usual clinical practice.
214302930|NCT07190170|BEHAVIORAL|TRE|Participants randomized to the TRE arm will be instructed to consume all food and beverages in a self-selected 10-hr eating window.
214302931|NCT07190170|BEHAVIORAL|Weight-Loss Maintenance Advice|The CON arm participants will receive written baseline advice following randomization assignment that includes determinants associated with long-term weight-loss maintenance success (e.g., physical activity, and strategies to limit calorie intake).
214906295|NCT07111468|DRUG|YHR2402|Total 7 days of treatment and The daily dose is tid.(Placebo of YHP2401 + YHR2402 + Placebo of YHR2403)
214906296|NCT07111468|DRUG|YHR2403|Total 7 days of treatment and The daily dose is tid.(Placebo of YHP2401 + Placebo of YHR2402 + YHR2403)
214906297|NCT07111988|DRUG|Valbenazine|Selective vesicular monoamine transporter 2 (VMAT2) inhibitor
214906298|NCT07111988|DRUG|Placebo|Pill that contains no medicine
214906299|NCT06084936|DRUG|Obinutuzumab|Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1
214906300|NCT06084936|DRUG|Glofitamab|Participants will receive IV glofitamab beginning Cycle 1 Day 8 for 12 cycles (cycle length = 21 days).
214906301|NCT06084936|DRUG|Rituximab|Participants will receive IV rituximab every 28 days for up to 6 cycles (when in combination with bendamustine), or until disease progression (when in combination with lenalidomide).
214906302|NCT06084936|DRUG|Bendamustine|Participants will receive IV bendamustine on Days 1 and 2 Q4W for 6 cycles (cycle length = 28 days).
214906303|NCT06084936|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 Q4W until disease progression.
214302932|NCT07189793|DRUG|Toripalimab|PD-1 inhibitor administered intravenously every 3 weeks (Q3W) for up to 24 months. Starts during the first intravesical treatment cycle.
214906304|NCT06084936|DRUG|Tocilizumab|Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
215056936|NCT06488690|OTHER|All patients who were pregnant and underwent cesarean section|Our study aims to evaluate the use of early warning scores as a screening tool to predict obstetric mortality and morbidity in pregnant women who will undergo cesarean section.
214302933|NCT07189793|DRUG|Gemcitabine (GEM)|Intravesical instillation as part of a sequential regimen with mitomycin C: weekly for 6 weeks (induction); if no recurrence at first tumour assessment (\~month 3), maintenance instillations continue monthly up to 24 months.
214302934|NCT07189793|DRUG|Mitomycin C (MMC)|Intravesical instillation immediately after intravesical gemcitabine in the same visit (sequential regimen): weekly for 6 weeks (induction); if eligible, monthly maintenance up to 24 months.
214302935|NCT07189598|PROCEDURE|Adaptive Stereostatic Body RadioTherapy (SBRT) including both Whole Pelvic RadioTherapy (WPRT) and dose-escalation on the Dominant Intraprostatic Lesion (DIL)|"The doses delivered will be:~* the prostate gland, at a dose of 36.25 Gray, in 5 fractions,~* the dominant intraprostatic lesion, up to 50 Gray, in 5 fractions,~* seminal vesicles, at a dose of 25 Gray in 5 fractions,~* pelvic lymph nodes, at 25 Gray in 5 fractions"
214302936|NCT07189598|PROCEDURE|conventional or a moderately hypofractionated|"* Conventional fractionation includes the prescription of a total dose of 78 Gray in 39 fractions to the prostate gland (and seminal vesicles, in case of T3b disease), and a dose de 50Gy in 25 fractions to pelvic nodal areas.~* Moderate hypofractionation includes the prescription of a total dose of 60 Gray to the prostate gland (and seminal vesicles, in case of T3b disease), and 44 Gray to pelvic nodal areas in 20 fractions using a simultaneous integrated boost (SIB)"
214302937|NCT07189962|DRUG|SHR8554 Injection|SHR8554 injection.
214302938|NCT07190599|BEHAVIORAL|Proprioceptive neuromuscular facilitation (PNF) with neuromuscular electrical stimulation (NMES)|The NMES was applied during the plantarflexor contraction phase of the PNF stretching (described as below). Two electrodes (4 × 8 cm) were used for stimulation, placed on the triceps surae of the affected side: one positioned 5 cm below the popliteal fossa, and the other placed 5 cm below the first electrode, directly over the triceps surae. The hold-relax technique of proprioceptive neuromuscular facilitation (PNF) will be applied to stretch the triceps surae muscle. It will be performed ten times on the affected limb during each treatment session, lasting approximately 10 minutes in total. Participants will receive interventions three times per week for four weeks, for a total of twelve sessions.
214669920|NCT02838030|DRUG|acetylsalicylic acid|3 gr per day
214669921|NCT01615510|DRUG|Tapentadol immediate release|100 mg, single administration
214906305|NCT07118878|DRUG|AGMB-129|AGMB-129
214906306|NCT07118878|OTHER|Placebo|Placebo
214906307|NCT07109518|BIOLOGICAL|uCD7 CART|Subjects screened to meet the requirements for uCD7 CART use will enter clinical trials. Subjects were assessed at baseline. Fludarabine (Flu) and cyclophosphamide (CTX) based preconditioning should be performed within 1 week prior to uCD7 CART infusion: Flu 30mg/m2 ×3 days; CTX 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and etoposide. Infusion of uCD7 CART must be performed 24 hours after completion of chemotherapy preconditioning. uCD7 CART can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.
214906308|NCT07116915|DRUG|HRS-9821 Powder for Inhalation.|HRS-9821 Powder for Inhalation.
214906309|NCT07116915|DRUG|HRS-9821 Powder for Inhalation placebo|HRS-9821 Powder for Inhalation placebo
214906310|NCT07116915|DRUG|Moxifloxacin Hydrochloride Tablets|Moxifloxacin Hydrochloride Tablets
214906311|NCT06925737|DRUG|Ifinatamab deruxtecan|Administered via intravenous (IV) infusion every 3 weeks (q3W) until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
214906312|NCT06925737|DRUG|Docetaxel|Administered via IV infusion q3W until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
214906313|NCT06925737|DRUG|Prednisone|Oral tablet administered once per day or per approved product label
214906314|NCT06931327|DRUG|Test Drug|AJU-C711
215056937|NCT01202890|DRUG|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
214302939|NCT07190599|BEHAVIORAL|Proprioceptive neuromuscular facilitation (PNF) only|The hold-relax technique will be applied to stretch the triceps surae muscle. It will be performed ten times on the affected limb during each treatment session, lasting approximately 10 minutes in total. Participants will receive interventions three times per week for four weeks, for a total of twelve sessions.
214479364|NCT06615674|DRUG|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days. And the second group will have placebo for 14 days.
214479365|NCT06664957|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants in this arm will receive 400 mg of Vitamin C, administered as two 100 mg tablets in the morning and two 100 mg tablets in the evening, for a total of 12 months. The intervention aims to support antioxidant defense and improve clinical outcomes in COPD patients.
214302940|NCT07189403|DRUG|DS9051b|Administered orally
214479366|NCT06664957|OTHER|Placebo|Participants in this group will receive a placebo, identical in appearance to the active nutrient supplement (Vitamin C) tablets, with no active ingredients. The placebo will be administered as two tablets in the morning and two tablets in the evening (four tablets per day) for a duration of 12 months, serving as a control to compare the effects of the active intervention.
214479367|NCT06779825|COMBINATION_PRODUCT|fMRI Neurofeedback attention task|Neurofeedback is an attentive task where participants are shown their real-time brain signals while in the scanner with the use of a representation, such as a rocket moving towards a portal. Participants are able to increase this brain signal by more purposefully engaging certain brain regions, and this is reflected in the representation that they see. Ultimately, this study is interested in whether neurofeedback can replicate the effects of stimulant medication in ADHD.
214479368|NCT05570734|BEHAVIORAL|LUNA Care Coordination|Participants in this group will have 6 or more 30-minute care coordination sessions with the LUNA Care Coordinator. The LUNA Care Coordinator will assist with appointments and referrals, medications, and assist with accessing the health education videos. They will work closely with the participant's primary care provider and the LUNA Behavioral Health Provider.
214302941|NCT07189650|DEVICE|MRI|Proton Density Fat Fraction Magnetic Resonance Imaging (MRI-PDFF )
214302942|NCT07189468|DEVICE|Smartwatch and mobile application|Wearing a smartwatch and using a mobile application for one year
214906315|NCT06931327|DRUG|Reference Drug|C711R
214906316|NCT07126522|OTHER|Discussion|Ancillary studies
214906317|NCT07126522|OTHER|Internet-Based Intervention|Use the HERCaRE app
214906318|NCT07126522|OTHER|Interview|Ancillary studies
214906319|NCT07126522|OTHER|Survey Administration|Ancillary studies
214479369|NCT05570734|BEHAVIORAL|LUNA Behavioral Health|Participants in this group will have 6 or more 30-minute behavioral health sessions with the LUNA Behavioral Health Provider. The LUNA Behavioral Health Provider will screen and address life stressors, social support, and health care use. The purpose of these sessions is to check on participant's progress with their care plan. The behavioral health sessions will involve discussion of issues that may interfere with optimal diabetes self-management. The LUNA Behavioral Health Provider will help participants overcome any potential barriers to managing their diabetes by setting goals and helping to address life stress or other issues that may be interfering with their diabetes self-management.
214479370|NCT05570734|BEHAVIORAL|Health Education Videos|Participants in this group will have access to eight 20 to 30-minute health education video sessions with corresponding print material and activities to reinforce what they learn. The health education videos focus on medication adherence, self-monitoring, stress and coping, nutrition, physical activity and culturally driven beliefs and values.
214906320|NCT03923647|DEVICE|Laparoscopy|Laparoscopic insertion with carbon dioxide via open technique at the umbilicus
214906321|NCT07140289|DIAGNOSTIC_TEST|Ultrasound of gastric contents|An ultrasound examination of the abdomen to observe and measure gastric contents
214906322|NCT06930300|OTHER|Hypertonic 3% saline|Participants receive 10 ml/kg body weight of 3% saline infused over 1 hour. The aim is to stimulate copeptin release.
214906323|NCT06930300|OTHER|Water|Participants ingest 20 ml/kg water over 1h. The aim is to suppress copeptin release.
214906324|NCT06940349|DRUG|Palbociclib|Palbociclib and Sunitinib
214906325|NCT06940349|DRUG|Sunitinib|Palbociclib and Sunitinib
214906326|NCT06356688|DRUG|Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab|Paclitaxel Polymeric Micelles for Injection:Cycle 1: 230mg/m2, IV ≥3 hours; Cycles 2-4: If the patient has a neutrophil nadir ≥1.0 x 109/L along with a platelet nadir ≥80 x 109/L after Cycle 1 dosing and has not experienced grade II-IV non-hematologic toxicity, then give 260mg/m2, IV ≥3 hours, d1, q3w; Cisplatin: 25mg/m2/d x d1-3, IV drip, q3w; Cadonilimab: 10mg/kg, IV drip, d3, q3w;
214906327|NCT03525678|DRUG|Belantamab mafodotin frozen liquid|Belantamab mafodotin will be available as frozen liquid. Frozen liquid will be available as 30 milligram (mg)/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. Belantamab mafodotin will be administered as IV solution over at least 30 minutes. Frozen belantamab mafodotin will be diluted in 0.9 percent saline and administered via infusion pump.
214906328|NCT03525678|DRUG|Belantamab mafodotin lyophilized powder|Belantamab mafodotin will be available as lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 3.4 mg/kg. Lyophilized belantamab mafodotin will be reconstituted using water for injection and diluted with saline before use.
214906329|NCT06066749|OTHER|Filtration of all PM and VOC's|"During each exposure session, participants will wear a modified MaxAIR controlled air pressure respirator (CAPR) manufactured by Syntech International (BMD), Irvine, CA, USA, that will deliver filtered woodsmoke directly to the participant. The MaxAIR CAPR is a NIOSH approved (TC 21C-1050) powered air purifying respirator used for infectious disease control in laboratory and medical settings.~In the modified MAXAIR CAPR used during this study's exposure sessions, an external pump and different filtering media. For this intervention, virtually all particulate matter (PM) and volatile organic compounds (VOC's) will be removed using commercially available P100/VOC respirator filters (3M cartridge; 60925 or equivalent)."
214669922|NCT01615510|DRUG|placebo|placebo, single administration
214906330|NCT06066749|OTHER|Filtration of VOC's|"During each exposure session, participants will wear a modified MaxAIR controlled air pressure respirator (CAPR) manufactured by Syntech International (BMD), Irvine, CA, USA, that will deliver filtered woodsmoke directly to the participant. The MaxAIR CAPR is a NIOSH approved (TC 21C-1050) powered air purifying respirator used for infectious disease control in laboratory and medical settings.~In the modified MAXAIR CAPR used during this study's exposure sessions, an external pump and different filtering media. For this intervention, virtually all particulate matter (PM)will be removed using commercially available P100 respirator filters (DM; cat. # 2097)."
214906331|NCT06401421|DIAGNOSTIC_TEST|ctDNA MRD test|Blood and tissue samples will be collected for the ctDNA MRD test
214906332|NCT03775174|DRUG|Mepsevii|
214906333|NCT06364488|DEVICE|TrueBlue App|The use of the TrueBlue App, to generate automated measures of mood that can be assessed for agreement with validated clinical scales eg. PHQ9.
215056938|NCT01202890|DRUG|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
215056939|NCT02377414|DRUG|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
215056940|NCT02377414|DRUG|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
215056941|NCT02025634|DRUG|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
215056942|NCT02025634|DRUG|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
214302946|NCT07190079|DIAGNOSTIC_TEST|Saline contrast Electrical Impedance Tomography method|"This study will enroll patients with clinically suspected or confirmed acute pulmonary embolism (PE) presenting with acute respiratory failure, who undergo electrical impedance tomography (EIT) with saline contrast within 24 hours before or after computed tomography pulmonary angiography (CTPA). The EIT procedure is performed as follows:~1. Breath-Hold Maneuver: (1)Spontaneous breathing patients: Supine position, instructed to hold expiration for ≥8 seconds. (2)Mechanically ventilated patients: Expiratory hold (\>8 sec) achieved via ventilator; deeper sedation will be applied when feasible to prolong breath-hold.~2. Venous Access: (1)Preferred: Central venous catheter (internal jugular or subclavian vein).(2)Alternative: Peripheral forearm vein (preferably the median cubital vein).~3. Contrast Administration:(1)Central venous route: 10 mL of 10% NaCl.(2)Peripheral venous route: 15 mL of 5% NaHCO₃."
214302947|NCT07190079|DIAGNOSTIC_TEST|Computed Tomography Pulmonary Angiography (CTPA)|Patients who meet the inclusion criteria will undergo CTPA examination using conventional clinical diagnostic methods.
214302948|NCT07190820|PROCEDURE|digital impression|complete arch implant impression with intraoral photogrammetry
214302949|NCT07190820|PROCEDURE|conventional impression|conventional open tray splint impression
214906334|NCT05585606|DRUG|Placebo|Volume Matched Placebo
214302950|NCT07189910|DRUG|Eltrombopag|Participants assigned to the observation group will be treated with eltrombopag oral suspension (EPAG-pfos).
214302951|NCT07189910|OTHER|Placebo|Participants in the control group will receive a placebo at the same dose, instead of eltrombopag oral suspension (EPAG-pfos).
214302952|NCT07191496|OTHER|Questionnaire|The questionnaires include the Ferrans and Powers QLI, EORTC QLQ-C30, FCR-7 Scale, HADS, and MOS Social Support Survey.
214669923|NCT01272531|DRUG|Mood stabilizer treatment|lithium or valproate
214669924|NCT02986373|BIOLOGICAL|risankizumab|Risankizumab administered by subcutaneous injection.
214669925|NCT04403737|DEVICE|Rothman Index|The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
214669926|NCT01930071|DEVICE|PQ Bypass Guide Wire Delivery System|The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
214669927|NCT00631462|DRUG|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
214906335|NCT05585606|DRUG|scp776 (1.9 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~\- 1.9 mg/kg"
214906336|NCT05585606|DRUG|scp776 (3.8 mg/kg)|"Cohort 2 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~\- 3.8 mg/kg"
214906337|NCT05585606|DRUG|scp776 (4.8 mg/kg)|Cohort 3 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes - 4.8 mg/kg
214479371|NCT05570734|BEHAVIORAL|Virtual Integrated Visits|Participants in this group will have two virtual integrated visits with the LUNA care team. Through video conferencing, they will meet at the same time with the LUNA Care Coordinator, the LUNA Behavioral Health Provider, and their primary care provider to ensure an integrated care plan.
214906338|NCT05585606|DRUG|scp776 (all dose levels)|A composite group encompassing all participants who received any dose level of the investigational drug under evaluation.
214906339|NCT05770349|PROCEDURE|coronary artery bypass grafting|Coronary artery bypass grafting
214906340|NCT04417660|DRUG|M7824|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
214906341|NCT03339128|DRUG|Eluxadoline|Oral tablets
214906342|NCT03339128|DRUG|Placebo|Oral tablets
214906343|NCT03927833|DEVICE|Phototherapy lights|Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.
214906344|NCT05906602|DEVICE|Real Ischemic Conditioning|10-minute cycles of blood flow restriction (5 minutes) followed by blood flow release (5 minutes), repeated 5 times for a total of 50 minutes.
214906345|NCT05906602|DEVICE|Sham Ischemic Conditioning|Sham ischemic conditioning will mirror ischemic conditioning procedures, differing solely in cuff pressure during blood flow restriction to replicate to replicate perceived tightness without arterial blood flow restriction.
214906346|NCT06427811|DRUG|Asciminib|Film-coated tablets with 40 mg dose strength taken orally
214906347|NCT06783491|DRUG|Mitomycin (MM)|Mitomycin 30mg/m2/4 litres of perfusion liquid (dextrose 1.5%). Single intraoperative dose.
214906348|NCT06783491|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|FOLFOX6 consists in oxaliplatin 85 mg/m2 iv. on day 1, 5FU 400 mg/m2 iv. in bolus followed by 2400 mg/m2 in a continuous infusion for 46 hours. Leucovorin: 400mg/m2 folinic acid (racemid dl) in a continuous infusion for 2 hours. Repeat every 2 weeks. Haematological recovery to ANC \>1.5x109/L and platelets \>75x109/L should be ensured prior to Day 1 of each 14-day cycle.
214906349|NCT06783491|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery will be defined as complete tumour resection including oncologic colectomy and adjacent structures with suspicious of infiltration to achieve a R0, bilateral oophorectomy is recommended in post-menopausal women
214906350|NCT06467357|DRUG|Gemcitabine|Standard of care chemotherapy by intravenous infusion
214906351|NCT06467357|DRUG|Cisplatin|Standard of care chemotherapy by intravenous infusion
214906352|NCT06467357|DRUG|Durvalumab|Standard of care immunotherapy by intravenous infusion
214906353|NCT06467357|DRUG|Trastuzumab deruxtecan|Experimental therapy by intravenous infusion
214906354|NCT06467357|DRUG|Rilvegostomig|Experimental therapy by intravenous infusion
214906355|NCT06467357|DIAGNOSTIC_TEST|Agilent HercepTest™ mAb pharmDx|"A semi-quantitative immunohistochemical assay to determine HER2 overexpression in FFPE breast cancer tissues routinely processed for histological evaluation.~Based on a primary monoclonal rabbit antibody which visualises Her2 overexpression utilising a fully automated IHC platform (Dako Omnis)."
214906356|NCT06467357|DIAGNOSTIC_TEST|Ventana PD-L1 SP263 assay|A qualitative immunohistochemical assay to determine the level of PD-L1 expression in FFPE non-small cell lung cancer (NSCLC) tissues routinely processed for histological evaluation. Based on a rabbit monoclonal anti-PD-L1 clone SP263 which visualises PD-L1 protein using a VENTANA BenchMark ULTRA instrument
214906357|NCT01205815|OTHER|Tissue and blood collection|Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
214906358|NCT03267433|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
214906359|NCT03267433|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214906360|NCT03267433|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
214906361|NCT03267433|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
214906362|NCT03267433|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214906363|NCT03267433|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
214906364|NCT03267433|BIOLOGICAL|Rituximab|Given IV
214479372|NCT06666855|DRUG|DE-117B Eye Drops|Investigational Product: 0.002% DE-117B Eye Drops
214479373|NCT06666855|DRUG|Latanoprost|Active Control: 0.005% Latanoprost Eye Drops
214669928|NCT03466554|DEVICE|Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes|60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
214906365|NCT03267433|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
214906366|NCT04756063|DRUG|Ascorbic acid|Intravenous vitamin C
214906367|NCT04756063|OTHER|Placebo|Normal Saline
214906368|NCT04486118|DRUG|Lisinopril Pills|Tablets will be taken by oral administration daily, based on titration
214906369|NCT04486118|DRUG|Benazepril Pill|Tablets will be taken by oral administration daily, based on titration
214906370|NCT03777215|DRUG|Angiotensin-(1-7)|This is a biologically active beneficial hormone of the renin-angiotensin system.
214906371|NCT03777215|DRUG|Saline|Saline will be used as the placebo comparator.
214906372|NCT05865054|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Combined orbital and cranial vessel wall MRI
214906373|NCT06792981|OTHER|Universal primary prevention program based on ICTs|"The intervention adopts a multicomponent approach, addressing three agents in the prevention and management of eating disorders: parents, teachers and students.~1. Intervention with parents:~   Parents will receive specific materials, including an informative guide on early identification of warning signs, promoting healthy lifestyle habits, and fostering effective communication with their children.~2. Intervention with teachers:~   A two-hour in-person session will train teachers on platform use and provide tools for eating disorder prevention through role-playing techniques. Online resources will complement the training, while researchers ensure adherence via weekly follow-ups and parent reminders.~3. e-Preta program: The intervention for minors is delivered through an online platform, structured into 9 sessions of 45 minutes each, over 3 months. Weekly, platform-guided activities are proposed for classroom use with minimal teacher interaction, along with voluntary at-home activities."
214906374|NCT06959225|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
214669929|NCT02319772|DRUG|BCX4430|
214669930|NCT02319772|DRUG|Placebo|
214302953|NCT07190235|DEVICE|Transcranial Magnetic Stimulation|The repetitive transcranial magnetic stimulation (rTMS) at different frequencies will deliver 10 sessions over 2 weeks. The participants will receive 25 Hz rTMS, 1 Hz rTMS, or sham stimulation protocol to the supplementary motor area while seated using a double-cone coil connected to a transcranial magnetic stimulator.
214669931|NCT00055198|DRUG|daptomycin|
214302954|NCT07189832|PROCEDURE|Intralesional Injections|Intralesional Injections
214302955|NCT07185087|DEVICE|passive self-ligating, Damon Ultima brackets|Patients will receive Damon Ultima self-ligating brackets (Ormco Corp., Glendora, California, USA) bonded from the second molar to the second molar in each arch. Archwires will follow a standardized sequence: 0.014-inch CuNiTi, 0.018-inch CuNiTi, and 0.014 × 0.0275-inch CuNiTi (Ormco Corp., Glendora, California, USA). All bonding procedures will follow a standardized protocol, including enamel cleaning, acid etching, primer application (Ortho Solo), and adhesive curing (Green Glow).
214906375|NCT06959225|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
214906376|NCT05763407|DEVICE|NORM™ System|NORM™ System
214906377|NCT06500845|OTHER|Bevel marginal design endocrown for endodontically treated teeth|Bevel marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
214906378|NCT06500845|OTHER|Butt marginal design endocrown for endodontically treated teeth|Butt marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
214906379|NCT05127226|DRUG|ION582|ION582 will be administered by IT injection.
214906380|NCT06632457|DRUG|Survodutide|Subcutaneous injection
214906381|NCT06632457|DRUG|Placebo matching survodutide|Subcutaneous injection
214906382|NCT04559139|DRUG|Cisplatin|Given IV
214906383|NCT04559139|DRUG|Gemcitabine Hydrochloride|Given IV
214906384|NCT04559139|PROCEDURE|Lymphadenectomy|Undergo portal lymphadenectomy
214906385|NCT04559139|PROCEDURE|Partial Hepatectomy|Undergo partial hepatectomy
214906386|NCT04763915|OTHER|Correlative Studies (Survey)|Administer surveys
214906387|NCT04763915|OTHER|Correlative Studies (Interview)|In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention
214906388|NCT04763915|BEHAVIORAL|GeneSHARE|Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.
214906389|NCT04763915|BEHAVIORAL|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
214906390|NCT04763915|BEHAVIORAL|Standard-of-care & Adaptive Intervention|Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.
214906391|NCT04763915|OTHER|Access to Education Materials|Receive access to VUS educational materials
214906392|NCT04059822|OTHER|Slow and deep breathing|Please see arm description
214906393|NCT03140748|OTHER|To evaluate the initial levels and kinetics of serum β-D-glucan|To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
214669932|NCT06156098|OTHER|No Intervention|No Intervention
214669933|NCT04800315|DRUG|CC-93538|Specified dosages on specified days
214669934|NCT04800315|OTHER|Placebo|Specified dosages on specified days
214669935|NCT05707572|DRUG|methylprednisolone|a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
214669936|NCT05707572|PROCEDURE|manual manipulation|The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
214669937|NCT00753922|DEVICE|Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface|Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
214906394|NCT04355572|DRUG|Vitamin D 4000IU daily|Randomized to receive vitamin D 4000IU daily
214906395|NCT04355572|DRUG|Placebo|Randomized to placebo daily
214906396|NCT06144684|DRUG|GUB014295|GUB014295 is a long-acting amylin analogue in development, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
214906397|NCT06144684|DRUG|GUB014295-PLACEBO|GUB014295-PLACEBO is matching GUB014295 in appearance, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
214906398|NCT05880706|DRUG|BL-B01D1|Administration by intravenous infusion
214906399|NCT05880706|DRUG|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.
214906400|NCT05679674|RADIATION|Stereotactic Ablative Body Radiation (SABR)|50 Gy in 5 fractions, once per day for 5 days
214906401|NCT05679674|DEVICE|Tumor Treating Fields (TTF)|Participant will use the system for at least 18 hours per day starting on the first day of SABR until abdominal disease progression. Short treatment breaks are permitted for personal needs (such as to take a shower) and during radiation therapy. An additional treatment break is permitted for up to 48 hours every 21 days.
214906402|NCT05053191|BEHAVIORAL|Partnership, Assessment, Care and Transition training intervention|Partnership, Assessment, Care and Transition to psychosocial resources. Nurses who participate in PACT will receive 8 hours of training in a single, full-day workshop. We will train nurses in clusters of 10-12 nurses at one time, which will allow for cross-coverage with minimal disruption to workflow, and provide a more intimate, small-group learning environment.
214479374|NCT05433103|OTHER|Low-Load Exercise with Blood Flow Restriction|Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
214479375|NCT05433103|OTHER|Low-Load Exercise Control Group|Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
214479376|NCT00674882|OTHER|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
214479377|NCT05275556|DEVICE|Computer-Assisted Detection (CADe) Device|The CADe Device uses artificial intelligence to aid in identifying colorectal polyps during High Definition White Light Endoscopy (HD-WLE) based colonoscopies. This device connects the Gastroenterologist's colonoscopy video output source to the main monitor and highlights the regions of interest where the device detects a potential lesion. The CADe Device overlays graphical markers onto video from the endoscope camera and does not perform further processing to the endoscope video signal. This device is not intended to replace clinical decision making.
214479378|NCT04122677|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw.
214479379|NCT06997835|BEHAVIORAL|Control group：The interactive management nursing model on the wechat platform|The intervention subjects of the control group: targeted at the pregnant and postpartum women themselves. Specifically, conduct routine outpatient prenatal examinations and health education for pregnant women. Regularly receive health education and pregnancy guidance intervention provided by the wechat platform. It includes: ① Setting specific wechat ringtones, 60-second voice messages and picture reminders every day; ② Basic knowledge education every Monday ③ Dietary guidance is provided every Tuesday. ④ Exercise guidance every Wednesday ⑤ Guidance on blood glucose monitoring every Thursday; Weight guidance is provided every Friday.
214479380|NCT06997835|BEHAVIORAL|Intervention group：Family-centered early care intervention|"The intervention subjects of the intervention group were parturients and their primary caregivers (spouses and parents).~The specific measures are as follows:~1. Establish a family-centered healthcare team (FCC) It includes one chief physician, two attending physicians, one diabetes specialist nurse, two responsible nurses, one psychotherapist, and one nutritionist. The organization members will conduct FCC concept learning and knowledge training.~2. Interactive management nursing model on the wechat platform~   * Set specific wechat ringtones, 60-second voice messages and picture reminders every day;~     * Basic knowledge education every Monday; ③. Dietary guidance every Tuesday;~       ④. Exercise guidance every Wednesday;~       ⑤ Guidance on blood glucose monitoring every Thursday;~       ⑥. Weight guidance every Friday;~       ⑦. Strengthen home care guidance every Saturday and Sunday."
214479381|NCT03372057|DRUG|Duvelisib|Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
214906403|NCT06148246|BEHAVIORAL|Family Fit Condition|Dyads in the Family Fit condition will use the Family Fit app and a Fitbit for 12 weeks, working to increase their moderate- to vigorous-intensity physical activity.
214906404|NCT06230796|DEVICE|FES-cycling|30 minutes of active leg cycling with or without FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
214906405|NCT06230796|DEVICE|SHAM-cycling|30 minutes of active leg cycling with SHAM FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
214906406|NCT06417684|DRUG|Amitriptyline|25 mg prescribed to be taken once daily for 90 days each evening.
214906407|NCT06417684|BEHAVIORAL|Lifestyle Modification|Written and video instructions to instruct the participant to improve restful sleep, exercise, avoidance of dietary triggers, and mealtime regularity.
214906408|NCT04445649|DIAGNOSTIC_TEST|Coma-Recovery-Scale-Revised (CRS-R)|CRS-R assessments (15 minutes) are repeated weekly after study entry
214906409|NCT03896503|DRUG|Berzosertib|Given IV
214906410|NCT03896503|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
215056943|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep is crucial for processing emotional memories and consolidating implicit memories. By using targeted memory reactivation (TMR), a known method where sound S1 and sound S2 are associated with a waking experience(i.e.negative emotional words is associated with alcohol-related cues and positive emotional words is associated with healthy lifestyle cues) and strengthened during REM sleep, the investigators aim to augment the control of craving levels in patients with Alcohol Use Disorder.
215056944|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification|These patients will receive the treatment of emotional attention bias modification (EABM) without association with the sound S1 and sound S2.
215056945|NCT01248988|OTHER|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
215056946|NCT00143494|PROCEDURE|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
215056947|NCT04400916|DRUG|Tranexamic acid|A single drop administered topically
215056948|NCT04400916|OTHER|Balanced Salt Solution|A single drop administered topically
215056949|NCT00084708|DIETARY_SUPPLEMENT|calcitriol|
215056950|NCT00084708|DRUG|dexamethasone|
215056951|NCT00084708|DRUG|gefitinib|
215056952|NCT05388383|DEVICE|Ti-robot|Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital
215056953|NCT06421506|PROCEDURE|Less invasive surfactant administration during high flow nasal cannula treatment|Surfactant distilled through a small tube inserted into the windpipe via the mouth whilst the baby is awake and supported with HFNC.
215056954|NCT02315807|DEVICE|transcranial direct current stimulation|
214669938|NCT05078034|DEVICE|Helmet Non-Invasive Ventilation (HNIV)|HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.
214669939|NCT05078034|DEVICE|High Flow Nasal Oxygen|HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.
214669940|NCT05263843|DIAGNOSTIC_TEST|Biological markers of myocardial fibrosis|Blood sample for measurements of NET activation and collagen biomarkers
214669941|NCT01301326|DEVICE|subthreshold and threshold laser treatment|subthreshold laser treatment
214669942|NCT01301326|DEVICE|Threshold laser treatment|threshold laser treatment
214906411|NCT03896503|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214302956|NCT07185087|DEVICE|Conventional ligation, MBT brackets|Patients will receive MBT Mini Diamond brackets (Ormco Corp., Glendora, California, USA) bonded in the same manner, with the same archwire sequence.
214302957|NCT07190807|DEVICE|Boston Scientific WaveWriter Alpha™ SCS Systems|Time Varied Pulse (TVP)-SCS settings
214302958|NCT07190196|DRUG|Rilzabrutinib|Pharmaceutical form:Tablet-Route of administration:Oral
214302959|NCT07190196|DRUG|Placebo|Pharmaceutical form:Tablet-Route of administration:Oral
214302960|NCT07190196|DRUG|Glucocorticoid|Pharmaceutical form:Tablet, solution, suspension formulations according to local standard practices-Route of administration:Oral
214302961|NCT07189767|BEHAVIORAL|psychoeducation|The nurse/midwife-led psychoeducation intervention aims to encourage pregnant women to express their feelings about childbirth. It also provides a counseling framework to help women identify and overcome the distressing elements of childbirth. Psychoeducation allows pregnant women to obtain complete, evidence-based information about labor and to discuss their feelings and thoughts about the method of delivery and birth. Providing evidence-based information by nurses/midwives during psychoeducation helps pregnant women make informed decisions about their birth preferences. In addition to evidence-based information, the psychoeducation intervention includes discussing myths and misconceptions, increasing social support, reinforcing positive coping strategies, and focusing on problem solutions. Nurses/midwives encourage pregnant women to develop a positive birth plan through psychoeducation.
214302962|NCT07190859|DIETARY_SUPPLEMENT|L. reuteri|Supplementation with drops containing L. reuteri once daily for 21 consecutive days
214302963|NCT07190859|DIETARY_SUPPLEMENT|Placebo|Supplementation with identical drops without L. reuteri once daily for 21 consecutive days
214479382|NCT03372057|DRUG|Duvelisib|Duvelisib PO 75 mg BID in 28-day cycles.
214479383|NCT03372057|DRUG|Duvelisib|Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase).
214906412|NCT03896503|PROCEDURE|Computed Tomography|Undergo a CT scan
214906413|NCT03896503|DRUG|Topotecan Hydrochloride|Given IV
214669943|NCT04933630|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
214302968|NCT07189780|PROCEDURE|Surgical approach|"Control Group:Incising the peritoneum 0.5-1 cm above the lowest point of the peritoneal reflection to enter the dissection plane.~Experimental Group:Incising the peritoneum precisely at the lowest point of the peritoneal reflection (in the rectovesical or rectouterine pouch) to enter the dissection plane."
214302969|NCT07191054|DEVICE|LifeFlow Rapid infuser|Use of rapid infuser to fluid resuscitate
214302970|NCT07191054|DEVICE|Push Pull|Use of Push Pull syringe technique to fluid resuscitate
214302971|NCT07189559|BEHAVIORAL|Digital Bodies|The Digital Bodies intervention consists of a one-hour interactive session. The core of the intervention involves the use of cognitive dissonance techniques and the development of critical literacy skills to encourage adolescents to critically reflect on appearance ideals, as well as to foster the skills needed to challenge such ideals.
214302972|NCT07190794|DEVICE|OverStitch™ or OverStitch NXT™|The OverStitch™ or OverStitch NXT™ Endoscopic Suturing System was used as part of each patient's ESG procedure within the routine clinical practice.
214302973|NCT07190794|BEHAVIORAL|Lifestyle Modification|Patients participated in a lifestyle modification program for weight loss management.
214669944|NCT00902837|DRUG|Oxycodone naloxone prolonged release tablets (OXN)|
214669945|NCT00902837|DRUG|oxycodone prolonged release tablet|
214906414|NCT04871542|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214906415|NCT04871542|OTHER|Questionnaire Administration|Complete questionnaires
214669946|NCT00902837|DRUG|oxycodone naloxone tablet|
214669947|NCT06041347|DIAGNOSTIC_TEST|Transvaginal ultrasound|Preoperative detection with TVUS of proximity or the involvement of the sacral nerve roots in women diagnosed with deep endometriosis or other benign or malignant pelvic tumors would also contribute to the safety of surgical interventions (e.g laparoscopy, tru-cut biopsy) It aslo provides correct counseling and select the appropriate surgical team and assess the likely operative complexity of the surgery. Until now the diagnosis was based on MRI.
214669948|NCT04820985|OTHER|Vaginal swab|Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing
214906416|NCT06131788|BEHAVIORAL|Educational hand hygiene intervention|The intervention combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB
214302974|NCT07190781|DEVICE|Flow-Diverting Dense-Mesh Stent|Surface-Modified Flow-Diverting Dense-Mesh Stent for Mid-Term Follow-Up Study of Endovascular Embolization Therapy for Cerebral Aneurysms
214302975|NCT07189975|OTHER|High intensity eccentric cycling training|This intervention is a high intensity interval training using an eccentric ergocycle
214302976|NCT07189975|OTHER|Moderate intensity eccentric cycling training|This intervention is a moderate intensity continuous training using an eccentric ergocycle
214302977|NCT07189975|OTHER|High intensity concentric cycling training|This intervention is a high intensity interval training using a concentric ergocycle
214302978|NCT07191327|DEVICE|HD-tDCS sessions|This project translates decades of observational neuroimaging research into a biologically plausible stimulation target (i.e., DAN) and uses functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) to plan personalized brain stimulation and to ensure target engagement. When available; those not MRI compatible will receive a standard montage with per channel amplitudes of up to 5 milliamperes (mA) or a montage derived from other imaging methods. Participants will receive 4 days of HD-tDCS sessions in person. During these sessions participants will have electrodes placed on different areas of the head and held in place with headgear. Participants may also have memory and thinking tests during and after the sessions as well as questionnaires about the experience. Additionally, on the fourth day participants may have repeat immersive virtual reality (iVR) as well as other study activities.
214479384|NCT06997536|PROCEDURE|Ilioinguinal/iliohypogastric Nerve Block|The aim of this study is to compare the analgesic efficacy of IL/IH block, TAP block, and QLB applied in inguinal hernia cases operated under spinal anesthesia, with each other and with a control group that did not receive any additional block to spinal anesthesia.
214479385|NCT06997536|PROCEDURE|Transversus abdominis plane (TAP) block|The aim of this study is to compare the analgesic efficacy of IL/IH block, TAP block, and QLB applied in inguinal hernia cases operated under spinal anesthesia, with each other and with a control group that did not receive any additional block to spinal anesthesia.
214479386|NCT06997536|PROCEDURE|Quadratus Lumborum Block (QLB)|The aim of this study is to compare the analgesic efficacy of IL/IH block, TAP block, and QLB applied in inguinal hernia cases operated under spinal anesthesia, with each other and with a control group that did not receive any additional block to spinal anesthesia.
214479387|NCT02475161|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 20 mg tablet orally.
214479388|NCT02475161|DRUG|Rabeprazole|Rabeprazole will be administered as 20 mg tablet orally.
215056955|NCT02617407|DRUG|Livionex® Dental Gel|Oral application Dental Plaque, Gingivitis and Oral Microbiome Control.
215056956|NCT02617407|DRUG|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Oral application for Dental Plaque, Gingivitis and Oral Microbiome Control.
215056957|NCT02617407|DEVICE|Kolibree Toothbrush|Electric Toothbrush
215056958|NCT02552745|DRUG|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
215056959|NCT06106061|DEVICE|Decompression + FFX®|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression associated with the use of FFX® implant
214669949|NCT04820985|OTHER|Blood test|Blood sample to measure plasma dose of progesterone
214906417|NCT05067868|BIOLOGICAL|Replagal|Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.
214906418|NCT04362527|DRUG|Milrinone 1 Mg/mL Solution for Injection|Blinding procedure will be set up for the administration of the treatment
214906419|NCT04362527|DRUG|Saline solution for injection|Blinding procedure will be set up for the administration of the treatment
214906420|NCT06637293|DEVICE|DeepECG plateform diagnosis & recommendations|EchoNeXT\& ECG-AI algorithm
214906421|NCT03425838|DRUG|CDK 4/6 inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
214906422|NCT03425838|DRUG|Non-Steroidal Aromatase Inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
214906423|NCT03425838|DRUG|Fulvestrant|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
214906424|NCT06058585|DRUG|Finerenone|Finerenone 10mg or 20mg tablets, oral, once daily
214906425|NCT06058585|DRUG|Placebo Finerenone|Finerenone matched placebo tablets, oral, once daily
215056960|NCT06106061|PROCEDURE|Decompression alone|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression alone
215056961|NCT03640325|BEHAVIORAL|PRISM (Promoting Resilience in Stress Management)|Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
214906426|NCT02511028|DRUG|Ferumoxytol|510mg (17mL) IV
214906427|NCT06392841|DRUG|Androgen Deprivation Therapy (ADT)|Medical castration per ADT with GnRH agonist or antagonist (or surgical castration per orchiectomy)
215056962|NCT05368259|DEVICE|AGBS|The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
215056963|NCT06097533|DRUG|Cannabisextrakt Avextra 10/10 Lösung|medical cannabinoids
215056964|NCT05906472|OTHER|Feeds continued|Enteral feeds are continued up until time of surgery
214906428|NCT06392841|DRUG|Niraparib/Abiraterone Acetate DAT|Niraparib 200 mg/ Abiraterone acetate 1000 mg orally
214906429|NCT06392841|DRUG|Abiraterone Acetate|1000 mg orally
214906430|NCT06392841|DRUG|Prednisone|5 mg orally
214906431|NCT06392841|DRUG|Docetaxel|75 mg/m2 IV
214906432|NCT04522336|DRUG|Docetaxel|Given IV
214906433|NCT04522336|DRUG|Fluorouracil|Given IV
215056965|NCT05906472|OTHER|Feeds held|Enteral feeds are stopped 6 or more hours before surgery
215056966|NCT03721783|PROCEDURE|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
214906434|NCT04522336|DRUG|Oxaliplatin|Given IV
214906435|NCT04522336|BIOLOGICAL|Pembrolizumab|Given IV
214906436|NCT04522336|RADIATION|Radiation Therapy|Receive radiation therapy
215056967|NCT03880045|DRUG|Topical TA|A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
215056968|NCT03880045|DRUG|vasopressin|intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy
215056969|NCT03880045|OTHER|placebo to TA|(120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.
215056970|NCT03168165|OTHER|Pain neuroscience education training|PNE training will consist of 6 weeks online training followed by one day training session.
215056971|NCT02572297|OTHER|video-EEG|Registration of seizures during video-EEG
215056972|NCT04888026|DEVICE|Quantitative sensory testing|"The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation"
215056973|NCT00282633|DEVICE|Dermabond|
214479389|NCT06351215|DRUG|Methadone group|5mg PO methadone for participants \&lt;50kg or 10mg PO methadone for participants \&gt;50kg
215056974|NCT03046927|DRUG|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
215056975|NCT03046927|OTHER|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
215056976|NCT02052661|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
215056977|NCT04290247|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging for fracture diagnosis before conventional X-ray
215056978|NCT01133756|DRUG|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
215056979|NCT01133756|DRUG|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
215056980|NCT01133756|DRUG|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
215056981|NCT05502926|DIAGNOSTIC_TEST|lung ultrasound score|peroperative and postoperative 12 point trans-thoracic lung ultrasound
215056982|NCT01116999|PROCEDURE|light guided tracheal intubation|Tracheal intubation light guided technique.
215056983|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
215056984|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
215056985|NCT02234713|BEHAVIORAL|Motivational Interview|
215056986|NCT02234713|OTHER|Video Attention Control|
215056987|NCT02904850|BIOLOGICAL|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
215056988|NCT00479505|DRUG|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
215056989|NCT00479505|DRUG|Placebo|Placebo
215056990|NCT03276728|DRUG|AMG 986 IV|AMG 986 solution for infusion
215056991|NCT03276728|DRUG|AMG 986 PO|AMG 986 tablets for oral (PO) administration
215056992|NCT03276728|DRUG|Placebo PO|Matching placebo tablets for oral administration
215056993|NCT03276728|DRUG|Placebo IV|Matching placebo solution for infusion
215056994|NCT00023933|DRUG|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
215056995|NCT02295228|OTHER|No intervention|There are no interventions. This is an observational trial.
215056996|NCT02565693|DRUG|Apixaban|
215056997|NCT02565693|DRUG|Aspirin|
214906437|NCT05801029|DRUG|Osimertinib|Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.
214906438|NCT05801029|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at 1050 mg (\< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1 to 2) and then every 2 weeks in subsequent cycles) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg \[body weight \< 80 kg\] or 1050 mg \[body weight ≥ 80 kg\] on day 2.
214906439|NCT04327063|DRUG|Saline|Injection of the solution of Saline not exceeding 30 mL of maximal volume.
215056998|NCT02565693|DRUG|Carbasalate calcium|
215056999|NCT02565693|DRUG|Clopidogrel|
215057000|NCT02565693|DRUG|Dipyridamole|
215057001|NCT02565693|OTHER|No antithrombotic treatment|
215057002|NCT00069875|DRUG|Gemcitabine|
215057003|NCT00069875|DRUG|LY293111|
215057004|NCT00069875|DRUG|cisplatin|
215057005|NCT06010784|BEHAVIORAL|Family support|"* Family tip sheets sent via mobile text at the start of the program and then every 3 weeks, to a total of 6 mobile text messages~* Weeks 1-4 (4 weeks):~  i. Welcome package mailed in the first week of the program ii. Weekly: one 10-lbs box of produce iii. Recipes accompanying each box (sample recipe card attached to submission) iv. Bi-Weekly: Grocery store gift cards (2x USD 20, to a total of USD 40)~* Weeks 5-19 (total of 10 weeks over the 19-week study timeline):~  i. An optional online form (goal sheet) is sent to the parent/caregiver every other week (total 5) with questions about trying new FV items to be submitted in the next 7 days. As an incentive, a USD 10 gift card is sent to those who complete it (a potential total of USD 50).~ii. Week 11: an extra USD 20 gift card in the week after a school holiday to re-engage participants due to the school-year break."
214302979|NCT07191327|DEVICE|Sham HD-tDCS sessions|Participants will receive 4 days of sham HD-tDCS sessions in person. During these sessions participants will have electrodes placed on different areas of the head and held in place with headgear. Participants may also have memory and thinking tests during and after the sessions as well as questionnaires about the experience. Additionally, on the fourth day participants may have repeat immersive virtual reality (iVR) as well as other study activities.
214302980|NCT07191327|DEVICE|HD-tDCS sessions - Open-label (after randomized treatment)|Optional 26 weeks of additional HD-tDCS sessions. Participants can complete up to 5 days per week, but most people will complete about 3 days per week. The study team may also collect audio recordings of these sessions. Participants can complete this in person or at-home via using a secure, HIPAA-compliant videoconferencing with the supervision of a research staff member. Participant's that decide to complete the additional sessions at home, a research staff member will train a study partner during the first 4 HD-tDCS sessions in the office. This option may not be available or appropriate for all participants and the study team member will discuss this with participant's and study partners.
214669950|NCT03598777|BIOLOGICAL|Botulinum toxin type A|Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.
214669951|NCT03598777|DRUG|Placebo|The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
214669952|NCT04358250|PROCEDURE|Direct Superior Approach|GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.
214669953|NCT04358250|PROCEDURE|posterolateral approach|GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
214669954|NCT03299023|OTHER|Medibyte Portable Monitor|Patients will be provided with the portable monitor in order to measure their apnea/hypopnea index.
214906440|NCT04327063|DRUG|Ropivacaine|Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume
214906441|NCT06509009|DRUG|Nimotuzumab|nimotuzumab, toripalimab, gemcitabine, cisplatin
214302981|NCT07189676|BEHAVIORAL|Dietary advice (PHD)|It consists of a written document outlining the PHD diet recommendations. Participants will receive: 1) information about the PHD guidelines by EAT-Lancet (a high-quality plant-based diet with a low allowance of intake of eggs, dairy, chicken, and fish, but strictly avoiding red and processed meat) adapted to be nutritionally adequate and culturally accepted in Denmark, 2) a meal planner for their calorie demands (templates for 2000 kcal/day; 2500 kcal/day; and 3000 kcal/day), 3) guidance on alternatives for substituting meat when cooking at home or eating out, and 4) information on seasonal fruits and vegetables. The meal planner will specify the amounts of eggs, dairy, chicken, and fish that each participant should consume based on their total energy demands. The PHD dietary advice focuses on limiting certain food groups (without excluding them) based on their health and environmental impact.
214479390|NCT06351215|DRUG|Placebo|sugar pill that is identical look-alike to study drug
214669955|NCT06454968|DRUG|Orelabrutinib, obinutuzumab, lenalidomide|Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
214669956|NCT02894515|DRUG|Idalopirdine commercial tablet (test)|single dose, 10 mg, oral
214669957|NCT02894515|DRUG|Idalopirdine clinical tablet (reference)|single dose, 10 mg, oral
214669958|NCT00105872|BEHAVIORAL|Cognitive-Behavioral Therapy|
214669959|NCT05998343|BEHAVIORAL|Intergenerational HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 19-39 years old who has received training to provide strength-based support sessions weekly for 12 weeks.
214669960|NCT05998343|BEHAVIORAL|Same-Generation Peer Support HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 60 years or older who has received training to provide strength-based support sessions weekly for 12 weeks.
214669961|NCT01919411|DRUG|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
214669962|NCT01919411|DRUG|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
214906442|NCT05762172|OTHER|early 18F-FDOPA uptake|"During the usual patient care protocol for the 18F-FDOPA TEP examination, a 10 min acquisition starts after a 15 minutes waiting period following the injection of the radiotracer. This allows the reconstruction of a single late image volume. In the framework of this project, the patient is placed in the machine at the time of injection so as to acquire early 18F-FDOPA uptake and then reconstruct intermediate image volumes in addition to the usual final volume.~The total duration of the patient's examination is therefore not changed."
215057513|NCT06351423|BEHAVIORAL|Forest Bathing (FB)|"The forest bathing (FB) intervention will be comprised of four 2-hour sessions held in a country park on four consecutive weekends during the daytime. The FB sessions will cover 1-2 kilometers per forest visit. Participants will convene at the country park entrance. An FB guide will provide a briefing and commence the forest trip. Following 20 minutes for participants to slow down and share their experiences, they will be invited to mindfully center themselves using their five senses for another 20 minutes. Subsequently, the participants will be afforded 20 minutes to wander along a designated forest path, followed by another 20 minutes during which they will be encouraged to stroll in a designated area to help foster a deep connection with the forest.~Participants will have a 20-minute interval between each activity to share their experiences. A tea ceremony will be held at the end of each FB session."
214669963|NCT02438930|BEHAVIORAL|Motivational interviewing intervention during HIV testing|
214669964|NCT02438930|BEHAVIORAL|Standard-of-care counseling during HIV testing|
214669965|NCT06255886|DRUG|Protein pump inhibitor. Continuing nutrition containing cows' milk protein.|1 mg/kg /day
214669966|NCT06255886|BEHAVIORAL|Mother or infant diet|Mother on cow milk protein diet or infant on hypoallergenic formula in case of bottle fed
214906443|NCT06830395|BIOLOGICAL|CM313|CM313(SC) injection
214906444|NCT06830395|DRUG|Placebo|Matched placebo
214906445|NCT06310746|DRUG|GARP/TGF-β1 monoclonal antibody|It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).
214906446|NCT06310746|DRUG|Placebo|It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).
214906447|NCT05058651|BIOLOGICAL|Atezolizumab|Given IV
214906448|NCT05058651|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214906449|NCT05058651|DRUG|Carboplatin|Given IV
214906450|NCT05058651|DRUG|Cisplatin|Given IV
214906451|NCT05058651|PROCEDURE|Computed Tomography|Undergo CT scan
214906452|NCT05058651|DRUG|Etoposide|Given IV
214906453|NCT05058651|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214906454|NCT05058651|OTHER|Patient Observation|Undergo observation
214906455|NCT05681767|BEHAVIORAL|Motivational multicomponent lifestyle intervention + Treatment as usual|"Study intervention and treatment as usual~The study intervention is a multicomponent lifestyle intervention that targets exercise, diet, and stress management, and is conducted by motivational interviewing. The study nurse provides the study intervention. The intervention is conducted by motivational interviewing and includes the key elements of lifestyle interventions identified as effective (assessment of behavior at the baseline, giving information and advising, individualized goal setting, setting an action plan, monitoring a behavioral change, and giving feedback).~The intervention consists of individual appointments (2 x 45-60 min) and a telephone session ( 2 x 15 min) for three months. The participants receive a short educational guide (A4) on the lifestyle behavior recommendations."
214906456|NCT05681767|OTHER|Treatment as usual|Treatment as usual
214906457|NCT05380531|DIAGNOSTIC_TEST|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
214906458|NCT03773770|DRUG|Triheptanoin|Liquid for oral (PO) or enteral tube administration
214906459|NCT04772131|DEVICE|Desara® One Single Incision Sling|Single incision sling
214906460|NCT04772131|DEVICE|Desara® Blue Transobturator Sling|Standard mid-urethral sling
214906461|NCT04449666|DIAGNOSTIC_TEST|Neuropsychological assessment and structural MRI|Complex neuropsychological assessment testing attentional and memory functions. Additionally, a structural MRI is measured.
214906462|NCT05301192|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
214906463|NCT05301192|DRUG|Saline|Saline will be used as the placebo comparator.
215057006|NCT06010784|BEHAVIORAL|BGCAA's after-school program with CATCH curriculum|"1. The whole BGCAA's after-school program runs for 3h, Mon-Fri for the school year across all sites where the organization offers the program. All children enrolled are expected to attend a minimum of 2x/week.~2. In the BGCAA's after-school program, children participate in active recreational time (approx. 60 min, offered 1x/week at a minimum) which is a mixture of free play, structured physical activity games, and/or sports activities (including soccer, football, and basketball).~3. Uniquely to sites participating in the study, BGCAA's staff will deliver selected CATCH (Coordinated Approach to Child Health) curriculum components in blocks of 45-60 min, 2x/week, as part of the after-school program. The curriculum will focus on healthy eating education and physical activity designed for elementary school-aged children. More information on CATCH at https://catch.org/ (accessed 8/11/2023)"
215057007|NCT03501992|BEHAVIORAL|Current care|The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
214906464|NCT04472338|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and/or tissue samples
214669967|NCT06255886|DRUG|Placebo|Placebo medicine (appearing substantially like Omeprazole) 1mg/ ml, and continuing nutrition containing cows' milk protein
214669968|NCT00072189|DRUG|7-hydroxystaurosporine|Given IV
214906465|NCT04472338|OTHER|Laboratory Biomarker Analysis|Correlative studies
214906466|NCT04472338|OTHER|Quality-of-Life Assessment|Ancillary studies
214906467|NCT04472338|OTHER|Questionnaire Administration|Ancillary studies
214906468|NCT05338489|DRUG|Selpercatinib|Administered orally.
214906469|NCT05338489|DRUG|Itraconazole|Administered orally.
214906470|NCT05338489|DRUG|Rifampin|Administered orally.
214906471|NCT05974774|DRUG|iMAB|no treatment until significant PSA increase as per treating physician at which point patient restarts ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide). Once PSA \< 0.2 ng/mL, treatment stops again.
214906472|NCT05974774|DRUG|cMAB|LHRH agonist or antagonist + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)
214906473|NCT05546866|DRUG|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
214906474|NCT03915366|DRUG|Valganciclovir Oral Solution [Valcyte]|Treatment for CMV
214906475|NCT03915366|DRUG|Tuberculostatic Agents|Treatment for tuberculosis
214906476|NCT02818595|DEVICE|electroencephalogram (HR-EEG)|
214906477|NCT02818595|DEVICE|Near Infra Red Spectroscopy (NIRS)|
214906478|NCT05063656|DRUG|Gabapentin|8 weeks of gabapentin, titrated up to 20 mg/kg in 3 divided doses daily
214669969|NCT00072189|OTHER|laboratory biomarker analysis|Correlative studies
214669970|NCT00072189|OTHER|pharmacological study|Correlative studies
214302982|NCT07189676|BEHAVIORAL|Dietary advice (Ovo-lacto-vegetarian diet)|It consists of a written document outlining the ovo-lacto-vegetarian diet guidelines. Participants will receive information to adhere to a stricter plant-based diet with an intake of eggs and dairy, but avoiding chicken, fish, and red and processed meat, and guidance on alternatives for substituting meat when cooking at home or eating out. Recommendations on food quantity or on consuming local and seasonal foods will not be given to pinpoint differences in the environmental aspect between interventions.
214479391|NCT05342974|DRUG|Atorvastatin|Oral dose of atorvastatin (80 mg) to swallow at the clinic in the presence of a study provider with additional 6 doses (80 mg each) of atorvastatin to administer at home once daily for the next six days. These 6 pills should be taken orally. Return to the clinic for a follow-up visit approximately 3, 8 and 10 days after enrollment visit. At these visits, trained study clinician will evaluate abortion status using ultrasound and blood draw. At 8-day visit post-enrollment, 800 mcg of misoprostol will be provided to be taken vaginally or allowed to dissolve between cheek and tongue for 30 minutes, within 24 hours of the visit. At the final clinic visit, 10 days post-enrollment, if the termination of pregnancy has failed, standard abortion care at the clinic will be offered. A final phone call to assess any side effects, need for medical care or complications will occur 30 days after enrollment.
214479392|NCT05342974|DRUG|Misoprostol|On Study Day 8, participant will be provided will two doses of misoprostol 800 mcg for vaginal or buccal use. Participant will take a single dose of misoprostol on study day 8 (± 1 day), and be instructed to take an additional 800 mcg vaginal or buccal misoprostol if no significant bleeding consistent with passage of tissue (heavier than a menses) has occurred within 24 hours of first misoprostol dose.
214479393|NCT05272163|BEHAVIORAL|Stimulus Type|Targets can be specific or categorical
214479394|NCT05272163|BEHAVIORAL|Target Presence|There is or is not a target present on each trial
214479395|NCT05272163|BEHAVIORAL|Checklist|In fact, there is a checklist on every trial but these results will be compared to a non-checklist condition from another experiment
214906479|NCT06211673|OTHER|Semi-structured interviews|"3 semi-structured interviews will be administered to the legal guardians or legal representative of the patient:~* Vineland Adaptive Behavior Scales II (VABS-II): assessment of adaptive skills;~* Kiddie-SADS-Lifetime Version (K-SADS-PL): assessment of general psychopathology;~* Autism Diagnostic Interview-Revised (ADI-R): assessment of autistic symptoms. The K-SADS-PL will be administered directly to the participant provided the participant is of an equivalent age of at least 5 years 11 months for receptive language and expressive language on the VABS-II, with raw scores of 35 and 92, respectively."
214906480|NCT06211673|OTHER|Heteroquestionnaires|7 heteroquestionnaires assessing: Hyperactivity symptoms and behavioral disorders measured by the ABC Attention deficit/hyperactivity symptoms measured by the Conners 3 scale and the SAID-P Psychotic symptoms measured by the adapted GPS-ID Sensory peculiarities measured by the Sensory Profile 2 Anxiety symptoms measured by the ADAMS Sleep disorders measured by the SDSC For children, the questionnaires: ABC, Sensory Profile 2, ADAMS, SDSC will be completed collectively by the legal guardians, and the questionnaires: Conners 3, SAID-P, adapted GPS-ID will be independently completed by each legal guardian. The same for adult patients with possible second caregiver. The questionnaires Conners 3, SAID-P and adapted GPS-ID will be completed twice, with a 28-day interval, at the time of inclusion and then after the semi-structured interviews.
214906481|NCT04700631|DIAGNOSTIC_TEST|urinary extracellular vesicle concentration|urinary extracellular vesicle concentration will be determined in urine samples from CRF and healthy patients
214906482|NCT04700631|DIAGNOSTIC_TEST|blood sample|blood sample in order to determine creatin level
214906483|NCT06100289|DRUG|Vedolizumab IV|Vedolizumab IV injection.
214906484|NCT06100289|DRUG|Vedolizumab SC|Vedolizumab SC injection.
214302983|NCT07189676|BEHAVIORAL|Dietary advice (control)|It consists of a written document outlining the general recommendations of a healthy diet (i.e. consumption of fruits and vegetables, decreasing the intake of sugar-sweetened beverages, etc.) without any specific advice on the consumption of animal products.
214479396|NCT05545449|BEHAVIORAL|PrEP Peer Mentor Program|Five PrEP peer mentors will provide outreach, education, and referral for HIV pre-exposure prophylaxis. Peer mentors have received training on HIV, PrEP, family planning, adolescent development, peer support, and action planning. Interactions will include 1:1 informal interactions as well as planned group outreach interactions.
214479397|NCT05611372|DRUG|Rasagiline|1 mg rasagiline
214906485|NCT05404737|OTHER|transthoracic echocardiography (TTE)|In order to evaluate the interchangeability of RV-LSF, a TTE will be performed just after the placement of general anesthesia, when the patient is under mechanical ventilation
214906486|NCT05404737|OTHER|transoesophageal echocardiography (TEE).|During cardiopulmonary bypass surgery patients is monitored by a TEE as recommended.
214906487|NCT05411016|DRUG|Placebo|Placebo is administered single dose or multiple dose by IV or SC injection
214906488|NCT05411016|DRUG|KK4277|KK4277 is administered single dose or multiple dose by IV or SC injection
214669971|NCT02007837|DRUG|Combined aspirin and multinutrient supplement|Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
214669972|NCT02007837|OTHER|Daily text reminder text messages|
214669973|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
214669974|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
214906489|NCT06474676|DRUG|Cyclophosphamide|Given by IV
214906490|NCT06474676|DRUG|T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy|Given by IV
214906491|NCT05439005|DRUG|Dexmedetomidine|Dexmedetomidine+Lidocaine
214906492|NCT02615600|DEVICE|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): \<100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
215057008|NCT03501992|BEHAVIORAL|Reminder-recall|The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
214906493|NCT02979587|DEVICE|Harmony TPV System|"The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame.~The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 Model HTPV254952 is not applicable for Continued Clinical Experience).~The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter."
214906494|NCT01727388|PROCEDURE|lateral decubitus|
214906495|NCT01727388|PROCEDURE|supine decubitus|
214906496|NCT01539967|PROCEDURE|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance"
214906497|NCT05372393|PROCEDURE|Local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. The care provider pinches from the area of median nerve blockade prior to performing local anaesthesia. All the anaesthetic solution is injected locally. Additional anaesthetic solution can be injected locally if necessary.
214906498|NCT05372393|PROCEDURE|Distal median nerve block with local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. Half of the anaesthetic solution is injected into the median nerve area 5-7 cm proximally from the distal wrist crease. The other half is injected locally. Additional anaesthetic solution can be injected locally if necessary.
214906499|NCT06084364|DRUG|Injection of triamcinolone acetonide into the CMC-1 joint|intraarticular injection with triamcinolone acetonide
214906500|NCT06084364|BEHAVIORAL|Multimodal Occupational therapy for CMC-1 joint OA|Patient education, instructions about hand exercises, orthosis and training
214906501|NCT06084364|DRUG|Placebo|Intraarticular injection with saline
214906502|NCT06475859|OTHER|Montreal Imaging Stress Test|A mental stress test that induces stress via a series of arithmetic tasks participants need to solve in a few seconds.
214906503|NCT06475859|OTHER|Relaxation breathing|3 short sessions (4 minutes) of relaxation breathing
214906504|NCT05814549|DIAGNOSTIC_TEST|NavDx|"Evaluation of HPV presence via NavDx (v1) at two (or three) timepoints~o If one of the two blood samples is positive, the subject will have a third NavDx (v1) test approximately 1 month after the second timepoint. If the test is positive, the subject will move to surveillance phase."
214906505|NCT05389449|DRUG|Danicopan|Oral tablet
214906506|NCT05795101|DRUG|Trastuzumab deruxtecan|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
214906507|NCT05795101|DRUG|Durvalumab|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
214906508|NCT06055361|DRUG|BxC-I17e (primed iMSC derived Extracellular vesicles(EV))|Pharmaceutical form : solution for injection
214906509|NCT06055361|DRUG|Placebo|Pharmaceutical form : solution for injection
214906510|NCT05796479|DRUG|Amlitelimab DP1|"Injection solution 1~Subcutaneous"
214906511|NCT05796479|DRUG|Amlitelimab DP2|"Injection solution 2~Subcutaneous"
214906512|NCT00210210|DRUG|Ketamine|
214906513|NCT00210210|DRUG|Saline solution|
215057009|NCT03501992|BEHAVIORAL|Audit-and-feedback|The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff-nurses, medical secretaries, receptionists, and clinical assistants-regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
215057010|NCT03501992|BEHAVIORAL|Combined reminder-recall and audit-and-feedback|The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
215057011|NCT03941873|DRUG|Sitravatinib|Administered orally as a capsule
215057012|NCT03941873|DRUG|Tislelizumab|Administered intravenously
215057013|NCT01575236|DEVICE|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
214906514|NCT03433170|PROCEDURE|Quadrupled semitendinosus graft|Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
214906515|NCT03433170|PROCEDURE|ST-Gracilis graft|Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
214906516|NCT04026490|BEHAVIORAL|Immediate Intervention|The Interventionist will use motivational interviewing skills, assess ethnic and racial microaggressions, and provide support, screen for posttraumatic stress, and, if appropriate, link student to advanced care. The student may meet with the Interventionist several times during the remainder of the school year. These meetings will be approximately 10-30 minutes in length and occur during the school day in a private location determined by the Interventionist. The student may be referred to additional resources as a result of the meetings. The meetings will be documented by the Interventionist using a case management system (in RedCap).
214906517|NCT04026490|BEHAVIORAL|Waitlist Intervention|In order to compare outcomes contemporaneously, students from waitlisted schools will be asked to complete baseline and follow-up surveys, which will be collected at approximately the same time as in the immediate intervention schools. The data will be captured for analysis at the end of the study. Students will complete intervention following the waitlist period.
214302984|NCT07189676|BEHAVIORAL|Behavioural support PHD|This component is designed to help participants adhere to the PHD through four individual and personalized dietary visits with a dietitian. Participants will also have access to a digital recipe collection in the study app. Recipes will be tagged by meal type and by season.
215057014|NCT01575236|DEVICE|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
215057015|NCT02033681|PROCEDURE|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
215057016|NCT02033681|PROCEDURE|Saline Solution|Saline solution is injected into the tissue as a placebo control.
215057017|NCT00816010|BEHAVIORAL|telephone contact|for lifestyle and compliance counseling
214302985|NCT07189676|BEHAVIORAL|Food boxes PHD|Food boxes will be sent to participants' homes. PHD food boxes will include seasonal and local fruits and vegetables, whole grain products, legumes, nuts, and dairy or milk alternatives. If allergies or intolerances are identified, the food boxes will be modified to maintain safety and dietary compliance.
214302986|NCT07189676|BEHAVIORAL|Group visits PHD|Group visits will provide support through nutritional education, social interaction, and peer learning, all focused on the dietary behavior changes required by the intervention. PHD group visits will cover topics such as PHD principles, and the related environmental and health outcomes.
215057018|NCT05891015|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
215057019|NCT02565875|BEHAVIORAL|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
215057020|NCT02565875|BEHAVIORAL|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
214302987|NCT07189676|BEHAVIORAL|Behavioural support (Ovo-lacto-vegetarian diet)|This component is designed to help participants adhere to the ovo-lacto-vegetarian through four individual and personalized dietary visits with a dietitian. Participants will also have access to a digital recipe collection in the study app. Recipes will be tagged by meal type.
214302988|NCT07189676|BEHAVIORAL|Food boxes (Ovo-lacto-vegetarian diet)|Food boxes will be sent to participants' homes. Ovo-lacto-vegetarian food boxes will include fruits and vegetables, whole grains, legumes, nuts, soy-based products, eggs, and cheese. Local and seasonal aspects will not be taken into consideration. If allergies or intolerances are identified, the food boxes will be modified to maintain safety and dietary compliance.
214479398|NCT05495360|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|twice daily serving of the study product
214906518|NCT03294954|GENETIC|GINAKIT Cells|"Six dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~* Dose Level 5 = 3 x 10\^8~* Dose Level 6 = 1 x 10\^9"
214906519|NCT03294954|BIOLOGICAL|GINAKIT cells + Etanercept|"Four dose levels of GINAKIT cells in combination of Etanercept will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Combination Dose level 1: 3 x 10\^6 + Etanercept\*~* Combination Dose level 2: 1 x 10\^7 + Etanercept\*~* Combination Dose level 3: 3 x 10\^7 + Etanercept\*~* Combination Dose level 4: 1 x 10\^8 + Etanercept"
214906520|NCT05785910|DIAGNOSTIC_TEST|IUDS|a battery of neuropsychological test
214479399|NCT05953740|DRUG|MK-5720|IM injection
214906521|NCT03096418|DRUG|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
214906522|NCT02932956|GENETIC|GAP T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
214906523|NCT02932956|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
214906524|NCT02932956|DRUG|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
214906525|NCT06578481|OTHER|Exercises|Individuals in the first group underwent cervical stabilization (CS) exercises and additional scapular and lumbopelvic stabilization (SLPS) exercises three times a week for 6 weeks. The second group was treated with only CS exercises for the same period. In addition, stretching exercises and a 20-minute hot pack were applied to the muscles around the neck of all patients.
215057021|NCT02565875|OTHER|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
215057022|NCT02866162|GENETIC|High-throughput exome sequencing|
215057023|NCT01234480|DEVICE|BD SurePath Plus Pap test|BD SurePath Plus Pap test
215057024|NCT01234480|DEVICE|BD SurePath Pap test|BD SurePath Plus Pap test
215057025|NCT01234480|PROCEDURE|colposcopy with biopsy/ECC|Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
215057026|NCT01234480|DEVICE|HPV DNA test|digene HC2 HPV DNA test
215057027|NCT02982772|OTHER|Combination Therapy|"Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks."
214479400|NCT05953740|DRUG|Placebo to MK-5720|Placebo IM Injection matched to MK-5720
214906526|NCT04367181|DEVICE|Diffuse Correlation Spectroscopy (DCS)|Diffuse correlation spectroscopy uses light in the near infrared spectral region to quantify non-invasively cerebral blood flow. The DCS device will be use to monitor blood flow changes over time in all ELGA enrolled babies
214906527|NCT04367181|DEVICE|Amplitude Integrated Electroencephalography (aEEG)|Amplitude Integrated Electroencephalography like EEG it is used clinically to monitor brain function in intensive care settings over longer periods of time. aEEG data will be correlated with CBF variation over time
215057028|NCT02982772|OTHER|Standard Care Intervention|"Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks"
215057029|NCT00371202|PROCEDURE|keratoplasty|
215057030|NCT01435473|PROCEDURE|Cardiac Surgery|
215057031|NCT03714984|OTHER|Pre operative exercise|After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
214302989|NCT07189676|BEHAVIORAL|Group visits (Ovo-lacto-vegetarian diet)|Group visits will provide support through nutritional education, social interaction, and peer learning, all focused on the dietary behavior changes required by the intervention. Ovo-lacto-vegetarian group visits will cover topics such as plant-based eating and nutritional adequacy.
214302990|NCT07189676|BEHAVIORAL|Behavioral support (control)|Participants will attend four short individual dietary visits with a dietitian, where they will review the recorded dietary data. Participants of the control group will not have access a recipe collection or meal planner.
214302991|NCT07189676|BEHAVIORAL|Food boxes (control)|Food boxes will be sent to participants' homes. Control food boxes will include fruits and vegetables, potato, nuts, cheese, animal protein products and canned food. Local and seasonal aspects will not be taken into consideration. If allergies or intolerances are identified, the food boxes will be modified to maintain safety.
215057032|NCT03714984|OTHER|Control Group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
214302992|NCT07189676|BEHAVIORAL|Group visits (control)|Group visits will provide support through general health education, social interaction, and peer learning. Control group visits will cover topics such as the role and importance of controls in RCTs and general well-being.
214669975|NCT02128568|BEHAVIORAL|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
214669976|NCT01933672|DRUG|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
214479401|NCT05953740|DRUG|MK-8189|Oral Tablet
215057033|NCT02552173|RADIATION|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
215057034|NCT01465867|DIETARY_SUPPLEMENT|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
215057035|NCT01465867|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
215057036|NCT01465867|OTHER|Selenium + L-Thyroxine (LT4)|"83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~\+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
215057037|NCT01465867|OTHER|Sugar Pill Placebo + L-Thyroxine (LT4)|"Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~\+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
214479402|NCT05953740|DRUG|Placebo to MK-8189|Placebo oral tablet matched to MK-8189
214669977|NCT01933672|DRUG|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
214669978|NCT01933672|DRUG|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
214669979|NCT04358458|BIOLOGICAL|GEN3009|GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
214669980|NCT04358458|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
214906528|NCT03354351|BEHAVIORAL|Stepped-care model|The intervention proposed in this study is a stepped-care model (comprising 3 steps) integrating cognitive-behavioural therapy or trauma-focused therapy and emotion-focused therapy that involves matching individuals to the most appropriate level of care, based on their specific needs . When patients do not show improvement they move to higher, more intensive levels of care.
214906529|NCT03289520|DRUG|Clopidogrel|
214906530|NCT03289520|DRUG|Placebo|
214906531|NCT01220843|DRUG|Placebo|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
214906532|NCT01220843|DRUG|Sevelamer carbonate|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
214906533|NCT04225715|DRUG|Nucleos(t)ide (NUC)|Nucleos(t)ide (NUC) will be administered orally
214906534|NCT04225715|DRUG|CpAM (RO7049389)|CpAM (RO7049389) will be administered orally
214906535|NCT04225715|DRUG|TLR7 (RO7020531)|TLR7 (RO7020531) will be administered orally
214906536|NCT04225715|DRUG|siRNA (RO7445482)|siRNA (RO7445482) will be administered subcutaneously
214906537|NCT04225715|DRUG|PEG-IFN|PEG-IFN will be administered subcutaneously
214906538|NCT04225715|DRUG|PD-L1 LNA (RO7191863)|PD-L1 LNA (RO7191863) will be administered subcutaneously
214906539|NCT01506115|DRUG|Photofrin|Photodynamic therapy: Intravenous Photofrin at a dose of 2 mg/kg body weight, 48 hours before photoactivation by intraluminal light illumination
214906540|NCT04741750|OTHER|Simplified HCV care within a mobile medical unit|Delivers guideline-based care for HCV in a stream-lined manner on a mobile medical unit
214906541|NCT03019861|BEHAVIORAL|Ayurvedic nutritional counseling|
214906542|NCT03019861|BEHAVIORAL|Conventional nutritional counseling|
214906543|NCT05872854|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment
214669981|NCT06509698|OTHER|virtual reality|STEP I: For the warm-up, the examiner will perform passive stretching exercises to maintain the range of motion. STEP II: The patient will receive the game instructions by the examiner. STEP III: The patient will play the Adventure games and Sport games including tennis, boxing and kicking. virtual reality (20 minutes) using Nintendo Wii®, Wii Fit game will be used to stimulate and reinforce the improvement of balance and gait and enhance the quality of life.(30) Balance game: Soccer Heading, Penguin Slides, Balance Bubble, Torso Twists, and Single Leg Stance. Motor function: Boxing, Kicking, Tennis and Bowling Aerobic Games: 2-P run, advanced step, Title city and Basic Run. Step IV: (cool-down): Same as step one.
214906544|NCT05872854|OTHER|Visible Light|After application of HyBryte (0.25% hypericin ointment), participants will be placed in a light booth containing fluorescent light bulbs to activate the HyBryte.
214906545|NCT03152773|PROCEDURE|MRI Heart guidewire catheterization|to conduct left and right heart guidewire catheterization using real-time MRI fluoroscopy in human research subjects already undergoing medically necessary left and right heart catheterization. We will use only passive MRI-compatible catheters and a specific guidewire shown to be safe under specific conditions. Under the conditions of use, the guidewire is not susceptible to heating.
214906546|NCT02936297|DIETARY_SUPPLEMENT|High dose Gluten|
214906547|NCT02936297|DIETARY_SUPPLEMENT|Low dose Gluten|
214906548|NCT02936297|DIETARY_SUPPLEMENT|Lactose free placebo|
214906549|NCT05662072|BEHAVIORAL|Motor imagery|Mental imagery of respiratory exercises
214906550|NCT05662072|BEHAVIORAL|Action observation|Action observation of respiratory exercises
214906551|NCT05662072|OTHER|Placebo Intervention|Placebo observation
214906552|NCT05131841|DRUG|Cipterbin Combined With Vinorelbine|"1. Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~2. Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer"
214906553|NCT05014659|DIETARY_SUPPLEMENT|Creatine monohydrate|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
214906554|NCT05014659|DIETARY_SUPPLEMENT|Placebo|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
214906555|NCT04934813|OTHER|Alveolar ridge preservation|application of different bone graft and sealing means after tooth extraction
214906556|NCT01715532|DRUG|Huachansu|
214906557|NCT01715532|OTHER|TACE|
214906558|NCT05251337|DRUG|Essential oils|Participants will receive Wyndmere Naturals, Inc. aromatherapy patches. The hydrogel adhesive patches are infused with essential oil for inhaled aromatherapy treatment. The aromatherapy patches provide an occlusive barrier that is hypoallergenic, allowing essential oils to be inhaled without coming in direct contact with the skin. Participants indicating nausea/vomiting is their symptom of concern will receive peppermint aromatherapy patches (or mandarin if peppermint sensitivity). Participants indicating anxiety is their symptom of concern will receive lavender aromatherapy patches.
214906559|NCT05251337|DRUG|Placebo|Patients assigned to either control group (nausea/vomiting or anxiety) will receive Wyndmere Naturals non-scented patches (i.e., blank hydrogel adhesive patches without essential oil infusion).
214906560|NCT00887575|DRUG|Paclitaxel|IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2
214906561|NCT00887575|DRUG|Carboplatin|IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4
214906562|NCT00887575|DRUG|Sunitinib|By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
214906563|NCT06509737|BEHAVIORAL|Face to face group|With this research, it is expected that parents' knowledge levels, symptom management levels for food allergies, and treatment knowledge levels will increase by providing Life with Food Allergy Training based on the Health Promotion Model with face-to-face training in parents of children diagnosed with food allergy.
214906564|NCT06509737|BEHAVIORAL|social mediagroup|With this research, it is expected that parents' knowledge levels, symptom management levels for food allergies, and treatment knowledge levels will increase in parents of children diagnosed with food allergy by providing Life with Food Allergy Education based on the Health Promotion Model through social media.
214906565|NCT03684707|DRUG|Metformin Hcl 500Mg 24Hr Sa Tab|Glucophage 500 mg once daily
214906566|NCT03684707|OTHER|starch tablet|starch tablets
215057038|NCT00626782|DRUG|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
215057039|NCT00626782|DRUG|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
215057040|NCT04200794|BEHAVIORAL|musical instrumental training|Learning to play a string instrument in a group setting (school class)
215057041|NCT04200794|BEHAVIORAL|sensitization to music|sensitization to music via listening, theory, moderate practice on small percussive instruments and choir singing in a group setting (school class)
215057042|NCT00100256|DRUG|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
215057043|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
214302997|NCT07190183|PROCEDURE|washed microbiota transplantation|The prepared microbiota suspension was infused into the patients' gut.
214906567|NCT02011685|BEHAVIORAL|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
215057044|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
215057045|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
215057046|NCT06293534|DIAGNOSTIC_TEST|TSH,T3,T4|Diagnosis of the psychiatric disorders among study group will be assessed and recorded and history of Electroconvulsive therapy (ECT) also will be recorded , physical examination for signs that suggests actual thyroid disease such as unexplained bradycardia or tachycardia, hypothermia , goiter or non palpable thyroid among study group will be assessed
214302998|NCT07191145|DRUG|Eptinezumab|Eptinezumab 300mg IV
214302999|NCT07191145|OTHER|Placebo|Control - placebo IV
214303000|NCT07191431|DRUG|Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide|"* Orelabrutinib 150mg qd + Selinexor 40mg qw~* Combined chemotherapy (choose one):~  * MTX 3.5g/m² IV d0~ * Temozolomide 150mg/m² PO d1-5~ * Thiotepa 40mg/m² IV d3~* Every 3 weeks for 6 cycles"
214303001|NCT07191002|OTHER|placement depth of the double lumen tube|the anesthesiologist will select the appropriate DLT size and placement depth entirely at their discretion, as per routine practice, and confirm both using fiberoptic bronchoscopy (FOB). If malposition occurs, it will be corrected under FOB guidance, and the tube will be secured in the correct position
214303002|NCT07191119|DEVICE|Soterix tVNS device|"Active transcutaneous auricular vagus nerve stimulation (tVNS) using the Soterix device.~Stimulation is delivered nightly for 20 minutes at 80% of the participant's discomfort threshold."
214303003|NCT07191119|DEVICE|Soterix tVNS device (sham programmed)|The sham stimulation used the Soterix device, but without active electrical stimulation. The procedure mimics the verum condition in duration and setup. Inactive stimulation is delivered nightly for 20 minutes at 80% of the participant's discomfort threshold.
214303004|NCT07191119|BEHAVIORAL|Sleep Quality|Receive Pittsburgh Sleep Quality Index (PSQI); Insomnia Severity Index (ISI); Sleep diaries; Actigraphy via Fitbit Charge 5
214303005|NCT07191119|BEHAVIORAL|Neurocognitive and mental health outcomes|Measured using CNS Vital Signs and DASS-21.
214303006|NCT07189585|DRUG|inulin|Inulin is a fermentable prebiotic fiber derived from chicory root. For this study, inulin is packaged into single-dose sachets containing 5 g, 10 g, or 15 g of powder. Participants in the 10 g arm escalate from 5 g/day for 3 days to 10 g/day, then continue with sachets containing a 2:1 blend of inulin and maltodextrin to provide a daily 10 g inulin dose. Participants in the 15 g arm escalate from 5 g/day for 3 days, 10 g/day for 4 days, then 15 g/day for the remaining 8 weeks. Sachets are mixed with food or beverage and taken once daily with the largest meal.
214303007|NCT07189585|DRUG|Maltodextrin (Placebo)|Maltodextrin is a carbohydrate powder widely used as a food additive. For this study, maltodextrin is used as the placebo comparator. It is packaged into single-dose sachets identical in appearance and taste to inulin sachets. Participants receive escalating doses (5 g/day for 3 days, 10 g/day for 4 days, then 15 g/day) for a total of 8 weeks. Sachets are mixed with food or beverage and taken once daily with the largest meal.
214303008|NCT07190300|DRUG|Tulmimetostat|Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))
214303009|NCT07190300|DRUG|Darolutamide|600 mg is administered orally BID
214303010|NCT07190300|DRUG|Abiraterone|abiraterone 1000 mg is administered orally QD
215057047|NCT04619238|DIAGNOSTIC_TEST|King's Health Questionnaire|patients fulfilled questionnaire
215057048|NCT04619238|DIAGNOSTIC_TEST|the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form|patients fulfilled ICIQ-SF questionnaire
215057049|NCT03920462|DEVICE|Programme of intelligent electric bike for health|It is a programme of 6 excursions with an intelligent electric bike for health and connected vests during 1 month (two excursions per week according the weather)
214669982|NCT06509698|OTHER|Frenkel's exercise|Frenkel's activities, which included learning how to turn around, sit down, and get up using a variety of commonplace objects like chairs, beds, or traces drawn on the floor, as well as learning how to walk with upper limb coordination. This is a typical workout regimen used in testing and rehabilitation centers. Patients engaged in the following activities, each activity time is 1.5 minutes
215057050|NCT02797301|OTHER|synthetic test|The children performed the synthetic test with no time restriction.
215057051|NCT02797301|OTHER|computerised test|The children performed the computerised test with no time restriction.
215057052|NCT06095934|OTHER|neo-antigen vaccine|anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy
215057053|NCT03370419|BEHAVIORAL|Treatment|Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.
215057054|NCT03370419|BEHAVIORAL|Usual care|Usual care
215057055|NCT01297608|DRUG|caoted suppository|coated suppository with active drug
215057056|NCT01297608|DRUG|coated suppository|coated suppository with placebo
215057057|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
215057058|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
215057059|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
215057060|NCT05875727|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|One dose of 20vPnC will be administered intramuscularly.
215057514|NCT06351423|BEHAVIORAL|MIND diet|The participants will undertake four three-month nutrition programmes consisting of four nutrition counselling sessions in an activity room at each participating community centre. All intervention sessions will be conducted by a registered nutritionist. In the nutrition sessions, the participants will learn to modify their diet to meet the MIND diet guidelines. The MIND diet promotes 10 healthy food groups and limits five unhealthy food groups (Morris et al., 2015a; Arjmand et al., 2022). As a reference, a 7-day sample menu will be provided which meets the required number of servings per day.
214303012|NCT07190027|DRUG|Arm 1： Standard Synchronous Group|Arm 1: Concurrent PD-1 + Chemotherapy (Standard Synchronous Group) Participants in this group will receive PD-1 inhibitor and chemotherapy on the same day (D1) during each treatment cycle.
215057061|NCT03451513|BEHAVIORAL|Pride Body Project|"PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity."
214479403|NCT06473103|DEVICE|Two photon fluorescence microscopy imaging|Excised tissues will be imaged with two photon fluorescence microscopy prior to submission for histological processing.
214906568|NCT02011685|BEHAVIORAL|Nurse Case Management (NCM)|Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
214906569|NCT01044407|DEVICE|Pacemaker manipulation|Alternation of cardiac output by modulation of heart rate, atrioventricular delay and modulation from biventricular pacing to right ventricular pacing (where applicable)via a cardiac pacemaker
214906570|NCT03318861|GENETIC|KITE-585|A single infusion of KITE-585 autologous anti-BCMA CAR T cells
215057062|NCT03451513|BEHAVIORAL|Media Advocacy|We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
214303013|NCT07190027|DRUG|Arm 2：Fixed Delay Group|Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint inhibitor + Chemo (Day 3)
214669983|NCT06374498|DEVICE|OCT-NIRAF|Subjects will be imaged with OCT-NIRAF research catheter during their clinically indicated coronary angiogram. In addition, the subject will also receive two Coronary Computed Tomography Angiography (CCTA) 12 months apart, and images will be analyzed.
214906571|NCT03318861|DRUG|Cyclophosphamide|Administered intravenously
214906572|NCT03318861|DRUG|Fludarabine|Administered intravenously
214906573|NCT06362083|OTHER|Questionnaires and data collection|It is a non-interventional, single-center, non-randomized, prospective observational study obtaining data and patient-reported outcomes.
215057063|NCT03272386|OTHER|Observational study|Completing a questionnaire
214303014|NCT07190027|DRUG|Arm 3： Individualized Delay Group|"Arm 3: Individualized PD-1 Timing Based on Immune Window Score (IWS) (Individualized Group) Participants in this group will receive chemotherapy on D1 and undergo daily immune monitoring (CD8⁺PD-1⁺ T cells, Treg, IFN-γ, NLR, ALC, CRP).~Based on the immune window score (IWS):~If IWS ≥ 2, PD-1 inhibitor will be administered the same day. If IWS = 1-1.5, dosing may be delayed to D3-D5 depending on immune recovery. If IWS remains 0 by D5, PD-1 inhibitor will be administered on D6 as fallback."
214303015|NCT07189442|DIETARY_SUPPLEMENT|L-theanine and paraxanthine|200 mg L-theanine + 200 mg paraxanthine capsule
214303016|NCT07189442|DIETARY_SUPPLEMENT|Placebo|400 mg corn starch capsule
214906574|NCT02741661|OTHER|No intervention. Observational study|No intervention
214303017|NCT07191210|BEHAVIORAL|Comprehensive Transition Programme (CTP)|A co-designed, multicomponent educational programme delivered over three months to support nurses transitioning into first-line management roles. The programme integrates classroom training modules, online learning, mentorship by senior nurse managers, and structured reflective practice.
214303018|NCT07190482|DRUG|Olanzapine 5 Mg ORAL TABLET|OLANZAPINE ARM
214303019|NCT07190482|DRUG|Placebo Drug|placebo administered for 8 weeks
214479404|NCT03880955|DEVICE|ReUnion RSA System|The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
214906575|NCT00917852|DEVICE|Gore Conformable TAG Thoracic Endoprosthesis|Endovascular stent graft
214906576|NCT02623933|RADIATION|MRI assisted focal boost with HDR monotherapy|Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
214906577|NCT02932488|DRUG|Sumatriptan|Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
214906578|NCT02059655|DRUG|Bimatoprost|
214906579|NCT02059655|DRUG|Eye drop solution|Artificial tear drops
215057064|NCT05915195|OTHER|Postural and Kinesthetic Awarness|Firstly, patient performed therapeutic activities/exercise to achieve balance in sitting position using chair with arm rest and with planted feet then progressed to sitting on chair without arm rest with proper feet placement. Once the patient achieved balance in sitting on chair then shifted to sitting on the stool and later standing in parallel bar that leads to balance training in independent standing.
215057065|NCT05915195|OTHER|Routine Physical Therapy|Range of motion exercises (Active assisted), stretching exercises, strengthening and positioning.
215057066|NCT01386489|BIOLOGICAL|VRC-HIVDNA016-00-VP|
214303020|NCT07191106|PROCEDURE|adapted physical activity|Comparative before-and-after study over a 3-month period of remote Adapted Physical Activity (APA) delivered through the MOOV+ application
214303021|NCT07191379|OTHER|The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting.|The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting. To reduce potential bias, patients will function as their own controls by receiving alternating treatments at home and in the outpatient clinic.
214303022|NCT07191028|DRUG|MLC 901|Oral capsule, 2 capsules 3 times a day for 12 months
214906580|NCT03285516|BEHAVIORAL|Safety Aid Reduction Treatment|START includes many of the key elements found in empirically supported treatments for emotional disorders including a) psychoeducation regarding the nature of distress and b) exposure to internal sensations and external situations that are connected to one's distress response via identification and reduction in safety aids. Safety aids discussed in the current protocol include cognitive avoidance, situational avoidance, checking behaviors, reassurance seeking, avoidance of bodily sensations, companions, and use of alcohol and other substances.
215057067|NCT01386489|BIOLOGICAL|VRC-HIVADV014-00-VP|
215057068|NCT05236179|OTHER|Integrative therapies|Integrative therapy methods used at the Filderklinik, such as music therapy, therapeutic painting, therapeutic sculptural forming, speech therapy, eurythmy therapy, rhythmical massage, external applications, coloured light therapy
215057069|NCT04050787|PROCEDURE|D2 Lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
215057070|NCT04050787|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
214906581|NCT04386655|BEHAVIORAL|Brain Injur Coping Skills - Telemedicine|"BICS sessions (both in-person and telemedicine) will occur once a week for 12 weeks. Each session will last two hours.~Modules of BICS include: Introduction to Brain Injury, Expectations for Recovery, Tips on Managing Challenging Problems, Learning about Depression after the Brain Injury, The 4 R's of Stress Management, Communicating Effectively with Professionals"
215057071|NCT01530178|DRUG|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
215057072|NCT01530178|DRUG|Placebo Oral Tablet|
215057073|NCT05222412|DRUG|Iptacopan|Patients receive Iptacopan
214303023|NCT07191028|DRUG|Placebo|Oral capsule, 2 capsules 3 times a day for 12 months
214303024|NCT07191067|DEVICE|Pulsed radiofrequency|Pulsed radiofrequency will be applied to the femoral and sciatic nerves prior to TKA.
214303025|NCT07191067|DEVICE|Non-therapeutic stimulation|Electrical square wave stimulation performed to mimic the duration of the active arm and mimic the procedure for blinding purposes.
214303026|NCT07188935|DRUG|ciprofloxacin 500 mg tablet|Administration of oral ciprofloxacin 500 mg twice daily for 7-14 days for the treatment of recurrent urinary tract infections in patients with type 2 diabetes mellitus, following local and international guidelines.
214303027|NCT07190456|OTHER|Exposure to neutral images visualization|The patient will have to walk on a treadmill at their preferential walking speed for 10 minutes while visualizing neutral images (landscapes, monuments...)
214906582|NCT00471081|BIOLOGICAL|Meningococcal vaccine GSK134612|One or 2 intramuscular injections.
215057074|NCT03965104|BEHAVIORAL|Hypertension Canada Professional Certification Program: HC-PCP|The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
215057075|NCT01434901|DRUG|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
215057076|NCT01434901|DRUG|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
214303028|NCT07190456|OTHER|Exposure to nocive images visualisation|The patient will have to walk on a treadmill at their preferential walking speed for 10 minutes while visualizing images interpreted as nocive (cutting, jumping, contact...)
214303029|NCT07190456|OTHER|Exposure to anticipated realisation of a feared movement|Before the start of the experimental condition, the patient will be asked to think about their willingness to perform the first movement visualised in the video, while a researcher places a jumping platform inside the laboratory. During the test, the patient will have to walk on a treadmill at their preferred speed for 10 minutes, while watching a video showing a drop jump followed by images interpreted as nocive for the rest of the time.
214303030|NCT07189624|OTHER|Exercise|30-minutes exercise on a bicycle with heart rate monitor and gas exchange analyzer.
214479405|NCT05243966|DEVICE|Myriad Matrix™ and Myriad Morcells™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
214479406|NCT04567316|DRUG|[14C]-radiolabelled BI 1358894|Part 1
214479407|NCT04567316|DRUG|BI 1358894|Part 2
214303031|NCT07190092|PROCEDURE|Deep brain stimulation electrode implantation with an electrode target in the dentate nucleus|The intervention will involve implantation of a directional electrode with a target in the dentate nucleus of the cerebellum, ipsilateral to the limbs affected by spasticity. Electrode implantation will be performed using a stereotaxic frame, following prior planning of the electrode trajectory and tractography of the dento-ruborothalamic tract using a planning station. The procedure will be performed under general anesthesia. The IPG stimulator will be placed in the subclavicular region.
214906583|NCT01131364|DRUG|F16IL2 in combination with doxorubicin|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
214906584|NCT01265108|DRUG|Iron sucrose.|Volunteers will receive an intravenous infusion of 200 mg iron sucrose, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
214906585|NCT01265108|DRUG|Normal saline|Volunteers will receive an intravenous infusion of 100 ml normal saline, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
214906586|NCT05776784|PROCEDURE|dental procedure|questionnaire for patient with dental procedure
214906587|NCT03768908|DRUG|Artemether-lumefantrine|Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation
214906588|NCT03768908|DRUG|Artesunate + Amodiaquine|Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation
214906589|NCT00277238|DRUG|CPG10101|CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
214906590|NCT00277238|DRUG|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
214906591|NCT00277238|DRUG|Control|Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks
214303032|NCT07189715|BEHAVIORAL|Imagery Rescripting Intervention (AI-Generated)|Participants listened to a series of personalized audio scenarios based on their childhood memories of parental criticism and neutral events. At the end of the session, one critical scenario was presented in a modified version that included a therapeutic imagery rescripting (ImRs) intervention. In this script, a therapist figure entered the scene and addressed the child's unmet needs, following the standard rescripting format. The scripts were generated using the Gemini large language model and reviewed by trained experimenters to ensure coherence and therapeutic validity. The intervention aimed to reduce distress and intrusive thoughts related to the memory.
214303033|NCT07189455|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
214303034|NCT07189455|DRUG|Topotecan|Topotecan will be administered per local standard of care
214303035|NCT07189949|DRUG|HRS-2329 Tablet|Oral HRS-2329 tablet.
214303036|NCT07191262|OTHER|0.12% CHX and Essential Oil mouthrinse|0.12% CHX mouthrinse will be used to rinse for 1 minute with 15 mL twice daily starting day 1 after surgery through day 14. Patients will be instructed to use OTC essential oil mouthrinse 15mL once daily until the conclusion of the study (day 15 to day 84).
214303037|NCT07191262|OTHER|2.6% EDTA and 0.2% EDTA mouth rinse|.6% EDTA mouthrinse will be used to rinse for 1 minute with 15 mL twice daily starting day 1 after surgery through day 14. Patients will be instructed to use 0.2% EDTA mouthrinse 15mL once daily until the conclusion of the study (day 15 to day 84).
214303038|NCT07191444|BIOLOGICAL|Firsekibart|Firsekibart will be administered according to the protocol
214303039|NCT07191444|BIOLOGICAL|Anakinra|Anakinra will be administered according to the protocol
214303040|NCT07190833|DRUG|OTS-412|1×10E8 pfu, once, 1 cycle, IT
214303041|NCT07190833|DRUG|Hydroxyurea (HU)|15 mg/kg/day, 14 days, 1 cycle, PO
214906592|NCT00277238|DRUG|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
214303042|NCT07190833|DRUG|Hydroxyurea (HU)|25 mg/kg/day, 14 days, 1 cycle, PO
214906593|NCT04145050|OTHER|Carbohydrate dosing|The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.
214906594|NCT00123838|DEVICE|Calypso® 4D Localization System|Localization of prostate irradiation.
214906595|NCT02844933|DRUG|Cannabidiol|Oral solution
214906596|NCT02844933|DRUG|Placebo|Matching oral solution
215057077|NCT01434901|DRUG|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
214303043|NCT07190833|DRUG|Hydroxyurea (HU)|35 mg/kg/day, 14 days, 1 cycle, PO
214303044|NCT07190833|DRUG|Hydroxyurea (HU)|optimal dose, 14 days, 1 cycle, PO
214303045|NCT07190833|DRUG|Atezolizumab|1,200 mg, once, 1 cycle, IV
214303046|NCT07190833|DRUG|OTS-412|3×10E8 pfu, once, 1 cycle, IT
215057078|NCT01434901|DRUG|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
215057079|NCT05400850|OTHER|YOGA|Five different YOGA Asana's will made randomly
215057080|NCT01734798|RADIATION|Radiation|
214303047|NCT07190833|DRUG|OTS-412|optimal dose, once, 1 cycle, IT
214303048|NCT07190872|BEHAVIORAL|sleep hygiene education|Students in the intervention group will receive face-to-face sleep hygiene training in a total of 4 sessions, once a week for 40 minutes over a period of four weeks. The education is designed within the framework of the Transtheoretical Model and focuses on topics such as the concept of sleep hygiene, regular sleep hours, limiting caffeine and screen use, organizing the sleep environment, and stress management. The training will be provided by a nurse experienced in sleep health.
215057081|NCT01734798|DRUG|gemcitabine and cisplatin|
215057082|NCT01734798|OTHER|Radiotherapy and Drug|
214906597|NCT06134284|DRUG|Orelabrutinib combined with rituximab|This is a single-arm trial. Patients with relapsed/refractory marginal zone lymphoma will be treated with the OR regimen. The treatment plan is as follows: Orelabrutinib 150mg oral administration once a day, Day 1-21; Rituximab 375mg/m² intravenous infusion, Day 1. Each cycle is 21 days. PET-CT evaluation will be conducted after 4 cycles. If a partial response (PR) or better is achieved, the patient will receive further treatment with the OR regimen for an additional 4 cycles before transitioning to single-agent maintenance therapy with either rituximab or obinutuzumab. If a PR or better is not achieved after 4 cycles, the patient will discontinue from the trial.
214303049|NCT05311696|OTHER|psychoeducation|The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
214303050|NCT04952870|OTHER|Inhaled NO|Newborn or young infants (\< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure
214303051|NCT04952870|OTHER|routine care|Patients treated for respiratory failure
214906598|NCT03787784|OTHER|AI presentation|Automatic diagnosis information of AI is visible to endoscopist
214303052|NCT02064907|DRUG|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
214303053|NCT02064907|DRUG|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
214303054|NCT00265473|BIOLOGICAL|Allogeneic Islets of Langerhans|Intraportal infusion of islets of Langerhans
214303055|NCT02409836|DRUG|Marketed Dentifrice|Marketed Dentifrice
214906599|NCT04446338|DIAGNOSTIC_TEST|Antibody Test|Presence and Titer of Anti-Sars-CoV-2 Antbodies
214906600|NCT01256489|DRUG|Infliximab|The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
215057083|NCT04737356|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
215057084|NCT04322409|DEVICE|Neuromuscular Electrical Stimulation|"5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session."
215057085|NCT04322409|DEVICE|Transcutaneous Electrical Nerve Stimulation|5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
215057086|NCT06549504|DRUG|AG2202T|AG2202T Single-dose
215057087|NCT06549504|DRUG|AG2202R|AG2202R Single-dose
215057088|NCT01384565|DRUG|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
215057089|NCT01384565|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
214303056|NCT02409836|DRUG|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
214303057|NCT02409836|DRUG|Marketed Flavored Dentifrice|Bubble Gum Flavored
214303058|NCT02259153|BEHAVIORAL|Changes in cholesterol metabolism|
214303059|NCT02259153|OTHER|Lean red meat diet|
214906601|NCT04851028|BEHAVIORAL|Music Therapy|Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).
214906602|NCT04050163|BIOLOGICAL|MiSaver®|Intravenous administration of MiSaver® Stem Cell via peripheral vein access.
214906603|NCT00858455|DRUG|GSK1349572 and MaaloxAdvanced Maximum Strength|A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
214906604|NCT00858455|DRUG|GSK1349572 and Maalox Advanced Maximum Strength|A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
214906605|NCT00858455|DRUG|GSK1349572 and One A Day|A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
214906606|NCT00858455|DRUG|GSK1349572|A single dose of GSK1349572
214303060|NCT02259153|OTHER|Fat red meat diet|
214303061|NCT04802265|PROCEDURE|Epiretinal membrane surgery|"The surgery consists of a 23 or 25-gauge pars plana vitrectomy (PPV). The surgery was performed peri-bulbar anesthesia and could be combined with phacoemulsification.~An intraocular dye is used to well visualized and facilitate ERM peeling. The ILM is not actively peeled. A search for iatrogenic breaks is performed towards the end of the procedure. Areas suspicious for breaks are treated with cryotherapy or peripheral endolaser."
214303062|NCT05575323|OTHER|Same-day SBRT and spinal surgery|SBRT and surgical stabilization with or without decompression within 24 hours
214303063|NCT05575323|OTHER|Standard of care|Surgical stabilization with or without decompression followed by cRT or SBRT as soon as the wound is healed sufficiently
214303064|NCT05455606|OTHER|Best Practice|Receive usual care
214303065|NCT05455606|OTHER|Chart Abstraction|Ancillary studies
214906607|NCT06273514|OTHER|TECAR|"TECAR therapy performs using a WINBACK® 1s device (Daeyang Medical Co. Ltd, South Korea) with a maximum power of 100W. A 500 kHz frequency capacitive electrode is applied directly to the active MTrP in the UT. The closed electrode is placed distally on the arm. Lowpulse modulation use during treatment with half-second pauses. This enables the application of the current directly into the MTrP without enrolling the entire muscle. The single exposure last for 10 min. The current dose participant-dependent and ranged from 40 to 60% (100% = 100 Watts).~Each time, before and after treatment, and 30 days after the first therapy, the following features will be asses: pain intensity, muscle strength, and ROM."
214906608|NCT06273514|OTHER|Dry needling|"Dry needling performs using SOMA needles (25 mm x 0.3 mm). During the therapy, the participant is in a prone position. The affected UT region is disinfect before needling. The taut band localizes between the thumb and index finger of the researcher. The needle within the plastic guide tube is place over the MTrP at the UT. The needle directly inserts into the MTrP. A local twitch response confirms the accuracy of the puncture. Needling performs using Hong's fast in, fast out technique. The needle will be withdrawn if no twitching will observe."
214906609|NCT03091543|DRUG|Madopar® HBS 125|1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.
214906610|NCT03091543|DRUG|Placebo|2 capsules of placebo
214906611|NCT03091543|DRUG|BIA 6-512 25 mg dose|1 capsule of 25 mg plus 1 capsule of placebo
214906612|NCT03091543|DRUG|BIA 6-512 50 mg dose|2 capsules of 25 mg
214906613|NCT03091543|DRUG|BIA 6-512 100 mg dose|1 capsule of 100 mg plus 1 capsule of placebo
214906614|NCT03091543|DRUG|BIA 6-512 200 mg dose|2 capsules of 100 mg
214906615|NCT02185196|DRUG|Vitamin D3|20,000 IU vitamin D3 in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
214906616|NCT02185196|DRUG|Placebo|20,000 IU Miglyol-oil in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
214906617|NCT00443690|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
214906618|NCT00443690|DRUG|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
214906619|NCT03209271|DRUG|Ringer's Acetate (warm)|Body temperature fluid
215057090|NCT03293355|BEHAVIORAL|VPN|Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
215057091|NCT00284414|PROCEDURE|Ultrasonography or MRI|
215057092|NCT04401150|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
215057093|NCT04401150|DRUG|Control|Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
215057094|NCT01420224|OTHER|Commercial airline flight|Normal scheduled passenger flight
214303066|NCT05455606|OTHER|Educational Intervention|Physicians access genomic testing education materials
214906620|NCT03209271|DRUG|Ringer's Acetate (cold)|Room temperature fluid
214303067|NCT05455606|PROCEDURE|Genomic Profile|Patients undergo genomic testing
214303068|NCT05455606|OTHER|Interview|Ancillary studies
214303069|NCT05455606|OTHER|Questionnaire Administration|Ancillary studies
215057095|NCT00795444|DRUG|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
214303070|NCT05455606|OTHER|Tumor Board Review|Patients undergo genomic tumor board review
214303071|NCT04095624|BEHAVIORAL|Spinal Fusion Preoperative Opioid Taper|Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
214303072|NCT04095624|OTHER|Non-taper Control|Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
214479408|NCT04870359|PROCEDURE|Pre-emptive increase of immunosuppressive treatments|"1. Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~2. Adjustment of the 2nd agent would be as follows:~   1. For patients who receive AZA \<75mg/day; increase the dose of AZA to 75 mg/day.~  2. For patients who receive MMF \<1g/day, increase the dose of MMF to 1g/day."
214906621|NCT04827095|OTHER|Web-Based Support and Education Program 1|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
214906622|NCT04827095|OTHER|Web-Based Support and Education Program 2|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
214906623|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
215057096|NCT01897727|DRUG|Spironolactone|
215057097|NCT01897727|DRUG|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
214906624|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
214906625|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
214906626|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)
214906627|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)
214906628|NCT00728455|DRUG|placebo|Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
214906629|NCT00728455|DRUG|placebo|Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
214906630|NCT00728455|DRUG|placebo|Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
214906631|NCT00728455|DRUG|placebo|Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
214906632|NCT00728455|DRUG|placebo|Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
214906633|NCT04403724|DRUG|Bupivacaine-fentanyl-Morphine.|2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
214906634|NCT02845024|DRUG|Doxycycline Group|Oral doxycycline 100mg was taken within 15 days
214906635|NCT02845024|DRUG|placebo Group|Oral placebo was taken within 15 days
214906636|NCT03781908|DRUG|Silver Nitrate|First, pleural fluid drainage will be done after administration of 5 cc of local anesthetic lidocain1% either by insertion of chest tube (26F or 28F ) or by using ultrasonography. Pleural fluid drainage will be terminated when the patient want to cough to make sure that the pleural cavity is empty, then the sclerosant material will be injected, patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%.
215057098|NCT05211674|OTHER|quantified analysis of postural control during activities of daily living|functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)
215057099|NCT00395070|BIOLOGICAL|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
215057100|NCT00395070|DRUG|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
215057101|NCT00395070|DRUG|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
214479409|NCT04870359|DRUG|Prednisolone and/or AZA/MMF|Prednisolone and/or AZA/MMF
214669984|NCT06057129|DEVICE|Supervised and minimally-supervised therapy with ReHandyBot|During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a supervisor (i.e., therapist or researcher). Minimally-supervised therapy means that participants try to perform therapy with the device by themselves, while the supervisor is still present but helps only in case participants encounter problems or if they have any questions. During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes.
214669985|NCT06057129|DEVICE|Unsupervised therapy|"After the familiarization phase, participants train without supervision at the clinic until discharge and then at home for six weeks.~If the therapist thinks that the participant have properly learnt how to use the device and can train with it safely, the participant can keep training with the device unsupervised (both at the clinic and at home).~If participants are not ready for unsupervised therapy with the device, they receive a booklet of exercises to perform without supervision (both at the clinic and at home). These exercises do not imply the use of the robot but are exercises discussed with the therapists and meaningful for the specific patient."
214669986|NCT06358417|BEHAVIORAL|Nutrition-enhanced CHW|CHW provides nutrition education and skills training in addition to the usual care (Basic CHW) hypertension management.
214669987|NCT06358417|BEHAVIORAL|Basic CHW|CHW provide usual care for hypertension management.
214669988|NCT06105957|BEHAVIORAL|Core|The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals. Weekly tips and discussion board postings invite participants to apply skills introduced in the modules and prompt interaction and social support within the closed group which starts the program simultaneously.
214906637|NCT03781908|DEVICE|Indwelling Pleural Catheter|"First , insert the wire into the pleural effusion at approximately the anterior axillary line. A 1-2 cm incision is made over the wire. A chest wall tunnel (5-8 cm in length) is created with a counter incision. The catheter is pulled through the tunnel and out next to the wire. After dilation of the wire tract with a Teflon peel-away sheath, the indwelling catheter is inserted into the chest. The counter incision is closed primarily, and the catheter is secured to the skin medially with a suture."
214906638|NCT04682808|DRUG|FCN-338|FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.
214906639|NCT04815070|PROCEDURE|Ultrasonic measurement of antral area|"Ultrasound exam is done before the induction of spinal anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~The cross-sectional area (CSA) of antrum is shown by the following formula: CSA = AP x CC x ㅠ/4.~Antral area will correspond to the average of the three measures."
214906640|NCT00922077|BEHAVIORAL|standard physical therapy program with emphasis on dynamic balance exercises|
214906641|NCT00000292|PROCEDURE|Cocaine|
214906642|NCT03439241|DEVICE|Coloplast ostomy device|the test product is a newly developed Coloplast ostomy device
215057102|NCT05754398|BEHAVIORAL|six independent and interconnected educational training sessions|"Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach."
215057103|NCT01748188|PROCEDURE|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
215057104|NCT01748188|PROCEDURE|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
214479410|NCT05809986|OTHER|Ofatumumab|There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
215057105|NCT01748188|PROCEDURE|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
214479411|NCT06474260|BEHAVIORAL|"One All Intervention"|"One-all is a Three-year curriculum targeted at specific outcomes for each yearfacilitated by young people from the community. The facilitators are inducted througha rigorous facilitators programme of three to five months' length. The facilitators areencouraged to adapt the program to their needs and provide the programme incustomized forms appropriate and as required for the communities. The interventionhas thus far been provided to the fishermen communities in Chennai and anecdotalfield evidence suggest, gains in the intended goals. After these experiences theintervention was being tried amongst the tribal adolescents in Gudalur. One-alltargets to provide the undermentioned skills to achieve the mentioned Goals andSkills:~* self-management • understanding feelings~* social awareness • conflict resolution~* relationship skills • empathy building~* self-awareness Skills •nurturing interpersonal relationships~* identity building • awareness about gender stereotypes"
214479412|NCT05112939|DRUG|RPV LA|RPV LA will be administered at different formulations.
214479413|NCT05112939|DRUG|CAB LA|CAB LA will be administered at formulation 3.
214479414|NCT05192707|DIAGNOSTIC_TEST|TcPO2 measurement on the upper limb|Measurement of the transcutaneous Oxygen Pressure in the upper limb of 30 healthy volunteers and of at least 30 patients.
214479415|NCT04312399|PROCEDURE|blood take|Blood is taken to analyse degradation products of the metabolism of amyloid
214479416|NCT05197855|DEVICE|Deem 3 Headband|The patient will wear the Dreem 3 headband and pulse oximeter at home before initiation of CPAP (for 7 nights) and during a month of treatment (for a minimum of 9 nights), after the initiation of CPAP. He will also wear a glucose sensor and a pedometer during the entire study period before and after CPAP treatment.
214479417|NCT05146284|DRUG|PXL770|Tablet
214479418|NCT06488573|BEHAVIORAL|Nutritional intervention|7 individual sessions + 8 small group sessions
214479419|NCT06452329|DRUG|Nivolumab|As prescribed by treating physician
214479420|NCT05441618|DEVICE|Lyoplant®|replacement and extension of connective tissue structures in neurosurgery
214479421|NCT05281276|DRUG|chidamide|During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
214479422|NCT05281276|DRUG|celecoxib|During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
214479423|NCT06854367|DEVICE|TBS|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive neurostimulation that uses focused magnetic field pulses to directly stimulate cortical neurons. Theta burst stimulation (TBS) is a briefer form of patterned rTMS that has been shown to be effective against major depressive disorder. Each treatment will consist of either 1) cTBS of right DLPFC followed by iTBS of left DLPFC; or 2) iTBS of left DLPFC.
214479424|NCT05807724|OTHER|Phone-based fall-prevention strategy|Written education material and Phone-Based Fall-Prevention Strategy
214479425|NCT05807724|OTHER|Home-visit fall prevention strategy|Written education material and Home visit-Based Fall-Prevention Strategy
214479426|NCT04409795|DRUG|Metformin Extended Release Oral Tablet|Initial oral hypoglycemic agent added to existing insulin treatment
214669989|NCT06105957|BEHAVIORAL|Facilitated Weekly Group Sessions|Participants will receive 24 facilitated online video-conference-based weekly group sessions. These groups will be 60 minutes long and will be facilitated by a trained professional, who reinforces the information and behavioral strategies introduced in the weekly modules, elicits the experiences of participants in applying behavioral skills to establish new diet and exercise habits, and guides problem solving. Group cohesion to offer social support is promoted.
214669990|NCT06105957|BEHAVIORAL|Counselor Crafted Feedback|Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message. The emailed feedback will provide positive reinforcement for successful goal achievement, identify possible areas for improvement, and suggest possible strategies for identified challenges.
214906643|NCT04678518|DIAGNOSTIC_TEST|Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF|1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours)
214479427|NCT04409795|DRUG|Sitagliptin|Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
214906644|NCT00626002|DRUG|ABT-874|100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
214906645|NCT02881853|DRUG|XmAb7195|
214906646|NCT02881853|DRUG|Placebo|
214906647|NCT04719572|OTHER|Basic treatment group|A total of 60 subjects were recruited in the group.
214906648|NCT04719572|OTHER|Basic treatment+ anti-osteoporosis drug group|A total of 60 subjects were recruited in the group.
214479428|NCT06112340|DRUG|linsitinib|Study medication taken twice daily by mouth
214906649|NCT04719572|OTHER|Basic treatment + non-drug treatment group|A total of 60 subjects were recruited in the group.
214906650|NCT00338416|DRUG|Epoetin alfa|
214479429|NCT06865066|BEHAVIORAL|e-CBT|Electronically delivered cognitive behavioural therapy with acceptance commitment therapy components
214479430|NCT04889066|RADIATION|Stereotactic Radiation Therapy|"24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm."
214906651|NCT02544438|DRUG|Astarabine (BST-236)|"Cohort # Astarabine Dose Number of Patients~1. 0.5 gr/m2 (0.3 age\>50) 3~2. 1.5 gr/m2(0.8age\>50) 3~3. 3.0 gr/m2(1.5 age\>50) 3~4. 4.5 gr/m2(2.3 age\>50) 6~5. 4.5 gr/m2 (no age limit) 3 up to 6~6. 6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24"
214906652|NCT02629315|OTHER|Carnoy's solution|
214906653|NCT02629315|OTHER|10% neutral buffered formaldehyde|
214906654|NCT04578301|OTHER|No Intervention|No Intervention
214906655|NCT01211834|DRUG|tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
214906656|NCT01211834|DRUG|DMARDs|Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
214906657|NCT01211834|DRUG|Placebo|intravenously over 1 hour infusion every 4weeks
214906658|NCT01211834|DRUG|DMARDs|Methotrexate(MTX) and/or 1 DMARDs
214906659|NCT00803608|DEVICE|TrueContour® Insole|Novel designed insole
214906660|NCT00803608|DEVICE|Current standard of care insole|Current Medicare approved A5513 insole
214906661|NCT02154607|DEVICE|CO2-Laser Treatment|
214906662|NCT04537078|DRUG|Duphaston|will be used for pituitary suppression in the first arm:20 mg/day will be started from the first day of the ovulation induction in the follicular phase and in the luteal phase will be started the next day after oocyte pickup at 20 mg/day.
214906663|NCT04537078|DRUG|Gonadotropin|will be used for controlled ovarian hyperstimulation in both arms
214906664|NCT04537078|DRUG|Cetrotide Injectable Product|will used in the second arm for pituitary suppression in the second group daily when the biggest oocyte reaches size 14 mm till ovulation triggering
215057106|NCT01748188|PROCEDURE|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
215057107|NCT01748188|PROCEDURE|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
214906665|NCT04537078|DRUG|Decapeptyl|will be used for ovulation triggering.in the first arm:in a dose of 2 ampules of 0.2 mg will be administered when leading follicle \>18 mm in diameter. in the second arm:in a dose of 2 ampules 0.2 mg will be administered when leading follicle \>18 mm in diameter in the first cycle only.
214906666|NCT04537078|DRUG|Chorionic Gonadotropin|will be used in the second cycle of the second arm for ovulation triggering in a dose of 10,000 IU when the leading follicle \>18 mm in diameter.
214906667|NCT04537078|DRUG|Combined Oral Contraceptive|luteal phase priming from day 21 of the cycle before controlled ovarian stimulation for one week .
215057108|NCT02061072|OTHER|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
214303073|NCT05793528|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone. The injection site is cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is inserted just below the pedicle. It is advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position is confirmed through a lateral view. Using lateral views, the needle is placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
214303074|NCT05793528|PROCEDURE|Ultrasound Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone placed. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a low-frequency convex ultrasound probe. The lateral edge of the relevant vertebral lamina is visualized by sonographic scanning in the horizontal plane. Local anesthesia is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is advanced to the lateral edge of the relevant vertebral lamina under ultrasound image guidance. Then, anteroposterior imaging is performed with fluoroscopy to confirm needle localization when the lamina margin is reached, and the needle is guided into the foramen under the guidance of fluoroscopy. The contrast agent is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 2 mL of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
214906668|NCT04537078|DRUG|Cyclo-Progynova|Starting from cycle Day 3 of the intented cycle for thawed embryo transfer, patients will receive the white tablets of Cyclo-Progynova daily. From Day 10 onwards, endometrium growth will be monitored by transvaginal ultrasound.
214906669|NCT04537078|DRUG|progesterone|in the intended cycle of embryo transfer when endometrial thickness ≥ 7 mm. Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after embryo transfer and in pregnant cases will continued till the 12 weeks of gestation.
214906670|NCT01568892|DRUG|Dolutegravir 50 mg twice daily|Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
214906671|NCT01568892|DRUG|Dolutegravir placebo twice daily|Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
214906672|NCT01762644|DRUG|Oral Cyclosporine and Oral Omeprazole|
214906673|NCT01762644|DRUG|Oral Omeprazole|
214906674|NCT01567774|DRUG|Atorvastatin|os, 20 mg, once per day, for 30 days
214906675|NCT01567774|DRUG|Rosuvastatin|os, 10 mg, once per day, for 30 days
214906676|NCT01275365|DRUG|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
214906677|NCT01275365|DRUG|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
214906678|NCT02199431|DRUG|Lu AF11167|
214906679|NCT02199431|DRUG|Itraconazole|
215057109|NCT04982341|PROCEDURE|prone position|patients are returned from prone to supine position while receiving oxygenation through HFNC
215057110|NCT01308814|DRUG|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
215057111|NCT01308814|DRUG|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
215057112|NCT02013778|DRUG|HCQ|
214303075|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
214303076|NCT00708942|DRUG|Placebo|Placebo suppository, for 3-7 hours application
214303077|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
214303078|NCT00708942|DRUG|Placebo|Placebo ointment for 5 hours application
214303079|NCT00001749|DRUG|Antithymocyte globulin|
214303080|NCT00001749|DRUG|Cyclosporine|
214303081|NCT04838366|DIETARY_SUPPLEMENT|Carbohydrate loading|study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). Surgical patients will be asked to drink a beverage containing 100 grams carbohydrate the night before surgery. On the day of surgery, patients will drink a beverage containing 50 grams carbohydrate 2 hours before surgery under the supervision of research team member. We will provide glucose-D (Dabur Nepal Private Limited, Bara, Nepal, (Regd No.: 3506/045/046, DFTQC No.: 01-33-55-03-218).
214303082|NCT00939809|BIOLOGICAL|Urokinase-Derived Peptide A6|Given SC
214906680|NCT01836731|BEHAVIORAL|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
214303083|NCT00939809|OTHER|Laboratory Biomarker Analysis|Correlative studies
214303084|NCT04887792|DRUG|Acetazolamide|ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
214303085|NCT04887792|DRUG|Placebo|Identical gelatin capsules will be prepared by filling with inert excipients.
214303086|NCT06308809|OTHER|PNF training|The subjects underwent rehabilitation training for 8 weeks, three times a week (Monday, Wednesday and Friday, 6:00 PM to 10:00 PM in the Physical Education College of Guangxi Normal University), and the rehabilitation training time was about 40-45 minutes per person. Before each rehabilitation training, the subjects warmed up the ankle and lower leg muscles for 5 minutes, followed by the corresponding rehabilitation training for 30-35 minutes, and relaxed the ankle and lower leg muscles for 5 minutes after the training.
214303087|NCT03801564|DEVICE|Platelet Rich Plasma Treatment Group (PRP)|EASY PRP is in category IIa and manufactured by Neotec Biotechnology Industry and Foreign Trade Company. (Item No. 8680976403603; UNSPSC 42295470; GMDN 46923; certificate no: M.2016.106.7294).
214303088|NCT03801564|DEVICE|Hyaluronic Acid Treatment Group (HA)|REGENFLEX STARTER is a class III intraarticular viscosupplementation device (Art. No. 8681065100076; UNSPSC 42295509). Sodium hyaluronate is obtained by bacterial fermentation (STREPTOCOCCUS EQUI) method. The product is in disposable packages, sterile and contained in a 2 ml pyrogen-free syringe.
214303089|NCT03356496|DEVICE|AirLife 4000 cc incentive spirometry device|Incentive spirometry device provides improved lung expansion and respiratory muscle strength
214303090|NCT00275210|DRUG|Oxaliplatin (SR96669)|
214303091|NCT00861107|BIOLOGICAL|AlloStim-7|intradermal injection once a week for 3 weeks
214303092|NCT00861107|PROCEDURE|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
214303093|NCT00861107|BIOLOGICAL|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
214303094|NCT00861107|BIOLOGICAL|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10\^8 cell dose and if no toxicity dose escalates to 10\^9 cell dose.
214303095|NCT04767074|OTHER|Non-pharmacological Cough control Therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management.~Session 1 General assessment Prescription and taught of one cough suppression technique.~Session 2 Cough principles: mechanism, cough reflex, chronic cough, the importance of cough and negative effects of repeated coughing.~Cough control: identify triggers, use cough suppressions and distractions techniques.~Session 3 Breathing pattern retraining and laryngeal hygiene: reinforce nasal breathing and pursed lips breathing as strategies to avoid the urge to cough, identification of risk factors for laryngeal dehydration and hydration education.~Session 4 Reinforcement: Clarification of doubts, techniques' reinforcement and application during daily life situations."
214303096|NCT01918904|DRUG|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
214303097|NCT01918904|DRUG|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
214303098|NCT05149846|PROCEDURE|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
214303099|NCT04020393|PROCEDURE|SPGB|SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
214303100|NCT05966324|DRUG|baxdrostat|Baxdrostat is an aldosterone synthase inhibitor
214303101|NCT00087711|DRUG|pemetrexed|500 mg/m2, IV q 21 days x 6 cycles
214303102|NCT00087711|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
214303103|NCT00087711|DRUG|cisplatin|75 mg/m2, IV, q 21 days x 6 cycles
214303104|NCT02654535|OTHER|Dietary tree nuts & peanuts|An intervention in which tree nuts and/or peanuts are included in the diet
214303105|NCT05773547|DEVICE|MSOT measurements|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
214303106|NCT04706195|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
214303107|NCT01277523|DRUG|tiotropium high dose|2 actuations once daily
214303108|NCT01277523|DRUG|placebo|2 actuations once daily
214303109|NCT01277523|DRUG|tiotropium low dose|2 actuations once daily
214906681|NCT01836731|BEHAVIORAL|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
214906682|NCT00094731|PROCEDURE|Memory Training|
214303110|NCT06523036|PROCEDURE|Combined chiropractic care and Tai Chi|Chiropractic will be personalized to the patients clinical needs within the scope of chiropractic practice in the Commonwealth of Massachusetts including: posture correction/spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation/mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports. Chiropractic will be administered by one of two chiropractors at the Osher Clinical Center. Tai Chi will take place at one of two schools used in prior NIH funded trials.
214906683|NCT03657420|DRUG|ABI-009|ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.
214303111|NCT06449807|BEHAVIORAL|crossover point intensity exercise|crossover point intensity exercise
214303112|NCT04504799|DEVICE|Body composition measurement with HAG-BIA scale|Bio-impendance analysis
214303113|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of anemia.
214303114|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of fatigue.
214303115|NCT04474951|DIETARY_SUPPLEMENT|Peppermint|Eligible patients will take 40 drops TID of Fluid Extract of Peppermint for control of nausea.
214303116|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
214303117|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
214906684|NCT03657420|DRUG|Pomalidomide|Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.
214906685|NCT03657420|DRUG|Dexamethasone|Dexamethasone is a steroid which is believed to kill cancer cells
214906686|NCT02964520|BEHAVIORAL|Neurofeedback training|uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
214906687|NCT02964520|BEHAVIORAL|Sham comparator: Sham neurofeedback training|in UNEVEN neurofeedback sessions (1,3,5,7,9): up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz) in EVEN neurofeedback sessions (2,4,6,8,10): down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)
214906688|NCT06348069|BEHAVIORAL|Pharmacy-based PrEP refill and gift voucher|The intervention arm of this study introduces the opportunity for a pharmacy-based PrEP refill system for sex workers, coupled with financial incentives to increase adherence. Participants receive PrEP medications from selected pharmacies, a strategy designed to improve PrEP access and enhance privacy/discretion. Additionally, participants in the intervention are awarded escalating gift card values for each successful refill collection at study pharmacies, aiming to incentivize continued PrEP use for effective HIV prevention. The intervention seeks to enhance convenience and motivate adherence through financial rewards.
214906689|NCT06348069|BEHAVIORAL|Control (Standard of care)|For sex workers in the control group, PrEP refill pick-up will be available through CESHHAR's existing network of clinical sites. There is no gift card incentive and no pick-up at private pharmacies.
214906690|NCT03432104|DIETARY_SUPPLEMENT|Oxxynea®|Oxxynea® is a blend of polyphenol-rich extracts from olive, grape, pomegranate, green tea, grapefruit, orange and blueberry. Dosage is 1 x 450 mg-capsule.
214906691|NCT03432104|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Dosage is 1 x 450 mg-capsule of identical appearance than the verum capsule.
214303118|NCT05669560|COMBINATION_PRODUCT|PerioProtect ™= plastic tray +1.7% hydrogen peroxide|Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
214303119|NCT00426283|DRUG|Flovent|1760 mcg daily
214303120|NCT00426283|OTHER|Placebo|Placebo
214303121|NCT06386614|OTHER|Routine treatment|Both groups were given routine treatment
214303122|NCT06386614|OTHER|Transcranial Direct Current Stimulation|The common group routine training used sham TDCS stimulation, and the experimental group used real TDCS stimulation
214303123|NCT05326594|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
214303124|NCT05326594|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
214303125|NCT05326594|DEVICE|Inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
214303126|NCT05326594|PROCEDURE|Heat Therapy|superficial heating for 20 minutes
214303127|NCT04260737|OTHER|Decision Aid for Men with Localized Prostate Cancer|The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.
214303128|NCT03911440|DRUG|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
214303129|NCT03911440|DRUG|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
214303130|NCT01220479|BEHAVIORAL|Exercise training program|"Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive."
214303131|NCT06308068|DRUG|Diacerein 50 mg Capsule|Diacerein 50 mg Capsule
214303132|NCT02746211|BIOLOGICAL|High Titre Influenza virus|High Titre Influenza virus
215057113|NCT06464705|DEVICE|PEMF treatment|Pulsed electromagnetic field (PEMF) therapy is an emerging modality for the treatment of musculoskeletal disorders. Time-varying magnetic pulses are generated by passing an electrical current through a coil. PEMF has been shown to be effective in vitro and in vivo studies for tissue repair and accelerating muscle regeneration. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
215057114|NCT06464705|DEVICE|Placebo treatment|In this study the placebo group uses the same PEMF machine, but it does not generate any electrical current that have treatment effect. As the active PEMF device does not produce heat or cause any sensation to the tissue, participants are blinded to the treatment. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
215057115|NCT03172078|PROCEDURE|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
215057116|NCT00422643|DRUG|Sodium hyaluronate (hyaluronic acid)|
214906692|NCT05396027|OTHER|Audio-guided deep breathing|2 weeks of audio-guided deep breathing for participants (healthy and physically disabled)
214906693|NCT02809729|DRUG|Cefazolin|2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction
214906694|NCT02809729|DRUG|sterile saline|0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
214906695|NCT02809729|PROCEDURE|oncologic breast surgery|The patient will be submitted to a conservative oncologic breast surgery
214906696|NCT02809729|OTHER|Microbiology|Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
215057117|NCT06388096|DIAGNOSTIC_TEST|Pattern Electroretinogram|Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.
215057118|NCT04102709|DEVICE|Health Tag|Health Monitoring Device
215057119|NCT00293813|DRUG|Alendronate|Alendronate 70 mg PO QW
215057120|NCT00293813|DRUG|Denosumab|denosumab 60 mg SC q 6 mos
215057121|NCT00293813|DRUG|Placebo|Placebo for alendronate and placebo for denosumab
215057122|NCT03397524|OTHER|optima4BP|optima4BP will provide the treating physician with a treatment action recommendation for consideration.
215057123|NCT05415423|BEHAVIORAL|Developing an objective measure of experienced pain|"At the beginning of each study, participants are randomly allocated into one of two groups.~Within each group all participants are exposed to the same painful stimulus. One group experiences a painful stimulus of higher intensity compared to that of the other group. The painful stimuli are physically identical for every subject within the same group and within the standard of previous pain research.~Participants are then asked to evaluate the painful stimulus they just received according to a self-reported scale (NRS, VAS, gLMS, NRS-MB). Participants are also asked to decide multiple times whether they prefer a larger amount of money and experience the same or more painful stimulus they received before or a smaller amount of money and no (or a less) painful stimulus. The smaller amount of money is progressively increased across choices until it matches the larger amount, similar to multiple price-list methods (MPL) which are standard in economics."
215057124|NCT06277947|PROCEDURE|China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)|The C-HIPEC would be performed at bedside in the general ward within 24 hours after surgery. The HIPEC treatment instruments are BR-TRG-II system, which can control the temperature stably to 43℃±0.1℃.
215057125|NCT04345029|DIETARY_SUPPLEMENT|Dietary supplement consumption|"The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days."
214303133|NCT02746211|BIOLOGICAL|Medium - High Influenza virus|Medium - High Influenza virus
214303134|NCT02746211|BIOLOGICAL|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
214303135|NCT02746211|BIOLOGICAL|Low titre|Low titre
214303136|NCT03933787|DRUG|Saxagliptin 5mg|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
214303137|NCT03933787|DRUG|Placebo oral capsule|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
214303138|NCT03933787|OTHER|ergometric test in healthy volunteers|The volunteers will undergo an ergometric test in each session
214303139|NCT02996864|OTHER|Healthy Detours App|"The app features:~* Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~* User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~* Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring."
214303140|NCT02996864|OTHER|Fat Secret App|Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
215057126|NCT03839849|PROCEDURE|: i-PRF|The description of this intervention has been already given before
215057127|NCT03839849|PROCEDURE|saline|The description of this intervention has been already given before
215057128|NCT03777254|BIOLOGICAL|RC28-E|RC28-E intravitreous injection 50ul
215057129|NCT05207644|DRUG|30 mg letrozole followed by 800 mcg misoprostol|30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
215057130|NCT01299337|DRUG|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
215057131|NCT01087658|DRUG|Glutamine|Per os
215057132|NCT01087658|DRUG|Calcium and Magnesium|Intravenous
214303205|NCT01165255|DRUG|3. Exposure to other antidepressants during the first trimester comparison cohort|"Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy."
214907587|NCT05534009|OTHER|Follow up of the first known immunization event|"The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved.~HCWs can be enrolled in the category of:~(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection."
214907588|NCT05279027|DRUG|Zirconium Zr 89 Crefmirlimab Berdoxa|Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans pre and post therapy initiation
214907589|NCT05832671|PROCEDURE|Erector Spinae muscle block|In the ESB group, the patient will be placed in the lateral position. The site of surgery is upward. After skin preparation using 10% povidone-iodine, a high-frequency linear ultrasound transducer will be placed over the ipsilateral site of surgery 1-2 cm lateral to the spine at the T10 level, counting upward from the sacrum. After identifying the erector spinae muscles and transverse process, a needle will be inserted with an in-plane technique in the craniocaudal direction
214907590|NCT05832671|PROCEDURE|caudal block|In the CB group, patients will be placed in a lateral position. An ultrasound transducer is first placed transversely at the midline to obtain a transverse view of the 2 cornua, the sacrococcygeal ligament, sacral bone, and sacral hiatus. At this position, the ultrasound transducer will be twisted to 90° to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the 2 cornua and on visualization of the frog sign (the 2 sacral cornua identified as 2 hyperechoic reverse U-shaped structure) the needle will be inserted into the sacral canal under direct real-time longitudinal visualization. After negative aspiration for blood or cerebrospinal fluid, bupivacaine (0.25%) 2.5 mg/kg will be injected over a one minute period while observing an ultrasound longitudinal image.
214907591|NCT04579848|DRUG|Methotrexate Tablets|Methotrexate 2.5mg oral tablet.
214907592|NCT04579848|DRUG|Placebo|Placebo capsule
214907593|NCT04579848|DRUG|Folic Acid 1 MG|Folic acid
214907594|NCT04556890|DEVICE|Active rTMS/Active iTBS DFPLC/Sham Pain M1|Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
214907595|NCT04556890|DEVICE|Active rTMS/Active iTBS|Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
214907596|NCT05267236|OTHER|Intervention #1: Treatment Group Receiving On-Demand TYRO Services|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
214907597|NCT05267236|OTHER|Intervention #2: Control Group Receiving In-Person TYRO Services|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
214907598|NCT05815511|DIETARY_SUPPLEMENT|Probiotic mixture|Oral capsule consumption once a day for 12 weeks
214907599|NCT05815511|DIETARY_SUPPLEMENT|Placebo|Oral capsule consumption once a day for 12 weeks
214907600|NCT04318977|DEVICE|high-frequency rTMS|repetitive transcranial magnetic stimulation
214907601|NCT04318977|DEVICE|TBS|theta burst stimulation
214907602|NCT04318977|DEVICE|placebo|placebo transcranial magnetic stimulation
214907603|NCT03210714|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214907604|NCT03210714|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
214907605|NCT03210714|PROCEDURE|Bone Scan|Undergo a bone scan
214907606|NCT03210714|PROCEDURE|Computed Tomography|Undergo a CT scan
214907607|NCT03210714|DRUG|Erdafitinib|Given PO
214907608|NCT03210714|OTHER|Laboratory Biomarker Analysis|Correlative studies
214907609|NCT03210714|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214907610|NCT03210714|OTHER|Pharmacological Study|Correlative studies
214907611|NCT03210714|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
214907612|NCT03210714|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
214907613|NCT03210714|PROCEDURE|X-Ray Imaging|Undergo an x-ray
214907614|NCT05691166|BEHAVIORAL|High-intensity progressive resistance training|Supervised high-intensity progressive resistance training twice per week for 12 months
214907615|NCT05691166|OTHER|General practitioner care|Referred to general practitioner (GP) for further follow-up. The GPs will be informed about participants sarcopenia status with results from assessments of muscle strength, muscle mass, and physical performance. The management of the sarcopenia is at the GPs own discretion.
214907616|NCT06807463|DRUG|TEV-53408|Solution for subcutaneous (sc) injection
214907617|NCT06807463|DRUG|Placebo|Solution for subcutaneous (sc) injection
214907618|NCT01909934|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
215077705|NCT01231542|DRUG|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
214907619|NCT03969004|DRUG|Cemiplimab|Intravenous (IV) infusion over 30 minutes
214907620|NCT03969004|DRUG|Placebo|Intravenous (IV) infusion over 30 minutes
215077706|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
214303206|NCT01165255|DRUG|2. Exposure to bupropion outside the first trimester comparison cohort|"Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester."
214907621|NCT05907161|DEVICE|SRP+LASER (Dentsply Sirona - SIROLaser Blue)|adjunct irradiation with a diode laser (Dentsply Sirona - SIROLaser Blue) intrasulcularly to all sites with PD ≥ 4mm
214907622|NCT05907161|DEVICE|SRP+HA|adjunct hyaluronic acid (Regedent, HyaDENT Cross linked hyaluronic intrasulcularly to all sites with PD ≥ 4mm
214907623|NCT05907161|DEVICE|SRP|non-surgical periodontal therapy (SRP) with utrasonic device and curretes
214907624|NCT06090097|DEVICE|KneeBRIGHT System|The KneeBRIGHT system includes electromyogram sensors and video game software that leads participants through physical therapy exercise.
214907625|NCT06090097|OTHER|Control Exercise|The control group will complete a 10-week regimen of conventional PT exercise
214907626|NCT02795663|DEVICE|NIRS EEG HR recording|NIRS EEG HR recording
214907627|NCT05671172|DRUG|Hyaluronidase|hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS
214907628|NCT05671172|DRUG|Bupivacaine Injection|20ml bupivacaine will be injected without additives in the transversus abdominis plane block on each side for postoperative analgesic after CS
214907629|NCT00592306|DRUG|thymoglobulin (intraoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses."
214907630|NCT00592306|DRUG|thymoglobulin (postoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin."
214907631|NCT03732664|DRUG|Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab|One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.
214907632|NCT00826969|DRUG|Ciclesonide|320µg Ciclesonide versus Placebo
214907633|NCT00826969|DRUG|Placebo|Placebo
214907634|NCT03696134|OTHER|questionnaire|questionnaire
214907635|NCT04091516|BEHAVIORAL|Low-fat plant-based diet|Participants will follow a diet that consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
214907636|NCT06483009|DEVICE|Cryoablation|Cryoablation: For subjects assessed as stable disease (SD) after two cycles of medication, one session is performed under local anesthesia after assessment. The multidisciplinary team, including investigators and radiologists, evaluates the feasibility of tumor ablation based on the size, location, and proximity to major blood vessels. Criteria for eligible lesions include a maximum diameter \<5cm, relatively isolated lesion location, and not adjacent to major blood vessels or vital structures. Cryoablation is performed using a 17G IceRod Plus 1.5 cryoablation needle, guided by CT, and avoiding nearby anatomical structures using the Visual-ICE cryoablation system.
214907637|NCT04230928|OTHER|Very low carbohydrate diet|Participants will learn to follow a very low carbohydrate diet in modified versions of GLB modules 2,3,5 \& 10. Participants will learn to track carbohydrate intake
214907638|NCT04230928|OTHER|Standard DPP-GLB diet|Participants will learn to follow a very low fat, calorie-restricted diet and track fat grams and caloric intake in standard GLB modules 2,3,5, \& 10
214907639|NCT04230928|BEHAVIORAL|Standard DPP-GLB program modules|Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22
214907640|NCT03751176|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
214907641|NCT03751176|DRUG|Irinotecan|Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
214907642|NCT03751176|DRUG|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
214907643|NCT03751176|DRUG|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
214907644|NCT02816736|DRUG|LCZ696|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively."
214954810|NCT05219097|DIAGNOSTIC_TEST|CBA Assay|Comparsion of specificity, sensitivity and clinical correlation of CBA, ELISA and RIPA assay in autoantibodies detection of myasthenia gravis
214954811|NCT00700154|PROCEDURE|Insulin infusion|The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
214954812|NCT00538954|DRUG|Post operative laxation (Magnesium Oxide)|20 ml of Magnesium Oxide twice daily from the day after surgery until discharge
214907645|NCT02816736|DRUG|valsartan|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.~The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets)."
214907646|NCT02816736|DRUG|LCZ696 placebo|LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
214907647|NCT02816736|DRUG|valsartan placebo|Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
214907648|NCT01139775|DRUG|Pemetrexed|Administered intravenously as a continuous 10-minute infusion
214907649|NCT01139775|DRUG|Cisplatin|Administered intravenously as a continuous 1-hour infusion
214907650|NCT01139775|DRUG|LY2603618|Administered intravenously as a continuous 1-hour infusion
214907651|NCT02774941|DEVICE|Jet Nebulizer|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
214907652|NCT02774941|DEVICE|Vibrating Mesh Nebulizer|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
214907653|NCT01542242|DRUG|Liraglutide|Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
214907654|NCT06583174|BEHAVIORAL|Breastfeeding Attitudes|Relationship between Breastfeeding Attitudes and Nutrition Knowledge Levels
214907655|NCT02050386|OTHER|Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds
214907656|NCT02050386|OTHER|Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds
214907657|NCT03193853|DRUG|Tak-228 & Tak-117|Patients will receive 4mg oral TAK-228 and 200mg TAK-117 tablets until disease progression.
214907658|NCT03193853|DRUG|Cisplatin & Nab Paclitaxel|following Tak-228 \& Tak-117 standard nab paclitaxel 175-220 mg/m2 plus cisplatin 60-75 mg/m2 infusion for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion
214907659|NCT06318416|DIAGNOSTIC_TEST|urine spectrophotometry for rifampin absorbance|All participants will received conventional weight-based TB therapy, standard of care for active TB disease. After enrollment, participants will be randomized to early Day 14 or delayed Day 21 dose modification of rifampin informed by urine spectrophotometry where absorbance is determined above or below a threshold. Below a threshold, single tablets of rifampin are added to conventional fixed drug combination standard of care, above a threshold, no additional rifampin is added. Dose adjustment of rifampin may be up to \~30mg/kg and will be continued through day-56.
214907660|NCT04886219|OTHER|Eye examination|"* Multimodal fundus imaging (color fundus photography, optical coherence tomography (OCT))~* orthoptic assessment (Visual acuity, Refraction, Cover test, Stereopsis evaluation~* ocular biometry~* corneal topography~* monocular photographs in photopic and scotopic condition"
214907661|NCT06482853|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
214907662|NCT06482853|DRUG|Saline|Saline will be used as the placebo comparator.
214907663|NCT06684951|DRUG|hCG|observe hCG effect on endometrial receptivity
214907664|NCT05797519|DEVICE|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System.
214907665|NCT03872427|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214907666|NCT03872427|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214907667|NCT03872427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214907668|NCT03872427|OTHER|Pharmacodynamic Study|Correlative studies
214907669|NCT03872427|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214907670|NCT03872427|DRUG|Telaglenastat Hydrochloride|Given PO
214907671|NCT06644781|DRUG|Ifinatamab deruxtecan|Intravenous administration
214907672|NCT06644781|DRUG|Docetaxel|Intravenous administration
214907673|NCT06644781|DRUG|Paclitaxel|Intravenous administration
214907674|NCT06644781|DRUG|Irinotecan hydrochloride (HCl)|Intravenous administration
214907675|NCT06855498|DRUG|povorcitinib|Study drug will be taken orally as defined by the protocol.
214907676|NCT05112185|BEHAVIORAL|Healthy Drinks, Healthy Futures|The Healthy Drinks, Healthy Futures intervention consists of increased access to healthy beverages in childcare centers and education directed to children and their families to increase the intake of healthy beverages, including motivational beverage counseling for families and lessons for children in childcare centers.
214907677|NCT06842667|BEHAVIORAL|Papageno video|"The intervention will be a video (14 min 13 sec in length) of a series of clips from the Papageno interviews developed during the pilot phase of this project. The decision to combine the videos and shorten the total length of the video was based on the feedback we received during the acceptability and feasibility phase of this study. Interviewees were asked questions about a time in their life when they came close to suicide but found non-suicide alternatives (their Papageno story)."
214907678|NCT06842667|BEHAVIORAL|Control video|The control condition will involve viewing a mental health education video (12 min 14 sec in length) created by our team. It is a simple informational video, aimed at psychoeducation about suicide and safety promotion. It includes a list of mental health and crisis resources. Both videos are interview-style.
214907679|NCT06882876|DRUG|JS014 Combined With Toripalimab and TACE|JS014 (60μg/kg,QW)+Toripalimab (240mg , Q3W)+ dTACE (60mg/m2)
214907680|NCT06983730|DIETARY_SUPPLEMENT|Vitamin B3|1000mg once a day orally for two days, once the day before the exercise session, and once the day of the exercise session.
214907681|NCT05976386|DRUG|Dupilumab (SAR231893)|Injection solution Subcutaneous
214907682|NCT06657144|DRUG|CHS-114|Solution for infusion
214907683|NCT06657144|DRUG|Toripalimab|Solution for infusion
214907684|NCT06657144|DRUG|5 Fluorouracil|Solution for infusion
214303207|NCT01165255|DRUG|1. Exposure to bupropion during the first trimester|"Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy."
214303208|NCT01552252|DIETARY_SUPPLEMENT|apple juice|unaltered(0% POs-Ca) commercially available apple juice
214303209|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
214303210|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
214907685|NCT06657144|DRUG|Cisplatin|Solution for infusion
214303211|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
214907686|NCT06983223|DIETARY_SUPPLEMENT|Sucrosomial® Vitamin B12|Sucrosomial® B12 is an advanced oral vitamin B12 supplement formulated with Sucrosomial® technology to enhance absorption. Participants in this group will receive 1,000 mcg of Sucrosomial® B12 (single sachet of orally dissolving powder) once daily for 4 weeks.
214907687|NCT06983223|OTHER|Placebo (Oral)|Participants in the placebo group will receive an identical powder that matches the Sucrosomial® B12 in appearance, packaging, and administration. The placebo will be administered once daily for 4 weeks.
214907688|NCT06985706|PROCEDURE|Subthreshold Micropulse Laser (SML)|SML will be applied in line with the DAME Guideline and follow the DAME participant pathway.
214907689|NCT06985706|DRUG|Anti-VEGF Monotherapy (standard care)|Anti-VEGFs including ranibizumab and biosimilars, aflibercept, faricimab, and brolucizumab will be used, as per the standard of care at participating sites. The anti-VEGF should be administered in line with the summary of product characteristics (SmPC).
214907690|NCT06982573|DEVICE|Effects of applying magnetic stimulation|The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients with End-Stage Renal Disease (ESRD)
214907691|NCT06820099|DRUG|HRS-7535 tablet|HRS-7535 tablet.
214907692|NCT06820099|DRUG|HRS-7535 tablet placebo|HRS-7535 tablet placebo.
214907693|NCT01956773|OTHER|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
214907694|NCT00450437|BIOLOGICAL|MenACWY CRM|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
214907695|NCT00450437|BIOLOGICAL|Meningococcal ACWY Conjugate vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
214907696|NCT05880875|BEHAVIORAL|Reflective Supervision Enhancement|The Reflective Supervision enhancement is a professional development series designed to train and support directors and education coordinators supervising state pre-kindergarten classrooms in using a reflective supervision approach with their staff.
214907697|NCT05694793|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
214907698|NCT05694793|DEVICE|Glean Urodynamics System|Wireless and catheter free urodynamics system
214907699|NCT06824688|PROCEDURE|Single-port robotic total mesorectal excision|Single-port robotic total mesorectal excision
214907700|NCT06824688|PROCEDURE|Multi-port robotic total mesorectal excision|Multi-port robotic total mesorectal excision
214907701|NCT06859918|BEHAVIORAL|TUNE In: Training to Understand and Navigate Emotions and Interactions|A cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, and social skills.
214907702|NCT06990581|OTHER|regular core exercises|regular core exercises on trunk stability and balance
214907703|NCT06990581|OTHER|specific type of core exercises|specific type of core exercises on trunk stability and balance
214907704|NCT06478498|BIOLOGICAL|Necator americanus L3 larvae|Necator americanus L3 larvae
214907705|NCT00097097|PROCEDURE|Neonatal Resuscitation|
214907706|NCT05114889|BIOLOGICAL|BSI-045B|BSI-045B will be administered weekly, subcutaneously
214907707|NCT06669780|DEVICE|AMMO PTH DTx|An online cognitive behavioral therapy program accessed through a online program.
214907708|NCT06669780|DEVICE|AMMO SHAM|Online activities not including CBT in the AMMO online program.
214907709|NCT06994338|DRUG|Tirzepatide|Tirzepatide (sc)
214907710|NCT06994338|DRUG|Placebo injections|Placebo injections
214907711|NCT01502657|DEVICE|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
214907712|NCT05137119|DRUG|Cefazolin|Cefazolin
214907713|NCT05137119|DRUG|Penicillin|benzylpenicillin
214907714|NCT05137119|DRUG|Clindamycin|Clindamycin
214907715|NCT05137119|DRUG|Vancomycin|Vancomycin or Daptomycin
214907716|NCT05137119|OTHER|Effectiveness of early switch to oral antibiotics|This involves testing a strategy rather than individual antibiotic agents
214907717|NCT05137119|RADIATION|Whole body FDG PET/CT Imaging|Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.
215077707|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
214907718|NCT07000123|DRUG|AZD0780|Participants will receive daily oral dose of AZD0780
214907719|NCT07000123|DRUG|Placebo|Participants will receive daily oral dose of placebo
215077708|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
215077709|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
214303212|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
214303213|NCT06063577|DEVICE|Stratafix suture|Stratafix symmetric suture
214303214|NCT06063577|DEVICE|Standard of care suture|Standard of care suture
214303215|NCT02255721|BEHAVIORAL|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
214907720|NCT07001332|DEVICE|Elevate|The Elevate System is a catheter- mounted, self-expanding and retrievable, continuous-flow pump, designed to unload the left ventricle by actively transporting blood from the left ventricle into the ascending aorta, thus augmenting cardiac output and maintaining systemic arterial pressure during complex/high-risk coronary interventions. Subjects will receive an Elevate prior to their high-risk percutaneous intervention.
214303216|NCT02255721|BEHAVIORAL|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
214303217|NCT02686879|DEVICE|Multifocal contact lenses|
214303218|NCT02686879|DEVICE|Single vision contact lenses|
214303219|NCT03845907|DEVICE|Gen 1B|Diagnostic Ultrasound and Optoacoustic Imaging
214303220|NCT03845907|DEVICE|Gen 1|Diagnostic Ultrasound and Optoacoustic Imaging
214907721|NCT07001332|DEVICE|Impella|Subjects will receive an Impella prior to their high-risk percutaneous intervention.
214907722|NCT06588348|DRUG|Steroid treatment|All enrolled subjects will be prescribed a 14-day course of corticosteroid therapy in the form of Prednisone 20 mg to be taken once daily by mouth.
214907723|NCT06588348|PROCEDURE|Esophageal Manometry|On the final day of Prednisone use, all subjects will undergo esophageal manometry testing to assess for treatment response.
214907724|NCT06588348|OTHER|Survey|All enrolled subjects will be asked to complete follow-up Eckardt and BEDQ surveys.
214907725|NCT06679946|DRUG|Vutrisiran|Vutrisiran administered SC q3M
214907726|NCT06680622|DRUG|bemarituzumab, paclitaxel, ramucirumab|Cohort 2 will receive bemarituzumab plus SOC treatment with paclitaxel and ramucirumab
214907727|NCT06680622|DRUG|bemarituzumab, irinotecan|Cohort 1 will receive bemarituzumab plus SOC treatment with irinotecan
214907728|NCT06680622|DRUG|bemarituzumab, trifluridine/tipiracil|Cohort 3 will receive bemarituzumab plus SOC treatment with trifluridine/tipiracil
214907729|NCT06866964|DRUG|Low-dose ASA|81 mg by mouth daily for 26 weeks
214907730|NCT06615050|DRUG|Tacrolimus (Tac)|Tablet or intravenously (IV)
214907731|NCT06615050|DRUG|Methotrexate (MTX)|Intravenously (IV)
214907732|NCT06615050|DRUG|Ruxolitinib (Rux)|Tablet
214907733|NCT06615050|DRUG|Cyclophosphamide|Intravenously (IV)
214907734|NCT06615050|DRUG|Mycophenolate mofetil (MMF)|Tablet or intravenously (IV)
214907735|NCT07011056|DRUG|Purinostat Mesylate for Injection|"The subjects in the experimental group will receive treatment with Purinostat Mesylate for injection. The dosage is 11.2 mg/m2. Each administration cycle consists of intravenous infusion on days 1, 4, 8, and 11. The administration cycle lasts for 21 days, and the total treatment cycle is 6 cycles.~After 6 cycles, the investigator will assess whether the subjects can continue to benefit, whether they can sustain the treatment with the investigational drug, and adjust the frequency of continuous administration based on the evaluation results of the efficacy over these 6 cycles."
214907736|NCT07011056|DRUG|Selinexor Tablets|The recommended dose of selinexor tablets is 60 mg per administration, taken orally on the 1st and 3rd day of each week (for example, Monday and Wednesday, or Tuesday and Thursday), with a 4-week course as one treatment cycle. Patients who achieve partial response (judged by the investigator as the best expected response for the subject) or have better efficacy can switch to maintenance treatment, with a maintenance dose of 60 mg taken orally once a week.
215077710|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
214303221|NCT03777007|DEVICE|SPARTA force plate|The Sparta Platform includes force plate hardware coupled with Sparta Scan software that enables quick assessment of an individual's movement and balance within minutes
214303222|NCT05741411|OTHER|RPM-assisted specialist access|Participants will be prompted to report current symptoms and activity once a day via remote patient monitoring chat technology for up to 28 days following injury. Patients with either escalating or plateauing symptoms will be flagged, with an electronic alert sent via the electronic health record to a nurse navigator. The nurse navigator will have access to the symptom data and facilitate scheduling an in person or telehealth specialist visit as indicated. Symptoms will continue to be monitored through the 28-day acute study period with additional clinical visits occurring according to clinical need.
214907737|NCT03820063|DRUG|PTC-Pz|"* Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~* Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~* Carboplatin AUC 6mg•ml/min administered intravenously on day 1~* Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~* Treatment cycles are repeated on day 22~In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles."
214907738|NCT04118062|BEHAVIORAL|Questionnaires|Questionnaires
214907739|NCT04118062|BEHAVIORAL|Semi-structured individual interviews|Semi-structured individual interviews
214907740|NCT04118062|OTHER|Focus Group|Focus Group
214907741|NCT04118062|OTHER|DELPHI Consensus Method|DELPHI Consensus Method
214954813|NCT00538954|DIETARY_SUPPLEMENT|Preoperative metabolic conditioning postoperative nutritional supplementation|Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30
214954814|NCT00538954|OTHER|Standard ERAS group|
215077711|NCT05372731|OTHER|Recruitment Maneuver|RM after BAL
215077712|NCT04048707|DRUG|Angiotensin II|Intravenous
215077713|NCT04048707|DRUG|Midodrine|Pill
214303223|NCT02193373|OTHER|Osteopathic Manual Medicine|Osteopathic Manual Medicine
214303224|NCT02193373|OTHER|Sham|Osteopathic Manual Medicine
214303225|NCT03646461|DRUG|Ibrutinib 560mg PO daily (Imbruvica)|BTK inhibitor combined with PD-1 inhibitor
215077714|NCT04048707|DRUG|Octreotide|Subcutaneous
214303226|NCT03646461|DRUG|Cetuximab|Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
214303227|NCT03646461|DRUG|Nivolumab|Nivolumab 3mg/kg biweekly 28 day cycle
214907742|NCT07023224|OTHER|Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)|The Turkish adaptation of the Parkinson's Disease Dyskinesia Scale (PDYS-26) is administered to individuals diagnosed with Parkinson's disease who have a dyskinesia score of ≥1 based on the Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia item. The scale is used to evaluate dyskinesia severity and assess its clinical applicability in Turkish-speaking populations.
214907743|NCT05726591|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
214907744|NCT01774682|PROCEDURE|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
214907745|NCT05379595|BIOLOGICAL|Amivantamab IV|Amivantamab will be administered as intravenous infusion.
214907746|NCT05379595|BIOLOGICAL|Fluorouracil|Fluorouracil will be administered as intravenous infusion.
214907747|NCT05379595|BIOLOGICAL|Leucovorin|Leucovorin will be administered as intravenous infusion.
214907748|NCT05379595|BIOLOGICAL|Oxaliplatin|Oxaliplatin will be administered as intravenous infusion.
214907749|NCT05379595|BIOLOGICAL|Irinotecan|Irinotecan will be administered as intravenous infusion.
214907750|NCT05379595|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
214907751|NCT06441331|DRUG|Lutetium Lu 177-Edotreotide|lutetium Lu 177 edotreotide At least two cycles and a maximum of six cycles at eight-week (± 2 we-ek) intervals. Extrapolation from standard maximum adult dose of 100 Megabecquerel(MBq)/kg for a 75 kg adult for the first cohort. Dosing decision for the subsequent cohorts by Data Monitoring Committee (DMC), based on (at least) cycle 1 dosimetry and safety data from at least four participants of the preceding cohort. Route of administration: Intravenous (IV) infusion. Duration of treatment: 16-48 weeks
214907752|NCT06441331|OTHER|Amino Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
214907753|NCT06874959|DEVICE|Ear acupuncture|"(According to the guidelines provided in the BFA - Acupuncture Manual of the USAF Center for Integrative and Complementary Medicine.)~Procedure:~* Practitioner: Traditional medicine doctor with a practicing certificate.~* Tools: Khanh Phong auricular acupuncture needles (license: 287/BYTYDCT)~* Before needling: Disinfect the skin on both outer ears.~* Insertion depth: Auricular needles penetrate the skin to a depth of 1.3 mm. Insert the auricular needles alternately on the right and left sides at the following acupoints: Cingulate gyrus, Subcortex, Omega 2, Shen Men, and Zero point. The insertion process stops when one of the following three criteria is met: (1) The patient experiences a 40% reduction in pain on the Visual Analog Scale (VAS), (2) The patient refuses to continue the insertion, or (3) A total of 10 needles have been inserted.~* After needling: Patient may feel slight pain in the ear area or de qi (a sensation of aching, warmth, and redness at the needling site)."
214907754|NCT06874959|DEVICE|Electro-acupuncture|"According to the Guidelines for the Diagnosis and Treatment of Diseases by Traditional Medicine, combining Traditional Medicine with Modern Medicine - 2020 - Ministry of Health of Viet Nam.~Procedure:~* Practitioner: Traditional medicine doctor with a practicing certificate.~* Tools: Khánh Phong ARLO acupuncture needles, size 0.3 x 25 mm (lincense: TKHQ:102664344900)~* Disinfect the lumbar region skin.~* Needle insertion: Insert needles perpendicular to the patient's skin, to a depth of 20 mm. Location: Dai truong du (BL25), Than du (BL23), Jiaji at L4-L5, L5-S1 (Ex-B2), Uy trung (BL40), Yeu duong quan (GV3). After insertion, attach the electrode clips to the needle ends.~* Electric stimulation: Use a current of 100Hz for 20 minutes - mixed wave.~* Post-needling: Patient may feel a sensation of de qi (aching, warmth, and redness at the needling site)."
214303228|NCT06490328|DRUG|DKF-MA102|Administered twice at 12-week intervals
214303229|NCT00988754|BEHAVIORAL|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
214907755|NCT06874959|DRUG|Paracetamol 500 mg|"According to the Guidelines for the Diagnosis and Treatment of Diseases by Traditional Medicine, combining Traditional Medicine with Modern Medicine - 2020 - Ministry of Health of Viet Nam.~* Prescriber: Traditional medicine doctor with a practicing certificate.~* Paracetamol 500mg x 9 tablets: Take 1 tablet per dose, to be used when the pain score on the Visual Analog Scale (VAS) is ≥ 30mm, not exceeding 6 tablets/day. (If the patient still has medication from the previous visit, only prescribe the total amount needed to make up 9 tablets)."
214907756|NCT06874959|DEVICE|Sham ear acupuncture|"Study uses patches with non-skin-penetrating cotton, at the intervention acupoint areas. Using acupoints matching with the intervention group helps reduce the patients' ability to predict their study group, and the non-penetrating and non-rotating cotton ensure that there is no analgesic effect on the lumbar area caused by auriculotherapy.~Acupoint location: Cingulate gyrus, Subcortex, Omega 2, Shen Men, and Zero points"
214907757|NCT07029932|DRUG|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability, and PK data from SAD and previous MAD cohorts. Daily dosing will continue for a total of 7-10 consecutive days (as per schedule)."
215077715|NCT04048707|DRUG|Albumin solution|Intravenous suspension
215077716|NCT01868620|DEVICE|Iontophoretic CXL|
215077717|NCT01868620|DEVICE|Standard CXL|
214303230|NCT03024307|OTHER|pharmacists involved OPCSP|This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
214303231|NCT06038279|DRUG|INI-2004|INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.
214303232|NCT06038279|DRUG|Placebo|The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
214303233|NCT01224847|DRUG|Tetracaine|1 gtt
214303234|NCT01224847|DRUG|Cocaine|1 gtt
214907758|NCT07029932|DRUG|Placebo|SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive a matching placebo.
214907759|NCT06499129|BEHAVIORAL|Sensory ball, progressive relaxation exercise, training|The effect of sensory ball use on fatigue, peripheral neuropathy and anxiety will be examined
214907760|NCT07030257|DRUG|CP-383|Novel anti-cancer agent inhibiting pyrimidine synthesis in cancer cells
214907761|NCT06263153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214907762|NCT06263153|PROCEDURE|Computed Tomography|Undergo CT
214907763|NCT06263153|BIOLOGICAL|Durvalumab|Given IV
214907764|NCT06263153|DRUG|Futibatinib|Given PO
214907765|NCT06263153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214907766|NCT06263153|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
214907767|NCT07027046|PROCEDURE|Robotic surgical staging|The intervention includes hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph node mapping, with possible lymphadenectomy or omentectomy, depending on histology.
214907768|NCT06706622|DRUG|Lu AF82422|Solution for infusion
214907769|NCT06706622|DRUG|Placebo|Commercially available saline solution
214907770|NCT06707012|DRUG|Metformin Hydrochloride|"Participants will be divided in 2 groups~1 group will receive metformin and 2nd group will receive placebo"
214907771|NCT06707688|DEVICE|Amulet™ 2 Left Atrial Appendage (LAA) Occluder|Patient will undergo the implantation of the Amulet™ 2 Left Atrial Appendage (LAA) Occluder
214907772|NCT07138417|OTHER|Compassion-Based Family Therapy|"Draw ideas from traditional Chinese culture, the investigators have developed the compassion-based family intervention therapy to improve the mental health of both parents and children by enhancing their synchronization.~The 6-week program followed a progressive thematic structure. Week 1 focuses on introduction and connection, themed Setting Sail: The Additions and Subtractions for a Happy Family. Weeks 2 and 3 address self-compassion: Week 2 is themed Self-compassion: Embrace yourself with compassion here and now.; Week 3 is themed Self-compassion: Accepting growing pains.. Weeks 4 and 5 explored developing compassion for others: Week 4 is themed Listening to the heart: Enhancing communication, bringing us closer.; Week 5 is themed Building a harbor together: Managing conflict, creating happiness Week 6 involves integration and review, themed Integrating knowledge and action: Practicing compassion, lighting the path forward."
214303235|NCT01224847|DRUG|Lidocaine|Lidocaine soaked pledget
214907773|NCT07036692|DIETARY_SUPPLEMENT|Placebo|To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
214907774|NCT07036692|DIETARY_SUPPLEMENT|FibreGum|To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
214907775|NCT06713369|DRUG|Saruparib (AZD5305)|PARP-inhibitor
214907776|NCT06713369|DRUG|[14C]-AZD5305 microtracer|IV radiolabeled microtracer
214907777|NCT06713369|DRUG|[14C]-AZD5305 (therapeutic dose)|IV radiolabeled PARP inhibitor
214907778|NCT06877702|DRUG|BMS-986460|Specified dose on specified days.
214907779|NCT06880562|DEVICE|Splanchnic Nerve Denervation|Catheter-based endovascular denervation (CDN) of renal arteries and splanchnic nerves (celiac + SMA) using radiofrequency ablation
214907780|NCT06880562|DEVICE|Renal Denervation Only|Catheter-based endovascular denervation (CDN) of renal arteries only, without splanchnic nerve denervation
214907781|NCT06881823|DRUG|AAA602|\[177\]Lu-PSMA-R2 Radiopharmaceutical solution for injection/infusion.
214907782|NCT06881823|DRUG|AAA802|\[225\]Actinium-PSMA-R2 radiopharmaceutical solution for injection/infusion
215077718|NCT02975011|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
214303236|NCT04658537|RADIATION|Radiation Therapy|Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours
214303237|NCT05481073|DEVICE|UV sensor|Use of UV sensor to be informed about the sun exposure daily through a mobile application
214907783|NCT06881823|DRUG|Gallium (68Ga) gozetotide|Radioligand Imaging compound. Provided as a kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide. Solution for injection.
214907784|NCT06881823|DRUG|Piflufolastat (18F)|Radioligand Imaging compound. Provided as a ready-to-use radiopharmaceutical.
214907785|NCT06881823|DRUG|Flotufolastat F 18|Radioligand Imaging compound. Provided as a ready to use radiopharamceutical.
214907786|NCT06881823|DRUG|18F-PSMA-1007|Radioligand Imaging compound. Provided as a ready to use radiopharmaceutical.
214907787|NCT07038343|DRUG|AVZO-1418|Specific dose in protocol specified schedule
214907788|NCT07038343|DRUG|Combination Agent 1|Per label based on combination agent used
214303238|NCT00323518|DRUG|velafermin|administered intravenously as 100mL single dose over 15 minutes on day 1
214303239|NCT00323518|DRUG|placebo|administered intravenously as 100mL single dose over 15 minutes on day 1
214907789|NCT07038343|DRUG|Combination Agent 2|Per label based on combination agent used
214907790|NCT07039708|BEHAVIORAL|E-MinD Life Semantic|The E-MinD Life programme is designed to teach semantic memory strategies. The memory strategies are applied to 12 common daily activities required for community living, e.g. meal preparation, laundry activities, and built into the E-MinD Life programme on a computer-based platform. The intervention runs over 9 weeks with one 45-minute individual face-to-face or online healthcare-professional-led session and two 30-minute, family-assisted home sessions per week. During the home sessions, participants will complete the same activities as those learnt during the healthcare-professional-led sessions. Family members or carers will be invited to join the healthcare-professional-led sessions as observers and support the participants in the home sessions if needed.
214907791|NCT07039708|BEHAVIORAL|Cognitive stimulation|Participants will receive stimulation for visual attention and memory through activities such as playing a game that requires them to find missing pieces, and auditory attention and memory through activities such as remembering a song. The intervention will adopt a similar structure as the E-MinD Life Semantic group, with one 45-minute individual face-to-face or online healthcare-professional-led session and two 30-minute, family-assisted home sessions per week for 9 weeks.
215057603|NCT01605357|DRUG|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
215057604|NCT01605357|DRUG|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium \< 135 mmol/L) is to be corrected at the discretion of the provider.
215057605|NCT00087087|DRUG|pemetrexed disodium|
214303240|NCT03997149|BEHAVIORAL|Acute Laboratory Stressor|The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
214303241|NCT03997149|BEHAVIORAL|Low affect video|The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
214303242|NCT01754233|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
214907792|NCT06719245|PROCEDURE|Targeted Muscle Reinnervation (TMR)|In short: each transected nerve is identified after amputation and is dissected proximally for length. A nerve stimulator is used to identify functional motor nerve branches. Near the point where the motor branch enters the muscle, the motor nerve branch is transected and an end-to-end coaptation is performed with a nearby amputated nerve.
214907793|NCT06719245|PROCEDURE|Standard neurectomy|During the amputation a standard neurectomy will be performed based on the surgeons preference. Standard neurectomy will include cutting of the nerve, with or without traction, with or without coagulation, and with or without infiltration with a local anesthetic (i.e., ropivacaine) or phenol. Ligation of the nerve will not be allowed.
214303243|NCT00045279|BIOLOGICAL|PEG-interferon alfa-2b|
214303244|NCT00005888|BEHAVIORAL|Fortified Pasteurized Donor Human Milk supplement|
214303245|NCT00005888|BEHAVIORAL|Preterm Formula supplement|
214303246|NCT06180291|OTHER|PRECOP program|"PRECOP program is the first program combining early detection of cerebral palsy with implementation of early interventions following the latest international recommendations (multidisciplinary program at home, with the possibility of intensive courses, coaching parental, in the first 2 years of life).~This comprehensive monitoring is implemented as soon as the infant arrives at home, by a multidisciplinary team and continues during the child's first 2 years. It includes:~* Follow-up organized primarily at home~* Monitoring of psychomotor development~* Screening for possible cerebral palsy~* Comprehensive support for the child's development: weight, diet, sleep...~* Reeducation, implementation of SMART type objectives (Specific, Measurable, Achievable, Achievable, Timely defined) determined with parents~* Creation of equipment if necessary: early seating installation in particular~* Parental support and guidance for optimizing early care~* Parental psychological support."
214303247|NCT00391989|DRUG|Dasatinib|
214303248|NCT06074237|OTHER|Immersive resident education|Using the AIMS framework (Announce, Inquire, Mirror, Secure), residents will complete online modules designed to improve vaccine education, promote vaccine confidence and improve vaccine counseling in general. There will also be modules dispelling myths and controversies specific to HPV, MMR, Covid and influenza vaccines that often limit or prevent vaccination uptake.
214303249|NCT06074237|OTHER|Standardized patient (SP) encounter|"After completion of the Immersive Resident Education modules, residents will participate in a telemedicine standardized patient encounter. They will interview a vaccine-hesitant patient and this encounter will be video recorded. At the end of the encounter, the SP will provide the resident with patient-centered feedback on their communication skills. The SP will also complete a communication checklist regarding each resident encounter and the research team will review the recorded encounters for accuracy of medical content conveyed during each encounter."
214303250|NCT03184415|DRUG|DWC20155|tablet
214907794|NCT06716801|DRUG|Cenobamate|Adult patients affected by epilepsy with focal-onset seizures with or without secondary generalization who have not been adequately controlled despite a history of treatment with 2 or 3 anti-seizure medications.
214907795|NCT03907488|PROCEDURE|Biospecimen Collection|Undergo peripheral blood collection
214303251|NCT03184415|DRUG|DWC20156|tablet
214303252|NCT03184415|DRUG|placebo of DWC20155|tablet
214303253|NCT03184415|DRUG|placebo of DWC20156|tablet
214303254|NCT05161169|GENETIC|Genome Sequencing|20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
214907796|NCT03907488|DRUG|Brentuximab Vedotin|Given IV
214907797|NCT03907488|PROCEDURE|Computed Tomography|Undergo PET/CT or CT scan
214303255|NCT03797209|DEVICE|EUS-guided fistulization AXIOS|By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
214303256|NCT03338426|DRUG|Fimasartan 120mg|Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
214907798|NCT03907488|DRUG|Dacarbazine|Given IV
214907799|NCT03907488|DRUG|Doxorubicin Hydrochloride|Given IV
214907800|NCT03907488|BIOLOGICAL|Filgrastim|Given SC or IV
214907801|NCT03907488|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214303257|NCT03338426|DRUG|Atorvastatin 40mg|Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
214303258|NCT03338426|DRUG|Placebo for Fimasartan 120mg|Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
214907802|NCT03907488|BIOLOGICAL|Nivolumab|Given IV
214907803|NCT03907488|BIOLOGICAL|Pegfilgrastim|Given SC
214907804|NCT03907488|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214907805|NCT03907488|OTHER|Quality-of-Life Assessment|Ancillary studies
214907806|NCT03907488|OTHER|Questionnaire Administration|Ancillary studies
214907807|NCT03907488|RADIATION|Radiation Therapy|Receive radiation therapy
214907808|NCT03907488|DRUG|Vinblastine Sulfate|Given IV
214907809|NCT05585476|DEVICE|C02 microablative laser|The C02 microablative laser was the first to be used in the treatment of menopausal genitourinary syndrome. Its mechanism of action is based on the emission of light at a wavelength of 10600nm that is absorbed by the water molecules contained in the vaginal mucosa, leading to local remodeling of connective tissue and neoformation of collagen, elastic fibers and other components of the extracellular matrix.
214907810|NCT05585476|COMBINATION_PRODUCT|Regenerative topical treatment|It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.
214907811|NCT07042412|BEHAVIORAL|Ta'am Mustadam Intervention|"The Ta'am Mustadam intervention, guided by the BCW and BCT, will be implemented over six weeks with a four-week follow-up among adults in the CMHS canteen.~The intervention will consist of the following elements:~1. Education: The educational messages will be shared via WhatsApp on Fridays \&Tuesdays, with additional dietary tips on Wednesdays, timed before main meal. Moreover, weekly video recipes will be shared on Saturdays~2. Behavioral Practice: This component engages participants withs sustainable eating habits through biweekly cooking competitions and hands-on meal preparation activities held on Thursdays.~3. The environmental restructuring component aims to promote sustainable food choices at CMHS canteen by enhancing healthy food availability, appeal, and visibility through local produce, improved dish palatability, and visual/nutritional cues via QR codes, tray mats, and banners.~The evaluation of Ta'am Mustadam intervention will be guided by RE-AIM framework."
214907812|NCT06705946|BEHAVIORAL|Aqua vest group|Participants in this group will perform Dynamic Stability Training (DST) sessions twice a week for 12 weeks while wearing an aqua vest. Each session will focus on dynamic stability exercises aimed at improving balance, lower limb joint moment distribution, and gait. Each session will last for 50 minutes
214907813|NCT06705946|BEHAVIORAL|Weight vest group|Participants in this group will perform the same Dynamic Stability Training (DST) sessions twice a week for 12 weeks, but with a weight vest instead of an aqua vest. Each session will focus on balance, lower limb joint moment distribution, and gait, lasting for 50 minutes
214907816|NCT02858999|DRUG|PAD-VCD|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles
214907817|NCT06925750|BIOLOGICAL|Sotatercept|SC injection administered every 3 weeks
214907818|NCT06925750|DRUG|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists
214907819|NCT06885671|RADIATION|Multiple Fraction PBI|Participants randomized to Arm 1 will receive PBI with a dose of 26 Gy in 5 daily fractions.
214907820|NCT06885671|RADIATION|Single Fraction PBI|Participants randomized to Arm 2 will receive PBI in a single fraction with a dose of 13 Gy.
214303259|NCT03338426|DRUG|Placebo for Atorvastatin 40mg|Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
214907821|NCT06736691|DRUG|emodepside (BAY 44-4400)|Treatment with single dose of oral 15 mg emodepside
214907822|NCT06736691|DRUG|matching placebo of emodepside|Treatment with single dose of oral emodepside matching placebo
214907823|NCT06736691|DRUG|Mebendazole|Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
214907824|NCT06736691|DRUG|similar placebo to mebendazole|Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
214907825|NCT06643598|BEHAVIORAL|Abecedarian Approach|The Abecedarian Approach is an early childhood behavioral education program that aims to improve the learning and cognitive development of children in high-risk or at-risk communities. This study will test the efficacy of implementing this approach in a virtual format.
214907826|NCT03283384|DRUG|Letrozole|Letrozole 2.5 mg daily.
214907827|NCT03283384|DRUG|Chemotherapy|Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
214907828|NCT03283384|DRUG|Ribociclib plus letrozole|Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).
214907829|NCT06614712|OTHER|Pre-pricing & reimbursement, incident renal disease cohort (study observation period 2020- 2024)|"Incident renal disease patients in this cohort are defined as those that newly met the renal function measurement definition stated above, with first-ever registered laboratory UACR and/or eGFR measurements or CKD diagnosis on or after the start date of this cohort study period, the 1st August 2020 and until the 1 st February 2023 (DAPA\_CKD P\&R date in Spain). The first of the dates fulfilling any of the criteria defined above for the renal function measurement or CKD diagnosis, is defined as the patient index date-1 of this study cohort.~At the index date-1, the renal disease will be staged based on eGFR (and/or UACR measurements in addition, if available) as specified in the KDIGO guidelines.~Patients will be followed up from the index date-1 until the end of continuous enrolment, last date of available data or date of death, until the end of the overall observation period."
214303260|NCT04165512|COMBINATION_PRODUCT|bupivacaine and triamcinolone|a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)
214303261|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
214303262|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
214907830|NCT06614712|OTHER|Post-pricing & reimbursement, incident renal disease cohort (study observation period 2023-2024)|We define the post-P\&R cohort including all incident renal disease patients observed in the dapagliflozin-CKD post-pricing and reimbursement period. Patients in this cohort newly met the renal function measurement definition stated above, with first-ever registered laboratory UACR and/or eGFR measurements or CKD diagnosis on or after the 1 st February 2023 (DAPA\_CKD P\&R date in Spain) and until the end of the study observation period. The first of the dates fulfilling any of the criteria defined above for the renal function measurement or CKD diagnosis, is defined as the patient index date-2 of this study cohort. At the index date-2, the renal disease will be staged based on eGFR (and/or UACR measurements in addition, if available) as specified in the KDIGO guidelines. Patients will be followed up from the index date-2 until the end of continuous enrolment, last date of available data or date of death, until the end of the overall study period
215057606|NCT02274220|DIETARY_SUPPLEMENT|Rapid advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.
215057607|NCT02274220|DIETARY_SUPPLEMENT|Standard advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 3 mL every three hours for 24 hours. Bolus feeds then up-titrated by 1 mL/kg every-other feed (Q 6 hours) for 24 hours. Bolus feeds then up-titrated by 1mL/kg every feed for to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will reach target feeds by 60-63 hours after protocol initiation.
215057608|NCT01618240|OTHER|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
215057609|NCT01618240|OTHER|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
215057610|NCT05226832|PROCEDURE|40mg Triamcinolone Injections in the Bladder|Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic. Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy. Injections will be performed using a 17fr flexible cystoscope in the outpatient setting. There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline. The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip. The patient may experience discomfort with cystoscopy and injections. Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section. This is estimated to take 30 minutes.
214303263|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
215057611|NCT01148901|DRUG|Infliximab|Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
215057612|NCT06495892|DRUG|Diuretic therapy|Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach
215057613|NCT06097078|DEVICE|Eso-SPONGE®|minimally invasive treatment and prevention of anastomotic leakages and perforations in the upper gastrointestinal tract (upper GIT)
215057614|NCT05878977|DRUG|Immune checkpoint inhibitor|Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
215057615|NCT05715138|PROCEDURE|GPi-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into the posteroventral part of bilateral GPi nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
215057616|NCT05715138|PROCEDURE|STN-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
215057617|NCT05715138|DEVICE|GPi-DBS devices|"1. DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
215057618|NCT05715138|DEVICE|STN-DBS devices|"1. DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
215057619|NCT01465438|DRUG|Adalimumab|Adalimumab 40 mg every other week
215057620|NCT01503346|DRUG|DaHuang GanTsao Tang|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
215057621|NCT00502580|BEHAVIORAL|Interview|Interview taking about 10 minutes to complete.
214303264|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
214303265|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
214346923|NCT03058770|OTHER|Sensorimotor retraining|Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
214907831|NCT07053891|DRUG|Voclosporin (LUPKYNIS)|In general, for adults, voclosporin should be administered orally at a dose of 23.7 mg BID. The dosage may be appropriately reduced depending on the patient's condition. In principle, at the start of treatment with voclosporin, it should be used in combination with corticosteroids and mycophenolate mofetil.
214907832|NCT06750809|DEVICE|PermeaDerm Biosynthetic Wound Matrix|Study participants randomized (1:1) to this arm will receive PermeaDerm Biosynthetic Wound Matrix prior to skin graft.
214907833|NCT06750809|DEVICE|Frozen Human Cadaveric Allograft (FHCA)|Study participant randomized (1:1) to this arm will receive Frozen Human Cadaveric Allograft (FHCA) prior to skin graft.
214907834|NCT02269098|OTHER|Diabetes medication management|As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
214907835|NCT02155127|BEHAVIORAL|walking|
214303266|NCT04409743|BEHAVIORAL|Remote Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
214303267|NCT00123864|PROCEDURE|Intensity-modulated radiation therapy|
214303268|NCT03678467|COMBINATION_PRODUCT|EB-CMF|Autologous, anatomically shaped bone graft
214907836|NCT01766076|OTHER|atorvastatin, Lipitor®|PBMC collected for immune activation assays using flowcytometry
214907837|NCT01766076|DRUG|Placebo|PBMC collected for immune activation assays using flowcytometry
214907838|NCT00893880|DRUG|1% gaseous Nitric Oxide blended in Oxygen|1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
214907839|NCT04848155|OTHER|socially assistive robot|"The intervention group will work with the ReMIND-system. This ReMIND-system consists of:~1. An existing socially assistive robot called James® that will be adapted based on the needs of the older adults and the robot's own functionality. For example, exercise videos and games to stimulate physical and cognitive activity will be developed and made available on the robot. The robot has to be programmed by the researcher using the ZBOS Control© application on a separate tablet that is connected to the robot.~2. The Keosity-app, an application specifically designed to support people in telling, documenting and sharing their life stories with others. This application will be available on the robot."
214907840|NCT04211688|BEHAVIORAL|Group Schema therapy|Bimonthly outpatient psychotherapy delivered in individual setting
214907841|NCT04211688|BEHAVIORAL|Individual Schema therapy|weekly outpatient psychotherapy delivered in group setting
214907842|NCT04903431|BEHAVIORAL|Crisis Response Planning for Suicide Risk|Crisis Response Planning is focused on creating personalized set of steps for individuals to follow in case of a crisis and includes individuals' personal warning signs of distress, behavioral coping strategies, reasons for living, social supports to contact, and contact information for professional services, including emergency services. Personalization of the Crisis Response Plan is encouraged, and individuals are instructed to handwrite each step of the Crisis Response Plan on an index card to review.
214907843|NCT02075567|PROCEDURE|Experimental|
214907844|NCT02201004|DRUG|TOFOGLIFLOZIN CSG452|Pharmaceutical form:tablet Route of administration: oral
214907845|NCT02201004|DRUG|insulin|Pharmaceutical form:solution Route of administration: subcutaneous
214907846|NCT02201004|DRUG|placebo|Pharmaceutical form:tablet Route of administration: oral
214907847|NCT06414941|DRUG|Dexmedetomidine administration|atients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
214907848|NCT06414941|DRUG|Dexmedetomidine plus low-dose esketamine administration|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
214907849|NCT06414941|DRUG|Dexmedetomidine plus high-dose esketamine administration|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
215057622|NCT06554249|PROCEDURE|Vulsellum group|"The patients are asked to empty the bladder before IUD insertion. The vulsellum is applied on the cervix, sounding of the uterus is done and the IUD is inserted according to the standard technique of IUD insertion.~Pain intensity is assessed after the procedure using a visual analogue scale."
215057623|NCT06554249|PROCEDURE|Ultrasound group|"During the two hour period before IUD insertion, the patients are asked to drink about one liter of water and to avoid micturition.~Abdominal ultrasound is used to obtain a sagittal view of the uterus and the IUD is introduced into the uterine cavity under ultrasound guidance.~The vulsellum and uterine sound are not used during IUD insertion. Pain intensity is assessed after the procedure using a visual analogue scale.."
215057624|NCT04169204|DIAGNOSTIC_TEST|Measurement of microcirculation|As a simple clinical test, every patient will receive the assessment capillary refill time and mottling-score. Additionally, repetitive measurements of lactate will be done. The SDF-camera (MicroVision Medical®, Amsterdam, Netherlands) will measure sublingual microcirculation at different time points (Admission and 24h).
214303269|NCT00245141|BIOLOGICAL|dactinomycin|
214303270|NCT00245141|DRUG|cyclophosphamide|
214303271|NCT00245141|DRUG|vincristine sulfate|
214907850|NCT05521581|OTHER|Hand massage|Hand massage will be applied to primiparous mothers who gave birth by cesarean section and its effect on pain, comfort and gas release times will be evaluated.
214907851|NCT05011838|OTHER|1. Health Services Redesign|"1.1. Healthy Hearts service: a nursing station providing blood pressure measurement, cardiovascular risk assessment, preventive counselling and effective follow-up in extended opening hours.~1.2. Hypertension screening: All adults attending health care facilities who did not have their blood pressure measured in the previous year will be referred to the Healthy Hearts Service for screening.~1.3. Clinical management: 1.3.1. Creation of the cardiovascular risk team: a group of doctors supervising hypertension management and coordinating improvement.~1.3.2. Guideline-based standardized diagnostic and treatment protocols: a simplified diagnostic and treatment algorithm will identify a core set of primary and secondary antihypertensive medications.~1.3.3. Availability of antihypertensive medications: it will be assured through procurement mechanisms and its availability will be communicated to clinicians at the beginning of each week and ad hoc in case of stock-outs."
214907852|NCT05011838|OTHER|2. Clinical Staff Training|"2.1. Training on good clinical management of hypertension: focused on correct blood pressure measurement, use of evidence-based guidelines, cardiovascular risk assessment, use of a standardized diagnostic and treatment algorithm, correct prescription of pharmacological and non-pharmacological treatment, patient counselling, and how to tackle clinical inertia.~2.2. Training on communication skills and patients' needs assessment for all health workers involved in hypertension care. This training will be designed under the patient-centred medicine framework, aiming at equipping health providers with tools for understanding patients' feelings and experience of illness, and to improve their capacity to address social, psychological, and behavioural dimensions of hypertension care."
215057625|NCT04945525|OTHER|Care Continuity Program|The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
215057626|NCT00295789|DRUG|chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Cisplatin
215057627|NCT00295789|DRUG|chemotherapy: Paclitaxel/Carboplatin|Drug: chemotherapy: Paclitaxel/Carboplatin
215057628|NCT02712996|DRUG|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
215057629|NCT02712996|DRUG|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
215057630|NCT02778984|DEVICE|QuadraLite masks|The intervention is identical in the two group
215057631|NCT02778984|OTHER|standard mask|
215057632|NCT04815200|DEVICE|Copper Nickel titanium arch wire|Patient will receive 0.014 round Copper Nickel titanium CuNiTi archwire and will be ligated using a ligature wire.
215057633|NCT03623438|BEHAVIORAL|Self-administered acupressure group|Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.
215057634|NCT03623438|BEHAVIORAL|Sleep hygiene education (SHE) group|Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
215057635|NCT01016132|DEVICE|lotrafilcon A contact lens|Investigational silicone hydrogel, single-vision, soft contact lens worn for four weeks at least as often as and on the same basis as participant's habitual lenses, as prescribed by participant's eye care practitioner -- ie., on a daily wear, flex wear, or extended wear basis.
215057636|NCT02607410|DRUG|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
214303272|NCT00245141|RADIATION|radiation therapy|
214303273|NCT03329690|DRUG|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
214303274|NCT03329690|DRUG|Physician's Choice|"Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)"
214303275|NCT02233322|DIETARY_SUPPLEMENT|Iron|All subjects will receive iron supplementation based on iron levels in the blood
214303276|NCT04243187|OTHER|Chilean Native Beans|"In each visit the participant would have to:~1. Fill a survey of gastrointestinal symptoms and basal bowel movements (THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS))~2. Fill a survey of food consumption~3. Bean plate intake~4. Expired hydrogen test, which consists of exhaling air in a syringe every 20 minutes for 12 times (4 hours in total). During this time the participant can do quiet activities (not physical activity).~5. Fill surveys of gastrointestinal symptoms (online or on paper), during the hydrogen test, at 12 and 24 hours (3 times). During this time (1 day before and 2 days later) the participant cannot eat other bloating foods (legumes, cauliflower, broccoli, lettuce, cabbage, artichokes, onions, topinambur and others described in the food survey)."
214303277|NCT06271252|DRUG|OriCAR-017|Anti-GPRC5D CAR-T cell product
215057637|NCT02607410|DRUG|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
214303278|NCT00151320|DRUG|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
215057638|NCT04160312|DIETARY_SUPPLEMENT|Mitopure™ (Proprietary Urolithin A)|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
214907853|NCT05011838|OTHER|3. Patient and Community Engagement|"3.1. Patient empowerment: expert hypertensive patients , under the supervision of a social worker, will provide support and transmit their know-how to other patients in need, particularly those newly diagnosed or non-adherent to treatment or presenting uncontrolled hypertension.~3.2. Community engagement: a Community Hypertension Outreach Group will be set up, composed of existing voluntary community health workers, who will be trained and certified. This group will conduct blood pressure measurements in selected public areas of the commune, referring those with positive screening to the nearest health facility for diagnosis confirmation. It will also provide health information with emphasis on healthy lifestyles. Existing local communication channels such as the community radio and the local newspaper will be engaged."
214907854|NCT03194542|DRUG|Luspatercept|Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.
214907855|NCT04274933|DRUG|Venetoclax|Tablet; Oral
214907856|NCT04274933|DRUG|Capecitabine|Tablet; Oral
214907857|NCT01357837|DRUG|Matching Placebo|2 capsules of matching placebo once a day, in the morning, for a total of 28 days
214907858|NCT01357837|DRUG|GRT6005|2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
214907859|NCT01357837|DRUG|GRT6005|2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
214907860|NCT01357837|DRUG|GRT6005|2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
214907861|NCT02082015|DEVICE|Low frequency rTMS|Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
214907862|NCT02448485|PROCEDURE|Aortic Valve Intervention (surgical or transcatheter)|Surgical or interventional aortic valve implantation
214907863|NCT00155597|BEHAVIORAL|home physical therapy|
214907864|NCT01381211|DRUG|TACE-DEB|Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
214907865|NCT01381211|DRUG|90Y-RE|Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
214907866|NCT05669105|DIAGNOSTIC_TEST|Specimen sample|Participants will have up to 100 mL of whole blood collected.
214907867|NCT05359354|BIOLOGICAL|Personalized neoantigen tumor vaccine|Biological: neoantigen tumor vaccine with or without PD-1 In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1
214907868|NCT05643937|BEHAVIORAL|Routine health education|The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
214907869|NCT05643937|BEHAVIORAL|Routine health education + precise health education|On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
214907870|NCT01622647|OTHER|Nasal Continuous Positive Airway Pressure (NCPAP)|Subjects will receive NCPAP
215057639|NCT04160312|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice (approximately 1 glass equivalent)
215057640|NCT05795270|OTHER|Treatment|Nocturnal ventilotherapy, positional therapy and oro-mandibular devices
215057641|NCT00718536|DRUG|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
215057642|NCT02227810|OTHER|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
215057643|NCT02227810|OTHER|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
215057644|NCT02227810|OTHER|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
215057645|NCT01451749|DRUG|Shenwu Capsule|"1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months."
215057646|NCT01451749|DRUG|Donepezil|"This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.~Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months."
215057647|NCT04303429|DRUG|FOLFOX/XELOX/Capecitabine|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
215057648|NCT02132572|DEVICE|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
215057649|NCT03905915|DEVICE|Virtual reality (VR) session with AQUA module|A device with virtual reality is given to the patients with a film of 15 minutes
215057650|NCT04093960|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
215057651|NCT02308267|OTHER|Lung explants|Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
215057652|NCT02308267|OTHER|Sputum, nasal fluid and serum|Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
214907871|NCT05135065|OTHER|Artificial Intelligence-Assisted Supervision Protocol|Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
215057653|NCT02308267|PROCEDURE|Bronchoscopy|Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
214907872|NCT03134144|DEVICE|"Exoskeleton Chairless Chair"|One solution to reduce the exposure of employees to associated risks for developing work-related musculoskeletal disorders is to use exoskeletons. Using such a device in dynamic environments has the advantage over, e.g., robotics because it does not need any programming or teaching of robots. Moreover, exoskeletons are worn at the body and do not have to overcome spatial issues. In a recent review, 26 different exoskeletons have been described of which only two were designed to support the lower body during heavy work (de Looze et al. 2015). For lower intensive work tasks, like assembly tasks in the automobile industry, no study has focused on using exoskeletons to relieve employees while performing the work standing.
214907873|NCT02514486|BEHAVIORAL|Questionnaire|
214907874|NCT03048214|PROCEDURE|Infraclavicular nerve block|Infraclavicular nerve block is a relatively safe and straightforward brachial plexus nerve block that can be used to provide intraoperative regional anaesthesia for upper limb surgeries from the elbow to fingers.
214907875|NCT03048214|PROCEDURE|General anaesthesia|Usual practice for upper limb surgeries.
214907876|NCT05479864|PROCEDURE|anterior cervical corpectomy and fusion|removal of damaged vertebrae and intervertebral disc that are compressing the spinal cord and spinal nerves
215057654|NCT02824692|DEVICE|heart lungs and abdomen ultrasound|
215057655|NCT04691037|DIAGNOSTIC_TEST|CCTA|All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
215057656|NCT05532228|PROCEDURE|Adenotonsillectomy|adenotonsillectomy by cold dissection
215057657|NCT05481983|OTHER|Walk exercise|The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
215057658|NCT05481983|OTHER|One-on-one clinical exercise training|One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
215057659|NCT03063606|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|CBT specialist treatment
215057660|NCT03063606|DRUG|NB Medication (on-going from acute treatment)|Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
215057661|NCT04944615|PROCEDURE|The guidewire successfully passed the CTO lesion|"The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery."
215057662|NCT03079531|DRUG|Secukinumab|Secukinumab 300 mg administered subcutaneously.
215057663|NCT01941927|DRUG|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
215057664|NCT01941927|DRUG|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
215057665|NCT02288299|DEVICE|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
215057666|NCT05207748|DIAGNOSTIC_TEST|Bone mineral density|Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.
215057667|NCT05135572|DIAGNOSTIC_TEST|Fibromiyalgia and foot pain|Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
215057668|NCT06059807|DEVICE|maxillary expansion|Maxillary Expansion Using Hyrax and Hybrid Hyrax Appliances
214346924|NCT03058770|OTHER|Relaxation technique|Subjects will perform guided relaxation by using the Jacobson technique.
214907877|NCT04020666|DRUG|Urinary Kallidinogenase|
214907878|NCT01611883|DRUG|Ezetimibe|10 mg oral dose once daily for 24 weeks
214907879|NCT01611883|DRUG|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks.
215057669|NCT01170234|DEVICE|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
215057670|NCT02798744|DRUG|Empagliflozin|25mg once daily to be taken orally for the duration of the study (24 weeks)
215057671|NCT02798744|BEHAVIORAL|Diet|Daily energy restriction diet to be followed for the duration of the study (24 weeks)
215057672|NCT02798744|DRUG|Placebo|Placebo once daily for the duration of the study (24 weeks)
214907880|NCT01955928|BEHAVIORAL|Online Cognitive behavioral treatment for insomnia|
214907881|NCT00000162|PROCEDURE|Macular Argon Laser Photocoagulation|
214907882|NCT00000162|PROCEDURE|Peripheral Scatter Argon Laser Photocoagulation|
214907883|NCT00000162|PROCEDURE|Scatter Argon Laser Photocoagulation|
214907884|NCT05159531|DRUG|PrEP|Participants will receive Descovy® 200/25mg 1 tablet once daily for 72 weeks.
214303279|NCT00540345|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
214303280|NCT00540345|DRUG|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
215057673|NCT05363722|DRUG|IBI310（0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W
214907885|NCT05159531|OTHER|mHealth Model of Care|Freddie® allows for asynchronous contact between patients and care providers, meaning that it does not require both groups to be connected in real time, instead allowing communication over a number of days.
214907886|NCT05159531|OTHER|Standard of Care|Delivery of PrEP care through the local standard of care
214907887|NCT06780007|DIETARY_SUPPLEMENT|Probiotic|The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).
214907888|NCT06780007|DIETARY_SUPPLEMENT|Placebo|The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).
214907889|NCT06897358|DRUG|Leniolisib|Planned dose will range from 10 mg twice daily to 70 mg twice daily
214907890|NCT06779630|DEVICE|Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System|Orsiro Mission is composed of a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
214907891|NCT06802185|DRUG|ADA Liquid Filled Capsules (Test Product)|ADA liquid filled capsules containing 125 mg ibuprofen and 250 mg acetaminophen.
214907892|NCT06802185|DRUG|ADA Caplets (Reference Product)|ADA Caplets containing 125 mg ibuprofen and 250 mg acetaminophen.
214907893|NCT06802185|DRUG|Advil Liqui-gels (Reference Product)|Advil Liqui-gels containing 200 mg ibuprofen.
214907894|NCT01358461|BIOLOGICAL|Blood sampling|Blood sampling
214907895|NCT01358461|OTHER|ECG-Holter 24 h tape and sino-carotid stimulation test|ECG-Holter 24 h tape and sino-carotid stimulation test
214907896|NCT03757312|DIAGNOSTIC_TEST|Ultrasound|Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
215057674|NCT05363722|DRUG|IBI310（0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W
215057675|NCT05363722|DRUG|sintilimab|sintilimab 200 mg IV d1 Q3W
215057676|NCT05363722|DRUG|bevacizumab|bevacizumab 15 mg/kg IV d1，Q3W
215057677|NCT03785353|BEHAVIORAL|PNE lecture|A translated (from English to Spanish) lecture on Pain Neuroscience Education
215057678|NCT04369456|OTHER|blood sample|a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms
214303281|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
214303282|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
214303283|NCT03822676|DEVICE|Prophylactic pancreatic stent|Prophylactic pancreatic stent before segmental pancreatic surgery
214303284|NCT00188513|PROCEDURE|conformal intensity modulated radiotherapy (IMRT)|
214907897|NCT06673043|DRUG|Anifrolumab|Anifrolumab 300 mg concentrate for solution for infusion
214907898|NCT06004245|DRUG|RO7589831|RO7589831 will be administered orally and once daily (QD) in 3-week cycles.
214907899|NCT06004245|DRUG|Pembrolizumab|Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.
214907900|NCT07082725|DRUG|Nizubaglustat|AZ-3102
214907901|NCT07082725|DRUG|Placebo|Matching placebo
214907902|NCT04351958|BEHAVIORAL|"Experimental: Augmented Reality (No Time Wasted)"|"No Time Wasted will be an innovative, immersive intervention using novel technology that will captivate the target audience with narrative and gaming elements to scaffold the educational message."
214907905|NCT06237920|DRUG|Nivolumab|Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
214907906|NCT06237920|DRUG|Relatlimab|Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
214907907|NCT07137728|DEVICE|Dual Frequency Low-Level Laser Therapy|DF-LLLT (830 nm, 100 mW/cm², 9.12 Hz, 5 J/cm²) applied over each identified trigger point for 3 minutes 9 seconds per point, twice weekly for 4 weeks.
215057679|NCT04062981|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
215057680|NCT04690218|DIAGNOSTIC_TEST|Hospital anxiety and depression scale|Self assessment scale suitable for hospital community as well as public community. Applying the scale does not require any psychopathologic training.
215057681|NCT04690218|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index|Self assessment scale for public community. Applying the scale does not require any specially trained personnel.
215057682|NCT04690218|BEHAVIORAL|Nutritional Status Questionnaire|It consists of 26 items, questioning the frequency and amount of certain nutritional elements (ones known to worsen and benefit mastalgia) consumed by the individual.
215057683|NCT01704508|DRUG|Artemether-lumefantrine|
215057684|NCT01704508|DRUG|Dihydroartemisinin-piperaquine|
215057685|NCT03519724|DRUG|Sugammadex|Reversal of deep NMB
215057686|NCT03519724|DRUG|Neostigmine|Reversal of moderate NMB
215057687|NCT02454530|BIOLOGICAL|Nivestim®|
214907908|NCT07137728|DEVICE|Sham Laser|Inactive laser device identical in appearance and sound to the active laser but without light emission, applied for 3 minutes 9 seconds per point, twice weekly for 4 weeks.
214907909|NCT07137728|OTHER|Conventional Therapy (Stretching and Strengthening Program)|A standardized physiotherapy program including stretching and strengthening exercises for the cervical and shoulder muscles. The program is performed under physiotherapist supervision twice weekly for 4 weeks. Exercises are identical across both study arms and include stretching of the upper trapezius and strengthening of the neck and scapular stabilizer muscles.
214907910|NCT06906042|RADIATION|Imaging examinations|"* Cardiovascular MRI~* Hepatic MRI~* Hepatic ultrasound"
214907911|NCT06906042|OTHER|Paramedical examinations|"* Urinary pregnancy test for women of childbearing age.~* Blood sample for cardiometabolism profiling~* Blood samples for biobanking (according to the information and consent form)~* Impedancemetry~* AGE reader: combined non-invasive measurement of aging and accumulation of glycated proteins in the subcutaneous tissue will be performed with a CE-marked device."
214907912|NCT06906042|OTHER|Medical examination|"* Review of risk factors~* Review of previous history~* Recording of current medication (dci, dose, start date)~* Recording of medication in the last 6 months and discontinued since (dci, dose, start date)"
214907913|NCT06906042|OTHER|Echocardiography|Echocardiography including: 12-lead digital ECG
214907914|NCT05649943|DRUG|APA + ADT|"All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment."
214907915|NCT05649943|PROCEDURE|Local Treatmetn RT or RP|"Patients who will undergo radiotherapy as a local treatment must be treated according to the following scheme:~External beam radiotherapy administered at 36 Gy in six consecutive weekly fractions of 6 Gy, or 55 Gy in 20 daily fractions of 2・75 Gy over 4 weeks.~Radiation therapy will be given with the patient supine and with a full bladder and an empty rectum. The planned target volume is prostate only, with an 8 mm margin posteriorly and a 10 mm margin elsewhere.~No RT on lymph nodes is foreseen. RT should begin 6 months after the first dose of apalutamide (+/- 2 weeks).~Radical prostatectomy should be performed 6 months after the first dose of apalutamide (+/- 2 weeks)."
214907916|NCT03929289|BEHAVIORAL|Social Facilitation|During the functional Magnetic Resonance Imaging (fMRI) scans, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
214907917|NCT06909071|DEVICE|Hybrid Closed-Loop Artificial Pancreas System|The total daily insulin requirement is calculated as 0.3 - 0.6 U/(kg·d) according to patient's weight. The system automatically adjusts the basal rate during operation. Nurses enter bolus dose orders in AAPS software as directed by physicians. Blood glucose is monitored via continuous glucose monitoring and 4 daily fingerstick measurements (fasting and 2 hours after each meal).
214907918|NCT07102615|DRUG|Intracervical injection of Vasopressin|Intracervical injection of Vasopressin
214907919|NCT07102615|DRUG|Intracervical Injection of saline|Intracervical Injection of saline
214907920|NCT06773767|DRUG|150 mg trazodone hydrochloride|To compare the bioavailability of 150 mg trazodone hydrochloride tablets (new polymer) vs. 150 mg trazodone hydrochloride Contramid® tablets at steady-state.
214907921|NCT06773767|DRUG|300 mg trazodone hydrochloride|To compare the bioavailability of 300 mg trazodone hydrochloride tablets (new polymer) vs. 300 mg trazodone hydrochloride Contramid® tablets at steady-state
214907922|NCT07102641|DRUG|Acetaminophen|Acetaminophen 1000 mg q6H
214907923|NCT07102641|DRUG|NSAID (Ketorolac/Ibuprofen)|NSAID (ketorolac 30 mg q6H for first 24 hours post-op followed by ibuprofen 600 mg q6H)
214907924|NCT06911749|DIAGNOSTIC_TEST|MSOT with ICG|Application of Multispectral Optoacoustic Tomography (MSOT) in combination with the oral contrast agent Indocyanine Green (ICG) to measure gastrointestinal transit time
214907925|NCT06911749|DIAGNOSTIC_TEST|MRI|Non-invasive MRI imaging technique will be employed to assess the peristalsis of intestinal segments
214907926|NCT06439836|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214907927|NCT06439836|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214907928|NCT06439836|PROCEDURE|Computed Tomography|Undergo CT
214907929|NCT06439836|BIOLOGICAL|Emavusertib|Given PO
214907930|NCT06439836|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214907931|NCT06439836|BIOLOGICAL|Pembrolizumab|Given IV
214907932|NCT06439836|PROCEDURE|Positron Emission Tomography|Undergo PET
214907933|NCT06236815|DRUG|Delta-9-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
214907934|NCT06236815|DRUG|Delta-8-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
215057688|NCT04124094|DRUG|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
215057689|NCT04124094|DRUG|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
215057690|NCT04124094|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
214907935|NCT06236815|DRUG|Placebo|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
214907936|NCT07111117|PROCEDURE|18F-MFBG PET/CT imaging|Participants will receive the 18F-MFBG tracer and undergo a PET/CT imaging.
214907937|NCT07110844|DRUG|Teclistamab|Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.
214303285|NCT03202147|DRUG|Cromolyn|Active capsules for inhalation.
214907938|NCT07110844|DRUG|Daratumumab and Hyaluronidase-fihj|Daratumumab is an monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.
214907939|NCT00109174|DEVICE|3T and 7T device|3T and 7T device
214907940|NCT06922630|BEHAVIORAL|WIN|Weight-neutral health intervention
214907941|NCT07113509|PROCEDURE|mechanical polishing|mechanical polishing of implant resin crowns with polishing paste and discs
214907942|NCT07113509|PROCEDURE|glazing|glaze liquid application followed by light-curing of the resin implant crowns
214907943|NCT07114900|BEHAVIORAL|PA4Health app physical activity intervention|PA4Health app intervention Arm Description: During the app intervention consists of six components: 1) Goal setting and monitoring, 2) Tailored motivational messages based on survey data on barriers and facilitators of physical activity, 3) Education, which consists of twenty-two physical activity (PA) related topics, 4) a semi-structured chatroom where 3-5 participants per chatroom interact with one another to receive and provide peer support for PA, 5) Locator, which provides information about community resources (e.g., community parks, museums) based on participant's zip code, and 6) Steps, which allow participant to monitor their daily level of exercise. Participants wear a Fitbit tracker during the program
214907944|NCT07114900|BEHAVIORAL|Wellness Text Messaging Program|Participants set goal for PA and are encouraged to monitor their level of physical throughout the program. They receive a daily wellness related message during the program as a contact control. They also wear Fitbit tracker during the program.
214907945|NCT07116148|OTHER|The Homeostasis-Enrichment-Plasticity (HEP®) Approach|The HEPApproach intervention and clinical reasoning process follow a systematic order based on the data-driven decision-making model. There are 11 phases to the HEP Approach process. Phase 1 involves referral to the program. Phase 2 includes a meeting with the family to introduce them to the HEP Approach. Phase 3 is a comprehensive assessment of the child and family systems. Phase 4 is the identification of family and child strengths and challenges based on the assessment. Phase 5 involves formulating hypotheses about how underlying factors or systems impact the child's challenge areas. Phases 6 and 7 include collaborative goal setting and outcome measure identification with the family. Phase 8 is intervention planning. Phase 9 implements the intervention through an individualized process that generally involves four steps that prioritize different areas of need (e.g., self-regulation and homeostasis of the child, adaptation of the physical and social home environment to support succes
214907946|NCT05927545|PROCEDURE|Patient education and preventive exercise|Educational training program and prevention exercises about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
214907947|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with Manual Therapy protocol|Manual therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
214907948|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with BETY approach|BETY therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
214907949|NCT05009602|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
214907950|NCT05009602|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery.
214907951|NCT05009602|DIAGNOSTIC_TEST|Exercise Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery, following the participant completing 50 consecutive repetitions of active dorsiflexion whilst standing.
214907952|NCT05009602|DIAGNOSTIC_TEST|Audible handheld Doppler|Audible CW Doppler interrogation of the dorsalis pedis and posterior tibial artery.
214907953|NCT05009602|DIAGNOSTIC_TEST|Visual handheld Doppler|Visual CW interrogation of the dorsalis pedis and posterior tibial artery was performed using the handheld Huntleigh Digital Dopplex device.
214907954|NCT05009602|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|"Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.~To be used in 3 participating centers only."
214907955|NCT07120152|DRUG|Subcutaneous infliximab CT-P13 Remsima®SC|Subcutaneous infliximab
214907956|NCT01954576|DEVICE|NovoTTF-100A|
214907957|NCT01954576|PROCEDURE|Quality-of-life assessment|
214907958|NCT01954576|GENETIC|Laboratory biomarker analysis|
214907959|NCT06932302|DEVICE|Electrical Stimulation|Electrical stimulation of the dorsal genital nerve will be accomplished using the UCon system and patch electrodes developed by InnoCon. The UCon system includes a programmable control unit; leads that connect to the control unit and electrodes; a silicone surface electrode; a reference electrode; and a remote control for quick on and off toggling of stimulation.
214907960|NCT06932302|DEVICE|Smart vibrator|Subjects will use a smart vibrator at home twice a week during the study. The Lioness smart vibrator records physiological responses during use.
214907961|NCT07116499|DRUG|Placebo|Single oral dose of matching placebo
214303286|NCT03202147|OTHER|Placebo|Non-active capsules for inhalation.
214303287|NCT02882555|BEHAVIORAL|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity \<10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
214907962|NCT07116499|DRUG|K-645 dose level 1|Single oral dose of K-645 dose level 1
214907963|NCT07116499|DRUG|K-645 dose level 2|Single oral dose of K-645 dose level 2
215057691|NCT00055926|DRUG|CP-724,714|
215057692|NCT00543270|DEVICE|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
215057693|NCT00543270|PROCEDURE|Open Surgery|Open surgical abdominal aortic aneurysm repair
215057694|NCT00175565|DRUG|inhaled fluticasone 500 mcg b.i.d.|
215057695|NCT04923334|BEHAVIORAL|Brief Pain Teleconsult|The Brief Pain Teleconsult intervention includes 2 sessions provided by a licensed physical therapist over about 1 week. The sessions focus on pain education from a biopsychosocial perspective that is designed to address negative pain appraisals and catastrophizing thoughts, providing advice to be active and engage in exercise and physical activity, and reassurance that activity is beneficial and safe.
214907964|NCT07125157|BEHAVIORAL|Task-Specific Training with Biofeedback|Participants in this group will undergo task-specific training focused on improving balance and reducing fall risk. Real-time biofeedback (e.g., visual or auditory cues) will be integrated into the training to enhance motor learning and postural adjustments. Sessions will be supervised and conducted multiple times per week over the intervention period.
214907965|NCT07125157|BEHAVIORAL|Task-Specific Training without Biofeedback|Participants will receive task-specific training aimed at improving balance and fall prevention without any biofeedback assistance. The same set of functional exercises and session frequency will be followed as in the experimental group, ensuring the only difference is the absence of feedback stimuli.
214907966|NCT07133633|DRUG|Tulisokibart|Subcutaneous (SC) administration
215057696|NCT04923334|BEHAVIORAL|Telehealth Physical Therapy|The Telehealth Physical Therapy intervention involves weekly telehealth sessions provided over 10 weeks. Telehealth Physical Therapy is provided by a licensed physical therapist. Key components of the intervention include reinforcing biopsychosocial education messages and developing an exercise and physical activity program using cognitive behavioral principles such as goal setting and positive reinforcement. Pain coping strategies including mindful breathing and progressive relaxation techniques will be included.
215057697|NCT03826459|PROCEDURE|Non-Locking Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& non-locking technique. The second layer cannot be of a locking technique.
215057698|NCT03826459|PROCEDURE|Locked Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& locking technique. The second layer can be locking or non-locking.
215057699|NCT02949050|BIOLOGICAL|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
215057700|NCT02949050|BIOLOGICAL|SCIT|Treatment group consists of patients who completed \> 1 year of SCIT while control group patients did not undergo SCIT
215057701|NCT02505022|DRUG|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
215057702|NCT02505022|BEHAVIORAL|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
215057703|NCT04202666|DEVICE|convex skin barrier|Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)
215057704|NCT00265486|DRUG|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
215057705|NCT00647244|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
214303288|NCT02882555|DRUG|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
214303289|NCT02882555|DRUG|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
214303290|NCT01824186|PROCEDURE|SILC|Underwent single-incision laparoscopic cholecystectomy
214303291|NCT01824186|PROCEDURE|LC|Underwent conventional 4-port laparoscopic cholecystectomy
214907967|NCT07133633|DRUG|Placebo|SC administration
214907968|NCT07139873|DRUG|DZD8586|Orally, 50 mg, once daily until treatment discontinuation criterion is met.
214907969|NCT07139873|DRUG|Bendamustine|Administered intravenously
214907970|NCT07139873|DRUG|Idelalisib|Administered orally
214907971|NCT07139873|DRUG|Rituximab|Administered intravenously
214907972|NCT06936527|BIOLOGICAL|Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI|XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously
214907973|NCT06936527|BIOLOGICAL|Drug: XS-03|XS-03 orally
214907974|NCT06936527|BIOLOGICAL|Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI|Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously
215057706|NCT00647244|DRUG|Abacavir|Abacavir 300 mg oral tablet twice daily
215057707|NCT03265145|DRUG|Stiolto Respimat|Duration - 12 months
214346925|NCT04122417|OTHER|The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby|The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
215057708|NCT03265145|DRUG|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
215057709|NCT03265145|DRUG|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
215057710|NCT03265145|DRUG|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
215057711|NCT02070328|OTHER|Registry|
215057712|NCT06353152|DRUG|Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection|single-/multiple-dose infusion
215057713|NCT00328718|DRUG|montelukast (5mg QD)|
214907975|NCT06936462|DRUG|topical cyclosporine eyedrops and hyaluronic eyedrops|topical cyclosporine eyedrops and hyaluronic eyedrops
214907976|NCT01226160|PROCEDURE|Postoperative face-down posturing|Postoperative face-down posturing for 10 days after surgery.
215057714|NCT00328718|DRUG|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
215057715|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
215057716|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
215057717|NCT00331877|PROCEDURE|family conference with bereavement information leaflet|
214907977|NCT01226160|PROCEDURE|Postoperative non-posturing group|avoid a face-up position only for 10 days after surgery
214907978|NCT05723094|RADIATION|Ga-Al-As diode laser (Ilase, USA)|The laser parameter used in previous study： Laser type：Ga-Al-As Wavelength：940 nm Emission type：Continuous Irradiation dosage/per tooth：75J/cm2 Application technique：Direct contact with the mucosa Exposure time per point：6 second Laser classification：3B Laser application time：Once in a month (4-week intervals) for the maxilla and mandibular incisors and canines Output：100Mw Diameter of the optical fiber：0.04 cm2
214907979|NCT05723094|OTHER|placebo|Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
214907980|NCT06946290|PROCEDURE|Intertransverse process block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle. ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 20 ml 0.25% levobupivacaine is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume of study medication.
214907981|NCT06946290|PROCEDURE|Sham block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany). ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 20 ml placebo is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume study drug.
214907982|NCT06952894|DEVICE|RUS Lung|The RUS Lung is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the thoracic surgical environments, allowing for the visualization of tumor, bronchovascular structures and thoracic organs during the surgical planning process and the operation. RUS Lung utilizes preoperative CT images of the patients to segment tumor, organs, blood vessels, and bronchus and reconstructs them into a 3D model. Although there is no direct intervention on the patient, the surgeon uses RUS Lung as a surgical navigation tool to simulate the surgery before performing the actual procedure.
214907983|NCT06955104|DRUG|JW0108 + C2407|JW0108 + C2407
214907984|NCT06955104|DRUG|JW0108 + C2407 placebo|JW0108 + C2407 placebo
214907985|NCT07141862|DIAGNOSTIC_TEST|RT-qPCR|Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using RT-qPCR
214907986|NCT07141862|DIAGNOSTIC_TEST|ddPCR|Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using ddPCR
214907987|NCT07152990|OTHER|Transcutaneous Oxy-Capnography|Patients will be monitored using transcutaneous oxy-capnography to evaluate the prevalence of nocturnal alveolar hypoventilation in these population. Nocturnal alveolar hypoventilation is defined with PTcCO2 \> 49 mmHg more than 10% of the time of capnographic recording.
214907988|NCT07152990|OTHER|Quality of life questionnaires|"Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, and the Patient-Reported Hypoventilation Questionnaire."
214907989|NCT07152990|OTHER|Arterial gasometry|Arterial blood gas analysis will be performed only in patients presenting nocturnal hypoventilation.
214907990|NCT07152990|OTHER|Body plethysmography|Plethysmography will be performed only in patients presenting nocturnal hypoventilation. It will be used to measure lung volume and assess pulmonary function. This non-invasive procedure involves the patient breathing into a device that measures changes in pressure within a sealed chamber.
214907991|NCT07152990|OTHER|Spirometry with reversibility test|The intervention will be performed only in patients presenting nocturnal hypoventilation. Spirometry with a reversibility test will be performed to assess lung function and evaluate the response to bronchodilators. The procedure involves measuring forced expiratory volume and forced vital capacity before and after the administration of a bronchodilator.
214907992|NCT07152990|OTHER|Clinical examination|Clinical exam will be performed only in patients presenting nocturnal hypoventilation. It will consists of standard interview/clinical examination: vital signs, cardiological, pulmonary, abdominal, neurological examination, search for clinical signs of nocturnal hypoventilation, search for signs of hypoxia/hypercapnia, pulmonary auscultation.
214907993|NCT07152977|OTHER|Radiological evolution of ano-perineal lesions by MRI|Patients selected retrospectively will have benefited from an MRI at diagnosis and a control MRI during follow-up. They will be selected during a follow-up consultation or a biotherapy injection in a day hospital. Patients selected consecutively are monitored at the Rouen University Hospital for perineal Cohn's disease, treated with Biotherapy: Infliximab, Adalimumab, Ustekinumab, Vedolizumab.
214907994|NCT07152665|BEHAVIORAL|Video-Based Education|Parents of children in the intervention group were informed that the educational videos used in the study aimed to reduce the child's pain, fear, and anxiety.
214907995|NCT07152483|DIETARY_SUPPLEMENT|High resistant starch staple foods|Participants in the intervention group will intake high resistant starch staple foods (achieving daily intake of ≥28g resistant starch)
214907996|NCT07152483|DIETARY_SUPPLEMENT|Regular starch staple foods|Participants in the control group will intake isocaloric regular starch staple foods
214907997|NCT07151482|DIETARY_SUPPLEMENT|Collagendep|The purpose of this study is to evaluate the improvement of quality of life, vulvovaginal atrophy (VVA) and of initial Urinary Incontinence (UI) in menopausal women with GSM symptoms following oral administration of a food supplement treatment containing 2.5 g of BCP® and other functional ingredients taken once daily over a period of 16 weeks.
214346926|NCT02385448|DRUG|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
214907998|NCT07151885|DIAGNOSTIC_TEST|SHAPE|Use an ultrasound probe to scan the liver to locate the portal vein and hepatic vein. In the angiography mode, the portal vein and hepatic vein of the same depth were selected for measurement respectively. Ultrasound contrast agent was injected through the elbow vein to observe the changes of sub-harmonic signals in the portal vein and hepatic vein. Collect the sub-harmonic signal data of the portal vein and hepatic vein, and calculate the difference between the two, that is, the SHAPE gradient.
214907999|NCT07151768|DIAGNOSTIC_TEST|Observational Study|"* assignment of PVD-B65 score derived from standard of care testing~* no therapeutic intervention or other treatment"
214908000|NCT07151430|DEVICE|Service Package Group|patients receive comprehensive multimorbidity management service package (digital tools, MDT decision support, lifestyle interventions, long-term management tools).
214908001|NCT07151313|DEVICE|Bee Venom Phonophoresis|Ultrasound therapy device
214908002|NCT07151313|DRUG|Standard Care (oral decongestants + saline nasal irrigation)|(oral decongestants + saline nasal irrigation)
214908003|NCT07151313|BIOLOGICAL|Bee Venom Phonophoresis|bee venom extract prepared for topical use)
214908004|NCT07151898|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT|Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two and/or four cycles of Trop2-ADC therapy.
214908005|NCT07151833|DIETARY_SUPPLEMENT|GlucoBites (with Gynura procumbens)|Participants receive 4 cookies per day for 12 weeks. The cookies contain standardized Gynura procumbens extract.
214908006|NCT07151833|DIETARY_SUPPLEMENT|Control Cookies (without Gynura procumbens)|Participants consume 4 cookies per day for 12 weeks. The cookies are identical in packaging, size, weight, and flavor to the GlucoBites cookies but do not contain Gynura procumbens.
214908007|NCT07152275|DEVICE|Percussive Therapy|"Percussive therapy will be administered using the Hypervolt Go 2 Black, a massage gun commonly used in clinical and athletic settings.~Participants will lie in a prone position on a treatment table. To promote hamstring muscle relaxation, a support roll will be placed under the ankle. The intervention will be delivered by the same researcher for all participants to ensure consistency. Using the round head attachment, percussive therapy will be applied longitudinally along the hamstring muscle group (from proximal to distal) for a total of 120 seconds per leg. Specifically, 60 seconds will be applied to the semitendinosus and semimembranosus, and 60 seconds to the biceps femoris. The same procedure will then be repeated on the opposite leg."
214908008|NCT07152314|DIAGNOSTIC_TEST|Digital plaque quantification using intraoral scanner|Participants will undergo three-dimensional intraoral scanning at three time points during a single session: initial scanning (T0), after biofilm disclosure with plaque disclosing solution (T1), and after supervised toothbrushing (T2).
214908009|NCT07151677|DEVICE|tDCS (active)|The investigators will administer active tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For active tDCS, the current will slowly be increased to 2mA and applied for 20 minutes.
214908010|NCT07151677|BEHAVIORAL|Attention-focused sentence comprehension treatment|This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. Participants will receive 10 sessions of this treatment.
214908011|NCT07151677|BEHAVIORAL|Sentence comprehension treatment|This is a specific type of speech-language therapy that focuses on improving auditory comprehension . Participants will receive 10 sessions of this treatment.
214908012|NCT07151677|DEVICE|tDCS (sham)|The investigators will administer sham tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For sham tDCS, the current will slowly be increased to 2mA over the course of 30 seconds and then immediately ramped back down to zero.
214908013|NCT07152145|DEVICE|Active stimulation tSCS|Active transcutaneous spinal cord stimulation (tSCS) delivered with the SCONE™ device. Electrical currents are applied non-invasively through surface electrodes placed on the skin over the spine. Sessions are combined with standardized upper limb rehabilitation therapy. Participants receive stimulation twice per week for 12 weeks.
214908014|NCT07152145|DEVICE|Sham: stimulations using a non-active electric stimulation|Sham stimulation delivered with the SCONE™ device, using identical setup and procedures as the active intervention but without effective current. This procedure is designed to mimic the sensation and experience of active stimulation while delivering no therapeutic neuromodulation. Participants also perform standardized upper limb rehabilitation therapy twice per week for 12 weeks.Transcutaneous Spinal Cord Stimulation (tSCS) - Sham (SCONE™)
215057718|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]
215057719|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]
215057720|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]
215057721|NCT02095392|DIETARY_SUPPLEMENT|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
215057722|NCT05698394|DRUG|Esketamine|0.2 mg/kg S-ketamine in 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth
215057723|NCT05698394|DRUG|Placebo|20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
214346927|NCT02385448|DRUG|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
214346928|NCT04711265|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|Intramuscular injection with 3 doses of QHPV
215057724|NCT06614036|DRUG|Remimazolam|Byfavo 20 mg powder for solution for injection, remimazolam. Each vial contains remimazolam besylate equivalent to 20 mg remimazolam. Concentration after reconstitution: 2.5 mg/ml.
215057725|NCT06614036|DRUG|Midazolam|Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.
215057726|NCT05593315|OTHER|Mindfulness and Buteyko techniques|Joint implementation of a general relaxation program and a respiratory rehabilitation program in patients with poorly controlled asthma.
215057727|NCT03469622|DEVICE|EndoRings|EndoRings-assisted colonoscopy
215057728|NCT03469622|DEVICE|Standard colonoscopy|Standard colonoscopy without any additional devices
215057729|NCT01163305|DRUG|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
214303292|NCT01808053|DEVICE|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
214303293|NCT00212823|DRUG|almotriptan malate|
214303294|NCT02395796|PROCEDURE|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
214303295|NCT03176992|DRUG|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
214303296|NCT03458533|PROCEDURE|Bariatric surgery|
214908015|NCT07152145|BEHAVIORAL|Occupational/Upper Limb Rehabilitation Therapy|Standardized occupational therapy program focused on upper limb function. Sessions are delivered in combination with either active or sham transcutaneous spinal cord stimulation.
214908016|NCT07153120|DEVICE|Erich Arch Bars|Stainless steel plates with hooks for wire placement are adapted over the facial aspect of teeth so the wires would be inserted to go around the necks of teeth (circumdental wiring), then both maxillary and mandibular plates are ligated to each other in order to achieve MMF.
214908017|NCT07153120|DEVICE|Hybrid Arch Bars|Screw retained titanium plates with hooks for wires are adapted properly then self drilling self locking screws will be drilled in between roots of teeth to avoid injury, after fixation both jaws will be wired to accomplish MMF
214908018|NCT07153120|DEVICE|IMF Screws|A total of four self drilling screws two in the maxilla and the other two in the mandible will be inserted in the bone above and below teeth roots apices to avoid injury, to be ligated to each other in a vertical and an X pattern to achieve MMF.
214303297|NCT03458533|BEHAVIORAL|Diet and lifestyle changes|
214303298|NCT02302651|DEVICE|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
214303299|NCT01687491|DRUG|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
214303300|NCT01687491|DRUG|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
214303301|NCT04626869|OTHER|Evaluation of Diaphragm Movement|Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.
214303302|NCT04738110|OTHER|MRI|Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC
214303303|NCT06477601|OTHER|Assigning cooling agent type cigarettes|This study is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol cigarettes but allows cooling agent cigarettes.
214303304|NCT06477601|OTHER|Assigning traditional tobacco type cigarettes|This comparison group is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol and cooling agent cigarettes.
214303305|NCT06477601|OTHER|Assigning menthol type cigarettes|This comparison group is for where the Food and Drug Administration does not ban menthol cigarettes.
214303306|NCT02418468|DRUG|Indacaterol|Indacaterol 150µg capsules for inhalation daily
214303307|NCT02418468|DRUG|Placebo|Matching placebo indacaterol capsules for inhalation daily
214303308|NCT02914769|DRUG|Ayahuasca|patients will receive a single dose of ayahuasca.
214908019|NCT07152392|DRUG|IBI311|IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 500-mg glass vials as a Injection solution containing.
214908020|NCT07152392|OTHER|Follew-up|recived follow-up every six months
214908022|NCT07153146|DRUG|PN-881 Oral Solution|PN-881 Oral Solution
214908023|NCT07153146|DRUG|PN-881 Oral Tablet|PN-881 oral tablet
214908024|NCT07153146|DRUG|Placebo|Placebo
214303309|NCT02914769|DRUG|placebo|patients will receive a single dose of a passive placebo.
214303310|NCT05044754|PROCEDURE|Local treatment of the prostate (SCAP or HIFU)|Once the local involvement of the recurrent prostate cancer is confirmed, patient will undergo local treatment of the prostate (SCAP or HIFU)
214303311|NCT05219929|DRUG|Tetracycline 500 Mg|500 mg three times daily
214303312|NCT05219929|OTHER|Placebo|Placebo for Tetracycline given same way as Tetracycline.
214303313|NCT06268561|OTHER|Visual acuity analysis|Collection of information on visual acuity from the medical file concerning the surgery
215057730|NCT01643057|DEVICE|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
215057731|NCT05954949|PROCEDURE|Adenomas detection rate with the different observation methods|Films performed in white light high definition, NBI and indigo-carmine dye, will be compared blindly to detecte number of adenomas with the different observation methods
215057732|NCT01327235|DRUG|Endostar|intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
214908027|NCT07152769|DRUG|Iparomlimab and Tuvonralimab + GC|Iparomlimab and Tuvonralimab: 5mg/kg, iv, q3w; Gemcitabine: 1000 mg/m2，iv，d1、d8，q3w; Cisplatin: 25 mg/m2，iv，d1、d8，q3w
214908028|NCT07152769|DRUG|Sintilimab + GC|Sintilimab: 5mg/kg, iv, q3w; Gemcitabine: 1000 mg/m2，iv，d1、d8，q3w; Cisplatin: 25 mg/m2，iv，d1、d8，q3w.
214908029|NCT07151326|DRUG|Cabozantinib|All patients will be treated with cabozantinib at 60 mg once daily.
215057733|NCT01327235|DRUG|Cisplatin|cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
215057734|NCT03159468|BEHAVIORAL|Cognitive Restructuring|Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
214908030|NCT07152574|DEVICE|TAVR using a tele-operated Robot|TAVR procedure with TAVIPILOT tele-operated robot by Caranx Medical enhancing the precision of transcatheter aortic valve positioning during TAVR.
214908031|NCT07152236|BIOLOGICAL|CAR-T|Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
214908032|NCT07152522|OTHER|cross sectional observational|the therapist measured ROM in six directions: flexion, extension, right and left side bending, and right and left rotation to investigate the association between NDI and ROM of cervical spine
214908033|NCT07152925|DEVICE|Beta-frequency transcranial alternating current stimulation|Active beta-frequency transcranial alternating current stimulation: 20 Hz tACS delivered through a 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak, 100 % intensity, gradually ramped up over 30 s, maintained for 20 min, then ramped down over 30 s; two sessions per day with at least 4 h between sessions, repeated for 7 consecutive days (14 total sessions).
214908034|NCT07152925|DEVICE|sham beta-frequency transcranial alternating current stimulation|Sham transcranial alternating current stimulation: identical 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak current ramped up over 30 s and immediately ramped down to 0 mA, followed by 19.5 min of no stimulation to match the 20-min session duration of active tACS; delivered twice daily (≥4 h apart) for 7 consecutive days (14 total sessions).
215057735|NCT03159468|BEHAVIORAL|Mindfulness|Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
215057736|NCT03159468|OTHER|Alcohol consumption|Participants consume an alcoholic beverage in the lab.
215057737|NCT00475553|OTHER|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
215057738|NCT00475553|OTHER|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
215057739|NCT06521385|DEVICE|Makani Science Respiratory Monitoring System|Subjects monitored by the Makani Science Respiratory Monitoring System
215057740|NCT05414448|DEVICE|ENDOCUFF|ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
215057741|NCT01120470|DRUG|OGX-427|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
214303314|NCT06268561|OTHER|Intraocular pressure analysis|Collection of information on intraocular pressure from the medical file concerning the surgery
214908035|NCT07152509|OTHER|Observational Assessment|The demographic, clinical, and personal characteristics of the individuals will be collected and recorded through a questionnaire. For all participants, body fat percentage (%), skeletal muscle mass percentage (%), visceral fat percentage (%), and resting metabolic rate (kcal), measured using the Omron Body Composition Monitor, will be recorded. Waist and hip circumference will be measured with a tape measure; lower extremity muscle strength (M. Quadriceps) will be assessed with a muscle hand-held dynamometer; grip strength will be assessed with a hand grip dynamometer; physical activity level will be evaluated using the International Physical Activity Questionnaire-Short Form (IPAQ-SF); functional capacity will be measured with the 6-Minute Walk Test (6MWT); postural stability and balance will be assessed with the Biodex Balance System; clinical balance will be assessed with the Berg Balance Scale; quality of life will be evaluated using the Nottingham Health Profile (NHP)
214908036|NCT07152873|DRUG|AD-117|AD-117 1Tab., Per Oral
214908037|NCT07152873|DRUG|AD-117A|AD-117A 1Tab., Per Oral
214908038|NCT07152457|OTHER|No intervention|None intervention
214908039|NCT07151690|DRUG|anti-BCMA/CD3 bispecific antibody|CM336 is a bispecific T-cell engager targeting B-cell maturation antigen (BCMA) and CD3. In this study, CM336 is administered subcutaneously with a step-up dosing strategy in Cycle 1 (3 mg Day 1, 20 mg Day 4, 40 mg Day 8 and onwards weekly). Patients who achieve ≥VGPR by Cycle 4 may switch to 80 mg every two weeks from Cycle 5. The total treatment duration is up to 12 cycles (28 days per cycle), with follow-up for safety and efficacy endpoints including hematologic and organ response.
214908040|NCT07152171|BEHAVIORAL|Pain Neuroscience Education During Aerobic Exercise|Participants will cycle on an ergometer for 20-30 minutes at light intensity (Borg CR10 = 3; 40-50% HRmax). During cycling, they will receive interactive pain neuroscience education delivered by a therapist, including neurobiology of pain, central sensitization, and self-management strategies. Visual aids and metaphors will be used to facilitate understanding.
214908041|NCT07152171|BEHAVIORAL|Aerobic Exercise Alone|Participants will perform 20-30 minutes of supervised cycling on an ergometer at light intensity (Borg CR10 = 3; 40-50% HRmax). No educational content will be provided. Sessions will include warm-up, main phase, and cool-down, matched in duration and intensity to the experimental group.
215057742|NCT01120470|DRUG|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427"
215057743|NCT00802997|DEVICE|Sinergy|radiofrequency denervation
215057744|NCT00802997|DEVICE|Placebo sham|sham procedure
215057745|NCT03706742|BEHAVIORAL|Mailed outreach|The investigators will randomize all baby boomer patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
215057746|NCT04524715|DEVICE|Non-invasive red LLLT treatment to chest of patient.|Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
215057747|NCT04524715|DEVICE|Sham Device Treatment|Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
214303315|NCT06268561|OTHER|Analysis of optical coherence tomography (OCT) images|Collection and analysis of optical coherence tomography (OCT) images of the medical file concerning the surgery
214303316|NCT06268561|OTHER|Analysis of retinograms|Collection and analysis of retinography images of the medical file concerning the surgery
215057748|NCT03280303|OTHER|non-interventional|
215057749|NCT05315115|OTHER|Sham intervention|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust.
215057750|NCT05315115|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
215057751|NCT05315115|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
215057752|NCT05730556|DEVICE|Nerivio ®|Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.
215057753|NCT05730556|DEVICE|Sham|Electrical stimulation to mimic study treatment intervention
215057754|NCT02700035|OTHER|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
215057755|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
214303317|NCT05494450|DEVICE|ExufiberAG+|confirm performance and safety of the Exufiber Ag+ dressing in medium to high exuding chronic wounds
214303318|NCT02935608|DRUG|BIIB074|Administered as specified in the treatment arm
214908042|NCT07151495|DIAGNOSTIC_TEST|Speckle tracking and 2D echocardiography|The study will involve only the collection of data obtained from routine clinical procedures and a telephone follow-up. Preoperative echocardiographic data and pre-operative left atrial speckle tracking data will be retrieved
214908043|NCT07152405|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
214908044|NCT07152405|DRUG|Investigator's choice of chemotherapy|Administration by intravenous infusion for a cycle of 2 or 3 or 4 weeks.
214908045|NCT07152444|DRUG|QLS1410 (CYP11B2 inhibitor)|QLS1410 tablets
214908046|NCT07152444|DRUG|placebo|Matching placebo tablets
214908047|NCT07152899|OTHER|Unilateral anodal tDCS|Evaluates the effects of unilateral, anodal tDCS applied to the swallowing motor cortex in post-stroke patients with dysphagia
214908048|NCT07152899|OTHER|Bihemispheric anodal tDCS|Evaluates the effects of bihemispheric, anodal tDCS applied to the swallowing motor cortex in post-stroke patients with dysphagia and in Parkinson's disease-related dysphagia
214908049|NCT07152899|OTHER|Sham tDCS|Evaluates the effects of Sham tDCS applied to the swallowing motor cortex in post-stroke patients with dysphagia and in Parkinson's disease-related dysphagia
214908050|NCT07152899|OTHER|NMES + swallowing therapy|Examines the effects of NMES therapy on swallowing function in both post-stroke and Parkinson's disease patients
214908051|NCT07152899|OTHER|Sham NMES + swallowing therapy|Examines the effects of Sham therapy on swallowing function in both post-stroke and Parkinson's disease patients
214908052|NCT07151560|DRUG|6 cycle RC48 and JS001|Different medication cycles
214908053|NCT07151560|DRUG|12 cycle RC48 and JS001|Different medication cycles
214908054|NCT07152587|DRUG|Low dose steroids|Receive 0.5mg/kg Methylprednisolone
214303319|NCT02935608|DRUG|Placebo|Matched placebo
214908055|NCT07152587|DRUG|Moderate dose steroids|Receive 1.0mg/kg Methylprednisolone
214908056|NCT07152587|DRUG|Saline (0.9% NaCl)|Saline 100ml
214908057|NCT07151664|OTHER|Quality of life progression after parathyroidectomy|Study the progression of quality of life
214908058|NCT07153172|DRUG|INV-347|Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.
214908059|NCT07153276|DEVICE|Fractional CO2 laser (vaginal)|Vaginal fractional CO2 laser applications will be performed once a month for three consecutive months.
214908060|NCT07153276|DRUG|Promestriene Vaginal|Patients in the group treated with promestriene will apply a 10 mg vaginal capsule at night for fifteen consecutive days and, after this period, one application every three days, until completing six months of treatment.
214908061|NCT07152366|DRUG|IBI311|IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 10-mL glass vials as a Injection solution containing.
214908062|NCT07152366|DRUG|Glucocorticoids|500mg methylprednisolone was intravenously injected once a day for 3 consecutive days. The next treatment was carried out with an interval of 2 weeks for a total of 8 times.
214908063|NCT07152340|DRUG|IBI311|IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 10-mL glass vials as a Injection solution containing.
214908064|NCT07152340|DRUG|Glucocorticoids|500mg methylprednisolone was intravenously injected once a day for 3 consecutive days. The next treatment was carried out with an interval of 2 weeks for a total of 8 times.
214908065|NCT07151300|DEVICE|Ultrasound therapy unit|Ultrasound therapy unit
214908066|NCT07151300|BIOLOGICAL|Bee venom topical preparation (for phonophoresis)|Bee venom topical preparation (for phonophoresis)
214908067|NCT07151131|OTHER|Watching Cartoons|"Cartoon Group Intervention Children assigned to the cartoon group will be taken from the clinic to the preoperative room. Approximately 30 minutes before being transferred to the operating room, children will be allowed to watch a cartoon of their choice on a 60-inch screen TV placed approximately 200 cm away. The duration of the cartoon viewing session will be limited to 20 minutes.~The measurement tools used in the study will be administered at five different time points:~Immediately before watching the cartoon,~Immediately after watching the cartoon but before being transferred to the operating room,~In the postoperative period at the 60th minute,~At the 120th minute postoperatively,~And finally, at the discharge phase."
214908068|NCT07151131|OTHER|Reflexology|"Massage Group Intervention Children assigned to the massage group will be transferred from the clinic to the preoperative room. Approximately 30 minutes before being taken to the operating room, reflexology massage will be applied by the researcher physician Xxx XXXXX, who holds a valid reflexology certification. The massage will be administered to both the right and left feet, with 10 minutes per foot, for a total duration of 20 minutes.~The measurement tools used in the study will be applied at five distinct time points:~Before the massage,~Immediately after the massage but before operating room transfer,~In the postoperative period at the 60th minute,~At the 120th minute postoperatively,~And finally, during the discharge phase."
214303320|NCT01742741|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
214303321|NCT02192918|BEHAVIORAL|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
214303322|NCT02192918|BEHAVIORAL|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
214908069|NCT07151911|DRUG|abemaciclib, olaparib and endocrine therapy|Patients receiving abemaciclib, olaparib and endocrine therapy.
214908070|NCT07151404|PROCEDURE|Acupuncture at LU7 (Lieque) + Electroacupuncture|Participants will receive filiform needle acupuncture at Lieque (LU7) combined with electroacupuncture at Jiaji (Ex-B2, C4-C7) and neck-shoulder acupoints including Fengchi (GB20), Jianjing (GB21), Tianzhu (BL10), and Dazhu (BL11). Sterile disposable filiform needles (0.3 × 25 mm) will be inserted at LU7 using standard manual acupuncture technique. Electroacupuncture will be delivered with continuous wave stimulation at 60 Hz for 30 minutes per session. Treatment will be performed once daily for a total of 20 sessions over approximately 4 weeks, excluding Sundays.
214908071|NCT07151404|PROCEDURE|Electroacupuncture Only|Participants will receive electroacupuncture at Jiaji (Ex-B2, C4-C7) and neck-shoulder acupoints including Fengchi (GB20), Jianjing (GB21), Tianzhu (BL10), and Dazhu (BL11), without acupuncture at Lieque (LU7). Electroacupuncture will be delivered with continuous wave stimulation at 60 Hz for 30 minutes per session. Treatment will be performed once daily for a total of 20 sessions over approximately 4 weeks, excluding Sundays.
214908072|NCT07151456|DRUG|Conventional 24-week glucocorticoid regimen|Weeks 1 - 4, Prednisolone 1mg/kg/day (max 80mg); Weeks 5 - 6: Prednisolone 0.8mg/kg/day (max 60mg); Weeks 7 - 8: Prednisolone 0.6mg/kg/day (max 50mg); Weeks 9 - 10: Prednisolone 0.5mg/kg/day (max 40mg); Weeks 11 - 12: Prednisolone 0.4mg/kg/day (max 30mg); Weeks 13 - 16: Prednisolone 0.3mg/kg/day (max 25mg); Weeks 17 - 20: Prednisolone 0.2mg/kg/day (max 15 Weeks 21 - 24: Prednisolone 0.1mg/kg/day (max 10mg).
214908073|NCT07151456|DRUG|short-term course (12 week) glucocorticoid regimen|Weeks 1 - 4, Prednisolone 1mg/kg/day (max 80mg); Weeks 5-8: Prednisolone 1mg/kg/day (max 80mg) on alternate days; 9-12: Prednisolone 0.5mg/kg/day (max 40mg) on alternate days
214303323|NCT02192918|BEHAVIORAL|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
214908074|NCT07151183|OTHER|No intervention|No intervention
214908075|NCT07153302|OTHER|Prunus dulcis (sweet almonds)|Almonds are functional food items that contain bone essential micronutrients.
214908076|NCT06546488|BEHAVIORAL|Assessments|A standardized assessment battery will be administered. It will consist of cognitive, functional and motor assessments.
214908077|NCT07152678|DRUG|Nivolumab (240 mg)|After the first cycle of nivolumab administered in the screening phase (1st cycle), nivolumab in the study phase was administered intravenously over 30 minutes at a dose of 240 mg every 2 weeks for at least 2 doses, with 1 cycle after to first brachytherapy (2nd cycle), and 1 more cycle after to second brachytherapy (3rd cycle) if feasible. (each cycle was 2 weeks), until disease progression assessed by the investigator per RECIST version 1.1, or unacceptable toxicity.
214908078|NCT07152678|RADIATION|Brachytherapy|Brachytherapy protocol starts within 3 weeks after first cycle of nivolumab was administered. After brachytherapy applicator placement, CT simulation scan(s) with dummy source in place will be done for further planning procedure, including adjustment of the applicator and 3D treatment planning. High-dose-rate (HDR) 5-Gy per fraction is delivered to the gross tumor volume (GTV) of esophageal tumor(s), second treatment if applicable will be finished within 2 weeks after the first fraction, a total of 5-12 Gy in 1-2 fractions will be delivered. GTV coverage D90 should equal 100% of prescription. Efforts should be made to spare the adjacent normal organ and to avoid hot spot on normal esophageal mucosa. It is NOT allowed to give concurrent chemotherapy on the days of HDR brachytherapy.
214908079|NCT07152379|DEVICE|INTERCEPT RBCs|Transfusion of fresh (≤14 days old) allogeneic INTERCEPT RBCs.
214908080|NCT07152795|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
214908081|NCT07152795|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
214908082|NCT07152158|OTHER|multicomponent training combined with multi-professional intervention|The MCT protocol consisted of an initial three-week period of neuromotor adaptation characterized by low volume and intensity. In the subsequent weeks, a gradual progression of volume and intensity was implemented (Table 1), following a classic linear periodization model (Fleck \& Kraemer, 2017; Prestes et al., 2016).
214908083|NCT07151872|DRUG|QLS31905 for Injection|QLS31905 for Injection
214908084|NCT07151872|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection
214908085|NCT07151872|DRUG|Cisplatin for Injection|Cisplatin for Injection
214908086|NCT07151872|DRUG|QL2107 Injection|QL2107 Injection
214908087|NCT07151872|DRUG|Oxaliplatin Injection|Oxaliplatin Injection
214908088|NCT07151872|DRUG|Capecitabine Tablets|Capecitabine Tablets
214908089|NCT07151651|PROCEDURE|Endoscopic lumbar discectomy|Uniportal and boportal endoscopic lumbar discectomy (transforaminal or interlaminar)
215057756|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
215057757|NCT04008641|OTHER|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
215057758|NCT00377845|PROCEDURE|Regular Tampax used in 3 hours|
214303324|NCT04176276|OTHER|no interventions required.|The study does not require any interventions.
214303325|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
214303326|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of the cycle.
214303327|NCT01888146|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
214303328|NCT02290106|DRUG|pitavastatin|
214303329|NCT02290106|OTHER|PLACEBO|
214303330|NCT02337907|DRUG|Placebo|for blinding purposes
214303331|NCT02337907|DRUG|Placebo|
214908090|NCT07151989|PROCEDURE|Mitral valve replacement|"All operations were performed through median longitudinal sternotomy or mini-sternotomy.~Intraoperative transesophageal echocardiography (TOE) was used in all patients. Arterial cannulation was central and venous cannulation was achieved with a common two-stage cannula in the right atrium. Left ventricle was vented through the right superior pulmonary vein. In minimally invasive procedures, venous cannulation was achieved percutaneously. Myocardial protection was achieved by administration of cold crystalloid or blood cardioplegia at the surgeon's discretion in an antegrade (indirect or selective) or retrograde fashion. The removal of the calcified cusps and the decalcification of the annulus was performed according to traditional techniques. All the prosthesis were be implanted with supranular technique and 2-0 U-shaped pledgeted sutures."
214908091|NCT07153068|BIOLOGICAL|supCD7 CART cells|Subjects screened to meet the requirements for supCD7 CART cells use will enter clinical trials. Subjects were assessed at baseline. Fludarabine and cyclophosphamide based preconditioning should be performed within 1 week prior to supCD7 CART cells infusion: fludarabine (Flu) 30mg/m2 ×3 days; cyclophosphamide (CTX) 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and VP-16. Infusion of supCD7 CART cells must be performed 24 hours after completion of chemotherapy preconditioning. supCD7 CART cells can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.
214908092|NCT07152223|BIOLOGICAL|CAR-T|Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
214908093|NCT07152210|BIOLOGICAL|CAR-T|Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
214908094|NCT07152639|BIOLOGICAL|5μg/ml EEC|0.1ml, one time, containing high dose 5μg/ml of active ingredients
214908095|NCT07152639|BIOLOGICAL|5 unit（U） EC|0.1 ml , one time, containing 5U of active ingredients
214908096|NCT07152639|BIOLOGICAL|5 IU TB-PPD|0.1 ml , one time, containing 5IU of active ingredients
214908097|NCT07152639|DIAGNOSTIC_TEST|IGRA|96-well/plate x 2 plates; 100 tubes/box x 1 box
214908098|NCT07151755|PROCEDURE|Vitrectomy + Direct Intra-Arterial Microneedle Thrombolysis + Standard Care|The patients will receive standard pars plana vitrectomy (PPV) combined with direct intra-arterial microneedle thrombolysis under microscopic visualization, in addition to standard clinical treatment for RAO. A 47G microneedle will be used to deliver thrombolytic agent intra-arterially per protocol.
214908099|NCT07151755|PROCEDURE|Standard Clinical Care Only|The patients will receive standard clinical treatment for RAO without vitrectomy or intra-arterial microneedle thrombolysis.
214908100|NCT07151287|DIAGNOSTIC_TEST|TCCD|Patients receive non-invasive assessments of TCCD using bedside ultrasound.
214908101|NCT07151287|DIAGNOSTIC_TEST|ONSD|Patients receive non-invasive assessments of ONSD using bedside ultrasound.
214908102|NCT07151287|DIAGNOSTIC_TEST|ODH|Patients receive non-invasive assessments of ODH using bedside ultrasound.
214908103|NCT07151287|DIAGNOSTIC_TEST|Invasive ICP|Patients receive invasive assessments of ICP.
215057759|NCT01848977|DEVICE|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
215057760|NCT01848977|DEVICE|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
214303332|NCT02337907|DRUG|BI 409306|
214303333|NCT02337907|DRUG|Donepezil|
214303334|NCT00954642|DRUG|bevacizumab|Intravenous repeating dose
214303335|NCT00954642|DRUG|MNRP1685A|Escalating intravenous dose
214303336|NCT00954642|DRUG|paclitaxel|Intravenous repeating dose
214303337|NCT02876900|DRUG|Low Dose Asenapine maleate transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patch
214303338|NCT02876900|DRUG|High Dose Asenapine maleate transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patch
214303339|NCT02876900|DRUG|Placebo|The study will evaluate placebo transdermal patch.
214303340|NCT02838056|DRUG|epidural injection|drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
214303341|NCT00417092|PROCEDURE|Postoperative Pacing|
214303342|NCT04644614|DEVICE|Magnetic Stimulation - Armchair type|MS and Sham MS will be applied two days a week, 20 minutes a day, for 8 weeks, a total of 16 sessions.
214303343|NCT00497172|DEVICE|CYPHER Sirolimus-eluting stent|drug-eluting stent
214303344|NCT00497172|DEVICE|Bx SONIC bare metal stent|bare-metal stent
214303345|NCT00002384|DRUG|Cidofovir|
214303346|NCT05755009|RADIATION|High- and Low-dose radiotherapy|High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain a total of two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.
214303347|NCT00405873|DRUG|AMT2003|
214303348|NCT02140658|BEHAVIORAL|multiple health education interventions|
214303349|NCT02140658|BEHAVIORAL|conventional health education|
214303350|NCT04211701|PROCEDURE|Connective Tissue Massage|Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
214303351|NCT04211701|PROCEDURE|Classical Massage|Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
214678606|NCT03709888|DRUG|Memantine XR-pregabalin combination therapy|Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
215057761|NCT03601442|BIOLOGICAL|CTL019|CTL019
214303352|NCT02192255|BEHAVIORAL|Intervention Phone Call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted \< than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
214303353|NCT01592344|DEVICE|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 100-250 µsec~* Pulse Rate: 50-100 Hz~* Intensity: 0-30mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
214303354|NCT01592344|DEVICE|StimRouter - Control|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 200 µsec~* Pulse Rate: 1 Hz~* Intensity: 0 mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
214303355|NCT05074030|BEHAVIORAL|Personalized Normative Feedback|Normative Feedback on drinking behaviors.
214303356|NCT05074030|BEHAVIORAL|Coping-Motive Specific Personalized Feedback Intervention plus an Ecological Momentary Intervention (PFIcope+EMI)|An EMA plus EMI intervention to decrease drinking to cope behaviors among emerging adults receiving psychiatric treatment.
214908104|NCT07152626|DRUG|LITFULO|Following central randomization, patients will be assigned to receive either ritlecitinib 100mg daily (QD) or a combined therapy using ritlecitinib 100mg QD + twice weekly narrowband UVB treatment for a duration of 52 weeks. At the end of this period, all participants will continue for the open-label phase, receiving ritlecitinib 100mg QD. Eligible participants will be stratified by Fitzpatrick Skin Type (FST, also known as phototype).
214303357|NCT00003733|DRUG|carboplatin|
214303358|NCT00003733|DRUG|paclitaxel|
214303359|NCT00003733|DRUG|topotecan hydrochloride|
214303360|NCT06361862|DEVICE|Active alarms from WARD software|Wireless continuous vital sign monitoring with real time staff alerts
214303361|NCT03533192|BEHAVIORAL|It's Your Game...Keep it Real|It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
214303362|NCT04811170|OTHER|Counselling|Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.
214908105|NCT07152626|PROCEDURE|LITFULO and UVB|Following central randomization, patients will be assigned to receive either ritlecitinib 100mg daily (QD) or a combined therapy using ritlecitinib 100mg QD + twice weekly narrowband UVB treatment for a duration of 52 weeks. At the end of this period, all participants will continue for the open-label phase, receiving ritlecitinib 100mg QD. Eligible participants will be stratified by Fitzpatrick Skin Type (FST, also known as phototype).
214908106|NCT07152756|PROCEDURE|Esophagogastroduodenoscopy|Assess the gastric retention and the endoscopic mucosal visibility score during esophagogastroduodenoscopy
214908107|NCT07151950|DEVICE|One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils|"This study explores the stakeholders' experiences in recommending and using Obi. Stakeholders/Participants include:~1. Persons with disabilities or conditions which prevent them from successfully using their upper extremities (UE) to self-feed independently~2. Caregivers of the persons with disabilities described above~3. Providers (OT, SLP, PT, ATP, etc.) who provide services to persons with disabilities"
214908108|NCT07153133|BIOLOGICAL|albumin platelet rich fibrin|sixteen teeth extraction socket filled by albumin platelet rich fibrin
214908109|NCT07151976|DEVICE|PCI|PCI with athero-thrombotic aspiration and subsequent pathological analysis: Pathologic Characteristics of Athero-Thrombotic AsPirated Material of OCT-Verified Culprit Lesion in Acute Coronary Syndrome
214908110|NCT07153055|DRUG|Lurbinectedin|Two lurbinectedin does of 3.2 mg/m2 or 2.6 mg/m2. The initial starting dose is 3.2 mg/m2. Patients will receive lurbinectedin, until disease progression or unacceptable toxicity, once every 21 days.
214908111|NCT07153055|DRUG|Osimertinib|Two osimertinib does of 80 mg or 40 mg orally once daily, as assigned by the dose de-escalation cohort for each 21 day cycle.
214303363|NCT00629499|DRUG|nab paclitaxel|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
214303364|NCT00629499|DRUG|Cyclophosphamide|600 mg/m2 of IV cyclophosphamide
214303365|NCT00629499|DRUG|Trastuzumab|8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
215057762|NCT03302689|DRUG|Levobupivacaine Solution|TAP-block with Levobupivacaine 0,3% - 25 ml from each side
215057763|NCT03302689|DRUG|Ropivacaine Solution|TAP-block with Ropivacaine 0,3% - 25 ml from each side
215057764|NCT03069742|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
215057765|NCT03069742|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
214908114|NCT05687136|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214908115|NCT05687136|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214908116|NCT05687136|PROCEDURE|Computed Tomography|Undergo CT
215057766|NCT04447235|DRUG|Placebo|Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
215057767|NCT04447235|DRUG|Ivermectin|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
215057768|NCT04447235|DRUG|Losartan|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
215057769|NCT01541735|DRUG|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
214908117|NCT05687136|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214908118|NCT05687136|DRUG|Peposertib|Given PO
214908119|NCT05687136|PROCEDURE|Positron Emission Tomography|Undergo PET
215057770|NCT01541735|DRUG|placebo|Placebo 40 mg dose.
215057771|NCT04858815|BEHAVIORAL|yogic breathing|participation in yogic breathing
215057772|NCT04876404|DIAGNOSTIC_TEST|PET/MR Imaging|The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.
215057773|NCT03947281|OTHER|Almond snack|The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
215057774|NCT03947281|OTHER|Cereal-based snack|The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
215057775|NCT05832606|OTHER|Food box containing 30 different plants|Food boxes during first 12 weeks of therapy. Clinical follow-up until end of immunotherapy.
215057776|NCT02092636|OTHER|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
215057777|NCT02092636|OTHER|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
214908120|NCT05687136|DRUG|Tuvusertib|Given PO
214908121|NCT07183566|DEVICE|Ct|Ct volume measurement of HCC after TACE or MWA
214908122|NCT07182305|DRUG|Efficacy of albendazole for early stage intervention of alveolar echinococcosis|Participants in the treatment arm will be treated with albendazole, 2 x 400 mg daily for the duration of the study. Treatment may be prolonged beyond the end of the study if clinically appropriate.
214908123|NCT07182747|BEHAVIORAL|Nursing students' intervention programme|12-week intervention programme conducted by nursing students and students trained in Sciences of Physical Activity and Sport (CAFYD). Participants will receive weekly three sessions of 45-60 minutes. It will include physical exercise and occupational therapy sessions aimed at improving frailty and other related outcomes in the participating older adults through interdisciplinary collaboration and ongoing monitoring. Nursing students will implement personalised intervention programmes designed by a multidisciplinary team comprising CAFYD students, an occupational therapist, and nurses experienced in the care of older adults.
214908124|NCT07182747|BEHAVIORAL|Standard care from Public Andalusian Health Service|They will receive the standard care provided by the Andalusian Health Service as part of its portfolio of services offered to older adults residing in institutions, as well as the standard care provided by the institutions in which they live. As part of these services, older adults receive support such as accommodation, laundry, health promotion activities, health monitoring, assistance with activities of daily living, individual, group, and community social care, as well as means of communication with the outside world. The action plans or protocols established in care processes for older adults living in nursing homes do not include externally delivered multidisciplinary intervention programmes.
214908125|NCT07182864|DRUG|MH004 0.1% Ointment|MH004 0.1% ointment applied topically to the affected area as a thin film.
214908126|NCT07182864|DRUG|MH004 0.3% Ointment|MH004 0.3% ointment applied topically to the affected area as a thin film.
214908127|NCT07182864|DRUG|MH004 1.0% Ointment|MH004 1.0% ointment applied topically to the affected area as a thin film.
214908128|NCT07182864|DRUG|MH004 3.0% Ointment|MH004 3.0% ointment applied topically to the affected area as a thin film.
214908129|NCT07182864|DRUG|Vehicle Ointment|Matching vehicle ointment applied topically to the affected area as a thin film.
214908130|NCT07182006|BEHAVIORAL|Aerobic Exercise|Submaximal cardiovascular endurance testing on a treadmill
214908131|NCT07183800|OTHER|Water|Participants will undergo a standardized 10-minute high-intensity trampoline jumping protocol designed to elicit mechanical loading on the pelvic floor. Prior to the jumping session, bladder volume will be assessed via transabdominal ultrasound. If a participant's bladder contains less than 100 mL of urine, they will be asked to drink water and wait until a target range of 100-200 mL is reached to ensure consistent pre-jump bladder filling across participants. This approach minimizes variability in bladder volume, which could influence pelvic floor measurements.
214908132|NCT07183124|DIAGNOSTIC_TEST|AI-Assisted 3D Imaging Model for Tumor and CRM Assessmen|This study uses an AI-assisted 3D imaging model to analyze existing CT and MRI images of stage II-III locally advanced rectal cancer patients. The system reconstructs tumor boundaries and spatial relationships, predicts circumferential resection margin (CRM) status, and supports staging assessment. No interventions are performed on participants, and all data are collected retrospectively from routine clinical care.
214908133|NCT07182773|BEHAVIORAL|Exercise|The exercise programme will be prescribed at a moderate intensity (Target Heart rate: 60%-65% Heart Rate Reserve + resting heart rate) for 30 minutes immediately prior to infusion therapy, on their treatment days over 12- weeks. Exercise will be completed on a stationary cycle ergometer. Target heart rate will be adjusted to 50-55% Heart Rate Reserve + resting heart rate if patient is complaining of fatigue/nausea, is on beta-blockers or if haemoglobin \<9g/dL. Heart rate monitoring by chest strap using the polar heart rate monitor will allow participants to self-regulate their exercise intensity. Participants should discontinue exercise and await medical review if they develop chest pain, dizziness or pre-syncope, cyanosis or pallor appearance, new musculoskeletal pain.
214908134|NCT07184450|BIOLOGICAL|BCMA/CD70-targetd CAR-T|Subjects underwent lymphocytetion cheotherapy and then received a single intravenous cell infusion
214908135|NCT07183423|OTHER|Novel barrier repair topical product|Novel barrier product (containing ceramide, virgin coconut oil, cholesterol)
214908136|NCT07183423|OTHER|Petrolatum|Petrolatum application
214908137|NCT07183345|OTHER|Dynamic Pain Assessment and Management System|Personalized nursing education was adopted. These measures include the use of preoperative analgesic drugs, postoperative Traditional Chinese Medicine (TCM) fumigation, and wrist-ankle acupuncture for pain relief.
214908138|NCT07183345|DRUG|Routine drug analgesia|adopted routine drug analgesia and conventional nursing education
214908139|NCT07183774|DIAGNOSTIC_TEST|Sarcopenia will be assessed using the STAR (Sonographic Thigh Adjustment Ratio) method.|A detailed evaluation of shoulder MRI scans will be conducted. The presence and severity of supraspinatus tendon tears, as well as the presence of muscle atrophy (assessed using the tangent sign), will be recorded. In addition, tears in other rotator cuff tendons, signs of tendinitis, and any other pathological findings will also be documented.
214908140|NCT07182110|DRUG|Dexamethasone enhanced TAP Block|20 ml Marcaine containing 0.25% bupivacaine + 4 mg dexamethasone + normal saline
214908141|NCT07182110|DRUG|Marcaine- 0.25%|20 ml solution containing 0.25% bupivacaine + normal saline
214908142|NCT07174726|BIOLOGICAL|Adeno-associated virus vector expressing a human RPGR gene|Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501
214908143|NCT07183618|PROCEDURE|Mental training group|"Mental Training Group: Residents in the Mental Training group received a mental preparation session led by an anaesthesia physician qualified in medical pedagogy. Inspired by the Breathe, Talk, See, Focus procedure"
214908144|NCT07182500|OTHER|Probiotic|Daily 6-drops of Bifidobacterium longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536 in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1.5 × 109 CFU/day)
214908145|NCT07182500|OTHER|Placebo|Daily 6-drops of non-GMO corn starch in medium-chain triglyceride oil
214908146|NCT07184099|DRUG|Phloroglucinol|Phloroglucinol was administered as intravenous stat infusion with Ringer Lactate infusion.
214908147|NCT07184359|BEHAVIORAL|Traditional Learning|All participants will have access to the conventional teaching-learning process (lecture-based classes). These theoretical classes will be delivered as part of the Dental Radiology course. During the semester, the topics covered will include intraoral radiographic techniques, radiographic processing, intraoral radiographic anatomy, and dental and periodontal alterations and lesions.
214908148|NCT07184359|BEHAVIORAL|Passive Social Media|The second group (Passive Social Media Supplement Group) will participate in the conventional teaching-learning process, supplemented by the passive consumption of educational content on social media, produced by the third group. The materials consumed will include the following content: intraoral radiographic techniques, radiographic processing, intraoral radiographic anatomy, and dental and periodontal alterations and lesions.
214908149|NCT07184359|BEHAVIORAL|Active Social Media|The third group (Active Social Media Engagement Group) will participate in the conventional teaching-learning process, supplemented by the creation of educational audiovisual materials, which will subsequently be shared on social media and accessed both by their own group and by the second group. The materials will cover the following topics: intraoral radiographic techniques, radiographic processing, intraoral radiographic anatomy, and dental and periodontal alterations and lesions.
214908150|NCT07183930|PROCEDURE|Tubeless Percutaneous Nephrolithotomy (PCNL)|Mini-PCNL with tract dilation up to 18 Fr and stone fragmentation by pneumatic lithotripsy. Following clearance, a double-J stent is placed; no nephrostomy tube is inserted.
214908151|NCT07183930|PROCEDURE|Standard Tube Percutaneous Nephrolithotomy (PCNL)|Mini-PCNL with tract dilation up to 18 Fr and stone fragmentation by pneumatic lithotripsy. Following clearance, a 14 Fr nephrostomy tube and a double-J stent are placed.
214908152|NCT07184086|DRUG|CagriSema (Cagrilintide B + semaglutide I)|Cagrilintide and semaglutide will be administered subcutaneously.
214908153|NCT07184086|BEHAVIORAL|Low Energy Diet|Participants will receive dietary intervention as per diet intervention manual.
214908154|NCT07182968|OTHER|Questionnaire study|Questionnaire application
214908155|NCT07182214|OTHER|Collect blood sample|Collect venous blood sample from subjects prior fasting, any operation or treatment
214908156|NCT07184242|OTHER|Shoulder Exercise & Proprioceptive Training Program|"The study includes two intervention modalities. The experimental group will combine conventional treatment with a structured 12-week therapeutic exercise program, with two supervised group sessions per week (50-60 minutes), which will include proprioceptive somatosensory work, multi-joint strength exercises, and adapted specific movements. Progression will be individually adjusted based on each participant's pain tolerance, physical condition, and clinical progress, complemented by home activities and supporting educational materials.~The control group will receive only conventional treatment provided at their rehabilitation center and general guidelines on the benefits of physical activity according to WHO recommendations for people over 60 years of age."
214908157|NCT04301076|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
214908158|NCT04301076|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214908159|NCT04301076|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
214908160|NCT04301076|DRUG|Cyclophosphamide|Given IV
215057778|NCT02092636|OTHER|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
215057779|NCT06353633|DIETARY_SUPPLEMENT|formula|The calories needed by the person are calculated and half of the calories are provided by formulas and the other half based on the elimination diet
215057780|NCT06353633|BEHAVIORAL|exclusion diet|In this group, only the elimination diet is considered as an intervention
215057781|NCT05945602|OTHER|Neurophysiologic Biomarker Assessments|Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.
214908161|NCT04301076|DRUG|Doxorubicin Hydrochloride|Given IV
214908162|NCT04301076|DRUG|Etoposide|Given IV
214908163|NCT04301076|DRUG|Lenalidomide|Given PO
214908164|NCT04301076|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214908165|NCT04301076|DRUG|Prednisone|Given PO
214908166|NCT04301076|DRUG|Vincristine Sulfate|Given IV
214908167|NCT04413097|PROCEDURE|Delayed Cord Clamping with Low Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.
214908168|NCT04413097|PROCEDURE|Delayed Cord Clamping with High Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.
214908169|NCT03631017|DRUG|[18F]- PARPi|injection of a microdose (\< 100 ug) of \[18F\]- PARPi
214908170|NCT03631017|DIAGNOSTIC_TEST|PET/CT Scans|"Patients will be injected with approximately 10 mCi of \[18F\]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings."
214908171|NCT05945251|OTHER|Internet-delivered cognitive behavioral therapy|Ten weekly modules for children and ten weekly modules for parents. Exposure-based cognitive behavioral therapy delivered online with asynchronous support via text messages from psychologists.
214908172|NCT06131372|DRUG|Cagrilintide|Participants will receive Cagrilintide subcutaneously.
214908173|NCT06131372|DRUG|Semaglutide|Participants will receive semaglutide subcutaneously.
214908174|NCT06131372|DRUG|Placebo|Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
214908176|NCT05679401|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
214908177|NCT05679401|PROCEDURE|Plasma exchange (PLEX)|PLEX removes the patient's pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
214908178|NCT05679401|DRUG|Cyclophosphamide (CYC)|Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
214908179|NCT05679401|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
214908180|NCT06141902|OTHER|Jing Si Herbal Drink|Jing Si Herbal Drink
214908181|NCT06776848|OTHER|Observation phase|Start of the observation phase for all patients for a period of 6 months. Group B: continuation of the observation phase for a further 6 months
214908182|NCT06776848|DRUG|Lithium treatment|The daily dose of lithium will be increased until the target lithiaemia is reached, while monitoring tolerance and possible adverse effects.
214908183|NCT06776848|BIOLOGICAL|biological monitoring|"The blood level of lithium will be monitored by regular blood tests~\- every 4 days until a targeted blood level is obtained"
214908184|NCT03834155|OTHER|Hospital-based CR + Movn Application|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.
214908185|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.
214908186|NCT03834155|OTHER|Hospital-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.
214908187|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.
214908188|NCT05372640|DRUG|Abemaciclib|Given PO
215057782|NCT05168371|BEHAVIORAL|Cognitive-Behavioural Therapy - Online (CBT-O)|"Face-to-face CBT was adapted for web-based self-directed therapy. CBT-O was found to be feasible and usable (Stephenson et al., 2021; Zippan et al., 2020).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to CBT; 2) The cognitive model and thought records; 3) Unhelpful thinking patterns; 4) Cognitive restructuring; 5) Behavioral experiments; 6) Self-touch and sensate focus; 7) Sensate focus with your partner; and 8) Maintaining (and extending) your gains."
214908189|NCT05372640|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214908190|NCT05372640|PROCEDURE|Biopsy Procedure|Undergo biopsy
214908191|NCT05372640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214908192|NCT05372640|PROCEDURE|Diagnostic Imaging Testing|Undergo imaging evaluation
214908193|NCT04783428|OTHER|No intervention|Access to any treatment is through authorized commercial use and not as part of this DMP
214908194|NCT05542381|DRUG|Loteprednol Etabonate Ophthalmic Gel [Lotemax]|Loteprednol (ophthalmic corticosteroid) will be stored in the clinic according to the instructions on the package. The vial will be stored upright between 15°-25°C (59°-77°F). In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
214908195|NCT05542381|OTHER|Refresh Lubricant Eye Drops [Artificial Tears]|REFRESH® Brand Lubricant Eye Drops are artificial tears. In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
214908196|NCT05866094|BEHAVIORAL|Nutritional Intervention|"Nutrition training will be provided to home care staff to deliver the intervention via the participating Home Care Providers from two localities (South and North of England).~This phase will involve identification of people with dementia on their caseload, preliminary assessment of potential impact via collection of quantitative data at baseline (pre-intervention), and at 4 months follow-up (4 months after the first visit by trained home care workers, following baseline).~A process evaluation will be conducted to gather data on intervention fidelity and implementation (quantitative and qualitative)."
214908197|NCT04219254|DRUG|BI1206|"BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase"
214908198|NCT05681039|DRUG|Tiragolumab|Given by IV (vein)
214908199|NCT05681039|DRUG|Atezolizumab|Given by IV (vein)
214908200|NCT05681039|BEHAVIORAL|Standard of Care|after care from surgery
214908201|NCT05681039|BEHAVIORAL|Questionnaires|Quality of life
214908202|NCT05681039|RADIATION|Cisplatin|Given by IV (vein)
214908203|NCT05681039|RADIATION|Carboplatin|Given by IV (vein)
214908204|NCT06242080|BEHAVIORAL|Mindfulness|Mindfulness meditation has been described as a behavioral technique involving the intentional self-regulation of attention to present-moment experience, combined with release of cognitive fixation on thoughts (whether simple images or complex story lines) regarding the past or future. Through training in mindfulness, individuals learn to evoke and sustain a non-judgmental state of present-moment awareness.
214908205|NCT05673200|PROCEDURE|Biopsy Procedure|Undergo biopsy
214908206|NCT05673200|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214908207|NCT05673200|PROCEDURE|Computed Tomography|Undergo CT
214908208|NCT05673200|DRUG|Decitabine and Cedazuridine|Given PO
214908209|NCT05673200|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214908210|NCT05673200|DRUG|Paclitaxel|Given IV
214908211|NCT05673200|BIOLOGICAL|Pembrolizumab|Given IV
214908212|NCT05738174|DEVICE|high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold
214908213|NCT05738174|DEVICE|sham high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold with angled coil
214908214|NCT04857372|DRUG|IAG933|Capsule
214908215|NCT05452642|BEHAVIORAL|DASH diet|Participants in this arm will be taught a DASH diet plus psychological skills to support dietary adherence.
214908216|NCT05452642|BEHAVIORAL|Very low-carbohydrate diet|Participants in this arm will be taught a very low-carbohydrate diet plus psychological skills to support dietary adherence.
214908217|NCT06437444|BEHAVIORAL|The implementation strategy to encourage the adoption of the Care Pathway|"1. Dissemination of the most novel aspects of the agreed Care Pathway via corporate mail.~2. Integration of information and communication tools into electronic health records to facilitate the recording and the standardized implementation of recommended practice.~3. Audit \& Feedback (A\&F) data reports, sent monthly, to each paediatrician on the rate of prescription of bronchodilators administered with a spacer chamber, together with the rates of the other indicators established in the pathway, in their health centre and in the rest of the centres in the participating health areas.~4. Interactive training sessions, in which epidemiological data and data on the health, economic and social impact of asthma attacks were presented, together with data on other indicators associated with the care pathway, and key messages on current treatment recommendations based on the latest clinical practice.~5. Distribution of reminder posters in paediatrics consultations, PEDs and health centers."
214908218|NCT04660344|DRUG|Atezolizumab|ctDNA positive participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
214908219|NCT04660344|OTHER|Placebo|ctDNA positive participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle
214908220|NCT04660344|DEVICE|Signatera|Signatera will be used to evaluate whether circulating tumor DNA (ctDNA) is detected during serial monitoring of peripheral blood samples for participants enrolled in surveillance. Participants with a ctDNA positive result will be screened for inclusion in the treatment phase. Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter follow-up.
214908221|NCT02710448|DRUG|Metformin|Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
214908222|NCT06077864|DRUG|survodutide|once weekly subcutaneous injection
214908223|NCT06077864|DRUG|Placebo|once weekly subcutaneous injection
214908224|NCT06787690|DEVICE|Cohealyx|Cohealyx application, followed by autologous split-thickness skin graft
214908225|NCT06788990|DRUG|Ficerafusp alfa|Investigational
214908226|NCT06788990|DRUG|Pembrolizumab (KEYTRUDA®)|Immunotherapy agent used in combination with investigational agent
214908227|NCT06788990|DRUG|Placebo|Placebo Control
214908228|NCT05104736|DRUG|PT-112|PT-112 will be administered intravenously in 28-day cycles, on Days 1 and 15 at a dose of 360 mg/m2 for cycle 1, and on day 1 at 250mg/m2 for each subsequent cycle,
214908229|NCT06955221|PROCEDURE|Ultrasound-guided aspiration and alcohol sclerotherapy|Ultrasound-guided puncture and alcohol sclerotherapy
214908230|NCT06226610|DRUG|Dupilumab|injection every two weeks while on study
214908231|NCT06226610|OTHER|Placebo|injection every two weeks while on study
214908232|NCT06833970|OTHER|Colgate use|An evaluation of Colgate total toothpaste currently in use will be provided.
214908233|NCT06833970|OTHER|Curaprox use|An evaluation of Curaprox toothpaste currently in use will be provided.
214908234|NCT06833970|OTHER|ROCS use|An evaluation of ROCS toothpaste currently in use will be provided.
214908235|NCT06833970|DEVICE|Fixed orthodontic treatment|For standard fixed orthodontic treatment, orthodontic brackets and mechanics will be applied.
214908236|NCT06064929|DRUG|Felzartamab|Administered IV
214908238|NCT05510128|OTHER|Pharmacist management|"When a patient comes to the pharmacy with signs of urinary burning, the following will follow:~* Completion of the acute cystitis symptoms score (ACSS) questionnaire.~* Measure the temperature.~* Perform a urine dipstick.~If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made."
214908239|NCT01812031|OTHER|medical imaging|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
214908240|NCT06449144|OTHER|Mindfulness education|The mindfulness-based stress reduction method was examined and a two-step mindfulness education is planned. To reveal the experience of pain: It was planned to conduct interviews with the participants to realize what they think about the pain they have experienced before or what they think about the pain they have experienced here and now, what emotions they have, and their experiences related to their coping processes with pain. Participants will be encouraged to notice negative thoughts that could impact their coping with pain negatively, and they will be provided with education on the benefits of managing the process of changing these negative thoughts. Attempts will be made to establish positive thinking. Attention: Recognizing the relationship between pain sensation and attention and encouraging its expression is included in the intervention. Information on distraction was given and two exercises we planned to increase the level of awareness.
214908241|NCT06270485|PROCEDURE|PEEP|Application of different PEEP-Levels during invasive mechanical ventilation
214908242|NCT03576326|BEHAVIORAL|Drawing Incentive|The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
214908243|NCT01015417|DRUG|Amoxicillin clavulanic acid|Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams
214908244|NCT01015417|OTHER|No medication|no postoperative antibiotics
214908245|NCT05830266|BEHAVIORAL|"Mindful with your Baby group-based therapist-guided intervention"|"This 8-sessions long intervention is one of very few interventions that actively includes the baby in the therapy sessions. The intervention includes the following sessions: Becoming aware of the autopilot, Practice to really look at your baby, Getting back in touch with yourself, Responding sensitively to your baby, Taking care of yourself in the difficult moments, Distance and proximity: it's both part of it, Dealing with expectations of yourself and the environment and Mindful parenting: trial and error. The intervention is a group-based therapist-guided intervention via a video-conferencing tool (e.g., Zoom)."
214908246|NCT05830266|BEHAVIORAL|"Mindful with your baby self-guided online intervention"|"This 8-sessions long intervention includes the following sessions: Autopilot, Fresh view, At home in your body, Responsive versus reactive parenting, Kindness to yourself, Distance and proximity, Boundaries and taking care of yourself and Mindful parenting - day by day. The intervention is an individual self-guided online intervention."
214908247|NCT04829136|DIETARY_SUPPLEMENT|Kate Farms 1.0|Given enteral nutrition via nasoenteric feeding
214908248|NCT04829136|DIETARY_SUPPLEMENT|Standard of Care Nutritional Support|Given standard of care, which may be parenteral nutrition
214908249|NCT04829136|OTHER|Survey Administration|Ancillary studies
214908250|NCT04829136|DIETARY_SUPPLEMENT|Dietary Supplement|Receive fiber supplementation orally or enterally
214908251|NCT04829136|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
214908252|NCT04829136|OTHER|Electronic Health Record Review|Ancillary studies
214908253|NCT04829136|OTHER|Fiber and Dietary Assessments|Ancillary studies
214908254|NCT05740280|DRUG|iCP-NI|20 mg/mL iCP-NI solution for intravenous injection
214908255|NCT05740280|DRUG|Placebo|Placebo solution for intravenous injection
214908256|NCT06958211|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
214908257|NCT06958211|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
214908258|NCT02908061|PROCEDURE|Surgery Radical Cystectomy|All surgeries will be performed in an open or laparoscopic fashion.
214908259|NCT02908061|PROCEDURE|Ultrapro mesh|Surgery Mesh Placement. All surgeries will be performed in an open or laparoscopic fashion.
214908260|NCT06011434|BEHAVIORAL|Mammography Screening Conversation Aid|"Web-based, Decide Together conversation aid designed to be used by PCP and participant for shared decision making and to provide information on the benefits and harms of mammography screening as well as educational talking points."
214908261|NCT04069299|DRUG|68Ga-DOTATATE|The NETspot kit is 2 vials, Vial 1 contains 40 mcg dotatate, 5 mcg 1,10phenanthroline; 6mcg gentisic acid and 20 mg mannitol. Vial 2 contains 60 mg formic acid, 56.5 mg sodium hydroxide and water for injection
214908262|NCT04069299|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Scan|PET scan is an imaging test using radioactive tracers.
214908263|NCT05142722|DRUG|Placebo|placebo tablet made to resemble active
214908264|NCT05142722|DRUG|Obicetrapib|10mg obicetrapib tablet
214908265|NCT06708351|OTHER|Best Practice|Receive standard care
214908266|NCT06708351|OTHER|Health Promotion and Education|Receive instructions on how to use HPV self-testing kit
214908267|NCT06708351|PROCEDURE|HPV Self-Collection|Undergo HPV self-collection
214908268|NCT06708351|OTHER|Text Message-Based Navigation Intervention|Receive text messages for HPV testing results and triage and treatment reminders
214908269|NCT01339195|BEHAVIORAL|French adaptation of NINDS-Canadian Stroke Network battery|"* clinical: post-stroke neurological follow-up assessment~* neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~* MRI"
214908270|NCT04222010|DRUG|loco-regional anesthesia serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia
214908271|NCT04222010|DRUG|Loco-regional anesthesia : paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
214908272|NCT04222010|DRUG|Loco-regional anesthesia : serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
214908273|NCT06215716|DRUG|Efruxifermin|Administered by subcutaneous injection
214908274|NCT06215716|DRUG|Placebo|Administered by subcutaneous injection
214908275|NCT05612035|DRUG|Frespaciguat|Frespaciguat 380 µg administered as dry powder inhalation once daily.
214908276|NCT05612035|DRUG|Placebo|Placebo administered as dry powder inhalation once daily.
214908277|NCT06832618|DRUG|Ruxolitinib|The study cream will be applied topically as defined in the protocol for each period.
214908278|NCT06832618|DRUG|Vehicle Cream|Matching vehicle cream will be applied topically as defined in the protocol for each period.
214908279|NCT06548542|DRUG|Risankizumab|Subcutaneous Injection
214908280|NCT06548542|DRUG|Lutikizumab|Subcutaneous Injection
214908281|NCT06548542|DRUG|ABBV-382|Intravenous Infusion
214908282|NCT06548542|DRUG|Risankizumab|Intravenous Infusion
214908283|NCT06548542|DRUG|ABBV-382|Subcutaneous Injection
214908287|NCT06828861|DRUG|Placebo|200 mg BID (twice per day) for 1 week, 400 mg BID for 1 week, 800 mg BID for 10 weeks
214908288|NCT06828861|DRUG|ARD-101|200 mg BID (twice per day) for 1 week, 400 mg BID for 1 week, 800 mg BID for 10 weeks
214908289|NCT06291376|DRUG|Ravulizumab|Participants will receive ravulizumab via weight-based intravenous (IV) infusion.
214908290|NCT06291376|DRUG|Placebo|Participants will receive placebo via weight-based IV infusion.
214908292|NCT03555162|OTHER|fMRI|Imaging examination
215057783|NCT05168371|BEHAVIORAL|Mindfulness-Based Therapy - Online (MBT-O)|"The content of MBT-O was adapted from an efficacious face-to-face mindfulness intervention for women with Sexual Interest/Arousal Disorder (Brotto et al., 2021; Paterson et al., 2017). MBT-O was found to be feasible and usable (Brotto et al., under review).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to mindfulness; 2) Increasing awareness of physical sensations in the body; 3) Exploring movement and body image; 4) Awareness of sexual thoughts and beliefs; 5) Working with aversion, self-touch; 6) Exploring sexual sensations, knowing limits; 7) Integrating the partner into mindful touching; and 8) Maintaining (and extending) your gains."
215057784|NCT04505644|DRUG|lidocaine patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
215057785|NCT04505644|DRUG|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
214908293|NCT04252950|BEHAVIORAL|CB-SET|Community-based structured exercise therapy (CB-SET) programs for PAD have potential merit as an alternative to hospital-based SET, as they may provide similar benefit to hospital-based programs but in a convenient location for the exercise to be completed
214908294|NCT04252950|PROCEDURE|Revascularization|Endovascular revascularization is a primary treatment option for patients with PAD
214908295|NCT05582122|BIOLOGICAL|HPV16 Ct-DNA dosing|"Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.~ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.~ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.~DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma."
214908296|NCT05774691|DRUG|Protamine sulfate|Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin
215057786|NCT04505644|DRUG|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
215057787|NCT02905838|DEVICE|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
214908297|NCT05774691|DRUG|Protamine sulfate|Selective protamine administration, in case of (threatening) bleeding
215057788|NCT02905838|DEVICE|CAD/CAM CARES Abutment|"Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).~All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position."
215057789|NCT02415244|PROCEDURE|TEE|Spinal cord segments will be imaged using the TEE
215057790|NCT02777450|PROCEDURE|lumbar facet block|injection of Levobupivacaine 0,25% and corticosteroids
214303366|NCT06362434|DEVICE|Audiovisual stimulation|The MOT IVR audiovisual stimulation task involves the 3D multiple-object-tracking paradigm composed of 6-8 high-contrast spheres which features are adapted to the visual ability of individuals with low-vision (luminosity = 80 nits, size = 1° to 3° visual angle). The spheres move for 20s. following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. The participant, comfortably seated, is asked to track the moving cued target among moving distractors for 20s. A spatial sound is correlated to the movement of the cued target. After 20s., the movement stops and the participant is asked to select, using a laser pointer, the cued sphere among the distractors (mark-all procedure). Speed of the spheres is regulated by a staircase 1:1 procedure. The stimulation can here be stopped by the participant if required. After 3 blocks of 15x20s., the system stops and goes on stand-by mode until the next session. Data are collected in real time.
214908298|NCT06326255|BEHAVIORAL|laughter yoga|each class, including warm-up exercises, laughter yoga exercises, breathing and a relaxation session and sharing
214908299|NCT04103762|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
214908300|NCT04103762|DIAGNOSTIC_TEST|systematic intraoperative cholangiography|systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)
214908301|NCT05506254|DRUG|hLB-001|hLB-001 gene therapy
214908302|NCT06843434|DRUG|Balstilimab|Balstilimab is a fully human monoclonal IgG4 antibody designed to block PD-1 binding to PD-L1 and PD-L2
214908303|NCT06843434|DRUG|Botensilimab|Botensilimab is a novel fully human fragment crystallizable (Fc)-engineered immunoglobulin 1 kappa (IgG1κ) anti-CTLA-4 immunoglobulin G1 (IgG1) antagonist antibody that is designed to optimally promote fragment-crystallizable gamma receptor (FcγR) effector functions that are important for enhancing T cell priming and regulatory T cell (Treg) depletion.
214908304|NCT06205784|OTHER|Prehabilitative exercise|3-4 weeks of heavy resistance exercise
214908305|NCT03461900|OTHER|Minifluid challenge|Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.
214908306|NCT03461900|OTHER|Usual practice|Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.
214908307|NCT06846476|OTHER|Insole|"The production process of the insoles will be produced by Computer Aided Design and Computer Aided Manufacturing (CAD-CAM) method by making plantar pressure analysis and physical evaluation of the individual.~The insoles will be designed to reduce the load in areas where the pressure is high with off loading technique. The design of the insoles to be produced individually will be made by the researcher (expert orthotist). The materials to be used in the production of insoles will be determined according to the needs of the participant and materials suitable for diabetic individuals will be preferred. In this context; mostly Ethyl Vinyl Acetate (EVA) and materials with cellular air permeability on the upper surface will be used."
214908308|NCT06846476|OTHER|Demographic Information and Anamnesis Form|Demographic information and anamnesis form; demographic information of the participant, disease history, physical condition of the foot, skin condition, medications used, allergic status, surgical history, presence of edema, discolouration and temperature increase.
214908309|NCT06846476|OTHER|Pedobarographic analysis|"Pedobarographic analysis and evaluation of postural balance are widely used by clinicians and researchers to examine the foot structure and to determine the loading patterns of the foot. The data are obtained with electronic sensors placed on the platform where the gait takes place. The sensors are directly connected to the platforms and the computer system programmed to perform foot analysis. With the pedobarography device, pressure distribution data in the foot are obtained in both static and dynamic conditions.~Foot plantar pressure analysis and postural balance will be performed using the EsCoSCAN® static and dynamic pedobarographic assessment device.~During the analysis, the individual will be made to stand without moving while looking straight ahead in the standing position for static analysis. This evaluation will be performed before and 3 months after the use of insoles."
215057791|NCT04008303|PROCEDURE|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
214303367|NCT01393808|DRUG|Paricalcitol|1-month Paricalcitol 2mcg/day
214303368|NCT01393808|OTHER|placebo|1-month Placebo Treatment
214303369|NCT00783601|DRUG|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
215057792|NCT05824663|DRUG|HBM1020|Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
215057793|NCT00753727|DRUG|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
214303370|NCT00783601|DRUG|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
214303371|NCT00783601|DRUG|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
215057794|NCT00753727|RADIATION|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
215057795|NCT00418600|DRUG|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
214908310|NCT06846476|OTHER|Postural balance|Postural balance assessment in the study will be performed with 'Becure Balance System (Becure Global GmbH)'. Individuals will be evaluated for balance on the device with eyes open-closed, single foot-double foot. This evaluation will be performed before and 3 months after the use of insoles.
214908311|NCT06846476|OTHER|The Foot Functional Index (FFI)|"The Foot Functional Index (FFI) consists of pain, disability and activity limitation and contains a total of 23 items. Pain and disability titles consist of 9 questions each. The pain item measures the severity of foot pain in different situations. The 9 items in the inability heading assess the severity of the difficulty in performing functional activities due to the person's foot problems.~The activity limitation heading consists of 5 items and measures the activity limitations of the person due to foot problems. AFI is a self-completed scale. Individuals answer the questions with a Visual Analogue Scale (VAS), taking into account their foot condition one week ago. A high score indicates more pain, inability and activity limitation. This evaluation will be performed before and 3 months after the use of insoles."
214908312|NCT06846476|OTHER|Sensory Evaluation|"Diabetic foot ulcer (DFU), which is one of the microvascular complications of diabetes, frequently occurs in association with loss of protective sensation due to peripheral neuropathy, ischaemia due to peripheral arterial insufficiency, poor foot care and infection. Loss of pressure sensation caused by peripheral nerve damage will be evaluated with 'Semmes Weinstein' monoflaments. The 5.07 nylon monoflament used in the test was produced to bend when 10 g force was applied. This pressure is applied to specific points on the plantar and dorsal aspect of the foot.~This evaluation will be performed before and 3 months after the use of insoles."
214908313|NCT06846476|OTHER|Orthotic Satisfaction Questionnaire- Q-YTKMD (QUEST 2.0)|It is a standardised and widely used questionnaire developed to examine the satisfaction of individuals using orthotics with the device they use. In 2020, a Turkish validity and reliability study was conducted. QUEST 2.0 consists of 12 items. Of these, 8 items question the assistive device and 4 items question service satisfaction. Scale scoring is calculated with a 5-point Likert scale (1=Not satisfied at all, 5=Very satisfied). This evaluation will be performed after the use of insoles.
214908314|NCT06846476|OTHER|6 Minute Walk Test (6MWT)|Participants will walk for 6 minutes at a speed of their choice in a flat and suitable area of 30 metres. The distance walked in 6 minutes will be recorded in metres.
214303372|NCT00783601|DRUG|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
214303373|NCT01770483|DRUG|nitazoxanide|nitazoxanide 500mg twice daily
214908315|NCT06846476|OTHER|Pulse Oximeter Heart Rate and Oxygen Saturation|Heart rate and oxygen saturation (SpO2) will be recorded by pulse oximetry before and after the 6MWT. The pulse oximeter is a non-invasive device that attaches to a person's fingertip.
214303374|NCT01770483|DRUG|conventional interferon alfa|Inj interferon 3 Million International Units thrice weekly
214303375|NCT01770483|DRUG|Ribavirin|ribazole
214303376|NCT05619276|DEVICE|Standard serving utensil toolkit|Serving a meal using standard kitchen utensils (100% of subjects experiment with these tools first)
214303377|NCT05619276|DEVICE|Optimsed portion-control toolkit|Serving a meal using optimised, portion-control utensils (100% of subjects experiment with these tools second)
214303378|NCT02971267|OTHER|Observational|None, observational only
214303379|NCT00180895|DRUG|Rituximab|
214303380|NCT01739582|DRUG|Androxal|
214303381|NCT01557296|DIETARY_SUPPLEMENT|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
214303382|NCT01557296|RADIATION|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
214303383|NCT01557296|OTHER|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
214303384|NCT01557296|BIOLOGICAL|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
214303385|NCT01533454|OTHER|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
214303386|NCT01540708|DRUG|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
214303387|NCT01540708|DRUG|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
214908316|NCT03932786|PROCEDURE|Biospecimen collection|Collection of tissue and saliva samples
214908317|NCT03932786|OTHER|Vision assessment|Undergo vision assessment
214908318|NCT03932786|OTHER|Questionnaire administration|Complete questionnaires
214908319|NCT03932786|OTHER|Quality of life assessment|Complete questionnaires
214908320|NCT03932786|OTHER|Laboratory Biomarker Analysis|Correlative studies
214908321|NCT04026477|BEHAVIORAL|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop
214908322|NCT04026477|BEHAVIORAL|Waitlisted Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop following waitlist period
214908323|NCT03982836|DIETARY_SUPPLEMENT|Soluble Dietary Fibers|All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
214908324|NCT05731700|DEVICE|Drug Eluting Balloon|PCI of in-stent restenosis
214908325|NCT06423573|DRUG|Filsuvez|Topical gel
214908326|NCT06434935|COMBINATION_PRODUCT|CABA|Coronary Bypass
214908327|NCT05735080|DRUG|INX-315|Oral administration
214908328|NCT05735080|DRUG|Fulvestrant|Fulvestrant will be combined with INX-315
214908329|NCT05735080|DRUG|Abemaciclib|Abemaciclib will be combined with INX-315
214908330|NCT05094297|BEHAVIORAL|Investigate the effects of an exercise intervention on U.S. Veterans.|Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.
214908331|NCT05538663|DRUG|Gemcitabine|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
214908332|NCT05538663|DRUG|Docetaxel|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
214908333|NCT05538663|DRUG|Bacillus Calmette Guerin|intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
214908334|NCT06385678|DRUG|HRS-4642|administrated per dose level in which the patients are assigned
214908335|NCT06385678|DRUG|Adebrelimab|administrated per dose level in which the patients are assigned
214908336|NCT06385678|DRUG|SHR-9839|administrated per dose level in which the patients are assigned
214908337|NCT06385678|DRUG|Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection|administered as prescribed by the investigator.
214908338|NCT06385678|DRUG|Cetuximab Solution for Infusion|administrated per dose level in which the patients are assigned
214908339|NCT02422017|DRUG|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks applied on the ulcer of interest
214908340|NCT02422017|OTHER|Local care treatment|Local care treatment with dressing compression in accordance with standards applied every other day
215057796|NCT00418600|DRUG|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
214908341|NCT06572657|OTHER|cognitive stimulation|cognitive stimulation
214908342|NCT06572657|OTHER|physical exercise|physical exercise
214908343|NCT05365295|OTHER|DRM (Deese, Roediger et McDermott task)|"Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes."
214908344|NCT06571383|DRUG|Semaglutide|Participants will receive semaglutide s.c(under the skin) once weekly.
214908345|NCT04910269|BIOLOGICAL|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.
214908346|NCT04910269|OTHER|Placebo|Infusion of 35 milliliters standard isotonic saline
214908347|NCT06534918|OTHER|Fitbit|Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
214908348|NCT06534918|BEHAVIORAL|Nutrition Course: Group Sessions|The nutrition course will follow a combined asynchronous and synchronous approach. The asynchronous component will consist of a pre-recorded session covering educational nutrition content, which will be made available to participants for self-paced learning. This will be followed by a synchronous, 30-60 minute live group education class on nutrition information for cancer survivors, held once per week.
214908349|NCT06534918|BEHAVIORAL|Physical Activity Program: Group Sessions|The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.
214908350|NCT06534918|BEHAVIORAL|Nutrition Course: One on One Sessions with Registered Dietitian|Participants will be referred to weekly one on one nutrition counseling sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.
215057797|NCT00418600|DRUG|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
215057798|NCT01720875|DRUG|Vorinostat Velcade Dexamethasone|
214908351|NCT06534918|BEHAVIORAL|Physical Activity Program: One on One Sessions with an Exercise Physiologist|Participants will be referred to weekly one on one exercise training sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual
215057799|NCT05139745|DEVICE|BTL-899|BTL-899 treatment
215057800|NCT00924677|PROCEDURE|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
214303388|NCT01923454|PROCEDURE|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
214303389|NCT01923454|DRUG|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
214908352|NCT06534918|BEHAVIORAL|Nutrition and Physical Activity Prescription|Participants will receive a lifestyle medicine prescription pad, developed by the investigators, which serves as a checklist to assist participants in effectively monitoring their dietary habits and physical activity routines. Participants will also receive an 8-week text messages program which will direct participants to a webpage with nutrition and physical activity content.
214908353|NCT05943964|BEHAVIORAL|Virtual exercise and rehabilitation program|"Participants will have two 30-minute sessions per week for 12 weeks. The program will focus on aerobic exercises and stretching exercises. When applicable, stretching exercises will focus on areas of contractures, and joints with limited range of motion (ROM).~Sessions will be completed by a team of Physical Therapists using the established telemedicine platform at Children's Healthcare of Atlanta, as used routinely in the blood and marrow transplant clinic for clinical care (Epic). Adherence to the program will be encouraged during monthly standard clinic visits."
214908354|NCT06369025|BEHAVIORAL|Interaction Competencies with Children|"Interaction Competencies with Children - for Teachers (ICC-T) Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~Interaction Competencies with Children - for Parents (ICC-P) Core training components include parents-child interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the home"
214908355|NCT04166318|PROCEDURE|Biopsy|Undergo tissue biopsy
214303390|NCT01923454|PROCEDURE|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
214908356|NCT04166318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214908357|NCT04166318|DRUG|Capecitabine|Given PO
214303391|NCT04518254|BIOLOGICAL|Blood collection|A blood sample will be collected before and after treatment administration
214303392|NCT04518254|DRUG|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route
214908358|NCT04166318|PROCEDURE|Computed Tomography|Undergo PET/CT
214908359|NCT04166318|OTHER|Fludeoxyglucose F-18|Receive FDG
214908360|NCT04166318|DRUG|Fluorouracil|Given IV
214908361|NCT04166318|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214303393|NCT04518254|DRUG|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
214303394|NCT04518254|BEHAVIORAL|Cognitive tasks|The participants will perform cognitive decision-making tasks: Simon task and masking task after treatment administration
214303395|NCT04518254|OTHER|Stress exposure|Unpleasant but not painful skin stimulations will be administered to the participants at variable intervals on the left leg during the cognitive tasks
214908362|NCT04166318|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214908363|NCT04166318|DRUG|Mitomycin|Given IV
214908364|NCT04166318|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214908365|NCT04166318|OTHER|Quality-of-Life Assessment|Ancillary studies
214908366|NCT04166318|OTHER|Questionnaire Administration|Ancillary studies
214908367|NCT06445101|OTHER|Participatory Approach|The participatory approach is a stepwise, collaborative approach to the analysis and solvation of bottlenecks that cause stress in employees.
214908368|NCT04495946|BEHAVIORAL|Sepsis Transition and Recovery (STAR) program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
214908369|NCT04495946|BEHAVIORAL|Usual care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
215057801|NCT00924677|PROCEDURE|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
214303396|NCT04518254|BEHAVIORAL|Anxiety scale|Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks
214303397|NCT04518254|DEVICE|Electromyography (EMG)|Electromyography measurements will be performed during cognitive tasks.
214303398|NCT04518254|DEVICE|Electroencephalography (EEG)|Electroencephalography measurements will be performed during cognitive tasks.
214303399|NCT04052048|DIAGNOSTIC_TEST|Subtraction Normalized Expression of Phagocytes Blood Test|Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness
215057802|NCT02974140|DEVICE|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
214908370|NCT05530525|DIAGNOSTIC_TEST|The Computerized Adaptive Testing system of the Functional Assessment of Stroke|The Computerized Adaptive Testing system of the Functional Assessment of Stroke comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper limb, 11 items from the Fugl-Meyer Assessment-Lower limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. Results are automatically reported as Rasch scores (i.e., the minimum and maximum values are negative and positive infinity, respectively). A higher score indicates greater physical functions.
214670082|NCT05890222|BEHAVIORAL|Community Intervention|Community intervention strategies will be delivered by community volunteers (called Sangathis - which means companion in Konkani, one of the local languages) to i) enhance demand for the HAP treatment and ii) promote engagement with, and completion of, the HAP treatment. The community intervention is co-produced with local community members and includes strategies such as activities to increase awareness about depression (community meetings, street plays and health camps), and dissemination of psycho-educational materials (i.e., leaflets and posters), identify people with possible depression in the community, and facilitate access to HAP in the health centres. Additionally, the Sangathis will coordinate continuing care of people receiving HAP, through home visits to encourage behavioural activation, homework completion and following up with the counsellor, and engaging family members to support the patient in achieving treatment goals.
214670083|NCT05890222|BEHAVIORAL|Healthy Activity Program (HAP)|HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.
214670084|NCT06247033|DEVICE|Tibial Nerve Stimulation with TENS device|Tibial nerve stimulation was applied with TENS device transcutaneously and electrodes were positioned in medial part of the ankle. Negative transcutaneous electrode was positioned 3 centimeter posteriorly to the medial malleol. And positive transcutaneous electrode was positioned 10 centimeter above the negative electrode.
214670085|NCT06247033|BEHAVIORAL|Pelvic muscle training exercise with bladder training|Control group was followed with sham tibial nerve stimulation, which were performed by after starting electric current with TENS device, current were decreased and completely shut off. Sham stimulation was also applied for 6 weeks, 2 times in a week, 30 minutes. All patients were followed for PFTE and BT according to given standard schedule.
214670086|NCT03723564|DRUG|Lactated Ringers Solution for Injection|Using ultrasound guidance, a 22 gauge needle will be introduced into amniotic cavity. Warmed Lactated Ringers solution will be injected into the amniotic cavity until an AFI of 8.0 cm is achieved
214670087|NCT03270787|DRUG|Placebo|Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
214908371|NCT05530525|DIAGNOSTIC_TEST|The Barthel Index|The Barthel Index has 10 items, and the total score ranges from 0 to 100. Higher score indicates less disability on activity of daily living functions.
214908372|NCT05530525|DIAGNOSTIC_TEST|The National Institutes of Health Stroke Scale|The National Institutes of Health Stroke Scale comprises 11 items and was used to monitor the severity in the patients with stroke. The total score ranges from 0 to 42, with a higher score indicating greater severity. A National Institutes of Health Stroke Scale score of 1-5 indicates mild severity; 6-14, mild to moderate severity; 15-24, severe severity; and equal to or greater than 25, very severe severity.
215057803|NCT02974140|PROCEDURE|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
215057804|NCT02429804|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
215057805|NCT02429804|DRUG|Fludeoxyglucose F-18|Given IV
215057806|NCT02429804|DRUG|Fluorine F 18 Sodium Fluoride|Given IV
215057807|NCT02429804|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214303400|NCT01381133|BEHAVIORAL|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
214670088|NCT03270787|DRUG|Compound danshen dripping pills|Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
214670089|NCT04307966|BEHAVIORAL|The CIrCLE of Life Initiative|HIV and obesity prevention programme delivered directly to Grade 6 preadolescents and indirectly to their parents.
214670090|NCT02850250|DRUG|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
214670091|NCT02233725|DEVICE|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
214670092|NCT01079923|DIETARY_SUPPLEMENT|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
214670093|NCT01079923|DIETARY_SUPPLEMENT|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
214670094|NCT00001761|DRUG|Interleukin-10|
214678607|NCT01150994|BEHAVIORAL|Safety Assessment and Follow-up Telephone Intervention (SAFTI).|Mental health evaluation in ED, followed by Post-ED counseling
214678608|NCT05221450|PROCEDURE|primary endodontic treatment|
214678609|NCT03791983|OTHER|Scalp Acupuncture|Scalp acupuncture is a form of alternative medicine in which thin needles are inserted into the scalp. It is a key component of traditional Chinese medicine (TCM).
215057808|NCT02429804|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
215057809|NCT02183493|DRUG|BI 1356|
215057810|NCT04189796|DIETARY_SUPPLEMENT|Cheese|Daily oral intake of cheese
215057811|NCT03051880|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
215057812|NCT03051880|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
215057813|NCT00617084|DEVICE|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
215057814|NCT00617084|DEVICE|Abbott Xience V|Abbott Xience V
214303401|NCT01381133|BEHAVIORAL|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
214303402|NCT01381133|BEHAVIORAL|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
214303403|NCT03370003|OTHER|Standard medical care|All children will receive nutritional treatment and standard medical care in accordance with the nutritional guidelines of the national protocol, with the exception of the routine distribution of antibiotics.
214303404|NCT03782428|DIETARY_SUPPLEMENT|Probiotic|30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129
214303405|NCT03782428|OTHER|Placebo|Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
214303406|NCT05945277|BEHAVIORAL|Critical Time Intervention - Peer Support|CTI-PS is a time-limited, 9-month long intervention, provided at the critical time when a person is discharged from an inpatient psychiatric treatment facility.
214303407|NCT02488681|DEVICE|Micra Pacemaker Implant|
214303408|NCT00868933|OTHER|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
214303409|NCT00868933|OTHER|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
214303410|NCT04566315|PROCEDURE|Arteriography knee arteriography|arteriography and an injection of inert microparticles of 75 μm in neovessels
214303411|NCT06325956|DRUG|Metformin|Take metformin for six months.
214908373|NCT05975671|BEHAVIORAL|Multifaceted de-implementation strategy to reduce vancomycin overuse|"* Clinical guidelines and group-level feedback on vancomycin use will be provided to clinicians/sepsis stakeholders at each site.~* The semi-structured interviews will be performed by a trained member of the research team, under the supervision of a medical sociologist who is one of the co-investigators. A semi-structured interview guide will be used during the interviews. Interviews will be recorded and transcribed, then uploaded to a qualitative analysis software for management and coding. Names will not be recorded, and pseudonyms will be used in notes, communications about the study, and any presentations. Verbal consent will be obtained before conducting and recording the interviews.~* The surveys will be performed using REDCap survey software, and participation will be voluntary. No identifiers will be collected."
214908374|NCT03245892|DRUG|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
214908375|NCT03245892|DRUG|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
214908376|NCT03245892|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery
214908377|NCT03245892|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks x 3-6 cycles in the neoadjuvant setting (maximum 2 doses of ipilimumab)
214908378|NCT03381183|DRUG|Durvalumab|Phase 1 and Phase 2: 1500 mg every 4 weeks (Q4wks).
214908379|NCT03381183|DRUG|IRX-2 Regimen|"Phase 1 and Phase 2 - Every 12 weeks - IRX-2 Regimen:~Cyclophosphamide 300 mg/m\^2 - intravenously.~IRX-2: 460 units daily (4 injections of 115 units)."
214908380|NCT05208931|PROCEDURE|Anti-vascular endothelial growth factor therapy|0.05 ml anti-VEGF, intravitreal, monthly
215057815|NCT03573206|DEVICE|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
215057816|NCT02329977|OTHER|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
215057817|NCT00416494|BIOLOGICAL|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
215057818|NCT00416494|DRUG|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
215057819|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
215057820|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
215057821|NCT00042952|DRUG|imatinib mesylate|Given orally
215057822|NCT00042952|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
215057823|NCT00042952|OTHER|laboratory biomarker analysis|Correlative studies
214303412|NCT05194618|DIETARY_SUPPLEMENT|Valerian - lavender|1 tablet per day, half hour before bedtime, day 1 to day 28
214303413|NCT05194618|DIETARY_SUPPLEMENT|Placebo|1 tablet per day, half hour before bedtime, day 1 to day 28
214303414|NCT02007564|BEHAVIORAL|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
214303415|NCT02083731|BIOLOGICAL|MSCs|
214303416|NCT06167993|BEHAVIORAL|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy; It consists of manual therapy, skin care, compression therapy and therapeutic exercise.
214670095|NCT04661319|PROCEDURE|video editing training|"1. The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~2. Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~3. Select a random experimental group.~4. For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~5. Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation."
214670096|NCT02850198|DEVICE|scalp electroacupuncture|
214670097|NCT02850198|DEVICE|sham scalp electroacupuncture|
214908381|NCT04698395|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy for children with cerebral palsy
214908382|NCT04698395|BEHAVIORAL|Regular care|customary or usual care given to any infant/toddler with cerebral palsy
214908383|NCT03906760|OTHER|Magnetic resonance imaging (MRI)|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
214908384|NCT04010760|DIAGNOSTIC_TEST|Test of biomarkers for PE in EBC|"New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2\*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient."
214908385|NCT06187688|OTHER|Questionnaire|Patients to complete a questionnaire on measurement of pain intensity.
214908386|NCT01259622|DRUG|saline|intravenous infusion
214908387|NCT01259622|DRUG|K201|intravenous infusion
214908388|NCT05367609|DIAGNOSTIC_TEST|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
214908389|NCT04785066|DRUG|Administration of dornase alfa|Patient treated for a cerebral thrombectomy will be administred dornase alfa treatment by intravenous
215057824|NCT02222688|DRUG|cirmtuzumab|
215057825|NCT05711706|OTHER|Su Jok Application|Su Jok massage appplication
215057826|NCT00040781|DRUG|gefitinib|Given orally
214303417|NCT03513484|DRUG|Azacitidine|Given IV or SC
214303418|NCT03513484|OTHER|Laboratory Biomarker Analysis|Correlative studies
214303419|NCT03513484|DRUG|Nintedanib|Given PO
214303420|NCT03841734|DRUG|treatment|8 patients will be treat with bosentan at 145 mg per day during 14 days
214670098|NCT03590561|OTHER|High caloric diet|After dietary counseling, subjects will receive high caloric snacks for five days.
214670099|NCT05283707|BEHAVIORAL|Paula Method Exercises|The Paula Method Exercises were administered by the researcher for 6 to 8 hours, for 10 to 15 minutes on the post-op first day and post-op second day, to women who had a cesarean section.
214908390|NCT05826509|OTHER|Surgery alone|Radical prostatectomy with lymph node dissection will be performed.
214908391|NCT05826509|DRUG|Peri-operative darolutamide + surgery.|"Darolutamide: 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg; for a total duration of 9 months. Darolutamide will start at day 1.~Surgery: radical prostatectomy with lymph node dissection will be performed after at least 3 months of darolutamide treatment."
214908392|NCT06421753|DEVICE|SDSS|Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.
215057827|NCT00040781|OTHER|pharmacological study|Correlative studies
215057828|NCT00040781|OTHER|laboratory biomarker analysis|Correlative studies
215057829|NCT00001033|DRUG|Ethambutol hydrochloride|
215057830|NCT00001033|DRUG|Isoniazid|
215057831|NCT00001033|DRUG|Pyrazinamide|
215057832|NCT00001033|DRUG|Pyridoxine hydrochloride|
215057833|NCT00001033|DRUG|Levofloxacin|
215057834|NCT00001033|DRUG|Rifampin|
215057835|NCT06219967|DRUG|Activated Charcoal|Activated charcoal alone
215057836|NCT06219967|DRUG|Activated Charcoal|Activated charcoal mixed with cola
215057837|NCT03491813|DEVICE|oscillometric device|"The blood pressure will be measured by the Automatic blood pressure monitor(Oscillometric) named the OMRON M2 basic® device was provided by Omron Healthcare company.~This monitor uses inflation by Fuzzy-Logic controlled by electric pump and an automatic rapid pressure release valve for the deflation , its cuff allows BP measurements in arm circumference of 22-42 cm. The device measure BP and pulse rate with a pressure range of 0-299 mmHg and pulse rate range of 40-180 beats/min."
215057838|NCT03927547|DEVICE|Inclined Sleep|Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
215057839|NCT06431672|OTHER|interpersonal group psychotherapy|Interpersonal psychotherapy (IPT) was developed by Stuart and O'Hara (1995). It addresses four domains of conflict. The intervention is an eight-session P-IPTG, which consisted of four sessions in pregnancy and four in postpartum.
215057840|NCT06263907|PROCEDURE|Stellate gangalion block|The efficacy of Preoperative ipsilateral stellate gangalion block on the occurrence of postmastectomy depression and pain compared with no block
215057841|NCT03844672|BEHAVIORAL|Low Power|Participants will receive a low power e-cigarette to use for 3 weeks
214908393|NCT06421753|DEVICE|Standard Electrical Stimulation During Functional Electrical Stimulation|Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.
214908394|NCT06585514|DRUG|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
214908395|NCT05745831|OTHER|Therapeutic decision tool|A therapeutic decision tool will be used and its usefulness, comprehension and satisfaction will be evaluated
214908396|NCT05442216|DRUG|Tagraxofusp (Cycles 1-2)|12 mcg/kg intravenously Days 1-5
214908397|NCT05442216|DRUG|Azacitidine|75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
214908398|NCT05442216|DRUG|Tagraxofusp (Cycles 3-12)|12 mcg/kg intravenously Days 1-3
214908399|NCT02617342|BEHAVIORAL|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
214908400|NCT05603897|OTHER|Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)|Upon 1-2 days of admission to inpatient rehabilitation, the MASA will be administered for approximately 20 minutes during initial speech language pathology evaluation. The MASA will be administered at bedside as a cognitive/speech language evaluation as well as oropharyngeal function examination.
214908401|NCT05603897|OTHER|Non-standardized clinical swallow evaluation|Participants will receive current standard of care for dysphagia screening and treatment.
214908402|NCT05388227|OTHER|Pole walking|The intervention will consist of group sessions held at the participating communities, 2-3 times per week, for 20-60 minutes per session, over a 12-week period. Pole walking exercises are tailored for participants and progressive in nature. Sessions will be led by trained peer, staff, or student instructors and conducted outdoors (indoors if weather conditions do not permit).
214908403|NCT03375918|OTHER|CONSULT-BP Educational Intervention|CONSULT-BP is a two sessions training provided to healthcare trainees over a 5-week period. The first session focused on (1) didactic overview of healthcare disparities, social drivers of health, implicit bias and systemic racism and (2) interactive discussions and patient storytelling videos to raise awareness of the bi-directional role of racial and ethnic identity among clinicians and patients. The second session focused on skill building and included (1) bias mitigation strategies based on the RELATE bias mitigation tool and (2) skill practice using 2 standardized patient simulated clinical encounters focusing on hypertension management challenges.
214908404|NCT04874012|DRUG|Active comparator Taurine|Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
214908405|NCT04874012|OTHER|Placebo Comparator|Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle
214908406|NCT06120166|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
214908407|NCT05746390|BEHAVIORAL|Home Alone|See Home Alone description.
214908408|NCT06449209|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
214908409|NCT06449209|DRUG|BNT327 Dose Level 2 (DL2)|IV infusion
214908410|NCT06449209|DRUG|Etoposide|IV infusion
214908411|NCT06449209|DRUG|Carboplatin|IV infusion
214908412|NCT06449209|DRUG|Paclitaxel|IV infusion
214908413|NCT06449209|DRUG|Topotecan|IV infusion or oral capsules
214908414|NCT06798623|BIOLOGICAL|Autologous Mesenchymal Stromal Cells|Autologous mesenchymal stromal/stem cells extracted from the subject during a routine standard of care ACL reconstruction surgery and reintroduced in one clinic visit approximately 21 days after completion of the surgery. After being removed from the patient, the cells will be cultured, modified, and harvested to become the final investigational product. Each subject will receive 1.5 ml of the investigative drug. This will contain 5x10\^7 (50 million) autologous MSCs.
214908415|NCT04478084|BIOLOGICAL|Purified vero rabies vaccine - serum free VRVg-2|Pharmaceutical form:freeze-dried Route of administration: intradermal
214908416|NCT04478084|BIOLOGICAL|Purified inactivated rabies vaccine|Pharmaceutical form:freeze-dried Route of administration: intradermal
214908417|NCT04478084|BIOLOGICAL|Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)|Pharmaceutical form: liquid/solution in 5 mL vials Route of administration: intramuscular
215057842|NCT03844672|BEHAVIORAL|High Power|Participants will receive a high power e-cigarette to use for 3 weeks
215057843|NCT03844672|BEHAVIORAL|Low Concentration|Participants will receive a low concentration e-liquid to use for 3 weeks
215057844|NCT03844672|BEHAVIORAL|High Concentration|Participants will receive a high concentration e-liquid to use for 3 weeks
215057845|NCT01732705|BEHAVIORAL|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
215057846|NCT01253083|BEHAVIORAL|mobility training with dynamic body weight support|
215057847|NCT03000556|DRUG|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
215057848|NCT04248712|DRUG|Famotidine|40 mg tab twice daily by mouth for 12 week duration
215057849|NCT04248712|DRUG|Loratadine|10 mg tab once daily by mouth for 12 week duration
215057850|NCT04248712|DRUG|Placebo|Contains no active ingredient
214303421|NCT06159140|DEVICE|MRI|In vivo MRI
214303422|NCT06460649|OTHER|Progressive relaxation techniques|Participants received Progressive muscle relaxation along with Benson relaxing 3 times a week for 12 weeks. 36 sessions overall
214303423|NCT06460649|OTHER|Benson relaxation techniques|Participants received Benson relaxation techniques 3 times a week for 12 weeks. 36 sessions overall.
214303424|NCT02478242|DRUG|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
214303425|NCT02478242|DRUG|Normal saline|
214303426|NCT03084588|DRUG|methadone|Patients will be given methadone at induction of anesthesia
214303427|NCT03084588|PROCEDURE|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
214303428|NCT00720057|DRUG|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
214303429|NCT00720057|DRUG|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
214303430|NCT01136304|DRUG|Imiglucerase|Imiglucerase intravenous infusions regardless of dose or schedule of administration.
214908418|NCT04478084|BIOLOGICAL|Human rabies immunoglobulins (HRIG) (only Group 5 and Group 6)|Pharmaceutical form: liquid/solution in 2 mL vials Route of administration: intramuscular
214303431|NCT02930551|DRUG|Lidocaine|
214908419|NCT06482957|OTHER|Surveys|Complete surveys
214908420|NCT06482957|OTHER|Blood Collection|Undergo blood collection
214908421|NCT06482957|OTHER|Saliva Collection|Undergo salvia collection
214908422|NCT06482957|OTHER|Urine Collection|Undergo urine collection
214908423|NCT06482957|OTHER|Stool Collection|Undergo stool collection
214908424|NCT06482957|OTHER|Tissue collection|Undergo tissue collection
214908425|NCT06482957|OTHER|Physical Activity Monitoring|FitBit will be worn to track physical activity
214908427|NCT06668181|DRUG|Bimekizumab|Bimekizumab will be administered at pre-specified timepoints.
214908428|NCT03083548|DIAGNOSTIC_TEST|Imaging|Conventional radiographs (hands/feet), CT of dominant hand, MRI of dominant hand, ultrasound (hands/shoulder/feet/hips/knees), fluorescence optical imaging of hands
214908429|NCT03083548|DIAGNOSTIC_TEST|Physical examinations|Joint assessment of hands and feet, pain sensitization test and functional tests
214908430|NCT03083548|DIAGNOSTIC_TEST|Questionnnaires|Self-reported demographic factors, clinical variables and OA history and symptoms
214908431|NCT05607173|DRUG|Fexinidazole (HOE239)|Route of administration: oral; pharmaceutical form: tablet
214908432|NCT05990296|BEHAVIORAL|Multiprong CDS with referral to pharmacist co-management|Accepting the clinician-facing BPA default recommendation will have eligible patients within this arm referred to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
214908433|NCT05990296|BEHAVIORAL|Multiprong CDS with GDMT order set|Accepting the clinician-facing BPA default recommendation will open an order set for GDMT that lists common recommended options in such a way that facilitates optimal prescribing. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
215057851|NCT02522429|DEVICE|Low Intensity Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
215057852|NCT02956252|PROCEDURE|Spinal anesthesia|Spinal anesthesia was used in patients who underwent LC
215057853|NCT02956252|PROCEDURE|General anesthesia|General anesthesia was used in patients who underwent LC
215057854|NCT00936637|OTHER|Extensively hydrolyzed infant formula|
215057855|NCT02580032|OTHER|No treatment given|No treatment given.
215057856|NCT01000298|DRUG|Placebo|liquid placebo medication given twice per day for 7 days
215057857|NCT01000298|DRUG|Amoxicillin|liquid amoxicillin given twice per day for 7 days
214303432|NCT02930551|DRUG|Isotonic Saline|
214303433|NCT06172621|PROCEDURE|Spinal Cord Associative Plasticity (SCAP)|Paired non-invasive brain and spinal cord stimulation.
214303434|NCT06172621|PROCEDURE|Upper extremity task-oriented exercise|Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.
214303435|NCT05861856|OTHER|Manual therapy|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
215057858|NCT01000298|DRUG|Cefdinir|liquid cefdinir given twice per day for 7 days
215057859|NCT04438759|DEVICE|Oncomfort, commercially available Virtual Reality headset|Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
215057860|NCT00868972|PROCEDURE|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
215057861|NCT00868972|DEVICE|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
214908434|NCT05990296|BEHAVIORAL|Focused education|A series of focused, interactive education sessions will train clinicians in why, when, and how to prescribe GDMT to patients, with incentives such as continuing medical education (CME) credits, and with virtual and recorded options available to those who are unable to attend in-person meetings.
214908435|NCT06850571|DRUG|Bevacizumab Injection [Avastin]|1.25 mg intravitreal injection given once monthly for three consecutive months.
214908436|NCT06850571|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|2.0 mg intravitreal injection given once monthly for three consecutive months.
214908437|NCT05897775|DEVICE|Deep brain stimulation|"Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week."
214908438|NCT04886804|DRUG|zongertinib|zongertinib
214908439|NCT05531773|OTHER|follow up of COVID-19 Patients|"In each participating center a post COVID-19 outpatient clinic is already working or will be settled up to care COVID-19 patients after the acute phase. At the post COVID-19 clinic patients will undergo routine blood exams and will be visited by Infectious Diseases physicians after recovery from the acute episode of COVID-19 disease. According to the clinical issues of the patients and the procedures of the study, if necessary, the patients will be visited by other practitioners (Pneumologists, Cardiologists, Neurologists, Physiatrist and Psychologists or others).~Patients who have been already visited at the post COVID outpatient clinics from 01/03/2020 and for whom data of the acute phase and the follow up have been collected will be enrolled in the study and retrospectively analyzed."
214908440|NCT06376500|DEVICE|tDCS with cognitive training programme|Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes and it is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
214908441|NCT04979793|DRUG|L-citrulline|3 gram sachet, L-citrulline
214908442|NCT04979793|DRUG|Placebo|Milk powder placebo
214908443|NCT04604873|OTHER|Hospital day care follow-up|Regular follow up every month in hospital day care
214908444|NCT05853107|DEVICE|AuTNA I|AuTNA I means Au nanoparticle-decorated TiO2 Nanowire Arrays, a retinal prothesis designed for subretinal implantation.
214908445|NCT03133455|OTHER|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
214908446|NCT05997264|BIOLOGICAL|AV7909 Full Dose (0.5 mL)|AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
214908447|NCT05997264|BIOLOGICAL|AV7909 Half Dose (0.25 mL)|AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
214908448|NCT05468164|DRUG|Selpercatinib|Administered orally
214908449|NCT05468164|DRUG|Omeprazole|Administered orally
214908450|NCT02438306|BIOLOGICAL|Autologous cell therapy|Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.
214908451|NCT02438306|OTHER|Sham|An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
214908452|NCT04628026|DRUG|Venetoclax|Venetoclax will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
214908453|NCT04628026|DRUG|Placebo|Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
214908454|NCT04628026|COMBINATION_PRODUCT|Standard chemotherapy|"Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4, and daunorubicin 60 mg/m2 IV (days 1-3). Patients \>60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4 without daunorubicin.~Consolidation chemotherapy with intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are \>60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients \>60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment."
214303436|NCT05861856|OTHER|Virtual reality|Virtual reality supported core stabilization exercises will be performed.
214303437|NCT03064191|COMBINATION_PRODUCT|calcium hydroxide chlorhexidine combination|Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms
214303438|NCT03064191|OTHER|calcium hydroxide intra-canal medicament|Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
214908455|NCT04628026|OTHER|Allogeneic stem cell transplantation|Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
214908456|NCT04294628|PROCEDURE|Biopsy Procedure|Undergo biopsy
214908457|NCT04294628|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214908458|NCT04294628|PROCEDURE|Computed Tomography|Undergo CT scan
214908459|NCT04294628|PROCEDURE|Echocardiography Test|Undergo ECHO
214908460|NCT04294628|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214908461|NCT04294628|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214908462|NCT04294628|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
214908463|NCT01104805|BEHAVIORAL|Therapeutic Education System (TES)|Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.
214908464|NCT01104805|BEHAVIORAL|Treatment-as-Usual (TAU)|Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.
214908465|NCT03876535|OTHER|Nanomix eLab® System molecular diagnostic test (non-interventional)|This is not an interventional study. It involves performance equivalence demonstration of a point of care diagnostic system to FDA cleared predicate devices currently used in sepsis and SIRS diagnosis.
214908466|NCT04846569|BEHAVIORAL|Transition Theory-based Intervention|The behavioral intervention is a theoretically driven curriculum focused on supporting mothers from pregnancy through postpartum in order to promote sustained HIV treatment adherence. Sessions utilize motivational interviewing and consist of a range of topics including motherhood, preparing for baby, disclosure, HIV education, adherence, birth experiences, support systems, and living positively.
214908467|NCT04846569|BEHAVIORAL|Enhanced Standard of Care Control|In addition to standard of care, participants receive the first session of the Transition Theory-based Intervention curriculum which focuses on motherhood and preparation for baby but does not discuss the transition from pregnancy to postpartum or the postpartum period.
214908468|NCT01467713|DRUG|Ramelteon SL|Ramelteon sublingual (SL) tablets
214908469|NCT01467713|DRUG|Placebo|Ramelteon sublingual (SL) placebo-matching tablets
214908470|NCT00536939|DRUG|Enzastaurin|1125 milligrams (mg) loading dose on Day 1 of Cycle 1 only then 500 mg oral once daily, until disease progression
214908471|NCT00536939|DRUG|Bevacizumab|10 milligrams per kilogram (mg/kg) intravenously, Days 1 and 15 every 28 days, until disease progression
214908472|NCT00536939|DRUG|Paclitaxel|90 milligrams per square meter (mg/m\^2), intravenously, Days 1 ,8, and 15 every 28 days until disease progression
214908473|NCT00536939|DRUG|Placebo|Oral, daily, until disease progression
214908474|NCT05560568|OTHER|Sleep parameters data collection|Sleep parameters collected before and after hybrid close-loop pump activation. Data collected with adequate devices (i.e. actigraph and Dreem Band).
214908475|NCT03532425|DRUG|B/F/TAF|B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily
214908476|NCT03532425|DRUG|Atripla|Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily
214908477|NCT03532425|DRUG|B/F/TAF Placebo|Tablet taken orally once daily
214908478|NCT03532425|DRUG|Atripla Placebo|Tablet taken orally once daily
214908479|NCT04747119|OTHER|muscle energy technique|the patient was supine and the therapist fix the lower limb of the affected side then ask the patient to perform isometric contraction for abductors maintained for 3-5 seconds, then the patient was instructed to stop, exhale and relax then the therapist perform further adducted the patient's knee of the affected side as a stretching exercise for Three to five repetitions of these directions were performed.
214908480|NCT04747119|OTHER|conventional selected physical therapy|"1. life style modification~2. Transcutaneous electrical nerve stimulation (TENS)~3. Flexibility stretching exercises to the hip flexors"
214908481|NCT03600961|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
214908482|NCT05413213|PROCEDURE|Ambulatory rehabilitation program|Experimental group: Ambulatory rehabilitation program based on mobilization and muscular solicitation.
214908483|NCT06296771|OTHER|Dietary energy restriction group (D)|"The participants allocated to the dietary energy restriction group will receive instructions to change their usual dietary intake and maintain their regular physical activity routine for the duration of eight weeks.~The dietary energy restriction depends on a total calorie deficit of 5000 kcal per week, achieved by the consumption of reduced meal portions. This deficit is computed by subtracting the participants\&#39; energy expenditure, as measured by ActiheartTM, rather than relying on reported energy intake. This approach is employed to reduce potential difficulties arising from participants under-reporting their food consumption. The energy deficit is calculated by multiplying the weight of each food item recorded over a 5-day period by an individual factor obtained from energy expenditure data. This calculation enables the determination of the required energy intake for the intervention period."
215057862|NCT00439595|DEVICE|Hemocue 210 meter|Diagnostic device
215057863|NCT00439595|DEVICE|Copack HBCS|
215057864|NCT05924581|OTHER|Clinical assessment of spinal stiffness|"The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions."
215057865|NCT03987139|OTHER|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
214908484|NCT06296771|OTHER|Dietary energy restriction and exercise group (D+E)|"The individuals within the dietary energy restriction and exercise group will be instructed to reduce their habitual energy intake by 5,000 kcal per week while taking part in physical exercise with a frequency of three sessions per week of HIIT and two sessions per week of resistance exercise throughout a duration of 8 weeks. Sessions can be performed in any order, but we will recommend alternating HIIT and resistance training days and taking the two rest days separately to allow for recovery.~The exercise programme will start the session by participating in a gentle stretching routine with the objective of reducing the effects of exercise-induced shoulder discomfort. The treatment focuses on the four main muscle groups in the upper body: the latissimus dorsi, the triceps, the rhomboid, the pectoral, and the upper trapezius. Each pose is held in the stretched position for a length of 15 seconds throughout each set, for a total of 4 sets."
214908485|NCT04986345|OTHER|High-intensity interval training (HIIT)-4|4 intervals of 4 minutes at 90% of maximum cardiac frequency, interspersed with 3-minute rests at 70% of maximum cardiac frequency. The session will last 32 minutes, including warm-up and cooldown.
214908486|NCT04986345|OTHER|High-intensity interval training (HIIT)-10|10 intervals of 1 minutes at 90% of maximum cardiac frequency, interspersed with 1-minute rests at 70% of maximum cardiac frequency. The session will last 34 minutes, including warm-up and cooldown.
214908487|NCT04986345|OTHER|Rest|Participants are to stay seated for 30 minutes while reading or watching television.
214908488|NCT05448274|BIOLOGICAL|Placebo|The placebo will consist of solely glycerol-phosphate-buffered isotonic saline.
214908489|NCT05448274|BIOLOGICAL|Ruminococcus torques|10\^11 live bacterial cells in glycerol-phosphate-buffered isotonic saline
214908490|NCT01853813|DRUG|Bevacizumab and FOLFIRI|"The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.~After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity"
214908491|NCT01611935|DRUG|Vasopressin|After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
215057866|NCT03987139|OTHER|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
215057867|NCT03987139|OTHER|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
215057868|NCT03937388|OTHER|Cochlear stimulation strategy including time-fixed gaps|Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
215057869|NCT05538949|DRUG|EB-203|"* Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8."
215057870|NCT05538949|DRUG|Placebo|Placebo 1Drop, QD / Day1, BID / Day5\~Day8.
215057871|NCT03440463|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
214303439|NCT02414334|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|
214303440|NCT03141242|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
214303441|NCT03141242|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
214303442|NCT00002091|DRUG|Pentoxifylline|
214303443|NCT01673451|DRUG|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
214908492|NCT04875221|COMBINATION_PRODUCT|Connectivity-based neurofeedback|Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.
214908493|NCT00277225|DRUG|Abatacept|
214908494|NCT06413628|OTHER|screw tapered appliance|The appliance was digitally designed by solid works programs for 3rd CAD design software to obtain the STL file format. The virtual design of was approved. The printerwas loaded with material of 3D-printed denture base. The appliance was printed.
214908495|NCT05043974|OTHER|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
214908496|NCT06088290|DRUG|Lurbinectedin|IV Infusion
214670100|NCT02412007|OTHER|Individualized comprehensive home centred activity based programme|"Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~1. Standing up from squatting position to catch an object of interest.~2. Squatting from standing position to pick an object of interest.~3. Walking to reach an object of interest.~4. Climbing up steps to get an object of interest.~5. Climbing down steps to keep the above object of interest.~6. Cycling~7. Kicking a football~8. Dancing"
214670101|NCT01525511|DRUG|A|"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
214670102|NCT01525511|DRUG|B|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
214670103|NCT03995771|OTHER|Questionnaire delivery|A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
214670104|NCT03348683|DRUG|Propranolol|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
214670105|NCT03348683|DRUG|Placebo|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
214670106|NCT04507217|DRUG|Tislelizumab, Carboplatin, Pemetrexed|"Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle"
214670107|NCT01483846|DRUG|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
214670108|NCT01483846|DRUG|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
214670109|NCT04735900|PROCEDURE|Liquid biopsy sampling|Biweekly liquid biopsy sampling to measure circulating tumor DNA (ctDNA) level up to and including 9 months after start first-line therapy.
214670110|NCT03937986|DRUG|Suvorexant|The pharmacodynamic effects of suvorexant maintenance will be determined.
214670111|NCT03937986|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
214670112|NCT03937986|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
214908497|NCT06088290|DRUG|Doxorubicin|Short IV push or bolus (according to label)
214908498|NCT04521361|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).
214908499|NCT04293393|DRUG|Doxorubicin|Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
214908500|NCT04293393|DRUG|Cyclophosphamide|Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
214908501|NCT04293393|DRUG|Taxane|Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
214908502|NCT04293393|DRUG|Letrozole|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
215057872|NCT03440463|BEHAVIORAL|Norms-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare.
214670113|NCT06351410|DEVICE|Eye Wearing Contact Lens|Each participant will be given 2 types of a different group of contact lenses for each eye and need to wear for 8 hours only. Measurements will be done pre and post wearing of lenses
214670114|NCT02414295|DRUG|Mesenchymal stem cell injection|Aspirated bone marrow then separation for Mesenchymal stem cell
214670115|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
214670116|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
214670117|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
214670118|NCT01525212|DRUG|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
214670119|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
214670120|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
214670121|NCT00534846|DRUG|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
214670122|NCT00534846|DRUG|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
214670123|NCT02502422|DEVICE|Classic laryngeal mask airway|"1. measurement of head and neck~   * Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip\~sternal notch), modified mallampati classification under sitting position, thyromental distance.~2. laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~   * \# 4.0 for female, #5.0 for male~  * initial cuff volume(air) : maximum volume recommended by the manufacturer~  * check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~  * remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured."
214670124|NCT02752308|DRUG|Bupivacaine|Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)
214670125|NCT02752308|PROCEDURE|General anesthesia|Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide
214908503|NCT04293393|DRUG|Abemaciclib|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
214908504|NCT04293393|DRUG|LHRH Analogue|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
214908505|NCT05766267|DRUG|Rifabutin|Rifabutin (Rb) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
214908506|NCT05766267|DRUG|Delamanid|Delamanid (D or DLM) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
214908507|NCT05766267|DRUG|Bedaquiline|Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
214908508|NCT05766267|DRUG|Moxifloxacin|Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
214908509|NCT05766267|DRUG|Pyrazinamide|Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).
214908510|NCT05766267|DRUG|Isoniazid|Isoniazid is part of control regimen (HRZE).
214908511|NCT05766267|DRUG|Rifampin|Rifampin is part of control regimen (HRZE).
214908512|NCT05766267|DRUG|Ethambutol|Ethambutol is part of control regimen (HRZE).
214908513|NCT05889650|PROCEDURE|External Lumbar drainage|ELD @ 15 or 20mmHg based on intervention arm with maximum of 10ml/hour drainage
214908514|NCT06188715|DRUG|Moxidectin 2 mg Oral Tablet|Tablets of 2 mg moxidectin
214908515|NCT06188715|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
214908516|NCT06188715|DRUG|Placebo Moxidectin|Placebo tablets for moxidectin
214908517|NCT06188715|DRUG|Placebo Albendazole|Placebo tablets for albendazole
214908518|NCT05849532|DEVICE|Functional Electrical Stimulation|12-weeks of training sessions that include initial screening and clinical assessment (Week 1-2), onsite training sessions (Week 3-4), home training sessions (Week 4-8). There will also be pre (Week 1), mid (Week 7) and post-training (Week 12) assessment. Each session will consist of a 10-minute warm-up session with 5-6 stretching exercises. Warm-up will be followed by a 30 minute training session comprising of mobility, balance and walking exercises with FES. This will be followed by a cool down session for 10-minutes comprising of 5-6 muscle stretches. The participant will first watch video of the each exercise on the android tablet and then perform the exercises.
214908519|NCT03389932|BEHAVIORAL|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
214908520|NCT02290756|BEHAVIORAL|Parenting Program|The parenting program is an early childhood stimulation program aimed at newborns from their neonatal period till infancy. The implementation of the parenting program will be conducted through the link workers and parents of the newborns.
214908521|NCT02290756|BEHAVIORAL|Low cost evidence based toolkit|"The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:~1. Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials~2. Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information"
214908522|NCT01654185|DRUG|AI plus Dimethyldiguanide|AI 1 tablet per day Dimethyldiguanide 0.5 bid
214908523|NCT01654185|DRUG|Aromatase Inhibitor|1 tablet per day
214908524|NCT03658785|BIOLOGICAL|TIL|On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)
214908525|NCT03658785|DRUG|Aldesleukin|IL-2 125,000 IU/kg/day IV (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks
214908526|NCT03658785|DRUG|Cyclophosphamide|On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
214908527|NCT03658785|DRUG|Fludarabine|Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days
214908528|NCT03035383|PROCEDURE|Purse string technique|Thyroidectomy closure is performed using purse string suturing technique.
214908529|NCT03035383|PROCEDURE|Conventional technique|Thyroidectomy closure is performed using conventional suturing technique.
214908530|NCT04760977|DRUG|Drugs administration|Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents
214908531|NCT04760977|DEVICE|Resuscitative endovascular balloon occlusion of the aorta|Resuscitative technique for exsanguinating traumas
214908532|NCT04760977|BIOLOGICAL|Blood transfusions|Transfuion of transported blood products for exsanguinating traumas
214908533|NCT04760977|OTHER|Prehospital management|Stay and play strategy vs scoop and run
214908534|NCT04760977|DEVICE|Prehospital eFAST|Prehospital thorax/abdomen extended focused assessment sonography for trauma
214908535|NCT03264183|DIAGNOSTIC_TEST|Transesophageal Echocardiography|TEE measures of right ventricular function
214908536|NCT03264183|DIAGNOSTIC_TEST|Transthoracic Echocardiography|TTE measures of right ventricular function
214908537|NCT03817853|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
214908538|NCT03817853|DRUG|Bendamustine|Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
214908539|NCT03817853|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
214908540|NCT03817853|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
214908541|NCT03817853|DRUG|Prednisone/Prednisolone/Methylprednisolone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
214908542|NCT03817853|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
214908543|NCT02992353|PROCEDURE|Three-port pulmonary resection surgery|Three-port pulmonary resection surgery
214908544|NCT02992353|PROCEDURE|Single-port or two-port surgery|Single-port or two-port pulmonary resection surgery
214908545|NCT04727905|DIETARY_SUPPLEMENT|energy drink|The explosive force and muscle endurance of the lower limbs were tested first, and then the special training intervention for fire rescue was performed. Solution supplementation was carried out. The experiment group was divided into the control group and only drank 1 liter of pure water, and the sports drink group supplemented with commercially available sports drinks (using commercially available treasures). Mineral water powder configuration), mint-flavored sports drink group supplemented with mint-flavored commercially available sports drinks (using commercially available treasure mineral water powder configuration plus edible flavor 0.01% menthol)
214908546|NCT01496677|DRUG|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to elderly subjects
214908547|NCT01496677|DRUG|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to younger group (18-45 years old)
214908548|NCT03902262|PROCEDURE|appendicectomy|
214908549|NCT06189196|DEVICE|BLOW BOTTLE|Blow Bottle PEP' is the cost-effective device comparative to other PEP devices. Treatment (CPT) along with BBPEP twice a day. Therapist made a cost-effective BBPEP which generates 10 cm of H2O PEP and it was given for 10 breaths, 3 sets with 5 second hold.
214908550|NCT06189196|OTHER|ACBT|Active cycle of breathing technique (ACBT) is an alternative airway clearance technique. A typical ACBT cycle consists of breathing control, three to four thoracic expansion exercises, and a forced expiratory technique (huffing). ACBT has been shown to improve short-term secretion clearance in patients with chronic lung disease. It is also flexible, tolerated, and accepted well by patients. Although ACBT is widely used in patients with respiratory conditions characterized by chronic sputum production.
214908551|NCT04121819|DRUG|Cytarabine|cytarabine 100mg/m2 d1-5 subcutaneous
214908552|NCT00563693|DEVICE|ASV|Adaptive servo ventilator
214908553|NCT00563693|OTHER|without Autoset CS2|without Autoset CS2
214908554|NCT05477264|DRUG|Tislelizumab|"Induction therapy: Tislelizumab combined with radiation~* Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~* Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~* Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance."
214908555|NCT06563453|DEVICE|transcranial alternating current stimulation|Transcranial Alternating Current Stimulation (tACS) is a tool that administers a weak alternating current (in the range of 0.1 to 4 mA), most often with a sinusoidal waveform, between electrodes placed over target areas. This can entrain the subjacent neuronal networks favouring the firing at specific frequencies of interest, in certain cases, with effects outlasting the stimulation duration up to 70 min.
214908556|NCT04756882|DRUG|AbobotulinumtoxinA 500 UNT|"Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes"
214908557|NCT05990374|DRUG|Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc|The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.
215057873|NCT03440463|BEHAVIORAL|Norms-plus-Strategies booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare. These booster emails will also contain reminders of strategies they can use to protect themselves from alcohol-related harm, both ones they've reported using in the past and others they might consider using in the future.
214908558|NCT06193317|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
214908559|NCT06492759|RADIATION|Radiation Therapy|Undergo radiation therapy
214908560|NCT06492759|BIOLOGICAL|Pembrolizumab|Given IV
214908561|NCT06492759|DRUG|Nab-paclitaxel|Given IV
214908562|NCT06492759|DRUG|Paclitaxel|Given IV
214908563|NCT06492759|DRUG|Carboplatin|Given IV
214908564|NCT06492759|DRUG|Gemcitabine|Given IV
215057874|NCT03899025|RADIATION|CT|CT = computed tomography of the hand/wrist HRpQCT = high resolution peripheral quantitative CT scan of the hand/wrist
215057875|NCT01282385|DRUG|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
214908565|NCT06492759|PROCEDURE|Biopsy|Undergo biopsy
214908566|NCT06492759|PROCEDURE|Computed Tomography|Undergo CT
214908567|NCT06492759|PROCEDURE|Bone Scan|Undergo bone scan
214908568|NCT06492759|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214908569|NCT06492759|OTHER|Medical Chart Review|Ancillary studies
215057876|NCT01282385|DRUG|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
214908570|NCT03390023|BEHAVIORAL|Focus Group|Groups will last 60 to 90 minutes. Focus groups will be moderated by KUMC Juntos staff who are formally trained to conduct focus groups. General topics to be covered in focus groups include: attitudes, preferences and knowledge about prenatal care, clinical trial participation, and nutritional supplement use. Focus groups will be conducted in Spanish.
214908571|NCT01146119|BIOLOGICAL|Multimeric-001, 500 mcg|Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
214908572|NCT01146119|BIOLOGICAL|Adjuvanted PBS|Adjuvanted PBS was administered twice with an interval of 19-23 days.
214908573|NCT01146119|BIOLOGICAL|PBS and TIV 15%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
214908574|NCT01146119|BIOLOGICAL|PBS and TIV 50%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
214908575|NCT03415932|BEHAVIORAL|health education|Health information by a multimodal team
214908576|NCT04652115|DRUG|Defibrotide|Deibrotide via IV
214908577|NCT00314340|BEHAVIORAL|Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity|The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
214908578|NCT00314340|DRUG|ER Morphine|
214908579|NCT00314340|DRUG|hydrocodone plus acetaminophen|
214908580|NCT00314340|DRUG|placebo|
214908581|NCT03227289|OTHER|Stayed in NRDS|The neonates with NRDS are stayed in NRDS.
214908582|NCT03227289|OTHER|Converted to ARDS|The neonates with NRDS are converted to ARDS.
215057877|NCT03940846|DIAGNOSTIC_TEST|Virtual biopsy|Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
214908583|NCT00607620|BEHAVIORAL|Brief Intervention|Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
214908584|NCT01620138|DRUG|Pasireotide|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.~The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
215057878|NCT01251718|DRUG|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
215057879|NCT03773666|DRUG|Durvalumab|Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
215057880|NCT03773666|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
215057881|NCT06155006|DIAGNOSTIC_TEST|rapid diagnostic test HCV Ab Plus Rapid test|The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes. This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
215057882|NCT00230776|DRUG|pregabalin|
215057883|NCT00230776|DRUG|placebo|
215057884|NCT03551834|OTHER|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
215057885|NCT03551834|OTHER|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
215057886|NCT04116177|DEVICE|Deep brain stimulation|Stimulation using VerciseTM system
215057887|NCT00149240|BIOLOGICAL|Botulinum toxin type A|
215057888|NCT01663766|DRUG|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
215057889|NCT02467127|DIETARY_SUPPLEMENT|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
214303444|NCT01673451|DRUG|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
214303445|NCT06543069|DRUG|Sintilimab, Bevacizumab , Pemetrexed , Cisplatin|Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.
214303446|NCT02555033|OTHER|Resistance training|traditional resistance training
214908585|NCT01620138|DRUG|cabergoline|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.~The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
214908586|NCT06150937|BEHAVIORAL|AEGIDA intervention arm|The intervention arm has 4 sessions facilitated one-on-one by trained staff and lasting \~40 minutes. The first session focuses on establishing rapport, assessing HIV risk, and educating/training participants on HIV self-testing/PEP/PrEP. The second session on peer education/training, barriers to and facilitators of testing, and supporting peers in receiving reactive and/or indeterminate HIV test results, as well as self-care. The third session on stigma and discrimination and techniques to cope with and resist stigma. The final session is a culminating one focused on reviewing key skills and health promotion planning conducted in first three sessions. The intervention arm applies anti-intersectional stigma, empowerment, and harm reduction approaches. All participants will receive/have access to HIV self-test kits every three months.
214908587|NCT06150937|BEHAVIORAL|AEGIDA control arm|The control arm has 4 sessions via one-on-one facilitation by a trained facilitator and lasting \~40 minutes. It includes basic information on self-screening for common adverse health conditions among women in Kazakhstan, including STIs and HIV, as well as information on testing and risk reduction. All participants will receive/have access to HIV self-test kits every three months.
214908588|NCT04025099|OTHER|Internal Cues|"The intuitive eating curriculum that was pilot tested and adapted has been modified for use for the Internal Cues group with college-aged females for delivery over a 10-week time period.~The classes will be delivered by two Registered Dietitians and Certified Intuitive Eating Counselors from the University of Delaware, Julia Katcher and Maryann Eastep.~During the Internal Cues group's intuitive eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn the intuitive eating principles taught in class.~The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Jones, RYT."
214908589|NCT04025099|OTHER|External Cues|"The 10-week traditional healthy weight program for the External Cues group was created by a Graduate Assistant based on MyPlate principles.~The External Cues classes will be delivered by two Registered Dietitians from the University of Delaware, Julia Katcher and Maryann Eastep.~During the External Cues group's healthy eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn how to properly portion their meals to meet their caloric needs, in line with traditional education about weight control.~Students randomized to the External Cues group will receive a UD fitness pass and will be able to choose from select cardio-based fitness classes in order to meet public health recommendations for physical activity."
214908590|NCT05316207|OTHER|Telenursing|From the end of the first week after discharge to the end of the first month, patients were counseled over the phone during the home process. Complications were followed up.
214908591|NCT03602378|DIAGNOSTIC_TEST|salivary cortisol|5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).
214908592|NCT03602378|DEVICE|Holter Medilog AR12 Plus|Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV
214908593|NCT03602378|DEVICE|Polar V800|Polar V800 with sensor - during 5 minutes for measuring HRV
214908594|NCT03602378|DEVICE|AGE reader|for measuring Advanced Glycation End products (AGEs)
214908595|NCT04273347|OTHER|standard of care for patient with brain trauma and spinal cord injury|neurological examination, examination of articulation, infectious status, respiratory status, inflammatory status,kinesitherapy
214908596|NCT01982513|DEVICE|Ultrasound|The IVC will be visualized and images obtained using the intercostal window in both longitudinal and transverse planes.
214303447|NCT02555033|OTHER|Instability resistance training|training under unstable conditions
214303448|NCT04429893|DRUG|magnesium sulphate|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
215077719|NCT02975011|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
214303449|NCT04429893|DRUG|bupivicaine|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
214346929|NCT00823719|DRUG|ofatumumab + ICE|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m\^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m\^2 on days 1, 2 and 3 of dosing cycle."
214670126|NCT02752308|DRUG|Dilute epinephrine injection|Injection of 1/100000 epinephrine solution along all incision lines
214908597|NCT00279071|DEVICE|Acupuncture og acupressure when diagnosed with dystocia|Acupuncture points: sp6 li4 ki3 ki6 bl60 Acupressure points: bl67
214908598|NCT00141492|DRUG|Androgel (testosterone gel)|
214908599|NCT02551562|OTHER|NuDerm® System|The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
214346930|NCT00823719|DRUG|ofatumumab + DHAP|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m\^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m\^2 q12 hrs (2 doses) on day 2 of dosing cycle."
214908600|NCT02551562|OTHER|Placebo|Basic skin care regimen
214908601|NCT06309992|DRUG|Survodutide|Survodutide
214908602|NCT06309992|DRUG|Placebo|Placebo matching survodutide
214908603|NCT00629252|DRUG|Sertindole|oral 12-20 mg/day
214908604|NCT00629252|DRUG|Risperidone|oral 2-6mg / day
214908605|NCT05739383|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|Subcutaneous injection in pre-filled syringe.
214908606|NCT05739383|DRUG|Placebo in 1.5ml|Matching placebo in 1.5ml solution for injection
214908607|NCT02933385|BEHAVIORAL|Health Risks assessement|Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
214908608|NCT02933385|BEHAVIORAL|Web-based health discussions|Create interactions between the employees.
214908609|NCT02933385|BEHAVIORAL|SOScuisine website|Site that is personalized to the employee. It provides menus, grocery shopping list and other.
214908610|NCT02933385|BEHAVIORAL|Health screening|Screen for diabetes, cholesterol, blood pressure and body weight.
214908611|NCT02933385|BEHAVIORAL|Closing events|these aim to motivate the employees to continue into the program.
214908612|NCT02933385|BEHAVIORAL|Coaching|The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.
214908613|NCT02933385|BEHAVIORAL|Social Health platform|
214908614|NCT02933385|BEHAVIORAL|Accelerometer provided|Social Health Platform: employees can challenge themselves or each other.
214908615|NCT05509894|DRUG|Ngenla|As provided in real world practice
214908616|NCT04969328|OTHER|ParTNer-STEPs|"The intervention is a transfer program (ParTNer-STEPs), offered to the parents 1½ - ½ year before their child´s transfer to adult care.~ParTNer-STEPs consist of~1. an informative website available for parents from recruitment until follow-up.~2. online educational events for parents. The teaching events are offered twice a year as a web based seminar with short presentations on different topics. The seminars will not be available for parents after their child has transferred to adult care.~3. transfer consultations across the paediatric and adult department. The transition consultations consist of:~   * a preparatory consultation (3-6 months before transfer) with the paediatric nurse.~  * a farewell consultation with the paediatric nurse (0-3 months before transfer).~  * a joint consultation (at transfer) where both the pediatrician and the adult physician will be present.~  * a welcoming consultation with the nurse from the adult care (0-3 months after transfer)."
214908617|NCT05916937|DRUG|omalizumab 300 mg every four weeks|"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
214908618|NCT05916937|DRUG|omalizumab 300 mg every six weeks|"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
214908619|NCT03252535|BIOLOGICAL|Cellavita HD lower dose|The participants will receive a total of 9 intravenous administrations of 1x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
214908620|NCT03252535|BIOLOGICAL|Cellavita HD higher dose|The participants will receive a total of 9 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
214908621|NCT03252535|OTHER|Placebo|The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
214908622|NCT05900388|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain
214908623|NCT05900388|DRUG|Standard of care (SOC)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
214908624|NCT06966479|DRUG|Verekitug|Verekitug subcutaneous injection.
214908625|NCT06966479|DRUG|Placebo|Verekitug matching placebo.
214908626|NCT05583617|DRUG|Cevostamab|"Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles.~Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles."
214908627|NCT05583617|DRUG|Lenalidomide|Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.
214908628|NCT05583617|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
214908629|NCT05583617|DRUG|Iberdomide|Iberdomide will be administered PO on days 1-14 of a 21-day cycle.
214908630|NCT05583617|DRUG|Dexamethasone|Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.
214908631|NCT06967610|DRUG|Pirtobrutinib|Given PO 200mg daily
214908632|NCT06967610|DRUG|Venetoclax|Given PO daily
214908633|NCT06967610|DRUG|Obinutuzumab|Given IV 100mg day 1, 900 mg day 2, 100mg days 8, 15
214908634|NCT06529822|BIOLOGICAL|Synthetic long peptide personalized cancer vaccine|Neoantigen vaccines will be provided on a patient-specific basis
214908635|NCT06529822|DRUG|Poly ICLC|Poly-ICLC will be supplied by Oncovir, Inc.
214908636|NCT06529822|DEVICE|Signatera assay|Signatera is a clinically validated, personalized, tumor-informed, multiplex-PCR and next-generation sequencing (NGS) based clinical trial assay targeting 16 tumor-specific mutations. It is intended for the detection of ctDNA isolated from anticoagulated peripheral whole blood from post-surgical patients previously diagnosed with localized or advanced solid tumors to aid physician assessment and treatment decision-making, together with other clinical factors
214908637|NCT05323409|BEHAVIORAL|OPTIMISE|OPTIMISE is a multilevel intervention that seeks to improve patient activation for comorbidity self-management during cancer treatment and coordination of care between oncologists and primary care physicians from point of diagnosis through the first year of post-treatment survivorship.
214908638|NCT06852677|OTHER|Deep Squat position|"Participants assigned to the deep squat group will perform a cumulative total of 20 minutes of deep squatting per day, six days a week, for six weeks. The squatting time can be divided into multiple shorter sessions throughout the day, with a maximum interval of 48 hours between sessions. Participants will be instructed to maintain an upright posture with heels on the ground, feet shoulder-width apart, and knees aligned with toes. They will be encouraged to gradually increase their squat duration and comfort over time.~Before starting the intervention, participants will receive standardized instructions on proper squat form to ensure safety and maximize benefits. Their compliance will be monitored through a training diary in the experimental (Tulkit) app."
214908639|NCT06852677|OTHER|Cross-legged Sitting|"Participants assigned to the cross-legged sitting group will perform a cumulative total of 20 minutes of cross-legged sitting per day, six days a week, for six weeks. The squatting time can be divided into multiple shorter sessions throughout the day, with a maximum interval of 48 hours between sessions. Participants will be instructed to maintain an upright posture while sitting. They will be encouraged to gradually increase their cross-legged sitting duration and comfort over time.~Before starting the intervention, participants will receive standardized instructions on proper sitting form to ensure safety and maximize benefits. Their compliance will be monitored through a training diary in the experimental (Tulkit) app."
214908640|NCT06184204|DRUG|Trombix® (Rivaroxaban)|20mg or 15 mg as per the doctor's prescription
214908641|NCT04144894|DIAGNOSTIC_TEST|Shear Wave Elastography|Advanced ultrasound technique
214908642|NCT04612751|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
214908643|NCT04612751|DRUG|Durvalumab|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
214908644|NCT04612751|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
214908645|NCT04612751|DRUG|AZD2936|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
214908646|NCT04612751|DRUG|MEDI5752|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
214908647|NCT04612751|DRUG|AZD7789|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
215057890|NCT04934839|DIAGNOSTIC_TEST|Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.|"Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts."
214346931|NCT03856346|DIAGNOSTIC_TEST|Biometry|Biometry for phaco-vitrectomy procedures pre- and postoperatively
214346932|NCT01753024|DIETARY_SUPPLEMENT|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
214908648|NCT04248452|DRUG|Capecitabine|Given PO
214908649|NCT04248452|DRUG|Fluorouracil|Given IV
214908650|NCT04248452|DRUG|Leucovorin|Given IV
214908651|NCT04248452|DRUG|Leucovorin Calcium|Given IV
214908652|NCT04248452|DRUG|Oxaliplatin|Given IV
214908653|NCT04248452|RADIATION|Radiation Therapy|Undergo radiation therapy
214908654|NCT02683993|DEVICE|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
215057891|NCT00479570|DRUG|PF-00446687|Single 200mg dose
215057892|NCT00479570|DRUG|Placebo|
215077720|NCT02975011|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214346933|NCT00861939|DRUG|Bupropion HCI 300 mg Extended-Release Tablets EON|
214908655|NCT06496451|OTHER|Spinal tap for CSF collection|"A spinal tap will be done on you by your choice of bedside or in the interventional radiology (IR) suite in the Shands (Neuromedicine) hospital. This procedure will be done by trained technicians under medical supervision or the principal investigator. Local anesthesia will be used to numb the site of injection on your back. We plan to collect about 4 tablespoons of spinal fluid."
214908656|NCT06496451|OTHER|Venipuncture for blood sample|a sample of blood (approximately 4-5 tablespoonfuls) will be collected
214908657|NCT06617325|DRUG|DZP|Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.
214908658|NCT06617325|OTHER|Placebo|Study participants will receive placebo at prespecified time-points.
214346934|NCT00861939|DRUG|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
214346935|NCT04923386|OTHER|None (not interventional)|This is not an intervention
215057893|NCT02023580|BEHAVIORAL|Video treatments|"The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility."
214908659|NCT06668558|DRUG|Azacitidine (AZA)|"Dosing is 75 mg/m2 x 7 days (Q28days) After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)"
214908660|NCT06668558|DRUG|Venetoclax|"Dosing: 400 mg daily After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)"
214908661|NCT04712474|BEHAVIORAL|In-home decluttering practice|"The in-home decluttering intervention comprises 10, 1.5-hour home-visits over the course of 10 weeks.~These home visits are personalized, goal-oriented and focused on decluttering. They include 1) a brief check-in, 2) guided unclutter time 3) a reflective period during which participants share their thoughts and objectives for the coming week, and 4) homework assignments."
214908662|NCT04876157|DIAGNOSTIC_TEST|Artificial intelligence-aimed point-of-care ultrasound image interpretation system|improve the sensitivity and specificity of the AI-aimed ultrasound interpretation system
214908663|NCT05883293|DRUG|Cell Free Fat Extract(CEFFE)|The subjects inhaled 2ml of CEFFE each time in a nebulized inhalation method, inhaling every 3 days, for a total of 7 inhalations
214908664|NCT05691491|PROCEDURE|Biopsy Procedure|Undergo biopsy
214908665|NCT05691491|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214908666|NCT05691491|PROCEDURE|Computed Tomography|Undergo CT scan
214908667|NCT05691491|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214908668|NCT05691491|DRUG|Temozolomide|Given orally (PO)
215057894|NCT03720626|DRUG|crizanlizumab|IV formulation with 30 min infusion, 5mg/kg dosage
215057895|NCT00500357|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
215057896|NCT00003730|DRUG|fluorouracil|
215057897|NCT00003730|DRUG|vinorelbine tartrate|
215057898|NCT04776616|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
215057899|NCT04776616|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
215057900|NCT00078806|DRUG|Etanercept|Administered by subcutaneous injection twice a week
215057901|NCT00078806|DRUG|Placebo|Administered by subcutaneous injection twice a week
214908669|NCT05691491|DRUG|Tuvusertib|Given PO
214908670|NCT05600283|DIAGNOSTIC_TEST|Swab kit (COBAS HPV 4800 Assay -Evalyn brush)|Patient self-sampling swab kit to collect a vaginal sample for HPV testing
214908671|NCT05600283|DIAGNOSTIC_TEST|Clinician-collection of cervical sample for HPV testing|Speculum exam and collection of a cervical specimen using standard endocervical brush and spatula placed into ThinPrep medium for HPV testing (Evalyn brush)
214908672|NCT06463886|BEHAVIORAL|STEP-AD|This in-person STEP-AD intervention will consist of 10 sessions. Session 1: Life Steps Adherence Session 2: Psychoeducation on the treatment model Session 3: Substance Use and Enhancing Resilience Session 4: Trauma Impact Session 5: Cognitive Restructuring Session 6: Racial Discrimination Impact and Coping Session 7: HIV Stigma Impact and Coping Session 8: Gender-related Stressors and Coping Session 9: Body Image and Healthy Relationships Session 10: Practice, Review, and Relapse Prevention. Each session lasts for about 40 to 60 minutes.
215057902|NCT01734785|DRUG|Linagliptin|tablet
215057903|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
215057904|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
214670127|NCT02752308|DRUG|Fentanyl|fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
214670128|NCT02752308|DRUG|dextrose plus sodium chloride.|Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
215057905|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
215057906|NCT01734785|DRUG|Empagliflozin placebo + Linagliptin placebo|Matching Empagliflozin + Linagliptin low dose
215057907|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
215057908|NCT01212887|BIOLOGICAL|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
215057909|NCT01212887|BIOLOGICAL|aldesleukin|
215057910|NCT01212887|DRUG|cyclophosphamide|
215057911|NCT01212887|DRUG|fludarabine phosphate|
215057912|NCT01212887|OTHER|laboratory biomarker analysis|
215057913|NCT01212887|OTHER|pharmacological study|
215057914|NCT06534047|DEVICE|Brainsway H4 deep Repetitive Transcranial Magnetic Stimulation (rTMS) coil|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member."
215077721|NCT02975011|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214908673|NCT06463886|BEHAVIORAL|Enhanced treatment as usual (E-TAU)|Participants assigned to the E-TAU condition will receive 10 in person sessions to ensure comparable contact time with study staff and identical incentives. The first session will consist of a session on healthy living with HIV (CDC content on HIV 101 \[highlights importance of engaging in care, adhering to medication, finding support\], nutrition, and physical activity. The remaining 9 sessions will consist of neutral (daily events) writing. Women will be asked to write a description of their plans for the next 24 hours.
214908674|NCT06509763|DEVICE|ECGI system during LBBP implant|ECGI system to create non-invasive ventricular maps during the screwing steps of the LBBP electrode
215057915|NCT06534047|DRUG|Nicotine replacement|"Each participant will receive individualized NRT treatment through the advice of their study physician for 6 weeks. The study physician, in discussion with the participant, will decide the type, dosage, and combination of NRT to provide to the participant.~NRT provided can include:~* Patch (7mg, 14mg, and 21mg)~* Gum (2mg)~* Lozenge (2mg)~* Inhaler (10mg; 4mg of nicotine delivered)"
214908675|NCT04826757|OTHER|Coordinated care|"Coordinated care between general practioners; physiotherapists and occupational health services.~Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)"
214908676|NCT06323421|BEHAVIORAL|Mindfulness|Participants attend seven 60-90 min group mindfulness sessions each week and a 1/2 day retreat, with three sessions in-person and six sessions remote, led by a mindfulness interventionist. Additionally, participants will be encouraged to engage for at least 30 minutes per week in asynchronous mindfulness activities through a web-based program to increase exposure to mindfulness practices beyond group sessions.
214908677|NCT05966662|DEVICE|IVL with Shockwave C2+ 2Hz Coronary IVL Catheter|Lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
214908678|NCT04341597|OTHER|cervical ultrasound|All volunteer patients for whom a cervical ultrasound is indicated will have with a first operator the performing the usual technic, and with a second operator performing the trans perineal technic without being aware of the first measurement.
214908679|NCT05445609|DRUG|VLP-encapsulated TLR9 Agonist CMP-001,|Given SC or IT
214908680|NCT05445609|BIOLOGICAL|Nivolumab|Given IV
214908681|NCT03831932|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214908682|NCT03831932|PROCEDURE|Computed Tomography|Undergo CT scan
214908683|NCT03831932|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
214908684|NCT03831932|DRUG|Osimertinib|Given PO
214908685|NCT03831932|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214908686|NCT03831932|DRUG|Telaglenastat Hydrochloride|Given PO
214908687|NCT03831932|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214908688|NCT06820957|PROCEDURE|Biopsy Procedure|Undergo bone marrow aspiration and biopsy
214908689|NCT06820957|PROCEDURE|Biospecimen Collection|Undergo tissue and/or blood sample collection
215057916|NCT03136224|DEVICE|Thermocautery|
214908690|NCT06820957|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214908691|NCT06820957|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214908692|NCT06820957|PROCEDURE|Computed Tomography|Undergo CT
214908693|NCT06820957|DRUG|Cyclophosphamide|Given IV
214908694|NCT06820957|DRUG|Doxorubicin Hydrochloride|Given IV
214908695|NCT06820957|PROCEDURE|Echocardiography Test|Undergo echocardiography
214908696|NCT06820957|DRUG|Etoposide|Given IV
215057917|NCT03136224|DEVICE|Plastic Clamping|
215057918|NCT03136224|DEVICE|Surgical Circumcision|
215057919|NCT00161616|DRUG|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
215057920|NCT06547333|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
215057921|NCT06547333|DRUG|Placebo|Placebo
215057922|NCT01722526|DRUG|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
215077722|NCT02975011|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214908697|NCT06820957|OTHER|Fludeoxyglucose F-18|Given FDG
214908698|NCT06820957|DRUG|Ifosfamide|Given IV
214908699|NCT06820957|DRUG|Irinotecan Hydrochloride|Given IV
214908700|NCT06820957|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214908701|NCT06820957|PROCEDURE|Positron Emission Tomography|Undergo FDG PET
214908702|NCT06820957|OTHER|Questionnaire Administration|Ancillary studies
214908703|NCT06820957|RADIATION|Radiation Therapy|Undergo radiation
214908704|NCT06820957|DRUG|Regorafenib|Given PO
214908705|NCT06820957|PROCEDURE|Surgical Procedure|Undergo surgery
214908706|NCT06820957|DRUG|Vincristine Sulfate|Given IV
214908707|NCT06650865|OTHER|Traditional Exercise Group|"It is important for the therapist to organize a exercise program to provide pain control. The exercise program should be specific and clear to the patient.~Exercises will be applied to this group. The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
214908708|NCT06650865|OTHER|Baduanjin Exercise Group|"In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
214908709|NCT06650865|OTHER|Telerehabilitation Group|"Baduanjin exercise will be applied simultaneously with the telerehabilitation method. In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
214908710|NCT06982235|DEVICE|Ureteroscope system|LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System with intrarenal pressure monitoring
214908711|NCT06982235|DEVICE|Laser system|Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology
215077723|NCT02975011|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
215077724|NCT02975011|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
214908712|NCT01815775|OTHER|clinical and imaging examinations|"Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation"
214908713|NCT06600412|DRUG|R3R01|R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.
214908714|NCT06600412|DRUG|Placebo|Please refer to arm/group description for further information.
214908715|NCT06594848|DIETARY_SUPPLEMENT|Black rice extract|Black rice extract is rich in a specific type of anthocyanins, cyanidin. It has been shown by our group that cyanidin-rich food can have beneficial health effects
214908716|NCT06594848|OTHER|Placebo|The placebo for this study is composed by maltodextrin and food colorant
214908717|NCT06595498|DIAGNOSTIC_TEST|Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)|The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the NGS Plasma-SeqSensei™ Solid Cancer IVD Kit (Sysmex) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles). Data analysis will be performed using Plasma-SeqSensei™ IVD Software (Sysmex).
214908718|NCT06595498|DIAGNOSTIC_TEST|cobas® EGFR Mutation Test v2 (Roche)|The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the cobas® EGFR Mutation Test v2 (Roche) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles).
214908719|NCT02839473|DEVICE|Castalie water spray|
214908720|NCT02839473|DEVICE|Hydrogel Hydrosorb®|
214908721|NCT06543277|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Participants will receive 18 goal-directed upper extremity rehabilitation therapy sessions with paired taVNS over six weeks, followed by a 90-day home exercise program.
214908722|NCT05188183|DEVICE|M1 anodal home-based tDCS|During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10 mA.
214908723|NCT05188183|BEHAVIORAL|Somatosensory Training|The somatosensory training will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks. Sessions will start with relaxation exercises using a body scan technique, whereby subjects in a relaxed state will be instructed to sequentially interchange their mind to different regions of the body while perceiving it and establishing contact with the body part. Subjects will be asked to concentrate on any feeling (kinetic, kinesthetic or exteroceptive) related to each body part. Phantom exercises will involve the use of imagined movements of the phantom limb. Therefore, patients will be asked to perform general exercises with their phantom limb. Exercises will include hip, knee, ankle, and toe movements.
214908724|NCT05188183|OTHER|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
214908725|NCT06290128|DRUG|Riliprubart|Pharmaceutical form: Solution Route of administration: IV Infusion
214908726|NCT06290128|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: IV Infusion
214908727|NCT06290128|DRUG|Riliprubart|Pharmaceutical form: Solution Route of administration: SC Injection
214908728|NCT06290128|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: SC Injection
214908729|NCT06980688|PROCEDURE|Propofol titration|Induction starts with propofol target-controlled Infusion (TCI) (Schnider model) at target effect-site drug concentration (Cet) 0.5-1.0 µg/mL and remifentanil TCI (Minto model) at Cet 0.5 ng/mL. If loss of consciousness (LOC) is not reached, propofol Cet is increased in 0.5-1.0 µg/mL steps. For intubation, remifentanil Cet increases up to 6.0 ng/mL.
214908730|NCT06980688|PROCEDURE|Conventional propofol induction|Induction starts with propofol TCI at Cet 4-8 µg/mL and remifentanil TCI at Cet 2.5-3.5 ng/mL.
214908731|NCT06979609|DRUG|Oral Vancomycin Prophylaxis|125mg PO BID for the duration of antibiotic re-exposure + 125mg PO QD for 7 days
214908732|NCT06979609|DRUG|Placebo|2 capsules PO BID for the duration of antibiotic re-exposure + 1 capsule PO QD x 7 days
214908733|NCT05604066|DIAGNOSTIC_TEST|Magnetic Resonance (MR) Elastography|Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues
214908734|NCT05604066|DIAGNOSTIC_TEST|MRI structural imaging|MRI structural imaging will be done at the same time as MR elastography.
215057923|NCT01404143|PROCEDURE|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
214670129|NCT02752308|DRUG|neostigmine and atropine|Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
214908735|NCT03945240|PROCEDURE|Group 1 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, \~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
214908736|NCT03945240|PROCEDURE|Group 2 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, \~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
214908737|NCT03945240|PROCEDURE|Group 3 -- using Phoenix Thera-Lase Device|"Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, \~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
214908738|NCT04048239|PROCEDURE|cochlear implantation|cochlear implantation is a system developed to restore hearing in people with profound sensorineural hearing loss, whose classical hearing aids are ineffective. Surgery is necessary to insert the internal part into the cochlea and requires milling the mastoid to access the round window. This approach is technically difficult, and is performed under a microscope by an experienced surgeon.
214908739|NCT04048239|OTHER|computerized tomography (CT) scan|computerized tomography (CT) scan of the facial nerve
214908740|NCT04048239|OTHER|electromyograph|electromyographic verification of the facial nerve
214908741|NCT06611839|DRUG|Ivosidenib, Venetoclax, Azacitidine|"phase I: Induction therapy：Ivosidenib 、Venetoclax、Azacitidine~Dose climbing stage: adopt the 3 + 3 design principle, and the dose level 0,-1and 1 are set as follows~dose level 0: Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1,800mg d1-14 Azacitidine 75mg/m2/d, d1-7~dose level -1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1, 600mg d1-14 Azacitidine 75mg/m2/d, d1-5~dose level 1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1 800mg d1-21 Azacitidine 75mg/m2/d, d1-7~Consolidation therapy intermediate-dose cytarabine regimen ： 3 courses~If IDH1 mutant residual disease was positive before consolidation chemotherapy, Ivosidenib was added;~Maintenance treatment:~Azacitidine、Venetoclax 、Ivosidenib： 6 courses~phase II: dose based on phase I results"
214908742|NCT05754190|DEVICE|SOMA pain manager smartphone application|SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
214908743|NCT06674226|DRUG|Ciprofol|0.25mg/kg for anesthesia induction ＋0.25\~1.5 mg/kg/h for maintenance
214908744|NCT06674226|DRUG|Propofol|1.0mg/kg for induction ＋1 \~ 6mg/kg/h for maintenace
214908745|NCT06860594|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214908746|NCT06860594|PROCEDURE|Computed Tomography|Undergo CT
214908747|NCT06860594|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214908748|NCT06860594|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214908749|NCT06860594|DRUG|Triapine|Given PO
214908750|NCT06998680|OTHER|VitaGreen Capsule A+VitaGreen Tonic|VitaGreen Capsule A+VitaGreen Tonic,use 24 weeks
214908751|NCT06998680|OTHER|VitaGreen Capsule B+VitaGreen Tonic|VitaGreen Capsule B+VitaGreen Tonic,use 24 weeks
215057924|NCT01404143|PROCEDURE|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
214346936|NCT05512494|BIOLOGICAL|Quadrivalent Influenza Vaccine (Split Virion), inactivated|The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains（including 4 antigens H1N1, H3N2, BV and BY, 15μg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
214908752|NCT06998680|OTHER|Capsule Placebo+VitaGreen Tonic|Capsule Placebo+VitaGreen Tonic,use 24 weeks
214908753|NCT06998680|OTHER|Capsule Placebo+Tonic Placebo|Capsule Placebo+Tonic Placebo,use 24 weeks
214908754|NCT06676319|DRUG|Lunsekimig|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
214908755|NCT06676319|DRUG|Short-Acting Beta Agonists (SABA)|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
214908756|NCT06676319|DRUG|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
214908757|NCT06676319|DRUG|Fluticasone/salmeterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
214908758|NCT06676319|DRUG|Budesonide/formoterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
214908759|NCT04933721|DRUG|berotralstat|BCX7353 capsules or granules administered orally once daily
214908760|NCT07004998|PROCEDURE|Cricoid Pressure (30 N)|Manual application of posterior pressure on the cricoid cartilage at a standardized force of 30 newtons. The pressure is applied by a trained operator using one or two fingers, with the goal of compressing the esophagus against the cervical spine. The maneuver is performed after induction of general anesthesia and immediately before videolaryngoscopy. A still image of the glottic view is captured during pressure application.
215057925|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.11 mL x subject height
215057926|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.22 mL x subject height
215057927|NCT03691337|DRUG|Sodium chloride|Fascia iliaca block with volume 0.11 mL x subject height
214908761|NCT07004998|PROCEDURE|Left Paratracheal Pressure (30 N)|Manual application of pressure to the left paratracheal region, lateral to the trachea and inferior to the thyroid cartilage, at a standardized force of 30 newtons. The pressure is applied by a trained operator using the thumb or fingers. The maneuver is performed after induction of general anesthesia and immediately before videolaryngoscopy. A still image of the glottic view is captured during pressure application.
214908762|NCT03228667|DRUG|N-803 + Pembrolizumab|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
214908763|NCT03228667|DRUG|N-803 + Nivolumab|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
214908764|NCT03228667|DRUG|N-803 + Atezolizumab|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
214908765|NCT03228667|DRUG|N-803 + Avelumab|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
214908766|NCT03228667|DRUG|N-803 + Durvalumab|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
214908767|NCT03228667|DRUG|N-803 + Pembrolizumab + PD-L1 t-haNK|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
214908768|NCT03228667|DRUG|N-803 + Nivolumab + PD-L1 t-haNK|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
214908769|NCT03228667|DRUG|N-803 + Atezolizumab + PD-L1 t-haNK|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
214908770|NCT03228667|DRUG|N-803 + Avelumab + PD-L1 t-haNK|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
214908771|NCT03228667|DRUG|N-803 + Durvalumab + PD-L1 t-haNK|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
214908772|NCT03228667|DRUG|N-803 + Docetaxel + Pembrolizumab|The study employs a 6-week cycle combination of: N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and pembrolizumab (200 mg IV).
214908773|NCT03228667|DRUG|N-803 + Docetaxel + Nivolumab|The study employs a 6-week cycle combination of:N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and nivolumab (240 mg IV). Nivolumab dosing may be increased to 480mg every four weeks as per the investigator's discretion.
214908774|NCT04204655|DIAGNOSTIC_TEST|BIA|Bioelectrical Impedance Analysis
214908775|NCT06593678|OTHER|Telerehabilitation Program|Participants in the intervention group will receive a home-based rehabilitation program delivered via an asynchronous digital telerehabilitation platform. The multimodal program is accessible at online platform and it is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
214908776|NCT06593678|OTHER|Booklet-based rehabilitation program|Participants in the control group will receive a booklet-based rehabilitation program at home, provided through a detailed printed guide (explanatory booklet). This guide includes instructions in pictures and text for the multimodal program. It is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
214908777|NCT07110610|DRUG|LTG-321|active investigational drug
214908778|NCT07110610|OTHER|Placebo|Placebo-to-match LTG-321
214908779|NCT06866106|BEHAVIORAL|Positive Psychology (PP) Intervention|This is an adapted, optimized, phone-based, 9-week positive psychology (PP) intervention. Participants will complete 9 weekly phone sessions (30 minutes each) with a study interventionist in which they will review PP exercises that they have independently completed in between phone sessions. The PP exercises will be completed in a treatment manual that describes the PP exercise and provides space to write about the exercise and its effects, and to answer associated questions. A total of 9 sessions will be completed over the course of the program.
214908780|NCT06866106|BEHAVIORAL|Educational Intervention|This is an educational intervention that will match the PP intervention in terms of both time and attention. Participants will complete 9 weekly phone sessions (30 minutes each) with a study interventionist in which they will review educational exercises that they have independently completed in between phone sessions. The exercises will be completed in a treatment manual that describes the exercise and provides space to write about the exercise and its effects, and to answer associated questions. A total of 9 sessions will be completed over the course of the program.
214908781|NCT06619509|DRUG|Brigimadlin|Brigimadlin
214908782|NCT06674733|PROCEDURE|Botox administration|Treatment for bruxism
214908783|NCT06674733|PROCEDURE|Aromatherapy|treatment for stress-bruxism
214908784|NCT06674733|PROCEDURE|Clinical evaluation|Before the procedure, and at 1 month and 3 months after the procedure, the Fonseca questionnaire, symptom assessment questionnaire, and Basic Scale on Insomnia Complaint and Quality of Sleep (BaSIQS) will be administered. At the 1st month and 3rd month, Subject Global Aesthetic Improvement Scale (GAIS), and satisfaction questionnaire will be administered
214346937|NCT01206335|DRUG|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
214908785|NCT06674733|PROCEDURE|Imaging Time|Ultrasonography and shear wave elastography examination will be performed before the procedure, one month after, and three months after the procedure.
214908786|NCT07006727|DRUG|225Ac-ETN029|Radioligand therapy
214908787|NCT07006727|DRUG|111In-ETN029|Radioligand imaging agent
214908788|NCT06871072|OTHER|Telerehabilitation|EG performed using an artificial intelli-gence (AI) application called RehBody, which detects body segments, assists in cor-recting the technique and monitoring the exercise, number of sets and repetitions done, and the adherence percentage
214908789|NCT06871072|OTHER|Exercise program|CG participants followed the exercise program and trained at home with images and videos as support.
214908790|NCT07010354|DEVICE|Stenting|Endovascular treatment of stenosed or occluded iliac arteries: Permanent intraluminal placement of a covered stent
214908791|NCT06095505|DRUG|Alisertib|Alisertib enteric-coated tablets
214908792|NCT05666726|OTHER|Pain|Thermal pain
214908793|NCT05666726|OTHER|Stress|Stress state induction
214908794|NCT05666726|BEHAVIORAL|Craving|Snack craving induction
214908795|NCT05666726|BEHAVIORAL|Frustration|Real effort task
214908796|NCT05666726|BEHAVIORAL|Negative valence emotion|Passive video watching with emotional valence
214908797|NCT06625437|BEHAVIORAL|Acceptance and commitment therapy|Acceptance and commitment therapy is a psychotherapy focused at increasing psychological flexibility and an individual\&#39;s engagement in valued activities rather than focusing solely or primarily on reducing psychiatric symptoms
214908798|NCT06684106|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|UDCA together with statin in eligible participants
214908799|NCT06684106|DRUG|Placebo|placebo together with statin in ASCVD patients
214908800|NCT06695949|OTHER|Percutaneous neuromodulation.|Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
214908801|NCT06695949|OTHER|Therapeutic Exercise.|These participants (n=50) will engage in resistance training for the cervical flexor muscles, following a progressive exercise program in a supine position with the head comfortably supported, as described by Falla et al. (2008). Participants will perform these exercises with a frequency of 3 days a week for 6 weeks, with each session lasting 30 minutes.
214908802|NCT06686056|COMBINATION_PRODUCT|AIM-CHD Mobile Health Intervention|The AIM-CHD platform synchronizes data from hospitalization records, questionnaires, AI-powered voice follow-ups, and wearable devices to perform risk stratification and manage uncontrolled risk factors. It provides individualized follow-up plans, medication reminders, and lifestyle education, with real-time assessments of vital health metrics to prompt necessary in-person consultations. The app offers online consultation access and emergency services through Fuwai Hospital. Additionally, it delivers personalized patient education, aligning with the latest clinical guidelines.
214908803|NCT06686056|COMBINATION_PRODUCT|Usual post-discharge care|Usual post-discharge care includes oral and written instructions on sustained pharmacotherapy regimens, recommended follow-up frequency, and lifestyle modifications.
214908804|NCT04577807|BIOLOGICAL|Lerapolturev|Lerapolturev administered via direct lesion injection
214908805|NCT04577807|BIOLOGICAL|Anti-PD-1 Checkpoint Inhibitor|Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions
214908806|NCT07023627|DRUG|INCB123667|Administered orally twice daily (BID).
214908807|NCT04948580|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
214908808|NCT06741410|DRUG|Ephedrine|Intravenous boluses of ephedrine
214908809|NCT06741410|DRUG|Phenylephrine|Intravenous continuous infusion of phenylephrine
214908810|NCT06743126|BIOLOGICAL|IMA203|one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
214908811|NCT06743126|BIOLOGICAL|nivolumab plus relatlimab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908812|NCT06743126|BIOLOGICAL|lifileucel|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908813|NCT06743126|BIOLOGICAL|nivolumab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908814|NCT06743126|BIOLOGICAL|pembrolizumab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908815|NCT06743126|BIOLOGICAL|ipilimumab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908816|NCT06743126|DRUG|Dacarbazine|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908817|NCT06743126|DRUG|temozolomide|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908818|NCT06743126|DRUG|paclitaxel|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908819|NCT06743126|DRUG|paclitaxel plus carboplatin|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908820|NCT06743126|DRUG|Albumin-Bound Paclitaxel|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
214908821|NCT06780306|BIOLOGICAL|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
214908822|NCT06780306|BIOLOGICAL|Saline (NaCl 0,9 %) (placebo)|300 mL Sterile, preservative free 0.9% NaCl
214908823|NCT06264531|DRUG|Bevacizumab|Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections
214908824|NCT06264531|DRUG|Placebo|NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections
215057928|NCT02453152|OTHER|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
214908825|NCT03875781|DRUG|Chemotherapy|"Arm A : Experimental~* Intervention Type : Drug~* Intervention Name : Modified FOLFIRINOX (experimental arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
214908826|NCT03875781|DRUG|Radiochemotherapy|"Arm B: Active comparator~* Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor."
214908827|NCT07058883|DEVICE|Juläine|Juläine is a sterile injectable implant containing poly-L-lactic acid microspheres, intended for intradermal use to improve skin depressions from acne scars.
214908828|NCT07058883|OTHER|Sterile Saline (Placebo)|Sterile saline solution used as a placebo control, administered in the same volume and schedule as Juläine.
214908829|NCT05516862|OTHER|Dragons acupuncture|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 needles placed in head, upper back, lower back and ankles."
214908830|NCT05516862|OTHER|Dragons acupressure|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 small acupressure adhesive bandages placed on head, upper back, lower back and ankles."
214908831|NCT05516862|OTHER|Dragons placebo|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and the doctor will touch 7 points on head, upper back, lower back and ankles."
214908832|NCT06270082|DRUG|IK-595|Oral tablet administered in 28-day or 30-day cycles until treatment discontinuation criteria are met.
214908833|NCT05810038|DRUG|Rimegepant|Rimegepant
214908834|NCT05810038|DRUG|Placebo|matching placebo
214908835|NCT07060950|BIOLOGICAL|Blood sampling C1|"Blood samples will be collected at four key time points :~* baseline (T1),~* first scan assessment (T2),~* second scan assessment (T3),~* and progression (T4)."
214908836|NCT07059975|DRUG|Idarubicin Hydrochloride|Idarubicin is given in combination with fludarabine and cytarabine for Ida-FLA, and in combination with venetoclax and cytarabine for VIA.
214908837|NCT07059975|DRUG|Fludarabine|Fludarabine is given in combination with idarubicin and cytarabine for Ida-FLA.
214908838|NCT07059975|DRUG|Cytarabine (Ara-C)|Cytarabine is given in combination with other chemotherapy agents in every cycle and both arms.
214908839|NCT07059975|DRUG|Venetoclax|Venetoclax is given in combination with idarubicin and cytarabine for VIA.
214908840|NCT07059975|DRUG|Etoposide|Etoposide is given in combination with cytarabine for AE, as Intensification 1 for IR patients.
214908841|NCT07059975|DRUG|Asparaginase Erwinia Chrysanthemi (recombinant)|Rylaze is given in combination with cytarabine for Intensification 3 for IR patients.
214908842|NCT07059975|DRUG|Intrathecal triple|Methotrexate, hydrocortisone and cytarabine are combined into one preparation for intrathecal administration at multiple time points during treatment.
214908843|NCT07059975|OTHER|SOC|Low-Risk Patients will receive Texas childern's Hospital practice standard for de novo AML.
214908844|NCT04958239|DRUG|BI 765179|BI 765179
214908845|NCT04958239|DRUG|Ezabenlimab|Ezabenlimab
214908846|NCT04958239|DRUG|Pembrolizumab|Pembrolizumab
214908847|NCT06423430|DEVICE|Sham-stimulation|Sham-stimulation
214908848|NCT06423430|DEVICE|Active-stimulation|Active DBS
214908849|NCT01344421|PROCEDURE|Minimally invasive approach for Periacetabular osteotomy|A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
214908850|NCT04696302|BEHAVIORAL|Focus of attention|Individuals were asked to laterally weight shift while seated with either internal focus or external focus instructions.
214908851|NCT01111773|DRUG|Heated Lidocaine and Tetracaine Patch|Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
214908852|NCT01825473|DRUG|Erythromycin|
214908853|NCT01825473|DEVICE|Multi-channel intra-luminal impedance (MII) pH monitoring|
214908854|NCT01825473|DRUG|Placebo (D5W)|
214908855|NCT05059873|DRUG|Prednisone|Oral prednisone 40mg/day for five consecutive days
214908856|NCT05059873|DRUG|Placebo|Oral placebo of 40mg/day for five consecutive days
214908857|NCT05328739|OTHER|home care|home care program
214908858|NCT01662492|BIOLOGICAL|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
214908859|NCT01662492|BIOLOGICAL|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
214908860|NCT01662492|DRUG|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
214908861|NCT00673439|DRUG|fondaparinux|Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
214908862|NCT00673439|DRUG|warfarin|Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
214908863|NCT02074241|OTHER|Expression analysis|Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.
214908864|NCT03175536|OTHER|HDHP with PDL|Enrollment in a Health Savings Account-eligible high-deductible health plan with an annual individual deductible of \>$1000 that includes a preventive drug list (a list of certain chronic medications that are exempt from the deductible)
214908865|NCT01938638|DRUG|BAY1143572|
214908866|NCT00605618|DRUG|BMS-777607|Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
214908867|NCT05211570|DRUG|AB8939|Intravenous injection (from an initial dose of 0.9 mg/m²)
214908868|NCT05211570|DRUG|Azacitidine|Subcutaneous injection (75 mg/m²)
214908869|NCT02442947|OTHER|clothing type, protective garments of Paul Boye Technologies|The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment \[charcoal base\], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
214908870|NCT06776250|DRUG|Tarlatamab|Tarlatamab is a BiTE molecule designed to direct T effector cells toward DLL3-expressing cells.
214908871|NCT00722969|DRUG|sorafenib + erlotinib|sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
214908872|NCT04012021|DIAGNOSTIC_TEST|7T Magnetic Resonance Imaging|"* T1-weighted and T2-weighted sequences~* quantitative magnetic resonance imaging approach~* proton spectrum analyses"
214908873|NCT06456775|BEHAVIORAL|Tele-SSM|Tele-SSM an individual-level psychosocial intervention based on cognitive behavior therapy principles and non-violent communication. The intervention consists of the following 10 sessions delivered through 10 weekly coaching calls delivered by Zoom (audio only).
214908874|NCT02729259|BEHAVIORAL|Virtual Reality Snowworld|The subjects will receive Virtual Reality Snowworld during their wound care procedure. The nurse will be doing their wound care.
214908875|NCT02729259|BEHAVIORAL|Virtual Reality slides of nature|The subjects will receive Virtual Reality Slides of Nature during their wound care procedure. The nurse will be doing their wound care.
214908876|NCT02729259|BEHAVIORAL|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
214908877|NCT01066832|DRUG|Paclitaxel|Paclitaxel-coated balloon (3 µg/mm2)
214908878|NCT02853877|BEHAVIORAL|Weekly Incentive|The tailored incentives intervention aims to assess the impact of tailored messaging and financial incentives on weight loss among obese employees.
214908879|NCT04033354|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
214908880|NCT04033354|DRUG|carboplatin and nab paclitaxel|chemotherapeutics
214908881|NCT04033354|DRUG|Placebo|Placebo
214908882|NCT06649955|DEVICE|Multi-site direct current stimulation (DCS)|The MyoRegulator® treatment is a non-invasive intervention that suppresses motor neuron hyperexcitability and activates protein degradation pathways through the use of multi-site direct current stimulation (multi-site DCS).
214908883|NCT07137312|PROCEDURE|Blood Draw|"Participants have a standard blood draw or apheresis on study. Some participants may provide a specimen via apheresis one time (the blood draw group) and then elect to provide a second optional specimen via a standard blood draw (the apheresis draw group) or vice versa."
214908884|NCT07137312|PROCEDURE|Apheresis|"Participants have a standard blood draw or apheresis on study. Apheresis is a procedure where blood is drawn from your body, specific components like plasma, platelets, and/or white blood cells are separated out, and the rest of the blood is returned. Some participants may provide a specimen via apheresis one time (the apheresis group) and then elect to provide a second optional specimen via a standard blood draw (the blood draw group) or vice versa."
214670130|NCT02752308|PROCEDURE|Hypospadias repair|Surgical repair of hypospadias, using tubularized incised plate technique
214908885|NCT06941441|OTHER|Home exercise program|A tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring
214908886|NCT06941532|DIETARY_SUPPLEMENT|GMP Intervention Product|Condition specific GMP based intervention product
214908887|NCT06943469|OTHER|Test formula|Partially hydrolyzed formula with synbiotics
214908888|NCT06943469|OTHER|Control formula|Intact protein formula without synbiotics
214908889|NCT01125397|BEHAVIORAL|LEARN group|Participants will complete a 12-week behavioral weight management intervention (the LEARN program) prior to bariatric surgery, which is the current standard clinical practice at Mayo Clinic Rochester. This involves weekly group meetings, weigh-ins, and goal setting.
214908890|NCT07141446|DRUG|Neem gel|1.5% Neem Gel in orabase formulation, twice daily application for 3 months
214908891|NCT07141446|DRUG|Triamcinolone Acetonide|0.1% oral paste to be applied twice daily for 3 months
215057929|NCT02453152|OTHER|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
215057930|NCT02453152|OTHER|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
215057931|NCT02453152|OTHER|Peak cough flow|Subjects' strongest coughs will be measured.
215057932|NCT02453152|OTHER|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
215057933|NCT02453152|OTHER|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
215057934|NCT02453152|OTHER|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
215057935|NCT00854724|DRUG|Puerarin, Placebo|400 mg, three times a day for 7 days
215057936|NCT00239993|DRUG|glatiramer acetate|
215057937|NCT00239993|PROCEDURE|Warm compress prior to injection of glatiramer acetate|
215057938|NCT05993988|OTHER|Exercise|Muscle relaxing Technique
215057939|NCT03922672|BEHAVIORAL|Group piano training|The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
215057940|NCT02064049|DRUG|Sofosbuvir/velpatasvir|The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
215057941|NCT00879034|DRUG|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
214670131|NCT01312155|OTHER|Intubation|Intubation, endotracheal
214908892|NCT07139236|PROCEDURE|Preoperative Endoscopic Ultrasound Elastography (EUS Elastography)|"All enrolled patients will undergo a preoperative EUS-E examination within one weeks prior to pancreaticoduodenectomy. The EUS-E will be performed by experienced endosonographers using a radial or linear array echoendoscope connected to a compatible ultrasound processor. Both qualitative (color mapping) and quantitative (strain ratio, strain histogram) data will be obtained. Multiple measurements of the strain ratio will be taken from a region of interest within the pancreatic parenchyma adjacent to the lesion. The mean strain ratio will be recorded for analysis. Standard EUS imaging will also be recorded.~Standard pancreaticoduodenectomy will be performed . Intraoperative pancreatic texture will be subjectively assessed by the surgeon and recorded. Postoperative monitoring for pancreatic fistula will follow established clinical guidelines."
215057942|NCT00879034|DRUG|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
215057943|NCT00879034|DRUG|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
215057944|NCT00528502|DRUG|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
215057945|NCT00528502|DRUG|Saline|Saline is misted into the air that you breathe during the surgery.
215057946|NCT05714449|DEVICE|eye patch|standard amblyopia treatment
215057947|NCT05714449|DEVICE|After-image and MIT trainer|Common clinical training for foveation
214670132|NCT03000114|PROCEDURE|Percutaneous Needle Aponeurotomy|
215057948|NCT00861757|DRUG|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
215057949|NCT00861757|DRUG|Placebo|PO, QD (30 min after meal) for 12 weeks
215057950|NCT00861757|DRUG|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
214670133|NCT03000114|DRUG|XIAFLEX|
214670134|NCT05495399|PROCEDURE|Spondylectomy|Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
214670135|NCT05495399|RADIATION|SBRT|Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
214670136|NCT00249886|DRUG|Citalopram|
214670137|NCT00345371|DRUG|Topiramate|
214670138|NCT00345371|DRUG|Placebo Oral Tablet|
214670139|NCT04354051|DRUG|Sodium Nitrite|Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
215057951|NCT04709003|DIAGNOSTIC_TEST|Serologic test|A blood test to check antibodies type and amount
215057952|NCT04709003|DIAGNOSTIC_TEST|Respiratory swabs|PCR test to Covid-19
214670140|NCT01853228|DRUG|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
215057953|NCT02140970|DRUG|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
215057954|NCT02140970|DRUG|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
215057955|NCT01789086|DRUG|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
215057956|NCT01789086|DRUG|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
215057957|NCT02705105|BIOLOGICAL|Mogamulizumab + Nivolumab|i.v. administration
215057958|NCT01149005|DRUG|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
215057959|NCT01149005|DRUG|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
215057960|NCT01861704|DEVICE|Lyric|Extended wear hearing instrument
215057961|NCT01861704|DEVICE|Lyric2|Extended wear hearing instrument
214908893|NCT06944353|BEHAVIORAL|STIRRED|"The STIRRED intervention is a behavioral intervention directed at the treating ED clinicians.~An Our Practice Advisory (OPA) will alert the clinician to the radiology finding of hepatic steatosis at the time of preparing the discharge materials. The OPA will prompt the clinician to discuss this finding with the patient and will automatically add hepatic steatosis to the discharge diagnoses and insert patient-facing discharge information about hepatic steatosis. It will additionally prompt the clinician to refer the patient for follow-up which will be stratified based on their fibrosis risk level."
214908894|NCT03285347|DEVICE|Computer-based cognitive training|Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
214908895|NCT04409145|DRUG|VT30|VT30 gel is intended as a topical treatment of cutaneous VMs, LMs, or VLMs that driven by inappropriate PI3K activation. In the skin, VT30 is rapidly metabolized to VT10, an active drug form, and is intended to sufficiently permeate the stratum corneum and achieve target engagement. It is expected that VT30 will lead to amelioration of the signs and symptoms of cutaneous VMs, LMs and/or VLMs.
214908896|NCT06948084|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
214908897|NCT06948084|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214908898|NCT06948084|DRUG|Carfilzomib|Given IV
214908899|NCT06948084|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214908900|NCT06948084|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
214908901|NCT06948084|DRUG|Dexamethasone|Given PO or IV
214908902|NCT06948084|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET/CT
214908903|NCT06948084|DRUG|Pomalidomide|Given PO
215057962|NCT01449396|OTHER|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
215057963|NCT01449396|PROCEDURE|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
215057964|NCT01449396|PROCEDURE|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
215057965|NCT00219193|DRUG|aliskiren|
215057966|NCT00292279|DRUG|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
215057967|NCT00292279|DRUG|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
214908904|NCT06948084|DRUG|Teclistamab|Given SC
214908905|NCT03293537|DIAGNOSTIC_TEST|Skin conductance and Heart rate measurement|while observing selected photos the Skin conductance and heart rate will be measured.
214908906|NCT07140809|BIOLOGICAL|JMT202 injection|Subcutaneous injection
214908907|NCT07140809|OTHER|Placebo|Matching Placebo
214908908|NCT07151612|DRUG|Esculin and Digitalisglycosides Eye Drops|Interventions were performed using esculin and digitalis glycosides eye drops (Pharma Stulln GmbH). The carer instructed the patient to apply 1 drop to the affected eye three times a day and to strictly follow aseptic techniques to prevent contact of the dropper with the ocular surface. The treatment lasted for 1 month.
214908909|NCT07151612|DRUG|Normal saline solution|Sterile, preservative-free, and non-irritating dropper saline was used. The carer instructed the patient to apply 1 drop to the affected eye three times a day and to strictly follow aseptic techniques to prevent contact of the dropper with the ocular surface.
214908910|NCT07152782|DRUG|Neratinib|Neratinib, as an irreversible pan-HER tyrosine kinase inhibitor (TKI), holds a unique position in the treatment of HER2-positive breast cancer. From a molecular perspective, Neratinib irreversibly binds to the intracellular kinase domains of HER1 (EGFR), HER2, and HER4 through covalent bonds, comprehensively blocking signal transduction of the HER family. This mechanism of action is markedly different from reversible TKIs such as lapatinib. Neratinib's irreversible binding characteristic allows for a more sustained inhibition of target activity, maintaining anti-tumor effects even after drug plasma concentrations have decreased. This feature is particularly important for HER2-positive breast cancer, which requires continuous suppression of proliferative signals.
215057968|NCT05126511|DEVICE|Application of CES via ear clips|Use of 100µA CES for one hour per day over PR program
215057969|NCT05126511|DEVICE|Sham: No application of CES via ear clips|Use of Sham CES for one hour per day over PR programm
215057970|NCT03861104|OTHER|medical educational video|information based on visual and auditory communication
215057971|NCT03465137|BEHAVIORAL|Coordinated Anxiety Learning and Management (CALM)|Exposure-focused cognitive behavioral therapy
215057972|NCT01709110|DRUG|Teriparatide|Administered SC
215057973|NCT01709110|DRUG|Risedronate|Administered orally
215057974|NCT01709110|DRUG|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
215057975|NCT01709110|DRUG|Calcium|Administered orally
215057976|NCT01709110|DRUG|Vitamin D|Administered orally
215057977|NCT02145052|OTHER|Continuous suture|A continuous suture is considered standard of care.
215057978|NCT02145052|OTHER|Interrupted suture|Interrupted sutures are considered standard of care.
215057979|NCT02740244|DEVICE|active iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
215057980|NCT02740244|DEVICE|sham iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
215057981|NCT02076529|DRUG|Ramosetron 0.3mg|
215057982|NCT02076529|DRUG|Ramosetron 0.45mg|
215057983|NCT02076529|DRUG|Ramosetron 0.6mg|
215057984|NCT05215470|DRUG|Nivolumab|Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
215057985|NCT05215470|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
215057986|NCT00504439|DRUG|SB-656933-AAA|The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
215057987|NCT00504439|DRUG|Matching placebo|SB-656933-AAA matching placebo tablets will be administered orally.
214908911|NCT07152782|DRUG|Trastuzumab Deruxtecan|"Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor (an exatecan derivative). It targets and binds to HER2-positive tumor cells, internalizes, and releases cytotoxic drugs to induce DNA damage and apoptosis. It also has a bystander effect that can kill neighboring tumor cells with low HER2 expression, enhancing anti-tumor activity. T-DXd has shown significant efficacy in HER2-positive advanced breast cancer, with key clinical trials (such as DESTINY-Breast03) confirming that its progression-free survival (PFS) and overall survival (OS) are superior to traditional second-line treatments, with a median PFS reaching 28.8 months. Additionally, for HER2-low-expressing (IHC 1+ or 2+/ISH-) metastatic breast cancer (in the DESTINY-Breast04 study), T-DXd can extend PFS and OS, becoming the first targeted therapy to alter the survival outcomes of such patients"
214908912|NCT07151378|DRUG|LECIG (levodopa, carbidopa, entacapone intestinal gel)|intestinal L-Dopa + entacapone (Lecigon®)
214908913|NCT07151378|DRUG|Best oral medication|Best oral medication
215057988|NCT00504439|DRUG|Simvastatin|Simvastatin will be provided as a 40 mg tablet.
215057989|NCT00292526|DRUG|Enalapril|enalapril orally administered
215057990|NCT02456207|DRUG|SCT400|
215057991|NCT02456207|DRUG|Rituximab|
215057992|NCT06032858|DRUG|Apremilast 30mg|Apremilast 30mg twice daily
215057993|NCT02077777|DRUG|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
215057994|NCT00033566|DRUG|S-3304|
215057995|NCT03332173|DRUG|Zanubrutinib|Oral administration using 80 mg capsules
215057996|NCT00408265|BEHAVIORAL|Contingency Management|
215057997|NCT02227030|DRUG|BIIB 722 CL solution|
215057998|NCT02227030|DRUG|BIIB 722 CL tablet|
215057999|NCT02227030|DRUG|Placebo solution|
215058000|NCT02227030|DRUG|Placebo tablet|
214303450|NCT06214650|OTHER|Radiofrequency|"Experimental group will receive the common exercise program associated with a radiofrequency treatment using INDIBA® (INDIBA Activ 7, Barcelona, INDIBA S.A.) at a frequency of 448 hertz. It will use the capacitive electrode as a method of preparation and vascularization of the superficial tissues and immediately, within the same session, the resistive electrode to stimulate deep tissues. This treatment is based on the protocols established by INDIBA® S.A.~It will consist of one weekly diathermy session of thirty minutes during ten weeks. The use of diathermy will not be interrupted throughout the session.~The common exercise program consist in a ten abdominal exercises (including recti abdominis, transversus and obliques). It will practised at home only just three days at week."
214303451|NCT06214650|OTHER|Control|Control group will receive a weekly INDIBA® session in the abdominal area with the same protocol as the experimental group in athermic mode (placebo treatment) and the common exercise program. The session will last thirty minutes and will be carried out by the research physiotherapist during ten weeks.
215058001|NCT00158626|BEHAVIORAL|pelvic floor muscle training|
215058002|NCT04404101|PROCEDURE|1). EUS-FNA plus MFB|The cyst will be punctured using a 19-G EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed and the wall of the cyst biopsied using the micro forceps passed through the 19 G needle under direct EUS visualization. A minimum of 4 cyst wall biopsies will be obtained to procure at least 4 visible tissue fragments. Cyst fluid will be aspirated and sent for CEA and cytology.
215058003|NCT04404101|PROCEDURE|2). EUS-FNA Alone|The cyst will be punctured using an EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed, and cyst fluid will be aspirated and sent for CEA, and cytology.
215058004|NCT04792034|DRUG|Cocaine Hydrochloride Topical Solution|Topical Anesthetic
215058005|NCT00742521|PROCEDURE|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
215058006|NCT00742521|PROCEDURE|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
215058007|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
215058008|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
215058009|NCT02417610|DEVICE|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
215058010|NCT02417610|DEVICE|Hyaluronic acid - HA - Ialart|Hyaluronic acid
215058011|NCT02168101|DRUG|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg."
214670141|NCT01853228|DRUG|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
214908914|NCT07151092|BEHAVIORAL|Adolescent Grief Group|The intervention will include psycho-education, peer-support, and professional supportive counseling from licensed clinicians.
214908915|NCT07151638|DEVICE|Implantation (injection) of a new biomatrix for soft tissue support.|Implantation of a new injectable medical device, Fractomer Biomatrix, to study the safety of the product in healthy human participants.
214908916|NCT07153211|DIAGNOSTIC_TEST|Immunological Factors|Assessment of interleukins and other molecues in CSF and blood of patients with SCS.
214908917|NCT07152717|DEVICE|A connected-health, pressure-sensing system for monitoring sub-bandage pressure during compression therapy|The Tight Alright system, developed by FeelTect Limited, consists of a wearable, pressure sensing device that measures sub-bandage pressure at three regions along the length of the lower leg. The wearable device transmits data wirelessly to a mobile app on a smart device, which then displays the data in real-time. The mobile app is also capable of transmitting data to a remote cloud database, via the internet, where it can be viewed on a remote dashboard (i.e., via a secure webpage).
214908918|NCT07151625|OTHER|Diet, whole food provided to participants over 5 x 9 day period|5 diets provided to participants over 9 days each and whole body protein synthesis, protein breakdown and protein balance assessed after each period.
214908919|NCT07151625|OTHER|Diet|5 different diet types
214908920|NCT07151781|OTHER|Video-guided Mindfulness Exercise|Mindfulness interventions are emerging as effective, low-risk approaches to managing depression and enhancing emotional and maternal well-being in pregnant women. Rooted in ancient meditative practices that originated from Buddhist religion and traditions and adapted for clinical use, mindfulness intervention cultivates present-moment awareness and nonjudgmental acceptance of thoughts, emotions, and bodily sensations. Mostly, mindfulness interventions include elements such as mindful breathing and body scanning and have shown effectiveness in reducing depressive symptoms and enhancing emotional regulation. It is the ability to maintain attention to an immediate experience with a sense of adopting an open and accepting attitude toward that experience. However, further research is important to evaluate its effectiveness across diverse sociodemographic and socioeconomic settings.
214908921|NCT07151352|OTHER|Starting Condition - Barefoot|Participants walk barefoot along a 10-meter walkway without wearing shoes or socks.
214908922|NCT07151352|OTHER|Barefoot-Style Footwear|Participants walk along a 10-meter walkway wearing minimalist footwear with a 3 mm flexible sole, 0 mm heel drop, wide toe box, and no rigid heel counter.
214908923|NCT07151352|OTHER|Conventional Footwear with Heel Drop|Participants walk along a 10-meter walkway wearing structured footwear with a rigid sole (12 mm heel / 7 mm forefoot), 5 mm heel drop, reinforced heel counter, and narrow toe box.
214908924|NCT07151703|PROCEDURE|Intranasal Injection of Autologous PRP|Under topical anesthesia and decongestion, approximately 1 mL of freshly prepared autologous platelet-rich plasma will be injected into multiple sites of the olfactory cleft mucosa bilaterally using a 25-gauge needle under endoscopic guidance. Single treatment session.
214908925|NCT07151703|PROCEDURE|Carrier-Assisted Topical Application of Autologous PRP|Four pieces of sterile, bioabsorbable carrier (Gelfoam sponge) will be soaked with approximately 5 mL of freshly prepared autologous platelet-rich plasma. Under endoscopic guidance, two pieces will be placed gently into each olfactory cleft, ensuring contact with the olfactory mucosa. Carriers will remain briefly to allow PRP diffusion before dissolving naturally or being removed. Single treatment session.
214670142|NCT01853228|DRUG|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
214908926|NCT07151703|COMBINATION_PRODUCT|platelet-rich plasma|This study adopts a fully automated, closed-system PRP preparation technique to ensure the stability of the blood product. A total of 60 mL of whole blood is drawn and processed using the Phoenix Q1 centrifuge (TFDA Medical Device Manufacturing License No. 004461) for blood component separation in a closed, sterile environment. An optical sensor identifies and automatically collects the buffy coat layer (rich in platelets and monocytes), yielding approximately 6 mL of autologous platelet-rich plasma (PRP). The centrifugation and PRP collection process takes about 5 minutes. Compared with traditional methods requiring manual identification and collection, this approach enhances the precision and safety of centrifugation-based preparation.
214908927|NCT07151703|DEVICE|olfactory training|Participants will perform olfactory training for 12 weeks following the PRP intervention. Training is conducted twice daily using four odor bottles containing standardized odorants from Sigma-Aldrich (Germany): lemon (citronellal, #27470), rose (phenylethanol, #77861), clove (eugenol, #W246700), and eucalyptus (eucalyptol, #C80601). Each odor is sniffed gently for about 20 seconds, with a 20-second pause between bottles. Participants will record the perceived intensity of each odor in a training diary after every session.
214908928|NCT07152288|DRUG|HSK39297 tablets|oral
214908929|NCT07152288|DRUG|HSK39297 tablets|oral
214908930|NCT07152288|DRUG|HSK39297 tablets|oral
214908931|NCT07153185|DEVICE|Dental Barrier Membrane|Patients treated with creos xenoprotect dental barrier membrane in the past
214908932|NCT07152561|DRUG|Zirconia crown cemented with Predicta® Bioactive Cement|• For the bioactive cement group (Predicta® Bioactive Cement), the prepared tooth will be dried using compressed air but not desiccated. Cement will be dispensed through the auto-mixtip directly into the crown, and the crown will be properly positioned over the tooth; cement will be allowed to self-set for 20 seconds while maintaining gentle pressure on the crown. Buccal and lingual margins will be flash-cured for 10 seconds each using a light-curing unit to immediately cure the excess cement for easier removal, and buccal and lingual surfaces will then be light-cured for an extra 10 seconds each.
214908933|NCT07152561|DRUG|Zirconia crown cemented with resin-cement|• For the resin-cement group, the tooth will be dried with compressed air but not desiccated. The sealant will be applied with the syringe; then, the crown will be appropriately positioned over the tooth, and cement will be allowed to self-set for 2 minutes and cured while maintaining gentle pressure on the crown. Excess cement will be removed before the cement is completely set.
214670143|NCT03328611|DEVICE|Hip and Knee Joint Replacement|Hip and Knee Joint Replacement
214670144|NCT01398254|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Participants will be randomly assigned an access site, radial or femoral, for PPCI.
214670145|NCT05107414|PROCEDURE|Total Knee Arthroplasty|Participants have previously undergone a total knee replacement surgery.
214908934|NCT07152600|DRUG|Saline (0.9%, sterile, for infusion)|Sailine as control
214908935|NCT07152600|DRUG|low dose Methylprednisolone|Methylprednisolone 0.5mg/kg ivgtt qd
214908936|NCT07152600|DRUG|Moderate dose Methylprednisolone|Methylprednisolone 1.0mg/kg ivgtt qd
214908938|NCT07153042|BEHAVIORAL|Biweekly monitoring and feedback (BMF)|School coordinators will monitor teachers' implementation progress biweekly and provide feedback to teachers.
214908939|NCT07153042|BEHAVIORAL|Site-based assistance and mentorship (SAM)|High-performing teachers will serve as team leaders and guide non-responding teachers on preparation and planning. The team leader will promote group activities and enhance interaction among teachers in these meetings.
214908940|NCT07153042|BEHAVIORAL|Enhanced site-based assistance and mentorship (Enhanced SAM)|A FOYC coach (with FOYC implementation and training experience) will provide tailored in-person support, facilitate goal-setting, opportunities to interact with consultants, supportive text messaging, continuing education, networking strategies, and monthly check-ins.
214908941|NCT07153042|BEHAVIORAL|FOYC+CImPACT|"Focus on Youth in the Caribbean (FOYC) is an evidence-based, eight-session life skills curriculum designed to reduce risk-taking behaviors related to HIV/STI transmission and teen pregnancy. Woven throughout FOYC is a decision-making model that provides guidance and practice in problem solving with a focus on how to obtain factual information on sexual health.~CImPACT is a single-session intervention including a 24-min educational video filmed in The Bahamas. The video focuses on effective parent-adolescent communication and listening strategies related to difficult topics including safe-sex followed by two role-plays for the parent and youth, a discussion, and a condom demonstration."
214908942|NCT07151729|DEVICE|Anodal tDCS|This anodal tDCS is applied over the contralateral dorsal premotor cortex (instead of the ipsilateral motor cortex in previous studies).
214908943|NCT07151729|DEVICE|Sham tDCS|Sham tDCS is applied
214908944|NCT07151417|DRUG|PAI|Standard PAI: 30 mg Toradol/ketorolac (30mg/ml), 49.25ml 0.5% ropivacaine (5mg/ml), and 0.5 mg
214908945|NCT07151417|DRUG|PAI + steroid|Standard PAI + 40mg methylprednisolone (n = 40)
214908946|NCT07151417|DRUG|PAI + zilretta|Standard PAI + 32mg Zilretta (triamcinolone acetonide extended release injectable suspension)
214908947|NCT07151586|DRUG|Sacituzumab Govitecan / Trastuzumab Deruxtecan|"Sacituzumab govitecan is administered intravenously at a dose of 10 mg/kg on Day 1 and Day 8 of each 3-week cycle. In this study, patients receive two cycles of sacituzumab govitecan followed by two cycles of trastuzumab deruxtecan, alternating throughout the study.~Trastuzumab deruxtecan is administered intravenously at a dose of 5.4 mg/kg on Day 1 of each 3-week cycle. In this study, patients receive two cycles of trastuzumab deruxtecan followed by two cycles of sacituzumab govitecan, alternating throughout the study.~Both Treatment are continued until disease progression as defined by RECIST 1.1, unacceptable toxicity, withdrawal of consent, or the end of the study."
214908948|NCT07153198|OTHER|VIPP-SD|Consists of four sessions (with the option of one or two additional booster sessions), held biweekly, depending on the family's needs and availability. Specifically, VIPP-SD addresses disciplinary strategies alongside sensitivity themes through: (1) the differentiation between attachment and exploration behaviors; interpretation of child's behavior and significance of a sensitive response to it; and the importance of sharing emotions (2) the application of distraction and induction as non-coercive techniques in response to challenging child behaviours or conflict-prone situations; (3) the utilization of positive reinforcement, whereby parents praise adaptive behaviours and ignore maladaptive, attention-seeking actions; (4) the implementat of a sensitive interaction pause to de-escalate conflict or temper tantrums; and (5) the demonstration of empathy towards the child in conjunction with consistent disciplinary approaches and explicit boundary-setting
214908949|NCT07151157|DRUG|add-on sirolimus therapy|On the basis of the existing treatment, oral sirolimus will be added at a dose of two capsules per day, one in the morning and one in the evening.
214908950|NCT07152964|DEVICE|Caliper|Measure medial rectus tendon width with caliper intraoperative
214908951|NCT07151599|DEVICE|Microneedling|Microneedling performed with an electronic pen and sterile disposable cartridge with 12 needles and 2mm depth, three treatment sessions at four-week intervals.
214908952|NCT07151599|DEVICE|Fractionated Er:Glass Laser combined to Fractionated Thulium Laser|Fractional Erbium:Glass laser will be applied first, focused on scarred areas (50 mJ, 15 ms e 100 PPA) , followed immediately by fractional Thulium 1927 nm over the full face (10 mJ, 1 ms e 100 PPA), three treatment sessions at four-week intervals.
214908953|NCT07151209|DRUG|Iparomlimab and Tuvonralimab combined with lenvatinib and SOX|Iparomlimab and Tuvonralimab:5 mg/kg Q3W lenvatinib:8 mg/day orally SOX：oxaliplatin (130 mg/m² Q3W intravenous infusion), and S-1 (40 mg/m² BID orally on days 1-14)
214678610|NCT03791983|OTHER|Body Acupenture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM).
214908954|NCT07152886|DRUG|Clostridium butyricum capsules|Clostridium butyricum capsules , 6 capsules tid (each capsule containing ≥6.3 × 10⁶ CFU of Clostridium butyricum).
214908955|NCT07152886|OTHER|placebo capsules|Oral administration of placebo capsules, 6 capsules tid., containing corn starch. The appearance and weight of the placebo capsules are identical to those of intervention group.
214908956|NCT07151443|PROCEDURE|Conventional approach to infraclavicular block|Conventional approach to infraclavicular block will be performed on the patients using 20 ml of 0.5% bupivacaine 5ml of %2 lidocaine under ultrasound guidance.
214908957|NCT07151443|PROCEDURE|Retroclavicular approach to the infraclavicular block|Retroclavicular approach to the infraclavicular block will be performed on the patients using 20 ml of 0.5% bupivacaine 5ml of %2 lidocaine under ultrasound guidance.
214908958|NCT07153159|DRUG|Etrasimod|Oral 2 milligrams tablet, once a day for 7 days
215058012|NCT05361538|DEVICE|True circular microwave needle|Use true circular microwave needle for thermal ablation
215058013|NCT01435694|BEHAVIORAL|Lokomat (Hocoma, Switzerland)|
215058014|NCT01435694|BEHAVIORAL|Conventional Therapy|
215058015|NCT03953677|DRUG|Dexmedetomidine 100 Mcg/mL Intravenous Solution|Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
215058016|NCT03953677|DRUG|5% glucose Infusion solution|Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
215058017|NCT06513923|DRUG|Remimazolam|In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.
215058018|NCT06513923|DRUG|Flumazenil|Immediately after the cessation of remimazolam infusion in PACU(PACU, Postanesthesia care unit), the nurses who are blind to the anesthesia management were asked to administer the flumazenil.
215058019|NCT06513923|DRUG|Propofol|For propofol group, the induction of propofol is 1.5-2.0 mg/kg, followed by the maintenance of propofol infusion with 6-8 mg/kg/hr throughout the surgical procedure.
215058020|NCT04791657|PROCEDURE|Appendectomy|Surgical treatment for appendicitis
214908959|NCT07151742|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|"Participants in this arm will receive a 12-week intradialytic combined exercise program, performed three times per week during the first two hours of hemodialysis. Each session will begin with a 10-minute warm-up and end with a 10-minute cool-down (stretching and breathing exercises).~Aerobic component: Supine cycling using a portable ergometer at 45-70% of maximum heart rate, monitored with pulse oximetry and Borg scale, progressively increased every 1-2 weeks.~Resistance component: Exercises with elastic bands and ankle weights targeting major upper and lower extremity muscle groups (non-fistula arm). Performed in 2 sets of 8-12 repetitions, with progressive loading based on ACSM guidelines.~All sessions will be supervised by trained physiotherapists and dialysis staff to ensure safety and adherence"
214908960|NCT07152418|BIOLOGICAL|Lecanemab 10 mg/kg|Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg.
214908961|NCT07152418|DRUG|Conventional anti-dementia treatment group|Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.
214908962|NCT07152067|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT to the macroscopic prostate tumor component defined at MRI
214303452|NCT03192592|OTHER|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
214303453|NCT00463749|DRUG|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
214908963|NCT07152353|DEVICE|Proton Beam Therapy (PBT)|PROTEUS® PLUS
214908964|NCT07152028|OTHER|Exercise program with supervised and home-based components|The 12-week program targets balance, muscular strength, core endurance, and cardiovascular fitness. Weeks 1-6 are supervised; weeks 7-12 are home-based via a video catalogue. Walking ≥30 min on ≥2 non-training days is advised. Intensity, repetitions, and sets are individualized using Borg CR-6-20. Adherence is monitored via exercise diaries and weekly phone calls with adjustments as needed.
214908965|NCT07152028|OTHER|Fully supervised exercise program|The 12-week program is fully supervised and includes warm-up, balance, aerobic, strength, and core exercises. Walking ≥30 min on ≥2 non-training days is included. Intensity, repetitions, and sets are individualized using Borg CR-6-20. Adherence is monitored by a physiotherapist using exercise diaries.
214908966|NCT07153354|DEVICE|patient-specific screw holes locating surgical guide and pre-bent plates|Virtual reduction of the fracture will be done, followed by 3D printing of the corrected mandible model. Plates will be pre-bent on the model, then scanned in position to create a surgical guide for accurate screw hole placement during surgery.
214908967|NCT07153354|DEVICE|2 titanium per-bent mini plates|The fixation will be performed according to established surgical principles for managing class iv mandibular fractures, without patient-specific planning
214908968|NCT07153094|DEVICE|Proton Beam Therapy (PBT)|PROTEUS® PLUS
214908969|NCT07151859|DEVICE|PN30 (RDM16)|PN30 is a viscoelastic, sterile gel, in a disposable prefilled syringe for intradermal infiltration.PN30 contains polynucleotides (3%). The polynucleotides contained in the device are substances of natural, fish-derived origin, highly purified.
215058021|NCT00910910|DRUG|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
215058022|NCT00910910|DRUG|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
215058023|NCT01101893|DRUG|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
214303454|NCT00463749|DRUG|Placebo|NaCl as placebo
214303455|NCT05688189|DEVICE|different starting temperature setting of HFNC|The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
214303456|NCT02391155|PROCEDURE|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
215058024|NCT01101893|DRUG|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
215058025|NCT01101893|DRUG|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
215058026|NCT01973231|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
215077725|NCT02975011|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
214908970|NCT07168928|BEHAVIORAL|School-Based Nutrition Education Program|The intervention consisted of an eight-week, school-based nutrition education programme delivered to fourth-grade students by a school dietitian. Sessions were conducted once per week and included interactive lectures, games, and educational activities focusing on healthy eating, food groups, balanced meals, and the risks of processed food consumption. In addition, parents of students in the intervention group received a four-week educational programme on child nutrition, meal planning, and healthy lifestyle practices.
214908971|NCT07183761|BIOLOGICAL|Experimental Group|On day 0, day 7, and day 28 after enrollment, the study subjects will receive intramuscular injections of hUC-MSCs suspension in normal saline into the medial and lateral muscle groups of both lower legs. Concurrently, all patients will continue to receive conventional therapy.
214908972|NCT07183761|DRUG|Conventional therapy group|The conventional therapy include fundamental blood glucose management, basic treatment for diabetic neuropathy along with pain management therapy, as well as management of comorbidities and risk factors.
214908973|NCT07182656|DRUG|CIGB-814 (single-dose group)|CIGB-814, single ascending dose, SC injection
214908974|NCT07182656|DRUG|CIGB-814 placebo (single-dose group)|CIGB-814 placebo, single ascending dose, SC injection
214908975|NCT07182656|DRUG|CIGB-814 (multiple-dose group)|CIGB-814, multiple ascending dose, SC injection
214908976|NCT07182656|DRUG|CIGB-814 placebo (multiple-dose group)|CIGB-814 placebo, multiple ascending dose, SC injection
214908977|NCT07183670|DIAGNOSTIC_TEST|decannulation protocol|"Step 1: The patient's clinical stability is confirmed. Step 2: Tolerance to the speaking valve is assessed. Step 3: The wearing time of the speaking valve is extended continuously for 4 h, and no tracheostomy cannula is used for sputum suction within 4 h.~Step 4: Cough strength is evaluated to be good before decannulation. Decannulation Criteria: Pass Step 1 + Step 2 + Step 3 + Step 4"
214908978|NCT07184073|BEHAVIORAL|assessment Mini mental state examination|pre operatively four weeks postoperatively
214908979|NCT07184073|BEHAVIORAL|assessment FRAIL scale|pre operatively four weeks postoperatively
214908980|NCT07184073|OTHER|collecting cerebrospinal fluid during regional anesthesia|In the operating room regional anesthesia was administered according to the surgical plan
214908981|NCT07183696|OTHER|breathing exercises|"* breathing exercises as needed 3 times per week during dialysis sessions.~* chest percussion as needed 3 times per week during dialysis sessions.~* vibration as needed 3 times per week during dialysis sessions."
214908982|NCT07183085|BEHAVIORAL|Intervention|Digital mental health program incorporating personalized physical and mental health exercises focused on physical activity, sleep hygiene, and mindfulness.
214908983|NCT07183215|DRUG|Curcuminoid Standardized Turmeric Capsules|Samples were made from extracted turmeric and then optimized. The capsule formulation is made from turmeric rhizome extract which contains 30 mg of curcuminoids per capsule. In the study, standardized curcuminoid turmeric extract was given in capsules at 30 mg 3 times a day for 3 weeks
214908984|NCT07183215|OTHER|Placebo|The capsule formulation is made from maltose which contains 10 mg of curcuminoids per capsule. In the study, the capsule was given in capsules at 30 mg 3 times a day for 3 weeks.
214908985|NCT07182253|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha® capsule|Single off-white capsule contains 300 mg Ashwagandha root extract powder only
214908986|NCT07182253|OTHER|Identical Placebo capsule|Single off-white capsule contains starch powder only
214303457|NCT02391155|PROCEDURE|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
214303458|NCT01788670|DIETARY_SUPPLEMENT|Ethanol|
214908987|NCT07183280|OTHER|operation|Enucleation, spleen-preserving distal pancreatectomy, or duodenum-preserving pancreatic head resection, etc
214908988|NCT07182708|DRUG|Firmonertinib Mesilate Tablets|Firmonertinib Mesilate Oral administration 160 mg once daily for 3 months before surgery. Radical tumor resection will be performed at least 6 weeks after completion of Bevacizumab treatment. After surgery, the treatment plan was determined by the researchers, with options including Firmonertinib Mesilate Tablets: Oral administration once daily, 80mg per dose, for 3 years or until disease progression or intolerable toxicity occurs.
214908989|NCT07182708|DRUG|Bevacizumab injection|Bevacizumab injection (intravenous infusion, 7.5 mg/kg) administered every 21 days as one cycle, for a total of 2 cycles. Radical tumor resection will be performed at least 6 weeks after completion of Bevacizumab treatment.
214908990|NCT07182422|DRUG|AST-120 (Kremezin®)|AST-120 (Kremezin®) Dosage: 6 g/day (2 g TID, oral) Duration: 14 days Background treatment: Standard post-AKD care
214908991|NCT07182279|DRUG|Brachytherapy|All patients will receive a single fraction of HDR-B (15Gy) 4-8 weeks prior to RALP. Patients with high genomic risk or node positivity will receive short course adjuvant AAB.
214908992|NCT07182370|DIETARY_SUPPLEMENT|Capsules containing plant extracts, including resveratrol, ellagic acid and isoflavones|Eight-week intake of three capsules per day, containing a total of 2.1 g of plant extracts (PPs), including 150 mg of resveratrol (found in grapes and red wine), 100 mg of ellagic acid (present in strawberries, walnuts, pomegranate, etc.), and 50 mg of the isoflavone daidzein, among others (found in soy, red clover, etc.).
214908993|NCT07182370|DIETARY_SUPPLEMENT|Consumption of placebo|Daily intake of three capsules (2.1 g/day) of microcrystalline cellulose for eight weeks
215077726|NCT02030197|BEHAVIORAL|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
215077727|NCT02030197|OTHER|Control Group|no treatment
215077728|NCT00027365|BIOLOGICAL|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
215077729|NCT00027365|BIOLOGICAL|NefTat|
215077730|NCT00027365|DRUG|AS02A Adjuvant|
215077731|NCT00027365|BIOLOGICAL|gp120W61D|
215077732|NCT04673942|BIOLOGICAL|AdAPT-001|Oncolytic virus administered by intratumoral injection
214303459|NCT01788670|OTHER|Water|
214303460|NCT05662566|PROCEDURE|Epidural replacement|"Insufficient analgesic effect of epidural anesthesia to the extent were replacement of the catheter is needed.~Defined as insertion of a new epidural catheter"
214303461|NCT00525733|DRUG|darunavir 800 mg|darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
214303462|NCT00525733|DRUG|FTC 200 mg/TDF 300mg|Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
214908994|NCT07183176|DEVICE|Chattanooga CEFAR Tens|"* The patient will be assigned to one of two groups:~  1. The intervention group: called the REAL TENS group (R- TENS)~ 2. The control group: called the FAKE TENS group (F-TENS)~     Step 2: The doctor investigator 1 will place the TENS on the painful area identified by the patient, following the model proposed in appendix 1.~     Step 3: The doctor investigator 1 will explain to patients in both groups that they may feel a slight tingling sensation or no sensation at all.~     Step 4: The doctor investigator 1 will make the following settings on the TENS:~* For the interventional group (REAL TENS) a combined setting will be used:~  1. Tens Burst (P2) at 2Hz and 180 µs with an action on muscle pain.~ 2. Tens gate control (P9) at 100 Hz and 250 µs with an action focused on nociceptive pain.~* For the control group (FAKE TENS), the doctor will not make any real adjustments.~The patient will not be able to see the settings made by the doctor investigator 1.~Stage 5: The doctor investigator"
214908995|NCT07184138|DRUG|Interleukin-23 Inhibitors (IL-23i)|Adult patients will receive treatment with an interleukin-23 inhibitor (IL-23i), including guselkumab or risankizumab, as prescribed in routine clinical practice in China. This observational study does not mandate dosing, administration schedule, or concomitant medications; treatments follow standard of care. Patients will be prospectively monitored for clinical effectiveness, endoscopic outcomes, and safety over 52 weeks.
214303463|NCT00525733|DRUG|Maraviroc|Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
214908996|NCT07183878|DRUG|Venetoclax|Venetoclax is administered orally at 400 mg/day for participants ≥14 years or 360 mg/m²/day for those aged 12-14 years, from day -14 to -8 before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Dose is adjusted to 100 mg/day (or 90 mg/m²/day for pediatric patients) if used with strong CYP3A4 inhibitors such as posaconazole.
214908997|NCT07183878|OTHER|None-placebo|Participants in this arm will not receive venetoclax as part of their conditioning regimen. They will undergo standard myeloablative conditioning with BUCY (busulfan, cyclophosphamide, and MeCCNU), prior to allogeneic hematopoietic stem cell transplantation. This arm serves as the active comparator to evaluate the addition of venetoclax in the experimental arm.
214908998|NCT07183748|DRUG|Psilocybin (drug)|0.4 grams
214908999|NCT07183748|OTHER|Placebo|Placebo
214909000|NCT07184424|DRUG|lenalidomide|For patients with hepatocellular carcinoma who have experienced disease progression after receiving standard clinical treatment with lenvatinib in combination with PD-1 inhibitors, the addition of lenalidomide capsules to the three-drug combination therapy was followed by a 2-month follow-up liver imaging examination to observe changes in the target lesion and whether new lesions had developed in other areas.
214909001|NCT07182461|DEVICE|Dynamic Tape|Dynamic Tape is a viscoelastic tape designed to assist movement and absorb load. The material is composed of either Nylon/Lycra or Recycled PET/Lycra.
214909002|NCT07182461|DEVICE|Swiss Ball|A 75 cm diameter Swiss ball was used to provide an unstable surface during the exercise intervention.
214909003|NCT07182461|DEVICE|Dumbbells|During the exercise intervention, 1 kg and 2 kg dumbbells were used as external resistance.
214909004|NCT07182461|DEVICE|Visual Feedback Laser Device|A headband was prepared to attach the laser pointer securely, allowing participants to wear it . This visual feedback laser device was used during proprioceptive training to provide real-time feedback.
214909005|NCT07183488|OTHER|Propionate followed by Butyrate|The participants will consume Short-chain fatty acid propionate (SCFA-PRO) followed by Short-Chain Fatty Acid Butyrate (SCFA-BUT).
214909006|NCT07183488|OTHER|Butyrate followed by Propionate|• The participants will consume Short-chain fatty acid Butyrate (SCFA-BUT) followed by Short-Chain Fatty Acid Propionate (SCFA-PRO).
214909007|NCT07183488|OTHER|Propionate followed by Butyrate|• The participants will consume Short-Chain Fatty Acid propionate (SCFA-PRO) followed by Short-Chain Fatty Acid Butyrate (SCFA-BUT).
214909008|NCT07183488|OTHER|Butyrate followed by Propionate|The participants will consume Short-Chain Fatty Acid Butyrate (SCFA-BUT) followed by Short-Chain Fatty Acid Propionate (SCFA-PRO).
214909009|NCT07182240|DEVICE|LC-OCT Imaging|handheld imaging device will take high resolution images of lesion
214909010|NCT07183007|OTHER|Low gluten diet|Systemic lupus erythematosus patients with HLA-DQ2 or DQ-8 positive will be randomized to dietary intervention group or control group. Those who are randomized to dietary intervention group will get dietary planning and intervention from a nutritionist with low gluten diet
214909011|NCT07183410|DIAGNOSTIC_TEST|Blood culture taken from an arterial catheter|Blood culture taken from an arterial catheter (instead of peripheral venous puncture)
214909012|NCT07183917|BEHAVIORAL|Forest Therapy and Mindfulness|Weekly 2-hour guided sessions for 8 consecutive weeks in natural forest environments. Each session includes mindful walking, multisensory awareness (sight, sound, smell, touch), breathing exercises, and guided relaxation practices. Facilitated by certified Forest Therapy and Mindfulness instructors. The intervention is non-invasive, focused on stress reduction, emotional regulation, and improved subjective well-being through mindful immersion in nature.
214909013|NCT07183917|BEHAVIORAL|Indoor Wellness Control|Weekly 2-hour structured sessions for 8 consecutive weeks conducted indoors (classroom or wellness center). Activities include health education talks on stress and wellness, guided music-based relaxation, and eco-friendly culinary tasting experiences. Designed to provide an active comparator condition controlling for attention, group interaction, and wellness-related content without exposure to forest environments or formal mindfulness practices.
214909014|NCT07184203|DRUG|Itraconazole (ITZ)|therapy for tinea capitis orally
214909015|NCT07182149|DRUG|NRM-823|NRM-823 is a bispecific T-Cell Engager
215077733|NCT04673942|DRUG|Checkpoint Inhibitor, Immune|Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
215077734|NCT05404347|DIAGNOSTIC_TEST|Next generation sequencing|NGS is carried out on DNA isolated from paraffin embedded tissue
214303464|NCT00525733|DRUG|Raltegravir|Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
214303465|NCT00525733|DRUG|Ritonavir 100 mg|one tablet of ritonavir is taken with darunavir daily
214303466|NCT00778011|DRUG|Ondansetron|dosage
214303467|NCT00778011|DRUG|Ondansetron|4 mg
214303468|NCT00778011|DRUG|Metoclopramide|10 mg IV
214303469|NCT01768481|DRUG|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
214303470|NCT01768481|DRUG|sugar pill|placebo controlled arm receives similarly looking placebo.
215058027|NCT01973231|DRUG|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
214303471|NCT04263701|OTHER|Therapeutic exercises|Conventional physiotherapy exercises for children with cerebral palsy
214909016|NCT07183397|DIAGNOSTIC_TEST|VExUS & Cardiac Ultrasound|The VExUS system provides a semi-quantitative assessment of systemic venous congestion by integrating ultrasound evaluations of the inferior vena cava diameter, hepatic vein flow, portal pulsatility, and renal venous flow, offering a practical and comprehensive bedside tool
214909019|NCT07184489|OTHER|implementation strategies|"1. Analysis of barrier factors: A focus group interview will be conducted. Purposive sampling was used to include senior nurses in the ward, members of the evidence-based group, and doctors for the analysis of barrier factors. Then the CFIR-ERIC matching tool will be used to develop implementation strategies based on the barrier factors.~2. The best - worst scaling method will be used to generate relatively reliable and valid preference evidence of stakeholders for implementation strategies from CFIR-ERIC matching tool.~3. The implementation strategies will be developed specifically by an expert group. This group includes nursing managers and experts in evidence-based practice.~4. Implement the strategies."
214909020|NCT07183904|PROCEDURE|Hematoma Block|Injection of 5-10 mL of 2% mepivacaine directly into the fracture hematoma under aseptic conditions.
214909021|NCT07183904|PROCEDURE|Median Nerve Block|Injection of 3-5 mL of 2% mepivacaine adjacent to the median nerve at the wrist, using anatomical landmarks.
214909022|NCT07175467|OTHER|Haptic-asissted virtual simulation|The virtual reality application will be developed using the Unity game engine. The VR simulation environment, which will progress through scenarios, will include taking vital signs, performing aspiration, performing a nasogastric catheterization, oxygen therapy, performing physical examinations, and performing subcutaneous injections.
214909023|NCT07183683|DEVICE|group 1: electrical stimulation of acupuncture points plus routine care|The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min electrical stimulation per foot with 10Hz and an intensity up to individual tolerance level.
214909024|NCT07183683|OTHER|group 2: acupressure plus routine care|The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min massage per foot
215058028|NCT01485796|BIOLOGICAL|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
215058029|NCT01485796|BIOLOGICAL|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
214303472|NCT04263701|OTHER|Dual Task Training|Dual task training in addition to conventional physiotherapy exercises for children with cerebral palsy
214303473|NCT05882799|PROCEDURE|Ultrasound-guided dry needling|Ultrasound-guided dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle while monitoring the needle's progress with real-time ultrasound imaging. In this technique, a trained practitioner visualizes the piriformis muscle and the surrounding structures using an ultrasound machine, and then inserts the needle through the skin and into the muscle tissue, guided by the ultrasound image.
214909025|NCT07181967|DRUG|Sodium Fluoride Varnish (5%)|Topical application of 5% sodium fluoride varnish (22,600 ppm fluoride) to cavitated dentin caries lesions (ICDAS 3-5) on the contralateral side of the mouth. Applied once using a disposable applicator per manufacturer's instructions. This distinguishes it from lower-concentration fluoride gels or multiple-application protocols in other clinical trials.
214909026|NCT07181967|DRUG|Silver Diamine Fluoride (38%)|"Topical application of 38% silver diamine fluoride solution (44,800 ppm fluoride) to cavitated dentin caries lesions (ICDAS 3-5) on the assigned side of the mouth. Applied once with a microbrush for 1 minute, per manufacturer's instructions, without subsequent rinsing. This concentration and protocol distinguish it from other concentrations of SDF or repeated-application protocols used in other clinical studies."
214303474|NCT05882799|PROCEDURE|Blinded dry needling|Blinded dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle without using real-time imaging guidance. In this technique, the practitioner relies solely on their palpation skills to locate the trigger points of the piriformis muscle and inserts the needle through the skin and into the muscle tissue.
214303475|NCT03713203|DEVICE|pagetex PDT|2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
214909027|NCT07183553|OTHER|maintenance training|information has been provided in accordance with the content of the training booklet.
214909028|NCT07182526|DRUG|Quercetin|Quercetin 500 mg capsule daily after meal for three months
214909029|NCT07182526|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha lipoic acid 600mg SR capsule daily after meal for three months period.
214909030|NCT07182526|DRUG|MetFORMIN 500 Mg Oral Tablet|metformin 500 mg daily for three months
215058030|NCT04380909|BEHAVIORAL|Internet-based self-help|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
214909031|NCT07182435|BIOLOGICAL|personalized neoantigen mRNA tumor vaccine|RH125 is a personalized neoantigen mRNA tumor vaccine which is constructed based on the results of patients' neoantigen sequencing.
215058031|NCT04380909|BEHAVIORAL|Internet-based self-help after 3 weeks|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
214303476|NCT00613015|DRUG|Guanfacine|
214303477|NCT00613015|DRUG|Modafinil|
214303478|NCT00613015|DRUG|Placebo|
214303479|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with intraocular lens implantation and monovision correction
214909032|NCT07182201|BEHAVIORAL|Foot core control training|(1) Toe Yoga : When MTPJ1 actively dorsiflexes, the other four toes remain in contact with the ground. The subject lifts the big toe while the remaining four toes stay on the ground; conversely, when the big toe contacts the ground, the other four toes lift upward, alternating this pattern. (2)Doming: While keeping MTPJ1 in contact with the ground, elevate the foot arch. This exercise strengthens intrinsic foot muscle strength, helping stabilize the arch and first metatarsal. The subject tightens the toes, bringing the forefoot toward the heel to form and enhance the arch. Maintain all toes firmly planted on the ground, ensuring no ankle inversion, no forced flexion or extension of toes, and hold at maximum position. Perform training seated to avoid compensatory movements by external muscles during exercise. (3) Toe Abduction Exercises（4）Dynamic Exercise Progression
214909033|NCT07182201|BEHAVIORAL|CPF Conventional training|The key points of the exercise are as follows: (1) Fascia ball release of plantar fascia (2) Plantar fascia stretching (3) Gastrocnemius muscle stretching (4) Toe grab towel
214909034|NCT07176442|BEHAVIORAL|MOOC (E-Learning)|Participants complete a structured Massive Open Online Course (MOOC) hosted on Canvas. The course includes four 4-5 minute video modules on diabetic ketoacidosis, with interactive quizzes between modules.
214909035|NCT07176442|BEHAVIORAL|Simulation Training|Participants take part in a high-fidelity simulation session using a mannequin programmed for diabetic ketoacidosis management. Each session is followed by a structured debriefing led by the instructor.
214909036|NCT07176442|BEHAVIORAL|Educational Escape Game|Participants join a 30-minute educational escape game with 10 puzzles that guide them through the diagnosis and management of diabetic ketoacidosis. The activity emphasizes collaboration and problem-solving.
215058032|NCT04226625|DRUG|Propofol|Intravenous administration
215058033|NCT04226625|DRUG|Desflurane|Volatile administration
215058034|NCT02562846|OTHER|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
215058035|NCT05985798|DRUG|Sin-Bev-TACE|Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
215058036|NCT05985798|DRUG|Len-TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated on demand.
215058037|NCT03133494|OTHER|ABG analysis|ABG analysis was performed and compared between two groups
215058038|NCT00618735|DRUG|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
215058039|NCT00618735|DRUG|BIIB021|Twice daily dosing
215058040|NCT01174979|DRUG|Caroverin|treatment with eardrops 2 times for 48 hours
215058041|NCT04381052|DRUG|Clazakizumab|Dose is 25mg intravenously over 30 minutes.
215058042|NCT04381052|OTHER|Placebo|Intravenously administered over 30 minutes.
215058043|NCT02357537|BEHAVIORAL|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
214303480|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with multifocal intraocular lens implantation
214303481|NCT06071715|DEVICE|ACTIVE cryoneurolysis|Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium Initial treatment: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.
214303482|NCT06071715|DEVICE|SHAM cryoneurolysis|SHAM cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.
214678611|NCT02367170|PROCEDURE|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation \>92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
215077735|NCT02933073|BIOLOGICAL|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
215077736|NCT00615446|DRUG|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
214670146|NCT00678496|OTHER|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
214670147|NCT00678496|OTHER|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
214909037|NCT07172009|OTHER|Chlorhexidine mouthwash|Rinsing the mouth with chlorhexidine mouthwash for 2 minutes before consuming 50 g of carbohydrates
214909038|NCT07172009|OTHER|Placebo mouthwash|Rinsing the mouth with placebo mouthwash for 2 minutes before consuming 50 g of carbohydrates
214909039|NCT07182448|OTHER|Saliva and serum sampling|"Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes.~Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis."
214909040|NCT07183189|DRUG|SHR-A2009 ; Aumolertinib|SHR-A2009 administered intravenously, Aumolertinib administered orally.
214909041|NCT07183189|DRUG|Aumolertinib|Aumolertinib administered orally
214909042|NCT07182136|PROCEDURE|Pancreaticoduodenectomy|Retrospective study evaluating postoperative NAFLD and metabolic outcomes in patients with stage I-II pancreatic cancer after PD.
214909043|NCT07182955|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Remote 4 weeks of high-intensity interval exercise training on three non-consecutive days of the week.
214909044|NCT07182682|DRUG|sunvozertinib|Participants will receive oral administration of sunvozertinib 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).
214909045|NCT07182682|DRUG|Matching Placebo|Participants will receive oral administration of placebo 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).
214909046|NCT07182877|DEVICE|Closed-type peripheral cannula|We will use closed-type peripheral catheters (BD Nexia Closed IV Catheter System.
214909047|NCT07182877|DEVICE|Open type peripheral cannula|We will use POLYMED Ultra Intravenous cannula in the control arm
214909048|NCT07184346|OTHER|Control|Control Group
214909049|NCT07184346|DEVICE|Intra Oral Scanner|Experimental group 1
214909050|NCT07184346|DEVICE|Mod Jaw|4 D Jaw Tracker
214909051|NCT07182942|DRUG|Xiqing|oral intervention of Xiqing
214909052|NCT07182942|DRUG|probiotics|oral intervention of probiotics
214670148|NCT02226016|DEVICE|FG-5000A|a measuring device for the assessment of levator muscle strength
214909053|NCT07183072|OTHER|Questionnaire and functionality application for child and adult scleroderma patients|Scales and functionality tests will be applied to cases diagnosed with scleroderma
214909054|NCT07176546|DRUG|Avacopan|BID dose of 30 mg TAVNEOS (3-10mg capsules)
214909055|NCT07176546|DRUG|Placebo|BID dose of 30mg TAVNEOS-matching placebo (3-10mg capsules)
214670149|NCT03167619|DRUG|Olaparib Oral Product|olaparib 300mg twice daily
214670150|NCT03167619|DRUG|Olaparib Oral Product in combination with Durvalumab|olaparib 300mg twice daily plus intravenous durvalumab every 28 days
214909056|NCT07183202|OTHER|Case-based learning (CBL)|"During the training session, students were given a detailed explanation of an artificial intelligence (AI)-assisted case presentation structured according to the ERAS protocol. They were briefed on the data collection tools they would need to complete before and after the session. A convenient time was set, considering all participants' accessibility, and students were provided a link they could access from their mobile phones, tablets, or computers. Students participated in the AI-assisted case session online using this link.~During the training process, a case scenario developed by the researchers and optimized with AI was presented to students on a digital platform. The case encompassed the entire patient care process, from diagnosis to discharge, simulating a real-life clinical environment. On the AI-assisted platform, students followed the case flow step by step, actively participating by entering their own responses at each stage of the clinical decision-making process. The plat"
214909057|NCT07183865|RADIATION|radiotherapy|25-40Gy/5Fx or 15-30Gy/5Fx (previous pelvic radiation) for pelvic recurrence. 25-50GY/5Fx for all metastasis tumors. Dose Constraints are based on SABR-COMET 10 trial.
214909058|NCT07183865|DRUG|Irinotecan Hydrochloride Liposome|70mg/m2 (UGT1A1\*28 6/6) or 55mg/m2 (UGT1A1\*28 6/7), IV, q2w
214909059|NCT07183865|DRUG|5-FU|400 mg/m\^2 bolus over 2 hours followed by 2400 mg/m\^2 continuous infusion over 48 hours d1, q2w
214303483|NCT02528656|DEVICE|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
214303484|NCT02528656|DEVICE|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
214909060|NCT07183865|DRUG|Leucovorin|400mg/m2, IV, q2w
214909061|NCT07183865|DRUG|SG001|240mg, IV, q2w
214909062|NCT07183865|DRUG|C225|500 mg/m2, IV, q2w
214909063|NCT07183865|DRUG|Bevacizumab|5mg/kg, IV, q2w
214909064|NCT07183631|OTHER|Platelet rich fibrin|Platelet-rich fibrin (PRF) was prepared according to the manufacturer's instructions. A blood sample was collected from the cubital vein in 10 ml tubes without anticoagulant and centrifuged at 3000 rpm for 10 minutes using a GLO GT416 table centrifuge (GLO Glotech Co. Ltd, Korea) and GLO PRP collection kit (GLO PRP-Kit, Glotech Co, Asan Choong-nam, Korea/ Glofinn, Finland).
214909065|NCT07183631|OTHER|Enamel matrix derivate|"In the control group, the root surface was conditioned with 24% ethylenediaminetetraacetic acid (EDTA) gel for two minutes, washed with physiological saline solution, dried, and treated with enamel matrix derivative (EMD), (Emdogain, Straumann, Switzerland) per manufacturer recommendations."
214909066|NCT07183982|DIAGNOSTIC_TEST|MoCA: Montreal Cognitive Assessment (MoCA) and Positive and Negative Syndrome Scale (PANSS)|"MoCA: A 30-point screening tool assessing attention, memory, language, visuospatial and executive functions; quick and sensitive to mild cognitive deficits.~PANSS: A 30-item scale rating positive, negative, and general psychopathology symptoms in psychotic disorders; widely used to track severity and change."
214909067|NCT07183982|BEHAVIORAL|Rehabilitation program in the form of : psychodynamic group therapy, music and art therapy , cognitive stimulation techniques|"Participants received a structured 6-month program designed to address persistent psychotic symptoms and associated deficits. The intervention included:~Art Therapy: Weekly sessions promoting self-expression, emotional regulation, and enhancement of social interaction.~Cognitive Stimulation: Structured group exercises aimed at improving attention, memory, executive functions, and problem-solving.~The program was delivered by a multidisciplinary team in a group of 10 patients, ensuring active participation, individualized support, and integration of therapeutic modalities."
214909068|NCT07182981|OTHER|Questionnaire application for child and adult scleroderma patients|Scales will be applied to cases diagnosed with scleroderma
214909069|NCT07182734|DEVICE|Supervised and minimally-supervised therapy with ReHandyBot and RehabCoach|"During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a therapist or researcher. Minimally-supervised therapy means that participants try to perform therapy independently with the device, while the supervisor is present to provide assistance only if problems occur or if participants have questions.~A few days after the study begins, participants are introduced to the RehabCoach application, which provides conversational support, reminders, and educational content throughout the intervention.~During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. In each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes."
214909070|NCT07182734|DEVICE|Unsupervised Therapy with ReHandyBot and RehabCoach|"After the familiarization phase, participants continue training without direct supervision at the clinic until discharge and then at home for six weeks. If the therapist considers the participant capable of training safely and effectively with the device, the participant will keep training with the ReHandyBot unsupervised, both at the clinic and at home, while supported by the RehabCoach application. RehabCoach provides reminders, motivational support, and educational material to guide the home-based therapy.~If participants are not considered ready for unsupervised therapy with the device, they will not proceed to the unsupervised phase."
214909071|NCT07183163|OTHER|Clinical and biochemical assessment|Assessment of peri-implant clinical parameters (probing depth, bleeding on probing, plaque index) and biochemical markers (IL-1β, TNF-α, MMP-8) in peri-implant crevicular fluid. No therapeutic or experimental intervention administered.
214909072|NCT07183787|DRUG|Letrozole|Letrozole 2.5 mg orally once daily for 12 weeks.
214909073|NCT07183787|DRUG|danazol|Danazol 200 mg orally twice daily for 12 weeks.
214909074|NCT07182890|DRUG|Clostridium butyricum|"Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Clostridium butyricum 1260 mg twice daily.~Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Clostridium butyricum 1260 mg twice daily."
214909075|NCT07182890|DRUG|placebo|"Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency).~Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency)."
214303485|NCT00257842|PROCEDURE|Standard treatment, sham feedback and biofeedback therapy|
214303486|NCT01738854|PROCEDURE|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
214303487|NCT04043091|PROCEDURE|percutaneous coronary intervention (stenting)|percutaneous stent implantation in coronary artery
214670151|NCT00021866|BEHAVIORAL|Differential Abilities Scale|IQ measurement at 3, 4.5 and 6 years of age
214670152|NCT00021866|BEHAVIORAL|Neuropsychological Testing|Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
214670153|NCT03587909|PROCEDURE|Phacoemulsification Cataract SUrgery|Phacoemulsification in eyes with shallow anterior chamber (\<2.5mm depth)
215058044|NCT01143961|DEVICE|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
214303488|NCT04034173|DRUG|Panitumumab|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes."
214303489|NCT04034173|DRUG|Irinotecan|Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
214909076|NCT07184268|PROCEDURE|full mouth non-surgical scaling|All patients will receive a full mouth scaling using ultrasonic scalers and hand instrumentation
214909077|NCT07184372|OTHER|Radiofrequency and manual tecniques|"We apply manual tecniques while we use the radiofrequency, the treatment is divided into 3 phases:~* PHASE 1: With the patient in the supine position, treatment was performed along the diaphragm for 10 minutes, of which 5 minutes were spent with the capacitive electrode and the other 5 minutes with the resistive electrode. The plate was placed on the back at the level of the diaphragm.~* PHASE 2: The patient was placed in the lateral decubitus position on their right side and 3 minutes were spent with the capacitive electrode and 7 minutes with the resistive electrode. The patient was asked to breathe costal-diaphragmatically throughout the entire duration of the resistive electrode. The plate was placed on the right side, at lung level.~* PHASE 3: The same procedure was performed as in the second phase, only this time on the contralateral side, i.e., on the left side."
214909078|NCT07184372|OTHER|Manual tecniques|Manual techniques are used to increase inspiratory capacity, working on the diaphragm and rib cage to increase their mobility along with breathing exercises.
214909079|NCT07184372|OTHER|Placebo|The radiofrequency is turn off
214909080|NCT07182786|DEVICE|LMA Gastro|LMA Gastro, is a laryngeal mask airway device that is specifically designed for air way management in GIT endoscopic procedures due to having a channel dedicated for endoscope introduction. the safety and efficacy of LMA Gastro was researched in many studies, but its role in preventing Hypercarbia during ERCP procedures is yet to be researched and tested.
214909081|NCT07183540|PROCEDURE|operation opportunity-within 6 weeks after the DC operation.|The autologous skull repair surgery will be completed within 6 weeks after the DC operation.
214909082|NCT07183540|PROCEDURE|operation opportunity-within 90 to 180 days after the DC operation.|The autologous skull repair surgery should be completed within 90 to 180 days after DC.
214909083|NCT07184307|BIOLOGICAL|Platelet-Rich Plasma|Autologous platelet-rich plasma prepared from approximately 50 milliliters of venous blood using a two-step centrifugation protocol. Ten milliliters of platelet-rich plasma are obtained and injected into the sub-urothelial layer of the bladder wall during cystoscopy under anesthesia.
214909084|NCT07184307|DRUG|Intravesical Botulinum Toxin Injection|Botulinum toxin (100 units) reconstituted in 10 milliliters of saline and injected into the bladder detrusor muscle at multiple sites under cystoscopic guidance, sparing the trigone.
214909085|NCT07183605|PROCEDURE|catheter flushing techniques|"Two catheter flushing techniques will be compared:~* Method A: A 5 mL flush performed with a syringe over 5 seconds.~* Method B: A 5 mL flush using a vacuum tube (standard discard tube)."
214909086|NCT07184333|BEHAVIORAL|Interprofessional Education with Digital Case Management for Home-Based Elder Care|A structured interprofessional education programme for nursing and physiotherapy students that includes: (1) a 3-hour workshop on frailty assessment, digital case documentation, and care planning; (2) a 30-minute orientation on home visit safety and communication; (3) supervised home visits to older adult participants involving health and fitness assessments, medication support, and health education; (4) use of a tablet-based digital case management platform for collaborative care documentation; and (5) a 4-week follow-up with personalised mobile health messages and a final home visit. The intervention aims to enhance students' clinical, collaborative, and digital competencies in community-based elder care.
214909087|NCT07183358|BEHAVIORAL|Family-supervised Multimodal Prehabilitation|"A comprehensive prehabilitation program initiated at the start of neoadjuvant chemotherapy and continued until the day before surgery. The intervention includes:~1. Nutritional support: individualized dietary counseling and supplementation plans supervised by clinical nutritionists;~2. Exercise training: home-based aerobic and resistance exercises monitored via wearable devices and weekly video/phone follow-ups;~3. Psychological support: structured counseling sessions to reduce anxiety, improve treatment adherence, and enhance quality of life.~Family members are trained to assist with supervision and compliance. The total duration is approximately 10-16 weeks, depending on the chemotherapy schedule."
214909088|NCT07183358|OTHER|Standard Care|Standard neoadjuvant chemotherapy followed by radical gastrectomy with standard ERAS-based perioperative management, without any additional prehabilitation intervention. Participants receive routine nutritional, nursing and medical care according to hospital guidelines. The aim is to maintain current clinical practice as the control condition for comparison with the experimental prehabilitation program.
215058045|NCT03697161|DRUG|OV101 (gaboxadol)|OV101 (gaboxadol)
215077737|NCT02023801|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
215077738|NCT01097642|DRUG|Cetuximab|Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.
214303490|NCT04034173|DRUG|Folinic acid|Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
214303491|NCT04034173|DRUG|5-FU|5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
214303492|NCT03623360|DIAGNOSTIC_TEST|Free breathing DCE-MRI|Free breathing DCE-MRI
214303493|NCT05769790|DIAGNOSTIC_TEST|ddPCR|The search for cfDNA will be performed using assays available in the literature for the search for E. granulosus cfDNA developed for PCR analysis in biological samples, targeting EgG1 Hae III repeat region, cox1 and nad1 (Zhao et al 2021). Appropriate controls (synthetic sequences and Parasitic reference DNA, provided by the Echinococcosis Reference Center of the Istituto Superiore di Sanità, Rome) will be included in each experiment.
214303494|NCT00534274|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
214670154|NCT03587909|PROCEDURE|Femtosecond Cataract Surgery|Femtosecond Cataract Surgery in eyes with shallow anterior chamber \< 2.5mm
214303495|NCT01413555|OTHER|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
214303496|NCT04051047|DRUG|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
214303497|NCT04051047|PROCEDURE|Tumor biopsy and blood draw|As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
214303498|NCT05130931|OTHER|Multimodal conservative treatment|"15 min of Pain education + 20 min of Specific mobilization of the forearm musculature, pronator teres, tendons of the palmar flexors of the wrist and fingers, transverse carpal ligament and palmar fascia through manual mobilization assisted by Diacutaneous Fibrolysis technique + 10min of self-management and explanation of home-based exercise.~3 sessions of 45 minutes will be taken to perform this protocol and the patient will be shown a self-treatment to be performed 3-5 times a day. The protocol will be carried out over 3 weeks (1 session per week)."
214909089|NCT07183059|DIAGNOSTIC_TEST|Electromyography|"we will perform questionnaire, clinical neurological exam, nEMG and if applicable short exercise test on patients with variants in genes associated with mus-cular channelopathies.~Safety Monitoring and reporting: Needle EMG is generally well-tolerated, but transient mild proce-dural pain and discomfort are widespread and the most frequent side effect that patients will ex-perience. Hematomas are infrequent and, in most cases, asymptomatic and selflimiting. Moreover, the bleeding risk is reduced by the investigator's experience, testing superficial muscles (avoiding complications like compartment syndrome), and by not conducting an EMG when patient is treated with anticoagulants. Infectious complications at the site of needle insertion are extremely infre-quent since disposable needle electrodes are used. Needle insertion is avoided in in-jured/potential infected skin and will not be performed in immune-compromised patients and endocarditis risk."
214909090|NCT07183514|BIOLOGICAL|eggshell-derived calcium hydroxyapatite|eggshell-derived calcium hydroxyapatite will be placed as an indirect pulp capping material after chemo-mechanical caries removal and before final restoration with glass ionomer cement and composite resin.
214909091|NCT07183514|BIOLOGICAL|Calcium hydroxide|Calcium hydroxide will be placed as an indirect pulp capping material after chemo-mechanical caries removal and before final restoration with glass ionomer cement and composite resin.
214909092|NCT07183111|OTHER|Instructions given via artificial intelligence chatbot in form of voice instructions at chair side with Customized chatbot for remote home support|Instructions given via artificial intelligence chatbot in form of voice instructions at chair side with Customized chatbot for remote home support
214909093|NCT07183111|OTHER|Control group instructions given by chair side orthodontist verbally and written pamphlet as home care support|Control group instructions given by chair side orthodontist verbally and written pamphlet as home care support
214909094|NCT06085781|OTHER|fMRI|Functional Magnetic Resonance Imaging
214909095|NCT06085781|OTHER|Oral Pimonidazole|200 mg and 300 mg tablets
214909096|NCT03117179|OTHER|Discharge from patient after consultation in emergency department|Discharge from patient after consultation in emergency department
214909097|NCT05630781|DRUG|Belsomra|randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional approximately 7 days and then scanned a final time.
214909098|NCT05630781|DRUG|Placebo|comparator taken for approximately 10 days
214909099|NCT05630781|DRUG|Methylphenidate|Control Arm: Baseline visit with 2 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
214909100|NCT04960579|BIOLOGICAL|P-BCMA-ALLO1 CAR-T cells|Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
214909101|NCT04960579|DRUG|Rimiducid|Safety switch activator
214909102|NCT03117478|OTHER|Magneto-encephalography (MEG)|Magneto-encephalography
214909103|NCT03117478|OTHER|Electro-encephalography (EEG)|Electro-encephalography
214909104|NCT03117478|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
214909105|NCT03117478|OTHER|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
214909106|NCT03117478|OTHER|Meditation|Meditation
214909107|NCT03007147|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
214909108|NCT03007147|DRUG|Calaspargase Pegol|Given IV
214909109|NCT03007147|DRUG|Cyclophosphamide|Given IV
214909110|NCT03007147|DRUG|Cytarabine|Given IV, SC, or IT
214909111|NCT03007147|DRUG|Daunorubicin Hydrochloride|Given IV
214303499|NCT06260007|DRUG|Tribulus terrestris|Tribulus terrestris
214303500|NCT06260007|OTHER|Placebo|Placebo
214909112|NCT03007147|DRUG|Dexamethasone|Given PO or IV
214909113|NCT03007147|DRUG|Dexrazoxane Hydrochloride|Given IV
214909114|NCT03007147|DRUG|Doxorubicin|Given IV
214909115|NCT03007147|DRUG|Etoposide|Given IV
214909116|NCT03007147|BIOLOGICAL|Filgrastim|Given SC or IV
214346938|NCT05302466|DEVICE|gymnastics plus silicon dental bite pad|Gymnastics (see below) plus dental bite pads. The dental bite pads TJ Motion (BELY Balance GmbH \& Co. KG, Weisendorf, Germany) are made of medical silicone. Accordingly, they are BPA- and latex-free, odourless, tasteless and dimensionally stable. The splints are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise. After use, the splints are rinsed with water and placed dry in the corresponding storage box.
214909117|NCT03007147|DRUG|Ifosfamide|Given IV
214909118|NCT03007147|DRUG|Imatinib Mesylate|Given PO
214909119|NCT03007147|OTHER|Laboratory Biomarker Analysis|Correlative studies
214909120|NCT03007147|DRUG|Leucovorin Calcium|Given PO or IV
214303501|NCT06516991|DEVICE|Temporal Interference Stimulation|"Specific electrode sites are customized for the subject through magnetic resonance scanning, the deep nucleus cluster to be stimulated-nucleus accumbens is calibrated through electric field simulation before treatment, and the stimulation target can be accurately positioned by stimulating the specific electrode sites of the subject during treatment.~During the treatment period, all subjects were treated with a fixed time interference stimulation (TI) device at a frequency of 30 minutes twice a day, 5 days a week, for a total of 10 treatments. The output current intensity during treatment is 3.64 mA+4.36 mA."
214909121|NCT03007147|DRUG|Levoleucovorin|Given PO or IV
214303502|NCT01042327|DEVICE|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
214303503|NCT01042327|DEVICE|Fresenius FX100 dialyzer|
214303504|NCT06471985|COMBINATION_PRODUCT|Music and pain|In both arms of the study the participant will take the same pain test. They will either listen to Enya or slayer, depending on the arm
214909122|NCT03007147|DRUG|Mercaptopurine|Given PO
214909123|NCT03007147|DRUG|Mercaptopurine|Given PO
214909124|NCT03007147|DRUG|Methotrexate|Given IT
214909125|NCT03007147|DRUG|Methylprednisolone|Given IV
214909126|NCT03007147|DRUG|Pegaspargase|Given IV
214909127|NCT03007147|DRUG|Prednisolone|Given PO
214909128|NCT03007147|OTHER|Questionnaire Administration|Ancillary studies
214909129|NCT03007147|DRUG|Therapeutic Hydrocortisone|Given IT
214909130|NCT03007147|DRUG|Thioguanine|Given PO
214909131|NCT03007147|DRUG|Vincristine Sulfate|Given IV
214909132|NCT04854122|BEHAVIORAL|Combined exercise intervention|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week. Aerobic exercise will be part of all three sessions, with resistance exercise during two out of three sessions. Training sessions will be supervised by personal trainers to ensure the safe use of the equipment and the correct form when performing each exercise. The first 3 weeks of the intervention will be familiarization with the exercises and the program. After a warm-up, the participant will perform 30 min of aerobic exercise at a heart rate of 65% of the participant's maximum heart rate \[43\], which increases to 65-85% during weeks 4-12 of the intervention. The resistance exercise part will include all major muscle groups, both upper and lower body.
214909133|NCT04854122|BEHAVIORAL|Usual care / Sham intervention|The control condition consists of usual activities.
214909134|NCT05234905|DRUG|Recombinant human adenovirus type 5＋Camrelizumab|"Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×1012vp (3 injections) on day 1, 1.0×1012vp (2 injections) on day 4.~② Tumor maximum diameter \>5cm but ≤10cm, 3.0×1012vp (6 injections) on day 1 and 2.0×1012vp (4 injections) on day 4.~③ Tumor maximum diameter \>10cm, 4.5×1012vp (9 injections) on day 1 and 3.0×1012vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV."
214909135|NCT05294237|BEHAVIORAL|Happy program|The Happy program consists of handball specific warm-up components and resistance training components and will be available online.
214909136|NCT05294237|BEHAVIORAL|Support|The support consists of a coach workshop at the beginning of the season and the opportunity for additional support for the coaches throughout the season.
214909137|NCT04158167|DRUG|oxytocin|24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced
214909138|NCT00382200|DRUG|decitabine|
214909139|NCT00382200|DRUG|tretinoin|
214909140|NCT00382200|GENETIC|DNA methylation analysis|
214909141|NCT00382200|GENETIC|cytogenetic analysis|
214909142|NCT00382200|GENETIC|microarray analysis|
214909143|NCT00382200|OTHER|flow cytometry|
214909144|NCT00382200|OTHER|immunohistochemistry staining method|
214303505|NCT03393546|BEHAVIORAL|Auricular Point Acupressure|It includes 4 weekly auricular point acupressure treatments.
214303506|NCT01335581|DEVICE|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
214909145|NCT04580810|BEHAVIORAL|CBT4CBT in the Black Church|Use of Computer Based Treatment for Cognitive Behavioral Therapy for alcohol use disorder offered in a Black church setting
214909146|NCT04451057|DEVICE|high flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
214909147|NCT04451057|DEVICE|low flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
214909148|NCT06576349|BEHAVIORAL|Compassionate And Loving Mindset towards Heart Health Risk (CALM Hearts) Intervention|Self-compassion and health behaviour change intervention for women at risk for cardiovascular disease
214909149|NCT02989870|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Participants will receive 3-5 fractions of radiation as determined by the dose level at time of enrollment. The starting dose level will be Dose Level 1: 8 Gy x 3 fractions for a total of 24 Gy. If sufficient treatment related toxicity is observed at the initial starting dose, then the dose will be reduced to 16 Gy in 2 fractions of 8 Gy. The dose per fraction for each participant will be provided at the time of registration based on the toxicity experience of the previous participants on study. This will be escalated to 40 Gy in 5 fractions of 8 Gy."
214909150|NCT02989870|DRUG|Sorafenib|Sorafenib by mouth (PO): 200 mg twice a day (BID) then 400 mg BID.
214909151|NCT02989870|DRUG|Bavituximab|Bavituximab intravenously (IV): 3 mg/kg every week (q wk).
214909152|NCT05340088|PROCEDURE|Retrograde intrarenal surgery after DJ stent placement|Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
214909153|NCT01529333|DEVICE|Middle Ear Implant with MET V Transducer|The MET V System is indicated for use in addressing the amplification needs of adults, 18 years of age and older, who have mixed hearing loss.
215058046|NCT01056406|BEHAVIORAL|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
215058047|NCT03780530|PROCEDURE|subcuticular suturing|Those undergoing Subcuticular suturing of perineal skin using 910 polyglactin vicryl No 2/0 (EGYCRYL®).
215058048|NCT03780530|PROCEDURE|Surgical glue|Those undergoing perineal skin closure using adhesive glue n-butyl-2-cyanoacrylate (Histoacryl®).
215058049|NCT03780530|PROCEDURE|adhesive steri-strip tape|Those undergoing closure of perineal skin via Adhesive surgical water-resistant tape application. (3M® Transpore™ Surgical Tapes).
215058050|NCT01842672|DRUG|Clofarabine|Dose Escalation of Clofarabine
215058051|NCT01842672|DRUG|Mitoxantrone|
215058052|NCT01775553|DRUG|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
215058053|NCT03240861|OTHER|18F-FHBG|Given IV
215058054|NCT03240861|BIOLOGICAL|Aldesleukin|Given SC
215058055|NCT03240861|DRUG|Busulfan|Given IV
215058056|NCT03240861|BIOLOGICAL|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
215058057|NCT03240861|PROCEDURE|Computed Tomography|Undergo PET/CT
214909154|NCT04148586|OTHER|Whole Breast Irradiation|Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
214909155|NCT01100086|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken without food
215058058|NCT03240861|BIOLOGICAL|Filgrastim|Given SC
215058059|NCT03240861|DRUG|Fludarabine|Given IV
215058060|NCT03240861|PROCEDURE|Leukapheresis|Undergo leukapheresis
214670155|NCT05115201|PROCEDURE|Scaling and root planing with antibiotics|Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.
214909156|NCT01100086|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
214909157|NCT04967924|OTHER|neuromuscular training|Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)
214909158|NCT04967924|OTHER|Sports specific training|Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
215058061|NCT03240861|DRUG|Plerixafor|Given SC
215058062|NCT03240861|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215058063|NCT00988052|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
215058064|NCT01523743|DEVICE|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
215058065|NCT01523743|DEVICE|Standard care|The coated intermittent catheter normally used by subject
215058066|NCT02180685|OTHER|Anchor fixation|
215058067|NCT04129983|COMBINATION_PRODUCT|Drugs and Stimulation|60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
215058068|NCT01389453|PROCEDURE|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
215058069|NCT04594135|DRUG|anti-CD5 CAR T cells|anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
215058070|NCT00164008|DRUG|zoledronic acid vs pamidronate|
215058071|NCT03532698|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
215058072|NCT03532698|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
214670156|NCT05115201|PROCEDURE|Scaling and root planing only|Patients will be treated with scaling and root planing
214909159|NCT03090334|DIAGNOSTIC_TEST|De-escalation|Antifungal therapy will be stopped according with BG results
214909160|NCT03391219|DRUG|injection bevacizumab|1.25 mg/0.05 cc bevacizumab
214909161|NCT03391219|DRUG|injection Combined Bevacizumab and Fasudil|1.25 mg/0.05 cc bevacizumab and 0.15mg/0.05 cc fasudil
214909162|NCT01707810|PROCEDURE|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
215058073|NCT06204588|PROCEDURE|control group: SFA only|Single flap approach
215058074|NCT06204588|PROCEDURE|Test group 1: VCMX + Low level LASER therapy + Single flap approach|using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
215058075|NCT06204588|PROCEDURE|Test group 2: Low level LASER therapy + Single flap approach|Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).
215058076|NCT03474913|DEVICE|Upright MRI|Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
215058077|NCT03474913|DEVICE|Standard MRI|standard of care closed 3T MRI
215058078|NCT05033886|DRUG|fezolinetant|oral
215058079|NCT05033886|DRUG|placebo|oral
215058080|NCT06107374|DRUG|[18F]F-AraG|Two PET scans
215058081|NCT02569476|DRUG|Zanubrutinib|
215058082|NCT02569476|DRUG|Obinutuzumab|
215058083|NCT01989429|DRUG|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
215058084|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using liposomal bupivacaine and bupivacaine mixture|Liposomal bupivacaine and bupivacaine mixture were used for transverse thoracic muscle plane block (TTMPB) in experimental group.
215058085|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using bupivacaine hydrochloride|Bupivacaine hydrochloride was used for transverse thoracic muscle plane block (TTMPB) in active control group.
214909163|NCT01707810|PROCEDURE|conventional method|
215058086|NCT00002322|DRUG|Atevirdine mesylate|
215058087|NCT00002322|DRUG|Zidovudine|
215058088|NCT01929200|DRUG|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
215058089|NCT01929200|DRUG|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
215058090|NCT04782349|OTHER|mulligan mobilization with low level laser therapy and traditional physical therapy exercises|"for mulligan mobilization: for improving the limited range of motion of shoulder joint, the therapist will apply posterolateral mobilization for the shoulder joint. Three sets of painless glides of 10 repetitions will be applied with a rest interval of 30 s between each set.~For low level laser application: Laser specifications is as follows: 850 nm wave length and pulsed application with 8 W applied for 20 minutes. laser will be applied over painful points of the shoulder.~For traditional physical therapy exercises: the patients will receive the following exercise program: self stretching exercises for shoulder joint, pully exercises, back climbing exercises, finger ladder exercises, circumduction exercises and pendulum exercises"
214678612|NCT02367170|DRUG|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
214909164|NCT01174823|DRUG|bepotastine besilate ophthalmic solution|sterile ophthalmic solution
214909165|NCT01174823|DRUG|placebo comparator ophthalmic solution|sterile ophthalmic solution
214909166|NCT02840123|BIOLOGICAL|Autologous dendritic cells|
215058091|NCT04782349|OTHER|low level laser therapy and traditional physical therapy exercises|patients in this group will receive low level laser and traditional physical exercises as described before for group (A)
215058092|NCT04782349|OTHER|physical therapy exercises|The patients will receive traditional physical therapy exercises only as described before for group (A)
215058093|NCT04595643|OTHER|Combination of different dysphagia training modalities|Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
215058094|NCT02569346|DRUG|Triumeq|Single-dose Triumeq as a whole tablet
215058095|NCT02569346|DRUG|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
215058096|NCT02569346|DRUG|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
215058097|NCT04301323|DRUG|BHVI1 eye drops|Including 35 children enrolled to receive BHVI1 eye-drops once nightly
215058098|NCT04301323|DRUG|BHVI2 eye drops|Including 35 children enrolled to receive BHVI2 eye-drops once nightly
215058099|NCT04301323|DRUG|BHVI3 eye drops|Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
215058100|NCT02042287|DEVICE|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
215058101|NCT02042287|DRUG|Metronidazole|Oral antibiotic
215058102|NCT04907630|BEHAVIORAL|Antenatal Education|educational intervention
215058103|NCT06393803|DRUG|2mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
215058104|NCT06393803|DRUG|5mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
215058105|NCT06393803|DRUG|10mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
215058106|NCT06393803|DRUG|20mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
215058107|NCT06393803|DRUG|30mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
215058108|NCT06393803|DRUG|40mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
215058109|NCT06393803|DRUG|50mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
215058110|NCT06393803|DRUG|60mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
215058111|NCT01382914|OTHER|chlorhexidine 0.12%|twice daily, 10 ml, topical
215058112|NCT03731403|OTHER|MI varnish|CPP- ACP with 5 % sodium fluoride GC
215058113|NCT02494154|DEVICE|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
215058114|NCT02494154|DEVICE|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
215058115|NCT00222144|DRUG|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
214303507|NCT01335581|DRUG|Retin-A and microdermabrasion|Microdermabrasion and topical lightening agent regimen
214909167|NCT02767011|OTHER|Tele-Health Electronic Monitoring (THEM)|Patients in the intervention group (THEM) will receive a tablet computer and home monitoring medical devices with sensors to transmit the information to a central website that will be monitored by care managers. Medical devices will include weight scales, blood pressure cuffs and blood glucometers. Clinical care mangers will remotely monitor the patients and all electronic readings. Clinical care managers will call or send text messages to the patients based on alerts generated by the tele-health monitoring system.
214909168|NCT02350491|OTHER|Collection of biological samples|collection of biologic samples ( blood and urine) befor and after woman pregnacy
214909169|NCT02954601|DRUG|ORMD-0801 (qd)|Dose 1 = ORMD-0801 (qd)
214909170|NCT02954601|DRUG|ORMD-0801 (bid)|Dose 2 = ORMD-0801 (bid)
214909171|NCT02954601|DRUG|ORMD-0801 (tid)|Dose 3 = ORMD-0801 (tid)
214909172|NCT02954601|OTHER|Placebo|fish oil placebo
214909173|NCT03667222|DRUG|minocycline topical gel|Once daily administration of BPX-04 minocycline gel for 12 weeks
214909174|NCT03667222|DRUG|topical gel vehicle|Once daily administration of BPX-04 gel vehicle for 12 weeks
214909175|NCT04341493|DRUG|Nitazoxanide 500 MG|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs
214909176|NCT04341493|DRUG|Hydroxychloroquine|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug
214909177|NCT02063061|DEVICE|Sham treatment|Patients will receive simulated treatment, with the same ESWT unit as in other arm. Placebo gel-pad is design to prevent shockwaves emission. Looks identical as active gel-pad.
214909178|NCT02063061|DEVICE|ESWT treatment|ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
214909179|NCT01438905|OTHER|Small amplitude (Grade IV) mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
214909180|NCT01438905|OTHER|High velocity, low amplitude (Grade V) mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
214909181|NCT00188773|DRUG|N-acetylcysteine, intralipid, heparin|One visit subject will receive N-acetylcysteine plus intralipid and heparin, another visit n-acetylcyksteine plus saline, another visit intralipid and heparin and another visit saline alone
214909182|NCT04391673|BEHAVIORAL|Vestibular rehabilitation|Vestibular rehabilitation (treatment as usual).
214909183|NCT05904873|PROCEDURE|Mandibular Third Molar Surgery|All surgical procedures were carried out by a single dental(maxillofacial) surgeon different from the clinician performing the cold testing. A total of 4 cc of local anesthetic solution containing 40 mg/ml articaine and 0.005 mg/ml epinephrine was applied to the inferior alveolar and buccal nerve blocks before the surgical procedure. In all cases, the mucoperiosteal flap was raised and bone was removed from the buccal and distal parts of the impacted tooth with burs, while protecting the papilla between the first and second molars during flap design. Before extraction, if necessary, the third molar was divided and tooth extraction was performed with elevators. The flap was brought to its original position and closed with silk suture material.
215058116|NCT03210857|OTHER|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
215058117|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube plus bougie|"Use of a straight, malleable, semirigid bougie on first-attempt intubation. The required bougie is at least 60cm length, a coudé tip is recommended but not required. Operator may choose whether to bend the bougie prior to intubation.~During laryngoscopy, the operator will insert the bougie into the trachea under direct or indirect visual control. If the bougie is successfully placed in the trachea, an assistant will load the endotracheal tube directly over the bougie while the operator will manually stabilize the bougie. Once the bougie has reached the mouth, the assistant will then stabilize the bougie, and the operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube. Then, the assistant will withdraw the bougie from the endotracheal tube.~The use of a stylet is not permitted."
215058118|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube alone|"During laryngoscopy, the operator will insert the endotracheal tube alone into the trachea under direct or indirect visual control. The operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube.~The use of a stylet is not permitted."
214303508|NCT01899300|DEVICE|Metal Stent (WallFlex™ Esophageal RX)|
214303509|NCT02187601|DEVICE|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
214303510|NCT02187601|DEVICE|BreathID|BreathID is the name of the original Exalenz breath analyzer system
214303511|NCT00391274|DRUG|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
214303512|NCT00391274|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
214303513|NCT03762824|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccination during antirheumatic treatment
214909184|NCT06572059|OTHER|assesments for once|"* EDSS score (patient reports recorded in the physician's record will be used.)~* Demographic information~* Fatigue Severity Scale (FSS)~* Beck Depression Inventory (BDI)~* Kinesthetic and Visual Imagery Questionnaire (KSVI)~* Mental Chronometer Test (Nine-Hole Peg Test (DDPT)) will be used.)~* Jebson-Taylor Hand Function Test (JHEFT)~* Manual Ability Test (MAM-36)~* Multiple Sclerosis Impact Scale (MSIS-29)"
214909185|NCT05801536|DEVICE|SCONE|This is a noninvasive (nonsurgical) electrical neuromodulation device to reactivate and retrain the neurons and neural networks in the spinal cord to improve function after neurological trauma. The device will be used to stimulate the cervical spinal cord as participants practice tasks involving upper limb control.
214909186|NCT04744649|DRUG|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40\~60mg Bid，d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
214909187|NCT04744649|DRUG|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
214909188|NCT00162110|DRUG|cetuximab|mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
214909189|NCT00951743|DRUG|Adaptavir (monomeric DAPTA)|"Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day."
214909190|NCT05668416|OTHER|education|The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital. Education brochure (Day surgery training brochure); An educational brochure was prepared by the researchers in line with the literature and practices in the institution. The brochure was composed of 3 sections: pre-operative, on the day of the operation and after the operation.
214909191|NCT06212414|BEHAVIORAL|Mind Programme|Intervention based on Acceptance and Commitment Therapy, mindfulness, and compassion approaches
214909192|NCT06212414|BEHAVIORAL|Support Group|This intervention promotes the sharing of cancer-related experiences, active listening, and a sense of community between participants
214909193|NCT01158846|DRUG|prasugrel/bivalirudin|60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)
214909194|NCT01158846|DRUG|clopidogrel/abciximab|600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.
214909195|NCT00333983|DEVICE|Robotic Upper Extremity Neurorehabilitation|Upper extremity exercise using a planar robot Upper extremity exercise using a planar and vertical robot
214303514|NCT03762824|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccination during antirheumatic treatment
214909196|NCT00333983|OTHER|Traditional Upper Extremity Exercise Group|Upper extremity stretching, skateboard reaching activities, and arm ergometer
214909197|NCT00839683|DRUG|simvastatin|Tablets, Oral, 20 mg, Single Dose
214909198|NCT00839683|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
214909199|NCT00839683|DRUG|simvastatin|Oral, 40 mg, Single Dose
215058119|NCT02597530|DEVICE|TEAS|According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
215058120|NCT01410929|PROCEDURE|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
215058121|NCT00146861|DEVICE|sensor programming|
215058122|NCT06059677|DRUG|Active smoked cannabis|Assessment of active cannabis smoking and driving impairment
215058123|NCT06059677|DRUG|Placebo smoked cannabis|Assessment of placebo cannabis smoking and driving impairment
215058124|NCT04824703|DRUG|Oxygen|"* Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function~* administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1"
215077739|NCT01097642|DRUG|Ixabepilone|Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
214303515|NCT05513495|OTHER|The effect of drip versus intermittent feeding on splanchnic oxygenation|After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
214303516|NCT05244577|DRUG|Olanzapine Tablets|Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant
214303517|NCT05244577|DRUG|Placebo|Placebo,Ondansetron,Dexamethasone,Fosaprepitant
214909200|NCT00839683|DRUG|valsartan|Tablets, Oral, 320 mg, Single Dose
214909201|NCT06247605|DRUG|AL8326 tablets|10mg/tablet, Oral administration, once daily.
214909202|NCT06247605|DRUG|placebo|Oral administration, once daily.
214909203|NCT04558801|DEVICE|Mobile application-based lifestyle change program|Usage of the Mobile application-based lifestyle change program
214303518|NCT05281991|DEVICE|Doppler ultrasonography|color flow Doppler ultrasonography
214909204|NCT06041854|PROCEDURE|Freeze-dried bone allograft combined with Enamel Matrix derivative|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft mixed with enamel matrix derivative.~Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle.The major components of EMD are amelogenins, a family of hydrophobic porcine tooth-derived proteins. They account for more than 95% of the total EMD protein content. Other proteins found in the enamel matrix include enamelin, ameloblastin, amelotin, apin and various proteinases, which have found in trace amounts in EMD. EMD adsorbs on decontamined root surfaces and alveolar bony defects and forms an insoluble scaffold complex."
214909205|NCT06041854|PROCEDURE|Freeze-dried bone allograft|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft .~Allogeneic bone graft refers to bony tissue that is harvested from one individual and transplanted to a genetically different individual of the same species, principally osteoconductive, although it may have some osteoinductive capability, depending on how it is processed."
214909206|NCT00833105|DEVICE|AMES treatment|The AMES device rotates the fingers-thumb or the wrist in the flexion-extension directions over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that are lengthened by the thumb-finger or hand movement. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
214909207|NCT00763425|PROCEDURE|cold polypectomy|The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
214909208|NCT00763425|PROCEDURE|conventional polypectomy|The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
214909209|NCT01575951|RADIATION|MRI-DCE|"The treatment follows the standard practice including radiation dose and treatment volumes.~DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.~Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.~MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.~Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week."
214909210|NCT01262222|OTHER|endothelial function testing|After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.
214909211|NCT02298153|DRUG|atezolizumab|atezolizumab: administered intravenously (IV) every three weeks (q3w)
214909212|NCT02298153|DRUG|epacadostat|epacadostat: Oral daily dosing
214909213|NCT01739231|BIOLOGICAL|ACE527|"3x10\^9 cfu ACE527 vaccine strain. Comprised of three genetically attenuated and engineered strains of E. coli, with antigen profiles covering a wide range of ETEC surface colonization factor antigens (CFA/I, CFA/II \[CS1, CS2, CS3\] and CFA/IV \[CS5, CS6\]) and also expressing LTB, the inactive subunit of LT (ETEC heat labile toxin). The constituent strains of ACE527 were:~* ACAM2025: a live, attenuated, CFA/I, LTB positive strain~* ACAM2022: a live, attenuated, CS5, CS6, LTB positive strain, and~* ACAM2027: a live, attenuated, CS1, CS2, CS3, LTB positive strain."
214909214|NCT01739231|BIOLOGICAL|dmLT|A derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine (13). These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
215058125|NCT03182283|BEHAVIORAL|Person-centered psychosis care|Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
215058126|NCT03589287|BIOLOGICAL|Chondrochymal®|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
215058127|NCT04651465|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
214303519|NCT05281991|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
214303520|NCT04675203|PROCEDURE|Tooth extraction|Tooth extraction
214303521|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
214303522|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
214303523|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
214303524|NCT03079908|OTHER|da Vinci Skills Simulator®|Initial robotic virtual reality surgical simulator Training (da Vinci Skills Simulator ® System), then laparoscopic dry box evaluation
214303525|NCT03079908|OTHER|LapSim®|Initial laparoscopic virtual reality surgical simulator training (LapSim ® System), then laparoscopic dry box evaluation
214303526|NCT03079908|OTHER|Dry lab box laparoscopic training|No initial simulator training. Dry lab box laparoscopic Training only.
214303527|NCT05467436|DRUG|Local anesthetics, IV sedation drugs and analgesics.|Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
214303528|NCT06221514|OTHER|Core Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
214909215|NCT01739231|BIOLOGICAL|CeraVacx placebo|CeraVacx® is used to neutralize gastric acidity upon ingestion of vaccine. It was also used as the placebo in this study. CeraVacx® was prepared from the commercial product (Cera Products, Inc.); 9.5 grams were added to sterile water for each dose and mixed. Each dose contained 7 grams of rice syrup, 2 grams of sodium bicarbonate, and 0.5 grams of trisodium citrate.
214909216|NCT01739231|BIOLOGICAL|H10407 challenge strain|Approximately 2 x 10\^7 cfu of the fully virulent ETEC strain. Previously administered to 91 volunteers at this challenge dose by the CIR clinical team over the previous 4 years in conjunction with other Phase 1/2b trials.
214909217|NCT01448473|OTHER|4-views series|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
214909218|NCT01448473|OTHER|2-views serie|The 2-film series will include the following views: anterior-posterior and one lateral.
214909219|NCT06624670|DRUG|Spesolimab|Solution for infusion
214909220|NCT06624670|DRUG|Placebo matching to spesolimab|Placebo matching to spesolimab
214909221|NCT06624670|DRUG|Prednisone|Prednisone
214909222|NCT06624670|DRUG|Prednisolone|Prednisolone
214909223|NCT05649839|OTHER|garment|patient randomized in the experimental arm will wear the specially designed garment
214909224|NCT03204786|DRUG|Vasopressin (USP) Injectable Solution [Vasostrict]|Nasal Spray
214909225|NCT03204786|DRUG|Placebo|Placebo Nasal Spray
214909226|NCT05765539|DEVICE|echOpen O1 Handheld Ultrasound device|"The performance of the Handheld ultrasound device (echOpen O1 device) will be assessed during these visits for all evaluation criteria.~* One examination with the US machine by the midwife focused on 4 targets ;~* One examination with a classic US machine by the same midwife (comparator) including the search for the four targets ;~* One examination with the US machine by a second operator ; Review of the images obtained by the US machine by the referring radiologist at a separate point of time.~The mode of delivery and the vital status of the mother and newborn will also be collected.~Operator A will start by using either the echOpen O1 device or the US machine (random order, via sealed envelopes) and will then perform the other type of examination.~Another operator (Operator B) will come to perform an examination with the Handheld ultrasound device (blind to the result of the first operator).~The switch between operators A and B will also be random."
214909227|NCT03029403|DRUG|Pembrolizumab|Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.
214909228|NCT03029403|BIOLOGICAL|DPX-Survivac|Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.
214909229|NCT03029403|DRUG|Cyclophosphamide|Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
214909230|NCT04167540|BIOLOGICAL|AAV2-GDNF|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
214909231|NCT05464524|OTHER|Main questionnaire|10-15 minute questionnaire asking about environmental factors (i.e daily lifestyle questions), quality of life, comorbidities among others.
214909232|NCT05464524|OTHER|Optional 12-week follow up questionnaire|A 5-minute questionnaire asking about changes to the quality of life and DFU status since the initial questionnaire.
214909233|NCT06123286|DRUG|Tart Cherry|1 ounce of Tart Cherry Concentrate (King Orchard) mixed with 8 ounces of water daily for 12 weeks
214909234|NCT06123286|DRUG|Omega 3 FA (Fish Oil)|2 capsules of Omega 3 FA (Fish Oil) (Nordic Naturals Ultimate Omega) \[650 mg EPA and 450 mg DHA per capsule\] daily for 12 weeks
214909235|NCT06200545|OTHER|PrEP eligibility assessment|PrEP eligibility assessment
214303529|NCT06221514|OTHER|Shoulder Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
214909236|NCT06200545|DIAGNOSTIC_TEST|Rapid HIV antibody testing prior to provision and/or refill of PrEP|Rapid HIV antibody testing prior to provision and/or refill of PrEP
214909237|NCT06200545|OTHER|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines
214909238|NCT06200545|BEHAVIORAL|Evaluation of barriers and facilitators to ongoing PrEP use|Evaluation of barriers and facilitators to ongoing PrEP use
215058128|NCT00604552|DEVICE|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
215058129|NCT02253095|DRUG|Albendazole|
215058130|NCT02253095|DIETARY_SUPPLEMENT|Zinc|
214346939|NCT05302466|OTHER|gymnastics only|Gymnastics, which are completed daily (7x/week), each consist of three to six exercises and have a total duration of three minutes. The gymnastic programme contain low-intensity exercises from functional gymnastic or physiotherapy.
214909239|NCT06200545|OTHER|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement
214909240|NCT06200545|OTHER|Tracing for any missed PrEP visits|Tracing for any missed PrEP visits
214909241|NCT06200545|OTHER|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"
214909242|NCT05493709|DRUG|Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
214909243|NCT05095818|OTHER|PrEP-RN|Patients randomized to the intervention arm will be counseled on HIV risk factors in general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP (Emtricitabine 200 mg/Tenofovir disoproxil fumarate 300 mg).
214909244|NCT05779020|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan (dose 0.25ml and 0.50ml)
214909245|NCT05779020|BIOLOGICAL|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage/dose 0.50ml
215058131|NCT02253095|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|
215058132|NCT02253095|DRUG|Placebo|
215058133|NCT05970926|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the extremity arteries, which is non-invasive, and the parameters of arterial structure and blood flow will be measured.
215058134|NCT06085235|BEHAVIORAL|exercise|cycling exercise for 15min, with 5min warm up
215058135|NCT05833009|DEVICE|Acupuncture|All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
215058136|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.
215058137|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.
215058138|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
215058139|NCT00703963|DEVICE|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
215058140|NCT00703963|OTHER|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
215058141|NCT03103646|DRUG|Lu AF35700|Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
215058142|NCT03103646|DRUG|Itraconazole (200 mg)|100 mg Capsules for oral use, 200 mg/day. In a fed state
215058143|NCT03103646|DRUG|Itraconazole (300 mg)|100mg Capsules for oral use, 300 mg/day. In a fasted state.
215058144|NCT04805476|DEVICE|Non invasive mechanical ventilation|Prophylactic non invasive mechanical ventilation
215058145|NCT04805476|DEVICE|GP|GP subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to team routine and patient need.
215058146|NCT01288170|DRUG|Nebcinal Tobi|
215058147|NCT01288170|DRUG|Tobi Nebcinal|
215058148|NCT01103440|DRUG|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
215058149|NCT01103440|DRUG|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
215058150|NCT00260728|DEVICE|vascular access graft implantation|vascular access graft implantation
215058151|NCT00110045|DRUG|caspofungin acetate|
215058152|NCT04295811|DEVICE|EsoGuard (lab assay)|EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
215058153|NCT04295811|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
215058154|NCT06503627|PROCEDURE|bladder flap dissection|bladder flap dissection during caesarean section
215058155|NCT00402324|DRUG|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
215058156|NCT00402324|DRUG|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
215058157|NCT00402324|DRUG|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
215058158|NCT01466205|DRUG|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
215058159|NCT01466205|DRUG|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
215058160|NCT02452385|DRUG|CM082 tablet|CM082 tablets taken orally
215058161|NCT01277822|DRUG|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
215058162|NCT01277822|DRUG|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
215058163|NCT01277822|DRUG|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
215058164|NCT01277822|DRUG|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
215058165|NCT02625220|DEVICE|Prototype toric lens senofilcon A|Investigational prototype
215058166|NCT03835182|DEVICE|Ultrasound group|Ultrasound 1 MHz, 1.5 W/cm2 for a total of 10 min applied to the lower back
215058167|NCT03835182|DEVICE|Short wave diathermy group|SWD frequency of 27.12MHz applied in continuous mode (thermic) applied to the lower back for twenty minutes
215058168|NCT03835182|OTHER|Control group|superficial heat, analgesic physical modality and exercise only
215058169|NCT04224441|DRUG|Chlorpromazine Pill|The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
215058170|NCT04449107|BEHAVIORAL|Android based mobile phone application|An android based mobile application will be developed. The application will have features and capacity for text messages, voice messages, pictorial messages and video messages. The content of the messages will be according to the findings of Paigham e sehat project and the four messages domains would be educational, reminder, religious and adverse effects. In addition, pictorial and video messages would be used as per freely available through EPI programme Pakistan.
215058171|NCT03619434|PROCEDURE|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
215058172|NCT03619434|PROCEDURE|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
215058173|NCT00650663|DRUG|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
214909246|NCT05779020|BIOLOGICAL|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage/dose 0.25ml
214909247|NCT06323928|DRUG|Lu AG09222|Lu AG09222 will be administered per the arm description.
214909248|NCT06323928|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per the arm description
214909249|NCT04489173|DRUG|trifluridine/tipiracil|"Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.~Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days."
214909250|NCT06451263|BEHAVIORAL|Nudge|Referral to gynecologic oncology is recommended when patients are diagnosed with a complex adnexal mass on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT). When patients are identified as having an adnexal mass, the order will be pended by the clinical research coordinator and sent to the ordering provider with a message to sign. The order will be pended within 48 hours of resulting imaging. The message will include content about national guidelines on referral to gynecologic oncology with opt-out framed language.
214909251|NCT06474143|DEVICE|Apneal device|Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
214909252|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
214909253|NCT04499248|OTHER|Lumigan|Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
214909254|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.
214909255|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
214909256|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
214909257|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.
214909258|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
214909259|NCT02075203|BIOLOGICAL|AERAS-404|The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK \& a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 \& saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
214909260|NCT02075203|DRUG|Placebo|Saline
214909261|NCT02075203|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
214909262|NCT04077593|DEVICE|RRate Mobile app|Test respiratory rate with RRate application
214909263|NCT01365871|PROCEDURE|anesthetics injection|Basal injection of anesthetics or basal + apical injection of anesthetics.
214909264|NCT00843765|OTHER|acupuncture, massage and basic TCM treatment|"1. During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.~2. After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes."
215058174|NCT00650663|DRUG|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
215058175|NCT02923531|DRUG|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
215058176|NCT02923531|DRUG|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
215058177|NCT00514722|OTHER|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
215058178|NCT02198859|DRUG|Lithium Carbonate|
215058179|NCT00997984|DRUG|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
215058180|NCT00997984|DRUG|placebo|dosed in the AM or PM
215058181|NCT00997984|DRUG|extended-release guanfacine hydrochloride|Dosed in the PM
215058182|NCT01140867|DRUG|zonisamide|zonisamide 100 mg tablet
215058183|NCT04023760|DRUG|Apixaban|Study subjects given a single-dose of apixaban 10 mg.
215058184|NCT03584126|DIAGNOSTIC_TEST|Electrocardiography, ecocardiography and MRI.|AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
215058185|NCT06467786|DRUG|Irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection combined with platinum
215058186|NCT03954886|DEVICE|Plus powered optical lens|A plus powered optical lens will be placed in front of one eye.
214303530|NCT03341533|PROCEDURE|Ice packs plus usual post-op analgesia|A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
214909265|NCT00843765|OTHER|rehabilitation and WM basic treatment|"there two steps:~1. during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education~2. After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet"
214909266|NCT03035617|DRUG|Bupivacaine|Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .
214909267|NCT03035617|OTHER|Saline|In control arm mesh will be soaked in normal saline solution as is routinely done.
214909268|NCT01828723|BIOLOGICAL|SVF|
214909269|NCT03214224|DEVICE|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
214909270|NCT03214224|DEVICE|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
214909271|NCT05506618|DIAGNOSTIC_TEST|Nasal Swab|Collection of one more nasal swabs
214909272|NCT05506618|DIAGNOSTIC_TEST|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
214909273|NCT02715193|BIOLOGICAL|REMD-477|
214909274|NCT02715193|BIOLOGICAL|Placebo Comparator|
214909275|NCT02595918|PROCEDURE|Metastasectomy|Undergo metastasectomy
215058187|NCT02182778|DRUG|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
215058188|NCT02182778|DRUG|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
215077740|NCT03307161|OTHER|osteopathic manual therapy|Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
214303531|NCT03341533|OTHER|Usual post-op analgesia|Standard post-operative analgesia orders will be followed.
214303532|NCT04946539|DIAGNOSTIC_TEST|Ultrasonography|Enthesitis assessment via ultrasonography
214303533|NCT04208594|DRUG|Ivabradine|comparing between both drugs for the effect of hypotensive anesthesia
214303534|NCT04208594|DRUG|Propranolol|comparing between both drugs for the effect of hypotensive anesthesia
214303535|NCT01687959|OTHER|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
214303536|NCT04229615|DRUG|Fluzoparib; Apatinib|Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
214303537|NCT04229615|DRUG|Fluzoparib|Fluzoparib Orally twice daily
214303538|NCT04229615|DRUG|Placebo|Placebo
214303539|NCT03352986|BIOLOGICAL|biological analysis|biological analysis will be performed in the 6 groups of patients
214303540|NCT03352986|OTHER|peripheral arterial tonometry|peripheral arterial tonometry will be performed in the 6 groups of patients
214303541|NCT04234321|DRUG|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
214303542|NCT04234321|DRUG|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
214303543|NCT04234321|DRUG|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
214303544|NCT02090647|BEHAVIORAL|aesthetic outcome|
214303545|NCT00112593|DRUG|fludarabine phosphate|Given IV
214909276|NCT02595918|PROCEDURE|Nephrectomy|Undergo nephrectomy
214909277|NCT02595918|BIOLOGICAL|Nivolumab|Given IV
214909278|NCT00101270|DRUG|irinotecan hydrochloride|Given IV
214909279|NCT00101270|DRUG|oxaliplatin|Given IV
214909280|NCT04666987|DRUG|Insulin degludec and liraglutide (IDegLira)|Paricipants will be treated with commercially available Xultophy® according to routine clinical practice at the discretion of the treating physician, following approved label in Italy. The decision to initiate treatment with commercially available Xultophy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
214909281|NCT05928078|BEHAVIORAL|intervention|Participants will be required to use the MOVI-ageing platform 3 times a week for 12 weeks. The platform will include videos of cognitively demanding physical activities designed and guided by health professionals, who will also be able to check compliance with the intervention.
214909282|NCT02712320|DRUG|LMIS 50 mg|Subcutaneous injection of 50 mg Leuprolide Mesylate
214909283|NCT03596957|DRUG|Tolvaptan|At baseline the tolvaptan dosing will start with daily morning and afternoon doses of 45 mg and 15 mg respectively, with weekly increases to 60 mg and 30 mg and then to 90 mg and 30 mg according to subject tolerability
214909284|NCT01729390|OTHER|Energy density and portion size feeding study|In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
214909285|NCT05313503|OTHER|ketogenic diet|We propose a type of KD named MAD (Modified Atkins Diet) characterized by the following percentages of macronutrients: 65% fats, 27% proteins and 8% carbohydrates.
214909286|NCT05227859|PROCEDURE|Piezocision|After anesthesia, three vertical incisions will be made (3-mm depth and 8-10 mm length) mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar. The surgical procedures will be repeated after six weeks (only the mesial and distal canine incisions will be done)
214909287|NCT05227859|DEVICE|Low-level laser|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal. The middle of the extraction site will be also irradiated in 4 sites (2 buccally and 2 palatally). The LLLT will be applied 5 times in the first month of canine retraction, then every two weeks until class I canine relationship will be achieved.
214909288|NCT05227859|DEVICE|Conventional treatment|The upper canine destalization will be done using NiTi springs. The force level will be controlled every 2 weeks. Retraction will be stopped when a class I canine relationship in both sides.
214909289|NCT00685100|OTHER|PDT plus intravitreal triamcinolone|PDT plus intravitreal triamcinolone
214909290|NCT04324424|DRUG|HMS5552|single dose of HMS5552 25mg
214909291|NCT01077297|DRUG|Tezosentan|single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
214909292|NCT06016205|PROCEDURE|intrathecal morphine injection|Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia
214909293|NCT06016205|PROCEDURE|ultrasound guided PECS2 block|ultrasound guided PECS2 block will be performed with 30 ml bupivacaine 0.25%
214909294|NCT03982511|BEHAVIORAL|PCIT-Health|PCIT-Health (also known as Parents Active in Their Children's Health; PATCH) is an adaptation of Parent-Child Interaction Therapy. PCIT-Health targets (1) the parent-child relationship and (2) parenting efficacy both in general contexts (child play time and clean up time) and specifically in the context of obesity risk-related behaviors (child feeding, family mealtime, and child screen time).
214909295|NCT00491283|DEVICE|Swab Specimen Collection (QuickVue)|
214909296|NCT02885545|DEVICE|Watchman|If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart
214909297|NCT02885545|DRUG|Continued therapy with the prescribed oral anticoagulant|If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
214909298|NCT00568451|DRUG|carboplatin|AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
215058189|NCT04130776|DIAGNOSTIC_TEST|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from \<1% to \>95% of a man having aggressive cancer in a prospective biopsy.
215058190|NCT00925665|DEVICE|Glidescope|Patients are to be intubated using the Glidescope technique
215058191|NCT00925665|DEVICE|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
215058192|NCT02805959|DEVICE|MTS2|
215058193|NCT02261064|DRUG|Telmisartan/Amlodipine low dose|
215058194|NCT02261064|DRUG|Telmisartan/Amlodipine high dose|
215058195|NCT02261064|OTHER|Japanese meal|
215058196|NCT02521038|DRUG|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
215058197|NCT03232827|BEHAVIORAL|Flavored-Sweetened Waterpipe Tobacco|Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
215058198|NCT03232827|BEHAVIORAL|Unflavored-sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
215058199|NCT03232827|BEHAVIORAL|Unflavored-very low sweetened waterpipe tobacco|Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.
215058200|NCT03232827|BEHAVIORAL|Flavored-very low sweetened waterpipe|Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
214303546|NCT00112593|RADIATION|total-body irradiation|Undergo TBI
214303547|NCT00112593|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
214909299|NCT00568451|DRUG|paclitaxel|100mg/m\^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
214909300|NCT00568451|DRUG|temozolomide|150mg/m\^2 at cycle 1, 200mg/m\^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
214909301|NCT05266053|DEVICE|PICO 7 dressing|The PICO 7 dressing consists of a negative pressure wound therapy pump (NPWT) connected to an absorbent gentle adhesive dressing that is applied to a wound. When the pump is activated, it acts by pulling excess fluid from the wound. The dressing absorbs this fluid and helps to prevent bacteria from entering the wound. It has been shown to prevent wound infections and promote healing.
214909302|NCT05266053|OTHER|Standard wound dressing|Standard abdominal dressing at the time of cesarean
214909303|NCT02509819|DEVICE|Heel Cushion Material Bulk (foam)|The heel wedge is made of a rubber style urethane foam. Heel wedges of specified heights and durometers will be inserted into the standard shoes, one at a time, during the test session only. The heel wedges used during the test session are made of the same foam as the heel wedges that are used clinically.
214909304|NCT05344560|DEVICE|soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore|TEST Lens
214909305|NCT05344560|DEVICE|ACUVUE OASYS 1-Day for Astigmatism|CONTROL Lens
214909306|NCT03096860|OTHER|Active alcohol consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
214303548|NCT00112593|DRUG|cyclosporine|Given IV or PO
214303549|NCT00112593|DRUG|mycophenolate mofetil|Given IV or PO
214909307|NCT03096860|OTHER|Placebo consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
214909308|NCT06573684|DIAGNOSTIC_TEST|Electromyography|All of groups will have assessment of electromyography result
214909309|NCT04463407|OTHER|Educational talk about physical activity and nutritional recommendations before a critical period of fat gain in university students|An intervention was performed emulating a traditional nutritional session from a primary healthcare center (public health system). Traditionally, this session lasts around 20 minutes and includes a body composition measurement, nutritional assessment, and a brief educational talk about healthy eating. Just the intervention group received a series of healthy recommendations specially focused on the National Holiday.
214909310|NCT01593670|DRUG|Decitabine|administered intravenous (IV), 10 mg/m\^2/day over 1 hour on days 1-5.
214909311|NCT01593670|DRUG|Vorinostat|200 mg by mouth (PO) twice a day on days 6-15
214909312|NCT01593670|BIOLOGICAL|Interleukin-2|6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
214909313|NCT01593670|OTHER|Natural killer (NK) cells|infusion intravenously (IV) over 15 to 60 minutes day 17
214909314|NCT05459961|DIETARY_SUPPLEMENT|oral spermidine|oral supplement
214909315|NCT05645848|DEVICE|Ultrasonography|Abdominal ultrasound in pregnant women with placenta previa
214909316|NCT02767167|OTHER|Semi-skimmed cow's milk|430ml of semi-skimmed cow's milk / day for 12 weeks
214909317|NCT03630926|DIAGNOSTIC_TEST|NV-VPAC1 PCa Urine Diagnostic Test|The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.
214909318|NCT03426592|DRUG|Vitamin D3, 10000 Intl Units Oral Capsule|"Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
214909319|NCT03426592|DRUG|Placebo oral capsule|"Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
214909320|NCT05990322|BEHAVIORAL|Project EMPOWER|Experimental Condition
214909321|NCT03079986|OTHER|Standard care irrespective of CL|Removal of surgical drains despite persistent CL, without dietary restrictions or dietary treatment for CL.
214909322|NCT03079986|OTHER|Dietary treatment (MCT-diet)|Dietary treatment with MCT-diet until resolution of CL.
214909323|NCT04714424|DEVICE|Virtual Reality Headset|Virtual reality (VR) - a 3-D reality right in a headset
214909324|NCT04689035|DRUG|AVLX-144|Test drug
214909325|NCT04689035|DRUG|Placebo|Placebo
214909326|NCT01343043|DRUG|NY-ESO-1(c259)T Cells|Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
214909327|NCT01343043|DRUG|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy.
214909328|NCT01343043|DRUG|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy.
214909329|NCT03514524|OTHER|PET-MR imaging|Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)
214909330|NCT01071642|DRUG|stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure|ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
214909331|NCT01071642|DRUG|ACE/ARB stopped 24 hours before procedure and start immediately after|ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
214909332|NCT04122300|DRUG|Euphrasia Officinalis Preparation|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
214909333|NCT04122300|DRUG|Placebo|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
214909334|NCT01294176|DRUG|Lipoic Acid|Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
214909335|NCT03517176|DRUG|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
214909336|NCT03517176|DRUG|Nab-paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
214909337|NCT03517176|DRUG|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
214909338|NCT03197480|DRUG|Aflibercept Injection [Eylea]|All subjects will receive 4 monthly intravitreal injections of aflibercept
214909339|NCT02556320|DRUG|anti-epileptic drug|Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
214909340|NCT02556320|BIOLOGICAL|Blood sampling|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
214909341|NCT06449729|DIAGNOSTIC_TEST|Blood sample and urine collection|Blood sample and urine collection as per clinical practice
214909342|NCT05310682|OTHER|Data informed Platfrom for health|The DIPH promotes local data use for decision-making, priority-setting, planning and course correction at the district level by introducing a structured and collaborative process within the administration cadre. The DIPH is delivered as a package of job aids and guidelines. It involves grouping stakeholders who are brought together to deliberate on issues in a virtual platform facilitated by regular meetings. The package facilitates stakeholders' meetings in five steps: Assessment, Engagement, Definition, Planning and Follow-up. Together, these steps make up one whole cycle of the DIPH completed over four months. Each cycle looks at a specific health theme, identified in the early stages of the cycle itself. The package also includes a digital interface where everyone can regularly review data and check on progress. Note: LSHTM has exempted this study from having a sponsor, as DIPH is implemented at the health system administration level.
214909343|NCT02300831|OTHER|Data Collection|Non interventional prospective data collection
214909344|NCT02771067|PROCEDURE|Fluid infusion|Fluid infusion will be performed using 6% hydroxyethyl starch. Pulse pressure variation and stroke volume will be measured before and after fluid infusion.
214909345|NCT04231526|DRUG|Pembrolizumab|2 cycles of neoadjuvant pembrolizumab (200mg IV every 21 days)
214909346|NCT04231526|PROCEDURE|Surgery|Standard of care surgery
214909347|NCT05565248|COMBINATION_PRODUCT|VCTX211|CRISPR-Cas9 genetically modified PEC211 cells loaded into a delivery device
214909348|NCT00360282|DRUG|Rizatriptan|10 mg Rizatriptan in an unlabeled pill given once on one of two visits
214909349|NCT00360282|OTHER|Placebo|In an unlabeled pill given once on one of two visits.
214909350|NCT05244057|DRUG|Hepalatide|6.3mg, s.c., qd for 48 weeks
214909351|NCT05244057|DRUG|Placebo of Hepalatide|s.c., qd for 48 weeks
214909352|NCT05244057|DRUG|Tenofovir Alafenamide Tablets|25mg, p.o., qd for 48 weeks
214909353|NCT05244057|DRUG|Pegylated Interferon alfa 2a|90ug, s.c., qw for 48 weeks
214909354|NCT01481948|BEHAVIORAL|Food, Fun, & Fitness Internet Program for Girls|This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
214909355|NCT00925704|DRUG|Calcitriol|Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
214909356|NCT00925704|DRUG|Lanthanum carbonate + Calcitriol|Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
214909357|NCT00925704|DRUG|Sevelamer carbonate + Calcitriol|Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
214909358|NCT06465862|DEVICE|TruTag System|TruTag technology system, consisting of microparticle-tagged Biktarvy and companion smartphone app.
214909359|NCT06465862|DRUG|Biktarvy Pill|Biktarvy prescribed with TruTag system and tagged with TruTag microparticles.
214909360|NCT04283240|DRUG|Sildenafil|50 mg sildenafil, one dose
214909361|NCT04283240|DRUG|Placebo|Placebo
214909362|NCT03017404|DRUG|Doxorubicin Hydrochloride Liposome Injection|
214909363|NCT03017404|DRUG|Cyclophosphamide|
214909364|NCT03017404|DRUG|docetaxel|
214909365|NCT04980430|DEVICE|Virtual Reality|Virtual Reality Demonstration
214909366|NCT03035825|DIETARY_SUPPLEMENT|Oral moisturizing jelly|Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
214909367|NCT03035825|OTHER|Artificial saliva|A non-edible oral lubricating gel for dry mouth patients
214909368|NCT06476301|DRUG|Rivaroxaban|To compare the efficacy and safety of rivaroxaban as an early anticoagulant therapy for BPV patients with the traditional postoperative anticoagulant warfarin
214909369|NCT01244568|BEHAVIORAL|Prostate cancer treatment DESI|DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
214909370|NCT02930772|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z46-100)"
214909371|NCT00581672|BEHAVIORAL|questionnaires of quality of life|Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
214909372|NCT05602168|OTHER|experimental:Acute leukemia/myelodysplastic or myeloproliferative disease|blood sampling, bone marrow aspirate and buccal swab
214909373|NCT02996968|PROCEDURE|Self-removal|Self-discontinuation of a transurethral catheter
214909374|NCT03634969|DRUG|BMS-986224|Specified dose on specified days
214909375|NCT06058546|DRUG|Jiuweihuaban Pill placebo|Jiuweihuaban pill placebo 1 bag(12 g placebo per bag),p.o.,tid,for 12weeks.
214909376|NCT06058546|DRUG|low dose Jiuweihuaban Pill|Low dose Jiuweihuaban pill 1 bag(3 g placebo per bag and 9 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
214909377|NCT06058546|DRUG|high dose Jiuweihuaban Pill|High dose Jiuweihuaban pill 1 bag(12 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
214909378|NCT03943043|DRUG|nab-paclitaxel|"Phase I dosing regimens:~The dose of treatment will be assigned at the time of enrolment in one of these 3 subsequent dose-levels:~\- 1° level: gemcitabine 800 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 80 mg/m2 0° level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 100 mg/m2~1. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 125 mg/m2~2. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 150 mg/m2 each administered on day 1, every 14 day~Phase II:~Gemcitabine plus oxaliplatin plus nab-paclitaxel according to RP2D."
214909379|NCT01772810|DRUG|Human spinal cord stem cells.|Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
214909380|NCT01380912|DRUG|methylprednisoloneacetate|Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
214909381|NCT06114381|OTHER|Home Based Physical Exercise|"Home Exercise protocol consists of one hour divided to 3 minutes warm up,9 minutes' full body (lower limbs, abdomen, back and upper limbs) exercise composed of (aerobic and strengthening) and 3 minutes cool down 4 times per day and 15 minutes for each session 6 days with one day recovery and, with every day follow up with each patient to ensure they did the whole sets and instructed them the ways to each exercise, The total duration was 36 sessions (6 weeks) for each patient. Daily communication with all subjects through sending mobile messages 3 times every day. The message was to remind the participants and confirmation of their response."
214909382|NCT06114381|DIETARY_SUPPLEMENT|Vitamin D3 Supplements|Vitamin D3 supplement (400mg) once daily.
214909383|NCT06114381|OTHER|Diet Management|Patients receive weekly diet program contains dietary sources of Vitamin D such as yolk eggs, tuna and milk.
214909384|NCT06114381|BEHAVIORAL|Sun Exposure|Patients regular exposure to sun once a day 30 minutes of sun exposure, between 10 a.m. and 4 p.m. daily. Exposure to the face, arms, hands, and legs without sunscreen
214909385|NCT03454334|DEVICE|multifocal intraocular lens IOLs|clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts
214909386|NCT01207024|OTHER|knee MRI|knee MRI before surgery (inclusion) and one year after
214909387|NCT00216125|DRUG|Cisplatin|Cisplatin 50 mg/m2 day 1, 8, 29, 36
214909388|NCT00216125|DRUG|Etoposide|Etoposide 50 mg/m2, days 1-5, 29-33
214303550|NCT00112593|OTHER|laboratory biomarker analysis|Correlative studies
214909389|NCT00216125|RADIATION|Radiation|Radiation 5940 cGy (180 cGy/day)
214909390|NCT00216125|DRUG|Docetaxel|docetaxel 75mg/m2 q3wk x 3 cycles
214909391|NCT05885425|BEHAVIORAL|Telemedicine correction of medical treatment|On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine
214909392|NCT05885425|BEHAVIORAL|Education for proper lifestyle|Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle
214909393|NCT03322202|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a communication style that is intended to give patients the tools to reach goals through their own desires and actions.
214909394|NCT02044302|DRUG|Bupivacaine|
214909395|NCT02044302|DRUG|Botulinum Toxins|
214909396|NCT02044302|DRUG|Analgesics|
214909397|NCT04029584|DRUG|rifampin IV|A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.
214909398|NCT04029584|DRUG|Rifadin 300Mg Capsule|Rifadin 600mg by mouth as two 300mg rifadin capsules
214909399|NCT04029584|DRUG|Fluvastatin 20 MG|one oral dose of fluvastatin (Lescol ) 20mg capsule
214909400|NCT02374970|OTHER|Lumbar stability exercises|Four individualized learning sessions will be held during the same period of protocolized physiotherapy. Biofeedback training using the ultrasound machine will be performed in the first session, in order to show the specific contraction of the abdominal muscles with the stability exercises. The other three learning sessions will be performed without feedback, for the patient learn the exercises to make at home during the follow-up period.
214909401|NCT02374970|OTHER|Protocolized Physiotherapy|Therapeutic exercises and thermotherapy during 12 daily sessions
214909402|NCT01618175|DEVICE|Home oxygen therapy|"Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.~During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration."
214909403|NCT02544620|OTHER|Does fulfil of discharge criteria on the day of the surgery|
214909404|NCT02544620|OTHER|Does not fulfil of discharge criteria on the day of the surgery|
214909405|NCT04798794|OTHER|ECMO for neonates|Neonates (\<28 j) supported by ECMO for severe respiratory failure
214909406|NCT05261087|OTHER|No intervention|Individuals will not receive any interventions
214909407|NCT02899182|DRUG|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
214909408|NCT02899182|OTHER|O2|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
214909409|NCT00452296|DRUG|tight insulin treatment in patients hospitalized with COPD exacerbation|treatment with basal plus bolus insulin
214909410|NCT00452296|PROCEDURE|tight glycemic control|treatment with basal and bolus insulin
214909411|NCT04644523|OTHER|Dermoscopy|"dermoscopy is currently used in daily practice in dermatology, for melanoma screening. Dermoscopy will be used in this study on peri-ungueal area.~This is a non-invasive and painless exam."
214909412|NCT01808417|DRUG|Near Infrared Imaging|The intervention to be administered is the drug indocyanine green.
214909413|NCT00916669|DRUG|Etoposide|Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
214909414|NCT00916669|DRUG|Cisplatin|Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
214909415|NCT00916669|DRUG|enoxaparin sodium|Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
214909416|NCT04161469|PROCEDURE|Laser closure of the anal fistula tract (FiLaC)|The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s
214909417|NCT04161469|PROCEDURE|Internal orifice closure|Closure of internal orifice with a purse-string suture using 2-0 polyglactin suture material.
214909418|NCT06117839|PROCEDURE|using antibiotic loaded cement and regular cement after total knee arthroplasty in primary knee osteoarthritis.|-There are 2 groups ,first group is patients will betreated with regular bone cement ,the second one is patient will be treated with antibiotic loaded bone cement, commonly used antibiotics include Gentamycin powder .
214909419|NCT01444664|PROCEDURE|Surgical Clipping of Aneurysm|Surgical clipping of intracranial aneurysm
214909420|NCT05487443|DRUG|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
214909421|NCT02647008|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
214909422|NCT01868737|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamnosus GG and Bifidobacterium infantis'
214909423|NCT01868737|DIETARY_SUPPLEMENT|Placebo|MCT oil
214909424|NCT04268771|BIOLOGICAL|Experimental: Arm A: DRL_RI|Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion
214909425|NCT04268771|BIOLOGICAL|Arm B: Rituxan®/Mabthera®|Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion
214909426|NCT03191383|BIOLOGICAL|RSV vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
214909427|NCT03191383|BIOLOGICAL|RSV vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
214909428|NCT03191383|BIOLOGICAL|RSV vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
214909429|NCT03191383|DRUG|Placebo (Formulation buffer S9b)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
214909430|NCT00070005|PROCEDURE|conventional surgery|
214909431|NCT00070005|PROCEDURE|management of therapy complications|
214909432|NCT03956979|DRUG|JM-010 group A|JM-010 fixed combination drug (Group A) + Placebo 2
214909433|NCT03956979|DRUG|JM-010 group B|JM-010 fixed combination drug (Group B) + Placebo 1
214909434|NCT03956979|DRUG|Placebos|Placebo 1 + Placebo 2
214909435|NCT01585415|DRUG|Vemurafenib|Vemurafenib will administered orally twice a day at a dose of 960 mg from day -21 (+/- 7 days)until disease progression or patients are taken off protocol.
214909436|NCT01585415|BIOLOGICAL|Young TIL|Young TIL will be administered intravenously on day 0(1x10e9 to 2x10e11) in the Patient Care Unit over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
214909437|NCT01585415|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
214909438|NCT01585415|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
214909439|NCT01585415|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
214909440|NCT00483015|BEHAVIORAL|smoking|
214909441|NCT01237574|OTHER|Intervention according to the standard of care.|Every 6 months, patients will have clinical, biological and morphological evaluation according to the standard of care.
214909442|NCT00006429|PROCEDURE|body weight-supported treadmill training|
214909443|NCT03970629|DEVICE|PERSONA Total Knee|Primary Total Knee Arthroplasty
214303551|NCT05797558|PROCEDURE|Unilateral adrenalectomy|Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference.
214909444|NCT02491866|OTHER|to develop and validate a Computerized Adaptative Testing|"* Elaboration of a pool of items, based on literature review and interview with patients.~* Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.~* Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.~* Metrological validation of the CAT.~* Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients."
214909445|NCT00449865|DRUG|creatine|"Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo."
214909446|NCT00449865|OTHER|placebo|an inactive substance
214909447|NCT02529657|RADIATION|Low Level Laser Therapy|In 23 randomized patients, LLLT (B-Cure, Good Energies ®, Israel), with CW diode laser - semiconductor Gallium Arsenide and aluminum (GaAlAs) will be applied during surgery (λ = 804 nm ± 2 , total exposure time of 240 s, energy density of 2.48 J/cm2 , average power of 40 mW , spot area of 3,876 cm2), in contact mode, for 60 seconds on the laminectomy site, 60 seconds and 120 seconds in the subcutaneous tissue of the skin over the wound bed, respectively. In the first and second day post surgery, will be collected the drainage output for analysis of interleukin 1, 4, 6, 8 and 10 (IL- 1, IL-4, IL -6, IL-8 and IL -10 ) and tumor necrosis factor alpha ( TNF -alpha ).
214909448|NCT02529657|PROCEDURE|Placebo|In the operating room, lumbar laminectomy will be performed in 46 patients. During the surgery, 24 hours and 48 hours after surgery, the patients received the regular treatment after laminectomy and were induced to thing that were receiving low level laser therapy in their wound.
214909449|NCT00133848|DRUG|SB-275833 ointment, 1%|
214909450|NCT04412031|OTHER|non applicable|non applicable
214909451|NCT01912092|DEVICE|Askina Calgitrol paste|
214909452|NCT04197466|OTHER|Pelvic Floor Exercise Group|The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..
214909453|NCT04197466|OTHER|Kinesio tape|Kinesio tape application will be performed by ligament technique to the sacral region.
214909454|NCT04197466|OTHER|Electrical stimulation|External electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
214909455|NCT00444535|DRUG|lapatinib|1500 mg oral lapatinib (once daily)
214909456|NCT00444535|DRUG|bevacizumab|10 mg/kg intravenous bevacizumab (every two weeks)
214909457|NCT03984500|OTHER|Education|SCTaware education (Phase II) will be compared to Ohio's current in-person SCT education (Phase I).
214909458|NCT01492907|RADIATION|MeIQx|On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
214909459|NCT01492907|PROCEDURE|Pancreatectomy|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
214909460|NCT04598061|DRUG|Dexmedetomidine IV|Dexmedetomidine IV
214909461|NCT05423288|PROCEDURE|Distal pancreatectomy (DP)|Any scheduled distal pancreatectomy performed for any diagnosis
214909462|NCT04545671|OTHER|trifocal lens|not applicable as patients are already implanted with the trifocal lens
214909463|NCT04208451|DIETARY_SUPPLEMENT|Alixir 400 Protect|During 30 days all patients take every day 30ml of Alixir 400 protect
214909464|NCT03898453|BEHAVIORAL|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
214909465|NCT03898453|BEHAVIORAL|support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques… Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
214909466|NCT04230551|PROCEDURE|PTSMA|Alcohol Septal Ablation
214909467|NCT01412567|DRUG|Vaccine+HBIG|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
214303552|NCT05797558|DRUG|Medical treatment (eplerenone)|The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
214303553|NCT02786316|OTHER|HIT program|HIT program for the rehabilitation of persons with NSCLBP
214303554|NCT02786316|OTHER|conventional rehabilitation program|a conventional rehabilitation program in persons with NSCLBP
214303555|NCT06136702|BEHAVIORAL|Educational session|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.
214909468|NCT01412567|DRUG|Vaccine+Placebo|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
214909469|NCT04730596|DRUG|Ketamine|Ketamine at a dose of 0.3 mg/kg dissolved in normal saline.
214909470|NCT04730596|DRUG|Dexmedetomidine|Dexmedetomidine at a dose of 0.5 ug/kg dissolved in normal saline.
214909471|NCT04730596|DRUG|Normal saline|Normal saline in a labeled syringe
214909472|NCT03827499|DIETARY_SUPPLEMENT|HMB dietary supplementation|Intervention groups including HMB supplementation (Ex-HMB and NoEx-HMB) will receive a 3 g daily dose of free acid HMB in powder form dissolved freely into 250 mL of water during a 24-week intervention
214909473|NCT03827499|OTHER|Multicomponent physical exercise program|Intervention groups including exercise (Ex-HMB and Ex-Plac) will complete an individualized multicomponent training program, five days a week during 24 weeks.
214909474|NCT05289336|PROCEDURE|Transoral Laser Microsurgery|
214909475|NCT02556775|BIOLOGICAL|A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment|To be determined by the physician
214909476|NCT02556775|BIOLOGICAL|HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
214909477|NCT01354652|DRUG|entecavir, lamivudine|"entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.~lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
214909478|NCT05496270|PROCEDURE|total mesorectal excision|
214909479|NCT06574152|DEVICE|PBM treatment|Immediately after the apical microsurgery, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, North Carolina, USA), with an 8 mm tip diameter . The laser tip will be placed following the outline of the incision flap in a contact mode . The power output of the laser will be 50 milliwatt (mW) and verified by a Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2
214909480|NCT06574152|DEVICE|PBM sham treatment|Immediately after the apical microsurgery, sham therapy will be performed without activating the laser.
214909481|NCT06574152|DEVICE|EMS|Patients will be anesthetized. All surgeries will be performed using a surgical microscope. After reflection of a mucoperiosteal flap, osteotomies will be performed to access the root apices and apical lesions. Root apices will be resected at 3 mm, and the pathological tissue curetted out. Next, root-end preparations will be made with ultrasonic tips and filled with calcium silicate-based materials. Methylene blue dye will be used for inspection after root-end resection before the root-end preparation and filling. After cleaning the osseous crypt, the wound margins will be reapproximated with 5-0 single interrupted sutures. A gauze will be placed for 30 minutes for wound compression. Sutures will be removed seven days postoperatively
214909482|NCT01011816|BIOLOGICAL|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
214909483|NCT01011816|DRUG|Saline|One injection of up to 4 mL of saline using the Biostat Delivery Device
214909484|NCT02613832|OTHER|EPAP|The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.
214909485|NCT02613832|OTHER|Breath Stacking|The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
214909486|NCT01472042|OTHER|Banyan Biomarkers|Biomarkers to detect specific proteins.
214909487|NCT00753285|DEVICE|Renal Denervation|
214909488|NCT01610674|OTHER|Tailored improvement strategy|"A step-wise implementation model is applied:~1\) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients."
214909489|NCT00521820|DRUG|Pioglitazone|Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.
214909490|NCT00521820|DRUG|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
214303556|NCT06136702|BEHAVIORAL|Self-sampling|Women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site, to measure the uptake of the self-sampling test (% of women who take the self-sample). Furthermore, two self-administrated questionnaires are applied to 1) assess attitudes regarding self-sampling (pre-intervention), and 2) assess users' experience regarding self-sampling (post-intervention). The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time. All women will be contacted 1-2 weeks after the self-sample taking to inform them on their test result.
214303557|NCT06136702|BEHAVIORAL|Follow-up assessment|To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.
214909491|NCT03794648|BEHAVIORAL|Mobile Interactive Supervised Therapy (MIST)|MIST system will send a reminder notification (via push or SMS) to participants 10 to 15 minutes before the scheduled time for taking their medication. Participants will then activate the recording function of the MIST app on their phone, and record themselves taking their medication.Participants will be asked to go through a series of steps for recording the video.
214909492|NCT03754868|DIAGNOSTIC_TEST|Detailed coagulation monitoring|Monitoring of coagulation using activity of coagulation factors, rotational thrombelastometry and multiple electrode aggregometry
214909493|NCT00558467|DRUG|pramipexole immediate release (IR)|
214909494|NCT00558467|DRUG|Placebo|
214909495|NCT01510301|DEVICE|Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)|"To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;~* Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;~* Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence."
214909496|NCT00178672|DEVICE|Angioguard XP distal protection device|Standard of care stenting of carotid arteries protocol is used.
214909497|NCT00178672|PROCEDURE|Heart Catheterization -Angioplasty|Standard of care carotid stenting. A catheter is inserted in the femoral vein into the carotid artery where a balloon is inflated and shortly thereafter a stent is placed in the target lesion area.
214909498|NCT00178672|DEVICE|stenting|stenting of carotid arteries
214909499|NCT00698672|DEVICE|charnley OGEE|charnley OGEE
214909500|NCT00698672|DEVICE|Spectron Reflection CoCr|Spectron Reflection CoCr
214909501|NCT00698672|DEVICE|Spectron XLPE CoCr|Spectron XLPE CoCr
214909502|NCT00698672|DEVICE|Spectron Reflection Oxinium|Spectron Reflection Oxinium
214909503|NCT00698672|DEVICE|Spectron XLPE CoCR|Spectron XLPE CoCR
214909504|NCT06311916|DRUG|HAIC + Tirelizumab +lenvatinib +liver resection|Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days) + Tirelizumab (First treatment with Tirelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)+ lenvatinib (Oral 8 mg or 12mg once a day depending body weight). Assessment of tumor status and surgical safety after receiving neoadjuvant therapy, and eligible patients then underwent surgical resection.
214909505|NCT06311916|PROCEDURE|liver resection|Direct liver resection or laparoscopic liver resection depending on tumor status.
214909506|NCT01780090|OTHER|iPad software|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
214909507|NCT01448343|DEVICE|Fluid management system 2000 (FMS)|The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
214909508|NCT00034281|DRUG|TAK-165|Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
214303558|NCT03447990|DRUG|MYK-491|Single Ascending Dose and Multiple Ascending Dose of MYK-491
214303559|NCT03447990|DRUG|Placebo|Single Ascending Dose and Multiple Ascending Dose of placebo
214909509|NCT02840539|DRUG|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim|"Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle~Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older~Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle~Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles"
214303560|NCT00265954|BEHAVIORAL|internet, in-person and internet+in-person|All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
214909510|NCT02344238|OTHER|ID Capsule|Capsule containing ingestible sensor
214909511|NCT02344238|DIETARY_SUPPLEMENT|Riboflavin|50mg
214909512|NCT02344238|BEHAVIORAL|Prompts|Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
214909513|NCT05028790|DEVICE|Single vision contact lens|Participants will wear a single vision soft contact lens during the study visit
214909514|NCT05028790|DEVICE|Multifocal contact lens|Participants will wear a multifocal soft contact lens during the study visit
214909515|NCT05002790|DIAGNOSTIC_TEST|Data collection group|"Magnetic resonance imaging (MRI) allows measurement of the axes described to suggest which head and neck position would provide best anatomical alignment to reduce anterior impingement.~All the MRI scans will be conducted using 3.0 Tesla (Optima 750w, GE Medical, Milwaukee, WI, USA) using the cervical spine section of the coil. T2-weighted images in the sagittal plane will be acquired using a fast recovery fast spin echo (FRFSE) technique. The scans will take around two and half minutes and a member of the anaesthetic investigator team will be present to facilitate positional changes and maintain consistency. MRI scanning will be performed in following 3 head and neck positions:~Neutral position, Sniffing position and the Extension position."
214303561|NCT00231335|DRUG|escitalopram|
214909516|NCT04384003|DEVICE|Shear Wave Ultrasound Elastography|"Scanned protocols of sonographic imaging will be used in this study to measure extrinsic (FDL, FHL and PER) and intrinsic (AbdH, FDB and FHB) muscle CSA and thickness, and plantar fascia thickness (at heel, mid and forefoot sites).~The muscle stiffness will be calculated from the program provided by the US machine as shown real time elastography (RTE, unit: KPa)."
214909517|NCT04384003|DEVICE|The 3-D Motion Analysis|The 3-D Motion Analysis, Forceplates and EMG acquisition system and full body kinematic model (Bonita, VICON Corp, UK) in the Biomechanics and Motor Control Laboratory (BMCL).
214909518|NCT04384003|DEVICE|Electromyographic|Electromyographic activity (EMG) of AbdH, TA, PL, SO, gluteus medius (Glut Med) and gluteus maximus (Glut Max) will be recorded bilaterally using pairs of surface electrodes. Motor coordination of these muscles will be evaluated through assessment of temporal and spatial parameters of EMG during functional tasks such as kicking in one leg standing. The primary outcome measure will be percentage of EMG relative to maximal voluntary contraction (MVC) on the same side. In order to remove the potential for investigator bias, all data will be presented individually without identification of the muscle, order of trials or whether the trials precede or follow the intervention.
214909519|NCT04384003|DIAGNOSTIC_TEST|Foot intrinsic muscle assessment and training device|The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing.
214909520|NCT00053690|BEHAVIORAL|Cognitive Behavior Treatment|
214909521|NCT05473832|OTHER|Day Cream cosmetic product compared to untreated side|Applied once daily in the morning
214909522|NCT05473832|OTHER|Night cream cosmetic product compared to untreated side|Applied once daily in the evening
214909523|NCT05473832|OTHER|Eye cream cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening around the eye area
214909524|NCT05473832|OTHER|Serum cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening
214909525|NCT01549587|DRUG|0.243% sodium fluoride|dentifrice: brush thoroughly twice daily
214909526|NCT01549587|DEVICE|toothbrush|brush thoroughly twice daily
214909527|NCT01549587|DEVICE|dental floss|floss the whole mouth once daily
214909528|NCT01549587|DRUG|0.454% stannous fluoride|dentifrice: twice daily brush thoroughly for 2 minutes
214909529|NCT01549587|DEVICE|toothbrush|twice daily brush thoroughly for 2 minutes
214909530|NCT01549587|DRUG|0.07% Cetylpyridinium chloride|mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
214909531|NCT01549587|DEVICE|dental floss|floss the whole mouth once daily
214909532|NCT04394949|BEHAVIORAL|Center for Independent Living SEEKS Team|Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
214909533|NCT04394949|OTHER|Usual Care|Consumers will get same CIL services they would get if they were not enrolled in the study.
214909534|NCT01532856|DRUG|Thalidomide, Cyclophosphamide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
214909535|NCT01532856|DRUG|Thalidomide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
214909536|NCT01532856|DRUG|Thalidomide, Melphalan, Prednisone|thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
214909537|NCT02941211|DEVICE|Aqueduct -100|
214909538|NCT01822093|BIOLOGICAL|Cytovir-ADV|"A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results \> 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at ≥ 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.~This is a feasibility/pilot study and has no control group"
214909539|NCT05031611|BEHAVIORAL|Intuitive Eating Treatment|"Participants received a brief web-based intervention for disordered eating which focused on a style of eating behavior called intuitive eating. Please see arm description for more details."
214909540|NCT06213584|OTHER|conservative rehabilitation|Hotpack + TENS + streching exercises
214909541|NCT06213584|OTHER|mullgan mobilization techniques|Passive mobilization techniques during active movements
214909542|NCT06213584|OTHER|pnf|hold relax active movements
214909543|NCT01698892|DRUG|I.V Sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
214909544|NCT01698892|DRUG|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
214909545|NCT04016129|BIOLOGICAL|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
214909546|NCT05818501|DEVICE|The dysphagia cups|"After the training period of the one of dysphagia cups, participants will start using cup to consume water during a designated period of time every day.~Participants consuming water with Cup A will drink from a static position with their chins towards their chests, the so-called Chin-Tuck maneuver. This position leads epiglottal naturally covering the trachea and causes liquid only ﬂowing to the esophagus and thus stomach. The restoring force of the membrane ensures a constant level of liquid at the upper edge of the cup and thus enables this preferred and safe drinking position.~Cup B limits the maximum volume of water flowing out of the Cup B designated by the staff. Controlled liquid flow prevents overflowing the mouth and gulping, thus reduces the risk of choking and liquid aspiration. Participants can choose to drink the water from Cup B with a straw when necessary."
214909547|NCT03540316|COMBINATION_PRODUCT|Two short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 2 minutes.
214909548|NCT03540316|COMBINATION_PRODUCT|Two short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 4 minutes.
214909549|NCT03540316|COMBINATION_PRODUCT|Four short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 2 minutes.
214909550|NCT03540316|COMBINATION_PRODUCT|Four short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 4 minutes.
214909551|NCT02025725|DRUG|Metoclopramide Nasal Spray|nasal spray formulation of metoclopramide
214909552|NCT02025725|DRUG|Placebo Nasal Spray|nasal spray formulation with vehicle only
214909553|NCT06504914|BEHAVIORAL|Assigned Interventions|Behavioral: RN-CHeFRx The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
214909554|NCT05708118|DIAGNOSTIC_TEST|Echocardiographic assessment.|Patients will be contacted to carry out an echocardiography at least 90 days after surgery. Measurements will be taken for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta. Aortic valve will be assessed as well.
214909555|NCT05708118|DIAGNOSTIC_TEST|Computed-tomography assessment|All enrolled patients will undergo a multislice CT scan (retrospectively ECG-gated, whenever possible) with standard contrast medium injection protocol of nonionic contrast agent. All post-surgery controls will be performed at least 90 days after surgery. All CT datasets will be analysed on a dedicated workstation for the qualitative and quantitative assessment of the aortic root including measurements for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta.
214909556|NCT06374238|BEHAVIORAL|CBT+ Health coach|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in CBT w/ Health coach group will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. In addition participants will have weekly contact with a peer health coach.
214909557|NCT06374238|BEHAVIORAL|CBT w/o Health Coach ( self-guided)|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants CBT w/o Health coach groups will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool.
214909558|NCT06374238|BEHAVIORAL|Usual Care|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in the UC group will be asked to engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. All other care will be at the discretion of their treating provider
214909559|NCT05103618|DRUG|[F-18] Fluorodopa Positron Emission Tomography|Subjects will receive FDOPA imaging at baseline and 2-3 months after practicing the OM Meditation for evaluation of the dopamine function, \[F-18\] Fluorodopa (FDOPA), dose (5-10 mCi, ± 20%) will be injected intravenously into an antecubital vein. In accordance with the standard imaging protocol for FDOPA; subjects will be pre-medicated with 200 mg of carbidopa orally approximately one hour prior to injection.
214909560|NCT05103618|BEHAVIORAL|OM Meditation|Couple pairs will engage in OM Meditation together approximately 3-4 times a week approximately 2-3 months.
214909561|NCT05990179|OTHER|Genome sequencing-based newborn screening|Dried blood spots collected at birth for routine newborn screening will be used for genome sequencing based screening of a defined set of conditions.
214909562|NCT06577194|DRUG|Sintilimab + IL-2 Combined with CAPOX|Sintilimab + IL-2 Combined with Capox
214909563|NCT06577194|RADIATION|Short-course radiotherapy|Short-course radiotherapy+IL-2
214909564|NCT01441557|DRUG|3,4-diaminopyridine|test dose 10 mg then 20 mg, then depending on tolerance and efficacy full-dose administration(from 10mg /8h to 20 mg /8h)
214909565|NCT06278077|DRUG|Neurexan|The active ingredients are Passiflora incarnata Dil. D2 (0.6 mg / tablet), Avena sativa Dil. D2 (0.6 mg / tablet), Coffea arabica Dil. D12 (0.6 mg/tablet) and Zincum isovalerianicum Dil. D4 (0.6 mg / tablet). Inactive excipients are lactose monohydrate and magnesium stearate.
214909566|NCT06278077|DRUG|Placebo|Contains lactose monohydrate, magnesium stearate and looks identical to Neurexan in terms of taste, size, color and labelling.
214909567|NCT04817592|PROCEDURE|Corneal lenticule extraction for advanced refractive correction (CLEAR)|Routinely conducted procedure for correction of Myopia
214909568|NCT04155619|BEHAVIORAL|No change in meal timing|Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
214909569|NCT04155619|BEHAVIORAL|No change in light exposure|Participants will not change their light exposure habits.
214909570|NCT04155619|BEHAVIORAL|Early Time-Restricted Feeding|Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
214909571|NCT04155619|BEHAVIORAL|Timed Light Therapy|Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
214909572|NCT06494397|DRUG|VHX-896 and iloperidone|oral tablet
214909573|NCT06494397|DRUG|Iloperidone and VHX-896|oral tablet
214909574|NCT05330221|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education Other Names: Pragmatic personalized, adaptable approach to lifestyle and life circumstance
214909575|NCT05330221|DRUG|PHARM-PAL2|"All intervention arm participants will be referred to our study pharmacist who will prescribe a antihypertensive medication as per standard of care medical treatment algorithm to achieve BP control.~Per AHA recommended guidelines, participants with an indication of diabetes mellitus (DM) and/or CKD will be started on SGLT2 inhibitor within the first month of starting the study intervention."
214909576|NCT06509438|DEVICE|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|2 milliliters of Embella injectable solution containing 20 milligrams of deoxycholic acid
214909577|NCT06974279|DEVICE|Precision TMS with SFA|Excitatory TMS delivered using a precision site finding approach and intermittent theta burst stimulation protocol
214909578|NCT06974279|DEVICE|Control TMS with SFA|Excitatory TMS using intermittent theta burst stimulation delivered to a control vertex site.
214909579|NCT01513005|PROCEDURE|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance"
214909580|NCT06310655|RADIATION|Proton SBRT|Patients will receive SBRT over 5 days, either every day or every other day, to a dose of 25-50 Gy.
214909581|NCT05851560|DRUG|Oxidized regenerated cellulose(ORC)|Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
214909582|NCT05851560|DRUG|Hyaluronic acid(HA)|Hyaluronic acid(HA)
214909583|NCT04697940|BIOLOGICAL|Decitabine-primed Tandem CAR19/20 engineered T cells|"Phase I dose escalation (3+3) : dose 1 (0.5 × 10\^6 cells per kg) dose 2 (2 × 10\^6 cells per kg) dose 3 (5 × 10\^6 cells per kg)~Phase II: Appropriate dose"
214909584|NCT04697940|DRUG|Fludarabine|Intravenous fludarabine 25-30 mg/m\^2/day on days -5, -4, and -3.
214909585|NCT04697940|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
214909590|NCT05863195|BIOLOGICAL|Bevacizumab|Given IV
214909591|NCT05863195|BIOLOGICAL|Cetuximab|Given IV
214909592|NCT05863195|PROCEDURE|Computed Tomography|Undergo SPECT/CT and/or CT
214909593|NCT05863195|DRUG|Floxuridine|Given via HAI pump
214909594|NCT05863195|DRUG|Fluorouracil|Given IV
214909595|NCT05863195|PROCEDURE|Implantation|Undergo surgery to place the HAI pump
214909596|NCT05863195|PROCEDURE|Intrahepatic Infusion Procedure|Undergo HAI
214909597|NCT05863195|DRUG|Irinotecan|Given IV
214909598|NCT05863195|DRUG|Leucovorin|Given IV
214909599|NCT05863195|DRUG|Oxaliplatin|Given IV
214909600|NCT05863195|BIOLOGICAL|Panitumumab|Given IV
214909601|NCT05863195|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214909602|NCT03331796|DEVICE|Active rTMS (Bilateral DLPFC)|TMS Stimulation Parameters for the active DLPFC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
214909603|NCT03331796|DEVICE|Active rTMS (Bilateral LPC)|TMS Stimulation Parameters for the active LPC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
214303562|NCT01627054|DRUG|AT7519M|Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
214909604|NCT03331796|DEVICE|Placebo rTMS (Inactive)|For the Placebo rTMS (Inactive) group, the participant will wear scalp electrodes through which a low voltage, low electric current (2-20mA at no more than 100V) is passed to mimic the sensation of receiving actual rTMS. Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
214909605|NCT06967480|DRUG|Ravulizumab|Participants will receive Ravulizumab.
214909606|NCT03598842|DIETARY_SUPPLEMENT|Nutritional Supplementation Meal|Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.
214909607|NCT03598842|DIETARY_SUPPLEMENT|Multivitamin|Study participants will be given a daily multivitamin to take for 6 months.
214909608|NCT03598842|DRUG|Anti-parasitic medications|Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
214909609|NCT05900336|DRUG|Sodium Naproxen|One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
214909610|NCT05900336|DRUG|Placebo|One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
214909611|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
214909612|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
214909613|NCT05004051|DEVICE|ViTAA Analysis|Imaging Analysis Software
214909614|NCT05958121|BIOLOGICAL|IMA402 (Phase Ia)|Intravenous infusions in escalating dose levels
214909615|NCT05958121|BIOLOGICAL|IMA402 (Phase Ib)|Treatment at MTD and/or RDE (Phase Ib)
214909616|NCT05958121|BIOLOGICAL|IMA402 (Phase II)|Treatment at MTD/RDE based on a manageable/favorable safety profile and initial signs of anti-tumor activity of selected ISEC (Phase II)
214909617|NCT02867592|DRUG|Cabozantinib|Given PO
214909618|NCT02867592|DRUG|Cabozantinib S-malate|"Given PO~Note: Capsule formulation (Cometriq) not used in this trial."
214909619|NCT02867592|OTHER|Pharmacological Study|Correlative studies
214909620|NCT04821635|DEVICE|Rower assisted by electrostimulation (FES-ROW)|"1. Pre-inclusion visit~2. Inclusion visit~3. Phase 1 Rower-FES with lower limbs (Month 0 to Month 3: M0-M3):~   Training on a rower with solicitation of the electrostimulated lower limbs only for a period of 3 months at the rate of 3 sessions of 30 minutes per week~4. Interim assessment visit at Month 3 (M3)~5. Phase 2 Rower-FES with lower limbs + upper limbs (Month 3 to Month 6: M0-M6):~   Training on with solicitation of the electrostimulated lower and upper limbs for a period of 3 months at the rate of 3 sessions of 30 minutes per week~6. Final assessment visit at Month 6 (M6)~7. End of clinical research visit, 3 months after the end of training (Month 9, M9)"
214909621|NCT06084481|DRUG|ABBV-400|Intravenous (IV) Infusion
214909622|NCT06084481|DRUG|Itraconazole (ITZ)|Oral Solution
214909623|NCT06094192|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
214909624|NCT02655614|DRUG|GDC-0134|GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.
214909625|NCT02655614|DRUG|Placebo|Placebo matching to GDC-0134
214909626|NCT02655614|DRUG|Rabeprazole|Rabeprazole 20 mg twice daily orally
214909627|NCT02655614|DRUG|Midazolam|2mg of liquid formulation of midazolam orally
214909628|NCT02655614|DRUG|Caffeine|100 mg tablet or solution of caffeine orally
214909629|NCT00519116|DRUG|Rapamune® (Sirolimus)|
214303563|NCT02533154|DRUG|Prosicca|Prosicca eyedrops Dosage: on demand Route of administration: topical
214909630|NCT00519116|DRUG|Tacrolimus|
214909631|NCT00519116|DRUG|Perioperative Corticosteroids|The corticosteroids use was left up to the investigators decision.
214909632|NCT06209190|RADIATION|total marrow and total lymphoid irradiation|doses of 12 Gy on days -3 to -1 divided into 6 fractions of 2 Gy every 12 hours for 3 days, which will be administered through a computed tomography tomotherapy system plus conditioning scheme of our institution
214909633|NCT02992041|DRUG|VVZ-149 Injections|IV infusion of 900 or 1100 mg of VVZ-149
215058201|NCT05795673|OTHER|Peer support program (intervention phase)|"Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints."
215058202|NCT03132558|DRUG|Radiopaque Media|
214303564|NCT02533154|DRUG|Prosicca sine|Prosicca sine eyedrops Dosage: on demand Route of administration: topical
214909634|NCT02992041|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
214909635|NCT02618291|OTHER|Active Geriatric Evaluation (AGE tool)|Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.
214909636|NCT02618291|OTHER|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
214909637|NCT00594165|DRUG|Rotigotine|"Rotigotine trans-dermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year:~The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
214909638|NCT04006639|PROCEDURE|Analgesic Technique|Patients undergoing tracheostomy procedure must be administered with analgesics, such Lidocaine 20% or Bupivacaine 0.5%
214909639|NCT02734537|DRUG|Cisplatin|Given IV
214909640|NCT02734537|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214909641|NCT02734537|OTHER|Laboratory Biomarker Analysis|Correlative studies
214909642|NCT06140056|OTHER|Airway pressure release ventilation|Mechanical ventilation mode
214909643|NCT06140056|OTHER|Volumen controlled mechanical ventilation|Mechanical ventilation mode
214909644|NCT06575166|DEVICE|Abdominal wall tension|"Abdominal wall tension measurement All patients will have the tension of their abdominal wall measured during surgery using a tension scale or tensiometer."
214909645|NCT06575166|DEVICE|Intra-abdominal pressure|Intra-abdominal pressure All patients will have their intra-abdominal pressure continuously monitored using Sentinel's FDA approved TraumaGuard catheter, a pressure-sensing urinary catheter.
215058203|NCT04951375|PROCEDURE|arthroscopic repair|arthroscopic repair
214909646|NCT06505993|BEHAVIORAL|Health Communication|Participants will experience a coordinated social marketing campaign including targeted messaging related to vaccine education, self-efficacy, and informative resources to receive the COVID-19 vaccine. The intervention messaging will be strategically layered and disseminated to this intervention arm predominately via Facebook by trusted and local communicators in the study counties.
214909647|NCT06505993|BEHAVIORAL|Health Communication + Structural|This multi-level intervention will include the defined health messaging intervention components, as well as a combination of structural-level intervention strategies targeted to better facilitate access to community-based vaccination delivery. Health organizations will receive a toolkit, which will include community-specific resources and training modules such as: up to date evidence-based vaccination guidance that can be delivered to patients; strategies for navigating conversations with patients about vaccination; any applicable reimbursement, insurance, or qualifying enrollment information specific to the healthcare organization; identifying locations that facilitate access for the community members; provided advertising to promote the locations and timing of the vaccinations; and generating community-based branding for all vaccination delivery based on the trusted information sources identified.
214909648|NCT02127515|PROCEDURE|Non Invasive Prenatal Testing|
214909649|NCT02127515|PROCEDURE|Invasive Prenatal Testing|
214909650|NCT06808750|DIAGNOSTIC_TEST|S. haematobium egg detection by single urine filtration|The urine samples of children participating in the initial screening will be tested with a single urine filtration by human microscopy.
214909651|NCT06808750|DIAGNOSTIC_TEST|S. haematobium egg detection by quintuple urine filtration|Five urine samples will be collected from children participating in the diagnostic study over five days. Each of the five urine samples collected per participant will be tested with a single urine filtration by human microscopy.
214909652|NCT06808750|DIAGNOSTIC_TEST|S. haematobium egg detection by artificial intelligence (AI) microscopy|The urine samples collected on Day 5 of the diagnostic study will be tested with artificial intelligence (AI) microscopy.
214909653|NCT06808750|DIAGNOSTIC_TEST|Haematuria assessment using reagent strips|The urine samples collected from children participating in the initial screening and in the diagnostic study, respectively, will be tested with reagent strips.
214909654|NCT06808750|DIAGNOSTIC_TEST|S. haematobium antigen detection by up-converting reporter particle-lateral flow circulating anodic antigen assay (UCP-LF CAA)|The urine samples collected on Day 5 of the diagnostic study will be tested with the up-converting reporter particle-lateral flow circulating anodic antigen assay (UCP-LF CAA).
215058204|NCT05011253|OTHER|Electronic Trigger Microhematuria Alert|To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
215058205|NCT02356523|DIAGNOSTIC_TEST|Confusion Assessment Method|Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge
215058206|NCT01119066|RADIATION|total body irradiation|dose of 1375-1500 cGy
214303565|NCT02533154|OTHER|Bacterial culture|bacterial cultures obtained with conjunctival swabs
214909655|NCT06808750|DIAGNOSTIC_TEST|S. haematobium DNA detection by recombinase polymerase amplification assay (RPA)|The urine samples collected on Day 5 of the diagnostic study will be tested with the recombinase polymerase amplification assay (RPA).
214909656|NCT06808750|DIAGNOSTIC_TEST|S. haematobium DNA detection by qPCR|The urine samples collected on Day 5 of the diagnostic study will be tested with qPCR
214909657|NCT07128550|DRUG|Tobevibart|Tobevibart administered by subcutaneous injection
214909658|NCT07128550|DRUG|Elebsiran|Elebsiran administered by subcutaneous injection
214909659|NCT07128550|DRUG|Bulevirtide|Bulevirtide administered by subcutaneous injection
214909660|NCT07133399|DRUG|vicadrostat / empagliflozin combination 1|vicadrostat / empagliflozin combination 1
214909661|NCT07133399|DRUG|vicadrostat / empagliflozin 2|vicadrostat / empagliflozin 2
214909662|NCT05367960|DRUG|Zatolmilast/ BPN14770|25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)
214909663|NCT06983275|DEVICE|Vibrational stimulation|Fifteen minutes before bedtime, participants will wear a vibration stimulation device on the forehead while lying down in a comfortable position. The stimulation intensity will be set to 60% of the device's maximum output. Participants will receive a 15-minute session of 40 Hz vibration stimulation with a 50% duty cycle: 15 seconds of stimulation followed by 15 seconds of rest, repeated continuously. After the session, participants will remove the device and prepare for sleep immediately.
214909664|NCT06983275|OTHER|Sham|Fifteen minutes before bedtime, participants will lie down in a comfortable position and listen to the 40 Hz noise generated by the vibration device (without receiving actual vibration). After the session, they will remove the device and prepare for sleep immediately.
214909665|NCT06983938|DEVICE|Double Perclose Proglide|Upon completion of valve replacement, closure will proceed using two Perclose Proglide devices.
214909666|NCT06983938|DEVICE|Single Perclose Proglide plus Angioseal|Upon completion of valve replacement, closure will proceed using one Perclose Proglide device plus one Angioseal device.
215058207|NCT01119066|DRUG|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
215058208|NCT01119066|DRUG|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
215058209|NCT01119066|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
214303566|NCT00148889|DEVICE|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
214303567|NCT05023265|RADIATION|Stereotactic body radiotherapy|SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.
214909667|NCT05782140|DEVICE|Mayo Clinic Watch Device|Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
214909668|NCT05710328|DRUG|Chemotherapy|Receive standard of care chemotherapy
214909669|NCT05710328|PROCEDURE|Computed Tomography|Undergo PET/CT
214909670|NCT05710328|OTHER|Fludeoxyglucose F-18|Given IV
214909671|NCT05710328|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214909672|NCT05710328|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
214909673|NCT06469437|BEHAVIORAL|Providing the physicians with a proposed glycated hemoglobin target|"Through the geriatric assessment, the investigators will categorize the groups proposed by the Diabetes Canada Clinical Practice Guidelines Expert Committee guideline recommendations into functionally independent, functionally dependent and frail. The investigators will provide the physician with the glycated hemoglobin target proposed by the guideline."
214909674|NCT06758596|DRUG|Placebo Oral Capsule|A capsule that contains only dextrose filler administered during the first or second laboratory visit.
215058210|NCT01119066|DRUG|Melphalan|70mg/m2/day x 2
215058211|NCT01119066|DRUG|Fludarabine|25mg/m2/ day x 5
214303568|NCT02340598|OTHER|cold vest|The lowering of body temperature increases basal metabolic rate
214303569|NCT01721421|OTHER|extended treatment time|patients receive extended dialysis treatment time time of 6 hours
214303570|NCT01721421|OTHER|Standard treatment time|
214303571|NCT03282188|BIOLOGICAL|Reolysin|Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
214303572|NCT03282188|DRUG|GM-CSF|GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
214303573|NCT00893750|BEHAVIORAL|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
214303574|NCT00893750|BEHAVIORAL|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
214909675|NCT06758596|DRUG|THC|A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
214909676|NCT07061613|OTHER|NeoThelium FT (HCT/P 361)|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue.
214909677|NCT07058467|OTHER|Joint Manipulation|"A joint manipulation is defined as a manual treatment by a clinician that uses controlled force to improve joint function. For the purpose of this study, the terms manipulation and mobilization may be used interchangeably. The knee joint is specifically defined as the tibiofemoral articulation for the purpose of this study.~All knee joint manipulation in this study will coincide with grade III or IV manipulations. This category coincides with evidence that mobilizations at or above grade III has the greatest impact on somatosensation and are most likely to produce a positive effect on neurocognitive function. Joint manipulation(s) will be delivered with a vector corresponding to the functional deficits found with manual joint palpation and will only occur with the involved ACLR knee. If both knees have experienced an ACL injury, the most recently injured knee will be manipulated."
214909680|NCT06767813|DRUG|TQB2868 injection|TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.
214909681|NCT06767813|DRUG|Gemcitabine injection|Gemcitabine injection
214909682|NCT06767813|DRUG|Albumin paclitaxel injection|Albumin paclitaxel injection
214909683|NCT06767813|DRUG|Anlotinib capsules|Anlotinib capsules
214909684|NCT02565680|DRUG|placebo|Xyzall 5mg during 5 days + placebo 40mg during 4 days
215058212|NCT01119066|DRUG|Clofarabine|20mg/m2/ day x 5 (or, for children \<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
215058213|NCT01119066|PROCEDURE|(CliniMACS) T-cell depleted PBSC Transplant|
215058214|NCT05059093|DIAGNOSTIC_TEST|Classification and segmentation deep learning models|Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
215058215|NCT03079687|DRUG|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
215058216|NCT04789473|GENETIC|Polygenic Risk Score Generation|PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.
215058217|NCT03936907|DRUG|OWCP Orally Disintegrating Tablet|Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
215058218|NCT03936907|DRUG|Sativex|Sativex® Oromucosal Spray
215058219|NCT01896778|PROCEDURE|Hyperthermia Treatment|Undergo B-WARM
215058220|NCT01896778|OTHER|Laboratory Biomarker Analysis|Correlative studies
215058221|NCT01876680|OTHER|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
214909685|NCT02565680|DRUG|prednisone|Xyzall 5mg during 5 days + prednisone 40mg during 4 days
214909686|NCT00000967|DRUG|Interferon alfa-2a|
214909687|NCT00000967|DRUG|Zidovudine|
214909688|NCT00259181|PROCEDURE|saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation|
214909689|NCT06749457|DRUG|AZD7760|Participants will receive AZD7760 as a single intravenous infusion.
214909690|NCT06749457|OTHER|Placebo|Participants will be administered placebo through intravenous infusion.
214909691|NCT03877380|OTHER|semi-structured interview|Semi-strucured interview to identify the difficulties when first applying for a personalised autonomy allowance by beneficiaries and their relatives
214909692|NCT06760637|DRUG|PF-07220060|CDK4 inhibitor
214909693|NCT06760637|DRUG|letrozole|endocrine therapy
214909694|NCT06760637|DRUG|abemaciclib|CDK4/6 inhibitor
214909695|NCT06760637|DRUG|palbociclib|CDK4/6 inhibitor
214909696|NCT06760637|DRUG|ribociclib|CDK4/6 inhibitor
214909697|NCT07060118|DIETARY_SUPPLEMENT|Gluten Free Diet in Hashimoto's Hypothyroidism|Gluten Free Diet in patients with Hashimoto's Hypothyroidism
214909698|NCT07069400|OTHER|No intervention|This is an observational study
214909699|NCT05395117|DRUG|AZD5462|"Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin~Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin"
214909700|NCT05395117|DRUG|Midazolam|Participants will receive a single dose of midazolam in the morning of Day 1 and in the morning of Day 15 in both the arms.
214909701|NCT05395117|DRUG|Rosuvastatin|Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
214303575|NCT00893750|BEHAVIORAL|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
214909702|NCT05395117|DRUG|Digoxin|Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
214909703|NCT01879384|DEVICE|CMA 70 catheter directly positioned in bone tissue|At the end of the surgery the CMA microdialysis catheter is placed inside the bone
214909704|NCT06368297|DIETARY_SUPPLEMENT|Ketone Monoester Supplementation|Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate \[β-HB\], and acetone).
214909705|NCT06368297|DIETARY_SUPPLEMENT|Ketogenic diet|The ketogenic diet typically reduces total carbohydrate intake to less than 50 grams a day-less than the amount found in a medium plain bagel-and can be as low as 20 grams a day. Generally, popular ketogenic resources suggest an average of 70-80% fat from total daily calories, 5-10% carbohydrate, and 10-20% protein.
214909706|NCT02757053|DEVICE|Guardian Cap|The Guardian Cap is a third party add-on device attached to the facemask of a football helmet that covers the outside of the helmet with a soft material to reduce the initial impact severity, thus reducing the forces transmitted to the brain
214909707|NCT03177291|DRUG|Pirfenidone|"Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation."
214909708|NCT03177291|DRUG|Carboplatin|Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
214909709|NCT03177291|DRUG|Paclitaxel|200 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
214909710|NCT03177291|DRUG|Pemetrexed|500 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
214909711|NCT06104020|OTHER|Intraoperative fluid management stratigies.|"Regimens of different intraoperative fluid management The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.~The other group of patients, the liberal group (LG), will receive a 10 ml/kg bolus at anesthesia induction,followed by an intraoperative crystalloid infusion at a rate of 8 ml/kg/hr."
214909712|NCT07065773|DRUG|Trichostatin A|Topical Study Drug
214909713|NCT06379997|DIETARY_SUPPLEMENT|Collagen, Hyaluronic Acid, Vitamin C, and Manganese|The Group 1 (G1) will begin taking a dietary supplement the day after enrollment.
214909714|NCT06379997|DRUG|Intra-articular infiltration|Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
214909715|NCT01421979|DIETARY_SUPPLEMENT|Energy Drink, Taurine, Caffeine|
214909716|NCT03585933|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Echocardiography: assessment of aortic stenosis severity, evaluation of LV diastolic and systolic function; CMR: chambers quantification, LGE, T1 mapping; Intraoperative myocardial tissue biopsy for patients undergoing SAVR; DPD scintigraphy: assessment of cardiac transthyretin amyloidosis
214909717|NCT00925951|DEVICE|Wet Cupping|Wet cupping (Seongho trade \& company, Korea) will be practiced at two selected points (among the 6 acupoints, left or right BL23, BL24, BL25)
214909718|NCT00925951|DRUG|Acetaminophen|Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
214909719|NCT00571727|DRUG|mecasermin|injections BID of rhIGF-1, mecasermin
214909720|NCT01018927|DEVICE|Administering three additional MRI images|Three additional MRI images to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
214909721|NCT02448394|OTHER|Community Support Worker|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
214909722|NCT06782373|DRUG|Pacritinib|Supplied in hard capsules.
214909723|NCT06782373|DRUG|Placebo|Supplied in hard capsules.
214909724|NCT06319989|OTHER|Biplane Ultrasound|During a standard of care caudal epidural block, biplane ultrasound will be used.
214909725|NCT06319989|OTHER|Single plane ultrasound|During a standard of care caudal epidural block, single plane ultrasound will be used.
214909726|NCT06632444|DRUG|Survodutide|Subcutaneous injection
214909727|NCT06632444|DRUG|Placebo|Subcutaneous injection
214909728|NCT06745908|DRUG|N-803|N-803 1.2 mg SC
214909729|NCT06745908|DRUG|Tislelizumab|Tislelizumab 200 mg IV
214909730|NCT06745908|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV
214909731|NCT07076199|DRUG|Insulin icodec|Insulin icodec will be administered as subcutaneous injection
214909732|NCT07076199|DRUG|Insulin glargine|Insulin glargine will be administered as subcutaneous injection.
214909733|NCT07076199|DRUG|Insulin aspart|Insulin aspart will be administered as a subcutaneous injection.
214909734|NCT07081646|DRUG|AZD0120|Participants will receive AZD0120 via intravenous (IV) infusion.
214909735|NCT07084922|OTHER|No interventions. This is an observational study where participants undergo assessments of plantar pressure and postural balance without any treatment or intervention.|No interventions. This is an observational study where participants undergo assessments of plantar pressure and postural balance without any treatment or intervention.
214909736|NCT06302400|DEVICE|166Holmium microspheres (QuiremSpheres®)|QuiremSpheres® are a biocompatible microsphere that contain the radionuclide holmium-166 (166Ho), which emits gamma-radiation (81 keV) and high-energy (1.81 MeV) beta-particles.
214909737|NCT06930716|DEVICE|Transcutaneous vagus nerve stimulation (taVNS)|A non-invasive nerve stimulator that stimulates the vagus nerve through the ear.
214909738|NCT06930716|DEVICE|Physical therapy using Hocoma|Progressive verticalization and mobilization using a robotic tilt table with robotic stepping (Erigo, Hocoma)
214909739|NCT06930716|BEHAVIORAL|Standard of Care|Standard of care with no study interventions. This will include observation of whatever rehabilitation or medical care the patient is currently receiving.
214909740|NCT06928402|OTHER|No intervention|no interventions will be performed by the research team
214909741|NCT07086794|DRUG|Placebo|The effects of placebo will be determined.
214909742|NCT07086794|DRUG|Cocaine (IV)|The effects of IV Cocaine will be determined.
214909743|NCT07086794|DRUG|Pentoxifylline|The effects of pentoxifylline will be determined.
214909744|NCT06903884|DRUG|3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion|This arm is to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution
214303576|NCT06202391|PROCEDURE|Autogenic Inhibition-MET|Autogenic Inhibition-MET protocol: 3-5 repetitions of post isometric relaxation (PIR) (30- 50% isometric contraction of the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold. A total of 12 sessions, four times a week, for three consecutive weeks.
214909745|NCT06903884|DRUG|0.1% Cyclosporin A cationic ophthalmic emulsion|This arm is a control group to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution
214909746|NCT06834997|DRUG|Dronabinol Capsules|Eligible subjects will be randomized (2:1) to dronabinol or placebo, administered orally. The dose of dronabinol will be titrated such that on Day 1, subjects will take 2.5 mg, twice. On subsequent days patients may gradually increase the total number of doses, by one dose each day, as needed and tolerated until either the optimal dose is achieved, or the dose reaches 30 mg THC per day.
214909747|NCT06834997|DRUG|Placebo|Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.
214909748|NCT06746129|PROCEDURE|embryo transfer|transfer of embryo(s) into the uterine cavity
214909749|NCT06019169|OTHER|Yoga arm|Participation in YOGA classes performed by Mme Laura BOGANI from The Blue Fish LAB Association. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.
214909750|NCT06019169|OTHER|storytelling activities|Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
214909751|NCT03026140|DRUG|Nivolumab|Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
214909752|NCT03026140|DRUG|Ipilimumab|Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
214909753|NCT03026140|DRUG|Celecoxib 200mg|celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
214909754|NCT03026140|DRUG|BMS-986253|BMS-986253 2400mg IV will be administered on day 1 and 15 (only applicable for patients with MSS tumors)
214909755|NCT03026140|DRUG|BMS-986016|Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29, in cohort 7 160mg on day 1, day 29 and day 57
214909756|NCT04594642|DRUG|AZD0486 IV|AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
214909757|NCT06906302|BEHAVIORAL|RISE|RISE is personalized, trauma-informed, empowerment-oriented and variable-length, consisting of an initial 60-minute session and up to 7 additional 45-minute sessions (1-8 sessions total).
214909758|NCT06906302|BEHAVIORAL|Advocacy-based ECAU|Advocacy-based ECAU is a single 60-minute trauma-informed counseling intervention that includes supportive education, validating and empathetic statements, safety planning, resource provision and referrals.
214909759|NCT06907784|DIAGNOSTIC_TEST|Pharmacogenomic testing|The PGx testing will analyse genetic variants across 16 key pharmacogenes in each given DNA sample, all of which focus on variants with established implications for drug response as recommended by published Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines Testing will be performed immediately in the intervention arm or at three months in the standard of care arm.
214909760|NCT02864888|RADIATION|Radiation|Children with a diffuse, intrinsic brain stem glioma will receive radiation.
214909761|NCT02864888|DRUG|Atengenal|Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
214909762|NCT02864888|DRUG|Astugenal|Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
214909763|NCT06290778|BEHAVIORAL|Brief Unified Protocol|The Brief Transdiagnostic Treatment of Emotional Disorders Unified Protocol.
214909764|NCT06290778|BEHAVIORAL|Psychoeducation|Psychoeducation regarding mental health challenges in fire service.
214909765|NCT04434729|DEVICE|Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils|The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.
214909766|NCT06907875|BIOLOGICAL|EPI-321|EPI-321 IV Infusion
214909767|NCT07087834|OTHER|CASEM (Cancer Screenings Education for Men)|"Experimental Group After the initial meeting, pre-tests will be administered to the individuals in the experimental group. Subsequently, the days and times of the training sessions will be determined, taking into account the working hours and schedule of the institution and the availability of the employees. The four planned training sessions will then be conducted once a week. The post-test (Cancer Screening Perception Scale, Cancer Screening Attitude Scale, Cancer Screening Knowledge Scale) will be administered to the experimental group one month and three months after the final training session.~Content and Materials of the Training to Be Provided to the Experimental Group The intervention described in the appendix will be applied to the experimental group. This intervention is an educational intervention consisting of three sessions aimed at increasing men's perceptions, attitudes, and knowledge levels regarding cancer screening. ... It covers basic information about cancer, commo"
214909768|NCT02975245|PROCEDURE|Semen collection and analysis|Semen sample will be collected prior to the initiation of chemotherapy and one week after the first round of chemotherapy.
214909769|NCT04200937|DEVICE|Tactra Malleable|The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.
214909770|NCT04200937|DEVICE|Spectra™ Concealable Penile Prothesis|The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.
214909771|NCT04200937|DEVICE|AMS Ambicor™ Inflatable Penile Prosthesis|The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.
214909772|NCT04200937|DEVICE|AMS 700™ Inflatable Penile Prosthesis w/Momentary Squeeze (MS) Pump|The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).
214909773|NCT04200937|DEVICE|AMS 700™ Inflatable Penile Prosthesis w/Tenacio™ Pump|The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).
214909774|NCT06807021|DRUG|IP1 control cream (Vehicle base)|Without FS2
214909775|NCT06807021|DRUG|IP2 - 0.5% w/w FS2|FS2 in pharmaceutical compounding base
214909776|NCT07084558|DIAGNOSTIC_TEST|blood sample for Signatera (TM) test|ctDNA: Evaluation of ctDNA-status prior to treatment start (ctDNA not detected or ctDNA-positive) until the last of five follow-up visit
214909777|NCT07084558|DIAGNOSTIC_TEST|biopsy for Ki-67 assessment|Ki67: Evaluation of Ki-67-value after 3 weeks of aromatase inhibitor
214909778|NCT07084558|DIAGNOSTIC_TEST|FFPE tumor sample for Signatera (TM) test (archived)|Evaluation of ctDNA status prior to treatment start
214909779|NCT06877676|DRUG|TAR-200|Participants will undergo insertion of TAR-200 transurethrally into the bladder via catherization using the co-packed urinary placement catheter only in accordance with the Instructions for Use (IFU).
214909780|NCT07092553|DEVICE|C-arm PCD-CBCT|A single research PCD-CBCT scan will be performed directly after the participant's SOC scan.
214909781|NCT00775853|DRUG|6-[18F]Fluorodopamine|
214909782|NCT00775853|DRUG|6-[18F]Fluorodopa|
214909783|NCT00775853|DRUG|13N-Ammonia|
214909784|NCT07091318|BEHAVIORAL|Sleep quality improvement therapy|8 virtual CBTi sessions will be provided through a therapist weekly for the first four weeks and every other week for the last eight weeks of the study.
214909785|NCT07091318|BEHAVIORAL|Healthy Living|Health education emails and brief coaching calls will be provided weekly. The phone coaches will not provide counseling or goal setting but can clarify what participants had questions on like terms and concepts.
214909786|NCT07090148|BIOLOGICAL|pTVG-HP DNA vaccine|The vaccine will be injected into the outer side of the upper area of the arm in two adjacent sites, with 0.25 mL administered at each site.
214909787|NCT07090148|DRUG|Anti-PD-1 monoclonal antibody|Nivolumab is a potent human immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Participants will receive two 10mg doses.
214909788|NCT07093073|DRUG|ssCART-19|Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
214909789|NCT02873637|DEVICE|under sartorial catheter|
214909790|NCT02873637|DEVICE|femoral catheter|
214909791|NCT06027632|OTHER|Cognitive exercises with supervision|"The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the PRESCO program of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
214909792|NCT06027632|OTHER|Cognitive exercises without supervision|"Patient will have access to the program named PRESCO of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
214909793|NCT04982497|BEHAVIORAL|Video game based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker \& Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
214909794|NCT04982497|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
214909795|NCT06365268|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns a period of three years maximum.
214909796|NCT07088757|DRUG|standard dose indomethacin|Patients randomized to this intervention receive 100mg indomethacin suppositories within 30 min before ERCP.
214909797|NCT07088757|DRUG|low dose indomethacin|Patients randomized to this intervention receive 50mg indomethacin suppositories within 30 min before ERCP.
214909798|NCT06813911|DRUG|Pelacarsen|Pelacarsen will be provided as solution for injection in prefilled syringe 80 mg for subcutaneous injection.
214909799|NCT06813911|DRUG|Placebo|Placebo will be provided as solution for injection in prefilled syringe for subcutaneous injection.
214909800|NCT06813911|DRUG|Inclisiran|All participants will be administered two loading doses of inclisiran as background treatment at Run-in 1 and Run-in 2, separated by 3 months, according to the approved label. After that inclisiran will be administered every 6 months, i.e., Month 5 and Month 11.
214909801|NCT07092033|DEVICE|Bimodal Neuromodulation|The device is a non-invasive stimulation device that consists of a controller that connects to headphones for sound delivery to the ears and connects to a mouth component that provides gentle electrical stimulation to the tongue surface. The sound is currently configured according to a tinnitus person's audiogram (i.e., hearing threshold profile for different sound frequencies) during device fitting. Individuals are recommended to use the device for 60 minutes daily (two 30-minute sessions consecutively or at different times of the day) for at least 12 weeks.
214909802|NCT06928272|DRUG|Pirfenidone|"Initial dose titration:~First week (days 1-7): 1 capsule (267 mg), 3 times daily (801 mg/day)~Second week (days 8-14): 2 capsules (534 mg), 3 times daily (1602 mg/day)~Maintenance dose:~Third week and thereafter (days 15-90): 3 capsules (801 mg), 3 times daily (2403 mg/day)"
214909803|NCT06928272|DRUG|Placebo for pirfenidone|"First week (days 1-7): 1 capsule, 3 times daily~Second week (days 8-14): 2 capsules, 3 times daily~Third week and thereafter (days 15-90): 3 capsules, 3 times daily"
214909804|NCT06928272|DRUG|Upadacitinib|1 capsule (15 mg), once daily for 90 days
214909805|NCT06928272|DRUG|Placebo for upadacitinib|1 capsule, once daily for 90 days
214909806|NCT07095920|DEVICE|Device: Q Therapeutic System (BQ 3.0) - Active|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.
214909807|NCT07098715|DEVICE|Kerecis fish skin|To assess shot-term outcomes (rates of healing) using Kerecis intact fish skin to heal cryptoglandular fistula-in-ano and associated chronic non-healing draining wounds.
214909808|NCT05944562|DRUG|Tulmimetostat|Patients should take DZR123 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following DZR123 dosing). Each dose of DZR123 should be taken with a glass of water and consumed over as short a time as possible.
214909809|NCT07022483|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg IV Q3W.
214909810|NCT07022483|DRUG|Chemotherapy|Carboplatin AUC 5 or 6 and paclitaxel will be administered at a dose of 175 mg/m2 Q3W, or carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W followed by chemoradiotherapy.
215058222|NCT01876680|OTHER|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
214303577|NCT06202391|PROCEDURE|Reciprocal Inhibition-MET protocol|Reciprocal Inhibition-MET protocol: 3-5 repetitions of Reciprocal Inhibition (RI) MET (30- 50% isometric contraction of the muscle opposite to the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold A total of 12 sessions, four times a week, for three consecutive weeks
214303578|NCT05515757|BEHAVIORAL|Mobile-app based contingency management|We are adapting an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with stimulant use disorders requiring prolonged hospitalization. Participants will be enrolled into an 8-week mobile-app based contingency management intervention.
214909811|NCT05272176|BEHAVIORAL|Coping Long Term with Active Suicide Program (CLASP)|Telehealth-based case management intervention designed to reduce suicidal behavior among individuals at high risk for suicide across the transition from inpatient hospitalization to the community.
215058223|NCT00521729|PROCEDURE|Exposure to Cold Temperature|
215058224|NCT00821158|DRUG|Antioxidant|Antioxidant iv bolus
214303579|NCT04135833|DRUG|BPI-7711|BPI-7711 60 mg
215058225|NCT00821158|OTHER|Placebo|Placebo tablet and iv
215058226|NCT00821158|DRUG|Anti-inflammatory drug|Anti-inflammatory tablet
215058227|NCT04424394|DEVICE|DualStim Therapy|6 DualStim Therapies over a period of 7 weeks.
215058228|NCT04424394|BIOLOGICAL|Umbilical cord-derived Wharton's Jelly|2 intracavernosal injections over a period of 7 weeks.
215058229|NCT04424394|OTHER|Saline|2 intracavernosal injections over a period of 7 weeks.
214303580|NCT04135833|DRUG|BPI-7711|BPI-7711 180 mg
214909812|NCT07104292|BEHAVIORAL|PFMT|The motivation-informed intervention will tackle both exercise engagement and exercise adherence. Participating women will be introduced to the app and its videos following training. The participants will be introduced not only to muscle training, but also to muscle relaxation. The training will be recommended three to four times a week during pregnancy with further continuity after giving birth.
214909813|NCT07104292|BEHAVIORAL|Standard care|Standard care
214909814|NCT07096271|BEHAVIORAL|Get Better Together (GBT)|"Get Better Together is a couple-based, primary prevention program designed to reduce risk for suicidal thoughts and behaviors, problematic alcohol use, and intimate partner violence by addressing two transdiagnostic drivers: emotion dysregulation and relationship conflict. The intervention is an adaptation of the empirically supported Prevention and Relationship Enhancement Program (PREP), modified in collaboration with military stakeholders to meet the unique cultural and contextual needs of military couples.~The GBT curriculum includes approximately 10 hours of structured content presented using didactic instruction, video demonstrations, group discussions, and guided couple exercises. Skills focus on interpersonal emotion regulation (e.g., emotion identification, acceptance, reappraisal, and problem solving) and evidence-based communication strategies (e.g., structured communication strategies, conflict de-escalation)."
214909815|NCT06548360|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
214909816|NCT06548360|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
214909817|NCT07107906|BEHAVIORAL|The CONNECT Program|A group-based telehealth intervention grounded in Acceptance and Commitment Therapy (ACT), self-compassion, and successful aging theories, aimed at reducing social isolation, loneliness, and mental health symptoms among adults 55+. Delivered over six weeks via group phone or Zoom sessions. The CONNECT Program includes 6 weekly 90-minute group sessions, with structured workbooks and homework. The CONNECT Program is delivered in two modalities (group telephone or Zoom videoconferencing).
214909818|NCT07107906|BEHAVIORAL|Community Participation as Usual (Service as Usual)|These community-based programs may include social, educational, or recreational group sessions that are already offered by local organizations - either in person, by phone, or virtually.
214909819|NCT07103850|DIAGNOSTIC_TEST|Suicidal Crisis Syndrome Checklist (SCS-C)|The Suicidal Crisis Syndrome Checklist (SCS-C) is a clinician-rated tool designed to diagnose Suicidal Crisis Syndrome (SCS), a suicide-specific state associated with imminent risk. It includes Criterion A (entrapment)-a required symptom-and Criterion B, which requires at least one symptom from each of four domains: affective disturbance, loss of cognitive control, hyperarousal, and social withdrawal. The checklist offers a structured assessment for identifying acute suicide risk, complementing traditional risk evaluations.
214909820|NCT07103850|DIAGNOSTIC_TEST|Suicide Crisis Inventory-Revised (SCS-2)|The Suicide Crisis Inventory-Revised (SCS-2) is a 61-item self-report scale developed to assess the severity of Suicidal Crisis Syndrome (SCS), a clinical state associated with imminent suicide risk. Items are rated on a Likert scale and grouped into five empirically derived factors: entrapment, affective disturbance, loss of cognitive control, hyperarousal, and social withdrawal. The SCS-2 has shown strong internal consistency and predictive validity for suicidal behavior within weeks of discharge. It is currently undergoing cultural adaptation and psychometric validation in Spanish for use in high-risk psychiatric populations in Chile.
214909821|NCT06675565|DRUG|ALN-AGT01 RVR|ALN-AGT01 RVR will be administered subcutaneously (SC)
214909822|NCT06675565|DRUG|Placebo|Placebo will be administered SC
214909823|NCT06572605|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214909824|NCT06572605|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214909825|NCT06572605|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214909826|NCT06572605|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
214909827|NCT06572605|OTHER|Electronic Health Record Review|Ancillary studies
214909828|NCT06572605|RADIATION|External Beam Radiation Therapy|Undergo EMD-EBRT
214909829|NCT06572605|PROCEDURE|Image Guided Biopsy|Undergo image-guided EMD biopsy
215058230|NCT01236261|OTHER|Non intervention|Non interventional study
215058231|NCT03636672|PROCEDURE|perturbation training|perturbation training during stationary bicycle riding
215058232|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
215058233|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
214303581|NCT04135833|DRUG|Itraconazole|Itraconazole 200 mg
214303582|NCT04135833|DRUG|Rifampicin|Rifampicin 600 mg
214303583|NCT03559257|DRUG|Galcanezumab|Administered SC.
214303584|NCT03559257|DRUG|Placebo|Administered SC.
214909830|NCT06572605|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214909831|NCT06572605|BIOLOGICAL|Talquetamab|Given SC
214909832|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
214909833|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
214909834|NCT06777433|DRUG|RAD101 (18F-FPIA)|A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.
214909835|NCT05711615|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214909836|NCT05711615|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214909837|NCT05711615|PROCEDURE|Computed Tomography|Undergo CT scan
214909838|NCT05711615|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214909839|NCT05711615|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214909840|NCT05711615|DRUG|Peposertib|Given PO
214909841|NCT07107763|OTHER|short foot exercise|The short foot exercise group will receive stretching exercises and short foot exercises, administered three sessions per week for a duration of six weeks.
214909842|NCT07107763|OTHER|Mobilization|The mobilization group will undergo a program consisting of 3 sessions per week for a duration of 6 weeks. The sessions will begin with stretching exercises, followed by subtalar joint mobilization.
214909843|NCT07107763|COMBINATION_PRODUCT|Short foot exercise and mobilization|The combined intervention used in this group will include both of the approaches applied in the other two groups.
214909844|NCT07103720|DIAGNOSTIC_TEST|Skin Testing|Participants will undergo skin prick testing and intradermal test injections at 5 increasing concentrations of midazolam, ketamine and/or ondansetron during one single study visit.
214909845|NCT06921317|DRUG|GVB-2001-high dose|GVB-2001 is a self-complementary adeno-associated viral vector (scAAV) injection to deliver human dnRhoA gene to trabecular meshwork cells in patients with primary open angle glaucoma. A single dose of high dose GVB-2001 will be injected intracamerally to the target interventional eye.
214909846|NCT06921317|DRUG|GVB-2001-low dose|GVB-2001 is a self-complementary adeno-associated viral vector (scAAV) injection to deliver human dnRhoA gene to trabecular meshwork cells in patients with primary open angle glaucoma. A single dose of low dose GVB-2001 will be injected intracamerally to the target interventional eye.
214909847|NCT07115680|OTHER|human participants, data or material|Articles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies
214909848|NCT07114380|DEVICE|Cold snare polypectomy|Unlike traditional hot snare polypectomy or endoscopic mucosal resection, which use electrocautery to resect larger or pedunculated polyps, cold snare polypectomy uses mechanical transection alone without cautery. The procedure is performed using a dedicated cold snare by experienced endoscopists.
214909849|NCT07117240|DRUG|lixisenatide + glargine|Participants assigned to Group 1 will receive standard insulin therapy. Those in Group 2 will be treated with a combination of insulin glargine and lixisenatide, with dosages individually adjusted based on current glucose levels. All participants will be trained in insulin administration and dose adjustment based on glucose readings.
214909850|NCT07117240|DRUG|Intensive insulin therapy|Participants assigned to Group 1 will receive standard insulin therapy. Those in Group 2 will be treated with a combination of insulin glargine and lixisenatide, with dosages individually adjusted based on current glucose levels. All participants will be trained in insulin administration and dose adjustment based on glucose readings.
214909851|NCT07117539|DEVICE|visual bronchial blocker (VBB)|lung isolation with visual bronchial blocker
214909852|NCT07117539|DEVICE|double-lumen endotracheal tube (DLT)|lung isolation with double-lumen endotracheal tube
214909853|NCT03374865|OTHER|Facetalk|Area of interest: communication during Facetalk consultations
214909854|NCT03374865|OTHER|Face-to-face consultation|Area of interest: communication during face-to-face consultations
214909855|NCT05132517|DIAGNOSTIC_TEST|Kölner Neuropsychologische Screening für Schlaganfall-Patienten|The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.
214909856|NCT06918964|DEVICE|transcutaneous auricular vagus nerve stimulation device|Place the stimulation device on the left auricle and set the stimulation parameters according to the following conditions: a. Waveform: biphase, square wave; b. Wave width: 200 μs; c. Frequency: Alternating between low frequency (4 Hz for 4 s), high frequency (40 Hz for 8 s), and a 4 s pause; d. Intensity: The maximum intensity that induces the strongest sensation the individual can tolerate without causing pain, usually 1.5-3.5 mA; e. Treatment duration: Each treatment lasted 30 minutes, twice daily (8:00, 16:00) for 10 days.
214909857|NCT06918964|DEVICE|Sham device|The sham taVNS group received the same parameters with a current intensity of 0.06 mA.
214909858|NCT03581292|RADIATION|Radiation Therapy|Undergo radiation therapy
214909859|NCT03581292|DRUG|Temozolomide|Given PO
215058234|NCT02092727|BEHAVIORAL|Behavioral Interventions for Dialysis Facilities|"1. Educational seminars and monthly educational webinars~2. Peer-to-peer mentoring program~3. Bulletin boards about transplantation~4. Facility-specific feedback reports detailing transplant referral data for their center compared to state average~5. Formulate a facility-specific improvement plan to increase transplant referrals.~6. Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.~7. Monthly monitoring and reporting of patient referrals to ESRD Network~8. Conduct a patient and family education session about transplantation~9. Host a movie day to show Living ACTS (About Choices in Transplantation \& Sharing) video"
214303585|NCT06040554|OTHER|Elastic Band Resistance Exercises|8 Warm-Up Exercises followed by 10 Elastic Band Exercises followed by 8 Post-Workout Exercises.
214909860|NCT03581292|DRUG|Veliparib|Given PO
214909861|NCT06934122|OTHER|manipulation with classical massage and spinal manipulation technique|All participants will first receive a massage to relax the muscles and then be manipulated with a spinal manipulation technique.
214909862|NCT06934603|OTHER|Clear Aligner Treatment|This study is observational. Only patients who are previously scheduled to receive clear aligner treatment from their orthodontic provider will be recruited.
214909863|NCT06934187|PROCEDURE|Carpal tunnel release|The operating surgeons will make a skin incision distally from the distal wrist crease and ulnar to the thenar crease. The appropriate tissues, including the subcutaneous tissue, palmar fascia, flexor retinaculum, and antebrachial fascia, will then be divided in CTR group. Haemostasis will be achieved using bipolar coagulation. The skin will be closed, and an appropriate dressing will be applied.
214909864|NCT06934187|PROCEDURE|Placebo surgery|Only an skin incision will be made and the same time as CTR operation takes will be waited until skin closure. An appropriate dressing will be applied.
214909865|NCT07140874|DRUG|Zinc citrate|Oral zinc citrate 30 mg daily
214909866|NCT07140874|DRUG|Placebo|Placebo
214909867|NCT07139990|RADIATION|Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)|Radiographic response-adapted thoracic tumor radiotherapy given as single doses ('pulses') before standard of care chemoimmunotherapy cycles. Adaptive Changes Allowed: Tumor target (size/shape), # of doses (reduction) Adaptive Changes Allowed: Tumor target (size/shape), # of doses (reduction)
214909868|NCT07139990|RADIATION|Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)|"Intervention: Fractionated stereotactic radiosurgery (SRS, 5 doses total) for brain metastasis given in two pulses (3 fractions + 2 fractions) with second pulse adapted to interim radiographic response Adaptive Changes Allowed: Omission of 2nd pulse in \>=25% responders or tumor target size/shape change in remainder"
214909869|NCT07141277|OTHER|None (Observational study)|Not applicable since it's an observational study.
214909870|NCT06932081|DRUG|SGLT2 inhibitors|Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.
214909871|NCT06737536|DRUG|NNC0662-0419|Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.
214909872|NCT06737536|OTHER|Placebo (NNC0662-0419)|Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.
214909873|NCT06880523|DRUG|STRIDE (durvalumab + tremelimumab)|As first treatment
214909874|NCT06880523|DRUG|Durvalumab|monotherapy every 4 weeks
214909875|NCT06880523|DRUG|Lenvatinib|Daily
214909876|NCT05042102|COMBINATION_PRODUCT|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
214909877|NCT05042102|COMBINATION_PRODUCT|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
214909878|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
214909879|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
214909880|NCT01047527|DRUG|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
214909881|NCT06942923|DRUG|AZD4144|AZD4144 will be administered orally as per arms they have been assigned.
214909882|NCT06942923|DRUG|Placebo|Placebo will be administered orally as per arms they have been assigned.
214909883|NCT06182241|BEHAVIORAL|Retention in cervical cancer care intervention|Aim 1 data will inform this intervention, however the participant intervention will likely be one or two sessions, conducted in-person, coupled with text- or phone-based client navigation with women who received abnormal high-risk Pap smear results. We anticipate that the intervention may integrate (1) information to improve awareness of cervical cancer susceptibility and treatment, (2) motivational interviewing to assess pros and cons of attending a follow-up appointment and completing treatment; (3) brief cognitive behavioral therapy (CBT) skills to reduce individual-level barriers, (4) problem-solving to increase social support, and (5) patient navigation tools to mitigate clinic-level challenges.
214909884|NCT02002572|OTHER|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
214909885|NCT07137585|DRUG|Placebo|RO7204239 matching placebo will be administered as per the schedule specified in the treatment arm.
214909886|NCT07137585|DRUG|RO7204239|RO7204239 will be administered as per the schedule specified in the treatment arm.
214909887|NCT05484570|OTHER|Interval History|"The study coordinator or another team member will review standard health questions relevant to DNA repair disorders. The control group will not undergo an interval history. These questions will include:~1. How the participant's appetite and general weight trajectory has been since the last assessment~2. Any episodes of unexplained bleeding or bruising~3. Any jaundice~4. General level of alertness and interaction with family and others~5. Any changes in cognitive function such as speech, following commands, comprehension~6. Any changes in motor function, including the development of tremors and stiffness in movements"
214909888|NCT05484570|OTHER|Physical Examination|A board-certified neurologist (the principal investigator) will perform a general physical examination and a neurological examination and complete a standard CRF to document relevant findings. The control group will not undergo a physical examination.
214954815|NCT02798354|BEHAVIORAL|Quality Improvement Collaborative|1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
214909889|NCT05484570|OTHER|ECAB Assessment|"An Early Clinical Assessment of Balance (ECAB) will be performed by the physical therapist. Part I can be assessed in all affected individuals, and Part II requires ambulation. For non-ambulatory individuals, only Part I will be applied. The items in the ECAB are summarized as follows:~Part I. Head and trunk postural control (maximum 36 points) Head righting - lateral (right and left) Head righting - extension Head righting - flexion Rotation in trunk (right and left) Equilibrium reactions in sitting (right and left) Protective extension - side Protection extension - backward Part II. Sitting and standing postural control (maximum 64 points) Sitting with back unsupported but feet supported on floor or on a stool Sitting to standing Standing unsupported with eyes closed Standing unsupported with feet together Turns 360 degrees Placing alternate foot on the step while standing unsupported"
214909890|NCT05484570|OTHER|Gait Assessment|"For ambulatory participants, the physical therapist will also assess standardized gait outcome measures, including:~1. Gait Speed: may be measured over a 10 meter distance, assessing both comfortable walking speed and fast walking speed~2. 10-meter walk/run: timed assessment at fastest gait attainable. This assessment would be omitted for those participants who are determined to have a high fall risk.~3. Timed Up and Go (TUG): time to stand from a chair, walk 3 meters, go around a cone, and return to the chair (with or without an assistive device)~4. Dynamic Gait Index (DGI): assesses 8 balance challenges while walking"
214909891|NCT05484570|OTHER|Specimen Sample Collection|"Total blood volumes collected at each visit will be limited to 5mL/kg body weight, with a maximum of 18mL.~Saliva samples may be obtained if research is taking place where blood samples cannot be drawn or transferred."
214909892|NCT07139106|DRUG|Ketamine hydrochloride infusion|single racemic ketamine hydrochloride 0.5 mg/kg infusion
214909893|NCT06944535|PROCEDURE|Modified Lip Repositioning Surgery (Retrospective)|Patients previously underwent a modified lip repositioning surgery technique without frenectomy and without myotomy. For this retrospective study, only existing medical records and clinical photographs were reviewed. No new surgical intervention was performed.
214909894|NCT05863351|PROCEDURE|Computed Tomography|Undergo CT
214909895|NCT05863351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214909896|NCT05863351|OTHER|Questionnaire Administration|Ancillary studies
214909897|NCT05863351|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SAbR
214909898|NCT05863351|PROCEDURE|Systemic Therapy|Given standard of care systemic therapy
214909899|NCT06948825|DRUG|Metformin Hcl 850Mg Tab|Participants randomized to Metformin will have a prescription of Metformin 850mg orally twice a day. The participant will get blood drawn for testing, undergo a urine pregnancy test, and meet with the study provider to discuss the medication.
214909900|NCT06948825|BEHAVIORAL|Lifestyle Intervention|Participants in the Lifestyle Intervention will meet once a week via zoom with the study health counselor to go over lesson plans. After 4 weeks, participants will meet via zoom every other week.
214909901|NCT06948825|BEHAVIORAL|Enhanced Lifestyle Intervention|Participants in the Enhanced Lifestyle Intervention will meet every other week, and will get a free instacart membership to have access to free grocery delivery. Additionally, participants in this intervention will have a 1:1 virtual meeting focused on meal planning with the study health counselor.
214909902|NCT02573597|DRUG|Bupivacaine|Continuous or bolus administration
214909903|NCT02573597|DRUG|Sufentanil|Continuous or bolus administration
214909904|NCT07148245|PROCEDURE|Blood Sample|Blood samples will be collected
214909905|NCT07148245|OTHER|Health Related Quality of Life Questionnaires (HRQoL)|Participants may be given HRQoLs during the course of data collection
214909906|NCT07148245|OTHER|Medical Chart Review|Participants will undergo medical charts review during the course of data collection
214909907|NCT06893029|DIAGNOSTIC_TEST|Postural Response upon physical optokinetic stimulation|The physical optokinetic stimulation consists of rotating stimulation in either direction using a physical disc (de Vestel, et al., 2022; Guerraz et al., 2001; van Ombergen et al., 2016). The assessment is conducted in complete dark, unless the fluorescent dots (approx. 11% covered of the disc area.). The disc has a diameter of 1 m. Stimulation time per trial will be 30 s.
214909908|NCT06893029|DIAGNOSTIC_TEST|Postural Response upon virtual optokinetic stimulation|The virtual optokinetic stimulation is implemented in virtual reality goggles (Meta Quest 3, Meta Platforms, Menlo Park, CA, USA) applying oscillating and rotating stimulation in frontal and vertical axis with coherent or incoherent stimuli. The assessment in the virtual environment will be as similar as possible compared the physical stimulation. Hence, the virtual environment simulation complete dark, unless the fluorescent dots (approx. 15% covered of the disc area.). In addition to the rotating condition, the virtual dots are able to oscillate on the horizontal or vertical axis to create a more sensitive evaluation method than the physical one (Laurens et al., 2011). Stimulation time per trial will be 30 s.
214909909|NCT06953583|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
214909910|NCT06953583|DRUG|Placebo|Administered as specified in the treatment arm.
214909911|NCT07140731|DEVICE|Symani Surgical System|To assess the safety and effectiveness of the Symani Surgical System
214909912|NCT07152041|DRUG|olverembatinib|"All Ph+-ALL patients will uniformly use the 3rd generation of TKI olverembatinib (OVB) instead of dasatinib throughout the regimen.~OVB is combined with Vincristine and Prednisone (VP) during the first 2 weeks and with blinatumomab during the last 4 weeks of remission induction in this protocol.~Patients will receive blinatumomab for 28 days as induction instead of CAT to improve induction response and avoid toxicity.~All patients will receive two cycles of HDMTX+Blina-14 and 4 times of triple intrathecal therapy (TIT) throughout the consolidation 1 phase.~To decrease the toxicities of high-dose AraC, the dosage will be reduced to 1 g/m2 in the consolidation 2 phase in contrast to 2 g/m2 in 2020 protocol.~Throughout the early Maintenance Therapy, dexamethasone and vincristine combination will be added with either venetoclax or daunorubicin alternatively for five cycles, given after MTX and 6-MP."
214909913|NCT07149415|DRUG|Omaveloxolone|Oral capsules
214909914|NCT07149415|DRUG|Omeprazole|Oral tablet
214909915|NCT06529419|DRUG|AZD8630|The drug will be administered by inhalation
214303586|NCT05576740|PROCEDURE|Determination of hormone level concentrations|Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.
214303587|NCT05576740|PROCEDURE|Jump height determination|by Chronojump contact mat, determine five types of jump in centimeters: Squat jump without additional weight, Squat jump with 50% of body weight, Countermovement jump, Abalakov jump, and Drop jump, during the early follicular phase, late follicular phase, and mid-luteal phase.
214909916|NCT06529419|DRUG|Placebo|The placebo will be administered by inhalation
214909917|NCT06529419|DEVICE|Inhaler|The drug/placebo will be administered by inhalation using the inhaler
214909918|NCT07149857|DRUG|Cilta-cel|Cilta-cel will be administered as intravenous infusion.
214909919|NCT07149857|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as intravenous infusion.
214909920|NCT07149857|DRUG|Induction therapy|Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd), will will be administered.
214909921|NCT07149857|DRUG|Fludarabine|Fludarabine will be administered as intravenous infusion.
214909922|NCT07155746|OTHER|Incremental walking exercise on an AlterG treadmill (anti-gravity)|One visit with their current weight (BW) One visit with simulated weight loss in adolescents to determine their normal weight (NW-SBW) One visit with simulated weight loss in adolescents to determine their overweight status (OW-SBW).
214909923|NCT07154368|DRUG|Pemetrexed injection|Randomization to either JYP0322 or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (JYP0322: platinum-based doublet-chemotherapy) ratio
214909924|NCT07154368|DRUG|Cross-over to JYP0322|Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by BICR, they will be given the opportunity to begin treatment with JYP0322 150mg tid. These subjects may continue treatment with JYP0322 if they are continuing to show clinical benefit until disease progression as judged by the investigator.
214909925|NCT07154368|DRUG|JYP0322 tablets|JYP0322, 150 mg, administered orally three times daily (tid) after meals; sample size (N) = 60.
214303588|NCT05576740|PROCEDURE|Grip strength determination|measuring of changes in muscle strength by handgrip dynamometer in the hand to be tested (handgrip test) during the early follicular phase, late follicular phase, and mid-luteal phase. Three attempts on each hand.
214909926|NCT03598309|DRUG|Curcumin C3 complex®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
214909927|NCT03598309|DRUG|Lovaza®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
214909928|NCT03598309|OTHER|Placebo|Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
214909929|NCT07156786|DRUG|N-acetylcysteine (NAC)|N-Acetylcysteine effercescent 1200 mg orally twice a day for 7 days. One day before cisplatin based chemotherapy, on the chemotherapy day, and five days after.
214909930|NCT07156786|DRUG|Placebo|Patient will get placebo
214909931|NCT07160153|DIAGNOSTIC_TEST|Neurocognitive assessment|"Neurocognitive battery:~TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs~Other psychometrics:~The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)"
214909932|NCT07160153|DIAGNOSTIC_TEST|Urine toxicological assessment|Urine toxicological assessment
214909933|NCT07163221|DEVICE|Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1|Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 1 for 20 minutes once per day
214909934|NCT07163221|DEVICE|Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2|Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 2 for 20 minutes once per day
214909935|NCT07163221|DEVICE|Sham ultrasound stimulation (control)|Sham ultrasound stimulation for 20 minutes once per day
214909936|NCT07163221|DRUG|Conventional Synthetic DMARD|All subjects will take at least one type of conventional synthetic DMARD at the same stable dose for at least 8 weeks prior to the treatment period and continuing through study close out
214909937|NCT07155317|PROCEDURE|Biopsy Procedure|Undergo tumor tissue biopsy
214909938|NCT07155317|PROCEDURE|Biospecimen Collection|Undergo check swab and blood sample collection
214909939|NCT07155317|PROCEDURE|Computed Tomography|Undergo CT
214909940|NCT07155317|BIOLOGICAL|Ipilimumab|Given IV
214303589|NCT05576740|PROCEDURE|Flexibility determination|measurement of changes in the range of motion of the hamstring musculature, by sit and reach test (cm), during the early follicular phase, late follicular phase, and mid-luteal phase. Three tries.
214303590|NCT05576740|PROCEDURE|Indirect maximum oxygen consumption determination|by the Course Navette test, the indirect oxygen consumption is calculated using the formula: VO2max = (6xFA) - 27,4 (FA = Speed of the last stage of the test completed. It takes place during the early follicular phase, late follicular phase, and mid-luteal phase.
214909941|NCT07155317|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214909942|NCT07155317|OTHER|Medical Device Usage and Evaluation|Wear an actigraphy device
214909943|NCT07155317|BIOLOGICAL|Nivolumab|Given IV
214909944|NCT07155317|OTHER|Questionnaire Administration|Ancillary studies
214909945|NCT07163208|DEVICE|Low-Level Laser Therapy (LLLT)|Low-level laser therapy using the Omega XP Model with wavelengths of 675nm (30mW), 820nm (200mW), or 46-cluster LED probe (mixed wavelengths: 660nm, 950nm, 870nm, 880nm, 940nm, 820nm), applied three times weekly for 30 minutes over 6 weeks to target cervical lymphatic chain, musculature, and trigger points for pain relief in cervicogenic headache.
214909946|NCT07163208|OTHER|Routine Physical Therapy (RPT)|Warm-up: Active cervical ROM (5-10 reps, pain-free range). Stretching: Upper trapezius, levator scapulae, SCM; hold 15-30 sec, 3-5 reps, NRS ≤ 3/10. Therapeutic exercises: cervical deep flexors, scapular stabilization (2-3 sets × 10-15 reps, Borg 11-13), progressed weekly. Modalities: Hot pack 15 min at 40-45°C; TENS 80-100 Hz, 50-100 µs pulse width, 20 min. Frequency: 3× weekly for 6 weeks. Safety: contraindications screened; pain/exertion monitored pre/post.
214909947|NCT01573481|OTHER|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
214954816|NCT03721211|DRUG|[11C]Martinostat|a type of dye used for radiographic imaging of the HDAC protein
214909948|NCT01573481|OTHER|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate \> or equal to 12 breath per min).
214909951|NCT07166081|DRUG|BGM0504|Administered orally
214909952|NCT07166081|DRUG|BGM0504|Administered orally
214909953|NCT07166081|DRUG|BGM0504|Administered orally
214909954|NCT07166081|DRUG|Placebo|Administered orally
214909955|NCT07166081|DRUG|BGM0504|Administered orally
214909956|NCT07166224|DEVICE|Oral-B Powered toothbrush|"Intervention Group B:~Participants receive standardized oral hygiene instructions and use an Oral-B iO powered toothbrush during the test period.~The Oral-B iO is an advanced powered toothbrush that combines oscillating-rotating and micro-vibrating bristle movements with real-time feedback technology. It is CE-marked for home use and designed to improve plaque removal and overall oral hygiene compared to manual toothbrushing. The device incorporates pressure sensors and guided brushing modes to support optimal brushing technique and patient adherence, which may contribute to improved periodontal outcomes."
214909957|NCT07166224|DEVICE|Dual-Light aPDT Treatment - Lumoral|"Intervention Group A:~Participants receive standardized oral hygiene instructions and use only a manual toothbrush during the test period, with the addition of an adjunctive antimicrobial photodynamic therapy (aPDT) device (Lumoral®).~The Lumoral® treatment device is a CE-marked antibacterial device intended for home use. It is designed to support the treatment and prevention of oral diseases caused by bacterial biofilms. The device functions by emitting light at a specific wavelength, which activates a CE-marked photosensitizing mouthrinse, Lumorinse®. This light-activated process enhances antibacterial efficacy, targeting pathogenic microorganisms in the oral cavity and supporting improved oral hygiene outcomes."
214909958|NCT07170800|DRUG|JDB0131 100mg|"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~JDB0131 (J): 100 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
214909959|NCT07170800|DRUG|JDB0131 200mg|"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~JDB0131 (J): 200 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
214909960|NCT07170800|DRUG|Delamanid (D)|"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~Delamanid (D): 100 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
214909961|NCT07168720|DRUG|Dexmedetomidine hydrochloride Microneedles|Randomized in a 1:1 ratio through the randomization system, and assigned to medium-pressure group or low-pressure group.
214909962|NCT07168720|DRUG|Dexmedetomidine hydrochloride Microneedles|"In the high weight group, 8 subjects will receive a high dose of Dexmedetomidine hydrochloride Microneedles.~In the high weight group, 8 subjects will receive a low dose of Dexmedetomidine hydrochloride Microneedles."
214909963|NCT07168720|DRUG|placebo|In the high weight group, 8 subjects will receive Dexmedetomidine hydrochloride Microneedles blank preparation.
214909964|NCT07168720|DRUG|Dexmedetomidine hydrochloride Microneedles|"In the low weight group, 8 subjects will receive a low dose of Dexmedetomidine hydrochloride Microneedles.~In the low weight group, 8 subjects will receive a high dose of Dexmedetomidine hydrochloride Microneedles."
214909965|NCT07168720|DRUG|Placebo|In the low weight group, 8 subjects will receive Dexmedetomidine hydrochloride Microneedles blank preparation.
214909966|NCT07174115|DRUG|HTMC0658|HTMC0658 tablet
214909967|NCT07173985|BEHAVIORAL|Standard FIT kit|Receive a standard FIT kit
214909968|NCT07173985|BEHAVIORAL|Enhanced FIT kit|Receive a enhanced FIT kit that includes a video brochure, disposable gloves, and a disposable stool collection device
214909969|NCT07173985|BEHAVIORAL|Telephone patient navigation|Receive telephone-based patient navigation
214909970|NCT07173985|BEHAVIORAL|Text message patient navigation|Receive text message-based patient navigation
214909971|NCT07174271|OTHER|Patient satisfaction survey upon completion of anterior composite restorations and during follow-up sessions|"This study focuses on evaluating patient satisfaction with anterior composite restorations immediately after treatment and during subsequent follow-up visits. A structured questionnaire, based on modifications of the Fédération Dentaire Internationale (FDI) criteria, was administered to patients. Since the original FDI criteria were primarily designed for dentist-based evaluation, the questions were adapted into a patient-friendly format.~Participants were asked to rate restorations across multiple domains, including esthetic anatomical form, color harmony and translucency, surface smoothness, the condition of the adjacent mucosa, and post-operative sensitivity and tooth vitality. Each parameter was scored on a numerical scale ranging from 0 to 10, allowing patients to express their subjective perception of treatment outcomes.~By collecting these patient-reported outcomes both immediately after the procedure and during follow-up sessions, the study aims to provide a comprehensive under"
214909972|NCT07170930|OTHER|Friendly Match-Play Exposure: extended vs. limited|This research explores the multidimensional physiological and biochemical responses to differing volumes of friendly match-play (i.e., extended vs. limited) during the late pre-season phase in soccer players.
214909973|NCT07174440|DRUG|Ropivacaine (Epidural analgesia)|The block solution will consist of 1% ropivacaine 3 mg/Kg ideal body weight (IBW) mixed with dexmedetomidine 0.5 mcg/Kg IBW and diluted with 10 mL iohexol 300 mg/mL and normal saline for a total volume of 40 mL. All medications used are standard of care
214909974|NCT07174440|DRUG|Dexmedetomidine|The block solution will consist of 1% ropivacaine 3 mg/Kg ideal body weight (IBW) mixed with dexmedetomidine 0.5 mcg/Kg IBW and diluted with 10 mL iohexol 300 mg/mL and normal saline for a total volume of 40 mL. All medications used are standard of care
214909975|NCT07174440|DRUG|Iohexol|The block solution will consist of 1% ropivacaine 3 mg/Kg ideal body weight (IBW) mixed with dexmedetomidine 0.5 mcg/Kg IBW and diluted with 10 mL iohexol 300 mg/mL and normal saline for a total volume of 40 mL. All medications used are standard of care except for iohexol which is used for study purposes.
214909976|NCT07174440|PROCEDURE|QST Procedure|The QST procedure (test of buzzing sensation and temperature sensation through pads applied to your skin) to assess the numb areas.
214909977|NCT07174739|DEVICE|Quantum Molecular Resonance (QMR) Treatment|Quantum Molecular Resonance (QMR) treatment will be administered using the Rexon-Eye® device (Resono Ophthalmic, Sandrigo, Italy) according to the protocol recommended by the manufacturer. The device features a contact electrode embedded in a mask worn over the participant's closed eyes, and it delivers stimulation to the epidermis of the closed eyelids, extending up to the lid border with an intensity setting of 4-5 on a scale of 0-10. The treatment is non-invasive and painless.
214909978|NCT07175376|OTHER|Supportive Care|Geriatric assessment (GA) -guided supportive care and weekly Patient Reported Outcomes (PRO) symptom assessment
214909979|NCT07183293|DRUG|Peginterferon alfa-2b combined with NAs|Subcutaneous injection therapy,Treatment will continue for 48 weeks, with follow-up assessments conducted every 12 weeks. The dosage will be adjusted based on the patient's disease status.
214909980|NCT07183293|DRUG|NAs|Treatment will continue for 48 weeks, with follow-up assessments conducted every 12 weeks. The dosage will be adjusted based on the patient's disease status.
214909981|NCT07182318|DIAGNOSTIC_TEST|The FIGO Nutrition Checklist|patient fulfilled the questionnaire twice. period of time 2-3 days
214909982|NCT07183267|DEVICE|Photobiomodulation|Participants will received a daily treatment of photobiomodulation via a LED photobiomodulation device alongside their proton or photon treatment fraction. The photobiomodulation will be administered to the skin in the site of the patients proton or photon therapy treatment area.
214909983|NCT07184021|DRUG|Gemcitabine and Cisplatin (DD GC)|Participants will receive neoadjuvant ddGC, consisting of gemcitabine and cisplatin administered at shortened intervals (e.g., gemcitabine 1200 mg/m² on days 1 and 8, fractionated cisplatin 35 mg/m² on day 1and 8, every 14 days) with appropriate growth factor support. A total of four cycles are planned before radical cystectomy.
214909984|NCT07184294|OTHER|Best Practice|Receive no massage therapy
214909985|NCT07184294|PROCEDURE|Biospecimen Collection|Undergo saliva sample collection
214909986|NCT07184294|PROCEDURE|Massage Therapy|Receive FL therapy
214909987|NCT07184294|PROCEDURE|Massage Therapy|Receive HNS therapy
214909988|NCT07184294|PROCEDURE|Massage Therapy|Receive HA therapy
214909989|NCT07184294|PROCEDURE|Massage Therapy|Receive combination FL, HNS, and HA therapy
215058235|NCT00841243|DIETARY_SUPPLEMENT|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
215058236|NCT05198076|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation|The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
215058237|NCT02531360|DRUG|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
214909990|NCT07184294|OTHER|Questionnaire Administration|Ancillary studies
215058238|NCT04875494|BEHAVIORAL|Counseling/support group therapy|6 weeks of counseling group therapy; 2 sessions of 30 min each week, with a psychologist and two former victims
215058239|NCT04875494|BEHAVIORAL|Physical Exercise|6 weeks of physical exercise training; 2 sessions of 30 min each week, with an instructor
214303591|NCT05576740|DEVICE|Sensory and pain threshold determination|by electrical muscle stimulator (Digitimer DS7A), during the early follicular phase, late follicular phase, and mid-luteal phase.
214303592|NCT05576740|OTHER|Physical and mental symptoms associated with the menstrual cycle|By The Daily Record of Severity of Problems (DRSP) questionnaire, during a full menstrual cycle.
214303593|NCT05576740|DEVICE|Daily activity|by accelerometer (GENEActiv) during a full menstrual cylcle: Wrist-worn device measuring accelerations as a measure of daily activity, in cpm, counts per minute.
214303594|NCT05576740|PROCEDURE|Biochemical parameters determination|Determination of concentration of iron (μg/dL), ferritin (ng/mL), and transferrin (mg/dL), during the early follicular phase, late follicular phase, and mid-luteal phase.
214909991|NCT07182357|BEHAVIORAL|Dementia Care Management Checklist for Hospice Transitions|"Intervention: After appropriate care partners of hospice-eligible PLWD are identified who will be receiving the checklist intervention, care managers will perform telephonic outreach to engage them in a conversation about care needs (as they would in typical clinical practice). The telephonic outreach will be followed up with a recommendation for follow up by a medical provider who may conduct a hospice care assessment and engage the care partner in decision-making surrounding the hospice referral and enrollment process.~This intervention was co-designed with care partners, home healthcare professionals, administrators, and medical providers. It is meant to be comprehensive and speak to the needs of all relevant parties engaged in the care of persons with dementia. It is developed so that it can be scaled and implemented widely."
214909992|NCT07182591|DRUG|DS5361b|"Dose Escalation Part: DS5361b will be administered at escalating doses to determine the RDE.~Dose Expansion Part: DS5361b will be administered at RDE."
214909993|NCT07182591|DRUG|Pembrolizumab|"Dose Escalation Part: Pembrolizumab will be administered at a standard dose.~Dose Expansion Part: Pembrolizumab will be administered at a standard dose."
214909994|NCT07182539|OTHER|PRVC ventilation|Ventilation in PRVC mode.
214909995|NCT07182539|OTHER|VCV ventilation|Ventilation in VCV mode.
215058240|NCT04119765|BIOLOGICAL|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
215058241|NCT04119765|BIOLOGICAL|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
215058242|NCT04119765|PROCEDURE|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
214909996|NCT07182071|BEHAVIORAL|Physical Activity Program|Three 60-minute supervised group exercise sessions per week for 10 weeks, led by a certified instructor.
214909997|NCT07182071|BEHAVIORAL|Waitlist for Physical Activity Program|Three 60-minute supervised group exercise sessions per week for 10 weeks, led by a certified instructor.
214909998|NCT07182552|DRUG|NTB003|NTB003 dose 1, dose 2, dose 3, dose 4
214909999|NCT07182552|DRUG|Placebo|Placebo dose 1, dose 2, dose 3, dose 4
214910000|NCT07183332|BEHAVIORAL|High frequency follow-up|Patients in the high-frequency group received regular follow-ups at a high frequency after discharge.
214910001|NCT07184463|OTHER|Evaluation of chronic pain at 3 and 6 months after thoracic surgery|The presence of persistent postoperative pain, defined as ipsilateral chest pain (on the same side as the surgery) occurring at rest and/or with coughing on a daily basis. Assessed by a 'yes' or 'no' response when asked at 3 and 6 months postoperatively.
214910002|NCT07183722|OTHER|Microbiota analysis|Analysis of microbiota in patients admitted to the following departments: General Anesthesia and Resuscitation, Cardio-Thoracic-Vascular Anesthesia and Resuscitation, Internal Medicine, and MeCAU.
214910003|NCT07183020|DIAGNOSTIC_TEST|Oligoclonal bands and kappa free light chains (KFLC)|Comparison of oligoclonal bands and kappa free light chains (KFLC) in patients with multiple sclerosis (MS) / clinically isolated syndrome (CIS)
214910004|NCT07182721|DRUG|SKB264 Plus Inetetamab|SKB264: 5 mg/kg administered on Day 1 of each 2-week cycle. Inetetamab: an initial loading dose of 6 mg/kg is administered, followed by subsequent maintenance doses of 4 mg/kg. Dosing occurs on Day 1 of each 2-week cycle.
214910005|NCT07183384|BIOLOGICAL|Mesenchymal Stem Cell-Derived Exosomes|Mesenchymal stem cell-derived exosomes isolated from adipose-derived stem cells (ASC). The exosomes contain bioactive molecules including microRNAs (particularly miR-126-3p), proteins, and lipids that promote endothelial repair and regeneration. The product is manufactured under GMP conditions and administered as a single Intravenous or Intramuscular infusion.
214910006|NCT07183384|OTHER|Placebo (Sterile Saline Solution)|Sterile saline solution (0.9% sodium chloride) administered Intravenous or Intramuscular as placebo control. The volume and administration method are identical to the active treatment to maintain blinding.
214910007|NCT07183462|DRUG|Intravenous Ampicillin followed by Oral Amoxicillin|This intervention consists of intravenous Ampicillin 2 grams every 6 hours for 48 hours, followed by oral Amoxicillin 500 mg every 8 hours for 5 days
215058243|NCT04119765|PROCEDURE|central pressure measurement|central pressure will be measured thank to the Complior® device
215058244|NCT06264466|DEVICE|POEM with Speedboat Ultraslim|POEM procedures, with or without fundoplication, will be conducted by expert endoscopists who have undergone prior training in the utilization of the ultraslim Speedboat. Incisions, whether anterior or posterior, submucosal tunneling, and myotomy will be performed using the Bipolar Radiofrequency Ablation (RFA) integrated into the device's tip. Additionally, for vessel coagulation, the microwave energy integrated into the device's tip will be employed. Successful myotomy will be confirmed by passage of the endoscope through the esophagogastric junction (EGJ) without restriction.
214303595|NCT05576740|PROCEDURE|Blood count determination|Determination of concentration of hemoglobin (g/dL), red blood cells (10\^6/μL), hematocrit (%), white blood cells (10\^3/μl), platelets (10\^3/μl), during the early follicular phase, late follicular phase, and mid-luteal phase.
214910008|NCT07183462|DRUG|Ampicillin/Amoxicillin plus single-dose IV Azithromycin|This intervention includes intravenous Ampicillin 2 grams every 6 hours for 48 hours, followed by oral Amoxicillin 500 mg every 8 hours for 5 days, plus a single dose of intravenous Azithromycin 1 gram administered once at the start of treatment
214910009|NCT07183501|PROCEDURE|Combined hystroscopic and laparoscopic repair|Hystroscopic isthmoplasty will be done first to ensure removal of chronically inflamed Unhealthy edges of niche, then laparoscopic exison of scar will be dine, followed by repair of the defect
214910010|NCT07184411|OTHER|Activities-based locomotor training|Activities-based locomotor training involves placing the child in a partial body-weight supported (PBWS) system over a treadmill. The child is given assistance by trained clinicians to attempt standing and walking on the treadmill for 1 hour. The child then participates in play-based activities aimed to foster independence in an overground (regular) environment for 1 hour. The final hour of the 3-hour session is conducted in the PBWS system with a focus on standing and walking.
214910011|NCT07184411|OTHER|physical therapy|In this intervention, the child will attend their usual physical therapy sessions.
214910012|NCT07172581|BEHAVIORAL|Online low-FODMAP diet|Participants were invited to follow the online low-FODMAP diet offered by SOSCuisine®, characterized by three specific features. First, participants received customized weekly low-FODMAP menus based on the Monash University protocol. Second, a virtual assistant accompanied participants from the beginning to the end of the diet implementation, providing personalized recommendations tailored to individual's preferences and intensity of symptoms. For the reintroduction phase, the assistant guided individuals through the process of testing specific FODMAP subgroups, offering food suggestions based on individual preferences, and portion sizes. The last feature of the platform was the access to a peer support group on Facebook©, designed to foster communication among participants. This group allowed individuals to ask questions and receive valid answers, as the group was moderated by a FODMAP-specialized registered dietitian.
214910013|NCT07183098|OTHER|Participiants at high risk of malnutrition who received standard nutritional care|The overall clinical managment of people by ward's staff includes also nutritional care. Within 24-48 h after hospitalization, the ward's nursing staff screens people for nutritional risk using the Malnutrition Universal Screening Tool (MUST) tool. The attending ward's physician prescribes nutritional support and laboratory analyses in accordance with people's clinical needs and the underlying disease. Ward's physician cllinical judgement guides the decision to reassess and monitor the people's nutritional risk and status.
214910014|NCT07183098|OTHER|Participiants at high risk of malnutrition who received specialized nutritional care|People referred to the Dietetic and Clinical Nutrition Service (DCNS) receive a structured, evidence-based diagnostic and therapeutic nutritional support. A dietitian performs a dietary assessment and the attending physicians of the DCNS prescribe a baseline set of laboratory analyses relevant for nutritional status. People referred to the DCNS are monitored regularly and systematically, daily or weekly according to the people's clinical condition and nutritional problems.
214303596|NCT05576740|PROCEDURE|Body composition parameters determination|Determination of weight (kg), total body water (L), proteins (kg), minerals (kg), body fat mass (kg), body mass index (BMI) (kg/m2), basal metabolic rate (kcal) by Bioelectrical Impedance Analysis, during the early follicular phase, late follicular phase, and mid-luteal phase.
215058245|NCT04092803|OTHER|Virtual Reality|The system includes a VR headset with VR software already loaded in to it.
215058246|NCT05600829|BEHAVIORAL|BWLT+CR|Patients will attend twelve 2-hour group-based weekly sessions (over Zoom) in addition to their twice-weekly CR exercise sessions, followed by biweekly follow-up sessions alternating between individual phone-based sessions with a facilitator, and group-based sessions for an additional 12 weeks. The empirically validated ASPIRE BWLT was recently adapted for an AF population with obesity. Briefly, the BWLT was modified to incorporate education and practical strategies requested by patients, including AF risk factor management, pathophysiology, medications, and disease course; exercising with AF; and coping with difficult emotions regarding AF. Weekly treatment goals focus on nutrition and moderate calorie reduction while emphasizing adherence to an individualized CR exercise prescription. The BWLT program will be delivered by senior clinical psychology PhD students and supervised by a registered Clinical Health Psychologist.
214910015|NCT07183098|OTHER|3 month-post discharge evaluation|Three months after discharge (follow-up), participiants of both groups were monitored through telephone interview to collect data regarding rate of hospital readmission, number of emergency department admissions, general practitioner visits, outpatient visits, diagnostic tests, daily medication use and survival.
215058247|NCT05600829|BEHAVIORAL|CR-Only|The CR program consists of education, medication management, risk factor modification and 12 weeks of twice-weekly supervised cardiovascular exercise sessions. Patients with AF undergo a symptom-limited graded exercise stress test at intake, 12-weeks, 24-weeks, and 1-year post-randomization, where cardiorespiratory fitness (i.e., peak metabolic equivalents \[METS\]) and cardiometabolic risk factors (blood pressure, blood lipid profile, BMI, waist circumference, depression and anxiety symptoms, tobacco use, and exercise volume) are assessed.
215058248|NCT01765036|DRUG|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
215058249|NCT06192472|PROCEDURE|Chemical sclerotherapy|Sclerosant will be retained within the vein
214303597|NCT05576740|PROCEDURE|Vital signs|Determination of blood pressure (mmHg) and heart rate (bpm) at baseline, one minute and three minutes after the Course Navette test
214910016|NCT07184255|OTHER|Patient Education Video Intervention|Animated video with high-contrast visuals and audio narration in the patient's preferred language, covering diagnosis, surgical steps, and post-operative positioning.
214910017|NCT07182331|DEVICE|Continuous Theta Burst Stimulation to Bilateral DLPFC|Participants receive continuous theta burst stimulation (cTBS) targeting both the left and right dorsolateral prefrontal cortex (DLPFC) during each session. Each hemisphere is stimulated with 600 pulses (triplets at 50 Hz repeated at 5 Hz) over \~40 seconds, at 80% of the individual's active motor threshold. Sessions are administered once daily over 10 treatment days.
214910018|NCT07182331|DEVICE|Sham Continuous Theta Burst Stimulation|Participants receive sham continuous theta burst stimulation (cTBS) to both the left and right dorsolateral prefrontal cortex (DLPFC) using a placebo coil that mimics the auditory and tactile sensations of real stimulation but does not produce a magnetic field capable of affecting brain activity. Coil positioning, session timing, and procedure match the active cTBS protocol, including consecutive stimulation to both hemispheres. Both participants and TMS technicians wear earplugs to mask subtle sound differences between active and sham coils. This setup maintains participant and operator blinding and controls for placebo-related effects.
214910019|NCT04343495|DEVICE|Wearable Ultra Violet (UV) and blue-light sensors|Non-blinded
214910020|NCT06431932|DRUG|Fisetin|Subjects will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.
214910021|NCT06431932|DRUG|Placebo|Subjects will receive a corresponding number of placebo capsules for two consecutive days.
214910022|NCT00921609|DIAGNOSTIC_TEST|Oral glucose tolerance test|An oral glucose tolerance test is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
214910023|NCT01016951|DRUG|AZD9164 Turbuhaler®|"Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg."
214303598|NCT05576740|OTHER|Checking for correct use of contraceptive methods|Pre-test questions about possible forgetfulness or mishandling of the method
214303599|NCT05576740|PROCEDURE|Urinary LH determination|Urine LH test strips are performed from day 8 of the cycle until positive.
214910024|NCT01016951|DRUG|Placebo Turbuhaler®|Dry powder for inhalation via Turbuhaler, MAD
214910025|NCT05608915|OTHER|No Cue|There will be no visual cues at all. Will be tested off-medication (after holding morning dopaminergic medications).
214910026|NCT05608915|OTHER|Conventional Cue|Physical lines taped to floor at regular intervals. Will be tested off-medication (after holding morning dopaminergic medications).
214303600|NCT03104595|DRUG|EC-18|oral administration
214910027|NCT05608915|OTHER|Constant Cue|The augmented-reality visual cue will always be turned on. Will be tested off-medication (after holding morning dopaminergic medications).
214910028|NCT05608915|OTHER|Patient hand-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient clicks a handheld button. Will be tested off-medication (after holding morning dopaminergic medications).
215058250|NCT06192472|DRUG|1% Sodium Tetradecyl Sulphate|1% Sodium Tetradecyl Sulphate
215058251|NCT06192472|DRUG|3% Sodium Tetradecyl Sulphate|3% Sodium Tetradecyl Sulphate
215058252|NCT06192472|DRUG|0.5% Polidocanol|0.5% Polidocanol
214910029|NCT05608915|OTHER|Patient eye-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient looks down at the floor near their feet. Will be tested off-medication (after holding morning dopaminergic medications).
214910030|NCT05608915|OTHER|Examiner-triggered|The augmented-reality visual cue will be turned on, intermittently, by an examiner, whenever they feel the patient is having a freezing episode or at risk of having a freezing episode. Will be tested off-medication (after holding morning dopaminergic medications).
214910031|NCT02184338|DRUG|BIBR 1017 BS powder|
214910032|NCT02184338|DRUG|Placebo|PEG 400
214910033|NCT03225209|OTHER|OPTIFAST|OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
214910034|NCT02565628|DRUG|PF-06669571|1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
214910035|NCT02565628|DRUG|Placebo|Placebo
214910036|NCT03892044|DRUG|Duvelisib|Given PO
214910037|NCT03892044|BIOLOGICAL|Nivolumab|Given IV
214910038|NCT02281435|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures, but in this study the procedure consist an incision on to the foreskin.
214910039|NCT04568915|OTHER|Dry Needling|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, DN
214910040|NCT04568915|OTHER|Maitland Mobilization|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, Maitland joint mobilization
214910041|NCT03795961|DEVICE|transcranial direct current electrical stimulation|anodal tDCS of M1 for 20 minutes, at 2 mA for 5 sessions (day after day)
214910042|NCT04267289|BEHAVIORAL|Beating the Blues|Automated, cognitive behavioral therapy delivered via a website. There are 8 sessions, each taking one to 1.5 hours to complete. Sessions are prerecorded and sequenced. Sessions are based on the principles of cognitive behavioral therapy and include techniques such as cognitive restructuring and behavioral activation. The entire program takes about 8 to 12 weeks to complete.
214910043|NCT04286269|OTHER|Music Based Intervention|Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.
214910044|NCT04286269|OTHER|Sham Treatment|Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
214910045|NCT00261209|DRUG|Collagenase|Collagenase injection into adhesion restricting tendon gliding
214910046|NCT00261209|DRUG|Collagenase injection|injection of collagenase into adhesion restricting tendon gliding
214910047|NCT02449486|DRUG|Ropivacaine|
214910048|NCT04560270|DIAGNOSTIC_TEST|Blood samples|Blood samples to determine ctDNA levels during chemotherapy
214910049|NCT04960241|PROCEDURE|Homebased telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
214910050|NCT04960241|PROCEDURE|Homebased rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
214910051|NCT04960241|PROCEDURE|No physical rehabilitation|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
214910052|NCT06189937|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Therapy (CA-CBT)|"In this study, an 8- session (90 to 120 minutes) group version of the transdiagnostic intervention CA-CBT tailored for earthquake survivors will be applied.~Contents of the sessions are:~1. Education on psychological trauma and its treatment, and basics of emotion regulation techniques~2. Education on anxiety and depressive disorders and their treatment~3. Muscle relaxation and stretching exercises~4. Education about depressive and grief-related disorders and disturbing memories protocol~5. Interoceptive exposure: head rotation and hyperventilation~6. Anxiety, worry, and stress~7. Anger and anger protocol; breathing exercises~8. Somatic complaints, sleep disturbance, and closing~There will be one facilitator and one co-facilitator. Groups will consist of 12-13 participants."
214910053|NCT04216290|PROCEDURE|Biopsy of Bladder|Undergo bladder biopsy
214910054|NCT04216290|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample collection
214910055|NCT04216290|DRUG|Cisplatin|Given IV
214910056|NCT04216290|PROCEDURE|Computed Tomography|Undergo CT
214910057|NCT04216290|PROCEDURE|Cystoscopy|Undergo cystoscopy
214910058|NCT04216290|BIOLOGICAL|Durvalumab|Given IV
214910059|NCT04216290|DRUG|Fluorouracil|Given IV
214910060|NCT04216290|DRUG|Gemcitabine Hydrochloride|Given IV
214910061|NCT04216290|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214910062|NCT04216290|DRUG|Mitomycin|Given IV
214910063|NCT04216290|OTHER|Patient Observation|Undergo observation
214910064|NCT04216290|RADIATION|Radiation Therapy|Undergo radiation therapy
215058253|NCT06192472|DRUG|3% Polidcanol|3% Polidcanol
215058254|NCT01954459|DEVICE|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
215058255|NCT01954459|DEVICE|Continuous glucose sensor|Glucose sensor inserted without warming patch
214910065|NCT04671420|DRUG|HLX01|Patients will receive HLX01 intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
214910066|NCT04671420|DRUG|Mabthera®|Patients will receive Mabthera® intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
214910067|NCT00778219|DEVICE|devices for tracheal intubation|tracheal intubation by laryngoscope or lightwand
214910068|NCT03252977|OTHER|Tailored regimen of IV PCA according to pain sensitivity|In tailored group, fentanyl dosage in IV PCA will be determined according to preoperative pain sensitivity. In control, group, fentanyl dosage in IV PCA will be determined without consideration of patient's pain sensitivity.
214910069|NCT03252977|OTHER|Regimen of IV PCA without considering pain sensitivity|In control group, regimen of IV PCA will be determined without consideration about patient's pain sensitivity.
214910070|NCT06026735|OTHER|lung cancer with brain /leptomeningeal metastasis|Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.
214910071|NCT01735916|DEVICE|CRT-P Implant|"The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care."
214910072|NCT01735916|DEVICE|CRT-P OFF|Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
214910073|NCT03914716|DIAGNOSTIC_TEST|Study group|Subjects will have physical, imaging examinations and provide samples for biological markers
214910074|NCT06310733|DRUG|LGG|Participants will take 10 mL of a suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution, supplied in a 10-mL dark bottle with a delivery cap.
214910075|NCT06310733|DRUG|Placebo|Participants will take 10 mL of an identical aqueous solution in appearance and taste but without LGG, supplied in a 10-mL dark bottle.
214910076|NCT04031040|DEVICE|Genio(TM) system therapy|Hypoglossal nerve stimulation system
214910077|NCT01164189|BIOLOGICAL|Bevacizumab|Bevacizumab (vial of 400mg/16mL) at a dose of 10 mg/kg bodyweight i.v. in 90 min on day 1 and day 14 of 4 week cycles
214910078|NCT01164189|DRUG|Temozolomide|Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
214910079|NCT01220466|DEVICE|STAR S4IR LASIK with iDesign Aberrometer|CustomVue LASIK targeted for emmetropia
214910080|NCT03466463|GENETIC|GNT0003|Intravenous infusion, single dose
214910081|NCT04455412|PROCEDURE|Laser Assisted ICSI|using OCTICS laser device to do small opening or zona thinning to improve ICSI outcome
214910082|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg \[S,S\]-reboxetine for 5 and one half weeks.
215058256|NCT01123031|DRUG|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
215058257|NCT01123031|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
214910083|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg \[S,S\]-reboxetine for 5 and one half weeks.
214910084|NCT00636246|DRUG|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
214910085|NCT00636246|DRUG|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
214910086|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks.
215058258|NCT05895123|DRUG|Rosuvastatin 20 mg|patients will receive one tablet rosuvastatin 20 mg every night
215058259|NCT05895123|DRUG|Atorvastatin 40mg|patients will receive one tablet Atorvastatin 40 mg every night
215058260|NCT04364815|DRUG|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine and standard preventive measures
215058261|NCT04364815|DRUG|Placebo plus standard preventive measures|Placebo tablet plus standard preventive measures as defined by PGH-HICU
214303601|NCT00445159|DRUG|UT-15C SR (treprostinil diethanolamine) 1mg oral tablets|
214910087|NCT00636246|DRUG|Placebo|Tablets, orally once per day for 8 weeks
214910088|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks
214910089|NCT00636246|DRUG|[S,S]-reboxetine monotherapy|Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
214910090|NCT02271646|DRUG|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
214910091|NCT03481868|BIOLOGICAL|Collection of blood and bone marrow|Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment
214910092|NCT03633123|DRUG|D_PLEX|D\_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
214303602|NCT03630120|DRUG|Lenvatinib|"Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
214303603|NCT03630120|DRUG|Sorafenib|"Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
214910093|NCT03633123|OTHER|Standard of Care (SoC)|"Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure"
214910094|NCT05003310|DEVICE|Active Stimulation|Stimulation will be turned ON and applied during each day of the period.
214910095|NCT05003310|DEVICE|Sham Stimulation|Sham stimulation will be provided during the period
214910096|NCT05003310|DRUG|Baricitinib|Baricitinib (2 mg) is administered daily during the period.
214910097|NCT05003310|DRUG|Background Treatment|Stable dose of standard background treatment (e.g., csDMARD therapy)
214954817|NCT03721211|DEVICE|MR-PET scanner|PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
214954818|NCT05872880|PROCEDURE|Modified radical surgery|The modified radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and local extended resection was performed according to the scope of the residual tumor lesions after induction therapy: the incisal margin was 1 to 1.5cm outside the boundary of the residual tumor lesions, and multi-point incisal rapid disease detection was performed intraoperatively to ensure negative incisal margin and complete resection of the residual tumor lesions. Under this premise, the surgical trauma should be minimized, and the organs and appearance of the patient should be preserved. For example, facial skin should not be penetrated, mandible should not be cut off, and tongue tissue should be preserved as much as possible. Direct suture or local tissue flap should be used to repair the defect during the operation. At the same time, improved radical neck dissection was performed on the affected side of the neck.
214954819|NCT05872880|PROCEDURE|Radical surgery|Radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and a wide range of radical surgical resection was performed according to the tumor scope before induction therapy: the incisal margin was 1 to 1.5cm outside the tumor boundary before induction, the lower lip and mandible could be incised if necessary, the facial skin could be excised, the mandibular bone segmentectomy was feasible, and pedicle or free skin (bone) flap was used to repair the defect. At the same time, improved radical neck dissection was performed on both sides of the affected neck.
214954820|NCT04401280|DRUG|BiominF|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
214954821|NCT04401280|DRUG|Novamin|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
214954822|NCT04401280|DRUG|CPP-ACP|applied in accordance with the manufacturer's specifications
214954823|NCT05032729|OTHER|Trypophan, Theanine and 5'AMP|250 ml beverage consumed at 21:00 hours
214954824|NCT05032729|OTHER|Placebo|250 ml beverage consumed at 21:00 hours, matched in appearance and taste to the active beverages
214954825|NCT00766844|DEVICE|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
214954826|NCT05155930|BEHAVIORAL|Internal Family Systems (IFS)|Weekly individual psychotherapy
214954827|NCT04629872|DRUG|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.
215058262|NCT05600985|PROCEDURE|FS-LASIK|Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.
215058263|NCT05088434|DIETARY_SUPPLEMENT|Anaerobically Cultivated Human Intestinal Microbiota (ACHIM)|One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Vallingby, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
215058264|NCT05088434|DIETARY_SUPPLEMENT|Donor fecal microbiota transplantation|Only 60 ml of sterile 0.9% normal saline were added to a stool specimen, collected from the respective donor, with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
214910098|NCT04554810|OTHER|Medication Management Service|Medication review was delivered to the Syrian refugees by accredited pharmacists at the baseline visit. This followed by identifying the treatment-related problems (TRP) by the clinical pharmacist, and correction of the approved TRPs by the corresponding physicians and finally convey these changes in medications to the patients. In addition, counselling and education were delivered to the refugees' patients in the base line visit.
215058265|NCT05088434|DIETARY_SUPPLEMENT|Placebo|Only 60 ml of sterile 0.9% normal saline were added to the patient's own stool specimen with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
215058266|NCT04762836|DRUG|D-cycloserine|Antibiotic medication that augments the function of NMDA-receptors
215058267|NCT04762836|BEHAVIORAL|Conditioning|During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
215058268|NCT04762836|BEHAVIORAL|Extinction|During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
215058269|NCT04762836|OTHER|fMRI|In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
215058270|NCT04762836|DRUG|Placebo|Placebo control in oral form
215058271|NCT05216939|OTHER|Flannel mask with ear loops|Participants will have a mask fit test and will wear a flannel mask with ear loops. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort and fit of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
215058272|NCT05216939|OTHER|Flannel mask with ties|Participants will have a mask fit test and will wear a flannel mask with ties. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
214910099|NCT05970510|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg|orally once a day
214910100|NCT05970510|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg|orally once a day
214910101|NCT05970510|DRUG|placebo|orally once a day
215058273|NCT05216939|OTHER|Twill mask with ear loops|Participants will have a mask fit test and will wear a twill mask with ear loops. While wearing the twill mask with ear loops, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
215058274|NCT05216939|OTHER|Twill mask with ties|Participants will have a mask fit test and will wear a twill mask with ties. While wearing the twill mask with ties, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
215058275|NCT05407116|OTHER|NCI PRO-CTCAE Questionnaire / EORTC QLQ-C30 Questionnaire|"PROs data will be collected prospectively via electronic questionnaires (PRO-CTCAE™), which is a patient-reported outcomes measurement system created to assess symptomatic toxicity in patients of cancer clinical research. PRO-CTCAE items evaluate frequency, severity, interference, amount, presence/absence symptoms. Each symptomatic adverse effect is measured by 1-3 features. GI items included nausea, vomiting, flatulence, bloating of the abdomen, constipation, diarrhea, abdominal pain, and loss of control of bowel movements. Urinary symptoms include the urge to urinate suddenly, frequency, urine colour change, loss of urine control (leakage).~Patients will also self-report health-related quality of life (QoL) in real-time, electronic PRO questionnaires (EORTC QLQ CX24, EN 24, C30) about QoL. Question 29 and 30 ask the patients to rate their overall health and QOL respectively during the past week on a scale between 1-7, where one is equivalent to very poor and seven is excellent."
215058276|NCT06039215|OTHER|Ventilatory adjustments by nurses|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
214670157|NCT05205239|DIAGNOSTIC_TEST|Endoluminal image analysis by capsule endoscopy|Studies will be performed after discontinuation of medications that could affect gastrointestinal motility for at least 48 hours and overnight fast. Endoluminal images were obtained with the Pillcam capsule (Pillcam SB3 video capsule; Medtronic). Images will be obtained at a fixed 2 per second rate and recorded for a total of 8 hours with the subjects lying comfortably on a hospital bed and the trunk raised 30° above horizontal. Forty-five minutes after gastric exit, participants will be instructed to ingest a liquid meal (Ensure HN; Abbott; 300 mL,1 Kcal/mL). Endoluminal images of the small bowel will be analyzed with a computer program specifically developed in our laboratory for the evaluation of intestinal motility. This previously validated program is based on computer vision techniques, which allow the detection and quantification of contractile and non-contractile patterns characterizing small bowel motility.
214910102|NCT04227197|OTHER|Down Syndrome Clinic to You (DSC2U)|DSC2U is a web-based tool for families to get up-to-date, personalized health and wellness information, based on national guidelines and expert consensus, for a person with Down syndrome.
214910103|NCT04815811|OTHER|Blood collection|Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.
214303604|NCT03630120|DRUG|Cabozantinib|"Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
214303605|NCT03630120|DRUG|Vandetanib|"Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
214303606|NCT00176007|PROCEDURE|Hypoxia|
214910104|NCT04815811|OTHER|Stool collection|Fecal sample collection to delineate microbiome contribution, we will study the gut microbiota in faecal samples obtained from the recruited patients.
214910105|NCT04860648|OTHER|lung ultrasound|doctors treat the patients combining the Lus results and clinical practice
214910106|NCT02127840|DRUG|Synacthen infusion during adrenal venous sampling|Adrenal venous sampling during Synacthen infusion
214910107|NCT00275743|PROCEDURE|MRI|
214910108|NCT00570141|DEVICE|OASIS Wound Matrix|OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
214910109|NCT00502385|DRUG|AZD2171|
214910110|NCT06505707|BEHAVIORAL|Health Seeking Behavior Training Based on Motivational Interviewing Techniques|The Effect of Health Seeking Behavior Training Based on Motivational Interviewing Techniques on Health Seeking Behavior, Illness Self-Management and Anxiety in Migrant Elderly Women with Chronic Diseases.
215058277|NCT02366923|DEVICE|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
215058278|NCT02366923|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
215058279|NCT06554119|PROCEDURE|Huanlei Huang|tricuspid valve replacement or plasty
215058280|NCT00298298|BIOLOGICAL|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
215058281|NCT04861272|BEHAVIORAL|Survey|Online survey
215058282|NCT06373900|PROCEDURE|wound closure|Group A wound will be closed with Polypropylene and Group B wound will be closed with Polyglactin 910 suture. both wound closure followed for healing, infection and scar formation till 30th post operative day.
215058283|NCT01759342|BEHAVIORAL|Aerobic exercise|
215058284|NCT01759342|BEHAVIORAL|Resistance exercise|
215058285|NCT01759342|BEHAVIORAL|Flexibility and postural exercise|
215058286|NCT01759342|BEHAVIORAL|Balance exercise|
214910111|NCT04547985|DRUG|Naltrexone HCl 50 MG Oral Tablet|Generic, oral tablet.
214670158|NCT02927223|DRUG|Atropine|
214303607|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
214303608|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
214670159|NCT02927223|PROCEDURE|Exercise treadmill test|
214670160|NCT02625519|DRUG|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
214670161|NCT02625519|DRUG|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
215058287|NCT03902392|DIETARY_SUPPLEMENT|NaturOx Group (A)|Comparison between dietary supplement and placebo
214670162|NCT01348919|DRUG|CEP-18770|CEP-18770 will be administered per dose and schedule specified in the arm description.
215058288|NCT03902392|OTHER|Placebo Group (B)|Comparison between dietary supplement and placebo
215058289|NCT03343678|DRUG|Venetoclax|Venetoclax given alone and then in combination with BI 836826
215058290|NCT03343678|DRUG|BI 836826|Venetoclax given in combination with BI 836826
215058291|NCT06192290|BEHAVIORAL|Home-based transitional Cardiac Telerehabilitation|This comprehensive series is divided into 16 parts, each addressing crucial aspects of open-heart surgery recovery. Part 1 introduces open-heart surgery, heart disease symptoms, and preoperative preparations for elderly patients. Part 2 delves into cardiac rehabilitation, defining objectives and detailing recovery stages. Part 3 covers care for surgical incisions and infection signs. Part 4 explores sleep and rest, while Part 5 guides patients on a healthy post-surgery diet. Part 6 focuses on nursing interventions for dyspnea, and Part 7 addresses post-surgery cough. Part 8 discusses nursing interventions for thrombosis prevention
214670163|NCT01348919|DRUG|Lenalidomide|Lenalidomide will be administered per dose and schedule specified in the arm description.
214670164|NCT01348919|DRUG|Dexamethasone|Dexamethasone will be administered per dose and schedule specified in the arm description.
214670165|NCT06302634|OTHER|Exercise-based cardio-oncology rehabilitation|Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.
214670166|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
214910112|NCT04547985|DRUG|Placebo|Composed of filler material and encapsulated to appear identical to naltrexone.
215058292|NCT01460706|DRUG|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
215058293|NCT04297150|DRUG|Apixaban|Drug indicated for the treatment of NVAF
215058294|NCT04297150|DRUG|Edoxaban|Drug indicated for the treatment of NVAF
215058295|NCT04297150|DRUG|Rivaroxaban|Drug indicated for the treatment of NVAF
214910113|NCT01616238|DRUG|Chemotherapy|Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
214910114|NCT00019929|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
214910115|NCT00019929|PROCEDURE|adjuvant therapy|
215058296|NCT04297150|DRUG|Dabigatran|Drug indicated for the treatment of NVAF
215058297|NCT06421480|OTHER|Detecting Risky Behaviors and Providing a Safe Environment in Patients Receiving Inpatient Treatment in a Psychiatric Clinic Using Machine Learning Model|Using machine learning, the computer will be trained to detect suicide and violent behavior. Cameras will be placed in patient rooms. These cameras will transfer the image to the computer. The computer will process these images and detect suicidal and violent behavior early. A warning will appear on the computer screen
214670167|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
214910116|NCT05460819|OTHER|Acupuncture treatment|"Acupoint selection: Hegu-Yinxi acupoint group (clearing heat and relieving sweat), Sanyinjiao-Fuliu acupoint group (nourishing yin and tonifying kidney), Tianshu-uteri acupoint group (special effect points) (12 acupoints on both sides).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
214910117|NCT05460819|OTHER|Sham Acupuncture treatment|"Selecting acupoints: Select the side opening positions of the 6 acupuncture points in the real acupuncture group, and select non-meridian and non-points (points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
214910118|NCT03783819|OTHER|Hypericum perforatum oil|Ointment containing Hypericum perforatum oil
214910119|NCT03783819|OTHER|Placebo|Ointment containing plant oils used in Hypericum perforatum oil production and dye
214910120|NCT03783819|PROCEDURE|SLS induced irritation|60 uL of 1% w/v sodium lauryl sulphate (SLS) will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis. Procedure will be performed to specified skin sites, according to randomization protocol.
214910121|NCT03783819|PROCEDURE|Tape-stripping|Skin barrier disruption will be induced by tape-stripping. Procedure will be performed to specified skin sites, according to randomization protocol.
214910122|NCT03783819|PROCEDURE|UV radiation|UV radiation will be used to induce skin erythema and damage. Procedure will be performed to specified skin sites, according to randomization protocol.
214910123|NCT03783819|PROCEDURE|Intact skin|Healthy, intact skin. Procedure will be performed to specified skin sites, according to randomization protocol.
214910124|NCT02992236|DRUG|VAS203|Infusion of NO-Synthase inhibitor VAS203
214910125|NCT02992236|DRUG|Saline|Infusion of saline
214910126|NCT06578533|DRUG|Sodium Zirconium Cyclosilicate|"The recommended starting dose of Lokelma is 10 g, administered three times a day.~If, at any time during the study, sK is \> 6.5 mEq/L, treatment for acute hyperkalemia will be started following common clinical practice and local protocols, and investigator will consider RAASi / MRA withdrawal, or downtitration. In this case (confirmed sK \> 6.5 mEq/L despite the maximum SZC dose) patient will leave the IP and will be counted as a treatment failure.~If sK is ≤ 3.0 mEq/L, discontinue SZC. The subject should immediately receive appropriate medical intervention.~If sK is between 3.1-5.1 mEq/L, pause SZC and re-evaluate in a week. This one-week SCZ treatment temporary discontinuation can only be applied once; if a new sK value between 3.1-5.1 mEq/L is detected, patient will leave the IP permanently.~Depending on the serum potassium levels at each visit, the dose of SZC will be adjusted."
214910127|NCT03469856|DRUG|Prasugrel monotherapy|A multicenter, single arm, open-label trial of in patients with chronic stable angina
214910128|NCT04358185|DRUG|Itacitinib (INCB039110)|Novel and small molecule selective inhibitor of JAK1
214910129|NCT06574113|DEVICE|Perin Health Patch|The Perin Health Patch (PHP)is a multimodal wearable health patch, which combines auscultation, electrocardiography (ECG), pulse oximetry via photoplethysmography (PPG), bioimpedance (BioZ), skin temperature, and motion and tilt sensors. The PHP integrates multiwavelength PPG (MWPPG) with blue, green, red, and IR LEDs, allowing for precise calculation of PTT, PWV, and related unique parameters, that are used for the calculation of cuffless blood pressure.
214910130|NCT06240169|PROCEDURE|DPC with MTA in AGEI|DPC using MTA in 18-40 years
214910131|NCT06240169|PROCEDURE|DPC with BD in AGEI|DPC using BD in 18-40 years
214910132|NCT06240169|PROCEDURE|DPC with MTA in AGEII|DPC using MTA in 41-60Years
214910133|NCT06240169|PROCEDURE|DPC with BD in AGEII|DPC using BD in 41-60Years
214910134|NCT02946372|PROCEDURE|internal limiting membrane transplantation (ILMT)|internal limiting membrane autologous transplantation (ILMT)
214910135|NCT03446027|DEVICE|NMES|NMES device to be used for up to 3 hours daily in 30 minute sessions for 3 months.
214910136|NCT05939960|DIAGNOSTIC_TEST|CGT test|GCT、PRP-CT、PPP-CT monitor
214910137|NCT05687396|DEVICE|virtual reality|virtual reality designed as cycling in the forest
214910138|NCT05687396|OTHER|conventional pulmonary rehabilitation|pulmonary rehabilitation
214910139|NCT03097341|DRUG|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
214910140|NCT03097341|DRUG|xisomab 3G3-Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
214910141|NCT03097341|DRUG|xisomab 3G3-Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
214670168|NCT02114203|DRUG|placebo for PDE9i|oral dose, every 12 hours for 28 days
214910142|NCT03097341|DRUG|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
214910143|NCT03097341|OTHER|Placebo|Participants will receive a single intravenous dose of placebo.
214910144|NCT03284814|DIETARY_SUPPLEMENT|Single dose intervention with Standard product (SP)|hard capsules, 100 mg
214910145|NCT03284814|DIETARY_SUPPLEMENT|Single dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg
214910146|NCT03284814|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP)|syrup, 100 mg
214910147|NCT03284814|DIETARY_SUPPLEMENT|Multiple dose intervention with Standard product (SP)|hard capsules, 100 mg - 14 days
215058298|NCT05227495|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
215058299|NCT05227495|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
215058300|NCT00843258|DEVICE|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
214910148|NCT03284814|DIETARY_SUPPLEMENT|Multiple dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg - 14 days
214910149|NCT03284814|DIETARY_SUPPLEMENT|Multiple dose intervention with Investigational product (IP)|syrup, 100 mg - 14 days
214910150|NCT01209949|DRUG|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|Apply adapalene BPO gel once daily in the evening for 12 weeks
214910151|NCT03683225|COMBINATION_PRODUCT|CTC-413|pramipexole ER, given with aprepitant
214910152|NCT01067781|BIOLOGICAL|Heat-Labile Enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
214910153|NCT01067781|BIOLOGICAL|Placebo|Travelers' Diarrhea Vaccine System
214910154|NCT01798810|PROCEDURE|Supplemental Perioperative Oxygen|Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
214910155|NCT05736016|DEVICE|medial wedge insoles ((corrective insoles are equipped with hard 10-degree medial wedge, while sham insoles are equipped with pliable 10-degree medial wedge)|All study participants will be instructed to use insoles for exercising, walking, and other everyday activities.
214910156|NCT06685003|BEHAVIORAL|Digital Tutorial overview|Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 7 weeks and revisited over 6 months.
214910157|NCT06685003|BEHAVIORAL|Digital Tutorial plus training Materials|Self study of a digital tutorial covering an overview of CRAFT and deeper materials designed to be reviewed within 7 weeks and revisited over 6 months.
214910158|NCT06685003|BEHAVIORAL|Digital Tutorial plus training Materials plus feedback and Coaching|Self study of a digital tutorial covering an overview of CRAFT and deeper materials designed to be reviewed within 7 weeks and revisited over 6 months. Plus group coaching and feedback on audio recordings of CRAFT procedures used in sessions
214910159|NCT04428697|PROCEDURE|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .
214910160|NCT00729612|DRUG|carboplatin|
214910161|NCT00729612|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
215058301|NCT00442533|DRUG|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
215058302|NCT00293930|DRUG|Tacrolimus|
214670169|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
214910162|NCT00729612|GENETIC|protein expression analysis|
215058303|NCT03448016|RADIATION|[C-11]|Radiolabel
215058304|NCT03448016|DRUG|NOP-1A|Tracer
215058305|NCT03890523|PROCEDURE|Airway stent implantation|The segmented airway stent modified with 3D printing were implanted to treat gastro-respiratory fistula involving carina and distal bronchi. The stents were removed because of stent-related complications or tracheobronchial healing.
215058306|NCT01437111|DRUG|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
215058307|NCT05689489|OTHER|Puzzle Method|While preparing the puzzle to be used in the study, the puzzle preparation program will be used (Crossword Puzzle Maker). Students in the initiative group will be asked to solve a total of 6 puzzles, one puzzle each week. The answers to the prepared puzzles will cover the theoretical course topics of psychiatric nursing. In the puzzles, students will be expected to place their answers in the specified rows and columns. Students will be asked to solve puzzles individually. In addition, the answer to each puzzle will be found on the reverse on the back page. Students will be reminded that there is no time limit for solving the puzzles. Researchers will guide students while students solve puzzles.
214670170|NCT03054727|OTHER|Villalta phone score > or = to 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \> or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination."
214670171|NCT03054727|OTHER|Villalta phone score < 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires."
214670172|NCT02368444|BEHAVIORAL|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
214910163|NCT00729612|OTHER|immunoenzyme technique|
214910164|NCT00729612|OTHER|immunohistochemistry staining method|
214910165|NCT00729612|OTHER|laboratory biomarker analysis|
214910166|NCT05883072|BEHAVIORAL|Exploring AI-Chatbot|All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
214910167|NCT01125241|DRUG|wuling capsule|orally, three tablets each time,three times a day
214910168|NCT01125241|DRUG|placebo of wuling capsule|orally, three tablets each time and three times a day
214910169|NCT02483039|BEHAVIORAL|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.
214910170|NCT00801385|DRUG|erlotinib hydrochloride|
214910171|NCT00801385|DRUG|sorafenib tosylate|
214910172|NCT00801385|GENETIC|DNA analysis|
214910173|NCT00801385|GENETIC|mutation analysis|
214910174|NCT00801385|GENETIC|polymerase chain reaction|
214910175|NCT00801385|GENETIC|protein analysis|
214910176|NCT00801385|GENETIC|protein expression analysis|
214910177|NCT00801385|OTHER|immunohistochemistry staining method|
215058308|NCT05689489|OTHER|Ongoing Education|Students in the control group will only take the theoretical course of psychiatric nursing.
214910178|NCT00801385|OTHER|laboratory biomarker analysis|
214910179|NCT01414582|DEVICE|Anodal tDCS|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
214910180|NCT01414582|OTHER|Motor Training|All participants will receive a standardised motor training intervention for the upper paretic limb
215058309|NCT03107858|DRUG|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
214303609|NCT04232072|OTHER|Group ESPB|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
214910181|NCT00003909|DRUG|motexafin gadolinium|Given IV
214910182|NCT00003909|RADIATION|radiation therapy|Undergo radiation therapy
214910183|NCT00003909|OTHER|pharmacological study|Correlatives studies
214910184|NCT00006339|DRUG|Indinavir sulfate|
214910185|NCT00006339|DRUG|Ritonavir|
214910186|NCT00006339|DRUG|Hydroxyurea|
215058310|NCT03107858|DRUG|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
215058311|NCT00187538|BEHAVIORAL|Dietary|dietary
215058312|NCT05116956|OTHER|non interventional|Multinational prospective, standard care data collection, non-interventional, study not involving human subjects
214910187|NCT00006339|DRUG|Stavudine|
214910188|NCT00006339|DRUG|Didanosine|
214910189|NCT06159166|DRUG|Mirdametinib|This study is designed to assess Mirdametinib safety and efficacy in two phases: phase 1 tests the safety of up to four dose regimens of Mirdametinib, administered continuously or intermittently (3 weeks on/1 week off) to identify up to two recommended phase 2 doses. Phase 2a of the study will test the safety and efficacy of the recommended phase 2 dose(s) in adults with NF1 and cNF. The following dosing strategy will be assessed in participants ≥ 18 years old with NF1 and a minimum of 12 measurable cNF who desire systemic treatment of their cNF due to disfigurement, pain or itching. Each treatment cycle in this study is 28 days.treatment cycle in this study is 28 days.
214910190|NCT03912064|DRUG|Ipilimumab|Ipilimumab is an antibody that acts against CTLA-4
214910191|NCT03912064|BIOLOGICAL|CD25hi Treg depleted DLI|Donor lymphocyte product
214910192|NCT04556305|BEHAVIORAL|Mind|See arm description.
214910193|NCT04556305|BEHAVIORAL|Move|See arm description.
214910194|NCT03606785|DRUG|Tranexamic Acid Injection|The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision
214910195|NCT03606785|DRUG|placebo injection|patients will receive a placebo of 100 mL 0.9% normal saline
214910196|NCT00632060|PROCEDURE|Manual / Manipulative Therapy (M/MT)|Subjects will receive M/MT twice a week for 4 weeks
214910197|NCT05353465|PROCEDURE|Radiofrequency denervation of the cervical facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the cervical facet joint with a three-tined expandable needle.
214910198|NCT00392366|DEVICE|MR-guided Laser Interstitial Thermal Therapy System|
214910199|NCT01646372|OTHER|Standard Simulation Based ACLS Refresher Teaching|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
214910200|NCT01646372|OTHER|Cognitive Aid based ACLS Refresher training|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
214910201|NCT01595880|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day
214910202|NCT01595880|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
214910203|NCT03125967|OTHER|Philips GoLite Blu HF3429/60|Exposure to daily morning colored light in the 440-485 nm wavelength range
214910204|NCT03125967|OTHER|Philips LivingColor Aura 70998/60/48|Exposure to daily morning colored light in the 625-740 nm wavelength range
214910205|NCT02323412|DRUG|Amoxicillin (Amoksicillintrihydrat)|Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
214910206|NCT02323412|DRUG|Placebo|Placebo tablets 1x3 for 100 days (oral intake).
214910207|NCT04903119|DRUG|Nilotinib 100mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
214910208|NCT04903119|DRUG|Nilotinib 200mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
214910209|NCT04903119|DRUG|Nilotinib 300mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 300mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
214910210|NCT04903119|DRUG|Nilotinib 400mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 400mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
214910211|NCT04903119|DRUG|Dabrafenib|All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.
214910212|NCT04903119|DRUG|Trametinib|All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.
214910213|NCT04903119|DRUG|Encorafenib|encorafenib will be administered orally 450mg once daily for 28 consecutive days
214910214|NCT04903119|DRUG|Binimetinib|binimetinib will be administered orally 45mg twice daily for 28 consecutive days
214910215|NCT03808948|DEVICE|VFI|The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
215058313|NCT06426875|DIAGNOSTIC_TEST|Isometric Exercises|Isometric External Rotation (Perform isometric external rotation exercises with a resistance band to strengthen the rotator cuff.) Hold each contraction for 10-15 seconds. Isometric Internal Rotation (Hold each contraction for 10-15 seconds) Isometric Abduction (Supraspinatus). ( each contraction for 10 -15 sec) 10 repetition 3 sets Isometric Adduction (Subscapularis) Overhead Isometric Holds (Hold each contraction for 15-20 seconds) Isometric Shoulder External Rotation Against Resistance: (Hold each contraction for 15-20 seconds) Isometric Shoulder Press (Hold each contraction for 15-20 seconds) 15 to 20 repetitions 4 sets Total duration of 30 to 35 minute session three sessions per week total four weeks of intervention, reading will be taken on baseline and after 2nd week and 4th week
214910216|NCT04704310|BEHAVIORAL|Enhancing exercise training for adults with COPD: The roles of peers and functional tasks|A proof-of-concept online 8-week exercise training program for adults with COPD that incorporates both a peer mentorship and a functional tasks component.
214910217|NCT03971032|PROCEDURE|Hysteroscopy|Diagnostic procedure
214910218|NCT03971032|DEVICE|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of malignancy
214910219|NCT01387087|DRUG|ASP015K|oral
214910220|NCT01387087|DRUG|Placebo|oral
214910221|NCT01918488|DIETARY_SUPPLEMENT|Standardized salt diet|200 mmol NaCl per day given as three meals daily for 4 consecutive days.
214910222|NCT01918488|DRUG|Amiloride|Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
214910223|NCT02158156|BEHAVIORAL|Exercise|Ten weeks of home-training on a cycle ergometer 3 times a week for 30 minutes.
214910224|NCT04092556|DEVICE|transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
214910225|NCT00000807|DRUG|Etoposide|
214910226|NCT03207815|DRUG|Filgotinib|Tablet(s) administered orally
214910227|NCT03207815|DRUG|Placebo to match filgotinib|Tablet(s) administered orally
214910228|NCT03207815|DRUG|Prednisone|Tablet(s) administered orally
214910229|NCT02444208|BEHAVIORAL|Active Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of cocaine cues.
214910230|NCT02444208|BEHAVIORAL|Neutral Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of neutral cues.
214910231|NCT00391768|DRUG|oseltamivir (Tamiflu®)|Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
214910232|NCT05846100|PROCEDURE|Preprocedural spinal ultrasound|a preprocedural spinal ultrasound was performed in a non sterile manner with a sitting position.Both paramedian and transverse planes The intersection of the longitudinal and transverse lines is the point of needle insertion The distance from the skin to the dura mater is noted
214910233|NCT05846100|PROCEDURE|fictional preprocedure spinal ultrasound|fictional preprocedure spinal ultrasound Fictional ultrasound identification Screen device shut down
214910234|NCT00172198|DRUG|Omegaven 10%|
214910235|NCT03827681|PROCEDURE|Trans Intrahepatic Portosystemic Shunt|"* The most common approach is through the right internal jugular approach.~* After infiltrating the puncture site with 2% lignocaine and puncturing the vein a guide wire is advanced into the IVC followed by a 9F/10F vascular sheath.~* A wedged venogram is performed with a peripherally placed hepatic vein catheter, which may identify a portion of the portal vein to facilitate subsequent puncture.'~* A stiff guide wire is then passed through the catheter and the vascular sheath is advanced into the right hepatic vein. With the vascular sheath in place a rigid needle with 15-20 degrees of distal angulation is advanced over the guide wire and through the vascular sheath to enter the hepatic vein."
214910236|NCT03827681|PROCEDURE|Self Expanding Metallic Stent|"* At upper endoscopy, a 0.35 Superstiff radiological guidewire with a soft tip (supplied with the stent insertion kit) is delivered into the stomach under direct vision and the endoscope is removed.~* The stent delivery device is then advanced over the guidewire into the stomach, and the distal portion of the stent delivery system is withdrawn to allow inflation of the gastric balloon.~* The gastric balloon is then inflated with 100 mL of air, and the whole delivery system is withdrawn until resistance is felt, which signifies that the balloon is impacting at the cardia, thus anchoring the distal end of the stent during deployment.~* After stent deployment, the gastric balloon is deflated and the stent delivery system is withdrawn. The stent is then examined endoscopically. When deployed, the stent is 135 mm long and 25 mm wide."
214910237|NCT03827681|DRUG|Vasoactive Agent|Vasoactive Agent
214910238|NCT00406367|DRUG|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection"
214910239|NCT00406367|DRUG|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
214910240|NCT04022057|DRUG|Ropivacaine injection|Local anesthetic injection
214910241|NCT04022057|DRUG|Dextrose 5|Sham Injection
214910242|NCT05598112|BIOLOGICAL|FMT capsules|FMT capsules containing extensively screened donor stool.
214910243|NCT05598112|OTHER|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug.
214910244|NCT05338840|OTHER|MULLIGAN ROTATIONAL MOVEMENT|12 sessions over 6 weeks
214910245|NCT05338840|OTHER|Medial gapping technique|12 sessions over 6 weeks
214910246|NCT06256601|DEVICE|Theracal (calcium silicate)|selective removal to soft dentin, restorations with calcium silicate
214910247|NCT06256601|DEVICE|Dycal (calcium hydroxide)|selective removal to soft dentin, restoration with calcium hydroxide
214910248|NCT01540201|OTHER|Conventional I:E ratio|conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
214910249|NCT01540201|OTHER|I:E = 1:1 ratio|I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
214910250|NCT00261586|DRUG|aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib|
214303610|NCT04232072|OTHER|Group Ibuprofen|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period. In Group Ibuprofen, patients will be administered ibuprofen 800 mgr IV every 8 hours in the postoperative period.
214303611|NCT01387347|DRUG|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
214910251|NCT06204263|OTHER|finger feeding|The fathers of premature babies in intensive care will be interviewed and an educational booklet will be prepared about finger feeding, cleaning, hygiene, hand washing, the importance of sucking, and the rules to be followed to prevent infection in the newborn, and how to apply it will be explained by the researcher. Babies will be breastfed three times a day for seven days.
214910252|NCT01286610|DEVICE|ProMedVi Vibrosphere|vibration therapy
214910253|NCT01286610|DEVICE|schwa-medico MUSKELaktiv|Electrical muscle stimulation
214910254|NCT01286610|DEVICE|Galileo Home Plus (ICU)|vibration therapy
214910255|NCT00171210|DRUG|Deferasirox|Tablets taken orally once a day.
214910256|NCT05917535|BEHAVIORAL|Mentalizing course|6 hour mental health education course about mentalizing.
214910257|NCT00253435|BIOLOGICAL|Filgrastim|Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0. The first dose should begin four hours after the stem cell infusion is completed. Filgrastim will continue daily until the ANC \>=1500/uL for three consecutive days.
214910258|NCT00253435|DRUG|Carboplatin|"The carboplatin will be administered as a continuous IV infusion Day - 7 through Day - 4, with dosing based upon pretreatment GFR levels. The carboplatin should be diluted to a concentration of 0.3 mg/ml in D5W 0.45NS and infused concomitantly with etoposide through the same central venous catheter using a Y connector; a controlled rate infusion pump is used for each arm of the Y."
215058314|NCT01979718|DEVICE|Mirrored Virtual reality|Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
215058315|NCT02795299|DRUG|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
215058316|NCT02795299|DRUG|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
215058317|NCT02795299|DRUG|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
215058318|NCT02795299|DRUG|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
215058319|NCT01219101|DRUG|clomiphene citrate with ethinyl esteradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
215058320|NCT01219101|DRUG|clomiphene citrate with plasebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
215058321|NCT01027962|OTHER|ICBT Program|Intensive Computerized Brain Training.
215058322|NCT00310336|DRUG|S-adenosyl-L-methionine|
215058323|NCT00310336|DRUG|betaine|
215058324|NCT00310336|DRUG|pegylated interferon alpha2b|
214910259|NCT00253435|DRUG|Etoposide|The etoposide shall be administered day -7 through day -4 via continuous intravenous infusion over 96 hours. For patients with a corrected GFR \>= 100 ml/min/1.72 m\^2, a dose of 300 mg/m\^2/day (10 mg/kg/day if child is \< 12 kg) shall be given. For patients with a corrected GFR 60-99 ml/min/1.72 m\^2, the etoposide will be administered at a dose of 160 mg/m\^2/day (5.3 mg/kg/day). The etoposide will be diluted in D5W 0.45%NS at a concentration of \< 0.4 mg/ml. Etoposide should not be mixed with carboplatin, but administered using a Y-connector.
214910260|NCT00253435|DRUG|Melphalan|For patients in either the normal GFR strata (\>=100 ml/min/1.73 m\^2), or reduced GFR strata (60-99 ml/min/1.73m\^2), melphalan shall be administered at a dose of 60 mg/m\^2/day (2 mg/kg/day if child is \< 12 kg) on day -7, -6, and -5 of study. The melphalan should be infused at a rate of less than 10 mg/minute, and should complete within 1 hour of reconstitution each day. The melphalan should be diluted in 0.9% NaCl at a concentration \< 2 mg/ml. The total dosage of melphalan to be administered will be 180 mg/m\^2.
214910261|NCT00253435|PROCEDURE|Peripheral blood stem cell infusion|Stem cells or marrow will be infused on day 0 of study therapy. Where the DMSO concentration in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over two days to meet this standard. For purged PBSC: A minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. For unpurged PBSC, a minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. Having a back-up of 2.0 x 10\^6 viable CD34+ cells/kg purged or unpurged PBSC is recommended but not required. For purged bone marrow, a minimum of 1.5 x10\^8 mononuclear cells/kg must be available.
215058325|NCT00310336|DRUG|ribavirin|
215058326|NCT06005558|DRUG|Normal saline|100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
215058327|NCT06005558|DRUG|Methylene Blue low dose|A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
215058328|NCT06005558|DRUG|Methylene Blue high dose|A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
214303612|NCT01387347|DRUG|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
214303613|NCT01096121|DRUG|Enalapril|"* during 1 month : 0,2 mg/kg/day~* then during 2 months (if no adverse event): 0,35 mg/kg/day~* and then during 6 months (if no adverse event): 0,5 mg/kg/day"
214303614|NCT01096121|DRUG|Placebo|Glucose
215058329|NCT01559337|PROCEDURE|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
215058330|NCT04732923|OTHER|Assigned intervention - procedure|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks 6 minute walk test, questionnaires~STEP 2 : monitoring at 6 months after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires~STEP 3 : monitoring at one year after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires"
215058331|NCT00183144|BEHAVIORAL|Contingency management|
215058332|NCT02977429|OTHER|standardized fluid therapy|The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.
214303615|NCT02658357|DRUG|Risperidone Implant|
214303616|NCT01518010|BEHAVIORAL|Play game|Participants engage in non-game activity (establish baseline) 7 \* 1 hr weekly; play single-player game 7 \* 1 hr weekly; play multi-player game 7 \* 1 hr weekly.
214346940|NCT02357836|DRUG|Itraconazole|"Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure."
215058333|NCT02977429|OTHER|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
215058334|NCT00996957|BIOLOGICAL|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
215058335|NCT03857932|PROCEDURE|Participants receive SLNB as well as non SLNs resection|Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
215058336|NCT01018017|DRUG|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
215058337|NCT01018017|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
215058338|NCT01689987|DRUG|Cyclophosphamide|Given IV
215058339|NCT01689987|DRUG|Dexamethasone|Given PO
214910262|NCT00253435|RADIATION|131I-MIBG|Therapeutic 131I MIBG will be synthesized by Draximage Canada.with specific activity between 15 and 25mCi/ml. Radiopurity will be initially determined by Draximage, prior to shipment to participating centers. Free radioiodide content must then be rechecked at the treating center prior to infusion using HPLC or Sep-Pac methodology.
214910263|NCT00253435|RADIATION|Radiation therapy|Local irradiation is to be given to previously non-irradiated primary and metastatic sites of disease. Local irradiation should not start till the patient is medically stable, has an ANC \> 1000/uL, platelets \> 30,000 / uL, and is \> 42 days post transplant. Recommended radiation guidelines consist of 2160 cGy total, given over 12 days using a single 180 cGy fraction/day. Any delay in local radiation that would extend treatment beyond day +84 should be discussed with the study chair. Local radiation will be administered at a participating NANT member site.
214910264|NCT03910036|BIOLOGICAL|platelet rich plasma|Thirty ml of venous blood was taken from every patient and collected in sodium citrated sterile tubes. Platelet concentrates obtained by adjusting centrifuge at 1800 rpm for 15 min to separate erythrocytes, then at 3500 rpm for 10 min to concentrate the platelets. The preparation was done by a single laboratory technician. Thus 5 ml of PRP were obtained, 0.2 mL of 10% calcium chloride was added to the final product to activate the platelets and injected immediately without storage.
215058340|NCT01689987|DRUG|Hydroxychloroquine|Given PO
215058341|NCT01689987|OTHER|Laboratory Biomarker Analysis|Correlative studies
215058342|NCT01689987|OTHER|Pharmacological Study|Correlative studies
214303617|NCT06478537|DRUG|Hetrombopag Olamine|"Treatment period: 24-week Hetrombopag (2.5mg/d\~7.5mg/d) treatment.~* Two consecutive visits with PLT\>600 × 10\^9/L: daily dose reduction of 2.5mg; If the lowest dose has been used, extend the dosing interval.~* Two consecutive visits with PLT\<300 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached.~* Two consecutive visits with PLT\<50 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached; If PLT is still\<50 × 10\^9/L with7.5mg/d × 28d, the patient will be withdrawn.~Drug discontinuation period：8-week Hetrombopag (2.5mg/d\~7.5mg/d) reduction. Hetrombopag reduces by 2.5mg every 2 weeks, and after reducing to the minimum dose of 2.5mg/d x 2 weeks, it is changed to 2.5mg once every other day (Qod) treatment, with a maximum reduction time of 8 weeks. If the PLT during two consecutive visits is less than 30 × 10\^9/L, the patient will be withdrawn."
214303618|NCT06478537|DRUG|Aspirin|Aspirin 100mg, qd
214303619|NCT03437720|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
214303620|NCT03437720|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
214303621|NCT01973907|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
214303622|NCT04599894|DRUG|37.5mg Pregabalin + 75mg Pregabalin|37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively
214910265|NCT03632928|OTHER|Ultrasound Elastography|Measuring muscle hardness at the trapezius and neck bilateral
214910266|NCT03632928|OTHER|Pressure Pain threshold|Measuring Pressure pain threshold at the trapezius and neck bilateral
214910267|NCT04087993|DRUG|Polyglucoferron|intravenous administration
214910268|NCT04087993|DRUG|Ferric carboxymaltose|intravenous administration
215058343|NCT01689987|DRUG|Sirolimus|Given PO
215058344|NCT04492241|DRUG|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.
215058345|NCT04492241|DRUG|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
215058346|NCT02019615|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
215058347|NCT01469936|DIETARY_SUPPLEMENT|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~* First Week of intervention : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
215058348|NCT01469936|DIETARY_SUPPLEMENT|PLACEBO|"Duration : 5 weeks +/- 1 week.~Dosage:~* First Week : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
215058349|NCT00577707|DRUG|erlotinib|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
215058350|NCT00577707|DRUG|Pemetrexed|pemetrexed 500 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
215058351|NCT00577707|DRUG|Cisplatin|cisplatin 75 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
215058352|NCT00577707|PROCEDURE|Resection|
215058353|NCT00331656|DEVICE|Non-invasive positive pressure mask ventilators|
215058354|NCT00331656|DEVICE|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
215058355|NCT06552832|OTHER|CAVEAT|Brief manualized parent-child psychotherapy
215058356|NCT02452216|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
214303623|NCT04599894|DRUG|75mg Pregabalin|75mg pregabalin postoperatively
214303624|NCT05302544|OTHER|Mixed Reality training|Mixed Reality training: Mixed Reality game with appearance of virtual balloons in the game area that the subject must find and pierce with finger
214910269|NCT04087993|DRUG|Ferrous Sulfate|oral administration
214910270|NCT03324568|BEHAVIORAL|Parent Education Videos|Participants will receive educational videos describing behavioral techniques to improve parent and child eating behavior.
214910271|NCT03324568|BEHAVIORAL|Educational Handout|Participants will receive educational handouts describing behavioral techniques to improve parent and child eating behavior.
214910272|NCT03790501|OTHER|No intervention|As an observational study, no intervention will be associated with the study group.
214910273|NCT03187301|DRUG|APL-130277|APL-130277 single dose
214910274|NCT03187301|DRUG|Placebo|Placebo single dose
214910275|NCT03187301|DRUG|Moxifloxacin|moxifloxacin 400mg single dose
214910276|NCT02498704|PROCEDURE|Dry Needling|Trigger point dry needling to hamstring muscle group.
214910277|NCT02498704|OTHER|Sham Needling|Superficial palpation of trigger point, skin is not punctured.
214910278|NCT04610801|DRUG|Nasal Spray|Randomized to placebo and Xlear
214910279|NCT00000122|DRUG|5-Fluorouracil|
214910280|NCT04553939|DRUG|Toripalimab|Toripalimab 3mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
214910281|NCT04553939|DRUG|Gemcitabine|Gemcitabine 800mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
214910282|NCT00133419|DRUG|Vitamin + Zinc + micronutrient mixture|
214910283|NCT00133419|DRUG|Vitamin A|
214910284|NCT00133419|DRUG|Vitamin A + Zinc|
214910285|NCT00304096|BIOLOGICAL|synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine|
214910286|NCT06304987|COMBINATION_PRODUCT|Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor|In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
214910287|NCT06304987|COMBINATION_PRODUCT|Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor|In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
214910288|NCT02790099|DRUG|Bupivacaine|Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.
214910289|NCT02790099|DRUG|Morphine|0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.
214910290|NCT02158585|DRUG|Lamotrigine|Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
214910291|NCT02158585|DRUG|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
214910292|NCT05005507|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks.
214910293|NCT05005507|DRUG|PegIFN-alpha-2a|PegIFN-alpha-2a will be administered subcutaneously once weekly.
214910294|NCT05005507|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
214910295|NCT05005507|DRUG|TAF|TAF film-coated tablet will be administered orally once daily.
214910296|NCT05005507|DRUG|ETV|ETV film-coated tablet will be administered orally once daily.
214910297|NCT05178615|OTHER|preoperative education|Education about knee anatomy, patophysiology, total knee arthroplasty surgery, pain neurophysiology, management of pain, the importance of exercise
214910298|NCT00942578|DRUG|Bevacizumab|15 mg/kg cycle 1 day 1, repeated every 21 days
214910299|NCT00942578|DRUG|Lenalidomide|Once daily days 1-14 of every 21
214910300|NCT00942578|DRUG|Docetaxel|75 mg/m\^2 intravenous (IV) over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle)
214910301|NCT00942578|DRUG|Prednisone|10 mg orally every day
214910302|NCT04276480|DRUG|Piperacillin-tazobactam|"At the time of ventilator-associated pneumonia diagnosis, patients will receive an initial 4g loading dose of piperacillin-tazobactam with a continuous maintenance dose of 16g per day the first day of treatment. The dose of the piperacillin-tazobactam administered the following days will be adjusted to the renal function.~The antimicrobial treatment will be adjusted to the narrower-spectrum agent after the antimicrobial susceptibility determination for a total length of treatment of seven days."
214910303|NCT01072773|DRUG|bortezomib|1.3 mg/m\^2, by IV on days 1, 8 and 15 every 28 days
214910304|NCT01072773|DRUG|cyclophosphamide|300 mg/m\^2, orally, on days 1, 8, 15 \& 22 every 28 days.
214910305|NCT01072773|DRUG|dexamethasone|40 mg, orally, on days 1, 8, 15 \& 22 every 28 days
215058357|NCT02452216|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
215058358|NCT02452216|PROCEDURE|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
215058359|NCT01777464|BIOLOGICAL|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
214910306|NCT05808374|DRUG|HRS-5635|50mg HRS-5635；100mg HRS-5635；200mg HRS-5635；400mg HRS-5635；600mg HRS-5635；800mg HRS-5635
214910307|NCT05808374|DRUG|HRS-5635|100mg HRS-5635，Q4W；200mg HRS-5635 ，Q4W；400mg HRS-5635，Q4W；200mg HRS-5635, Q2W
214910308|NCT05808374|DRUG|HRS-5635|200mg HRS-5635，Q4W
214910309|NCT05808374|DRUG|Placebo|Placebo
214910310|NCT03389074|PROCEDURE|Radiofrequency catheter ablation|minimally-invasive procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias.
215058360|NCT01777464|BIOLOGICAL|sham|sham solution
215058361|NCT03973554|OTHER|pearl powder|natural product, support bone and joint health
214910311|NCT04116840|DRUG|MT1002 for injection|Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
214910312|NCT03977064|BEHAVIORAL|Life style change and weight reduction|Nutritional, behavioural, and exercise counselling to reduce body weight by 10%, normalise blood glucose, lipids, blood pressure, and testosterone level.
214910313|NCT06577129|OTHER|Ladder training|Players exercised three times a week for sixty minutes apiece on a ladder for eight weeks. The drills were divided into three categories: steady state drills, burst drills, and elastic reaction drills. While steady state training focused on agility and endurance, burst drills were more focused on fast foot movement. Elastic response drills targeted the reactive speed components of the lower leg.
214910314|NCT06577129|OTHER|Plyometric training|For eight weeks, the players performed a 60-minute plyometric training program three times a week. A fifteen-minute warm-up, stretching, and jogging session comes after the thirty minutes of plyometric training. The cool-down consists of fifteen minutes of light running and stretching.
214910315|NCT04005430|DRUG|Episcleral Dexamethasone|Sequestered Transscleral, Controlled-Release Dexamethasone
214910316|NCT00925444|DEVICE|FOREseal|a pair of alginate sleeves for linear cutting staplers used in lung surgery
214910317|NCT00925444|DEVICE|Stapling|Stapling alon or associated with sealants
214910318|NCT05468294|DRUG|F16IL2|F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.
214910319|NCT05468294|DRUG|Nivolumab, fixed dose|Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
214910320|NCT04062929|BEHAVIORAL|4-day physical activity program with behavioral intervention|Each program included 8-12 patients. During the four days, the participants had 4 collective sessions of educational information on PA and heart disease and 2 one-to-one sessions for promoting personal advice and experience on PA behavior. The participants had 6 sessions of PA and 2 food-counseling sessions.
214910321|NCT04114929|OTHER|Threshold-based Training|Specific ventilatory markers determined from a cardiopulmonary test and the correlating heart rate will be used to determine exercise intensity
214910322|NCT04114929|OTHER|Standard Care|Using the standard care cardiac rehabilitation guidelines exercise will be based on estimated heart rate maximum followed by the karvonan method to calculate 40-70% heart rate reserve
214910323|NCT04129489|DRUG|Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally
214910324|NCT02770794|DRUG|Infliximab|Discontinue infliximab; receive Infliximab when relapse
214910325|NCT05429801|OTHER|Ozone therapy|Rectal ozone treatment along with standard medical treatment was administered to the patients, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks. First week: 25 mg/l, 100 ml; second week: 30 mg/l, 150 ml; third week: 35 mg/l, 200 ml; fourth week: 40 mg/l, 200 ml rectal ozone treatment was applied.
214910326|NCT04600765|DIAGNOSTIC_TEST|hsCRP serum measurement of inflammation|hsCRP inflammation change as result of non-contaminated diet
214910327|NCT02848144|OTHER|blood samples|
214910328|NCT02848144|OTHER|Collection of nosocomial infections|
214910329|NCT04943146|DRUG|Prednisone 10 MG+aspirin 100MG|Discontinue medication based on early pregnancy outcome
214910330|NCT06019546|OTHER|PEQUOD|During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
214910331|NCT03489668|DRUG|MetFORMIN 500 Mg Oral Tablet|metformin administration 1500mg per day
214910332|NCT01703572|DRUG|OMP-52M51|
215058362|NCT03973554|DRUG|CPP-ACP|Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
214910333|NCT00169572|DRUG|Aprepitant|
214910334|NCT00169572|DRUG|Ondansetron|
214910335|NCT00169572|DRUG|GW679769|
214910336|NCT00169572|DRUG|Dexamethasone|
214910337|NCT04630002|DRUG|GSK3640254|GSK3640254 will be available as oral tablets.
214910338|NCT04630002|DRUG|Darunavir/Ritonavir (DRV/RTV)|DRV/RTV will be available as oral tablets.
214303625|NCT05302544|OTHER|motor activities|motor activities usually performed
214303626|NCT01721642|DEVICE|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
214303627|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
214910339|NCT04630002|DRUG|Etravirine (ETR)|ETR will be available as oral tablets.
214910340|NCT01223118|PROCEDURE|Vitrification and PGD|Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination. All embryos will undergo biopsy for PGD prior to transfer.
214910341|NCT04873921|OTHER|sterile kinesio taping|Application area will be cleaned and dried prior to application to increase the adhesiveness of the tape and application will be done by an experienced physiotherapist during ACLR surgery.
214910342|NCT03872206|BIOLOGICAL|HPN536 Fixed IV 6 to 560 ng/kg|Fixed dose IV cohorts at doses from 6 to 560 ng/kg
214910343|NCT03872206|BIOLOGICAL|HPN536 1 Prime Step IV 600-1200 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (200/600 ng/kg, 200/1200 ng/kg, and 500/900 ng/kg)
214910344|NCT03872206|BIOLOGICAL|2 Prime Step IV 900-14000 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (200/600/900 ng/kg and 200/600/1200 ng/kg; 500/900/1200 ng/kg, 500/900/1800 ng/kg, 500/900/3600 ng/kg, 500/900/7200 ng/kg, and 500/900/14400 ng/kg)
214910345|NCT06142500|GENETIC|Analysis of biological samples of saliva from testicular cancer patients and from their first-degree family members|The project aims to collect biological samples of saliva from testicular cancer patients and from their first-degree family members; demographic-clinical variables will be also collected in order to draft a comprehensive panel of genes and gene modifications related to the testicular cancer, combining this survey with a very detailed descprition of this cohort of patient in terms of clinical features and quality of life
215058363|NCT00431444|DRUG|Raloxifene|
215058364|NCT00431444|DRUG|Zoledronic acid|
215058365|NCT00431444|DRUG|Placebo oral pills|
215058366|NCT00431444|DRUG|Placebo intravenous (i.v.) infusion|
215058367|NCT05303506|DIAGNOSTIC_TEST|serum ferritin and AST|observiational study
215058368|NCT03803670|DIAGNOSTIC_TEST|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
214910346|NCT01047059|DRUG|Erlotinib, Bevacizumab|Erlotinib 150mg/d d1-d43 p.o. Bevacizumab 15mg/kg b. w. d1, d22, d43 i.v.
214910347|NCT01047059|DRUG|Fluoro-D-glucose|Tracer for PET imaging
214910348|NCT01047059|DRUG|Fluoro-L-thymidine|FLT-PET tracer for imaging
214910349|NCT01047059|DRUG|Gadolinium-DPTA|Contrast agent for DCE-MRI imaging
214910350|NCT02450149|DRUG|sorafenib|
214910351|NCT01555632|DRUG|atorvastatin calcium|Given PO
214910352|NCT01555632|DRUG|placebo|Given PO
214910353|NCT02762942|DRUG|Misoprostol|Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses
214910354|NCT02762942|DEVICE|Foley catheter|Insertion of a Foley catheter (16French) through the internal os for a maximum of 12 hours
214910355|NCT04644432|DRUG|Medication (A specification is listed under each arm)|Study drugs and dosages are listed in the description of arms.
214910356|NCT04644432|OTHER|Patient reported outcomes measurement|"PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish."
214910357|NCT01984333|BEHAVIORAL|Online cognitive training|Online cognitive training is a web-based video game that offers systematic training of response inhibition capabilities. Participants will be guided to make progress in an individually-tailored fashion to master increasingly difficult game levels.
214910358|NCT04381728|DEVICE|Womed Leaf|Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.
214910359|NCT00736697|DRUG|moxidectin|
214910360|NCT00442897|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
215058369|NCT05494463|DEVICE|Miller blade|After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
215058370|NCT01603043|DRUG|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
214486644|NCT04617587|BEHAVIORAL|Early Intervention|The early intervention (EI) is delivered during the NICU stay. It is a multisensory intervention which consists in three parts: parental training, massage therapy and visual interaction. The EI is first focused on parental training, according to PremieStart Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior through the identification of infant's behavioral states; adopt principles of graded stimulation; sustain infant's attention and respond to infant's cues; optimize interactions and avoid overwhelming infants through facilitation strategies. The program is held in eight main sessions and one additional post-discharge session. In addition, parents are trained and invited to daily promote preterm baby massage therapy and visual interaction (visual fixation/tracking and visual attention).
214910361|NCT00442897|DRUG|Comparator: atorvastatin|atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
214910362|NCT02564653|BEHAVIORAL|Technical Assistance, training and clinical reminders|Technical Assistance, training and clinical reminders (TTC)
214910363|NCT02564653|BEHAVIORAL|TTC+Referral to Community Health Worker|TTC+ referral to a VHW for additional counseling and follow-up
214910364|NCT05184205|DEVICE|Nasal Photodisinfection|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
214910365|NCT05184205|DEVICE|Sham Comparator: Control|Patients who are SARS-CoV-2 positive whose PCR levels are followed but no active intervention will be done. Saline will be used in their nose and the light device will be inserted but not turned on. Patient will be wearing light protecting glasses.
214910366|NCT04498182|DRUG|AR-15512 Ophthalmic Solution|Ophthalmic solution administered via topical ocular instillation in one of two dose concentrations: 0.0014% (lower dose) or 0.003% (higher dose)
214910367|NCT04498182|DRUG|AR-15512 Ophthalmic Solution Vehicle|Ophthalmic solution vehicle administered via topical ocular instillation
214910368|NCT04396262|OTHER|Food-1|HTD-blueberry beverage with white bread.
214910369|NCT04396262|OTHER|Food-2|Sweetened water with white bread as a control.
214910370|NCT01545531|DRUG|Iohexol|Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration \[13\]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
214910371|NCT02592577|BIOLOGICAL|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
214910372|NCT02986022|BEHAVIORAL|Resilience|Self-efficacy, optimism, altruism, goal setting
214910373|NCT02986022|BEHAVIORAL|Information|Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
214910374|NCT05017350|PROCEDURE|radiofrequency ablation|Under the ultrasound guidance, the electrode is inserted into the bleeding focus of the liver and the bleeding focus is ablated.
215058371|NCT01603043|DRUG|Sham injection|Mock injection administered as an empty hub without needle
215058372|NCT05945498|BIOLOGICAL|TB/Flu-05E vaccine|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the TB10.4 and HspX antigens of M. tuberculosis
215058373|NCT05945498|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of placebo buffer solution
214910375|NCT06209723|OTHER|Vegetarian diet|Participants will follow a vegetarian diet during a period of five weeks
214910376|NCT00513981|DRUG|leucovorin calcium|
214910377|NCT00513981|DRUG|methotrexate|
214910378|NCT00513981|OTHER|mass spectrometry|
214910379|NCT00513981|OTHER|pharmacological study|
214910380|NCT01821235|DRUG|Neurontin® (gabapentin) batch A|Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times
214910381|NCT01821235|DRUG|Neurontin® (gabapentin) batch B|Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
214910382|NCT01821235|DRUG|Gabasandoz® (gabapentin) batch A|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times
214910383|NCT01821235|DRUG|Gabasandoz® (gabapentin) batch B|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
214910384|NCT05759741|DRUG|MIYAIRI 588|4 tablets of MIYAIRI 588 were inserted into the distal ileostomy once a week for 6 months
214910385|NCT00636519|BIOLOGICAL|Botulism Antitoxin Bivalent (Equine) Types A and B|One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
214910386|NCT00636519|BIOLOGICAL|Botulism Antitoxin Heptavalent (Equine) Types A-G|One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
214910387|NCT05859919|DRUG|"The drug Rutan 0.1."|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 0.1 100mg. Excipients: potato starch, calcium stearate, lactulose."
214910388|NCT05859919|OTHER|Basic treatment|"Basic treatment without the drug Rutan 0.1."
214910389|NCT02367118|DRUG|Prednisone|
214910390|NCT02367118|DRUG|Placebo|
214910391|NCT00152334|DRUG|Botox|All patients meeting the inclusion criteria will undergo manipulation and casting until hindfoot stall is encountered. Hindfoot stall is defined as forefoot abduction to 60 degrees but persistence of hindfoot equinus. At hindfoot stall, subjects received Botox injections at 10 IU/kg into the gastrosoleus muscle complex. Following injections, subjects were recasted.
214910392|NCT03174535|DRUG|Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.|The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
214910393|NCT05541003|DRUG|NBT-NM108|All patients will consume NBT-NM108 in the form of 2 muffins daily.
214486645|NCT06799052|DEVICE|Transcervical single-balloon catheter|A single-balloon (Foley) catheter will be placed through the cervix and filled to 30cc of water or saline. The balloon will remain in the participant until their procedure, usually 3-4 hours, or earlier if it falls out on its own.
214486646|NCT06799052|DEVICE|Synthetic osmotic dilators|Dilators will be maintained in the cervix between 3-4 hours, during which each dilator rod will swell several times its initial dried diameter.
214910394|NCT05971784|OTHER|Telerehabilitation Group|The group that will receive upper extremity training via telerehabilitation in addition to an exercise program consisting of balance and walking activities
214910395|NCT05971784|OTHER|Control Group|The group that will receive an exercise program consisting of balance and walking activities
214910396|NCT01330823|DIETARY_SUPPLEMENT|L-Carnitine|L-Carnitine, 4g/day, orally (Juice)
214910397|NCT01330823|DIETARY_SUPPLEMENT|Placebo|tartaric acid same dose like L-Carnitine as placebo
214910398|NCT02182843|BIOLOGICAL|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
214910399|NCT05388279|DRUG|JS012|JS012, i.v., q3w
214910400|NCT05388279|COMBINATION_PRODUCT|JS012 combine with chemotherapy|JS012 i.v., q3w combine with chemotherapy
214910401|NCT00390871|DRUG|Fentanyl/Dexmedetomidine|
214910402|NCT00390871|DRUG|Fentanyl/Propofol|
214910403|NCT00390871|DRUG|Fentanyl|
214910404|NCT02375971|DRUG|Ranibizumab|Administered as an intravitreal injection
214910405|NCT02375971|PROCEDURE|Laser therapy|Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
214910406|NCT02667704|DRUG|Bosentan|
214910407|NCT02667704|DRUG|Nintedanib|
214910408|NCT00754104|DRUG|ABT-869|0.25 mg/kg. daily.
214910409|NCT00754104|DRUG|Tarceva|150mg, daily.
214910410|NCT03498430|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)
214910411|NCT01640119|DIETARY_SUPPLEMENT|Bicarbonate|bicarbonate administration
214910412|NCT01534338|BEHAVIORAL|Mindfulness Meditation|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
214910413|NCT01534338|BEHAVIORAL|Sleep Education|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
214910414|NCT01504464|BIOLOGICAL|mesenchymal stem cell|intra articular injection of mesenchymal stem cell
214910415|NCT01504464|BIOLOGICAL|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
214910416|NCT05874128|DEVICE|Prospective evaluation of HeartFocus Device (Software)|The primary objective of the study is to evaluate if exams, performed with the HeartFocus software by novices, are of sufficient quality to analyze visually
214910417|NCT00832455|DRUG|montelukast sodium|Montelukast 4-5 mg for 12 weeks, oral tablet
214910418|NCT03010384|OTHER|Rehabilitation program|
214910419|NCT04181892|PROCEDURE|Coronally advanced flap + connective tissue graft|connective tissue graft covered by a coronally advanced flap with connective tissue graft apical of the cementoenamel junction level
214910420|NCT00937079|OTHER|111In-exendin-4 imaging|90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once
214910421|NCT00963300|PROCEDURE|blood-oxygen-level-dependent functional magnetic resonance imaging|
214910422|NCT00963300|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214910423|NCT00963300|PROCEDURE|magnetic resonance spectroscopic imaging|
214910424|NCT00963300|PROCEDURE|tissue-oxygen-level-dependent functional magnetic resonance imaging|
214910425|NCT02439541|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10\^7)
214303628|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
214303629|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
214303630|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
214910426|NCT03577496|OTHER|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares.
214910427|NCT01396135|DRUG|CP-601,927|Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
214910428|NCT01396135|DRUG|CP-601,927|Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
214910429|NCT01396135|DRUG|CP-601,927|Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
214910430|NCT01396135|DRUG|Placebo|Single dose of placebo given as a matching number of oral tablets
214910431|NCT01396135|DRUG|CP-601,927|Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
214910432|NCT01396135|DRUG|Placebo|Multiple doses of placebo given as a matching number of oral tablets
214910433|NCT03078764|OTHER|Mobile health system|Patients will receive weekly automated IVR telephone calls for 12 weeks to assess their glycemic symptoms, medication adherence, dietary consumption, physical activity, sleep, and foot care. These 5-10 minute calls will follow a standardized Thai language IVR script developed specifically for this study.
214910434|NCT03078764|OTHER|E-mail reports and technical support for mHealth system|Nurses will also receive a technical troubleshooting guide, and have similar access to live telephone technical support. Once their patients' calls begin, nurses will begin receiving weekly e-mail reports summarizing each patients' assessment results, any active self-management problems the patients reported, and suggested strategies for supporting the patient's self-management.
214910435|NCT02275819|OTHER|Exercise|Exercise (walking 3 times a week for 60 minutes) or Inspiratory Muscle Therapy (breathing against an inspiratory resistive load 3 times a week for up to 60 minutes)
214910436|NCT00011141|DRUG|Oral lactobacillus administration|
214910437|NCT01346059|DRUG|Vancomycin|Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
214910438|NCT01346059|DRUG|Saline|Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
214303631|NCT02153112|DRUG|Placebo|Placebo saline solution
214303632|NCT00561080|BIOLOGICAL|Zostavax|
214303633|NCT05775315|OTHER|Action Observation Therapy|"Exercises of AO protocol MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
214910439|NCT00343044|DRUG|Topotecan|Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
214910440|NCT00343044|DRUG|Bevacizumab|bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
214910441|NCT04519268|DIAGNOSTIC_TEST|Adult patients scheduled for an elective general surgical operation.|"The anesthesiologist, who is in charge of preoperative assessment at each hospital unit, will assess patients who are scheduled for elective surgery; and will inform senior anesthesiologists (with a minimum 3 years of experience) \& consultant anesthesiologists, about the patients' data.~Patients data with all requested preoperative investigations \& required preparations, peri-operative course and post-operative outcome will be collected."
214910442|NCT06418022|DEVICE|Trendelenburg positioning VTI|"There are essentially two arms, whereby the patients is being compared to themselves. The intervention arm is the same patient undergoing TP from the baseline supine position to determine the change in VTI after subjecting to TP.~We will be using a Sonosite PX ultrasound system, which is intended for diagnostic ultrasound imaging or fluid flow analysis of the human body and, more specifically, for our echocardiographic measurements of velocity time integral (VTI; surrogate for stroke volume and cardiac output). The Sonosite PX is a general-purpose ultrasound system intended for use by qualified physicians and healthcare professionals, for evaluation by ultrasound imaging or fluid flow analysis of the human body. This is an FDA-cleared (510K# K200964) commercial device legally marketed in the United States that is being used in accordance with labeling."
214910443|NCT04806243|DRUG|Regorafenib Pill&Camrelizumab|Regorafenib，80 mg，QD，Q3w Camrelizumab，200 mg，IV，Q3w
214303634|NCT05775315|OTHER|Action Observation Therapy along with visual feedback|"Exercises of AO protocol in front of a mirror MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
214303635|NCT04460547|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion to COVID-19 infected patients.
214303636|NCT04460547|DRUG|Hydroxychloroquine|Hydroxychloroquine administration to COVID-19 infected patients.
214910444|NCT02508350|DRUG|Daptomycin|Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days
214910445|NCT02508350|OTHER|determination of plasma concentration|A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
214910446|NCT01308021|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days
214910447|NCT01308021|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days
214910448|NCT01308021|BIOLOGICAL|Placebo|Placebo entero-coated capsules
214910449|NCT00230659|OTHER|Blood sample to be taken.|Blood sample to be taken.
214910450|NCT00122837|DRUG|Duloxetine|
214910451|NCT00122837|DRUG|venlafaxine|
214910452|NCT00122837|DRUG|placebo|
214910453|NCT05047211|DRUG|Ferrous sulfate|one tablet 325 milligrams three times a day
214910454|NCT05047211|DRUG|Iron dextran|1000 mg intravenous infusion
214910455|NCT03378674|DRUG|Remifentanil Injectable Product|remifentanil: 0,15 mcg/kg/min
214910456|NCT00561392|DRUG|Rivastigmine 5 and 10 cm^2 patch|
214910457|NCT00771342|DRUG|Nitric Oxide|1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
214910458|NCT00771342|DRUG|Nitrogen|Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
214910459|NCT02276755|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
214910460|NCT02276755|OTHER|Placebo|Placebo group will receive placebo (Tishcon, USA) weekly.
214910461|NCT01575834|DRUG|Romosozumab|Administered by subcutaneous injection once a month (QM)
214910462|NCT01575834|DRUG|Placebo|Administered by subcutaneous injection once a month (QM)
214910463|NCT01575834|DRUG|Denosumab|Administered by subcutaneous injection once every 6 months (Q6M)
214910464|NCT03704025|BEHAVIORAL|Current guidelines rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. All the patients will have a detailed and personalized training diary.
214910465|NCT03704025|BEHAVIORAL|Mobile device guided rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. Study group will have virtual glasses or mobile device to motivate and control exercise training program.
214910466|NCT02254590|PROCEDURE|Irrigation Endoscopic Decompressive Laminotomy|2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
214910467|NCT06575985|OTHER|Heat acclimation and exercise training|10-day intervention consisting of daily 60-min exercise sessions aimed to induce increases in core body temperature, conducted in a climactic chamber set to 35°C and 50% relative humidity.
214910468|NCT06575985|OTHER|Thermo-neutral exercise training group|10-day intervention consisting of daily 60-min exercise sessions conducted in a climactic chamber set to 23°C and 50% relative humidity.
214910469|NCT05730361|BIOLOGICAL|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
214910470|NCT05730361|BIOLOGICAL|ScTIL injection and B lymphocytes adjuvant|B lymphocyte are also isolated from PBMCs. If the percentage of subject's B lymphocyte in total lymphocytes is \> 5%, the autologous B lymphocyte adjuvant will be prepared. If this percentage is ≤ 5%, PBMCs will be collected from haploidentical donor of the subject via apheresis, and B lymphocyte will be isolated for preparation of allogeneic B lymphocyte adjuvant.
214910471|NCT01324986|PROCEDURE|Laparoscopic anti-reflux surgery|
214910472|NCT05175391|OTHER|Meat based protein with added spice; Plant based protein with added spice|Either meat or plant based protein entrees will have herbs and spices added (in addition to salt and pepper in the base recipe) to intensify the flavor profile in order to see if protein consumption is affected.
214303637|NCT04460547|DRUG|DAS181|DAS181 administration to COVID-19 infected patients.
214910473|NCT01905917|OTHER|Tele-rehabilitation|
214910474|NCT02854332|DEVICE|tDCS session|Direct current transcranial magnetic stimulation
214910475|NCT02854332|DEVICE|rTMS session|Repetitive transcranial magnetic stimulation.
214910476|NCT00002691|BIOLOGICAL|filgrastim|
214910477|NCT00002691|DRUG|asparaginase|
214910478|NCT00002691|DRUG|cyclophosphamide|
214910479|NCT00002691|DRUG|cytarabine|
214910480|NCT00002691|DRUG|daunorubicin hydrochloride|
214910481|NCT00002691|DRUG|dexamethasone|
214910482|NCT00002691|DRUG|etoposide|
214910483|NCT00002691|DRUG|leucovorin calcium|
214910484|NCT00002691|DRUG|mesna|
214910485|NCT00002691|DRUG|methotrexate|
214910486|NCT00002691|DRUG|vincristine sulfate|
214303638|NCT04460547|DRUG|Ivermectin|Ivermectin administration to COVID-19 infected patients.
214910487|NCT01548040|DEVICE|Kneehab XP|NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively
214346941|NCT05734482|BIOLOGICAL|Secukinumab|for subcutaneous injection only
214910488|NCT01548040|DEVICE|Quadriceps TENS|on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
214910489|NCT01069510|DRUG|Spironolactone 25mg|Spironolactone 25 mg daily for 12 months
214910490|NCT01069510|OTHER|Placebo|Placebo daily for 12 months
214910491|NCT05791136|RADIATION|Radiotherapy|95% PGTV56-60Gy/28-30 fractions, 2Gy/1 fractions; 95% PTV50.4-54Gy/28-30 fractions, 1.8Gy/1 fractions; 5 days a week; 6 weeks.
214910492|NCT05791136|DRUG|Toripalimab|Toripalimab (200 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision
214910493|NCT03858998|OTHER|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
214910494|NCT03858998|OTHER|Control|Current routine HIV care in Tanzania.
214910495|NCT02430246|DIETARY_SUPPLEMENT|Urex Plus|Probiotic
214910496|NCT02430246|OTHER|Placebo|capsule without active ingredient
214910497|NCT02430246|DIETARY_SUPPLEMENT|Probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14|
214910498|NCT05970523|OTHER|Core Stabilization Exercises|Core stabilization exercises are known as a very effective exercise method based on the motor learning principle, performed with the individual's own body weight to strengthen the muscles, improve balance, posture, trunk muscle endurance and flexibility.Each exercise was performed for 7-8 seconds with 10 repetitions. Progression in the exercises was achieved by increasing the difficulty level of the exercises according to the participant's condition once every two weeks.
214910499|NCT05035290|DEVICE|Negative pressure ventilation|Negative pressure ventilation - cuirass will be applied on the patient´s ches and abdomen immediately after extubation
214910500|NCT04744025|DEVICE|Microfluidics chamber|Unwashed sperm will be placed into the inlet chamber of the microfluidics device. The most motile sperm will swim to the outlet chamber, and these sperms will be used for intracytoplasmic sperm injection (ICSI) into the eggs.
214910501|NCT04744025|OTHER|Density Gradient Centrifugation|Sperm will be washed and centrifuged according to standard protocol, and these washed sperm will be used for ICSI.
214910502|NCT03807427|BEHAVIORAL|READY-Nepal|Regulating Emotions through Adapted Dialectical behavior skills for Youth in Nepal (READY-Nepal) is a brief (10-session), emotion-focused intervention targeting prevention and reduction of trans diagnostic problems related to emotion regulation. The culturally adapted program is divided into 5 modules, and includes both didactic and experiential instruction in skills related to mindfulness, stress tolerance, emotional awareness and regulation, validation of self and others, and mastery of interpersonal relationships.
214910503|NCT04991441|DIETARY_SUPPLEMENT|Controlled Dietary Sodium Restriction|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
214910504|NCT04991441|DIETARY_SUPPLEMENT|Control Diet & Controlled Dietary Sodium Restriction|Participants will follow a Observational Control Diet (CON) diet (Months 1-5) followed by an Controlled Dietary Sodium Restriction (INT) diet (Months 6-7).
214910505|NCT01000155|DRUG|vorinostat|
214910506|NCT03332355|DRUG|PAC-1 Compound|PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1). PAC-1 will be taken in the morning on days 1-21 in each 28 day cycle. Temozolomide 150 mg/m2 dose is given for the 5 days starting at day 8 of cycle 1 in cohorts of 3-6 patients. The combination cohort that reaches MTD will expanded to at least 9 patients, similar to the PAC-1 alone cohort at MTD.
214910507|NCT02254317|DIETARY_SUPPLEMENT|0 mg placebo|Not containing GSE (Placebo)
214910508|NCT02254317|DIETARY_SUPPLEMENT|300 mg GSE|300 mg GSE
214910509|NCT02254317|DIETARY_SUPPLEMENT|600 mg GSE|Containing 600 mg of GSE
214910510|NCT02254317|DIETARY_SUPPLEMENT|900 mg GSE|Containing 900 mg of GSE
214910511|NCT03303235|DRUG|Methylergonovine|IV vs IM
214910512|NCT03193684|DRUG|Empagliflozin 25 MG|subjects will receive daily dose of 25mg of empagliflozin for 3 months
214910513|NCT03193684|DRUG|Control|Placebo
214910514|NCT00537849|DEVICE|Sonablate 500(SB-500)|
214910515|NCT06263933|OTHER|Insight Scale|Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group
214910516|NCT06263933|OTHER|Semi-directional interviews|"In the end of the intervention. In the end of DIPEM Or in the end of control group.~This intervention will be held after one month of hospitalization."
214910517|NCT06263933|OTHER|routine care|routine care
214910518|NCT06263933|OTHER|session of mutual assistance with a mediator psychologist|session of mutual assistance with a mediator psychologist
214910519|NCT03569410|BEHAVIORAL|increased protein intake via natural foods|Patients had to eat 1.4g/kg/day of natural protein.
214910520|NCT03569410|BEHAVIORAL|increase protein intake via protein supplements|Patients ate enough protein supplements in addition to their regular diet to reach eat 1.4g/kg/day of protein intake.
214910521|NCT02052024|DRUG|Botox|Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
214910522|NCT02052024|DRUG|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
214910523|NCT03480490|DIAGNOSTIC_TEST|Pleural fluid C-reactive protein|"C-reactive protein is an acute phase protein that is synthesized by the liver in response to various stimuli.~The pleural fluid c-reactive protein levels are likely to reflect the serum levels because the presence of c-reactive protein in the pleural fluid may be due to increased diffusion from the blood as a result of inflamed capillary leakage.~Pleural c-reactive protein has been proposed as a specific biomarker for the differential diagnosis of pleural effusions and reportedly exhibits higher sensitivity and specificity than serum c-reactive protein.~c-reactive protein can be considered a good candidate due to its 1000-fold elevation in response to infection and the positive correlation between the serum and pleural c-reactive protein levels.~Pleural fluid c-reactive protein level was significantly higher in exudates than that in transudative effusion."
214910524|NCT04849403|PROCEDURE|CTSP|In all patients Carter Thomasson Suture Passer (CTSP) were used for closing fascial defect peroperatively
214910525|NCT00720213|DEVICE|Respironics BiPAP autoSV2|Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.
214910526|NCT00720213|DEVICE|Respironics BiPAP autoSV3|Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.
214954828|NCT03718169|BEHAVIORAL|questionnaires|Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
214910527|NCT02843048|BEHAVIORAL|Exercise training program|"Participants allocated to the Exercise training plus standard medical care group will undergo an exercise-training program of 11 months duration, 3 sessions/week, and 60 minutes/session, starting one month after the surgery. Each exercise session will be supervised and will include 5 major components: i) warm-up, ii) multidirectional jumps, iii) balance, iv) strength and, v) cool down. This structure is planned to meet two main objectives: i) enhance bone formation and, ii) reduce fall risk by improving muscle strength, cardiorespiratory fitness and balance."
214910528|NCT02843048|BEHAVIORAL|Standard medical care|Standard follow-up medical care following bariatric surgery
214910529|NCT00097448|DRUG|prednisone|Oral, 19 days
214910530|NCT00097448|DRUG|methylprednisolone sodium succinate|Four intratympanic injections delivered to the middle ear over 2 weeks
214910531|NCT02092298|DRUG|Mitomycin C|Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
214910532|NCT02092298|DRUG|Cisplatin|Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
214910533|NCT02092298|DRUG|Sodium Thiosulfate|Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
214910534|NCT00620945|DRUG|Phenoxybenzamine|"Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~* For patients with obstructing lesions on systemic side:~  * 0.25 mg/kg dose in the bypass circuit~ * None intravenous~* For patients without obstructing left sided lesions:~  * 0.5 mg/kg in the bypass circuit~ * 0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~* 0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~* 0.3 mg/kg P.O. every 8 hours for next 24 hours~* 0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~* Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group"
214910535|NCT02462798|OTHER|Whole grain rye bread|Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)
214910536|NCT02462798|OTHER|Whole grain sourdough rye bread|Whole grain rye bread fermented with sourdough culture before baking
214910537|NCT06302673|DEVICE|Laserpuncture|Laserpuncture : using RJ Laser with Nogier B wave setting, frequency 584 Hz, power 50 mW, wavelength 785 nm, and energy of 2 Joules at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan)
214910538|NCT06302673|DEVICE|Sham Laserpuncture|Sham Laserpuncture: The laser is turned on but not activated at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan).
214910539|NCT01808066|DEVICE|Groundskeeper|Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
214910540|NCT04997330|DEVICE|Active rTMS|Bilateral high frequency (20Hz) rTMS will be delivered (over dorsolateral prefrontal cortex), at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive days on working day, 1500 pulses/session, 110% of motor threshold determined, 30 trains, 50 pulses per train and 15s inter train. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
214910541|NCT04997330|DEVICE|Sham rTMS|Sham rTMS will be delivered (over dorsolateral prefrontal cortex) , at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive working days. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
214910542|NCT03410576|PROCEDURE|Carotid artery stenting|Patient undergo elective carotid artery stenting. In this patient group blood sampling was performed at three time points: T1, at the time of the insertion of the arterial line; T2, 60 min after stent insertion; and T3: the first postoperative morning.
214910543|NCT03410576|PROCEDURE|Carotid endarterectomy|Patient undergo elective carotid endarterectomy. Group samples were collected at the following four time points: T1, at the time of the insertion of the arterial line; T2, 60 min after cross-clamp release; T3, the first postoperative morning; and T4, the third postoperative morning. A matched subgroup of patients from the previously obtained data served as a historical control.
214910544|NCT06119776|PROCEDURE|Whipple over the splenic artery|Treatment for pancreatic ductal cell adenocarcinoma
214910545|NCT06119776|PROCEDURE|Total pancreatectomy|Treatment for pancreatic ductal cell adenocarcinoma
214910546|NCT01252095|DRUG|PG545|PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
214910547|NCT04570839|DRUG|COM701 in combination with BMS-986207 and nivolumab.|Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).
214910548|NCT04845750|DEVICE|Rodeo Micro Mapping Catheter|The Rodeo Micro Mapping Catheter is used during cryoablation of atrial fibrillation patients for determination of pulmonary vein isolation
214910549|NCT02839304|DEVICE|Cryoablation System|Pulmonary Vein Isolation, Posterior Wall Isolation. May Include Mitral Line ablation, AF Driver ablation, and Cavo-tricuspid Isthmus ablation as indicated
214910550|NCT00655993|DRUG|simvastatin|40 mg po daily
214910551|NCT00365794|DRUG|Topical testosterone gel 10 g/day|Testosterone gel therapy for 20 weeks
214910552|NCT00686608|DIETARY_SUPPLEMENT|glucose|0.3mg/kg of glucose
214910553|NCT00686608|DIETARY_SUPPLEMENT|fructose|fructose IV bolus
214910554|NCT00686608|DIETARY_SUPPLEMENT|saline|IV saline
214910555|NCT02123264|DRUG|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
214954829|NCT00528372|DRUG|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
214954830|NCT00528372|DRUG|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
214954831|NCT00528372|DRUG|Metformin|
214303639|NCT04460547|DRUG|Interferon Beta-1A|Interferon Beta-1A administration to COVID-19 infected patients.
214303640|NCT00300950|BIOLOGICAL|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
214303641|NCT00300950|DRUG|Gemcitabine|Chemotherapy
214303642|NCT04389424|DRUG|Tamoxifen|Use of tamoxifen for breast cancer recurrence prevention
214910556|NCT06127316|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthoses (CDOs) used in this study will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee. The CDO will be modular in design which will allow three carbon fiber struts of the same stiffness and differing lengths to be used to implement 0cm, 1cm, and 2cm levels of heel distraction height. A longer posterior strut will move the carbon fiber footplate away from the participants foot to create the heel distraction height.
214910557|NCT03088202|OTHER|Educational program|E-learning lectures, group exercises, skills training
214910558|NCT03088202|OTHER|Standardized care pathways|Pathways for systematic follow-up
214910559|NCT03088202|OTHER|Early palliative care|Compulsory referral to palliative care at inclusion
214910560|NCT03504319|OTHER|Exposure to high-fat smoothie|Both groups will drink the high-fat smoothie and the study team will observe how they respond metabolically in the subsequent four hours using metabolic analyzer and blood draws.
214910561|NCT01935141|PROCEDURE|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
214910562|NCT01935141|DEVICE|Siemens Sensation 64-MDCT scanner.|The device will be used to perform CT Pulmonary Angiograms
214910563|NCT01935141|DRUG|Visipaque 320 non-ionic isoosmolar contrast agent|Single Dose of Intravenous Iodixanol will be administered per CT scan.
214910564|NCT00180882|DRUG|rituximab|
214910565|NCT03238560|DRUG|Montelukast Chewable Tablet|Montelukast treatment was used at a dosage of 5mg/day once daily
214910566|NCT00745901|DRUG|Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol|
214910567|NCT02615782|DRUG|CKD-397|CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
214910568|NCT01978132|PROCEDURE|forearm ischemia and reperfusion|both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
214910569|NCT04059835|OTHER|OptiBra study|compare two different bra after breast cancer surgery
214910570|NCT03469700|OTHER|general anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr
214910571|NCT03469700|OTHER|Paravertebral block|Bilateral paravertebral block guided by a nerve stimulator will be performed by injecting local anesthetic mixture from levels T11 to T6. Each 20 ml of the mixture will contain: 6 ml lidocaine 2%; 6 ml lidocaine 2% with adrenaline 5 μg /ml; 5 ml bupivacaine 0.5%; 50μg fentanyl (1 ml); and 2 ml saline 0.9%
214910572|NCT03469700|OTHER|Placebo PVB|Placebo bilateral paravertebral block guided by a nerve stimulator will be performed by injecting normal saline from levels T11 to T6.
214910573|NCT05017792|BIOLOGICAL|Astrazenica vaccine|COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.
214910574|NCT00515970|PROCEDURE|Curettage|"Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm."
214910575|NCT00515970|PROCEDURE|Deep excision|12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
214910576|NCT00515970|PROCEDURE|Shave excision|Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
214910577|NCT00515970|PROCEDURE|Curettage|"Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining."
214303643|NCT04389424|DRUG|Exemestane|Use of exemestane for breast cancer recurrence prevention
214303644|NCT04389424|DRUG|Anastrozole|Use of anastrozole for breast cancer recurrence prevention
214303645|NCT04389424|DIAGNOSTIC_TEST|Basal|Initial diagnosis of breast cacner by biopsy or mastectomy
214303646|NCT04389424|DIAGNOSTIC_TEST|Recurrence|Breast cancer recurrence under endocrine therapy
214303647|NCT02953327|BIOLOGICAL|Bacille Calmette-Guerin|Vaccine against tuberculosis
214303648|NCT02953327|BIOLOGICAL|BCG solvent|Simple solvent
214303649|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks
214910578|NCT03137641|OTHER|Nurses urine samples|Collected urine samples from nurses in contact with antineoplastic drugs.
215058374|NCT05827289|DEVICE|Cancer Patients Better Life Experience (CAPABLE)|The CAPABLE system serves three main goals for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing. These are available to the patient as a smartphone application that is connected to a smartwatch to monitor activity, blood pressure, sleep and heart rate. Patients are able to report symptoms experienced from the treatment and are eligible to do interventions such as mindfulness or yoga. Patients will receive the CAPABLE application and smartwatch for a minimum 3 to a maximum of 6 months after start treatment.
215058375|NCT03265444|BIOLOGICAL|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
214910579|NCT04505657|DRUG|celecoxib plus lidocaine|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
214910580|NCT04505657|DRUG|Celecoxib|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
214910581|NCT04505657|DRUG|lidocaine|placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
214910582|NCT00884117|DRUG|Oseltamivir|Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.
214910583|NCT02365441|DRUG|Regorafenib|
215058376|NCT01763333|DRUG|BI 1026706 Placebo|Placebo to BI 1026706
215058377|NCT01763333|DRUG|BI 1026706|different dose formulations
215058378|NCT05266846|DRUG|Pembrolizumab injection|Pembrolizumab 20mg ivgtt once every 21day Platium based Chemotherapy ivgtt once every 21day Bevacizumab 15mg/kg ivgtt once every 21day
215058379|NCT01530646|BEHAVIORAL|Weight loss|-750kcal/d
214303650|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 280μg/kg, s.c., once a week, for 52 weeks
215058380|NCT01530646|DIETARY_SUPPLEMENT|Soy|2 x 25g/d SPC
214303651|NCT05838885|DRUG|rhGH|rhGH, 245μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
214910584|NCT02365441|DRUG|imatinib|
214303652|NCT05838885|DRUG|rhGH|rhGH, 470μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
214303653|NCT03330522|OTHER|Love, Sex, & Choices video series|Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.
214346942|NCT01186523|OTHER|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
214910585|NCT04593485|DRUG|Camrelizumab for injection|Carrelizumab will be administered at a fixed dose
214910586|NCT02631642|DRUG|HMPL-689|selective PI3Kδ inhibitor
214346943|NCT00344682|DRUG|memantine|memantine 5mg - 20mg PO daily
214346944|NCT00344682|DRUG|Placebo|5mg - 20mg PO daily over 8 weeks
214910587|NCT02631642|DRUG|HMPL-689 placebo|placebo of HMPL-689
214910588|NCT01822730|DRUG|paliperidone|Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
214910589|NCT01822730|DRUG|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
214910590|NCT02449031|DRUG|TOBI® PODHALER®|
214910591|NCT02449031|DRUG|TOBI®|tobramycin inhalation solution, USP
214910592|NCT02449031|DRUG|Bethkis®|tobramycin inhalation solution
214910593|NCT02449031|DRUG|Cayston®|aztreonam for inhalation solution
214910594|NCT04900428|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
214910595|NCT04900428|DRUG|Placebo|Diluent solution
214910596|NCT01868802|DRUG|Ketamine|A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
214910597|NCT01868802|DRUG|Placebo|Saline at 0.9% intravenous infusion will be administered over 40 minutes.
214910598|NCT00153179|DRUG|acipimox|subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
214910599|NCT00153179|DRUG|placebo|matching placebo
214910600|NCT05510037|OTHER|no intervention|no intervention was needed
214910601|NCT00262197|BEHAVIORAL|Customized Physician Intervention|
215058381|NCT01530646|DIETARY_SUPPLEMENT|Whey|2 x 25g/d WPI
215058382|NCT01527877|DRUG|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
215058383|NCT01663311|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
214910602|NCT00262197|BEHAVIORAL|Customized Patient Intervention|
214910603|NCT04495829|DEVICE|Phorcides Analytical Engine|Surgery planning using the Phorcides analytical engine.
214910604|NCT01445782|DRUG|AZD2115|Multiple dose, oral inhalation (nebuliser solution)
214910605|NCT01445782|DRUG|Placebo|Multiple dose, oral inhalation (nebuliser solution)
214910606|NCT04061174|OTHER|Shoulder stabilization exercises|When participants are able to do the exercise 15 repetitions without difficulty, the exercise will be advanced by modifying or adding the weight.The exercises include chin tulk exercise, shoulder closed chain weight transfer, prone and iso-abdominal exercises, push-up exercise, lower trapezius muscle strengthening exercise, dead bug exercise, ball rolling on the wall, bench press with dumbbell and internal/external rotation (IR / ER) strengthening exercises
214910607|NCT04061174|OTHER|Office exercises training|Information will be given in a brochure that includes the appropriate chair height and work table, sitting position, distance between eyes and monitor, and table chair dimensions.approved and standardized office-based stretching and strengthening exercises will be given for workplaces
214910608|NCT04563663|PROCEDURE|Posteriorization of the talus.|Three sets of a 30-s grade IV anteroposterior mobilization.
214910609|NCT03845686|DIAGNOSTIC_TEST|Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)|The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.
214910610|NCT05173155|PROCEDURE|surgical approach|Comparison of short-term outcomes (patient mobility, quality of life, function, pain, and safety parameters) for the direct anterior approach and Lateral approach for hemiarthroplasty for patients who have experienced a femoral-neck hip fracture.
214910611|NCT02641743|DIETARY_SUPPLEMENT|Inslow|carbohydrate adjusted liquid food using palatinose as the major carbohydrate (\>50%)
214910612|NCT02641743|DIETARY_SUPPLEMENT|standard balanced formula|
214910613|NCT03691454|DRUG|Docetaxel|Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.
214910614|NCT03691454|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.
214910615|NCT06035965|OTHER|Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19)|19 items assessing post-surgery satisfaction.
214910616|NCT06035965|OTHER|Quality of Life in Epilepsy Inventory (QOLIE-31)|31 items to assess different dimensions of quality of life
214910617|NCT06035965|OTHER|Generalized Anxiety Disorder 7 (GAD7)|7 items, rated from 0 to 3, to detect anxiety disorders.
214910618|NCT06035965|OTHER|Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)|to screen for depressive disorders
214910619|NCT06035965|OTHER|Evaluation of Changes in Daily Life after Epilepsy Surgery (EVOCQUE)|self-questionnaire developed by the Toulouse epileptology team in 2023 for patients who have undergone epilepsy surgery. It aims to collect the feelings of patients concerning the changes induced by surgery in their daily life according to a 7-point Likert scale.
214910620|NCT02701465|OTHER|Exercise: local high intensity interval exercise|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
215058384|NCT01663311|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
215058385|NCT01202240|DRUG|Tasocitinib (CP-690,55) plus Ketoconazole|Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
215058386|NCT05312840|DRUG|Cisplatin / Carboplatin，Gemcitabine，Cindilimab|1\. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.
215058387|NCT04768205|DEVICE|Kinesio tape|The Kinesio tex tape is a medical tape that had been certified and patented.
215058388|NCT03548896|PROCEDURE|Post extraction socket|\*\*Dental implant will be placed 3 months after tooth extraction
215058389|NCT00343564|DRUG|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
215058390|NCT00343564|DRUG|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
214910621|NCT02701465|OTHER|Exercise: best clinical practice|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
215058391|NCT06154148|PROCEDURE|Sustained Diagonal Flexion positioning|This position is a semi reclined positioning, the infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infant's head turns toward the mother's face and is located between the nipple and the clavicule. Their arms and legs are flexed,in a naturally adopted asymmetrical tonic neck posture, according to the infant's term and comfort. The infant is naked and positioned inside the mother's clothes.
214910622|NCT02743325|PROCEDURE|SVT ablation by ALARA protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The usage of CartoUnivuTM allows a seamless combination of a fluoro image and Carto® 3 System maps into a single view.
214910623|NCT02743325|PROCEDURE|SVT ablation by conventional protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The convention Ablation procedure works without a 3D navigation System.
214910624|NCT03622125|DIAGNOSTIC_TEST|Vital signs|Axillary temperature sampling, at the site of the scorpion sting and the contralateral site with infrared thermometer, and heart rate, respiratory rate and blood pressure on admission, 30 minutes after applying the vial and the medical discharge
214910625|NCT01008566|BIOLOGICAL|Cixutumumab|Given IV
214910626|NCT01008566|OTHER|Laboratory Biomarker Analysis|Correlative studies
214910627|NCT01008566|DRUG|Sorafenib Tosylate|Given orally
214910628|NCT00970346|DRUG|OligoG CF-5/20|Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
215058392|NCT06154148|PROCEDURE|Traditional prone position|The infant is placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
215058393|NCT01165125|DRUG|FF / GW642444|200mcg/25mcg Novel DPI
215058394|NCT01165125|DRUG|ketoconazole|400mcg overencapsulated tablets
214303654|NCT03330522|OTHER|Messages in text|"The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. …. If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension."
214910629|NCT01735084|BIOLOGICAL|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg)."
214910630|NCT01735084|BIOLOGICAL|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
214910631|NCT05348759|DIAGNOSTIC_TEST|Pulmonary function test|Spirometry was performed by trained nurse at division of pulmonology, Vajira hospital. The forced vital capacity (FVC), forced expiratory volume in first second of exhalation (FEV1), forced mid-expiratory flow (FEF25-75%), and the FEV1/FVC ratio before and after bronchodilators (2 puffs of salbutamol via spacer) were collected in all cases. Total lung capacity (TLC) using the spirometry (Masterscreen PFT, Jaeger, Germany) and diffusion capacity of carbon monoxide was performed in selected case with abnormalities of lung parenchyma found from computed tomography of the chest.
215058395|NCT01165125|DRUG|ketoconazole (placebo to match)|placebo to match overencapsulated tablets
215058396|NCT00644826|BEHAVIORAL|preventive home visit|A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
215058397|NCT02434211|OTHER|Questionnaire and focus group|
215058398|NCT02065349|DRUG|ASP8477|oral
215058399|NCT02065349|DRUG|Placebo|oral
215058400|NCT06213207|OTHER|Simulator based training to manage asphyxia and essential newborn care using neonatalie|The intervention, HBB training package will be used which was applied to train the hospitals staff in Nepal (Chaulagain et al., 2021) and Laerdal Global Health (Laerdal Global Health, 2021) to enhance the competencies on the resuscitation to newborn using NeoNatalie. Health workers will receive 5 days simulation training by expert pediatrician and pediatric nurse who have prior working experience in Neonatal Intensive Care Unit (NICU) or Special Neonatal Care Unit. After the training, mentoring and coaching will be provided experienced newborn coach/trainer on a monthly basis for six months.
215058401|NCT01718158|BIOLOGICAL|Peginterferon Lambda-1a|
215058402|NCT01718158|BIOLOGICAL|Peginterferon Alfa-2a|
214910632|NCT05348759|DIAGNOSTIC_TEST|Chest computer scan|High-resolution computed tomography (HRCT) was performed in a single breath-hold on a 128 slice multidetector computed tomography (MDCT) scanner (Philips Healthcare Nederland B.V, Ingenuity 128, Netherlands). HRCT was performed with the patient in the supine position during end-inspiration, supine position during end-expiration, and prone position during end-inspiration with 1 millimeter (mm) slice thickness.
214910633|NCT02712554|DRUG|CL-108|7.5 mg/325 mg/12.5 mg tablet
214910634|NCT02712554|DRUG|M366|7.5 mg/325 mg tablet
214910635|NCT02712554|DRUG|Placebo|
214910636|NCT01095276|DRUG|Pulmozyme (nebulized dornase alpha)|nebulized dornase alpha: 2.5 mg by in-line nebulizer BID
214910637|NCT01095276|DRUG|Saline|Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).
214910638|NCT03859427|DRUG|Carfilzomib|Once weekly IV over 30 minutes on day 1, 8 and 15 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 day 1 and 56 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
214910639|NCT03859427|DRUG|Carfilzomib|Twice weekly IV over 10 minutes on day 1, 2, 8, 9, 15 and 16 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 27 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
214910640|NCT03859427|DRUG|Lenalidomide|Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
214910641|NCT03859427|DRUG|Dexamethasone|Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
214910642|NCT03392727|DEVICE|Study Box|Baby box (bassinet) with infant items
214910643|NCT03392727|DEVICE|Community Box|Baby box (bassinet)
214910644|NCT03392727|BEHAVIORAL|Education Session|Face to face education and baby box orientation session
214910645|NCT03392727|BEHAVIORAL|Online Education|Online baby box education
214910646|NCT02503540|DRUG|Aflibercept|Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
214910647|NCT01700972|PROCEDURE|Myocardial perfusion imaging|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
215058403|NCT01718158|DRUG|Ribavirin|
215058404|NCT01718158|DRUG|Daclatasvir|
215058405|NCT01718158|DRUG|Telaprevir|
215058406|NCT01823081|DRUG|Intravitreal injection of bevacizumab (Avastin)|
215058407|NCT01823081|DRUG|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
214303655|NCT01824407|DEVICE|Electrohydraulic-generated shock wave|
214303656|NCT01824407|DEVICE|Sham device plus standard of care|
214303657|NCT04325958|DRUG|Cannabis|750mg cigarette of plant material
214303658|NCT04325958|DRUG|Placebos|750mg cigarette of plant material
214303659|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
214910648|NCT02932501|PROCEDURE|Conservative treatment|Disinfectant mouth rinses, Antibiotic therapy, Antifungal therapy
214910649|NCT02932501|PROCEDURE|Surgical treatment|Superficial debridement, Complete removal of necrotic bone, Complete bone resection, When applicable revision and soft tissue coverage
214910650|NCT02932501|PROCEDURE|Adjuvant non-surgical treatment|Hyperbaric oxygen therapy Pentoxifylline and tocopherol Ozone therapy Low level laser therapy Pain relief Anti-inflammatory treatment Platelet rich plasma Parathyroid hormone and teriparatide Bone morphogenetic protein
214910651|NCT03649568|OTHER|Pork|1 oz lean pork
214910652|NCT03649568|OTHER|Egg|1 large whole egg
214910653|NCT03649568|OTHER|Black beans|0.5 cups cooked black beans
214910654|NCT03649568|OTHER|Almonds|1 oz almonds
214910655|NCT01674881|OTHER|Mindfulness-Based Cognitive Therapy|"MBCT consists of 8 sessions, incl. 1 whole-day session, weekly meetings of app. 2 hours duration. Daily homework (app. 30-45 min).~Group format (app. 20 persons pr. group). Two trained instructors will manage the groups, both are MSc cand.psych, PhD."
214910656|NCT01674881|OTHER|Waitlist|Waitlist: participants are offered the intervention (MBCT) after the completion of the main study
214303660|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
214910657|NCT04933019|GENETIC|Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|Detection of Clindamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
214910658|NCT00550355|DRUG|PD 0360324|3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
215058408|NCT04522934|BEHAVIORAL|Pain Neuroscience Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of pain neuroscience education. The latter was focused on the influence of psychosocial factors in the experience of pain, differences between acute and chronic pain and central-peripheral awareness.
215058409|NCT04522934|BEHAVIORAL|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of biomedical education. The latter was focused on the anatomy and pathomechanics of the shoulder.
215058410|NCT04704713|DRUG|Afamelanotide|
215058411|NCT04704713|DRUG|Placebo|
215058412|NCT05312606|OTHER|Aftoral Oral gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
215058413|NCT05312606|OTHER|Unidea Chlorhexidine digluconate mouthwash 0.20%|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
214303661|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
214910659|NCT00550355|DRUG|PD 0360324|3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
214910660|NCT00550355|DRUG|PD 0360324|3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
214910661|NCT00550355|DRUG|Placebo|3 doses of Placebo administered over 12 weeks
214910662|NCT05228223|DIAGNOSTIC_TEST|Neuromuscular monitoring|TOF monitoring
214910663|NCT05228223|OTHER|reverse of NMB with sugammadex|Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.
214910664|NCT05228223|OTHER|reverse of NMB with Sugammadex and neostigmin low dose|Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg
214910665|NCT05228223|OTHER|reverse of NMB with Sugammadex and neostigmin high dose|patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg
214910666|NCT00160849|DRUG|Lopinavir/r|
214910667|NCT02844413|OTHER|aerobic interval training|In the first group (G1), aerobic interval training (AIT) was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC hypertension guidelines
214910668|NCT03588403|RADIATION|TOMO|Tomotherapy
214910669|NCT03588403|RADIATION|IMRT|Intensity modulated radiotherapy
214910670|NCT04361773|RADIATION|Photobiomodulation|Treatment with a device with 144 light emitting diodes (LEDs) at wavelengths of 420, 660 and 850nm, 3J per point for 10 minutes.
214910671|NCT04361773|OTHER|Sham Photobiomodulation|Simulation of the LED application, with a device with external characteristics identical to that of the PBM group, for the same period of time.
214910672|NCT02590744|BEHAVIORAL|eye patch|cover the sick eye with eye patch preoperatively for 3 hours
214910673|NCT02590744|BEHAVIORAL|non-eye patch|do not cover the sick eye with eye patch preoperatively
214910674|NCT01804946|DRUG|Ergoferon|Safety and Efficiency of Ergoferon in treatment of Influenza
214910675|NCT01804946|DRUG|Oseltamivir|Safety and Efficiency in treatment of Influenza
214910676|NCT02045342|OTHER|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
214910677|NCT02045342|OTHER|Placebo|Ingest 500ml of placebo prior to metabolic measures.
214910678|NCT06189300|OTHER|Education and counseling intervention|In addition to standard training, training and consultancy will be provided to individuals with stoma intermittently within a month.
214910679|NCT00722137|DRUG|Rituximab 375 mg/m^2|Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.
214910680|NCT00722137|DRUG|Cyclophosphamide 750 mg/m^2|Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
214910681|NCT00722137|DRUG|Doxorubicin 50 mg/m^2|Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
214303662|NCT05678829|OTHER|Education|The trainings for the Virtual Reality group will continue in accordance with the training titles according to the weeks, using virtual reality glasses.
214303663|NCT02942446|DEVICE|Investigative Headgear with CPAP mask|Investigative Headgear with CPAP mask
214346945|NCT01846338|DIETARY_SUPPLEMENT|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
214910682|NCT00722137|DRUG|VELCADE 1.3 mg/m^2|Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles
214910683|NCT00722137|DRUG|Prednisone 100 mg/m^2|Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
214910684|NCT00722137|DRUG|Vincristine 1.4 mg/m^2|Intravenous vincristine 1.4 mg/m\^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
214910685|NCT01160705|DRUG|docetaxel|
214910686|NCT01160705|GENETIC|RNA analysis|
214910687|NCT01160705|GENETIC|reverse transcriptase-polymerase chain reaction|
214910688|NCT01160705|OTHER|circulating tumor cell analysis|
214910689|NCT01160705|OTHER|laboratory biomarker analysis|
214910690|NCT01129557|DRUG|Aliskiren|
214910691|NCT01129557|DRUG|Valsartan|
214910692|NCT03525080|DIAGNOSTIC_TEST|PET imagery|Every patients will have a PET imagery in addition to standard MRI
214910693|NCT02308930|DIETARY_SUPPLEMENT|Vitamins + DHA supplement (Vitamins A,D, E and algal oil)|
214910694|NCT02308930|DIETARY_SUPPLEMENT|Vitamins supplement (Vitamins A,D, E and corn oil)|
214910695|NCT06231225|BEHAVIORAL|Incentive Spirometer respiratory training|The incentive spirometer is a handheld mechanical breathing device that uses a one-way valve to prevent exhalation. It consists of a corrugated tube and a nozzle connected to three consecutive plastic chambers, each containing a ball. The external chambers are marked with the minimum flow required to raise the ball internally. The ball rises when the patient performs slow, deep breathing through the nozzle. If the patient breathes too quickly, the balls in the chambers rise to the top, and if breathing is too slow, the balls fall to the bottom. The number of increasing balls measures the volume of inhaled air. When all three balls reach the top of the chambers, the patient's flow rate can reach 1200 ml/s. After the patient has maximized their inhalation, they are asked to hold the balls in the same position for more than 3 sec.
214910696|NCT00836225|DRUG|ISIS 388626|"4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline"
214910697|NCT05482217|BEHAVIORAL|Psychoeducation, problem solving and rehearsal (cognitive behavioural intervention)|"The highlights of the intervention.~Session 1: Rapport building and knowledge of HIV~Session 2: Identifying and Dealing with barriers to good adherence~Session 3: Identifying and dealing with problems in relation to depression and adherence:~Session 4: Identifying and dealing with negative cognitions, handling privacy, accessing social Support, and adjusting to HIV and antiretroviral treatment~Session 5: Rehearsal of practical tips on adherence, handling slips, and strategies to improve quality of life.~All sessions involved brief periods of relaxation, homework, and a homework review. The last session was concluded with the assessment of satisfaction with the program. The programs were conducted for 60 minutes weekly for five weeks.~They were delivered by a trained lay counselor and supervised by the principal investigator for five weeks."
214910698|NCT00669669|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal IMRT
214910699|NCT00669669|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
214910700|NCT00669669|DRUG|Carmustine|Given IV
214910701|NCT00669669|BIOLOGICAL|Filgrastim|Given SC
214910702|NCT00669669|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
214910703|NCT00669669|RADIATION|Intensity-Modulated Radiation Therapy|Undergo 3D conformal IMRT
214910704|NCT00669669|OTHER|Laboratory Biomarker Analysis|Correlative studies
214910705|NCT00669669|DRUG|O6-Benzylguanine|Given IV
214910706|NCT00669669|DRUG|Plerixafor|Given SC
214910707|NCT00669669|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
214910708|NCT00669669|DRUG|Temozolomide|Given PO
214910709|NCT01446302|DIETARY_SUPPLEMENT|Double meal|A standardized meal is served 1 h after start of HD and 1 h after end of HD.
214910710|NCT05090436|OTHER|Schroth Exercise|two month (three session per week)
214910711|NCT05090436|OTHER|Functional Electrical Stimulation (physiotherapy techniques)|two month (three session per week)
214910712|NCT00400023|DRUG|S-1|"During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.~During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
214910713|NCT00400023|DRUG|FT|During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
214303664|NCT01148121|OTHER|Skeletal Status Assessment of a Down Syndrome Population|The investigators hypothesize that the bone deficits seen in Down Syndrome patients are similar to the phenotype seen in the down syndrome mouse model (Ts65Dn).The bone turnover markers, CBC, and DXA scan results will be used to assess the skeletal status of the down syndrome patients. This data will form the basis to establish the Ts65Dn as a reasonable proxy for pathogenesis and treatment in humans.
214303665|NCT04730245|DRUG|sodium phosphate enema, oral rifaximin and polyethylene glycol|Patients were hospitalized for 4-5 hours to receive two saline colon enemas with sodium phosphate Fleet®, 2 to 3 hours apart, appropriate hydration was provided during the procedure. If signs of fecal impaction were observed, the stools were removed manually prior to the first enema. Patients were discharged with oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days, but it was continued if necessary. Importantly, no modifications in time and dose of dopaminergic therapy or anti-dyskinetic medication (i.e. amantadine) were done at baseline or during the study
214303666|NCT03896243|DIAGNOSTIC_TEST|Uterine artery ligation (UAL)|"Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
214303667|NCT00827983|DRUG|Progesterone|25 mg, s.c., once à day
214303668|NCT00827983|DRUG|Progesterone|90 mg, vaginally, once à day
214303669|NCT00939913|DRUG|intravenous NAC|intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
214303670|NCT00939913|DRUG|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
214910714|NCT00848718|DRUG|MK-2206|MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)
214910715|NCT00848718|DRUG|docetaxel|Administered as an IV infusion on Day 1 of each 21-day cycle
214910716|NCT00848718|DRUG|erlotinib|Administered daily (QD) PO in each 21-day cycle
214910717|NCT00848718|DRUG|carboplatin|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
214910718|NCT00848718|DRUG|paclitaxel|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
214910719|NCT00848718|DRUG|corticosteroid|Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
214910720|NCT04253418|DEVICE|Nano-Pulse Stimulation (NPS)|Electrical pulses (nanosecond duration) applied directly to target SH lesions using sterile single-patient use treatment tips with microneedles.
214910721|NCT02689154|DEVICE|W8Loss2Go|The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
214910722|NCT06219811|DEVICE|Two implant -retained overdenture reinforced with Co-Cr framework|The intervention is made from polymethylmethacrylate reinforced with cobalt chromium ( Co-Cr) framework.
214910723|NCT06219811|DEVICE|Two implant -retained overdenture reinforced with PEEK framework|The intervention is made from polymethylmethacrylate reinforced with Polyetherketoneketone ( PEEK) framework.
214910724|NCT05369897|DEVICE|VR training|The intervention group will receive cognitive training through VR headsets three times a week for 12 weeks. The intervention will be delivered in a virtual setting using images and music. The participants will be allowed to select the type of music and virtual environment during the intervention. The intervention will include four modules targeting attention and working memory through immersive VR.
214910725|NCT05369897|DEVICE|VR activity|High-quality 360º images and videos from natural environments, such as a relaxing mountain environment. The participants in the control group will not receive cognitive training.
214910726|NCT01734005|DIETARY_SUPPLEMENT|Red Ginseng|Red Ginseng (1.4g/day)
214910727|NCT01734005|DIETARY_SUPPLEMENT|Placebo|Placebo (1.4g/day)
214910728|NCT02935127|PROCEDURE|Absorbable suture|Vascular anastomoses will be performed with absorbable materials
214910729|NCT02935127|PROCEDURE|Non-Absorbable suture|Vascular anastomoses will be performed with non-absorbable materials
214910730|NCT06261489|DRUG|THC|Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.
214910731|NCT06261489|DRUG|CBD|Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.
214910732|NCT06231329|DEVICE|ultrasound elastography|examining patient's testis with ultrasound elastography technique and collect data and results
214910733|NCT05006079|DRUG|Morphine|immediate release oral 15mg dose
214910734|NCT05006079|DRUG|Alprazolam|oral 0.25mg dose
214910735|NCT05006079|DRUG|Placebo|Lactose
214910736|NCT06136533|OTHER|Assessment-OHS|Demographic information of individuals diagnosed with OHS without sarcopenia risk is recorded.Bioelectrical Impedance Analysis is used to analyze body composition.The comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index',sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index' and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'.The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'.Patients' physical activity levels are monitored with a pedometer.Quadriceps muscle strength is measured with Hand-held dynamometer and grip strength is measured with Jamar hand dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with 'Nottingham Health Profile' and 'Functional Outcomes of Sleep Questionnaire'.
214910737|NCT06136533|OTHER|Assessment-Sarcopenic Obesity With OHS|The sarcopenia diagnostic algorithm is used as a reference in the assessment of the presence of sarcopenic obesity. Demographic information of patients diagnosed with sarcopenic obesity is recorded. Then, the comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index', sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index', and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'. The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'. Patients' physical activity levels are monitored with a pedometer. Quadriceps muscle strength is measured with Hand-held dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with the 'Nottingham Health Profile' and the 'Functional Outcomes of Sleep Questionnaire'.
214910738|NCT02563054|DRUG|5-Fluorouracil|Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m\^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
214910739|NCT02563054|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
214910740|NCT02563054|DRUG|Cisplatin|Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
214910741|NCT03144661|DRUG|INCB062079|In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
214910742|NCT02418182|DRUG|Acetaminophen|Acetaminophen total dose of 1000mg
214910743|NCT02418182|DRUG|placebo|subjects randomized to this group will be given placebo tablets
214910744|NCT02499731|BEHAVIORAL|Strong Hearts, Healthy Communities|"We will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized controlled intervention trial. We will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 8 intervention and 8 control communities. In addition, we will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
214910745|NCT02499731|BEHAVIORAL|Strong Hearts, Healthy Women|"The Strong Hearts, Healthy Women (minimal intervention) will meet once per month for an hour each time for 6 months.~Participants will learn and discuss techniques and strategies to improve personal health."
214910746|NCT03334344|DEVICE|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
214910747|NCT04090229|DRUG|ASLAN004|Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
214910748|NCT04090229|DRUG|ASLAN004 Placebo|Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
214910749|NCT02431676|DRUG|Metformin|Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.
215058414|NCT01010451|PROCEDURE|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
215058415|NCT01010451|PROCEDURE|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
215058416|NCT05498740|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
215058417|NCT02953561|DRUG|Avelumab|Given IV
215058418|NCT02953561|DRUG|Azacitidine|Given SC or IV
215058419|NCT02953561|OTHER|Laboratory Biomarker Analysis|Correlative studies
215058420|NCT00899418|GENETIC|gene expression analysis|
215058421|NCT00899418|GENETIC|polymerase chain reaction|
215058422|NCT00899418|GENETIC|polymorphism analysis|
215058423|NCT00899418|OTHER|immunohistochemistry staining method|
215058424|NCT02214901|DRUG|BIBW 2948 BS for oral inhalation|
214910750|NCT02431676|BEHAVIORAL|Coach Directed Behavioral Weight Loss|Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals
214910751|NCT02431676|BEHAVIORAL|Self-control weight loss|
214910752|NCT04774627|DRUG|PARP inhibitor|All patients treated at least with 1 PARPi
214910753|NCT01776437|DRUG|BMN 673|500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
214910754|NCT06833190|DRUG|REGN5381|Administered per the protocol
214910755|NCT06833190|DRUG|Placebo|Administered per the protocol
214910756|NCT02576080|DRUG|Imatinib|
214910757|NCT02576080|OTHER|Surveillance|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan.
214910758|NCT03721874|DRUG|Dapagliflozin 10mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered dapagliflozin 10 mg during Period 1 or Period 2."
214910759|NCT03721874|DRUG|Placebo matching to Dapagliflozin 10 mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered placebo during Period 1 or Period 2."
214910760|NCT01057147|DRUG|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
214910761|NCT01057147|DRUG|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
214910762|NCT05053945|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|"To set up a prospective study and registry (HAR-P) for patients with H. pylori infection, atrophic gastritis or intestinal metaplasia to evaluate their clinical features and outcomes. The objectives include:~1. Assess the short- and long-term patient outcomes of H. pylori patients~2. Characterize factors involved in the progression or regression of pre-neoplastic lesions, namely atrophic gastritis and intestinal metaplasia~3. Gather information for a better understanding on the efficacy and role of surveillance~4. Potential for the development of new screening/surveillance strategies and tools for better risk stratification of patients~5. Establish a biobank for H. pylori, atrophic gastritis and intestinal metaplasia patients"
214910763|NCT05189977|DRUG|Propranolol|"Propranolol (tablet, oral ): 40 mg QD Day 3 and Day 21~Intervention 1 is a single dose of prazosin administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
214910764|NCT05189977|DRUG|Prazosin|"Prazosin (tablet, oral): 1 mg QD Day 2 and Day 20~Intervention 2 is a single dose of propranolol administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
214910765|NCT07071909|BIOLOGICAL|Commercial CAR-T|Twenty subjects will receive investigational CAR-T through a University of North Carolina at Chapel Hill clinical trial.
214910766|NCT07071909|BIOLOGICAL|Investigational CAR-T|Thirty subjects will receive investigational CAR-T through a University of North Carolina at Chapel Hill clinical trial.
214910767|NCT03914612|DRUG|Carboplatin|Given IV
214910768|NCT03914612|PROCEDURE|Computed Tomography|Undergo CT scan
215058425|NCT02214901|DRUG|Placebo|
214910769|NCT03914612|DRUG|Paclitaxel|Given IV
215058426|NCT04587882|BEHAVIORAL|Telehealth|Participants will receive weekly activity summaries and tailored notifications about their activity and goal setting behaviors.
215058427|NCT04587882|BEHAVIORAL|Control|Participants will get usual care and wear a smartwatch.
214303671|NCT01498458|DRUG|Pazopanib plus capecitabine|"Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~* dose level I: 400 mg~* dose level II: 600 mg~* dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level."
214910770|NCT03914612|BIOLOGICAL|Pembrolizumab|Given IV
214910771|NCT03914612|OTHER|Placebo Administration|Given IV
215058428|NCT05523557|BEHAVIORAL|Urban Training|1\) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
215058429|NCT04212078|DRUG|Levofloxacin Ophthalmic|0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
215058430|NCT04212078|DRUG|Cefuroxime|The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
214910772|NCT03914612|OTHER|Quality-of-Life Assessment|Ancillary studies
215058431|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
215058432|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
214910773|NCT03914612|OTHER|Questionnaire Administration|Ancillary studies
214910774|NCT06506916|DRUG|bimekizumab|Study participants receive bimekizumab (BKZ) administered subcutaneously at pre-specified timepoints during study.
214910775|NCT06752876|DRUG|CB-010|CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
214910776|NCT06516952|DRUG|Povorcitinib|Oral Tablet
215058433|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
214910777|NCT06516952|DRUG|Placebo|Oral Tablet
214910778|NCT07074249|PROCEDURE|"Anatomical Accuracy of Blind Dry Needling Procedures on the Lumbar Paraspinal Muscles: An Ultrasonography-Assisted Observational Study"|"* All interventions will be performed by a physical medicine and rehabilitation specialist with clinical experience.~* Targeted muscles:~* \*Iliocostalis lumborum (ICL)\*~* \*Longissimus thoracis (LT)\*~* \*Multifidus (M)\*~* Interventions will be performed from the right side, between the L2-L5 levels.~* A total of \*three different dry needling applications\* will be performed for these three muscles for each participant."
214910779|NCT07074249|PROCEDURE|"Anatomical Accuracy of Blind Dry Needling Procedures on the Lumbar Paraspinal Muscles: An Ultrasonography-Assisted Observational Study"|\*All interventions will be performed by a physical medicine and rehabilitation specialist with clinical experience. \* Targeted muscles: \* \*Iliocostalis lumborum (ICL)\* \* \*Longissimus thoracis (LT)\* \* \*Multifidus (M)\* \* Interventions will be performed from the right side, between the L2-L5 levels. \* A total of \*three different dry needling applications\* will be performed for these three muscles for each participant. After each intervention, the needle tip position will be evaluated by a second specialist with \*high-resolution linear probe ultrasound\*.
214910780|NCT07079033|PROCEDURE|Blinded Dry Needling|Dry needling is performed using anatomical landmarks without ultrasound guidance. Needle placement is then confirmed via ultrasound imaging.
214910781|NCT07075081|OTHER|Ceremony|Lifecourse ceremony led by Elders that used to be offered to everyone prior to colonization
214910782|NCT07078019|OTHER|Voice Recording Procedure|"Participants will be asked to read a standardized one-minute text aloud in a quiet room. Their voices will be recorded using a high-quality microphone. The recordings will later be analyzed for acoustic features such as pitch, speech rate, pauses, and intonation.~This procedure is non-invasive and does not involve any clinical or pharmacological intervention."
214910783|NCT07077616|BIOLOGICAL|Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced;|"TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)~* TAMAVAQ VACCINE : Each one of our TAMAVAQ VACCINE is consisted of 1-35 (LIMPs, ASPs, and bEPTs) Personalised Synthetic Neoantigenic Peptides mixed with GBM TAAs, including MAGE-1, HER-2, gp100, AIM-2, TRP-2, EphA2,105 survivin50, IL13Rα2, heat-shock peptide protein complex-96 (HSPPC-96), and Smac-TLR7/8 peptides.~* TAMAVAQ vaccine products are composed of 1-35 peptides from the Biogenea Pharmaceuticals Ltd warehouse.~* TAMAVAQ vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with TAMAVAC VACCINE"
214910784|NCT06858839|DRUG|Maridebart Cafraglutide|Maridebart cafraglutide will be administered SC.
214910785|NCT06858839|DRUG|Placebo|Placebo will be administered SC.
214910786|NCT05649748|DRUG|Treprostinil Palmitil|Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
214910787|NCT05649748|DRUG|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
214910788|NCT07080034|BIOLOGICAL|anti-TL1A monoclonal antibody, low dose|injection
214910789|NCT07080034|BIOLOGICAL|anti-TL1A monoclonal antibody, medium dose|injection
214910790|NCT07080034|BIOLOGICAL|anti-TL1A monoclonal antibody, high dose|injection
214910791|NCT07080034|OTHER|Placebo|injection
215058434|NCT00848237|DEVICE|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
215058435|NCT00329576|BIOLOGICAL|Hepatitis B vaccine|
214303672|NCT05995158|PROCEDURE|Metagenomic testing of the subgingival plaque samples|sampling, extraction and sequencing of the oral microbiome in the samples
214910792|NCT06212999|DRUG|Povorcitinib|Oral; Tablet
214910793|NCT05346198|DRUG|CART-BCMA|The CART-BCMA (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
214910794|NCT06300190|PROCEDURE|Biceps tenodesis alone|Biceps tenodesis in superior labrum anteroposterior lesion type IV
214910795|NCT06300190|PROCEDURE|Biceps tenodesis and labrum repair|Biceps tenodesis and labrum repair by anchors in superior labrum anteroposterior lesion type IV
214303673|NCT03640585|OTHER|Music therapy|Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
214303674|NCT05150353|PROCEDURE|MRI|Wrist MRI
214303675|NCT01815125|DRUG|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
214303676|NCT01815125|DRUG|PLacebo|placebo
214910796|NCT06764849|PROCEDURE|CONVENTIONAL OPEN EXCISIONAL HEMORRHOIDECTOMY|Hemorrhoidectomy performed based on the conventional technique described by Milligan-Morgan
214910797|NCT06764849|PROCEDURE|MINIMALLY INVASIVE OPEN EXCISIONAL HEMORRHOIDECTOMY|Hemorrhoidectomy performed based on the tecnique described by Milligan Morgan, using a minimally invasive approach.
214910798|NCT05198154|DIAGNOSTIC_TEST|ctDNA detection|High-depth sequencing method is used to detecting ctDNA.
214910799|NCT01305421|PROCEDURE|grip test|Muscle strength measurement by hand-held dynamometer
214910800|NCT00188474|BEHAVIORAL|LCADLS, FACIT-PAL, FACIT-TS questionnaires|LCADLS, FACIT-PAL, FACIT-TS questionnaires
214910801|NCT03350282|DIETARY_SUPPLEMENT|GAA-creatine|
215058436|NCT00556439|DRUG|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
215058437|NCT00556439|DRUG|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
215058438|NCT03877003|OTHER|Eggs|Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
215058439|NCT03130998|BEHAVIORAL|Remote Knowledge Broker (rKB)|The intervention is the tailored support received by a knowledge broker via technology in Group B. The rKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the rKB, learn new evidence, and work with the rKB on how to best implement the evidence.
215058440|NCT03130998|BEHAVIORAL|Emails|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
215058441|NCT00496977|PROCEDURE|annual CT screening|
214303677|NCT06202781|DRUG|SOX plus PD-1 inhibitor|S-1, Oxaliplatin and nivolumab/sintilimab
214303678|NCT06202781|PROCEDURE|Gastroscopic biopsy|Gastroscopy and biopsy
214670173|NCT03065803|PROCEDURE|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
215058442|NCT02100423|DRUG|curcumin|Given PO
214910802|NCT03350282|DIETARY_SUPPLEMENT|Creatine|
214910803|NCT03646383|PROCEDURE|Radiofrequency ablation|The procedure will include an ultrasound with radiofrequency ablation of the benign thyroid nodule percutaneously
214910804|NCT06914921|DIETARY_SUPPLEMENT|Peppermint Oil|"Enteric-coated peppermint oil capsules (\~180 mg total peppermint oil/ capsule) to ensure release in the small intestine.~1 capsule three times daily, 30 minutes before meals, for 12 weeks."
214910805|NCT06914921|DRUG|A standard antispasmodic|A standard antispasmodic (e.g., mebeverine 135 mg). 1 tablet three times daily, before meals, for 12 weeks.
214910806|NCT06932965|BEHAVIORAL|Cervical Stabilization Group|Participants performed supervised cervical stabilization exercises for 8 weeks, 3 sessions per week.
215058443|NCT02100423|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
215058444|NCT02100423|OTHER|laboratory biomarker analysis|Correlative studies
214910807|NCT06932965|BEHAVIORAL|combined group|Participants performed both exercise protocols as described above over the same period
215058445|NCT02100423|OTHER|pharmacological study|Correlative studies
215058446|NCT00804050|DRUG|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
214303679|NCT01876485|BEHAVIORAL|Empowering Patients in Chronic Care (EPIC)|EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
214346946|NCT03579979|DRUG|Methylene Blue|Subcutaneous injection of injection point at the periphery of the areola or tumor, injecting 1% methylene blue 0.5ml at each point, a total of 2-3 points.
214910808|NCT06931145|DRUG|Benmelstobart|Benmelstobart injection, 1200 mg/dose, given once every 21 days, intravenously.
214910809|NCT06931145|DRUG|Anlotinib|"Anlotinib hydrochloride capsules, 8 mg/dose, administered orally for 2 consecutive weeks and stopped for 1 week.~During the course of the study, subjects may be adjusted upward to a dose of 12 mg if well tolerated, as determined by the investigator, and the dose of anlotinib hydrochloride may be adjusted downward during the course of the study due to drug-related adverse events."
214910810|NCT06931145|DRUG|Carboplatin or cisplatin|Carboplatin for injection, administered on day 1, AUC 5 mg/mL/min, intravenously (maximal dose used is 750 mg); or cisplatin administered on day 1, 75-80mg/m2, IV.
214910811|NCT06931145|DRUG|Etoposide|Etoposide injection, 100mg/m2 on days 1, 2 and 3, IV.
214910812|NCT06934512|DEVICE|Needleless jet injector|To assess the pain score through (VAS) scale of needleless jet injector for local anesthesia. Scale has minimum zero number that indicates best outcome and maximum number is ten that indicates worst outcome.
214910813|NCT06934512|PROCEDURE|Conventional needle injection|To assess the pain score through (VAS) scale of traditional needle injection for local anesthesia. Scale has minimum zero number that indicates best outcome and maximum number is ten that indicates worst outcome.
214910814|NCT06934590|DRUG|RX001|Subjects will receive a single RX001 (AAV-hRUNX3) treatment via Intra-tumoral injection
215058447|NCT00804050|DRUG|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
215058448|NCT02013349|DEVICE|coronary intervention|
214910815|NCT06940700|DRUG|SHR4597|SHR4597
214910816|NCT06940700|DRUG|Budesonide inhalant|Budesonide inhalant
214910817|NCT06940466|OTHER|Online cognitive intervention|A 4 x 2-hour intervention with the following key components: education about menopause and cognition, cognitive strategies (memory, attention and executive functioning), CBT techniques and emotional support.
214910818|NCT06941116|DIAGNOSTIC_TEST|Steroid-Based Screening (LC-MS/MS)|This diagnostic intervention is a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based steroid profiling assay. It measures a panel of 21 adrenal steroid hormones (e.g., aldosterone, 18-hydroxycortisol, 18-oxocortisol, corticosterone) from plasma samples. In this study, it is used to screen for Primary Aldosteronism (PA) while patients remain on their usual antihypertensive medications. By comparing these steroid profiles against standard aldosterone-renin measurements, the method aims to reduce the need for medication washout and improve diagnostic accuracy for PA.
214910819|NCT06941558|DEVICE|INFINITY™ with ADAPTIS™ and EVERLAST™|The INFINITY™ with ADAPTIS™ and EVERLAST™ ankle replacement system is a development of the Infinity ankle implant, designed to attach to the bone better and to wear out more slowly.
214910820|NCT06940102|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day)
214910821|NCT06940102|DRUG|TKI-Based Therapy|TKI-Based Therapy
214910822|NCT00901550|DRUG|Methotrexate|All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
214910823|NCT00901550|DRUG|Infliximab|Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
214910824|NCT05871281|PROCEDURE|Pelvic floor muscle exercises|Pelvic floor muscle exercises were performed from different body positions. Duration of interventions - 4 weeks. Frequency - 2 times per week, number of individual contact sessions - 8 .
214910825|NCT07182617|BEHAVIORAL|Standard Coaching (SOC)|Participants received BetterNight's standard CPAP coaching program. Monitoring was conducted through manufacturer platforms (ResMed AirView, Philips Care Orchestrator) and BetterNight's internal Clarity dashboard. Coaches contacted patients at scheduled checkpoints (10, 20, 45, 60, and 80 days) to provide education, support, and troubleshooting to help patients achieve Medicare adherence.
215058449|NCT04328896|OTHER|CGM-Tele-monitoring|"Baseline Visit-Visit 0~1. Obtain informed consent~2. Administer questionnaires~3. Measure A1C~4. Start study Dexcom CGM device (those already on CGM will change to the study device).~5. The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~1. 14 days worth of data will be downloaded from the patient's CGM device.~2. Systems will be checked to be sure they are functioning~3. Remote monitoring program will be activated.~4. Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~1. Administer questionnaires~2. Measure A1C.~3. Collect CGM data and compare to baseline~Testing and Assessments:~* Continuous glucose monitoring~* Tidepool cloud upload~* HbA1c~* T1D REDEEM diabetes distress questionnaire~* Hypoglycemia Fear Survey~* Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis"
215058450|NCT00540930|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
215058451|NCT00981162|DRUG|sorafenib tosylate|Given PO
215058452|NCT00981162|DRUG|everolimus|Given PO
214910826|NCT07182617|BEHAVIORAL|MonitAir RPM|Participants received the standard BetterNight coaching program enhanced with the MonitAir remote patient monitoring platform. MonitAir enabled weekly reviews of CPAP usage data, automated text follow-ups, and at least one interactive telehealth visit per month. Coaches escalated issues such as poor adherence, high residual AHI, or mask leak to physicians as needed. The intervention aimed to improve CPAP adherence and patient satisfaction compared with standard care.
214910827|NCT07182032|DRUG|ketamine|Participants will receive general anesthesia with protocoled ketamine infusion
214910828|NCT07183852|DRUG|Autologous Tumor Infiltrating Lymphocytes (TIL)|Cohort 1: Administered via hepatic arterial infusion Cohort 2: Administered via intravenous infusion
214910829|NCT07183852|DRUG|Melphalan|1 mg/kg, IV
214910830|NCT07183852|DRUG|Interleukin-2|2 MIU, subcutaneous twice daily for up to 14 days.
215058453|NCT00981162|OTHER|laboratory biomarker analysis|Correlative study
215058454|NCT00981162|OTHER|pharmacogenomic studies|Correlative study
214303680|NCT01876485|BEHAVIORAL|Enhanced Usual Care (EUC)|Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
214303681|NCT03011359|OTHER|Optimizing B.I (New) PCA mode|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).
214303682|NCT03011359|OTHER|Conventional PCA mode|(Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
214303683|NCT01234233|PROCEDURE|duration of preoperative active warming|"duration of prewarming by forced air warming"
214910831|NCT07182396|PROCEDURE|Experimental Group|"VIDEO GAME-TAPD: Week 1st-6th: Start with kids level and progress upto expert level and Participants will automatically progress to advanced level based on their individual ability and progress in game in progressing weeks.~(kids level to expert level: according to game levels) Hand eye coordination game:Tap changing illuminating squares. Week1- 3 repetitions(2sets),Week2- 4 repetitions(2 sets),Week3- 5 repetitions(2 sets),Week4- 6 repetitions(2 sets),Week5- 7 repetitions(2 sets),Week6- 8 repetitions(2 sets) Ball tossing intervention:Week 1-2 (Exercise 1 (2 sets, 20/30/40 repetitions) and Exercise 2(2 sets, 20/30/40 repetitions) with ground tap catch Week 3-4 (Exercise 2 (2 sets, 20/30/40 repetitions) with direct catch and Exercise 3 (2 sets, 20/30/40 repetitions) Week 5-6 (Exercise 1 (2 sets, 50 repetitions) , Exercise 2 (2 sets, 50 repetitions) with direct catch and Exercise 3 (2 sets, 50 repetitions) Number of reps adjusted according to session number per week"
215058455|NCT00981162|OTHER|pharmacological study|Correlative study
215058456|NCT00562432|DEVICE|Plexisyl-AF|Plexisyl-AF implants
215058457|NCT00562432|OTHER|No Treatment|CABG without the experimental treatment
215058458|NCT02981862|OTHER|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
215058459|NCT05782985|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)|Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
215058460|NCT05749367|DRUG|Ropivacaine + saline solution|SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
215058461|NCT05749367|DRUG|Saline solution + Ropivacaine|SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
215058462|NCT00315510|DRUG|Rosuvastatin|
215058463|NCT04310319|DIETARY_SUPPLEMENT|Sodiumchloride|Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
215058464|NCT04310319|DIETARY_SUPPLEMENT|Protein|Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
215058465|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (salt)|Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
215058466|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (protein)|Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
215058467|NCT04554732|DRUG|Keratinocyte growth factor|At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
215058468|NCT01599598|BEHAVIORAL|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
215058469|NCT01599598|BEHAVIORAL|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
215058470|NCT02713113|DRUG|sugammadex reversal of neuromuscular blockade|
214303684|NCT04931485|OTHER|Fluid management according to the REDUCE Fluid Protocol|Fluid management according to the protocol will be guided by pre-defined clinical signs for impaired perfusion and fluid overload.
214303685|NCT04931485|OTHER|Standard of care|Fluid resuscitation and de-resuscitation will be managed according to the standard of care
214303686|NCT00084669|DRUG|venlafaxine|
214303687|NCT00084669|DRUG|zolpidem tartrate|
214303688|NCT00084669|PROCEDURE|management of therapy complications|
214303689|NCT05478447|PROCEDURE|Vibration|whole-body vibration, and tendon vibrations will be applied to the human body
214303690|NCT06040749|OTHER|Virtual group-based handcycling|Virtual group-based handcycling
214303691|NCT06573086|OTHER|Resistance Training|12-week resistance training
215058471|NCT01915537|DRUG|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX\>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
214910832|NCT07182396|PROCEDURE|Control Group|"Week 1-2 (Exercise 1 (2 sets, 20/30/40 repetitions) and Exercise 2(2 sets, 20/30/40 repetitions) with ground tap catch Week 3-4 (Exercise 2 (2 sets, 20/30/40 repetitions) with direct catch and Exercise 3 (2 sets, 20/30/40 repetitions) Week 5-6 (Exercise 1 (2 sets, 50 repetitions) , Exercise 2 (2 sets, 50 repetitions) with direct catch and Exercise 3 (2 sets, 50 repetitions) Number of reps adjusted according to session number per week e.g~* Day 1: 20 reps per week~* Day 2: 30 reps per week~* Day 3: 40 reps per week Progression: Participants will progress to advanced level based on their individual ability and progress. Levels of complexity will be adjusted according to patient progress."
214910833|NCT07183969|OTHER|lower limb muscle strength training program|"Each plyometric training session consists of warm-up stretching, lower limb plyometrics, and gentle stretching.~Warm-up stretching, there are 6 movements, push the window, pull the rope, hands up, stretch from side to side, lift one foot and open and close both feet. Do 10 repetitions of each movement, 2 rounds, and keep breathing normally for a few repetitions.~Lower Extremity Plyometrics: 3 rounds of 6 plyometrics with 1 minute of recovery time between each round. The six lower body plyometrics exercises are performed by gradually increasing the load in a manner that increases the number of seconds the exercise is held.~Gentle Stretching: Continuous training of muscles makes them tense, stretching can lengthen muscle fibers, increase muscle elasticity, and improve blood circulation to eliminate post-training fatigue (H.K. Chen, 2022). Perform each gentle stretching movement left and right once, hold for 30 seconds each time, and keep breathing normally (no shutting up of breath)."
214910834|NCT07175961|OTHER|Multicomponent telehealth care coordination|Participants randomised into the intervention group will be assigned a recovery navigator prior to discharge from hospital. The recovery navigator will provide the participant with a study tailored discharge summary, arrange the patients first appointment with their general practitioner and will ensure medications are reconciled prior to hospital discharge. The recovery coordinator will arrange weekly calls with the participant for the first 4 weeks and then fortnightly until week 12 to set recovery goals and assess recovery goals and navigator further primary care support if required. Participants will also be called at Day 90 and 180 by outcome assessors to collected patient reported outcomes.
214303692|NCT06420778|OTHER|electroacupuncture|The patient takes the supine position, the whole body relaxes, the facial skin is routinely sterilized. Local acupuncture points along the head and face herpes zoster lesion branches with 0.18 × 25 mm millimetre needle series of shallow stabbing method row stabbing method.Han's Acupoint Neurostimulator (model HANS-200) was selected, local acupoints were chosen as Xiaguan+Quanliao or Xiaguan+Jiache, and distal acupoints were chosen as Hegu+Waiguan connected with electroacupuncture, sparse and dense wave 2/100 Hz was selected, and the treatment time was 60 minutes, and the intensity of the current was all to the extent that the patient could tolerate it. The needles were left in place for 60 minutes each time, once every other day, and the treatment was performed 3 times a week for 4 weeks, for a total of 12 treatments.
214910835|NCT07183644|DEVICE|Pulse Dye laser|"Pulse Dye Laser (PDL) standard settings. This is the same procedure children would receive as standard of care if these individuals were not participating in this study.~The surgeon will perform 1 pass with the PDL over the area of the Port wine birthmark (PWB)."
214910836|NCT07183644|DEVICE|Pulse Dye Laser (PDL) pulse width stacking|"This procedure is used for some patients as standard of care depending on the severity and depth of the lesion.~The surgeon will perform 3 passes with the PDL over the PWB, gradually increasing the pulse duration with each pass to effectively target both superficial and deeper blood vessels."
214910837|NCT07183644|DEVICE|Pulse Dye Laser (PDL) followed by Nd:YAG (Neodymium-doped Yttrium Aluminum Garnet laser) laser.|The combination of these two lasers is one of the investigational treatments. The surgeon will perform 1 pass per laser over the PWB. The 1st pass will be with the PDL to target the blood vessels closer to the top of the skin, followed by a 2nd pass with the Nd:YAG laser to target the blood vessels that deeper in the skin.
214910838|NCT07183644|DEVICE|IPL (Intense Pulsed Light) followed by Pulse Dye Laser (PDL)|The surgeon will perform 1 pass with the IPL followed by 1 pass with the PDL over the PWB
214910839|NCT07183644|DEVICE|Cupping followed by Pulse Dye Laser (PDL)|The combination of these modalities is one of the experimental procedures. The surgeon will place a small suction cup over the PWB target region of the PDL for a few seconds to stop the blood flow and accumulate the blood in that spot. The PDL treatment will then quickly proceed. Since the PDL targets red blood cells, it will allow the laser to target the pooled blood in the abnormal blood vessels better.
214910840|NCT07183241|BEHAVIORAL|Physical exercise and cognitive exercises|The intervention will be based on the Vivifrail program, which is a multicomponent physical exercise program designed specifically for older adults.
214910841|NCT07183527|BEHAVIORAL|CARES|Integrated screening and stepped collaborative care
214910842|NCT07183527|BEHAVIORAL|Standard of Care (SOC)|Screening and referral of patient to provider in the community or cancer center
214910843|NCT07182838|BIOLOGICAL|HIV Therapeutic Biologic Mix - HIV GP120 plus HIV GP41 plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* HIV GP120 0.5 mL plus HIV GP41 0.5 mL plus BCG Organism 50 MG Mix"
215058472|NCT01915537|DRUG|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
215058473|NCT01515579|DRUG|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
215058474|NCT01515579|DRUG|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
215058475|NCT03948893|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
215058476|NCT03948893|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
214303693|NCT06420778|DRUG|Pregabalin|Subjects in this group will be treated with oral pregabalin capsules only, 150 mg twice daily for 4 weeks.Pregabalin was administered with Lerica (specification: 75 mg\*8 capsules,manufactured by Pfizer Pharmaceuticals Ltd).
215058477|NCT02970591|OTHER|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
214910844|NCT07182916|OTHER|No intervention|Only observation
214910845|NCT07183033|BEHAVIORAL|VR-Based Resistance Training Intervention|"Participants in the intervention group will engage with a self-developed VR resistance training program entitled Kitten Crossing the Bridge. This program is designed to guide older adults through static lower-limb resistance exercises, while integrating rhythm control, spatial judgment, and visual feedback. The intervention will be administered over 4 weeks, with two sessions per week; each session will last approximately 20 minutes (excluding equipment setup and rest periods). All training sessions will be supervised by qualified staff to ensure participant safety and provide necessary support."
214910846|NCT07183033|BEHAVIORAL|Standardized Leg-Raising Training|Participants in the control group will implement a standardized leg-raising exercise protocol, which is designed to match the intensity and rhythm of the VR-based intervention. Training will be guided by pre-recorded verbal prompts and demonstration videos developed by the research team, ensuring procedural uniformity. Each session will last approximately 20 minutes (excluding equipment setup and rest periods), with two sessions per week over a 4-week duration. All sessions will be supervised by trained staff, who will monitor participant adherence and ensure safety throughout the process.
214910847|NCT07182994|PROCEDURE|Elbow joint immobilization|Immobilization of the elbow joint during peripheral venous line cannulation in pediatric patients on the success of the technique
214910848|NCT07182994|PROCEDURE|Arm restraint without elbow immobilization|Use of arm restraint without immobilization of the elbow joint during peripheral venous line cannulation in pediatric patients.
214910849|NCT07184437|DEVICE|OVD-F device Minivisc®PLUS 14 mg/ml|MINIVISC® PLUS 14 mg/ml is intended to protect, lubricate and support delicate ophthalmic cells or tissues, to assist in maintaining intraocular space and to enhance visualization during surgery.
214910850|NCT07183306|DRUG|HT-101|HT-101 given by subcutaneous injection.
214910851|NCT07183306|DRUG|HT-102|HT-102 given by subcutaneous injection.
214910852|NCT07182604|OTHER|educational program on the POP prevention|During a regular prenatal class meeting, parents belonging to this group received information about POP and how to prevent it (a presentation by a physiotherapist, a video shown to all centers participating in the study, practical demonstrations of activities using a doll, and a brochure with prevention tips). The children were then assessed at birth to rule out congenital disorders and at 3 months to detect any POP and associated postural problems. They were then sent a questionnaire to assess their perceived quality of the educational intervention carried out by the physiotherapist during the prenatal course.
214910853|NCT07182799|DIAGNOSTIC_TEST|Plaque vulnerability assessment|"The purpose of the OCT-AGEM registry is to confirm the clinical utility of plaque OCT assessment over the standard coronary angiography evaluation. In particular, this ambispective cohort study aims to validate the predictive value of the OCT-based plaque vulnerability criteria:~* Minimum lumen area \<3.5 mm2;~* Fibrous cap minimum thickness \<65 µm;~* Lipid arc extension \>180°;~* Presence of macrophages;~* Superficial and deep calcified nodules~* Ulceration/Erosion/Dissection~* Layered tissue~* Optical flow ratio (OFR)"
214910854|NCT07182799|DIAGNOSTIC_TEST|Stent implantation optimization|The purpose of the OCT-AGEM registry is to confirm the clinical utility of OCT guidance during PCI over the standard coronary angiography evaluation. In particular, this ambispective cohort study aims to validate the predictive value of the OCT-derived plaque/stent parameters reported in expert consensus OCT documents, utilizing the cut-off points identified in the previous OCT registries
215058478|NCT02970591|OTHER|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
215058479|NCT02970591|OTHER|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
215058480|NCT01469481|DRUG|PF-04991532|a single oral dose of \[14C\]PF-04991532 (450 mg/100 uCi suspension)
215058481|NCT04824664|OTHER|survey|survey among surgeon
215058482|NCT02947802|OTHER|Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages|In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
215058483|NCT02947802|OTHER|Control condition|In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
215058484|NCT04666142|OTHER|Comparison of the personal characteristics of the experimental and control groups|General characteristics of the individuals in the experimental and control groups were compared.
215058485|NCT04666142|OTHER|Light applied experimental group, control group treated with standard intensive care lighting|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"
215058486|NCT04285554|DEVICE|iRF System Hepatic Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).
215058487|NCT01504893|PROCEDURE|Protective one lung ventilation|Low tidal volume, PEEP and alveolar recruitment maneuver
215058488|NCT03863561|BEHAVIORAL|Diabetes self-management education (DSME) program|Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
215058489|NCT03804892|DIAGNOSTIC_TEST|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
215058490|NCT03804892|DIAGNOSTIC_TEST|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
215058491|NCT03804892|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
215058492|NCT03804892|OTHER|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
215058493|NCT03804892|OTHER|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
214910855|NCT07182344|DEVICE|Intermittent Theta Burst Stimulation to Right DLPFC|Participants receive intermittent theta burst stimulation (iTBS) applied to the right dorsolateral prefrontal cortex (DLPFC). The protocol consists of 600 pulses delivered in bursts of 3 pulses at 50 Hz, repeated at 5 Hz for 2 seconds, every 10 seconds, over approximately 3 minutes per session. Stimulation is delivered at 80% of the participant's active motor threshold. Ten sessions are administered across two weeks.
214910856|NCT07182344|DEVICE|Sham Intermittent Theta Burst Stimulation|Participants receive sham intermittent theta burst stimulation (iTBS) to the right dorsolateral prefrontal cortex (DLPFC) using a placebo coil. The coil replicates the sound and scalp sensation of active stimulation without generating sufficient magnetic output to alter cortical excitability. Session length, coil placement, and stimulation parameters are matched to the active iTBS condition. To preserve blinding, both participants and administering staff wear earplugs to minimize auditory differences between sham and active coils. This condition serves as a placebo control for evaluating iTBS effects on attention in children with ADHD.
214910857|NCT07183371|BIOLOGICAL|R21|A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein
214910858|NCT07183371|BIOLOGICAL|RH5.1|A soluble protein vaccine against the RH5 antigen
214910859|NCT07183371|BIOLOGICAL|R78C|A soluble RIPR EGF-CyRPA fusion protein vaccine
214910860|NCT07183371|BIOLOGICAL|Matrix-M™|A saponin-based vaccine adjuvant
214910861|NCT07183371|BIOLOGICAL|Rabivax-S|Rabivax-S is an inactivated, freeze-dried, single-dose vaccine. The vaccine contains purified, inactivated rabies antigen produced using Vero ATCC CCL 81 cells as the cell substrate, Pitman Moore (PM3218) as the virus strain, and sucrose, glycine and HSA (Human Serum Albumin) as excipients
214910862|NCT07183371|BIOLOGICAL|Menveo|Menveo is a tetravalent meningitis vaccine that consists of one vial of MenA powder and one vial of Men CWY solution.
214910863|NCT07183371|BIOLOGICAL|Avaxim 80|Avaxim 80 is an inactivated, adsorbed hepatitis A vaccine. Each immunising dose contains 80 antigen units of inactivated hepatitis A virus (GBM strain).
215058494|NCT01941654|RADIATION|preemptive local ablative therapy|
215058495|NCT01941654|DRUG|Oral TKI|
215058496|NCT02931838|DRUG|BMS-986165|
215058497|NCT02931838|DRUG|Placebo for BMS-986165|
215058498|NCT00693446|DRUG|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day."
215058499|NCT00693446|DRUG|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids."
215058500|NCT03238274|DEVICE|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
214303694|NCT06399354|DIETARY_SUPPLEMENT|acute intake of medium-chain fatty acids or long-chain fatty acids in patients|The intake of an oil comprising of either medium -chain fatty acids or long-chail fatty acids
214954832|NCT04467710|PROCEDURE|Laparoscopic common bile duct exploration.|"Laparoscopic common bile duct exploration. ERCP (Endoscopic Retrograde Cholangiopancreatography) with sphincterotomy : : removal of common bile duct stones trought the cystic duct (transcystically) with a Dormia or a choledoscope, or throught the common bile duct with a choledoscope introduced throught an incision of the common bile duct.~ERCP with sphincterotomy: removal of common bile duct stones throught the duodenal papilla, and a sphincterotomy of the oddi sphincter during the same time."
215058501|NCT04893512|DRUG|Orally Suspension of CoV2-OGEN1|CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
215058502|NCT03666338|OTHER|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
215058503|NCT02701764|DRUG|Pregabalin|
214303695|NCT06399354|DIETARY_SUPPLEMENT|Acute intake of medium-chain fatty acids or long-chain fatty acids in healthy individuals|Acute intake of MCT and LCT in healthy individuals in a cross-over design
214303696|NCT02382822|OTHER|No intervention.|
214303697|NCT03992729|DRUG|Pregnant women exposed to tildrakizumab|Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
215058504|NCT02701764|DRUG|Placebo|
215058505|NCT01633255|DRUG|18F-Fluciclatide|
215058506|NCT06295900|OTHER|Intervention 1 Group|20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.
215058507|NCT06295900|OTHER|Intervention 2 Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.
215058508|NCT06295900|OTHER|Placebo Control Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.
215058509|NCT05883202|DEVICE|Connect®|Restoration of multiple implants with a Connect® abutment between the implant and the prosthesis.
215058510|NCT05883202|DEVICE|Multi-unit|Restoration of multiple implants with a conventional multi-unit abutment between the implant and the prosthesis.
214910864|NCT07183254|OTHER|administration of questionnaires|"During this visit, the investigator will again explain the study objectives and procedure. Once these explanations have been provided, healthy volunteers will be able to give their informed consent to participate.~After signing the consent form, the following will be conducted during this visit:~* A medical examination.~* An electronic questionnaire including two consumption frequency assessment tools, adapted in French, to measure daily sugar and artificial sweetener intake.~* Five tests assess the level of dependence on alcohol, drugs (cannabis, solvents, tranquilizers, barbiturates, cocaine, stimulants, hallucinogens, or narcotics), gambling, video games, and possible eating disorders. Volunteers with a score deemed above the norm for at least one of these six tests will be excluded from this study.~* A urine screening test for drug use (cannabis, opiates, amphetamines, cannabinoids, benzodiazepines, cocaine) will be performed during this visit."
214910865|NCT07183254|OTHER|carrying out a MRI scan|"A functional exploration using resting-state fMRI and microstructural tissue organization using DTI will take place in the days following the inclusion visit, depending on the availability of research slots in the Department of Radiology and Imaging, Clermont-Ferrand University Hospital."
214910866|NCT07183254|DIETARY_SUPPLEMENT|"Can distribution visit for subjects in the non/low sweetener consumption group"|During this visit, scheduled following the MRI, subjects will go to the PIC/CIC where they will be given cans for the 5 weeks of the nutritional intervention (660 ml of sweetened beverage, or 2 cans per day). Subjects will be advised to arrive by car if possible and to park in the PIC/CIC parking lot at the foot of the building. Drinks will be provided to the subject in one or two batches (with an additional visit to the center to pick up any missing drinks) at the subject's convenience. They will also receive instructions for completing the electronic questionnaire to assess daily sugar and sweetener consumption. Subjects will complete this questionnaire weekly, which they will receive by email. Their email address will be collected during this visit.
214910867|NCT07183254|OTHER|carrying out a MRI scan|"A functional exploration using resting-state fMRI and microstructural tissue organization using DTI, post-nutritional intervention (5 weeks) in non- and low-sugar consumers: this exploration will take place depending on the availability of research slots at the Department of Radiology and Imaging, Clermont-Ferrand University Hospital."
214910868|NCT07184216|BEHAVIORAL|Person-centered care intervention|The intervention will be delivered by primary care nurses, in coordination with doctors, social workers, and psychologists from each center. Nurses, previously trained in person-centred care, will collect the family narrative regarding their experiences, needs, goals, and available resources. Based on this, a health plan will be co-created with the family, incorporating short- and long-term objectives, concrete actions, and the supports required. The plan will be reviewed and adapted in monthly follow-up consultations during a three-month period.
214910869|NCT07184125|DRUG|To measure anxiolysis, satisfaction level of patient after receiving Midazolam|Anxiety \& satisfaction
214910870|NCT07182825|BEHAVIORAL|Modified Multifidus Lift Exercise (MLE)|A supervised stabilization exercise protocol designed to selectively activate the lumbar multifidus muscle. In the quadruped position, the contralateral knee is maintained approximately 10 cm above the ground while the participant performs controlled trunk stabilization. Sessions are conducted twice weekly for 6 weeks, each including warm-up (5 minutes brisk walk, mobilization, hamstring stretch), the modified Multifidus Lift Exercise with progressive repetitions (weeks 1-2: 8-10, weeks 3-4: 10-12, weeks 5-6: 12-15), and cool-down (static stretches). All sessions are supervised to ensure correct form, breathing control, and safety.
214910871|NCT07181980|OTHER|Intercostal mulligan mobilization with shoulder abduction|"Intercostal mulligan mobilization with shoulder abduction: is mulligain technique where the patient was Side lying with affected side up and the therapist Therapist placed ulnar side of his hand along the intercostal space of affected rib in oblique direction on the patient's wall of chest. Therapist's other hand hold the patient's elevated arm close to his abdomen 3sets 10 reptations~* Assistive range of motion exercises (AAROME): Two sets of 15 repetitions of each exercise were performed for AAROME .~* Active stretching: Two sets of 10 repetitions with 15- sec hold and relax times were performed for active stretching.~* Strengthening exercises for the shoulder joint: Two sets of 15 repetitions of each exercise .~* Postural correction exercises: 3 sets of postural correction were performed with 3-5 repetitions per set.~* Scapular strengthening exercises : two sets of ten repetitions~* The Intervention protocol: 45 to 50 minutes sessions 3 days per week for 8 week"
214910872|NCT07181980|OTHER|Exercise|"1.3.b. Therapeutic Exercise:~* Therapeutic exercise included: (prior to 3 month post mastectomy).~* Assistive range of motion exercises (AAROME): Two sets of 15 repetitions of each exercise were performed for AAROME .~* Active stretching: Two sets of 10 repetitions with 15- sec hold and relax times were performed for active stretching. .~* Strengthening exercises for the shoulder joint: Two sets of 15 repetitions of each exercise .~* Postural correction exercises: 3 sets of postural correction were performed with 3-5 repetitions per set. .~* Scapular strengthening exercises : Strengthening exercises performed using weights were initiated with two sets of ten repetitions, beginning with a weight of 0.5kg and progressed to 0.75 and then 1 kg.~* The Intervention protocol: 45 to 50 minutes sessions 3 days per week for 8 week"
214910873|NCT07183046|BEHAVIORAL|Implementation Intention Guide|The intervention is the addition of implementation intention guide document provided with the FIT. This is a one-page piece of paper that was developed by the investigator team and finalized with input/feedback from patient partners. The implementation intention guide includes instructions about the importance of developing a plan to complete FIT. It also includes fillable fields for participants to enter their plan for when to complete, where to store, when to return, and where to return their FIT. Participants will also be able to follow a QR code on the implementation intention guide document to a link to complete an anonymous, electronic version of the guide and share feedback on the intervention.
214910874|NCT07182643|DIAGNOSTIC_TEST|Endometrial fluid|Endometrial fluid collection in the day of OPU
214910875|NCT07182643|DIAGNOSTIC_TEST|Endometrial biopsy|Endometrial biopsy on the OPU day, Pipelle
214910876|NCT07182643|DIAGNOSTIC_TEST|Follicular fluid|Follicular fluid sampling on the OPU day
214954833|NCT02238938|PROCEDURE|en-bloc resection|En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
215058511|NCT04625530|DRUG|ferric carboxymaltose|Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.
215058512|NCT04625530|DRUG|tranexamic acid|Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.
215058513|NCT04625530|DRUG|ferric carboxymaltose and tranexamic acid|Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
215058514|NCT02521974|BIOLOGICAL|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
215058515|NCT06716541|PROCEDURE|ERCP implantation of a biodegradable stent|Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a biodegradable stent to treat anastomotic biliary stricture (possibly combined with removal of previous plastic stents).
214910877|NCT07182292|DIETARY_SUPPLEMENT|Anti-Inflammatory Supplement|"A daily oral dose of Alisenoc™, an anti-inflammatory nutritional supplement specifically designed for older adults. Alisenoc™ contains olive oil polyphenols, omega-3 fatty acids (EPA/DHA), leucine-enriched protein, and antioxidant micronutrients to target inflammaging, sarcopenia, and nutritional deficiencies.~Participants will be followed at 12 weeks, and at 6 and 12 months for functional, biochemical, and clinical outcomes."
214910878|NCT07182292|DIETARY_SUPPLEMENT|Conventional Nutritional Supplement|"they will receive a conventional oral nutritional supplement that is isocaloric and protein-equivalent to the experimental product, but without anti-inflammatory ingredients.~This standard supplement reflects routine nutritional support typically provided in geriatric clinical practice for malnourished patients. It contains energy, protein, and micronutrients but no specific anti-inflammatory components such as olive polyphenols or omega-3 fatty acids."
214910879|NCT07184112|BEHAVIORAL|The Embedded Micro-Scenario Simulations (EMSS)|he Embedded Micro-Scenario Simulations (EMSS) for nursing students include a series of engaging clinical cases designed to bridge the theory-practice gap. In Prioritization of Care, students must prioritize three patients with varying degrees of urgency, honing their critical thinking skills. The Patient Education on Discharge scenario tasks them with effectively communicating self-care instructions. In End-of-Life Care, students provide compassionate support to a terminally ill patient and facilitate family discussions.
214910880|NCT07183735|DIETARY_SUPPLEMENT|BEAM Dream Powder|A powdered sleep supplement. Administered daily, mixed with 8-12 oz hot water, 30 minutes before bedtime during Weeks 3-6.
214910881|NCT07183735|DIETARY_SUPPLEMENT|Placebo Control|A powdered placebo product. Administered daily, mixed with 8-12 oz hot water, 30 minutes before bedtime during Weeks 1-2.
215058516|NCT06716541|PROCEDURE|ERCP implantation of plastic stents|Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a plastic stent or multiple stents to treat anastomotic biliary stricture (possibly combined with removal of previous plastic stents).
215058517|NCT06715020|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET scan.
215058518|NCT06714968|OTHER|Digital|After the pre-test application is completed, the students in the experimental group will be allowed to install the designed game application on their phones. After the installation process, students will be allowed to play the game for 2 weeks. After 2 weeks from the date of downloading the game, access to the game will be automatically blocked. After completing the application steps, when the student thinks that he/she is ready to apply the post-test, he/she will be able to perform the post-test application. In the post-test application, there will be no repeated return of the student to the questions or multiple answer submission. Two weeks after the application is completed, the knowledge test will be applied to the students again in order to objectively evaluate the learning. In this process, students will be prevented from accessing the application.
215058519|NCT02317198|DRUG|Clopidogrel|
215058520|NCT02317198|DRUG|Ticagrelor or Prasugrel|
214303698|NCT03992729|DRUG|Pregnant women not exposed to tildrakizumab|Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
214303699|NCT03297281|OTHER|Maintenance of OAC in surgery of BPH by PVP.|The maintenance of AVK or DOACs treatment in the perioperative setting (without interruption of oral treatment).
215058521|NCT06718959|DEVICE|the test product (Jet Floss EX)|subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add used the test product (Jet Floss EX) twice a day. Subjects used the test product (standard sprinkler, water twice) to flush all gingival margins and adjacent spaces with 440ml of water, start with water pressure gear 1 for the first time and continued with this gear after reaching the highest level that can be asapted. If felt uncomfortable, eligible subjects can adjust it to a suitable gear. The specific installation and usage of the teeth punch refer to the product instruction.
215058522|NCT06718959|OTHER|the control product (interdental brush)|subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add auxiliary product (interdental brush) twice a day.
215058523|NCT02949024|DRUG|IVT Aflibercept|IVT aflibercept \[2 mg (50 µL)\]
215058524|NCT02949024|DRUG|SC CLS-TA|\[4 mg (100 µL)\]
215058525|NCT02779868|DIETARY_SUPPLEMENT|Omega-3|patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.
215058526|NCT02779868|DIETARY_SUPPLEMENT|Olive oil|patients included in this group will take 4 capsules per day of olive oil.
214910882|NCT07183475|DIAGNOSTIC_TEST|Return to sports test|"The return-to-sport-tests are based on validated procedures commonly used in sports orthopedics, particularly following the stepwise testing concept described.~Initially, the participant's individual sport level is determined via structured anamnesis. This is then followed by level-specific functional testing. Participants who do not perform Level 1 testing correctly will not proceed to Level 2 testing-even if their anamnesis suggests a higher sport level. This stepwise approach ensures safety and prevents injury during the testing process."
214910883|NCT07183228|BEHAVIORAL|Lifestyle Intervention for Obesity|A multimodal obesity lifestyle program delivered via the Eatit app. The dietitian-led intervention consists of 11 structured modules with weekly dietitian support (video consultations and messaging) during the first 11 weeks, followed by monthly video consultations up to six months. The program integrates behavior change techniques with individualized nutrition counseling provided by licensed dietitians.
214910884|NCT07182578|OTHER|Aquatic Occupational Therapy|Aquatic Occupational Therapy sessions will be 60 minutes long, with 45 minutes spent in the pool. Sessions will include a gentle floating, stretching, or aqua yoga warm-up and an ai chi cooldown. Exercises in the first month will include a focus on balance, breathing, and sensory work. Exercises in the second month will focus on building strength and endurance, while the third month will combine all of the above with dual-task completion. Activities will be graded down (made less difficult) or graded up (made more challenging) according to individual participant needs.
214910885|NCT07183943|OTHER|Proprioceptive neuromuscular facilitation (PNF)|Training was performed in different positions (decubitus, sitting, and standing) according to the specific exercise. the participants performed 10 minutes of diagonal scapula exercises (anterior and posterior elevation) and 30 minutes of upper limb diagonals (Flexion-Abduction-External Rotation and Extension-Abduction-Internal Rotation), including the 5 initial minutes of stretching.
214910886|NCT07183943|OTHER|Visual reality (VR)|The site of the intervention was a 20-square-meter room equipped with a multimedia projector, which projected the image on the wall at a height of 1 m and 20 cm. A professional physical therapist supervised the treatment continuously, and every participant received prior instructions on the conduct of the games. The therapeutic protocol included 4 electronic games: Balance Bubble Plus, Rhythm Parade, Tennis, and Box.
214910887|NCT07183943|OTHER|PNF and VR|The total duration of the sessions remained consistent. The participants performed 5 minutes of scapula diagonals and 15 minutes of upper limb diagonals in the weekly session. The games for the PNF/VR group were the same as those for the VR group, except for their duration. Whereas they were performed for 20 minutes each in the VR group, the session including 5 minutes of stretching.
214910888|NCT07182812|BEHAVIORAL|Blood Flow Restriction Sit-to-Stand Exercise|Participants perform sit-to-stand (STS) exercises with blood flow restriction applied using a pneumatic cuff placed on the thigh. Cuff pressure is set at 60-80% of the participant's systolic blood pressure. Sessions are supervised by a physiotherapist twice per week for six weeks.
214910889|NCT07182812|BEHAVIORAL|Sit-to-Stand Exercise without Blood Flow Restriction|Participants perform the same sit-to-stand (STS) exercise protocol as the experimental group, but without blood flow restriction. Sessions are supervised twice weekly for six weeks, and outcomes are assessed before and after the program.
214910890|NCT07184320|BEHAVIORAL|AI-Based Video Education on Denture Care|The intervention consists of an AI-based educational video module, approximately 8 minutes in duration, designed to improve denture care practices. It uses step-by-step, visually engaging demonstrations with AI-guided narration to enhance understanding, recall, and adherence.
215058527|NCT02136225|BEHAVIORAL|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
215058528|NCT01027650|DRUG|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
215058529|NCT01027650|DRUG|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
215058530|NCT05031143|DRUG|Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease|Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
215058531|NCT00994825|DRUG|Levosimendan|
215058532|NCT00994825|DRUG|placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
215058533|NCT01189344|DRUG|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
215058534|NCT05712577|OTHER|Questionnaire|Rosenberg Self- Esteem scale
215058535|NCT05712577|OTHER|Questionnaire|Short Form 36 scale
215058536|NCT05712577|OTHER|Questionnaire|Coping orientation to the problems experienced - New Version in Italian
215058537|NCT05712577|OTHER|Questionnaire|Outcome Questionnaire - version 42.5
215058538|NCT04244695|DRUG|Dexamethasone Oral|To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
215058539|NCT04695353|PROCEDURE|Telemedicine: Virtual visits (videoconferences, texts)|Patients will receive clinical care by using telemedicine (virtual visits)
215058540|NCT00076089|DRUG|Roflumilast|
214303700|NCT03297281|OTHER|Discontinuation of OAC in surgery of BPH by PVP.|The discontinuation of AVK or DOACs treatment with perioperative heparin relay during postoperative course.
214303701|NCT03813979|DRUG|Dolutegravir|Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach
214303702|NCT03842124|OTHER|Force gauge|The investigators postulate that use of bidirectional traction (superior and inferior directions) and feedback from a digital force gauge is associated with minimal lead displacement compared to conventional lead extraction.
214910891|NCT07184320|BEHAVIORAL|Conventional Oral Health Instruction|Participants in the control group will receive conventional oral health education delivered verbally and chairside by the prosthodontic team. The standardized instruction includes information on denture hygiene techniques, appropriate storage of dentures overnight, mucosal care
214910892|NCT06667219|BEHAVIORAL|A relevant physical fitness training program intervention|"54children who participated in after-school sports activities in Guangzhou Kindergarten (Guangzhou, China) were randomly selected as the experimental group.~Intervention group Length:12 weeks, 40 minutes, twice a week.~Intervention content:~The intervention will be conducted using a relevant physical fitness training program , as follows: Week 1 / 4 first: Run quickly;Durian ball;Throw;Fast jogging (200 m) Week 1 / 4 second: Dodge run,Raise your legs high and go over the small hurdles; Durian ball (standing on one foot);standing long jump Week 2 / 5 first: Bow step transformation jump;Throw;Turn back 10 meters Week 2 / 5 second: Hop ;Stand on one foot with your eyes open Week 3 / 6 first:Skip over the small hurdles;Durian ball (standing on one foot);Throw; Fast jogging (200 m) Week 3 / 6 second:Jump on your feet and dodge running;Durian ball (squat);Jump support Weeks 7-12,Repeat the above content. FMS index was tested before the experiment, and once after the intervention."
214910893|NCT06667219|BEHAVIORAL|control group,Physical exercise using kindergarten standards|"54 children who did not participate in after-school sports activities were selected as the control group.~control group Duration: 12 weeks. Content: Physical exercise using kindergarten standards. FMS index was tested the same to intervention group before the test and FMS index was measured once again after 12 weeks."
214303703|NCT02446990|DRUG|Ivabradine|5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
214303704|NCT02446990|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
214303705|NCT03398057|OTHER|Health education|SHEP included a comprehensive lecture about BC, with a generally deep focus on detection and screening tools, which were illustrated by a PowerPoint presentation with pictures and videos. The program also included a practical session about BSE (on breast silicon model). At the end of SHEP, a focused group discussion was conducted to answer participants' questions, and to discuss important barriers regarding BSE practice and visiting primary health care centers or clinics to undergo CBE and mammography. Different scientific and administrative solutions were discussed. SHEP materials were distributed as a hard copy (booklet) and in electronic format (CD) for all participants in the health education group at the end of training.
214303706|NCT03398057|OTHER|Control group|Placebo health education (pamphlets) will be applied to this group participants during study.
214910894|NCT02946476|OTHER|prognostic impact of non cardiac comorbidities|
214910895|NCT01120184|DRUG|docetaxel|75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
214910896|NCT01120184|DRUG|paclitaxel|80 mg/m2 intravenously weekly for a minimum of 18 weeks
214303707|NCT02409992|BEHAVIORAL|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
214303708|NCT02409992|BEHAVIORAL|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
214910897|NCT01120184|DRUG|pertuzumab|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
214910898|NCT01120184|DRUG|pertuzumab-placebo|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
214910899|NCT01120184|DRUG|trastuzumab [Herceptin]|trastuzumab \[Herceptin\] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
214910900|NCT01120184|DRUG|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks
214910901|NCT04003636|BIOLOGICAL|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
214910902|NCT04003636|DRUG|Gemcitabine|Gemcitabine by IV infusion
214910903|NCT04003636|DRUG|Cisplatin|Cisplatin by IV infusion
214910904|NCT04003636|DRUG|Placebo|Placebo to pembrolizumab
214910905|NCT03611647|DIETARY_SUPPLEMENT|Probiotic|Probiotic dietary supplement containing a mixture of Lactobacillus and Bifidobacterium species, taken by mouth once daily for 4-6 weeks.
214910906|NCT03611647|DIETARY_SUPPLEMENT|Placebo|Placebo, taken by mouth once daily for 4-6 weeks.
214910907|NCT00209261|DRUG|MINIRIN Oral Lyophilisate|
214910908|NCT00209261|DRUG|Minirin tablet|
214910909|NCT05058482|DEVICE|embolism|Cerebral arteriovenous malformation embolism
214910910|NCT01747031|DEVICE|PressureWire™ Certus(St. Jude Medical Systems, Sweden)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
214910911|NCT04536974|DIAGNOSTIC_TEST|SEFI tool|Detect the risk of malnutrition with the SEFI tool
214910912|NCT04771572|DRUG|LP-118|novel, oral, selective treatment for hematological malignancies tested through ascending dose levels
214910913|NCT00457145|DRUG|Ranibizumab|
214910914|NCT05651048|OTHER|Control Group|Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
214910915|NCT05651048|OTHER|BEMER Group|BEMER therapy and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
214910916|NCT05651048|OTHER|Kinesiotape Group|Kinesiotape application and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
214910917|NCT02348788|DRUG|Artemether-lumefantrine + Primaquine|
214910918|NCT02348788|DRUG|Chloroquine + Primaquine|
214910919|NCT05561270|DEVICE|White LED light|Exposure to white LED light for 1-2 hours/day x 10 weeks
215058541|NCT03569358|DEVICE|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
214910920|NCT05561270|DEVICE|Green LED light|Exposure to green LED light for 1-2 hours/day x 10 weeks
214910921|NCT02838797|DRUG|RQ-00000010|orally administered serotonin 4 receptor partial agonist
214910922|NCT02838797|DRUG|Placebo|oral acetate buffer
214910923|NCT00312273|DRUG|Aminophylline (250mg IV +/- a second dose of 250mg IV)|
214910924|NCT05783440|BEHAVIORAL|direct patient feedback|"Participants in the intervention group report postoperative pain scores and other pain related outcomes with their own smartphone. Pain scores reported by smartphone \> 3 (NRS 0-10) are immediately passed on to the nurse who will receive a notification on a smartphone.~All patient reported pain-scores by smartphone are stored in a database that is not accessible to medical or nursing staff from the nursing ward."
214910925|NCT02649491|OTHER|Cohort Observation|Study participation will be offered to women, newly diagnosed with a gynecological malignancy who are due to be treated with pelvic radiotherapy.
214910926|NCT05749744|OTHER|cardiac telerehabilitation program by videoconference|"* A video conference interview with an Adapted Physical Activity (APA) teacher before starting physical training~* Exercise training for 3 weeks via distance coaching~* Therapeutic patient education (TPE) workshops conducted remotely with 1 workshop per week.~* Medical follow-up via teleconsultation~* Psychological and/or dietetic follow-up if necessary.~* Final assessment at 1 month with evaluation of aerobic metabolism, functional evaluation and final shared educational assessment (BEP).~* Appointment with an association Cœur et Santé and Sport-Santé 42 or setting up of an individual physical activity"
214910927|NCT03656068|DRUG|Nitazoxanide 500mg BID|Patients will receive 500mg of Nitazoxanide BID daily for 24 weeks
214910928|NCT02333344|DRUG|Zoledronic acid 5mg|two-year Zoledronic acid 5mg infusion treatment
214910929|NCT02040103|DEVICE|pneumatic compression|All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.
214910930|NCT00020072|OTHER|laboratory biomarker analysis|
214910931|NCT03040778|DRUG|Pentoxifylline|Pentoxifylline is a commonly used medication for muscle pain associated with peripheral artery disease. It is a methylated xanthine derivative that improves peripheral blood flow, flexibility of red blood cell membranes, microcirculation, and tissue oxygenation and reduces viscosity of blood.
215058542|NCT03569358|DEVICE|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
214910932|NCT03040778|DRUG|Placebo|Placebo tablets
214910933|NCT03040778|DRUG|Tocopherol|Tocopherol (vitamin E) impairs tissue fibrosis and is a potent oxygen radical scavenger that may reduce damage caused by free radicals impacting necrosis.
214910934|NCT04033731|BEHAVIORAL|Attention Network Task|The Attention Network Test (ANT) is a computerized cognitive task designed to efficiently probe three independent but interactive attentional networks (alerting, orienting, executive control) in a single task paradigm.
215058543|NCT00912782|DRUG|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
215058544|NCT00912782|DRUG|Placebo|Placebo one time per week for 3 weeks
215058545|NCT03173976|DRUG|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
215058546|NCT05551923|OTHER|intestinal flora disturbance|To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
215058547|NCT03419897|DRUG|Tislelizumab|Administered intravenously
215058548|NCT04769323|DEVICE|Virtual Reality|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
215058549|NCT04769323|OTHER|Traditional home exercises|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
215058550|NCT06378632|DEVICE|Hearo App|No intervention - only data collection
215058551|NCT00202215|BEHAVIORAL|Chrysalis Day Program|
215058552|NCT06138600|DRUG|Cabotegravir Injection [Apretude]|White to slightly pink free flowing suspension suspension for injection contained in a brown coloured vial. Each vial is for single use and does not require dilution prior to administration.
215058553|NCT06138600|DRUG|Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)|TDF/FTC is currently available as standard of care for PrEP in the public sector as per the department of health guidelines.
214910935|NCT04989478|OTHER|Fasting|After the standardized breakfast meal, all participants will only consume water for 24 hours
214910936|NCT01904526|DRUG|Guanfacine|3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
214910937|NCT06477133|DRUG|Magnesium sulfate|Pre-mixed solution of 2 grams of magnesium sulfate dissolved in 20 mL sterile water
214910938|NCT05323812|DRUG|TW001|daily dose of 100 mg TW001/placebo
214910939|NCT05323812|DRUG|Placebo|daily dose of 100 mg TW001/placebo
214910940|NCT03829605|OTHER|Measurement of hydrogen sulfide|Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia
214910941|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 1|0.5 mL, intramuscular (1 middle dose)
214910942|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 2|0.5 mL, intramuscular (2 low doses)
214910943|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 3|0.5 mL, intramuscular (2 middle doses)
214910944|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 4|0.5 mL, intramuscular (2 middle doses)
214910945|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 5|0.5 mL, intramuscular (2 high doses)
214910946|NCT01444339|BIOLOGICAL|Placebo|0.5 mL, intramuscular
215058554|NCT00867958|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
215058555|NCT03337867|DEVICE|Magstim Super Rapid2 System|Intermittent theta-burst-stimulation (iTBS) protocol
214303709|NCT06261554|DIETARY_SUPPLEMENT|Dietary Supplement: Low dose OIT|Following the building-up phase (up to 14 months), patients will receive a daily low dose of sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread for 3 months (12 +/- 3 weeks).
214910947|NCT03270657|DEVICE|IPG; RC+S|We will measure the effects of varying stimulation parameters on the neural activity in subjects with Parkinson's disease (PD).
214910948|NCT00810212|PROCEDURE|PLF with autograft|6 subjects
214910949|NCT00810212|BIOLOGICAL|PLF with NeoFuse|6 subjects low dose
214910950|NCT00810212|BIOLOGICAL|PLF with NeoFuse|6 subjects medium dose
214910951|NCT00810212|BIOLOGICAL|PLF with NeoFuse|6 subjects high dose
214910952|NCT00017810|BEHAVIORAL|Dietary intervention|"The dietary intervention focused on diarrhea management using skill-building techniques that provided subjects with knowledge and a sense of confidence about making food choices.~Behavioral dietary intervention (Condition 1: treatment) - a low-fat, lactose-free, low insoluble fiber, high soluble fiber, and caffeine-free diet based on normal foods"
214910953|NCT00017810|BEHAVIORAL|HIV Self-Care|Standard information regarding self-care and healthy living with HIV - focused on healthy living with HIV and did not include dietary restrictions or dietary information that could affect bowel movements.
214910954|NCT00162981|DRUG|Clobazam Low Dose|5 to 10 mg/day with doses in the morning and at bedtime; orally
214910955|NCT00162981|DRUG|Clobazam High Dose|5 to 40 mg/day with doses in the morning and at bedtime; orally
214910956|NCT04181086|PROCEDURE|surgical excision of intracranial cavernoma|microvascular excision of intracranial cavernoma
214910957|NCT04930744|DRUG|Isoniazid|Isoniazid, dose prescribed by participant's physician, will be taken by mouth daily. Isoniazid, is in a combination pill pack with the other standard ATT medications.
214910958|NCT04930744|DRUG|Rifampicin|Rifampicin, dose prescribed by participant's physician, will be taken by mouth daily. Rifampicin is in a combination pill pack with the other standard ATT medications.
214910959|NCT04930744|DRUG|Ethambutol|Ethambutol, dose prescribed by participant's physician, will be taken by mouth daily. Ethambutol is in a combination pill pack with the other standard ATT medications.
214910960|NCT04930744|DRUG|Pyrazinamide|Pyrazinamide, dose prescribed by participant's physician, will be taken by mouth daily. Pyrazinamide is in a combination pill pack with the other standard ATT medications.
214910961|NCT04930744|DRUG|Metformin hydrochoride|Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to study twice daily through study week-12 (11 weeks total metformin treatment).
214910962|NCT04977895|DIAGNOSTIC_TEST|Minimal residual disease (MRD) monitoring|Minimal residual disease (MRD) assay using IgH-V(D)J NGS and FCM
214910963|NCT01323517|DRUG|Ipilimumab, Melphalan and Dactinomycin|Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
214910964|NCT04152135|PROCEDURE|vena cava inferior diameter measurement|Ultrasound equipment with convex probe will be used to measure IVC diameters of the patients in supine position.The IVC sagittal section is described with the probe in the area of subxiphoid. IVC diameters at the junction point of the IVC and right atrium (2cm caudal) are standardized measurement.
214910965|NCT03154541|DRUG|Synrinse|"Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse."
214910966|NCT03312036|DEVICE|Coupled plasma filtration and adsorption (CPFA)|"Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a bridge to liver transplantation"
214910967|NCT04453319|PROCEDURE|Femoral Wound Closure and dressing|Femoral Wound Closure and dressing
214910968|NCT06250621|PROCEDURE|Implant placement|"Implants were placed by means of a template for a guided surgery approach (GD Group) or with a standard free-hand surgical approach without any additional device (FH Group). A non expert doctor (less that 20 implants placed in the professional activity) was selected for the procedures related to the GD Group; a skilled operator (more than 1000 implants placed in the professional activity) was selected for the procedures related to the FH Group, respectively.~A two-stage surgical technique was chosen. Implants were placed (Anyridge, Megagen Implants, Seoul, Korea) 1 mm below the crestal level, as recommended by the manufacturer. After flap elevation the height of the supra-crestal soft tissue (STH) was measured by means of a calibrated probe.~An inter-implant distance of 3 mm at least, and/or an interproximal space from 1.5 to 3 mm between an implant and the adjacent tooth were observed.~Flaps were sutured over the implants to allow a submerged healing."
215058556|NCT03337867|DEVICE|Magstim Super Rapid2 System|Sham stimulation
214303710|NCT03509025|DRUG|Jointstem|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
214303711|NCT00865774|BEHAVIORAL|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
215058557|NCT03759639|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
215058558|NCT03752996|DEVICE|ACURATE TF™ Aortic Valve System|Transcatheter Aortic Valve Implantation
214303712|NCT00865774|BEHAVIORAL|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
214303713|NCT03158051|BEHAVIORAL|Home Blood Pressure Monitoring|Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.
214910969|NCT04181021|BEHAVIORAL|Values Clarification and Attitudes Transformation (VCAT) Workshop|VCAT is a participatory workshop aimed to provide accurate information about abortion and family planning and space to engage in critical self-reflection, provoke dialogue on beliefs, values and professional ethics and responsibilities around providing abortion and contraceptive care, and provide a deeper understanding of the range of circumstances in which women seek abortion and contraception.
214910970|NCT00455403|DRUG|Chloroquine|One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
214910971|NCT00455403|DRUG|Placebo Comparator|Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
214910972|NCT01985243|BEHAVIORAL|Nutrition and agriculture|The intervention includes two components: (1) nutrition education on infant and young child nutrition, and (2) agriculture and small animal husbandry intervention to increase women's income and the accessibility of animal source foods for infants and young children.
214910973|NCT01985243|BEHAVIORAL|Iron-rich food & business literacy|The intervention includes two components: (1) a behavioural change intervention to improve school meals and increase the available iron in adolescents' diets, (2) savings \& business literacy program for young female adolescents to encourage them to stay in school.
214910974|NCT04162743|DRUG|Trazodone|take trazodone 100mg before polysomnography
214910975|NCT04162743|DRUG|Placebo oral tablet|take placebo oral tablet before polysomnography
214910976|NCT01408290|BIOLOGICAL|Vaccination with FAB-3511|One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
214910977|NCT01408290|BIOLOGICAL|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
214910978|NCT01408290|BIOLOGICAL|Vaccination with FAB-9011|One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
214910979|NCT01408290|BIOLOGICAL|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
214910980|NCT03015337|BEHAVIORAL|New physical education instructions|
214910981|NCT03513237|PROCEDURE|Cervical dilation|manual dilatation of the cervix using surgeon's finger.
214910982|NCT02391688|DRUG|Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam|
214910983|NCT02391688|DRUG|Bupropion|
214910984|NCT02391688|DRUG|Fexofenadine|
214910985|NCT02389478|PROCEDURE|Oropharyngeal administration of colostrums|rubbing drops of colostrum inside a baby's cheeks using a sterile syringe
214910986|NCT02389478|PROCEDURE|Oropharyngeal administration of Normal saline|rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
214910987|NCT00350207|DRUG|Tiotropium bromide|
214910988|NCT00350207|DRUG|Placebo|
214910989|NCT00350207|DRUG|Salmeterol xinafoate|
214910990|NCT03342378|RADIATION|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) will be delivered over 6.5 weeks in 33 daily fractions. Treatments will be initiated on Monday or Tuesday. Missed treatments will be compensated for by delivering an additional BID treatment during the week given at least 6 hours apart OR treating on the Saturday of that week, OR adding to the end of treatment. Gross disease will receive 70 Gy in 2.12 Gy fractions, areas at high-risk for subclinical disease will receive 60 Gy in 1.82 Gy fractions, and areas at low-risk for harboring subclinical disease will receive 56 Gy in 1.70 Gy fractions.
214910991|NCT03342378|DIAGNOSTIC_TEST|PET-MRI|All imaging data will be acquired using a 3.0T PET-MRI scanner with a standard bore size of 60 cm. Patients will be placed in standard non-ferrous head and neck immobilization devices during PET-MRI to simulate their anticipated positioning during subsequent CT simulation and treatment. A head and neck PET-MRI study will be performed with scan sequences tailored for the site of interest. The PET-MRI exam will take approximately 90 minutes to complete.
214303714|NCT03158051|BEHAVIORAL|Telephone Health Coaching|Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
214303715|NCT05249361|OTHER|no intervention|no intervention
214303716|NCT00215163|DRUG|Cognitive-behavioral therapy and paroxetine-CR|
214910992|NCT02554071|OTHER|Pharmacist - Smoking Cessation Support|Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
214910993|NCT00495391|DRUG|Nitazoxanide|One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
215058559|NCT00958360|OTHER|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
214910994|NCT00495391|DRUG|Placebo|One oral placebo tablet twice daily for 52 weeks.
214910995|NCT00495391|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
214910996|NCT00495391|DRUG|Ribavirin|1000 mg (if \<75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
214910997|NCT01492829|BEHAVIORAL|individual and group-based, community health worker delivered|Pre-test will be individual, tablet-based; participants will receive correct information for incorrect HIV/STI knowledge responses and will watch a brief HIV/STI educational video. This will be followed by participants attending 6 weeks of group educational sessions focused on: HIV, STI, interpersonal relationships, communication and decision-making, mental health and coping, creating social change
214910998|NCT03813173|PROCEDURE|lymph node dissection|The patient was operated under general anesthesia with cervical hyper extension. The affected side or bilateral glandular lobes were resected routinely, which was confirmed as PTC by frozen section. Then one or both central lymph node dissection were separately packed and sent for examination. Scope of lymph node dissection in central carotid region: hyoid bone at the upper border, anonymous artery at the lower border, bilateral common carotid artery at the inner edge, shallow from the superficial layer of deep cervical fascia, deep to the deep layer of deep cervical fascia (anterior fascia). The right recurrent laryngeal nerve (RLN) passes through the central area of the right neck and should be specially protected.
214910999|NCT06347224|PROCEDURE|Virtual placement of lag screws in both columns of the acetabulum on 3D pelvic CT models.|The intervention aims to simulate a percutaneous fixation technique that could be applied in a real surgical environment, offering insights into the potential for personalized surgical planning and optimization of outcomes for patients with acetabular fractures. This virtual approach allows for the exploration of various screw placement strategies without the ethical and practical constraints of direct clinical experimentation.
214911000|NCT01366924|DIETARY_SUPPLEMENT|Essential Amino Acids|10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
214911001|NCT01366924|OTHER|Endurance exercise|60 minute endurance exercise session
214911002|NCT04604756|DRUG|Losartan|administration of losartan (50 mg) (oral)
214911003|NCT04604756|DRUG|Placebo Oral Tablet|administration of placebo (oral)
214911004|NCT01310842|BEHAVIORAL|Questionnaires|Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.
214911005|NCT01310842|DRUG|Nicotine Patch Therapy|4 weeks of nicotine patch therapy
214911006|NCT01310842|BEHAVIORAL|Counseling Sessions|5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.
214911007|NCT03566199|DRUG|Panobinostat Nanoparticle Formulation MTX110|Given IT
214911008|NCT03566199|DRUG|Convection-Enhanced Delivery (CED)|Undergo CED
214911009|NCT02352571|BIOLOGICAL|GC1118|"For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.~For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.~For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers.~Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease."
214911010|NCT04509076|BEHAVIORAL|PrEP iT! (plus usual PrEP care)|"The PrEP iT! intervention is a mobile-optimized website, with the following components:~* PrEP Adherence, PrEP Appointment, and Sexual Activity Self-Monitoring~* Tailored feedback on PrEP adherence/non-adherence~* PrEP and sexual health information tailored for YMSM~* Text message reminders for PrEP adherence and healthcare appointments~* An ask the expert feature"
214911011|NCT04509076|BEHAVIORAL|Usual PrEP care|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
214911012|NCT06577168|OTHER|Levonogestrel Intrauterine system (LNG-IUS)|Contraception method
214911013|NCT03707223|BEHAVIORAL|The Interfaces Program|career development program
214911014|NCT03707223|BEHAVIORAL|IPS|supported employment using the individual placement and support (IPS) model
214911015|NCT00459862|OTHER|laboratory biomarker analysis|Correlative study
214911016|NCT00459862|DRUG|pazopanib hydrochloride|Given orally
214911017|NCT00038402|DRUG|Herceptin|Starting dose of 4 mg/kg by vein, then 2 mg/kg weekly after that until the end of all cycles of neo-adjuvant chemotherapy and during FEC therapy for a total of 24 doses.
214911018|NCT00038402|DRUG|Taxol|225 mg/m\^2 by vein as a continuous infusion over 24 hours each cycle for a total of 4 cycles.
214911019|NCT00038402|DRUG|Fluorouracil|500 mg/m\^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.
214911020|NCT00038402|DRUG|Cytoxan|500 mg/m\^2 on Day 1 of each cycle for 4 cycles.
214911021|NCT00038402|DRUG|Epirubicin|75 mg/m\^2 IV on Day 1 of each cycle for 4 cycles.
214911022|NCT05340764|DRUG|Infliximab|Infliximab is an effective and commonly used medication to treat patients with IBD
214911023|NCT01953302|PROCEDURE|"modified open mesh technique"|We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.
214911024|NCT00502242|DRUG|ramipril|Capsule - initial treatment is 5 mg (active)- oral - once per day
214911025|NCT00502242|DRUG|ramipril|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
214911026|NCT02361099|OTHER|Monitoring by SENTINEL application|Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application
214911027|NCT05392842|DIETARY_SUPPLEMENT|Corchorus Olitorius Buccal fast dissolving Films|Corchorus Olitorius Buccal fast dissolving Films
214911028|NCT05392842|DIETARY_SUPPLEMENT|plain mucoadhesive fast dissolving film|plain mucoadhesive fast dissolving film
214911029|NCT05335837|PROCEDURE|Regional Anesthesia and Sedation|Preoperative ilioinguinal/iliohypogastric nerve block and moderate to deep intraoperative sedation.
214911030|NCT04646265|OTHER|periodontal treatment|non-surgical root debridement
214911031|NCT00998920|DRUG|S-equol|oral, BID, 14 days
214911032|NCT00998920|DRUG|Placebo|oral, BID, 14 days
214911033|NCT03425591|DRUG|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.
215058560|NCT00958360|OTHER|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
215058561|NCT00425022|PROCEDURE|thoracoscopy|
215058562|NCT02719691|DRUG|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
214911034|NCT01812109|DEVICE|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy|Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes \~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
214911035|NCT05584956|DRUG|L_carnitine|l-carnitine stabilizes red blood cell membranes and thus improves the anemic state\[
214911036|NCT05584956|DRUG|Sildenafil|selective and potent inhibitor of cGMP-specific phosphodiesterase 5 (PDE5), which promotes smooth muscle relaxation in lung vasculature, has been used successfully in the treatment of primary and secondary PH.
214911037|NCT03285828|BEHAVIORAL|motivationnal interviewing training|"The students received three four-hour sessions of basic motivationnal interviewing training :~1. Viewing and commenting on video clips illustrating motivational and non-motivational doctor-patient interactions.~2. Lectures and the distribution of memory aids.~3. Practical exercises: making reflections, asking open questions; exploring ambivalence; dealing with resistance; expressing empathy, summarising.~4. Role-playing, based on several situations, each involving two students. The investigators deliberately chose a non-medical situation (conflict between a mother and a student asking her for pocket money to go out for fun, the day before a university examination) for the first situation. All the other situations concerned changes to healthier behaviour in a medical setting, but with a goal different from that used for the first or the second simulated interview before motivationnal interviewing training."
214911038|NCT05820529|PROCEDURE|adenotonsillectomy|removal of adenoid,tonsil in one session
214911039|NCT05820529|PROCEDURE|adenoidectomy|removal of adenoid
214911040|NCT05820529|PROCEDURE|tonsillectomy|removal of tonsil
214911041|NCT03313180|DRUG|Nintedanib|Administered twice daily
214911042|NCT00461630|DRUG|ER niacin/laropiprant|
214911043|NCT00461630|DRUG|simvastatin|40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
214911044|NCT00461630|DRUG|ezetimibe/simvastatin|10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
214911045|NCT00444522|DRUG|Alprazolam thermal aerosol|
214911046|NCT01215396|DIETARY_SUPPLEMENT|AminoVital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener.
214911047|NCT01215396|DIETARY_SUPPLEMENT|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and an amino acid mixture (2.4g of AA as: leucine, isoleucine, valine, arginine and glutamine).
214911048|NCT01215396|DIETARY_SUPPLEMENT|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and a double dose of the amino acid mixture (4.8 g of AA as: leucine, isoleucine, valine, arginine and glutamine).
215058563|NCT02719691|DRUG|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
215058564|NCT05420181|OTHER|Short 10hr fast|Participants will fast from 11pm the night before the study day
215058565|NCT05420181|OTHER|Long 16h fast|Participants will fast from 5pm the night before the study day
215058566|NCT00336284|OTHER|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
215058567|NCT00336284|OTHER|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
215058568|NCT02159898|DEVICE|EndoMAXX Endoluminal Valve Technology (EVT)|
214911049|NCT02920502|DIETARY_SUPPLEMENT|Arm 2: cholecalciferol 50,000 IU|One time dose of cholecalciferol 50,000 IU
214911050|NCT02920502|DIETARY_SUPPLEMENT|Arm 3: cholecalciferol 100,000 IU|One time dose of cholecalciferol 100,000 IU
214911051|NCT02920502|DIETARY_SUPPLEMENT|Arm 4: cholecalciferol 200,000 IU|One time dose of cholecalciferol 200,000 IU
214911052|NCT02920502|OTHER|Arm 1: Placebo|One time dose of Placebo
215058569|NCT02159898|DEVICE|EndoMAXX|
215058570|NCT06304181|DRUG|Paracetamol and Mannitol Injection|Paracetamol and Mannitol Injection 500mg
215058571|NCT06304181|DRUG|Parecoxib|40mg of parecoxib
215058572|NCT02810912|OTHER|the effect of surgical position|Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
215058573|NCT01185314|PROCEDURE|Testing for mutation status|EGFR mutation test
215058574|NCT04897230|BEHAVIORAL|Hatha Yoga|The yoga poses were chosen for providing a restorative session based on their purported relationship to restorative effects to best promote cardiac autonomic recovery from mental stress.
215058575|NCT04897230|BEHAVIORAL|Video Watching|The video was about the history of the Earth which encompasses the development of the planet Earth from its formation to the present day.
214346947|NCT03579979|DRUG|Indocyanine Green|Within 5 minutes after MB injection, 2.5mg/ml ICG 0.5ml was injected at each point, a total of 2-3 points. Methylene blue and ICG injection points do not coincide
214911053|NCT05087264|DRUG|Indocyanine green|ICG retention test and clearance test: intravenous injection, 0.5mg/l. Liver blood flow measurement: intravenous drip, dissolve 25mg ICG in 100ml injection water, and drip at a constant speed for about 50min to make the ICG concentration reach equilibrium.
214911054|NCT02546375|DRUG|Bosutinib|Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
214911055|NCT04640454|PROCEDURE|nipple sparing mastectomy|The investigators categorized the incisions into radial, inframammary, and periareolar incisions with planned reconstruction types; direct to implant (DTI), transversus rectus abdominis myocutaneous (TRAM) flap, latissimus dorsi myocutaneous (LD) flap, or LD with implant.
214911056|NCT04183296|DRUG|propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
214911057|NCT04183296|DRUG|sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
214911058|NCT05373732|BEHAVIORAL|meditation|meditation practice 20 minutes twice a day at home and attending classes at the clinic.
214911059|NCT05373732|BEHAVIORAL|Health education control|didactic based classes in CVD risk factor reduction and prevention
214911060|NCT04487015|BEHAVIORAL|MP|The app-based menu planner (MP) given to the participants has an automated carbohydrate periodisation menu planning tool, an educational and motivational nutrition content (infographics, video and text articles), and recipes. Participants using the app will input their training schedule into the app to produce their own menu plans. The behaviour change techniques (BCT) underlying the intervention are goal \& planning, feedback \& monitoring, shaping knowledge, natural consequences, comparison of behaviour, comparison of outcome, associations, repetitions, reward \& threat, regulation and antecedents.
214911061|NCT04487015|BEHAVIORAL|Call|A 30-45 minutes coaching consultation telephone/Skype call from the nutrition coaching to give social support. The BCT underlying the intervention is goal \& planning, social support, natural consequences.
214911062|NCT04487015|BEHAVIORAL|MesC|Nutrition coach-led messaging (MesC) is where the mobile app (MP) has the text messaging feature activated, and the nutrition coach proactively initiates a conversation via text messaging up to three times a week to offer nutrition support to the participant. The BCT underlying the intervention is goal \& planning, social support, natural consequences.
214911063|NCT02907723|DEVICE|Sleep Recording|the device records movements during patients' sleep
214911064|NCT03986307|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid supplementation|Daily supplementation with omega-3 capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
214911065|NCT03986307|OTHER|Resistance exercise|Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).
214911066|NCT03986307|DIETARY_SUPPLEMENT|Placebo - appearance-matched oil supplementation|Daily supplementation with placebo capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
214911067|NCT03680378|DRUG|Cefepime 2 gram|Combination of cefepime 2 gram with AAI101 1 gram
214911068|NCT06116188|DIAGNOSTIC_TEST|FDG-PET study|"Hyperinsulinemic, euglycemic clamp technique will be used to promote tissue glucose uptake and measure insulin sensitivity. Two cannulas will be inserted, one in a radial or an antecubital vein for PET tracer injection and infusion of glucose and insulin, another in the opposite radial or antecubital vein for blood sampling. In the clamp study subjects are administered intravenous insulin at a steady rate of 40 mU/m2/min and normoglycemia is maintained using a variable rate infusion of 20% glucose based on plasma glucose measurements, which are performed every 5min from arterialized venous blood. We will also collect samples to determine plasma insulin, serum free fatty acid and metabolic biomarkers during the study.~The clamp will be performed together with \[18F\]-FDG-PET/CT."
214911069|NCT02689193|OTHER|Blood sampling|Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
214911070|NCT01729078|DIETARY_SUPPLEMENT|Dietary intervention|three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
214911071|NCT00353509|DEVICE|Device Closure of a Septal Defect|
214911072|NCT04725162|RADIATION|18F-FDG|All subjects received 18F-FDG PET examination.
214911073|NCT00618592|DIETARY_SUPPLEMENT|PreOp carbohydrate drink|800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
214911074|NCT02645240|DRUG|Heparin injection|Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
214911075|NCT06574776|OTHER|Observation and collecting data|In that single cohort we will collect data on MDRO infection and colonization prevalence, clinical characteristics, infections, causative organisms and mortality.
214911076|NCT00302380|RADIATION|PET imaging using C-11 altropane as the ligand.|A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
215058576|NCT01388049|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
214911077|NCT00256412|DRUG|Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
214911078|NCT00256412|DRUG|Placebo|4 capsules of placebo each day
215058577|NCT00769171|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
215058578|NCT00769171|DRUG|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
215058579|NCT01498744|DRUG|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
215058580|NCT03017872|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
215058581|NCT03017872|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
215058582|NCT03017872|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
215058583|NCT03017872|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
215058584|NCT01230996|DRUG|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
215058585|NCT01230996|RADIATION|Intensity-modulated radiation therapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
215058586|NCT01230996|PROCEDURE|Intracavitary brachytherapy|Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
215058587|NCT03308968|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
215058588|NCT03308968|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
215058589|NCT05223179|BIOLOGICAL|CODA-VAX H1N1|Intramuscular Live Attenuated Influenza H1N1 Vaccine
215058590|NCT05223179|BIOLOGICAL|Flucelvax Quad|Licensed Seasonal Injectable Influenza Vaccine
215058591|NCT05223179|OTHER|Saline|Saline
215058592|NCT02812264|BEHAVIORAL|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
215058593|NCT02812264|BEHAVIORAL|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
215058594|NCT02812264|BEHAVIORAL|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
215058595|NCT02812264|BEHAVIORAL|scale|Connected scale that will transfer weight information to app
215058596|NCT05456373|DEVICE|ClearEdge device|ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
215058597|NCT01964157|DRUG|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
214911079|NCT00891020|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous every 4 weeks for 24 weeks
214911080|NCT00891020|DRUG|tocilizumab [RoActemra/Actemra]|4 mg/kg every 4 weeks for 24 weeks
214911081|NCT00891020|DRUG|Nonbiologic DMARDs of investigator's choice|Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
214911082|NCT02042989|DRUG|MLN9708|"Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase."
214911083|NCT02042989|DRUG|Vorinostat|"Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
214911084|NCT00436189|PROCEDURE|Blood Draw|
214911085|NCT04737629|BEHAVIORAL|Expectancy and Water|In the expectancy and water condition, participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script for this condition will inform them of research that has shown water to decrease appetite by up to 50% (attempting to create an expectancy).
214303717|NCT06493695|BEHAVIORAL|Both EGChat and CES intervention|"1. A exercise-promoting chatbot called EGChat, integrated into an established online health promotion platform.~2. Intervention of CES (Cranial Electrotherapy Stimulation) at Home"
214303718|NCT06493695|OTHER|Exercise Chatbot|Exercise Chatbot
214303719|NCT06493695|DEVICE|CES (Cranial Electrotherapy Stimulation)|Intervention of CES (Cranial Electrotherapy Stimulation)
214303720|NCT05629390|DRUG|Lotilaner|Lotilaner Ophthalmic Solution
214303721|NCT05629390|DRUG|Vehicle Control|Vehicle of TP-03 ophthalmic solution
214911086|NCT04737629|BEHAVIORAL|No Expectancy and Water|Participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script will inform them of research that has shown water to decrease appetite by up to 50%. In this condition, however, the research team will also inform them that this herb is expected to counteract the effects of water on appetite because it decreases water retention, causing water to pass through the stomach and intestines at a faster than normal rate (attempting to create no water expectancy or nullify any pre-existing expectancy).
214911087|NCT04737629|BEHAVIORAL|No Water|Participants will be instructed to consume the mint herb and 50mL of water before the start of the taste test. Participants will be given 100mL of water during the taste test to aid in their ability to taste and consume food, and to avoid acute thirst interfering with food consumption. Access to fluids during a taste test has been used in control conditions in similar studies. The script for this condition will inform participants of research that has shown water to decrease appetite by up to 50% but acknowledge that they will not be receiving water (thus, they should not expect an effect on appetite).
214911088|NCT03188289|DRUG|Placebo gel|Placebo is the control group treated with a placebo gel.
214911089|NCT03188289|DRUG|Clorhexidine gel|Clorhexidine will be compare with placebo, clorhexidine-chitosán and hyaluronic acid bioadhesive gels
214911090|NCT03188289|DRUG|Clorhexidine-Chitosan gel|Clorhexidine-chitosan will be compare with placebo, clorhexidine and hyaluronic acid bioadhesive gels.
214911091|NCT03188289|DRUG|Hyaluronic Acid gel|Hyaluronic acid will be compare with placebo, clorhexidine, clorhexidine-chitosan bioadhesive gels
214911092|NCT00156780|DRUG|AI-700|
214303722|NCT04758819|PROCEDURE|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)|In vitro Fertilization by ICSI then embryo culture until Day 5/6; all blastocysts with morphological scores compatible with TE biopsy and vitrification will be submitted to Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB) and vitrified.
214911093|NCT03291080|DRUG|Liquid 13-Cis Retinoic Acid|Liquid 13-Cis Retinoic Acid
214911094|NCT03291080|DRUG|Extracted capsules 13-CRA|Extracted capsules 13-CRA
214911095|NCT02318680|OTHER|Review of follow home visits after discharge from Nykøbing Falster Hospital|The intervention is follow home visits which is randomized and is an intervention that is assigned by the investigator.
214911096|NCT01339260|DRUG|Netupitant and Palonosetron|
214911097|NCT01339260|DRUG|Palonosetron|
214911098|NCT01339260|DRUG|Dexamethasone|
214911099|NCT03137160|BIOLOGICAL|Ixekizumab|Injection
215058598|NCT05439174|OTHER|Intradialytic Parenteral Nutrition|"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."
215058599|NCT03890926|RADIATION|radioactive Iodine-125 seed implantation under the guidance of 3D template|3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
214911100|NCT01932060|DRUG|Oxytocin Infusion|Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
214911101|NCT03853174|OTHER|Endurance Training ET|Endurance training were prformed. Intensity was gradually increased.
214911102|NCT03853174|OTHER|Resistance Training RT|Resistance training were prformed. Intensity was gradually increased.
214911103|NCT04110626|OTHER|Questionnaires|The questionnaires are completed at the 3 survey times (T0, T1 and T2) by all pupils involved. Collected data are quantitative
214911104|NCT04110626|OTHER|Non-directive Interviews|The interviews are conducted with 80 pupils/year randomly selected (i.e. 2 per class and 8 per establishment/year). Collected data are qualitative
214911105|NCT02364830|DRUG|Anise-oil EC Capsule|Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
214911106|NCT02364830|OTHER|Placebo|One Placebo Capsule/Day for 4 Weeks
214911107|NCT02364830|DRUG|Colpermin®|Colpermin® Capsule/Day for 4 Weeks
214911108|NCT03114930|OTHER|"To study the absence of increased complications and events occurring in the mother-newborn"|"To study the absence of increased complications and events occurring in the mother-newborn couple who made a standard exit compared to the mother-newborn couples who had benefited from an extra day of  Hospitalization in maternity."
214911109|NCT04504448|DRUG|HNC664 capsules Single dose|HNC664 capsules,single ascending doses Single dose, PO,starting dose of 40mg escalating up to 500mg
214911110|NCT04504448|DRUG|HNC664 placebos Single dose|HNC664 placebos single ascending doses,PO,Single dose, matching placebo
214911111|NCT04504448|DRUG|HNC664 capsules FED|HNC664 capsules,single doses Single dose, PO,food effect（dosage will be based on data from SAD cohorts and decided by the IDRC）
214911112|NCT00285740|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) in a Group Format|
214911113|NCT04735601|PROCEDURE|Ahmed Valve|Ahmed valve implantation coated with poly lactic -co-glycolic acid (PLGA) saturated with Mitomycin-C in the management of adult onset glaucoma in Sturge Weber syndrome
214911114|NCT03074825|DRUG|Chiauranib|Take 50mg orally once daily
214911115|NCT06497530|DRUG|Serplulimab|"Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle for 4 cycles in the induction phase.~Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle in the maintenance phase."
214911116|NCT06497530|DRUG|Lurbinectedin|Lurbinectedin will be administered intravenously at a fixed dose of 4 mg on Day 1 of each 21-day cycle in the maintenance phase.
214911117|NCT06497530|DRUG|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
214911118|NCT06497530|DRUG|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
214911119|NCT04505930|BEHAVIORAL|Interventional HPV vaccination video modules|The study team provide participants in the intervention group with interventional education, using interactive video watch and dynamic discussion. The educational videos were aiming to reinforcement and improvement the awareness, knowledge, attitude, intention and actual uptake of HPV vaccination shots among Chinese parents.
214911120|NCT04505930|BEHAVIORAL|General Vaccination Education|Education session conducted using only handouts of vaccinations including HPV
214911121|NCT00320710|DRUG|Zoledronic acid|4mg IV
214911122|NCT00320710|DRUG|Placebo|Placebo to zoledronic acid
214911123|NCT04412655|DEVICE|Percutaneous Coronary Revascularization for STEMI|Percutaneous Mechanical Reperfusion for STEMI
214911124|NCT04944914|DRUG|camrelizumab|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy
214911125|NCT04944914|RADIATION|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.
214911126|NCT03448419|DRUG|Empagliflozin|Film-coated tablet
214911127|NCT03448419|DRUG|Placebo|Film-coated tablet
214911128|NCT05029518|DRUG|SMP-100|In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.
214911129|NCT05372835|OTHER|La Chlogen mouthwash|Patients with periodontal disease were randomized into mouthwash group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the commercially available La Chlogen mouthwash in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
215058600|NCT01337843|OTHER|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
215058601|NCT01337843|OTHER|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
215058602|NCT05769855|DRUG|HR18034|HR18034 380mg
215058603|NCT05769855|DRUG|ropivacaine HCl|ropivacaine HCl 75mg.
214303723|NCT02738151|DRUG|Insulin glargine, 300U/mL|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
215058604|NCT05769855|DRUG|Sodium Chloride Physiological Solution|Sodium Chloride Physiological Solution 20ml
215058605|NCT01814319|DRUG|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
214303724|NCT02738151|DRUG|Insulin degludec, 100 U/mL|"Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous"
214303725|NCT02738151|DRUG|Non-insulin anti-diabetic treatment|Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
214911130|NCT05372835|OTHER|water|Patients without periodontal disease were selected as a control group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the pure water in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
214911131|NCT05372835|OTHER|La Chlogen mouthwash and La Chlogen periodontal flosser|Patients with periodontal disease were randomized into mouthwash and periodontal flosser group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the La Chlogen mouthwash in conjunction with the La Chlogen periodontal flosser were applied in mouth without spitting for interventions. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
214911132|NCT03227744|BEHAVIORAL|Group therapy|Twelve 1-hour group therapy sessions with a licensed psychologist for prostate-cancer related anxiety.
214911133|NCT03227744|OTHER|Surveys|MAX-PC, GAD and FACT-P
214911134|NCT02215369|DEVICE|VenaCure EVLT 400 µm fiber Procedure Kit|The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit.
214911135|NCT00003646|DRUG|allovectin-7|
214911136|NCT00413946|DRUG|Recombinant human Erythropoietin|3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
215058606|NCT01814319|DRUG|Placebo|Matching placebo oral twice daily
215058607|NCT06221761|DRUG|not using antibiotic|no antibiotic application
215058608|NCT06221761|DRUG|using antibiotic|antibiotic application
214911137|NCT00413946|DRUG|saline|three doses of 1.0 ml saline per body weight
214911138|NCT04075214|DEVICE|transcutaneous auricular neurostimulation (tAN)|Phoenix tAN system
214911139|NCT03353714|OTHER|Pudendal block|Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)
214911140|NCT02764814|OTHER|Cryopreserved amniotic membrane|subjects will receive cryopreserved amniotic membrane
214911141|NCT02146014|OTHER|Placebo|"Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.~In the placebo group the current will be off."
215058609|NCT00678769|DRUG|Cixutumumab|Given IV
215058610|NCT00678769|OTHER|Laboratory Biomarker Analysis|Correlative studies
215058611|NCT00678769|OTHER|Pharmacological Study|Correlative studies
215058612|NCT00678769|DRUG|Temsirolimus|Given IV
215058613|NCT05961241|OTHER|runnin training program|gradual training program
215058614|NCT00776594|DRUG|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
215058615|NCT00776594|DRUG|bicalutamide|50mg orally daily for 6 months
214911142|NCT02146014|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
214911143|NCT05829538|BEHAVIORAL|SuJok|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale.
215058616|NCT00776594|DRUG|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
215058617|NCT01017744|DEVICE|Anesthetic Conserving Device|"* Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~* Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
215058618|NCT05993429|DIAGNOSTIC_TEST|The sampling method selected in patients with suspected hilar cholangiocarcinoma|The appropriate sampling approach was selected as EUS-FNA/B or ERCP with or without POCS-TB based on experts' overall evaluation. This study will compare the histopathological diagnosis of the selected sampling method with the final diagnosis.
214911144|NCT05829538|BEHAVIORAL|Massage|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale
215058619|NCT01961297|DRUG|Sodium oxybate|Sodium oxybate
215058620|NCT03489655|BEHAVIORAL|Maintenance Phase Intervention|The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
215058621|NCT01651819|PROCEDURE|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
215058622|NCT04207411|DRUG|Bupivacaine|Injection of anesthetics blocks once a week during 4 weeks.
215058623|NCT04207411|DRUG|Lidocaine|Injection of anesthetics blocks once a week during 4 weeks.
215058624|NCT06058429|OTHER|no intervention|This is an observation study after vaccination, no intervention will be used
215058625|NCT02661555|OTHER|Aerobic exercise|
215058626|NCT00446823|DEVICE|XCell cellulose wound dressing|
215058627|NCT00446823|DEVICE|Impregnated gauze dressing|
214911145|NCT01203514|DRUG|Erythropoietin|Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.
214911146|NCT01203514|OTHER|Sham Comparator|Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
214911147|NCT02463903|BEHAVIORAL|Coping Effectiveness Training (CET)|The participants in the intervention group will receive a work book explaining the theme and home assignment as well as providing a brief summary of every group session. The group leader has a manual. Both work book and manual have been translated to Swedish and adjusted to patients with chronic heart failure.
215058628|NCT01932229|DRUG|Afatinib treatment|
214911148|NCT00175123|DRUG|Botulinum A toxin|Intravesical injection. 12 IE/kg b.w.
215058629|NCT02141633|PROCEDURE|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
215058630|NCT02141633|PROCEDURE|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
215058631|NCT02141633|DRUG|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
215058632|NCT02141633|DRUG|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
215058633|NCT02482298|DRUG|Ticagrelor|Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
215058634|NCT02482298|DRUG|Placebo|10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
215058635|NCT03792438|DIAGNOSTIC_TEST|Transvaginal 3D Power Doppler Ultrasound|Samsung H60 ultrasound machine with 4-9 MHz volume transducer using VOCAL system and Histogram Facility
215058636|NCT00752739|DIETARY_SUPPLEMENT|selenium|Given orally
215058637|NCT00752739|OTHER|placebo|Given orally
215058638|NCT00565149|BEHAVIORAL|PROOF|dietary overfeeding with high, low or normal protein content
215058639|NCT00263042|DRUG|Rimonabant|Tablet, oral administration
215058640|NCT00263042|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
215058641|NCT00568373|DEVICE|Enterra Gastric Pacemaker|Gastric Pacemaker
215058642|NCT01626586|BEHAVIORAL|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
215058643|NCT00106119|DRUG|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
215058644|NCT05723731|DEVICE|taVNS|"Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)"
215058645|NCT05723731|DRUG|Laxative Agent|Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
215058646|NCT02414607|BIOLOGICAL|Elderberry Juice|
215058647|NCT02414607|OTHER|Placebo|
214911149|NCT04382781|DRUG|NO-Immunosuppressive|Patients not receiving immunosuppressive drugs
215058648|NCT04676087|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
215058649|NCT04676087|BIOLOGICAL|Mogamulizumab|Given IV
215058650|NCT04676087|OTHER|Quality-of-Life Assessment|Ancillary studies
215058651|NCT05117684|PROCEDURE|Novel|Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
214911150|NCT04382781|DRUG|Immunosuppressive|Patients receiving immunosuppressive drugs (overall, and specific drugs)
214911151|NCT04382781|DRUG|Immunoglubulins|Patients receiving immunoglubulins
214911152|NCT04653181|DRUG|Ferric carboxymaltose|Iron-arm treated with Ferric carboxymaltose, non-iron arm without
214911153|NCT02756143|BEHAVIORAL|Exercise|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
214911154|NCT03089723|BEHAVIORAL|Visual Analog Scale (VAS)|Answer Visual Analog Scale (VAS) questionnaire at baseline, 1 month, 3 months and 6 months
214911155|NCT03089723|BEHAVIORAL|Range of Motion (ROM)|submitted to ROM at at baseline, 1 month, 3 months and 6 months
215058652|NCT05117684|PROCEDURE|Conventional|Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
214911156|NCT03089723|BEHAVIORAL|Palmar grip strength|submitted to palmar grip strength at at baseline, 1 month, 3 months and 6 months
214911157|NCT03089723|BEHAVIORAL|Lateral grip strength|submitted to lateral grip strength at at baseline, 1 month, 3 months and 6 months
215058653|NCT01188551|DRUG|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
215058654|NCT01188551|DRUG|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
215058655|NCT01188551|DRUG|Midazolam|Sedative given pre-op.
215058656|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 1|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
215058657|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 2|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
215058658|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 3|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
215058659|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 4|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
215058660|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 5|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
215058661|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 1|Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
214911158|NCT03089723|BEHAVIORAL|Pulp-pulp pinch strength|submitted to pulp-pulp pinch strength strength at at baseline, 1 month, 3 months and 6 months
214911159|NCT03089723|DRUG|Lavage with physiologic saline solution|Joint lavage with physiologic saline solution. After emptying of the joint, 1mL saline solution will be injected.
214911160|NCT03089723|DRUG|Lavage with physiologic saline solution and Osteonil® Mini|Joint lavage with physiologic saline solution and Osteonil® Mini
215058662|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 2|Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
215058663|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 3|Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
215058664|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 4|Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
215058665|NCT05369364|DRUG|Zanubrutinib|Zanubrutinib 80mg qd po, 6 consecutive weeks
215058666|NCT05369364|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
215058667|NCT02681653|DRUG|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
215058668|NCT02681653|DRUG|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
215058669|NCT03585725|DRUG|Ribavirin|"Ribavirin is FDA-approved oral medication for antiviral indications. Ribavirin will be obtained commercially for this trial.~Treatment will be administered on an outpatient basis. Ribavirin should be administered with food."
214303726|NCT01518920|DRUG|PF-04958242|PF-04958242 0.35 mg oral solution
214303727|NCT01518920|DRUG|PF-04958242|PF-04958242 0.27 mg oral solution
214303728|NCT01518920|DRUG|Placebo|Placebo oral solution
214911161|NCT03089723|BEHAVIORAL|Quick Dash|Answer Quick Dash questionnaire at baseline, 1 month, 3 months and 6 months
214911162|NCT03089723|BEHAVIORAL|Sollerman Test|Perform Sollerman Test at baseline, 1 month, 3 months and 6 months
215058670|NCT00000277|DRUG|Mazindol|
215058671|NCT02837471|DEVICE|PiezoRx medical grade pedometer|"Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.~Participants have access to a personal account created online and can record the daily steps count and physical activity.~Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program"
215058672|NCT02468440|OTHER|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
215058673|NCT02998684|DEVICE|Active Transcranial Direct Current Stimulation|
214911163|NCT04687839|PROCEDURE|Induction of suction blister|For each subject, 2 superficial wounds will be made on the inner aspect of each forearm using the suction blister model.
215058674|NCT02998684|DEVICE|Sham Transcranial Direct Current Stimulation|
215058675|NCT02998684|BEHAVIORAL|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
215058676|NCT05756023|PROCEDURE|the pregnancy rate at IVF / ICSI cycles|To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
215058677|NCT02668705|OTHER|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
215058678|NCT02267291|OTHER|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
215058679|NCT03528655|OTHER|Decision aid|Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
215058680|NCT03080571|BIOLOGICAL|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
215058681|NCT03080571|OTHER|standard care|
215058682|NCT00883948|BEHAVIORAL|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
215058683|NCT00883948|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
214486647|NCT06136260|OTHER|CommunityRx-Bereavement|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For CRx-B, a Grief Navigator from Missing Pieces will text and/or call the parent after receiving the referral; share information about grief and support resources; learn what resources the parent needs for themselves and their family; send the parent a personalized list of grief and social support community resources called a HealtheRx via text, email, or mail; and plan future text message communications with bidirectional functionality and, if requested, subsequent calls or texts from the Grief Navigator to occur at least 3, 6, and 12 months after the child's death."
215058684|NCT05493878|DIAGNOSTIC_TEST|mRNA expression|Tumor educated platelets ITGA2b and SELP mRNA by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
215058685|NCT05524636|DEVICE|Exercise with peripheral magnetic stimulation of the abdominal wall muscles|8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
215058686|NCT05524636|OTHER|Exercise of the abdominal wall muscles|8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
215058687|NCT04789954|BIOLOGICAL|Eptacog alfa, activated|A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
214911164|NCT04687839|OTHER|Transepidermal water loss (TEWL)|"* At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~* For subsequent visits, before product application"
214911165|NCT04687839|OTHER|Macrophotography|"* At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~* For subsequent visits, before product application"
214911166|NCT04687839|DEVICE|Wound healing medical device|Twice daily application on superficial wounds
214911167|NCT00212550|PROCEDURE|Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.|Sputum induction
214911168|NCT05739838|DEVICE|Biolase ;Low Level Laser|Low Level laser ,940 nm
215058688|NCT04909840|OTHER|Instructions oral hygiene with toothbrush plus dental floss|Instructions of oral hygiene with toothbrush plus dental floss
215058689|NCT04909840|OTHER|Instructions oral hygiene with toothbrush only|Instructions only with toothbrush
215058690|NCT05202899|DRUG|sugammadex|The use of sugammadex
215058691|NCT03346187|DRUG|Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)|Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)
215058692|NCT03346187|DRUG|Test drug(CKD-337)|CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
215058693|NCT05484466|DRUG|ZM-H1505R|There are three groups in this study. ZM-H1505R will be used in group A and Group B ，Subjects can use it for 48 weeks Group A: 30 subjects； ZM-H1505R 50 mg QD +ZM-H1505R placebo； Group B: 30 subjects； ZM-H1505R 100 mg QD
215058694|NCT05484466|OTHER|ZM-H1505R placebo|There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD
215058695|NCT05484466|COMBINATION_PRODUCT|Baraclude|All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
215058696|NCT03782259|DRUG|dapagliflozin|Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
215058697|NCT03782259|OTHER|Placebo|Placebo
214911169|NCT00619450|OTHER|3D C-arm CT scan|The patient will be given an intravenous contrast dye and then hold their breath for 15 seconds while pictures are taken. The equipment used to take the pictures is like an arch that will rotate around the body. As the arch rotates, it will collect the pictures of the heart. These pictures will then be used to compute a three-dimensional image of the heart. The physicians will then continue with the planned procedure. The three-dimensional images will be reconstructed and available for the doctor to view during the case. The images will also be examined after the procedure by the physician.
214911170|NCT03137238|OTHER|Investigation of self-perception in Parkinson's disease|There is no therapeutic intervention.
214911171|NCT02445638|OTHER|Whole egg|Subjects will be provided with the equivalent of 2 whole eggs daily.
214911172|NCT02445638|OTHER|Yolk-free egg|Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
214911173|NCT00967239|GENETIC|DNA analysis|
214911174|NCT00967239|GENETIC|polymorphism analysis|
214911175|NCT00967239|OTHER|laboratory biomarker analysis|
215058698|NCT03451487|DRUG|Panadol®|Acetaminophen 500mg Tablet
215058699|NCT03451487|DRUG|SafeTynadol®|Acetaminophen 500mg Tablet
215058700|NCT00603941|DRUG|CS-7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
215058701|NCT00603941|DRUG|Paclitaxel|Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
215058702|NCT00828958|DRUG|Risperidone long-acting injectable|
215058703|NCT00128024|DRUG|lipid-lowering treatment|
215058704|NCT05243121|DIAGNOSTIC_TEST|MRI|undergoing enhanced MRI
215058705|NCT02120768|PROCEDURE|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
215058706|NCT06521827|RADIATION|short course radiotherapy|short course palliative radiotherapy
214911176|NCT00967239|OTHER|pharmacogenomic studies|
214911177|NCT00223041|DRUG|Fluvastatin|Arm A receives fluvastatin Arm b receives no fluvastatin
214911178|NCT06340113|PROCEDURE|MCKENZIE AND STABILIZATION EXERCISES|"In this group 11 participants will receive McKenzie protocol with stabilization exercises. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week. At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold"
214911179|NCT06340113|PROCEDURE|MULLIGAN AND STABILIZATION EXERCISES|. The technique will include Self-sustained Natural Apophyseal Glide (SNAGs), Natural Apophyseal Glides (NAGs), and mobilization techniques.. The participants will receive three sets of Mulligan Mobilization, each set involving 10 repetitions of the exercise, with an interval of 15 to 20 seconds between the sets.At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold.
214911180|NCT05885503|BIOLOGICAL|RC-28E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
214911181|NCT05885503|BIOLOGICAL|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
214911182|NCT04424043|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
214911183|NCT04424043|PROCEDURE|Surgery alone|hepatic resection remove the liver tumors
214911184|NCT01328990|DRUG|sulfadoxine-pyrimethamine plus amodiaquine|one dose of sulfadoxine-pyrimethamine 25/1.25 mg/kg plus three daily doses of amodiaquine, 10 mg/kg/day
214911185|NCT01316003|OTHER|Optical coherence tomography|Optical coherence tomography
214911186|NCT02531308|DRUG|Metformin|Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
215058707|NCT04370587|BIOLOGICAL|T3011|T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
214303729|NCT02047747|DRUG|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
214911187|NCT02531308|DRUG|Rituximab|monoclonal antibody against protein CD20 primarily found on the surface of B-cells
215058708|NCT04370587|COMBINATION_PRODUCT|T3011 + pembrolizumab|T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
215058709|NCT03797066|DRUG|ZEPATIER 50Mg-100Mg Tablet|Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA\> 800,000 iu/ml or baseline NS5A resistance.
214303730|NCT05958355|OTHER|Functional postural control training|All participants will receive functional postural control training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
214911188|NCT02531308|DRUG|Cyclophosphamide|Interferes with DNA replication
214911189|NCT02531308|DRUG|Doxorubicin|anthracycline antitumor antibiotic
214303731|NCT05958355|OTHER|Treadmill training|All participants will receive treadmill training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
214911190|NCT02531308|DRUG|Vincristine|Inhibits cell mitosis causing cell death.
214911191|NCT02531308|DRUG|Prednisone|a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
214911192|NCT02531308|DRUG|pegfilgrastim|stimulates the level of white blood cells (neutrophils).
214911193|NCT06116279|DEVICE|Insertion of electrode during planned neurosurgery for epilepsy|A novel, 300 micrometer, ultraflexible, low-impedance electrode proposes to cause minimal parenchymal (brain tissue) damage, and provide multiple contacts at multiple depths to allow unit-level recordings for a period of 15 minutes.
214911194|NCT01050933|DRUG|250 ppm carbon monoxide|250 ppm of inhaled carbon monoxide over one hour
214911195|NCT04234490|PROCEDURE|Parenteral nutrition|Impact of parenteral nutrition on patient quality of life over time and impact on carer burden
214911196|NCT06428279|BEHAVIORAL|Survey|survey
214911197|NCT05668208|DEVICE|E-CUBE i7 ultrasound system (Alpinion Medical Systems, Seoul, Republic of Korea)|ONSD measurement will be made using the E-CUBE i7 ultrasound system.
214911198|NCT01311271|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~* Real: unaffected M1 hotspot~* Sham: coil perpendicular to scalp"
214911199|NCT01937611|DRUG|Dexmedetomidine|Dexmedetomidine
214911200|NCT01937611|DRUG|Midazolam|Midazolam
214911201|NCT02825628|DRUG|Osteodex|formulation: solution for infusion route of administration: intravenous infusion
214911202|NCT01056471|OTHER|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells.Dose:4\*10e6 cells/Kg.
214911203|NCT01056471|OTHER|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
214911204|NCT01193933|PROCEDURE|autologous HSCT|T-cell ALL patients recieve late consolidation with BEAM conditioning and stem cell support
214911205|NCT05710653|BEHAVIORAL|Exercise training intervention|The intervention will consist in adhering to high-intensity interval training and/or resistance training three times a week
214303732|NCT03649711|DRUG|Ticagrelor 90mg|Ticagrelor Pill
214303733|NCT03649711|DRUG|Clopidogrel 75mg|Clopidogrel Pill and a matching placebo to conceal frequency
214303734|NCT03649711|DRUG|Aspirin 81 mg|Aspirin Pill
214303735|NCT01892371|DRUG|Azacitidine|Given SC or IV
214303736|NCT01892371|DRUG|Cytarabine|Given SC
214303737|NCT01892371|DRUG|Quizartinib|Given PO
214911206|NCT02721277|DRUG|SMOFlipid|SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
214303738|NCT02606565|BIOLOGICAL|Intervention arm: 4% chlorhexidine|See previous description
214303739|NCT05556447|BEHAVIORAL|Internet delivered pain coping skills training|Participants in the intervention group will complete 8 weeks of pain coping skills training delivered online
214303740|NCT03768349|DRUG|Ga-68 PSMA11|Ga-68 PSMA11 PET/CT for detection of tumor location
214303741|NCT03768349|DRUG|F-18 PSMA 1007|F-18 PSMA 1007 PET/CT for detection of tumor location
214911207|NCT04548193|BEHAVIORAL|Behavioral Dietary Intervention|Receive live phone call
214303742|NCT01864733|OTHER|Physical rehabilitation (exercise).|
214911208|NCT04548193|BEHAVIORAL|Behavioral Dietary Intervention|Receive IVR phone messages
214911209|NCT04548193|OTHER|Educational Intervention|Receive educational materials
214911210|NCT04548193|OTHER|Questionnaire Administration|Ancillary studies
214911211|NCT04367545|DIAGNOSTIC_TEST|Saliva collection|Saliva collection will be done in addition to standard diagnosis collection (nasopharyngeal collection using swab)
214911212|NCT03422068|DRUG|BI 1015550|Tablet formulation
214911213|NCT03422068|DRUG|Placebo|Tablet formulation
214911214|NCT06574477|PROCEDURE|Planning of alignment with HoloLens 2|Planning of attachment position and traction direction with HoloLens 2 goggles
214911215|NCT06574477|PROCEDURE|No planning of alignment with HoloLens 2|No planning of attachment position and traction direction with HoloLens 2 goggles
214911216|NCT00001030|DRUG|Clarithromycin|
214911217|NCT00001030|DRUG|Rifabutin|
214911218|NCT00630825|DRUG|LY2189265|
214911219|NCT00630825|DRUG|Placebo|
214911220|NCT05374122|DIAGNOSTIC_TEST|DSOC with AI biopsy guidance|Patients with a presumptive diagnosis of biliary malignancy will undergo DSOC + Artificial intelligence model (AIWorks) guidance for detection of neoplastic lesion during real-time procedure, tissue sampling acquisition, and histopathological analysis.
214911221|NCT05374122|DIAGNOSTIC_TEST|DSOC biopsy without AI guidance|"Patients with lesions suggestive of malignancy will undergo DSOC without AI guidance for sampling.~Based on the observer´s criteria regarding areas suggestive of malignancy, the collected tissue sample will be sent for histopathological studies."
214911222|NCT02562001|DEVICE|Outpatient active group|active tDCS during 20 minutes before Lokomat training for outpatients
214911223|NCT02562001|DEVICE|Outpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for outpatients
214911224|NCT02562001|DEVICE|Inpatient active group|active tDCS during 20 minutes before Lokomat training for inpatients
214911225|NCT02562001|DEVICE|Inpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for inpatients
214911226|NCT00351195|DRUG|Etoposide|
214911227|NCT00351195|DRUG|Oxaliplatin|
214911228|NCT00351195|DRUG|Capecitabine|
214911229|NCT04389164|PROCEDURE|Tissue-engineered skin grafts of autologous scar dermal scaffolds|"1. scar excision. The thickness of scar tissue in the middle of scar is removed with a roller cutter and the thickness is about 0.01 -- 0.02mm.~2. take autologous skin slices of the patient with an electric skin knife, cut out a small piece of skin, and prepare autologous epidermal basal cell suspension for use;The rest of the skin should be the same size as the wound.~3. the prepared autogenous scar dermal stent was grafted onto the scar resection wound surface, and the prepared autoepidermal basal cells were sprayed between the mesh and on the dermal stent, and autologous skin slices were grafted onto the wound surface and fixed with pressure bandaging;~4. after the operation, the outer dressing should be changed regularly according to the conventional treatment, and the wound surface condition should be observed and recorded according to the experimental scheme."
214911230|NCT04654195|GENETIC|polymorphism analysis|DNA will be purified from whole blood samples by commercial DNA isolation kits. Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR.
214911231|NCT04654195|DRUG|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
214911232|NCT00950014|OTHER|Presentation of drug efficacy and side effect data|Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
214911233|NCT02478424|DRUG|Cannabidiol|"Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.~Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100."
214911234|NCT02478424|DRUG|cyclosporine|
214911235|NCT02478424|DRUG|Methotrexate|
214911236|NCT05268224|DIAGNOSTIC_TEST|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
214911237|NCT03863639|DIAGNOSTIC_TEST|Neuroimaging Procedures|"Subjects will complete neuroimaging procedures at 2-6-week postpartum or during hospitalization after delivery prior to discharge, which will consist of high-resolution anatomic, perfusion and resting-brain fMRI sequences; all of which will be acquired on a 3-Tesla General Electric magnetic resonance scanner~provided by the Brain Imaging and Analysis Center (BIAC) at Duke University. No contrast agent will be administered in these imaging procedures."
214911238|NCT03863639|DIAGNOSTIC_TEST|Neuropsychological Assessment Procedures|Once identified as meeting study criteria and consented for participation, parturients will be tested during hospitalization or as outpatients for controls, and at 2-6 weeks postpartum with the following cognitive battery. Wechsler Test of Adult Reading (WTAR), CANTABeclipse Computerized Cognitive Assessment Measures, Stroop Color-Word Test, Controlled Oral Word Association Test, EuroQol, Beck Depression Inventory Revised
214911239|NCT04903158|DRUG|test SHR3680 tablets|Subjects receiving a single oral dose of SHR3680 tablets with 240mg (80mg\*3)
214911240|NCT04903158|DRUG|reference SHR3680 tablets|subjects receiving a single oral dose of SHR3680 tablets with 240mg (100mg\*2+20mg\*2).
214911241|NCT00202124|DRUG|Tryptophan|
214911242|NCT02000635|OTHER|Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day|
214911243|NCT01411800|DRUG|250 mg capsule|Two 250 mg capsules will be administered for 500 mg dose
214911244|NCT01411800|DRUG|250 mg tablets|Two 250 mg tablets will be administered for a 500 mg dose
214911245|NCT03870932|OTHER|Motor Imagery physical therapy|
214911246|NCT03870932|OTHER|Conventional physical therapy|
214911247|NCT03892642|DRUG|Avelumab|"Induction phase:~* once weekly for weeks 1-6,~* once every 2 weeks at week 8, 10, and 12~Maintenance phase:~* Once every week for weeks 1-3~* Once every 2 weeks starting at week 5, until the next BCG treatment"
214911248|NCT03892642|BIOLOGICAL|BCG|"Induction phase (cycle 1):~• Once weekly for weeks 1-6~Maintenance phase (Month 3, 6, and 12):~• Once weekly for 3 weeks"
214911249|NCT03929133|DEVICE|automatic screening machine on congenital heart disease|
214954834|NCT02238938|PROCEDURE|piecemeal resection|"Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done."
214954835|NCT06393010|BEHAVIORAL|online rehabilitation program|Participants in the research will undergo a three-week online rehabilitation program, three times a week, lasting 40-45 minutes each session. The program includes posture, stretching, joint range of motion, strengthening exercises, pain education, and discussions. Conducted via Zoom, only the practitioner will be present during sessions. Non-attendance for two consecutive sessions or failure to provide feedback will result in exclusion. Exercises cover various body areas and types, including posture correction, range of motion, stretching, isometric neck and shoulder exercises, stick exercises, and strengthening exercises.
214954836|NCT03284112|BEHAVIORAL|Old SCHOOL Hip-Hop|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
214954837|NCT03284112|BEHAVIORAL|My Plate|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
214954838|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative CISS-MRI Sequences|Compare pre-operative MRI diagnosis to intra-operative findings on if both are in agreement
214911250|NCT04084418|OTHER|Control Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
214911251|NCT04084418|OTHER|VLCHF Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
214911252|NCT04670549|OTHER|Implementation of treatment guidelines|To improve knowledge of OA treatment recommendations among people with hip and knee OA, a lay language summary will be emailed all OA patient participants. A second summary of the treatment recommendations, targeting general practitioners (GPs) will also be emailed the OA patient participants. The patients will be encouraged to print and bring this summary to their GP at the next visit (user-initiated implementation). Barriers and facilitators for providing evidence-based OA care among primary care physiotherapists will be mapped through interviews. Thereafter, a tool-kit of strategies and practical aids intended to help overcome these barriers will be developed and made available for the physiotherapists.
214911253|NCT01544985|DRUG|88% sucrose po solution|88% sucrose solution (Syrup B.P.)
214911254|NCT01544985|DRUG|placebo po|sterile water
214911255|NCT06163885|OTHER|Stoma care education with flipped classroom|Flipped classroom model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
214911256|NCT06163885|OTHER|Stoma care education with peer-supported education model|Peer-supported education model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
214911257|NCT02211209|DRUG|Volanesorsen|
214911258|NCT02211209|DRUG|Placebo|
214911259|NCT03497520|BEHAVIORAL|asymmetric spinal stabilization exercise|"The patients were educated to strengthening weakness side of spinal muscle, as asymmetric spinal stabilization exercise(ASSE)~* before teach ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity~* after perform ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity"
214911260|NCT05496647|OTHER|Virtual Reality|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Preferred video will be watched with Virtual Reality Glasses for approximately 20 minutes during the process, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form, Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; At the 1st hour after the procedure, Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale and Satisfaction Evaluation Form will be filled."
214911261|NCT05496647|OTHER|Music Therapy|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; During the procedure, the preferred music for Music Therapy will be played for approximately 20 minutes, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
214911262|NCT05496647|OTHER|Stress Ball Application|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Stress ball will be played for approximately 20 minutes during the process.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
214954839|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative Interictal Laryngoscopy|Compare pre-operative laryngoscopy diagnosis to intra-operative findings on if both are in agreement
214954840|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative Unilateral and Contralateral Botox|Compare pre-operative diagnosis using Botox to intra-operative findings on if both are in agreement
214954841|NCT05271123|DIAGNOSTIC_TEST|Assessment of respiratory function and growth motor function classiffication level|Assessment of respiratory function using spirometer and assessment of growth motor function classiffication level using GMFCs
214911263|NCT05496647|OTHER|Control|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; Women in the control group will not undergo any intervention other than routine surgery.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure, the Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
214911264|NCT01695174|DRUG|Xifaxan|
214911265|NCT04111120|DIAGNOSTIC_TEST|SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI|Coagulation assessment using heparinase treated SONOCLOT
214911266|NCT01086631|DRUG|Rituximab|
214911267|NCT01438892|DRUG|tDMARDs|Traditional DMARDs for RA
214911268|NCT01438892|DRUG|biodmards|Biologic DMARDs
214911269|NCT02792062|DRUG|TAK-385 40 mg|TAK-385 40 mg tablet
214911270|NCT04297748|COMBINATION_PRODUCT|89Zirconium-M7824|PET imaging agent
214911271|NCT04297748|DRUG|M7824|Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.
214911272|NCT03220269|OTHER|Out-of-hospital cardiac arrest (OHCA)|Data collection
214911273|NCT03220269|OTHER|In-hospital cardiac arrest (IHCA)|Data collection
214911274|NCT02462772|DRUG|cabotegravir|Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
214911275|NCT02462772|DRUG|Placebo|Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
214911276|NCT01626196|OTHER|No intervention|This was an observational study
214911277|NCT00002596|BIOLOGICAL|bleomycin sulfate|
214911278|NCT00002596|BIOLOGICAL|filgrastim|
214911279|NCT00002596|DRUG|carboplatin|
214911280|NCT00002596|DRUG|cisplatin|
214911281|NCT00002596|DRUG|cyclophosphamide|
214911282|NCT00002596|DRUG|etoposide|
214911283|NCT00002596|PROCEDURE|autologous bone marrow transplantation|
214911284|NCT00002596|PROCEDURE|bone marrow ablation with stem cell support|
214911285|NCT00002596|PROCEDURE|conventional surgery|
214911286|NCT00002596|PROCEDURE|peripheral blood stem cell transplantation|
214911287|NCT00002596|RADIATION|radiation therapy|
214911288|NCT05598424|DRUG|Oral Glucocorticoids|Oral Glucocorticoids（methylprednisolone） 24mg qd, 2-week duration
214911289|NCT05711355|PROCEDURE|Use of Platelet-Rich Plasma after meningomyelocele sac repair|Wound healing with the use of Platelet-Rich Plasma after surgical meningomyelocele pouch repair
214911290|NCT05711355|PROCEDURE|meningomyelocele sac repair|meningomyelocele sac repair without Platelet-Rich Plasma
214911291|NCT06362538|OTHER|International Physical Activity Questionnaire|Assessments of physical activity level and functional capabilities (aerobic capacity, muscular strength and power, flexibility
214911292|NCT06362538|OTHER|Six minute walking test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
214911293|NCT06362538|OTHER|SF-36, Euro-Qol 5D-5L, Perceived stress scale-10, Pittsburgh Sleep Quality Index, Depression Anxiety Stress scale- 21.|Evaluation of the quality of life, the psychological sphere (anxiety, stress, depression) and the quality of sleep
214911294|NCT06362538|OTHER|MEDAS|Evaluation of adherence to the Mediterranean diet
214911295|NCT06362538|OTHER|Intima-media thickness (IMT)|Bmode ultrasonography
214911296|NCT06362538|BIOLOGICAL|Blood sampling|Measurement of parameters for defining cardiovascular risk and biomarkers.
214911297|NCT06362538|BIOLOGICAL|Stool Sample Culture Test|Evaluation of Gut Microbiota
214911298|NCT02923323|DEVICE|MRI including DTI , EEG, CGMS|Will be connected to continuous simultaneous systems
214911299|NCT02923323|BEHAVIORAL|Neurocognitive tests|Will perform multiple tests of neurocognitive functions after lunch
214911300|NCT00023855|DRUG|bortezomib|
214911301|NCT00023855|DRUG|doxorubicin hydrochloride|
214911302|NCT00931255|DRUG|Tacrolimus|3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
214911303|NCT00931255|DRUG|Sirolimus|5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
214911304|NCT01372995|DRUG|Enteral Vitamin D3 50,000 IU|Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)
214911305|NCT01372995|DRUG|Enteral Vitamin D3 100,000IU|Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)
214911306|NCT01372995|OTHER|Inactive substance|Inactive substance given enterally for 5 days.
214911307|NCT01483963|BIOLOGICAL|AA4500 0.29 mg/1 mL|treatment of adhesive capsulitis
214911308|NCT01483963|BIOLOGICAL|AA4500 0.58 mg/2 mL|treatment of adhesive capsulitis
214911309|NCT01483963|BIOLOGICAL|AA4500 0.58 mg/1 mL|treatment of adhesive capsulitis
214911310|NCT01483963|BIOLOGICAL|AA4500 0.58 mg/0.5 mL|treatment of adhesive capsulitis
214911311|NCT01483963|OTHER|Shoulder exercises|Home shoulder exercises, minimum of 3 times per day
214911312|NCT00131313|DRUG|Nipent, Cytoxan, Rituxan|
214911313|NCT01230086|DEVICE|ICD Implantation without DFT testing|Implantation
214911314|NCT01230086|DEVICE|Upper limit of vulnerability testing|Upper limit of vulnerability testing
214911315|NCT01230086|DEVICE|T-wave shock with induction of ventricular fibrillation|Traditional safety margin testing for defibrillation threshold
214911316|NCT03576963|DRUG|Guadecitabine|Given SC
214911317|NCT03576963|BIOLOGICAL|Nivolumab|Given IV
214911318|NCT00336401|DRUG|Sevoflurane or Propofol|
214911319|NCT03369886|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCTA)|The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).
214303743|NCT06040567|OTHER|Validity and reliability of outcome measures in polyneuropathy|Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.
214911320|NCT01297517|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
214911321|NCT01297517|DRUG|Brinzolamide ophthalmic suspension, 1%|
214911322|NCT01297517|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
214911323|NCT04614935|BEHAVIORAL|Action Plan|See arm description.
214911324|NCT03194633|DRUG|Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Nifedipine GITS 60 mg (once per day)
214911325|NCT01927315|DRUG|Fenofibrate 145 mg|Tablets of Fulcrosupra 145 mg to be taken at 8.00 am daily for 12 weeks.
214911326|NCT01927315|DRUG|Placebo|Oral Placebo tablets once daily
214911327|NCT03948412|DEVICE|Closed Incision Negative Pressure Wound Therapy (Prevena)|Closed Incision Negative Pressure Wound Device (Prevena) applied to closed wound at completion of operation.
214911328|NCT03948412|OTHER|Control - Standard Dressings|Standard wound dressings applied to closed wound at completion of operation.
214911329|NCT00470717|PROCEDURE|Weekly telephone call|Details of feeding and health/sickness will be obtained
214911330|NCT00857090|DRUG|OMS201|"Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery"
214911331|NCT00857090|DRUG|Vehicle|Stages 1-2: Vehicle irrigation solution during surgery
214911332|NCT05229159|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|Segmental multi-frequency bioelectrical impedance analysis are carried out at all patient admitted to our ICU for postoperative care after cardiac surgery with cardiopulmonary bypass. Our objective is to evaluate the relevance of phase angle to predict mortality or a prolonged hospital length of stay. Phase angle is evaluated at ICU admission and will be compared to well-known prognostic scores computed in preoperative (EuroSCORE II) and at day one after surgery (SOFA, CASUS and SAPS II).
214911333|NCT03542942|OTHER|treatment with EXIT-target volume|exclusion of the unaffected part of the uterus out of the treatment field
214911334|NCT04936100|DEVICE|"Assessment of distance and near visual acuity using Vision Screening module of Easy Vision application"|"The presenting visual acuity will be assessed using the Vision Screening module of the Easy Vision application."
214303744|NCT06040567|OTHER|Healthy controls|Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.
214303745|NCT04406727|BIOLOGICAL|UB-421|UB-421 in combination with their ARV
214911335|NCT04936100|DEVICE|"Assessment of distance and near visual acuity using Test Yourself module of Easy Vision application"|"The presenting visual acuity will be assessed using the Test Yourself module of the Easy Vision application."
214911336|NCT04936100|DEVICE|"Assessment of distance and near visual acuity using Peek Acuity application"|"The presenting visual acuity will be assessed using the Peek Acuity application."
214911337|NCT04936100|OTHER|Assessment of distance and near visual acuity using the conventional methods|"The presenting visual acuity will be assessed using the conventional methods \[Chart: Tumbling E optotype for assessing distance visual acuity and Handheld chart: Tumbling E Near Point Vision Chart for assessing near visual acuity\]"
214911338|NCT06392659|DRUG|VX-993|Suspension for Oral Administration.
214911339|NCT06392659|DRUG|Gemfibrozil|Tablets for Oral Administration.
214911340|NCT06392659|DRUG|Itraconazole|Capsules for Oral Administration.
214911341|NCT06392659|DRUG|Midazolam|Solution for Oral Administration.
214911342|NCT00669500|BEHAVIORAL|Lifestyle intervention|Alive!TM web-based, 12 week lifestyle intervention sent via NutritionQuest.
214911343|NCT01741688|BIOLOGICAL|Tocilizumab|Tocilizumab was administered according to the local label.
214911344|NCT01834742|DRUG|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
214911345|NCT01834742|DRUG|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
214911346|NCT01834742|DRUG|NER1006|Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
214911347|NCT01834742|DRUG|Moviprep|Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
214911348|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
214911349|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
214303746|NCT04406727|OTHER|Antiretroviral (ARV)|Antiretroviral (ARV)
214303747|NCT06913920|DEVICE|Continuous Passive Motion (CPM)|"Materials: A CPM device configured for wrist flexion-extension with an adjustable range of motion set between 0° and 30°.~Procedure:~The participant's wrist is gently secured in the device. The CPM device is programmed to deliver 20 minutes of continuous, passive motion through the set range.~Device settings (e.g., speed) may be modified if the participant reports pain \>4/10 on the NPRS."
214911350|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
214303748|NCT06913920|DEVICE|Intermittent Pneumatic Compression (IPC)|"Materials: An IPC sleeve designed for the forearm-to-hand region with a baseline compression setting of approximately 30 mmHg.~Procedure:~After CPM treatment, the IPC device is applied to the affected limb. The sleeve provides 15 minutes of intermittent compression with programmed intervals of inflation and deflation.~Compression levels may be adjusted based on participant comfort and pain ratings."
214303749|NCT06913920|BEHAVIORAL|Standard Therapy Program|"Procedures:~Active/active-assisted wrist/forearm range of motion exercises led by a certified hand/physical therapist.~Progressive grip-strengthening exercises using resistance bands or putty. Manual edema management techniques, including gentle massage and manual lymphatic drainage, as well as scar mobilization if needed."
214303750|NCT06914258|COMBINATION_PRODUCT|Inhibition Compression|"Group A will receive conventional Physiotherapy treatment along with the scapular mobilization which will include;~* Electrotherapy (TENS and hot pack) for 10 min~* Active and passive ROMs for 5 min~* pectoral stretching for 5min~* shoulder joint mobilization. To mobilize the shoulder joint, distraction of the glenohumeral joint, posterior glide and caudal glide were performed to the patient in supine position at a frequency of two to three oscillations/second for one to two minutes. (10 min)~* Manual scapular mobilization will be done in sideline with their back towards the physiotherapist."
214911351|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
214911352|NCT04173156|DEVICE|Labrida Bioclean|The brush bristles of the test device (Labrida BioClean®, LABRIDA, Oslo, Norway) are made of the biopolymer chitosan
214911353|NCT04173156|DEVICE|Gracey Periodontal curettes|Regular commercially available area specific and medical grade steel Gracey periodontal curettes
214911354|NCT04424420|DRUG|Paracetamol|Paracetamol oral tablet
214911355|NCT04424420|DRUG|Ibuprofen|Ibuprofen oral tablet
214911356|NCT04424420|DRUG|Placebo oral tablet|Sugar pill manufactured to mimic the Paracetamol and Ibuprofen.
214911357|NCT01225016|DRUG|Definity contrast agent|Thyroid ultrasound using contrast agent
214911358|NCT02282813|DRUG|CTAP101 Capsules|At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
214911359|NCT02282813|DRUG|Calcitriol|At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
214911360|NCT02282813|DRUG|Doxercalciferol|At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
214911361|NCT02282813|DRUG|Paricalcitol|At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
214911362|NCT05943236|DEVICE|Radiographic assessment of the medial-distal tibial angle|A long ankle view will be generated within a standard radiographic assessment and the medial-distal tibial angle will be assessed.
214911363|NCT05170048|DRUG|EG-301|The investigation drug, EG-301 Tablets 150mg, is for oral use.
214911364|NCT05170048|DIETARY_SUPPLEMENT|AREDS2 supplements|AREDS2 supplement is the stand of care
214911365|NCT01514292|DEVICE|Continuous Glucose Monitoring of glucose levels (Dexcom)|Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
214911366|NCT01742988|DRUG|fimepinostat|
214911367|NCT01742988|DRUG|Rituximab|
214911368|NCT01742988|DRUG|venetoclax|
214911369|NCT01152879|DIETARY_SUPPLEMENT|Home Parenteral Nutrition|Cancer Patients who are discharged on HPN will be monitored for quality of life, nutrition status, pain and nausea medication usage
214911370|NCT00274300|BIOLOGICAL|pPJV7630 administered by PMED|
214911371|NCT02437773|BEHAVIORAL|Cognitive Behavioral Therapy - Adolescents|"A therapy which gradually yet repeatedly exposes adolescent patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
214911372|NCT02437773|BEHAVIORAL|Stress Management Therapy - Adolescents|An active control therapy with minimal effects on OCD symptoms.
214911373|NCT02437773|BEHAVIORAL|Optional CBT - Adolescents|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
214911374|NCT02437773|BEHAVIORAL|Cognitive Behavioral Therapy - Adults|"A therapy which gradually yet repeatedly exposes adult patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
214911375|NCT02437773|BEHAVIORAL|Stress Management Therapy - Adults|An active control therapy with minimal effects on OCD symptoms.
214911376|NCT02437773|BEHAVIORAL|Optional CBT - Adults|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
214911377|NCT02437773|OTHER|fMRI only - Healthy Control Adults|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adults and is used only as a means for observation, NOT as an intervention to be studied.
214911378|NCT02437773|OTHER|fMRI only - Healthy Control Adolescents|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adolescents and is used only as a means for observation, NOT as an intervention to be studied.
214911379|NCT01116271|DRUG|AZD6244|50 or 75mg, capsules, PO, BID, 28 days
214911380|NCT01116271|DRUG|Irinotecan|180mg/m2, IV, Day 1\& 15 of each cycle
214911381|NCT02391922|BEHAVIORAL|First aid course|
214911382|NCT02391922|BEHAVIORAL|First aid instructions by mobile phone|
214911383|NCT03266146|DRUG|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.
214911384|NCT03266146|DRUG|48 weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
214911385|NCT05788172|OTHER|Iron isotope dilution|Menstrual blood loss will be determined using the iron isotope dilution technique and compared to the amount determined via the alkaline hematin method.
214911386|NCT05788172|OTHER|Alkaline hematin method|Menstrual blood loss will be determined using the alkaline hematin method and compared to the amount determined via the iron isotope dilution technique.
214911387|NCT00305019|DRUG|clevudine|
214911388|NCT01742546|DEVICE|Therapeutic ultrasound combine TENS|"Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius)."
214911389|NCT05698901|DRUG|Agalsidase beta|The treatment is following local reimbursement criteria and judge by physician
214911390|NCT06214195|DRUG|Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)|Ginseng 6g , Ophiopogon japonicus 12g ,Schisandra chinensis 5g , other secondary Chinese medicines can be added according to the doctor's judgment and the patient's condition，decoction in water, one dose and two decoctions, taken twice a day, continuously for 7 days from the start of each chemotherapy cycle (± 3 days), including anthracyclines and taxanes (the frequency and dosage of medication can be adjusted according to adverse reactions in the later stage); The total duration of medication interventionis 7 days per cycle, with a total of 8 cycles. If the chemotherapy is less than 8 cycles, continue taking for 7 consecutive days from the start of each subsequent trastuzumab cycle (the frequency and dosage can be adjusted based on adverse reactions) until a total of 8 cycles are reached.
214911391|NCT02220764|DEVICE|Teeth abutment|
214911392|NCT02220764|DEVICE|Implant abutments|
214911393|NCT04022538|PROCEDURE|Anterior maxillary vertical segmental sandwich osteotomy with simultaneous implant placement|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The first implant osteotomy will be prepared and placed while a chisel is placed between the down fractured segment and the basal bone, and then the second implant will be installed.~* The gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
214911394|NCT04022538|PROCEDURE|Anterior maxillary vertical segmental sandwich osteotomy using micro-plates fixation|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The created gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* The mobilized segment is to be fixed to the basal bone using micro-plates and micro-screws.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
214303751|NCT06914258|COMBINATION_PRODUCT|Scapular Mobilization Technique|"Group B will receive the same baseline physiotherapy treatment as in group A along with the Inhibition compression therapy which is a (MET). MET was performed on shoulder. Patient position: supine lying position. Following are the steps involved in application of MET: (1) stretch the muscle to a felt 'barrier' or to their tolerance of stretching (2) create a voluntary contraction that is isometric of the muscle being stretched while being resisted with equal and regulated counterforce by the physiotherapist for 7-10 seconds. (3) a stretch is held for a set amount of time after the muscle relaxes (4) the physiotherapist takes up the slack once the muscle relaxes Duration of treatment was approximately 15-20 minutes."
214303752|NCT07159269|BEHAVIORAL|Cardiac point-of-care ultrasound (POCUS) training and clinical pathway|Participants will complete a cardiac POCUS simulation session and a hands-on observed structured clinical skill exam (OSCE) post-training led by ultrasound-trained faculty. Then as part of standard clinical care, advanced practice providers (APPs) will perform POCUS while supervised by emergency medicine (EM) attending physicians. To assess program feasibility and acceptability, participants will complete a pre/post and 6-month post-survey and semi-structured interview, as well as a knowledge and technical skills assessment.
214303753|NCT07162337|BEHAVIORAL|Increased Plant-Based Diet and Decreased Animal-Based Diet|Self-regulated diet; increased plant-based foods with decreased animal-based foods
214303754|NCT07190521|OTHER|hypnobreastfeeding education|"Hypnobreastfeeding education is an antenatal training method that combines:~Hypnotherapy principles~Guided imagery~Affirmations~Breathing and deep relaxation techniques"
214303755|NCT07190521|OTHER|Traditional prenatal education|"Traditional prenatal education programs, often referred to as antenatal or maternity school classes, are structured group sessions provided to pregnant women, typically in clinical or community settings. These classes aim to:~Prepare expectant mothers for labor, birth, and postpartum care,~Provide evidence-based information about breastfeeding, newborn care, and maternal recovery,~Promote positive health behaviors during pregnancy,~Reduce fear and anxiety by increasing knowledge and confidence."
214954842|NCT03818555|OTHER|Sebacia Microparticles Treatment|Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
214954843|NCT03965455|DEVICE|Diode laser|In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.
214954844|NCT03965455|PROCEDURE|Conventional|In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
214954845|NCT04782414|PROCEDURE|Hot AXIOS® prosthesis|endoscopic trans digestive drainage using of the Hot AXIOS prosthesis in the treatment of pancreatic collections (incompletely fluid or necrotic)
214954846|NCT00006355|DRUG|pyrazoloacridine|
214954847|NCT00006355|PROCEDURE|adjuvant therapy|
214954848|NCT00006355|RADIATION|radiation therapy|
214911395|NCT06095921|BEHAVIORAL|Self Management Intervention Program|SSc, the course of the disease, symptoms and coping strategies, medications and treatment methods? The importance of exercise for individuals with SSc, and how to create an action plan for an exercise? were discussed. What are fatigue and its symptoms? How can we protect our articular-energy and how should a quality rest be? What is pain and what are coping approaches? What is the pain-related area of influence? What are body image problems, how to use problem solving approach and what is its importance? What is Stress? What is mindfulness? What are mindfulness exercises? What are the ways to cope with stress? What are the daily life occupations and how can we facilitate them? How can we solve problems in difficult occupations? How to create an occupation plan to facilitate daily occupations? What are oral stretching exercises and how to do them? What are the factors affecting sleep? What is advocacy and why is it important? Answers to these questions were sought.
214911396|NCT05733169|OTHER|Frequency lowering intervention|Modified parametrization of the current frequency lowering parametrization.
214911397|NCT05733169|OTHER|Frequency lowering reference|Current frequency lowering parametrization
214911398|NCT05000164|DEVICE|Bausch + Lomb Ultra® Multifocal for Astigmatism|Study Lens
214911399|NCT02996825|DRUG|Gemcitabine|Given IV
214911400|NCT02996825|DRUG|Gemcitabine Hydrochloride|Given IV
214911401|NCT02996825|OTHER|Laboratory Biomarker Analysis|Correlative studies
214911402|NCT02996825|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
214911403|NCT02996825|OTHER|Pharmacological Study|Correlative studies
214911404|NCT03493854|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.
214911405|NCT03493854|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
214911406|NCT03493854|DRUG|Docetaxel|As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.
214911407|NCT03493854|DRUG|Paclitaxel|As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
214911408|NCT03493854|DRUG|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
215058710|NCT05087433|OTHER|Progressive Relaxation Exercises|The trainer performed the PRE exercise online with the nurses. The video recording of the progressive relaxation exercises was shared with the nurses participating in the study on WhatsApp groups. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month. The PRE application was reminded daily from the WhatsApp group for the nurses to apply regularly to the sessions and not to disrupt the sessions. Nurses shared the messages stating that they were doing the PRE application on a daily basis for four weeks on WhatsApp groups.
215058711|NCT05069597|DRUG|CREON|Capsule; Oral
215058712|NCT05315934|OTHER|Upper body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.
215058713|NCT05315934|OTHER|Lower body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
215058714|NCT00400218|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
214911409|NCT03493854|DRUG|FDC of Pertuzumab and Trastuzumab SC|The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
214911410|NCT03493854|DRUG|Trastuzumab IV|Trastuzumab will be administered as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
214911411|NCT03493854|DRUG|Trastuzumab SC|After surgery (from Cycle 9 onwards), participants in Arm A will be allowed to switch from trastuzumab IV to trastuzumab SC, at the discretion of the investigator, in the countries where trastuzumab SC is routinely used. For participants who switch, a fixed dose of 600 mg trastuzumab SC (irrespective of the patient's weight) will be administered in the adjuvant phase.
214911412|NCT03493854|PROCEDURE|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
214911413|NCT03493854|RADIATION|Post-operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
214911414|NCT03493854|DRUG|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
214911415|NCT04275011|OTHER|Progressive Resistance and Impact Exercise|Full body resistance and impact exercises will be performed twice a week for 30-45 minutes over a 6 month period. There will be at least one day of rest between scheduled exercise sessions. Participants will be individually prescribed variations of push, pull, squat, lift and carry movements targeting major muscle groups that they can safely complete, and accessory exercises to help develop movement patterns. Exercises will challenge both the upper and lower body using functional movement patterns. Each muscle group will be trained twice a week. During the first month, participants will focus on completing exercises with good form at a low intensity. Once form is mastered, exercises will be progressed (by increasing load, or challenge of the movement) to a moderate to high exercise intensity (80-85% 1RM) so that the participant can complete a maximum of 8 (\~80% 1RM) or 6 (\~85% 1RM) repetitions with 1-2 repetitions in reserve for 3 sets at a rating of perceived exertion (RPE) of 8-9.
215058715|NCT02840188|OTHER|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
214303756|NCT07190326|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic cream to facilitate making long strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then re-draped before moving to another part. The primary techniques used in the research protocol therapy are effleurage, petrissage, kneading, tapotement and thumb friction. These techniques are performed in a very precise, carefully elaborated manner. The session starts with the subject fully draped in a prone position on the massage table and after approximately 22 minutes the subject is instructed to turn to the supine position. Finally, the therapist moves to the head area of the subject, begins working on the shoulders, neck and head using effleurage and thumb friction, and concludes by using light tapotement on the head. The total time for the entire massage is 45 minutes. Subjects randomized to SMT will undergo two sessions per week for 6-weeks."
214303757|NCT07190326|OTHER|Light Touch Control|The Light Touch Control protocol entails the same duration and sequence of procedures as the massage protocol, except that the therapist employs only light-touch hand placement on the subject's body. This condition isolates the effect of the mechanical intervention of SMT. Subjects randomized to LT will undergo two sessions per week for 6-weeks.
214911416|NCT04275011|OTHER|Static Balance and Postural Exercise|Participants in the attention control group will perform static posture and balance exercises (e.g., low intensity yoga poses) and will be given the same attention as the participants in the intervention group. The small group exercises will be performed twice a week, 30-45 minutes per session, over 6 months, with at least one day of rest between each session. The exercise program will be supervised by a certified personal trainer and yoga instructor who is BoneFit trained.
214911417|NCT01864902|BIOLOGICAL|CART33 cells|genetically modified lymphocyte therapy
214911418|NCT01864902|BIOLOGICAL|anti-CD33 CART|
214911419|NCT01864902|BIOLOGICAL|anti-CD33 CAR T cells|
214911420|NCT02892890|PROCEDURE|Muscle Magnetic Resonance Imaging (RMI) evaluation|
214911421|NCT02892890|DEVICE|MRI|
214911422|NCT02480569|OTHER|FFR Measurement|
214911423|NCT02422446|DRUG|Icosapent ethyl|icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
214911424|NCT02464332|DRUG|BLZ-100|"All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.~Three different imaging windows will be investigated during the study:~Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)~All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups."
215058716|NCT04744220|OTHER|Yoga Training Program (exercises)|Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.
215058717|NCT04098185|DEVICE|CT|Non-contrast Multidetector Computed Tomography will be done for all patients using 16 or 64 MDCT scanner. Standard scanning parameters of chest CT are used with slice thickness 5 mm, 120kv and automated mAs.The evaluation of pleural effusion attenuation will be done using the average measure of 3 slices with greatest amount of fluid. A region of interest (ROI) is placed for measurement of Hounsfield unit values, where pleural fluid is observed to be most intense and the density values of the pleural fluid and of the aorta are quantitatively measured in the same section with taking care not to involve adjacent ribs, lung parenchyma or areas of pleural thickening.
214303758|NCT07191197|OTHER|MRI|structural and functional resting state MRI
214303759|NCT07191197|OTHER|Psychometric|2 cognitive research tasks of semantic learning and neuropsychological assessment
214303760|NCT07191366|PROCEDURE|Handstimulation of breast|Hand stimulation of the breast
214911425|NCT00739661|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
214911426|NCT00739661|DRUG|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
214911427|NCT02198664|BIOLOGICAL|AR101 - Peanut protein capsule|Study product provided as peanut protein in pull-apart capsules at 5 dosage strengths (0.5, 1, 10, 100, and 475 mg) or sachets at 2 dosage strengths (300 and 1000 mg)
214911428|NCT04467567|OTHER|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after Lutathera® treatment (at 24h, 96h and 168h after the infusion of Lutathera®) on the conventional camera and on the VERITON-CT camera
214911429|NCT03066713|OTHER|Skin Off French Fry|Skin Off French Fries will be provided at breakfast and lunch
214911430|NCT03066713|OTHER|Skin On French Fry|Skin On French Fries will be provided at breakfast and lunch
214911431|NCT03066713|OTHER|Hash brown|Hash brown potatoes will be provided at breakfast and lunch.
214911432|NCT03066713|OTHER|Carbohydrate control|A pancake will be provided at breakfast, and pretzels will be provided at lunch.
214911433|NCT02523508|BEHAVIORAL|Experimental group|Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.
214911434|NCT02523508|OTHER|Control group|Passive limb mobilization which did not involve the spine
214911435|NCT00722774|BIOLOGICAL|H2N2 1960 AA ca recombinant vaccine|Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
214911436|NCT04316104|BEHAVIORAL|CuidaTXT|Culturally tailored text messages including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
214911437|NCT00999609|BIOLOGICAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
214911438|NCT03991650|BEHAVIORAL|Monitoring with a device|Participants will be monitored by an App.
214911439|NCT06476119|DRUG|Adjuvant chemotherapy|adjuvant chemotherapy according to local/ national guidelines
214911440|NCT06476119|OTHER|No adjuvant chemotherapy|no adjuvant chemotherapy
215058718|NCT04789629|DEVICE|low level laser therapy|3 session per week laser with exercises
215058719|NCT03389698|DEVICE|GRASP Dynamic Contrast-Enhanced (DCE) MRI|Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.
215058720|NCT03389698|DEVICE|3T Brain Scan|Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.
215058721|NCT03389698|DRUG|Gadolinium-based Contrast Agent (GBCA) for MRI|Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.
215058722|NCT04430608|DEVICE|Dexcom G6|"The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC."
215058723|NCT06070389|DEVICE|Sansa device|The Sansa device will be used during a single overnight polysomnography study.
215058724|NCT06242990|BEHAVIORAL|Y-PATH NI|"The Y-PATH NI intervention provides a whole of school approach with student, teacher, parent and guardian components. Student components: Y-PATH resources delivered by physical education teachers (6 lesson plans, resource cards to use as teaching prompts), student handbook. Posters are also displayed in the sports hall/ PE department.~Teacher components: Teachers will receive online and in-person training to deliver the Y-PATH programme. This component also targets all non-specialist PE teachers and includes workshops, information leaflets, development of a physical activity promotion charter and a step challenge.~Parent/guardian components: Information session and leaflets distributed across the intervention period."
215058725|NCT05447520|DRUG|Montelukast|Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
215058726|NCT05447520|DRUG|Placebo|Oral tablet once daily
214303761|NCT07191275|DEVICE|Experimental continuous 30 Hz thetaburst transcranial magnetic stimulation|"Bilateral continuous theta burst stimulation (cTBS) 30 Hz to the temporo-occipital cortex~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right temporo-occipital cortex (MNI: -47, -77, 4; 50, -69, -4)~* Duration: 33.3 seconds for each side~* Timing: Immediately before showing IAPS pictures (off-line)"
214303762|NCT07191275|DEVICE|Control continuous 30 Hz thetaburst transcranial magnetic stimulation|"Active control condition using bilateral continuous theta burst stimulation (cTBS) 30 Hz to the superior parietal cortex~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right superior parietal cortex (MNI: -17, -70, 60; 17, -70, 60)~* Duration: 33.3 seconds~* Timing: Immediately before showing IAPS pictures (off-line)"
215058727|NCT05447520|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
215058728|NCT00922376|DEVICE|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
215058729|NCT02519478|BEHAVIORAL|Helmetless Tackling Training (HuTT)|see previous sections
214303763|NCT07190430|DRUG|PF-08049820|Administered orally
215058730|NCT00556608|DEVICE|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
215058731|NCT00556608|DEVICE|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
215058732|NCT04251234|OTHER|Light intensity, ~30 lux|\~30 lux compared to very dim light baseline condition \<1 lux
215058733|NCT04251234|OTHER|Baseline light intensity, <1 lux|Very dim light condition
215058734|NCT04345484|BEHAVIORAL|Goal-management training|9-week goal-management program
215058735|NCT04345484|BEHAVIORAL|Control|Healthy Lifestyle Program
215058736|NCT05757518|OTHER|Cryosauna|The intervention was Cryosauna - cryostimulation at -110°C for 1.5 minutes, for four consecutive days.
215058737|NCT02410642|PROCEDURE|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
215058738|NCT04116983|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
215058739|NCT05922007|OTHER|Validation of the Questionnaire|Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)
214303764|NCT07190430|DRUG|Midazolam|Administered orally
214303765|NCT07190430|DRUG|Dabigatran Etexilate|Administered orally
214303766|NCT07190430|DRUG|Portia (EE and LN) or equivalent oral tablet|Administered orally
214346948|NCT01380327|BIOLOGICAL|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
215058740|NCT05922007|OTHER|Prospective quantitative study - questionnaire survey|A questionnaire survey will be carried out using the questionnaire set three times
215058741|NCT00863044|PROCEDURE|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
214303767|NCT07189754|DIETARY_SUPPLEMENT|Sabroxy™ (Oroxylum indicum extract)|Sabroxy™ is a standardized extract derived from the bark of Oroxylum indicum. In this study, participants will receive Sabroxy™ in capsule form. Each capsule contains a fixed dose of the extract and will be administered orally at a regimen of one capsule twice daily after meals for 12 weeks. The supplement is provided in visually identical containers to maintain blinding and is compared to a placebo control. The intervention is designed to evaluate potential improvements in cognitive function, including memory, attention, and executive performance, as well as effects on circulating Brain-Derived Neurotrophic Factor (BDNF) levels.
214911441|NCT04039568|BEHAVIORAL|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
214911442|NCT04039568|BEHAVIORAL|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
214911443|NCT03680586|DRUG|Radiation Therapy|Undergo ultra low-dose radiation
214911444|NCT04956120|DEVICE|Citrate Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. When used, citrate is provided in the acid concentrate. The acid concentrate with citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
214911445|NCT04956120|DEVICE|Standard Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. The acid concentrate without citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
214911446|NCT05343364|DRUG|Vonoprazan|Oral Tablet
214911447|NCT04566978|DRUG|89Zr-DFO-REGN3767|89Zr-DFO-REGN3767 is comprised of the anti-LAG-3 antibody, REGN3767 labeled with the positron-emitter zirconium-89 (89Zr) through the chelator-linker DFO. REGN3767 is an investigational monoclonal antibody that target LAG-3 receptors.
214911448|NCT04566978|DIAGNOSTIC_TEST|PET/CT|"A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution.~Part A patients will be imaged at three time points post-injection to allow for selection of optimal imaging time and dosimetry determination. For these patients, top of skull to feet scans will be acquired:~* Within one to four hours following injection of tracer on Day 1~* 24-72 hours post-injection (Day 2-4)~* 20-168 hours post-injection (once during days 5-7)"
214911449|NCT06342375|OTHER|Outbound phone call|Participants will receive either a live or pre-recorded outbound phone call
214911450|NCT04351113|DIETARY_SUPPLEMENT|MITO-AO|Participants will receive 160 mg with breakfast on day 1 of bed rest and 40 mg with breakfast on days 2-5.
214911451|NCT04351113|DIETARY_SUPPLEMENT|PB-125|Participants will receive 100 mg on days 1-5 of bed rest.
214911452|NCT04351113|OTHER|Placebo|Participants will receive Placebo on days 1-5 of bed rest.
214911453|NCT04351113|OTHER|Passive Leg Movement (PLM)|Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.
214911454|NCT04351113|OTHER|Plantar flexion|Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.
214911455|NCT04351113|OTHER|Isometric knee extensor test|Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.
214911456|NCT04351113|OTHER|Bed rest|Participants will undergo 5 days bed rest after 5 day baseline assessments
214911457|NCT06624293|DIAGNOSTIC_TEST|BNP|Blood collected during this study will be tested on separate IUO BNP assay on a separate protocol. No active interventions will occur during this study.
214911458|NCT02600156|PROCEDURE|Focal laser ablation of the prostate|MR guided laser ablation of the focal prostatic lesion which has been identified by MRI and biopsy prior to ablation.
214911459|NCT02392572|DRUG|Akt/ERK Inhibitor ONC201|Given PO
214911460|NCT02392572|DRUG|Venetoclax|Given PO
214911461|NCT04322097|DEVICE|Lingual Muscle Stimulation|Tongue protrudor muscles will be stimulated
214911462|NCT04322097|OTHER|Mandibular advancement|Outcome variables will be assess with and without mandibular advancement
214911463|NCT04322097|OTHER|Postural maneuvers|Outcome variables will be measured with and without postural maneuvers
214911464|NCT04322097|OTHER|Digital Morphometrics|A digital camera with laser pointers will be used to capture a series of craniofacial photographs (frontal, profile and neck extended) and intra-oral photographs (junction of the hard and soft palate, airway, or base of tongue).
214911465|NCT04322097|OTHER|Tongue Force Exercise|The patient will place a small bulb behind their lower incisors and will press using their tongue as hard as possible for two seconds. This exercise will be repeated four times, with 30 seconds of rest in between each attempt. The patient will then be instructed to press and hold their tongue against the bulb as hard as possible for 35 seconds. This exercise will be repeated three times, with 2 minutes of rest in between each attempt.
214911466|NCT04322097|OTHER|Magnetic resonance imaging (MRI)|The patient will undergo an MRI scan of the head and neck.
214911467|NCT04322097|OTHER|Polysomnography (PSG) - Split Night|The patient will undergo a polysomnography (PSG). The PSG study will include monitoring of EEG, submental EMG, EOG, SpO2, tidal airflow, thoraco-abdominal efforts, and body position. The patient will spend half of the night at baseline (i.e. no intervention), and the second half with lingual muscle stimulation activated.
214911468|NCT02251821|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
214911469|NCT02251821|DRUG|Busulfan|Given IV
214911470|NCT02251821|DRUG|Cyclophosphamide|Given IV
214911471|NCT02251821|DRUG|Fludarabine Phosphate|Given IV
214911472|NCT02251821|OTHER|Laboratory Biomarker Analysis|Correlative studies
214911473|NCT02251821|DRUG|Melphalan|Given IV
214911474|NCT02251821|DRUG|Methotrexate|Given IV
214911475|NCT02251821|DRUG|Mycophenolate Mofetil|Given IV or PO
214911476|NCT02251821|DRUG|Ruxolitinib|Given PO
214911477|NCT02251821|DRUG|Tacrolimus|Given IV or PO
214911478|NCT02251821|RADIATION|Total-Body Irradiation|Undergo TBI
214911479|NCT02251821|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
214303768|NCT07189754|OTHER|Placebo|The placebo is an inert capsule formulated to be visually identical to the Sabroxy™ capsules in size, shape, color, and packaging. It contains inactive ingredients only, with no active botanical extract. The placebo will be administered orally at the same regimen as the active intervention: one capsule taken twice daily after meals for 12 weeks. The use of a placebo ensures blinding of participants and study staff, allowing accurate comparison of cognitive and biomarker outcomes between groups.
214303769|NCT07190417|OTHER|LEDs and laser light|"Experiment 1：Measure the heart rate parameters before, during, and after laser acupuncture or LED light therapy within a 25-minute experimental period, and observe the changes in the subjects' meridian energy before and after the treatment, followed by analysis. Acupoint selections mainly include Daling, Neiguan, and Shenmen.~Experiment 2：randomly assigns subjects to wear either a low-energy LED device or a sham device. The indicators, duty cycles, and sounds of the low-energy LED device and the sham device are all the same.~Experiment 3：Place light sources of different wavelengths on the earlobes or auricles of subjects with different skin tones. By observing the changes in light power before and after, the investigators can infer the effects of skin tone on light attenuation and transmission of light sources with different wavelengths."
214911480|NCT04076163|OTHER|serious game|a serious game was performed by the investigators in order to enhance the critical appraisal practice of students
214911481|NCT02358239|PROCEDURE|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
214911482|NCT00726193|DEVICE|OsteoGen|OsteoGen Implatable stimulator
214911483|NCT03228888|OTHER|Administration of rhytmic acoustic stimuli for gait training|The intervention consist in 5 weeks, 20 min/day gait training assisted by rhythmic acoustic stimuli administered using a portable MP3 player
214911484|NCT00947921|PROCEDURE|Plasty|Restrictive Annuloplasty
214911485|NCT00947921|PROCEDURE|Prosthesis|Valve replacement
214911486|NCT06199284|DEVICE|Atalante exoskeleton|The gait training program using Atalante exoskeleton consisted of 3 sessions per week for 6 weeks. For each participant, the assistance of the exoskeleton can be specifically adjusted and can be set symmetrically or asymmetrically bases on his capabilities.
214911487|NCT01868906|DRUG|18F-FMISO|18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
214911488|NCT01868906|PROCEDURE|PET without SCS|PET-scanning using 18F-fluoromisonidazole without SCS
214911489|NCT01868906|DEVICE|SCS|Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.
214911490|NCT01868906|PROCEDURE|PET without/with SCS|Second PET-scanning using 18F-fluoromisonidazole: without/with SCS
214911491|NCT01868906|RADIATION|Radiotherapy|Standard radiation therapy
214911492|NCT01868906|DRUG|Temozolomide|Standard treatment with concurrent and adjuvant Temozolomide.
214911493|NCT04785872|OTHER|Education|NEUMAN SYSTEMS MODEL BASED NURSING APPROACH
214911494|NCT05405504|DEVICE|Remote Dielectric Sensing (ReDS)|Non-invasive device designed for the measurement of lung fluid using extremely low power electromagnetic waves. The ReDS Pro System V2.7 system has CE approval (3900874CE01) and FDA clearance.
214911495|NCT05854004|DIAGNOSTIC_TEST|Therapeutic Ultrasound|Therapeutic Ultrasound to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
214911496|NCT05854004|DIAGNOSTIC_TEST|Myofascial Release Technique|Myofascial Release Technique to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
214911497|NCT02531048|DEVICE|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
214911498|NCT02531048|DEVICE|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
214911499|NCT02531048|DEVICE|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
214911500|NCT02531048|DEVICE|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
214911501|NCT05058079|BEHAVIORAL|Intraoperative Hand Held|Intraoperative hand holding
214911502|NCT02105987|DRUG|ABC/DTG/3TC FDC|Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
214911503|NCT02105987|DRUG|Ongoing cART regimen|Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
214911504|NCT03588143|DEVICE|Electrical stimulation|Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention
214911505|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
214911506|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
214911507|NCT01262872|BIOLOGICAL|Synflorix™|Intramuscular injection
214911508|NCT01262872|BIOLOGICAL|Prevnar13™|Intramuscular injection
214911509|NCT01262872|BIOLOGICAL|Tritanrix™-HepB/Hib|Intramuscular injection
214911510|NCT01262872|BIOLOGICAL|Polio Sabin™|Orally
214911511|NCT01262872|BIOLOGICAL|M-Vac™|Intramuscular injection
214911512|NCT01262872|BIOLOGICAL|Stamaril™|Intramuscular injection
214911513|NCT01753570|DRUG|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
214911514|NCT01753570|DRUG|RBV(24 weeks)|RBV: 600 - 1000mg/day based on body weight for 24 weeks
214911515|NCT01753570|DRUG|IFN beta(24 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
214911516|NCT01753570|DRUG|RBV(48 weeks)|RBV: 600 - 1000mg/day based on body weight for 48 weeks
214911517|NCT01753570|DRUG|IFN beta(48 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
214911518|NCT03856411|DRUG|TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
214911519|NCT02350283|DEVICE|Interventional treatment with Solitaire|Patients will be treated for mechanical recanalization with Solitaire within 12 hours after stroke onset plus standard medical management.
214303770|NCT07190898|OTHER|core exercises|The participants performed core exercises three times per week for a total of six weeks
214303771|NCT07190898|OTHER|functional strength exercises|The participants performed functional strength exercises three times per week for a total of six weeks.
214911520|NCT06443528|DIAGNOSTIC_TEST|lung ultrasound|All enrolled infants underwent LUS examination performed by two ultrasound physicians. Monitoring included a complete lung scan in the first 24 hours of life (T0) and at day 3 (T1). All neonates underwent weekly ultrasound examinations until 36 weeks postmenstrual age (T2, T3…), so that the T2 scan was carried out at the end of the first week of life. LUS was performed according to a standardized protocol \[13\] when the neonate was in a quiet state, during routine clinical care to minimise discomfort. All ultrasound images and videos were digitally recorded, anonymised, and reviewed by a senior independent ultrasonographer blinded to patients' clinical information. Each lung was divided into three regions according to the anterior and posterior axillary lines and the mammary line. The regions were the upper-anterior, lower-anterior, and latera regions.
215058742|NCT00863044|PROCEDURE|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
214911521|NCT00001000|DRUG|Ampligen|
214911522|NCT00204906|DIETARY_SUPPLEMENT|vitamin D supplementation|
214911523|NCT02841761|DRUG|Midalozam|Syrup for oral use
214911524|NCT02841761|DRUG|Aprocitentan|Capsules for oral use
214911525|NCT04709562|DEVICE|High Velocity Nasal Insufflation (HVNI)|The purpose of this intervention is to evaluate the efficacy of HVNI in clinically stabilizing patients presenting with hypercapnic respiratory distress.
214911526|NCT04709562|DEVICE|Noninvasive Positive Pressure Ventilation (NIPPV)|The purpose of this intervention is to evaluate the efficacy of NIPPV in clinically stabilizing patients presenting with hypercapnic respiratory distress.
214911527|NCT05410665|PROCEDURE|Standard treatments for sepsis|Standard treatments for others
214911528|NCT05754905|OTHER|Magnetic resonance examination|the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence
214911529|NCT00920439|BIOLOGICAL|PoliorixTM|Single dose, intramuscular administration.
214911530|NCT03507868|PROCEDURE|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy includes oral hygiene education and scaling and root planning approaches to eliminate microbial dental plaque that is the primary etiology of periodontal diseases.
214911531|NCT04418557|DIAGNOSTIC_TEST|RT-PCR and antibody testing|Testing of amniotic fluid, cord blood, amnion and chorion, umbilical cord, vaginal mucous, maternal and neonatal sera, neonatal throat swab, and breast milk.
214911532|NCT02266784|BEHAVIORAL|Contingency Management (CM)|
214303772|NCT07190898|OTHER|education group|During the educational session, participants were provided with information on proper posture, ergonomic movements, the importance of posture in daily life, and pain management.
214303773|NCT07191340|DEVICE|Vagus nerve stimulator|Vagus nerve stimulator placed on neck and activated
214303774|NCT07191340|DEVICE|Placebo comparator sham|Vagus nerve stimulator placed on neck and not activated
214911533|NCT02266784|DRUG|Transdermal nicotine skin patches (i.e. Habitrol)|
214911534|NCT02266784|OTHER|Supportive Counseling|
214911535|NCT01244438|DRUG|FP-1039|FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
214911536|NCT01420068|DRUG|SPP100|
214911537|NCT05060536|PROCEDURE|Removal of infrapatellar fat pad|"There is no agreed protocol for retaining or excising the infrapatellar fat pad with many surgeons routinely completely removing the fat pad to improve view of the proximal tibia while others opt to retain or minimally excise the tissue.~We are aware of no risks involved in performing this procedure and current practice of many orthopaedic surgeons is either to routinely remove or routinely retain the infrapatellar fat pad when performing total knee arthroplasty.~The potential benefits are that we will understand better whether removing or retaining this tissue does have a role in influencing outcomes after total knee replacement surgery. The results will be disseminated to the wider orthopaedic community to inform practice with the aim or improving outcomes from total knee arthroplasty."
214911538|NCT05060536|PROCEDURE|No removal of infrapatellar fat pad|Retaining the infrapatellar fat pad during total knee replacement- no surgical removal.
214911539|NCT03468491|OTHER|combined training|The whole intervention period will last for 6 weeks, 2 visits per week, 1 hour per visit in the Research Building Room 630 of National Yang Ming University. All programs will be under the supervision of a physiotherapist with 2-year experience individually. 1. Hallux valgus correction: 1.1 Joint alignment correction (Grade II joint mobilization, 10 times/set, 3 sets/visit) - 1st MTP joint distraction - Proximal talofibular joint anteroposterior glide - (Grade III joint mobilization if any restriction being found) 1.2 Biomechanical taping (using Dynamic taping, 1 time/ visit, keep the taping for 2 days minimum) 1.3 Foot intrinsic muscle strengthening (10 times/set for each exercise, 3 sets/visit): - Short foot exercise - Toespread out exercise - Heel-rise exercises 2. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 2.1 Single lunge 2.2 Stepping down 2.3 Vertical squat 2.4 Vertical jumping
214911540|NCT03468491|OTHER|Proximal training|1\. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 1.1 Single lunge 1.2 Stepping down 1.3 Vertical squat 1.4 Vertical jumping All exercises will first start on firm surface without additional resistance/weight. Later, settings will be gradually shifted into on firm surface with resisted band from random direction, on a cushion with/ without resisted band, on a BOSU balance trainer. Progression are made every 2 weeks ideally, while adjustments may be taken into concern due to individual differences.
214911541|NCT03034980|OTHER|Training intensity (workload) during ergospirometry|The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
214911542|NCT03981250|BEHAVIORAL|12-week home-based resistance exercise programme|Participants will perform 6 exercises (press-ups, squats, squat jumps, plank, upright row and seated row) for one minute, aiming for the maximum number of repetitions. Participants will perform one exercise per day, for 6 days a week, for 12 weeks.
214911543|NCT00291070|DRUG|L-theanine|This study will examine the effects of L-theanine (an amino acid found in green tea) on the behavior, cognitive performance and sleep quality of boys with ADHD.
214911544|NCT00929370|DRUG|Glycine Transporter-1 inhibitor|GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
214911545|NCT00758290|DRUG|Triclosan/Fluoride|Brush twice daily for 3 weeks
214911546|NCT00758290|DRUG|Fluoride/triclosan|Brush daily for 3 weeks
215058743|NCT02243319|DRUG|HGP1201|
214911547|NCT03225469|BEHAVIORAL|reinforced family member education|Based on regular instructions for patent education, at least one family member who lives with the patient together will be given special instruction.
214911548|NCT04948502|DEVICE|SaExten vena cava filter system|Subjects will undergo intervention, be implanted with a SaExten filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
214911549|NCT04948502|DEVICE|Denali inferior vena cava filter|Subjects will undergo intervention, be implanted with a Denali filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
214911550|NCT01699373|PROCEDURE|Ultrasound scan|Pre-procedural ultrasound scan was performed
214911551|NCT04863001|DRUG|Antiarrhythmic drug|all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university
214911552|NCT04698044|DIAGNOSTIC_TEST|Hospital Anxiety Depression Scale|HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).
214911553|NCT00497523|DRUG|Beclomethasone dipropionate|
214911554|NCT00497523|DRUG|Beclomethasone dipropionate/Salbutamol combination|
214911555|NCT00497523|DRUG|Salbutamol|
214911556|NCT00290953|DRUG|SR48692|
214911557|NCT01004497|DRUG|Dasatinib|After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks
214911558|NCT01004497|DRUG|Cyclophosphamide|300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
214911559|NCT01004497|DRUG|Vincristine|1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 \& 11
214911560|NCT01004497|DRUG|Daunorubicin|45 mg/m2/day, IV for 1 hour, days 4 \& 11
214911561|NCT01004497|DRUG|Dexamethasone|40 mg/day, IV push, days 1-4 \& days 11-14
214911562|NCT01004497|DRUG|Cytarabine|2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5
214911563|NCT01004497|DRUG|Mitoxantrone|12 mg/m2/day, IV for 30 minutes, days 1-2
214911564|NCT06577974|DRUG|Combined contraceptive pills (Yasmin)|medical pretreatment prior to ICSI
214303775|NCT07190638|PROCEDURE|Medullary-only suturing (single-layer)|Only the base layer (medulla) is sutured after tumor excision, Cortical suturing is omitted. Hemostatic agents are applied.
214911565|NCT02473939|DRUG|VR942 delivered via a Vectura Dry Powder Inhaler|
214911566|NCT02473939|DRUG|Placebo delivered via a Vectura Dry Powder Inhaler|
214911567|NCT03464188|BEHAVIORAL|Project Cornerstone|"Project Cornerstone basic elements are:~1. The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician;~2. 6 base telephone/in-person sessions: Sessions cover specific topics (every 1-2 weeks, 20-60 minutes/session; by phone or in-person), followed by monthly follow-up and additional coaching sessions as needed;~3. Regular caregiver distress thermometer screening and problem support and self-care coaching.~4. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions. Project Cornerstone begins within 60 days of a care recipient being diagnosed with advanced cancer and ends 1 year after care recipient death."
214911568|NCT03107390|OTHER|Evaluate the blood level of NTproBNP|Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.
214911569|NCT04338841|OTHER|HOME-CoV rule implementation|"HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.~Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments."
214911570|NCT05160623|DRUG|Povidone-Iodine 1 % Topical Solution|Povidone-Iodine 1 % topical solution on a makeup remover pad, used to clean the lids and lashes once daily
214911571|NCT05160623|DRUG|Eyelid cleansing wipes|EYECARE FORTE eyelid wipes (Dr. Fischer, Israel), used to clean the lids and lashes once daily
214911572|NCT05209568|DIETARY_SUPPLEMENT|Gluten Powder|Single oral dose of gluten powder
214911573|NCT01862978|DRUG|Heparin|
214303776|NCT07190638|DEVICE|Suture|Synthetic absorbable monofilament suture (Caproyl™ 3-0).
214303777|NCT07190638|PROCEDURE|Medullary and cortical suturing (two-layer)|Both medullary and cortical layers are sutured after tumor excision, Performed with robotic assistance using absorbable sutures. Hemostatic agents are applied
214303778|NCT07190638|DEVICE|Suture|Synthetic absorbable monofilament suture (Caproyl™ 3-0), absorbable braided suture (Vicryl™ 0)
214303779|NCT07190638|DEVICE|Hemostatic Agent|Hemostatic agents (e.g., Bleed Stp Plus, Surgicel® Fibrillar, Hemopatch®).
214303780|NCT07189858|DEVICE|Nasal antimicrobial photodisinfection therapy|The Steriwave Nasal Photodisinfection System is applied using a photosensitizer in the nose followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.
214911574|NCT01862978|DRUG|Nadroparin|
214911575|NCT01862978|DRUG|Placebo|
214911576|NCT02170220|DRUG|Vortioxetine|Vortioxetine tablets
215058744|NCT02243319|DRUG|HGP0904|
214346949|NCT01380327|OTHER|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume \[w/v\]) was achieved.
214911577|NCT06509087|PROCEDURE|Transarterial microembolization (TAME)|TAME primarily targets abnormal neovascularization for embolization in chronic shoulder or knee joint pain.
215058745|NCT02243319|DRUG|HGP0904 and HGP1201 co-administraion|
214911578|NCT01636271|DRUG|darapladib|darapladib enteric coated tablets 160 mg
214911579|NCT01636271|DRUG|placebo|placebo
214911580|NCT03608033|BIOLOGICAL|OMS721|Biological: OMS721
214911581|NCT03608033|OTHER|Vehicle (D5W or saline)|5% Dextrose in water or normal saline solution
214911582|NCT01495650|BEHAVIORAL|Tailored program of PA and nutritional counseling|Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
214911583|NCT01153815|DRUG|GSK1358820(Botulinum toxin type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
214911584|NCT01153815|DRUG|placebo|placebo
214911585|NCT01786993|DEVICE|MultiPoint Pacing|Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
214911586|NCT01786993|DEVICE|Traditional Biventricular Pacing|Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
214911587|NCT03977870|OTHER|vital status determination|consultation of national registries
214911588|NCT03228979|OTHER|Structured Semi-Interactive Stroke Prevention Package|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines.
214911589|NCT05791097|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous infusion. 900 mg of ociperlimab will be administered on Day 1 of each 21-day cycle
214911590|NCT05791097|DRUG|Placebo|Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle
214911591|NCT05791097|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of tislelizumab will be administered on Day 1 of each 21-day cycle
214911592|NCT05791097|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of pembrolizumab will be administered on Day 1 of each 21-day cycle
214911593|NCT05791097|DRUG|Carboplatin|Carboplatin is a chemotherapy agent formulated for intravenous infusion. Carboplatin will be administered (AUC 6 mg/mL\*min) on Day 1 of each 21-day cycle
214911594|NCT05791097|DRUG|Cisplatin|Cisplatin is a chemotherapy agent formulated for intravenous infusion. Cisplatin will be administered (75 mg/m\^2) on Day 1 of each 21-day cycle
214911595|NCT05791097|DRUG|Pemetrexed|Pemetrexed is a chemotherapy agent formulated for intravenous infusion. Pemetrexed will be administered (500 mg/m\^2) on Day 1 of each 21-day cycle
214911596|NCT05791097|DRUG|Paclitaxel|Paclitaxel is a chemotherapy agent formulated for intravenous infusion. Paclitaxel will be administered (200 mg/m\^2) on Day 1 of each 21-day cycle
214911597|NCT05791097|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent formulated for intravenous infusion. Nab-paclitaxel will be administered (100 mg/m\^2) on Day 1, 8 and 15 of each 21-day cycle
214911598|NCT00521105|OTHER|Virtual visit|Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
214911599|NCT05845632|OTHER|Treatment|Patients were treated with surgery, radiotherapy or surgery with postoperative radiotherapy.
214911600|NCT00000668|DRUG|Ganciclovir|
214911601|NCT03920839|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks.
214911602|NCT03920839|DRUG|Gemcitabine|Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.
214911603|NCT03920839|DRUG|Cisplatin|Cisplatin administered intravenously on Day 1 of 21-day cycles.
214911604|NCT03920839|DRUG|Pemetrexed|Pemetrexed administered intravenously on Day 1 of 21-day cycles.
214911605|NCT03920839|DRUG|Carboplatin|Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.
214911606|NCT03920839|DRUG|Paclitaxel|Paclitaxel administered intravenously on Day 1 of 21-day cycles.
214911607|NCT01672502|BEHAVIORAL|Sleep health education provided via a web-based program|All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
214911608|NCT01672502|OTHER|Sleep disorder detection and treatment|Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
214911609|NCT01672502|OTHER|Optimization of Sleep in Fire Station|First, we will review and retrofit the sleeping quarters to provide a better environment for napping and sleep; light, noise, bed type, space, temperature, and location would all be considered and where possible, changes made to improve the sleeping environment. Secondly, we will work with management and union personnel to develop a 'sleep friendly' policy during the daytime, with specified protected times for naps during the day before the overnight work in order to reduce sleepiness during overnight work. Finally, we will upgrade the alerting systems, that is, we will work with management and union personnel to consider changing the policy that requires the sleeping areas of all stations to receive all alarm calls, even if that particular station is not required to attend the alarm.
214911610|NCT01890122|DRUG|Alogliptin|Alogliptin tablets
214911611|NCT01890122|DRUG|Metformin HCl|Metformin HCl capsules
214911612|NCT01890122|DRUG|Alogliptin and Metformin Fixed-Dose Combination (FDC)|Alogliptin and metformin FDC tablets
214911613|NCT01890122|DRUG|Alogliptin Placebo|Alogliptin placebo-matching tablets
214911614|NCT01890122|DRUG|Metformin Placebo|Metformin placebo-matching capsules
214911615|NCT01890122|DRUG|Alogliptin and Metformin FDC Placebo|Alogliptin and metformin FDC placebo-matching tablets
214911616|NCT02482688|BEHAVIORAL|A New Rehabilitation Treatment following Stroke|A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
214911617|NCT02533440|PROCEDURE|EXPAREL and Local Anesthetics|Patients will receive EXPAREL and local anesthetics, as well as opioid and non-opioid analgesics prescription, (only use if needed, for post surgical pain)
214911618|NCT02533440|PROCEDURE|Oral Opioid and Local Anesthetics|Patients will receive local anesthetics, as well as oral opioid or non-opioid analgesics, (only use if needed, for post surgical pain)
214911619|NCT04983472|OTHER|Observational|Respiratory muscle electromyographic activations of individuals will be taken during supine, normal sitting and dyspnea reduction positions. Individuals with chronic obstructive pulmonary disease will be asked to perform normal breathing, pursed lip breathing, and breathing control during these positions. Respiratory muscle activation measurement of individuals will be taken during different breathing patterns in each position. Respiratory functions will be evaluated with pulmonary function test, respiratory muscle strength, intraoral pressure measurement device, respiratory muscle activation with surface electromyographic device, health status disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
214911620|NCT03023215|PROCEDURE|Meditation|Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
214911621|NCT03023215|PROCEDURE|Electroencephalogram|Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
214911622|NCT03023215|BEHAVIORAL|Questionnaires|Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.
214911623|NCT03023215|PROCEDURE|Heart Rate|Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
214911624|NCT03274388|PROCEDURE|nutritional therapy|protein-rich nutritional therapy and counseling, during study period of 12 weeks
214303781|NCT07190612|DRUG|Dexmedetomidine and propofol|"Dexmedetomidine infusion syringe (50mls): will be filled with 2mls of dexmedetomidine (200µg) diluted in 48 ml of 0.9% normal saline to make a final volume of 50mls and a final dexmedetomidine concentration of 4µg/ml. It will be infused as 1µg~/kg/hr iv. Propofol infusion syringe (50mls): will be filled with 20mls of 1% propofol (200mg) diluted in 30mls 0.9% normal saline to make a final volume of 50mls and a final propofol concentration of 4mg/ml. It will be iv administered as 0.5 mg/kg slow iv for 10 minutes, then infused at a rate of 0.5mg/kg/hr."
214911625|NCT03274388|PROCEDURE|WB-EMS combined with nutritional therapy|protein-rich nutritional therapy and counseling plus whole body electromyostimulation exercise training, twice a week for 20 min., during study period of 12 weeks
214911626|NCT00941486|DRUG|FST-100 Ophthalmic Suspension|FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.
214911627|NCT00941486|DRUG|Placebo|A regimen of 2 drops 4 times a day while awake for 5 days.
214911628|NCT04295408|PROCEDURE|Pericapsular nerve group block with saline solution|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the saline solution was injected in 5-mL increments while observing for adequate fluid spread in this plane.a total volune of 40 ml saline solution was injected.
214911629|NCT04295408|PROCEDURE|Pericapsular nerve group block with ropivacaine|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, local anesthetic was injected in 5-mL increments while observing for adequate fluid spread in this plane. a 2 mg.kg-1Ropivacaine in 40 ml of saline was injected
214911630|NCT01123811|DRUG|Cetuximab IF|Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36
214911631|NCT02841839|DRUG|Stannous Fluoride|
214911632|NCT02062450|DEVICE|Primary surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
214911633|NCT02062450|DEVICE|Revision surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
214911634|NCT03585023|DIAGNOSTIC_TEST|Spontaneous miscarriage|Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
214911635|NCT03585023|DIAGNOSTIC_TEST|Voluntary pregnancy interruption|Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
214911636|NCT05386459|DRUG|Interferon Gamma|injection form
214911637|NCT02555228|DRUG|Simethicone|100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
214911638|NCT02555228|OTHER|Water|5mls of water is given at least 30 minutes before the gastroscopy.
214911639|NCT02045069|DRUG|2 days Ivermectin|200-400 µg/kg once daily for 2 days and placebo once daily at D3
214911640|NCT02045069|DRUG|3 days Ivermectin|200 -400 µg/kg once daily for 3 days
214911641|NCT02045069|DRUG|Placebo|Placebo once daily for 3 days
214911642|NCT04119869|OTHER|iaya|The iaya app is a smartphone application intervention that -through a variety of approaches, such as exercises aimed at identifying and changing thoughts and behaviors, imagery, and relaxation- seeks to enhance coping with the emotional impact of cancer.
214911643|NCT00475488|PROCEDURE|Coronary artery bypass grafting|Surgery performed due to coronary artery disease.
214911644|NCT04287075|PROCEDURE|Surgical Management of Neuroma|Surgical procedures targeted to treat the source of a participant's chronic, neuropathic pain
214911645|NCT04796532|OTHER|Home based HIIT|"Intervention will consist in a 16-week exercise program with HIIT with a frequency of 3 days/week. The Home-HIIT group participants will attend HIIT workout sessions supervised by a specialised instructor via a videoconference application. Every HIIT workout session will have a 10 minutes' warm-up, followed by an 8/12/16/20 minutes of HIIT (stages of physical adaptation every 4 weeks) training and 5 minutes' cool-down. Tabata method will be used with eight sets of 20 seconds of exercise bouts separated by 10 seconds rest, in 2 to 5 blocks. The intervention will have four stages of physical adaptation.~This group will have a follow-up period of 16 weeks."
214911646|NCT04796532|OTHER|Traditional HIIT|"Intervention will consist in a 16-week exercise program with HIIT with a frequency of 3 days/week. The Traditional HIIT group participants will attend a group HIIT workout sessions supervised by a specialised instructor in a sport facility. Every HIIT workout session will have a 10 minutes' warm-up, followed by an 8/12/16/20 minutes of HIIT (stages of physical adaptation every 4 weeks) training and 5 minutes' cool-down. Tabata method will be used with eight sets of 20 seconds of exercise bouts separated by 10 seconds rest, in 2 to 5 blocks. The intervention will have four stages of physical adaptation.~This group will have a follow-up period of 16 weeks."
214911647|NCT01221519|DRUG|AZD1656|3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
214911648|NCT02545959|DRUG|Rituximab IT|CSF injection of intrathecal rituximab (20mg)
214911649|NCT02545959|DRUG|methylprednisolone IV|blood infusion of methylprednisolone IV (120mg)
214911650|NCT02545959|DRUG|Rituximab IV|Blood infusion of rituximab (375mg/m2)
214911651|NCT05643703|PROCEDURE|Suture method|One-layered Suture: Single layer intermittent suture; Two-layered Suture:Single layer intermittent suture plus U type reinforcement stitching
214911652|NCT00971438|PROCEDURE|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
215058746|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
215058747|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
215058748|NCT02777411|BIOLOGICAL|EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
215058749|NCT02777411|BIOLOGICAL|EV71 vaccine (2 μg total protein per dose)|Two vaccinations at 28 days apart
215058750|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
214303782|NCT07190612|DRUG|Midazolam and propofol|Midazolam infusion syringe (50mls): will be filled with 10mls of Midazolam (50mg) diluted in 40mls 0.9% normal saline to make a final volume of 50mls to reach a final midazolam concentration of 1mg/ml. It will be administered as a bolus dose of 0.05 mg/kg iv over 2 minutes then infused at a rate of 0.025mg/kg/hr. Propofol infusion syringe (50mls): will be filled with 20mls of 1% propofol (200mg) diluted in 30mls 0.9% normal saline to make a final volume of 50mls and a final propofol concentration of 4mg/ml. It will be iv administered as 0.5 mg/kg slow iv for 10 minutes, then infused at a rate of 0.5mg/kg/hr.
214911653|NCT02856932|OTHER|Conventional high viscosity glass ionomer|Dental restorative material
214911654|NCT02856932|OTHER|Glass ionomer with glass hybrid technology|Dental restorative material
214911655|NCT01737632|BEHAVIORAL|Multidimensional Family Therapy (MDFT)|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
214911656|NCT01737632|BEHAVIORAL|Adolescent Residential Treatment|The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
214911657|NCT02691052|OTHER|Quality of Life questionnaire|EORTC QLQ-C30 questionnaire
214911658|NCT02104674|DRUG|lebrikizumab|Given SC on Days 1, 29, and 57
214911659|NCT02104674|DRUG|montelukast [Singulair]|10 mg given orally once daily for 12 weeks
214911660|NCT02104674|OTHER|placebo|SC injection given on Days 1, 29, and 57
214911661|NCT04299815|DRUG|Oral Sodium Lactate|25 grams of D/L lactate dissolved in 300mL water.
214911662|NCT04299815|DRUG|Intravenous sodium lactate|intravenous sodium lactate + oral sodium-chlorid solution
214911663|NCT03152877|DRUG|Bupivacaine Liposome Injectable Product|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
214911664|NCT03152877|DRUG|0.25% plain bupivacaine|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
214911665|NCT02591160|PROCEDURE|HCTZ cessation|Patients will stop taking their HCTZ for 3 months
214911666|NCT05046262|DRUG|Calcium chloride|Calcium electroporation
214911667|NCT02035371|DRUG|Faster-acting insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
215058751|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
215058752|NCT02777411|BIOLOGICAL|EV71 vaccine (1 μg total protein per dose)|Two vaccinations at 28 days apart
215058753|NCT05507567|DRUG|Neumifil|Liquid for intranasal spray administration
215058754|NCT05507567|DRUG|Placebo|Liquid for intranasal spray administration
215058755|NCT01229046|DRUG|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
215058756|NCT02890745|DRUG|Empagliflozin|
214479553|NCT06866626|BEHAVIORAL|Theory-Based Nutrition Education Intervention to Improve Infant and Young Child Feeding Practices and WASH Practices Among Turkana Caregivers|This nutrition education intervention was designed following the DESIGN procedure, informed by the Theory of Planned Behavior, and employed health literacy principles. The nutrition education sessions were held Monday through Saturday for a total of 8 weeks in a community building. This nutrition education intervention had 4 modules, module one covered the recommended breastfeeding practices, including early initiation of breastfeeding, exclusive breastfeeding and continued breastfeeding. The second module was on the young child feeding practices, with a focus on the quality and quantity of the child's meal. The third module entailed WASH practices such as disinfection of drinking water, harms of open defecation, and other personal and household hygiene practices. The fourth module served as a comprehensive review of all previous modules.
214911668|NCT02035371|DRUG|insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
214911669|NCT03866252|DRUG|LSD|LSD administration per os
214911670|NCT02907177|DRUG|Ponesimod|One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).
214911671|NCT02907177|OTHER|Placebo|One tablet of matching placebo administered orally once daily in the morning
214911672|NCT06555003|DRUG|Drug-Eluting Embolic Bead|A minimum of 2 sessions of DEBIRI treatment and 2-4 cycles of systemic chemotherapy are administered (based on tumor size, bilobar or unilobar involvement of the liver, treatment response rate, treatment tolerance, occurrence of side effects, and liver function). Prior to performing DEBIRI, initial angiography is done via the femoral or axillary artery to determine the anatomy of the right and left hepatic arteries as well as the arteries supplying the tumor. Subsequently, a vial of irinotecan (100 mg) eluted with a vial of beads(hepaSphere 25mg) is injected into the blood vessels feeding the tumor. The intervention will be repeated to deliver 200 mg of irinotecan intravascularly to the liver mass. A 14-day interval between the procedures is established to minimize side effects. Targeted therapy administration for each treatment group based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status as explained in control arm.
214911673|NCT06555003|DRUG|Chemotherapy drug|Control group will receive 2-4 cycles of systemic chemotherapy based on functional status of the patient, adverse event rate and treatment tolerance, tumor size and characteristics. Targeted therapy administration for each treatment group in based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status (e.g., administration of Pembrolizumab for patients with high rosatellite instability (MSI-H) or Bevacizumab for tumors harboring KRAS mutations). Due to the targeted nature of these therapies, they can not be administered to all participants of the trial, while It is not ethically justifiable to withhold targeted therapies from patients who are candidates for these treatments based on their tumor characteristics and deprive them of potentially life-extending options.
214911674|NCT02518061|OTHER|No intervention|This is a retrospective study
214911675|NCT01862926|DRUG|Rituximab|
214911676|NCT01862926|DRUG|Cyclophosphamide|
214911677|NCT01487395|DRUG|Donepezil .|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
214911678|NCT01487395|DRUG|Placebo|the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
214911679|NCT04699474|DEVICE|Leg ergometer|Leg cycling in bed using motorized ergometer
214911680|NCT04931732|BIOLOGICAL|ctDNA analysis|ctDNA analysis of patients with suspected primary glioma tumors and in patients with suspected recurrence.
214911681|NCT02198170|DRUG|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period. Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period.
214911682|NCT02198170|DRUG|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
214911683|NCT05374031|OTHER|descriptive study|descriptive study
214911684|NCT00569972|DRUG|PD 0200390|Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
214911685|NCT00569972|DRUG|PD 0200390|Capsules, 30 mg, 3 capsules each night before bedtime; Duration - Visit 3-7 for 28 days
214911686|NCT00569972|DRUG|PD 0200390|Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days
214911687|NCT00569972|DRUG|PD 0200390|Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
214911688|NCT00569972|DRUG|Placebo|Matched oral placebo for weeks 2-7.
214911689|NCT06874647|OTHER|AI-generated report for reference|The Janus-Pro-CXR group has the AI-generated report for reference and can make changes to the AI-generated report. Another group completes the report independently.
214911690|NCT01347723|OTHER|scrambler therapy|Undergo scrambler therapy
214911691|NCT01347723|OTHER|questionnaire administration|Ancillary studies
214911692|NCT01347723|PROCEDURE|management of therapy complications|Undergo scrambler therapy
214911693|NCT02120118|RADIATION|Radiation|2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.
214911694|NCT02120118|OTHER|Hyperthermia|42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
214911695|NCT02120118|DRUG|Cisplatin|30mg/m2
214911696|NCT02120118|DRUG|Taxotere|20mg/m2
214911697|NCT06577012|PROCEDURE|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (XJ, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
214911698|NCT00379418|DRUG|Abciximab|
215058757|NCT02890745|DRUG|Placebo|
215058758|NCT01882712|DRUG|CD07805/47 Gel 0.5%|
215058759|NCT01882712|DRUG|CD07805/47 Gel Placebo|
214911699|NCT03231813|PROCEDURE|Sodium lauryl sulphate induced irritation|Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.
214911700|NCT03231813|OTHER|Emollient, moisturizing cream|Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.
214303783|NCT07190612|DRUG|ketamine and propofol|Ketamine infusion syringe (50mls): will be filled with 2mls of ketamine (100mg) diluted in 48mls 0.9% normal saline to make a final volume of 50mls to reach a final ketamine concentration of 2mg/ml. It will be administered as a bolus dose of 0.25 mg/kg iv then infused at a rate of 0.25mg/kg/hr. Propofol infusion syringe (50mls): will be filled with 20mls of 1% propofol (200mg) diluted in 30mls 0.9% normal saline to make a final volume of 50mls and a final propofol concentration of 4mg/ml. It will be iv administered as 0.5 mg/kg slow iv for 10 minutes, then infused at a rate of 0.5mg/kg/hr.
214911701|NCT03077815|OTHER|Systematically intermittent arm exercise|While holding a rubber ball for 5 minutes a day, together with strappy elastic compression arm veinElastic bandages defined for using this research provides of standard bandages, according to research personnel Guide, reached hand elbow near heart end 4 (2\~6) cm at of arm local pressure strong 50 mm-Hg (+/-10 mm-Hg) (about equivalent to provides pressure strong 6.67 thousand PA (kPa), also about equivalent to 0.97 PSI (pound per square inch)), to reached 5 minutes arm movement Shi short reduced vein return, promotion pathway vein extended of effect
214911702|NCT06733181|OTHER|REMINDER intervention|The REMINDER intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). As for the structure of the sessions, each starts with a mindfulness exercise and concludes with a review of the homework assignments. Every session includes a psychoeducation component focused on a specific topic, a time for sharing and reflection, and a practical activity.
214303784|NCT07189741|PROCEDURE|hemodialysis|Three times a week.
214303785|NCT07191132|BEHAVIORAL|Standardised Verbal Instructions|Participants receive verbal post-extraction care instructions delivered by a trained investigator using a calibrated script. The content includes guidance on bleeding control, diet, oral hygiene, activity restrictions, and medication use.
214303786|NCT07191132|BEHAVIORAL|Verbal Instructions + PDEC-kit|Participants receive the same standardised verbal instructions as the control group, supplemented with the PDEC-kit. The kit includes a two-minute educational video, illustrated flashcards, a live gauze demonstration using a dental model, and a bilingual (English and Bahasa Melayu) illustrated brochure with QR code access to a digital version.
214303787|NCT07189533|BEHAVIORAL|Co-created intervention|Intervention generated by a participatory research process (co-creation) in the elderly population living in rural areas to co-create solutions to improve their lifestyles, quality of life and health.
214303788|NCT07190742|DRUG|TVAX-008|TVAX-008
214303789|NCT07190742|DRUG|Placebo|Placebo
214303790|NCT07190001|DRUG|YOLT-204|The intervention group will receive YOLT-204 on day0
214303791|NCT07189728|DIAGNOSTIC_TEST|MRI|The MagnaSafe-2 Registry is designed to determine the risks of MRI in patients with limited MRI access not previously addressed in peer-reviewed literature and to improve access for approximately 70% of whom are predicted to have a future clinical need for MRI.
214911703|NCT01610817|OTHER|InPAct : Information for Participating Actively in cardiovascular treatment|Educational guide presented by general practitioners to the patients. A first part of the guide contains some information on cardiovascular risk and on the benefits and risks of antihypertensive drugs. A second part of the guide consists of encouraging the patient to take an active part in monitoring of its treatment.
214911704|NCT06839222|DEVICE|Hydrogel OA 2%|Hydrogel OA 2% is a sterile, nonpyrogenic viscoelastic hydrogel suspension, designed using highly purified biopolymers in a phosphate-buffered saline solution. The main component is a cross-linked protein (ultra-pure bovine gelatin). The other main component is a polysaccharide cellulose nanocrystal (CNC) that acts as the crosslinker. Hydrogel OA 2% is supplied in pre-filled 2.25ml Luer lock syringe. Each package contains one syringe containing 2.0 mL Hydrogel OA 2%. Hydrogel OA 2% is designed to provide symptomatic relief by restoring joint lubrication and cushioning, potentially leading to reduced pain and improved joint function. The device is suitable for use in early and moderate OA (Kellgren and Lawrence, K\&L, II-III).
214911705|NCT06839222|DEVICE|Hyaluronic Acid (Durolane)|DUROLANE contains 20 mg/mL of stabilized non-animal hyaluronic acid in buffered physiological sodium chloride solution pH 7. DUROLANE is a sterile, transparent viscoelastic gel supplied in a 3 mL glass syringe.
214303792|NCT07189429|DIAGNOSTIC_TEST|PA-100 AST|Results of the PA-100 AST were made available to the treating physician
214303793|NCT07191457|DEVICE|Elimax Green Lotion with Emogreen|"STEP 1:~Apply the lotion to dry hair, completely saturating hair and scalp. Use a towel to cover eyes and exposed skin areas. Massage from the roots to the tips, paying particular attention to the area behind the ears and the hairline at the back of the head. Leave the lotion in the hair for 10 minutes (no longer). In the case of long hair, pin the hair up away from the skin after application.~STEP 2:~Wash out by applying shampoo to the hair and rinsing thoroughly. Repeat if needed to fully rinse out the lotion.~STEP 3:~Comb to remove lice and nits. Part the hair into sections and comb one section at a time. Place the teeth of the comb as close as possible to the scalp and comb away from the scalp to the end of the hair. Use clips to pin back each section of combed hair. Clean the comb during use by wiping onto a tissue. Discard the tissue into a sealable bag. Discard the sealed bag.~Check hair for the following 7 to 10 days. If lice or nits are present, repeat steps 1-3."
214911706|NCT00753311|DRUG|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
214911707|NCT03746847|DRUG|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
214911708|NCT01603693|DEVICE|Bio-Oss (by Geistlich)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
214911709|NCT01603693|DEVICE|BondBone (by Augma)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
214911710|NCT02264626|DRUG|Remifentanil|infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
214911711|NCT06409273|OTHER|Hybrid course on medical thesis for post graduates general practice students|Students randomised to the intervention group will log on to interactive online teaching for a maximum time of 2.5 hours, and then follow face-to-face socio-constructivist teaching in small groups (n=22 max), building on the knowledge they have acquired. The aim of this peer-to-peer face-to-face teaching is to develop problem-solving skills.
214911712|NCT06409273|OTHER|Face-to-face teaching on medical thesis for post graduates general practice students|Students randomised to the control group will be taught entirely face-to-face in small groups (n=22 max). The course duration and teaching objectives are identical to those of the intervention group. Student consent and randomization will be carried out on the morning of the course to avoid contamination and attrition bias.
214911713|NCT04712214|DEVICE|Intra-operative multispectral / hyperspectral analysis|During surgery, the operating surgeon will be using standard NHS neurosurgical equipment such as an endoscope and/or a microscope. This equipment is operated in exactly the same way as with any other procedure, but either the microscope or the endoscope in use will be connected to the system of camera and filters for multispectral/hyperspectral analysis. During each surgical intervention, tissue-specific spectral data will be collected at specific stages - mostly once the brain surface is exposed and at the end of the resection on the surgical cavity. The operation will be visually recorded in order to sync visual data with the spectral data obtained at the same moment in time. The video recording will not be patient identifiable and will be viewed only by members of the research team working on this project (see below). The use of video recording equipment will be included in the patient information sheet given to all patients prior to gaining consent
214911714|NCT01875146|OTHER|4x4 min HIT|Conventional 4x4 min high-intensity interval training
214911715|NCT01875146|OTHER|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
214911716|NCT01875146|OTHER|4x4 min HIT + (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
214911717|NCT01875146|OTHER|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
214911718|NCT01030302|DRUG|bortezomib|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
214911719|NCT05577533|BEHAVIORAL|O-Kidia game battery|Children will be playing on a series of games with a touch screen tablet while video and digit trajectories data will be collected from this mobile device to analyze eye-, face-, sound-recognition.
214911720|NCT05577533|BEHAVIORAL|O-Brain|Electrical recordings and measurements - A mobile EEG headset will be used during the visit - 30 min
214911721|NCT00867659|DRUG|Cetrotide acetate|cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
214911722|NCT03852654|DRUG|18F-DCFPyL|"Subjects with biopsy proven prostate cancer, no prior local therapy, and:~PSA ≥ 10 ng/dl, or Gleason Sum ≥ 4+3, or clinical stage ≥cT2c Staging by 99mTc-MDP or NaF PET bone scan, and Diagnostic CT (pelvis) or MRI will undergo 18F DCFPyL PET CT scan."
214346950|NCT01380327|BIOLOGICAL|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
214911723|NCT00528047|DRUG|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
214911724|NCT00361647|PROCEDURE|Diagnostic screening for occult malignancy|
214911725|NCT01547429|DEVICE|Artisan Aphakia Intraocular Lens|Implantation of lens to correct refractive error in aphakic eye
214911726|NCT05089591|DEVICE|Intense Pulsed Light therapy|The LacryStim System is a CE marked device for treatment of meibomian gland dysfunction. It stimulates and reactivates meibomian glands and improves the related dry eye condition. Intense pulsed light is emitted with a light spectrum from 610nm to 1200nm. Each treatment consists of short individual pulses lasting for 4ms separated by a 26ms lasting interval to hinder tissue temperature increase, thermal damage to the skin and inflammatory reaction. During this phase 8 to 12 J / cm2 are delivered. Selection of total energy levels depends on the skin type (Fitzpatrick Skin Types) as recommended by the manufacturer.
214911727|NCT05089591|DEVICE|Sham Treatment|The fellow eye serves as the control eye. Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations). The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
215058760|NCT06123273|BEHAVIORAL|Exercise-oriented training|IG received an exercise-oriented training with a 20-minute presentation including graphics, in line with clinical guidelines, in addition to routine recommendations. The training included information about the benefits of exercise and the harms of a sedentary life, the relationship between exercise and chronic diseases, suggestions to have a more active lifestyle and on how to exercise, the duration and form of exercise necessary for a healthy life, and the things to be considered while exercising. During the three-month follow-up, the subjects in the IG were called every two weeks to ask about their weight measurements, their level of exercise, and how much they walked. The subjects' questions, if any, were answered, and the interview was completed by making exercise suggestions.
214911728|NCT03783767|BEHAVIORAL|Leadership Intervention|Grade 6/7 teachers will take part in a workshop on developing transformational leadership among their Grade 6/7 students, and provide teachers with a 4-week training program. Teachers will implement a 4-week leadership development component to their Grade 6/7 students. Grade 6/7 students will then deliver a 10-week peer-led FMS program to Grade 3/4 students. The Grade 6/7 peer leaders will lead 2 x 30 min sessions per week during physical education classes, recess, or lunch times. In weeks two and three, peer leaders will be observed by members of the research team and provided with feedback using a structured checklist regarding their delivery in the session. Mid-way through the 10-week program teachers will deliver a booster leadership training component to the Grade 6/7 peer-leaders.
214911729|NCT05049395|DEVICE|High Flow Nasal Cannula oxygen (HFNO)|The AIRVO2 is set at 30L/min, FiO2 100%, and 37℃ before anesthesia induction，and then 60L/min until the end of the procedure of sedated hysteroscopy.
214911730|NCT05049395|DEVICE|Regular oxygen|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
214911731|NCT04766177|DRUG|Bumetanide|bumetanide 0.5 mg twice daily
214911732|NCT04766177|DRUG|Placebo|placebo tablets twice daily
214911733|NCT04099745|DEVICE|CGM|Continuous Glucose Monitoring System
214911734|NCT04099745|DEVICE|FGM|Flash glucose monitoring System
214911735|NCT02565745|COMBINATION_PRODUCT|Skin dressing|Pre-determined skin areas at risk for PUs (3 or more, depending on the prevaliing body position, prone, supine or Sims') will be covered. Dressings will be changed every 6-7 days unless found wet/contaminated
214911736|NCT02565745|OTHER|Moisturizing cream|It will be applied twice a day to the same skin areas as the experimental group
214911737|NCT02003404|DEVICE|Control Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
214911738|NCT02003404|DEVICE|Peristomal Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
214911739|NCT02100462|DRUG|Chlorthalidone 12.5 mg|
214911740|NCT02100462|DRUG|Hydrochlorothiazide 25 mg|
215058761|NCT02058004|PROCEDURE|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
215058762|NCT00974506|OTHER|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
215058763|NCT00974506|OTHER|Routine care therapy|Routine care therapy by general practitioner
215058764|NCT05072054|DRUG|Atorvastatin Oral Tablet|Atorvastatin 40 mg
214346951|NCT06298903|OTHER|Hip Activation|Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.
214911741|NCT02100462|DRUG|Aspirin 81 mg|
214911742|NCT05514015|DRUG|rituximab combined with corticosteroids|"Induction therapy:~Rituximab intravenous infusion of 1g, d1, d15, combined with glucocorticoid therapy, oral prednisolone, initial dose of 0.5mg/(kg·d), once a day, after 8 weeks of treatment, reduce by 5mg every 4 weeks until 0.25mg/kg, this dose was maintained for 8 weeks, and then reduced by 2.5mg every 4 weeks, until 5-10mg is maintained, and the total course of treatment was about one year or so;"
214911743|NCT05514015|DRUG|rituximab|Control group (treated with Rituximab monotherapy treatment) :Rituximab intravenous infusion of 1g, d1, d15
214911744|NCT02473172|DEVICE|Pressure Support ventilation|Assisted mechanical ventilation
214911745|NCT02473172|DEVICE|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
214911746|NCT06411964|DIETARY_SUPPLEMENT|Prebiotic|Commercially available supplement (Bimuno)
214911747|NCT06411964|DIETARY_SUPPLEMENT|Placebo control|maltodextrin control supplement
215058765|NCT05072054|DRUG|Rosuvastatin Oral Tablet|Rosuvastatin 20 mg
215058766|NCT05016024|DEVICE|Colilen IBS|Patients will take Colilen IBS in First or Second Period
215058767|NCT05016024|OTHER|Placebo|Patients will take PlaceboS in First or Second Period
215058768|NCT00375427|DRUG|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
215058769|NCT02049346|DRUG|Epoetin alpha or beta (Epoetin group)|"Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
214911748|NCT06940479|PROCEDURE|GAE procedure|Genicular artery embolization
214911749|NCT06941064|DIAGNOSTIC_TEST|Anthropometric and sports performance assessment|"According to the International Society for the Advancement of Kinanthropometry (ISAK) standards, sixteen anthropometric variables have been assessed to characterize the athlete's anthropometric profile. The counter-movement jump assessments were conducted using a ForceDecks Max platform. During matches, the players' GPS-derived external Load Metrics were monitored using 18 Hz WIMU Pro GPS units. Normality tests of all variables will be performed.~Certificated anthropometrists performed the anthropometric assessment twice. A third measurement will be performed if the difference between these measures exceeds 5% for skinfolds and 1% for all other variables. Countermovement jump tests were conducted in duplicate, and the higher measurements were recorded. In-match GPS-derived external load metrics of different matches will be downloaded and analyzed."
214911750|NCT06941103|OTHER|Spinal stabilization exercise training and recommendation|"Spinal stabilization exercise training will be applied 3 days a week for 8 weeks under the supervision of a specialist physiotherapist. Exercises consist of a 5-10 minute warm-up period, 40 minutes SSET and a 5-10 minute cool-down period.~Within the scope of the recommendation, information will be given about the definition of constipation, risk factors, and treatment methods.. A brochure will be prepared to be distributed to individuals regarding these issues."
214911751|NCT06941103|OTHER|Recommendation|Within the scope of the recommendation, information will be given about the definition of constipation, risk factors, and treatment methods.. A brochure will be prepared to be distributed to individuals regarding these issues.
214911752|NCT06939764|OTHER|Geriatric Screening using the sG8 scale|Geriatric screening using the sG8 scale
214911753|NCT06940115|OTHER|titanium trapezoidal plates|ORIF subcondylar fracture using trapezoidal titanium plates
214911754|NCT06940115|OTHER|PEEK trapezoidal plates|ORIF subcondylar fracture using trapezoidal PEEK plates
214911755|NCT06940856|OTHER|Incomplete response|"Infants died before 36 weeks PMA, infants diagnosed to have BPD at 36 weeks PMA and infants developed major complications before 36 weeks PMA:~1. \>Stage 2 necrotizing enterocolitis according to Bell classification~2. Hemodynamically significant patent ductus arteriosus~3. \>Grade 2 intraventricular hemorrhage,~4. Retinopathy of prematurity, ICROP classification stage \>2~5. \>Stage 2 cystic periventricular leukomalacia~6. Ventricular dilatation/hydrocephalus requiring intervention"
214911756|NCT06940856|OTHER|Complete response|"Infants discharged before 36 weeks PMA and infants who reached 36 weeks PMA without BPD and major complications:~1. \>Stage 2 necrotizing enterocolitis according to Bell classification~2. Hemodynamically significant patent ductus arteriosus~3. \>Grade 2 intraventricular hemorrhage,~4. Retinopathy of prematurity, ICROP classification stage \>2~5. \>Stage 2 cystic periventricular leukomalacia~6. Ventricular dilatation/hydrocephalus requiring intervention"
214911757|NCT06940856|OTHER|Bad response|Infants died before 36 weeks PMA and infants diagnosed to have BPD at 36 weeks PMA
215058770|NCT02049346|DRUG|Darbepoetin alfa|"Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used."
214303794|NCT07191457|DRUG|Walgreens Lice Killing Shampoo|"Apply thoroughly to dry hair or other affected area. For head lice, first apply behind ears and to back of neck Allow product to remain for 10 minutes, but no longer Use warm water to form a lather, shampoo, then thoroughly rinse For head lice, towel dry hair and comb out tangles Remove lice and their eggs (nits) Use a fine-tooth or special lice/nit comb. Remove any remaining nits by hand (using a throw-away glove) Hair should remain slightly damp while removing nits If hair dries during combing, dampen slightly with water For head lice, part hair into sections. Do one section at a time starting at the top of the head. Longer hair may take 1 to 2 hours. Lift a 1- to 2- inch wide strand of the hair. Place comb as close as possible to the scalp and comb with a firm, even motion away from the scalp.~Pin back each strand of the hair after combing Clean comb often. Wipe away nits with tissue and discard in a plastic bag. Seal bag and discard bag to prevent lice from coming back."
214303795|NCT07189702|OTHER|Control|Regular Diet with Cancer-Related Wellness Education and Support
214303796|NCT07189702|OTHER|Whole Food, Plant-Based Diet with Behavioral Education and Support|Whole Food, Plant-Based Diet with Behavioral Education and Support
214911758|NCT06940362|BEHAVIORAL|Changing narrative intervention modules|Training and mentoring of 12-16 year old youth in non-violent personal/career trajectories, supported by a social media campaign and a community steering committee.
214911759|NCT06939829|DRUG|treatment with CAZ-AVI|Randomize subjects to receive CAZ-AVI via either continuous infusion or intermittent infusion. The total daily dose and dosing interval should be determined according to the subject's body weight, renal function, and estimated drug clearance based on standard prescribing guidelines. Regardless of administration method, the same criteria for dose adjustment (including indications for modification and monitoring parameters) must be consistently applied to both control and experimental groups.
214911760|NCT06940570|DRUG|PCA plus methadone (Experimental)|This study is novel. There are no other interventions to distinguish in this or another study.
214911761|NCT06940570|DRUG|PCA Alone (SOC)|PCA Alone (Control) arm. PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine).
214911762|NCT05672602|DIAGNOSTIC_TEST|Measurement of ncRNAs and cytokines|Measurement of lncRNAs in PBMCs samples and miRNAs in plasma samples.
214303797|NCT07190729|DEVICE|Propofol sedation + Audiovisual distraction|The participants will receive standard propofol sedation procedure and the mask -RV Deepsen™
214303798|NCT07190729|OTHER|Propofol sedation|The participants will receive standard propofol sedation procedure
214911763|NCT00000427|DRUG|Parathyroid hormone|
214911764|NCT00000427|DRUG|Alendronate|
214911765|NCT05760989|DEVICE|Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System|Replacement of the native tricuspid valve through a transcatheter approach
214911766|NCT00570687|DRUG|Technosphere Insulin|Inhalation 15U/30U
214911767|NCT06089343|DIAGNOSTIC_TEST|Coronary CT angiography|Comprehensive hemodynamic and plaque features derived from CTA and verified by OCT of all culprit and non-culprit lesions to predict ACS.
214911768|NCT06683131|DRUG|Tafolecimab|450mg of tafolecimab (150mg each one) was injected subcutaneously before primary PCI and then every month till totally 12 months.
214911769|NCT05736120|OTHER|No treatment given|No treatment given
214911770|NCT05709678|OTHER|Standard Education|Sport nutrition education
214911771|NCT05709678|OTHER|Enhanced Education|Sport nutrition education with peer testimonials on negative effects of REDs
214911772|NCT06229561|COMBINATION_PRODUCT|Acellular Dermal Matrix|Feasibility of soft tissue graft after immediate implant placement
214303799|NCT07190287|DEVICE|NEUSleeP system (FUS-EEG wearable device)|"The NEUSleeP system is a wearable FUS-EEG device integrating hydrogel-based EEG and focused ultrasound neuromodulation. The intervention includes:~1. Device testing in 4 healthy volunteers to assess EEG signal and impedance over 4 weeks vs. wet electrodes;~2. STN targeting validation in up to 20 participants using MRI-guided tFUS with NEUSleeP and BrainSonix Pulsar 1002, with fMRI analysis of BOLD activation in stress-related areas (amygdala, insula);~3. REM sleep modulation in 16 healthy participants across two nights, evaluating REM sleep architecture and stress-related fMRI changes following STN stimulation during REM;~4. A similar protocol in 12 individuals with self-reported poor sleep and moderate stress, assessing subjective stress (PSS), sleep dynamics, and connectivity changes post-tFUS."
214911773|NCT01912586|OTHER|vacuum erection device|sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months
214911774|NCT01015365|PROCEDURE|Cementless one-stage surgical revision|A Cementless one-stage surgical revision is to be performed for all included in the cohort.
214911775|NCT04707521|BEHAVIORAL|3M tape ship-shaped combined with strap fixing method|During fixation, the endotracheal intubation and dental pad were located in the center of the mouth, and one end of one piece of medical cloth adhesive was pasted on the patient's cheek near the side. When it reached one side of the mouth, the endotracheal intubation and dental pad were wound around twice, and then the other side of the adhesive tape was pasted on the cheek opposite the side from the other side of the mouth,The other is fixed in reverse with the same sticking method, and the two pieces of adhesive tape are finally crossed and fixed at the corners of the mouth.Finally, fasten it with a lacing
214911776|NCT01624740|DEVICE|Low Rate Stimulation|Stimulation was given at a rate of 2 Hz.
214911777|NCT01624740|DEVICE|High Rate Stimulation|Stimulation was given at a rate of 1200 Hz.
214911778|NCT05069116|OTHER|Training in surgery|The study evaluates the training process of general surgery residents - in classic surgery, as well as laparoscopic surgery, from hospital activity to extracurricular activities.
214911779|NCT05931172|OTHER|Dual tasking|"Dual-task training is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Dual tasking is given by therapist in unexpected directions to challenge patients reactive balance. In this study dual tasking will be given manually and on hurdles.~Daily 45 mins of exercise sessions of dual-task training like walking with talking , walking with a filled cup of water, walking with looking on clock performed for total eight weeks and 5 days a week."
214911780|NCT05931172|OTHER|PNF(proprioceptive neuromuscular facilitation exercises)|"PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1\&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session will be given to patients. 45 mins session/each day for 5 days a week."
214911781|NCT00894439|DRUG|BLI-489/Piperacillin|
214911782|NCT00894439|DRUG|BLI-489|
214911783|NCT00894439|DRUG|Piperacillin|
214911784|NCT05125796|DRUG|paracetamol|1000 mg intravenous paracetamol in 100 mL normal saline
214911785|NCT05125796|DRUG|Dexketoprofen Trometamol|50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline
214911786|NCT05125796|DRUG|Lidocaine topical|Application of 5 gr of 5% topical lidocaine
214911787|NCT05125796|DRUG|Placebo|100 mL intravenous normal saline infusion+ placebo topical pomade application
214911788|NCT02346838|DIETARY_SUPPLEMENT|Inulin|The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
214911789|NCT02346838|DIETARY_SUPPLEMENT|Placebo|The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
214911790|NCT06510270|DRUG|Dapagliflozin 10 mg once daily|Dapagliflozin 10 mg once daily will be given to all patients in symptomstic heart failure group
214911791|NCT06510270|DRUG|Loop diuretics|Loop diuretics (IV or orally) will be given to all patients in symptomatic heart failure group
214911792|NCT06510270|DRUG|Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)|Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)
214911793|NCT02999269|DEVICE|MECTA Spectrum 5000Q Amplitude|Current
214911794|NCT06531941|DRUG|400 µg of MBX 2109 once-weekly by subcutaneous injection|"Supplied as 1.5 mg per vial, to be reconstituted in 1.4 mL water for injection (diluent) to a concentration of 1.0 mg/mL.~Patients who received Placebo in the Phase 2 MBX-2H1002 study, will initiate treatment with 400 µg subcutaneous MBX 2109 once-weekly"
214911795|NCT06531941|DRUG|200-1600 µg of MBX 2109 once-weekly by subcutaneous injection|"Supplied as 1.5 mg per vial, to be reconstituted in 1.4 mL water for injection (diluent) to a concentration of 1.0 mg/mL.~Patients treated with MBX 2109 in the Phase 2 MBX-2H1002 study will continue at the screening visit in the extension study on the same dose they were receiving at the Week 11 Visit in Study MBX-2H1002.~The maximum allowed dose is 1600 μg weekly administered subcutaneously in the abdomen, rotating injection sites. Doses of MBX 2109 study drug greater than 1000 μg will be administered subcutaneously in two separate, equal injections."
214911796|NCT01102257|DRUG|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA"
214303800|NCT07190287|DEVICE|BrainSonix Pulsar 1002|The BrainSonix Pulsar 1002 is a research-grade focused ultrasound device used to evaluate STN targeting in up to 20 healthy participants. COMSOL 2D acoustic simulations and structural MRI are used to localize the STN. The BrainSonix system is tuned and installed for STN stimulation during fMRI scanning. Pre- and post-stimulation fMRI is conducted to verify BOLD signal changes in the STN and related regions. These responses are compared with those from NEUSleeP stimulation, using identical imaging protocols. Ultrasound parameters are iteratively adjusted to optimize targeting while adhering to FDA diagnostic ultrasound safety limits. A linear mixed model is used to assess stimulation-induced changes.
214911797|NCT01102257|DRUG|Olive Oil|Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
214911798|NCT05404646|OTHER|Thoracic mobility exercises with conventional physical therapy for cervical radiculopathy|Thoracic mobility exercises These techniques include mobilization, manipulation and glides to check and treat the joints. Here, these techniques will be used to mobilize the thoracic spine. In this treatment mobility exercises (Unilateral posterior anterior, Central posterior anterior and transverse glides) + hot pack (10 min) + neck stretching (neck flexors, extensors, side benders) + cervical Traction will be given to patient. A total session time will be 45 min and thrice a week on alternate days for three weeks.
214911799|NCT05404646|OTHER|Thoracic stretching exercises with conventional physical therapy for cervical radiculopathy|Thoracic stretching exercises Thoracic stretching exercises. Thoracic stretching exercises are used to correct the musculature of thoracic region. In this treatment group stretching exercises (passive stretches and therapist facilitated exercises) +hot pack (10 min) +neck stretching (neck flexors, extensors, side benders) + tractions will be given to patient. A total of 45 min session thrice a week on alternate days for three weeks will be given. Only the eligible patients who fulfil the inclusion criteria will be included in the study.
214911800|NCT04519372|DIAGNOSTIC_TEST|Testing for SARS-CoV-2|All Patients admitted to the hospital were routinely tested for SARS-CoV-2 within 72 hours of admission by nasopharyngeal swabs.
214911801|NCT01537601|PROCEDURE|Circumcision|Circumcision
214911802|NCT01537601|OTHER|Antibiotic prophylaxis alone|Antibiotic prophylaxis alone
214911803|NCT03048747|DRUG|Tolvaptan Oral Tablet|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
214911804|NCT04781803|DRUG|Cyclosporine|Cyclosporine 6 mg/kg and mycophenolic acid 1 gram orally on day 0 post-transplant
214911805|NCT00426946|DRUG|Reboxetine|
214911806|NCT05717296|OTHER|anxiety survey|surgery and anesthesia anxiety questionnaire
214911807|NCT05717296|OTHER|scale of satisfaction|scale of satisfaction of multimedia
214911808|NCT05717296|OTHER|Multimedia Information|"Patients randomized to the with multimedia support arm will have access to educational videos focused on the vascular surgery they are to receive."
214911809|NCT03711708|DRUG|Zoloft Oral Solution|Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water
214911810|NCT03711708|DRUG|Zoloft tablets|Reference Product: 50 mg sertraline administered as 1x Zoloft 50 mg tablet
214911811|NCT00005055|DRUG|glufosfamide|
214911812|NCT00866281|DRUG|midostaurin|Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
214911813|NCT01074801|OTHER|Closed-loop insulin delivery|Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.
214911814|NCT01074801|OTHER|Standard insulin pump treatment|Subcutaneous insulin delivery to be performed based on subjects' standard treatment
214911815|NCT02678793|DRUG|CNTX-4975|
214911816|NCT04542486|PROCEDURE|"Excision of gingival hyperplasia using Soft tissue trimmer ."|Gingivoplasties and removal of excess gingival tissues using Soft tissue trimmer.
214911817|NCT04542486|PROCEDURE|Excision of gingival hyperplasia using the conventional scalpel technique|Excision of gingival hyperplasia in gingivoplasties using the conventional technique reverse bevel using 15c blade.
214911818|NCT00730483|DRUG|PVA microporous hydrospheres/doxorubicin hydrochloride|
214911819|NCT00529087|DRUG|N-methylnaltrexone bromide (MOA-728)|Subcutaneous
214911820|NCT00529087|OTHER|placebo|placebo
214911821|NCT03538860|BEHAVIORAL|Active comparator: Human interpreter|A Spanish-speaking patient is diagnostically assessed in-person by an English-speaking psychiatrist through a Spanish-speaking interpreter.
214911822|NCT03538860|BEHAVIORAL|Intervention: Asynchronous Telepsychiatry|A Spanish-speaking patient is interviewed in Spanish by a trained mental health interviewer. The interview is video-recorded in real-time, automatically translated into English with sub-titles added to the video file, and sent to a psychiatrist and to 3 English-speaking psychiatrists to asynchronously review the video and make a diagnosis.
214911823|NCT04001725|DRUG|Dexamethasone|A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.
214911824|NCT04001725|DRUG|Metformin|A minimum daily dosage of Dexamethasone 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day and 2550 mg daily (maximum dose), oral administration (OS) of Metformin; starting dose will be 850 mg/day, to be progressively increased to 1700 mg/day on day 4 and 2550 mg/day on day 7, if well tolerated.
214911825|NCT00318474|DRUG|Mycophenolate Mofetil (MMF)|Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.
214911826|NCT00318474|DRUG|MMF Placebo|Placebo only, oral administration
214911827|NCT00318474|DRUG|ACEi|Administer same as pre-treatment regimen.
214911828|NCT00318474|DRUG|FOS|Administer same as pre-treatment regimen
214911829|NCT01346566|DEVICE|Cionni Modified Capsule Tension Ring|Cionni ring was used to fixate the capsular bag to the sclera and IOL was implanted in-the-bag
214911830|NCT01888172|BEHAVIORAL|Weight Watchers Online Program|Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.
214911831|NCT01888172|DEVICE|Philips ActiveLink|Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.
214911832|NCT01888172|BEHAVIORAL|Eating and Activity Newsletter|General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
214911833|NCT06436911|DRUG|COVIGENIX VAX- 002|ENTVAX-001-01
214911834|NCT06577688|OTHER|Blood pressure measurement|Blood pressure measurement using a standard cuff device and a smartphone
214911835|NCT02019316|DIETARY_SUPPLEMENT|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
214911836|NCT02019316|DIETARY_SUPPLEMENT|Isoenergetic Control|Participants will ingest 500ml of Gatorade 3 times during an exercise session.
214911837|NCT01775813|DRUG|Metformin|After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
214911838|NCT01775813|DRUG|Placebo|Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
214911839|NCT04509336|DRUG|Orphenadrine|100 mg twice daily
214911840|NCT04509336|DRUG|Baclofen|initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
214911841|NCT00204919|DRUG|Vitamin D|once-monthly vitamin D oral capsules (50,000 units)
214911842|NCT00204919|DRUG|placebo|once-monthly placebo capsules
214911843|NCT00457002|DRUG|Apixaban|"Apixaban: Twice daily, 30 days~Placebo: Once daily, 6-14 days"
214911844|NCT00457002|DRUG|Enoxaparin|"Enoxaparin: Once daily, 6-14 days~Placebo: Twice daily, 30 days"
214911845|NCT05117502|DEVICE|intermittent Theta Burst Stimulation|intermittent Theta Burst Stimulation (iTBS) is a type of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered by the MagVenture MagPROX100 with MagOption Stimulator and MagPro Cool Coil B65 A/P. The MagPro Cool Coil B65 A/P can be switched from active to placebo.
214911846|NCT05117502|DEVICE|Placebo intermittent Theta Burst Stimulation|The placebo coil magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active iTBS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e. clicking) nearly identical to that of the active coil.
214911847|NCT02731352|DRUG|Apatinib|Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects.
214303801|NCT07190924|BEHAVIORAL|12 week training|Anti-inflammatory and oxidative environment following 12-weeks of CF training by evaluating inflammatory markers and oxidative precursors in untrained participants
214303802|NCT07190924|BEHAVIORAL|12 week training|Anti-inflammatory and oxidative environment following 12-weeks of resistance training by evaluating inflammatory markers and oxidative precursors in untrained participants
214303803|NCT07189637|OTHER|Face-to-face nutrition education|All participants will receive face-to-face nutrition education from specialist dietitians in accordance with the principles of nutrition for hypertension. Nutrition education will be provided through prepared brochures. The brochures will be given to participants as gifts. Nutrition education will cover topics such as hypertension and nutrition, nutrients, the importance of micronutrients, foods containing salt, reading labels, limiting salt consumption, healthy fat consumption, fibre consumption, water consumption, and healthy cooking methods.
214911848|NCT02731352|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg q.d. p.o. in 11-20 cases of differentiated thyroid cancer subjects.
214911849|NCT05749705|OTHER|Fat to Lean Mass Ratio|"The study will be conducted for people who suffer from excess fat mass and their age is over 18 years.~years will be calculated with G power"
214911850|NCT01149564|DRUG|iv ibuprofen|
214911851|NCT01149564|DRUG|oral ibuprofen|
214911852|NCT05776264|BEHAVIORAL|Music Condition|During one of the sessions, participants will listen to music while walking on the treadmill for 10 minutes.
214911853|NCT05776264|BEHAVIORAL|Podcast Condition|During one of the sessions, participant will listen to a podcast for 10 minutes while walking on the treadmill.
214911854|NCT00249340|BEHAVIORAL|Weight Watchers|
214911855|NCT00249340|BEHAVIORAL|brief behavioral weight loss treatment|
214911856|NCT00249340|BEHAVIORAL|brief behavioral + Weight Watchers combined treatment|
214911857|NCT05270616|PROCEDURE|robotic surgery|minimally invasive surgery using the Davinci robotic system
214911858|NCT05270616|PROCEDURE|uniport surgery|VATS minimally invasive surgery under the uniportal status
214911859|NCT05270616|PROCEDURE|multiple- port surgery|VATS minimally invasive surgery under the multiple- port status
214911860|NCT05225610|OTHER|Valsalva Manoeuvre|Blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds
214911861|NCT05225610|DRUG|Dexmedetomidine Injection [Precedex]|The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released
214911862|NCT05225610|DRUG|normal Saline|5 ml saline will be administered.
214911863|NCT02680808|DRUG|Midazolam with F901318|Pharmacokinetics of midazolam with F901318
214911864|NCT04539184|OTHER|Motion Style Acupuncture Treatment (MSAT)|MSAT required a part of the patient's body to move passively or actively while acupuncture needles are retained.
214911865|NCT04539184|OTHER|Acupuncture|General acupuncture
214479554|NCT06866626|DIETARY_SUPPLEMENT|Harvest Lentil Vegetable Blend|Harvest Lentil Vegetable Blend is a dehydrated supplemental food produced from natural ingredients namely, rice, carrots, lentils and onions. This product was prepared by mixing it with water and boiling the mixture for approximately 25-35 minutes to a mid-consistency. In this study we implemented a blanket supplementary feeding program where all the recruited children in the intervention group received a meal of Harvest Lentil Vegetable Blend. The feeding program was on-site, and participating children aged 6-12 months received three-quarters of a cup of the supplemental food, (\~ 52 kcal/d). Children aged 13-23 months received 1 cup of the supplemental food (∼69 kcal/d), whereas children aged 24-59 months received 2 cups of the supplemental food (∼138 kcal/d). The feeding was implemented for 6 days a week (Monday through Saturday) for a total of eight weeks.
214911866|NCT03821454|DRUG|Capecitabine|Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
214911867|NCT03821454|DRUG|Placebos|Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
214911868|NCT03531203|DIETARY_SUPPLEMENT|Soursop supplementation|The soursop supplementation was given to treatment group (with soursop group) 2 times a day for 100 g each for 3 months period.
214911869|NCT03531203|OTHER|Placebo|Control group (without soursop group) was left without treatment during study period
214911870|NCT06524869|DIAGNOSTIC_TEST|Isokinetic neuromuscular assessment|All sports patients who had a muscle evaluation in addition to functional testing at 6-12 months after ACLR since March 2024
214911871|NCT02918565|BEHAVIORAL|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
214911872|NCT02918565|BEHAVIORAL|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
214911873|NCT02918565|BEHAVIORAL|Adaptive Goal Support (AGS)|12 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
214911874|NCT02918565|BEHAVIORAL|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
214911875|NCT05464966|DRUG|Glucose insulin potassium|After induction of anaesthesia,cardiac systolic-diastolic function was first measured by TEE, GIK solution was continuously pumped until the end of the procedure at a dose of 30 mU/kg/h of insulin, 0.12 g/kg/h of glucose and 0.06 mmol/kg/h of potassium chloride
214911876|NCT02283268|BIOLOGICAL|Recombinant von Willebrand Factor (rVWF)|rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
214911877|NCT04500990|RADIATION|MRI test|Patients will receive diagnostic MRI test on d0.
214911878|NCT04500990|RADIATION|MRI test|Patients will receive diagnostic MRI test on d8±1.
214911879|NCT04500990|RADIATION|MRI test|Patients will receive diagnostic MRI test on d30±2.
214911880|NCT01357499|DEVICE|blood pressure cuff|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.
214911881|NCT01357499|DEVICE|blood pressure cuff + electric muscle stimulator|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
214911882|NCT01017874|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
214911883|NCT01017874|DRUG|Cisplatin|75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
214911884|NCT01017874|DRUG|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
214911885|NCT01017874|DRUG|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
214303804|NCT07189637|OTHER|Intermittent Fasting Diet|Training will be provided to all participants through a food and nutrition photo catalogue so that portions can be recorded correctly and within standard limits when keeping a food diary. Participants will restrict their food intake to a 16-hour period by applying the 16/8 Intermittent Fasting Diet model and will eat and drink whatever they want during the remaining 8 hours. During this 16-hour period, they will consume non-energy drinks consisting of water, unsweetened tea, unsweetened herbal teas and black coffee. It will be recommended that intermittent fasting be maintained from 6:00 p.m. to 10:00 a.m. However, participants may also choose other 16-hour periods, such as 7:00 p.m. to 11:00 a.m. or 8:00 p.m. to 12:00 p.m. Participants will be given a tracking chart to record the first and last times they consume food or energy-containing beverages during the day, and their adherence to the diet will be monitored based on their declarations.
214479555|NCT06868680|BEHAVIORAL|Balance Program|A comprehensive program of tailored exercise therapy, educational content spanning a variety of topics related to balance improvement and fall prevention, a personalized clinical approach to improving balance, and access to a board-certified health coach and physical therapist.
214479556|NCT06868680|OTHER|Educational Reading Content|Informational articles on reducing risk for falls.
214911886|NCT01803672|BEHAVIORAL|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.
214911887|NCT01803672|BEHAVIORAL|Placebo control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
214911888|NCT04025060|BEHAVIORAL|Commercially-available caffeine-free soda|Subjects are asked to consume caffeine-free soda daily for two weeks
214911889|NCT04025060|BEHAVIORAL|Carbonated water|Subjects are asked to consume unsweetened, carbonated water daily for two weeks
214911890|NCT04025060|BEHAVIORAL|Regular soda|Subjects are asked to consume regular soda daily for two weeks
214911891|NCT05519826|DEVICE|Vascular surgery|"POLYMAILLE® EXTRA THIN vascular prostheses are indicated for replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral) and/or femoro-popliteal bypass above the knee."
214911892|NCT02201693|DIETARY_SUPPLEMENT|MODULEN IBD|2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).
214911893|NCT02201693|DIETARY_SUPPLEMENT|MODULEN IBD|25% of daily caloric requirements, approx. 500mL/day
214911894|NCT00471224|OTHER|Observational Trial|No intervention is being used in this study.
214911895|NCT05261542|DIAGNOSTIC_TEST|flow cytometry|evaluation of intraoperative flow cytometry in detecting cancer cells in colorectal epithelium
214911896|NCT02395250|BIOLOGICAL|anti-GPC3 CAR T|
214911897|NCT02055924|DRUG|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
214911898|NCT02439060|OTHER|Acellular Cadaveric Dermal Matrix|Undergo intraperitoneal prophylactic mesh placement
214911899|NCT01109485|DRUG|Olopatadine hydrochloride ophthalmic solution 0.1%|1-2 drops 4 times per day
214911900|NCT02498197|BEHAVIORAL|Participatory Intervention|
214911901|NCT02498197|BEHAVIORAL|Control|
214911902|NCT02894645|DRUG|Prednisolone|Oral
214911903|NCT02894645|DRUG|Dexamethasone|Oral
214911904|NCT02894645|DRUG|L-Asparaginase|Intramuscular injection
214911905|NCT02894645|DRUG|Vincristine|Intravenous
214911906|NCT02894645|DRUG|Methotrexate|Intrathecal/ Intravenous/ Oral
214911907|NCT02894645|DRUG|Daunorubicin|Intravenous
214911908|NCT02894645|DRUG|Doxorubicin|Intravenous
214911909|NCT02894645|DRUG|Cyclophosphamide|Intravenous
214911910|NCT02894645|DRUG|Cytarabine|Intravenous/ Subcutaneous injection
214911911|NCT02894645|DRUG|6-Mercaptopurine|Oral
214911912|NCT02894645|DRUG|Thioguanine|Oral
214911913|NCT02894645|DRUG|Fludarabine|Intravenous
214911914|NCT02894645|DRUG|Imatinib|Oral (For BCR-ABL ALL only)
214911915|NCT06367504|DIETARY_SUPPLEMENT|DBMF|Once a day daily 30 minutes before lunch
214911916|NCT06367504|DIETARY_SUPPLEMENT|Placebo|Once a day daily 30 minutes before lunch
214911917|NCT03004651|OTHER|Power Doppler ultrasound|Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)
214911918|NCT03004651|OTHER|Clinical evaluation|swollen joint count (SJC) as componant of SDAI
214911919|NCT06181214|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
214911920|NCT06181214|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
214479557|NCT06871358|DRUG|Atorvastatin 80mg|80 mg of Atorvastatin are loading in first medical contact (Emergency Department) before primary PCI
214911921|NCT01702623|DRUG|Oxcarbazepine|
214911922|NCT04028050|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks.
214911923|NCT04028050|DRUG|Carboplatin|Carboplatin will be administered after completion of atezolizumab by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min (Calvert formula dosing) with standard anti-emetics per local practice guidelines.
214911924|NCT04028050|DRUG|Etoposide|Etoposide will be administered by IV infusion over 60 minutes following carboplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
214911925|NCT00780884|DEVICE|acupuncture|16 sessions of acupuncture treatment, twice a week.
214911926|NCT06133608|OTHER|MOBILIZATION TRAINING|"Things to consider in the hospital in the early period after surgery: The first day in the hospital after surgery, the importance of the abduction pillow and early mobilization,~* Exercises performed in bed in the early period after surgery: Exercises such as ankle pump, ankle rotation, bed-supported knee bending, hip contraction, opening exercise, thigh exercise, straight leg raise,~* Early standing up: Activities such as sitting in bed or on a chair, standing up with the help of a walker, walking,~* Exercises performed while standing: Exercises such as lifting the knee, opening the leg to the side,~* Daily living activities: It will provide information on regulating ADLs such as bathing, dressing, using the toilet, getting into and driving the car, going up and down stairs, eating, sleeping, doing housework, sexual life, and information about the safety precautions that should be taken at home."
214911927|NCT06576999|DEVICE|Sensor-based Balance Training|10 sessions of sensor-based balance training with exergaming feedback. For this training an adaptive integrated audio-visual feedback system composed of five IMUs and a force platform connected wirelessly to a computer has been used. The training protocol include exercises of balance control, encompassing a total of five distinct exercises: i) Latero-lateral load shifting while seated; ii) Load shifting while standing: latero-lateral and antero-posterior, to simulate the balance control performed during the day; iii) Load control during sit-to-stand; iv) Gait swing and loading phase response: to stimulate a correct load shifting during the swing and stance phase; v) Latero-lateral load shifting with knee flexion.
214911928|NCT06576999|OTHER|Usual Balance Trainging|10 sessions of usual balance training. The training includes: gait control exercises, weight shifting, and relies on both stable surfaces (i.e., steps) and unstable surfaces (i.e., oscillating platforms and various-sized fitballs). The protocol encompassed the application of stabilization techniques and the reaching of targets with the upper limb during upright position emulating the activity of daily living.
214911929|NCT05603871|PROCEDURE|ligamentoplasty of ligamentum teres|"An addition to the steps of the open reduction, the following were done:~1. Identification of ligamentum teres~2. Ligamentoplasty of ligamentum teres"
214911930|NCT00784329|DEVICE|Optical Frequency Domain Imaging (OFDI) System|Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
214911931|NCT02323373|DRUG|Tranexamic Acid - topical|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.
214911932|NCT02323373|DRUG|Placebo|100 ml of saline solution administered with anesthesia during 10 minutes
214911933|NCT02323373|DRUG|Tranexamic Acid - intravenous|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.
214911934|NCT01966120|DRUG|BF-200 ALA gel|BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.
214911935|NCT01966120|DRUG|Placebo to BF-200 ALA gel|The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
214911936|NCT01966120|PROCEDURE|Photodynamic therapy with BF-RhodoLED|After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
214911937|NCT05628935|PROCEDURE|peripheral nerve block|local anesthetic application to the brachial plexus
214911938|NCT02368535|OTHER|Survey|25-item questionnaire on pereception of interdisciplinary rounds
214911939|NCT05864703|PROCEDURE|Adjustment|Instrument-assisted, high velocity, low amplitude adjustment
214911940|NCT05864703|PROCEDURE|Sham|Instrument-assisted light touch to neck
214911941|NCT01788631|DRUG|Regadenoson|Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-\[4-\[(methylamino)carbonyl\]-1H-pyrazol-1-yl\]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
214911942|NCT01788631|DRUG|Placebo|This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
214911943|NCT01764360|OTHER|KS structured clinical care training|Eight primary care sites in Zimbabwe will receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
214911944|NCT02810366|OTHER|Physician versus Computer Coded Verbal Autopsy|Comparing the performance of computer coded verbal autopsies (CCVA) to physician coded verbal autopsies (PCVA) at the population level.
214911945|NCT00937274|OTHER|T4 phage cocktail test|T4 phages 106 PFU/ ml up to 5 days
215058771|NCT02049346|DRUG|Methoxy polyethylene glycol-epoetin beta|"Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
215058772|NCT01304615|BEHAVIORAL|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
215058773|NCT01304615|BEHAVIORAL|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
215058774|NCT01304615|BEHAVIORAL|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
215058775|NCT00130104|PROCEDURE|Transthecal Metacarpal Block|
215058776|NCT03976050|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
214911946|NCT00937274|OTHER|Commercial T4 phage cocktail|Treatment as recommended by the manufacturer (Microgen phages)
214911947|NCT00937274|OTHER|standard oral rehydration solution (ORS)|Standard hospital treatment with ORS
214911948|NCT04477148|DEVICE|endotracheal intubation|patients were intubated with 3 different blades
214479558|NCT06871358|DRUG|Placebo|Only given a loading DAPT without loading Atorvastatin 80 mg
214911949|NCT00932048|DRUG|Atorvastatin|Atorvastatin 10mg once daily for 12 weeks
214911950|NCT06298448|DIAGNOSTIC_TEST|laboratory experiments before and after mepolizumab treatment|Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome
214911951|NCT02588612|DRUG|letetresgene autoleucel (GSK3377794)|letetresgene autoleucel (GSK3377794) as an IV infusion.
214911952|NCT02588612|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
214911953|NCT02588612|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
214911954|NCT03053037|PROCEDURE|final apical size instrumentation|root canal instrumentation to two different final preparation sizes
214911955|NCT02594293|DRUG|PegIFN alfa-2a|180 μg/ 0.5 ml ,hypodermic injection once a week
214911956|NCT06577844|OTHER|video support|video support provided to the patient before surgery
214911957|NCT00410540|DRUG|OROS hydromorphone HCL ; Morphine sulfate|
214911958|NCT01915602|DRUG|Refametinib (BAY86-9766)|Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
214911959|NCT01915602|DRUG|Sorafenib (BAY43-9006)|Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
214911960|NCT04996901|OTHER|no intervention|no intervention
214911961|NCT04894825|DRUG|M108|Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)
214911962|NCT04894825|DRUG|M108|IV infusion Q3W. (21-day cycles)
214911963|NCT03525223|PROCEDURE|Change of dialysate [Na+]|Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week
214911964|NCT02007681|BEHAVIORAL|Reduction of sedentary time by breaking it with low intensity physical activity|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
214911965|NCT01117922|OTHER|Psychological intervention|Subjects will be randomized into either usual care or interconceptional intervention groups. If the subject is randomized into the intervention group, she will receive targeted interventions to reduce one of several risk factors: smoking, depression, infectious disease burden and maternal stress, and achieving an appropriate BMI. A woman who is randomized to the intervention group may receive interventions on one, two, three, four, or five of the targeted intervention methods, depending on her needs.
214911966|NCT01117922|OTHER|Usual Care Group|
214911967|NCT02841995|DRUG|Belumosudil (KD025)|Pharmaceutical form: Capsules or Tablets Route of administration: Oral
214911968|NCT00717912|OTHER|Experimental sweetener syrup|3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber
214911969|NCT00717912|OTHER|Classical sweetener syrup|1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber
214911970|NCT00717912|OTHER|Classical sugar syrup|3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
214911971|NCT01999816|BEHAVIORAL|Lifestyle Redesign|Individualized program for lifestyle redesign aimed at decreasing the risk of medically serious pressure ulcers led by licensed occupational therapists trained in the implementation of the lifestyle redesign program
215058777|NCT03096392|DRUG|HDV insulin lispro 100 UNT/ML|HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
215058778|NCT03096392|DRUG|Insulin Lispro 100 UNT/ML|Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
214911972|NCT02283424|DRUG|Icotinib|compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
214911973|NCT02283424|DRUG|chemotherapy (Carboplatin and Docetaxel)|as control group,compared with Icotinib
214911974|NCT02639624|DRUG|Low bicarbonate dialysate First|
214911975|NCT02639624|DRUG|Normal bicarbonate dialysate First|
214911976|NCT02639624|DRUG|Normal bicarbonate dialysate|
214911977|NCT02639624|DRUG|Low bicarbonate dialysate|
214911978|NCT03809663|DRUG|Tezepelumab|Solution for injection
214911979|NCT03809663|OTHER|Placebo|Placebo solution for injection
214911980|NCT05261516|DRUG|Magnesium Sulfate|The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.
214911981|NCT04287257|DEVICE|Fracture Healing Patch (FHP)|The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.
214911982|NCT01051596|DRUG|Temozolomide|150mg/m2 Days 1-5 of each 28 day cycle
214911983|NCT01051596|DRUG|ABT-888|40mg orally BID Days 1-7 of each 28 day cycle
214911984|NCT01227590|DRUG|Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
214911985|NCT06205914|PROCEDURE|fixation of patella fractures by craniofacial mesh plate osteosynthesis augmented by screws|patellar fracture fixation using MatrixNEURO Contourable Mesh plates (Synthes®). Made of titanium with an incredibly low profile
214911986|NCT04432610|DRUG|Bisoprolol versus Nebivolol|All subjects will receive both drugs, but at different time periods determined by randomization, with 1 week washout period
214911987|NCT02514499|OTHER|Questionnaires|
214911988|NCT00216580|DRUG|Risperidone, long-acting injectable|
214911989|NCT01818271|BEHAVIORAL|conventional physical therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
214911990|NCT01818271|BEHAVIORAL|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~* Advanced dynamic tasks, including stepping and other transitional tasks to treadmill \& over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~* Treadmill walking exercise program."
215058779|NCT02084498|DEVICE|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
215058780|NCT02084498|BEHAVIORAL|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
214303805|NCT07189637|OTHER|Mediterranean Diet|Training will be provided to all participants through a food and nutrition photo catalogue to ensure that portions are recorded correctly and within standard limits when keeping a food diary. In addition, the dietician will provide this group with a diet plan calculated for energy, macro and micro nutrients, which will be different each week for the first four follow-ups. The diet plans provided will be prepared in accordance with the Mediterranean Diet food pyramid. Participants' energy requirements will be calculated using the Schofield Equation for basal metabolic rate, with adjustments made according to their physical activity levels. Energy requirements will be met by 45-50% from carbohydrates, 15-20% from protein, and 25-35% from fats.
214911991|NCT06182202|DEVICE|Powered Prosthesis|Custom in-house powered prosthetic device (used in prior studies, see Citations).
214911992|NCT02875626|DRUG|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
214911993|NCT00294866|DRUG|Paricalcitol|Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
214911994|NCT01707394|DRUG|Apixaban|Specified dose on specified days
214911995|NCT01703260|DRUG|Roflumilast|Roflumilast dose
214303806|NCT07190053|OTHER|Secukinumab|This is an observational study, there is no treatment allocation
214911996|NCT01703260|DRUG|Pioglitazone|Pioglitazone dose
214911997|NCT01703260|DRUG|Placebo|Pioglitazone placebo-matching dose
214911998|NCT01703260|DRUG|Placebo|Roflumilast placebo-matching dose
214911999|NCT04876326|BIOLOGICAL|Autologous Adipose Mesenchymal Stem Cell Implantation|"Before taking adipose tissue, each subject was screened including HbSAg, Anti HbS, Anti HCV, HIC, MCV and syphilis tests.~Adipose tissue was taken through 5 grams of subcutaneous fat biopsy from the abdomen of each subject and put into a transport medium and then sent to the RSCM-FKUI cGMP IPT Stem Cells Laboratory for immediate isolation of mesenchymal stem cells.~MSC that has been isolated will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.~The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture.~The MSC to be injected into the subject will be prepared in 2cc physiological NaCl transport medium just before implantation.~The adipose secretion used is prepared in whole form as much as 10cc in a 10cc syringe."
214912000|NCT04876326|BIOLOGICAL|Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation|"Before taking the umbilical cord tissue, a pregnant woman's donor was screened including HbSAg, Anti HbS, Anti HCV, HIC, MCV and syphilis tests.~Immediately after delivery, the umbilical cord was collected and stored in a sterile specimen plate containing 0.9% NaCl at 4⁰C.~The umbilical cord is transported to the GMP standard culture laboratory at the UPT TK Stem Cells RSCM-FKUI for isolation process of mesenchymal stem cells. Sample processing was carried out within 8 hours of delivery to maintain cell viability.~MSC that has been isolated will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.~The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture.~The MSC to be injected into the subject will be prepared in a suitable transport medium just prior to implantation."
214912001|NCT04876326|BIOLOGICAL|Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation|"Before taking adipose and umbilical cord tissue, each subject was screened. -For Adipose tissue : The adipose secretion used is prepared in whole form as much as 10cc in a 10cc syringe.~-Uc-MSC : Immediately after delivery, the umbilical cord was collected and stored in a sterile specimen plate containing 0.9% NaCl at 4⁰C.~The umbilical cord is transported to the GMP standard culture laboratory to have isolation process of mesenchymal stem cells. Sample processing was carried out within 8 hours of delivery to maintain cell viability.~Later it will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture."
214912002|NCT03097276|PROCEDURE|blood sample|blood sample will be collected
214912003|NCT03097276|RADIATION|CT scan|CT scan
214912004|NCT04633967|DRUG|Alemtuzumab Injection|"This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol~Premedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion.~Premedication with 50 mg of prednisone orally for 5 days before the infusion.~During Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion.~Post Infusion Medication~Post-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion.~Post-medication with 50 mg of prednisone orally for 5 days after the infusion.~Medications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed"
214912005|NCT05860192|DEVICE|Virtual Reality|Use of this virtual reality headset to deliver a single mindfulness session
214912006|NCT05860192|OTHER|application for mindfulness|Application used to realize mindfulness in virtual reality
215058781|NCT03024112|DEVICE|Heated humified high-flow nasal cannula Oxygen|
215058782|NCT03024112|OTHER|Standard oxygen therapy|
215058783|NCT01845246|DEVICE|Prospective TDM Arm of colistin|
215058784|NCT00290719|DRUG|cisplatin|
215058785|NCT00290719|DRUG|gefitinib|
215058786|NCT00290719|DRUG|irinotecan hydrochloride|
215058787|NCT00290719|PROCEDURE|conventional surgery|
215058788|NCT00290719|PROCEDURE|neoadjuvant therapy|
215058789|NCT00290719|RADIATION|radiation therapy|
215058790|NCT06289894|DRUG|BRY805 injection|BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested
214303810|NCT07190950|PROCEDURE|Low Level Laser Therapy|Patients will receive LLLT at one side after third molar extraction surgery. There will be 7 sessions at the day of surgery, then first, third, seventh, fourteenth, twenty first, twenty eighth day after surgery.
214303811|NCT07190690|DEVICE|ihtDEStiny® DES implanted|ihtDEStiny® DES implanted
214303812|NCT07190690|DEVICE|Xience™ DES implanted|Xience™ DES implanted
215058791|NCT06014151|OTHER|questionnaires|we will use a quantitative and a qualitative approach. For the first one, a psychosocial approach on a large number (500 women and 500 men) of candidates to donation. Of course, gender and parenthood will be considered in the analyses, as in the previous study. We will use two questionnaires for this study: 1) the one that was validated for the previous study, including socio-demographic data, donors' motivations and representations, 2) the second exploring personality, the NEO-PR inventory, which was also used for the previous study.
214303813|NCT07189507|OTHER|Simulated indoor temperature upper limit|Older adults exposed to an 8-hour simulated exposure.
214303814|NCT07190222|DRUG|Lunsekimig|Pharmaceutical form: solution for injection in prefilled syringe - Route of administration: Subcutaneous injection
214479559|NCT06868550|BEHAVIORAL|Comprehensive Oral Health Promotion Program|The principal investigator will carry out all treatment procedures, and the patients will be randomly assigned to any of them.
214912007|NCT03903991|OTHER|Temperature recording|Tympanic and oesophageal temperatures will be recorded during the procedure
215058792|NCT02869581|OTHER|Data collection|
214912008|NCT05333601|BEHAVIORAL|eSCCIP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
214912009|NCT02042014|DRUG|QTI571|QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
215058793|NCT03969290|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
214303815|NCT07190222|DRUG|Placebo|Pharmaceutical form:s olution for injection - Route of administration: Subcutaneous injection
214912010|NCT03023917|PROCEDURE|umbilical cord milking|Infants were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
214912011|NCT03023917|PROCEDURE|umbilical cord clamping immediately|umbilical cord was cut immediately after birth
214912012|NCT00551239|BIOLOGICAL|rituximab|Given IV
214912013|NCT00551239|DRUG|fludarabine phosphate|Given IV
214912014|NCT00551239|DRUG|pixantrone dimaleate|Given IV
214303816|NCT07189923|PROCEDURE|Ablative Fractional CO₂ Laser|Participants will receive ablative fractional CO₂ laser therapy on one side of the face using the SmartXide DOT Fractionated CO₂ Laser system. Treatment parameters: 15 W power, 800 µm spacing, 600 µs dwell time, stack level 2. Sessions: 3, each one month apart.
214303817|NCT07189923|PROCEDURE|Platelet-Rich Plasma (PRP) With Microneedling|Participants will receive intradermal autologous PRP injections prepared by double-spin centrifugation from 8 mL of venous blood, followed by microneedling with a Dermapen (12-needle cartridge, 1.5 mm depth). Endpoint: pinpoint bleeding. Sessions: 3, each one month apart.
214303818|NCT07190313|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic cream to facilitate making long strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then re-draped before moving to another part. The primary techniques used in the research protocol therapy are effleurage, petrissage, kneading, tapotement and thumb friction. These techniques are performed in a very precise, carefully elaborated manner. The session starts with the subject fully draped in a prone position on the massage table and after approximately 22 minutes the subject is instructed to turn to the supine position. Finally, the therapist moves to the head area of the subject, begins working on the shoulders, neck and head using effleurage and thumb friction, and concludes by using light tapotement on the head. The total time for the entire massage is 45 minutes. Subjects randomized to SMT will undergo a single session."
214303819|NCT07190313|OTHER|Light Touch Control|The Light Touch Control protocol entails the same duration and sequence of procedures as the massage protocol, except that the therapist employs only light-touch hand placement on the subject's body. This condition isolates the effect of the mechanical intervention of SMT. Subjects randomized to LT will undergo a single session.
214303820|NCT07190261|DRUG|enatumab|The recommended subcutaneous injection dose of this product is as follows: an incremental dose of 12mg on day 1, an incremental dose of 32mg on day 4, an initial treatment dose of 38mg on day 8, and subsequent treatment doses of 38mg in weeks 4 and 6.
214479560|NCT05323487|DRUG|Bumetanide Injection|Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
214479561|NCT06870643|OTHER|Gluten free diet for 3 weeks then parabiotic (Lacteolfort®) for another 3 weeks|Gluten free diet for 3 weeks then parabiotic (Lacteolfort®) for another 3 weeks.
214479562|NCT06869655|DEVICE|Threshold Loading device|threshold loading device for diaphragmatic resistance training
214479563|NCT06869655|DEVICE|Volumes Oriented Spirometry|group B will receive this interentions
214479564|NCT06870955|PROCEDURE|using biomimetic abutments|The subjects recieved the biomimetic healing abutments during the second-stage surgery, and the biomimetic prosthetic abutments were used to complete the implant restoration.
214912015|NCT05017675|OTHER|High fructose diet|"4 week high fructose diet.~Intended composition (En%):~Carbohydrates: 60-70 Fat: 20-30 Protein: 10-15 Fructose: 20 SFA: 5"
214912016|NCT05017675|OTHER|High saturated fat diet|"4 week high saturated fat diet.~Intended composition (En%):~Carbohydrates: 35-45 Fat: 40-50 Protein: 10-15 Fructose: 5 SFA: 20"
214912017|NCT06574932|BEHAVIORAL|Multi-Strategic Approach|The experimental group will be engaged in multi-strategy approaches including screen time and sanity challenges, weekly screen-free days, screen time reduction goals, screen time tracking, structured daily routines, parental involvement, and monitoring, family media plans, alternative engagements, and promotion of offline social interactions.
214912018|NCT01719367|DRUG|Atenolol|
214912019|NCT01701440|DEVICE|Biofusionary Bebe|
214912020|NCT04932369|BEHAVIORAL|Emotion Regulation training based on DBT|trained about emotion regulation and problem solving during eight 90-min group sessions
214912021|NCT03307772|DIETARY_SUPPLEMENT|Probiotics|
214912022|NCT03307772|DIETARY_SUPPLEMENT|Prebiotics|
214912023|NCT03307772|DIETARY_SUPPLEMENT|Prebiotics and Probiotics|
214912024|NCT03307772|DIETARY_SUPPLEMENT|Placebo|
214912025|NCT04726696|BEHAVIORAL|ROLE-AP programme|The intervention group will be split in two groups of 7-8 primary care nurses each. These two groups will receive the ROLE-AP program over a three weeks period. Each workshop will be divided into two sessions of 90-120min. The first workshop focuses on the clarification of health promotion concepts and the discussion of the state of nursing practice in health promotion. Participants will discuss the misalignments between this description of nursing practice and the ideal one portrayed by the Ottawa Charter. The second workshop will allow the presentation of the objectives of the health care organization, showing its alignment with the Ottawa Charter areas of action. In addition, it will present a standardized instrument that reflects expectations about nurses' activities in health promotion that will serve for discussing and realigning participants' expectations on nurses' role in health promotion. The third workshop will continue with the discussion of nurses' expected activities.
214912026|NCT01216241|DRUG|Daptomycin|8 MG/KG IV
214912027|NCT01216241|OTHER|Saline Placebo|50 ml normal saline once daily
214912028|NCT01216241|DRUG|Daptomycin|8 mg/kg once daily
214912029|NCT04895657|DRUG|Piperacillin/Tazobactam Continuous infusion|Continuous infusion
214912030|NCT04895657|DRUG|Piperacillin/Tazobactam Intermittent infusion|Intermittent infusion
214912031|NCT03309943|DRUG|Propranolol|Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
214912032|NCT03309943|DRUG|Placebo|Participants will take one dose of Placebo on two separate occasions.
214912033|NCT06344195|DRUG|Valacyclovir 500 mg|Valtrex 2g immediate dose followed by 500mg 2 times daily for 3 days along with the analgesic (SOS, if needed) for 6 days
214912034|NCT06344195|DRUG|Naproxen Sodium 550mg|550mg (as needed, SOS) for 6 days
214912035|NCT03895008|OTHER|Cardia and Non-cardia gastric cancer|We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.
214912036|NCT02530723|OTHER|power training|Resistance training machines with CAM devices will be used for training.
214912037|NCT00004990|DRUG|Dexamethasone|
214912038|NCT01890681|BEHAVIORAL|Baby NAP SACC|
214912039|NCT01890681|BEHAVIORAL|Back to Sleep|
214912040|NCT02817295|OTHER|clinical measurements|follow up on the number of complications, revisions, hospitalization and co-morbidities
214912041|NCT04275739|BEHAVIORAL|Academic Episodic Future Thinking|Brief Academic goal related EFT intervention involving desirable outcomes of current academic goals
214912042|NCT04275739|OTHER|Vivid Memory Task|Matched for time control task involving recall of vivid memories of distinct events/actions from a children's story
214912043|NCT06297018|BEHAVIORAL|Bioenergy application|Bioenergy application: This group includes liver transplant recipients and recipients who underwent intervention. Depression, anxiety and stress levels are measured in the pre-test. Bioenergy is then applied. As a post-test, depression, anxiety and stress levels are measured again.
214912044|NCT01661335|DRUG|Ondansetron, dexamethasone, aprepitant|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
214912045|NCT01661335|DRUG|Ondansetron, Dexamethasone, placebo|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
214912046|NCT04122742|PROCEDURE|skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.|Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.
214912047|NCT04122742|OTHER|Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy|induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons
214912048|NCT04122742|OTHER|Histone acetylation profiles of cells of SRT patients with CREBBP mutations|Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing
214912049|NCT04122742|OTHER|Functional involvement of identified epigenetic alterations|Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.
214912050|NCT04122742|BIOLOGICAL|Culture of lymphoblastoid line from blood sample|Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation
214912051|NCT03710837|OTHER|Pain neuroscience education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
214912052|NCT03710837|OTHER|Red flag education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
214912053|NCT05775393|PROCEDURE|Serratus anterior plane block for MRM|"They will randomly assigned to two groups of 30 patients each, at 1:1 allocation ratio using computer-generated random numbers concealed in sealed opaque envelopes.~Group (A):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0 .25 % and dexamethasone 4 mg).~Group (B):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0.25% and dexamethasone 4mg with ketamine 50 mg).~All the medications were prepared by an anesthesiologist not participating in the study."
214912054|NCT03123393|DRUG|TAK-659|TAK-659 Tablets
214912055|NCT04557215|DRUG|Rifaximin|Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
214912056|NCT04557215|DRUG|N-acetylcysteine|N-acetylcysteine (NAC) is a clinically approved mucolytic agent.
214912057|NCT04557215|DRUG|Placebo|An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.
214912058|NCT01846364|DIETARY_SUPPLEMENT|Diindolylmethane (DIM)|300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
214912059|NCT05863260|DRUG|Treatment Group|Treatment Group
214912060|NCT03289026|DRUG|Aripiprazole|Doses were flexibly titrated to between 10 and 30 mg once daily based on the individual needs of the patient as determined by the investigator.
214303821|NCT07190495|DRUG|Ginger|Patients will receive 800 mg of oral ginger 2 hours before laparoscopic cholecystectomy
214479565|NCT06868342|PROCEDURE|High-frequency nerve conduction block|A high-frequency nerve conduction block applied to a muscular branch of the tibial nerve and assessed by intraoperative EMG, performed before the nerve is cut as a part of a standard tibial neurectomy for focal spasticity.
214912061|NCT05245526|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
214912062|NCT00558701|DEVICE|Microcurrent stimulator|Microcurrent stimulation from 15-50 microamps
215058794|NCT03969290|DEVICE|Etafilcon A contact lenses|Daily disposable contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
214479566|NCT06867237|DEVICE|Suction cuff pressure|Use the device to do continuous management of suction cuff pressure and subglottic irrigation suction
214912063|NCT00558701|DEVICE|Silverlon Wound Contact Dressing|Silver coated nylon dressing FDA approved for use on donor sites in burn patients
214912064|NCT01496001|PROCEDURE|Lumpectomy, axillary block dissection, breast conserving surgery|Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.
214912065|NCT01496001|OTHER|Radiotherapy|Adjuvant radiotherapy carried out by institutional protocols.
214912066|NCT04009525|DRUG|Busulfan|Busulfan（4 mg/kg/day,4 days）
214912067|NCT04009525|DRUG|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
214912068|NCT04009525|DRUG|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
214912069|NCT04009525|DRUG|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
214912070|NCT04009525|DRUG|cyclosporine A|cyclosporine A
214912071|NCT04009525|DRUG|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
214912072|NCT04009525|DRUG|Tacrolimus|Tacrolimus
214303822|NCT07190495|DRUG|Placebo|Patients will receive an oral placebo capsule identical in appearance to ginger, administered 2 hours before laparoscopic cholecystectomy
214303823|NCT07190755|OTHER|Remote symptoms moniotring|Participants in the intervention arm will use Resilience PRO, a mobile phone application regularly asking participants about their symptoms. For clinically important symptoms, an alert is sent to the care team that can incorporate that information to timely adjust the care of the participants.
214303824|NCT07191392|DEVICE|Temporal Interference Stimulation (TIS)|The total stimulation duration was 30 minutes, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end.
214303825|NCT07191392|DEVICE|Sham temporal interference stimulation (TIS)|Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation
214479567|NCT06867861|DIETARY_SUPPLEMENT|Fiber|Psyllium fiber supplement capsules, 2g soluble fiber per capsule. They will be instructed to take 4 capsules twice daily for a total of 16g supplemental soluble fiber per day. This will be continued throughout pregnancy.
214479568|NCT06867432|DRUG|Combination Product：t: SIRT-Y90 +HAIC+Atezolizumab + Bevacizumab|"Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.~HAIC：administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks."
214912073|NCT04009525|DRUG|Methotrexate|Methotrexate
214912074|NCT01631539|DEVICE|DC Bead™|chemoembolization with DC Bead™ loaded with Irinotecan
214912075|NCT01631539|DRUG|Cetuximab|400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly
214912076|NCT01631539|DRUG|5 FU|every 2 weeks IV
214912077|NCT01631539|DRUG|Irinotecan|every 4 weeks chemoembolization
214912078|NCT00427648|DRUG|alkalinized xylocaine|30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
214912079|NCT00427648|DRUG|placebo|normal saline
214912080|NCT06535334|DRUG|Chemotherapy|Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer
214912081|NCT02536079|DRUG|NeuroAiD|
214912082|NCT06175078|DEVICE|Ultrasound Imaging 3D and Spectroscopy|Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
214912083|NCT01332760|OTHER|narrow diameter heavy dental tool|8mm diameter, heavy periodontal tool made from steel
214912084|NCT01332760|OTHER|large diameter light weight tool|Periodontal tools (4-8) provided to dental practitioners to use for all dental scaling or cleaning. This tool handle diameter is 11 mm diameter and it is made from lightweight Delrin.
214912085|NCT03809780|DRUG|Lenalidomide|-high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
214912086|NCT03809780|DRUG|Dexamethasone|-high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
214912087|NCT04631601|DRUG|Acapatamab|Acapatamab will be administered as an intravenous (IV) infusion.
214912088|NCT04631601|DRUG|Enzalutamide|Enzalutamide will be administered orally.
214912089|NCT04631601|DRUG|Abiraterone|Abiraterone will be administered orally.
214912090|NCT04631601|DRUG|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
215058795|NCT02097628|PROCEDURE|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
215058796|NCT02097628|PROCEDURE|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
215058797|NCT04359862|DRUG|Sevoflurane|25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
214479569|NCT06866470|BEHAVIORAL|relaxation group|exercise group
214912091|NCT02356939|DEVICE|intraductal removable stent custom-made segment (2 cm)|": In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 5th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1."
214912092|NCT02356939|PROCEDURE|stent extraction by ERCP|stent extraction by endoscopic retrograde cholangio-pancreatography
214912093|NCT00376155|DRUG|sulfadoxine /pyrimethamine plus amodiaquine|
214912094|NCT05486195|DRUG|SDI-118|SDI-118 Powder in Capsule
214912095|NCT05486195|DRUG|Placebo|Matching Placebo
214912096|NCT02079350|DRUG|%6 HES and %4 Gelofusine|
214912097|NCT01117038|DRUG|avanafil and enalapril|enalapril twice a day for 11 days avanafil/placebo once a day for 2 days
214912098|NCT01117038|DRUG|avanafil and amlodipine|amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days
214912099|NCT00289419|DRUG|Epidural Ropivacaine, morphine|Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
214912100|NCT00289419|DRUG|Ropivacaine, Ketorolac and Adrenaline|Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
214912101|NCT05666635|BIOLOGICAL|LTC004|"LTC004 Phase I:Participants will be allocated to one of the following dose groups: 3, 15, 45, 90, 180，270,360 and 450 ug/kg, and receive a treatment of LTC004 followed by 21 days of dose limited toxicity (DLT) observation period.~Phase Ib indication exploration~Other Name: LTC004 for Injection"
214912102|NCT05408208|DRUG|Intralesional Injection of Methotrexate|"One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment ."
214912103|NCT05408208|DRUG|Triamcinolone Acetonid|One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
214912104|NCT02637206|DRUG|GSK2894512 Cream|GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
214912105|NCT02637206|DRUG|Vehicle Cream|Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
214912106|NCT02637206|DRUG|Empty Patch|Empty patches without any ingredients will be used as negative control.
214912107|NCT04028609|BEHAVIORAL|Healthy at Home|In addition to receiving medical services as usual, subjects receive services from Community Healthy Workers during the transition from the hospital to their community residence.
214912108|NCT04028609|OTHER|Services as Usual|Routine medical services
214912109|NCT02156037|BEHAVIORAL|Diabetes Dashboard Intervention|The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.
214912110|NCT02156037|BEHAVIORAL|Usual Diabetes Care|The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
214912111|NCT04189315|DRUG|asfotase alfa|Asfotase alfa is administered subcutaneously.
214912112|NCT01870011|DRUG|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
214912113|NCT01870011|DRUG|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
214912114|NCT00872911|DIETARY_SUPPLEMENT|Amino acids|mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d
215058798|NCT04359862|DRUG|Propofol|25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
215058799|NCT04089527|DRUG|CC-95775|CC-95775
215058800|NCT03268889|DRUG|Chidamide|Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
215058801|NCT01377909|DRUG|statin|daily statin orally for 48 weeks
215058802|NCT03703232|DEVICE|Investigational prosthetic foot|Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
214912115|NCT00872911|DRUG|Exercise|progressive exercise training
214912116|NCT00905983|DRUG|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
214912117|NCT05360147|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.
214912118|NCT05360147|DRUG|Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides|oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
214912119|NCT02677571|PROCEDURE|Paravertebral Thoracic block|
215058803|NCT00886860|DRUG|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
215058804|NCT00886860|DRUG|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
214912120|NCT02677571|PROCEDURE|Pectorals nerve block|
214912121|NCT02677571|DRUG|Levobupivacaine 0.25%|
214912122|NCT02677571|DRUG|Morphine|
214912123|NCT00775229|DRUG|Naltrexone|pill, by mouth, 50mg-150mg/day for the duration of the study
214912124|NCT00775229|DRUG|Placebo|pill, by mouth, daily
214912125|NCT06534593|OTHER|Standard medical treatment|Standard medical treatment
214912126|NCT06534593|DEVICE|Lumbar Traction|Lumbar traction using traction table
214912127|NCT06534593|OTHER|Mckenzie Extension Protocol|Mckenzie Extension Exercises
214912128|NCT06534593|DEVICE|Interferential Therapy|Interferential Therapy for 20 minutes
215058805|NCT05075018|OTHER|Observational|Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
215058806|NCT04535973|DIAGNOSTIC_TEST|unstimulated saliva sample for hormone analysis|hormone levels will be determined in frozen samples of unstimulated saliva
215058807|NCT04535973|OTHER|quality of life questionnaire|all participants will fill out self-perceived quality of life questionnaire
215058808|NCT02941770|BEHAVIORAL|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
215058809|NCT02941770|OTHER|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
215058810|NCT01771991|DRUG|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
214912129|NCT06534593|DEVICE|Heat Therapy|Heat Therapy for 20 minutes
214912130|NCT06534593|OTHER|Sustained Natural Apophyseal Glides (SNAGs)|3-5 reptations of Mulligan's lumbar extension Sustained Natural Apophyseal Glides (SNAGs)
214912131|NCT00297440|BEHAVIORAL|Cognitive-behavioral treatment|
214912132|NCT00297440|BEHAVIORAL|Exercise|
214912133|NCT01155180|DRUG|Leptin|Hormone - daily self injections for 6 months
214912134|NCT01155180|DRUG|Placebo|Placebo
214912135|NCT06286527|OTHER|anonymous self-administered online questionnaire|proposition to participate through billboards with a QR code leading to the questionnaire.
214912136|NCT00937027|DRUG|Aminopterin|oral tablets, 1.0 mg dose, once weekly, two weeks
214912137|NCT02604992|DRUG|Treatment A|Dronabinol oral solution, under fed conditions
214912138|NCT02604992|DRUG|Treatment B|Dronabinol oral capsule, under fed conditions
214912139|NCT02604992|DRUG|Treatment C|Dronabinol oral capsule, under fasted conditions
214912140|NCT01149980|DRUG|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
214912141|NCT05517148|DEVICE|Therapeutic VR|Treatment module categories included: (1) Mindfulness-based stress reduction training: an audio conducting practice with breathing-based biofeedback training in immersive and interactive environments to support self-regulation and relaxation.
214912142|NCT06325735|DIAGNOSTIC_TEST|None intervention|None intervention, observational study
214912143|NCT02724657|OTHER|Buteyko Method|Intervention will be held twice a week during 3 weeks.
214912144|NCT02754804|DEVICE|Biomechanic parameters|recording of biomechanic parameters and surface electromyography at the thigh and calf level throughout the walking period, in PAD patients .
214912145|NCT03870269|DEVICE|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
214912146|NCT00628212|DRUG|Teneligliptin 10mg|
214912147|NCT00628212|DRUG|Teneligliptin 20 mg|
214912148|NCT00628212|DRUG|Teneligliptin 40 mg|
214912149|NCT00628212|DRUG|Placebo|
214912150|NCT05252572|BIOLOGICAL|CLL1 CAR T-cells|Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection
214912151|NCT06445712|BEHAVIORAL|Parental Support Cold Pressor Task|Child will submerge their hand in cold water alone and holding the hand of a parent.
214912152|NCT05760196|DRUG|GM-CSF|PD1 antibody is held every three weeks, and GM-CSF is used once every three weeks on days 1-14. Until the patient progresses disease or intolerable toxicity.
214912153|NCT03458481|DRUG|SOF|400 mg tablet administered orally once daily
214912154|NCT03458481|DRUG|DAG181|Capsule administered orally once daily
214912155|NCT06001710|DEVICE|Needleless jet injector|Device consist of injection pen, ampule and activator.
214912156|NCT04090671|DIAGNOSTIC_TEST|Multidimensional Dyspnea Profile|The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.
214912157|NCT01852149|DEVICE|MPAS Implant|The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
214912158|NCT00616148|DRUG|YKP3089|Oral dosage form
214912159|NCT00616148|DRUG|Placebo|
214912160|NCT00921531|DRUG|Thalidomide|"Thalidomide is used for adjuvant therapy for TACE~Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day."
214912161|NCT00921531|DRUG|TACE|TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
214912162|NCT01681212|DRUG|Ipilimumab|
214912163|NCT01681212|DRUG|Dacarbazine|
214912164|NCT05978050|DRUG|nimotuzumab plus paclitaxel|Nimotuzumab injection: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
214912165|NCT05978050|DRUG|placebo plus paclitaxel|placebo: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
214912166|NCT04203446|OTHER|Assessment of correctness of inhaling technique|Assessment of correctness of inhaling technique in patients with asthma or COPD
214912167|NCT00093314|DRUG|HuMax-CD20|
214912168|NCT03197038|BEHAVIORAL|Partially supervised home-based walking exercise|Participants will be asked to exercise at home by walking at a moderate intensity. Each participant will receive an exercise prescription. Participants will receive a heart rate monitor. The heart rate monitors will be used to achieve a desired exercise intensity and to monitor adherence levels. The participants will receive biweekly to weekly phone calls, and monthly in person meetings will be used to address any barriers, provide encouragement, and progress the exercise.
215058811|NCT01771991|DRUG|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
215058812|NCT02859285|OTHER|Placebo vulvar cream|
215058813|NCT02859285|OTHER|Estradiol vulvar cream|
215058814|NCT04444271|DRUG|Mesenchymal stem cells|1\. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
214912169|NCT03197038|BEHAVIORAL|Control|Participants will be asked to exercise at home by walking at a moderate intensity. The participants will receive biweekly phone calls, but will not receive a heart rate monitor, individual exercise prescription, or meet with the investigators monthly.
214912170|NCT01464424|DRUG|Travoprost 0.004% ophthalmic solution|
214912171|NCT01464424|DRUG|Bimatoprost 0.01% ophthalmic solution|
214912172|NCT00264719|DRUG|Metoclopramide (Maxolon)|Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
214912173|NCT00264719|DRUG|placebo|placebo 10 mg
214912174|NCT04393519|DEVICE|TIPS procedure|Implantation of TIPS for portal hypertension
215058815|NCT04444271|OTHER|Placebo|100 ml of normal saline will be given intravenously to control arm
215058816|NCT02143856|DRUG|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
215058817|NCT01188902|DIETARY_SUPPLEMENT|walnut|walnut consumption 48 g/d
215058818|NCT03130517|DRUG|intravenous immunoglobulin|giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
215058819|NCT05237063|BIOLOGICAL|Blood and urine samples|Additional Blood and urine samples will be collected at inclusion, 1, 3 and 5 years follow up visits
214912175|NCT02958735|OTHER|Exercise Challenge|Participants randomized to an exercise condition will perform treadmill exercise for 30 minutes. Participants will self-select a comfortable walking speed. The treadmill grade will be adjusted to elicit and maintain the target heart rate.
214912176|NCT02069041|BIOLOGICAL|Ramucirumab|Administered IV.
214912177|NCT02069041|DRUG|FOLFOX4|Administered IV.
214912178|NCT00771719|DRUG|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
214912179|NCT00152802|BIOLOGICAL|The polysaccharide vaccine Pneumovax (Merck-Frosst)|
215058820|NCT04291196|OTHER|VR-ECT 360o Video|Patients in the VR arm will be immersed in the ECT process in first person utilizing Google Cardboard headsets. Patients will experience in 360 entering the procedure room, IV insertion, pretreatment checks, anesthetic induction followed by induction of seizure, and recovery. The experience will also have voice-over narration simultaneously describing the procedure and its risks and benefits.
215058821|NCT04291196|OTHER|Standard Treatment|Patients will receive preparation for their ECT as per standard of care, i.e. a discussion with a Psychiatrist.
215058822|NCT04901663|DRUG|Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG|Orally twice daily for 2 weeks
214912180|NCT00152802|BIOLOGICAL|The conjugate vaccine used will be Prevnar (Wyeth vaccines)|
214912181|NCT00730535|DRUG|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 1 months
214912182|NCT00730535|DRUG|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 3 months
214912183|NCT00730535|DRUG|Tolterodine 6|Extended release tolterodine tartrate 4 mg, once daily, for 6 months
214912184|NCT04981002|OTHER|Telemedicine Consultation with self orthopedic exam|Brief telemedicine consultation, with self orthopedic exam,blinded to subsequent face-to-face evaluation.
214912185|NCT04981002|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
214912186|NCT04023032|BEHAVIORAL|multicomponent cognitive intervention|"The intervention takes place in groups of 6-10 participants and is leaded by one occupational therapist. It includes 16 sessions, 90 minutes each.~The first part of each session starts with a 15-minute review of previous homework or relaxation. The second part, which lasts 35 minutes, involves structured training with activity-sheets, board games, role-playing and computerized games. The third part, which lasts 30 minutes, is the lifestyle interventions. The instructor explains the generalization of the previous activities toward daily life, and introduces healthy lifestyles. Through group discussions, the therapist guides participants to develop solutions and strategies for their memory or cognition-related problems and application to daily life. The last 10 minutes are used to suggest homework."
214912187|NCT03882983|DRUG|Antria Cell Preparation Process|"Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft~Other Names:~* Stromal Vascular Fraction~* Adiployx Biological/Vaccine:"
214912188|NCT04740398|DRUG|CBP-1008|CBP-1008 for injection; IV infusion; Infusion for 90 minutes
215058823|NCT04901663|DRUG|Vonoprazan 20 MG; Amoxicillin 1000 MG|Orally twice daily for 2 weeks
215058824|NCT05594771|PROCEDURE|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion
214912189|NCT05296083|DIETARY_SUPPLEMENT|G3P-01|G3P-01 is a food-grade pectic product derived from squash.
214912190|NCT04386330|BEHAVIORAL|Distance-delivered NET|One-on-one intervention delivered by a paraprofessional; 12 weekly videoconference sessions at 90 minutes.
214912191|NCT03268226|DRUG|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
214912192|NCT03669926|RADIATION|Digital Breast Tomosynthesis+synthetic mammography|Two-view tomosynthesis performed with GE Senographe Pristina.
214912193|NCT00789373|DRUG|Pemetrexed|Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
214912194|NCT00789373|DRUG|Cisplatin|Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles
215058825|NCT05594771|PROCEDURE|epidural catheter|the loading dose for labor analgesia administrated via epidural catheter
215058826|NCT06095869|OTHER|progressive relaxation exercise|Breastfeeding mothers in the progressive relaxation exercise group were applied gradual relaxation exercise before going to bed 3 days a week and for 4 weeks, under the supervision of the researcher, accompanied by a training CD prepared by the Turkish Psychologists Association.
215058827|NCT06095869|OTHER|relaxation background music|In the relaxation background music group, breastfeeding mothers were listened to relaxation background music on the Progressive Relaxation Exercise CD before going to bed 3 days a week and for 4 weeks.
215058828|NCT06095869|OTHER|control group|Mothers in this group received routine care practices in the clinic. No intervention was made to the mothers in the control group, only data collection tools were applied.
215058829|NCT06294262|BIOLOGICAL|TETRALITE|Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
215058830|NCT03809078|DRUG|68Ga RM2|PET radiopharmaceutical
215058831|NCT03809078|DRUG|68Ga-PSMA-11|PET radiopharmaceutical
215058832|NCT03809078|DEVICE|Investigational PET scanner coils and software|GE Healthcare non-approved PET scanner coils and software
215058833|NCT01485276|PROCEDURE|DBS Surgery|
215058834|NCT04644146|GENETIC|GENETIC|It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
214912195|NCT00789373|DRUG|Placebo|Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
214912196|NCT00789373|DRUG|Pemetrexed|Maintenance therapy: 500 mg/m\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
214912197|NCT00789373|OTHER|Best Supportive Care|Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
214912198|NCT01214291|DRUG|Toremifene|Toremifene 80mg daily
214912199|NCT00142831|DRUG|Pharmacotherapies for Smoking Cessation|Bupropion-SR or Identical Placebo
214912200|NCT01314339|DRUG|Desloratadine|Desloratadine Tablets, 5 mg
214912201|NCT01069042|DRUG|Enalapril|All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
215058835|NCT02350075|PROCEDURE|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
214912202|NCT03293992|DRUG|0.01% RO7058584|Once daily morning administration for 7 days
214912203|NCT03293992|DRUG|0.1% RO7058584|Once daily morning administration for 7 days
214912204|NCT03293992|DRUG|1% RO7058584|Once daily morning administration for 7 days
215058836|NCT02350075|DEVICE|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
215058837|NCT02104791|DRUG|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
215058838|NCT01488461|GENETIC|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
215058839|NCT05435131|DIAGNOSTIC_TEST|GCF obtaining|GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
215058840|NCT05435131|DIAGNOSTIC_TEST|Saliva Obtaining|Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
215058841|NCT05435131|DIAGNOSTIC_TEST|Serum obtaining|Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
215058842|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose."
214912205|NCT03293992|DRUG|Matching Placebo|Once daily morning administration for 7 days
214912206|NCT03293992|DRUG|Latanoprost 0.005%|Once daily morning or evening dosing
214912207|NCT00113048|DRUG|CAMPATH (alemtuzumab)|
214912208|NCT03321968|BIOLOGICAL|Quadrivalent VLP Influenza Vaccine|Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine
214912209|NCT05071625|PROCEDURE|percutaneous vertebroplasty|percutaneous vertebroplasty under combined CT/fluoroscopy guidance for non-union after posterior fixation performed for a traumatic non-neurologic thoraco-lumbar vertebral fracture.
214912210|NCT04040140|OTHER|APA Treatment|Light touch using vaccaria seeds on corresponding ear points related to patient's pain.
214912211|NCT05258266|DRUG|ZX-101A|Q.D., oral dosing
214912212|NCT00407238|DEVICE|Multi-purpose solutions (polyquaternium-1 and PHMB)|
214912213|NCT01805466|DEVICE|EVADO|EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.
214912214|NCT01805466|DEVICE|Conventional CPB|conventional miniature cardiopulmonary bypass technique
214912215|NCT00225524|DRUG|Effexor XR|
214912216|NCT02307422|GENETIC|IL-1 Genotypes, other SNPs associated with CAD|Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
214912217|NCT00002924|OTHER|mutation analysis|
214912218|NCT03667885|DIAGNOSTIC_TEST|Blood sample|basic blood sample
214912219|NCT03667885|DIAGNOSTIC_TEST|urine sample|basic urine sample
214912220|NCT03667885|DIAGNOSTIC_TEST|Multi planar MRI|T1 (with reduced affinity for fatty tissue) +/- contrast, diffusion weighted sequences and wash in/wash out
214912221|NCT02609971|OTHER|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
214912222|NCT00940615|OTHER|aerobic exercise|, participants assigned to the exercise treatment group of the proposed study will participate in an aerobic exercise regimen of brisk walking on a treadmill for a 60 minute interval, three times a week
214912223|NCT00940615|OTHER|stretching/toning|Individuals in the control group will participate in a low intensity stretching and toning session for 60 minutes, three times a week
214912224|NCT03894826|DRUG|Vorinostat 100 MG|Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks
214912225|NCT04830969|DRUG|Chlorhexidine gluconate oral rinse|Paroex® is a non-alcohol chlorhexidine preparation. Participants are to use 15 mL morning and evening for 3 months. With use of chlorhexidine, there is risk of reversible staining of teeth and the possibility of some alteration in taste. There is increased likeliness of staining in smokers, coffee drinkers and those who are susceptible to teeth staining in general. The cleaning of the front teeth is provided at the 3-month visit and helps to reduce any staining that may occur. If there is any alteration in taste, it should go away when use of chlorhexidine stops.
214912226|NCT04830969|PROCEDURE|Scaling & Root Planing|SRP is standard treatment of periodontitis. It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
214912227|NCT04830969|DEVICE|Soft Picks|Soft Picks are a rubber interdental bristle cleaner. Participants are to use Soft Picks morning and evening for all 12 months of the study. They may cause some bleeding of the gums at first usage, but the bleeding should lessen and stop as use is continued (as gums heal). Soft-Picks are a readily available consumer product sold in supermarkets and drug stores.
214912228|NCT06041451|DRUG|Intravenous Immunoglobulins, Human|patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
214912229|NCT06041451|DRUG|Methylprednisolone 500 MG Injection|patients were treated with methylprednisolone
214912230|NCT03529513|DIAGNOSTIC_TEST|Medibio Depression Diagnostic Aid|The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.
214912231|NCT03529513|DIAGNOSTIC_TEST|Mini International Neuropsychiatric Interview|The Mini International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview that was developed as a simple tool to assist clinicians to conduct psychiatric diagnoses according to the DSM-IV and International Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10) criteria.
214912232|NCT03529513|DIAGNOSTIC_TEST|Hamilton Rating Scale for Depression - 17 Item|The clinician-administered Hamilton Depression Rating Scale (also known as the HAM-D) is the most widely used depression assessment scale . The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. There are numerous versions with varying lengths that include the HDRS21, HDRS24, and HDRS29. This study will utilize the HDRS17 (HAMD-17) version.
214912233|NCT06509633|OTHER|Pain Neuroscience education and standard rehabilitation regime|Median nerve gliding exercises, wrist and forearm muscle stretches, wrist mobilizations and finger joint mobilizations
214912234|NCT06509633|OTHER|standard Rehabilitation regime|standard Rehabilitation regime
214912235|NCT05799833|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance scan - 3T scanner (Siemens Vida)|4 study groups will undergo testing with 12-lead ECG, blood test, cardiac MRI, cardiopulmonary exercise testing and 24 hour holter monitor. A subgroup (N=50 anticipated) will undergo genetic testing.
214912236|NCT03171805|DRUG|Propranolol|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
214912237|NCT00605631|DEVICE|Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System|No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
214912238|NCT01677468|PROCEDURE|Intermediate embolization|TACE with substasis using gelfoam
214912239|NCT01677468|PROCEDURE|Complete embolization|TACE with complete embolization using gelfoam
214912240|NCT03690843|OTHER|Test Battery|All toddlers (DCD children + TD children) included in the study will be tested at three points in time, that is at the age of 3y, 4y and 5y with an extensive test battery. Questionnaires will be filled in by parents and teachers. Children will be tested using different instruments.
214912241|NCT05574218|PROCEDURE|Glycine air powder|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with glycine powder air-polishing.
214912242|NCT05574218|PROCEDURE|Rubber cup polishing|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with rubber cup and a polishing paste.
214912243|NCT04856306|OTHER|Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure|See previous descriptions
214912244|NCT04856306|DRUG|Elagolix Oral Product|See group 3 description
214912245|NCT04856007|DRUG|Dapagliflozin/metformin XR FDC 5/500 mg|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
214912246|NCT04856007|DRUG|Dapagliflozin/metformin XR FDC 10/1000 mg|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
214912247|NCT04856007|DRUG|Dapagliflozin 5 mg + Metformin 500 mg XR|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
214912248|NCT04856007|DRUG|Dapagliflozin 10 mg + Metformin 1000 mg XR|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
214912249|NCT05376774|OTHER|Admitted to intensive care units|Admitted to intensive care units
215058843|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose"
215058844|NCT06380725|DEVICE|Transcranial alternating current stimulation(real stimulation)|Real tACS is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of weak current to the brain by means of electrodes placed in the skull.
215058845|NCT06380725|DEVICE|Transcranial alternating current stimulation(sham stimulation)|Transcranial alternating current stimulation (sham-stimulation) is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of a weak current to the brain by means of electrodes placed in the skull. The subjects felt the same as the real stimulus when receiving the sham-stimulus treatment, but the sham-stimulus did not have the current stimulation.
215058846|NCT02343601|DEVICE|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
215058847|NCT01463163|DRUG|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
214479570|NCT06865690|OTHER|Eductional training program|"Arms and Interventions~Arms:~VAK Learning Model Group:~Description: Participants in this group will receive an educational program based on Fleming's VAK (Visual, Auditory, Kinesthetic) learning model. The program will tailor teaching methods to participants' sensory preferences (visual, auditory, or kinesthetic).~Kolb Learning Cycle Group:~Description: Participants in this group will receive an educational program based on Kolb's Experiential Learning Cycle. The program will emphasize experiential learning through concrete experiences, reflective observation, abstract conceptualization, and active experimentation.~Interventions:~VAK Educational Training Program:~Description: A structured CPR training program designed to align with participants' sensory preferences (visual, auditory, or kinesthetic). The program includes:~Visual components: Demonstrations, diagrams, and videos.~Auditory components: Verbal instructions, discussions, and feedback.~Kinesthetic components: Hands-on"
214479571|NCT05098379|BEHAVIORAL|Tele-Rehabilitation Home Exercise Program|"Participants will engage in 150 minutes of exercise per week (30 min/day for 5 days/week) for 8 weeks and will have weekly virtual Exercise Coaching sessions with a trained project team member. Customized home exercise programs will be reviewed weekly during the coaching sessions and will be modified as needed to ensure participants can complete their exercises safely and effectively. Exercise coaches will send weekly messages to 'check-in' with participants in order to motivate and remind participants to adhere to their tailored home exercise programs.~During weekly exercise coaching sessions, exercises will be reviewed for form, safety, and progression. Exercises will be revised as needed to ensure that they are in line with participants' goals, needs, and preferences."
215058848|NCT01463163|DRUG|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
215058849|NCT01489501|PROCEDURE|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
215058850|NCT04954300|OTHER|no intervention|No intervention
214912250|NCT03545685|OTHER|specific memory and attention realtime training|The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
214912251|NCT06017609|DRUG|JTT-861 Capsules|Active drug capsules containing JTT-861
215058851|NCT04661111|DEVICE|Hymovis® ONE (32 mg/4 ml)|Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
215058852|NCT03688334|DRUG|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
214912252|NCT06017609|DRUG|Placebo Capsules|Placebo capsules matching in appearance to the active drug capsules
214912253|NCT06575556|DIAGNOSTIC_TEST|Cardiac CT and MRI|"• Cardiac MRI Protocol~The cardiac MRI protocol will include cine imaging, aortic flow, and 3D navigator of the aorta. These sequences will be performed to assess aortic root dimensions, including aortic root, sinuses of Valsalva, and sinotubular junction and ascending aorta diameters.~• CT Aortography Protocol:~The CT aortography protocol will include non-contrast and contrast-enhanced CT imaging. The non-contrast images will be used for calcium scoring, while the contrast-enhanced images will be used to assess aortic root dimensions"
214912254|NCT04700917|BEHAVIORAL|Cognitive Behavioural Therapy|Internet-Based CBT
214912255|NCT04902638|PROCEDURE|Intraarticular injection of dexamethasone|Intraarticular injection of dexamethasone
214912256|NCT02798380|DRUG|HTS-519 Insert|Maximum feasible dose of HTS-519 Insert per diseased nail
214912257|NCT04430556|DRUG|Sertraline|Sertraline will be started in all patients, unless it is contraindicated, in this case, Escitalopram will be indicated.
215058853|NCT03688334|DRUG|Medical air (sham O2)|Medical air supplementation via Venturi mask
214479572|NCT06865911|OTHER|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infiltration of cold tumescent solution at 4 C for lipoplasty.
214479573|NCT06865911|OTHER|Warm saline|Infiltration of warm tumescent solution at body temperature for lipoplasty.
214912258|NCT05836350|DRUG|4.8 g/m^2/day NaPB|12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
215058854|NCT02929160|PROCEDURE|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
215058855|NCT02929160|PROCEDURE|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
215058856|NCT05068505|BEHAVIORAL|Community health worker delivered multicomponent intervention|"The multi-component intervention will be centered on monthly household visits by trained CHWs for a period of seven months in a rural setting in Nakaseke, Uganda, consisting of the following; (1) blood pressure and sugar monitoring; (2) BMI monitoring; (3) cardiovascular disease risk assessment; (4) Using checklists to guide monitoring and referral to clinics; (5) healthy lifestyle counselling and education. During home visits, CHWs will remind patients of follow-up visits. We will measure blood pressure at baseline and 3-monthly for the entire cohort. We will conduct individual-level mixed effects analyses of study data, adjusting for time and clustering by patient and community.~We will conduct an interim analysis at 3 months to assess differences between groups. If a statistically significant difference is detected the intervention will be applied across the remaining clusters"
215058857|NCT00606411|DRUG|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
215058858|NCT01253694|DRUG|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
215058859|NCT03726658|DRUG|AGN-241751|AGN-241751 is supplied in tablet form
215058860|NCT03726658|DRUG|Placebo|Placebo is supplied in tablet form
215058861|NCT00412958|DRUG|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
215058862|NCT00412958|DRUG|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
214303826|NCT07190547|OTHER|ShotBloker|ShotBlocker is a flat, horseshoe-shaped device used to reduce pain during subcutaneous or intramuscular (IM) injections. It features short, blunt, non-sharp projections approximately 2 mm in height and is designed to be placed against the skin, with a central opening that exposes the injection site. The device is applied to the skin just prior to injection, with its textured surface making contact with the skin. Although the projections do not penetrate the skin, they are believed to create a sensory stimulus associated with pain modulation based on the gate control theory.
215058863|NCT00412958|DRUG|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
215058864|NCT00412958|DRUG|Placebo|Intravitreal injection of placebo
214303827|NCT07190547|OTHER|Helfer skin tap|"Helfer Skin Tap Technique:~After determining the injection site, gently tap the skin several times with the fingertips of the dominant (most commonly used) hand for approximately 5 seconds to relax the muscle. After the skin is wiped with antiseptic solution and stretched, the cap of the syringe in the dominant (most commonly used) hand is opened. A large V is made with the thumb and index finger of the non-dominant hand. The skin is tapped three times quickly using the whole hand to stimulate the major muscle fibers. The nurse/midwife counts to 3, and the needle is inserted into the muscle at a 90-degree angle simultaneously. To remove the needle from the skin, the skin is tapped three times quickly (again in a V shape) with the whole non-dominant hand, and the needle is withdrawn simultaneously with the final tap (tapping)."
214303828|NCT07190664|OTHER|Patients were randomly grouped|All patients included in the study, were randomized
214303829|NCT07190209|DRUG|Lunsekimig|Pharmaceutical form: solution for injection in prefilled syringe Route of administration: Subcutaneous injection
214303830|NCT07190209|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: Subcutaneous injection
214912259|NCT05836350|DRUG|4.8 g/m^2/day placebo|12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
215058865|NCT00090779|DRUG|Emtricitabine/ tenofovir disoproxil fumarate|once daily
214912260|NCT05183165|OTHER|Patients with Wilson's disease declaring pregnancy,|Blood and urine biological assessment Dietary assessment
215058866|NCT00090779|DRUG|Lopinavir/Ritonavir|twice daily
215058867|NCT03376711|BEHAVIORAL|Online Peer Support Program|"The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers \& peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs."
215058868|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
215058869|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
215058870|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
215058871|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
215058872|NCT05036655|PROCEDURE|Perioperative glycemic management pathway|The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
214912261|NCT03038568|DIAGNOSTIC_TEST|CT scan|Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
214912262|NCT06349226|OTHER|cell isolation from intervertebral disc tissue and biomarker investigation|metabolomic, cellular and molecular analysis on intervertebral disc derived cells and investigation of tissue neuroinflammatory and pain-related biomarkers
214912263|NCT05334524|OTHER|kinesiotaping with combined chain exercises|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension.~Combined chain exercises will apply with 10 secs hold with 10 repetitions which will include quadriceps setting, SLR, full arc extension, cycling in the air, wall slides and step-up and step-down exercises"
215058873|NCT02818764|PROCEDURE|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
214303831|NCT07191418|DEVICE|Habib™ EndoHPB|This study will hold greater weight compared to previous ones, as it is randomized. It includes 178 patients, exclusively with pancreatic cancer, and is designed as a prospective investigation.
214303832|NCT07191418|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) as part of clinical routine.
214479574|NCT06865911|PROCEDURE|Liposuction of the arms|Infiltration of tumescent solution in both arms, VASER fat emulsification then power-assisted liposuction of the arms.
215058874|NCT02818764|PROCEDURE|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
215058875|NCT02818764|DEVICE|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
214912264|NCT05334524|OTHER|kinesiotaping|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension"
214912265|NCT04964050|DRUG|Capozide|Capozide will be administered as per the treatment sequence.
214912266|NCT04964050|DRUG|ACE-Hemmer-Ratiopharm|ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.
214912267|NCT02771847|BEHAVIORAL|survey|anonym survey is given to people
214912268|NCT06320184|DIAGNOSTIC_TEST|Artificial Intelligence risk model|Combining blood-based biomarkers, radiologic parameters, clinical features, and AI tools to create a robust model to predict lung cancer risk.
214912269|NCT04918017|DRUG|Treatment based on subtypes: Esomeprazole or Itopride|"Esomeprazole 40mg OD for EPS and Itopride 50mg TDS for PDS~In overlapped EPS/ PDS: treat with Itopride 50mg TDS first and then add Esomeprazole 40mg OD (if partially responded- assessed at week 4) or treat with Itopride 50mg TDS first and then change to Esomeprazole 40mg OD (if not responded- assessed at week 4)"
214912270|NCT04918017|DRUG|Treatment with proton pump inhibitor regardless of subtype: Esomeprazole|Esomeprazole 40mg OD
214912271|NCT05214651|PROCEDURE|novel double row|The large - massive rotator cuff tears in in this group will be treated using a novel double row repairing techniques.
214912272|NCT05214651|PROCEDURE|suture bridge double row|The large - massive rotator cuff tears in in this group will be treated using a suture bridge double row repairing techniques.
214912273|NCT02147834|DRUG|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
214912274|NCT02147834|DRUG|Sugar pill|"sugar pill manufactured to mimic ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
214912275|NCT05315037|OTHER|Resistance Training|"Bench press: Exercise performed with participant lying supine with hands in prone position. Barbell is lowered vertically from fully extended elbow position to sternum, then returned to starting position. Barbell will be weighted with plates dependent on their strength and workout demands.~Deadlift: Consists of gripping bar while in a squat position. Extension of ankles, knees, and hips while gripping the bar brings the weight up until joints are locked completing the exercise concentric portion. The eccentric lowering of the weight follows and consists of flexion of joints.~Seated overhead press machine: This multi-joint exercise, deltoid and trapezius are the prime movers and triceps are secondary movers, with hands on the grips and a position allowing back and buttocks to be completely supported. They push against a load vertically until glenohumeral joint fully extends, then load is returned to starting position and process continues until all repetitions desired are achieved"
214912276|NCT06545539|OTHER|Fall Preparedness Exercise Class|The class will be held bi-weekly at two different locations. To ensure consistency across groups, the instructor(s) will adhere to a standardized class outline. Exercise modifications will be provided as necessary to adjust the intensity, ensuring all participants can follow the program.
214912277|NCT05018182|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² Q2w(2 h) before surgery rection and 130 mg/m² Q3w (2 h) after surgery
214912278|NCT05018182|DRUG|Irinotecan|Irinotecan 150 mg/m² ivgtt(1.5 h) Q2w before surgery rection
214912279|NCT05018182|DRUG|Folinic Acid|Folinic acid 400 mg/m² ivgtt(2 h) Q2w before surgery rection
214912280|NCT05018182|DRUG|5FU|5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection
214912281|NCT05018182|DRUG|Capecitabine|Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection
214912282|NCT02894372|DEVICE|Oral spray 1|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
214912283|NCT02894372|DEVICE|Oral spray 2|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
214912284|NCT02726009|DRUG|Degarelix|
214912285|NCT05419219|DEVICE|the multi-domain Tai Chi Digital therapy Software Application|regular Tai Chi exercise, 40 Hz gamma sound stimulation and 18 BPM breath control exercise
214912286|NCT03547375|DRUG|Apatinib|Apatinib 500mg/d po,28 days as one cycle
214912287|NCT03771911|DEVICE|AED|Instructions provided by an AED
214912288|NCT03771911|DEVICE|Telephone|Instructions provided by emergency Call Center (telephonically) with the help of an AED.
214912289|NCT06577909|DRUG|Prednisone|Prednisone po, 20mg per day for 4 weeks, if response (Plt 30-100×100\^g/L), gradually taper to the maintenance dose of 5-10mg per day until 6 weeks after delivery; if not response, gradually taper to withdrawal.
214912290|NCT06577909|DRUG|IVIg|IVIg 400mg/kg (≤20g for the total dose) per day for 5 days, and repeated in the case of lack of response by day 14
214912291|NCT00046137|DRUG|teriparatide|
214479575|NCT06866197|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
214912292|NCT00046137|DRUG|raloxifene|
214912293|NCT00046137|DRUG|placebo|
214912294|NCT00239265|DRUG|Tamuslosin|
214912295|NCT02706431|PROCEDURE|Hyperventilation|
214954849|NCT06303414|PROCEDURE|Carotid Endarterectomy (CEA)|Carotid endarterectomy (CEA) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
214954850|NCT06303414|PROCEDURE|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, general anesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is advised for all patients who undergo CAS.
214303833|NCT07189819|DEVICE|Model-Predictive Controller (MPC) Functional Electrical Stimulation (FES)|The model-predictive controller (MPC) determines the timing and intensity of electrical stimulation delivered for FES. MPC combined with real-time ultrasound-based feedback delivers optimal FES intensities and minimizes fatigue. FES is delivered to the ankle dorsiflexor muscles using a commercially available FDA-approved electrical stimulator.
214303834|NCT07189819|DEVICE|Conventional Functional Electrical Stimulation (FES)|For functional electrical stimulation, surface electrodes are placed on the paretic leg on skin overlying the tibialis anterior (TA) muscle, with intensity pre-set to elicit dorsiflexion to neutral against gravity. FES will be delivered to the ankle dorsiflexor muscles using a commercially available FDA-approved electrical stimulator.
214303835|NCT07190651|OTHER|Home questionnaire|Administration of a questionnaire at each 28-days cycle, to select patients who need to access to hospital for clinical visit during treatment with CDK4/6i + hormone therapy for advanced breast cancer.
214303836|NCT07191015|BEHAVIORAL|Low-Intensity Continuous Exercise|Participants ran continuously for 30 minutes at 50% of their MAS without rest.
214303837|NCT07191015|BEHAVIORAL|Moderate Intensity Interval Exercise|Participants ran continuously for 30 minutes at 70% of their MAS without rest.
214303838|NCT07191015|BEHAVIORAL|High-Intensity Interval Exercise|Participants ran at 105-110% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 5 minutes, constituting one set. A total of four 5-minute sets were completed, interspersed with 2,5-minute passive rest periods, yielding a total exercise time of 30 minutes.
214479576|NCT06869525|BEHAVIORAL|Acupuncture|Dingchuan, Shanzhong, Tiantu, Feishu, Kongji, after obtaining qi, connect the electric needle (continuous wave, The frequency was 2Hz, the current intensity was 1\~5mA, and the current intensity was gradually increased according to patient tolerance), and the treatment was 30min.
214670174|NCT03065803|PROCEDURE|Guided bone regeneration technique for post-extraction dental socket preservation|After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
214670175|NCT01518699|DRUG|Ha44|Abametapir Lotion 0.74%
214670176|NCT01518699|DRUG|Ha44 Placebo|Ha44 Vehicle Gel without Abametapir
214670177|NCT01518699|DRUG|Moxifloxacin Placebo|Moxifloxacin Placebo
214954851|NCT06303414|PROCEDURE|Hybrid Surgery|Hybrid Surgery Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 5 days before the hybird surgery procedure. If they had stenting procedure, they will receive a daily dose of 100 mg aspirin and 75 mg clopidogrel thereafter. If not, they will take either 100mg aspirin or 75mg clopidogrel daily for life.
214954852|NCT00973895|BIOLOGICAL|VRC-FLUDNA057-00-VP|DNA Vaccine Expressing H1 HA from Influenza A/California/04/2009 H1N1 Virus
215058876|NCT02818764|DEVICE|Cerebral blood flow and oxygen extraction fraction|NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
215058877|NCT05483699|OTHER|Squeezing a ball|The children in the squeezing soft ball group were given the ball before the procedure. They were told to squeeze and loosen the ball with the hand that was not used for the procedure while intravenous cannula was being inserted.
215058878|NCT05483699|OTHER|Blowing bubbles|The children in the blowing bubble group were shown the bubble blower before intravenous cannulation and they were told how bubbles were formed and how they would blow. During intravenous cannulation, the child blew the blower
215058879|NCT05483699|OTHER|Kaleidoscope|Children in the Kaleidoscope group were given the kaleidoscope before intravenous cannulation and they were shown how to use it. The children were told to look at the kaleidoscope during the procedure until the procedure ended
215058880|NCT05614258|DRUG|ADG206|All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
215058881|NCT01809509|PROCEDURE|Endometrial biopsy|
215058882|NCT00899821|BIOLOGICAL|aldesleukin|
215058883|NCT00899821|BIOLOGICAL|recombinant interleukin-12|
215058884|NCT00899821|BIOLOGICAL|sargramostim|
214670178|NCT01518699|DRUG|Moxifloxacin|Moxifloxacin 400mg
214670179|NCT02110108|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
214670180|NCT02453412|DEVICE|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
214670181|NCT01623687|DEVICE|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
215058885|NCT00899821|OTHER|immunologic technique|
215058886|NCT00899821|PROCEDURE|biopsy|
215058887|NCT01869036|DRUG|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
215058888|NCT01869036|DRUG|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
215058889|NCT04679623|COMBINATION_PRODUCT|Midazolam|Midazolam Injection, 10mg
215058890|NCT04679623|DRUG|Seizalam|Seizalam, 10 mg
215058891|NCT00002509|BIOLOGICAL|filgrastim|
215058892|NCT00002509|DRUG|carboplatin|
215058893|NCT00002509|DRUG|cyclophosphamide|
215058894|NCT00002509|DRUG|etoposide|
215058895|NCT00002509|DRUG|mesna|
215058896|NCT00002509|PROCEDURE|autologous bone marrow transplantation|
215058897|NCT00002509|PROCEDURE|peripheral blood stem cell transplantation|
215058898|NCT01156025|DRUG|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
215058899|NCT01156025|DRUG|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
215058900|NCT05832515|DRUG|Fludarabine Phosphate for Injection|Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.
215058901|NCT02179424|BEHAVIORAL|Workshop|Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
215058902|NCT02179424|BEHAVIORAL|Face-to-face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
214912296|NCT04154254|DIAGNOSTIC_TEST|PET/MR|The PET will be performed with one of the following tracers: 18F-FDG, 18F-DOPA or 18F-flutemetamol (Vizamyl). Proper tracer will be determined by the physician according to the condition. Patients that will agree, will be asked to perform two scans each with different tracer. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, perfusion and diffusion images. Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Hidden image parameters will also be extracted for texture analysis purposes. Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity.
214912297|NCT06055517|RADIATION|Pulsed low dose-rate radiotherapy (pLDRT)|Radiation treatment will be carried out with high-energy photons (6MV) using intensity modulated radiation therapy (IMRT) or volumetric arc radiation therapy (VMAT). The daily dose is 2 Gy, divided into 10 subfractions of 0.2 Gy spaced by 3 minutes. The cumulative dose will be individualized for each patient and can range from a minimum of 40 Gy to a maximum of 60 Gy.
214912298|NCT02627664|OTHER|observational study|natural history of non dopaminergic signs
214912299|NCT00813384|DRUG|AMG 208|AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
214912300|NCT02189005|DIETARY_SUPPLEMENT|Study dietary supplement (PreCrea 600 mg capsules)|Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.
214912301|NCT02189005|DIETARY_SUPPLEMENT|Placebo|
214912302|NCT00243126|BEHAVIORAL|Family-Based Risk Reduction Intervention|The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
214912303|NCT06322641|OTHER|No treatment given|No treatment given
215058903|NCT02179424|BEHAVIORAL|Phone counseling|Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
215058904|NCT02179424|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
214912304|NCT06670079|BEHAVIORAL|Prolonged exposure therapy + incentives for therapy session attendance|Prolonged exposure therapy plus incentives for therapy session attendance
214912305|NCT06485102|PROCEDURE|Carotid Surgery in patients with symptomatic or asymptomatic stenosis|Carotid Surgery in patients with symptomatic or asymptomatic stenosis
214912306|NCT02768480|OTHER|Primary Care|Patients will be followed by primary care team according to the usual health system routine.
214912307|NCT02768480|OTHER|Phone Calls Support and Primary Care|Patients in intervention group will receive periodic phone calls (every three months) and will have a toll-free number to resolve questions about the disease management. The phone-calls will be performed by trained nurses and will follow a structured format. Nurses will address some topics: patient's treatment adherence, technique of insulin administration, disease understanding, hypoglycaemia management, healthy diet, smoke cessation and foot care.
215058905|NCT02179424|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
215058906|NCT02179424|BEHAVIORAL|SMS|Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
215058907|NCT00296465|DRUG|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
215058908|NCT00296465|DRUG|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
214670182|NCT01623687|DEVICE|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
215058909|NCT00296465|DRUG|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
215058910|NCT00296465|DRUG|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
215058911|NCT01794312|DEVICE|T4020|
215058912|NCT01794312|DEVICE|Vehicle|
215058913|NCT03632460|DRUG|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
215058914|NCT01632852|BIOLOGICAL|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
215058915|NCT04715841|OTHER|gait assessment|gait assessment were done using 3DMA system
215058916|NCT03277001|DRUG|Rivaroxaban|Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and \< 50 ml/min) po.
215058917|NCT03277001|DRUG|Enoxaparin|Enoxaparin 40mg IH
214912308|NCT04153461|PROCEDURE|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
214912309|NCT04153461|PROCEDURE|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
214912310|NCT01934582|DRUG|UT-15C SR|
214912311|NCT01934582|DRUG|treprostinil diethanolamine|Open label study drug.
214912312|NCT03019237|DRUG|anti-IgE|intranasal anti-IgE
214912313|NCT03019237|OTHER|intranasal allergen|intranasal allergen
214912314|NCT03019237|OTHER|intranasal saline|intranasal placebo
214912315|NCT03926832|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea Syndrome (OSAS) management when moderate-to-severe. Subjects with OSA will be trained in the use of CPAP and will be instructed to use it every night for 3 months. These subjects will then return for a post-treatment completion of questionnaires (ESS and FAS) and compliance analysis.
214912316|NCT06621914|DEVICE|BFR 80|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
215058918|NCT04349358|OTHER|FDG and FCH PET/CT|"* during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)~* just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams"
215058919|NCT04579536|OTHER|Light curable resin modified glass ionomer varnish|Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
214912317|NCT06621914|DEVICE|BFR40|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 40% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
214912318|NCT02355392|OTHER|Telemedical home blood pressure measurements|
214912319|NCT06684821|PROCEDURE|Racz catheter|Patients will undergo epidural neuroplasty using Racz catheter during lumber fixation.
214912320|NCT06684821|PROCEDURE|Classic lumber fixation|Patients will undergo classic lumber fixation.
215058920|NCT04579536|OTHER|Vanish White Varnish|5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
215058921|NCT05878678|DEVICE|Fixed positions of arm down and arm up|In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.
215058922|NCT05074680|DIAGNOSTIC_TEST|Blood sampling|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
215058923|NCT03010943|DEVICE|Virtual reality headset|Feasibility and tolerance
215058924|NCT04767061|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
214479577|NCT06869525|BEHAVIORAL|Sham Acupuncture|Dingchuan, Shanzhong, Tiantu, Feishu, hole the most points open 5\~10mm, shallow piercing through the skin, connected with the electric needle but no electricity, treatment 30min.
214479578|NCT06870266|DRUG|Nafarelin nasal spray|NAFARLIN 200 MCG X2 DAY
214479579|NCT06870266|DRUG|Utrogestan®|UTROGESTAN 200 MG X2 DAY
214912321|NCT02731430|DRUG|intrathecal morphine|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
214912322|NCT02731430|DRUG|intrathecal saline|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
214912323|NCT04912908|OTHER|Images taken during knee replacement surgery|Images taken during knee replacement surgery will be compared to CT-Scan that was performed before surgery
214912324|NCT01174381|BEHAVIORAL|lifestyle modification|Lifestyle modification for six months
215058925|NCT06012539|OTHER|Qualitative (interviews)|Interviews were held with participants at three different time points, approximately six months apart. Interviews were taped and analyzed for common themes.
215058926|NCT03479450|DRUG|surfactant|surfactant is given when neonatal respiratory distress syndrome is diagnosed
215058927|NCT03446963|BEHAVIORAL|Groups for Health|Group sessions, 5 modules x 1.5 hours (once per week). Modules focus on psychoeducation, mapping existing social networks, examining barriers to engagement in existing networks, goal setting and identifying new groups to join.
214912325|NCT02174510|DRUG|20mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
214912326|NCT02174510|DRUG|40mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
214912327|NCT02174510|DRUG|80mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
214912328|NCT02174510|DRUG|placebo|
214912329|NCT02746250|DRUG|Amitriptyline|The investigator recruits patients who have already discussed and agreed to the amitriptyline treatment with their physician. The patients start the treatment after the investigator have measured them once.
214912330|NCT02940262|RADIATION|Gallium Ga 68 Gozetotide|Given IV
214912331|NCT02940262|OTHER|Laboratory Biomarker Analysis|Correlative studies
214303839|NCT07191405|DIETARY_SUPPLEMENT|oral Lactobacillus johnsonii (1×10¹¹ CFU, twice daily)|Lactobacillus johnsonii, as a member of gut probiotics, has recently gained attention for its potential role in tumor immunotherapy due to its ability to modulate the immune system and maintain gut microbiota balance. Below is a summary of its possible mechanisms and applications: 1.Modulating Gut Microbiota and Immune Microenvironment. 2.Direct or Indirect Activation of Anti-Tumor Immunity. 3.Enhancing Efficacy of Immune Checkpoint Inhibitors (ICIs) . 4.Anti-Tumor Effects of Microbial Metabolites. 5.Preclinical and Clinical Research Progress.
214303840|NCT07191405|DIETARY_SUPPLEMENT|Placebo|oral take placebo twice a day
214479580|NCT06865625|BEHAVIORAL|mobile application|In this study, unlike similar studies in the literature, participants were grouped based on their oral hygiene status.
214479581|NCT06865625|BEHAVIORAL|traditional oral hygiene motivation|The group demonstrating the brushing technique on a braces model
214912332|NCT02940262|PROCEDURE|Positron Emission Tomography|Undergo PET imaging
214912333|NCT04933344|OTHER|patients having had BJI or PJI treated with daptomycin|patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK
214912334|NCT05509387|DEVICE|transcranial direct current stimulation and naming training|Participants will receive mild stimulation or no stimulation along with naming training
214912335|NCT05232760|DEVICE|Supera™ Peripheral Stent System|The device will be employed for treatment of juxta-anastomotic stenosis in failing AV fistula after previous percutaneous angioplasty procedures
214912336|NCT01334229|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
214912337|NCT01334229|DRUG|Placebo|Placebo for 6 weeks
214912338|NCT02627313|DEVICE|GammaPod Tumour Bed Boost|Single fraction Tumour Bed boost of 8Gy in 1 Fraction
215058928|NCT04760483|DEVICE|SoracteLite(TM) TPLA for BPH|see prior section
215058929|NCT03202212|PROCEDURE|mixed on-line hemodiafiltration|This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session
215058930|NCT03202212|PROCEDURE|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
215058931|NCT02564588|DRUG|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
215058932|NCT02564588|DRUG|Placebo|Placebo once daily
215058933|NCT06275828|DEVICE|slow beat mesic listening by headphone|classic slow beat type from researcher
215058934|NCT00729443|DRUG|AZD3241|single oral dose
215058935|NCT00729443|DRUG|Placebo|
215058936|NCT00161044|DRUG|Galantamine|
215058937|NCT06046092|BIOLOGICAL|H7HLAII|DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules
215058938|NCT03012828|DRUG|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
215058939|NCT03012828|OTHER|Placebo|
215058940|NCT00480831|DRUG|bevacizumab|Intravenous repeating dose
215058941|NCT00480831|DRUG|carboplatin|Intravenous repeating dose
215058942|NCT00480831|DRUG|paclitaxel|Intravenous repeating dose
215058943|NCT00480831|DRUG|placebo|Intravenous repeating dose
214912339|NCT00894621|DRUG|Norepinephrine|Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
214912340|NCT00894621|DRUG|Placebo|
214912341|NCT04939298|DEVICE|Ultrasound|Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation.
214912342|NCT03433573|DEVICE|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring System and will be asked to perform 4 blood glucose tests per day (pre-meal and before bedtime). Subjects will be asked to scan the sensor when each blood glucose test is performed.
214912343|NCT03111940|PROCEDURE|Optimisation of the result of intracoronary stenting according to specific algorithm|
215058944|NCT00480831|DRUG|PRO95780|Intravenous repeating dose
215058945|NCT00003776|BIOLOGICAL|filgrastim|
215058946|NCT00003776|DRUG|cisplatin|
215058947|NCT00003776|DRUG|doxorubicin hydrochloride|
215058948|NCT00003776|DRUG|ifosfamide|
215058949|NCT00003776|DRUG|leucovorin calcium|
215058950|NCT00003776|DRUG|methotrexate|
214912344|NCT04021888|OTHER|Exercise|Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
214912345|NCT01800747|OTHER|Antibiotic prescription strategies|The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
215058951|NCT00003776|DRUG|trimetrexate glucuronate|
215058952|NCT00003776|PROCEDURE|surgical procedure|
214303841|NCT07191093|PROCEDURE|pulmonary valvuloplasty|Pulmonary balloon valvuloplasty (PBV) is the treatment of choice for moderate to severe valvular pulmonary stenosis. It is a minimally invasive, catheter-based intervention that involves dilation of the stenotic pulmonary valve using an appropriately sized balloon. The goal is to relieve obstruction, reduce right ventricular pressure, and prevent long-term complications such as RV hypertrophy, dysfunction, and arrhythmias. The procedure has shown excellent immediate and long-term outcomes, particularly in patients with a pliable, doming pulmonary valve and no significant regurgitation or associated congenital lesions.
214912346|NCT02134431|DEVICE|flexible sigmoidoscopy or colonoscopy with biopsies|Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
214912347|NCT02696343|DEVICE|NTrainer|pulsed orocutaneous stimulation paired with tube feedings
214912348|NCT02696343|DEVICE|SHAM blind pacifier|regular green Soothie pacifier paired with tube feedings
214912349|NCT05775887|BIOLOGICAL|UQSC2 Vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373. The Study will be unblinded after Day 29, to enable subjects who received the investigational vaccine (UQSC2 vaccine) to seek vaccination with a TGA (Therapeutic Goods Administration) approved COVID-19 booster vaccine if indicated by public health authorities.
214912350|NCT05775887|BIOLOGICAL|NVX-CoV2373 vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373
214912351|NCT01628731|DRUG|furosemide|furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
214912352|NCT01628731|DRUG|ethacrynic acid|ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
215058953|NCT04994639|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
215058954|NCT02100930|BIOLOGICAL|Anti-GD2 3F8 Monoclonal Antibody|
215058955|NCT02100930|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
215058956|NCT02100930|DRUG|oral isotretinoin|
215058957|NCT03115411|DEVICE|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
215058958|NCT02522169|DRUG|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year."
215058959|NCT00693927|PROCEDURE|Unmanipulated PBSC after nonmyeloablative conditioning|"Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).~Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor"
215058960|NCT00693927|PROCEDURE|CD8-depleted PBSC after nonmyeloablative conditioning|
215058961|NCT00205517|PROCEDURE|Daily interruption of sedation versus sedation algorithm|
215058962|NCT01838460|DRUG|sublingual nicotine tablets|6 mg = 3 tablets
215058963|NCT01838460|OTHER|Smokeless tobacco|Swedish type moist snuff
215058964|NCT03825640|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
215058965|NCT03751371|DEVICE|Training with HWA device|Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
214912353|NCT04753008|DRUG|Dopamine administration|Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
214912354|NCT05051852|OTHER|Follow up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
214912355|NCT03452670|BEHAVIORAL|Active Group|Participants will be provided with a contemplative well-being application (CWA) which will facilitate meditation for 10 minutes daily during the 8 week study period.
214912356|NCT03452670|OTHER|Waitlist Group|The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in CWA at the end of the 8 week study period.
214912357|NCT02188147|DEVICE|Short Term Wearable Defibrillator|Short-term Wearable Defibrillator (SWD 1000)
214912358|NCT01022476|DRUG|Raltegravir potassium|one pill of raltegravir 400 mg twice a day
214912359|NCT06438614|DRUG|HITS|Four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF. Irinotecan 50mg/m2/day IV will be administered from day 1-5concurrently with temozolomide 150mg/m2/day orally. Hu3F8 2.25mg/kg IV will be administered on days 2, 4, 9and11. GM-CSF 250mcg/m2/day SC will be administered on days 7-11
214912360|NCT06438614|DRUG|Naxitamab + GM-CSF cycles|Patients that achieve CR after 2 or 4 cycles of HITS will move on to 5 cycles of Naxitamab + GM-CSF cycles.
214912361|NCT06438614|DRUG|NICE|Patients that do not have an objective response (CR/PR) will receive NICE within 3 weeks from last dose. Each cycle of NICE consists of four doses of hu3F8, five doses of GM-CSF, one dose of carboplatin, and 3 doses each of ifosfamide and etoposide (table 2). Hu3F8 2.25mg/kg IV will be administered on days 2, 4, 9and 11. GM-CSF 250mcg/m2/day SC will be administered on days 7-11. Ifosfamide 1.5 gr/m2/day IV will be administered from day 1-3 concurrently with etoposide 100 mg/m2/day IV. Carboplatin 400 mg/m2/day IV will be administered on day 1
214912362|NCT03911232|DRUG|sugammadex|standard general anesthesia protocol with sugammadex
214912363|NCT03125252|OTHER|Bundle|"Awakening and Breathing Coordination Delirium monitoring and management (detection and management of delirium) Early mobility~Factors of environment:~* thirst~* noise~* pain and well-being~* sleep~* isolation"
214912364|NCT03125252|OTHER|Standard Paramedical and Medical practices|"The current recommendations recommend the following scheme:~* Identification and correction of an organic cause / factors (sepsis, metabolic disorders, withdrawal syndrome, pain)~* Use of non-pharmacological means (early mobilization, correction of sensory deficits, temporo-spatial reorientation strategies)~* Use of reference antipsychotic pharmacological means"
214912365|NCT05550233|DEVICE|drug-coated balloon|drug-coated balloon in big de novo coronary disease
214912366|NCT01537042|DRUG|Rotigotine|"Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal."
214912367|NCT01537042|DRUG|Placebo|"Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period."
214912368|NCT01395147|DRUG|Lu AA21004|Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
214912369|NCT00979654|DRUG|Sifalimumab|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
214912370|NCT04145154|OTHER|Application of platelet rich plasma in chronic wounds of diabetic origin|Application of plasma rich in autologous growht factors after advanced healing
214912371|NCT05908877|OTHER|History and Clinical evaluation|"HISTORY and CLINICAL EVALUATION and recording of the following parameters:~* Gestational Age~* Birth Weight~* Gender~* Weaning habits~* Anthropometric indices: actual age; actual weight; actual height; body mass index BMI (kg/m2) + percentile; waist circumference; age for height; weight for height; height for age; height standard deviation score (SDS)~* Vital parameters: heart rate (beats/min); respiratory rate (breaths/min); blood pressure (mmHg)~* Adipose tissue~* Subcutaneous fat tissue distribution~* Acanthosis Nigricans~* Stretch marks (striae)~* Tanner Puberty Stage"
214670183|NCT01623687|DEVICE|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
214912372|NCT05908877|DIAGNOSTIC_TEST|Biological evaluation of the metabolic syndrome and components|"LABORATORY INVESTIGATIONS will include:~* Lipid Profile: total cholesterol (mmol/L); LDL - cholesterol (mmol/L); HDL - cholesterol (mmol/L); triglycerides (mmol/L)~* Glucose - Insulin Profile: HbA1c (%); serum glucose (mmol/L); insulinemia (µUI/mL); HOMA Index~* Liver Function: alanine aminotransferase (ALT or TGP) (U/L); gamma glutamyl transferase (GGT) (U/L)~* Cardio-Vascular Risk - Inflammation - Oxidative Stress: ultrasensitive C-reactive protein (ng/mL); leptin (ng/mL); adiponectin (ng/mL); serum selenium (μg/L); glutathione peroxidase (GPx) (U/L)"
214912373|NCT05908877|DIAGNOSTIC_TEST|Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage|"ULTRASOUND EVALUATION by:~* Carotid Intima-Media Thickness (cIMT) Measurement using B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) with a high frequency linear array probe (5-13 MHz) and a semi-automated software (Auto IMT+), according to the Mannheim Consensus~* Measurements of Visceral-to-Subcutaneous-Fat Ratio using B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) with a 7.5 (12) MHz linear transducer for subcutaneous fat and a 3.5 MHz convex transducer for visceral fat measurement~* Ultrasound Quantification of Hepatic Steatosis: assessed with B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) using 3.5 MHz convex transducer; increased liver echogenicity, blurring of vascular margins and increased acoustic attenuation are the parameters considered in the quantification of hepatic steatosis"
215058966|NCT03751371|OTHER|Usual Care|The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
214479582|NCT06867198|DIETARY_SUPPLEMENT|Peanuts|43 g of peanut butter (1 snack cup) 3 x/week, 42 g of dry roasted peanuts (1/3 of a cup) 3x/week, or 56 g of peanut flour 1x/week for 6 months.
214912374|NCT05908877|OTHER|Nutritional assessment|"NUTRITION CONSULT Initial consult will include: food habits survey aiming at identifying the nutritional factors that led to an increased Body Mass Index (BMI) and recommendations At reevaluations the food diary of the patients will be evaluated and recommendations will be adapted accordingly.~The final visit will include evaluation of the food diary looking to identify the factors that have or have not helped to normalize BMI in order to recommend a long-term healthy lifestyle."
214912375|NCT05908877|BEHAVIORAL|Psychological evaluation of the impact of obesity/overweight|"PSYCHOLOGICAL ASSESSMENT by:~Evaluation of pediatric health-related quality of life will be assessed with Pediatric Quality of Life Inventory (PedsQL). The questionnaire has 23 items and undertakes the four types of functioning: physical, emotional, social, and educational. It can be filled in by children as well as parents. Higher scores indicate better health-related quality of life.~Another questionnaire that will be used is the the Rosenberg Self-Esteem Scale. It is composed of 10 questions and measures positive and negative feelings about the self. The answer range is from strongly agree to strongly disagree. A higher score means higher self-esteem.~Drawing in children is a communicative tool, many times more than reading or language. It can measure the image of the self and the image of the others and is representative of the unconscious.~Questionnaires and drawing interpretation will be done at the initial presentation and at every control visit."
214912376|NCT02473627|DRUG|DS-1971a|200mg tablet
214912377|NCT02473627|DRUG|midazolam hydrochloride|2.5mg oromucosal liquid
214912378|NCT02473627|DRUG|Omeprazole|20mg gastro-resistant capsule
214912379|NCT02473627|DRUG|Pioglitazone hydrochloride|15mg tablet
214912380|NCT02473627|DRUG|Buproprion|150mg Prolonged release tablet
214912381|NCT02473627|DRUG|Tolbutamide|500mg tablet
214912382|NCT01969773|DRUG|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
214912383|NCT01969773|DRUG|Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
214912384|NCT02925962|OTHER|Clinical Decision Support System (CDSS)|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
215058967|NCT02108327|PROCEDURE|surgical blade|Using surgical blade all the time of surgery
214479583|NCT06870110|DEVICE|Bias Modification Biofeedback|The device uses EEG-based bias modification biofeedback intended to reduce attention to drug-related cues and increase attention to non-drug pleasant scenes. Specifically, the device measures perceptual biases from Event-Related Potential biomarkers related to Substance Use Disorders.
214479584|NCT06869239|DRUG|Etoposide + cisplatin/carboplatin|Four courses of intravenous cisplatin (75 mg/m² of body surface area on day 1 or divided into 3 days of each cycle) or carboplatin (area under the curve of 5 mg/mL per min on day 1 of each cycle) and intravenous etoposide (100 mg/m² of body surface area on days 1-3) every 3 weeks
214479585|NCT06869239|RADIATION|Thoracic radiotherapy|High-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) concurrent with chemotherapy initiated at the beginning of cycles 1-3
214912385|NCT02925962|OTHER|Clinic Decision Sup System + Pharmacist|Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
214912386|NCT03055676|OTHER|Early drain removal|Removing drain(s) on postoperative day 3
214912387|NCT03055676|OTHER|Late drain removal|Removing drain(s) on postoperative day 5 or later
214912388|NCT04691362|DRUG|Tranexamic Acid Oral Product|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
214912389|NCT04691362|DRUG|Tranexamic acid injection|Intravenous administration of 1 gramme tranexamic acid 30 minutes before skin incision and 1 gramme intravenous tranexamic acid 4 hours after first administration
214912390|NCT01779440|BEHAVIORAL|Electronic Decision Support System|
214912391|NCT02248844|BIOLOGICAL|Botulinum Toxin Type A|Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
214912392|NCT01842230|DRUG|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"* Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~* over the period I \& II(cross-over)"
214912393|NCT01842230|DRUG|Telmisartan 80mg and S-amlodipine 5mg|"* Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* over the period I \& II(cross-over)"
214912394|NCT01545167|GENETIC|blood sampling|blood samples obtained to extract biomarkers and dna for analysis, questionnaires
214912395|NCT01205269|DRUG|AZD8683, 50 mcg|Dry powder for inhalation, single dose
214912396|NCT01205269|DRUG|Placebo|Dry powder for inhalation, single dose
214912397|NCT01205269|DRUG|AZD8683, 200 mcg|Dry powder for inhalation, single dose
215058968|NCT02108327|PROCEDURE|electrocautery|Using electrocautery all the time except at skin incision
215058969|NCT04396795|DRUG|Autologous Platelet Rich Plasma|Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.
215058970|NCT04396795|OTHER|Saline solution|Each injection session will consist of a total of 5 mL saline solution infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum
215058971|NCT02827344|BIOLOGICAL|blood sample collection for CTC and MDSC analysis|"* Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~* Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~* Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
214479586|NCT06869239|RADIATION|Prophylactic cranial irradiation (PCI)|PCI (25Gy in 10 fractions, once daily over two weeks) 3-4 weeks post-chemoradiotherapy for patients achieving PR or CR
215058972|NCT02113423|RADIATION|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID\*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID\*2F
215058973|NCT01833910|OTHER|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
215058974|NCT01833910|OTHER|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
215058975|NCT04706780|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
215058976|NCT03060993|DRUG|Cannabis|Patients will be administered cannabis (THC/CBD) in vaporized form.
215058977|NCT03060993|DRUG|Placebo|Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
214912398|NCT04131660|DEVICE|AVAPS-AE mode during NIV|NIV will be setup in AVAPS-AE mode, with a Trilogy ventilation device (Respironics, Murrysville, PA). The range of positive expiratory pressure will be set between 4 and 14 cmH2O. The range of inspiratory pressure support will be set between 14 and 24 cmH2. The target tidal volume will be set to achieve 8 to 10 mL/kg of ideal body weight (Size (m) \* Size (m) \* 23).
214912399|NCT04131660|DEVICE|S/T mode during NIV|"NIV will be setup in ST mode, with a Trilogy ventilation device (Respironics, Murrysville, PA).~The physician will decide the level of positive expiratory pressure and of pressure support."
214912400|NCT02192463|DRUG|NVP ER 300 mg (KCR 20%) Medium Release|
214912401|NCT02192463|DRUG|NVP ER 300 mg (KCR 25%) Medium Release|
214670184|NCT01623687|DEVICE|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson \& Johnsson, USA).
214912402|NCT02192463|DRUG|NVP ER 300 mg (KCR 30%) Slow Release|
214912403|NCT02192463|DRUG|NVP ER 400 mg (KCR 25%) Medium Release|
214912404|NCT02192463|DRUG|NVP ER 300 mg (KCR 40%) Slow Release|
214912405|NCT02192463|DRUG|NVP ER 300 mg (ECR 20%) Fast Release|
214912406|NCT02192463|DRUG|NVP ER 400 mg (KCR 20%) Medium Release|
214912407|NCT02192463|DRUG|NVP ER 400 mg (KCR 30%) Slow Release|
214912408|NCT02192463|DRUG|NVP ER 400 mg (KCR 40%) Slow Release|
214912409|NCT02192463|DRUG|NVP ER 400 mg (ECR 20%) Fast Release|
215058978|NCT01098331|PROCEDURE|Radical Prostatectomy|
215058979|NCT01098331|PROCEDURE|Brachytherapy|
214303842|NCT07189520|OTHER|Artificial Intelligence|Benchmark AI scoring vs expert raters (GEARS/OCHRA κ ≥0.75)• Assess performance gains after GenAI feedback (≥15% improvement)• Measure usability, cognitive load, and ecological footprint reduction
214303843|NCT07190248|DRUG|MK-1084|Administered as an oral tablet
214670185|NCT04842344|DEVICE|ECCO2R|extracorporeal carbon dioxide removal
214670186|NCT03546478|BIOLOGICAL|99mTc-ABH2|99mTc-ABH2 were injected into the patients before the SPECT/CT scans
214912410|NCT02192463|DRUG|Nevirapine immediate release (IR) 200 mg|
214912411|NCT04667923|DIAGNOSTIC_TEST|Respiratory monitoring|Measurement of the tidal volume, peak inspiratory flow, inspiratory time, respiratory rate and the pressure gap during triggering on NIV and plateau pressure on mechanical ventilation
214912412|NCT04667923|DIAGNOSTIC_TEST|Respiratory muscles ultrasound|Measurement of the diaphragm thickening fraction, assessment of the contraction of scalene and sternocleidomastoid muscles
214912413|NCT04667923|DIAGNOSTIC_TEST|Electro impedance tomography|Measurement of the lung impedance changes in 4 quadrants, measurement of regional ventilation delay in 4 quadrants
214912414|NCT04667923|DIAGNOSTIC_TEST|Capnography|Measurement of end-tidal carbon dioxide tension
214912415|NCT04667923|DIAGNOSTIC_TEST|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
214912416|NCT04667923|DIAGNOSTIC_TEST|Quasistatic pressure-volume curve|Quasistatic pressure-volume curve
215058980|NCT03744195|OTHER|Group I Experimental Kinesotaping|"For application of kinesotaping following procedure will be adopted:~1. The skin will be cleaned properly with alcohol~2. The first strip will be applied in Y-shape (15-20% stretch) surrounding the deltoid muscle to provide inhibition and muscle relaxation~3. A second strip (I-shape) will be applied for functional correction (50-75% stretch), passing over the supraspinatus, trapezius, glenohumeral joint and middle deltoid Daily Strengthening Exercises (3 sets / 10\~30 reps) Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval"
214303844|NCT07190248|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Administered as a SC injection
214303845|NCT07190248|DRUG|Pemetrexed|Administered as an IV Infusion
214303846|NCT07190248|DRUG|Cisplatin|Administered as an IV Infusion
214303847|NCT07190248|DRUG|Carboplatin|Administered as an IV Infusion
214303848|NCT07189897|DRUG|Enoxaparin|For DVT prophylaxis
214303849|NCT07189897|DRUG|Apixaban|For DVT prophylaxis
214670187|NCT05019183|OTHER|Physical training|The subjects will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) with a target heart rate zone of 60%.
214670188|NCT05019183|OTHER|Virtual reality|The subjects will be able to move freely in virtual environments while training on the indoor rower.
214912417|NCT01408303|DRUG|Olive oil, 4g|Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin
214912418|NCT01408303|DRUG|omega-3-carboxylic acids, 2g|Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
214912419|NCT01408303|DRUG|omega-3-carboxylic acids, 4g|Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
214912420|NCT01207687|BIOLOGICAL|bevacizumab|Given IV
214912421|NCT01207687|OTHER|laboratory biomarker analysis|Correlative studies
214912422|NCT01207687|PROCEDURE|quality-of-life assessment|Ancillary studies
214912423|NCT02280837|OTHER|Determination of plasma GLP-1 level|Determination of GLP-1 level in samples of oral glucose tolerance tests
214912424|NCT00006105|DRUG|amifostine trihydrate|
214912425|NCT00006105|DRUG|cisplatin|
214912426|NCT00006105|DRUG|gemcitabine hydrochloride|
214670189|NCT05019183|DEVICE|Single-photon emission computed tomography (SPECT)|SPECT allows the measurement of cerebral perfusion, reflecting the global synaptic activity, via a 3D acquisition of 20 minutes, 15 minutes after injection of 740 MBq of radiotracers (ECD - Neurolite or HMPAo - Cerestab), with iterative reconstruction. The data will be processed at the voxel scale by the SPM12 software, with analysis of brain connectivity.
214912427|NCT00006105|PROCEDURE|adjuvant therapy|
214912428|NCT05258305|DEVICE|AuraGen 1-2-3 with AuraClens|Autologous fat transfer (AFT) is a minimally invasive medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen 1-2-3 with AuraClens is a lipoaspirate wash system designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister.
214912429|NCT00765505|BEHAVIORAL|Exercise Group|Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
214912430|NCT00765505|BEHAVIORAL|Health Education Group|Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
214912431|NCT00333827|DRUG|optimal therapy for cardiaca failure|optimal therapy for cardiaca failure
214912432|NCT00333827|PROCEDURE|cell|stem cell
214912433|NCT01129427|DRUG|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
214912434|NCT01129427|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
214912435|NCT01129427|DRUG|Pantoprazole|"Pharmaceutical form: delayed-release tablet~Route of administration: oral"
214912436|NCT02685176|DEVICE|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)|A heater (STK Heatpac) will be used in the active warming arms of the study.
214912437|NCT02685176|OTHER|No heat|No active heating provided post cooling
214912438|NCT03776266|PROCEDURE|No intervention is required due to retrospective observational study|Red blood cell transfusion on or after percutaneous coronary intervention
214912439|NCT05962723|PROCEDURE|EUS|EUS examination and cystic fluid will be aspirated for analysis, including cystic fluid Glucose, CEA, amylase. Morey's biopsy will be done in the cases feasible for biopsy.
214912440|NCT04368546|DRUG|Sunitinib|
214912441|NCT04491825|DIAGNOSTIC_TEST|Skin suction blistering and skin biopsies|Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.
214912442|NCT01486446|DRUG|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
214912443|NCT01486446|DRUG|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
214912444|NCT01801865|DEVICE|GE OPTIMA MR430s with HDX/GE Electronics|
214912445|NCT05066425|DIETARY_SUPPLEMENT|Soluble Corn Fiber|Participants will be asked to consume a packet of 22g Soluble Corn Fiber/day for 4 weeks
214912446|NCT05066425|DIETARY_SUPPLEMENT|Maltodextrin|Participants will be asked to consume a packet of 22g Maltodextrin/day for 4 weeks
214912447|NCT00523848|DRUG|bortezomib|IV
214912448|NCT00523848|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
214912449|NCT00523848|DRUG|thalidomide|Oral
214912450|NCT03856125|OTHER|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency - 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week"
214912451|NCT03856125|OTHER|Sham PENS plus exercise|"The technique will be performed on the radial nerve, the places of the needle's. The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle.~* Needle wil be placed at the at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's.~The current will not be working, and the needles will be placed during 30 minutes.~\- Administration - One per week"
214912452|NCT05063422|DRUG|polymyxin b/trimethoprim ophthalmic, Carboxymethyl cellulose|3 forms of denture adhesives from each brands are used to compare the retentive strength on highly resorbed ridges
214912453|NCT01367886|DRUG|fesoterodine|Fesoterodine 4 mg. tablet by mouth daily for six weeks
214912454|NCT01938092|DRUG|Diazepam|
214303850|NCT07190365|BEHAVIORAL|GOALS TH|The Goal-Oriented Attentional Self-regulation training involves ten 2-hour sessions of group-based telehealth training, three individual 1-hour telehealth training sessions, and approximately 20 hours of home practice. It is conducted in a small group format.
214912455|NCT01938092|DRUG|Placebo|
214912456|NCT04939831|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
214912457|NCT04939831|OTHER|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
214912458|NCT00985504|DRUG|Duloxetine|60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
214912459|NCT00985504|DRUG|Escitalopram|10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
214912460|NCT01884246|BEHAVIORAL|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
215058981|NCT03744195|OTHER|Group II conventional training group|Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval) Strengthening Exercises (3 sets / 10\~30 reps)
215058982|NCT00886327|PROCEDURE|Colonic capsule endoscopy|
214912461|NCT01884246|OTHER|Referral to primary care provider for CVD risk management|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
214912462|NCT02174692|OTHER|Exercise|"One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 mins rest between sets"
214912463|NCT00574704|DRUG|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 6 visits
214912464|NCT00574704|DRUG|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 6 visits
214912465|NCT00574704|DRUG|CYT003-AllQbG10 in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
214912466|NCT00574704|DRUG|CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
214912467|NCT01006304|DRUG|JNJ-39439335, Placebo|
214912468|NCT03729167|PROCEDURE|Scaling and root planing|Non-surgical instrumentation will be performed with specific instruments prior to treatment planned extraction by another provider.
214912469|NCT05237167|PROCEDURE|Shoulder reduction|This is standard of care and only measure as a time component outcome in the study
214912470|NCT06370169|DEVICE|Endoscopic ultrasound placement of Coil and glue|The standard treatment of bleeding gastric varices is obliteration with placement of coil and glue
214912471|NCT00371410|PROCEDURE|vitrectomy|
215058983|NCT04820062|OTHER|Content Validity|For the validity of built, it is generally advisable to include a ratio of 100 participants for 30 questionnaire items. In order to have a suitable questionnaire, we will limit ourselves to 30 items which will be the size of our questionnaire. It was therefore planned to include 100 participants The selection of experts will be based on experience in this area, knowledge and availability. It will be a rescimant physician and an infectious disease doctor. Each expert will be invited in isolation to comment on the items in the questionnaire
214912472|NCT00371410|DRUG|intravitreal triamcinolone acetonide|
214912473|NCT00371410|PROCEDURE|macular focal laser photocoagulation|
214912474|NCT03711786|OTHER|Basic implementation package|The basic implementation package will involve identifying an internal coordinator who is one of the full-time on-site providers at the clinic. The internal coordinator provides mentoring to peers and support to leadership in implementing the treatment program and aligning it with clinic priorities.
214912475|NCT03711786|OTHER|Enhanced implementation package|The enhanced implementation package will combine the internal coordinator with an external quality assurance committee. This committee will complete quarterly audits at the facility to evaluate compliance with the depression treatment protocol as well as providing high-level support in implementing the treatment program through clinical expertise and limited on-site presence.
215058984|NCT03127696|PROCEDURE|Fecal Microbiota Transplantation|FMT
214912476|NCT01057316|DEVICE|Formula PTX Stent - Dose 1|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
214303851|NCT07190365|BEHAVIORAL|EDU TH|The EDU TH training is an active control training matched with GOALS TH for therapist time, homework load, and participation in a group. It involves ten 2-hour telehealth sessions of group-based training, three individual 1-hour telehealth training sessions, and approximately 20 hours of home practice.
214303852|NCT07190352|DEVICE|iTBS to the DMN|Intermittent theta-burst frequency rTMS (iTBS) targeted to the parietal node of the default mode network.
214303853|NCT07190352|DEVICE|cTBS to the DMN|Continuous theta-burst frequency rTMS (cTBS) targeted to the parietal node of the default mode network
214912477|NCT01057316|DEVICE|Formula PTX Stent - Dose 2|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
214912478|NCT01057316|DEVICE|Formula PTX Stent - Dose 3|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
214954853|NCT05210270|RADIATION|Hypofractionation|"Phase 1 (Dose Escalation Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with nSIB 45 Gy (first dose level) and 48 Gy (second dose level); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)~Phase 2 (Efficacy Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with (or without) nSIB 45-48 Gy (depending on phase 1 results); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)"
214954854|NCT00671099|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
214954855|NCT00671099|DIETARY_SUPPLEMENT|Placebo|Placebo
215058985|NCT03127696|BEHAVIORAL|Lifestyle Modification Program|Lifestyle
215058986|NCT03127696|PROCEDURE|Sham|Sham
214954856|NCT05822206|BEHAVIORAL|CBT-TSC|Cognitive Behavioral Therapy for Trauma and Self-Care
215058987|NCT05576298|BIOLOGICAL|Insulin degludec injection, RD15003|single dose, s.c. injection
215058988|NCT05576298|BIOLOGICAL|Insulin degludec, Tresiba|single dose, s.c. injection
214303854|NCT07190352|DEVICE|Sham rTMS|Sham rTMS: coil flipped 180 degrees and applied to the parietal node of the DMN using an iTBS sequence. For this sham condition, rTMS felt and sounded like active stimulation, but no actual stimulation was delivered.
214912479|NCT00762814|DEVICE|Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)|Eligible subjects will be perform walking tests involving the use of the TENS device (Select Unit by Empi) on the lower leg bilaterally during gait: uncued (wearing the unit but, but with the device turned off) or with a tactile cue (wearing the device with it turned on until a tactile stimulus is felt). The TENS unit is a battery-operated, single-channel electrical stimulator worn around the proximal calf that can used to provide a constant tactile stimulus. All subjects will undergo a single visit in which the two walking conditions are tested. During these visits, the patient will perform the same gait assessments measured with the device turned off as well as turned on. Testing the two conditions on the same day/time will provide the investigators with a consistent comparison of the two tested conditions, as mobility and function in patients with PD can vary significantly within and between days.
214912480|NCT02972619|OTHER|Structured Multicomponent Intervention (MCI)|Multicomponent Intervention (MCI) includes 1) algorithm-driven antihypertensive treatment for all hypertensive individuals using fixed-dose combination (FDC) and lipid lowering for high risk hypertensive individuals, 2) motivational conversation for high-risk hypertensive individuals and 3) telephone based follow-ups of all hypertensive individuals by a team of physician supervised nurse, and 4) discounts on FDC antihypertensive medications
214912481|NCT01982617|OTHER|Motivational Interviewing|
214912482|NCT01982617|OTHER|Psychoeducation|
214912483|NCT04993716|OTHER|observational|Collect from a bank of biological samples, identification of prognostic factors associated with survival without serious neurological heavy sequelae
214912484|NCT00004208|DRUG|ATG + CSA|Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
214912485|NCT00004208|BEHAVIORAL|Supportive care|Patients randomized to this arm will be treated as outpatients.
214912486|NCT02566213|OTHER|Parabolic flight|
214912487|NCT02566213|OTHER|Motor skills measurements|"* the kinematics measurements of the right hand with a motion analysis system;~* the measurements of forces applied by the hand on the object to be grasped and moved with a 6 degree of freedom force sensor;~* the measurement of position of the moved object with an inductive position encoder."
214912488|NCT02688543|PROCEDURE|RF treatment|the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.
214912489|NCT02688543|RADIATION|radiofrequency ablation|
214912490|NCT02688543|DEVICE|ultrasound|
214912491|NCT02553018|DRUG|Methotrexate|
214912492|NCT03836690|BIOLOGICAL|CD62L- Tem|Donor memory T cells that have been depleted of CD62L+
214912493|NCT00466245|DRUG|MVA Smallpox vaccine|Two 0.5mL subcutaneous injections, separated by 28 days
214912494|NCT00466245|DRUG|Placebo|Two 0.5mL subcutaneous injections, separated by 28 days
214912495|NCT00715273|DRUG|Atorvastatin|10 to 80 mg of atorvastatin each day
214912496|NCT00715273|DRUG|Niacin|2000 mg of niacin each day
214912497|NCT00715273|DRUG|Colesevelam|3.8 g of colesevelam each day
214912498|NCT00715273|DRUG|Placebo Niacin|Placebo niacin each day
214912499|NCT00715273|DRUG|Placebo Colesevelam|Placebo colesevelam each day
214954857|NCT05822206|BEHAVIORAL|Life Steps and Sexual Decision-Making|
214954858|NCT02350699|DEVICE|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
214954859|NCT04282837|DIAGNOSTIC_TEST|AI classification of patients with obesity|Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.
214954860|NCT02772809|DEVICE|Haptic Robot Therapy with Games|Commercial Joystick and Wheels Plus the Haptic TheraDrive Robot will be used. Haptic Theradrive is a low-cost robotic system for post-stroke upper extremity rehabilitation. The system uses off-the-shelf computer gaming wheels with force feedback to help reduce motor impairment and improve function in the arms of stroke survivors.
214954861|NCT03090451|BEHAVIORAL|Aerobic Exercise|Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
214954862|NCT05131932|PROCEDURE|Endoscopic ablation of inlet patch|Endoscopic ablation of inlet patch using argon plasma coagulation (APC)
214954863|NCT02860507|DRUG|sugammadex|
214954864|NCT02860507|DRUG|Neostigmine|
214954865|NCT02860507|DRUG|Glycopyrrolate|
214954866|NCT00003037|DRUG|cisplatin|
214954867|NCT00003037|DRUG|docetaxel|
214954868|NCT00003037|DRUG|gemcitabine hydrochloride|
214954869|NCT02169388|DRUG|Probiotic|Microbial composition using probiotic
214954870|NCT02169388|DRUG|placebo（for probiotic）|microbiota modulation using placebo
214954871|NCT05460637|BEHAVIORAL|No BS just Fitness|The participants receive lessons on the physical activity guidelines, goal setting, physical activity planning, habit development, identity formation, and how to apply all these tools together. In addition, there are numerous resources provided to other existing web resources, including exercise videos and other informational webpages (e.g., USDA nutritional recommendations).
214954872|NCT06220409|OTHER|Dance classes|A 12-week dance class training program two times a week for 3 months
214954873|NCT02774005|DRUG|Idebenone|
214954874|NCT00479297|DRUG|SAM-531|
214954875|NCT04978077|OTHER|Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)|After a night fast participants will drink the test meal
214954876|NCT00534105|OTHER|Total Cholesterol|
214954877|NCT00534105|OTHER|Triglyceride|
214954878|NCT00534105|OTHER|HDL|
214954879|NCT00534105|OTHER|LDL|
214954880|NCT02577627|DEVICE|PrediCare|
214954881|NCT02156973|OTHER|Video information|A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
214954882|NCT04262960|DEVICE|Device: active CPAP|auto-PAP with pressure between 4 and 20 cm H2O will be administered to randomized patients
214954883|NCT04262960|DEVICE|Device: sham-CPAP|The sham-CPAP will be fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al, with pressure that no greater than 1cm H2O.
214912500|NCT03379727|DRUG|Midostaurin|Induction Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for 1 - 2 cycles; a cycle = 28 days; Consolidation Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for up to 4 cycles; Maintenance Phase: Continuous dosing (days 1 - 28) for up yo 12 cycles or until relapse, unacceptable toxicity, death, physician's decision, subject/guardian decision, protocol deviation, study termination by Sponsor, lost to follow-up, technical problems, pregnancy, subject withdrew consent, or until the end of study, whichever event occurred first.
214912501|NCT03379727|DRUG|Cytarabine|Induction Phase (standard dose) (7 + 3 arm): 100-200 mg/m2/day by Continuous intravenous infusion (CIVI) days 1-7 (168 hours infusion); Induction Phase (5 + 2 arm): 100 mg/m2/day by CIVI days 1-5; Consolidation Phase: 1-3 g/m2 infusion over 3 hours every 12 h on days 1, 3 and 5, up to 4 cycles based on age and per investigator discretion
214912502|NCT03379727|DRUG|anthracycline ((daunorubicin or idarubicin): Induction Phase only|daunorubicin (7 + 3 arm): 60-90 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); daunorubicin (5 + 2 arm): 60 mg/m2/day by IV push on days 1-2; idarubicin (7 + 3 arm): 12 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); idarubicin (5 + 2 arm): 12 mg/m2/day by IV push on days 1-2
214912503|NCT06270576|DRUG|Lipopolysaccharides|LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.
214912504|NCT02481089|OTHER|validation group|
214912505|NCT00712192|PROCEDURE|coronary artery bypass grafting|patient with coroary artery diseases underwent coronary artery bypass grafting surgery
214912506|NCT01837264|DEVICE|Magellan®|
214912507|NCT00651833|DRUG|S-1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
214912508|NCT02367651|DRUG|Pazopanib 800 mg|Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib
214912509|NCT02367651|DRUG|Placebo|Tablets matching the 200 mg and 400 mg pazopanib tablets
214912510|NCT01076673|BIOLOGICAL|Peripheral blood stem cells and hyaluronic acid injections|Peripheral blood stem cells and hyaluronic acid injections
215058989|NCT00995098|DIETARY_SUPPLEMENT|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
215058990|NCT00995098|DIETARY_SUPPLEMENT|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
215058991|NCT04099498|BEHAVIORAL|Online Program: Healthy Eating Promotion with Self-regulation|Online-Intervention group
214346952|NCT06298903|OTHER|Hip activation + Single leg balance|"Hip activation HEP: Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.~Single leg balance: variety of single leg balance exercises with different upper extremity and lower extremity positions to provide different balance stimuli. Weeks are alternated performing these exercises with eyes open and eyes closed."
214479587|NCT06869239|DRUG|PD-L1 inhibitor|Maintenance therapy with PD-L1 inhibitors (Durvalumab 1500 mg Q4W or Atezolizumab 1200 mg Q3W or Sugemalimab 1200 mg Q3W or Adebrelimab 1200 mg Q3W) post-PCI until disease progression, death, or intolerable toxicity, up to 2 years
214912511|NCT01076673|DRUG|Hyaluronic Acid|Hyaluronic acid injections
214912512|NCT00697905|DRUG|Gemcitabine|Intravenous administration on days 1, 8 of a 21-day cycle
214912513|NCT00697905|DRUG|Carboplatin|Intravenous following Gemcitabine infusion on day 1
214912514|NCT00697905|DRUG|Cisplatin|Intravenous on day 1 prior to 5-FU infusion on days 2 to 5 of a 28-day cycle
214912515|NCT00697905|DRUG|5-fluorouracil (5-FU)|Intravenous infusion on day 2 to day 5
214912516|NCT04356547|DEVICE|Fiberoptic intubation with laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator.
214912517|NCT04356547|DEVICE|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator.
214912518|NCT02972905|DRUG|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
214912519|NCT02972905|DRUG|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose
214912520|NCT04031846|DRUG|Rotarix™|Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)
214912521|NCT04031846|DRUG|Infanrix™ hexa|Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)
215058992|NCT04099498|BEHAVIORAL|Enhanced Online Program: Healthy Eating Promotion with Self-regulation|Enhanced-online-Intervention Group
214912522|NCT04031846|DRUG|V114|15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevenar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,
214912523|NCT04031846|DRUG|Prevenar 13™|13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.
214912524|NCT05695612|OTHER|Novaloc Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Novaloc attachments. The proper Novaloc abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
214912525|NCT05695612|OTHER|Locator Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Locator attachments. The proper Locator abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
214912526|NCT00012376|DRUG|bryostatin 1|Given IV
214912527|NCT00012376|BIOLOGICAL|sargramostim|Given subcutaneously
214912528|NCT00012376|OTHER|laboratory biomarker analysis|Correlative studies
214912529|NCT00012376|OTHER|pharmacological study|Correlative studies
214912530|NCT02180529|DRUG|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.
214912531|NCT02180529|DRUG|Placebo|
214912532|NCT00786760|OTHER|Cohort: 3000 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
214912533|NCT00786760|OTHER|Pilot study: 150 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
214912534|NCT03859479|PROCEDURE|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
214912535|NCT03859479|PROCEDURE|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
214912536|NCT03809754|PROCEDURE|Percutaneous Coronary Intervention under OCT|After randomization, subjects receive primary PCI under the guiding of OCT
214912537|NCT03809754|PROCEDURE|Percutaneous Coronary Intervention under Angiography|After randomization, subjects receive primary PCI under the guiding of angiography
214912538|NCT00772876|DRUG|P1446A-05|P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
214912539|NCT00042159|DEVICE|repetitive transcranial magnetic stimulation|1 Hertz stimulation for 16 minutes per day at 90% motor threshold, 5 sessions each to the two primary cortical targets
214912540|NCT06491173|DEVICE|InfraScanner 2500™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
214912541|NCT04007120|DRUG|RVT-1601|Inhaled RVT-1601 administered once daily over two days
214912542|NCT06868654|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
214912543|NCT06868654|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
214912544|NCT06868654|DRUG|Bortezomib|Proteasome Inhibitor
214912545|NCT06868654|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
214912546|NCT06521697|DRUG|Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture|Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture vs placebo normal saline
214912547|NCT06521697|DEVICE|Minimal flow sevoflurane|Minimal flow sevoflurane anesthesia (0.5 L/min) vs low flow sevoflurane (1 L/min)
214954884|NCT04858360|DRUG|Emla 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.
214954885|NCT04858360|DRUG|EMLA 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.
214954886|NCT04858360|OTHER|Vehicle cream for 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.
214479588|NCT06870669|BEHAVIORAL|progressive relaxation exercise|We will use progressive relaxation exercises to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
214670190|NCT05019183|BIOLOGICAL|Metabolomics|This qualitative approach will aim to identify pathways that are not known (or have not been explored) to optimize the chances of detecting metabolites present depending on the group (physical activity coupled or not with VR). This method is favorable for biomarker discovery.
214912548|NCT05306691|DRUG|Bio-smart Light Cured Protective Shield with bioactive S-PRG (Surface Pre- Reacted Glass ionomer) filler technology (PRG Barrier Coat) by (By SHOFU Inc., Japan).|Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas.
214912549|NCT04138498|DRUG|Dexmethylphenidate 5 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
214912550|NCT04138498|DRUG|Dexmethylphenidate 6.25 mg Tablet|Experimental drug for comparative BA evaluation
214912551|NCT04138498|DRUG|Dexmethylphenidate 40 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
214912552|NCT04138498|DRUG|Dexmethylphenidate 50 mg Tablet|Experimental drug for comparative BA evaluation
214912553|NCT06928493|OTHER|oral examination|"The pre-examination behaviors and attitudes of the children included in the study were measured by an independent dentist (Ş.Y.İ) using the Frankl Behavior Rating Scale (FS). Following this, the children were randomly divided into two groups PCC and CCC . The oral examination of PCC group was done in an isolated dental environment with white overalls, an FFP3 mask, and a visor. The oral examination of CCC group was done in normal dental environment with a standard white coat and surgical mask.After that, patients were asked to draw themselves or the pediatric dentist who performed the examination. A child psychiatrist (B.A.S.) and a pediatric dentist (R.D) with an internationally valid Child Drawing Analysis training certificate evaluated the children's drawings independently."
214912554|NCT03990467|BIOLOGICAL|Plasma dosage of amikacin, piperacillin and tazobactam|Pharmacokinetic (PK) criteria will be used to judge whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam
214912555|NCT05095116|DRUG|APT-1011 3 mg HS|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
214912556|NCT03953976|RADIATION|Intensity modulated radiation therapy (IMRT)|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). 6.5-7 weeks of radiotherapy or chemoradiotherapy
214912557|NCT06914934|DIETARY_SUPPLEMENT|High-dose resveratrol 500 mg/day|High-dose resveratrol 500 mg/day (preferably a high-bioavailability formulation, e.g., trans-resveratrol with piperine or liposomal).
214912558|NCT06914934|OTHER|Placebo|Placebo capsules, identical in appearance and schedule.
214912559|NCT06313398|BIOLOGICAL|Biotin-labeled red blood cells|Cellular Product (patient's own red blood cells washed in Biotin and infused back to patient)
214912560|NCT00764660|DRUG|SCH 900435|tablets
214912561|NCT00764660|DRUG|Placebo|tablets
214912562|NCT01131455|BIOLOGICAL|Autologous Concentrated Plasma|Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
214912563|NCT06919055|OTHER|PCG auditory stimulation|PCG auditory stimulation during mental stress
214912564|NCT06919055|OTHER|MHR stimulation|MHR auditory stimulation during mental stress
214670191|NCT02636790|PROCEDURE|Surgery wait time|VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
214912565|NCT06919055|OTHER|Control-no treatment|no stimulation during mental stress
214912566|NCT06922123|BEHAVIORAL|Tactile stimulation|Patients will undergo a resting-state EEG and fNIRS recording, followed by the administration of the SECONDs scale. Tactile stimulation will then be performed on eight areas of the body (internal and external forearms, palms and backs of the hands on both sides) using six different stimuli categorized as pleasant, neutral, or unpleasant. Stimuli will be applied manually in randomized blocks. EEG and fNIRS data will be recorded before, during, and after stimulation. Behavioural responses will be evaluated through video analysis by independent raters. The session will last approximately 90 minutes.
214954887|NCT04858360|OTHER|Vehicle cream for 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.
214954888|NCT04858360|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
215058993|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 10 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
214670192|NCT06274359|BEHAVIORAL|Digital storytelling|Caregivers will receive text messages with embedded digital stories and messaging to encourage influenza vaccination.
214670193|NCT05823506|COMBINATION_PRODUCT|PDE5 inhibitor (tadalafil) and BTL-6000 fSWT|The mechanism of low-intensity shockwave therapy in patients with ED based on the effect on the endothelium of the cavernous arteries, the release of NO and the enhancement of vascularization due to release of angiogenic factors.
214954889|NCT05547776|BEHAVIORAL|Mindfulness app|The mindfulness app contains 6 modules with a variety of features to help caregivers reduce their stress.
214954890|NCT00214292|PROCEDURE|fluorescence spectroscopy and diffuse spectroscopy|
214954891|NCT01443325|DRUG|lidocaine patch|1 patch for 12 hours within each 24 hours period
214954892|NCT04151966|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for markers of myocardial injury
215058994|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 20 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
214912567|NCT06922123|DEVICE|Neurophysiological Monitoring with SedLine|SedLine is a non-invasive neurophysiological monitoring device used to record the brain's electrical activity (EEG) through frontal electrodes. In this study, SedLine is employed to measure resting-state and stimulus-evoked cortical responses in patients with disorders of consciousness (DoC), in combination with functional near-infrared spectroscopy (fNIRS). The EEG signals are used to assess changes in neural activity before, during, and after tactile stimulation with various affective valences (pleasant, neutral, unpleasant). This combined multimodal approach enhances the understanding of sensory processing and cortical reactivity in patients with impaired consciousness.
214912568|NCT05354869|DEVICE|Urostym|electric pelvic floor muscle stimulator
214912569|NCT05354869|BEHAVIORAL|Standard care|patient education on home exercises and stretching
214912570|NCT06941168|PROCEDURE|Robotic Total Gastrectomy and Laparoscopic Total Gastrectomy|"RTG:Robotic total gastrectomy with D2 lymphadenectomy performed using the Da Vinci Surgical System, following the Japanese Gastric Cancer Treatment Guidelines.~LTG:Laparoscopic total gastrectomy with D2 lymphadenectomy performed by experienced surgeons following standardized procedures, based on the Japanese Gastric Cancer Treatment Guidelines."
214912571|NCT06941363|RADIATION|SBRT|Eligible patients are those with (1) persistently detectable PSA post-operatively or (2) developing biochemical recurrence after prostatectomy with initially undetectable PSA, without evidence of macroscopic local relapse and/or regional and distant metastases at restaging, proposed for receiving up to 15 Gy in a single session to the prostate bed.
214912572|NCT06940583|OTHER|VR|Participants will view a relaxing virtual environment (e.g. nature landscapes, lightly animated themes) for 5 minutes prior to the colposcopy procedure and during the colposcopy wearing a VR headset.
214912573|NCT06940583|OTHER|Podcast|Participants will listen to a podcast of relaxing or informative content for 5 minutes before and 5 minutes during colposcopy. The content will be selected according to individual preferences (e.g. storytelling, humorous content or educational content).
214912574|NCT06940661|DRUG|Obinutuzumab|"Patient will receive 1000 milligrams intravenous (IV) infusion on week 0, week 2, week 24 and week 26.~Patients will receive the same standardized glucocorticoid tapering schedule (prescribe as a standard of care management and considered as auxiliary medicinal product)~Premedication for obinutuzumab infusion related reactions (considered as auxiliary medicinal products) :~* 100 mg methylpredinisolone~* 1000 mg paracetamol~* 5 mg dexchlorpheniramine"
214912575|NCT03103152|DRUG|High dose Aspirin & Vitamin D|Aspirin 1 x 300mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
214912576|NCT03103152|DRUG|High dose Aspirin, Vitamin D placebo|Aspirin 1 x 300mg tablet daily \& Vitamin D placebo (8 drops).
214912577|NCT03103152|DRUG|Low dose Aspirin , Vitamin D|Aspirin 1 x 100mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
214912578|NCT03103152|DRUG|Low dose Aspirin, Vitamin D placebo|Aspirin 1 x 100mg tablet daily \& Vitamin D placebo 8 drops daily.
215058995|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 10 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
215058996|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
215058997|NCT02968498|DIETARY_SUPPLEMENT|Oral glucose 20 g|White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
214303856|NCT07190768|OTHER|Kinesio Taping|"Participants received Kinesio Taping (KT) applied to the affected shoulder using standard 5-cm Kinesio Tex tape. Before application, an allergy test was performed by placing a small patch of tape on the contralateral forearm for 15 minutes. The taping procedure included three regions: supraspinatus muscle, deltoid muscle, and glenohumeral joint.~Application technique:~Supraspinatus: Y-strip applied from insertion on the greater tubercle along the muscle to its origin with 20-25% stretch.~Deltoid: Y-strip applied from 3 cm below insertion to the origin, with anterior and posterior tails placed along corresponding edges.~Glenohumeral joint: I-strip applied from the coracoid process, laterally under the acromion, around the posterior deltoid edge.~Schedule: Tape was applied at baseline (Day 0), reapplied at Day 7, and removed permanently at Day 14."
214912579|NCT03103152|DRUG|Aspirin Placebo, Vitamin D|Aspirin 1 x 300mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
214912580|NCT03103152|DRUG|Aspirin placebo, Vitamin D placebo|Aspirin 1 x 100mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
214912581|NCT06081218|OTHER|activity test|Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
214912582|NCT06194240|BEHAVIORAL|DiabACT|E-program proposed to diabetic patients based on ACT therapy.
214912583|NCT05976997|DRUG|Duvelisib, Chidamide|Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;
214912584|NCT04080388|DIAGNOSTIC_TEST|Lung Impedance Device|The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.
214912585|NCT04080388|DRUG|Anti-congestive treatment|Continuation of in-hospital anti-congestive treatment
214912586|NCT04170738|DRUG|Adderall|3 weeks of Adderall
214912587|NCT02514798|OTHER|Esophageal and gastric balloons|Esophageal and gastric pressures will be measured with an esophageal ballon positioned at the lower third of the esophagus, filled with 0.5 mL of air and a gastric balloon filled with 1 mL of air. The proper position of balloons will be verified using the occlusion test as previously described. Transdiaphragmatic pressure (Pdi) is calculated as the difference between gastric (Pga) and esophageal (Pes) pressure. The pressure time integrals of the diaphragm and the other inspiratory muscles are calculated per breath (PTPdi/b and PTPes/b, respectively) and per minute (PTPdi/min and PTPes/min). Measurements will be collected at baseline, at each randomized HFNC and CPAP settings during the last 4 minutes of each 10 minutes session.
215058998|NCT02968498|DIETARY_SUPPLEMENT|Still water|Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
215058999|NCT02514291|BEHAVIORAL|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
214912588|NCT02514798|OTHER|Respiratory Inductance Plethysmography (RIP) system|Inspiratory tidal volume (VTi), respiratory rate (RR), breath duration (Ttot), inspiratory time (Ti) and fractional inspiratory time (Ti/Ttot) will be determined using a Respiratory Inductive Plethysmography (RIP) system. This will measure the thoracic and abdominal excursion of the subjects via two inductive wires which are sewn into the elastic bands that encircle the thorax and abdomen. The acquired signals represent changes in cross-sectional area and, following calibration to determine the relative contribution of each signal, and volume calibration using spirometry, their weighted sum will reflect VTi. The RIP companion software will be used to derive RR, Ttot, Ti and Ti/Ttot on a breath by breath basis.
214912589|NCT02514798|OTHER|Sentec transcutaneous monitoring system|The oxygenation, the level of carbon dioxide, and the heart rate will be recorded using the Sentec transcutaneous monitoring system: a probe will be placed at the earlobe or on the forehead, and it will measure in a noninvasive way these parameters.
214912590|NCT02514798|DEVICE|High-flow humidified nasal oxygen delivery system|
214912591|NCT02514798|DEVICE|CPAP (Positive Control)|
214912592|NCT06570148|OTHER|semi-directed interview or focus group|Participants will be recruited using purposive sampling with maximum variation. If they meet the inclusion criteria, they will be invited to take part in an online interview or focus group, lasting between 40 minutes and 1.5 hours. During the Zoom interview or focus group, they will be asked to answer several pre-defined open-ended questions based on an interview grid co-constructed with the co-investigators, including a patient partner and parent partners. They will be asked to answer closed socio-demographic questions at the end of the interview or focus group. The Zoom meeting will be recorded (audio) and then transcribed into anonymized written form.
214912593|NCT06661226|OTHER|Accleration drills|14 participants will be in experimental group A, giving them acceleration drill protocol for six weeks. Measure all values before giving them protocol and after protocol.
214912594|NCT06661226|OTHER|Change in Direction Drills|14 participants will be in experimental group B, giving them Change in direction drill protocol for six weeks. Measure all values before giving them protocol and after protocol.
214912595|NCT00787982|DEVICE|MRI-Guided Laser Induced Thermal Therapy|LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor
214912596|NCT05007431|OTHER|Questionnaires|Data collection will be carried out by hetero-questionnaire carried out in the presence of the questioned.
214912597|NCT02128854|BEHAVIORAL|Tablets Intervention|The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
214912598|NCT04105296|DEVICE|EKSO+ES|6 months of exoskeleton training with epidural stimulation.
214912599|NCT01540487|DRUG|linagliptin/metformin(high dose)|patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
214912600|NCT01540487|DRUG|Linagliptin/metformin(low dose)|patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
214912601|NCT04981808|DEVICE|Telemonitoring|Telemonitoring of CGM and insulin pen data
214303857|NCT07190768|OTHER|Dry Needling|"Participants received dry needling (DN) applied with sterile, disposable stainless-steel needles (0.30 mm × 50 mm). Target muscles included the supraspinatus, deltoideus, infraspinatus, subscapularis, and pectoralis major.~Technique: The fast-in, fast-out method (Hong technique) was used. After cleaning the skin with alcohol, the needle was inserted into a palpable taut band until the first local twitch response (LTR) was elicited. The needle was moved vertically (5-10 mm) at \~1 Hz for 25-30 seconds. DN was applied for 45-60 seconds per muscle.~Schedule: Twice per week, for 3 weeks (total of 6 sessions)."
214912602|NCT01754350|DIETARY_SUPPLEMENT|calorie-restricted ketogenic diet and transient fasting|"On day 1-3 and day 7-9, restriction of carbohydrates to \< 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by Tavarlin."
214912603|NCT01754350|DIETARY_SUPPLEMENT|standard nutrition|nutrition as recommended by the german society for nutrition, 30 kcal/kg per day
214912604|NCT03804450|PROCEDURE|Regenerative endodontic procedures (REPs)|Instrumentation using rotary Pro-Taper Next, disinfection using sodium hypochlorite and calcium hydroxide as intracanal medication followed by induction of blood and application of Biodentine as a cervical plug.
214912605|NCT00513045|BEHAVIORAL|IRT|Cognitive behavior intervention
214912606|NCT00513045|BEHAVIORAL|Exposure|Exposure intervention
214303858|NCT07190768|BEHAVIORAL|Exercise Program|"All participants were instructed in a standardized home-based exercise program designed to improve shoulder mobility and stability.~Content: Exercises included active range-of-motion movements, scapular stabilization, and strengthening of rotator cuff and periscapular muscles. Ergonomic advice and posture correction were also provided.~Delivery: Participants were taught the program in person and instructed to perform the exercises at home.~Schedule: Exercises were performed daily for 3 weeks, in addition to the assigned intervention for each study arm."
214479589|NCT06869772|PROCEDURE|Closure of sternotomy|In group I, spreading of BW on the sternal surfaces by digital pressure immediately after sternotomy and before closing the chest. In group II ORC will be cut and laid along the sternotomy over the intramedullary area immediately after sternotomy and it will be removed before closing the chest.
214303859|NCT07190768|DEVICE|Conventional Physical Therapy (TENS/Ultrasound/Heat pack)|"Participants in this arm received conventional physical therapy modalities commonly used for the management of subacromial pain syndrome.~Modalities: Transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, or superficial heat pack were applied based on standard clinical practice.~Additional care: Sessions also included passive mobilization of the shoulder into end range, scapular stabilization exercises, and ergonomic/postural advice.~Schedule: One-hour treatment sessions, 5 days per week, for 3 consecutive weeks."
214303860|NCT07190716|BIOLOGICAL|GR2301 injection|IL15 monoclonal antibody
215059000|NCT04717271|OTHER|Movement Guidance Group|"Participants of the MVG will received kinesthetic stimuli by manual assistance of the physiotherapist, which has the intention of guiding and improving the quality of movement during XBOX Kinect training for balance and gait.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
215059001|NCT04717271|OTHER|No Movement Guidance Group|"Participants of the NO-MVG will not received kinesthetic stimuli by manual assistance of the physiotherapist during XBOX Kinect training for balance and gait.~They will perform the exercises without any manual correction. Although, the physiotherapist will be present during all session to ensure their safety.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
214303861|NCT07191470|DEVICE|The Anaesthetic Conserving Device (AnaConDa)|The Anaesthetic Conserving Device (AnaConDa) was developed to facilitate the use of volatile anesthetics like isoflurane and isoflurane in mechanically ventilated patients outside the operating room. The device functions as a passive vaporizer, conserving anesthetic agents and reducing environmental contamination. Studies have demonstrated that AnaConDa-based inhaled sedation offers several advantages over intravenous sedation like better hemodynamic stability, reduced systemic inflammation, and faster recovery times.
214912607|NCT02025140|DEVICE|Computer controlled anesthesia|The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD
214912608|NCT02025140|DEVICE|conventional anesthesia syringe|Active control
214912609|NCT02525783|DEVICE|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty
214912610|NCT01508611|OTHER|30% silver diammine fluoride|"The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.~Anteroposterior toothbrushing technique will be explained to the children."
214912611|NCT01508611|BEHAVIORAL|Oral hygiene|With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique
214912612|NCT01894841|BEHAVIORAL|Coping Long Term with Active Suicide (CLASP)|6 month behavioral telephone-based intervention. Calls assess risk, problem solve any immediate issues, and case management
214912613|NCT01894841|OTHER|Safety Assessment and Follow Up Evaluation|enhanced risk monitoring with full assessment protocol at 3, 6, 9, and 12 month follow up. Results sent as a note to the patient's VA mental health provider
214912614|NCT02235064|DRUG|Sertraline|Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
214912615|NCT02235064|DRUG|Placebo|Capsule containing cellulose powder of same color as experimental arm
214912616|NCT06516237|PROCEDURE|to determine molecular and epigenetic biomarkers|In addition, up to 8 biopsies will be performed, at clinical judgment, in distal colon to determine molecular and epigenetic biomarkers.
214912617|NCT03208335|DRUG|recombinant human endostatin|The cycles of rh-endostatin's treatment depends on the effect of reaction and tolerance.
214912618|NCT03628664|RADIATION|CT scan|Assessment of the actual posterior condylar angle using the CT scan
214912619|NCT05362617|DRUG|FOLFIRI|FOLFIRI as first line chemotherapy versus mFOLFOX6 after adjuvant chemotherapy
214912620|NCT05953519|BEHAVIORAL|Unified Protocol|The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety.
214912621|NCT04679766|PROCEDURE|Ice cream cone technique with immediate implant as a flapless bone regenerative method in management of patients with labial plte dehiscence|Atraumatic extraction will be done The extraction socket will be debrided to remove any residual debris using surgical curettes Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence. Implant placement will be done. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability Resorbable collagen membrane will be cut confirming to the size and shape of the defect of labial bone plate dehiscence. The membrane will be placed against internal surface of the extraction socket against the remaining buccal plate of bone. The gap between the collagen membrane and the implant fixture will be filled with xenograft particulates.The membrane will be folded in palatal direction to seal the socket in an ice cream cone shape, then will be secured using non-resorbable sutures
214303862|NCT07190404|BEHAVIORAL|A metacognitive strategy for cognitive rehabilitation called the Multicontext Approach.|The Multicontext Approach is a strategy training approach to cognitive intervention provides ways to maintain daily function despite the presence of cognitive deficits. It involves teaching people to use metacognitive, compensatory, or adaptive techniques to optimize information processing or bypass cognitive limitations and achieve task-related goals. Strategy training is recommended for those with mild (vs. more severe) cognitive deficits because it requires learning, capitalizes on existing cognitive resources, and aims to prevent or delay functional decline.
214912622|NCT00454246|DRUG|methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
215059002|NCT00180557|DEVICE|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
215059003|NCT01501890|DRUG|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
215059004|NCT01501890|DRUG|Placebo|0.9% NaCl
214912623|NCT00454246|DRUG|epoetin alfa|Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
214912624|NCT00454246|DRUG|darbepoetin alfa|Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
214912625|NCT02014311|PROCEDURE|CTA+CTP guided treatment strategy|CTA+CTP guided treatment strategy
214912626|NCT02014311|PROCEDURE|CTA guided treatment strategy|CTA guided treatment strategy
214912627|NCT06208839|DEVICE|SBIRT/eIntervention for those with moderate risk drug or alcohol use|"The Connections App is available on iOS or Android and will be offered to the patient during the referral process and contains the following functionalities:~* Online view of the referrals made for them e.g. to healthcare provider~* Secure messaging with the referring provider~* Secure messaging with the destination provider(s) to support them to adhere to the referral, and/or the patient can seek assistance with the destination provider,~* Informative multimedia content filtered from a library to fit the patient including testimonial content from peers thus showing the patient that others like them have shared their addiction experience and successfully received treatment and achieved recovery,~* Capture structured feedback from the patient~The patient may access more functionality within the Connections App for those who wish to modify behavior using eTherapy and eRecovery. eRecovery includes ecological momentary assessments (EMA) selected by the provider."
214912628|NCT06208839|DEVICE|SBIRT/eIntervention those assessed with high risk.|"The Connections App is available on iOS or Android and will be offered to the patient during the referral process and contains the following functionalities:~* Online view of the referrals made for them e.g. to healthcare provider~* Secure messaging with the referring provider~* Secure messaging with the destination provider(s) to support them to adhere to the referral, and/or the patient can seek assistance with the destination provider,~* Informative multimedia content filtered from a library to fit the patient including testimonial content from peers thus showing the patient that others like them have shared their addiction experience and successfully received treatment and achieved recovery,~* Capture structured feedback from the patient~The patient may access more functionality within the Connections App for those who wish to modify behavior using eTherapy and eRecovery. eRecovery includes ecological momentary assessments (EMA) selected by the provider."
214912629|NCT06208839|OTHER|SBIRT/TAU for those with moderate risk drug or alcohol use|Treatment as usual
214912630|NCT06208839|OTHER|SBIRT/TAU for those assessed with high risk.|Treatment as usual for high risk group
214912631|NCT01964482|OTHER|Strength training|Strength training followed by intake of a protein drink
214912632|NCT02185118|DRUG|oxygen|"1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
214912633|NCT02185118|DRUG|Sevoflurane|"1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
214912634|NCT02185118|DRUG|Isoflurane|"1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
214912635|NCT06237738|BEHAVIORAL|Stress Ball Use|The intervention in this study involves the use of stress balls provided to participants in the intervention group. These are specially designed medium-firm silicone balls intended for squeezing with the hand opposite the one receiving cannulation during hemodialysis sessions. The primary objective of this intervention is to offer a simple, non-pharmacological method to potentially alleviate the pain associated with the cannulation process. Participants are instructed to use the stress ball for a period of three minutes before the start of cannulation. This activity is hypothesized to focus the participant's attention and possibly reduce the perception of pain, contributing to a more comfortable and less distressing cannulation experience.
214912636|NCT03809338|DIAGNOSTIC_TEST|amh test|Antral follicle count with ultrasound on the 3rd day of menstruation
214912637|NCT05326529|OTHER|Hospital Based Cardiac Rehabilitation Exercise Classes|Participants will attend 8 Hospital based CR exercise sessions. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
215059005|NCT00705770|DRUG|Anecortave Acetate|"Low dose~Sustained release depot suspension"
215059006|NCT00705770|DRUG|Anecortave Acetate|"Middle dose~Sustained release depot suspension"
215059007|NCT00705770|DRUG|Anecortave Acetate|"High dose~Sustained release depot suspension"
215059008|NCT00705770|DRUG|Placebo|Placebo treatment with vehicle
215059009|NCT01222819|DRUG|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
215059010|NCT04855240|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
214346953|NCT04695171|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
214479590|NCT06868810|OTHER|Injection of hypertonic saline|Injection 10 mL of 10% NaCl through central venous catheter
215059011|NCT04855240|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
215059012|NCT04855240|DRUG|Placebo|Oral dose of placebo
215059013|NCT02385903|OTHER|Flammacerium|
215059014|NCT02385903|OTHER|Standard dressing procedure|
215059015|NCT03450239|OTHER|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
215059016|NCT04014894|DRUG|ET019003-T Cells|Fludarabine 25 mg/day on day -5, -4 and -3; Cyclophosphamide 250 or 300 mg/day on day -5, -4 and -3; ET019003-T Cells on day 0.
215059017|NCT01537471|DRUG|Placebo|Placebo
215059018|NCT01537471|DRUG|Meclizine|Meclizine 12.5 mg
215059019|NCT01537471|DRUG|Meclizine|Meclizine 25 mg
215059020|NCT01321853|OTHER|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
215059021|NCT01321853|OTHER|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
215059022|NCT03409952|DEVICE|LaseMD and DUAL 1927nm Laser|Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
215059023|NCT03409952|DEVICE|LaseMD|Laser treatment of benign pigmented lesion using optimized treatment settings.
215059024|NCT02955108|PROCEDURE|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
214346954|NCT04695171|PROCEDURE|Fundoplication|A surgical procedure where the fundus of the stomach is wrapped around and sutured to the distal esophagus to restore the function of the lower esophageal sphincter in limiting stomach contents from refluxing into the esophagus.
214479591|NCT06868810|OTHER|Injection of 5% NaHCO3|Injection of 5% NaHCO3 through central venous catheter
214912638|NCT05326529|OTHER|Web-based Cardiac Rehabilitation Exercise Sessions|Participants will complete 8 weeks of Web-based CR exercise sessions using the MyHeart app. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
214912639|NCT03160690|PROCEDURE|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy for open angle glaucoma
214912640|NCT05563779|OTHER|Volume Control mode|Volume Control mode for mechanical ventilation
214912641|NCT05563779|OTHER|Pressure Control mode|Pressure Control mode for mechanical ventilation
214912642|NCT05563779|OTHER|Adaptive Pressure Control mode|Adaptive Pressure Control mode for mechanical ventilation
214912643|NCT02084043|DRUG|Nebulization of Amikacin during NIV (RR: 15 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
214912644|NCT02084043|DRUG|Nebulization of Amikacin during NIV (RR: 25 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
214912645|NCT01594736|DRUG|ORSIRO|due randomization ORSIRO will be implanted
214912646|NCT01594736|DEVICE|XIENCE PRIME DES|due randomization XIENCE PRIME DES will be implanted
214912647|NCT02590549|PROCEDURE|Corneal Collagen Crosslinking|"Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes.~After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,"
214912648|NCT02590549|DEVICE|Ufalink|UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation
214912649|NCT02909335|DRUG|Tacrolimus|"Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~* between 6 and 10 ng / ml during the first 2 months,~* between 5 and 8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
214912650|NCT02909335|DRUG|Everolimus|"Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~* between 6 and 10 ng / ml during the first 2 months,~* between 5-8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
214912651|NCT02909335|DRUG|Mycophenolate mofetil|mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
214912652|NCT02909335|DRUG|Prednisolone, Prednisone or Methylprednisolone|Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
214912653|NCT00427102|DRUG|Oral MRX-1024|
215059025|NCT02955108|PROCEDURE|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
215059026|NCT02840305|OTHER|Evaluation of visual function|
215059027|NCT02840305|OTHER|Magnetic Resonance Imaging|
215059028|NCT03472495|DRUG|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)
215059029|NCT03472495|DRUG|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
215059030|NCT05521347|BEHAVIORAL|caffeine|we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.
215059031|NCT04148703|OTHER|Follow up post Pacemaker implantation in office|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up
215059032|NCT04148703|OTHER|Follow up post Pacemaker implantation by home monitoring|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
214912654|NCT00427102|PROCEDURE|Standard Fractionation Radiation Therapy|
215059033|NCT04671563|DRUG|Tenofovir Disoproxil Fumarate 300 MG|One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
214303863|NCT07190404|BEHAVIORAL|Cognitive (Process) Training|This treatment is functional task training, a widely-used approach in neurorehabilitation153,154 that parallels the cognitive training used in PD to-date but with functional cognitive tasks (vs. computer or paper \& pencil tasks) to improve ecological validity. It has the same structure within and across treatment sessions and uses the same treatment activities as the MC intervention. However, the OT does not use mediated learning techniques or explicitly address strategies, metacognition, or transfer/generalization. Rather, participants practice functional cognitive tasks with knowledge of results feedback and cueing by the OT to improve task performance.
214912655|NCT00427102|DRUG|High-Dose Cisplatin Chemotherapy|
214912656|NCT04384575|DIAGNOSTIC_TEST|blind spots|missed part during map the entire stomach through endoscopy
214912657|NCT01534442|DRUG|Atropine|1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
214912658|NCT01534442|DRUG|Placebo|
214912659|NCT01379768|DEVICE|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
214912660|NCT01379768|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
214912661|NCT01379768|DEVICE|Clear Care Cleaning and Disinfection Solution|Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
214912662|NCT05576272|DRUG|QL1706|5 mg/kg#D1#Q3W IV, 4-6 cycles
214912663|NCT05576272|DRUG|Carrelizumab|200mg#D1#Q3W IV, 4-6 cycles
214912664|NCT05576272|DRUG|Gemcitabine|1000mg/m2#D1\&D8#Q3W IV, 4-6 cycles
214912665|NCT05576272|DRUG|Cisplatin|80mg/m2#D1#Q3W IV, 4-6 cycles
214912666|NCT05416580|DRUG|UDCA (Ursodeoxycholic acid)|UDCA is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
214912667|NCT05416580|DRUG|Placebo|Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
214912668|NCT05416580|DRUG|Metformin|Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.
214912669|NCT01513720|DRUG|Lamotrigine|Lamotrigine Tablets 200 mg
214912670|NCT01513720|DRUG|Lamictal®|Lamictal® 200 mg Tablets
214912671|NCT03748173|COMBINATION_PRODUCT|Aerosolized Infasurf|Infants randomized to aerosol treatment will receive Infasurf® aerosol at a rate of 12 ml/hour (the maximal rate using the Solaris CAG). The initial treatment will be for 60 minutes, with reevaluation every 30 minutes thereafter, with a maximum dose of 6 mL/Kg body weight or 2 hours of aerosolization. Treatment will be stopped after 60 minutes (and subsequently at 30-minute intervals) if a 2 point reduction in bronchiolitis score or a score ≤ 4 is achieved. Treatment will also be stopped at any time should there be evidence of other-than-transient deterioration in oxygenation or clinical status or for any serious adverse effect deemed by the infant's clinician to be possibly related to the drug administration.
215059034|NCT04074083|BEHAVIORAL|electronic IMCI|Participants will be trained to use an electronic version of the Integrated Management of Childhood Illness (IMCI) guidelines
215059035|NCT04074083|BEHAVIORAL|paper IMCI|Participants will be trained to use routine paper version of Integrated Management of Childhood Illness (IMCI) guidelines
215059036|NCT05147532|PROCEDURE|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
215059037|NCT02188940|BEHAVIORAL|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
215059038|NCT02188940|BEHAVIORAL|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
214346955|NCT06961539|OTHER|The group with virtual visits|"On the first day after open-heart surgery in the intensive care unit, in addition to face-to-face visits, video calls were made through the researcher's phone in the morning and evening."
214912672|NCT02497560|DIETARY_SUPPLEMENT|proprietary formula|
214912673|NCT03349073|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
214912674|NCT04452214|DRUG|CAN04|Administered intravenously
214912675|NCT04452214|DRUG|Pembrolizumab|Administered intravenously
214912676|NCT04452214|DRUG|Carboplatin|Administered intravenously
214912677|NCT04452214|DRUG|Pemetrexed|Administered intravenously
214912678|NCT03132857|OTHER|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.
214912679|NCT01135329|DRUG|Fludarabine|30 mg/m\^2 IV daily on Day -6 through Day -2.
214912680|NCT01135329|DRUG|Busulfan|1 mg/kg PO OR 0.8 mg/kg IV four times daily on Day -6 through Day -3.
214912681|NCT01135329|DRUG|Cyclophosphamide|50 mg/kg IV daily on Day +3 and Day +4.
214912682|NCT01135329|DRUG|Mycophenolate Mofetil|15 mg/kg PO three times daily (max daily dose of 3g) starting on Day +5.
214912683|NCT01135329|DRUG|Tacrolimus|Dosed based on drug levels; begin on Day +5 at 1 mg IV daily.
214912684|NCT00781040|OTHER|Severe sepsis vs. non-severe sepsis|To compare these two groups
214912685|NCT03740087|OTHER|Omnivorous diet|Determine if the transfer of bovine miRNAs is carried out after a meal containing beef.
214912686|NCT03740087|OTHER|Vegan diet|Used as a baseline for miRNA levels in blood
214912687|NCT02030340|PROCEDURE|lower urinary tract dysfunction|Urodynamic investigation with a double (two systems: air-charged and water filled) catheter system
214912688|NCT03417557|DEVICE|Comfilcon A lens (test)|contact lens
214912689|NCT03417557|DEVICE|Omafilcon B lens (control)|contact lens
214912690|NCT00114439|DRUG|Lithium carbonate|
214912691|NCT00168363|DRUG|brimonidine|
214912692|NCT01475708|DRUG|Doxycycline|100 mg PO bid, 14 days
214912693|NCT04490512|BIOLOGICAL|FluBHPVE6E7|Multiple subcutaneous, intradermal or intramuscular administrations
214912694|NCT04955314|OTHER|PA vertebral mobilization|A PA mobilization is a technique in which one vertebra slides over another due to a force applied with the hands of the physiotherapist
214912695|NCT01762436|DRUG|bisoprolol|
214912696|NCT01762436|DRUG|atenolol|
214912697|NCT05203796|DEVICE|Transcutaneous pulsed electrical stimulation (NuEyne 02)|Arm 1: Experimental: Experimental group: Dry eye disease patients (n=12) Device: Pulse Electrical Stimulation Pulse Electrical Stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
214912698|NCT05203796|DEVICE|Sham stimulation|Arm 2: Sham Comparator: Comparison group: Dry eye disease patients (n=12) Device: Sham stimulation Sham stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
214912699|NCT01295671|BEHAVIORAL|Provision of beverages|Home delivery of specified beverage type
214912700|NCT03743805|DRUG|Flumazenil|0.2 mg IV push, which may be repeated every 20 minutes for up to a total of 1 mg
214912701|NCT03743805|DRUG|Naloxone|0.4 mg IV push, which may be repeated every 2 minutes for up to a total of 2 mg
214912702|NCT00058656|PROCEDURE|Infusion of Activated & Expanded Autologous T Cells|
214912703|NCT06328556|DRUG|botulinum toxin type A|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use.
215059039|NCT02188940|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
214912704|NCT06328556|PROCEDURE|Injection|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
214912705|NCT05445414|DEVICE|"SteWARdS Antibiotic Defense app"|"The SteWARdS Antibiotic Defense app is an evidence-based serious game app developed by the study team. The app uses gamification theories to increase user engagement and to deliver bite-sized information to participants. For example, players will learn about the uses of antibiotics through the messages delivered through the game and the cost of tackling antibiotic-resistant infections through purchasing an expensive antibiotic with the virtual currency earned from the games."
214912706|NCT01232413|DRUG|Placebo|Oral
214912707|NCT01232413|DRUG|ASP1941|Oral
214912708|NCT01232413|DRUG|Moxifloxacin|Oral
214912709|NCT02774330|OTHER|Policy|This local policy change (i.e., the Minneapolis Staple Foods Ordinance) establishes minimum stocking criteria for a wide array of healthy foods as a requirement of food store licensing. To our knowledge, it is the first and only policy of its kind in the U.S. This Staple Foods Ordinance requires stores to stock specific types of foods in minimum quantities and varieties, including fruits and vegetables, low-fat dairy, and whole grains. A full list of all requirements can be found online through the City of Minneapolis: http://www.minneapolismn.gov/health/living/eating/staple-foods.
214912710|NCT03558763|DEVICE|Telemonitoring|During the telemonitoring treatment period the subjects will register; vital functions (blood pressure, heart rate, weight, SpO2) twice a week, physical movement daily by using a fitness device, have video calls with a nurse weekly the first 4 weeks and thereafter every fourth week the last 5 months. Twice a week (± 2 days) questionnaires (CAT and MRC) should be filled out at home.
214912711|NCT03558763|OTHER|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
214346956|NCT03877718|DRUG|Arm 1: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)
214346957|NCT03877718|DRUG|Arm 2: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
214912712|NCT03030560|DRUG|Lidocaine|patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.
214912713|NCT03030560|DRUG|0.9% Sodium-chloride|patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.
214912714|NCT00708552|DRUG|SB-742457|investigational drug
214912715|NCT00708552|DRUG|Donepezil|comparator
214912716|NCT00708552|DRUG|Placebo|comparator
214912717|NCT02528006|DEVICE|Type 2 Thyroplasty using Titanium Bridges|
214912718|NCT00616343|DRUG|Zonisamide|100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
214912719|NCT04664023|PROCEDURE|Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
214670194|NCT05823506|DRUG|PDE5 inhibitor (tadalafil)|Tadalafil improves erectile function by inhibiting PDE5 isoenzyme, thereby blocking cGMP degradation. As a result, the PDE5 inhibitors act synergistically with NO to markedly increase the levels of cGMP, which in the presence of sexual stimulation, lead to an erection. In the absence of sexual stimulation, NO is not released locally and the PDE5 inhibitors do not affect the penis. Thus, sexual stimulation is needed to initiate the erectile mechanism for the PDE5 inhibitors to take effect.
214670195|NCT00122499|DRUG|tadalafil|
214912720|NCT04664023|PROCEDURE|Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
214912721|NCT00675012|DRUG|NGR-hTNF|iv 0.8 or 45 mcg/sqm q3W
214912722|NCT00675012|DRUG|Oxaliplatin|iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion
214912723|NCT00675012|DRUG|capecitabine|orally 825 mg/sqm 2qDx14
214912724|NCT01257113|OTHER|supervised exercise|This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
214912725|NCT01257113|OTHER|homebased exercises|This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
214912726|NCT01702285|DRUG|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
214912727|NCT01561326|BEHAVIORAL|Cognitive-affective barriers counseling|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
214912728|NCT01561326|BEHAVIORAL|Cognitive-affective barriers counseling via brochure|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence via brochure, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
214912729|NCT01561326|BEHAVIORAL|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
214912730|NCT00707681|DRUG|MS-20|4 ml/vial
214912731|NCT00707681|DRUG|Placebo|4ml/vial
214912732|NCT00032149|BIOLOGICAL|bleomycin sulfate|
214912733|NCT00032149|BIOLOGICAL|filgrastim|
214912734|NCT00032149|DRUG|cyclophosphamide|
214912735|NCT00032149|DRUG|etoposide|
214912736|NCT00032149|DRUG|mitoxantrone hydrochloride|
214912737|NCT00032149|DRUG|prednisolone|
214912738|NCT00032149|DRUG|vincristine sulfate|
214912739|NCT03643601|OTHER|Non-Interventional|Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs
214912740|NCT05924191|DEVICE|Photobiomodulation|Intra-oral irradiations wll be performed with a low intensity Laser device at 4 anatomical points, with a wavelength of 660 nm. The extraoral FBM will be applied with 1 cluster (20cm2) with a wavelength of 630nm. Subsequently, the same region will be irradiated with the same cluster, using the 4 LEDs with a wavelength of 850 nm 1 hour before performing the surgery.
214912741|NCT05924191|DRUG|Placebo Corticosteroid|Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
214303864|NCT07190404|BEHAVIORAL|MC Approach Booster Session|MC+B participants will come from the MC Approach group only. They will receive 2 additional treatment sessions with their original OT within the month following their 6mo FU assessment. The OT will review the participant's relevant Post and FU data beforehand for treatment planning purposes. The first session will involve a review of goals, prior learning, and strategies and discussion of successes/challenges related to functional cognitive performance and strategy application since initial treatment. Then the same protocol (treatment activities with metacognitive framework and mediation, strategy bridging discussions, homework action planning and review) will be followed for the rest of the booster treatment to reinforce or re-activate prior learning, address new concerns, and develop supports for maintenance.
214303865|NCT07191249|DRUG|Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.|In this study, Mosunetuzumab will be administered subcutaneously over 8 treatment cycles: 5 mg on Day 1 of Cycle 1, followed by 45 mg in all subsequent cycles.
214346958|NCT03877718|DRUG|Arm 3: Sumatriptan Succinate 100 mg capsule|One capsule of sumatriptan succinate 100 mg
214346959|NCT03877718|DRUG|Arm 4: Promethazine HCl 18.75 mg|One capsule of promethazine HCl 18.75 mg
214346960|NCT03877718|DRUG|Arm 5: Promethazine HCl 37.5 mg|One capsule of promethazine HCl 37.5 mg
214346961|NCT03877718|OTHER|Placebo|One capsule of placebo
214670196|NCT03498872|DEVICE|AMPfoot 4.0|The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.
214670197|NCT03498872|OTHER|No intervention|The control group included healthy subjects. Comparisons were made between amputees and able-bodied individuals.
214670198|NCT00234117|DRUG|Rabeprazole|
214912742|NCT05924191|DEVICE|Simulation Photobiomodulation|The irradiation simulations will be practiced in the same anatomical points described in the experimental group. This protocol will be carried out 1 hour before the surgical procedure (Baseline). The Laser device will be disconnected and its beep sound will be recorded and run on simulating the irradiation.
214912743|NCT05924191|DRUG|Corticosteroid|The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
214912744|NCT04163133|PROCEDURE|two days later trigger than regular timing|During ovarian stimulation, two days later of trigger after three follicles reach 17mm bilateral with contineous using of Gonadotrophin in antagonist protocol.
214912745|NCT02418390|PROCEDURE|prophylactic central lymph node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
214912746|NCT01317095|DEVICE|Sternalock Rigid Fixation|Patients will have their sternum closed by rigid fixation using Sternalock plates.
214912747|NCT02965001|DRUG|68Ga-NOTA-AE105|The patients are refered to an uPAR-PET/CT scan before initiation of the routine radiotherapy and the prognostic efficacy is assessed by registration of recurrence rate and death at routine clinical follow-up.
214912748|NCT03168711|DRUG|Inosine|Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.
214912749|NCT03168711|DRUG|Placebo|Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
214912750|NCT01761604|DEVICE|Nasal ganglion block for TN|
214912751|NCT05999201|OTHER|craniocervical neural mobilization|the patients will receive The craniocervical neural mobilization in the form of passive craniocervical flexion in which An anterior rotation of the head will be done which stimulates the meninges.To increase mechanical stress in the nervous system, patients will be asked to do a descent and retropulsion of the shoulders while gradually extending both elbows. in addition to Passive lateral cervical sliding and Craniocervical flexion with mouth opening.The neural mobilization should be mild, progressive, and slow. The protocol lasted 15 minutes and also the patients will receive selected physiotherapy program
214912752|NCT05999201|OTHER|selected physiotherapy program|the patients will receive selected physiotherapy program in the form of Suboccibital muscles inhibition suboccipital inhibition technique (SIT), from supine lying position, the therapist will sit at the patient's head head with the elbows rested on the surface of the table. Then, the therapist will place both hands behind the head of the patient with the palms facing upwards, the fingers flexed, and the finger pads positioned on the posterior arch of the atlas to allow the occiput to rest in the palm of the hands. the patients will receive also trigger point release technique in the form of An ischemic compression for sternocleidomastoid muscle, temporal muscle, upper trapezius muscle and splines muscles
214912753|NCT06575504|DIAGNOSTIC_TEST|Ultrasonographical examination|Study size and Doppler / blood flow / of the suprarenal gland
215059040|NCT02188940|OTHER|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
214479592|NCT06869863|BIOLOGICAL|Medicinal product MediReg® (Human Mesenchymal Stromal Cell Secretome), lyophilizate for preparation of solution for injection in patients with severe spermatogenesis disorders|Human mesenchymal stromal cell secretion1 containing vascular endothelial growth factor (VEGF)2 ≥ 5,0 нг
214670199|NCT00281411|PROCEDURE|Computed Tomography Angiography|Computed Tomography Angiography
214670200|NCT00281411|PROCEDURE|Magnetic Resonance Angiography|Magnetic Resonance Angiography
214670201|NCT01463852|DRUG|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
214670202|NCT01196910|DEVICE|treatment by HLPFC coil|"DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase."
214303866|NCT07191301|BEHAVIORAL|Functional Strength Training, Kinesio Taping, and Proprioceptive Neuromuscular Facilitation|Participants will undergo 8 weeks of supervised treatment, 3 sessions per week (24 sessions). Each session includes a warm-up with stretches, range-of-motion exercises, and Functional Strength Training (mini hops, stair climbing, ramp walking, sit-to-stand). Kinesio Taping will be applied from the foot's dorsum along the tibialis anterior and peroneus longus with 25-50% stretch for ankle support and dorsiflexor facilitation, re-applied every 3-4 days. In addition, Proprioceptive Neuromuscular Facilitation (PNF) lower-limb D1 flexion/extension patterns with manual resistance will be performed in 3 sets of 5 repetitions, lasting 35-40 minutes per session.
214479593|NCT06869863|OTHER|Clostilbegit (clomiphene) 50 mg 1 tablet x 1 p a day - 3 months, Triovit - 1 tablet x 1 p a day - 3 months, Folic acid - 1 tablet x 1 p a day - 3 months.|Combination treatment recommended by standards
214479594|NCT03022071|OTHER|Cognitive behavior therapy|In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.
214670203|NCT04724486|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
214670204|NCT04724486|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
214670205|NCT04724486|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
214912754|NCT02861105|DRUG|LMWH|LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
214912755|NCT02861105|OTHER|0.9% saline solution|0.9% saline solution will be given subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
214912756|NCT03136237|DRUG|BCX7353|Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3
214670206|NCT04724486|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
214912757|NCT03136237|DRUG|Digoxin|Day 1 of Cohort 1
215059041|NCT02188940|OTHER|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~\*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
214912758|NCT03136237|DRUG|BCX7353 + digoxin|Day 19 of Cohort 1
214912759|NCT03136237|DRUG|Rosuvastatin|Day 1 of Cohort 2
214912760|NCT03136237|DRUG|rosuvastatin + BCX7353|Day 15 of Cohort 1
215059042|NCT01813201|DRUG|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
215059043|NCT01813201|DRUG|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
215059044|NCT02136004|DEVICE|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
214912761|NCT03136237|DRUG|Cyclosporine + BCX7353|Day 14 of Cohort 3
214303867|NCT07191301|BEHAVIORAL|Functional Strength Training and Kinesio Taping|Participants will undergo 8 weeks of supervised treatment, 3 sessions per week (24 sessions). Each session includes a warm-up with stretches, range-of-motion exercises, and Functional Strength Training (mini hops, stair climbing, ramp walking, sit-to-stand). Kinesio Taping will be applied from the foot's dorsum along the tibialis anterior and peroneus longus with 25-50% stretch for ankle support and dorsiflexor facilitation, re-applied every 3-4 days. No PNF techniques will be applied.
214303868|NCT07189884|DRUG|Pyrotinib Maleate Tablets + Dalpiciclib Isethionate Tablets + Standard Endocrine|"Pyrotinib Maleate Tablets: 320 mg/day administered continuously from the first day of the first course of treatment, orally within 30 minutes after breakfast, missed doses without refill, every 21 days as a cycle.~Dalpiciclib Isethionate Tablets: 125 mg orally every 28 days as a treatment cycle, with continuous medication for the first 3 weeks (Day 1 to Day 21), and rest (no medication) for the next 1 week (Day 22 to Day 28).~Endocrine therapy: The endocrine therapy drug is selected by the investigator."
214303869|NCT07190846|OTHER|No Intervention (Observational Echocardiographic Evaluation)|This is an observational study. No therapeutic intervention is administered. Participants undergo standard echocardiographic assessment of left ventricular diastolic function during pregnancy.
214303870|NCT07189988|OTHER|psilocybin|All study participants were provided low dose psilocybin.
214670207|NCT00744055|DRUG|Prazosin|prazosin (16mg/day) 2 times a day
214912762|NCT06142487|OTHER|Silk Pillowcase|100% Mulberry Silk Pillowcase
214912763|NCT06142487|OTHER|Cotton Pillowcase|100% Cotton Pillowcase
214912764|NCT01609010|DRUG|rituximab|375 mg/m2 rituximab i.v. weekly for 4 weeks
214912765|NCT01609010|DRUG|interferon-a-2a|3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
214912766|NCT02110303|DRUG|Ticagrelor|oral, 90mg tablets, twice daily, 12 month duration
214912767|NCT02110303|DRUG|Placebo|Oral tablet (identical to ticagrelor), twice daily, 12 month duration
214912768|NCT05361577|DEVICE|Exoplulse Mollii suit|Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
214912769|NCT05361577|DEVICE|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
215059045|NCT01107392|DRUG|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
215059046|NCT01107392|DRUG|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
214670208|NCT00744055|DRUG|Placebo|Placebo
214670209|NCT02565823|OTHER|Exercise bout|Participants will exercise for 45min at 75% of VO2peak
214912770|NCT01450215|DRUG|Revlimid|Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .
214912771|NCT00126256|DRUG|5-fluorouracil|
214912772|NCT00126256|DRUG|leucovorin|
214912773|NCT00126256|DRUG|irinotecan|
214912774|NCT00126256|DRUG|oxaliplatin|
214912775|NCT02529046|DIETARY_SUPPLEMENT|CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
214912776|NCT02529046|BEHAVIORAL|Placebo|Placebo group received 4 g/day of olive oil. Aerobic exercise
214912777|NCT01542489|DRUG|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
214912778|NCT01542489|DRUG|insulin aspart|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
215059047|NCT04168164|OTHER|aquatic therapy|The exercises of Ai Chi were performed in a specific order, until completion of the total possible movements.
215059048|NCT04168164|OTHER|Dry land therapy|sessions including exercises for gait, trunk mobility and exercises involving the upper and lower limbs
215059049|NCT04168164|OTHER|Combined therapy|alternate sessions of therapy on dry land and aquatic therapy with Ai Chi
215059050|NCT03952767|OTHER|Digital Physical Measures and Survey Assessments|Data from at home and in clinic visits will assess physical function and survey data will be collected
215059051|NCT01539070|BEHAVIORAL|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
215059052|NCT02408679|PROCEDURE|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
215059053|NCT02408679|OTHER|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
214303871|NCT07189611|BEHAVIORAL|A blended online and offline teaching model for internal medicine nursing practice based on generative artificial intelligence|This study will employ a convergent mixed-methods design. Participants will be convenience-sampled undergraduate nursing students from the 2024 cohort (intervention group) and the 2023 cohort (control group) at Changsha Medical University. The intervention group will experience the new blended model, which includes: 1) Optimizing a GAI-assisted clinical case library with progressive scenarios; 2) Utilizing online resources (Learning Terminal platform, virtual simulation experiments with an AI assistant); 3) Engaging in offline interactive sessions (card-based desktop deduction games and scenario simulations). The control group will receive traditional teaching methods. Quantitative data will include course scores (theoretical knowledge and practical skills) and teaching satisfaction questionnaires. Qualitative data will be collected via semi-structured interviews to explore students' experiences deeply.
214912779|NCT01542489|DRUG|human soluble insulin|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
214912780|NCT01202578|DEVICE|tympanostomy tube|tympanostomy tube delivery system
214912781|NCT00070720|BEHAVIORAL|Opinion Leaders, Academic Detailing, Reminders, and Feedback|
214912782|NCT06045455|DIAGNOSTIC_TEST|Multimodal brain CT|Multimodal brain CT includes NCCT, CTP, and CTA
214912783|NCT06045455|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI examination will be performed between the 3rd and 7th day after the admission to the hospital
214912784|NCT02463929|DRUG|Diphenhydramine|Intravenous Injection
214912785|NCT02463929|DRUG|normal saline|Intravenous Injection
214912786|NCT02463929|DRUG|Ketamine|Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation
214912787|NCT02463929|DRUG|Sevoflurane|Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent
214912788|NCT02463929|DRUG|Bupivacaine|Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
214912789|NCT04793009|DEVICE|funnel-shaped, intraperitoneal mesh placement|Implantation of a prophylactic, 3D funnel-shaped, intraperitoneal, non-absorbable and synthetic mesh (Dyna Mesh IPST 2x15x15 cm™ and 3x16x16 cm™, FEG Textiltechnik, Aachen, Germany,)
215059054|NCT03495141|BEHAVIORAL|Supervision/Coaching|Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
215059055|NCT04171908|OTHER|Conventional therapy|Conventional Physical therapy for the upper limb
215059056|NCT04171908|OTHER|semi-inversive tech|Conventional Physical therapy for the upper limb plus Semi-inversive tech
215059057|NCT02998671|BIOLOGICAL|CJM112|
215059058|NCT02998671|OTHER|Placebo|
215059059|NCT04560686|DRUG|Bintrafusp Alfa|Given IV
215059060|NCT04560686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
215059061|NCT02038946|DRUG|Nivolumab|
214303872|NCT07189871|DRUG|177Lu-BetaBart|BetaBart administered by intravenous (IV) infusion every 6 weeks
214303873|NCT07190989|DIETARY_SUPPLEMENT|Nutritional Supplement|A mixed juice containing 15000 mg cherry juice concentrate, 220 mg cherry extract, 250 mg cocoa extract, 200 mg of tryptophan, 100 mg of L-5-Hydroxytryptophan, 3000 mg of glycine, 300 mg of magnesium, 200 mg of theanine manufactured by Science in Sport (https://sport.wetestyoutrust.com/supplement-search/science-sport/rest-juice).
214303874|NCT07190989|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|A 40g dual-source carbohydrate gel, having a 1:0.8 ratio of maltodextrin and fructose manufactured by Science in Sport (https://sport.wetestyoutrust.com/supplement-search/science-sport/beta-fuel-dual-source-energy-gel-beta-fuel-maltodextrin-fructose).
214303875|NCT07191314|DEVICE|nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device|The NPA-OSA is a flexible, medical-grade silicone, tube-like device that is self-inserted into the user's nasopharyngeal airway through one nostril prior to sleep and worn throughout the night to reduce or alleviate snoring and obstructive sleep apnea.
214303876|NCT04689048|DRUG|18F fluciclovine|Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
214303877|NCT02650401|DRUG|Entrectinib|TRKA/B/C, ROS1, and ALK inhibitor
214303878|NCT00075166|PROCEDURE|Stereotactic surgery (SRS)|
214303879|NCT00075166|PROCEDURE|Craniotomy|
214303880|NCT04282252|DRUG|I.V. SOLUTIONS|All i.v. fluids used in an Intensive Care Unit.
214303881|NCT02410382|DRUG|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
214303882|NCT02410382|DRUG|Placebo|oral placebo
214303883|NCT03012100|DRUG|Cyclophosphamide|Given PO
214303884|NCT03012100|OTHER|Laboratory Biomarker Analysis|Correlative studies
214303885|NCT03012100|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
214303886|NCT03012100|OTHER|Placebo Administration|Given ID
214479595|NCT06671730|BEHAVIORAL|8-Week Telehealth-based Occupational Therapy Program|The telehealth-based OT program will be grounded in SDT. The program will be designed to help BC survivors transition from recovery after surgery to achieving levels of aerobic PA and MSE that are recommended according to each participants' specific treatment course and desired outcomes. Participants will engage in eight once-weekly OT sessions with a licensed occupational therapist via Zoom-lasting for up to about an hour. Each session will teach psychoeducational and skill-building techniques that support decreasing functional limitations associated with BC and BC treatment as well as improving behavioral skill sets necessary for maintenance of aerobic PA and MSE. Participants will receive study-provided exercise equipment and a fitness tracker (Fitbit Charge 6) for use engaging in greater amounts of aerobic PA and MSE (keeping these materials post-study)
214479596|NCT03649971|DRUG|Guselkumab|Guselkumab SC will be administered every 4 weeks.
214479597|NCT03649971|DRUG|Placebo|Placebo SC will be administered every 4 weeks.
214912790|NCT05977660|DIAGNOSTIC_TEST|Cumberland ankle instability tool for diagnose to determine ankle instability and its severity|CAIT is a Patient-reported measures of outcome (PROM) and it is very simple, reliable, and valid measurement tool that is used without comparing with the contralateral ankle, which consists of 9 questions and is scored between 0 and 30, developed by Hiller and her colleagues in 2006 to measure the severity of functional ankle instability. Low scores of the participants indicate poor ankle stability, while high scores indicate good ankle stability.
214912791|NCT02209051|OTHER|AMNIOEXCEL|Application of AMNIOEXCEL every 1-2 weeks for a period of 6 weeks or until wound closure, whichever is sooner.
214303887|NCT03012100|BIOLOGICAL|Sargramostim|Given ID
214303888|NCT00702403|DRUG|nilotinib|Given PO
214303889|NCT00702403|DRUG|imatinib mesylate|Given PO
214303890|NCT00702403|OTHER|pharmacological study|Correlative studies
214303891|NCT05546684|OTHER|footbath|footbath for patients before sleeping
214303892|NCT00102674|DRUG|cangrelor|
214303893|NCT04612647|OTHER|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)
214303894|NCT04612647|BEHAVIORAL|Physical Activities & Activity Booklets|expected to engage in physical activity at least 3 hours per week
214303895|NCT02916615|OTHER|High nitrate vegetables|vegetables naturally high in nitrate
214479598|NCT05907616|BEHAVIORAL|Produce purchase incentive|Participants will be provided with a specific incentive amount per month for 10 months to purchase produce, nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
214479599|NCT02911805|BEHAVIORAL|Aerobic exercise|Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
214479600|NCT02911805|BEHAVIORAL|Balance exercise|Instructor-led exercises done in a group setting for strengthening, balance, flexibility
214670210|NCT00623155|DRUG|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
214912792|NCT02209051|OTHER|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure
214912793|NCT00143442|DRUG|[S,S]-Reboxetine|
214303896|NCT02916615|DIETARY_SUPPLEMENT|Low nitrate vegetables + nitrate|pill containing KNO3
214303897|NCT02916615|OTHER|Low nitrate vegetables|vegetables naturally low in nitrate
214303898|NCT02577237|BEHAVIORAL|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
214303899|NCT02577237|BEHAVIORAL|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
214912794|NCT06146465|OTHER|speciality|Not
214303900|NCT02577237|OTHER|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
214303901|NCT02577237|OTHER|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
214670211|NCT01009775|DRUG|YM155|intravenous infusion
214670212|NCT01009775|DRUG|Docetaxel|intravenous infusion
214912795|NCT03104140|DRUG|Ketamine|After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
214912796|NCT03104140|DRUG|Thiopental|After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
214912797|NCT00238472|DRUG|nateglinide|
215059062|NCT05653401|DRUG|Magnesium sulfate and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
215059063|NCT05653401|DRUG|Lidocain and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
215059064|NCT05653401|DRUG|Placebo and diclofenac|Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
215059065|NCT01864681|DRUG|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
215059066|NCT01864681|DRUG|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
214303902|NCT03257553|DIAGNOSTIC_TEST|fecal calprotectin , doppler and ultrasound|faecal sample for measurement of calprotectin level ultrasound and doppler
214670213|NCT02767570|OTHER|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.
214912798|NCT05031312|PROCEDURE|inferior oblique weakening|inferior oblique myectomy versus inferior oblique anterior nasal transposition in superior oblique palsy treatment
214912799|NCT00808210|DRUG|Infliximab|Intravenous repeating dose
215059067|NCT01211977|DRUG|XOMA 052|
215059068|NCT05631314|PROCEDURE|operative treatment|Operative treatment can consist of open reduction and volar and/or dorsal plating or closed reduction and fixation with K-wires, external fixateur.
215059069|NCT05631314|PROCEDURE|non-operative treatment|Non-operative treatment will consist of immobilization in a below the elbow cast for 4-6 weeks with or without prior closed reduction.
214303903|NCT05798572|DRUG|Sildosin group|Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.
215059070|NCT01013324|DRUG|XL147 (SAR245408)|dosed as capsules taken orally daily
214303904|NCT05798572|PROCEDURE|Placebo/control group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
214303905|NCT05094934|DRUG|NNC0385-0434 A 100 mg|All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
214670214|NCT02767570|OTHER|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
214670215|NCT06574269|DRUG|TLC590|Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590
214670216|NCT06574269|DRUG|TLC590|TLC590 Dose 1
214670217|NCT06574269|DRUG|TLC590|TLC590 Dose 2
214670218|NCT06574269|DRUG|TLC590|The MTD of TLC590
214670219|NCT06574269|DRUG|TLC590|TLC590 Dose 3 (The SMC-suggested dose)
214670220|NCT06574269|DRUG|Ropivacaine|Ropivacaine
214670221|NCT06574269|DRUG|TLC590|TLC590
214670222|NCT05327478|PROCEDURE|NRP|Normothermic Regional Perfusion
214670223|NCT05327478|PROCEDURE|DHOPE|Dual Hypothermic Oxygenated Perfusion
214670224|NCT05327478|PROCEDURE|COR-NMP|Controlled Oxygenated Rewarming Normothermic Machine Perfusion
214670225|NCT00151411|DRUG|Metformin|Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
214912800|NCT00808210|DRUG|Methotrexate|Oral or parenteral repeating dose
214912801|NCT00808210|DRUG|Methylprednisolone|Intravenous repeating dose
214912802|NCT00808210|DRUG|Ocrelizumab|Intravenous repeating dose
215059071|NCT02272036|PROCEDURE|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
215059072|NCT02272036|DEVICE|mobile phone|SMS received by mobile phone
215059073|NCT04628702|BEHAVIORAL|tablet training|1.5 year training period
215059074|NCT01301053|OTHER|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
215059075|NCT01301053|OTHER|"Current UVA intensive care insulin protocol with brakes"|"Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose \<70 mg/dl)and severe hypoglycemia (blood glucose\<50 mg/dl)."
215059076|NCT03456258|DIAGNOSTIC_TEST|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
215059077|NCT01918241|DRUG|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
215059078|NCT01918241|DRUG|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
215059079|NCT01918241|DRUG|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
214912803|NCT00808210|DRUG|Placebo|Intravenous repeating dose
214912804|NCT03816020|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside capsules 250mg x 2 BID
214912805|NCT03816020|OTHER|Placebo|Placebo capsules BID
214912806|NCT04651933|GENETIC|Homologous recombination deficiency model|A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
214912807|NCT00337701|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 8 weeks
214912808|NCT00337701|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.
214912809|NCT04178902|DRUG|ABBV-467|Intravenous (IV) Infusion
214912810|NCT03192449|DRUG|Albendazole.|Single dose 400mg orally
214912811|NCT04752956|OTHER|"Total nasal symptom score (TNSS)"|TNSS contains 4 parameters in assessing the severity of allergic rhinitis: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored out of 4 points, from 0 to 3. 0, none- there are no complaints 1- mild- any symptom that exists but is not particularly annoying; 2, moderate, - any annoying symptom but does not interfere with daily activities or sleep; 3, severe - any symptom preventing daily activities or disturbing during sleeping. The total score is calculated by summing all the scores of 4 fields, which vary ranges from 0 to 15 .In our study, all patients will be instructed to record their TNSS symptom scores on their diary cards each morning before taking the drug. Patients will be graded on baseline TNSS parameters compared to 4 weeks before starting treatment.
214912812|NCT04752956|BEHAVIORAL|"Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)"|"PRQLQ, is a self-administered, disease-specific questionnaire, evaluating physical, emotional, and social status of individuals with AR. It contains 23 items in 5 domains: nose symptoms (RS), eye symptoms (ES), practical problems (PF), activity limitation (RL) and other symptoms (OS). One score is given to each domain. 7-point scale (from 0, not problematic; to 6, very problematic). The overall score is derived from the average score of all items (20). In our study, the Turkish validated form of PRQLQ was used~Patients will be asked to answer PRQLQ questions at the end of each week during treatment. At the end of the treatment, an average of 4 weeks will be taken as the PRQLQ score. Basal PRQLQ questions will be evaluated by the participants based on 4 weeks prior to treatment."
214912813|NCT04752956|DIAGNOSTIC_TEST|Nasal cytology|In anterior rhinoscopy, nasal cytology will be scraped off the middle part of the lower turbinate with the help of a small sterile cotton swab. The cellular material obtained will be fixed by air drying on a glass slide and then stained by the May-Grünwald-Giemsa method. Preparations that do not contain respiratory epithelium or contain less than 10 epithelium at high magnification will be excluded from the study. A percentage of cells per 100 cells will be reported. NECs (nasal eosinophilic count) will be evaluated according to the quantitative classification of Gelardi et al. An experienced cytologist who is blind to the study groups will perform this test. Eosinophil percentages in nasal smears of all patients will be evaluated before and after the treatment.
214912814|NCT04752956|DIAGNOSTIC_TEST|anterior rhinomanometry|Children's right, left and total nasal airway resistance (NAR) and nasal airflow (NAF) will be measured with active anterior rhinomanometry ZAN 100 USB Rhinomanometry (Longmont, Colo., USA). In the evaluation, the NAR- pressure difference / air flow (R = P / V) formula will be used at a constant 150 Pascal prescribed by the European Rinomanometry Standardization Committee in 1984. After the patient is rested for 20 minutes, measurements will be made at 20-22 ° C and the nasal secretion will be cleared. NAR and NAF values of the participants will be measured before starting treatment and 4 weeks after treatment.
214912815|NCT04769193|OTHER|Adipeau face cream|Adipeau face cream contains the natural actives Carthamus Tinctorius (Safflower) Seed Oil and Kaempferia Parviflora Rhizome Extract (Black Ginger).
214912816|NCT04888793|DIAGNOSTIC_TEST|Serologic immune response evaluation|Detection of total and neutralizing antibodies against SARS-CoV-2
214912817|NCT02093780|BEHAVIORAL|Alberta Anti-inflammatory diet|Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.
215059080|NCT01918241|DRUG|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
215059081|NCT00414323|DRUG|Duloxetine|
215059082|NCT00414323|DRUG|Escitalopram|
215059083|NCT00414323|DRUG|Placebo|
215059084|NCT04609605|DEVICE|speckle tracking echocardiography|speckle tracking echocardiography of right ventricle
215059085|NCT02623205|DRUG|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
215059086|NCT02623205|DRUG|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
215059087|NCT03162796|DRUG|Guselkumab|Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
215059088|NCT03162796|DRUG|Placebo|Participants will receive matching placebo as SC injection.
215059089|NCT02473471|DEVICE|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
215059090|NCT01928290|DRUG|Irinotecan|
215059091|NCT01928290|DRUG|Trastuzumab|
214303906|NCT02016625|DRUG|Faldaprevir|
214303907|NCT02016625|DRUG|Faldaprevir|
214303908|NCT02016625|DRUG|Cyclosporine|
214303909|NCT02016625|DRUG|Tacrolimus|
214670226|NCT00151411|DRUG|Placebo|Placebo
215059092|NCT01928290|DRUG|Oxaliplatin|
214303910|NCT06251856|BEHAVIORAL|lymphedema education program|On post-op day 2, patients will receive Symptom Management Model-Based Lower Extremity Lymphedema Training. Brochures will be introduced and delivered to the patient.
214346962|NCT02785367|PROCEDURE|Cord blood samples|"After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth."
214479601|NCT05708105|DIAGNOSTIC_TEST|Cerebral near-infrared spectroscopy|Continuous cerebral NIRS will be monitored using the INVOS 5100C or 7100 Cerebral Oximeter (Medtronic, Minneapolis, MN, USA), initiated as early as feasible after birth or postnatal consent and continued until 48 hours of age. Neonatal sensors applied over a light-permeable barrier will be placed on the right or left side of forehead, like the methods used in our pilot study and in line with our clinical protocol. The continuous parameters recorded for this study using cerebral NIRS will include CrSO2 and COIx.
214479602|NCT05708105|DIAGNOSTIC_TEST|Functional echocardiography|"The first echocardiogram will be completed as soon as possible after consent and \< 24 hours of age in all cases. This will be to capture markers of early low systemic blood flow and document patent ductus arteriosus and its size, as known to be associated with IVH.~The second scan will be performed at the end of the monitoring period, between 48-60 hours of age. This scan is planned to record the change in LVO from baseline (re-perfusion), which has been postulated to relate to development of IVH."
214670227|NCT00151411|BEHAVIORAL|Lifestyle Intervention|A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
214670228|NCT03533478|DIETARY_SUPPLEMENT|Oral treatment Alzer y Diamel|"Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year."
215059093|NCT01928290|DRUG|Leucovorin|
215059094|NCT01928290|DRUG|Fluorouracil|
215059095|NCT00190736|DRUG|Atomoxetine Hydrochloride|
215059096|NCT00190736|DRUG|placebo|
215059097|NCT02342288|PROCEDURE|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
214346963|NCT05635214|PROCEDURE|real time remote tele mentored ultrasound exam|A patient will have a point of care ultrasound exam performed by a local provider with a remote expert guiding them through the exam using video conferencing.
214479603|NCT05708105|DIAGNOSTIC_TEST|Head Ultrasound|HUS will be paired with both echocardiograms. The first HUS will document baseline IVH status (paired with the first ECHO). The final HUS will be performed between days 4-7 of age, as per the standard clinical practice by site radiology service and will be used to confirm the final IVH status.
214670229|NCT03533478|DIETARY_SUPPLEMENT|Placebo|Placebo treatment
214670230|NCT01712438|BIOLOGICAL|Human cl rhFVIII|
214912818|NCT02093780|BEHAVIORAL|Canada's Food Guide Diet|Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
214912819|NCT00865228|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
214912820|NCT00865228|DRUG|Lapaquistat acetate|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.
214912821|NCT00865228|DRUG|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.
214912822|NCT00865228|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
214912823|NCT00640120|DEVICE|WIM-PC™ device|wheeze detection during dynamic bronchial situations in infants
214912824|NCT00192231|BIOLOGICAL|CAIV-T|
214912825|NCT03915301|PROCEDURE|Satisfaction assessed by the VAS [followed by its scale information in the Description]|Erector spinae plane block provided in thoracic part of spine, VAS scale 0-10
215059098|NCT02342288|PROCEDURE|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
215059099|NCT01091038|OTHER|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
215059100|NCT01091038|OTHER|Routine Care|Routine Care
215059101|NCT05358743|OTHER|Probiotic group|Participants will use the probiotic product once daily (1 tablet/day) for 8 weeks
214912826|NCT03719469|DIETARY_SUPPLEMENT|Green tea group|
214912827|NCT04723446|DRUG|Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate|Corsodyl® Alcohol-free is a clear to slightly opalescent oromucosal solution with an odour of peppermint that contains 0.2% w/v chlorhexidine digluconate which is an antimicrobial preparation for external use. It is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is active against a wide range of important oral pathogens and is therefore effective in the treatment of many common oral conditions.
214912828|NCT04723446|DRUG|Colgate Peroxyl® -1.5% Hydrogen peroxide|Peroxyl mouthwash is a clear aqua-blue liquid oromucosal solution which 100ml of solution contains 1.5g of Hydrogen peroxide (as 30% Hydrogen Peroxide solution). It is an oral antiseptic cleanser for external use. The principal action is brought about by contact of hydrogen peroxide with peroxidases and catalases present in tissues and saliva, which causes the rapid release of oxygen. This provides mechanical cleansing which flushes out mouth debris and helps in the treatment of oral irritations. This mouthwash is used as a cleanser in the symptomatic relief of minor mouth and gum irritations.
214912829|NCT04723446|OTHER|Oral-B® Gum & Enamel Care -Cetylpyridinium chloride|The Oral-B® Gum \& Enamel Care mouthwash is an oromucosal solution containing Cetylpyridinium chloride (CPC) and used as an adjunct to oral hygiene.
214912830|NCT04723446|OTHER|No rinsing|No rinsing
214912831|NCT02851121|OTHER|Sensorial stimulations|
214912832|NCT02851121|OTHER|Experimental protocols|
214912833|NCT02851121|BEHAVIORAL|Emotional protocols|
214912834|NCT02851121|OTHER|Protocol with a spatial dimension|
214912835|NCT02838732|DIETARY_SUPPLEMENT|L-carnitine supplementation (500 mg per tablet per day, purchased from GNC company)|
214912836|NCT04410107|DIAGNOSTIC_TEST|Lung Function tests|Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)
214912837|NCT04410107|DIAGNOSTIC_TEST|Exercise capacity|6-minute walk test (6MWT distance)
214912838|NCT04410107|DIAGNOSTIC_TEST|Exercise physiology|Cardiopulmonary exercise test (CPET)
214303911|NCT04874337|OTHER|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.|The subjects for the training program were prepared by the researchers by scanning the relevant literature. In particular, the ICN Framework of Disaster Nursing Competencies developed by the International Nurses Association (ICN) and the World Health Organization (WHO), the second is the universal standards that should be fundamental in nursing and midwifery education (Global Standards for the Initial Education of Professional Nurses and Midwives). The training program was conducted both theoretically and practically. The theoretical section is based on Jenning's disaster nursing management model. Investigator is a First and Emergency Aid instructor. In addition, support was received from an experienced psychologist and AFAD trainers who provided support to the victims of the Izmir earthquake during the training process. In this context, an 8-module training program was created.
214303912|NCT03160833|DRUG|HMPL-453|oral administrative
214912839|NCT04410107|DIAGNOSTIC_TEST|Health-related quality of life|Short-Form Health Survey Questionnaire (SF-36)
214912840|NCT04410107|DIAGNOSTIC_TEST|Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening|"1. Adapted translation American Thoracic Society respiratory symptoms questionnaire;~2. Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~3. Questionnaire for screening for post-traumatic stress symptoms (PTSD)."
214912841|NCT02356588|DRUG|Sufentanil Tablet 30 mcg|
214912842|NCT02356588|DRUG|Placebo Tablet|
214912843|NCT00571142|PROCEDURE|Bevacizumab + Pars plana vitrectomy|2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
214912844|NCT00571142|PROCEDURE|Bevacizumab + pars plana vitrectomy|2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
214912845|NCT01659827|OTHER|Marcaine|Injection of 2cc of Marcaine
214912846|NCT01659827|OTHER|0.5cc AmnioFix|Injection of 0.5cc of AmnioFix Injectable
214912847|NCT01659827|OTHER|1.25cc AmnioFix|Injection of 1.25cc of AmnioFix Injectable
214912848|NCT01659827|OTHER|Saline|Injection of 1.25cc of Saline
215059102|NCT05358743|OTHER|Placebo group|Patients will chew placebo products (blueberry tablets) once daily (1 tablet/day) for 8 weeks.
214912849|NCT04483830|DRUG|Sulodexide|an oral dose of 2 capsules each day for 21 days
214912850|NCT04483830|DRUG|Placebo|an oral dose of 2 capsules each day for 21 days
214303913|NCT04974658|PROCEDURE|Inter-semispinal plane block|Ultrasound Inter-semispinal plane block in block group
214303914|NCT00009048|DRUG|EMD 128130|
214303915|NCT00009048|DRUG|IV Levodopa|
214303916|NCT02639104|RADIATION|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;~1. The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~2. If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~3. The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
214912851|NCT00702767|DRUG|INTRALIPIDS|INTRAVENOUS FAT EMULSIONS
214912852|NCT01987089|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.
215059103|NCT01019122|RADIATION|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
215059104|NCT05301621|OTHER|Akcelerometry follow up|The patients and control group will be followed up with single accelerometer.
214346964|NCT00619021|DRUG|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m\^2, 800 mg/m\^2, 1000 mg/m\^2, 1200 mg/m\^2
214670231|NCT06569537|DRUG|Lidocaine topical|4%
215059105|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|"Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.~Serum irisin."
215059106|NCT05144672|OTHER|Anthropometric measurements|Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI
215059107|NCT05144672|PROCEDURE|Electrocardiogram and Fundus examination|Fundus examination by direct ophthalmoscope
214912853|NCT03538730|BEHAVIORAL|Memory Reframing|The intervention will draw from existing narrative-based interventions, past pain memory reframing interventions and findings from our recent data. Specifically, parents will be taught to reminisce with their children about the in-hospital and post-surgery periods by encouraging children to provide more explanations, using less utterances about pain, avoiding repetitions, emphasizing positive aspects of the child's surgery memory (e.g., when children used coping methods such as deep breathing, when they got a treat), and enhancing children's self-efficacy regarding their ability to cope with pain.
214912854|NCT04390490|DEVICE|Graphene quantum dots combined with Si nanowire photoelectrochemical immunosensor|Graphene quantum dots combined with Si nanowire is a new method of photoelectrochemical immunosensor
214912855|NCT05888363|OTHER|No Intervention|Difference in outcomes in patients with rectal foreign bodies removed in the emergency department or in the operating room.
214912856|NCT02838823|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
214912857|NCT01591135|DRUG|Paclitaxel plus 5-fluorouracil|5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
214912858|NCT01591135|DRUG|Cisplatin plus 5-fluorouracil|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
214912859|NCT01591135|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
214912860|NCT01591135|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
214912861|NCT05020158|OTHER|Family Talk Intervention|A psychosocial family-based intervention that is designed to give support to an entire family when a child has life-threatening illness.
214912862|NCT01641458|OTHER|5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G\>A, c.1679T\>G, HapB3/c.1129-5923C\>G and c.2846A\>T).
214912863|NCT01641458|OTHER|Therapeutic drug monitoring of 5FU|Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
214912864|NCT00722358|DRUG|BMS-650032|"Capsule, Oral, Q12h, 3/5 days~Panel 1: 200 mg~Panel 2: 400 mg~Panel 3: 600 mg"
214912865|NCT00722358|DRUG|Placebo|"Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo"
214912866|NCT03150719|DRUG|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
215059108|NCT05144672|OTHER|Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.
215059109|NCT05144672|OTHER|Brachial index|The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm
214670232|NCT06569537|DRUG|BLT|Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
214670233|NCT06062368|BEHAVIORAL|Rate of Entry|The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.
215059110|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).
215059111|NCT05144672|RADIATION|Abdominal ultrasound.|It will be performed for patients only.
214670234|NCT02819596|DRUG|Savolitinib|
214670235|NCT02819596|DRUG|MEDI4736|
214670236|NCT02819596|DRUG|Tremelimumab|
214670237|NCT04094506|DRUG|ASP1948|Intravenous
214670238|NCT05907928|OTHER|Scotchbond universal adhesive plus|New generation BPA free universal adhesive
215059112|NCT04032925|DEVICE|PICSO|"PICSO therapy is delivered through the PICSO Impulse System, which consists of the PICSO Impulse console and PICSO impulse catheter. The PICSO therapy is delivered in each patient for a minimum of 20 minutes to a maximum of 45 minutes.~The PICSO Impulse catheter is automatically activated by the PICSO Impulse console. It is inserted in the coronary sinus via femoral vein access. The PICSO Impulse Console cyclically inflates and deflates the balloon at the tip of the PICSO Impulse catheter, generating transient increase in coronary sinus pressure."
215059113|NCT05707338|PROCEDURE|Gastrectomy with lymph node dissection|"prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group)."
214670239|NCT05907928|OTHER|Single bond Universal|Radiolucent universal adhesive
214303917|NCT02639104|OTHER|Electromyography|"Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
214670240|NCT04219540|DRUG|XR-B (SUBLOCADETM)|XR-B (SUBLOCADETM) contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days. Following induction and dose adjustment with sublingual buprenorphine, the recommended starting dose is 300 mg monthly for the first two months followed by a maintenance dose of 100 mg monthly thereafter. XR-B is administered monthly only by subcutaneous injection in the abdominal region. Study clinical staff will have flexibility to continue the 300mg dose for greater than 2 months, or use the 100mg dose for initial induction, if the participant's opioid use history or clinical status at the time of dosing support these decisions.
214912867|NCT03150719|DRUG|Ivacaftor|IVA 150 mg tablet.
214912868|NCT03150719|DRUG|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
214303918|NCT05427396|DRUG|JS004|Usage and dosage: Inject 200mg once every 3 weeks
214303919|NCT05427396|DRUG|Toripalimab Injection|Usage and dosage: Inject 240mg once every 3 weeks
214303920|NCT03303404|DEVICE|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
214303921|NCT03121092|DRUG|ACEI or ARB|Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
214303922|NCT05791474|DRUG|ATI-2231|Provided by Aclaris Therapeutics, Inc.
214303923|NCT02356783|DEVICE|Pedometer|Wireless pedometer
214303924|NCT00391352|DRUG|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
214303925|NCT05875857|BEHAVIORAL|Opioid destruction education|Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
214303926|NCT04110132|PROCEDURE|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative."
214303927|NCT04110132|PROCEDURE|Ganglion impar block with normal saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
214303928|NCT03084029|DRUG|Oxytocin|40 international units
214303929|NCT03084029|DRUG|Placebo|40 international units
214303930|NCT00380978|PROCEDURE|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
214479604|NCT06679283|PROCEDURE|Open flap debridement with a chemo-electric device + PRF|The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed followed by application of PRF clots and membrane. Then, the flap will be closed and sutured.
214912869|NCT03150719|DRUG|Placebo|Placebo matched to IVA tablet.
214912870|NCT01790984|OTHER|High sugar low starch diet|
214912871|NCT01790984|OTHER|Low sugar high starch diet|
214912872|NCT02597504|OTHER|Pen and paper neuropsychological test|Will be administered for Construct Validity to determine agreement with Quick Test
214912873|NCT02597504|DEVICE|Quick Test|Quick Test, computerized test will be administered to all subjects.
214912874|NCT00640757|DIETARY_SUPPLEMENT|Methionine deficient diet|Hominex with a low protein diet
214912875|NCT00640757|DIETARY_SUPPLEMENT|Methionine sufficient diet|Hominex, low protein diet and methionine capsules
214912876|NCT01997476|PROCEDURE|Combined EUS, e-PFT and sEUS Testing|"advantage of combined EUS, ePFT \& sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
214912877|NCT01812460|OTHER|Intervention-training-group|As descriped in Arm Description
214912878|NCT00571740|BIOLOGICAL|bevacizumab|Given IV
214479605|NCT06679283|PROCEDURE|Open flap debridement with a chemo-electric device alone (control)|The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed. Then the flap will be closed and sutured.
214479606|NCT05974358|PROCEDURE|Kono-S anastomosis|Kono et al. described a new operative technique that could reduce the rate of post-operative recurrence: a termino-terminal ileocolonic anastomosis, anti-mesenteric, with a supporting column to prevent distortion and anastomotic stenosis (Kono-S anastomosis).
214479607|NCT05974358|PROCEDURE|Conventional anastomosis for ileocolonicresection of Crohn's disease|conventional anastomosis for ileocolonicresection of Crohn's disease
214912879|NCT00571740|BIOLOGICAL|cetuximab|Given IV
214912880|NCT00571740|DRUG|fluorouracil|Given IV
214912881|NCT00571740|DRUG|leucovorin calcium|Given IV
214912882|NCT00571740|DRUG|oxaliplatin|Given IV
214912883|NCT04200989|BIOLOGICAL|Peanut allergen|Intralymphatic immunotherapy injections.
214912884|NCT04303689|DRUG|Colchicine Tablets|patients with essential hypertension are randomized to receive either 3 weeks of colchicine
214912885|NCT04303689|DRUG|Placebo|patients with essential hypertension are randomized to receive either 3 weeks of placebo-treatment
214303931|NCT00380978|PROCEDURE|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
214303932|NCT04146545|BEHAVIORAL|"Community Rx-Dementia CRxD Caregiver Resources"|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
214303933|NCT02985229|DRUG|Mifepristone|The option of home or clinic administration of 200 mg oral mifepristone
214303934|NCT02985229|DRUG|Misoprostol|800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
214912886|NCT00383760|DRUG|eribulin mesylate|Given IV
214912887|NCT01925430|DEVICE|Screening device|Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
214912888|NCT01925430|DEVICE|Comparative product|A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
214912889|NCT05944848|DRUG|1 mg CL-197 capsules|Single oral dose of 1 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
214912890|NCT05944848|DRUG|10 mg CL-197 capsules or CL-197 placebo|Single oral dose of 10 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
214303935|NCT01729754|DRUG|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
214303936|NCT01729754|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
214912891|NCT05944848|DRUG|30 mg CL-197 capsules or CL-197 placebo|Single oral dose of 30 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
214912892|NCT05944848|DRUG|60 mg CL-197 capsules or CL-197 placebo|Single oral dose of 60 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
214303937|NCT01729754|DRUG|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
214303938|NCT01729754|DRUG|Etanercept Placebo|Matching placebo to etanercept administered SC
214303939|NCT01729754|DRUG|Etanercept 50 mg|Etanercept 50 mg administered SC
214303940|NCT02637700|DRUG|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
214303941|NCT02637700|DRUG|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
214303942|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique|It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
214303943|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique|Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
214303944|NCT00690014|DRUG|probenecid|500 mg q 6 hrs
214303945|NCT04371887|OTHER|Local Tailoring|"The guided local tailoring approach will employ a standard structured process, including (1) convening a project team, (2) conducting a local diagnostic process to identify likely barriers using provider/patient survey and interviews with providers/administrators, (3) selecting from a pre-developed menu of implementation strategies categorized by core function (form and function menu), and (4) deploying the selected strategies in collaboration with local implementation and improvement consultants."
214303946|NCT00773292|DRUG|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
214303947|NCT04798547|PROCEDURE|Short Myotomy|Evaluation of short length myotomy
214303948|NCT04798547|PROCEDURE|Standard Length Myotomy|Standard Length Myotomy
214303949|NCT04666233|PROCEDURE|Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection
214303950|NCT04666233|PROCEDURE|Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
214479608|NCT06681545|OTHER|one to one interviews and or focus groups|one to one interviews and or focus groups
214912893|NCT05944848|DRUG|100 mg CL-197 capsules or CL-197 placebo|Single oral dose of 100 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
214912894|NCT03839004|BEHAVIORAL|Integrated approach to pregnancy|Yoga classes, mindfulness classes, coaching, nutrition counselling and osteopathy
214912895|NCT00004872|BIOLOGICAL|recombinant human endostatin|
214912896|NCT04029025|PROCEDURE|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
214479609|NCT06151730|OTHER|Non-Interventional Study|Non-interventional study
214479610|NCT06786312|DRUG|Apatinib|250mg, P.O, qd, 21 days per cycle;
214479611|NCT06786312|DRUG|Adebrelimab|20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;
214479612|NCT06786312|DRUG|Etoposide Injection|100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.
214479613|NCT06786312|DRUG|Carboplatin Injection|Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.
214912897|NCT04029025|PROCEDURE|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
214912898|NCT04029025|PROCEDURE|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C)
214912899|NCT05519930|OTHER|hereditary high risk pancreatic cancer|Data collection trial for hereditary high risk pancreatic cancer patients.
214912900|NCT04021030|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention consists of 8, one-hour individual therapy sessions delivered over the course of 2 to 4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both chronic pain and substance use.
214303951|NCT02902185|DRUG|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
214303952|NCT02902185|DRUG|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
214303953|NCT00824044|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
214303954|NCT00824044|DRUG|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
214303955|NCT00002233|DRUG|Indinavir sulfate|
214303956|NCT00002233|DRUG|Abacavir sulfate|
214303957|NCT00002233|DRUG|Amprenavir|
214303958|NCT00002233|DRUG|Lamivudine|
214303959|NCT01291056|OTHER|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
214303960|NCT01291056|DRUG|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
214303961|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0
214303962|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0
214303963|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0
214303964|NCT00192504|OTHER|Placebo|Single dose of placebo administered intravenously (in the vein) on Day 0
214479614|NCT06803498|PROCEDURE|Receipt of significant resuscitation intervention at birth|Receipt of CPAP, PPV, intubation, or CPR at birth in a hospital delivery room
214479615|NCT06885996|DRUG|Psilocybin|See treatment arm description.
214479616|NCT06886516|DRUG|Apixaban|A factor Xa inhibitor, 2.5 and 5 mg tablets, by mouth per protocol.
214670241|NCT04219540|DRUG|XR-NTX|XR-NTX (Vivitrol®) produces a 30-day mu opioid receptor antagonist blockade Induction procedures require detoxification off opioids (5-7 days since last opioid use), a negative opioid urine toxicology, negative self-report of any recent opioid use, and a naloxone challenge. The naloxone challenge consists of 0.4-0.8mg of IV/SC/IM naloxone followed by the observation of no opioid withdrawal symptoms, or the use of oral naltrexone (12.5-25mg) followed by 1-2 hours of observation. XR-NTX is then delivered as a 380mg (4cc) intramuscular injection to the upper outer gluteus (buttock). Study interventions are FDA-approved, used in accordance with FDA-labeling and will be administered by a study clinician
215059114|NCT03200483|OTHER|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
214303965|NCT03047642|DIAGNOSTIC_TEST|Biomarker assay|There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients
214303966|NCT06537349|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in OK lens related dry eye
214303967|NCT03742609|OTHER|ii) the reminder|Participants assigned to the prompt group were received instruction to use their hearing aid box as a physical prompt to remind participants to use their hearing aid(s)
214303968|NCT03742609|OTHER|ii) written behavioural plan|Participants assigned to this group were received instruction to create at least one written plan for hearing aid use. Specifically, participants were asked to plan where and when to use their hearing aid(s).
214303969|NCT03742609|OTHER|iv) all materials|i) provision of written information regarding consequences of using a hearing aid and not using a hearing aid, ii) the provision of a physical prompt for the purpose of prompting or cueing the behavior (hearing aid use) development, and iii) creation of a written behavioural plan for hearing aid use.
214303970|NCT02448238|OTHER|VSL#3® probiotic|"Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (\~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator"
214479617|NCT06856382|DIAGNOSTIC_TEST|gastric cancer|Patients diagnosed with gastric cancer by pathological biopsy.
214479618|NCT06668012|DEVICE|Palomacare® vaginal gel is a medical device with CE class IIa.|"The duration of the study for each patient will be approximately 11-12 days and the treatment for groups A and B will be 6 days.~In a first pilot study in asymptomatic women, a tendency towards a positive effect on the composition of vaginal fluid was already observed, as assessed by diagnostic tests and classified using a Likert scale. A subsequent study showed that treatment with a different vaginal gel but with an identical concentration of ingredients from Palomacare® vaginal gel, for 21 consecutive days, is able to improve the composition of vaginal fluid.~Based on these preliminary data, it is possible to hypothesize that the action of Palomacare® vaginal gel will have a positive effect on the composition of vaginal fluid in patients affected by dysbiosis, whether asymptomatic or not."
214479619|NCT04567056|DIAGNOSTIC_TEST|Blood sample|A separate blood sample will be taken for methylation-analyses
214479620|NCT06872060|DRUG|Glucagon|Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes.
214670242|NCT02983084|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
215059115|NCT03200483|OTHER|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
214670243|NCT02924792|DEVICE|Reinfusion - Sternal IO needle|
214912901|NCT02711696|BEHAVIORAL|GCED, Gluten Contamination Elimination Diet|"A Gluten Free diet based exclusively on naturally gluten-free products and foods, with the elimination from the diet of all commercially available processed food and products labeled gluten free  (Gluten Contamination Elimination Diet, GCED)."
214303971|NCT06065579|OTHER|Well-Being Promotion Program|the well-being promotion program (Suldo,2016) , an intervention designed to improve subjective well-being. It was postulated that this intervention will eventually assist in managing emotional and behavioural problems among adolescents enrolled in the program.
214303972|NCT04779255|DRUG|Procedure (Tumesent anesthesia)|Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.
214303973|NCT04779255|DRUG|Control Arm (Paracetamol)|Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.
214303974|NCT01139450|DRUG|0417|Topical 0417 test product applied twice daily for 4 weeks
214303975|NCT01139450|DRUG|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
214303976|NCT01139450|DRUG|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
215059116|NCT03200483|OTHER|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
214912902|NCT01346696|DEVICE|OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)|
214912903|NCT05010538|DRUG|Sarecycline|60 mg sarecycline tablets will be given for subjects with a body weight of 33 to 54 kg, 100 mg sarecycline tablets will be given for subjects with a body weight of 55 to 84 kg, and 150 mg tablets will be given for subjects with a body weight between 85 and 136 kg.
214912904|NCT05522998|DRUG|Ciprofol|Ciprofol (0.4-0.5mg/kg) for anesthesia induction
214912905|NCT05522998|DRUG|Propofol|propofol(2-2.5mg/kg) for anesthesia induction
214912906|NCT01854190|DEVICE|WatchPAT|BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
214303977|NCT00895258|BEHAVIORAL|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
214303978|NCT00895258|BEHAVIORAL|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
214303979|NCT05324540|OTHER|Cool therapy|Application of cool therapy. A chilled (between 5C and 10C) instrument will be applied to the oblique sinus while the patient is in atrial fibrillation.
214303980|NCT00935870|DEVICE|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
214303981|NCT04608500|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
214303982|NCT04608500|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
214303983|NCT02417012|BEHAVIORAL|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
214303984|NCT02417012|BEHAVIORAL|Standard care|Standard individual diabetes support
214303985|NCT00696514|DIETARY_SUPPLEMENT|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
214303986|NCT00696514|DIETARY_SUPPLEMENT|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
214479621|NCT06872060|DRUG|Glucagon+Exendin9-39|Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes, plus a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-¹·min-¹), given intravenously from -30 to 60 minutes
214479622|NCT06872060|DRUG|Sodium chloride|Placebo (0.9% NaCl).
214479623|NCT06872762|BEHAVIORAL|Exercise|Exercise for 90 minutes (cycling) while minimizing thermal strain
214479624|NCT06872762|BEHAVIORAL|Heat strain|Exercise for 90 minutes (cycling) while maximizing thermal strain
214479625|NCT06593691|OTHER|conventional treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise
214479626|NCT06593691|OTHER|Conventional treatment + multi-wave locked system laser treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise + multi-wave locked system laser treatment
214479627|NCT06871748|OTHER|Low FODMAP Diet|A standardized diet containing low levels of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs), designed to reduce bloating and gastrointestinal symptoms. Meals are pre-prepared, calorie-matched, and visually identical to those in the high FODMAP group to maintain blinding. Participants will consume three main meals and one snack daily for two weeks, with adherence monitored through food diaries and photos.
214479628|NCT06871748|OTHER|High FODMAP Diet|A standardized diet containing high levels of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) to assess its impact on bloating and gastrointestinal symptoms. Meals are calorie-matched and visually identical to those in the low FODMAP group to maintain blinding. Participants will consume three main meals and one snack daily for two weeks, with adherence tracked through food diaries and photos.
214479629|NCT06873126|COMBINATION_PRODUCT|Counselling sessions|The study provides insights into the use of awareness counselling sessions for physical activity promotion, which may have a significant impact on physical activity education, promotion, practice and policy making and will be more effective to ensure adherence to activity among young adults.
214479630|NCT06873165|DIETARY_SUPPLEMENT|Probiotics|1 capsule(with three different dosage) per day for 12 weeks
214479631|NCT06873165|DIETARY_SUPPLEMENT|Placebo|1 capsule per day for 12weeks
214303987|NCT03371901|OTHER|Physical therapy with BFR-LLST|"The criteria-based rehabilitation protocol for the patients with cartilage or meniscus repair may vary according to the surgical procedures.~Patients will attend 5 individual treatments, and a 6-week supervised group-based rehabilitation program with BFR-LLST (Blood Flow Restriction - Low Load Strength Training) twice a week at the rehabilitation centre. Patient will be instructed to perform BFR-LLST 5 times a week in total (twice supervised, 3 times at home).~During each BFR-LLST session, patients are encouraged to perform 4 sets of 30 repetitions, 15 repetitions, 15 repetitions, and 15 repetitions (or to fatigue in the final set), respectively.~The exercise intervention will adhere to TIDieR (template for intervention description and replication)."
214303988|NCT06032247|BEHAVIORAL|Resistance exercise program- UL|"Unilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include single-leg squats, split squats, single-leg deadlifts, single-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
214303989|NCT06032247|BEHAVIORAL|Resistance exercise program- BL|"Bilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include double-leg squats, double-leg deadlifts, double-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
214670244|NCT02924792|DEVICE|Reinfusion - Intravenous needle|
214912907|NCT04083885|OTHER|Virtual Reality|Participants will be provided with a virtual reality training program, personalized with respect to their abilities, endurance, needs and treatment goals. They will be trained to use the program and it will be installed in their home or provided at their long-term care facility. Participants will be suggested to perform VR 3-5 times a week for 8 weeks. Sessions will be 20-30 minutes long, depending on tolerance.
214912908|NCT01610089|OTHER|stable isotope infusion|"Control subjects: \[15N2-ureido\] arginine (0.69 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of \[15N2-ureido\] arginine (0.69 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr).~Citrullinemia type 1 subjects,\[15N2-ureido\] arginine (4.14 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of \[15N2-ureido\] arginine (4.14 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr)."
214912909|NCT02821026|PROCEDURE|Omental Islet transplant|The intervention is transplanting the islets into an omental pouch instead of into the liver. The omentum is a large apron-like fold of membrane inside the abdomen that drapes over the intestines. This study will test to see if omental islet transplantation is safe and effective. Standard immunosuppressive medicines (anti-thymocyte globulin, tacrolimus, mycophenolic acid, sirolimus, etanercept) will be used in this study to prevent rejection of the islets.
214912910|NCT02821026|DRUG|Anti-Thymocyte Globulin|
214912911|NCT02821026|DRUG|Mycophenolate mofetil|
214912912|NCT02821026|DRUG|Tacrolimus|
214912913|NCT02821026|DRUG|Etanercept|
214912914|NCT02821026|DRUG|Sirolimus|Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
214912915|NCT01506401|DEVICE|SensorMedics 3100B High Frequency Oscillatory Ventilator|High Frequency Oscillation
214912916|NCT01506401|PROCEDURE|Lung Protective Ventilation|Tidal Volume 6ml/kg; plateau pressure \< or = 35cmH20; Prescribed PEEP/FiO2 chart
214912917|NCT01588769|BIOLOGICAL|ALECSAT cell based immunotherapy|I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
214912918|NCT01292512|OTHER|Prognostic screening for complicated grief|Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
214912919|NCT01789112|OTHER|Blood sample|Taking of blood sample
214912920|NCT04545008|DRUG|Famotidine|Oral Famotidine
214912921|NCT04545008|DRUG|N-Acetyl cysteine|Oral N-Acetyl Cysteine
214303990|NCT00263146|PROCEDURE|recruitment maneuver|
214303991|NCT03928847|DRUG|Epigallocatechin-3-gallate (EGCG)|Epigallocatechin-3-gallate (EGCG) capsules
214303992|NCT04738773|DRUG|Naltrexone|On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.
214303993|NCT04738773|DRUG|Placebo|Placebo
214670245|NCT06364748|DEVICE|Cellular enabled blood pressure cuff|Smart cuff
214670246|NCT06364748|DEVICE|Standard of Care Cuff|Standard blood pressure cuff
214670247|NCT02911987|OTHER|high intensity training (HIT) program|The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
214912922|NCT03062930|BEHAVIORAL|Track 1|Training of non-paretic arm followed by sham condition
214912923|NCT03062930|BEHAVIORAL|Track 2|Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training
214912924|NCT06526481|PROCEDURE|Endoscopic Transsphenoidal pituitary surgery : Double Nasoseptal Flap Technique|"Patients with with symptomatic pituitary macroadenoma and tumor size ≥ 2 cm will have transsphenoidal endoscopic excision of pituitary adenoma.~-On one side full sized nasoseptal flap will be elevated and a smaller sized nasoseptal flap will be elevated on the other side."
214912925|NCT06526481|PROCEDURE|Endoscopic Transsphenoidal pituitary surgery : Rescue Flap Technique|"Patients with with symptomatic pituitary macroadenoma and tumor size ≥ 2 cm will have transsphenoidal endoscopic excision of pituitary adenoma.~\- A horizontal incision will be performed in the nasal septum in a posterior to anterior direction starting from the sphenoid ostium to a point opposite anterior end of the middle turbinate ( approximately up to one half of septum)."
215059117|NCT03082677|DRUG|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
215059118|NCT02596139|OTHER|No Interventions|
215059119|NCT04230616|PROCEDURE|total knee arthroplasty|total knee arthroplasty
214303994|NCT01010906|DRUG|Vaniprevir 300 mg|single dose administration of 300 mg oral tablet
214912926|NCT05658770|BEHAVIORAL|5 days/ week|"The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1.~The exercises to be carried out in phase 1 are:~Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax.~Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action.~Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO."
214912927|NCT05658770|BEHAVIORAL|3 days/ week|The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.
214912928|NCT05658770|BEHAVIORAL|2 days/ week|The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.
214912929|NCT05358054|OTHER|Mobilization with movement lateral Glides and Conventional Physiotherapy|"(The Mobilization with movement technique is(lateral glide) applied to the patient by a physiotherapist to patients at supine level position.~First we identify pain free region each patients. The lateral humerus above the condyle of elbow joint are fixed by therapist. Then therapist ask to patients perform the active movement ten times. The same procedure repeats number of 3 sets, 10 number of repetition. The rest of interval fifteen to twenty seconds with in the sets Grip strength (pain Free Strength ) was evaluated in kilogram using a dynamometer. The measurements using dynamometer patients posture is erect sit position , the elbow at 90 degree flexion , shoulder would be abducted , rest of joint forearm and wrist in neutral during measurements.~conventional therapy list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching"
214912930|NCT05358054|OTHER|Progressive Resistance Exercises and Conventional Physiotherapy|4 STEPS Progressive resistive EXERCISES have a 4 step to application Step 1 Clenching fist strongly, resisted wrist Flexion, Extension, wrist rotation with a stick) Step 2 The therapeutic band exercised performed at wrist Flexion(WF), Wrist Extension(WE), Wrist Ulnar Deviation(WED) , and Wrist Radial Deviation(WRD).Step 3 Patient asked to perform combined wrist rotatory movements using e.g. table top as a support. Step 4 Soft ball compressing exercises, Transferring buttons from cup into another, Twisting a towel into the roll, Hand Rotating both directions at table AND CONVENTIONAL PHYSIOTHERAPY and list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching
214912931|NCT00510211|DRUG|olanzapine|
214912932|NCT02819037|PROCEDURE|gas chromatography|
214912933|NCT02819037|PROCEDURE|Stool analysis for detection of malabsorption|
214912934|NCT00090714|GENETIC|pVGI.1(VEGF2)|
214912935|NCT03561714|BEHAVIORAL|Cardometabolic Team Intervention|The CMC-TI team included a registered nurse/certified diabetes educator (RN/CDE) Care Manager, medical assistant (MA) Health Coach, and RN Depression Care Manager. Decision support tools guided therapy for glucose, BP, low-density lipoprotein cholesterol (LDL-c), and depression. At the intervention clinic, the 12-month CMC-TI was delivered to all qualifying patients; surveys were administered to evaluate relevant patient-reported outcomes over 12 months.
214303995|NCT01010906|DRUG|Vaniprevir 200 mg|single dose administration of 200 mg oral tablet
214303996|NCT03669692|BEHAVIORAL|Caloric Restriction|Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
214303997|NCT03669692|BEHAVIORAL|Control|Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
214303998|NCT00542919|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
214303999|NCT00655967|DRUG|Acamprosate (Campral)|"During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.~Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above)."
214304000|NCT00655967|DRUG|Acamprosate|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
214304001|NCT01157507|DRUG|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
214304002|NCT01157507|PROCEDURE|Bladder overdistension|Bladder overdistension
214304003|NCT01157507|DRUG|Placebo|One single injection of placebo
214304004|NCT06302192|DIAGNOSTIC_TEST|ARDS+AKI|according to the clinical practice Reanl doppler and VeXUS score will be performed
214304005|NCT00919776|DRUG|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
214304006|NCT00919776|DRUG|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
214304007|NCT02670655|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
214304008|NCT02670655|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
214479632|NCT02225301|OTHER|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention.
214912936|NCT05244070|DRUG|BMS-986403|Specified dose on specified days
214912937|NCT05244070|DRUG|Fludarabine|Specified dose on specified days
214304009|NCT02670655|DRUG|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
214304010|NCT02670655|DEVICE|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
214304011|NCT02670655|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
214304012|NCT03068273|DEVICE|Real-time CGM data|
214304013|NCT01170182|DRUG|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
214304014|NCT01170182|DEVICE|Prilosec® 40 mg|Prilosec® 40 mg
214304015|NCT04171973|DEVICE|Driving an electric wheelchair in real condition|For the control group, 3 test circuits of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
214304016|NCT04171973|DEVICE|Driving an electric wheelchair in virtual condition|For the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
214304017|NCT06429462|DIAGNOSTIC_TEST|smartphone camera sensor tool|The study will involve the development and validation of a computer vision-based approach (using cameras to assess movements) to monitor knee flexion and extension, and a walking pattern assessment.
214304018|NCT01791842|DRUG|Tocilizumab|8 mg/kg/month
214304019|NCT01791842|DRUG|Placebo|
214912938|NCT05244070|DRUG|Cyclophosphamide|Specified dose on specified days
214912939|NCT03803007|DRUG|Intravenous ACT017 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
214912940|NCT03803007|OTHER|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
214912941|NCT04440215|OTHER|Telerehabilitation and team meetings and team care plans|A mix of home or rehabilitation center visits and telerehabilitation will be planned by the rehabilitation team for a maximum of 16 weeks. Moreover, for each participant enrolled, a multidisciplinary meeting will be organised. The patient/family will participate in the meeting and the decision making process using the telerehabilitation platform. The team will generate an interprofessional individualized treatment plan, aiming for an interprofessional shared decision making process.
214912942|NCT04440215|OTHER|Usual care|Rehabilitation teams will be instructed to provide care as they have been doing previously. Currently, this translates into no telerehabilitation, and interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals.
214304020|NCT06155591|OTHER|Community Nurse Case Manager (CNCM)|"Their action protocol has been designed and sequenced according to the circumstances in which the Complex and Pluripathological Chronic Patient finds themself:~* Pre-hospital discharge. The hospital Nurse Case Manager (HNCM) will contact the CNCM to inform of the imminent hospital discharge.~* Hospital discharge: A comprehensive nursing assessment of the CPCP based on Marjory Gordon's functional patterns will be carried out.~* Planned visits: An infographic will be provided to identify signs and symptoms of decompensation/exacerbation and a direct dial telephone number.~* Proactive telephone follow-up: The CNCM will make comfort calls every week for the first month, every 15 days until the 3-months visit and every month until the 6- and 12-months visits.~* Exacerbations/decompensations: An appointment will be arranged with their Primary Care physician.~* Hospital readmission: The CNCM will be kept informed of the process through the HNCM and CPCP's digital clinical history."
214304021|NCT01430481|DIETARY_SUPPLEMENT|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
214304022|NCT02308462|BEHAVIORAL|CHIMPS intervention|"CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).~The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid \& Plass, 2011)."
214304023|NCT03790839|DRUG|Sitagliptin|Sitagliptin (Januvia® 100 mg tablets for oral administration)
214304024|NCT03790839|DRUG|Dorzagliatin|Glucokinase activator currently under development
214304025|NCT03727503|OTHER|PPV from the capstesia|we will challenge the application by doing 2 maneuvers: the first one is to increase the PEEP level from 5 to 15 cmH2O and the second one is the infusion of a mini-fluid challenge (100 ml) followed by the other 400 ml.
214304026|NCT01881230|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
214912943|NCT06378593|DRUG|3HP-2827|3HP-2827 will be administered orally once daily in 28-day cycles.
214912944|NCT01317888|DRUG|MAB-425 radiolabeled with I-125|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
214912945|NCT03306628|OTHER|CO2 Laser Administration|The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).
214912946|NCT06236789|DRUG|Ifosfamide/mesna|Ifosfamide 2,500 mg/m2/day for 3 days every 3 weeks with mesna until disease progression
214912947|NCT02087540|DRUG|Telmisartan 80mg|
214912948|NCT02087540|DRUG|Rosuvastatin 20mg|
214304027|NCT01881230|DRUG|Carboplatin|Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
214304028|NCT01881230|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
214304029|NCT00017303|DRUG|carboplatin|
214304030|NCT00017303|DRUG|oglufanide disodium|
214304031|NCT00017303|DRUG|paclitaxel|
214304032|NCT00017303|PROCEDURE|conventional surgery|
214304033|NCT00112502|DRUG|Celecoxib|400 mg orally twice a day continuous dosing
214304034|NCT00112502|DRUG|Isotretinoin|40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.
214304035|NCT00112502|DRUG|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
214304036|NCT00112502|DRUG|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
214304037|NCT00410644|DRUG|OROS Hydromorphone HCI|
214670248|NCT02911987|OTHER|moderate intensity training (MIT) exercise therapy|MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
214670249|NCT01819935|DRUG|linezolid (Zyvox)|As prescribed-this is retrospective cohort of existing clinical data.
214912949|NCT02087540|DRUG|Rosuvastatin 10mg|
214912950|NCT02087540|DRUG|Placebo(for Telmisartan 80mg)|
214912951|NCT02087540|DRUG|Placebo(for Rosuvastatin 20mg)|
214912952|NCT02087540|DRUG|Placebo(for Rosuvastatin 10mg)|
214304038|NCT04639609|OTHER|Characterization of Neuromuscular Function and Fatigue|at inclusion
214304039|NCT01689129|DRUG|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
214304040|NCT01689129|DRUG|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
214304041|NCT02385266|DRUG|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
214304042|NCT02385266|DRUG|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
214304043|NCT01280292|DRUG|Eltroxin|Eltroxin dosage titration according to free T4 measurement every 3 months
214912953|NCT04262089|DRUG|Pembrolizumab (Keytruda)|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.
214912954|NCT01599260|OTHER|Resistance Exercise|Two 30-minute individually supervised exercise sessions per week for 16-weeks
214304044|NCT02747420|DEVICE|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
214304045|NCT02747420|DEVICE|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
214304046|NCT01195428|DRUG|Simvastatin|Simvastatin 40 mg daily
214304047|NCT01195428|DRUG|Placebo|Placebo
214304048|NCT01496092|DRUG|Keto Acid|12 tablets per day
214304049|NCT03961607|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
214479633|NCT05954546|DRUG|Enco+bini|Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment
214479634|NCT06870786|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|Evaluation of T-PRF membrane structures obtained from the blood of patients before and after vitamin D supplementation.
214479635|NCT06261112|OTHER|kaleidescope|used to kaleideskope
214479636|NCT06871735|PROCEDURE|Acellular matrix|Wound closure is obtained by use of acellular matrix material placed over the exposed barrier membrane. The procedure itself is not part of the research study, nor is the decision to use this procedure, but it is the condition of interest to the research.
214479637|NCT06871735|PROCEDURE|Surgical closure|Wound from the graft is surgically closed, with no use of the acellular matrix. The procedure itself is not part of the research study, nor is the decision to use this procedure, but it is the condition of interest to the research.
214479638|NCT06872619|DEVICE|PROSTest|Multianalyte Algorithm Analysis of circulating prostate cancer transcripts
214912955|NCT05617157|OTHER|Stair stepping|stepping up and down 32 stairs for 1 minute
214304050|NCT02469428|OTHER|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
214304051|NCT02469428|OTHER|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
214304052|NCT01678963|DRUG|Squalamine lactate|Ophthalmic solution 0.2%
214304053|NCT01678963|DRUG|Vehicle control|Ophthalmic solution vehicle control
214304054|NCT04134247|DRUG|PD-1 combined with chemotherapy|"PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
214304055|NCT04134247|DRUG|chemotherapy|"Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
214304056|NCT02576561|BIOLOGICAL|TVGV-1|Antigen + Adjuvant
214304057|NCT02576561|BIOLOGICAL|GPI-0100|Adjuvant Alone
214304058|NCT02576561|BIOLOGICAL|Placebo|Placebo
214304059|NCT01697865|PROCEDURE|Transfer group|
214670250|NCT01819935|DRUG|vancomycin|As prescribed-this is retrospective cohort of existing clinical data.
214912956|NCT01075165|OTHER|silicone spray|application of silicone spray to predefined area qd 12 weeks
214912957|NCT01075165|OTHER|saline spray|application of saline spray to predefined area qd 12 weeks
214912958|NCT03929120|BIOLOGICAL|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)|Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.
214912959|NCT01226966|DRUG|liraglutide|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.
214912960|NCT01215591|PROCEDURE|Gradual weaning from Nasal CPAP in preterm neonates|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
214912961|NCT05552248|DEVICE|LumbarBelt SOFT 300|15 patients will be included in this group and will used the medical device LumbarBelt SOFT 300 during sport practice (at least 2 sport sessions per week), for 12 weeks.
214912962|NCT05552248|OTHER|Control group LumbarBelt SOFT 300|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt SOFT 300), for at least 2 sport sessions per week during 12 weeks.
214912963|NCT05552248|DEVICE|LumbarBelt MID 500|15 patients will be included in this group and will used the medical device LumbarBelt MID 500 during sport practice (at least 2 sport sessions per week), for 12 weeks.
214912964|NCT05552248|OTHER|Control group LumbarBelt MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt MID 500), for at least 2 sport sessions per week during 12 weeks.
214912965|NCT05284331|OTHER|addition of two follow-up visits post infection|"Addition of an additional follow-up visit 6 months post infection and one follow-up visit 1 year post infection.~No treatment will be given specifically for this study. The change in medical management will only be modified by the addition of these 2 consultations at 6 months and 1 year post infection"
214912966|NCT00562172|DRUG|Insulin glargine|Once daily in the morning
214304060|NCT01697865|PROCEDURE|Control group|
214304061|NCT03732885|DEVICE|densah burs osseo densification drills|maxillary sinus floor elevation during implant placement using Densah burs
214304062|NCT03732885|DEVICE|Summer's Osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
214304063|NCT03691064|DRUG|LUTATHERA|Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.
214304064|NCT03365817|DRUG|Opioids taper off|Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.
214912967|NCT00562172|DRUG|Glimepiride|Once daily in the morning
214912968|NCT00562172|DRUG|Metformin|At least 1000 mg/day
214304065|NCT03365817|DRUG|Opioid stable treatment|No changes on prescribed opioids and adjuvant medication for the next six months
214670251|NCT03429647|DIAGNOSTIC_TEST|visible light spectroscopy|Sigmoid perfusion was assessed using visible light spectroscopy
214670252|NCT00488943|DEVICE|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
214670253|NCT02571413|OTHER|score before teaching|score the check-point of correct INCS usage before teaching
214670254|NCT02571413|OTHER|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
214670255|NCT02571413|OTHER|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
214670256|NCT00080210|DRUG|Puricase|
214912969|NCT03153904|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
214912970|NCT03153904|OTHER|Monitoring and Feedback System|For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.
214912971|NCT00205023|PROCEDURE|Sonohysterography|SHG during surgery for endometrial cancer.
214912972|NCT00255463|DRUG|Anastrazole|
214912973|NCT00255463|DRUG|Gefitinib|
214912974|NCT06090825|OTHER|Observational study|Observational study
214912975|NCT05208463|BEHAVIORAL|Joint Academy|Digitally deliverd exercise and education first line treatment for hip and knee osteoarthritis
214912976|NCT04351919|DRUG|Hydroxychloroquine|400mg per day during 10 days
214912977|NCT04351919|DRUG|Azithromycin|500 mg per day during 5 days
214912978|NCT05576935|BEHAVIORAL|Stroop task|The task is partitioned in 4 blocks of 360 stimuli and each word will be presented on screen in 34 point font for 1000 ms with an inter-stimulus interval based on their performance on the Stroop max test. This max test will be performed during the familiarization trial, and is divided in blocks of 96 stimuli. After each block, the accuracy (ACC) will be calculated. When ACC \> 85%, the difficulty of the Stroop task will be increased by decreasing the stimulus presentation time (SPT). If ACC \< 85%, this block will be considered as an 'error' and the subject must redo the block without changing the SPT. The first block will have a SPT of 1500 ms. When the required ACC is achieved, the SPT will decrease in the following order: 1100, 900, 800,… to determine the individualized cognitive load. When the subject makes 3 errors in a row, or 5 errors during the whole trial, the trial will end. The SPT of the last block will be considered as the maximum capacity of that individual.
214912979|NCT05576935|BEHAVIORAL|Documentary|In order to avoid under- and over-arousal, participants will have the opportunity to choose between several documentaries. The participants will also receive a list of the available documentaries (based on selections from Netflix and Disney+) after the familiarization trial so that the trial can go as smoothly as possible.
214912980|NCT03754335|PROCEDURE|Lumbar puncture|"Patient will be managed according to the current international recommendations in the Toulouse acute stroke center.~In the absence of clear recommendation in the literature headache will be treated according to our local predefined analgesic protocol: paracetamol 1g/6 h, and if the numerical scale ≥ 4 : continuous intravenous morphine starting at 1mg/h and increased per 0.5 mg/h every hour if numerical scale remains ≥ 4.~Lumbar puncture will be performed between day 3 and day 5 after subarachnoid hemorrhage onset by an independent scientist from our clinical investigator center. 30-mL CSF will be removed by LP.~Sham LP consisting in superficial skin puncture by a subcutaneous needle (27 gauge needle) during the usual procedure will be performed at the same time point."
214912981|NCT04445038|DRUG|610|Recombinant anti-IL-5 Humanized Monoclonal Antibody
214912982|NCT04445038|DRUG|Placebo|Placebo
214912983|NCT00105079|DRUG|saquinavir [Invirase]|1000 milligram (mg) Oral (po) twice daily (bid)
214912984|NCT00105079|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg po bid
214912985|NCT00105079|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
214912986|NCT00105079|DRUG|Ritonavir|100 mg po bid
214912987|NCT03677284|OTHER|Time assistive products|The decision on the specific time assistive product to be prescribed will be decided based on current knowledge and the personal goal of the PwD.
214912988|NCT03677284|OTHER|Information brochure|The information brochure will provide information frequent problems about daily time management and suggest strategies to manage them.
214912989|NCT01569971|OTHER|Assessment|In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
214912990|NCT05914493|OTHER|The effect of posture on cognitive function in early adolescence athletes|"Posture evaluation:~The form of Corbin et al. will be applied.~Evaluation of cognitive functions:~Basically, the Stroop test will be used, which evaluates the concentration and maintenance of attention depending on time and the task given."
214912991|NCT02387671|BEHAVIORAL|Device: FitBit Flex wrist band|Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.
214912992|NCT02387671|BEHAVIORAL|Device: FitBit Aria weight scale|Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.
215059120|NCT04230616|RADIATION|CT scan|The first 52 participants will recieve a pre- and postoperative CT scan of the hip, knee and ankle.
215059121|NCT01110525|DRUG|AZD1981|4X100 mg per oral, twice daily for 28 days
215059122|NCT01110525|DRUG|Neovletta 21/28|Once daily with (21) or without (28) pause for bleeding.
215059123|NCT01110525|DRUG|Placebo AZD1981|4X100 mg per oral, twice daily for 28 days
215059124|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
215059125|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
215059126|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
214912993|NCT02387671|BEHAVIORAL|Diet Intake Messages|The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.
214912994|NCT02387671|BEHAVIORAL|Behavioral Counseling|Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue \& dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
215059127|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
215059128|NCT01916824|DRUG|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
215059129|NCT03996681|DRUG|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
215059130|NCT03163134|DEVICE|Lumbar Drain|
215059131|NCT04513769|BEHAVIORAL|Vegan diet|Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
215059132|NCT01626573|DRUG|Itacitinib|
215059133|NCT01626573|DRUG|Itacitinib Placebo|
215059134|NCT05475028|OTHER|RRBS|Reduced Representation Bisulfite Sequencing
215059135|NCT00109252|DRUG|Raptiva (efalizumab)|
215059136|NCT00935506|DRUG|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
214304066|NCT01315756|DEVICE|Use of Few Touch Application (FTA)|"The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user."
214479639|NCT04106830|DRUG|Intravenous steroid|This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
214912995|NCT05844293|DRUG|FXI-GalNAc-siRNA|FXI-GalNAc-siRNA solution for injection
215059137|NCT00935506|DRUG|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
215059138|NCT04758286|PROCEDURE|Emergency surgical procedures|COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
215059139|NCT04102904|OTHER|Observational|Patients will be asked to donate a semen sample which will be analysed and compared with their eventual diagnosis.
214912996|NCT05844293|OTHER|Placebo|Saline
214912997|NCT03415971|PROCEDURE|EMG befor denture treatment|
214912998|NCT03415971|PROCEDURE|EMG in a month after termination of treatment|
214912999|NCT03415971|PROCEDURE|EMG in a 3 months after termination of treatment|
214913000|NCT05618678|BEHAVIORAL|DIGNITY|DIGNITY is a multi-component, multi-level intervention that guides shared decision-making in nursing homes to support person-centered dementia care. Based in theory, this intervention targets nursing home staff attitudes and behaviors around assessing and judging whether to engage in risk situations to support resident preferences for everyday living and care despite cognitive decline due to dementia. It includes a protocol manual, baseline training on how to implement the DIGNITY strategy, and six ECHO sessions to help frontline staff negotiate intrinsic and cultural factors in preference situations that carry a risk to residents' health and safety.
215059140|NCT05028699|OTHER|Snack|Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
215059141|NCT06354348|DIAGNOSTIC_TEST|USG, Grip strength, Chair stand test (CST)|Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.
215059142|NCT02209792|DRUG|Placebo|
215059143|NCT02209792|DRUG|BIBR 796 BS, 5 mg|
215059144|NCT02209792|DRUG|BIBR 796 BS, 20 mg|
215059145|NCT01331746|DRUG|APD515|20 mg oromucosal-oral administration qds for 7 days
215059146|NCT01331746|DRUG|Placebo|qds for 7 days
215059147|NCT00410969|DEVICE|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
215059148|NCT00096642|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
215059149|NCT00876707|DEVICE|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
215059150|NCT00876707|DEVICE|ReSTOR implant|Implant of multifocal IOL ReSTOR
215059151|NCT00876707|DEVICE|ReZoom implant|Implant of multifocal IOL ReZoom
215059152|NCT04644198|BIOLOGICAL|Convalescent Plasma Infusion|250 mls of convalescent plasma on day 1 \& 2.
214913001|NCT05618678|BEHAVIORAL|Infection Control|This is an attention control intervention with similar dose of educational content and attention from interventionist. It includes distribution of links to the CDC Infection Control Practice Guidelines for nursing homes, a baseline training on infection control practices for frontline workers, and six ECHO coaching sessions.
214913002|NCT00584493|DRUG|CP-675,206|"This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma~Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206."
214913003|NCT01255345|OTHER|Chronic pelvic pain|A physioterapeutic examination of abnormal muscular findings, i.e tonus, elasticitt and strength, in the pelvic area connected to female CPP.
214913004|NCT05792033|OTHER|Prospective registry|Prospective registry of patients with primary diagnosis of T1 urinary bladder cancer
214913005|NCT05300711|PROCEDURE|Bilateral salpingectomy|Removal of both fallopian tubes.
214913006|NCT05300711|PROCEDURE|Colorectal surgery|Colorectal surgery as indicated by attending surgeon.
214913007|NCT01421680|DIETARY_SUPPLEMENT|Ensure powder|Ensure powder(500kcal) per day for 7 weeks
214913008|NCT02053766|DRUG|Sevoflurane|Sevoflurane up to 8% will be administered to study subjects
214913009|NCT02053766|DRUG|Dexmedetomidine|Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
214913010|NCT02053766|DRUG|Propofol|Propofol up to 50 mcg/ kg/min will be administered to study subjects.
214913011|NCT02028260|DRUG|Modafinil|200 mg daily
214479640|NCT06871956|DIAGNOSTIC_TEST|PMRA and Shapley-Based Machine Learning for Predicting Lymph Node Metastasis in Central Subregions of Clinically Node-Negative Papillary Thyroid Microcarcinoma|PMRA and Shapley-Based Machine Learning for Predicting Lymph Node Metastasis in Central Subregions of Clinically Node-Negative Papillary Thyroid Microcarcinoma: A Prospective Multicenter Validation and Development of a Web Calculator
214479641|NCT06869356|PROCEDURE|D2 gastrectomy|Under the requirement of the guideline for laparoscopic gastrectomy for gastric cancer (2016 edition), laparoscopic radical gastrectomy is performed in patients.
214913012|NCT02028260|DRUG|Placebo|similar appearing inert tablet
214913013|NCT02185326|DRUG|Growth hormone (Norditropin, Novo nordisk)|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
214913014|NCT00418860|DRUG|Aspirin, Clopidogrel|Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
214913015|NCT03058562|DRUG|ABX-1431|ABX-1431, capsules, 40 mg in the fasting state
214913016|NCT03058562|DRUG|Placebo Comparator|Matching Placebo
214913017|NCT03058562|DRUG|ABX-1431|ABX-1431, capsules, 20 mg with a high fat meal
214913018|NCT04411901|DRUG|Cholecalciferol (vitaminD3)|Theraputic vitamin D3 for CF and non CF bronchiectasis children
214913019|NCT05487001|PROCEDURE|dexamethasone group|"1\) Arm l (dexamethasone group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 188 ml + dexamethasone 10 mg (2 ml))~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
214913020|NCT05487001|PROCEDURE|sham group|"2\) Arm ll (sham group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 190 ml~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
214913021|NCT03955822|OTHER|Phone survey|Phone Survey in order to evaluate adverse effect of the permanently implanted birth control device for women (Essure) will be proposed to wmen Treated between 2002 and 2017 with Essure.
214913022|NCT03510039|BEHAVIORAL|Early device / Follow up|"Early device:~Standardized Nursing Interview (30 minutes) with the Third Party Person Measure and follow the anxiety of the Third Party by rating the AMDP-AT scale, on D0 and D7~Telephone follow-up by nurses:~Interviews built and standardized, to M2, M4 and M6 Quantification of the AMDP-AT anxiety scale on each call"
214913023|NCT03510039|OTHER|Usual care|"Group Before : usual care by nurses"
214913024|NCT02431286|DRUG|Aprepitant|aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
214913025|NCT02431286|DRUG|Placebo|Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
214913026|NCT02431286|DRUG|Dexamethasone|Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
214913027|NCT03569930|DRUG|flavonoid-based supplements|Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
214913028|NCT03569930|DRUG|Centella Complex|The components are: Centella Asiatica, Beta-glucan, Arnica, Aloe Vera, Menthol, Devil's claw, perform actions useful to alleviate the painful symptomatology, restore the tone of the venous wall, assist the treatment of microcirculatory damage.
214913029|NCT03569930|BEHAVIORAL|standard of care|diet rich in water and vegetable fibers, hygienic and anal dilator
215059153|NCT02961504|BIOLOGICAL|HLCM051|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
215059154|NCT02961504|BIOLOGICAL|Placebo|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
215059155|NCT03884387|OTHER|Patient Decision Aid|The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
214913030|NCT04791722|BEHAVIORAL|Adaptive Intervention|The investigators will conduct an adaptive intervention using six key implementation strategies identified in earlier research on the experiences of public housing authorities adopting a smoke-free housing policy: resident engagement, smoking cessation support, smoker compliance strategies, smoke-free policy enforcement, staff training and community partnership development. The implementation approach will be tailored for each property by varying the order and intensity of smoke-free policy implementation approaches. The design will determine the optimal plan for utilizing the six implementation strategies by learning from the challenges and successes of other properties (previous waves) and providing support to property managers to refine an implementation plan.
214913031|NCT04027530|DRUG|Ertugliflozin 15 mg|Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
214913032|NCT01343810|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
214913033|NCT01343810|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
215059156|NCT02063984|BEHAVIORAL|Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
214913034|NCT04244955|OTHER|Semi-directive interviews|The interviews, carried out by the child psychiatrist, will be semi-directive and short (15 to 30 minutes) one-on-one with the child or adolescent so that the presence of the parents does not influence the responses. The CPTS-RI index, which has 20 questions, will be filled, as well as other questions to understand what is problematic for the child.
214913035|NCT05497310|DRUG|Arsenic trioxide|Patients will receive ATO 0.3mg/kg/day for days 1-5 (5 doses) and then 0.25 mg/kg/day every other day twice a week for the next 3 weeks (6 doses).
214913036|NCT05497310|DRUG|all-trans retinoic acid|Patients will receive ATRA 25/mg/m2/day for 28 continuous days without interruption.
214913037|NCT05737381|OTHER|Differential oxygen tension|By culturing the embryos in a differential O2 set-up, changing the O2 tension from reduced (5% O2) to ultralow (2% O2) from day 3 to day 5 of embryo development in vitro, we mimic the physiological differential changes in O2 as the embryo migrate from the oviduct to the uterus and develops in vivo.
214913038|NCT04409223|DRUG|Famitinib capsules|Oral KIT/PDGFRA kinase inhibitor
214913039|NCT04409223|DRUG|Sunitinib Capsules|Oral receptor tyrosine kinase (RTK) inhibitor
215059157|NCT02063984|BEHAVIORAL|Working Memory Training|25 computer-delivered sessions of neurocognitive training
215059158|NCT05978349|DRUG|adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
215059159|NCT01958580|DRUG|Gemcitabine Hydrochloride|Given IV
214479642|NCT06872385|OTHER|Answering a questionnaire|The subject have to answer an online questionnaire about her perceptions on menopause and opinion on treatments for the condition
214479643|NCT06873607|DEVICE|mobile app|Mobile application content: general information about rheumatoid arthritis (causes, symptoms, treatment), lifestyle changes, coping strategies for symptoms, nutrition and exercise recommendations, and daily life considerations.
214670257|NCT04133753|BEHAVIORAL|Facilitator-Based Intervention|Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
215059160|NCT01958580|DRUG|Docetaxel|Given IV
215059161|NCT01958580|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
215059162|NCT01958580|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214479644|NCT06873607|OTHER|Control (Standard treatment)|Routine medical check-ups and the information provided during these visits
214670258|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
214670259|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
215059163|NCT01958580|RADIATION|External Beam Radiation Therapy|Undergo EBRT
215059164|NCT01958580|OTHER|Laboratory Biomarker Analysis|Correlative studies
215059165|NCT01631487|DRUG|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
215059166|NCT01631487|DRUG|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
215059167|NCT01631487|DRUG|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
214913040|NCT05990712|DIETARY_SUPPLEMENT|Omega-3|Omega-3 is a fatty acid and there is evidence that the consumption of re-esterified oral omega-3 supplements over the course of 6 to 8 weeks aid in reducing inflammation, dry eye, and optimizing tear osmolarity. The oral omega-3 supplement taken daily.
214913041|NCT05990712|DRUG|Trehalose|Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.
214913042|NCT05990712|DRUG|Zocular Eyelid System Treatment|A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.
214913043|NCT05990712|OTHER|Blephadex cleansing eyelid wipes|Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.
214913044|NCT02414243|OTHER|New Amino Acid formula|Ordesa's Amino-Acid based Infant Formula
214913045|NCT02414243|OTHER|Commercially available Amino Acid Formula|Commercially available Amino Acid Formula
215059168|NCT01631487|DRUG|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
215059169|NCT01018173|DRUG|placebo|sc weekly
215059170|NCT01018173|DRUG|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
214670260|NCT03442127|BEHAVIORAL|CaringGuidance™ After Breast Cancer Diagnosis|Web-based, psychoeducational, self-management tool
214670261|NCT06034223|OTHER|Proprioceptive training using head mounted laser|Exercises include head relocation practice, i.e., relocating the head back to the natural head posture and to pre-determined positions in range with eyes open using feedback from a laser attached to their head. And then tracing the figure of eight with the help of laser.
214913046|NCT00113581|DRUG|EMD 72000 (matuzumab) + ECX|
214954893|NCT06730048|OTHER|Experimental Group|An appointment will be made to meet with the students in the experimental group in a suitable classroom of the school. After the pre-test data, the students in the experimental group will be shown the preeclampsia case with virtual glasses for about 5-10 minutes. Then the post-test will be applied. A scenario including preeclampsia case and nursing care practices will be created in the virtual reality environment, and 10 experts will be consulted about the scenario before the students are shown it. This application will not have any side effects.
214954894|NCT06730048|OTHER|Control group (placebo)|After the pre-test data, the preeclampsia case will be explained to the students in the control group with the classical lecture method in the Women's Health and Diseases Nursing course and the post-test will be applied.
214954895|NCT05636982|OTHER|Telecare-based intervention program|A 3-month telecare-based intervention program
214954896|NCT02259829|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
214954897|NCT02259829|DRUG|Telmisartan|
214954898|NCT02259829|DRUG|Amlodipine|
214954899|NCT03402230|DRUG|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
214954900|NCT03402230|OTHER|Laboratory Biomarker Analysis|Correlative studies
214954901|NCT03402230|OTHER|Questionnaire Administration|Ancillary studies
214954902|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
214954903|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
214954904|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1+AS03|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
214954905|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
214954906|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
214954907|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1+AS01|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
214954908|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
214954909|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
214954910|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
214954911|NCT03275389|BIOLOGICAL|Placebo|1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
214954912|NCT03275389|BIOLOGICAL|Fluarix Quadrivalent|1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
214954913|NCT00332631|DRUG|N-acetylcysteine|
214954914|NCT00332631|DRUG|Placebo|
214954915|NCT02379273|DEVICE|Nucleus Hybrid L24 Implant|Subjects have already been implanted with the Nucleus Hybrid L24 implant.
214954916|NCT05765825|DRUG|serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
214954917|NCT05765825|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
214954918|NCT05765825|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
214954919|NCT05765825|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
214913047|NCT01489436|PROCEDURE|Single-port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.
214913048|NCT01489436|PROCEDURE|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
214913049|NCT05817149|PROCEDURE|Blood samples|Blood samples
214913050|NCT04714879|OTHER|Device: anodal tDCS|anodal current modulated by an oscillatory component including a fixed (0,75 Hz) versus individually adapted so-tDCS frequency with three different stimulation durations (5 min, 2 min, 30 sec)
214913051|NCT04714879|OTHER|Device: no stimulation|sham stimulation
214913052|NCT04415164|DRUG|Xueshuantong lyophilized powder|Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
214913053|NCT04415164|DRUG|Placebo|Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
214913054|NCT04415164|OTHER|Guidelines-based standard care|Guidelines-based standard care for acute ischemic stroke
214913055|NCT05643469|OTHER|Self-determination theory-based intervention plus instant messaging|subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Follow-up booster intervention with WhatsApp/WeChat messages to help them to adhere to their schedules and independent 1-minute videos will be delivered.
214913056|NCT05643469|OTHER|AWARD model|Subjects will receive a brief intervention using the AWARD model and all of them will advise to quit immediately. Only general health advice via WhatsApp/WeChat will be delivered.
214913057|NCT01609296|DEVICE|IN.PACT Admiral™ Drug Eluting Balloon|IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
214913058|NCT00879905|DRUG|HSP990|
214913059|NCT04806711|DEVICE|Menicon Z Night|Menicon Z Night orthokeratology contact lenses were used to assess their efficacy in reducing myopia progression in children
214913060|NCT04806711|DEVICE|Control|Distance, single-vision glasses were used as a control
214913061|NCT00386360|DRUG|Placebo comparator|oral weekly for one year
214913062|NCT00386360|DRUG|risedronate|35 mg risedronate, once a week for one year
214913063|NCT03742362|DEVICE|MRI scans of distal radius|MRI scans to monitor the fat fraction in the bone marrow of the distal radius
214913064|NCT02908165|DRUG|conventional TACE in combination with sorafenib, administered on a continuous schedule|Patients assigned to Group A will begin sorafenib on a continuous schedule starting at 400mg BID from Cycle 1 Day 1, one week prior to cTACE treatment on Cycle 1 Day 8. After week 6, cTACE will be provided on demand (as needed, up to 4 treatments total in the first 4 cycles) at week 2 in subsequent cycles, and sorafenib will continue to be administered. Patients will be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
214913065|NCT02908165|DRUG|conventional TACE in combination with sorafenib, administered on a sequential schedule|Patients assigned to Group B will undergo cTACE up to 4 treatments within the first 4 cycles as needed prior to starting sorafenib. After it is determined that no further TACE treatment is necessary (via imaging and clinical assessment on follow-up), administration of sorafenib will begin on Day 1 of the following cycle. Dosing will begin at 400mg BID and maintained continuously provided no unmanageable toxicities develop, with follow-up assessments performed on week 6 of every 1-2 cycles as needed. Patients in Group B will also be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
214913066|NCT02230904|DRUG|Rotigotine (Test product PR 2.3.1)|"* Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal"
214913067|NCT02230904|DRUG|Rotigotine (Reference product PR 2.1.1)|"* Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal"
214913068|NCT03964857|OTHER|Refined olive oil (ROO)|Consumption of chicken dishes made with ROO for a period of 8 weeks
214913069|NCT03964857|OTHER|Blended Oil 1 (BO1)|Consumption of chicken dishes made with BO1 for a period of 8 weeks
214913070|NCT03964857|OTHER|Blended Oil 2 (BO2)|Consumption of chicken dishes made with BO2 for a period of 8 weeks
214913071|NCT01994434|PROCEDURE|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
214913072|NCT05787717|OTHER|Parental presence|The parent is encouraged to stay close to their child and are given ample room on one side of the OR table for this purpose
214913073|NCT01797887|BEHAVIORAL|Diet and Lifestyle Counseling|Diet and Lifestyle Counseling
214913074|NCT01532518|DRUG|Nepadutant|Nepadutant oral solution
214913075|NCT06294639|DRUG|Esketamine|esketamine will be given intravenously
214913076|NCT04332081|DEVICE|hyperbaric oxygen therapy (HBOT)|The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.
214913077|NCT03805035|DEVICE|electroacupuncture|Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
214913078|NCT03805035|DRUG|antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 3 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 1 tab);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
214913079|NCT03805035|DRUG|antihistamine(high dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 4 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate2mg/tab, 2 tabs);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
214913080|NCT03805035|DEVICE|acupuncture|Minimal needling at ST36 and GB34
214913081|NCT02074423|DIETARY_SUPPLEMENT|MealShape cinnamon extract|Acute administration of 1 g PO (2 capsules of 500 mg)
215059171|NCT01875393|DRUG|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
214304067|NCT01315756|DEVICE|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
214304068|NCT03662542|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered as IV infusion.
214304069|NCT03662542|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered as SC injection.
214304070|NCT03662542|DRUG|Golimumab Dose 1|Golimumab Dose 1 will be administered as SC injection.
214913082|NCT02074423|DIETARY_SUPPLEMENT|Placebo|Acute administration of 1 g PO (2 capsules of 500 mg)
214913083|NCT04754828|OTHER|Assigned to a rounding style|Team rounded on new admissions either in hallway or at the bedside
214913084|NCT02249728|DRUG|IV PBT2 microtracer and oral PBT2 single dose|
214913085|NCT02249728|DRUG|oral 14C-PBT2|
214913086|NCT02155283|DEVICE|Continuous Passive Motion|Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
214913087|NCT00232739|DEVICE|CYPHER Sirolimus-eluting Coronary Stent|2.25 Cypher Sirolimus-eluting Coronary Stent
214913088|NCT03061825|DEVICE|Zenith Alpha™ Abdominal Endovascular Graft|Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.
214913089|NCT02679417|BEHAVIORAL|exercise|12 weeks of aerobic or resistant exercise
214913090|NCT02744430|DRUG|Mirabegron|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
214913091|NCT02744430|OTHER|Placebo|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
214913092|NCT02921984|DRUG|Docetaxel|Docetaxel only: 80 mg/m2 on day one, every 21 days if
214913093|NCT02921984|RADIATION|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
214913094|NCT02921984|DRUG|Pemetrexed|Pemetrexed only: 500 mg/m2 on day one, every 21 days
214913095|NCT02921984|DRUG|Cisplatin|Cisplatin only: 70 mg/m2 on day one to day three, every 21 days
214913096|NCT02778009|RADIATION|iDEXA Scan|Subjects will receive pre study and post study scans to assess body mass composition
214913097|NCT02778009|OTHER|Wellness Lectures|Subjects in the Fit Physician Arm will be required to attend monthly wellness lectures
214913098|NCT02778009|OTHER|Exercise intervention|Subjects in the Fit Physician Arm will be required to attend weekly exercise interventions
214913099|NCT02778009|OTHER|Activity monitor|Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
214913100|NCT03135054|DRUG|Quizartinib|Quizartinib is an oral FLT3 receptor tyrosine kinase inhibitor
214913101|NCT03135054|DRUG|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
214913102|NCT00463047|DRUG|Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone|Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
214913103|NCT03283787|DEVICE|MicroMatrix® and Cytal™ Wound Matrix 2-Layer|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
214913104|NCT03283787|DEVICE|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
214913105|NCT03283787|DEVICE|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy
214913106|NCT01735721|PROCEDURE|Open Sinus Lift|"A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).~The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material."
214913107|NCT01034436|DIETARY_SUPPLEMENT|fatty acid quality and overweight|Duration 12 weeks
215059172|NCT04042597|DRUG|Anlotinib Hydrochloride|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
215059173|NCT00164658|BEHAVIORAL|Familial risk assessment and personalized prevention messages|
215059174|NCT04685980|PROCEDURE|spinal anaesthesia with local anaesthetic and intrathecal morphine|Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
214913108|NCT06684093|DEVICE|Back squat with Blood flow restriction machine|The blood flow restriction (BFR) machine is a specialized device designed to safely apply controlled pressure to the proximal limbs during exercise. It typically consists of adjustable cuffs or bands that are placed around the upper arms or thighs, which are connected to a pressure monitoring system. The device enables practitioners to restrict venous blood flow while allowing arterial blood flow to the working muscles. This method enhances the effects of low-intensity resistance training by promoting muscle hypertrophy and strength gains, similar to those achieved through high-intensity training. The BFR machine is commonly used in rehabilitation settings and athletic training programs to optimize performance and recovery while minimizing the risk of injury.
214913109|NCT06684093|BEHAVIORAL|Back squats|Back squats without any blood flow restriction
214913110|NCT02847091|DRUG|Ipragliflozin|Oral administration, 50mg once daily
214913111|NCT02847091|DRUG|Insulin|Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
214913112|NCT00434174|DRUG|Everolimus|"RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed."
214913113|NCT00434174|DRUG|Pemetrexed|Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
214913114|NCT06683404|DEVICE|Electrochemotherapy (ECT)|Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane induced by the local administration of electrical impulses (electroporation). ECT represents an effective therapy for loco-regional control of this disease.
214913115|NCT06683404|DRUG|Bleomycin|Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane
214913116|NCT01175096|DRUG|RAD001 (everolimus, Afinitor®)|"RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.~2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days."
214913117|NCT03442608|PROCEDURE|Zoll 2000 and/or CureWrap 3500 cooling system|Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
214913118|NCT06154980|PROCEDURE|Preoperative Ultrasound TLIP|TLIP will be performed in preop with 20cc of 0.2% ropivacaine administered bilaterally, 40cc total. Blocks will be performed under ultrasound guidance with an in-plane technique.
214913119|NCT06154980|PROCEDURE|Intraoperative TLIP|TLIP will be performed intraoperatively with 20cc of 0.2% ropivacaine bilaterally, 40cc total. Blocks under direct surgical visualization.
214913120|NCT00426166|DEVICE|Low Level Laser Therapy|7500 megawatts with a 980 nm treatment beam every 48 hours for two weeks beginning at suture removal.
215059175|NCT01490216|DRUG|lisdexamfetamine|20mg q.d. to 70mg b.i.d
215059176|NCT03619577|BEHAVIORAL|Sequential training|For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
215059177|NCT02619591|OTHER|Ultrasound Imaging|views of a hemithorax was obtained using the Zonare Ultrasound machine.
215059178|NCT02403063|DRUG|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
214304071|NCT03662542|DRUG|Golimumab Dose 2|Golimumab Dose 2 will be administered as SC injection.
214304072|NCT03662542|DRUG|Placebo|Placebo will be administered.
214304073|NCT01437007|DRUG|TKM-080301|
214304074|NCT06267404|OTHER|Iliopsoas Positional release therapy|Group A(Iliopsoas Positional release group) Patient supine, with both hips are fully extended .Find a Tender point in Iliopsoas muscle, at the initiation of pain Passively try combination of flexion Adduction/Abduction medial or lateral rotation at hip joint and stop where pain start to diminished. Hold this position of relief for 30 seconds until minimum of 75% of relief is achieved. Apply three times, than passively take lower limb in extension. Administered on both limbs.
214913121|NCT03366480|DRUG|ABTL0812 in combination with paclitaxel and carboplatin|ABTL0812 in combination with paclitaxel and carboplatin.
214913122|NCT00799890|DRUG|Sunphenon EGCG|200-800mg (1-4 capsules)
214913123|NCT00799890|DRUG|Placebo|1-4 capsules
214913124|NCT03563430|OTHER|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate as a recovery method following a single bout high-intensity interval exercise program
214913125|NCT03563430|OTHER|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session as a recovery method following a single bout high-intensity interval exercise program.
214913126|NCT03563430|OTHER|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position as a recovery method following a single bout high-intensity interval exercise program.
214954920|NCT05765825|RADIATION|Thoracic radiation therapy (TRT)|Participants will receive concurrent low-dose radiotherapy treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle, third cycle（ For patients with primary lung lesions (intrathoracic lesions) evaluated as small PR (tumor shrinkage \< 80%)/SD/PD），forth cycle（for subjects evaluated as PD/SD/PR with extrathoracic residual metastases).
214954921|NCT05859763|DRUG|99mTc-HFAPI|Each patient receive a intravenous injection of 99mTc-HFAPI, and undergo SPECT/CT scan within specified time.
214304075|NCT06267404|OTHER|Conventional exercises|Group B (conventional Physical therapy) For Ultra sonic therapy Patient prone lying, Aqua-sonic gel is applied to lumbosacral area and ultrasonic head is moved in circular motion. For TENS Electrodes are placed in crossed pattern, Paravertebral at L1 and L5 (Box Pattern)with circuit crossing at L3 and current is applied for 10 minutes, Hot pack which is kept in hydro-collateral at 70°C and 75°C is, wrapped in several towel layers, applied for 10 minutes.
214479645|NCT06866015|OTHER|Activation-socialization intervention programme|"The proposed A-S IP (Author, 2021) includes 40 activities of three domains focusing mainly on the social-psychological level of education: the Laughter Therapy Concept (13), the Reminiscence Therapy Concept (13), and the Cognitive and Social Skills Stimulation Intervention Concept (14).~The implementation of the A-S IP activities was designed for a time period of four weeks during weekdays. In the Hriňovčan care facility for older adults, mainly in the common room, two activities were implemented daily during the morning and afternoon hours reserved for this purpose. Morning activities (active) were from 10:00 to 11:00 a.m., and afternoon activities (passive) were from 1:00 to 2:00 p.m. The application of the activities was strictly determined and organised according to a time-thematic schedule that applied rules. The participants participated in group activities, and their participation was voluntary."
214479646|NCT06867562|DRUG|Paclitaxel Lipid Suspension|The formulation consists of uniformly sized (\< 100 nm) particles of Paclitaxel suspended in a lipid-based formulation. The advantage of such a Lipid-Based formulation of Paclitaxel is an improvement of the safety profile by eliminating excipients, Cremophor and ethanol which are present in conventional Paclitaxel formulations (Taxol®).
214479647|NCT06867562|DRUG|Conventional paclitaxel or Taxol|Conventional formulation with detergent Cremophor and alcohol
214670262|NCT06034223|OTHER|Conventional Physical therpay|Conventional physical therapy for mechanical neck pain which includes cervical range of motion (flexion, extension, lateral rotation, and rotation), neck isometric exercises, stretching's (scalene, trapezius, SCM) and TENS with heating pad.
214670263|NCT03251690|DRUG|Tenofovir/Emtricitabine/Rilpivirine|Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
214913127|NCT02446067|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
214913128|NCT04037787|PROCEDURE|ERAS protocol|In colorectal cancer surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting with administration of oral carbohydrates before surgery, use of intestinal preparation for selected cases only (rectal surgery), the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, preference for minimally invasive surgery, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
214913129|NCT03020992|DRUG|Certolizumab Pegol|"* pharmaceutical form: solution for infusion in prefilled syringe~* concentration: 200 mg/mL~* route of administration: subcutaneous"
214913130|NCT02915731|DIETARY_SUPPLEMENT|Vitamin A supplement|200 000 IU vitamin A (once-off dose), given to participants as part of the national vitamin A supplementation program
214913131|NCT01006122|DRUG|Placebo|Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
214913132|NCT01006122|DRUG|PF-03654746|Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
214913133|NCT02560922|BEHAVIORAL|Pain Coping Skills Training (CST)|The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
214913134|NCT02949596|BEHAVIORAL|Quality of life and quality of sexual life questionnaires|
214913135|NCT05519917|DRUG|Afatinib|Subjects will receive evaluations at the beginning of treatment, after every three cycles and at the end of the whole study.
214913136|NCT04227223|DIAGNOSTIC_TEST|biochemical measurements|TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
214913137|NCT04439942|OTHER|cardiac magnetic resonance imaging (MRI)|Cardiac MRI is a mandatory examination for Hypertrophic cardiomyopathy patients as it provides important information about the presence of fibrosis which is also directly associated with sudden cardiac death.
214913138|NCT01501539|PROCEDURE|Standard Hydrocolloid Dressing|Treatment placed over insertion site.
214304076|NCT02034786|PROCEDURE|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
214304077|NCT02034786|BIOLOGICAL|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
214304078|NCT02034786|PROCEDURE|Transdermal injection|Transdermal injection of hyaluronic acid only.
214304079|NCT00006294|DRUG|Chlorthalidone|participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study
214913139|NCT01501539|PROCEDURE|Silver Hydrocolloid Dressing|Place dressing against skin under gastrostomy tube
214913140|NCT02458144|PROCEDURE|Total hip arthroplasty|"The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.~The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed."
214913141|NCT05008432|DIAGNOSTIC_TEST|Home sleep apnea testing|Participants will be monitored with a WatchPAT device for home based diagnosis of OSA (for patients hospitalized with HFpEF, the sleep test may be performed in the hospital or at home).
214913142|NCT02094352|DRUG|Ketamine Infusion + Epidural Infusion|The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
214913143|NCT02094352|DRUG|Control Group + Epidural infusion|The saline and epidural infusions will be administered over 96 hours with appropriate titration.
214913144|NCT02094352|DRUG|Ketamine Booster Infusion|Patients will receive three ketamine booster infusions over the course of three months.
214913145|NCT02094352|DRUG|Control Group Booster Infusion|Patients will receive three saline booster infusions over the course of three months.
214913146|NCT02312323|DEVICE|Definitive 65 HPT contact lenses|
214913147|NCT02312323|DEVICE|Definitive 65 contact lenses|
214913148|NCT04168723|DRUG|MD1003|Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
214913149|NCT04168723|DRUG|Moxifloxacin 400mg|Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
214304080|NCT00006294|DRUG|Lisinopril|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
214304081|NCT00006294|DRUG|Amlodipine|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
214304082|NCT00006294|DRUG|Doxazosin|participant's drug dose will be titrated from 2mg to 8mg over the course of the study
214304083|NCT03535428|DIAGNOSTIC_TEST|VENOUS exploration|venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
214304084|NCT01217060|DRUG|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
214304085|NCT01217060|DRUG|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
214304086|NCT01217060|RADIATION|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
214304087|NCT01217060|PROCEDURE|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
214304088|NCT01217060|DRUG|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
214913150|NCT04168723|DRUG|Placebo for MD1003|Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
214304089|NCT03739112|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
214304090|NCT03739112|BIOLOGICAL|Fluarix Quadrivalent® Comparator Vaccine|Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
214913151|NCT04168723|DRUG|Placebo for moxifloxacin|Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
214913152|NCT06574646|DEVICE|LAL+|LAL+ IOL allows for refractive error (both sphere and cylinder) enhancements post-IOL implantation by exposing the IOL to ultraviolet (UV) light through a series of noninvasive treatments with a Light Delivery Device.
214913153|NCT06574646|DEVICE|Clareon Vivity Toric IOL|Clareon Vivity Toric IOL utilizes an extended depth of focus (EDOF) design, which incorporates nondiffractive wavefront shaping (X-WAVE) technology.
214913154|NCT03474185|BEHAVIORAL|Taking Charge of your Heart Health patient education classes|"Taking Charge of your Heart Health patient education classes held at TotalCardiology cardiac rehabilitation in Calgary, Canada. Consists of four, 2.5-hour long group-based classes focused on focused on physiology, risk factors, medications, nutrition, exercise, and stress management"
214913155|NCT00529308|DEVICE|Transcranial Magnetic Stimulation (active)|Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
214304091|NCT02631863|DRUG|Aminolaevulinic acid|Aminolaevulinic acid with illumination
214304092|NCT02631863|DRUG|Placebo|Placebo with illumination
214913156|NCT00529308|DEVICE|Transcranial Magnetic Stimulation (sham)|Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
214913157|NCT03365635|DRUG|Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]|Same as described in arm description
214913158|NCT05748743|PROCEDURE|glove changing|Surgical gloves were changed prior to abdominal closure during Cesarean section to evaluate its effectiveness in reducing wound complications after surgery
214913159|NCT03028207|PROCEDURE|Medical tests|During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.
214913160|NCT03028207|OTHER|Questionnaire|During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.
214913161|NCT04279431|DEVICE|EEG Recording|EEG recording acquired on BrainScope One device.
214304093|NCT03492099|DRUG|buprenorphine|Patients in this study will receive dosages to be determined by a physician that are specific to each patient.
214304094|NCT01854905|OTHER|No Treatment|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
214304095|NCT01047956|DRUG|Methadone; NAC|Methadone NAC
214304096|NCT01047956|DRUG|Methadone|Methadone
214304097|NCT05891678|RADIATION|doppler study of central retinal artery|pulsed wave Doppler after decreasing the sample volume to fit inside the center of CRA. We will measure the peak systolic velocity (PSV), end diastolic velocity (EDV), and the resistivity index which equal PSV-EDV/PSV, we will measure 3 times and the expected normal value is less than 0.7.
214479648|NCT06868862|OTHER|Exercise|Two Exercise Modalities: HIIE and MICE
214479649|NCT06871137|OTHER|Welfare Benefits Advice (WBA)|Appointment offered to receive financial advice from a Welfare Benefits Advisor (WBA) co-located with routine 6-8 week newborn health checks
214479650|NCT06871137|OTHER|Usual care|No intervention, existing London Borough of Tower Hamlets 'service as usual'
214479651|NCT06871657|PROCEDURE|Sinus lift using osseodensification technique|Osseodensification dislocates existing bone into trabeculated space by using a bur that turns in anti-clockwise direction. The procedure itself is not part of the research, but is the intervention of interest to the study.
214479652|NCT06871657|PROCEDURE|Sinus lift using the osseocondensation technique|This procedure is performed by using osteotome hand instruments. The procedure itself is not part of the research, but is the intervention of interest to the study.
214913162|NCT04279431|OTHER|Neurocognitive Tests|Cognitive performance tests performed on BrainScope One device.
214913163|NCT04279431|OTHER|Clinician Evaluation|Clinician evaluation performed as part of standard of care at the clinical site.
214913164|NCT04279431|OTHER|22-item CSI|Self assessed 22-item Concussion Symptom Inventory (CSI).
214913165|NCT00660517|DRUG|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
214913166|NCT00660517|DRUG|azelastine Hcl|azelastine Hcl nasal spray one spray per nostril two times a day
214913167|NCT00660517|DRUG|fluticasone propionate|fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
214913168|NCT00660517|DRUG|placebo|placebo nasal spray one spray per nostril two times a day
214479653|NCT06873087|DRUG|İsotretinoin|Isotretinoin treatment at a dose of 0.3 mg/kg/day for 3 months
214479654|NCT06871618|OTHER|Retrospective|Retrospective Operative risk in patients undergoing instrumental abortion
214913169|NCT03926117|BIOLOGICAL|Ziltivekimab|human IgG1k anti-human IL-6 monoclonal antibody
214913170|NCT03972748|DRUG|Itraconazole 200 mg|Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.
214913171|NCT03678610|OTHER|Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A|Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes
214913172|NCT00140387|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
214913173|NCT02554682|BEHAVIORAL|Sexual Health|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about sexual health, sexually transmitted disease (STD) prevention, and safe sex practices for teenager.
214913174|NCT02554682|BEHAVIORAL|Alcohol Prevention|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about alcohol prevention and safety, underage drinking, and drinking and driving.
214913175|NCT02554682|BEHAVIORAL|Teen Driving|Psychoeducational workbook, worksheets, videos, tip sheets, and health coaching session about how parents can help supervise their teens' safe driving practices and how to talk with their teen about important safety topics for teen drivers.
214913176|NCT04733066|DRUG|Teduglutide|Intervention group consists of patients, who receive teduglutide within routine medical care
214913177|NCT02705365|OTHER|Patient Navigation|One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
214913178|NCT02705365|OTHER|Usual Care|Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
215059179|NCT02403063|DRUG|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
215059180|NCT02403063|DRUG|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
215059181|NCT02455336|DRUG|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
215059182|NCT02455336|OTHER|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
215059183|NCT02094378|DRUG|Esketamine|84 mg esketamine administered intranasally
214670264|NCT03251690|DRUG|Tenofovir/Emtricitabine/Efavirenz|as a active comparator
214913179|NCT01159041|BEHAVIORAL|Family Focused Treatment (FFT)|FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.
214913180|NCT01159041|BEHAVIORAL|Individual Treatment (IP)|The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.
214913181|NCT04526288|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
214913182|NCT04526288|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214913183|NCT03138213|PROCEDURE|Total laparoscopic pancreaticoduodenectomy|Total laparoscopic pancreaticoduodenectomy
214913184|NCT03138213|PROCEDURE|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
214913185|NCT05399784|BEHAVIORAL|Early postpartum visit|The early postpartum visit will be an in-person visit with a medical provider at 14-21 days postpartum.
214913186|NCT05399784|BEHAVIORAL|Standard postpartum visit|The standard postpartum visit will occur at 35 to 56 days postpartum.
214913187|NCT01315938|DRUG|Abatacept Active Treatment|Participants will be treated with abatacept by intravenous infusions a total of seven times at week(s) 0, 2, 4, 8, 12, 16 and 20 weeks.
215059184|NCT02094378|DRUG|Placebo|Placebo administered intranasally
215059185|NCT01158820|DRUG|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
215059186|NCT01158820|DRUG|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
215059187|NCT01158820|DRUG|Midazolam load|2 mg bolus prior to bronchoscopy
215059188|NCT01158820|DRUG|Fentanyl load|50 µg bolus prior to bronchoscopy
215059189|NCT01158820|DRUG|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
215059190|NCT01158820|DRUG|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
215059191|NCT01158820|DRUG|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
214479655|NCT06873100|DRUG|Upadacitinib|Upadacitinib is an oral Janus kinase (JAK) inhibitor used in this study to treat patients with relapsing polychondritis. The drug is administered at a dose of 15 mg once daily for a duration of 24 weeks.
214479656|NCT06873100|DRUG|corticosteroids and immunosuppressants|Corticosteroids combined with immunosuppressants is a conventional treatment for relapsing polychondritis. In this study, it serves as the control arm against Upadacitinib for the treatment of relapsing polychondritis. Dosing is tailored to the individual patient's condition, with the selection of different types of corticosteroids and immunosuppressive agents based on the specific needs of the patient's clinical profile.
214913188|NCT01315938|DRUG|Abatacept Delayed-Onset Treatment|Participants will be treated with abatacept for 6 months and received a total of seven intravenous infusions at weeks 12, 14, 16, 20, 24, 28 and 32.
214913189|NCT00086138|DRUG|Sertraline (Zoloft)|Sertraline: range of 25 to 125 mg per day for 24 weeks
214913190|NCT00086138|DRUG|Placebo|Placebo designed to mimic sertraline taken daily for 24 weeks
214913191|NCT02407613|DEVICE|Philips Sonalleve MR-HIFU Breast Tumor Therapy System|Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) is a completely non-invasive treatment technique. HIFU uses focused ultrasound to achieve temperature rise in the targeted tissue. Real time monitoring of the treatment with MR-thermometry is used to ensure optimal safety.
214913192|NCT05079542|PROCEDURE|Timepoint of Implant placement of Bonelevel tapered implants|Implant surgery on different time points
214913193|NCT05079542|COMBINATION_PRODUCT|Material for tooth restoration - Lithiumdisilicate glass ceramic or zirconia|Tooth restoration with a certain material
214913194|NCT06111378|DIETARY_SUPPLEMENT|fish oil|fish oil
214913195|NCT06111378|DIETARY_SUPPLEMENT|linseed oil|linseed oil
214913196|NCT06111378|DIETARY_SUPPLEMENT|walnut oil|walnut oil
214913197|NCT01902745|BEHAVIORAL|Social Cognitive Theory|Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
214913198|NCT01373502|DEVICE|DES Limus Carbostent|DES Limus Carbostent Carbofilm Coated Coronary Stent
214913199|NCT01373502|DEVICE|Taxus Liberté Stent|Taxus Liberté Coronary Stent
214913200|NCT00996125|BIOLOGICAL|CervarixTM|Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
214913201|NCT00996125|OTHER|Control|Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
214913202|NCT00922064|PROCEDURE|ECT|ECT series consisting of 6 to 14 ECTs
214913203|NCT03279757|DRUG|AHES 5 minutes|Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
215059192|NCT01158820|DRUG|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
215059193|NCT01158820|DRUG|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
215059194|NCT01095991|DRUG|AZD1656|Oral tablet bd,
215059195|NCT01095991|DRUG|Sitagliptin|Oral tablet od
215059196|NCT06426563|PROCEDURE|Ablation treatment of thyroid nodule|Use Radiofrequency or Microwave ablation device to treat thyroid nodule
215059197|NCT02467192|DEVICE|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
215059198|NCT00771212|OTHER|Observational pain control study|Observational pain control study
215059199|NCT05573698|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
215059200|NCT05573698|DRUG|Placebo|Matching Placebo will be administered by intravenous (IV) injection
215059201|NCT00392977|DIETARY_SUPPLEMENT|remove Mn from PN if evidence of increased brain Mn on MRI|trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
215059202|NCT01276548|DRUG|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
215059203|NCT01276548|DRUG|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
214479657|NCT06681870|DRUG|ASP1893|Intravenous infusion
214479658|NCT06626308|OTHER|brain functional MRI|visual protocol stimulation during brain functional MRI
214913204|NCT03279757|DRUG|AHES 15 minutes|Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
214913205|NCT03279757|DRUG|AHES 25 minutes|Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
214913206|NCT03279757|DRUG|LTC 5 minutes|Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
214913207|NCT03279757|DRUG|LTC 15 minutes|Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
214913208|NCT03279757|DRUG|LTC 25 minutes|Topical application of LTC with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
214913209|NCT03279757|DEVICE|fractional CO2 laser, 50 mJ, 5% density|Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
214913210|NCT04521179|DRUG|KN026 combination|30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046
214913211|NCT06237569|DRUG|Application of ketamine and midazolam or ketamine alone to patients undergoing cesarean section under spinal anesthesia|"A single dose of 0.5 mg/kg IV diluted to 5 ml with 0.9% saline was planned to be administered simultaneously to the Ketamine Group (GROUP 1), ketamine and midazolam within 5 minutes after the newborn umbilical cord was clamped (Group 2). After midazolam 0.03 mg/kg is given, a single dose IV bolus of 0.5 mg/kg diluted to 5 ml with 0.9% saline will be administered.~Patients experience dizziness, hallucinations, nausea, headache, vomiting, diplopia and blurred vision, the time until the first analgesic request; Depression parameters will be evaluated with the Edinburgh Postpartum Depression Scale (EPDS) in all patients before cesarean section and at the 1st, 2nd and 4th weeks after birth."
214913212|NCT05905315|DRUG|Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2, followed by carboplatin 5 area under the curve (AUC). This will be administered in a 3-weekly scheme.
214913213|NCT05905315|COMBINATION_PRODUCT|Chemoradiation|According to standard treatment.
214913214|NCT05031195|OTHER|1st tertile, 2nd tertile, 3rd tertile|Patients will be divided into 3 groups according to the preoperative NLR value.
214913215|NCT00865878|DRUG|Aminolevulinic Acid|20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
214913216|NCT00865878|OTHER|Vehicle|Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
214913217|NCT02284061|OTHER|physical activities adapted to children|
214913218|NCT03549728|DRUG|Granulocyte Colony-Stimulating Factor|In group A, at the day of oocyte retrieval, after oocytes collection, 30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion with IUI catheter (AINSEGREY, RIMOS, Italy). In controls, normal saline was used for intrauterine infusion instead of G-CSF.
214479659|NCT01438853|BIOLOGICAL|TNX-832|Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
214913219|NCT03549728|PROCEDURE|Intrauterine infusion of normal saline|In group B (controls), normal saline will be used for intrauterine infusion instead of granulocyte colony-stimulating factor on the day of oocyte retrieval.
214479660|NCT01438853|DRUG|Placebo|Single intravenous dose of saline control
214913220|NCT06576154|DRUG|Cefazolin 1000 MG|"* Medication: Cefazolin~* Dosage: 1 gram~* Administration Timing: A single dose will be administered preoperatively."
214913221|NCT04106804|DRUG|Abatacept 125 MG/ML|Patients will receive weekly abatacept (Orencia®) s.c. Abatacept in the dose regimen given in the label for RA and PsA for six months
214479661|NCT06625658|DEVICE|Direct printed clear aligners|chang aligner every 10 days
214479662|NCT06675539|DIAGNOSTIC_TEST|French version PAWSS|French version of the Prediction of Alcohol Withdrawal Severity Scale
214479663|NCT06676189|DEVICE|total knee arthroplasty with medial pivot polyethylene|total knee arthroplasty with medial pivot polyethylene
214479664|NCT06676189|DEVICE|total knee arthroplasty with ultra-congruent polyethylene|total knee arthroplasty with ultra-congruent polyethylene
214479665|NCT06684028|DRUG|68Ga-FAPI-JNU|Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person
214479666|NCT05625646|OTHER|quality assurance program|The program consists of an online quiz using a multiple choice questionnaire (MCQ) design. The participants are expected to complete the online MCQ at 3, 6, 9, and 12 months following baseline. The MCQ includes still-pictures and video sequences of the 10 application specific POCUS examinations from the course curriculum. Through 15-20 questions, the quiz tests the OSAUS dimentions Each question has four possible answers of which up to three answers are correct. Each MCQ will have ten questions pertaining to pathologies within the ten applications of the curriculum. Further, there will be five to ten questions relating to image recognition, image optimisation, ultrasound artifacts. Once each MCQ is finalized, the participating GP's will receive feed-back on the answers with suggestions for improvement and guidance toward continuing self-directed learning.
214913222|NCT05161052|DEVICE|Corvis ST (dynamic Scheimpflug technology)|"* Measurement of corneal stiffness parameters { Deformation Amlitude (DAR1), Integrated radius, Stress parameter (SP A1), Stress strain index (SSI) and Corvis biomechanical index (CBI) } in keratoconic corneas before and after 3 and 6 months CXL using Corvis ST.~* Measurement of demarcation line depth using anterior segment OCT and correlate between corneal stiffness following CXL and demarcation line depth"
214913223|NCT00054431|DRUG|imatinib mesylate|Given orally
214913224|NCT00054431|DRUG|decitabine|Given IV
214913225|NCT00054431|OTHER|laboratory biomarker analysis|Correlative studies
214913226|NCT00952068|DRUG|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
214913227|NCT02523755|DRUG|Epidural analgesia Ropivacaine|Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics
214913228|NCT02523755|DRUG|Absence of epidural analgesia|Measurement of regional distribution as assessed by EIT before and after delivery
214913229|NCT01873846|DEVICE|Silicone Hydrogel Contact Lens|
214913230|NCT02824055|DRUG|Placebo|Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
214913231|NCT02824055|DRUG|RO5545965|Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
214913232|NCT04486937|DRUG|S410914 tablet|S410914 tablet
214913233|NCT03147690|DRUG|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
214913234|NCT04227431|OTHER|Insulin degludec|Participants have been treated with Tresiba® (insulin degludec) for at least 20 weeks before entering the study. The study will be based on data already recorded in participants' medical records for approximately the last year and no new tests or procedures are required as part of the study.
214913235|NCT03721796|OTHER|Audio recording of initial consultation and debriefing interviews.|Semi-structured debriefing interviews with participating oncologists and HIV-infected newly diagnosed cancer patients will follow the initial encounter. Interviews will be conducted over 45-60 minutes and will be semi-structured with open-ended questions to allow the interviewee to direct the flow of the conversation.
214913236|NCT02056210|DRUG|Mozobil|Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
214913237|NCT04712162|OTHER|Other|Compare time to awakening and quality of recovery after general anesthesia between two groups.
214913238|NCT01657721|BEHAVIORAL|Cogmed Working Memory Training Program|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
214913239|NCT02830503|PROCEDURE|Feeding tube daily replacement|Feeding tubes replaced once a day in the first week of life.
214913240|NCT04597177|RADIATION|ST-IMRT SW-IMRT|
214913241|NCT02972879|PROCEDURE|Therapeutic modalities: Orthotic (Group 1)|participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness
214913242|NCT02972879|PROCEDURE|Therapeutic modalities: LLLT (Group 2)|"The LLLT parameters are:~* LASER 904nm~* P: 1.5W/cm²~* 30mV/cm²~* Area 2 cm²~* 1 Joule por ponto ( in the A1 pulley)"
215059204|NCT03318445|DRUG|Rucaparib|All participants will take rucaparib by mouth
215059205|NCT03318445|DRUG|Irinotecan|Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
215059206|NCT00709150|BEHAVIORAL|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
215059207|NCT00709150|BEHAVIORAL|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
215059208|NCT02517398|DRUG|MSB0011359C|Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
215059209|NCT01413295|DRUG|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
215059210|NCT01413295|OTHER|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
214304098|NCT05902039|OTHER|MRI|All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2\*-weighted gradient echo (T2\*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
214304099|NCT04031833|DRUG|MAT2203|Encochleated amphotericin B
214913243|NCT02972879|PROCEDURE|Therapeutic modalities: Paraffin (Group 3)|"Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:"
214913244|NCT02972879|PROCEDURE|Corticosteroid injection (Group 4)|The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
214913245|NCT05024188|DRUG|Antibiotics|Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.
214913246|NCT05024188|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation is the process of transferring stool from a healthy donor to another.
214913247|NCT05024188|OTHER|Cellules Pills|7 days of cellules placebo pills.
215059211|NCT03287323|OTHER|Proactive Palliative Care|In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
214913248|NCT05024188|OTHER|Agarose Capsules|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
214913249|NCT04749485|DRUG|HX008|Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
214913250|NCT05002231|DRUG|Losmapimod 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fasted conditions.
214913251|NCT05002231|DRUG|Losmapimod two 7.5 mg oral tablets|Subjects will receive two losmapimod 7.5 mg tablets by mouth under fasted conditions.
214913252|NCT05002231|DRUG|Losmapimod one 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fed conditions.
214913253|NCT03308097|BEHAVIORAL|PrEP Mobile Messaging Intervention|See group description
214913254|NCT03308097|BEHAVIORAL|Enhanced Standard of Care|See group description
214913255|NCT05063279|OTHER|Progressive resistance training|Progressive resistance training, performed with a target number of repetitions of 10 per set. Sets are performed to exhaustion, and external load will be adjusted to meet the target number of repetitions.
214913256|NCT04178460|DRUG|Niraparib combined with MGD013|"The dose escalation part will enroll about 9 - 24 Gastric cancer (including gastroesophageal junction cancer) subjects, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level.~For the dose expansion part, patients with advanced or metastatic Gastric cancer (including gastroesophageal junction cancer), Triple negative breast cancer, Biliary tract carcinoma, Endometrial carcinoma will be enrolled, about 35 subjects for each expansion cohort during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation)."
214913257|NCT02191774|PROCEDURE|Medical abortion at home|Medical abortion using Mifepristone at the clinic followed by Cytotec at home
214913258|NCT05392205|DIAGNOSTIC_TEST|18F-FDG|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-2286, and undergo PET/CT imaging within the specified time. A part of participants will also undergo additional 68Ga-FAPI-46 PET/CT for comparison.
214913259|NCT02353546|BEHAVIORAL|CALM|
214913260|NCT06576700|BIOLOGICAL|Grape Seed Extracts|2 capsules/day for 8 weeks
214913261|NCT05284318|DRUG|Antibiotics treatment|After receiving intravenous antibiotics treatment for 2 weeks, and clinician determines whether to continue with any antibiotics.
214913262|NCT03355131|BEHAVIORAL|Adapted NASA's Mission X program|8 Weeks Adapted National Aeronautics and Space Administration's (NASA's) Mission X (MX) program
214913263|NCT02568293|OTHER|SBCV|SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
214670265|NCT05295329|DRUG|Compound Danshen Dropping Pills|use Compound Danshen Dropping Pills
214913264|NCT02568293|OTHER|Saline|Saline is used as a control.
214913265|NCT00327873|OTHER|Oxygen|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
214913266|NCT00327873|OTHER|Medical Air|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
214913267|NCT05979012|BEHAVIORAL|MIndfulness Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.It is up to them if they want to listen to the daily recordings."
214913268|NCT05979012|BEHAVIORAL|Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.They will have access to electronic audio recordings, with the order of listening labeled for each day. The recordings will increase gradually throughout the study, starting with about 10 minutes each day in the first week and reaching 30 minutes each day in the final week. The schedule is as follows: Week 1= 10 minutes, Week 2= 15 minutes, Week 3= 20 minutes Week 4= 30 minutes. It is up to them if they want to listen to the daily recordings."
214304100|NCT04031833|DRUG|Amphotericin B|Intravenous amphotericin B
214304101|NCT00982813|OTHER|Periodontal screening|"Periodontal screening in all patients giving birth between 24 and 37 gestational weeks.~Bacteriological sampling in the periodontal pocketing. Search for specific cytokines in the periodontal pocketing. Professional prophylaxis and oral hygiene instruction."
214304102|NCT01959542|DEVICE|MRI|
214304103|NCT01959542|OTHER|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
214913269|NCT03692234|DIETARY_SUPPLEMENT|125 mg L-homoarginine|capsules for oral supplementation
214913270|NCT03692234|OTHER|placebo|capsules for oral supplementation
214913271|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; low dose
214670266|NCT05295329|DRUG|Placebo|use placebo
214670267|NCT05337449|OTHER|silver diamine fluoride|silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries
214913272|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; middle dose
214913273|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; high dose
214913274|NCT06672172|DRUG|HRS-7535 placebo tablet|HRS-7535 placebo tablet
214913275|NCT05006287|DRUG|Non-vitamin K oral anticoagulants (NOACs)|"NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated."
214913276|NCT05006287|DRUG|Warfarin|"Warfarin Group (Comparator):~Patients randomized to the warfarin group will receive warfarin titrated to achieve a target International Normalized Ratio (INR) of 2.5 (range 2.0 to 3.0). Warfarin will be started as early as post-operative day 1 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until INR is 2.0 or above."
214479667|NCT02624050|DRUG|Methohexital|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
214479668|NCT02624050|DRUG|Propofol|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
214479669|NCT06060535|BEHAVIORAL|Suicide Attempt Risk Model Care Pathway|The suicide attempt risk model uses documented histories of medical and psychiatric diagnoses, medications, and health service utilization to predict risk of a suicide attempt in the 90 days following an outpatient visit in behavioral health clinics.
214913277|NCT06399380|OTHER|Manual mobilization of the carpal bones.|The mobilization of the carpal bones will be done in the following way: patient in supine position, with elbow flexion of approximately 90º, so that the forearm and wrist are almost vertical. The examiner positions the thumb on the dorsal aspect of the scaphoid and trapezius, and the index finger on the dorsal aspect of the piriformis and hamate. Next, a manual ventral force is applied until the resistance of the wrist tissues is felt for 30 seconds. The technique will be repeated 5 times, with a 10-second rest between each application.
214913278|NCT06399380|OTHER|Placebo|A technique will be performed that will have no effect; the hands will be placed at a point that will not be the carpal tunnel, such as the forearm.
214913279|NCT01368601|PROCEDURE|CPAP (Continuous airway pressure)|To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
215059212|NCT02008149|OTHER|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
214479670|NCT06687226|DIETARY_SUPPLEMENT|Reconstitutable food powder|During the intervention week, participants will be asked take one dose of a reconstitutable food powder provided in a ziplock bag. This powder will be a mix of Gatorade Zero Powder (1 serving) and 1 serving of commercially available powders of either one or all of the following: camu camu, kelp or maqui. The powder mix in the bag will be added to water and drunk by the participant as soon as possible after having a bowel movement (baseline stool sample). Food powders are sourced from reputable companies and are safe for consumption (Gatorade is a wellrecognized brand and available in grocery stores nationally, Navitas Organics provides certified organic, third-party tested plant food powders with fairtrade certification).
214670268|NCT05337449|OTHER|conventional composite resin restoration|Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
215059213|NCT00513084|BEHAVIORAL|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
215059214|NCT00005947|BIOLOGICAL|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
215059215|NCT00005947|BIOLOGICAL|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
215059216|NCT00402129|PROCEDURE|1064nm Nd:YAG laser at 12 J/cm2, 20 ms and 10mm spot size.|
215059217|NCT05287243|OTHER|inspiratory muscle training|Participants will complete inspiratory muscle training daily in their homes for 12 weeks. The dosage will depend on their initial maximum pressure. At the end of the 12 week intensive period, participants will reduce the inspiratory resistance by a third and continue a maintenance training for an additional 12 weeks.
215059218|NCT00577694|DRUG|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
215059219|NCT00577694|DRUG|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
214304104|NCT05872581|BEHAVIORAL|Hand scanner instant feedback|Participants will be informed about their hand scanner results of the first hand washing attempt to get individualized feedback about their hand wash performance.
214304105|NCT05872581|BEHAVIORAL|Video training|Participants will watch a training video about the 7 steps of hand washing after the first hand washing attempt.
214479671|NCT06690983|DIAGNOSTIC_TEST|18F-S16/T807|Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.
214479672|NCT06622590|BIOLOGICAL|QIV|Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
214479673|NCT06622590|BIOLOGICAL|QIV control|Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
214479674|NCT04546113|PROCEDURE|Ultrasound-guided Bilateral Paravertebral Block performed with a 20 ml injection of Ropivacaine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaine 3,75 mg/ml/side
214913280|NCT02514720|OTHER|cigarette|Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
214913281|NCT00580151|DRUG|clonidine|3-5 microgram per kilogram every 6 hours for 10 days
214913282|NCT00580151|DRUG|placebo|1 dose every 6 hours
214913283|NCT00408642|BEHAVIORAL|Enhanced adherence support|The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
214913284|NCT00408642|BEHAVIORAL|Standard adherence support|The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
215059220|NCT05043948|DIAGNOSTIC_TEST|Blood samples|for evaluation of the genome-wide association study
214304106|NCT05750927|PROCEDURE|Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)|TAVI and PCI to be administered as per physician's indication and choice, in one or more stages
214913285|NCT03364660|DEVICE|Acute epidural stimulation for cardiovascular stability|Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord. Participants received mapping for cardiovascular stability.
214913286|NCT03364660|DEVICE|Long Term Epidural Stimulation for Cardiovascular Stability|Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily.
214913287|NCT03364660|DEVICE|Participants undergo approximately 4 months of epidural stimulation for voluntary movement.|Participants undergo approximately 4 months of epidural stimulation for voluntary movement 4-7 days weekly.
214913288|NCT03364660|DEVICE|Long Term Epidural Stimulation for Cardiovascular Stability plus Stand Training|Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.
214913289|NCT03364660|DEVICE|Participants undergo approximately 4 months of epidural stimulation for voluntary movement plus stand training.|Participants undergo approximately 4 months of epidural stimulation for voluntary movement, 4-7 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.
214913290|NCT00708461|BEHAVIORAL|weight gain prevention|"1. Changes in the food environment that increase the availability of healthy foods and beverages, reduce food and beverage portion sizes, reduce prices on healthy food items, and increase prices on less healthy food items.~2. Changes in the activity environment that increase cues and incentives for walking at work and at home, using stairs, and to increase exposure of employees to information about active recreational opportunities at work and at home.~3. Changes to the environment to increase cues and incentives for regular weight monitoring by providing scales at convenient locations.~4. Changes in the informational environment that increase frequency of exposure of the employee population to accurate information about healthy food and activity choices."
214913291|NCT01786161|DRUG|Vancomycin continuous infusion|Vancomycin 24 hour intravenous continuous infusion
214913292|NCT01786161|DRUG|Vancomycin intermittent dosing interval|Vancomycin intravenous infusion at rate 1000mg/hr
214913293|NCT06569199|DEVICE|Functional Bracing|Premade fabricated braces in three sizes (small, medium and large) that have been designed for the pediatric age group between 0-5 years old will be stocked at the Alberta Children's Hospital. Braces will be applied to participants in the emergency department. As these braces are designed to allow for positional adjustments, if deemed necessary adjustments will be made by the attending orthopaedic surgeon at subsequent follow-up visit(s).
214913294|NCT06569199|DEVICE|Hip Spica Cast|The current standard of care for diaphyseal pediatric hip fractures in children aged 6 months to 5 years old is hip spica casting. A hip spica is a hard cast that covers a child's body from the chest down to their knees or ankles allowing for fracture immobilization to promote healing. Application of the spica cast occurs in the operating room and requires a general anaesthetic. Caring for a child in a hip spica cast presents significant challenges for caregivers due to the cast's cumbersome size and restricted mobility which makes routine caregiver activities like daily hygiene, toileting, transportation and skin surveillance difficult. Inadequate maintenance of the spica cast may result in skin complications, necessitating extra visits for cast adjustments, or potentially requiring revision casting in the operating room.
214913295|NCT04865263|DEVICE|Digital Pain-Management Tool|Self management digital tool for chronic pain
214913296|NCT06509958|DRUG|HR18034|HR18034
214913297|NCT06509958|DRUG|Ropivacaine Hydrochloride Injection|Ropivacaine Hydrochloride Injection
214913298|NCT00745342|BEHAVIORAL|Family Teamwork Intervention|Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
214913299|NCT00363233|DRUG|flax lignans|
214913300|NCT02630251|DRUG|GSK2820151|GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
214913301|NCT03907761|PROCEDURE|Hydrodissection|high velocity stream of normal saline is given to the dissection area by help of 10 ml syringe
214913302|NCT06123637|BEHAVIORAL|Analgesia nociception index-guided anesthesia|Maintaining the blood pressure based on analgesia nociception index of \>50 value
214913303|NCT06123637|BEHAVIORAL|Standard anesthesia|Maintaining the blood pressure based on anesthesiologist's decision
214913304|NCT06443957|DRUG|Intranasal normal saline|The patient was given 1ml of normal saline intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
214913305|NCT06443957|DRUG|Intranasal insulin-20U|The patient was given 1ml of 20U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
214913306|NCT06443957|DRUG|Intranasal insulin-40U|The patient was given 1ml of 40U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
214913307|NCT04311333|DIAGNOSTIC_TEST|Endostomal three-dimensional ultrasonography|Examination with rectal probe enclosed by water-filled balloon. Rectal mode. Dynamic examination in different positions with and without increased intra-abdominal pressure.
214913308|NCT04311333|DIAGNOSTIC_TEST|Computerized tomography of the abdomen|"Supine position, without increased intra-abdominal pressure. Experienced radiologist interprets the examination.~If adequate examination has already been performed within the last 10 months, these images will be used and the patient will thus not undergo computerized tomography within the study."
215059221|NCT02320864|PROCEDURE|Total knee replacement surgery|The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
215059222|NCT04982705|DRUG|[Part 1.1] IDG-16177|\[Part 1.1\] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
214913309|NCT04311333|DIAGNOSTIC_TEST|Clinical examination|Patients will be clinically examined with inspection and palpation in supine and erect position with and without increased intra-abdominal pressure.
215059223|NCT04982705|DRUG|[Part 1.1] Placebo of IDG-16177|\[Part 1.1\] subjects will receive a single oral dose of IMP.
215059224|NCT04982705|DRUG|[Part 2] Sitagliptin|Administration of Sitagliptin 100mg once daily for 4 weeks.
214913310|NCT04311333|DIAGNOSTIC_TEST|Evaluation at laparotomy/laparoscopy|During laparotomy or laparoscopy, inspection and/or palpation of the stoma at the abdominal wall orifice is performed.
214913311|NCT01453088|DRUG|Melphalan|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
214913312|NCT01453088|DRUG|Bortezomib|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
214913313|NCT01796392|DEVICE|EBV|This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
214913314|NCT01796392|OTHER|Optimal Medical Management|This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
214913315|NCT00731354|DEVICE|Suction-assisted Lipoplasty|Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
214913316|NCT00731354|DEVICE|VASER-assisted lipoplasty|VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
214913317|NCT02012322|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg/day for three months
214913318|NCT02012322|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg/day for three months
214913319|NCT02012322|DIETARY_SUPPLEMENT|Placebo|Three month period
214913320|NCT01270568|OTHER|Positive Psychology|Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states
214913321|NCT01270568|BEHAVIORAL|Relaxation Response|Daily practice of relaxation response, reviewed on a weekly basis
214913322|NCT01270568|BEHAVIORAL|Recollection|Subjects record daily events on a weekly basis for 8 weeks
214913323|NCT06875440|DRUG|CHX mouthwash|A total of 84 individuals diagnosed with gingivitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a twice-daily dose of CHX, while Group B received a daily dose of Green tea. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total Neutrophil level and determine if there were any changes over time.
214913324|NCT04301011|BIOLOGICAL|TBio-6517|Engineered Oncolytic Vaccinia Virus
214913325|NCT04301011|BIOLOGICAL|Pembrolizumab|Immune checkpoint inhibitor.
214913326|NCT03408938|DEVICE|of Masimo Radical-7¿ Pulse CO-Oximeter|"The Masimo pulse oximetry model:~The pulse oximetry model which Masimo developed accounts for saturation values contributed by the true arterial signal, and by one or more motion or noise signals. lt is assumed that under conditions of motion, the detected IR and RD signals comprise both the true arterial saturation signal and a venous (or non-arterial) motion noise signal. Masimo uses a highly sophisticated adaptive filter with, Discrete saturation transform (DST) four other parallel engines, to leverage each algorithm's unique strengths to ensure accurate readings through all patient conditions. Masimo SET's most powerful algorithm is Signal extraction technology (SET). All algorithms depend upon assumptions. The more assumptions, the weaker the algorithm. DST makes only one assumption -that arterial blood has a higher oxygenation than venous - making it the most powerful pulse oximetry algorithm"
215059225|NCT04982705|DRUG|[Part1.2] IDG-16177|\[Part 1.2\] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
214479675|NCT04546113|PROCEDURE|Ultrasound-guided Bilateral Erector Spinae plane Block performed with a 20 ml injection ropivacaine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaine 3,75 mg/ml/side
214479676|NCT06623331|OTHER|AI-enhanced endoscopy training|Endoscopists trained in AI-enhanced environment. Their quality indicators are measured after completing training, without additional AI enhancement.
215059226|NCT04982705|DRUG|[Part 2] IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
215059227|NCT04982705|DRUG|[Part 1.2] Placebo of IDG-16177|\[Part 1.2\] Administration once daily for 14 days.
215059228|NCT04982705|DRUG|[Part 2] Placebo of IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
214479677|NCT06623331|OTHER|Conventional endoscopy training|Endoscopists trained conventionally
214479678|NCT06875674|DIETARY_SUPPLEMENT|supplementation with control strawberry|control strawberry supplementation (100 grams/day) for 30 days
215059229|NCT06197074|OTHER|Ultrasound assessment|The morphological characteristics of the quadriceps muscle of the participants will be assessed using ultrasound.
215059230|NCT03939338|OTHER|Treg levels and CMR results|This is an observational study. Exposure: Different Treg levels and CMR results.
215059231|NCT00778167|BIOLOGICAL|cixutumumab|Given IV
215059232|NCT00778167|DRUG|erlotinib hydrochloride|Given PO
215059233|NCT00778167|OTHER|laboratory biomarker analysis|Correlative studies
215059234|NCT02046837|BEHAVIORAL|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
215059235|NCT02046837|BEHAVIORAL|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
214913327|NCT04000139|DRUG|Standardized anthocyanin-rich extract|3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
214913328|NCT04000139|DRUG|Placebo|3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
214913329|NCT05182060|BEHAVIORAL|Transition Intervention|"We will implement a bundle of care transition safety strategies with the assistance of home care coordinators at the study site and corresponding home health provider teams (nurses, rehabilitation therapists).~Home care coordinators will approach patients at the study site being referred for home health and provide resources to assist them with preparing for their transition home. These resources include a link to a video about home health services, a caregiver assessment, a care task role assignment sheet, and a shopping list. The study team will contact the older adult and caregiver by telephone within 48 hours of the home visit to confirm eligibility, explain the study, obtain consent for participation, and ask them to complete the the Hospital-to-Home Health Transition Quality Index (H3TQ) over the phone. Home health providers in the home will also complete the H3TQ."
214913330|NCT01931436|DRUG|Qing'E pill|Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
214913331|NCT01069601|BIOLOGICAL|Focetria (2x H1N1 vaccine with MF59 adjuvants)|7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
214913332|NCT05689346|DEVICE|high tone power therapy|high tone power therapy
214913333|NCT05689346|OTHER|traditional physical therapy exercises|traditional physical therapy exercises for improving balance
214913334|NCT00953654|OTHER|Strength Training|6 weeks of strength training exercise sessions involving leg press, leg curl, and leg extension exercises twice weekly at an intensity progressing from 50% to 75% of predicted one-repetition maximum across the 6 weeks of the trial.
214913335|NCT00953654|OTHER|Endurance Training|Six weeks of lower-body dynamic cycling exercise completed on an electronically-braked cycle ergometer twice weekly. The intervention will be matched to the strength training intervention on total work completed, total time actively engaged in exercise, a focus on leg muscles, and load (intensity) progression across the 6 week training protocol.
214913336|NCT01709487|PROCEDURE|HIPEC|HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
214913337|NCT01124994|PROCEDURE|Endoscopic mucosal resection|Confocal laser endomicroscopy will be used to target endoscopic mucosal resection of Barrett's oesophagus-associated neoplasia
214913338|NCT02570464|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
214913339|NCT02570464|BIOLOGICAL|Blood drawn|Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
214913340|NCT01225250|DEVICE|Polydioxanone (PDS) plates|0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
214913341|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
214913342|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
214913343|NCT05265338|DRUG|KC1036|60mg QD
214913344|NCT05751213|OTHER|knack technique.|"It consists of 11 patients who will receive pelvic floor muscle exercise and knack technique at outpatient clinic and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine sustained for 6s with a resting interval twice as long between contractions, followed by 3 fast contractions. 3 times per day. 3 days per week at home for 3 months. 3 exercises in supine position. 8 repetitions of each exercise 3times per day , 3 days per week. .~Orientation to perform the knack during activities of daily life. The knack consists of voluntary pelvic floor muscles contraction before and during activities that increase abdominal pressure.~The exercise will be performed in the supine (first month), sitting (second month), and standing (third month) positions twice a month for 3 months at outpatient clinic. (6 outpatient sessions)"
214913345|NCT05751213|OTHER|pelvic floor muscle exercises|It consists of 11 patients who will receive pelvic floor muscle exercises at the outpatient and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine position sustained for 6s with a resting interval twice as long between contractions followed by 3 fast contractions. 3 times per day , 3 days per week at home for 3 months. Two sessions per month at outpatient clinic for 3 months
215059236|NCT02046837|BEHAVIORAL|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
215059237|NCT05402254|OTHER|Pharmacovigilance Program|Knowledge of the risks in the use of the drug, identification and notification of ADE
215059238|NCT05629585|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion
215059239|NCT05629585|DRUG|Durvalumab|Experimental drug. Provided in 50mg vials. IV infusion
215059240|NCT05629585|DRUG|Capecitabine|Active Comparator. Tablet. Oral route of administration
215059241|NCT05629585|DRUG|Pembrolizumab|Active Comparator. Provided in 100mg vials. IV infusion
215059242|NCT05104866|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
214304107|NCT04093778|OTHER|Low dose high frequency training and Safe Delivery Phone Application|The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
215059243|NCT05104866|DRUG|Capecitabine|Tablet. Oral route of administration. Active comparator
215059244|NCT05104866|DRUG|Gemcitabine|IV Infusion. Active comparator
215059245|NCT05104866|DRUG|Eribulin|IV Infusion. Active comparator
215059246|NCT05104866|DRUG|Vinorelbine|IV Infusion. Active comparator
214670269|NCT01123889|BIOLOGICAL|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
214670270|NCT01123889|DRUG|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
214913346|NCT00691730|OTHER|laboratory biomarker analysis|Only sample collection, no other intervention - Correlative studies
214913347|NCT05442229|OTHER|establish a new Chinese children's speech and language norm|1063 normally developing children and 96 abnormally developing children will be retrospectively enrolled from the medical records of stratified, randomly selected centers. A total of 4137 children with normal development and 448 children with abnormal development aged from 2 to 6 years old will be selected from 11 hospitals in China by multi-center, stratified, unequal proportion random sampling and face-to-face survey. Children's speech and language development was assessed by the Speech and Language Development Scale for children aged 2 to 6, compiled by the Linguistics and Language Research Centre of the Education University of Hong Kong.
214913348|NCT03807544|DEVICE|TENS|Transcutaneous electrical nerve stimulation
214913349|NCT03308890|DRUG|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
214913350|NCT03308890|DRUG|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
214913351|NCT05581277|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-individual format.
214913352|NCT00509951|BEHAVIORAL|One-session exposure treatment|Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.
215059247|NCT04014751|OTHER|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
215059248|NCT06004154|DIAGNOSTIC_TEST|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries added to the usual follow-up at 1, 3, 6 and 12 months
214670271|NCT03551886|BEHAVIORAL|Advanced Emotion App|The app is designed to help TAY better recognize their emotions using enhanced features
214670272|NCT03551886|BEHAVIORAL|Basic Emotion App|The app is designed to help TAY better recognize their emotions using basic features
215059249|NCT02811120|OTHER|venepuncture only|single venepuncture
215059250|NCT01899638|DRUG|UMEC/VI 125/25 mcg|Combination in high dose
215059251|NCT01899638|DRUG|UMEC/VI 62.5/25 mcg|Combination in low dose
215059252|NCT01899638|DRUG|UMEC 125 mcg|LAMA mono in high dose
215059253|NCT01899638|DRUG|UMEC 62.5 mcg|LAMA mono in low dose
215059254|NCT01899638|DRUG|VI 25 mcg|LABA mono
215059255|NCT05318495|DEVICE|Standard Colonoscopy|The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).
215059256|NCT05318495|DEVICE|CAD-EYE|CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.
214670273|NCT03730389|DEVICE|External Physical Vibration Lithecbole (EPVL)|Using the the way of external physical vibration to promote separation of stones from ureteral mucosa and promoting the excretion of ureteral stones
215059257|NCT05318495|DEVICE|G-EYE|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
215059258|NCT03132961|OTHER|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
215059259|NCT01010672|DRUG|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
215059260|NCT01446887|OTHER|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
215059261|NCT04201639|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
215059262|NCT00087984|BIOLOGICAL|MB-002|Dendritic Cell Immunotherapy
215059263|NCT05572879|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
215059264|NCT05572879|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
215059265|NCT00967681|DIETARY_SUPPLEMENT|Oncoxin|(caplets 300 mg), three oral caplets per day for 24 weeks
215059266|NCT00967681|DIETARY_SUPPLEMENT|Placebo|(caplets 300 mg), three oral caplets per day for 24 weeks
215059267|NCT04799457|OTHER|Suture technique|We wil apply additional sutures to classical caesarean procedure.
215059268|NCT04187248|DRUG|Asparaginase|
214913353|NCT00509951|BEHAVIORAL|Augmented one-session exposure treatment|Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
215059269|NCT05626140|DRUG|Lacosamide 50 MG Oral Tablet [Vimpat]|Oral tablet lacosamide is a 3rd generation anti convulsant drug. it is given in a dose of 50 mg 12 hourly for 15 days. It has a longer half life than the other two drugs in comparison and fewer drug interactions as it doesnot interact with the hepatic cytochrome enzymes.hence it is seen to have better pharmacokinetics and pharmacodynamics than the other drugs in study
215059270|NCT05626140|DRUG|Codeine Phosphate|Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
214304108|NCT03202264|OTHER|TAPER|"The intervention is medication reduction. This arm is comprised of:~* Medication reconciliation~* Identification of patient priorities for care~* Identification of medications that are potentially appropriate for discontinuation/dose reduction~* Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~* Identification of medications for trial of discontinuation/dose reduction (shared decision making)~* Pause of medication and clinical monitoring"
214304109|NCT03877627|PROCEDURE|Pelvic and Peritoneal Lymphadenectomy|Patients in arm 2 will be randomized to undergo pelvic and peritoneal lymphadenectomy to treat their endometrial carcinoma.
214304110|NCT04415632|OTHER|low glycemic index diet|• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
214913354|NCT03517540|DRUG|Tropifexor (LJN452)|Comparison with monotherapy and different combination doses
214913355|NCT03517540|DRUG|Cenicriviroc (CVC)|Comparison with monotherapy and different combination doses
214913356|NCT01461694|DEVICE|Intense Pulsed Light (IPL)|Half Face Treated with IPL
214913357|NCT01461694|DEVICE|Alexandrite Laser|Half face treated with Alexandrite Laser
215059271|NCT05626140|DRUG|Diclofenac Sodium|Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
215059272|NCT04535089|DRUG|Dexmedetomidine injection|receive IV bolus dose of 0.5 ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5 ug/kg/h
215059273|NCT04535089|DRUG|Lidocaine Iv|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
215059274|NCT04335448|OTHER|No intervention is planed|No intervention is planed
215059275|NCT05737823|BEHAVIORAL|Carers-ID online support programme|The Carers-ID online programme, which consists of ten modules which cover topics including: promoting resilience, reducing anxiety, managing stress, accessing local supports, managing family conflict and information for siblings who are carers.
215059276|NCT05737823|BEHAVIORAL|Carers-ID online support programme - Wait-list control|The same programme as above delivered to the wait-list control after the T2 follow-up data has been collected.
215059277|NCT02648009|DRUG|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
215059278|NCT02648009|DRUG|Gadolinium|MRI with Gadolinium
215059279|NCT03228784|PROCEDURE|LASIK|
215059280|NCT00976157|PROCEDURE|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
215059281|NCT04345692|DRUG|Hydroxychloroquine|oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
214479679|NCT06875674|DIETARY_SUPPLEMENT|supplementation with biofortified strawberry|selenium biofortified strawberry supplementation (100 grams/day) for 30 days
214913358|NCT04578873|DRUG|QPX7831|capsule
214913359|NCT04578873|DRUG|placebo comparator|oral matched placebo capsule
214913360|NCT00616213|BIOLOGICAL|filgrastim|filgrastim will be administered at a standard dose and schedule
214913361|NCT00616213|DRUG|PR104|PR104 is administered intravenously once every 21 days
214913362|NCT00616213|OTHER|F-18-fluoromisonidazole|F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan
214913363|NCT02536092|DEVICE|755nm and 1064nm Nd:YAG laser|Dual wavelength 755nm and 1064nm Nd:YAG laser
214913364|NCT00170027|DEVICE|Magnetocardiograph|
214913365|NCT03726827|OTHER|Fibroscan screening|A single Fibroscan screening for fat content and liver stiffness
214913366|NCT02219880|DIETARY_SUPPLEMENT|Kava (240mg of kavalactones per day)|Kava 60 milligrams per tablet = 240mg of kavalactones per day
214913367|NCT02219880|DIETARY_SUPPLEMENT|Placebo|Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
214913368|NCT04632082|BEHAVIORAL|Telepsychoeducation with personalized videos|1 session with a psychologist plus 1 video a week for 4 weeks chosen based on symptom presentation
214913369|NCT04632082|BEHAVIORAL|Telepsychoeducation without personalized videos|1 session with a psychologist focused on reassurance and aspects of the outbreak
214913370|NCT05963633|BEHAVIORAL|Episodic Future Thinking (EFT)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
214913371|NCT05963633|BEHAVIORAL|Episodic Recent Thinking (ERT)|In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
214479680|NCT06875674|DIETARY_SUPPLEMENT|supplementation with selenium in tablet|selenium supplementation in tablet (100 micrograms/day) for 30 days
214913372|NCT06931704|DRUG|Elranatamab|"Each injection may be up to 2 mL in volume; however, if the maximum volume allowed per institution's policy is lower than 2 mL, the number of injections may be increased to accommodate this difference in volume and ensure the correct dose is delivered. Elranatamab should be administered to the abdomen, with preference given to the lower quadrants when possible.~Each participant may receive study intervention for a maximum of 24 cycles."
214913373|NCT06931704|DRUG|Daratumumab|1800 mg will be administrated every cycles
214913374|NCT06931704|DRUG|Lenalidomide|Daily administarted during 21 days, at each cycle
214913375|NCT05412550|BEHAVIORAL|Exercise self-management|Six walking exercise self-management telehealth sessions will focus on behavior change techniques and personalized action plans. Peer support groups will be held every three months, and will be focused on supporting participants in attaining sustained exercise. Text message prompts will focus on encouraging exercise and health self-management.
214913376|NCT05412550|BEHAVIORAL|Attention control|The six individual telehealth sessions, six peer-group sessions, and text message prompts will focus on general health education. No prompts for exercise or health self-management will be given.
214913377|NCT06364891|OTHER|VMMC NEXUS Digital application|A handheld digital application which supports segmentation of potential VMMC Clients
214670274|NCT00117962|BIOLOGICAL|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
214670275|NCT00117962|DRUG|carboplatin|AUC = 5 q 21 days for 4 cycles
214913378|NCT06775340|DRUG|RSS0343 Tabella|RSS0343 tablets, oral;
214913379|NCT05675930|DEVICE|Photobiomodulation Therapy|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation/PBM (via Thor LX2.3 system device) for 28 days
214913380|NCT05675930|OTHER|Placebo sham device|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days
214913381|NCT05368493|OTHER|MRI task|Task fMRI (Simon) \[ Time Frame: Children will undergo MRI scans when they are 6-11 years of age. \] Children will also complete a task, which will allow exploratory analyses of the functionality of attention-related neural circuits. The Simon fMRI task is a non-verbal task equivalent to the Stroop that tests sustained attention and inhibitory control and discriminates children with and without ADHD. Exploratory fMRI time-series data for each participant will be modeled using a general linear model with 3 predictors: congruent correct, incongruent correct, and incorrect. Contrast images for each participant (e.g., incongruent-minus-congruent) will be generated and entered into a group-level random-effects model. Analyses are exploratory, and will focus on frontal lobe activity during each type of trial.
214670276|NCT00117962|DRUG|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
214670277|NCT00117962|RADIATION|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
214913382|NCT06139575|DRUG|Lutetium Lu 177 JH020002 Injection|Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)
214913383|NCT06019845|DEVICE|MAGiC™|Robotic magnetic radiofrequency (RF) ablation catheter
214913384|NCT03208166|DEVICE|Doctormate|Ischemic conditioning device
214913385|NCT03208166|OTHER|Usual Care|Standard medical care
214913386|NCT03668119|BIOLOGICAL|Nivolumab|Specified dose on specified days
214913387|NCT03668119|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214913388|NCT02252393|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RARC with IUD
214913389|NCT02252393|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RARC with EUD
214913390|NCT02252393|OTHER|intraoperative complication management/prevention|Undergo RARC with IUD
214913391|NCT02252393|OTHER|intraoperative complication management/prevention|Undergo RARC with EUD
214913392|NCT02252393|OTHER|quality-of-life assessment|Ancillary studies
214913393|NCT04385082|DRUG|Active Cannabis|Smoked cannabis with THC
214913394|NCT04385082|DRUG|Placebo Cannabis|Placebo smoked cannabis (no THC)
214913395|NCT05355051|DRUG|Azacytidine|Given by Vein (IV)
214913396|NCT05355051|DRUG|Pembrolizumab|Given by Vein (IV)
214913397|NCT03158064|DRUG|Durvalumab|1500 mg by IV
214913398|NCT03158064|DRUG|Tremelimumab|"75 mg by IV~\*300mg"
214913399|NCT05977335|DIAGNOSTIC_TEST|Autonomic Function Testing|Autonomic Function Testing (AFT) includes Valsalva Manoever, Deep Breathing Test, and Head-up Tilt Table Testing.
214913400|NCT04978168|BEHAVIORAL|Core Intervention|Staff are provided with a core set of implementation strategies to facilitate interorganizational linkages between probation agencies and local community treatment providers.
214913401|NCT04978168|BEHAVIORAL|Peer Support Specialists (PSS)|Participants randomized to PSS will meet with a PSS for 6 months. Contact scheduled is flexible and based on the participant's needs and wants, plus written guidance for PSS-participant interactions.
214913402|NCT04978168|BEHAVIORAL|Treatment as Usual (TAU)|Participants randomized to TAU will receive the services that will be offered at the time the Core Implementation intervention is completed.
214913403|NCT05301114|BEHAVIORAL|Community Health Worker support|Participant will receive weekly or monthly support (via phone or in person) from a community health worker. The community health worker will be responsible for continuously assessing the patient's social needs, providing referrals to community based organizations, and assisting with the patient's non-medical needs as they progress through survivorship (e.g. social support, referrals, etc). Individuals who identify no risk factor will receive monthly phone calls, while individuals who identify 1-3 risk factors will receive monthly home visits with interim phone calls for 6 months. Those who identify 4 or more risk factors or have intensive needs such as behavioral health will receive the same services as the medium risk group and will also be connected with the social work teams within each institution.
214913404|NCT04973930|BEHAVIORAL|Interpersonal Psychotherapy|Time-limited, affect-focused, empirically supported psychotherapy
214913405|NCT04973930|DRUG|Venlafaxine HCl ER|FDA-approved antidepressant medications
214913406|NCT05336227|BEHAVIORAL|Virtual Reality Exergaming|The VR intervention will include home-based exercise using the Oculus Quest, a heart rate monitor (Polar OH1), BP cuff, and mobile application. The games will include rhythmic movements to music and sport/recreation activities that elicit high energy expenditure. Participants will be instructed to reach 150 minutes per week of moderate-exercise in week 1 and maintain this volume across the 12-week intervention. The intervention will include behavioral, physical education coaching through videoconference, which we refer to as Tele-PE. Tele-PE will aim to enhance adherence, provide basic exercise knowledge, and increase mastery playing the games. Calls will last 15 minutes, and be provided weekly in month 1, bi-weekly in month 2, and one call at the end of month 3.
214913407|NCT05940168|BEHAVIORAL|I-Navigator ACT|The intervention is an internet-delivered ten module Acceptance and Commitment Therapy treatment program for stressed and distressed parents of children with disabilities. The contents of the program is mostly text based, but also includes videos, mindfulness exercises and written exercises, as well as homework between modules.
214913408|NCT05940168|BEHAVIORAL|Navigator ACT group|The intervention is a five session Acceptance and Commitment Therapy group treatment for stressed and distressed parents of children with disabilities. All five sessions have different themes and are held by two group leaders. Sessions are around two and a half hours long. Homework is given between sessions.
214913409|NCT06794086|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy (SBRT) is a highly precise form of external beam radiation therapy used to treat tumors in various parts of the body. Enrolled patients will initiate SBRT treatment within 2 weeks after the first course of chemotherapy. Intensity-modulated radiation therapy (IMRT) will be used, with the gross tumor volume (GTV) receiving a dose of 8-12 Gy in 5 fractions, resulting in a total dose of 40-60 Gy. The biologically effective dose (BED) is equivalent to 72-132 Gy. The treatment will be administered from Monday to Friday.
214913410|NCT06794086|DRUG|PD-1 Monoclonal Antibody|PD-1 monoclonal antibody is a type of immunotherapy drug designed to treat various cancers by targeting the programmed death receptor-1 (PD-1) pathway.The PD-1 monoclonal antibody used in this study is sintilimab at a dose of 200 mg, administered via intravenous infusion on Day 1. Participants will be considered eligible only if they have completed four or more cycles of PD-1 monoclonal antibody treatment both before and after SBRT.
214913411|NCT06794086|DRUG|Chemotherapy|Chemotherapy regimens based on fluorouracil (5-FU), such as CAPOX with a 3-week cycle or mFOLFOX6/FOLFIRI/FOLFOXIRI with a 2-week cycle, may be combined with targeted therapy. During chemotherapy or chemoradiotherapy, optimal supportive care will be provided.
215059282|NCT04224103|DRUG|Inhaled nitric oxide|"Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation."
215059283|NCT00589173|BEHAVIORAL|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
215059284|NCT00589173|BEHAVIORAL|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
215059285|NCT02250469|DEVICE|Treatment with the Axium SCS system|
215059286|NCT02250469|DEVICE|Treatment with the Medtronic SCS System|
215059287|NCT02195700|DRUG|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
215059288|NCT02195700|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks.
215059289|NCT01130909|DRUG|AZD6765|75 mg
215059290|NCT01130909|DRUG|AZD6765|150 mg
215059291|NCT01130909|DRUG|Ketamine|0.5 mg/kg
215059292|NCT01130909|DRUG|Placebo|125 mL sterile NaCl 0.9%
214670278|NCT02857712|DRUG|Axitinib|Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
214913412|NCT04850989|DEVICE|Pico Goblin VR headset|We worked with Limbix to tailor content on a Pico Goblin VR headset by creating two exposure therapy themes (general social skills training/dinner party or job interview) based on CBT principles and literature. The Pico Goblin VR headset projected a 5.5-inch diagonal screen size (depth: 139.7 mm; height: 122mm; width: 68mm) with 2560 x 1440-pixel resolution, 3 degrees of freedom, 92° field of view, a refresh rate of 70Hz, and 54-71mm interpupillary distance (Kyoto, 2017). It was chosen because displays of the pre-recorded VRE videos could be smoothly operated wirelessly with a tablet that showed the selected scenes in real-time. Further, the headset could be conveniently switched on and off, and dovetailed the participant's head motion. These scenes were filmed with a 360° stereoscopic camera, each lasting between 1.5 to 10 min.
214913413|NCT01608802|OTHER|Palliative care|Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
214913414|NCT01608802|OTHER|Standard care|Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
214913415|NCT03466684|OTHER|BIA-guided fluid resuscitation protocol|"In both groups, a multi-frequency BIA with eight tactile electrodes (Inbody S10 Biospace, Biospace Co. Ltd., Seoul, Korea) was used to assess body fluid status every 6h within the first 72h after admission to the ICU and daily for a period of 4 days.~BIA recording was not adjusted by clinicians in fluid restrict, pharmacological and mechanical means of therapy.~In contrast, in group BIA, fluid resuscitation protocol with adjustment determined according to HL measured by BIA."
214913416|NCT03466684|OTHER|Traditional fluid resuscitation protocol|Traditional fluid resuscitation strategy determined by treating clinicians according to usual clinical parameters.
214913417|NCT06067906|OTHER|Hypocaloric diet|Hypocaloric diet
214913418|NCT06067906|OTHER|Dissociated diet|Dissociated diet
214913419|NCT05676606|DEVICE|Remote 1-minute single-lead electrocardiogram (ECG) monitoring in cancer patients after the first polychemotherapy cycle.|Recording of the ECG using smart-phone at rest, 15 minutes before registering ECG patient should not smoke,having tea, coffee, alcohol. During the ECG recording hands should be fixed to avoid poor quality. Patient sitting on a char with tow hands fixed on a table holding electrocardiograph with index fingers placed at the ECG electrode (left) and at the photoplethysmograph sensor(right).ECG signals are recorded from the fingers using first standard ECG lead. After registration, all ECG and photoplethysmography data will be sent to the server. The data will be automatically compared with a standard for data quality, after that the data will be sent to cardiologist. If quality will be not sufficient, the data will be deleted and the doctor will contact the patient to solve the quality issue. Thereafter, the parameters will be carried out by cardiologist, on the basis of which value of ECG monitoring will be estimated.
214913420|NCT01068678|DRUG|insulin degludec|Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
214913421|NCT01068678|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
214913422|NCT00789841|DEVICE|Magnetic Tracking System (MTS) and radio-opaque markers|MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
214913423|NCT00347958|BIOLOGICAL|Tetanus-diphtheria-acellular pertussis (Tdap) vaccine|0.5mL, Intramuscular (IM)
214913424|NCT06576635|DRUG|Docetaxel|75 mg/m2 IV over 1-hour Day 1 of each 21-day cycle
214913425|NCT06576635|DRUG|Paclitaxel|135 mg/m2 IV over 3 hours Day 1 of each 21-day cycle
214913426|NCT06576635|DRUG|Gemcitabine|"1000 mg/m2 or 1250 mg/m2 IV over 30 min Days 1, 8, and 15 of each 28-day cycle or Days 1 and 8 of each 21-day cycle 28 days (1000mg/m2 cohort)~21 days (1250mg/m2 cohort)"
214913427|NCT06576635|DRUG|Pemetrexed|500 mg/m2 IV over 10 minutes Day 1 of each 21-day cycle
214913428|NCT06576635|DRUG|Vinorelbine|30 mg/m2 IV through a weekly injection over 6-19 minutes Days 1, 8, and 15 of each 21-day cycle
214913429|NCT00754234|BEHAVIORAL|My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7|Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks
214913430|NCT00840567|PROCEDURE|Skin biopsy|
214913431|NCT00840567|PROCEDURE|Blood draw & sample|
214913432|NCT00004828|DRUG|liothyronine I 131|
214913433|NCT06255756|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
215059293|NCT06718309|DRUG|Chemotherapy|Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin. The chemotherapy treatment lasts 3 cycles.
215059294|NCT06718309|DRUG|Immunotherapy|Investigators choose PD-1 or PD-L1 according to drug indication and the immunotherapy lasts 3 cycles preoperatively and 1 year after surgery.
215059295|NCT06718309|PROCEDURE|Radical resection of lung cancer|Radical resection of lung cancer with lymph node dissection
215059296|NCT06718309|RADIATION|SBRT|SBRT for primary lung lesion 8Gy\*3F after first cycle of chemoimmunotherapy
215059297|NCT03436498|DRUG|Insulin aspart SAR341402|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
215059298|NCT03436498|DRUG|Insulin aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
215059299|NCT05238272|DEVICE|Transcranial random noise stimulation (tRNS)|There will be 20 minutes of stimulation (real tRNS or sham tRNS), 40 minutes of MT (unilateral or bilateral) and 30 minutes of functional task training.
215059300|NCT05238272|DEVICE|sham tRNS|the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds
215059301|NCT05238272|BEHAVIORAL|the unilateral MT|For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task.
215059302|NCT05238272|BEHAVIORAL|the bilateral MT|For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task. The activities practiced during MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen).
214304111|NCT04415632|OTHER|High glycemic index diet|Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
214913434|NCT06255756|BEHAVIORAL|Swallowing rehabilitation training|"Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced."
214913435|NCT06255756|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
214913436|NCT02504242|DEVICE|Inject BMP|
214913437|NCT02504242|PROCEDURE|Locally Harvested Bone|
214913438|NCT02693470|DRUG|Ustekinumab|50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
214913439|NCT01941849|DRUG|Vandetanib|100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
214913440|NCT01941849|RADIATION|131I-mIBG|Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
214913441|NCT00001680|DRUG|Thalidomide|
214913442|NCT01808781|OTHER|Exercises plus walking program|"Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become somewhat active or active by the end of the 8-week intervention."
214913443|NCT01808781|OTHER|Walking only program|Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
214913444|NCT01534039|DEVICE|Sur-Fit Natura|ConvaTec Moldable Skin Barrier for ostomy patients
214913445|NCT01534039|DEVICE|FormaFlex|Hollister skin barrier for ostomy patients
214304112|NCT05930730|BIOLOGICAL|Comvigen (Bivalent, ChulaCov19 BNA159.2)|single dose of COMVIGEN at 50 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
214913446|NCT02901210|PROCEDURE|Modified delorme procedure|
214913447|NCT06167837|DRUG|Metoclopramide Sulfone|Metoclopramide 10mg+NSS 10 ml IV 30-60 minutes before EGD
214913448|NCT06167837|DRUG|Normal Saline 10 mL Injection|Normal saline 10 ml IV 30-60 minutes before EGD
214913449|NCT03055338|DRUG|MK-8189|Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
214913450|NCT03055338|DRUG|Risperidone|Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
214913451|NCT03055338|DRUG|Placebo matching MK-8189|Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.
214913452|NCT03055338|DRUG|Placebo matching risperidone|Oral placebo capsule(s) matching the risperidone capsule, administered QD.
215059303|NCT03110029|DRUG|Efinaconazole 10% Topical Application Solution [JUBLIA]|Topical efinaconazole 10% solution (Jublia)
215059304|NCT03110029|OTHER|Application of Nail Polish|Application of Nail Polish
214304113|NCT05930730|BIOLOGICAL|BIVALENT Pfizer/BNT vaccine|single dose of BIVALENT of Pfizer/BNT Bivalent vaccine at 30 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
214304114|NCT00046332|DRUG|GW810781|
214913453|NCT03441802|OTHER|High quality extra virgin olive oil|Cases and controls were given 40 g/die high quality extra virgin olive oil
214913454|NCT03236961|DRUG|Ertapenem|I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days
214913455|NCT03236961|DRUG|Moxifloxacin|P.o. moxifloxacin 400 mg x1 for 7 days
214913456|NCT05601115|PROCEDURE|Robot assisted therapy|In addition to the conventional treatment for 60 minutes in the RYT group, it was planned to perform robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience
214913457|NCT05601115|PROCEDURE|Conventional Therapy Group|An exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) and 15 minutes of NMES was planned, accompanied by a physiotherapist experienced for at least 5 years in stroke rehabilitation, in the conventional therapy group.
214913458|NCT00579579|BEHAVIORAL|Questionaires|Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
214913459|NCT00975611|DRUG|Amantadine Hydrochloride, USP|amantadine tablets 100 mg. BID for 4 weeks
214913460|NCT00975611|DRUG|Amantadine Hydrochloride, USP|amantadine 200 mg. tablets BID for 4 weeks
214913461|NCT00975611|DRUG|Placebo|tablets BID, for 4 weeks
214913462|NCT04173780|DRUG|Atropine 0.01%|1 drop per day in both eyes for 1 year
214913463|NCT04173780|DRUG|Placebo|1 drop per day in both eyes for 1 year
214913464|NCT02608983|DIETARY_SUPPLEMENT|Agar H1CC2013|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
215059305|NCT05807412|DRUG|PrabotulinumtoxinA-Xvfs|"All subjects will receive one injection of 4 units or 0.1 cc of prabotulinumtoxin A into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of prabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
214913465|NCT02608983|DIETARY_SUPPLEMENT|Agar H1CC2012|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
214913466|NCT02608983|DIETARY_SUPPLEMENT|Maltodextrin|Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
214913467|NCT02056015|DRUG|[68Ga]MLN6907|IV Administration of \[68Ga\]MLN6907 on Day 1
214913468|NCT03058705|DRUG|Hexaminolevulinate HCL|Intravesical instillation of 100 mg hexaminolevulinate HCL will be performed via foley catheter at the initiation of the procedure. Although NIRF is more sensitive than bluelight cystoscopy, the current FDA approved dose will be used. Hexaminolevulinate has a favorable safety profile at this dose.
214913469|NCT03058705|DEVICE|Near Infrared Fluorescence (NIRF)|NIRF is a highly sensitive multi-spectral imaging modality that speeds the detection of bladder cancer fluorescence after infusion of hexaminolevinulate.
214913470|NCT05234736|DRUG|CBL-514|CBL-514 800 mg (unit dose: 2.0 mg/cm\^2)
214913471|NCT00294372|DRUG|BILR 355 BS|
214913472|NCT00294372|DRUG|Placebo|
214913473|NCT03530592|DEVICE|Seated Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system over a 6-week intervention period.
214913474|NCT01682226|DEVICE|CliniMACS Fractionation system (Arm A)|"7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)~1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
214913475|NCT01682226|DEVICE|CliniMACS Fractionation system (Arm B)|"8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3~1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood~1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
214913476|NCT01682226|BIOLOGICAL|Haploidentical donor CD34+ cells|CB grafts will consist of two CB units 4-6/6 HLA-matched to the patient to augment graft cell dose and additional T-cell depleted PBSC from a haplo-identical donor.
214913477|NCT01625819|BEHAVIORAL|Tai Chi|32 1-hour bi-weekly group sessions of Tai Chi instruction
214913478|NCT01625819|BEHAVIORAL|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
214913479|NCT01625819|BEHAVIORAL|Health Education|32 1-hour bi-weekly group sessions of health education
214913480|NCT05709028|DRUG|Fosfomycin|"Fosfomycin trometamol is a white crystalline powder which is very soluble in water. The granules are mixed with 90ml of cool water for the constitution to dissolve and will be administered soon after reconstitution. Each 30ml will contain 1g fosfomycin base.~* Children ≥ 6 months to \<1 year old will be administered 30ml (=1g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥ 1 to 11 years will be administered 60ml (=2g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥12 and \<18 years will be administered the entire 90ml solution (= 3g fosfomycin base) for each dose."
214913481|NCT05709028|DRUG|Standard of care antibiotics|Standard of care antibiotics will be chosen by the treating clinician according to institutional prescribing practices, local antibiograms and medication availability.
214913482|NCT00915408|DRUG|Lenalidomide|Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.
214479681|NCT05934136|BEHAVIORAL|My Healthy Brain 1|My Healthy Brain 1 is an 8-week group program delivered via 90-minute Zoom meetings led by a clinical psychologist. It provides education on the link between dementia and lifestyle factors, including poor exercise, sleep, diet/nutrition, mental and social stimulation, alcohol, and smoking. My Healthy Brain 1 participants learn evidence-based mindfulness and behavior change skills to address common barriers to healthy habits, such as stress and setting achievable goals. My Healthy Brain 1 participants wear an activity watch to monitor lifestyle changes during the program.
214913483|NCT00915408|DRUG|Dexamethasone|Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.
214913484|NCT00915408|DRUG|Cyclophosphamide|Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
214913485|NCT06960681|DIAGNOSTIC_TEST|External validity of the SFA score|Testing the external validity of the SFA score for the detection of in adult emergency departments
214913486|NCT03458832|DIAGNOSTIC_TEST|FSHD-specific functional rating scale|The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
214913487|NCT03458832|DEVICE|Electrical Impedance Myography|EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
215059306|NCT05807412|DRUG|OnabotulinumtoxinA|"All subjects will receive one injection of 4 units or 0.1 cc of onabotulinumtoxinA into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of onabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
215059307|NCT02088125|OTHER|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
214304115|NCT03388138|COMBINATION_PRODUCT|etafilcon A with ketotifen|Etafilcon A with ketotifen
214304116|NCT03388138|DEVICE|1-Day ACUVUE|1-Day ACUVUE
214304117|NCT04588987|BIOLOGICAL|PD-1|Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
214304118|NCT00621881|DRUG|naproxcinod|750 mg bid
214304119|NCT04779684|OTHER|Advance care planning by proxy for health care proxies of people without medical decision making capacity|Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.
214304120|NCT05812521|PROCEDURE|Paravertebral block with methylene blue|The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
214304121|NCT05812521|PROCEDURE|Thoracic Epidural Anesthesia|The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
214304122|NCT01528072|DEVICE|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
214304123|NCT04577937|DIAGNOSTIC_TEST|LAM patients underwent PSG|Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
214304124|NCT02984033|RADIATION|Head and Neck patients|Treatment consists of Intensity Modulated Radiation Therapy (until 2.2 Gy) with a total dose of 50-66 Gy in post-operative setting and 66-72 Gy in radical setting.
214913488|NCT06331546|DIETARY_SUPPLEMENT|Low-oxalate diet|4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
214913489|NCT06331546|DIETARY_SUPPLEMENT|High-oxalate diet|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)
214913490|NCT06331546|OTHER|soluble oxalate gut absorption test|Oral ingestion of 13C2-oxalate and sucralose.
214304125|NCT01268111|DRUG|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
214304126|NCT01268111|DRUG|Placebo|matching placebo
214304127|NCT02164305|OTHER|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
214486648|NCT06136260|OTHER|General Bereavement Support Information|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For GBSI, Missing Pieces sends parents a unidirectional text message providing a link to a webpage with a general list of grief resources (e.g., support groups) and information about grief and bereavement within two weeks of the child's death and again 3, 6, and 12 months after the child's death."
214486649|NCT02332850|BIOLOGICAL|Isatuximab|Given IV
214486650|NCT02332850|DRUG|Carfilzomib|Given IV
214913491|NCT00655408|DRUG|elemental iron|Iron supplementation.
214913492|NCT02151851|BIOLOGICAL|Certolizumab Pegol|"* Active substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection"
214913493|NCT02151851|DRUG|Methotrexate|"* Active substance: Methotrexate~* Pharmaceutical form: Tablet~* Concentration: Maximum dose 10 mg per week~* Route of administration: Oral"
214913494|NCT02151851|OTHER|Placebo|"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringes~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"
214913495|NCT02037178|OTHER|First ultrasound reading|First ultrasound reading of the sub-renal abdominal aorta by a general practitioner.
215059308|NCT02088125|OTHER|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
215059309|NCT01866748|DRUG|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
214913496|NCT02037178|OTHER|Second ultrasound interpretation|The untrasound images recorded by general practitioners will be interpreted a second time by an expert in vascular medecine, and evaluated for their image quality.
214913497|NCT01663961|DRUG|YM178 OCAS|oral
215059310|NCT01866748|DRUG|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
215059311|NCT01866748|DRUG|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
214304128|NCT02164305|OTHER|Neuromuscular group|Closed-chain exercise for shoulder muscles
215059312|NCT01866748|DRUG|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
215059313|NCT03527511|OTHER|Measure of etecalcetide on osteoclastic biology|In vitro evaluation of osteoclastic biology after blood sampling of patients.
214304129|NCT02164305|OTHER|Control|No exercise training
214304130|NCT06224842|DRUG|mitoxantrone liposome 16 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
214486651|NCT02332850|DRUG|Dexamethasone|Given IV or PO
214486652|NCT03466476|DEVICE|Consensus TracPatch|Consensus TracPatch will be attached to the participant's shin approximately two inches below the knee through use of an adhesive strip similar to a standard bandage for 6 weeks after total knee arthroplasty.
214486653|NCT04493476|DRUG|Chinese herbal formula|Chinese herbal formula
214304131|NCT06224842|DRUG|mitoxantrone liposome 18 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
214486654|NCT06386419|DRUG|inclisiran|Inclisiran sodium 300 mg SC. Three single doses of inclisiran sodium will be administered to the participants on Day 1, Day 90, and Day 270, respectively
214913498|NCT01663961|DRUG|Digoxin|oral
214913499|NCT02159053|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
214913500|NCT02159053|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
214913501|NCT02159053|BIOLOGICAL|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
214913502|NCT02143505|DRUG|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
214913503|NCT06035367|DEVICE|Non-invasive continuous monitoring device to record photoacoustic signal|"Neogly is in two parts, the measurement head, to be worn on the wrist and the power box, to be worn on the forearm or upper arm. The ribbon cable makes the connection between the two parts.~A handset is used to start/stop the device. The medical device record a continuous photoacoustic signal."
214913504|NCT00229996|DRUG|Oral Contraceptive|
214913505|NCT00229996|DRUG|Depot-Leuprolide/Norethindrone|
214913506|NCT03824795|DRUG|MGB-BP-3|MGB-BP-3
214913507|NCT05598450|DEVICE|rTMS and MEG for auditory hallucinations via self controlled clinical trials|"a 4 weeks, weekly 345（23min\*3times\*5day） minutes, 1Hz, 100%RMT-rTMS protocol~Detail precedure:~Before intervention, each patient was scheduled to collect three magnetoencephalogram data sessions. Apply MEG technology to calculate possible locations and determine three intervention targets. Pseudo stimulation in the first week, 5-day intervention, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. Evaluate the scale after the first week of pseudo stimulation. Week 2-4 real stimulation, intervention 5 days a week, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. After the end of the fourth week, evaluate the scale. And follow-up evaluations will be conducted on the 7th, 14th, 30th, 60th, and 90th days after the intervention."
215059314|NCT04212130|OTHER|BCA method for assessing environmental cleanliness|"Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
215059315|NCT01043744|DRUG|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)"
214913508|NCT03032042|DRUG|Azithromycin|
214913509|NCT03032042|DRUG|Albendazole|
215059316|NCT00921115|DRUG|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
215059317|NCT00921115|DRUG|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
214913510|NCT03032042|DRUG|Delayed treatment|Albendazole+Azithromycin
214913511|NCT06329349|OTHER|Exercise|12 weeks, 3 times a week of progressive endurance aerobic exercise (150 to 400kcal AEE per session)
215059318|NCT02400970|OTHER|malignant cells|
215059319|NCT03961555|BIOLOGICAL|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
215059320|NCT03961555|BIOLOGICAL|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
215059321|NCT03961555|BIOLOGICAL|Rabies vaccine|it should be administered in deltoid muscle
215059322|NCT04831476|OTHER|Patients with Benign Prostate Hyperplasia|patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin
215059323|NCT00095472|DRUG|L-NMMA|
215059324|NCT00095472|DRUG|Sodium Nitrite|
215059325|NCT05174338|OTHER|Registry|Observational, data collection
215059326|NCT05701839|PROCEDURE|face mask ventilation|In participants with face mask ventilation, oxygen inhaled through face mask at a flow rate of 5 L/min.
215059327|NCT05701839|PROCEDURE|nasopharyngeal tube ventilation|In participants with nasopharyngeal tube ventilation, oxygen inhaled through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min.
215059328|NCT05701839|DEVICE|oxygen saturation monitoring|In participants with oxygen saturation monitoring, assist ventilation through face mask will be performed when oxygen saturation drops to 95%, it lasts for another 10 seconds when oxygen saturation restores to 100%.
215059329|NCT05701839|DEVICE|oxygen reserve index monitoring|In participants with oxygen reserve index monitoring, assist ventilation through face mask will be performed when oxygen reserve index drops to 0.1, it lasts for another 10 seconds when oxygen reserve index restores to 0.1.
214304132|NCT06224842|DRUG|mitoxantrone liposome 20 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
214304133|NCT04482504|DIAGNOSTIC_TEST|3 tests: Posturography, Questionnaire, vitamin D|Posturography platform Kistler 9281B Questionnaire focused on exercise activities and self-evaluation of postural stability The investigators also determine level of vitamin D in the blood.
214913512|NCT06329349|OTHER|Combined Exercise + Diet|12 weeks, 25% caloric reduction, based on PMID: 37069434
214913513|NCT01135381|BEHAVIORAL|IVR-Enhanced Care|Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
214913514|NCT04625881|DIETARY_SUPPLEMENT|Apple derived fiber|This is a combination of soluble and insoluble fiber
214913515|NCT05174832|DRUG|Cisplatin|75 mg/m2 IV days 1 of each 21-day cycle
214913516|NCT05174832|DRUG|Nab-paclitaxel|125 mg/m2 IV days 1 and 8 of each 21-day cycle
214304134|NCT00123539|DRUG|Estrogen Replacement Therapy|
214304135|NCT00123539|PROCEDURE|Surgery|
214304136|NCT02372669|DEVICE|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
214913517|NCT05174832|DRUG|Pembrolizumab|200 mg IV every 21 days
214913518|NCT05174832|DRUG|Olaparib|300 mg PO BID
214913519|NCT05997069|OTHER|Posterior-anterior vertebral mobilizations followed by Prone press-up exercise|"Posterior-anterior vertebral mobilizations of the lumbar spine are achieved by applying a force on to a spinous process in a posteroanterior direction (Back to front).~Prone press-up exercise is started in the prone position (lying on stomach) on a flat surface. Participant keeps hands underneath the shoulders then press up his or her upper body while trying to keep the hips on the floor."
214913520|NCT05997069|OTHER|Conventional physiotherapy|Traditionally used physiotherapy for the treatment of nonspecific low back pain (thermotherapy and general stretching exercises)
214913521|NCT05025644|DRUG|Pre and post-CPB Drug: Dobutamine Hydrochloride|"* Pre-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) until a PG ≥ 50mmHg is achieved (DBT peak dose). The DBT peak dose (DBT-pd) will be recorded.~* Post-CPB provocation test at the DBT-pd achieved preoperatively."
214913522|NCT05025644|DRUG|Post-CPB Drug: Dobutamine Hydrochloride|"* Pre-CPB no intervention will be required.~* Post-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) or until postoperative provocable PG is \>16 mmHg."
214913523|NCT05163457|OTHER|Data collection|frailty evaluation
215059330|NCT05978336|BEHAVIORAL|Health Coaching Program|"The HC program will be delivered over 26-weeks. Participants will have an initial hour-long HC session where the BAP coach will conduct a brief physical assessment and work with the participant to establish their physical activity goals and develop a plan. After the initial consult, coaches will conduct 8 x 20-minute phone calls with participants over the 26-week trial decreasing from bi-weekly phone calls in weeks 1-12 to monthly phone calls in weeks 13-26.~Participants in the HC group will have an overall goal of increasing their weekly participation in moderate to vigorous physical activity by 50 minutes, via 5-, 7-, or 10-minute bouts of progressive exercises, at a rate of perceived exertion range of 13-14 (somewhat hard) by week 16. Participants will have access to specific exercise sessions made available by YouTube and/or hardcopy manuals created by the research team."
215059331|NCT05978336|BEHAVIORAL|Health Education Program|Participants will begin with a one-hour, group-based, interactive education session on falls prevention delivered either in-person or by Zoom. Following the initial education session, ED participants will receive additional group education sessions (in-person or by Zoom) with the same duration and schedule as the HC program covering a variety of healthy aging topics.
214913524|NCT06137859|BEHAVIORAL|Weekly-based functional fitness training|Participants will receive a 12-week duration of functional fitness training in daycare centers, which will be implemented twice a week. The 60-minute per session training series will be delivered and guided by qualified elderly health and fitness instructors, who will be provided with a workshop before this intervention. The workshop will be designed and delivered by the research team. The first session will focus on the physical literacy of older adults and the second session will focus on how to lead functional fitness training under the FITT principle for older adults. The main goal of functional training is to improve the range of joint motion, increase muscle strength and flexibility, and boost blood circulation safely. Therefore, symmetry training together with cardiovascular training is the core of the training program. Examples of the main training activities include cardio-full-body exercises, upper-body exercises, lower-body exercises and sensory integrative training.
214913525|NCT06137859|BEHAVIORAL|Mastering Physical Literacy Class|"A 30-minute MPLC program will be conducted by experienced elderly health and fitness instructors after WBFFT. This MPLC program aims to enhance the knowledge and understanding of physical literacy. Referring to the newly developed consensus statement, the MPLC includes the following five domains related to the relationship with movement and physical activity throughout life:~i) Why physical literacy matters - improves health, well-being and quality of life.~ii) Understanding physical literacy - value, enjoy and engage in physical activity for life.~iii) Everyone's physical literacy is different - their individual needs and experiences of movement and physical activity.~iv) Building physical literacy - think, feel, move and connect with others. v) How experience affects physical literacy - people, places and spaces around us."
214913526|NCT06137859|BEHAVIORAL|Daily based reflective writing|At the end of the baseline stage of this study, each participant of the intervention group will receive a template notebook for daily-based reflective writing. The required columns consist of the daily diet, physical activity, mood and sleep quality. Participants will be required to write down their behavior in this notebook daily. In each week's functional training course, there will be a life-sharing session, where the participants will be reminded to bring their notebooks and share their daily activities with others. They will receive feedback, advice and encouragement from the instructor and each other. The notebook will be collected during the last week of the intervention.
214913527|NCT06137859|BEHAVIORAL|Buddy Peers Support Group|Peer-support groups with buddy members will be arranged in each daycare center. Three pairs of buddies and hence about 6 participants will be formed per group. A total of 6 buddy pairs and 2 groups will be formed per daycare center. Buddy peers will encourage each other to do functional exercises regularly or to perform functional exercises together. The time and place for the practice will be decided among buddy members. A member in each group will be nominated as the leader to assist in the liaison and coordination of group activities. The group will perform weekly group-based functional exercises, and the time and place for the practice will be decided among group members. The group will be encouraged to hold monthly gatherings with their fitness instructor in order to strengthen social support.
214913528|NCT01256164|DEVICE|Fibrocaps (fibrin sealant)|Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
214913529|NCT01256164|DEVICE|Gelfoam|An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
214913530|NCT06573450|OTHER|questionnaire survey|subjects fill out questionnaires
214913531|NCT01242670|BIOLOGICAL|Ross River Virus Vaccine|Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant
214913532|NCT05422378|DRUG|STP705|STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.
214913533|NCT03304977|OTHER|questionnaire via smartphone|questionnaire via smartphone
214913534|NCT05243433|DEVICE|Laparoscopic surgery using the Maestro Platform|Laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic bariatric surgery (gastric sleeve or gastric bypass), or laparoscopic colectomy performed using the Maestro Platform.
214913535|NCT02318355|OTHER|normal saline|Crystalloid intravenous solution
214913536|NCT02318355|OTHER|lactated ringers|Crystalloid intravenous solution
215059332|NCT03340285|DIETARY_SUPPLEMENT|AkP06|first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet
215059333|NCT03340285|DIETARY_SUPPLEMENT|Placebo|first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
215059334|NCT02524145|OTHER|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
215059335|NCT02524145|DRUG|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
215059336|NCT02524145|DRUG|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
215059337|NCT02524145|DRUG|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
215059338|NCT05340868|DRUG|Semaglutide Pill|Oral semaglutide treatment
214913537|NCT03567395|DIETARY_SUPPLEMENT|Melatonin|Melatonin (5 mg sublingual tablet) administered for 3 days
214913538|NCT03567395|DIETARY_SUPPLEMENT|Honey|Raw Honey (1.5 tablespoons) administered for 3 days
214913539|NCT02953210|DRUG|dexter ketamine|multimodal anesthesia without opioids ketamine as induction drug
214913540|NCT02953210|DRUG|Lidocaine Hydrochloride|continuous infusion intravenous
214913541|NCT02953210|DRUG|Fentanyl Hydrochloride|intravenous
214913542|NCT02953210|DRUG|Clonidine Hydrochloride|clonidine intravenous pre induction
214913543|NCT02953210|DRUG|Midazolam Hydrochloride|premedication
214913544|NCT02953210|DRUG|Isoflurane Volatile Liquid|maintenance of general anesthesia
214913545|NCT02953210|DRUG|Rocuronium Injectable Solution|induction of general anesthesia
215059339|NCT04357730|DRUG|Alteplase 50 MG [Activase]|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (\>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
214913546|NCT02953210|DRUG|Propofol 1 % Injectable Suspension|induction of general anesthesia
215059340|NCT04357730|DRUG|Alteplase 50 MG [Activase]|wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
215059341|NCT01335893|DRUG|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
215059342|NCT00283803|DRUG|Exisulind|Oral antineoplastic agent that induces apoptosis in cancerous cells.
215059343|NCT00283803|DRUG|luteinizing hormone-releasing hormone (LHRH) agonist|Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
215059344|NCT00283803|DRUG|Antiandrogen|Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
215059345|NCT01127607|DRUG|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
215059346|NCT06788197|DRUG|SHR-A1811+ Fulvestrant|SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular
215059347|NCT06788197|DRUG|SHR-A1811+ Fulvestrant+HS-10352|SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular ； HS-10351 is administered orally
214913547|NCT02953210|DRUG|Dexamethasone-21-Sulfobenzoate, Sodium Salt|at the end of the procedure 4mg IV
214913548|NCT02953210|DRUG|Ranitidine Hydrochloride|at the end of the procedure
215059348|NCT06464380|DIETARY_SUPPLEMENT|Saffranal|HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.
214913549|NCT02953210|DRUG|Ondansetron Hydrochloride|at the end of the procedure
214913550|NCT02953210|DRUG|Ketorolac Injectable Solution|at the of the procedure
214913551|NCT02953210|DRUG|Bupivacaine Hydrochloride|at the end of the procedure for infiltration of trocar wounds
214913552|NCT01356303|DRUG|cisplatin, docetaxel|"All patients met the eligibility criteria will undergo treatment with chemotherapy.~Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles."
215059349|NCT06464380|DIETARY_SUPPLEMENT|Placebo|HCC patients will receive Placebo in dose of once per day for six months.
214913553|NCT04232917|DRUG|2LPAPI®|Treatment
214913554|NCT04232917|DRUG|Placebo|Placebo
214913555|NCT03503370|DRUG|Chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
214913556|NCT03503370|DRUG|Placebo|Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
214913557|NCT04353544|OTHER|delayed cord clamping|delayed cord clamping
214913558|NCT06684249|PROCEDURE|Nerve Block Injections|This intervention involves the administration of supratrochlear and greater occipital nerve block injections. The injections consist of a mixture of local anesthetics and corticosteroids, designed to reduce the frequency and severity of migraine episodes. The procedure will be repeated every 12 weeks for a total duration of 6 months to assess the long-term efficacy and safety in managing chronic migraine.
214913559|NCT06684249|DRUG|Botulinum Toxin A|Participants in this arm will receive Botulinum toxin A injections as per the PREEMPT protocol tailored for chronic migraine treatment. The treatment involves multiple injections around the head and neck regions, administered every 12 weeks over a 6-month period. This standard approach aims to reduce migraine frequency through neuromodulation of pain pathways.
214913560|NCT03773172|DRUG|MEDI6012|MEDI6012 is recombinant human lecithin-cholesterol acyltransferase (rhLCAT), an approximately 60 kilodalton, glycosylated, single-chain protein consisting of 416 amino acids produced via Chinese hamster ovary cell culture. It is being explored as an acute treatment to reduce the risk of recurrent cardiovascular events as an adjunct to the standard of care in patients with acute myocardial infarction (MI). MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.
214913561|NCT03773172|DRUG|Placebo|The placebo will mimic the active treatment.
215059350|NCT00346281|DEVICE|32P BioSilicon|
215059351|NCT01500915|DRUG|Ranibizumab|0,5mg intravitreal ranibizumab
215059352|NCT02220855|DRUG|BKM120|
215059353|NCT06492902|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly in four weeks using patches (four sessions), each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. The patch with the needle will remain in place for one week.
214670279|NCT02928419|DRUG|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
214913562|NCT06482788|DRUG|Adebrelimab (anti-PD-L1) + XELOX|"Adebrelimab: 1200mg, i.v., each infusion lasts 30-60 minutes and is administered on the first day of each cycle (3 weeks).~Capecitabine: 1000mg/m2 , bid, orally, from day 1 to day 14 of each cycle (3 weeks).~Oxaliplatin: 130mg/m2, i.v., each infusion is administered on the first day of each cycle (3 weeks)."
214913563|NCT04292262|OTHER|Observational|Observational
214913564|NCT06581341|DEVICE|Repetitive Transcranial Magnetic Stimulation and Percutaneous Tibial Nerve Stimulation|"Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.~Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used."
215059354|NCT06492902|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is conducted weekly for four weeks using patches (four sessions), each with a square shape and a side length of 10 mm. The patches will not contain any needles and will remain in place for one week.
214913565|NCT06581341|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.
215059355|NCT03830476|BEHAVIORAL|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents of children with (any kind of) disabilities.
215059356|NCT03830476|BEHAVIORAL|Treatment as usual.|Treatment as usual within outpatient disability services.
215059357|NCT03459534|DRUG|Radotinib HCl|"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."
215059358|NCT04327362|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
215059359|NCT04327362|BEHAVIORAL|Prolonged Exposure Therapy|All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
215059360|NCT06315413|PROCEDURE|Socket preservation using xenograft and composite plug|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with injected flowable composite plug which will then be stabilized using 5.0 polypropylene suture material with a figure of eight suture.
215059361|NCT06315413|PROCEDURE|Socket preservation using xenograft and intentionally exposed d-PTFE|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with d-PTFE membrane which will the be left exposed intentionally. This will be followed by securing the membrane using 5.0 polypropylene suture material with a figure of eight suture.
215059362|NCT06532071|DRUG|[68Ga]CBP8|Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8
214670280|NCT02928419|OTHER|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
215059363|NCT06532071|DRUG|Gadoterate Meglumine|Participants will receive a single intravenous injection of 0.05 mmol/kg gadoterate meglumine during DCE-MRI
215059364|NCT04986566|OTHER|Best Practice|Use standard reporting procedures
215059365|NCT04986566|BEHAVIORAL|Health Education|Use Aetonixx app
215059366|NCT04986566|OTHER|Medical Device Usage and Evaluation|Wear Vivofit 4
214479682|NCT05934136|BEHAVIORAL|My Healthy Brain 2|My Healthy Brain 2 condition controls for the effect of time spent and support/feedback from the group and interventionist. Participants in My Healthy Brain 2 will receive education on lifestyle, brain health, and cognitive decline symptoms in addition to usual care as determined by their medical team. Each weekly session will focus on a different topic: 1) lifestyle and brain health, 2) physical activity, 3) sleep, 4) nutrition, 5) medical adherence, 6) cognitive health, 7) social support, and 8) a program overview. My Healthy Brain 2 is conducted in the same format as My Healthy Brain 1 (8 weekly Zoom sessions, 90 minutes each), but does not include behavior change strategies. My Healthy Brain 2 participants wear an activity watch to monitor lifestyle changes during the program.
214913566|NCT06581341|DEVICE|Percutaneous Tibial Nerve Stimulation|Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used.
214913567|NCT05154175|DEVICE|Ottobock helmet|Patients treated in current practice
214913568|NCT02974686|DRUG|Everolimus|
214304137|NCT02372669|PROCEDURE|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
215059367|NCT04986566|OTHER|Quality-of-Life Assessment|Complete questionnaires
215059368|NCT03654170|DRUG|BI 425809 mixed with [C-14] BI425809|Oral Solution
215059369|NCT04941183|DRUG|NTR-441|NTR-441
215059370|NCT04941183|DRUG|Placebo|Placebo
215059371|NCT03574610|DEVICE|Transcranial Rotating Permanent Magnet Stimulator (TRPMS)|"TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller."
215059372|NCT03654924|DEVICE|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
215059373|NCT00005077|DRUG|oxaliplatin|
215059374|NCT02428751|DRUG|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
214304138|NCT03471195|DIAGNOSTIC_TEST|Total Salivary Cytokine profile|Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
214304139|NCT02560337|DRUG|Cabazitaxel|
214913569|NCT02974686|DRUG|Mycophenolic Acid|
214913570|NCT02862665|DRUG|iron isomaltoside 1000 (Monofer®)|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
214913571|NCT02862665|DRUG|normal saline 100 ml|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
215059375|NCT02428751|DRUG|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
215059376|NCT02428751|DRUG|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
214913572|NCT01977755|DRUG|danegaptide|
214913573|NCT01977755|DRUG|Placebo|
215059377|NCT02428751|DRUG|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
215059378|NCT02428751|DRUG|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
215059379|NCT02428751|DRUG|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
215059380|NCT03631004|DRUG|Olanzapine|olanzapine 10 mg is given before surgery
215059381|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with mechanical debridement|Non-surgical treatment of peri-implantitis with mechanical debridement .
214304140|NCT01530295|DRUG|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
214304141|NCT04346472|OTHER|Repeated Measurements of the relative regional cerebral blood volume|Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
214304142|NCT05463185|OTHER|Stretching exercises|Stretching exercises along with manual lymphatic drainage
214304143|NCT05463185|OTHER|Soft tissue mobilization|Soft tissue mobilization along with manual lymphatic drainage
214304144|NCT04019743|DRUG|CKD-330 16/10mg Tab. 1T and D086 Tab. 1T|single oral administration under fasting condition
214304145|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 1 Tab. 1T|single oral administration under fasting condition
214304146|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 2 Tab. 1T|single oral administration under fasting condition
214304147|NCT03096652|PROCEDURE|Approach for cancer resection|
215059382|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with air polishing|Non-surgical treatment of peri-implantitis with air polishing
215059383|NCT03994887|DEVICE|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
215059384|NCT01032954|DRUG|Botulinum toxin|"Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs."
215059385|NCT06000462|DRUG|Dapagliflozin 10mg Tab|Mentioned in detailed description.
214304148|NCT03946735|BEHAVIORAL|Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination|Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.
214670281|NCT02928419|DRUG|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
214913574|NCT06377813|OTHER|Mode-Kinetic Chain Exercise With Core Stability Exercises|the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
214913575|NCT06377813|OTHER|Mode-Kinetic Chain Exercise|the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
214913576|NCT02114424|DEVICE|Positional vibrator belt|Belt with vibarator to avoid sleep supine
214913577|NCT06139471|BEHAVIORAL|Virtual Reality-Enhanced Gagne's Instructional Model|Virtual Reality-Enhanced Gagne's Instructional Model
214913578|NCT04228679|DEVICE|Erbium laser|Erbium laser device
214913579|NCT04228679|DEVICE|Sham Laser|Sham laser device
214913580|NCT03367182|DRUG|Weekly paclitaxel|Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
214913581|NCT03367182|DRUG|Topotecan|Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
214913582|NCT03367182|DRUG|Pegylated liposomal doxorubicin|Drug: liposomal doxorubicin 40mg/m2 iv every 4 weeks
214913583|NCT03367182|DRUG|Bevacizumab|Drug: bevacizumab \[Avastin\] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
214913584|NCT00298272|BIOLOGICAL|IDEC-C2B8 (rituximab)|Participants will receive 500 mg rituximab on Day 1 and Day 15
214913585|NCT00298272|DRUG|Placebo|Participants will receive placebo on Day 1 and Day 15
214913586|NCT00298272|DRUG|Methotrexate|Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
214913587|NCT00298272|DRUG|Etanercept|Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
214913588|NCT00298272|DRUG|Adalimumab|Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
214913589|NCT00298272|DRUG|Methylprednisolone|Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
214913590|NCT00298272|DIETARY_SUPPLEMENT|Folate|All subjects also received a stable dose of folate (≥5 mg per week).
214913591|NCT03522012|DRUG|Tocilizumab|Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.
214913592|NCT02503124|BEHAVIORAL|Single night's wake therapy|Eligible patients are assisted in maintaining total sleep deprivation during one night
214913593|NCT02503124|DEVICE|Bright light|Bright light according to patients´ own circadian rhythm each morning for a week.
214913594|NCT02503124|OTHER|Treatment as usual - inpatient care|All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
214913595|NCT02503124|OTHER|Informative meeting|A short sleep hygiene consultation.
215059386|NCT06000462|DRUG|Metformin 1000 mg (ttd)|A dose of 1000 mg, PO, once daily, given over 8 months period
215059387|NCT06000462|OTHER|Placebo|a non-medicated pill will be used as a placebol
214913596|NCT02503124|DRUG|Treatment as usual - medicine|Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
214913597|NCT04168112|DRUG|Dextenza|Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain
214913598|NCT04168112|DRUG|Prednisolone Acetate|post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
214913599|NCT01598064|DIETARY_SUPPLEMENT|GK#10|GK#10, 1 pack tid
214913600|NCT01598064|DRUG|Placebo|Placebo 1 pack tid po
214913601|NCT05587595|OTHER|questionnaires & data collection|questionnaires
214913602|NCT04939233|DEVICE|Exoskeleton glove|A robotic hand orthosis (exoskeleton glove) will have been developed that is able to naturalistically bend the finger joints of the individuals based on intuitive voice commands
214913603|NCT02984865|DRUG|Sulfentanyl|
214913604|NCT02984865|DRUG|Nalbuphine|
214913605|NCT02984865|DRUG|flubiprofen axetil|
214913606|NCT02984865|PROCEDURE|rectus sheath block|Transversus abdominis plane (TAP) block combined with rectus sheath (RS) block will be applied in Group ESRD
214913607|NCT03379766|DEVICE|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants indivudal hearing loss.
215059388|NCT03424993|OTHER|Dietary Sodium Restriction|A registered dietician will counsel participants to reduce daily habitual dietary salt intake below 2000mg over 4 weeks
214913608|NCT03379766|DEVICE|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
214913609|NCT02225639|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
214913610|NCT02225639|DRUG|Placebo|Oral placebo capsule
214913611|NCT02225639|DRUG|PRC-063 35 mg|Oral 35 mg capsule - active
214913612|NCT02225639|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
214913613|NCT02225639|DRUG|PRC-063 55 mg|Oral 55 mg capsule - active
214913614|NCT02225639|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
214913615|NCT02225639|DRUG|PRC-063 85 mg|Oral 85 mg capsule - active
214304149|NCT03741036|PROCEDURE|Autogenous bone graft as space filling in immidiate implant placment|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with autogenous bone graft)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
214304150|NCT03741036|PROCEDURE|Deprotinized bovien as space filling in immidate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with deprotinized bovien material)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
214304151|NCT03741036|PROCEDURE|Nano-hydroxiapatite alloplast in immidiate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with nano-hydroxiapatite alloplast material )~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
214304152|NCT01859494|DEVICE|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
214670282|NCT01938222|PROCEDURE|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
214670283|NCT04732377|PROCEDURE|erector spinae block with bupivacaine|"Group (A) (control group):~Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5."
214670284|NCT04732377|PROCEDURE|erector spinae block with bupivacaine and dexmedetomidine|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
214670285|NCT05036538|DEVICE|Intervention with natural sounds administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
214913616|NCT02225639|DRUG|PRC-063 100 mg|Oral 100 mg capsule - active
214913617|NCT02575326|OTHER|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
214913618|NCT02575326|BEHAVIORAL|a provider administered, tailored discussion guide|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
214913619|NCT01636193|BIOLOGICAL|Oral Rotarix®|2 doses administered orally.
214913620|NCT01636193|OTHER|Data collection|Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
214913621|NCT01063426|DRUG|High dose Atorvastatin+enoxaparin|High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
214913622|NCT01063426|DRUG|Enoxaparin|Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
214913623|NCT04860973|DEVICE|Weighted blankets|Weighted blankets given to patient for 7 days/nights
214913624|NCT05061940|DIAGNOSTIC_TEST|Tumor Profiling|Testing TAA and HPV expression. HLA typing.
214913625|NCT05042661|DEVICE|acupuncture-like transcutaneous electrical nerve stimulation|The intervention group performed Al-TENS therapy 3 times a week for at least 20 minutes each time for 4 consecutive weeks. The second, fourth, and eighth week after the intervention.
214913626|NCT03555318|OTHER|Ambulatory visit|All patients will have an ambulatory visit with the cardiologist.
214913627|NCT03555318|OTHER|Combined ambulatory visit|Both the geriatrician and cardiologist will evaluate the patient and cardiac treatment will be agreed on between both specialists.
214913628|NCT03555318|OTHER|Geriatric intervention|After the geriatric assessment, measures to improve frailty will be started.
214913629|NCT04682717|DEVICE|perfusion index monitoring for postinduction hypotension|Hemodynamic parameters will be recorded at 1-min intervals till 10 min after intubation. Hypotension will be defined as a drop in SBP to \<30% of baseline or absolute MAP \<60 mmHg. MAP \<55 mmHg (severe hypotension) will be treated immediately by rapid intravenous fluid administration (10 ml/kg) and ephedrine sulphate 6 mg IV boluses. Bradycardia will be defined as HR \<50 bpm or decrease by more than 30% below baseline value, whichever will be lower and will be treated with atropine 0.6 mg IV boluses. The incidence of hypotension will be calculated in 2 sets - 5 min after induction of anesthesia (effect of induction agent) and first 15 min after induction (effect of induction process and endotracheal intubation).
214913630|NCT04431349|DRUG|Ticagrelor 180mg|Patient received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
214913631|NCT04431349|DRUG|Clopidogrel 75mg|Patient received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
215059389|NCT03424993|OTHER|Control|Participants will consume their routine habitual dietary sodium intake \> 3400mg per day with regular pre determined check in phone calls from a registered dietician.
214913632|NCT00044070|DRUG|YM872 (zonampanel)|
214913633|NCT04159857|PROCEDURE|Fetal head extraction technique during the cesarean section|see above for the description about one-hand and two-hand fetal head extraction technique
214913634|NCT01344824|BIOLOGICAL|bevacizumab|15 mg/kg once per 21 day cycle (up to 4 cycles).
214913635|NCT01344824|DRUG|carboplatin|Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
214913636|NCT01344824|DRUG|erlotinib hydrochloride|150mg, daily for 21 day cycle (up to 4 cycles)
214913637|NCT01344824|DRUG|pemetrexed disodium|500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
214913638|NCT03492723|DIETARY_SUPPLEMENT|Aged Garlic Extract|NR
214913639|NCT00780130|OTHER|No Intervention|male \& female college students ages 20 to 50, asymptomatic normals
214913640|NCT06246240|OTHER|Chewing gum with vitamin C|Will chew vitamin C gum as soon as nausea begins
214913641|NCT03942458|DRUG|Vicagrel 6mg|Vicagrel 24mg loading followed by 6mg/day for 6 days
214913642|NCT03942458|DRUG|Clopidogrel 75mg|Clopidogrel 300mg loading followed by 75mg/day for 6 days
214913643|NCT03850470|DIAGNOSTIC_TEST|clinical examination|Thorough examination including history, screening, motion testing, strength testing, special testing
214913644|NCT03850470|OTHER|MRI|Low field MRI .25 Tesla
214670286|NCT05036538|DEVICE|Intervention with natural sounds and binaural beats administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
214670287|NCT05036538|DEVICE|Intervention with natural sounds and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
214913645|NCT03738670|PROCEDURE|Percutaneous RFA|Single session percutaneous extra-spinal bone metastasis destruction to achieve pain relief
214913646|NCT06321406|DEVICE|NMES (neuromuscular electrical stimulation)|With this application, swallowing muscles are stimulated and muscle strength increases.
214913647|NCT06321406|BEHAVIORAL|Exercise|Traditional Conservative swallowing treatment
214913648|NCT03773406|DEVICE|Offline tDCS-before therapy|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
214913649|NCT03773406|DEVICE|Sham tDCS|Stimulation will be given for a total 30 seconds (including ramp-up and ramp-down of current) and then the tDCS device will be turned off. The brief stimulation will produce tDCS-induced sensation so that participants will not be aware when the tDCS was turned off .We will use standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
214913650|NCT03773406|DEVICE|Offline tDCS-after therapy|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
214913651|NCT03773406|DEVICE|Online tDCS|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
214913652|NCT00409487|DEVICE|Continuous positive airway pressure (CPAP)|8 weeks of CPAP
214913653|NCT00409487|DRUG|Valsartant treatment|8 weeks of Valsartant treatment (160 mg / day)
214913654|NCT03647618|OTHER|Ultrasound|Ultrasound-guided regional anaesthesia
214913655|NCT05221151|DRUG|Melatonin|In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
214913656|NCT05221151|DRUG|Pregabalin|In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
214913657|NCT05221151|DRUG|Ondansetron 4 MG|before spinal anaesthesia
215059390|NCT06444854|PROCEDURE|early chest tube removal|Chest tube removal
215059391|NCT04473950|DRUG|Naloxone Hydrochloride|An intramuscular (IM) injection of naloxone will be given.
215059392|NCT04473950|DRUG|Placebo|An IM injection of 0.9% normal saline will be given.
215059393|NCT05798546|BIOLOGICAL|Neo-T|Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
215059394|NCT05798546|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.
215059395|NCT05798546|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.
214913658|NCT04527289|DRUG|Amantadine (100mg) as add on therapy.|Amantadine (100mg) as add on therapy to the management regimen of traumatic brain injury - 100mg twice daily Oral or feeding tube
214913659|NCT04527289|DRUG|Placebo|patients will be managed with placebo as add on to the standard regimen.
214913660|NCT04963322|OTHER|extracorporeal membrane oxygenation therapy|Extracorporeal membrane oxygenation for the management of severe refractory heart and lung dysfunction
214913661|NCT02075216|PROCEDURE|Myoblast Transplantation|For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
214913662|NCT02075216|BIOLOGICAL|Neonatal Cystourethroscope Injection|4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
214913663|NCT05677256|BIOLOGICAL|nOPV2|Vaccination
214913664|NCT01692925|DRUG|turoctocog alfa|Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
214913665|NCT01692925|DRUG|turoctocog alfa|Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
214670288|NCT05036538|DEVICE|Intervention with natural sounds, binaural beats and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
214304153|NCT00862186|BEHAVIORAL|'Fatigue Facts & Fixes'|"'Fatigue Facts \& Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
214304154|NCT00365196|BEHAVIORAL|CBT Hostility Reduction Program|
214304155|NCT04073758|DRUG|Dexmedetomidine|Comparing effects of remifentanil versus dexmedetomidine
214304156|NCT03897452|DRUG|Fentanyl (5 microgram/ml) prediluted ampoules|"Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation)."
214304157|NCT02381418|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
214670289|NCT01805115|DRUG|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
214913666|NCT04506463|DRUG|MM-II dose I|Intra-articular injection
214913667|NCT04506463|DRUG|MM-II dose II|Intra-articular injection
214913668|NCT04506463|DRUG|MM-II dose III|Intra-articular injection
214913669|NCT04506463|DRUG|Placebo|Intra-articular injection
214913670|NCT04506463|DRUG|Placebo|Intra-articular injection
214913671|NCT04506463|DRUG|Placebo|Intra-articular injection
214913672|NCT02273063|DEVICE|Transcranial Magnetic Stimulation (TMS)|Up to 40 sessions of TMS delivered with the first 35 sessions delivered over 7 weeks, and final 5 treatments delivered in taper schedule over 3 weeks. Treatment is adjunct to ongoing stable pharmacotherapy.
214913673|NCT03324386|BEHAVIORAL|Experimental: Individual Orientation|This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.
214913674|NCT03324386|BEHAVIORAL|Experimental: VLE for Distance Learning|Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
214913675|NCT03324386|BEHAVIORAL|Experimental: E-blended Lerarning|This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
214913676|NCT03324386|OTHER|Conventional Therapy - Control Group|This approach may be individual orientation with conventional therapy may be making 2 nursing visits at baseline and 1 after 120 days,
214913677|NCT04274010|DIAGNOSTIC_TEST|PillCamTM Crohn's capsule|Capsule endoscopy for small and large bowel to assess Crohn's disease activity.
214913678|NCT04274010|DIAGNOSTIC_TEST|Magnetic resonance enterography|MRI scan of small bowel to assess small bowel Crohn's disease activity.
214913679|NCT04274010|PROCEDURE|Ileo-colonoscopy|Endoscopic procedure to assess Crohn's disease activity in colon and terminal ileum.
214304158|NCT00891358|BEHAVIORAL|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
214304159|NCT00003681|BIOLOGICAL|epoetin alfa|
214304160|NCT00003681|DRUG|amifostine trihydrate|
214913680|NCT00901108|PROCEDURE|Trabectome-IOL|"Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.~Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery."
214913681|NCT00901108|PROCEDURE|Trab-IOL|"Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.~Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C."
214913682|NCT05593081|GENETIC|HLA|Distinguish based on clinical features
215059396|NCT05798546|DRUG|Interleukin-2|500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
215059397|NCT02634775|OTHER|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
214913683|NCT00109655|BIOLOGICAL|Oncolytic adenovirus (serotype 5) - CG0070|Intravesical administration of CG0070 (in suspension) directly into the bladder
215059398|NCT04704297|DRUG|Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.|We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
215059399|NCT04704297|DRUG|Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.|Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
215059400|NCT04704297|DRUG|Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.|60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
214304161|NCT02270164|DIETARY_SUPPLEMENT|Artichoke Leaf Extract|Capsule
214304162|NCT02270164|OTHER|Placebo|Capsule
214304163|NCT01903304|OTHER|Olive Oil|3 months intervention
214304164|NCT01254435|PROCEDURE|Colonoscopy|Recording of colonoscopic extubation
214913684|NCT05125848|DEVICE|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.
214913685|NCT03428503|DRUG|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb\_UK) intravenous (IV) was given 100patients
214913686|NCT03428503|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
214913687|NCT04048213|OTHER|questionnaire|questionnaire send to the parents
214913688|NCT00125749|BIOLOGICAL|Dendritic cell vaccination|Autologous Dendritic Cells Derived from PBMC, Cultured with Cytokines, Pulsed Ex Vivo with Irradiated Allogeneic (Colo 829) Melanoma Cells
214913689|NCT06451536|DIAGNOSTIC_TEST|Ga-68 FAPI PET/CT|imaging of FAP expression of tumor before immunotherapy
214913690|NCT06445803|BIOLOGICAL|KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）|"CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.~Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.~Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)"
214913691|NCT01501461|PROCEDURE|Harvesting and implantation of stem cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.
214913692|NCT03255161|BEHAVIORAL|community health worker-audiologist communication education and support group|A 5-week educational program on hearing loss, communication strategies, and peer support facilitated by community health workers supervised by an audiologist.
214913693|NCT06127693|DRUG|Tetravalent Influenza Vaccine|All participants will receive the tetravalent influenza vaccine
214913694|NCT06127693|BEHAVIORAL|High-frequency electrical stimulation|All participants will receive High-frequency electrical stimulation
215059401|NCT03980743|BEHAVIORAL|iOTA text messaging intervention|Over 6 months, participants in the iOTA arm will have monthly in-person visits with a health coach who will work with the participant to set goals for the upcoming month related to healthy eating and activity. The participant will receive daily text message health tips related to their goals, and will be prompted once a week to respond with a text indicating their weight and how they are doing with their goals. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
214304165|NCT04458753|OTHER|Lumbar focused exercises|Transersus abdominis activation Multifidus activation Back extension exercise Curl up abdominal exercise
214304166|NCT04458753|OTHER|Knee focused exercises|Strengthening of quadriceps Stretching of calf and Hamstring muscles
214304167|NCT05678062|DIAGNOSTIC_TEST|Point-of-care ultrasound|An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
214304168|NCT06368232|OTHER|püPatients undergoing bariatric surgery|Patients will not be intervened. Only nutritional status after bariatric surgery will be evaluated.The data of 76 patients aged 19-64 years who had undergone bariatric surgery and were followed by a dietitian dietitian for at least 6 months were included.
214670290|NCT01805115|DRUG|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
214913695|NCT04152811|BEHAVIORAL|Cooking Matters for Diabetes|Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.
214913696|NCT04152811|OTHER|Usual Diabetes Care|Usual Diabetes Care
214913697|NCT04181528|DEVICE|Total knee arthroplasty implant|In patients undergoing unilateral TKA, decide the implant of TKA (anatomically aligned or conventional TKA implant) will be decided using ramdon number table
214913698|NCT01372293|DRUG|oral contraceptive pill|ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
215059402|NCT03980743|BEHAVIORAL|Health Education text messaging intervention|Over 6 months, participants in the Health Ed arm will also have monthly in-person visits with a health coach who will provide education on energy balance and problem-solving. Specific goals will not be set, but the health coach will assist participants in problem-solving any challenges. Participants will receive a weekly automated motivational text message health tip from the study related to what they learned in their health coaching sessions. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
215059403|NCT03740399|PROCEDURE|spinal anesthesia|Investigators will perform spinal anesthesia for section
215059404|NCT02014259|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
215059405|NCT05070455|BIOLOGICAL|Asceniv™|Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
215059406|NCT01277705|BIOLOGICAL|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
215059407|NCT01277705|BIOLOGICAL|Boostrix™|Intramuscular, single dose
215059408|NCT01277705|BIOLOGICAL|GSK Biologicals' IPV vaccine|Intramuscular, single dose
214304169|NCT01879228|DRUG|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
214304170|NCT01879228|DRUG|Placebo|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
214913699|NCT05209815|BEHAVIORAL|Questionnaire|Questionnaire
214304171|NCT01609920|DRUG|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
214304172|NCT05324163|DRUG|X0002 Spray|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
214304173|NCT05324163|DRUG|Celecoxib capsules|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
214304174|NCT05324163|DRUG|placebo|X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
214913700|NCT03303456|OTHER|Mobile health application - Ginger.io|the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data
214913701|NCT02854956|BEHAVIORAL|Neuropsychological, cognitive and behavioral assessment|"The assessment includes mainly :~* The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient~* The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient~* The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).~* The Vineland adaptive behavioral scale which allow to assess the adaptive behavior~* The Nisonger child behavior rating form which allow to assess the behavior disorders~* Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.~* Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component."
214913702|NCT01112488|OTHER|Patient Engagement Programme|Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
214913703|NCT02975388|DRUG|RO7079901|Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
215059409|NCT01277705|BIOLOGICAL|Revaxis®|Intramuscular, single dose
215059410|NCT04830306|BEHAVIORAL|Exercise|Completion of exercise in accordance with assigned protocol
215059411|NCT00332579|DRUG|Naltrexone|daily
215059412|NCT00332579|DRUG|Placebo|daily
215059413|NCT00485563|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
215059414|NCT00485563|BIOLOGICAL|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
215059415|NCT00485563|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
214913704|NCT03205956|DRUG|Levodopa|"At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above."
214913705|NCT01835795|DEVICE|Swiss DolorClast® CLASSIC applicator|Radial Extracorporeal Shock Wave applicator use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
214479683|NCT06870825|DEVICE|High-intensity Magnetic Field Muscle Stimulation|"1. The procedure is performed for 20 min., 1k/d, 5k/week, a total of 14 times (rehabilitation duration 14 days).~2. Parameters: applied parameters according to the manufacturer's specified program for muscle stimulation: muscle strengthening program~3. Stimulation site: quadriceps femoris muscle, applied above the motor point approximately 60% of the distance from the upper medial border of the patella to the anterior upper wing of the iliac bone.~4. device: BLT Super Inductive System~   * Along with muscle stimulation techniques, all subjects will undergo a standardized outpatient rehabilitation plan."
215059416|NCT00485563|DRUG|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
214304175|NCT01172951|OTHER|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
214304176|NCT01172951|OTHER|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
214304177|NCT01972269|DRUG|Bupivacaine-fentanyl|0.125% bupivacaine-fentanyl 5mcg/mL
214304178|NCT01972269|DRUG|Lidocaine|2% lidocaine
214304179|NCT04091503|DRUG|Intranasal Modified Temozolomide|"Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated"
214304180|NCT04720326|DRUG|Tacrolimus Pill|Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
214304181|NCT04720326|DRUG|Tacrolimus capsule|Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
214304182|NCT00878007|DRUG|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
214304183|NCT00878007|BEHAVIORAL|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness \& vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
214304184|NCT00878007|OTHER|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
214670291|NCT01805115|DRUG|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
214670292|NCT01805115|DRUG|Control|The control group was not given any cervical priming agents or placebo.
214670293|NCT03933501|DRUG|amoxicillin and metronidazole|375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.
214670294|NCT03933501|DRUG|Placebos|Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
214670295|NCT00600002|BIOLOGICAL|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
214670296|NCT00189358|DRUG|ZD1839|
214670297|NCT00189358|DRUG|tamoxifen|
215059417|NCT00485563|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
215059418|NCT04627090|OTHER|Data collection|Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
215059419|NCT01132950|BEHAVIORAL|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
214304185|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
214304186|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
214304187|NCT03210610|DIAGNOSTIC_TEST|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
214913706|NCT01835795|DEVICE|Swiss DolorClast® CLASSIC placebo applicator|Placebo applicator, use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
214304188|NCT03599050|BEHAVIORAL|Audiotaped Counseling Session|Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
214304189|NCT05016557|DIETARY_SUPPLEMENT|Protein ingestion|Bolus ingestion of 25g protein
214304190|NCT03285971|OTHER|Electronic CPP pager alert|Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
214304191|NCT05069766|OTHER|BioXmark™|During a scheduled outpatient gastroscopy, the tumor margins will be endoscopically marked by BioXmark™. BioXmark™ will be implanted at the most proximal margin of the tumor and 5 cm proximally of the tumor border.
214304192|NCT04020133|PROCEDURE|saphenous nerve block|"The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary."
214304193|NCT04020133|PROCEDURE|popliteal plexus block|After doing saphenous nerve block , we will move distally with the artery in the adductor canal until it moves away from the sartorius muscle to enter adductor hiatus . here , we will inject L.A above artery and so , popliteal plexus block will be accomplished
214304194|NCT04020133|DRUG|Plain bupivacaine|15ml of plain bupivacaine 0.5% will be given in both blocks
214304195|NCT04020133|DRUG|0.05 mg epinephrine|0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
214304196|NCT05855031|DIAGNOSTIC_TEST|Transient Elastography|One transient elastography 1-2 weeks after randomization
214304197|NCT03446742|OTHER|Cardiovascular rehabilitation|The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
214304198|NCT00003463|DRUG|carmustine|
214304199|NCT00003463|DRUG|irinotecan hydrochloride|
214304200|NCT00003463|DRUG|polifeprosan 20 with carmustine implant|
214913707|NCT02359487|BEHAVIORAL|Alcohol-HIV Risk Reduction Counseling|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
214913708|NCT02359487|BEHAVIORAL|Placebo Intervention|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
214913709|NCT01436370|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose \[60 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
215059420|NCT01132950|OTHER|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
214304201|NCT00003463|PROCEDURE|surgical procedure|
214304202|NCT03854617|DRUG|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
214304203|NCT03854617|DRUG|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period
214304204|NCT03566368|DIAGNOSTIC_TEST|Electrocardiogram|a 12 lead surface electrocardiogram taken after connecting limb and chest electrodes
214304205|NCT03566368|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|Transthoracic echocardiogram performed to evaluate Cardiac function in parasternal - long and short axis, Apical - 4 chamber and 5 chamber views.
214304206|NCT03566368|DIAGNOSTIC_TEST|Cardiac enzyme - Troponin I Levels|Blood sample - venous collected to measure blood troponin - I levels.
214304207|NCT05916729|DRUG|Miconazole|Protocol for active control groups includes use of Miconazole Oral gel for 14 days with frequency of four time per day.
214304208|NCT05916729|DIETARY_SUPPLEMENT|CandBerrol® lozenges|Protocol for experimental groups includes use of Miconazole Oral gel and CandBerrol® lozenges for 14 days with frequency of four time per day
214670298|NCT03194425|DIAGNOSTIC_TEST|Pelvic floor EMG|Define pelvic floor EMG template measured by probe
214670299|NCT02396147|DRUG|TAK-385 T2 Formulation|TAK-385 T2 Formulation tablets
214670300|NCT02396147|DRUG|TAK-385 T4 Formulation B|TAK-385 T4 Formulation B tablets
214913710|NCT01436370|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® \[15 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
214913711|NCT04694599|DEVICE|Low flow oxygen|Low flow oxygen delivered via nasal prong or facial mask. The flow rate is adjusted according to oxygen saturation of the patient.
214913712|NCT04180514|DIAGNOSTIC_TEST|intradialytic hypotension episode|Intradialytic hypotension episode under regular hemodialysis
214913713|NCT03246308|RADIATION|Phototherapy|Taking blood sample.
214913714|NCT02395848|DRUG|Fidaxomicin|200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
214913715|NCT03829826|BIOLOGICAL|HyQvia|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
214913716|NCT01551914|DEVICE|Ultrasonic Scissors (Ethicon)|Haemostasis using Ultrasonic scissors
214913717|NCT01551914|DEVICE|Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)|bipolar, monopolar or clip coagulation techniques
214913718|NCT01311765|OTHER|Duration of antibiotic therapy limited to 8 days|Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
215059421|NCT00463138|BEHAVIORAL|Crisis intervention|
215059422|NCT04517695|DEVICE|BVA-100|The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.
214304209|NCT04853745|DEVICE|AIR-FLOW® Master Piezon|AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.
214304210|NCT02307357|BEHAVIORAL|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
214304211|NCT00005831|BIOLOGICAL|trastuzumab|Given IV
214304212|NCT00005831|DRUG|paclitaxel|Given IV
214913719|NCT05978544|DRUG|Itolizumab|Patients to be treated with Itolizumab.
214913720|NCT06287476|OTHER|Acute exercise bout on visit 2 and 3|1\) a 5-minute warm-up, 2) 4 minutes at 60% of the maximal workload (determined on Study Day 1), 3) 2 minutes active break at 15 watt, 4) 4 minutes at maximal workload.
214913721|NCT01024140|DRUG|Escitalopram|Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
214913722|NCT02058537|DRUG|Bethanechol|Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
214913723|NCT03253549|DEVICE|SMArTVIEW|Remote automated, continuous monitoring in hospital after cardiac or vascular surgery, followed by 30-day at home monitoring, daily nurse video visits and a self-management training program.
215059423|NCT04517695|DEVICE|Transpulmonary Thermodilution (TPTD)|TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.
215059424|NCT04517695|DEVICE|Sublingual Microcirculation|With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.
214304213|NCT00005831|DRUG|carboplatin|Given IV
214304214|NCT00005831|DRUG|gemcitabine hydrochloride|Given IV
214304215|NCT00005831|OTHER|laboratory biomarker analysis|Correlative studies
214304216|NCT02702440|OTHER|Liquid calories from sugars|
214670301|NCT02396147|DRUG|TAK-385 T4 Formulation C|TAK-385 T4 Formulation C tablets
214670302|NCT04752280|RADIATION|Proton irradiation|proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)
214670303|NCT04752280|RADIATION|Photon irradiation|proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy
214913724|NCT05053022|DEVICE|Skinpen Precision System|Subjects will receive a total of 8-12 treatments with the Skinpen Precision system targeting their Vitiligo lesions.
214913725|NCT02610374|OTHER|Agrarian Diet|A diet higher in carbohydrates and lower in fats and sugars
214913726|NCT02610374|OTHER|Western-type Diet|A diet higher in fats and lower in carbohydrates
215059425|NCT01322854|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
215059426|NCT04348812|BEHAVIORAL|ABMT|mobile attention bias modification training for anxiety, using the app Personal Zen
214304217|NCT00150839|DRUG|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
214304218|NCT00150839|DRUG|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
214304219|NCT02063854|DRUG|NE-58095 IR|NE-58095 IR tablets
214304220|NCT02063854|DRUG|NE-58095 IR Placebo|NE-58095 IR placebo-matching tablets
214304221|NCT02063854|DRUG|NE-58095 DR|NE-58095 DR tablets
214304222|NCT02063854|DRUG|NE-58095 DR Placebo|NE-58095 DR placebo-matching tablets
214304223|NCT01107587|BIOLOGICAL|GSK Biologicals' human rotavirus vaccine 444563|Oral, two doses.
214304224|NCT01107587|BIOLOGICAL|Placebo|Oral, two doses.
214913727|NCT02469935|PROCEDURE|ultrasound|surgeon-performed ultrasound
215059427|NCT04348812|OTHER|Transcranial direct current stimulation|Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
214304225|NCT01462084|DEVICE|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
214913728|NCT05704374|DIAGNOSTIC_TEST|sympathetic stimulation maneuver (mental arithmetic test, cold pressure test)|Mental arithmetic calculation and cold pressure increase sympathetic tone. For the mental arithmetic task, the subject is asked to mentally subtract a two-digit number from a four-digit number and respond within 5 seconds. This arithmetic calculation is repeated for different numbers. This test is continued for three minutes. For the cold pressure test, subjects are asked to immerse their right hand in 2-4 degrees cold water up to the elbow and hold it in the water for three minutes. The mental arithmetic task and cold stress test will be applied simultaneously.
215059428|NCT03753360|BEHAVIORAL|Internet-Based Mindfulness Program - Stress Free Now for Healers|Stress Free Now for Healers is an online stress management program developed at Cleveland. It's delivered in 4 components:1Weekly introductions to the concepts and meditation theme are delivered via Web page views or a 5to10-min audio clip2Weekly guided meditations 5-20 min ea.available as embedded/downloadable mp3 on the website or via the Stress Free Now for Healers phone app,which participants are invited to practice at least 4 times each week and to record those practices3Daily articles provide the scientific underpinnings and merits of each week's theme or discuss various cognitive and behavioral strategies,activities,and concepts supporting or related to mindfulness4Daily tips suggesting how to manage stress or incorporate mindfulness in daily activities,including motivational quotes.Participants will have access to a smartphone app with recordings of the 11 guided meditations.Ea. participant will be assigned an e-coach that will communicate with the participant at least weekly.
214913729|NCT05704374|DRUG|Pregabalin 150mg|In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to FMS patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes.
214913730|NCT03629938|OTHER|evaluation|evaluation and classification of medial longitudinal arch height of foot in adults
214913731|NCT02600468|DRUG|Orencia|
215059429|NCT03753360|BEHAVIORAL|Active Control Group - Relaxing Music|The control group will be given a flash drive and a link to a website where they can download several digital recordings of relaxing music and will be instructed to quietly listen to one or more of the recordings for at least 5 minutes every day for 6 weeks.
215059430|NCT04454320|OTHER|INTUSSUSCEPTION IN CHILDREN|the seasonal variation and management outcomes of childhood intussusception.
215059431|NCT02515799|DRUG|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
215059432|NCT02515799|OTHER|Placebo|Inhaled Placebo
215059433|NCT01461499|DRUG|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
214304226|NCT01462084|DEVICE|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
214304227|NCT03580850|OTHER|No intervention in this restrospective study|This study is an obervational study
214304228|NCT01537510|BEHAVIORAL|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
214304229|NCT03538158|BEHAVIORAL|Intervention Condition|Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.
214304230|NCT03538158|BEHAVIORAL|Control Condition|Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
214304231|NCT00390533|DRUG|Saredutant|oral administration (capsules)
214304232|NCT00390533|DRUG|Placebo|oral administration (capsules)
214304233|NCT00150072|DRUG|imatinib|
214304234|NCT04484233|DEVICE|iAnemia Decision Support System|iAnemia permits to display the appropriate guideline using several inputs about a patient: age, type and delay of the surgery, gender, hemoglobin level, and iron deficiency status.
214304235|NCT03302988|OTHER|Everted closure|Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion
214304236|NCT03302988|OTHER|Planar closure|The planar side will be closed with traditional buried simple closure and running cuticular sutures
214670304|NCT01927458|DEVICE|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
214670305|NCT06140108|DRUG|Empagliflozin 10 MG|Each participant will receive empagliflozin 10mg daily for 6 months.
214913732|NCT06482190|DRUG|RSN0402 Part 1|Participants will receive single ascending doses of 2mg, 4mg, 8mg, 12 mg, and 16mg of RSN0402 or placebo on Day 1 for Cohort 1 to 5. Cohort 2(4mg) will also a single dose of 150 mg nintedanib soft capsule will be administered orally after at least 7-days washout period.
214913733|NCT06482190|DRUG|RSN0402 Part 2|Participants will receive multiple ascending doses of 4mg ,8mg,12mg ,16mg of RSN0402 or placebo administered once daily from Day 1 to Day 7 for Cohort 6 to 9.
214913734|NCT06482190|DRUG|Placebo|Participants will receive matching placebo across Part 1 and Part 2 of the study.
214913735|NCT02809079|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 500mg Bid
214913736|NCT02809079|DRUG|Prednisone|prednisone 10mg Qd
214913737|NCT03373084|OTHER|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
214913738|NCT03373084|OTHER|ultrasound|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
214913739|NCT03373084|OTHER|Self-questionnaire|Self-questionnaire will be completed by patient. In this questionnaire patients will describe the circumstances of the injury and their personal characteristics and level of sporting practice.
214913740|NCT02126579|BIOLOGICAL|Peptide Vaccine (LPV7) + Tetanus peptide|1.5 mL administered half intradermally and half subcutaneously.
214304237|NCT06521359|DEVICE|flow cytometry|Two ml of peripheral venous blood samples will be collected in heparinized tubes from patients and controls for assessment of levels of TFH and TFReg cells by flow cytometry.
214304238|NCT01977508|DEVICE|ePTFE vascular access grafts|
214304239|NCT02311738|OTHER|Training intensity intervention|High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
214304240|NCT02382458|BEHAVIORAL|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
214304241|NCT02382458|BEHAVIORAL|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
214304242|NCT00930579|DRUG|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
214304243|NCT00695396|DRUG|Placebo|Matching volume 2 mLfor 48 weeks
214304244|NCT00695396|DRUG|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
214304245|NCT00695396|DRUG|Placebo|Matching volume 1 mL for 48 weeks
214304246|NCT00695396|DRUG|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
214304247|NCT04536155|OTHER|questionnary SF36|"This is a validate questionnary:~Ware et al,1992, McHorney et al, 1993, McHorney et al, 1994 French version : Author : Alain Leplège; et coll. En 2001"
214304248|NCT04536155|OTHER|Hospital Anxiety and Depression Scale|this is a validate scale: author: Zigmond A.S., Snaith R.P. in 1983
214304249|NCT04536155|OTHER|Chronic Pain Acceptance Questionnaire|"This is a validate questionnaire:~Fish, R., McGuire, B.E., Hogan, M., Stewart, I. \& Morrison, T. (2010)."
214304250|NCT04536155|OTHER|digital pain scale|this is a validate scale A.N.A.E.S. February 1999
214304251|NCT03698474|DRUG|Natrium picosulfate / Magnesium citrate|bowel preparation formula
214913741|NCT02126579|OTHER|PolyICLC|1 mL administered half intradermally and half subcutaneously
214913742|NCT02126579|OTHER|Resiquimod|500 mg applied to vaccine site after vaccine administration
214913743|NCT02126579|OTHER|IFA|2 mL administered half intradermally and half subcutaneously
214913744|NCT02295046|DRUG|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
214913745|NCT00911469|DRUG|AS902330|3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
214913746|NCT00911469|DRUG|Placebo|Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
214913747|NCT00935402|BEHAVIORAL|Sleep|Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
214913748|NCT03324555|DRUG|ORIC-101|Oral suspension
214913749|NCT00981214|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
214913750|NCT03574272|OTHER|Patient Transfer Monitoring System|The subjects will be provided with portable oximeter and smart-phone which application for monitoring is installed, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward.
214913751|NCT04229095|DRUG|Suvorexant 20 mg|Single-dose administration of 20 mg suvorexant given on an inpatient clinical research unit
214913752|NCT04229095|DRUG|Placebo oral tablet|Single-dose administration of placebo given on an inpatient clinical research unit
214913753|NCT06144216|OTHER|CLOE Outreach Intervention|The CLOE outreach intervention is a community-led, strengths-based, and trauma-informed program to support self-identifying women and youth who experience interpersonal and structural gender-based violence. Outreach services are designed to mitigate the effects of gender-based violence, build trusting relationships with service providers, and improve safety, well-being and engagement with health and social care.
214913754|NCT05322941|DRUG|AEF0117|AEF0117 (1.0, 0.3, and 0.1 mg) capsules
214913755|NCT05322941|DRUG|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
214304252|NCT03698474|DRUG|Polyethylene glycol / Ascorbic acid|bowel preparation formula
214670306|NCT06140108|DRUG|MetFORMIN 500 Mg Oral Tablet|Each participant will receive metformin 1000mg daily for 6 months.
214670307|NCT02598713|DRUG|Aspiration Marker|Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.
214913756|NCT02371317|BEHAVIORAL|Mindfulness-Based Stress Reduction|Patients are randomized to an intervention
214304253|NCT03698474|DRUG|Natrium/ Kalium/ Magnesium sulfate|bowel preparation formula
214304254|NCT04640090|BEHAVIORAL|Smartphone app (Wysa)|The commercially available smartphone application, Wysa, offers evidence-based wellness tools such as supportive listening, deep breathing techniques, guided meditation, yoga, and more. Users can communicate via text to a virtual artificial intelligence (AI) chatbot and/or a human well-being coach.
214304255|NCT03532919|DIAGNOSTIC_TEST|Serum Tropinin|Blodsamples will be taken 4 times from preoperatively to 2 Days postoperatively
214304256|NCT00930995|DRUG|Candesartan|16mg po daily
214304257|NCT00930995|DRUG|Placebo|once daily
214304258|NCT04777708|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given by intratumoral injection
214304259|NCT04777708|BIOLOGICAL|Pembrolizumab|Given IV
214913757|NCT02371317|BEHAVIORAL|Stress Management Education|Patients are randomized to an intervention
214913758|NCT02371317|OTHER|American Heart Association Recommended Self-Care|All Patients receive AHA Recommended Self-Care
215059434|NCT01461499|DRUG|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
215059435|NCT05960643|OTHER|Training and application in breast modeling|BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.
215059436|NCT05960643|OTHER|Control|No intervention will be made against people in this group.
215059437|NCT06014853|DRUG|SOL-804-F|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
215059438|NCT06014853|DRUG|Zytiga|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
215059439|NCT02378233|DIETARY_SUPPLEMENT|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
215059440|NCT02378233|DIETARY_SUPPLEMENT|Placebo|Patients are given a non-iodine containing multivitamin tablet
215059441|NCT03005561|BEHAVIORAL|Play Back Sessions|"100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool."
214304260|NCT00159640|DRUG|PD-217,014|
214304261|NCT04746703|RADIATION|Magnetic Resonance Imaging|Pancreatic MRI will be performed in severe-obese patients with a planned bariatric surgery, before and 6 months after bariatric surgery.
214304262|NCT04765579|BEHAVIORAL|visual analogy scala|We will investigate the effect of 4in1 block by questioning the vas score of the patients, its effect on quadriceps strength, and additional analgesia needs for 24 hours.
214304263|NCT04823039|OTHER|Blood sample taken|For patients with sepsis who require vaccination during hospitalization, we will analyze the immunogenicity of pneumococcal conjugate vaccine (PCV13) by taking blood samples
214304264|NCT05304754|BIOLOGICAL|NK cells stimulated ex vivo with IL-15|When patient and donor are KIR-HLA match, the patient submits all HLA class I molecules, or in the absence of any, your donor does not have this molecule, or having it lacks the corresponding KIR receiver. For more information detailed information on the product under investigation, reference is made to the Dossier of the Research Product (IMPD): PEI 09-008
214304265|NCT05304754|BIOLOGICAL|Alloreactive NK cells|When the patient lacks the HLA class I molecule and his donor has this molecule and also the donor NK cells have the KIR receptor that recognizes the absence of the corresponding HLA class I ligand
214304266|NCT00772707|DEVICE|Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|OPTI-FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
214304267|NCT00772707|DEVICE|Contact Lenses|Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
215059442|NCT03107052|DRUG|Fremanezumab|Fremanezumab
215059443|NCT02263326|DRUG|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
214304268|NCT06057792|DEVICE|negative pulsed pressure AeroFlow system|"For the application of pulsatile negative pressure, the AeroFlow® equipment will be used, carried out by one of the researchers participating in the project.The application will be carried out addressing the structure of interest (scar), following the protocol established by INDIBA to release adhesions between the different depth planes. The work will consist of an application of pulsed negative pressure using suction cups, which will work automatically at a frequency and intensity tolerable by the patient.~Treatment protocol in 2 phases Total application time 15min~1. Static cup: preparation: Prepare the tissue surrounding the scar. 5min~2. Dynamic Cup: work: Lock the tissue around the scar and the scar itself.10min Suction mode: continuous with continuous sliding of the cup The number of treatment sessions will consist of a total of 6 sessions, so there will be two sessions over 3 weeks."
214670308|NCT02329925|DEVICE|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
214913759|NCT03079141|DRUG|Eplerenone|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
215059444|NCT02263326|DRUG|lamivudine|300 mg tablet by mouth once daily for 48 weeks
215059445|NCT02263326|DRUG|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
215059446|NCT01520649|DRUG|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
215059447|NCT01520649|DRUG|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
215059448|NCT02397915|DRUG|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
214913760|NCT03079141|OTHER|Photodynamic therapy|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
214913761|NCT05483686|BEHAVIORAL|Shine|This tailored, multifaceted mobile intervention aims to improve HIV-related outcomes and increase gender affirmation among African American transgender women. Potential users will opt-in by texting from their own mobile phone and, once registered, will be enrolled into a program that will be theory-based, targeted, tailored, and personalized. Users will receive three main types of texts: informational, motivational, and skill-building. Finally, the program will include three web-based video components: scripted vignettes, unscripted peer narratives, and educational instruction. By developing an intervention using a technology that is part of the everyday lives of most African Americans, the aim is to reduce HIV disparities. The proposed intervention can be used by clinics and community-based organizations that serve transgender women.
214913762|NCT05483686|BEHAVIORAL|Control|A playlist of CDC-developed videos designed to provide information on HIV for transgender women
215059449|NCT02397915|DRUG|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
215059450|NCT00321243|BEHAVIORAL|Visual clues|
215059451|NCT00933608|DRUG|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
215059452|NCT00933608|DRUG|Placebo|participants will be asked to take 2 tablets per day to match active drug
215059453|NCT02033629|DRUG|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
215059454|NCT02033629|DRUG|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
215059455|NCT02033629|DRUG|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
214913763|NCT00184717|DRUG|somatropin|0.033 mg/kg/day of NN-220 for s.c. injection in cartridge
214913764|NCT00184717|DRUG|somatropin|0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
214913765|NCT01543178|DRUG|open-label rifaximin|550 mg three times a day (open-label)
214913766|NCT01543178|DRUG|double-blind placebo|3 times a day (double-blind)
214913767|NCT01543178|DRUG|double-blind rifaximin|550 mg three times a day (double-blind)
214913768|NCT04831853|OTHER|nasopharyngeal swabbing procedure (self swabbing first)|Patient realises the nasal swabbing himself first, then undergoes conventionnal swabbing
214479684|NCT06870825|DEVICE|Transcutaneous Neuromuscular Electrical Stimulation|"1. the procedure is performed for 20 min., 1k/d, 5k/week, a total of 14 times (rehab. duration 14 days).~2. Parameters: applied parameters according to the manufacturer's specified program for muscle stimulation (EMS, P3)~3. Stimulation site: quadriceps femoris muscle, applied above the motor point.~4. device: ITO ES-5200~   * Along with muscle stimulation techniques, all subjects will undergo a standardized outpatient rehabilitation plan."
214479685|NCT05815667|BEHAVIORAL|Individualised Active Communication Education (I-ACE)|The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
214479686|NCT06363591|PROCEDURE|Surgery|Wise or wide excision
214479687|NCT06363591|OTHER|No Surgery|No wide local excision
214913769|NCT04831853|OTHER|nasopharyngeal swabbing procedure (conventionnal swabbing first)|patient undergoes conventionnal swabbing first then realises the nasal swabbing himself
214913770|NCT04150978|OTHER|High Protein Polymeric Formula|Component: 22.4% protein from total calorie Preparation of Peptisol: 5 spoons of Peptisol powder diluted in 200 ml warm water to have 250 ml Peptisol (equal to 250 kcal). Given as written in the group descriptions
214913771|NCT04150978|OTHER|Oligomeric Formula|Component: Component: 22.4% protein from total calorie Preparation: 5 spoons of Peptamen powder diluted in 165 ml warm water to have 200 ml Peptamen (equal to 200 kcal). Given as written in the group descriptions
214913772|NCT04150978|DRUG|5% Dextrose|500 ml of 5% Dextrose administered to a peripheral vein.
214913773|NCT06046495|DRUG|PLB1004|PLB1004 will be orally self-administered by the patient as a mono-therapy.
214913774|NCT04587869|BEHAVIORAL|CBT Coping Intervention|A cognitive behavior therapy group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
215059456|NCT05317715|OTHER|Group A, who will complete a questionnaire before receiving information about intrauterine devices|Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.
215059457|NCT05317715|OTHER|Group B who will answer a questionnaire after having the information about the intrauterine devices|Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
215059458|NCT04873141|DRUG|Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)|Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
215059459|NCT00455819|PROCEDURE|home treatment|
215059460|NCT02426567|OTHER|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
215059461|NCT02426567|OTHER|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
214479688|NCT06124690|DEVICE|Catheter ablation|Pulmonary vein isolation and ablation of low voltage areas.
214479689|NCT02905110|DRUG|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
214479690|NCT02905110|DRUG|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
215059462|NCT06328270|OTHER|Ozone - oxygen Therapy|Ozone gas is a structurally unstable molecule that contains three oxygen atoms.
215059463|NCT06328270|OTHER|Corticosteroid|1 ml betamethasone
215059464|NCT05788419|DIAGNOSTIC_TEST|sonography|imaging method, functional test of hip joint
215059465|NCT01685242|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
214913775|NCT05566899|PROCEDURE|esophagogastroduodenoscopy (EGD)|"After colonoscopy, the patient will undergo the EGD at which time biopsy specimens will be obtained.~Participants will also be provided with a home stool collection kit which they can bring to the endoscopy visit or mail back. Satisfaction questions will be administered 3-7 days after EGD-SC"
214913776|NCT03351608|DRUG|Sugammadex 2 mg/kg|For moderate NMB reversal, a single i.v. bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
214913777|NCT03351608|DRUG|Sugammadex 4 mg/kg|For deep NMB reversal, a single i.v. bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
214913778|NCT03351608|DRUG|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
215059466|NCT01685242|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
215059467|NCT06538051|OTHER|lying positions|All patients were placed in supine, semi-fowler's and lateral positions, respectively. The effects of positions on hemodynamic parameters were examined.
215059468|NCT04060069|OTHER|Ringer Lactate|Fluids
215059469|NCT01697475|BEHAVIORAL|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
215059470|NCT03576196|OTHER|Preoperative Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
215059471|NCT03576196|OTHER|Usual Care|This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
214913779|NCT03351608|DRUG|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
215059472|NCT03625778|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
215059473|NCT03625778|DRUG|Placebo|Placebo will be administered subcutaneously daily according to the Placebo cohorts.
214913780|NCT04843917|DIAGNOSTIC_TEST|Immunoglobulin G detection|Detection of immunoglobulin G against Spike Receptor Binding Domain against severe acute respiratory syndrome coronavirus 2
214913781|NCT02877004|DEVICE|3 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatment - at a frequency of 3 times per week for 4 weeks
214913782|NCT02877004|DEVICE|2 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatments - at a frequency of 2 times per week for 6 weeks
215059474|NCT04091932|DRUG|Pembrolizumab|Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
215059475|NCT03998514|DRUG|CB4211 Dose 1|Administered by subcutaneous injection
214913783|NCT02877004|DEVICE|1 Low-Level Laser Therapy Treatment Weekly|Receive 12 LLLT treatments - at a frequency of once per week for 12 weeks
214913784|NCT02727478|OTHER|HiBalance training program|The program consists of physiotherapist led highly challenging balance exercises, which are adapted and progressed on both a group and individual basis throughout the training period.
214913785|NCT04400383|DRUG|AB011 Injection|"Stage 1 Single treatment: AB011 Injection with dose escalation of 1mg/kg up to 40mg/kg, as well as dose expansion with recommended dose level from dose escalation.~Stage 2 Combo Treatment: AB011 combine XELOX( GC) or Gem/nab-P (PC) Injection with dose escalation of 10mg/kg up to 30mg/kg, as well as dose expansion with recommended dose level from dose escalation."
214913786|NCT00000115|DRUG|Acetazolamide|
214913787|NCT00933907|DRUG|LACTIC ACID(ND)|Treatment duration: 6 weeks
214913788|NCT03230578|OTHER|Pharmacists & women's perspectives on pharmacist prescribed hormonal contraception|The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.
215059476|NCT03998514|DRUG|CB4211 Dose 2|Administered by subcutaneous injection
215059477|NCT03998514|DRUG|CB4211 Dose 3|Administered by subcutaneous injection
215059478|NCT03998514|DRUG|CB4211 Dose 4|Administered by subcutaneous injection
215059479|NCT03998514|DRUG|CB4211 Dose 5|Administered by subcutaneous injection
215059480|NCT03998514|DRUG|CB4211 Dose 6|Administered by subcutaneous injection
215059481|NCT03998514|DRUG|CB4211 Dose TBD|Administered by subcutaneous injection
215059482|NCT03998514|DRUG|Placebo|Administered by subcutaneous injection
215059483|NCT02998879|DRUG|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
215059484|NCT00491036|DEVICE|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
215059485|NCT00234663|DRUG|PTC124|
215059486|NCT03989375|DEVICE|transcutaneous vagus nerve electric stimulator|The stimulator that can be attached to ears of the patient.We suppose that this device can reduce the incidence of perioperative neurocognitive disorders(PND)
215059487|NCT04976881|BEHAVIORAL|Medication Reconciliation (MedRec) Tool|Patients will receive a print MedRec tool, generated via the EHR, which includes a list of medications prescribed according to the patient record. Patients are asked to review this list, to add/remove drugs to reflect actual use, to note how they are taking each medication, and to describe any concerns.
214913789|NCT01077778|PROCEDURE|Gadolinium-enhanced Magnetic Resonance Imaging|Gadolinium-enhanced Magnetic Resonance Imaging
214913790|NCT02334878|BIOLOGICAL|Stem Cells,Mesenchymal|The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.
214913791|NCT02334878|PROCEDURE|surgery (TVT)|A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40\*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra \& through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted \& the remaining tape cut off at the level of the skin.
214913792|NCT01408511|DRUG|Mapracorat|Application of the investigational product on the affected skin areas
214913793|NCT05961956|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention.
214913794|NCT02633293|DRUG|Inhaled Treprostinil|Inhaled treprostinil up to 15 breaths (90 mcg) four times daily
214913795|NCT01671228|OTHER|Decision Aid|The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
214913796|NCT01671228|OTHER|Decision aid + patient stories|The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
214913797|NCT01671228|OTHER|Decision Aid + values task|The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
214913798|NCT01212237|PROCEDURE|fMRI Evaluation|Functional magnetic resonance imaging (fMRI) uses MR imaging to measure the tiny metabolic changes that take place in an active part of the brain. fMRIs are used for many reasons, for example, to determine precisely which part of the brain is handling critical functions such as thought, speech, movement and sensation, to help assess the effects of stroke, trauma or degenerative disease (such as Alzheimer's) on brain function, and to guide the planning of surgery and radiation therapy.
214913799|NCT03877068|DEVICE|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay up to 10 days using the Dexcom Studio software to download the Dexcom receiver data.
214913800|NCT03877068|DIAGNOSTIC_TEST|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.
214913801|NCT00778817|BIOLOGICAL|IMC-A12|Given IV
214913802|NCT00778817|DRUG|mitotane|Given orally
214913803|NCT03357523|DEVICE|Omnilux new-U (Red LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Red LED) light source, while the right wrist will not be illuminated
214913804|NCT03357523|DEVICE|Omnilux new-U (Near infrared LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Near infrared LED) light source, while the right wrist will not be illuminated
214913805|NCT03357523|DEVICE|RESPeRATE|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm
214913806|NCT03357523|DEVICE|Heating bag|Applying a standard 10X13 \[cm\] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
214913807|NCT01757093|DEVICE|Automatic Tube Compensation plus CPAP|SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
214913808|NCT01757093|DEVICE|Continuous Positive Airway Pressure|SPONTANEOUS BREATHING TRIAL WITH CPAP
214913809|NCT05440045|DRUG|6MW3211|6MW3211 injection, 30mg/kg, Q2W
214913810|NCT01699672|OTHER|Group information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
214913811|NCT06088680|DEVICE|Glycar Pericardial Patch|Glycar Bovine pericardial patch with AldeCaptm Technology (aka SJM with EnCaptm technology)
214913812|NCT01418378|DEVICE|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
214913813|NCT01418378|DEVICE|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
214913814|NCT03866681|DRUG|sirolimus|The dose of sirolimus is adjusted according to monitored serum concentration, maintain Rapamycin concentration ranging from 4 to 10ng/ml.Warfarin was administered orally at a dose of 1mg per day for a year,then gradually reduced to stop.
214913815|NCT04608396|DRUG|AXS-05|AXS-05 taken daily for up to 52 weeks, until relapse.
214913816|NCT04608396|DRUG|Placebo|Placebo taken daily for up to 52 weeks, until relapse.
214913817|NCT04816617|BEHAVIORAL|Aerobic exercise intervention|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
214913818|NCT04816617|BEHAVIORAL|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
214913819|NCT01063738|DIETARY_SUPPLEMENT|Amino acid supplement|Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
214913820|NCT01063738|OTHER|PEPSE|Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
214913821|NCT01063738|OTHER|Intensive Care Unit (ICU) Recovery Manual|Standard self-directed 6 week rehabilitation package
214913822|NCT01063738|DIETARY_SUPPLEMENT|Placebo nutritional supplement|Cherry flavoured low calorie and low protein placebo drink
214913823|NCT04103125|DEVICE|Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.|The subjects will receive at baseline the first IMD by the Investigator in accordance with the CIP
214479691|NCT02905110|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
214913824|NCT05350618|OTHER|Ultrasound evaluation|A single transperineal ultrasound assessment session
214913825|NCT01450306|DRUG|D-cycloserine|50 mg d-cycloserine, oral, 1 dose
214913826|NCT01450306|BEHAVIORAL|Exposure therapy|Single session graded in vivo exposure therapy, 60-180 minutes
214913827|NCT01450306|DRUG|Placebo|Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
214913828|NCT03784742|OTHER|Nitrate rich beetroot juice|James White Drinks Limited beetroot juice (0.4-0.45 g nitrate/70 ml drink).
214913829|NCT03784742|OTHER|Placebo beetroot juice|James White Drinks Limited Placebo beetroot juice (0 nitrate/70 ml drink).
214913830|NCT03239249|OTHER|IKO-model|A systematic model for drop-out prevention.
214913831|NCT03239249|OTHER|Treatment as usual|Schools randomized to control group (22) work as previously with school dropout
214913832|NCT05233553|OTHER|control of liver enzymes|follow-up with clinical and laboratory measurements
214913833|NCT04757025|DEVICE|Electrical Impedance Tomography|In 27 patients ventilation will be guided with an Electrical Impedance Tomography system
214913834|NCT04757025|DEVICE|Peripheral arterial Saturation|The ventilation of 27 patients will be guided by Peripheral arterial Saturation alone
215059488|NCT04976881|BEHAVIORAL|Provider Alert and Decision Support|During the clinic visit, an automated, EHR alert will notify the provider that the patient is a woman of reproductive age with T2DM and should receive counseling on the importance of glycemic control, the use of contraception until glycemic control is achieved, and the benefits of folic acid.
215059489|NCT04976881|BEHAVIORAL|PREPSheet|When patients leave an encounter, they will receive a patient-friendly educational material (a.k.a. the PREPSheet) that reviews potential risks of pregnancy in the context of T2DM and highlights the importance of: 1) achieving glycemic control through diabetes self-care, 2) using effective contraception until glycemic control is achieved and pregnancy is desired, 3) discussing medication use with a provider if planning or becoming pregnant, and 4) taking folic acid daily to reduce increased risk of neural tube defects.
214913835|NCT06134310|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
214913836|NCT06134310|PROCEDURE|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
214913837|NCT06134310|PROCEDURE|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
214913838|NCT06134310|BEHAVIORAL|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
214913839|NCT03004781|BEHAVIORAL|Parenting program|
214913840|NCT00878943|DRUG|Sildenafil citrate|20 mg tablet to be taken thrice daily for 1 year
214913841|NCT02737488|BEHAVIORAL|Trauma Systems Therapy (TST)|Treatment will be delivered by clinicians and trainees working at the CSC who have been trained in delivering TST. Participants who begin treatment in the safety-focused phase will have their treatment sessions in their homes. Whenever a child enters a different phase of treatment, he or she will go to the site for office visits. At the beginning of treatment, TST clinicians will do a brief diagnostic assessment. All documentation that is completed by the clinician as part of TST treatment at the NYU Langone Medical Center will be documented using Epic, a standard of care integrated health information system for patient safety. Although we are not providing the CSC's standard of care in this study,we are replicating standard care as TST is standard care in other settings. Providing medication is part of standard TST treatment and conforms to good usual practice integrated with psychotherapy. Medication will not be prescribed for research purposes.
214913842|NCT02737488|BEHAVIORAL|Treatment as Usual (TAU)|"Youth in the control group will be referred to a mental health clinic in close proximity to their residence, in order to receive an evaluation and trauma treatment as usually provided. It cannot be specifically determined, in advance, the nature of this treatment.~The clinics will be contacted after the family enrolls to determine if there was a specific protocol followed. An NYU CSC research coordinator will contact the clinic and assist in scheduling the subject's first visit. Families who do not enroll in any community treatment or dropout of treatment will be followed according to the research protocol for data collection. At the 3, 6, and 9 month assessments, the research coordinator will request the patient's records from the community treatment clinic they are attending in order to track and keep record of the youth's treatment modality, progress, and visit frequency."
214670309|NCT06482060|DEVICE|Stabilization splint|Stabilization splint application is a treatment that improves the function of TMJ and masticatory muscles by creating a balanced, stable occlusion to reduce the effects of occlusal interference and parafunctional habits and eliminate associated pain.
214670310|NCT04298346|OTHER|no intervention|no intervention
214913843|NCT03195829|BEHAVIORAL|Computerized Cognitive Stimulation|The intervention group performed 12-week, 90-minutes per week of cognitive stimulation in group using a tablet with a commercial software with specific exercises to train the cognitive functioning and promote the relation ties in group-session.The program's difficulty level was adjusted to the MMSE score, and was gradually increased.
214913844|NCT03195829|BEHAVIORAL|Multimedia-based internet|The active control group had access to different Multimedia contents (travel, photos, music, TV program, cooking recipes) using a tablet, 90-minutes per week each week during 3-months. Each group session was centered in a particular topic, participants were able to select different media free available in Internet.
214913845|NCT00375973|DRUG|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
214913846|NCT00375973|DRUG|Placebo|Sugar pill dose comparable to duloxetine
214913847|NCT02166931|DIETARY_SUPPLEMENT|Chicken Essence|BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
214913848|NCT02829320|DRUG|GSK1278863|GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
214913849|NCT02829320|DRUG|Iron|Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
214913850|NCT02006589|DRUG|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets with PX 8 embossed in one face.
214913851|NCT02006589|DRUG|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (008 embossment in the plain face and A CG in the scored face).
214913852|NCT04236492|PROCEDURE|Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
215059490|NCT04976881|BEHAVIORAL|Text Messaging|Within \~5 days of their index clinic visit, intervention patients will begin to receive daily, unidirectional text messages to reinforce diabetes self-care behaviors.
215059491|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
215059492|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
215059493|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
214670311|NCT02525172|DRUG|Rituximab|
214670312|NCT02525172|DRUG|intravenous immune globulin|
214670313|NCT02525172|DRUG|Bortezomib|
214670314|NCT02525172|DRUG|Methotrexate|
214670315|NCT02238613|DEVICE|radioactive stent|radioactive stent carrying seed iodine 125
214670316|NCT02238613|DEVICE|plastic stent|common plastic stent without carrying seed iodine 125
214670317|NCT03846947|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
214913853|NCT03403140|DRUG|Etanercept|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
214913854|NCT01976962|RADIATION|Stereotactic body RT with MR-guided boost|Patients will receive radiotherapy over 5 fractions delivered once per week over 29 days, with 7.25 Gy per fraction to the whole prostate and 8 Gy per fraction to the dominant intraprostatic lesion. There will be a minimum of 120 hours and maximum of 192 hours between fractions. The entire course of treatment should be completed within no less than 27 days and no longer than 30 days.
214913855|NCT01051791|DRUG|Everolimus 10mg daily|RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
215059494|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
214913856|NCT05644626|DRUG|BGB-B167|Intravenous administration
214913857|NCT05644626|DRUG|Tislelizumab|Intravenous administration
214913858|NCT01691560|DRUG|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
214913859|NCT01691560|DRUG|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
215059495|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
215059496|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
214670318|NCT06152601|PROCEDURE|anticipated bipedal standing position in the immediate post-operative phase|"Realization of a first stand-up within 6 hours after entry into PACU or extubation for admitted patients intubated, in PACU or on admission to ICU by a state-certified physiotherapist.~Immediately postoperatively, during his stay in a Intensive Care Unit, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position."
214913860|NCT01691560|DRUG|Sodium monofluorophosphate dentifrice|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
214913861|NCT01691560|DRUG|Sodium fluoride dentifrice|Dentifrice containing 1100 ppmF as sodium fluoride
214913862|NCT01041157|OTHER|Resistance training|Neck muscle trainings effect on botulinum toxin efficiency
214913863|NCT00288626|DRUG|Granulocyte-colony stimulating factor (G-CSF) and prednisone|Growth factor regimen; occurs at study entry
214913864|NCT00288626|DRUG|Carmustine, etoposide, cytarabine, and melphalan (BEAM)|High-dose chemotherapy; occurs seven or more days following collection of autologous graft
214913865|NCT00288626|PROCEDURE|Autologous hematopoietic stem cell transplant|Occurs after growth factor regimen and collection of autologous graft
214913866|NCT03946319|DIAGNOSTIC_TEST|Introspect Health|Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools. The software is delivered via the internet using a mobile device or computer.
214913867|NCT01706341|DRUG|administer acetate Ringer's solution|During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
214913868|NCT01706341|DRUG|acetate Ringer's solution containing no glucose|
214913869|NCT01706341|DRUG|acetate Ringer's solution containing 1% glucose|
214913870|NCT02348918|DRUG|Luminate 1.0mg|
214913871|NCT02348918|DRUG|Luminate 2.0mg|
214913872|NCT02348918|DRUG|Luminate 3.0mg|
214913873|NCT02348918|DRUG|Avastin|
214913874|NCT02348918|DRUG|Luminate 0.5mg|
214913875|NCT00506415|DRUG|Rivastigmine 5 cm^2|5 cm\^2 transdermal patch
214913876|NCT00506415|DRUG|Rivastigmine 10 cm^2|10 cm\^2 transdermal patch.
214913877|NCT00506415|DRUG|Rivastigmine 15 cm^2|15 cm\^2 transdermal patch.
214913878|NCT00506415|DRUG|Placebo to 15 cm^2 patch|Placebo of rivastigmine transdermal patch 15 cm\^2.
214913879|NCT00506415|DRUG|Placebo to 10 cm^2 patch|Placebo of rivastigmine transdermal patch 10 cm\^2.
214913880|NCT05428683|DRUG|intra-vitreal triamcinolone-moxifloxacin injection after cataract surgery as a prophylactic measures against post-operative endophthalmitis|At the end of surgery, 4mg triamcinolone acetonide and 0.2mg moxifloxacin from 0.5 moxifloxacin preservative-free eye drop) were injected once inferotemporally 3.5 mm posterior to the limbus via pars plana into the vitreous cavity by using 30 G needle.
214913881|NCT01742130|DRUG|sodium bicarbonate solution|
215059497|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
215059498|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
215059499|NCT02574559|BEHAVIORAL|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
215059500|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
215059501|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
215059502|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
215059503|NCT00391053|BIOLOGICAL|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
215059504|NCT04908384|BEHAVIORAL|Improving Asthma Care Together (IMPACT)|IMPACT is a novel health application and wearable device
215059505|NCT05002985|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
214913882|NCT01742130|DRUG|Isotonic saline|
214913883|NCT04578457|DEVICE|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
214913884|NCT04578457|DEVICE|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
214913885|NCT04578457|DEVICE|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
214913886|NCT04578457|DEVICE|Hearing Aid with NR(3)|Each participant will be fitted with a third noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1) and NR(2).
214913887|NCT04674215|BEHAVIORAL|Turning in Bed|Preoperative Turning in Bed Training
214913888|NCT04674215|BEHAVIORAL|Mobilization|Preoperative Mobilization Training
214913889|NCT04674215|OTHER|information|Routine Clinical Care
214913890|NCT03950830|DRUG|Disulfiram|Disulfiram 400mg daily, continuously
214913891|NCT06577740|OTHER|Otago Exercise|Group-based otago exercises were performed for 4 weeks. They were also given a brochure containing otago exercises twice a week and applied individually and followed remotely. They were asked to walk normally for 30 minutes twice a week. They then entered a 4-week washout period.
214913892|NCT06577740|OTHER|Dual Task Focused Otago Exercise|After a 4-week washout period, face-to-face group-based and dual-task focused otago exercises were applied once a week for 4 weeks. Participants were given a brochure containing otago exercises including dual-task exercises twice a week and applied individually and monitored remotely. They were asked to walk normally for 30 minutes twice a week.
214913893|NCT03039504|DIETARY_SUPPLEMENT|Potensa, a succinate-based dietary supplement|Potensa - a dietary supplement: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
214913894|NCT03039504|DIETARY_SUPPLEMENT|Placebo|Placebo: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
214913895|NCT05284786|DEVICE|nerve ultrasonography|Ultrasonography of different nerves was performed using a high frequency 18 MHz probe (esaote Ultrasound systems). Each nerve was scanned in axial plane, and the cross-sectional area (CSA) was measured at standardized anatomical points, in brief: median nerve in upper arm, elbow, forearm; ulnar nerve in upper arm and forearm; tibial nerve in popliteal and ankle; peroneal nerve in popliteal fossa, sural nerve in the calf and the vagus nerve.
214913896|NCT03641014|OTHER|pH Effect on blastocyst formation|to investigate which pH is suitable for each stage of embryo development
214913897|NCT01411150|DRUG|Creatine Monohydrate|Up to 30 grams daily creatine monohydrate
214913898|NCT04711590|OTHER|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
214913899|NCT03451890|DRUG|E2730|oral capsule
214913900|NCT03451890|DRUG|Placebo|oral capsule
214913901|NCT05772949|DEVICE|Experimental group intervention|"The caregivers will calibrate the smart hearing aids for the participants in the experimental group at the first day of week 1 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the experimental group can use the smart hearing aids whenever they want during the trial period (i.e. from week 1 to week 6). For participants living in residential setting, caregivers will facilitate them to use the smart hearing aids upon request from the participants or when the caregivers deem the aids beneficial. For participants living in community setting, they will use the smart hearing aids when needed. Their caregivers shall provide assistance in facilitating the participants to use the smart hearing aids. The smart hearing aids do not require any payment from the study participants. They have to return the hearing aids after the study."
214913902|NCT05772949|DEVICE|Wait-list control group intervention|"The caregivers will calibrate the smart hearing aids for the participants in the wait-list control group at week 8 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the wait-list control group will continue the current practice (i.e. using conventional hearing aids or no hearing aids) from week 1 to week 8, and will use the smart hearing aids from week 8 to week 14. Caregivers will facilitate the participants to use the smart hearing aids."
214913903|NCT03248999|DIAGNOSTIC_TEST|rectal swab|stool samples by rectal swab
214913904|NCT03725306|DEVICE|Librata|Hyperthermic endomyometrial treatment via Librata catheter and balloon device
214913905|NCT05009693|OTHER|White Light Application|White Light Therapy
214913906|NCT04911777|DRUG|Pentarlandir™ UPPTA|Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
214913907|NCT04911777|DRUG|Placebo|The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
214913908|NCT01585051|DRUG|25(OH) vitamin D|300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
214913909|NCT01585051|DRUG|0.9 % NaCl|1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months
214913910|NCT03387371|DEVICE|Ultrasonics|ultrasonic scalers
214913911|NCT03387371|DEVICE|Gracey Curettes|Spesific gracey curettes
214913912|NCT03387371|DEVICE|Er:YAG Laser|2940 nm wavelenght Er:YAG laser
214913913|NCT02485262|DRUG|Sofosbuvir and simeprevir|Hepatitis C treatment using Direct Acting Agents
214913914|NCT00245128|DRUG|imatinib mesylate|Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
214913915|NCT04529629|OTHER|surgery or drug|pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
214913916|NCT05951829|OTHER|Action Observation Therapy|Action Observation Therapy Mirror Therapy
214913917|NCT02522364|DEVICE|BioMonitor device|Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration
214913918|NCT02522364|OTHER|Standard|Clinical and intermittent electrocardiographic follow-up of patients
214913919|NCT01462760|DEVICE|Assessment with inclinometer|joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer
214670319|NCT02976831|DRUG|AZD0284|Oral solution, concentration: 2 mg/mL and 15 mg/mL
214670320|NCT02976831|DRUG|Placebo|Placebo matching AZD0284 in the form of an oral solution with water.
214913920|NCT01462760|DEVICE|Assessment with actigraph|joint assessment with actigraph The actigraph used in this trial is the Motion Pod. It's an analysis and reeducation systems by biofeedback. The manufacturer is Movea.
214913921|NCT03563963|DRUG|Ropivacaine 0.5% Injectable Solution|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
215059506|NCT05752097|DEVICE|[18F]AlF-NOTA-FAPI-04 PET/CT examination|The intravenous radiotracer dose is 1.85-2.59 MBq/kg, and imaging will be performed 50-60 min after radiotracer injection. All patients are required to urinate as much as possible for imaging preparations, which reduces the influence of the residual radiotracer in the renal pelvis and calyces. Some patients with poor renal function (GFR\<60 mL/min, urine volume \< 1000 mL/24 h) will be given diuretics (Furosemide, 0.57 mg/kg). The scope of the whole-body inspection is from the base of the skull to the base of the thigh, using five to six beds (3 min/bed). The matrix was 128×128, the PET layer thickness was 3 mm, and all PET images are reconstructed iteratively.
215059507|NCT05752097|PROCEDURE|Renal puncture biopsy|The patients undergo renal puncture biopsy one day after PET/CT examination. Pathological results of renal biopsy will be collected after surgery, including but not limited to: pathological diagnosis, proportion of glomerulosclerosis, extent of inflammatory cell infiltration, and degree of renal interstitial fibrosis.
215059508|NCT04077424|BIOLOGICAL|Fluzone-High Dose Quadrivalent|Seasonal influenza vaccination with FDA approved vaccines for this age group.
215059509|NCT04077424|BIOLOGICAL|Fluad|Adjuvanted (MF59) inactivated influenza vaccine
214670321|NCT05316363|OTHER|OMT|"Suboccipital Release - Finger pads are placed onto suboccipital musculature and a smooth, gentle, and rhythmic laterocephalad traction is applied to reduce muscle tension.~Paraspinal Inhibition - Hands are placed under the patient's thoracolumbar spine and contract the erector spinae tissue to draw the thoracolumbar spine into extension and hold until relaxation is felt.~Rib Raising - Hands are placed under the subject's thorax and contact the rib angles with finger pads. Fingers are flexed while adding an anteriolateral traction directed at the rib angle while maintaining neutral wrists. Arms are used as a lever by leaning forward thus creating a fulcrum with the treatment table with a smooth, rhythmic motion. This motion is repeated several times throughout the entire thoracic region, unilaterally and then switch sides.~Diaphragm Release - Hands apply a gentle pressure until a barrier or point of ease of the fascia is felt and hold that position until tissue response is felt."
214670322|NCT00004934|DRUG|carboplatin|
214913922|NCT03563963|DRUG|Lidocaine 2% Preservative-Free Injectable Solution|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
214913923|NCT03563963|OTHER|Air|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
214913924|NCT03627663|BEHAVIORAL|Dialectic Behavior Therapy - Skills System|Treatment with Dialectical Behavior therapy adapted for cognitively challenged individuals
214913925|NCT03155464|PROCEDURE|Order of two elements of surgical procedure|Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.
214913926|NCT03155464|DRUG|Indocyanine Green|Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
214913927|NCT05131217|OTHER|Acute bout of Continuous Moderate Intensity Exercise|In this experimental intervention subjects will cycle continuously at moderate intensity (VO2 corresponding to lactate threshold) until a 200 kcal equivalent energy expenditure is reached.
214913928|NCT05131217|OTHER|Acute bout of High Intensity Interval Training|In this experimental invention subjects will alternate between 1 minute of high intensity cycling (watts corresponding to 85% VO2peak) and 1 minute of low intensity cycling (watts corresponding to 35-40% VO2peak) until a 200 kcal equivalent energy expenditure is reached.
214913929|NCT05131217|OTHER|Control|In this intervention placebo, subjects will lay down on a flat, soft surface for 30 minutes in a dimly light room. They will not be allowed to use any electronic devices or read during this time to avoid potentially influencing continuous data recording.
214913930|NCT02569970|DRUG|fluoxetine 20 mg|"Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
214913931|NCT02569970|DRUG|placebo 20 mg|"Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
215059510|NCT04077424|BIOLOGICAL|Flublock|Recombinant hemagglutinin vaccine
215059511|NCT01458548|DRUG|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
215059512|NCT01458548|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
214670323|NCT00004934|DRUG|epirubicin hydrochloride|
214670324|NCT00004934|DRUG|paclitaxel|
214670325|NCT00004934|PROCEDURE|conventional surgery|
214913932|NCT03538288|DEVICE|rTMS|rTMS will be applied at 10 Hz to the DLPFC
214913933|NCT00114075|PROCEDURE|Surgery with gait analysis report|Orthopaedic surgery with access to gait analysis report
214913934|NCT00114075|PROCEDURE|Surgery without gait analysis report|Orthopaedic surgery without access to gait analysis report
214913935|NCT00749073|DEVICE|Minimally Invasive Lumbar Decompression (MILD™)|The arthroscopic devices in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
214913936|NCT01733940|DEVICE|Application of a dressing with clorhexidine gluconate in intravascular catheters.|
214913937|NCT01733940|DEVICE|Application of a dressing without clorhexidine gluconate|
214913938|NCT03230058|DRUG|Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops|instillation of drops
214913939|NCT01168414|DRUG|Ganfort|Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)
214913940|NCT01168414|DRUG|Duotrav|Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
214913941|NCT04994210|DRUG|Sintilimab|"1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects."
214913942|NCT04994210|DRUG|Chidamide|"1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects."
214913943|NCT03189095|BEHAVIORAL|WOWii (Workout on Wheels Internet Intervention)|"Participants will self-monitor their exercise on the WOWii website, which has a page to record the type, duration, and intensity of daily exercise bouts.~Two devices will track participants' exercise, a Polar heart rate monitor (RS300X, Polar®), which will provide data on the day, duration, and intensity (average and maximum) of aerobic activity and an ActiGraph accelerometer (model GT3X), which detects movement in three planes to indicate frequency and intensity of movement throughout the day. Experimental participants will be provided a Polar heart rate monitor to wear during each exercise bout for the entire length of the 6-month study, and exercise data will be collected weekly.~Physiological outcomes on fitness will be assessed by measuring weight and aerobic capacity in a Cardiopulmonary Lab by a doctoral-trained physical therapist.~Participants will complete surveys to report on their exercise self-efficacy and perceived barriers."
214913944|NCT05206006|OTHER|routine care|The choice of the initial antibiotic regimen will be let to the discretion of the emergency physician
214913945|NCT05206006|OTHER|Computerized Decision support app (CDSA)|Implementation of an Computerized Decision support app (CDSA) : physician will use this app to help him in the antibiotic choice. This app is an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics. Secondly, the application is also designed to propose an algorithm of antibiotic revaluation at day 3 for hospitalized patients, depending on patient clinical course, and biological and microbiological results. The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines.
214913946|NCT02682303|DEVICE|Elastic Bandage (Idealplast C®)|"Elastic bandage~One anchor strip is applied around the ankle with no tension applied to the tape to avoid restricting blood flow. A supporting stirrup strap is applied from the inside of the ankle, under the heel with no tension up to this point. As the tape is passed up the outside of the ankle tension is applied to the tape with the foot in slight dorsiflexion and secured to the anchor strap (black arrow).~For heel lock, a second strip is applied on the outside of the ankle, taken across the front of the ankle and just above the bony part on the inside of the ankle and back towards the heel (red arrow). Then taken around and under the heel back the way you have just come and around the front of the ankle (orange arrow). The tape then passes above the bony part of the ankle on the outside and diagonally towards the heel, across to the inside of the ankle then around the top to finish"
215059513|NCT01642901|DRUG|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
215059514|NCT01642901|DRUG|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
215059515|NCT02676700|BEHAVIORAL|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
215059516|NCT02676700|BEHAVIORAL|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
215059517|NCT06190470|DRUG|Cannabis|Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.
214479692|NCT05276219|DRUG|Furosemide Injection|A diuretic (iv furosemide) strategy for decongestion in acute heart failure
214670326|NCT00812110|DRUG|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
214670327|NCT04248777|OTHER|standardised OCT-guided intervention|The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
214670328|NCT02750566|PROCEDURE|Osteopathic Manipulative Treatment|Manual treatment of musculoskeletal restrictions that may be prevent proper healing post-concussion.
214670329|NCT02750566|OTHER|Counseling|Patients will be counseled on concussion awareness, symptoms, and treatment for 30 minutes by a physician.
214670330|NCT06153381|OTHER|Chatbot|Rehabilitation program based on standard care, but assisted via an instant messaging application using a personal smartphone
215059518|NCT06190470|DRUG|Placebo|Placebo is similar to Cannabis product but do not contain THC.
215059519|NCT00785590|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
214913947|NCT02682303|DEVICE|Pretape cramer® (non standarized tape)|"Pretape cramer® was used.~The individual is in supine position keeping the foot and ankle in a neutral position.~The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.~This is the only intervention carried out in this group."
215059520|NCT00422448|GENETIC|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
215059521|NCT04074070|OTHER|Ultrasound examination|Ultrasound examination of joints, tendons and entheses.
215059522|NCT02557776|GENETIC|Germline genetic testing of BRCA1 and BRCA2|
215059523|NCT02943070|DEVICE|Rezum System|"The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
215059524|NCT03180580|BEHAVIORAL|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
215059525|NCT05536557|OTHER|Bilateral External Oblique İntercostal (EOI) Plane Block|External Oblique İntercostal (EOI) Plane Block will be provided for postoperative pain for Laparoscopic Cholecystectomy with Bupivacaine. And patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
215059526|NCT05536557|OTHER|Standard perioperative and postoperative multimodal analgesia|Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol for Laparoscopic Cholecystectomy.
215059527|NCT02501967|OTHER|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
215059528|NCT01717196|OTHER|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
215059529|NCT06290531|DEVICE|Buzzy device (cold and vibration)|The device produces cold and vibration to act on the gate control theory and provide painless injection by nerve distraction
215059530|NCT06290531|DEVICE|Buzzy device (vibration only)|The device produces vibration to act on the gate control theory and provide painless injection by nerve distraction
214479693|NCT05276219|DRUG|Isosorbide Dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
214479694|NCT05276219|DRUG|Furosemide and isosorbide dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
215059531|NCT06290531|OTHER|precooling|Ice cubes used for applying coolness at the injection area
215059532|NCT06290531|OTHER|Flavored Benzocaine topical anesthetic gel 20%|Topical anesthetic gel
215059533|NCT00037518|DRUG|AMG 073|
214479695|NCT06872255|PROCEDURE|Per Oral Endoscopic Myotomy (POEM)|"All procedures will be performed by an experienced endoscopist, with a sufficient experience in third space endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center."
214670331|NCT06153381|OTHER|Standard car|Rehabilitation program based on standard care, assisted with one education session plus informative brochure
214913948|NCT02019264|DRUG|Lorcaserin hydrochloride|APD356 10 mg twice daily
214913949|NCT02019264|DRUG|Placebo|Placebo twice daily
214913950|NCT02409199|DRUG|Docetaxel|
214913951|NCT02409199|DRUG|apatinib|
214913952|NCT00089687|DRUG|GBR 12909|
214913953|NCT02391415|BIOLOGICAL|VPM1002|Tuberculosis vaccine
214913954|NCT02391415|BIOLOGICAL|BCG|commercially available live vaccine BCG
214913955|NCT02391415|BIOLOGICAL|VPM1002(Hyg+)|Tuberculosis vaccine
214913956|NCT05494944|PROCEDURE|ThuLEP|Minimal invasive prostate intervention
214913957|NCT05831501|PROCEDURE|Trans abdominis plane block|Ultrasound guided infiltration of local anaesthetic bupivacaine via 22G Quincke needle between internal oblique and trans abdominis muscle layers in abdominal wall.
214913958|NCT02928653|DIETARY_SUPPLEMENT|Beverage|Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
214913959|NCT01961739|DRUG|2% lidocaine|Topical application, twice per day for 15 consecutive days
214913960|NCT01961739|DRUG|placebo|topical application, twice per day for 15 consecutive days
214913961|NCT05527535|DIAGNOSTIC_TEST|Diabetic retinopathy screening by artificial intelligence|Screening diabetic patients' eyes with AI through digital health platform
214913962|NCT05527535|DIAGNOSTIC_TEST|Diabetic retinopathy screening by healthcare personnel|Screening diabetic patients' eyes by conventional method (healthcare personnel)
215059534|NCT06379503|OTHER|HEART YOGA|Heart yoga; It includes regular, balanced, safe light physical exercises, breathing exercises that provide breathing control, and meditation practices that include relaxation techniques.
214913963|NCT02511938|OTHER|Menu Only|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants.
215059535|NCT06379503|OTHER|routine nursing care|Basic nursing care after heart surgery
215059536|NCT04353375|DRUG|HMPL-453|Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
215059537|NCT01669252|DRUG|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
215059538|NCT03093948|PROCEDURE|Remote ischemic post-conditioning|Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
215059539|NCT03391830|DRUG|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
215059540|NCT03391830|DRUG|Placebo|Placebo
215059541|NCT00483054|DRUG|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
215059542|NCT00483054|DRUG|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
215059543|NCT06234579|DIAGNOSTIC_TEST|Biopsy (tissue or liquid)|"At the time of diagnosis, all newly diagnosed ALK+ NSCLC patients eligible for first line treatment with alectinib or brigatinib or lorlatinib will be considered for the study.~In case of progression, a multidisciplinary team (oncologists, interventional pneumologists and radiologists, surgeons) will discuss case-by-case the feasibility to procure an adequate biopsy from progressing lesions. Repeat biopsies will be performed within 2 weeks from multidisciplinary evaluation and before the start of subsequent treatment. If repeat biopsies are not technically or safely feasible or fail to yield sufficient material for genomic analysis, we will collect a whole blood drawn by venepuncture for the analysis of ctDNA."
215059544|NCT00146926|DRUG|kétamine 20mg|
215059545|NCT00146926|DRUG|ephedrine 3mg|
215059546|NCT00146926|DRUG|lidocaine 40mg|
215059547|NCT05092828|DRUG|Intrathecal Morphine Injection|In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.
214913964|NCT02511938|OTHER|Menu Plus intervention|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants. In addition, project will provide promotional materials and brief restaurant staff trainings to promote the new menu.
215059548|NCT05092828|DRUG|Pain Relieving|Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
215059549|NCT03962088|DIAGNOSTIC_TEST|miRNA|"15 ml of whole blood samples are collected in Vacutainer tubes with spray-coated K2EDTA and stored at room temperature. To minimize the hemolysis and nucleic acids degradation, plasma separation undergoes within 2 h.~Within 1 h, tubes are subjected to a first centrifugation step at 2200 x g and room temperature for 15 min. Plasma supernatants are transferred to 15 mL tubes, carefully avoiding contact with the lymphocytic ring, and tubes are centrifuged a second time at 3000 x g and RT for 10 min to remove cellular debris.~Plasma samples are then collected into 1.5 mL cryovials and all the aliquots are stored at -80 °C."
214913965|NCT03792399|BEHAVIORAL|feedback counseling|Professoinal CGM in combination with diet and exercise record is used as teaching material to help patient realize their blood glucose pattern and to modify their behavior after counseling feedback.
215059550|NCT03286829|DRUG|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
215059551|NCT03286829|DRUG|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
215059552|NCT03286829|DRUG|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
214670332|NCT04394169|BEHAVIORAL|Intervention program|"Medical visits:~There will be three medical visits stipulated as follows:~* Visit 1 Intervention Group, four weeks after hospital discharge.~* Visit 2 Intervention Group, eight weeks after hospital discharge.~* Visit 3 Intervention Group, 18 weeks after hospital discharge.~Components of visits:~* Interview and physical examination.~* Therapeutic education about the intensive care syndrome orally and with a specific document that will be delivered at the end of the visit.~* Therapeutic education around pain. If the patient reports pain, a specific document will be prepared that will be delivered at the end of the visit.~Psychological intervention:~Inclusion criteria for psychological intervention: Patients with a score higher than 8 on the HAD (hospital anxiety and depression) test depression subscale.~Description :~The intervention protocol consists of 7 weekly sessions lasting one hour and a half. The intervention in depression is based on Rehm's model of self-control."
215059553|NCT03286829|DRUG|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
215059554|NCT00998322|BIOLOGICAL|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
215059555|NCT00998322|DRUG|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
215059556|NCT01508377|BEHAVIORAL|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
215059557|NCT01508377|BEHAVIORAL|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
215059558|NCT04884217|DRUG|Pro-ocular™ Topical Gel|Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
214304269|NCT05315518|DIAGNOSTIC_TEST|single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
214304270|NCT05508074|DRUG|IFB-088 50mg/day|Tested product
215059559|NCT04884217|DRUG|Placebo Topical Gel|Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
215059560|NCT03789513|DIAGNOSTIC_TEST|HPV test with partial genotyping and VIA triage|HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
215059561|NCT04123093|DEVICE|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
214304271|NCT05508074|DRUG|Placebo|Placebo
214670333|NCT01855438|BEHAVIORAL|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
214304272|NCT05508074|DRUG|Riluzole 100mg/day|Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo
214304273|NCT01091389|PROCEDURE|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
214304274|NCT04156568|DRUG|INH、RFT|6INH 10mg/kg 3INH+RFT 15mg/kg
214304275|NCT00304499|DRUG|Oxybutynin|
214304276|NCT05031533|RADIATION|Dose-Painting Radiation|"Radiation therapy:~1. Delineation of target area:~   The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~2. Exposure dose:~1\) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy"
214304277|NCT06326294|DEVICE|Thermal ablation|Thermal ablative uses heat (100°C to 120°C) to cause localized tissue damage at the cervical transformation zone and destroy the abnormal epithelium.
214304278|NCT06326294|PROCEDURE|LOOP ELECTROSURGICAL EXCISION PROCEDURE|Cervical tissue excision
214304279|NCT01463371|DRUG|Azithromycin|250 mg three times a week during three months
214304280|NCT02592746|DRUG|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
214304281|NCT02592746|DRUG|Exemestane|Exemestane 25mg, orally once daily
214670334|NCT04883073|DEVICE|Use of Endo App|Use of Endo App
214670335|NCT03414125|OTHER|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
214913966|NCT01137149|BEHAVIORAL|Behavioral Activation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
214913967|NCT01137149|BEHAVIORAL|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
214913968|NCT03390972|DRUG|Placebo|Placebo (NaCl 0.9%) TCI infusion
214913969|NCT03390972|DRUG|Dexmedetomidine|Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml
214913970|NCT05282992|DIETARY_SUPPLEMENT|Native type II collagen|1 capsule/day
214913971|NCT05282992|DIETARY_SUPPLEMENT|Placebo|1 capsule/day
214913972|NCT00167583|DRUG|Cyclosporin A|3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
214913973|NCT00167583|DRUG|Interferon-alpha2a|3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
214913974|NCT02523183|DRUG|Medical Cannabis|Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
214913975|NCT04573049|DRUG|Levosimendan|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.
214913976|NCT04573049|OTHER|Placebo|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.
214913977|NCT01775059|DEVICE|Integrated sensor and infusion set.|
214913978|NCT06307132|OTHER|Aximus capsules（test）|Aximus capsules test preparation
214913979|NCT06307132|DRUG|Aximus capsules（reference）|Aximus capsules reference preparation
214913980|NCT00080756|BIOLOGICAL|therapeutic estradiol|0.35mg/100ul per day as a nasal spray
214913981|NCT00080756|DRUG|deslorelin|1mg/100ul per day as a nasal spray
214913982|NCT00080756|DRUG|therapeutic testosterone|0.275mg/100ul per day as a nasal spray
214913983|NCT00080756|PROCEDURE|therapeutic conventional surgery|Undergo risk reduction mastectomy
214913984|NCT00080756|OTHER|active surveillance|Undergo continued surveillance
214913985|NCT00080756|PROCEDURE|quality-of-life assessment|Ancillary studies
214913986|NCT00080756|OTHER|laboratory biomarker analysis|Correlative studies
214913987|NCT01511978|DRUG|Continuous 3,4-DAP|Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
214913988|NCT01511978|DRUG|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
214913989|NCT02187198|DRUG|Buprenorphine|
214913990|NCT06444776|DIAGNOSTIC_TEST|Repetitive (semi-)objective and subjective taste, smell, and saliva analysis|"Study participants will undergo repetitive assessments of their taste, smell and saliva, using quality of life questionnaires, taste strips, sniffin sticks, and analysis of salivary function and composition.~Assessments will be done before treatment, in the 4th week (+/- 1 week) and last week of radiation therapy (+/- 1 week), and at 6 months (+/- 1 months) and 1 and 2 years post-therapy (+/- 3 months).~At the minimum, participants are expected to complete the assessments at baseline and 1 year after the end of radiation therapy. Assessments at all other time points are strongly encouraged but will be optional."
214304282|NCT02592746|DRUG|Leuprolide Acetate|Leuprolide Acetate 3.75mg SC q 4weeks
214304283|NCT02592746|DRUG|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
214304284|NCT04564612|DRUG|BIIB091|Administered as specified in the treatment arm
214304285|NCT04564612|DRUG|Rabeprazole|Administered as specified in the treatment arm
214304286|NCT04564612|DRUG|Itraconazole|Administered as specified in the treatment arm
214304287|NCT01959620|BEHAVIORAL|1-Session Exposure Therapy|One exposure therapy session lasting one hour
214304288|NCT01959620|BEHAVIORAL|3-Session Exposure Therapy|Three exposure therapy sessions lasting one hour each, delivered one week apart
214304289|NCT02208856|DRUG|BIBR 796 BS|
214304290|NCT02208856|DRUG|Placebo|
214304291|NCT02208856|OTHER|high fat standardized breakfast|
214304292|NCT02735551|DRUG|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
214304293|NCT02735551|OTHER|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
214304294|NCT02735551|OTHER|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
214304295|NCT05562167|DRUG|KNO3|10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
214913991|NCT00546377|BIOLOGICAL|filgrastim|
214913992|NCT00546377|BIOLOGICAL|pegfilgrastim|
214913993|NCT00546377|BIOLOGICAL|rituximab|
214913994|NCT00546377|BIOLOGICAL|sargramostim|
214913995|NCT00546377|DRUG|cyclophosphamide|
214913996|NCT00546377|DRUG|mitoxantrone hydrochloride|
214913997|NCT00546377|DRUG|pentostatin|
214913998|NCT00546377|GENETIC|fluorescence in situ hybridization|
214913999|NCT00546377|GENETIC|gene rearrangement analysis|
214914000|NCT00546377|GENETIC|polymerase chain reaction|
214914001|NCT00546377|GENETIC|protein expression analysis|
214914002|NCT00546377|OTHER|flow cytometry|
214914003|NCT00546377|PROCEDURE|biopsy|
214914004|NCT06564298|DRUG|Sintilimab|Sintilimab 200mg iv.gtt d1, every 21 days
214914005|NCT06564298|DRUG|Ramucirumab|Ramucirumab 10mg/kg iv.gtt d1, every 21 days
214914006|NCT06564298|DRUG|SOX/XELOX|SOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and S-1 40mg/m2 po bid d1-14, every 21 days XELOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and Capecitabine 1000mg/m2 po bid d1-14, every 21 days
214914007|NCT02582892|DRUG|Vit D|20 mg/day
214914008|NCT02906501|PROCEDURE|The Penn Web-Based Computerized Neurocognitive Battery|The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
214914009|NCT02906501|PROCEDURE|The Iowa Gambling Test (IGT)|The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
214914010|NCT04614025|BIOLOGICAL|PLX-PAD|PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells
214914011|NCT01964222|BEHAVIORAL|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
214914012|NCT03883230|DIAGNOSTIC_TEST|GLYWD|As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
214914013|NCT03325816|DRUG|Nivolumab|Nivolumab is administered intravenously
214914014|NCT03325816|RADIATION|177Lu-DOTA0-Tyr3-Octreotate|"177Lu-DOTA0-Tyr3-Octreotate will be administered every 8 weeks. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Each dose is infused over 30 minutes. On the day of 177Lu-DOTA0-Tyr3-Octreotate infusion, an intravenous bolus of anti-emetics will be given (suggested options: ondansetron (8 mg), granisetron (3 mg), or tropisetron (5 mg)). Administration of 177Lu-DOTA0-Tyr3-Octreotate may be given one day earlier or delayed up to 1 week due to holidays, inclement weather, conflicts, or similar reasons.~Concurrent amino acids are given with each dose of 177Lu-DOTA0-Tyr3-Octreotate since co-infusion of amino acids leads to a significant reduction (47%) in the mean radiation dose to the kidneys. The amino acid solution and 177Lu-DOTA0-Tyr3-Octreotate are administered in parallel by peripheral vein infusion"
214914015|NCT06363331|BEHAVIORAL|Emotional Training|Emotional Training Therapy following the programme in the computer
214914016|NCT00501410|DRUG|5-FU|2400 mg/m\^2 by vein over 46 Hours On Days 1 \& 2.
214914017|NCT00501410|DRUG|Cetuximab|Initial Dose = 400 mg/m\^2 by vein, then 250 mg/m\^2 Weekly On Days 1 \& 8
214914018|NCT00501410|DRUG|Dasatinib|Starting dose level: 100 mg by mouth daily on days 1-14.
214914019|NCT00501410|DRUG|Leucovorin|400 mg/m\^2 by vein on day 1.
214914020|NCT00501410|DRUG|Oxaliplatin|85 mg/m\^2 by vein on day 1.
214914021|NCT01972243|OTHER|no intervention|
214914022|NCT06534099|OTHER|Control|Without changing their original lifestyle habits, weekly follow-ups were conducted by the experimenters via telephone or face-to-face interviews to ensure that the participants did not engage in other forms of regular fitness activities.
214914023|NCT06534099|OTHER|Experimental|The Wuqinxi exercise regimen was conducted under the guidance of a professional Wuqinxi instructor, where the experimental group practiced the five animal forms of the exercise, which include the Tiger, Deer, Bear, Ape, and Bird forms. The exercise period was 24 weeks, with the first 4 weeks designated as the learning phase and weeks 5 to 24 as the consolidation and reinforcement phase. The frequency of exercise was three times per week, with each session lasting 70 minutes, including 10 minutes for warm-up and relaxation activities.
214914024|NCT01737710|BIOLOGICAL|Fluzone® Intradermal Vaccine|A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
214914025|NCT01737710|BIOLOGICAL|Fluzone® (Intramuscular) vaccine|A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
214914026|NCT04851990|OTHER|To Better Days Large Patch|Large patch containing vitamin D \& Dextrose for transdermal absorption
214914027|NCT04851990|OTHER|To Better Days Small Patch|Small patch containing vitamin D \& Dextrose for transdermal absorption
214914028|NCT01360242|PROCEDURE|MIMI procedure (two-step strategy)|A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
214914029|NCT01360242|PROCEDURE|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
214914030|NCT04679532|OTHER|Gx sweat patch|Adhesive-backed flexible epidermal wearable regional sweat patch to collect and analyze sweat via microfluidics and colorimetric assay
214914031|NCT04679532|OTHER|Reference sweat patch|Adhesive Tegaderm with absorbent pad regional sweat patch to collect sweat, followed by standard benchtop gravimetry and ion chromatography methods to analyze sweat
214914032|NCT03143985|DRUG|Vactosertib|Vactosertib is an inhibitor of protein serine/threonine kinase activity of TGF-β receptor type 1 (TGFBR1; ALK5). Vactosertib inhibits the phosphorylation of the ALK5 substrates, Smad2 and Smad3, and the intracellular signaling of TGF-β. Dosing begins at 60mg by mouth, daily and may increase to 240mg by mouth daily in the absence of dose limiting toxicities
214914033|NCT03143985|DRUG|Pomalidomide|POM, an analog of thalidomide, is an immunomodulatory agent with antineoplastic activity. Myeloma tumor cells exposed to POM, undergo growth arrest and increased apoptotic cell death. POM enhances T cell- and natural killer cell-mediated immunity and inhibit production of pro-inflammatory cytokines by monocytes. POM may be taken orally with water. Capsules should not be broken, chewed or opened. POM should be taken without food (at least 2 hours before or 2 hours after a meal). POM will be commercially available. POM will be taken by mouth at a dose of 4mg per day
214914034|NCT05057598|OTHER|Community-based participatory research on diet and lifestyle|"The intervention use a web site that contains a section to exchange information on recipes and on strategy to comply with the recommendations, and an agenda to inform on meetings, conferences, kitchen classes, walking groups, organised by the participant themselves. The investigators are developed specific recommendations for women with different characteristics. The investigators intend to improve the specificity of information with short questionnaires on portion size of relevant items using photographs or usual container in the kitchen and develop a health application for smartphone to facilitated a more efficient and timely exchange on information.~The participants will receive a free phone number for emergencies, active 2 hours a day for 5 days a week."
214914035|NCT04604171|BEHAVIORAL|Action Observation Training|Action Observation Training (AOT) is composed, according to Franceschini et al. (2012), by 20 different videos of daily activities (actions) carried out with the upper limbs. Patients underwent only one task per day for 20 sessions, starting from the easiest. Each action (unimanual or bimanual) is observed from a first-person perspective. Actors in the videos are young non-disabled people, either men or women. Patients are asked to carefully observe the videos, in order to prepare themselves to imitate the presented actions, while the therapist consistently holds the patient's attention with verbal feedback. At the end of each sequence, the therapist prompts the patient to perform the same movement with the paretic upper limb over a time period of 2 minutes, providing verbal instructions or help, if needed. Each session lasts about 30 minutes (3 min of sequence observation and 2 min of action performance for 3 motor sequences repeated twice).
214914036|NCT04604171|BEHAVIORAL|Task Oriented Training|In Task Oriented Training patients performed functional activities with the upper limbs, using the same objects for AOT, in both unimanual and bimanual modalities, without watching the video beforehand. The therapist just provided for verbal instructions and feedback, avoiding demonstrative or imitative indications. The therapist could passively support the movement if patients were completely unable to perform the actions. When necessary, the therapists could also actively facilitate the upper limb movement if patients were unable to correctly perform the actions. Based on the patient's level of motor ability and progress, the levels of movement and task difficulty could be adjusted accordingly. Patients underwent one task per day for 20 sessions. Each session lasted about 30 minutes.
214914037|NCT04604171|BEHAVIORAL|Conventional Treatment|Conventional treatment consists of a range of different patient-tailored interventions, selected by the therapist on the basis of the functional level of the patient. Treatment sessions include training for transfers, mobility, walking up and down steps, balance tasks and tailored functional tasks for the upper limbs (unimanual and bimanual). Moreover, it is also provided for joint and soft tissue mobilization, specific sensory stimulation, exercises to increase strength, both for lower and upper limbs. Each session lasted about 60 minutes.
214914038|NCT04120649|PROCEDURE|hysterectomy|total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
214914039|NCT02271152|PROCEDURE|FAST mapping and ablation|
214914040|NCT02271152|PROCEDURE|PVI|
214914041|NCT05711251|OTHER|Physical Activity in Health Promotion|During the term, the participants in the study group took lessons on many subjects, from the benefits of physical activity to suggestions to increase physical activity at work and in daily life.
214914042|NCT06461936|DRUG|Sintilimab|Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
214914043|NCT06461936|DRUG|Lenvatinib|Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.
214914044|NCT03945955|DIETARY_SUPPLEMENT|Melatonin|Participants will be randomized into two groups (Group A and Group B). Group A will initially be treated with 3 mg melatonin supplements over a 4-week period while Group B will initially receive placebo supplements over a 4-week period. After a 4-week washout period, Group A will receive placebo supplements while Group B will receive 3 mg melatonin supplements.
214914045|NCT03945955|OTHER|Placebo|Placebo
214914046|NCT05252208|OTHER|Stretching exercise|Stretching (30-45 minutes, 5 days per week, 6 months)
214914047|NCT05252208|OTHER|Walking exercise|Walking (30-45 minutes, 5 days per week, 6 months)
214914048|NCT04707677|DEVICE|Titanium and ceramic dental Implants|Two types of implant placement and follow-up to compare the esthetic, clinical and radiographic parameters between them.
214914049|NCT00942890|DEVICE|NMES (EMPI 300PV stimulator) plus standard of care|In addition to the standard rehabilitation, the NMES treatment group will receive neuromuscular electrical stimulation to the quadriceps muscle of the residual and intact limb. The name of the NMES device is EMPI 300PV. NMES training will consist of performing 15 to 20 minute stimulation sessions with a 5-minute patient treatment log, 5 times per week for 12 weeks. During each training session, 15 NMES contractions per leg will be completed. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device. This will be performed at home.
214914050|NCT00942890|BEHAVIORAL|TMARP standard of care|The usual care is 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
214914051|NCT00968643|RADIATION|radiation therapy|Given in multiple fractions or as a single fraction
214914052|NCT00081224|DRUG|capecitabine|
214914053|NCT00081224|DRUG|celecoxib|
214914054|NCT00081224|RADIATION|radiation therapy|
214914055|NCT00081224|PROCEDURE|surgery|
214914056|NCT06340841|BEHAVIORAL|Personal Incentives|The participant receives incentives directly if they complete an activity on a given day.
214914057|NCT06340841|BEHAVIORAL|Personal Restorative Incentives|The participant receives incentives directly if they complete an activity on a given day. They are given an additional incentive to return to completing activities if they did not complete an activity on a prior day.
214914058|NCT06340841|BEHAVIORAL|Charity Incentives|The participant earns compensation for charity if they complete an activity on a given day.
214914059|NCT06340841|BEHAVIORAL|Charity Restorative Incentives|The participant earns compensation for charity if they complete an activity on a given day. They are given an additional incentive for charity to return to completing activities if they did not complete an activity on a prior day.
214914060|NCT06352008|DRUG|Anlotinib|12mg once a day, taken orally before breakfast for 2 consecutive weeks and stopped for 1 week. Without special circumstances, it is recommended to take at a fixed time every day; If there is a missing dose during the administration, confirm that the time before the next administration is less than 12 hours, no more refilling. The maximum duration of drug use is tentatively 1 year.
214914061|NCT00926471|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Program|12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
214914062|NCT04116060|DIETARY_SUPPLEMENT|Dietary Nitrate|Oral dietary nitrate supplementation with (0,12 mmol/kgBW sodium-nitrate)
214914063|NCT04116060|DIETARY_SUPPLEMENT|Control|Placebo Comparator: Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day)
214914064|NCT03356080|DRUG|Decitabine|Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks
214914065|NCT03356080|DRUG|Cytarabine|cytarabine, iv,15mg/m2 q12h, Day1-Day10
214914066|NCT03356080|DRUG|All-transretinoic acid|All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20
214914067|NCT03356080|DRUG|G-CSF|G-CSF 300ug,sc,Day 0 until CR is achieved
214914068|NCT06575257|DRUG|Darolutamide|600 mg orally twice daily for 12 weeks before radical prostatectomy
214914069|NCT06575257|DRUG|Goserelin 3.6 mg|3.6 mg goserelin hypodermic once per 4 weeks
214914070|NCT05846490|DEVICE|CPAP|Continuous positive airway pressure + anti-hypertensive treatment intensification (if necessary)
214914071|NCT05846490|DRUG|Usual care|Anti-hypertensive treatment intensification (if necessary)
214914072|NCT01707966|DRUG|Orteronel|
214914073|NCT01707966|DRUG|Placebo|
214914074|NCT02541357|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
214914075|NCT02541357|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
214914076|NCT04408339|OTHER|No Intervention|No Intervention
214914077|NCT06159751|OTHER|serum albumin level|serum albumin level in gonarthrosis
214914078|NCT00468351|PROCEDURE|Intravitreal Injection of 1,5 mg of bevacizumab|
214914079|NCT00468351|PROCEDURE|Intravitreal injection of 4 mg of Triamcinolone acetonide|
214914080|NCT02818946|DEVICE|MRI|Detection of cancer by MRI for pathologic nipple discharge
214914081|NCT05383365|OTHER|Suboccipital Myofascial Release(MFR) with sham Deep Neck Flexor(DNF)exercise|"The treatment includes Suboccipital MFR in the supine position.The therapist places the supinated forearm on the bed and positions the tips of the middle three fingers inferior to the occiput bone and the head is supported by the thenar eminences.The therapist will develop a line of tension through the suboccipital tissues by supinating the forearms and pulling apart two hands from each other;Then, for the second level in the first position of hands,pressure is applied to the anterior and superior direction.The pressure is held and increased until the therapist feels the decrease of muscle tone.These techniques last 10 minutes.~Another intervention in this group is the sham DNF exercise with a Pressure Biofeedback Unit(PBU).Considering that minimum detective change with PBU is 15 mmHg; After placing the airbag of PBU under the occiput bone in the supine position and inflating it to a base pressure of 11 mmHg,the participant will increase the pressure to 12 mmHg by nodding action."
215059562|NCT04123093|DEVICE|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
215059563|NCT00434980|BEHAVIORAL|Family-Directed Cognitive Adaptation Program|
215059564|NCT06318078|OTHER|eCHIS|The electronic Community health Information System (eCHIS) is a Government of Uganda owned application used by community health workers for quality health assessments and improved reporting. The eCHIS intervention allows for the registration of longitudinal profiles for client centered care as well as provides care guidance to aid decision making. For its users, the app has a task tab for schedule management and dashboards for performance help management and impact tracking by supervisors. This app is interoperable with national reporting tools such as DHIS2. The app has ten workflows including registration of households and new persons, death reporting, iCCM assessment, treatment and referral follow up, stock monitoring, data synchronization, pregnancy registration, ANC danger signs and follow up, family planning registration, and screening (tuberculosis, hypertension, sickle cell, tobacco use and net use).
215059565|NCT03516773|DRUG|EB612 (EBP05)|Entera Bio's proprietary drug for the administration of PTH(1-34) orally
215059566|NCT03516773|DRUG|NATPARA/NATPAR|A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
214914082|NCT05383365|OTHER|Deep Neck Flexor(DNF)exercise with sham Suboccipital Myofascial Release(MFR)|"The treatments include the DNF exercise with a PBU. The treatment is performed in the supine position and the airbag is placed under the occiput bone and is inflated to a base pressure of 20 mmHg. The participant will increase and hold the pressure to a special point by nodding action. The exercise is repeated for 3 sets, in each set 2 mm Hg is added to the pressure. The pressure will be increased from 22 to 32 mm Hg during 4-week of treatment, and each goal is held for 10 seconds and repeated 10 times. There will be 5 sec of rest between each repetition and 2 min of rest between each set.~Another intervention in this group is sham MFR. The therapist's hands will be placed only inferior to the occipital bone and a superficial touch is applied without any upward or lateral pressure. sham treatment in this group, like the opposite group, lasts 10 minutes."
215059567|NCT04556591|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
215059568|NCT04556591|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a three-month (90 day) period
215059569|NCT04245267|BEHAVIORAL|DIABEMPIC|Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
215059570|NCT01540630|DRUG|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
215059571|NCT01540630|DRUG|Placebo|Double-blind placebo comparator for 28 days.
215059572|NCT02465723|DEVICE|MRI with IVIM DW-MRI|
214914083|NCT06665321|BEHAVIORAL|Internet-based psychodynamic therapy (IPDT)|The intervention is 9 week long with weekly modules that the participants work with while receiving weekly support from an assigned therapist.
214914084|NCT02932774|DRUG|Cetirizine|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
214914085|NCT02932774|DRUG|Loratadine|Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
214914086|NCT02932774|OTHER|Placebo|Placebo syrup once daily before 10:00 AM for 2 weeks
214914087|NCT03346681|DRUG|N-acetyl cysteine|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
215059573|NCT02465723|OTHER|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
215059574|NCT05421130|DEVICE|Selective Cerebral Perfusion Catheter|This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
214914088|NCT04922255|DEVICE|Reusable Underwear|Reusable Underwear are similarly available for purchase online and are absorbent underwear for bladder leak protection
214914089|NCT04922255|DEVICE|Disposable urethral support|The disposable urethral support is a tampon-like device that is available over the counter to help women with urinary incontinence (UI)
214914090|NCT04922255|BEHAVIORAL|Pelvic floor physical therapy|Experienced pelvic health physical therapists (at University of Pittsburgh) will complete two visits one week apart.
214914091|NCT00683124|DRUG|Losartan and nebivolol|"Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.~Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations"
214914092|NCT00683124|DRUG|Losartan|Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
214304296|NCT05562167|DRUG|Placebo|10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
214304297|NCT01185938|DRUG|Rosuvastatin|One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
214914093|NCT00683124|DRUG|Nebivolol|Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
214914094|NCT02677922|DRUG|AG-120|Specified dose on specified days
214914095|NCT02677922|DRUG|Azacitidine|Specified dose on specified days
214914096|NCT02677922|DRUG|AG-221|Specified dose on specified days
214914100|NCT05475990|DRUG|Hydroxyethyl starch|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214914101|NCT05475990|DRUG|Crystalloid|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214914102|NCT00439985|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
214914103|NCT00968747|BEHAVIORAL|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
214914104|NCT00968747|BEHAVIORAL|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
214914105|NCT00968747|BEHAVIORAL|Diet|Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
214914106|NCT00968747|DIETARY_SUPPLEMENT|oral carbohydrate challenge|Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
214914107|NCT05801705|DRUG|Aromatase inhibitor|Aromatase inhibitor includes Arimidex, Aromasin, Femara.
214914108|NCT05801705|PROCEDURE|ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)|Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin
214914109|NCT05801705|DRUG|Tamoxifen|tamoxifen,10mg, bid
214914110|NCT05801705|DRUG|toremifene|toremifene, 60 mg, qd
214914111|NCT03261414|PROCEDURE|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
214914112|NCT03261414|PROCEDURE|usual care|Standard care before induction of anesthesia
214914113|NCT01268670|DRUG|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
214304298|NCT01787227|DEVICE|xTAG RPP|
214304299|NCT00142571|DRUG|Gemcitabine|
214304300|NCT00142571|DRUG|Docetaxel|
214304301|NCT02429518|DRUG|Miltefosine|
214304302|NCT06238232|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient's weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
214914114|NCT01268670|DRUG|Oxycodone|Subjects will receive topical LET and oral oxycodone.
214914115|NCT01268670|OTHER|Placebo|Subjects will receive topical LET and oral placebo.
214914116|NCT01791894|DRUG|arsenic trioxide|Given IV
214914117|NCT05816629|DIAGNOSTIC_TEST|Multiparameter ultrasound based-AI|Multiparameter ultrasound based-AI for the diagnosis of thyroid nodules
214914118|NCT02699346|DEVICE|HS-1000 recording|
214914119|NCT06576336|PROCEDURE|laparoscopic adrenalectomy|laparoscopic adrenalectomy
214914120|NCT00266292|BEHAVIORAL|Fish oil (Bio-Marine, Pharma Nord)|
214914121|NCT00266292|BEHAVIORAL|n-6 PUFA intake (Margarine+sunflower oil vs. butter product+rapeseed oil)|
214914122|NCT03004638|DRUG|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
214914123|NCT03004638|DRUG|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
214914124|NCT03004638|DRUG|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
214914125|NCT03004638|DRUG|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
214914126|NCT03004638|DRUG|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
214914127|NCT03004638|DRUG|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
214914128|NCT02268916|BEHAVIORAL|Counseling|OT led counseling
214914129|NCT02268916|BEHAVIORAL|Usual education|At the end of the study, will receive OT-led counseling
214914130|NCT02291042|DRUG|B+O Suppository|
215059575|NCT00460694|BIOLOGICAL|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
214304303|NCT04434365|DRUG|Berberine|Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).
215059576|NCT03181061|OTHER|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
215059577|NCT00001106|DRUG|Zidovudine|
215059578|NCT04176991|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
215059579|NCT04176991|BIOLOGICAL|Placebo|Placebo Comparator
215059580|NCT03096795|DRUG|MEDI3506|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.
215059581|NCT03096795|DRUG|Placebo|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
215059582|NCT04150666|DIETARY_SUPPLEMENT|Hydration|the same with arm descriptions
215059583|NCT04551963|DRUG|Zanubrutinib|Capsules administered at a dose and frequency as specified in the treatment arm
215059584|NCT04551963|DRUG|Fluconazole|Capsules administered at a dose and frequency as specified in the treatment arm
215059585|NCT04551963|DRUG|Diltiazem|Capsules administered at a dose and frequency as specified in the treatment arm
215059586|NCT04551963|DRUG|Voriconazole|Capsules administered at a dose and frequency as specified in the treatment arm
215059587|NCT04551963|DRUG|Clarithromycin|Capsules administered at a dose and frequency as specified in the treatment arm
215059588|NCT03379259|DRUG|BGB-A333|Anti-PD-L1 antibody
215059589|NCT03379259|DRUG|BGB-A317|Anti-PD-1 antibodies
215059590|NCT05134285|OTHER|blood pressure,BMI, blood sample|Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
215059591|NCT00211354|DRUG|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
215059592|NCT00654836|BIOLOGICAL|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
214914131|NCT02418949|DRUG|Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
214914132|NCT02418949|DRUG|Placebo for Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
214914133|NCT02418949|OTHER|Active Movement Practice (AMP)|Participants will alternate between active training with a custom video game and a robot active-assistive Voice and EMG-Driven Actuated (VAEDA) glove during active training occupational therapy.
215059593|NCT00654836|DRUG|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
215059594|NCT00654836|DRUG|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
215059595|NCT04907825|DRUG|Oral anticoagulant|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines
215059596|NCT04791215|OTHER|Observational|All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
214304304|NCT04434365|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
214914134|NCT02418949|OTHER|Passive Cyclical Stretching|Participants will wear the actuated device/glove for the duration of the training sessions (2 20-min stints followed by 10 min of rest) during which time the actuated glove will cyclically stretch the joints of the digits in the hand between flexion and extension while remaining passive/relaxed.
214914135|NCT02001311|DRUG|Chlorhexidine gluconate|
214914136|NCT04435418|DRUG|Apixaban|The decision to treat with apixaban and the timing of initiation will be at the attending physicians' discretion, independent of enrolment in EASSE.
214914137|NCT03146806|DRUG|Intranasal ketamine|"10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse."
215059597|NCT04021316|OTHER|dCELL® Human Dermis (decellularised dermal skin allograft - DCD)|DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
215059598|NCT04021316|OTHER|Compression bandaging therapy|Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
215059599|NCT00700622|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
215059600|NCT00700622|DRUG|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
215059601|NCT00700622|DRUG|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
215059602|NCT02069873|BEHAVIORAL|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
215059603|NCT00792311|PROCEDURE|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
215059604|NCT02444507|DRUG|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
215059605|NCT02444507|DRUG|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
215059606|NCT04320212|PROCEDURE|lumber epidural analgesia|the lumber epidural analgesia will be given after induction of general anesthesia.
215059607|NCT04320212|PROCEDURE|erector spinae analgesia|the erector spinae analgesia will be given after induction of general anesthesia.
215059608|NCT04096950|BIOLOGICAL|MT-3921 Low dose|MT-3921 Low dose, intravenous, single dosing
215059609|NCT05134610|DEVICE|AEROBIKA POSITIVE EXPIRATORY PRESSURE DEVICE|Intervention arm patients use the OPEP device twice daily for 2 weeks before and after surgery
215059610|NCT04498286|DIAGNOSTIC_TEST|Testing of SARS-CoV-2 antibodies|Sars-CoV-2 RBD total antibody test developed by Sanquin
215059611|NCT00385385|DRUG|Rifalazil|
215059612|NCT06224907|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
214914138|NCT01788826|PROCEDURE|Prophylactic mesh|Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.
215059613|NCT06351982|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"1. Disclosure of biofilm with erythrosine,~2. Removal of supragingival and subgingival (up to 4 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS- Dental, Nyon Switzerland).~3. Supra- and sub- gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
215059614|NCT06351982|OTHER|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥4 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
214914139|NCT01788826|PROCEDURE|No prophylactic mesh closure|Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
214914140|NCT01265862|PROCEDURE|Tracheal intubation through LMA-Fastrach®|Tracheal intubation through a supraglottic airway device (LMA-Fastrach®) using a GlideRite® endotracheal tube
215059615|NCT00273091|DEVICE|ICD with CRT therapy|permanently CRT pacing
215059616|NCT04434547|BIOLOGICAL|PRP|During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
215059617|NCT00678171|DEVICE|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
215059618|NCT01598714|DEVICE|Darco shoe|Darco shoe
215059619|NCT01598714|DEVICE|Podalux shoe|Podalux shoe
215059620|NCT01598714|DEVICE|Standard dressing shoe|Standard dressing shoe
215059621|NCT03274947|DEVICE|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
214914141|NCT01265862|PROCEDURE|Tracheal intubation through I-gel®|Tracheal intubation through a supraglottic airway device (I-gel®) using a GlideRite® endotracheal tube
214914142|NCT05953935|DEVICE|OKTO|Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz
215059622|NCT03274947|DEVICE|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
215059623|NCT01243008|DRUG|Application of SHB001|"* Cohort 1: Application of SHB001 on the skin of right thigh~* Cohort 2:~  1. Application of SHB001 on the skin of right thigh~ 2. punch biopsies of treated skin areas"
215059624|NCT03306472|DRUG|Megestrol Acetate 40 MG|Progesterone Agonist
215059625|NCT03306472|DRUG|Megestrol Acetate 160 MG|Progesterone Agonist
214304305|NCT04434365|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
215059626|NCT03306472|DRUG|Letrozole|Aromatase Inhibitor
215059627|NCT03061877|OTHER|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
215059628|NCT03754556|DEVICE|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
214304306|NCT04434365|DRUG|Statin|Statins once daily for 12±1 weeks.
214304307|NCT05757531|DRUG|[¹⁴C]-LY3437943|Administered SC.
214914143|NCT05953935|DEVICE|Standard clinical procedures|standard clinical procedures
214914144|NCT03918824|OTHER|Data extraction from medical files|Data extraction from medical files
214914145|NCT05513482|DIAGNOSTIC_TEST|Tissue Doppler Imaging|With tissue Doppler ultrasonography (TDI), the maximum contraction rate of the diaphragm, maximum relaxation rate, and integral against time will be examined.
215059629|NCT01204905|DRUG|Raltegravir and Maraviroc in combination|"Raltegravir 400 mg tablet twice a day, \~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, \~12 hours (10 to 14 hours) apart"
215059630|NCT01794507|DRUG|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
215059631|NCT01794507|DRUG|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
215059632|NCT01794507|DRUG|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
215059633|NCT00068263|RADIATION|radiation therapy|
214304308|NCT04735120|DEVICE|iLASE DIODE LASERS|940nm diode laser with 1.5 watts activated in a continuous mode and applied on to the canal orifices during root canal treatment to reduce intraoperative pain and further its effect on post operative pain is assessed
215059634|NCT06260449|PROCEDURE|Surgical removal|Removal of the granuloma
215059635|NCT04918381|DEVICE|CellFX System|Nano-Pulse Stimulation (NPS)
215059636|NCT03634098|DEVICE|new quantitative imaging techniques with contast products|magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue
215059637|NCT03634098|DIAGNOSTIC_TEST|blood sample|extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
215059638|NCT03634098|DIAGNOSTIC_TEST|second generation tests|second generation tests NIT-NASHr et NIT-A2F2
215059639|NCT02583633|DRUG|Transdermal nitroglycerin|
215059640|NCT02583633|DRUG|nifedipine|
215059641|NCT02601430|OTHER|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
215059642|NCT05366127|OTHER|IGA score|IGA score will be assessed by 2 blinded investigators
215059643|NCT05366127|OTHER|BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)|BPDAI will be assessed by 2 by 2 blinded investigators
214914146|NCT05513482|DIAGNOSTIC_TEST|M Mode Imaging|Diaphragm displacement during inspiration and expiration will be measured with M mode imaging
214304309|NCT04535791|DRUG|Cholecalciferol|4,000 IU orally daily for 30 days
214914147|NCT02684097|DRUG|Tralokinumab|All groups will receive study drug every two weeks for 24 weeks.
214914148|NCT02684097|DRUG|Placebo|Matching placebo given every two weeks for 24 weeks
214914149|NCT00460811|DRUG|Linaclotide Acetate|Oral, once daily
214914150|NCT00460811|DRUG|Matching placebo|Oral, once daily
214914151|NCT05468905|OTHER|None of intervention|None of intervention
214914152|NCT02748356|DRUG|Lactobacillus|Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
214914153|NCT01602861|DRUG|Spironolactone|"One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (\>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo)."
214914154|NCT01602861|DRUG|placebo|
214914155|NCT06575231|DIAGNOSTIC_TEST|in-vitro|responding smartphone. It is intended for quantitative measurement of HbA1c in capillary whole blood and use in the home by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.
214914156|NCT01888055|DEVICE|transcranial direct current stimulation|
214914157|NCT01888055|DEVICE|sham stimulation|
214914158|NCT00664573|BIOLOGICAL|Baminercept alfa (BG9924)|dosage administered as per Biogen-Idec protocol
214914159|NCT06128902|OTHER|tele health|home based exercise and telenursing
214914160|NCT03546491|DRUG|Preventive Gel|0.4% Stannous Fluoride
214914161|NCT03546491|DRUG|Marketed Control|0.243% Sodium Fluoride
214914162|NCT03515811|DEVICE|Signia™ Stapling System|Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri- Staple™ 2.0 Intelligent Reloads.
214914163|NCT00237458|DRUG|Lacosamide|"Dosage: Lacosamide up to 400 mg/day;~Dosage form: Film-coated tablets;~Dosage Frequency and Duration: Two times per day; 9.5 years"
214914164|NCT04331067|DRUG|Paclitaxel|-Given standard of care
214914165|NCT04331067|DRUG|Carboplatin|-Given standard of care
214914166|NCT04331067|BIOLOGICAL|Nivolumab|-Given standard of care
215059644|NCT01434628|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
215059645|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
215059646|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
215059647|NCT03978611|DRUG|Relatlimab|Specified dose on specified days
215059648|NCT03978611|DRUG|Ipilimumab|Specified dose on specified days
214304310|NCT05215301|DIAGNOSTIC_TEST|Multidimensional Voice Program|"MDVP (Multidimensional Voice Program) is a computerized acoustic analysis used to analyze sound quality using various parameters. Multidimensional Voice Program (MDVP) 4500 produced by Kay Elemetric Corp was used for voice evaluation.~Research subjects were asked to make a vowel sound /a/ using the same tone and intensity as the subject's daily speech. The researcher will give an example before letting the research subject tries. Voice recording was done using a microphone connected to a computer with the MDVP program. Voice recording was done in a quiet room for at least 3 seconds with a microphone distance of 10 cm from the mouth of the research subject. The recorded sound will be directly analyzed with the MDVP program. Sound recording was done 3 - 5 times, and the best sound acoustic analysis results were used for the study."
214914167|NCT04331067|BIOLOGICAL|Cabiralizumab|-Will be provided by Bristol Myers Squibb
214914168|NCT04331067|PROCEDURE|Tumor biopsy|-Baseline, week 5, surgery, and at time of relapse (optional)
214914169|NCT04331067|PROCEDURE|Bone marrow|-Time of port placement (baseline), time of surgery, and time of recurrence (optional)
214914170|NCT04331067|PROCEDURE|Blood draw|-Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)
214914171|NCT04339062|DRUG|Cemiplimab|Cemiplimab: via IV, flat predetermined dosage every 21 days.
214914172|NCT04339062|DRUG|Everolimus|Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
214914173|NCT04339062|DRUG|Sirolimus|Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
214914174|NCT04339062|DRUG|Prednisone|40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
214914175|NCT02748642|DRUG|BITS7201A|BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
214914176|NCT02748642|DRUG|Placebo|Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
214914177|NCT05870371|BEHAVIORAL|Feldenkrais Awareness Through Movement technique|10 group sessions, 50 minutes each, over a period of five weeks, which will include the application of the Feldenkrais Awareness Through Movement technique
214914178|NCT05870371|BEHAVIORAL|Acupuncture|10 sessions, two per week, of 25 minutes acupuncture each, which will include the insertion of a sterile disposable needle into standardized local, regional, and systematic or general acupuncture points that modify pain behavior in area of Cervical Spine.
214914179|NCT05870371|BEHAVIORAL|Stretching|10 sessions, two per week, of 15 minutes stretching each, which will include lateral flexion and counterrotation of the head performed for the upper part of the trapezius and the anterior scalene, lateral flexion and corresponding rotation for the levator scapulae, and flexion for the extensors of the Cervical Spine. The following muscles will be applied: upper trapezius, levator scapulae, scalenes, extensors of the Cervical Spine (splenoid, spinous, semispinalis, longus cephalic and cervical, iliocostalis cervical, multifidus and subscapularis), and sternocleidomastoid.
214479696|NCT06867510|PROCEDURE|Block for Anterior Cervical Spine Surgery|The patient will be positioned supine with a slight elevation of the head and the head turned away from the blocked side. After sterilizing the skin, the ultrasound probe will be placed over the middle of the posterior border of the sternocleidomastoid muscle. The needle will be inserted in-plane while keeping the probe in a transverse position. The needle tip will be placed under the sternocleidomastoid muscle and below the superficial fascia, and then, a total volume of 15 ml of 0.25% bupivacaine will be injected bilaterally. The spread of the local anesthetic will be visualized using ultrasound guidance. The same steps will be repeated on the other side
214479697|NCT06867510|DRUG|Saline (NaCl 0,9 %) (placebo)|Total volume of 15 ml of saline 0.9% will be injected subcutaneous bilaterally
214479698|NCT06627075|PROCEDURE|Surface Guided RadioTherapy (SGRT) without mask|"Firstly, patients are positioned in a vacuum mattress that moulds their head, neck and shoulders for a reference scan.~During the treatment sessions, patients are positioned according to the reference scan, using the surface camera system.~Once the observed offsets have been applied, the patient's surface is captured. Treatment can then begin, with continuous monitoring of displacements by the surface camera system. Automatic beam interruption is provided during treatment in the event of motion detection exceeding the standard tolerance threshold (\>3 mm).~If the use of a thermoformed mask during your treatment prove necessary, for whatever reason, will not result in a halt to the research.~Patients receive between 10 and a max of 35 radiotherapy sessions. The follow-up period begins after the last radiotherapy session, and patients are assessed at 4 or 6 weeks and at 3 months by a radiotherapist."
214479699|NCT00591175|BEHAVIORAL|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
214479700|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
214479701|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
214479702|NCT06817564|BEHAVIORAL|AI-PEF|Participants will follow a 12-week walking program with five 30-minute sessions per week, progressively increasing intensity based on heart rate and effort indices. Garmin fitness trackers will monitor adherence and intensity. Remote guidance will support participants via weekly digital health messages on the LINE app, offering personalized feedback, goal reinforcement, and lifestyle recommendations. Participants will also receiThese AI feedback implementations will be tailored to complement the in-person education and will include reminders of the individualized goals set during the remote exercise intervention and consultation . The digital component will also offer a platform for patients to share their progress and seek further guidance during the scheduled in-person consultation. The use of digital AI feedback aligns with the trend of integrating technology into healthcare services, providing a convenient and accessible modality for supporting parents engaging in regular exercise.
214914180|NCT03027141|BEHAVIORAL|Face recognition task|Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
215059649|NCT05159687|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
215059650|NCT05159687|DRUG|Placebo|Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
215059651|NCT02793973|DEVICE|shoe lifts|
214914181|NCT00020787|BIOLOGICAL|G17DT Immunogen|Dose: 500 micrograms in 0.2mL Route: Deep intramuscular Schedule: Days 8, 36, and 64; an additional dose at week 2, cycle 7 will be administered
214914182|NCT00020787|DRUG|cisplatin|dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
215059652|NCT04535817|DRUG|Omalizumab Injection [Xolair]|300mg via 2 subcutaneous injections every 4 weeks
215059653|NCT02205268|PROCEDURE|Near infrared spectroscopy neurofeedback training|
215059654|NCT01736423|DRUG|YM060|oral
215059655|NCT02526212|BEHAVIORAL|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
215059656|NCT02526212|BEHAVIORAL|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
215059657|NCT02526212|DRUG|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
215059658|NCT03391557|DIAGNOSTIC_TEST|UE|All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
214914183|NCT00020787|DRUG|fluorouracil|Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
215059659|NCT04790669|PROCEDURE|Daily adjustable progressive resistance exercises (DAPRE)|Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
215059660|NCT04790669|PROCEDURE|Close kinetic chain exercises (CKC).|Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline \& post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
215059661|NCT02303756|DEVICE|Pillcam® COLON Capsule|colonoscopy
214304311|NCT01830439|DRUG|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
214304312|NCT01830439|DRUG|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
214304313|NCT04407312|DRUG|Cilostazol Tablets|Cilostazol-SR, capsule, 200mg, once daily, 30 days.
214304314|NCT04407312|DRUG|placebo|Placebo, tablet, 200mg, once daily, 30 days.
214304315|NCT04407312|DRUG|Aspirin|Astrix, capsule,100mg, once daily, 30 days.
214304316|NCT04407312|DRUG|Clopidogrel|Plavix, tablet, 75mg, once daily, 30 days.
214304317|NCT00367952|DRUG|apricitabine|800mg apricitabine twice daily orally for 96 weeks
214304318|NCT02456610|BIOLOGICAL|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
214304319|NCT04120974|BEHAVIORAL|Optimal insulin injection|subjects receive training in optimal injection technique.
214304320|NCT05837624|DRUG|Estetrol/Drospirenone|6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration
214304321|NCT03338062|DIAGNOSTIC_TEST|Hepatobiliary Iminodiacetic Acid (HIDA) scan|HIDA scan was used as the planning scan for SBRT.
215059662|NCT00304616|DRUG|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
215059663|NCT04279119|DRUG|ARQ-151- cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
215059664|NCT03645096|DRUG|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
215059665|NCT03645096|DRUG|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
214304322|NCT06493305|BEHAVIORAL|Neurolinguistic programming|In the NLP application protocol, the visual, auditory and/or tactile representation system that the woman uses most frequently will be determined. Then, using the anchoring technique, the internal reactions and external reactions created by the woman's current symptoms and emotions and thoughts regarding the urination process will be combined using the anchoring technique. Existing negative emotions will be reduced and positive emotions will be reinforced. Then, with the swish technique, the intensity of the woman's existing negative emotions will be erased from the most frequently used visual, auditory or tactile representation system. Then, taking into account the representation system that the woman uses most frequently, the belief change model will be used in her negative thoughts about the current symptom, and her negative feelings and thoughts will be replaced by positive feelings and thoughts and reinforced.
214304323|NCT04622293|DRUG|Solriamfetol Oral Tablet [Sunosi]|Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
214304324|NCT04622293|DRUG|Placebo|A placebo encapsulated to look the same as the experimental drug will be given to the control group.
214304325|NCT02826707|BEHAVIORAL|SPPAC intervention|A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
214304326|NCT04256785|DIETARY_SUPPLEMENT|VSL#3|sachets containing probiotic
214304327|NCT04256785|DIETARY_SUPPLEMENT|Placebo|sachets containing placebo
214304328|NCT04669587|DRUG|ZB716|Pharmaceutical form: capsule Route of administration: oral
214304329|NCT04669587|DRUG|Palbociclib|Pharmaceutical form: capsule Route of administration: oral
214304330|NCT00306605|BEHAVIORAL|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
214304331|NCT01519414|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214304332|NCT01519414|OTHER|Placebo|Given PO
214304333|NCT01519414|DRUG|Tivantinib|Given PO
214304334|NCT04265781|DRUG|BAY1817080|Three different doses over the course of study
214304335|NCT04265781|DRUG|Matching Placebo|Matching Placebo to BAY1817080
214304336|NCT05147493|DRUG|Isatuximab|Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
214304337|NCT05147493|DRUG|Bortezomib|Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
214479703|NCT06817564|BEHAVIORAL|Theory-based digital exercise|The theory-based digital exercise group will follow the same in-person clinic visits and walking program as AI-PEF but without AI-driven feedback
214914184|NCT05713890|OTHER|Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation|"Observation of a VR scenario depicting multiple repetitions of a specific upper limb motor task belonging to typical activities of daily living, followed by mental imagination of the action observed and then by the execution of the same task, using objects provided in a kit.~In each session, patients will watch 2 different videos and will perform the two corresponding actions. The time scheduled for observation, imagery and execution of each action will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes. New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
215059666|NCT03645096|DRUG|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
215059667|NCT00040742|DIETARY_SUPPLEMENT|ginger|Given orally
215059668|NCT00040742|OTHER|placebo|Given orally
215059669|NCT00392834|BIOLOGICAL|filgrastim|given subcutaneously
215059670|NCT00392834|BIOLOGICAL|pegfilgrastim|given subcutaneously
215059671|NCT00392834|BIOLOGICAL|rituximab|given IV
215059672|NCT00392834|DRUG|cyclophosphamide|given IV
215059673|NCT00392834|DRUG|cytarabine|given intrathecally
215059674|NCT00392834|DRUG|doxorubicin hydrochloride|given IV
215059675|NCT00392834|DRUG|etoposide|given IV
215059676|NCT00392834|DRUG|ifosfamide|given IV
214914185|NCT05713890|OTHER|Home-based landscape observation with virtual-reality for upper limb rehabilitation|"Observation of virtually explorable landscapes followed by rest with eyes closed without focusing on any thought in particular and then execution of the same actions requested to VR-AOT-group. In each session, patients will explore 2 different landscapes and perform 2 different actions. The time scheduled for observation, rest and action execution will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes.New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
214914186|NCT04524793|OTHER|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
214914187|NCT04524793|OTHER|Physical examinations|GSV/SSV/AASV reflux, CEAP Classification (Clinical, Aetiological, Anatomical and Pathophysiology), Venous Clinical Severity Score (VCSS) and duplex ultrasound
215059677|NCT00392834|DRUG|leucovorin calcium|given IV
215059678|NCT00392834|DRUG|liposomal cytarabine|given intrathecally
215059679|NCT00392834|DRUG|methotrexate|given intrathecally
215059680|NCT00392834|DRUG|therapeutic hydrocortisone|given intrathecally
215059681|NCT00392834|DRUG|vincristine sulfate|given IV
214304338|NCT05147493|DRUG|Cyclophosphamide|Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
214304339|NCT05147493|DRUG|Dexamethasone|Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
214304340|NCT05147493|DRUG|Lenalidomide|Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
214304341|NCT03194321|DRUG|Tacrolimus Extended-Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
214914188|NCT04408170|DIAGNOSTIC_TEST|Point-of-care test for SARS-CoV-2|Throat and nose swabs and/or saliva samples and/or whole blood and/or finger stick samples may be taken to be tested on Point-of-care tests for SARS-CoV-2
214914189|NCT06589219|DRUG|CMR316|CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort
215059682|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
215059683|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
215059684|NCT03520920|DRUG|Zanubrutinib|Administered zanubrutinib 160 mg orally (PO) BID continuously
215059685|NCT03520920|DRUG|Rituximab|Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.
215059686|NCT04081402|BIOLOGICAL|HU-014|Hutox Inj(Clostridium botulinum type A)
215059687|NCT04081402|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
215059688|NCT02370823|PROCEDURE|Regenexx SD|stem cell treatment
215059689|NCT00201422|OTHER|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
215059690|NCT05025397|DRUG|Danavorexton|Danavorexton intravenous infusion.
215059691|NCT05025397|DRUG|Danavorexton Placebo|Danavorexton placebo-matching intravenous infusion.
215059692|NCT05025397|DRUG|Propofol|Propofol intravenous bolus.
215059693|NCT05025397|DRUG|Sevoflurane|Sevoflurane inhalation.
215059694|NCT05025397|DRUG|Propofol|Propofol intravenous infusion.
215059695|NCT00405392|DRUG|Ibandronate (SB743830HD)|
215059696|NCT05034042|DRUG|Fezolinetant|oral
215059697|NCT05034042|DRUG|Placebo|oral
215059698|NCT01326091|OTHER|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
215059699|NCT03685318|DEVICE|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
214914190|NCT06589219|DRUG|Placebo|Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration
214914191|NCT02441738|PROCEDURE|Hybrid Ablation|The procedure will be performed following standard of care guidelines.
214914192|NCT02441738|PROCEDURE|Catheter Ablation|The procedure will be performed following standard of care guidelines.
214914193|NCT02229760|DRUG|Tipranavir capsules|
214914194|NCT02229760|DRUG|Ritonavir capsules|
214914195|NCT04104503|DRUG|Lu AF11167|Lu AF11167 - 2 mg modified release tablets (reference formulation), up to 5 prototype MR tablet formulations (test formulations)
215059700|NCT03685318|DEVICE|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
215059701|NCT00833963|DRUG|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
215059702|NCT00833963|DRUG|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
215059703|NCT00833963|DRUG|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
215059704|NCT00955643|OTHER|oxygen|
215059705|NCT00955643|OTHER|other|
215059706|NCT01118403|DRUG|Sultamicillin|Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
215059707|NCT02032758|DRUG|Propranolol|Single oral dose of 10 mg propranolol
215059708|NCT02032758|DEVICE|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
215059709|NCT02032758|PROCEDURE|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
215059710|NCT02032758|DEVICE|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
215059711|NCT03826654|DIETARY_SUPPLEMENT|fortified oil|35 g fortified sunflower oil
215059712|NCT03826654|DIETARY_SUPPLEMENT|Placebo|plain oil
215059713|NCT06287541|PROCEDURE|Urine biomarker -Guided without reTURBT|Participants will proceed without reTURBT
215059714|NCT04904419|DIAGNOSTIC_TEST|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
215059715|NCT02596568|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
215059716|NCT02596568|OTHER|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
215059717|NCT03641781|OTHER|isometric strength training and isokinetic strength training|"Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps."
215059718|NCT01703091|DRUG|Ramucirumab|Administered IV
215059719|NCT01703091|DRUG|Placebo|Administered IV
215059720|NCT01703091|DRUG|Docetaxel|Administered IV
215059721|NCT02184091|DRUG|Nevirapine|
215059722|NCT05965583|DRUG|BI 1815368|BI 1815368
215059723|NCT05965583|DRUG|Itraconazole|Itraconazole
215059724|NCT04904744|OTHER|Low tailored message|2 low tailored text or phone message reminders that child is overdue for well child check visit
214914196|NCT04104503|DRUG|[14C]-Lu AF11167|single iv microdose administered as a 15 minutes infusion
214914197|NCT04104503|DRUG|Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)|Single oral dose
214914198|NCT03313557|DRUG|Wee-1 kinase inhibitor AZD1775|Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
214914199|NCT01777282|DRUG|Albiglutide|Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
214914200|NCT01777282|DRUG|Sulfonylurea|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
214914201|NCT01777282|DRUG|Biguanide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
214914202|NCT01777282|DRUG|Glinide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
214914203|NCT01777282|DRUG|Thiazolidinedione|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
214914204|NCT01777282|DRUG|Alpha-glucosidase inhibitor|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
215059725|NCT04904744|OTHER|No message|No reminders are sent
215059726|NCT04904744|OTHER|Low tailored message plus COVID-19 vaccine message|2 low tailored text or phone message reminders that child is overdue for well child check visit and that COVID-19 vaccine is available
215059727|NCT02777047|OTHER|Anticoagulation Coordinated Care|see above
215059728|NCT05449340|DEVICE|BEAUTIFY application|Interview with the coordinating nurse in the postoperative period to install the BEAUTIFY application on the patient's smartphone and to train her to record any Patients will monitor their symptoms weekly. In case of toxicity grade \> 2, the nurse will contact the patient for further information.
215059729|NCT04610619|OTHER|Immunological challenge|In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
214914205|NCT04089579|BIOLOGICAL|Cord Tissue Mesenchymal Stromal Cells|Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.
214914206|NCT04089579|OTHER|Placebo Infusion|Placebo comparative infusion
214914207|NCT05992337|DIAGNOSTIC_TEST|Blood sampling|Blood sample collection for mRNA determination
214914208|NCT05992337|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for detection of ventricular dysfunction
214914209|NCT05992337|DIAGNOSTIC_TEST|Cardio MRI|MRI for early detection of myocardial impairment caused by chemotherapy
214914210|NCT05992337|DIAGNOSTIC_TEST|24-hours monitoring of ECG|Diagnostic test for detection of arrhythmias as a consequence of cardiotoxicity
214914211|NCT05992337|DIAGNOSTIC_TEST|24 hours monitoring of BP|Diagnostic test for detection of hypertension as a consequence of cardiotoxicity
214914212|NCT06940076|DRUG|gayo arabica coffee skin extract cream|Assessment of glagou scale, skin analyzer, corneometer, and tewameter was done before and after the treatment . The subject will receive directions on how to use the cream before the study starts. The cream was used 2 times daily (7.40 AM and 1.00 PM) for 8 weeks.
214914213|NCT06940765|DEVICE|GID SVF-2 Device System|The GID SVF-2 device is indicated for use for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue.
214914214|NCT06941285|OTHER|Data collection|Data collection
214914215|NCT06941207|BEHAVIORAL|virtual reality video viewing group|The caregivers, the first group in the experimental group, will be shown a total of 8 sessions of virtual reality-based videos (nature, forest walks and city tours, etc.) for an average of 30 minutes, twice a week for 4 weeks.
214914216|NCT06941207|BEHAVIORAL|benson relaxation exercise group|The second group in the experimental group, the caregivers, will have a total of 8 sessions of Benson relaxation exercises for 20-25 minutes, twice a week for 4 weeks.
214914217|NCT06940687|BEHAVIORAL|Pre-recorded Music Session|A pre-recorded concert session
214914218|NCT06940687|BEHAVIORAL|Live Music Session|A 45-minute live music performance
214914221|NCT02511418|DRUG|Simvastatin|
214914222|NCT06940947|PROCEDURE|eFTR|endoscopic full thickness resection
214914223|NCT06940947|PROCEDURE|Surgery|standard-of-care surgery
214914224|NCT06939998|PROCEDURE|FOBIET|"an endotracheal tube (ET) is initially inserted into the nasal cavity, and then a flexible fiberoptic bronchoscope is introduced through it. The endotracheal tube will be connected to a catheter mount by which the investigator can deliver oxygenation. When using a nasal endotracheal tube, the tip is lubricated with 2% lignocaine jelly before being inserted into the nasal cavity and pushed up and down to allow the jelly to spread. The fiberoptic bronchoscope descends through the endotracheal tube after being inserted into the nasal passage as a nasal airway in the direction of the vocal cords until they can be seen.~After identifying the vocal cords, 2 ml of 2% lidocaine will be sprayed over the supraglottic area using the bronchoscope's working channel. An additional 2 ml of 2% lidocaine will then be sprayed directly onto the vocal cords, after which the tip of an endotracheal (ET) tube will be carefully inserted into them."
214914225|NCT06939998|PROCEDURE|CFOBI|a 5.0-mm flexible fiberoptic bronchoscope (Pentax) will be loaded with an endotracheal tube of the proper size (7.5 for male and 7.0 for female patients). The bronchoscope tip will then be introduced into the nasal cavity, and the vocal cords will be detected.
214914226|NCT05311059|PROCEDURE|Laparoscopic ovarian drilling|Drilling needle was introduced and connected by monopolar current, held against ovarian surface for 4 seconds using a power of 40 watt, 4 puncture was done in each ovary with putting into consideration that the puncture must be not superficial and it must go deep through the main substance of the ovary
215059730|NCT05342012|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
215059731|NCT05342012|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|(Nitrate depleted beetroot juice
215059732|NCT02550288|DRUG|Ezetimibe 10 mg|
215059733|NCT02550288|DRUG|Atorvastatin 10 mg|
215059734|NCT02550288|DRUG|Placebo for Ezetimibe 10 mg tablet|
215059735|NCT02550288|DRUG|Placebo for Atorvastatin 10 mg capsule|
215059736|NCT02550288|BEHAVIORAL|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
215059737|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
215059738|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
215059739|NCT01016717|DRUG|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
215059740|NCT01016717|DRUG|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
215059741|NCT04131322|DRUG|Amgevita 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
215059742|NCT04131322|DRUG|HUMIRA 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
215059743|NCT03998800|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
215059744|NCT03998800|BEHAVIORAL|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
215059745|NCT01220102|DRUG|0.1% adapalene/ 2.5% benzoyl peroxide|topical application, once per day
215059746|NCT02984670|BEHAVIORAL|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
214914227|NCT03899792|DRUG|LOXO-292|Oral LOXO-292
214914228|NCT03258918|BEHAVIORAL|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.
214914229|NCT06326398|OTHER|Stoma Care|Nursing students practice stoma care with low and high fidelity simulation
214914230|NCT04044066|BIOLOGICAL|Plasma biomarker|New emerging plasma biomarkers carrying prognositic information
214914231|NCT02056041|PROCEDURE|Hepatectomy|
214914232|NCT00003118|DRUG|cisplatin|
214914233|NCT00003118|DRUG|fluorouracil|
214304342|NCT03792308|DRUG|SPR206|"SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13."
214304343|NCT03792308|DRUG|Placebo|0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
214304344|NCT01204164|DRUG|TG02 citrate|TG02 citrate capsules given orally.
214304345|NCT01204164|DRUG|Carfilzomib|Carfilzomib per PI
214304346|NCT01204164|DRUG|Dexamethasone|Dexamethasone (Oral or IV)
214304349|NCT04648345|PROCEDURE|Erector spinal plane block|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
214304350|NCT04919577|DIAGNOSTIC_TEST|X-ray|We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.
214304351|NCT02721927|OTHER|Syrian Refugees|Adult Syrian patients who visited the Emergency Department
214914234|NCT00003118|PROCEDURE|surgical procedure|
214914235|NCT00003118|RADIATION|radiation therapy|
214914236|NCT01780038|BEHAVIORAL|Receipt of Genetic Results|Participants will receive the results of genotyping for RS1051730
214914237|NCT01780038|BEHAVIORAL|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
214914238|NCT01584986|BIOLOGICAL|ACP injections|Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)
214914239|NCT04601519|OTHER|Cross-sectional observational study|Online questionnaire on the impact of type 1 diabetes on sleep quality
214914240|NCT05349110|DEVICE|Computer-aided diagnosis (CADx) systems|"* AI4CRP (artificial intelligence for colorectal polyps), a CNN based computer-aided diagnosis system for diagnosis of colorectal polyps (COMET-OPTICAL research group);~* CAD EYE, a computer-aided diagnosis system for diagnosis of colorectal polyps (Fujifilm® Corporation, Tokyo, Japan)."
214914241|NCT06462950|BEHAVIORAL|Do men and women differ in their reactions to the experimental conditions.|Do men and women differ in their reactions to the experimental conditions.
214914242|NCT01415817|OTHER|Training session|Series of two training sessions after the first phase of study followed by monthly feedback.
214914243|NCT01085630|DRUG|pemetrexed disodium|Given IV
214304352|NCT05014750|OTHER|None intervention|There is no intervention included in this study.
215059747|NCT02984670|BEHAVIORAL|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
215059748|NCT02984670|BEHAVIORAL|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
215059749|NCT00989508|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
215059750|NCT00989508|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
214304353|NCT01320462|DRUG|Smoking cessation counselling group|The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
214304354|NCT01320462|OTHER|Control group:|Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
214914244|NCT01085630|OTHER|clinical observation|
214914245|NCT00641030|DRUG|clofarabine|Administered at the appropriate dose level(dose level one = 30 mg/m2, dose level two and three = 40 mg/m2)on days -9 to day -5 from transplant
214914246|NCT00641030|DRUG|melphalan|Administered at the appropriate dose level (dose level one and two = 100 mg/m2, dose level three = 140 mg/m2) on day -4 from transplant
215059751|NCT02065934|OTHER|cardio-pulmonary resuscitation|
215059752|NCT02613520|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
215059753|NCT02613520|OTHER|Normal Saline|0.9% Sodium chloride
214914247|NCT00641030|GENETIC|gene expression analysis|Peripheral blood draw on day -9 and day -4 prior to transplant
214914248|NCT00641030|GENETIC|reverse transcriptase-polymerase chain reaction|Peripheral blood draw on day -9 and day -4 prior to transplant
215059754|NCT02613520|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
214914249|NCT00641030|OTHER|flow cytometry|Bone marrow aspirate and biopsy to confirm diagnosis prior to transplant, day -9 pre-transplant, day 30 post-transplant, day 100 post-transplant, 6 months post-transplant, one year post-transplant, then yearly through year 5 post-transplant
214914250|NCT00641030|OTHER|laboratory biomarker analysis|Peripheral blood draw day -9 or earlier pre-transplant, day 14 post-transplant, day 30 post-transplant, day 60 post-transplant, day 100 post-transplant, 6 months and one year post-transplant.
214914251|NCT00641030|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Infusion of allogeneic hematopoietic stem cells on day 0 of transplant
214914252|NCT02529449|DRUG|Placebo|Oral
214914253|NCT02529449|DRUG|ASP1941|Oral
214914254|NCT01237041|DRUG|Niacin First|Niacin 500 mg po four times on one of the inpatient days, then placebo on another inpatient day
214914255|NCT01237041|DRUG|Placebo First|Placebo po four times on one of the inpatient days, then Niacin 500 mg po four times on another inpatient day
214914256|NCT01237041|DRUG|Dose-Establishing Study 1 Niacin 250mg|Niacin 250 mg po three times at 2 hour intervals on an inpatient day
214914257|NCT01237041|DRUG|Dose-Establishing Study 1 Niacin 500mg|Niacin 500 mg po three times at 2 hour intervals on an inpatient day
215059755|NCT06448130|DRUG|Henagliflozin 5mg|Henagliflozin 5mg + lifestyle intervention
215059756|NCT06448130|DRUG|Henagliflozin 10mg|Henagliflozin 10mg+ lifestyle intervention
215059757|NCT06448130|DRUG|Placebo|Placebo+ lifestyle intervention
215059758|NCT00003322|DRUG|cisplatin|
215059759|NCT00003322|DRUG|paclitaxel|
215059760|NCT00003322|PROCEDURE|quality-of-life assessment|
215059761|NCT03121300|OTHER|CT Scan|Quantitative lung SPECT-CT
215059762|NCT03121300|OTHER|Lung CT|CT lung ventilation
214304355|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
214304356|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
214304357|NCT00425230|DRUG|Duloxetine|
214304358|NCT02589574|OTHER|electronic text message|"Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.~it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority."
214304359|NCT03774277|BEHAVIORAL|Packed Promise for a Healthy Heart|"Voucher for fresh vegetables and fruits (referred to as a fresh check); Home delivered food boxes that contain Dietary Approaches to Stop Hypertension (DASH)-approved ingredients for preparing low-salt, and traditional healthy Chickasaw meals; Heart-healthy recipes (available at getfreshcooking.com) that are tailored to traditional Chickasaw diet and culture; Educational materials; Personalized invitation to attend local cooking demonstrations; Assistance to link the Fitbit and AYA app"
214304360|NCT01736150|DRUG|Placebo|"* Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals."
214304361|NCT01736150|DRUG|Sevelamer carbonate|"* Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals."
214304362|NCT02176850|DRUG|Micardis®|
214304363|NCT00130221|DRUG|2% chlorhexidine gluconate impregnated cloth|
214304364|NCT00130221|OTHER|Daily bathing with Bar soap|bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
214304365|NCT02692599|BIOLOGICAL|investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
214304366|NCT02692599|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
214914258|NCT01237041|DRUG|Dose-Establishing Study 2 Niacin 500mg|Open-Label Niacin 500mg four times at 1 hour intervals on an inpatient day
214914259|NCT02892539|RADIATION|Coronary Angiography|
215059763|NCT03121300|OTHER|MRI|DCE MRI
215059764|NCT03121300|OTHER|Walk Test|6 minute hall walk test
215059765|NCT03121300|OTHER|SGRQ|St. George Respiratory Questionnaire
215059766|NCT03121300|OTHER|Biological Sample Collection|Blood Draw
215059767|NCT03121300|OTHER|Toxicity|Toxicity Evaluation
215059768|NCT03121300|OTHER|Cardiac Assessment|Cardiac MRI Scan
215059769|NCT04075305|RADIATION|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
215059770|NCT04209023|DEVICE|Transcranial Magnetic Stimulation|Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
215059771|NCT01296971|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
214304367|NCT05783362|BEHAVIORAL|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion. Conditioned pain modulation will be calculated as the average pain ratings of the second testing stimulus series minus the average pain ratings of the first testing stimulus series.
214304368|NCT02154191|PROCEDURE|Surgical Intervention|The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
214479704|NCT06817564|BEHAVIORAL|Active Control|Participants in the active control group will receive standard TBI care, including Garmin-based self-monitoring and routine clinic visits at baseline (T0), 3 months (T1), and 6 months (T2). These visits will include general health education and recommendations on daily physical activity. No personalized or digital exercise strategies will be provided. Participants completing the 6-month protocol will have the option to access the AI-PEF program after the study.
214479705|NCT05215054|DEVICE|Gana V®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
214479706|NCT05215054|DEVICE|Sculptra®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
214479707|NCT02272309|PROCEDURE|EEG and EP measurement|
214479708|NCT04165733|DIAGNOSTIC_TEST|Online questionnaire|Clinical psychologists in Germany currently working with patients with mental disorders
214479709|NCT06693921|PROCEDURE|AI/guided block graft|The allo-dentin tooth graft will be prepared by placing a dentin block from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template.
214914260|NCT00563641|OTHER|Very early surfactant and bubble NCPAP|For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
214914261|NCT00563641|OTHER|bubble NCPAP|"Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria."
214914262|NCT05901441|DRUG|Hydromorphone|For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
214914263|NCT05901441|DRUG|Sufentanil|For those in SF group: they will be administered with 40 ug/ml sufentanil
214914264|NCT05901441|DRUG|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
214914265|NCT04333095|DRUG|Liposomal bupivacaine|Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
214914266|NCT04333095|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
214914267|NCT06189144|OTHER|Emollient cream treatment|Rilastil Difesa Sterile cream
214914268|NCT06189144|OTHER|no treatment|no treatment
214914269|NCT05478460|OTHER|Hookwire localization|Patients were performed CT -guided hook wire localization(20G×120mm, PAJUNK medizintechnologie, Geisingen in Germany). patients were placed on a CT table in a suitable position(supine, prone, lateral) to obtain the shortest needle insertion route for their initial CT scan. Local anesthesia of the skin and planned puncture tract was performed using 10ml Lidocaine 1%. Next, the needle was inserted into or near the pulmonary nodule.
214914270|NCT02430649|PROCEDURE|Irreversible electroporation (IRE)|
214914271|NCT02430649|DEVICE|NanoKnife|
214914272|NCT05457218|DIETARY_SUPPLEMENT|Whey protein|The participant will consume a supplemental dose of whey protein (0.25 g/kg body weight)
214914273|NCT05457218|DIETARY_SUPPLEMENT|IPC80|The participant will consume a supplemental dose of IPC80 (0.25 g/kg body weight)
214914274|NCT05457218|DIETARY_SUPPLEMENT|Whole Buffalo Powder|The participant will consume a supplemental dose of Whole Buffalo Powder (0.25 g/kg body weight)
214914275|NCT02355938|DRUG|Fidaxomicin 200 mg|Fidaxomicin 200 mg every 12 hours
214914276|NCT02355938|DRUG|Placebo|1 dose of placebo every 6 hours x 2 doses
214914277|NCT02355938|DRUG|Vancomycin|Vancomycin 125 mg every 6 hours
214914278|NCT04176419|DRUG|Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
214914279|NCT04176419|DRUG|Placebo Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
214914280|NCT04176419|DRUG|Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
215059772|NCT01296971|DRUG|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
215059773|NCT01296971|DRUG|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
215059774|NCT02819297|DRUG|BLI400 Laxative|21 gm BLI400 powder
215059775|NCT02819297|DRUG|BLI400 Placebo|Equivalent amount of placebo powder
215059776|NCT01569737|DRUG|ella|ella, single intake, tablet 30mg
215059777|NCT06005012|DRUG|Semaglutide|Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
215059778|NCT06005012|DRUG|Placebo|Placebo
215059779|NCT02648594|DEVICE|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
214914281|NCT04176419|DRUG|Placebo Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
214914282|NCT04176419|DRUG|Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
214914283|NCT04176419|DRUG|Placebo Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
214914284|NCT04176419|DRUG|Gabapentin|600 mg orally at time of check in to the preoperative unit
214914285|NCT04176419|DRUG|Placebo Gabapentin|600 mg orally at time of check in to the preoperative unit
214914286|NCT04176419|DRUG|Celecoxib|200 mg orally at time of check in to the preoperative unit
215059780|NCT02546726|BEHAVIORAL|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
215059781|NCT02546726|BEHAVIORAL|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
215059782|NCT00628459|DIETARY_SUPPLEMENT|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
215059783|NCT01071252|DRUG|AIN457|
215059784|NCT01071252|DRUG|Placebo|
215059785|NCT04852549|OTHER|Oculomotor exercise|"1. While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~2. While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~3. With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~4. The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions."
215059786|NCT01945996|BEHAVIORAL|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
215059787|NCT01945996|BEHAVIORAL|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
215059788|NCT01160133|OTHER|Systane|Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)
215059789|NCT01160133|OTHER|Refresh Tears|Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)
215059790|NCT01055717|OTHER|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
215059791|NCT04558541|OTHER|Sensitivity to phonological rules|Assess whether children with developmental language disorder (DLD) are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon; children with speech sound disorder (SSD) are not predicted to be sensitive to the same phonological patterns.
214304369|NCT04392297|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells
215059792|NCT04558541|OTHER|Sensitivity to semantic category cues.|Assess whether all children, including those with DLD, show improved learning of OR rules when a semantic category cue is used.
214304370|NCT04392297|DIAGNOSTIC_TEST|CMV specific T-cells|CMV specific T-cells detected by flow cytometry
214304371|NCT04392297|DIAGNOSTIC_TEST|serum CMV IgM / IgG antibodies|serum CMV IgM / IgG antibodies detected by ELISA
214479710|NCT06693921|PROCEDURE|AI/guided shell graft|The allo-dentin shell graft will be prepared by placing a dentin shell from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template
214479711|NCT06695494|DIAGNOSTIC_TEST|Gene panel array|Blood sample collection for gene panel testing
214479712|NCT06695494|OTHER|Blood Sample Collection|Blood sample collection for research purposes
214479713|NCT06688123|DRUG|SHR-3167|Dose level 1.
214479714|NCT06688123|DRUG|SHR-3167|Dose level 2.
214479715|NCT06688123|DRUG|Insulin glargine|Dose level 3.
214479716|NCT06686381|PROCEDURE|Maximum TURBT|Total removal of the bladder tumor through TURBT
214479717|NCT06686381|DRUG|Chemotherapy + Immunotherapy Induction|Chemotherapy: DDMVAC (6 cycles) or Gemcitabine-Cisplatin (4 cycles) Immunotherapy: Avelumab (6 cycles)
214914287|NCT04176419|DRUG|Placebo Celecoxib|200 mg orally at time of check in to the preoperative unit
214914288|NCT02893150|BEHAVIORAL|TAU|"TAU (Treatment as Usual), individuals presenting with overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, teams of primary care (PC) organized care plans to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²).~For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities, evaluates the need for individual dietary prescription by the nutritionist. This decision is discussed among the team of PC and Matrix support team"
215059793|NCT04169516|DIAGNOSTIC_TEST|index of microcirculatory resistance|Physiological parameters of the culprit artery after PCI were determined with the restoration of Thrombolysis in Myocardial Infarction (TIMI) 3 flow. Aortic pressure (Pa), distal intracoronary pressure (Pd), fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) were measured using a 0.014 coronary temperature and pressure-sensing guidewire (PressureWireCertus, ST. Jude Medical, MN, USA).
214479718|NCT06686381|RADIATION|Radiotherapy|Hypofractionated radiotherapy: 20 fractions, 55 Grays
214479719|NCT06686381|DRUG|Immunotherapy Maintenance|Maintenance Avelumab every 2 weeks for 12 months
214479720|NCT06686381|OTHER|Watchful waiting with supportive care|1 year watch and wait
214304372|NCT04506476|DEVICE|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
214304373|NCT03582020|DIETARY_SUPPLEMENT|menu plans|menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
214914289|NCT02893150|BEHAVIORAL|TAU+MBHP|"TAU (Treatment as Usual) + MBHP. We used a general (general vulnerability, not specific) mindfulness-based intervention (MBI) developed by our research group, an 8-week-group-based MBI called Mindfulness-Based Health Promotion (MBHP) program . It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems, which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice; more feasible to be implement in health services and facilities"
214479721|NCT06691165|OTHER|Low oxygen therapy (LOT)|"Participants will breathe variable concentrations of inspired oxygen, carbon dioxide, and nitrogen. The concentrations will be adjusted on a breath-by-breath basis to maintain end-tidal targets.~Each daily session of the intervention will consist of forty 1-minute intervals. Each 1-minute interval will consist of 40 seconds of hypercapnic hypoxia, increasing the partial pressure of end-tidal carbon dioxide by +4 mmHg and decreasing the partial pressure of end-tidal oxygen to 45 mmHg, followed by 20 seconds in simulated room air to return to baseline carbon dioxide and oxygen levels."
214479722|NCT06688396|DEVICE|Mobile 6L AI-EKG Screening|"Participants (probands) with DCM will invite their first-degree relatives to undergo DCM screening procedures.~Probands and first-degree relatives will complete a mobile 6L AI-EKG which will be transmitted to a mobile app and interpreted by the AI-EKG algorithm. Results will be shared electronically or verbally to the participant.~If available, the probands clinical 12L EKGs will be obtained if recorded within 30 days of their Kardia 6L recording.~All participating FDR will be encouraged to pursue cardiac screening per ACC/AHA recommendations. Study staff will obtain echocardiogram results up to 6 months of participant enrollment."
214914290|NCT02893150|BEHAVIORAL|TAU+MB-EAT|TAU (Treatment as Usual) + MB-EAT (mindfulness-based eating awareness training). Adapted from the MBSR, Mindfulness-based Eating Awareness Training (MB-EAT) or awareness training. This program was specially developed for the compulsive eating disorders and related problems\[47\]. In addition the four main techniques of meditation mentioned in the MBHP program includes modifications to these basic techniques, and include experimentation with different flavors, sweet and savory foods, etc. Has 10 weekly sessions of 2,5h
214914291|NCT04859400|DIETARY_SUPPLEMENT|Whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB)|The whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB) is ingested once daily, preferably either in the evening before going to bed or within two hours after having finished exercising.
214914292|NCT04859400|BEHAVIORAL|Standardized nutritional program|During at least two personal counseling meetings with a dietician, the patient's diet is assessed and individual nutritional interventions - based on the personal needs and individual preferences of the patient - are developed. The overall goal is to optimize protein an energy intake.
214914293|NCT04859400|BEHAVIORAL|Standardized exercise program|In at least two personal counseling meetings with a physiotherapist, the patient's individual training plan is compiled and agreed upon (mainly including strength, endurance and balance exercises). The patient then exercises at home and records the trainings with the app.
215059794|NCT01150786|DIETARY_SUPPLEMENT|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
215059795|NCT01150786|OTHER|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
215059796|NCT00303654|PROCEDURE|biopsy|
215059797|NCT00303654|PROCEDURE|therapeutic conventional surgery|
215059798|NCT05066152|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)
215059799|NCT05066152|DIETARY_SUPPLEMENT|Placebo|Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
215059800|NCT04743219|PROCEDURE|Selective removal to soft dentin, Biodentine|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the Biodentine group, Biodentine (Septodont) will be placed on the base of the cavity with a thickness of 2 mm.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
215059801|NCT04743219|PROCEDURE|Selective removal to soft dentin, No Base|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the No base group, no bioactive material will be placed as a liner, the 3M Scothcbonf Universal Plus adhesive will be placed directly over the remaining dentin surface.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
215059802|NCT03928418|BEHAVIORAL|In-person counseling session|Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
214479723|NCT06691659|DIAGNOSTIC_TEST|CT-DACE|Photon Counting CT scan
215059803|NCT03928418|BEHAVIORAL|Live phone call booster session|Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
214304374|NCT05884047|DEVICE|Virtual Glasses|"In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel \& Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video."
214304375|NCT04484363|DRUG|Pevonedistat|Pevonedistat 20 milligram per square meter (mg/m\^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
214914294|NCT06191952|DIAGNOSTIC_TEST|Cognigram|Cognigram (previously known as the Cogstate Brief Battery) is a brief, computer-administered cognitive test battery requiring about 20-25 minutes for administration, consisting of four cognitive tasks to measure psychomotor function, attention, working memory, and learning and memory. Eisai owns the commercial rights for Cognigram and has kindly agreed to offer the required licenses for the present project free of charge. Digital cognitive testing will take place in the respective social and care centers on a tablet which is not connected to the internet. Testing will be performed pseudonymized and data from the cognitive tests will be downloaded regularly by the study team and added to the database at LMU hospital.
214914295|NCT06191952|DIAGNOSTIC_TEST|Subjective cognitive decline questionnaire (SCD-Q)|The SCD-Q is a validated questionnaire assessing the presence of subjective cognitive deterioration in abilities such as memory, attention, language, and executive function. The scale includes 24 dichotomous questions (yes/no), evaluating decline in daily life during the last two years. The SCD-Q score ranges from 0 to 24, with higher scores indicating greater perceived cognitive change (cut-off classified as SCD equal or greater as 7).
214304376|NCT04484363|DRUG|Azacitidine|Azacitidine 75 mg/m\^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.
214304377|NCT06155942|PROCEDURE|7 Tesla MRI|Patients will have a 7T MRI and questionnaires
214304378|NCT06142435|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan the eyes of participants up to 3 times (\~45 seconds each) at the time of admittance to study. The participant is to place the chin in the chin-rest and fixate on the illuminated light on the device.
214304379|NCT01718652|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
214304380|NCT01718652|DRUG|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
214304381|NCT03019939|DRUG|Isavuconazole|Given PO or IV
214304382|NCT03644745|BEHAVIORAL|VM @ Home Usability|Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
214914296|NCT06191952|DIAGNOSTIC_TEST|blood-based biomarkers|Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer. All test results (including the respective cut-off measurements for normal vs abnormal) will be forwarded directly to the participants' GPs. No further explanations and instructions will be provided to avoid any unwanted bias, and participants will only be informed about their results by their doctors. Roche has kindly offered to provide blood biomarker assays free of charge for the present project.
214914297|NCT06191952|DIAGNOSTIC_TEST|ki:elements digital speech biomarker for cognition (ki:e SB-C)|The ki:elements digital speech biomarker for cognition (ki:e SB-C) can be collected remotely in fully automated telephone visits, taking 15 minutes to complete based on three specific assessments measuring learning and memory, processing speed, executive function, and language capabilities. The ki:e SB-C uses artificial intelligence and automatic speech analysis to process and transcribe speech, followed by an extraction of relevant features, combined into four subdomain and one global cognition score.
214914298|NCT02609607|DRUG|Bisacodyl|Rectal suppository
214914299|NCT02609607|OTHER|Placebo|Rectal suppository
214914300|NCT06327529|OTHER|SER 118|Bean High in Phytic Acid and High in Inhibitory Polyphenols
214914301|NCT06327529|OTHER|LMP 1001|Bean Low in Phytic Acid and High in Inhibitory Polyphenols
214914302|NCT06327529|OTHER|LPA 586|Bean Low in Phytic Acid and Low in Inhibitory Polyphenols
214914303|NCT06327529|OTHER|KAT B1|Bean High in Phytic Acid and Low in Inhibitory Polyphenols
214914304|NCT04893447|BEHAVIORAL|SPI+|Suicide prevention hotline follow-up specialists will call participants to (1) conduct a brief suicide risk assessment; (2) review and discuss the participant's connection and support plan or safety plan; and (3) provide referrals to social services or other support with treatment engagement, if indicated. Participants will receive at least one and optional additional phone calls, generally delivered according to the following schedule: days 3, 7, 14, 30, 60, 90. Modifications may be made to the schedule due to weekends, holidays, or participant availability, and additional calls may be scheduled as desired by the participant. The follow-up will stop once the participant is successfully engaged in outpatient treatment or does not desire further follow-up support.
214479724|NCT05269992|OTHER|Real food products|As per arm/group descriptions.
214479725|NCT01536938|DRUG|LEO 90100|
214479726|NCT01536938|DRUG|Calcipotriol|
215059804|NCT03928418|BEHAVIORAL|Technology (IVR or SMS) booster session|Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
215059805|NCT00887367|DRUG|GSK598809|Two 175 mg doses of GSK598809 will be given.
214479727|NCT01536938|DRUG|Betamethasone|
214479728|NCT06870435|BIOLOGICAL|Blood, nasopharyngeal swab and saliva|Collect blood, nasopharyngeal swab and saliva samples from participants.
214479729|NCT06870435|DIAGNOSTIC_TEST|EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA|Detect EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA for all participants.
214479730|NCT06870435|DIAGNOSTIC_TEST|Novel screening biomarkers|Next-generation sequencing for EBV and castoff cells using nasopharyngeal swabs, etc..
214914305|NCT04893447|BEHAVIORAL|SP+CC (Caring Contacts)|SP+CC follow-up includes one phone conversation with a suicide prevention hotline follow-up specialist and a series of personalized caring messages sent over the course of 12 months via text or email (based on participant preference). Caring contacts will generally be sent according to the following schedule: 3 in the first week, 6 weekly, 6 bi-weekly, 4 monthly; 2 bi-monthly, and one each for the participant's birthday, Thanksgiving, Christmas, and New Year's (total of 25 over 12 months). Slight variation in the schedule is allowed. There is no expectation that participants respond to the text messages; if they do, follow-up specialists reply to any incoming texts. Replies are individually-tailored and caring.
214914306|NCT05446701|DIAGNOSTIC_TEST|serum level of FAM19A5|Detection of serum level of FAM19A5 of patients and controls by using ELISA technique.
214914307|NCT01512004|DRUG|Propiverine Hydrochloride|drug of oral capsule
215059806|NCT00887367|OTHER|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
215059807|NCT04147429|BEHAVIORAL|Early Literacy Intervention|Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
215059808|NCT03626012|DRUG|BIIB078|Administered as specified in the treatment arm.
215059809|NCT03626012|DRUG|Placebo|Administered as specified in the treatment arm.
215059810|NCT00763256|DRUG|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
214479731|NCT06870435|DIAGNOSTIC_TEST|Endoscopic examinations with or without biopsy|High-risk participants will refer to endoscopic examinations with or without biopsy
214479732|NCT06224855|DRUG|DXC006|"Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose."
214479733|NCT06872476|OTHER|bed bath|
214479734|NCT06872476|OTHER|bed bath with heat|
215059811|NCT00763256|DRUG|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
215059812|NCT01021176|OTHER|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
214479735|NCT06869213|DRUG|Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin|All subjects were given 3 cycles of neoadjuvant therapy with adebrelimab (1200 mg D1, IV, Q3W)+Nab-paclitaxel(250 mg/m2 D1，IV，Q3W)+Cisplatin(75 mg/m2 D1，IV，Q3W) preoperatively. Within 4-8 weeks of completion of neoadjuvant therapy, all subjects who were suitable for surgery underwent radical surgery, and patients who underwent radical esophageal cancer with R0 resection were given adebrelimab monotherapy postoperatively until disease recurrence or metastasis, toxicity intolerance, initiation of a new antitumor therapy, subject-initiated request to withdraw from the study, and subject's judgement that the subject needed to be withdrawn from the study. The maximum duration of adebrelimab in the adjuvant phase is 16 cycles.
214479736|NCT06872580|DRUG|QLS1209|Levels of QLS1209 will be explored in dose escalation, and determine the maximum tolerated dose.
214479737|NCT06872580|DRUG|QLS1209|Every 21 days is one cycle.1-3 dose levels of QLS1209 will be explored in dose optimization, and determine the recommended dose (RD) of QLS1209 and evaluate the preliminary anti-tumor activity of QLS1209.
214914308|NCT01512004|DRUG|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
215059813|NCT01021176|DRUG|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
215059814|NCT03824873|PROCEDURE|Internal iliac artery ligation|Internal iliac artery ligation and cesarean hysterectomy
214304383|NCT00916747|DRUG|Lonafarnib, Zoledronic Acid, and Pravastatin|"Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily."
214304384|NCT03925740|DRUG|MI Varnish|Application of MI varnish material versus the standard 1.23% APF.
214304385|NCT03925740|DRUG|PreviDent Varnish|Application of PreviDent Varnish material versus the standard 1.23% APF.
214304386|NCT03925740|DRUG|1.23% APF|Standard 1.23% APF application
214304387|NCT02474992|BEHAVIORAL|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
214304388|NCT06415409|OTHER|Water|Plain water
214304389|NCT06415409|OTHER|Gatorade|Sport Drink Gatorade
214304390|NCT06415409|OTHER|BodyArmor|Sport Drink BodyArmor
214304391|NCT06415409|OTHER|GoodSport|Sport Drink GoodSport
214304392|NCT03496948|BEHAVIORAL|TeGeCoach|"12-month long telephone health coaching carried out by specially trained coaches. The health coaching is a patient-centered approach based on motivational interviewing, shared decision-making and active listening techniques. Primary care physicians will be constantly involved receiving regular health reports from the coach.~The walking exercise is based on the principle of interval training. Patients will continuously wear an activity monitor device to review their exercise performance and for remote exercise monitoring by the coach. This activity information will be regularly reviewed by the coach to ensure that the patient adheres to the individual walking exercise prescription."
214304393|NCT03594279|BEHAVIORAL|Community Mobilization|Community Mobilization
214304394|NCT03594279|BEHAVIORAL|Community Mobilization and Community Incentive|Community Mobilization and Community Incentive
214304395|NCT03314155|DIAGNOSTIC_TEST|Cerebral neuroinflammation evaluation|Pet scan following an injection of the radiotracer (\[18F\]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.
214914309|NCT06022315|COMBINATION_PRODUCT|caloric restrction high carbohydrate low fat diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold. The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the high CHO-low FAT diet, carbohydrates, fat, and protein will provide 60%, 25%, and 15% of individually predicted daily energy intake, respectively. Variety (n=7) of daily menus for calorie-restricted high FAT-low CHO diet will be provided and menus for high CHO-low FAT diet on pasta, rice, oats, fruit, and vegetable.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
215059815|NCT03824873|PROCEDURE|cesarean hysterectomy|cesarean hysterectomy
215059816|NCT01565408|DRUG|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
214304396|NCT01423487|DRUG|Metformin|0.5g bid 26 weeks
214304397|NCT01423487|OTHER|Starch tablets|0.5g bid 26 weeks
214304398|NCT03194555|DRUG|Low-Dose Naltrexone and Acetaminophen Combination|Twice daily
214304399|NCT03194555|DRUG|Placebo|Twice daily
215059817|NCT01565408|DRUG|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
215059818|NCT01877681|PROCEDURE|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
215059819|NCT01877681|PROCEDURE|Active comparator|Usual care as specified in the PU practice guideline
215059820|NCT02544750|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
215059821|NCT04089852|DRUG|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
214304400|NCT03831347|BEHAVIORAL|Hatha Yoga|12 weeks of Hatha Yoga
214304401|NCT00642239|DRUG|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
214304402|NCT00642239|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
214304403|NCT05348161|PROCEDURE|Samples including blood and tissue collection|Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
214304404|NCT05348161|PROCEDURE|CTC detection|Peripheral blood collected from patients will be administrated to CTC detection.
214304405|NCT05348161|PROCEDURE|ctDNA detection|DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
214304406|NCT05348161|PROCEDURE|10×genomics single cell RNA sequence|Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
214670336|NCT03414125|OTHER|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences. Outreach includes: 1) invitation letter, 2) choice grid 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
214670337|NCT05590299|OTHER|Fish oral immunotherapy (codfish)|Codfish in mixture of potato prepared under food manufacturing regulations provided in varying doses
214304407|NCT05348161|PROCEDURE|Whole exon sequence|DNA will be extracted from patients' tissue and administrated to whole exon sequence.
214304408|NCT05348161|PROCEDURE|Proteomics detection|Peripheral blood collected from patients will be administrated to proximity extension assay .
214670338|NCT05590299|OTHER|Placebo oral immunotherapy|Placebo in potato mixture prepared under food manufacturing regulations provided in varying doses
214670339|NCT01099826|BEHAVIORAL|Tailored counseling|education tailored to baseline beliefs by trained counselor over phone
214670340|NCT01099826|BEHAVIORAL|Motivational Interview|motivational interview by trained MI counselors by phone
214914310|NCT06022315|COMBINATION_PRODUCT|caloric restrction high fat low carbohydrate diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold.The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the low CHO-high FAT diet, the proportion of energy provided by CHO, fat, and protein will consist of 25%, 60%, and 15%, respectively. Variety (n=7) of daily menus for calorie-restricted low CHO-high FAT diet will be provided and menus for high FAT-low CHO group will be based on meat, fish, cheese, butter, and nuts.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
214914311|NCT04471688|DIAGNOSTIC_TEST|infectious disease screening|Explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening
214304409|NCT02865993|OTHER|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
214304410|NCT02865993|OTHER|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
214304411|NCT03068247|DRUG|Duloxetine|10 week treatment
214304412|NCT03068247|DRUG|Placebo|10 week treatment
215059822|NCT04089852|DRUG|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
215059823|NCT04133662|BEHAVIORAL|Sleep Manipulation Protocol|A structured sleep duration intervention will be taught to patients
214304413|NCT01237535|DRUG|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
214304414|NCT01237535|DRUG|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone \[(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg\].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
214304415|NCT01237535|PROCEDURE|Insemination without luteal support|Routine insemination procedure without luteal support
214479738|NCT06872398|OTHER|Blood and saliva sampling|"Physical and biological evaluation at inclusion visit V0 and at follow up visit V1 (after 1 year).~the biological evaluation includes blood and saliva sampling at the 2 visits."
214670341|NCT04834986|DRUG|Tislelizumab combined with Lenvatinib|"Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84.~Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year."
214304416|NCT03929861|DRUG|Fluconazole (BAYT006267) 150 mg capsules|Fluconazole 150 mg
214479739|NCT06872853|OTHER|diagnosis, surgery, drugs for rare neoplasms|diagnostic and surgical procedures, drugs (pharmacological active substance, dose, regimen)
214670342|NCT05198986|OTHER|Prone Position during Extra Corporeal Membrane Oxygenation (ECMO)|Pronation will be executed according to a predefined protocol: 4 caregivers will be required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube and the ventilator lines. The others will stand at each side of the bed. In the first step, the direction of the rotation will be decided giving priority to the side of the central venous lines. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. In the third step, the patient will be moved in the sagittal plane and maintained in that position for a short while to attach the cardiac electrodes to her/his back and to set a new bed sheet. In the last step, the patient will be turned to the complete prone position.
214670343|NCT00006669|BIOLOGICAL|rituximab|
214670344|NCT00006669|BIOLOGICAL|sargramostim|
214670345|NCT00006669|DRUG|EPOCH regimen|
214670346|NCT00006669|DRUG|cyclophosphamide|
214670347|NCT00006669|DRUG|doxorubicin hydrochloride|
214670348|NCT00006669|DRUG|etoposide|
214670349|NCT00006669|DRUG|prednisone|
214670350|NCT00006669|DRUG|vincristine sulfate|
215059824|NCT05870462|DRUG|Semaglutide Pen Injector|"* 0.25 mg/week (non-therapeutic dose) during Weeks 1-4~* 0.50 mg/week during Weeks 5-8~* 1.0 mg/week during Weeks 9-24~Participants experiencing side effects (e.g. nausea, stomach pain, constipation, diarrhea, vomiting) at the maximum dose (1.0 mg/week) may be down-titrated to 0.50 mg/week.~Participants who had been receiving a dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin) will stop taking their DPP-4 inhibitor upon randomization to this arm."
214304417|NCT03929861|DRUG|Fluconazole 150 mg capsules (DiflucanTM)|Fluconazole 150 mg
214304418|NCT02355119|DRUG|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
214304419|NCT02355119|DRUG|Gemcitabine|
214304420|NCT01750099|PROCEDURE|Combined Spinal-epidural|See arm description
214304421|NCT01750099|PROCEDURE|Continuous Lumbar epidural|See arm description
214304422|NCT00790881|DRUG|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
214304423|NCT00790881|DRUG|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
214304424|NCT00238121|DRUG|sorafenib tosylate|Given orally
214304425|NCT05507255|OTHER|Relaxation training|Relaxation training in the form of deep breathing exercises
214304426|NCT05507255|OTHER|An aerobic exercise program|An aerobic exercise program of a moderate intensity, based on the target heart rate (THR) that will be calculated in accordance with Karvonen's equation, using resting heart rate (HRrest), maximal heart rate (HRmax) and training fraction. THR = HRrest (bpm) + (HRmax (bpm) - HRrest (bpm)) × training fraction.The exercise session will have three phases, warming up, active phase and cooling down.
214304427|NCT03816059|DIAGNOSTIC_TEST|Respiratory virus testing|All patients will be tested for respiratory viruses
214670351|NCT01205243|DRUG|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
214914312|NCT03254745|OTHER|Pharmacist led pharmaceutical care|The intervention in the study will be a pharmacist's intervention that will be provided to rheumatoid arthritis patients in order to improve their treatment outcomes. It will be in the form of a single (1) session by pharmacist (face-to-face) followed by written material for use at home. The pharmacist will look at the patient's baseline data and provide counseling. The venue for counseling will be the hospitals.
214914313|NCT01010412|DEVICE|Ultrasound (Sonosite Titan T-shaped ultrasound probe)|Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.
214914314|NCT01010412|DEVICE|Electrical Nerve Stimulation (Stimuplex (B Braun) needle)|
214914315|NCT06210113|BEHAVIORAL|Mindfulness-based Stress Reduction|An 8-week Mindfulness-based stress reduction training programme
214670352|NCT00479440|DRUG|SAM-315|
214670353|NCT00677963|DRUG|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
214914316|NCT00651261|DRUG|cytarabine|Given IV
214914317|NCT00651261|DRUG|daunorubicin|Given IV
214914318|NCT00651261|DRUG|midostaurin|Given orally
214914319|NCT00651261|OTHER|placebo|Given orally
214914320|NCT00651261|DRUG|dexamethasone acetate|ocular medication administration
215059825|NCT00039039|DRUG|carboplatin|
215059826|NCT00039039|DRUG|chemotherapy|
215059827|NCT00039039|DRUG|cisplatin|
215059828|NCT00039039|DRUG|paclitaxel|
215059829|NCT00039039|RADIATION|radiation therapy|
215059830|NCT05533944|OTHER|Simulation training in Boškoski-Costamagna ERCP Trainer|Coached simulation training in Boškoski-Costamagna ERCP Trainer, by participating in three intensive courses during the first three months of training, with a monthly basis
215059831|NCT03700840|DEVICE|Interdental brushes|interdental brush at 4 sites and PCR analysis
215059832|NCT03672851|DRUG|anti-CD123 CAR-T treatment|Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
215059833|NCT04550780|DRUG|Mepolizumab|The first administration of mepolizumab.
215059834|NCT00244725|DRUG|Odiparcil|
215059835|NCT00244725|DRUG|Warfarin|
215059836|NCT00244725|DRUG|Coumadin|
215059837|NCT01737983|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10\^10 colony-forming units) for 6 months.
215059838|NCT01737983|DIETARY_SUPPLEMENT|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
214304428|NCT02155647|DRUG|Avelumab|Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
214304429|NCT05190731|OTHER|Osteopathic cranial manipulative medicine|Osteopathic cranial manipulative medicine technique using compression of 4th ventricle technique
214304430|NCT05190731|OTHER|Sham|Touch only, no osteopathic cranial manipulation
214304431|NCT02450110|DEVICE|Spinal cord stimulation|
214304432|NCT03706794|BEHAVIORAL|Clinical Decision Support Tool|Tailored education provided via a smartphone application.
214304433|NCT03706794|BEHAVIORAL|Headache Education|Non-tailored education provided via a smartphone application.
214670354|NCT00728507|DRUG|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects \<= 45kg and 450mg for those \>45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
214914321|NCT06578026|BEHAVIORAL|Resilience Builder Program|The Resilience Builder Program® group therapy will meet for one class period once a week during the semester (12 sessions). The group aims to improve resilience skills: areas such as the ability to control emotions and behavior, social skills and interactions with peers, problem-solving skills, ability to be flexible in different situations, self-esteem, and optimistic thinking. The groups involve the group leader presenting a new topic and skill, the students discussing this topic and developing strategies associated with the skill, the students practicing the skill while getting feedback from the group leader, and a period focused on self-control strategies. A letter reviewing each session will be sent home to the parent/guardian each week. Also, each child will be asked to do an assignment between weekly sessions to help him/her practice new skills.
214304434|NCT04102592|OTHER|Permethrin-treated Lesu (baby wrap)|0.5% permethrin application
214304435|NCT04102592|OTHER|Untreated Lesu (baby wrap)|Matching untreated lesu
214304436|NCT01675128|DRUG|ISIS 183750|
214304437|NCT01675128|DRUG|Irinotecan|
214304438|NCT00832585|DRUG|Alefacept|Alefacept 15mg IM every week for 12 weeks
214304439|NCT01396460|OTHER|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
214304440|NCT03295253|PROCEDURE|Autologous adipose tissue harvesting/grafting using Lipogems|Adipose tissue harvesting and grafting in the urethra using fat micro-fragmentation and processing device Lipogems
214304441|NCT02162342|OTHER|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
214304442|NCT00967993|DRUG|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
214304443|NCT02360592|DRUG|Entecavir|In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
214304444|NCT02360592|DRUG|Interferon alfa-2b|In arm 2 and 3, interferon alfa-2b is used for 48 weeks
214304445|NCT02360592|DRUG|Interleukin 2|In arm 3, Interleukin 2 is used for 12 weeks
214304446|NCT02360592|DRUG|Hepatitis B Vaccine|In arm 3, Hepatitis B Vaccine is used for 48 weeks
214304447|NCT04418999|DRUG|dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use|Experimental
214304448|NCT04418999|DRUG|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Active Comparator
214914322|NCT03408769|OTHER|Medical questionnaire|"* Brief Index of Sexual Functioning for Women questionnaire~* Quality of life questionnaire (EORTC QLQ-BR23)~* Partnership questionnaire (partnerschaftsfragebogen; PFB)~* Short interview about their sexual intimacy"
214304449|NCT01648855|OTHER|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
214304450|NCT04748133|DEVICE|acupuncture needles|"Site of acupuncture points:~* Du 26: At junction of the upper and middle third of philtrum.~* Ren 17: On the midline level with the 4th intercostal space midway between the nipples.~* LI4 (Large Intestine 4): On the dorsum of the hand, between the 1st and 2nd metacarpal bones~* HT7 (Heart 7): On the ulnar end of the transverse crease of the wrist, in the small depression between the pisiform and ulna bones~* LV3 (Liver 3): On dorsum of the foot in a depression distal to the junction of the 1st and 2nd metatarsal bones.~* ST36 (Stomach 36): Antero-lateral leg, 1 middle-finger breadth next to the anterior crest of tibia, 3 cun under the depression lateral to the patellar ligament.~* PC6 (Pericardium 6): Palmar aspect of the forearm, between the tendons, 2 cun away from the transverse crease of the wrist"
214304451|NCT04748133|OTHER|placebo|no treatment
214304452|NCT01374087|DRUG|Triptorelin 22.5 mg|Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
214304453|NCT01374087|RADIATION|Brachytherapy|Brachytherapy: Low or high dose rate.
214304454|NCT03830944|DIAGNOSTIC_TEST|Blood sampling|Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
214304455|NCT03830944|DIAGNOSTIC_TEST|transthoracic echocardiography|Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
214304456|NCT03830944|DIAGNOSTIC_TEST|Late Gadolinium-Enhancement Cardiac Magnetic Resonance|Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
214304457|NCT03830944|DIAGNOSTIC_TEST|Coronary Angio Computed Tomography|Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
214304458|NCT00606476|DRUG|Bapineuzumab (AAB-001)|IV q13w
214304459|NCT00004159|DRUG|gemcitabine hydrochloride|
214304460|NCT00004159|DRUG|paclitaxel|
214304461|NCT03526458|DEVICE|Holmium:YAG laser|Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
214304462|NCT00271947|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
214304463|NCT04816695|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
214304464|NCT01782664|DRUG|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
214304465|NCT01782664|DRUG|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
214304466|NCT01782664|DRUG|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
214304467|NCT01782664|DRUG|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
214304468|NCT02400502|BEHAVIORAL|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
214304469|NCT03006744|BEHAVIORAL|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
214304470|NCT03006744|BEHAVIORAL|Reading enjoyment training|Training on how to make reading enjoyable for children.
214670355|NCT00728507|DRUG|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
214670356|NCT01852864|DRUG|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
214914323|NCT03095144|DEVICE|Spinal anesthesia|Pyloromyotomy under spinal anesthesia
214914324|NCT03095144|DEVICE|General anesthesia|Pyloromyotomy under general anesthesia
214914325|NCT01134107|DRUG|Insulin Lispro 6 Day (6D)|Administered by infusion pump for 12 week treatment period
214304471|NCT03410355|PROCEDURE|BMAC/PRP Injection|Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.
214304472|NCT03410355|PROCEDURE|Cortisone Injection|An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.
214304473|NCT04110093|DRUG|Regorafenib and PD-1 inhibitor|All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
214304474|NCT01067222|DRUG|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
214304475|NCT01067222|DRUG|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
214304476|NCT01067222|DRUG|Placebo|Placebo oral capsules, 4 capsules per day
214304477|NCT06039423|PROCEDURE|The M-TAPA block|A high frequency (6-12 MHz) US linear probe was placed in the sagittal plane on the 10 th costal margin in the midline. The probe was then angulated deeply to visualize the lower surface of the costal cartilage. Via in plane technique, a 21 gauge Tuohy needle was inserted cranially between the lower fascia of the costal cartilage and upper fascia of the transversus abdominis muscle by moving the needle tip towards the posterior aspect of the 10 th costal cartilage and 20 mL bupivacaine (0.25 %) was injected.
214304478|NCT06039423|DRUG|Ketorolac|conventional general anaesthesia receiving multimodal analgesia
214304479|NCT01531712|DRUG|Gemcitabine|1000mg/m2 / / 40mg/m2
214304480|NCT01531712|RADIATION|Radiotherapy|50.4 Gy
214914326|NCT01134107|DRUG|Insulin Aspart 6 Day (6D)|Administered by infusion pump for 12 week treatment period
215059839|NCT00348959|BEHAVIORAL|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
215059840|NCT02655952|DRUG|Foxy-5|
214670357|NCT02413398|DRUG|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
214670358|NCT02413398|DRUG|Matching Placebo for Dapagliflozin|Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
214914327|NCT00687271|DRUG|MK-6213|MK-6213 160 mg for 4 weeks.
214914328|NCT00687271|DRUG|Atorvastatin calcium|atorvastatin calcium 20mg for 4 weeks.
214914329|NCT00687271|DRUG|Placebo for MK-6312 160 mg|
215059841|NCT05079802|DRUG|Double antibiotic paste mixed with chitosan nanoparticles|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with chitosan nanoparticles gel
215059842|NCT05079802|DRUG|Double antibiotic paste mixed with propylene glycol|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
214304481|NCT01531712|DRUG|Tarceva|100mg/day
214304482|NCT01531712|DRUG|Oxaliplatin|100mg/m2 (only in QT)
214304483|NCT04959942|OTHER|scapular stabilization exercise|In the supine position, the subject will instruct to take a deep breath to relax the body. In croock-lying position, the subject will raise his dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. In the quadruped position, the subject lifts up his arms alternatively with shoulder abduction and 120 ° flexion. In a sitting position with 90° knee flexion on a stool or bed without back support, the subject held a pair of dumbbells (2 kg) in each hand and laterally lifted them up while maintaining the height of scapulae below 80°. Each stage will instruct to be held for 10 seconds before returning to the starting position and three laps of 10 repetitions with a 30-second break in between will perform. In the sitting position, a mirror will place in front of the patient. The subject will instruct to check and correct his posture by him
214304484|NCT04959942|OTHER|postural correction exercise|The program consisted of two strengthening (deep cervical flexors and scapular retractors) and two stretchings: cervical extensors (sub-occipital muscles) and pectoral muscles). The program was based on a program by Harman and Kendall.
214304485|NCT04959942|OTHER|advice|all subjects will be instructed to maintain normal alignment of the cervical vertebry
214304486|NCT01786954|DEVICE|Icare rebound tonometry|
214304487|NCT01786954|DEVICE|Tonopen applanation|
214304488|NCT01786954|DEVICE|Goldmann applanation|
214670359|NCT02690467|DEVICE|Insupen G34x3,5mm|
214670360|NCT02690467|DEVICE|Insupen G32x4mm|
214914330|NCT00687271|DRUG|Placebo for Atorvastatin 20 mg|
214914331|NCT03656692|DRUG|Acthar Gel|Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL)
214914332|NCT00299338|DRUG|SP01A|
214914333|NCT00904761|OTHER|exercise training|The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
214914334|NCT04012593|BEHAVIORAL|Diary|
214914335|NCT01478672|PROCEDURE|Health Coaching and Life-long Monitoring|Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
214914336|NCT00281177|BEHAVIORAL|Asthma Disparity Reduction Strategy|
214914337|NCT02463851|DEVICE|PVAC GOLD multielectrode catheter|Cardiac ablation for Atrial Fibrillation
214304489|NCT02968303|DRUG|Vemurafenib and Cobimetinib|Combination of Vemurafenib with Cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with Nivolumab and Ipilimumab
214304490|NCT01522365|DEVICE|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
214304491|NCT01522365|DEVICE|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
214914338|NCT02463851|DEVICE|Contact Force single-tip ablation catheter|
214914339|NCT00280280|DRUG|intramuscular Botox versus oral baclofen|Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
214914340|NCT01951534|BEHAVIORAL|Breast Reconstruction Decisional Aid (BRDA)|
214914341|NCT01951534|BEHAVIORAL|Usual Care|
214914342|NCT02618603|DRUG|Botulinum toxin A|
214914343|NCT02618603|DRUG|Triamcinolone Acetonide|
214914344|NCT03161743|PROCEDURE|venipuncture|blood draw for the purpose of determining the platelet concentration in PRP
214914345|NCT05354856|DRUG|Indocyanine green|A bolus of ICG (0.2 mg/kg body weight) will be injected intravenously and flushed with 5 mL of saline. Gastric perfusion will subsequently be assessed along specific regions of interest (ROI) with q-ICG (quantitative perfusion assessments with ICG) to obtain baseline perfusion values.
214914346|NCT02314260|OTHER|bishop score calculation|Assessment of bishop score by vaginal examination
214914347|NCT02314260|OTHER|Trans-vaginal ultrasound|trans-vaginal ultrasound assessment of cervical length.
214914348|NCT02314260|OTHER|Modified bishop score calculation|using the cervical length and the original bishop score to calculate modified bishop score
214914349|NCT02314260|PROCEDURE|labour induction|Induction of labor was carried out as per our hospital's standard protocol.
214914350|NCT01656135|OTHER|Blood drawing for immune monitoring and questionnaires|
214914351|NCT00126347|PROCEDURE|supplementation with betaine, serine, and folic acid|
214914352|NCT02521142|OTHER|Non-invasive OCT based optical angiography|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
214914353|NCT02521142|OTHER|Oxymap T1|The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
214304492|NCT04234035|BEHAVIORAL|Decision Aid|Decision aid to facilitated shared decision-making
214304493|NCT04234035|OTHER|Standardized Educational Material (informational pamphlet)|Pamphlet with information about kidney stones
214914354|NCT02521142|OTHER|OCT|non-invasive imaging of retinal and choroidal structures.
214914355|NCT02521142|OTHER|FLA/ICG angiography|Fluorescein Angiography and Indocianine Angiography
214914356|NCT06476912|OTHER|weight-shifting exercise|lateral weight-shifting balance training and VNS
214914357|NCT06649968|DEVICE|DESC-Glove (active)|Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, receiving vibratory stimuli that are synchronized with the exercises being performed.
214914358|NCT06649968|DEVICE|DESC-Glove (sham)|Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, but will not receive any vibratory stimuli.
215059843|NCT05473455|PROCEDURE|Experimental: Follicular aspiration with addition of follicular flushing.|Follicular flushing if necessary up to 5 times using a double lumen needle for oocyte recovery
214304494|NCT05387733|DRUG|10 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514."
214304495|NCT05387733|DRUG|15 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514."
214304496|NCT03320772|DRUG|TMVP1-ICG|Detection of SLN
214304497|NCT03320772|DRUG|ICG|Detection of SLN
214304498|NCT00673179|DRUG|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.
214304499|NCT00673179|DRUG|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m\^2/day for 2 days continuous infusion.
214304500|NCT00673179|DRUG|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m\^2, max 20 gm over 4 hours.
214304501|NCT00673179|DRUG|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
214304502|NCT00673179|DRUG|Dexrazoxane|Dose 900 mg/m\^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
214304503|NCT00673179|DRUG|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2. Dose 2.8 grams m\^2/day.
214914359|NCT06649968|OTHER|Traditional rehabilitation|Traditional rehabilitation treatment for the upper limb. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20- minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. The DESC- Glove will not be used during this treatment.
214914360|NCT06407765|OTHER|Dual task training|Dual task training incorporates both cognitive and motor tasks. Tasks like walking and asking the patient to point towards objects, collect start from the objects hanging above the patient and asking the patient to name the objects shown to him/her. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.
214914361|NCT06407765|OTHER|Dual task training with backward walking|This group will get both dual task training and backward walking. For dual task training same protocol as active comparator is followed. For backward walking; the patient is firstly asked to walk backward with complete physiotherapist assistance. Secondly, the patient is asked to walk for 15 m through the treatment room's hallway while holding a safety bar with the hand on the unaffected side. Third, without using a safety bar, the participants were urged to walk freely. Lastly, the participants tried to walk backwards at a reasonable pace while progressively increasing their distance travelled and speed. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.
214914362|NCT01644292|OTHER|EPIC WheelS|EPIC WheelS is a user-centred program for wheelchair skills training that combines two structured 1-hour sessions with an expert trainer and four weeks of self-directed practice and training in the natural (home) environment.
214304504|NCT00673179|BEHAVIORAL|Questionnaire|Questionnaires to be completed on 5 different days during the study.
214914363|NCT06682845|OTHER|Collection of data in patients' medical files|"* Demographic data~* Health data: body mass index, weight, tobacco consumption, history of hyperglycemia/ diabetes mellitus, Eastern Cooperative Oncology Group (ECOG) status, glomerular filtration rate, hemoglobin rate~* Cancer-related data: date of diagnosis, tumoral site, tumor histology type, histology grade, date of first metastases involvement, presence of visceral metastases, presence of liver metastases, presence of lymph node-only metastases~* Treatment-related data: previous line of treatment, co-treatment with anti-PD1, enfortumab vedotin (EV) treatment start date, EV treatment end date, EV posology, presence of EV reduction of dose or increased interval between perfusions, number of EV cycles~* Adverse events (AE)-related data: occurrence of cutaneous AE, grade of cutaneous AE, date of cutaneous AE, type of cutaneous AE, management of cutaneous AE, discontinuation of EV treatment, rechallenge of EV treatment~* Outcomes data: best overall response rate"
214914364|NCT05797961|BEHAVIORAL|HIV self-testing with online supervision|A pilot study to assess the feasibility of HIV self-testing with online supervision
214914365|NCT05797961|OTHER|Control|venue-based HIV testing
214914366|NCT02780726|DRUG|roxadustat|Oral
214914367|NCT00858533|BEHAVIORAL|Health at Work workplace health advice and support|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
214479740|NCT06872970|PROCEDURE|Open reduction of femoral neck fractures and internal fixation by dynamic hip screws|Open reduction of femoral neck using watson jones or smith peterson approach fractures then fixation of fractures by dynamic hip screws
214914368|NCT05525403|OTHER|Knee Extension Exercise|Participants will be seated in a Steel Flex machine with weight equal to 50% of their 1 repetition maximum added to the machine. Participants will extend the dominant knee until the assigned fatigue level.
214914369|NCT05525403|OTHER|Quiet Rest|Participants will sit quietly for two minutes, three times.
214914370|NCT03250754|DEVICE|Electroacupuncture|Needles on the extremities were stimulated by electro-stimulation device applied by a biphasic pulse generator apparatus at a frequency of pulses alternated between 2 Hz and 100 Hz and the maximum tolerable intensity.
214914371|NCT05164484|DEVICE|Transpulmonary thermodilution|Through the analysis of the thermodilution curve recorded at the tip of an arterial catheter after the injection of a cold bolus in the venous circulation, transpulmonary thermodilution intermittently measures cardiac output.
214914372|NCT06684184|DRUG|Blinatumomab|The initial dose is 9 µ g, administered intravenously continuously for 5 days, with a total dose of 38.5 µ g. After stopping the medication for one week, the patient received a second infusion of Blinatumomab for a total of 5 days, with a total dose of 38.5 µ g.
214914373|NCT01704690|DRUG|S-1 and Paclitaxel|S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
214914374|NCT01704690|DRUG|Paclitaxel and Cisplatin|The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
214914375|NCT01704690|DRUG|5-FU and Cisplatin|The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
214304505|NCT00673179|DRUG|Gemcitabine|IV over 1 hour, every other week.
214304506|NCT00673179|DRUG|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
214304507|NCT00673179|PROCEDURE|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
214304508|NCT00673179|DRUG|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2/day.
214304509|NCT00888095|PROCEDURE|deep brain stimulation|electrode implantation in either STN or cZI
214304510|NCT03822208|BIOLOGICAL|AL003|"Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort"
214304511|NCT03822208|OTHER|Saline Solution|Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
214304512|NCT02404285|DRUG|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
214304513|NCT02404285|DRUG|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
214304514|NCT05945654|PROCEDURE|Anastomotic Leak after Ivor Lewis Oesophagectomy|Surgical resection of the esophagus with oesophagogastrostomy. Groups depend on postoperative complication
214304515|NCT02466555|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
214479741|NCT06872970|PROCEDURE|Open reduction of femoral neck fractures using watson jones or smith peterson approachand internal fixation by cannulated screws and medial buttress plate|Open reduction of femoral neck fractures then fixation of fractures by cannulated screws and medial buttress plate
214914376|NCT06149364|BEHAVIORAL|ISKE|"The intervention will consist of an e-health software Programme that we have named Istumisen Keskeyttäminen (ISKE) will be installed on the desktop of participants.~Functionality of the software: the primary purpose of the software is to remind users (basically office-based workers) to take a break on a regular basis (recommended time 30 minutes).~At the end of the workday, the software provides information on the number of breaks taken and how long each lasted. The user will also have access to such information.~What happens during the prompted break: once the software prompts the user to take a break, she/he can click the Continue button to proceed with the break. The software will include activities that are suggested for the user to do during break. After the break, the record of the time (duration of the break, and when the break was taken) can be taken."
214914377|NCT01333904|DRUG|PUR118|inhaled
214914378|NCT03092765|DRUG|E6011|Intravenous administration
214914379|NCT03092765|DRUG|Placebo|Intravenous administration
214914380|NCT02362672|DRUG|NKTR-181 BID tablets|NKTR-181 tablets 100-400 mg twice daily (BID)
214914381|NCT02362672|DRUG|Placebo to match NKTR-181 BID tablets|Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)
214914382|NCT00695292|DRUG|irinotecan|irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
214914383|NCT00695292|DRUG|Carboplatin|carboplatin AUC=4 on Day 1
214914384|NCT00695292|DRUG|sunitinib|sunitinib 25 mg orally (PO) daily after initial chemotherapy
214914385|NCT04439968|OTHER|Clinical algorithm|In order to maintain cerebral saturations within targeted range, subjects in the targeted Csat arm will undergo clinical interventions based on clinical algorithm. Interventions may include administration of inotropes, fluid resuscitation, transfusion of blood products, and/or adjustment to respiratory support.
214914386|NCT00998075|DRUG|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
214914387|NCT00998075|DRUG|Esomeprazole - Nexium|Clinical Trial Capsule or MUPS Tablet, oral, single dose
214914388|NCT00998075|DRUG|ASA|Tablet, oral, single dose
214914389|NCT00254800|DRUG|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
214914390|NCT00254800|DRUG|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
214304516|NCT04870333|DRUG|Niclosamide|140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
214304517|NCT04870333|DRUG|Placebo|140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
214914391|NCT00254800|DRUG|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
214914392|NCT04494061|PROCEDURE|blood collection|Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.
214304518|NCT04870333|DRUG|Ciclesonide|"Participants will be prescribed ciclesonide once daily, administered as follows:~Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
215059844|NCT06519240|RADIATION|18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18F-FDG PET CT)|Each participant will prepare for their study PET CT by following an initial 18 hour of zero carbohydrate diet followed by another 18 hours of fasting (water allowed). After confirming preparation, each study participant will have a single rest rubidium and 18F-FDG PET CT scan.
214304519|NCT04870333|DRUG|Placebo|"Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose.~Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
214479742|NCT06873893|PROCEDURE|Midpoint transverse process block|This group will receive a volume of 20ml of bupivacaine 0.5% at midpoint of the line between the posterior border of the transverse process of T4 and the pleura ( injection will be deep to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligament )
214479743|NCT06873893|PROCEDURE|Pectoral Nerve Block|This group will receive a volume of 10ml of bupivacaine 0.5% will be injected between the pectoralis major and pectoralis minor muscle then another 10ml bupivacaine will be injected between pectoralis minor and serratus anterior muscle
214670361|NCT03435029|BEHAVIORAL|Cognitive Remediation Program (REHACOP)|The REHACOP group received cognitive remediation sessions 3 times per week for 3 months in 60 minute per session. The rehabilitation consisted of 39 sessions divided into: attention and concentration unit (sustained, selective, alternating, and divided attention) 4 weeks; learning and memory unit (verbal and visual memory and learning strategies) 3 weeks; language (verbal fluency, syntax, grammar, vocabulary, and comprehension) 3 weeks; and executive functioning (objectives planning and attainment, verbal reasoning, categorization, and conceptualization). In addition, processing speed was trained transversely during all the sessions.
214914393|NCT06665048|DRUG|Oxycodone HCl|Administer oxycodone hydrochloride (0.1 mg/kg) intravenously half an hour before surgery.
214914394|NCT04743544|DRUG|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
214914395|NCT02321657|OTHER|iPad app containing art, music and games|An iPad app that takes demographic information on a child and suggests suitable art, music and games for use by the anaesthetist and nurse to distract them during anaesthetics
214914396|NCT02321657|OTHER|Toys, books and games|Games, books and toys used to distract
214914397|NCT04439474|DRUG|Vitamin D3|For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.
214914398|NCT04439474|DRUG|Routine treatment|In this group, patients receive their usual medications and treatments
214914399|NCT02108548|DRUG|ASP7657|oral
214914400|NCT02108548|DRUG|Placebo|oral
214914401|NCT02108548|DRUG|naproxen|oral
214914402|NCT00735969|DRUG|Peginterferon|
214914403|NCT00735969|DRUG|Ribavirin|
214914404|NCT06303401|OTHER|SI joint thrust manipulation|"experimental group given the thrust manipulation along with heating pad. 3 sessions per week will be given for 4 weeks. The pain measure by using NPRS, functional status and disability through ODI will be evaluated.~after every 3 sessions."
215059845|NCT05145751|OTHER|Simple inflammatory biomarkers measurement|In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured
214304520|NCT04870333|DRUG|Sotrovimab|"There will be a single infusion of sotrovimab administered at the beginning of the study.~500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter. Four vials will be required for a 2000 mg dose."
214304521|NCT04870333|DRUG|Placebo|There will be a single infusion placebo, in the form of 100mL 0.9% sodium chloride, administered at the beginning of the study.
214304522|NCT02304263|DRUG|iohexol|5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
214304523|NCT03604042|COMBINATION_PRODUCT|Protein fortifier|Protein Fortifier to be added to Fortified human milk according to feeding regimen
214304524|NCT04308837|DRUG|Paclitaxel|50 mg/m2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
214304525|NCT04308837|DRUG|Carboplatin|Carboplatin AUC = 2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
214304526|NCT04308837|DRUG|Dexamethasone|All patients receiving Paclitaxel will receive institutional standard premedications, which include Dexamethasone (10 mg IVPB)
214304527|NCT04308837|DRUG|Diphenhydramine|All patients receiving Paclitaxel will receive institutional standard premedications, which include diphenhydramine (50mg IVP)
214304528|NCT04308837|DRUG|Famotidine|All patients receiving Paclitaxel will receive institutional standard premedications, which include Famotidine (20mg IVPB)
214304529|NCT04308837|DRUG|Palonosetron|All patients receiving Paclitaxel will receive institutional standard premedications, which include Palonosetron (0.25mg IVP)
214304530|NCT04308837|RADIATION|3D conformal or intensity modulated radiotherapy|Treatment will be given 5 days per week. Photon beams \>6 MV are required. Treatment may be delivered either by a 3D conformal technique or IMRT. IMRT via dynamically moving MLCs, step-and-shoot with a multileaf collimator, Rapid Arc, binary multileaf collimator, and tomotherapy are allowed. Proton therapy is not allowed.
214304531|NCT04308837|PROCEDURE|Surgical resection|Surgical resection will constitute subtotal or total gastrectomy (depending on tumor size and location) and D2 lymphadenectomy.
214304532|NCT04308837|RADIATION|Adjuvant Chemotherapy|The patient will begin adjuvant chemotherapy 4-12 weeks after surgery. The adjuvant chemotherapy will consist of FOLFOX every 2 weeks for 6 cycles (i.e. 3 months)
214479744|NCT06873971|DRUG|Topical estrogen therapy based on estriol (E3)|Patients will use low-dose isolated topical estrogen therapy in the form of estriol 1mg/g vaginal cream (Generic), with disposable, individualized vaginal applicators pre-set at the recommended dosage of 5g/dose each. Initially, they will use it for 14 consecutive nights, and then use it 2 times a week, always during the night, on Mondays and Thursdays, for 16 consecutive weeks from the start of the research. The treatment will be provided in fractions for each 30-day period and will always be delivered after each laser session, along with a leaflet containing usage, storage, and application instructions for the vaginal cream. The patients will be monitored through a messaging app, reinforcing the instructions and the days of application correctly.
214479745|NCT06873971|RADIATION|Laser Er:YAG On|All participants in the group will undergo 3 applications of the Er:YAG laser with an interval of 4-5 weeks between them. The intimate laser session consists of 2 stages, using a PS03-fractional tip: the internal stage (vaginal canal) and the external stage (region of the vestibule and introitus).
214479746|NCT06873971|RADIATION|Laser Er:YAG Off|All participants in the group will undergo 3 applications of the Er:YAG laser with the device turned off, with an interval of 4-5 weeks between them. The intimate laser session consists of 2 stages, using a PS03 fractional tip: the internal stage (vaginal canal) and the external stage (vestibule and introitus region).
214479747|NCT06693518|DRUG|Treatment B|Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg
214479748|NCT06693518|DRUG|Treatment A|Dabigatran Etexilate 150 mg
214479749|NCT04330040|DRUG|Olaparib|Tablet
214479750|NCT03386513|DRUG|IMGN632|CD123-targeted ADC
214914405|NCT06303401|OTHER|pelvic stabilization exercises|Heating pad for 10- 15 mints Pelvic stabilization exercises include Bridging (3 sets x 10 reps with 10 secs hold) Pelvic Tilt exercise(3 sets x 10 reps with 10 secs hold) Bird-Dog Exercise (3 sets x 10 reps with 10 secs hold) clamshell Exercise (3 sets x 10 reps with 10 secs hold) .3 sessions per week will be given for 4 weeks. The pain using NPRS , functional status and disability will be evaluated by using ODI after every 3 sessions.
214479751|NCT06460467|DEVICE|scintigraphy of 177Lu-DOTATATE|The medical device under study is a hybrid wide-field CZT solid-state camera, the VERITON-CT ™ camera.
214670362|NCT03435029|OTHER|Occupational Therapy|The control group received occupational group activities (reading the newspaper, drawing, singing or doing crafts) with the same frequency and format as the experimental group.
214670363|NCT01893723|PROCEDURE|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
214304533|NCT02011347|DRUG|Ketamine|
214304534|NCT02011347|DRUG|Placebo|
214304535|NCT05158868|DIAGNOSTIC_TEST|HiF-1 alpha measurement|HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology
214304536|NCT05481567|OTHER|Questionnaire|A series of 14 questions about with the impact of periodontitis on quality of life.
214304537|NCT01082965|DRUG|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
214670364|NCT01893723|PROCEDURE|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
214670365|NCT01827540|DRUG|Cenicriviroc|
214914406|NCT03925948|BEHAVIORAL|PLAN 4 Success-Diabetes|The study intervention-PLAN 4 Success-Diabetes-consisted of four 1 to 1 ½-hour weekly health literacy training and disease knowledge education sessions for four weeks (4 in-person sessions), followed by two home visits and monthly phone counseling for over 6 months (5 phone sessions). The intervention is theory-driven and builds on von Wagner's model to incorporate key elements such as health literacy, disease knowledge, and self-efficacy for better glucose outcomes.
214304538|NCT01082965|DRUG|Placebo|matching placebo
214304539|NCT06213168|OTHER|HFNC|Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization
214304540|NCT06213168|OTHER|CPAP and HFNC|Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
214670366|NCT01827540|DRUG|Dolutegravir|
214670367|NCT01827540|DRUG|Midazolam|
214670368|NCT02874794|DRUG|LCZ696 (sacubitril/valsartan)|24/26mg, 49/51mg and 97/103mg oral, tablets.
214670369|NCT02874794|DRUG|Enalapril|2.5mg, 5mg, and 10mg, oral, tablets
214670370|NCT02874794|DRUG|Placebo of Enalapril|matching placebo (2.5mg, 5mg and 10mg) oral, tablets
214670371|NCT02874794|DRUG|Placebo of LCZ696|matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
214914407|NCT01020630|DRUG|Sunitinib|Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
214914408|NCT01020630|DRUG|Placebo|Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
214914409|NCT02801617|DRUG|PRO-067|1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
214914410|NCT02801617|DRUG|GAAP Ofteno®|1 drop QD during 30 days Active comparator, reference medication.
214304541|NCT01467947|BIOLOGICAL|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
214304542|NCT06297109|DEVICE|Patient-specific implants|Application of patient-specific implants for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
214304543|NCT06297109|DEVICE|Conventional mini-plates|Application of conventional mini-plates for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
214304544|NCT05045976|OTHER|Web-based interactive self-management support program|The intervention group will receive a 60-90 minute introduction to the web-based interactive self-management support program. They will be instructed to do the weekly online self-assessment on symptoms, emotion, and health behaviors and how to use the web-based program to manage their health by applying self-manage skills and behavior change techniques. The contents of the interactive colorectal cancer self-management website include the following five main components: Health Support Station, Knowledge Supply Station, Sharing Stories, My Dear Friend, and Asking a Nurse.
214304545|NCT02587065|DRUG|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
214304546|NCT05350319|RADIATION|A low-dose CT scan of the shoulder|Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
214304547|NCT04252755|BEHAVIORAL|EEG Neurofeedback|Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
214304548|NCT04476979|DRUG|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3
214304549|NCT04476979|DRUG|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
214304550|NCT00243178|DRUG|clopidogrel (SR25990C)|75 mg once daily in combination with aspirin
214304551|NCT00077103|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
214304552|NCT00077103|BIOLOGICAL|pegfilgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
214304553|NCT00077103|DRUG|cisplatin|cisplatin IV over 30-60 minutes on day 1
214304554|NCT00077103|DRUG|doxorubicin hydrochloride|doxorubicin IV over 5-10 minutes
214304555|NCT00077103|DRUG|fosbretabulin disodium|Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
214304556|NCT00077103|RADIATION|radiation therapy|Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.
214304557|NCT03022292|DRUG|Aflibercept Ophthalmic|IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
214304558|NCT03022292|DEVICE|optovue angiovue|FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
214304559|NCT04035161|COMBINATION_PRODUCT|Investigational Product|2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation
214304560|NCT04035161|OTHER|Reference Standard|60% (v/v) 1-propanol skin preparation
214304561|NCT04035161|COMBINATION_PRODUCT|Active Comparator|ChloraPrep® SEPP® skin preparation
214304562|NCT04035161|OTHER|Negative Control|0.9% Normal Saline skin preparation
214304563|NCT05466747|BIOLOGICAL|RYMPHYSIA|RYMPHYSIA administered through an IV injection.
214304564|NCT05466747|BIOLOGICAL|Another Available A1PI|Another available A1PI administered through an IV injection.
214304565|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
214304566|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given continuously for 3 years
214304567|NCT02935790|DRUG|ACY-241|tablet
214304568|NCT02935790|DRUG|nivolumab|infusion
214304569|NCT02935790|DRUG|ipilimumab|infusion
214304570|NCT00089349|BIOLOGICAL|alemtuzumab|Given IV
214304571|NCT00089349|DRUG|methotrexate|Given IV
214304572|NCT00089349|DRUG|mercaptopurine|Given PO
214304573|NCT00445965|GENETIC|DNA analysis|
214304574|NCT00445965|OTHER|immunologic technique|
214304575|NCT00445965|OTHER|pharmacological study|
214304576|NCT00445965|RADIATION|iodine I 131 monoclonal antibody 3F8|
214670372|NCT02199977|OTHER|Free Malaria Rapid Diagnostic Test|Malaria RDT is offered free if patients choose to be tested
214670373|NCT02199977|OTHER|Conditional ACT voucher|"Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug."
215059846|NCT06238336|DRUG|CAR-T cell therapy|The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
214304577|NCT00445965|RADIATION|131I-3F8|Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
214304578|NCT01528956|GENETIC|DNA methylation analysis|
214304579|NCT01528956|GENETIC|RNA analysis|
214304580|NCT01528956|GENETIC|gene expression analysis|
214304581|NCT01528956|GENETIC|nucleic acid sequencing|
214304582|NCT01528956|GENETIC|polymorphism analysis|
214304583|NCT05667038|DRUG|Probiotic|"The probiotics sachet contains a granular powder with 6 microorganism strains (30 × 109 CFU/gram): Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, and Bifidobacterium longum BCMC®02120.~The drug is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
214304584|NCT05667038|DIETARY_SUPPLEMENT|Placebo|"Placebo:~Subjects in the placebo group will receive the placebo consisting of only the carrier of the probiotic product, that is maize starch and maltodextrins.~The sachet is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
214304585|NCT03591016|OTHER|Recording number of IV attempts|Recording number of IV attempts in the operating room
214304586|NCT02950077|BEHAVIORAL|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
214304587|NCT02964468|RADIATION|3DCRT treatment (sequential boost)|"Radiotherapy:~3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.~3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.~Chemotherapy:~According to routine clinical practice of the participating centers."
214304588|NCT02964468|RADIATION|Dose Escalation Intensity Modulated Radiotherapy treatment|"Radiotherapy:~IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.~Chemotherapy:~According to routine clinical practice of the participating centers."
214304589|NCT01276093|PROCEDURE|PVI ablation|Pulmonary Vein Ablation using RF.
214304590|NCT01276093|DRUG|Amiodarone|Amiodarone tablets
214304591|NCT06059911|DIETARY_SUPPLEMENT|Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA)|Administration of a multi-ingredient dietary supplement consisting of 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g branched chain amino acids
214304592|NCT06059911|DIETARY_SUPPLEMENT|Placebo dietary supplement (97% maltodextrin)|Administration of an isoenergetic placebo comparator dietary supplement consisting of 97% maltodextrin
214304593|NCT05252611|OTHER|Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8)|The aim of this study is to test the validity of the Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8).
214304594|NCT03479307|DRUG|Bilastine Ophthalmic Solution 0.6%|1 drop in each eye at 2 separate times during an 8 day period.
214479752|NCT02639754|BEHAVIORAL|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
214670374|NCT02199977|OTHER|Malaria Rapid Diagnostic test for a charge|Participants can receive a malaria RDT for a set amount (i.e., not for free).
214304595|NCT03479307|DRUG|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|1 drop in each eye at 2 separate times during an 8 day period.
214304596|NCT03479307|DRUG|Vehicle of Bilastine Ophthalmic Solution|1 drop in each eye at 2 separate times during an 8 day period.
214479753|NCT02639754|BEHAVIORAL|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
214304597|NCT03141281|BEHAVIORAL|BrainHQ|BrainHQ
214304598|NCT03141281|BEHAVIORAL|Rise of Nations|Rise of Nations
214479754|NCT06396689|DIETARY_SUPPLEMENT|Synbiotic|The capsule contains Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, and Bifidobacterium bifidum R0071 (3 billion bacteria per capsule), as well as zinc oxide, potato starch fructooligosaccharides, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
214670375|NCT00537940|DRUG|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
214670376|NCT00537940|DRUG|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
214670377|NCT00001933|DRUG|Nefiracetam|
214479755|NCT06396689|DIETARY_SUPPLEMENT|Placebo|The capsule contains zinc oxide, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
214479756|NCT05906199|DRUG|Renexin CR 200/160mg|Single oral administration of Renexin CR 200/160mg, QD
214479757|NCT05906199|DRUG|Aspirin 100mg|Single oral administration of Aspirin 100mg, QD
214479758|NCT05418140|OTHER|Ultrasound diagnosis of adenomyosis|The diagnosis of adenomyosis will be made using transvaginal ultrasound scan (TVS) (2D and 3D Ultrasound and applying Morphological Uterus Sonographic Assessment (MUSA) criteria (Van den Bosch et al, 2015).
214914411|NCT01372618|DRUG|SOM 230 / Pasireotide|SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
214304599|NCT03141281|BEHAVIORAL|IADL Training|IADL Training
214304600|NCT03141281|BEHAVIORAL|Active Control|Puzzle solving
214304601|NCT00458523|BIOLOGICAL|alemtuzumab|
214304602|NCT00458523|GENETIC|fluorescence in situ hybridization|
214479759|NCT05560724|DEVICE|Transcranial direct current stimulation (tDCS)|Anodal stimulation or sham
214914412|NCT03524417|BIOLOGICAL|Equine rabies immunoglobulin injection on day 7|The patients with WHO category III rabies exposure, who have received first dose of rabies vaccination a week before and have not received rabies immunoglobulin were enrolled. Blood for Rabies neutralizing antibody titers (RNab) would be examined on day 0. On the same day, Equine rabies immunoglobulin (ERIG) at the dosage of 40 IU/kg would be injected into and around the wound as much as possible and the rest would be injected intramuscularly at the site distance from rabies vaccine. Then blood for RNab would be serially examined on day 7, 14, 90, 365.
214914413|NCT02690818|BEHAVIORAL|Regularly scheduled LTBI medication reminder text messages|"Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication."
214914414|NCT04646343|OTHER|administration of F-CISS and F-PWES pre version|the CISS questionnaire is a 6 items questionnaire, the PWES is a 3 items questionnaire. Only 10 minutes are required to fulfilled the questionnaires.
214914415|NCT04646343|OTHER|administration of definitive version of F-CISS and F-PWES plus F-DASH, F-HFS and F-SF 36|The administration will required 25 minutes
215059847|NCT05096143|DRUG|Sacubitril/valsartan|Participants who were prescribed with Sacubitril/valsartan
215059848|NCT05096143|DRUG|ACEi/ARB|Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
215059849|NCT03260855|OTHER|Questionnaires/Scales|Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.
214304603|NCT00458523|GENETIC|mutation analysis|
214304604|NCT00458523|OTHER|flow cytometry|
214304605|NCT00714519|DRUG|Xenaderm® Ointment|Topical, BID or as needed
214304606|NCT00714519|DRUG|Placebo Comparator|Topical, BID or as needed
214304607|NCT03904758|DIAGNOSTIC_TEST|Pepsin in saliva test|The presence of pepsin in the saliva will be tested in both groups of patients.
214479760|NCT06293911|OTHER|Biorepair Plus Parodontgel Intensive|The Biorepair Plus Parodontgel Intensive gel will be used after home oral hygiene once a day.
214479761|NCT06293911|OTHER|Placebo gel|The placebo gel (without hyaluronic acid, Lactobacillus Ferment, Aloe Barbadensis Leaf Juice Powder and lactoferrin) will be used after home oral hygiene once a day.
214479762|NCT06696300|OTHER|Classical Physiotherapy Group|"Classical physiotherapy group (CF) will be treated face to face for 30 sessions in total, 3 days a week, 10 weeks. Hotpack, Ultrasound, TENS and Basic Exercises will be applied to the CF group. Hotpack will be applied superficially to the lumbar region for 15 minutes. Ultrasound 1MHz- 1.5 Wt/cm2 will be applied to the lumbar region. TENS 50 Hz will be applied for 15 minutes, leaving the painful area in the middle. Basic exercises will be applied as 8-12 repetitions, 2 sets. The number of repetitions and sets will be increased as the tolerance of the patients increases.~Pelvic tilt exercises Supine hip flexor stretch Supine lumbar extensor stretch Crunches Cat-Camel Exercises"
214670378|NCT01496261|DRUG|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
215059850|NCT03260855|OTHER|Human blood sample|The intervention is based on blood test.
215059851|NCT00117780|DRUG|insulin detemir|
214304608|NCT00419198|PROCEDURE|Postconditioning|Postconditioning during angioplasty
214304609|NCT00419198|PROCEDURE|standard angioplasty|standard angioplasty without postconditioning
214304610|NCT03322033|DEVICE|Valiant PS-IDE Stent Graft|Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
214304611|NCT06485063|OTHER|Myofascial Reorganization|It is a manual technique in which the therapist applies a manual sustained oblique load of 45° with subsequent shear load. In general, the technique is divided into two stages, the first when the oblique load is accompanied by a passive shear load (applied by the therapist) during 1minute, and the second stage, when the shear oblique manual load is maintained but the shear load provoked by the participants' active movement (active shear load) during 1minute.
214670379|NCT01496261|DRUG|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
214670380|NCT06554613|DRUG|Olanzapine|Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.
215059852|NCT00117780|DRUG|insulin aspart|
215059853|NCT00232323|BEHAVIORAL|simulation training|
215059854|NCT02388464|DRUG|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
215059855|NCT02388464|DRUG|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
215059856|NCT02388464|DRUG|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
214304612|NCT06485063|OTHER|PLACEBO Myofascial Reorganization|it is light touch to the skin applied by the therapist, without provoking compression, or any constant or shear load during the fist minute. In the second minute, the participant adds active movements to the light touch. This two stage (each one during 1minute) is constructed to mimic the passive and the active stages of the real myofascial reorganization technique.
214479763|NCT06696300|OTHER|Foundation Inspiratory Muscle Training in Addition to Classical Physiotherapy|In addition to Classical Physiotherapy, Foundation Inspiratory Muscle Training (IKE) will be treated face to face for 30 sessions, 3 days a week, 10 weeks. On other days, IKE will be applied at home for 15 minutes in the morning and evening for a total of 30 minutes and will be followed up with a diary. IKE will be applied with a device that can load with threshold pressure. The IKE group will continue the exercise program for 10 weeks. The intensity of the exercise will be adjusted to 40-50% MIP for the exercise group. After 10 consecutive respiratory cycles, 3-4 respiratory controls will be asked. As tolerance increases, the consecutive respiratory cycle will be increased. The intensity will be adjusted by taking weekly MIP measurements. Daily monitoring forms will be created for each participant to ensure exercise follow-up.
214479764|NCT06696300|OTHER|Functional Inspiratory Muscle Training Group in Addition to Classical Physiotherapy|Functional Inspiratory Muscle Training Group will receive functional inspiratory muscle training in addition to classical physiotherapy, 3 days a week, 10 weeks, 30 sessions in total, face-to-face treatment. On other days, foundation-ICE will be applied at home for 15 minutes in the morning and evening, for a total of 30 minutes, and will be followed with a diary. The same protocol will be applied with the foundation IKE group for teaching the respiratory cycle in the first 4 weeks, and resisted breathing will be worked simultaneously with the exercises in Table 2 in the last 6 weeks. The exercise program will be continued for a total of 10 weeks, including F-ICE, foundation IKE for the first 4 weeks, and F-ICE for 6 weeks thereafter. The intensity of the exercise will be adjusted to 40-50% MIP for the exercise group. After 10 consecutive respiratory cycles, 3-4 respiratory controls will be requested. As tolerance increases, the number of consecutive respiratory cycles will be increase
214479765|NCT03116061|OTHER|Questionnaire|This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
214670381|NCT06554613|DRUG|Nivolumab|Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
214670382|NCT06638502|DRUG|HRX215 capsules|HRX215 capsules 250 mg orally twice daily
214670383|NCT06638502|DRUG|Placebo capsules|placebo capsules matching appearance of HRX215
214670384|NCT06528171|PROCEDURE|Brain MRI|non injected brain MRI
214914416|NCT06224556|COMBINATION_PRODUCT|Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program|"Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.~The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).~Saliva sample will be collected and analyzed."
214304613|NCT02295995|BEHAVIORAL|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
214914417|NCT01954056|DRUG|Hydrocortisone|"• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
214914418|NCT01954056|DRUG|Placebo|"7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
214304614|NCT04422028|DRUG|Desogestrel 0.075 MG|Test Drug
214304615|NCT04422028|DRUG|Desogestrel 0.075 MG|Reference Product
214304616|NCT02447081|DEVICE|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
214304617|NCT01787175|OTHER|Integrated Medication Manager|A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
214304618|NCT03621852|DEVICE|Endoultrasound guided FNB|EUS FNB with Aquire TM device
214304619|NCT05487742|DRUG|Dexmedetomidine|dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient
214304620|NCT05487742|DRUG|placebo salin infusion|salin infused as aplacebo for 72 hours
214304621|NCT00819338|DIETARY_SUPPLEMENT|Efamax|5g daily as capsules for 3 months
214304622|NCT03079609|PROCEDURE|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
214670385|NCT06528171|BIOLOGICAL|Specific blood samples|blood samples to find immunological and inflammatory markers
214670386|NCT03874884|DRUG|Olaparib|"During dose escalation doses of olaparib that can be administered are 50mg BD D2-15, 100mg BD D2-15, 150mg BD D2-15, 200mg BD D2-15,250mg BD D2-15, 300mg BD D2-15, 200mg BD D4-14, 300mg BD D-4-14 or 400mg D-4-18 of a 42 day cycle for up to 6 cycles.~The recommended phase 2 dose of olaparib will be used in 2 consecutive dose expansion cohorts. The first cohort will received the recommended phase 2 dose of Olaparib on D4-14 of a 42 day cycle. Patients enrolled in the second dose expansion cohort will receive Olaparib continuously from cycle 1 day -4 to cycle 6 day 42."
214670387|NCT03874884|COMBINATION_PRODUCT|177Lu-PSMA|A fixed 7.4Gbq administered activity of 177Lu-PSMA will be given 6 weekly for up to 6 cycles.
214914419|NCT05042999|DEVICE|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments. Non pharmacological technique to reduce pain and anxiety during a procedure.
214914420|NCT00840957|BIOLOGICAL|infliximab|chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
214914421|NCT02752243|DRUG|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
214914422|NCT05664022|PROCEDURE|Global postural reeducation|"The GPR involves a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles, and enhancing the contraction of antagonist's muscles, thus avoiding postural asymmetry.~The GPR method includes eight therapeutic postures, lying, sitting or standing, to be held for 15/20 minutes each. Postures can be variously combined during sessions. Postures are chosen on the basis of some parameters, such as the amount of pain, load capacity and age of the patient, and muscle chains to be stretched. to increase the standardization of treatment, it will be proposed only 2 or 3 postures."
214304623|NCT03079609|PROCEDURE|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
214304624|NCT05263154|OTHER|Goal directed low oxygen|Oxygen is titrated until oxygen saturation is 100% in one-minute steps before the induction of anesthesia, with increasing fraction of inspired oxygen (FiO2) from 0.25 to 0.30 to 0.35 and so on. After intubation, the FiO2 is set to 0.25 to achieve a target saturation of 94-96%. Supplementary oxygen after surgery will be given with the same targets and with as little oxygen as necessary.
214304625|NCT05263154|OTHER|High oxygen|FiO2 1.0 before induction until end-tidal oxygen concentrations of 0.80 occur. The FiO2 will be reduced to 0.35 during anesthesia, followed by an increase in FiO2 to 0.80 during 5 minutes before extubating the patient, followed by FiO2 0.40 for at least thirty minutes after anesthesia. Oxgen will then be given at 3 liters a minute with a oxygen saturation goal of 98%
214914423|NCT02192996|DIETARY_SUPPLEMENT|Probiotic|blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
215059857|NCT02388464|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
215059858|NCT02882438|DRUG|infected group|Ginkgo Biloba in different dosage forms
215059859|NCT02882438|DRUG|control group|placebo without Ginkgo Biloba
215059860|NCT04294381|BEHAVIORAL|Decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
215059861|NCT04294940|OTHER|Wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients"
215059862|NCT04294940|OTHER|Use the mobile application CardiCare™ and wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients~* wear their smartphone everyday and use the mobile application CardiCare™"
215059863|NCT00834600|DRUG|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg
215059864|NCT00834600|DRUG|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
215059865|NCT05619120|DRUG|Mexiletine|Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.
215059866|NCT05619120|OTHER|Conventional therapy|Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
215059867|NCT04930913|DIAGNOSTIC_TEST|Three-dimensional Ultrasound|women suspected of having adhesions will perform 3D US
215059868|NCT00287001|DEVICE|Cold air cooling|
215059869|NCT01602601|DRUG|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
215059870|NCT01602601|DRUG|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
215059871|NCT02777359|PROCEDURE|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
215059872|NCT05340946|PROCEDURE|general anaesthesia|intraoperative general anaesthesia followed by postoperative IV patient analgesia
215059873|NCT05340946|PROCEDURE|spinal anaesthesia|patient received spinal followed by continuous ultrasound guided femoral never block.
215059874|NCT01023685|BIOLOGICAL|CAD106|
215059875|NCT02515968|DRUG|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
215059876|NCT02515968|DRUG|Propofol|
215059877|NCT02368600|BEHAVIORAL|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
215059878|NCT01908543|DRUG|Ferrous sulphate 200mg oral tablet|Administration by mouth
215059879|NCT00369850|OTHER|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
215059880|NCT00369850|PROCEDURE|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
214304626|NCT01352299|DEVICE|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
214304627|NCT01352299|DEVICE|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
215059881|NCT00369850|PROCEDURE|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
215059882|NCT06089733|DRUG|Part A ABSK201 and Itraconazole|Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
214914424|NCT05390333|BEHAVIORAL|Self-Care Sampler for Family Carer Partners|The 6-week Self-Care Sampler for Family Caregivers program was created to provide a variety of evidence-based self-care practices that improve the mental and physical health of caregivers by relieving stress. Sessions will take place once a week for 90 minutes, each starting with a centering exercise and focusing on a new form of self-care. The first 30 minutes will be used for a support group and the last 60 minutes will be for a self-care practice. Self-care practices that will be offered throughout the 6 weeks include mindfulness, mindful drawing, exercise, and health prevention and promotion.
214914425|NCT01081769|DRUG|paliperidone palmitate injection|injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
214914426|NCT01081769|DRUG|oral antipsychotics|daily treatment according to local label for maximally 24 months
214914427|NCT01566266|DRUG|Amoxicillin|2 capsules of 250mg, 3 times per day during 1 week
214914428|NCT01566266|DRUG|Placebo capsule|2 capsules of 250mg, 3 times per day during 1 week
214914429|NCT01633723|DRUG|DA-6886|"single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)~multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)"
214914430|NCT01633723|DRUG|Placebo of DA-6886|DA-6886 placebo
215059883|NCT06089733|DRUG|Part A ABSK201 and Rifampicin|Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
215059884|NCT04539054|DIETARY_SUPPLEMENT|ENGN Shred|ENGN Shred is a multi-ingredient pre-workout supplement.
215059885|NCT04539054|DIETARY_SUPPLEMENT|Nutricost caffeine powder|Caffeine powder.
214670388|NCT05665335|DEVICE|Renuvion APR System|"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."
215059886|NCT04539054|DIETARY_SUPPLEMENT|Crystal Light|Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
215059887|NCT06026540|BEHAVIORAL|Pilates Exercise|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
215059888|NCT02131311|DEVICE|disposable, single-use pessary|
215059889|NCT00418093|DRUG|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
215059890|NCT00418093|DRUG|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
214304628|NCT01352299|DEVICE|Miller|Laryngoscopy performed with Miller Laryngoscope
214304629|NCT01352299|DEVICE|TrueView|Laryngoscopy performed with TrueView laryngoscope
214670389|NCT03352440|DEVICE|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
214914431|NCT00768703|DEVICE|Percutaneous endoscopic fetal tracheal occlusion/unocclusion|Between 26-28 wks' gestation, percutaneous endoscopic placement of the tracheal balloon. Between 32-34 wks' gestation, percutaneous endoscopic removal of the balloon.
214914432|NCT06131814|OTHER|2 groups|up 5 times repetition twice a week in first 4 week and then progress to 10 times repetition twice a week from 5-8th week of session
214914433|NCT00507455|DRUG|solifenacin succinate|Solifenacin succinate tablets
214914434|NCT00507455|DRUG|tamsulosin hydrochloride|Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
214914435|NCT00507455|DRUG|Placebo to solifenacin|
214914436|NCT00507455|DRUG|Placebo to tamsulosin|
214914437|NCT01631643|DEVICE|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
214914438|NCT03885895|DRUG|Tranexamic Acid Injectable Product|Ampoules used for intradermal injection
214914439|NCT03885895|DEVICE|Q switched KTP (532nm)|LASER
214914440|NCT02368223|DEVICE|YouGrabber|2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
214304630|NCT04909320|BEHAVIORAL|AWARD advice|Ask about smoking history; Warn about the high risk; Advise to quit; Refer smokers to smoking cessation services (with a referral card); Do it again
214914441|NCT00540150|BIOLOGICAL|specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)|We treat each patient with mite-allergen following the two different protocols.
215059891|NCT00418093|DRUG|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
215059892|NCT01201824|PROCEDURE|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
215059893|NCT05849194|DIAGNOSTIC_TEST|POCUS examination|Point of care ultrasound examination
215059894|NCT02594228|BEHAVIORAL|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
215059895|NCT02594228|BEHAVIORAL|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
214479766|NCT06696794|DRUG|Mitomycin C (MMC)|When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (mitomycin) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
214479767|NCT06696794|DRUG|Normal Saline (Placebo)|When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (Normal Saline) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
214914442|NCT01509313|DEVICE|hysteroscopic morcellator (TruClear)|It can be used to treat uterine pathology with a mechanical cutting edge
214914443|NCT01509313|DEVICE|Bipolar Electrical resectoscope (Versapoint)|It can be used to treat uterine pathology with an electrical cutting edge
214914444|NCT04303806|DRUG|rosuvastatin|receive rosuvastatin orally once daily.
214914445|NCT05109533|OTHER|Lactobacillus rhamnosus BMX 54, Lactobacillus reuteri RC-14, Lactobacillus rhamnosus GR-1|Probiotics implementation
214914446|NCT03786328|BEHAVIORAL|Standard Psychiatric Treatment|Standard psychiatric treatment is offered individuals identified with a clinical mental disorder. Treatment will follow golden standard treatment in the psychiatric clinic, meaning a combination of therapy and psychopharmacological treatment.
214914447|NCT03786328|BEHAVIORAL|Preventive Psychological Treatment|Preventive Psychological Treatment is offered individuals identified with a sub-clinical mental condition. Treatment consists of 8 sessions of cognitive-behavioural therapy.
215059896|NCT01726543|PROCEDURE|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
215059897|NCT01726543|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
215059898|NCT06270446|OTHER|Community based physiotherapy|Physiotherapy at community rehabilitation center
215059899|NCT06270446|OTHER|Outpatient physiotherapy|Physiotherapy at hospital
215059900|NCT00006695|DRUG|carmustine|300 mg/m2 IV on Day -6
215059901|NCT00006695|DRUG|cytarabine|100 mg/m2 BID on Days -5 through -2
215059902|NCT00006695|DRUG|etoposide|100 mg/m2 BID on Days -5 through -2
215059903|NCT00006695|DRUG|melphalan|140 mg/m2 IV on Day -1
214304631|NCT04909320|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking and remind them to call the Department of Health SC hotline 183 3183.
214304632|NCT04909320|OTHER|Referral card|The contents consist of brief information and highlights of existing SC services, contact methods, motivation information, and strong supporting messages or slogans.
214304633|NCT04909320|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
214304634|NCT04909320|BEHAVIORAL|Positive psychological support through 3-people group chat using instant messaging apps|Each IM chat group will consist of a trained SC counselor (HKU staff), a peer supporter (former smoker), and a participant (smoker). The 3-month group chat-based intervention will consist of regular messages and real-time support through group chat. Regular messages will generally include goal setting, health warnings, abstinence support, positive psychological exercises, and encouragement and will be delivered in a tapering style. During the real-time chatting, SC counsellors and peer supporters will provide real-time chat-based support, and peer supporters will share their quitting experience as appropriate.
214304635|NCT04909320|BEHAVIORAL|E-messages via SMS|Regular e-messages via SMS at twice per month within 3 months (total 6).
214304636|NCT05511051|DRUG|Fruquintinib|Fruquintinib
214304637|NCT05511051|DRUG|HAIC|HAIC
214304638|NCT05096507|PROCEDURE|Hip fracture Surgery (Primary)|Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
214304639|NCT03310554|PROCEDURE|26cm suspended overlength biliary stents|The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP
214304640|NCT03310554|PROCEDURE|30cm suspended overlength biliary stents|The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
214304641|NCT03310554|PROCEDURE|ordinary plastic biliary stents|The control group will be placed ordinary plastic biliary stents in bile duct in ERCP
214304642|NCT02124863|DEVICE|Intrapulmonary Percussive Ventilation|20 min IPV freq 300/min, p 10cmH2O
214304643|NCT02813603|PROCEDURE|EBUS|19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
214304644|NCT02113956|BEHAVIORAL|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
214304645|NCT00535548|BIOLOGICAL|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
214304646|NCT05347316|DRUG|Colchicine|0.5 mg per day colchicine for 12 months
214304647|NCT01899534|OTHER|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
214479768|NCT06699199|DRUG|Silver diamine Fluoride 38%|"Intervention is the application of Silver diamine fluoride 38% to children Group in arm 1 (Arm 1): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth~SDF: (Silver diamine fluoride 38% is a material used for arresting caries lesions in primary and permanent teeth)~\- SDF Product generic name and information (E-SDF: it is a 1-step Technique) - The 38% SDF solution comprised a blend of silver, fluoride, and ammonia at a total concentration of 38%."
214914448|NCT06119815|DIAGNOSTIC_TEST|CO2 GAP|"CO2 gap will be measured by insertion of radial arterial cannula and internal jugular C.V.P~* I.V.C collapsibility will be measured by abdominal us at the subcostal area and the IVC diameters will be measured in M-mode coupled to 2D mode 3 cm before the IVC joined the right atrium to ensure that IVC diameter measurements are accurate and that the inter- and intra-observer variability of IVC can be minimized. The IVC collapsibility index (IVCCI) will be calculated as follows: (maximum diameter on expiration (IVC max) - minimum diameter on inspiration (IVC min).~* Echocardiography for all patients to asses cardiac index in a parasternal (2D) view. The aortic diameter (AoD) will be measured at the aortic valve annulus. The aortic area (AA) will be calculated using the formula: AA = π × (AoD2/ 4). We measured the aortic blood flow using pulsed"
215059904|NCT00006695|PROCEDURE|peripheral blood stem cell transplantation|Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
214304648|NCT00575055|DRUG|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
214304649|NCT00575055|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
214304650|NCT00575055|DRUG|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
214304651|NCT02406651|DRUG|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
214304652|NCT02406651|DRUG|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
214304653|NCT05594394|BEHAVIORAL|Orai: Master Public Speaking|"Participants will access the Orai: Master Public Speaking (Sani, Dhamani, \& Gupta, 2020) platform with mobile and web-based applications. Communication skill-building moduleswill be assigned using exercises, case scenarios, and AI-assisted feedback debriefing through the Orai application.~Participants will also complete case scenarios created with specific nursing conflict issues a charge nurse may encounter in an acute care facility. Upon completion of the competency development program, participants will complete the CMCSS to determine the effect on confidence levels and a brief survey (Appendix C) to assess the amicability of the program."
214304654|NCT04336891|DRUG|Testosterone gel|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
214304655|NCT04336891|DRUG|Estradiol ovules|Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
214304656|NCT04336891|DRUG|Moisturizer|Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed
214304657|NCT04336891|DRUG|Testosterone gel + Estradiol ovules|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
214304658|NCT02408393|DRUG|Saline|
214304659|NCT02408393|DRUG|Ropivacaine|
214304660|NCT03467113|DRUG|ZX008 0.2 to 0.8 mg/kg/day|ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
214304661|NCT03467113|DRUG|Cannabidiol|Cannabidiol
214304662|NCT01885546|DEVICE|AgaMatrix Blood Glucose Monitor|
214304663|NCT00496756|DRUG|Sorafenib|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
214914449|NCT04476693|OTHER|Breakfast consumption|"Consumption of breakfast: The breakfast provided was designed based on the characteristics of an ideal breakfast outlined in Giovannini et al., (2008). The breakfast provided in the present study will include the following: all-bran cereals (Kellogg's), semi-skimmed milk (Tesco), Royal Gala Apple (Tesco) and Orange Juice from Concentrate (Tesco) containing the amount of carbohydrates usually consumed at breakfast in the UK (Reeves et al., 2013). The portion for each participant will contain 0.06 g of carbohydrate per kcal of measured RMR. As the portion size (20% of daily calorie intake) will be calculated based on individual RMR , no leftovers will be allowed."
214914450|NCT04476693|OTHER|Breakfast Omission|Omission of breakfast. Participants will consume water within 15 min, the individual volume of which will be calculated based on the liquid content of the breakfast \[milk (ml)+ orange juice (ml)\].
214304664|NCT06535711|RADIATION|Acute CT|Acute CT (a CT within 24 h)
214304665|NCT06535711|RADIATION|Deferred CT|Deferred CT (a CT within 3-4 weeks)
214304666|NCT02588833|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214304667|NCT04994977|DRUG|Melphalan|Given at 0.5 mg/ml.
214304668|NCT04994977|DRUG|Carboplatin|Given at 5 mg/ml.
214304669|NCT04994977|DRUG|Topotecan|Given at 0.2 mg/ml.
214304670|NCT02921776|OTHER|Aim 1 - VidaTalk - post-extubation|"Observation of task completion will be made while patients complete a series of messages using the VidaTalk app:~* Tell me you are tired~* Tell me you are having pain~* Rate this pain~* Tell me there is pain in your back~* Tell me your pain is sharp~* Ask to see the doctor~* Write your favorite color by drawing with your finger~* Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task.~Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak.~Group 1 only:~Patients will be asked about their preferences for customizing the VidaTalk app."
214304671|NCT02921776|OTHER|Aim 2 - VidaTalk - intubated|Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).
214304672|NCT02921776|DEVICE|Aim 3 - VidaTalk tablet app|Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
214304673|NCT02921776|OTHER|Aim 3 - attention-control with non-VidaTalk tablet|Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
214304674|NCT02946047|DRUG|Ixazomib 1 MG|1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
214479769|NCT06699199|DRUG|Silver diamine fluoride- potassium iodide|"Intervention is the application of Silver diamine fluoride 38% + potassium iodide to children Group in arm 2 (Arm 2): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth, Followed by an second minute of potassium iodide solution application~\- SDF Product generic name and information (Riva-star: it is a 2-step Technique) 30-35% SDF solution (1st step) comprised a blend of silver, fluoride, and ammonia applied in combination with a second application of potassium iodide solution (2nd step)"
214479770|NCT06701357|DRUG|CR-CHOP+PD1 inhibitor|Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； PD1 200mg D1
214914451|NCT03245528|DRUG|LJPC-501|angiotensin II
214914452|NCT01579786|PROCEDURE|Acetaminophen and acupuncture|All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
214304675|NCT02946047|DRUG|Ixazomib 2 MG|2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
214304676|NCT02946047|DRUG|Ixazomib 3 MG|3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
214304677|NCT02946047|DRUG|Ixazomib 4 MG|4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
214304678|NCT04786223|DRUG|C-11 ER-176|Participants will receive a one-time administration of C-11 ER176 and undergo a PET/CT imaging study. Blood samples for plasma biomarker testing will be obtained as part of the study.
214304679|NCT04786223|DIAGNOSTIC_TEST|Blood Test|Participants will undergo a one time venipuncture blood collection to evaluate the presence of inflammatory and genetic markers.
214670390|NCT03352440|DEVICE|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
214304680|NCT06575920|BEHAVIORAL|Breathing excercizes|The intervention comprised six sessions. The first week involved obtaining informed consent, taking measurements and providing a brief introduction to breath and coherent breathing exercises. This was followed by four weekly sessions, each consisting of 90 minutes combining lectures and breathing exercises. At the final session, measurements and feasibility data were collected.
214304681|NCT00782145|OTHER|educational intervention|
214304682|NCT00782145|OTHER|informational intervention|
214304683|NCT00782145|OTHER|internet-based intervention|
214304684|NCT00782145|OTHER|questionnaire administration|
214304685|NCT00782145|OTHER|study of socioeconomic and demographic variables|
214914453|NCT00703586|DRUG|Maraviroc|"ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~* 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~* 600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~* Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~* Addition of an alternate FDA approved NRTI \[such as zidovudine (AZT) or didanosine (ddi)\] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~* Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc."
214914454|NCT01921322|DEVICE|Pump|722 Paradigm Real-Time System
214914455|NCT01921322|OTHER|CGMS Gold|Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm
214914456|NCT04994691|OTHER|No Message|No messages are sent
214914457|NCT04994691|OTHER|Standard message|2 MyChart reminders that child is overdue for well child check visit
214914458|NCT04994691|OTHER|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
214914459|NCT04359940|DIAGNOSTIC_TEST|Cardiac MRI|For clinical surveillance
214914460|NCT05684861|DRUG|Isotretinoin|systemic isotretinoin was given to all 90 patients , dose was prescribed according to weight for 3 months
214914461|NCT05684861|DIAGNOSTIC_TEST|ELISA Assays of Serum TWEAK.|: From each subject, 5mL of blood was collected into vacutainers before and after treatment with isotretinoin. The blood samples were centrifuged at 3000g for 10 min at a temperature of 4°C, then . Quantitative determinations for serum TWEAK were achieved using the corresponding commercially available ELISA kit supplied by the AssayMax
214914462|NCT03178188|DEVICE|Pulsed-dye Laser|595 nm Pulsed-dye Laser; 7mm spot sizes, 6msec pulse durations, 8j/cm2 fluences, dynamic cooling device 30/20, 4 sessions with 4 weeks interval
214914463|NCT03178188|DEVICE|Sham|Cryogen spray with the setting of dynamic cooling device 30/20
214914464|NCT05930626|OTHER|Biomarkers of acrylamide, glycidol, POPs, PFAS|These are food contaminants (acrylamide, glycidol) and environmental pollutants (POPs, PFAS). Assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with POPs and PFAS using a prospective cohort study utilizing and integrating various 'OMICs' technologies.
214914465|NCT02846181|DRUG|[14C]-SK-1405|
214914466|NCT04160234|OTHER|web-based questionnaires|Patients will be asked to complete web-based questionnaires on a tablet computer
214914467|NCT06143241|DEVICE|Threshold IMT|Threshold is used in respiratory muscle training in the form of resistance loading.
214914468|NCT06143241|DRUG|Antiepileptic medication|They will continue their antiepileptic medication prescribed by their doctor.
214914469|NCT03731819|DIAGNOSTIC_TEST|Abbreviated PB MRI|Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).
214914470|NCT02605343|OTHER|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
214914471|NCT05835037|DRUG|Zinc Gluconate 30 MG|Participants will take one tablet per day (30 mg Zinc gluconate) for 1 year
214914472|NCT05835037|DRUG|Placebo|Participants will take one placebo tablet per day for 1 year
214914473|NCT05347576|DRUG|CKD-393(2)|QD, PO
214914474|NCT05347576|DRUG|CKD-501, D759, D150, D029|QD, PO
214914475|NCT00044629|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|
214914476|NCT00044629|DRUG|zolpidem tartrate (Ambien)|
214304686|NCT00782145|OTHER|survey administration|
214304687|NCT00782145|PROCEDURE|psychosocial assessment and care|
214304688|NCT00782145|PROCEDURE|quality-of-life assessment|
214304689|NCT00782145|PROCEDURE|standard follow-up care|
214304690|NCT05132829|DRUG|Azithromycin 1 gram IV|Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
214304691|NCT05132829|DRUG|Cefazolin and indomethacin|Perioperative standard of care with cefazolin and indomethacin
214304692|NCT00091351|PROCEDURE|conventional surgery|
214304693|NCT00091351|RADIATION|radiation therapy|
214304694|NCT04204954|OTHER|Tea Tree Oil Shampoo|Twice a day eyelid margin cleansing for three days.
214304695|NCT04204954|DRUG|Ciprofloxacin Ophthalmic Ointment 0.3%|Applied topically in the eyelid margin every four hours for three days.
214304696|NCT04204954|OTHER|Baby shampoo|Twice a day eyelid margin cleansing for three days.
214304697|NCT04204954|OTHER|Blephaclean|Twice a day eyelid margin cleansing for three days.
214304698|NCT03084081|DEVICE|CO2 standard therapy|Standard therapy using carbon dioxide for freezing of tissue
214304699|NCT03084081|DEVICE|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
214304700|NCT03084081|DEVICE|Thermocoagulator|Thermoablation
214914477|NCT00044629|DRUG|Placebo|
214914478|NCT04715074|BEHAVIORAL|Interviews|We will understand the impact psychosocial, lifestyle, and familial aspects play on an EOCRC diagnosis through 20 one-hour interviews with EOCRC patients and survivors.
214914479|NCT04715074|BEHAVIORAL|Pilot|Utilizing the Behaviour Change Wheel in conjunction with results gathered from Aims 1 and 2 we will develop a theory-driven, multi-media campaign intervention to increase awareness of EOCRC, risk factors, and early detection benefit.
214304701|NCT04814433|DRUG|Tranexamic acid|"FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.~Total dose of 500 mg (20 mL) total will be given."
214304702|NCT04814433|DRUG|Aminocaproic acid|"FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.~Total of 1000 mg total will be given."
214304703|NCT04814433|DRUG|Recombinant Human Thrombin|"Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.~Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.~For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given"
214479771|NCT06701357|DRUG|CR-CHOP + Orelabrutinib|Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Orelabrutinib 150mg/qd D1-21
214670391|NCT03352440|DEVICE|Control Group - Kinect|Group with typical development that will perform the task on Kinect
214914480|NCT03363776|BIOLOGICAL|BMS-986277|Specified dose on specified days
214914481|NCT03363776|BIOLOGICAL|Nivolumab|Specified dose on specified days
215059905|NCT00006695|RADIATION|tositumomab and iodine I 131 tositumomab|"Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject"
215059906|NCT01901484|DRUG|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
215059907|NCT00003566|PROCEDURE|videothoracoscopy|
215059908|NCT03611218|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX P600 (Fresenius Medical Care), comparator Sureflux-17UX and comparator Polyflux 170 H
215059909|NCT02059564|DRUG|HM11260C|doses of 6 mg, 16 mg
215059910|NCT02059564|DRUG|Placebo|Normal saline solution
215059911|NCT02059564|DRUG|Victoza|doses of 1.8 mg
214914482|NCT02972684|DEVICE|Thrombo-elastometry POC testing|Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
214304704|NCT04814433|DRUG|Lidocaine Hydrochloride with Epinephrine|"Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.~Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given"
214914483|NCT03451591|DRUG|Isosorbide Mononitrate XL (ISMN)|Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
214914484|NCT03451591|DRUG|Cilostazol|Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models.
214914485|NCT03451591|DRUG|ISMN XL and Cilostazol|Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models. Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
214914486|NCT03451591|OTHER|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol administered for the entire duration of the study.
214914487|NCT02084108|OTHER|intervention|intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
214914488|NCT04974996|DRUG|Loncastuximab tesirine|Intravenous (IV) infusion
214914489|NCT04974996|DRUG|Prednisone|Orally via tablet or capsule
214914490|NCT04974996|DRUG|Rituximab|Intravenous (IV) infusion
214914491|NCT04974996|DRUG|Cyclophosphamide|Intravenous (IV) infusion
214914492|NCT04974996|DRUG|Doxorubicin|Intravenous (IV) infusion
214914493|NCT04974996|DRUG|Vincristine|Intravenous (IV) infusion
214914494|NCT03157271|OTHER|Intramuscular Dry Needling|Dry Needling is a procedure in which a solid filament needle is inserted into the skin and muscle directly at a myofascial trigger point. A myofascial trigger point consists of multiple contraction knots, which are related to the production and maintenance of the pain cycle and interfere with movement patterns.
214479772|NCT06701357|DRUG|CR-CHOP + decitabine|Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Decitabine 10mg/m2 D-5 - -1
214479773|NCT03745716|DRUG|APR-246 + azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
214479774|NCT03745716|DRUG|Azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
214479775|NCT06700733|DEVICE|PEEK prosthesis|For the PP, The PEEK framework will be constructed, the fit of the PEEK framework will be verified intraorally, and the final screw-retained prosthesis will be constructed of PMMA teeth and a visiolign pink composite estimating the gingival tissue.
214914495|NCT00861393|BEHAVIORAL|CBT|12 Session CBT group
214914496|NCT00861393|BEHAVIORAL|Waitlist CBT|Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
214914497|NCT01875757|DRUG|Vitamin D3|
214914498|NCT01875757|DRUG|Placebo|
214914499|NCT05681325|DIETARY_SUPPLEMENT|green tea|It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.
214914500|NCT05681325|DIETARY_SUPPLEMENT|matcha tea|It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.
214914501|NCT01022320|PROCEDURE|Lateral Pharyngoplasty|surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
214914502|NCT03928587|DIETARY_SUPPLEMENT|2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.|One lozenge once daily for 12 months
214914503|NCT03928587|DIETARY_SUPPLEMENT|Placebo|Placebo once daily for 12 months
214914504|NCT05903625|DIETARY_SUPPLEMENT|Control Group - Standard White Bread|Participants consume commercially available standard white bread, serving as the control intervention.
214914505|NCT05903625|DIETARY_SUPPLEMENT|Lysine Group - Lysine-Fortified Bread|Participants consume bread fortified with lysine, an essential amino acid, in a specified dosage, frequency, and duration.
214914506|NCT05903625|DIETARY_SUPPLEMENT|Phosphorus Group - Phosphorus-Fortified Bread|Participants consume bread fortified with phosphorus, an essential mineral, in a specified dosage, frequency, and duration
214914507|NCT05903625|DIETARY_SUPPLEMENT|Lysine and Phosphorus Group - Double Fortified Bread|Double Fortified Bread: Participants consume bread fortified with both lysine and phosphorus in specified dosages, frequencies, and durations.
214914508|NCT00933621|PROCEDURE|Autologous bone marrow intracoronary infusion|Percutaneous intracoronary mononuclear bone marrow cell infusion
214914509|NCT06253364|DRUG|PD-1 monoclonal antibody and lenvatinib|"Adjuvant PD-1 group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.~Adjuvant PD-1 plus Lenvatinib group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV 21 days for 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months."
214914510|NCT00737906|PROCEDURE|Surgical turbinate reduction procedure|Surgical turbinate reduction using the COBLATION device
214479776|NCT06700733|DEVICE|Titanium prosthesis|For the TP, the framework will be milled from Ti blocks according to the virtual design of the final prosthesis framework. PMMA teeth then will be cemented, and the final prosthesis will be screwed.
214914511|NCT03124589|BEHAVIORAL|Online Gambling Internet Intervention|CAMH's online gambling intervention which includes self-help materials as well as a personalized feedback component.
215059912|NCT01650948|DEVICE|RetnaGene AMD LDT|
215059913|NCT02645032|BIOLOGICAL|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
214914512|NCT06299384|OTHER|LyssnCrisis|LyssnCrisis is an AI-based coding and feedback tool for implementation in crisis counseling settings, training counselors (call-takers) in suicide risk assessment skills.
214914513|NCT05865496|DRUG|611|611 subcutaneous (SC) injection.
214914514|NCT05865496|DRUG|Placebo|Placebo subcutaneous (SC) injection.
214914515|NCT02049892|OTHER|Metal Ion Levels|
214914516|NCT02097238|DRUG|Eribulin Mesylate|Given IV
214914517|NCT02097238|OTHER|Pharmacological Study|Correlative studies
214914518|NCT05628428|OTHER|Exercise to strengthen neck area.|An exercise protocol will be carried out through educational videos. There will be a total of four videos which will pose exercises for two weeks each. These exercises will be done twice a week. A reminder will be sent by email on the days that they must be carried out.
214914519|NCT05628428|OTHER|Information|Information will be provided on neck pain and how exercise is able to help prevent it.
214914520|NCT05047705|BEHAVIORAL|Distress Tolerance Skills Training|Individuals with TS will receive distress tolerance skill training. Therapeutic skill training will consist of 4 weekly 1-hour sessions. Skill training will occur either in-person or remotely via videoconferencing software. Sessions will focus on building participants' distress tolerance skills with strategies drawn from third-wave CBT.
214914521|NCT01106911|DEVICE|tomosynthesis and screening mammography|All eligible subjects will undergo both full field digital mammography and digital breast tomosynthesis.
214304705|NCT04814433|DRUG|Bupivacaine Hydrochloride with Epinephrine|"Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.~Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given"
214914522|NCT03383640|OTHER|Active exercises|Active flexion movements every waking hour of the replanted digits
214914523|NCT03728348|DIAGNOSTIC_TEST|mt-sDNA screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
214914524|NCT03728348|PROCEDURE|Colonoscopy|Subjects will undergo a screening colonoscopy.
214914525|NCT05140746|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Baseline 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans before NAC followed by abdomen 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans after one cycle of NAC treatment or before surgery.
214914526|NCT04641325|OTHER|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 8 weeks all patients will return for re-assessment.
214914527|NCT01814696|DEVICE|MedSentry System|Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
214914528|NCT03356639|DRUG|ASP6981|Oral
214914529|NCT03356639|DRUG|Placebo|Oral
214304706|NCT06762392|OTHER|Blood Flow Restriction|Blood Flow Restriction (BFR) therapy in this study involves the application of a pneumatic cuff around the proximal thigh to restrict arterial blood flow during specific rehabilitation exercises. The cuff will be inflated to achieve 70-80% of arterial occlusion, while participants perform low-intensity resistance exercises at 15-20% of their one-repetition maximum (1RM). BFR therapy will be used during Phase 2 of rehabilitation (weeks 2-12) alongside a standardized rehabilitation protocol. The intervention will be closely monitored by trained Physical Therapists to ensure safety and efficacy, with pressure adjustments made in real-time based on the participant's exercise performance. This intervention distinguishes itself by its use of BFR, a technique that is not part of conventional ACL rehabilitation
214304707|NCT06762392|OTHER|Standard Rehabilitation|The Standard Rehabilitation (RHB) intervention in this study consists of a structured, evidence-based protocol designed to optimize recovery after anterior cruciate ligament (ACL) reconstruction. This rehabilitation protocol is implemented across four phases. The rehabilitation will be supervised by experienced Physical Therapists, and participants will be given a tailored home exercise program to complement the supervised sessions. The intervention aims to optimize recovery, restore function, and reduce the risk of re-injury.
214914530|NCT03523364|DEVICE|dental restorations|partial or complete ceramic restorations bonded to dental tissues after WAB and total etching or after total etching
214914531|NCT03232879|BEHAVIORAL|Motor Imagery|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R).
214914532|NCT03232879|BEHAVIORAL|Action Observation|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R). Before the subjects performed the mental MI practice, they were presented with a 30 seconds video that displayed the task that they ought to imagine later. A video was played prior to the first practice of imagination and after the second mental practice, a second video was shown.
214914533|NCT02084732|DRUG|Sorafenib|drug
214914534|NCT02146196|DEVICE|4 weeks robotic assisted training with the Lokomat®|During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
214914535|NCT02146196|DEVICE|One week robotic assisted gait training with the Lokomat®|During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
214914536|NCT00573274|DEVICE|Physioflow Impedance|6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
214304708|NCT04873661|BEHAVIORAL|Hypnosis group intervention|See arm description
214304709|NCT04873661|BEHAVIORAL|Cognitive trance group intervention|See arm description
214914537|NCT02737969|DEVICE|Transesophageal Echocardiography/angiography (TEE/Angio)|"The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.~The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor."
214914538|NCT02315404|PROCEDURE|CAP|CAP fitted to the end of the endoscope
214914539|NCT02811146|DEVICE|Bilevel Positive Pressure Airway|Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week
214914540|NCT02811146|OTHER|Heart rehabilitation|Heart rehabilitation, for 12 weeks, 3 times a week
214914541|NCT02897219|DRUG|ipragliflozin|Oral administration once daily
214914542|NCT02897219|DRUG|Placebo|Oral administration once daily
214914543|NCT02897219|OTHER|Insulin Therapy|Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
214914544|NCT02995174|DEVICE|Dichoptic video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with 'contrast-balanced' images displayed on the screen of an i-Pod touch device. The eye with weaker eyesight will see the image with high contrast, and the good eye will see the image with low contrast. The subject will play the game one hour per day for 6 weeks.
214914545|NCT02995174|DEVICE|Video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with equal contrast images displayed on the screen of an i-Pod touch device. Both eyes will see the image of same contrast. The subject will play the game one hour per day for 6 weeks.
215059914|NCT02645032|BIOLOGICAL|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
215059915|NCT02645032|BIOLOGICAL|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~\*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
214304710|NCT04873661|BEHAVIORAL|Meditation group intervention|See arm description
214914546|NCT00663390|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
214914547|NCT04468568|DRUG|Atosiban|Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
214914548|NCT04468568|DRUG|Terbutaline|Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
215059916|NCT02569567|PROCEDURE|Smart-Shear Wave(SSW) imaging|"1. All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.~2. The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.~3. Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement."
214914549|NCT03303313|DRUG|Cemdisiran|Subcutaneous (sc) injection of Cemdisiran
214914550|NCT05339633|DRUG|[14C]-D-0502|Drug: \[14C\]-D-0502 and D-0502
214304711|NCT05737706|DRUG|MRTX1133|KRAS G12D Inhibitor
214304712|NCT02496533|PROCEDURE|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
214304713|NCT06300463|DRUG|Botensilimab|75 mg IV Q6W
214304714|NCT06300463|DRUG|Balstilimab|450 mg IV Q3W
214304715|NCT06300463|DRUG|AGEN1423|30 mg/kg IV Q3W
214304716|NCT06300463|RADIATION|Radiation|8Gy x 3 between Day 0 - 18; Allowed techniques for radiation are 3D conformal, intensity modulated radiotherapy (IMRT), or SBRT
214304717|NCT06844357|DRUG|tirapazamine|Intra-arterial injection into the tumor feeding artery
214479777|NCT03236935|DRUG|L-NMMA|pan-nitric oxide synthase inhibitor
215059917|NCT02569567|PROCEDURE|Transient elastography(TE)|"1. Using the M probe in patients with BMI \<30 kg/m2.~2. Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.~3. Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results."
215059918|NCT03020004|DRUG|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
215059919|NCT03020004|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
214479778|NCT03236935|DRUG|Pembrolizumab|PD-1 inhibitor
214479779|NCT00626795|DRUG|TD1414 2% cream|BID 7 days
214479780|NCT00626795|DRUG|TD1414 2% cream|TID 7 days
214479781|NCT00626795|DRUG|Bactroban® (mupirocin) 2% cream|BID 7 days
214479782|NCT06632613|DRUG|ENN0403 capsules, low dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at low dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
214479783|NCT06632613|DRUG|ENN0403 capsules, high dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at high dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the placebo capsules will be administrated through a nasogastric tube/oral gastric tube.
214479784|NCT06632613|DRUG|Placebo|Placebo capsules will be orally administered once a day for 5 consecutive days based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
214479785|NCT04159519|DRUG|Symbicort®|Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
214479786|NCT04159519|DRUG|Fasenra®|Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.
214914551|NCT06139900|OTHER|Assessment|No intervention will be applied to the participants. Postural stability will be evaluated in the virtual reality environment and real environment.
214304718|NCT06844357|PROCEDURE|Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
214304719|NCT06844357|PROCEDURE|TACE|TACE with epirubicin
214304720|NCT06900153|OTHER|phone questionnaire|the investigator calls the patient and asks her questions about her parental project and her pregnancies
214304721|NCT03488420|DRUG|Edoxaban Pill|Subjects will be taking edoxaban 30 or 60 mg
214479787|NCT04159519|DRUG|Ventolin®|Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.
214670392|NCT03352440|DEVICE|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
214914552|NCT03799640|OTHER|Standard Yoga|Yoga using standard poses and linear movements
214914553|NCT03799640|OTHER|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses.
215059920|NCT03020004|DRUG|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
215059921|NCT03020004|DRUG|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)
215059922|NCT05015647|DIETARY_SUPPLEMENT|LP group|LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
215059923|NCT05015647|OTHER|NP group|NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
214304722|NCT02556333|DRUG|FTC/TAF|Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
214479788|NCT05305560|DRUG|Ivermectin Tablets|Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
214479789|NCT05305560|DRUG|Matching placebo tablets|Daily placebo tablets intake for 28 days
214479790|NCT04918316|OTHER|Corneal gas permeable lens|Fit in corneal gas permeable contact lens first.
214486655|NCT05362006|DEVICE|Exopulse Mollii Suit|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
214914554|NCT03799640|OTHER|Educational Control|Lectures on health and fitness
214914555|NCT06181188|DRUG|Ketamine|Patients will receive a combination of ketamine and midazolam for conscious sedation
214914556|NCT06181188|DRUG|Midazolam|Patients will receive 1mg of midazolam regardless of which arm they are in and my be given 1mg doses for added sedation as needed every 3-5 minutes
214914557|NCT06181188|DRUG|Fentanyl|Patients randomized to the midazolam and fentanyl arm will receive 25mcg incremental doses for procedural sedation
214914558|NCT02861807|DEVICE|Brain stimulation with mindfulness-based relapse prevention|Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
214914559|NCT05864079|DIAGNOSTIC_TEST|Platelet count|Platelet count in study groups
214914560|NCT05864079|DIAGNOSTIC_TEST|Developmental endothelial locus-1 (DEL-1)|Serum DEL-1 in study groups
214914561|NCT05864079|DIAGNOSTIC_TEST|soluble P-selectin (sP-sel)|Serum sP-sel in study groups
214914562|NCT04217096|DRUG|Paclitaxel liposome|Patients receive paclitaxel liposome 175 mg/m\^2 (iv, 3h) on day 1 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic
214914563|NCT04217096|DRUG|S-1|Patients receive S-1 at a dose according to the body surface area（\<1.25m\^2，40mg Bid；1.25\~1.5m\^2,50mg Bid；\>1.50m\^2,60mg Bid）on days 1-14 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
214914564|NCT01632293|BEHAVIORAL|progressive resistance training|The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
214914565|NCT03416205|DEVICE|Erbao electric knife|Erbao electric knife is used to cut the Duodenal sphincter
214914566|NCT03416205|DEVICE|Three-cavity incision knife|Three-cavity incision knife is used to cut the Duodenal sphincter
214914567|NCT03416205|DEVICE|Columnar expansion balloon|Columnar expansion balloon is used to expand the the Duodenal sphincter
214914568|NCT03543748|DEVICE|Transcranial Magnetic Stimulation|A total of 2000 trains will be delivered successively. The pulses will be delivered at 80% of motor thresholds.
214914569|NCT03543748|DEVICE|Sham Transcranial Magnetic Stimulation|The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
214914570|NCT04565197|BIOLOGICAL|convalescent plasma|"Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~* Transfuse first aliquot for 2-3 hours (\~1.4 to 2 mL/min)~* Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
214914571|NCT02597439|DRUG|Omega-3 fatty acids|
214914572|NCT02597439|OTHER|Placebo|
214914573|NCT02484846|BEHAVIORAL|Time in bed|Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
214914574|NCT06261307|BEHAVIORAL|Music intervention|Group intervention focusing on musical activities
214914575|NCT06261307|BEHAVIORAL|Circus intervention|Group intervention focusing on acrobatics and circus activities
214914576|NCT05928507|DIAGNOSTIC_TEST|Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections|"The FINDER FLU A/B, RSV, SARS-CoV-2 Test real-time RT-PCR test for the qualitative detection of viral RNA from RSV, FLU A, FLU B and SARS-CoV-2 in nasopharyngeal (NP) specimens from individuals suspected of respiratory tract infection by their healthcare provider.~Nucleic acids from respiratory viruses identified by this test are typically detectable in nasopharyngeal swabs (NP) during the acute phase of infection. The detection and identification of specific viral nucleic acids from individuals signs is an indication of the presence of the identified microorganism and assist in the diagnosis of respiratory infection when considered alongside other clinical and epidemiological information."
214486656|NCT05362006|DEVICE|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
214914577|NCT00857987|DRUG|EMS Expectorant|Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
214914578|NCT00857987|OTHER|Placebo|Vehicle
214914579|NCT04709146|DIAGNOSTIC_TEST|Audio-Vestibular evaluation|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
214914580|NCT02405546|OTHER|Pre-Rotated (Group R)|In group R, placement of ETT over the FOS was done with 90° CCR from the beginning so that the bevel of the ETT faced posteriorly before it was advanced through the larynx.
214914581|NCT02405546|OTHER|No pre-rotation|ETT was not pre-rotated but rotated only if necessary
215059924|NCT00889850|DRUG|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
215059925|NCT00889850|DRUG|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
215059926|NCT00255723|DRUG|carboplatin|Given IV
215059927|NCT00255723|DRUG|etoposide|Given IV
215059928|NCT00255723|DRUG|ifosfamide|Given IV
215059929|NCT00791050|DEVICE|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
215059930|NCT00169702|BEHAVIORAL|weight management program|12 sessions, psychoeducation
214486657|NCT05249842|DIAGNOSTIC_TEST|Spirometric evaluation|Evaluation of: forced vital capacity (FVC),, FEV1', FEV 1/FVC, FEF 25-75
214914582|NCT00410813|DRUG|dasatinib|given orally
214914583|NCT00954941|DRUG|Ondansetron|8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
214914584|NCT00954941|DRUG|Aprepitant|125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
214914585|NCT02691949|DRUG|Mycophenolate mofetil|mycophenolate mofetil 1# BID-2# BID
214914586|NCT01257334|DRUG|BI 10773|patients with type 2 diabetes mellitus with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea
215059931|NCT00169702|BEHAVIORAL|weight management program|2 weekly, 12 sessions, psychoeducational weight management
215059932|NCT03820336|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
215059933|NCT03820336|DIETARY_SUPPLEMENT|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
215059934|NCT02749201|DEVICE|Gastrisail|Light Intensity and gastric wall thickness assessment
214304723|NCT06892496|OTHER|Visual Analog scale (VAS) questionnaire|"A Visual Analog Scale (VAS) questionnaire is a type of self-report tool where respondents mark a point on a continuous line to indicate the intensity of a subjective experience, like pain, fatigue, or happiness, between two extreme anchor points (e.g., no pain at one end and worst possible pain at the other), allowing for a more nuanced response compared to a standard Likert scale; essentially, it measures the degree of a symptom along a visual continuum."
214304724|NCT06892496|OTHER|Vacuum-formed retainer (VFR) technique|On the day of surgery, the stent will be positioned to cover the palate and the anterior and posterior teeth, including their occlusal and buccal surfaces bilaterally, to provide retention. Vacuum-formed retainers are a common clinical practice used after harvesting a palatal graft, in order to provide a mechanical barrier to reduce post-operative pain.
214304725|NCT06892496|OTHER|3-D printed acrylic resin stent (3DS) technique|On the day of surgery, the previously made palatal stent (3DS) will be placed in position and stabilized by mechanical retention in the palate and palatal surface of the maxillary teeth, bilaterally.
214914587|NCT06180096|DRUG|Riociguat film coated tablets|1 tablet of 2.5 mg Riociguat
214914588|NCT06180096|DRUG|Adempas Filmtabletten|1 tablet of 2.5 mg Riociguat
214914589|NCT05027451|DRUG|IXT-m200|Anti-methamphetamine chimeric monoclonal antibody (mAb)
214914590|NCT05027451|OTHER|Placebo|Normal saline
214914591|NCT00271063|DRUG|Liposomal Annamycin|3-day IV infusion
214914592|NCT02761421|OTHER|observation study|observation study
214914593|NCT04504188|DEVICE|Heart Rate Monitor Enhanced Treatment Optimization|Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.
214914594|NCT03656653|BEHAVIORAL|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder
214914595|NCT03755557|DRUG|Rhinocort|Application of a nasal spray
215059935|NCT05695794|OTHER|the group with a bed head height of 45 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving a 45 degree head height to 30 patients determined by Randomizer.org.
215059936|NCT05695794|OTHER|the group with a bed head height of 30 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving 30 degrees of bed head height to 30 patients determined by Randomizer.org.
215059937|NCT05576324|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Elexacaftor / Ivacaftor / Tezacaftor is a triple drug therapy that modulates CFTR availability at (apical) cell membranes and increases opening probability.
215059938|NCT01882387|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
215059939|NCT04809519|OTHER|Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives|In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.
214304726|NCT06892496|OTHER|Flowable resin composite stent (FRC) technique|On the day of surgery, a layer of flowable composite will be added, covering all the wound dimensions, restricted to the wound (no extension to the adjacent teeth). Flowable composite has been shown to help reduce pain using the same principal of providing a mechanical barrier to protect the palatal wound from the oral cavity
214486658|NCT05249842|DIAGNOSTIC_TEST|Physical component summary|Evaluation of the physical component summary of SF-36 quality of life
214486659|NCT05249842|DIAGNOSTIC_TEST|6MWT|6 minute walk test
214914596|NCT03755557|DRUG|Budesolv|Application of a nasal spray
214914597|NCT03755557|OTHER|Placebo|Application of a nasal spray
214914598|NCT00001504|DRUG|9-cis-Retinoic Acid|
214914599|NCT01644708|BEHAVIORAL|Self empowerment|"1\. Group meeting, introducing the method and the assessment tools~1. Self-empowerment,~2. Handing over the journal,~3. Questionnaire about emotional states and motivations for losing weight and for change.~The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant weighs himself and he notes his weight down in his journal."
214914600|NCT06575023|PROCEDURE|Tamponade of lower uterine segment in management of placenta accreta spectrum cases|To compare the efficacy of lower uterine tamponade and partial lower myometrial resection in the management of intraoperative bleeding in cases with placenta accreta spectrum
214914601|NCT06575023|PROCEDURE|partial myometrial resection of lower uterine segment in management of placenta accreta spectrum cases|tamponade vs partial myomertial resection of lower uterine segment in managment of placenta accreta spectrum cases
214914602|NCT04657588|DEVICE|Navina anal insert|The Navina anal device is a single-use, pre-lubricated, liquid-filled rectal insert with a plastic applicator. The insert is filled with liquid mineral oil. The primary advantage of this new instrument is the fact that the liquid-filled insert will move and adapt as the fluid is transferred throughout the device making it easy to insert/remove and comfortable to wear. The design is intended to adjust to the contours of the individual anatomy to prevent leakage.
214914603|NCT04657588|OTHER|Care as usual|Care as usual means participants are to continue their usual treatment for FI, like they would if they would not have participated in this study.
214486660|NCT05080413|DEVICE|Laser shoes|Path Finder® is a device that is fixed to the noses of the patient's shoes using a rubber strap, and laser-marks the place to be stepped on the ground of the opposite foot when walking. It is installed on both feet to relieve the symptoms of freezing of gait.
214914604|NCT00890370|PROCEDURE|Airway clearance technique|
214486661|NCT05080413|DEVICE|Metronome|The metronome, which makes a sound with a constant beat, is known to have an effect on the symptoms of Freezing of Gait in Parkinson's disease patients. At a rate of 80 beats per minute, the volume of sound that the patient can fully recognize is set to resolve the freezing of gait using the metronome sound.
214486662|NCT06100939|COMBINATION_PRODUCT|Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment|"Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source"
214486663|NCT06100939|COMBINATION_PRODUCT|Placebo and sham treatment|"Drug: placebo ophthalmic solution~Device: UV-3000 light source"
214486664|NCT06647303|BEHAVIORAL|Training on communication framework|Surgeons will receive training on the Better Conversations framework
214304727|NCT06892496|OTHER|Photographs of the patient's palate|At the 14-day, 30-day and 3-month follow-up visits, photographs of the patient's palate (Canon EOS 60D DSLR, Canon, USA) will be taken for healing evaluation as well as intraoral scans (TRIOS 4, 3Shape) of the palatal wound for linear and volumetric changes analysis.
214304728|NCT06892496|OTHER|Measuring graft dimensions|The graft dimensions will be measured with the use of a periodontal probe and recorded on the data collection form. The professional preference in regard to technique applied and the time spent by the surgeon to adjust the stent intraorally will also be recorded in the same form.
214304729|NCT06909058|BEHAVIORAL|Study Postoperative Care|The study group will be given general postoperative instructions. They will also receive liberal activity restrictions instructing the patient to resume normal activities of daily living at their own discretion without specific restrictions.
214304730|NCT06906133|OTHER|Urinary-hCG|Ovulation days will be detected using a commercial urine test for luteinizing hormone (LH) (PREGMATE, Ovulation Midstream Test Predictor Kit; sensitivity level:25mlU/mL). Participants will be instructed to use ovulation tests, starting 5 days before the expected ovulation (day 10) and for the next 7-10 days or until the first the first positive results are detected notify the study co-ordinator and share a photo of the results. Then participants will be asked to continue using the ovulation test for 3 more days.
214304731|NCT06913608|COMBINATION_PRODUCT|CLBR001 + SWI019|Investigational switchable CAR-T cell therapy for autoimmune disorders
214304732|NCT06913907|DRUG|Methotrexate (MTX)|Single arm study
214304733|NCT06913894|BEHAVIORAL|Supervised Therapy for DRF Rehabilitation|Participants assigned to the Supervised Therapy Group (STG) will receive in-person, supervised rehabilitation sessions in an outpatient clinic. Each session lasts 30-45 minutes and is conducted by a licensed physical therapist. The therapy focuses on progressive range of motion exercises, light strengthening, proprioception training, and functional task practice. In addition, participants are prescribed a daily home exercise program (lasting 10-15 minutes) to reinforce gains made during the clinic sessions. The intervention is provided over a 6-week period following cast removal, with adherence monitored via attendance records and home exercise logs.
214304734|NCT06913894|BEHAVIORAL|Home-Based Rehabilitation Program for DRF|Participants assigned to the Home-Based Program Group (HBG) will follow a standardized, detailed home exercise program specifically designed for distal radius fracture rehabilitation. The program includes instructions for range of motion, strengthening, and functional tasks similar to the supervised protocol. Participants receive a comprehensive written and online exercise manual, and they are instructed to perform the exercises daily. In addition, they will have weekly telephone or video check-ins (approximately 10 minutes per call) with a research assistant to review progress, address questions, and ensure proper exercise technique. The home program is implemented over a 6-week period following cast removal, with adherence documented via exercise logs submitted by participants.
214304735|NCT06913894|BEHAVIORAL|Minimal Educational Intervention for DRF|"Participants assigned to the No Therapy Group (NTG) will receive a minimal intervention consisting solely of general educational material. At the time of cast removal, they will be provided with a simple, standardized educational brochure that contains basic instructions for wrist and hand movement (e.g., move your wrist as tolerated). No additional therapy sessions, home exercise logs, or follow-up telephone calls will be provided beyond routine care. This intervention is intended to reflect the absence of a formal rehabilitation program and serves as the control for evaluating the added benefit of supervised and home-based therapy."
214304736|NCT06913322|PROCEDURE|flush endovenous laser ablation of great saphenous vein|A 4 French sheath is advanced over the wire and positioned in the great saphenous vein below knee. Diode laser (SmartM; Lasotronix) with a 600-mm radial fiber catheter was used. The tip of the laser was be placed flush at saphenofemoral junction.
214304737|NCT06913322|PROCEDURE|standard endovenous laser ablation of great saphenous vein|A 4 French sheath is advanced over the wire and positioned in the great saphenous vein below knee. Diode laser (SmartM; Lasotronix) with a 600-mm radial fiber catheter was used. The tip of the laser was be placed 2 cm distal to saphenofemoral junction.
214304738|NCT03103997|PROCEDURE|EUS-guided liver biopsy|EUS-guided liver biopsy using needles with various preparations
214304739|NCT01816893|OTHER|Hypoglycemic hyperinsulinemic clamp|
214304740|NCT01816893|OTHER|Euglycemic hyperinsulinemic clamp|
214304741|NCT06312735|DEVICE|VR (Reducept)|Reducept is a novel VR intervention that consists of a combination of pain neuroscience education (PNE) and pain management techniques. It includes different psychological therapy modalities (e.g. acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT) and hypnotherapy) into a single application.
214304742|NCT05714111|OTHER|Radiology evaluations and interventions|Diagnostic and interventional radiology procedures
214304743|NCT02805335|DEVICE|KTFIX PLUS|
214914605|NCT03600402|OTHER|Experimental|6 sessions of ankle manual therapy
214914606|NCT03600402|OTHER|Control|6 sessions of placebo intervention
214914607|NCT02533245|OTHER|Home-based indiviualized exercise training program|Based on these results of the cardiopulmonary exercise test (CPET) on a cycle ergometer, an individualized training program (cycling/hiking) is prescribed by a physical therapist for 6 months (3x/week, ≥30min/session).
214914608|NCT02533245|OTHER|Supervised group training sessions|7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist
214914609|NCT02533245|OTHER|Climb of the Mont Ventoux|Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)
214914610|NCT06682403|BEHAVIORAL|Received cable lock as default|Participants will receive a cable lock as the default safety device option after filling out the survey. If the participant took a cable lock during their hospital visit and noted this in the survey, they will not be shipped a cable lock. If participants did not take a cable lock and noted this in the survey, they will be shipped a cable lock.
215059940|NCT04809519|OTHER|Ongoing treatment|The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
215059941|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
215059942|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
215059943|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
215059944|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
215059945|NCT01608737|DRUG|BI 201335|BI 201335 once daily low dose for 24 weeks
214914611|NCT06682403|BEHAVIORAL|Choice between cable lock or lock box|Participant will have the option to select a lock box or cable lock shipped to their address after filling out the study survey.
214914612|NCT02693145|OTHER|Anti-Retroviral Treatment and Access to Services (ARTAS)|Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result. ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology. SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
214914613|NCT04237064|DIAGNOSTIC_TEST|Photoacoustic imaging|Photoacoustic imaging
214914614|NCT00812981|BIOLOGICAL|GSK1562902A|new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm
214304744|NCT03669835|DIETARY_SUPPLEMENT|Mare milk supplement|Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
214304745|NCT03669835|DRUG|Standard therapy|For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
214914615|NCT00812981|BIOLOGICAL|GSK1562902A|comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm
214304746|NCT05311371|OTHER|Breathing exercise group|"The exercise was applied in accordance with the Guideline on Breathing Exercise for Reducing Nausea and Vomiting prepared by the researcher in accordance with the literature. In addition, the researcher has a breath coaching certificate. The guideline include the application steps of breathing exercise. First, the researcher will demonstrate to the patients the practice of breathing exercise in accordance with the guideline. In the next step, patients they will be asked to do this application on themselves. The training is planned to take about 15-20 minutes for each patient. This guide will be given to patients after the training. They will be asked to do this breathing exercise correctly and effectively in accordance with the guideline for at least 5 min in case of sensation of nausea and vomiting for 14 days. The researcher will follow up the patients for 14 days by visiting room them every day."
214304747|NCT05311371|OTHER|Control group|No intervention
214304748|NCT05986162|DRUG|Itolizumab|Patients to be treated with Itolizumab.
214304749|NCT05324995|DRUG|Multimodal Drug|The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally
214914616|NCT02758938|OTHER|Urologic biofeedback software|All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.
214914617|NCT01391208|DRUG|GI heptapeptide|GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Chemical Formula: Ala1-Ser2-Tyr3-Asn4-Tyr5-Asp6-Ala7-Gly8- Gly9-Gly10-Ser11-Lys12 (5-FITC) -NH213.Investigational Agent Manufacturer: CPC Scientific, 1245 Reamwood Ave, Sunnyvale, CA 94089 Investigational Agent information: Lot Number: 10031701, M.W. 1577.6, 97.2% pure. Stored at -20C Yellow, lyophilized powder in single use amber vials. 5-FITC is light-sensitive, therefore stored protected from light. Manufactured under cGMP with Certificate of Analysis (COA) provided.
214914618|NCT06197438|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
214914619|NCT06197438|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
214914620|NCT06197438|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
214914621|NCT06197438|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
214914622|NCT06197438|DRUG|Irinotecan Hydrochloride|Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 once every 14 days.
214914623|NCT06197438|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 90 mg/m2 once every 14 days.
214304750|NCT05324995|DRUG|epinephrine|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary
214304751|NCT05324995|DRUG|celecoxib|The third group administered celecoxib (200 mg) orally immediately before the surgery
214304752|NCT04729127|BEHAVIORAL|Project ImPACT|Project ImPACT (Improving Parents As Communication Teachers) is an evidence-based parent-mediated intervention program based on best practices in early intervention. The program is designed for young children up to age six with social communication delays, including autism spectrum disorder. Project ImPACT focuses on social engagement, language, social imitation, and play. Project ImPACT is a naturalistic developmental behavioral intervention (NDBI).
214304753|NCT04923503|BEHAVIORAL|diurnal fasting|subject conduct fasting in Ramadan for 30 days
214304754|NCT05721833|DEVICE|Non-invasive high-frequency oscillatory|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
214304755|NCT05721833|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation.
214914624|NCT01725581|PROCEDURE|Observed Structured Assessment Tool in Pelvic Examination|Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
214914625|NCT05349981|DEVICE|Phonak Lyric self-replacement procedure|The self-replacement procedure is an experimental procedure in which the Lyric user replaces the Lyric devices independently at every other device replacement, using dedicated candidacy, training, and management procedures, conducted by and at the discretion of his/her hearing care provider (HCP).
214914626|NCT02199795|DEVICE|Contralaterally Controlled Neuromuscular Electrical Stimulation|
214914627|NCT02199795|DEVICE|Cyclic Neuromuscular Electrical Stimulation|
214914628|NCT05905523|OTHER|Assessing prewriting skills in children|"In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
214914629|NCT05088174|DRUG|Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule|"Drug:~Hetrombopag Olamine Tablet Ciclosporin Soft Capsule"
214914630|NCT04861350|OTHER|motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will mentally simulate each exercise with video 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
214914631|NCT04861350|OTHER|physical training|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will physically perform each exercise with supervision of investigator 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
214914632|NCT04861350|OTHER|combine physical training and motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, each exercises will be mentally simulated with video for a set and physically performed with supervision of investigator for 2 sets, 10 times for each set and 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
214914633|NCT00937469|BEHAVIORAL|Social skills training, parental tr. and standard tr.|Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
214914634|NCT00937469|OTHER|Standard treatment|The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
214914635|NCT00182455|DRUG|Topiramate|25 - 400 mg/day x 12 weeks
214914636|NCT00182455|DRUG|Placebo|25 - 400 mg/day x 12 weeks
214914637|NCT03485742|OTHER|No intervention|No intervention. Collection of data on statin eligibility in patients admitted with MI
215059946|NCT01326806|BEHAVIORAL|Families Talking Together|The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
215059947|NCT01326806|BEHAVIORAL|Active Control on Hygiene & Nutrition|The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
215059948|NCT03336086|COMBINATION_PRODUCT|weight loss program|A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
215059949|NCT00536718|GENETIC|gene expression analysis|
214304756|NCT01682317|BEHAVIORAL|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, \< 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
215059950|NCT00536718|GENETIC|molecular diagnostic method|
215059951|NCT00536718|GENETIC|polymorphism analysis|
215059952|NCT00536718|GENETIC|protein expression analysis|
215059953|NCT00536718|OTHER|medical chart review|
215059954|NCT00536718|OTHER|questionnaire administration|
215059955|NCT04389710|DRUG|Convalescent Plasma|One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
215059956|NCT00581399|DEVICE|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
215059957|NCT00581399|DEVICE|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
214304757|NCT03302013|PROCEDURE|Vanguard XP Bi-cruciate Retaining Knee Replacement System|Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.
214304758|NCT03302013|PROCEDURE|Vanguard CR Single Cruciate Retaining Knee System|Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.
214304759|NCT01365507|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
214304760|NCT03503786|DRUG|Carboplatin|Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles
214304761|NCT03503786|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles
214304762|NCT03503786|DRUG|Avelumab|Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
214304763|NCT00212732|DRUG|ONO-8025 (KRP-197)|
214304764|NCT02297828|DEVICE|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
214304765|NCT02297828|DEVICE|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
214304766|NCT01210365|DRUG|Diurisa®|Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
214304767|NCT01210365|DRUG|Lasix ®|One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
214304768|NCT02723968|OTHER|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
214304769|NCT02723968|PROCEDURE|HGPIV diagnosis test|
214304770|NCT02723968|PROCEDURE|HOMAR-IR diagnosis test|
214304771|NCT05316012|DEVICE|Smart diapers|"Residents receive standard continence care while using the smart diaper (without the alerting system) - fase 1~Diapers are changed as usual, e.g., after morning care, visual soiling, unpleasant odor, saturation, leakage.~Residents receive continence care while using the smart diaper with the alerting system - fase 2"
214304772|NCT02794103|DEVICE|Virtual Reality Distraction|VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
214304773|NCT02583776|DEVICE|Unblinded - CGM|Data from device will be readable and alarms on
214304774|NCT02583776|DEVICE|Blinded - CGM|Data from device will be blinded and alarms off
214914638|NCT02488343|BEHAVIORAL|Behavioral Intervention|Three types of intervention will be used: a) Interventions aimed to dealing with cognitions and habits will be based on cognitive-behavioral therapy (CBT) principles. b) Interventions aimed to dealing with affective factors that interfere with adherence will be based on dynamic therapy, crisis intervention and supportive elements. c) In the case of condition-related or therapy related barriers to adherence, psycho-educational multidisciplinary interventions of 1-2 appointments will be offered. Education about injection techniques and about reasonable expectations from therapy, and from MS itself, are a key strategy to successfully maintaining adherence.
214914639|NCT05121311|DIAGNOSTIC_TEST|NeoprediX B1 algorithm|Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
214304775|NCT03562039|PROCEDURE|M-MIST|minimal invasive surgical technique without thorough removal of granulation tissue
214304776|NCT05871359|DEVICE|Transcranial Direct Current Stimulation|The stimulator will be connected to two electrodes .The active electrode will be placed on the areas of the dorsal lateral pre-frontal cortex (DLPFC) contralateral to the more affected side.The other one on the supra orbital area.
214479791|NCT06874686|PROCEDURE|Minimally invasive laparoscopic pull-through surgery|"Pediatric patients diagnosed with Hirschsprung's Disease from 2017-2023 at the National Children's Hospital underwent two minimally invasive procedures: conventional laparoscopic pull-through (CLP) and single-incision laparoscopic pull-through (SILPS).~CLP involves three to five small incisions for trocars, allowing laparoscopic visualization and instrument access. Pneumoperitoneum is established, and the aganglionic colon segment is identified and mobilized using laparoscopic energy devices. The rectum is dissected circumferentially to preserve mesenteric blood supply, and a transanal approach is used to excise the diseased segment, followed by coloanal anastomosis with absorbable sutures.~SILPS follows the same principles but is performed through a single umbilical incision using a multi-port device for all instruments. This technique offers benefits like reduced scarring and less postoperative pain but requires advanced laparoscopic skills due to instrument crowding."
214479792|NCT05430230|DRUG|Naproxen 500 Mg|naproxen tablets
214479793|NCT05430230|DRUG|Placebo|lactose NF
214914640|NCT00279461|DRUG|Placebo in arm A and Vitamin D in arm B|Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
214914641|NCT00279461|DRUG|vitamin D 3 for arm A ,and matching placebo for arm B|Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
214914642|NCT05283135|DRUG|risankizumab|Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
214304777|NCT05871359|PROCEDURE|Dual task|The Dual Task consists of walking for 20 minutes along a hallway, simultaneously patient has to answer to a different ecological cognitive (attention, fluences, calculation) and motor tasks (hold a tray, turn head, ecc..)
214304778|NCT03161431|DRUG|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
214304779|NCT03161431|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
214304780|NCT01218074|DEVICE|Aggregometry+Thromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
214304781|NCT01218074|DEVICE|Thromboelastography Alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
214304782|NCT00525174|DEVICE|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
214304783|NCT00525174|DEVICE|Patching|2 hours daily patching of the sound eye
214304784|NCT00525174|PROCEDURE|Near activities|one hour near visual activities
214304785|NCT04782856|DRUG|Levothyroxine|levothyroxine sodium tablet for oral use
214304786|NCT04782856|DRUG|Liothyronine|Liothyronine sodium tablets for oral use treatment of hypothyroidism
214304787|NCT04782856|DRUG|Placebo|inert sugar tablets for oral use blinding for treatment of hypothyroidism
214304788|NCT05719363|DEVICE|Inogen Rove 6 Portable Oxygen Concentrator|"The Inogen Rove 6 POC is designed to provide a flow of high-purity oxygen. Inogen Rove 6 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen Rove 6 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient."
214304789|NCT01214707|OTHER|Exercise|Exercise during EMU stay
214304790|NCT06504199|DRUG|Obinutuzumab|No dose adjustment of Obinutuzumab is allowed.
214304791|NCT06504199|DRUG|Zanubrutinib|Zanubrutinib was allowed to be titrated to 80 mg bid or 80 mg qd
214304792|NCT06504199|DRUG|Lenalidomide|Lenalidomide was allowed to be titrated to 15 mg/day (induction phase) or 5 mg/day (maintenance phase).
214304793|NCT06504199|DRUG|Cytarabine|The specific dose is determined by the investigator according to the actual situation of the patient.
214304794|NCT06504199|BIOLOGICAL|CAR-T|zanubrutinib in combination with lenalidomide was allowed for maintenance treatment in high-risk patients for 1 year and zanubrutinib for 2 years after recovery of hemogram 2 months after CAR-T. High-risk Patients with any of the following conditions: Mantle cell lymphoma International Prognostic Index (MIPI-c) high-risk, blastic/pleomorphic type, TP53 mutation/deletion, CDKN2A deletion, MYC amplification/translocation, or incomplete response at induction stage; Non-high-risk group: no high-risk features.
214914643|NCT05310071|DRUG|Aducanumab|Administered as specified in the treatment arm.
214304795|NCT03503721|PROCEDURE|BipolEP|the prostate will be transurethrally enucleated using a bipolar current
214304796|NCT03503721|PROCEDURE|bipolarTURP|the prostate will transurethrally resected using a bipolar current
214304797|NCT05375552|DEVICE|Transcranial direct current stimulation|Participants will experience two repeated 20 minute sessions of tDCS (1.2 mA), with a 10-minute break.
214304798|NCT01932827|BEHAVIORAL|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
214304799|NCT00877695|BEHAVIORAL|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
214304800|NCT03974815|DEVICE|ACTIVE|"We will use 28.26cm\^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
214304801|NCT03974815|DEVICE|SHAM|"We will use 28.26cm\^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
214304802|NCT02663635|DEVICE|Safe'N'Sound|
214304803|NCT00870363|DRUG|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
214304804|NCT00870363|DRUG|maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
214479794|NCT06693635|DIAGNOSTIC_TEST|Implant planning|The implant planning will be carried out using various software programs. The AI assistance provided by each software will be evaluated.
214914644|NCT05310071|DRUG|Placebo|Administered as specified in the treatment arm.
214304805|NCT00870363|DRUG|efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]|efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
214304806|NCT01465022|DRUG|Combined estrogen-progestin pill|1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
214304807|NCT01465022|DRUG|Progestin-only pill|.35 mg norethindrone once a day orally
214304808|NCT04139954|OTHER|There is no intervention in the study|There is no intervention in the study
214304809|NCT06388395|PROCEDURE|Accuracy of full-arch surgical guides|The accuracy of the surgical guides will be assessed by superimposing the pre and post-treatment CBCT scans.
214304810|NCT06388395|PROCEDURE|Survival and complications of the prostheses|Two different prostheses will be assessed (conventional and PEEK). All complications will be recorded for a period of 3 years
214304811|NCT06388395|PROCEDURE|Survival and complications of the implants|The effect of the two different prostheses on implants will be assessed in terms of survival and success rates.
214304812|NCT06388395|PROCEDURE|Conventional (metal-resin) implant-supported prosthesis|Full-mouth implant-supported conventional prosthesis will be constructed and evaluated for up to 3 years.
214304813|NCT06388395|PROCEDURE|PEEK implant-supported prosthesis|Full-mouth implant-supported PEEK prosthesis will be constructed and evaluated for up to 3 years.
214304814|NCT00652236|OTHER|Physiotherapy|The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
214304815|NCT05717010|DEVICE|Near infrared spectroscopy|The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
214304816|NCT04009421|DIAGNOSTIC_TEST|Coronary artery plaque assessment by CT coronary angiography QAngio CT RE|Assessment of segmental plaque volume and composition
214304817|NCT00006240|BIOLOGICAL|sargramostim|
214304818|NCT00006240|DRUG|dexamethasone|
214304819|NCT00006240|DRUG|oral sodium phenylbutyrate|
214304820|NCT05366439|DRUG|AT-752|Parallel Assignment
214304821|NCT05366439|DRUG|Placebo Comparator|Parallel Assignment
214304822|NCT01327300|DRUG|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
214304823|NCT01327300|OTHER|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
214304824|NCT00002137|DRUG|Tecogalan sodium|
214304825|NCT03674060|DRUG|SYO-1644|"100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet"
214304826|NCT03674060|DRUG|Nexavar tab|Nexavar 200mg/tablet, PO, 1 tablet
214304827|NCT01199211|OTHER|Exercise training, women, marathon|Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
214304828|NCT02807350|DEVICE|Overminus treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
214304829|NCT02807350|DEVICE|Non-overminus treatment|spectacles with full cycloplegic refraction without overminus
214304830|NCT00115973|DEVICE|pump|
214304831|NCT00115973|DRUG|insulin aspart|
214304832|NCT03020823|DRUG|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214304833|NCT03890770|DRUG|BMS-986165|Oral administration
214304834|NCT03676322|DRUG|M5049|Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
214479795|NCT06413355|DRUG|[F-18]-FAPI-74|A positron-emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo expression of FAP with positron emission tomography (PET/CT).
214304835|NCT03676322|DRUG|Placebo|Participants will receive placebo matched to M5049.
214304836|NCT04149951|DEVICE|Vestal Device|Vestibular nerve stimulator
214304837|NCT04149951|DEVICE|Placebo device|Sham nerve stimulator
214304838|NCT02877277|DIETARY_SUPPLEMENT|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
214304839|NCT02877277|DIETARY_SUPPLEMENT|Placebo|Oral intake of placebo tablet daily for 56 days
214304840|NCT00006209|DRUG|Tucaresol|
214304841|NCT05403242|DRUG|RC48-ADC|2.0 mg/kg, IV, d1, every 2 weeks; or 2.5 mg/kg, IV, d1, every 2 weeks
214304842|NCT05403242|DRUG|S-1|40-60 mg, bid po, d1-10, every 2 weeks
214304843|NCT03217227|OTHER|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
214304844|NCT03217227|PROCEDURE|Cardiac Catheterization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries.~If there is no significant narrowing lesions, the interventionist may perform additional flow resistance measurements of the small vessels to further investigate the cause of angina"
214304845|NCT03217227|OTHER|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
214304846|NCT03217227|DIAGNOSTIC_TEST|I123 MIBG Scintigraphy (Optional)|"The test studies the cardiac sympathetic signalling that may help to identify patients with high risks of adverse events. The scan consists of 2 acquisitions of images 3-4 hours apart.~For this study, only patients without clinically significant lesions (diagnosed via the cardiac catetherisation and have normal FFR results) will undergo this test."
214304847|NCT05805761|PROCEDURE|Conventional Treatment|A bicarbonate jet will be used to remove the biofilm from the surface of the teeth.
214304848|NCT05805761|PROCEDURE|Antimicrobial Photodynamic Therapy|aPDT will be performed before each cleaning/prophylaxis session, only in one of the groups. Participants will swish with the photosensitizer erythrosine for 1 min of pre-irradiation time, so that the drug can stain all the bacterial biofilm. The D-2000 LED (DMC) will be applied, emitting at a wavelength of ʎ = 430-490 nm and 900-1100 mW/cm2. Irradiation will be performed until the biofilm of the cervical region is illuminated for 2 min per point. Each irradiation point will be approximately 0.4 cm2.
214479796|NCT06871540|OTHER|Probiotic Agent|Patients in the test group were instructed to take one tablet immediately after tooth brushing (before bedtime) once daily for 30 consecutive days. Probiotic was administered in tablets containing 1x109 cfu/g S. salivarius K12.
214479797|NCT06871540|OTHER|Non-Surgical Intervention|Patients in the control group received non-surgical periodontal treatment only.
214479798|NCT06871761|DRUG|HR17031 injection|HR17031 injection
214479799|NCT06871761|DRUG|insulin glargine|insulin glargine
214479800|NCT04539808|DRUG|Capecitabine|Given PO
214479801|NCT04539808|DRUG|Fluorouracil|Given IV
214479802|NCT04539808|DRUG|Irinotecan Hydrochloride|Given IV
214479803|NCT04539808|DRUG|Leucovorin Calcium|Given IV
214479804|NCT04539808|DRUG|Losartan Potassium|Given PO
214479805|NCT04539808|DRUG|Oxaliplatin|Given IV
214479806|NCT04539808|RADIATION|Radiation Therapy|Undergo short-course or long-course RT
214479807|NCT04539808|PROCEDURE|Resection|Undergo surgical resection
214479808|NCT04539808|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
214479809|NCT04539808|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214914645|NCT03752034|OTHER|Muscle Fiber Fragments (MFFs)|During the rotator cuff repair procedure, a biopsy of muscle will be taken from the pectoralis major and processed under sterile conditions in the operating room to obtain MFFs. The final product, composed of autologous MFFs in suspension, will be delivered via targeted injection into the muscle belly of the supraspinatus through the Naviaser Portal with visual guidance after rotator cuff repair is complete.
214479810|NCT04717700|DRUG|Selinexor 20 MG Oral Tablet|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
214479811|NCT04717700|DRUG|Bortezomib Injection|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
214479812|NCT04717700|DRUG|Lenalidomide capsule|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
214479813|NCT04717700|DRUG|Dexamethasone Oral|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
214479814|NCT06876311|DEVICE|Anterior Cervical Interbody Fusion|Standard Anterior Cervical Interbody Fusion with Stand-alone Cervical Cages
214479815|NCT06876311|DEVICE|Anterior lumbar Interbody Fusion|Standard Anterior Lumbar Interbody Fusion with Stand-Alone Lumbar Cages
214479816|NCT06876311|DEVICE|Lateral Lumbar Interbody Fusion|Standard Lateral Lumbar Interbody Fusion with Stand-alone Lumbar cage
214914646|NCT01012726|PROCEDURE|Colonoscopy|During the colonoscopy, we instill Acetylcystein and Doxycyline into the fistula.
214914647|NCT02570789|DRUG|patients with sunitinib or pazopanib|The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
214914648|NCT01391858|DRUG|lyrica|150mg of pregabalin/placebo
214914649|NCT04205643|BIOLOGICAL|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
214479817|NCT06695767|BEHAVIORAL|Neurobehavioral therapy|Participants will receive an introduction session and 12 1-hour long online sessions once per week for a total of 12 weeks that are guided by the investigator who is trained in NBT.Participants will engage in tools to aid in assuming control over their seizures; contextualize their environment; identify moods, situations, and thoughts; train healthy communication and support seeking; understand central nervous system medications and seizures; conduct a functional behavioral analysis; learn relaxation techniques; examine external stressors and internal triggers; and prepare for life after the intervention. Participants will be asked to complete weekly homework, thought records, seizure logs that are found in their workbooks and to engage in journal entries.
214479818|NCT03998488|DRUG|Fecal Microbiota Transplantation|"The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery."
214479819|NCT03998488|DIETARY_SUPPLEMENT|Psyllium Husk Powder|"All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat."
214479820|NCT06871878|OTHER|PRACTISE Physiotherapy Intervention|The PRACTISE programme is a 16-week personalised physiotherapy programme, incorporating tele-rehabilitation, which aims to support individuals to achieve optimal dose of exercise to improve motor and functional outcomes after stroke. There are three core components to the intervention: goal setting, exercise and a supported self-management approach. PRACTISE comprises of nine therapist supported sessions: five in person, home-based rehabilitation sessions (weeks 1-4, two visits in week 1) and four telephone or video consultations (Near Me) (weeks 6, 8, 12 and 16), a simple self-management workbook (with space to record personal goals, action plans and progress) to develop skills for self-management, and a personalised online exercise programme delivered through the Giraffe platform five times per week.
214304849|NCT03202862|DRUG|Fulvestrant|Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
214304850|NCT04709328|DRUG|SCTA01|Diluted by 0.9% normal saline，IV
214304851|NCT04709328|OTHER|Placebo|IV
214304852|NCT03451877|GENETIC|TGFB1 AND LAMA1 GENE POLYMORPHISMS|we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
214304853|NCT03050619|DRUG|Empagliflozin|
214304854|NCT03050619|DRUG|Other SGLT2 inhibitors|
214304855|NCT03050619|DRUG|Other non-insulin GLDs|metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists
214304856|NCT02933242|RADIATION|Stereotactic Ablative Body Radiotherapy|The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
214304857|NCT06274541|GENETIC|Somatic and Germline BRCA1/2 Testing|Germline BRCA1/2 mutation testing will be undertaken by NGS using blood samples. Somatic BRCA1/2 mutation testing will be undertaken by NGS using tumour tissue.
214304858|NCT01145768|DRUG|TC-5214|4 mg tablet, oral, BID, group 1
214304859|NCT01145768|DRUG|TC-5214|TBD tablet, oral, BID, groups 2-6
214304860|NCT01145768|DRUG|Placebo|
214304861|NCT03340337|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
214304862|NCT03340337|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
214304863|NCT03340337|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
214304864|NCT03179150|DIAGNOSTIC_TEST|Computed Tomography|CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
214479821|NCT06885892|PROCEDURE|Posterior Tibial Artery Perforator-Pedicled Propeller Flaps|Posterior tibial artery perforator-pedicled propeller flaps are feasible, safe, and effective procedure in the reconstruction of the defects in the lower leg.
214479822|NCT06885892|PROCEDURE|Perforator-Pedicled Propeller Flaps|Posterior Tibial Artery Perforator-Pedicled Propeller Flaps
214914650|NCT04205643|OTHER|Placebo SC|Subcutaneous injection of Placebo SC
214914651|NCT03337087|DRUG|Fluorouracil|Given IV
214914652|NCT03337087|DRUG|Irinotecan Sucrosofate|Given IV
214479823|NCT06882330|BEHAVIORAL|Dialectical behavior therapy|A complex psychotherapy program for patients with borderline personality disorder.
214914653|NCT03337087|OTHER|Laboratory Biomarker Analysis|Correlative studies
214304865|NCT03929848|PROCEDURE|Cuff pressure|observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery
214479824|NCT06726850|DRUG|Placebo|In the placebo arm, participants will consume a placebo matching GenSci1-144 for 12 consecutive weeks.
214479825|NCT06726850|DRUG|GS1-144|In the GS1-144 arm, participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks
214479826|NCT06735976|DEVICE|PAVM Embolization|This study consists of one group. All participants will undergo PAVM embolization with a LOBO™ device.
214479827|NCT06735976|DEVICE|PAVM Embolization with a LOBO™ device|Participants will undergo PAVM embolization with the LOBO™ device per standard of care.
214479828|NCT06738030|DEVICE|Transcranial current stimulation|The transcranial alternating current stimulation is delivered during the speech stimulus and the current matches the envelope of the target speech
214479829|NCT06738030|BEHAVIORAL|Auditory training|An at-home auditory training program that adaptively and interactively trains the listener in degraded speech, cognitive skills, and communication strategies
214914654|NCT03337087|DRUG|Leucovorin Calcium|Given IV
214914655|NCT03337087|DRUG|Rucaparib|Given PO
214914656|NCT05877118|BEHAVIORAL|Enhanced Overdose Education (EOE)|"EOE was adapted by Co-I Dr. Monique Miley at HHC's premier addiction hospital-The Rushford Center. It follows the guidelines set by Co-PI Jonathan Craig Allen when working with opioid patients reluctant to obtain naloxone:~* Express confidence in naloxone~* Provide a clear statement about suitability (You are an excellent candidate for naloxone)~* Begin discussion using presumptive language (You must be ready for an overdose)"
214914657|NCT05877118|BEHAVIORAL|Standard education|Written instructions that accompany a kit prescription in many EDs throughout the country.
214914658|NCT02435537|DRUG|Dexmedetomidine (Precedex)|intrathecal administration
214914659|NCT02435537|DRUG|Bupivacaine|intrathecal 10 mg bupivacaine
214914660|NCT02435537|DRUG|Morphine|intrathecal 0.5mg morphine
214914661|NCT06266195|DIAGNOSTIC_TEST|sierological test|sierological test: circulant vescicles
214914662|NCT02231567|OTHER|Neurocognitive Rehabilitation|The patients will be treated in inpatient clinic with a neurocognitive rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
214304866|NCT01160068|DRUG|Metformin|Metformin Tablets 1000 mg
214304867|NCT01160068|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
214304868|NCT04728269|OTHER|Lactibiane Topic AD|Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area
214304869|NCT04728269|OTHER|Placebo|Application of placebo twice a day (morning and evening) on the symmetrical lesional area
214304870|NCT03145896|DIETARY_SUPPLEMENT|vitamin D|After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
214304871|NCT01049321|DIETARY_SUPPLEMENT|DASH diet|
214304872|NCT01049321|DIETARY_SUPPLEMENT|a usual diabetic diet|
214304873|NCT05511142|OTHER|Classic Peyton's Four-Step Approach|Instructor demonstrated endotracheal intubation and mask ventilation procedural skills directly to the preclinical students, followed by direct hands-on practice using manequin, ended with giving feedback to the students
214304874|NCT05511142|OTHER|Modified Peyton's Four-Step Approach|Video tutorial of endotracheal intubation and mask ventilation were given to the students without explanation, followed by video tutorial making using manequin (without instructor) by the students which will be uploaded to Youtube
214304875|NCT05159895|DRUG|[14C]-DZD9008|Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration
214304876|NCT04307446|DEVICE|Immersive Virtual Reality|Immersive Virtual Reality
214479830|NCT06738589|DEVICE|non-invasive ventilation|Non-invasive ventilation adds positive pressure to the upper airway via a mask on the face.
214914663|NCT02231567|OTHER|Traditional Rehabilitation|The patients will be treated in inpatient clinic with a traditional rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
214914664|NCT01049256|OTHER|carbon dioxide|sinusoidal carbon dioxide administration
214914665|NCT03039764|DEVICE|Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
214914666|NCT05643742|BIOLOGICAL|CTX112|CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
214914667|NCT02097745|DRUG|methotrexate|a 10-25 mg stable dose given orally or parenterally throughout study
214914668|NCT02097745|DRUG|rituximab [MabThera/Rituxan]|1 g given by intravenous infusion on Days 1 and 15 of each treatment course
214914669|NCT00425750|DRUG|bortezomib|1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
214914670|NCT00425750|DRUG|docetaxel|40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
214914671|NCT00425750|OTHER|laboratory biomarker analysis|Tissue and blood collection.
214914672|NCT00425750|OTHER|pharmacological study|Blood collection.
214914673|NCT01871844|DRUG|ITF2984 (500, 1000, 2000 mcg bid for 7 days)|
214304877|NCT03001258|OTHER|Presbyopia screening training|The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
214304878|NCT03078621|BIOLOGICAL|Stem Cell Therapy|Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
214304879|NCT04354207|DIAGNOSTIC_TEST|Peripheral vein punction|Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood
214304880|NCT04354207|DIAGNOSTIC_TEST|Stool collection|Gut microbiome will be investigated in stool samples.
214304881|NCT00078026|DRUG|Apomine|
214304882|NCT04067128|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to three phone calls
214479831|NCT06870604|PROCEDURE|do open surgery|Open surgery was performed in patients undergoing gastric perforation
214479832|NCT06870604|PROCEDURE|do laparoscopic surgery|Laparoscopic surgery was performed in patients undergoing gastric perforation
214486665|NCT06647303|OTHER|Focus Group|Participants will attend a focus group to discuss the survey instruments used in this study which will help with future study design
214914674|NCT01871844|DRUG|octreotide 50 mcg tid|
214304883|NCT01246947|PROCEDURE|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
214304884|NCT01246947|OTHER|Mitral surgery alone|Randomized to Mitral surgery alone
214914675|NCT01871844|DRUG|Placebo|
214914676|NCT05847374|DEVICE|Polysomnography|Sleep architecture will be recorded using portable PSG (Prodigy) from 24:00 to 8:00. Pulse oximetry (SpO2) and heart rate were recorded continuously during the PSG. Simultaneously, the waveforms from the ventilator were recorded using Bettercare (R) system.
214914677|NCT01757184|DRUG|Sebelipase Alfa|IV infusions of sebelipase alfa
214914678|NCT01757184|DRUG|Placebo|IV infusions of matched placebo
214914679|NCT04245748|DRUG|Escitalopram|Escitalopram, a SSRI, commercially known as LexaproTM, is commonly prescribed for anxiety disorders and is FDA-approved for acute and maintenance treatment of MDD and GAD.
214914680|NCT04245748|DRUG|Duloxetine|Duloxetine, a SNRI, commercially known as CymbaltaTM, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults.
214304885|NCT03815097|PROCEDURE|Mapleson circuit and nasal trumpet|The Mapleson Circuit is a breathing system used to deliver oxygen and remove carbon dioxide during anesthesia. It consists of fresh oxygen flow, a reservoir bag, an expiratory valve, tubing, and a connection to the patient. There are different types of Mapleson circuits depending on the different arrangements of its components. We plan to use a Mapleson D circuit attached to a nasal trumpet via a connector.
214670393|NCT02660554|OTHER|Polymerase Chain Reaction (PCR)|Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
214670394|NCT05450055|PROCEDURE|intraperitoneal lidocaine analgesic or normal saline as control|Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
214670395|NCT05221125|BEHAVIORAL|Psychologically-Informed Physical Therapy (PIPT)|The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
214670396|NCT01993355|OTHER|Physiotherapy|Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
214670397|NCT01993355|OTHER|Intervention 1|Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
214670398|NCT01993355|BEHAVIORAL|Intervention 2|Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
214670399|NCT01691118|DRUG|Fimasartan|
214670400|NCT01691118|DRUG|Antihypertensive treatment|
214670401|NCT03210077|DEVICE|Monitoring|Monitoring
215059958|NCT05733741|DRUG|Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)|"For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%.~The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
215059959|NCT05733741|DRUG|Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).|"The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
214304886|NCT05075226|DEVICE|Vivity Extended Depth of Focus|Cataract surgery
214486666|NCT06647303|OTHER|Surveys|Participants will complete surveys regarding the surgeon's communication skills
214486667|NCT03678441|BEHAVIORAL|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
214486668|NCT03678441|PROCEDURE|Cognitive Assessment|Receive pen and paper cognitive assessment
214486669|NCT06346249|OTHER|Electrical Stimulation Therapy|Ten Electrical Stimulation Therapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
214486670|NCT06346249|OTHER|Manual Therapy|Manual Therapy consistin of soft tissue mobilization and release techniques over the neck and craniocervical regions. Ten sessions.
214486671|NCT06346249|OTHER|Exercise Therapeutic|The exercise therapeutic program consisting of neck movement control and stretching exercise. Ten sessions.
214486672|NCT03786926|DRUG|HMPL-689|HMPL-689 is a PI3Kδ inhibitor
214486673|NCT03957252|DIAGNOSTIC_TEST|Blood test: ClarityDX Prostate|PSA on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
214486674|NCT05123261|BEHAVIORAL|the mindfulness-based elder care (MBEC) therapy|According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
214486675|NCT01167010|DRUG|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
214486676|NCT01167010|DRUG|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
214486677|NCT01167010|DRUG|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
214486678|NCT03740867|OTHER|Pulmonary rehabilitation|Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.
214486679|NCT05133076|BIOLOGICAL|Lactobacillus gasseri BGP345A|Active and placebo capsules for oral use
214486680|NCT05133076|BIOLOGICAL|Placebo|Placebo
214486681|NCT04315571|DEVICE|Gore® Viatorr® Endoprosthesis with controlled expansion|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is a minimally invasive procedure in which a new path is made through the liver to carry blood from the portal vein to the heart, thus helping to alleviate the problems associated with elevated portal vein pressure.
214304887|NCT06496841|DRUG|Transnasal Sphenopalatine ganglion block|The transnasal approach to the sphenopalatine ganglion block allows for non-invasive access to the sphenopalatine ganglion, which is located deep in the nasopharynx in a recess posterior to the middle turbinate. A long cotton swab is inserted posterior to the nasopharynx until it is properly seated, and 2 mL of 2% lidocaine is injected through the outer end of the swab and left for 30 minutes. Patients are monitored for any potential complications or adverse effects throughout the procedure and for a period of time afterwards.
214304888|NCT06496841|DRUG|Ultrasound-guided suprazygomatic sphenopalatine ganglion block|The ultrasound transducer is placed in the infrazygomatic area, above the maxilla, at approximately a 45 cephalad angle. With this transducer position, the ptrigopalatine fossa, bounded anteriorly by the maxilla and posteriorly by the pterygoid process, is visualized. A 25 gauge spinal needle is inserted 1 to 1.5 cm above the zygomatic arch and posterior to the posterior orbital rim and advanced through an out-of-plane approach to reach the pterigolapalatine fossa. After the aspiration test, 3 mL of 2% lidocaine is injected and the spread of the drug is monitored by ultrasound. Patients are monitored for possible side effects and complications.
214304889|NCT05231590|BIOLOGICAL|Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (12.5 µg) with Advax-SM adjuvant (7.5 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
214304890|NCT05231590|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
214304891|NCT00146874|DEVICE|cardiac resynchronization therapy|
214304892|NCT02253212|DEVICE|SonoCloud|SonoCloud : dose escalation
214304893|NCT02253212|DRUG|Carboplatin|Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
214304894|NCT02430337|BEHAVIORAL|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
214304895|NCT02430337|BEHAVIORAL|SafeCare|SafeCare, an evidence-based home visiting program
214304896|NCT05222061|DEVICE|Drug coated balloon for the side brunch|Intervention is explained in group description
214914681|NCT02921724|DEVICE|TreC-Onco|"TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:~1. Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.~2. Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher."
214914682|NCT01902641|DRUG|Succinylcholine|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.
214304897|NCT05222061|DEVICE|Conventional balloon for the side brunch|Intervention is explained in group description
214914683|NCT01902641|DRUG|Rocuronium/Sugammadex|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
214914684|NCT01902641|DRUG|Rocuronium|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
214914685|NCT00018187|DRUG|Bupropion|
214914686|NCT00018187|DRUG|Mecamylamine|
214304898|NCT02477995|BIOLOGICAL|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
214304899|NCT02477995|BIOLOGICAL|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
214304900|NCT03257631|DRUG|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
214304901|NCT03257631|DRUG|Pomalidomide|Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
214304902|NCT04965194|PROCEDURE|erector spinae plane block|Superficial probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic (LA), and 20 ml of 0.25% bupivacaine will be administered to perform ESP block. LA spread to both cranial and caudal directions will be seen.
214304903|NCT04965194|PROCEDURE|Quadratus lumborum plane block|"A curved array transducer for the transmuscular QL (TQL) nerve block is placed in the axial plane on the patient's flank just cranial to the iliac crest. The shamrock sign is visualized: The transverse process of vertebra L4 is the stem, whereas the erector spinae posteriorly, QL laterally, and psoas major anteriorly represents the three leaves of the trefoil. The target for injection is the fascial plane between the QL and psoas major muscles. The needle is inserted using an in-plane technique from the posterior end of the transducer through the QL muscle. The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1."
214304904|NCT04965194|OTHER|placebo|patients received no regional block
214914687|NCT00018187|DRUG|Nicotine Patch|
214914688|NCT04700241|DIETARY_SUPPLEMENT|Potassium nitrate|Acute intervention (5.5 hours)
214914689|NCT04700241|DIETARY_SUPPLEMENT|Placebo|Acute intervention (5.5 hours)
214304905|NCT04667039|BIOLOGICAL|GNR-067|GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
214914690|NCT03428243|DEVICE|truSculpt|Device comparison of Circumference measurement at Baseline vs 18 months post treatment
214914691|NCT01514981|DRUG|AMG 761|Single dose of AMG 761 on study day 1.
214914692|NCT01514981|DRUG|Placebo|Single dose of placebo on study day 1.
214914693|NCT06388460|OTHER|Asthma Link|Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook
214914694|NCT06388460|OTHER|Enhanced Usual Care|Providers enroll patients to receive an asthma educational workbook
214914695|NCT02783495|BEHAVIORAL|Device: iPad|All patients will receive baseline neurocognitive and quality of life testing, followed by 3 months of the iPad-based intervention. At the end of the baseline visit, subjects will be lent an iPad to take home (or will be assisted in the installation of the ReMind app on their personal iPad) and instructed in the use of the ReMind app (and more basic iPad skills, if necessary). Subjects will review the intervention schedule (approximately 3 hours per week). Testing will be repeated 3 months after the baseline visit (i.e., immediately after the intervention) and 9 months after the baseline visit (i.e., 6 months after completion of the intervention), both time-points including a new MRI.
214914696|NCT02421705|OTHER|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
214914697|NCT03490552|PROCEDURE|mechanical thrombectomy|Mechanical thrombectomy whatever it type ( SRT , ASPT or Mixed )will be used to extract the thrombi from stroke causing occlusion to be preserved biologically for genomic lab. transfer to be processed by RNA sequencing analysis technique for identifying markers for its composition pointing to its source.
214914698|NCT03919552|DRUG|Docetaxel,Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.
214914699|NCT03919552|DRUG|Docetaxel,Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.
214914700|NCT03919552|RADIATION|Carboplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.
215059960|NCT04651686|OTHER|Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
215059961|NCT05363501|DRUG|IM Naloxone Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
215059962|NCT05363501|DRUG|Naloxone Nasal Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
215059963|NCT05363501|DRUG|Naloxone Nasal Swab|4 mg naloxone nasal swab administered in nostril
214914701|NCT03919552|RADIATION|Cisplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
214914702|NCT05696990|OTHER|3/7 Resistance Training Method|3/7 Resistance Training Method
215059964|NCT05363501|DRUG|Naloxone Nasal Swab|8 mg naloxone nasal swab administered in nostril
215059965|NCT05363501|DRUG|Naloxone Nasal Swab|12 mg naloxone nasal swab administered in nostril
214304906|NCT04667039|BIOLOGICAL|Lucentis®|Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
214304907|NCT05978154|OTHER|Thigh muscle mass and muscle wasting (exposure)|Thigh muscle mass and muscle wasting (exposure variable)
214304908|NCT03468907|DRUG|Telbivudine 600mg|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.
214304909|NCT03468907|DRUG|Tenofovir disoproxil fumarate 300mg|Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.
214304910|NCT00233623|DRUG|Iressa (Gefitinib)|
214304911|NCT00233623|DRUG|Irinotecan|
214304912|NCT00233623|DRUG|5Fluorouracil|
214304913|NCT00233623|DRUG|Leucovorin|
214304914|NCT00940212|DRUG|AZD2423|oral, single administration
214914703|NCT05696990|OTHER|3X9 Resistance Training Method|3X9 Resistance Training Method
214914704|NCT03101631|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment (CGA)|"CGA includes a set of evaluations to determine therapeutic decision based on mortality risk, toxicity risk and frailty group. Evaluations includes:~* Nutritional Assessment: Mini Nutritional Assessment (MNA)~* Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~* Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~* Psychological status: Geriatric Depression Scale (GDS)~* Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~* Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~* Age~* Haemoglobin~* CrCl~* Presence of geriatric syndromes"
215059966|NCT05363501|DRUG|Naloxone Nasal Swab|12.5 mg naloxone nasal swab administered in nostril
215059967|NCT04087031|OTHER|control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
215059968|NCT04087031|OTHER|virtual reality games|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Tymo system (Tyromotion, Austria), a wireless static and dynamic platform, for evaluating and rehabilitating posture.
215059969|NCT04087031|OTHER|robotic treadmill|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Walker View (TecnoBody, Italy) a treadmill equipped with a sensorized belt with eight load cells and a 3D camera
215059970|NCT06525688|OTHER|Bone, Serum and Plasma sample|Intervention: Bone samples will be collected during surgery from the femoral neck (which is typically removed and discarded in these operations) and fasting morning blood samples.
214304915|NCT00940212|DRUG|Placebo|oral administration and single dose
214304916|NCT02338869|BEHAVIORAL|Dialogue-based psychosocial rehabilitation|
214304917|NCT01613521|OTHER|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
214304918|NCT05811546|DIAGNOSTIC_TEST|Immunohistochemical staining for DNMT1 and EZH2|Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.
214304919|NCT00587483|DRUG|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
214304920|NCT00587483|DRUG|Amiodarone|300 mg
214304921|NCT00587483|DRUG|Placebo|Saline
214304922|NCT03303846|PROCEDURE|Magnetic Resonance Imaging|Undergo high risk breast cancer screening MRI
214914705|NCT05372432|OTHER|Handgrip strengths measurements with Jamar-type hand dynamometer and, tip pinch strengths measurements with pinchmeter|The handgrip strength and tip pinch strength of the participants were measured using the Jamar-type hand dynamometer and pinch meter available in our clinic. The handgrip strengths were measured with shoulders in adduction and neutral rotation, elbows in 90 degrees flexion, and forearms and wrists in a neutral position, while the tip pinch strengths were measured by squeezing a pinch meter between the thumb and index finger. Participants took a deep breath and then applied gripping force with maximal force while exhaling. In the analysis, the average of the three measurements made with an interval of five minutes was taken as the basis for the analysis.
214914706|NCT05372432|OTHER|The Nine Hole Peg Test|This test was used to evaluate the hand dexterity of the participants. This test consists of a square area and nine holes in this area, nine cylinders suitable for these holes, and a storage box. Participants quickly took the nine cylinders from the storage box and placed them in the holes, and after placing all the cylinders, they put the cylinders back in the storage box one by one. In the evaluation of the test, the time elapsed during these operations was measured in seconds with a chronometer, and shorter times were considered to indicate better hand dexterity.
214304923|NCT03303846|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214304924|NCT03303846|OTHER|Laboratory Biomarker Analysis|Correlative studies
214914707|NCT04812223|PROCEDURE|Delayed umbilical cord clamping|The umbilical cord will be clamped 60 seconds after the baby is born.
214914708|NCT04812223|PROCEDURE|Early umbilical cord clamping|The umbilical cord will be clamped 15 seconds after the baby is born.
214914709|NCT04812223|PROCEDURE|Milking of the umbilical cord|The cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
214914710|NCT04710654|OTHER|connective tissue manipulation|Individuals in CTM group, will sit on a stool with hips and knees flexed at 90° and their hands free on the thighs. The application will start from the basic area in the first session, and in the other sessions, the lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment as soon as possible according to the state of the vascular reaction. CTM will be applied three days a week, for four weeks.
214914711|NCT04710654|OTHER|Interferential current stimulation (100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 100 Hz frequency three days a week, for four weeks.
215059971|NCT02311036|OTHER|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
215059972|NCT05729113|BEHAVIORAL|Distraction technique|Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
215059973|NCT03711370|OTHER|Clear Bottle|These mothers received usual care from their pediatric providers and each mother was given 12 conventional, clear bottles of various sizes (4-12 ounces) that were compatible with a variety of different nipples manufactured by leading bottle companies. Mothers were also given handouts about proper formula preparation and paced bottle-feeding, which included messages about feeding in response to infant cues.
215059974|NCT03711370|OTHER|Opaque Bottle|These mothers received everything provided to the clear group, but instead received 12 opaque bottles of various sizes (4-12 ounces). These bottles were stainless steel and compatible with a variety of different nipples manufactured by a leading bottle company. Mothers in the intervention group also received an additional handout that contained safety tips for their opaque bottles (e.g., never microwave your bottle).
215059975|NCT00407602|DEVICE|Implant of Argus II Retinal Prosthesis|epiretinal implantation of device
214304925|NCT01834287|BEHAVIORAL|Physical Activity Intervention|Participants in the Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
214304926|NCT01834287|BEHAVIORAL|Wellness Control|Participants will receive a Spanish language, Internet-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
214304927|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in a day ight
214304928|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in the artificial lightning
214914712|NCT04710654|OTHER|Interferential current stimulation (0-100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 0-100 Hz frequency three days a week, for four weeks.
214914713|NCT04710654|OTHER|behavioural therapy|"The behavioral therapy includes patient education (description of the disease, symptoms, risk factors, treatment, defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advices (diet, water consumption, fiber food, etc.), teaching effective defecation posture, timed toilet training, self-abdominal massage.~Constipation Behavioral Therapy Booklet will be prepared within the scope of behavioral therapy."
214914714|NCT04710654|OTHER|exercise program|"Exercise program consisting of physical activity, core stabilization exercises and pelvic floor muscle exercises.~Exercise Program Booklet will be prepared within the exercise training."
214914715|NCT04867226|DRUG|Colchicine 0.5 MG|participant will be given a Colchicine regimen in a dose of 0.5mg twice daily for 14 days or until symptoms subsides,those with low body weight and develop side effect like diarrhea and vomiting dose will be reduced and supportive treatment will be given .
214479833|NCT06735638|PROCEDURE|OTC MIE Esophagectomy|"Consenting patients will undergo minimally invasive esophagectomy (MIE) using the Out of the Cage (OTC) robotic-assisted technique. The procedure will follow the exact standard steps of traditional VATS/RATS esophagectomy, except the thoracic ports will be placed in the subcostal plane. The number of ports (1-4) will be determined based on the patient and case characteristics.~The Da Vinci Xi® surgical system will be used to perform the thoracic portion of the esophagectomy through subcostal ports using the standard technique. Once the procedure is completed, the robotic arms and ports will be removed from the chest, and figure-of-8 stitches with non-absorbable sutures will be placed to close the diaphragm at the port sites. A 24 Fr soft chest tube will be left in place, as per standard VATS/RATS esophagectomy protocols. Incisions will be closed in the standard manner."
214914716|NCT04867226|DRUG|usual care treatment|control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.
214914717|NCT01322243|OTHER|Dietary manipulation|Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
214914718|NCT00662584|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|transcranial magnetic stimulation (TMS) at .5 HZ for 20s
215059976|NCT05992844|OTHER|KB Exercises Program|"Kinesthetic Brain Exercises will carried out for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
214914719|NCT04439877|BEHAVIORAL|Peri-implant disease diagnosis|Diagnosis of peri-implant disease
214914720|NCT03418688|DRUG|COR388|COR388 administered for 10 or 28 days.
214914721|NCT03418688|DRUG|Placebo|Placebo administered for 10 or 28 days.
214479834|NCT06735846|DEVICE|Guide wire|Insert the distal end of the guide wire into the introducer sheath and enter the blood vessel through the introducer sheath;5.Insert the catheter directly into the blood vessel through the guide wire, and when the catheter reaches the target position, exit the guide wire.
214914722|NCT05999071|DIETARY_SUPPLEMENT|Coriandrum sativum seeds|Each group consisted of 50 students. In the C. sativum group, dried powdered seeds of C. sativum were administered, while in the control group, starch was provided as a placebo. Both the C. sativum and placebo capsules were identical in shape, color, and outer packaging to maintain the blinding of the participants.
214914723|NCT03622060|DRUG|Nitroglycerin|200 microgram intraarterial nicardipine and 500 microgram nitroglycerin administered before sheath removal
214914724|NCT02299622|GENETIC|Genetic test|Next-generation sequencing (AmpliSeq) \& fusion analysis
214914725|NCT04398108|DRUG|Margetuximab Margetuximab-IV|Drug: Chosen Chemotherapy (Capecitabine) -Oral Capecitabine tablet Drug: Chosen Chemotherapy (Vinorelbine) Vinorelbine -IV Drug: Chosen Chemotherapy (Gemcitabine) Gemcitabine -IV
214914726|NCT02683928|BIOLOGICAL|GBR 830|
214914727|NCT02683928|BIOLOGICAL|Placebo|
214914728|NCT00723502|DRUG|Finafloxacin + Amoxicillin|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
214914729|NCT00723502|DRUG|Finafloxacin + Esomeprazole|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
214914730|NCT01629251|DEVICE|Closed-loop insulin delivery|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
214914731|NCT03723850|DEVICE|Active tDCS|The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
214914732|NCT03723850|DEVICE|Sham tDCS|The brain is not stimulated for 20 minutes with mild electrical current, but instead a sham procedure is administered using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
214914733|NCT02791919|DRUG|Cytarabine|Given IV or IT
214914734|NCT02791919|BIOLOGICAL|Filgrastim|Given IV or SC
214914735|NCT02791919|DRUG|Fludarabine Phosphate|Given IV
214914736|NCT02791919|OTHER|Laboratory Biomarker Analysis|Correlative studies
214914737|NCT02791919|OTHER|Pharmacological Study|Correlative studies
214914738|NCT02791919|DRUG|WEE1 Inhibitor AZD1775|Given PO
215059977|NCT05992844|OTHER|Conventional Rehabilitation program|Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
215059978|NCT03743714|OTHER|yoga treatment; flexibility, balance and strength exercises.|yoga treatment including flexibility exercises, balance exercises, and strength exercises.
214304929|NCT05112549|DRUG|Nivolumab [Opdivo]|Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
214479835|NCT06742463|DRUG|Venetoclax|BCL-2 inhibitor
214914739|NCT02146937|DRUG|Bicalutamide plus Finasteride- Combination therapy|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
214914740|NCT01749475|DRUG|Midazolam|The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.
214914741|NCT01749475|OTHER|hypnotherapy|A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.
214914742|NCT01624571|DRUG|LD02GIFRO|comparison of different dosages of drug
214914743|NCT04521062|DEVICE|Dilapan S|Placement of Dilapan S
214914744|NCT00348777|DRUG|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
214914745|NCT00348777|DRUG|3 days access to watering place at 6 months|access to watering place for movement in swimming pool, sauna and hammam.
214914746|NCT03739086|PROCEDURE|erector spinae plane block|unilateral or bilateral or bilevel erector spinae plane block performance for postoperative pain or acute pain
214914747|NCT00656825|DRUG|P144 cream|P144 cream will be given at a dose of 100 μg/mL
214914748|NCT00656825|DRUG|P144 cream|P144 cream will be given at a dose of 200 μg/mL
214914749|NCT00656825|DRUG|P144 cream|P144 cream will be given at a dose of 300 μg/mL
214914750|NCT00656825|DRUG|Placebo|Placebo will be randomly given to 4 subjects in each panel
214914751|NCT03393325|OTHER|Observation of treatment with Tadalafil-Delivra|Tadalafil 2% in a Delivra base (Transdermal Application)
214914752|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
214914753|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
214914754|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
214914755|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
215059979|NCT01169701|DRUG|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
214304930|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|remifentanil 0 ng/ml
214304931|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
214304932|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
214304933|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
214479836|NCT06742463|DRUG|homoharringtonine|alkaloid
214914756|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
214914757|NCT01014169|BEHAVIORAL|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.
214914758|NCT01276756|DRUG|Pegylated interferon alfa-2a|Pegylated interferon 160ug once weekly 48 weeks
214914759|NCT01276756|DRUG|Nitazoxanide|Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
214914760|NCT01276756|DRUG|Ribavirin|Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
214914761|NCT04120259|DRUG|Metformin Oral Tablet|A biguanide drug used as a first line therapy for Diabetes MellitusType 2
214914762|NCT04120259|DIETARY_SUPPLEMENT|Vinegar|A common herbal/dietary supplement used for centuries as an anti bacterial, cleaning,cooking, anti diabetic agent, to name a few uses.
215059980|NCT01169701|DRUG|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
215059981|NCT01169701|DRUG|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
215059982|NCT01846962|DRUG|Budesonide|The administered dose of topical steroid was 400mcg or 800mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
215059983|NCT01846962|DRUG|Fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
214479837|NCT06742463|DRUG|Cytarabine (Ara-C)|Metabolic antagonist.
214479838|NCT06742463|DRUG|G-CSF|Granulocyte colony-stimulating factor
214479839|NCT03441971|DEVICE|GORE PV1|Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).
214914763|NCT02589639|DRUG|Empagliflozin|
214914764|NCT02589639|DRUG|Placebo|
214914765|NCT02589639|DRUG|Placebo|For blinding purposes
214914766|NCT03388684|PROCEDURE|Conjoined twin separation surgery|This study included 4 case reports on conjoined twins (CT), 2 male and three female patients; 3 of them were parasitic and one was conjoined. We operated upon 2 parasitic and one conjoined. The 1st case died preoperatively.
214914767|NCT02203721|DEVICE|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|
214914768|NCT02203721|DEVICE|TECNIS Monofocal IOL, Model ZCB00|
214914769|NCT04403230|PROCEDURE|Retreatment of teeth prepared without finish line|Retreatment of teeth treated using biologically oriented preparation technique (BOPT). The sample (149 teeth) was divided into two groups: Seventy four teeth restored with crowns, and 75 teeth supporting fixed partial dentures (FPD).
214914770|NCT06571721|OTHER|Topical Product: Almond Oil|1-2 Drops of randomized topical product will be applied on entire face nightly.
214914771|NCT06571721|OTHER|Topical Product: Almond oil augmented with 0.5% Vitamin E|1-2 Drops of randomized topical product will be applied on entire face nightly.
214914772|NCT06571721|OTHER|Topical Product: 0.025% Tretinoin oil augmented with castor oil|1-2 Drops of randomized topical product will be applied on entire face nightly.
214914773|NCT01877642|DRUG|Lorazepam 1 mg IM|Lorazepam 1 mg intramuscular
214914774|NCT01877642|DRUG|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg
214914775|NCT01877642|DRUG|Inhaled Placebo|Inhaler with no drug in it to mimic the ADASUVE inhaler
214914776|NCT01877642|DRUG|Placebo IM|intramuscular placebo to mimic lorazepam 1 mg IM
214914777|NCT00255866|BEHAVIORAL|Skills training for the care of dementia patients|
214914778|NCT04063553|OTHER|Volunteers Service|"Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.~All volunteers are recruited from TTSH volunteers pool managed by Center of Health Activation (CHA). TKR volunteers are trained by the study team, including a formal classroom session and a practical and role play session. After the training, volunteers need to pass 3 assessment by the physiotherapists in order to attend to patients independently by themselves. Volunteers who are bilingual will attend to the subject alone, or else those who can only converse in Chinese/ English will pair up with another volunteer who knows another language to make sure there is no communication barrier between volunteers and patients."
214914779|NCT04063553|OTHER|Exercise brochure|. The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given. The exercises in the brochure and exercises taught by the volunteers are the same. The video and brochure are available in both English and Chinese version.
214670402|NCT02298244|PROCEDURE|PV isolation + GP Ablation|In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
214670403|NCT02298244|PROCEDURE|PV isolation + GP ablation + Pulmonary GP ablation|"The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.~8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min."
214670404|NCT00693381|DRUG|Tacrolimus|oral
214670405|NCT00693381|DRUG|Mycophenolate Mofetil|oral
214670406|NCT00693381|DRUG|methylprednisolone and prednisone|IV and oral
214670407|NCT02590679|DEVICE|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
214914780|NCT04722705|DEVICE|fractional Er:YAG laser|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed 2,940 nm Er:YAG fractional laser. (long pulse mode, 1500mJ, 2Hz, 2 pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
214914781|NCT04722705|DEVICE|Intense pulse light|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed IPL. (irridation energy: 12.5J/cm2, pulse duration: 10ms, 1pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
214914782|NCT02593097|DRUG|Metformin|Metformin 500mg twice daily
214914783|NCT02593097|DRUG|Matching Placebo|Matching Placebo twice daily
214914784|NCT05215977|DRUG|MW031|"The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
214914785|NCT05215977|DRUG|Placebo|"subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
214914786|NCT01413126|DIETARY_SUPPLEMENT|Whole peanuts without skins, Peanut butter, or no peanuts (control)|In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
214914787|NCT03495531|DEVICE|Virtual Reality|Virtual Reality headset with calming scenery
214914788|NCT00703157|PROCEDURE|Catheter Ablation|Patients undergoing left atrial circumferential pulmonary vein ostia ablation.
214304934|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
214914789|NCT00703157|PROCEDURE|Surgical Ablation|patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.
214914790|NCT02295969|DRUG|Oralair|Observational study, Oralair is used as prescribed by the prescriber phycisian.
215059984|NCT01846962|BEHAVIORAL|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
214304935|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
214304936|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
214304937|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
214304938|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
214304939|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
214304940|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
214304941|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
214304942|NCT04985851|DRUG|durvalumab + anlotinib|Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.
214304943|NCT04985851|DRUG|Durvalumab|durvalumab
214304944|NCT06496776|PROCEDURE|Choukroun's technique|Suturing will be done using the method described by Choukroun.
214304945|NCT02829463|RADIATION|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
214914791|NCT04554901|DIETARY_SUPPLEMENT|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
215059985|NCT01846962|DRUG|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1mg/day or 2mg/day (\<150 cm or \>150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
215059986|NCT03311581|DRUG|Propofol|Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
214304946|NCT06209892|PROCEDURE|Extended anticoagulation|This study plan will extend the duration of rivaroxaban 20mg in the experimental group to 12 months. The regular anticoagulation group will take the drug for 6 months
214914792|NCT03085966|BIOLOGICAL|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
214670408|NCT04269512|PROCEDURE|lymph node dissection|At least 10 lymph nodes must be removed.
214914793|NCT05446857|DRUG|Glecaprevir / Pibrentasvir Pill|Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
214914794|NCT04018846|PROCEDURE|Revascularization using a BIOPROTEC Graft|It is about a routine care study not changing the usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular Doctor in 1 month, 6 months, 12 months, 18 months and 2 years.
214914795|NCT00979316|DRUG|BMS-708163|Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
214914796|NCT00979316|DRUG|BMS-708163|Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
214914797|NCT00979316|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
214914798|NCT00979316|DRUG|Moxifloxacin|Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
214914799|NCT01567917|PROCEDURE|CRC surgery|"Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~\- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE"
214304947|NCT03811431|PROCEDURE|Contrast enhanced ultrasound guided liver biopsy|Conventional liver biopsy
214304948|NCT03888196|DIETARY_SUPPLEMENT|Panax Ginseng Supplementation|500 mg/day of Panax Ginseng
214304949|NCT03888196|DIETARY_SUPPLEMENT|Placebo Supplementation|500 mg/day of Cellulose
214304950|NCT06093009|PROCEDURE|pancreatectomy|
214304951|NCT02672423|DRUG|Abemaciclib Capsules (Reference Formulation)|Administered orally
214304952|NCT02672423|DRUG|Abemaciclib Tablet (Test Formulation)|Administered orally
214304953|NCT03066674|OTHER|McKenzie group|Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.
214304954|NCT03066674|OTHER|Control group|TENS,Exercises,Postural education ,Home exercises program.
214304955|NCT02204787|DEVICE|transcranial direct current stimulation|
214304956|NCT01056809|PROCEDURE|Chemotherapy and surgery|Treatment not specified but in accordance with national guidelines
214304957|NCT01312818|DRUG|Bortezomib|1.3 mg/m\^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
214304958|NCT01312818|DRUG|Vorinostat|180 mg/m\^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
214304959|NCT01312818|DRUG|Dexamethasone|6 mg/m\^2 by mouth (PO) divided twice a day (BID) on days 4-15.
214304960|NCT01312818|DRUG|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
214304961|NCT01312818|DRUG|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for \>18 years on Days 1-16."
214304962|NCT01046682|DRUG|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
214304963|NCT00912990|DRUG|Cisatracurium|One intravenous dose: 0.2mg/kg/dose
214304964|NCT00912990|DRUG|Normal saline|One Intravenous dose
214304965|NCT03533452|DRUG|Ropivacaine|Local anesthetic injection
214304966|NCT03533452|DRUG|Normal saline|Sham injection
214479840|NCT06812936|DRUG|Acetaminophen|"This intervention involves the administration of acetaminophen 500mg tablets, taken up to three times within the first 24 hours following archwire insertion to manage pain associated with orthodontic treatment. Acetaminophen is a centrally acting analgesic that reduces pain without significantly affecting tooth movement, making it a preferred choice for pain relief in orthodontic patients. Participants will be instructed to record their pain levels using a visual analog scale (VAS) over a five-day period post-bonding to assess the effectiveness of this treatment."
214479841|NCT06812936|PROCEDURE|Acupressure|This intervention involves the application of acupressure to two specific acupressure points: Jaw Chariot (St 6) and Facial Beauty (St 36). Participants will be trained to apply firm pressure to these points up to five times within the first 24 hours after archwire insertion to alleviate orthodontic pain. Acupressure is a non-invasive therapy based on traditional Chinese medicine that aims to stimulate the body's natural healing processes and promote pain relief by balancing energy flow. Participants will be instructed to record their pain levels using a visual analog scale (VAS) over the first five days post-bonding to assess its effectiveness.
214479842|NCT06811779|DRUG|Sodium Hypochlorite|Sodium hypochlorite used in 5% concentration for disinfection
214479843|NCT06811779|DRUG|Chlorhexidine|Chlorhexidine 0.2% concentration for disinfection
214479844|NCT06877117|BEHAVIORAL|Pictorial Framing|Visual aids illustrating collimation benefits
214479845|NCT06877117|BEHAVIORAL|Traffic Light Color Coding Framing|Decision cues using color-based risk indicators
214479846|NCT06855628|OTHER|[6,6-²H₂]-Glucose|\[6,6-²H₂\]-Glucose is a stable isotope-labeled glucose used as a metabolic tracer. It is administered orally to assess glucose metabolism using Deuterium Metabolic Imaging (DMI).
214479847|NCT06818084|COMBINATION_PRODUCT|TAVR+GDMT|"The patient will undergo transcatheter aortic valve replacement on the basis of guideline-directed medical therapy with The VitaFlow™ system.~The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve."
214479848|NCT06818084|COMBINATION_PRODUCT|SAVR+GDMT|The patient will undergo conventional surgical aortic valve replacement on the basis of guideline-directed medical therapy.
214486682|NCT04315571|PROCEDURE|Large Volume Paracentesis with albumin infusion|For therapeutic (large-volume) paracentesis, a 14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid. Concurrent infusion of IV albumin is recommended during large-volume paracentesis to help avoid significant intravascular volume shift and postprocedural hypotension.
214486683|NCT06853275|BEHAVIORAL|Experimental: External Focus|Participants will perform a short, standardized warm-up (1 set of 10 repetitions of 20% of the participant's estimated 1-repetition maximum). Following the warm-up, participants will perform 30 repetitions using 50% of their estimated 1-repetition maximum on a leg press machine. Participants will receive visual feedback from a linear position transducer for each repetition, indicating the speed of the last repetition/movement.
214486684|NCT06853275|BEHAVIORAL|Other: Internal Focus|Arm Description: Participants will perform a short, standardized warm-up (1 set of 10 repetitions of 20% of the participant's estimated 1RM). Following the warm-up, participants will perform 30 repetitions using 50% of their estimated 1-repetition maximum on a leg press machine. Participants will NOT receive visual feedback for each repetition. This is the control condition.
214486685|NCT06379490|DRUG|Ropivacaine 0.2% Injectable Solution|30 ml of Ropivacaine 0.2% = 60 mg ropivacaine
214486686|NCT06379490|DRUG|Lidocaine epinephrine|30 ml of Lidocaine 1% with 5 μg/ml epinephrine = 300 mg lidocaine + 150 μg epinephrine
214486687|NCT06379490|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL of Ropivacaine 0.5% = 150 mg Ropivacaine
214486688|NCT05875701|BIOLOGICAL|NVX-CoV2373|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
214486689|NCT05875701|BIOLOGICAL|SARS-CoV-2 rS antigen/Matrix-M Adjuvant|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
214486690|NCT04548830|PROCEDURE|Transbronchial cryobiopsy|After enrollment, and pre-treatment procedures are complete, patients will undergo flexible bronchoscopy with a therapeutic bronchoscope under general anesthesia via an advanced airway at Memorial Hospital in an inpatient or outpatient setting.
214486691|NCT04799119|BEHAVIORAL|Do As I Do (DAID) dog training|Children and their family dog will participate in this dog training program.
214486692|NCT06507371|RADIATION|node-sparing modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
214304967|NCT00006202|DRUG|Lutein|
214486693|NCT06507371|DRUG|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
214486694|NCT06507371|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
214486695|NCT06507371|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
214486696|NCT06507371|RADIATION|standard short-course radiotherapy|radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx
214304968|NCT00298181|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
214304969|NCT03469479|DRUG|FOLFOX|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
214304970|NCT03469479|PROCEDURE|Hepatic resection|R0 resection
214304971|NCT05595889|DRUG|Surufatinib|250 mg/day p.o. QD
214304972|NCT05595889|DRUG|Irinotecan|Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
214304973|NCT04935112|DRUG|Sitravatinib|100 mg sitravatinib on Day 1
214304974|NCT04935112|DRUG|Pantoprazole|40 mg QD on Day 1 to Day 7 of Period 2 in Group 1
214486697|NCT05110261|DRUG|Nirsevimab|Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
214486698|NCT05110261|DRUG|Placebo|Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)
214486699|NCT05708534|DRUG|Belatacept|Switching from anticalcineurins to belatacept in a cohort of kidney transplant recipients seropositive for CMV
214486700|NCT05667610|OTHER|Immune-supportive diet|The intervention includes a immune-supportive diet over a period of 4 months
214304975|NCT04935112|DRUG|Famotidine|40 mg PO 2 hrs after sitravatinib in Period 2 of Group 2
214304976|NCT04977076|OTHER|Uninterrupted NOAC use|Continuing NOAC use in advance of elective CAG or PCI.
214304977|NCT04977076|OTHER|Interrupted NOAC use|Usual care, interruption of NOAC prior to procedure.
214914800|NCT01957098|DIETARY_SUPPLEMENT|Placebo comparator: 0% pentose|14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours
215059987|NCT03311581|DEVICE|Sevoflurane|sevoflurane inhalation 2\~4%
214304978|NCT05188651|BEHAVIORAL|face masks|wearing face masks
214304979|NCT01454570|DEVICE|powered exoskeleton|
215059988|NCT00553436|DEVICE|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
214304980|NCT04577287|DEVICE|Transcranial direct current stimulation|Cathodal/Anodal tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
214304981|NCT03333954|DEVICE|PRIMA|"The PRIMA Bionic Vision System is a device for treatment of patients who have lost their sight through outer retinal degenerative conditions of the eye such as atrophic dry age related macular degeneration.~The PRIMA System is designed to provide partial restoration of the patient's visual function through electrical stimulation of the retinal neurons by a sub-retinally implanted stimulator that replace part of the degenerate photoreceptors"
214304982|NCT01216579|OTHER|mannitol (an airway challenge agent)|
214304983|NCT01992861|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214304984|NCT01992861|PROCEDURE|Diffusion Weighted Imaging|Undergo DW MRI
214304985|NCT01992861|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
214304986|NCT01992861|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
214304987|NCT01992861|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
214304988|NCT01992861|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
214304989|NCT04018833|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|
214304990|NCT04018833|DRUG|Aflibercept 40 MG/ML Intraocular Solution [EYLEA]|
214304991|NCT02081482|RADIATION|18F-FDG PET|
214304992|NCT02905682|DRUG|Desmopressin|
214304993|NCT02905682|DRUG|Placebo|
214304994|NCT00783445|BEHAVIORAL|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
214304995|NCT00783445|BEHAVIORAL|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
214304996|NCT04342845|BEHAVIORAL|Experimental: Motivational interviewing Placebo Comparator: Traditional lectures|Patients in the intervention group (n=117) received a four-session patient empowerment program in small groups over one month by trained nurses and doctors. he control group received traditional lectures that consisted solely of conveying healthcare information to patients.
214479849|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
214486701|NCT05667610|OTHER|Standard care|Standard care: Peanut or nut free diet
214914801|NCT01957098|DIETARY_SUPPLEMENT|Active comparator: 4% D-xylose|
214914802|NCT01957098|DIETARY_SUPPLEMENT|Active comparator: 8% D-xylose|
214914803|NCT01957098|DIETARY_SUPPLEMENT|Active comparator: 8% L-arabinose|
214914804|NCT06410677|DIAGNOSTIC_TEST|DNA Sequencing, RNA Sequencing|"High-coverage Whole-Exome Sequencing sequencing of DNA samples from ESCC was performed.~RNA expression was analyzed using the NanoString PanCancer Immuno-Oncology 360TM Panel that includes a set of more than 700 genes involved in the main biological pathways of human immunity. These experiments were performed by the Genomics platform of Institut Curie. Total RNAs were used as templates."
214914805|NCT05433532|DRUG|Azacitidine|Azacitidine: 75mg/m2 qd, d1-d7, subcutaneous injection
214914806|NCT05433532|DRUG|Venetoclax|Venetoclax: 100mg d1, 200mg d2, 300mg d3, 400mg d4-d14 or 21, oral (Adjusted according to the peripheral blood BCR/ABL1 results on day 14)
214914807|NCT05433532|DRUG|Flumatinib|Flumatinib: 600mg qd, d4-d21, oral
214914808|NCT03702335|BEHAVIORAL|Dietary Counselling|Intervention group will be given a comprehensive dietary guidance on how to choose healthier options when eating out, as well as how to personally prepare a healthy meals.
214914809|NCT06369454|DRUG|Ritlecitinib|Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg) with 153Sm2O3
214914810|NCT06939959|DRUG|Artificial tear|commercially available artificial tears will be used consisting of same ingredients.
214914811|NCT06939959|DRUG|insulin human|injection humulin will be used to make topical insulin drops
214914812|NCT00801489|DRUG|Cytarabine|Given IV
214914813|NCT00801489|DRUG|Decitabine|Given IV
214914814|NCT00801489|BIOLOGICAL|Filgrastim-sndz|Given SC
214914815|NCT00801489|DRUG|Fludarabine Phosphate|Given IV
214914816|NCT00801489|DRUG|Gemtuzumab Ozogamicin|Given IV
214914817|NCT00801489|DRUG|Idarubicin|Given IV
214914818|NCT00801489|OTHER|Laboratory Biomarker Analysis|Correlative studies
214304997|NCT01561820|BEHAVIORAL|5-month aerobic exercise intervention|The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5\[HRmax-HRrest\]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
214304998|NCT00536107|DRUG|Gefitinib|250 mg oral
214304999|NCT00536107|PROCEDURE|CT or MRI|performed at screening and every 6 weeks
214305000|NCT00536107|DRUG|Docetaxel|60mg/m2 intravenous infusion
214305001|NCT02740166|DRUG|propranolol|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
214305002|NCT02975219|DRUG|Bevacizumab-800CW|4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
214305003|NCT03449160|DEVICE|UPRIGHT|A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day
214305004|NCT03449160|OTHER|physical therapy|routine physical therapy
214305005|NCT04455269|DEVICE|AIRFLOW® with PLUS® powder and PIEZON® scaler|Air-polishing will be use as main instrument for biofilm and stains removal, followed by ultrasonic scaling
214305006|NCT04455269|DEVICE|PIEZON® scaler and rubber cup with abrasive paste|Application of ultrasonic scaler on the entire dentition, followed by residual biofilm and stains removal and polishing
214305007|NCT02047357|OTHER|Learning Through Play Plus|Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
214479850|NCT04751851|BEHAVIORAL|Long duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
214479851|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.
214479852|NCT04751851|BEHAVIORAL|Long duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
215059989|NCT04900246|PROCEDURE|Visual Inspection|"The examiners will evaluate the surfaces included in the study independently and without knowledge of the results of the other examiner, after prophylaxis, using a mouth mirror and a WHO probe or Ball point. The evaluations will be carried out in a dental chair with the aid of a reflector. The teeth will be examined moist, and afterwards, they will be dried for 5 seconds with the use of a triple syringe.~For visual inspection, the International Caries Detection and Assessment System (ICDAS) evaluation system will be used. Complete ICDAS has seven categories, the first for healthy teeth (code 0) and the next two for limited enamel caries, white/brown stain (codes 1 and 2). The following two categories (codes 3 and 4) are considered to be caries that extend to the enamel without exposed dentin. And the two remaining categories (codes 5 and 6), are considered caries with exposed dentin."
214305008|NCT04426331|BEHAVIORAL|Voucher Without Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free."
214305009|NCT04426331|BEHAVIORAL|Voucher With Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free."
214305010|NCT03945474|OTHER|Sham|See description in sham arm.
214479853|NCT06269913|OTHER|FeSC|Iron/yeast complex
214305011|NCT03945474|OTHER|Osteopathic Manipulation, OMT|See description in OMT arm
214305012|NCT02278107|DEVICE|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
214305013|NCT02278107|DEVICE|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
214479854|NCT05288452|BEHAVIORAL|Digital Health Coaching|The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.
214479855|NCT05288452|DIETARY_SUPPLEMENT|Food Box Delivery|The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.
214914819|NCT00816998|PROCEDURE|Physical therapy|Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
214914820|NCT00816998|PROCEDURE|Physical Therapy|Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
214914821|NCT03092778|PROCEDURE|Cryoablation|"A computed tomography (CT) scan will be completed to map out where to insert the cryoablation needle. Numbing medicine will be used to numb the skin and deeper tissues before inserting the needle.~The cryoablation needle will be inserted and directed toward the target area of the vagal nerve. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle in place, the study doctor(s) will freeze the zone over 3 minutes, a 2 minutes thaw will follow, then 2 more cycles of 3 minutes freeze and 2 minute thaw will complete the procedure. This portion of the procedure can last from 25 to 35 minutes. Once the targeted area has been properly treated, the cryoablation needle will be withdrawn."
214914822|NCT02968173|DRUG|Palivizumab|Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.
214914823|NCT00161005|PROCEDURE|PCI|Immediate transport to invasive center after thrombolysis
214914824|NCT02670525|GENETIC|Leukemia Profiling|Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
214914825|NCT00124501|BEHAVIORAL|Biofeedback-assisted relaxation training|10 sessions BART
214305014|NCT02229942|DRUG|Rituximab|"Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months."
214305015|NCT02229942|DRUG|Placebo|Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
214305016|NCT04324580|OTHER|Splint|Participants will have their open reduction internal fixation of distal radius fractures treated with volar locked plating. for 2 weeks. Which will be replaced by a custom thermoplastic splint for 5 weeks.
214914826|NCT02125383|PROCEDURE|Active tDCS|Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
214914827|NCT02125383|PROCEDURE|Sham tDCS|Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
214305017|NCT04324580|BEHAVIORAL|Formal Physical Therapy|Participants will also receive a prescription for formal physical therapy. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks.
214305018|NCT04324580|BEHAVIORAL|Self directed physical therapy|Participants will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
214914828|NCT06305455|BIOLOGICAL|Escherichia coli ESBL|To evaluate the change in the resistance profile of infections of community origin caused by Escherichia coli, isolated from any culture material in patients admitted to the intensive care unit of a tertiary hospital.
214914829|NCT06174103|DEVICE|BiVACOR TAH System|The BiVACOR pump is an implantable rotary biventricular blood pump that uses magnetic levitation technology for increased durability to replace both ventricles of a failing heart. The device is intended to replace the diseased heart in patients suffering from heart failure to bridge the time to heart transplant.
214305019|NCT04324580|OTHER|Soft dressing (No Splint)|Participants will have their open reduction internal fixation of distal radius fractures placed in a soft dressing which will be kept in place for 2 weeks.
214305020|NCT05780619|DIAGNOSTIC_TEST|Transcranial Doppler|Measurement of resistance index on the middle cerebral artery (MCA) (index test) and the Holter (reference test). Patients will be randomized for order of tests
214305021|NCT05749198|DIAGNOSTIC_TEST|MRE|MRE was performed using a 3T system (Magnetom Skyra; Siemens, Erlangen, Germany) equipped with a combination of a 30-channel body and a 32-channel spine matrix coil.
214486702|NCT06037889|DRUG|Tirofiban|Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.
214486703|NCT06037889|DRUG|Aspirin tablet|Aspirin. Oral administration.
214486704|NCT06037889|DRUG|Clopidogrel tablet|Clopidogrel. Oral administration.
214305022|NCT03360370|OTHER|Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)|"This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.~It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities."
214305023|NCT02418507|DIETARY_SUPPLEMENT|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
214305024|NCT02418507|OTHER|Placebo|The placebo is administered to randomized healthy participants
214305025|NCT06470425|OTHER|Standard therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
214305026|NCT06470425|OTHER|AI-Guided group|Participants receive supplement prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
214305027|NCT03326973|BEHAVIORAL|EuroQoL EQ-5D-3L|Overall QOL
214305028|NCT03326973|BEHAVIORAL|EORTC QLQ-C30|General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales
214305029|NCT03326973|OTHER|PRO-CTCAE|Additional potential immune-specific symptoms
214305030|NCT03326973|BEHAVIORAL|Fatigue severity score questionnaire|Fatigue severity
214305031|NCT03326973|BEHAVIORAL|The COST|Financial toxicity; satisfaction with ability to work
214305032|NCT03326973|BEHAVIORAL|Physician information|Details on outside health providers
214305033|NCT01628601|DRUG|Fixed combination 0.3 mg bimatoprost and 5 mg timolol|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
214305034|NCT00791466|DIETARY_SUPPLEMENT|Placebo|Daily placebo supplementation from enrolment \<14 wk of gestation until delivery
214305035|NCT00791466|DIETARY_SUPPLEMENT|Iodine|Daily supplementation with 200 µg iodine from enrolment \<14 wk of gestation until delivery
214305036|NCT00523250|DRUG|AR-102 0.003% Ophthalmic Solution|
214479856|NCT05288452|BEHAVIORAL|Remote Patient Monitoring (RPM)|The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
214479857|NCT05288452|BEHAVIORAL|Diabetes Education Class|The diabetes education class will be administered by a certified diabetes educator.
214914830|NCT05823935|PROCEDURE|Bakay purse string|After developing the bladder flap, Vicryl polyglactin 910 sutures (Ethicon, Inc, Somerville, NJ) will be placed on the line between the cervicovaginal junction and the bladder starting at either 4 to 3 o'clock or 8 to 9 o'clock, as anchor sutures. Paying attention not to get closer than 1 cm to the bladder, the first suture will be passed from 4 o'clock to 3 o'clock and continued circumferentially in a full-thickness purse string fashion through 3, 1, 10, 8, 7, 5 o'clock completing a circle while including both uterosacral ligaments.
214914831|NCT05823935|PROCEDURE|Cuff closure via vaginal route group|After the uterus will be removed via vaginal route, vaginal cuff ends will be grasped via vaginal approach and sutured continuous locked sutures using Vicryl polyglactin 910 sutures in one layer.
214305037|NCT00523250|DRUG|AR-102 0.005% Ophthalmic Solution|
214305038|NCT00523250|DRUG|AR-102 0.01% Ophthalmic Solution|
214305039|NCT00523250|DRUG|AR-102 0.03% Ophthalmic Solution|
214305040|NCT00523250|DRUG|AR-102 Vehicle Ophthalmic Solution|
214305041|NCT04122092|DIAGNOSTIC_TEST|The level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
214305042|NCT05864508|DRUG|Oxytocin nasal spray|intranasal oxytocin treatment once a day during 6 weeks
214305043|NCT02814123|OTHER|24-hour inpatient intervention|Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
214305044|NCT01729507|OTHER|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
214305045|NCT01729507|BEHAVIORAL|standardised behavioural therapy|"The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session."
214305046|NCT04528082|DRUG|Apremilast|Participants will receive apremilast orally.
214305047|NCT04528082|DRUG|Placebo|Participants will receive the matching placebo orally.
214305048|NCT05953454|OTHER|Pain neuroscience Education|A pain neuroscience education session geared towards fear-avoidance beliefs
214305049|NCT03695510|DRUG|Afatinib Oral Tablet|40mg oral, daily, continuously
214305050|NCT03695510|DRUG|Pembrolizumab Injection|200mg, intra-venous injection, every 3 weeks, for 35 cycles
214305051|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months)
214305052|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)
214305053|NCT01154621|DRUG|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
214305054|NCT01154621|DRUG|Placebo|Sterile 5% dextrose solution
214305055|NCT01895660|BEHAVIORAL|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
214305056|NCT00625859|DRUG|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
214305057|NCT00625859|DRUG|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
214305058|NCT00625859|DRUG|Placebo|Placebo tablets will be given to subjects.
214305059|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-087|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
214305060|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-088|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
214305061|NCT00862810|BIOLOGICAL|Received HPV vaccine first|
214305062|NCT00862810|BIOLOGICAL|Received concomitant vaccines first|
214305063|NCT01768351|DRUG|Paricalcitol|Zemplar cp 1 mcg/day per os
214305064|NCT01768351|DRUG|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
214305065|NCT02246673|DRUG|RDEA3170 15 mg|
214914832|NCT05503537|PROCEDURE|post-isometric relaxation technique|Post-isometric relaxation technique will be performed by asking the patient to contract his calf muscles using 20% of his strength. Maintain the contraction for 10 second with 15 second of rest time between each contractions. A total of 4 contractions will be performed.
214305066|NCT02246673|DRUG|RDEA3170 10 mg|
214305067|NCT02246673|DRUG|RDEA3170 2.5|
214305068|NCT02246673|DRUG|RDEA3170 5 mg|
214305069|NCT02246673|DRUG|Febuxostat 40 mg|
214305070|NCT02246673|DRUG|Febuxostat 80 mg|
214305071|NCT01555268|BIOLOGICAL|trebananib|Given IV
214305072|NCT01555268|DRUG|cytarabine|Given SC
214305073|NCT01555268|OTHER|laboratory biomarker analysis|Correlative studies
214305074|NCT01555268|OTHER|pharmacological study|Correlative studies
214305075|NCT03911895|DEVICE|Stent more than 26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
214914833|NCT05503537|PROCEDURE|Static stretching|Static stretching will be performed by asking patient to perform dorsiflexion till the point of discomfort. The patient will hold the stretch for 15 second and 5 repetitions will be performed.
214914834|NCT05503537|PROCEDURE|Basic Cardiac Rehabilitation Protocol|Ankle pumps, leg slides, walking
214914835|NCT00107861|DRUG|Ad.hIFN-β (BG00001, IDEC-201)|
214914836|NCT02939677|OTHER|Targeted exercise|"12 weeks of targeted and supervised exercise intervention vs. care as usual (home based exercises)"
214914837|NCT01195311|DRUG|INCB024360|INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
214914838|NCT02245009|PROCEDURE|Cardioversion|
214914839|NCT06257654|DEVICE|REZUM|The 3rd and 12th month follow-ups of the patients who underwent REZUM operation were evaluated.
214914840|NCT03858751|DRUG|Placebo oral capsule|Placebo capsule before bedtime
214305076|NCT03911895|DEVICE|Stent equal to or less than26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
214305077|NCT01199744|DRUG|zanamivir|zanamivir
214305078|NCT04567875|OTHER|No Intervention on patients|No Intervention on patients
214305079|NCT03329495|PROCEDURE|SMA-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.
214305080|NCT03329495|PROCEDURE|SMV-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.
214305081|NCT04318236|BEHAVIORAL|HERMES (Online Self-Help Intervention based on problem-solving therapy)|"The Online Self-Help Intervention is an online program based on the problem-solving therapy (an evidence based approach of psychotherapy). All participants will receive the exact same intervention.~However, what will be experimentally varied are the four listed interventions."
214305082|NCT02507635|DRUG|Levocetirizine|administration of Levocetirizine 5 mg/day for 4 weeks
214305083|NCT02507635|DRUG|Desloratadine|administration of Desloratadine 5 mg/day for 4 weeks
214305084|NCT04361162|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
214305085|NCT04361162|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
214305086|NCT04361162|RADIATION|Radiation|3D Conformal Radiotherapy to shrink or kill tumors
214305087|NCT03211949|PROCEDURE|axillary block|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
214914841|NCT03858751|DRUG|LTM1201AZ|LTM1201AZ oral capsule before sleep
214914842|NCT03858751|DRUG|LTM1201AT|LTM1201AT oral capsule before sleep
214914843|NCT03858751|DRUG|LTM1201AG|LTM1201AG oral capsule before sleep
214914844|NCT03858751|DRUG|LTM1201AD|LTM1201AD oral capsule before sleep
214914845|NCT01554527|PROCEDURE|CPAP treatment|6 months of treatment with PAP (CPAP or BPAP)
214914846|NCT01554527|OTHER|No CPAP treatment|Children randomized to the comparison group will receive routine care
214914847|NCT00755027|DRUG|Rasagiline|rasagiline 1 mg daily, oral use, during 12 weeks
214914848|NCT05630573|BIOLOGICAL|TNM001|intramuscular injection
214914849|NCT05630573|BIOLOGICAL|Placebo|intramuscular injection
214914850|NCT01052480|BIOLOGICAL|Anti-Influenza Immune Plasma|2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
214305088|NCT03211949|DRUG|Scandicaine|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
214479858|NCT05174650|DRUG|Atezolizumab|Infusion i.v. of atezolizumab on day 1 of a 3-week cycle, first infusion rate over 60 minutes, subsequent infusion rates 30 minutes if tolerated for a maximum of 20 cycles in total
214479859|NCT05174650|DRUG|Derazantinib|Oral intake of 300 mg derazantinib continuously on day 1 to day 21 of a 3-week cycle for a maximum of 20 cycles in total
214914851|NCT01052480|DRUG|Standard Care|All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
214305089|NCT05133219|OTHER|Occupational Therapy|Occupational therapy is the only profession that helps people across the lifespan to do the things they want and need to do through the therapeutic use of daily activities (occupations). Occupational therapy practitioners enable people of all ages to live life to its fullest by helping them promote health, and prevent-or live better with-injury, illness, or disability.
214305090|NCT06387992|OTHER|Three-dimensional dental acquisition|Consultation with a trained nurse who will perform a three-dimensional dental acquisition using a 3D intraoral camera
214305091|NCT02488655|DEVICE|Echopulse|HIFU Under ultrasound guidance
214305092|NCT03344042|DRUG|Fentanyl|100mcg Fentanyl
214479860|NCT06543667|BIOLOGICAL|Limbal Stem Cell Derived Exosomes Eye Drop|Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drops 0.15 ml/single eye/one time, four times a day for 3 months. The follow-up visit will be 12 weeks since the administration of LSC-Exo eye drops.
214479861|NCT04338581|BIOLOGICAL|AMG 714|anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)
214479862|NCT04338581|BIOLOGICAL|Placebo|Placebo for AMG 714
214479863|NCT04338581|PROCEDURE|nbUVB phototherapy|Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.
214479864|NCT06317038|DEVICE|Total 30 Contact Lens|Patients will be give a contact lens for 1 month
214479865|NCT06949462|OTHER|PEAR|"Participants in the intervention arm will receive anaesthesia risk counselling through the PEAR (Patient Education of Anaesthesia Risks) chatbot prior to their face-to-face consultation with an anaesthetist. PEAR is a multilingual, AI-powered conversational tool designed to provide personalized, interactive education on anaesthesia-related procedures, risks, and safety information.~The chatbot delivers content aligned with institutional guidelines and allows patients to explore topics at their own pace, ask questions in natural language, and revisit information as needed. After completing the chatbot interaction, patients proceed with their standard preoperative consultation, where any further questions are addressed by the anaesthetist.~This approach is designed to enhance patient understanding, reduce anxiety, and optimize the in-person consultation by preparing patients in advance."
214914852|NCT02284776|BEHAVIORAL|Therapeutic education|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
214914853|NCT04229862|PROCEDURE|Laryngeal mask airway insertion|Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection
214914854|NCT02345980|DRUG|Sildenafil|
214914855|NCT02345980|DRUG|Placebo|
215059990|NCT04900246|RADIATION|BWX Radiographic Assessment|Participants will be radiographed with a digital X-ray device (DIOX-602, Micro Imagem, Indaiatuba, Brazil) with a regulation of 60 kV and 2 mA and exposure time of 0.10s. The technique used will be the interproximal/bitewing (BWX), with the FIT T1 Digital Sensor (external dimensions: 36.7mm x 24.3mm/sensitive area dimensions: 30.0mm x 20.0mm - 600mm²) and the sockets will be standardized with use of Han-Shin radiographic positioners (Jon, São Paulo, Brazil).
214305093|NCT03344042|DRUG|Sufentanil|10mcg sufentanil
214305094|NCT03501758|DIAGNOSTIC_TEST|Ultrasound|Transabdominal ultrasound of the bowel for categorisation of disease activity
214305095|NCT03501758|DIAGNOSTIC_TEST|Analysis of prouroguanyline and uroguanyline in full blood|Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
214305096|NCT04829773|DRUG|Palovarotene|oral capsules
214305097|NCT04829773|DRUG|midazolam|oral syrup
214305098|NCT02716558|OTHER|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
214305099|NCT02716558|OTHER|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
214914856|NCT05415176|DIETARY_SUPPLEMENT|Taurine supplementation|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
214305100|NCT04356963|BEHAVIORAL|Virtual Reality Session (VR Blu)|20-30 minute session of virtual reality immersive content.
214305101|NCT04356963|BEHAVIORAL|Tablet-based Session (Tablet Blu)|20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.
214305102|NCT04356963|BEHAVIORAL|Use of Virtual Reality Head Mounted Display without Content (VR Blank)|20-30 minutes session using head mounted display to reduce light and sound.
214305103|NCT00017264|DRUG|atrasentan hydrochloride|
214479866|NCT06953739|DRUG|P-GEMD|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (12 mg/m2) on day 1, every 3 weeks; Drug: Pegaspargase Pegaspargase(3750 IU) on day 2, every 3 weeks; Drug: Gemcitabine Gemcitabine (1000 mg/m2) on day 1, every 3 weeks; Drug: Etoposide Etoposide (65 mg/m2) on day 2-4, every 3 weeks. Drug: Dexamethasone Dexamethasone (40 mg/d) will be taken orally from day 1-4, every 3 weeks; Patients \> 65 years of age may be adjusted according to the investigator's decision.
214479867|NCT06953739|DRUG|P-Gemox|Drug: Pegaspargase Pegaspargase(2000-2500 IU/m2) on day 1, every 3 weeks; Drug: Gemcitabine Gemcitabine (1000 mg/m2) on day 1 and day 8, every 3 weeks; Drug: Oxaliplatin Oxaliplatin (130mg/m2) on day 1, every 3 weeks; Patients \> 65 years of age may be adjusted according to the investigator's decision.
214479868|NCT04756076|DIAGNOSTIC_TEST|Metal level measurements|Measure multiple metal levels
214479869|NCT02267993|DRUG|recombinant human thrombopoietin|Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of \< 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
214479870|NCT06420440|PROCEDURE|Hepatic arterial infusion chemotherapy|Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days)
214479871|NCT06420440|DRUG|Lenvatinib|Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued approximately two weeks before surgery, Oral 8 mg or 12mg once a day depending body weight).
214479872|NCT06420440|DRUG|Tislelizumab|Patients in the neoadjuvant therapy group received two cycles of Tislelizumab therapy before surgery (First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)
214479873|NCT06420440|PROCEDURE|Liver resection|Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.
214479874|NCT06420440|DRUG|Tislelizumab|Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.
214479875|NCT06783660|DEVICE|Peptide-loaded collagen sponge and collagen gel complex|A piece of peptide-loaded collagen sponge (Regenomer®) and collagen gel complex
214479876|NCT06783660|DEVICE|Collagen sponge|Type 1 Collagen sponge (Regenomer)
214479877|NCT05794399|DRUG|Rivaroxaban|"Intervention Group:~The patients in the intervention group will be treated with Rivaroxaban 20 mg once daily with the evening meal in patients with a CrCl \>50 mL/min OR 15 mg in cases of moderate-to-severe renal impairment dose with the dosing of once daily with the evening meal in patients with a CrCl ≤50 mL/min. The patient in the intervention group will be requested for follow-up after 3 months of commencing the treatment or whenever the signs and symptoms of bleeding events are noted."
214479878|NCT05794399|DRUG|Warfarin|"Control Group:~The patients in the control group will be treated with Warfarin. The dose will be started with 5 mg and will be titrated based on the International Normalized Ratio (INR) which will be targeted at the range of 2.0 to 3.0. The dual antiplatelet duration will be based on the latest guidelines. The patients will be asked for frequent INR monitoring on an OPD basis until the INR is within the therapeutic range, after which patients will be asked for monthly follow-up INR reports. The patients in the control group will not be treated with heparin or low molecular weight heparin before the INR is maintained in the therapeutic range."
214479879|NCT06784141|BEHAVIORAL|personalized Cognitive Behavior Therapy including third-wave|In the personalized CBT, patients first complete 21 days of EMA with six assessment points daily to assess relevant processes of CPP models. Person-specific networks are estimated based on the EMA data. A network-based algorithm indicates the treatment target. The individual CBT modules are selected for the participants from a matching matrix that contains experts' module recommendations for specific treatment targets. After that, participants will receive one out of ten CBT modules addressing their treatment target. All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behavior Therapy, Acceptance and Commitment Therapy or Mindful Selfcompassion.
214479880|NCT06784141|BEHAVIORAL|standardized Cognitive Behavior Therapy including third-wave|The standardized CBT intervention is manual-based and contains five sessions of cognitive behavioral therapy. Based on the evaluated manual from EFFECT Back, a short version with 5 modules is used: attention control, relaxation techniques, behavioral activation, cognitive strategies, and consolidation.
214479881|NCT02313623|PROCEDURE|Prostate Fusion Biopsy|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
214479882|NCT05064514|DEVICE|Transcatheter Tricuspid Valved Stent Graft|All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.
214479883|NCT05770375|DRUG|MDMA 40mg|MDMA 40mg
214479884|NCT05770375|DRUG|MDMA 80mg|MDMA 80mg
214479885|NCT05770375|DRUG|MDMA 120mg|MDMA 120mg
214479886|NCT06058897|OTHER|MRI|MRI examinations will be conducted on the 3T MRI technical platform. During the MRI examination, images reflecting the integrity of the LC (quantification of neuromelanin as well as its functional connections with the different brain regions (resting functional MRI) will be acquired. High-resolution T1 and T2 weighted images of the the entire brain will also be acquired for the volumetry of cerebral areas.
214305104|NCT02285907|OTHER|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
214479887|NCT06058897|OTHER|eye-tracking|Eye tracking examinations will be conducted using an EyeBrain medical device (class IIa) developed by Suricog. This eye tracker will be installed in a box, in an experimental room. The eye tracker is combined with a computer to present visual cognitive tasks. Pupillary dilation/constriction measurements will be acquired at rest (when fixing a cross presented on the screen) and during the performance of different cognitive tasks (exploration and processing of scenes visuals, reading texts, making saccades or anti-saccades when presenting visual targets). These pupillary measurements will then be linked to the memorization of the stimuli presented, this recognition being tested at the end of the exam.
214479888|NCT06058897|OTHER|cognitive exams|Cognitive measures will be acquired during an evaluation session through interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare (Covirtua Cognition software). Some exercises will test cognitive systems a priori dependent on NA release (episodic memory, working memory, selective attention, selective inhibition, planning) and other a priori independent of NA (semantic memory: categorization, naming).
214305105|NCT02285907|OTHER|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
214305106|NCT02285907|OTHER|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
214305107|NCT02285907|OTHER|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
214305108|NCT04834947|PROCEDURE|prone position|Choice of prone positioning a patient is at the discretion of the anesthesia physician.
214305109|NCT01361438|OTHER|Total therapy approach|Total therapy approach
214305110|NCT04222569|PROCEDURE|T-piece|Spontaneous breath trial with a T-piece
214305111|NCT04222569|PROCEDURE|PSV 7 and PEEP 0|Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure
214479889|NCT06055322|BEHAVIORAL|Adapted Dialectical Behavior Therapy|DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
214479890|NCT05056818|OTHER|Electronic Health Record Review|Review of medical records and past imaging examinations
214479891|NCT05977673|DRUG|Tislelizumab|Tislelizumab 200mg IV day1
214914857|NCT05415176|OTHER|Pshysical exercise|Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks
214914858|NCT05415176|OTHER|Placebo control|The participants will receive a supplementation capsule containing placebo in the morning in single-dose capsules. The intervention will last 16 weeks.
214914859|NCT01707160|DRUG|biphasic insulin aspart 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
215059991|NCT04900246|DEVICE|Assessment of the iTero Element 5D scan|For scanning, the iTero 5D (Align Technology) equipment featuring NIRI Technology will be used. The Infrared Imaging Technology (NIRI) is a diagnostic tool that allows the detection of interproximal and occlusal caries in several stages, from the initial enamel caries to lesions in the amelo-dentin junction, without the use of ionizing radiation. Infrared is the region of the electromagnetic spectrum between 0.7 and 2.0 micrometers (µm). The iTero Element 5D imaging system uses wavelength light (= 850 nm) in an electromagnetic spectrum that, in interaction with the hard tooth tissue, provides additional data on its structure.
214305112|NCT04222569|PROCEDURE|PSV 0 and PEEP 0|Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator
215059992|NCT00133263|BEHAVIORAL|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
214305113|NCT02726074|DRUG|Perampanel|
214305114|NCT05063110|DRUG|Itacitinib|Administration of 300 mg of ITACITINIB per os every day for 30 days.
214305115|NCT06448559|OTHER|Semi-directive interview|Semi-directive interviews are individual interviews used in a qualitative approach to collect information in order to perform a thematic analysis
214305116|NCT03547388|DEVICE|Moderate whole body hyperthermia using water-filtered IR-A-radiation|four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
214305117|NCT01356797|DRUG|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
214305118|NCT01356797|DRUG|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
214305119|NCT04790032|DRUG|Cangrelor|All patients receiving Cangrelor during PCI will be enrolled and analyzed for platelet function tests.
214305120|NCT01679002|DRUG|BIA 2-093|
214305121|NCT01679002|DRUG|Oxcarbazepine|
214305122|NCT05051189|DRUG|Fentanyl Citrate|Ventilatory response to fentanyl in patients with OSA Specifically: respiratory changes, CO2, RR, TV
214305123|NCT00205426|DRUG|Natrecor|Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
214305124|NCT06490263|DRUG|Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects|Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.
214305125|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with single dose in healthy subjects|Parts Two: Administered by swallowing after meals with four distinct dosage groups.
214305126|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
214305127|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
214305128|NCT06092099|DEVICE|TENA SmartCare Change Indicator|The TENA SmartCare Change Indicator is an accessory to absorbent incontinence products, intended for use on individual(s) with urinary incontinence who are dependent on one or more caregivers to change the absorbent incontinence product. The TENA SmartCare Change Indicator estimates the degree of urine saturation in the absorbent incontinence product and notifies the caregivers. This facilitates the caregiver's decision regarding when to change the absorbent incontinence product. As the current study is needed to validate the updated device, the full system will not be used, only the sensor part.
214305129|NCT06527131|DEVICE|pulsed electromagnetic field therapy|PEMF is regarded as an efficient physical therapy method that has been utilized clinically to treat a variety of orthopedic conditions, including delayed union and nonunion of fractures. According to studies, PEMF has been authorized for its biological effects, which include the mineralization of bone matrix, osteogenic differentiation of mesenchymal stem cells, and osteoblast proliferation
214305130|NCT06527131|DEVICE|Transcutanous electrical nerve stimulation|Electrical stimulation consider a safe and cost-effective method for pain management. It has no side effects and few contraindication in addition to no drug interaction . According to studies ,electrical stimulation decreases pain through reducing central transmission of pain signals because of nociceptive inhibition at the presynaptic level in the dorsal horn.
214305131|NCT06527131|DRUG|Vancomycin|medical antibiotics
214305132|NCT04287712|DIAGNOSTIC_TEST|Plasma lipids|Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
214305133|NCT06162442|DRUG|Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)|"The procedures during the study consist of ophthalmological activities and attention to the participating subject with a diagnosis of DED and who starts using a specified ocular lubricant, free of preservatives. The ophthalmologist will notify the subject of the wash out, which will consist of suspending the usual treatment medication for 7 days, to then start with the lubricant Glicolub Ultra®, with a dosage of 1 drop every 6 hours in both eyes. Self-assessment questionnaires will be delivered for their respective completion. An assessment will be made by the comprehensive ophthalmologist in all clinical tests for dry eye with a mild to moderate diagnosis, under compliance with the TOSF DEWS II criteria and study inclusion criteria."
214305134|NCT05434806|DIETARY_SUPPLEMENT|Jarlsberg cheese|Daly oral intake
214305135|NCT01176266|DRUG|asfotase alfa|
214914860|NCT01707160|DRUG|biphasic human insulin 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
214914861|NCT05364866|DRUG|Antiarrhythmic drug Therapy|Propafenone, Sotalol and Amiodarone
214914862|NCT05364866|DEVICE|cryoballoon ablation|Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters including 23mm and 28mm.
214914863|NCT04535492|BEHAVIORAL|Decision Making Support Tool|Primary care practices randomized in a stepped wedge cluster design will implement a newly developed predictive model and analytic tool to improve shared decision-making for patients.
214914864|NCT06136273|BEHAVIORAL|Treatment measures and intervention strategies|To conduct observational process improvement and hypothesis-deriving studies related to penetrating traumatic injuries using data from the Methodist trauma registry and open source data repositories.
214914865|NCT01707173|BEHAVIORAL|Tailored education|Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information
214305136|NCT02229136|DRUG|Miracle Mouthwash Plus Hydrocortisone|Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
214305137|NCT02229136|DRUG|Prednisolone|Prednisolone oral solution 15 mg/5 ml
214305138|NCT04398069|PROCEDURE|hemodynamic optimisation aiming to achieve normal cerebral perfusion|hemodynamic optimisation aiming to achieve normal cerebral perfusion: titration of catecholamin infusion.
214305139|NCT05263700|DRUG|68Ga-FAPi-46|FAPI-46 is a small molecular radiopharmaceutical that binds to the fibroblast activated protein on cancer associated fibroblasts. Gallium-68 (68Ga) is a positron-emitting isotope with a half-life of 68 minutes.
214305140|NCT05263700|PROCEDURE|PET/CT imaging|PET with the investigational tracer 68Ga-FAPI-46 with accompanying low-dose CT for anatomical localisation
214305141|NCT01140321|DRUG|Neridronate|"Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta."
214914866|NCT01707173|BEHAVIORAL|Standard Education|Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices
214914867|NCT03898791|DRUG|LY3295668 Erbumine|oral capsules
214914868|NCT00529373|DRUG|Odanacatib|50 mg tablet orally once weekly (OW)
214914869|NCT00529373|DRUG|Placebo for Odanacatib|50 mg tablet orally OW
214914870|NCT00529373|DIETARY_SUPPLEMENT|Vitamin D3|5600 IU orally OW
214914871|NCT00529373|DIETARY_SUPPLEMENT|Calcium carbonate|If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
214479892|NCT02246127|DRUG|Drug: Everolimus|10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
214479893|NCT02246127|DRUG|STZ-5FU|"0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops."
214479894|NCT05257772|DEVICE|AV Delay Optimised RV Pacing|AV Delay Optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems) and Echo to assess LVOT gradient change.
214479895|NCT06283108|DEVICE|Standard Child Life Preparation and Support + Meta Quest 2 VR headset with Gurney Journey (a mixed reality experience)|Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental or gastrointestinal procedure. Child life specialist's will utilize Gurney Journey as part of their support for induction. Gurney Journey is a mixed reality experience, using the Meta Quest 2 VR headset that was designed to mitigate patient anxiety during transport from pre-admission rooms to the procedure room/operating room for surgical procedures.
214479896|NCT06283108|BEHAVIORAL|Standard Child Life Preparation and Support|Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental procedure.
214479897|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
214305142|NCT03265197|DRUG|Intra-tympanic injection of drugs|Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
214305143|NCT03265197|OTHER|Data management of intratympanic drugs|intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
214479898|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Placebo group will have sham treatment by standing on the LMHFV platform for 20 minutes/day
214479899|NCT06952829|OTHER|evaluation of intravenous access of patients with Adult-Difficult IntraVenous Access (A-DIVA) score prior to puncturing subject|The patient's intravenous access will be evaluated using the A-DIVA score by the study nurse at the time of admission, prior to venipuncture performed by the care nurse
214479900|NCT06952829|OTHER|evaluation of intravenous access of patients with modified Adult-Difficult IntraVenous access(A-DIVA modified) score prior to puncturing subject|The patient's intravenous access will be evaluated using the A-DIVA-m score by the study nurse at the time of admission, prior to venipuncture performed by the care nurse
214479901|NCT06295263|OTHER|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups
214914872|NCT01094574|DRUG|Alfentanil|An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.
214914873|NCT01094574|DRUG|Propranolol|An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.
214914874|NCT01094574|DRUG|Placebo|An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
214914875|NCT03692286|COMBINATION_PRODUCT|Silver nanoparticle/Calcium hydroxide|Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide
214914876|NCT03692286|DRUG|Silver Nanoparticles in gel form|Intracanal medication composed of silver nanoparticles in gel form
214914877|NCT03692286|DRUG|Calcium Hydroxide Intracanal medication|Calcium hydroxide intracanal medication
214479902|NCT04998305|DRUG|TJ-68|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of TJ-68 for three times per day before meals. It will be administered by dissolving 2.5 g of TJ-68 powder in 1 oz. of lukewarm water.
214479903|NCT04998305|DRUG|Placebo|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of placebo for three times per day before meals. It will be administered by dissolving 2.5 g of the placebo powder in 1 oz. of lukewarm water.
214479904|NCT05299346|OTHER|Follow up|Comprehensive follow up in dedicated follow up unit
214479905|NCT06172374|GENETIC|Sano Genetics Testing Kit|Genetic testing spit collection tubes for DNA testing
214479906|NCT05862909|OTHER|CHD-specific web-based emotion regulation intervention|CHD-specific web-based emotion regulation intervention with ten video-based sessions covering emotional challenges of CHD and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in the daily life of patients with CHD, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
214486705|NCT06965257|OTHER|Continuous non-invasive blood pressure monitoring|Addition prior to anaesthetic induction of the non-invasive monitoring device (digital sleeve available at the investigation site) for blood pressure measurement on the side ipsilateral to the arterial catheter
214914878|NCT03273101|DEVICE|Mechanical assisted sit-to-stand training group|Mechanical assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
214914879|NCT03273101|OTHER|Manual assisted sit-to-stand training group|Manual assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
214305144|NCT02413541|PROCEDURE|Polymyxin-B Hemoperfusion|Endotoxin removal
214305145|NCT02413541|PROCEDURE|Standard treatment|
214305146|NCT04783805|DIAGNOSTIC_TEST|Conservative management with regular follow-up|Women will be followed-up every 4 months, with colposcopy and cytology at each visit.
214305147|NCT04783805|PROCEDURE|Conization|Women with progression of HSIL, HSIL persistence after 24 months of follow-up, or that no longer meet the criteria for surveillance will have conization
214305148|NCT00814086|DRUG|Paclitaxel|Given IV or intraperitoneally
214305149|NCT00814086|DRUG|Cisplatin|Given intraperitoneally
214305150|NCT01756495|DRUG|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
214305151|NCT01756495|DRUG|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
214914880|NCT01863667|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
214914881|NCT01863667|DRUG|Glimepiride|Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
214305152|NCT01756495|DRUG|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
214305153|NCT01756495|DRUG|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
214305154|NCT03163888|PROCEDURE|Navigation TKR|Traditional over Conventional TKR
214914882|NCT01863667|DRUG|Omarigliptin Placebo|Matching placebo to omarigliptin capsule administered orally once weekly
214914883|NCT01863667|DRUG|Glimepiride Placebo|Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
214305155|NCT01179477|DEVICE|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
214305156|NCT00189228|DRUG|Xolair|Patients are administered Xolair
214305157|NCT03031808|DRUG|Lidocaine spray (2%)|Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes
214305158|NCT03031808|DRUG|Muscle Relaxant (Rocuronium)|After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
214305159|NCT03031808|OTHER|No Muscle relaxant, no Lidocaine|This group get general anesthesia without Rocuronium or Lidocaine
214305160|NCT05601323|DEVICE|Suizenji|HIFU treatment
214305161|NCT05601323|DRUG|Nal-IRI/FL|Nanoliposomal irinotecan, Fluorouracil, Levofolinate
214914884|NCT02539940|DEVICE|Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV|Angioplasty for revascularization in below-the-knee arteries
215059993|NCT00133263|BEHAVIORAL|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
214305162|NCT05601323|DRUG|mFOLFIRINOX|Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
214305163|NCT05601323|DRUG|Gem/nab-PTX|Gemcitabine, nab-Paclitaxel
214305164|NCT00152581|DRUG|Pegylated interferon-alfa2a (Pegasys); ribavirin|
214305165|NCT06529731|DRUG|Interferon gamma-1b|ACTIMMUNE/Interferon gamma-1b is a single-chain polypeptide containing 140 amino acids that is produced by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the recombinant protein. Interferon gamma-1b is part of a drug regimen used to treat Chronic Granulomatous Disease, or CGD. CGD is a genetic disorder, usually diagnosed in childhood, that affects some cells of the immune system and the body's ability to fight infections effectively.
214305166|NCT06529731|BIOLOGICAL|Donor Leukocyte Infusion (DLI)|Donor lymphocyte infusion is a procedure that transfers healthy white blood cells (lymphocytes) from a bone marrow or stem cell donor to a recipient's blood. An infusion of healthy lymphocytes helps the recipient's immune system get rid of remaining cancer cells if they have a relapse after a bone marrow or stem cell transplant for blood cancer.
214305167|NCT05980520|DIETARY_SUPPLEMENT|Taurine+corn starch+white sugar|Taurine granules mixed with corn starch and white sugar, 0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day. The use of taurine is strictly in accordance with the specifications of Chinese Pharmacopoeia.
214305168|NCT05980520|DIETARY_SUPPLEMENT|Corn starch+white sugar|0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day.
214305169|NCT05980520|BEHAVIORAL|Behavioral rehabilitation therapy|Structured training courses which included: visual arrangement, routine, environmental arrangement, program schedule, personal work system consists of five parts. The course is designed and implemented by qualified behavioral rehabilitators who have worked for more than 5 years, with the participation of parents. The daily training time is about 6-8 hours, and the total intervention time is not less than 40 hours per week.
214479907|NCT05862909|OTHER|General web-based emotion regulation intervention|General web-based emotion regulation intervention with ten video-based sessions covering topics related to emotional awareness and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in daily life, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
214914885|NCT03481972|DRUG|Doxycycline and tauroursodeoxycholic acid|doxycicline and tauroursodeoxycholic acid
214914886|NCT03481972|DRUG|Standard of care|Standard of care
214914887|NCT03236467|BEHAVIORAL|Progressive Exercise Training|Designed to ease primarily sedentary individuals into exercise training, increasing in intensity up to 80% of maximum Heart Rate Range over time.
214914888|NCT05949346|BEHAVIORAL|Multiple Family Narrative Therapy (MFNT)|MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.
214914889|NCT05949346|BEHAVIORAL|School services for families of children with Dyslexia|Selected school personnel will deliver services as usual for the control group.
214914890|NCT02687568|OTHER|EEG monitoring|Value of EEG monitoring as adjunct to standard monitoring
215059994|NCT01595971|BEHAVIORAL|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
215059995|NCT01595971|OTHER|usual care|Received the usual care provided
215059996|NCT01519544|DRUG|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
215059997|NCT01519544|DRUG|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
214305170|NCT04188652|OTHER|Detailed symptomregistration|Information on symptoms, specialized ultrasound in accordance to IOTA, and HE4 is registered in women with ovarian cysts. Participation in the study including symptom registration, description of the cyst using IOTA terminology, and HE4 determination will not affect further diagnostics or treatment. HE4 will not be informed to the patient or clinician.
214479908|NCT04611113|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
214479909|NCT04611113|DIETARY_SUPPLEMENT|Control Nutritional Support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
214914891|NCT03627546|OTHER|Rapid Treatment strategy|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during 12 weeks of provided sofusbuvir/velpatasvir treatment."
214914892|NCT03627546|OTHER|Usual Care (facilitated referral)|articipants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then followed separately. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
214914893|NCT03045263|BEHAVIORAL|Pivotal Response Treatment|Behavioral intervention for autism
214914894|NCT06511635|OTHER|Qualitative interview|Interview between participant and a researcher, in order to identity the determinants of participation in a clinical trial among participants in the CMVictory vaccine trial.
214914895|NCT06511635|OTHER|Quantitative questionnaire|Anonymous online survey using a 3-part questionnaire, studying knowledge of clinical research and the determinants of participation in a preventive vaccine study in a population of young women (aged 18-40).
214914896|NCT02822014|OTHER|FDG-PET/CT|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
214914897|NCT00184886|DRUG|Methotrexate 15 mg/week for 12 weeks|
214914898|NCT05804214|OTHER|Dairy and plant based infant formula feeding|Parents have already decided to feed their infant with the product (a dairy and plant based infant formula) daily, starting within the first 4 months of life, continuing for at least 2 months
214914899|NCT00543881|DEVICE|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
214914900|NCT00543881|DEVICE|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
214914901|NCT06208917|DRUG|Ondansetron (Oral soluble film OR injections) ,Dexamethasone|Participants will randomly assigned 1:1 to receive treatment (Oral soluble film of Ondansetron plus dexamethasone OR Ondansetron injections plus dexamethasone).
214914902|NCT03288155|DIETARY_SUPPLEMENT|Cocoa|Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
214914903|NCT03450317|DRUG|Aspirin 80mg|No treatment
214914904|NCT00134823|OTHER|weight based dosing decision support|weight based dosing decision support
214914905|NCT04653038|DRUG|MGD013|A fixed dose of MGD013 600mg IV Q2W will be administered to subjects
214914906|NCT03393923|OTHER|Application of the anterior wedge|Application of anterior wedge in tennis
214914907|NCT04057742|DIAGNOSTIC_TEST|AlloSure ddcfDNA assay|2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
214914908|NCT04057742|DIAGNOSTIC_TEST|AlloMap assay|10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
214914909|NCT04057742|DIAGNOSTIC_TEST|Inflammatory Cytokines|10 mL collection at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A
214914910|NCT04057742|DIAGNOSTIC_TEST|Immune Cell Phenotypes|Collection of up to 1 cup of urine for per participant each study visit
214914911|NCT03975673|PROCEDURE|hip replacement|Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
215059998|NCT05962645|DRUG|Vapendavir|This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
214914912|NCT03105180|OTHER|A mixture of 2.7% sorbitol-0.54% mannitol solution|Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.
214914913|NCT01115244|DRUG|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
214914914|NCT02763930|OTHER|Control diet|
214305171|NCT01755884|DIETARY_SUPPLEMENT|Wheat oral immunotherapy|Cooked spaghetti
214305172|NCT00004323|DRUG|anti-thymocyte globulin|
214305173|NCT00004323|DRUG|cyclophosphamide|
214305174|NCT00004323|DRUG|cyclosporine|
214305175|NCT00004323|DRUG|mesna|
214305176|NCT00004323|DRUG|methotrexate|
214305177|NCT00004323|DRUG|methylprednisolone|
214305178|NCT01715311|DRUG|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
214305179|NCT01715311|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
214305180|NCT01715311|DRUG|Tiotropium|Tiotropium capsules for inhalation once daily
214914915|NCT02763930|OTHER|Milk diet|
214305181|NCT01715311|DRUG|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
214305182|NCT04317456|DEVICE|Hearing Aids and Hearing Implants|Hearing Aids and Hearing Implants (age at first fitting and implantation and aided audibility)
214305183|NCT04317456|BEHAVIORAL|Family Centred Early Intervention|Family Centred Early Intervention
214305184|NCT00044395|DRUG|Ruboxistaurin mesylate|
214914916|NCT02763930|OTHER|GABA-rich cheese diet|
214914917|NCT02965573|BIOLOGICAL|ARGX-113|
214914918|NCT02965573|DRUG|Placebo|
214914919|NCT05169801|DRUG|BP102, paclitaxel, carboplatin|BP102, paclitaxel, carboplatin
214914920|NCT05169801|DRUG|Avastin®, paclitaxel, carboplatin|Avastin®, paclitaxel, carboplatin
215059999|NCT02922816|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
214305185|NCT06174753|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg daily X 7 days
214305186|NCT06174753|DIAGNOSTIC_TEST|CMR|CMR 3-5 days post randomization
214305187|NCT06407544|PROCEDURE|peripheral nerve block|peripheral nerve block guided by ultra sound through Ultrasound-guided quadratus lumborum block versus FICB or fascia iliaca block
214305188|NCT06407544|DRUG|PCA device as rescue medication with IV morphine 1mg if VAS more than 4|PCA device as rescue medication with IV morphine 1mg if VAS more than 4 with a 10 min lock-out time
214305189|NCT03070574|DRUG|mesalamine 2400 MG (5-ASA)|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
214305190|NCT03070574|DRUG|mesalamine 1200 MG|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
214914921|NCT06033027|DEVICE|Carbonhand|During this phase, participants use the Carbonhand soft-robotic glove system in daily life for 6 weeks to support the performance of daily activities with their affected hand in the home environment. The participants are free to choose for which activities, when and for how long they use the Carbonhand. However, it is recommended to use the Carbonhand at least 180 minutes a week during the most common ADL, such as household activities, dressing/undressing, eating/drinking/cooking, and/or leisure activities.
214914922|NCT00613769|DRUG|trimethoprim-sulfamethoxazole + metronidazole|trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.
214914923|NCT00613769|DRUG|cefuroxime and metronidazole|cefuromime 1500mg i.v. + metronidazole 1500mg i.v.
214914924|NCT06427746|PROCEDURE|Standard|Basic ambulance personnel are trained in the application of the CPSS scale in suspected stroke. The CPSS scale is a tool used to quickly assess stroke severity in pre-hospital settings. It is a three-point scale that takes into account the patient's level of consciousness, facial droop, and arm weakness. If a patient with suspected stroke meets certain criteria, they will be coded as having a suspected stroke by the SOREU. These criteria include having one item in three of the CPSS scale, being of adult age, and being independent at home.
214914925|NCT06427746|PROCEDURE|Video call|Among the tools already available to improve evaluation of patients rescued in the field, SOREU has video calls between the dispatch room physician and the rescuer in the field. Thus, the rescuer in the field will perform the CPSS during ongoing video call with the dispatch room, allowing the remote evaluation of the patient by the healthcare worker present in the control room, potentially increasing the ability to identify a stroke.
215060000|NCT02922816|PROCEDURE|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
215060001|NCT02922816|PROCEDURE|Stool or perirectal swab sampling|Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
215060002|NCT02922816|OTHER|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
214305191|NCT03070574|OTHER|Placebo|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
214305192|NCT01819454|DEVICE|pH monitoring (Restech)|"see in detail description of the study part of the protocol"
214305193|NCT05542875|PROCEDURE|Thrust Manipulation|Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants of Group A (Experimental group). Intervention will be applied on alternate days with a total of 4 treatment sessions
214305194|NCT05542875|PROCEDURE|Non-Thrust manipulation|Maitland grade III or IV thoracic 0manipulation will be given to participants of Control group from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Intervention will be applied on alternate days with a total of 4 treatment sessions
214305195|NCT05542875|PROCEDURE|Standard Treatment|"Standard treatment protocol includes moist heat, TENS and Post isometric relaxation technique. Standard treatment will be given to both groups on every session. Standard treatment consists of:~Superficial Moist Heat (Device): Superficial moist heat will me applied for 10 minutes on Upper Trapezius TENS (Device): TENS will be applied for 10 minutes at 80-100Hz, the electrodes will be placed at upper trapezius.~Post-isometric Relaxation (procedure/surgery): 5-10 repetions of Post Isometric relaxation technique will be applied on various muscle groups which include Upper trapezius, levator scapulae, sternocleidomastoid and scalenes."
215060003|NCT00207623|BEHAVIORAL|Arthritis Basics for Change Education program|
214914926|NCT06427746|PROCEDURE|Video call + LARIO|LARIO scale's effectiveness in identifying patients with ischemic stroke caused by a large vessel occlusion in the anterior cerebral circulation. The anterior cerebral circulation supplies blood to the front and upper parts of the brain. Occlusion of a large vessel in this area can lead to a severe stroke. Rescuer in the field will perform the CPSS and the LARIO during ongoing video call with the dispatch room, allowing the remote evaluation of the patient by the healthcare worker present in the control room.
214914927|NCT03654612|DRUG|Apatinib|Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
214914928|NCT00315458|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
214914929|NCT00315458|DRUG|Placebo transdermal patch|Placebo to match buprenorphine transdermal patch 10 or 20.
214914930|NCT06479538|OTHER|Post isometric relaxation|17 participants will be in experimental group A giving them Post isometric relaxation of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
214914931|NCT06479538|OTHER|Post facilitation stretching|17 participants will be in experimental group A giving them Post facilitation stretching of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
214914932|NCT02279875|DRUG|Linezolid|
214914933|NCT02279875|DRUG|HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)|isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
214914934|NCT04717752|DRUG|Ovidrel|recombinant human chorionic gonadotropin for injection
214914935|NCT04717752|DRUG|Troprilin|triptorelin acetate injection
214914936|NCT02382575|DRUG|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
214914937|NCT02382575|DRUG|Tacrolimus|Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
214914938|NCT00987337|DRUG|Filibuvir|300 mg BID
214914939|NCT00987337|DRUG|Filibuvir|600 mg BID
214914940|NCT00987337|DRUG|Placebo|BID
214914941|NCT05159947|DRUG|SPT-07A injection|20mg (2), dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.
214914942|NCT05159947|OTHER|placebo|2 Injection simulants, dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.
214914943|NCT01807754|PROCEDURE|X-ray and ultrasound imaging scanning|Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. The participant will be seated and her breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.
214914944|NCT01807754|PROCEDURE|Photoacoustic imaging scans for breast cancer screening|The participant will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the participant's chest to allow the computer to record ultrasound blood flow in the breast. The low intensity laser light will be focused on the targeted area of the breast.
214914945|NCT01768377|DRUG|Nerve block with Lidocain|Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg
214914946|NCT01768377|DRUG|Fentanyl|Fentanyl 2 microgram/Kg BW IV
214914947|NCT01768377|DRUG|Midazolam|Midazolam 0.05 mg/kg BW IV infusion
215060004|NCT01814046|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
215060005|NCT01814046|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
215060006|NCT01814046|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
214305196|NCT01353417|OTHER|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
215060007|NCT01814046|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
215060008|NCT06110364|DEVICE|Low-Level Tragus Stimulation|Low-Level Tragus Stimulation via TENS unit will be monitored with a Holter.
214305197|NCT02914652|DRUG|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
214305198|NCT02914652|DRUG|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
214305199|NCT04489576|PROCEDURE|Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)|Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
214305200|NCT03837561|DRUG|Cunox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
214914948|NCT02109627|DRUG|Ficlatuzumab|5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
214914949|NCT02109627|DRUG|Cytarabine|2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.
214914950|NCT03011827|OTHER|Fibrinogen and/or platelets administration|Fibrinogen and/or platelets administration to maintain clot amplitude at 10 minutes of the thromboelastometry between 35-40 mm along liver transplant procedure
214914951|NCT01047566|DRUG|Dronedarone|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)
214914952|NCT01047566|DRUG|Beta blocker or calcium antagonist or digoxin|Dose increase of beta blocker or calcium antagonist or digoxin
214914953|NCT00802048|DRUG|Local anesthetic (Ropivacaine)|Local anesthetic infusion
214914954|NCT00802048|DRUG|Saline|Saline serum infusion
214914955|NCT02220738|DRUG|ABT-957|ABT-957 administered twice-daily for 7 days
214914956|NCT02220738|OTHER|Placebo for ABT-957|Placebo for ABT-957 administered twice-daily for 7 days
214914957|NCT02276248|RADIATION|Intensity-modulated radiation therapy|total dose: 50 to 56 grays per fraction: 2 grays
214914958|NCT02276248|DRUG|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
214914959|NCT02263430|DEVICE|Deep Brain Stimulation|
214914960|NCT02499848|DRUG|PRX302|Single prostate cancer lesion injected with PRX302.
214914961|NCT04166474|DRUG|Dolutegravir|Dosed at 50 mg bd on 3 separate occasions with low, medium and high doses of rifampicin. Dosed at 50 mg od without rifampicin.
214914962|NCT01669863|DEVICE|ECMO|Use of veno-venous ECMO in non-intubated patients with ARDS
214914963|NCT01669863|PROCEDURE|ECMO in non-intubated patients|Use of veno-venous ECMO in non-intubated patients with ARDS
214914964|NCT05182684|DEVICE|Vital Patch(TriBell Lab)|"Electrocardiograms were recorded using VP-100 for more than six hours and transmitted to a central data server located in Seoul National University Hospital.~The data on a central server was confirmed and evaluated."
214305201|NCT03837561|DRUG|Botox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
214305202|NCT00199784|DRUG|Phenylephrine|
214914965|NCT00086619|DRUG|synthetic hPTH 1-34|Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
214914966|NCT00489918|DRUG|teriparatide|Macroflux® patch applied to the abdomen for 30 minutes daily
214914967|NCT00489918|DRUG|teriparatide|FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
214914968|NCT03550495|BEHAVIORAL|psychiatry involvement|See arm description.
214914969|NCT04273113|OTHER|Difficulties in Emotional Regulation Scale, Five Facet Mindfulness Questionnaire, Becks Depression and Becks Anxiety|Patients asked to complete these 4 questionnaires pre, during and post biofeedback training
214914970|NCT04273113|BEHAVIORAL|HRV Biofeedback (Healing Rhythms)|Sensors placed on fingers to capture heart rate and skin temperature
214914971|NCT00987818|OTHER|Procalcitonin measurement|Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
214914972|NCT04207606|BEHAVIORAL|Post Epidural Steroid Injection Follow-up|All enrolled patients will undergo epidural steroid injection with fluoroscopy per the Spine Intervention Society guidelines as part of their normal care. Patients will then be contacted for survey responses every 3 days for a maximum of 23 days, to assess pain intensity and change.
214914973|NCT03454061|OTHER|physical activity|Physical education program (PEP) of 16-week length
214914974|NCT00224861|BEHAVIORAL|Self-Management|
214914975|NCT00224861|BEHAVIORAL|Adherence|
214914976|NCT02869347|DRUG|Conestat alfa|Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.
214914977|NCT02869347|DRUG|Sodium chloride 0.9%|Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
214914978|NCT04003883|DEVICE|Holter ECG|A Holter ECG will be recorderd during shifts
214914979|NCT01772173|OTHER|Vessel measurements|Measurement of retinal vessels
214305203|NCT04889339|DEVICE|Test brace versus control brace: Immediate correction|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
214914980|NCT02914782|OTHER|Observational Study|
214914981|NCT03484962|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
214914982|NCT03484962|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
214914983|NCT02034929|DEVICE|EndoCuff-assisted colonoscopy|EC-assisted colonoscopy
214914984|NCT02034929|DEVICE|Standard colonoscopy|Standard colonoscopy
214914985|NCT06265129|DIAGNOSTIC_TEST|Complete blood picture (done in the morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW)|morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW)
214914986|NCT05202197|OTHER|Smart cupboard|Development of a memory task with the help of a smart cupboard
214914987|NCT03199560|DRUG|Tc 99m tilmanocept|lymphatic mapping agent
214914988|NCT03199560|DRUG|Tc 99m filtered sulfur colloid|lymphatic mapping agent
214914989|NCT03063060|OTHER|vitamin D levels and Calcium levels examination|observational
214914990|NCT05385263|DRUG|Nivolumab Injection [Opdivo]|Nivolumab ( 3mg/kg IV) on day +5. If CAR-T expansion\<100 cells/microL on day +7 one additional dose of nivolumab (3mg/kg IV) will be given on day +19
214914991|NCT06358547|DIAGNOSTIC_TEST|PGT-A|PGT-A is a technique that allows for the prediction of embryo ploidy status through analysis of a trophectoderm biopsy conducted prior to embryo transfer.
214914992|NCT01209520|DRUG|Cisplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
215060009|NCT06110364|BEHAVIORAL|Heart Rate Variability- Biofeedback|Heart Rate Variability- Biofeedback will be monitored with a Holter.
214670409|NCT02803372|OTHER|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP \> 95 mmHg, SVV \< 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
214914993|NCT01209520|DRUG|Carboplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
214914994|NCT01209520|DRUG|Paclitaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
214914995|NCT01209520|DRUG|Vidaza|Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
214914996|NCT01209520|PROCEDURE|Tumor Specimen for Methylation Analysis|Obtained from tissue of resected NSCLC tumor.
214914997|NCT01209520|PROCEDURE|Blood Sample for Methylation Analysis|Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
214914998|NCT01209520|DRUG|Vinorelbine|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
214914999|NCT01209520|DRUG|Docetaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
214915000|NCT01209520|DRUG|Pemetrexed|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
214915001|NCT00874874|DRUG|sorafenib tosylate|
214915002|NCT06031740|PROCEDURE|Sclerotherapy with 1.5% polidocanol|"2mL (3%) polidocanol = 60mg; maximal dose: 1mL/column and 4mL/session.~\- Group 2: Foam sclerotherapy."
214915003|NCT06031740|PROCEDURE|Foam sclerotherapy.|Tessari's technique; 4mL 3% poilidocanol +16mL air; maximal dose: 2mL/column and 20mL/session.
214915004|NCT01200147|OTHER|study withdrawn no details|
214915005|NCT01630187|DRUG|Carbetocin|Administration of carbetocin 50 mcg , after clamping the umbilical cord
214915006|NCT01630187|DRUG|Carbetocin|Administration of carbetocin 100 mcg , after clamping the umbilical cord
214915007|NCT04723927|OTHER|Older adults|The data for motor function and gait pattern analysis was obtained.
214915008|NCT00961350|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
214915009|NCT00961350|DRUG|EC Aspirin 325|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
214915010|NCT06537427|OTHER|Data collection|"The data to be collected are the following:~* Demographic data: gender and age of the patient at diagnosis of SCI;~* Drug assumption and drug abuse at the time of SCI;~* A complete assessment of patients' comorbidities;~* Complete neurological examination on admission and at 6-8 months follow-up according to ASIA protocol;~* Neuro-radiological data: spinal CT and MRI performed within 48 hours of admission to document the type, level and extent of the lesion of the spine and the spinal cord;~* CSF pressure, chemical and biological markers;~* Serum chemical and biological markers;~* Data coming from surgical procedure: type of decompression, type of stabilization, extension of the stabilization, surgical approach, staged surgery, timing of surgery, length of surgery, eventual intraoperative, postoperative or long-term surgical-related complications \[13\];~* Data on hospitalization: length of stay, hospital-acquired infections, any adverse event occurred during hospitalisation."
214915011|NCT05435729|DRUG|DSP-9632P 27.5 mg|Single dose of DSP-9632P 27.5 mg
214670410|NCT02803372|OTHER|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output \> 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
214915012|NCT05435729|DRUG|DSP-9632P 82.5 mg|Single dose of DSP-9632P 82.5 mg
214915013|NCT05435729|DRUG|Placebo|Placebo for DSP-9632P
214915014|NCT05435729|DRUG|DSP-9632P 55.0 mg|Multiple dose of DSP-9632P 55.0 mg
214915015|NCT05435729|DRUG|Levodopa formulation|Single dose of Levodopa formulation
214915016|NCT05654376|BEHAVIORAL|Art therapy|"Participant's creativity is stimulated by visual arts materials and various art therapy techniques, in relation to 6 topics: self-care, stress management, flourishing caregiving, challenging caregiving, loss and grief, and sense of professional meaning.~The strategy consists of stimulating an observant and symbolic gaze, facilitating visual expression, promoting communication about what it has been expressed, and gather learning from the multidimensional impact of the creative art process (sensations, emotions, cognitions and spiritual experiences)."
214915017|NCT02678065|DEVICE|InPact Admiral DEB|
214915018|NCT03778892|BEHAVIORAL|'Project Raincoat' Mobile Phone Application|Mobile phone application with weekly input channels for PrEP use, condom use, number of sex partners and sex acts and a calculation of self-HIV risk feedback scoring. Scoring system for attendance of visits, normal blood tests and use of application. Points redeemable for cash. Optional alarm system to remind to take medications and attend visits.
214915019|NCT04825691|DIAGNOSTIC_TEST|Immunohistochemistry of prostate biopsy|Sections of formalin fixed paraffin embedded tissue blocks will be stained with ERG oncoprotein. Antibody dilution, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions
214915020|NCT06578676|DRUG|Empagliflozin 25 MG|PO, QD
214915021|NCT06578676|DRUG|Ezetimibe/Rosuvastatin 10/10mg|PO, QD
214915022|NCT06578676|DRUG|Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg|PO, QD
214915023|NCT03924180|DIETARY_SUPPLEMENT|Dietary Supplement for PKU patients|For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
214915024|NCT01574365|DRUG|RTA 402|
214479910|NCT05357768|OTHER|data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue|"Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification."
214479911|NCT04769817|OTHER|177Lu-PSMA|Lu-PSMA will be administered as a standard-of-care procedure following assessment of suitability by a nuclear medicine physician and managed in close collaboration with the patient's medical oncologist.
214479912|NCT06099405|BEHAVIORAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
214479913|NCT06099405|BEHAVIORAL|Traditional yoga|Participants will perform controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
214479914|NCT05438862|PROCEDURE|State of art aortic valve surgery|Optimal surgical treatment (aortic valve-sparing surgery, aortic valve replacement, Ross procedure).
214479915|NCT05370352|BEHAVIORAL|Standard smoking cessation treatment|Standard smoking cessation treatment (behavioural and pharmacotherapy) provided by Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation
214915025|NCT03617380|OTHER|Usual Care|patients participating Usual Care discharge services
214479916|NCT05370352|BEHAVIORAL|Personalised chat messaging|Personalised chat messaging focusing on smoking relapse prevention for 3 months from randomisation. A trained counsellor will interact with a participant individually and provide relapse prevention advice via WhatsApp. The participant can also access a supportive chatbot in WhatsApp, which will provide on-demand smoking relapse prevention support when the counsellor is not available (e.g., during nighttime).
214479917|NCT05370352|BEHAVIORAL|SMS text messaging|SMS text messaging on generic information about the harms of smoking and the benefits of quitting for 3 months from randomisation.
214479918|NCT03107416|PROCEDURE|Hepatic artery embolization (HAE)|The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.
214479919|NCT03107416|DRUG|Bumetanide|Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
214479920|NCT03031262|DRUG|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
214479921|NCT03031262|DRUG|Chidamide|Chidamide at a dose of 20mg/d twice a week for 3 months.
214479922|NCT02246374|DEVICE|ExAblate Transcranial System|ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
214479923|NCT02632175|BIOLOGICAL|Adalimumab|every other week or weekly subcutaneous injection
214479924|NCT05284097|DRUG|Ad26.ZEBOV, MVA-BN-Filo|"Ad26.ZEBOV - is an adenovirus serotype 26 vector expressing the glycoprotein (GP) of the Ebola virus (EBOV) Mayinga variant~MVA-BN-Filo - is a Modified Vaccinia Ankara (MVA) - Bavarian Nordic (BN) vector expressing the GPs of EBOV, Sudan virus (SUDV) and Marburg virus (MARV) and the nucleoprotein of Tai Forest virus"
214479925|NCT04864899|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging (CMR)|Imaging
214670411|NCT00623012|DRUG|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
214915026|NCT03617380|OTHER|PharmD TOC|patients participating in a community pharmacy-based Transitions of Care Program (PHARMD-TOC)
214915027|NCT00466362|BEHAVIORAL|The Evje Model|Lifestyle intervention
214915028|NCT00674960|RADIATION|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
214915029|NCT03952273|COMBINATION_PRODUCT|PCI with BioMatrix Alpha™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
215060010|NCT06110364|OTHER|Conventional Medical Therapy|Conventional Medical Therapy by Beta Blockers will be added to subjects usual care by their doctor if they are not already taking this medication.
215060011|NCT03770741|OTHER|Modify cardio-respiratory support to avoid cerebral hypoxia|modification of cardio-respiratory support based on an evidence-based treatment guideline
214479926|NCT04864899|DIAGNOSTIC_TEST|Blood test|Blood investigation
214479927|NCT04864899|DIAGNOSTIC_TEST|6-minute walk test|Correlating the cardiac MRI parameters with functional capacity
214479928|NCT05311176|BIOLOGICAL|IMU-131|IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
214479929|NCT05311176|DRUG|Ramucirumab plus Paclitaxel|Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
214479930|NCT05311176|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
214479931|NCT01880515|DRUG|Tetracycline|The experimental group will receive tetracycline 250mg every 12 hours for 1 month the same day at initiation of BIBW2992 whereas the non-intervention group will recieve general dermatological recomendations while on treatment with BIBW2992.
214479932|NCT04726293|DIETARY_SUPPLEMENT|Mango|Mango beverage -1 cup fresh mango equivalent, twice a day for 4 weeks
214479933|NCT04726293|DIETARY_SUPPLEMENT|Control|control beverage 1 cup, twice a day for 4 weeks
214670412|NCT00623012|DRUG|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
215060012|NCT03770741|OTHER|Treatment as usual|Monitoring and treatment according to local guidelines and practice
215060013|NCT02368093|DRUG|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
214305204|NCT04889339|DEVICE|Test brace versus control brace: Long-term correction|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
214305205|NCT03933150|DEVICE|ultrasound guided caudal epidural injection|"A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor"
214305206|NCT01251549|DEVICE|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device
214305207|NCT00174655|DRUG|Doxorubicine + docetaxel sequential|doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
214305208|NCT00174655|DRUG|doxorubicine + cyclophosphamide sequential|doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
214305209|NCT00174655|DRUG|doxorubicine + cyclophosphamide combined|doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
214305210|NCT00174655|DRUG|doxorubicine + docetaxel combined|doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
214915030|NCT03952273|COMBINATION_PRODUCT|PCI with Combo™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
214915031|NCT06831448|DEVICE|Prototype dressing|Five-layer foam dressing with polyurethane, cellulose, bicomponent, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE. Size: 10cm x 10 cm. Topical application. Single use.
214305211|NCT01807897|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
214305212|NCT01807897|DEVICE|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
214305213|NCT01807897|BEHAVIORAL|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
214305214|NCT02014363|DRUG|ETS6103 (low dose)|
214305215|NCT02014363|DRUG|ETS6103 (high dose)|
214305216|NCT02014363|DRUG|Amitriptyline|
214305217|NCT03412760|DIAGNOSTIC_TEST|Exome sequencing|Expansive genetic test performed for affected fetus or neonate.
214305218|NCT05075850|DEVICE|Neuroblate System|"All subjects will undergo comprehensive neuropsychological assessment post-LITT per standard of care practice.~Visual field testing will be conducted in a subset of enrolled patients."
214305219|NCT01622361|DRUG|Adriamycin+Cyclophosphamide>Docetaxel|"1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~   * Route: by slow intravenous bolus~  * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~   * Route: intravenous as per local practice~  * Schedule: every 3weeks for 4 cycle"
214305220|NCT01622361|DRUG|GnRHa with Tamoxifen|"1. Goserelin(GnRHa) 3.6mg~   * Route: subcutaneously under the abdominal skin~  * Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~2. Tamoxifen 20mg/day~   * Route: Oral~  * Schedule: everyday"
214305221|NCT02663609|OTHER|No intervention|No treatment (intervention) was administered.
214305222|NCT04540757|PROCEDURE|Surgery|Participants will be randomised to receive surgery as part of multi-modality treatment
214305223|NCT04540757|PROCEDURE|No surgery|Participants will be randomised to receive no surgery as part of multi-modality treatment
214305224|NCT01265849|BIOLOGICAL|LI|LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
214305225|NCT01265849|DRUG|Cyclophosphamide|Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
214915032|NCT06831448|DEVICE|Marketed dressing 1|Five-layer foam dressing with polyurethane, polyethylene, cellulose, bicomponent, superabsorbent polymer, silicone adhesive, acrylic adhesive, polypropylene. Size: 12.9cm × 12.9cm. Topical application. Single use.
214915033|NCT06831448|DEVICE|Marketed dressing 2|Five-layer foam dressing with silicone, polyurethane, polyacrylate, cotton, viscose, polyester and polyolefin. Size: 10cm x 10 cm. Topical application. Single use.
214305226|NCT01265849|DRUG|Indomethacin|One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
214915034|NCT00485251|PROCEDURE|hand-assisted laparoscopic right hemicolectomy|using the lap disc that allows the insertion of single and into the abdomen for operation
214915035|NCT00485251|PROCEDURE|total laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
214915036|NCT00485251|PROCEDURE|hand-assisted right hemicolectomy|hand-assisted right hemicolectomy
214915037|NCT00485251|PROCEDURE|laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
214305227|NCT01265849|DIETARY_SUPPLEMENT|Zinc|One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
214305228|NCT01265849|PROCEDURE|Surgery|Excise tumor and nodes
214305229|NCT01265849|DRUG|Cisplatin|Cisplatin was administered 100mg/m\^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m\^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
214305230|NCT01265849|RADIATION|Radiotherapy|Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m\^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
214305231|NCT01794052|OTHER|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~1. A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~2. Treating patients as per a standard clinical guidelines~3. Giving health education to patients on lifestyle changes for better self-care~4. Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~5. Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
214670413|NCT04886830|PROCEDURE|laparoscopic appendectomy using a single endoloop for appendiceal stump closure|laparoscopic appendectomy using a single endoloop for appendiceal stump closure before resecting the appendix
214305233|NCT00674453|DRUG|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
214305234|NCT00674453|OTHER|Placebo|Matching placebo tablet given once daily for 2 years
214305235|NCT04396431|BEHAVIORAL|education|"The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat."
214305236|NCT01172184|PROCEDURE|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
214305237|NCT02440477|OTHER|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
214305238|NCT04843748|DEVICE|cataract surgery and intraocular lens implantation - both eyes|cataract surgery and intraocular lens implantation for both eyes
214305239|NCT02139527|DEVICE|Total Disc Replacement|
214305240|NCT05728346|DRUG|Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers|stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers
214305241|NCT01425957|PROCEDURE|Lumbar puncture|"All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36)."
214305242|NCT03886012|DEVICE|Otoband|The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.
214305243|NCT03886012|DEVICE|Otoband sham|The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.
214305244|NCT01798472|PROCEDURE|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
214305245|NCT01798472|PROCEDURE|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
214479934|NCT05698615|BEHAVIORAL|Chess training|"The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises."
214915038|NCT05137782|OTHER|Specialty Palliative Care|Specialty palliative care, as opposed to primary palliative care.
215060014|NCT02941328|DRUG|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
214915039|NCT02892773|DEVICE|Incentive Spirometry|"A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times per therapy session.~* Each I.S. therapy session will last about 15 minutes, 3 times per day.~* Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery."
214915040|NCT02892773|DEVICE|EzPAP® Positive Airway Pressure|"A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times.~* Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.~* Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery."
214915041|NCT04663633|OTHER|Core stability training|Functional Rhythmic Core Stability exercises performed by the experimental group. 30 minutes insert included in the Gymnasts regular training.
214915042|NCT02134015|DRUG|Patritumab|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
214915043|NCT02134015|DRUG|Erlotinib|Oral erlotinib 150 mg/day
214915044|NCT02134015|DRUG|Placebo|Placebo infusion every 3 weeks
214305246|NCT01798472|PROCEDURE|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
214305247|NCT01798472|PROCEDURE|uncemented hemiarthroplasty|"Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel."
214915045|NCT06303089|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, tobacco-related knowledge, perceptions of tobacco harm. Smokers will be asked the history of smoking cessation sheet, the Fagerstrom Test of Nicotine Dependence, Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, Intention to Quit Smoking sheet, Motivation to Quit Smoking sheet, Alcohol Use Disorders Identification Test, and International Physical Activity Questionnaire.
214915046|NCT00326716|DRUG|Atazanavir + Ritonavir + Combivir|Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
214305248|NCT01547000|DRUG|placebo|Administered up to 8 weeks.
214305249|NCT01547000|DRUG|extended-release guanfacine (Intuniv)|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
214305250|NCT02433756|DEVICE|CRTD|
214305251|NCT05706142|OTHER|Motor Imagery Education|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
214305252|NCT00646529|DRUG|budesonide/formoterol (Symbicort)|
214305253|NCT00646529|DRUG|budesonide (Pulmicort)|
214305254|NCT01895855|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 5x10\^8
214305255|NCT01895855|BIOLOGICAL|placebo|
214305256|NCT03617081|DRUG|NNC0113-2023|Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
214305257|NCT03617081|DRUG|Placebo (NNC0113-2023)|Participants will receive NNC0174-0833 matched placebo orally.
214305258|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
214305259|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
214305260|NCT00605670|BEHAVIORAL|questionnaires|patients will fill out two questionnaires post surgery
214305261|NCT00605670|BEHAVIORAL|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
214305262|NCT06435533|DEVICE|low energy argonplasma coagulation|see above
214305263|NCT06420479|PROCEDURE|Bariatric surgery|A well-known intervention known to induce substantial weight loss
214305264|NCT06316141|OTHER|Aqua Jogging|This group performed aqua jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
214915047|NCT04353713|DIETARY_SUPPLEMENT|40% Dextrose Gel|Prophylactic administration of 40% dextrose gel via buccal mucosa to prevent newborn hypoglycemia
214915048|NCT04353713|DIETARY_SUPPLEMENT|2% carboxymethylcellulose gel|placebo
214915049|NCT00684411|DRUG|Imatinib mesylate|
215060015|NCT02941328|DRUG|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
215060016|NCT05783128|OTHER|Airway management techniques (exposure)|The exposure reffers to the different methods of airway management during general or regional anesthesia.
215060017|NCT05084248|DRUG|Ergocalciferol Capsules|Capsules of ergocalciferol at 400 IU and 4000 IU
215060018|NCT01922882|BEHAVIORAL|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
214305265|NCT06316141|OTHER|Land based Jogging|This group performs land jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
214915050|NCT03871751|BEHAVIORAL|Safe and Sound Protocol|The auditory intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
214915051|NCT04258644|DRUG|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Combination therapy of 4 drugs, 21 days for one cycle.
214915052|NCT03487627|BEHAVIORAL|Electronic and Care Support Manager Contact|This intervention will consist of electronic and Care Support Manager (CSM) contacts with parents from the first week following their adolescent's discharge from hospitalization through the first 3 months after discharge. The electronic application content will be accessible and delivered to parents weekly. Parents will also be able to enter a keyword on their electronic device to access content and material in real time. The CSM contacts will supplement the informational content delivered electronically by providing opportunities to ask questions about the electronic application material, and by checking on progress toward treatment follow through for their youth, identifying and problem solving any difficulties and concerns, and addressing health needs of each parent.
214915053|NCT03487627|BEHAVIORAL|Enhanced Treatment-as-usual (TAU)|TAU typically involves a discharge planning session by unit staff with the adolescent and their parent(s) to discuss safety monitoring and referrals for mental health services following discharge from psychiatric hospitalization. Investigators will augment this usual care by providing written materials to families outlining some of the key considerations for caring for their adolescent. These written materials will include brochures with information for parents following adolescent suicidal behavior, a listing of resources including instructions for when to call 911 or go to the emergency room, and information regarding the National Suicide Prevention Lifeline. Written materials will be provided to both the enhanced TAU participants as well as participants receiving the electronic and CSM intervention.
214915054|NCT05253573|DRUG|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
214915055|NCT05253573|BEHAVIORAL|Self-help materials (to support smoking cessation)|"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help material in this study."
214915056|NCT05253573|BEHAVIORAL|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 12-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
214915057|NCT03937895|BIOLOGICAL|'SMT-NK' Inj (allogeneic Natural Killer cell)|In 120 mL, 3x10\^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.
214915058|NCT03937895|DRUG|Pembrolizumab Injection [Keytruda]|Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).
214915059|NCT00010010|DRUG|exemestane|
214915060|NCT00010010|DRUG|goserelin acetate|
214915061|NCT05189990|DIAGNOSTIC_TEST|Electrical impedance tomography|Fatty liver patients will be recruited from the Department of Medicine at Queen Mary Hospital. Gender- and age- matched control subjects will be publicly recruited. Subjects will undergo the EIT-liver scan and FibroScan®. Selected subgroups will also undergo MRI-PDFF scan. The performance characteristics of the device and with respect to Fibroscan/ MRI-PDFF for liver fat quantification will be assessed.
214915062|NCT02786875|OTHER|low Glycemic Index Mediterranean diet|All carbohydrate foods will be low GI choices (GI\<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).
214915063|NCT02786875|OTHER|Mediterranean diet|General recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).
214915064|NCT02786875|BEHAVIORAL|Moderate physical activity|Brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.
214305266|NCT01818154|OTHER|LED phototherapy|
214305267|NCT01818154|OTHER|narrowband UVB phototherapy|
214305268|NCT01067014|DEVICE|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
214305269|NCT00198757|BEHAVIORAL|Medifast Plus for Diabetics Meal Replacement Supplements|
214305270|NCT00198757|BEHAVIORAL|Standard ADA recommended diet for type 2 diabetics|
214479935|NCT06490627|DRUG|Thalidomide|"Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 5-6mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period."
214305271|NCT06536803|OTHER|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks
214305272|NCT06536803|OTHER|high-load strength training with routine physiotherapy|high load strength training with routine physiotherapy for 12 weeks
214915065|NCT02786875|BEHAVIORAL|Basic physical activity|General recommendations for physical activity
214305273|NCT01190709|PROCEDURE|Dynamic Compression Plate|we made a longitudinal incision 1 cm lateral to the tibial crest, expose the fracture, and retract the muscles laterally. After determining the length of plate, we used bending instruments to contour the plate to the anatomy then threaded plate holders used to position the plate on the bone. After that we placed the drill guide at the edge of the dynamic compression unit (DCU) portion of the plate hole without applying pressure and tightening of the cortex screws results in dynamic compression. We verified the screw position with a guide wire before insertion and then inserted the locking screw.
214915066|NCT02786875|DRUG|high level Vitamin D|Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach normal blood levels of 60-80 ng/ml of 25(OH)D.
214915067|NCT02786875|DRUG|normal level Vitamin D|Vitamin D (cholecalciferol) will be given only if vitamin D insufficiency is detected to bring blood levels up to normal ranges of 30ng/mL.
214915068|NCT05250570|BEHAVIORAL|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) to assist individuals in tolerating benzodiazepine withdrawal symptoms and teaching skills to prevent relapse to benzodiazepine use. It will also provide psychoeducation about benzodiazepine use in OAT. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
214479936|NCT06490627|DRUG|Thalidomide|"Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 7-8mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period."
214915069|NCT05250570|BEHAVIORAL|Relaxation Therapy|The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
214915070|NCT03805568|DRUG|dexmedetomidine infusion group|dexmedetomidine as anaesthetic adjuvant
214915071|NCT03805568|DRUG|remifentanil infusion group|remifentanil as anaesthetic adjuvant
214915072|NCT06573606|DEVICE|CX-HA and CS|Sterile Isotonic ophthalmic solution
214915073|NCT00918411|DRUG|Ramosetron|oral
214479937|NCT04166799|DEVICE|Mepitel Film|Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
214479938|NCT02115295|DRUG|Cladribine|Given IV
214479939|NCT02115295|DRUG|Cytarabine|Given IV
214479940|NCT02115295|DRUG|Gilteritinib|Given PO
214479941|NCT02115295|DRUG|Idarubicin|Given IV
214670414|NCT04886830|PROCEDURE|laparoscopic appendectomy using two endoloops for appendiceal stump closure|laparoscopic appendectomy using a two endoloops for appendiceal stump closure before resecting the appendix
214670415|NCT04886830|PROCEDURE|laparoscopic appendectomy using a clip for appendiceal stump closure|laparoscopic appendectomy using an endoclip for appendiceal stump closure before resecting the appendix
214915074|NCT00918411|DRUG|Placebo|oral
214915075|NCT05280626|DRUG|Sintilimab|After one cycle of standard R-CHOP chemotherapy, Group A uses Sintilimab with R-CHOP, with Sintilimab administered on day 10 post-chemotherapy, scheduled for 5 cycles. After 5 cycles CR patients in group A continue Sindilizumab treatment for 8 times, once every 21 days.
214915076|NCT05280626|DRUG|Rituximab|After one cycle of standard R-CHOP chemotherapy, Group B uses R-CHOP for 5 cycles. After 5 cycles, CR patients in group B are followed up for observation.
214915077|NCT02657122|DRUG|TD-1473 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
214915078|NCT02657122|DRUG|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
214915079|NCT02657122|DRUG|TD-1473 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
214915080|NCT02657122|DRUG|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
214479942|NCT02115295|OTHER|Laboratory Biomarker Analysis|Correlative studies
214479943|NCT02115295|DRUG|Midostaurin|Given PO
214479944|NCT02115295|DRUG|Venetoclax|Given PO
214479945|NCT00641381|DRUG|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
214670416|NCT04018170|DRUG|Study drug|oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
214670417|NCT04018170|DRUG|Placebo|oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
214915081|NCT06098339|DEVICE|Lens A (fanfilcon A)|Daily wear for one month
214915082|NCT06098339|DEVICE|Lens B (lotrafilcon B)|Daily wear for one month
214915083|NCT01722825|DRUG|LY2157299|Administered orally.
214670418|NCT01105403|DRUG|POL6326|IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
214670419|NCT02465034|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 hertz (Hz)) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
214915084|NCT04134767|BEHAVIORAL|Health Linkage|Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.
214915085|NCT04134767|BEHAVIORAL|Overdose Education|Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
214915086|NCT02276560|DRUG|Neoadjuvant Cisplatin, nab-paclitaxel|Cisplatin (75mg/m2) D1, nab-paclitaxel 125 mg/m2) D1, 8, 15; repeat each 28 D cycle x 2 then surgery
214915087|NCT02276560|DRUG|Adjuvant Cisplatin,nab-paclitaxel|Cisplatin 75mg/m2 D1,nab-paclitaxel 125mg/m2 D1, 8, 15, repeat each 28D cycle x 2
214915088|NCT02276560|DRUG|Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine|Cisplatin 75mg/m2 D1 + pemetrexed 500mg/m2 D1 or Gemcitabine 1000 mg/m2 D1, 8 (if SqCC) repeat each 21 D Cycle x 4
214915089|NCT00781729|BEHAVIORAL|Yoga, one hour class, 3 times per week, for 24 weeks|Yoga, one hour class, 3 times per week, for 24 weeks
214915090|NCT00781729|BEHAVIORAL|Luncheon Seminar Series, once per month, for 24 weeks|Luncheon Seminar Series, once per month, for 24 weeks
214915091|NCT05883657|DEVICE|Condition 1 : Prototypes (816-v1) every weeks|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214915092|NCT05883657|DEVICE|Condition 2 : Prototypes (816-v1) every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
214915093|NCT03486080|DRUG|Dutogliptin Tartrate|Active treatment
214915094|NCT03486080|DRUG|Filgrastim Injectable Product|Active treatment
214915095|NCT03486080|DRUG|Placebos|placebo control
214915096|NCT04028804|PROCEDURE|FDG PET|Each patient will receive a single intravenous injection of FDG (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FDG are being drawn up or radioactive decay has reduced the amount of available.
214915097|NCT04028804|PROCEDURE|FLT PET|The FLT PET scan will be performed 1-5 days after FDG PET in order to ensure consistency between imaging findings. Each patient will receive a single intravenous injection of FLT (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FLT are being drawn up or radioactive decay has reduced the amount of available.
214915098|NCT00794248|DRUG|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
214305274|NCT01190709|PROCEDURE|Unreamed intramedullary nailing|we inserted the nail, without reaming, across the fracture site, with particular attention being paid to the prevention of over distraction and the achievement of cortical contact of the fracture ends. An upper diameter limit of 10 mm and a nail measuring at least 2 mm less than the diameter measured at the isthmus of the tibia on anteroposterior and lateral radiographs were stipulated.
214915099|NCT00794248|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
214915100|NCT00300885|DRUG|Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
214915101|NCT00300885|DRUG|Carboplatin plus Paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
214915102|NCT02582242|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
214915103|NCT06489470|PROCEDURE|Strokectomy/Necrosectomy|After obtaining CT-/MRT-perfusion, the infarcted area (e.g. infarct core) of malignant MCA-infarction is localized. By using the neuronavigation, surgical resection of necrotic tissue is performed in a non-eloquent area until the space occupying effect is released. At the end of the surgery, the bone flap is reinserted and fixated.
214915104|NCT05366348|OTHER|Recreational activity|Horse-back riding
214915105|NCT05648942|DIAGNOSTIC_TEST|Anemia testing|Patients will undergo a point of care test to identify possible anemia
214305275|NCT04425707|DRUG|Ivermectin|use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
214305276|NCT05436847|OTHER|Proprioceptive Training|Proprioceptive Training using increased joint to joint approximation through ankle weights and joint splints.
214305277|NCT05436847|OTHER|Routine Physical Therapy|Neurodevelopmental treatment- age appropriate
214305278|NCT02130661|DRUG|Rilapladib 25 mg|White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
214305279|NCT02130661|DRUG|Rilapladib 250 mg|White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
215060019|NCT02474303|DRUG|Truvada|Demonstration Study
215060020|NCT03146663|DRUG|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
214915106|NCT01019395|DRUG|Daptomycin|"Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion."
214915107|NCT00001409|DRUG|Interleukin-2|
214915108|NCT04373395|PROCEDURE|D-CLAG|Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor
214915109|NCT05182710|BEHAVIORAL|Stress Inoculation Training|"The SIT programme/intervention will involve~1. 30 minute educational phase of preparatory information to allow participants to conceptualise the types of stressors they are likely to face and the role of stress on performance~2. 30 minutes of skills acquisition which will involve discussion of and teaching participants techniques to reduce stress in simulated resuscitation events~3. Inoculation through the application of acquired skills in 1-2 resuscitation scenarios"
214915110|NCT05182710|BEHAVIORAL|Alternative Training|"1. 30 minutes of teaching on management of a drowning patient (in order that both control and intervention perceive they have had teaching of the same length as the other group)~2. 1-2 resuscitation simulation events (same scenario and tasks as in the intervention group)"
214915111|NCT04213066|DEVICE|Portable tablet|Each training session was limited to 15 minutes a day, 5 days a week. The entire training period was 6 months.
214915112|NCT01985529|OTHER|Exercise|
214305280|NCT02130661|DRUG|Itraconazole|100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
214305281|NCT05603689|DIETARY_SUPPLEMENT|Isocaloric ketogenic diet|The ICKD definition was based on the works of Sansone (2018) and Trimboli (2020). We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption. Participants self-selected their own diet based on a list of advised and forbidden foods developed to fit the definition of ICKD. There were no instructions to limit calories.
214305282|NCT03597958|GENETIC|Next generation sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
214305283|NCT06404606|COMBINATION_PRODUCT|Black cumin and turmeric with Quantum Acoustic Waves (QAW)|Black cumin and turmeric are known to be helpful in reduction of inflammation of human body so it will be used in combination with Quantum Acoustic Waves (QAW) to determine effects on initial degenerative changes in osteoarthritis.
214305284|NCT04826770|DRUG|BNT162b2|vaccination against COVID-19
214305285|NCT04826770|DRUG|AZD 1222|vaccination against COVID-19
214915113|NCT05473949|DRUG|Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
214305286|NCT04826770|DRUG|mRNA-1273|vaccination against COVID-19
214305287|NCT01709851|DEVICE|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
214305288|NCT01709851|DEVICE|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
214305289|NCT05543876|PROCEDURE|suturing procedure|Children presenting to the emergency department for suturing
214305290|NCT02046460|DRUG|Acetylsalicylic acid|Acetylsalicylic acid, 300mg o.p.d.
214305291|NCT02046460|DRUG|Vitamin K antagonist|Vitamin K-antagonists, target INR 2.0-3.0
214915114|NCT05473949|DRUG|Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
214915115|NCT02086149|BEHAVIORAL|Aerobic Exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals. Two month course of the nicotine patch initiated during week 5.
214915116|NCT02086149|BEHAVIORAL|Health Education|12-week health education control. Weekly sessions about 12 different topics related to the health effects of smoking, led by an expert in smoking cessation.
214915117|NCT03867136|DRUG|PZA sensitivity guided ultra-short all Oral Regimen|Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, \>50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, \>50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
214305292|NCT04988711|DIAGNOSTIC_TEST|Hb Oxymeter|Measurement of Hb Oximeter
214305293|NCT05546047|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
214305294|NCT01136850|DRUG|chloroquine, sulphadoxine pyrimethamine, LLIN|"\> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~\< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~Given at enrolment, 14-26 weeks gestation, by mouth."
214305295|NCT01136850|DRUG|azithromycin, sulphadoxine pyrimethamine, LLIN|"sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation."
214305296|NCT06317155|OTHER|Occupational therapy|Occupation Therapy, specifically interoception informed interventions which aim to improve sensory integration and emotional regulation. Additionally, occupational therapy models which focus on augmenting well-being and functionality, facilitating participation and engagement within communities, and promoting involvement in meaningful activity.
214305297|NCT04367688|DRUG|Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg|daily use for PrEP
214305298|NCT02496247|OTHER|Canned Herring|Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
214305299|NCT02295033|RADIATION|Boost irradiation|
214305300|NCT02154581|DEVICE|SLActive implant|
214915118|NCT03867136|DRUG|Standardized Shorter Regimen|Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, \>50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, \>50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
215060021|NCT03146663|DRUG|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
214915119|NCT03916549|DEVICE|Acupuncture|The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
214305301|NCT01039233|DRUG|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
214305302|NCT06241079|OTHER|non-intervention|non-intervention
214305303|NCT05505357|PROCEDURE|Breast surgery omission|For patients who are expected to achieve pathologic complete response after neoadjuvant chemotherapy based on MRI findings, vacuum-assisted biopsy will be performed on the main primary lesion marked with a clip. In case of pCR on vacuum-assisted biopsy specimen, breast surgery will be omitted.
214305304|NCT01092182|DRUG|EPOCH-R|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
214305305|NCT01092182|DRUG|EPOCH-RR|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 3 cycles
214305306|NCT01754844|DRUG|AZD7624|Single dose inhaled IMP via a nebulizer
214305307|NCT01754844|DRUG|Placebo to match|Single dose inhaled Placebo via a nebulizer
214305308|NCT00001758|DRUG|Abacavir|
214305309|NCT00001758|DRUG|Amprenavir|
214305310|NCT00001758|DRUG|Efavirenz|
214305311|NCT03942354|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
214305312|NCT03942354|DRUG|Pretomanid|Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
214305313|NCT03942354|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
214305314|NCT03942354|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
214305315|NCT03942354|DRUG|Clofazimine|Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
214305316|NCT03942354|DRUG|Directly observed therapy (DOT)|Standard therapy
214305317|NCT05297825|BEHAVIORAL|Vegan diet|Healthy vegan diet.
214305318|NCT05297825|BEHAVIORAL|Omnivore diet|Healthy omnivore diet.
214305319|NCT02591147|DEVICE|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
214305320|NCT02591147|DEVICE|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
214305321|NCT04002596|DEVICE|ExAblate Neuro Thalamotomy Treatment|Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
214305322|NCT03451318|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray NASONEX
214479946|NCT00641381|DRUG|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
214305323|NCT03451318|PROCEDURE|tonsillar adenoidectomy|tonsillar adenoidectomy
214305324|NCT03451318|PROCEDURE|Maxillary expander plus Twin-Block|Twin-block appliance combined with maxillary expander
214305325|NCT02515045|DRUG|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
214305326|NCT02515045|DRUG|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
214305327|NCT02515045|DRUG|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
214305328|NCT02515045|DRUG|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
214305329|NCT02664909|DRUG|Tranexamic Acid|
214305330|NCT02664909|DRUG|Placebo (saline)|
214305331|NCT03106155|DRUG|vistusertib (AZD2014)|vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
214305332|NCT03214159|DRUG|Ritonavir Tablet 100mg|Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
214305333|NCT03214159|DRUG|NORVIR tablet 100mg|NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
214305334|NCT00014209|DRUG|cisplatin|
214305335|NCT00014209|DRUG|dexamethasone|
214479947|NCT00641381|DRUG|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
214479948|NCT00641381|OTHER|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
214479949|NCT00641381|PROCEDURE|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
214479950|NCT00641381|PROCEDURE|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
215060022|NCT04362306|BEHAVIORAL|Planned Intervention|Intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic.
214305336|NCT00014209|DRUG|gemcitabine hydrochloride|
214305337|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection|Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
214305338|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection simulation|Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
214305339|NCT05663307|DRUG|Aspirin|plus aspirin at a dose of 100 mg per day for 90 days.
214305340|NCT03255382|DRUG|Fumaderm|Fumaderm tablet administered orally
214305341|NCT03255382|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
214305342|NCT02221284|DRUG|Alogliptin|Alogliptin tablets
214305343|NCT04178187|DRUG|Caps Lactolevure|One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
214305344|NCT04178187|DRUG|Caps Placebo|Caps Placebo
214305345|NCT02711046|PROCEDURE|single stage nasolabial flap|The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
214305346|NCT00140647|DRUG|Ramipril|
214305347|NCT00140647|DRUG|Rosiglitazone|
214305348|NCT04385823|DEVICE|patients receiving nasal high flow|patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow
215060023|NCT04362306|BEHAVIORAL|No planned intervention|Anxiety and patient satisfaction questionnaires will be completed prior to CT simulation.
214305349|NCT02725242|DRUG|Budesonide/formoterol (160/4.5 μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
214305350|NCT02725242|DRUG|Budesonide (400μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
214305351|NCT05947201|DRUG|Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil|If the addition of Cadonilimab to neoadjuvant chemotherapy further improve the efficiency for locally advanced esophageal squamous cell carcinoma
214305352|NCT02749812|DEVICE|Constant Continuous Positive Airway Pressure|
214305353|NCT02749812|DEVICE|Automatic continuous Positive Airway Pressure|
214305354|NCT02071888|DRUG|CB-839|Glutaminase inhibitor
214305355|NCT02071888|DRUG|CB-839 and low dose dexamethasone|CB-839 and low dose dexamethasone
214305356|NCT02071888|DRUG|CB-839, pomalidomide, and low dose dexamethasone|CB-839, pomalidomide, and low dose dexamethasone
214305357|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
214305358|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
214305359|NCT02225756|DRUG|Placebo|Oral administration for a short time of placebo
214305360|NCT00136305|BEHAVIORAL|Pictorial asthma action plan|
214305361|NCT00136305|BEHAVIORAL|Written asthma action plan|
214305362|NCT01487590|OTHER|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
214305363|NCT01487590|OTHER|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
214305364|NCT04511793|DEVICE|Medtronic Synchromed II pump|The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
214305365|NCT05418192|OTHER|Enriched Environment|Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.
214305366|NCT05418192|OTHER|Traditional Physcial Therapy|Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
214305367|NCT03525210|BIOLOGICAL|9-valent HPV vaccine|Vaccination
214305368|NCT03809507|OTHER|Qualtrics survey questions|"Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication"
214305369|NCT01380509|DRUG|Metronidazole|Capsules, single-dose, fasting
214305370|NCT01380509|DRUG|Flagyl|Capsules, single-dose, fasting
214305371|NCT03011307|DRUG|Oxytocin|spinal injection of oxytocin
214305372|NCT03011307|DRUG|Placebo|spinal injection of placebo
214305373|NCT01695694|BEHAVIORAL|supporting positive and healthy relationships|
214305374|NCT01695694|BEHAVIORAL|community support group|
214305375|NCT01185119|DRUG|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
214915120|NCT04824326|BEHAVIORAL|PSAI-CA|"The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day."
214915121|NCT03382626|DEVICE|anodal tDCS|Anodal tDCS will be applied on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for EEG electrode placement) with the following parameters: electrode size of 25-35 cm², 2mA, 0.057 mA/cm² and duration of 20 minutes. The cathode will be placed over the supra-orbital region.
214305376|NCT02157155|BIOLOGICAL|LPS|LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
214305377|NCT03475966|OTHER|Exercise|A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
214305378|NCT03475966|OTHER|Nutrition|Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
214305379|NCT03475966|BEHAVIORAL|Relaxation techniques|Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.
214305380|NCT03305328|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
214305381|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (oral fluid HCVST)|"The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits."
214305382|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (blood-based HCVST)|The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
214305383|NCT05537077|OTHER|Prolotherapy|DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
214305384|NCT05537077|OTHER|Home based exercise program|Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.
214479951|NCT06562348|OTHER|Standard of care|Patients will be offered palliative systemic treatment according to standard of care. Response evaluation will be performed with the imaging-based RECIST according to standard guidelines. Treatment pauses according to institutional guidelines. Blood samples will be analyzed retrospectively to evaluate ctDNA.
214305385|NCT05537077|OTHER|Hotpack therapy|Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.
214305386|NCT00985842|DEVICE|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
214305387|NCT00985842|DEVICE|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
214305388|NCT00985842|DEVICE|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
214305389|NCT00985842|DEVICE|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
214305390|NCT00985842|DEVICE|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
214305391|NCT00091273|BIOLOGICAL|incomplete Freund's adjuvant|
214479952|NCT06562348|OTHER|ctDNA-RECIST guided palliative systemic treatment|"Patients are offered palliative systemic treatment according to standard of care. Response evaluation will be performed using ctDNA-RECIST.~ctDNA is measured before start of treatment. If the baseline sample is ctDNA negative the patient is transferred to an observational cohort, and sampling procedures continues as in the standard arm. If the baseline sample is ctDNA positive the patient continues in the ctDNA-RECIST guided arm. Treatment response is evaluated according to ctDNA-RECIST, and further sampling follows a predefined decision schedule."
214479953|NCT04734197|DRUG|SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|combination of a topical immunosuppressant and a topical corticosteroid solution
214305392|NCT00091273|BIOLOGICAL|ovarian cancer peptide vaccine|
214305393|NCT00091273|BIOLOGICAL|sargramostim|
214305394|NCT00091273|BIOLOGICAL|tetanus toxoid helper peptide|
214305395|NCT00091273|PROCEDURE|adjuvant therapy|
214305396|NCT02677987|DEVICE|Intervention systematic light exposure|Bright light using Litebook device.
214305397|NCT02677987|DEVICE|Comparison systematic light exposure|Dim light using modified Litebook device.
214305398|NCT05836064|DEVICE|GastroBot|An artificial intelligence-developed and WhatsApp-based software bot. It will send the instructions to the patient through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results.
214305399|NCT05836064|OTHER|Conventional explanation|Patients will receive in writing detailed explanation about bowel preparation with polyethylene glycol
214305400|NCT01496547|DRUG|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
214305401|NCT01843764|DEVICE|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
214305402|NCT00651755|DRUG|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
214305403|NCT00651755|DRUG|Cyclophosphamide|750 mg/m\^2 By Vein On Day 1
214305404|NCT00651755|DRUG|Doxorubicin|25 mg/m\^2 By Vein Over 48 Hours On Days 1-2
214305405|NCT00651755|DRUG|Vincristine|2 mg By Vein On Day 1
214305406|NCT00651755|DRUG|Prednisone|100 mg PO for 5 Days
214305407|NCT00651755|DRUG|Rituximab|375 mg/m\^2 By Vein On Day 1.
214305408|NCT00651755|DRUG|Ondansetron|8 mg daily for 2 days
214305409|NCT04495127|DRUG|Selumetinib|Selumetinib 25 mg/m2 BID
214305410|NCT01492322|RADIATION|TRODAT|Smoker will receive a TRODAT injection
214305411|NCT02694406|DEVICE|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
214305412|NCT02287064|DRUG|Intravenous Immune Globulin (IVIG)|"IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion"
214305413|NCT02294344|OTHER|DFPP&CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35\~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented."
214305414|NCT02294344|DRUG|CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count \<3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count \<3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study."
214305415|NCT00263068|DRUG|Rotigotine|"Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day"
214305416|NCT02474108|PROCEDURE|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
214305417|NCT02474108|DEVICE|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
214305418|NCT00624052|DRUG|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
214479954|NCT04734197|DRUG|Mycophenolic Acid 0.1%|topical immunosuppressant
214305419|NCT00624052|DRUG|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
214305420|NCT04064918|OTHER|Netarsudil 0.02% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
214305421|NCT04064918|OTHER|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
214305422|NCT03190655|DEVICE|Aluminaid|Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
214305423|NCT03190655|DEVICE|Hydrogel|Hydrogel based wound dressing
214305424|NCT01438918|DRUG|SD-6010|200 mg tablets once a day for 2 years
214305425|NCT01438918|DRUG|SD-6010|50 mg tablets once a day for 2 years
214305426|NCT01438918|DRUG|Placebo|Placebo tablets once a day for 2 years
214305427|NCT03084887|BEHAVIORAL|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
214305428|NCT03541265|DRUG|Exparel|long-acting Bupivacaine extended release liposome compound
214305429|NCT03541265|PROCEDURE|Adductor block protocol|Adductor block using Exparel
214305430|NCT03541265|PROCEDURE|peri-articular injection protocol|peri-articular injection using Exparel
214305431|NCT02576288|DRUG|Sitagliptin|anti-inflammatory properties
214915122|NCT03382626|DEVICE|Computer-assisted training|The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.
214915123|NCT03382626|DEVICE|sham tDCS|Sham tDCS will be applied with the same parameters and electrode placement of active anodal tDCS. However, the current flow will be interrupted by the device after few seconds.
214915124|NCT02129413|DEVICE|Delta system|
214305432|NCT02576288|DRUG|Placebo|No anti-inflammatory properties
214305433|NCT00281684|DRUG|SB705498 400 mg|SB705498 400 mg
214305434|NCT00281684|DRUG|SB705498 1000 mg|SB705498 1000 mg
214305435|NCT00281684|DRUG|Placebo|Placebo
214305436|NCT00281684|DRUG|Co-Codamol|Co-Codamol
214305437|NCT05409144|PROCEDURE|Thoracic epidural infusion|Upon locating the desired site spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle. Once achieving local anesthesia, the epidural needle advanced with its stylet in place and with its bevel point cephalad; this will ultimately contribute to the proper location of the epidural catheter. The epidural needle must be advanced through the skin, subcutaneous tissue, supraspinous, and interspinous ligaments. Once there, the stylet must be removed, and the Loss of Resistance syringe (filled up with saline, air, or both) must be attached to the needle. The needle must be advanced while applying pressure to the plunger. Once the ligamentum flavum is pierced, a loss in resistance will be noted; this is the epidural space, and 5 to 10 cc of saline is injected to expand the epidural space; this may decrease the risk of vascular injury.
214305438|NCT05409144|DEVICE|Erector Spinae Plane Block|The block-level will be at T5. The ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which the following layers will be visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle and T5 transverse process. 3ml lidocaine 1% will be used on skin and subcutaneous fat, Echogenic block needle will be inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process.
214305439|NCT05409144|DEVICE|Serratus Anterior Plane Block|The block is performed with full aseptic precautions. Arm abduction is preferred. The ultrasound probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, then, 3ml lidocaine 1% will be used for skin and subcutaneous fat, using ultrasound guidance, a 38-mm 22-gauge regional block needle is going to be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep into the serratus anterior muscle.
214305440|NCT03006159|DRUG|SHR0534|
214305441|NCT03006159|DRUG|Placebo|
214305442|NCT04022096|DRUG|Tegoprazan 25mg QD|Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.
214305443|NCT04022096|DRUG|Lansoprazole 15mg QD|Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
214305444|NCT05162209|DIETARY_SUPPLEMENT|Synbiotic|Oral sachet, for 12 weeks
214305445|NCT06180590|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Evaluate the efficacy of Vosevi in DAAs-experienced patients
214305446|NCT05228145|GENETIC|NGN-101|Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.
214305447|NCT04026048|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia (CBT-I)|CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
214305448|NCT01948128|DRUG|Vitamin D3|Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
214915125|NCT00444938|DEVICE|H1 -coil TMS device|
214915126|NCT05330819|OTHER|Non-interventional|Blood thrombogenicity in patients with previous history of myocardial infarction will be studied using Badimon perfusion chamber, SEM and TEG.
214305449|NCT01948128|OTHER|Placebo|Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
214305450|NCT02628795|BEHAVIORAL|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
214305451|NCT02628795|OTHER|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
214305452|NCT00506155|DRUG|Avastin|10 mg/kg by vein over 90 minutes
214305453|NCT00506155|DRUG|Cisplatin|70 mg/m\^2 by vein over 4 hours
214305454|NCT00506155|DRUG|Doxorubicin|30 mg/m\^2 by vein over 15 minutes
214915127|NCT00603902|DRUG|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
214305455|NCT00506155|DRUG|Methotrexate|30 mg/m\^2 by vein over 30 minutes
214305456|NCT00506155|DRUG|Vinblastine Sulfate|3 mg/m\^2 by vein over 30 minutes
214305457|NCT03760146|BIOLOGICAL|20vPnC|20vPnC
214305458|NCT03760146|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
214305459|NCT03760146|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
214305460|NCT03760146|OTHER|Saline|Placebo
214305461|NCT04287777|DRUG|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
214305462|NCT04287777|DRUG|Mupirocin ointment|Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days
214915128|NCT00603902|DRUG|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
214915129|NCT00603902|DRUG|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
214915130|NCT01676935|DRUG|ABT-126|See arm description
214915131|NCT00459290|DRUG|mifepristone|
214915132|NCT02889939|OTHER|UC + ETT|"UC: A 3-week UC period, where the participants were not offered any new rehabilitation activities but were allowed to continue their regular treatment for a maximum of 3 hours per week.~ETT: The rehabilitation facilities were located in a climate that allowed and encouraged both indoor and outdoor activities. The ETT was individually tailored. Participants exercised in the same room/place as the other participants in groups of 4-9. Physical exercise was scheduled 3.5-6 hours per day, 5½ days per week for 3 weeks. The training was characterized by repetitive mass practice of gradually increasing difficulty and noncompensatory strategies, such as enforcing use of the affected side.~Beyond scheduled activities, participants were encouraged to physically engage themselves in a challenging outdoor environment."
214915133|NCT01180699|BIOLOGICAL|Influenza vaccine: Vaxigrip or Fluviral and Intanza|Patients will be randomized to receive either one intradermal dose of 0.1 mL or one intramuscular injection of 0.5 mL of the standard influenza vaccine in the deltoid muscle of the nondominant arm.
214915134|NCT02366637|DRUG|Placebo|Orally inhaled placebo twice a day (BID) for 4 weeks
214915135|NCT02366637|DRUG|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
214915136|NCT02145442|DIETARY_SUPPLEMENT|Obex|Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.
214915137|NCT02944552|DRUG|bicyclol tablet 25mg|Patients in the low dose group administrated bicyclol tablet 25mg, one bicyclol blank analog tablet and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
214915138|NCT02944552|DRUG|bicyclol tablet 50mg|Patients in the high dose group administrated bicyclol tablet 50mg and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
214915139|NCT02944552|DRUG|polyene phosphatidylcholine capsule 456mg|Patients in the positive drug control group administrated polyene phosphatidylcholine capsules 456mg and two bicyclol blank analog tablets orally, three times daily for 4-8 weeks.
214915140|NCT02309411|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
214915141|NCT00471341|DRUG|Celecoxib|
214915142|NCT00471341|DRUG|placebo|
214915143|NCT04520750|DRUG|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita
214915144|NCT03551171|DRUG|ZL-2306 (niraparib)|"About 30 subjects will be enrolled to the study, and randomised into 300mg, 200mg and 100mg dose groups (about 10 subjects per group).~All subjects will be randomised into indicated dose group (300mg, 200mg or 100mg) at the first day of the first cycle. A single administration of ZL-2306 (niraparib) will be given to the subjects at indicated dose."
214915145|NCT00717834|BIOLOGICAL|Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant|Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
214915146|NCT02760823|DRUG|Alpha Lipoic Acid (Thioctacid)|600 mg/12 hours, IV (in the vein)
214305463|NCT04287777|DRUG|Placebo|Topical administration of Placebo (ointment) TID during 7 days
214305464|NCT01334203|DRUG|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
214915147|NCT02760823|DRUG|Placebo (for Alpha Lipoic Acid)|Normal saline in syringe simulating Alpha Lipoic Acid 600mg
214915148|NCT00093912|DRUG|clevidipine|
214915149|NCT00093912|DRUG|sodium nitroprusside|
214915150|NCT05663112|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy will be performed.
214915151|NCT05663112|PROCEDURE|Breast massage|Breast massage will be performed for a duration of 5 minutes.
214305465|NCT03379649|COMBINATION_PRODUCT|Platelet rich plasma|Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
214305466|NCT03379649|COMBINATION_PRODUCT|Placebo|Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
214479955|NCT04734197|DRUG|Mycophenolic Acid 0.3%|topical immunosuppressant
214479956|NCT04734197|DRUG|Betamethasone Sodium Phosphate 0.01%|topical corticosteroid solution
214479957|NCT04734197|DRUG|Placebo Comparator: Vehicle|topical vehicle solution
214479958|NCT04734197|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|topical ophthalmic emulsion
214479959|NCT04734197|DRUG|Lifitegrast 5% Ophthalmic Solution|topical ophthalmic solution
214915152|NCT05663112|PROCEDURE|Blue dye injection|Isosulfan blue dye will be injected in the subareolar region of the breast
214915153|NCT00384618|DRUG|pravastatin|
214915154|NCT00384618|DRUG|vitamin E|
214915155|NCT02221336|DEVICE|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
214915156|NCT02221336|DEVICE|Non-MONARCA II system|Daily use of smartphone for normal communicative purposes. No self-monitoring in the MONARCA II system.
214915157|NCT00932308|DIETARY_SUPPLEMENT|Western-style diet (WD)|Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
214915158|NCT00932308|DIETARY_SUPPLEMENT|Prudent Diet (PD)|Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
214915159|NCT06214663|OTHER|0.9 NaCl solution|Saline injections will be administered over the sacral area (both posterior iliac spines and 2 cm downward and medial), and this technique was described by Lytzen et al in 1989 and later standardized. The results will be compared between the three groups.
214915160|NCT04742400|DRUG|tolebrutinib 60mg|60 mg orally
214915161|NCT04742400|DRUG|tolebrutinib 120mg|120 mg orally
214305467|NCT04839094|DIAGNOSTIC_TEST|rapid antigen testing versus RT-PCR|Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients.
214305468|NCT03839212|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
214305469|NCT03839212|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
214305470|NCT03839212|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
214305471|NCT03839212|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for three months post intervention for reinforcement.
214305472|NCT03809520|RADIATION|pedCAT|Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.
214305473|NCT00739037|DRUG|Placebo|
214305474|NCT00739037|DRUG|PAZ-417|
214915162|NCT04220788|OTHER|Enhanced pharmacist service|Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
214305475|NCT00482235|DRUG|MK0359|
214305476|NCT01809873|BEHAVIORAL|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
214479960|NCT05117151|DIAGNOSTIC_TEST|hypotension prediction index|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
215060024|NCT01728142|DEVICE|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
214479961|NCT03417531|DIETARY_SUPPLEMENT|Protein Supplement|Predosed protein powder; can be added to various dishes and drinks
214915163|NCT04220788|OTHER|Usual care|Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
214915164|NCT02480673|DIETARY_SUPPLEMENT|Chia|The subject will eat 25 gr of chia in 2 oatmeal cookies at day
214915165|NCT02480673|DIETARY_SUPPLEMENT|Oatmeal|The subject will eat 2 oatmeal cookies a day containing the exactly same quantity of oats in the oatmeal cookies with chia.
215060025|NCT01728142|OTHER|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
214305477|NCT02280564|BEHAVIORAL|health coaching with technology support|Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
214305478|NCT01650038|OTHER|treatment with faecal transplantation (donor faeces)|faecal transplantation
214479962|NCT03417531|DIETARY_SUPPLEMENT|Protein-free Supplement|Predosed protein-free powder; can be added to various dishes and drinks
214305479|NCT01650038|OTHER|treatment with faecal transplantation (own faeces)|faecal transplantation
214305480|NCT04562285|DIAGNOSTIC_TEST|Serologic immunoassays to SARS-CoV-2 antibodies|Detect and characterize antibodies to SARS-CoV-2
214305481|NCT02526940|PROCEDURE|rectal biopsies|6 rectal biopsies
214305482|NCT02526940|OTHER|Blood samples|Blood samples
214305483|NCT05552872|DIAGNOSTIC_TEST|mNGS, IDSeq UltraTM|pathogen detection
214479963|NCT03417531|PROCEDURE|Active Exercise|Program includes five strength exercises that can be easily performed at home
214479964|NCT03417531|PROCEDURE|Control Exercise|Program includes five flexibility exercises that can be easily performed at home
214479965|NCT01098955|BEHAVIORAL|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
214479966|NCT01098955|BEHAVIORAL|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
214479967|NCT01098955|DRUG|Varenicline|2 mg daily for 12 weeks
214305484|NCT03309358|DRUG|Inhaled SNSP113|A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
214305485|NCT03309358|DRUG|Inhaled Placebo|A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
214305486|NCT00679263|DRUG|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
214305487|NCT00679263|DRUG|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
214305488|NCT00679263|DRUG|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
214305489|NCT02453763|DEVICE|Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
214479968|NCT06890091|OTHER|Fatigue assessment|Fatigue score measured by the EORTC QLQ-FA 12 fatigue self-assessment scale
214479969|NCT04158024|OTHER|Erector Spinae Plane Block|The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
214479970|NCT04342572|DRUG|Melphalan|-The drug is commerically available
214305490|NCT02453763|PROCEDURE|MRI|All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
214305491|NCT00649675|DRUG|Meloxicam Tablets 15 mg|15mg, single dose fed
214305492|NCT00649675|DRUG|Mobic® Tablets 15 mg|15mg, single dose fed
214305493|NCT01464346|DEVICE|Enlite Sensor|This is the Enlite sensor (all subjects)
214305494|NCT02741908|BEHAVIORAL|Calorie counting diet|
214305495|NCT02741908|BEHAVIORAL|Fixed diet plan|
214305496|NCT05719012|BIOLOGICAL|UC-MSCs|Intravenous injection three times with one-month interval
214305497|NCT02099097|OTHER|web-based video game (Quit IT)|
214305498|NCT02099097|BEHAVIORAL|Questionnaires|In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
214305499|NCT02099097|OTHER|Salvia sample|The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
214305500|NCT04444414|OTHER|Manual therapy|bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
214305501|NCT04444414|OTHER|Control group|The control group received no treatment, they only attended the evaluations.
214479971|NCT06963242|DEVICE|Dynamic Navigation System for Implant Placement Using Bone Screws as Landmarks|This study uses a dynamic navigation system for implant placement in fully edentulous patients requiring full arch prosthesis rehabilitation. The system incorporates bone screws (placed as reference points on the jaw arch) to guide the accurate placement of implants. Unlike traditional freehand implant placement, this dynamic navigation system aims to minimize deviation from the planned implant positions while also reducing the time required for the surgical procedure. The results will be compared to a group where landmarks are based on remaining teeth to assess accuracy and time efficiency of the system.
214915166|NCT02480673|BEHAVIORAL|Normocaloric diet|The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.
214915167|NCT03357068|PROCEDURE|Control|Control side will receive only perforations on recipient site, which is the conventional technique for bone blocks graft.
214915168|NCT03357068|PROCEDURE|Acid|Test side will receive treatment with citric acid (10%) for 30s at bone block surface and recipient site
214915169|NCT05879289|DIETARY_SUPPLEMENT|A power supplement|A dietary supplement containing vitamins and collagen
214915170|NCT02464592|PROCEDURE|Transbronchial lung biopsy.|Transbronchial lung biopsy with cryoprobe and with conventional forceps.
214915171|NCT02268292|BEHAVIORAL|bicycle exercise|All enrolled subjects received a scheduled twelve-week exercise program. A commercially available bicycle (Giant CS800, Taichung, Taiwan) with an indoor bicycle stand (Giant Cyclotron Mag, Taichung, Taiwan) was used as the home exercise training modality.
214305502|NCT00260858|DRUG|Test Meal: Reference food (glucose or white bread)|
214305503|NCT00260858|DRUG|Test Meal: Pirate's Booty|
214305504|NCT00260858|DRUG|Test Meal: Ceaprove wafer|
214305505|NCT00260858|DRUG|Test Meal: Stretch Island Strawberry Fruit Leather|
214305506|NCT00087451|DRUG|AP23573|ridaforolimus
214305507|NCT01073852|DRUG|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
214305508|NCT01073852|DRUG|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
214305509|NCT04980677|DEVICE|Tangiball|"To enable baseline scores comparison, children will be matched according to age and score on the four-strand Hands-On assessment tool which takes 30 minutes to complete. Children will then play with the Smart Toy during a 20 minute session. Sessions will be recorded using an SD card within the Smart Toy which captures information on user speed and accuracy of placement of the detachable segments of the toy when placed into the main hub of the toy, allowing comparison between neuro-typical children and children with Autism. The intervention will run either in clinic (preferred option) or in children's homes-and in this case will be sent to them via post with the Standard Operating Procedure which can then be employed when children are taking part in the intervention via online video link (not recorded)."
214305510|NCT03088254|DRUG|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
214305511|NCT03088254|DRUG|Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
214305512|NCT03088254|DRUG|Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)|Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
214305513|NCT05678556|BEHAVIORAL|all2GETHER|all2GETHER is an HIV prevention and relationship education program designed for young MSM and other individuals who have sex, date, and are in relationships with MSM. all2GEHTER consists of 3 online didactic skills modules that include videos, activities, and other self-paced education components and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV and STI prevention in couples, effective communication skills, coping skills for LGBTQ and relationship stress, problem-solving and acceptance. Individualized couple sessions led by facilitators focus on implementation of skills specific to the needs of each couple.
214305514|NCT04546347|RADIATION|[14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|Dose of \[14C\]AZD9833 Solution for Infusion
214305515|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet A Dose 1
214305516|NCT04546347|DRUG|AZD9833 Oral Solution|AZD9833 Oral Solution
214305517|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 1|AZD9833 film-coated tablet B Dose 1
214305518|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 2|Dose 1 of AZD9833 film-coated tablet A Dose 2
214305519|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 2|Dose 1 of film-coated tablet B Dose 2
214915172|NCT02360969|OTHER|Examination of the eye|"Before planed surgery, an ophthalmologist measures the patient's visual acuity and realise an oculomotor examination. Measurement the refraction and the axial length of the eye is performed. Photographs wakefulness are performed.~During surgery, participation in this study does not involve any change in the course of anesthesia and surgery.~Pictures of the eye will be performed under general anesthesia.~Timing photos will be dictated by the values of BIS and train-of-four (TOF). Photos will be conducted at different times, with the top given by the anesthetist under the following conditions:~Deep anesthesia: BIS \<50 Deep anesthesia and muscle relaxation: BIS \<50 and TOF 0/4"
214915173|NCT02386267|DRUG|L-leucine|L-leucine pills per os for 6 months
214915174|NCT03558425|DRUG|CKD-381|1 tablet administered before the breakfast during 7 days
214915175|NCT03558425|DRUG|D026|1 tablet administered before the breakfast during 7 days
214915176|NCT06242548|OTHER|physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic)|"organisation of 4 physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic).~During each of of the 4 physical activity outings, collection of capillary blood samples (blood sugar, ketone levels), non-invasive biometric data (weight, oxygen saturation by transcutaneous sensor), and questionnaires (BORG scale, food consumption before/during/after exercise)."
214915177|NCT05922566|COMBINATION_PRODUCT|fMRI + Mukbang videos|Specific video program + fMRI will be allocated to the participants in this group. The specific video program includes control videos without food information, eating and food images without sound, chewing and swallowing sound without images, and Interactive content in Mukbang. Participants will undergo structural image scans, resting state scans, and task state scans. The task-fMRI will be performed while watching Mukbang to explore the activation of brain functional areas.
214915178|NCT05967013|COMBINATION_PRODUCT|Injections in thigh of 0.625 mL of physiological serum with ZENEO® injector, on bare skin and through clothing.|"All injections with ZENEO® injector will be performed in the thigh. Due to MRI performance constraints, injection sites will be identified on the same thigh/leg at each treatment period: first leg on treatment period 1, opposite leg on treatment period 2.~At each treatment period, two injection sites will be identified spaced 8 to 15 cm apart. The 2 injections should be performed on the same leg at each treatment period.~In total, 2 injections will be performed per treatment period, and subjects will receive 4 injections during the study :~* 2 injections on bare skin: 1 with GAMMA configuration of ZENEO® injector \& 1 with GAMMA-Low configuration ZENEO® injector.~* 2 injections through clothing: 1 with GAMMA configuration of ZENEO® injector \& 1 with GAMMA-Low configuration ZENEO® injector."
214915179|NCT00839800|DRUG|Symbicort Turbuhaler|160/4.5 µg
214915180|NCT00839800|DRUG|Terbutaline Turbuhaler|0.4 mg
214915181|NCT04687137|DRUG|TAK-743 300 mg|TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks
214915182|NCT02779010|BEHAVIORAL|Hand washing with soap and Health education|Health education on key environmental variables and hand washing with soap
214915183|NCT02510664|BEHAVIORAL|Diabetes Strengths Study|"The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments."
214915184|NCT01422564|DEVICE|Metal on Metal Hip System|Total hip arthroplasty with a metal on metal component system
214915185|NCT01422564|DEVICE|Highly Cross Linked Polyethylene cup System|Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
214915186|NCT01757002|BEHAVIORAL|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.|Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.
214915187|NCT01757002|BEHAVIORAL|Teens in the control group will receive generic, web-based asthma education.|Web-based, generic asthma management intervention delivered in 4 sessions.
214915188|NCT01598493|DEVICE|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
214915189|NCT01598493|DRUG|Flamazine|Silver sulfadiazine cream
214915190|NCT04394780|PROCEDURE|cooling|First, patients underwent peritoneal dialysis (PD) at 37 C (standard temperature) and then patients underwent PD cooling. After each PD session, the patient had a CT scan for the study team to study myocardial perfusion at rest and after introduction of a pharmacological stressor.
214915191|NCT03648320|OTHER|Peanut oral immunotherapy|Daily doses of peanut flour (with 2-weekly incremental interval)
214305520|NCT03245008|DRUG|MT-5547|Solution for injection in pre-filled syringe
214479972|NCT06963242|DEVICE|Dynamic Navigation System for Implant Placement Using Remaining Teeth as Landmarks|In this arm, participants will undergo implant placement using a dynamic navigation system, where the reference points for implant positioning are based on the remaining teeth to be extracted. This approach, in contrast to the bone screw method used in Group 1, relies on the teeth that will be removed as landmarks to guide the accuracy of implant placement. The primary goal is to evaluate the accuracy of the implant placement and the time required for the procedure using this method. The results from this group will be compared to those from Group 1, where bone screws are placed as reference points, to assess the accuracy and time efficiency of both approaches.
214305521|NCT03245008|DRUG|MT-5547-matching placebo|Solution for injection in pre-filled syringe
214305522|NCT00000586|DRUG|hydroxyurea|
214305523|NCT05818579|OTHER|Virtual reality experience|The VR experience is launched on the participants using all-in-one VR head-mount devices. Tablet computers are used to optimize the settings by the intervention facilitators. Each session lasts for approximately one hour with 10 minutes spent on the briefing, 20 minutes spent on the VR experience, and 30 minutes spent on the post-VR group discussion. There are two sessions per week. The whole course lasts for six weeks and there are a total of 12 sessions.
214915192|NCT02021344|BEHAVIORAL|Mental Health First Aid|Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.
214915193|NCT00392340|BIOLOGICAL|filgrastim|
214305524|NCT02075658|DEVICE|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
214305525|NCT02075658|DEVICE|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
214305526|NCT01286012|DRUG|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
214305527|NCT01286012|DRUG|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
214305528|NCT01286012|DRUG|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
214305529|NCT01286012|DRUG|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
214305530|NCT04991571|DRUG|Zibotentan (Treatment A)|Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.
214305531|NCT04991571|DRUG|Dapagliflozin (Treatment A)|Dapagliflozin tablet will be administered orally as single dose in Part 2.
214305532|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
214305533|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
214305534|NCT04073381|COMBINATION_PRODUCT|Prehabilitation Program|This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
214305535|NCT00718328|DRUG|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
214305536|NCT00718328|DRUG|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
214305537|NCT04034420|OTHER|Online training platform|Self-paced training and learning materials in relation to family services
214305538|NCT01726153|BEHAVIORAL|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
214305539|NCT03096379|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
214305540|NCT01064401|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
214305541|NCT01064401|DRUG|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
214305542|NCT01064401|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a for intramuscular injection
214305543|NCT01064401|DRUG|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
214305544|NCT05755685|DRUG|Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)|5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
214305545|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
214305546|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
214305547|NCT01395433|DRUG|Escitalopram|1 x 20 mg, single dose
214305548|NCT04007094|OTHER|ViviGen Cellular Bone Matrix|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10
214479973|NCT06962033|BEHAVIORAL|Opioid Agonist Therapy|Opioid Agonist Therapy (OAT) as HIV prevention
214305549|NCT01372280|DRUG|Reminyl|Galantamine Hydrobromide Tablets 4 mg
214305550|NCT06912997|OTHER|Exercise|The home-based inspiratory muscle training (IMT) protocol will use an inspiratory threshold loading device (PowerBreathe Wellness, Southam, United Kingdom). IMT for experimental group will start with a minimal load (\~9 cmH2O) during the first week, aiming for a familiarization process. During the second week, the IMT targeted a moderate load of 45% of maximal inspiratory pressure (MIP) previously defined, which will be gradually increased by 10% of MIP each week until reaching 75% of MIP in the final week.
214305551|NCT06912997|OTHER|Sham Comparator|The Sham group will performer the same training protocol that experimental group, but at 5% of MIP during all weeks. Therefore, the sham group will not increase the training load during the protocol.
214479974|NCT01709292|DRUG|Vemurafenib (All Groups)|960 mg by mouth 2 times a day 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56.
214915194|NCT00392340|DRUG|doxorubicin hydrochloride|
214915195|NCT00392340|DRUG|topotecan hydrochloride|
214915196|NCT00392340|DRUG|vincristine sulfate|
214305552|NCT01581307|DRUG|FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)|The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
214915197|NCT04722068|OTHER|Kinetics test|Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.
214915198|NCT02309476|DEVICE|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
214915199|NCT02309476|DEVICE|PASCAL Laser, Green Laser 1|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
214305553|NCT01581307|DEVICE|TheraSpheres|TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
214305554|NCT05556239|BEHAVIORAL|Resistance Exercise Training|Supervised resistance training program planned as 3 sessions per week of approximately 60 minutes. The resistance training program comprises 6 exercises for the major muscle groups, starting at 2 sets of 15 repetitions maximum progressing to 4 sets of 8 repetitions maximum. Each session will be supervised by physiotherapist to ensure proper technique, and progression in training load. The participants will choose an exercise ambassador from their network, who during the period will be encouraged to, on a weekly basis, to be in contact with the participant.
214305555|NCT04368819|DRUG|Allopurinol 300 MG|Allopurinol 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
214305556|NCT04368819|DRUG|Placebo oral tablet|Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
214305557|NCT04811313|DRUG|Tranexamic acid|patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA
214305558|NCT04811313|PROCEDURE|caudal epidural block|regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss
214305559|NCT04811313|OTHER|Placebo|participants will receive standard care but neither TXA nor caudal epidural block
214305560|NCT04994444|DRUG|Nicoderm CQ 21Mg/24Hr Transdermal System|Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
214305561|NCT05706025|DEVICE|EnteroTracker|The EnteroTracker® is a capsule device that includes an absorbent string.
214305562|NCT06865820|BEHAVIORAL|Project UPLIFT|Project UPLIFT is a Mindfulness-based Cognitive Behavioral Therapy program teaching participants methods that include challenging thoughts, behavioral activation, coping, problem-solving, and mindfulness. The program is group-based and provides weekly sessions, delivered remotely via telephone or video conferencing platform, over an 8-week period.
214305563|NCT02117999|DEVICE|Cross-linking with iontophoresis|The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.
214305564|NCT02117999|DEVICE|Standard corneal cross-linking|In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
214305565|NCT00378209|DRUG|Bortezomib|Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
214915200|NCT02309476|DEVICE|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
214915201|NCT02309476|DEVICE|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
214915202|NCT02309476|DEVICE|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
214305566|NCT00378209|DRUG|Lenalidomide|Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles
214305567|NCT00378209|DRUG|Dexamethasone|Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
214305568|NCT04206969|BEHAVIORAL|Transcultural psychotherapy|In addition to usual care, the participants receive transcultural psychotherapy
214305569|NCT06912932|BEHAVIORAL|Preventive|systematically investigate the acute physiological responses induced by three levels of %Pmax intensities (50% and 75% of Pmax and all-out efforts) with three varying rest periods (15, 30, and 45-s) between thirty 4-s sprints.
214915203|NCT02309476|DEVICE|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
214305570|NCT06913868|BEHAVIORAL|Consensus-Based Physiotherapy Program|Physiotherapy for fibromyalgia (Baroni et al., 2023 Delphi consensus). Includes pain neuroscience education (PNE), tailored aerobic, strengthening, and sensorimotor exercises (graded exposure), and self-management strategies. 8-week program: 1-2 sessions/week (60 min) + home exercise (20 min, 3x/week). Therapist training and fidelity monitoring.Pain Neuroscience Education (PNE): Approximately 20 minutes per session, focusing on explaining the neurobiology of pain in fibromyalgia, emphasizing central sensitization mechanisms, and reconceptualizing pain as an output of the brain rather than solely a marker of tissue damage. PNE aims to reduce threat value associated with pain and improve understanding of pain fluctuations.
214305571|NCT06913868|BEHAVIORAL|Standardized Physiotherapy Care|Standardized physiotherapy for fibromyalgia. Includes general exercise (aerobic, stretching), manual therapy (within guidelines), and basic pain education (excluding PNE). 8-week program: 1-2 sessions/week (60 min) + home exercise (20 min, 3x/week). Therapist training and fidelity monitoring.
214305572|NCT06914284|OTHER|Actigraphy and MRI|All participants will wear a wGT3X-BT actigraph (wGT3x-BT) for 4 days. Actigraphs are collected back at Day 4, after full 96 hours, when coming to the MRI platform. There, they will undergo 45 minutes MRI that acquire MRI signals to quantify degenerative, inflammatory, vascular and functional cerebral features.
214305573|NCT01918761|DRUG|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
214305574|NCT06913270|BEHAVIORAL|Immersive Virtual Reality Distraction (IVRD)|"Intervention Description:~Participants assigned to this intervention will receive standard analgesic care per institutional protocol in addition to an immersive virtual reality (VR) distraction intervention. During each burn dressing change, participants will wear a head-mounted display (HMD) that delivers an interactive and engaging virtual environment designed specifically to distract from procedural pain and reduce anxiety. The VR session will last for the entire duration of the dressing change (approximately 10-15 minutes) and will be administered during every session. The VR system is calibrated to provide high levels of sensory immersion to effectively divert attention from painful stimuli."
214305575|NCT06913270|BEHAVIORAL|Nature Video Distraction (NVD)|"Intervention Description:~Participants in this intervention will receive the same standard analgesic care provided to all subjects and, in addition, will watch a nature video on a tablet device during the burn dressing change. The video distraction serves as an active comparator to the immersive VR. The nature video is selected to be calming and engaging, and it will be played continuously during the dressing change session (approximately 10-15 minutes). This intervention allows evaluation of whether immersive VR provides additional benefit in reducing procedural pain and anxiety over a standard video distraction."
214305576|NCT05040360|DRUG|Capecitabine|Given PO
214305577|NCT05040360|DRUG|Temozolomide|Given PO
214305578|NCT04919278|PROCEDURE|Chiropractic adjustments|Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body's physical function.
214305579|NCT06110676|BIOLOGICAL|LZM012|Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
214305580|NCT06110676|BIOLOGICAL|Secukinumab|Cosentyx
214305581|NCT05845788|PROCEDURE|Peripheral nerve block|Ultrasound guided peripheral nerve block
214305582|NCT00579514|GENETIC|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
214305583|NCT02145039|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
214305584|NCT02145039|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
214305585|NCT02145039|RADIATION|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
214305586|NCT02145039|BIOLOGICAL|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
214915204|NCT00746889|DRUG|triamcinolone acetonide|single intraarticular injection of 40 mg of triamcinolone acetonide
214915205|NCT00746889|DRUG|saline|Single intraarticular injection of 1 ml of 0.9% saline
214915206|NCT00136929|DRUG|Thrombolytic therapy|
214305587|NCT00268138|DRUG|elmex gel|elmex gel once a week
214305588|NCT02306356|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
214305589|NCT06083883|DRUG|Fludarabine phosphate|Given by IV (vein)
214305590|NCT06083883|DRUG|NY-ESO-1 TCR/IL-15 NK|Given by IV (vein)
214305591|NCT06083883|DRUG|Cyclophosphamide|Given by IV (vein)
214915207|NCT00136929|PROCEDURE|Percutaneous coronary intervention (PCI)|
214915208|NCT06110494|DRUG|Iron oxide nanoparticles treatment Ferumoxytol/H2O2|Participants receive a topical treatment through a root canal irrigation needle containing A mixture of 6mg/mL Ferumoxytol nanoparticles solution mixed with 3% H2O2 for 10 minutes contact time
214915209|NCT06110494|DRUG|NaOCl|Participants receive a topical treatment through a root canal irrigation needle containing 3% NaOCl for 10 minutes contact time
214915210|NCT06110494|DRUG|NaCl|Participants receive a topical treatment through a root canal irrigation needle containing 0.89% NaCl for 10 minutes contact time
214915211|NCT06110494|DRUG|supplementary irrigation|"All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously"
214915212|NCT03095326|DIETARY_SUPPLEMENT|Zinc|formula of ZnSO4, usually used to treat zinc deficiency.
214915213|NCT03095326|DRUG|Sucrose|Placebo of sucrose syrup
214915214|NCT03095326|BIOLOGICAL|PCV Vaccine|Pneumococcal conjugate vaccine
214915215|NCT03095326|BIOLOGICAL|PPV Vaccine|Pneumococcal polysaccharide vaccine
214915216|NCT00326274|DRUG|Helioblock® SX Cream|
214915217|NCT02289248|DRUG|Ketamine|Subjects will undergo a twice weekly two week course of IV infusions of ketamine
214915218|NCT02289248|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Subjects will undergo twice weekly CBT for a total of 8 weeks
214305592|NCT03115983|DEVICE|LimiFlex|LimiFlex implantation at a single level after surgical decompression.
214305593|NCT03115983|DEVICE|Fusion Instrumentation|Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).
214305594|NCT03115983|PROCEDURE|Decompression|Surgical decompression at one or two contiguous levels from L1 to S1.
214305595|NCT03115983|PROCEDURE|Fusion|Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
214305596|NCT06394531|DIETARY_SUPPLEMENT|Jaboticaba Peel Extract|Jaboticaba peel extract. Patients will ingest 4 capsules/day of jaboticaba (Plinia Cauliflora) peel extract, providing 3.3g of jabuticaba peel extract daily, containing 600mg of phenolic compounds, for one month.
214305597|NCT06394531|OTHER|Placebo|Placebo. Patients will ingest 4 capsules/day of placebo (corn starch), providing 3.3g of placebo, for one month.
214305598|NCT05722873|BEHAVIORAL|Fasting arm|Study participants will fast one day per week for 12 weeks
214305599|NCT05722873|BEHAVIORAL|Weight maintenance|Study participants will be counseled to maintain body weight
214305600|NCT05722873|BEHAVIORAL|Counseling|Study participants will be counseled on optimal diet and activity recommendations for maintaining/achieving a normal BMI
214305601|NCT05950633|OTHER|Standard of Care|Participants will receive standard of care postoperative instructions
214305602|NCT05950633|OTHER|Active Recovery|Participants will receive instructions to increase their fitness to walking at least 30 minutes a day for 5 days a week following surgery and abdominal and pelvic floor exercises will focus on abdominal wall strengthening and abdominal pressure management, urinary urgency and retention, bowel and constipation management
214305603|NCT05489705|DRUG|Mavacamten|As per product label
214305604|NCT05489705|DRUG|Non-mavacamten symptomatic oHCM therapy|Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
214305605|NCT01536379|DRUG|Belimumab|Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
214305606|NCT01536379|DRUG|Placebo|Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
214305607|NCT05191446|BEHAVIORAL|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|"Step 1 includes three sessions of motivational interviewing (MI). MI will consist of three video (Zoom) or telephone sessions: an initial 45-minute session, followed by two 20-minute sessions. Treatment is based on Motivational Interviewing by Miller and Rollnick, and includes exploring ambivalence about change, reflective listening, expressing empathy, and discussion about change. To support increased motivation to reduce drinking, discussion will center on effects of hazardous drinking on liver disease.~Step 2 includes referral to addiction medicine for participants who do not reduce unhealthy alcohol use or requested by patient. Specialty addiction services include both direct treatment and coordination of addiction care. After an evaluation, the addiction medicine physician may recommend pharmacotherapy (in consultation with hepatology provider if indicated), and/or referral to intensive outpatient, or residential level of care depending on clinical judgement."
214305608|NCT05191446|OTHER|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
214305609|NCT04273776|DRUG|Suvorexant 10 mg|10 mg of suvorexant
214305610|NCT04273776|DRUG|Zolpidem|5 mg of zolpidem
214305611|NCT04273776|DRUG|Placebos|Avicel
214305612|NCT05906082|BEHAVIORAL|E-cigarette cessation text-messaging intervention|This is the intervention for e-cigarette cessation using text messages targeting young adults in rural areas.
214305613|NCT05906082|BEHAVIORAL|Standard care control using standard national resources|This is the standard care with national resources from smokefree.gov.
214305614|NCT05831761|DRUG|Comparison of analgesic efficacy protocol|Comparison of 4 possible analgesic protocols
214305615|NCT00561756|BIOLOGICAL|plasmid DNA vaccine therapy|
214305616|NCT00561756|OTHER|flow cytometry|
214305617|NCT00561756|OTHER|immunoenzyme technique|
214305618|NCT02423616|OTHER|Healthy individuals|INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
214305619|NCT00002417|DRUG|Amprenavir|
214305620|NCT04159597|DRUG|Upadacitinib|Upadacitinib will be administered as oral solution.
214305621|NCT04304339|OTHER|Hypercapnic respiratory failure|Patients with hypercapnic respiratory failure will be followed without any additional intervention
214305622|NCT02293226|DEVICE|CoopDech|Video-laryngoscopy 1
214305623|NCT02293226|DEVICE|CoPilot|video-laryngoscopy 2
214305624|NCT02293226|DEVICE|Intubrite|Video-laryngoscopy 3
214305625|NCT02293226|DEVICE|Vividtrack|video-laryngoscopy 4
214305626|NCT03759561|PROCEDURE|intubation with videolaryngoscope vs fiberoptic bronchoscope|Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations
214305627|NCT04320264|PROCEDURE|Weight loss surgery|Severely obese women (BMI \>40) undergo sleeve gastrectomy
214305628|NCT04900064|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI). The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
214305629|NCT04900064|BEHAVIORAL|Self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering self-help CBT will need four days of reading and two days of training as well as regular supervision to be able to make initial assessments and problem profiling and use the self-help books.
214305630|NCT06063603|PROCEDURE|Acupuncture Therapy|Undergo acupuncture therapy
214305631|NCT06063603|BEHAVIORAL|Cancer Pain Management|Receive pain clinic referral
214305632|NCT06063603|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBT
214305633|NCT06063603|PROCEDURE|Discussion|Participate in focus group
214305634|NCT06063603|OTHER|Educational Intervention|Receive self-guided pain management education materials
214305635|NCT06063603|OTHER|Exercise|Participate in exercise
214305636|NCT06063603|OTHER|Interview|Complete interview
214305637|NCT06063603|PROCEDURE|Massage Therapy|Receive massage
214305638|NCT06063603|BEHAVIORAL|Mindfulness Relaxation|Practice mindfulness
214305639|NCT06063603|PROCEDURE|Pain Therapy|Receive pain treatment/medicine
214305640|NCT06063603|OTHER|Palliative Therapy|Receive palliative care referral
214479975|NCT01709292|DRUG|Vemurafenib (Post Surgery) - Group A + C|"Group A: 960 mg by mouth twice a day 2 weeks post-surgery. Restaged 8 weeks after resuming drug. If patients demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until they are no longer benefitting from the drug.~Group C: Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56. Vemurafenib 960 mg by mouth twice a day, continued unless there is evidence of progressive disease on day 56 CT scan. Patients restaged every 8 weeks and continue vemurafenib until no longer benefitting from the drug. Patients evaluated for resectability after each CT scan is performed. If patient is scheduled for resection, then patient will continue vemurafenib until surgery and will follow the same treatment schema as patients in Groups A and B."
214305641|NCT06063603|BEHAVIORAL|Patient Navigation|Undergo visits with PCM and CHW for pain management
214305642|NCT06063603|OTHER|Referral|Receive pain management referrals
214305643|NCT06063603|PROCEDURE|Spiritual Therapy|Receive spiritual support
214305644|NCT06063603|PROCEDURE|Spiritual Care Referral|Receive spiritual care referral
214305645|NCT06063603|OTHER|Survey Administration|Ancillary studies
214305646|NCT05732389|DRUG|Nivolumab|Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.
214305647|NCT05732389|DRUG|Ipilimumab|Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
214305648|NCT04439253|DRUG|Crizotinib|Given PO
214305649|NCT06451952|OTHER|Virtual darkness|Chronotheraphy
214305650|NCT04995523|DRUG|AZD2936|Anti-TIGIT/Anti-PD-1 Bispecific Antibody
214305651|NCT01272609|DRUG|Timolol + LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
214305652|NCT01272609|DEVICE|LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
214305653|NCT05966896|DEVICE|implanted epidural stimulator|implantable multi-programmable neurostimulation system to deliver electrical stimulation to neural targets in the spinal cord
214305654|NCT03971695|DRUG|BI 706321|Capsule or Oral Solution
214479976|NCT01709292|OTHER|Post Surgery - Group B|Patients who have had a complete surgical resection, and who do not have evidence of metastatic disease will discontinue vemurafenib after surgery. Patients restaged with CT neck 8 weeks after surgery.
214479977|NCT06470984|BEHAVIORAL|Educational intervention|Professional development program provided online to small groups of professional nurse leaders via an educational platform over a 6-week period.
214305655|NCT03971695|DRUG|Placebo|Capsule or Oral solution
214305656|NCT01883414|DEVICE|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
214305657|NCT05059860|DEVICE|Tandem Control IQ Hybrid Closed Loop Insulin Delivery System|The Tandem Control IQ hybrid closed loop insulin delivery system is made up of an externally worn Tandem insulin pump which communicates wirelessly to the Dexcom G6 CGM worn as a patch on the skin. The CGM measures glucose levels transmitting them into the computer within the pump. The computer then calculates how much insulin is required then dose delivery completes the cycle. The Control-IQ™ advanced technology adjusts insulin delivery to avoid glycaemic excursions, while still allowing the user to manually bolus at mealtimes.
214305658|NCT06482489|DEVICE|Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).|Performing low-field MRI to evaluate image quality with patients carrying metallic implants and assess the detection of suspicious prostate lesions.
215060026|NCT04853771|BEHAVIORAL|progressive muscle relaxation exercise training|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
214305659|NCT05643716|BEHAVIORAL|Aerobic Exercise|The aerobic exercise intervention is described in the Aerobic Exercise Arm description.
214305660|NCT04447417|DRUG|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214305661|NCT05705284|OTHER|Structured multidisciplinary medication review|Multidisciplinary process for medication review/deprescribing: The intervention will be a structured process for performing a shared-decision, person-centred medication review among those living with frailty involving GPs, PCN-pharmacist and ANPs.
214305662|NCT04835025|DRUG|PD-1/PD-L1 inhibitor|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
214305663|NCT05402150|BEHAVIORAL|Behavioral Activation|"* instruction to create a list of individual positive activities.~* instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity."
214305664|NCT05402150|BEHAVIORAL|Mindulness and Gratitude|"* instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with these pleasant impressions of the situation they reflected upon~* instruction to do a gratitude exercise and name one or more things they are generally grateful for each day."
214305665|NCT05402150|BEHAVIORAL|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
214305666|NCT02109614|DRUG|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
214479978|NCT06635642|BEHAVIORAL|Dichotic Interaural Intensity Difference (DIID) Training|A total of five trials will be presented in a sequence and there will be 10 sequences per training session. Each of the 25 consonant-vowel-consonant words or digits 1 through 10 (excluding 7) will be presented to each ear during the session. The pairs will be randomized every time, and a word will never be paired with itself. After a sequence is completed, the difficulty of the task will be adjusted, in real time, based on performance on the prior task. If the child scored 4 or 5 of 5 correct in the poorer ear, then the IID will be decreased by 2 dB making the task more difficult. If the child scores 0, 1, or 2 of 5 correct, then the IID will be increased by 2 dB making the task easier. Last, if the child scores 3 of 5 correct, then the IID will remain unchanged for the next sequence.
214479979|NCT01144455|DRUG|Gemzar (Gemcitabine)|1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
214479980|NCT01144455|DRUG|TH-302|240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
214305667|NCT02109614|DRUG|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
214305668|NCT00047021|BIOLOGICAL|sargramostim|Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.
214305669|NCT00047021|DRUG|cytarabine|high-dose cytarabine IV over 1 hour on days 1-5
214305670|NCT00047021|DRUG|mitoxantrone hydrochloride|high-dose mitoxantrone IV over 15-30 minutes on day 5.
214305671|NCT03836547|BEHAVIORAL|Coaching and Weight Loss for patients with dyspnea|Patients with lung disease and a BMI of 35 or greater who suffer from shortness of breath will be invited to participate in a study involving a commercial weight loss application with health coaching. The patients will subscribe on their own to the weight loss application. The patients will be provided with a blue tooth scale so that they may weigh themselves weekly. A health coach will call them weekly for 8 weeks.
214479981|NCT01144455|DRUG|TH-302|340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
214305672|NCT03836547|BEHAVIORAL|Active Control|Participants will receive usual care for 12 weeks followed by the active intervention.
214305673|NCT01010308|DRUG|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
214479982|NCT06772090|BIOLOGICAL|Lactobacillus and Bifidobacterium|"Each lot of Lactobacillus and Bifidobacterium and placebo capsules to be used in this study will undergo bioburden testing (tested as per USP \<61\>) to ensure that each lot has:~* Not more than 2000 colony forming unit (CFU) of contaminating (other than the seven strains of bacteria used in the Lactobacillus and Bifidobacterium capsules) aerobic bacteria per gram or dose (whichever is greater);~* Not more than 200 CFU of yeasts and molds per gram or dose (whichever is greater); and~* No bile-tolerant Gram-negative bacteria, Escherichia coli, Salmonella species (in 10 gm), Pseudomonas aeruginosa, Staphylococcus aureus, and Clostridium species per gram or dose (whichever is greater; tested as per USP\<62\>)."
214479983|NCT06772090|OTHER|Placebo|Placebo capsule manufactured in same facility as experimental capsule.
214305674|NCT06787521|OTHER|evidence-based labor guide|Participants will be provided with written education about potential complications and interventions. Information will be provided at the time of admission for labor induction.
214305675|NCT03767920|DRUG|bupivacaine|TAP block with 20 ml of 0.25% bupivacaine bilaterally
214305676|NCT03767920|DRUG|dexamethasone|TAP block with 4 mg dexamethasone bilaterally
214305677|NCT03767920|DRUG|placebo to dexamethasone|TAP block with 4 mg placebo to dexamethasone bilaterally
214305678|NCT03609515|OTHER|Patient-controlled admission|The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.
214305679|NCT06118840|DEVICE|True-AI-integrated intracranial aneurysms diagnosis strategy|The True-AI deep-learning based model for intracranial aneurysms detection had a patient-wise sensitivity, lesion-wise sensitivity and specificity of 0.96, 0.87, and 0.80 in the internal validation dataset.
214305680|NCT06118840|DEVICE|Sham-AI-integrated intracranial aneurysms diagnosis strategy|The Sham-AI deep-learning based model for intracranial aneurysms detection is designed to have a sensitivity close to 0% and a similar specificity to the True-AI. In the internal validation dataset, the Sham-AI had a patient-wise sensitivity, lesion-wise sensitivity, specificity of 0.02, 0.01, and 0.80, respectively.
214305681|NCT04733742|DRUG|rhTNK-tPA|intravenous thrombolysis with rhTNK-tPA followed by endovascular treatment
214305682|NCT04733742|OTHER|Endovascular treatment|endovascular treatment
214305683|NCT01204476|BIOLOGICAL|Cixutumumab|Given IV
214305684|NCT01204476|DRUG|Everolimus|Given PO
214305685|NCT01204476|OTHER|Laboratory Biomarker Analysis|Correlative studies
214305686|NCT01204476|DRUG|Octreotide Acetate|Given IM
214305687|NCT01204476|OTHER|Pharmacological Study|Correlative studies
214305688|NCT01341600|DRUG|Clopidogrel|Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
214305689|NCT01341600|DRUG|Omeprazole/Clopidogrel|After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
214305690|NCT04877275|DRUG|Selinexor (80mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;"
214305691|NCT04877275|DRUG|Selinexor (100mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;"
214305692|NCT04877275|DRUG|Pegylated liposomal doxorubicin|25 mg/m\^2 intravenously on day 1 , QW
214305693|NCT04877275|DRUG|Dexamethasone|Dexamethasone 40mg/d QW
214305694|NCT04877275|DRUG|Cyclophosphamide|Cyclophosphamide：300mg/m2, d1 QW，
214305695|NCT04749953|PROCEDURE|Maxillary sinus floor augmentation|The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla
214305696|NCT06376162|DRUG|Ziftomenib|Oral capsule
214305697|NCT06376162|DRUG|Cytarabine|Intravenous (IV) infusion
214305698|NCT06376162|DRUG|Fludarabine|IV infusion
214305699|NCT05533853|OTHER|Posture corrective exercises|The exercises are of two types strengthening exercises and starching exercise ,). The strengthening exercises are to be done for 15 repetitions in 2 sets, Progression will be by increasing to 3 sets and adding 1 Kilogram of resistance in dumbbells exercises, the targeted muscles are teres minor, infraspinatus, medial and lower trapezius, rhomboids, and cervical flexor muscles. On the other hand, stretching exercises are to be hold for 30 seconds for 2 sets then progressed to 3 sets, the targeted muscles are pectoralis minor, sternocleidomastoid and levator scapulae.
214305700|NCT05533853|OTHER|Denneroll extension traction|The participants will be instructed to lie supine and keep their legs extended. Based on the apex of each participant's cervical curvature on the initial radiograph, the therapist will position the apex of the denneroll in one of two regions (mid cervical placement or lower cervical placement). The duration of the traction session will start at 2-3 min and increased 1 min per session until reaching the goal of 20 min, the traction will repeated three times per week for 6 weeks
214305701|NCT04014257|DRUG|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
214305702|NCT01802957|OTHER|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
214479984|NCT06545279|PROCEDURE|Hall Crown Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation.
214305703|NCT01802957|OTHER|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
214305704|NCT01802957|OTHER|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
214305705|NCT01802957|OTHER|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
214915219|NCT05127317|DIAGNOSTIC_TEST|Mechanical power|"In our study, mechanical power (MP) will be calculated during mechanical ventilation in patients who will be operated under general anesthesia.~MP will be calculated with the simplified formula applied by Gattinoni et al. MPvcv: RR x Tv x (PIP-\[(Pplat-PEEP)/2\]) x 0.098(2) In pressure-controlled ventilation, the simplified MP formula of Becher et al. well be used.~MPpcv: RR x Tv x (ΔPinsp + PEEP) x 0.098 (11)~For MP calculated according to the weight of the patients; Indexed MP: MP /kg according to IBW. For the force applied to the lungs in each inspiration; Dynamic power (mJ/min): Vt x RR x \[(Pplato+ tPEEP)/2\]. For the driver power that provides the gas flow; Driving power (mJ/min): Vt x RR x \[ (Pplat - tPEEP) / 2\]. Calculating mechanical energy; Mechanical energy (mJ/kg): 0.098 x (V x kg ) x (PIP - \[(P plateau- PEEP) / 2\]) formulas were used"
214915220|NCT06272539|PROCEDURE|Exercise|The exercise The exercise will be adapted according to the phases based on the results already published, limiting in each phase the degrees of flexion and extension of the spine in order to avoid the risk of electrode migration.
214915221|NCT06272539|PROCEDURE|Spinal Cord Stimulation|Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy
214915222|NCT00002202|DRUG|Indinavir sulfate|
214915223|NCT00002202|DRUG|Amprenavir|
214915224|NCT03622684|BEHAVIORAL|Muscle relaxation according to Jacobson|
214915225|NCT06205043|DEVICE|StimSearch programming algorithm software|This is an algorithm based method to program deep brain stimulation in patients of Parkinson's disease
214915226|NCT06205043|DEVICE|Clinician based programming|This is Standard of Care programming performed for patients undergoing deep brain stimulation for Parkinson's disease
214915227|NCT02182115|DRUG|antiseptic bundle|"1. Chlorhexidine gluconate liquid soap for bathing daily.~2. Chlorhexidine gluconate mouthrinse to use twice daily.~3. Nasal mupirocin to apply twice daily."
214915228|NCT02182115|DRUG|standard of care|Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
214305706|NCT01802957|OTHER|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
214305707|NCT01802957|OTHER|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
214479985|NCT06545279|PROCEDURE|Modified Hall Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation but with interproximal slicing.
214479986|NCT06136936|DEVICE|CT-156-C-001|CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
214479987|NCT05657639|DRUG|CAV Regimen|Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
214479988|NCT05657639|DRUG|MEC Regimen|Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
214479989|NCT05201352|DRUG|trifluridine/tipiracil + XB2001|trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
214479990|NCT05201352|DRUG|trifluridine/tipiracil + placebo|trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
214479991|NCT00550849|DRUG|RTA 402|5 mg oral capsules
214915229|NCT02148978|DRUG|Saxagliptin|The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
214915230|NCT00380133|DRUG|SB681323|5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
214915231|NCT00380133|DRUG|Prednisolone|5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
214305708|NCT01802957|OTHER|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
214305709|NCT01802957|OTHER|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
214305710|NCT03072966|DEVICE|Wearable device (Fitbit Charge HR® or Fitbit Alta ®)|Physical activities will be monitored by wearable device.
214915232|NCT00380133|DRUG|Placebo|Tablets matched to SB681323 or prednisolone
214305711|NCT01277354|BEHAVIORAL|Cognitive Processing Therapy|"CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others."
214305712|NCT01277354|BEHAVIORAL|Waitlist Placebo|Behavioral ratings are conducted by a blind rater.
214305713|NCT03893552|DEVICE|Negative expiratory pressure|Using a cough assist, a negative expiratory pressure will be applied while recording the respiratory flow in patients suffering from sleeping disorders or snoring.
214305714|NCT02943733|DRUG|TAS-102|Anti-metabolite agent, taken orally.
214305715|NCT02943733|DRUG|Temozolomide|Oral chemotherapy drug.
214305716|NCT02943733|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
214305717|NCT02943733|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
214305718|NCT04698733|DEVICE|BEST™ HVPC microcurrent electrical stimulation Pro-Sport Ultra® device|"Participants will receive two (2) 20-minute treatments a week on nonconsecutive days for 6 weeks in the clinic. At the end of 6 weeks, participants will have a 6-week pause in treatment.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
214305719|NCT02753062|DRUG|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
214305720|NCT02245542|DRUG|ALNA®OCAS®|
214305721|NCT02121587|BEHAVIORAL|Pain self-management course|This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
214305722|NCT05049993|DEVICE|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty using the Aequalis Pyrocarbon Humeral Head
214305723|NCT05423067|PROCEDURE|bilateral permanent occlusion of uterine arteries|bilateral permanent Occlusion of uterine arteries through abdominal route
214305724|NCT05754606|DIAGNOSTIC_TEST|Audio recordings|Automatica analysis of audio recordings
214305725|NCT04529889|OTHER||
214915233|NCT04319263|DRUG|induction regimen of intravesical BCG|intravesical instillation of 6 weekly doses of BCG
214305726|NCT01280552|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with immunogenic antigens
214305727|NCT01280552|BIOLOGICAL|Placebo DC|Autologous dendritic cells (DC) that have not been pulsed with antigens
214305728|NCT02155738|DRUG|IV Acetaminophen|
214305729|NCT02155738|DRUG|IV normal saline|IV normal saline
214305730|NCT04147065|DRUG|Duration of eradication regimen|14 day eradication regimen
214305731|NCT05282550|DRUG|Trazodone|50mg of trazodone administered for 4 weeks.
214305732|NCT05282550|DRUG|Placebo|Placebo administered for 4 weeks.
214305733|NCT02699203|BEHAVIORAL|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
214915234|NCT04596410|RADIATION|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
214915235|NCT04596410|RADIATION|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily
214915236|NCT03279822|OTHER|not any intervention|not any intervention
214305734|NCT02699203|BEHAVIORAL|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
214479992|NCT00550849|DRUG|RTA 402|25 mg oral capsules
214479993|NCT00550849|DRUG|RTA 402|50 mg oral capsules
214479994|NCT00147056|DEVICE|ExAblate transcranial system|MRI-Guided Focused Ultrasound Feasibility Study for Brain
214479995|NCT02436941|RADIATION|Proton or Photon|
214305735|NCT03459664|BEHAVIORAL|RECOVER|"For each patient baseline assessment and individual support by a diagnostic and crisis resolution home treatment team is available. In addition, patients will be treated with specific interventions based on their severity grade:~Grade 1 (mild): social support, information about mental disorder, e-therapy, consultation, self help, peer-support, supported employment.~Grade 2 (medium): psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 3 (medium to severe): case management, psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 4 (severe): assertive community treatment, psychotherapy, medical treatment, e-therapy, peer-support, supported employment."
214305736|NCT03459664|BEHAVIORAL|Treatment as usual|"For each patient all common care options within the German health care system are available, depending on the severity grade 1 to 4.~This includes the following options: hospital based in-patient, out-patient treatment and day care, community based health care services, general practitioners, private psychiatrists and psychotherapists, self help."
214305737|NCT01190254|DRUG|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
214479996|NCT03775161|DEVICE|V-LAP™ System|Delivery of the V-LAP™ implant via a catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
214479997|NCT06964932|DIETARY_SUPPLEMENT|Probiotc|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
214479998|NCT06964932|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
214479999|NCT06262347|BEHAVIORAL|Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)|The TOME intervention is a modified version of the personally-tailored opioid overdose prevention education and naloxone distribution (PTOEND) intervention (Winhusen et al. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend. Nov 1 2020;216:108265). Modifications include updating the knowledge assessment/education to reflect changes in the drug supply (i.e., the current high prevalence of fentanyl and increasing prevalence of xylazine) and the addition of items specific to pregnancy. Like PTOEND, TOME is a computer-guided intervention which utilizes REDCap to complete assessments and automatically generate personally-tailored feedback reports.
214480000|NCT06262347|BEHAVIORAL|Control|Participants randomized to the control condition will be offered three SAMHSA handouts.
214480001|NCT01746979|DRUG|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
214480002|NCT01746979|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
214480003|NCT01746979|DRUG|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
214915237|NCT05669417|DRUG|Magnesium sulfate|Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.
214915238|NCT02647190|DRUG|Erwinia Chrysanthemi asparaginase|
214915239|NCT05992142|DRUG|5-ASA|Assessment of the different levels of remission (clinical, endoscopic, histological) in UC patients treated only by 5-ASA, who report to be in clinical remission during a routine follow-up visit
214915240|NCT03915587|DEVICE|CardioQ-EDM and CipherOx-CRI|A CardioQ-EDM probe will be placed on the day of surgery after induction of general anesthesia. The anesthesiologist will inform the investigator of plans to provide a fluid or blood bolus per clinical judgement in addition to the protocolized 10 ml/kg bolus provided after induction. While the anesthesiologist is preparing to administer volume expansion, a co-investigator will collect pre-fluid bolus data. Measurements will be recorded for data analysis at the completion of the trial. Additionally, a CipherOx-CRI probe will be placed on the patient's index finger (recorded data will be interpreted post hoc) and a bedside ultrasound will be performed by either the principal investigator (PI) or one of two co-investigators to measure the IVC CI. Ultrasound cine-loops will be recorded, and CI will be calculated post-hoc. Data will be recorded on the Data Collection Form for each fluid bolus administered. The PI and co-investigators will manage all aspects of investigational devices.
214480004|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~* 14mg/ms day +1 and +8~* 10mg/ms day +1 and +8~* 8mg/ms day +1 and +8~CHOEP-21~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
214480005|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~* Romidepsin dose according to phase I iv day +1 and +8~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
214480006|NCT05184114|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Blood Tests|Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)
214915241|NCT01155934|DRUG|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
214305738|NCT01190254|DRUG|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
214305739|NCT01190254|DRUG|placebo|asenapine-matched placebo tablets for sublingual administration
214305740|NCT00422266|DRUG|Omega 3 fatty acids and plant sterol enriched drink|
214305741|NCT00422266|DIETARY_SUPPLEMENT|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
214305742|NCT02140437|DRUG|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
214305743|NCT02140437|DRUG|Anastrozole|standard endocrine therapy
214305744|NCT00234195|DRUG|bupropion extended release (Wellbutrin XL)|
214305745|NCT06365021|BEHAVIORAL|Acceptance and Commitment Therapy|The ACT protocol for this study was developed by ACT psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 12-session protocol that combines psychoeducation elements, mindfulness exercises, experiential exercises, discussions and group processes, homework assignments, and flexible repertoire modeling and training. The protocol is designed to fit into a single trimester. It covers all the basic aspects of Bipolar Disorder and the six processes of ACT.
214305746|NCT06365021|OTHER|Bipolar Disorder Psychoeducation Therapy|The psychoeducation protocol for this study was developed by clinical psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 3-session protocol that combines psychoeducation elements, mindfulness exercises, and discussions regarding the main aspects and symptoms of BD. The protocol is designed to fit into a single month, and has a specifically brief format in order for it not to crossover with psychotherapy. It covers all the basic aspects of Bipolar Disorder.
214305747|NCT02603809|DRUG|Aprocitentan 5 mg|One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
214305748|NCT02603809|DRUG|Aprocitentan 10 mg|Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
214305749|NCT02603809|DRUG|Aprocitentan 25 mg|One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
214480007|NCT05512650|DEVICE|Virtual Reality Meditation|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
214305750|NCT02603809|DRUG|Aprocitentan 50 mg|One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
214305751|NCT02603809|DRUG|Lisinopril 20 mg|One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
214305752|NCT02603809|DRUG|Placebo|One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
214305753|NCT00238277|DRUG|temozolomide|
214305754|NCT00238277|PROCEDURE|adjuvant therapy|
214480008|NCT05512650|DEVICE|Non-VR Meditation|Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
214480009|NCT06239259|OTHER|Questionare As described in Secondary Outcomes|All patients will recieve Questionare As described in Secondary Outcomes, and will be interviewd by a well-trained reaserch assistanced
214480010|NCT03364127|OTHER|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
214480011|NCT03364127|OTHER|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
214915242|NCT04699318|PROCEDURE|Group B|To release the pediatric hypospadias using Double Dartos Tubularized incised plate (TIP) Urethroplasty
214305755|NCT00238277|PROCEDURE|chemotherapy|
214305756|NCT00238277|PROCEDURE|radiation therapy|
214305757|NCT00006374|BIOLOGICAL|filgrastim|
214305758|NCT00006374|DRUG|cisplatin|
214305759|NCT00006374|DRUG|etoposide|
214305760|NCT00006374|DRUG|paclitaxel|
214305761|NCT00006374|DRUG|topotecan hydrochloride|
214305762|NCT06838793|PROCEDURE|Single Level Intertransverse Process Block|"Patients will then be positioned in the lateral decubitus position with the side to be blocked facing upwards, the neck slightly flexed and the upper arm resting on the pillow for the USG ITPB.~The thoracic intervertebral levels (T3, T5, T7) will be identified and marked on the patient. Ultrasound gel will be applied to the skin foracoustic coupling and the transducer is placed 2-3 cm lateral to the spinous process, at the target vertebral level, in the t After obtaining the target transverse ultrasound window at the articular process level, under strict aseptic precautions and local infiltration (Lignocaine 1%), a SonoTap nerve block needle (Pajunk, 22G, 80 mm, Pajunk, Geisingen, Germany) will be inserted in-plane and slowly advanced from a lateral to medial direction until its tip is located at the medial aspect of the retro-SCTL space. After negative heme aspiration, 25 ml of LA mixture containing 0.5% ropivacaine with 1: 200,000 adrenaline will be injected slowly in small aliquots."
214305763|NCT06838793|PROCEDURE|Three Level Intertransverse Process Block|Patients will then be positioned in the lateral decubitus position with the side to be blocked facing upwards, the neck slightly flexed and the upper arm resting on the pillow for the USG ITPB. After obtaining the target transverse ultrasound window at the inferior articular process level (described above) at the T7 level, under strict aseptic precautions and local infiltration (Lignocaine 1%), a SonoTap nerve block needle (Pajunk, 22G, 80 mm, Pajunk, Geisingen, Germany) will be inserted in-plane and slowly advanced from a lateral to medial direction until its tip is located at the medial aspect of the retro-SCTL space. After negative heme aspiration, 8 ml of LA mixture containing 0.5% ropivacaine with 1:200,000 adrenaline will be injected slowly in small aliquots. Subsequently, similar injections will be performed at T5 and T3 level with 8 ml and 9 ml LA mixture, respectively (Total LA mixture volume: 25 ml).
214915243|NCT04699318|PROCEDURE|Group A|To release the pediatric hypospadias using Single Dartos Tubularized incised plate (TIP) Urethroplasty
214915244|NCT02914613|DRUG|SF0166 Topical Ophthalmic Solution|
214305764|NCT03112044|DRUG|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
214305765|NCT03112044|DEVICE|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
214305766|NCT03409172|OTHER|CTR|no counseling or nutritional therapy and no exercise
214305767|NCT03409172|OTHER|MICT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).
214305768|NCT03409172|OTHER|HIIT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)
214305769|NCT00156533|DRUG|Zolpidem|10 mg of Zolpidem
214305770|NCT00156533|DRUG|Sugar Pill|
214305771|NCT00887354|DRUG|Teriparatide|Administered subcutaneously
214305772|NCT00887354|DRUG|Risedronate|Administered orally
214305773|NCT00887354|DRUG|Placebo|"Weekly: Administered orally~Daily: Administered subcutaneously"
214305774|NCT00887354|DIETARY_SUPPLEMENT|Calcium|Approximately 500 to 1000 mg/day administered orally throughout study.
214305775|NCT00887354|DIETARY_SUPPLEMENT|Vitamin D|Approximately 800 International Units per day (IU/day) administered orally throughout study.
214305776|NCT03775980|DEVICE|Emprint Microwave Ablation System|Microwave Ablation of colorectal liver metastases
214305777|NCT06241339|OTHER|Mat Pilates|"Mat Pilates training will last 12 weeks, with three weekly trial sessions being held at 48-72h intervals. Each session will last approximately 60 minutes, including: 5 minutes of warm-up (light calisthenic exercises for the shoulder and pelvic girdles); 50 minutes of Mat Pilates exercises; 5 min back to calm.~Upon arriving at the training site, volunteers will rest for 10 minutes in a sitting position, after which BP measurements will be taken and HR at rest. Throughout consecutive training sessions, participants will perform Pilates method exercises with a progressively greater degree of difficulty and complexity, following the official recommendations for prescription of resistance exercise for individuals with BP elevated and post-stroke. The exercises will be performed in single sets of 10 repetitions. Groups will be advised to maintain daily activities without physical exercise during the 12-week period."
214305778|NCT03265249|DEVICE|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
214305779|NCT00001053|BIOLOGICAL|HIV p17/p24:Ty-VLP|
214305780|NCT00001053|BIOLOGICAL|Aluminum hydroxide|
214305781|NCT01914185|OTHER|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
214305782|NCT00914810|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
214305783|NCT00914810|DIETARY_SUPPLEMENT|Placebo|Placebo (sugar pill) daily for 6 weeks
214305784|NCT02670044|DRUG|Cobimetinib|Cobimetinib will be administered orally as per schedule in Arm description.
214305785|NCT02670044|DRUG|Idasanutlin|Idasanutlin will be administered orally as per schedule in Arm description.
214305786|NCT02670044|DRUG|Venetoclax|Venetoclax will be administered orally as per schedule in Arm description.
214305787|NCT02994732|DRUG|[14C]-BVD-523|\[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
214305788|NCT04428892|BEHAVIORAL|Pedagogyc Strategy|Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.
214305789|NCT03163745|PROCEDURE|paracentesis|paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
214305790|NCT02696642|DRUG|Anetumab ravtansine (BAY94-9343)|All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
214305791|NCT02564614|DRUG|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
214305792|NCT01442415|BEHAVIORAL|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
214305793|NCT04566419|DEVICE|HFNC - Airvo 2|high flow nasal cannulae delivering 60 l/min
214305794|NCT04566419|OTHER|Oxygen|oxygen delivered by Venturi mask
214305795|NCT00164346|BEHAVIORAL|neurocognitive habilitation|
214305796|NCT04415099|OTHER|Muscle fatigue protocol|"Tibialis posterior was fatigued using 2 exercises:~1. Unilateral heel raise exercise~2. Close chain resisted foot adduction exercise"
214305797|NCT02312726|PROCEDURE|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
214305798|NCT01223144|BEHAVIORAL|Iowa Gambling Task and Ekman facial recognition test|"Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger)."
214305799|NCT01217970|DRUG|Ibudilast 20mg|Ibudilast 20mg BID
214305800|NCT01217970|DRUG|Ibudilast 50mg|Ibudilast 50mg BID
214305801|NCT01217970|DRUG|Placebo oral tablet|
214305802|NCT02057471|DRUG|Intravenous ferric carboxymaltose|1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
214305803|NCT03042234|OTHER|Group Insulin-Resistant|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
214305804|NCT03042234|OTHER|Group Insulin-Sensitive|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
214305805|NCT03144492|BIOLOGICAL|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
214305806|NCT05629338|COMBINATION_PRODUCT|Autologous Spray Dried Plasma|Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers
214305807|NCT05425901|OTHER|biopsy|endoscopy biopsies (6)
214305808|NCT06008119|DRUG|Tunlametinib plus Vemurafenib|12mg BID Tunlametinib+720mg BID Vemurafenib
214305809|NCT06008119|DRUG|Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab|According to investigators' suggestion
214305810|NCT03548792|RADIATION|RSA radiostereometric analysis|Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
214305811|NCT03548792|BEHAVIORAL|Clinical comparison|ActivePAL, walking speed
214305812|NCT06022250|DRUG|JS207|Patients will receive specific dose of JS207 via intravenous infusion.
214305813|NCT06387732|OTHER|Aerobic exercise|This will be delivered by coaches in a small group class format. Participants will complete the trial in staggered cohorts, with no more than six participants per class. Intervention activities will be tailored to each individual's own ability and fitness level.
214305814|NCT06387732|OTHER|Stretching and relaxation|This will be delivered by coaches in a small group class format. Participants will complete the trial in staggered cohorts, with no more than six participants per class. Intervention activities will be tailored to each individual's own ability and fitness level.
214305815|NCT06410209|OTHER|Goal Setting|Set physical activity goals
214305816|NCT06410209|OTHER|Interview|Participate in a one-on-one interview
214305817|NCT06410209|OTHER|Interview|Ancillary studies
214480012|NCT05015868|DIAGNOSTIC_TEST|Standard of care|"Enrollment of patients afferent to our Center with cryptogenic drug-resistant epilepsy with onset in pediatric age, subject to informed consent;~* acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data (previous negative brain magnetic resonance imaging);~* execution of a complete neuropsychological assessment for the classification of cognitive aspects and evaluation of executive functions;~* execution of genetic tests through Next generation sequencing epilepsies panel or exome sequencing"
214305818|NCT06410209|OTHER|Media Intervention|View private social media peer support group content
214305819|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit physical activity tracker
214305820|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a research grade activity measuring device
214305821|NCT06410209|OTHER|Questionnaire Administration|Ancillary studies
214305822|NCT06410209|OTHER|Reward|Receive badges
214305823|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive text messages
214305824|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive reminders
214305825|NCT05961735|OTHER|PECS II Block|The Pecs II block is applied to the patients after induction of anesthesia .
214305826|NCT05961735|OTHER|Combined Serratus Anterior Plane Block|Combined Serratus Anterior Plane Block is applied to the patients after induction of anesthesia .
214305827|NCT05095987|PROCEDURE|Laparoscopic Appendectomy|Laparoscopic Appendectomy for acute uncomplicated appendicitis in children
214305828|NCT03009929|OTHER|Observational study|No intervention, observational only
214305829|NCT01516957|DRUG|AMG 827 140|140 mg AMG 827 SC (subcutaneous)
214305830|NCT01516957|DRUG|Placebo|Placebo SC (subcutaneous)
214305831|NCT01516957|DRUG|AMG 827 280|280 mg AMG 827 SC (subcutaneous)
214305832|NCT01516957|DRUG|AMG 827 210|210 mg AMG 827 SC (subcutaneous)
214305833|NCT02817165|DIETARY_SUPPLEMENT|Probiotic (BioK+)|Probiotic (BioK+) with 3 stains of Lactobacillus
214305834|NCT02817165|OTHER|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
214305835|NCT06414967|OTHER|Music Intervention|Music therapy carried out with Music Care
214305836|NCT05595681|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The investigational product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).~C2C\_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C\_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C\_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The exipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
214305837|NCT03506750|DRUG|IVC|Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
214305838|NCT03506750|PROCEDURE|Blood and aqueous humor at the time of IVC|Initial blood and aqueous humor will be harvested at the time of IVC.
214305839|NCT03506750|PROCEDURE|Collect blood, aqueous humor, and initial vitreous at the time of surgery.|Blood, aqueous humor, and vitreous will be collected at the time of surgery.
214305840|NCT03506750|PROCEDURE|IVC-sham|Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
214305841|NCT02206425|DRUG|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
214305842|NCT02206425|DRUG|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
214305843|NCT02206425|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
214305844|NCT02206425|DRUG|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
214305845|NCT02206425|DIETARY_SUPPLEMENT|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
214305846|NCT02206425|DRUG|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
214305847|NCT02206425|DRUG|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
214305848|NCT02206425|DRUG|Pomalidomide|Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
214305849|NCT01290666|DEVICE|Fistula Plug|Bioabsorbable fistula plug
214305850|NCT05368740|DEVICE|integrated pulmonary index monitor|Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention \[2\].
214305851|NCT05982054|PROCEDURE|core decompression with local bone marrow mononuclear cells injection|under local anesthesia ,anterior approach, with ultrasound and fluoroscopy guide
214305852|NCT00708539|DRUG|progesterone|90 mg, vaginal, once daily
214305853|NCT00708539|DRUG|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
214305854|NCT02063516|DEVICE|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
214305855|NCT02063516|DEVICE|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
214305856|NCT04757727|OTHER|Decriptive study of EDB|data on EDB will be register
214305857|NCT03018041|DRUG|Omacor|"As described in Arms."
214305858|NCT03018041|DRUG|Placebo Oral Capsule|"As described in Arms."
214305859|NCT03301194|OTHER|RAMP-HT|RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
214305860|NCT00072618|DRUG|Exisulind|
214305861|NCT01318447|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
214305862|NCT03213821|OTHER|protein intake|For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (\>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
214305863|NCT00402961|OTHER|Acupuncture|Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
214305864|NCT00402961|OTHER|Sham Acupuncture|Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
214305865|NCT05955118|DEVICE|Hydrus Microstent|Hydrus Microstent placed at the time of cataract surgery
214305866|NCT01592929|RADIATION|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
214305867|NCT01592929|OTHER|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
214305868|NCT01592929|RADIATION|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
214305869|NCT01592929|RADIATION|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
214305870|NCT01592929|OTHER|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
214305871|NCT01792947|PROCEDURE|Percutaneous electroneurostimulation of dermatome T6|The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
214305872|NCT01792947|BEHAVIORAL|Diet 1200 Kcal|The patients assigned to this group must follow a 1200 Kcal diet during months
214305873|NCT06293885|DRUG|Dextrose 50|a solution of 50% glucose (D50) will be injected into your pleural space
214305874|NCT06293885|OTHER|Standard of Care - No Dextrose 50|Standard of Care
214305875|NCT03118154|OTHER|Manual Physical Therapy|Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
214305876|NCT00654407|DRUG|Rosuvastatin|
214305877|NCT00654407|DRUG|Atorvastatin|
214305878|NCT00654407|DRUG|Simvastatin|
214480013|NCT05015868|DIAGNOSTIC_TEST|Functional magnetic resonance imaging-Electroencephalogram combined analysis|"A functional brain magnetic resonance imaging is executed analysing blood oxygenation level dependent signal.~During the functional recording, a contemporary electroencephalogram is registered in order to analyse the space-time relationship between the epileptic discharges and the bold abnormalities."
214915245|NCT05387096|OTHER|Definitive multi-faceted intervention consisting of several components|The definitive intervention will consist of the following components: structured history of medication (SHiM), Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) screening for PIMs and PPOs, drug-drug and drug-disease interactions screening, face-to-face consultation with attending hospital physicians to discuss PIMs, PPOs, interactions and other issues, pre-discharge medication review and adjustment, detailed medication adjustment discharge report to patients' general practitioners (GPs), post-discharge follow-up contact with patients' GPs and community pharmacists at 1 week, 1 month and 3-6 months post -discharge. The interventions will be applied by a trained physician or pharmacist.
214305879|NCT03503903|PROCEDURE|Wet Cupping|CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46), which are the recommended sites for headache (12). The cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Secondary suction and bloodletting,Removing and dressing.
214305880|NCT01057420|DRUG|oxygen inhalation|Inhalation of 80% oxygen via face mask
214305881|NCT05175417|OTHER|MRI|3 tesla (T) MRI to provide higher resolution and quality brain images.
214305882|NCT00507442|DRUG|VELCADE (bortezomib)|bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
214305883|NCT00507442|DRUG|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
214305884|NCT00507442|DRUG|cyclophosphamide|cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
214305885|NCT00507442|DRUG|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
214305886|NCT01873001|DRUG|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
214305887|NCT01873001|DRUG|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
214305888|NCT04019314|PROCEDURE|Blood Collection|Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
214305889|NCT04019314|PROCEDURE|Blood Volume Analysis|A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
214305890|NCT06002347|BEHAVIORAL|STAC Parent Module for Middle School|"The STAC Parent Module is a 30-minute pre-recorded online presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies parents can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
214305891|NCT04919954|DRUG|Tebipenem Pivoxil Hydrobromide|Tebipenem 300 mg or 600 mg will be administered orally every 8 hours for total of 3 to 7 doses
214480014|NCT05015868|DIAGNOSTIC_TEST|High density- electroencephalogram or 7 Tesla magnetic resonance imaging|"In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~* execution of High Density-electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~* 7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone (PI, italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
214305892|NCT05824533|DEVICE|onlay patella button|Total knee arthroplasty (TKA) with a patella onlay button placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
214480015|NCT00527410|DRUG|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
214480016|NCT06494098|PROCEDURE|Nasoalveolar Molding|presurgical orthopedics
214480017|NCT06494098|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch and nose
214480018|NCT06702631|DRUG|Nitrous oxide|After a no-drug control period, subjects will inhale nitrous oxide, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration is reached. During the drug condition, subjects will receive low-dose nitrous oxide (% corresponding to Minimum Alveolar Concentration).
214480019|NCT06702631|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
214480020|NCT06806553|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT) With Motor Relearning Program (MRP)|"Intensive training sessions of 3 hours/day for 6 weeks, focusing on functional tasks with the paretic arm while constraining the unaffected arm using a mitt or sling. Implement a constraint on the non-paretic arm to encourage increased use of the affected arm in daily activities. Use shaping techniques to gradually increase the complexity and difficulty of tasks performed with the affected arm (Rahman, 2016).~MRP: Standard physiotherapy sessions of 1 hour/day for 6 weeks, including exercises for both affected and unaffected arm. Focus on improving strength, range of motion, and coordination through repetitive task practice, neuromuscular re-education and compensatory strategies (Brkić, 2016; Ghrouz et al., 2023)."
214480021|NCT06806553|BEHAVIORAL|Bobath Therapy|The first step in the Bobath approach is a thorough assessment of the individual's movement patterns, muscle tone, strength, coordination, and functional abilities. This assessment helps in identifying specific impairments and setting goals for treatment. Bobath therapists use specific handling techniques to facilitate normal movement patterns and inhibit abnormal muscle tone. These hands-on techniques aim to promote efficient movement and improve motor control. The Bobath approach emphasizes task-oriented training, where functional activities relevant to the individual's daily life are incorporated into therapy sessions. This helps in improving motor skills in a context that is meaningful to the individual (Grozdek Čovčić et al., 2022; Kuciel et al., 2021).
214480022|NCT06605443|DEVICE|Breath analyzer|The study subject will be advised to sit quietly for minimum 10 minutes prior the sampling to avoid temporal changes in levels of volatile organic compunds (VOCs) related to body movement or try to avoid abrupt changes in body posture. Then, he/she will be asked to blow in the breath analyzer in order to obtain the exhaled VOCs profile.
214480023|NCT06605443|DEVICE|Skin patch|A skin patch will be placed in the anterior part of the patient's arm for the obtention of the skin VOCs profile (estimated sampling time of around 1 h). These profiles will be recorded with a dedicated software and analyzed using standard statistical methods.
214480024|NCT06605443|GENETIC|Liquid biopsy|Circulating free tumor DNA (cfDNA) will be extracted from patient's blood and analyzed to detect mutations in BRAF and other prognostic genes.
214480025|NCT05830799|DRUG|Drug Drug Interaction|The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated
214480026|NCT06811558|BIOLOGICAL|Ixekizumab|injected with ixekizumab
214480027|NCT06811558|BIOLOGICAL|Secukizumab|injected with secukizumab
214305893|NCT05824533|PROCEDURE|Conventional procedure; NO onlay patella button|Total knee arthroplasty (TKA) placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
214305894|NCT06127992|DEVICE|Cold stimulation tests / critical temperature threshold|ICT was performed following a standard protocol. Briefly, a melting ice cube in thin plastic bag was placed on the volar surface of the patient forearm for 5 min, with macroscopic assessment of the test site 10 min later. TempTest® CSTs were done with TempTest® 4.0 (Courage \& Khazaka, Cologne, Germany), which has a single Peltier element (length: 350 mm, width: 2 mm) that provides a continuous temperature gradient from 4°C to 44°C. The use of TempTest® allows for reproducible and standardized cold (and heat) provocation tests and the identification of CTTs. TempTest® CST results were also assessed 10 min after the end of cold exposure.
214305895|NCT02165436|OTHER|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
214305896|NCT02165436|OTHER|Control|No intervention will be assessed for this group.
214305897|NCT04823637|DIAGNOSTIC_TEST|Ultrasonography vs Osteopathic manipulative medicine structural exam|Structural examination of the thoracic spine using ultrasound and osteopathic palpatory examination on skin.
214305898|NCT01192282|PROCEDURE|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
214305899|NCT04708938|OTHER|High voltage electrical stimulation+exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
214305900|NCT04708938|OTHER|Exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
214305901|NCT03441841|DRUG|Lidocaine + Prilocaine|Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
214305902|NCT03441841|DRUG|Lidocaine|Single topical dose of 2g lidocaine 2.5 % formulation.
214305903|NCT03441841|DRUG|Prilocaine|Single topical dose of 2g prilocaine 2.5 % formulation.
214305904|NCT02555332|OTHER|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
214305905|NCT04460820|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2,IV on Day 1 of each cycle
214305906|NCT00105703|BEHAVIORAL|Case management using advanced nurse practitioners|
214305907|NCT04546165|PROCEDURE|manipulation plus exercise|HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction
214305908|NCT04546165|PROCEDURE|suboccipital inhibition plus exercise|Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region
214305909|NCT04546165|PROCEDURE|exercise|Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
214305910|NCT05411237|DRUG|Pegylated liposomal doxorubicin|PLD 20 mg/m2 on Day 1 of every 21-day cycle
214305911|NCT05411237|DRUG|Paclitaxel|PTX 100 mg/m2 on Day 1 of every 21-day cycle
214305912|NCT04572074|OTHER|Guided imagery|10 minutes of guided imagery experience
214305913|NCT04572074|OTHER|Virtual reality|10 minutes of virtual reality experience
214305914|NCT02490722|OTHER|Patient education|Four times two hours group based patient education
214305915|NCT00846937|DIETARY_SUPPLEMENT|Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo
214305916|NCT00818428|BEHAVIORAL|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
214480028|NCT06594120|BEHAVIORAL|Multimodal rehabilitation with additional work specific training|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
214305917|NCT00818428|BEHAVIORAL|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
214305918|NCT00818428|BEHAVIORAL|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
214305919|NCT00818428|BEHAVIORAL|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
214305920|NCT05322174|BEHAVIORAL|Baby Sleep|See arm description
214305921|NCT05322174|BEHAVIORAL|Baby Care|See arm description
214305922|NCT01508780|DEVICE|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
214305923|NCT01508780|DEVICE|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
214305924|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
214305925|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
214480029|NCT06769568|DRUG|reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia|reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia
214915246|NCT05387096|OTHER|Sham Intervention|Sham intervention in the form of the modified Medication Adherence Rating Scale (MARS) questionnaire in addition to standard care.
214305926|NCT03581656|DEVICE|ChordArt System|The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
214305927|NCT01343563|PROCEDURE|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
214305928|NCT00630968|DRUG|Levetiracetam (Keppra)|
214305929|NCT02449174|BIOLOGICAL|Frozen Microbiota|Frozen Microbiota will be delivered via enema route.
214305930|NCT02449174|BIOLOGICAL|Lyophilized Microbiota|Lyophilized Microbiota will be delivered orally.
214305931|NCT03525015|OTHER|A decision aid booklet about cataract surgery choice|Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
214305932|NCT03525015|OTHER|An usual booklet about cataract and cataract surgery|Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
214305933|NCT02296385|DIETARY_SUPPLEMENT|Triple Strength Fish Oil|Triple Strength Fish Oil
214305934|NCT02410954|DEVICE|NeuroConn Direct Current stimulator Multiple Channel -4|(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
214305935|NCT05874752|DIAGNOSTIC_TEST|Transthoracic echocardiography|noninvasive myocardial work
214305936|NCT06212219|BEHAVIORAL|Neurofeedback procedure|Personalized NF will consist of adding to these motor imagery tasks, personalized aspects depending on the patient's profile, for example in terms of level of support and emotional support (addition of a relaxation exercise using an audio recording at the start of training - and in the middle of training if necessary, adding the presence of a companion is to provide social presence and emotional support, depending on the user's performance and progress.), of the virtual environment.
214305937|NCT06212219|OTHER|Fugl-Meyer test|419 / 5 000 Résultats de traduction Résultat de traduction This questionnaire assesses the motor selectivity of the upper limb. Several questions are asked about the movements that the patient can perform and to each question, the patient can answer either 0 (minimum) and 2 (maximum)
214305938|NCT06212219|OTHER|Intrinsic Motivation Inventory questionnaire|This psychometric motivation questionnaire offers the patient words representative of their motivation to carry out the neurofeedback session and for each proposition they can respond between rather positive (maximum) or rather negative (minimum)
214305939|NCT06212219|OTHER|Hospital Anxiety and Depression Scale|This questionnaire assesses the patient's state of anxiety and depression. Concerning anxiety, to each proposition, the patient can answer a number between 0 at minimum (never/not at all) and 3 at maximum (very often) and about depression, the patient can answer a number between 0 at minimum (often, always) and 3 at maximum (never/not at all) The patient can calculate his score at the end
214305940|NCT06212219|OTHER|State Anxiety Inventory scores|"This questionnaire measures the patient's anxiety at a given time. It features a number of statements that people have previously used to describe themselves. For each statement, choose a grade from 1 (not at all) to 4 (Very much)"
214305941|NCT06212219|OTHER|Acceptability questionnaire (BCI-ACCEPT)|This questionnaire asks the patient about their level of acceptability of NF training using words representative of their motivation to carry out the neurofeedback session and for each proposal they can respond on their feelings regarding the proposals.
214305942|NCT06212219|OTHER|System Usability Scale questionnaire|This questionnaire evaluates the usability of personalized NF procedures compared to standard procedures. To each statement, the patient can respond between a minimum of 1 (strongly disagree) and a maximum of 5 (totally agree).
214305943|NCT06212219|OTHER|NASA Task Load Index questionnaire|"This scale assesses psychological validity from the perspective of mental workload. 6 words are offered to the patient about his mental load and he can respond at least little and at maximum A lot"
214480030|NCT06765304|BEHAVIORAL|Transtheoretical education intervention group|The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
214305944|NCT06212219|OTHER|Agency test|Questionnaire in which statements referring to the patient's general feeling and/or beliefs are presented. the patient has the choice between completely disagree (minimum) and totally agree (maximum)
214305945|NCT06212219|OTHER|Visual and Kinesthetic Imagery Questionnaire|"The aim of this questionnaire is to obtain an index of individuals' ability to mentally represent different movements. Different movements to imagine are indicated and the patient responds based on their ability to imagine the movement.~He has the choice between as clear as a film (maximum) and no image (minimum)"
214915247|NCT03495479|DRUG|OMN54|Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.
214305946|NCT06212219|OTHER|Technology Locus of Control Assessment Questionnaire|"The questionnaire focuses on patients' opinions on problems related to the use of technical devices. It presents twelve statements that the patient can affirm or deny, depending on their personal point of view. The patient can respond at least disagree at all and at maximum agree completely"
214305947|NCT06212219|OTHER|POSITIVE AFFECTIVITY AND NEGATIVE AFFECTIVITY SCALE|"This scale is made up of a list of words that indicate certain emotions or feelings. The patient must carefully read each of these words and spontaneously indicate at what level he feels this way at the time he responds to this scale. To do this, he can answer at least Very little or not at all and at maximum A lot"
214305948|NCT06212219|OTHER|Self-questionnaire: OCEAN of the five major factors of per- sound (or Big Five model)|"The model for measuring personality factors is the Anglo-Saxon model known as the Big Five or OCEAN in French. It measures 5 major personality traits: openness to experiences, conscientiousness, extroversion, agreeableness and neuroticism. The OCEAN questionnaire is a self-administered questionnaire to be given to a person who wishes to evaluate themselves. It includes 45 items presented in the table below. For each item, patients have 5 response possibilities numbered from 1 to 5: 1 for strongly disapproves and 5 for strongly approves. The patient can calculate his score at the end"
214305949|NCT06212219|OTHER|Feeling VAS scores|"The EVA scale relates to the patient's personal feelings: perceived difficulty, perceived fatigue, perceived ease of learning, level of embodiment, Relevance, Demonstrability of results, Fun aspect, Benefit/risk ratio, Self-efficacy.~For each statement, the patient can respond on a scale ranging from strongly disagree (minimum) to totally agree (maximum)."
214305950|NCT06212219|OTHER|Reaching Performance Scale|This scale analyzes the evolution of speed, precision and range of movement using motion capture tools. For each statement, the patient has a rating between 0 (corresponds to not possible) and 3 (corresponds to entirely possible)
214305951|NCT05442944|PROCEDURE|Physiotherapeutic procedures|As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
214305952|NCT00916474|DRUG|telaprevir|
214305953|NCT02869594|OTHER|Data collection|
214305954|NCT04419038|PROCEDURE|conjunctival autografting augmented with topical application of Mitomycin C|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
214305955|NCT04419038|PROCEDURE|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
214305956|NCT04873752|BIOLOGICAL|UDI-001|2.5 x 10\^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.
214305957|NCT05071859|OTHER|Whole Genome Sequencing|Saliva collection and request for banked blood and tumor samples for sequencing
214305958|NCT05071859|OTHER|Questionnaire Administration|Study questionnaire will include modules that collect information on maternal reproductive history, exposure to known teratogens, medical history, and previous genetic testing.
214305959|NCT05071859|OTHER|Biospecimen collection|Saliva collection and request for banked blood and tumor samples for sequencing and biomarker analysis
214305960|NCT05071859|OTHER|Laboratory Biomarker Analysis|Saliva collection and request for banked blood and tumor samples for biomarker analysis
214305961|NCT05779878|OTHER|Post Isometric Relaxation|Post-isometric relaxation (PIR) is a soft tissue stretching technique used by many health care professionals to lengthen both acute and chronic short muscles.
214305962|NCT05779878|OTHER|Myofascial arm pull technique|Myofascial therapy is described as the promotion of psychophysiological, neurological and structural adaptive capability as multiplexed via the myofascial system. Fascia covers all body structures, particularly muscles and their constituent myofibrils
214305963|NCT02778997|PROCEDURE|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
214305964|NCT04324801|OTHER|Homeostatic plasticity induction using transcranial direct current stimulation|Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
214305965|NCT06403735|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
214305966|NCT02857478|DRUG|BAY 987519, SPF 50, Y51-002|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
214305967|NCT02857478|DRUG|BAY 987519, SPF 50, P04-147|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
214305968|NCT05871827|PROCEDURE|Intraoperative Fluoroscopic Computer Navigation|Computer technology used during surgery
214915248|NCT02671799|DEVICE|VenTouch System Implant|The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.
214305969|NCT05748756|OTHER|Enucleation and filling by Bone marrow aspirate|"The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique."
214305970|NCT05748756|OTHER|Conventional enucleation only|patients were treated conventionally by enucleation and plain collagen sponge only.
214305971|NCT05543525|OTHER|Echocardiography|Transthoracic echocardiography
214305972|NCT05543525|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing
214305973|NCT00814398|PROCEDURE|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
214305974|NCT00814398|PROCEDURE|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
214305975|NCT02436551|OTHER|Observation|
214305976|NCT02558712|OTHER|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
214305977|NCT00271609|DRUG|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
214305978|NCT00500851|DEVICE|Electromagnetic imaging for jejunal tube placement (CORTRAK)|Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)
214670420|NCT02465034|DEVICE|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
214915249|NCT03693183|DRUG|Ketorolac/HPMC|0.30% Ketorolac/0.80%HPMC Ophthalmic solution administered 4 times per day for 2 days
214915250|NCT03693183|DRUG|HPMC|0.80% Hydroxypropyl Methylcellulose solution 4 times per day for 2 days
214915251|NCT03693183|DRUG|Vehicle|Vehicle
214915252|NCT02461966|OTHER|Aflatoxin|Evaluation of Aflatoxin level
214305979|NCT00500851|DEVICE|Endoscopy|Endoscopic placement of jejunal feeding tubes
214305980|NCT00369551|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
214305981|NCT00369551|DRUG|paclitaxel|Given IV
214305982|NCT00369551|BIOLOGICAL|bevacizumab|Given IV
214305983|NCT00369551|DRUG|carboplatin|Given IV
214305984|NCT00369551|OTHER|laboratory biomarker analysis|Correlative studies
214305985|NCT03391596|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.
214305986|NCT03391596|BEHAVIORAL|Standardized rehabilitation|Standardized institutional rehabilitation in a rehabilitation center
214305987|NCT03391596|BEHAVIORAL|Support by voluntary caregiver associations|Support given by voluntary caregiver associations
214305988|NCT02188589|DEVICE|INEX nasal implant|Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
214305989|NCT04278079|PROCEDURE|Pars Plana Vitrectomy with Internal Limiting Membrane peel|Pars plana vitrectomy with staining and peeling of internal limiting membrane
214305990|NCT05077592|DRUG|10% Povidone Iodine|Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
214305991|NCT04971473|BIOLOGICAL|rhTSH|Scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.
214305992|NCT02333695|DEVICE|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
214305993|NCT00227162|BEHAVIORAL|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
214305994|NCT00227162|BEHAVIORAL|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
214305995|NCT00227162|BEHAVIORAL|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
214305996|NCT00867451|BEHAVIORAL|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
214305997|NCT00867451|DRUG|Melatonin|Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks
214305998|NCT05614375|PROCEDURE|endoscopic surgery|transnasal endoscopic surgery
214305999|NCT03773887|OTHER|collection of liver biopsies collection of blood samples|blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies
214306000|NCT05127447|DEVICE|ES application|Electrical stimulation (ES) application will be given to the ES group
214306001|NCT05127447|OTHER|Sham application|Only vacuum was applied and no current was given from the applied device
214306002|NCT06010940|DIETARY_SUPPLEMENT|Dietary supplement|nasogastric tube and oral care
214306003|NCT06010940|OTHER|Physical therapy|Designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
214306004|NCT03893812|DEVICE|MRI|diffusion weighted MR
214306005|NCT03893812|DEVICE|Ultrasound|Color Doppler ultrasound
214306006|NCT01834014|DRUG|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214306007|NCT01834014|DRUG|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214306008|NCT01834014|DRUG|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214306009|NCT01834014|DRUG|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214306010|NCT01834014|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214306011|NCT01834014|DRUG|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
214306012|NCT01209364|DEVICE|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
214306013|NCT03938584|DIETARY_SUPPLEMENT|Vitamin C|Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91
214915253|NCT00274612|DRUG|Telmisartan|
214915254|NCT00274612|DRUG|Ramipril|
214915255|NCT03819712|PROCEDURE|Collection of blood samples|23 mL of blood will be collected during the inclusion visit
214915256|NCT03819712|OTHER|Collection of fecal samples|Fecal sample self-collected after the inclusion visit
214915257|NCT03819712|OTHER|Collection of urine samples|10 mL of urine will be collected during the inclusion visit
214306014|NCT03938584|OTHER|Placebo|Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).
214480031|NCT06765304|BEHAVIORAL|Preconceptional Period Healthy Life Behaviours Classical Education Intervention Group|The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
214915258|NCT03819712|OTHER|Collection of vaginal swaps|Sample of vaginal microbiota collected during the inclusion visit
214915259|NCT03782012|BEHAVIORAL|Supported|Visual organization of knowledge base items plus discourse-based discussion supporting knowledge availability and accessibility
214915260|NCT03907748|OTHER|Music Intervention|After training, caregivers will deliver the music intervention to the person with dementia whom they care for. The music intervention will include: a) singing familiar/preferred music followed by discussions facilitated by the caregiver about any associated meanings or memories; b) movement to music (e.g. upper body and arms imitating familiar dance movements to music); c) instrument playing; and d) listening to familiar/preferred relaxing or enlivening music (dependent upon symptoms present in the moment). These methods are known to assist in emotion regulation and increase cognitive reserve (e.g. attention and perceptual-motor function).
214306015|NCT01776775|DEVICE|Abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position."
214306016|NCT01748981|OTHER|Physical training|"Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls"
214306017|NCT01748981|OTHER|As usual|Controls, not training
214306018|NCT01172457|PROCEDURE|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
214306019|NCT01172457|PROCEDURE|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
214306020|NCT00975481|DRUG|dimebon|Oral tablet; 20 mg dimebon, single dose
214306021|NCT00975481|DRUG|dimebon|Oral tablet; 40 mg dimebon, single dose
214306022|NCT00975481|DRUG|dimebon|Oral tablet; 60 mg dimebon, single dose
214306023|NCT00975481|DRUG|placebo|Oral tablet or capsule; placebo, single dose
214306024|NCT00975481|DRUG|alprazolam|Oral capsule; 1 mg alprazolam, single dose
214915261|NCT03907748|OTHER|Reading Intervention|After training, caregivers will deliver the reading intervention to the person with dementia whom they care for. The reading intervention will include: a) the caregiver reading aloud to the person they are caring for; b) the person with dementia reading aloud to their caregiver; and c) discussion of the text and personal responses. Strategies to engage the person with dementia and to create opportunities for meaningful dialogue will be provided, as well as guidance on selecting reading material that is accessible to the person's level of cognitive impairment.
215060027|NCT03089047|BIOLOGICAL|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
215060028|NCT03089047|BIOLOGICAL|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
215060029|NCT02615418|DEVICE|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
215060030|NCT03599518|DRUG|DS-1205c|DS-1205c 200 mg capsule for oral administration
214306025|NCT00975481|DRUG|alprazolam|Oral capsule; 3 mg alprazolam, single dose
214306026|NCT00643682|OTHER|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
214306027|NCT01248442|DRUG|Cholecalciferol|monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
214306028|NCT01248442|DRUG|Placebo|Matching Placebo
214306029|NCT03907293|BEHAVIORAL|Exercise-based cardiac rehabilitation|Moderate intensity aerobic exercise, lifestyle advice, and psychological support.
214306030|NCT00206947|DRUG|donepezil (5-10 mg/day)|Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
214306031|NCT00206947|DRUG|Placebo|Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
214306032|NCT04846660|OTHER|Production pressure|Participant exposed to production pressure
214306033|NCT00002067|DRUG|Megestrol acetate|
214306034|NCT05300906|BEHAVIORAL|personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
214306035|NCT05300906|BEHAVIORAL|non-personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
214306036|NCT04311424|DRUG|14C Tirzepatide|Administered SC.
214306037|NCT01079091|DEVICE|ADVOS (Hepa Wash)|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
214306038|NCT01079091|PROCEDURE|Standard Medical Therapy|Standard of care treatment
214306039|NCT03874520|OTHER|Video triage|The operator will offer the parent calling regarding the sick child to assess the child on video, as compared to the current standard; on the telephone.
214306040|NCT05736107|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
214306041|NCT05736107|OTHER|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
214306042|NCT02258321|DRUG|PPI-668 tablet|
215060031|NCT03599518|DRUG|Gefitinib|Gefitinib 250 mg tablet for oral administration
214306043|NCT02258321|DRUG|PPI-668 capsule|
214306044|NCT06320145|DEVICE|Cryotherapy|This device used at the first, second and third day of period to decrease pain for 20 min at first, second and third day
215060032|NCT01973010|OTHER|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
215060033|NCT01973010|DRUG|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
215060034|NCT01927523|BEHAVIORAL|BAM|BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
215060035|NCT01927523|OTHER|Match|An intensive math tutoring program.
214306045|NCT06320145|OTHER|core stability exercises|core stability exercises
214306046|NCT00469560|DRUG|Deferasirox|
214306047|NCT02598427|DRUG|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
214306048|NCT02598427|DRUG|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
214306049|NCT02692781|DRUG|MOD-6031|
214306050|NCT02692781|OTHER|Placebo control|
214306051|NCT02084147|DEVICE|positron emission tomography|Undergo PET
214306052|NCT02084147|DEVICE|computed tomography|Undergo CT
214306053|NCT02084147|DEVICE|magnetic resonance imaging|Undergo MRI
214306054|NCT01826487|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
214306055|NCT01826487|DRUG|Placebo|Placebo will be administered as per the schedule specified in the arm.
214306056|NCT01069146|PROCEDURE|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
214306057|NCT01408030|DRUG|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
214306058|NCT01408030|DRUG|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
214306059|NCT01408030|DRUG|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
214306060|NCT01408030|DRUG|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
214306061|NCT04142554|DRUG|Parsaclisib|Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
214306062|NCT05701410|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin amyloidosis.
214306063|NCT01169610|DRUG|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
214306064|NCT03755414|PROCEDURE|Stem cell transplantation|Standard of care
214306065|NCT03755414|DRUG|Itacitinib|Itacitinib may be taken without regard to food.
214915262|NCT03616873|OTHER|Early Mobilization|The EM program consists of a progression of functional activities from level of function (LOF) 0 (lowest mobility) to 5 (highest mobility). Each LOF has 3 primary activities designed to promote the patient to the next level. The nurse will begin with mobility activities based on the LOF that matches the patient's current status. The nurse and clinical partner will attempt and/or complete each LOF activity once per shift.
214915263|NCT03612596|BEHAVIORAL|Narrative visualization|Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior
214915264|NCT03612596|BEHAVIORAL|Standard self-regulation|Participants self-monitor steps using a wearable device, app, and a hand-written step log
214306066|NCT03755414|OTHER|Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)|"* Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
214915265|NCT01154114|DRUG|darapladib|darapladib 40 mg oral dose
214915266|NCT02573181|BIOLOGICAL|V114|V114 contains 2 µg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F, and 4 μg of serotype 6B; and 30 µg of CRM₁₉₇ and 125 µg of Aluminum Phosphate Adjuvant (APA) per 0.5 mL dose.
214915267|NCT02573181|BIOLOGICAL|Prevnar 13™|Prevnar 13™ contains 2.2 μg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4.4 μg of serotype 6B; and 34 μg of CRM₁₉₇ and 125 μg of aluminum per 0.5mL dose.
214915268|NCT03421210|DRUG|Nicotine patch|Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.
214915269|NCT03259464|DRUG|BI 685509|3 sequential dose groups
214915270|NCT03259464|DRUG|Placebo|3 sequential dose groups
214915271|NCT04062201|DRUG|Bedaquiline Oral Tablet|Weight Group 16 - 29.9kg: 200mg daily for two weeks; followed by 100mg three times weekly for weeks 3 - 24 Weight Group: 30 - \>50kg: 400mg once daily for 14 days followed by 200mg three times weekly for weeks 3 - 24
214306067|NCT03755414|OTHER|Human Activity Profile|"* Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
214306068|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
214306069|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
214306070|NCT01682902|DRUG|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
214480032|NCT06765304|BEHAVIORAL|Placebo|The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
214480033|NCT06654843|BEHAVIORAL|Comparator Arm|In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.
214480034|NCT06654843|BEHAVIORAL|Enhanced intervention arm|"In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.~In addition to childcare, Arm C will also receive peer support activities. Peer support activities will consist of group volunteer activities at food pantries, free deliveries of food pantry groceries, and group play dates at local playgrounds. A Community Champion will also facilitate group text messages."
215060036|NCT04114916|DIETARY_SUPPLEMENT|Apigenin, luteonin, grapefruit extract and citrolive|Two capsules daily at breakfast and dinner.
214915272|NCT04062201|DRUG|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - \>50kg: 600mg daily
214915273|NCT04062201|DRUG|Delamanid in Oral Dosage Form|Weight Group 16 - 23kg: 25mg twice daily for 24 weeks Weight Group 23.1 - 33.9kg: 50mg twice daily for 24 weeks Weight Group 34 - \>50kg: 100mg twice daily for 8 weeks followed by 200 mg daily for 16 weeks
214915274|NCT04062201|DRUG|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - \>50kg: 100mg daily
214306071|NCT00825045|DRUG|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
214306072|NCT00000976|DRUG|CD4-IgG|
214306073|NCT00000976|DRUG|Zidovudine|
214306074|NCT05023525|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
214306075|NCT05023525|DRUG|Placebo, tablet|Matching placebo
214306076|NCT02910076|DRUG|Hydroxychloroquine|200 MG Plaquenil three times a day
214306077|NCT00758030|DRUG|Paliperidone ER OROS|
214480035|NCT05755997|DRUG|Cerebrolysin|40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year
214480036|NCT05755997|DRUG|0.9 % NaCl|100 ml 0.9% NaCl per day for 4 days every month for 1 year
214480037|NCT02375802|BIOLOGICAL|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
214915275|NCT04062201|DRUG|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group \>50kg:1000mg daily
214915276|NCT04062201|DRUG|Isoniazid Oral Product|Weight Group 16 - 23kg: 300mg daily Weight Group 23.1 - 50kg: 400mg daily Weight Group \>50kg: 600mg daily
214915277|NCT04062201|DRUG|Ethambutol Oral Product|Weight Group 16 - 23kg: 400mg daily Weight Group 23.1 - 29.9kg: 600mg daily Weight Group 30 - 50kg: 800mg daily Weight Group \>50kg: 1200mg daily
214915278|NCT04062201|DRUG|Pyrazinamide Oral Product|Weight Group 16 - 23kg: 750mg daily Weight Group 23.1 - 29.9kg: 1000mg daily Weight Group 30 - 33.9kg: 1250mg daily Weight Group 34 - 50kg: 1500mg daily Weight Group \>50kg: 2000mg daily
214306078|NCT04689295|OTHER|exercise programme 1|Schroth three dimensional scoliosis therapy method
214306079|NCT04689295|OTHER|exercise programme 2|Traditional scoliosis exercises
214480038|NCT02375802|DRUG|Adipose-derived stromal cells|
214480039|NCT04979455|OTHER|Core temperature monitoring|Core temperature will be monitored on the day of exercise
214480040|NCT04979455|BEHAVIORAL|Questionnaires|Questionnaires will be completed at baseline and on the day of exercise
214915279|NCT04062201|DRUG|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - \>50kg: 600mg daily
214915280|NCT04062201|DRUG|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - \>50kg: 100mg daily
214306080|NCT02101047|DRUG|Phenylephrine|
214306081|NCT04156776|OTHER|Muscle Energy Technique|Muscle energy technique was repeated 4 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.
214306082|NCT04156776|OTHER|Active Isolated Stretching|"The patient was asked to sit in an upright seated position and flex his/her knees 12 to 18 inches. Patient was asked to tuck the chin, exhale, and firmly contract the abdominal muscles as he/she curls their body forward. He/she was also guided not to bounce or make rapid movements at the end range of the active motion. Then, he was asked to move back to the starting position and repeat the same procedure for 8 to 10 times. Stretch on the end range was not more than 2 seconds.~This technique was repeated 10 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session."
214306083|NCT04156776|OTHER|Conventional Treatment|Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.
214306084|NCT02786628|OTHER|Physical performance testing and patient-generated health data|All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
214306085|NCT00244946|BIOLOGICAL|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
214306086|NCT00244946|DRUG|carmustine|
214306087|NCT00244946|DRUG|cytarabine|
214306088|NCT00244946|DRUG|etoposide|
214306089|NCT00244946|DRUG|melphalan|
214480041|NCT04979455|OTHER|Heart rate monitoring|Heart rate will be monitored on the day of exercise
214480042|NCT04979455|OTHER|Urine collection|Urine samples will be collected at baseline and on the day of exercise
214480043|NCT04979455|OTHER|Sleep monitoring|Sleep will be monitored at baseline and on the day of exercise
214480044|NCT04979455|OTHER|Blood collection|Blood samples will be completed at baseline
214480045|NCT04979455|OTHER|Saliva collection|Saliva samples will be collected at baseline and on the day of exercise
214480046|NCT04979455|OTHER|Throat swab collection|Throat swab samples will be collected at baseline and on the day of exercise
214915281|NCT04062201|DRUG|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group \>50kg:1000mg daily
214915282|NCT01210846|DRUG|tivozanib|1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
214915283|NCT02251457|DRUG|Ranolazine|Ranexa is FDA approved for chronic angina
214915284|NCT05875896|PROCEDURE|Total wrist fusion|Observation after implantation of Medartis Aptus Wrist Arthrodesis Plate
214915285|NCT02118116|OTHER|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
214306090|NCT00244946|PROCEDURE|peripheral blood stem cell transplantation (PBSCT)|
214306091|NCT03755687|OTHER|Art Therapy Intervention|Standardized mixed media art directives.
214306092|NCT05245760|DRUG|Intravenous Tislelizumab|Participants will receive 200mg, every three weeks for up to 51 weeks
214306093|NCT05245760|DRUG|Chemotherapy|Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
214306094|NCT05245760|RADIATION|Fractionated radiation|Concurrent with chemo, x5 weeks
214306095|NCT05245760|PROCEDURE|Esophagectomy|Surgical resection of cancer after chemoradiation therapy when no disease progression found.
214306096|NCT02512432|DEVICE|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
214306097|NCT04474860|DIAGNOSTIC_TEST|gene sequencing|Gene fragment analysis, Sanger sequencing method and/or high-throughput whole-genome sequencing will be performed to find the pathogenic gene and mutation site of MH in Chinese population.
214306098|NCT03168308|DRUG|Sugammadex|Sugammadex 2 mg/kg
214306099|NCT03168308|DRUG|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
214306100|NCT04039412|DRUG|Hybrid regimen|two-step (dual-quadruple) treatment
214306101|NCT04039412|DRUG|Reverse hybrid regimen|one-step two-phase (quadruple-dual) treatment
214306102|NCT04039412|DRUG|Levofloxacin quadruple regimen|non-Clarithromycin non-Bismuth quadruple therapy
214306103|NCT00014677|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
214306104|NCT00014677|PROCEDURE|conventional surgery|
214915286|NCT03850496|DEVICE|Revitive IX Neuromuscular Stimulation Device|Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.
214915287|NCT04586816|COMBINATION_PRODUCT|1% red maple leaf extract in cream base|1% red maple leaf extract is combined in a cream base
214306105|NCT02258230|DEVICE|3D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
214306106|NCT02258230|DEVICE|2D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
214306107|NCT00690092|BIOLOGICAL|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
214306108|NCT01568931|DRUG|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
214306109|NCT01568931|DRUG|Saline|intracoronary, saline, bolus 1 cc
214306110|NCT02653287|BEHAVIORAL|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary.
214306111|NCT02653287|OTHER|Control|The control group will receive four individual phone calls focusing on education for SLE disease management, as well as answering any questions the participants have about the study. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Each call will last about 10-15 minutes, and occur shortly after randomization, then at 1.5, 3, and 6 months.
214306112|NCT03866343|OTHER|Diet low or high in advanced glycation endproducts|All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
214306113|NCT05829486|PROCEDURE|gastroscopy|anaesthetic management of ambulatory endoscopic procedures
214306114|NCT00345137|DRUG|Ng-monomethyl-L-arginine (drug)|
214306115|NCT02838680|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
214306116|NCT05133518|DRUG|MELT-300|Sublingual tablet
214306117|NCT05133518|DRUG|Midazolam alone|Sublingual tablet
214306118|NCT05133518|DRUG|Ketamine alone|Sublingual tablet
214306119|NCT05133518|DRUG|Placebo|Sublingual tablet
214306120|NCT00984243|PROCEDURE|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm\^2 Excimer-dye laser: 100-200 Joules/cm\^2"
214306121|NCT04324060|DRUG|Danazol + rhTPO (recombinant human thrombopoietin injection)|subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased \>50×10e9/L, total course is 6 months
214306122|NCT04324060|DRUG|Danazol + sodium chloride|Danazol 0.2g tid po+ control (sodium chloride)
214306123|NCT05950789|OTHER|Virtual reality application|"During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.~With virtual reality glasses, patients watch three-dimensional video nature images, which we determined according to the patient's preference, accompanied by music. They put on the virtual reality glasses before the process started and removed them after the process was over."
214306124|NCT01002950|DRUG|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
214480047|NCT04979455|OTHER|Stool collection|Stool samples will be collected at baseline and on the day of exercise
214306125|NCT01002950|DRUG|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
214306126|NCT02722850|BEHAVIORAL|ALIVE|ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.
214306127|NCT05810792|DRUG|Histamine Dihydrochloride (HDC)|HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.
214306128|NCT05810792|DRUG|Interleukin-2 (IL-2)|IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
214306129|NCT03498625|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
214306130|NCT04814758|DIAGNOSTIC_TEST|MRI DWI sequence (ADC values)|Initially and after pre-operative chemotherapy To evaluate the differences in ADC values according to the malignancy degree of nephroblastoma in children
214306131|NCT00955942|DIETARY_SUPPLEMENT|flaxseed|Given orally
214306132|NCT00955942|OTHER|placebo|Given orally
214306133|NCT05476341|DRUG|Bevacizumab injection|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
214306134|NCT05476341|DRUG|Bevacizumab injection（Avastin）|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
214306135|NCT00944450|DRUG|Sitagliptin phosphate anhydrous formulation|Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
214480048|NCT05590455|DRUG|Adalimumab Injection|one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids
214480049|NCT06820125|DEVICE|Cognitive rehabilitation: CG group|60 minutes of cognitive training with a computerized device
214480050|NCT06820125|DEVICE|Motor rehabilitation: MG group|60 minutes of robot-assisted gait training with the G-EO System
214480051|NCT06820125|DEVICE|Combined rehabilitation: CbG group|30 minutes of cognitive training with a computerized device + 30 minutes of robot-assisted gait training with the G-EO System. To mitigate the effects of fatigue in sequential training, the patients included in this group will undergo the cognitive (treatment CG) and motor (treatment MG) sessions in a counterbalanced order (half of the participants will follow the CG-MG sequence, and the other half will follow the MG-CG sequence). Five-minute breaks will be provided between the cognitive and motor sessions.
214915288|NCT04586816|COMBINATION_PRODUCT|5% red maple leaf extract|5% red maple leaf extract is combined in a cream base
214480052|NCT06816225|OTHER|Actigraphy|Actigraphy is a validated complementary means of diagnosis, the gold standard for the assessment of circadian rhythm.
214306136|NCT00944450|DRUG|Comparator: sitagliptin phosphate monohydrate form|Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.
214306137|NCT00116532|DRUG|Escitalopram|
214306138|NCT06201533|BEHAVIORAL|combined physical-cognitive exercise|A combined physical-cognitive exercise will be delivered in the form of exergame, where the participants move their body to interact with the game.
214306139|NCT00451386|DRUG|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
214306140|NCT00451386|DRUG|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
214306141|NCT05844189|PROCEDURE|Physical therapy modalities on pelvic floor (manual therapy)|Intravaginal treatment (perineal massage)
214306142|NCT05844189|DEVICE|CRMRF|"CRMRF application on pelvic floor:~* Externally over the urogenital triangle of the patient,~* Intracavitary application (intravaginal)~* Externally over the urogenital triangle of the patient while the physical therapist performs the intracavitary manual therapy (intravaginal),~The device used is named Intradermik and it is the portable CRMRF device of the brand RÖS'S Estética SL.~It has these features:~* Frequency: 448kHz~* Capacitive power: 450 voltamperes~* Resistive power: 200 watts"
214306143|NCT05844189|DEVICE|Sham CRMRF|The physical therapist applies the same treatment as the Treatment Group but the device is switched off.
214306144|NCT02235142|OTHER|Blood sample|
214306145|NCT05221333|DEVICE|Sorrel Wearable Injector|Use of Sorrel Wearable Injector in pilot study
214306146|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients \>65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
214480053|NCT06816225|OTHER|Schedule of Growing Skills II|Assessment scale for skills in child development from 0 to 6 years.
214480054|NCT06816225|OTHER|Questionnaire Children Sleep habits|Questionnaire for assessing sleep habits, validated for the Portuguese population (4) which allows us to understand the sleep hygiene habits of the child
214480055|NCT06816225|OTHER|Melatonin evaluation|Melatonin will be measured in the first-morning urine and it is considered to be a good marker of plasma MLT level since its concentration is highly correlated with nocturnal plasma melatonin.
214915289|NCT04586816|COMBINATION_PRODUCT|vehicle|vehicle cream base only
214915290|NCT02322112|OTHER|Microcrystalline Cellulose Supplementation|Fifty overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of MCC (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
215060037|NCT04114916|DIETARY_SUPPLEMENT|maltodextrina|Two capsules daily at breakfast and dinner.
215060038|NCT01658605|DRUG|GSK1605786|500 mg twice daily administered orally
214915291|NCT02322112|OTHER|Acacia Gum Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AG (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
214915292|NCT02322112|OTHER|Resistant Starch Type 4 Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of RS4 (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
214915293|NCT02541513|DRUG|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
214915294|NCT00000918|DRUG|Indinavir sulfate|
214915295|NCT00000918|DRUG|Lamivudine/Zidovudine|
214915296|NCT00000918|DRUG|Ritonavir|
214306147|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls \> or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
214306148|NCT03659981|OTHER|MRI 7T|The imaging parameters will come from the 7 Tesla Siemens MRI
214306149|NCT03879382|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
214306150|NCT03879382|DRUG|Fludarabine|30mg/m2/d
214306151|NCT03879382|DRUG|Cyclophosphamide|300mg/m2/d
214306152|NCT02070835|DEVICE|autologous skin cell|autologous skin cell and skin graft
214306153|NCT02070835|PROCEDURE|skin graft|split-thickness skin graft
214306154|NCT06210490|DRUG|Disitamab Vedotin|Disitamab vedotin (RC48-ADC) is a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E via a cleavable linker. Two phase II studies, RC48-C005 (NCT03507166) and RC48-C009 (NCT03809013), have shown its significant antitumor potential in patients with la/mUC with HER2 overexpression (immunohistochemistry (IHC) 3+ or 2+). In 2022, RC48-ADC was approved for patients with HER2 overexpressing la/mUC who had received prior chemotherapy in China.
214306155|NCT06210490|RADIATION|Radiotherapy|Radiotherapy dose: 45-50 Gy/25f/5w to lymph node drainage area; 62.5 Gy/25f/5w to metastatic or suspected metastatic lymph nodes.
214306156|NCT06210490|OTHER|Standard of Care|Standard of Care
214306157|NCT01680718|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
214306158|NCT01680718|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
214306159|NCT01680718|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
214306160|NCT01563718|DRUG|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
214306161|NCT02360384|DRUG|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
214915297|NCT00000918|DRUG|Amprenavir|
214915298|NCT00000918|DRUG|Efavirenz|
214915299|NCT00000918|DRUG|Saquinavir|
214915300|NCT00000918|DRUG|Lamivudine|
214915301|NCT00000918|DRUG|Stavudine|
214306162|NCT02360384|DIETARY_SUPPLEMENT|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
214306163|NCT01620710|RADIATION|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
214306164|NCT01620710|RADIATION|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
214306165|NCT02081079|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
214915302|NCT00000918|DRUG|Zidovudine|
214306166|NCT05363384|DRUG|CT-L01|FDC tablet, single dose, oral administration
214306167|NCT05363384|DRUG|Alogliptin Benzoate 25 mg|Alogliptin Benzoate 25 mg, oral administration
214306168|NCT05363384|DRUG|Metformin HCl XR 1,000 mg|Metformin HCl XR 1,000 mg, oral administration
214306169|NCT00657007|BIOLOGICAL|belimumab|"1. 1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~2. 1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
214915303|NCT00000918|DRUG|Didanosine|
214915304|NCT03080064|BEHAVIORAL|Health Coach Intervention|Please see arm description.
214915305|NCT03777436|DRUG|Apremilast|Oral
214915306|NCT03777436|OTHER|Placebo|Oral
214915307|NCT06578403|DEVICE|external microneedling|external micro\_needling
214915308|NCT06578403|OTHER|minimally invasive non- surgical periodontal therapy|minimally invasive non- surgical periodontal therapy
214915309|NCT06578403|DEVICE|internal micro_needling|internal micro\_ needling
214915310|NCT00447343|PROCEDURE|Decompressive cervical spine surgery|"Treatment group (25 patients) will undergo decompressive anterior cervical spine surgery~Healthy volunteers will ONLY undergo two scans 6 months apart."
214915311|NCT00447343|PROCEDURE|fMRI and MRS scan|A scan pre-op and 6 months post-op.
214915312|NCT03636802|OTHER|Questionnaire BPI|Brief Pain Inventory (BPI) This is a scale of self-assessment, the Concise Pain Questionnaire in French. For all adult patients For any type of pain This is to ask the patient to answer questions in order to learn about us characteristics of his pain (its intensity and its repercussions on the plane biopsychosocial).
215060039|NCT01658605|OTHER|Placebo|500 mg twice daily administered orally
214915313|NCT02877875|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with Attention-deficit/hyperactivity disorder (ADHD). MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
214915314|NCT02877875|OTHER|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Feelings Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
214915315|NCT02877875|BEHAVIORAL|Treatment as usual|Treatment in the UC condition will use the procedures therapists (e.g., school counselors) and their supervisors consider appropriate and believe to be effective.
214915316|NCT03821259|OTHER|Psychological measures|Participants will be asked to provide basic demographic information and to complete five measures, screening for cognitive impermanent and measuring PTSD symptoms, lifetime trauma exposure, emotion regulation and group identification.
214915317|NCT02316600|DEVICE|smart insole|smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
214915318|NCT01342770|OTHER|Laboratory Biomarker Analysis|Correlative studies
214915319|NCT01342770|DRUG|Pioglitazone Hydrochloride|Given PO
214306170|NCT00657007|BIOLOGICAL|belimumab|"1. 4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~2. 4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
214306171|NCT00657007|BIOLOGICAL|belimumab|"1. 10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~2. 10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
214306172|NCT00657007|BIOLOGICAL|belimumab|"1. 20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~2. 20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
214306173|NCT00657007|BIOLOGICAL|Placebo|"1. IV (in the vein) on Day 0 (Cohorts 1-4).~2. IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
214306174|NCT01712854|DRUG|Budesonide|budesonide 80 mcg
214306175|NCT01712854|DRUG|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
214306176|NCT01831154|DRUG|Tight Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
214306177|NCT01831154|DRUG|Conventional Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
214306178|NCT01831154|DRUG|Standard Glycemic|Insulin was Regular Insulin administered intravenous bolus.
214306179|NCT00123591|DRUG|activated recombinant human factor VII|
214306180|NCT04094467|DRUG|Cetrorelix|0.25 mg subcutaneous injection daily for 6 days
214306181|NCT04094467|DRUG|Leuprolide Acetate|0.1 mg subcutaneous injection daily for 12 days
214915320|NCT01342770|OTHER|Quality-of-Life Assessment|Ancillary studies
214306182|NCT02225743|OTHER|Observation Of Temperature|Participants temperature will be recorded perioperatively.
214306183|NCT05195723|DRUG|WP1122|Oral solution
214306184|NCT05195723|DRUG|Placebo|Oral solution
214306185|NCT06054087|PROCEDURE|Basal therapy+EA|"1. Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.~2. Main acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). Supporting acupoints: for pain in the upper limbs, add Baxie, Quchi (LI11), Shousanli (LI10), Hegu (LI4), and Ashixue; for pain in the lower limbs, add Bafeng, Neiting (ST44),Kunlun (BL60). Operation: Acupuncture needles of size 25\*40mm will be used. The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject."
214306186|NCT06054087|OTHER|Basal therapy|Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.
214306187|NCT01347541|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
214306188|NCT01347541|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
215060040|NCT02175485|DRUG|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
214306189|NCT01347541|DRUG|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
214306190|NCT01347541|BEHAVIORAL|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
214915321|NCT02169375|OTHER|Brain computer Interface Mu (SMR) rhythm|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
215060041|NCT01625416|BEHAVIORAL|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
214306191|NCT02146547|DRUG|Aripiprazole|Administration in once-a-day schedule without regard to meals.
214306192|NCT02146547|DRUG|Aripiprazole depot|Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
214306193|NCT02146547|DRUG|Paliperidone|Administration once a day orally standardised in relation to food intake.
214306194|NCT02146547|DRUG|Paliperidone palmitate|In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
214480056|NCT06815939|DIAGNOSTIC_TEST|HPV Test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
214480057|NCT06815939|DEVICE|EVA System|Digital colposcope
214915322|NCT01146899|OTHER|Provider Alert|Provider influenza vaccine alert
215060042|NCT00511628|DRUG|Risperidone|As prescribed
215060043|NCT04944238|DEVICE|Ankoris|Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
215060044|NCT04884750|BEHAVIORAL|ECA-ACE Vaccination Promotion Intervention|A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
214915323|NCT00869999|DRUG|Everolimus|Taken orally once daily in the morning
214915324|NCT00869999|DRUG|rituximab|Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
214915325|NCT00552370|DRUG|Lantus®|
214915326|NCT02236871|BEHAVIORAL|2 servings|Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.
214915327|NCT02236871|BEHAVIORAL|4 servings|Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
214915328|NCT02127411|BEHAVIORAL|Mindfulness-Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
214915329|NCT03788993|OTHER|Blue-depleted evening light condition|"A 20-bedded ward with tunable light emitting diode (LED) lamps. At 18:00h the lighting undergoes a 30-minute transition during which the green and blue LEDs are dimmed to produce blue-depleted amber colored lighting. At 06:50h a new 10-minute transition changes the light color to ordinary indoor lighting. From 07:00h to 18:00h, there is ordinary indoor lighting (3000K colour temperature). The light intensity is dimmed to 20% of the maximum from 23:00h to 6:50h.~Blue-blocking window filters are deployed also in the evening. All TV sets have permanent blue-blocking filters and individuals are provided with blue-blocking screens that can be attached to the front of personal electronic devices. If the patients leave the blue-depleted unit after 18:30 they are offered blue-blocking glasses to wear. The light spectrum in the ward was assessed prior to commencing the RCT and is well-matched to what has been shown in laboratory settings to minimally suppress melatonin."
214915330|NCT03788993|OTHER|Normal light condition|"The other half of the unit (20 patient rooms and their corresponding bathrooms and common areas) have ordinary indoor light installed (Glamox, Norway). This has a 3000K color temperature. The light is dimmed to 20% of max in the night, similar to the blue-depleted condition.~The light in the normal light condition and the blue-depleted light condition have similar levels of photopic lux throughout the 24h cycle, but different levels of melanopic lux between 1830h and 0700h."
214915331|NCT02186860|BIOLOGICAL|CAR-T cells|Given IV
214306195|NCT03886220|DRUG|Elagolix|Oral; Tablet
214306196|NCT03886220|DRUG|Placebo|Oral; Tablet
214306197|NCT00768300|DRUG|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
214480058|NCT06815939|PROCEDURE|Visual Inspection with Acetic Acid (VIA)|unaided visual inspection with acetic acid
214915332|NCT05434195|DIETARY_SUPPLEMENT|Arcofolin® 5-Methyltetrahydrofolate|5-methyltetrahydrofolate (5-MTHF) is the biologically active form of reduced folate, which can increase BH4 availability. 5-MTHF is available as a nutritional vitamin (Merck \& Cie) for human use including during pregnancy. Two out of three preeclamptic study groups will receive 5-MTHF - one at a low dose and the other at a high dose.
214915333|NCT05434195|DIETARY_SUPPLEMENT|Arcofolin® Placebo|The placebo, this consists of the same excipients as 5-MTHF, microcrystalline cellulose and silica with no active ingredient.
215060045|NCT05690399|RADIATION|Radiotherapy|Effect of radiotherapy on patients
215060046|NCT06305780|DRUG|IVIG + Coordinated Care|Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
214306198|NCT00768300|DRUG|Placebo|Placebo to match ambrisentan was administered orally once daily.
214306199|NCT02535845|BEHAVIORAL|Project Voice|Project Voice tablet-based intervention plus informational video
214306200|NCT02535845|BEHAVIORAL|HPV Informational Video|Informational video only
214480059|NCT06815939|DIAGNOSTIC_TEST|Automated Visual Evaluation (AVE)|Digital diagnostic classification, quality classifier using captured images from EVA System
214480060|NCT06815939|OTHER|Image Capture with Mobile Phone|Compare performance of AVE installed on a mobile phone vs. on the EVA System
214480061|NCT06815939|DIAGNOSTIC_TEST|Pregnancy test|Urine based pregnancy test
214306201|NCT02146573|BEHAVIORAL|Continuity Care Intensivist Communication Training|Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.
214306202|NCT02146573|BEHAVIORAL|Continuity Care Intensivist (CCI) Provider Program|"After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:~* CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.~* Help patients/families navigate decisions in concert with preferences and beliefs~* Help patients/families and other care providers look at bigger picture; trajectory of illness, goals, and hopes for the patient.~* Serve as point person for active intensivists on service and other specialists~* Help resolve conflict when multiple providers have different opinions on course of action"
214306203|NCT00532584|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
214306204|NCT01254526|DRUG|GDC-0980|Oral repeating dose
214306205|NCT01254526|DRUG|bevacizumab|Intravenous repeating dose
214480062|NCT06815939|DIAGNOSTIC_TEST|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
214480063|NCT06815939|PROCEDURE|Colposcopy with biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
214480064|NCT06815939|PROCEDURE|Thermal Ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
214306206|NCT01254526|DRUG|paclitaxel|Intravenous repeating dose
214480065|NCT06815939|PROCEDURE|Loop electrosurgical excision procedure (LEEP)|LEEP is utilized to remove abnormal tissue from the cervix. This may include tissue with precancerous cells (called cervical dysplasia) or cancerous cells. The loop is heated using electricity to remove the tissue. LEEP may also be called a loop excision or large loop excision of the transformation zone (LLETZ).
214670421|NCT02465034|DEVICE|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1 milliseconds (ms) rectangular pulses at an intensity to evoke a 1 millivolt (mV) response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
214915334|NCT04478695|DRUG|AMG 330|Continuous intravenous (IV) infusion.
214915335|NCT04478695|DRUG|Pembrolizumab|Intravenous (IV) infusion.
214915336|NCT03525938|PROCEDURE|TAP block|Whilst the patient is in the supine position, a high frequency ultrasound probe (10 MH) is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Upon reaching the plane, 2 ml of saline is injected to confirm correct needle position after which 20 ml of levobupivacaine, 25% plus triamcinolone, 80 mg solution is injected for TAP group and 20 ml of saline only is injected for SHAM group.. The transversus abdominis plane is visualized expanding with the injection ( appears as a hypoechoic space)
214915337|NCT02158325|PROCEDURE|anterior capsulorhexis sizes|Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0\~3.9, 4.0\~5.0, 5.1\~6.0 mm in diameter)
214915338|NCT01191125|OTHER|medical food with AN777|Two(220 mL)servings every day for six months
214915339|NCT01191125|OTHER|oral nutritional formula|Two (220 mL) servings daily for six months
215060047|NCT06305780|DRUG|IVIG Placebo + Coordinated Care|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration.~Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator."
214306207|NCT05821842|DEVICE|Sonu|Acoustic energy delivery
214306208|NCT04703439|BEHAVIORAL|Medication-taking reminders & educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
214306209|NCT04703439|BEHAVIORAL|Educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
214306210|NCT01879774|OTHER|Neuropsychological and motoric tests|"1. Neuropsychological tests~   * Mini Mental Status Test~  * Dem-Tect~  * Rey-Osterrieth Complex Figure Test~  * Trailmaking Test~  * Beck Depression Inventory~  * d2-R (optional)~2. Motoric tests~   * modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~  * Timed-up-and-go Test~  * Halstead Fingertapping Test~  * AIMS (Abnormal involuntary movement scale)~3. EEG (only in patients with hyponatremia)~4. MRI (only in patients with hyponatremia)"
214306211|NCT02518867|OTHER|high intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
214306212|NCT02518867|OTHER|low intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
214306213|NCT02518867|OTHER|sham iTBS|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
214306214|NCT01599871|DRUG|theophylline|theophylline 100 mg, twice at day
214306215|NCT01599871|OTHER|placebo|Placebo
214306216|NCT00495833|BEHAVIORAL|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
214306217|NCT00495833|BEHAVIORAL|Promotional gift|half of participants who go to a fire station will receive a gift card.
214306218|NCT00003814|DRUG|eflornithine|
214306219|NCT00983151|DRUG|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
214306220|NCT02068222|DRUG|ABT-450/ritonavir (r)|Tablet
214306221|NCT02068222|DRUG|ABT-530|Tablet
214306222|NCT02068222|DRUG|Ribavirin (RBV)|Tablet
214306223|NCT03518333|DEVICE|Injection of adipose derived cells into penis|Injection of Icellator-derived cells
214915340|NCT01872117|OTHER|Shortwave therapy|Will be conducted in four stages, on different days: i) lower limb in extension and application of 180° for 20 min, ii) Lower limb knee flexion of 90° and application for 20 min; iii) lower limb extension in 180° without application iv) lower limb knee flexion of 90° without application.
214915341|NCT01872117|OTHER|Microwave therapy|Will be held in two stages, on different days: i) lower limb in extension with angle of 180° and application for 20 min, ii) lower limb in extension of 180° without application.
214915342|NCT00644917|DRUG|Xenaderm|20mg under Finn chambers
214915343|NCT00644917|DRUG|Placebo|20mg under Finn chambers
214915344|NCT01544842|DRUG|0.1 % tacrolimus ointment|applied topically to oral mucosa
214915345|NCT01544842|DRUG|0.1 % triamcinolone paste|applied topically to oral mucosa
214915346|NCT01544842|DRUG|Orabase paste|applied topically to oral mucosa
214915347|NCT02099617|PROCEDURE|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent|
214915348|NCT02099617|PROCEDURE|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent|
214306224|NCT04552392|OTHER|No intervention|No intervention
214306225|NCT02448654|DRUG|Tolcapone|Tolcapone will be compared to sugar pill
214306226|NCT02448654|DRUG|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
214306227|NCT03724409|DRUG|[90]Y-DOTATOC|Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
214480066|NCT06816810|DRUG|Hydroxychloroquine (HCQ)|The intervention involves hydroxychloroquine (HCQ), administered orally in 200 mg tablets, with a dosing schedule of 200 mg twice daily (400 mg per day). The treatment duration is 48 weeks, after which participants will enter a 4-week safety follow-up period. HCQ will be taken alongside stable doses of Parkinson's disease (PD) medications, with no anticipated changes during the study. Monitoring for adverse events, laboratory assessments, and efficacy evaluations will occur regularly throughout the 12-month period. The study does not include a placebo group or other treatment arms.
214480067|NCT06817577|DRUG|NG004|repeated intrathecal injections of NG004
214915349|NCT02099617|PROCEDURE|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent|
214306228|NCT04380259|BEHAVIORAL|Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)|"MBTR-R is a mindfulness-based group intervention of nine 2.5-hour weekly sessions. MBTR-R format and structure parallel MBSR (mindfulness-based stress reduction) and MBCT (mindfulness-based cognitive therapy). MBTR-R includes systematic training in formal and informal mindfulness practices with trauma-sensitive adaptations and home practice. Trauma-sensitive adaptations include a safe place practice, psychoeducation about posttraumatic stress, stress reactivity, as well as self-compassion practices to cope with fear, self-judgement, guilt and shame. Socio-cultural adaptations include real-time linguistic translation of each session by a cultural mediator from the refugee community and use of socio-culturally specific metaphors. MBTR-R groups were conducted for men and women separately and delivered in an accessible, safe space in the local refugee community. Group meetings included a shared meal of traditional Eritrean food and female participants were offered free child care."
214306229|NCT02541747|BEHAVIORAL|massage|massage
214306230|NCT04011501|PROCEDURE|Continuous Erector spinae block|Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
214306231|NCT02685631|OTHER|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
214306232|NCT05422677|DRUG|Hanmi Tams® Capsule|Hanmi Tams®, Once daily administered per the locally approved product information
214915350|NCT05330156|PROCEDURE|Transurethral resection of the prostate|\- After an initial cysto-urethroscopy assessment done, Transurethral resection of the prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
214915351|NCT05330156|PROCEDURE|transurethral enucleation of prostate|After an initial cysto-urethroscopy assessment done, transurethral enucleation of prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
214306233|NCT01120756|BEHAVIORAL|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
214306234|NCT01120756|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
214306235|NCT06161805|DRUG|Esketamine hydrochloride|Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour). This dosage regimen is similar to that used earlier by Sigtermans et al. \[1\].
214306236|NCT06161805|DRUG|Placebo|8 hour infusion with saline (NaCl 0.9%)
214306237|NCT03145168|OTHER|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
214306238|NCT03145168|OTHER|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
214306239|NCT03056391|DRUG|Paracetamol|"\>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
214306240|NCT04706143|BIOLOGICAL|COVID-19 Vaccines|different available vaccines: live inactivated, mRNA and viral vector vaccines
214480068|NCT06817057|DEVICE|Virtual Reality headset + headphones|The intervention involves patient use of a Virtual Reality headset (the Oculus Quest 2) and headphones (Beats Ep Wired On-Ear) during their wide-awake hand operation.
214915352|NCT00758485|DRUG|Sugammadex|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
214306241|NCT04177602|COMBINATION_PRODUCT|Trifluridine/tipiracil chemoradiation|Trifluridine/tipiracil based chemoradiation
214306242|NCT04177602|COMBINATION_PRODUCT|Capecitabine based chemoradiation|Capecitabine based chemoradiation
214306243|NCT01215370|OTHER|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
214306244|NCT01215370|OTHER|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
214306245|NCT01215370|OTHER|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
214306246|NCT01215370|OTHER|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
214306247|NCT01215370|OTHER|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
214306248|NCT05750355|DRUG|TPN171H 10 mg Group|6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
214306249|NCT05750355|DRUG|TPN171H 30 mg Group|6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
214306250|NCT05750355|DRUG|TPN171H 40 mg Group|6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
214306251|NCT05750355|DRUG|TPN171H 50 mg Group|6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
214306252|NCT03098173|PROCEDURE|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
214306253|NCT03098173|PROCEDURE|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
214306254|NCT01207518|BEHAVIORAL|Intervention Group|This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.
214306255|NCT01207518|BEHAVIORAL|Control Group|This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.
214306256|NCT02742987|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily
214306257|NCT02742987|DRUG|Clopidogrel|Clopidogrel 150 mg once daily
214306258|NCT02742987|DRUG|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
214306259|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
214306260|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
214480069|NCT04510129|DIAGNOSTIC_TEST|OncoPrism™ assay|OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
214480070|NCT06816628|OTHER|comedy therapy|After patients came to the clinic after transplantation surgery and their condition was stable, 10-minute Turkish comedy films prepared by the researchers were shown.
214480071|NCT06816511|PROCEDURE|magnetic resonance-guided focused ultrasound surgery, MRgFUS|Magnetic Resonance-Guided Focused Ultrasound Surgery The clinical symptoms, brain imaging, and cognitive function status were followed up for 2 years before and after surgery.
214915353|NCT00758485|DRUG|0.9% sodium chloride (NaCl)|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
214915354|NCT02347774|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CS) nebulizer
214915355|NCT02347774|DRUG|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg BID eFlow (R) Closed System (CS) nebulizer
214915356|NCT02347774|DRUG|Placebo eFlow (CS) nebulizer|Placebo BID eFlow (R) Closed System (CS) nebulizer
214915357|NCT03269630|OTHER|No intervention. Biospecimen collection only|Biospecimen collection
214915358|NCT00846248|DIETARY_SUPPLEMENT|Chromium|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
214306261|NCT04300595|PROCEDURE|Combination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery|"all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).~In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes."
214306262|NCT00736008|OTHER|Observational|Data summary only
214306263|NCT05568784|OTHER|Straight Leg Raise exercise|Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)
214306264|NCT02690610|PROCEDURE|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
214346965|NCT04340206|BEHAVIORAL|face-to-face support and Chatbot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to support adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program. In addition, they meet and get support from their human coach (i.e., psychology student) twice in the face-to-face meetings.
214915359|NCT00846248|DIETARY_SUPPLEMENT|placebo|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
214915360|NCT00656292|DRUG|Simvastatin|40 mg po/nasogastric tube (NG) every day for 6 days
214915361|NCT00656292|DRUG|Placebo|1 pill po/NG every day x 6 days
214915362|NCT04758468|BEHAVIORAL|Telerehabilitation-based pelvic floor muscle training|"Telerehabilitation-based pelvic floor muscle training group will individually receive telerehabilitation-based pelvic floor muscle training under the guidance of a physiotherapist 2 sessions per week for 8 weeks. Participants will do their exercises themselves 2 times on the days where sessions are held with a physiotherapist. Participants will continue to exercise 3 times a day in the remaining days.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
214915363|NCT04758468|BEHAVIORAL|Home-based pelvic floor muscle training|"The home-based pelvic floor muscle training group will do their individual exercises 3 times a day for 8 weeks.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
214915364|NCT00921557|DRUG|Alendronate|Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg
214915365|NCT00921557|DRUG|Placebo|Oral tablet taken once weekly
214915366|NCT00921557|DIETARY_SUPPLEMENT|Calcium carbonate/vitamin D|Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL
214915367|NCT03711565|DEVICE|Regular Nasal CPAP using a conventional ventilator|The Nasal CPAP is connected to the patient via prongs in the nose. Pressure adjustments are made to improve lung inflation. The frequency and pressure can be adjusted as needed to improve the patient's oxygen and carbon dioxide levels
214915368|NCT03711565|DEVICE|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The Bronchotron produces a pressure that is variable with an adjustable frequency that is equal or greater than 500 times per minute connecting to prongs in the patient's nose. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation.
214670422|NCT02465034|DEVICE|Corticocortical Paired Associative Stimulation|Cortico-cortical Paired Associative Stimulation (CC-PAS) is a combination of TMS and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. The interstimulus interval will range from 5-15 ms depending on site of stimulation.TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This CC-PAS may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
214915369|NCT04346667|DRUG|Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
214915370|NCT04346667|DRUG|Hydroxychloroquine Sulfate Loading Dose|Hydroxychloroquine administered as a loading dose only
214915371|NCT04346667|DRUG|Chloroquine|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
214915372|NCT04346667|DRUG|Placebo|Standard of Care plus placebo
214915373|NCT01704118|DEVICE|I-gel|Supraglottic airway device
214915374|NCT01704118|DEVICE|ProSeal Laryngeal mask|Supraglottic airway device
214915375|NCT05393869|OTHER|Health communications|Participants are assigned to view health communications with risk and efficacy statements.
214915376|NCT01421823|DRUG|alpha agonist ointment|2 weeks local treatment with alpha agonist ointment
214915377|NCT01421823|DRUG|Placebo|2 weeks local treatment with placebo ointment
214306265|NCT06189222|DEVICE|virtual reality glasses|The population of the study consisted of children who were aged between 7- 12 and were on treatment using an intravenous catheter in the pediatric emergency unit of a state hospital in Turkey.Participants were divided into two groups, namely experimental and control groups, by using simple randomization software. The design and implementation of the study were based on the principles in the CONSORT list (Consolidated Standards of Reporting Studies). Descriptive data form for children,this form was prepared to collect information about the children included in the sample. It consists of seven questions on children's sociodemographic characteristics and previous intravenous catheter insertion experience.The Children's Emotional Manifestation Scale (CEMS), this scale was developed by Li \& Lopez (2005) to measure children's emotional responses during stressful medical procedures. The VR glasses we used in our study were connected to a mobile phone.
214306266|NCT01611181|DRUG|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
214306267|NCT01611181|DRUG|Kräuterblut|40 mg iron, 20 ml twice daily.
214306268|NCT01611181|DRUG|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
214306269|NCT03807011|DRUG|fentanyl group|fentanyl 2 μg/kg
214306270|NCT03807011|DRUG|remifentanil group|remifentanil 0.2 μg/kg/min
214306271|NCT05796011|DEVICE|hearing aids|Hearing aid(s) fitted for one or two sides of ear.
214306272|NCT05796011|OTHER|without hearing intervention|neither earing aids nor other heaing treatment were applied.
214306273|NCT05796011|OTHER|healthy control|healthy control
214306274|NCT04597307|COMBINATION_PRODUCT|IN.PACT™ Admiral™ Drug Coated Balloon (DCB)|For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
214306275|NCT03645551|DIAGNOSTIC_TEST|checkup, no test|In this study we would like to examine if existing restorations already applied in teeth which we treated with laminate veneers had an effect. We will evaluate the laminate veneers by sight and take pictures and use a questionnaire
214306276|NCT02049333|PROCEDURE|Phacoemulsification|
214306277|NCT02049333|PROCEDURE|Endoscopic Cycloplasty (ECPL)|
214306278|NCT00449644|DRUG|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
214306279|NCT00449644|DRUG|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
214306280|NCT00449644|DRUG|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
214306281|NCT02081144|OTHER|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of \~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
214306282|NCT02081144|DRUG|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
214306283|NCT02081144|DRUG|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
214306284|NCT02081144|BEHAVIORAL|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
214306285|NCT00149981|DRUG|everolimus (RAD)|Everolimus
214306286|NCT03642717|DRUG|JARDIANCE DUO®|empagliflozin and metformin
214670423|NCT02465034|DEVICE|Sham Paired Associative Stimulation|The sham PAS is a combination of TMS and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25 Hz for 12 minutes. TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
214670424|NCT03717324|OTHER|Procedure created in co-creation group|Interventions will be those obtained from the co-creation workshop with patients
214670425|NCT00581711|OTHER|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
214670426|NCT00581711|OTHER|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
214306287|NCT04000204|DEVICE|HYAJOINT Plus|60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
214306288|NCT04000204|DEVICE|Durolane|60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
214670427|NCT00581711|OTHER|1-part intervention|Provision of feedback on otitis media quality indicators
214915378|NCT04971135|DRUG|SAN711|SAN711 liquid formulation
214306289|NCT03930446|DRUG|Ethanol|The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
214306290|NCT03930446|OTHER|Placebo|The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
214306291|NCT02847546|DEVICE|True™ Flow Valvuloplasty Perfusion Catheter|Balloon Aortic Valvuloplasty as preparation step in implantation of a Tanscatheter Aortic Valve Implantation (TAVI).
214306292|NCT04954547|BEHAVIORAL|Subsidy Treatment|Participants will be awarded $50 for reaching the PBF goal at the end of 12 weeks. Regardless of goal-attainment, participants will be reimbursed 50% of approved health-improving expenses up to a cap of $300 in the 12 weeks. The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts and simply be reimbursed at the end of the experiment (subject to approval from the research team).
214306293|NCT04954547|BEHAVIORAL|Cash Treatment|Participants will be awarded $350 for reaching the PBF goal at the end of 12 weeks.
214670428|NCT00120796|DRUG|Lamivudine|
214670429|NCT00120796|BIOLOGICAL|Recombinant hepatitis B surface antigen|
214915379|NCT04971135|OTHER|Placebo|Matching placebo
214915380|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
214915381|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
214306294|NCT04130451|DRUG|PYODINE AND TALC SLURRY|"pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate"
214306295|NCT05034107|OTHER|Aromatherapy|Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.
214306296|NCT02183831|DEVICE|Insertion of the capsular tension ring|
214915382|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program|Inoculate 1 dose of control vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
214915383|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program|Inoculate 1 dose of control vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
214915384|NCT01431716|DRUG|EFI/ACT-385781A|
214915385|NCT05306912|BIOLOGICAL|Blood samples|Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.
214915386|NCT01644799|DRUG|idelalisib|oral
215060048|NCT06305780|DRUG|Ivabradine + Coordinated Care|Participants will receive Ivabradine for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
215060049|NCT06305780|DRUG|Ivabradine Placebo + Coordinated Care|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive Ivabradine placebo for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, feedback, nutrition counseling, motivation, education, and assisted care through care coordinator."
214306297|NCT04902755|OTHER|Questionnaire|validation of the French linguistic version and the cross-cultural adaptation of the NBSS-SF.
214306298|NCT05375695|OTHER|Time-restricted eating|"The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.~Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care."
214306299|NCT03647228|DRUG|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
214306300|NCT03647228|DRUG|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
214306301|NCT01559012|DRUG|Clonidine|transdermal clonidine patch 5 mg q. 5 days
214306302|NCT04535895|RADIATION|Simultaneous integrated boost|Adjuvant breast cancer irradiation including simultaneous integrated boost
214306303|NCT00946712|BIOLOGICAL|Bevacizumab|Given IV
214306304|NCT00946712|DRUG|Carboplatin|Given IV
214306305|NCT00946712|BIOLOGICAL|Cetuximab|Given IV
214306306|NCT00946712|OTHER|Laboratory Biomarker Analysis|Correlative studies
214306307|NCT00946712|DRUG|Paclitaxel|Given IV
214915387|NCT01644799|DRUG|lenalidomide|oral
214915388|NCT05524168|RADIATION|SBRT|SBRT for metastatic lesions
214306308|NCT02467569|DRUG|Hemay020|
214306309|NCT03401983|OTHER|Pelvic Floor Muscle Training and Abdominal Training|Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.
214306310|NCT03401983|OTHER|Pelvic Floor Muscle Training|Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
214306311|NCT00302458|DRUG|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
214306312|NCT00302458|DRUG|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
214306313|NCT00302458|DRUG|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
214915389|NCT05524168|DRUG|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance for 1 year.
214915390|NCT05524168|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
214915391|NCT05524168|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
214915392|NCT06574971|DEVICE|Low intensity focused ultrasound using the NeurGear Zenbud|The NeurGear Zenbud is a wearable earbud that delivers low intensity focused ultrasound to the auricular branch of the vagus nerve
214915393|NCT05567653|DIETARY_SUPPLEMENT|Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 (Sanprobi Stress)|3-month, multi-strain probiotic supplementation (one a day, 3 x 10⁹ CFU)
214915394|NCT05567653|DIETARY_SUPPLEMENT|Starch (placebo)|3-month placebo
214915395|NCT05424510|DRUG|Ringer's Lactate|500 ml of Ringer's Lactate
214915396|NCT05424510|OTHER|IV line|Placing of an IV line before surgery
214915397|NCT02158013|OTHER|Levorag Emulgel|
214915398|NCT02158013|DRUG|Diltiazem|
214306314|NCT04665050|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
214306315|NCT04665050|BIOLOGICAL|PNEUMOVAX™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
214306316|NCT02291055|DRUG|ADXS11-001|
214306317|NCT02291055|DRUG|MEDI4736|
214306318|NCT03766854|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks
214306319|NCT03766854|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
214306320|NCT00994955|DEVICE|selective retina therapy (SRT)|laser treatment
214306321|NCT06284226|DRUG|Allogeneic NK（CCT-ANK-11)|allogeneic natural killer cells
214306322|NCT01828892|PROCEDURE|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
214306323|NCT01828892|PROCEDURE|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
214915399|NCT01564108|DRUG|Ranibizumab|Series of intravitreal injections of Ranibizumab
214915400|NCT03552055|OTHER|Non-interventional Study|no interventions in this study, just specimen collection
214915401|NCT02730403|OTHER|Treatment As Usual|
214915402|NCT02266797|DRUG|Dexamethasone|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
214306324|NCT01828892|DRUG|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
214306325|NCT01828892|DIETARY_SUPPLEMENT|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
214306326|NCT01375387|DRUG|Lacosamide|100 mg oral tablet, single dose
214306327|NCT01375387|DRUG|Lacosamide|Lacosamide 2 X 100 mg tablet
214306328|NCT01375387|DRUG|Lacosamide|Lacosamide 4 X 100mg tablet
214306329|NCT01375387|OTHER|Placebo 3|Placebo - 3 tablets
214306330|NCT01375387|OTHER|Placebo 4|Placebo - 4 tablets
214306331|NCT01375387|OTHER|Placebo 2|Placebo - 2 tablets
214306332|NCT00853723|DRUG|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
214306333|NCT00853723|DRUG|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
214915403|NCT02266797|OTHER|Saline|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.
214915404|NCT00694473|DEVICE|Freestyle Navigator|Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
214915405|NCT02162537|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.
214306334|NCT00853723|DRUG|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
214306335|NCT03041246|PROCEDURE|Pelvic floor fascial mobilization|The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
214306336|NCT01531387|DRUG|Hydroxyurea|Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
214306337|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|"The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~* Lactobacillus gasseri KS-13 1.2~* Bifidobacterium bifidum G9-1 0.15~* Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
214306338|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
214306339|NCT02616042|OTHER|Centella asiatica and bamboo salt|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.
214306340|NCT02616042|OTHER|Centella asiatica|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
214306341|NCT03873870|DIAGNOSTIC_TEST|68Ga -DOTATATE PET scans|PET scan using 68Ga-DOTATATE contrast
214915406|NCT02162537|DRUG|Pemetrexed|500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks
214915407|NCT02162537|DRUG|Bevacizumab|7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.
215060050|NCT06305780|DRUG|IVIG + Usual Care|Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.
214306342|NCT02517996|DRUG|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
214306343|NCT02517996|DRUG|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
214306344|NCT05566210|DEVICE|acupuncture|acupuncture
214306345|NCT05566210|DEVICE|Sham acupuncture|Sham acupuncture
214306346|NCT01983358|DRUG|JPI-289|PARP-1 inhibitor
214306347|NCT01983358|OTHER|Placebo|Placebo
214915408|NCT02162537|RADIATION|Cerebral Radiotherapy|Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.
214915409|NCT05653479|DRUG|UPB-101|UPB-101 Subcutaneous injection
214915410|NCT02707484|DRUG|Thalidomide (100mg)|Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
214915411|NCT02707484|DRUG|Thalidomide (50mg)|Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
214306348|NCT00452829|DRUG|Folic Acid and inositol|Folic Acid and inositol
214306349|NCT00452829|DRUG|Folic acid and placebo|Folic acid and placebo
214306350|NCT00002173|BIOLOGICAL|HIV-1 Immunogen|
214306351|NCT03837873|DRUG|Rituximab|rituximab 750mg/m2 i.v. on day 0
214306352|NCT03837873|DRUG|Etoposide|50mg/m2, continuous i.v. on day 1-4
214306353|NCT03837873|DRUG|Vincristine|0.4mg/m2, continuous i.v. on day 1-4
214306354|NCT03837873|DRUG|Doxorubicin|10mg/m2, continuous i.v. on day 1-4
214915412|NCT02707484|DRUG|placebo|Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
214915413|NCT04249102|DEVICE|Guardian Connect, Medtronic|Guardian Connect is real-time continuous glucose sensor systems which provide glucose information updated every 5 minutes
214915414|NCT04249102|DEVICE|Abbott Diabetes Care|Abbott Diabetes Care is a Flash Glucose Monitoring system that provides up to 8 hours of retrospective continuous glucose monitoring data to users when the monitor is waved in proximity with the sensor.
215060051|NCT06305780|DRUG|IVIG Placebo + Usual Care|"Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG.~Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration."
214306355|NCT03837873|DRUG|Dexamethasone|30mg/day, i.v. on day 1-5 for R-DA-EDOCH regimen; 40mg/day, i.v. on day 1-4 for R(2)-DHAP regimen
214306356|NCT03837873|DRUG|Cyclophosphamide|750mg/m2, i.v. on day5
214915415|NCT02327871|DEVICE|Esophageal cooling device (and usual standard procedure)|Standard treatments for resuscitation after CA will follow local, national, and international guidelines. Core temperature is measured using urinary Foley catheters and/or arterial temperature monitoring if available. During TH, sedation and analgesia is performed in routine. Neuromuscular blockade is induced to favor cooling and prevent shivering if necessary. Circulatory function is monitored by arterial catheter if necessary and blood pressure is maintained as usually. Hypotension is treated with dobutamine catecholamines titrated according cardiac output monitored using echocardiogram, or PiCCO® systems. Fluid management is left at the discretion of the attending physician. Prognostication after CA uses serial clinical examinations, biomarkers, transcranial Doppler, Electro-Encephalo-Gram, cerebral CT-scan or MRI, and/or Somato-Sensory-Evoked-Potential.
215060052|NCT06305780|DRUG|Ivabradine + Usual Care|Participants will receive Ivabradine for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
214306357|NCT03837873|DRUG|Lenalidomide|25mg/day, p.o. on day 0-9
214306358|NCT03837873|DRUG|Cisplatin|100mg/m2 continuous i.v. on day 1
214306359|NCT03837873|DRUG|Cytarabine|2g/m2 q12h, i.v. on day 2
214306360|NCT00046696|DRUG|NM-3|
214306361|NCT03336775|PROCEDURE|acupuncture|Acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks).
214306362|NCT00000766|DRUG|Foscarnet sodium|
214306363|NCT00000766|DRUG|Ganciclovir|
214306364|NCT00311337|DRUG|bortezomib|
214306365|NCT00149942|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
214306366|NCT02642432|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
214306367|NCT02871388|BEHAVIORAL|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
214306368|NCT00733746|DRUG|erlotinib hydrochloride|oral administration
214306369|NCT00733746|DRUG|gemcitabine hydrochloride|Intravenous administration
214306370|NCT00733746|PROCEDURE|therapeutic conventional surgery|
214306371|NCT03999892|BEHAVIORAL|ACHIEVE|The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (\~20-30 minutes) and group exercise (\~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
214915416|NCT00663416|DRUG|NTx™-265: rhCG, then rEPO|"* rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
214915417|NCT00663416|DRUG|Saline placebo|"* Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation"
214915418|NCT04634344|DRUG|DZD2269|A single dose of DZD2269 starting at 5 mg will be given on Cycle 0 and then followed by a wash-out period. Multiple doses of DZD2269 at the same dose level will be given once daily after the wash-out period.
214915419|NCT01901458|DEVICE|Spectra Optia® IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
214915420|NCT01901458|DEVICE|Spectra Optia® Collection Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
214915421|NCT02239731|DRUG|FDX104 (4% Doxycycline)|FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
214915422|NCT05317039|OTHER|silica-calcium phosphate nanocomposite SCPC|Patients will be treated with the buccal plate repositioning technique and grafted with SCPC then the grafted defect will be covered with a platelet-rich fibrin membrane.
214915423|NCT05317039|OTHER|freezed dried bone|Patients will be treated with the buccal plate repositioning technique and grafted using DFDBA. then the grafted defect will be covered with a platelet-rich fibrin membrane.
214915424|NCT03966300|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
214915425|NCT01580852|PROCEDURE|Dead Sea water|Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
214306372|NCT03204513|DEVICE|Vanderbilt Powered Knee-Ankle Prosthesis|The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.
214306373|NCT03204513|DEVICE|Microprocessor (MP) Knee Prosthesis|Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
214306374|NCT04366037|OTHER|Routine training|Training will be defined by each club coach
214306375|NCT04366037|OTHER|Routine training + proprioceptive exercise in warm-up|"Training will be defined by each club coach, adding four proprioceptive exercises in warm-up:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
214480072|NCT06820411|BEHAVIORAL|Young Stroke Clinic Lifestyle Intervention|"The Young Stroke Clinic Lifestyle Intervention is a structured program designed for young adults (18-65 years) recovering from ischemic stroke or high-risk TIA. It includes:~* Personalized risk factor management targeting blood pressure, cholesterol, smoking cessation, and lifestyle habits.~* Intensive lifestyle counseling to improve diet, physical activity, and overall cardiovascular health.~* Wearable device monitoring (Whoop 4.0) to track heart rate variability, sleep patterns, and physical activity.~* Regular follow-up visits at a dedicated stroke clinic with tailored guidance from neurologists."
214915426|NCT01580852|PROCEDURE|Pool water|Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
214915427|NCT01357317|OTHER|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
214915428|NCT01357317|OTHER|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
214915429|NCT01357317|DRUG|Phosphorus binder|If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
214915430|NCT01088763|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
214915431|NCT01088763|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214915432|NCT01088763|OTHER|pharmacological study|Correlative studies
214915433|NCT01088763|DRUG|dexamethasone|Given IV
214915434|NCT01401764|OTHER|Formulation buffers|Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
214915435|NCT00608777|DRUG|Calcipotriene/betamethasone|One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
214915436|NCT05881564|OTHER|blood use for priming cardiopulmonary bypass circuit|one arm will have the cardiopulmonary bypass circuit primed with blood
214915437|NCT05881564|OTHER|clear prime for cardiopulmonary bypass|this arm will not have bypass circuit primed with blood
214915438|NCT00792051|BIOLOGICAL|Inactivated influenza vaccine|0.5ml intramuscular single dose
214915439|NCT00792051|BIOLOGICAL|Saline|0.5ml intramuscular, one dose
214915440|NCT06155955|DRUG|"Emicizumab, HEMLIBRA®"|low dose
214480073|NCT06820411|OTHER|Standard Post-Stroke Care|"The Standard Post-Stroke Care group will receive usual medical management based on current clinical guidelines for secondary stroke prevention. This includes:~* Routine follow-up visits with healthcare providers.~* Standard medical treatment for stroke risk factors (e.g., blood pressure, cholesterol, diabetes).~* General lifestyle recommendations on diet, physical activity, and smoking cessation as part of routine clinical care."
214480074|NCT06619275|DRUG|Ripretinib|Switch-Control Tyrosine Kinase Inhibitor
214480075|NCT04241666|DIAGNOSTIC_TEST|renal scintigraphy|Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys
214480076|NCT04241666|DIAGNOSTIC_TEST|renal doppler sonography|doppler ultrasound of both kidneys
214480077|NCT06825572|BIOLOGICAL|MSC-EVs|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
214480078|NCT06664177|PROCEDURE|Transversalis Fascia Plane Block|In the Transversalis Fascia Block group, the same procedure will be followed as in the Quadratus Lumborum block group, with the ultrasound probe being placed in the same location, and the same in-plane technique will be applied with a 22G 100 mm peripheral block needle. After hydrodissection, 20 mL of 0.5% bupivacaine will be injected slowly in the same manner.
214480079|NCT06664177|PROCEDURE|Quadratus Lumborum Block (QLB)|In the Quadratus Lumborum block group, in the lateral decubitus position, a convex ultrasound probe will be sterilely placed in the subcostal area and above the iliac crest. The quadratus lumborum and psoas major muscles, as well as the L4 vertebra's transverse process, will be visualized. Using the in-plane technique and a 22G 100 mm peripheral block needle, the placement will first be identified through hydrodissection in the subfascial area between the quadratus lumborum and psoas major muscles. After localization, 20 mL of 0.5% bupivacaine will be injected slowly, aspirating every 5 cc, while visualizing the local anesthetic pushing the fascia in the ultrasound image.
214306376|NCT04366037|OTHER|Routine training + proprioceptive exercise in cool-down|"Training will be defined by each club coach, adding four proprioceptive exercises in cool-down:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
214306377|NCT05705492|DRUG|Olanzapine|Given PO
214306378|NCT05705492|DRUG|Placebo Administration|Given PO
214306379|NCT05705492|OTHER|Questionnaire Administration|Ancillary studies
214306380|NCT01848756|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
214480080|NCT06663631|DRUG|chlorpromazine and promethazine|C+P were diluted to 50 ml saline solution and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
214480081|NCT06663631|DRUG|Placebo group|50 ml saline solution was set as placebo and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
214480082|NCT06663631|PROCEDURE|endovascular thrombectomy|All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.
214915441|NCT05300581|OTHER|OPAT for PWID|Observational: Patients with a history of injection opioid use will receive home OPAT while also receiving substance use disorder care including medications for opioid use disorder and multidisciplinary health coach and case management support.
214915442|NCT04132323|PROCEDURE|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group
214480083|NCT06663631|DRUG|rt-PA|All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
214915443|NCT02755467|DEVICE|KTP laser|Dual Wavelength Laser Emitting 532 nm Laser Energy
214915444|NCT04856267|DEVICE|"LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)"|Implantation of an implantable cardiac monitor device (brand name LINQ device, Medtronic) will be performed under local anaesthetic using an aseptic sterile technique. They will undergo frequent follow-up and monitoring for arrhythmias through remote monitoring of the device
214915445|NCT06120426|PROCEDURE|total en bloc spondylectomy|Total enbloc resection (TES) is one of the most challenging surgeries in spinal surgery and a classic surgical method. It not only relieve spinal cord compression and delays tumor recurrence, but also prolongs patient survival, significantly reduces hand surgery trauma, and improves surgical safety. However, for cases with extensive tumor invasion, methods such as separation surgery should be used to relieve spinal cord nerve compression, rebuild spinal stability, and provide conditions for postoperative radiotherapy.
214306381|NCT03209427|DRUG|Morphine 100 μg|Intrathecal injection of morphine100 μg
214306382|NCT03209427|DRUG|Morphine 200 μg|Intrathecal injection of morphine 200 μg
214306383|NCT01916356|OTHER|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
214306384|NCT05059067|DEVICE|Direct laryngoscopy for endotracheal intubation|Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
214480084|NCT01653678|DIETARY_SUPPLEMENT|Vitamin D-3 (cholecalciferol), 2000 IU|
214480085|NCT01653678|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
214480086|NCT01653678|DIETARY_SUPPLEMENT|Vitamin D placebo|
214480087|NCT01653678|DRUG|Fish oil placebo|
214480088|NCT06819150|OTHER|Newborn bathing|The babies in the experimental group will have a bathtub bath before starting phototherapy treatment.
214306385|NCT06912828|OTHER|Med-LFD intervention|In the beginning of the intervention, blood and stool samples will be collected. All participants of the group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs). In the end of intervention, stool samples will be collected again.
214306386|NCT00170716|DEVICE|Cortical Stimulation and rehabilitation|Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
214306387|NCT00170716|OTHER|Rehabilitation|Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
214306388|NCT01498718|BIOLOGICAL|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
214306389|NCT01498718|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
214306390|NCT05447754|OTHER|Combined RAGT and TBT|Combined RAGT and TBT: Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
214306391|NCT05447754|OTHER|balance exercises|TBT
214306392|NCT06676072|DEVICE|PFA Ablation catheter|Deliver RF and/or PF energy using the TactFlex PFA system
214306393|NCT01894581|DIETARY_SUPPLEMENT|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
214306394|NCT01894581|DRUG|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
214306395|NCT05206617|OTHER|No intervention - pure observational study|No intervention
214306396|NCT01252940|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
214306397|NCT01252940|DRUG|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
214306398|NCT01252940|DRUG|RTV|Ritonavir (RTV) was administered according to prescribing information.
214480089|NCT06824922|BEHAVIORAL|"Be yourself, educational intervention with chatbot to promote self-determined motivation and prevent adolescent pregnancy: pilot trial protocol"|"The Be Yourself educational intervention stands out for its focus on self-determined motivation and teen pregnancy prevention. Unlike traditional interventions, which focus on transmitting information, this intervention promotes adolescent autonomy in making responsible sexual decisions. It uses interactive technology such as a web page and a chatbot, which provide personalized follow-up and reinforcement activities between sessions, encouraging active participation. It also employs competency-based learning, which strengthens practical and emotional skills, such as effective communication and problem solving. Sessions include role-plays and practical activities to apply what has been learned. This comprehensive approach and the use of digital platforms distinguish Be Yourself from other interventions, offering continuous and personalized accompaniment to reinforce learning throughout the process."
214915446|NCT02332057|DRUG|Diclofenac plus lidocaine|The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
214915447|NCT02332057|DRUG|Placebo|The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
214915448|NCT01231451|DRUG|DMPA|All subjects will take DMPA
214915449|NCT00746148|OTHER|Reflexology|10 weekly sessions of 45 minutes each
214915450|NCT03735277|BIOLOGICAL|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10\^8 total nucleated cells with a minimum of 1.25 × 10\^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
214915451|NCT04084951|BIOLOGICAL|SQZ-PBMC-HPV|antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16
214915452|NCT04084951|DRUG|Atezolizumab|programmed cell death ligand 1 (PD-L1) blocking antibody
214915453|NCT04084951|DRUG|Ipilimumab|cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
214915454|NCT04084951|DRUG|Nivolumab|programmed cell death 1 (PD-1) blocking antibody
215060053|NCT06305780|DRUG|Ivabradine Placebo + Usual Care|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive Ivabradine placebo for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine placebo administration."
215060054|NCT03091088|OTHER|walking at an intense pace|Participants walk 6 kilometers in 1 hour at least 3 times per week
214915455|NCT04955405|OTHER|The seven visit telemedicine protocol|The transition of care team (pharmacist, advanced practice provider, social worker) will conduct an initial visit as a team with the patient using the telemedicine platform. During the visit, the team will assess the clinical, social, and pharmaceutical needs of the patient. The transition of care team will then meet to discuss the specific needs of the patient and to develop a care plan for the next 6 telemedicine visits. Either the social worker or the advanced practice provider will conduct the next 6 visits. The pharmacist will provide medication counseling as needed and recommended by the entire care team. The next 3 visits will occur weekly, the following 2 visits will occur biweekly, and the remaining 1 visit will occur at some point during the third month.
214915456|NCT02089373|PROCEDURE|Probe-based confocal laser endomicroscopy|In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.
214306399|NCT01252940|DRUG|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
214306400|NCT05828979|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
214306401|NCT00605982|PROCEDURE|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
214306402|NCT05230693|BEHAVIORAL|Sarcoidosis Patient Assessment and Resource Companion App|"The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day"
214306403|NCT05230693|BEHAVIORAL|Enhanced Standard Care|Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
214306404|NCT06879340|DRUG|DuoCAR20.19.22-D95|Patient derived autologous T cells, lentiviral transduced to generate, using the Miltenyi CliniMACS Prodigy® closed transduction system, a Duo-CAR-T cells targeting cell surface antigens CD19/20/22.
214306405|NCT06879340|DRUG|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
214306406|NCT06879340|DRUG|Cyclophosphamide (Conditional therapy)|Lymphodepletion chemotherapy
214306407|NCT05781698|DRUG|Mesalamine|mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
214306408|NCT05781698|DRUG|Fenofibrate|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
214306409|NCT06710340|DIETARY_SUPPLEMENT|Nuts in the first meeting|30g of walnuts
214306410|NCT06710340|OTHER|Nuts in the second meeting|30g of walnuts
214306411|NCT06913725|DRUG|FCN-159|An investigational oral MEK inhibitor
214306412|NCT06912958|DIETARY_SUPPLEMENT|Drinking of matcha tea|Japanese tea that will take twice daily for one month
214306413|NCT06912958|DIETARY_SUPPLEMENT|Organic Japanese Matcha, Jade Leaf, Japan|dietary intake
214306414|NCT06913829|COMBINATION_PRODUCT|base-out exercising prisms|"Participants in the experimental group will use base-out exercising prisms as their primary intervention. This involves:~1. Procedure:~   * Wearing customized prism glasses designed to increase the convergence demand during near tasks.~  * Performing near vision activities such as reading or viewing objects while wearing the prisms.~2. Schedule:~   * Prisms will be prescribed based on individual clinical measurements.~  * Participants will use the prisms during near tasks for 15-20 minutes daily, 5 days a week, for a total duration of 6 weeks.~3. Monitoring:~   * Initial training will be provided to ensure proper use of the prisms.~  * Adherence will be checked during weekly follow-up visits, where adjustments to the prism strength will be made if necessary."
214306415|NCT06913829|DIAGNOSTIC_TEST|pencil pushup exercises|Participants in the control group will perform pencil pushup exercises as their primary intervention. This involves: 1. Procedure: o Holding a pencil or similar object vertically at arm's length and focusing on a letter or small mark on it. o Gradually moving the pencil closer to the nose until the participant experiences visual blur or sees double. o Returning the pencil to the starting position and repeating the process. 2. Schedule: o Exercises will be prescribed for 15-20 minutes daily, 5 days a week, for a total duration of 6 weeks. 3. Monitoring: o Participants will receive instructions during the initial session and periodic supervision at follow-up visits to ensure proper technique and adherence. o Progress will be monitored weekly through symptom reporting and clinical measurements.
214306416|NCT01964703|DRUG|Rubus occidentalis extract|
214306417|NCT06912971|BEHAVIORAL|Self-Knowledge Training Program|The intervention consists of a self-knowledge training program based on the Enneagram framework. Participants attend 7 sessions, focusing on self-awareness, emotional regulation, and personal development. The sessions include theoretical explanations, guided self-reflection exercises, and group discussions to help participants better understand their personality patterns and how these influence their perception of pain and well-being.
214306418|NCT03759379|DRUG|Patisiran|Patisiran will be administered by IV infusion.
214306419|NCT03759379|DRUG|Vutrisiran|Vutrisiran will be administered by SC injection.
214306420|NCT00183716|BEHAVIORAL|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
214306421|NCT00183716|BEHAVIORAL|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
214306422|NCT05280535|BEHAVIORAL|Cue Reactivity Task|In the cue-reactivity task, participants will be exposed to either a combustible cigarette or e-cigarette cue (within-subjects randomized order across laboratory sessions) and a neutral water bottle cue. Participants will report their craving for cigarettes and e-cigarettes.
214306423|NCT05280535|BEHAVIORAL|Computerized Visual Dot Probe|In the computerized visual dot probe task, participants will view a series of substance (cigarette or e-cigarette by trial block) versus neutral (water bottle) image trials and then respond to a subsequent image presented behind either the neutral or substance image. Order of block presentation within the task is randomized within-subjects across study sessions (i.e., cigarette OR e-cigarette block first).
214306424|NCT05280535|BEHAVIORAL|Choice Task|In the choice task, participants will choose between smoking their usual brand cigarette or their own e-cigarette over ten sequential ad-libbed trials.
214306425|NCT06835803|RADIATION|Dose-escalated radiation therapy|Dose-escalated radiation therapy involves higher doses of radiation therapy each day of treatment over the three week course of radiation therapy
214915457|NCT02089373|PROCEDURE|White light endoscopy|In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
214915458|NCT04595045|DRUG|Botulinum toxin type A infiltrations|Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice
214306426|NCT06835803|RADIATION|Standard hypofractionated radiation|Standard hypofractionated radiation therapy over 3 weeks
214306427|NCT03485378|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
214306428|NCT02386800|DRUG|ruxolitinib|ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study
214306429|NCT02386800|DRUG|panobinostat|panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
214306430|NCT02717624|DRUG|Acalabrutinib in combination with BR|
214306431|NCT02717624|DRUG|Acalabrutinib in combination with VR|
214306432|NCT04938765|DRUG|Magnesium sulfate|Effect of 40mg/kg Magnesium sulfate bolus dosed to ideal body weight on intraoperative neuromonitoring
214306433|NCT04938765|DRUG|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
214306434|NCT06500052|DRUG|BL-M17D1|Administration by intravenous infusion for a cycle of 3 weeks.
214306435|NCT06401330|PROCEDURE|Bone Scan|Undergo bone scan for patients with metastatic sites outside the chest/abdomen/pelvis documented during therapy
214306436|NCT06401330|DRUG|Carboplatin|Given IV
214306437|NCT06401330|PROCEDURE|Computed Tomography|Undergo CT
214306438|NCT06401330|DRUG|Cyclophosphamide|Given IV
214670430|NCT02698761|OTHER|Comprehensive Care Plan|"Care Plan~1. Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.~2. Other Medications. All medications will be given during daytime hours, if possible.~3. Pain Psychology.~4. Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.~5. Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.~6. Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).~7. Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily."
214670431|NCT05401097|DRUG|Azacitidine|Given IV or SC
214670432|NCT05401097|PROCEDURE|Biopsy|Undergo biopsy of the bone marrow
214670433|NCT05401097|DRUG|Enasidenib|Given PO
214306439|NCT06401330|BIOLOGICAL|Dactinomycin|Given IV
214306440|NCT06401330|DRUG|Doxorubicin|Given IV
214306441|NCT06401330|DRUG|Etoposide|Given IV
214306442|NCT06401330|DRUG|Irinotecan|Given IV
214306443|NCT06401330|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214306444|NCT06401330|PROCEDURE|Nephrectomy|Undergo nephrectomy
214306445|NCT06401330|OTHER|Patient Observation|Undergo observation after nephrectomy
214306446|NCT06401330|PROCEDURE|Positron Emission Tomography|Undergo PET for patients with metastatic sites outside the chest/abdomen/pelvis documented during therapy
214306447|NCT06401330|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
214306448|NCT06401330|DRUG|Vincristine|Given IV
214306449|NCT06401330|PROCEDURE|X-Ray Imaging|Undergo X-ray
214306450|NCT06153797|BEHAVIORAL|PATH-C|PATH-C, a phone-delivered positive psychology intervention for caregivers of patients undergoing HSCT, consists of the following nine sessions: 1) Enhancing gratitude and increasing awareness for physical activity; 2) Expressing gratitude and goal setting for physical activity; 3) Integrating gratitude and goals for physical activity; 4) Personal strengths and environmental scan to enhance physical activity; 5) Enhancing strengths via reflection on past successes; 6) Integrating strengths to enhance well-being and physical activity; 7) Engaging in enjoyable and meaningful activities; 8) Promoting optimism and integrating long-term activity habits; 9) Integrating meaning for sustainable physical activity goals. Each session takes about 30 minutes, and a trained interventionist will guide participants to complete the sessions.
214306451|NCT04728893|DRUG|Nemtabrutinib|Nemtabrutinib tablets administered orally QD.
214306452|NCT06011954|DRUG|Enfortumab Vedotin|Intravenous
214306453|NCT04293562|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
214306454|NCT04293562|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
214306455|NCT04293562|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214306456|NCT04293562|PROCEDURE|Bone Marrow Aspiration|Undergo BM aspiration
214306457|NCT04293562|PROCEDURE|Bone Marrow Biopsy|BM biopsy
214306458|NCT04293562|PROCEDURE|Computed Tomography|Undergo CT
214306459|NCT04293562|DRUG|Cytarabine|Given IV or IT
214306460|NCT04293562|DRUG|Daunorubicin Hydrochloride|Given IV
214306461|NCT04293562|DRUG|Dexrazoxane Hydrochloride|Given IV
214306462|NCT04293562|DRUG|Etoposide|Given IV
214306463|NCT04293562|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
214306464|NCT04293562|DRUG|Gemtuzumab Ozogamicin|Given IV
214670434|NCT05401097|DRUG|Ivosidenib|Given PO
214480090|NCT06824922|OTHER|Conventional Sex Education|For the CG, two theoretical sessions are planned. In the first, an orientation on adolescent sexual health will be provided through a one-hour PowerPoint presentation. Topics of anatomy, physiology, biological changes in adolescence and contraceptive methods will be addressed, highlighting their proper use and the prevention of adolescent pregnancy. The second session, also lasting one hour, will develop sexual health self-care skills, discussing the importance of self-care, self-respect and informed decision making. There will be a question and answer session to address concerns and reflect on how self-care contributes to a healthy and safe sexual life.
214480091|NCT06598345|BEHAVIORAL|Routine Pet Fish Care|Participants in the Routine Group will be provided specific instructions for coupling the daily and weekly fish care and diabetes care throughout the 12-week intervention They will also be told to monitor BG four times daily, review BG readings with their parent weekly and document the BG checks and weekly reviews on their device's software.
214480092|NCT06598345|BEHAVIORAL|Collaborative Communication|Parents and participants in the Collaborative Communication group will be given recommendations for how to conduct weekly meetings in a collaborative approach based on a modified version of the Minute Meeting protocol.
214480093|NCT06842446|DIAGNOSTIC_TEST|POC D-dimer|POC D-dimer will be compared to laboratory D-dimer in hospital setting and used in a machine learning model
214480094|NCT06842446|DIAGNOSTIC_TEST|POC ultrasound|Point of care (POC) ultrasound performed by ED physicians compared to ultrasound performed by radiologist. POC ultrasound 3 point examination performed by ED physician will be compared with POC ultrasound full leg examination performed by ED physician.
214480095|NCT06842446|DIAGNOSTIC_TEST|Machine learning model|The DSS will be compared to the usual strategy. It will also be estimated how many participants where DVT could have been excluded without ultrasound.
214480096|NCT06842095|OTHER|Transcranial Alternating Current Stimulation (beta-tACS)|"The study intervention is transcranial alternating current stimulation (tACS).~The electrode montage will include one electrode positioned on the scalp over the left or right motor cortex (either C3 or C4 using the international 10-20 EEG system), depending on the location of the stroke, and a second electrode over posterior area (Pz). A low intensity of stimulation (max. 4 mA peak to peak amplitude) will be used for up to 30 minutes in total (delivered in short bouts of up to 5 seconds based on the timing of movement of the upper limb)."
214480097|NCT06842095|OTHER|Transcranial Alternating Current Stimulation (sham)|The comparator is sham stimulation. Stimulation is delivered for a very short duration or timed in such a way relative to movement to mimic the scalp sensations of the active stimulation without delivering stimulation that would be anticipated to impact relevant brain activity rhythms.
214480098|NCT06841497|OTHER|Dolabi|herbal remedy for DM II
214480099|NCT06810752|DIETARY_SUPPLEMENT|thyme honey|Topical application on the oral mucosa
214480100|NCT06810752|DRUG|Triamcinolone Acetonide|Topical application on the oral mucosa
214915459|NCT04620447|OTHER|Intelligent Virtual Reality Therapy System (IVRTS)|The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.
214915460|NCT00306020|DRUG|topical morphine|
214306465|NCT04293562|DRUG|Gilteritinib Fumarate|Given PO/NG/G-tube
214306466|NCT04293562|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214306467|NCT04293562|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214306468|NCT04293562|DRUG|Methotrexate|Given IT
215060055|NCT03091088|OTHER|osteoporosis specific-oriented training|1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
214480101|NCT05757193|DIETARY_SUPPLEMENT|DeltaG (250 mg/kg)|250 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
214480102|NCT05757193|DIETARY_SUPPLEMENT|DeltaG (500 mg/kg)|500 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
214480103|NCT05997979|DRUG|Capsaicin 8% patch|Patients will receive Capsaicin 8% patch at the inclusion of the study and three months later if it is necessary (persistant pain). Qutenza should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
214306469|NCT04293562|DRUG|Mitoxantrone Hydrochloride|Given IV
214306470|NCT04293562|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
214306471|NCT04293562|OTHER|Questionnaire Administration|Ancillary studies
214306472|NCT04293562|DRUG|Therapeutic Hydrocortisone|Given IT
214480104|NCT05997979|DEVICE|Hydrocolloid dressing|Patients will receive Hydrocolloid dressing at the inclusion of the study and three months later if it is necessary (persistant pain). Hydrocolloid dressing should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
214480105|NCT05043259|BIOLOGICAL|inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
214480106|NCT05043259|BIOLOGICAL|Low dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
214480107|NCT05043259|BIOLOGICAL|High dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
214480108|NCT06147336|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, fixated within the inter-atrial septum.
214306473|NCT05373043|DIETARY_SUPPLEMENT|Mitoquinone|Mito-Q is a supplement that targets mitochondrial function. Linking a triphenyl-phosphonium cation to coenzyme-Q, to produce Mito-Q, results in a lipophilic compound, which, due to the large mitochondrial membrane potential, selectively accumulates within mitochondria. This targeted antioxidant approach results in 50- to 100-fold more Mito-Q accumulation compared to non-targeted antioxidant delivery.
214306474|NCT05373043|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
214306475|NCT04993781|BEHAVIORAL|eSTEPS CDS|Primary care clinics at Brigham and Women's Hospital will be randomized to receive the eSTEPS CDS or usual care. The University of Texas Medical Branch (UTMB) will be the replication site, with all participating primary care practices receiving the eSTEPS CDS.
214670435|NCT05401097|DRUG|Venetoclax|Given PO
214670436|NCT04553809|PROCEDURE|ENB|ENB for biopsy sampling of peripheral lung lesion
214306478|NCT03055247|DRUG|Ibuprofen|Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
214306479|NCT03055247|DRUG|Myelostim|Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
214306480|NCT03055247|DRUG|Mozobil|Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are \< 10 /μL) to the day of the last LP.
214306481|NCT03127449|DRUG|Alflutinib|patients take Alflutinib orally once per day at different dose
214306482|NCT04700358|OTHER|Blood sampling|"Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)"
214306483|NCT00715325|DEVICE|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
214306484|NCT02732483|DRUG|Endo-Clot(TM)|The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
214306485|NCT06629662|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy with laparoscopic or robotic approach
214306486|NCT00734279|DRUG|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
214306487|NCT00734279|DRUG|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
214306488|NCT00734279|DRUG|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
214306489|NCT00734279|DRUG|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
214480109|NCT06392867|DEVICE|intermittent theta-burst stimulation (iTBS)|"iTBS treatment will be performed as comprising 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. Repeat trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20) which equals the standard number of pulses in a daily iTBS treatment session, as approved by the FDA. The stimulation site over the left DLPFC will be determined using the international 10-20 system for EEG electrodes corresponding to the F3 location. 20 daily treatment sessions will be performed from Mondays to Fridays for four weeks for all included patients.~Treatments will be performed at the brain stimulation laboratory at the Hong Kong Polytechnic University. Stimulation will be delivered using a MagPro X100 model (details about MagPro X100: magventure.com/en\_eur/products/magpro-x100/ ) and a Cool-B65 A/P Butterfly Coil is used in this study."
214480110|NCT05888532|DRUG|Copper-64 labeled Granzyme B (64Cu-GRIP B)|Given IV prior to imaging
214915461|NCT02585947|DRUG|Tenofovir|Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).
214915462|NCT06385574|OTHER|Virtual reality therapy|Conventional hand therapy
214306490|NCT05447156|BEHAVIORAL|Tailored QuitGuide app|This is an app not available to the public. It was developed/tailored based on an app available to the public and can be downloaded.
214306491|NCT05447156|BEHAVIORAL|Standard QuitGuide app|This is an app available to the public.
214480111|NCT05888532|PROCEDURE|Positron Emission Tomography (PET)|Imaging procedure
214480112|NCT06667167|DRUG|Induction Carboplatin|Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan
214480113|NCT06668116|DRUG|Ropivacaine 0,1%|"The study uses ropivacaine for nerve blocks, starting at 0.1% concentration and capped at 0.5% for safety. Concentration adjustments are made based on each participant's response 60 minutes post-injection:~* Increase by 0.025% if pain reduction is \<50%~* Increase by 0.025% if reduction is 50-75% without sensory/motor block~* Decrease by 0.025% if reduction is 50-75% with sensory/motor block~* Decrease by 0.025% if reduction is \>75%. Pain is assessed using a Numerical Rating Scale. The study employs Dixon's up-and-down method for five cycles to determine the optimal concentration for effective pain relief without significant numbness or weakness."
214480114|NCT06668116|OTHER|NaCl (placebo)|0.9 % NaCl solution (saline) injection
214670437|NCT04553809|PROCEDURE|ENB in combination with rEBUS|The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions
214670438|NCT00971646|OTHER|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
215060056|NCT00429182|DRUG|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
215060057|NCT00429182|DRUG|Cyclophosphamide|1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
214306492|NCT02143440|BEHAVIORAL|The initial assessment of daily insulin dose.|
214306493|NCT02029833|OTHER|Regular Canola Oil|
214306494|NCT02029833|OTHER|High Oleic Canola Oil|
214306495|NCT02029833|OTHER|Western Type Diet - Common Dietary Oils|
214306496|NCT01254227|DRUG|Deferasirox and Deferoxamine|
214306497|NCT02002364|PROCEDURE|tracheal intubation|
214480115|NCT06611098|DEVICE|Viscosupplements|intra-articular injection
214480116|NCT04819191|BEHAVIORAL|SHARING Choices|SHARING Choices is a multicomponent communication intervention to proactively engage family members or friends and to support advance care planning in primary care
214306498|NCT04372667|BEHAVIORAL|Community score card approach|"The CSC intervention is a participatory community approach. Health care workers (HCWs), PMTCT clients identified the issues that most impacted PMTCT service quality and uptake, and came together to implement actions for improvement. The core implementation strategy is using dialogue in a participatory forum that engages both service users and service providers. The CSC consists of five core phases, repeated on a regular basis (called rounds), for the life of the project. The five core phases include:~1. Phase I: Planning and preparation~2. Phase II: Conducting the Score Card with the community~3. Phase III: Conducting the Score Card with service providers~4. Phase IV: Interface meeting and action planning~5. Phase V: Action plan implementation and follow-up"
214306499|NCT01948817|DRUG|Deferasirox|Deferasirox 20mg/kg taken BID
214306500|NCT00891644|OTHER|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
214306501|NCT00891644|OTHER|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
214306502|NCT00891644|OTHER|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
214306503|NCT01511523|DIETARY_SUPPLEMENT|RGMA001|3 capsules administered BID once a day.
214306504|NCT01511523|DIETARY_SUPPLEMENT|Sugar Pill|Placebo
214306505|NCT01940809|DRUG|Dabrafenib|Given PO
214306506|NCT01940809|BIOLOGICAL|Ipilimumab|Given IV
214306507|NCT01940809|OTHER|Laboratory Biomarker Analysis|Correlative studies
214306508|NCT01940809|BIOLOGICAL|Nivolumab|Given IV
214306509|NCT01940809|DRUG|Trametinib|Given PO
214306510|NCT01263301|DEVICE|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
214480117|NCT06610747|PROCEDURE|Home-based Care Monitoring|For participants in the home-based care group, home service appointments will be scheduled during the 'pro re nada' (PRN) treatment phase. Participants will receive a home self-administered visual acuity tester and a self-administered Home OCT to use at home every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. The results of the visual acuity and OCT measurements will be transmitted to the clinician at the hospital. An online discussion between the clinician and the participant will be held. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
214480118|NCT06610747|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|Each eye will receive three to five q4week loading anti-VEGF injections of aflibercept (2-mg, EYLEA®) after enrollment to complete the initial loading phase of 5 doses. Each eye will then be treated according to the PRN treatment protocol described in the study protocol.
214480119|NCT06610747|PROCEDURE|Laser Treatment|Panretinal photocoagulation (PRP) may be administered if deemed necessary by the investigator, typically for high-risk proliferative diabetic retinopathy (PDR). However, individuals are not eligible for this study if it is expected that they will require PRP within 6 months at the time of enrollment. In general, PRP should not be given to study participants with less than high risk PDR. For previously untreated eyes exhibiting PDR with high-risk characteristics, PRP should be administered promptly, while it can be considered, although generally not recommended, for persons with non-high-risk PDR or severe non-PDR who are being monitored monthly in this protocol. Focal/grid laser typically should be withheld until sometime after the final visit.
214915463|NCT01760174|DRUG|Ropivacaine bolus in transversus abdominis plane catheter|"Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours."
214915464|NCT01760174|DRUG|Bupivacain-infusion in epidural catheter|"Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours"
214306511|NCT04592029|DRUG|TACE combined with sintilimab and bevacizumab|Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg/kg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.
214306512|NCT05339620|PROCEDURE|implant driver facilitated micro-osteoperforations|"3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention ."
214306513|NCT00834210|DRUG|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
214306514|NCT00834210|DRUG|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
214306515|NCT06250023|OTHER|Early shift til oral antibiotic treatment for osteomyelitis|To investigate whether early transition to oral AB treatment after one week of IV treatment is non-inferior to the current national guideline of continued IV AB treatment for two to four weeks followed by oral AB treatment for PVO.
214306516|NCT01196546|DRUG|vildagliptin/metformin|
214306517|NCT03684512|BEHAVIORAL|Group Exercise Sessions|Remote exercise sessions delivered over group video conference
214306518|NCT03684512|BEHAVIORAL|Individual Support Sessions|Individual education/support/feedback sessions delivered over video chat
214306519|NCT03684512|BEHAVIORAL|Facebook Group|Facebook group for parents to provide additional support and education
214306520|NCT05963087|DRUG|Cetuximab Dabrafenib Tislelizumab|Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
214306521|NCT05627882|DIAGNOSTIC_TEST|Forward viewing endoscope|Additional examination with standard forward viewing endoscope
214306522|NCT01441674|BEHAVIORAL|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
214306523|NCT02539381|PROCEDURE|Formal Perimetry (Goldman or Octopus visual Field)|
214306524|NCT02539381|PROCEDURE|Albert's visual inattention test|
214306525|NCT02539381|PROCEDURE|Star cancellation visual inattention test|
214670439|NCT00971646|OTHER|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
214306526|NCT02539381|PROCEDURE|Visual field assessment to confrontation|
214306527|NCT02539381|PROCEDURE|Visual inattention assessment to bilateral stimuli|
214306528|NCT02539381|DEVICE|Digital tumbling E visual accuity assessment|
214306529|NCT02539381|DEVICE|Digital visual field assessment|
214306530|NCT02539381|DEVICE|Digital line crossing assessment|
214306531|NCT02539381|DEVICE|Digital shape cancellation assessment|
214306532|NCT05301088|OTHER|Chocolate Scent|"Chocolate Scent:Children in this group will be given chocolate scent sniffing as a non-pharmacological distraction method.~Stress Ball:Stress ball squeezing will be used as a non-pharmacological distraction method for children in this group."
214306533|NCT06055855|PROCEDURE|Traditional Two-Needle Arthrocentesis|Participants in this group will undergo arthrocentesis using the traditional two-needle technique. The procedure involves the placement of one or two needles into the temporomandibular joint (TMJ) to irrigate the joint space. Needle placement is guided by anatomical landmarks.
214306534|NCT06055855|PROCEDURE|Surgery-Guided Arthrocentesis|Participants in this group will receive arthrocentesis facilitated by a surgical guide. The guide is generated through pre-operative planning and is designed to aid in the accurate placement of the needle into the TMJ.
214306535|NCT03559712|OTHER|Collaborative care, Telemental health|Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
214306536|NCT02535741|DEVICE|Triathlon CR Total Knee System|Primary total knee replacement
214306537|NCT04369794|BIOLOGICAL|BCG|0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose
214306538|NCT04369794|BIOLOGICAL|Placebo|0.9% saline in the same volume as the BCG vaccine in a single dose
214306539|NCT03873987|DRUG|Current Formulation of Oritavancin|Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
214306540|NCT03873987|DRUG|Kimyrsa|New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
214306541|NCT00729729|DRUG|PCA|Placebo tablet, once
214306542|NCT00729729|DRUG|PCA|PO, 700mg, once
214670440|NCT00971646|OTHER|EuroQol-5D|This questionnaire grades the health condition of the subject.
215060058|NCT00429182|DRUG|Thiotepa|120 mg/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
214306543|NCT00729729|DRUG|PCA|PO, 1000mg, once
214306544|NCT05739851|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
214306545|NCT05739851|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
214306546|NCT00749320|OTHER|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
214306547|NCT05646511|RADIATION|SCRT|5x5 Gy: 25 Gy
214306548|NCT05646511|DRUG|CAPOX|Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
214306549|NCT05646511|DRUG|CAPOXIRI|Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks
214306550|NCT05563753|DRUG|ABT|any antibiotic therapy in the first week of life
214670441|NCT00971646|OTHER|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
214670442|NCT05074784|DEVICE|IOPI Therapy|Obtain IOPI reading at start of session, record the best of 3 readings as baseline strength. Calculate exercise resistance for session at 60% of baseline strength. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets.
214306551|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
214306552|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
214306553|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
214306554|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
214306555|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
214306556|NCT00798369|DRUG|Triamcinolone acetonide|Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
214306557|NCT03573986|BIOLOGICAL|[18F]fluoromisonidazole|positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
214306558|NCT03573986|DRUG|Bevacizumab|Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
214306559|NCT03573986|RADIATION|positron emission tomography (PET/CT).|PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
214306560|NCT06020560|DRUG|Dalteparin Prefilled Syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
214306561|NCT06020560|DRUG|Tinzaparin profiled syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
214306562|NCT00930150|BEHAVIORAL|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
214306563|NCT00930150|BEHAVIORAL|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
214670443|NCT05074784|DEVICE|Tongue Depressor Traditional Intervention|Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set
214670444|NCT04391868|DRUG|Viagra Tablet|50 mg tablet on Day 1 of each period
214670445|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
214670446|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
214915465|NCT05442502|PROCEDURE|The overlap guiding tube(OGT) method|The overlap guiding tube(OGT) is used to assist the anvil fork placed into the esophageal cavity.
214915466|NCT05442502|PROCEDURE|The conventional overlap method|After firing the stapler, two openings were converted into a single entry hole to create an end-to-side esophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
214915467|NCT01920412|DEVICE|LAmbre Left Atrial Appendage(LAA) Occluder|Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
214915468|NCT06578572|BIOLOGICAL|R21Matrix M|A mixture of R21/Matrix M at a dose of 5 μg (for children up to 14 years of age) or 10 μg ( for individuals ≥ 15 years old) with 50 μg of Matrix-M will be administered monthly over 3 months (one dose per month over 3 months (May, June, and July 2024) plus a booster dose in June 2025.
214306564|NCT00930150|BEHAVIORAL|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
214306565|NCT00930150|BEHAVIORAL|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
214306566|NCT04173026|OTHER|Provider-level intervention|Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
214306567|NCT04173026|OTHER|Patient-level intervention|50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
214306568|NCT04475588|DRUG|Itolizumab IV infusion|"First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B"
214480120|NCT06610747|PROCEDURE|Standard Hospital/clinic-based Care Monitoring|For participants in the standard Hospital/clinic-based group, hospital service appointments will be scheduled during the \&amp;amp;amp;#39;pro re nada\&amp;amp;amp;#39; (PRN) treatment phase. Participants will be instructed to return to the clinic for hospital-based visual acuity examinations and standard OCT measurements every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. A discussion between the clinician and the participant will be held in clinic. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
214480121|NCT06609538|OTHER|Control Group|Receives standard preoperative instructions and propofol or ketamine infusion.
215060059|NCT00429182|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0.
214306569|NCT04475588|DRUG|Best supportive care (BSC)|Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
214670447|NCT00320671|DRUG|Aripiprazole|The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
214670448|NCT00320671|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
214306570|NCT02407769|DIETARY_SUPPLEMENT|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
214306571|NCT01483105|BEHAVIORAL|DVD Self-Hypnosis Training Program|The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
214306572|NCT04311879|DEVICE|Soft tissue Diode laser application|post-operative soft tissue diode laser application
214306573|NCT04311879|OTHER|Placebo|mock diode laser application
214306574|NCT00001487|DRUG|Dehydroepiandrosterone|
214915469|NCT01767246|OTHER|PFS Algorithm treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.
214915470|NCT01767246|OTHER|Multimodal treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
215060060|NCT04348071|DRUG|Ruxolitinib|Participants will receive 10 mg ruxolitinib twice daily.
214306575|NCT04991545|DEVICE|Application of Infrared (Active IRD/ IRRIS) device|"The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~1. Group A: control group~2. Group B: Intervention group using Infrared"
214306576|NCT02804984|GENETIC|ICUS|
214306577|NCT05277246|OTHER|Irrigant concentration|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on level of IL-8 different concentration will be evaluated.
214306578|NCT05277246|DRUG|NaOCI|NaOCI
214306579|NCT01119989|DIETARY_SUPPLEMENT|Fructose+maltodextrin placebo|
214306580|NCT01119989|DIETARY_SUPPLEMENT|amino-acid + fructose|
214915471|NCT04826081|OTHER|data collection|data collection
214915472|NCT01708382|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
214306581|NCT01475630|PROCEDURE|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
214306582|NCT01475630|PROCEDURE|control|relaxation
214306583|NCT00588822|BIOLOGICAL|Rituximab|Rituximab will be given as a 375 mg/m\^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
214306584|NCT05686213|BEHAVIORAL|combined aerobic exercise + resistance exercise intervention (AE + RE)|The AE + RE intervention group will be offered a supervised exercise program which includes both aerobic and resistance exercise. Exercise sessions will take place twice a week with a duration of 60 minutes. The training load will be tailored to a patient's individual fitness level throughout the intervention. Patient will be asked to be physically active on an additional day in the week on their own (for at least 30 minutes at moderate intensity) according to the ACSM guidelines for patients with cancer.
214915473|NCT01061112|DRUG|Flurbiprofen Control - Flurbiprofen Only|A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
214915474|NCT01061112|DRUG|Flurbiprofen Inhibition - Flurbiprofen & Fluconazole|A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
215060061|NCT01667250|DEVICE|GammaCore Active Device|
215060062|NCT01667250|DEVICE|GammaCore Sham Device|
215060063|NCT03902795|DIAGNOSTIC_TEST|Microperimetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
215060064|NCT03902795|DIAGNOSTIC_TEST|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
215060065|NCT01290146|DRUG|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
215060066|NCT01290146|DRUG|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min"
214480122|NCT06609538|OTHER|Suggestion Group|Receives positive preoperative suggestions and propofol or ketamine infusion.
214480123|NCT06611358|OTHER|Kinesiology Taping and Exercise|Individuals meeting the inclusion criteria will receive kinesio taping applied to the temporomandibular joint by a physiotherapist every three days for two weeks. The kinesio tape will be applied along the origin-insertion line with zero tension. In addition to the kinesio taping, participants will follow a exercise program prescribed three days a week. This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol
214915475|NCT01061112|DRUG|Ketoprofen Control - Ketoprofen Only|A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
214915476|NCT01061112|DRUG|Ketoprofen Inhibition - Ketoprofen & Fluconazole|A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
214480124|NCT06611358|OTHER|Convansionel Exercise|This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol.
214480125|NCT06610032|PROCEDURE|Mesotherapy|A total of 3 sessions of mesotherapy will be applied to the shoulder area of the patients, 7 days apart in group 1.
214480126|NCT06610032|PROCEDURE|Intra-articular steroid injection|Single session intra-articular 20 mg triamcinolone hexacetonide injection will be applied for patients in group 2.
214480127|NCT06611007|DRUG|embolization therapy|Hand arterial embolization with Lipiodol in emulsion with iodinated contrast agent
214480128|NCT06611228|OTHER|Multidomain Interventions|Multidomain Interventions The intervention group will receive a personalized MDI approach from a multidisciplinary team, including a digital coach, physiotherapist, clinical nutrition expert, neuropsychologist, geriatrician, and nurse. This approach will encompass physical activity program, nutritional interventions, cognitive training and stimulation, medication reconciliation, coaching on the use of technological supports, and group activities. Environmental modifications at home will also be proposed
214480129|NCT06856681|DIAGNOSTIC_TEST|PrecivityAD2 - Early Testing|Participants in Cohort A will receive PrecivityAD2 testing at Visit 1, with results disclosed shortly after testing.
214480130|NCT06856681|DIAGNOSTIC_TEST|PrecivityAD2 - Delayed Testing|Participants in Cohort B will receive PrecivityAD2 testing at Visit 2, with results disclosed shortly after testing.
214480131|NCT06696638|DEVICE|EIT-guided Phigh settings during APRV|The Phigh level selected for the patients in the Intervention group was the intercept point of cumulated collapse and overdistension percentage curves, providing the best compromise between collapsed and overdistended lung.
214480132|NCT06855069|DRUG|HS-20089|HS-20089 dose 1
214915477|NCT01061112|DRUG|Tolbutamide Control - Tolbutamide Only|A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
214915478|NCT01061112|DRUG|Tolbutamide Inhibition - Tolbutamide & Fluconazole|A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
214915479|NCT03745846|BIOLOGICAL|Composite Gel Containing Black Raspberry|Composite Gel Containing Black Raspberry 3,000/preparation
214915480|NCT03745846|BIOLOGICAL|placebo|Composite Gel Containing Black Raspberry-placebo
214306585|NCT05686213|BEHAVIORAL|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Patients in the ExPR in-hospital exercise intervention group will be offered an aerobic exercise program at moderate intensity. The exercise sessions will take place 5 days a week (only weekdays), and will have a duration of 30 minutes including a warming-up (5 min) and cooling-down (5 min). Total exercise volume will be aimed at 150 min per week. The sessions will take place within an hour before the daily radiotherapy session.
214306586|NCT06112028|DRUG|Tongxinluo capsule|On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
214480133|NCT06855069|DRUG|Paclitaxel|Paclitaxel dose 2
214480134|NCT06855069|DRUG|Doxorubicin|Doxorubicin dose 3
214915481|NCT00813072|DRUG|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
214915482|NCT00813072|DRUG|irinotecan|300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214915483|NCT00813072|DRUG|docetaxel|"75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
214915484|NCT01303172|BIOLOGICAL|IMM-101|"IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.~A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine."
214915485|NCT01303172|DRUG|Gemcitabine|"Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.~Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol."
214915486|NCT05003804|BIOLOGICAL|STMC-103H|STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
214480135|NCT06855069|DRUG|Topotecan|Topotecan dose 4
214480136|NCT06841146|PROCEDURE|routine cesarean section|cesarean section
214480137|NCT02670395|DRUG|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
214480138|NCT02670395|DRUG|Placebo|Placebo solution will be administered orally.
214480139|NCT04560179|DRUG|Tobramycin solution for inhalation 78mg dose|Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
214480140|NCT04560179|DRUG|Tobramycin solution for inhalation 150mg dose|Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
214915487|NCT05003804|BIOLOGICAL|Placebo|Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
214915488|NCT00504712|DRUG|Testosterone|Sustanon- 200mg- Intramuscular testosterone every 2 weeks
214915489|NCT00504712|DRUG|saline|Saline injection every two weeks
214306587|NCT06112028|OTHER|Primary therapy|Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)
214915490|NCT02359955|DEVICE|zero degree teeth|zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture
214915491|NCT02359955|DEVICE|anatomic teeth|when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture
214915492|NCT05430750|DRUG|Nitrous oxide|In conventional nitrous oxide carrier group 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min will be delivered to achieve MAC 0.5.
214915493|NCT05430750|DRUG|Nitrous oxide|In streamed-in nitrous oxide carrier group 2% Sevoflurane in O2 -Air (60 % FiO2) will be delivered @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %.
214915494|NCT05430750|DRUG|Sevoflurane|Ventilation will be initiated with 2% sevoflurane in all the groups
214915495|NCT02119403|OTHER|There are no other inteventions.|This device gives patients the opportunity to receive nitrous oxide where no such opportunity exists. There is no other intervention available that creates immediate short term minimal sedation.
214306588|NCT01948739|DEVICE|MAHI EXO-II exoskeleton augmented with BMI system|In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
214306589|NCT03302585|DRUG|Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days
214306590|NCT03302585|DRUG|Placebo/Standard of Care Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 40,000 IU/d of oral vitamin D3 x 85 days
214306591|NCT02082210|DRUG|Emibetuzumab|Administered Intravenously (IV)
214306592|NCT02082210|DRUG|Ramucirumab|Administered Intravenously (IV)
214306593|NCT04190134|BEHAVIORAL|Socially Assistive Robot for Low Vision Rehabilitation|A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.
214306594|NCT02520011|DRUG|Alvocidib|
214306595|NCT02520011|DRUG|Cytarabine|
214306596|NCT02520011|DRUG|Mitoxantrone|
214306597|NCT00485238|PROCEDURE|Argon laser Iridoplasty|
214306598|NCT00485238|DRUG|Intravenous acetazolamide|
214306599|NCT03232385|DEVICE|MR-US Fusion Arm|Use of Clear Guide SCENERGY for MR-US fusion guidance
214306600|NCT03232385|PROCEDURE|Renal Biopsy or Ablation|Standard of Care
214480141|NCT04560179|DRUG|Tobramycin solution for inhalation 216mg dose|Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
214915496|NCT03930355|OTHER|Blood transfusion|Patients who received blood transfusion in the perioperative period
214915497|NCT03930355|OTHER|Control|Patients who did not receive blood transfusion in the perioperative period
214915498|NCT00991237|OTHER|Pulsed Radiofrequency|Pulsed Radiofrequency
214915499|NCT03326570|BEHAVIORAL|Medical Data Collection|Medical information collected after bronchoscopy for up to 2 years.
214306601|NCT04029714|PROCEDURE|Active Surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
214306602|NCT01340157|DRUG|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
214306603|NCT05506202|OTHER|Individual basic body awareness therapy|"Basic Body Awareness Therapy (BBAT) is a physiotherapeutic intervention directed toward patients' functional movement quality. The development of BBAT was based on the hypothesis of persons' lacking contact with and lacking awareness on their own body, with their inner life, external environment and in the relation to other persons. Thus, it leads to dysfunctional movement, pain and other body functions. BBAT focus on multi-perspective within a person including physical, physiological, psycho-social-cultural and existential perspectives. It directs patients to be aware, guides patients to have mental contact with their body, monitors internal sensations and external environment, and thus, to enhance the self-regulated behavior and positive emotional state."
214306604|NCT05506202|OTHER|Respiratory physiotherapy interventions|Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.
214306605|NCT04157946|DIAGNOSTIC_TEST|CT|"Patients with ARDS were included. We excluded patients with emphysema, asthma, pneumothorax, or serious conditions of instability: oxygen saturation ≤ 88%; severe shock, ventricular arrhythmia, or myocardial ischemia.~To allow comparison between groups, patients were ventilated in volume control under similar conditions of tidal volume (TV; 6 ml/kg-PBW), plateau pressure (PPlat 30 cmH2O), respiratory rate (18 bit/min) and constant flow. PEEP was adjusted to reach objective PPlat.~Transpulmonary pressures (TP) were measured and a chest CT scan performed during an expiratory and inspiratory pause. Global and regional volumes of lungs were measured using specific software (Volume Analysis Software,Toshiba, Japan). Three regions were identified: basal (from the diaphragm to the carina), middle (from the carina to the aortic arch) and apical (above the aortic arch)."
214306606|NCT02436759|DRUG|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
214306607|NCT02436759|DRUG|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
214480142|NCT04560179|DRUG|Tobramycin solution for inhalation 300mg dose|Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
214480143|NCT04602611|OTHER|Oncology Nurse Navigation|Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
214915500|NCT00128232|DRUG|Octreotide LAR|
214915501|NCT04947007|DRUG|Bupivacaine hydrogen chloride (HCl) 0.025 % in 15+15 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 15 ml +15 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
214915502|NCT04947007|DRUG|Bupivacaine HCl 0.025 % in 10+10 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 10 ml +10 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
214915503|NCT04947007|DRUG|Bupivacaine HCl 0.025 % in 5+5 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 5 ml +5 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
214915504|NCT04947007|DRUG|Isotonic solution|In this group, US guided suprascapulary and axillary block will be performed with isotonic solution
215060067|NCT05312684|PROCEDURE|cardiac surgery|cardiovascular surgery including valve repair/replacement or CABG or combined procedures
214670449|NCT06149884|PROCEDURE|Sentinel lymph node biopsy, axillary lymph node dissection|"SLNB was performed using single or dual tracers. For the single tracer technique, Technetium 99, a radioactive substance, was administered periareolarly prior to surgery, and SLNs were identified intraoperatively via a gamma detection system (Neoprobe®). The dual tracer method employed both an isosulfan blue dye and Technetium 99 concurrently. The choice of SLNB technique was contingent upon the surgeon's discretion. SLNs were categorized as one or multiple, and any LN identified by either or both methods was defined as SLN. LNs resected during SLNB without tracer signal were not classified as SLNs.~ALND was characterized by the removal of all LNs in axillary levels I and II. Patients documented to have undergone ALND in surgical records were primarily selected from our registry. Among them, those with fewer than 10 LNs were excluded, based on the assumption that a competent ALND necessitated the removal of 10 or more LNs as defined in previous studies"
214670450|NCT05496426|DRUG|KL130008/Placebo|Drug: KL130008 Drug: Placebo
214480144|NCT06858072|OTHER|Instrument assissted soft tissue mobilization(IASTM)|IASTM (Instrument-Assisted Soft Tissue Mobilization) in four specific body areas. The quadratus lumborum, posterior fascia, sacrum, hip lateral rotators, and hamstring bilaterally were these areas. The subjects were asked to kneel directly on the bed to stimulate the lumbar posterior muscles erector spinae (iliocostalis, longissimus), lumborum, and multifidus. At the same time, the IASTM treatment was applied to the rear fascia. The same treatment was applied to the sacrum while the subject kneeled on the bed. For hip lateral rotators, the IASTM treatment was applied to the gluteus maximus and gluteus medius while kneeling in a prone position with knee and hip flexion. Similarly, for the hamstring bilaterally, the IASTM treatment was applied to the biceps femoris, semitendinosus, and semimembranosus while in a prone position. The instrument was used for about 20 seconds in a direction parallel to the muscle fibers being treated and then for an additional 20 sec perpendicular to fibres
214480145|NCT06858072|OTHER|Transverse friction massage|patient was lying prone while the therapist administered a transverse friction massage to the affected area. Before the massage, the therapist cleansed and dried the place to be treated, ensuring it was free of dirt or debris. The therapist used their palpation skills to locate the site of pain and apply the massage technique accordingly. The therapist performed the transverse friction massage using their thumb to apply pressure across the muscle fiber, with each repetition lasting for two minutes
214670451|NCT05851846|BEHAVIORAL|Amygdala insula retraining|Mind body intrevention
214670452|NCT06179212|DIAGNOSTIC_TEST|Exercise Tests|Patients will complete 4 different cardiopulmonary exercise tests in random order.
214915505|NCT05189652|OTHER|Myofascial Release and Exercise Group|"The exercise program will be applied 3 days a week for 4 weeks. Participants will warm up by walking for 5 minutes before exercise. Stretching exercises - Reach forward with sitting and hamstring (3 reps\*30 sec).~First 2 weeks:~Squat exercise (3 sets of 10 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (30 seconds).~Star Excursion balance training (2 rounds to be applied). Foam Roller massage will apply to thoracolumbar posterior chain (1 set of 30 seconds will be applied with a rolling period of 2-4 seconds).~Last 2 weeks:~Squat exercise (3 sets of 15 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (40 seconds).~Star Excursion balance training (3 rounds to be applied). Foam Roller massage will apply to thoracolumbar posterior chain (2 sets of 30 seconds will be applied to each area with a rolling period of 2-4 seconds)."
215060068|NCT04530305|DRUG|Upadacitinib <15 MG [Rinvoq]|Patients with RA for who the introduction of upadacitinib has been decided will be proposed the study. If they accept, they will be followed for 6 months with 3 visits (baseline, 3 and 6 months) which is the usual standard care. In addition to routine markers, stool and blood will be collected at baseline and 3 months specifically for the study.
214306608|NCT01412203|BEHAVIORAL|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
214306609|NCT06226727|DRUG|BR1019|One tablet administered alone
214306610|NCT06226727|DRUG|BR1019-1|One tablet administered alone
214306611|NCT06226727|DRUG|BR1019-2|One tablet administered alone
214306612|NCT04357210|PROCEDURE|fistula tract excision and anal sphincter reconstruction|The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
214306613|NCT00978328|DRUG|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
214306614|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
214306615|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
214306616|NCT02292290|DRUG|Sulfonylurea or Pioglitazone|Addition to Metformin
214306617|NCT02292290|DRUG|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
214306618|NCT05224505|OTHER|GNT0006|Single intravenous infusion
214306619|NCT05224505|OTHER|Day 0: Placebo|Single intravenous infusion
214306620|NCT05224505|OTHER|Day 0: GNT0006|Single intravenous infusion
214306621|NCT05224505|OTHER|Day 365 (year 1): Placebo|Single intravenous infusion
214306622|NCT05224505|OTHER|Day 365 (year 1): GNT0006|Single intravenous infusion
214306623|NCT03054857|DRUG|Dexmedetomidine|After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
214306624|NCT03054857|DRUG|Placebo|The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
214306625|NCT00448071|DRUG|MTR107|
214306626|NCT01727141|DRUG|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
214306627|NCT01727141|DRUG|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
214306628|NCT01727141|DRUG|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
214915506|NCT05189652|OTHER|Exercise Group|"The exercise program will be applied 3 days a week for 4 weeks. Participants will warm up by walking for 5 minutes before exercise. Stretching exercises- Reach forward with sitting and hamstring (3 reps\*30 sec).~First 2 weeks:~Squat exercise (3 sets of 10 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (30 seconds).~Star Excursion balance training (2 rounds to be applied).~Last 2 weeks:~Squat exercise (3 sets of 15 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (40 seconds).~Star Excursion balance training (3 rounds to be applied)."
214915507|NCT02619357|DEVICE|SenseWear Armband Gecko|Subjects will wear SenseWear Armband Gecko up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
215060069|NCT00389376|DRUG|Placebo|Placebo
214306629|NCT01727141|DRUG|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
214306630|NCT01957748|BEHAVIORAL|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
214306631|NCT03462316|BIOLOGICAL|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
214306632|NCT02998801|OTHER|IPAD|Patients undergoing surgery will watch the video using an PAD
214306633|NCT02998801|OTHER|VR Goggles|Patients undergoing surgery will watch the video using goggles
214306634|NCT03291210|OTHER|normal inspired oxygen fraction|receives inspired oxygen fraction of 0.3
214306635|NCT03291210|OTHER|high inspired oxygen fraction|receives inspired oxygen fraction of 0.8
214306636|NCT01321788|DRUG|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
214306637|NCT01321788|DRUG|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
214306638|NCT04014075|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
214306639|NCT00017433|DRUG|arsenic trioxide|
214306640|NCT03462212|DRUG|Carboplatin|chemotherapy medication
214306641|NCT03462212|DRUG|Paclitaxel|chemotherapy medication
214306642|NCT03462212|DRUG|Bevacizumab|Angiogenesis inhibitor
214306643|NCT03462212|DRUG|Rucaparib|PARP inhibitor
214480146|NCT06858748|OTHER|Observational|This is a 24-month observational study in adults in three disease domains, consisting of screening visit, baseline visit, quarterly telemonitoring visit and end of monitoring period
215060070|NCT00389376|DRUG|Silymarin|140 mg every 8 hours
215060071|NCT00389376|DRUG|Silymarin|280 mg single dose
215060072|NCT00389376|DRUG|Silymarin|280 mg single dose + every 8 hours
215060073|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
215060074|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
214306644|NCT02666183|BEHAVIORAL|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
214306645|NCT02666183|BEHAVIORAL|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
214306646|NCT02666183|BEHAVIORAL|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
214306647|NCT00802399|PROCEDURE|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
215060075|NCT00389376|DRUG|Silymarin|280 mg every 8 hours
214306648|NCT05531435|DRUG|local anaesthetic injection|Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
214306649|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|\- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 25-gauge pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
214306650|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 27G Whitacre needle|\- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 27-gauage pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
214306651|NCT03616912|DRUG|Baricitinib|Administered orally.
214306652|NCT03616912|DRUG|Placebo|Administered orally.
214306653|NCT02541071|BEHAVIORAL|Stress Film|
214306654|NCT02541071|DRUG|Yohimbine|
214480147|NCT06858176|OTHER|No intervention was implemented in this observational study|No intervention was implemented in this observational study
214306655|NCT02541071|DRUG|Clonidine|
214306656|NCT02541071|DRUG|placebo|
214306657|NCT02848677|BEHAVIORAL|Nutritional counseling|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
214306658|NCT02848677|BEHAVIORAL|usual care|usual care of hypertensive patients.
214306659|NCT02782416|OTHER|Examination of latent tuberculosis|
214480148|NCT06859060|BEHAVIORAL|BRIDGES Healthcare Manager Intervention|A culturally adapted, multilevel intervention consisting of monthly 60-minute sessions over a 12-month period. Sessions will be conducted by graduate clinical psychology students acting as healthcare managers. The intervention focuses on care coordination, patient activation, and reducing provider stigma to improve access to preventive primary care services.
214670453|NCT05921916|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
214306660|NCT04257812|DRUG|Ceftolozane/tazobactam|"The dose will be 1g ceftolozane + 0,5 g tazobactam every 8 hours or 2 g ceftolozane + 1 g tazobactam, it´s recommended to use this last dose regimen in patients with pneumonia or septic shock of any focus.~The patients will be followed as it´s done habitually. There will be done infection focus cultures and others according to usual clinical practice. It´ll be determined the clinical response and mortality in the days 14 and 30 after the beginning of the medicine, respectively.~The Ceftolozane-Tazobactam levels determination will always be made in state of equilibrium (after the third dose). Four samples will be collected:~1. Just before the antibiotic infusion.~2. One hour after the antibiotic infusion.~3. Three hours after the antibiotic infusion.~4. Six hours after the antibiotic infusion."
214306661|NCT04090593|OTHER|Patient Education 101: Mobile Health Education Tool|Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.
214915508|NCT02619357|DEVICE|SenseWear Armband MF|Subjects will wear SenseWear Armband MF up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
214306662|NCT04377282|OTHER|Food-1|Cooked buckwheat
214306663|NCT04377282|OTHER|Food-2|Cooked couscous
214306664|NCT04377282|OTHER|Food-3|Water
214306665|NCT02584504|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
214306666|NCT02584504|DRUG|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
214306667|NCT02584504|DRUG|Atorvastatin|Atorvastatin 5 mg tablet orally.
214306668|NCT02584504|DRUG|Non-statin Lipid-Modifying Therapy|Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
214306669|NCT02584504|OTHER|Diet Alone|Stable cholesterol-lowering diet as background therapy.
214306670|NCT02606591|PROCEDURE|Electroencephalograph|EEG performed at beginning and end of school year.
214306671|NCT02606591|BEHAVIORAL|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
214480149|NCT06859060|OTHER|Enhanced Treatment as Usual (ETAU)|Participants will continue to receive standard psychiatric care, including routine visits with their mental health providers at the designated clinical sites. They will also receive a booklet with information on how best to link with primary care providers. This ensures that participants are aware of available resources and basic health care recommendations, but does not include any active follow-up or intervention components.
214670454|NCT05921916|DRUG|Placebo oral capsule|Placebo oral capsule solid microcrystalline cellulose
214915509|NCT02619357|DEVICE|Actigraph GT9x wristband and waistband|Subjects will wear Actigraph GT9x wristband and waistband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
214915510|NCT02619357|DEVICE|Garmin Vivofit 2 wristband|Subjects will wear Garmin Vivofit 2 wristband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
214915511|NCT02619357|DEVICE|SOMNOwatch plus EEG 6 sleep monitor|In a subset of subjects, this device will be worn as a comparator for monitoring sleep quality and duration.
214915512|NCT02619357|OTHER|Strength exercises|Subjects will perform strength exercises using elastic bands of varying resistance
214915513|NCT02619357|OTHER|Field-based exercise tests|Subjects will perform an Incremental Shuttle Walk Test (ISWT) and each individual component of a Short Physical Performance Battery (SPPB).
214915514|NCT02619357|OTHER|Laboratory-based exercise tests|Subjects will perform an incremental, symptom-limited cardiopulmonary exercise test on a cycle ergometer and will walk at various speeds on a treadmill
214915515|NCT00462709|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
214915516|NCT04952805|DRUG|MAD0004J08|MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.
214306672|NCT02606591|OTHER|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
214306673|NCT01716013|DEVICE|BondEase|topical skin adhesive
214306674|NCT01716013|PROCEDURE|CWCD|traditional closure methods of sutures, staples or adhesive strips
214306675|NCT02506335|DRUG|Cholate testing|The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
214306676|NCT01138280|DEVICE|CWP 103H (Gambro, Sweden): a heat disinfection device|Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
214306677|NCT01268384|DRUG|Gemcitabine plus Capecitabine|Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
214306678|NCT01458899|DRUG|TC-5214|Oral tablets, single 4mg dose
214306679|NCT05850650|OTHER|Application of a collagen sponge after surgical extraction of impacted 3rd molar|Application of a collagen sponge after surgical extraction of impacted 3rd molar
214306680|NCT05850650|OTHER|No collagen sponge application after surgical extraction of impacted 3rd molar|No collagen sponge application after surgical extraction of impacted 3rd molar
214306681|NCT02627612|BEHAVIORAL|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
214306682|NCT02627612|BEHAVIORAL|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
214306683|NCT03839589|BEHAVIORAL|Mindfulness Based Stress Reduction Adapated (MBSR-A)|Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.
214306684|NCT03430583|DRUG|Udenafil|Open-label extension with Udenafil 87.5 mg BID treatment for 52 weeks.
214306685|NCT03762655|DEVICE|Neuro-Spinal Scaffold|"The investigational product (Neuro-Spinal ScaffoldTM or Scaffold) is a porous bioresorbable polymer scaffold comprised of a synthetic biomaterial, poly(lactic-co-glycolic acid)-b-poly(L-lysine) (PLGA-PLL). The Scaffold is cylindrical in shape (3 mm diameter) and is available is three lengths (6 mm, 8 mm, 10 mm) for optimal fit in the intraspinal lesion cavity.~Based upon pre-clinical testing, the Scaffold is expected to be resorbed from the site of implant within 4 to 8 weeks."
214306686|NCT03595410|OTHER|Recurrence laryngeal cancer|Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
214306687|NCT05947851|DRUG|Nemtabrutinib|5 and 20 mg tablets
214306688|NCT05947851|DRUG|Venetoclax|10, 50, and 100 mg tablets
214306689|NCT05947851|BIOLOGICAL|Rituximab|100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
214306690|NCT05953584|DRUG|Etavopivat|Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
214306691|NCT05953584|DRUG|Hydroxyurea|Participants will receive a stable dose of HU.
214306692|NCT05268289|DRUG|Iptacopan (part 1)|Taken for 52 Weeks
214306693|NCT05268289|DRUG|Iptacopan (part 2)|Taken for 52 Weeks
214915517|NCT04952805|OTHER|Placebo|Placebo matching to MAD0004J08, 2.5 mL 2R vial. The pharmaceutical form is solution for intramuscular injection.
214915518|NCT00204698|DRUG|Aciphex|20 mg of aciphex taken twice daily
214915519|NCT05099497|OTHER|Using Practice Facilitators to Support Physicians|Utilize practice facilitators to empower family physicians to contact those who remain unvaccinated have better access to the COVID-19 vaccine.
214915520|NCT01736345|GENETIC|Genetic Providers|Genetic providers (genetic counselors or nurses) will follow the standardized disclosure protocol for in-person and telephone disclosures whle completing a disclosure flow checklist.
214915521|NCT01736345|OTHER|Visual Aids|Visual aids targeted to facilitate communication of genetic test results were developed based on our preliminary studies and modified based on our initial pilot study.
215060076|NCT00389376|DRUG|Silymarin|700 mg single dose + every 8 hours
215060077|NCT05082519|BEHAVIORAL|IDEAL2 Intervention|Intervention of diet and exercise to improve outcomes for ALL patients
214306694|NCT05268289|DRUG|Placebo + standard of care|Taken for 52 Weeks
214306695|NCT05268289|DRUG|Iptacopan + placebo|Taken for 52 Weeks
214306696|NCT04970901|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion
214306697|NCT04970901|DRUG|Polatuzumab Vedotin|IV infusion
214306698|NCT04970901|DRUG|Glofitamab|IV infusion
214306699|NCT04970901|DRUG|Mosunetuzumab|Subcutaneous (SC) injection
214306700|NCT04970901|DRUG|Obinutuzumab|IV infusion
214306701|NCT06289101|BEHAVIORAL|text4FATHER|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
214306702|NCT03642821|DEVICE|intracranial aneurysm coiling|endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system
214306703|NCT03446040|BIOLOGICAL|BMS-986258|Specified dose on specified days
214306704|NCT03446040|BIOLOGICAL|Nivolumab|Specified dose on specified days
214306705|NCT03446040|DRUG|rHuPH20|Specified dose on specified days
214915522|NCT01736345|OTHER|Post-Disclosure Asessments|Within 72 hours of completion of disclosures, participants will be asked to complete post-disclosure survey again being the option to complete by the aforementioned means.
214306706|NCT06175273|DIETARY_SUPPLEMENT|Oral Nutrition Supplement|8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL
214915523|NCT01736345|OTHER|In-person Clinical Follow-Up|Participants who receive their test results in person will meet with a Physician, Physician Assistant or Nurse Practitioneras part of their in person disclosure session. Participants randomiZed to telephone disclosure will be recommendedto schedule an in-person clinical follow-up appointment with a Physician, Physician Assistant or Nurse Practitioner
214306707|NCT06175273|DIETARY_SUPPLEMENT|Tube Feed|EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs
214306708|NCT06175273|DRUG|Cyproheptadine|0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
214306709|NCT06175273|DRUG|Olanzapine|2.5mg once a day (at night). May titrate by 2.5mg increments to max of 10mg/day
214306710|NCT06175273|OTHER|Standard of Care|Diet education on high protein, high calorie food consumption
214306711|NCT03741556|OTHER|questionaire|a questionaire is sent to each participans
214306712|NCT01094496|BIOLOGICAL|CDX-1307 Vaccine Regimen|CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
214306713|NCT01094496|DRUG|Chemotherapy|
214306714|NCT06546904|DEVICE|Artificial intelligence empowers anesthesia with ultrasound assistance|Artificial intelligence empowers anesthesia with ultrasound assistance
215060078|NCT06454279|OTHER|Dual Task Training|"Exercise which combines cognitive task with motor task e.g Backward counting during sit ups.~Calculation questions during stationary cycle for 10 mins. Sequentially perform movements on commands like normal standing (bipedal support with feet separated at shoulder width, Feet together (bipedal support with feet side by side), Semitandem stance, Tandem stance, one leg support on the dominant leg, one leg support on the nondominant leg by first laterally moving the trunk with shoulder abducted at least above 60 degree"
215060079|NCT06454279|OTHER|Task Specific Training|"Wide based gait training.~Auditory forward digit span:~Remember as many as possible of the number/letter forward sequence, you were told~Auditory backward digit span:~Remember as many as possible of the number/letter back sequence, you were told~Visual forward digit span:~Remember as many as possible of the number forward sequence shown to you by means of cardboard~Visual backward digit span:~Remember as many as possible"
214915524|NCT01736345|OTHER|6 Month and 12 Month Assessments|At 6 months and 12 months after disclosure participants will be asked to complete survey assessments.
214915525|NCT02861222|DRUG|Doxorubicin|
214915526|NCT02293512|BEHAVIORAL|Coping Effectiveness Training|A CET psychoeducational intervention is provided to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
214915527|NCT02293512|BEHAVIORAL|Cognitive-behavioral therapy|CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
214915528|NCT02293512|BEHAVIORAL|Acceptance and Commitment Therapy|An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
214915529|NCT04804423|DRUG|38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)|38% silver fluoride will be applied to the surface of the isolated hypersensitive carious lesion followed by application of potassium iodide solution and according to manufacturer's instructions.
214915530|NCT04804423|DRUG|Sodium fluoride varnish (generic name; Duraphat®)|22,600 ppm sodium fluoride varnish will be applied on the surface of the affected hypersensitive active carious lesions.
214915531|NCT01448330|DRUG|HCP0911 / clopidogrel, aspirin|combination tablet vs coadministration
214915532|NCT03350646|OTHER|Volume of medium during embryo transfer|
214306715|NCT04283006|DRUG|CD20/CD22 dual Targeted CAR T-cells|Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
214306716|NCT02717988|DRUG|SKI-O-703 capsule|SKI-O-703 25 mg capsule or 200 mg capsule without excipient
214306717|NCT02717988|DRUG|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose
214306718|NCT03131336|DRUG|PeproStat|solution for local application
214306719|NCT03131336|DRUG|Saline|solution for local application
214306720|NCT03314727|OTHER|High salt (NaCl) intake|Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels
214306721|NCT04724954|DEVICE|Rehabilitation Therapy on Experimental Robotic Table and standard of care|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation
214306722|NCT04724954|GENETIC|Rehabilitation Therapy as part of Standard of Care (Control)|Control group will receive Standard of Care training only
214306723|NCT01652664|DRUG|Travoprost 0.004% PQ ophthalmic solution|
214306724|NCT01652664|DRUG|Timolol, 0.5% or 0.25% ophthalmic solution|Patients 2 months to \< 3 years of age received 0.25%
214306725|NCT01652664|DRUG|Travoprost Vehicle|Inactive ingredients used to maintain masking
214306726|NCT02357069|DRUG|Enbrel|Etanercept
214306727|NCT02357069|DRUG|LBEC0101|Etanercept
214306728|NCT01980043|PROCEDURE|endoluminal rectal prolapse repair under sedation|endoluminal rectal prolapse repair under sedation
214306729|NCT05853250|OTHER|Reiki/manual therapy|Reiki is delivered by gentle hand placement either on or slightly above the body by certified Reiki practitioners. In this study, Reiki will be delivered first, for 15 minutes and will involve light placement of hands on patients' head, chest, shoulders, hands, knees, and feet (\~ 3 minutes to each body part). Manual therapy techniques include light effleurage to head and feet (for 5 minutes; \~ 2.5 minutes to each body part) by the Reiki practitioner who delivered the Reiki therapy.
214306730|NCT02155140|DIETARY_SUPPLEMENT|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
214915533|NCT04950348|DEVICE|Personalized TKA prosthesis|TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy
214306731|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin)|"Participants will receive one of the following Gemcitabine-based systemic therapy alone:~Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~Duration: 3 months (in addition to 3 months previously received)"
214915534|NCT04950348|DEVICE|Zimmer NexGen prostheses|Commercial products used on a large scale
214915535|NCT05646264|DRUG|Agomelatine|Agomepratine is added to a second-generation antipsychotic drug (olanzapine, aripiprazole, risperidone, etc.)
214915536|NCT04644302|DIAGNOSTIC_TEST|microcirculation recording|non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
214915537|NCT04468347|DRUG|Flortaucipir F18|IV injection, 240 megabecquerel (MBq) (6.5 mCi)
214915538|NCT04468347|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
214915539|NCT01666158|BEHAVIORAL|Exercise|The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
215060080|NCT00952328|DIETARY_SUPPLEMENT|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
214306732|NCT06214572|RADIATION|RT|"Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.~This is followed by systemic therapy as in the Systemic therapy alone arm."
214306733|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus oxaliplatin)|"Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~Duration: 3 months"
214306734|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)|"Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~Duration 3 months Durvalumab (12 months)"
214915540|NCT01984632|PROCEDURE|Single-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture (control group) in terms of operative time (esp. suturing time).
214915541|NCT01984632|PROCEDURE|Multi-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture(control group) in terms of operative time (esp. suturing time).
214915542|NCT02139202|BEHAVIORAL|Social Influence|
215060081|NCT03365063|OTHER|Active Knowledge Translation|"1. Integration of the KFRE in the CPCSSN DPT - The DPT will report the output from the KFRE for all patients with CKD Stages G3-G5 from the clinic sites. The risk output will include interpretation and automated categorized risk of progression to kidney failure, and will recommend actions based on the KFRE risk based care pathway.~2. Audit and Feedback - Providers at CPCSSN clinics receive sentinel feedback reports on a panel of chronic conditions and quality improvement targets. The investigators will add CKD to the feedback report for the intervention sites, and provide detailed feedback on the practices' risk profile.~3. Medical Detailing - The intervention CPCSSN clinics will receive a standardized presentation to clinic staff by the principal investigator, who will provide the evidence for the accuracy of the KFRE and guidance on implementation of a risk based treatment pathway, as well as describe the supporting visual aids."
214306735|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)|Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w Duration: 3 months
214306736|NCT03036098|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
214306737|NCT03036098|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
214306738|NCT03036098|DRUG|Gemcitabine|Specified Dose on Specified Days
214306739|NCT03036098|DRUG|Cisplatin|Specified Dose on Specified Days
214306740|NCT03036098|DRUG|Carboplatin|Specified Dose on Specified Days
214915543|NCT02139202|BEHAVIORAL|Electronic Pill Bottles|
214915544|NCT02139202|BEHAVIORAL|Financial Incentives|
215060082|NCT02591472|PROCEDURE|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
214306741|NCT06410118|BEHAVIORAL|DreamChanger+IRT|Families will receive the DreamChanger remote along with 3 instructional videos for parents, explaining how to present the remote to children, and how to rehearse alternative dream imagery using the DreamChanger remote.
214306742|NCT06187467|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires to quantify cortical and motor activities using portable EEG and lower limb sensors during dynamic balance and gait activities.
214306743|NCT04028206|DIETARY_SUPPLEMENT|Hydroxymethylbutyrate|Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.
214306744|NCT04028206|DEVICE|Low-magnitude High Frequency Vibration (LMHFV)|Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
214306745|NCT04028206|BEHAVIORAL|Elastic-band Exercise|"Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching."
214306746|NCT05760807|DRUG|Oxytocin nasal spray|Intranasal oxytocin, administered dose 24 international units (IU) twice daily, delivered over 7 days of a residential inpatient withdrawal admission.
214306747|NCT03453684|DRUG|Administration of Vancomycin|Intravenous Vancomycin Administration
214306748|NCT01319812|DEVICE|Astron Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
214306749|NCT01319812|DEVICE|Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
214915545|NCT04454983|DEVICE|Lipiflow Thermal Pulsation System|The LipiFlow Console provides the user interface and control elements of the system, including all software, algorithms and control elements. The Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland. Its contoured design vaults the cornea and protects the eye allowing a maximum therapeutic temperature of 43 degrees Celsius to reach glands from the inner eyelid. Insulation protects the cornea from exceeding a safe 39.5 degrees Celsius, while a pressure feedback loop sends pulsed sequences to expel blockages. Force equalization protects the globe from pressure transmission by focusing energy only on the eyelid. Delivered through the LipiFlow Activator, Vectored Thermal Pulse™ technology applies a combination of heat and pressure to the inner eyelid to safely remove gland obstructions and stagnant gland content. Therapeutic motion provides proximal-to-distal peristalsis to clear gland contents.
214915546|NCT04454983|DEVICE|iLux System|The iLux™ System is used to apply localized heat and pressure to a patient's eyelids. The system consists of a handheld instrument coupled to a single-use, sterile disposable component that is positioned to bridge the eyelid. The iLux device allows view of the eyelid through a magnifier, then warms the eyelid to 40 to 42˚C, then force-limited compression is applied manually to express the melted meibum from obstructed glands. Warming is accomplished using light energy emitted from LEDs in the Instrument. The LEDs are located behind a clear window on the open end of the Shroud. Two wavelengths of light are used: lime-green (568 nm) and near-infrared (850 nm). A mechanism in the Instrument allows the operator to apply pressure to the eyelid by controlling the movement of the Outer Pad using finger pressure applied to the Compression Control button. The force applied to the Compression Control is measured by a sensor in this mechanism.
214306750|NCT02979847|PROCEDURE|hybrid approach|Before transseptal puncture, epicardial puncture is performed through subxyphoid approach. Atrial epicardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Endocardial potentials are also recorded in the same fashion. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
214306751|NCT02979847|PROCEDURE|conventional endocardial approach|Atrial endocardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
214306752|NCT02803151|RADIATION|Stereotactic ablative radiotherapy|SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
214306753|NCT05023187|BEHAVIORAL|SCOT|"A 8-week social and cognitive online training to improve both cognitive and social functioning, which includes 2 sessions (\~45 minutes each) of individual cognitive training through the BrainHQ© program 2020 (BrainHQ© Posit Science) and a psycho-educational group session for each week (24 sessions in total).~In the experimental intervention, all activities are focused on enhancing executive functions (working memory, processing speed, inhibitory control etc.) and social cognition abilities (identifying/recognizing facial expressions, styles attribution, drawing conclusions etc.)."
214306754|NCT05023187|BEHAVIORAL|CON|"A 8-week active control intervention consisting of 2 sessions (\~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics."
214306755|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C antibody test|Qualitative point-of-care test for hepatitis C antibodies (saliva sample)
214306756|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C RNA test|Hepatitis C Viral Load point-of-care test (fingerstick wholeblood sample)
214306757|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antibody test|Qualitative hepatitis B surface antibody point-of-care test (fingerstick wholeblood sample)
214480150|NCT06860126|BEHAVIORAL|Intergenerational Activity Program: This indicates a program that involves activities designed for interaction between older adults and younger participants|"Engage in 90-minute intergenerational interaction sessions, three times a week for three months, in a controlled indoor environment.~* Spend the first 45 minutes actively interacting with a younger participant in pairs, collaborating on activities of interest to the senior.~* Participate in group activities such as book reading, puzzles, joke-telling, and sharing experiences for the remaining 45 minutes.~* Attend 36 sessions held on odd days in the main hall of the Neshat Center.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
214915547|NCT00554515|DRUG|HD IL2|
214915548|NCT00521638|BIOLOGICAL|TRU-015|Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
214915549|NCT03442686|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
214915550|NCT05333302|BIOLOGICAL|CD19 CAR-T-cells|One dose of CD19 CAR-T cells (1\*10e6 CAR+ T-cells/kg) by intravenous infusion.
214915551|NCT05333302|DRUG|Tocilizumab|Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
214915552|NCT05899283|DEVICE|OCI-HF160|OCI-HF160 are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
214915553|NCT05899283|DEVICE|FX800HDF|FX800HDF are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
214306758|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antigen test|Qualitative hepatitis B surface antigen point-of-care test (fingerstick wholeblood sample)
214306759|NCT05839522|DIAGNOSTIC_TEST|Point-of-care HIV antibody test|Qualitative HIV antibody point-of-care test (saliva sample)
214306760|NCT05839522|BEHAVIORAL|Interview-style survey|Interview-style survey regarding demographics, risk behaviours, BBV testing and treatment history, and point-of-care testing acceptability
214306761|NCT04829565|DRUG|Botulinum toxin|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of botulinum toxin 50 IU
214306762|NCT04829565|DRUG|Placebo|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of placebo
214306763|NCT05623267|DRUG|Sugemalimab|Recombinant anti-PD-L1 fully human monoclonal antibody
214306764|NCT05623267|DRUG|Placebo|Placebo of Sugemalimab
214306765|NCT00464568|DRUG|GSK256066|
214480151|NCT06860126|BEHAVIORAL|Yoga and Mindfulness Sessions|"Participate in 90-minute intergenerational yoga sessions, three times a week for three months, in a gym setting.~* Perform modified yoga exercises suitable for seniors, including:~* 20 minutes of warm-up with stretching and joint rotations.~* 50 minutes of main exercises (asanas and pranayama).~* 20 minutes of relaxation and meditation (Shavasana).~* Attend sessions on odd days at 9 AM in the Neshat Center yoga hall.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
214306766|NCT04801771|DEVICE|Inspire Upper Airway Stimulation (UAS) System|The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.
214306767|NCT04772222|DRUG|Dexmedetomidine Hydrochloride|Potent α2-adrenergic receptor agonist that provides sedation, analgesia, and prevents shivering but does not suppress ventilation.
214915554|NCT03658161|BEHAVIORAL|Communicating About Sexual Concerns and Dysfunction Effectively|The coaching intervention will include two parts: 1) initial coaching session, and 2) follow-up appointment to check in on use of the intervention strategies.
214306768|NCT04772222|DRUG|Morphine Sulfate|Opioid agonist that provides analgesia, pain management and sedation and may suppress ventilation.
214306769|NCT02140099|BEHAVIORAL|Healthy Relationships Plus Program (HRPP)|The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
214306770|NCT02140099|BEHAVIORAL|Control Condition (Classroom Activities)|
214306771|NCT06380751|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
214915555|NCT03240289|BEHAVIORAL|Texting group|Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
214915556|NCT00003441|DRUG|Irofulven (MGI-114)|IV over 5 minutes daily for 5 consecutive days. Courses repeated every 28 days. Minimum treatment period is 2 courses.
214915557|NCT02085629|BIOLOGICAL|Donor M reg (Mreg_UKR)|"Experimental: M reg treatment~Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a living donor renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus background immunosuppression (as described in detail in the arm description)."
214915558|NCT04693208|DEVICE|Laser therapy|Laser treatment parameters will be two combined wavelength (660 and 970 nm), 3.2 Watt peak power, 320 milliWatt/cm2, 36.8 Joule/cm2 fluency, and 50% frequency, for a total time of 3 minutes for each site
214915559|NCT00488644|DRUG|Levothyroxine|75 mcg by mouth (PO) Daily for 8 Weeks
214915560|NCT00488644|DRUG|Liothyronine|15 mcg PO Daily for 8 Weeks
214915561|NCT06576778|PROCEDURE|PROVSIONALIZATION|glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
214306772|NCT06380751|DRUG|Camizestrant|Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .
214306773|NCT06380751|DRUG|Abemaciclib|CDK4/6 Inhibitor
214306774|NCT06380751|DRUG|Ribociclib|CDK4/6 Inhibitor
214915562|NCT03221816|DRUG|Tenavit®|The experimental group received one tablet of Tenavit® daily for a period of 4 months.
214915563|NCT03221816|DRUG|Placebo Oral Tablet|Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
214306775|NCT06380751|DRUG|Palbociclib|CDK 4/6 Inhibitor
214306776|NCT06380751|DRUG|Fulvestrant|Endocrine Therapy
214306777|NCT06380751|DRUG|Letrozole|Endorcine Therapy
214306778|NCT06380751|DRUG|Anastrozole|Endocrine Therapy
214306779|NCT06380751|DRUG|Exemestane|Endocrine Therapy
214306780|NCT06136559|DRUG|Nemtabrutinib|Administered orally
214306781|NCT06136559|DRUG|Ibrutinib|Administered orally
214915564|NCT05356520|PROCEDURE|Endoscopy Ivor-lewis|Endoscopy Ivor-lewis
214915565|NCT05356520|PROCEDURE|Laparoscopic transabdominal enlarged gastrectomy|Laparoscopic transabdominal enlarged gastrectomy
214306782|NCT06136559|DRUG|Acalabrutinib|Administered orally
214306783|NCT00547742|PROCEDURE|PET/CT Scan|
214306784|NCT00547742|PROCEDURE|phlebotomy|
214306785|NCT03696810|DIAGNOSTIC_TEST|Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
214306786|NCT05694936|DRUG|Sodium Valproate|Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL); Refer to arm description.
214915566|NCT01509417|OTHER|ad lib feedings after pyloromyotomy|ad lib feedings after pyloromyotomy
214915567|NCT01509417|OTHER|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
214915568|NCT00485199|PROCEDURE|Pneumatic Retinopexy|
214915569|NCT00485199|PROCEDURE|Vitrectomy with Gas|
214915570|NCT05349656|PROCEDURE|TQL block|Ultrasonography-guided quadratus lumborum block (QLB) where we will infiltrate local anesthetic solution adjacent to the anterolateral aspect of the quadratus lumborum muscle
214915571|NCT05349656|PROCEDURE|PENG block|Ultrasound-guided local anesthetic infiltration will be injected in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
214915572|NCT03877601|DRUG|Bevacizumab-IRDye800CW|Topical administration of Bevacizumab-IRDye800CW during the endoscopic procedure.
214306787|NCT05694936|DRUG|Panitumumab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
214306788|NCT05694936|DRUG|Cetuximab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
214306789|NCT03036787|BEHAVIORAL|family based intervention|behavioural advises to family for normal motor development
214306790|NCT00058604|BIOLOGICAL|Intravenous injection of EBV specific CTLs|Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
214306791|NCT02761707|OTHER|Electrical Brainstem Responses|Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
214306792|NCT02761707|OTHER|Olfactory Tests|Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
214306793|NCT02761707|OTHER|Visual Deprivation|During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
214306794|NCT02761707|OTHER|Peripheral Nerve Stimulation|Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
214306795|NCT02763033|DRUG|Bob's Red Mill®|Standard bone marrow transplant (BMT) diet + potato-based starch
214306796|NCT02763033|OTHER|Starch Placebo|Standard bone marrow transplant (BMT) diet + corn-based starch
214306797|NCT03721341|RADIATION|Palliative Radiation|Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
214306798|NCT03721341|DRUG|Chemotherapy|Chemotherapy may be given as indicated.
214306799|NCT03721341|DRUG|Immunotherapy|Immunotherapy may be given as indicated.
214306800|NCT03721341|DRUG|Hormones|Hormones may be given as indicated.
214306801|NCT03721341|OTHER|Observation|Observation only is acceptable if this is the standard practice.
214306802|NCT03721341|RADIATION|Stereotactic Ablative Radiotherapy|Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).
214306803|NCT05017363|PROCEDURE|ENGAGE|Goal-setting approach and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS), which is established goal setting tools for children aged 5-9. Administration of the Canadian Occupational Performance Measure (COPM), the most widely used goal-setting tool in paediatric rehabilitation that has been used with children as young as seven years. Introducing simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
214306804|NCT05471518|OTHER|No intervention|No intervention
214480152|NCT06860126|BEHAVIORAL|Physical Exercise and Storytelling|"Engage in 60-minute light aerobic exercises, three times a week for three months, in a park setting.~* Follow warm-up and aerobic exercises led by a senior fitness instructor.~* Spend 30 minutes in a friendly group discussion, sharing experiences and memories with younger participants.~* Attend sessions on even days at 9 AM in Mashhad's Mellat Park.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
214480153|NCT06860126|BEHAVIORAL|Outdoor Interaction Games|"Participate in 90-minute intergenerational interaction sessions, three times a week for three months, in a park setting.~* Engage in non-exercise activities such as group discussions, storytelling, and sharing experiences with younger participants.~* Attend sessions on even days at 9 AM in Mashhad's Mellat Park.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
214480154|NCT06860126|BEHAVIORAL|Social Visits to Nursing Homes|"Engage in 90-minute intergenerational interaction sessions, three times a week for three months, in a nursing home setting.~* Participate in non-exercise activities such as group discussions, storytelling, and sharing experiences with younger participants.~* Attend sessions on odd days at 9 AM in the nursing home.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
215060083|NCT02591472|PROCEDURE|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
215060084|NCT02591472|OTHER|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
215060085|NCT02591472|OTHER|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
214306805|NCT04291651|OTHER|Survey|There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.
214306806|NCT04665037|DRUG|Posaconazole IV 6 mg/kg|POS 6 mg/kg body weight by IV infusion
214306807|NCT04665037|DRUG|Posaconazole PFS 6 mg/kg|POS nominal 6 mg/kg body weight based on weight bands taken orally
214306808|NCT05264623|DEVICE|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser use for refractive surgery
214306809|NCT05704738|DRUG|Rocatinlimab|Subcutaneous (SC) injection
214306810|NCT05704738|DRUG|Placebo|SC injection
214915573|NCT03877601|DIAGNOSTIC_TEST|Fluorescence endoscopy|Device: Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.
214915574|NCT06142994|DIETARY_SUPPLEMENT|Atusin CAP|This food supplement contains a distillate of 4 types of purified oils - eucalyptus, sweet orange, lemon and myrtle, rich in 1,8-cineol, limonene, alpha-pinene in the ratio: 66:32:1:1, bromelain and green Brazilian propolis in a gastro-resistant capsule. The product contains excipients: microcrystalline cellulose, silica dioxide, copovidone, magnesium stearate.
214915575|NCT06142994|DIETARY_SUPPLEMENT|Placebo|The placebo product will be identical in shape, appearance and color to the active product and will have the same composition but without the active ingredients.
214915576|NCT02977572|DEVICE|Non-Invasive Ventilation|In arm description
214915577|NCT02977572|DEVICE|Continuous Positive AirwayPressure CPAP|In arm description
214915578|NCT04357067|DEVICE|Lingual brackets|A type of bracket that applied lingual surface of teeth.
214915579|NCT04357067|DEVICE|Labial brackets|A type of bracket that applied labial surface of teeth.
214915580|NCT03691987|BIOLOGICAL|Preprocessed thawed donor FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
214915581|NCT03691987|BIOLOGICAL|Preprocessed thawed autologous FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
214306811|NCT02884596|DRUG|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
214306812|NCT04335279|OTHER|SPIN-CHAT Program|Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
214306813|NCT06256419|DRUG|GLP-1 receptor agonist|Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.
214306814|NCT06256419|DRUG|responders group and nonresponders group|"For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks.~Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months.~According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated."
214306815|NCT06544265|BIOLOGICAL|SynKIR-310|Autologous T Cells transduced with CD19 KIR-CAR
214306816|NCT04484454|DIETARY_SUPPLEMENT|ProdromeNeuro Omega 3 Oil Nutritional Supplement|ProdromeNeuro is an algae-derived Omega 3 oil nutritional supplement product comprised of naturally occurring alkylglycerol and natural fatty acids. ProdromeNeuro functions as a natural plasmalogen precursor which can be administered orally.
214306817|NCT00284479|BEHAVIORAL|Walking 45 mins 2x p.w.|
214306818|NCT06167109|RADIATION|CTV optimized IMRT|The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as a potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
214915582|NCT06030323|OTHER|No intervention|This is not an interventional study. The study is classified as 'pre-clinical device development or performance testing'. The purpose of the study is to develop and validate the AI models using data collected from people affected by stroke in a hospital environment, to test the accuracy of the optimised models, and to ascertain patient preference for sensor location.
214915583|NCT04750265|DEVICE|Robotic assisted early mobilization|Robotic assisted early mobilization Robotic assisted early mobilization started within 72 hours of ICU admission.
214915584|NCT05107492|DRUG|450mg|following a single subcutaneous dose of PF-06480605 450 mg
215060086|NCT02591472|OTHER|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
214306819|NCT05549258|DRUG|Inebilizumab|Inebilizumab administered intravenously (IV) over a total of 28 weeks.
214915585|NCT05107492|DRUG|150mg|following a single subcutaneous dose of PF-06480605 150 mg
214915586|NCT05107492|DRUG|Placebo|following a single subcutaneous dose of placebo
214915587|NCT03957473|DEVICE|Indigo Aspiration System|Indigo Aspiration System with CAT RX Aspiration Catheter and optional Indigo Separator 4
214306820|NCT05541627|GENETIC|AB-1001 Gene Therapy|One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
214306821|NCT06850636|PROCEDURE|Epidural Analgesia|Labour epidural analgesia
214306822|NCT04846803|BIOLOGICAL|ABU bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)
214306823|NCT04846803|BIOLOGICAL|Saline bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline
214306824|NCT06849986|DRUG|Tislelizumab+liposomal doxorubicin+ifosfamide|Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 Ifosfamide (IFO) 3 g/m2/day on days 1 to 3 Tislelizumab 200mg on day 1, administered by intravenous infusion, every 3 weeks
214306825|NCT05416437|DEVICE|PneumoCool|Device to channel medical air to the patient to alleviate dyspnea
214306826|NCT05416437|OTHER|Current supportive measures that are used in the hospital for standard of care|a room fan, or any other currently used supportive measures can be used for patients in the control arm
214306827|NCT05815121|OTHER|Acupressing|Acupuncture with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.
214306828|NCT05815121|OTHER|Control|with stickers only on the points, and the points should not be massaged.
214306829|NCT00885755|DRUG|Standard taxane therapy|As prescribed
214306830|NCT00885755|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
214306831|NCT00885755|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
214306832|NCT06518187|OTHER|Assessing the impact of three different catheter advancement techniques on needle tip movement during intravenous insertion|Each participant will perform 3 simulated IV catheter insertions using each of the specified techniques. Participants will use the instrumented 16ga IV catheter to insert into the peripheral vascular access simulator. Needle tip movement (from intent of catheter advancement to 5mm of advancement off the needle) will be measured with 0.2mm accuracy using the electromagnetic tracking technology of the simulator. Data collected will include needle movement after simulated vein punction and during initial catheter advancement off the needle (in mm) which will be recorded within the simulation program and output as a de-identified Excel file
214306833|NCT03134560|DEVICE|Vein Display Instrument|
214306834|NCT05617560|OTHER|Telemedical care|Telemedical care will be provided to all participants after stationary hospital stay. This care will be in form of telephone consultations and / or videocall consultations with a medical physician. Depending on the individual medical history and the planned aftercare and procedure of the participants it will comprise of one or more such telephone consultations.
214306835|NCT04585087|OTHER|Dietary Intakes|6 levels of threonine intake will be provided by the protein liquid drink
214306836|NCT06493864|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
214306837|NCT06138730|BEHAVIORAL|Appa Complete|Weekly mentorship meetings \& guided CBT videos. Participants assigned to Appa Complete will have unlimited access to the Appa website and materials described in Appa Lite, along with weekly mentorship meetings with a trained and supervised near-peer mentor with whom they have been matched. Matching is based on preference for mentor gender, racial/ethnic minority status, and LGBTQ status and is designed to increase the sense of identification with the mentor and peer-mentor alliance. Virtual meetings begin with a review and discussion of the video and other materials for the week. Mentors ask about how clients are incorporating their CBT learnings into their life, share ways they have used the focal skills in their own lives, illustrate skills use in popular culture, and provide problem solving strategies. Each week has a specific prompt to ensure that clients are applying the concepts and skills they are learning and can talk about any questions or reflections with their mentors.
214915588|NCT05961306|DIAGNOSTIC_TEST|SCID 5|"SCID 5 is a semi-structured standard clinical interview. We will focus on current depressive episode, (hypo)manic episode, anxiety disorders, OCD and PTSD.~The interview will be conducted by phone."
214915589|NCT05587504|OTHER|E-cigarette with sweetness type 1 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 1."
214915590|NCT05587504|OTHER|E-cigarette with sweetness type 1 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 2."
214915591|NCT05587504|OTHER|E-cigarette with sweetness type 2 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 1."
214480155|NCT06860126|OTHER|control group|"Continue with their daily routines without participating in any intergenerational interaction or structured activities.~* No specific interventions or programs are provided.~* Gender Representation:~* 78 participants (39 women and 39 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population."
214915592|NCT05587504|OTHER|E-cigarette with sweetness type 2 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 2."
214915598|NCT06768944|DRUG|Psilocybin 25 mg|The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)
214915599|NCT06768944|DRUG|Psilocybin 1 mg|The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)
214915600|NCT06768944|DRUG|Metyrapone 750 mg|metyrapone 750mg capsules, which will be administered in 2 doses
214915601|NCT06768944|DRUG|Placebo|inactive placebo
214915602|NCT01197534|DRUG|fostamatinib|fostamatinib 100 mg twice daily
214915603|NCT01197534|DRUG|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
214915604|NCT01197534|DRUG|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
214915605|NCT01741987|OTHER|Optive ®|instilation of 1 drop each eye 4 times per day
214480156|NCT06860048|DEVICE|Arm sleeve|Randomised to wear arm sleeve on left or right
214915606|NCT01741987|OTHER|Fresh Tears ®|instilation of eye drop 4 times a day (qid)
214915607|NCT03117153|OTHER|DA-5502 liquid toothpaste|6 weeks study, brush three times daily, liquid toothpaste
214915608|NCT03117153|OTHER|placebo|same flavor solution, brush three times daily
214915609|NCT05630287|DRUG|[14C]-Selpercatinib|Administered as an oral solution
214915610|NCT05630287|DRUG|Selpercatinib|Administered orally
214306838|NCT06138730|BEHAVIORAL|Appa Lite|Unguided EBP videos and materials. Participants assigned to the Appa Lite condition will have unlimited access to the Appa website, including short form CBT-based videos and materials such as an emotions wheel pdf and thoughts, feelings, and behavior worksheets. The website is structured so that the materials are presented in a developmentally appropriate manner consistent with evidence-based principles in a 12-week format, beginning with general psychoeducation to define mental health, proceeding to introducing CBT and basic CBT skills such as identifying thoughts, feelings, and behaviors, layering on applying specific CBT skills, and ending with reflective journal exercises. Client progress through the materials will be completely unguided.
214306839|NCT04343521|OTHER|Targeted Indoor Residual Spraying (TIRS)|Spraying of insecticide Actellic 300CS will start in May or June extending for 1 to 2 months. Residents will be asked to temporarily leave the house during treatment and wait half an hour to one hour for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed by the Centers for Disease Control and Prevention (CDC), Emory University, and the Universidad Autónoma de Yucatán.
214306840|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 \[13mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
214306841|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 \[22mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
214306842|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 \[13mg of liposomes/kg\]
214306843|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 \[22mg of liposomes/kg\]
214306844|NCT00301210|DRUG|Tramadol|oral doses four times per day
214306845|NCT03405779|PROCEDURE|Lung ultrasonography|Mechanically ventilated patients suffering from pulmonary diseases will undergo a lung ultrasonography during their stay in the intensive care unit (ICU)
214306846|NCT06505824|DRUG|BL-M14D1|Administration by intravenous infusion for a cycle of 3 weeks.
214306847|NCT00107198|PROCEDURE|Conventional Surgery|Undergo surgery
214306848|NCT00107198|DRUG|Cyclophosphamide|Given IV
214306849|NCT00107198|DRUG|Doxorubicin Hydrochloride|Given IV
214306850|NCT00107198|DRUG|Prednisone|Given IV or PO
214306851|NCT00107198|RADIATION|Radiation Therapy|Undergo IFRT
214306852|NCT00107198|DRUG|Vincristine Sulfate|Given IV
214306853|NCT06554795|DRUG|DB-1419|Administered Injection of Vein (I.V.)
214306854|NCT02788461|RADIATION|Chemoradiotherapy|Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
214306855|NCT02788461|RADIATION|Chemoradiotherapy with Integrated Boost Dose|Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
214480157|NCT06859580|DRUG|Zoledronic acid 4 mg|Product name/EU MP number: Zoledronic Acid Oresund Pharma 4 mg/100 ml infusionsvätska, lösning/PRD8924813 (Test) Substance (name/ code): ZOLEDRONIC ACID/SUB00176MIG Strength: Zoledronic Acid 0.04mg Pharmaceutical form: SOLUTION FOR INFUSION Route of administration: INFUSIÓN INTRAVENOSA Marketing authorisation status (MA number, MS where authorised etc): 52486 / SE Modified in relation to MA: No Max Dosage: mg milligram(s) Duration of use: Week
214306856|NCT02053467|OTHER|Champlain BASE eConsult Service|After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
214480158|NCT06859580|DRUG|Natriumklorid 9 mg/ml, Fresenius Kabi|"Product name/EU MP number: Natriumklorid Baxter ClearFlex 9 mg/ml,infusionsvæske, opløsning/PRD456031 (Placebo) Substance (name/ code): SODIUM CHLORIDE/SUB12581MIG Strength: Sodium Chloride 0.9g / 100mL Pharmaceutical form: SOLUTION FOR INFUSION Route of administration: INFUSIÓN INTRAVENOSA Marketing authorisation status (MA number, MS where authorised etc): 32466 / DK Modified in relation to MA: No Max Dosage: ml millilitre(s) Duration of use: Week"
214915611|NCT05630287|DRUG|[14C]-Selpercatinib|Administered intravenously
214306857|NCT01948973|DEVICE|Subsensory|The stimulation is here set to 90% of the sensory threshold
214306858|NCT01948973|DEVICE|OFF|The stimulation is here turned OFF
214306859|NCT01948973|DRUG|Suprasensory|The stimulation is here set suprasensory
214306860|NCT02143609|DRUG|oxygen|Nocturnal nasal oxygen during stay at 2048 m
214306861|NCT02143609|DRUG|sham oxygen (room air)|Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
214306862|NCT03451149|DEVICE|Radiofrequency wire (Powerwire)|Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
214480159|NCT06859801|DEVICE|Percutaneous Ablation|Percutaneous ablation is a minimally invasive alternative therapy for metastatic bone disease and can be used for destruction of nerves mediating pain signals, tumor destruction, decompression, or inhibition of tumor growth.
214480160|NCT06859801|RADIATION|Radiation Therapy|Radiation therapy (RT) is a widely accepted treatment for painful bone metastases and provides palliation of pain for patients.
214480161|NCT06860191|DRUG|Root Canal Sealants|In this study, different irrigation agitation methods and different root canal sealers will be compared.
214480162|NCT06858267|BEHAVIORAL|PeSSKi questionnaire survey|The control group will only receive the questionnaire without meditation. The PeSSKi questionnaire survey will be receive in 4 time point, First questionnaire will sent via email after the appointment for the surgery is scheduled. The second PeSSKi questionnaire survey will share via email at halfway point to the surgery. The third questionnaire survey will be done immediately before the day of surgery in person to assess how anxious the patient is. The final questionnaire survey will be done 1 week postoperatively to assess how much pain the patient is still in after the quantity of analgesic usage logged throughout the week.
214480163|NCT06858267|BEHAVIORAL|Meditation Video|"The experimental group pediatric patients selected for this study and their parents will be receiving meditation and PeSSKi (Perceived Stress Scale for Kids) questionnaire. The ideal meditation schedule will be 3-5 meditations per week for 5 minutes beginning 3 weeks before surgery. This will provide a dose-response relationship of meditation to anxiety and postoperative pain for data analysis. The Patient and their parents will open the link, enter their assigned number, and follow the guided meditation embedded in the Qualtrics. This will track how many times and for how long the patients are following the regimen.~The questionnaire has eleven questions on a five-point scale ranging from Not at all to A lot. An example of the meditation video questionnaire is linked here:~https://augusta.qualtrics.com/jfe/form/SV\_3DeFFKdJVupMJQq (experimental group) https://augusta.qualtrics.com/jfe/form/SV\_2b2DZ9x16jY9IzQ (PeSSKi questionnaire)"
214480164|NCT06859229|DEVICE|Innovative technology pathway for gait neurorehabilitation|Participants will be assigned to either an advanced or traditional training pathway based on the protocol. The innovative tehcnology pathway for gait rehabilitation will incorporate devices such as exoskeletons, virtual reality systems, and body-weight suspension (BWS) devices to enhance gait rehabilitation. At the end of the training period, participants will undergo follow-up evaluation tests to assess outcomes.
214480165|NCT06859229|OTHER|Conventional gait rehabilitation strategy|The control group will undergo a traditional rehabilitation program that follows standard clinical protocols for gait recovery. This program will include conventional therapeutic exercises aimed at improving strength, balance, coordination, and functional mobility
214480166|NCT06826170|RADIATION|hypofractionated radiosurgery|The total dose will be 25 Gy, delivered in 5 fractions, in 5 consecutive days
214480167|NCT06859086|PROCEDURE|class II restoration|A class II cavity will be prepared after local anesthesia has been given as requierd . Rubber dam isolation will be done. Sectional matricing and wedging will be done. Followed by placement of restorative material according to the randomization sequence.
214480168|NCT06859255|DIAGNOSTIC_TEST|MRI|The patients will be undergo to a MRI without contrast after 1 month from the procedure/surgery to test the hwmodynamic performance 4d flow in the implanted valve
214480169|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Guava Consumption|Participants eat a defined portion of guava.
214480170|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Pineapple Consumption|Participants consumed fresh-cut pineapple purchased from street vendors. Health outcomes, including potential microbial contamination and GI symptoms, were assessed for five days after consumption.
214480171|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Watermelon Consumption|Fresh-Cut Watermelon Consumption Description: Participants consumed fresh-cut watermelon obtained from street vendors. GI symptoms and microbial contamination effects were monitored for five days following consumption.
214480172|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Guava Consumption (With Gastric Acidity)|Same as intervention 2, but in participants with acidity
214480173|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Pineapple Consumption (With Gastric Acidity)|Same as intervention 3, but in participants with acidity.
214480174|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Watermelon Consumption (With Gastric Acidity)|Same as intervention 4, but in participants with acidity.
214915612|NCT04407182|DIETARY_SUPPLEMENT|Viusid and Asbrip|"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours plus standard care. Viusid and Asbrip will be administered orally.~Treatment duration: 21 days."
214915613|NCT05989061|DEVICE|PEEK customized healing abutment|Guided delayed implant and a customized PEEK healing abutment placed simultaneously with implant surgery
214306863|NCT06208293|BEHAVIORAL|KPZ Program (KPZ)|The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level.
214306864|NCT06208293|BEHAVIORAL|Enhanced Usual Care (EUC)|Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
214306865|NCT02955979|OTHER|CT scan with iodinated contrast agents|"Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.~After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.~Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary."
214306866|NCT03576001|DRUG|Testosterone Undecanoate|administered through injections by study staff
214306867|NCT03576001|BEHAVIORAL|hybrid exercise|hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
214306868|NCT04194346|PROCEDURE|Lung ultrasound|Healthy volunteers will have lung ultrasonography at 15 predetermined sites for a common volume continuum between 5 and 15 cc/kg. For each volume, 3 respiratory cycles will be recorded.
214306869|NCT04394663|DRUG|High-dose oral omeprazole|Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.
214306870|NCT04394663|DRUG|Standard IV PPI|Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
214306871|NCT03170128|PROCEDURE|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
214306872|NCT03170128|BEHAVIORAL|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
214306873|NCT06381531|DIAGNOSTIC_TEST|Imaging with CT and MRI|Quantitative and anthropometric analysis of brain and skull strutcure of imaging (CT/ MRI) undertaken as part of diagnosis or treatment for patients with brain tumor
214306874|NCT00367081|DRUG|TMX-SMX (Bactrim(R))|
214306875|NCT00367081|DRUG|Pyrimethamine plus Sulfadiazine plus leucoverin|
214306876|NCT03959085|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214306877|NCT03959085|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214306878|NCT03959085|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214306879|NCT03959085|PROCEDURE|Bone Scan|Undergo bone scan
214306880|NCT03959085|DRUG|Calaspargase Pegol|Given IV
214306881|NCT03959085|PROCEDURE|Computed Tomography|Undergo CT
214306882|NCT03959085|DRUG|Cyclophosphamide|Given IV
214306883|NCT03959085|DRUG|Cytarabine|Given IV, IT, or SC
214306884|NCT03959085|DRUG|Daunorubicin Hydrochloride|Given IV
214306885|NCT03959085|DRUG|Dexamethasone|Given PO or IV
214480175|NCT06858371|BEHAVIORAL|AI Depression Literacy and Support Training|"The intervention consists of two AI-based chatbots designed to enhance depression literacy, reduce stigma, and improve confidence in supporting others with depression.~AI Depression Education Teacher - This chatbot provides interactive psychoeducation on depression, covering symptoms, causes, treatments, and ways to support others. Participants engage in a structured conversation to enhance their understanding and receive real-time feedback.~AI Depression Patient Simulation (Beibei) - Participants interact with a simulated individual experiencing depression to practice empathetic communication and support strategies. Through guided conversations, they learn to recognize depressive symptoms, offer emotional support, and encourage help-seeking.~This two-phase intervention provides both knowledge and practical experience in a safe, interactive environment. Participants will engage with both chatbots sequentially within a one-hour session."
214306886|NCT03959085|DRUG|Doxorubicin Hydrochloride|Given IV
214306887|NCT03959085|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214306888|NCT03959085|DRUG|Leucovorin Calcium|Given PO or IV
214306889|NCT03959085|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214306890|NCT03959085|DRUG|Mercaptopurine|Given PO
214306891|NCT03959085|DRUG|Methotrexate|Given IT or IV
214306892|NCT03959085|DRUG|Pegaspargase|Given IV or IM
214306893|NCT03959085|PROCEDURE|Positron Emission Tomography|Undergo PET
214306894|NCT03959085|DRUG|Prednisolone|Given PO or IV
214306895|NCT03959085|OTHER|Questionnaire Administration|Ancillary studies
214306896|NCT03959085|RADIATION|Radiation Therapy|Undergo testicular radiation therapy
214306897|NCT03959085|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
214306898|NCT03959085|DRUG|Thioguanine|Given PO
214306899|NCT03959085|DRUG|Vincristine Sulfate|Given IV
214306900|NCT00048607|DRUG|aprepitant|
214306901|NCT00048607|DRUG|Comparator: paroxetine HCL|
214306902|NCT00048607|DRUG|Comparator: Placebo (Unspecified)|
214306903|NCT05308446|BIOLOGICAL|Cetuximab|Given IV
214306904|NCT05308446|DRUG|Encorafenib|Given PO
214306905|NCT05308446|BIOLOGICAL|Nivolumab|Given IV
214306906|NCT04061811|DIAGNOSTIC_TEST|Diagnostic biomarker study|Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
214480176|NCT06858371|BEHAVIORAL|AI Depression Literacy Education|This intervention consists of interaction with an AI chatbot, i.e., AI Depression Education Teacher, which provides interactive psychoeducation on depression, covering symptoms, causes, treatments, and ways to support others.
214480177|NCT06858371|BEHAVIORAL|Psychoeducation Material Group|"The intervention contains standard psychoeducation materials about depression. Participants will be directed to:~A depression-related article - Provides general information about depression, including its symptoms, causes, and treatment options.~A video describing the lived experience of a depression patient - Shares a personal story to help participants understand the real-life impact of depression."
214915614|NCT05989061|DEVICE|Titanium customized healing abutment|Guided delayed implant and a customized Titanium healing abutment placed simultaneously with implant surgery
214480178|NCT06857747|DRUG|Capecitabine|metronomic capecitabine, 500 mg, tid， po
214480179|NCT06857747|DRUG|Vinorelbine|metronomic vinorelbine, 40mg/d, TIW1, po
214480180|NCT06857747|DRUG|Etoposide|metronomic etoposide, 50mg/d, po
214915615|NCT03725488|OTHER|Questionnaire|"students were involved in the pre-clinical prosthodontic lab. Participation in these labs were mandatory and it involved crown and bridge preparations on typodont models. There were 2 sessions of these labs per week, one for each gender. Each session lasted for 3 hours.~The study was conducted in 2 phases. At the beginning of the first phase of the study, the labs were conducted without any BM for 4 weeks. PSS(perceived stress scale), a standardized and validated, self-reporting international test was used for measuring the level of psychological stress were administered to all participants."
214915616|NCT03527589|DEVICE|Prostate artery embolization|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.
214306907|NCT01191580|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
214306908|NCT01191580|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
214306909|NCT01191580|BEHAVIORAL|Brief Supportive Psychotherapy|"The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures."
214306910|NCT01569958|OTHER|transcranial direct current stimulation|transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
214670455|NCT01264991|PROCEDURE|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
214480182|NCT06855758|DRUG|terlipressin|Terlipressin was given prior to the opening of the graft circulation (with the possibility of reperfusion hypotension) when the blood pressure is suboptimal and does not respond well to dobutamine or fluid volume resuscitation. 1 mg terlipressin + 100 ml of sodium chloride injections was given for intravenous infusion.
214915617|NCT05772377|DRUG|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 10 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 8mg will be taken.
214915618|NCT05772377|DRUG|cis Platinum/carboplatin|Concurrent chemotherapy with cisplatin at 75mg/m2 during radiotherapy will be the most preferred regimen. For patients who cannot tolerate the toxicity of cisplatin, 75 mg/m2 nedaplatin will be used as an alternative drug.
214915619|NCT05772377|RADIATION|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 40Gy total dose and 3D-brachytherapy of 30Gy/2.5F. Duration of radiotherapy will be no more than 5 weeks
214915620|NCT03686059|DRUG|Omega 3|daily intake of 250 mg
214915621|NCT03686059|DEVICE|punctal plug|punctal plug will be inserted in inferior punctum
214915622|NCT05584033|DIAGNOSTIC_TEST|Mansora Arabic test battery for childhood apraxia of speech|Searching of apraxia of speech in children with Specific Language Impairment in able to better management of these cases.
214915623|NCT03507634|DRUG|Opioid free Anesthesia dexmedetomidine and lidocaine|Opioid free anesthesia with dexmedetomidine and lidocaine
214915624|NCT03507634|DRUG|Opioid based anesthesia Fentanyl and Remifentanyl|Opioid based anesthesia with Fentanyl and Remifentanyl
214915625|NCT05508048|BEHAVIORAL|The existential approach and logotherapy-based psychosocial support program|Existential Approach and Logotherapy Based Support Program, which raises awareness about the meaning and purpose of the individual's life, enables them to produce solutions to the sense of meaninglessness, anxiety, feeling of emptiness, and many other problems, and develops different perspectives.The content of the program is base on existential analysis and logotherapy. The program lasted for eight weeks, with the first and last session of the scale applications. Additional sessions were set for each session where the aims and objectives of the session could not achieve. A session lasting at least 50 minutes were held each week.
214915626|NCT03389204|OTHER|PHYSICAL THERAPY|EXERCISES AND EDUCATION TO FOLLOWING AFTER DISCHARGE PHYSICAL TREATMENT
214915627|NCT00033722|DIETARY_SUPPLEMENT|folic acid|
214306911|NCT01569958|OTHER|Sham stimulation|1 mA stimulation for 30 seconds every 900 seconds per session
214306912|NCT05947682|OTHER|Adipose tissue harvesting|Adipose tissue harvesting (40-60g) during the abdominal liposuction or lipoaspiration under general anaesthesia which is performed according to usual care
214306913|NCT01761214|DRUG|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
214306914|NCT01761214|DRUG|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
214306915|NCT05064033|OTHER|Pragmatic Set of intervention and posterior capsular stretch|Group 1 will receive a pragmatic set of interventions, including Serratus Anterior Stretch,Rotator Cuff Facilitation,Acromilcalavicular joint Mobilization,Stretch of Pectoralis Major and Minor,Thoracic Manipulation and posterior capsular stretch.
214306916|NCT05064033|OTHER|Pragmatic Set of intervention and Sleeper Stretch|Group 2 will receive a pragmatic set of interventions, including Serratus Anterior Stretch, Rotator Cuff Facilitation, Acromilcalavicular joint Mobilization, Stretch of Pectoralis Major and Minor, Thoracic Manipulation and sleeper stretch.
214306917|NCT02391103|DEVICE|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
214306918|NCT02391103|DEVICE|sham-stimulation|no electricity applied
214306919|NCT06570473|DRUG|Empagliflozin|Tablet
214306920|NCT06570473|DRUG|Ranolazine|Tablet
214915628|NCT00033722|DRUG|lometrexol|
214915629|NCT00357799|DEVICE|VeinViewer|Using the VeinViewer, IV attempts will be made
214306921|NCT05759468|DRUG|Investigational Product - MIB 626|The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
214306922|NCT05759468|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
214306923|NCT03605797|OTHER|follow up of cases fixed by posterior tension band plate|Follow up of the reduction and functional outcome evaluation using the Majeed functional outcome score
214306924|NCT01909908|DEVICE|ECM|ECM in saline applied to wound
214306925|NCT01909908|BIOLOGICAL|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
214306926|NCT01909908|DEVICE|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
214306927|NCT05404373|OTHER|Normobaric Hyperoxia (NBO)|NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups
214306928|NCT05404373|OTHER|Low flow oxygen|immediately given oxygen inhalation at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
214306929|NCT03836482|DEVICE|Selective Cytopheretic Device|Treatment will be delivered for 4 hours a day for up to 6 consecutive days.
214915630|NCT02596555|DRUG|Dabigatran|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
214306930|NCT03491683|BIOLOGICAL|INO-5401|INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.
214306931|NCT03491683|BIOLOGICAL|INO-9012|INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
214306932|NCT03491683|BIOLOGICAL|Cemiplimab|Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
214306933|NCT03491683|RADIATION|Radiation Therapy|Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.
214306934|NCT03491683|DRUG|Temozolomide|Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m\^2).
214480183|NCT06856512|OTHER|Remote ischaemic preconditioning|The dialysis protocol integrates a sequence of five ischaemia/reperfusion blocks applied to the upper limb. Each block consists of a 5-minute period of cuff inflation at a supra-systolic pressure individualized to each patient-20 mmHg above the limb occlusion pressure-followed by a 25-minute period of cuff deflation. This intervention begins 30 minutes after the start of dialysis and is referred to as hemodialysis remote ischaemic preconditioning (HD-rIPC).
214480184|NCT06856512|OTHER|Exercise|The exercise protocol consists of five sequential bouts of physical activity, initiated 30 minutes after the start of dialysis. Each bout comprises a 5-minute cycling exercise at moderate intensity, corresponding to a Borg Scale rating of 12-14, followed by a 25-minute passive recovery phase. This structured intervention is referred to as hemodialysis exercise (HD-EX).
214480185|NCT06856512|OTHER|standard dialysis|The hemodialysis control condition (HD-CONT) consists of standard hemodialysis treatment without the integration of any additional interventions, such as exercise or ischaemia/reperfusion protocols.
214915631|NCT05827133|OTHER|No intervention|No intervention
214915632|NCT05316961|DEVICE|Active PEMF|PEMF 1.5mT, 10Hz, 10 minutes
214915633|NCT05316961|DEVICE|Sham PEMF|PEMF 0mT, 0Hz, 10 minutes
214915634|NCT05316961|OTHER|Eccentric exercise|Eccentric exercise, 10 repetitions, 3 sets
214915635|NCT04195204|DRUG|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia and once daily for 7 days after surgery.
214306935|NCT05820932|GENETIC|Blood-based assay|Blood samples will be collected
214480186|NCT06855914|PROCEDURE|surgerical repair|surgical repair of AVF aneurysm
214915636|NCT04195204|DRUG|Placebos|Investigators administrated intravenously saline solution as a placebo
214915637|NCT04075071|BEHAVIORAL|Teacher-Child Interaction Training - Universal|Teacher-Child Interaction Training - Universal (TCIT-U) is an empirically-supported classroom-based intervention designed to strengthen teacher-child relationships, reduce and prevent child behavior problems, and promote social-emotional skills. TCIT-U is based in behavioral and attachment principles and was developed as a modification of Parent-Child Interaction Therapy (PCIT), an evidence-based treatment with well-established support for decreasing disruptive child behaviors and parental stress with children ages two to seven years old. In TCIT-U, teachers of children, preschool through second grade, are taught and coached in skills to manage challenging classroom behaviors and improve the quality of relationships. TCIT-U is delivered to teachers through group didactic training and live individualized coaching.
214915638|NCT03074058|DRUG|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol orally disintegrating tablet, ODT (Lanthanum Carbonate, BAY77-1931) 500 mg, TID
214306936|NCT05820932|DIAGNOSTIC_TEST|Cognitive assessments|Cognitive assessments will be both participant- and partner-reported
214306937|NCT05820932|OTHER|Quality of Life Surveys|Participant-reported Quality of Life Surveys
214306938|NCT06285695|DEVICE|Clareon Toric IOL|Aspheric hydrophobic acrylic IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery for the visual correction of aphakia and preexisting corneal astigmatism
214306939|NCT06285695|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon Toric IOL
214915639|NCT03074058|DRUG|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID
214306940|NCT05400928|DEVICE|Pulsed Field Ablation|pulmonary vein isolation will be performed with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
214306941|NCT00751348|BIOLOGICAL|PriorixTM|Subcutaneous administration in left upper arm
214306942|NCT00751348|BIOLOGICAL|VarilrixTM|Subcutaneous administration in right upper arm
214306943|NCT00751348|BIOLOGICAL|Priorix-Tetra®|Subcutaneous injection in left upper arm
214306944|NCT03997656|BEHAVIORAL|MyDiPP (Malaysia Diabetes Prevention Program)|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
214306945|NCT03997656|OTHER|usual care|standard health education from primary care providers in the clinic
214306946|NCT05976802|DRUG|High dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
214306947|NCT05976802|DRUG|Low dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
214306948|NCT05976802|DRUG|Matching placebo rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
214306949|NCT01874496|DIETARY_SUPPLEMENT|GDS, no meal|GDS, no meal
214306950|NCT01874496|DIETARY_SUPPLEMENT|GDS, meal|GDS, meal
214306951|NCT01874496|DIETARY_SUPPLEMENT|control, no meal|control, no meal
214306952|NCT01874496|DIETARY_SUPPLEMENT|control, meal|control, meal
214306953|NCT00358085|PROCEDURE|Endovascular Repair of Abdominal Aortic Aneurysm|
214306954|NCT00358085|PROCEDURE|Conventional open repair of Abdominal Aortic Aneurysm|
214306955|NCT04295148|PROCEDURE|ACL Reconstruction with Semitendinosus graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft
214306956|NCT04295148|PROCEDURE|ACL Reconstruction with Quadriceps tendon-bone graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
214306957|NCT04037319|DIAGNOSTIC_TEST|24 Hour Holter Monitor|24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
214306958|NCT04380610|DIAGNOSTIC_TEST|iohexol GFR|We will perform mGFR in 400 SCA patients
214306959|NCT04830202|DRUG|Telisotuzumab vedotin|Intravenous Infusion
214306960|NCT04280510|GENETIC|Blood sample collection; gastrointestinal biopsy|Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
214306961|NCT05474378|DRUG|B7-H3CART|"B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:~Dose Level -1: 5 x 10\^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10\^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10\^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10\^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10\^6 CAR+ cells (+/- 20%)~B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)~Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12."
214306962|NCT05379439|OTHER|Structured Family Deliberation|Intervention families will be guided through the six modules included in the web-based decisional aid using a Structured Family Deliberation Tool. Parents will view narrated videos corresponding to each module and will be asked a series of questions related to their own lives and values. The process will continue until all modules are reviewed and all questions are completed.
214306963|NCT04191382|DRUG|Amcenestrant (SAR439859)|Pharmaceutical form: Capsules, Route of administration: Oral
214306964|NCT04191382|DRUG|Letrozole|Pharmaceutical form: Tablets, Route of administration: Oral
214480187|NCT05309785|DRUG|Invokana 300 mg and 100 mg tablet|"Substudy 1 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 12+2 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12+2 weeks (phase 2) and then stopped. If not tolerated, the dose will be reduced to 100 mg until the end of follow-up.~Each phase of 12 weeks is followed by a 2-week window to ascertain surrogate efficacy outcomes.~Substudy 2 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 9 days."
214480188|NCT06857734|DRUG|Vitamin B Complex|group of vit. B will recieve as an oral capsules for 4 days preoperative , and infusion of vitamin B complex 1ml diluted in 100 ml normal saline administered intravenously after anathesia induction .
214306965|NCT04251026|DRUG|tividenofusp alfa|Intravenous repeating dose
214306966|NCT02097355|OTHER|TriVox for clinical care|Use TriVox disease modules to manage patients
214306967|NCT05035173|OTHER|Survivorship Clinic Assessments|"Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit."
214306968|NCT05035173|OTHER|Survivorship Clinic Nurse Resource|"Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement.~\- ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes."
214480189|NCT06857734|DRUG|vitamin C|group of vitamin C will recieve 1000 mg as an oral capsule for 4 days and infusion at dose of 50 mg/kg diluted in 100 ml normal saline administered iv after induction of anathesia .
214480190|NCT06857734|DRUG|Placebo|patients will recieve placebo tablets with identical regimen preoperative and a placebo infusion of 100 ml normal saline after induction of anathesia ,prepared with identical appearance and taste by the pharmacist according to the randomization group.
214480191|NCT06858423|DRUG|Budesonide buffered with 0.9% isotonic saline.|120 patients received budesonide buffered with 0.9% isotonic saline.
214480192|NCT06858423|DRUG|Fluticasone propionate nasal spray.|120 patients received fluticasone propionate nasal spray.
214480193|NCT06858423|OTHER|0.9% saline for nasal irrigation.|120 patients used 0.9% saline for nasal irrigation.
214306969|NCT05035173|OTHER|Survivorship Clinic Dietitian Resource|"Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement.~\- ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise."
214480194|NCT06858449|DIETARY_SUPPLEMENT|Whey protein (20 grams)|20 grams of whey protein
214480195|NCT06858449|DIETARY_SUPPLEMENT|Whey protein (60 grams)|60 grams of whey protein.
214480196|NCT06663657|OTHER|Cognitive Sensorimotor Exercises|Patients in group A will receive cognitive sensorimotor exercises for 30 minutes, sessions for 5 days per week for 8 weeks.
214480197|NCT06663657|OTHER|Task Oriented Training group|Patients in group B will receive task oriented training for 30 minutes, sessions for 5 days per week for 8 weeks.
214480198|NCT06664125|DRUG|JMKX003002 will be administered orally|tablets for oral administration.
214480199|NCT06664125|DRUG|Sevelamer carbonate|tablets for oral administration.
214480200|NCT06663969|OTHER|Temporal Interference|Researchers applied temporal interference (TI) stimulation to the deep brain nuclei of patients who had undergone SEEG monitoring, recording changes in electrical activity detected by SEEG.
214480201|NCT06659445|DRUG|ONL1204 Opthalmic solution|Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
214480202|NCT06659445|DRUG|Avacincaptad Pegol intravitreal solution|Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
214480203|NCT06659445|OTHER|Sham|Sham injection
214480204|NCT06664528|DIAGNOSTIC_TEST|ECHOCARDIOGRAPHY|A complete echocardiographic exam will be performed during each cardio-oncologic evaluation.
214480205|NCT06664528|DIAGNOSTIC_TEST|ELECTROCARDIOGRAPHY (ECG)|An ECG tracing will be obtained during each cardio-oncologic evaluation.
214480206|NCT06664528|DIAGNOSTIC_TEST|LABORATORY TESTS|The cardiac biomarkers high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be dosed according to the current recommendations of Cardio-Oncology Guidelines.
214480207|NCT04631016|DRUG|Tozorakimab|Participants will receive SC injection of tozorakimab as stated in arm description.
214480208|NCT04631016|OTHER|Placebo|Participants will receive SC injection of placebo as stated in arm description.
214480209|NCT06377215|DEVICE|Open-source master hearing aid|The investigators will administer the intervention by fitting the device to the participant's audiometric profile. Testing will be counter-balanced across conditions with half the conditions requiring no intervention and the other half with the intervention.
214480210|NCT06669182|DEVICE|Intermittent Theta-Burst Transcranial Magnetic Stimulation|50Hz, stimulation intensity of 100% RMT, duration of 40s as a group of stimulation, 600 stimulation pulses, repeated stimulation of bilateral cerebellar dentate nuclei, with a 5-minute interval between each group, 1200 stimulation pulses per site, 5 times a week, treatment for 4 weeks, then treat once a week for 8 weeks.
214480211|NCT06669104|DEVICE|Medtronic Hugo™ surgical robotic system|undergoing robotic thoracic surgery by the Medtronic Hugo™ surgical robotic system
214480212|NCT06670963|DRUG|Iron|Iron derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg (lower limit for the local laboratory reference range for reticulocyte hemoglobin equivalent)
214306970|NCT05207995|BIOLOGICAL|Autologous tolerogenic dendritic cells|Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous.
214480213|NCT06670963|DRUG|EPO|Epoetin alfa 50 units/kg IV 3 times weekly
214480214|NCT06670963|DRUG|0.9 % NaCl|Volume of 0.9% NaCl identical as volume of medications used in experimental arm
214480215|NCT06670716|OTHER|Examination by a speech therapist|MASTcz test
214480216|NCT06670716|DIAGNOSTIC_TEST|Cognitive examination|ALBA test, PICNIR test
214480217|NCT06670716|OTHER|Examination of delirium|CAM-ICU and ICDSC questionnaire
214480218|NCT06670716|OTHER|History taking|The first page includes several sections: personal information, pre-stroke history, time-related data, neurological deficit data, radiological evaluation, pre-admission and admission treatment, and a medical examination focused on motor and speech impairments. The third page will document the physician's delirium examination and the speech therapy assessment. A questionnaire will be given to the relatives or close persons of the patients to fill out in order to collect systematic personal and pre-stroke anamnestic data and to assess the presence of dementia signs before the stroke using the Blessed Dementia Scale (BDS) questionnaire. All pages of the record form and the Questionnaire for Relatives are included in the appendices.
214480219|NCT06010836|BEHAVIORAL|Script guided conversation|Patients getting script guided intervention of 3 domains in the preoperative period
214480220|NCT05505942|BEHAVIORAL|LPA Sessions|"A study interventionist will conduct phone/video sessions and provide information regarding the acute and long-term psychological and physical benefits of increasing PA. Participants will be introduced to the concept of utilizing brief bouts of PA as a coping strategy for managing emotions and urges to drink alcohol in-the-moment. Participants will also be given information on the public health guidelines for PA (and how these translate into step counts) as well as how to determine if their PA is moderate intensity (e.g., measuring heart rate and identifying rate of perceived exertion). Study clinicians will also orient participants to the proper use of the Fitbit activity tracker and tips for self-monitoring step counts with the tracker and on the app and/or website."
214480221|NCT05505942|OTHER|Fitbit Only|Interventionists will provide participants information about the proper use of the Fitbit activity tracker and offer tips for self-monitoring step counts with the tracker and on the app and/or website.
215060087|NCT02591472|OTHER|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
214306971|NCT05207995|OTHER|Standard treatment according to the clinical protocols|Standard treatment of type 1 diabetes mellitus according to the clinical protocols
214306972|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
214306973|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
214306974|NCT06254014|DRUG|Placebo|0.6 ml, placebo injection, biweekly subcutaneous abdominal injections for 26 weeks (core treatment period), after which placebo was randomized 1:1 to JY09 (1.2 mg) and JY09 (2.4 mg) continued subcutaneous abdominal injections biweekly for 28 weeks (extended treatment period).
214306975|NCT05811442|DRUG|50561 high dose|study drug
214306976|NCT05811442|DRUG|50561 low dose|study drug
214306977|NCT05811442|DRUG|Placebo|Non-active study drug
214306978|NCT06538766|OTHER|Strength training with an internal focus of attention|A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific internal focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
214306979|NCT06538766|OTHER|Strength training with a proprioceptive external focus of attention|A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific proprioceptive external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
214306980|NCT06538766|OTHER|Strength training with a visual external focus of attention|A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific visual external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
214306981|NCT05100823|PROCEDURE|Nasal cells sampling|Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.
214306982|NCT05100823|PROCEDURE|Rectal biopsy sampling|Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.
214306983|NCT05237206|BIOLOGICAL|SUPLEXA|PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.
214306984|NCT04079179|DRUG|Cobimetinib|Cobimetinib will be administered at a maximal dose of 60 mg daily for patients \<18 years old and a flat dose of 40 mg daily for patients ≥18 years for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
214306985|NCT04090567|DRUG|Cediranib|Given PO
214480222|NCT06228781|PROCEDURE|Autologous haemopoietic stem cell transplantation|"Immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT).~Stem cell mobilization with cyclophosphamide 2g/m2 and filgrastim 10 ug/kg/d x 5 day.~Stem cell collection with cobe cpectra stem cell purification with Miltenyi CliniMACS Stem cell transplant conditioning with busulphan 3.2 mg/kg ; fludarabine 30mg/m2 or cladribine 10mg ；cytarabine 1-2g/m2 or idarubicin 8mg/m2；cyclophosphamide 40mg/kg followed by CD34 selected autologous hematopoietic stem cell transplant."
215060088|NCT02591472|OTHER|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
215060089|NCT02591472|OTHER|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
214306986|NCT04090567|DRUG|Ceralasertib|Given PO
214306987|NCT04090567|DRUG|Olaparib|Given PO
214306988|NCT01966640|BIOLOGICAL|Basophil Activation Test|blood sample for Basophil Activation Test
214306989|NCT04569903|DEVICE|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
214306990|NCT04716387|OTHER|Standard LLIN|Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.
214306991|NCT04716387|OTHER|Piperonyl butoxide ITN|Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.
214306992|NCT04716387|OTHER|Pyriproxyfen ITN|Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
215060090|NCT02591472|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
215060091|NCT02591472|OTHER|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
214306993|NCT04716387|OTHER|Chlorfenapyr ITN|Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
214306994|NCT06050252|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
214306995|NCT06050252|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214306996|NCT06050252|DRUG|Cisplatin|Given IV
214306997|NCT06050252|PROCEDURE|Computed Tomography|Undergo CT scan
214306998|NCT06050252|BIOLOGICAL|Durvalumab|Given IV
214306999|NCT06050252|DRUG|Gemcitabine|Given IV
215060092|NCT06379633|BEHAVIORAL|In vivo exposure|Exposure in vivo involves the confrontation with fear-evoking situations in real life.
214307000|NCT06050252|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
214307001|NCT06050252|PROCEDURE|Resection|Undergo surgical resection
214480223|NCT06148181|DRUG|ABBV-141|Infusion; intravenous (IV)
214480224|NCT06148181|DRUG|Placebo for ABBV-141|Infusion; IV
214307002|NCT05224973|BEHAVIORAL|speech therapy|speech therapy during 2 months
214307003|NCT06533332|DRUG|ERX-315|Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg/kg.
214307004|NCT05409781|OTHER|No Intervention|No Intervention
214307005|NCT06258655|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational program for the neonatal staff to improve their skills to collaborate with parents and provide support to parenting during an infant's hospitalization. First, experienced nurses and doctors from the units will undergo a 14-day to become unit mentors. Then these unit mentors will train other members of staff. The training of the units is based on bedside practices, a reflection of the practices, and the application of the knowledge in everyday work. Theoretical learning, preceding clinical bedside mentoring, will occur through an e-learning module. Staff members will spend about 4 working days in training alongside their routine work. The unit mentors will function as facilitators for the staff, and they have dedicated time for this. The content of the bedside practices is guided by a manual. The training team will provide frequent remote and contact support for the implementation."
214307006|NCT06294964|BEHAVIORAL|sleep education, behavioral education|Provide health education materials which covering sleep education, behavioral education, chronic diseases such as cardiovascular diseases. Topics touch on such as why you need healthy sleep? What methods can be used to regulate insomnia, and how to regulate sleep breathing problems? How do the elderly maintain a good sleep? What are the risk factors for cardiovascular and cerebrovascular diseases? How to reduce the risk of developing sleep disorders or chronic diseases through changing everyday life?
214307007|NCT04962009|COMBINATION_PRODUCT|Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug|Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
214307008|NCT05218473|DIAGNOSTIC_TEST|Prolonged ECG monitoring|Using 14-day continuous electrocardiography patch monitoring to increase the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation.
214307009|NCT05218473|DIAGNOSTIC_TEST|Conventional procedure group|Using serial 12-lead electrocardiograms once daily for five days or conventional 24-h Holter monitoring to detect new atrial fibrillation
214307010|NCT05461651|PROCEDURE|Knee arthroplasty|total or unilateral knee arthroplasty
214307011|NCT02441608|DEVICE|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
214307012|NCT00817115|DEVICE|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
214307013|NCT01256554|PROCEDURE|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
214307014|NCT01256554|BEHAVIORAL|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
214307015|NCT03343873|DRUG|Midazolam|Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.
214307016|NCT03343873|DRUG|Propofol|Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;
214307017|NCT03343873|DRUG|Dexmedetomidine|Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;
214307018|NCT04684381|DRUG|L-glutamine|Pharmacokinetic study
214307019|NCT01297907|OTHER|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
214307020|NCT01297907|OTHER|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
214307021|NCT01297907|OTHER|Blood Test|Blood Tests (Eosinophil Count)
214307022|NCT01297907|OTHER|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
214307023|NCT00000560|DRUG|adrenergic beta antagonists|
214307024|NCT04750031|PROCEDURE|Liver Biopsy|Liver biopsy is a procedure to obtain small amount of liver by a needle.
214307025|NCT02867709|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
214307026|NCT02867709|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
214307027|NCT01301495|DEVICE|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
214307028|NCT01139736|DIETARY_SUPPLEMENT|VSL#3|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
214307029|NCT04476433|OTHER|Ten Vida (10Vida)|10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.
214307030|NCT00032643|DRUG|DITPA|
214480225|NCT06148181|DRUG|ABBV-141|Injection; subcutaneous (SC)
214480226|NCT06148181|DRUG|Placebo for ABBV-141|Injection; SC
214480227|NCT04882839|COMBINATION_PRODUCT|psychotherapy assisted psilocybin|psychotherapy for patients while under the influence of psilocybin
214480228|NCT04496752|DEVICE|DCTclock|Cognitive Test
214480229|NCT06134076|OTHER|Unfermented chickpea|Frozen meals containing 100 g unfermented chickpeas
214480230|NCT06134076|OTHER|Fermented chickpea|Frozen meals containing 100 g fermented chickpeas
214480231|NCT06310005|DRUG|BI 3006337|BI 3006337
214480232|NCT06310005|DRUG|Placebo|Placebo
214480233|NCT06988384|OTHER|Bike fitting|Participants underwent bike fitting using the idmatch system, which utilizes three-dimensional motion capture to optimize rider position.
214480234|NCT05834673|OTHER|SMS messages|Participants will receive monthly SMS messages regarding cardiovascular health (low touch engagement nudges)
214307031|NCT04414709|OTHER|Double short implant|Patients receives 2 short implants to restore missing posterior teeth, loaded with splinted screw retained crowns.
214307032|NCT04414709|OTHER|Single short implant|Patients receives single short implants, loaded with single screw retained crowns.
214307033|NCT01395329|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
214307034|NCT01395329|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
214307035|NCT01395329|DRUG|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
214480235|NCT05834673|OTHER|Telephone-based support calls|Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.
214307036|NCT01395329|OTHER|Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)|The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.
214307037|NCT01395329|OTHER|FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
214307038|NCT01395329|OTHER|FBF response to Acetylcholine|The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.
214307039|NCT01395329|OTHER|FBF response to Sodium Nitroprusside|The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.
214307040|NCT01395329|OTHER|FBF response to BQ-123+BQ-788+ACh|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
214307041|NCT01722253|PROCEDURE|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
214307042|NCT02865915|DRUG|MLE4901|For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
214480236|NCT05834673|OTHER|GP Education|Education of GPs on the European Society of Cardiology (ESC) guidelines and Guideline Directed Management Therapy
214480237|NCT06086613|DRUG|AGA2115|"In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection."
214480238|NCT06086613|DRUG|Placebo|"In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection."
214480239|NCT06984367|OTHER|socio-technical intervention|A daily cognitive stimulation at home with specific software (Brainer) and 1 group session per week. Furthermore, each participant will receive the NAO robot at home.
214480240|NCT06984367|OTHER|Usual care|The subjects will receive a booklet containing information and activities on well-being. They will be invited to do whatever they wish with the information booklet and the proposed exercises, as they would do outside the framework of the experiment. In any case, they will be free to read and do the proposed exercises.
214480241|NCT02506673|DEVICE|Zeiss, Cinema ProMED (audiovisual equipment)|
214480242|NCT02506673|DRUG|Midazolam|
214480243|NCT02506673|DEVICE|Skin Conductance Monitor|
214307043|NCT02865915|DRUG|Placebo|Placebo to match active drug
214307044|NCT00663052|DRUG|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
214307045|NCT00663052|DRUG|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
214307046|NCT00564655|PROCEDURE|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
214307047|NCT00564655|PROCEDURE|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
214307048|NCT05053529|OTHER|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
214307049|NCT05053529|OTHER|CIMT group|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
214307050|NCT03808168|DRUG|Nivolumab|Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
214307051|NCT01757119|DRUG|Tardyferon 80 mg|Oral administration (2 tablets)
214307052|NCT05228886|BEHAVIORAL|SINCERE|"Each goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered action plan specifying what, when, how much, and how often patients will engage in a behavior (e.g., I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening). Again, following clear prompts, ISs negotiate the action plan with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10."
214307053|NCT05228886|BEHAVIORAL|Scheduled Follow-Up|Adding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.
214307054|NCT05228886|OTHER|Standard of Care|211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
214307055|NCT06057441|DEVICE|Auditory noise stimulation|Auditory white noise stimulation delivered at 78dB through earphones
214480244|NCT06613009|DRUG|IBI3009|Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)
214480245|NCT06612047|PROCEDURE|Prostate biopsy|All patients were required to underwent transperineal prostate biopsy (Systemetic + Targeted) and have corresponding pathological diagnosis results.
214480246|NCT04524689|DRUG|SAR408701 (Tusamitamab ravtansine)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
214307056|NCT06057441|DEVICE|Visual noise stimulation|Visual white pixel noise stimulation, backgound pixel noise visible at computer screen
214307057|NCT05760300|DRUG|Bulevirtide (BLV)|Administered via subcutaneous (SC) injections
214307058|NCT06181669|DIAGNOSTIC_TEST|Pathogen and Host Directed testing|"This study will compare up to 6 pathogen-directed tests and 3 host biomarker tests. Pathogen-directed tests detect and identify the most common causes of bacterial pneumonia, while host biomarker tests assess the host's immune response to infection. Testing will occur at various testing centers.~Evaluable participant specimens will be sent to a central laboratory for distribution to the testing centers that will perform the index testing. Testing centers will be blinded to whether the samples were collected at baseline or clinical change. Further, each testing center will prepare and test the specimens according to documented procedures, then transfer the testing results to the ARLG Statistics and Data Management Center for analysis. Neither the study sites, participants, nor adjudicators will receive the results from the index testing. After the study, untested aliquots of specimens will be stored in the ARLG Physical Biorepository."
214307059|NCT05616741|DEVICE|Cerebri biofeedback|Daily use of a mobile application connected with two wireless sensors for measurement of muscle tension, heart rate variability, and peripheral finger temperature, to be used for home-based biofeedback treatment.
214307060|NCT05616741|OTHER|Cerebri headache diary|Daily registration of headache and medication with the Cerebri mobile application. This intervention is identical for both study arms.
214307061|NCT06428305|OTHER|Providing hygiene education based on the method of teaching what has been learned in the context of a genital hygiene guide|As shown in the Flow Chart of the study, research data were collected from pregnant women who were in the control group at the December intervals with the experimental group. After the completion of the study, this group will also be given an education and training booklet.
214307062|NCT05330325|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
214307063|NCT05330325|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
214307064|NCT06273891|DRUG|Erythromycin|"Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
214307065|NCT06273891|DRUG|Azithromycin|"Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
214307066|NCT01719666|PROCEDURE|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
214307067|NCT01719666|PROCEDURE|conventional surgery|conventional surgery: MPFL reconstruction
214307068|NCT05227326|DRUG|PCNA Inhibitor AOH1996|Given PO
214307069|NCT00284661|PROCEDURE|FAST FIX|Fast fix repair of a meniscal tear
214307070|NCT00284661|PROCEDURE|Meniscal suturing|standard suturing of meniscal tear
214307071|NCT00877058|BEHAVIORAL|preventive home visit|
214480247|NCT04524689|DRUG|Pembrolizumab|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
214480248|NCT04524689|DRUG|Cisplatin|Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
214307072|NCT00877058|BEHAVIORAL|senior meetings|
214307073|NCT01722240|DRUG|Liraglutide 1.8mg|
214307074|NCT01722240|DRUG|Placebo|
214307075|NCT03514784|DRUG|BB-12 with LGG (Higher Dose)|BB-12 with LGG - Higher Dose (10 billion CFUs)
214307076|NCT03514784|DRUG|Placebo|Maltodextrin
214307077|NCT03514784|DRUG|BB-12 with LGG (Lower Dose)|BB-12 with LGG - Lower Dose (1 billion CFUs)
214307078|NCT05920577|OTHER|exergames and resistance training|"In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software Nintendo Switch Sports will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training."
214307079|NCT05920577|OTHER|Resistance training|The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
214307080|NCT06095011|DEVICE|UpRight Go|The UpRight Go posture trainer is a commercially available biofeedback sensor that externally attaches to the wearer via a necklace or silicon adhesive. It vibrates when it senses that the wearer is slouching and connects to a smartphone application which sets daily goals, tracks usage, and provides assistance and support. It complies with International Electrotechnical Commission (IEC) standards.
214307081|NCT05663866|DRUG|Dexamethasone|Dexamethasone will be administered orally.
214307082|NCT05663866|DRUG|Montelukast|Montelukast will be administered orally.
214307083|NCT05663866|DRUG|Methotrexate|Methotrexate will be administered subcutaneously.
214307084|NCT05663866|DRUG|Amivantamab|Amivantamab will be administered intravenously.
214307085|NCT05663866|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
214480249|NCT04524689|DRUG|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
214480250|NCT04524689|DRUG|Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
214480251|NCT04344158|DRUG|AK105 Injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
215060093|NCT06379633|BEHAVIORAL|(Virtual reality) exposure|Exposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
214307086|NCT07130734|BEHAVIORAL|Digital Physical Activity|The Pathverse mobile application platform will be downloaded on each participant's smartphone. Participants will be guided on how to download and use the application, as well as how to interact with the application during the intervention period. Participants will choose approximately five types of physical activity they enjoy before the intervention and will be prompted to complete these physical activities throughout the intervention. Participants will also self-report the duration and type of physical activity performed each day of the intervention.
214307087|NCT06228560|BIOLOGICAL|LP-003|Liquid in vial
214307088|NCT06228560|BIOLOGICAL|Placebo|Liquid in vial
214307089|NCT06228560|BIOLOGICAL|Omalizumab|Liquid in vial
214307090|NCT06812481|OTHER|Anticholinergic load was calculated using anticholinergic cognitive load (ACB)|"Bone mineral density was measured using a Dual Energy X-ray Absorptiometry (DEXA) device.~Fracture Risk Assessed with Fracture Risk Assessment Tool (FRAX)."
214307091|NCT00966602|DRUG|VX-809|VX-809 capsule, once daily for 14 days
214307092|NCT00966602|DRUG|VX-770|VX-770 tablet, once every 12 hours for 14 days
214307093|NCT00966602|DRUG|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
214307094|NCT00966602|DRUG|Placebo|Matching Placebo
214307095|NCT00772200|PROCEDURE|Cognitive Assessment|Complete COG Standard Neuropsychological and Behavioral Battery
214307096|NCT00772200|OTHER|Quality-of-Life Assessment|Ancillary studies
214307097|NCT04105933|OTHER|CS-CBT|Culturally sensitive Cognitive Behavioural Therapy was delivered individually, focused on potential cultural beliefs and attitudes that might collide with core values of CBT.
214307098|NCT04105933|OTHER|CBT|CBT was delivered at an individual level, dealing with thoughts, feelings and behaviours in the present. Thoughts are identified and then challenged, to make them more objective and rational.
214307099|NCT06576843|DRUG|INDV-6001|Extended-release subcutaneous injection
214307100|NCT06576843|DRUG|Suboxone|Oral sublingual film
214307101|NCT06576843|DRUG|Sublocade|Extended-release subcutaneous injection
214307102|NCT06246539|BEHAVIORAL|VR mindfulness|VR-based mindfulness
214480252|NCT04344158|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
214480253|NCT04344158|DRUG|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
214480254|NCT03033641|DEVICE|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
214480255|NCT05943821|DRUG|Allopurinol 200 mg|The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
214480256|NCT05943821|DRUG|Optional intervention|"Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels \>5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up."
214307103|NCT05859269|DRUG|Methylprednisolone|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course.~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
214307104|NCT05859269|OTHER|Standard of Care|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
214307105|NCT05304585|PROCEDURE|Biopsy|Undergo tumor biopsy
214307106|NCT05304585|PROCEDURE|Bone Scan|Undergo bone scan
214307107|NCT05304585|PROCEDURE|Computed Tomography|Undergo CT scan
214307108|NCT05304585|DRUG|Cyclophosphamide|Given IV
214307109|NCT05304585|BIOLOGICAL|Dactinomycin|Given IV
214307110|NCT05304585|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
214307111|NCT05304585|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214307112|NCT05304585|RADIATION|Radiation Therapy|Undergo radiation
214307113|NCT05304585|DRUG|Vincristine|Given IV
214307114|NCT06985069|PROCEDURE|General anesthesia applying multimodal anesthesia|"In the multimodal anesthesia-group a combination of different opioid-sparing drugs are added for general anesthesia, dosages are as follows:~* Magnesium 2g IV~* Dexmedetomidine IV 0.3mcg/kg IBW bolus over 10 minutes, followed by 0.3mcg/kg IBW until 30 min. before the end of surgery or the maximal dosage of 1.4mcg/kg IBW.~* Ketamine IV 0.3mg/kg IBW bolus, followed by 0.3 mg/kg IBW or a max. Dose of 25mg/h, until 30 min. before the end of surgery.~* Lidocaine IV 1mg/kg IBW bolus, followed by 1mg/kg/h IBW until in PACU/ICU"
214307115|NCT06985069|PROCEDURE|General anesthesia using conventional opioid-based regimen|Opioids (Fentanyl, Methadone, Hydromorphone) at the discretion of the treating anesthetist
214670456|NCT01264991|PROCEDURE|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
214480257|NCT05868577|DRUG|Corticosteroid injection (CSI) with local anesthetic (LA)|The PI will then administer the injection using an infracalcaneal needle peppering
214670457|NCT00073333|BEHAVIORAL|Social Skills Training|Social skills training once per week
214307118|NCT05042440|DRUG|Efanesoctocog alfa|Solution for injection Intravenous
214307119|NCT05042440|DRUG|Octocog alfa|Solution for injection Intravenous
214307120|NCT05042440|DRUG|Rurioctocog alfa pegol|Solution for injection Intravenous
214480258|NCT05868577|DRUG|Local anesthetic (LA) with Saline injection|The PI will then administer the injection using an infracalcaneal needle peppering
214480259|NCT05692011|DEVICE|blood purification(PS)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days
214480260|NCT05692011|DEVICE|blood purification(AN69ST)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days
214480261|NCT04967599|BEHAVIORAL|Phenotype Feedback Intervention|Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.
214670458|NCT00073333|BEHAVIORAL|Exposure Treatment|Exposure once per week
214670459|NCT00073333|BEHAVIORAL|Placebo|Placebo
214307121|NCT04827914|BEHAVIORAL|Enhanced Care|Smokers in the enhanced care group will receive live counseling (either in person or telehealth consult) while hospitalized combined with post-hospital discharge automated calls using interactive voice recognition (IVR) technology.
214307122|NCT04827914|BEHAVIORAL|Basic Care|Smokers assigned to the basic care group will only receive the post-discharge IVR phone calls.
214307123|NCT06286280|DEVICE|cytokine adsorber (CytoSorb®)|binding of cytokines to the sorbent polystyrene of the adsorber during cardiac surgery with extracorporeal circulation
214670460|NCT01651923|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
214307124|NCT06591949|OTHER|BETY|The cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) will be applied for 24 one-hour sessions, two days a week.
214307125|NCT06591949|OTHER|Control group|Control group will be followed up with a home exercise program, and notes will be taken.
214307126|NCT06593600|DRUG|REGN7544|Subcutaneous (SC) administration
214480262|NCT04967599|BEHAVIORAL|Genotype Feedback Intervention|Online session providing personalized feedback on alcohol metabolism genotypes and associated health-related risks.
214480263|NCT05666947|OTHER|Home-based exercise|Eight weeks of home-based exercise programs
214915640|NCT06610097|OTHER|Nutritional Counseling|The nutritional intervention for the treatment group -- personalized counseling on increasing fiber intake and maintaining adequate caloric intake during treatment -- will be administered as (1) a 60-minute initial telehealth consultation within the first week of study enrollment, and (2) up to two 30-minute follow-ups throughout the study, ideally the first follow-up within 6 weeks of study enrollment. These sessions will be led by a registered dietitian using cultural awareness and symptom assessment.
214915641|NCT02671838|BEHAVIORAL|Musculoskeletal ultrasound program|Using a musculoskeletal ultrasound program to help improve medication adherence
214915642|NCT06286683|DEVICE|lung ultrasound|Used to diagnose and monitor pulmonary aeration in the context of prolonged decubitus disorders (atelectasis) via the lung ultrasound score (LUS).
214307127|NCT06593600|DRUG|Placebo|SC administration
214480264|NCT06149273|BEHAVIORAL|Sleep School|Sleep school is a structured method for the treatment of insomnia, which is based on cognitive behavioral therapy for insomnia (CBT-I). The central element of the method is a workbook for the patients. The essential parts of the method are strengthening the patient's self-efficacy, introducing the therapeutic exercises, and supporting the continued use of the exercises. The main themes of the Sleep school are information about sleep and the factors affecting it, behavioural components of CBT-I, like restricting the time spent in bed, cognitive components of CBT-I, like constructive worrying -exercise, and the exercises that aim to calm down mind and the autonomic nervous system. The Sleep School is held by an educated nurse.
214480265|NCT06149273|BEHAVIORAL|Treatment as usual|Oral and written information about improving sleep habits given by an educated nurse.
214670461|NCT01593982|OTHER|repetitive Transcranial Magnetic Stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
214670462|NCT02305433|OTHER|Home-based physiotherapy (physical exercise)|Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
214670463|NCT00367471|DRUG|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
214670464|NCT00367471|DRUG|carboplatin|An alkylating agent used in the treatment of some cancers
214670465|NCT00367471|DRUG|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
214670466|NCT00367471|DRUG|paclitaxel|A mitotic inhibitor used in cancer treatment
214307128|NCT05819554|PROCEDURE|Trans-sphenoidal surgery|Surgical removal of pituitary tumor by trans-sphenoidal approach
214307129|NCT04129138|OTHER|Survey Administration|Complete survey
214307130|NCT06654219|OTHER|GLP-1 RA users with prolonged fasting instructions|NPO for solids: 24 hours prior to procedure, clear liquid diet (CLD) for 24 hours with last intake of clears no less than 2 hours prior to a procedure.GLP-1 RA will not be held prior to surgery and usual dosing schedule will be followed prior to procedure.
214480266|NCT06118853|BEHAVIORAL|yoga or gentle massage plus standard treatment for HSCT|The yoga sessions will be conducted at the patient's bedside, using one or more of the following techniques: gentle stretches (asanas), guided relaxation (savasana), slow and deep diaphragmatic breathing (pranayama), and meditative exercises focusing on natural breathing or visualization of a soothing place (dhyana). From these techniques, the integrative therapist will choose what best suits the patient for each session, based on their psychophysical state and symptoms presented, as there can be many variations during HSCT. Gentle massage is characterized by soft touches using light pressure, primarily using the palm of the hand, with a slow and steady rhythm across the entire body. It can be performed over clothing or even over the bedsheet and blanket.
214480267|NCT06299150|OTHER|IPS e.max CAD|CAD CAM Restoration
214915643|NCT06286683|DEVICE|Transcranial Doppler|Non-invasive, bedside method of measuring cerebral blood flow.
214915644|NCT06286683|DEVICE|near-infrared spectroscopy (NIRS)|Non-invasive, bedside method of cerebral oximetry that requires no advanced expertise.
214915645|NCT06286683|DEVICE|clinical examination|clinical examination
214307131|NCT06654219|OTHER|GLP-1 RA users with standard NPO instructions|NPO after midnight prior to procedure; Minimum solid fasting duration of 8 hours for solids and 2 hours for liquids. Last dose of GLP-1 RA no less than 7 days prior to procedure.
214307132|NCT00119418|DRUG|TU 025 Keishi Bukuryo Gan|
214307133|NCT02653560|DRUG|Potassium chloride powder|
214307134|NCT02653560|DRUG|Potassium magnesium Citrate (KMgCit)|
214307135|NCT02653560|DRUG|Potassium citrate powder|
214307136|NCT02653560|DRUG|Placebo|
214307137|NCT06282562|OTHER|High-Intensity Interval Training (HIIT)|Individualized High-Intensity Interval Training (HIIT) program with two exercise sessions per week for 12 weeks. The exercise sessions will be conducted on a stationary bike, with intensity tailored to each participant's maximum exercise capacity.
214307138|NCT06656364|DEVICE|Esprit BTK System|The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.
214670467|NCT05274438|DRUG|JS001+Imatinib mesylate|"This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered."
214670468|NCT03431389|DEVICE|Tracheostomy tube|Tracheostomy done to all patients by open surgical technique and was done in ICUs without need to transfer to theatre.
214670469|NCT01646710|BEHAVIORAL|Pretesting food based recommendations|
214670470|NCT02214589|OTHER|Oral glucose, facilitated tucking, NNS|
214670471|NCT02214589|OTHER|Oral glucose and NNS|
214480268|NCT03267563|BEHAVIORAL|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
214670472|NCT02214589|OTHER|Facilitated tucking and NNS|
214915646|NCT02522884|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
214915647|NCT05657561|OTHER|early mobilization|Mobilization training was given to the intervention group.
214915648|NCT03970005|BEHAVIORAL|Step-Based Care Model|Care model comprised of psychosocial and pharmacological interventions in which individuals start with low-intensity interventions and progress onto progressively higher-intensity interventions until their reach remission criteria.
214480269|NCT03267563|BEHAVIORAL|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
214480270|NCT03267563|BEHAVIORAL|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
214915649|NCT03494634|DRUG|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
214915650|NCT01521520|DRUG|ferumoxytol|Ferumoxytol at a dose of between 1 and 6 mg iron/kg body weight (maximum 510 mg/injection) will be administered via intravenous injection. Ferumoxytol will be administered with each series of MRIs.
214915651|NCT02078245|OTHER|MRI|MRI
214915652|NCT04063293|BIOLOGICAL|Platelet Rich Plasma|PRP injection into tha anal canal in patients underwent low anterior resection for rectal cancer
215060094|NCT00331916|DRUG|quinolone|
215060095|NCT02870985|DEVICE|Coronary Stent|
214307151|NCT03628703|DEVICE|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
214307152|NCT06818695|OTHER|Imaginal Exposure for Anorexia Nervosa|Imaginal exposure aims to use the power of imagining the fearful situation to heighten anxiety and by not engaging in imaginative restriction or other eating disorder behaviours, the individual, in theory, can habituate to the anxiety until it naturally subsides.
214307153|NCT06818695|OTHER|Treatment as Usual (TAU)|TAU includes specialist nurse monitoring, occasional medical reviews, and dietetic support (depending on the individual's particular needs)
214307154|NCT06661850|PROCEDURE|Fusion or TDR determined by investigator.|The surgical treatment will be decided by the treating investigator based on their clinical judgement.
214307155|NCT06198712|DRUG|Etavopivat|Participants will receive oral tablets of etavopivat once daily.
214307156|NCT04460209|OTHER|Standard of Care|Standard of care mapping and/or ablation
214307157|NCT06770985|OTHER|Artificial Intelligence|"Ollama (Ollama., 2024, https://ollama.ai/) artificial intelligence program and PYTHON 3 Programming Language and open source libraries will be used for the necessary algorithms for data review and analysis. In case of deficiencies in the data of the patients; the missing data will be edited using Data Imputation techniques. Number of files to be reviewed and/or date range to be covered: Patients who underwent lung resection between January 2023 and October 2024 will be included. An estimated 2000 files are planned to be scanned."
214915653|NCT02788409|OTHER|Not applicable for study|Provide external perspective on background second primary cancer incidence rates for REASSURE study.
214915654|NCT04689620|DEVICE|laser|treating the venous ulcer with laser
214915655|NCT00591565|DRUG|Acamprosate|acamprosate 333mg tab, 3 by mouth 3 times a day
215060096|NCT05745337|DRUG|As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)|Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
215060097|NCT03675113|OTHER|Upper extremity aerobic exercise|"Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
214307158|NCT06985238|DEVICE|MRI|Will receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
214307159|NCT06981884|OTHER|core stabilization exercises|Participants will be given core stabilization exercises 2 days a week, 45 minutes per session, for 2 months. At the end of 2 months, the outcome measurements will be taken by an evaluator physiotherapist who is not present during the treatment.
214307160|NCT06981884|OTHER|motor imagery training group|core stabilization exercise + motor imagery training group Participants will be given core stabilization exercises and motor imagery training 2 days a week, 60 minutes per session, for 2 months. Motor imagery training will be applied for 15 minutes immediately after the core stabilization exercisesAt the end of 2 months, the outcome measurements will be taken by the same evaluator physiotherapist who is not present during the treatment
214307161|NCT06586177|DRUG|Anti-CD20 antibody|Study participants receive an anti-CD20 antibody according to the summary of product characteristics.
214307162|NCT01928524|DRUG|DOS2w Dose level 1A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
214307163|NCT01928524|DRUG|DOS2w Dose level 2A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
214307164|NCT01928524|DRUG|DOS2w Dose level 3A|Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
214307165|NCT01928524|DRUG|DOS2w Dose level 4A|Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
214307166|NCT01928524|DRUG|DOS3w Dose level 1B|Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
214307167|NCT01928524|DRUG|DOS3w Dose level 2B|Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
214307168|NCT01928524|DRUG|DOS3w Dose level 3B|Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
214307169|NCT06611072|PROCEDURE|Bone marrow aspiration|Bone marrow samples (40 ml) will be obtained from the sternum or the iliac crest according to standard practice by experienced operators during the surgery patients will undergo as part of their medical treatment. BM mononuclear cells will be isolated using Ficoll-Paque and progenitor cells will be enriched using positive selection with CD34 beads by MACS. Progenitor cell composition will be identified using flow cytometry. HSPC proliferation assays (standard CFU assays) to assess myeloid colony-forming potential will be performed. In addition, single-cell RNA- sequencing and epigenetic assessment (ATAC-seq, ChIP-seq, DNA methylation) will be performed.
214307170|NCT06611072|PROCEDURE|Vena puncture|Whole blood (60 ml) will be collected and peripheral blood mononuclear cells (PBMC) will be isolated using Ficoll-Paque. Cellular subpopulations will be purified using negative selection of monocytes with PanMonocyte beads by MACS.
214307171|NCT06611072|PROCEDURE|Peritoneal fluid|Peritoneal fluid will be collected during the surgery.
214307172|NCT06611072|PROCEDURE|Spleen biopsy|Spleen samples will be obtained by experienced surgeons during the debulking surgery. Spleen mononuclear cells will be isolated using Ficoll-Paque and progenitor cells will be enriched using positive selection with CD34 beads by MACS. Cellular subpopulations will be further purified using negative selection of monocytes with PanMonocyte beads by MACS. Progenitor cell composition will be identified using flow cytometry. HSPC proliferation assays (standard CFU assays) to assess myeloid colony-forming potential will be performed. In addition, single- cell RNA-sequencing and epigenetic assessment (ATAC-seq, ChIP-seq, DNA methylation) will be performed.
214307173|NCT06611072|PROCEDURE|Tumor biopsy|During debulking surgery, all visible tumor tissue will be removed by experienced surgeons.
214307174|NCT06611072|PROCEDURE|Omental biopsy|During debulking surgery, an omental biopsy will be done.
214307175|NCT06857422|BEHAVIORAL|Hand Fan Application|Participants in the experimental group will be instructed to use a hand fan to cool their face for 10 minutes each day for a period of 6 weeks. The fan should be held approximately 15 cm from the face, focusing on the middle area. This intervention aims to alleviate symptoms of dyspnea and improve psychological well-being, including anxiety, depression, and illness perception. The participants will receive daily reminders to ensure consistent application of the intervention.
214915656|NCT06574763|DRUG|RC48/Carboplatin|RC48, 2.5mg/kg, iv, Q3W Carboplatin, AUC 5, iv, D1, Q3W
214915657|NCT00937365|BEHAVIORAL|Exercise|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
214915658|NCT00937365|PROCEDURE|Spinal Manipulation|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
215060098|NCT03675113|OTHER|Control Group|Deep breathing exercises combinated with arm movements
215060099|NCT01552837|DRUG|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
214307176|NCT06857422|OTHER|Standard Care for COPD Patients|Participants in the control group will receive standard care for chronic obstructive pulmonary disease (COPD) patients. This includes routine management and treatment as prescribed by their healthcare providers, such as medication and lifestyle recommendations. They will not be instructed to use a hand fan or any other cooling device during the study period. The control group will continue their regular care without any additional interventions from the research team.
214307177|NCT04350788|OTHER|Survivorship Care Plan|Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care
214307178|NCT04350788|OTHER|Enhanced Survivorship Care Plan|In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers. Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support
214307179|NCT06989658|DEVICE|SCL miniaturized scleral lens positioning|"1. Experimental evaluation:~   1. TESTs withSCL system~      * Before positioning the SCL lens: slit lamp examination~     * After positioning the SCL lens: slit-lamp examination~     * Tests performed on projected screen.~  2. Tests with a conventional oculometer: tests performed on a projected screen.~2. Ophthalmological assessment:~   1. slit lamp examination~  2. An end-of-study follow-up phone call."
214307180|NCT03615105|RADIATION|Hyperfractionated total body irradiation|Hyperfractionated TBI is administered by a linear accelerator at a dose rate of \<20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).
214307181|NCT03615105|DRUG|Thiotepa|Thiotepa 5 mg/kg IV
214307182|NCT03615105|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV
214307183|NCT03615105|DRUG|Busulfan|Busulfan (adult/ped dose)
214307184|NCT03615105|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV
214307185|NCT03615105|DRUG|Melphalan|Melphalan 70 mg/m2 IV
214307186|NCT03615105|DRUG|Clofarabine|Clofarabine 20-30 mg/m2 IV
214307187|NCT03615105|PROCEDURE|HPC(A) stem cell allograft|All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.
214307188|NCT03615105|DRUG|Rituximab|Rituximab 200 mg IV flat dose
214915659|NCT00937365|PROCEDURE|Neuroemotional Technique (NET)|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
215060100|NCT03693144|OTHER|Full LIITA3H App|This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
215060101|NCT03693144|OTHER|Partial LIITA3H App|This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
214307189|NCT03615105|DEVICE|Rabbit antithymocyte globulin|Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.
214307190|NCT03253107|DRUG|Chemotherapy|"Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin"
214307191|NCT03465241|DIAGNOSTIC_TEST|the ctDNA dynamic monitoring|To detect ctDNA in patients using the second generation of high-throughput gene sequencing (NGS)
214915660|NCT03938350|BEHAVIORAL|Dialectical Behavior Therapy (DBT) Skills Training|Standard DBT skills training is a comprehensive intervention for emotion dysregulation that includes four skills modules: (1) mindfulness skills; (2) emotion regulation skills; (3) interpersonal effectiveness skills; and (4) distress tolerance skills designed to target adaptive skills deficits that define emotion dysregulation. The sessions will be delivered virtually via a HIPAA-compliant video platform.
215060102|NCT03693144|OTHER|LIITA3H Location only|This is a version of the LIITA3H mobile app that will only track participants' location.
214307192|NCT06872905|DEVICE|GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)|Treatment of Target Lesions with the VBX Device in the aortic and common iliac positions during the CERAB procedure.
214307193|NCT07015281|OTHER|Dry Needling with Percutaneous Electrical Nerve Stimulation (PENS) and Therapeutic Exercises.|Patients assigned to this group (n=50) will receive an intervention in which PENS will be applied for 30 minutes with low frequency parameters (2 Hz) and a pulse width of 120 μs. After 30 minutes of PENS in both groups, the needle will be removed and a compression will be applied for 90 seconds. Once the compression will carried out, the technique will be concluded. Patients will develop a session of PENS and a session with therapeutic exercise once a week.
214915661|NCT02980068|DRUG|15N Nitrate|1,000 mg/11.8 mmol, oral, on day one, hour zero
215060103|NCT02861339|DEVICE|Opthalmologic measure with DM OPD scan III (Nidek)|Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
214307194|NCT07015281|OTHER|Therapeutic Exercise|These participants (n=50) will engage in an exercise protocol with aerobic, isometric, resistence, strength, and stretching exercises. Participants will perform these exercises with a frequency of 3 times a week for 6 weeks, with each session lasting 30 minutes.
214307195|NCT07016620|PROCEDURE|Transperineal Laser Ablation (TPLA)|Outpatient treatment with Transperineal Laser Ablation (TPLA) as a salvage therapy after previous Minimally Invasive Surgical Therapies (MIST)
214307196|NCT03313804|DRUG|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
214915662|NCT02980068|DRUG|14N Nitrate|1,000 mg/11.18 mmol, oral, on day hour, hour zero
214915663|NCT05468684|OTHER|no intervention|there are no interventions planned, we observe the patients in a cohort study which is named inception cohort study because we test participants before the condition develops.
214307197|NCT03313804|RADIATION|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
214307198|NCT06485843|DRUG|OA-SYS|OA-SYS is made of several types of cells obtained from fat tissue for the treatment of osteoarthritis.
214307199|NCT04686435|OTHER|Non-surgical treatment such as physiotherapy, exercise, corticosteroid injection, medication, acupuncture|Treatment consisting of different non-surgical interventions as recommended by the orthopedic specialist and decided upon in shared decision making with the patient
214307200|NCT04686435|PROCEDURE|Surgery|Surgery can consist of rotator cuff repair, Bankart repair, subacromial decompression, biceps tenodesis or tenotomy, acromioclavicular joint resection.
214307201|NCT07020494|DIETARY_SUPPLEMENT|Lipase Thera-blend|Participants will be instructed to consume take one capsule three times a day with food for the duration of the study period.
214307202|NCT07020494|DIETARY_SUPPLEMENT|Lipase Thera-blend + tributyrin|Participants will be instructed to consume take one capsule three times a day with food for the duration of the study period.
214307203|NCT07020494|OTHER|Placebo|Participants will be instructed to consume take one capsule three times a day with food for the duration of the study period.
214307204|NCT05864846|DRUG|Cannabidiol Oral Solution [Epidiolex]|100 mg/ml Cannabidiol Oral solution
214307205|NCT06629259|DRUG|Guanfacine Extended Release (XR)|3mg tablet once daily
214307206|NCT06629259|DRUG|Placebo|placebo tablet once daily
214307207|NCT06872892|DRUG|BI 1291583|BI 1291583
214307208|NCT06872892|DRUG|Placebo matching BI 1291583|Placebo matching BI 1291583
214307209|NCT07022730|DRUG|Noradrenaline 0.2 mcg/kg/min at 5 minutes before induction|noradrenaline will be given at a rate of 0.2 mcg/kg/min that will start 5 minutes before induction
214307210|NCT07021482|DIAGNOSTIC_TEST|10 mmHg Pneumoperitoneum|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 10 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
214307211|NCT07021482|DIAGNOSTIC_TEST|14 mmHg Pneumoperitoneum|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 14 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
214307212|NCT07022600|DEVICE|Diaphragmatic ultrasound|diaphragmatic excursion will be conducted at baseline and at 2 and 24 hours postoperatively
214307213|NCT07024615|DRUG|ASP2138|Subcutaneously
214307214|NCT07024615|DRUG|Oxaliplatin|Injection
214307215|NCT07024615|DRUG|Leucovorin|Injection
214307216|NCT07024615|DRUG|5-FU|Injection
214307217|NCT07024615|DRUG|Irinotecan|Injection
214307218|NCT07024615|DRUG|Gemcitabine|Intravenously
214307219|NCT07024615|DRUG|Nab-paclitaxel|Intravenously
214307220|NCT07024615|DRUG|Capecitabine|Oral
214307221|NCT04383743|DRUG|Cisplatin|Given IV
214307222|NCT04383743|DRUG|Doxorubicin|Given IV
214307223|NCT04383743|DRUG|Methotrexate|Given IV
214307224|NCT04383743|BIOLOGICAL|Pegfilgrastim|Given SC
214307225|NCT04383743|BIOLOGICAL|Pembrolizumab|Given IV
214307226|NCT04383743|PROCEDURE|Radical Cystectomy|Undergo standard of care radical cystectomy
214307227|NCT04383743|DRUG|Vinblastine Sulfate|Given IV
214307228|NCT06692036|OTHER|Adaptive Blood Purification (ABP)|Patients in the intervention group, based on standard treatment, received two 6-hour adaptive blood purification (ABP) treatments within 24 hours after enrollment, that is, patients did not indicate renal replacement therapy (RRT), only coupled plasma filtration-adsorption (PFAD) therapy is used to adsorb inflammatory factors; for patients with acute kidney injury (AKI) and meeting RRT indications, PFAD-RRT treatment is used.
214307229|NCT05926011|DEVICE|RGn600|RGn600 with a 10 Hz-pulsed wave mode light emission
214307230|NCT05926011|DEVICE|RGn600 Sham|RGn600 inactivated
214307231|NCT06271967|DEVICE|TactiFlex™ Ablation Catheter Sensor Enabled™|Pulsed field ablation (PFA)/radiofrequency (RF) ablation with the TactiFlex™ Ablation Catheter Sensor Enabled™
214307232|NCT06704347|BIOLOGICAL|XT-150|XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).
214307233|NCT06599580|BEHAVIORAL|Training caregivers to screen children for malnutrition relapse|Caregivers enrolled in the trial who are assigned to the two experimental arms, will be provided mid-upper arm circumference tapes and trained on how to screen their child for malnutrition relapse and asked to bring their child back to the clinic if relapse is detected.
214307234|NCT06599580|OTHER|Reduced follow-up schedule|Caregivers in one of the caregiver mid-upper arm circumference screening arms, will be asked to adhere to a reduced follow-up clinic visit schedule for when they bring their child to the clinic for planned visits. The standard of care includes monthly visits for the first 3 months post recovery, but those randomized to the reduced follow-up schedule arm, will not bring their child to the clinic for planned visits 1 month and 2 months after baseline.
215060104|NCT01603225|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
214307235|NCT04837131|DRUG|Ixazomib|Ixazomib 4 mg capsule taken orally on days 1, 8, and 15 of a 28-day treatment cycle repeated for 6 cycles
214307236|NCT04292288|DIAGNOSTIC_TEST|Biochemical observational|no intervention - observational
214307237|NCT06887231|OTHER|VR+TENS|Patients will perform task-oriented movements in an immersive scenario while receiving congruent electrical stimulation. During each session, multiple games will be played, with the type and difficulty calibrated based on the patient's level of impairment.
214307238|NCT06887231|OTHER|Conventional rehabilitation|Patients will perform dose-matched conventional rehabilitation (aligned with the intervention group), which will include physiotherapy, occupational therapy, and physical therapy.
214307239|NCT01275495|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK II)|
214307240|NCT01275495|BEHAVIORAL|Information, Support, and Referral (ISR)|
214307241|NCT03442738|PROCEDURE|Endocuff group|Endocuff Vision cap on Standard colonoscope
214307242|NCT06894225|DRUG|ACT001|Patients recruited and have signed informed consent will be initiated on ACT001 400mg twice a day. Treatment course will repeat every 28 days in the absence of disease progression or unacceptable toxicity
214480271|NCT06157411|BEHAVIORAL|Mindful Eating Intervention (AC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Mindful eating program: group sessions one evening a week (8x2h) and home exercises (30 min/day).~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1~Focus groups: Each participant will be asked to describe the program and talk about their perceptions and feelings, as well as the potential changes in behavior they have observed in their daily life."
214480272|NCT06157411|BEHAVIORAL|Conventional Dietetic Intervention (DC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1"
214480273|NCT05567978|PROCEDURE|pupillometry index|Admission to the intensive care unit, measurement of pupillometry index every 4 hours for 7 days or at extubation of brain damaged patients
214480274|NCT04369911|PROCEDURE|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
214480275|NCT06814951|PROCEDURE|TAR Method|Patients selected for the intervention group will undergo thoracoabdominal rebalancing management such as abdominal supports and/or in the ileocostal space, inspiratory assistance, release of the shoulder girdle, thoracic balance, release of the pectoralis major and deltoid muscles together with aspiration if necessary.
214480276|NCT06814951|PROCEDURE|Conventional physiotherapy|Patients selected for the control group (conventional physiotherapy) will be exposed to respiratory physiotherapy techniques such as vibrocompression, manual passive expiratory therapy, acceleration of expiratory flow, fractional inspiration in times, diaphragmatic breaths and aspiration when necessary.
214307243|NCT04369846|DRUG|GM-XANTHO onitment|Onitment application
214480277|NCT03782818|DRUG|Olaparib|Olaparib up to 300 mg BID for 24 weeks
214480278|NCT00194298|PROCEDURE|FDG-PET Imaging|
214480279|NCT05210374|DRUG|Disulfiram|"To be taken orally (PO) daily in the AM, rounded for pill size (max 480mg/day).~To be administered day 1-7 of lead-in week and day 1-28 cycles~Cycle length: 28 days,~maximum 12 cycles Level -1 (150mg/m\^2/day) Level~0 (225mg/m\^2/day) Level 1 (300mg/m\^2/day), max~480mg/day"
214480280|NCT05210374|DRUG|Copper Gluconate|"To be taken orally (PO), 5.2mg/m2/day daily in the PM, rounded~for pill size (max 9mg/day) To be administered day 1-7~Lead-in week and day 1-28 cycles Cycle length: 28~days, maximum 12 cycles"
214480281|NCT05210374|DRUG|Liposomal Doxorubicin (Doxil)|"To be given IV, 30mg/m2/dose~To be administered day 1 of cycles~Cycle length: 28 days, maximum 12 cycles"
214480282|NCT03971955|OTHER|Mixed Meal Test|a standard liquid mixed meal will be administered to the participant. The test meal with 1 kcal/ml and with the following caloric distribution Protein: 25%, Carbohydrate: 53%, Fat: 22% is given at a dose of 6 mL per kilogram body weight. Maximum dose is 360 mL and it will be ingested over 5 minutes. Blood samples will be taken 10 min prior to ingestion (t=-10), at baseline (t = 0), and at 15, 30, 60, 90, and 120 minutes.
214480283|NCT03971955|OTHER|Dual Energy X-Ray Absorptiometry (DEXA)|DEXA Scans will be performed to obtain body composition measures (body fat and estimated muscle mass) using a General Electric (GE) Lunar iDXA whole-body scanner.
214915664|NCT02588768|DEVICE|Photobiomodulation therapy (Phototherapy)|PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
214915665|NCT03935139|BIOLOGICAL|glucose measurement|Glucose values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
214480284|NCT03971955|PROCEDURE|Adipose Tissue Biopsy|The abdominal skin 6-10 cm lateral to the umbilicus will be cleansed with chlorhexidine. A sterile drape is placed, and the skin and adipose tissue will be anesthetized using Lidocaine. A 3-4 mm Mercedes Liposuction cannula will be inserted for aspiration of up to 2g of adipose tissue.
214480285|NCT05636085|DEVICE|Mainz Biomed Colorectal Cancer Screening Test|There is no intervention.
214480286|NCT05451693|BEHAVIORAL|Outreach-ER|The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
214915666|NCT03935139|BIOLOGICAL|lactacte measurement|Lactate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
214915667|NCT03935139|BIOLOGICAL|pyruvate measurement|pyruvate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
214307244|NCT04369846|DRUG|Placebo onitment|Onitment application
214307245|NCT06788028|BEHAVIORAL|Usual Care|All participants receive the usual care via standard mental health services offered by the NMHC to the public free of charge. Participants will have access to these public services regardless of whether or not they choose to participate in this study. If they refuse to participate in the research study, they will still have access to usual care.
214307246|NCT06788028|BEHAVIORAL|Family Strengthening|Families will engage in 12 weekly (1-1.5 hours) of family strengthening sessions, led by trained facilitators from the Research and Education Center. Groups will be composed of approximately 5 caregiver-child dyads. Sessions are designed to improve family functioning, strengthen child-parent relationships, enhance parenting strategies, and prevent emotional and behavioral problems among at-risk children.
214307247|NCT06788028|BEHAVIORAL|Mental Health Screening, Referral and Connection to Services|Children will receive 12 sessions of individual mental health services. Clinicians are trained in the Attachment, Regulation, and Competency (ARC) framework. Services include a clinical assessment performed by a psychiatrist, development of an individual care plan, and corresponding mental health services, informed by ARC.
214307248|NCT06788028|OTHER|Economic Empowerment|Child Development Accounts (CDAs) will be opened to facilitate family savings. The project will provide $50 as seed money to open a savings account in the child's name. Savings of up to $20 per month will be matched with study funds at a rate of 2:1 and placed in the CDA account. Caregivers and children will also engage in 12 weekly (1-1.5 hours) of financial education sessions, led by facilitators from the Research and Education Center.
214307249|NCT03283449|DRUG|18F-AV-1451|
214307250|NCT03283449|DEVICE|PET|PET scanner for brain imaging
214307251|NCT06887049|BEHAVIORAL|ARISE Learning Community Diabetes Distress Screening and Intervention|In-depth training for frontline community health center staff on ARISE algorithm to screen for degree of diabetes distress using T2-DDAS Core. If positive, screen for sources of diabetes distress using T2-DDAS Sources. Discuss results with patient and make any relevant referrals.
214307252|NCT06887049|BEHAVIORAL|ARISE Enhanced Care brief training|Brief training on American Diabetes Association guidelines for screening for diabetes distress using the 7A's model
214307253|NCT06633016|DRUG|ABX-002|ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
214307254|NCT06633016|OTHER|Placebo|Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
214307255|NCT06902454|DEVICE|densah drill technique|ten patients with maxillary sinus pneumatization will be undergo sinus floor elevation using densah drill technique with implant placement
214307256|NCT06903845|PROCEDURE|video call|Conduct video training every two weeks emphasizing medication adherence.
214307257|NCT06903845|DEVICE|Medication reminder app|Medication reminder app will remind patients to take your medication.
214307258|NCT03482791|RADIATION|Proton beam therapy|"* The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~* The Mevion S-250 Proton Radiation Beam Therapy System will be used."
214307259|NCT03482791|OTHER|Patient-Reported Outcome Measures|-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation
214307260|NCT06631846|OTHER|Music therapy|"Participants in the music therapy group (MTG) will be comfortably lying on the bed in a reclined position of 30-45 degrees. Using a headphone, participants will be instructed to select a volume that is comfortable to their ears and listen to the music titled as The Best Relaxing Piano and Flute Music Ever which will be played for 30-minutes every day for 1-week. Patients will be encouraged to focus on the music and let it fill their senses."
214307261|NCT06631846|OTHER|Mindfulness meditation|Mindfulness meditation group (MGT)will be listening to audio of Guided Mindfulness Meditation Series 1 by Jon Kabat-Zinn. Similar to MTG, participants in MMG will be lying on the bed in a reclined position of 30-45 degrees. A headphone to listen to the audio of guided MM will be provided to all the participants. Participants will begin with relaxation technique by focusing on deep breathing to help calm their body and mind. This will be followed by focusing on the present moment, letting go of any thoughts or distractions that come up. Participants can focus on their breath, bodily sensations, or a specific object in their environment. Finally, the session will end by expressing a gratitude for their body and mind and setting an intention to carry the feelings of relaxation and mindfulness with them throughout the day. Similar to MTG, MMG will engage in 30-minutes of MM every day for 1-week.
214307262|NCT06631846|OTHER|Music therapy and mindfulness meditation|Music therapy and mindfulness meditation group will be receiving both music therapy and mindfulness meditation in the same body position as MTG and MMG. Firstly, participants will listen to MT for 30-minutes followed by MM for another 30-minutes. In between the 2 interventions, a 15-minute of break will be provided to all participants. Intervention will be carried out every day for 1-week.
214307263|NCT06631846|OTHER|Cardiac rehabilitation|Control Group will not receive any other therapy except the conventional post-operative cardiac rehabilitation. Other 3 intervention groups will also be participating in the usual cardiac rehabilitation program. Cardiac rehabilitation will be conducted during phase I, where rehabilitation will focus on early mobilization and ambulation of participants with a target heart rate of resting heart rate + 30 beats, with the non-strenuous exercises in the bed or at the bedside, focusing on a range of motion and limiting hospital deconditioning.
214307264|NCT06908616|DIAGNOSTIC_TEST|Cord blood|Cord blood samples will be collected during routine G6PD testing. An additional 3 mL will be obtained non-invasively from the umbilical cord to determine the expression of Duffy antigens using serologic gel testing.
214307265|NCT06907186|OTHER|Psychological Support|Carrying out a systematic and organized path of psychological support interviews on a monthly basis in person or remotely.
214307266|NCT04246333|OTHER|Mode of Delivery of Feeds|Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
215060105|NCT02311881|DRUG|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
215060106|NCT02311881|DRUG|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
214307267|NCT06909968|OTHER|palliative care|"As this study is intended to be observational (not interventional), the patient's medical record will be the source of all data to be recorded.~No additional procedures/patient visits should be planned in the study with respect to clinical practice.~Two tools will be used to to analyze appropriateness and timeliness of progressive palliative care approach: NECPAL CCOMS-ICO(©), specific for the assessment of needs in palliative care, and the PaP score, for the assessment of prognosis."
214307268|NCT06911034|DRUG|Iron Carboxymaltose|In ferrous carboxymaltose treatment maximum dose per sitting was 1000 mg, diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.
214307269|NCT06911034|DRUG|Iron Sucrose Injection|Iron sucrose infusion was administered as 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.
214307270|NCT06906965|OTHER|Carob beverage|The participants consumed a carob beverage made with 30gr of Imera carob cultivar powder in water
214307271|NCT06906965|OTHER|Sucrose beverage|The participants consumed a sucrose beverage made with 14gr of sugar in alike concentration with sugars in the experimental beverage
214307272|NCT03089801|OTHER|Tablet-Enabled Video Telehealth|Veterans referred for tablet-enabled video telehealth will receive a VA-issued tablet that can be used to communicate via video with health care providers (e.g., for chronic disease management, mental health treatment, palliative care).
214307273|NCT06913673|OTHER|Bio-c Temp|Intra-canal medication
214307274|NCT06913673|OTHER|Metapex|Intra-canal medication
214307275|NCT06913426|COMBINATION_PRODUCT|Pelvic Tilt, Hip and Knee Focused Exercises (Intervention Group)|The treatment program is between one to six weeks with strictly 18 sessions with at least thrice in a week to give room to recuperate from muscle fatigue. This protocol is set in a 45 minutes session that involves a series of exercises and stretches. The quadriceps muscles strengthening exercises, hamstring and the calf raising workouts such as the hamstring curls and heel raise are done in 3 sets of 10-15 reps. Patellofemoral joint mobilization which should not last more than 2-3 minutes due to possible patient discomfort is performed and its primary goal is increasing joint mobility. After that the patient is to perform exercises for pelvic tilt in three approaches, each made in 10 to 15 repetitions.
214307276|NCT06913426|DIAGNOSTIC_TEST|Hip and Knee Focused Exercises(Control Group)|The treatment program covers a time frame of one to six weeks, three sessions a week, total of 18 sessions, over six weeks. Each session takes 45 minutes and contains a schedule of activities. The quadriceps muscles strengthening exercises, hamstring and the calf raising workouts such as the hamstring curls and heel raise are done in 3 sets of 10-15 reps. Patellofemoral joint mobilization which should not last more than 2-3 minutes due to possible patient discomfort is performed and its primary goal is increasing joint mobility. Then Patient performs hip exercises; hip abductor as well as hip extension, which are done in three sets of 10 to 15 repetitions each. Likewise, the knee-focused workouts such as quad sets, straight leg raises and step-up are conducted in the same 3 sets of 10-15 repetitions style. Static flexibility exercises includes Hip Flexor Stretch, IT Band Stretch and these exercises are performed with 5 sets of 30 seconds.
214307277|NCT06912594|DEVICE|PCOS-App|The PCOS-App helps to implement multimodal self-help measures in the daily lives of PCOS patients through various functions such as symptom diary and interactive exercises.
214307278|NCT06914076|COMBINATION_PRODUCT|Structured Psychosocial Counseling|"Group A (Experimental Group):~Participants in the Experimental group will be divided into groups with the persons having visual acuity 6/60, counting fingers and light perception will receive low vision aids etc and structured psychosocial counseling tailored for individuals with low vision. Counseling will be delivered over a 12-week period, consisting of weekly 60-minute sessions conducted by trained counselors. The program will focus on the following:~Coping mechanisms for depression and anxiety. Strategies to improve functional independence and daily living skills. Social integration techniques to enhance participation in community activities. Low visions aids under supervision of low vision specialist."
214307279|NCT06914076|DIAGNOSTIC_TEST|Standard Care|Group B (Control Group): The control group will continue receiving standard care, including referrals and informational support.
214307280|NCT06913504|DIAGNOSTIC_TEST|Blue cut filter|Group 1 will be prescribe with blue cut filter feature
214307281|NCT06913504|DIAGNOSTIC_TEST|blue cut glasses|Group 2 will be prescribed with blue cut glasses
214307282|NCT06914310|DRUG|Memantine|Memantine will be given either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital and then continued for 3 weeks. The memantine dose in the first 7 days is 30 mg twice daily, while during the remaining 3 weeks the dose is 10 mg twice daily
214480287|NCT01286766|DRUG|DCS (docetaxel with cisplatin with TS-1)|"1. S-1: 70 mg/m2 #2 bid PO, D1-14~2. Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~3. Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks."
214480288|NCT01286766|DRUG|DCF (docetaxel with cisplatin with 5-FU)|"1. 5-FU: 1,000 mg/m2 CI, D1-3~2. Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~3. Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~   * Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~  * treatment is repeated until 4 cycles"
214480289|NCT06605001|OTHER|Delay of Gratification|Children will complete a delay of gratification task with 1 of 2 rewards
214480290|NCT06607913|OTHER|Exercise|The participants will exercise 2 days a week for 16 weeks. The exercises will include 4 movements: squats, shoulder press, seated row, and bicep curl focusing on internal load and contraction velocity.
214915668|NCT03935139|BIOLOGICAL|glycerol measurement|glycerol values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
214915669|NCT03935139|PROCEDURE|Bone free flap monitoring|Bone free flaps will be monitored with a microdialysis catheter directly positioned in bone tissue.
214915670|NCT03808181|DEVICE|ChloraSolv|Weekly application of ChloraSolv for 6 weeks
214915671|NCT03472430|DEVICE|Transcutaneous electrical nerve stimulation|The TENS machine used in the study will be the Endomed 482 that delivers biphasic pulsed currents using pulse duration of 400 µs and pulse frequencies between 80-100 pulses.
214480291|NCT04905914|DRUG|ATRN-119|ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
214480292|NCT02044484|BEHAVIORAL|Multi-component intervention|"The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.~Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.~The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.~At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex."
214480293|NCT06164106|BEHAVIORAL|Virtual Crisis Response Planning|Individuals complete a chat-based experimental collaborative suicide intervention virtually.
214480294|NCT06164106|BEHAVIORAL|In-Person Crisis Response Planning|Individuals complete a collaborative suicide intervention in-person.
214480295|NCT06164106|BEHAVIORAL|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
214480296|NCT03662022|DRUG|Rifampicin|Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
214480297|NCT06650475|PROCEDURE|Using low or standart pressure|Written consent will be obtained before the randomized study. Randomization will be done on the computer using a software program. Participants will be divided into two groups. Patients in Group S will undergo laparoscopy under standard pressures (12-16 mmHg) in laparoscopic surgery, while patients in Group L will undergo laparoscopy under low pressure (8-10 mm Hg).
214915672|NCT03472430|DEVICE|TENS machine with electrodes not emitting any impulses.|TENS machine with electrodes not emitting any impulses.
214915673|NCT06710353|DRUG|Albumin solution|"A 20% albumin solution is administered over one hour starting from the induction of anesthesia, using the following formula:~(4.0-preoperative serum albumin (g/dL))×plasma volume (kg×0.65-0.8 dL)"
214480298|NCT06650163|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
214915674|NCT06710353|DRUG|Crystalloid solutions|The same volume of crystalloid solution as the administered albumin is infused.
214915675|NCT01099618|DRUG|metformin|The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
214915676|NCT01099618|DRUG|placebo|The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
214915677|NCT01099618|DRUG|Sitagliptin|The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
215060107|NCT02311881|DRUG|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
215060108|NCT02178319|PROCEDURE|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
215060109|NCT02178319|PROCEDURE|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
215060110|NCT04318054|OTHER|Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
214480299|NCT06650163|PROCEDURE|Brain Surgery|Undergo brain surgery
214480300|NCT06650163|OTHER|Electronic Health Record Review|Ancillary studies
214480301|NCT06650163|PROCEDURE|Immuno-Positron Emission Tomography Scan|Undergo immuno-PET
215060111|NCT00819156|DRUG|degarelix|Degarelix was given as subcutaneous injections.
215060112|NCT05762042|OTHER|dietary supplement|"Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally."
215060113|NCT02130674|DRUG|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
215060114|NCT00790582|DRUG|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
215060115|NCT01266330|DIETARY_SUPPLEMENT|Low Dairy|Less than 0.5 standard servings of dairy products per day
215060116|NCT01266330|DIETARY_SUPPLEMENT|Adequate Dairy|3.5 standard servings of dairy foods per day
215060117|NCT01582334|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
215060118|NCT04232982|PROCEDURE|Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).|Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.
215060119|NCT04232982|PROCEDURE|G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)|"Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas."
214480302|NCT06650163|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214480303|NCT06650163|PROCEDURE|Stereotactic Biopsy|Undergo stereotactic image-guided biopsy
214670473|NCT04429750|PROCEDURE|Immediate umbilical cord clamping|"In the immediate cord clamping group, the umbilical cord will be clamped within the first 20 seconds after birth and the infant will be transferred to the resuscitation room. The newborn infant will be intubated and mechanically ventilated as quickly as possible on the resuscitation table as recommended in the French Programme National de Soins.~After cardiorespiratory stabilization (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%), the infant will be transferred to the neonatal intensive care unit (NICU). Oxytocin is infused to the mother as recommended in the local protocol (usually just after birth or cord clamping)."
214307283|NCT06914310|DRUG|Mannitol|Mild to moderate TBI patients will receive mannitol in case of brain edema to reduce brain swelling and analgesic for headache such as; acetaminophen.
214307284|NCT06914063|COMBINATION_PRODUCT|Rapid-Onset Cycloplegic Drops|Rapid-Onset Cycloplegic Drops (e.g., tropicamide with phenylephrine) to assess patient comfort, anxiety, and satisfaction with quicker onset and shorter duration.
214307285|NCT06914063|DIAGNOSTIC_TEST|Conventional Cycloplegic Drops|Conventional Cycloplegic Drops (e.g., cyclopentolate) to provide a baseline for comparison with the rapid-onset treatment.
214307286|NCT06914037|DRUG|CHT101|CD70 UCAR-T
214307287|NCT06914219|BEHAVIORAL|Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program|A combined a) screening/diagnosis, b) Cognitive Behavior Therapy +/- pharmacotherapy, and c) interdisciplinary team approach for managing disordered eating in patients post-weight loss surgery.
214307288|NCT06913036|DEVICE|Low-frequency fatigue - Myocene|Low frequency fatigue will be measured using Myocene
214307289|NCT06914388|OTHER|Self-Management Strategies|Stretching exercises, strengthening exercises, massage, relaxing exercises, breathing exercises, patient education
214307290|NCT06912750|OTHER|4-7-8 Breathing Exercise with Teach-Back Method|"In the experimental group, patients will be provided with information regarding the purpose and significance of the 4-7-8 breathing technique using the Teach-Back method one day before surgery. To confirm comprehension, patients will be asked to repeat the information. The exercise will be demonstrated in a one-on-one session using the Teach-Back method, and patients will be guided through practical application. Following the training, patients will be instructed to perform the exercise independently, with the researcher monitoring its correct implementation. Each patient will be given a 4-7-8 Breathing Exercise Application Guide, which outlines the exercise steps based on relevant literature.~Before surgery, patients will complete the Patient Information Form, the Visual Analog Scale (VAS) for pain, the State-Trait Anxiety Inventory (STAI), and the Richards-Campbell Sleep Questionnaire (RCSQ). Postoperatively, the VAS and STAI will be administered both before (pre-test) and after"
214307291|NCT06912815|BIOLOGICAL|ustekinumab and semi enteral nutrition|Preoperative treatment optimization involves a single intravenous induction with UST, followed by 6 weeks of oral/nasal feeding with semi-enteral nutrition.
214307292|NCT06912815|OTHER|Exclusive enteral nutrition|Preoperative optimized treatment with 6 weeks of oral/nasal feeding of exclusive enteral nutrition alone.
214307293|NCT06913309|DEVICE|Bright light therapy（High light intensity）|"In this study, we will utilize the optocoupler-controllable light source, a product jointly developed by the School of Physics at Peking University and Peking University Sixth Hospital, which granted a national patent in China, for the purpose of intervention.~Participants randomly assigned to the high light density intervention group will receive bright white light therapy interventions with light intensities of 10000 lux, and the main wavelength of light source is 476.4nm. The intervention plan is to receive 40 minutes of light therapy from 7:00-9:30 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source."
214307294|NCT06913309|DEVICE|Bright light therapy（Low light intensity）|In this study, we will utilize the optocoupler-controllable light source, a product jointly developed by the School of Physics at Peking University and Peking University Sixth Hospital, which granted a national patent in China, for the purpose of intervention. Participants randomly assigned to the low light density intervention group will receive bright white light therapy interventions with light intensities of 5,000 lux,and the main wavelength of light source is 476.4nm. The intervention plan is to receive 40 minutes of light therapy from 7:00-9:30 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
214307295|NCT06913309|DEVICE|Dim red light placebo-controlled intervention|In this study, participants randomly assigned to the placebo-controlled group will receive dim red light therapy interventions with light intensities of 100 lux, and the main wavelength of light source is 690.4nm. The placebo-controlled intervention plan is to receive 40 minutes of red light therapy from 7:00-9:30 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
215060120|NCT02494635|OTHER|Laboratory Biomarker Analysis|Biomarker analysis
214307296|NCT06914843|BEHAVIORAL|OptimalWork|An online intervention that teaches concepts of cognitive restructuring, mindfulness, and behavioral activation as they apply in one's daily life and work. Users are given personalized content recommendations based on their inventory results and instructed to complete 15-25 minutes of content per day, 5 days/week for 4 weeks. (optimalwork.com)
214307297|NCT06914843|BEHAVIORAL|Podcast Listening|A curated series of podcasts on topics unrelated to cognitive behavioral therapy or mindfulness, modeled after a similar control from a study of a mindfulness based intervention (Basso et al. 2019). Users are instructed to complete one podcast per day on a digital platform (\~15 minutes/day), 5 days/week for 4 weeks.
214307298|NCT06914414|PROCEDURE|Using the flow model in cerebral aneurysm embolization|"Since the 1970s-1980s, surgical techniques for intracranial aneurysms have evolved. In recent years, endovascular embolization of aneurysms has demonstrated a better approach to the pathology, as well as better results in terms of both vital prognosis, but also in terms of quality of life (disability, logical disorders, etc.). However, this treatment modality remains little known to the general public, and generates a high level of anxiety for patients.~The anxiety of these patients could be reduced by the addition of a paramedical consultation and the use of a flow model to explain and visualize the procedure.~The study will include 72 patients per group (i.e. a total of 144 patients, with a 10% loss of blood pressure) to achieve a two-point reduction in the anxiety score measured by the APAIS grid."
215060121|NCT00459641|DRUG|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
215060122|NCT00459641|OTHER|Standard of Care|Bone marrow aspirate or steroids
215060123|NCT04980469|OTHER|Vitex negundo + Zingiber officinale|200 mg/ Capsule
214307299|NCT06913881|DRUG|GLP-1|We will compare people who have picked up GLP1 to those who have picked up insulin at any Swedish pharmacy
214307300|NCT06913543|COMBINATION_PRODUCT|Group 1 (Experimental Group - OKC + NMES)|"OKC Knee Extension Exercises:~Seated Knee Extensions:~Resistance bands or machine, 10-15 reps, 2-3 sets.~Straight Leg Raises:~With or without ankle weights, 12-15 reps, 2-3 sets.~Quadriceps Isometric Holds:~Held for 5-10 seconds, 10 reps, 2-3 sets.~Neuromuscular Electrical Stimulation (NMES):~Electrode Placement:~Over the motor points of the quadriceps.~Frequency:~35-50 Hz.~Pulse Duration:~200 microseconds.~Intensity:~Adjusted for strong yet tolerable contractions.~On-Off Cycle:~10 seconds on, 20 seconds off."
214307301|NCT06913543|DIAGNOSTIC_TEST|Group 2 (Control Group - OKC Only|Open Kinetic Chain Knee Extension Exercises without NMES. Method \& Details: The same OKC exercises as the experimental group but without NMES. All exercises are supervised by trained physiotherapists.
214307302|NCT06914687|DRUG|Tislelizumab|recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip，d1, q3w
214307303|NCT06914687|DRUG|S-1|40\~60mg Bid，d1\~14, q3w
214307304|NCT06914687|DRUG|Oxaliplatin|130mg/m2，iv drip for 2h，d1, q3w
214307305|NCT06914687|DRUG|Docetaxel|Docetaxel at a dose of 20 mg/m2 or paclitaxel at a dose of 40 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)
214307306|NCT06914687|DRUG|Paclitaxel|Paclitaxel at a dose of 40 mg/m2 or docetaxel at a dose of 20 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)
214307307|NCT06914115|COMBINATION_PRODUCT|TANS Group|The TANS Group will receive low-frequency electrical stimulation (20-30 Hz) via a TENS device on the auricular vagus nerve for 30 minutes, 3-4 times per week for 8 weeks. This non-invasive therapy aims to reduce spasticity, enhance neuroplasticity, and improve motor function and independence, assessed through standardized scales.
214307308|NCT06914115|COMBINATION_PRODUCT|Body Rocking Exercise|Group 2: Body Rocking Exercise Group Participants will perform rhythmic body rocking exercises for 20-30 minutes, 3-4 times per week for 8 weeks to reduce spasticity and improve motor coordination. Group 3: Control Group (Usual Rehabilitation) Participants will receive standard stroke rehabilitation (therapy, stretching, functional training) for 20-30 minutes, 3-4 times per week for 8 weeks as a baseline comparison.
214307309|NCT06913647|DRUG|Canagliflozin 300 MG|Canagliflozin 300 mg once daily
214307310|NCT06914427|DIAGNOSTIC_TEST|PET/CT|Scanning time: acquisition starts 60±10 minutes after 68Ga/18F probe injection; 10-20 minutes after 11C-MET injection; 60 minutes after 11C-CFT injection; Scanning parameters: whole-body imaging (cranial vault to mid-thigh), routine single-nuclide 3 min/bed; dual-nuclide 5-10 min/bed.
214307311|NCT06913439|DIAGNOSTIC_TEST|Exercise Group|technique was implemented with three sets of ten repetitions on each treatment occasion for a period of 3 days/ week for 8 weeks. In this group, the adjustable couch was used to treat the patients effectively. During MWM, position of the patients was prone lying and high sitting position with swinging bilateral leg out of the couch at available various range of motion of affected knee joint. In prone lying position, the therapist was stand just behind the patient towards the affected knee joint. The mulligan belt placed at proximal tibia ends which already wrapped with the lower back of the therapist. In high or couch sitting position, the therapist was sitting on rest chair. The method using of mulligan belt was same as in prone lying position. After stabilization, the mobilization with movement (MWM) started in order with the therapist mobilized the knee joint followed by active movement of knee joint performed by the patients
214307312|NCT06913439|COMBINATION_PRODUCT|Parafin Wax Bath|Group B will receive Paraffin Wax Bath Therapy in combination with standard care exercises. In this treatment, the affected knee joint will be immersed in warm paraffin wax to deliver thermotherapy, which helps reduce joint stiffness, improve circulation, and enhance joint mobility. Each paraffin wax session will last 15-20 minutes. Following the thermotherapy, participants will perform standard care exercises targeting knee mobility, flexibility, and strength. These sessions will also occur 3 times per week over a period of 8 weeks.
214307313|NCT06914622|BEHAVIORAL|Mental Health Recovery Star (MHRS)|"The personal recovery-oriented treatment is the Mental Health Recovery Star (MHRS), a recovery-oriented tool developed in England to support and monitor personal recovery. It features a 10-point star representing life dimensions grouped into four areas: health, functioning, self-image, and social networks. Residents assess their progress on each point using a Scale of Change  with five recovery stages, from feeling stuck to self-reliance.~After assessment, residents and professionals set recovery goals (up to three at a time) and create a shared care plan.~The MHRS shows good psychometric properties, with strong validity, consistency, and ease of use, despite some inter-rater reliability issues. It is best suited for shared rehabilitation plans rather than clinical monitoring.~Peer review meetings will be provided. The personal recovery-oriented treatment will last six months and will be considered complete upon follow-up evaluation."
214307314|NCT06914830|OTHER|Musical video demonstration with virtual reality glasses|The research was explained to the patient before the operation. The patient was started to watch a video with music with virtual glasses at the 5th minute of the operation and watched it throughout the operation. Two hours after the surgery, the patient who underwent ureteroscopy completed the Data Collection Form, Surgery Specific Anxiety Scale and Perianesthesia Comfort Scale.
214307315|NCT06913348|PROCEDURE|Popliteal sciatic nerve block|Procedure/Surgery: Patients will receive either an ultrasound-guided sciatic popliteal nerve block or an ultrasound-guided erector spinae plane block for anesthesia during endovascular management of critical lower limb ischemia.
214307316|NCT06914466|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation
214307317|NCT06913257|DEVICE|ESWT Combined with Standard Rehabilitation|Participants in the experimental arm will receive a combination intervention comprising ESWT delivered by certified technicians using a validated device for post-burn scars, along with standard rehabilitation therapy. ESWT sessions will be standardized (e.g., 3,000 pulses per session, weekly for 8 weeks) and will be integrated with a comprehensive rehabilitation program encompassing physical therapy, scar management exercises, and patient education. The specific parameters (e.g., energy level, frequency) will be reported based on established guidelines.
214307318|NCT06913257|BEHAVIORAL|Standard Rehabilitation Therapy Alone|Participants in the control arm will receive the institution's standard rehabilitation therapy for managing post-burn scars, including physical therapy, occupational therapy, and scar-massage techniques. Treatment frequency and duration will mirror the experimental arm's rehabilitation component to ensure consistency. No ESWT will be provided.
214307319|NCT06913582|BEHAVIORAL|Yoga|A 12-week pregnancy yoga program was delivered to experimental group (n=30) including one weekly 60-minute remote online yoga class and followed by 2 times of DVD yoga exercise.
214307320|NCT06912763|DRUG|Pravastatin (drug)|Given PO
214307321|NCT06912763|DRUG|Pentoxifylline|Given PO
214307322|NCT06912763|DRUG|ketoprofen|Given PO
214307323|NCT06912763|DRUG|Pirfenidoneone|Given PO
214307324|NCT06912763|OTHER|Standard of Care (SOC)|SOC
214307325|NCT06912763|DRUG|tocopherol|Given PO
214307326|NCT06913816|DIAGNOSTIC_TEST|Grouyp 1 (without blinking exercises).|Group B (Control Group) The control group will continue receiving only the routine rehabilitation (without blinking exercises). Routine rehabilitation included the 20-20-20 rule, blue light-blocking glasses, and polyvinyl alcohol eye drops.
214480304|NCT06650163|DIAGNOSTIC_TEST|Zirconium Zr 89 Crefmirlimab Berdoxam|Undergo Zirconium Zr 89 Crefmirlimab Berdoxam PET
214307327|NCT06913816|COMBINATION_PRODUCT|EXP group (Routine CVS treatment)|"Group A (Experimental Group): Individuals in the Experimental group will receive Routine CVS treatment with optimized blinking exercise.~Routine rehabilitation includes the 20-20-20 rule, blue light-blocking glasses, and polyvinyl eye drops.~The blinking exercise involved the individuals looking at an object 6 meters away for 5 seconds, followed by complete eyelid closure for 5 seconds. This cycle was repeated for 5 minutes, twice a day."
214307328|NCT06913621|DRUG|amino acid formula|amino acid formula for 6 months
214307329|NCT06913621|DRUG|low bile acid binding blenderized diet|low bile acid binding blenderized diet for 6 months
214307330|NCT06913621|DRUG|high bile acid binding blenderized diet|high bile acid binding blenderized diet for 6 months
214307331|NCT06913296|PROCEDURE|parathyroidectomy|typical open parathyroidectomy
214307332|NCT06913803|DIAGNOSTIC_TEST|Stretching|The group A contains 34 patients and received STM for twice a week for three weeks with each session lasting approximately 20 min.focusing on mobilizing soft tissue to enhance circulation, reduce scar tissue and improve tissue flexibility.
214307333|NCT06913803|COMBINATION_PRODUCT|Soft Tissue Mobilization|Group B received both STM and stretching twice a week for three weeks with each session lasting approximately 20 min.encourage the patient to breathe deeply and slowly to promote relaxation.The stretching of tight muscles 1 set of 10 repetitions hold of 5 second of each exercise,then breathing for 1 min
214307334|NCT06913218|BIOLOGICAL|AK154|AK154 is neotigeon personalized mRNA vaccine
214307335|NCT06913218|BIOLOGICAL|Cadonilimab|a PD-1/CTLA-4 bispecific antibody
214307336|NCT06913218|BIOLOGICAL|Ivonescimab (SMT112 or AK112) Injection|a PD-1/VEGF bi-specific antibody
214307337|NCT06913218|DRUG|mFOLFORINOX|mFOLFIRINOX:Fluorouracil+leucovorin+Irinotecan+Oxaliplatin
214307338|NCT06914674|DRUG|Tamoxifen 20 mg|Tamoxifen: 10 mg orally twice daily. Combination therapy: Chemotherapy, radiotherapy, surgery, or other treatments per NCCN guidelines and patient condition.
214307339|NCT06913751|BEHAVIORAL|standard of care|standard of care therapy with behavioural and occupational therapy along with other pharmacological therapy as required
214307340|NCT06913361|DIAGNOSTIC_TEST|Gongs Mobilization|The treatment begins with moist heat for 10 minutes, Gong's mobilization with conventional therapy for 8 minutes. The total treatment time was 45 minutes once a day for four days per week for four weeks.
214307341|NCT06913361|COMBINATION_PRODUCT|Reverse Distraction Technique|The treatment begins with moist heat for 10 minutes, Reverse Distraction technique with conventional therapy for 8 minutes. The total treatment time was 45 minutes once a day for four days per week for four weeks. Position of the patient: side-lying. The patient is lying at the plinth's edge on the unaffected side. In front of the patient is the therapist's position.
214307342|NCT06913686|BEHAVIORAL|Music intervention|"experimental controlled study will be conducted at the La Marsa tennis club in Tunis, Tunisia, utilizing a rigorous methodology to collect data from competitive young tennis players aged 12-18. This study employs a three-phase design: first, participants' musical preferences are profiled to create personalized music sequences; second, their mental performance is evaluated through pre- and post-intervention questionnaires measuring perception of success, emotional state, emotion regulation, and flow, with a 45-minute training session followed by a music-accompanied exercise; and third, physical performance is assessed using a battery of tests for muscular strength, endurance, agility, and flexibility, conducted both with and without music to determine its impact.~Data collection will be done using a questionnaire that has been developed based on the literature."
214307343|NCT05017506|OTHER|A survey will be made.|A survey will be made.
214480305|NCT06593262|BEHAVIORAL|app-based digital cognitive behavioral therapy for insomnia with AI chatbot|digital cognitive behavioral therapy for insomnia with two-way interactive, intelligent, and patient-centered conversational agents
214480306|NCT06593262|BEHAVIORAL|app-based digital cognitive behavioral therapy for insomnia without AI chatbot|digital cognitive behavioral therapy for insomnia without two-way interactive, intelligent, and patient-centered conversational agents
214307344|NCT02921009|DEVICE|Crosslinking using UV light of two different fluence rates|The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
214480307|NCT06601452|DRUG|a compound prescription of Chinese medicine|The enrolled patients were treated with 3 cycles of sequential treatment with Nourishing Yin and Replenishing Yang formula before entering the cycle (Tuning Weekly Nourishing Yin Granules + Tuning Weekly Replenishing Yang Granules), and the egg retrieval cycle used an antagonist regimen to obtain the eggs.
214480308|NCT06862726|DRUG|Anti Xa dosage|VKA: quadriseparable tablet Apixaban: 5 mg twice daily or 2.5 twice daily Rivaroxaban: 20 mg once a day or 15 mg once a day
214480309|NCT06862726|DRUG|Dosage of PT-INR|This arm contain 40 pateints treated by VKA,. PT-INR dosage will be performed.
214480310|NCT06599190|OTHER|pelvic floor exercises, nutritional instructions|They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.
214480311|NCT06599190|OTHER|abdominal hypopressive exercises, pelvic floor exercises, nutritional instructions|consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months.
214480312|NCT06862427|BEHAVIORAL|Healthy Lifestyle Application (Traditional Chinese Version)|A firefighter-oriented Healthy Lifestyle Application (Traditional Chinese Version)
214480313|NCT06593457|DRUG|IP|NX-5948 oral
214480314|NCT06593457|DRUG|Matching Placebo|Fluconazole
214307345|NCT06913049|OTHER|Social Engagement Support System|In this protocol, we will develop and deploy a set of machine learning models that use multiple individual- and community-level data sources to predict which members use the emergency department to fulfill social or non-urgent needs as opposed to treatment for urgent medical conditions. These models will identify individuals whose social needs are driving inappropriate utilization so that high-risk individuals will be given enhanced outreach services to facilitate completion of a comprehensive social needs assessment. We will also develop and deploy an engagement support system that identifies and displays the characteristics of members that prevent them from engaging with a Community Based Organization (CBO). This system will use artificial intelligence techniques to identify characteristics of individuals who have historically disengaged from the social service pipeline before receiving social services and suggest potential strategies for increasing engagement.
214307346|NCT01239368|PROCEDURE|Adoptive Immunotherapy|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
214307347|NCT01239368|BIOLOGICAL|Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)|Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
214307348|NCT01239368|BIOLOGICAL|Th1/Tc1 Rapa Cell Therapy|Th1/Tc1Rapa: 5 x 10e(6) cells/kg
214307349|NCT04790682|BIOLOGICAL|assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.|"* At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~* Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~* Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood)."
214307350|NCT05904665|DIAGNOSTIC_TEST|ctDNA methylation dynamic monitoring|ctDNA methylation detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years.
214307351|NCT04269759|OTHER|Survey|pregnant women will answer to a survey regarding their oral health knowledge, attitudes and practices for themselves and their unborn child
214307352|NCT04269759|OTHER|dental care|pregnant women will have a dental care
214307353|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
214480315|NCT06861465|BEHAVIORAL|Online Mind-Body Wellness Program|Online program (mindful movement, meditation, breathwork)
214480316|NCT06861465|BEHAVIORAL|Online Mind-Body Wellness Program + Nutritional Counselling|Online program (mindful movement, meditation, breathwork) + nutrition counselling
214480317|NCT06860672|GENETIC|Dual vector DNA base editor|The base editor is delivered using a dual vector adeno-associated virus (AAV) system and introduced into the child via intrathecal injection to correct the mutated CHD3 gene. The vital signs of the child will be closely monitored during treatment to assess possible acute adverse effects. The child will be followed up regularly after treatment to monitor the success of gene editing and the neurodevelopmental improvement of the child. Possible long-term adverse events will be closely monitored to assess the safety of the treatment.
214670474|NCT04429750|PROCEDURE|intact cord resuscitation|The umbilical cord will be kept intact during the initial phase of the resuscitation. The infant will be placed on a specifically designed compact trolley with a warmed platform, suitable for commencing resuscitation between the mother's legs in case of vaginal birth or near the operating table beside the mother in case of cesarean section. This trolley will be fully equipped for resuscitation, including a suction device, gas flowmeter/blender, ventilatory support, and monitoring system. Its height can be adjusted in order to position the infant close to the maternal perineum. The infant will be intubated and mechanically ventilated on this trolley. The cord will be clamped once cardiorespiratory stabilization will be obtained (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%) or in case of spontaneous placental expulsion. The infant will be then transferred to the neonatal intensive care unit (NICU).
214670475|NCT01736683|DRUG|Sotatercept|Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
214670476|NCT04632849|BEHAVIORAL|GEM + CGM|Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
214670477|NCT04229147|RADIATION|Radiotherapy|Patients who received a total dose of 30 Gy
214480318|NCT06588907|DRUG|Bupivacaine Hydrochloride|After preparing the infraclavicular block site, a 22-gauge needle, guided by ultrasound, will be placed in the 6-7 o'clock position in the same plane as the ultrasound probe. Subsequently, lateral, medial, and posterior cords described as hypoechoic nerve fascicles within hyperechoic structures will be identified. Initially, 2 mL of saline will be administered to confirm proper spread. Once confirmed, 20 mL of 0.25% bupivacaine (prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline) will be injected in fractional doses with intermittent negative aspiration. Fifteen minutes after this procedure, anesthesia depth will be assessed using a cold-hot test, followed by reduction and application of the cast.
214915678|NCT05691582|DEVICE|GRAIL|"The subjects experiment GRAIL virtual reality for three days, during which they deal with 4 different activities.~In the first activity subjects are required to ask over the treadmill in a snow environment.~in the second they are required to stand over the moving platform in a simulation of a boat pitch.~in the third they have to walk over a bridge with a slope. in the fourth the subjects are required to try so interact with virtual reality and to ski between snowman.~if it is possible, on the last day a gait analysis is executed"
214307354|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
214307355|NCT05375968|DRUG|Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
214307356|NCT05375968|DRUG|Compare change is SVC and SMA flow due to saline|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
214307357|NCT06456593|DRUG|Obefazimod|Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).
214307358|NCT06456593|OTHER|Placebo|Matching placebo will be administered QD in fed condition (ideally at the same time in the morning).
214307359|NCT04774523|PROCEDURE|Echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.|"Patients in the AutoAdapt group undergo the echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.~Three steps must be followed:~1. Standard AV programming: perform echo for AoVTI assessment.~2. Echo-optimized AV programming: perform standard echo-based AV-optimization (Ritter method or iterative method, according to routine at investigational site); measure AoVTI at optimized setting.~3. AutoAdapt optimized programming: The system allows different programming options for the parameter 'Adaptive AV reduction'. The nominal value is 0.7, but it can be modified to different values ranging from 0.5 to 0.9. The AoVTI shall be measured at standard setting of the Adaptive Av reduction parameter, 0.7."
214307360|NCT04774523|PROCEDURE|Echocardiography AV optimization|Patient in the control group undergo the routine echo-based AV-optimization that is usually performed at the investigational site (Ritter method or iterative method). Performance of an additional VV-delay optimization is left to the investigator discretion
214307361|NCT04774523|PROCEDURE|Echocardiography|Echocardiography must be performed at baseline and 12 month Follow Up to collect the LVEF/LVESD(V)/LVEDD(V)
214307362|NCT04774523|OTHER|Self Assessment Score|Patient must complete the self assessment score at 6 and 12 month Follow Up, that will be use for the Packer Clinical Composite Score
214307363|NCT06174805|DEVICE|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm
214307364|NCT04216719|BEHAVIORAL|OCM-RISE|OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
214307365|NCT05686317|DEVICE|Edwards APTURE transcatheter shunt system|Treatment with APTURE shunt
214307366|NCT05686317|DIAGNOSTIC_TEST|Sham procedure|CS angiography
214915679|NCT03464331|BEHAVIORAL|Zero-time exercises|The Investigators/research staff (RS) will help EXP download, operate the Zero-time exercises (ZTE) app and ZTE e-diary. The EXP can enter their goal for the chosen exercise by setting the target duration or number of completed repetitions, review their previous record, and compare their exercise frequency and time ranking with those of the other EXP. After the EXP uploads the goal and results to the ZTE e-diary, the data will be automatically sent to the ZTE app database for data analysis. The EXP will be given a paper diary to record their Zero-time exercises (ZTE). Twenty-five EXP will be given activity trackers (e.g. Fitbit) to record their steps/motion throughout the 3 months.
214307367|NCT01284725|DRUG|mycophenolate mofetil or azathioprine|
214307368|NCT01284725|OTHER|immunosuppressive treatment discontinuation|
214307369|NCT05872620|DRUG|Orforglipron|Administered orally
214307370|NCT05872620|DRUG|Placebo|Administered orally
214480319|NCT06588907|DRUG|Ketamine|Until the recovery period, patients will be closely monitored by an experienced doctor or nurse during sedation. Emergency equipment will be readily available in case of any complications. The following protocol will be used for procedural sedation-analgesia (PSA): Ketamine will be administered intravenously at a dose of 0.5-1 mg/kg. Patients with Numeric Rating Scale (NRS) scores above 5 may receive additional doses of 0.25-1 mg/kg, repeated every 5 to 10 minutes as needed.
214670478|NCT05842798|DRUG|TNM002|TNM002, intramuscular injection
215060124|NCT04980469|OTHER|Placebo (MCC)|200 mg/ Capsule
214670479|NCT05842798|DRUG|Placebo|Placebo, intramuscular injection
214915680|NCT03464331|BEHAVIORAL|relaxation exercises and deep-breathing exercises|The Investigators/RS will teach the CON group (CON) to do relaxation exercises (RE) and deep-breathing exercises (DBE) for at least 30 mins every day. They will be helped download and use the electronic diary (CON\_e-diary) to record their RE and DBE. The CON will also be given a paper diary to record RE and DBE they have done if they prefer to use paper diary.
214915681|NCT05547139|OTHER|Protocolized weaning of respiratory support|The protocolized weaning aims to keep babies on CPAP for a longer period of time and will measure how long it takes babies to wean to 2L nasal cannula support or come off all support (room air, RA).
214307371|NCT05802004|DEVICE|Acoustic Stimulation (STIM)|During the in-lab overnight, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
214307372|NCT05802004|DEVICE|No Acoustic Stimulation (SHAM)|During the in-lab overnight, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
214307373|NCT05802004|DEVICE|Daily acoustic stimulation (STIM2)|During the \~2 weeks at home, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
214307374|NCT05802004|DEVICE|No daily acoustic stimulation (SHAM2)|During the \~2 weeks at home, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
214307375|NCT03595124|DRUG|Axitinib|Given PO
214307376|NCT03595124|BIOLOGICAL|Nivolumab|Given IV
214307377|NCT02967692|BIOLOGICAL|Spartalizumab|Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks
214307378|NCT02967692|OTHER|Placebo|Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks
214307379|NCT02967692|DRUG|Dabrafenib|Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.
214307380|NCT02967692|DRUG|Trametinib|Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
214307381|NCT05223413|DEVICE|RIPC|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to 200 mmHg to stop blood flow in the arm.
214307382|NCT05223413|DEVICE|Simulated RIPC (Sham)|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to a low pressure not stopping blood flow in the arm.
214480320|NCT06028776|BEHAVIORAL|MS Ballroom Fitness|A personalized dance-based concept focusing on balance, walking capacity, and well-being.
214915682|NCT00631046|DIETARY_SUPPLEMENT|Fish Oil|Daily dosage of 5 ml of fish oils from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
214915683|NCT00631046|DIETARY_SUPPLEMENT|Sunflower Oil|Daily dosage of 5 ml of sunflower oil from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
214915684|NCT05649761|DRUG|QL1604 injection|Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
214915685|NCT06107569|OTHER|Fecal microbiota transplant (Promicrobioma)|Fecal microbiota transplant with Promicrobioma (freeze-dried isolated microbiota)
214915686|NCT06107569|DRUG|Antibiotic|Antibiotics for Clostridioides infection (oral vancomycin) or association of intravenous metronidazol for severe cases.
215060125|NCT04350801|DIAGNOSTIC_TEST|home-based cognitive monitoring|a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0\~30; higher score indicates better cognition)
215060126|NCT00270751|PROCEDURE|1 apical pleurectomy|
215060127|NCT00270751|PROCEDURE|2 pleural abrasion + minocycline pleurodesis|
215060128|NCT05214066|DRUG|Rabbit ATG|ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
215060129|NCT02990975|DRUG|ketamine|
214307383|NCT05828108|DRUG|Bitopertin|Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
215060130|NCT00731861|DRUG|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
214307384|NCT06783881|DRUG|Kylo-12|Administered SC.
214480321|NCT06861842|DRUG|Theralite®|Reference
214480322|NCT06861842|DRUG|Actilitio®|Test
214480323|NCT06862349|DRUG|Group T received propofol at a dose of 2-2.5 mg/kg based on total body weight|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group T received propofol at a dose of 2-2.5 mg/kg based on total body weight. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison.
214670480|NCT05293938|DRUG|Obeticholic Acid 5 MG|once daily, oral administration
214670481|NCT05293938|DRUG|Obeticholic Acid 10 MG|once daily, oral administration
214307385|NCT06783881|DRUG|Placebo|Administered SC.
214915687|NCT01236469|PROCEDURE|Echocardiogram|A prospective follow-up Study Echocardiogram will be performed, as applicable, for those subjects who do not have echo data as of January 1, 2009.
214915688|NCT01452243|DRUG|Vitamin D and calcium suplementation|The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
214915689|NCT00161603|BEHAVIORAL|Semi-structured, open-ended interviews|
214915690|NCT05876806|DRUG|Dabrafenib|Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis
214915691|NCT05876806|DRUG|Trametinib|Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
215060131|NCT02032576|DEVICE|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
215060132|NCT02816268|OTHER|Pulmonary vein isolation|
215060133|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
215060134|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
214915692|NCT00213109|DRUG|Miglitol|
214915693|NCT02254382|DEVICE|Adaptive servo ventilation (ASV)|Non-invasive Ventilation used to control central and obstructive sleep apnea.
214915694|NCT04454255|BEHAVIORAL|FunSpeech|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week) and parent-supervised home use of a serious game. It will be recommended to use FunSpeech every day, 15 minutes per day.
215060135|NCT00099502|DRUG|Copaxone|20 mg administered s.c. once daily.
215060136|NCT04029428|DRUG|90Y-DOTATATE|Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
215060137|NCT04029428|DRUG|(177Lu-DOTAOTyr3)Octreotate|Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
215060138|NCT04029428|DRUG|90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)|Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
215060139|NCT03212508|DEVICE|RAM cannula and Hudson prongs|Measuring intraoral pressure using two different nasal interface for applying nasal continuous positive airway pressure
215060140|NCT05253755|BIOLOGICAL|DBI-001|Topical application of DBI-001 gel on skin affected with atopic dermatitis.
215060141|NCT05253755|BIOLOGICAL|Aqueous gel|Topical application of aqueous gel on skin affected with atopic dermatitis.
215060142|NCT01159678|BEHAVIORAL|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:~1. Important of sexuality to quality of life. \& Definitions of sexual desire and arousal.~2. Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.~3. Sexual beliefs.~4. Mindfulness.~5. Genital anatomy and physiology.~6. Body Image.~7. Relationship satisfaction and communication.~8. Body-oriented mindfulness exercises (focusing and self-observation).~9. Using Thought records.~10. Mindfulness and the thought stream.~11. Sexual aids to boost arousal.~12. Moving on.~In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
215060143|NCT01530503|DRUG|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
215060144|NCT01530503|DRUG|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
215060145|NCT03173989|DEVICE|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
215060146|NCT03173989|BEHAVIORAL|Orientation|Orientation for home.
215060147|NCT04446221|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
215060148|NCT06659848|OTHER|high intensity interval training|The subjects in the four groups performed 12 weeks of supervised HIIE program on a motorized treadmill (h/p/cosmos, Pulsar 4.0, Nussdorf-Traunstein, Germany) with a rate of three sessions weekly. The session commenced with a 5 min warming-up and concluded with a 5 min cooling down period. The exercise effort component consisted of 5 intervals of HIIT. Each interval continues for four min of HIIT with exercise intensity ranging from 75% to 90% of the peak heart rate. Each active recovery period between exercise intervals included moderate exercise at intensity of 50% to 60% of the peak heart rate. Every 3 weeks, the exercise intensity was increased by 5% starting with 75% of the HRmax in the first 3 weeks, 80% in the following 3 weeks and progressed to 90% the HRmax in the last 3 weeks. The subject's heart rate throughout the HIIT session was monitored using a polar heart rate monitor (Polar, Kempele, Finland).
215060149|NCT05356273|PROCEDURE|Baby massage|Starting from the baby's face first, then the abdomen and chest, back, upper extremities and finally the lower extremities were massaged with semi-circular movements, respectively.
215060150|NCT02781961|OTHER|cellvizio|pCLE during gastroscopy
214307386|NCT06190951|DRUG|cemiplimab|Administered per the protocol
214307387|NCT06190951|DRUG|Fixed Dose Combination (FDC) cemiplimab+fianlimab|Or coadministration, depending on availability.
214307388|NCT06190951|DRUG|Placebo|Administered per the protocol
214307389|NCT05311488|DIAGNOSTIC_TEST|neurofilament light chain|Blood test
214307390|NCT05311488|DIAGNOSTIC_TEST|In-vivo Meissner Corpuscle imaging|Imaging
214307391|NCT05311488|DIAGNOSTIC_TEST|Nerve conduction study|Nerve conduction study
214915695|NCT04454255|BEHAVIORAL|Control|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week).
214670482|NCT05293938|DRUG|Standard of Care: UDCA|No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
214670483|NCT03918993|DRUG|Tadalafil 5mg tablet|Once-a-day 5 mg dose of tadalafil for 8 weeks
214670484|NCT05518786|OTHER|Exposure of interest: critical illness|Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae
214670485|NCT05060042|OTHER|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week
214915696|NCT03564119|DRUG|S5G4T-1|Once a day topical cream
214915697|NCT03564119|DRUG|S5G4T-2|Once a day topical cream
214915698|NCT00508599|OTHER|Study 2 (48 hours of complete bed rest)|Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
214915699|NCT00634036|DRUG|pioglitazone|pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
214915700|NCT00634036|DRUG|placebo|matching placebo (inert tablet)
214915701|NCT01946828|DEVICE|FIM|Field Induced Mydriasis device
214915702|NCT02431611|BEHAVIORAL|Biomarker feedback (phone based smoking cessation counseling)|Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
214915703|NCT02431611|BEHAVIORAL|Control condition (phone based smoking cessation counseling)|phone-based behavioral smoking cessation counseling
214915704|NCT04573322|DRUG|Trans Sodium Crocetinate|TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days
214915705|NCT04573322|DRUG|Normal saline|Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
214915706|NCT02811965|OTHER|Pillow Condition 1|The heel is offloaded by placing the heel on a standard hospital pillow.
214915707|NCT02811965|OTHER|Pillow Condition 2|The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
214915708|NCT02811965|DEVICE|Heel Foam Pillow|An economy heel offloading device constructed of egg shell foam.
214915709|NCT02811965|DEVICE|Offloading Device A|Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
214915710|NCT02811965|DEVICE|Offloading Device B|Heel offloading device that utilizes pressure absorbing filling to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate
214915711|NCT02811965|DEVICE|Offloading Device C|Heel offloading device that utilizes a similar pressure absorbing filling to Offloading Device B; however this device does not have published clinical literature demonstrating effectiveness at reducing heel ulceration in the clinic.
214915712|NCT03896022|DEVICE|Acupressure with Beads|Single-use gold-plated 1.2mm beads/balls attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
214915713|NCT03896022|DEVICE|Acupuncture with Needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
214915714|NCT03896022|DEVICE|Placebo Adhesive Disks|Single-use adhesive disks without needles or beads.
214915715|NCT03207269|OTHER|Dietary|Diet will be manipulated by providing different bedtime snacks within an otherwise isocaloric diet.
214915716|NCT02438423|BIOLOGICAL|Inactivated influenza vaccine|Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
214915717|NCT02438423|OTHER|Placebo|
214915718|NCT01341275|BIOLOGICAL|hepatitis B vaccine|10 ug dose, one-time administration
214915719|NCT01341275|BIOLOGICAL|hepatitis B vaccine|20 ug dose, one-time administration
214915720|NCT03253900|DEVICE|Stable rowing simulator|a standard stable/fixed rowing simulator
214915721|NCT03253900|DEVICE|Slides based rowing simulator|a slides based rowing simulator, i.e. horizontal plane unstable
214915722|NCT03253900|DEVICE|Tilt board based rowing simulator|a tilt board based rowing simulator; i.e. frontal plane unstable
214915723|NCT02401152|OTHER|Sports drink 1|Sports drink with a specific source of CHO.
214915724|NCT02401152|OTHER|Sports drink 2|Sports drink with a specific source of CHO
214915725|NCT02401152|OTHER|Placebo|iso-caloric sports drink with maltodextrin as CHO source
214915726|NCT05330117|PROCEDURE|TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
214915727|NCT05330117|PROCEDURE|Control TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
214915728|NCT03231163|OTHER|No Music|Participants lie supine on a table while no music is played.
214915729|NCT03231163|OTHER|Relaxing Classical Music|Participants lie supine on a table while classical music is played.
215060151|NCT00257569|DRUG|Cetirizine Dry Syrup|
215060152|NCT06715098|DEVICE|RoboGait|RoboGait: robotic-assisted gait training
215060153|NCT06715098|DEVICE|RehaWalk|RehaWalk: body weight-supported treadmill training
215060154|NCT06715098|OTHER|Conventional|Conventional: conventional walking training
215060155|NCT06844604|PROCEDURE|robotic colorectal procedures|any colorectal procedure planed robot-assisted
215060156|NCT06844604|PROCEDURE|laparoscopic colorectal procedures|any colorectal procedure planed laparoscopically
215060157|NCT06844604|PROCEDURE|open colorectal procedures|any colorectal procedure planed open
215060158|NCT01059357|DEVICE|Da Vinci Robotic Transoral Robotic Surgical System|(TORS) Da Vinci Robotic Transoral Robotic Surgical System
215060159|NCT04068454|DEVICE|Virtual reality device|Functional exercises will be done by virtual reality group
215060160|NCT04068454|OTHER|EBM rehabilitation exercises|scapular exercises will be done
215060161|NCT03464526|DRUG|Orvepitant|Tablet, once daily, oral
215060162|NCT03464526|DRUG|Placebo|Tablet, once daily, oral
215060163|NCT03469167|DEVICE|CEGP003|Application of CEGP003 to peptic ulcer bleeding
215060164|NCT03469167|DEVICE|Injection Tx|Injection of epinephrine to peptic ulcer bleeding
215060165|NCT04661605|DIAGNOSTIC_TEST|Recurrent Neural Network|We will propose a similar Moiré feature analyzing approach based on Recurrent Neural Network to process the measured Slip Pulse wave-images with 'Chun', 'Guan' and 'Chy' in order to prepare this visualization engineering platform.
215060166|NCT01715389|OTHER|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
215060167|NCT02743767|PROCEDURE|Introducing five different treating adaptations|Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
215060168|NCT01575808|DEVICE|GP1101|Endovascular stent graft implantation
215060169|NCT05754411|DRUG|[14C]STI-1558|Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
215060170|NCT04436445|COMBINATION_PRODUCT|dry cupping|represents the location and clinical importance of each acupoint. First, the position of the patient will be supine lying for SP6, SP9, KI6, GB34 and CV6 acupoints and it will be prone lying for B23 acupoint. Second, the skin will be cleaned by alcohol then cups will be placed on the acupoints. Dry cupping for SP6, SP9, KI6 and GB34 acupoints will be applied using small cups while dry cupping for CV6 and B23 will be applied using large cups. Third, a negative pressure will be applied with a manual handle. Finally, the cups will be removed after 5 to 15 minutes by pressing one side of the skin with a finger to release the vacuum slowly.
215060171|NCT04436445|OTHER|Life style modification|Life style modification
215060172|NCT02465476|PROCEDURE|telemedicine|treatment pathway organized by telemedicine
215060173|NCT01527045|DRUG|Atorvastatin Calcium|Given PO
215060174|NCT01527045|DRUG|Cyclosporine|Given PO
215060175|NCT01527045|DRUG|Fludarabine Phosphate|Given IV
215060176|NCT01527045|OTHER|Laboratory Biomarker Analysis|Correlative studies
215060177|NCT01527045|DRUG|Mycophenolate Mofetil|Given PO or IV
214915730|NCT03231163|OTHER|Self-Selected Relaxing Music|Participants lie supine on a table while self-selected relaxing music is played.
214915731|NCT04242810|DEVICE|rTMS|TMS will be applied over task-based target at an intensity up of 130% rMT. The optimal coil placement during stimulation will be guided using the BrainSight neuronavigation system.
214915732|NCT04242810|DEVICE|Sham rTMS|An electrical sham coil that produces the same auditory and somatosensory stimulations, without a significant magnetic field, will be used as an active control.
215060178|NCT01527045|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
215060179|NCT01527045|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
215060180|NCT01527045|RADIATION|Total-Body Irradiation|Undergo TBI
215060181|NCT01218217|DRUG|SQ109|SQ109 150 mg tablet
215060182|NCT01218217|DRUG|Rifampicin|Rifampicin 150 mg capsules
215060183|NCT00649285|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
215060184|NCT00649285|DRUG|Macrobid® Capsules 100 mg|100mg, single dose fed
215060185|NCT06100146|DIETARY_SUPPLEMENT|Folic acid and vitamin B12 fortified flour|Standard bags of fortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. The dose of vitamins will be added to the flour of the intervention group and mixed with batch mixing technique. The concentration of folic acid and vitamin B12 per 1kg of flour will be 2mg and 0.02mg, respectively. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
214480324|NCT06862349|DRUG|Group L received propofol at 2-2,5mg/kg dose based on lean body weight, which was calculated from CT imaging by a radiologist.|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group L received propofol at 2-2,5mg/kg dose based on lean body weight, which was calculated from CT imaging by a radiologist. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison.
214670486|NCT05060042|OTHER|Bilateral proprioceptive training|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
214670487|NCT06270992|DIAGNOSTIC_TEST|NCCN (National Comprehensive Cancer Network) diagnosis|For diagnostic evaluation, the necessary procedures from the standard protocols consisting of anamnesis, physical examination, laboratory tests, radiological imaging methods, and tissue biopsy will be followed. Computerized Tomography (CT) and Positron Emission Tomography-Computed Tomography (PET-CT) will be used as imaging methods, while fiberoptic bronchoscopy and video-assisted mediastinoscopy will be applied for tissue diagnosis and staging.
214915733|NCT04242810|PROCEDURE|MRI scan|Participants will undergo an MRI scan directly after rTMS stimulation that will last less than 120 minutes. During the scan, subjects will encode and retrieve object pictures.
215060186|NCT06100146|OTHER|Unfortified cereal flour|Standard bags of unfortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
214670488|NCT01359540|DEVICE|OMNI Apex Modular™ Hip Device|
214670489|NCT01359540|DEVICE|OMNI Apex ARC™ Hip Device|
215060187|NCT06472037|DRUG|Cadonilimab|10mg/kg，IV，D1，Q3W
214915734|NCT00718614|PROCEDURE|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
214915735|NCT01136941|DRUG|Zileuton|Zileuton is available as a 600 mg tablet. Dosing begins at 2.4gm/day and will be increased to 3.0gm/day. Tablets will be taken twice daily for the 6 week duration of the study.
214915736|NCT03971396|OTHER|Physiotherapists working in intensive care|Physiotherapists working in intensive care will be reached by mail or telephone. Physiotherapists will be asked to complete the prepared questionnaire.
214915737|NCT00615550|DRUG|progesterone|8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
214915738|NCT00615550|DRUG|placebo|vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
214915739|NCT00677521|DRUG|Acarbose|50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
214915740|NCT03676608|BIOLOGICAL|Bee Wax Mammary Areolae|The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams.
214915741|NCT03676608|OTHER|Usual educational care|The WHO protocol for maternal lactation.
214915742|NCT00564850|DRUG|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|One intra muscular injection at day 1 and month 3.
214915743|NCT02640664|DRUG|Ranibizumab|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
214915744|NCT01493518|DRUG|AMG 557 or PLACEBO|Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.
214915745|NCT03059043|DEVICE|viscoelastic-free implantation system|Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation
214915746|NCT03059043|DEVICE|standard viscoelastic-assisted Implantation system|This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation
214915747|NCT01194232|DRUG|Sildenafil|8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
214915748|NCT00314327|DRUG|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
214915749|NCT00413582|DRUG|Epidural Analgesia|Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
215060188|NCT06472037|DRUG|Gemcitabine|1000mg/m2，IV，D1、D8、D15，Q4W
215060189|NCT06472037|DRUG|Nab-Paclitaxel|125mg/m2，IV，D1、D8、D15，Q4W
215060190|NCT05823974|BIOLOGICAL|F2C22C/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
215060191|NCT05823974|BIOLOGICAL|F2B22A/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
215060192|NCT05823974|BIOLOGICAL|F2B22B/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
215060193|NCT05823974|BIOLOGICAL|F2B22C/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
214480325|NCT06862414|DEVICE|Smartphone-based deep learning system|The smartphone-based deep learning system was trained using a dataset of over 50,000 white-light macroscopic images collected between 2006 and 2013 to develop the YOLOv7 model. Lesions were categorized into three referral grades: benign (green), potentially malignant (yellow), and malignant (red).
214480326|NCT06862050|BEHAVIORAL|BREATHE Free Curriculum|Curriculum will teach practices: love, perspective, prudence, hope, humility, forgiveness, spirituality, self-control, teamworking, perseverance, gratitude, and joy.
214480327|NCT03681912|BEHAVIORAL|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 45-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
214670490|NCT01923064|DRUG|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
214670491|NCT01923064|DRUG|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
214670492|NCT03910699|DEVICE|Three-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a three-row circular stapler, defunctioning colostomy is performed.
214307392|NCT04960046|PROCEDURE|Placement of an infraclavicular perineural catheter using a costoclavicular approach|"The high-frequency linear probe will be used to image the axillary artery in the long axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, also in its distal third. The needle will be inserted with a latero-medial orientation in the plane. The initial injection will be a single injection laterally to the axillary artery, where the three nerve bundles are still joined together.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
214307393|NCT04960046|PROCEDURE|Placement of an infraclavicular perineural catheter by paracoracoid approach|"The high-frequency linear probe will be used to image the axillary artery in the short axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, in its distal third. The needle will be inserted with a cranio-caudal orientation in the plane. The initial injection will be a single injection posterior to the axillary artery, the expected distribution being a U distribution around the artery.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
214307394|NCT01538693|DRUG|escitalopram oxalate|10 mg 4.5 hours prior to testing
214307395|NCT01538693|DRUG|Cyproheptadine|8mg 4.5 hours prior to testing
214307396|NCT01538693|DRUG|sugar pill|4.5 hour prior to testing
214307397|NCT01538693|OTHER|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
214307398|NCT06518746|OTHER|Cryopreservation of gonadal tissue|Patients at risk for primary gonadal tumors will undergo unilateral or bilateral gonadectomy for clinical purposes as a standard of care, and a portion of the surgically removed tissue will be cryopreserved for fertility preservation. The pathologist will assess the tissue using sterile technique and every other section will undergo histologic analysis, including evaluation for the presence of tumor or viable germ cell elements. The sections of the tissue for fertility preservation will be refrigerated and held until a final diagnosis is made on the tissue sections that are being processed for histologic analysis. If no tumor is identified and viable germ cell elements are identified, the tissue sections allotted for preservation will be sent in holding media for processing and cryopreservation.
214307399|NCT04916600|DEVICE|NET|NET is an investigational device that received CE-Mark in April 2009 as a Class IIa active medical device
214307400|NCT05887765|DRUG|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the popliteal nerve block
214307401|NCT05887765|DRUG|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
214307402|NCT05887765|DRUG|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
214307403|NCT03941535|DRUG|Vitamin K|Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
214307404|NCT02493699|OTHER|physical exercise- based intervention (Karate techniques training)|
214307405|NCT02822521|OTHER|Mobile Application|A mobile health application that asks daily questions about participants' pain, function, and disease activity.
214307406|NCT02822521|OTHER|Population Management System|Study staff will act as care managers behind a web-based dashboard to monitor participants' responses to the daily questions on the mobile application and connect them with their HCPs.
214915750|NCT00413582|DRUG|Patient-Controlled IV Analgesia|In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are \> 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of \> 4/10 throughout the duration of PCA use.
214307407|NCT03324763|OTHER|stool sampling|A stool sample will be collected to perform the H. pylori antigen test
214307408|NCT06145542|BEHAVIORAL|AR group: aerobic training before resistance training|"Exercise are performed 3 times/wk for 8 wks.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve (HRR). Real-time heart rate monitors are worn by each participant during the session. Aerobic training session lasts for 30 minutes, with an additional 5-minute warm-up and 5-min relaxation training before and after the session, respectively.~Participants perform resistance exercise on a set of strength training equipment. Load of resistance exercise is between 60-80% of repetition maximum (RM) in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 seconds. Between each two sets, there are 60 s of rest time."
214307409|NCT06145542|BEHAVIORAL|RA group: resistance exercise before aerobic exercise|"Exercise are performed 3 times/wk for 8 wks.~Following a 5-min warm-up exercise, the participants perform resistance training on a set of equipment. Load of resistance exercise is set between 60-80% of repetition maximum in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 s. Between each two sets, there are 60 seconds of rest time.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve. Real-time heart rate monitors are worn during the entire session. Each aerobic training session lasts for 30 minutes, with an 5-minute relaxation training after the session."
214915751|NCT05691127|DIAGNOSTIC_TEST|Complete blood count (CBC), C reactive protein (CRP(., Chest x ray, ABG, Electrolytes, Random blood sugar, Creatinine|I will use these investigations in my study
214915752|NCT04902027|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
214307410|NCT03650907|BEHAVIORAL|Group exercise program|"Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks."
214307411|NCT03650907|BEHAVIORAL|Self exercise program|Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
214307412|NCT06530849|DRUG|GC012F Injection|GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19
214307413|NCT05751798|DRUG|Part A: OSE-279 100mg|Human IgG4 mAb against PD-1
214307414|NCT05751798|DRUG|Part A: OSE-279 300mg|Human IgG4 mAb against PD-1
214307415|NCT05751798|DRUG|Part A: OSE-279 600mg|Human IgG4 mAb against PD-1
214307416|NCT05751798|DRUG|Part B: OSE-279 600 mg and OSE2101|OSE-279: OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine
214307417|NCT05751798|DRUG|Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive|OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine
214307418|NCT05751798|DRUG|Part C: OSE-279 600 mg - HLA-A2 positif|OSE-279: Human IgG4 mAb against PD-1
214307419|NCT05751798|DRUG|Part C: OSE-279 600 mg - HLA-A2 negative|OSE-279: Human IgG4 mAb against PD-1
214307420|NCT05704361|DRUG|RO7121932 IV|Participants will receive RO7121932, as an IV infusion, per the schedule specified in the treatment arms.
214307421|NCT05704361|DRUG|RO7121932 SC|Participants will receive RO7121932, as SC injection, per the schedule specified in the treatment arms.
214307422|NCT06958731|DEVICE|TuoRen Ultrasonic System|The Single-operator Laser-assisted T-shaped probe consisted of TuoRen Ultrasonic System (TUR200, Shenzhen Tuoren Bio-Medical Electronics Co., LTD) with a T-shaped probe (L38T7C), a 3D-printed probe-carrying enclosure with a linear laser transmitter ( ZLM120AL650-22130BXS, Shenzhen Zhonglai Technology Co., Ltd.) and ultrasonic probe manipulator.
214307423|NCT06958731|DEVICE|Huasheng Color Ultrasonic Diagnostic System|Ultrasonic (Huasheng Color Ultrasonic Diagnostic System, Navi s, Shenzhen Huasheng Medical Technology Co., LTD.) and a 4.0MHz phased probe were used for the short-axis out-of-plane internal jugular vein catheterization
214307424|NCT04171817|DRUG|Chlorhexidine|The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
214307425|NCT05643235|DEVICE|Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)|Patients initiating BTK inhibitors will be offered the option of monitoring using the Medtronic Insertable Cardiac Monitor (ILR). The device will be implanted by a certified and credentialed electrophysiologist to enable monitoring to begin at least 24 hours prior to the first administration of the BTK inhibitor. Monitoring data will be collected prospectively until the patient withdraws consent, the device is removed, or up to 60 months
214307426|NCT01541969|DEVICE|CR Neuromodulation|"Ear level device which delivers patterned sound stimulation.~The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour."
214307427|NCT01541969|DEVICE|Tinnitus masking|The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
214307428|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with rhubarb root|TeTrimTeas welsh Herbal tea with green tea and rhubarb root
214307429|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with senna|TeTrimTeas welsh Herbal tea with green tea and senna
214307430|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with green tea|TeTrimTeas welsh Herbal tea with green tea
214307431|NCT01614990|DRUG|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
214307432|NCT01614990|DRUG|Placebo|placebo (Powerade®) daily for 7 days.
214915753|NCT01036282|BEHAVIORAL|Computerized Cognitive Skill Training|Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
214307433|NCT03213652|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214307434|NCT03213652|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
214307435|NCT03213652|PROCEDURE|Bone Scan|Undergo a bone scan
214307436|NCT03213652|PROCEDURE|Computed Tomography|Undergo a CT scan
214915754|NCT01036282|BEHAVIORAL|CRT and Social Cognition|Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
214915755|NCT02040129|DEVICE|Acrysof Toric IOL|Lens implantation following cataract surgery
214307437|NCT03213652|DRUG|Ensartinib|Given PO
214307438|NCT03213652|OTHER|Laboratory Biomarker Analysis|Correlative studies
214307439|NCT03213652|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214915756|NCT06143280|OTHER|Data collection|Data collection using entries in the medical records of the respective patients (surgery reports, progress notes, consultation reports, imaging and pathology reports) who underwent surgery with the new dynamic technique for soft palate reconstruction.
214307440|NCT03213652|OTHER|Pharmacological Study|Correlative studies
214915757|NCT02920762|OTHER|on-interventional study - retrospective database review|
215060194|NCT05823974|BIOLOGICAL|F2B22D/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
214307441|NCT03213652|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
214480328|NCT03681912|BEHAVIORAL|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
214307442|NCT03213652|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
214307443|NCT03213652|PROCEDURE|X-Ray Imaging|Undergo an x-ray
214307444|NCT04843709|DRUG|MRG004A|Administrated intravenously
214307445|NCT04699682|OTHER|Control|During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
214307446|NCT04699682|OTHER|BHR Case|"During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:~\- stool samples taken at different times:~* every 7 days during the first month (M1)~* every 14 days for the following months until the end of the patient's participation (M2 to M12)."
214307447|NCT02307851|BIOLOGICAL|Quadrivalent VLP Vaccine|
214307448|NCT02307851|BIOLOGICAL|Comparator TIV|
214307449|NCT01012622|DRUG|Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride|OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
214307450|NCT03646110|PROCEDURE|Minimally invasive esophagectomy|Minimally invasive esophagectomy is a surgical procedure for esophageal resection
214307451|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307452|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307453|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307454|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307455|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307456|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307457|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307458|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214480329|NCT03681912|BEHAVIORAL|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
214307459|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307460|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307461|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
214307462|NCT05102110|DIAGNOSTIC_TEST|Oricol Test|Assessment of rectal mucus for material from aero-digestive cancers.
214480330|NCT03893903|DRUG|IDH1R132H peptide vaccine|"The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks."
214480331|NCT03893903|DRUG|Avelumab|"Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression."
214307463|NCT01591291|DRUG|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
214307464|NCT01591291|DRUG|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
214307465|NCT00175721|PROCEDURE|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
214307466|NCT04475133|OTHER|Ultrasound guided percutaneous neuromodulation|It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
214307467|NCT00942396|DEVICE|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
214307468|NCT02164227|OTHER|Respiratory pattern|
214307469|NCT00002052|DRUG|Ceftriaxone sodium|
214307470|NCT00002052|DRUG|Ampicillin sodium|
214307471|NCT00002052|DRUG|Amoxicillin trihydrate|
214307472|NCT01504321|DRUG|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
214307473|NCT01504321|DRUG|Placebo|Encapsulated lactose powder
214307474|NCT03229265|DRUG|Patiromer|Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
214480332|NCT06859437|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain Placebo|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~One capsule of placebo orally per a day during the entire period of antibiotic therapy."
214915758|NCT02741076|DRUG|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
214915759|NCT02741076|DRUG|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
214915760|NCT05179889|DRUG|mFOLFIRINOX|"Irinotecan 150 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion\] 12 cycles per 2 weeks~mFOLFOX 6 \[Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week"
214915761|NCT05179889|DRUG|mFOLFOX 6|Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks
214915762|NCT05595967|BEHAVIORAL|Health education intervention|Both the two session contains modules focusing on heath related knowledge and pelvic floor muscle exercise. Both two session will be delivered by primary healthcare women workers in small groups (about 20 women per group). The local healthcare workers are responsible for making appointment with each participant through group activities. Each participant will receive a healthy calendar practice to record the number of exercises per day which will be supervised by primary healthcare workers. All healthcare workers are required to attend a full-day workshop organized base on the scheme and teaching materials developed by our research team. The contents of the workshop include: (1) introduction of pelvic floor dysfunction; (2) risk factors and prevention of pelvic floor dysfunction; (3) kegel movement; (4) methods of dealing with severe illness; (5) a standard procedure of group activities or one-on-one activities; (6) skills needed for the delivery of health education intervention.
214915763|NCT06155344|OTHER|Food Frequency Questionnaire|We will obtain a global index of vegetalization of the diet (the Plant based Diet Index: PDI) from data obtained using semi-quantitative questionnaires on food frequency (Food Frequency Questionnaire (FFQ)) validated on the national ELFE cohort (French Longitudinal Study from Childhood (https://www.elfe-france.fr)) and completed by women in the 1st trimester of pregnancy (T1) and at delivery.
214915764|NCT06155344|OTHER|Collection of 4 mL maternal blood|One tube collection of 4 mL maternal blood in the first trimester and at delivery.
214915765|NCT02964481|GENETIC|Whole exome sequencing|DNA sequencing of protein coding sections of all genes
214307475|NCT03320252|DEVICE|Endurant Chimney Graft Technique|Medtronic Endurant II and Endurant IIs Stent Graft Systems and balloon-expandable covered stent graft systems approved for use in the renal arteries. These devices will be utilized in a chimney graft configuration.
214307476|NCT02094716|DRUG|Permethrin Foam 4%|Topical application, whole-body treatment
214307477|NCT02094716|DRUG|Permethrin Foam 5%|Topical application, whole-body treatment
214307478|NCT02094716|DRUG|Vehicle Foam|Topical application, whole-body treatment
214307479|NCT03547713|BEHAVIORAL|Social feedback|Social feedback regarding performance of a public speech is delivered to participants
214307480|NCT03547713|BEHAVIORAL|Self-referential paradigm|Exposure to traits varying in valence (positive vs. negative) and social domain (power vs. affiliation)
214307481|NCT03547713|BEHAVIORAL|Reward vs. punishment task|Reception of monetary gains vs. losses
214307482|NCT03547713|BEHAVIORAL|Emotional reactivity task|Exposure to emotional faces vs. shapes
214307483|NCT00099125|DRUG|irinotecan hydrochloride|
214307484|NCT00099125|DRUG|temozolomide|
214307485|NCT00099125|PROCEDURE|adjuvant therapy|
214480333|NCT06859437|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain LP299v|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~One capsule of LP299v orally per a day during the entire period of antibiotic therapy."
214480334|NCT06862817|DRUG|Aloe vera gel|Aloe vera mouthgel not only as a potent agent for prevention mucositis, but also as a prevention of candidiasis in patients undergoing radiotherapy of head and neck with its antifungal and immunomodulation properties
214915766|NCT03809975|OTHER|Multidisciplinary Community Program|"Patient will undergoes 12 weeks of structured and personalized multidisciplinary community-based program, which consists of Physiotherapy, Dietetics and Psychology sessions. Patients will also attend 2 educational sessions. Physiotherapy and educational sessions are mandatory for all participants, while the need for dietetics and psychological interventions are determine using individual's BMI measurements and psychological questionnaires.~Inclusion criteria:~Dietetics: 23.5 \< BMI \<32.5; Psychology: PEG \> 4 or PHQ-4 \> 5 or PAM level \< 3"
215060195|NCT05823974|BIOLOGICAL|F2B22E/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
215060196|NCT05823974|BIOLOGICAL|F2F22A/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
214307486|NCT00099125|RADIATION|radiation therapy|
214307487|NCT00149916|DRUG|Mycophenolate sodium (enteric coated)|
214307488|NCT03656419|PROCEDURE|photodynamic therapy|aPDT with methylene blue and red led irradiation.
214307489|NCT03656419|PROCEDURE|Tongue scraper|Tongue scraper 10 times from de back to the top.
214307490|NCT02088983|DIETARY_SUPPLEMENT|CDP-Choline|Capsule
214307491|NCT02088983|DIETARY_SUPPLEMENT|Cellulose|Capsule
214307492|NCT01063764|DRUG|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
214307493|NCT01878201|DRUG|Fimasartan|Fimasartan 30 mg
214307494|NCT01878201|DRUG|Valsartan|Valsartan 80 mg
214307495|NCT02310919|DRUG|Low dose hCG plus FSH co-trigger|Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
214307496|NCT02310919|DRUG|Standard dose of hCG|Standard dose of hCG (10,000 or 5,000 IU) trigger
214307497|NCT05377021|BEHAVIORAL|Lifestyle change|"In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention."
214307498|NCT01185795|DIETARY_SUPPLEMENT|Cardioviva™ yogurt|L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
214480335|NCT06862817|DRUG|Benzydamine Hydrochloride 0.15% Oral gel|. Benzydamine's mechanisms of action are rooted in its anti-inflammatory, anesthetic, and analgesic properties. It has been shown to reduce the synthesis of TNF-α, IL-1β and prostaglandins while also acting as an antioxidant by scavenging reactive oxygen species (ROS) benzydamine inhibits leukocyte-endothelial interactions, thereby decreasing neutrophil degranulation, and helps mitigate histamine-induced vasodilation and vascular permeability.
214480336|NCT06862817|DRUG|bioadhesive gel|bioadhesive These polymers increase viscosity through a liquid-to-semi-solid phase transition, improving retention at the administration site and providing a sustained release profile ,Mucoadhesive Dosage Forms These dosage forms are typically employed to administer medications to epithelial surfaces, including the buccal cavity, sublingual area, oral cavity, eyes, nasal passages, vagina, and lungs
214480337|NCT02526368|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
214480338|NCT02526368|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
214480339|NCT02526368|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
214480340|NCT06861556|PROCEDURE|Ultrasound guided Transversus Abdominis Plane block with 0.2ml/kg bupivacaine 0.25%|The operator applied a linear ultrasound probe transversally to the mid-axillary line between the costal margin and iliac crest. Landmarks were then identified as three muscles layers beneath the subcutaneous tissue; from external to internal lay respectively the external oblique muscle (EO), the internal oblique muscle (IO) and the transversus abdominis (TA). The needle was inserted in plane from the iliac crest level on the midaxillary line advancing towards the midline to the fascia laying between the IO and the TA muscles until pop detection. A clear aspiration ruled out vascular effraction. Finally, the space between the two muscle planes was hydrodissected with the bupivacaine.The end goal was visualizing the IO moving upward leaving room to a hypoechoic lens-shaped local anesthetic distribution.
214670493|NCT03910699|DEVICE|Two-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a two-row circular stapler, defunctioning colostomy is performed.
214915767|NCT03809975|OTHER|Current model of care|No controlled set of treatment assigned to patient. It is based totally on the discretion of the attending clinicians. It will generally contain an unspecific number of physiotherapy sessions. Other allied health involvement such as dietetics and psychological interventions will be on an ad hoc basis. In some cases, the orthopaedic surgeon may recommend for surgery.
214915768|NCT06280859|BEHAVIORAL|Hoosier Sport|Hoosier Sport is a sport-based youth development intervention. The intervention targets physical activity levels, exercise and nutrition knowledge, and leadership skills. The intervention is delivered in person twice a week (Tue/Thu) during PE class. Each class lasts 45-minutes, and covers sport skills, and then a brief lecture and activity on exercise/nutrition/leadership skills. Additionally, once a week Hoosier Sport is delivered virtually (via Zoom) during home room for 20-minutes. This involves activities to allow the students to be active during the school-day.
214915769|NCT05953051|PROCEDURE|ACL reconstruction with bone/PrP-composite|"During standard ACL reconstruction, the drilled bone debris is collected in a sterile filtered chamber.~Then the bone debris is mixed with PrP. After fixation of the graft the composite is inserted into the drilled tunnel at the interface between tendon to bone. The intraarticular aperture sites are sealed by use of fibrin that is previously gathered out of the PrP as well."
214915770|NCT05953051|PROCEDURE|ACL reconstruction (Standard)|Standard ACL reconstruction with Semitendinosus alone or plus gracilis, femoral fixation via extracortical fixation by adjustable loop device, tibial fixation via a bio-interference screw or adjustable device
214307499|NCT01185795|DIETARY_SUPPLEMENT|Placebo yogurt|yogurt, twice per day (BID), 6 weeks
214670494|NCT01596829|DIETARY_SUPPLEMENT|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
214670495|NCT01596829|DIETARY_SUPPLEMENT|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
214915771|NCT01294241|DRUG|Oleogel-S10|1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
214915772|NCT01294241|DEVICE|Mepilex® soft silicone faced polyurethane foam dressing|Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
214915773|NCT04387565|OTHER|magnesium and vanadium measurements and compare|Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).
214915774|NCT02571673|BEHAVIORAL|Assessments|Usability outcomes will come from patient surveys and interviews and a nurse practitioner interview in Aim 1: Part 1. In Aim 1: Part 2, patients and their primary care providers will complete online surveys regarding feasibility. Health outcomes and data regarding health care actions will be collected from HN-STAR and the clinic note will be collected to assess feasibility of collecting these metrics in a future trial. Directly after each clinic visit, the NP will complete one brief online survey for each participant.
214670496|NCT02941731|DRUG|HIP1403|Oseltamivir 6mg/mL
214670497|NCT02941731|DRUG|HGP0919|Oseltamivir phosphate 6mg/mL
214307500|NCT00697515|DRUG|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
214307501|NCT00697515|DRUG|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
214307502|NCT05160688|BEHAVIORAL|Contingency management|Participants will be paid to abstain from cannabis use.
214307503|NCT02174458|PROCEDURE|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
214480341|NCT06861556|PROCEDURE|Ultrasound-guided Quadratus Lumborum block with 0.2ml/kg bupivacaine 0.25%|The patient was laid in a lateral decubitus position. The operator applied the probe transversally on the iliac crest directing the indicator to display the back muscles encompassed by the thoracolumbar fascia (TLF).The intended image was spotted by the emergence of the transverse process L4, delimiting the stem of a shamrock-like shape. Quadratus lumborum (QL) muscle represented the upper leaf of the shamrock, and psoas major (PM) and erector spinae (ES) stood respectively for the anterior and posterior leaves. The needle was inserted in plane from the postero-median lumbar wall directed antero-laterally with tip aiming at the posterior border of the QL muscle adjacent to the ES muscles. Pop detection indicated the middle TLF where the local anesthetic would spread, homogenous and resistance-free
214480342|NCT06858956|DRUG|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
214480343|NCT06862388|BIOLOGICAL|Device: Phase Ⅰ Dose Level 1|Patients in the first dose level will receive a cell dose of 1×10\^6 cells/kg.
214480344|NCT06862388|BIOLOGICAL|Device: Phase Ⅰ Dose Level 2|Patients in the second dose level will receive a cell dose of 2×10\^6 cells/kg.
214480345|NCT06862388|BIOLOGICAL|Device: Phase Ⅰ Dose Level 3|Patients in the third dose level will receive a cell dose of 4×10\^6 cells/kg. Based on these findings, the maximum tolerated dose (MTD) will be determined.
214670498|NCT05247177|DRUG|dexmedetomidine, ketamine co-administration with sevoflurane for general anesthesia|co-administration of sevoflurane, iv. dexmedetomidine and iv. ketamine to maintain a predefined EEG density spectrum array pattern for general anesthesia
214307504|NCT01088009|DRUG|lamivudine|patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104
214307505|NCT01088009|DRUG|lamivudine|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
214307506|NCT01088009|DRUG|lamivudine, adefovir|patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
214307507|NCT03455465|OTHER|Community Health Worker Assessment|Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
214307508|NCT04398758|DRUG|SanaCutan Basiscreme|In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
214307509|NCT03127657|DRUG|Cock's comb extract 0.01%|Applied topically twice daily for 12 weeks
214307510|NCT03858491|DRUG|Cobicistat|Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).
214480346|NCT06862388|BIOLOGICAL|Device: Phase II MTD in Phase I|This group subjects received the MTD obtained in phase I.
214670499|NCT05247177|DRUG|Conventional general anesthesia by administration of sevoflurane alone|Administration of sevoflurane alone to maintain anesthesia with a bispectral index between 40-60
214670500|NCT04154618|DEVICE|Continuous wireless vital sign monitoring|Infants will receive wireless vital sign monitoring throughout their birth hospitalization.
214670501|NCT04649281|DEVICE|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
214915775|NCT04432766|DRUG|BAT2020|After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.
214307511|NCT00912314|PROCEDURE|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
214307512|NCT00322010|PROCEDURE|early PT OT|"1. Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~2. Sessions began with active assisted and active range of motion exercises in the supine position.~3. If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~4. Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. The session progresses to transfer training, and finally pre-gait exercises and ambulation.~6. Progression of activities is dependent on patient tolerance and stability.~7. Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
214307513|NCT02915653|OTHER|Educational materials on a new diagnostic service|Educational materials on a new diagnostic service
214307514|NCT03488316|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
214307515|NCT03488316|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
214307516|NCT03488316|DRUG|Manipulation of the temporary filling material based on Calcium Hydroxide|Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
214670502|NCT03334214|DRUG|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
214670503|NCT03334214|DRUG|Placebo|Saline 0.9%
214307517|NCT03488316|DRUG|Manipulation of the temporary filling material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.
214307518|NCT03488316|PROCEDURE|Material insertion on the root canal|Material insertion on the root canal according to the manufacturer's recommendations
214307519|NCT03488316|PROCEDURE|Material re-insertion on the root canal accordging to the infection needs.|Material re-insertion on the root canal according to the manufacturer's recommendations
214307520|NCT03488316|PROCEDURE|Definiteve canal root obturation|Definiteve canal root obturation with gutta-percha and definitive cement.
214307521|NCT03488316|PROCEDURE|Definitve restoration|Definitve restoration confecction.
214307522|NCT02477501|DRUG|Norepinephrine|continuous infusion
214307523|NCT02477501|DRUG|Ephedrine|continuous infusion
214307524|NCT06496802|OTHER|no intervention|no intervention
214915776|NCT05520073|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus product 1 pack daily
214915777|NCT05520073|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablet 1 pack daily
214307525|NCT01457599|PROCEDURE|Computertomography-guided marking of colorectal liver metastases|Computertomography-guided marking of colorectal liver metastases
214307526|NCT00469482|OTHER|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
214307527|NCT00469482|OTHER|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
214307528|NCT05727228|OTHER|cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,|p16/Ki67 dual stain cytology, extended genotyping and DNA methylation will be performed from the residual cell-pellet from the HPV-positive screening samples. If no cytology-triage testing is performed as a part of the screening algorithm, a cytology will be performed at inclusion. If any residual material is left after DS, extended genotyping and DNA methylation, it will be stores at -80 degrees for future purposes.
214307529|NCT04049942|OTHER|Multimodal prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
214307530|NCT04049942|BEHAVIORAL|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
214307531|NCT00218374|DRUG|Gabapentin|Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
214307532|NCT03756298|DRUG|Atezolizumab|Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
214307533|NCT03756298|DRUG|Capecitabine|capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
214307534|NCT02603432|BIOLOGICAL|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
214307535|NCT02603432|OTHER|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
214307536|NCT02603432|BIOLOGICAL|Following the planned interim analysis for this study: Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
214915778|NCT01916096|DEVICE|Delica Device|
214915779|NCT02748213|DRUG|Xeloda|Participants will receive oral Xeloda, 950 mg/m\^2 twice a day on Days 1 to 14 of each 21-day cycle.
215060197|NCT05823974|BIOLOGICAL|F2F22B/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
214307537|NCT05250024|DEVICE|UHMWP Cranioplasty|patient specific cranial implant
214307538|NCT05250024|DEVICE|PEEK Cranioplasty|patient specific cranial implant
214307539|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
214307540|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
214307541|NCT00277069|DRUG|Carboplatin|Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
214307542|NCT00277069|DEVICE|Capecitabine|Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
214307543|NCT00277069|DRUG|Vinorelbine|Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
214307544|NCT01957462|DEVICE|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
214307545|NCT01957462|DEVICE|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
214307546|NCT05954052|DRUG|Glutathione|Giving supplement orally
214307547|NCT02972216|DRUG|Nolbaxol|
214307548|NCT02972216|DRUG|Taxotere|
214307549|NCT02972216|DRUG|cisplatin|
214307550|NCT04906785|DRUG|CKD-385|Test Drug
214307551|NCT04906785|DRUG|D744|Reference Drug
214480347|NCT06862388|BIOLOGICAL|Device: Phase II lower than the MTD in Phase I|This group subjects received a dose lower than the MTD
214480348|NCT06856109|DIAGNOSTIC_TEST|68Ga-Pentikra PET/CT Scan|68Ga-Pentikra Injection, Intravenous, administered at 0.05 mCi/kg by weight.
214480349|NCT06861166|DRUG|Geranium wilfordii combined with androgen deprivation treatment|Geranium wilfordii 15g decoction (Geranium 15g, decocted by the decocting machine in the decocting room of the pharmacy Department of the hospital) was taken orally, 200mL/ time, once/day, for 3 months + continuous androgen deprivation treatment
214480350|NCT06861166|DRUG|Androgen deprivation treatment|Continuous androgen deprivation therapy
214480351|NCT06861166|PROCEDURE|radical prostatectomy|After completion of treatment, radical prostatectomy was performed 3 weeks later (±7 days).
214480352|NCT04490109|BIOLOGICAL|B244|B244 suspension
214915780|NCT02748213|DRUG|Taxotere|Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m\^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m\^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
214915781|NCT02748213|DRUG|Herceptin|Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
214915782|NCT03051451|DRUG|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Group A will receive metformin 1000 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
214915783|NCT03051451|DRUG|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Group B will receive metformin 1700 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
214480353|NCT04490109|BIOLOGICAL|Vehicle|Vehicle suspension
214307552|NCT03528746|OTHER|Isotonic Exercise|Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.
214307553|NCT03528746|OTHER|Isometric exercise|Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
214307554|NCT01856790|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
214670504|NCT04929873|BEHAVIORAL|Closed transdyser|When the average arterial pressure ≥ 50mmHg, it is indicated that the basic blood supply of the lower extremities is satisfied without special treatment, and when the average arterial pressure \< 50mmHg, it indicates insufficient perfusion, by adjusting the pipe position, changing the ECMO flow rate, and properly clamping the artery end to divert part of the blood flow to the side branch circulation, so that the average arterial pressure is maintained above 50mmHg.
214915784|NCT03051451|DRUG|Placebo Oral Tablet|Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
214915785|NCT00588133|DRUG|tranexamic acid|"Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr~Renal Insufficiency (normal loading dose and prime dose):~Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = \>6.6: reduce infusion to 1.5 mg/kg/hr"
214307555|NCT01856790|DRUG|liraglutide|Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
214307556|NCT01124604|DRUG|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
214307557|NCT01124604|DRUG|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
214307558|NCT03810066|DRUG|Osimertinib|All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
214307559|NCT01686841|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214307560|NCT06475131|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
214307561|NCT06034821|DRUG|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.
214307562|NCT06034821|DEVICE|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks. The Initial ECT treatment will be Right Unilateral (RUL) ultra-brief pulse at 6x seizure threshold determined during titration at first visit. If there is not satisfactory improvement with RUL the investigator may change to Bilateral (BL) utilizing brief pulse using 0.5 modified half-age method to determine stimulus intensity. The seizure threshold may increase during the course of treatment and the dose of the electric stimulus may need to be increased incrementally. It is suggested to change to bilateral after three to five RUL treatments if response to treatment is not satisfactory. Treatments will be given three times a week for up to 4 weeks.
214307563|NCT00107211|BIOLOGICAL|therapeutic autologous dendritic cells|
214307564|NCT00107211|PROCEDURE|conventional surgery|
214307565|NCT00107211|PROCEDURE|neoadjuvant therapy|
214307566|NCT02596854|DEVICE|Neurological MRI|Neurological MRI image collection
214307567|NCT00632333|BIOLOGICAL|URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil|Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
214670505|NCT04929873|BEHAVIORAL|Routine monitor|Obtain oxygen saturation, skin color, temperature, etc
214670506|NCT03528252|OTHER|Written advice LDL Cholesterol|One A4 paper with written information on both sides
214915786|NCT00588133|DRUG|tranexamic acid|10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
214915787|NCT04200651|DRUG|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
214307568|NCT05340881|BEHAVIORAL|Bright Light Exposure|Research coordinator will follow-up with participant on Days 2 \& 5, and weekly thereafter to assess for the presence of potential side effects. If side effects are present with bright light initiation and they do not resolve by Day 5, the intervention will be discontinued.
214307569|NCT05340881|BEHAVIORAL|Dim Light Exposure|A placebo pair of glasses that is identical in form to the bright light glasses with the exception of light intensity will be used in a manner identical to the bright light glasses.
214307570|NCT05340881|OTHER|Cognitive Assessment|Cognitive examinations will be completed in-person and remotely via an online platform; caregivers and participants will also be asked to complete questionnaires assessing fatigue, sleep, and mood. These outcomes will be completed at baseline (prior to intervention/placebo), Week 4, Week 6 (end of intervention/placebo), and Week 8 (2-weeks post intervention/placebo).
214307571|NCT04701281|COMBINATION_PRODUCT|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
214480354|NCT06666361|OTHER|Experimental Group|"The experimental group participates in the Mobio Health Multimedia Hypertension Promotion Program, which includes a hypertension education manual and a mobile health (m-health) intervention aimed at enhancing participants' health literacy and promoting healthy behaviors. In the first week, participants receive the health-education manual on-site, with face-to-face explanations and guidance on using mobile resources, such as text messaging, provided by the Sub-Investigator.~The mobile health intervention transforms the manual's content into six video units, each covering a specific topic, and these videos are continuously pushed over a two-month period. Distributed through LINE@, the official LINE account of the nursing platform, participants can easily access information via the chat menu at the bottom of the screen. This setup improves accessibility, making it convenient for participants to locate and use essential health information directly from the chat window."
214670507|NCT03528252|OTHER|Written advice Triglycerides|One A4 paper with written information on both sides
214670508|NCT04303585|PROCEDURE|SAP block|The anesthesiologist performs SAP block immediately before surgery under ultrasound guide
214670509|NCT04303585|PROCEDURE|ESP block|The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
214915788|NCT04200651|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
214915789|NCT01226082|DEVICE|Transcranial Direct Current Stimulation|Patients will recieve tDCS in a 5-day period of treatment
214915790|NCT05148676|OTHER|Residual Symptoms and the Quality of Life in Individuals Recovered from COVID-19 Infection: A Survey from Pakistan|An anonymous online survey was administrated in Pakistan from November 2020 to April 2021 in COVID-19 survivors. The questionnaire used the 12-Item Short Form Health Survey (SF-12) to assess mental and physical QoL. Multivariate linear regression was used to explore factors associated with mental and physical QoL scores.
215060198|NCT05823974|BIOLOGICAL|F2F22C/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
215060199|NCT05823974|BIOLOGICAL|F2F22D/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
214307572|NCT04345614|DRUG|Auxora (Part 1)|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
214307573|NCT04345614|DRUG|Standard of Care (Part 1)|Patients received standard of care
214307574|NCT04345614|DRUG|Auxora (Part 2)|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
214307575|NCT04345614|DRUG|Placebo (Part 2)|Placebo will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Placebo will be administered intravenously (IV) over 4 hours.
214307576|NCT06154447|DRUG|VX-828|Suspension for Oral Administration
214307577|NCT06154447|DRUG|Placebo|Suspension for Oral Administration
214670510|NCT00061308|DRUG|Topotecan|
214670511|NCT00061308|DRUG|Gemcitabine|
214915791|NCT00913263|DRUG|2-hydroxyflutamide (2-HOF) [Liproca Depot]|Ready made paste including 600 mg 2-HOF for injection as a single dose
215060200|NCT05823974|BIOLOGICAL|F2F22E/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
215060201|NCT05823974|COMBINATION_PRODUCT|Control 1|Control vaccine was administered intramuscularly in Phase 1, at Day 1.
214307578|NCT06154447|DRUG|Itraconazole|Solution for Oral Administration
214307579|NCT06154447|DRUG|Midazolam|Syrup for Oral Administration
214307580|NCT06154447|DRUG|Tezacaftor|Tablets for Oral Administration
214307581|NCT06154447|DRUG|VX-118|Tablets for Oral Administration
214307582|NCT06154447|DRUG|Placebo|Suspension and Tablets for Oral Administration
214307583|NCT06154447|DRUG|Deutivacaftor|Tablets for Oral Administration
214307584|NCT06154447|DRUG|VX-828|Tablets for Oral Administration
214670512|NCT06962943|OTHER|Auto-regulated Blood Flow Restriction Training|This group was recruited to conduct auto-regulated blood flow restriction exercise for 30-min, three times a week for six weeks by a trained physiotherapist, the subjects were asked to perform the following exercises: standing single leg calf raises with lateral resistance using a band, seated soleus raise, single leg balance on the edge of a step clearing the front foot with band on the big toe. SmartCuff 3.0 BFRT tool was used to automatically determine the individualized 50% arterial blood occlusion pressure for the BFRT group at the femoral artery, the cuff was connected to the smart tool device for the auto-regulated group to regulate the cuff pressure during muscle contraction and relaxation. The cuff was deflated in between exercises.
214915792|NCT00913263|DRUG|2-Hydroxyflutamide|The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.
215060202|NCT05823974|BIOLOGICAL|F2F23D/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
215060203|NCT05823974|BIOLOGICAL|F2F23A/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
215060204|NCT05823974|BIOLOGICAL|F2F23B/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
214307585|NCT05867628|OTHER|Activities-based locomotor training (physical therapy)|AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
214307586|NCT03826862|RADIATION|CT three-dimensional reconstruction|All patients will receive CT three dimensional reconstruction before surgery
214307587|NCT03284996|DEVICE|Doppler ultrasonography|Examination of the whole cases \& controls by doppler ultrasound to measure renal resistive index.
214307588|NCT02062333|DRUG|Dexmedetomidine|1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
214307589|NCT02062333|DRUG|esmolol|500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
214307590|NCT05565911|OTHER|no intervention|this is an observational study, there is no intervention.
214307591|NCT02618174|BEHAVIORAL|Neutral Control Condition|Message about age of University of Birmingham
214307592|NCT02618174|BEHAVIORAL|Food-based Control Condition|Message about variety of vegetables in the world
214307593|NCT02618174|BEHAVIORAL|Health Condition|Message about the health benefits of eating vegetables
214307594|NCT02618174|BEHAVIORAL|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
214307595|NCT02618174|BEHAVIORAL|Liking Social Norm|Message suggesting most people like eating vegetables
214307596|NCT06027866|DEVICE|SRAVI (Speech Recognition Application for the Voice Impaired)|Speech Recognition Application for the Voice Impaired (SRAVI) is a novel communication aid developed by Liopa (a company formed by Queen's University Belfast (QUB) and the Centre for Security Information Technologies (CSIT), QUB). SRAVI is an application-based lip-reading system, and the application ('app') can be downloaded onto any device with a standard forward facing camera (e.g., smartphone, tablet). When the device is held in front of a patient, it will track lip movement and identify phrases being mouthed.
214307597|NCT05299749|OTHER|stg-rt-fMRI-Neurofeeback|the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
214307598|NCT05299749|OTHER|sham-rt-fMRI-Neurofeedback|the patients will receive real-time feedback from the brain activity of the somato-motor cortex
214307599|NCT05898581|PROCEDURE|PENG Block|Participants will receive a PENG block with local anesthetics (which is a freezing medication, in this case, 0.5% ropivacaine) before receiving spinal anesthesia. Patients in this group will also receive a sham ILAI procedure with 60 mL of saline (performed by the operating surgeon).
214307600|NCT05898581|PROCEDURE|Control Group|Participants will receive a sham PENG block performed with 20ml of normal saline solution before spinal anesthesia. After, patients will receive ILAI (performed by the operating surgeon) with a plain solution of ropivacaine 0.25% 60ml.
214480355|NCT06666361|OTHER|control group|The control group received one copy of the same health education manual as the experimental group. The sub-Investigator only explained how to use the manual, and afterwards, no face-to-face teaching or m-Health interventions were conducted. After the experiment concluded, the m-Health program used by the experimental group would be provided to the control group.
214480356|NCT06614205|DIAGNOSTIC_TEST|tumoral dosimetry by scintigraphy|The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment
214480357|NCT06269926|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|CBT-CP consists of skill-based therapy sessions completed weekly for 12 weeks. Participants are oriented to CBT and set individualized goals (sessions #1-3) before focusing on cognitive and behavior skill building including physical activity, pacing, relaxation training, and cognitive restructuring (#4-10) then focusing on maintenance and discharge planning (#11-12). It will be completed in Maryland in an online real-time audio/video virtual group therapy format.
214480358|NCT06670027|OTHER|Family voice|Group A receives the family voice
214307601|NCT03102294|OTHER|inspiratory muscle training|inspiratory muscle training with 50% of MIP
214307602|NCT03102294|OTHER|"Placebo training"|placebo training with PowerBreathe (without inspiratory load)
214307603|NCT05494242|OTHER|Surgical intervention|Pars-plana vitrectomy.
214307604|NCT05266807|DRUG|oral capsulized Fecal Microbiota Transplantation|FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
214307605|NCT05266807|DRUG|Vancomycin or Fidaxomicin|Vancomycin or Fidaxomicin per os as initially prescribed per SoC
214307606|NCT04306315|BIOLOGICAL|Brodalumab|Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.
214307607|NCT05563077|OTHER|Moderate-intensity interval training (MIIT)|MIIT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period (∼6-7 reps of 4 min at ∼4.2 METs, with 3 min of active recovery at ∼2.2 METs between each interval), and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs). We will select the same aerobic dose of training (i.e., kcal/kg of body weight per week) to match total energy expenditure in both exercise groups.
214307608|NCT05563077|OTHER|Moderate-intensity continuous training (MICT)|MICT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period at ∼3.2 METs, and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs).
214307609|NCT06320730|OTHER|Observational study, records of blood glucose level after reperfusion|Analyzes blood glucose level after reperfusion by dividing it into two groups: those with blood glucose levels between 110 and 180 and those with blood glucose levels below 110 or above 180.
214307610|NCT00829374|DRUG|Dimebon|5 mg orally three times daily
214307611|NCT00829374|DRUG|Dimebon|20 mg orally three times daily
214480359|NCT06670027|OTHER|Nature sound|Group B receives the nature sound.
214480360|NCT06449183|DIAGNOSTIC_TEST|VIDAS® TBI Test [GFAP and UCH-L1 assays]|The VIDAS® TBI (GFAP, UCH-L1) test is composed of two automated assays - VIDAS® TBI (GFAP) and VIDAS® TBI (UCH-L1) - to be used on the VIDAS® family of instruments for the quantitative measurement of Glial 15 Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase- L1 (UCH-L1) in human serum using the Enzyme Linked Fluorescent Assay (ELFA) technique. The results of both assays are required to obtain an overall qualitative test interpretation.
214307612|NCT00829374|DRUG|Placebo comparator|Placebo orally three times daily
214307613|NCT05601986|OTHER|Physiotherapy and Rehabilitation Program|"The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board."
214480361|NCT04323397|DEVICE|Non-invasive ventilation|Intervention nasal high frequency oscillatory ventilation (nHFOV) and nasal synchronized intermittent positive pressure ventilation (nSIPPV) were generated by neonatal ventilators (SLE6000 infant ventilators, United Kingdom) using bi-nasal prongs (RAM cannula, NEOTECH®, USA) or the nasal mask of the same type for both ventilation modes. The size of the prongs was determined by the infant's weight. The largest possible prongs were used, with a snug fit to avoid leakage. Pacifier for preterm and term neonate (Jollypop™, USA) was taken to avoid leakage from the mouth. The disposable ventilator circuit (Fisher \& Paykel RT268™, Evaqua Dual Limb Infant Breathing Circuit Kit with Evaqua 2 Technology and Pressure Line, Flow \> 4L/min, New Zealand) was used. The initial NIV setting was (7) described in arm description. (above)
215060205|NCT05823974|COMBINATION_PRODUCT|Control 2|Control vaccine was administered intramuscularly in Phase 2, at Day 1.
215060206|NCT05823974|BIOLOGICAL|F2F23C/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
215060207|NCT05823974|COMBINATION_PRODUCT|Control 3|Control vaccine was administered intramuscularly in Phase 2, at Day 1.
215060208|NCT05823974|BIOLOGICAL|F2F22F/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
215060209|NCT05835505|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
215060210|NCT05835505|DRUG|Placebo|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
214307614|NCT05601986|OTHER|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
214307615|NCT05115110|DRUG|RO7204239|"RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1."
214307616|NCT05115110|DRUG|Placebo|Placebo will be administered Q4W by SC injection into the abdomen.
214307617|NCT05115110|DRUG|Risdiplam|Risdiplam will be administered orally once daily (QD) for the duration of the study.
214307618|NCT06098807|BEHAVIORAL|Family Centered Treatment for Problematic Gaming and Excessive Screen Use|Based on earlier implementation research with parents and children the treatment is likely to consist of a low number of sessions ;one session per week during a period of four weeks with high quality content. The sessions will be performed at CAP location in Lund. The treatment will be performed by a clinician at CAP who could be a doctor, psychologist or health counselor - all with cognitive behavioral therapy competence. The sessions will be in group settings, separately for children and parents. In that sense, children will be included in a group with other children and parents will be included in a group with other parents. Each group will have 1-2 therapists leading the program. The theme of the week will be the same for both parent and child group, although the delivery will potentially differ. We expect that a session will last approximately 90 min with a 15-minute coffee break included.
214307619|NCT03870828|DIAGNOSTIC_TEST|Bronchoalveolar lavage and taking bronchial mucosa samples|"Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units.~Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved."
214307620|NCT03870828|DIAGNOSTIC_TEST|6minute walk test|a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation
214307621|NCT03870828|DIAGNOSTIC_TEST|Arterial blood gas|If SpO2 is measured to be \< 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.
214307622|NCT03870828|PROCEDURE|Blood drawing|A vein will be punctured in order to take a blood sample for further tests
214307623|NCT02969824|BEHAVIORAL|Supervised Aerobic Exercise|The AE protocol will consist of eight sessions that proceed in a stepwise fashion in terms of duration and intensity over 11 days. Exercise will be performed on the Velotron Pro stationary cycle ergometer (RacerMate Inc., WA, USA), which will be digitally connected to a heart rate monitor and programmed to monitor the wattage of the bike based on the participant's heart rate. Exercise duration (15min-20min) and intensity (60%-75% max HR) will increase over the intervention period. For the remotely supervised sessions, exercise intensities and heart rate will be monitored via FitBit.
214307624|NCT02631954|DRUG|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
215060211|NCT05364775|OTHER|Focus group|Focus group
215060212|NCT00000428|DRUG|Amitriptyline|Amitriptyline 25 mg po
214307625|NCT02631954|DRUG|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
214307626|NCT03905122|DEVICE|bioreactans tool|It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
214307627|NCT05771207|DIETARY_SUPPLEMENT|soy protein|The intervention is made up of soy protein supplements (30g/d) and dietary pattern modification.
214307628|NCT05771207|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (30g/d) and dietary pattern modification.
214307629|NCT05771207|DIETARY_SUPPLEMENT|placebo|The intervention is made up of maltodextrin (30g/d) and dietary pattern modification.
214670513|NCT06962943|OTHER|Non-regulated Blood Flow Restriction Training|This group was recruited to conduct a non-regulated blood flow restriction exercise for 30-min, three times a week for six weeks by a trained physiotherapist, the subjects were asked to perform the following exercises: standing single leg calf raises with lateral resistance using a band, seated soleus raise, single leg balance on the edge of a step clearing the front foot with band on the big toe. SmartCuff 3.0 BFRT tool was used, whilst the cuff was not connected to the device in the non-regulated blood flow restriction training group and the pressure was stabilized as the initial pressure determined by the device in the non-regulated group. The cuff was deflated in between exercises.
214670514|NCT06962943|OTHER|Control group|This group was recruited to conduct no blood flow restriction exercise 30 min, three times a week for 6 weeks. SmartCuff 3.0 BFRT tool was used, whilst the cuff was not connected to the device and the pressure was 0 (zero) in this group. The cuff was deflated in between exercises.
214307632|NCT06365853|DRUG|Mirvetuximab Soravtansine|Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα monoclonal antibody (mAb) M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
214307633|NCT06365853|DRUG|Lubricating Eye Drops|Lubricating artificial tears should be administered at least 15 minutes after corticosteroid or brimonidine eye drop administration.
214307634|NCT06365853|DRUG|Prednisolone acetate ophthalmic suspension 1% eye drops|Self-administration of prednisolone acetate ophthalmic suspension 1% eye drops as prescribed by the treating physician.
214307635|NCT06365853|DRUG|Brimonidine tartrate ophthalmic solution eye drops|Self-administration of brimonidine tartrate ophthalmic solution eye drops as prescribed by the treating physician.
214307636|NCT06107413|DRUG|ABBV-400|Intravenous (IV) Infusion
214307637|NCT06107413|DRUG|Bevacizumab|IV Infusion
214307638|NCT06107413|DRUG|Folinic Acid|IV Infusion
214307639|NCT06107413|DRUG|Fluorouracil|IV Infusion
214480362|NCT06021678|DRUG|EX103 injection|Administered as specified in the treatment arm.
214307640|NCT06107413|DRUG|Irinotecan|IV Infusion
214307641|NCT06813872|BIOLOGICAL|ABRYSVO Vaccination|"The primary exposure of interest for the TND study is maternal history of vaccination with Pfizer's ABRYSVO vaccine during pregnancy with the infant who presented for care. Infants will be considered exposed to ABRYSVO if their birth parent has documented evidence of receiving ABRYSVO ≥14 days before the date of the infant's birth, during the licensed gestational age window of 32 0/7 to 36 6/7 weeks."
214480363|NCT05440084|PROCEDURE|Chronic total occlusion percutaneous coronary intervention|Chronic total occlusion percutaneous coronary intervention
214670515|NCT06963099|OTHER|INTACS implantation|intra corneal segments implantation
214670516|NCT03933917|PROCEDURE|Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
214307642|NCT05228522|BEHAVIORAL|Lifestyle Intervention|16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
214480364|NCT05138510|BEHAVIORAL|Focus Group|"Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred.~We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material.~Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison."
214307643|NCT02133950|PROCEDURE|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
214480365|NCT06478173|BEHAVIORAL|Exercise training|Exercise training will be performed as supervised small sided soccer games (3v3 to 7v7) 3 times a week for 14 weeks. Each session will last \~1 hour. Patients allocated to soccer training will undergo a ramp-up phase consisting of walking soccer training during weeks 1 and 2, after which normal soccer training will be applied from weeks 3 to 14.
214307644|NCT02133950|PROCEDURE|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
214307645|NCT03425331|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
214307646|NCT03425331|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
214307647|NCT05235165|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood
214307648|NCT05235165|PROCEDURE|Computed Tomography|Undergo CT
214307649|NCT05235165|OTHER|Questionnaire Administration|Ancillary studies
214307650|NCT05235165|PROCEDURE|Thoracoscopy|Undergo video-assisted thoracoscopic surgery or VATS
214307651|NCT05235165|PROCEDURE|Thoracotomy|Undergo open thoracic surgery
214307652|NCT00979888|OTHER|educational intervention|
214307653|NCT00979888|OTHER|informational intervention|
214307654|NCT00979888|OTHER|psychosocial support for caregiver|
214307655|NCT00979888|OTHER|questionnaire administration|
214307656|NCT00979888|PROCEDURE|dyspnea management|
214480366|NCT06350539|OTHER|Biological Sample Collection|Excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
214480367|NCT03640858|DEVICE|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
214915793|NCT04637503|BIOLOGICAL|GD2, PSMA and CD276 CAR-T cells|infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
214915794|NCT02644954|DRUG|Metformin|Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
214915795|NCT02644954|DRUG|Placebo|Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
214307657|NCT00979888|PROCEDURE|management of therapy complications|
214307658|NCT04483908|DIAGNOSTIC_TEST|blood draw|2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)
214307659|NCT04483908|DIAGNOSTIC_TEST|fingertip tests for POC assays|performing POC test by taking two blood drops from the fingertip
214307660|NCT04483908|DIAGNOSTIC_TEST|saliva collection|saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.
214307661|NCT04483908|DIAGNOSTIC_TEST|collection of swabs|collection of nasopharyngeal and oropharyngeal swabs for PCR testing on the control group (eg negative subpopulation)
214307662|NCT00470574|BIOLOGICAL|QS21|
214307663|NCT00470574|BIOLOGICAL|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
214307664|NCT00470574|OTHER|immunoenzyme technique|
214307665|NCT00470574|OTHER|immunologic technique|
214307666|NCT00470574|OTHER|laboratory biomarker analysis|
214307667|NCT06519188|OTHER|Nebulization application with 5 ml isotonic sodium chloride|Nebulization application with 5 ml isotonic sodium chloride in the morning and evening for two months.
214307668|NCT06004700|OTHER|Mobile Application|The current app contains a disease activity questionnaire, a mood scale, a sleep scale, a pain scale, and a functional status scale. The app triggers a brief set of questions each day and allows patients to answer them within 24 hours.
214307669|NCT02864251|BIOLOGICAL|Nivolumab|Specified dose on specified days
214307670|NCT02864251|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214307671|NCT02864251|DRUG|Pemetrexed|Specified dose on specified days
214307672|NCT02864251|DRUG|Cisplatin|Specified dose on specified days
214307673|NCT02864251|DRUG|Carboplatin|Specified dose on specified days
214307674|NCT05920421|PROCEDURE|diaghragm affection by ultrasound before and after the blocks|the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others
214915796|NCT02644954|DRUG|Topical Coal tar|Topical coal tar to be applied once daily
214307675|NCT04478006|GENETIC|RNA-seq|Gene expression and fusion transcripts analysis
214307676|NCT04478006|GENETIC|whole exon sequencing|Genetic alternation analysis
214307677|NCT04478006|OTHER|Cytogenetics test|Remission and relapse are monitored by cytogenetic analyses.
214307678|NCT05030298|RADIATION|Radiation Therapy|Undergo radiation therapy
214307679|NCT05030298|RADIATION|Radiosurgery|Undergo radiosurgery
214307680|NCT05030298|PROCEDURE|Stereotactic Biopsy|Undergo MRI-guided stereotactic biopsy
214307681|NCT05030298|DRUG|Temozolomide|Drug
214915797|NCT02644954|DRUG|Topical calcipotriol|Topical calcipotriol to be applied once daily
215060213|NCT00000428|DRUG|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
214307682|NCT05030298|PROCEDURE|Tumor Treating Fields Therapy|Undergo TTF
214307683|NCT05030298|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214307684|NCT05030298|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214307685|NCT05030298|PROCEDURE|Biopsy|Undergo biopsy
214307686|NCT05030298|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214480368|NCT06865365|DRUG|Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions|Liraglutide daily (0.6-3.0mg, highest tolerable dose) as additional preoperative method for weight loss
214480369|NCT06865365|BEHAVIORAL|Dietologic measures and lifestyle optimization for weight loss|all subjects will receive dietary measures and lifestyle opitmization suggestions in order to drop weight preoperatively.
214915798|NCT05087511|OTHER|motor and sensory development assessment|Peabody Motor Development Scale 2 was used to evaluate motor development and Dunn's Sensory Profile was used to evaluate sensory processing.
215060214|NCT04109807|OTHER|Ozone|ozone exposure
214307687|NCT04746664|BEHAVIORAL|Nutritional counselling|Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
214307688|NCT00703612|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
214307689|NCT05087147|DEVICE|0.7 mm stainless steel orthodontic wire|0.7 mm stainless steel orthodontic wire
214307690|NCT05087147|DEVICE|Banded space maintainer|band and loop space maintainer
214307691|NCT06961266|DRUG|JZP441|Administered orally
214307692|NCT06961266|DRUG|Matching Placebo|Administered orally
214307693|NCT06538818|DEVICE|Ultra Phonophoresis|"Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of a hyaluronic acid-containing gel will be applied gel pad over the wrist and along the course of median nerve at the carpal tunnel.~The following parameters will be used: intensity of 1.0 W/em2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the hyaluronic acid-containing gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.~The following parameters will be used:~* intensity of 1.0 W/cm2~* 1MHz frequency~* pulsed (25%)~* 5 min/session, 5 d/wk, for 3 weeks."
214307694|NCT01917201|PROCEDURE|IVUS-guided group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used."
214307695|NCT01917201|PROCEDURE|Non-IVUS group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used."
214480370|NCT06864611|BEHAVIORAL|Pre-Game Safety Huddles|Before every regular season game, participating teams in league randomized to the Pre-Game Safety Huddle condition will hold brief Pre-Game Safety Huddles. Pre-Game Safety Huddles have three core components: (1) Gather (Athletes, coaches, officials, and other stakeholders come together before the start of the game); (2) Share (Opinion leaders (coaches, referees) affirm the importance of seeking care for suspected concussion, and (3) Repeat (Process is repeated before every game)
214480371|NCT06857110|PROCEDURE|ultrasound-guided supracondylar block of the radial nerve|75 mg of intramuscular diclofenac will be administered, or 1 gram of oral acetaminophen in case of contraindications for the administration of Non-Steroidal Anti-inflammatory Drugs
214915799|NCT03373877|DRUG|PU-H71|PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.
214915800|NCT03373877|DRUG|Ruxolitinib|Dosing will be in accordance with current package insert and dose subject was on during study entry.
214915801|NCT00075205|DRUG|SR141716 (Rimonabant)|
214915802|NCT06578754|OTHER|This is an non-interventional study|Only blood samples will be required in this study. It is noninterventional.
214915803|NCT05383430|DIAGNOSTIC_TEST|: Conners rating scale-Stanford-Binet Intelligence Scales- stuttering severity index third edition (SSI-3) .|Questionaire tests for ADHD -IQ-Stuttering severity assessment
215060215|NCT04109807|OTHER|FA|Filtered air exposure
215060216|NCT00316706|BIOLOGICAL|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
215060217|NCT00316706|BIOLOGICAL|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
215060218|NCT01186042|OTHER|Observational|No intervention
215060219|NCT06108726|DRUG|Envafolimab Injection|Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
215060220|NCT02349659|DEVICE|Implantation with the commercially available Axium neurostimulator|
215060221|NCT01020409|PROCEDURE|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
215060222|NCT04009018|OTHER|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
215060223|NCT05562518|DRUG|Estrogen|1 vaginal ovule daily for three consecutive weeks, followed by 1 vaginal ovule 2 times per week
215060224|NCT05562518|DRUG|dehydroepiandrosterone|1 vaginal ovule daily
214480372|NCT06857110|PROCEDURE|hematoma block|The orthopedic surgeon will perform a hematoma block before closed reduction. Intramuscular diclofenac (75 mg) or oral acetaminophen (1 g) will be administered if NSAIDs are contraindicated. With the patient in a supine position, the fracture site will be identified through palpation. After antisepsis with 2% chlorhexidine gluconate, a 10 cc syringe with a 21-gauge needle will be inserted to aspirate and confirm placement over the fracture hematoma. Then, 1% lidocaine (2 mg/kg) without epinephrine will be infiltrated. A 10-minute waiting period will be observed before performing closed reduction maneuvers.
214480373|NCT06857110|DRUG|5 mg of intramuscular diclofenac|the orthopedic surgeon on duty will perform the hematoma block prior to closed reduction in the procedure room as follows: 75 mg of intramuscular diclofenac will be administered
214480374|NCT06856369|PROCEDURE|Platelet rich fibrin|sub-gingival administration of platelet rich fibrin following open flap surgery
214307696|NCT05344859|BEHAVIORAL|Weekly Automated Health Coaching|This intervention will involve health coaching delivered by Artificial intelligence (AI). The automated health coaching mechanism will be coupled with AI-based responses, and recent advancements have made the voices generated through the AI, almost human-like voices. Every week participants enrolled in automated health coaching intervention will receive a health coaching and goal-setting call that will help guide the participants in managing their Type 2 Diabetes Mellitus. This technology-driven study group will inform us whether trained human coaches are required or if the automated technologies are sufficient to create clinically meaningful HbA1c improvements.
214307697|NCT05344859|BEHAVIORAL|Weekly Human Health Coaching|Every week participants enrolled in human health coaching intervention will receive a health coaching call and goal-setting call from their respective health coaches to guide them in managing their Type 2 Diabetes Mellitus.
214307698|NCT05344859|BEHAVIORAL|Adapted Reward Level|In the adapted reward (gamified) variation, participants will receive 25 cents per day for the first week of daily-monitoring calls, 50 cents per day in the second week, 75 cents per day in the third week, and a dollar per day from the fourth week until the end of the study (Aim 2). In the adaptive variation, missing one day of monitoring (in the past seven days), drops the reward value by one level (example: 75 cents becomes 50 cents), two days of missed calls drop the reward level by two levels, and similarly for three days. In the adaptive variation, participants have to continue to daily monitor their behavior to again build up their reward levels.
214307699|NCT05344859|BEHAVIORAL|Fixed Gamified Reward Level|In our fixed-reward arm, participants will be awarded 25 cents per day for answering the daily monitoring call - this serves simply as a reward for answering the daily calls. It is important that the rewards are for answering the calls and not for the actual values of the responses provided.
214480375|NCT06856369|DRUG|Metformin hydrochloride powder|subgingival administration of 1% Metformin Hydrochloride gel with platelet rich fibrin following open flap surgery
214480376|NCT06856369|DRUG|alendronate sodium powder|subgingival administration of 1% Alendronate gel with platelet rich fibrin following open flap surgery
214480377|NCT05520060|OTHER|Physical support|Pharmacological and non-pharmacological methods in pain management, Mobilization, Position preferred by the woman, Fluid and nutritional support, Massage applications, Sacral pressure, Listening to music, Breathing and relaxation exercises
214915804|NCT02263560|BEHAVIORAL|Kinematic measurements|
214915805|NCT00975182|DRUG|GDC-0941|Oral repeating dose
215060225|NCT05562518|DRUG|Estrogen + probiotics|1 vaginal ovule daily for 12 consecutive days, followed by 1 vaginal ovule 2 times per week
214307700|NCT04466540|DRUG|Hydroxychloroquine|Hydroxychloroquine pharmaceutical form will be tablets of 400 mg.
214307701|NCT04466540|DRUG|Placebo|Hydroxychloroquine placebo
214480378|NCT05520060|OTHER|Psychospiritual support|Effective communication, Encouragement to speak up and express fears, Support for faith-oriented practices
214480379|NCT05520060|OTHER|Environmental and sociocultural support|egulating the temperature, light and sound of the room, Environment that promotes respect for privacy, Reducing environmental noise, Information, Social support, Talking about cultural practices, Social support
214480380|NCT05520060|OTHER|Routine care|Admission to the delivery room, preparation for birth, delivery, postpartum care, etc.
214480381|NCT06860061|PROCEDURE|Laser refractive surgery|"This prospective comparative interventional study will enroll patients with low and moderate myopia who seek laser vision correction at Sohag Center for LASIK and Corneal Surgeries, Sohag, Egypt. Eyes included will be divided into 3 groups according to the type of refractive surgery used (conventional LASIK, Femto-LASIK and PRK) and each group will be subdivided into 2 groups according to the degree of myopia (low and moderate).~All patients will be subjected to routine comprehensive preoperative examinations including manifest uncorrected distant visual acuity (UCDVA), best corrected distant visual acuity (BCDVA), slit-lamp examination, intraocular pressure, and fundus examination.~Corneal topography and corneal aberrometry will be performed on all patients using Sirius's Scheimpflug-Placido topography (CSO, Florence, Italy). The CSO topography system analyzes a total of 6144 corneal points of a corneal area within a circular annulus outlined by an inner radius of 0.33 mm and an outer"
214670517|NCT05428371|DIAGNOSTIC_TEST|Multiomic analyses of blood and surgical specimens|"The following items will be evaluated:~* cell free dna length and integrity~* presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples~* qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)"
214915806|NCT00975182|DRUG|erlotinib HCl|Oral repeating dose
214915807|NCT04133701|BEHAVIORAL|Time-Restricted Feeding|After baseline measurements have been completed, participants will enroll in a time-restricted feeding intervention. Participants will be asked to restrict the time in which they eat each day to 10 hours, fasting for the remaining 14 hours. Participants will also be asked to finish their last meal of the day at least 2 hours prior to bedtime.
214915808|NCT03055780|DEVICE|CT-FFR. CTA. FFR|Study is to compare results of CT FFR against CTA and interventional FFR
215060226|NCT05562518|DRUG|Moisturizer|1 vaginal ovule daily for 14 consecutive days, followed by 1 vaginal ovule every three days
215060227|NCT05143593|DIAGNOSTIC_TEST|results of SSBD are used to guide antibiotics adjustment|secretions from low resipratory will be obtained on day1,day 3 and day7 after enrollment and detected by SSBD at bedside at once. Antibiotics will be adjusted on the results by experienced doctors.
215060228|NCT02656966|DEVICE|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
214307702|NCT00725556|OTHER|Speech Therapy|Speech Therapy
214307703|NCT05726552|OTHER|Laughter therapy|"Laughter therapy will be applied for 50 minutes, 12 sessions, 3 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality.~The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
214307704|NCT00232258|DRUG|Nolpitantium besylate|
214307705|NCT06639412|BEHAVIORAL|Networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention & control services.|The intervention will be networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention \& control services. In this major activity, the project team will establish the network by incorporating agricultural development agents and parents- teacher associations to the health post as foundational actors for educating the community on NCD prevention and control measures. We will implement tier system training to effectively create awareness on NCD and to enhance the NCD care-seeking behavior of the community.
214307706|NCT06639412|OTHER|Usual care|The community in the control group will get noncommunicable disease prevention and control measures given through the health care system.
214307707|NCT02989350|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
214307708|NCT02989350|DIETARY_SUPPLEMENT|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
214307709|NCT03169647|BEHAVIORAL|Listening-based intervention|Participants will listen to pre-specified material on a CD
214480382|NCT06860581|DIETARY_SUPPLEMENT|Intervention (Sanprobi®Stress)|The composition of lyophilized strains of Bifidobacterium longum Rosell®-175 and Lactobacillus helveticus Rosell®-52 (trade name: Sanprobi®Stress; manufacturer: Sanprobi sp. z o.o. sp. k., Szczecin, Poland) was placed in capsules, the shell of which consisted of hydroxypropylmethylcellulose. The total bacterial content per capsule was 3x109 CFU. Filling substances were potato starch and magnesium stearate. The weight of the capsule was 420 mg. Dosage: 1 capsule/day for 12 weeks.
214480383|NCT06860581|OTHER|Placebo|Filling substances were only potato starch and magnesium stearate.
214480384|NCT06861725|OTHER|Silver Diamine Fluoride (SDF)|"Silver Diamine Fluoride has been used extensively around the globe for decades. Advantage Arrest silver diamine fluoride 38% will change how you offer your patients the protection they deserve.~Advantage Arrest:~Provides immediate relief from dentinal hypersensitivity Kills pathogenic organisms Hardens softened dentin making it more acid and abrasion resistant Does not stain sound dentin or enamel Can provide important clinical feedback due to its potential to stain visible or hidden lesions Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity."
214480385|NCT06861725|OTHER|VOCO Fissurit|Transparent Light-cured pits and fissure sealant, with high stability and good adhesion to enamel
214480386|NCT06361225|DIAGNOSTIC_TEST|evaluation with RUSH protocol|Daily evaluation of the patient via ultrasound using the RUSH protocol
214480387|NCT05940272|BEHAVIORAL|Hematolo-GIST Training|Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
214307710|NCT04994717|DRUG|Blinatumomab|Continuous intravenous (cIV) infusion
214307711|NCT04994717|DRUG|Low-intensity chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
214307712|NCT04994717|DRUG|SOC chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
214480388|NCT05940272|BEHAVIORAL|Participants Appointment|Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
214480389|NCT06857773|DRUG|Intra arterial infusion Floxuridine (FUDR) combined with systemic therapy|Floxuridine is administered via the hepatic arterial infusion pump directly to the hepatic artery with a continous flowrate for a period of 2 weeks. Intra arterial infusion of FUDR is combined with systemic therapy (FOLFOX/FOLFIRI) intravenously. Administration of FUDR via the chemopump is every 4 weeks and systemic therapy is administered every 2 weeks.
214480390|NCT06857773|DEVICE|Hepatic arterial infusion pump (HAIP)|The HAIP (pump) is implanted during surgery combined with resection of the primary tumor before start of induction treatment with Floxuridine and concomitant systemic therapy
214480391|NCT06857773|DRUG|Systemic therapy (standard of care)|Patient included in the control arm will receive systemic therapy according to standard clinical practice. Induction therapy regimens include: CAPOX (3 weekly) or FOLFOX/FOLFIRI/FOLFOXIRI (2weekly) with optional addition of Bevacizumab (2 weekly)
214480392|NCT00817193|BEHAVIORAL|Physical Activity|Physical Activity program
214307713|NCT05442554|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion.
214307714|NCT06451523|OTHER|Alliance180 Program|The Alliance180 Program promotes feelings of neuropsychological safety and trust in the context of a 3-day program, which includes the transformative equine experience.
214307715|NCT06166277|PROCEDURE|Ablation procedure|Cardioneuroablation procedure or permanent pacemaker placement
214480393|NCT00817193|BEHAVIORAL|Wellness|Wellness program
214480394|NCT06755866|DIAGNOSTIC_TEST|The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer|Chest MRI scan outside of standard treatment options
214480395|NCT06873594|PROCEDURE|three-ports laparoscopic cholecystectomy|in this arm, laparoscopic cholecystectomy will be done with three ports
214480396|NCT06873594|PROCEDURE|four-port laparoscopic cholecystectomy|in this arm, laparoscopic cholecystectomy will be done with four ports
214480397|NCT06873048|DEVICE|Control Contact Lens (stenfilcon A Sphere)|One week of wear
214480398|NCT06873048|DEVICE|Test Contact Lens (stenfilcon A Toric)|One week of wear
214480399|NCT01884961|OTHER|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
215060229|NCT02810288|BEHAVIORAL|Voluntarily response all items in the questionnaire.|"The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician."
215060230|NCT02346903|DRUG|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
215060231|NCT04359524|DIETARY_SUPPLEMENT|Vitamin D3 (1200 IU/30µg)|
215060232|NCT04359524|DIETARY_SUPPLEMENT|Placebo|Placebo oil capsule
215060233|NCT00109213|PROCEDURE|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
214480400|NCT06869369|OTHER|Turkish PNE4Kids|"Participants in the intervention group will receive 'Turkish PNE4Kids Programme'. The PNE4Kids program was developed based on the book Explain pain by Butler and Moseley and includes an explanation and reassurance on the cause of pain, a brief summary of relevant pain mechanisms, and the integral role of psychosocial and physical factors in precipitating and maintaining pain. This programme has been translated and validated in Turkish children."
214480401|NCT06872541|DRUG|Clopidogrel|Clopidogrel 75 mg uma vez ao dia durante 14 dias
214915809|NCT06283329|DIAGNOSTIC_TEST|vocal cords echography|Ultrasound assessments of the amplitude of the vocal cords movement were performed on a sagittal median section of the arytenoid cartilages with a 30° inclination using a Golf Head ultrasound probe at 3 different time points: before induction (T0), after extubation (T1), in recovery room 30 minutes after extubation(T2). We have defined H0, H1 and H2, the maximum course of the vocal cords measured respectively at T0, T1 and T2
214915810|NCT02922751|OTHER|Liver Stiffness Measurement (LSM)|LSM will be measured via transient elastography utilizing the non-invasive FibroScan™ ultrasound device. LSM will be measured at Baseline, Year 1 and Year 2 visits.
214915811|NCT03225105|DRUG|M3541|Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).
214915812|NCT03225105|RADIATION|Palliative Radiotherapy (RT)|Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).
214915813|NCT05661474|DRUG|Fitostimoline ® hydrogel group|Treatment of DFUs with Fitostimoline® hydrogel every day for 12 weeks.
214915814|NCT05661474|DRUG|Saline gauze group|Treatment of DFUs with saline gauze every day for 12 weeks.
214915815|NCT05122182|DRUG|Candesartan Cilexetil|Angiotensin Receptor Blocker (ARB)
215060234|NCT00109213|PROCEDURE|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
215060235|NCT05856929|OTHER|no Intervention|no intervention
215060236|NCT05313269|OTHER|ISAFE technique for adductor canal catheter insertion|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
215060237|NCT05313269|OTHER|Conventional technique for adductor canal catheter insertion|Adductor canal block catheter tip located lateral to the femoral artery.
215060238|NCT01282242|DRUG|IV rt-PA|open-label
215060239|NCT01680354|PROCEDURE|ReLEx|
215060240|NCT01680354|PROCEDURE|LASIK|
214915816|NCT05122182|DRUG|Repagermanium|C-C chemokine receptor type 2 (CCR2) antagonist
214915817|NCT05122182|DRUG|Candesartan Placebo|Angiotensin Receptor Blocker (ARB) placebo
215060241|NCT03292874|DIAGNOSTIC_TEST|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
215060242|NCT02800694|DRUG|"bupivacainediluted with 1 ml of normal saline and 25 μg fentanyl "|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) diluted with 1 ml of normal saline and 25 μg fentanyl. Then, the parturients were placed in the supine position with left lateral displacement produced by placing a wedge under the right hip to prevent aortocaval compression and hypotension. Supplemental oxygen was applied using nasal cannula (2-4 L/min). Routine monitoring included maternal vital signs, uterine contractions and fetal heart rate tracing. The cardiotocogram was recorded continuously throughout the study period
215060243|NCT05130905|DIETARY_SUPPLEMENT|RiteStart Supplement|RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity \[6, 7, 8\]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
215060244|NCT04916977|OTHER|FD patients|Patients with Fabry disease diagnosis
214915818|NCT05122182|DRUG|Repagermanium Placebo|C-C chemokine receptor type 2 (CCR2) antagonist placebo
215060245|NCT02110433|DEVICE|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
214307716|NCT04548596|DIAGNOSTIC_TEST|Transcranial Doppler|"In this study, the investigators will primarily use the monitor mode of the Transcranial Doppler (TCD, non-invasive FDA approved device) to record cerebral blood flow velocity (CBFV) signals from the Middle Cerebral Artery and Internal Carotid Artery. TCD data and intracranial pressure (ICP) data will be collected in the following four scenarios. Each recording is up to 60 minutes in length:~External ventricular drain (EVD) closed to drainage for a 24 hour period as part of the EVD weaning protocol per standard of care (SOC): The Initial reading will be done within 4 hours of EVD closing. The second reading will be done within 4 hours of anticipated removal of EVD.~EVD closed most of the time and opened to drainage when the ICP becomes elevated per SOC~EVD with Intra-Parenchymal fiber optical ICP sensor per SOC~Intra-Parenchymal fiber optical ICP sensor per SOC"
214307717|NCT05196841|BEHAVIORAL|Anastatica Hierochuntica|During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
214307718|NCT04053101|DEVICE|PET CT|Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).
214307719|NCT04165083|BIOLOGICAL|Pembrolizumab|IV infusion
214307720|NCT04165083|BIOLOGICAL|MK-4830|IV infusion
214307721|NCT04165083|BIOLOGICAL|MK-0482|IV infusion
214307722|NCT05852587|DRUG|Xylitol|Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.
214307723|NCT05852587|DRUG|Placebo|The placebo will be administered by the BWH investigational drug services. The placebo will be composed of cellulose microcrystal.
214307724|NCT06536257|OTHER|Predictive model|Patient who have not had immunotherapy will have tumour tested using the predictive model. This determines whether patients are likely to respond, or not to respond to immunotherapy. Results of the predictive model will be compared with the actual response to immunotherapy when this has been completed.
214307725|NCT04266197|COMBINATION_PRODUCT|Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)|RT234 capsules of a dry powder formulation containing vardenafil administered via oral inhalation with a non-invasive AOS DPI.
214307726|NCT05138133|DRUG|Anifrolumab|Anifrolumab intravenous infusion (IV)
214307727|NCT05138133|DRUG|Placebo|Placebo intravenous infusion (IV)
214307728|NCT05968690|DRUG|Propranolol|Propranolol will be administered to patients in all cohorts.
214915819|NCT05084027|COMBINATION_PRODUCT|venetoclax combining with fludarabine and melphalan|Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2
214307729|NCT05968690|DRUG|Naltrexone|Naltrexone will be administered to patients in cohorts 2, 3, and 4.
214307730|NCT05972551|DRUG|Romosozumab|Subcutaneous (SC) injection
214915820|NCT05238727|DRUG|1.8 ml mepivacaine hydrochloride|1.8 ml mepivacaine IANB
215060246|NCT02110433|DEVICE|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
214480402|NCT06871085|DEVICE|Stability Sock|Use of a stability sock
214307731|NCT05972551|DRUG|Bisphosphonate|Administration determined by investigator according to the local standard of care
214307732|NCT05676749|BIOLOGICAL|C-TIL051|C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab
214307733|NCT06799416|BIOLOGICAL|ARGX-109|administrations of ARGX-109
214307734|NCT06799416|OTHER|Placebo|administrations of placebo comparator
214307735|NCT06636383|OTHER|No Intervention|No investigational/study product will be administered in this DMP.
214307736|NCT06630806|DRUG|SAR446523|Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
214307737|NCT06316856|DRUG|Autologous CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
214307738|NCT06316856|DRUG|Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
214307739|NCT06316856|DRUG|Newly matched donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
214670518|NCT02975323|DRUG|Carvedilol|Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
214670519|NCT06090474|DRUG|NDC-002|Combination of NDC-002B and NDC-002C
214915821|NCT05238727|DRUG|3.6 ml mepivacaine hydrochloride|3.6 ml mepivacaine IANB
214915822|NCT05238727|DRUG|1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI|1.8 ml mepivacaine IANB plus 1.8 ml articaine BI
214915823|NCT02116127|DEVICE|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
214307740|NCT03011814|BIOLOGICAL|Durvalumab|Given IV
214307741|NCT03011814|OTHER|Laboratory Biomarker Analysis|Correlative studies
214307742|NCT03011814|DRUG|Lenalidomide|Given PO
214307743|NCT06225661|BEHAVIORAL|SAFE Intervention|Manualized individual youth and family psychotherapeutic intervention. Weekly individual and family sessions with a therapist for 6 weeks. Participants will continue to receive usual care.
214915824|NCT02116127|DEVICE|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
215060247|NCT02110433|DEVICE|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP \< 100 pg/ml or remaining stable (\< 30% increase).
215060248|NCT05664503|OTHER|Assigned Interventions STOMA-M|The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
215060249|NCT04314700|DEVICE|OCT- based investigational imaging device|Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
215060250|NCT02217423|OTHER|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
214307744|NCT06225661|BEHAVIORAL|NAV (Telephone Navigation)|Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed. Participants will continue to receive usual care.
214307745|NCT05858788|DRUG|SAR441566|Tablet
214307746|NCT05922631|PROCEDURE|Airway pressure release ventilation|ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
214307747|NCT05922631|PROCEDURE|low tidal volume|The ARDSnet method was used for LTV mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was \<30cmH2O
214307748|NCT06066515|DRUG|survodutide|once weekly subcutaneous injection
214480403|NCT06872307|BEHAVIORAL|RAMP-It-Up Initiation, Adherence, and Retention Intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills
215060251|NCT02217423|OTHER|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
215060252|NCT02685566|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
215060253|NCT02685566|DEVICE|FFDM|FujiFilm Aspire Cristalle System
215060254|NCT00694577|RADIATION|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
214307749|NCT06066515|DRUG|Placebo|once weekly subcutaneous injection
214480404|NCT06863714|DRUG|peritonsillar bupivacaine injection|Peritonsillar injection was superficially administered to the superior and inferior peritonsillar regions in a volume of 2-5 ml. A 23 Gouge needle syringe was used for injection. A 0.5% Bupivacaine was administered at a dose of 1 mg/kg (maximum dose of 25 mg)
214480405|NCT06866483|BEHAVIORAL|Social media recruitment|Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
214480406|NCT06866483|BEHAVIORAL|Self-Assessment|Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
214480407|NCT06866483|BEHAVIORAL|Follow-up|Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
214307750|NCT05231785|DRUG|ALN-APP|ALN-APP will be administered intrathecally (IT)
214307751|NCT05231785|DRUG|Placebo|Placebo will be administered IT
214307752|NCT03672331|OTHER|Mammogram|Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
214307753|NCT03672331|OTHER|Ultrasound|As required according to the national/regional guidelines or personalised schedule according to risk assessment
214307754|NCT03672331|OTHER|MRI|As required according to the national/regional guidelines or personalised schedule according to risk assessment
214307755|NCT03672331|OTHER|Tomosynthesis|As required according to the national/regional guidelines or personalised schedule according to risk assessment
214480408|NCT06867783|DEVICE|coquille|"Modalities: Elaboration of the personalized care project, follow-up parents-child single family, multi-family therapy (MFT).~Frequency: MFT weekly, bi-familial observation weekly for one month, single-parent child-parent monitoring weekly for five months, MFT father-child bimonthly for six months, three co-parents, three child psychiatric consultations to develop the personalized collaborative care project"
214670520|NCT04573959|DEVICE|SV-3 Capsule Endoscopy|The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
214670521|NCT00232037|DRUG|Tegaserod|
214915825|NCT00874627|OTHER|Milk|sublingual administration of milk
214915826|NCT00874627|OTHER|Milk|placebo
214915827|NCT04181476|DRUG|Sunscreening Agents|Four different sunscreens
214915828|NCT00269373|PROCEDURE|PET-CT|no drugs included
214915829|NCT06355076|PROCEDURE|New urethral reconstruction|This kind of reconstruction suture has larger area, higher firmness, better fixation of the position of broken end and prolongation of functional length.
215060255|NCT00694577|RADIATION|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
215060256|NCT00694577|RADIATION|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
214307756|NCT06502275|BEHAVIORAL|Mobile Health Management Frailty Care Program|"Through the LINE communication software, participants are provided with exercise and nutrition information three times a week, with a total of 36 messages. As well as 6 podcasts of health information and 6 sports videos in total. At weeks 2, 4, and 6, researchers scheduled 5- to 10-minute telephone consultations. Participants can receive guidance through telephone consultations and carry a Xiaomi sports band wearable device to monitor their exercise."
214307757|NCT02438722|DRUG|Afatinib Dimaleate|Given PO
214307758|NCT02438722|BIOLOGICAL|Cetuximab|Given IV
214307759|NCT02438722|OTHER|Laboratory Biomarker Analysis|Correlative studies
214307760|NCT06115863|OTHER|Early Cognitive Stimulation Interventions|early cognitive stimulation interventions refer to multi-dimensions of stimulative evidenced-based interventions, which are done during the first 24 hours from patient admission to the ICU. They are designed to stimulate cognitive function domains that are impacted by delirium such as attention, registration, recall, and language.
214307761|NCT06046729|DRUG|Eltrekibart|Administered SC
214307762|NCT06046729|DRUG|Placebo|Administered SC
214307763|NCT06544395|DEVICE|Non invasive neuromodulation therapy|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement."
214307764|NCT06544395|OTHER|Manual therapy|Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.
214307765|NCT06544395|DEVICE|Placebo with non invasive neuromodulation|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off."
214307766|NCT06044337|DRUG|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
214307767|NCT06468826|DRUG|Avacopan|Oral capsules
214307768|NCT04898465|OTHER|Social Paediatric Intervention|Family will meet the hospital's social-paediatrician and social worker. Together they will evaluate the need for social support, risk for neglect and refer families for local social services if needed. The visit will contain primary and secondary prophylaxis of child abuse and neglect.
214307769|NCT06149286|DRUG|Odronextamab|Administered by intravenous (IV) infusion
214307770|NCT06149286|DRUG|Lenalidomide|Administered orally (PO)
214307771|NCT06149286|DRUG|Rituximab|Administered by IV infusion, or subcutaneously (SC)
214307772|NCT04940299|BIOLOGICAL|Ipilimumab|Given IV
214307773|NCT04940299|BIOLOGICAL|Nivolumab|Given IV
214307774|NCT04940299|BIOLOGICAL|Tocilizumab|Given SC
214307775|NCT02889874|RADIATION|Omission of radiation therapy|Omission of radiation therapy (adjuvant endocrine therapy only).
214307776|NCT05334784|DEVICE|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
214307777|NCT06508333|BEHAVIORAL|alarm therapy|These patients will receive alarm therapy for 8 weeks.
214670522|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
215060257|NCT00760435|DRUG|Infliximab|5 mg/kg IV over 2 hours once
215060258|NCT00760435|DRUG|Placebo|Placebo (same volume as active drug)
215060259|NCT00485758|DRUG|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
214307778|NCT06508333|DRUG|Vitamin D3|These patients will receive high-dose vitamin D supplementation (more than 2000IU daily) (combined with alarm therapy) for 8 weeks.
214307779|NCT03353584|OTHER|Virtual Reality Therapy|The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
214307780|NCT05260463|DEVICE|Implantation|Fractures of the distal fibula are treated with a trauma implant.
214307781|NCT03962153|DIAGNOSTIC_TEST|Obstetric Ultrasonography|Obstetric Ultrasonography
214307782|NCT05729607|PROCEDURE|Vertical soft tissue augmentation|Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
214307783|NCT05729607|PROCEDURE|Vertical soft tissue augmentation|Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
214307784|NCT05711667|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214307785|NCT05711667|DRUG|Letermovir|Given PO or IV
214307786|NCT04779008|OTHER|remote ischemic preconditioning （RIPC）|Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
214307787|NCT04640545|DRUG|LBL-007|LBL-007 will be administered intravenously every two weeks (Q2W) .
214307788|NCT04640545|DRUG|Toripalimab|Toripalimab Injection will be administered by intravenously (Q2W) .
214307789|NCT04640545|DRUG|Axitinib Tablets|Axitinib Tablets On-demand administration
214307790|NCT04387227|DRUG|Carboplatin|Given IV
214307791|NCT04387227|BIOLOGICAL|Pembrolizumab|Given IV
214307792|NCT04387227|PROCEDURE|Computed Tomography|Undergo CT
214307793|NCT04387227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214307794|NCT04387227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214307795|NCT06015737|COMBINATION_PRODUCT|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
214307796|NCT06015737|OTHER|Placebo|Matching placebo solution for injection in aPFS.
214670523|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
214670524|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)|Single dose administered intranasally on Day 1
214670525|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
214670526|NCT04909021|OTHER|Placebo (single-dose)|Single dose administered intranasally on Day 1
215060260|NCT00485758|DRUG|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
214307797|NCT06015737|COMBINATION_PRODUCT|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
214307798|NCT06015737|OTHER|Placebo|Matching placebo solution for injection in aPFS.
214307799|NCT04583891|BEHAVIORAL|IntelliCare|IntelliCare is a self-guided, fully automated suite of 6 apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
214307800|NCT04583891|BEHAVIORAL|Psychoeducation|The Patient Education app will contain content relevant for general distress management. This includes information about thoughts/worries, prevalence of mood symptoms, CBT strategies for coping with negative affect, and other information typical of education-based mental health apps. The structure of this app will closely mirror patient education websites and apps which mimic the form and structure of apps that target cancer survivors and that primarily provide educational information about cancer and related symptoms.
214307801|NCT04583891|BEHAVIORAL|Coaching|The randomization of added coaching vs. no added coaching after 1 week will only be carried out in the IntelliCare group. Coaching is a human supported approach to optimizing the use and benefit of the IntelliCare apps.
214307802|NCT04203316|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214307803|NCT04203316|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214307804|NCT04203316|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214307805|NCT04203316|DRUG|Enasidenib|Given PO
214307806|NCT04203316|DRUG|Enasidenib Mesylate|Given PO
214307807|NCT06470464|DRUG|Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)|The oral dose of thalidomide is 1.5-2.5mg/kg/d daily (maximum 28g). Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
214307808|NCT04258943|DRUG|Bosutinib|"Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~\- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)"
214307809|NCT06325150|DEVICE|Light emitting glasses|Assess the capacity of 20 min use of AYO light emitting glasses on different outcomes
214480409|NCT06866561|OTHER|aerobic exercise|The exercise group participated in a supervised aerobic exercise program consisting of walking on a treadmill for 30 minutes per day, 3 days per week, at an intensity of 40-60% of maximal heart rate for 4 weeks. Additionally, they were shown an exercise program at the initial assessment that included balance, posture, and endurance exercises using body weight and weights to be performed 3 days a week, with 3 sets of 10 repetitions. The control group did not participate in any exercise program.
214480410|NCT06866561|OTHER|cholecalciferol|Participants were prescribed 2000 IU of vitamin D (cholecalciferol) daily for 12 weeks.
214480411|NCT06866561|OTHER|calcium carbonate|Participants were prescribed 1200 mg of calcium carbonate daily for 12 weeks.
214480412|NCT06867159|PROCEDURE|Autogenic Inhibition (AI) MET (Post Facilitation Stretch)|"Autogenic Inhibition (AI) MET (Post Facilitation Stretch)~1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.~2. The patient contracts the muscle isometrically, using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.~3. On release of the effort, a rapid stretch is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.~4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more."
214480413|NCT06867159|PROCEDURE|Reciprocal Inhibition (RI) MET|"Reciprocal Inhibition (RI) MET~1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.~2. The patient contracts the antagonist muscles (hip adductors), using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.~3. On release of the effort, a rapid stretch to TFL is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.~4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more."
214480414|NCT06661746|DRUG|Multimodal IV analgesia|Multimodal IV analgesia of lidocaine, ketamine and MS
214480415|NCT06661746|DRUG|epidural analgesia|Opioid-based and epidural analgesia
214480417|NCT06871163|PROCEDURE|inspiratory muscle training|Volunteers allocated to the Sham group will receive proton pump inhibitor medication at a standard dose of 20 mg Participants will perform home-based IMT with a moderate load set at 50% of maximal inspiratory pressure (PImáx), adjusted weekly during in-person sessions at LACAP-UFPE. Training will use the Powerbreathe® Classic Light device, provided to participants for the study duration. The protocol includes three cycles of 10 explosive respiratory incursions, with one-minute rest intervals, performed twice daily for eight weeks. Participants will record perceived exertion (Borg scale) and any occurrences in a training log.
214670527|NCT04909021|OTHER|Placebo (two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
214670528|NCT05572476|DRUG|Association of lurbinectedin and durvalumab|"A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.~Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks."
214670529|NCT05572476|DRUG|Association of carboplatin and etoposide|"Treatment will be administered on a 21-days cycle basis up to a maximum of 6 cycles.~Carboplatin will be administered by intravenous infusion on Day 1 every 3 weeks.~Etoposide will be administered by intravenous infusion on Day 1-3 every 3 weeks"
214670530|NCT03504033|DRUG|Xenon|inhalation to maintain anesthesia
214307810|NCT02939963|PROCEDURE|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O during 30 minutes then 30 minutes of basal pressure support then 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O
214307811|NCT02939963|PROCEDURE|Pressure support 7 cm H2O PEP 4 cm H2O then ATC|30 minutes with pressure support 7 cm H2O PEP 4 cm H2O then 30 minutes of basal pressure support then 30 minutes with spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O
214307812|NCT04098354|DIAGNOSTIC_TEST|home BP telemonitoring system .|Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A\&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
214307813|NCT05030428|DRUG|Inclisiran sodium 300 mg|Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
214307814|NCT05030428|DRUG|Placebo|Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
214307815|NCT05603273|BEHAVIORAL|non-weight bearing exercise|exercise on a non-weight bearing device at 50% of peak capacity, 3 days per week for 6 weeks
214307816|NCT05433623|PROCEDURE|Surgery|It will be documented if the patient underwent surgery for their vascular issue
214307817|NCT05846516|DRUG|VSV-GP154|VSV-GP154
214307818|NCT05846516|DRUG|ATP150|ATP150
214307819|NCT05846516|DRUG|ATP152|ATP152
214307820|NCT05846516|DRUG|Ezabenlimab|Ezabenlimab
214307821|NCT05846516|DRUG|ATP162|ATP162
214307822|NCT05067634|DRUG|Xcopri|Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
214307823|NCT05172544|BIOLOGICAL|HydroVax-002 YFV|Inactivated YFV vaccine
214307824|NCT05172544|OTHER|Placebo|NaCl 0.9%, Normal Saline
214307825|NCT06460519|OTHER|Non-invasive blood pressure measurements|Non-invasive blood pressure measurements to the tension cuff three times in a row on each side (right arm and left arm)
214307826|NCT06393712|DRUG|Placebo|Placebo will be administered intrathecally
214307827|NCT06393712|DRUG|ALN-APP|ALN-APP will be administered intrathecally
214307828|NCT06321302|DRUG|BI 764524|BI 764524
214307829|NCT06321302|DRUG|Sham comparator to BI 764524|Sham comparator to BI 764524
214307830|NCT06321302|DRUG|Aflibercept (Eylea®) - US only|Aflibercept (Eylea®) - US only
214307831|NCT05602194|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214307832|NCT05602194|DRUG|Calaspargase Pegol|Given standard of care calaspargase pegol
214480418|NCT06871163|PROCEDURE|inspiratory muscle training (IMT) combined with manual techniques for the lower esophageal sphincter (MTLES) and diaphragmatic release (DRT)|"Volunteers allocated to the group will receive proton pump inhibitor medication at a standard dose of 20 mg.~The IMT protocol will be the same as in Group 1. Intervention: IMT Combined with Manual Techniques (MTLES \& DRT) The IMT protocol follows Group 1. DRT (Rocha et al., 2015) involves manual traction during inspiration and deepened contact during expiration, applied in two sets of ten deep breaths. MTLES (Eguaras et al., 2019) is performed with the patient seated, applying epigastric pressure to access the lower esophageal sphincter through coordinated flexion-inspiration and extension-expiration for 5 minutes."
214670531|NCT03504033|DRUG|Desflurane|inhalation to maintain anesthesia
214307833|NCT05602194|DIETARY_SUPPLEMENT|Levocarnitine|Given PO or IV
214307834|NCT05602194|DRUG|Pegaspargase|Given standard of care pegaspargase
214307835|NCT05602194|OTHER|Quality-of-Life Assessment|Ancillary studies
214307836|NCT04829318|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
214307837|NCT04829318|DRUG|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
214307838|NCT06350773|DRUG|tadalafil 20 mg then 40 mg if tolerated|Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.
214307839|NCT06620003|BIOLOGICAL|cAd3-Marburg Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg Vaccine) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
214307840|NCT06620003|BIOLOGICAL|Placebo|0.9% NaCl solution for injection.
214480419|NCT06871163|PROCEDURE|Controle|Volunteers allocated to the Sham group will receive proton pump inhibitor medication at a standard dose of 20 mg, as prescribed for other participants. They will undergo a simulated treatment protocol, including inspiratory muscle training (IMT) without load to mimic device use and manual techniques where the therapist places hands on the intervention area without performing actual manipulation.
214670532|NCT03690518|OTHER|Cardiac rehabilitation|Educational/Counseling/Training : Rehabilitation, , cardiovascular rehabilitation in congenital heart disease
214915830|NCT06524362|BEHAVIORAL|Pelvic Floor Physiotherapy (PFR)|"Intervention: Participants will undergo a structured pelvic floor physiotherapy program for three months.~The program includes:~Eight Personal Sessions: Each session lasts 45 minutes.~Frequency:~Once a week for the first month (four sessions). Biweekly for the next two months (four sessions). Home Exercises: Participants will be guided on pelvic floor exercises to be performed at home throughout the three months."
214307841|NCT05457881|DIETARY_SUPPLEMENT|Scandi-Shake|Scandi-Shake \[any of 4 flavors - vanilla, strawberry, banana cream, and caramel\] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
214307842|NCT03306680|RADIATION|SBRT|Patients will be assigned to treatment doses using the TITE-CRM model.
214307843|NCT05577403|BEHAVIORAL|Mulligan's mobilization with movement MWM added isometric strength training|"Mulligan's mobilization with movement added isometric exercise:~the participants in the experimental group will receive a Mulligan's mobilization with movement added isometric exercise.~Treatment will be given for the period of three weeks, for five days a week in both groups.~Data will be collected before intervention and after 2nd \& 4th week of intervention."
214307844|NCT06964464|DRUG|Metoprolol Succinate|Metoprolol succinate is a beta-blocker used for the management of heart failure with reduced ejection fraction (HFrEF). In this study, participants in the metoprolol succinate group will remain on their current treatment regimen with metoprolol succinate. The dose will be titrated to the recommended target dose as per the study protocol. The intervention aims to evaluate the effectiveness of continued use of metoprolol succinate in patients with heart failure and an implantable cardioverter defibrillator (ICD).
214307845|NCT06964464|DRUG|Carvedilol|Carvedilol is a non-selective beta-blocker with alpha-blocking activity used in the treatment of heart failure. In this study, participants assigned to the carvedilol group will switch from metoprolol succinate to carvedilol at an equivalent dose. The carvedilol dose will be titrated to recommended target doses according to the study protocol. This intervention aims to compare the effectiveness of carvedilol versus metoprolol succinate in improving clinical outcomes in patients with heart failure and ICDs.
214307846|NCT06483334|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion at different dose levels
214307847|NCT06483334|BIOLOGICAL|Enfortumab Vedotin|IV infusion at different dose levels
214307848|NCT06483334|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
214307849|NCT05681871|DIETARY_SUPPLEMENT|Ferrous gluconate syrup or ferrous fumarate/folic acid tablets|Oral iron supplementation dosed based on body weight
214307850|NCT03054584|OTHER|Collecting Nevi|Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
214307851|NCT05782673|DEVICE|wearable MAIJU for motor assessment|The novel multisensor wearable MAIJU will be used to measure infants' motor performance at home. The recordings are repeated at 2 months intervals betveen 6 and 18 months of age.
214307852|NCT03919071|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214307853|NCT03919071|DRUG|Dabrafenib Mesylate|Given PO
214307854|NCT03919071|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214307855|NCT03919071|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214307856|NCT03919071|RADIATION|Radiation Therapy|Undergo RT
214307857|NCT03919071|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214307858|NCT02951338|BEHAVIORAL|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
214307859|NCT02951338|OTHER|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
214307860|NCT04431479|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214307861|NCT04431479|OTHER|Medical Chart Review|Review of medical chart
214307862|NCT04431479|OTHER|Quality-of-Life Assessment|Ancillary studies
214307863|NCT04431479|OTHER|Questionnaire Administration|Complete questionnaire
214307864|NCT05660928|OTHER|Multidimensional intervention|Multidimensional intervention, with mutidisciplinary approach.
215060261|NCT05358418|OTHER|AIS,START with films transferring|Excluding patients with incomplete clinical data of treatment
215060262|NCT02745704|DRUG|Peginterferon alfa|peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
214307865|NCT02861573|BIOLOGICAL|Pembrolizumab 200 mg|IV Q3W
215060263|NCT00654745|DRUG|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
215060264|NCT00654745|DRUG|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
214307866|NCT02861573|DRUG|Olaparib 400 mg|Eight 50-mg capsules PO BID
214307867|NCT02861573|DRUG|Docetaxel 75 mg/m^2|IV Q3W
214307868|NCT02861573|DRUG|Prednisone 5 mg|One 5-mg tablet PO BID
214307869|NCT02861573|DRUG|Enzalutamide 160 mg|Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
214307870|NCT02861573|OTHER|Dexamethasone 8 mg|Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
214307871|NCT02861573|DRUG|Olaparib 300 mg|Two 150-mg tablets PO BID
214307872|NCT02861573|DRUG|Abiraterone acetate 1000 mg|Two 500-mg or four 250-mg tablets PO QD
214307873|NCT02861573|DRUG|Lenvatinib|20 mg PO QD
214307874|NCT02861573|BIOLOGICAL|Pembrolizumab/Vibostolimab coformulation|IV Q3W
214307875|NCT02861573|DRUG|Carboplatin|IV Q3W
214307876|NCT02861573|DRUG|Etoposide|IV on Days 1, 2 and 3 of each cycle
214307877|NCT02861573|BIOLOGICAL|Belzutifan 120mg|PO QD
214307878|NCT06325722|OTHER|Low-carbohydrate Diet|Consisting of 15 percent protein, 75 percent fat, and 10 percent carbohydrate
214307879|NCT06325722|OTHER|Low-fat Diet|Consisting of 15 percent protein, 10 percent fat, and 75 percent carbohydrate
214307880|NCT05687994|BEHAVIORAL|Audiovisual Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, auditory, and visual cues for speaking
214307881|NCT05687994|BEHAVIORAL|Auditory Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, and auditory cues for speaking
214307882|NCT06247787|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214307883|NCT06247787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214307884|NCT06247787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214307885|NCT06247787|DRUG|Cytarabine|Given IV and IT
214307886|NCT06247787|PROCEDURE|Echocardiography Test|Undergo ECHO
214307887|NCT06247787|DRUG|Fludarabine|Given IV
214307888|NCT06247787|DRUG|Hydrocortisone Sodium Succinate|Given IT
214307889|NCT06247787|BIOLOGICAL|Imetelstat|Given IV
214307890|NCT06247787|DRUG|Leucovorin Calcium|Given IV or PO
214307891|NCT06247787|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214307892|NCT06247787|DRUG|Methotrexate|Given IT
214307893|NCT05774015|DIETARY_SUPPLEMENT|Magnesium Oxide tablet 500 mg|To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
214307894|NCT05225272|OTHER|Enhanced Recovery Program for on-pump cardiac surgery|Implementation of a Enhanced Recovery Program for on-pump cardiac surgery patients
214307895|NCT05370313|BEHAVIORAL|Market Price Condition (control)|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Cigarette taxes increased across trials at the same magnitudes used in the tax conditions.
214307896|NCT05370313|BEHAVIORAL|Tobacco Parity Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
214307897|NCT05370313|BEHAVIORAL|Nicotine-Content Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier.
214307898|NCT05370313|BEHAVIORAL|Harm-Reduction Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
214307899|NCT05370313|BEHAVIORAL|Modified Risk Tobacco Product (MRTP) Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier.
214307900|NCT06529406|DRUG|Ozanimod|De-escalation of anti-CD20 treatment using ozanimod.
214307901|NCT05382338|PROCEDURE|Audiometric Test|Ancillary studies
214307902|NCT05382338|PROCEDURE|Auditory Brainstem Response|Ancillary studies
214307903|NCT05382338|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
214307904|NCT05382338|DRUG|Cisplatin|Given IV
214307905|NCT05382338|DRUG|Cyclophosphamide|Given IV
214307906|NCT05382338|DRUG|Lomustine|Given PO
214307907|NCT05382338|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214307908|NCT05382338|OTHER|Quality-of-Life Assessment|Ancillary studies
214307909|NCT05382338|RADIATION|Radiation Therapy|Undergo radiation therapy
214307910|NCT05382338|DRUG|Sodium Thiosulfate|Given IV
214307911|NCT05382338|OTHER|Survey Administration|Ancillary studies
214307912|NCT05382338|DRUG|Vincristine|Given IV
214307913|NCT06557889|DRUG|Pembrolizumab + Cisplatin/Carboplatin + 5-FU|"* 4 cycles of combination treatment: 4 cycles of pembrolizumab (200 mg IV on Day 1 of each 3-week cycle) in combination with chemotherapy with platinum salts (cisplatin (100 mg/m2 IV on Day 1 of each 3-week cycle) or carboplatin (AUC 5 IV on Day 1 of each 3-week cycle), at the investigator's choice) and 5-FU (1000 mg/m2/day IV continuous from Day 1-4 of each 3-week cycle).~* Maintenance phase: pembrolizumab is continued as monotherapy for up to 24 months of treatment in total (from the first injection of cycle 1)."
214480420|NCT06869616|OTHER|Cognitive Remediation|10 patients will undergo a rehabilitative training (Cognitive Remediation), already published and demonstrated to be feasible for patients with schizophrenia. This program includes domain-specific neurocognitive exercises aimed at training specific cognitive areas known to be impaired in schizophrenia. The treatment plan includes 15 45-minutes sessions.
214307914|NCT05919940|DIETARY_SUPPLEMENT|Dietary Supplement: additional substitution of protein|"Day one (admission) no nutrition is applied.~Protein target is increased as follows:~* to a level of 1,2g/kg/d on day 1 after ICU admission~* to a level of 1,4g/kg/d on day 2 after ICU admission~* to a level of 1,6g/kg/d on day 3 after ICU admission~* to a level of 1,8g/kg/d on day 4 after ICU admission~* to a level of 2,0g/kg/d from day 5 onwoards~Additional protein is given within 2 hours after mobilization respectively:~* to 0,125g/kg/d on day 1 after ICU admission~* to 0,2g/kg/d on day 2 after ICU admission~* to 0,25g/kg/d on day 3 after ICU admission~* to 0,3g/kg/d from day 4 after ICU admission onwoards"
214307915|NCT05919940|DEVICE|Neuromuscular electrical stimulation|twice daily 60 minutes till day 28 or ICU discharge
214307916|NCT05919940|OTHER|Early Mobilization|at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
214480421|NCT06869096|PROCEDURE|Intraoperative area irrigation|After colorectal cancer surgery, flush the surgical area with chlorhexidine solution 1 minute before suturing the skin. According to abdominal cavity contamination, bleeding and tumor invasion to determine the flushing time and flush fluid volume. If the abdominal cavity infection is more serious or exudate more, the flushing time can be relatively prolonged. At last, there were no obvious blood residue, tissue fragments and suppurative secretions in abdominal cavity. Ensure that the surgical field of vision is clear, the surface of each organ is smooth, and there is no abnormal exudate.
214480422|NCT06868940|DEVICE|wearable multi-channel ECG acquisition devices|If patients do not meet the exclusion criteria, they will wear the wearable multi-channel ECG device for 7 days after enrollment, followed by a myocardial SPECT examination; there is no specific order for these examinations. After enrollment, baseline information of the patients (such as age, gender, height, weight, etc.), comorbidities (such as hypertension, diabetes, hyperlipidemia, chronic kidney disease, etc.), and auxiliary examination data (such as complete blood count, biochemistry, cardiac injury markers, BNP, echocardiography, wearable multi-channel ECG device data, SPECT-related examination data, such as ST-segment, total load score, total rest score, etc.) will be collected. The endpoint of this study is to evaluate the sensitivity, specificity, and accuracy of the wearable multi-channel ECG device in assessing myocardial ischemia in CHD.
214480423|NCT06870929|DEVICE|The Photogrammetry-assisted intraoral scanning|The Photogrammetry-assisted intraoral scanning; will be executed using the MUA-compatible ioConnect ® photogrammetry system components exactly in the same sequence as recommended by the manufacturer
214480424|NCT06870929|DEVICE|The modified approach of splinting-assisted intraoral scanning|The scan bodies will be mounted over the MUA and loosely connected with a power chain before the Medit scanner single-shot scanning procedure. Using the additional scan option in the Medit scanner software, another single-shot scan will be obtained and superimposed to the first scan yielding a color map that reflects the accuracy of the obtained scan and directs a highly precise final scan.
214480425|NCT06870929|DEVICE|Simple splinting-assisted intraoral scanning|The Medit i600 direct intraoral classical scans will be obtained while applying only a basic simple splinting
214480426|NCT06869668|OTHER|Correlation|Correlation between outcomes
214480427|NCT06869538|OTHER|Exercise|For the Pilates exercises, a Pilates instructor created movements (squeeze mini ball, stretch hoop, circle with large ball, back and forth with large ball, and squat) in the gymnasium of the pregnancy school for 8 weeks, 2 days a week. Auxiliary equipment (mini ball, resistance band, Pilates ring) was used. Kegel exercises were performed 4 days a week, 3 sessions a day for 8 weeks.
214480428|NCT06870747|DEVICE|use of Transcutaneous electrical neurostimulation|in this study we would like to use for the first time TENS device during non surgical periodontal therapy
214480429|NCT06870747|DEVICE|no TENS during non-surgical periodontal therapy|patients in the control group are going to have non surgical periodontal therapy without TENS
214480430|NCT06871345|OTHER|Semi-structured interviews SCID|"Structured Clinical Interview for DSM-5 Personality Disorder (SCID) :~The SCID is a 90-item semi-structured interview, covering all 10 categories of personality disorder as described in the DSM-5. Each item is rated on a three-point scale: absent, subclinical level and present."
214480431|NCT06871345|OTHER|Self-report questionnaires|Participants will complete a battery of self-report questionnaires, assessing emotional dysregulation (including SRD, the primary endpoint), childhood adversity, anxiety, depression, and premenstrual symptoms.
214480432|NCT06871345|OTHER|Cognitive assessment|"Cognitive assessment, coupled with the recording of physiological parameters (Biopac).~Participants will complete a battery of neuropsychological tests targeting emotional processes. These tests will make it possible to evaluate the hot component of executive functioning, i.e. specifically involved in the processing of socio-emotional information. Autobiographical verbal fluences and the emotional Hayling test will be used to measure initiation and inhibition processes, respectively."
214480433|NCT06871345|OTHER|Momentary Ecological Assessment (EMA)|A momentary ecological evaluation protocol will be proposed between visits V1 and V4 in order to assess the emotional and symptomatic dynamics in a context of daily life. During two menstrual cycles, subjects will be invited, via their smartphone, to take daily semi-random readings (indicated by SMS) of their subjective (4 times/day), but also spontaneous emotional experiences
214480434|NCT06870695|PROCEDURE|Electrocautery|Patients undergoing standard surgical de-epithelization with electrocautery.
214480435|NCT06870695|PROCEDURE|Surgical blade by scalpel|Patients undergoing standard surgical de-epithelization using surgical blade by scalpel.
214480436|NCT06871033|DRUG|TAP block with neostigmine|40 patients will receive postoperative TAP block with 20ml 0.25% plain bupivacaine (10ml 0.5% bupivacaine added to 10ml normal saline) and 500 microgram neostigmine for each side.
214480437|NCT06871033|DRUG|TAP block with Ketamine|40 patients will receive postoperative TAP block with 20 ml 0.25% plain bupivacaine (10ml 0.5% bupivacaine added to 10ml normal saline) and 0.5 mg/kg ketamine for each side.
214480438|NCT06870942|DRUG|Maintenance first-line treatment plus radiation therapy|Maintenance first-line treatment plus radiation therapy
214915831|NCT06524362|BEHAVIORAL|Conventional group|"Patients completing three months post-low anterior resection (LAR) for rectal cancer or six weeks post-diversion ileostomy closure following LAR will be recruited to Conventional group after randomization.~Recruited subjects in the conventional group recieves usual care following low anterior resection such as fluid intake, fiber intake, diet, toilet posture, life style advice etc"
214915832|NCT02588794|DEVICE|CytoSorb 300 ml device (3804606CE01)|additional cytokine adsorber
215060265|NCT00654745|DRUG|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
214307917|NCT06966258|BEHAVIORAL|Inspire HER Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
214307918|NCT06064643|OTHER|Online Survey|All participants will be asked to complete an online survey
214307919|NCT06064643|OTHER|Qualitative Interview|30 survey participants will take part in a single one-hour qualitative interview.
214307920|NCT06064643|OTHER|Bleed Diary|50 participants will complete a 30 day bleed diary
214307921|NCT06335381|OTHER|Northwell Pregnancy & Peds Chats|The Northwell Pregnancy \& Peds Chats is a personalized care digital chatbot delivered via the Conversa platform. At Northwell, patients are enrolled automatically to receive the chats when they initiate prenatal care. Chats are accessible on a smartphone, tablet, and computer. During the prenatal and postpartum periods, participants receive a weekly chat via text message or email with a link to the platform. Each chat begins with asking if there are any updates the patient wants to share regarding their pregnancy. The chats provide timely, brief educational tools and resources. They are also designed to capture clinical, behavioral health, and social health concerns that triggers yellow flags (e.g., lack of transportation to obstetrics appointment) or red flags (e.g., elevated blood pressure) that go to a 24/7 nurse-led call center who follows up to connect the participant to clinical, behavioral health, or social services as needed.
214307922|NCT06335381|BEHAVIORAL|Prenatal Telehealth Visits|The MOMs CMC/RN (interventionists) will deliver up to 12 bi-weekly self-management support telehealth visits during the prenatal period. The first telehealth visit will be 30-45 minutes in duration and follow-up visits will be 15-20 minutes. These telehealth visits will involve clinical and behavioral health check-ins; navigation to clinical, behavioral health, and social services as needed; screening for social needs during the initial telehealth visit; follow-up on referrals to resources to address social needs; and self-management support. MOMs CMCs/RNs will assess progress with engagement in self-management behaviors including asking about minutes and type of physical activity, self-monitoring (blood pressure, blood sugar, weight), and taking medications. The MOMs CMC/RN will provide brief maternal health education and support the participant in establishing behavior change goals and facilitating problem solving to address barriers to achieving goals each session.
214307923|NCT06335381|OTHER|Postpartum Telehealth Visits|The MOMs CMC/RN will conduct a telehealth visit (with navigation as needed) by phone 24 and 72 hours after labor and delivery. After the 72-hour call, telehealth visits with navigation will occur bi-weekly until 6 weeks postpartum. These telehealth visits will be 15-20 minutes in duration. Telehealth visits will include a brief clinical and behavioral health check-in, screening for social needs, navigation to clinical, behavioral health, and social services as needed, and follow-up on referrals to community resources and social services. During each visit, participants will be asked if they have experienced any signs or symptoms of concern (e.g., pain, discomfort, headaches, bleeding), screened for depression and anxiety, and be reminded about upcoming medical appointments. The CMC or RN will navigate the participant to the appropriate provider (e.g., OB, cardiologist, behavioral health) or services (e.g., emergency, social, community-based resources) as needed in a timely manner.
214307924|NCT06335381|OTHER|Home Blood Pressure Monitor|Participants will receive an Omron 10 home blood pressure monitor to use throughout the study period. Along with the cuff, participants will receive written (postcard) and video instructions (https://youtu.be/p9UEDv6nvwU) on how to accurately measure their blood pressure. Participants with diagnosed chronic hypertension or preeclampsia during the prenatal period will be encouraged to measure their blood pressure twice a day; participants without these conditions will be encouraged to measure their blood pressure twice a week. During the postpartum period, participants will be encouraged to follow their provider recommendations in terms of how often they should measure their blood pressure. Participants will be allowed to keep the blood pressure monitor after the study has completed.
214307925|NCT06335381|OTHER|Fitbit|Participants will receive a Fitbit to use during the study period. Participants will be asked to wear the Fitbit on their wrist throughout the day to track all activity (e.g., walking, other physical activity, sedentary activity, and sleep). All data including minutes of activity and step counts will be stored on a secure web-based platform that aggregates data from the Fitbit device. Participants will be encouraged to sync their Fitbit device every 5 days with their phone to ensure data is up to date. Participants will be allowed to keep the Fitbit after the study has completed.
214480439|NCT06870370|DRUG|propranolol|This group Will receive propranolol intravenously at a dose of 1 mg every 6 h for 7 days, and doses will be held if heart rate less than 60 bpm, mean arterial pressure less than 65 mmHg
214480440|NCT06870370|DRUG|normal saline IV|This group Will receive 1ml of sterile 0.9% normal saline IV every 6 hours for 7 days
214480441|NCT06871007|DRUG|Nivolumab|Nivolumab 40 mg on Day 2 is added to dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R).Standard guidelines for conducting the DA-EPOCH-R protocol will be used.
214480442|NCT06871371|DEVICE|Sevoflurane (Volatile Anesthetic)|Both groups will be given sevoflurane and one group will be given low current anesthesia and the other group will be given medium flow anesthesia.
214670533|NCT02913807|PROCEDURE|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
214670534|NCT02913807|PROCEDURE|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
214670535|NCT02391610|OTHER|No intervention|
214670536|NCT06232434|DRUG|Prospidelong|Prospidium chloride (in the form of prospidelong (a mixture of prospidium chloride and dextran sodium salt phosphate containing carbamate groups in a 1:1 ratio)) - 1000 mg.
214915833|NCT01500382|DRUG|Vibegron|Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
214307926|NCT04629248|DRUG|Obinutuzumab|Open Label: An intravenous (IV) infusion of 1000 milligram (mg) of obinutuzumab will be administered at Week 0, Week 2, Week 24, and Week 26. Participants who relapse during the open-label treatment period may be eligible for further treatment.
214307927|NCT04629248|DRUG|Tacrolimus|Open Label: Participants will receive tacrolimus at a starting oral dose (PO) of 0.05 mg/kilogram (kg) (participant dry weight) per day divided into two equal doses given at 12-hour intervals, titrated to serum trough level 5-7 Nanograms per millilitre (ng/mL). Optimized tacrolimus dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks. Participants who relapse during the open-label treatment period will have their dose of tacrolimus tapered over 8 weeks and may be eligible for further treatment.
214307928|NCT04629248|DRUG|Methylprednisolone|Premedication: Methylprednisolone 80 mg IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
214307929|NCT04629248|DRUG|Acetaminophen|Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
214307930|NCT04629248|DRUG|Diphenhydramine|Premedication: Diphenhydramine (50 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
214307931|NCT06110780|OTHER|acupuncture|"The insertion of the needles will be applied to a depth of 1-2 cm according to the thickness of the local tissues according to the standards of Traditional Chinese Medicine. The EA parameter will be set to a frequency of 2 HZ/100 HZ at a current that the patients' tolerance is best between 0.5 mA and 1.2 mA.~The patient will be electrically stimulated for 30 minutes until the patient feels Teh Chi - heaviness, numbness and swelling."
214307932|NCT06851559|DRUG|Vonoprazan|Vonoprazan will be administered orally as a tablet
214307933|NCT06851559|DRUG|Placebo|Placebo will be administered orally as tablet
214307934|NCT03965962|BIOLOGICAL|VRVg-2|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
214307935|NCT03965962|BIOLOGICAL|Purified Inactivated Rabies Vaccine|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
214307936|NCT03965962|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV)|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
214307937|NCT03965962|BIOLOGICAL|Rabies immune globulin (human)|"Pharmaceutical form: Solution for injection;~Route of administration: IM"
214307938|NCT06368817|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214307939|NCT06368817|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214307940|NCT06368817|DRUG|Carboplatin|Given IV
214307941|NCT06368817|DRUG|Etoposide|Given IV
214307942|NCT06368817|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214480443|NCT06871371|DEVICE|low- medium flow anesthetic machine|The study aims to compare the effects of low and normal flow sevoflurane anesthesia on the frontal QRS-T angle and cerebral oxygenation in laparoscopic cholecystectomy surgery.
214480444|NCT06868732|DRUG|JSKN016|Administered intravenously according to protocol.
214480445|NCT06868732|DRUG|Carboplatin|AUC 4, Q3W, administered intravenously according to protocol.
214480446|NCT06868732|DRUG|Furmonertinib Mesylate|160mg, qd, administered according to protocol.
214480447|NCT06868732|DRUG|Ivonescimab|20mg/kg, Q3W, administered intravenously according to protocol.
214480448|NCT06868732|DRUG|Docetaxel|60mg/m\^2, Q3W, administered intravenously according to protocol.
214307943|NCT06368817|PROCEDURE|Lumbar Puncture|Undergo LP
214307944|NCT06368817|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214307945|NCT06368817|OTHER|Questionnaire Administration|Ancillary studies
214307946|NCT06368817|PROCEDURE|Surgical Procedure|Undergo second-look surgery
214307947|NCT05109728|DRUG|[177Lu]Lu-DOTA-TATE|"Group 1: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed."
214307948|NCT05109728|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
214307949|NCT05109728|OTHER|Temozolomide|"Concomitant Phase: Temozolomide 75mg/m2/d p.o until last day of EBRT.~Maintenance Phase: Temozolomide p.o 150 mg/m2/d during cycle 1 then 200 mg/m2/d for the following cycles if tolerated well in Cycle 1. 6 cycles total (1 cycle = every 28 days)"
214307950|NCT05109728|OTHER|Radiotherapy|2 Gy/day, 5 days per week followed by 2 days of rest, for 6 consecutive weeks
214307951|NCT06484244|OTHER|5 Sessions of Split-belt Treadmill-based Locomotor Adaptation|Participants will complete 5 sessions of split-belt treadmill-based locomotor adaptation. The split-belt instrumented treadmill allows the two belt speeds to be operated independently, enabling different belt speeds for each leg. The split-belt walking assessment will consist of 3 phases: baseline phase in which the belts operated at the same speed (Pre-tied, 2-minutes), a phase in which the belts operated at different speeds (Split-belt, 15-minutes), and a final phase in which the belts operated at the same speed (Post-tied, 4-minutes).
214307952|NCT06363851|DRUG|Kylo-11|Administered SC.
214480449|NCT06868732|DRUG|Tislelizumab|200mg, Q3W, administered intravenously according to protocol.
214480450|NCT06868732|DRUG|Pembrolizumab|200mg, Q3W, administered intravenously according to protocol.
214480451|NCT06868888|OTHER|Blood collection|Erythrocyte osmotic deformability was evaluated via osmotic gradient ektacytometry.
214480452|NCT06868888|OTHER|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary Exercise Testing (CPET) is a non-invasive assessment that evaluates the integrated function of the cardiovascular, pulmonary, and muscular systems during exercise.
214307953|NCT06363851|DRUG|Placebo|Administered SC.
214307954|NCT06971289|OTHER|blood test|blood test as part of routine care
214480453|NCT06872801|DEVICE|High-Flow Nasal Cannula|To compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD.
214480454|NCT06872801|DEVICE|Noninvasive Ventilation|to compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD
214307955|NCT06971146|OTHER|Nurse-Led Self-Management Support|"The intervention offers four distinct support options. Patients are free to choose the option that best suits their preferences and needs.~I1: App-Based Monitoring - Patients receive an app that provides relevant health information, including short educational videos, images, and other resources. Every three months, the app sends a pop-up reminder.~I2: Reminder by Letter - Patients receive a friendly reminder every three months via e-Boks or postal mail (for those without e-Boks access) encouraging continued treatment adherence.~I3: SMS Reminder - Patients receive a text message every three months to remind them to continue their treatment.~I4: Phone Call Check-In - A nurse contacts the patient by phone three times per year at scheduled intervals to provide support and ensure they remain on track with their treatment."
214307956|NCT06971146|OTHER|GP-follow up|Patients in the control group will be discharged from the hospital and continue with routine care provided by their general practitioner (GP). The GP will receive a discharge letter outlining the recommended treatment plan. In addition, patients will receive a letter containing key information about their condition, along with a recommendation to consult their GP annually for ongoing disease monitoring.
214915834|NCT01500382|DRUG|Tolterodine ER|Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
214915835|NCT01500382|OTHER|Placebo (vibegron)|Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
214307959|NCT06151574|DRUG|zongertinib|zongertinib
214307960|NCT06151574|DRUG|pembrolizumab|pembrolizumab
214307961|NCT06151574|DRUG|cisplatin|platinum-pemetrexed chemotherapy
214307962|NCT06151574|DRUG|carboplatin|platinum-pemetrexed chemotherapy
214307963|NCT06151574|DRUG|pemetrexed|platinum-pemetrexed chemotherapy
214307964|NCT06531824|DRUG|BI 690517|BI 690517
214307965|NCT06531824|DRUG|Placebo matching BI 690517|Placebo matching BI 690517
214307966|NCT06531824|DRUG|Empagliflozin|Empagliflozin
214307967|NCT05525845|OTHER|Functional Magnetic Resonance Imaging (pCASL-MRI)|MRI's will be performed at multiple points on each visit day.
214307968|NCT05525845|OTHER|Intragastric Balloon|Intragastric Balloon will be placed during Visit 2 study day and inflated to maximum tolerated volume. Patient will then be scanned in the MRI.
214307969|NCT05525845|OTHER|Elemental Meal|Patient will ingest the tasteless elemental meal until their maximum level of fullness. Once full, the patient will be scanned in the MRI.
214307970|NCT05525845|OTHER|Hedonic Meal|Patient will ingest meal of their choice from a local food delivery service and eat until they reach their maximum level of fullness. Once full, the patient will be scanned in the MRI
214307971|NCT03642223|OTHER|Stable iron isotopes|Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
214307972|NCT00003641|BIOLOGICAL|interferon alfa-2b|Given IV
214915836|NCT01500382|OTHER|Placebo (tolterodine ER)|Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
214915837|NCT01500382|DRUG|Prophylactic Antibiotic|A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
214915838|NCT04423744|DRUG|BAY1817080|Film-coated tablet
214307973|NCT00003641|OTHER|observation|Patients undergo observation for 4 weeks.
214307974|NCT01817933|BEHAVIORAL|physical therapy|
214307975|NCT03659916|DRUG|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of IBAT
214307976|NCT00878709|DRUG|neratinib|
214307977|NCT00878709|OTHER|placebo|
214307978|NCT00322842|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
214480455|NCT06872281|DEVICE|Fractional bipolar radiofrequency|The treatment group will receive a single treatment of intravaginal fractional bipolar radiofrequency therapy.
214480456|NCT06872281|DEVICE|Sham device|The sham group will receive treatment with a specialized sham device that mimics the treatment group's equipment. There are no differences in the design of the tip device, the auditory signal (beeping), or the pulse count display.
214480457|NCT06681194|DRUG|Silver Nitrate|"See Silver nitrate only study arm"
214480458|NCT06681194|DRUG|triamcinolone|"See Triamcinolone only study arm"
214915839|NCT04423744|DRUG|Moxifloxacin|Film-coated tablet
214915840|NCT04423744|DRUG|Placebo|Matched placebo as film-coated tablet
214915841|NCT00415727|DEVICE|auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation|
214915842|NCT05399940|DIAGNOSTIC_TEST|Serum PSA,Delta Neutrophil Index(DNI),WBC|Urine culture, prostate volume
214915843|NCT00808912|DRUG|sildenafil|sildenafil 50 mg ingested orally 1 hour prior to exercise testing
214915844|NCT00808912|OTHER|placebo|matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
214915845|NCT03697343|RADIATION|Radiosurgery|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm)
214915846|NCT03697343|RADIATION|Fractionated stereotactic radiotherapy|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm
215060266|NCT05820568|BEHAVIORAL|ICBT-IU|Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
215060267|NCT05511376|DEVICE|AURICULAR VAGUS NERVE STIMULATION|For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.
215060268|NCT05511376|BEHAVIORAL|DIET|For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)
214307979|NCT05487482|OTHER|Ageing Safe from the Risk (ASRi) Model of safety culture|For the intervention groups, planning will be done to provide education and training. Families will be given modules on Safety Culture in the Elderly. Materials provided about the safety of the elderly include changes in the elderly, the concept of safety in the elderly, the type of danger to the elderly, how to prevent harm in the elderly, the first handling in case of accidents, and the role of the family in the efforts of elderly safety. The material will be delivered by experts in elderly health and patient safety (professionals from health centers, social services, and academics). In addition to education and training, families will also receive home visits to check and monitoring the condition of the elderly at home related to adverse events and the home environment. Measuring will be done every 4 weeks by using a monitoring book.
214307980|NCT01746927|OTHER|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
214307981|NCT06584396|OTHER|Non-Interventional Study|Non-interventional study
214307982|NCT03567707|BIOLOGICAL|C-section -Vaginal seeding|"Mother-infant pair randomized to vaginal microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the vaginal microbiota soaked gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding procedure once.~Additional Intervention:~Following the seeding procedure, infants will then receive the standard detailed examination for newborns and standard of care, except that the first infant bath will occur at least 12 hours after delivery."
214307983|NCT03567707|DRUG|C-section - Placebo Seeding|"Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding procedure once.~Additional Intervention:~Following the seeding procedure, infants will then receive the standard detailed examination for newborns and standard of care, except that the first infant bath will occur at least 12 hours after delivery."
214307984|NCT03567707|OTHER|Standard care|Mother-infant pair where mother undergoes spontaneous vaginal delivery, with both receiving standard of care.
214307985|NCT06824987|COMBINATION_PRODUCT|AZD2373-Arm 1|Accessorized Pre-Filled Syringe (Solution for injection)
214307986|NCT06824987|COMBINATION_PRODUCT|AZD2373-Arm 2|Accessorized Pre-Filled Syringe (Solution for injection)
214307987|NCT06824987|COMBINATION_PRODUCT|Placebo|Accessorized Pre-Filled Syringe (Solution for injection).
214307988|NCT06824987|DEVICE|APOL1 Genotyping Clinical Trial Assay|The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.
214307989|NCT06292780|DRUG|Linvoseltamab|anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody
214307990|NCT05287451|OTHER|RIsk-Reducing Salpingectomy (RRS)|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
214307991|NCT05287451|OTHER|Risk-Reducing Oophorectomy-RRO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
214307992|NCT05287451|OTHER|Risk-Reducing Salpingo-Oophorectomy-RRSO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
214307993|NCT06591377|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
214307994|NCT06591377|DRUG|Cilostazol 100 MG|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
214307995|NCT06591377|DRUG|Aspirin 75mg|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
214307996|NCT06591377|DRUG|Aspirin 75mg|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
214480459|NCT06681194|DRUG|Silver nitrate + triamcinolone|"See Combination group study arm"
214480460|NCT06873243|BEHAVIORAL|Learning Health System Approach|Our intervention will be informed by the framework for designing LHSs developed by The Health Foundation and the updated framework for developing and evaluating complex evaluations commissioned by the UK Medical Research Council and National Institute for Health Research.The updated framework considers not only if an intervention is effective, but also whether the intervention is acceptable, implementable, cost-effective, scalable, and transferrable across contexts. The trial will encompass three of the four key components of complex intervention design: Development of an intervention Assessment of feasibility of the intervention, and Evaluation of the intervention. . We anticipate that a Plan Do Study Act (PDSA) cycle of quality improvement will be most suited to the Thai context as this approach is currently being promoted by the Thai Ministry of Public Health.
214670537|NCT06232434|PROCEDURE|chemotherapy|"after diagnostic laparotomy/laparoscopy, systemic chemotherapy in accordance with the clinical protocol Algorithms for the diagnosis and treatment of malignant neoplasms (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018), namely the section regulating the treatment of patients suffering from metastatic gastric cancer with a degree of prevalence tumor process corresponding to sT1-4N0-3M1"
215060269|NCT05511376|BEHAVIORAL|EXERCISE|Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
214307997|NCT05502718|OTHER|Stretching and Strengthening Exercises|The patients in the study group will be given exercise videos. These exercise videos will be selected in accordance with the patient's cervical dystonia type (Torticollis, laterocollis, retrocollis, anterocollis). During the exercises, stretching exercises will be applied to the muscle groups that cause dystonia, and isometric strengthening exercises will be applied to the contralateral muscle groups. Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week. Patients will be asked to mark after each exercise on the exercise chart prepared to determine continuity and compliance with exercise. Patients will be called and followed up on a weekly basis with the exercise chart given to the patients and by telephone.
214954922|NCT05879224|COMBINATION_PRODUCT|Revised case management package|"1. Point-of-care quantitative G6PD testing using G6PDSTANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total)(Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PDactivity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DPactivity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding the importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
215060270|NCT05402007|OTHER|Pulmonary rehabilitation exercises at the Rehabilitation Center|Face-to-face intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will prescribe pulmonary rehabilitation exercises that will be performed at the pulmonary rehabilitation center.
215060271|NCT05402007|OTHER|Home Intervention|Home Intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will provide a portfolio of self-explanatory exercises, and guide participants on safety precautions.
215060272|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered orally
215060273|NCT06102512|DRUG|LOXO-783|Administered orally
215060274|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered IV
215060275|NCT04968626|RADIATION|PI-LL|The pelvic parameters were collected including PI, pelvic tilt (PT), sacral slope (SS) and LL ,and compared between IS patients and the AS group. Besides, spinopelvic malalignment was defined as an absolute value of PI-LL greater than 10.In the IS group,the clinical symptoms were assessed with the Japanese Orthopaedic Association (JOA) score and the visual analogue scale (VAS). We compared spinopelvic parameters between the asymptomatic adults and the IS patients. Additionally, we investigated correlations between spinopelvic parameters and clinical symptoms.
215060276|NCT01822769|OTHER|Cardiopulmonary rehabilitation|See Arm Description
215060277|NCT01822769|OTHER|Standard of care|See Arm Description
215060278|NCT01995526|DRUG|Insulin Peglispro|
215060279|NCT01487538|BEHAVIORAL|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
215060280|NCT01487538|BEHAVIORAL|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
215060281|NCT01487538|BEHAVIORAL|Discussion Boards|forum to exchange information and experiences
215060282|NCT01487538|BEHAVIORAL|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
215060283|NCT02363777|PROCEDURE|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
215060284|NCT02363777|PROCEDURE|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
215060285|NCT00383331|DRUG|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
215060286|NCT00383331|DRUG|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
215060287|NCT06200597|DRUG|LAD603|LAD603 SC injection.
215060288|NCT06200597|OTHER|Placebo|Matching placebo SC injection.
215060289|NCT00924612|DRUG|Oral testosterone undecanoate (containing 300 mg T)|
215060290|NCT00133159|BIOLOGICAL|Grass MATAMPL|
215060291|NCT00924001|DRUG|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3
215060292|NCT00924001|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
215060293|NCT00924001|DRUG|Fludarabine|25 mg/m\^2/day intravenously x 5 days
215060294|NCT00924001|DRUG|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
215060295|NCT00127491|PROCEDURE|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
215060296|NCT00127491|OTHER|Low tidal volume ventilation|Low tidal volume ventilation strategy (ARDSnet)
215060297|NCT00127491|OTHER|Transpulmonary pressure-directed ventilation (EPVent)|Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
215060298|NCT03614598|PROCEDURE|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
215060299|NCT03614598|PROCEDURE|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
215060300|NCT03614598|PROCEDURE|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
215060301|NCT04817839|BEHAVIORAL|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
214480461|NCT06681103|BEHAVIORAL|Personalized Normative Feedback|Those participating in this condition will receive a personalised brief report which summarises the results of their initial assessment. The PONF will comprise the following elements: (1) Details of the main gambling and trading activities performed, including frequency of engagement and amount of money spent; (2) Scores on the criteria of pathological trading and/or PGSI (pathological gambling), together with an interpretation of the results and the level of severity; (3) Summary of the areas (financial, emotional, etc.) that the participant has indicated as being affected by gambling or trading. All results will be accompanied by graphs enabling participants to compare their scores with the average scores of the Spanish population of the same sex and age range. To prevent an increase in behaviour in participants whose frequency or intensity of gambling/trading is below the norm, as recommended by Newall et al. (2023), the normative data will include extreme averages and percentages
214480462|NCT06871800|OTHER|blood withdrawal|10 ml of blood, two 5 ml tubes suitable for serum isolation. Blood collection will be done at admission in the rehabilitation department (T0), after completing 50% of their rehabilitation program (T1), and at discharge (T2)
214480463|NCT06871852|OTHER|a video-based physiotherapy and exercise program.|Video-Based Intervention Group: Participants in this group will receive videos detailing migraine triggers, precautionary measures, and a physiotherapy and exercise program. Each exercise will be thoroughly explained by a physiotherapist in the videos, enabling participants to perform the exercises correctly by following the verbal and visual instructions.
214307998|NCT05502718|OTHER|Breathing and Rhythmic Coordination Exercises|The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.
214307999|NCT06497556|DRUG|Divarasib|Divarasib will be administered orally QD
214308000|NCT06497556|DRUG|Sotorasib|Sotorasib will be administered orally QD
214308001|NCT06497556|DRUG|Adagrasib|Adagrasib will be administred orally BID
214308002|NCT06117813|DEVICE|Nu.T|Participants receive visual perceptual training using the Nu.T software.
214308003|NCT06117813|OTHER|No-Treatment Control|No-treatment was administered during control period.
214308004|NCT06923774|DEVICE|Ion endoluminal system|Lung nodule biopsy and/or localization procedure using the Ion endoluminal system per sites' standard of care
214670538|NCT06652828|OTHER|Conventional Treadmill Walking (CTT)|The CTT serves as a comparison to PBT. It involves standard treadmill walking without perturbations on the same treadmill. This intervention is conducted over the same defined period as PBT (3-6 weeks), with a matched frequency and exercise time compared to the PBT group for consistency. Participants are secured with safety harnesses while walking.
215060302|NCT04817839|BEHAVIORAL|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
215060303|NCT01903122|DRUG|Cevimeline|
215060304|NCT04501601|DIETARY_SUPPLEMENT|Fruit and vegetable solid drink|weight loss program supplement
215060305|NCT02729116|DRUG|Sitafloxacin|Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.
215060306|NCT02729116|DRUG|Ertapenem|Patients are given IV ertapenem for 14 days
215060307|NCT01458743|DRUG|Ceftaroline|60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
214308005|NCT06620302|BIOLOGICAL|Bcl-XL Proteolysis Targeting Chimera DT2216|Given IV
214670539|NCT06652828|OTHER|Perturbation-Based Balance Training (PBT)|Overall, 9 training sessions with different objectives and progression regarding perturbation directions, predictability, and intensity will be conducted within 3-6 weeks. During the initial sessions, familiarizing participants with the treadmill and establishing their individual walking pace will be focused. Pace can be individually adjusted in each training session. Participants are secured with safety harnesses while walking.
214670540|NCT05439928|DEVICE|DEXCOM G6 CGM|Continuous glucose monitoring
215060308|NCT01458743|DRUG|Ceftaroline|Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
214308006|NCT06620302|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214308007|NCT06620302|DRUG|Irinotecan|Given IV
214308008|NCT05214768|DRUG|CC-93538|Specified dose on specified days
214308009|NCT05214768|DRUG|Placebo|Specified dose on specified days
214308010|NCT07003594|OTHER|Jigsaw IV technique|The Intervention Group receives training in cardiothoracic examination using the Jigsaw IV technique.
214308011|NCT07007962|DRUG|rilzabrutinib|Pharmaceutical form:Tablet-Route of administration:Oral
214308012|NCT05041322|DRUG|Buspirone|Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
214308013|NCT05041322|DRUG|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
214308014|NCT06381141|DRUG|CLN-619|Anti-MICA/MICB monoclonal antibody
214308015|NCT05926947|DIETARY_SUPPLEMENT|Verum A|Formulation of polyphenols from olive leaf extract, blackcurrant extract, pomegranate extract, grapefruit extract
214308016|NCT05926947|DIETARY_SUPPLEMENT|Verum B|Formulation of polyphenols from olive leaf extract, blackcurrant extract, white kidney bean extract, chromium picolinate and Zinc bisglycinate
214308017|NCT05926947|DIETARY_SUPPLEMENT|Placebo|Micro crystalline cellulose
214308018|NCT06682208|PROCEDURE|ES catheter|ES catheter for postoperative pain control
214308019|NCT06682208|PROCEDURE|Intercostal nerve cryoablation (INC)|INC used for postoperative pain control
214308020|NCT07010406|DRUG|Povetacicept|Injection for Subcutaneous Administration.
214308021|NCT06685835|DRUG|Brensocatib|Film-coated Oral tablet
214308022|NCT06685835|DRUG|Placebo|Film-coated Oral tablet
214308023|NCT07007312|DRUG|Ziftomenib|Oral administration
214308024|NCT07007312|DRUG|Placebo|Oral administration
214308025|NCT07007312|DRUG|Venetoclax|Oral administration
214308026|NCT07007312|DRUG|Azacitidine (AZA)|Intravenous or subcutaneous administration
214308027|NCT07007312|DRUG|Daunorubicin|Intravenous administration
214308028|NCT07007312|DRUG|Cytarabine (Ara-C)|Intravenous administration
214308029|NCT03795298|DEVICE|WATCHMAN FLX Implant|Left atrial appendage closure with the WATCHMAN FLX device
214308030|NCT03795298|DRUG|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
214308031|NCT07012187|OTHER|They will watch a video on subcutaneous injection application using virtual reality technology (virtual reality glasses).|Students will watch a video on subcutaneous injection application using virtual reality technology (virtual reality glasses).
214308032|NCT07030465|DEVICE|The press needle, antihistamine, and moisturizer therapy|Device: Press Needle (PN) PN is applied unilaterally on acupoints LI11, SP10, ST36, and SP6 alternately. It consists of an adhesive patch with a small sterile needle retained for 3-4 days before replacement. This procedure is repeated over a 4-week period. Needle sizes is 0.22 × 1.5 mm), and all procedures follow standard aseptic protocols. PN provides prolonged stimulation with cumulative effects in a minimally invasive manner. Participants continue their routine hemodialysis and conventional treatments for CKD-associated pruritus (CKDaP).
214308033|NCT07030465|DEVICE|The sham press needle, antihistamine and moisturizer therapy|Sham PN uses adhesive patches without needles, applied to the same acupoints (LI11, SP10, ST36, and SP6) with the same retention schedule (3-4 days over 4 weeks) as the intervention group. All procedures, including placement and instructions, are performed identically to maintain blinding. There is no skin penetration or real acupoint stimulation. Participants continue their routine hemodialysis and conventional treatments for CKDaP.
214308034|NCT05737927|DRUG|Glucose 8 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
214480464|NCT06871852|OTHER|brochure-based physiotherapy and exercise program.|"Brochure-Based Intervention Group: Participants in this group will be provided with brochures that include information on migraine triggers, precautionary measures, and rehabilitation exercises accompanied by visual aids. The exercises will be detailed with written instructions and illustrations.~Exercise Program: The exercise program will include self-massage techniques for specific muscle groups, self C1-C2 joint mobilization, cervical region exercises, cognitive exercises, and progressive relaxation exercises for the back and face."
214480465|NCT06871605|PROCEDURE|ultrasound-guided transversalis fascia plane block|With the patient in the lateral decubitus position, an 8-12 Hz linear ultrasound (US) probe is placed transversely over the iliac crest. The external oblique (EO), internal oblique (IO) and transversus abdominis (TA) muscles are identified so that the abdominal muscles are in the field of view. The TA muscle is then advanced posteriorly until it tapers to the thoracolumbar fascia with its aponeurosis adjacent to the quadratus lumborum (QL) muscle. The 22 gauge block needle is advanced in plane with the US probe. After placing the needle tip in the virtual triangular plane between the posterior edge of the TA muscle, the QL and the underlying transversalis fascia, 4 mL of 0.5% bupivacaine + 2 mL of a total of 8 mg dexamethasone + 4 mL of saline are injected for a total volume of 10 mL.
214670541|NCT05475873|DRUG|normal saline|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
214670542|NCT05475873|DRUG|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
214670543|NCT05475873|DRUG|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
214954923|NCT04284163|BEHAVIORAL|Gamification|Teaching through gamification
214308035|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
214308036|NCT05737927|DRUG|Glucose 16 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
214308037|NCT05737927|DRUG|Glucose 12 g uncoated beads|After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
214308038|NCT05737927|DRUG|Glucose 12 g coated beads (60% w/w)|After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
214308039|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
214308040|NCT06703489|DEVICE|Sphere-9 Catheter with the Affera Mapping and Ablation System|Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia due to prior myocardial infarction will be enrolled and undergo ablation with the Sphere-9 Catheter with the Affera Mapping and Ablation System.
214308041|NCT07036003|DRUG|Somatropin (recombinant human growth hormone)|Study participants will deliver Somatropin via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks at a dose of 0.5mg/day per body surface area (0.5mg/m2/day).
214308042|NCT07036003|DRUG|bacteriostatic saline placebo|Study participants will deliver bacteriostatic saline via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks in an identical delivery device to the experimental arm.
214308043|NCT07036445|PROCEDURE|Epidural Steroid Injection|Intervention consists of interlaminar CT guided epidural steroid injection
214308044|NCT07036445|PROCEDURE|Epidural platelet-rich plasma injection|Intervention consists of interlaminar CT guided epidural platelet-rich plasma injection after recovery of plasma by blood sampling and centrifugation
214308045|NCT07038733|PROCEDURE|Peripheral Blood Sample for Immune Analysis|A peripheral blood sample will be collected at the time of surgery.
214480466|NCT06871605|PROCEDURE|ultrasound-guided ilioinguinal and iliohypogastric nerve block group|With the patient in the supine position, an 8-12 Hz linear ultrasound (US) probe is placed medial and cephalal to the anterior superior iliac spine (ASIS), transversely between the ASIS and the umbilicus. The external oblique (EO), internal oblique (IO) and transversus abdominis (TA) muscles are identified so that the abdominal muscles are in the field of view. The II-IH nerves are hyperechogenic in the fascial plane between the IO and TA muscles. A 22 gauge block needle is advanced in plane with the US probe. When the needle tip is advanced to the II and IH nerves, 4 mL of 0.5% bupivacaine + 2 mL total 8 mg dexamethasone + 4 mL saline is injected for a total volume of 10 mL.
214480467|NCT06873347|DEVICE|Procedure type|"• Patients undergoing one of the following surgeries:~* Supra cervical hysterectomy~* Total hysterectomy~* Breast conserving surgeries: B-plastic + periareolar mastopexy~* Breast conserving surgeries: segmental resection"
214480468|NCT06873347|DEVICE||"• A dataset from procedure types other than the above mentioned to the type unknown is assigned to this type."
214308046|NCT07038733|PROCEDURE|Tumor Sample for Analysis|Extra tumor which is left over following clinical diagnoses will be collected.
214308047|NCT07038733|PROCEDURE|Adjacent non-malignant kidney for analysis|Extra normal tissue which is left over following clinical diagnoses will be collected.
214480469|NCT06872333|DRUG|Alemtuzumab|Alemtuzumab (Campath) will be administered IV over 2 hours on day -8 to day -4.
214480470|NCT06872333|RADIATION|Total Body Irradiation|400 cGy in 2 split fractions will be administered per Department of RadiationOncology SOPs.
214915847|NCT04378725|BEHAVIORAL|School-based smoking prevention and cessation program (The KOTAK program)|"Advance Intervention: Following the screening process, this intervention package was inclusive of group-briefing for the smokers in at least 3 subsequent sessions in one academic year. The content delivered by the dentist were based on the KOTAK guidebook consisted of 8 Modules.The modules were as follows:~1. Introduction: Identifying students who smoke~2. Cigarette and addiction~3. The danger of smoking and passive smokers~4. Advantages of smoke-free lifestyle and adolescent perception on smoking~5. Legal and religious perception of smoking~6. The benefits of smoking cessation~7. Preparation and how to stop smoking~8. Nicotine withdrawal symptom and relapse prevention~The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval."
214915848|NCT01507792|DRUG|iron sulphate|1 or 2 330 mg/daily iron sulphate oral tablets
214915849|NCT01507792|DRUG|antiH1-histamine, proton pump inhibitor|This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
214915850|NCT00454688|DRUG|Asimadoline|Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
214915851|NCT00454688|DRUG|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
214915852|NCT00617890|BIOLOGICAL|robatumumab|Robatumumab IV every two weeks until disease progression.
214915853|NCT04357665|PROCEDURE|Bilateral TAPP Repair|laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
214915854|NCT04357665|PROCEDURE|Open PP Repair|Open pre-peritoneal repair using single mesh fixed by sutures
214480471|NCT06872333|BIOLOGICAL|Cell Infusion|On day 0 the cells will be infused per cell source specific institutional guidelines
214480472|NCT06872333|DRUG|Thymoglobulin|"ATG will be administered IV every 24 hours beginning on day -8 for all patients.~Dosing will be model-based using Bayesian methodology13,14,15. Total doses and total number of doses (1-4 doses) will be determined based on absolute lymphocyte count and weight."
214480473|NCT06872333|DRUG|Fludarabine|Fludarabine will be administered IV over 1 hour every 24 hours on day -5 to day - 2. The daily dose of fludarabine will be determined by model-based dosing utilizing Bayesian methodology with a cumulative area under the curve (cAUC) of 20 mg\*hr/L (range 18-22 mg\*hr/L).
214480474|NCT06872333|DRUG|Busulfan|Busulfan dosing and administration and therapeutic drug monitoring (TDM) per institutional guidelines. Initial busulfan dosing will be determined by model-based dosing utilizing Bayesian methods with a cumulative area under the curve (cAUC) of 75 mg\*hr/L.
214670544|NCT03449888|PROCEDURE|Regadenoson myocardial perfusion imaging stress test|Best fit model of pharmacologic myocardial perfusion imaging data, including summed stress and difference scores, gated left ventricular ejection fraction, transient ischemic dilatation, and heart rate response to regadenoson data.
214670545|NCT03449888|PROCEDURE|Arm exercise electrocardiographic stress test|Published arm exercise score and best fit model of arm exercise ECG stress testing data.
214915855|NCT04357665|PROCEDURE|Bilateral Lichtenstein Repair|Bilateral Lichtenstein Repair using 2 separate meshes fixed by sutures
214915856|NCT03266315|BIOLOGICAL|FloraBaby|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
214915857|NCT03266315|OTHER|Placebo|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
214915858|NCT06045325|DIAGNOSTIC_TEST|Orbscan II|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
214915859|NCT06045325|DIAGNOSTIC_TEST|IOL Master 700|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
214308048|NCT07038733|PROCEDURE|Draining lymph node(s) for analysis|Draining lymph nodes which have been identified by the surgeon visually, potentially using a tracer (injection of up to 5mg of ICG into the peritumor kidney) will be collected.
214308049|NCT07038733|PROCEDURE|Regional non-draining lymph node(s) for analysis|Regional lymph nodes which have been deemed as non-draining by the surgeon will be collected.
214308050|NCT07037901|DRUG|IMG-007|Participants will receive IMG-007 subcutaneously.
214308051|NCT07037901|DRUG|Placebo|Participants will receive a placebo subcutaneously.
214480475|NCT06872333|DRUG|Thiotepa|Thiotepa will be administered at a dose 5 mg/kg IV every 12 hours on day - 7 over 2 hours. Patients will undergo thiotepa skin care per institutional guidelines
214915860|NCT06045325|DIAGNOSTIC_TEST|IOL Master 500|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
214915861|NCT06045325|DIAGNOSTIC_TEST|Atlas 9000|Diagnostic assessment to measure white-to-white.
214308052|NCT06721091|DRUG|VNA-318|"Part 1 will consist of administration of VNA-318 at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of VNA-318 in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)~Once PK suggests that the therapeutic dose has been reached in the SAD part, the SAD and MAD parts of the study could be run in parallel"
214308053|NCT06721091|DRUG|Placebo|"Part 1 (SAD) will consist of administration of matching placebo at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of matching placebo in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)"
214308054|NCT07039721|OTHER|Evaluation of echogenicity|Patients ongoing a routine 2nd or 3rd trimester ultrasound will have an extra 5 minutes of ultrasound with a specific intestinal setting
214308055|NCT07036705|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Cognitive behavioral therapy for insomnia (CBT-I) is a behavioral (psychotherapeutic) intervention for insomnia disorder. Participants will complete digital CBT-I online using the Sleep Healthy Using the Internet (SHUTi) program.
214308056|NCT07036705|DEVICE|Passive Body Heating (PBH)|Passive body heating (PBH) is a body-based treatment that participants will complete using a sauna blanket, which is similar in form factor to an adult-sized sleeping bag (head is not within the heated area). Participants will complete at least three 15-minute PBH sessions per week. Participants will complete PBH sessions in the sauna blanket placed on the floor or on a couch (i.e., not in their bed) at a setting of Level 6, 1-2 hours before bed.
214308057|NCT06704152|DRUG|SOC + BSB-1001 Dose Escalation Cohort|Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic stem cell transplant (HCT).
214308058|NCT06704152|DRUG|SOC+BSB-1001 Expansion Dose|Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic cell transplant (HCT).
214308061|NCT07042802|DRUG|LBL-024 for Injection|LBL-024 Intravenous infusion.
214308062|NCT07042802|DRUG|Paclitaxel Injection|Paclitaxel Intravenous infusion.
214308063|NCT06885073|DEVICE|CPMX2|CPMX2 - Non-invasive pressure estimation
214308064|NCT07048340|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I intervention will include four 45-60 minute sessions with a clinician. The sessions will include CBT-I components such as sleep psychoeducation, bedtime routines and sleep hygiene, graduated exposure, cognitive restructuring, and SRT in one of the intervention groups. The protocol is based on previous studies of CBT-I for school-aged children.
214308065|NCT07048340|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia without SRT|This intervention will include four 45-60 minute sessions with a clinician. The sessions will include CBT-I components such as sleep psychoeducation, bedtime routines and sleep hygiene, graduated exposure, and cognitive restructuring. Sleep Restriction Therapy will not be included in the intervention. The protocol is based on previous studies that delivered CBT-I to school-aged children.
214308066|NCT06722157|DRUG|BI 771716|BI 771716
214308067|NCT06722157|DRUG|Pegcetacoplan|Pegcetacoplan
214480476|NCT06872333|DRUG|Cyclophosphamide|"Cyclophosphamide will be administered at a dose of 14.5 mg/kg over 2 hours IV daily on days -6 and -5. Cyclophosphamide dosing is calculated based on actual body weight (ABW).~For Arm D - Cyclophosphamide 50 mg/kg IV will be administered over 2 hours on days +3 and~+4. Cyclophosphamide dosing for post-transplant is calculated based on ideal body weight (IBW) unless patient weighs less than IBW, in which case actual body weight (ABW) will be used."
214480477|NCT06872333|DRUG|Sirolimus|Patients on Arm A and Arm D will receive sirolimus; beginning on day -3 and continuing until day +180 for patients on Arm A or beginning on day +5 and continuing until 1 year post transplant for patients on Arm D.
214308068|NCT06722157|DRUG|Sham comparator to BI 771716|Sham comparator to BI 771716
214670546|NCT03449888|PROCEDURE|Treadmill electrocardiographic stress test|Duke Treadmill Score and best fit model of treadmill exercise ECG stress testing data.
214670547|NCT03449888|PROCEDURE|Coronary artery calcium score and cardiac computed tomographic angiography|Coronary artery calcium score by Agatston criteria and severe obstructive coronary artery disease \> 70% by cardiac computed tomographic angiography or invasive coronary arteriography.
214670548|NCT01526356|DRUG|Placebo|Study cream is applied nightly to the affected areas on the face.
214480478|NCT06872333|DRUG|Tacrolimus|Patients on Arm B and Arm C will receive tacrolimus, beginning on day -3 and continuing until day +180. Tacrolimus dosing and monitoring will be per institutional guidelines.
214954924|NCT04284163|BEHAVIORAL|Traditional teaching|Teaching through master lesson methodology
214670549|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
214670550|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
214670551|NCT04358393|DRUG|APG-115|APG-115 given once daily on day 1-5 of every 28 day cycle
214480479|NCT06872333|DRUG|Mycophenolate Mofetil|MMF will begin on day -3 (Arm A, B \& C) or day +5 (Arm D). Patients treated on adult service will receive 15 mg/kg (max 1500 mg/dose) given every 12 hours, rounded to nearest 250 mg. Patients on pediatric service will receive 15 mg/kg (max 1000 mg/dose) given every 8 hours. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. MMF will be stopped at day +30 (Arms A, B \& C) or day +35 (Arm D) or 7 days after engraftment, whichever day is later, if no acute GVHD.
214480480|NCT06623630|DRUG|Cyclophosphamide|Standard of care
214480481|NCT06623630|DRUG|Ciltacabtagene Autoleucel|Standard of care
214480482|NCT06623630|RADIATION|Total body irradiation|Radiation doses delivered to the entire body
214480483|NCT05488522|BIOLOGICAL|SBRT + atezolizumab and bevacizumab|"Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT.~Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks.~Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks."
214480484|NCT06862570|DRUG|2% lignocaine with epinephrine 1.8 ml(36mg/ml lignocaine HCL, epinephrine bitartrate 0.0324mg/ml)|2% lignocaine with epinephrine 1.8 ml(36mg/ml lignocaine HCL, epinephrine bitartrate 0.0324mg/ml)
214480485|NCT06862570|DRUG|4% Articaine with epinephrine 1.7 ml (40mg/ml Articaine HCL, epinephrine bitartrate 0.018 mg/ml)|4% Articaine with epinephrine 1.7 ml (40mg/ml Articaine HCL, epinephrine bitartrate 0.018 mg/ml)
214480486|NCT06862804|BEHAVIORAL|practical group training|It is understood how important the issue is when it is considered that supporting these families, especially mothers, both socially and psychologically can be important in alleviating the difficulties they experience and that mothers with children with autism are in a risk group in terms of receiving this support. The research was designed considering that the applied training we will provide will be effective in increasing social support and developing self-compassion for the primary caregivers of children and will reduce the level of depressive symptoms.
214480487|NCT06862804|BEHAVIORAL|practical group training|practical group training
214480488|NCT06624592|DRUG|Sevoflurane|Subjects will receive standard of care anesthesia Sevoflurane, with intravenous push Dexmedetomidine
214308069|NCT06731998|PROCEDURE|Local Anesthesia|For local anesthetic administration at port sites, 30 mL of 0.1% ropivacaine is injected around the umbilical port site following the completion of the primary surgical procedure. Additionally, 5 mL of 0.1% ropivacaine is injected around each additional port site to ensure effective local anesthesia.
214308070|NCT06731998|PROCEDURE|Laparoscopic Transversus Abdominis Plane block|Surgeon will place 18 gauge needle into the fascial plane between the internal oblique and transversus abdominis muscles. Once the needle is accurately positioned surgeon will inject 15 mL of 0.1% ropivacaine slowly. This procedure is performed bilaterally to ensure comprehensive analgesia. The total volume utilized for the LapTAP block is 30 mL of 0.1% ropivacaine.
214308071|NCT06743503|GENETIC|UB-VV400|UB-VV400 is a third-generation, self-inactivating (SIN), replication-incompetent, lentiviral vector (LVV) investigational drug product
214308072|NCT06743503|DRUG|Rapamycin|In DF Stage 2, Rapamycin will be given in combination with UB-VV400. For subjects receiving rapamycin, rapamycin dosing will be once daily with a planned start date of Day 4 (approximately 72 hours after the administration of UB-VV400) and continuing for up to 60 days, as tolerated.
214308073|NCT06742190|BIOLOGICAL|Empasiprubart|Intravenous infusion of empasiprubart
214308074|NCT06742190|BIOLOGICAL|IVIG (Intravenous Immunoglobulin)|Intravenous infusion of IVIg
214480489|NCT06624592|DRUG|Isoflurane|Subjects will receive standard of care anesthesia Isoflurane
214480490|NCT05589363|DRUG|ABC block with bupivacaine/liposomal bupivacaine|Patients will be randomized to receive an ABC block using bupivacaine/liposomal bupivacaine solution
214480491|NCT05589363|DRUG|ABC block with saline|Patients will be randomized to receive an ABC block using normal saline
214308075|NCT06742190|OTHER|Empasiprubart-placebo|A placebo resembling the empasiprubart treatment
214308076|NCT06742190|OTHER|IVIg-placebo|A placebo resembling the IVIg treatment
214308077|NCT06888505|DRUG|Dapagliflozin (Forxiga)|Participants in the dapagliflozin arm received dapagliflozin 10 mg tablets, administered orally once daily for 4 months, in addition to their standard anthracycline-based chemotherapy regimen. This treatment was given continuously throughout the chemotherapy period to evaluate its cardioprotective effects against anthracycline-induced cardiac toxicity.
214308078|NCT06888505|OTHER|Placebo|Participants in the control arm received a placebo tablet identical in appearance, dosage form, frequency, and duration to dapagliflozin, but containing no active ingredients. The placebo was administered orally once daily for 4 months alongside the participant's standard anthracycline-based chemotherapy regimen and served as the control to evaluate the cardioprotective efficacy of dapagliflozin.
214308079|NCT07049276|PROCEDURE|Index lymph node resection|The largest lymph node affected with melanoma
214480492|NCT06624956|DRUG|glucose, insulin, and potassium (GIK)|"GIK formulation: 100 g/L glucose, 33 U/L insulin, and 40 mmol/L KCl~Reference PMID: 32151220. Formulation represents a 50% reduction in compounded solute combination from the reference study, which allows for administration via peripheral IV."
214480493|NCT06624956|DRUG|Crystalloid Infusion|placebo
214480494|NCT04114136|DRUG|Nivolumab or Pembrolizumab (dependent upon approved indication)|Anti-PD-1 mAb (monoclonal antibody)
214308080|NCT07049276|PROCEDURE|Therapeutic lymph node dissection|Removal of all nodes in the melanoma affected lymph node basin
214308081|NCT06748053|DRUG|GSK5784283|GSK5784283 will be administered.
214308082|NCT06748053|DRUG|Placebo|Placebo will be administered.
214308083|NCT07055269|OTHER|liver metabolic flux|All participants will be given heavy water (2H2O, deuterium-labelled) and \[U-13C6\]-fructose orally, each followed by the collection of one blood plasma sample. Additional biochemical and clinical parameters including liver fat content by MRI, liver fibrosis and cirrhosis by ultrasound imaging and plasma biochemical profiles will be analyzed.
214480495|NCT04114136|DRUG|Metformin|Acts directly or indirectly on the liver to lower glucose production, and acts on the gut to increase glucose utilisation, increase GLP-1 and alter the microbiome.
214480496|NCT04114136|DRUG|Rosiglitazone|A member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).
214480497|NCT03884439|DRUG|Infliximab [infliximab biosimilar 3]|\<Crohn's disease\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. \<Ulcerative colitis\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
214480498|NCT06613763|DRUG|RAY1225|Administered SC
214480499|NCT04700774|BEHAVIORAL|Behavioral activation|Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko \& Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.
214480500|NCT06860269|DRUG|Randomization + Blinatumomab + chemotherapy|Rando 1 : BLINA will be given at 28 µg/day IVC from D1 to D28 for 2 to 4 cycles (first cycle starts with 9 µg/day for 7 days)
214480501|NCT06860269|OTHER|Randomization + Standard frontline T-ALL chemotherapy backbone|Rando 3 : standard of care
214480502|NCT06860269|DRUG|Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone|Rando 3 : ISA will be given at 10 mg/kg IV for a maximum of 28 infusions starting at induction up to maintenance phase.
214308084|NCT07055269|OTHER|ureagenesis capacity|urea and urea cycle metabolites and their enrichment after oral administration of a stable isotope tracer 15NH4Cl will be measured to examine the liver's ability to detoxify ammonia.
214480503|NCT06860269|DRUG|Randomization + Blinatumomab + Ponatinib + chemotherapy|"Rando 2 :~* PONA will be given at 45 mg/day PO during 2 cycles, 30 mg/day during 2 additional cycles, and 15 mg/day during maintenance phase or after alloHSCT~* BLINA will be given at 28 µg/day IVC from D1 to D28 for 2 to 5 cycles (first cycle starts with 9 µg/day for 7 days). Patients allografted will receive two courses before transplant."
214480504|NCT06860269|OTHER|Randomization 1 + Allo HSCT|Rando 1 : standard of care - Allogeneic Hematopoietic Stem Cell Transplantation
214480505|NCT06860269|OTHER|Randomization 2 + Allo HSCT|Rando 2 : standard of care
214480506|NCT06269809|PROCEDURE|Temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Temporary clipping of the uterine arteries and the utero-ovarian ligaments using laparoscopic clips/bulldog clamps, during robotically assisted myomectomy.
214670552|NCT04358393|DRUG|5-azacitidine|5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days
214915862|NCT06045325|DIAGNOSTIC_TEST|Lenstar 900|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
214915863|NCT06045325|DIAGNOSTIC_TEST|Pentacam|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
214308085|NCT06894979|DRUG|ATM Kinase Inhibitor AZD1390|Given PO
214308086|NCT06894979|PROCEDURE|Biospecimen Collection|Undergo blood and cerebrospinal fluid collection
214915864|NCT06045325|DIAGNOSTIC_TEST|iTrace|Diagnostic assessment to measure white-to-white and corneal thickness.
214670553|NCT00995371|DEVICE|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
214915865|NCT06045325|DIAGNOSTIC_TEST|Argos|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
214915866|NCT06045325|DIAGNOSTIC_TEST|Manual caliper measurement|Manual diagnostic assessment to measure white-to-white.
214915867|NCT02640950|DEVICE|NeuroStar TMS|Transcranial Magnetic Stimulation
214915868|NCT05066204|OTHER|Sequence of teaching-/learningmethod|see: arm/group descriptions
214915869|NCT06682689|DEVICE|transcutaneous vagus nerve stimulation|Two groups will use a tVNS stimulator for 12 weeks. Group 1 will apply active stimulation for up to 4 hours daily at a comfortable level for 6 weeks, while Group 2 will use it at the lowest intensity (0.1 mA). After 6 weeks (T2), the groups will switch. Participants will be instructed to use the device for at least 1 hour a day, with a recommendation of 4 hours, following guidelines and recent studies. The CE-certified tVNS® E device non-invasively stimulates the vagus nerve via the ear. It is approved for treating a.o.depression. Device parameters (intensity, pulse length, frequency) mimic invasive VNS techniques, ensuring safe and effective signal transmission. Stimulation will be applied to the left ear, with intensity adjusted to a tingling sensation, avoiding discomfort. The study follows an approved protocol, with low-intensity stimulation as a control. The device delivers biphasic impulses at 25 Hz, with 28 seconds ON and 32 seconds OFF, and is safe for extended use.
214915870|NCT01431690|DRUG|warfarin|A single 25 mg dose of warfarin
214915871|NCT01431690|DRUG|omefas|4 x 1 g capsule dose of Epanova®
214308087|NCT06894979|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214308088|NCT06894979|RADIATION|Radiation Therapy|Undergo radiation therapy
214308089|NCT06894979|OTHER|Survey Administration|Ancillary studies
214308090|NCT05588609|DRUG|Afatinib Oral Tablet|anti epidermal growth factor receptor (EGFR)/HER2 agent
214308091|NCT05588609|DRUG|Enzalutamide Pill|second-generation androgen receptor antagonist
214308092|NCT05588609|DRUG|Abiraterone acetate tablets|androgen synthesis inhibitor
214308093|NCT05588609|BIOLOGICAL|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
214308097|NCT07059455|OTHER|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|Under general anesthesia, patients in the ESP group will be positioned in the left or right lateral decubitus position, depending on the side of the surgical procedure. After the T10 spinous process is identified by manual examination, sterile conditions will be established. The transverse process and erector spinae muscles will be visualized using an ultrasound probe. Using an in-plane technique, 20 ml of 0.25% bupivacaine will be injected between the transverse process and erector spinae muscles using a 22-gauge blocking needle.
214308098|NCT07059455|OTHER|Quadratus Lumborum (QL) Block|Following standard anesthesia monitoring, patients will be placed in the lateral decubitus position. After the field is sterilized, a 2-5 MHz convex ultrasound probe (Samsung, HM70 EVO) will be placed between the iliac crest and costal arch at the level of the posterior axillary line. The transverse process of the L4 vertebra, erector spinae, QL, and PM muscles will be visualized. After inducing local anesthesia with 2% lidocaine (2 ml), a blocking needle (22G\*100 mm, Braun) will be advanced from posterolateral to anteromedial, inserting it between the QL and PM muscles, and 20 ml of 0.25% bupivacaine will be injected.
214308099|NCT06311227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214308100|NCT06311227|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214308101|NCT06311227|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214308102|NCT06311227|PROCEDURE|Computed Tomography|Undergo CT scan
214308103|NCT06311227|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214308104|NCT06311227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214308105|NCT06311227|DRUG|Venetoclax|Given PO
214308106|NCT04303780|DRUG|AMG 510|21 day cycles
214308107|NCT04303780|DRUG|Docetaxel|21 day cycles
214308108|NCT06828120|DRUG|Taneasy 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
214308109|NCT06828120|DRUG|Fluimucil 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
214308110|NCT07074756|DRUG|Chemotherapy|Receive standard of care chemotherapy
214308111|NCT07074756|PROCEDURE|Computed Tomography|Undergo CT
214308112|NCT07074756|OTHER|Internet-Based Intervention|Receive access to the remote chemotherapy management and patient monitoring platform
214480507|NCT06269809|PROCEDURE|No temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Robotically assisted myomectomy, for which no temporary clipping of the uterine arteries and the utero-ovarian ligaments
215060309|NCT04852055|BEHAVIORAL|Advance Care Planning Video|Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
214308113|NCT07074756|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214308114|NCT07074756|PROCEDURE|Neurologic Examination|Ancillary studies
214308115|NCT07074756|OTHER|Questionnaire Administration|Ancillary studies
214308116|NCT07074756|BEHAVIORAL|Surveillance|Undergo surveillance
214308117|NCT06470542|DRUG|2 x 20 ml of Ropivacaine 0.2% Injectable Solution|2 x 20ml 0.2% Ropivacaine - ultrasound-guided iPACK + ACB
214308118|NCT06470542|DRUG|2 x 20ml of Ropivacaine 0.2% Injectable Solution|2 x 20ml 0.2% ropivacaine - ultrasound-guided ESPB at the L1 and S1 level
214308119|NCT06595238|DRUG|AZD6234|IMP injected subcutaneously, once a week. Unit dose strength as per CSP
214308120|NCT06595238|DRUG|Placebo comparator|Placebo matching IMP dose injected subcutaneously, once a week.
214308121|NCT07069738|DEVICE|CRT-D with a Quadripolar LV lead|Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead.
214308122|NCT07069738|DEVICE|CRT-D with INGEVITY+ pace/sense lead|Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA)
214480508|NCT00760630|DEVICE|FFR/CFR and IVUS|All patients with clinical indication for cardiac cath will have FFR and IVUS
214480509|NCT06445465|DRUG|[18F]MNI-1216|\[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
215060310|NCT04196855|DRUG|Teriparatide|"Terrosa 20 micrograms/80 microliters solution for injection. Each dose of 80 microliters contains 20 micrograms of teriparatide.~One cartridge of 2.4 mL of solution contains 600 micrograms of teriparatide (corresponding to 250 micrograms per mL).~Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone."
214308123|NCT04586023|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
214308124|NCT04586023|DRUG|Teriflunomide|Participants will receive teriflunomide.
214480510|NCT06363747|OTHER|Very Low Calorie Diet|Optifast is a medically supervised very low-calorie diet (VLCD) diet that safely induces caloric restriction
214670554|NCT00995371|DRUG|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
214670555|NCT05409105|DIETARY_SUPPLEMENT|Mangoes|Frozen mangoes, 2 cups per day, 2 weeks
214670556|NCT05409105|DIETARY_SUPPLEMENT|Water|2 cups/day bottled water, 2 weeks
214308125|NCT04586023|DRUG|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
214308126|NCT06297226|BIOLOGICAL|Arlocabtagene Autoleucel (BMS-986393)|Specified dose on specified days
214308127|NCT07078656|BEHAVIORAL|Postoperative management|"The patients who agreed to participate in the study will be asked to fill out a Patient Introduction Form by the researchers after obtaining permission from the experimental group with the Informed Consent Form the day before the surgery. On the 2nd day after laparoscopic colorectal surgery, virtual reality glasses will be worn by the patients and they will watch a 10-minute training video on the care of the patient after colorectal surgery. The training content will consist of topics such as dressing the surgical area, signs of infection in the surgical area (redness, swelling, discharge, color, temperature increase), pain management, unexpected situations (fever, nausea, abdominal pain, shivering, chan)"
214308128|NCT06759935|DEVICE|Sham Laser therapy|sham laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.
214308129|NCT06759935|DEVICE|Laser therapy|laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.
214308130|NCT06759935|OTHER|physiotherapy/exercise protocol|physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes Codman's pendulum exercise, range of motion (ROM) exercises, stretching and isometric strengthening exercises, for 4 consecutive weeks with a minimum of 3 sessions per week.
214308131|NCT04645160|DRUG|Tivozanib|Oral tivozanib taken daily for Days 1-21 continuously (of each 28-day cycle) followed with 7 days off medication (except for patients in DL-1, with dosing every other day of the 28-day cycle). Phase I: The starting dose (DL1) is 0.89 mg taken once a day continuously for Days 1-21 with 1 week off medication (except for those patients assigned to DL-1, where tivozanib should be taken every other day, around 48 hours apart in 28-day cycle). Patients may escalate to 1.34 mg taken once a day (DL2) continuously for Days 1-21 with 1 week off medication for their second cycle if there are no dose-limiting toxicities. Phase II: Tivozanib dose level will be at the recommended Phase II dose (RP2D) established in Phase I.
214308132|NCT07084402|DRUG|Contezolid|contezolid 800mg po q12h for 6 months
214308133|NCT07084402|DRUG|Azithromcyin|azithromycin 500mg po tiw (250mg po tiw if weight below 50kg) for 6 months.
214308134|NCT07084402|DRUG|Rifampicin (RIF)|rifampicin 600mg po tiw for 6 months.
214308135|NCT07084402|DRUG|Ethambutol|ethambutol 25mg/kg po tiw for 6 months.
214308136|NCT07082998|BEHAVIORAL|heated yoga|12-weeks of twice weekly 90-min heated yoga classes in the community
214308137|NCT07082998|BEHAVIORAL|sauna|12-weeks of twice weekly 40-min sauna sessions in the community
214308138|NCT07082998|BEHAVIORAL|mindfulness app|12-weeks of 80-mins a week of a mindfulness app
214308139|NCT07123753|OTHER|EXERCİSE|The aim of this study is to examine the effects of classical foot exercises and foot core exercises on pain, balance, gait and lower extremity performance in adolescents with pes planus. This study is planned to be a randomized controlled trial. Participants will be randomly divided into 2 groups. Classic foot exercises will be applied to individuals in the classical foot exercises group for 12-15 minutes, and foot core exercises will be applied to individuals in the core exercises group for 12-15 minutes twice a week for a total of 8 weeks. Pes planus status of individuals included in the study will be evaluated with the navicular drop test. Pain will be evaluated with the foot function test, balance with the star balance test, gait analysis with the footprint method and lower extremity muscle performance with the functional muscle strength assessment for individuals in both groups before and after the application. The evaluations will be applied face to face by the same physiotherapi
214308140|NCT06898957|DRUG|YL201|YL201 will be administered as an IV infusion.
214308141|NCT06898957|DRUG|Tarlatamab|Tarlatamab will be administered as an IV infusion.
214308142|NCT06898957|DRUG|Atezolizumab|Atezolizumab will be administered as an IV infusion.
214308143|NCT06898957|DRUG|Durvalumab|Durvalumab will be administered as an IV infusion.
214308144|NCT06436183|DRUG|Camoteskimab|Drug Product
214308145|NCT06436183|DRUG|Placebo|Inactive substance
214308146|NCT06792734|DRUG|BTM-3566|Oral Solution
214308147|NCT06797453|BEHAVIORAL|Shared Medical Visits|Shared group medical visits over eight weeks and two cooking classes.
214308148|NCT06797453|BEHAVIORAL|Full Plate Living|Online modules teaching how a high-fiber diet can lead to more energy, lower cholesterol, better blood sugar, and easier weight loss.
214308149|NCT05658510|DRUG|BXCL501|Sublingual Film
214308150|NCT05658510|DRUG|Matching Placebo|Sublingual Placebo Film
214308151|NCT06152250|OTHER|Liver Fine-Needle Aspiration|"At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy."
214670557|NCT03193905|PROCEDURE|Bairhugger Full Access Underbody Blanket|30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
215060311|NCT04565340|OTHER|Mode of delivery, maternal and neonatal outcomes/complications|Mode of delivery, maternal and neonatal outcomes/complications
214308152|NCT07088913|DRUG|Capivasertib|Capivasertib will be administered orally twice in Period 2.
214308153|NCT07088913|DRUG|Rosuvastatin|Rosuvastatin will be administered orally once in both Period 1 and Period 2.
214308154|NCT04927156|DEVICE|BALT medical devices|"Includes, but is not limited to, the following:~* Access devices~* Aneurysm treatment devices~* Ischemic Stroke and peripheral occlusive diseases treatment devices~* Arterio-Venous Malformations/fistulas treatment devices"
214308155|NCT05730036|DRUG|Linvoseltamab|REGN5458 will be administered by intravenous (IV) infusion
214308156|NCT05730036|DRUG|Elotuzumab|Elotuzumab will be administered by IV infusion
214308157|NCT05730036|DRUG|Pomalidomide|Pomalidomide capsules will be administered by mouth (PO)
214308158|NCT05730036|DRUG|Dexamethasone|Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
214670558|NCT03193905|PROCEDURE|Cotton blanket - control group|30 patients undergo standard procedure with a cotton blanket
215060312|NCT02229825|DRUG|Duloxetine|Capsule
215060313|NCT02229825|DRUG|Placebo|Capsule
214670559|NCT01849133|RADIATION|external fractionated radiotherapy|conventional external beam radiotherapy
214915872|NCT01431690|DRUG|omega-3-acid ethyl esters|4 x 1 g capsule dose of Lovaza®
214308161|NCT07094334|OTHER|Action Observation|This study, in contrast to prior research, will examine both the acute effects of action observation therapy and its impacts at the peripheral level.
214915873|NCT00915018|DRUG|Neratinib|Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
214308162|NCT07094334|OTHER|Action Observation combined with Motor Imagery|This study, in contrast to prior research, will examine both the acute effects of action observation therapy combined with motor imagery and its impacts at the peripheral level.
214308163|NCT07094334|OTHER|Sham (No Treatment)|Participants in this intervention group will watch landscape and nature-themed videos for the duration corresponding to the intervention period applied in the other groups.
214308164|NCT07090330|DRUG|ORKA-001 Induction Dose|ORKA-001 Induction Dose, administered by subcutaneous (SC) injection
214308165|NCT07090330|OTHER|Placebo|Placebo administered by subcutaneous (SC) injection
214308166|NCT07090330|DRUG|ORKA-001 Maintenance Dose|ORKA-001 Maintenance Dose, administered by subcutaneous (SC) injection
214308167|NCT06911424|DRUG|Fusidic Acid 1%|Fusidic acid 1%
214308168|NCT06911424|DRUG|Placebo|Placebo ophthalmic solution
214308169|NCT07101809|DEVICE|Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
214308170|NCT07101809|DEVICE|Standard Ureteroscopy (URS)|Arm Description: This is a treatment in which the urologist uses a laser to break a kidney stone into very small pieces and then places a tool called a stent to allows the remaining pieces to fall out.
214308171|NCT07100782|DRUG|Relugolix CT|Study medication will be provided by Sumitomo in pill bottles containing an 84-day supply of relugolix 40mg, estradiol 1mg, norethindrone acetate 0.5mg (Relugolix Combination therapy).
214670560|NCT01849133|RADIATION|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
214915874|NCT00915018|DRUG|Trastuzumab|Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
214915875|NCT00915018|DRUG|Paclitaxel|Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
214915876|NCT02752113|DRUG|Empagliflozin and Linagliptin|Empagliflozin and Linagliptin
214915877|NCT02752113|DRUG|Metformin and Insulin sc|Metformin and Insulin sc
214915878|NCT05126069|DEVICE|Ab interno gelatin microstent|Ab interno gelatin microstent
214915879|NCT05126069|PROCEDURE|Trabeculectomy|Trabeculectomy
214915880|NCT01304511|DRUG|Orgalutran|
214915881|NCT02673931|DRUG|Byetta (Lilly, Exenatide)|See description of arms
214915882|NCT02673931|DRUG|Conoxia (AGA, oxygen)|See description arms
215060314|NCT03415581|DRUG|Intranasal Oxycodone|Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
215060315|NCT03415581|BEHAVIORAL|Cue Session|During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
214670561|NCT04725682|DRUG|Tacrolimus|a single dose of 1 mg capsule per period
214308174|NCT06600321|DRUG|ALN-BCAT|Administered by intravenous (IV) infusion
214308175|NCT06600321|DRUG|Pembrolizumab|Administered by intravenous (IV) infusion
214308176|NCT06911385|DEVICE|Arm Remote Ischemic Conditioning plus Pneumatic Compression lower limb|Arm Remote Ischemic Conditioning (4 cycles) plus Pneumatic Compression lower limb (100 mmHg for 1 hour)
214308177|NCT07112872|DRUG|RO7795081|RO7795081 will be taken orally once daily (QD), according to the randomized dosing regimen, during the 30-week treatment period.
214308178|NCT07112872|DRUG|Semaglutide|Semaglutide 14 mg will be taken orally QD, with up-titration as per label, during the 30-week treatment period.
214308179|NCT07112872|DRUG|Placebo|Placebo will be taken orally QD during the 30-week treatment period.
214308180|NCT06916598|OTHER|Delphi study|This Delphi study involves multiple iterative rounds until a stable consensus or dissensus is reached on all the statements.
214670562|NCT00403104|DRUG|ONO-2506PO|1200 mg QD / 18 months
214670563|NCT00403104|DRUG|ONO-2506PO|0 mg QD / 18 months
214915883|NCT02673931|DRUG|20% Human Albumin|
214915884|NCT00904358|DIAGNOSTIC_TEST|cross sectional area|
214915885|NCT00044018|DRUG|CDC-501|
214915886|NCT05809232|OTHER|CARES-guided Group|Participants randomised to the CARES-guided arm will have their CARES-score calculated and entered into the Pre-Anesthesia Assessment electronic form within the Electronic Medical Records (EMR). This score and its relevant advisories will be prominently displayed on this electronic form. (Participants on this arm will receive this intervention in addition to the routine practice).
214915887|NCT04244552|BIOLOGICAL|ATRC-101|ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.
214915888|NCT04244552|BIOLOGICAL|Pembrolizumab|Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
214915889|NCT04244552|DRUG|Pegylated liposomal doxorubicin (PLD)|Pegylated liposomal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis. PLD is doxorubicin HCL encapsulated in liposomes formulated with surface-bound methoxypolyethylene glycol
214915890|NCT00154284|DRUG|Everolimus (Certican)|
214915891|NCT00154284|DRUG|Cyclosporine (Neoral)|
214915892|NCT00154284|DRUG|Steroid|Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
214915893|NCT00154284|DRUG|Basiliximab (Simulect)|
214915894|NCT04917003|OTHER|RIC plus EDAS|Patients who are allocated into RIC group will undergo EDAS surgery combined 3-month RIC treatment. The opposite operation will be performed at 3 months after the first operation.
214915895|NCT04917003|OTHER|EDAS|Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.
214915896|NCT03023618|DEVICE|FloTrac|Stroke Volume has been maintained at 90% of the maximal Stroke Volume as in NICE protocol 2011
214915897|NCT01090349|DEVICE|Implantation of an ICD/CRT-D device|The Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) device and leads are not the devices being evaluated in this investigation.
214915898|NCT01090349|DEVICE|Merlin.NET PCN|The Merlin.Net™ PCN is a dedicated computer system that connects physicians to patients outside of the clinic setting by centralizing data from remote transmissions, implant procedures and in-clinic follow-ups into single location with easy export to Electronic Health Record (EHR) systems
214915899|NCT00566020|DRUG|BW430C (lamotrigine)|lamotrigine 50mg/day-400mg/day
214915900|NCT04959981|DRUG|ERAS-007|Administered orally
214915901|NCT04959981|DRUG|ERAS-601|Administered orally
214915902|NCT04959981|DRUG|Osimertinib|Administered orally
214915903|NCT04959981|DRUG|Sotorasib|Administered orally
214915904|NCT04397016|BEHAVIORAL|Option Grid Decision Aid|-A table with side-by-side comparisons of treatment options organized as responses to patients' frequently asked questions
214915905|NCT06063070|DRUG|Fluzoparib Capsules|oral
214915906|NCT06063070|DRUG|Bevacizumab|Injectable solution
214915907|NCT01146093|DRUG|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
214915908|NCT03159871|DEVICE|Stratafix suture|Stratafix barbed sutures during C-Sections.
214915909|NCT03159871|DEVICE|Vicryl suture|Standart Vicryl suture during C- Sections.
215060316|NCT04917367|PROCEDURE|exploratory surgery|"For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies."
215060317|NCT03200197|OTHER|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
214915910|NCT03073031|DEVICE|Tablet: Samsung Galaxy Tab A|
214915911|NCT04836273|DRUG|Dasiglucagon|Abdominal s.c. self-administration 120 µg of dasiglucagon when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
214915912|NCT04836273|DEVICE|HyoPen|multi-dose reusable pen injector
214915913|NCT04836273|DRUG|Placebo|Abdominal s.c. self-administration with placebo when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
214915914|NCT00886444|DRUG|Ferucarbotran (Resovist)|single time intravenous bolus injection of a contrast agent
214915915|NCT01652768|OTHER|Research Questionnaires|Hospital Anxiety and Depression Scale Pearlin \& Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
214915916|NCT01652768|OTHER|Palliative Care Team|"Week 1: Early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse).~1. Introduce the palliative care team concept.~2. Provide contact information for the palliative care team given~3. Administer Initial Patient and Caregiver Psychosocial Assessments (Appendix A)~4. Offer community resources to patient and caregiver (Appendix B)~5. Provide additional resources/referrals for any needs that are identified by patient or care partner during initial psychosocial assessment~6. Provide supportive care"
214915917|NCT01652768|OTHER|Educational Information Session for Patients and Caregivers|"Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver Week 5 through 7: The PRESENCE Project Social Worker and oncology RN will provide an educational class.~Intervention (Length of time for class = 2 hours):~1. Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver.~2. Provide additional resources/referrals for any needs that are identified by patient or care partner during the educational class.~3. Provide supportive care."
215060318|NCT03200197|OTHER|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
215060319|NCT05659914|DRUG|olaparib+durvalumab|olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
215060320|NCT00179062|DRUG|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
215060321|NCT01532921|PROCEDURE|Tricuspid valve repair|
215060322|NCT01532921|PROCEDURE|Left-sided heart surgery|Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
215060323|NCT01532921|DEVICE|Contour 3D Tricuspid Annuloplasty Ring|Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
215060324|NCT04539613|DRUG|HPFSH & HMG|. Various gonadotropin preparations
215060325|NCT00070109|DRUG|trabectedin|Given IV
214308181|NCT06916598|OTHER|Structured Interview|"Structured interviews will be conducted by members of the steering committee and an independent qualitative research expert. A pilot-tested case vignette along with a Likert scale-based questionnaire, will be employed to gather insights regarding the impact and severity of PPCs. The impact of the individual components of PPCs will be evaluated on a 7-point Global Rate of Change (GRC) scale (from very much worse to very much better) to calculate the minimal clinical important difference. Patient care representatives will be engaged in anonymous voting on the questionnaire. PPCs' rankings and key themes synthesised from the interviews will be shared with the panel in the second Delphi round, facilitating the integration of patient perspectives into the consensus process."
214308182|NCT06920381|DRUG|Gebauer's Ethyl Chloride Topical Spray|Prior to injection of lidocaine, the investigator will apply ethyl chloride spray, Gebauer's Ethyl Chloride Topical Spray, continuously for 4 to 10 seconds until the skin turns white. This application will be done from a distance of 8 to 18 cm (3 to 7 inches) to the right side of the tumor lesion.
214308183|NCT06060860|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules:~1. emotion awareness,~2. cognitive appraisal \& reappraisal,~3. emotion avoidance \& emotion-driven behaviors,~4. awareness and tolerance of emotion-related physical sensations, \&~5. interoceptive and situational emotion-focused exposures.~There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth."
214480511|NCT06684080|OTHER|A care bundle|"1. Risk evaluation for PPH and Reserve plan;~2. Assess blood loss using Estimated Blood Loss Form and amnion fluid collection drape;~3. Satisfy any of the following conditions: i. If the estimated blood loss reaches 500ml but is less than 1000ml, and any of the following abnormal indicators are present; ii. If the estimated blood loss reaches 1000ml, no other indicators need to be considered: 1） Lack of uterine contractions 2） Persistent bleeding 3）Shock index (heart rate/systolic blood pressure) was greater than 0.9 Initiate the following protocols①, ②, ③, ④~   * Maintain uterus tone (Administration of Oxytocin and second-line medications to promote uterine contraction)~     * Intravenous infusion ③ Administered tranexamic acid ④ Multi-methods and Multi-disciplinary"
214480512|NCT02781883|DRUG|BP1001 in combination with Ventoclax plus decitabine|BP1001 in combination with Ventoclax plus decitabine
214670564|NCT05718115|DIAGNOSTIC_TEST|CT scan|Biphasic CT scan including arterial phase and portal venous phase after intravenous injection of 80-100 mL of non-ionic iodinated contrast at rate of 4ml/s using pressure injector.
214915918|NCT01652768|OTHER|Contact every 2 weeks|"The PRESENCE Project APN and/or Presence Project Social Worker will contact the patient and caregiver via telephone or office visit every two weeks and as needed until the second medical oncology visit.~(Anticipated length of time for phone intervention or visit is 20 minutes; however, length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Provide pain and/or symptom management intervention for any issues identified during the follow-up assessment~3. Provide resources/referrals for any needs identified during the social work follow-up assessment~4. Provide supportive care"
214915919|NCT01652768|OTHER|Follow-up Surgical Visit Session|"The PRESENCE Project APN will meet with patient and caregiver at the surgical follow-up visit, approximately two weeks after surgery.~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Administer Symptom Assessment Tool~3. Provide pain and/or symptom management intervention~4. Provide supportive care"
214915920|NCT01652768|OTHER|Medical and/or Radiation Oncology Appointment Session|"The PRESENCE Project APN and/or Presence Project Social Worker will meet with patient and caregiver at the first medical and/or radiation oncology appointment (weeks 3 and 4).~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Re-assess pain and/or symptom management issues and /or intervention~3. Provide resources/referrals for any needs identified during the social work follow-up assessment~4. Provide supportive care."
215060326|NCT00070109|OTHER|pharmacological study|Correlative studies
214670565|NCT01075425|DRUG|bortezomib|Given IV
214670566|NCT01075425|DRUG|belinostat|Given IV
214670567|NCT01075425|OTHER|laboratory biomarker analysis|Correlative studies
215060327|NCT01231334|DRUG|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
215060328|NCT01231334|DRUG|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
215060329|NCT01865318|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin)
215060330|NCT01553682|BEHAVIORAL|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
215060331|NCT01553682|BEHAVIORAL|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
214670568|NCT01075425|GENETIC|western blotting|Correlative studies
215060332|NCT01390298|OTHER|Observational|Observational study only
214480513|NCT02781883|DRUG|BP1001 plus decitabine|BP1001 plus decitabine in ventoclax intolerant or resistant subjects
214480514|NCT06684288|PROCEDURE|Access flap surgery|Granulation tissue attached to the alveolar bone was excised to ensure complete access and optimal visibility of the root surfaces. In addition, instrumentation was performed using a combination of ultrasonic and hand instruments, and no alveolar bone modification was undertaken during the flap procedure. Subsequently, the mucoperiosteal flap was repositioned and primarily closed with proximal simple sutures employing monofilament suture material (5/0 Propilen, Dogsan, Türkiye). Patients were given post-operative recommendations; however, no medication was prescribed.
214480515|NCT06681987|BEHAVIORAL|simulation training|One group of students will practice computer-based simulation for pre-eclampsia and eclampsia case management skills using a high-fidelity simulator (n = 15) (subgroups n=3), while the other group will practice with a low-fidelity model (n = 15; subgroups n=3). In the first stage, the case will be written for the high-fidelity simulator and will be submitted to the opinions of experts in the field. After the necessary arrangements are made, the groups will be randomized and allocated. In the second stage, the experimental group will be presented with a virtual reality simulator, and the control group will be presented with a case example of preeclampsia and eclampsia with a low-level simulator. In order to evaluate and increase the teamwork skills of the students in the experimental and control groups, the students will be divided into subgroups of three.
214480516|NCT06492642|OTHER|Patient Education for Chronic Low Back Pain|"Patient education on chronic low back pain (LBP), including:~Day 5: Basic LBP education, types of LBP, red flags; Day 8: LBP guideline recommendations re: imaging; Day 11: LBP guideline recommendations re: use of rehabilitation services, sitting and standing desks; Day 14: LBP guideline recommendations re:pharmacologic management; Day 17: LBP guideline recommendations re: injections and surgery."
214480517|NCT03685110|DEVICE|CoreHip Total Hip Arthroplasty|Replacement of the Hip Joint
214480518|NCT06686147|DIAGNOSTIC_TEST|Assessment of Joint Range of Motion|Joint range of motion (ROM) measurements will be conducted to assess the specific ranges of motion of participants' joints.
214308184|NCT06060860|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.
214308185|NCT06914505|BEHAVIORAL|visual restoration therapy|In this study, we used a reversing checkerboard pattern as a stimulus and acted on the relatively dark spots area of the patient's visual field.
214670569|NCT01075425|OTHER|pharmacological study|Correlative studies
214308186|NCT06913933|BEHAVIORAL|Static Progressive Splinting for Persistent Wrist Stiffness|"A commercially available static progressive splint with a turnbuckle mechanism allowing fine-tuned adjustments in wrist flexion and extension.~Instructional materials for home use including written guidelines and an adjustment log."
214670570|NCT01075425|OTHER|flow cytometry|Correlative studies
214670571|NCT00337948|DRUG|Epoetin alfa|
214954925|NCT01222663|DEVICE|standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
214954926|NCT01222663|DEVICE|hemoperfusion|Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
214954927|NCT00978341|DRUG|Pregabalin|Pregabalin 150mg capsules BID for 7.5 days
214954928|NCT00978341|DRUG|Placebo for pregabalin|Placebo capsules BID for 7.5 days
214308187|NCT06913933|BEHAVIORAL|Dynamic Splinting for Persistent Wrist Stiffness|"Materials:~A commercially available dynamic (spring-loaded) splint designed for the wrist. An instructional manual and daily usage log for participants."
214308188|NCT06907290|DRUG|Brelovitug 300 mg|Route of administration- Subcutaneous Injection
214308189|NCT06907290|DRUG|Brelovitug 900 mg|Route of administration- Subcutaneous Injection
214308190|NCT06907290|DRUG|Delayed Treatment with Brelovitug 300mg|Route of administration- Subcutaneous Injection
214308191|NCT06912893|DEVICE|radial shock wave therapy|treatment of the nervus medianus on the level of the carpal tunnel with radial shock wave therapy with 1500 impulses, 5 Hz and 1,5 bar
214308192|NCT06912893|DEVICE|focused shock wave therapy|treatment of the nervus medianus on the level of the carpal tunnel with focused shock wave therapy with 1500 impulses, 5 Hz and 0,05 mJ/mm²
214308193|NCT07118891|BIOLOGICAL|ABCL635|Participants will receive SC administrations of ABCL635
214308194|NCT07118891|BIOLOGICAL|Placebo|Participants will receive SC administration of placebo (5% dextrose solution)
214308195|NCT07119112|DEVICE|Surgical drain stripping device|We have developed a device to fully compress the surgical drain tubing without compromising the integrity of the tubing to clear the drain fluid/debris more effectively than the current standard of care.
214308196|NCT07119112|OTHER|Standard of Care (Investigator Choice)|Current standard of care for surgical drain tube stripping involves running fingertips down the length of the tubing compressing the drain tubing to clear fluid/debris.
214954929|NCT00752141|DRUG|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
214954930|NCT00752141|DRUG|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
214954931|NCT00752141|OTHER|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
214954932|NCT06314412|OTHER|Stoller's Afferent Nerve Stimulation (SANS)|15 sessions of SANS (5 sessions/week for 3 weeks)
214308197|NCT06917313|DRUG|Fezolinetant|45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks
214915921|NCT02101736|DRUG|Cabozantinib|This is an open label Phase II clinical trial. For both cohorts, subjects will receive cabozantinib orally in continuous cycles. Each cycle is 28 days. In absence of progressive disease or dose limiting toxicity (DLT), subjects may continue therapy for a total of 24 cycles. Subjects with radiographic response (20% or greater reduction in tumor volume) at the end of 12 cycles can continue on therapy for up to an additional year. However, for Cohort A, subjects who do not achieve 15% reduction in tumor volume after 8 cycles will be considered treatment failure and taken off study. For Cohort B, the criteria that subjects who do not achieve 15% reduction by 8 cycles are considered treatment failure and taken off study was eliminated. Subjects will be carefully monitored for toxicities associated with cabozantinib.
214915922|NCT06325839|OTHER|HypnoBirthing training and oxytocin massage group|HypnoBirthing training and oxytocin massage were applied for a total of 12 hours for 4 weeks with the experimental group.
214915923|NCT00003113|BIOLOGICAL|filgrastim|Filgrastim (granulocyte colony-stimulating factor; G-CSF) is given subcutaneously on days 5-21 and 33-42 of each cycle.
214915924|NCT00003113|DRUG|cyclophosphamide|Cyclophosphamide are given on days 22-31 of each cycle.
214915925|NCT00003113|DRUG|etoposide|Etoposide is given on days 1-3.
214915926|NCT00003113|DRUG|lomustine|Lomustine is given on day 1 of cycles 1 and 3 only.
214915927|NCT00003113|DRUG|procarbazine hydrochloride|Procarbazine are given on days 22-31 of each cycle.
214915928|NCT00003113|RADIATION|radiation therapy|Following the third cycle of chemotherapy, if residual disease is confined to 1 or 2 nodal sites, patients receive radiation therapy.
214915929|NCT00942591|DRUG|Interferon beta 1b|
214915930|NCT00942591|DRUG|Atorvastatin|
214915931|NCT05284448|DRUG|pentoxifylline (Trental SR®)|400 mg three times daily
214915932|NCT03258541|DEVICE|TraceIT®|This pilot study wishes to investigate feasibility and efficacy of the injected hydrogel spacers TraceIT® in sparing vagina/prostate in the treatment of rectal cancer patients.
214915933|NCT03258541|RADIATION|Volumetric Arc Therapy (VMAT)|VMAT - fractionation Schedule : 1.8 Gy per fraction, one fraction per day, 5 fractions per week for the elective PTV and 2 Gy per fraction, one fraction per day, 5 fractions per week for the PTV-boost using a simultaneous integrated boost technique.
214915934|NCT03258541|PROCEDURE|Surgery|Low anterior resection of the rectum: 8-10 weeks post-radiotherapy
214915935|NCT06580717|DRUG|enavogliflozin 0.3mg|"Enavogliflozin 0.3mg, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."
214915936|NCT06580717|DRUG|enavogliflozin Placebo|"A placebo pill identical to enavogliflozin, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."
215060333|NCT03995745|BEHAVIORAL|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
215060334|NCT00436046|BIOLOGICAL|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
215060335|NCT00436046|BIOLOGICAL|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
215060336|NCT02579148|BIOLOGICAL|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.'
214308198|NCT06917313|DRUG|Placebo|45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks
214915937|NCT02776436|DRUG|Dexamethasone|Dose of prophylactic dexamethasone will be reduced for all patients
214915938|NCT02776436|DRUG|Prednisone|standard prednisone 5 mg bid for patients with prostate cancer
214915939|NCT01033032|DRUG|Amrubicin|"Phase I: dose-escalating portion with the starting dose of amrubicin at 90mg/m\^2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m\^2; DL3 - 110mg/m\^2; and DL4 - 120mg/m\^2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days"
214915940|NCT00931437|DIETARY_SUPPLEMENT|vitamin K-rich dairy product|several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
214915941|NCT05532852|DRUG|standard-of-care plus Paxlovid|standard-of-care plus Paxlovid
214915942|NCT05532852|DRUG|standard-of-care|standard-of-care
214915943|NCT04821180|PROCEDURE|Three and four-part proximal humeral fractures' treatment|Open Reduction and Internal Fixation with angle stable plate PHILOS versus RSA (Reverse Shoulder Arthroplasty
214915944|NCT06339944|OTHER|sensory motor training|in this group 17 participants will receive conventional therapy and then followed by kinesthetic exercises. 3 sessions per week includes 10 repetitions with 3sets.
214915945|NCT06339944|OTHER|kinesthetic exercises|in this group 17 participants will receive conventional therapy and then followed by kinesthetic exercises. 3 sessions per week includes 10 repetitions with 3sets.
214915946|NCT02498444|DRUG|Treprostinil|Administration of drug (treprostinil) vs placebo (saline) in the post-operative period
214915947|NCT01224093|DRUG|Chemotherapy|as prescribed
214915948|NCT01224093|DRUG|rituximab [MabThera/Rituxan]|as prescribed
214915949|NCT05950893|PROCEDURE|pressure support level|Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Downward PS level titration was performed from 20 cmH2O to 2 cmH2O at a 2cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O.Inspiratory effort is measured as pressure generated by inspiratory muscles using esophageal pressure monitoring.
214915950|NCT02797457|PROCEDURE|Bilateral allograft of the hands and forearms.|Bilateral allograft of the hands and forearms.
214915951|NCT02797457|PROCEDURE|Prosthetic forehands|Prosthetic forehands
214670572|NCT01563510|PROCEDURE|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
214915952|NCT04566003|DRUG|[18F]GTP1|Participants will receive a bolus IV of approximately 7mCi of \[18F\]GTP1 radiotracer.
214915953|NCT04566003|DRUG|[18F]PI-2620|Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer.
214915954|NCT04566003|DRUG|[18F]MK-6240|Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer.
214915955|NCT02228733|DRUG|KBP-5074|Comparisons of different doses of study drug
214915956|NCT06683300|DRUG|DAPT for 3 months after vertebral artery stenting|After implantation of a drug-eluting stent in the vertebral artery, dual antiplatelet therapy (DAPT) were administered for 3 months. The types of antiplatelet medications are not limited, with the standard regimen consisting of aspirin 100 mg once daily combined with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily. Additional antiplatelet agents such as indobufen may also be considered acceptable.
214915957|NCT02027545|BEHAVIORAL|Decision Aid|Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise
214915958|NCT02027545|BEHAVIORAL|Provider Education|Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
214915959|NCT02027545|BEHAVIORAL|Performance Measure Modification|The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
214915960|NCT02027545|BEHAVIORAL|Simple Informational Booklet|A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
214915961|NCT03777592|PROCEDURE|erector spinae plane block|local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces
214915962|NCT04037163|DIAGNOSTIC_TEST|Fractional flow reserve, Coronary CT angiography|Coronary CT angiography was performed as part of routine clinical practice for patients with suspected coronary artery disease and the decision to perform coronary CT angiography before invasive angiography was at the judgment of the physicians in charge.
214915963|NCT04713839|OTHER|no intervention|We didn't have an intervention program, we used two questionnaires to evaluate participants.
214915964|NCT05359419|COMBINATION_PRODUCT|aminolevulinic acid hydrochloride gel, 10%|10% ALA with Red Light
214308199|NCT06919094|BEHAVIORAL|Life Story Club|Virtual group reminiscence therapy will be provided by the Life Story Club©. Participants will meet virtually via Zoom© with their group (6-10 people) weekly for one hour over a 12-week period to exchange life stories and share in conversation. Groups will be conducted in entirely in English or Spanish, based on participant preference. Each week, the LSC© facilitator will guide the group with question prompts to encourage participants to share personal information, build friendships \& rapport, and create a sense of community. LSC© facilitators are trained in group interview techniques, technology management, and know how to respond appropriately to sensitive information that may emerge during group exchanges.
214308200|NCT06914362|PROCEDURE|global postural reeducation|"Global postural reeducation included the following GPR postures according to the Souchard approach \[7\]: lying on back with the legs extended and arms folded, lying on back with the legs flexed and arms folded, lying on back with the legs extended and arms open, lying on back with the legs flexed and arms open, sitting with legs extended and standing with the back against the wall.~Each posture was performed by the patient under the physiotherapist supervision and was held for 15 to 20 minutes.~Besides, each patient was asked to repeat the exercises daily at home."
214308201|NCT06914362|PROCEDURE|conventional rehabilitation|"Conventional reeducation included manual therapy approaches such as spinal mobilization which aims to restore joint mobility and alleviate muscular tension.~It included also exercise therapy focusing on strengthening core muscles, improving lumbar flexibility, and enhancing posture to stabilize the spine and reduce strain on surrounding structures.~Modalities like heat therapy, cold therapy, and transcutaneous electrical nerve stimulation (TENS) were also used to manage pain and promote muscle relaxation. Additionally, education on ergonomic principles was part of the program to adopt healthy habits and prevent recurrence of pain."
214308202|NCT07110519|DRUG|[18F]-fluoromannitol|\[18F\]-fluoromannitol is an investigational, novel radiotracer for use with PET scan imaging to help detect disease or infection.
214308203|NCT03627533|PROCEDURE|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
214308204|NCT03207945|DRUG|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
214308205|NCT03207945|OTHER|Placebo|Placebo
214308206|NCT06915753|DRUG|TYRA-430|Oral TYRA-430 given daily.
214308207|NCT07123467|DRUG|Low-Dose Cannabidiol|Oral cannabidiol solution (EPIDIOLEX®) administered as an adjunct to cognitive behavioral therapy. Low-dose participants receive 5 milligram/kilogram/day throughout. The intervention targets emotion regulation circuitry and symptom improvement.
214308208|NCT07123467|DRUG|Placebo Matched to Moderate-Dose Cannabidiol|The placebo mimics the appearance, smell, and taste of EPIDIOLEX®. For blinding the moderate-dose cannabidiol arm, dosing starts at 5 mg/kg/day and titrates to 10 milligram/kilogram/day (divided twice a day) after 6 days.
214308209|NCT07123467|DRUG|Moderate-Dose Cannabidiol|Oral cannabidiol solution (EPIDIOLEX®) administered as an adjunct to cognitive behavioral therapy. Moderate-dose participants receive 5 milligram/kilogram/day for 6 days, then titrate to 10 milligram/kilogram/day. The intervention targets emotion regulation circuitry and symptom improvement.
214308210|NCT07123467|DRUG|Placebo Matched to Low-Dose Cannabidiol|The placebo mimics the appearance, smell, and taste of EPIDIOLEX®. For blinding the low-dose cannabidiol arm, dosing is maintained at 5 milligram/kilogram/day (divided twice a day) throughout the treatment period. No titration is required.
214308211|NCT07134127|DRUG|placebo|Placebo (without active ingredients) (cohort1, 2,4) Method of administration: oral, fasted administration. Placebo (without active ingredients) (cohort3) Method of administration: oral, administration after meal.
214308212|NCT07134127|DRUG|IBI3032|IBI3032: (cohort1, 2,4) Method of administration: oral, fasted administration. IBI3032: (cohort3) Method of administration: oral, administration after meal.
214308213|NCT00483223|DRUG|Cisplatin|Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
214308214|NCT00483223|DRUG|carboplatin|Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
214915965|NCT05359419|COMBINATION_PRODUCT|aminolevulinic acid HCl topical solution, 20%|20% ALA with Blue Light
214915966|NCT04998617|OTHER|Toothpaste with curcumin|Subjects will be given toothpaste to be used during this study with 0.5% curcumin
214915967|NCT04998617|OTHER|Toothpaste without curcumin|Subjects will be given toothpaste to be used during this study without curcumin
214915968|NCT06389903|BEHAVIORAL|assessment|post-surgery behavioral assessment using scales
214915969|NCT02453334|DRUG|Injectafer|
214915970|NCT02453334|OTHER|Normal Saline|
214915971|NCT04731090|DRUG|IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.|IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
214915972|NCT04731090|OTHER|Urine culture, antibiotic prophylaxis and hydrophilic-coated ureteral access sheaths|Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
214915973|NCT02772172|DEVICE|Surgical Template|
214915974|NCT01017276|DRUG|ASP1585|oral
214915975|NCT03710473|DIAGNOSTIC_TEST|Optical sensor, Pulse watch|Continuous blood pressure monitoring obtained by a Pulse watch
214915976|NCT06085326|OTHER|Smart Checklist|The digitized Smart Checklist includes three new features that currently do not exist on a paper checklist: 1) decision support prompts based on patient-provider dyad characteristics, 2) real time display of patient pertinent airway information from the EHR, and 3) high-risk warning alerts based on predictive analytics with potential explanatory factors from the model.
214308215|NCT02195440|DRUG|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
214308216|NCT06924957|OTHER|3D HRAM|The test will be performed both in supine and sitting position successively, using 3D HR-ARM. Resting, squeeze pressures, and bear down manoeuvre variables will be obtained. Diagnosis of dyssynergic defecation requires \< 20% relaxation of anal sphincter and/or intrarectal pressure\>40 mmHg during bear down manoeuvre.
214308217|NCT06935474|BIOLOGICAL|C-CAR168|This is a multi-center, Phase 1/2, open-label, dose-escalation and dose-expansion study evaluating C-CAR168 for the treatment of autoimmune diseases refractory to standard therapy. A traditional 3+3 design is used to identify the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) in disease-specific cohorts.
214308218|NCT06758232|OTHER|Exercise|It will consist of sessions that include neck anatomy, biomechanics, proper posture, ergonomics and neck exercise training.
214308219|NCT04534348|DEVICE|70% isopropyl alcohol-impregnated catheter caps|Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
214308220|NCT06933498|PROCEDURE|PREOPERATIVE ESPB|After 0.03 mg/kg IV midazolam sedation is applied to patients who will undergo preoperative ESPB, bilateral ultrasound-guided ESPB (in-plane approach) will be applied over the vertebral level that is equidistant from the highest and lowest vertebral levels planned for surgery in the prone position. ESPB will be performed by experienced anesthesiologists. After sterilization of the skin with povidone iodine, the probe with a sterile sheath is placed 3 cm lateral to the spinous process and the trapezius, rhomboid major, erector spinae muscles and the transverse process of the vertebrae are visualized. The needle is placed in the fascial plane on the deep surface of the erector spinae muscle on the bone shadow of the transverse process of the vertebra. A total of 40 mL of 0.25% bupivacaine is administered bilaterally after the LA spread is seen. After waiting for the effect of the block for 30 minutes, the patients will be taken to the operating room.
214308221|NCT06933498|PROCEDURE|INTRAOPERATIVE ESPB|Intraoperative ESPB will be performed by the neurosurgeon after LDH repair, starting from the level of the operated vertebra and covering all surgical segments. This procedure will be repeated for the other side (right/left). A total of 40 mL of 0.25% bupivacaine will be used for both sides.
214308222|NCT06935110|PROCEDURE|Cryopreserved aortic patch|After identifying the tracheal or bronchial defect with standard surgical techniques, the airway gap is reconstructed with a patch of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis. An silicon stent is inserted to prevent collapse for the aortic graft.
214308223|NCT01344161|DIETARY_SUPPLEMENT|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
214308224|NCT01344161|DIETARY_SUPPLEMENT|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
214308225|NCT00640445|BEHAVIORAL|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
214308226|NCT00640445|BEHAVIORAL|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
214308227|NCT04690751|DRUG|Cenobamate 200Mg Tab Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
214308228|NCT04690751|DRUG|Cenobamate Oral Suspension Fed|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
214308229|NCT04690751|DRUG|Cenobomate Oral Suspension Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
214308230|NCT05819515|PROCEDURE|Tunneled coronally advanced flap|Describes the flap design for both treatment arms
214308231|NCT00508807|DRUG|RTA 402|5 mg by mouth (PO) daily for 21 days
214308232|NCT06941324|BEHAVIORAL|Behavioral Intervention|Undergo SFBT-C
214308233|NCT06941324|OTHER|Best Practice|Receive eTAU
214308234|NCT06941324|OTHER|Communication Intervention|Receive check in calls from clinician
214308235|NCT06941324|OTHER|Discussion|Participate in discussions
214308236|NCT06941324|OTHER|Health Promotion and Education|Receive educational manual
214308237|NCT06941324|OTHER|Health Promotion and Education|Receive educational book
214308238|NCT06941324|OTHER|Interview|Ancillary studies
214308239|NCT06941324|OTHER|Questionnaire Administration|Ancillary studies
214308240|NCT06936943|DRUG|ONO-4538|every 4 weeks
214308241|NCT07142382|BEHAVIORAL|Ordinary sitz bath, manual flushing sitz bath, electric flushing sitz bath|Ordinary sitz bath, manual flushing sitz bath, electric flushing sitz bath
214308242|NCT06942754|DEVICE|post-surgical functional bracing|Quadriceps Autograft ACL Reconstruction with the use of post-surgical functional bracing, using the DonJoy Defiance Pro brace
214308243|NCT03899948|BEHAVIORAL|Teacher Anxiety Program for Elementary Students|TAPES consists of three core components: 1) training in evidenced-based anxiety reduction strategies that teachers will implement to identify and assist specific anxious students and classroom-wide strategies helpful to all students, 2) evidenced-based material for teachers to review with parents regarding how to reduce student anxiety at home, thus improving school-home communication and shared goals and 3) training in how to conduct 5 brief (30 minute) teacher-parent-student meetings to teach and practice the TAPES anxiety-reduction strategies.
214480519|NCT06179953|OTHER|NAO intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The robot provides instructions and if the child requests it, it elects prompts."
214670573|NCT01563510|PROCEDURE|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
214670574|NCT00542984|DRUG|teriparatide 20 micrograms/day subcutaneous|
214670575|NCT00542984|DRUG|salmon calcitonin 100 IU/day subcutaneous|
214308244|NCT03899948|BEHAVIORAL|Teacher Anxiety Training|The TAT is a 3-hour professional development training for teachers. Training focuses on recognizing the signs and symptoms related to child anxiety and utilizing classroom-wide strategies to help reduce anxiety in the classroom.
214308245|NCT00709774|DEVICE|Pacemaker Implantation|Implantation of right ventricular lead at septal or apex.
214308246|NCT07147829|BEHAVIORAL|digital detox|The digital detox intervention differs from other clinical interventions in several key aspects. Unlike pharmacological treatments or traditional psychotherapy, it focuses on behavioral modification by intentionally reducing or eliminating engagement with digital devices and social media for predetermined periods. The intervention emphasizes mindful technology use, limits screen time, and encourages offline activities to restore emotional balance and improve sleep quality. Additionally, it targets the cumulative effects of constant digital exposure, such as information overload, social comparison, and digital dependency, which are not typically addressed in standard mental health interventions. This unique focus on managing digital behavior positions digital detox as a complementary strategy for promoting psychological well-being in young adults.
214308247|NCT07151261|DIETARY_SUPPLEMENT|Ashwagandha|Sustained-Release, lower-dosage (150mg) Ashwagandha Supplement, 1 capsule 1 time per day.
214308248|NCT07151261|OTHER|Placebo|This placebo does not contain any of the interventional dietary supplement. The placebo consists of microcrystalline cellulose and is matched for shape, color, and smell. 1 capsule, 1 time per day.
214308249|NCT05932602|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.
214670576|NCT04292938|DIETARY_SUPPLEMENT|Low carbohydrate ketogenic diet|Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
214670577|NCT00104507|DRUG|APD356|
214670578|NCT04065763|OTHER|Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.
214915977|NCT06685705|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|patients will receive 15 mg of 0.5% hyperbaric bupivacaine + 50 mg Magnesium sulfate intrathecally.
214915978|NCT06685705|DRUG|bupivacaine and Neostigmine|patients will receive 15mg of 0.5% hyperbaric bupivacaine + 50 µg Neostigmine intrathecally
214915979|NCT06685705|DRUG|fentanyl and bupivacaine|patients will receive 15mg of 0.5% hyperbaric bupivacaine + 25µg of fentanyl intrathecally.
214915980|NCT00693498|BIOLOGICAL|Standard leukoreduced irradiated blood cell transfusion|standard vs washed blood cell transfusions
214915981|NCT00693498|BIOLOGICAL|Washed leukoreduced irradiated blood cell transfusions|washed leukoreduced irradiated blood cell transfusions
214915982|NCT04128969|DIETARY_SUPPLEMENT|CS+|Oral carnitine supplementation
214915983|NCT04128969|DIETARY_SUPPLEMENT|CS-|Placebo
214915984|NCT02693106|DIETARY_SUPPLEMENT|Control|Visit corresponding to a standardize breakfast taken alone (control visit) followed by a period of 4-hour with multiple blood sampling.
214915985|NCT02693106|DIETARY_SUPPLEMENT|Leucine|Visit corresponding to a standardize breakfast with 5 g of leucine followed by a period of 4-hour with multiple blood sampling.
214915986|NCT02693106|DIETARY_SUPPLEMENT|Butyrate -|Visit corresponding to a standardize breakfast with 3.6 g of butyrate followed by a period of 4-hour with multiple blood sampling.
214915987|NCT02693106|DIETARY_SUPPLEMENT|Butyrate +|Visit corresponding to a standardize breakfast with 7.2 g of butyrate followed by a period of 4-hour with multiple blood sampling.
214915988|NCT02693106|DIETARY_SUPPLEMENT|Octanoate -|Visit corresponding to a standardize breakfast with 5 g of octanoate followed by a period of 4-hour with multiple blood sampling.
214308250|NCT05932602|DEVICE|Dual Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
214308251|NCT07160491|OTHER|A novel artificial intelligence assisted mobile application|A novel artificial intelligence assisted mobile application will be used in the experimental group to guide entire reperfusion process in patients with STEMI. The functions of the application include patient screening, education and training, route planning for patient transfer, time management, and quality control, etc.The thrombolytic drug used in this study is tenecteplase (manufacturer: CSPC Pharmaceutical Group Limited, China ).
214308252|NCT05416307|DRUG|ELA026|Multiple doses of ELA026
214308253|NCT04364620|DRUG|AB-16B5|AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).
214308254|NCT04364620|DRUG|Docetaxel|Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer
214308255|NCT07162922|OTHER|8 mmHg pressure group|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 8 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
214308256|NCT07162922|OTHER|14 mmHg pressure group|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 14 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
214308257|NCT07164183|DRUG|Indole-3-carbinol|Indinol Forto (indolecarbinol (indole-3-carbinol)) 200 mg capsules orally twice a day during 24 weeks
214308258|NCT07164183|DRUG|Dienogest|Visanne (dienogest) 2 mg tablets orally once a day during 24 weeks
214308259|NCT07171424|OTHER|Behavioral therapy and transcutaneous posterior tibial nerve stimulation|Behavioral therapy included appropriate fluid intake, bladder training, habit training, pelvic floor muscle exercises (Kegel exercises), prompted voiding, and scheduled voiding. TPTNS will be applied in a biphasic square waveform with a frequency of 20 Hz and 200 cycles/sec in 30-minute sessions. The current intensity will be varied between 0.5-20 mA according to the patient's pain threshold.
214308260|NCT07170631|OTHER|Therapeutic exercise|Participants will follow a 3-month therapeutic exercise program combining general exercises with specific upper limb exercises, including hand proprioception and neurodynamic techniques. Two group sessions per week (1 to 1.15 hours each) will be conducted, with at least 24 hours between sessions. Each session includes warm-up, three progressive work blocks with strength, mobility, and balance exercises, and a cool-down. Strength training uses body weight and equipment, with intensity guided by the Rate of Perceived Exertion (RPE) scale, progressing safely from moderate to higher levels. Mobility and balance exercises target trunk, upper and lower limbs, and postural control. Neurodynamic techniques focus on median, radial, and ulnar nerves using neural sliding and intermittent tension, stopping exercises if pain exceeds 4/10. Supervised by experienced physiotherapists, the program aims to reduce lymphedema and neuropathy symptoms in breast cancer patients undergoing cancer treatment.
214308261|NCT07180433|DIAGNOSTIC_TEST|FAPI PET/MR|The patients will be injected intravenously with 2 MBq/kg 18F-FAPI, 60 minutes before the PET/MRI acquisition. The PET/MRI examinations will be performed on a Siemens Biograph mMR (Siemens Healthcare, Erlangen, Germany) with software version VE11P. Static PET will be acquired simultaneously with MRI using two protocols; a one bed position protocol in prone position covering the breast and a whole body 4-5 bed position protocol in supine position covering brain to thighs. Total acquisition time of the breast protocol will be approximately 20 minutes. Total acquisition time of the whole-body protocol will be approximately 30 minutes.
214308262|NCT07179887|DEVICE|Remote Ischaemic Conditioning|Cuff inflation to 20mmHg abocve systolic blood pressure for cycles of 5 minutes. Each session will consist of 4 cycles of 5 minte inflation followed by 5 minute deflation. Total session time 40 minutes
214308263|NCT07179887|DEVICE|Sham Remote Ischaemic Conditioning|Cuff inlfation to 20mmHg only for cycles of 5 minutes. Each session will consist of 4 cycles of 5 minute inflation followed by 5 minutes of deflation. Total session time of 40 minutes
214308264|NCT07181395|BEHAVIORAL|Hip Internal Rotation Mulligan Mobilization|Mulligan mobilization applied to hip internal rotation using a mobilization belt. Performed in 3 sets of 10 repetitions, twice weekly for 4 weeks, in addition to conventional physiotherapy.
214308265|NCT07181395|BEHAVIORAL|Straight Leg Raise Mulligan Mobilization|Mulligan mobilization applied to straight leg raise under manual traction. Performed in 3 sets of 10 repetitions (15-20 seconds hold), twice weekly for 4 weeks, in addition to conventional physiotherapy.
214308266|NCT07181395|BEHAVIORAL|Conventional Physiotherapy|Conventional physiotherapy including transcutaneous electrical nerve stimulation (20 minutes), massage, lumbar stretching and strengthening exercises, postural training, and patient education. Delivered twice weekly for 4 weeks.
214308267|NCT07180381|OTHER|PSA and MRI-monitoring|Men with PI-RADS 3 or 4 lesions and a PSA density ≤ 0.15 ng/mL² are actively monitored with PSA testing every six months and MRI annually, instead of undergoing immediate prostate biopsy.
214670579|NCT01215539|DRUG|panitumumab|Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
214670580|NCT00758615|BEHAVIORAL|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
214308268|NCT07179666|OTHER|Neural moblization group|The intervention will involve neural mobilization of the tibial nerve, beginning with distal sliding through ankle dorsiflexion and foot eversion, followed by dorsiflexion of the toes. The movement will then be reversed into plantarflexion to allow proximal nerve excursion. In addition, a tensioner technique will be applied, in which participants will perform 45° hip flexion combined with ankle dorsiflexion and eversion, followed by knee extension, to place a controlled tensile load along the tibial nerve pathway.
214308269|NCT07179666|OTHER|Conventional therapy group|The intervention will include manual therapy techniques such as myofascial release and soft tissue mobilization to reduce fascial tension and improve local circulation. Stretching exercises will be prescribed to target the plantar fascia, Achilles tendon, and gastrocnemius-soleus complex in order to enhance flexibility and reduce mechanical strain. In addition, ultrasound therapy will be utilized for its thermal and non-thermal effects to promote tissue healing and reduce inflammation.
214915989|NCT02693106|DIETARY_SUPPLEMENT|Octanoate +|Visit corresponding to a standardize breakfast with 10 g of octanoate followed by a period of 4-hour with multiple blood sampling.
214915990|NCT02693106|DIETARY_SUPPLEMENT|Carnitine|Visit corresponding to a standardize breakfast with 1.95 g of carnitine followed by a period of 4-hour with multiple blood sampling.
214915991|NCT02693106|DIETARY_SUPPLEMENT|Butter fraction|Visit corresponding to a standardize breakfast with 65 g of butter fraction followed by a period of 4-hour with multiple blood sampling.
214915992|NCT02594553|BEHAVIORAL|GP-parent information-exchange tool|The booklet incorporates already existing information about fever, alarm symptoms, advices use of medication and specific infectious diseases that frequently occur in childhood in combination with fever such as upper respiratory tract infections, and otitis media. The difference with these existing sources of information is the fact that they until now, were not incorporated into one booklet which can be physically handed over to parents.
214915993|NCT02509507|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10\^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 \& 2, up to 8mL in Cohorts 3 \& 4 of the Group A \& Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10\^6 PFU/mL to the 2nd dose at 10\^7 or 10\^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 \& 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10\^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10\^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 \[dated 26 October 2021\], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.
214915994|NCT02509507|DRUG|Pembrolizumab|Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
214915995|NCT00857675|DRUG|AAAA|Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
214915996|NCT00857675|DRUG|AAPA|Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
214915997|NCT00857675|DRUG|PAAA|Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
214915998|NCT00758901|DEVICE|Knee Replacement (with ROCC Knee prosthesis)|Knee Replacement (with ROCC Knee prosthesis)
214915999|NCT00287040|BEHAVIORAL|Tailored, interactive intervention for mammography screening|Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
214916000|NCT00302848|DRUG|Drospirenone|
214916001|NCT00302848|DRUG|Levonorgestrel|
214916002|NCT00302848|DRUG|Other progestin containing oral contraceptive|
214916003|NCT05684991|DIETARY_SUPPLEMENT|KMS-66 Ashwagandha 300mg|One capsule is taken by mouth twice daily with water
214916004|NCT05684991|DIETARY_SUPPLEMENT|placebo capsule|One capsule is taken by mouth twice daily with water
214670581|NCT05227573|PROCEDURE|Orthopedic surgery|Knee-, hip-, shoulder- and elbow surgery
214670582|NCT02471963|DRUG|Empagliflozin|
214670583|NCT02471963|DRUG|Placebo|
214670584|NCT01870492|DRUG|Activase|Patients treated with Activase
214670585|NCT01870492|DEVICE|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
214670586|NCT06811805|DEVICE|RenalGuard Therapy|RenalGuard Therapy
214670587|NCT06811805|OTHER|Standard of Care (SOC)|Standard of care
214916005|NCT02647957|PROCEDURE|Code Stroke|Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
214954933|NCT03035916|OTHER|Transversus abdominis plane block|Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
214954934|NCT03035916|OTHER|Epidural anesthesia|Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
214954935|NCT03035916|OTHER|control|The Control group receives standard IV-inhaled general anesthesia.
214954936|NCT00564317|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
214954937|NCT00564317|BEHAVIORAL|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
214954938|NCT06141421|PROCEDURE|procedure|procedure
214954939|NCT06521112|DRUG|Oral care with a solution containing 0.2% chlorhexidine gluconate a frequency determined according to the results of the Intensive Care Oral Care Frequency Rating Scale.|Every day for 10 days, Frequency determined according to Intensive Care Oral Care Frequency Rating Scale, Oral care was applied for 2 minutes a solution containing 0.2% chlorhexidine gluconate.
214954940|NCT03891823|DEVICE|MitraClip|Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.
214954941|NCT03891823|DRUG|Medical Therapy|Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
214954942|NCT01135836|PROCEDURE|Pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
214308270|NCT07180225|OTHER|Conventional therapy+manual therapy|Conventional therapy contains TENS and physiotherapist-supervised exercise program. These exercises are Wand exercises (15 repetitions each), codman exercises (1 minute in each direction), shoulder wheel exercises (5 minutes total), finger ladder exercises (10 repetitions), isometric exercises (10 repetitions each), capsular stretching exercises (10 repetitions each), pectoral muscle stretching and stabilization exercises (10 repetitions), shoulder stabilization exercises (5 minutes total), and strengthening exercises for the shoulder flexor, extensor, abductor, adductor, internal rotator, and external rotator muscles (15 repetitions each). In addition to them, manual therapy were applied to the shoulder region.
214308271|NCT07180225|OTHER|Conventional therapy+manual therapy+breathing exercises|In addition to the treatment program of Group I, breathing exercises were added. Each manual therapy technique was performed with 10 repetitions per participant. Similarly, participants were instructed to perform each breathing exercise with 10 repetitions. They were also asked to continue the breathing exercises at home, performing them three times a day with 10 repetitions per session for a duration of six weeks.
214308272|NCT07180602|BEHAVIORAL|Heart Math Biofeedback Breathing Practices|Phase I and II (0-6 months): Biofeedback will be implemented based on the Heart Math Protocol. Breathing practices will include a variety of yoga and qi gong techniques.
214308273|NCT07180602|BEHAVIORAL|Nutrition Counseling combined with Exercise Counseling|Phase II (3-6 months): Dietary education and an age-and gender-specific diet prescription based on the Mediterranean Diet. Nutrition counseling includes nutrition supplementation to correct deficiencies. Study participants will have a blood test to examine vitamins and minerals and identify deficiencies. Exercise counseling includes developmentally appropriate guidelines for cardiopulmonary, strength and flexibility activities based on guidelines from the ACSM and the AAP. Study participants and parents will be provided with a handout with exercise recommendations to follow at home and links to a website for additional suggestions for developmentally-appropriate physical activities and a tracking tool to assist parents with determining if their child is following the guidelines.
214916006|NCT06176274|OTHER|Prehabilition program|this program includes nutrition, physical activity, medical optimization and psychological support interventions.As a practice, the prehabilitation program (according to the surgery program) is planned in the preoperative period between 2-4 weeks Dec. it will be applied for 4 weeks before surgery. the first meeting is scheduled for 40 minutes. the program compliance process will be monitored by phone weekly. postoperative recovery and functional capacity measurements will be performed.
214916007|NCT00938769|OTHER|Self-Efficacy Training for Caregivers|"The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.~2-hour in-person instruction of home care issues for caregivers of patients with cancer."
214308274|NCT07180615|DRUG|Rifaximin (Xifaxan)|Preoperative gut decolonization protocol based on oral Rifaximin 2x550mg 10 am and 10 pm on the day preceding the surgery
214308275|NCT07180615|DRUG|Metronidazole|Preoperative gut decolonization protocols based on oral Neomycine 2x500mg and Metronidazole 2x500mg 10 am and 10pm on the day preceding the surgery
214308276|NCT07180615|DRUG|Neomycin Sulfate|Preoperative gut decolonization protocols based on oral Neomycine 2x500mg and Metronidazole 2x500mg 10 am and 10pm on the day preceding the surgery
214308277|NCT07180069|OTHER|diet education|Individualized dietary education focused on reducing phosphate intake (food choices, portion control, additives).
214670588|NCT02190591|DEVICE|Peanut Labor Ball|Peanut Labor Ball
214916008|NCT00938769|OTHER|Comparison Conditions for Caregivers|"Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.~2-hour counseling session for cancer caregivers to locate community support resources"
214308278|NCT07181434|DEVICE|The patient will be equipped with VR headsets|The patient will be equipped with VR headsets showing one of the six scenes from the HealthyMind® program in 3D, accompanied by hypnotic speech during the procedure.
214308279|NCT07180459|PROCEDURE|E-TACE|The 70/100μm drug-loaded microspheres were loaded with anthracyclines (30mg-50mg Idarubicin) at 2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded anthracyclines (30mg-50mg Idarubicin) with 2mL/3mLto embolize the tumor supplying arteries at different grades and diameters.
214670589|NCT00857246|DRUG|Cetuximab|
214670590|NCT00857246|DRUG|Irinotecan|
214670591|NCT00857246|DRUG|Cisplatin|
214670592|NCT00857246|PROCEDURE|Surgery|
214670593|NCT00857246|DRUG|5-FU|
214670594|NCT00857246|RADIATION|Radiation|
214916009|NCT01842360|BIOLOGICAL|Placebo|The subjects will receive daily dose of placebo during 12 months
214916010|NCT01842360|BIOLOGICAL|MV130|The subjects will receive daily dose of MV130 during 12 months
214916011|NCT03097757|RADIATION|Ultrasound - guided fracture reduction|Ultrasound will be used as a real-time imaging modality to guide forearm fracture reduction.
214916012|NCT03097757|PROCEDURE|Standard of care fracture reduction|Closed reduction of a fractured bone.
214670595|NCT02908802|DIETARY_SUPPLEMENT|Probiotic|Probiotic
214670596|NCT02908802|DIETARY_SUPPLEMENT|Placebo|Probiotics capsules without the active ingredient
214670597|NCT03488992|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 8 weeks
214670598|NCT03488992|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
214916013|NCT01767766|DRUG|TGR-1202|TGR-1202 Daily Oral Dose
214916014|NCT06128772|OTHER|Battlefield Acupuncture|5 points of acupuncture treatment in each ear weekly for 8 weeks
214916015|NCT03956563|DEVICE|Youlaser MT Group 2|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the control arm will receive 3 simulated laser treatments every 30 days.~A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject."
215060337|NCT02579148|BIOLOGICAL|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
214670599|NCT02405312|BEHAVIORAL|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
214670600|NCT04931602|DIAGNOSTIC_TEST|Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan|investigations for secondary causes of osteoporosis
214916016|NCT03956563|DEVICE|Youlaser MT Group 1|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the active arm will receive 3 laser treatments with the laser: one treatment administration every 30 days."
214916017|NCT00108017|DRUG|MK0507A, dorzolamide hydrochloride (+) timolol maleate|
214916018|NCT00108017|DRUG|Comparator: timolol maleate|
214916019|NCT00108017|DRUG|Duration of Treatment: Part 1) 6 wk timolol maleate run in|
214916020|NCT00108017|DRUG|Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds|
214954943|NCT01135836|PROCEDURE|Intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
214954944|NCT01135836|PROCEDURE|Control group|CO2 was removed by passive exsufflation through the port site.
214954945|NCT02479464|GENETIC|Genotyping results|Genotyping results provided in Phase II
214954946|NCT03885999|DEVICE|Fecobionics|Fecobionics is a new device for studying defecation
214308280|NCT07180459|DRUG|Donafenib|400mg QD
214954947|NCT02105649|OTHER|Strengthening exercise + Electrical stimulation of calf muscle|
214954948|NCT02105649|OTHER|selected physical therapy program|
214954949|NCT01630954|PROCEDURE|Suction and evacuation|In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
214954950|NCT01630954|PROCEDURE|Suction and evacuation|In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
214954951|NCT02452554|OTHER|Laboratory Biomarker Analysis|Correlative studies
214308281|NCT07181252|DIAGNOSTIC_TEST|Working length of root|"EAL Group: Working length was measured using the Root ZX apex locator (J. Morita Corp., Kyoto, Japan), following the manufacturer's instructions. A #15 K-file was connected to the device and advanced until the display indicated APEX, confirming the location beyond the apical foramen.~DR Group: Working length was determined using a #15 K-file inserted 1 mm short of the estimated radiographic apex. A digital periapical radiograph was taken, and the working length was adjusted accordingly. Repeated radiographs were obtained until the file tip was 1 mm short of the radiographic apex."
214308282|NCT07179952|DRUG|Slow Release DHEA|Slow-release dehydroepiandrosterone capsule
214308283|NCT07179952|DRUG|Placebo|placebo capsule
214308284|NCT07180303|OTHER|Remote training courses covering the latest CRC screening guidelines, identification of high-risk individuals and their standard of care, and dietary intervention strategies. Ongoing support services,|"Remote training courses covering the latest CRC screening guidelines, identification of high-risk individuals and their standard of care, and dietary intervention strategies.~Ongoing support services, such as regular knowledge updates and technical consultations."
214308285|NCT07180303|OTHER|Continuation of routine healthcare services without any additional training interventions.|Continuation of routine healthcare services without any additional training interventions.
214308286|NCT07180251|BEHAVIORAL|CARE program|The CARE program is an 8-week intervention using reflection assisted with CGM. The Abbott factory-calibrated Freestyle Libre Flash Glucose Monitoring (Freestyle Libre 2) system will be used to evaluate glycemic variability.
214308287|NCT07180251|OTHER|Usual Care|Usual care means the participants will receive care from their primary care physicians and nurses during clinic visits at the surgical OPD.
214308288|NCT07181564|DRUG|Propofol / Remifentanil|Maintenance of general anesthesia with propofol and remifentanil; no ketamine or magnesium administered.
214308289|NCT07181564|DRUG|Ketamine + Magnesium sulfate (drug combination)|Continuous intraoperative infusion per protocol.
214308290|NCT07181564|DRUG|Sevoflurane and Remifentanil|Continuous intraoperative infusion per protocol.
214954952|NCT02452554|BIOLOGICAL|Lorvotuzumab Mertansine|Given IV
214954953|NCT02452554|OTHER|Pharmacological Study|Correlative studies
214954954|NCT02304354|DRUG|Rituximab|For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
214954955|NCT06274151|DRUG|Naproxen 500 Mg|Attenuating the sub-acute inflammatory processes to monitor potential beneficial tissue healing following a muscle strain injury
214954956|NCT06274151|PROCEDURE|Rehabilitation|Rehabilitation after muscle strain injury
214954957|NCT06274151|DRUG|Placebo|Sub-acute inflammatory processes not attenuated. Group will be treated as control to monitor tissue healing following a muscle strain injury without pharmacological intervention.
214954958|NCT06313554|DRUG|Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin|"The first week dose of Surufatinib was 150mg, the second week and the subsequent cycle was 200 mg once a day (QD) orally, Q3W, and the drug was suspended for one day on the day of HAIC; Toripalimab: 240mg intravenous infusion d1, Q3W;~HAIC: All patients received HAIC treatment on D1. Hepatic arterial perfusion therapy (HAIC) : a treatment cycle every 3 weeks for 4-6 consecutive cycles:~Surufatinib and Toripalimab were administered continuously until intolerable toxicity, disease progression, withdrawal of informed consent, loss of follow-up, and investigator judgment that medication should be discontinued (whichever occurred first)."
214954959|NCT01658397|BEHAVIORAL|Fasting|Ten day fast
214954960|NCT02533297|OTHER|Providing clinical skills conditions|
214954961|NCT05740345|DRUG|Metformin|Metformin
214670601|NCT03085784|DRUG|Aflibercept|The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
214308291|NCT07180134|BEHAVIORAL|symptom management health informatics plus Resistance band exercise training|"Access to educational videos and an instant messaging platform for real-time communication, delivered over 12 weeks.~plus Structured resistance band exercise, 3 times per week, \~30 minutes per session, for 12 weeks under research team guidance."
214308292|NCT07180134|BEHAVIORAL|Usual Care Group|Standard postoperative nursing care and education routinely provided by the clinical team. No additional interventions will be given.
214308293|NCT07179575|DRUG|LW231|LW231 tablets
214308294|NCT07179575|DRUG|LW231 placebo|LW231 placebo tablets
214308295|NCT07181512|OTHER|Deep Learning Analysis of Non-contrast Chest CT|Analysis of clearly visualized coronary segments on non-contrast chest CT using deep learning models, compared with CCTA reference standard.
214308296|NCT07181642|BEHAVIORAL|Diaphragmatic Breathing Program|Participants will learn diaphragmatic breathing exercises and practice them daily for 4 weeks before bedtime.
214308297|NCT07181642|BEHAVIORAL|Neutral Music Listening|Participants will listen to neutral music of the same duration before sleep. This activity does not include any therapeutic breathing exercises and is intended as a control
214308298|NCT07180394|DRUG|Botox injection into extraocular muscles|Botulinum toxin in various doses by injecting it into the overacting extraocular musces in strabismus patients, especially pediatric, but also adult cases, to use it as an alternative for strabismus surgery. For children, it will be administered under sedation or general anesthesia and in adults, under topical anesthesia. The pre-operative measurements of the type of strabismus, patterns, deviation, and post-operative results will be studied both in the short and long-term.
214308299|NCT07180511|DRUG|10mg QY201 Placebo tablet|10mg QY201 Placebo tablet
214308300|NCT07180511|DRUG|20mg QY201 Placebo tablet|20mg QY201 Placebo tablet
214308301|NCT07180511|DRUG|10mg QY201 tablet|10mg QY201 tablet
214308302|NCT07180511|DRUG|20mg QY201 tablet|20mg QY201 tablet
214308303|NCT07181759|PROCEDURE|VISOR|Surgery will be performed using the VISOR through a 14Fr UAS
214308304|NCT07181759|PROCEDURE|fURS|Surgery will be performed using a standard single-use electronic ureterorenoscope through a 14Fr UAS
214308305|NCT07181265|DRUG|Amiodarone Hydrochloride Tablets|Cohort 1: The intervention is for study of drug drug interaction of JMKX003142 when administered with Amiodarone
214308306|NCT07181265|DRUG|Febuxostat Tablets|Cohort 2: The intervention is for study of drug drug interaction of JMKX003142 when administered with Febuxostat Tablets
214308307|NCT07180745|DRUG|Pioglitazone (PIO)|30 mg orally once daily
214670602|NCT05275114|DEVICE|tDCS stimulation with hand task|30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
214308308|NCT07180745|DRUG|Empagliflozin|10 mg orally once daily
214308309|NCT07180745|DRUG|Statin (Atorvastatin)|20 mg orally once daily
214308310|NCT07180745|DRUG|Empagliflozin plus Statin (Atorvastatin)|Orally once daily of each (10 mg, 20 mg respectively)
214308311|NCT07180745|DRUG|Pioglitazone plus Atorvastatin|Orally once daily of each (30mg and 20mg respectively)
214670603|NCT05275114|DEVICE|sham tDCS stimulation with hand task|30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
214308312|NCT07181928|BEHAVIORAL|Mentalization-Based Therapy (MBT)|MBT is a manualized psychodynamic therapy based on attachment theory, designed to restore adolescents' mentalizing in general and in emotionally stressful situations and relationships. It targets to rebuilt epistemic trust, to successfully mentalize oneself and others.
214308313|NCT07181928|BEHAVIORAL|Treatment-as-usual-plus (TAU-plus)|The adolescents receive supportive child psychiatric consultations. For the parents the EFST sessions combine mindfulness, theoretical input, and experiential practice. Parents learn and apply four core skills: validation, repair, motivation, and setting boundaries.
214308314|NCT07180082|DRUG|Pyrotinib|anti-HER2 tyrosine kinase inhibitor
214308315|NCT07179939|DRUG|Trastuzumab rezetecan|Trastuzumab rezetecan is a lyophilized powder for injection intravenously. Administered according to label.
214308316|NCT07179939|DRUG|Pyrotinib|320 mg/d, q.d., p.o. A course of treatment need 21 days.
214670604|NCT00144300|DRUG|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
214670605|NCT00144300|DRUG|Requip|Standard marketed product dispensed according to manufacturer's guidelines
214308317|NCT07179939|DRUG|Dalpiciclib|125 mg/d, q.d., p.o. day 1-21, every 28 days.
214308318|NCT07179939|DRUG|Trastuzumab|Administered according to label.
214308319|NCT07179939|DRUG|ET: Letrozole/ Anastrozole/ Exemestane/ Fulvestrant/ Leuprorelin/ Goserelin.|Administered according to label.
214308320|NCT07179926|DIAGNOSTIC_TEST|morphometric spine radiography|Patients already on treatment with Pasireotide LAR or Pegvisomant will be evaluated using morphometric spine radiography and lumbar and femoral densitometry. Patients will undergo a 1-year follow-up.
214308321|NCT07181096|DIAGNOSTIC_TEST|assessment of frailty|"This study is a prospective cross-sectional study to assess the prevalence of frailty among 80 cases of renal transplanted patients.~Specific tests will include:~1. Assessment of frailty by Clinical Frailty Scale.~2. Assessment of nutritional status using Patient Generated Subjective Global Assessment (PG-SGA).~3. Comorbidity assessment using Charlson comorbidity score.~4. Six minutes walk test.~5. Muscle strength assessment using hand grip strength (HGS) dynamometer."
214308322|NCT07181863|BEHAVIORAL|Health coaching|Health coaching is the active component of TECC-DM. In weekly 1-hour sessions, the coach builds a therapeutic relationship, supports goal-setting and behaviour change, addresses mental health needs, coordinates resources, and empowers participants to navigate care. Coaching is delivered according to a standardized protocol, in consultation with the virtual care team, and targets improvements in quality of life and goals of care. Coaches do not provide pharmacological treatment or replace usual diabetes care.
214670606|NCT06075914|OTHER|Ketogenic Intervention|Participants will receive ready-to-eat Ketogenic Diet meals.
214308323|NCT07181863|OTHER|Educational emails|Participants receive usual diabetes care (e.g., primary care, endocrinology, community supports) plus 10 standardized educational emails over 12 weeks, delivered according to a consistent protocol. Unlike TECC-DM, this approach does not involve a therapeutic relationship, health coach, or interdisciplinary care team.
214308324|NCT07181629|OTHER|Control|The Personal Information Form, Mini Nutritional Assessment-Short Form (MNA-SF), Zarit Caregiver Burden Scale, Short Form-36 (SF-36) Quality of Life Questionnaire, and the Dysphagia Management Knowledge Form for Stroke Patients administered to caregivers of stroke patients at each interview (at 0, 1, and 3 months).
214308325|NCT07181629|BEHAVIORAL|Dysphagia Management Education|The Personal Information Form, Mini Nutritional Assessment-Short Form (MNA-SF), Zarit Caregiver Burden Scale, Short Form-36 (SF-36) Quality of Life Questionnaire, and the Dysphagia Management Knowledge Form for Stroke Patients administered to caregivers of stroke patients at each interview (at 0, 1, and 3 months). The intervention group received dysphagia management training after the questionnaires were administered at the first meeting.
214308326|NCT04917042|DRUG|Tazemetostat|Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.
214308327|NCT04850222|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
214308328|NCT04850222|DRUG|Calcium|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
214308329|NCT04928326|DIAGNOSTIC_TEST|CorWatch|Non-invasive wearable monitor for the assessment of central venous pressure
214308330|NCT01882127|DRUG|All-Trans Retinoid Acid(ATRA)|patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
214308331|NCT01882127|DRUG|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
214308332|NCT01935765|OTHER|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
214308333|NCT01935765|OTHER|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
214308334|NCT01935765|OTHER|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
214308335|NCT01935765|OTHER|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
214308336|NCT01935765|OTHER|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
214308337|NCT01935765|OTHER|Electrocardiogram (ECG)|Electrocardiogram (ECG)
214308338|NCT01935765|OTHER|Carotid echography|Carotid echography
214308339|NCT01935765|OTHER|Blood pressure|Blood pressure
214308340|NCT03806413|OTHER|Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
214308341|NCT04523363|DRUG|Metformin|Maximum dosage of 500 mg tablets 2 times a day (with each meal)
214308342|NCT06233474|DRUG|Allocetra|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state
214308343|NCT06233474|OTHER|Placebo|The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.
214308344|NCT06835283|DEVICE|Brain Stimulation|This intervention is distinct because it combines two non-invasive brain stimulation techniques, intermittent theta burst stimulation (iTBS) and transcranial direct current stimulation (tDCS), in a sequential manner. Unlike studies that evaluate these techniques individually, this study explores their combined and complementary effects, with iTBS priming the brain to enhance the subsequent impact of tDCS. The sequential design leverages different mechanisms of action: iTBS delivers magnetic pulses to targeted brain areas to modulate neural activity, while tDCS applies a low electrical current for sustained modulation. This approach specifically targets neuropsychiatric symptoms (e.g., mood swings, apathy, and agitation) in individuals with Alzheimer's Disease and related dementias (ADRD), a population often underserved by traditional interventions. The study also evaluates the feasibility of at-home tDCS administration, making it unique in combining clinical and caregiver-managed treat
214308345|NCT04579380|DRUG|tucatinib|300 mg orally twice daily
214308346|NCT04579380|DRUG|trastuzumab|Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
214308347|NCT04579380|DRUG|fulvestrant|Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
214308348|NCT06075316|OTHER|Symptom monitoring|Alerts will be sent to providers via email and/or the electronic medical record at pre-specified response thresholds. Providers will be instructed to respond to and document the management of alerts per their clinical routine.
214308349|NCT05948930|BEHAVIORAL|Progressive aerobic exercise|Progressive aerobic exercise
214308350|NCT05948930|BEHAVIORAL|Adaptive cognitive training|Adaptive cognitive training
214308351|NCT05948930|BEHAVIORAL|Combined|Combine adaptive cognitive and progressive aerobic exercise training
214916021|NCT03950414|BIOLOGICAL|CMV specific T-cells|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMV-specific CD4+ and CD8+ T cells Suspension of CMV-specific T cells in 10 mL of 0.9% NaCl with 2% Human Serum Albumin(HSA) via IV bolus injection~* Low Dose Tier - Viral-Specific T cell infusion 5 x10\^3 cells/kg body weight(BW)~* Mid Dose Tier - Viral-Specific T cell infusion 1.25 x10\^4 cells/kg BW~* High Dose Tier - Viral-Specific T cell infusion 2.5 x10\^4 cells/kg BW Product will be administered fresh intravenously to recipient within four hours of collection."
214916022|NCT00053196|BIOLOGICAL|anti-thymocyte globulin|2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)
214308352|NCT03031171|BEHAVIORAL|Screening patient navigation|The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
214308353|NCT03031171|BEHAVIORAL|Non-Navigated|Randomly matched sample of non-navigated clinic patients
214308354|NCT01527552|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
214308355|NCT06117774|DRUG|Tarlatamab|Intravenous (IV) infusion
214308356|NCT06117774|DRUG|Placebo|IV infusion
214308357|NCT05581056|DRUG|CFTR modulators|Introduction of CFTR modulators by pneumologists for pneumologic issues
214308358|NCT04804189|BEHAVIORAL|Guardians 4 Health|Clubs will implement Guardians 4 Health's intervention into their community by incorporating Guardians 4 Health materials into standard Club educational activities.
214308359|NCT06258876|OTHER|PrEP in general practice|Prescription and follow-up of PrEP in general practice
214916023|NCT00053196|BIOLOGICAL|G-CSF|5 ug/kg/day subQ injection Day 7 until ANC\> 1000/uL for 3 consec days
214916024|NCT00053196|DRUG|busulfan|0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3
214916025|NCT00053196|DRUG|fludarabine phosphate|30 mg/sq m/day IVBP over 30 min Days -7 thru -3
214916026|NCT00053196|DRUG|methotrexate|5 mg/sq m/day IV infusion Days 1, 3, \& 6 for HLA-identical donor transplants and Days 1, 3, 6, \& 11 for MUD \& 9/10 related donor transplants
214916027|NCT00053196|DRUG|mycophenolate mofetil|15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)
214916028|NCT00053196|DRUG|tacrolimus|target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants
214916029|NCT00053196|PROCEDURE|allogeneic cell transplantation|2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1
214916030|NCT00053196|DRUG|allopurinol|300 mg/day PO Days -8 thru -1
214916031|NCT03337113|OTHER|Working Memory Training|The Working Memory Training condition: This condition will include 30 sessions across 4 weeks (10 remote sessions prior to initiation of the rTMS stimulation, and 20 lab sessions on rTMS stimulation days). Participants will complete three distinct WM tasks in each session: a visuospatial WM task, a backward digit span task, and a letter span task. In the training condition, the difficulty level of all three WM tasks will be automatically adjusted on a trial-by-trial basis. An identical protocol and software have demonstrated efficacy in increasing WM capacity, and this improvement in WM predicts reduction in addictive behavior.
215060338|NCT00624468|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
214308360|NCT06307275|OTHER|Fasting|Fasting for 16 hours from participant last meal of the previous evening's meal to the first meal of the next day. Then for 8 hours, participant is able to eat. During the fasting, participants are allowed to consume water and black coffee/tea. Participants will also keep their normal weekly exercise routine.
214308361|NCT06307275|OTHER|non fasting|Participants will not be fasting during these four weeks. They will eat their normal food intake and keep their normal physical activity levels.
214308362|NCT00643422|DEVICE|Cirrus™ HD-OCT, Carl Zeiss Meditec AG|the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.
214308363|NCT03598608|BIOLOGICAL|pembrolizumab|Administered as an IV infusion every 3 weeks (Q3W)
214308364|NCT03598608|BIOLOGICAL|Favezelimab|Administered as an IV infusion Q3W
214308365|NCT01154309|BEHAVIORAL|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
214308366|NCT06104566|DRUG|lisaftoclax +BTK inhibitor|lisaftolax + BTK inhibitor
214308367|NCT06104566|DRUG|BTK inhibitor|BTK inhibitor
214308368|NCT00476021|DEVICE|Levonorgestrel-releasing IUD (Mirena)|levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
214308369|NCT06315699|DRUG|Clemastine Fumarate Tablets|The dose was administered 2mg once daily in a double-blind random crossover method
214308370|NCT06315699|DIETARY_SUPPLEMENT|fructose|The dose was administered 2mg once daily in a double-blind random crossover method
214308371|NCT05761379|DEVICE|Photobiomodualtion Therapy|low lever light therapy with laser semi-conductor at wavelength of 650nm
214308372|NCT05761379|DEVICE|Single vision spectacles for correction myopia|Provide the distance best corrected vision acuity of refractive error of myopia for all the groups
214308373|NCT04076800|PROCEDURE|Acupuncture|Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
214308374|NCT00066066|PROCEDURE|Scaling and root planing|Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
214308375|NCT00066066|DRUG|Metronidazole|Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
214308376|NCT00066066|DRUG|Amoxicillin|Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
214916032|NCT03337113|OTHER|Sham Working Memory Training|In the Sham WMT condition, the difficulty level of the WM tasks will not be adjusted; instead it will remain at the initial easy level throughout each task (i.e., three items in each sequence). All other aspects of the condition are identical to the active WMT condition.
214308377|NCT00066066|DRUG|Doxycycline|The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
214308378|NCT02268409|DRUG|luspatercept|subcutaneous injection
214308379|NCT03023033|BEHAVIORAL|mHealth messaging|SMS appointment reminders and health messaging via mobile phones
214480520|NCT06179953|OTHER|Traditional intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The therapist provides instructions, and if the child has difficulty responding, he or she may ask the operator for prompts."
214916033|NCT03337113|DEVICE|repetitive Transcranial Magnetic Stimulation|"The rTMS Condition: rTMS will be delivered with a Magstim Rapid2 system using Magstim Air Film Coils. rTMS pulses will be delivered at 10 Hz (100% resting motor threshold, RMT) in 40, 5 second trains, with 15 second inter-train interval, for a total of 2000 pulses per session. Active or sham rTMS will be applied over the left DLPFC; corresponding with the standard F3 location on scalp (F3=left frontal lobe, location #3 for electrode placement using international 10-20 system for scalp measurements). Five consecutive daily sessions will occur on two consecutive weeks, for a total of 10 sessions. RMT, defined as the amount of energy required to induce movement in the contralateral abducer pollicis brevis in at least 50% of stimulations, will be assessed on first day of application."
214916034|NCT03337113|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS will be identical to active treatment, with the exception that mu-metal plates attached to the sham coil block the magnetic field while providing a sensation of stimulation.
215060339|NCT00624468|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
215060340|NCT03999099|DRUG|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
215060341|NCT03999099|DRUG|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
215060342|NCT03999099|DRUG|Placebo oral tablet|Placebo
214308380|NCT03023033|BEHAVIORAL|Transport Payments|A payment scaled to reflect the cost of typical return transport fare for residents of the clinic catchment area
214308381|NCT05352828|DRUG|Nivolumab|Dose: 480 mg or 6 mg/kg Q4W
214308382|NCT05352828|DRUG|Autologous CD30.CAR-T|Dose: 2 x 10e8 cells/m2
214308383|NCT05352828|DRUG|Fludarabine|Dose: 30 mg/m2/day x 3 days
214308384|NCT05352828|DRUG|Bendamustine|Dose: 70 mg/m2/day x 3 days
214308385|NCT00593307|OTHER|high GI|high GI and high carb breakfast
214308386|NCT00593307|OTHER|Low GI|low GI, high carb breakfast
214670607|NCT06075914|OTHER|Mediterranean Intervention|Participants will receive ready-to-eat Mediterranean Diet meals.
214670608|NCT06075914|DIETARY_SUPPLEMENT|Placebo|Participants will receive twice-daily placebo servings to be consumed once in the morning and once before sleep.
215060343|NCT00392158|DEVICE|Closed-loop anesthesia system|
215060344|NCT04878510|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
215060345|NCT04878510|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
214308387|NCT00593307|OTHER|Low GI Low Carb|low GI low carb breakfast
214308388|NCT00593307|OTHER|High GI Low carb|high GI low carb breakfast
214308389|NCT01257373|DEVICE|Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent|Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
214308390|NCT03752307|DRUG|Isoxsuprine Hydrochloride|Compounded Isoxsuprine hydrochloride capsules
214308391|NCT03752307|DRUG|Placebo|Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
214308392|NCT03752307|DRUG|Corticosteroid|This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
214308393|NCT02143115|PROCEDURE|Optical colonoscopy|Examination of the colon with a colonoscope
214308394|NCT02143115|RADIATION|CT-Colonography|A computerized X-ray that may find out if there are polyps or cancers and also pictures the contents of the abdomen and pelvis
214308395|NCT00685243|PROCEDURE|Laser treatment|Fraxel and pulsed dye laser
214308396|NCT00417794|DRUG|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
214308397|NCT00417794|DRUG|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
214308398|NCT00324831|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
214670609|NCT06075914|DIETARY_SUPPLEMENT|Ketone Ester|Participants will receive twice-daily ketone ester servings to be consumed once in the morning and once before sleep.
215060346|NCT01252160|DRUG|QUTENZA|Cutaneous patch
214308399|NCT00324831|DRUG|cyclophosphamide|
214308400|NCT00324831|DRUG|doxorubicin hydrochloride|
214308401|NCT00324831|DRUG|prednisone|
214308402|NCT00324831|DRUG|rituximab|
214308403|NCT00324831|DRUG|sargramostim|
214308404|NCT00324831|DRUG|vincristine|
214308405|NCT00324831|PROCEDURE|Intervention/procedure|
214308406|NCT00324831|PROCEDURE|antibody therapy|
214308407|NCT00324831|PROCEDURE|biological therapy|
214308408|NCT00324831|PROCEDURE|chemotherapy|
214308409|NCT00324831|PROCEDURE|colony-stimulating factor therapy|
214308410|NCT00324831|PROCEDURE|cytokine therapy|
214308411|NCT00324831|PROCEDURE|monoclonal antibody therapy|
214308412|NCT00324831|PROCEDURE|non-specific immune-modulator therapy|
214308413|NCT00324831|PROCEDURE|therapeutic procedure|
214308414|NCT00324831|PROCEDURE|tumor cell derivative vaccine|
214308415|NCT00324831|PROCEDURE|vaccine therapy|
214308416|NCT01230931|DEVICE|Vitagel|Vitagel (by Stryker) is a topical surgical hemostat spray that results in coagulation. The components are as follows: autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors; this is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
214308417|NCT01230931|PROCEDURE|Standard of care|Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
214308418|NCT04638465|PROCEDURE|Transoral robotic surgery|Transoral resection with neck dissection
214308419|NCT04638465|DRUG|Cisplatin - Dose Level 1|6 Cycles of 40 mg/m2
214308420|NCT04638465|DRUG|Cisplatin - Dose Level 2|7 Cycles of 40 mg/m2
214308421|NCT04638465|RADIATION|Dose Level 1|60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week
214308422|NCT04638465|RADIATION|Dose Level 2|70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
214308423|NCT03657888|BEHAVIORAL|Family Club Denmark (FCD)|Participation in Family Club Denmark
214670610|NCT06656949|PROCEDURE|injecting indocyanine green (ICG) dye Intraoperative|injecting indocyanine green (ICG) dye Intraoperative for patients with endometrial cancer
214308424|NCT03657888|OTHER|Wait-list control|Participants on the waiting list
214308425|NCT06450548|OTHER|Parametric acquisition|Parametric acquisition for 18F-FDG PET/CT and 68GA-PSMA PET/CT with 24 h at 15 days of interval
214308426|NCT04348513|DRUG|T3 solution for injection|For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.
214308427|NCT04348513|DRUG|Placebo|Same as with T3 solution for injection.
214308428|NCT06162754|OTHER|A questionnaire and TREALD scales were applied to parents.|The survey, which included questions about sociodemographic characteristics and space maintainer awareness, was administered to parents face to face. Then, parents' oral health literacy levels were measured with TREALD-30 and TREALD-30A scales.
214308429|NCT00143702|DRUG|d4T|See Detailed Description.
214308430|NCT00143702|DRUG|Abacavir|See Detailed Description.
214308431|NCT00143702|DRUG|Riboflavin and Thiamine (Supplementation)|See Detailed Description.
214308432|NCT04270981|DRUG|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C|960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition
214308433|NCT00489853|DRUG|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
214308434|NCT00489853|DRUG|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
214308435|NCT00489853|OTHER|Placebo|Placebo, 1 inhalation twice daily
214308436|NCT03593408|DRUG|Dexmedetomidine|Administered for sedation management per hospital protocol
214308437|NCT03593408|DRUG|Fentanyl|Administered for sedation management per hospital protocol
214308438|NCT03593408|DRUG|Midazolam|Administered for sedation management per hospital protocol
214308439|NCT03593408|DRUG|Morphine|Administered for sedation management per hospital protocol
214308440|NCT03653793|OTHER|Natural Health Product: LivRelief Varicose Veins Cream|This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
214308441|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
214308442|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
214308443|NCT05894850|OTHER|Manually remind the patients|Medical staff remind patients manually .
214308444|NCT00518908|DRUG|Sevoflurane|3.2 Vol % for postconditioning
214308445|NCT05515939|DEVICE|InPen Insulin Pen|The InPen is a reusable smart insulin pen for people living with diabetes. The device uses Bluetooth technology to send dose information to a mobile application. The InPen can be used to deliver insulin, help calculate insulin doses, and estimate carbohydrates for meals
214308446|NCT02619890|OTHER|Brain Glioma Registry|
214308447|NCT04760210|OTHER|Control Group|Treatment for this group is conventional physical therapy along with the bed rest.
214670611|NCT05128240|DIETARY_SUPPLEMENT|Placebo|1g corn oil capsules
214670612|NCT05128240|DIETARY_SUPPLEMENT|Ceto 10|1g capsules containing oil broad spectrum marine oil from north atlantic fish
214670613|NCT06604325|DRUG|Tranexamic acid injection|All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
214308448|NCT04760210|OTHER|Decompression Group|Treatment for this is conventional physical therapy along with the spinal decompression.
214308449|NCT04760210|OTHER|ELDOA|Treatment for this is conventional physical therapy along with the ELDOA.
214308450|NCT04678245|BEHAVIORAL|Above the Influence-Vaping (ATI-V)|Peer-nominated 8th grade and 9th grade Peer Leaders (PL) will be trained in a half day ATI-V training. Adult Advisors (AA) will attend a half day ATI-V AA training and the PL training. The training day builds leadership skills in the PLs, develops skills for rising above pressure to vape including identification of personal reasons to rise, identification of healthy support people, teaching accurate use statistics, and sharing stories of prior success in rising above negative pressures. The ATI-V team of PLs and AAs then will run four interactive messaging campaigns to reach the rest of the student body. These four campaigns are (1) Introduction to ATI-V and My Reasons to Rise (2) Gain and Loss (3) Who's Got My Back (4) The Facts. Each campaign features a portion in which PLs model healthy norms and behaviors, and a second portion in which all the rest of the students engage in an interactive component to build and demonstrate the target skill.
214308451|NCT06502288|DRUG|625 mg of amoxicillin with combined clavulanic acid tablet|The intervention group must take 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction.
214308452|NCT06030921|OTHER|Osteopathic Structural Exam, State - Trait Anxiety Questionnaire|During a single patient encounter they will fill out the State-Trait Anxiety Questionnaire , and undergo a Osteopathic Structural Exam
214308453|NCT05697042|BEHAVIORAL|MY-Skills for Long COVID|8 week online intervention with therapeutic yoga and self-management education
214308454|NCT03780153|OTHER|No intervention|Observation study. No intervention
214308455|NCT00646412|DEVICE|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
214954962|NCT04792047|DIAGNOSTIC_TEST|HRP frequency, plaque compostion and local immune-inflammatory activation|HRP frequency, plaque compostion were detected by CCTA method. Local T cell subsets and their intracellular cytokines levels were detected by Flow Cytometry.
214308456|NCT02953990|BEHAVIORAL|MOMS Program|
214308457|NCT05321303|OTHER|Serious Game|"Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability."
214308458|NCT05321303|OTHER|Standard Patients|Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
214308459|NCT05689788|DEVICE|High-intensity laser therapy|punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used.
214308460|NCT05689788|PROCEDURE|Stretching exercise|Three sets of bilateral passive static stretching will be performed for the upper trapezius, levator scapulae, and scalene muscles. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
214308461|NCT05689788|DEVICE|Sham High-intensity laser therapy|Intervention in which the therapist performs a HILT simulation application, performing all of the steps and movements for an administration without actually receiving the treatment.
214308462|NCT03181828|DRUG|Acetohydroxamic Acid Oral Tablet|A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
214308463|NCT03181828|OTHER|No treatment|No treatment
214308464|NCT06797440|OTHER|Dual tasks of digital technology|The intervention activities of this study were cognitive and physical activity training using Nintendo Switch twice a week, 60 minutes each time (5 minutes of warm-up and cool-down exercises, 10 minutes of stretching exercises, and 40 minutes of exercise combined with cognitive training) for a total of 8 weeks. train. Both groups filled in basic data (demographics and disease characteristics) and underwent cognitive function measurements and physical activity function measurements at pretest (T0), 4th week (T1), and 8th week (T2).
214308465|NCT06309017|OTHER|Nutrition specialist|Nutrition specialist to help improve nutritional status by diet, oral nutrition supplements or parenteral nutrition.
214308466|NCT06309017|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition shakes|All study subjects, including subjects without malnutrition, will be given the Ensure Surgery Immunonutrition Shakes for prior to surgery as per standard of care. All subjects will also receive additional shakes starting as an inpatient when diet is advanced.
214308467|NCT06958744|OTHER|Functional Inspiratory Muscle Training (FIMT) group|Training will be given with the Powerbreath inspiratory muscle training device. Unlike traditional inspiratory muscle training, the exercises given in FIMT aim to integrate the functional capacity of respiratory muscles into daily life activities and include dynamic exercises in different positions with variable resistances. In this respect, it is defined as functional. Preparatory training will be given 4 weeks before starting FIMT: participants will be taught basic respiratory muscle training, respiratory control and exercises, and will be taught to perform the exercises while maintaining the spine in a neutral position. Patients will then be taken to FIMT for 3 days/6 weeks with a physiotherapist. On the other 3 days of the week, only inspiratory muscle training will be performed. The intensity of inspiratory muscle training will be increased from mild to moderate (Mild: Effort level between 20-40% of MIP or between Borg 2-3, Moderate: 50-60% of MIP or Borg 4-6).
214308468|NCT06958744|OTHER|Control group|Thoracic expansion exercise will be performed for 10 weeks. The participant will be asked to practice 4 times a day as a home program.
214308469|NCT03762603|DEVICE|Robotic exoskeleton device|It is a non invasive and non significant risk medical device which wraps around operated knee to support motion.
214954963|NCT02313805|OTHER|Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
214954964|NCT05964127|DEVICE|Air flow device|An air/powder device for surface decontamination
214308470|NCT06470399|OTHER|Standard therapy group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
214308471|NCT06470399|OTHER|AI-Guided Group|Participants receive DS prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
214308472|NCT03913754|OTHER|Psycho-social consequences of lupus erythematosus|It will be necessary to take into account the psychosocial experience of the disease \[47\] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
214916035|NCT06534853|OTHER|Post Facilitation Stretch|"The patient is placed in the lateral decubitus position with the affected side up and a Dutchman's roll or pillow under the iliac crest. Positioned at the edge of the table, the patient's inferior leg is flexed with the foot at the table's edge. The patient grasps the headpiece of the table with the superior hand, allowing the superior leg to drop off the back of the table.The therapist stands behind the patient, providing support to prevent posterior pelvic rotation with their thigh behind the pelvis. The cephalad hand grasps the top of the iliac crest and applies a caudad force, while the caudad hand gently guides the affected leg without generating force.The patient hikes the hip against the resistance from the therapist's cephalad hand, creating an isometric contraction for 5-10 seconds. The patient then relaxes, followed by a rapid stretch held for 10 seconds until the next barrier is reached. This procedure is repeated 3-5 times."
214916036|NCT06534853|OTHER|Reciprocal Inhibition|"The patient is placed in the lateral decubitus position with the affected side up and a Dutchman's roll or pillow under the iliac crest. Positioned at the edge of the table, the patient's inferior leg is flexed with the foot at the table's edge. The patient grasps the headpiece of the table with the superior hand, allowing the superior leg to drop off the back of the table.The therapist stands behind the patient, providing support to prevent posterior pelvic rotation with their thigh behind the pelvis. The cephalad hand grasps the top of the iliac crest and applies a caudad force, while the caudad hand gently guides the affected leg without generating force.The patient hikes the hip against the resistance from the therapist's cephalad hand, creating an isometric contraction for 5-10 seconds. The patient then relaxes, followed by a rapid stretch held for 10 seconds until the next barrier is reached. This procedure is repeated 3-5 times."
214916037|NCT06534853|OTHER|Conventional Physical Therapy|"A comprehensive therapeutic regimen that includes a 10-minute session of hot pack therapy specifically targeted at the low back region. In addition to this, participants will receive trigger point release therapy to alleviate muscle tension.The treatment plan also incorporates a tailored exercise protocol designed to enhance back health and strength. This protocol includes:~1. Back isometric exercises~2. Bridging exercises~3. Cat and camel stretches~4. Prone press-ups~5. Abductor strengthening exercises"
214916038|NCT04939987|DRUG|Tramadol|Opioid Control Cohort (One treatment selected)
214916039|NCT04939987|DRUG|Gabapentin|Experimental Cohort (Multimodal Approach)
214916040|NCT04939987|DRUG|Hydrocodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
214916041|NCT04939987|DRUG|Oxycodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
214670614|NCT06604325|DRUG|Placebo|All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
214670615|NCT06657664|PROCEDURE|cryotherapy with sterile saline at 2.5ºC|the root canals are given a final irrigation with 20 mL cold (2.5oC) saline solution for 5 minutes before obturation
214670616|NCT06657664|PROCEDURE|intaoral cryotherapy|ice sticks (wrapped in sterile gauze if needed) using plastic pipette droppers filled with freezed sterile water are placed intraorally in the mouth on the apices of the treated tooth on both buccal and palatal sides for 30 minutes
214916042|NCT04939987|DRUG|Ketorolac|Experimental Cohort (Multimodal Approach)
214916043|NCT04939987|DRUG|Acetaminophen|Experimental Cohort (Multimodal Approach)
214916044|NCT04939987|DRUG|Ketorolac tromethamine|Experimental Cohort (Multimodal Approach)
214916045|NCT04939987|DRUG|Ketamine|Experimental Cohort (Multimodal Approach)
214916046|NCT02927951|DRUG|Pregabalin|150mg bid
214916047|NCT02927951|DRUG|Placebo|150mg bid
214916048|NCT01580605|DRUG|somatropin|"Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment"
214916049|NCT01851122|DIETARY_SUPPLEMENT|L-theanine capsule|L-theanine 250mg capsule
214916050|NCT01851122|DIETARY_SUPPLEMENT|Placebo capsule|
214916051|NCT02792712|DRUG|Ticagrelor|Ticagrelor 180 mg LD，then 90 mg BID
214916052|NCT02792712|DRUG|Clopidogrel|Clopidogrel 300 mg LD，then 75 mg QD
214916053|NCT06409481|DRUG|Antineoplastic Agents|small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics
214916054|NCT02165917|PROCEDURE|Excision plus hyaluronic acid gel|Excision of endometriosis foci by laparoscopic standard methods followed by an application of 10 cc Hyaluronic acid gel, in order to prevent postsurgical adhesions.
214954965|NCT05964127|OTHER|Hand instruments|Periodontal hand instruments
214916055|NCT02165917|PROCEDURE|Excision only|Excision of endometriosis foci by laparoscopic standard methods only.
214480521|NCT06874673|DRUG|Pronase|During the colonoscopy procedure on participants in Group A, when colitis with mucosal mucus impeding visualization is encountered, the gastroenterologist uses a solution of pronase (200 U/mL) delivered through the endoscope's biopsy forceps to irrigate the affected area. Images are captured before and after the irrigation, and a score for improvement in mucosal clarity is assigned. The location of the lesion, irrigation time, and volume of fluid used are recorded. During endoscope withdrawal, the same area is reassessed for improvement in clarity, and the disease activity is evaluated. Biopsy specimens are taken from the most severe inflammation site for histopathological examination.
214480522|NCT06874673|DRUG|Saline (NaCl 0,9 %) (placebo)|During the colonoscopy procedure on participants in Group B, when colitis with mucosal mucus impeding visualization is encountered, the gastroenterologist uses saline delivered through the endoscope's biopsy forceps to irrigate the affected area. Images are captured before and after the irrigation, and a score for improvement in mucosal clarity is assigned. The location of the lesion, irrigation time, and volume of fluid used are recorded. During endoscope withdrawal, the same area is reassessed for improvement in clarity, and the disease activity is evaluated. Biopsy specimens are taken from the most severe inflammation site for histopathological examination.
214308473|NCT06958458|BEHAVIORAL|Mother Integrated Care|In order to empower mothers whose premature infants have been hospitalized in the neonatal intensive care unit (NICU) for at least three days, a four-step neonatal care training program will be provided. Through the empowerment of the mother, the empowerment of the family will also be supported. The family will no longer be considered as visitors but will be involved in the infant's care in the NICU as parents. Data collection forms will be completed before the training begins, one day prior to discharge, and one week after discharge.
214480523|NCT06874231|OTHER|Neuroimaging|The investigators will collect imaging sequence, cognitive test scores, clinical data and biofluid samples
214916056|NCT04557579|PROCEDURE|Clear corneal phacoemulsification and IOL implantation|Clear corneal phacoemulsification and IOL implantation were performed by 2 surgeons (Chao-Kai Chang and Hung-Yuan Lin) by using an identical technique to minimize differences in surgically induced aberrations between groups. The surgical process involved topical anesthesia, a 3-step clear corneal incision (2.75 mm) at 180° (temporal in both eyes), a 5.0-mm continuous curvilinear capsulorhexis, phacoemulsification using the stop-and-chop technique, IOL implantation with an injector, IOL centration, and a sutureless incision. The study IOL models include EDOF Symfony IOL (AMO, Santa Ana, CA, USA), bifocal Restor +2.5D IOL (Alcon, Fort Worth, TX, USA), and monofocal Sensar AR40e IOL (AMO, Santa Ana, CA, USA).
214480524|NCT06118554|OTHER|Irrigation head position|Patients irrigated their sinuses with once daily 2 mg mometasone using 240 mL NeilMed sinus rinse bottles for 8 weeks. The only factor that varied between groups was the head position patients irrigated in.
214308474|NCT02505230|BEHAVIORAL|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
214308475|NCT05267626|DRUG|AU-007|Monoclonal Antibody Targeting IL-2
214308476|NCT05267626|DRUG|Aldesleukin|IL-2
214308477|NCT05267626|DRUG|Avelumab|Monoclonal Antibody Targeting PD-L1
214916057|NCT02215200|DRUG|Anti-Thymocyte Globulin (ATG)|Thymoglobulin
214916058|NCT02215200|DRUG|Granulocyte colony stimulating factor (GCSF)|Granulocyte colony stimulating factor (GCSF)
214916059|NCT02215200|DRUG|Placebo (for ATG)|Normal saline administered by IV infusion to mimic ATG
214916060|NCT02215200|DRUG|Placebo (for GCSF)|Placebo prepared to mimic 6mg subcutaneous injection of GCSF
214916061|NCT00433394|PROCEDURE|cancer prevention intervention|
214916062|NCT00433394|PROCEDURE|educational intervention|
215060347|NCT04963036|OTHER|Entropy and NOL-Guided Goal Directed Anesthesia|Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
214308478|NCT05267626|DRUG|Nivolumab|Monoclonal Antibody Targeting PD-1
214308479|NCT00292864|DRUG|SNS-032 Injection|
214308480|NCT00002733|BIOLOGICAL|aldesleukin|
214308481|NCT00002733|BIOLOGICAL|recombinant interferon alfa|
214308482|NCT00002733|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214308483|NCT00002733|DRUG|cimetidine|
214308484|NCT01572233|BEHAVIORAL|Personalized Physical Activity and Psycho-Education (PPAPE) Program|"1. Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~2. The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment."
214308485|NCT00256945|PROCEDURE|dental restorative material surface preparation|
214308486|NCT05853601|DRUG|Single Dose Theophylline|Subjects are given a single loading dose of theophylline, 5mg/kg IV, within 18 hours after birth. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
214308487|NCT05853601|DRUG|Repeat Dose Theophylline|Subjects are given a loading dose of theophylline, 5mg/kg IV, within 18 hours of birth, and then two subsequent doses (1.2mg/kg iv) at 12 hours and 24 hours after loading dose. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
214308488|NCT05900050|DRUG|VS-01 on top of SOC|Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC
214308489|NCT05900050|OTHER|SOC (Control Group)|Patients will receive SOC for decompensated cirrhosis and ACLF
214480525|NCT06874218|DEVICE|prefabricated CAD-CAM Zirconia crowns according to Egyptian sizes.|compare prefabricated zirconia crowns according to the Egyptian crown sizes with the international standard zirconia crowns sizes for primary upper central incisors
214916063|NCT03497104|OTHER|Surplus blood tests|Surplus blood donation
214916064|NCT02176655|DRUG|VVD-101|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
214916065|NCT02176655|DRUG|Placebo|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
214916066|NCT01599858|DRUG|YF476|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
214916067|NCT01599858|DRUG|Omeprazole|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
214308490|NCT04642456|DIAGNOSTIC_TEST|Balance Assessment Scale|The newly developed balance, based on the Balance Evaluation Systems Test (BESTest) and Trunk Control Measurement Scale (TCMS), will be administered by two raters (normative and clinical database + interrater reliability)
214308491|NCT04642456|DIAGNOSTIC_TEST|Trunk strength measurement with EMG|A trunk strength protocol in sitting position, using a hand-held dynamometer is developed. During the trunk strength measurements muscle activity of certain muscles of the trunk will be measured using surface electromyography (EMG)
214308492|NCT04642456|DIAGNOSTIC_TEST|MRI spine/pelvis|We will be capturing 3D Magnetic Resonance (MR) images of the subject lying supine with extended knees, using a T1 weighted spine-echo (SE) sequence with interslice distance 3 mm in the area of the hip) extended with full spine MRI images (sagittal full spine T1- and T2- weighted images as part of the standard sagittal view of full spine to check for significant stenosis or spinal cord pathology) and additional T1-weighted axial slices at level L4, T12 and T8 with interslice distance 4 mm.The field of view covers the full spine, pelvis and hip smaller trochanter.
214308493|NCT04642456|DIAGNOSTIC_TEST|EOS stereoradiographic full body exam|Every subject included in the study will undergo a stereoradiographic full body EOS exam completed with Gravity Line (GL) location, recorded by a force plate on the floor
214308494|NCT04642456|DIAGNOSTIC_TEST|Balance Assessment Scale 2|Repeating the newly developed balance test (test-retest reliability) within 2 weeks after first measurement
214308495|NCT04642456|DIAGNOSTIC_TEST|Trunk strength measurement with EMG 2|Repeating the trunk strength protocol with EMG within 2 weeks after the first measurement (test-retest reliability)
214308496|NCT05630274|DRUG|Selpercatinib|Administered orally
214308497|NCT05630274|DRUG|Moxifloxacin|Administered orally
214308498|NCT05630274|DRUG|Placebo|Administered orally.
214308499|NCT02255500|DRUG|Bupivacaine FNB|A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
214308500|NCT02255500|DRUG|EXPAREL Infiltration|A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
214308501|NCT05129488|DEVICE|All participants received Biotrue ONEday lenses with and without an alternate packaging solution (EPG03)|Participants were given both Commercially available Biotrue ONEday lenses and Biotrue ONEday Contact Lenses with EPG03 Packaging Solution. Lens material is made from a hydrophilic copolymer of 2- hydroxyethyl methacrylate and N-vinylpyrrolidone and is 78% water by weight when immersed in saline solution.EPG03 Packaging Solution contains a phosphate buffered saline solution containing potassium chloride, poloxamine, poloxamer 181, glycerol (glycerin), erythritol, and polyquaternium-1.
214308502|NCT02890979|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
214308503|NCT02890979|OTHER|Laboratory Biomarker Analysis|Correlative studies
214308504|NCT02890979|OTHER|Quality-of-Life Assessment|Ancillary studies
214308505|NCT02890979|DEVICE|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
214308506|NCT02608268|DRUG|MBG453|Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
214308507|NCT02608268|DRUG|PDR001|Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
214308508|NCT02608268|DRUG|Decitabine|commercially available chemotherapy
214308509|NCT04059731|DIETARY_SUPPLEMENT|Nutrition supplement|Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
214308510|NCT01840774|DRUG|Low-dose pain medication (Ketalar) and saline placebo|
214308511|NCT01925404|BEHAVIORAL|Free physical activity classes|100 hours of free activity classes will be provided
214308512|NCT01925404|BEHAVIORAL|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
214308513|NCT04602637|OTHER|Training load|Monitoring training load during covid
214308514|NCT03740425|PROCEDURE|Blood Transfusion|Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)
214308515|NCT03812692|DEVICE|MATRx plus|The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
214916068|NCT06485050|COMBINATION_PRODUCT|Photodynamic therapy|"Application of red laser-photodynamic therapy using Rapid Podia Laser diode® (MEDENCY). The following protocol will be followed: 1) mechanical debridement of the nail, 2) disinfection of the nail with alcohol, 3) application of topical photosensitiser (Toluidine blue gel) for 5 minutes with the area covered, 5) application of 635 nm diode laser for 10 minutes.~Daily application of ciclopirox 8% with ethyl acetate, ethanol (96%), ketosteryl alcohol, hydroxypropyl chitosan and purified water."
214916069|NCT02982681|DRUG|Platelet rich fibrin|In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site
214916070|NCT02982681|DRUG|Bioactive Glass|The control site were packed with the bioactive glass graft alone
215060348|NCT04963036|OTHER|Standard of Care Group (Entropy and blinded NOL)|"Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate…), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing)."
214916071|NCT01994941|DRUG|Clopidogrel|"A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients."
214916072|NCT01994941|DRUG|Ticagrelor|"A platelet aggregation inhibitor.~Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.~A loading dose of 180mg will be used."
215060349|NCT02531139|OTHER|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
215060350|NCT02531139|OTHER|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
214308516|NCT06304142|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
214308517|NCT06304142|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214916073|NCT04277364|DIETARY_SUPPLEMENT|phosphatidic acid supplementation|The total daily doses will be distributed in 3 individual doses: in the group that will ingest 750mg per day, the individual doses will be 250mg, while in the group that will ingest 375mg per day, the individual doses will be 125mg. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
214308518|NCT06304142|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
214308519|NCT04659746|DEVICE|MejoraCare|mHealth solution to support remote monitoring of symptoms and patient empowerment through education.
214308520|NCT04091646|DRUG|Roflumilast Foam 0.3%|Roflumilast foam for topical application.
214308521|NCT04091646|DRUG|Vehicle foam|Vehicle foam for topical application.
214308522|NCT03102918|DRUG|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
214308523|NCT03102918|DRUG|Placebo|Participants will receive placebo over a 6-week treatment period.
214308524|NCT03974230|OTHER|Collection of datas|Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
214308525|NCT03974230|BIOLOGICAL|blood sample|Blood sample will be performed (genetic analyses).
214308526|NCT03974230|OTHER|slit lamp examination|Slit lamp examination will be performed.
214916074|NCT04277364|OTHER|Placebo (corn starch supplementation)|Three individual doses of corn starch will be consumed per day. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
214308527|NCT00052728|DRUG|tamoxifen citrate|
214308528|NCT00052728|DRUG|tipifarnib|
214308529|NCT00079924|DRUG|teriparatide|
214308530|NCT00079924|DRUG|aldrenodate|
214308531|NCT00079924|DRUG|raloxifene|
214308532|NCT06115928|DEVICE|Virtual reality|Participants will perform cardiac rehabilitation with hardware-type technology consisting of a PICO 4® head mounted display (HMD) headset and the software TREADMILL XR®.
214308533|NCT01660893|DRUG|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
214480526|NCT06873906|PROCEDURE|Deep Parasternal intercostal plane block|Patients will receive bilateral deep parasternal plane block using, 1mg/kg of 0.25% bupivacaine on each side under ultrasound guidance. The total dose of bupivacaine amounting to 2 mg/kg.
214916075|NCT04277364|OTHER|Strength training|All participants will be submitted to a 8-week strength training program, with 3 training sessions per week, totaling 24 training sessions.
214916076|NCT02027454|DRUG|GSK1265744|White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
214916077|NCT02027454|DRUG|GSK1265744 matching placebo|GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
215060351|NCT02870517|OTHER|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have \<60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
215060352|NCT02870517|OTHER|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
215060353|NCT00190229|DRUG|Cyclophosphamide|Cyclophosphamide
214308534|NCT01660893|DRUG|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
214308535|NCT01660893|DRUG|Placebo|3 unilateral intranasal sprays per dose
214308536|NCT02734888|OTHER|No drug or device, only a test. The test is called a PET/CT|A single PET/CT scan will be performed
214480527|NCT06873906|PROCEDURE|Erector Spinae Plane Block|Patients will receive bilateral erector spinae plane block using, 1 mg/kg of 0.25% bupivacaine will be administered on each side under ultrasound guidance. The total dose of bupivacaine amounted to 2 mg/kg
214916078|NCT02027454|DRUG|Moxifloxacin|Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.
214916079|NCT04335851|OTHER|Video based aerobic exercise|"During social isolation induced by COVID-19, physically inactive people will do exercise in company with aerobic exercises named videoswalk at home which made by American Heart Association. 3 days a week in total 4 weeks. Each sessions will last approximately 30-40 minutes."
214916080|NCT06049563|DIAGNOSTIC_TEST|Diagnostic MRI|MRI scan of the upper abdomen performed with the low-field 0.4T MRI system.
214916081|NCT02464163|BIOLOGICAL|Panblok|Intramuscular injection
214916082|NCT02464163|BIOLOGICAL|rHA adjuvant|Intramuscular injection
214916083|NCT04267809|DRUG|Metformin Hydrochloride|Metformin 500mg tablets are registered and licensed in Singapore. For the study, we will be sourcing the Metformin tablets from Singapore General Hospital Formulary.
214916084|NCT04267809|DRUG|Calcium and Vitamin D|Calcium and Vitamin D tablets are registered and licensed in Singapore. For the study, we will be sourcing the Calcium and Vitamin D tablets from Singapore General Hospital Formulary.
214916085|NCT03660111|DIAGNOSTIC_TEST|spirometry|only measurement of spirometry
214916086|NCT06578689|BEHAVIORAL|Education|The control group received standard care, while the intervention group received standard care supplemented with formal educational session followed by ongoing education on foot care using mobile health by a clinical pharmacist.
214916087|NCT04848051|BEHAVIORAL|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
214916088|NCT04848051|BEHAVIORAL|CRC Reminder & Short message|Participants randomized to the CRC Reminder \& short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
214308537|NCT04929652|DRUG|Surufatinib,Camrelizumab,Irinotecan,GM-CSF|"1. Dose climbing stage design (n=12) :~   Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed \> DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with \> developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~2. Dose expansion phase design(n=36):~   1. Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~  2. PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~  3. Irinotecan: 200mg/㎡, iv, D1, 3w;~  4. GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w."
214308538|NCT02280980|OTHER|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
214308539|NCT03266068|GENETIC|DNA Analysis of Blood Sample|DNA analysis of the genes possibly involved in IBS.
214916089|NCT04848051|BEHAVIORAL|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
214308540|NCT03266068|PROCEDURE|Flexible sigmoidoscopy with colonic biopsies|Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.
214308541|NCT03266068|PROCEDURE|Small bowel and colonic gastrointestinal permeability|A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.
214308542|NCT03266068|DIAGNOSTIC_TEST|Stool sample analysis|Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
214308543|NCT00691496|BEHAVIORAL|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
214308544|NCT00458653|BIOLOGICAL|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
214308545|NCT06301100|OTHER|Dual energy CT after routine simulation|Dual energy CT after routine simulation
214916090|NCT04848051|BEHAVIORAL|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
214916091|NCT05802524|DIAGNOSTIC_TEST|Neurowave Group|"Neurosensory stimulation will consist in the administration of pairs of stimuli consisting of emotionally significant images and sounds in the personal life history (two rare stimuli) alternating with neutral images and sounds devoid of emotional significance (two distracting stimuli"
214916092|NCT03942471|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a well-defined and systematic patient-centered educational approach which provides training in mindfulness meditation to teach adolescents with Type 1 diabetes to take better care of themselves and live healthier and more adaptive lives by learning to become more connected to the present moment through the use of breath and training for awareness of the moment.
214916093|NCT02801513|BEHAVIORAL|Brief Mindfulness Training|Brief mindfulness training comprising of three weekly individual sessions and daily guided meditation home practice
214916094|NCT02801513|BEHAVIORAL|Resting Control Training|Brief resting control training comprising of three weekly individual sessions and daily home practice consisting of resting periods
214916095|NCT01601119|DRUG|Rebif|The subjects will receive Rebif as per the current practices or as directed by the physician.
214916096|NCT01601119|OTHER|Other: Disease modifying therapies (DMT)|The subjects will receive other DMTs as per the current practices or as directed by the physician.
214916097|NCT02138487|OTHER|liberal postoperative activity|Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.
214916098|NCT02138487|OTHER|Restricted postoperative activity|Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
214916099|NCT03718208|DIETARY_SUPPLEMENT|Paediatric Formula|Children will switch over to the low calorie paediatric feed. Intake diaries and tolerance diaries will be completed for one week.
214916100|NCT00002875|BIOLOGICAL|filgrastim|
214916101|NCT00002875|DRUG|cisplatin|
215060354|NCT03813758|DIAGNOSTIC_TEST|wrinkle test|soaking in 40 deg water for 40 min. every 10 min the hand will be photo
215060355|NCT02919202|PROCEDURE|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
214480528|NCT06873906|DRUG|conventional analgesic regimen|"Anesthesia will be induced with IV ketamine, 2 mg/kg, fentanyl, 2 µg/kg, and rocuronium 0.9 mg/kg, administered to facilitate endotracheal intubation.~Maintenance of anesthesia will be achieved by isoflurane at an end tidal concentration of 1-1.5% in FiO2 of 0.5, intravenous fentanyl at a dose of 1 µg/kg in incremental dosage, and intravenous rocuronium 0.15 mg/kg administration according to nerve stimulator."
214480529|NCT06875336|DIAGNOSTIC_TEST|biomarker analysis|"PAXgene blood for RNA will be collected and stored. Results from these additional examinations are not included in the treatment monitoring of the patient concerned. If M. tuberculosis can be cultivated, strains will be stored for genotyping and whole genome sequencing. Serum biomarkers will be tested using commercially available kits.~In addition, TAM-TB assays will be performed from samples stored at each time-point. For this purpose, PBMCs will be collected and frozen using well-established protocols."
214480530|NCT06875817|OTHER|Feldenkrais exercises|Feldenkrais exercises focused on pain, improving mobility, and disability.
214480531|NCT06875817|OTHER|Standard physical therapy interventions|"* Knee Isometrics: Isometric exercises targeting the quadriceps and hamstrings, performed for 10 minutes, twice a week.~* Knee Mobilization~* Transcutaneous Electric Nerve Stimulation (TENS).~* Heating Pad Duration: 30-minute sessions, conducted twice a week for 4 weeks."
214480532|NCT06874387|OTHER|Hypoxia, intermittent|Moderate-Intensity Aerobic Exercise (\~60-70% of maximum heart rate) and Intermittent Hypoxia (maintained between 80-90% during hypoxic phases)
214480533|NCT06874387|OTHER|physical exercise|Moderate-Intensity Aerobic Exercise (\~60-70% of maximum heart rate)
214480534|NCT06874387|OTHER|Sham (No Treatment) hypoxia|Exposure to normoxic air (FiO₂ \~20.9%) instead of actual hypoxia.
214480535|NCT03904576|DRUG|BI 1358894|Film-coated tablet
214916102|NCT00002875|DRUG|cyclophosphamide|
214916103|NCT00002875|DRUG|lomustine|
214916104|NCT00002875|DRUG|mesna|
214916105|NCT00002875|DRUG|vincristine sulfate|
214308546|NCT04113499|PROCEDURE|Direct Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes."
214308547|NCT04113499|PROCEDURE|Step-up Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention)."
214308548|NCT04777539|OTHER|At-home natalizumab treated MS patient|"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"
214308549|NCT01785576|BEHAVIORAL|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
214308550|NCT00898703|OTHER|flow cytometry|
214308551|NCT00898703|OTHER|immunoenzyme technique|
214308552|NCT00898703|OTHER|laboratory biomarker analysis|
214308553|NCT05433779|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
214308554|NCT06579586|BEHAVIORAL|Survey study|The Parent's State and Trait Anxiety Inventory (STAI), Anxiety Sensitivity Index-3 (AS-3), and Pain Catastrophising Scale for Parents (PPS-PPS) were completed one day before the operation to measure anxiety level.
214308555|NCT01469286|DEVICE|TEA|Electroacupuncture at ST36
214308556|NCT01469286|DEVICE|Sham-TEA|Electroacupuncture at sham-points
214480536|NCT03904576|DRUG|Placebo|Film-coated tablet
214480537|NCT05516576|DEVICE|endomina®|Endoscopic gastroplasty
214916106|NCT00002875|RADIATION|low-LET electron therapy|
214916107|NCT00002875|RADIATION|low-LET photon therapy|
214954966|NCT05964127|PROCEDURE|Access flap surgery|To improve the surgical access for implant decontamination
214954967|NCT01349127|DIETARY_SUPPLEMENT|20µg Vitamin D3|20µg (800IU) of vitamin D3/day for 12-weeks while lactating, commencing 10-14 days post-partum.
214954968|NCT01349127|DIETARY_SUPPLEMENT|20µg Vitamin D3 + 500 mg Calcium|20µg (800IU) of vitamin D3 + 500mg calcium carbonate/day for 12-weeks while lactating, commencing 10-14 days post-partum.
214954969|NCT01349127|DIETARY_SUPPLEMENT|Placebo|One gelatin placebo capsule containing zero vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
214954970|NCT01665482|OTHER|A 2000 kcal test meal|
214954971|NCT01665482|OTHER|A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate|
214954972|NCT05535322|DRUG|GLP-1RA|All T2D adults treated with Glucagon-like peptide-1 receptor agonists (GLP-1RA) or initiating a GLP-1RA during the study period
214954973|NCT05535322|DRUG|SGLT2i|SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
214954974|NCT05535322|DRUG|Insulin|Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i
214954975|NCT05535322|DRUG|Miscellany|Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
214916108|NCT04429100|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|One novel MRI sequence, i.e. the quantitative imaging of macromolecular proton fraction (MPF), will be introduced into this study. MPF is defined as the relative amount of protons associated with macromolecules involved in magnetization exchange with free water protons. This parameter is independent of the pool model used for quantification and the pulse sequences used for data acquisition. Recent studies have found a strong association between MPF and collagen content in the fibrotic liver, indicating MPF is a potential biomarker of early-stage liver fibrosis.
215060356|NCT02919202|PROCEDURE|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
214308557|NCT04332328|DIETARY_SUPPLEMENT|Diet|Group of diet types
214308558|NCT04765358|OTHER|Virtual Clinic|CGM, Clinical Care Support and Behavioral Health Support
214308559|NCT02731729|DRUG|ipilimumab|
214308560|NCT02731729|DRUG|nivolumab|
214308561|NCT03073096|PROCEDURE|LVA at time of nodal dissection|Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
214308562|NCT05658744|BEHAVIORAL|Video group|Insulin administration video was sent to the mobile phones of the patients assigned to the video group
214308563|NCT04625608|DRUG|Paracetamol|Standard care of 3 ml/kg water, plus 15 mg/kg oral paracetamol suspension, a minimum of 1 hour prior to the induction of general anaesthesia.
214308564|NCT04625608|OTHER|Standard care|Standard care of 3.6 ml/kg water, a minimum of 1 hour prior to the induction of general anaesthesia.
214308565|NCT03548012|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
214480538|NCT05347771|DRUG|Dupilumab|Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
214308566|NCT00159588|DRUG|Betablockers or other preventive drugs based on primary headache type|Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
214308567|NCT06424886|OTHER|Landing error scoring system (LESS)|Each group will perform two training blocks of 10 drop vertical jumping (DVJ) tasks. Knee joint position sense (KJPS), frontal plane projection angle (FPPA), and Landing Error Scoring System (LESS) assessments will be performed before and after the training blocks, and follow-up assessments will be performed 1 week later. The dominant limb of the participants (the side limb they use when kicking the ball) will be taken into account during the measurement.
214308568|NCT01626261|DEVICE|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
214308569|NCT02727348|PROCEDURE|Sciatic with or without femoral block|Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
214308570|NCT02727348|PROCEDURE|Spinal anaesthesia|Spinal anaesthesia with up to 3mls of 0.5% bupivacaine
214308571|NCT01571661|DRUG|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
214308572|NCT01571661|OTHER|Placebo|Placebo
214308573|NCT04377256|PROCEDURE|Ridge preservation: Tooth extration and immediat bone grafting in the socket|Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
214308574|NCT06574321|BEHAVIORAL|Teen Talk High School Refresher (TTHSR)|"TTHSR is designed to equip 11th and 12th grade students with the knowledge and skills necessary to make informed sexual health decisions as they move from high school into adulthood, in order to prevent behavioral risk factors that contribute to unintended pregnancy and sexually transmitted infections.~Most students this age will have received prior SHE. TTHSR is a 5-hour booster intervention, delivered in five 1-hour sessions during late high school, intended to enhance the effectiveness of previous SHE."
214308575|NCT05124860|DIAGNOSTIC_TEST|Indirect calorimetry|Measurement of metabolic rate (kcal/day) by respiratory gas analysis.
214308576|NCT06572085|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
214480539|NCT05347771|DRUG|Placebo|The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
214480540|NCT06408727|DRUG|CNM-Au8|CNM-Au8 (cellular energetic nanocatalyst). Faceted clean-surfaced catalytically-active Au nanocrystals.
214916109|NCT03316651|DRUG|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
214916110|NCT01541332|DRUG|Pomalidomide|Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.
214308577|NCT06572085|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
214308578|NCT03205059|BEHAVIORAL|LST MS curriculum+ Bullying/Cyberbulling serious game|The prevention materials for middle school bullying and cyberbullying will (1) utilize both interactive classroom sessions and serious/educational games (digital games used to educate in an entertaining format); (2) positively change social norms surrounding bullying and cyberbulling; (3) challenge positive expectancies about bullying and cyberbullying; (4) enhance protective factors by building social, self-regulation, and relationship skills throughout the interactive learning and behavioral rehearsal; and (5) include booster sessions.
214308579|NCT03205059|BEHAVIORAL|LST MS curriculum|The evidence-based LifeSkills Training program has been successfully used as a universal, school-based substance abuse and violence prevention program for middle school youth. The goals of the LST program are to teach youth the personal self-management skills, social skills, and other life skills needed to successfully resist drug and alcohol use, navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
214916111|NCT01541332|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle."
214308580|NCT01820481|DRUG|WIN-901X dose level 1|100mg Bid, PO, 12weeks
214308581|NCT01820481|DRUG|WIN-901X dose level 2|200mg Bid, PO, 12weeks
214308582|NCT01820481|DRUG|WIN-901X dose level 3|300mg Bid, PO, 12weeks
214308583|NCT01820481|DRUG|Placebo|Bid, PO, 12weeks
214308584|NCT04919356|GENETIC|G2019S LRRK2|No cost genetic testing for G2019S LRRK2
214308585|NCT04341909|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
214308586|NCT02066467|DEVICE|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
214308587|NCT04070391|DIETARY_SUPPLEMENT|vitamin B6|oral administration
214308588|NCT04070391|OTHER|control|oral administration
214308589|NCT02602587|BIOLOGICAL|Blood sample|additional samples of blood in acts planned in the prognostic or follow-up protocols.
214308590|NCT02602587|BIOLOGICAL|Bone marrow sample|additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
214670617|NCT06657664|PROCEDURE|Both intracanal and intraoral cryotherapy|Canal is irrigated with iced saline for 5 minutes before obturation . Root canal is obturated and coronal restoration is done. Then, application of intraoral cryotherapy is performed by ice sticks for 30 minutes.
214916112|NCT01541332|DRUG|Dexamethasone|Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
214916113|NCT05185037|DEVICE|Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)|The purpose of this study is to compare measurements of NIBP taken by the study device and measurements taken by the current FDA-approved algorithm included in Rev. N.0 software for the IntelliVue patient monitors during motion artifact in patients undergoing caesarian section deliveries under epidural anesthesia
215060357|NCT05648617|DIETARY_SUPPLEMENT|SUSTINEX Hydrolyzed Whey Protein|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein. The participants will be asked to add it to = to reach the goal of consuming 30g daily. SUSTINEX Whey Protein Plus is an authorized protein supplement which is manufactured and made in Malaysia by Nova Laboratories Sdn. Bhd. (179832-D). It consists of whey protein isolate and whey protein hydrolyze to achieve sufficient protein requirement.
215060358|NCT02544035|OTHER|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
214308591|NCT02617823|PROCEDURE|lateral position|patients placed on their left side after epidural catheter insertion
214308592|NCT00456521|DRUG|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
214308593|NCT00456521|DRUG|Placebo|
214308594|NCT00456521|BEHAVIORAL|Intensive group lifestyle modification counseling|
214308595|NCT02195076|OTHER|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
214308596|NCT02451228|OTHER|Serial blood collection|Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.
214308597|NCT01316276|DRUG|Liposomal amikacin for inhalation|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
214308598|NCT04820972|DRUG|Antiplatelet Agents|using antiplatelet agents in 3 days after surgery
214480541|NCT04827251|DIETARY_SUPPLEMENT|Coffee|"Participants will receive Nespresso coffee maker Essenza model. The coffee Nespresso blend voluto will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over)."
214480542|NCT06397716|GENETIC|ALDH2 Genotyping|Cheek swab for PCR testing of ALDH2 genotype.
214670618|NCT06657664|DEVICE|Low Level Laser Therapy|laser irradiation on the soft tissues covering the apices of the tooth on both buccal and palatal surfaces respectively
214916114|NCT04940793|DEVICE|POD FT|Cataract surgery
214916115|NCT04806893|DRUG|lerodalcibep|300 mg subcutaneous injection every month (Q4W)
214916116|NCT04806893|OTHER|Placebo|matching subcutaneous injection every month (Q4W)
215060359|NCT02544035|OTHER|Play Partner|Each child will first play alone then play with parent.
214916117|NCT05139771|DEVICE|THE ENDOART® IMPLANTATION (Artificial Endothelial layer)|Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSAEK/DMEK.
214916118|NCT05746728|DRUG|Surufatinib|"Safety run-in phase: 200-250mg, QD, Q3W~Dose expansion phase: according to the dose determined in the safety run-in phase"
214308599|NCT00992082|DRUG|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
214308600|NCT00992082|DRUG|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
214916119|NCT05746728|DRUG|Tislelizumab|200mg, d1, iv, Q3W
214916120|NCT05136105|BEHAVIORAL|Preventive Narrative Exposure Therapy (PreNET) family intervention|"Sessions: (1) Participants are invited to narrate the event in detail, in line with the protocol of the trauma-focused intervention NET. Furthermore, participants and caregiver(s) will receive a brief psychoeducation about expected symptoms and supportive behaviour in the aftermath of sexual violence.~(2) Two weeks after session 1, the second session focuses on caregiver only and their emotions. The narration of the event is read to the caregiver(s). Caregiver(s) receive assistance regulating their emotions. They receive psychoeducation on how to support their child.~(3) Two weeks after the second session, the children assisted by their caregivers lay a chronological lifeline of their most important life experiences. The chronology and the context of the traumatic events is reinforced. The narration of the sexual abuse is read again to the child and the caregiver(s). The caregiver(s) are encouraged to support emotionally their child during the renarration."
215060360|NCT02620423|BIOLOGICAL|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
215060361|NCT02620423|DRUG|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
215060362|NCT02620423|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
215060363|NCT02620423|DRUG|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
214308601|NCT00605475|DRUG|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
214308602|NCT00605475|DRUG|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
214308603|NCT00605475|DRUG|Metformin|Participants continued on their stable daily dose of metformin throughout the study
214308604|NCT06329479|BEHAVIORAL|Cognitive behavioural therapy for Insomnia (CBT-I)|A psychoeducational and evidence-based skills and strategies course for insomnia delivered online over four lessons through ThisWayUp. This will be completed during an 8-week feasibility trial.
214308605|NCT06329479|DEVICE|Bright Light Therapy|Daily bright light therapy for 30 minutes on waking delivered using the Lumie-L light box during an 8-week feasibility trial.
214480543|NCT03126292|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
215060364|NCT02620423|DRUG|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
214308606|NCT06329479|BEHAVIORAL|Individualised activity plan|An individualised activity plan is created at baseline and adjusted weekly aiming to increased daytime physical activity and reduce sedentary behaviours. The activity plan takes into consideration personal interests, perceived barriers to activity and develops an activity plan using Specific Measureable Achievable Realistic and Timely (SMART) goals. This will take place during an 8-week feasibility trial.
214308607|NCT06329479|OTHER|Clincial review|Two clinical reviews will take place during an 8-week feasibility trial and consider uncontrolled symptoms, medication and blood test abnormalities which may impact on rest and physical activity levels
214308608|NCT00183300|BEHAVIORAL|Prolonged Exposure Therapy|
214480544|NCT03126292|OTHER|Child Safety Handout|Handout regarding early child safety
214480545|NCT02296229|RADIATION|stereotactic body radiation therapy|Undergo SBRT
214480546|NCT02296229|OTHER|quality-of-life assessment|Ancillary studies
214480547|NCT02296229|OTHER|laboratory biomarker analysis|Correlative studies
214480548|NCT02296229|DRUG|androgen deprivation therapy|up to 9 months at the discretion of the treating physician
214480549|NCT06686082|DRUG|Biologics|The ultrasonic changes of synovitis and enthesitis were observed after 12 weeks of treatment with biologic agents
214480550|NCT06879353|DRUG|Tranexamic Acid (TXA)|A single intravenous dose of tranexamic acid (15 mg/kg) was administered before surgery to assess its efficacy in reducing perioperative blood loss and the need for transfusion.
214480551|NCT06879353|DRUG|Placebo|An equal volume of intravenous normal saline was administered as a placebo before surgery to compare outcomes with the tranexamic acid group.
214480552|NCT06878651|DEVICE|The Whole Body Vibration|Whole Body Vibration device may positively affect balance, dual-tasking and gait parameters by increasing the sensory input received under the sole in individuals diagnosed with diabetic foot. In individuals diagnosed with diabetic foot, the sensory/vibration perception threshold of individuals decreases due to the disease, so the balance of individuals is impaired. This may cause these individuals to experience gait disturbances in daily life. There are almost no studies in the literature on the use of whole body vibration for this patient group. This study will discuss the applicability of whole body vibration in the clinic for individuals diagnosed with diabetic foot and that it can be an additional adjunct to treatment.
214480553|NCT06885775|DEVICE|DXP01|PCL Dermal Filler
214670619|NCT06657664|PROCEDURE|Control (Standard treatment)|, all occlusal contacts were reduced by 1 mm
215060365|NCT02620423|DRUG|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
215060366|NCT02620423|DRUG|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
215060367|NCT03492957|OTHER|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
215060368|NCT02402205|BEHAVIORAL|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
215060369|NCT03660865|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary eye will receive Light adjustable lens with Light delivery Device treatments
215060370|NCT03660865|DEVICE|Control IOL|Fellow eye will receive control IOL
215060371|NCT02250508|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
215060372|NCT02250508|BIOLOGICAL|Haemate P® (Human Coagulation Factor VIII)|
214480554|NCT06885775|DEVICE|Juvederm ULTRA 3|HA Dermal filler
214480555|NCT06725576|PROCEDURE|Ablation|Thyroid ablation performed under ultrasound guidance to treat low-risk papillary thyroid carcinoma.
215060373|NCT05978440|PROCEDURE|onlay preparation|CAD-CAM onlay restorations will be fabricated using rubber dam scanning techniques and evaluated clinically up to 12 months
215060374|NCT06402526|OTHER|Mobile Epilepsy Education Package|"MEEP education section contains a range of topics. After completing the relevant section at the end of each week, participants complete the end-of-section test and switch to the next week's topic. Completion of the first part will take approximately 90-120 minutes per week for a total of 4 weeks of use.~Parental Monitoring Section, parents can actively record information on the mobile application related to their child's diagnosis (anonymous); treatments; timing and frequency of the seizures; and appointments; and schedule treatment and examination reminders to optimize compliance. Completion of this second part will take approximately 1-2 minutes and depends on the parental choice to use and how much information they would like to share. The second part, together with the first part, will be evaluated for a total of 1 month."
214480556|NCT06725212|DEVICE|Water Vapor Thermal Ablation|The water vapor thermal ablation system injects thermal energy in the form of water vapor into the hyperplastic prostate tissue in controlled doses. The injected water vapor quickly disperses through the gaps between tissue cells. When water vapor comes into contact with tissue, it cools and condenses immediately. The stored heat energy is released, denaturing the cell membrane, causing cell death and eventually being absorbed or shed by the body and excreted through urination, thus improving the lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
214480557|NCT06725212|DEVICE|Cystoscopy|Cystoscopy is a procedure that allows the doctor to examine the lining of patient's bladder and the tube that carries urine out of the body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into the bladder.
214480558|NCT03247309|BIOLOGICAL|IMA201 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
214480559|NCT03247309|DIAGNOSTIC_TEST|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only.
214480560|NCT04780581|DRUG|Dexamethasone|6 mg/24h - 10 days
214480561|NCT04780581|DRUG|Methylprednisolone|250 mg/ 24h - 3 days
214480562|NCT01756300|DEVICE|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
215060375|NCT06402526|OTHER|Standard care consisting of epilepsy education|This standard care includes the information and education provided by nurses and physicians during visits and hospitalisations. Standard information and education include topics such as: counseling by the neurologist regarding seizure safety precautions, prognosis, and sudden unexpected death in epilepsy (SUDEP); provision of paper or electronic resources regarding epilepsy; and telephone support provided by neurology clinic nurse regarding any issues or concerns). Information and education is usually provided orally and through printed brochures.
215060376|NCT02074670|OTHER|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
215060377|NCT06310642|OTHER|Immediate descent from altitude.|Immediate descent from altitude for severe symptoms or anyone who wished to discontinue their participation in the study.
215060378|NCT06310642|DRUG|Diphenhydramine|Diphenhydramine was available to counteract any potential extrapyramidal side effects of the study drug. The use of Diphenhydramine for this purpose is well established.
215060379|NCT06310642|DRUG|Prochlorperazine 10 mg|Subjects in the Prochlorperazine arm were administered 10mg PO Prochlorperazine immediately prior to ascent
215060380|NCT00297960|DRUG|ziprasidone or olanzapine|
215060381|NCT00297960|PROCEDURE|hyperinsulinaemic euglycaemic clamp|
215060382|NCT00297960|PROCEDURE|microdialysis (skeletal muscle)|
215060383|NCT04603313|OTHER|tele-advice system|The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
215060384|NCT00321074|DRUG|TACROLIMUS|Immunosuppression
215060385|NCT00969306|DRUG|Chloroquine, A-CQ 100|"Administration:~* Orally~* Timing: Once daily~* Tablets of 100 mg~* During or after meals~* In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~* Patients should always note date and time of intake on the chloroquine monitoring form."
214308609|NCT05875233|OTHER|Elix Daily Harmony|"Elix Daily Harmony is a clinical-strength, organic blend of hormone-balancing Traditional Chinese Medicine (TCM) herbs and adaptogens. Contains Angelica Sinensis, licorice, ginger, Bupleurum, Cyperus Rotundus, White Peony, Mint, Poria, Atractylodes, White Ginseng, Reishi, Rehmannia Root, and Astragalus.~Participants should add 3 droppers full (half a teaspoon or 2.5 ml) of Elix Daily Harmony to their tea or other warm or room temperature beverage each morning, 1-2 hours after their first meal. The product should not be taken with iced drinks or with food."
214916121|NCT04938180|BIOLOGICAL|AMB-05X|AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
214916122|NCT03371862|DRUG|Liraglutide Pen Injector [Victoza]|Pilot study of liraglutide in patients with short bowel.
214916123|NCT01188330|BEHAVIORAL|WITH Comprehensive Geriatric assessment|"Each month after randomization, a nurse practitioner will systematically review the intervention plan.~In case of hospitalisation, the nurse will go and meet the patient and his care giver to check each point of the intervention plan. If an action has not been done, a new proposal will be made to the patient. If the patient is at home or in institution, the nurse practitioner will call the patient and /or his care giver for the same purpose"
214308610|NCT05875233|OTHER|Elix Cycle Balance|A tailored blend of medicinal herbs to holistically support menstrual symptoms by treating underlying imbalances. Participants should take 3 droppers full (half a teaspoon or 2.5 ml) of Elix Cycle Balance daily before bed with tea or other warm or room temperature beverage. The product should not be taken with iced drinks or with food.
214308611|NCT03849404|BIOLOGICAL|Adalimumab|Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
214308612|NCT04187560|DRUG|LB-102|(N-Methyl amisulpride)
214308613|NCT00020696|DRUG|cisplatin|
214308614|NCT00020696|DRUG|tirapazamine|
214308615|NCT06434662|DRUG|mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (24 mg/m\^2) on day 1, every 4 weeks
214308616|NCT06434662|DRUG|Cytarabine|Cytarabine (1.0 g/m\^2, q12h ) on day 1,3,5, every 4 weeks
214308617|NCT06434662|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
214308618|NCT02109146|DRUG|Prophylactic Transcatheter Arterial Chemoembolization|Participants enrolled in the adjuvant TACE group received one to two cycles of TACE with an interval of 4\~6 weeks, and the first TACE was given within 1 week after randomization.
214308619|NCT02109146|OTHER|Observation|Participants enrolled in the observation group were subjected to active surveillance without any adjuvant treatment.
214308620|NCT00775931|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
214308621|NCT00775931|DRUG|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
214308622|NCT00775931|RADIATION|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
214308623|NCT00775931|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
214308624|NCT00775931|DRUG|Busulfan|patients\<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
214308625|NCT00775931|DRUG|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
214308626|NCT00775931|PROCEDURE|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
214916124|NCT01188330|BEHAVIORAL|Conventional|no Comprehensive Geriatric assessment
215060386|NCT04378491|OTHER|Collection of clinical measurements|"Collection of clinical measurements:~* Active and passive range of motion (ROM) of the knee, hip and ankle Joint bilaterally.~* Passive patellar translation in 30° of flexion billaterally in quadrants of translation.~* Patellar apprehension test (Fairbank's Test) and the Moving Patellar Apprehension (MPAT) test for the diagnosis of patellar instability. The Fairbank's Test is performed in 30° of Flexion while the MPAT is performed while flexing the knee from 0° to 90°."
214308627|NCT00002259|DRUG|Mitoxantrone hydrochloride|
214308628|NCT02433236|DRUG|Fostamatinib Disodium tablet 100 mg|
214308629|NCT02433236|DRUG|Fostamatinib Disodium tablet 150 mg|
214308630|NCT06409559|DEVICE|Pelvic reconstruction plate without interfragmentary screws|The posterior wall fracture will be operatively stabilized with a pelvic reconstruction plate and interfragmentary screws placed through the plate.
214308631|NCT06409559|DEVICE|Pelvic reconstruction plate with interfragmentary screws|The posterior wall fracture will be operatively fixed with a buttress plate applied under compression without interfragmentary lag or position screws.
214916125|NCT04562246|DIAGNOSTIC_TEST|Serologic assays for antibodies to SARS-CoV-2|Beckman Coulter and Roche automated immunoassays
214916126|NCT04124601|RADIATION|Chemoradiotherapy|Capecitabine tablet with fractionated radiotherapy
214916127|NCT04124601|DRUG|Ipilimumab|Infusion
214916128|NCT04124601|DRUG|Nivolumab|Infusion
214916129|NCT04813068|OTHER|Semi-structured interview|Semi-structured interview to identify attitudes to re-irradiation in lung cancer
214308632|NCT04634864|DEVICE|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously
214480563|NCT06727240|DEVICE|Intervention|The interventional device is a coupling device intended to prevent mechanical complications during peripheral intravenous infusions. While control will not receive the device.
214480564|NCT06726044|OTHER|Standard rehabilitaion after ACL reconstruction|"The SR group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks. Each session lasted approximately 60 minutes and was conducted by the same therapist.~After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests. Before rehabilitation involving kinesiotherapy (two weeks post-surgery), the following measurements were conducted:~Height and body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation~After the rehabilitation the following measurements and assessments were conducted:~Body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation Evaluation of the strength of knee extensor and flexor muscles under isokinetic conditions Evaluation of knee extensor strength under inertial conditions Postural stability assessment"
214480565|NCT06726044|OTHER|Standard rehabilitaion after ACL reconstruction plus inertial exercises|"The SR+I group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks including inertial exercises. Each session lasted approximately 70 minutes and was conducted by the same therapist.~Subjects also performed inertial exercises from the fifth week of rehabilitation. These exercises were conducted on an InerKnee. The inertial exercises protocol included: knee extension exercises performed in a seated position for the operated leg, 4 sets of exercises, each lasting 15 seconds individually, adjusted resistance to maintain a 1-second extension cycle, passive rest periods of 2 minutes between sets After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests the same as in SR group."
214480566|NCT06706206|OTHER|Observational trial|"Observational clinical trial. Participants will undergo cardiovascular risk assessment (clinical and blood tests) and coronary CT angiogram.~These results will be compared to a control population without haemophilia (recruited as part of a different clinical trial)."
214480567|NCT06881420|PROCEDURE|BASIS technique|Balloon AngioplaSty with the dIstal protection of Stent retriever
214916130|NCT04747886|BEHAVIORAL|WW Only|WW is a structured behavioral weight management program that focuses on diet, physical activity and mindset skills. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories. Specifically, the WW program assigns SmartPoints values to foods based on calories, sugar, saturated fat and protein. In addition, particular foods are assigned a points value of zero (0) to encourage a healthier eating pattern (e.g. fruits, vegetables, non-fat yogurt, fish).
214916131|NCT04747886|BEHAVIORAL|WW + PolyRules!|In addition to WW, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
214916132|NCT00017082|DRUG|oxaliplatin|
214916133|NCT04483960|DRUG|(Arm Closed) Nafamostat Mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
214308633|NCT04634864|DEVICE|sham tDCS|The stimulator was switched off after 2 minutes of stimulation.
214916134|NCT04483960|DRUG|(Arm Closed) Enoxaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h."
214916135|NCT04483960|DRUG|(Arm Closed) Dalteparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h."
215060387|NCT04378491|OTHER|Collection of data for muscle strength|"Collection of data for muscle strength:~* Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic Flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (3 x 5 repetitions) Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight"
215060388|NCT04378491|OTHER|Collection of EMG Data|"Collection of EMG Data:~* Surface electrodes will be placed bilaterally on the vastus medialis and lateralis rectus femoris, biceps femoris and semitendinosus muscles following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles). Simultaneously with the muscle strength measurements, EMG data will be collected using a 12-channel EMG system (myon AG, Schwarzenberg, Switzerland, sampling rate 2400 Hz)."
214308634|NCT04200807|DEVICE|Ultrasound Cardiac Output Monitor (USCOM 1A)|doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)
214308635|NCT02795728|OTHER|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
214308636|NCT02795728|OTHER|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
214308637|NCT05505032|DRUG|Oxygen|Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.
214308638|NCT05505032|DEVICE|Masimo Root Radical 7|We use it to measure the oxygen reserve index (ORi).
214308639|NCT03225911|DEVICE|Lateral wedge insole (insole)|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation.
214308640|NCT03225911|DEVICE|simple knee sleeve (sleeve)|The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
214916136|NCT04483960|DRUG|(Arm Closed) Tinzaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia)."
214916137|NCT04483960|BIOLOGICAL|(Arm Never Opened) Hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation. Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma
214670620|NCT04612088|BEHAVIORAL|Cognitive Dissonance|"A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study."
214916138|NCT04483960|DRUG|Nirmatrelvir-Ritonavir|The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD of Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR = 60 mL/min/1.73m2) of Nirmatrelvir. Investigators are advised to consider withholding treatment if participant's eGFR \< 30 mL/min/1.73m2.
214916139|NCT04483960|DRUG|Remdesivir|The dose of intravenous remdesivir is 200 mg on day 1 followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. Remdesivir will be administered as an intravenous infusion via a central or peripheral venous catheter over a 30-120 minute period, as per local practice.
214916140|NCT03581058|DRUG|Cannabis|Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
214916141|NCT01417741|DEVICE|Acupuncture Needle|A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
214916142|NCT03738436|OTHER|Physical therapy traditional neuromuscular training, NMT|The NMT program includes re-position exercise using Swiss ball roll squat, strengthening and stretching exercises in various positions or combined using Swiss ball, Thera-Band or suspension system (Redcord), balance exercise on wobble board, proper landing strategy practices, and etc.
214916143|NCT03738436|OTHER|Physical therapy modified visual feedback, MVF|traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles
214916144|NCT00098436|DRUG|laromustine|
214916145|NCT00098436|DRUG|temozolomide|
214916146|NCT04664036|DIAGNOSTIC_TEST|ultrasound|ultrasound to check for NAFLD according to Saverymuttu criteria
214916147|NCT04664036|DIAGNOSTIC_TEST|elastography|elastography to compare liver stiffness indices
214916148|NCT04664036|DIAGNOSTIC_TEST|controlled attenuation parameter (CAP)|CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis
214916149|NCT04664036|DIAGNOSTIC_TEST|FLI|the FLI is a score panel designed to screen for NAFLD
214916150|NCT04664036|DIAGNOSTIC_TEST|FIB-4|the FIB-4 is a score panel designed to screen for significant fibrosis
214916151|NCT04664036|DIAGNOSTIC_TEST|NFS|the NFS is a score panel designed to screen for significant fibrosis
214954976|NCT01560572|DRUG|tacrolimus OD, mycophenolic acid, prednisolone|tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
214308641|NCT03225911|DEVICE|simple knee sleeve + lateral wedge insole|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation. The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
214308642|NCT03330431|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|"All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation."
214308643|NCT05696834|PROCEDURE|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
214308644|NCT04173117|DIETARY_SUPPLEMENT|Low energy meal replacement plan (12 weeks)|Low energy meal replacement plan (12 weeks)
214308645|NCT02599181|OTHER|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland.
214308646|NCT05102786|OTHER|40007388|A non-combusted cigarette used with heated tobacco device 20020064
214308647|NCT05102786|OTHER|40007385|A non-combusted cigarette used with heated tobacco device 20020064
214308648|NCT05102786|OTHER|40007387|A non-combusted cigarette used with heated tobacco device 20020064
214308649|NCT05102786|OTHER|40007386|A non-combusted cigarette used with heated tobacco device 20020064
214308650|NCT00297037|DRUG|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
214308651|NCT00076011|DRUG|Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor|
214308652|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme|Pre-Workout Dietary Supplement
214308653|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
214308654|NCT02952014|DIETARY_SUPPLEMENT|Placebo|Pre-Workout Dietary Supplement
214308655|NCT03804112|DIAGNOSTIC_TEST|Ultrasound exam with Doppler|Ultrasound exam of the neck to search a perivascular inflammation at the level of the carotid bifurcation.
214308656|NCT03804112|BIOLOGICAL|Blood samples|blood count , CRP and viral serologies (herpes virus, chlamydia, mycoplasma),
214308657|NCT00581776|DRUG|Bortezomib|Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
214308658|NCT00581776|DRUG|Rituximab|Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
214308659|NCT00581776|DRUG|Cyclophosphamide|Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
214308660|NCT00581776|DRUG|Doxorubicin|Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
214308661|NCT00581776|DRUG|Vincristine|1 mg administered by IV on day 3 of each cycle.
214308662|NCT00581776|DRUG|Dexamethasone|40 mg orally on days 1-4 of each cycle.
214308663|NCT06019156|BEHAVIORAL|Exercise video distribution of Metaverse|Participants received a 10-minute exercise video each week with a load of about 4 to 8 metabolic equivalents of task (METs) in the metaverse space, for eight videos delivered to encourage exercise.
215060389|NCT04378491|OTHER|Collection of Clinical Scores|"Collection of Clinical Scores:~* patient's pain, range of motion and ability to perform daily living activities will be assessed using the Kujala Anterior Knee Pain Scale, Lysholm Knee Score, visual analog scale score (VAS) and the Tegner Activity Score"
214308664|NCT06019156|BEHAVIORAL|Exercise video distribution of YouTube|Participants view exercise videos with the same content as the metaverse group.
214308665|NCT06236711|DEVICE|tDCS|tDCS is a form of noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes. The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A (Soterix Medical, Inc., New York, NY, USA) device will be used in the study. The tDCS device is comprised of a small battery-operated control box that delivers the current through electrodes placed on the scalp, held in place by elastic bands or head straps and worn over the forehead like a headband.
214308666|NCT05992168|DEVICE|Stent-Retriever|all the participants in this group will be performed with Stent-Retriever
214308667|NCT06513962|OTHER|Best Practice|Receive standard chemotherapy
214670621|NCT01684826|RADIATION|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
214670622|NCT01684826|RADIATION|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
214308668|NCT06513962|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214308669|NCT06513962|OTHER|Electronic Health Record Review|Ancillary studies
214308670|NCT06513962|OTHER|Survey Administration|Ancillary studies
214308671|NCT06513962|DRUG|Triptorelin Pamoate|Given IM
214308672|NCT06580847|BEHAVIORAL|Group Singing|12 week choir program consisting of 1.5 hours of in-person instruction per week.
214308673|NCT06580847|BEHAVIORAL|Audiobook Club|12 week audiobook club program consisting of 1.5 hours of in-person discussion per week.
214308674|NCT04322318|PROCEDURE|Biopsy Procedure|Undergo a biopsy
214916152|NCT05209464|DEVICE|Tele-Tai Chi|Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via an application installed on a tablet. The intervention emphasizes essential TC movements that are easily comprehensible and can be performed repetitively in a flowing manner. The protocol includes up to six core TC movements based on the traditional Cheng Man-Ch'ing's Yang-style short form. Additionally, a set of traditional TC warm-up exercises that focus on loosening the physical body, incorporating mindfulness and imagery into movement, promoting overall relaxation, and coordinating breathing awareness are included. Chairs are used in the protocol for a subset of seated warm-up exercises, as well as for stability and rest as needed. Participants will be asked to practice the protocol (45-60 min) at home for at least 3 days a week for 12 weeks. The TC program will also include 2 or more live instructional sessions via Zoom with a TC instructor.
214916153|NCT00676364|DRUG|4% lidocaine topical anesthetic cream|A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
214916154|NCT00676364|DRUG|Placebo cream|A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
214916155|NCT00903708|DRUG|LY2275796|100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
214916156|NCT02782559|DRUG|Sildenafil|
214916157|NCT02782559|DRUG|Placebo|Color and size matched to active drug (sildenafil)
214916158|NCT04439448|RADIATION|dual-energy X-ray absorptiometry (DEXA) scan|Whole body dual-energy X-ray absorptiometry (DEXA) scan to assess lean and fat mass
214916159|NCT04439448|OTHER|Carotid and branchial artery ultrasound|Ultrasound to assess carotid plaque and brachial artery flow mediated dilation
214916160|NCT04439448|DIAGNOSTIC_TEST|2-hour oral glucose tolerace test|Ingestion of 75g of glucose syrup with blood collection for glucose and insulin at time 0, 90min and 120min
214916161|NCT04439448|DIAGNOSTIC_TEST|Blood collection|Blood collection for measurement of circulating proteins (cytokines) and isolation of immune cells
214916162|NCT01057966|DIETARY_SUPPLEMENT|ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)|Single full strength dose capsule taken one time
214916163|NCT01057966|DIETARY_SUPPLEMENT|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)|Single half strength dose capsule taken one time
214308675|NCT04322318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214308676|NCT04322318|PROCEDURE|Bone Scan|Undergo a bone scan
214308677|NCT04322318|DRUG|Carboplatin|Given IV
214308678|NCT04322318|PROCEDURE|Computed Tomography|Undergo a CT scan
214308679|NCT04322318|DRUG|Cyclophosphamide|Given IV
214308680|NCT04322318|DRUG|Doxorubicin|Given IV
214308681|NCT04322318|DRUG|Etoposide|Given IV
214308682|NCT04322318|DRUG|Ifosfamide|Given IV
214916164|NCT01057966|DIETARY_SUPPLEMENT|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)|Single, full strength dose tablet taken one time
214916165|NCT06450392|DRUG|Tranexamic acid injection|100 mg/mL (manufactured concentration) local TXA injection in the orbit
214308683|NCT04322318|DRUG|Irinotecan|Given IV
214916166|NCT06450392|DRUG|Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)|1g IV TXA
214916167|NCT06450392|DRUG|normal saline - injection|0.9% Normal Saline injection in the orbit
214916168|NCT06450392|DRUG|normal saline - intravenous|0.9% IV Normal Saline
214916169|NCT03200769|DEVICE|CPAP active|CPAP PR1 Philips Respironics with a pression between 4 and 14 mm Hg
214916170|NCT03200769|DEVICE|CPAP placebo|CPAP PR1 Philips Respironics with a constant pression of 4 mm Hg.
214308684|NCT04322318|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214308685|NCT04322318|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
214308686|NCT04322318|RADIATION|Radiation Therapy|Undergo RT
214670623|NCT00260221|BEHAVIORAL|using VR hypnosis/distraction and audio hypnosis|a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
214916171|NCT05143346|DEVICE|Intubation|Using video stylet and video laryngoscope in difficult intubation in patients with trauma or suspected to be have difficult intubation.
214916172|NCT02374268|BEHAVIORAL|Exercise program alone|
214916173|NCT02374268|DIETARY_SUPPLEMENT|Combined exercise program and nutrition supplement|
214916174|NCT02374268|OTHER|Waitlist control group|
214916175|NCT00256386|DEVICE|Electronic Medical Record (EMR) to clinician's in-basket|
214916176|NCT00256386|DEVICE|Automated Voice Message (AVM) reminder to patient's phone|
214916177|NCT00256386|PROCEDURE|Pharmacy Team phone call-letter followup|
214916178|NCT04398303|BIOLOGICAL|ACT-20-MSC|1 million cells / kg body weight in 100 ml in conditioned media
214916179|NCT04398303|BIOLOGICAL|ACT-20-CM|100 ml of conditioned media only
214308687|NCT04322318|PROCEDURE|Surgical Procedure|Undergo surgery
214308688|NCT04322318|DRUG|Topotecan|Given IV
214308689|NCT04322318|PROCEDURE|Transabdominal Ultrasound|Undergo abdominal ultrasound
214308690|NCT04322318|DRUG|Vincristine|Given IV
214308691|NCT04322318|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
214308692|NCT05469100|DRUG|Selpercatinib|Administered orally
214308693|NCT03056755|DRUG|Alpelisib|300 mg of alpelisib film-coated tablets administered orally once daily
214308694|NCT03056755|DRUG|Fulvestrant|500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
214308695|NCT03056755|DRUG|Letrozole|2.5 mg of letrozole film-coated tablets administered orally once daily
214308696|NCT03056755|DRUG|Goserelin|3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.
214308697|NCT03056755|DRUG|Leuprolide|7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
214308698|NCT02364544|BEHAVIORAL|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
214916180|NCT04398303|BIOLOGICAL|Placebo|100 ml of MEM-α
215060390|NCT04378491|OTHER|Collection of Imaging Data - Radiological measurements|Collection of Imaging Data - Radiological measurements: Xrays and MRIs which were already performed as part of the original diagnostic and follow-up procedures pre- and postoperative will be reviewed and analysed.
214916181|NCT01228890|BEHAVIORAL|CATCH-IT|"The CATCH-IT 2-R intervention has a motivational (3 PCP motivational interviews at time 0, 1.5 months and 12 months and 3 coaching phone calls at 2 and 4 weeks and 18 months) and an Internet component (with separate adolescent \[14 modules\] and parent \[5 modules\] programs). This revised and expanded intervention will include a comprehensive approach to reducing modifiable risk factors and enhancing resiliency factors associated with increased or decreased risk of depression, respectively, proposed by Spence and Reinecke.148 The revised CATCH-IT Tracker will monitor time in study and deploy elements of the intervention based on time since enrollment, including computer and human elements (e.g. calls, doctor visits)."
214308699|NCT02364544|BEHAVIORAL|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
214308700|NCT02364544|BEHAVIORAL|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
214308701|NCT02364544|BEHAVIORAL|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
214308702|NCT02364544|OTHER|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
214308703|NCT05230082|OTHER|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
214308704|NCT06416618|PROCEDURE|Surgical|Surgical group: After osteosynthesis, they will be provided with a sling and swathe immediately after the surgery. From the first postoperative day, only the sling will be used. Two weeks postoperatively, patients will undergo clinical and radiological follow-up in the outpatient clinic. They will be referred to post-operative rehabilitation in the municipalities. At 12 weeks postoperatively, patients will have another clinical and radiological follow-up. This is the current standard care for surgical treatment with a plate or intramedullary nail.
214308705|NCT06416618|PROCEDURE|Non surgical|Non-surgical group: Patients in the non-surgical group will be offered an optional sling for comfort for an additional 1-2 weeks at their first visit, 10-14 days post-injury. Patients will be referred to rehabilitation in the municipalities. At week 6 post-injury, all patients will undergo clinical and radiological follow-up. This represents the current standard care for non-surgical treatment of displaced PHF at the departments.
214308706|NCT01633892|PROCEDURE|Fat Grafting|
214308707|NCT05557539|BIOLOGICAL|blood samples, urine samples and nasopharyngeal swabs|The following samples will be collected: First time point : 6 blood sample tubes (5mL EDTA, 5mL heparinized and 7.5mL heparinized, 5mL citrate, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium). Second time point : 5 blood sample tubes (5mL EDTA,5mL heparinized and 7.5mL heparinized, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium).
214308708|NCT03615326|BIOLOGICAL|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
214308709|NCT03615326|BIOLOGICAL|Placebo|Solution for IV infusion on Day 1 of each 3-week cycle.
215060391|NCT02459431|OTHER|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
214308710|NCT03615326|DRUG|Cisplatin|80 mg/m\^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
214308711|NCT03615326|DRUG|5-FU|800 mg/m\^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
214308712|NCT03615326|DRUG|Oxaliplatin|130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
214308713|NCT03615326|DRUG|Capecitabine|1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
214308714|NCT03615326|DRUG|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.
214308715|NCT03615326|BIOLOGICAL|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
214670624|NCT06819202|OTHER|Hyperbaric oxygen treatment|HBO therapy is the process of inhaling 100% pure oxygen in an environment above one atmosphere (pressure range: 2.0-3.0 absolute atmospheres) to treat a disease.
214308716|NCT05181449|BEHAVIORAL|Twin Precision Treatment|Combination of Artificial Intelligence algorithms based on daily sensor input and live nutrition, exercise, sleep and breath coaching to help treat type 2 diabetes
214308717|NCT02981628|DRUG|Asparaginase Erwinia chrysanthemi|Given Asparaginase Erwinia chrysanthemi
214308718|NCT02981628|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214308719|NCT02981628|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
214308720|NCT02981628|DRUG|Calaspargase Pegol|Given IV
214308721|NCT02981628|DRUG|Cyclophosphamide|Given IV
214308722|NCT02981628|DRUG|Cytarabine|Given IV or SC
214308723|NCT02981628|PROCEDURE|Diagnostic Imaging|Undergo imaging
214308724|NCT02981628|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214308725|NCT02981628|DRUG|Leucovorin Calcium|Given PO or IV
214308726|NCT02981628|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214308727|NCT02981628|DRUG|Methotrexate|Given IT
214670625|NCT04680923|PROCEDURE|CPPLAI|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
214308728|NCT02981628|DRUG|Pegaspargase|Given IV or IM
214308729|NCT02981628|DRUG|Vincristine|Given IV
214308730|NCT03697668|DRUG|Imatinib|triple combination for the treatment of malaria
214308731|NCT03697668|DRUG|Dihydroartemisinin-piperaquine|standard malaria treatment
214308732|NCT04659850|OTHER|low fat, low AGE milkshake|low fat, low AGE milkshake given after an overnight fast
214670626|NCT04680923|OTHER|Placebo|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.
214954977|NCT03402672|OTHER|self-administered, e-health application|"AWAITS is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT when they were actively using. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
214308733|NCT04659850|OTHER|low fat, high AGE milkshake|low fat, high AGE milkshake given after an overnight fast
214308734|NCT04659850|OTHER|high fat, low AGE|high fat, low AGE milkshake given after an overnight fast
214308735|NCT04659850|OTHER|high fat, high AGE milkshake|high fat, high AGE milkshake given after an overnight fast
214308736|NCT03986320|DEVICE|Keeogo™ Dermoskeleton|This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
214308737|NCT01012687|DRUG|perindopril erbumine|8 mg tablet
214308738|NCT04692428|PROCEDURE|Locoregional analgesia|the supra-inguinal fascia iliaca block versus the femoral nerve block
214308739|NCT03442621|DRUG|Relacorilant Fasted|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast
214308740|NCT03442621|DRUG|Relacorilant with a high fat breakfast|Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast
214916182|NCT01228890|BEHAVIORAL|AMPE|The AMPE components are similar to those employed in previous primary care based quality improvement/Chronic Care Model Interventions (patient education \[psycho-education described below\], provider training \[described in Case Finding and Recruitment\], active monitoring and referral \[case management, discussed under assessments\], physician and nurse education and routine contact with PCP \[study design rationale\]). This Internet site will focus on assisting parents and adolescents in early identification of need for treatment and will also target stigma and negative attitudes toward treatment of mental disorders we have previously identified as barriers to seeking and adhering to treatment.
214916183|NCT00774514|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
215060392|NCT02459431|OTHER|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
214480568|NCT06722092|BEHAVIORAL|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
214480569|NCT06722092|BEHAVIORAL|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and prerecorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
214480570|NCT06730438|DEVICE|Transcranial Pulse Stimulation|Patients will receive TPS once a day for five days a week, each session will be separated from the previous one by 24h. Each stimulation and assessment session will be performed at the same hour of the day, in the morning preferably, to maximize the probability of observing responses to stimuli. Patients will be managed in a quiete room with stable light and temperature.
214480571|NCT06730373|DRUG|Disitamab Vedotin|2.5 mg/kg IV every 3 weeks
214480572|NCT06730373|DRUG|Sintilimab|200 mg IV every 3 weeks
214480573|NCT06730373|DRUG|S-1|40-60 mg BID for 14 days, every 3 weeks
214480574|NCT06730373|DRUG|Trastuzumab|First load dose is 8.0mg/kg , then 6.0 mg/kg IV every 3 weeks
214480575|NCT06730373|DRUG|Oxaliplatin|130 mg/m2 Q3W
214480576|NCT06730373|DRUG|Capecitabine|1000 mg/m² Q3W
214480577|NCT06730373|DRUG|5-FU|800 mg/m²
214480578|NCT06730373|DRUG|Cisplatin|80 mg/m²
214480579|NCT06634394|DRUG|APVO436|Infusion drug administered as a 4 hour infusion.
214480580|NCT06634394|DRUG|Venetoclax|Oral tablet given on days 1 through 22, of a 28 day cycle.
214480581|NCT06634394|DRUG|Azacitidine|Intravenous infusion given on days 1-8 of a 28 day cycle
214480582|NCT06872606|DRUG|Pucotenlimab|Pucotenlimab (200 mg IV, q3w)
214480583|NCT06872606|DRUG|Bevacizumab|Bevacizumab (7.5 mg/kg IV, q3w)
215060393|NCT02360670|OTHER|control imaging|
214480584|NCT06872606|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m² IV, q3w)
214480585|NCT06872606|DRUG|Trifluridine/Tipiracil Hydrochloride|TAS-102 (25 mg/m² orally, days 1-5 and 8-12).
214480586|NCT06872606|RADIATION|Short-course radiotherapy|(25 Gy/5 fractions)
214480587|NCT06872606|RADIATION|intracavitary brachytherapy|brachytherapy (3 Gy/3 fractions).
214480588|NCT06872736|DEVICE|WeFun-wearable activated|1 month daily routine program with weekly visits in natural environments (home, community, etc) together with WeFun-weareable to increase spontaneous use of the upper limb in children with UCP during activities of daily life and leisure. Activities are priorized by Canadian Occupational Performance Measure and Goal Atteinment Scale. Programs are designed together with a transdisciplinary team, acting as consultants. Children in the experimental group will have the wearable's experimental movement functions activated.
215060394|NCT02360670|OTHER|additional multimodal imaging|
215060395|NCT00346879|DRUG|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
215060396|NCT04813614|DEVICE|STYLAGE M Lidocaine|Injection in the lips
214480589|NCT06872736|DEVICE|WeFun-wearable desactivated|1 month daily routine program with weekly visits in natural environments (home, community, etc) together with WeFun-weareable to increase spontaneous use of the upper limb in children with UCP during activities of daily life and leisure. Activities are priorized by Canadian Occupational Performance Measure and Goal Atteinment Scale. Programs are designed together with a transdisciplinary team, acting as consultants. Children in the control group will not have experimental functions in their wearables.
214480590|NCT06726447|DEVICE|Artificial Intelligence Tool|The intervention in this study consists of the implementation of an artificial intelligence tool for clinical registration during outpatient consultations. This technology facilitates the documentation of interactions in real time, optimizing the workflow of professionals and enabling more patient-centered care.
214480591|NCT06706336|OTHER|radon mitigation system|standard radon mitigation system used to reduce radon in homes
214480592|NCT06706336|OTHER|Sham (No Treatment)|inactive radon mitigation system
215060397|NCT04813614|DEVICE|Active control group|Injection in the lips
215060398|NCT06556875|BEHAVIORAL|HIIT|high intensity interval training
215060399|NCT06556875|BEHAVIORAL|HIIT combined IET|high intensity interval training combined with isometric exercise training
215060400|NCT04651439|DRUG|Filgrastim|"Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~* 20 to \< 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~* 30 to \< 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 60 to \< 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* 90 to \< 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* \> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)"
214916184|NCT05961943|BEHAVIORAL|RESPONSE-2-PAD|The RESPONSE-2-PAD program will undergo evaluation through a pilot study includes 50 patients living with peripheral arterial disease. Participants will take part in an initial assessment which will measure their sedentary time/physical activity using activPAL and their six-minute walking distance. They will then take part in a 12-week tailored, coaching-based intervention delivered remotely. The intervention involves the use of an activity tracker (sedentary reminder) and an online structured education program coupled with coaching calls that review sedentary time and activity goals weekly. At 12-weeks all participants will be invited to a follow up assessment. Participants will also be invited to take part in a semi-structured interview to explore their views and opinions of the program and its acceptability. At six months all patients will be invited for a final follow-up measurements.
214916185|NCT00402688|DRUG|levofloxacin|750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
214916186|NCT00402688|DRUG|levofloxacin|750mg tablet once daily for 3 weeks followed by 1 week of placebo.
214916187|NCT00402688|DRUG|levofloxacin|500mg tablet once daily for 4 weeks.
214916188|NCT00221871|DRUG|Different dosages of Ketamine|
214916189|NCT04306965|DRUG|Apremilast|30 mg twice daily (BID)
214916190|NCT04973969|OTHER|Decapeptyl|diagnosis of predictio value
214916191|NCT02882581|RADIATION|11C-metformin|400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
214916192|NCT03259425|DRUG|Nivolumab|Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then participant will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
214916193|NCT03259425|DRUG|HF10|1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
214916194|NCT03267134|DEVICE|Hydrus Microstent|Device implanted into the Schlemm's canal of the eye for the purpose of providing a natural outflow pathway for aqueous humor. The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
214916195|NCT03267134|PROCEDURE|Ophthalmic surgery|Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
214916196|NCT02020538|OTHER|Low-chloride perioperative intravenous fluid strategy|The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
214916197|NCT02020538|OTHER|High-chloride perioperative intravenous fluid strategy|
214916198|NCT04157296|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The CBT intervention will consist of 12 weekly 60 minute sessions of the manualized therapy, adapted from the Coping Cat program, for the treatment of pediatric anxiety disorders.
214916199|NCT04157296|BEHAVIORAL|computerized cognitive training (CCT)|CCT intervention will consist of approximately 30 minutes of CCT games prior to each CBT session, to engage cognitive control capacity prior to receipt of CBT. The CCT games will be designed to target focused attention, response inhibition, working memory and multiple simultaneous attention to constitute a general executive function training, and activate neural systems associated with executive function/cognitive control. Difficulty of the games will be titrated individually and by session to avoid boredom and progressively activate the functional systems underlying cognitive control.
214916200|NCT00641602|DRUG|Esomeprazole|40mg once daily
214916201|NCT00641602|DRUG|Lansoprazole|30mg once daily
215060401|NCT04651439|DRUG|Placebo|"Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* \> 150kg = 20mL of Glucose 5% solution (by IV)"
214308741|NCT03442621|DRUG|Relacorilant with a moderate breakfast|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
214308742|NCT03240679|DEVICE|Acell MatriStem® Surgical Matrix|Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
214308743|NCT00405587|DRUG|PLX4032|Oral capsules administered BID
214308744|NCT06387914|DEVICE|Stimulation ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus at a level with potential to provide pain relief
214480593|NCT06733701|DEVICE|VR-based intervention (VRReliever Software V0.3.4 fromXRHealth)|The participant will be able to select between four VR environments: beach, lake, forest, or mountain scenery. Each provides an immersive audio and visual environment designed to reduce anxiety and promote relaxation. Each scene is rendered in a high-resolution and life-like fashion which participants can experience in a full 360 degrees. Participants will wear the headset for the duration of the egg retrieval procedure which is approximately 15-20 minutes.
214480594|NCT06733701|DEVICE|VR headset without any scenery|VR headset without any scenery
215060402|NCT01524224|DRUG|LY2495655|administered intravenously
215060403|NCT02998411|OTHER|Titration|
215060404|NCT01454609|DRUG|0.9% Normal saline|Saline
214308745|NCT06387914|DEVICE|Stimulation Pseudo-ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus S at a low level, not designed to provide pain relief
214308746|NCT00390325|DRUG|Sorafenib Tosylate|Given PO
214308747|NCT01280214|DRUG|Triamcinolone|Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
214308748|NCT06045806|BIOLOGICAL|idecabtagene vicleucel|Specified dose on specified days
214308749|NCT06045806|DRUG|Lenalidomide|Specified dose on specified days
214308750|NCT06045806|DRUG|Fludarabine|Specified dose on specified days
214308751|NCT06045806|DRUG|Cyclophosphamide|Specified dose on specified days
214916202|NCT02237196|BIOLOGICAL|AMG 157|AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
214916203|NCT02237196|BIOLOGICAL|Cat Immunotherapy|A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
214670627|NCT04680923|DRUG|Bupivacaine 0.25%|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
214916204|NCT02237196|BIOLOGICAL|Cat Immunotherapy Placebo|Placebo for allergen-specific immunotherapy administered subcutaneously
214916205|NCT02237196|BIOLOGICAL|AMG 157 Placebo|Placebo for AMG 157 administered intravenously
214916206|NCT06574841|OTHER|Blood Flow Restriction training|BFR training done 3 sessions per week, each session includes low intensity of 20% to 30% of 1RM, 3 sets of 15 to 30 reps with a 30sec resting period done for 6 weeks.Moreover, nerve and tendon-gliding exercises consists of 10 reps with a 5-second hold, 3-5 times done daily for 5 weeks.
214308752|NCT06124716|OTHER|Enhanced COACH CDS Tool|CDS tool with features to promote high blood pressure management
214308753|NCT06124716|OTHER|Usual Care COACH CDS Tool|CDS tool with limited features to promote high blood pressure management
214308754|NCT05434260|DEVICE|Surgiphor Irrigation Solution|use of Surgiphor wound irrigation solution during surgery
214308755|NCT05434260|DEVICE|Sterile saline|Use of sterile saline as a irrigation solution during surgery
214308756|NCT04696939|DRUG|Atezolizumab|Atezolizumab intravenous infusion was administered at a dose of 1200mg on Day 1 of each 21-day cycle.
214308757|NCT04696939|DRUG|Carboplatin|Carboplatin intravenous infusion was administered at a dose of 75mg/m\^2 on Day 1 of each 21-day cycle.
214308758|NCT04696939|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Day 1 of every 3-day cycle.
214916207|NCT00212342|DRUG|Norethisterone,Ethinylestradiol|
214916208|NCT00212342|DRUG|Sugar pill|
214916209|NCT01522378|DRUG|123 iodine metaiodobenzylguanidine|10 millicurie (mCi) (370 MBq)
214916210|NCT05251961|PROCEDURE|operative deformity correction|"* The participants will be subjected to surgical correction using growing rods as a novel technique for their long bone deformities.~* Procedure will be done under anaesethia~* Osteotomy , fracture reduction , deformity correction will be done , then introduction of the growing rod"
214916211|NCT05630261|BEHAVIORAL|Self-help CBT-I|The intervention will cover the following topics: (a) physiological linkage between the brain and stress, (b) sleep hygiene, (c) stimulus control, (d) sleep restriction, (e) cognitive restructuring, and (f) positive psychology. Each weekly session will be divided into 6-8 chapters. Chapters are supported by short videos and interactive games. Homework activities will be assigned after each session.
214954978|NCT03712267|BEHAVIORAL|Electronic Media Enhanced|Research assistants will provide participants' therapists with information from participants' electronic messaging prior to typically scheduled clinical appointments.
214954979|NCT03712267|BEHAVIORAL|Treatment as Usual|Research assistants will not review or provide participants' therapists with information from participants' electronic media and will compare with the Electronic Media Enhanced cohort to see if there was a difference in therapy outcomes.
214954980|NCT01422746|DRUG|Metformin|500-1000 mg PO BID (X12 weeks)
214954981|NCT00239499|DRUG|Tiotropium|
214954982|NCT00239499|DRUG|Salmeterol plus Fluticasone|
214954983|NCT00047788|DRUG|ZD6474|
214954984|NCT00047788|DRUG|VEGF-receptor tyrosine kinase (KDR)|
214954985|NCT05761704|DRUG|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
214954986|NCT05761704|DRUG|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
214954987|NCT05188729|DRUG|Part 1: VP-315 3 Day Dosing/Week|2-8 mg of VP-315 administered via intratumor injection into a single target lesion on W1D1. Each 500-μL dose will be divided into 2 injections given at least 15 minutes and no more than 30 minutes apart, with 30% (150 μL) administered in the first injection and the remaining 70% (350 μL) with the second injection. In all parts of the study, the targeted total volume of delivery is 500 μL daily.
214954988|NCT05188729|DRUG|Part 2: VP-315 3 Day Dosing/Week - Loading Dose|4mg (halt the target dose) loading dose on W1D1 administered via intratumor injection into a single target lesion, followed by total daily doses at the full target dose of 8 mg on the remaining days of treatment.
214954989|NCT05188729|DRUG|Part 2: VP-315 3 Day Dosing/Week - No Loading Dose|8 mg of VP-315 administered daily via intratumor injection into a single target lesion up to 3 consecutive daily doses/week for up to 2 weeks (W1D1, W1D2, W1D3 and W2D1, W2D2, W2D3 - up to 6 total doses).
214954990|NCT05188729|DRUG|Part 2: VP-315 2 Day Dosing/Week - Split Dose|8 mg of VP-315 administered daily via intratumor injection into a single target lesion up to 2 consecutive daily doses/week for up to 2 weeks (W1D1, W1D2, W1D3 and W2D1, W2D2, W2D3 - up to 6 total doses).
214954991|NCT05188729|DRUG|Part 2: VP-315 3 Day Dosing/Week - Split Dose|8 mg of VP-315 administered daily via intratumor injection into a single target lesion up to 3 consecutive daily doses/week for up to 2 weeks (W1D1, W1D2, W1D3 and W2D1, W2D2, W2D3 - up to 6 total doses).
214916212|NCT05630261|BEHAVIORAL|Self-help CBT-D|The intervention will cover the following topics: (a) physiological linkage between the brain and stress, (b) emotion management, (c) cognitive restructuring, (d) behavioral activation, and (e) positive psychology. Each weekly session will be divided into 6-8 chapters. Some chapters are supported by short videos and e-worksheets. Homework activities will be assigned after each session, which include weekly record of emotions or between-session practice.
214916213|NCT02049905|DRUG|Aldoxorubicin|
214916214|NCT02049905|DRUG|Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)|
214308759|NCT04323280|DRUG|Dexamethasone therapy|Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
214916215|NCT02166398|DRUG|UI15AML055MT|tab, PO
214916216|NCT02166398|DRUG|Amosartan 5/50|tab, PO
214916217|NCT06188871|DRUG|Dupilumab|Two injections of 300mg dupilumab, subcutaneous 14 days apart
214916218|NCT04441528|DRUG|Lid wipes containing terpinen-4-ol and sodium hyaluronate|Lid wipes will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
214916219|NCT04441528|DRUG|Baby shampoo|Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
214916220|NCT04830371|BIOLOGICAL|EuTCV (Vi-CRM Typhoid conjugate vaccine)|Single dose, Intramuscular administration
214308760|NCT04323280|DRUG|NSAID therapy|NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
214308761|NCT00299260|BIOLOGICAL|CMV gB vaccine|20 micrograms
214308762|NCT00299260|DRUG|Placebo|normal saline
214670628|NCT02633111|OTHER|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
214916221|NCT04830371|BIOLOGICAL|Typbar-TCV|Single dose, Intramuscular administration
214916222|NCT01488383|DRUG|Purified extract of Rebaudina Stevia-Stevioside|volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
214916223|NCT01488383|DRUG|Sodium saccharin|Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
214916224|NCT04284098|OTHER|General anesthesia (GA).|Patients received standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
214916225|NCT04284098|OTHER|PECS block using bupivacaine .|The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%, after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
214916226|NCT04284098|OTHER|PECS block using bupivacaine and dexmedetomidine|D group:The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%+dexmedetomidine (1µg/kg) after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
214916227|NCT02012361|PROCEDURE|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target FiO2 of 0.25, (25%oxygen / 75%nitrogen) the only exception being that they will not be treated with inspired heliox.
214916228|NCT02012361|PROCEDURE|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes over any convenient window prior to the inflation of the surgical tourniquet. This will be the only change in their clinical care. Their anesthesia will be conducted as per routine and as the anesthesia team sees fit with a target FiO2 of 0.25, the only exception being that they will receive 75/25 heliox prior to the inflation of the tourniquet.
214916229|NCT02012361|PROCEDURE|Muscle Biopsy|During the course of the operation a small muscle biopsy will be collected.
214916230|NCT03980145|DEVICE|G-EO System (Reha Technology AG: Olten, Switzerland)|Electromechanically-assisted gait training addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases.13,14 The G-EO System (Reha Technology: Olten, Switzerland) is a novel end-effector gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback.
214308763|NCT01701115|PROCEDURE|Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL"
214308764|NCT01701115|PROCEDURE|Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL"
214308765|NCT01701115|DRUG|Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
214308766|NCT01701115|DRUG|Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
214308767|NCT03506373|DRUG|Ibrutinib|Given PO
214308768|NCT03506373|DRUG|Ixazomib Citrate|Given PO
214308769|NCT03506373|OTHER|Laboratory Biomarker Analysis|Correlative studies
214670629|NCT02633111|OTHER|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
214916231|NCT03980145|OTHER|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training. Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
214916232|NCT02511145|OTHER|occlusive bandage|
214916233|NCT02511145|DEVICE|ablative fractional CO2 laser pretreatment|
214916234|NCT02511145|DEVICE|Microneedles pretreatment|
214916235|NCT02511145|DRUG|METVIXIA Cream|
214916236|NCT02962453|DEVICE|Morning walk|gait training with Morning walk three times during 5 minutes with 5 minute break a day over 5 weekdays
214954992|NCT01438931|DRUG|DA-9501|Dexmedetomidine hydrochloride variable dose
214954993|NCT01438931|DRUG|placebo|
214954994|NCT02552888|DRUG|Immediate release sodium nitrite|Immediate release sodium nitrite 40 mg by mouth twice per day
214916237|NCT02962453|DEVICE|Ground Walker|gait training with ground walker until corresponding 200 steps during 5 minutes with 5 minute break a day over 5 weekdays
214916238|NCT00532389|DRUG|LBH589|
214916239|NCT04791189|OTHER|questionnaire|questionnaire to survey the needs of adolescents with juvenile idiopathic arthritis and the views of their parents in the area of sexual health.
214916240|NCT01398969|BIOLOGICAL|Fresh FMT|Participants will receive fresh FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
214916241|NCT01398969|BIOLOGICAL|Frozen-and-Thawed FMT|Participants will receive frozen-and-thawed FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
214916242|NCT03317730|DRUG|Xtampza ER|Xtampza ER is a wax microsphere formulation of oxycodone that results in a nearly identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube as opposed to by mouth.
214916243|NCT06576310|DEVICE|Mandibular Advancement Device|In this research, participation in the protocol seamlessly integrates into routine care at the Odontology Department of the University Hospital of Toulouse. The visits include the provision of the orthosis at 3 weeks (T1), with EMGs and digital occlusal analysis. The 6-week follow-up visit (T2) adjusts therapeutic propulsion, subjectively resolving symptoms related to OSAS. At the T0 visit, the researchers collect the polysomnographic monitoring before fitting the orthosis (carried out in the patient's reference sleep laboratory) to assess treatment efficiency. The end-of-research visit (6 months after T1) comprehensively collects data, including questionnaires on stress, anxiety, sleep quality and quantity, oral habits, temporo mandibular dysfunction pain, and quality of life. Moreover, the researchers collect the polysomnographic monitoring after 3 months fitting the orthosis (carried out in the same patient's reference sleep laboratory than before fitting the orthosis).
214916244|NCT06196255|DRUG|anti-FcRL5 CAR-T|anti-FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.
214916245|NCT06577038|DEVICE|PCI with use of IVL|Use of IVL for the treatment of calcific coronary artery lesions at operator's discretion
215060405|NCT01454609|DRUG|Bupivacaine|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
214308770|NCT03506373|OTHER|Pharmacodynamic Study|Correlative studies
214308771|NCT03506373|OTHER|Pharmacokinetic Study|Correlative studies
214308772|NCT06848803|BEHAVIORAL|AI- driven simulation platform|This investigation will draw upon existing literature exploring the intersection of AI in education, reflective practice, emotional intelligence, and professional integration. By synthesizing these perspectives, we aim to provide a comprehensive overview of the transformative potential of AI-driven SLPs in shaping future professionals. Furthermore, this analysis will consider the ethical implications of using AI in education, including issues related to data privacy, algorithmic bias, and the potential displacement of human interaction.
214308773|NCT05779475|OTHER|No treatment given|Participants will not receive any investigational treatment in this study.
214308774|NCT04349618|OTHER|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
214308775|NCT04349618|OTHER|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
214670630|NCT02633111|DEVICE|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
215060406|NCT01454609|DEVICE|Bupivacaine with clonidine (combination)|"Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours~Clonidine - 0.5 - 1 microgram/ kg"
215060407|NCT04904406|DRUG|Dolutegravir / Lamivudine Oral Tablet|Discontinuing abacavir by switching from three-drug regimen with dolutegravir/abacavir/lamivudine to two-drug regimen with dolutegravir/lamivudine
215060408|NCT06501547|GENETIC|Leucocyte Telomere Length from blood draw|blood draw, PCR method to see leucocyte telomere length
215060409|NCT05142917|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
215060410|NCT05142917|BEHAVIORAL|Hand motor task|Various type of hand motor tasks are applied to stroke patients.
215060411|NCT00072046|BIOLOGICAL|bevacizumab|10mg/kg IV infusion on Days 1 \& 15 of each cycle
215060412|NCT00072046|BIOLOGICAL|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
215060413|NCT05416164|RADIATION|Omission of radiotherapy|Omission of radiotherapy
215060414|NCT05976815|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Apart from the neoadjuvant chemotherapy treatment (standard of care), participants allocated to the experimental group will additionally participate in a supervised physical exercise program that comprises 3 weekly sessions during the months that the patient is undergoing chemotherapy treatment. Each 75-minute session will comprise a 10-minute warm up, 30 minutes of strength training involving exercise for the major muscle groups, 30 minutes of aerobic training at 40-89% of heart rate reserve and a 5-minute cool down.
215060415|NCT00456625|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 dose
215060416|NCT01419600|DRUG|AZD8683|Single Dose Inhaled IMP via Turbuhaler
215060417|NCT01419600|DRUG|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
215060418|NCT06635434|DEVICE|AR Pain assessment|Age-stratified (age 7-11 and age 12-17 years old) augmented reality app to evaluate for pain and opioid-related adverse events with equivalent English and Spanish text, audio, and narration
215060419|NCT02596256|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
215060420|NCT02596256|DRUG|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
215060421|NCT04490213|OTHER|Allevyn, Aquacel and Tegaderm, Mediskin|Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
214916246|NCT02892110|DRUG|Varenicline|2 mg daily
214916247|NCT02892110|DRUG|Placebo|2 mg daily
214916248|NCT00595855|PROCEDURE|trabeculectomy|Cairns-like trabeculectomy, limbus based, with 5\_FU supplementation and argon laser suturelysis
214916249|NCT00595855|PROCEDURE|deep sclerectomy|deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
214916250|NCT03468114|BEHAVIORAL|Safe Start|Participant households will receive four visits over a 10 week period from health extension workers promoting safe food preparation, storage and feeding, and will be provided with products to support these practices (a bowl, spoon, cup, hand washing station, liquid soap dispenser).
214916251|NCT03468114|BEHAVIORAL|Active Control|Participant households will receive 4 visits by health extension workers delivering standard care
214916252|NCT01017770|DRUG|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
214916253|NCT01017770|DRUG|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
214308776|NCT06392984|DIAGNOSTIC_TEST|Pectus deformity study form|Pectus deformity study form consisting of clinical and radiological measurements of participants aged 6-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
214916254|NCT04396197|OTHER|Physiotherapy|Daily physiotherapy to include respiratory care and rehabilitation based on the individual therapists clinical reasoning
214308777|NCT06392984|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. Investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second) (Liter-L), FEV1 (%predicted), FVC (Forced Vital Capacity) (Liter-L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
214916255|NCT02308891|DRUG|lactated Ringer's solution (vigorous hydration arm)|"* Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~* Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~* At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
214916256|NCT02308891|DRUG|lactated Ringer's solution (standard hydration arm)|\- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.
214916257|NCT02308891|DEVICE|endoscopic retrograde cholangiopancreatography (ERCP)|endoscopic retrograde cholangiopancreatography
214916258|NCT03518762|PROCEDURE|Sustained lung inflation (SLI)|SLI was given using a peak pressure of 20 cm H₂O sustained for 15 seconds,using a T-piece resuscitator, Neopuff device
214916259|NCT03518762|PROCEDURE|Continuous positive airway pressure (CPAP)|CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
214916260|NCT04681820|DRUG|Flumatinib|Flumatinib mesylate tablets 600mg qd for 24 months
214916261|NCT04681820|DRUG|Nilotinib|Nilotinib Capsules 400mg bid for 24 months
214916262|NCT03350789|DEVICE|Real acupuncture|manual acupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral GB30) + electroacupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral EX-B2 (L4 \& L5), BL25, BL23, BL40, GB34), twice a week, for 4 weeks, common approaches for the treatment of chronic sciatica used by doctors of Korean medicine in Korea today
214954995|NCT02552888|DIETARY_SUPPLEMENT|Isoquercetin|Isoquercetin 225 mg by mouth once per day
214954996|NCT02552888|OTHER|placebos|placebos
214954997|NCT02844270|DEVICE|Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
214954998|NCT04710680|OTHER|no intervention|no intervention
214954999|NCT02442206|DRUG|QVA149|QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
214955000|NCT02442206|DRUG|Placebo|Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
214955001|NCT00497146|DRUG|paricalcitol|2 µg capsule
214955002|NCT00497146|DRUG|placebo|placebo capsule
214955003|NCT02594059|OTHER|endothelial function|measure of reactive hyperemia-peripheral artery tone index
214955004|NCT01619072|OTHER|Misoprostol + referral|800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
214955005|NCT01619072|OTHER|Placebo + referral|Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
214955006|NCT02155309|DRUG|Scopolamine|
214955007|NCT02155309|DRUG|Placebo|
214955008|NCT01359020|DRUG|ibuprofen, dipyrone, acetaminophen|The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
214955009|NCT03058718|OTHER|Procalcitonin|The application of antimicrobial agents is determined by PCT results.
214955010|NCT03058718|OTHER|Clinical Experience|The application of antimicrobial agents is determined by clinical experience of doctors.
214955011|NCT04769492|OTHER|#ChopViolence/#ChopHIV|Tailored, community-based violence prevention intervention
214955012|NCT05253144|RADIATION|Radiotherapy|Radiotherapy
214955013|NCT05253144|PROCEDURE|Surgery|Surgery
214955014|NCT05600153|PROCEDURE|implant exchange operation|To perform implant exchange via axillary incision.
214955015|NCT03625700|DRUG|Oxygen gas|Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
214955016|NCT03513471|BIOLOGICAL|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
214955017|NCT03513471|OTHER|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
214916263|NCT03350789|DEVICE|Sham acupuncture|sham acupuncture without skin penetration(0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) (unilateral GB30) + placebo electroacupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) without electrical stimulation (unilateral EX-B2, BL25, BL23, BL40, GB34), twice a week, for 4 weeks
214308778|NCT06392984|DIAGNOSTIC_TEST|Ultrasonographic Diaphragm Thickness Measurement|Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity-TLC) (millimeter-mm)) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
214308779|NCT04979169|BEHAVIORAL|Text Messaging|A series of theory-informed text messages encouraging them to contact their primary care provider and the UR LCS Program's Patient Navigator to coordinate screening, along with contact information to do so.
214670631|NCT06663371|BEHAVIORAL|Basic Physical Fitness|The single module training paradigm followed a circuit-style format, with each training module consisting of 6 to 8 distinct exercise movements. Taking the INT training intervention on Mondays as an example, the training protocol involved completing one major module (e.g., plyometric exercises) before transitioning to another module (e.g., core stability exercises). Specific exercise methods, such as box jumps, were performed until all sets were completed before moving on to the next exercise (e.g., continuous depth jumps).
214670632|NCT06663371|BEHAVIORAL|Traditional Physical Training|In the fundamental strength training, a circuit training modality is employed, with each training segment comprising 5 to 7 exercise movements. For instance, a series of squat exercises is performed initially, followed by upper body strength training such as bench presses; each movement must be completed with the specified number of sets and repetitions before proceeding to the next exercise. Explosiveness training enhances the rapid contraction capabilities of the muscles through a series of jumping and throwing movements, while flexibility exercises improve the range of motion of muscles and joints through a combination of static and dynamic stretching.
214308782|NCT03067181|OTHER|Best Practice|Undergo observation
214480595|NCT06732037|OTHER|Conventional physical therapy program|The conventional physical therapy program will be received for 8 weeks by the two groups. It includes the application of moist heat using a hot pack for ten minutes, followed by continuous ultrasound therapy operated at a frequency of 1 MHz and an intensity of 1.5 W/cm² for five minutes. Transcutaneous Electrical Nerve Stimulation (TENS) will also be utilized, with its development and application based on the Gate Control Theory. TENS will be applied for twenty minutes, with electrodes positioned on either side of the neck at the level of pain, using a pulse rate ranging from 2 to 50 Hz.
214480596|NCT06732037|OTHER|Kinetic control training|The Kinetic Control Retraining Program will be received for 8 weeks by the experimental group. It focuses on addressing uncontrolled movement (UCM) and muscle synergy retraining. UCM retraining starts with patient education on movement deficiencies, their symptoms, and adherence to training. Movement coordination is retrained in test positions, progressing to challenging ones using feedback from mirrors, walls, or hands. Corrections focus on lower cervical flexion, upper cervical extension, mid-cervical translation/extension, side-bending, and rotation, emphasizing controlled dissociation in supported and unsupported postures. Muscle synergy retraining targets global stabilizers (e.g., deep neck flexors and extensors) and mobilizers (e.g., sternocleidomastoid and suboccipital muscles) to enhance coordination, stability, and motor control.
214480597|NCT05293912|DRUG|SG2501|During study treatment, subjects will receive SG2501 treatment via IV infusion once every week at doses of: 0.01, 0.03, 0.1, 0.3, 1, 2, 4 and 6mg/kg.
214480598|NCT06729424|DEVICE|Digital patient education program|The education consists of 8 modules including main themes within osteoporosis, with content aiming to promote behavioural changes including psychoeducation and behavioural activation.
214916264|NCT00744965|DRUG|Glyburide|Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
214916265|NCT00744965|DRUG|Placebo|Sham dose adjustments of the placebo will be made.
214916266|NCT00000412|DRUG|Alendronate|
214916267|NCT00000412|DRUG|Calcitriol|
214308783|NCT03067181|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
214308784|NCT03067181|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214308785|NCT03067181|BIOLOGICAL|Bleomycin Sulfate|Given IV
214308786|NCT03067181|DRUG|Carboplatin|Given IV
214308787|NCT03067181|DRUG|Cisplatin|Given IV
214308788|NCT03067181|PROCEDURE|Computed Tomography|Undergo a CT scan
214308789|NCT03067181|DRUG|Etoposide|Given IV
214308790|NCT03067181|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214916268|NCT00000412|DRUG|Placebo Alendronate|
214916269|NCT00000412|DRUG|Placebo Calcitriol|
214916270|NCT00611572|DRUG|iomazenil|Given as IV infusion
214916271|NCT00611572|DRUG|iomazenil|saline IV infusion
214308791|NCT03067181|OTHER|Pharmacogenomic Study|Correlative studies
214308792|NCT03067181|PROCEDURE|Pulmonary Function Test|Undergo a pulmonary function test
214308793|NCT03067181|OTHER|Quality-of-Life Assessment|Ancillary studies
214308794|NCT03067181|OTHER|Questionnaire Administration|Ancillary studies
214308795|NCT05784506|OTHER|Macronutrients|Four successive food tolerance tests (glucose, protein, butter and olive oil) at one-week intervals.
214308796|NCT05784506|OTHER|Mixed meal tolerance test (MMTT)|Mixed meal tolerance test (MMTT)
214308797|NCT04165798|DIAGNOSTIC_TEST|Tumor Imaging|Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
214308798|NCT04165798|PROCEDURE|Tumor Tissue Collection|Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
214308799|NCT04165798|PROCEDURE|Blood Sample Collection|"Participants will have blood samples drawn for analysis of:~* genetics~* ribonucleic acid (RNA)~* serum biomarker~* plasma biomarker~* circulating tumor DNA (ctDNA)"
214308800|NCT06417385|DEVICE|taVNS soterix device|Soterix is a custom modified, FDA-cleared electrical stimulator that meets the criteria of the FDA for investigational use. Neoleads will be placed in order to deliver electrical stimulation using microcurrent (\<2.5mA) with breastfeeding, on with sucking and swallowing and off with rest for 5 feeds per week for 2 weeks.
214916272|NCT05537818|DEVICE|AVPI Device|"The AVPI device system consists of a small, hand-held, micro-pressure pulse generator device that is operated by a hand-held mobile smartphone (iPhone®) with a downloaded software application or app. The AVPI device is connected to an earpiece assembly that splits into two earbuds (right and left) that seat comfortably into each respective ear.~1. AVPI device for pressure regulation~2. Earpiece Assembly - a small, flexible, hollow tube that divides into right and left earpieces~3. Earbuds - replaceable, multiple sizes~4. Smartphone with the AVPI app"
214916273|NCT02389387|OTHER|Intensive Intervention|I.A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX):1) real-time communication between staff across healthcare settings, documenting the use of transplant education materials, 2) sending/receiving electronic referrals for transplant specific to a transplant center's requirements and 3) tracking patients' status in the transplant process (e.g., patient interest in transplant, referral for transplant, evaluation start/completion, waitlist status, and transplant) II. Educational webinars/seminars for staff, III. Facility-specific performance feedback reports, IV. Assistance with and review of center-specific action plans to increase transplant referral, V. Scheduled bi-annual phone calls with an SETC member to monitor progress, VI. Patient education on transplant via creation of an Education Station in facility lobby, VII. Development of a Peer Mentor program.
214916274|NCT02539433|PROCEDURE|F-18-F-DOPA|F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
214916275|NCT01263236|DRUG|LY2940094|Administered orally
214916276|NCT01263236|DRUG|Placebo|Administered orally
214916277|NCT03107585|PROCEDURE|bilateral cervical plexus block|with a linear probe and after disinfection vascular neck axis are identified at first. At the cricoid cartilage we conducted an apical scan to locate the carotid bifurcation.at this level is carried out a lateral translation to the visibility of the deep cervical space below the sternocleidomastoidien muscle then a needle 50 is introduced in plane. we proceed in inundation of cervical space
214916278|NCT03189693|OTHER|PVB|nerve stimulator-guided PVB will be performed at two levels
214916279|NCT03189693|OTHER|Placebo|nerve stimulator-guided PVB containing placebo will be performed at two levels
214916280|NCT03189693|OTHER|GA|All patients will receive general anesthesia.
214916281|NCT03189693|OTHER|Anesthetic injections|4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
214916282|NCT03547011|PROCEDURE|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
215060422|NCT05483231|BEHAVIORAL|Family integrated care intervention group|If the very low birth weight infants' vital signs are stable at 32 weeks of corrected gestational age, parents who have been fully trained will provide all non-medical care measures and developmental care for the VLBWIs in the NICU for not less than 6 hours per day for at least 3 weeks, and other medical practice and care measures will be the same as the routine group.
214308801|NCT06216691|OTHER|Coach-guided smartphone delivered CBT program.|All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
214308802|NCT05869604|BEHAVIORAL|HEALTHY AYA|8-session health lifestyle behavior intervention combining behavioral symptom management strategies with strategies to improve diet and increase physical activity.
214308803|NCT05869604|OTHER|Education Control|Participants will receive paper materials on topics of relevance to adolescent and young adult cancer survivors.
214308804|NCT06962826|DRUG|Empagliflozin|Empagliflozin
214308805|NCT04131634|RADIATION|Stereotactic Ablative Radiation|A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy
214308806|NCT03586609|DRUG|Azacitidine|Given SC or IV
214308807|NCT03586609|DRUG|Cladribine|Given IV
214308808|NCT03586609|DRUG|Cytarabine|Given SC
214308809|NCT03586609|DRUG|Venetoclax|Given PO
214308810|NCT05774860|OTHER|No intervention|No intervention
214308811|NCT03980769|DRUG|Thiotepa|Given IV
214308812|NCT03980769|DRUG|Treosulfan|Given IV
214308813|NCT03980769|DRUG|Fludarabine Phosphate|Given IV
214308814|NCT03980769|BIOLOGICAL|Rabbit Anti-Thymocyte Globulin|Given IV
214308815|NCT03980769|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT via infusion
214308816|NCT03980769|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214308817|NCT03980769|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214308818|NCT03980769|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214480599|NCT06889532|PROCEDURE|Intervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days.|Intervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days.
214480600|NCT06884904|DRUG|Low-dose experimental group|2.0\*10\^6/kg
214480601|NCT06884904|DRUG|High-dose experimental group|4.0\*10\^6/kg
214480602|NCT06884904|DRUG|Low-dose placebo control group|Equivalent volume of solvent calculated at 2.0×10\^6/kg
214480603|NCT06884904|DRUG|High-dose placebo control group|Equivalent volume of solvent calculated at 4.0×10\^6/kg
214308819|NCT03980769|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214308820|NCT02046408|OTHER|Computer Tablet|
214480604|NCT06142409|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Lozenge containing multiple enzyme combination
214670633|NCT01607892|DRUG|KPT-330|
214916283|NCT03547011|PROCEDURE|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
214308821|NCT02211131|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10\^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10\^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
214308822|NCT02211131|PROCEDURE|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
214308823|NCT01839552|DRUG|Fentanyl Citrate Nasal Spray (FCNS)|
214308824|NCT00696852|BEHAVIORAL|Mindfulness Meditation|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
214308825|NCT00696852|BEHAVIORAL|Yoga|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
214308826|NCT00696852|BEHAVIORAL|Exercise, Relaxation, and Health Education|The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
214308827|NCT05617365|COMBINATION_PRODUCT|Osteopathic Manipulative Therapy and Exercise Therapy|"At the physician's discretion, each subject will receive a minimum of 4 treatments up to a maximum of 8 treatments over the 12-week duration of the study (Haas et. al., 2018). The patients may be treated in the seated, prone and/or supine positions. Duration of treatment will depend on the degree of documented dysfunction but will be limited to one half hour. The techniques utilized by the physician may vary for many reasons including the degree of restriction, acuity, or patient cooperation.~The THE protocol will involve subjects performing cyclic voluntary retraction and protrusion of their head."
214308828|NCT04165070|BIOLOGICAL|Pembrolizumab|IV infusion
214308829|NCT04165070|DRUG|Carboplatin|IV infusion
214308830|NCT04165070|DRUG|Paclitaxel|IV infusion
214308831|NCT04165070|DRUG|Pemetrexed|IV infusion
214308832|NCT04165070|BIOLOGICAL|Vibostolimab|IV infusion
214308833|NCT04165070|BIOLOGICAL|Boserolimab|IV infusion
214308834|NCT04165070|BIOLOGICAL|MK-4830|IV infusion
214308835|NCT04165070|BIOLOGICAL|MK-0482|IV Infusion
214916284|NCT02882360|DEVICE|Kerlix-AMD|Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
214308836|NCT04165070|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
214308837|NCT04165070|BIOLOGICAL|HER3-DXd|IV Infusion
214308838|NCT02529618|DEVICE|integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)|iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.
214308839|NCT02529618|DEVICE|Riddell High Impact Technology (HIT) System|The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
214480605|NCT06721754|PROCEDURE|Negative Pressure Wound Treatment|Negative Pressure Wound Treatment promotes healing by applying subatmospheric pressure to reduce inflammatory exudate and stimulate granulation tissue.
214308840|NCT02529618|DEVICE|i1 Biometrics Vector Mouth Guard|The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
214308841|NCT02859051|DEVICE|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
214308842|NCT02120950|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea is administered as an intravitreal injection
214308843|NCT02120950|OTHER|Visudyne|Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
214308844|NCT02424383|DEVICE|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
214308845|NCT05533931|OTHER|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
214308846|NCT05533931|OTHER|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
214916285|NCT02882360|OTHER|placebo--normal gauze|Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
214916286|NCT03132844|OTHER|Analysis records of patients over 75 years of age|Demonstrate the percentage of patients over 75 years of age attending general medicine in the Somme, with an up-to-date vaccination schedule, in view of the HAS 2016 recommendations, for the following vaccines: DTp, influenza, pneumococcus, shingles.
214480606|NCT06853704|PROCEDURE|papillary unit advancement|"collagen matrix augmentation in papilla area using tunneling technique, up to my knowledge, it's the first time to use collagen matrix in treating papilla, in less invasive approach, only though tunneling with no primary and secondary incisions.~so, the technique is designed to be less invasive, maximizing papillary blood supply.~and to use xeno collagen matrix instead of connective tissue graft used in previous study. so \~ less morbidity, less postoperative pain with no Donar graft site ."
214308847|NCT00382954|DRUG|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
214308848|NCT00382954|DRUG|Idarubicin|I.V., 8, or 10 or 12 mg/m\^2 weekly (days 1, 8, 15, and 22) for 4 weeks
214308849|NCT02816060|PROCEDURE|manual therapy|manual therapy with neural exercise will be applied on patients with neck pain
214308850|NCT01097018|DRUG|Capecitabine|1000 mg/m2 BID/ Days 1-14
214916287|NCT05198063|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 6 months after the basic immunization (window period ± 1 month), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
214916288|NCT03532386|PROCEDURE|ICSI|ICSI for both couples
214916289|NCT01586923|BIOLOGICAL|RBC transfusion|RBC transfusion of different storage age
214916290|NCT04720924|DEVICE|Computer-aided Real-time Automatic Quality-control System|EGD automatic quality-control system(AQCS),developed based on deep convolutional neural network (DCNN) models,could facilitate real-time detection of upper gastrointestinal lesions, assess inspection completeness and mucosal visibility, and calculate time of EGD procedure.
214916291|NCT04942028|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
215060423|NCT05483231|BEHAVIORAL|Routine nursing care group|Routine practice and in-hospital education will be given to the very low birth weight infants and parents. All care measures will be led by the nursing staff, without the participation of parents.
215060424|NCT03886194|PROCEDURE|interventional treatment in pulmonary|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
215060425|NCT01360424|DRUG|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
215060426|NCT05003973|BEHAVIORAL|home-based anti-resistance exercise|It is a 12-week, middle-level, home-based, anti-resistance exercise. Exercise was recommended 1-2 times per day for 15-20 mins per session.
215060427|NCT05003973|BEHAVIORAL|usually care|The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage
215060428|NCT04896619|OTHER|Kori tofu bread|34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.
214308851|NCT01097018|DRUG|Perifosine|50 mg daily x 21 days
214308852|NCT01097018|DRUG|Placebo|1 pill daily x 21 days
215060429|NCT04896619|OTHER|Whey protein bread|Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread
215060430|NCT04154644|DEVICE|CryoPop|The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
214308853|NCT01578889|BIOLOGICAL|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
214308854|NCT01578889|BIOLOGICAL|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
214308855|NCT01578889|BIOLOGICAL|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10\^8 plaque-forming units (PFUs) administered as 5x10\^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
215060431|NCT01937663|DRUG|KWA-0711|
215060432|NCT02364245|DEVICE|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
215060433|NCT02364245|OTHER|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
215060434|NCT02364245|OTHER|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
214308856|NCT01578889|BIOLOGICAL|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
215060435|NCT06447155|DIETARY_SUPPLEMENT|Bolus feeding|The babies fed with bolus feeding during TH composed this group
214308857|NCT01578889|DEVICE|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
214308858|NCT04615611|DRUG|salbutamol|inhalation of salbutamol
214308859|NCT04615611|DRUG|Placebo|administration of placebo
214308860|NCT05735223|PROCEDURE|Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery). The subjects were blinded to the measurements to prevent bias. Multiparametric MRI (MP-MRI) of the prostate were reviewed when available for surgical planning. All subjects underwent RALP with MULP using the technique previously published by Hamada et al. Continence defined as requiring no pads was assessed at 3 and 6 months postoperatively.
214308861|NCT00510354|DRUG|Imatinib mesylate|
214670634|NCT05161962|COMBINATION_PRODUCT|One group received standard oral care.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
214916292|NCT04942028|BEHAVIORAL|Standardized education|Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise
214916293|NCT04942028|BEHAVIORAL|Prolonged assessment|Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
214916294|NCT01137058|DEVICE|U-healthcare service|Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.
214916295|NCT01137058|DEVICE|SMBG group|Glucose control with self monitoring of blood glucose.
214308862|NCT02694146|DRUG|Platelet rich plasma|Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
214308863|NCT02694146|DRUG|Hylan G-F 20|Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
214308864|NCT05624437|OTHER|data record|data record
214480607|NCT06736210|OTHER|Muscle Elastic Properties Measurement|Using the MyotonPro device, the elastic properties, including stiffness, elasticity, and tone, were evaluated for the tibialis anterior, gastrocnemius medialis, gastrocnemius lateralis, and peroneus longus muscles. Measurements were performed in a controlled laboratory setting.
214480608|NCT06736210|OTHER|Muscle Oxygen Saturation (SmO2)|Muscle oxygenation levels were measured before and after a standardized exercise protocol using the MOXY device. The exercise protocol consisted of a light-intensity dynamic task tailored to minimize fatigue and mimic functional activity.
214916296|NCT03453099|OTHER|Preoperative Questionnaires|"The participants will be asked to complete 5 questionnaires:~1. An abbreviated version of the Caffeine Assessment Tool (CAT)~2. Sleep Questionnaire (SQ)~3. Surgical Fear Questionnaire (SFQ)~4. WHO Alcohol AUDIT Tool~5. WHO Smoking Questionnaire~They will also be asked to complete a demographics sheet~All participants will undergo standard anaesthetic induction, a research participant will observe the dose of propofol and time taken for loss of consciousness"
214916297|NCT03453099|OTHER|Postoperative Subjective Pain Scores|After the operation, participants will be provide with a scale from 1-10 in which to rate their pain at rest and whilst coughing. This will be undertaken at 1hr postoperatively.
214916298|NCT03661931|DIAGNOSTIC_TEST|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a brief User Experience Questionnaire for each dietary assessment method.
214916299|NCT05055960|DIAGNOSTIC_TEST|Stroke simulation and machine learning|Using simulation and machine learning approaches to classify the source of embolic stroke.
214916300|NCT02739425|DEVICE|Sentimag Device|The programme will compare the Sentimag with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB
214916301|NCT01905020|OTHER|Carbohydrate-rich meal|At 19:30, patients will eat a standardized large meal (110g carbohydrate for males; 90g carbohydrate for females). Conventional insulin pump therapy or closed-loop system will be use to control glucose levels from 21:00 until 7:00 next morning.
214916302|NCT01905020|OTHER|Exercise|Study participants will go to a training facility around 18:00 to perform a 60min workout at 60% heart rate reserve. The workout will be on a treadmill and/or a stationary bicycle. Conventional insulin pump therapy or closed-loop system will be use to regulate glucose levels from 21:00 until 7:00 next morning.
215060436|NCT06447155|DIETARY_SUPPLEMENT|Continuous feeding|The babies fed with continuous feeding during TH composed this group
214308865|NCT02567006|BEHAVIORAL|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
214308866|NCT02567006|OTHER|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
215060437|NCT06447155|DIETARY_SUPPLEMENT|Placebo|The babies who were not fed during TH composed this group
214308867|NCT01852812|DRUG|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
214308868|NCT01852812|DRUG|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
214308869|NCT01684371|OTHER|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
214308870|NCT03610932|DIETARY_SUPPLEMENT|Vitamin C|Taken as 3 500mg capsules.
214308871|NCT03610932|OTHER|Placebo|Taken as 3 500mg capsules.
214308872|NCT00005926|DRUG|Gemcitabine|
214308873|NCT00005926|DRUG|Herceptin|
214308874|NCT00005926|PROCEDURE|Radiation therapy|
214308875|NCT03463564|DEVICE|Insulin pump|Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.
214308876|NCT03463564|DRUG|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or degludec at bed-time of basal insulin
214308877|NCT02182362|DRUG|BI 201335 NA|
214916303|NCT03121001|DRUG|ATG|0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
214308878|NCT02182362|DRUG|Placebo|
214308879|NCT04903327|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
214308880|NCT04903327|DRUG|Placebo|Excipient solution
214308881|NCT04760912|DRUG|Rocuronium|Rocuronium used for neuromuscular blokade during anesthesia and anesthesia without rocuronium
214308882|NCT04760912|PROCEDURE|General anesthesia for surgery|General anesthesia with standard anesthetic monitoring,
214308883|NCT01707953|DRUG|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
214480609|NCT06736210|OTHER|Plantar Pressure Analysis|Plantar pressure was assessed both statically and dynamically using a pressure-mapping platform. This provided data on pressure distribution, contact times, and high-pressure areas across the foot during various conditions.
214480610|NCT06723613|BEHAVIORAL|Exercise group|"Primiparous mothers assigned to the exercise group will attend classes in groups of 8-10. Mothers will be given 1 hour (120 minutes) of exercises to increase breast milk three times a week for 6 weeks. The total training time is 18 hours. Each session will include 60 minutes of warm-up and stretching exercises and 30 minutes of relaxation exercises.~Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF), LATCH-Breastfeeding Record System, IMDAT: Breast milk intake level assessment tool scales will be applied to mothers before exercise (8th week after birth) and after exercise (14th week)."
214480611|NCT06505746|OTHER|No intervention|No investigational drug will be administered to participants in this study.
214480612|NCT06711198|OTHER|virtual reality simulation|The student will be put on the Meta Quest 3 virtual reality glasses and the episiotomy application will be started via the computer integrated with the glasses. The episiotomy application will start with the image of a woman who has given birth in the delivery room on the delivery table. The student is expected to select the appropriate materials and complete the episiotomy repair of the woman with the correct steps.
214670635|NCT05161962|COMBINATION_PRODUCT|It was applied to the other group by aspiration.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
214916304|NCT03121001|DRUG|fludarabine|30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
214916305|NCT03121001|DRUG|cyclophosphamide|14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
214916306|NCT03121001|RADIATION|Total body irradiation|3 Gy on day -1
214916307|NCT03121001|PROCEDURE|Stem cell infusion|Stem cell product infused according to BMT unit policy on day 0.
214916308|NCT03121001|DRUG|Sirolimus|loading dose of 15 mg followed by 5 mg per day on day +5
214916309|NCT03121001|DRUG|mycophenolate mofetil|1 g every 8 h (until day 35) will be started on day 5
214955018|NCT03513471|DRUG|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
215060438|NCT00803361|DRUG|Duloxetine|60 to 120 mg, capsules, oral, once a day for 15 weeks
214308884|NCT01707953|DRUG|Placebo|Placebo capsule to mimic midodrine
214308888|NCT00097799|DRUG|Tipranavir|500 mg twice daily
214308889|NCT00097799|DRUG|Ritonavir|200 mg twice daily
214308890|NCT03966755|BEHAVIORAL|UFA dietary recommendations|The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
214308891|NCT00019396|DRUG|flt3 ligand|
214308892|NCT00019396|DRUG|gp100 antigen|
214308893|NCT00019396|DRUG|MART-1 antigen|
214308894|NCT00019396|DRUG|Montanide ISA-51|
214308895|NCT00019396|DRUG|tyrosinase peptide|
214308896|NCT00821470|PROCEDURE|core decompression|core decompression procedure only
214308897|NCT00821470|PROCEDURE|Bone marrow implantation into the necrotic lesion|
214308898|NCT01572337|PROCEDURE|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
214308899|NCT01572337|OTHER|Standard care|
214308900|NCT05462028|DEVICE|Vibration training|The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.
214308901|NCT05462028|BEHAVIORAL|ergometer exercise|ergometer exercise training
214308902|NCT02067910|DRUG|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept
214308903|NCT02250443|DRUG|BYM338 (Bimagrumab)|
214308904|NCT01549964|DRUG|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
214308905|NCT01549964|DRUG|Sitagliptin|Sitagliptin tablets
214308906|NCT01549964|DRUG|Placebo|Placebo-matching tablets
214308907|NCT00521196|DEVICE|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
214308908|NCT04181333|DRUG|TRASTUZUMAB BS|"Regimen A or regimen B is used for HER2-overexpressing breast cancer.~RegimenB is used for HER2-overexpressing unresectable advanced or recurrent gastric cancer in combination with other anti tumor agent(s).~Regimen A: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 4 mg/kg (weight) at initial dose and 2 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every week.~Regimen B: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 8 mg/kg (weight) at initial dose and 6 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every 3 weeks.~If the initial dose is well tolerated, the dosing time after the second dose can be shortened up to 30 minutes."
214308909|NCT02290821|DRUG|placebo|
214308910|NCT02290821|DRUG|Placebos|
214308911|NCT06301711|BEHAVIORAL|Rehabilitation therapy|"The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
214308912|NCT06301711|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214308913|NCT06301711|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214308914|NCT03747432|DRUG|Propofol|Procedural sedation during TAVR procedure using propofol
214308915|NCT03747432|DRUG|Dexmedetomidine|Procedural sedation during TAVR procedure using dexmedetomidine
214308916|NCT02128191|DRUG|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
214308917|NCT02128191|DRUG|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
214308918|NCT06488963|OTHER|NatraCure Cold Therapy gloves and socks|These gloves and socks will be adjusted and tied to the child's wrists and ankles. There are sizes suitable for all ages and the dimensions of the gloves and socks can be adjusted with a snap fastener. The gloves and socks contain a soft Lycra lining and four inner gel cold packs to ensure full length cold therapy treatments. When the children wear these gloves and socks, they can still move their fingers and toes easily. In addition, it is a great advantage that the iced gel packs do not touch the child's skin directly.
214308919|NCT01525147|BIOLOGICAL|YHB1411-2: Level 2|IV infusion
214308920|NCT01525147|BIOLOGICAL|YHB1411-2: Level 3|IV infusion
214308921|NCT01525147|BIOLOGICAL|YHB1411-2: Level 4|IV infusion
214480613|NCT05636397|DIETARY_SUPPLEMENT|L-Citrulline|Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
214670636|NCT04884243|DRUG|CBT-006|ophthalmic solution
214916310|NCT04754386|BEHAVIORAL|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening Oral fluid-based HIV test|The project offers HIV oral test kits to index parents/caregivers with children eligible for index testing services at facility settings to expand access to HIV testing and treatment services for children, and to ensure that all children who screen positive with an oral fluid-based HIV screening kit are linked to confirmatory testing, and newly diagnosed children are initiated on ART.
214916311|NCT04691843|DRUG|Iron Sulfate|Early, high dose, iron supplementation
214916312|NCT00832572|DRUG|Ranolazine|Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
214916313|NCT00832572|DRUG|Placebo|Placebo to match ranolazine administered twice a day for 6 weeks
214955019|NCT05165719|DIAGNOSTIC_TEST|Corona-T-test|Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells
214955020|NCT01528280|BIOLOGICAL|Vaccination against hepatitis A|Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
214955021|NCT01528280|OTHER|No Intervention|No Intervention
214955022|NCT01207011|DRUG|Amrubicin hydrocloride|AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
214955023|NCT01207011|DRUG|Docetaxel|DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
215060439|NCT00803361|DRUG|Placebo|placebo capsules, oral, once a day for 15 weeks
215060440|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
214308922|NCT01525147|BIOLOGICAL|YHB1411-2: Level 5|IV infusion
214308923|NCT01525147|BIOLOGICAL|Placebo|IV infusion
214308924|NCT01525147|BIOLOGICAL|YHB1411-2: level 1|IV infusion
214308925|NCT05217251|OTHER|frontal alpha asymmetry in EEG|frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.
214308926|NCT04537000|DIAGNOSTIC_TEST|clinical condition score|A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score\>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)\*body weight \*5.
214308927|NCT03413553|DEVICE|immediate implant|Patient will receive immediate implant alone.
214308928|NCT03413553|BIOLOGICAL|connective tissue graft|patient will receive immediate implant with connective tissue graft and platelet rich fibrin
214308929|NCT03413553|BIOLOGICAL|platelet rich fibrin|patient will recieve immediate implant combined with connective tissue graft and platelet rich fibrin
214308930|NCT04516083|DIAGNOSTIC_TEST|Mismatch repair instability somatic and germline testing|Each Endometrial Endometrioid adenocarcinoma is routinely stained for MMR mutation to seek for tumor genetic instability. If stains positive, the patient is called in for genetic blood testing to look for the same mutation in the germline.
214308931|NCT01637974|DRUG|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
215060441|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 3-8)
215060442|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
214308932|NCT02177448|DRUG|BIBR277 low dose|
214308933|NCT02177448|DRUG|BIBR277 medium dose|
214308934|NCT02177448|DRUG|BIBR277 high dose|
214308935|NCT02177448|DRUG|Enalapril low dose|
214308936|NCT02177448|DRUG|Enalapril medium dose|
214308937|NCT02177448|DRUG|Enalapril high dose|
214308938|NCT02177448|DRUG|Placebo matching BIBR277|
214308939|NCT02177448|DRUG|Placebo matching enalapril|
214308940|NCT05946538|DIAGNOSTIC_TEST|SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel|The SARS-CoV-2, Influenza and RSV PCR test is multiplex-tandem polymerase chain reaction (MT-PCR) based on qualitive in vitro diagnostic testing for the detection and identification of pathogens in nucleic acid extracts.
214308941|NCT05946538|DIAGNOSTIC_TEST|BioFire Respiratory Panel 2.1|The BioFire Respiratory Panel 2.1 (RP2.1) is a PCR-based multiplexed nucleic acid test intended for use with the BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.
214308942|NCT05686265|DRUG|Oxygen|Physiological intervention consisting of 1 hour of mild hypoxia (PaO2 9-10 kPa), 1 hour of mild hyperoxia (PaO2 13-14 kPa), and in healthy subjects also 1 hour of an inspired oxygen fraction of 100%.
214308943|NCT01674231|OTHER|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
214308944|NCT01674231|OTHER|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
214308945|NCT00728130|PROCEDURE|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
214308946|NCT06548230|DRUG|Nadunolimab|Give by IV
214480614|NCT06732713|OTHER|Swiss Ball|Swiss ball exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes , 3 to 4 sessions per week for 8 weeks
214308947|NCT06548230|DRUG|Azacitidine|Given by IV
214308948|NCT06548230|DRUG|Venetoclax|Given by mouth (PO
214308949|NCT04521972|DEVICE|Room light/light bulb|Room light will be ON/OFF or red light used in the room. Reducing/eliminating light in the room in the evening and night is expected to allow the natural release of melatonin, which is thought to promote uterine contractions in late pregnancy.
214308950|NCT06054555|DRUG|ABP 206|ABP 206 will be given intravenously over a period of 30 or 60 minutes, every 4 weeks (Q4W) for a total of 24 months.
214308951|NCT06054555|DRUG|Nivolumab|Nivolumab will be given intravenously over a period of 30 or 60 minutes, Q4W for a total of 24 months.
214308952|NCT03475381|DRUG|Ivacaftor+lumacaftor|1 year follow-up after initiation of ivacaftor+lumacaftor
214308953|NCT06640478|OTHER|NUTRI-Beta Counseling|Dietary Counseling focused on anti-inflammatory foods
214480615|NCT06732713|OTHER|Frenkel exercise|Frenkel exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes, 3 to 4 sessions per week for 8 weeks
214480616|NCT06884878|OTHER|Multi-omic approach to cancer diagnosis.|To assess the impact of intratumoral heterogeneity on the effectiveness of targeted therapies and immunotherapy.
214670637|NCT04665102|OTHER|Image classification using deep learning algorithm|Image classification using deep learning algorithm
214670638|NCT03843580|DEVICE|optiflow|we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
215060443|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
215060444|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 1-6)
215060445|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 3-8)
215060446|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 1-6)
214916314|NCT05193539|BEHAVIORAL|Augmented reality and virtual reality rehabilitation|"This group underwent augmented reality and virtual reality rehabilitation with 4 different systems.~The RAPAEL Smart Glove® is a wearable sensory system that contains a single 9-axis movement and position sensor with 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measures wrist movements, and 5 bending sensors that measure finger movements. The RAPAEL Smart Board® is a rehabilitation system used to improve arm function by practicing gravity-compensated movements. The RehabMaster® is a game-based Kinect sensor AR rehabilitation system which uses a 3D camera to digitize patient movements and quickly analyze their range of motion, speed, motion angle, and movement cycles. rehabilitation exercise using games to encourage active arm and trunk movements and promote successful rehabilitation. The COG-Trainer® is a VR system that uses a training device synchronized with the screen through simulation."
214480617|NCT06734793|DEVICE|Wearable stethoscope|The device is a soft, wearable stethoscope designed for continuous, comfortable monitoring of patients for abnormal breath sounds, such as wheezing, which can indicate asthma exacerbations. It automatically detects and diagnoses abnormal breath frequencies, wirelessly transmitting data for analysis. Preliminary materials have shown biocompatibility, ensuring the device is safe for use in children. A key feature is its machine-learning algorithm, which can classify and differentiate normal from abnormal sounds with an expected accuracy above 80%. Initial in vivo tests will compare the device's findings to those of a commercial-grade stethoscope in healthy subjects and individuals with asthma. Breath sound data will be used to improve the detection of wheezing sounds from these continuous recordings based on frequency and amplitude analysis of the recordings.
214480618|NCT06734793|OTHER|Routine Clinical lung Auscultation|The study PI will auscultate the participant's lungs at enrollment to ensure that wheezing is present before beginning the continuous recording of the participant's lung sounds. The PI will assess the participant's respiratory status daily at the start of each breath sound recording session.
214480619|NCT06891976|OTHER|Acupressure therapy|It will be applied to the first experimental group, three times per week for 3 weeks, with each session lasting 30 minutes. Each woman will receive a brief explanation about acupressure therapy and its effects to ensure her confidence and cooperation. Before starting, participants will be asked to empty their bladder for relaxation and assume a prone position. The therapy involves applying prolonged, slow, firm pressure with both thumbs on five key points (BL20, GV3, GB30, GB34, and BL25), which are commonly used for low back pain. Each point will receive three cycles of one-minute pressure followed by one minute of relaxation.
214480620|NCT06891976|OTHER|kinesio tape|It will be applied to the second experimental group, for 3 weeks. The tape, 5cm wide and 0.5mm thick, will be fixed in a standing lumbar flexion position on clean, grease-free skin. Four I-shaped bands, each 0.5mm in width, will be applied. The first 5cm of tape will be carefully placed on the skin without stretching, while the middle portion will be stretched 1-2 inches (50%). Two bands will be applied horizontally, and two more will be placed vertically along the lumbar spine, from the lower iliac crest to the upper twelfth rib. The tape will be rubbed to warm the adhesive, ensuring proper adhesion. It will be replaced every 3 days for 3 weeks.
214480621|NCT06891976|DRUG|Non-steroidal anti-inflammatory drugs|All the three groups will receive 400mg of Non-steroidal Anti-Inflammatory Drugs (Ibuprofen) once a day on the treatment days two hours before the session.
214480622|NCT06744829|DEVICE|Balloon placement and inflation and removal of the Balloon|STELLA Endogastric ballon will be inserted into the stomach and inflated with sterile saline solution and will remain in place for 6 months. After which the device will be removed
214480623|NCT06737250|DRUG|R2P -> RP|"Induction(R2P) 21 days per cycles, 6 cycles~* NB02 : 60mg BID PO, Day 1-21~* Rituximab 375mg/m2 DAY IV Day 1, 8, 15 at 1st cycle; D1 at 2nd to 6th cycles~* Lenalidomide : 20mg QD PO, Day 1-14~Maintenance(RP) 21 days per cycles, until Progression~* NB02 : 60mg BID PO, Day 1-21~* Lenalidomide : 20mg QD PO, Day 1-14"
214670639|NCT05505058|BEHAVIORAL|Audio-visual material|Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
214670640|NCT04002687|DRUG|ATV-PG 1000-400 mg + AQ 612 mg|The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
214916315|NCT05193539|BEHAVIORAL|Conventional occupational therapy|The group underwent standard ocupational therapy, such as range of motion and strengthening exercises for the affected upper extremity, table-top activities, and training for activities of daily living.
214916316|NCT02342158|PROCEDURE|biopsy or surgical sampling|
214916317|NCT02342158|OTHER|blood sampling|
214916318|NCT00863343|BIOLOGICAL|Public Health Notification|For any H5 positive results, notification of the result to the site's local public health authorities.
214916319|NCT04195243|DRUG|Dapagliflozin Pill|The patient will take one pill, every 24 hr, during 7 days
214916320|NCT04195243|DRUG|Empagliflozin Pill|The patient will take one pill, every 24 hr, during 7 days
214916321|NCT04195243|DRUG|Placebo pill|The patient will take one pill, every 24 hr, during 7 days
215060447|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
215060448|NCT01309789|DRUG|vincristine|1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
215060449|NCT04959227|OTHER|Sema activity|sema activity 3 days a week for at least a year
215060450|NCT06128850|OTHER|disease|compare to diseases
215060451|NCT03419637|OTHER|Mobile app|The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
215060452|NCT04727996|DRUG|Sitravatinib|120 mg will be administered orally once daily
215060453|NCT04727996|DRUG|Tislelizumab|200 mg will be administered intravenously (IV) once every 3 weeks
215060454|NCT03438708|DRUG|Axitinib Oral Tablet [Inlyta]|Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
215060455|NCT02993627|DIETARY_SUPPLEMENT|Spirulina|2 g(4\* 500 mg tablets) daily intake of Spirulina Platensis
215060456|NCT02993627|OTHER|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
214308954|NCT06640478|DIETARY_SUPPLEMENT|Standard dietary counseling|Standard of Care therapy: Nutrition counseling per the ADA clinical guidelines and USDA MyPlate model
214480624|NCT06740695|BEHAVIORAL|Education group|"The training materials were prepared in line with the researchers and expert opinions were obtained. Trainings will be given for two weeks. After the trainings are completed, reminder information will be sent to the pregnant women via text messages every other day to inform them that the trainings are continuing. Reminder information prepared as text messages will be sent to the pregnant women's mobile phones. 4 weeks after the first training, the same training will be reminded again via WhatsApp as a summary training by emphasizing key points.~The trainings will be carried out by an expert researcher in the field. In the training content prepared in line with WhatsApp, the risks that may be seen during pregnancy and Gestational Diabetes Mellitus;~* Sensitivity perception and Seriousness perception, perceived risks that may be seen during pregnancy~* Health motivation perception, the pregnant woman's beliefs and practices regarding being healthy,~* Benefit perception, pregnancy follow"
214480625|NCT06740227|PROCEDURE|Virtual Reality-Based Balance Training|Virtual reality workout session will be for about 30-40 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For Static Balance, Lotus Focus, Tree pose, Warrior Pose games will be used For Dynamic Balance, Soccer Heading, Ski Jump, Tight Rope Walk, Table Tilt, Ski Slalom games will be used 5 minutes will be given for cool down.
214480626|NCT06740227|PROCEDURE|Conventional Balance Training|one minute of rest for every five minutes of exercise Conventional Balance workout session will be for about 30-40 minutes Warm-up for 5 minutes For Static Balance, Static Balance, Single Leg Standing, Stork Standing will be used For Dynamic Balance, Weight Shifts, Tandem Walk, Single Leg Balance with Arm Movements 5 minutes will be given for cool down
214480627|NCT06740136|OTHER|Exercise|Muscle induced-damage eccentric exercise
214480628|NCT06739174|DEVICE|Confidence Be 1-Piece Closed Bag|Active Chamber Filter - Circle Shape
214916322|NCT04717531|DRUG|Pyrotinib|400mg, qd, po, day 1-21
214916323|NCT04717531|DRUG|Trastuzumab|6 mg/kg, day 1
214308955|NCT06640478|DIETARY_SUPPLEMENT|Free weekly produce foods|Free weekly produce
214308956|NCT02492529|OTHER|Neuropsychological tests|"Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood"
214308957|NCT02492529|DEVICE|A cranial MRI|
214308958|NCT02492529|OTHER|Experimental procedure|
214480629|NCT06739174|DEVICE|Confidence Natural 1-Piece Closed Bag|Protective Filter - Circle Shape
214480630|NCT06739174|DEVICE|Confidence Be go 1-Piece Closed Bag|Active Chamber Filter - Hexagon Shape
214916324|NCT04717531|DRUG|Pertuzumab|420 mg, day 1
214916325|NCT04717531|DRUG|Docetaxel|100 mg/m2, day 1
214916326|NCT04717531|DRUG|Epirubicin|90mg/m2, day 1
214308959|NCT05823571|DRUG|Itacitinib|A standard 3+3 design will be used to evaluate the safety of itacitinib plus different immunosuppression regimens. This study has four predefined Regimens that will be explored in the optimal Regimen-finding phase and are listed in Table 2 of the protocol. Itacitinib will be given in conjunction with each of four different regimens for immunosuppression. Regimen 1 is the current standard for our BMT patients, with a duration of MMF from day 5-35. Regimen 2 will decrease the duration of MMF from 35 to day 25. Regimen 3 will decrease the duration of MMF from 35 to day 15. Regimen 4 will eliminate MMF altogether. We will start with Regimen 1, which combines itacitinib with the current standard of immunosuppression. Progression through cohorts (Regimens) will be based on a standard 3+3 design to find the optimal regimen.
214308960|NCT05927714|OTHER|Amnion-chorion Membrane|Amnio-chorion membranes specifically for palatal wound healing following free soft tissue autografts (FTSA) procedures.
214308961|NCT05927714|OTHER|ActCel Cellulose Gauze|When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.
214308962|NCT03342547|PROCEDURE|Duodenal biopsy|Two duodenal biopsy samples will be collected from each participant
214308963|NCT03342547|PROCEDURE|Saliva|Saliva (1-2 mL) will be collected from each participant for secretor status testing
214308964|NCT05705531|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
214308965|NCT05705531|OTHER|Electronic Health Record Review|Undergo medical record abstraction
214308966|NCT05705531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214308967|NCT05705531|OTHER|Survey Administration|Complete surveys
214308968|NCT02864849|DRUG|Oxaliplatin|
214308969|NCT02864849|DRUG|Capecitabine|
214308970|NCT02864849|RADIATION|Intensity modulated radiotherapy|
214916327|NCT04717531|DRUG|Cyclophosphamide|600 mg/m2, day 1
214916328|NCT04049162|DIETARY_SUPPLEMENT|Blueberry Plus Exercise (BB-EX)|Pre-packaged blueberry powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
214916329|NCT04049162|DIETARY_SUPPLEMENT|Blueberry Placebo Plus Exercise (P-EX)|Pre-packaged placebo powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
214916330|NCT03991962|DRUG|mFOLFIRINOX|Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks
214670641|NCT03162289|OTHER|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
214670642|NCT03162289|OTHER|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
214670643|NCT03414359|DRUG|2% Lidocaine|2% Lidocaine using a combined spinal-epidural (CSE)
214308971|NCT02864849|PROCEDURE|Total mesorectal excision|
214308972|NCT06037421|OTHER|Human breast milk sampling|Human breast milk sampling
214308973|NCT06037421|OTHER|Saddle sampling|Saddle sampling
214916331|NCT03991962|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
214916332|NCT06578169|DRUG|Hormonal Therapy Agent|Women initiating either Hormonal Contraceptives or Hormone replacement therapy in menopause
214308974|NCT06037421|OTHER|Skin sampling|Skin sampling
214308975|NCT06037421|OTHER|Saliva sampling|Saliva sampling
214308976|NCT06037421|OTHER|blood sampling|blood sampling
214308977|NCT03126916|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HSCT
214308978|NCT03126916|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214308979|NCT03126916|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214308980|NCT03126916|DRUG|Busulfan|Given IV
214308981|NCT03126916|DRUG|Carboplatin|Given IV
214308982|NCT03126916|DRUG|Cisplatin|Given IV
214308983|NCT03126916|PROCEDURE|Computed Tomography|Undergo CT scan
214308984|NCT03126916|DRUG|Cyclophosphamide|Given IV
214308985|NCT03126916|DRUG|Dexrazoxane Hydrochloride|Given IV
214308986|NCT03126916|BIOLOGICAL|Dinutuximab|Given IV
214308987|NCT03126916|DRUG|Doxorubicin Hydrochloride|Given IV
214308988|NCT03126916|PROCEDURE|Echocardiography|Undergo echocardiography
214308989|NCT03126916|DRUG|Etoposide Phosphate|Given IV
214308990|NCT03126916|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214308991|NCT03126916|RADIATION|Iobenguane I-123|Given 123 I-MIBG
214308992|NCT03126916|RADIATION|Iobenguane I-131|Given IV
214308993|NCT03126916|DRUG|Isotretinoin|Given PO
214308994|NCT03126916|DRUG|Lorlatinib|Given PO
214308995|NCT03126916|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214308996|NCT03126916|DRUG|Melphalan Hydrochloride|Given IV
214308997|NCT03126916|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214308998|NCT03126916|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214308999|NCT03126916|BIOLOGICAL|Sargramostim|Given SC
214309000|NCT03126916|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214309001|NCT03126916|DRUG|Thiotepa|Given IV
214309002|NCT03126916|DRUG|Topotecan Hydrochloride|Given IV
214309003|NCT03126916|DRUG|Vincristine Sulfate|Given IV
214309004|NCT04626232|PROCEDURE|N-SLEEVE technique|The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).
214309005|NCT04626232|PROCEDURE|SLEEVE|SLEEVE Technique : Removal of 2/3 of the stomach
214670644|NCT03414359|DRUG|3% Chloroprocaine|3% Chloroprocaine using a combined spinal-epidural (CSE)
214670645|NCT04642664|DRUG|Apatinib plus Camrelizumab|Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
214670646|NCT03467230|DEVICE|NoL Index|Use of the PMD-200 in an observational study
214670647|NCT02346448|PROCEDURE|endoscopic sphincterotomy|sphincterotomy during ERCP
214916333|NCT01421225|DEVICE|Closed-loop Insulin Pump therapy|Subjects insulin doses were adjusted based on a proportional-integral-derivative algorithm using the continuous glucose monitor readings from 10 PM - noon.
214916334|NCT01421225|DEVICE|Standard Insulin Pump Therapy|Subjects insulin doses followed their usual home routine.
214916335|NCT05832853|BEHAVIORAL|Wu Qin Xi exercise|The training schedule for Wu Qin Xi consisted of two phases: the first phase lasted for eight weeks, while the second phase lasted for 16 weeks. In the first phase, Wu Qin Xi group was given twice repetitions of the intervention. The second phase consisted of three repetitions of the Wu Qin Xi group. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
214916336|NCT05832853|BEHAVIORAL|Wu Qin Xi, resistance training and endurance training|During the first 8 weeks, the training consists of learning and consolidating the movements of the Wu Qin Xi. In the second 16 weeks, participants perform a full set of movement exercises. Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and two sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 15 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
214309006|NCT02676505|BEHAVIORAL|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
214309007|NCT02676505|BEHAVIORAL|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
214309008|NCT06008509|PROCEDURE|Gastric echography preoperative|Patients with acute abdomen that are going to surgery, are going to recieve a gastric echography in the surgery room before the start of anesthesia. This procedure include vision of the stomach during supine position and lateral position with curve transductor.
214309009|NCT01154218|DRUG|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
214309010|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
214309011|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
214309012|NCT01712607|OTHER|Preoperative Warm-Up training|Preoperative Warm-Up training
214309013|NCT00881933|OTHER|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, \& -2) (if body weight \< 10 kg or if age \< 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, \& -8) total body irradiation (3G on days -1)
214309014|NCT03688750|OTHER|no intervention|
214309015|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
214309016|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
214309017|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
214309018|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
214916337|NCT05832853|BEHAVIORAL|Resistance training and endurance training|Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and three sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 30 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
214916338|NCT00505960|BEHAVIORAL|Diabetes Care for Korean Americans|Intervention group participants receive a 6-week in-class education offered by trained nurses, followed by home glucose monitoring with monthly nurse telephone counseling.
214309019|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
214309020|NCT00362115|DRUG|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
214309021|NCT00362115|DRUG|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
214309022|NCT00820157|PROCEDURE|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
214309023|NCT00820157|PROCEDURE|TACE|TACE alone or TACE followed by downstage resection for MNHCC
214309024|NCT01001611|DRUG|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
214309025|NCT01001611|DRUG|Placebo|Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
214309026|NCT05702645|PROCEDURE|Biospecimen Collection|Patients undergo saliva/buccal and blood sample collection
214309027|NCT05702645|OTHER|Clinical Evaluation|Undergo a clinical assessment
214309028|NCT05702645|OTHER|Neurocognitive Assessment|Undergo neurocognitive assessment
214309029|NCT05702645|OTHER|Questionnaire Administration|Ancillary studies
214309030|NCT05702645|OTHER|Survey Administration|Ancillary studies
214309031|NCT00003799|DRUG|fluorouracil|Given IV
214309032|NCT00003799|DRUG|oxaliplatin|Given IV
214309033|NCT00003799|RADIATION|radiation therapy|Undergo radiotherapy
214309034|NCT00003799|DRUG|leucovorin calcium|Given IV
214309035|NCT00003799|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214309036|NCT00335972|DRUG|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
214309037|NCT00335972|DRUG|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
214309038|NCT03812887|DIAGNOSTIC_TEST|Photopatchtesting|Photopatchtesting to the sunscreen series and extended series, irradiated at both 24 and 48 hours
214480631|NCT06735989|OTHER|Lecture on moral reasoning|One and a half-hour long lecture on moral justification and moral reasoning
215060457|NCT04981301|DRUG|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the convex probe will be covered with a sterile sheath and a 22G, 100 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles with the anterior approach, the needle will be punctured in the Petit triangle and 5 ml of saline will be injected into the anterolateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
214309039|NCT06473259|DRUG|Docetaxel|6 courses of docetaxel 75 mg/sqm iv
214309040|NCT06473259|DRUG|Apalutamide Oral Tablet|240 mg /daily orally
214309041|NCT06473259|DRUG|Enzalutamide Oral Tablet|600 mg /daily orally
214309042|NCT06473259|DRUG|Abiraterone acetate tablets|1000 mg /daily orally
214309043|NCT06473259|DRUG|Darolutamide Oral Tablet|600 mg/daily orally
214309044|NCT06473259|RADIATION|radiotherapy|radical radiotherapy on primary tumor
214309045|NCT06473259|DRUG|Triptorelin|3,75 mg im/4 w
214309046|NCT02736045|DEVICE|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
214309047|NCT03355586|COMBINATION_PRODUCT|Electromagnetic navigation|Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
214309048|NCT00159055|BIOLOGICAL|CMV vaccine|
214309049|NCT06125288|OTHER|lab investigation and radiation|"1. . Full history taking including~   * Environmental factors such as long term exposure to environmental hazards as bacteria, fungi, chemicals, tobacco smoke and air pollution.~  * Host factors Family history (you have a higher risk of ILD if a close relative has ILD). History of recurrent chest infection. History of exposure to medication such as radiation and chemotherapy. History of Multisystem autoimmune diseases~2. Full examination general and systemic especially chest examination~3. investigation~   * pulse oximetry.~  * lab investigation include complete blood count parameters .~  * radiological investigation including ( echocardiography - MSCT chest - chest -x ray"
214309050|NCT04087252|BIOLOGICAL|tumor neoantigen|tumor neoantigens
214309051|NCT01741181|DRUG|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
214309052|NCT01741181|DRUG|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
214309053|NCT01170806|DRUG|Orlistat|Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
214309054|NCT05762900|RADIATION|Ultra-fractionated radiation therapy|5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
214670648|NCT02346448|PROCEDURE|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
214670649|NCT02346448|PROCEDURE|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
215060458|NCT06421714|DRUG|Venglustat|Pharmaceutical form:Capsule-Route of administration:Oral
215060459|NCT06421714|DRUG|Itraconazole|Pharmaceutical form:Capsule-Route of administration:Oral
214480632|NCT06735989|OTHER|Lecture on logical reasoning|One and a half-hour long lecture on logical and argumentative principles
214480633|NCT06734299|OTHER|Sunscreen A|Sunscreen A will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
214480634|NCT06734299|OTHER|Sunscreen B|Sunscreen B will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
214480635|NCT06734299|OTHER|Sunscreen C|Sunscreen C will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
214480636|NCT06734871|DRUG|CAR T cells|chimeric antigen receptor T cells
214670650|NCT02273973|DRUG|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
214670651|NCT02273973|OTHER|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
214309055|NCT04804397|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened soft drinks
214309056|NCT05792228|OTHER|nurse-led standardized intervention|Once the patient in the intervention group decided to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and reported to the physicians. During the chemotherapy, nurses would provide education on prevention and control of CINV using web-based approaches. All patients received standard antiemetic regimen, which included Aprepitant, 5-Hydroxytryptamine3-receptor antagonists, and Dexamethasone. If the physician's prescription was not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients were recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy was performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up was delivered until the 5th day after chemotherapy.
214309057|NCT00001086|DRUG|Indinavir sulfate|
214309058|NCT00001086|DRUG|Abacavir sulfate|
214309059|NCT00001086|DRUG|Efavirenz|
214309060|NCT01907477|OTHER|Samples taken at the clinical hematology unit|
214309061|NCT05074238|OTHER|Zinc containing suncreen|"The study participant will be randomized via a randomization tool within the REDCap database as to which half of the wound (A or B) the patient will be asked to apply zinc containing sunscreen for the duration of the study."
214309062|NCT04991935|DRUG|CC-93538|CC-93538
214670652|NCT02273973|DRUG|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
214670653|NCT03294304|DRUG|Nivolumab|Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
214670654|NCT03294304|DRUG|Cisplatin|Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
214916339|NCT02037191|DRUG|Methotrexate|"Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
214916340|NCT02037191|DRUG|Placebo|"Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
214916341|NCT01322490|BIOLOGICAL|PROSTVAC-V|
214916342|NCT01322490|BIOLOGICAL|PROSTVAC-F|
214916343|NCT01322490|DRUG|GM-CSF|
214916344|NCT01322490|OTHER|GM-CSF Placebo|
214916345|NCT01322490|BIOLOGICAL|Placebo|PROSTVAC V/F Placebo
214916346|NCT04920201|OTHER|Over-ground walking without GEMS-H|Over-ground walking without GEMS-H (30 min per session, at least 3 times per weeks, total 10 sessions)
214916347|NCT04920201|DEVICE|Over-ground walking with GEMS-H with resist mode|Over-ground walking with GEMS-H with resist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
214916348|NCT04920201|DEVICE|Stair ascent with GEMS-H with assist mode|Stair ascent with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
214916349|NCT04920201|DEVICE|Incline walking with GEMS-H with assist mode|Incline walking with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
214916350|NCT02655822|DRUG|Ciforadenant|100 mg orally twice daily for the first 14 days of each 28-day cycle.
214916351|NCT02655822|DRUG|Ciforadenant|100 mg orally twice daily for 28 days of each 28-day cycle.
214916352|NCT02655822|DRUG|Ciforadenant|200 mg orally once daily for the first 14 days of each 28-day cycle.
215060460|NCT03149159|DRUG|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
215060461|NCT03149159|DRUG|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
214916353|NCT02655822|DRUG|Ciforadenant + atezolizumab|Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.
214916354|NCT02655822|DRUG|Ciforadenant|Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.
214916355|NCT02648139|DRUG|Dentifrice|3x/day for 7 days.
214916356|NCT00356148|DRUG|Ampicillin/Sulbactam|Ampicillin/Sulbactam 1 gr, once within onr hour before surgery
214916357|NCT05741801|OTHER|interviews|observations of healthcare professionals working in hospitals (outreach/sepsis team), one-on-one interviews with healthcare professionals, and focus groups or interviews with ex-patients/family members.
214916358|NCT02693002|DRUG|Estradiol/Norethindrone acetate|Estradiol/Norethindrone acetate 1mg/0.5 mg
214916359|NCT02693002|DRUG|Placebo|inactive ingredient
214916360|NCT06299358|OTHER|Foot massage|Infants in the foot massage group will receive foot massage by the researcher on two consecutive days of the week for a total of four times. The massage will be performed in accordance with the specified application steps for 10 minutes just before the baby's restlessness starts.
214916361|NCT06299358|OTHER|Mother heart sound|The sound recorded by the researcher under appropriate conditions will be played to the babies in the maternal heart sound group from an appropriate distance. The sound will be played a total of four times, on two consecutive days of the week, just before the baby's restlessness begins and for half an hour.
214916362|NCT06299358|OTHER|Foot massage and maternal heart sound|Infants in the foot massage and maternal heart sound group will receive foot massage by the researcher on two consecutive days of the week for a total of four times. The massage will be performed in accordance with the specified application steps for 10 minutes just before the baby's restlessness starts. From the beginning of the massage, the pre-recorded maternal heart sound will be played to the infant for 30 minutes from an appropriate distance.
214916363|NCT02208193|BEHAVIORAL|Cognitive and psycho-behavioral effects of an artistic dimension|
214309063|NCT03803774|PROCEDURE|Biopsy Procedure|Undergo biopsy
214309064|NCT03803774|DRUG|Birinapant|Given IV
214309065|NCT03803774|PROCEDURE|Computed Tomography|Undergo CT scan
214309066|NCT03803774|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRRT
214309067|NCT03803774|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214309068|NCT03803774|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214309069|NCT00841529|DEVICE|Medtronic LAA Occlusion Device|Placement of the occlusion band on the LAA
214309070|NCT06421779|BEHAVIORAL|Virtual reality (VR)|Children watch underwater experience video by wearing the virtual reality glass during the skin prick test.
214309071|NCT05894421|DRUG|TQB2223 injection+ Penpulimab Injection|TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
214309072|NCT01638806|PROCEDURE|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
214916364|NCT06138262|OTHER|Health promotion of education pre-conception nutritional preparation|Providing education on pregnancy nutritional preparation during the preconception period 3 months before the wedding
214916365|NCT01577212|RADIATION|Individualized dose escalation|Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
214916366|NCT00014495|BIOLOGICAL|filgrastim|
214916367|NCT00014495|DRUG|cytarabine|
214916368|NCT00014495|RADIATION|bismuth Bi213 monoclonal antibody M195|
215060462|NCT03149159|RADIATION|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
214309073|NCT03456596|OTHER|ENABLE|This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
214309074|NCT03332576|BIOLOGICAL|DPX-Survivac|SubQ injection
214309075|NCT03332576|BIOLOGICAL|DPX-Survivac(Aqueous)|SubQ injection
214309076|NCT03332576|DRUG|Cyclophosphamide|PO BID
214309077|NCT01057017|BIOLOGICAL|intervention|
214309078|NCT00064207|DRUG|gemcitabine hydrochloride|
214309079|NCT00064207|PROCEDURE|adjuvant therapy|
214309080|NCT00064207|RADIATION|radiation therapy|
214916369|NCT02598232|DEVICE|1,414nm Nd:YAG Laser System|It has high absorption coefficient in water and a short pulse width.
215060463|NCT02487758|PROCEDURE|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
214309081|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) Low Dose|BLB201 10\^6 PFU
214309082|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) High Dose|BLB201 10\^7 PFU
214309083|NCT05655182|DRUG|Placebo|The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
214309084|NCT00699556|DRUG|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
214309085|NCT00699556|DRUG|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
214309086|NCT00699556|DRUG|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
214309087|NCT03388229|BEHAVIORAL|not an intervention|it was observation not intervention
214309088|NCT04327219|OTHER|CDED diet|examine the microbial, mucosal and immunological changes of the pouch during one year post IPAA, and examine the impact of the CDED on disease activity and dysbiosis in adults suffering from active pouchitis.
214670655|NCT03294304|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
214916370|NCT01628900|OTHER|care management arm N°1 vs arm N°2|7 days for mono-antibiotherapy at hospital
215060464|NCT05912491|DIAGNOSTIC_TEST|Transperineal ultrasonography|Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
214309089|NCT05046886|BEHAVIORAL|Standardized|Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on macronutrient distribution.
214309090|NCT05046886|BEHAVIORAL|Usual Care Control (UCC)|Participants are instructed to follow a Mediterranean-style diet,
215060465|NCT00413673|PROCEDURE|PRK|PRK
214309091|NCT05046886|BEHAVIORAL|Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR)|Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on their predicted PPGR to meals and snacks at the time they enter them into their smart phone. PPGR predictions will be generated from a gut microbiome-based machine learning algorithm.
214309092|NCT06585449|DRUG|ALN-HTT02|ALN-HTT02 will be administered intrathecally
214309093|NCT06585449|DRUG|Placebo|Placebo will be administered intrathecally
214309094|NCT06374797|DRUG|Auxora|1.25 mL/kg (2.0 mg/kg of zegocractin) intravenously (IV) over 4 hours at 0 hours, and then 1.0 mL/kg (1.6 mg/kg of zegocractin) IV over 4 hours at 24, 48, 72 and 96 hours for a total of 5 doses.
214670656|NCT01442584|PROCEDURE|ovarian transplantation|ovarian transplantation
214670657|NCT02156700|PROCEDURE|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
214916371|NCT01628900|OTHER|Care management|Hospital vs home
214916372|NCT03916237|OTHER|Home assessment|Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
214916373|NCT03916237|OTHER|Home remediation|Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)
214309095|NCT06374797|DRUG|Placebo|1.25 mL/kg IV over 4 hours at 0 hours and then 1.0 mL/kg IV over 4 hours at 24, 48, 72, and 96 hours for a total of 5 doses.
214309096|NCT05166109|DRUG|Vamorolone|Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
214309097|NCT05166109|DRUG|Placebo|Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
214309098|NCT06287866|PROCEDURE|Pinch Graft|In the pinch graft technique, the investigators will numb and then shave off a thin piece of skin and place it in the wound bed.
214309099|NCT06281847|GENETIC|CCTx-001|Frozen CAR T-cells suspensions in media containing dimethyl sulfoxide (DMSO)
214309100|NCT03425929|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin.
214309101|NCT03425929|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
214309102|NCT04234568|PROCEDURE|Biospecimen Collection|Correlative studies
214309103|NCT04234568|PROCEDURE|Computed Tomography|Undergo CT
214309104|NCT04234568|DRUG|Lutetium Lu 177 Dotatate|Given IV
214480637|NCT06734676|DEVICE|Intermittent theta burst stimulation (iTBS)|iTBS: 90% RMT, 50Hz intraburst frequency, 3 pulses per burst, 5Hz interburst frequency, 2 seconds on/8 seconds off, totaling 1800 pulses over approximately 10 minutes. Each day includes 4 iTBS sessions (1800 pulses per session) with 50-minute intervals, totaling 7200 pulses per day for 14 consecutive days (100800 pulses total).
214480638|NCT06734195|DRUG|dexmedetomidine + propofol|Comparison of caudal dexmedetomidine + propofol sevoflurane-related emergence agitation in children undergoing congenital hernia repair.
214309105|NCT04234568|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214309106|NCT04234568|DRUG|Triapine|Given PO
214309107|NCT06469008|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
214309108|NCT04317417|BEHAVIORAL|EMPOWER|"Participants will receive weekly material for a total of 5 weeks consisting of 1-2 days of didactic content and several days of brief, real-life skills practice and reporting taking approximately 10-15 minutes to complete. Adolescents and young adults cannot skip ahead, but they can return to old lessons or exercises if they choose. Most exercises are done in a diary format in which past responses are displayed next to their new ones, so that every time they visit that exercise they see their growing list of past positive experiences. Participants will be permitted up to 8 weeks to complete this self-guided intervention."
214309112|NCT06002958|DEVICE|Horyzons USA|Client participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes therapeutic content that is tailored to each individual and their current needs and experiences, including social anxiety, generalized anxiety, mood, and social functioning, and distress intolerance. Further, the platform includes a moderated social media function, where individuals and peer support specialists can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
214309113|NCT04781088|DRUG|Lenvatinib|Given PO
214309114|NCT04781088|DRUG|Paclitaxel|Given IV
214309115|NCT04781088|BIOLOGICAL|Pembrolizumab|Given IV
214309116|NCT06647953|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214309117|NCT06647953|PROCEDURE|Biospecimen Collection|Tumor tissue is collected and centrally reviewed by a study pathologist
214309118|NCT06647953|PROCEDURE|Bone Scan|Undergo bone scan
214309119|NCT06647953|PROCEDURE|Computed Tomography|Undergo CT
214309120|NCT06647953|DRUG|Cyclophosphamide|Given IV
214309121|NCT06647953|BIOLOGICAL|Dactinomycin|Given IV
214309122|NCT06647953|DRUG|Dexrazoxane|Given IV
214309123|NCT06647953|DRUG|Doxorubicin|Given IV
214309124|NCT06647953|PROCEDURE|Echocardiography Test|Undergo ECHO
214309125|NCT06647953|DRUG|Ifosfamide|Given IV
214309126|NCT06647953|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214309127|NCT06647953|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214309128|NCT06647953|OTHER|Patient Observation|Undergo observation
214480639|NCT06734195|DRUG|Propofol alone|30 patients will receive propofol 1mg/kg before the start of skin closure, administered over 10 minutes and caudal block using 1 ml/kg of bupivacaine 0. 25 % plus 2 ml normal saline.
214480640|NCT06734195|DRUG|Dexmedetomidine|patients will receive caudal dexmedetomidine block using 1 ml/kg of bupivacaine 0. 25 % mixed with dexmedetomidie 1mic/kg diluted in 2 ml normal saline
214480641|NCT06736626|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents (DES), which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of DES, and received a subsequent course of dual antiplatelet therapy (DAPT), as clinically indicated.
214480642|NCT06743451|OTHER|Health workers training on GMP guideline|One day training will be conducted to health workers on updated GMP guideline for the health workers primarily engaged in Growth monitoring and promotion of the children.
214480643|NCT06743451|OTHER|Female community health volunteers' mobilization for inviting mothers and caretakers|Female community health volunteers will be mobilized for inviting mothers and caretakers for two consecutive months for enhancing GMP practices in the municipality
214480644|NCT02934867|OTHER|Protocol phone advice|Protocol phone advice
214480645|NCT02934867|OTHER|Usual phone advice|Usual phone advice
214480646|NCT06738693|PROCEDURE|External Fixation|External fixation involves the stabilization of unstable intra-articular distal radius fractures using an external fixator. The procedure is performed under anesthesia, with fixator pins placed percutaneously into the proximal and distal fragments of the radius. Postoperative care includes regular cleaning of pin tracts, early mobilization exercises for adjacent joints, and fixator removal upon radiological confirmation of fracture healing, typically between 6 to 8 weeks post-surgery.
214309129|NCT06647953|PROCEDURE|Positron Emission Tomography|Undergo PET
214916374|NCT03916237|OTHER|Referral to Medical Legal Partnership|Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)
214916375|NCT03916237|OTHER|Regular School Based Health Asthma Care|Regular care in the School Health Program
214916376|NCT04245436|DRUG|Duloxetine|Encapsulated duloxetine 30 mg, 60 mg; once-daily
214916377|NCT04245436|DRUG|Escitalopram|Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily
214916378|NCT00002659|DRUG|cisplatin-e therapeutic implant|
214916379|NCT03432637|PROCEDURE|spontaneous ventilation|thoracoscopic lobectomy under spontaneous ventilation
214916380|NCT03432637|PROCEDURE|intubated anesthesia with single-lung mechanical ventilation|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation
214309130|NCT06647953|DRUG|Topotecan|Given IV
214916381|NCT06498856|OTHER|Isotonic saline infusion|Volume expansion with one liter of isotonic saline intravenously over two hours.
214916382|NCT02921685|DRUG|Monalizumab|Four dose levels will be tested.
214916383|NCT00984542|DRUG|bendamustine hydrochloride|Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
214309131|NCT06647953|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
214309132|NCT06647953|DRUG|Vincristine|Given IV
214309133|NCT04481893|BEHAVIORAL|Use of a virtual reality headset|"The intervention will consist of 2 sessions of 30 minutes each, based on the use of a virtual reality headset with the AQUA® application.~* The 1st session will take place on the day of the surgical intervention, upon arrival in hospital, after reception in the room.~* The 2nd session will take place the same day, post-operatively, once the awakening is satisfactory (within 3 to 6 hours after the intervention)"
214670658|NCT05674773|PROCEDURE|Endoscopic or surgical resection|endoscopic or surgical (partial, (sub)total, proctocolectomy) resection
214916384|NCT01760135|DIETARY_SUPPLEMENT|high caloric nutritional supplement|high caloric nutritional supplement (25kcal/kg)
214916385|NCT01760135|DIETARY_SUPPLEMENT|low caloric nutritional supplement|low caloric nutritional supplement(15kcal/kg)
214916386|NCT01045187|RADIATION|brachytherapy|Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
214916387|NCT01045187|RADIATION|Xoft Axxent Electronic Brachytherapy System|21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
214916388|NCT00365404|BEHAVIORAL|Diet and exercise promotion|
214916389|NCT05882825|OTHER|Dry Needling Therapy Knowledge and Awareness Questionnaire|Dry Needling Therapy Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
214955024|NCT04156386|DIETARY_SUPPLEMENT|Recovery animal (20g whey) protein supplement|Animal protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
214955025|NCT04156386|DIETARY_SUPPLEMENT|Recover vegan (26g pea) protein supplement|Vegan protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
214955026|NCT04156386|DIETARY_SUPPLEMENT|Placebo (32g maltodextrin)|Placebo consumed post exercise to aid recovery of muscle function following strenuous exercise.
214955027|NCT00092976|DRUG|ReFacto|
214955028|NCT06540560|BEHAVIORAL|My Pelvic Plan website|"Following the baseline interview, participants will receive a link to a web-based self-guided program and have access for two weeks My Pelvic Plan that combines education on several individual conditions that often contribute to CPP, and will include instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Subsequent to this, participants will then complete another brief questionnaire after a two-week interval. This questionnaire will focus on willingness to consider specific treatment modalities, credibility/expectancy for specific treatment modalities, and a brief measure assessing self-efficacy for managing symptoms."
214955029|NCT04051697|BEHAVIORAL|SEA CHANGE intervention|The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.
214955030|NCT05798143|DEVICE|Accelerated Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
214955031|NCT03837457|DRUG|Cobomarsen|At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
214955032|NCT02532062|DIETARY_SUPPLEMENT|Cholecalciferol|4,000 IU, oral, once a day for one year
214955033|NCT02532062|DIETARY_SUPPLEMENT|multivitamin|oral, once a day for one year
214955034|NCT02532062|DIETARY_SUPPLEMENT|Placebo|oral, once a day for one year
214955035|NCT02953483|OTHER|Red blood cells|Packed red blood cells to final hematocrit of 14%
214955036|NCT02421302|DIETARY_SUPPLEMENT|RUTF|This is ready-to-use-therapeutic-food
214955037|NCT02050139|DIETARY_SUPPLEMENT|L-cysteine|
214955038|NCT02050139|OTHER|Placebo|
214955039|NCT04498702|DRUG|APL-1202 treatment|A modified 3+3 design was employed: The dose was started at 300 mg and increased to 450 mg, 600 mg and 750 mg if there was no dose-limiting toxicity (DLT) in 3 subjects after 4-week consecutive administration of APL-1202. When the dose-escalation study was in progress, the doses for any newly enrolled subjects would be the starting dose or the highest dose confirmed with no DLT by the dose-escalation cohort at the time of enrollment. When the MTD or the 750 mg daily dose was attained as a safe dose, the dose for all subjects in the study or subsequently enrolled subjects would be MTD or 750 mg/day.
214916390|NCT04194463|OTHER|ChemoFit exercise prehabilitation intervention|Exercise intervention consists of walking monitored by wearing a pedometer device. After a baseline measurement of participant's walking activity is done, increase in step count from baseline step count is prescribed. This increase in step count is achieved by walking or jogging at moderate intensity for a target of 30 minutes per day, each day. Participants are also encouraged to perform other physical if they wish and are able to. Patients are regularly contacted by a member of the research team on a weekly basis and given an option to maintain or to increase their step count further. The same approach is used after each week of the intervention. Strengthening exercises will form a further part of the exercise intervention. They are performed every day, 7 days a week. Patients are supplied with resistance bands with handles. They are educated on how to perform two repetitions of 5 simple exercises, each for 1 minute duration.
214309134|NCT03937154|DRUG|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
214309135|NCT03937154|DRUG|Placebo|Placebo comparator
214309136|NCT05497284|DRUG|LTP001|LTP001 administered once daily in the morning
214309137|NCT05497284|DRUG|Placebo|Placebo to LTP001 administered once daily in the morning
214309138|NCT05497284|DRUG|Standard of Care (SoC)|nintedanib, pirfenidone, or neither
214309139|NCT05093231|DRUG|Pembrolizumab|Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.
214309140|NCT05093231|DRUG|Olaparib|Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.
214309141|NCT05775614|DEVICE|UroTainer®|Clinical effect of preventive treatment - catheter flushing with UroTainer®
214309142|NCT05775614|DEVICE|Saline|Clinical effect of preventive treatment - catheter flushing with saline solution
214309143|NCT05644262|DRUG|T2:C100|"The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil. T2:C100 is a full spectrum oral solution with five non-reactive ingredients: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a pharmaceutical grade medium chain triglyceride (MCT) oil, and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL study drug (T2:C100) twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL study drug twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).~Participants who enter the Open Label Extension will receive 1mL study drug (T2:C100) twice daily for Week 12 - Week 13 (approximately 1 week), and will then increase to 2mL study drug twice daily for the remainder of the Open Label Extension (Week 13 - Week 26 (approximately 23 weeks))."
214480647|NCT06738693|PROCEDURE|Open Reduction and Internal Fixation (ORIF) with Volar Locking Plate|ORIF using a volar locking plate is performed to anatomically reduce and stabilize unstable intra-articular distal radius fractures. The procedure is conducted under anesthesia, involving an open approach through the volar aspect of the wrist. The volar locking plate is secured with screws to provide rigid fixation, enabling early mobilization. Postoperative follow-up includes evaluation of functional outcomes, union rates, and potential complications.
214309144|NCT05644262|DRUG|Placebo|"Matching placebo in a digestible oil. The placebo contains only three non-reactive ingredients: medium chain triglyceride (MCT) oil and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL placebo twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL placebo twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks))."
214309145|NCT06730347|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
214309146|NCT06285370|DRUG|Mogamulizumab|Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.
214309147|NCT06501118|OTHER|Education|"1. Standardized materials to discuss the rationale and procedural aspects of the intervention, including details on the specific oxygen target-related modifications to the mechanical ventilation order-set prior to starting the intervention phase.~2. Virtual respiratory therapist (vRT) - directed real-time feedback on adherence to the SpO2 target range as a part of the mechanical ventilation order-set embedded in UCHealth EHR (EPIC)."
214309148|NCT04726852|DEVICE|Concurrent comparison|Concurrent comparisons at defined procedure events
214309149|NCT06804239|BEHAVIORAL|User guide with prompts|A user guide and prompts to assist use of an Online Pain-Management Resource
214309150|NCT06143878|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
214480648|NCT06737003|DEVICE|Nasal high frequency oscillatory ventilation|NHFOV was administered using the SLE 6000 device manufactured by Wipro GE Healthcare Private Limited in Bengaluru, Karnataka. The initial amplitude was set at 25 cm H2O and adjusted to a maximum of 35 cm H2O based on clinical response. The frequency was set at 12 Hz. The mean airway pressure (MAP) was initiated at 6 cmH2O and titrated up to 10 cmH2O based on clinical assessment. The I:E ratio was maintained between 1:1 to 1:2 in cases of air trapping, using nasal prongs •
214670659|NCT02403206|DEVICE|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
214309151|NCT06143878|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
214916391|NCT04350125|BIOLOGICAL|Autologous Platelet Rich Plasma|One 4-5mL platelet rich plasma injection administered to each side of the intracavernosal space on the right and left side of the corpus cavernosum at the base of the penis, every two weeks for 6 weeks.
214916392|NCT01847586|PROCEDURE|Paired Associative Stimulation|PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
214916393|NCT01847586|PROCEDURE|Paired Associative Stimulation-Control|PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
214916394|NCT01156181|PROCEDURE|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
214916395|NCT01156181|PROCEDURE|control|Embryo transfer without any intervention
214916396|NCT01994148|PROCEDURE|Laparoscopy|In this study, laparoscopic intervention will be performed under carbon dioxide pneumoperitoneum (pressure, 10-12 mm Hg; flow volume, 8-10 L/min). A 12-mm trocar will be placed in the umbilicus with use of an open technique and to establish pneumoperitoneum.A 10-mm and a 5-mm trocar will be inserted in the right and left flanks,respectively.
214916397|NCT01342523|OTHER|CIS - telephone cessation quitline counseling|Up to 5 total tobacco cessation counseling calls
214916398|NCT01342523|OTHER|Lozenge - nicotine mini-lozenges|2-week starter pack of nicotine mini-lozenges
214916399|NCT01342523|OTHER|Emails - Brief smoking prevention messages|Brief email messages that could be accessed by any computer or mobile device that allowed email receipt
214916400|NCT01342523|OTHER|Full website - standard smokefree.gov website content|Over 50 web pages of resources for quitting smoking, including interactive features and referral links
214916401|NCT01342523|OTHER|Lite website - lite version of smokefree.gov|Reduced version of the smokefree.gov website developed for the research; reduced number of web pages and external links (considered a placebo intervention)
214916402|NCT01342523|OTHER|Full mailed booklet - NCI's detailed 36-page quit guide|NCI's Clearing the Air brochure for preparing to quit, quitting and preventing relapse
214916403|NCT01342523|OTHER|brief mailed booklet - smaller version of NCI's booklet|12-page booklet developed by the investigators for the research (considered to be placebo intervention)
214916404|NCT02360241|DEVICE|Robot|Use of the robot to locate the fictional needle
215077741|NCT04715789|BEHAVIORAL|graded exposure and activity|"1. Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner"
214309152|NCT06143878|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
214916405|NCT05531630|DEVICE|Nasal rinsing with saline 0.9%|"Nasal irrigations with saline (NaCl 0.9%) are considered golden standard in the treatment of chronic rhinosinusitis. Sachets consisting of mixtures for saline solutions, produced by DOS Medical®, consist of 1.875g sodium chloride and 0.625g sodium bicarbonate (figure 5). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the saline solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device and has a CE-label (CNK number 3309028)."
214916406|NCT05531630|DEVICE|Nasal rinsing with Xylitol|"Xylitol is a sugar-alcohol that is already implemented in the treatment of patients with (difficult-to-treat) chronic rhinosinusitis. Some (pilot) studies have already showed a positive effect in CRS patients without cystic fibrosis. Xylitol nasal rinsing salt, produced by DOS Medical®, is a mixture of 4g Xylitol, 1.875g sodium chloride, 0.625g sodium bicarbonate and 0,03g mint (Figure 3). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the Xylitol solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device, has a CE-label (CNK number 3309036) and is already commercially available in Belgium and The Netherlands."
214916407|NCT01780519|DRUG|lorazepam|single dose of 1 mg lorazepam
214309153|NCT06143878|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
214309154|NCT06279871|BIOLOGICAL|ARCT-2303|Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)
214309155|NCT06279871|BIOLOGICAL|Influenza vaccine|Licensed cell-based influenza vaccine
214309156|NCT06279871|BIOLOGICAL|Influenza vaccine, adjuvanted|Licensed influenza vaccine, adjuvanted
214309157|NCT06279871|OTHER|Placebo|0.9% saline
214309158|NCT03878446|DRUG|Somapacitan|Somapacitan injected under the skin once a week.
214309159|NCT03878446|DRUG|Norditropin®|Norditropin® injected under the skin once a day.
214309160|NCT06151704|RADIATION|High intensity laser therapy|The subject will receive high-intensity laser therapy in a prone position with a cushion under the abdomen and eye protection. The laser scanner, 50 cm from the skin, will target the area from the 12th ribs to the upper iliac crest, 4.2 cm lateral to the spine. The sciatic, tibial, and peroneal nerves will also be irradiated. A GaAlAs laser device will be used, with a power of 1.6 watts and a wavelength of 808nm. The initial dose will be 10 joules/cm², with an increment of 2 joules after every three sessions. The final dose will be 16 joules/cm².
214309161|NCT06151704|OTHER|Motor control exercise|Motor control exercise is defined as an exercise to increase control and coordination of the spine and pelvis. Normally, Motor control exercise increases the weak deep trunk muscles, such as transversus abdominis and multifidus, and reduces the overactive large external trunk muscles, such as rectus abdominal and erector spinae muscles. . All subjects participate in a foundational treatment regimen involving motor control exercises: isolated and combined contractions of the transverse abdominis and multifidus muscles in various positions. Contractions will initially be performed up to a maximum of 10 repetitions per movement, with each contraction sustained for a duration of 10 seconds. Commencing from the third week, the subject should be capable of comfortably executing 10 repetitions, sustaining the contraction for 10 seconds, and progressively increasing the intensity.
214309162|NCT06142357|OTHER|Secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled
214309163|NCT06979193|BEHAVIORAL|SAATHI intervention (Augmented PM+ counseling)|Study participants in this arm will attend six weekly peer-led sessions, each approximately 90-minutes in length, designed to empower them to make decisions about their lives and build resilience. PM+ is a psychological intervention developed by the World Health Organization, based on principles of cognitive behavioural therapy. It includes components such as understanding adversity and psychoeducation on mental health, managing stress, problem-solving, behavioural activation, and strengthening social support. The PM+ model in this study is augmented with additional elements, including self-empowerment strategies, motivational interviewing, psychoeducation on intimate partner and community violence, mindful meditation and safety planning. Participants will also be introduced to best practices and lessons learned that support danger assessments and avoidance of risk of future violence. The intervention aims to improve participants' overall circumstances and mental well-being.
214309164|NCT06979193|BEHAVIORAL|SAATHI intervention with Peer-Led Group Meetings|"These 11-monthly peer-led group sessions are designed to enhance social support, build resilience, and reinforce the application of augmented PM+ strategies in daily life. They provide a safe space for reflection and mutual encouragement among study participants. The group sessions focus on managing stress, strengthening self-regulation, building self-esteem, fostering social connectedness, and promoting positive identity development.~Group sessions involve identifying and discussing the barriers and facilitators related to practicing slow breathing techniques, problem-solving strategies, maintaining physical activity, navigating intimate partner and community violence, understanding social support networks, and planning for safety in various situations faced by sexual and gender minorities."
214309165|NCT00920114|BIOLOGICAL|blood sample|
214309166|NCT06818006|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR) with surgical oversight|Transcatheter Aortic Valve Replacement (TAVR) with surgical oversight
214916408|NCT02931344|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
214916409|NCT00116974|PROCEDURE|Scaling and root planing|Scaling and root planing
214916410|NCT05067608|BIOLOGICAL|Control arm receiving normal (never before frozen) platelets as per current clinical practice|Liquid platelets arm (control) and may receive multiple platelet transfusions per thrombocytopenic cycle.
214916411|NCT05067608|BIOLOGICAL|Treatment arm receiving cryopreserved platelets|Cryopreserved platelets arm (treatment) and may receive multiple platelet transfusions per thrombocytopenic cycle.
214916412|NCT00556946|DRUG|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
214309167|NCT06818006|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR) without surgical oversight|Transcatheter Aortic Valve Replacement (TAVR) without surgical oversight
214309168|NCT06988241|OTHER|positional release|All participants in group (A) will receive the same program of group B added to positional release . In order to make the positional release , the therapist will pick up the trigger points by palpation in the upper trapezius muscle by pincer palpation method and distinguished with dots on the skin. Participants will be made supine lying and relaxed by maintaining the cervical spine in a neutral position. Lateral flexion of subject's head toward the side of a tender point, the therapist grasps the subject's forearm and abducts shoulder to approximately 90° and adds slight flexion or extension to fine-tune.The most comfortable position achieved will be held for 90 seconds and after that passive return of the body part to an anatomically neutral position will be maintained for 5 minutes. All participants will be treated three times per week for 4 consecutive weeks and will be instructed to maintain their normal activities while avoiding any undue stress to the neck.
214480649|NCT06737003|DEVICE|Vapotherm Group|The Hi-VNI Vapotherm was administered using the Vapotherm device, manufactured by Vapotherm, INC, USA. Initially, the flow rate was set at 4 L/min and adjusted accordingly to achieve the desired clinical outcome, with a maximum flow rate of 8 L/min when necessary. The temperature was maintained at 36-37°C, and the FiO2 was adjusted as required to attain the target SpO2 range of 90% to 94%، using soft nasal cannula interface
214670660|NCT02403206|PROCEDURE|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
214916413|NCT05898828|DRUG|Nivolumab|Nivolumab 480 mg flat dose via intravenous infusion on Day 3 of every cycle starting at Cycle 2, for intended duration of 1 year.
214955040|NCT04069728|OTHER|Explanation with 3D printed fistula model|Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.
214955041|NCT04069728|OTHER|Standard explanation|Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
214955042|NCT00929994|BEHAVIORAL|Cardiac Rehabilitation|Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
215077742|NCT04074018|OTHER|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
215077743|NCT04074018|OTHER|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
214916414|NCT05898828|DRUG|Entinostat|Entinostat (5 mg) self-administered on Days -14 and -7 prior to the first vaccination cycle, then entinostat (3 mg) self-administered on Days 1, 8, 15, and 22 of each vaccine cycle (Cycles 1-6). Entinostat continuation for subjects with immunologic response and NED during additional 2 vaccine injections.
214916415|NCT05898828|BIOLOGICAL|Montanide(R) ISA-51 VG Adjuvant|H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
214916416|NCT05898828|BIOLOGICAL|H1299 Cell Lysates|H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
214916417|NCT06574711|OTHER|Sacha inchi oil yogurt|Sacha inchi oil was incorporated into a nonfat yogurt acting as a source of linolenic acid
214309169|NCT06988241|OTHER|Posture correction|Posture correction advices during lactation + posture correction exercises
214309170|NCT06664762|BEHAVIORAL|Left lateral position intervention|Patients will be randomized and asigned to start and remain in left lateral position during the colonoscopy
214309171|NCT06664762|BEHAVIORAL|Supine position intervention|Patients will be randomized and asigned to start and remain in supine position during the colonoscopy
214309172|NCT06663345|PROCEDURE|Transversus Abdominis Plan Block (TAPB), Lateral Quadratum Lumborum (QLB-1) Block|Following the acquisition of informed consent prior to surgery, 2 mg of intravenous midazolam will be administered to patients who volunteer. These patients will be monitored in the preoperative preparation room. Bilateral TAP or QLB-1 block will be performed, and this block is routinely applied for postoperative pain in our hospital.
214309173|NCT06985654|DRUG|Lactated Ringers|A bolus of Lactated Ringers (15mL/kg of ideal body weight) will be given to patients prior to anesthesia induction.
214309174|NCT06594315|DRUG|Deuterated Glucose|Given orally
214309175|NCT06594315|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure performed at University of California, San Francisco
215060466|NCT02317497|OTHER|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
214309176|NCT06594315|PROCEDURE|Blood Sample|Capillary blood from the fingertip
215060467|NCT02317497|DRUG|Vasopressors to maintain normal blood pressure values, if needed|
214309177|NCT06594315|PROCEDURE|MR spectroscopy (MRS)|Imaging procedure performed at University of California, San Francisco
214309178|NCT06985355|DRUG|MHB046C|IV administration of MHB046C Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214309179|NCT06663553|PROCEDURE|TU-LESS|patients in TU-LESS group will receive transumbilical laparoendoscopic single-site surgery (TU-LESS) for hysterectomy
214309180|NCT06663553|PROCEDURE|vNOTES|patients in vNOTES group will receive transvaginal natural orifice transluminal endoscopic surgery (TU-LESS) for hysterectomy
214309181|NCT05868629|OTHER|Non-investigational|Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
215060468|NCT02317497|DRUG|Osmotherapeutics to lowr intracranial pressure, if needed|
215060469|NCT02317497|PROCEDURE|Endovascular stroke care to treat brain vessel occlusions, if needed|
214309182|NCT06513780|OTHER|Observation|No intervention were made.
214309183|NCT03564691|DRUG|MK-4830|MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
214916418|NCT06574711|OTHER|Hybrid palm oil yogurt|Interspecific hybrid palm oil was incorporated into a nonfat yogurt as a source of bioactive compounds
214916419|NCT06574711|OTHER|Control yogurt|Conventional full-fat yogurt
215060470|NCT02317497|PROCEDURE|Decompressive neurosurgery, if needed|
215060471|NCT02858440|BIOLOGICAL|Infanrix-IPV/Hib|Subjects receive Infanrix-IPV/Hib three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
214309184|NCT03564691|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV Q3W.
214309185|NCT03564691|DRUG|Carboplatin|Carboplatin will be administered IV Q3W.
214309186|NCT03564691|DRUG|Pemetrexed|Pemetrexed will be administered IV Q3W.
214309187|NCT03564691|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily.
214309188|NCT03564691|DRUG|Paclitaxel|Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).
214309189|NCT03564691|DRUG|Cisplatin|Cisplatin will be administered IV Q3W.
214309190|NCT03564691|BIOLOGICAL|MK-4830A|MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.
214309191|NCT06590740|DRUG|Budesonide-Formoterol treatment|Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID
214309192|NCT06860516|OTHER|blood draw|a blood draw for testing of HLA-DRB1\*04:01
214309193|NCT06914128|DRUG|BAY 3713372|Daily oral administration
214916420|NCT01672554|DRUG|Quetiapine XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
214916421|NCT02929589|DRUG|Ibuprofen|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
215060472|NCT04023383|DRUG|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
214309194|NCT06997042|PROCEDURE|Terminolateral anastomotic technique|Suturing the vein and artery of the arteriovenous fistula with a terminolateral anastomotic suture.
214309195|NCT06997042|PROCEDURE|Piggyback anastomotic technique|Suturing the vein and artery of the arteriovenous fistula with a piggyback anastomotic technique.
214309196|NCT04365556|BEHAVIORAL|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
214309197|NCT02707705|DEVICE|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :~The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
214309198|NCT02707705|DEVICE|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
214309199|NCT02707705|PROCEDURE|Disinfection|The ear is disinfected by applying Chlorhexidine®.
214309200|NCT05382286|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
214309201|NCT05382286|DRUG|Pembrolizumab|Administered intravenously
214309202|NCT05382286|DRUG|Paclitaxel|Administered intravenously
214480650|NCT06737003|DEVICE|Nasal CPAP Group|CPAP therapy was administered using the MEDIN CNO device, developed by medin Medical Innovations GmbH in Olching, Germany. The initial pressure was set at 5 cmH2O and adjusted accordingly to achieve the desired clinical outcome, with a maximum pressure of 8 cmH2O. This approach aimed to maintain the target oxygen saturation (SpO2) levels between 90% and 94%، using bi-nasal with midline prongs
214670661|NCT03750838|BEHAVIORAL|Text Messaging Intervention|The content for the text messaging Intervention will be designed to be non-confrontational in tone, seek to increase motivation to drink lightly or not at all, and based both on general information about light and non-drinking as well as information provided during the baseline assessment.
214670662|NCT01408238|BIOLOGICAL|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
214670663|NCT02778698|DIETARY_SUPPLEMENT|Omegaven|
215060473|NCT04023383|DRUG|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
215060474|NCT04642118|PROCEDURE|Pulmonary recruitment maneuver|Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
215060475|NCT02283892|OTHER|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
215060476|NCT02283892|OTHER|Conventional evaluation|Physician evaluation without the use of checklists
215077744|NCT03264105|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
214309203|NCT05382286|DRUG|nab-Paclitaxel|Administered intravenously
214309204|NCT05382286|DRUG|Gemcitabine|Administered intravenously
214309205|NCT05382286|DRUG|Carboplatin|Administered intravenously
214309206|NCT06863402|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214309207|NCT06863402|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214309208|NCT06863402|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
214309209|NCT06863402|PROCEDURE|Echocardiography|Undergo ECHO
214309210|NCT06863402|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214309211|NCT06863402|DRUG|Nemtabrutinib|Given PO
214309212|NCT06863402|BIOLOGICAL|Pembrolizumab|Given IV
214309213|NCT06863402|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214309214|NCT06863402|OTHER|Questionnaire Administration|Ancillary studies
215077745|NCT03264105|OTHER|conventional resin-based flowable composite|retention rate evaluation of conventional resin-based flowable composite
215077746|NCT03798054|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
215077747|NCT03798054|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214916422|NCT02929589|DRUG|Opioid Medication|1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
214309215|NCT06673264|DEVICE|Soft Neural Probe|sub-acute insertion of the soft neural probe with neural signal recording
214309216|NCT06673004|PROCEDURE|Ovarian tissue allo-transplantation|Participants will receive donor ovarian tissue with immunosuppression
214309217|NCT06672445|DRUG|ARO-ATXN2 Injection|single dose of ARO-ATXN2 by intrathecal (IT) administration
214309218|NCT06672445|DRUG|Placebo|calculated volume to match active treatment by IT administration
214309219|NCT06995508|OTHER|Best Practice|Given standard of care symptom management
214309220|NCT06995508|DRUG|Olanzapine|Given PO
214309221|NCT06995508|OTHER|Questionnaire Administration|Ancillary studies
214309222|NCT06588322|OTHER|Blood samples will be taken on several times (36 mL of blood taken at each time):|"* Inclusion visit (T0): prior to initiation of Olaparib treatment~* Follow-up period (T1 to T8): every 3 months for a maximum of 24 months~* End of study (Tx): on definitive cessation of Olaparib treatment for any reason (progression, toxicity or definitive cessation of treatment after 2 years)."
214309223|NCT05410873|DRUG|MitoQ Compound|Mitoquinol mesylate
214309224|NCT05410873|DRUG|Placebo|Placebo
214309225|NCT07000708|BEHAVIORAL|TRE: Time-restricted eating|The daily eating pattern is reduced to 8 h/day. The first meal will be before 10:00 AM.
214309226|NCT06762730|DRUG|Zoledronic Acid 5 mg/Bag 100 ml Inj|Zolendric acid will be provided to HIV naïve patients with documented osteopnia
214309227|NCT07052903|DRUG|Nucresiran|Nucresiran 300 mg administered SC q6M
214309228|NCT07052903|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) administered SC once q6M
214309229|NCT06055231|BEHAVIORAL|Vape device|Consume THC via vape defice
214309230|NCT06055231|BEHAVIORAL|Joint|Consume THC via joint
214670664|NCT00385333|PROCEDURE|Feasibility Study - Imaging System|
214670665|NCT05459805|DRUG|traditional chinese medicine Xuanfei-Zhike formula|200ml, bid, for 8 weeks
214670666|NCT05459805|DRUG|inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)|one suction, q12h, for 8 weeks
214916423|NCT02929589|DRUG|Placebo|800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
214916424|NCT02929589|DRUG|Ibuprofen + Opioid medication|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
214916425|NCT01422889|DEVICE|ION™ Coronary Stent System|This study is intended to evaluate the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System across a range of institutions and physician users to observe and assess subject outcomes and technology performance in a real-world setting.
214309231|NCT06055231|DRUG|Marijuana via vape device|Given via vape device
214309232|NCT06055231|DRUG|Marijuana via joint|Given via joint
214309233|NCT05286814|DRUG|Floxuridine|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL \[pump volume\] / Pump Flow Rate)
214309234|NCT05286814|DRUG|5-Fluorouracil|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan). FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site.
214309235|NCT05286814|DRUG|Irinotecan|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
214309236|NCT05286814|DEVICE|Intera 3000 Hepatic Artery Infusion Pump (HAIP)|Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.
214309237|NCT05286814|DRUG|Oxaliplatin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
214309238|NCT05286814|DRUG|Leucovorin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
214916426|NCT02091089|DEVICE|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
214916427|NCT02772926|DIETARY_SUPPLEMENT|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day
214309239|NCT05286814|DRUG|PDS01ADC|PDS01ADC will be administered by subcutaneous injection on Day 15 of every cycle. Cycle 1 at 12 mcg/kg; Cycle 2 reduced to 8 mcg/kg with the addition of systemic chemotherapy, to continue for further cycles. Note: any dose reduction in FUDR = 50% due to liver enzyme elevations means that the dose of PDS01ADC will be reduced to 4 mcg/kg.
214309240|NCT05286814|DRUG|Gemcitabine|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
214309241|NCT05286814|DRUG|Dexamethasone|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Dexamethasone: (1 mg/day X pump volume / pump flow rate)
214916428|NCT02772926|DIETARY_SUPPLEMENT|Placebo|Placebo 900 mg per day
214916429|NCT06478472|DRUG|Orelabrutinib in combination with rituximab|"Induction Phase:~Orelabrutinib + rituximab for a total of 6 cycles of 28 days each Obrutinib (O) 150mg oral d1-28 Rituximab (R) 375mg/m2 IV d0~Maintenance phase:~Orelabrutinib 150mg po qd 24 cycles of 28 days each"
214309242|NCT07056166|PROCEDURE|epidural catheter|Epidural catheter placement for labor analgesia
214309243|NCT07056166|PROCEDURE|spine ultrasonography|An ultrasound scan will be performed on the spine to identify anatomical characteristics of potential interest
214309244|NCT06413680|DRUG|REGN10597|Administered as an intravenous (IV) infusion
214309245|NCT07095114|OTHER|Magic Ink|A novel ink that is only visible when exposed to Ultraviolet light and can be hidden using white light will be inserted into the dermis to tattoo a radiation guidance tattoo into the skin of the participant
214309246|NCT06235697|RADIATION|Radiation|"46Gy / 23 fractions of EBRT to pelvis and prostate + LDR or HDR boost to prostate OR 25Gy / 5 fractions of EBRT to pelvis and prostate (ultrahypofractionation EBRT (SBRT)) + LDR or HDR boost to prostate.~\+ Adjuvant ADT: Unfavourable Intermediate Risk: 6 months or High / Very High Risk: 24 months"
214309247|NCT06235697|RADIATION|Radiation SBRT only|25Gy / 5 fractions to pelvis + 40 Gy / 5 fractions to prostate (SBRT) (ultrahypofractionation EBRT (SBRT))
214309248|NCT06235697|DRUG|ADT|Assigned at enrollment
214309249|NCT06910579|DRUG|topical application of oxygenated gel|patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days
214309250|NCT06910579|DRUG|topical application of Triamcinolone acetonide gel|patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.
214309251|NCT07170670|BEHAVIORAL|CBIP - Cognitive-Behavioral Intervention Package|"Before the procedure, the researcher initiated social interaction with the child (cognitive distraction). Next, suggestions regarding the procedure were provided (guidance). A volunteer parent sat beside the child, providing support by holding the child's non-procedural hand. While the nurse performed the port catheter insertion, the researcher applied one of the behavioral distraction techniques chosen by the child during the pre-procedure phase, such as counting, singing, reading a poem, or answering questions (behavioral distraction). Upon completion of the procedure, the researcher provided positive reinforcement by praising the child (Well done! and You were very brave!) and rewarding the child with a star and smiley face sticker on the collar (positive reinforcement)."
214309252|NCT07168733|DEVICE|Inspiratory muscle training|The POWERbreathe® device is a pressure-threshold IMT device that provides resistance during inhalation. The user breathes in through a mouthpiece against an adjustable spring-loaded valve, which opens only when the inspiratory pressure exceeds the set threshold, thereby strengthening the inspiratory muscles over time. Following a one-week familiarization period, the IMT protocol was performed twice daily (morning and evening), five days per week, for four weeks. Each session consisted of 30 breathing cycles, resulting in a total of 60 cycles per day. Prior to training, the device resistance was calibrated to 40% of each participant's maximal inspiratory pressure (MIP), as reported by Çelikel et al. (2025) to promote increases in muscle size and thickness. MIP was reassessed weekly and resistance was increased by 10%; progression was paused if participants experienced excessive strain.
214309253|NCT07168733|OTHER|Control|The group that continues with their normal daily routines
214309254|NCT07171762|DEVICE|Ozonytron XP|This intervention involves the use of ozonated water as a final irrigation solution during root canal treatment in teeth diagnosed with asymptomatic apical periodontitis. Following standard chemomechanical preparation, ozonated water is delivered into the root canal system using a 30-gauge side-vented needle. The aim is to assess the biochemical changes in periapical tissues by evaluating oxidative stress markers (TAS, TOS, MDA, 8-OHdG) in the apical fluid samples collected before and after irrigation. The ozonated water is generated via a medical-grade ozone generator, and its application is designed to minimize cytotoxicity while maximizing antimicrobial and oxidative stress modulation properties. The outcomes are compared to a control group receiving saline irrigation under identical procedural conditions.
214670667|NCT02798523|DRUG|Methylprednisolone sodium succinate(Solu-Medrol)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
214916430|NCT01461486|DEVICE|Continuous Positive Airway Pressure (CPAP)|The device is a flow generator used to open the airway during sleep.
214916431|NCT01461486|DEVICE|Oral Appliance (BRD)|The device increases the volume of the airway by mandibular traction.
214916432|NCT02343939|DRUG|Entospletinib|Tablet(s) administered orally every 12 hours
214916433|NCT02343939|DRUG|Daunorubicin|60 mg/m\^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles
214916434|NCT02343939|DRUG|Cytarabine|100 mg/m\^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles
214916435|NCT02343939|DRUG|Decitabine|20 mg/m\^2 administered intravenously
214916436|NCT02343939|DRUG|Azacitidine|75 mg/m\^2 administered intravenously or subcutaneously
214916437|NCT03478566|DEVICE|Transcutaneous CO2 monitoring|The aim is to assess the accuracy of ambulatory, at home, transcutaneous CO2 monitoring in pediatric Neuromuscular Disease (NMD).
214916438|NCT04553822|OTHER|Assisted autogenous drainage group (DAA)|DAA, is used when the patient is not able to perform this technique autonomously and is assisted by the physiotherapist. Its greatest utility is in infants and preschoolers. The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes. The physiotherapist must ensure that the child takes 2 to 3 controlled breaths, close to the residual level, with the objective that the expiratory flow displaces the secretions, located distally, towards the central airways.
215060477|NCT06502522|OTHER|Whole-body electrical stimulation|"Symmetrical biphasic current, pulse width of 400 μs, frequency of 75 Hz, contraction time of five seconds and rest time of 10 seconds. The intensity will be individually adjusted to the patient's maximum tolerance limit to reach the motor threshold and the volunteer will be instructed to achieve a score of 7 on the modified BORG scale to ensure a moderate-intense effort. The session time will be 16 minutes, resulting in a total of 64 contractions per session. The progression of overload will only occur with an increase in the intensity of all muscle groups during the sessions.~Concomitantly with the electrical stimuli, the volunteer will perform exercises for the upper, lower limbs and trunk. After performing neuromuscular electrical stimulation, the patient will remain in the supine position to receive sensory stimulation throughout the body. The parameters used will be: frequency of 20 Hz and pulse width of 400 μs for 44 minutes."
214309255|NCT07171762|OTHER|Physiological saline solution (0.9% NaCl)|Physiological saline solution (0.9% NaCl) was used as the final irrigation agent in root canal treatment.Saline Irrigation Group (Control)
214309256|NCT07180550|OTHER|High-intensity interval training, running|Six sets of 2-minute runs will be performed at an intensity of 90-95% of the maximal aerobic speed (MAS) on a treadmill. The recovery between each set will be 2 minutes, during which the subject will walk at an intensity of 50-60% of MAS.
214309257|NCT07180550|OTHER|High-intensity interval training, cycling|Six sets of 2-minute cycling will be performed at an intensity of 90-95% of the maximal heart rate on a stationary bike. The recovery between each set will be 2 minutes, during which the subject will cycle at an intensity of 50-60% of maximal heart rate.
214309258|NCT07180550|OTHER|High-intensity functional training|Three sets of six repetitions will be performed at 80% of the one repetition-maximum (1-RM) for six exercises. The recovery between exercises will be the minimum time required to switch from one exercise to the next, and between sets, it will be two minutes. Participants will be instructed to move the load as quickly as possible during each repetition.
214309259|NCT07180550|OTHER|Moderate-intensity functional training|Three sets of six repetitions will be performed at 60% of the 1-RM for six exercises. The recovery between exercises will be the minimum time required to switch from one exercise to the next, and between sets, it will be two minutes. Participants will be instructed to move the load as quickly as possible during each repetition.
214309260|NCT07180550|OTHER|Moderate intensity traditional strength training|Three sets of six repetitions will be performed at 60% of the 1-RM for six exercises. The recovery after each set will be two minutes of passive rest. Participants will be instructed to move the load as quickly as possible during each repetition.
214309261|NCT07180550|OTHER|High intensity traditional strength training|Three sets of six repetitions will be performed at 80% of the 1-RM for six exercises. The recovery after each set will be two minutes of passive rest. Participants will be instructed to move the load as quickly as possible during each repetition.
214309262|NCT07181876|DEVICE|inguinal hernia repair|Robotic-assisted inguinal hernia repair with the DEXTER robotic surgery system
214309263|NCT07181538|DRUG|JLP-2302|taking JLP-2302
214309264|NCT07181538|DRUG|JP-1366|taking JP-1366
214309265|NCT07180654|DEVICE|transcranial magnetic stimulation|Subjects will receive a series of 60 10s trains that will be presented over the course of the \~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz). iTBS will be administered at 100% of the motor threshold (MT).
214309266|NCT07181109|DRUG|Zilebesiran|Zilebesiran will be administered SC
214309267|NCT07181109|DRUG|Placebo|Placebo will be administered SC
214346966|NCT04340206|BEHAVIORAL|only chat-robot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program.
214916439|NCT04553822|OTHER|Group prolonged slow expiration (ELPr)|Passive expiratory aid technique applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
214916440|NCT04553822|OTHER|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer. Once the nebulization is finished, you will wait 30 minutes in a closed room.
215060478|NCT01670279|DRUG|Brexpiprazole|up to 3mg oral dose once daily
215060479|NCT01670279|DRUG|Placebo|
215060480|NCT02202967|DRUG|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
215060481|NCT02202967|DRUG|Placebo|Placebo contains lactose granules
215077748|NCT03798054|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
215077749|NCT03798054|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
215077750|NCT03798054|DRUG|SGLT2 inhibitor|"Pharmaceutical form:tablet~Route of administration: oral"
215077751|NCT00444704|DRUG|PRA-027|
215077752|NCT02439450|BIOLOGICAL|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
214346967|NCT04340206|BEHAVIORAL|Control group, no intervention|Behavioral: No intervention
214309268|NCT07180706|DEVICE|Histotripsy|Histotripsy is a tumor ablation technique developed in recent years that allows for non-invasive treatment of solid tumors using High-Intensity Focused Ultrasound (HIFU). This method works by physically focusing ultrasound energy at a single point within biological tissue, creating a focal zone of high-power, low-frequency ultrasound that induces mechanical fragmentation (histotripsy) and cavitation effects, dissolving the tissue into fragments and destroying tumor cells. Under real-time ultrasound imaging guidance, various scanning treatment protocols are used to move the focal point throughout the treatment zone, effectively ablating the tumor tissue. The destroyed tumor tissue is gradually absorbed by the body. Since this technique does not require needle puncture, electrode insertion, radiation, or thermal effects, it is minimally invasive and holds the potential to overcome the limitations of existing ablation technologies.
214309269|NCT07180771|DRUG|BR101801|Patients will receive 200mg capsules (100mg+100mg)
214309270|NCT07181083|DEVICE|Rheolytic thrombectomy|Rheolytic thrombectomy via AngioJet ZelanteDVTTM Catheter (Boston Scientific Co., USA).
214309271|NCT07180173|RADIATION|Salvage Neck Treatment|Salvage neck treatment, including neck dissection with or without re-irradiation and/or systemic therapy, administered to patients with stage N3 nasopharyngeal carcinoma after completion of definitive concurrent chemoradiotherapy (CCRT) or induction chemotherapy followed by radiotherapy/CCRT.
214916441|NCT03187730|BEHAVIORAL|Integrated Smoking Cessation and Financial Counseling|Participants in the intervention group will receive up to nine counseling sessions that integrate two evidence-based counseling approaches: financial management counseling and smoking cessation counseling. Participants will also be eligible to receive a free four-week supply of NRT. Participants will be surveyed at baseline, 2- months, 6-months and 12-months to assess outcomes and treatment satisfaction.
214309272|NCT07179588|BEHAVIORAL|Nutrition Education Program|The participants will attend a monthly nutrition education session for 4 months (total 4 sessions). The sessions will be available in person and over teleconference platforms (i.e., Zoom). Each session will be up to 1-hour, which will include nutrition guidelines to manage diet quality.
214309273|NCT07179588|BEHAVIORAL|Nutrition Counseling|Participant will meet with a registered dietitian for one-on-one diet consults once a month for 4 months. These sessions can be in-person or via Zoom. Each session will be up to 1 hour, and will be done to assess if the nutrition guidelines taught during the education sessions are being implemented.
214309274|NCT07180953|DRUG|NaCl 0.9%|iPACK block with Adductor Canal Block (2 x 20ml 0.2% ropivacaine + 1ml 0.9% NaCl) + 2ml 0.9% NaCl iv
214309275|NCT07180953|DRUG|Dexamethasone 4mg|iPACK block with Adductor Canal Block (2 x 20ml 0.2% ropivacaine + 1ml 0.9% NaCl) + 4mg Dexamethasone iv
214309276|NCT07180953|DRUG|Dexamethasone 4mg|iPACK block with Adductor Canal Block (2 x 20ml 0.2% ropivacaine + 2mg Dexamethasone) + 2ml 0.9% NaCl iv
214309277|NCT07179965|OTHER|Observation|IBD patients
214309278|NCT07180485|BEHAVIORAL|whole body vibration training|whole body vibration training and health education booklet
214309279|NCT07180485|BEHAVIORAL|control group|health education booklet
214309280|NCT07181720|BIOLOGICAL|CD70-targeted CAR-T cells|Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214309281|NCT07181720|BIOLOGICAL|CD70-targeted CAR-T cells|Administration method: intrapleural infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214309282|NCT07181720|BIOLOGICAL|CD70-targeted CAR-T cells|Administration method: intraperitoneal infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214309283|NCT07180927|BIOLOGICAL|4SCAR DLL3 T cells|Infusion of 4SCAR DLL3 T cells at 10\^6 cells/kg body weight via intravenous route
214309284|NCT07180628|BEHAVIORAL|Speech Production During functional magnetic resonance imaging (MRI)|Participants will complete a speech production task with 2 conditions (stuttered, non-stuttered) while undergoing functional MRI to assess brain activity. Brain activity will be compared within subjects for the 2 conditions. The intervention is the combination of tasks delivered to all participants. The speaking task is the intervention (modifying agent) and the MRI is a measurement tool, not a therapeutic or modifying agent.
214309285|NCT07181174|DEVICE|Ultrasonographic examination and doppler ultrasonography will be performed using a convex transducer.|-Renal Resistive Index Measurement Method: Ultrasonographic examination and doppler ultrasonography will be performed using a convex transducer. First, the kidney is localised in the flanks with conventional B-mode ultrasonography, after which, color doppler images are acquired. The interlobar arteries were visualised, with the wavelength obtained by creating a 90-degree right-angle with the interlobar artery using a power doppler. After the manual determination of the peak systolic and end-diastolic velocities \* RRI will be calculated by the device using the formula: RRI = (peak systolic velocity - end-diastolic velocity) / (peak systolic velocity). RRI will be measured three times for each kidney and averaged
214309286|NCT07181824|OTHER|Diagnostic tedst|"* Radiologic signs: 2 consecutive thorax x-ray with new onset pneumonia AND~* One of the following criteria~  * Fever \>38,3°C without any other cause~ * Leucocytes \< 4000/mm3 or ≥ 12000 /mm3~* AND at least two of the following~  * Purulent secretions~ * Cough or dyspnoea~ * Desaturation or increase in FiO2 (+20%)"
214309287|NCT07181460|OTHER|Exercises Program|A program of low-intensity, safe, and functional movements was designed for older adults. It included a warm-up, breathing exercises, chair exercises, strength and mobility exercises, balance exercises, stretching, and a cool-down.
214309288|NCT07181369|DRUG|GTX-B001|Single infusion of one of up to five dosages of GTX-B001
214309289|NCT07181369|DRUG|Normal Saline|Single infusion of normal saline
214346968|NCT05967520|DRUG|JMKX000189|JMKX000189 will be administered orally once a day
214346969|NCT05967520|DRUG|Placebo|Placebo will be administered orally once a day
215060482|NCT03719001|DRUG|Phenylephrine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
215060483|NCT03719001|DRUG|Dexmedetomidine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
215060484|NCT03719001|DRUG|Clevidipine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
214309290|NCT07179601|PROCEDURE|Hemorrhoidal artery embolization|Hemorrhoidal artery embolization (HAE) involves the deliberate blockage of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve symptoms related to internal hemorrhoids, especially bleeding.
214916442|NCT03187730|BEHAVIORAL|Waitlist Integrated Smoking Cessation and Financial Counseling|Control participants in the waitlist control group will receive usual care for the first 6 months of the study, while the Intervention Arm receives integrated counseling. The waitlist control group will receive the same counseling program as the Intervention group 6 months after enrollment (up to nine counseling sessions and four weeks of NRT). Participants will be surveyed at baseline, 2-months, 6-months and 12-months to assess outcomes and treatment satisfaction.
214916443|NCT03187730|DRUG|Nicotine Replacement Therapy (NRT)|Participants in both arms will be eligible to receive a free four-week supply of NRT.
214309291|NCT07181616|BEHAVIORAL|Adapted W2W|HIV education sessions and questionnaires.
214309292|NCT07181616|BEHAVIORAL|Waitlist Control|HIV education sessions and questionnaires given 4 weeks after W2W intervention.
214309293|NCT07180732|PROCEDURE|Injection moulding technique|A dental technique that uses a transparent silicone index or stent to inject a low-viscosity composite into a pre-planned and approved tooth shape.
214480651|NCT06740097|DEVICE|Aspirate tissue monitoring|This multicenter controlled clinical trial investigates the clinical performance and outcomes from using an aspirate tissue monitor (ATM, Marginum Ltd HIVEN™) that detects cancerous tissue from the suction waste during the surgical treatment of suspected high-grade gliomas. The ATM provides near real-time audible feedback to the surgeon when tumor-related fluorescence is detected in the aspirated tissues. The trial investigates if the use of ATM to detect 5-ALA induced fluorescence contributes to faster tumor removal, less blood loss, less unintended residual tumor, less morbidity, longer survival and the frequency of local reoperations. The cases are compared with controls (n=50) from applicable local clinical site registers (matched controls). The cases are operated with the help of aspirate tissue monitoring and the controls without. Other preferred adjunct techniques are used in both groups.
214480652|NCT06740097|DEVICE|Fluorescence-guided surgery|Resection utilizing conventional visual fluorescence-guided surgery.
214480653|NCT06738550|DIETARY_SUPPLEMENT|inulin|In the patients of the experimental group, the nutritional intervention is personalized, agave inulin supplementation is provided 9 gr per day, A 6-month follow-up is provided
214916444|NCT05962333|BIOLOGICAL|Intra-arterial delivery of autologous MABs|three times intra-arterial administration of autologous mesoangioblasts in biceps brachii of the left arm at 4-6 week interval
214916445|NCT04668248|OTHER|Simulation|"The simulation will consist of a one-time, short immersive simulation session at the STRATUS Center for Medical Education at BWH. The session will be conducted for up to one intern at the same time, in accordance with social distancing practices at BWH. This simulation session will consist of one short, hands-on scenario of simulated patient experiences with expert facilitators in the simulated hospital rooms to help providers identify when they are in the hot state and their reactions, and work on improving communication skills, differential diagnoses, and alternative therapeutic options. These scenarios are intended to simulate both in-person and virtual interactions that are common in the inpatient setting. During these trainings, we will use behavioral principles like time pressure and increasing cognitive load to simulate a hot state environment. After the scenarios, the facilitator will perform a debriefing session for the interns."
215060485|NCT03719001|OTHER|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
215060486|NCT03719001|OTHER|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
215060487|NCT03719001|DRUG|Calcium Chloride|CaCl will be administered to increase blood pressure and plasma calcium concentration
214309294|NCT07180732|DIAGNOSTIC_TEST|Digital smile design|A modern approach that uses digital imaging, videos, and software to create a customized, virtual 3D model of a patient's ideal smile before any treatment begins
214309295|NCT07179822|BEHAVIORAL|Motor Evoked Potential (MEP) Operant Conditioning|Operant conditioning is a method to induce behavioral learning based on the consequence (reward) of the behavior. With operant conditioning of the motor evoked potential (MEP), the neuronal excitability and behavior of the corticospinal pathway that involves production of MEP is targeted and trained (i.e., up-trained with up-conditioning). The individual is rewarded only for changing the target muscle's MEP size without changing background muscle activity. Since MEP size reflects the corticospinal excitability at or just before the time of stimulation, during MEP up-conditioning trials, the individual is urged to increase the corticospinal excitability for the target muscle.
214309296|NCT07180108|DRUG|Psilocybin (high dose)|25 mg pill
214309297|NCT07180108|BEHAVIORAL|Playlist 1|Six hour playlist
214309298|NCT07180108|BEHAVIORAL|Playlist 2|A six hour playlist
214309299|NCT07180108|BEHAVIORAL|Playlist 3|A six hour playlist
214309300|NCT07180108|BEHAVIORAL|Playlist 4|A six hour playlist
214309301|NCT07180108|BEHAVIORAL|Playlist 5|A six hour playlist
214309302|NCT07179783|DRUG|Sacituzumab Tirumotecan|Drug reduction will be implemented according to the research plan.
214309303|NCT07179783|DRUG|Tagitanlimab|Treatment with Sacituzumab Tirumotecan (SKB264, 5mg/kg IV d1 Q2W) and Tagitanlimab (KL-A167 , 900mg IV d1 Q2W) until confirmed by the investigator as imaging disease progression, intolerable toxicity, subject's request to terminate treatment, or other treatment termination criteria specified in the protocol (based on the first patient), with a maximum treatment duration of 24 months for Tagitanlimab. Drug reduction will be implemented according to the research plan.
214309304|NCT07181577|DEVICE|Special blanket|Special blanket to be used at home every night in 4 weeks (Phase 1 - RCT) and opportunity for additional 8 weeks (Phase 2 - open trial)
214309305|NCT07181577|DEVICE|Different special blanket|Different special blanket to be used at home every night in 4 weeks (Phase 1 - RCT) and opportunity for additional 8 weeks (Phase 2 - open trial)
214309306|NCT07179848|DEVICE|Temporal Interference Stimulation - Treatment first|Receive treatment stimulation for 5 consecutive days, followed by a 2-days washout period, then complete the remaining 5 days of sham stimulation
214309307|NCT07179848|DEVICE|Temporal Interference Stimulation - Sham first|Receive sham stimulation for 5 consecutive days, followed by a 2-days washout period, then undergo 5 days of treatment stimulation
214309308|NCT07181187|DRUG|MH004 Ointment|MH004 1% ointment applied topically to the affected area as a thin film once or twice daily.
214480654|NCT06738550|DRUG|Lactulose oral solution|In the patients of the experimental group, the nutritional intervention is personalized, A 6-month follow-up is provided and taken syrup lactulose 10 ml every 8 hours
214480655|NCT06741059|OTHER|Transkutanöz Elektriksel Sinir Stimülasyonu - TENS|Transcutaneous Electrical Nerve Stimulation (TENS) has gained popularity in recent years as a non-invasive method for pain management. TENS works by modulating nerve stimulation through low-frequency electrical currents applied to the skin, reducing pain perception. Its potential effectiveness in alleviating menstrual pain has drawn increasing attention as an alternative treatment option
214480656|NCT06739967|BEHAVIORAL|Behavioral Treatment|"The SLT intervention will be entirely administered online through a web-based platform. While each of the treatments will engage semantics, phonology, and orthography, the protocols will be tailored relative to the characteristics of each PPA variant. Patients with svPPA and lvPPA will undergo a lexical retrieval training (LRT) intervention implemented using a training cascade.~Patients with nfvPPA will undergo Video-implemented Script Training (VISTA), a choral reading approach training accurate production of functional scripts. The method is based on that implemented in American-English individuals with PPA and aims at improving grammar and motor aspects of speech production by taking advantage of repetitive practice and automaticity."
214480657|NCT06739525|COMBINATION_PRODUCT|Blue Light-Blocking Glasses (Intervention Group)|Participants in this arm wore blue light-blocking glasses designed to filter out a portion of short-wavelength blue light. These lenses were intended to reduce eye strain and protect against blue light exposure, especially during prolonged screen time. Participants used blue light-blocking glasses consistently throughout the study period to assess their effect on contrast sensitivity and visual fatigue.
214670668|NCT02798523|DRUG|Topical methylprednisolone (Advantan emulsion 0 /1%)|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
214916446|NCT04668248|OTHER|Online educational training|Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines. This information will be in the form of electronically-delivered links to information already housed and available at BWH, including reviewing BWH guidelines and literature about transfusion reactions. The interns will be asked to answer several clinical questions about optimal prescribing. Albumin and related products are also high-risk medications often overprescribed on twilight shifts.
214916447|NCT04589377|BEHAVIORAL|Mindfulness Training|Training is focused on learning the principle of RAIN (recognize, accept, investigate, non-identify) in the context of physics learning.
214916448|NCT05102357|PROCEDURE|Conservative Treatment (splint)|splint 6 weeks
214916449|NCT00708383|OTHER|10% SSS embryo culture medium protein supplementation|10% SSS in addition to the 0.5% HSA already in the culture medium.
214916450|NCT00708383|OTHER|0.5% HSA embryo culture medium protein supplementation|0.5% HSA in the culture medium
214916451|NCT00669097|DRUG|TKI258|
214916452|NCT04852419|DRUG|ZN-c5|ZN-c5
214916453|NCT03131843|DRUG|Alcohol|Alcohol cleansing swab/wipe
214309309|NCT07181187|DRUG|Vehicle Ointment|Matching vehicle ointment applied topically to the affected area as a thin film once or twice daily.
214309310|NCT07181343|DRUG|HS-10374 tablets|From Day 8 to Day 19, participants will orally take HS-10374 Tablets 12 mg（6 mg×2） once daily under fasting conditions
214309311|NCT07181343|DRUG|Drospirenone and Ethinyl Estradiol tablets|On Day 1 and Day 14, participants will orally take one tablet of Drospirenone and Ethinylestradiol Tablets under fasting conditions.
214309312|NCT07180667|BEHAVIORAL|Intervention 1: Aerobic Running (AR) Warm-Up|15-minute aerobic running protocol. Heart rate maintained at 60-75% of age-predicted maximum (HRₘₐₓ). Includes 7 minutes light jogging followed by slight intensity increase.
214916454|NCT03131843|DRUG|No alcohol|No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
214916455|NCT01580670|DRUG|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
214916456|NCT03594981|BIOLOGICAL|CMV/AdV /EBV/BKV specific T cells|Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
214916457|NCT04471857|BEHAVIORAL|Hypnosis|
214916458|NCT00027066|DRUG|Active Aspirin|325mg tablet daily
214916459|NCT00027066|DRUG|Active Warfarin|2mg scored tablet daily
214916460|NCT00027066|DRUG|Aspirin placebo|325mg aspirin placebo pill
214309313|NCT07180667|BEHAVIORAL|Intervention 2: Static Stretching (SS) Warm-Up|5 minutes light jogging followed by static stretches of six lower-limb muscles (gastrocnemius, quadriceps, hamstrings, hip flexors, adductors, gluteals). Each muscle stretched twice for 30 seconds, finishing with 3-4 minutes of light dynamic movements.
214309314|NCT07180667|BEHAVIORAL|Intervention 3: Dynamic Stretching (DS) Warm-Up|5 minutes light jogging followed by dynamic stretches targeting the same six muscle groups over 10-15 meters with brief rest between repetitions.
214309315|NCT07180667|BEHAVIORAL|Intervention 4: Movement Preparation (MP) Warm-Up|Description: Combination of light jogging, multi-joint mobility drills (e.g., lateral shuffles, inchworms), submaximal sprinting (80-90% max velocity), and low-intensity balance drills adapted from FIFA 11+ and HarmoKnee.
214916461|NCT00027066|DRUG|Warfarin placebo|2mg scored placebo tablet
214309316|NCT07181785|COMBINATION_PRODUCT|Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy|Anthracycline-based combinations followed or not by involved-field radiotherapy
214309317|NCT07180199|PROCEDURE|Bilateral Lateral Rectus Recession (BLR Recession)|This procedure involved recession of both lateral rectus muscles to reduce large-angle exotropia.
214309318|NCT07180199|PROCEDURE|Bilateral Lateral Rectus Recession with Upward Transposition|This procedure involved bilateral lateral rectus recession combined with upward transposition of the insertion to enhance ocular alignment in patients with large-angle exotropia.
214309319|NCT07179536|PROCEDURE|Ambulation after ProGlide Closure|Ambulation time after femoral artery access site closure using the ProGlide vascular closure device was assigned to 2 hours, 6 hours, or 12 hours post-procedure.
214309320|NCT07180277|DRUG|Placebo|2 mg/kg diluted in 100 mL of normal saline (maximum dose 160 mg) , IV once daily for 5 days
214309321|NCT07180277|DRUG|Methylprednisolone (MP)|2 mg/kg diluted in 100 mL of normal saline (maximum dose 160 mg) , IV once daily for 5 days
214309322|NCT07179809|OTHER|Demographics/Lifestyle Survey|Participants will complete all sessions and instruments
214309323|NCT07179913|DRUG|Esketamine|For the subjects in the experimental group, esketamine 50mg/2ml was diluted with normal saline up to 50ml (with a concentration of esketamine at 1mg/ml), anesthesia induction begins with intravenous infusion of esketamine 0.25mg/kg (0.375ml/kg•h drug preparation solution), with a pumping duration of 40 minutes.After the operation, esketamine 0.25mg/kg and sufentanil 1.5ug/kg were added to the postoperative analgesic pump dilute to 100ml with normal saline, with a background dose of 2ml/h and a single booster dose of 2ml.
214309324|NCT07179913|DRUG|Dexmedetomidine|For the control group subjects, dexmedetomidine at a dose of 0.2mg/2ml was diluted with normal saline up to 50ml(dexmedetomidine concentration of 4μg/ml), anesthesia induction begins with intravenous infusion of 0.5μg/kg (0.083ml/kg•h), with a pumping duration of 40 minutes. The postoperative analgesic pump was added after the operation dilute with normal saline at a dose of 0.5μg/kg of dexmedetomidine and 1.5 μg/kg of sufentanil 100ml, with a background dose of 2ml/h and a single booster dose of 2ml.
214309325|NCT07181850|OTHER|Standard-of-Care Neoadjuvant Immunochemotherapy (nIT+nCT)|Adults with biopsy-confirmed ESCC received standard neoadjuvant immunochemotherapy before surgery (e.g., camrelizumab with paclitaxel plus cisplatin or carboplatin, typically 2 cycles every 2-3 weeks). Treatments were routine clinical care at participating centers and were not assigned by study protocol; this record captures the exposure for observational modeling of pathological complete response (pCR). Surgery (R0) occurred \~6-8 weeks after therapy.
214309326|NCT07180979|DRUG|0.9% Sodium chloride|"Sham ultrasound-guided pericapsular nerve group (PENG) block, lateral femoral cutaneous nerve (LFCN) block, lumbar erector spinae plane block (L-ESPB), and sacral erector spinae plane block (S-ESPB).~At each anatomical site, under ultrasound guidance, a block needle will be inserted to the correct position, and 1-2 mL of preservative-free normal saline (0.9% NaCl) will be injected to mimic the sensation of an active block. No local anesthetic will be administered. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty."
214309327|NCT07180979|DRUG|Ropivacaine 0.2% Injectable Solution|"Ultrasound-guided pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block, with sham lumbar and sacral ESPBs.~PENG block: 20 mL of 0.2% ropivacaine. LFCN block: 5 mL of 0.2% ropivacaine. Sham lumbar ESPB: 1-2 mL preservative-free normal saline at lumbar ESPB site. Sham sacral ESPB: 1-2 mL preservative-free normal saline at sacral ESPB site. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty."
214309328|NCT07180979|DRUG|Ropivacaine 0.2% Injectable Solution|"Ultrasound-guided lumbar erector spinae plane block (L-ESPB) and sacral erector spinae plane block (S-ESPB), with sham PENG and LFCN blocks.~Lumbar ESPB: 20 mL of 0.2% ropivacaine at L3 transverse process level. Sacral ESPB: 20 mL of 0.2% ropivacaine at sacral intermediate crest. Sham PENG block: 1-2 mL preservative-free normal saline at PENG site. Sham LFCN block: 1-2 mL preservative-free normal saline at LFCN site. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty."
214346970|NCT02040480|DRUG|GSK2110183 Gelatin Capsule|White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
214346971|NCT02040480|DRUG|GSK2110183 IR Tablet|White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
214916462|NCT05472272|OTHER|Formula diet|Participants will receive a low-calorie (815-835 kcal/day; approximately 43% carbohydrate, 29% protein, and 29% fat) formula diet product for 12 weeks, followed by a gradual food reintroduction phase combined with physical activity support for 12 weeks.
214916463|NCT05472272|OTHER|Food-based diet|Participants will receive a low-calorie (815-835 kcal/day; 45-50% carbohydrate, 20-30% protein, and 20-30% fat) food-based diet created by dietitians for 12 weeks. After 12 weeks, participants will increase energy intake gradually and be encouraged to increase daily physical activity to maintain weight loss for another 12 weeks.
214916464|NCT05460351|DIETARY_SUPPLEMENT|BRJ+Nitrate|Participants in this group drank a 70 mL bottle of Beet It Sport drink with nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
214916465|NCT05460351|DIETARY_SUPPLEMENT|Control|Participants in this group drank a 70 mL bottle of Beet It Sport drink without nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
214916466|NCT04571645|DRUG|Dociparstat|Dociparstat is a glycosaminoglycan derived from porcine heparin.
214916467|NCT04571645|OTHER|Control|0.9% Normal Saline
214916468|NCT00379717|DRUG|Cisplatinum|
214916469|NCT00379717|DRUG|Docetaxel|
214916470|NCT00379717|DEVICE|Tomotherapy|
214916471|NCT04917159|BEHAVIORAL|ACT (Acceptance and Commitment Therapy) plus brief CHF education|The participants will identify their values and clarify their alternative behavior, exploring their thoughts and feelings, and finding ways to meet their own and their family member's needs. The rational bond between the patient and his/her family caregiver will be emphasized. In addtion, the contents of brief CHF education are based on the latest national clinical practice guideline for CHF, including symptoms monitoring, medication adherence, fluid and salt restriction, smoking cessation, alcohol consumption, and physical activity maintenance.
214309329|NCT07174232|OTHER|Russian current and muscle energy techniques|The participants will have the electrodes placed on their biceps and triceps muscles for the Russian current treatment and were positioned comfortably, typically in a supine or seated position, depending on the muscle group being targeted. This positioning ensured stability and allowed for the effective application of the MET .
214309330|NCT07174232|OTHER|Russian Current|The participants will have the electrodes placed on their biceps and triceps muscles for the Russian current treatment. For the biceps, one electrode will be placed on the middle of the muscle, about halfway between the shoulder and elbow, while the second electrode will be placed slightly above it, closer to the shoulder
214309331|NCT07180342|BEHAVIORAL|Tourism-based intervention|Following the acquisition of participant consent and the signing of (electronic) informed consent forms, subjects were randomized into either an intervention group or a control group using a computer-generated randomization list. The intervention group received a tourism-based intervention, while the control group continued to receive usual care without any structured modifications to their daily living patterns or treatment plans. Both groups maintained a foundational treatment regimen of antidepressant medication.
214916472|NCT04917159|BEHAVIORAL|HE (Health Education)|The educational contents are based on the latest national clinical practice guideline for CHF. Besides the basic information on CHF education provided in intervention group, the contents of CHF education also include definition of CHF, epidemiology, diagnosis, comorbidity, and CHF treatment. ACT components are not covered.
214916473|NCT01710202|DRUG|Hydrocortisone|Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
214346972|NCT03498248|DRUG|lenograstim|injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
214346973|NCT05913622|DEVICE|Intra-aortic balloon pump|An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
214480658|NCT06739525|DIAGNOSTIC_TEST|Standard Lenses (Control Group)|Participants in this arm wore standard lenses without any blue light-blocking properties. These lenses allow the full spectrum of visible light to pass through and serve as a baseline control to measure against the blue light-blocking glasses. Participants used these lenses under the same conditions to assess contrast sensitivity and visual fatigue without blue light filtration.
215060488|NCT01901614|PROCEDURE|LALAK|"1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
215060489|NCT01901614|PROCEDURE|IEK|"1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
215060490|NCT01901614|DRUG|Retrobulbar Block or General Anesthesia|
214346974|NCT00291785|DRUG|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 \& 29 of each 42-day cycle
214346975|NCT00291785|DRUG|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
214346976|NCT00291785|DRUG|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
214916474|NCT00838656|DRUG|carboplatin|Given IV in one of two schedules
214916475|NCT00838656|DRUG|gemcitabine hydrochloride|Given IV in one of two schedules
214916476|NCT00838656|DRUG|paclitaxel|Given IV in one of two schedules
214916477|NCT06510543|DIETARY_SUPPLEMENT|Goal-directed EN therapy|The participants will be administered a supervised goal-directed nutritional therapy. The enteral nutrition (EN) regimens include homemade meals with or without ORAL IMPACT® according to the daily goal.
214916478|NCT06510543|DIETARY_SUPPLEMENT|Conventional EN therapy|The participants will be administered the conventional nutritional therapy according to the Chinese expert consensus on perioperative nutritional support in enhanced recovery after surgery (2019 edition).
214916479|NCT01359332|PROCEDURE|Moderate hypothermia|procedure of moderate hypothermia therapy, between 32 ° and 34 ° C for 24 hours
214916480|NCT05906615|DRUG|Lidocaine IV|Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.
214670669|NCT01170156|DEVICE|Hi-Lo Evac tube (Mallinckrodt Inc, USA) (Instilled blue dye)|The cuff pressure will be first checked and reset at 30 cm H2O if needed. Next, blue dye will be instilled just above the cuff through the lumen ending in the subglottic area of the Hi-Lo Evac tube. Then a suctioning manoeuvre will be performed with a suction pressure of - 400 mbar through a 16 French suction catheter. Thereafter, a fiberoptic bronchoscopy will be performed, looking for the presence of blue dye in the trachea and/or the bronchi.
215060491|NCT01901614|DEVICE|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
215060492|NCT01901614|DRUG|Topical Anesthesia|
215060493|NCT01901614|DEVICE|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
215060494|NCT02506855|DRUG|Ropivacaine|
215060495|NCT02506855|OTHER|Placebo|
215060496|NCT02506855|PROCEDURE|Transversus Abdominis Plane Block|
215060497|NCT02478814|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
215060498|NCT05801146|DRUG|Botulinum Toxin Type A Injection [HG102]|Single administration, Day 0, 20 units
215060499|NCT05801146|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
215060500|NCT05937386|DRUG|AGMB-129|Oral capsule
215060501|NCT05937386|DRUG|MDZ|Pre-filled oral syringes
215060502|NCT00110435|DRUG|MK0653A, ezetimibe (+) simvastatin|
214346977|NCT00586105|DRUG|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
214346978|NCT01733654|BIOLOGICAL|RO4995819|The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
214346979|NCT00389558|PROCEDURE|disinfection efficacy using Biseptine|Detersion and antiseptic application when changing catheter dressing
214346980|NCT00389558|PROCEDURE|disinfection efficacy using Amukin|Detersion and antiseptic application when changing catheter dressing
214346981|NCT01507168|DRUG|Placebo|iv Days 1 and 8, and every 2 weeks thereafter
214346982|NCT01507168|DRUG|GC33|1600 mg iv Day 1 and 8, and every 2 weeks thereafter
214346983|NCT03835533|DRUG|NKTR-214 (Cohort A)|NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
215060503|NCT00110435|DRUG|Duration of Treatment: 4 wk placebo run in then 6 wk active|
215060504|NCT00110435|DRUG|Comparator: atorvastatin|
215060505|NCT06268184|DIETARY_SUPPLEMENT|D3 LAB SYRUP|omega 3 suplementation
214309332|NCT07181304|BEHAVIORAL|PROMOTE|"PROMOTE components includes 1) peer support, 2) remote patient monitoring of blood glucose (RPM), and 3) integration with clinical care.~1. Peer support delivered by community health workers focused on -- assistance in applying diabetes self-management in daily life, emotional and social support, linkage to clinical care, and ongoing, as-needed support. CHWs visits will include: one-on-one in-person visit, then weekly phone calls for 3 months, then monthly calls for 3 months.~2. RPM team will supply the device and supplies to participants. Data is transmitted electronically to the RPM team through broadband connectivity. Protocols have been developed for research projects; participants will be instructed to monitor blood glucose up to four times a day, based on medication regimen. Levels will be monitored 8 a.m. to 5 p.m. M-F.~3. A monthly report of peer support activities and RPM data will be sent to participants' primary care providers."
214309333|NCT07181304|BEHAVIORAL|DSMES|Diabetes Self-Management Education and Support delivered virtually.
214309334|NCT07180498|DRUG|Chlorhexidine Gluconate 0.12% Mouthwash|Participants will be prescribed to gargle with chlorhexidine, which is the routine recommendation after brushing their teeth 3 times a day for 7 days after the impacted tooth extraction.
214309335|NCT07180498|DRUG|Tea Tree Oil mouthwash|Participants will be prescribed to gargle with tea tree oil-containing water after brushing their teeth three times a day for 7 days following the extraction of an impacted tooth.
214309336|NCT07181161|DRUG|AZD0516|AZD0516 will be administered via intravenous infusion.
214309337|NCT07181161|DRUG|AZD9574|AZD9574 will be administered orally.
214309338|NCT07181330|DIAGNOSTIC_TEST|SE-SPTM-PCR microRNA assay|SE-SPTM-PCR (Selective Enrichment and Specific Probe Terminal Mediated PCR) is a microRNA-based diagnostic assay designed to detect hcmv-miR-UL22A-5p in human plasma. In this retrospective observational study, the assay is used on archived plasma samples collected from patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT). The purpose is to evaluate the diagnostic performance of this method in identifying CMV reactivation, compared to standard CMV DNA qPCR testing. This test was not assigned or administered as part of patient care but is the primary focus of retrospective laboratory analysis.
214309339|NCT07181278|OTHER|Mobile unit with quasi point of care HPV testing and immediate triage + treatment|"A mobile team consisting of one or two midwives and a lab technician with a Genexpert platform visits the health centres on a regular basis.~After informed consent is granted, participants perform a vaginal self-sample, which is immediately analyzed with the Genexpert plateform. Participants who test HPV positive are invited for immediate triage and treatment if required."
214309340|NCT07181278|OTHER|Centralized screening|Self-collected samples are sent to a reference laboratory for HPV testing. Results are communicated to the participants and HPV positive women are invited to go to the reference centre where triage and treatment (when required) are performed.
214309341|NCT07179653|DRUG|TVAX-008|TVAX-008
214309342|NCT07179653|DRUG|Placebo|Placebo
214309343|NCT07180888|DIAGNOSTIC_TEST|Echocardiography|diastolic dysfunction in ESKD in hemodialysis by echocardiography
214480659|NCT06735105|DIAGNOSTIC_TEST|Scanning parameter|Based on abdominal scanning, TSE-DWI,ZOOMIT DWI and EPI-DWI scans were performed, and the study was divided into two steps according to the nanomotion criteria. The first step was self-controlled, which was divided into experimental group and control group. The experimental group included TSE-DWI,ZOOMit DWI, and the control group included EPI-DWI. Then the image quality was evaluated by subjective and objective evaluation indexes. In the second step, the three DWI stages were performed separately by four diagnosticians, with an interval of 1 month, and statistical analysis was performed at the end.
214480660|NCT06743412|OTHER|Regular music listening|Regular listening of self-selected music sung in Italian language during the hospital stay and after discharge till the follow-up visit after 3 months.
214670670|NCT06342167|RADIATION|Radiotherapy|Interventions consist of 50-60 Gy in 25-30 fractions of radiotherapy.
214670671|NCT06342167|DRUG|Programmed Cell Death Protein 1 Inhibitor|200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.
215060506|NCT06268184|DIETARY_SUPPLEMENT|placebo syrup|placebo syrup contains purified water, glycerin, xanthan gum, tween 80, methyl paraben, propyl paraben, sorbitol solution70% and apple flavor.
215060507|NCT01836536|DRUG|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
215060508|NCT03138525|OTHER|Blood sampling (MS)|Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
215060509|NCT03138525|OTHER|Blood sampling (controls)|Blood samples will be collected once at enrollment.
215060510|NCT05700058|OTHER|Dietary protein supplement|3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants
215077753|NCT02439450|DRUG|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
215077754|NCT02439450|DRUG|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
214309344|NCT07180888|DIAGNOSTIC_TEST|Echocardiographic assessment of diastolic dysfunction|non invasive transthoracic echocardiography including doppler and tissue doppler imaging will be used to assess left ventricular diastolic dysfunction parameters in hemodialysis patient
214309345|NCT07181603|BEHAVIORAL|Resilience Enhancement Training Program|A structured 10-week behavioral training program designed to improve resilience and reduce perceived stress among nursing students. The program includes 10 sessions covering self-awareness, self-regulation, stress and coping strategies, cognitive restructuring, self-compassion, gratitude practice, optimism training, self-esteem, and a wrap-up with evaluation. Each session aims to strengthen coping skills and psychological adaptability.
214309346|NCT07181681|DRUG|BG-C0902|Administered by intravenous infusion
214309347|NCT05367544|BEHAVIORAL|Health Education|All participants will receive education regardless of randomization status. On the day of enrollment, participants will be invited to attend education modules focused on HTN risk, diet, physical activity, stress management, and goal setting. Participants will also have access to culturally relevant, weekly online sessions, alternating between cooking shows and exercise
214916481|NCT04933552|OTHER|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod, that have started before inclusion of the patient into the study will be enrolled.
214916482|NCT02218437|DRUG|MSC+ATG|MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
214916483|NCT01307904|OTHER|Glucose|Each healthy and Diabetic volunteers received 50 grams of glucose
214916484|NCT01307904|OTHER|Dates|Each healthy and diabetic volunteers received 50 grams equivalent of carbohydrates of each of the five selected dates, on five separate days.
214916485|NCT05287035|DRUG|Dexamethasone injection|Dexamethasone will be injected at the dosage recommended by the FDA.
214916486|NCT05287035|OTHER|Saline injection|Saline will be injected for the placebo arm of the study.
215060511|NCT04635150|BEHAVIORAL|Close Collaboration with Parents|Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
215060512|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 1 mg|Singel-dose; Subcutaneous
215060513|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 4 mg|Singel-dose; Subcutaneous
215060514|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 8 mg|Singel-dose; Subcutaneous
215060515|NCT04916392|DRUG|Liposomal bupivacaine|5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
215060516|NCT01158443|BEHAVIORAL|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
215060517|NCT01158443|BEHAVIORAL|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
215060518|NCT01168843|OTHER|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
215060519|NCT01538576|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
215060520|NCT03742570|BEHAVIORAL|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
215060521|NCT00773643|OTHER|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
215060522|NCT01823198|BIOLOGICAL|Aldesleukin|Given SC
215060523|NCT01823198|BIOLOGICAL|Allogeneic CD56-positive CD3-negative Natural Killer Cells|Given IV
215060524|NCT01823198|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplant
214309348|NCT05367544|BEHAVIORAL|Individual-Level Peer Support|Participants will receive bi-weekly peer support calls for 6 months, followed by monthly calls for another 6 months.
214309349|NCT05367544|BEHAVIORAL|Community-Level Peer Support|Church Leadership in churches randomized to intervention will identify 2-3 Peer Health Advocates from the church who will receive training on ways to promote a culture of health, encouraging church members to attend on-line cooking shows and exercise sessions. After training, these individuals will also work with Church Leadership to form a committee that will develop a project (e.g., community food pantry, farmer's market, Zumba instruction, small church gym) aimed at overcoming structural barriers to healthy behaviors. Each church will receive a small stipend for their project. Churches randomized to education alone will receive the community-level intervention after 12 months of participation in the study (delayed intervention)
214916487|NCT03583580|RADIATION|Accelerated Partial Breast Irradiation|Patients are irradiated to the region of tumour bed using intensity modulated radiation therapy (IMRT)
214916488|NCT04398004|DRUG|Clarithromycin|Treatment with 500 mg Clarithromycin orally twice daily for seven days
214916489|NCT02527733|DRUG|Ranibizumab|
215060525|NCT01823198|DRUG|Busulfan|Given IV
214916490|NCT02527733|DRUG|Ranibizumab and laser|
214916491|NCT05705739|PROCEDURE|retrolaminar block|curved probe will be placed 1-1.5 cm lateral to the target spinous process after identification of the lamina, the needle will be advanced caudally until it contacts the lamina
214916492|NCT05705739|PROCEDURE|ESPB|curved probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle.
214916493|NCT04143698|DEVICE|endoscopic retrograde cholangiopancreatography|The duodenoscope will be passed to the duodenum in the standard fashion. Once the papilla has been identified in the duodenum, cannulation of the desired duct will be performed in the standard fashion, with the type of accessories used left to the discretion of the individual endoscopist performing the procedure. If cannulation is considered difficult, advanced cannulation techniques can be used per standard of care at the discretion of the individual endoscopist. The types of accessories used will be left to the discretion of the individual endoscopist and will be dependent on procedure indication and personal preference. Cross-over to the alternate duodenoscope type can be performed at any time if the desired technical maneuver cannot be performed with the designated duodenoscope.
214916494|NCT03216122|PROCEDURE|Conventional/Delayed Loading|
214916495|NCT03216122|PROCEDURE|Immediate Loading|
214916496|NCT00665431|DRUG|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
214916497|NCT00665431|DRUG|celebrex|200 mg celecoxib qd
214916498|NCT00665431|OTHER|Placebo|sugar pill bid
214916499|NCT00665431|DRUG|Rescue Antacid|Antacid Tablets
215060526|NCT01823198|DRUG|Fludarabine Phosphate|Given IV
215060527|NCT01823198|OTHER|Laboratory Biomarker Analysis|Correlative studies
214916500|NCT05463380|OTHER|standard of care|The patient will be treated following the satndard of care in the participating units
214309350|NCT04860141|DRUG|Gabapentin 600mg|The patient will take gabapentin 600mg 2 hours prior to the procedure
214670672|NCT06342167|DIETARY_SUPPLEMENT|Immunonutrition support|600-1600 ml of TPF-T per day according to the nutrition status evaluation
214670673|NCT01236885|OTHER|computer-assisted intervention|Undergo blood glucose management using Glucommander
214670674|NCT03385356|DRUG|Vitamin D|Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
214916501|NCT00513383|DRUG|Panitumumab|Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
214916502|NCT00513383|DRUG|Carboplatin|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
214916503|NCT00513383|DRUG|Paclitaxel|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
214916504|NCT00513383|RADIATION|Intensity Modulated Radiation Therapy|Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
214916505|NCT00513383|DRUG|5-Fluorouracil|Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
214916506|NCT00513383|DRUG|Docetaxel|Intravenously on day 1 of a 21-day cycle for 3 cycles
214916507|NCT00513383|DRUG|Cisplatin|Intravenously on day 1 of a 21-day cycle for 3 cycles
214916508|NCT04337905|DEVICE|ADHD-VR diagnosis tool|"Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments."
214916509|NCT04097054|PROCEDURE|Augmented preoperative planning|The study investigates the impact of augmented preoperative planning on OR time variance in complex and rare visceral surgical procedures.
214916510|NCT01056237|DRUG|Multi-target therapy|Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
214916511|NCT01056237|DRUG|Azathioprine|1.0-2.0mg/kg/d
214916512|NCT06577545|BEHAVIORAL|Behavioural Lifestyle (BL)|24-week behavioural lifestyle intervention
215060528|NCT01823198|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
215060529|NCT01823198|OTHER|Pharmacological Study|Correlative studies
215077755|NCT02439450|DRUG|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
215077756|NCT00406705|BEHAVIORAL|Helium-Hyperoxia|
214309351|NCT04860141|DRUG|Placebo|the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
214309352|NCT02485912|BIOLOGICAL|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
214309353|NCT02485912|BIOLOGICAL|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
214309354|NCT02674178|PROCEDURE|Invitro fertilization|"All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days~Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm \[18\]~Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval"
214309355|NCT06075485|OTHER|Ketocal|ketogene diet
214309356|NCT06051942|DEVICE|Robotic Waterjet Treatment|The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System. During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.
214309357|NCT03181399|DRUG|Triheptanoin|. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
214309358|NCT05448482|PROCEDURE|Transobturator tape|Mid urethral sling for treatment of female stress urinary incontinence
214670675|NCT00609440|OTHER|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
214670676|NCT04119908|DEVICE|Sublingual videomicroscopy|Measurement of sublingual capillary density by video microscopy
214916513|NCT05536232|BEHAVIORAL|Low carbohydrate diet|Low carbohydrate diet under 75 g per day
214916514|NCT04881695|OTHER|Questionary patients|"The patients will answer 1 questionnaire consisting of 5 parts :~* General (demographic information)~* Desire for a child~* Hospital Anxiety and Depression scale~* Sexual life~* Additional questions regarding medical care"
215077757|NCT02538419|BEHAVIORAL|CPAP + Peer Support|
215077758|NCT02538419|BEHAVIORAL|CPAP + Individual Education|
215077759|NCT00118313|BIOLOGICAL|incomplete Freund's adjuvant|
215077760|NCT00118313|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
214916515|NCT04881695|OTHER|Questionary controls|"Witnesses will complete 1 survey containing 4 parts:~* General (demographic information)~* Desire to have a child~* Hospital Anxiety and Depression scale~* Sexual life"
214309359|NCT04274647|DEVICE|NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
214309360|NCT06796075|BEHAVIORAL|Mom♥Health|12-week intervention involving 1) weekly phone calls to mothers regarding education and counseling related to heart healthy lifestyle, as well as strategies for stress reduction; 2) referral to clinical care for identified needs (e.g., elevated blood pressure); and 3) referral to available social resources (e.g., food pantry for identified food insecurity).
214480661|NCT06883071|PROCEDURE|Endoscopic ultrasound (EUS)-guided spring plug combined with ECI|Group A: Spring plug combined with ECI under the guidance of endoscopic ultrasound (EUS): Spring plug was placed to limit the flow of varicose veins by EUS, and then tissue glue was injected under EUS to block the varicose veins. Group B: Titanium clip plus EUS-guided spring plug placement to limit the flow combined with ECI: After partial titanium clip flow limitation under endoscopy, spring coil combined with tissue glue injection was placed in the varicose veins by judging the inflow and outflow tracts under the guidance of ultrasound (EUS).
214916516|NCT03751839|DIAGNOSTIC_TEST|Biochemical Tests|The investigators will perform blood tests in every participant.
214480662|NCT06883071|PROCEDURE|Titanium clip plus EUS-guided spring plug placement for flow limiting combined with ECI|Group A: Spring plug combined with ECI under the guidance of endoscopic ultrasound (EUS): Spring plug was placed to limit the flow of varicose veins by EUS, and then tissue glue was injected under EUS to block the varicose veins. Group B: Titanium clip plus EUS-guided spring plug placement to limit the flow combined with ECI: After partial titanium clip flow limitation under endoscopy, spring coil combined with tissue glue injection was placed in the varicose veins by judging the inflow and outflow tracts under the guidance of ultrasound (EUS).
214916517|NCT03751839|DIAGNOSTIC_TEST|Osteodensitometry|The investigators will perform an osteodensitometry in every participant.
214916518|NCT03751839|DIAGNOSTIC_TEST|Clinical Tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, chair rise test and timed up and go test in every participant.
214916519|NCT03751839|DIAGNOSTIC_TEST|HR-QCT|The investigators will perform HR-QCT measurements of the proximal femur and tibia in every participant.
214916520|NCT03751839|DIAGNOSTIC_TEST|HR-pQCT|The investigators will perform HR-pQCT measurements of the distal radius and distal tibia in every participant.
214916521|NCT03119350|OTHER|Physical Training|"Intervention with concurrent physical training: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
214670677|NCT04119908|BIOLOGICAL|blood sample|Collection of citrate tubes of 5 mL at baseline and at 36 months
214670678|NCT02628223|PROCEDURE|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
214916522|NCT05738057|DRUG|Camrelizumab|200mg on day1 of every 3 weeks, starting on day1 of cycle1
214916523|NCT05738057|DRUG|Gemcitabine Injection|1000mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
214916524|NCT05738057|DRUG|Cisplatin injection|25mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
214916525|NCT05738057|DRUG|Cisplatin-Eluting Beads|used for D-TACE
214916526|NCT05738057|PROCEDURE|D-TACE|TACE with Cisplatin-Eluting Beads (with Cis 30mg). More TACE can be done if clinically necessary.
215060530|NCT02674464|BEHAVIORAL|Provider Audit-Feedback, Stratified by Race and Ethnicity|Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as \<140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
214309361|NCT01838031|OTHER|thyroid screening|The thyroid function and antibody will be measured immediately. The subclinical hypothyroidism will be treated individually.
214916527|NCT00748462|DEVICE|Fractional CO2 Laser|"the treatment settings:~1. Pulse duration : 5 to 7ms depending on skin reaction~2. Spot Density: 49 MTZ/cm2 (Low density)~3. Power: 15 W = (75 - 105) mJ/MTZ"
214916528|NCT02060838|PROCEDURE|Acute normovolemic hemodilution (ANH)|Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
214916529|NCT02285101|BIOLOGICAL|PEG-BCT-100|
214309362|NCT06793371|DRUG|CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)|CK-4021586 administered orally
214309363|NCT06793371|DRUG|Placebo to match CK-4021586|Placebo administered orally
214309364|NCT04723381|OTHER|web based education|Expert support and consultancy were received for the design and preparation of the web page.
214309365|NCT01216527|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Surgery|"1. Radiotherapy combined with concomitant chemotherapy:~   Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.~   neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.~   Number of cycles:two~2. surgery:Mckeown Modification Surgery and total two-field lymphadenectomy"
214309366|NCT01216527|PROCEDURE|surgery|two field lymphadenectomy
214309367|NCT04382833|OTHER|HOT APPLICATION|HOT APPLICATION
214916530|NCT01496950|DEVICE|10Hz active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
214916531|NCT01496950|DEVICE|Placebo|10Hz placebo rTMS delivered to the vertex
215077761|NCT00118313|BIOLOGICAL|sargramostim|
214309368|NCT04382833|OTHER|MASSAGE|
214480663|NCT06739434|GENETIC|GCB-002|GCB-002 is a self-complementary AAV9 carrying a full length human MECP2 transgenetic product.
214480664|NCT06736951|OTHER|MMSH (Multi-Modal Sleep Hygiene) Bundle|Focus on Noise Reduce Noise Perception, Reduce Hallway Noise, Reduce Noise in Rooms Focus on Light Reduce Lights at Night, Increase Light in Day, Reduce Light Perception Focus on Staff-Patient Interactions Delirium Screening, Avoid Care Procedures at Night, Z-time Plan \&amp; Prep Focus on Daytime Activity Increased Mobility, Increase Patient Engagement Focus on Medications Pain Management, Medication Monitoring, Continue pharmacy protocols, Timing of Medications/Monitoring Labs
214480665|NCT06889909|DRUG|Trelagliptin 100 mg|Trelagliptin 100 mg was administered orally once weekly before breakfast on the same day of the week.
214480666|NCT06889909|DRUG|Vildagliptin 50 mg|Vildagliptin 50 mg was administered orally once daily.
214480667|NCT06750861|DRUG|QL1706|QL1706+AG
214480668|NCT06742372|OTHER|combined inspiratory and aerobic exercise training|combined inspiratory and aerobic exercise training will be performed in healthy individuals
214480669|NCT06742372|OTHER|aerobic exercise training|aerobic exercise training will be performed in healthy individuals
214480670|NCT06755684|DRUG|Befotertinib combined Bevacizumab|Befotertinib combined Bevacizumab
214480671|NCT06755684|DRUG|Befotertinib combined platinum-based double chemotherapy|Befotertinib combined platinum-based double chemotherapy
214916532|NCT04958213|DRUG|Dextrose prolotherapy injection|15% dextrose prolotherapy injection into the knee and 15% dextrose prolotherapy injection will be applied to the painful adhesions of the ligaments around the knee.
214480672|NCT06751797|OTHER|No intervention|No intervention
214480673|NCT06755164|OTHER|Simultaneous aerobic and cognitive training (SIM)|The SIMULTANEOUS Group (SIM) will undergo15 minutes of stretching and preparatory mobilization + 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic and cognitive training, 5 minutes cool-down) + 15 minutes of mobilization and deep breathing (total: 70 minutes). Patients will perform the cognitive training sited on the cyclette using an adapted computer screen and a joystick.
214480674|NCT06755164|OTHER|Sequential aerobic and cognitive training (SEQ)|The SEQUENTIAL Group (SEQ) will undergo 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic training, 5 minutes cool-down), + 30 minutes of cognitive training (total: 70 minutes). Patients will perform the cognitive training after the aerobic training, sited on a desk using a computer and a joystick.
214480675|NCT06754618|DEVICE|Delfi|Cuffs will be worn throughout the entire training session. Training session consist of lower intensity bicep curls. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
214480676|NCT06754033|DIAGNOSTIC_TEST|Interventional group I|Intervention Details: Participants in this arm will receive a Ganglion Impar Block, a minimally invasive injection aimed at blocking pain signals from the coccyx region (Ganglion Impar Block using Triamcinolone Acetate (40 mg) and Bupivacaine (0.25%) administered with a 22G Spinal Needle under Fluoroscopic Guidance). Participants in this arm will receive a Ganglion Impar Block, a minimally invasive procedure involving the administration of Triamcinolone Acetate (a corticosteroid) and Bupivacaine (a local anesthetic). This is intended to block pain signals originating from the coccyx region. The procedure will be conducted under fluoroscopic guidance to ensure precise delivery. The injection will be complemented by a structured physical therapy program, including heat therapy, ultrasound, posture training, core strengthening exercises, and mobility activities to improve pain relief and functional capacity.
214480677|NCT06754033|COMBINATION_PRODUCT|Interventional group II|Intervention Details: Participants in this arm will receive a Caudal Epidural Steroid Injection Caudal Epidural Steroid Injection using Triamcinolone Acetate (40 mg), Bupivacaine (0.25%), and Normal Saline (6 mL) administered with a 22G Spinal Needle under Fluoroscopic Guidance), designed to deliver anti-inflammatory medication directly to the epidural space, thereby reducing inflammation and pain. This will also be paired with a tailored physical therapy program, focusing on similar modalities as in Arm 1, including heat therapy, ultrasound, posture training, and strengthening exercises. The objective is to enhance pain relief and functional recovery in the context of coccydynia.
214916533|NCT04958213|COMBINATION_PRODUCT|conventional physical therapy|4 weeks (20 sessions) physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises).
214916534|NCT02550379|BEHAVIORAL|Intervention|Emotion Recognition Training
214916535|NCT02550379|OTHER|Placebo|Placebo Training
214916536|NCT02446210|DEVICE|Magstim 200|Transcranial Magnetic Stimulation
214916537|NCT02446210|DEVICE|Digitimer electrical stimulator|Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
214916538|NCT05102682|OTHER|Balance exercise program using exoskeleton device|Exercise program focused on strengthening core body muscles and balance supported by Rex exoskeleton device
214916539|NCT01702220|BEHAVIORAL|CBT|6-12 sessions of CBT in person or over the phone
214916540|NCT01702220|OTHER|ECC|6 biweekly sessions of ECC over the telephone
214309369|NCT05123222|BIOLOGICAL|ZIKV-SJRP/2016-184 Strain|Zika Virus Strain (San Jose Rio Puerto)
214309370|NCT05123222|BIOLOGICAL|Experimental: ZIKV-Nicaragua/2016 Strain|Zika Virus Strain (Nicaragua)
214309371|NCT05123222|BIOLOGICAL|Placebo|Saline
214309372|NCT00265343|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
214309373|NCT00265343|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
214309374|NCT02423863|BIOLOGICAL|Hiltonol|"Wk 1 Days 1, 3 and 5: Poly-ICLC (Hiltonol®) 1 mg (0. 5 ml) IntraTumoral (priming treatment course). Weeks 2-25 Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND either:~No additional immunotherapy OR~ONLY ONE of the Anti-PD1 or anti-PDL-1 regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows: (Not to be Administered on the same day as Poly-ICLC \[Hiltonol®\]) Either Nivolumab, OR Pembrolizumab, OR Atezolizumab, OR Cemiplimab, OR Durvalumab"
214309375|NCT04865354|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
214309376|NCT04865354|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
214916541|NCT01021462|PROCEDURE|Comparator: graded infusion of intravenous glucose|A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
214309377|NCT00706641|DRUG|Dasatinib|Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
214480678|NCT06740318|OTHER|Motivational enhancement therapy|The intervention consists of three motivational interviews with the focus to enhance the participants motivation to enter treatment of alcohol use disorder. the interviews are structured and based on the model Motivational enhancement therapy.
214916542|NCT06576713|DIAGNOSTIC_TEST|Combiner whole genome and RNA sequencing|High-throughput DNA and RNA sequencing
214916543|NCT00040274|DRUG|DPC 817|
214916544|NCT05954390|DIETARY_SUPPLEMENT|Undenatured beta-glucan solution|The active comparator is a solution containing undenatured beta-glucans
214916545|NCT05954390|OTHER|Placebo|The placebo comparator is the same solution as the active therapy except it does not contain any undenatured beta-glucans
214916546|NCT01992172|DRUG|Photocil for Atopic Dermatitis|Photocil for Atopic Dermatitis
214916547|NCT01992172|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
214916548|NCT02935712|DRUG|AZD8601+Placebo (SAD)|"Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.~Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg."
214916549|NCT02935712|DRUG|AZD8601+Placebo|Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
214916550|NCT02935712|DRUG|Placebo+Placebo|Subjects are randomized to receive 2 placebo treatments.
214916551|NCT04255576|DIETARY_SUPPLEMENT|Dietary Supplement: Calcium/Vitamin D|All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
214916552|NCT03631680|PROCEDURE|Bilateral Oophorectomy Surgery|Women undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.
214916553|NCT04124731|DRUG|sintilimab plus anlotinib|Sintilimab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21
214916554|NCT04124731|DRUG|Chemotherapy|"1. Pemetrexed combined with platinum regimen (non-squamous cell carcinoma): pemetrexed 500mg/m2, intravenous infusion on the first day of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle, 1 cycle every 3 weeks (Q3W), 4 cycles in total. Patients who did not progress after 4 cycles received maintenance monotherapy with pemetrexide at the same dose as before.~2. Gemcitabine combined with platinum regimen (squamous cell carcinoma): gemcitabine 1250mg/m2, intravenous infusion on day 1 and day 8 of each cycle, cisplatin: 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, 1 cycle every 3 weeks (Q3W), 4-6 cycles in total."
214916555|NCT01583140|BEHAVIORAL|Wellness control|Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.
214916556|NCT01583140|BEHAVIORAL|Physical Activity Intervention|Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
215060531|NCT02674464|BEHAVIORAL|Blood Pressure Measurement Standardization|"All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures."
214480679|NCT06769581|PROCEDURE|Infraclavicular Brachial Plexus Blocks|Lateral sagittal technique infraclavicular brachial plexus block
215077762|NCT00118313|BIOLOGICAL|tetanus toxoid helper peptide|
214309378|NCT00706641|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
214309379|NCT05047081|BEHAVIORAL|Scoring Your College Goals Workshop|A two-hour virtual college readiness workshop.
214309380|NCT05047081|OTHER|Placebo|Placebo Treatment-As-Usual Group which does not receive the workshop intervention
214309381|NCT01990274|PROCEDURE|GeneXpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
214309382|NCT01990274|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
214309383|NCT01112527|DRUG|PF-00299804|Taken orally once a day
214309384|NCT02397330|DRUG|bupivacaine|
214309385|NCT02397330|DEVICE|ultrasound|ultrasound guided nerve blocks
214916557|NCT04931277|PROCEDURE|cataract surgery|stepped surgery in the form of primary phacoemulsification and secondary posterior chamber intraocular lens (PCIOL) implantation in patients with uveitis.
214916558|NCT05610397|DEVICE|STALIF®|STALIF® C, or M, Ti or FLX
214916559|NCT04073927|DIETARY_SUPPLEMENT|Sodium butyrate|"Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane."
214916560|NCT06578260|BEHAVIORAL|Peer support groups with a solution-focused approach|To investigate the effectiveness of a support group intervention using a solution-focused approach among school children in 5th-7th grade in southeastern Norway
214916561|NCT02189031|DEVICE|Tactor array|
214916562|NCT02189031|DEVICE|Bypass Tactor|
215077763|NCT00118313|DRUG|dimethyl sulfoxide|
215077764|NCT00118313|DRUG|imiquimod|
214309386|NCT02397330|DRUG|morphine|
214309387|NCT06311890|DRUG|N-chlorin e6 triglumine|a photodynamic therapy with chlorin-e6
214309388|NCT06311890|PROCEDURE|acne removal surgery|acne removal surgery will be given before red light exposure
215077765|NCT00118313|PROCEDURE|adjuvant therapy|
215077766|NCT00006441|DRUG|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
215077767|NCT00006441|DRUG|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
214309389|NCT05041296|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters
214309390|NCT00003120|DRUG|paclitaxel|135 mg/m2 IV every 28 days
214309391|NCT02229318|DIETARY_SUPPLEMENT|FruitiVits|Daily administration of FruitiVits dietary supplement
214309392|NCT05279586|DRUG|lactulose|all interventions are used in secondary prophylaxis in cirrhotic patients
214309393|NCT05279586|DRUG|colistin|all interventions are used in secondary prophylaxis in cirrhotic patients
214309394|NCT00615277|DIETARY_SUPPLEMENT|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
214480680|NCT06759584|DRUG|Dexamethasone|To Compare clinical outcome of dexamethasone phonophoresis in a (continuous and pulsed) maneuver for management of Temporomandibular Disorders
214916563|NCT06416774|DRUG|68Ga-HX01 Injection(0.05mCi/kg)|"The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments."
214916564|NCT06416774|DRUG|68Ga-HX01 Injection(0.1mCi/kg)|"The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments."
215077768|NCT00006441|DRUG|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
215077769|NCT00068913|DRUG|Dichloroacetate|
214309395|NCT04881357|OTHER|test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
214309396|NCT04881357|OTHER|control group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
214309397|NCT04296552|OTHER|Dietary lowFODMAP intervention|Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
214309398|NCT02515942|DRUG|CLG561|
214309399|NCT02515942|DRUG|LFG316|
214309400|NCT02515942|DRUG|Sham injection|Empty syringe (without a needle) placed against the eye
214309401|NCT03335982|PROCEDURE|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
214309402|NCT01734564|BIOLOGICAL|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
214309403|NCT01734564|RADIATION|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
214309404|NCT00654277|DRUG|Ondansetron|ODT, 8 mg, single-dose
214309405|NCT00654277|DRUG|Zofran|ODT, 8 mg, fasting conditions
214346984|NCT03835533|DRUG|Nivolumab (Cohort A, B and C)|Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
214346985|NCT03835533|RADIATION|Stereotactic body radiation therapy (SBRT) (Cohort B)|Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
214346986|NCT03835533|DRUG|CDX-301 (Cohort B and C)|CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
214346987|NCT03835533|DRUG|Poly-ICLC (Cohort B)|Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
214346988|NCT03835533|DRUG|INO-5151 (Cohort C)|INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
214346989|NCT03835533|DEVICE|Cellectra 2000|Electroporation device
214346990|NCT05213845|PROCEDURE|Spine flexion/extension active range of motion exercises|Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
214346991|NCT04622358|DRUG|AD-214-02|1 tablet administered before the breakfast during 7 days
214346992|NCT04622358|DRUG|Rabeprazole|1 tablet administered before the breakfast during 7 days
214346993|NCT04144400|BEHAVIORAL|Direction Check App|Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.
214346994|NCT04144400|BEHAVIORAL|Direction Check App (Time Management Version)|Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
214346995|NCT03812458|BEHAVIORAL|website and brochure|website and brochure
214346996|NCT03867734|DRUG|Aztreonam|2g IM Aztreonam
214346997|NCT02696005|OTHER|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
214346998|NCT01136291|OTHER|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
214309406|NCT01810666|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
214309407|NCT02528162|BEHAVIORAL|education|Evaluation of education for GDM
214309408|NCT00919399|DRUG|Exemestane|25mg a day during 4 months
214309409|NCT00919399|DRUG|tamoxifen|One 20 mg tablet a day started 1 week after the first Aromasine intake
214309410|NCT00902564|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
214309411|NCT01901003|DRUG|Lorazepam|
214480681|NCT06826092|DRUG|Metformin Pill|Metformin 500mg TID、FOLFIRI (Leucovorin 200 mg/m2、5-FU 2800 mg/m2、Irinotecan 180 mg/m2) plus target therapy
214480682|NCT06826092|DRUG|FOLFIRI plus target therapy only|FOLFIRI (Leucovorin (LV), 200 mg/m2, 2-hour infusion, 5-FU, 2,800 mg/m2, 46-hour infusion, Irinotecan (IRI), 180 mg/m2, 2-hour infusion) plus target therapy
214480683|NCT06815731|PROCEDURE|lateral laparoscopic suspension (LLS)|lateral laparoscopic suspension (LLS)
214480684|NCT06815731|PROCEDURE|Sacropexy without posterior mesh fixation on the puborrectalis muscle|Sacropexy without posterior mesh fixation on the puborrectalis muscle
214480685|NCT06055608|DRUG|Sirolimus|Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight \<40 kg will receive 3mg/m\^ 2, with maintenance dose of 1 mg/m\^2 divided BID - weight \>= 40kg will receive 6mg/m\^ 2, with maintenance dose of 2 mg daily
214480686|NCT06055608|BIOLOGICAL|Belatacept|Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24
214480687|NCT06055608|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil-MMF will be initiated at 600 mg/m\^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m\^2 BID
214480688|NCT06055608|DRUG|Tacrolimus (Group1)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant
214480689|NCT06055608|DRUG|Anti-Thymocyte Globulin (ATG)|Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function
214480690|NCT06055608|DRUG|Tacrolimus (Group 2)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels
214916565|NCT06416774|DRUG|68Ga-HX01 Injection(0.07mCi/kg)|"The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments."
214916566|NCT03881189|DEVICE|SUNEKOS® 200|The intradermal injection procedure was performed bilaterally, on the area around the eyes including the eyelids, using periosteal and subepidermal injection techniques. This injective procedure consists of micro-wheals of 0.2 ml just above the periosteum and micro-wheals of 0.1 ml very superficially, just under epidermis.
214916567|NCT01035294|BEHAVIORAL|mindfulness based intervention (MBI)|Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.
214309412|NCT01901003|OTHER|no premedication|
214309413|NCT01901003|DRUG|Placebo (microcrystalline celluloses)|
214309414|NCT02793518|BEHAVIORAL|psychological tests|
214309415|NCT00922766|DRUG|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).
214309416|NCT00843713|DRUG|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
214309417|NCT00843713|DRUG|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
214309418|NCT02200848|DRUG|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
214309419|NCT02134873|OTHER|sucrose|Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
214309420|NCT02597556|DRUG|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
214309421|NCT02597556|DRUG|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
214309422|NCT03508856|DRUG|Ingenol Mebutate (Picato®) 0.015% gel|
214309423|NCT00576277|DRUG|AV411|
214670679|NCT02628223|DEVICE|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
214670680|NCT05578521|DRUG|Cerebralcare pills|a dose of 2 packages, twice a day of Cerebralcare pills
214670681|NCT05578521|DRUG|Cerebralcare pills placebo|Cerebralcare pills placebo will be administrated at the same rate with experimental group
214916568|NCT01035294|BEHAVIORAL|usual care|The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
214916569|NCT04102267|DRUG|Bupivacaine liposome injectable suspension|Liposomal bupivacaine 266 mg via injection
214309424|NCT04426565|BEHAVIORAL|motivational enhancement interview|Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
214309425|NCT04426565|BEHAVIORAL|the individual psychotherapy|It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
214916570|NCT04102267|DRUG|Bupivacaine HCl without epinephrine via continuous infusion|Bupivacaine HCl 300 mg via continuous infusion
214916571|NCT01812954|DRUG|Methotrexate|
214916572|NCT01812954|DRUG|Cyclosporins|
214916573|NCT01812954|DRUG|fumaric acid|
214309426|NCT04426565|BEHAVIORAL|the group psychotherapy|Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.
214480691|NCT05367037|DEVICE|PhysioVP|The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.
214480692|NCT05367037|DEVICE|DDD-VPA|In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
214670682|NCT00720707|PROCEDURE|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
214670683|NCT00720707|PROCEDURE|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
214670684|NCT00787735|BEHAVIORAL|Counseling compliance|Rates of attendance to call counseling session over specific time points
214916574|NCT01812954|DRUG|Acitretin|
214670685|NCT02552407|DEVICE|Manual Aspiration Thrombectomy|Thrombus aspiration
214670686|NCT00114907|BEHAVIORAL|Consumption of black tea|
214916575|NCT01812954|DRUG|Infliximab|
214916576|NCT01812954|DRUG|etanercept|
214916577|NCT01812954|DRUG|Adalimumab|
214916578|NCT01812954|DRUG|Ustekinumab|
214916579|NCT04471194|DIAGNOSTIC_TEST|Self-sampling HPV test|Tests for human papillomavirus from cervical cell sample
214916580|NCT04471194|DIAGNOSTIC_TEST|Fecal occult blood test|Tests for human hemoglobin from blood in fecal samples
214916581|NCT05629780|DRUG|Resuscitation fluid|Cristalloid fluids given as a resuscitational intervention
214916582|NCT04417855|DIAGNOSTIC_TEST|G-Walk|"Every individual will be examined with a non-invasive G-Walk device which is a sensor mounted on a belt and fasten on individuals' lumbar spine region during two test activities: Timed up and go and 6-meter walk tests. Data collection will include kinematic parameters. Oswestry Disability Index (ODI) score will also be collected."
214916583|NCT02123589|DRUG|Deep sedation(midazolam and fentanyl )|0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
214916584|NCT02123589|DRUG|Deep and daily interruption of sedation(midazolam and fentanyl )|0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
214916585|NCT02123589|DRUG|Light sedation(midazolam and fentanyl )|0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; The target level of sedation,RASS score between -2 and +1;
214916586|NCT02630173|PROCEDURE|Scaling and root planing|Scaling and root planing was done in both the groups
215077770|NCT01460355|DRUG|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
214670687|NCT05047393|OTHER|Current blood vitamin D level and painDetect questionairre score will be detected|PainDETECT neuropathic pain questionnaire will be used to evaluate the presence of nociceptive, mixed and neuropathic pain in patients. Patients with a total questionnaire score of 12 or less are considered nociceptive pain without a neuropathic pain component. If the total score is in the range of 13-18, the result is uncertain, but it is accepted that the neuropathic component can be found in the mixed type, and in the scores of 19 and above, it is accepted that the neuropathic pain component is present. Patients with previously obtained and finalized vitamin D levels \< 20 ng/mL, 20-30 ng/mL, and ˃30 ng/mL will be grouped as deficiency, insufficiency and normal, respectively.
214670688|NCT01769404|BIOLOGICAL|LY2605541|
214670689|NCT01769404|BIOLOGICAL|Insulin Glargine|
214670690|NCT01859429|OTHER|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
214670691|NCT03088423|RADIATION|SBRT delivers high dose selective irradiation with millimeter precision to a small volume. The Cyberknife® is a robotic SBRT dedicated device that can deliver 100 to 200 photobeams to the target|Seven to ten days before the scheduled CT, 2-4 fiducial markers were implanted percutaneously 2 to 5 cm next to the lesion under sonographic guidance following administration of local anesthesia, thus allowing real-time tracking during treatment. The total dose delivered was 45 Gy on the 80% isodose, in three fractions over 10 days. Gross tumor volume (GTV) was defined as the tumor mass that could be discerned by diagnostic imaging. An isotropic margin of 5 mm was added to account for the microscopic extension (clinical target volume, CTV) and another 3 mm margin was added to compensate for uncertainties regarding the position (previsional target volume, PTV)
214670692|NCT01214512|OTHER|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
214670693|NCT00108810|DRUG|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
214309427|NCT04426565|BEHAVIORAL|the family therapy|"According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence."
214309428|NCT03647540|PROCEDURE|fluorescent laparoscopic radical gastrectomy|The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
214309429|NCT03647540|PROCEDURE|traditional laparoscopic radical gastrectomy|The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
214670694|NCT00108810|DRUG|Placebo transdermal patch|12 hours application for 28 days
214670695|NCT02444169|DEVICE|Ultherapy|Focused ultrasound energy delivered below the surface of the skin.
214670696|NCT02444169|DRUG|Incobotulinumtoxin A|An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
214670697|NCT02444169|DEVICE|Radiesse|An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
214670698|NCT02444169|DEVICE|Belotero Balance|An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
214670699|NCT05870475|DRUG|Ruxolitinib|Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.
214670700|NCT05870475|DRUG|Pegylated interferon α-2b|Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.
214670701|NCT02050932|DIETARY_SUPPLEMENT|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
214670702|NCT00538733|DRUG|thalomid|"Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)"
215060532|NCT02674464|BEHAVIORAL|System Level Leadership Intervention|"This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase."
215077771|NCT01460355|DRUG|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
215077772|NCT04763486|DRUG|Cefazolin (Cefamezin)|Cefamezin 2 gr within 6 hour of delivery
214309430|NCT02935465|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
215077773|NCT05482815|DEVICE|Provox Vega Voice prosthesis|Voice prosthesis for speech rehabilitation, Provox Vega Voice prosthesis
214309431|NCT02935465|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
214309432|NCT04707261|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10 mg once daily
214309433|NCT04707261|DRUG|Placebo|Participants will receive placebo 10 mg once daily
214309434|NCT01649375|DRUG|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
214670703|NCT00538733|DRUG|lenalidomide|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle"
214670704|NCT00538733|DRUG|clarithromycin|"During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)"
214916587|NCT02630173|OTHER|Endodontic treatment|In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
214670705|NCT00538733|DRUG|dexamethasone|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)"
214916588|NCT00894270|PROCEDURE|Sterile air injection|Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.
214916589|NCT00894270|PROCEDURE|Placebo injection|Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.
214916590|NCT00894270|DEVICE|Novofine needle|Novofine 5mm needle
214916591|NCT00757042|DRUG|Tezepelumab|Administered by subcutaneous or intravenous injection
214916592|NCT00757042|DRUG|Placebo|Matching placebo administered by subcutaneous or intravenous injection.
214916593|NCT02915705|BIOLOGICAL|burosumab|solution for subcutaneous (SC) injection
214916594|NCT02915705|DRUG|Oral Phosphate Supplement|oral tablet; oral solution; oral powder
214916595|NCT02915705|DRUG|active vitamin D|tablet, oral solution
214916596|NCT02508077|DRUG|Fluorouracil|Given IV
214916597|NCT02508077|DRUG|Irinotecan Hydrochloride|Given IV
215060533|NCT02674464|BEHAVIORAL|Collaborative Care Team Intervention|The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, nurse, or social worker care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
215060534|NCT02674464|BEHAVIORAL|Community Health Worker Referral|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
215060535|NCT02674464|BEHAVIORAL|Specialist Care Consultation|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
215060536|NCT04672980|DRUG|RTX-321|RTX-321 monotherapy
215060537|NCT02078024|DRUG|IVM plus ALB|
215060538|NCT02078024|DRUG|IVM|
215060539|NCT05272722|DIAGNOSTIC_TEST|ECG,|Holter monitoring
215060540|NCT00637624|DRUG|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
215060541|NCT00637624|DRUG|Placebo|Placebo once every 3 weeks intravenous saline fluid
215060542|NCT00783835|DRUG|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
215060543|NCT01262638|DRUG|ETC-1002|ETC-1002 daily for 12 weeks
215060544|NCT01262638|DRUG|Placebo|Placebo daily for 12 weeks
215060545|NCT04414813|BIOLOGICAL|Human Amniotic Epithelial Stem Cells|Stereotactic transplantation of hAESCs for participants with PD.
214309435|NCT01649375|DRUG|Placebo|Placebo
214309436|NCT01649375|DRUG|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
214309437|NCT04939727|OTHER|OUD-CDS + Suicide Risk Model associated CDS|Access to OUD-CDS + Suicide Risk CDS
214309438|NCT01776788|DRUG|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
214309439|NCT01776788|DRUG|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
214309440|NCT03012113|DRUG|Mirabegron|
214309441|NCT03012113|OTHER|Short term mild cooling|
214309442|NCT03012113|DRUG|Placebo Oral Capsule|
214309443|NCT01762943|DRUG|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
214309444|NCT01762943|DRUG|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
214309445|NCT01762943|DRUG|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
215060546|NCT03794440|DRUG|Sintilimab|200mg IV d1， Q3W
215060547|NCT03794440|DRUG|IBI305|15mg/kg IV d1， Q3W
215060548|NCT03794440|DRUG|Sorafenib|400mg PO BID
215060549|NCT04079231|DRUG|Brolucizumab|Intravitreal Injection
215060550|NCT04079231|DRUG|Aflibercept|Intravitreal injection
215060551|NCT04773288|OTHER|Live feedback during handwashing|Live feedback provided during handwashing on display
215060552|NCT04732442|DIETARY_SUPPLEMENT|Immunonutrition|Impact Oral® Nestle, Switzerland
214916598|NCT02508077|OTHER|Laboratory Biomarker Analysis|Correlative studies
214916599|NCT02508077|DRUG|Leucovorin Calcium|Given PO
214309446|NCT00539838|DRUG|Prednisone|Oral repeating dose
214309447|NCT00539838|DRUG|Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
214309448|NCT00539838|DRUG|Methylprednisolone|Intravenous repeating dose
214309449|NCT00539838|DRUG|Ocrelizumab|Intravenous repeating dose
214309450|NCT00539838|DRUG|Placebo|Intravenous repeating dose
214309451|NCT00880529|DEVICE|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
214309452|NCT00880529|DRUG|IV opioid administration|Patient controlled analgesia with IV narcotics
214309453|NCT04409288|DRUG|Apalutamide|Androgen receptor inhibitor.
214309454|NCT04409288|DRUG|Enzalutamide|Androgern receptor inhibitor
214309455|NCT04227184|DRUG|Trospium|Drug to treat overactive bladder
214309456|NCT04227184|DRUG|Placebo oral tablet|Placebo tablet containing no active drug
214309457|NCT04145258|DRUG|Aspirin|Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
214309458|NCT04145258|DRUG|Placebo of aspirin|Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
214309459|NCT04145258|DRUG|WHO TBM treatment|2 months of (R-H-Z-E) + 7 months of (R-H)
214916600|NCT02508077|BIOLOGICAL|Panitumumab|Given IV
214916601|NCT04019782|DRUG|Collagen-PVP|Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine, administered by intraarticular injections (three doses, one each 7 days)
214309460|NCT04145258|DRUG|Intensified TBM treatment|2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
214309461|NCT02347566|BEHAVIORAL|Physical activity enhancing programme|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
214670706|NCT00986193|PROCEDURE|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
214309462|NCT02347566|OTHER|Usual care|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
214309463|NCT02534831|PROCEDURE|Soft tissue manual therapy protocol|The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
214309464|NCT00231101|DRUG|Quetiapine|
214309465|NCT00771433|BIOLOGICAL|filgrastim|Given subcutaneously
214670707|NCT00986193|PROCEDURE|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
214916602|NCT04019782|DEVICE|Hylan G-F 20|Infiltrations of 2 mL 0.8% Hylan G-F 20 (16 mg) solution, administered by intraarticular injections (three doses, one each 7 days)
214916603|NCT04881864|BEHAVIORAL|Tele-Enhance Fitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
214916604|NCT06043505|OTHER|Echographic hemodynamic algorithm guiding fluid resuscitation|"Ultrasound Hemodynamic Algorithm (UHA):~1. st step: 1/ Assessment of left ventricular filling pressures by Mitral Doppler echocardiography (2) 2/ Pulmonary ultrasound on 4 anterior dials (3)~   E/Ea \>14 and/or E/A \>2~  * YES =\> No filling test =\> Bilateral anterior B lines on lung ultrasound =\> YES =\> Consider administration of diuretics~  * NO =\> Step 2~2. nd step: Assessment of filling response by dynamic maneuvers VTI (Velocity Time Integral) increase \>15% after passive leg raising (4) or Mini-fluid challenge (5,6) Or decision of a 250ml filling test~   * YES =\> consider 250ml bolus filling~  * NO =\> stop vascular filling~3. rd step if dynamic maneuvers in favor of a response to filling: 1/ Assessment of response to 250ml filling 2/ If no response to vascular filling: Pulmonary ultrasound on 4 anterior dials (3) Change from a pulmonary profile A to a pulmonary profile B~   * YES =\> depletion~  * NO =\> stop vascular filling"
214916605|NCT00263705|DRUG|Adjuvant capecitabine|Capecitabine 2000 mg/m² daily six cycles
214309466|NCT05886166|OTHER|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
214309467|NCT02658890|DRUG|BMS-986205|
214309468|NCT02658890|DRUG|Nivolumab|
214309469|NCT02658890|DRUG|Ipilimumab|
214309470|NCT04498793|BIOLOGICAL|Tislelizumab|On Day 1 of the last seven cycles in the neoadjuvant and each cycle in the adjuvant phases of the study for a total of 21 cycles; intravenous (IV) infusion.
214309471|NCT04498793|DRUG|Nab paclitaxel|On Days 1 and 8 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
214309472|NCT04498793|DRUG|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
214309473|NCT04498793|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
214309474|NCT04498793|DEVICE|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
214309475|NCT02484495|OTHER|Program evaluation (impact assessment)|"The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.~Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day."
214670708|NCT06304272|PROCEDURE|Irrigating Traumatic Wound with Drinking Water|Irrigating Traumatic Wound with Drinking Water and Normal Saline
214670709|NCT02768129|DEVICE|transcranial direct current stimulation|active stimulation: 2 milliamp (mA), 20 mins
214309476|NCT02474199|BIOLOGICAL|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
214309477|NCT02474199|DRUG|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
214309478|NCT02474199|DRUG|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
214309479|NCT02474199|DRUG|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
214309480|NCT02474199|PROCEDURE|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
214309481|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product II 150 mg by mouth
214309482|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product I 150 mg by mouth
214309483|NCT00344383|DRUG|Norgestimate/Ethinyl Estradiol tablet|
214309484|NCT06438861|DRUG|Vibegron 75mg|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
214480693|NCT06298838|DEVICE|AURA10® Specimen PET/CT imager|The AURA10 PET-CT specimen imager detects and measures the electron density distribution of a specimen and the radiotracer distribution within a specimen. The function of the system is to acquire and visualize PET and CT images of a specimen, based on which a healthcare professional can rapidly verify whether the correct tissue has been resected. It can be used in any condition that requires resection surgery to visualize the resected specimen. The device is automated and semi-quantitative, i.e., qualitative regarding visualization of structure and radiotracer distribution and quantitative regarding tissue density (Hounsfield units) and radiotracer uptake in the specimen (Bq/ml). The type of specimen required is resected tissue from a patient undergoing resection surgery.
214480694|NCT05952141|BEHAVIORAL|Clinic Outreach|A member of the pathology team will contact the referring clinic to communicate the readiness of results.
214480695|NCT05952141|BEHAVIORAL|Enhanced Outreach|A member of the pathology team will contact both the referring clinic and the patient directly to communicate the readiness of results.
214480696|NCT05952141|BEHAVIORAL|Low-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging.
214916606|NCT00263705|DRUG|capecitabine in aduvant setting|capecitabine in aduvant setting in ederly with breast cancer
214916607|NCT00002205|DRUG|Abacavir sulfate|
214309485|NCT06438861|DRUG|Placebo|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
214309486|NCT01438970|DEVICE|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
214480697|NCT05952141|BEHAVIORAL|High-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging in combination with synchronous telephone-based patient navigation.
214480698|NCT06499415|DRUG|5FU-Calcipotriol|topical 5FU-CAL, twice daily, during 4 or 6 consecutive days, depending on the treatment location
214480699|NCT06499415|DRUG|5-FU 50 MG/ML Topical Cream|topical 5FU, twice daily, 7 days a week, during 4 weeks
214480700|NCT06656169|DRUG|Subcutaneous polyvidone collagen|Use collagen-polyvidone at a dose of 0.2 ml, applied to the affected area of the hand.
214480701|NCT06656169|OTHER|saline solution|administer saline solution at a dose of 0.2 ml, applied to the affected area of the hand.
214916608|NCT00002205|DRUG|Amprenavir|
214916609|NCT01039727|OTHER|care as usual + 5 specific CDs|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
214916610|NCT01039727|OTHER|care as usual + email assistance + AurelisOnLine (AoL) + CDs|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
214916611|NCT06134427|OTHER|basic combat training (investigator did not design the intervention)|12 weeks basic combat training is 12 weeks is a compulsory program for all cadets accepted in republic indonesia defense university
214916612|NCT01870973|PROCEDURE|root canal treatment, anesthesia, pain medications, and antibiotic|Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.
214916613|NCT01870973|PROCEDURE|no root canal treatment, anesthesia, pain medications, and antibiotic|
214916614|NCT04668079|OTHER|Modified cross body stretch|"Athlete was in side lying positioned. trunk was moved posteriorly 200 to 300 and shoulder is raised to 900 and semi flex both knees. Athlete was ask to passively pull the humerus across the body into horizontal adduction with the opposite hand.~5 reps once daily 3 sets for 4 weeks was given"
214916615|NCT04668079|OTHER|Modified sleeper stretch|"Athlete was in side lying positioned on the involved side, trunk was rolled posteriorly 200 to 300 and shoulder is raised to 900 and elbow is flexed to 900 and semiflex both knees. athlete was ask to perform internal rotation passively by using the opposite arm.~5 reps once daily 3 sets for 4 weeks was given"
214309487|NCT03460587|DEVICE|Telerehabilitation|The Telerehabilitation system will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
214309488|NCT00952341|DRUG|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
214309489|NCT00952341|DRUG|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
214309490|NCT00952341|DRUG|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
214309491|NCT00952341|DRUG|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
214309492|NCT00952341|DRUG|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
214309493|NCT00079833|DRUG|Esomeprazole magnesium (Nexium)|
214309494|NCT05071092|BEHAVIORAL|Dietary counselling|Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
214309495|NCT04069403|OTHER|Automated Reports on prescription patterns for their patients|de-identified aggregate reports
214309496|NCT06368674|OTHER|Intervention group Case Manager (CM)|The CM will be informed about the discharge plan from the nurse at the geriatric ward, as will the municipality for those with need of home help care. An outline of the intervention has been created with managers from primary care and rehabilitation within primary care and municipality care. Core components in the intervention will be active follow-up of the discharge, rehabilitation and care plans. If there are plans that have not been executed or unmet needs, the CM will take adequate contacts to ensure that actions are made to meet the needs. These contacts can be, e.g. the GP for medical needs, the rehabilitation unit in primary or municipality care for unmet rehabilitation needs, and the home help service for unmet care needs. The CM will have a network of contact persons in hospital, primary and community care, as well as in rehabilitation in primary and community care, in order to facilitate for prompt actions to meet the needs.
214309497|NCT06368674|OTHER|Control Group|The participants in the control group with a planned follow-up by a primary health care centre within the catchment area of the Sahlgrenska University Hospital that does not have CMs designated for active follow up of discharged frail older people. Thus, the participants in the control group will not actively be followed-up after discharge.
214309498|NCT00485446|PROCEDURE|blood analysis|
214309499|NCT03167762|DEVICE|Fluorescence and thermal imaging|Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
214309500|NCT04573036|DRUG|HRS4800 tablets|single oral administration
214480702|NCT06838572|PROCEDURE|Skin cooling to 20°C|According to the group, copper parts at a constant temperature of 20°C were placed on the superficial skin of the brachial plexus for 15 minutes.
214480703|NCT06838572|PROCEDURE|Skin cooling to 15°C|According to the group, copper parts at a constant temperature of 15°C were placed on the superficial skin of the brachial plexus for 15 minutes.
214480704|NCT06838572|PROCEDURE|Skin cooling to 8°C|According to the group, copper parts at a constant temperature of 8°C were placed on the superficial skin of the brachial plexus for 15 minutes.
214480705|NCT06838572|PROCEDURE|No skin cooling|According to the group, copper parts at room temperature (23°C) were placed on the superficial skin of the brachial plexus for 15 minutes.
214480706|NCT06592703|DRUG|Adipose tissue-derived Mesenchymal Stromal Cells|repeated allogenic ASCs IT injections
214916616|NCT06574542|DIAGNOSTIC_TEST|Push enteroscopy (PE)|All patients enrolled in this study underwent evaluation using push enteroscopy (PE)
214916617|NCT06574542|DIAGNOSTIC_TEST|Colonoscopy|After push enteroscopy (PE), all patients subsequently underwent a colonoscopy on the same day or the next day. However, if a culprit lesion was identified during PE and the patient was considered at risk for undergoing colonoscopy, the colonoscopy was not performed and was presumed to be negative.
215060553|NCT04732442|DIETARY_SUPPLEMENT|Standard Oral Nutritional Support|Fortimel Compact Protein® Nutricia, United Kingdom
215060554|NCT00894699|DRUG|Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
215060555|NCT00894699|DRUG|Placebo NanoTab™|Single dose of sublingual placebo NanoTab™
215060556|NCT01122446|OTHER|Placebo comparator|"Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo."
214309501|NCT04573036|DRUG|Placebo tablets|single oral administration
214309502|NCT01391390|DRUG|Melatonin|10mg/day, 12-week treatment
214309503|NCT01391390|DRUG|Placebo|10mg/day, 12-week treatment for TD
214309504|NCT01482793|PROCEDURE|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
214309505|NCT04011527|PROCEDURE|Rotational Atherectomy in Coronary Lesion/s|
214670710|NCT02768129|DEVICE|sham transcranial direct current stimulation|sham stimulation
214670711|NCT03505866|BEHAVIORAL|Community home-based care intervention|HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
214670712|NCT02680301|DRUG|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
214916618|NCT00150488|DEVICE|Uracyst|2% weekly for 6 weeks, monthly for 4 months
214309506|NCT06436846|OTHER|Biospecimen sample collection during standard-of-care surgery|Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.
214309507|NCT01126996|PROCEDURE|Venepuncture|"1. Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~2. A booster dose of a MenC conjugate vaccine (optional)."
214309508|NCT03100708|PROCEDURE|PIPAC|"* Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.~* Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.~The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system."
214309509|NCT03051048|PROCEDURE|Reperfusion|
214309510|NCT04220372|DRUG|Tongxinluo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
214309511|NCT04220372|DRUG|Placebo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
214309512|NCT04537858|DEVICE|Virtual reality therapy first|First day of the protocol with Virtual Reality intervention in the morning and conventional intervention in the afternoon
214309513|NCT04537858|DEVICE|Conventional therapy first|First day of the protocol with conventional intervention in the morning and Virtual Reality intervention in the afternoon
214309514|NCT02826681|DRUG|Injectafer® (Ferric Carboxymaltose - FCM)|Intravenous Iron
214309515|NCT02826681|DRUG|Placebo (Normal Saline)|Normal Saline Solution
214309516|NCT01998048|PROCEDURE|Latarjet|A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.
214309517|NCT01998048|PROCEDURE|Bankart|An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
214309518|NCT02062762|BEHAVIORAL|Online-MBSR|8 week mindfulness based stress reduction online
214670713|NCT02680301|DRUG|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
214670714|NCT03921372|DIAGNOSTIC_TEST|Isometric exercise|Squatting for 5 minutes
214916619|NCT01031511|BEHAVIORAL|Cognitive Behavioural Therapy|16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
214916620|NCT01031511|OTHER|Social Recreational|16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
214916621|NCT02173665|DRUG|BI 1356 BS - Powder in bottle (PIB)|
214309519|NCT02062762|BEHAVIORAL|Expressive Writing Online|Online distributed expressive writing intervention as active control
214309520|NCT04371679|OTHER|No interventions planned|No interventions planned. Observational.
214309521|NCT04922918|BIOLOGICAL|Ligilactobacillus salivarius MP101|Administration of the strain through a fermented milk
214309522|NCT04538703|BEHAVIORAL|acne vulgaris|Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease.
214309523|NCT06469775|DEVICE|Low intensity shock wave|6 sessions of low intensity shock wave therapy, applied in 15 minute appointments once weekly.
214670715|NCT00095121|DRUG|Placebo (PLB)|Matching placebo
214670716|NCT00095121|DRUG|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
214916622|NCT02173665|DRUG|BI 1356 BS - Tablet|
214916623|NCT02173665|DRUG|Placebo|
214916624|NCT01266291|DRUG|vigabatrin|Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
214916625|NCT03291431|DEVICE|Intermittent theta burst transcranial magnetic stimulation|20 iTBS sessions (active or sham) administered over the course of 2 weeks
214916626|NCT01348620|DEVICE|Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)|Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson \& Johnson Medical Spa)
214916627|NCT01348620|PROCEDURE|Four port laparoscopic cholecystectomy surgery|Four port laparoscopic cholecystectomy surgery
214916628|NCT04059029|PROCEDURE|Bariatric surgery|During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance.
214916629|NCT03177460|BIOLOGICAL|Daratumumab|Given IV
214916630|NCT03177460|DRUG|FMS Inhibitor JNJ-40346527|Given PO
214916631|NCT03177460|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
214916632|NCT01193374|BEHAVIORAL|Clinician enhanced screening and counseling prompts|PDA based health risk screening for well child issues and obesity risks
215060557|NCT01122446|DRUG|Diamyd|"20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd"
214309524|NCT06469775|COMBINATION_PRODUCT|Control|Standard of care treatment: phosphodiesterase 5 inhibitor therapy, vacuum erectile device, constriction bands, intracorporal injections, and penile implant.
214309525|NCT02258126|OTHER|Multidisciplinary intervention program|"Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
214309526|NCT02004028|DRUG|VS-6063|
214309527|NCT00163475|DRUG|Roflumilast|
214309528|NCT04464122|DRUG|Somatostatin analog; chemotherapy|According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
214309529|NCT02121288|DRUG|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
214309530|NCT02121288|DRUG|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
214309531|NCT02397421|DRUG|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
214309532|NCT02397421|DRUG|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
214309533|NCT01688258|PROCEDURE|Diagnostic swab|
214309534|NCT02327858|OTHER|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
214309535|NCT00206453|DRUG|Taxotere|Chemotherapy IV
214309536|NCT05943912|OTHER|Single Vision Spectacle Lens|36 months of therapy
214309537|NCT05943912|OTHER|Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens|36 months of therapy
214309538|NCT06424912|PROCEDURE|Vivifi's Surgical Procedure|"Subjects undergo Vivifi's surgical procedure for treatment of BPH. The study procedure will be performed in the operating room, under general anesthesia.~Subject will undergo a bilateral anastomosis of the internal spermatic vein to the inferior epigastric vein and ligation of the deferential vein via bilateral inguinal/subinguinal incision.~The investigators can use of a coupler with appropriate ring size (to be measured intra-operatively based on vessel size) to perform the vascular anastomosis and standard sutures for ligation. The coupler is an FDA approved commercial device. Alternatively, the anastomosis can also be performed using sutures. Incision closure will proceed per institution standard of care."
214309539|NCT05061979|DRUG|BAY1747846|Solution for intravenous (IV) injection, single dose
214309540|NCT05271955|DEVICE|"e-GOLIAH"|"Usual care plus electronic tablet with games application e-GOLIAH (Gaming Open Library for Intervention in Autism at Home)"
214480707|NCT05932628|OTHER|This study will observe participants who receive a supported self management approach for thumb base osteoarthritis but it is not an interventional study.|Participants will receive an occupational or physiotherapist led supported self-management programme, which equates to normal NHS care, having been adopted by the sites involved. This involves education, progressive exercises and hand splints if required. The educational materials used, and a minimum number of appointments will be consistent across the study sites. Additional treatments for coexisting conditions will be provided, additional stepped care for thumb base osteoarthritis will also be recorded.
214309541|NCT05271955|BEHAVIORAL|Usual care|Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.
214309542|NCT02419742|DRUG|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams\*milliliter/minute \[mg\*mL/min\]) multiplied by (Glomerular Filtration Rate \[GFR\] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
214309543|NCT02419742|DRUG|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
214480708|NCT06602778|OTHER|Biomarkers / blood|Analysis of routine biochemical parameters
214480709|NCT06602778|OTHER|Questionnaire|Physical activity level will be assessed using the International Physical Activity Questionnaire Short Form (IPQI) and sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The data to be obtained from blood will be obtained by selecting blood samples that will be sent to biological waste.
214480710|NCT05450133|OTHER|Systemic inflammatory index|neutrophil count x platelet count/lymphocyte count
214480711|NCT05450133|OTHER|BASDAI|Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.
214309544|NCT02419742|DRUG|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m\^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
214309545|NCT02419742|DRUG|Doxorubicin|Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
214916633|NCT01193374|BEHAVIORAL|Tailored education and motivational materials|Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.
214916634|NCT01193374|BEHAVIORAL|basic educational brochure|Booklet by ADA sent x 1.
214916635|NCT03640390|DRUG|Dexmedetomidine|This group will receive Dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour.
214916636|NCT03640390|DRUG|Magnesium Sulphate|This group will receive Magnesium sulphate infusion at a rate of 15 mg/Kg/hour
214916637|NCT03640390|DRUG|Normal saline|This group will receive normal saline infusion
215060558|NCT00814021|DRUG|sunitinib malate|
214480712|NCT05450133|OTHER|ASDAS-ESR|The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
214480713|NCT05450133|OTHER|ASDAS-CRP|The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).
214916638|NCT05944497|PROCEDURE|Interscalene brachial plexus block|Using a linear ultrasound transducer connected to an ultrasound machine, the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery. The transducer is moved cephalad to visualize the 5th to 8th cervical (C5 to C8) nerve roots located between the anterior and middle scalene muscles. Using an in-plane technique, a block needle is inserted close to a nerve root in a lateral-to-medial direction. The needle is moved to place 0.75% ropivacaine around each nerve root. The C8 nerve root is blocked first, and the C5 nerve root is blocked last. After blocking the four cervical nerve roots, ropivacaine is placed in the intermuscular plane between the sternocleidomastoid and scalene muscles to block the supraclavicular nerves. A total of 26 ml of 0.75% ropivacaine is used for the interscalene brachial plexus block (6 ml per nerve root and 2 ml for the supraclavicular nerves).
214916639|NCT00481351|DRUG|Simvastatin 20mg plus ezetimibe 10mg|simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
214916640|NCT00481351|DRUG|ezetimibe|ezetimiba 10mg once a day
214916641|NCT00481351|DRUG|simvastatin 20mg|simvastatin 20mg once a day
214916642|NCT00481351|DRUG|Simvastatin 80mg|simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
215060559|NCT01268540|DEVICE|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
215060560|NCT01268540|DEVICE|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
215060561|NCT05509062|PROCEDURE|Pressure|Subjects are randomized to one of three treatment groups
215060562|NCT04820114|OTHER|Proprioceptive wrist exercises|Exercises for recognition of writs position and thumb force sense.
215060563|NCT04820114|OTHER|Wrist exercises|Passive and active exercises for improve range of motion in flexion, extension, ulnar and radial deviation
214916643|NCT01427647|PROCEDURE|Laparoscopic technique and thoracic epidural anesthesia|We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
215060564|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 2 of Cycles 3-6
215060565|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 1 of Cycles 3-6
215060566|NCT02243371|DRUG|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
215060567|NCT02243371|BIOLOGICAL|GVAX|5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
215060568|NCT02243371|DRUG|CY|200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
215060569|NCT05020834|OTHER|Functional Electrical Stimulation|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
215060570|NCT05020834|OTHER|TheraTogs Orthotic Undergarment|TheraTogs Arm The participating children worn TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
215060571|NCT02148536|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
214916644|NCT05697172|OTHER|Low-intensity focused ultrasound|80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
214916645|NCT00180609|DEVICE|Automatic threshold test in Insignia Pacemakers from Guidant|
214916646|NCT06594146|BIOLOGICAL|CM313 injection|CM313
214916647|NCT06594146|OTHER|placebo|placebo
214916648|NCT06626230|DRUG|Curcuminoid Capsules|"500 mg curcuminoids from C3 Complex capsule. Curcuma longa (Turmeric), a constituent of the spice turmeric, is considered a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits Study participants will be instructed to insert the curcumin capsules gelatin intra-anally every day for a 14-day treatment period.~Escalating doses"
215060572|NCT05710003|BEHAVIORAL|breathing exercises|"A-breathing exercises: 20 times per hour. While setting down, deep breathing is taken from the nose while mouth is closed, breath holding for at least ten seconds, then slow maximal exhalation for at least 10 seconds.~B-Upper Limb Endurance Exercises (low weight and high repetition) : Study participants will be educated to perform upper limb exercises every 4 hours. Three exercises will be repeated 10×3 times with 1 minute rest in between.~Breathing exercise and upper limb endurance exercises is explained in the reminder in details"
214309546|NCT02419742|DRUG|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
215060573|NCT01234454|DRUG|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
215060574|NCT01234454|DRUG|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
215060575|NCT01369199|DRUG|Entecavir and peginterferon|Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
215060576|NCT00001335|DRUG|ADR-529|
215060577|NCT00001335|DRUG|Topotecan|
215060578|NCT00001335|DRUG|G-CSF|
214309547|NCT02419742|DRUG|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
214309548|NCT06404632|BEHAVIORAL|Lev-g|Lev-g includes three sessions + a booster session using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev-g is done in groups to enable support and tips from others.
214309549|NCT01906710|OTHER|integrated medicines management|"PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge"
214309550|NCT02806310|OTHER|Blood draw|blood sampling for biomarker levels
214309551|NCT01758185|BIOLOGICAL|recombinant hepatitis b vaccine|0.5ml intramuscular
214309552|NCT01758185|BIOLOGICAL|Aleph influenza vaccine|0.5ml intramuscular
214309553|NCT04974112|OTHER|Apply SGA and NRS2002|Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information
214309554|NCT01135758|DRUG|Ketamine|Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
214916649|NCT06909734|BEHAVIORAL|Trauma-Informed Motivational Interviewing|"Trauma-Informed Motivational Interviewing: Core Principles~TIMI integrates two evidence-based approaches: Trauma-Informed Care (TIC) and Motivational Interviewing (MI). TIC emphasises understanding and acknowledging the impact of trauma on individuals' behaviours and emotional well-being. MI, a client-centred approach, fosters intrinsic motivation for change by exploring ambivalence and strengthening personal autonomy."
214916650|NCT06257823|OTHER|No intervention|No intervention
214916651|NCT02042755|DEVICE|trifocal intraocular lens|Standard cataract surgery
214916652|NCT00550745|BIOLOGICAL|Zoster Vaccine, Live|single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
214916653|NCT00550745|BIOLOGICAL|Comparator: placebo|single 0.65 mL Placebo injection. 6 month treatment period.
214916654|NCT04540419|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
215060579|NCT02450435|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
215060580|NCT02450435|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
215060581|NCT01296893|BEHAVIORAL|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
214309555|NCT04896320|DRUG|Tucatinib|Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
214309556|NCT06214156|BIOLOGICAL|T3011|T3011 will be given intratumorally， Q2W；
214309557|NCT06169813|OTHER|Nicotine Replacement Therapy (NRT)|NRT (daily patches and lozenges). NRT strength will be according to the established dosing guidelines for tobacco treatment. NRT is the standard of care in tobacco treatment and helped reduce CPD in prior trials
214309558|NCT06169813|OTHER|E-Cigarette (EC)|EC with single-use pods. Nicotine - 48 mg/ ml (4.8% nicotine) concentration.
214309559|NCT06169813|BEHAVIORAL|Counseling|Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.
214309560|NCT06113133|DIAGNOSTIC_TEST|measurement of oxygen uptake|oxygen uptake is obtained during a maximal exercise test
214480714|NCT05450133|OTHER|MASES|It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
214480715|NCT06161584|DRUG|Pegcetacoplan|Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
214480716|NCT06891664|PROCEDURE|Day surgery regimen for patients|The protocol includes admission on the evening of Day -1 and the execution of the surgery on the morning of Day 0 under general anesthesia. The surgery will be performed with the aid of the Da Vinci Single-port robotic system with extraperitoneal access.
214480717|NCT06891664|OTHER|Ordinary management|Management of patients undergoing robotic radical prostatectomy in an inpatient setting based on a minimum of two nights of hospitalization
214480718|NCT06497764|DEVICE|Vibrational Anesthesia (VA) Device|The half of the patient's scalp randomized to receive VA during PRP treatment will receive VA via the Buzzy bee-striped personal. The device is powered by two AAA batteries and is indicated for use for pain reduction. It uses the Melzack and Wall's Gait Control theory, which states that activation of non-nociceptive fibers can interfere with signals from pain fibers to inhibit overall sensation of pain.
214480719|NCT06497764|PROCEDURE|PRP Treatment|PRP (a needle-related procedure) will be delivered per routine standard of care.
214480720|NCT06600386|OTHER|Alveolar recruitement|PEEP after alveolar reruitment maneuvres
214309561|NCT02885142|PROCEDURE|Local excision for early rectal cancer|
214309562|NCT01232920|DRUG|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
214309563|NCT01232920|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
214480721|NCT06600386|OTHER|Standard PEEP|PEEP 5 cmH2O
214480722|NCT06599086|DRUG|2 cc:(1 cc betamethasone dipropionate+1cc physiological saline)|Each patient will receive 2 cc:(1 cc betamethasone dipropionate+1cc physiological saline) perineural injection into the median nerve under US guidance, for 1 session.
214480723|NCT03610906|PROCEDURE|Tumor and Blood Specimens|If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
214480724|NCT06842472|DRUG|Ursodeoxycholic Acid (URSO)|UDCA 250 mg twice daily, starting 7 days before radiotherapy and continuing for 1 month after completion.
214480725|NCT06842472|RADIATION|Radiotherapy|Radiotherapy (SBRT) with a dose of 24Gy/3 fractions within 3 weeks after the first immunotherapy dose.
214480726|NCT06842472|DRUG|Adebrelimab (PD-L1 inhibitor)|Adebrelimab (PD-L1 inhibitor) 1200 mg on Day 1, every 3 weeks.
214480727|NCT06842277|BIOLOGICAL|Injectable albumin platelets rich fibrin|Using injectable albumin platelets rich fibrin which is minimally invasive non surgical technique with autogenous , slow degradable and rich in leukocytes and growth factors material .
214480728|NCT06858202|BEHAVIORAL|Mindfulness Intervention|Guided meditation or guided expressive writing
214480729|NCT06858202|BEHAVIORAL|Non-mindfulness Intervention|Standard inpatient and outpatient resources available for Huntsman Cancer Institute patients through social work and the Wellness and Integrative Health Center. Participants will be encouraged to ask their providers for more information or if appropriate more consults to the appropriate resources if interested.
214480730|NCT06283706|OTHER|Tryptophan|There are 7 different tryptophan test levels ranging from 0.5, 2, 4, 6, 8, 10, 12 mg.kg-1.day.1
214480731|NCT00503971|DRUG|Vorinostat plus Erlotinib|"Phase I:~Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily~Phase II:~Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily"
214916655|NCT04540419|BIOLOGICAL|Placebo|Intramuscular administration
214916656|NCT00994383|DRUG|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg
214309564|NCT04018092|DEVICE|Active NIR-PBM|Near infrared light was delivered to the head using two MedX Rehab Console systems (MedX Health, 1116). Each MedX console included a control unit and 3 superluminous light emitting diode (LED) clusters. Each LED cluster (3MedX MCT502) consisted of 52 near infrared diodes and 9 visible red diodes. The 9 red diodes were deactivated. The energy delivered by each cluster was 1 joule \[J\]/cm2 in 45 sec at treatment wavelength of 870 nm per each 20 min. The LED cluster has an irradiance of 22.2 mW/cm2, treats an area of 22.48 cm2, with an energy density of 26.64/cm2 per cluster (total energy of 599J/cluster). During each session, the 6 clusters were arrayed on the scalp in 2 configurations, 20 minutes per array. Each configuration targeted 6 transcranial sites, guided by the 10-20 system, for a total of 12 sites during the 40-min session. Total energy delivered was 599J/cluster X 12 sites = 7188J. Intranasal stimulation was delivered using..
214309565|NCT04018092|DEVICE|Sham NIR-PBM|The MedX sham and Vielight interventions device are identical in all respects to the active device, except that the MedX console and diode clusters were modified to NOT deliver NIR light when turned on. The sham MedX devices were modified to deliver 'warmth', similar to that of the active devices. As with the active condition, a total of six sham interventions were given over a 12-week period, following the identical procedures described in the active condition
214309566|NCT04859751|DRUG|VB4-845 Injection|Intravesical administration of VB4-845 Injection.
214309567|NCT02301273|OTHER|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
214309568|NCT02301273|OTHER|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (\>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
214309569|NCT06104059|DEVICE|Nociception level index (NOL™)|If a NOL value \>25 persists for \>1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.
214309570|NCT06104059|OTHER|Fentanyl|Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.
214309571|NCT05679518|BEHAVIORAL|ConquerFear intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
214309572|NCT05679518|BEHAVIORAL|CALM intervention|CALM is a semi-structured, manualized, individual psychotherapy intervention designed for patients with advanced cancer. It includes 3-6 individual therapy sessions, with each approximately lasts 45-60 minutes, delivered over 3-6 months. The sessions cover 4 domains: 1) symptom management and communication with health care providers; 2) changes in self and relations with close others; 3) sense of meaning and purpose; and 4) the future and mortality. All modules will be addressed with each patient, but the sequencing and time devoted to each domain can be varied, based on the concerns that are most relevant to each patient.
214309573|NCT05679518|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
214309574|NCT03916627|DRUG|cemiplimab|Administered intravenous (IV)
214309575|NCT03916627|DRUG|Platinum Doublet|Administered intravenous (IV)
214309576|NCT03916627|DRUG|fianlimab|Administered IV
214309577|NCT02127242|PROCEDURE|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
214309578|NCT05191706|DRUG|Dexamethasone|single anterior chamber injection
214309579|NCT05191706|DRUG|Prednisolone Acetate Ophthalmic|topical administration four times a day for 28 days, followed by treatment taper
214309580|NCT04592913|DRUG|Durvalumab|Human monoclonal antibody
214309581|NCT04592913|DRUG|FLOT chemotherapy|A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
214309582|NCT04850014|OTHER|Anthropomorphism|Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender
214309583|NCT04850014|OTHER|Relevant clinical datas|"Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.~Imaging."
214309584|NCT05153369|BEHAVIORAL|Enhanced Care|Enhanced care aims to educate participants about bipolar disorder using a didactic approach, in addition to teaching and practicing DBT skills in an applied and relevant manner based on the participant's needs. Participants will receive a total of four sessions (approx. 60 minutes in duration), to occur once a month, at a minimum. The content will be split up into psychoeducation (2 sessions) and selected DBT skills (2 sessions). Psychoeducation will be specific to youth bipolar disorder, covering topics such as symptoms of depression and hypo/mania, medications used to treat bipolar disorder, the role of biology and the environment in emotions, and vulnerability and protective factors to emotion dysregulation and mood episodes. The content of skills sessions will be individualized and based on participant needs and goals (e.g., learning and applying skills to optimize their overall functioning, address problem behaviors and/or stressors, and/or maintain commitment to treatment).
214309585|NCT05153369|BEHAVIORAL|DBT Skills Training|In DBT Skills Training, participants will only receive skills training and can choose to do this individually and/or with their individual family unit by including their parent(s) and/or sibling(s). Participants will receive 20-25 sessions (approx. 60 minutes in duration), to occur at least biweekly. Skills training will include the five standard youth DBT modules: psychoeducation about DBT and bipolar disorder, mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path. The primary focus of the skills training is to impart knowledge and acquire and strengthen pragmatic skills to replace dysfunctional behaviors. If participants choose to include their family members, they will be encouraged to coach one another in effective use of skills.
214309586|NCT05153369|BEHAVIORAL|Dialectical Behavior Therapy Full Intervention|The DBT full intervention is based on Miller et al.'s DBT for suicidal youth, with modifications for youth with BD. DBT will be conducted over 1 year with approximately 40-50 sessions. Sessions will alternate between individual and skills training sessions. Family involvement in skills training will be strongly encouraged, however will be up to the participant to decide. Participants in Level 3 will complete diary cards tailored for this population, assessing daily mood, suicidality, sleep, and medication adherence. Participants will report use of specified DBT skills on the diary card, and individualized treatment goals will be incorporated into the diary card (e.g., alcohol use). In addition, Level 3 will include skills coaching by phone (via phone and/or text). These brief, structured calls and/or texts function to promote skills generalization by helping the participant and any participating family member(s) use skills to achieve goals and solve problems.
214309587|NCT01014429|DRUG|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
214309588|NCT05504941|DIAGNOSTIC_TEST|Diagnostic, cerebral Digital Subtraction Angiography (DSA)|The DSA is the goldstandard for the visualization of brain vessels. For performing a diagnostic cerebral DSA, the femoral artery of the patient will be punctured in the groin. Over this arterial access a catheter will be advanced under fluoroscopy guidance to the target vessel in the brain. After navigation to the targeted brain vessel, contrast media will be injected over the catheter into the vessel. The efflux of the contrast media will be monitored and visualized with fluoroscopy. The additional radiation to the patient due to the DSA will be approx. 1.1 mSv. The duration of the DSA will be 15 to 20 minutes.
214309589|NCT02175420|BIOLOGICAL|BCG|
214309590|NCT02175420|BIOLOGICAL|TFV|
214309591|NCT01062282|DRUG|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
214309592|NCT03340025|DEVICE|PICO Single Use Negative Pressure Wound Therapy System|Class II negative pressure wound therapy powered suction pump
214309593|NCT03340025|DEVICE|xeroform gauze|traditional surgical dressing of xeroform gauze and padding
214309594|NCT02443142|DRUG|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
214309595|NCT02443142|DRUG|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
214309596|NCT01366339|DRUG|Oral methylnaltrexone|
214309597|NCT01366339|DRUG|Oral placebo|
215060582|NCT05435807|BEHAVIORAL|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
215060583|NCT01919073|BEHAVIORAL|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
215060584|NCT01919073|BEHAVIORAL|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
215060585|NCT01168830|DEVICE|AMS-3.0|
215060586|NCT01650649|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
214346999|NCT05531396|OTHER|Agility Training|Participants will receive 60 minutes of exercise, twice a week, for a total of 8 weeks, and training will be conducted by a well-trained physical therapist. The intervention will comprise a 5-minute warm-up, 45 minutes of main exercise, and a 10-minute cool-down period, for a total of 60 minutes each session. During the warm-up and cool-down, participants will do static and dynamic whole-body stretching exercises.
214309598|NCT00755131|OTHER|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
214309599|NCT03205410|PROCEDURE|remote ischemic preconditioning|The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
215060587|NCT01650649|DRUG|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
215060588|NCT05023291|DIAGNOSTIC_TEST|Positron Emissie Tomografie - Computer Tomografie|In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
214309600|NCT03205410|PROCEDURE|no - remote ischemic preconditioning|The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
214309601|NCT03491995|DRUG|Quadruple therapy|Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
215060589|NCT00061035|BIOLOGICAL|Transgenic Lymphocyte Immunization Vaccine (TLI)|
214309602|NCT03491995|DRUG|Classic treatment|Omeprazole, amoxycillin, clarithromycin
214347000|NCT05531396|OTHER|Health Education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education. The home-based exercise program will emphasize how to safely and properly perform stretching and whole-body exercises.
214347001|NCT00084058|DRUG|Lopinavir/ritonavir|
214347002|NCT00084058|DRUG|Saquinavir|
214347003|NCT02015897|PROCEDURE|Physical TherapyA|"Group A:~* Skin care~* Manual lymphatic drainage~* Bandaging using Coban™2Lite~* Guidance on physical activity"
214347004|NCT02015897|PROCEDURE|Physical TherapyB|"Group B:~* Skin care~* Bandaging using Coban™2Lite~* Guidance on physical activity"
214347005|NCT04638010|BEHAVIORAL|Cancer control navigation (CNN)|Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only.
214347006|NCT04638010|BEHAVIORAL|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
214347007|NCT05734859|DEVICE|Electrolyzed Alkaline Ionizer|Patients will drink EHARW calculated by 20 mL/kg body weight/day which can be divided into several times a day for drinking. The patient is recommended to drink water in an empty stomach and to drink water generated from the device as soon as possible.
214347008|NCT04989270|PROCEDURE|General Anesthesia|General anesthesia with intubation, ventilation, intravenous and inhalational anesthetics, opioids and muscle paralysis
214347009|NCT04989270|PROCEDURE|Regional Anesthesia|Spinal Anesthesia, Epidural Anesthesia
214347010|NCT02796339|DIETARY_SUPPLEMENT|Mastiha|
214347011|NCT02796339|DIETARY_SUPPLEMENT|Placebo|
214347012|NCT00125489|DRUG|chloroquine sulfate|
214347013|NCT00125489|DRUG|sulfadoxine/pyrimethamine|
214347014|NCT00735046|BEHAVIORAL|Cognitive behavioral therapy for early Alzheimer's disease|12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
214347015|NCT00735046|OTHER|Control|Patients and proxies who are assigned to treatment as usual
214347016|NCT00884585|DRUG|Cyclosporine Vehicle|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
214347017|NCT00884585|DRUG|Cyclosporine 0.010%|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
214347018|NCT05626829|DRUG|Tranilast|Tranilast capsules 100mg 3 times per day when reradiation
214347019|NCT02703103|OTHER|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
214347020|NCT02703103|DEVICE|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
214347021|NCT04121598|OTHER|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
214347022|NCT06182670|DEVICE|Gingival Former Abutment|"GFA is positioned on the sub-crestal implant during the surgery and it is no longer removed. This follows the one abutment one time concept and should prevent bone loss and transmucosal tunnel."
214347023|NCT06182670|PROCEDURE|Subcrestal Implant|Placement of the endosseous sub-crestal dental implant through dedicated drills with 35 Newton insertion torque. It is positioned 2 mm under the crestal bone.
214347024|NCT06182670|DEVICE|Healing Abutment|A healing abutment is positioned on crestal implant during surgery. It is removed at prosthetic finalization.
214347025|NCT06182670|DEVICE|Prosthetic Crown|A zirconia prosthetic crown finalizes the implant rehabilitation.
214347026|NCT06182670|PROCEDURE|Crestal Implant|Placement of the endosseous crestal implant through dedicated drills with 35 Newton insertion torque at level of the alveolar bone.
214347027|NCT04280198|BEHAVIORAL|Triple P Parenting Videos|Four video clips from the online Triple P Parenting program will be used to promote specific positive parenting practices.
214309603|NCT06801912|BEHAVIORAL|Behavior Change Technique Package|"Behavior Change Technique 1: Goal setting (Behavior) (BCT 1.1). Goal setting for behavior is defined as setting a goal for the behavior to be achieved.~Behavior Change Technique 2: Action planning (BCT 1.4). Action planning is defined as detailing the plan of where, for how long, and at what time taking medication is going to be performed.~Behavior Change Technique 3: Self-monitoring of behavior (BCT 2.3). Self-monitoring of behavior is defined as monitoring and recording behavior.~Behavior Change Technique 4: Prompts/Cues (BCT 7.1) This BCT is defined as prompt rehearsal and repetition of the behavior in the same context repeatedly, so that the context elicits the behavior."
214309604|NCT03035123|BEHAVIORAL|Therapeutic education|Interventional arm
214309605|NCT04390477|DIETARY_SUPPLEMENT|Probiotic|Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.
214309606|NCT01620073|OTHER|HIV counseling and testing|Male partner HIV counseling and testing
214309607|NCT00528723|DRUG|salbutamol 100 mcg|To be used as needed for symptom relief
214916657|NCT06922162|BEHAVIORAL|Tickle stimulation|"Patients will be subjected to tickling:~they will be tickled bilaterally in three areas, the soles of the feet, the armpits, and the ribs-plus a control area, the forehead. The stimulation will be manual and performed by rubbing the targeted body part while opening and closing the fingers in pairs in an arched motion. Additionally, patients will also undergo a neutral stimulation (in the same body areas), which consists of simply touching the area without inducing tickling."
215060590|NCT04839458|DEVICE|Dental Prescale II|"The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end."
215060591|NCT04320056|OTHER|Standard administration of oxygen flow|"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode"
214309608|NCT00528723|DRUG|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
214309609|NCT00528723|DRUG|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
214309610|NCT03897179|DEVICE|INVSENSOR00032 and INVSENSOR00033|Investigational pulse oximeter device
214309611|NCT04710706|OTHER|Colonoscopy insertion technique used during procedure|Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
214309612|NCT00704535|DRUG|Ezetimibe|1 tablet of 10 mg once daily
214309613|NCT01480076|DRUG|Fampridine|Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
215060592|NCT04320056|DEVICE|Automated oxygen administration - FreeO2|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
215060593|NCT01066104|DRUG|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
215060594|NCT01066104|DRUG|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
215060595|NCT00356772|DRUG|Azithromycin|
215060596|NCT04665427|OTHER|bilioenteric anastomosis i|The creation of communication between a bile duct and a segment of the digestive tract, often to restore a flow of bile in the digestive tract,
214309614|NCT02503332|DRUG|Pegcetacoplan|
214309615|NCT02503332|OTHER|Sham Procedure|
214309616|NCT04661748|DEVICE|real time alarm of deviating vital signs|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds
214309617|NCT01413360|DRUG|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
214309618|NCT00815438|PROCEDURE|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
214309619|NCT03375411|DEVICE|Stent INC1|Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
214309620|NCT03559179|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers.
214309621|NCT05962229|DRUG|(S)-Nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
214309622|NCT05962229|DRUG|(R)- nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (R)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
214309623|NCT05962229|DRUG|Racemic nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 50% (R)-nicotine and 50% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
214309624|NCT06339073|DEVICE|mechanical ventilation|Abdominal trauma patients were treated with mechanical ventilation according to their conditions.
214309625|NCT02891707|DEVICE|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
214916658|NCT06922162|DEVICE|Neurophysiological Monitoring with SedLine|SedLine is a portable, non-invasive EEG monitoring device used to record electrical brain activity through frontal electrodes. In the TICKLING-DOC study, SedLine is used to assess cortical responses in patients with disorders of consciousness (DoC) during manual tactile stimulation, specifically tickling, and neutral touch. The EEG data are recorded before, during, and after stimulation to detect neural reactivity and possible correlations with behavioral responses. The goal is to investigate whether tickle-evoked EEG activity reflects residual consciousness and contributes to diagnostic and rehabilitative strategies. SedLine allows continuous monitoring in a bedside setting, offering safe, real-time assessment of brain function.
214309626|NCT00837655|DRUG|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of \<1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of \<1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
214309627|NCT00837655|DRUG|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration \<1.8 mmol/l.
214309628|NCT05845879|OTHER|delivery|delivery
214309629|NCT01116297|DEVICE|Imaging with S-FLARE imaging system|Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
214309630|NCT01837628|DRUG|Lidocaine Gel|
214309631|NCT01837628|DRUG|Paraffin Oil|
214309632|NCT05638685|OTHER|Questionnaire|The questionnaire comprises demographics, job or school related questions, screen work questions, the International Physical Activity Questionnaire (IPAQ) and questions about the participant's health.
214309633|NCT03548402|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of anxiety and self-injury.
214309634|NCT02916563|DEVICE|Blood Glucose Monitoring System Altitude Performance|Performance as assessed against a reference method at an altitude of approximately 10,000 feet.
214309635|NCT02149173|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
214309636|NCT02149173|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214309637|NCT02149173|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
214309638|NCT02149173|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
214309639|NCT02149173|OTHER|Laboratory Biomarker Analysis|Correlative studies
214309640|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
214309641|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
214309642|NCT03823053|OTHER|Home Based Traditional Scoliosis Exercise|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.
214309643|NCT03823053|OTHER|Home Based Core Stabilization Training|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. In addition, the training group received core stabilization exercises for multifidus, transversus abdominis, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and pelvic floor muscles.Exercises will be applied 1 sets of 10 repetitions and once a day.
214309644|NCT01100242|DRUG|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
214309645|NCT06195397|OTHER|Evidence-Based Education intervention|A total of 12 hours of Evidence-Based Education intervention was applied to students in the intervention group, spread over 7 sessions.
214309646|NCT02725047|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
214309647|NCT02725047|OTHER|Placebo - Sand|Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
214309648|NCT01801150|DEVICE|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
214309649|NCT01242956|BEHAVIORAL|verum group|video-based training after stroke
214309650|NCT01242956|BEHAVIORAL|Placebo group|non-video group
214309651|NCT02418195|DRUG|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
214309652|NCT00731887|PROCEDURE|Blood and urine testing|complete blood count, routine chemistries, liver function test, retinol binding protein, transferrin, prothrombin time, partial thromboplastin time, fibrinogen, Vitamin A and Zinc, Insulin Growth Factor levels and binding proteins, cytokines (interleukins 1, 6, 12), insulin, thyroid hormones, cortisol, 25-hydroxyvitamin D, and osteocalcin.
214309653|NCT04338438|DRUG|Apatinib Mesylate tablets combined with S-1 capsules|Apatinib Mesylate tablets combined with S-1 capsules, p.o.
214916659|NCT04577560|GENETIC|First polar body biopsy in MII oocytes|Since PBs are by-products of the meiotic division of the oocyte and are not required for fertilization and subsequent embryo development, they can be removed to assess exclusively maternal chromosomal information without harming the embryo integrity. As previously described, PB biopsy does not impact the morphokinetic parameters of the embryo development and can be safely applied without the risk of impairing the reproductive potential of the embryo.
214309654|NCT01433510|DRUG|Grazax|1 tablet/day - pre and co-seasonal
214916660|NCT04577560|GENETIC|PGT-A blastocyst|preimplantation genetic screening for aneuploidies
214916661|NCT01419392|DRUG|Sildenafil citrate|25 mg orally, 4 times per day for 21 days
214309655|NCT03169946|PROCEDURE|RCT with CHX-MTZ,OFD|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
214916662|NCT01419392|DRUG|matching placebo|orally, 4 times per day for 21 days
214309656|NCT03169946|PROCEDURE|RCT with CHX,OFD|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
214916663|NCT06939673|DEVICE|Acellular Porcine-Derived Wound Matrix|This intervention is a sterile, acellular, three-dimensional biologic scaffold derived from porcine liver tissue using a proprietary perfusion decellularization and drying process. It retains the native extracellular matrix structure and supports tissue granulation and healing in complex wounds. Miro3D is applied topically to the debrided wound bed and rehydrated prior to use. It is indicated for use in a range of chronic and complex wounds, including diabetic foot ulcers, venous leg ulcers, pressure injuries, and surgical dehiscence. In this study, it is administered in an outpatient setting alongside standard of care treatments.
214916664|NCT06940557|DRUG|Bionerv|alpha lipoic acid; 300mg, methylcobalamin; 500mcg, vitamin B1; 39mg and vitamin B6; 8mg, 2 tablets once daily
214916665|NCT06940557|DRUG|Placebo|maltodextrin, microcrystalline cellulose, tricalcium phosphate, silicon gioxide, magnesium stearate 2 tablets once daily
214916666|NCT06940726|OTHER|Quality of Life questionnaires|Subjects will complete a number of self-questionnaires on subjects such as attention span, anxiety levels and sleep quality.
214916667|NCT06940726|OTHER|Hearing tests|listening to sounds on headphones and repeating words
214916668|NCT06940726|BEHAVIORAL|Auditory prediction task|listening to sounds and assessing auditory perception
214916669|NCT06940726|BEHAVIORAL|Attention task|assessment of reaction time to visual or auditory cues
214309657|NCT05865288|DRUG|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with the nursing staff supervising for proper administration of substance, after training and guiding the patient, and for supervision of side effects.
214309658|NCT03720912|BEHAVIORAL|Online Learning Modules|The modules will include information about common family management skills: social support, problem solving, communication, and supportive behavior change strategies.
214309659|NCT02999256|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|
214309660|NCT02999256|OTHER|Placebo|
214309661|NCT06496126|DEVICE|Cerasmart 270 (GC Coop, Tokyo, Japonya)|Hybrid Ceramic Block
214309662|NCT06496126|DEVICE|EverX Flow (GC Coop, Tokyo, Japonya)|Fiber Reinforced Composite Resin
214309663|NCT06496126|DEVICE|: G-CEM ONE (GC Coop, Tokyo, Japonya)|Universal Self Adhesive Resin Cement
214309664|NCT06496126|DEVICE|G-Premio Bond (GC Coop, Tokyo, Japonya)|Universal Adhesive
214309665|NCT06496126|DEVICE|G-ænial A'CHORD|Conventional Composite Resin
214309666|NCT04407910|COMBINATION_PRODUCT|AIRFLOW® Master device +Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
214309667|NCT04407910|COMBINATION_PRODUCT|rubber-cup+Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
214309668|NCT02701972|DEVICE|BACE Device|Implanted BACE device
214309669|NCT02179996|BIOLOGICAL|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
214309670|NCT02179996|BIOLOGICAL|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
214309671|NCT00793364|DIETARY_SUPPLEMENT|Stanol ester spread|Stanol ester spread 20 g every day
214309672|NCT00793364|DIETARY_SUPPLEMENT|Placebo spread|Placebo spread 20 g every day
214309673|NCT00793364|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet every day
214309674|NCT03850873|DRUG|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
214309675|NCT05164458|DRUG|IBI 308 injection|IBI308 IV 200mg Q3W Day1
214309676|NCT05164458|DRUG|IBI 389 Injection|IBI 389 IV Q2\~Q3W Day 1
214309677|NCT03559322|DEVICE|iNAP® Lite Sleep Therapy System|Class II intraoral devices for snoring and/or obstructive sleep apnea
214309678|NCT04483713|BEHAVIORAL|Educational Workshop|"The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires."
214916670|NCT06940544|DIAGNOSTIC_TEST|Stepwise Multimodal Home-Based HF Screening|The Stepwise Multimodal Home-Based HF Screening intervention involves a targeted community outreach program to identify undiagnosed heart failure (HF) in high-risk individuals. Participants randomized to the intervention arm (ACTIVE) are asked to self-collect dried blood spots for NTproBNP analysis. Those with elevated NTproBNP (≥125 pg/ml) in the dried blood spots are summoned to the study clinic and undergo confirmatory point-of-care NTproBNP testing and an AI-enabled echocardiogram, with the aim to confirm or rule out heart failure.
214916671|NCT06941467|DRUG|Timolol Maleate Solution|Timolol 0.5% solution. The number of drops delivered will be based on the initial wound size and will remain constant for the duration of the study period or until the wound is fully re-epithelialized which will be determined by the PI either by photo or in person visit.
214916672|NCT06941467|OTHER|Standard of Care|Vaseline
215077774|NCT03938220|DEVICE|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON\_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
215060597|NCT05469425|BEHAVIORAL|Preoperative home-based exercise training|"Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program."
214309679|NCT04483713|BEHAVIORAL|Educational Workshop plus J. H. N. EBP Guide Tools|"In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination."
214309680|NCT00909779|DRUG|Arformoterol|Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
214309681|NCT00909779|DRUG|Placebo|Placebo inhalation solution, twice daily (BID) for a duration of one year.
214309682|NCT04330560|DEVICE|Exercise telemonitoring connects to healthcare platform|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) link to the healthcare practitioner
214309683|NCT04330560|DEVICE|Exercise self-monitoring|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) for exercise self-monitoring.
214309684|NCT04330560|DEVICE|Exercise teleconsultation|Conducted through smartphone video call app.
214309685|NCT04330560|PROCEDURE|Other CR components|Including dietary, psychology, education conducted at the center.
214309686|NCT04330560|PROCEDURE|Standard care|Undergoing standard care by cardiac rehabilitation at the center
214309687|NCT04150276|PROCEDURE|ZEEP during awakening|ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
214309688|NCT04150276|PROCEDURE|PEEP during awakening|PEEP will be maintained throughout emergence preoxygenation and awakening.
214309689|NCT00117559|BEHAVIORAL|Telehealth Treatment|Participants receive a 15-minute telephone call for 8 weeks
214309690|NCT00208962|PROCEDURE|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
214309691|NCT03685084|DRUG|AAI101 i.v.|600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
214309692|NCT03685084|DRUG|Saline 0.9% infusion|Vehicle infusion
214309693|NCT03685084|DRUG|Piperacillin i.v.|piperacillin 3 g i.v.
214309694|NCT03685084|DRUG|Cefepime i.v.|cefepime 1 g i.v.
214309695|NCT03553407|DEVICE|Low Level Laser - Pulse|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
214309696|NCT03553407|DEVICE|Low Level Laser - continuous|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
214309697|NCT03553407|DEVICE|Low Level Laser - placebo|placebo will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
214347028|NCT04280198|BEHAVIORAL|Activity Boxes|There will be about 4 planned activities per week within activity boxes provided to families. The activities will be a context in which the positive parenting behaviors can be practiced. Each activity will take about 15 minutes. Families can pick each week whether they'd like their parenting practice to be embedded in reading activities, nature walks/active games, or arts and crafts. Instructions will be included with each activity, including prompts to allow the parent to apply learnings from that week's parenting video and to allow interactions to be child-led.
214347029|NCT05290259|OTHER|Ballroom Dance|The Ballroom Basics for Balance Program is a dance focused exercise program developed by a Physical Therapist in the Madison area.
214670717|NCT00095121|DRUG|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration \>= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained \>= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
214670718|NCT02627950|DRUG|Morphinhydrochloricum|5 mg morphine intravenously
214347030|NCT02308033|DRUG|Metronidazole|
214347031|NCT02308033|DRUG|Gel vehicle|
214347032|NCT04056806|DRUG|Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial|efficacy comparison between 2 days and 5 days
214347033|NCT05561959|OTHER|topical glyceryl trinitrate gel|topical nitroglycerin medication were treated with 1 gr nitroglycerin 2% gel
214670719|NCT02627950|DRUG|Metoclopramide|10 mg MCP intravenously
214347034|NCT05561959|OTHER|Eccentric exercises|stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee).
214670720|NCT02627950|DRUG|Ticagrelor|180 mg ticagrelor orally
214670721|NCT02627950|DRUG|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
214670722|NCT03050463|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
214670723|NCT03050463|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI related tasks
214670724|NCT03050463|OTHER|Questionnaire Administration|Ancillary studies
214670725|NCT04427657|PROCEDURE|autologous microfragmented lipoaspirate tissue (Lipogems®).|patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
214916673|NCT06939621|BEHAVIORAL|VR-based physical activity with motivational stimuli|"Participants will undergo four weekly supervised VR-based training sessions, each lasting approximately 35 minutes, over four weeks. Each session includes:~1. VR Warm-Up: Activities adapted from NVIDIA VR Fun House on SteamVR, involving repetitive movements through mini-games like throwing objects, archery, and sword handling.~2. Aerobic and Balance Exercises: Walking in place within a virtual natural environment, incorporating stretching steps and one-leg balance tasks.~3. Lower-Body Training: VR-based exercises such as Balloon Game for hip flexibility (popping balloons with foot movements), Cave Game for squatting motions, and sit-to-stand activities.~4. Upper-Body Training: VR exercises involving racket-based ball hitting and reaching activities at varied distances.~Participants received motivational messages from a virtual coach designed to enhance the three psychological needs outlined in Self-Determination Theory: competence, autonomy, and relatedness."
214916674|NCT06939621|BEHAVIORAL|VR-based physical activity without motivational stimuli|"Participants will undergo four weekly supervised VR-based training sessions, each lasting approximately 35 minutes, over four weeks. Each session includes:~1. VR Warm-Up: Activities adapted from NVIDIA VR Fun House on SteamVR, involving repetitive movements through mini-games like throwing objects, archery, and sword handling.~2. Aerobic and Balance Exercises: Walking in place within a virtual natural environment, incorporating stretching steps and one-leg balance tasks.~3. Lower-Body Training: VR-based exercises such as Balloon Game for hip flexibility (popping balloons with foot movements), Cave Game for squatting motions, and sit-to-stand activities.~4. Upper-Body Training: VR exercises involving racket-based ball hitting and reaching activities at varied distances.~In this condition, instead of motivational stimuli, participants received neutral information regarding the activity (e.g., This exercise is good for your legs )."
214916675|NCT06939621|BEHAVIORAL|Standard Physical Activity with motivational stimuli|"Participants will engage in four individual training sessions, supervised by a trainer, scheduled once per week for a total duration of four weeks. Each session will last approximately 35 minutes and include: 5 minutes of warm-up and stretching, 10 minutes of aerobic and balance exercises (walking in place, heel raises, knee lifts, leg curls), 10 minutes of lower-body exercises (squats), and 10 minutes of upper-body exercises (shoulder abduction 180°, shoulder flexion 180°, shoulder external rotation 90°, bending 35°, trunk extensions 80°).~Participants received motivational messages from a real coach designed to enhance the three psychological needs outlined in Self-Determination Theory: competence, autonomy, and relatedness."
214916676|NCT06939621|BEHAVIORAL|Standard Physical Activity without motivational stimuli|"Participants will engage in four individual training sessions, supervised by a trainer, scheduled once per week for a total duration of four weeks. Each session will last approximately 35 minutes and include: 5 minutes of warm-up and stretching, 10 minutes of aerobic and balance exercises (walking in place, heel raises, knee lifts, leg curls), 10 minutes of lower-body exercises (squats), and 10 minutes of upper-body exercises (shoulder abduction 180°, shoulder flexion 180°, shoulder external rotation 90°, bending 35°, trunk extensions 80°). In this condition, instead of motivational stimuli, participants received neutral information regarding the activity (e.g., This exercise is good for your legs )."
215060598|NCT01816191|DRUG|Diltiazem Hydrochloride Cream and Oral Diltiazem|
215060599|NCT01699126|DEVICE|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
215060600|NCT01699126|DRUG|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
215060601|NCT00586040|PROCEDURE|tissue bonding|application of rose bengal and treatment with green light
215060602|NCT00586040|PROCEDURE|sutures|interrupted superficial sutures
215060603|NCT00751959|DRUG|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
215060604|NCT00751959|DRUG|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
215060605|NCT00488020|PROCEDURE|stem cells transplant|
215060606|NCT02728648|DRUG|Oxycodone|Pain Management
215060607|NCT04691245|DEVICE|3D US|3D US guided access to femoral artery
215060608|NCT04691245|DEVICE|2D US|2D US guided access to femoral artery
214347035|NCT05641493|COMBINATION_PRODUCT|HLX208+HLX10|HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.
214670726|NCT04427657|PROCEDURE|arthroscopic debridment|patient in supine position. Under sedation is perform an arthroscopic debridement
214670727|NCT04741243|DEVICE|Extracorporeal Shock wave|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
214670728|NCT05761327|OTHER|Mediterranean Diet|In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
214670729|NCT05761327|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.
214309698|NCT00789893|DEVICE|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis \& assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st \& 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, \& the 2nd will be one month ± 2 weeks from last day of radiation.
214670730|NCT05761327|DIETARY_SUPPLEMENT|Resveratrol Supplementation|Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
214916677|NCT06940089|BEHAVIORAL|Attention Intervention using a customized BCI decoder|"During the offline phase of the intervention, participants will perform an attentional task while intracranial brain activity is recorded. Data from this session will be used to train a personalized decoder capable of classifying attentional engagement.~During the training phase, participants will receive real-time visual feedback contingent on their brain activity when attentional engagement is detected. This closed-loop feedback aims to reinforce successful attention and enhance performance over repeated sessions."
214916678|NCT06940089|BEHAVIORAL|Attention Intervention without using a customized BCI decoder|"During the offline phase, participants will perform an attentional task while intracranial brain activity is recorded. A personalized decoder will be created for each participant but will not be used during the training phase sessions.~During the training phase, participants will receive visual feedback while performing attentional tasks; however, the feedback will not be contingent on their brain activity. Instead, feedback will be non-contingent and unrelated to actual attentional engagement. This group is not expected to experience improvements in attentional performance through the training sessions."
214480732|NCT04866472|DEVICE|video-laryngoscope and GlideRite Rigid Stylet|Once subject is in the operating room, standard monitoring will be instituted including nerve stimulator. Induction will follow standard practice.Once full muscle relaxation is confirmed with a train of four of 0/4 laryngoscopy will be preformed using a video-laryngoscope (VLS) with a #3 blade for women and a #4 blade men. Endotracheal intubation will be performed using a #7 endotracheal tube in women and # 8 in men using the GlideRite Rigid Stylet. The stylet will be shaped to the curvature of the blade of the VLS and lubricated with a water-based lubricant. After successful tracheal intubation the circuit will be connected and ventilation confirmed with capnography and auscultation.
214670731|NCT02209597|DRUG|Bupropion XL 300|"Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
214916679|NCT06939517|DEVICE|SeaBand|Drug-free, reusable Acupressure elastic wristbands applied to bilateral wrists for nausea relief
215060609|NCT00008801|DRUG|hOKT3gamma1 (Ala-ala)|
215060610|NCT05712785|DEVICE|Use of shuotong ureteroscopy|Treatment of patients with ureteral stones using the Shuotong-scopy
215060611|NCT05163327|PROCEDURE|Oxygen-enhanced Cardiac MRI|The MRI scan will include assessment of cardiac function. Myocardial magnetic properties (T1, T2, T2\*) will be measured while patients are breathing room air, oxygen and during an infusion of adenosine. The scan will last for approximately 60 minutes. Prior to the scan patients will have an intravenous cannula (venflon) placed in an arm vein.
215060612|NCT02989116|BEHAVIORAL|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
215060613|NCT02989116|BEHAVIORAL|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
215060614|NCT02989116|BEHAVIORAL|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
215060615|NCT02989116|BEHAVIORAL|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
214309699|NCT02016482|BIOLOGICAL|Adalimumab|
214309700|NCT02016482|OTHER|Placebo|
214309701|NCT03710655|DRUG|Apitox - pure honeybee toxin|Intradermal injection of 0.01 microliters
214309702|NCT03710655|DRUG|Placebo|Intradermal injection of 0.01 microliters
214309703|NCT02730572|DRUG|Concerta|This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
215060616|NCT02989116|GENETIC|Saliva collection|Collection of a saliva sample for genotyping
215060617|NCT02989116|PROCEDURE|Brain Magnetic Resonance Imaging|Structural and functional MRI
215060618|NCT02989116|BEHAVIORAL|Cognitive testing|Battery of cognitive and academic tasks on executive functions
215060620|NCT02732795|OTHER|Morphine pharmacokinetic evaluation|Each group received morphine and blood drawn to evaluate morphine PK
215060621|NCT00315952|DRUG|Exubera|
215060622|NCT05780801|DRUG|Allogeneic Microbiota in Glycerol (10%) (AMG)|Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
215060623|NCT02442505|DEVICE|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
215060624|NCT04621994|OTHER|Dermabond|Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
215060625|NCT04621994|OTHER|Steri Strips|Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
215060626|NCT01584791|DRUG|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
215060627|NCT01584791|DRUG|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
215060628|NCT04875377|DIETARY_SUPPLEMENT|Reformulated pizza|Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).
215060629|NCT04875377|DIETARY_SUPPLEMENT|Control pizza|Control (placebo) meal to consume thrice weekly (no iodine supplementation).
214916680|NCT06939699|BEHAVIORAL|Social Media-Based Education|This intervention includes daily delivery of 56 infographic/video-based educational materials over 8 weeks via WhatsApp or Instagram. The content focuses on awareness of breast, cervical, and colorectal cancer screenings, healthy lifestyle behaviors, and digital health literacy. The materials are developed based on the Socio-Ecological Model.
214916681|NCT06939699|BEHAVIORAL|Standard Online Education|Participants receive two 40-minute online educational sessions one week apart via Microsoft Teams/Zoom. The content includes cancer screening awareness (breast, cervical, colorectal), preventive strategies, and the use of digital health tools such as e-Nabız and MHRS.
215060630|NCT04875377|DIETARY_SUPPLEMENT|Seaweed capsule|Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).
215060631|NCT04875377|DIETARY_SUPPLEMENT|Control capsule|Empty capsules (placebo)
215060632|NCT02771574|DRUG|Lyo avexitide|Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
215060633|NCT02771574|DRUG|Liq avexitide|Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
215060634|NCT01225133|OTHER|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
215060635|NCT01225133|OTHER|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
215060636|NCT02382874|BIOLOGICAL|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
215060637|NCT03985462|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
215060638|NCT04103944|PROCEDURE|Core Decompression|10 patients will be randomized chosen in this group
215060639|NCT04103944|PROCEDURE|Osteonecrotic Repair Device|10 patients will be randomized chosen in this group
215060640|NCT04423679|DEVICE|Evalyn Brush|a standard brush-based cervicovaginal self-collection device
215060641|NCT05719350|OTHER|Exercises for Knee|Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
215060642|NCT02593903|DRUG|Septra|
215060643|NCT03513315|BEHAVIORAL|Implementation of Community-based Home Heat Bundle|This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
215060644|NCT03513315|BEHAVIORAL|Regular Community Healthcare provision|The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
215060645|NCT01026090|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
215060646|NCT01026090|DRUG|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
215060647|NCT04573439|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary supplement: Protein intake|"Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."
215060648|NCT03976505|OTHER|reading a table format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
215060649|NCT03976505|OTHER|reading a textual format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
215060650|NCT03976505|OTHER|filling a virtual pillbox displayed on the screen as prescribed in the prescription|filling a virtual pillbox displayed on the screen as prescribed in the prescription
215060651|NCT03976505|OTHER|eye-tracker|In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
215060652|NCT03976505|OTHER|cognitive tests and questionary|Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
215060653|NCT04802031|BIOLOGICAL|Rapid Infusion Isatuximab|Given IV
215060654|NCT00283101|DRUG|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
215060655|NCT04322474|DEVICE|Catheter-based left atrial appendage occlusion|Catheter-based implantation of left atrial appendage occluder
214916682|NCT06941220|OTHER|mulligan group|SNAG technique was applied from a sitting position on the edge of the table while both feet were on a foot rest. A specialized Mulligan belt was used around the patient's waist and therapist's hips. The mobilizing force was applied parallel to the facet joint plane (cephalic direction) and over the spinous processes of the respective symptomatic spinal levels. The patients were asked to lean forward as much as possible during application of the mobilizing force and then return to the starting position while the therapist maintained his mobilizing force until the end. plus traditional therapy
214916683|NCT06941220|OTHER|Maitland mobilization|"The subjects were placed in the prone position on a plinth with their hands beside them, and the therapist stood on the subject's side, the ulnar surface of the hand (between pisiform and hamate) was placed over the hypomobile spinous process. The second hand was placed on top of the first to enhance its force. With the therapist's elbows slightly bent and shoulders exactly above the spinous process, an oscillatory movement of the vertebra was executed by applying a posterior-anterior force to the hypomobile or painful spinous process.~Grade III mobilization was applied four times, each with 60 s of oscillation and 20 s of rest in between them (2 or 3 oscillations per second) plus traditional therapy"
214916684|NCT06941220|OTHER|traditional therapy|the patients will receive traditional therapy in the form of passive stretching, strengthening, and lumbar stabilization exercises
214916685|NCT02056184|DRUG|Adalimumab|
214916686|NCT04092868|OTHER|Blood samples PK/ PD protamine|PK/ PD protamine
214916687|NCT06537362|DEVICE|Mouthpiece with cheek-holder|A cheek support integrated into the mouthpiece is used for the measures
214916688|NCT06939530|PROCEDURE|Hydrodilatation (20 ml)|"First, an SSNB will be performed with 4 ml of 0.25% anesthetic + 0.5 ml of corticosteroid in the suprascapular notch.~After 15 minutes of the SSNB, ultrasound-guided HD will begin. To do this, the patient will be placed in a lateral decubitus position on the unaffected arm. The arm to be treated will be positioned at the patient's side without forcing its extension. The joint cavity will then be approached posteriorly, introducing a spinal needle in the ultrasound plane between the humeral cortex and the labrum. The joint cavity will then be confirmed by introducing physiological saline solution and observing its reflux by pushing the plunger. Subsequently, 5 ml of 0.25% anesthetic + 0.5 ml of corticosteroid will be introduced, and the corresponding volume will be completed with saline solution, this case 20 ml."
214916689|NCT06939530|PROCEDURE|Hydrodilatation (40 ml)|"First, an SSNB will be performed with 4 ml of 0.25% anesthetic + 0.5 ml of corticosteroid in the suprascapular notch.~After 15 minutes of the SSNB, ultrasound-guided HD will begin. To do this, the patient will be placed in a lateral decubitus position on the unaffected arm. The arm to be treated will be positioned at the patient's side without forcing its extension. The joint cavity will then be approached posteriorly, introducing a spinal needle in the ultrasound plane between the humeral cortex and the labrum. The joint cavity will then be confirmed by introducing physiological saline solution and observing its reflux by pushing the plunger. Subsequently, 5 ml of 0.25% anesthetic + 0.5 ml of corticosteroid will be introduced, and the corresponding volume will be completed with saline solution, this case 40 ml."
214916690|NCT06940024|DEVICE|VSP Group|Digital surgical splints were generated using Dolphin software and a Form 3D printer
214916691|NCT06939543|BEHAVIORAL|empathy|physicians' awareness of their health status, empathy towards patients
214916692|NCT02835625|RADIATION|Synthetic Mammography + Digital Breast Tomosynthesis|Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
214916693|NCT02835625|RADIATION|Digital mammography|Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
214916694|NCT06055205|OTHER|PAC-plan|The participants will be asked to complete electronic questionnaires at baseline, and at 6 weeks and 52 weeks after discharge from the hospital. The completion of these questionnaires will take place during the 6-week follow-up appointment at the hospital (a standard follow-up for all patients undergoing surgery at the Division of Orthopedic Surgery, Oslo University Hospital, Norway). Additionally, participants will be invited for a phone-based follow-up appointment with the study coordinator 52 weeks after discharge. The participants will receive the questionnaires electronically via SMS or email. If electronic options are not feasible, data can be collected through paper questionnaires sent by mail. Data will not be directly obtained from general practitioners.
214916695|NCT00594867|DRUG|Acetaminophen - 4 grams per day + Placebo|Acetaminophen - 4 grams per day + Placebo
214916696|NCT00594867|DRUG|Aspirin - 325 mg per day + Placebo|Aspirin - 325 mg per day + Placebo
214916697|NCT00594867|DRUG|Acetaminophen 4 gram per day + Aspirin 325 mg per day|Acetaminophen 4 gram per day + Aspirin 325 mg per day
214309704|NCT02730572|DRUG|Concerta AG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
214309705|NCT02730572|DRUG|Concerta EG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
214309706|NCT04912934|PROCEDURE|A survey form was applied to individuals included in the study face-to-face.|This study was completed with a descriptive, cross-sectional and relational screening model
214309707|NCT03031093|RADIATION|inhalation protocol|technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
215060656|NCT03263910|DRUG|NPO-11|20 ml NPO-11
215060657|NCT03263910|DRUG|Placebo|20 ml NPO-11(Placebo)
215077775|NCT05933642|DRUG|Aminophylline|aminophylline 150mg
215077776|NCT05933642|DRUG|Frusemide|frusemide 120mg
214309708|NCT03031093|DEVICE|High Flow Nasal Cannula|aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.
214309709|NCT02608931|DRUG|Dronabinol|
214309710|NCT02608931|OTHER|Placebo|placebo
214309711|NCT01743287|DRUG|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
214309712|NCT01743287|DRUG|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
214309713|NCT06093412|PROCEDURE|unilateral epidural anesthesia|The patients received unilateral epidural anesthesia
214309714|NCT06093412|PROCEDURE|combined lumbar and epidural anesthesia|The patients received combined lumbar and epidural anesthesia
214309715|NCT06419387|DEVICE|Self-Therapy Mobile App|Self-Therapy Mobile App includes videos and guidelines for applying EMDR Flash Technique
214309716|NCT06419387|OTHER|Psycho-education Videos|Psycho-education Videos include guidelines for increasing emotion regulation skills.
214916698|NCT03850483|DRUG|PF-06700841|PF-06700841 topical cream
214916699|NCT03850483|DRUG|Vehicle (Placebo)|Vehicle topical cream
214916700|NCT04343040|DIETARY_SUPPLEMENT|carbohydrate supplement (Preload™)|carbohydrate supplement (Preload™) will be administered 4-hours prior to bariatric surgery (experimental treatment) Preload™ is a neutral-tasting carbohydrate loading drink mix specifically designed for use before elective surgery. Preload is presented in 50g pre-measured sachets which when added to water (400ml) produces a solution with low osmolality.
214916701|NCT04343040|PROCEDURE|6 hours of preoperative fasting|Standard of care. In this group, patients continue the standard of care treatment before surgery with fasting recommended 6 hours before surgery.
214916702|NCT03801005|BIOLOGICAL|Blood and Marrow sample|"Twenty patients will be included in a prospective way over a period of nine months. No additional medullary or serum samples will be carried out in addition to those required for the clinical routine. Only an additional blood sample taken during a routine blood test will be recovered as part of the research. Just as some leftover bone marrow, taken as part of a usual unused follow-up will be recovered as part of this trial.~The persons concerned will be recruited on the occasion of their hospitalisation in one of the hematology services participating in the research, or during their consultation with one of the hematologists of the corresponding service (or services). On this occasion, detailed information on their pathology and research will be given, as well as the information document on the proposed research protocol."
214916703|NCT02609815|DRUG|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
214309717|NCT02653456|DEVICE|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
214309718|NCT02738333|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214309719|NCT02738333|DRUG|SOF|400 mg tablet administered orally once daily
214309720|NCT02738333|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
214309721|NCT00949325|DRUG|temsirolimus plus liposomal doxorubicin|Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
214309722|NCT03273881|DRUG|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
214309723|NCT03273881|DRUG|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
214309724|NCT00574054|RADIATION|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
214309725|NCT02003131|BIOLOGICAL|Trophic factors from umbilical cord mesenchymal stem cells|
214309726|NCT00210821|DRUG|topiramate|
214309727|NCT01758653|OTHER|No study intervention|There is no study-related intervention.
214916704|NCT02609815|DRUG|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
214916705|NCT01882959|OTHER|Radiofrequncy Denervation|
214916706|NCT02828774|OTHER|there will be no intervention.|this study is observational, procedure are done in vitro and on animal models.
214916707|NCT05377944|DRUG|BAT2306|150 mg/1 ml/injection (2 injections/visit)
214916708|NCT05377944|DRUG|EU-approved Cosentyx|150 mg/1 ml/injection (2 injections/visit)
214916709|NCT03661619|PROCEDURE|Sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
214309728|NCT00798109|BEHAVIORAL|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
214309729|NCT00798109|BEHAVIORAL|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
214309730|NCT00791518|DRUG|No intervention|No intervention
214309731|NCT00387478|BIOLOGICAL|Tree MATA MPL or Tree MATA|"4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo"
214309732|NCT04739007|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation (VA-ECMO)|VA-ECMO used for resuscitation after cardiac arrest
214309733|NCT04739007|DEVICE|Electrical Impedance Tomography (EIT)|EIT used to demonstrate ventilation and perfusion distribution in intubated patients on VA-ECMO
214309734|NCT02009631|DRUG|Veliparib (ABT-888)|
214309735|NCT02009631|DRUG|Placebo|
214309736|NCT01914406|OTHER|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
214480733|NCT04866472|DEVICE|video-laryngoscope and TCI Articulating Introducer Device|In the operating room, standard monitoring will be instituted including nerve simulator. Induction will follow standard practice. Once full muscle relaxation is achieved (train of four of 0/4) laryngoscopy will be performed using a video-laryngoscope (VLS) using a #3 blade in women and a #4 blade in men. A #7 endotracheal tube will be used for women and a #8 for men. Endotracheal intubation will be performed by placing the tube on the back of the TCI articulating introducer, after shaft is lubricated with a water based lubricant. The tip of the TCI articulating introducer will be maneuvered into the trachea and advanced until the green zone of the introducer shaft is adjacent to the glottis. The handle of the articulating introducer will then be removed and the ETT will be advanced over the articulating introducer and into the trachea via Seldinger's technique. Once in place the respiratory circuit will be connected and confirmed with capnography and auscultation.
214916710|NCT03661619|PROCEDURE|Sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
214480734|NCT05725837|DRUG|Paroxetine|Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
214480735|NCT05592223|DRUG|BCG Vaccine USP|2x10\^6 cfu Tice® BCG (ID)
214480736|NCT05592223|DRUG|Isoniazid|INH in the dose of 300 mg for three days post BCG injection.
214480737|NCT05592223|DRUG|Rifampin|RIF in the dose of 600 mg for seven days post BCG injection.
214916711|NCT02400918|OTHER|The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)|An acceptance and commitment therapy-based self-help workbook for social anxiety and shyness. It includes an 8-week program.
214916712|NCT01842984|BEHAVIORAL|I-SOCIAL intervention|The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
214916713|NCT05939869|OTHER|Medical and Clinical History|Retrospective and prospective analysis of patients data will be done.
214916714|NCT02782117|DEVICE|Luminopia One|Luminopia One is a digital therapeutic that allows patients to watch videos with therapeutic modifications applied.
214916715|NCT04550689|DEVICE|Bone graft|Bone grafts produced by Straumann LLC
214309737|NCT01914406|OTHER|continuous moderate training|Continued exercise 45 min.
214309738|NCT01520363|DRUG|dextromethorphan|The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
214309739|NCT01520363|DRUG|placebo|The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
214309740|NCT05268588|BEHAVIORAL|MESSSSAGE intervention|group mHealth education and social support intervention
214309741|NCT04174287|DRUG|F-18-AV45|The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
214309742|NCT01272830|DRUG|Placebo|Two capsules taken twice daily with meals
214309743|NCT01272830|DRUG|Apatone®B|Two capsules taken twice daily with meals
214916716|NCT01971775|DEVICE|Ultrasonically activated Shears|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
214916717|NCT01971775|DEVICE|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
214916718|NCT02792894|BEHAVIORAL|Family networks program|Intervention, Family networks Program (FaNs), is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO parent skills training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
214916719|NCT05680246|DEVICE|DHOPE-PRO|Prolonged DHOPE preservation \>4 hours
214309744|NCT02658136|OTHER|Cardiac Computed tomography|
214309745|NCT05936866|OTHER|Pelvic floor stretching|Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises , seated pelvic tilts, cat stretches, seated hip openers (2 sets, 8 reps, sustained for 6 seconds) Week 5 to 8: Pelvic floor muscles awareness, Breathing exercises ,seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog (2 sets, 8 reps, sustained for 6 seconds) Week 9 to 13: Pelvic floor muscles awareness, Breathing exercises, seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog side lying clamshells, mini squats with support (2 sets, 9 reps, sustained for 7 seconds)
214309746|NCT05936866|OTHER|Pelvic floor strengthening|"Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises, 2 Sets of 10 Reps for pelvic floor squeeze and release Seated marching with elastic band with pelvic floor squeeze.~Week 5 to 8: 2 sets x 9 Reps for Pelvic floor squeeze and release, Seated marching with elastic band with pelvic. 2 Sets x 8 Reps for bridging with pelvic floor squeeze, side lying hip circles Week 9 to 13: 2 sets 10 reps for Pelvic floor squeeze-and-release, Seated marching with elastic band with pelvic floor squeeze, pelvic bridging with pelvic floor squeeze, side lying hip circles with pelvic floor squeeze. 2 sets, 8 reps for . side lying Clamshells with resistance band and pelvic floor squeeze and plie squats with pelvic floor squeeze"
214309747|NCT05632549|DRUG|Placebo|Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
214309748|NCT05632549|DRUG|L-Carnitine 500Mg Oral Tablet|Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
214480738|NCT04704869|BIOLOGICAL|Cryoprecipitate|Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
214916720|NCT05048381|DIAGNOSTIC_TEST|Next Generation Sequencing|Next Generation Sequencing of sweat and whole blood samples for non-coding miRNAs to define biomarkers that enable to differentiate between patients with active tuberculosis, a differential diagnostic disease and healthy individuals.
214916721|NCT02258438|BEHAVIORAL|Uninterrupted sitting|Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
214916722|NCT02258438|BEHAVIORAL|Sitting + 1 bout of activity|Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
214916723|NCT02258438|BEHAVIORAL|Sitting + microbursts of activity|Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
214309749|NCT05632549|DRUG|Biotin Capsules|Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
214309750|NCT01336075|PROCEDURE|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
214309751|NCT01336075|PROCEDURE|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
214309752|NCT05152888|DRUG|Evolocumab|Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
214309753|NCT00080743|DRUG|gefitinib|250 mg po once daily
214309754|NCT00080743|DRUG|tamoxifen citrate|20 mg po once daily
214309755|NCT00080743|DRUG|Placebo|One pill po once daily
214309756|NCT05695521|BIOLOGICAL|CK0803|CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously
214309757|NCT05695521|OTHER|Excipient|Excipient
214309758|NCT02859233|OTHER|Lack of hyperhydration|
214309759|NCT05450887|DRUG|Obeticholic Acid Tablets（OCA）|Obeticholic Acid：Once a day (QD) by mouth (PO).
214309760|NCT05450887|DRUG|UDCA|UDCA：13\~15 mg/kg/day
214309761|NCT05450887|DRUG|Placebo|Placebo：Once a day (QD) by mouth (PO).
214309762|NCT01861496|DRUG|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8
214309763|NCT01498952|DRUG|MEDI-573 (1 of 3 doses)|MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
214309764|NCT01498952|DRUG|Sorafenib|Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
214309765|NCT06348303|DRUG|Metaxalone m640 mg oral tablet|Metaxalone partially micronized 640 mg tablet
214480739|NCT04704869|BIOLOGICAL|Red Blood Cells|RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
214309766|NCT06348303|DRUG|Metaxalone 800 mg oral tablet|Metaxalone non-micronized 800 mg oral tablet
214309767|NCT05695716|DEVICE|CSI pVAD System|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
214309768|NCT01318031|DRUG|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
214309769|NCT01318031|DRUG|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
214309770|NCT00579826|DRUG|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
214309771|NCT00579826|DRUG|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
214309772|NCT02284646|OTHER|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
214309773|NCT04189458|OTHER|Multimodal exercise program|Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (30 min), cool-down (5 min), and finishing ritual (5 min). At the initial stage, the activation of different muscle groups will be performed. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities and will privilege IPS. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation - physical fitness (strength, balance and agility) - alternating with exercises mainly focused on cognitive stimulation - CF (planning ability, solving-problems, IPS, attention and DT performance). At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants sign an attendance sheet regarding the session, including perceived exertion (Borg Scale) and satisfaction (Caregiver Treatment Satisfaction questionnaire).
214309774|NCT04000048|GENETIC|sequencing of the complete exome|Once the pathological diagnosis is confirmed (WHO 2016), a tumor fragment will be selected and frozen for each lobe. DNA extraction will be performed for each fragment. The samples (4 different DNAs per GDBG corresponding to the DNA extracted from each of the 3 lobes and the blood DNA) will be sent to the Montpellier Genomix platform for sequencing of the complete exome.
214309775|NCT00446433|DRUG|CC-5013|
214916724|NCT06621290|OTHER|Semi-structured interviews|Semi-structured interviews on ED-patients experiences of frailty assessment with the CFS
214309776|NCT00454987|BIOLOGICAL|Menitorix|Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.
214916725|NCT02390102|DRUG|Erythropoietin|Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
215060658|NCT03082443|OTHER|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
214309777|NCT00454987|BIOLOGICAL|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
214309778|NCT00827970|BEHAVIORAL|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
214480740|NCT04704869|BIOLOGICAL|Plasma|Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
214480741|NCT04704869|BIOLOGICAL|Platelets|Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
214480742|NCT04704869|BIOLOGICAL|Whole Blood|Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
214916726|NCT02390102|DRUG|Placebo|Saline solution 0.9%
214916727|NCT03840395|DEVICE|Pharyngeal Electrical Stimulation (PES)|The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
214480743|NCT06860399|DRUG|Vardenafil|Oral Vardenafil
214480744|NCT06860399|DRUG|Sildenafil|Oral Sildenafil
214916728|NCT02452632|DRUG|ASP1941|oral
215060659|NCT02742233|DRUG|saxagliptin|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment"
215060660|NCT02742233|DRUG|placebo|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment"
215060661|NCT04031248|DEVICE|Whole body vibration|In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices \[Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)\]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
214480745|NCT06862271|PROCEDURE|Group 1 ( Caudal block group )|In the caudal block group, after the induction of caudal block with investigations, 0.2% bupivacaine will be applied to the epidural space in a volume of 0.8 mL/kg and a maximum of 20 mL will be injected into the epidural space and the surgical incision will be made at the 15th minute. For participants after surgery, Pediatric Anesthesia Emergence Delirium (PAED), Face Leg Activity Cry Consolability (FLACC) scales will be recorded, and for parental satisfaction, the LIKERT scale will be used. In addition, the child's walking time, first urination time, and need for additional painkillers will be questioned and recorded.
214916729|NCT02452632|DRUG|Placebo|oral
214309779|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Low dose)|0.2mL,Intramuscular other name:PBPV
214309780|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Low dose)|0.2mL,Intramuscular other name:PBPV placebo
214309781|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Middle dose)|0.5mL,Intramuscular other name:PBPV
214916730|NCT00950443|DEVICE|Acoustic reflection method|Acoustic reflection gives the longitudinal cross-sectional area profile along airway.Based on planar acoustic wave propagating in a rigid duct connected to airway.
214916731|NCT00950443|DEVICE|Acoustic method and breathing/endoscopic evaluation|Endoscopic evaluation done under general anaesthesia.
214916732|NCT04940286|BIOLOGICAL|Durvalumab|Given IV
214916733|NCT04940286|DRUG|Gemcitabine|Given IV
214916734|NCT04940286|DRUG|Nab-paclitaxel|Given IV
214916735|NCT04940286|BIOLOGICAL|Oleclumab|Given IV
214916736|NCT03924401|DRUG|Abatacept|All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
214916737|NCT05070949|BEHAVIORAL|Mindful Self-Compassion|Bi-weekly meeting will involve six lessons: What is Self-Compassion , Practicing Self-Compassion, Discovering your Compassionate Voice, Self-Compassion and Resilience , Self-Compassion and Burnout and Making it Count
214916738|NCT05111912|DRUG|XW003|XW003 (from 0.2 mg to 1.2 mg, 1.8 mg, and 2.4 mg once weekly), should take place during the first 14 weeks after randomization as described: Dose Escalation Schedule of Investigational Product (XW003). All eligible participants assigned to the XW003 study groups should aim to reach the respective final target dose of XW003 at 1.2 mg, 1.8 mg, or 2.4 mg once weekly.
214916739|NCT05111912|DRUG|Saxenda|If a participant does not tolerate the recommended target dose of Saxenda group (e.g., 3.0 mg once daily), the participant may stay at the preceding highest tolerable dose (e.g., 2.4 mg once daily).
214916740|NCT03038542|BEHAVIORAL|Gain-framed text messages|
215077777|NCT01081301|BEHAVIORAL|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
214309782|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Middle dose)|0.5mL,Intramuscular other name:PBPV placebo
214309783|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(High dose)|1.0mL,Intramuscular other name:PBPV
214309784|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(High dose)|1.0mL,Intramuscular other name:PBPV placebo
214916741|NCT03038542|BEHAVIORAL|Standard care text messages|
214916742|NCT00725153|DEVICE|Balafilcon A contact lenses (PureVision)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
214916743|NCT00725153|DEVICE|Etafilcon A contact lenses (Acuvue2)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
214916744|NCT00090025|DRUG|becatecarin|Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle
214916745|NCT00090025|DRUG|5-Fluorouracil Plus Leucovorin|5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
214916746|NCT06371235|OTHER|Pregiferon|This Study aims to study the transmission of anti-interferon alpha autoantibodies from mother to child viaplacental barrier
214309785|NCT01275274|DRUG|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of \< 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to \< 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
214309786|NCT01275274|DRUG|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
214347036|NCT02096653|PROCEDURE|X-ray SI joint steroid injection|Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
214347037|NCT02096653|PROCEDURE|Landmark-guided SI steroid injection|Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
214347038|NCT04488536|DIAGNOSTIC_TEST|Clinical Frailty Scale|Frailty assessment
214347039|NCT03756181|BEHAVIORAL|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
214347040|NCT03662945|OTHER|Mobile Geriatric Team intervention|Person-centred intervention based on Comprehensive Geriatric Assessment
214347041|NCT05372601|DIETARY_SUPPLEMENT|Relax+|Prebiotics, daily administered
214347042|NCT05372601|DIETARY_SUPPLEMENT|Maltodextrin|Placebo, daily administered
214347043|NCT04895267|DEVICE|Low-field thoracic magnetic stimulation (LF-ThMS)|A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
214347044|NCT01823744|DIETARY_SUPPLEMENT|micronutrient supplementation|
214916747|NCT03742518|DRUG|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
214916748|NCT03742518|DRUG|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
214670732|NCT00576498|OTHER|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
214670733|NCT00576498|OTHER|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
214916749|NCT03742518|DRUG|Topical vehicle solution|Vehicle solution application will be performed by the individual subject at approximately the same time each day.
214916750|NCT02124200|DEVICE|EGO/CE4, 9mg nicotine|
214480746|NCT06862271|PROCEDURE|Group 2 (Penile block and IV Fentanyl group)|In the penile block and IV fentanyl group, 1 µg/kg fentanyl will be administered by the investigations and 5 minutes later, penile block will be performed using 0.25% bupivacaine at a dose of 0.2 mL/kg. For participants after surgery, Pediatric Anesthesia Emergence Delirium (PAED), Face Leg Activity Cry Consolability (FLACC) scales will be recorded, and for parental satisfaction, the LIKERT scale will be used. In addition, the child's walking time, first urination time, and need for additional painkillers will be questioned and recorded.
214480747|NCT03285620|DRUG|AL-034|Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2
214480748|NCT03285620|DRUG|Placebo|Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
214480749|NCT05836012|BIOLOGICAL|HIL-214|2 injections - given at 4 months and the second at 6 months of age.
214480750|NCT05836012|BIOLOGICAL|Placebo|2 injections - given at 4 months and the second at 6 months of age.
214480751|NCT04497558|DIAGNOSTIC_TEST|Endometrium biopsy|In the experimental group, those patients undergo endometrial receptivity array. In the control group, those patients do not receive any treatment before next cycle of transfer. In the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. In the control group, no intervention will be performed.
214480752|NCT06590428|OTHER|Therapeutic Drug Monitoring for Linezolid|TDM with dose adjustment for trough concentration \>2.5 mg/L LZD
214480753|NCT05752474|BEHAVIORAL|Exercise|Physical therapy targeting flexibility, strength, and endurance will be delivered at the participant's home, center-based, or virtually via a twice-weekly (on average) schedule to provide a total of about 6-8 sessions during the 3-4 week study period. Participants will be asked to participate in self-directed exercise for at least 30 minutes per day for 4 or more days per week.
214480754|NCT05752474|BEHAVIORAL|Nutrition|One-hour virtual group nutrition education classes will be held once per week by a dietitian, focusing on optimal protein intake (1.2 grams per kg of body weight) for lean body mass preservation (from food sources and oral nutritional supplements) and muscle gain. Participants will also receive oral nutritional supplements (20-30 grams of protein/day provided by our study team).
214480755|NCT05752474|BEHAVIORAL|Meditation|One-hour virtual group meditation sessions will be held once per week by an experienced meditation teacher. Classes will focus on breathing techniques, yoga, and mindful meditation practices. Participants will be asked to participate in self-directed meditation for at least 12 minutes daily.
214480756|NCT05752474|BEHAVIORAL|Cognitive Behavioral Intervention|A 30-min telephone-based session with individual patients will take place to deliver cognitive behavioral strategies once per week by a professionally trained clinician. These strategies include education about frailty and surgery, increasing positive beliefs of the benefits of exercise and nutrition, discussing barriers, setting individualized goals for surgery and recovery, developing a detailed exercise and nutrition plan (including logistics), self-monitoring of progress using weekly exercise, diet, and meditation logs, and enhancing self-efficacy through the celebration of small wins.
214480757|NCT06864325|OTHER|VR-training|The VR gaming experience is based on the commercial rhythm game Beat Saber, featuring songs by Queen with varying rhythms and tempos. Players receive visual stimuli in the form of colored square blocks and must slice them in time with the music using the corresponding right or left hand. The blocks must be cut with a lightsaber of the same color. To ensure the safety of older adults, heart rate and energy expenditure were monitored throughout each session, while oxygen saturation was assessed before and after the exercises. Participants playe the game in comfortable conditions: the game loaded directly into the headset and VR glasses synchronized with portable screens to allow monitoring and assistance if needed. Before each session, the headset was adjusted to fit the participant's head dimensions, and corrective glasses were provided if required. The VR setup included a Meta Quest 2 headset with goggles and user-friendly controllers equipped with sensors (Meta Platforms, U.S.).
214480758|NCT06864182|DRUG|CX2101A tablet|CX2101A tablet
214916751|NCT04399018|OTHER|Diagnostic Test: Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection.~Blood sample will be stained according to the manufacturers' recommendations with a lyophilized cocktail (LyotubeTM ready-to-use, BD Bioscience).~At least 10,000 neutrophils will be acquired on a 3-laser, 8-color BD FACSCanto-II TM flow cytometer (BD Biosciences, San José, CA).~Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
215060662|NCT04031248|OTHER|EXERCISE group|The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
214916752|NCT03070600|OTHER|Universal PrEP Counseling|Counseling at universal sites, will use a standardized counseling script to state that PrEP is available for women at risk for HIV, explain that HIV prevalence in the region is high, and will note that women with HIV positive partners or who don't know their partner's status may be at risk. Counseling will specify that women may have their own reasons to feel at risk or to want PrEP. Following standardized counseling, women will select PrEP at the same visit or will be allowed to deliberate on the decision and come back at the next visit with a decision. Women will be informed that it is advisable to use PrEP if they know their partner is HIV positive or if they do not know their partner's status and will be encouraged to bring untested partners to clinic if status is unknown.
214916753|NCT03070600|OTHER|Targeted PrEP Counseling|"Following enrollment, the targeted PrEP clinics will provide two inter-related innovations over two ANC visits. In the targeted PrEP clinics, any of the following three criteria can trigger enhanced PrEP counseling. A participant that meets any one of these criteria will receive PrEP counseling during the study visit where the criteria is met:~1. Risk Score \>6 (Risk score includes male partner status known/unknown, syphilis infection, and lifetime number of male partners) or any National AIDS and STI Control Programme (NASCOP) risk factors~2. participant declines partner self-tests regardless of partner HIV status, and/or~3. their partner declines self-testing or tests positive."
214916754|NCT06092788|DRUG|NTP42:KVA4 Capsule|Single doses of NTP42:KVA4 administered to healthy volunteers as a capsule
214916755|NCT06092788|DRUG|NTP42:KVA4 Liquid|Single doses of NTP42:KVA4 administered to healthy volunteers as a liquid
214916756|NCT00204009|BEHAVIORAL|Disease Surveillance, Family Studies, Questionnaire Followup|
214916757|NCT03668444|BEHAVIORAL|TXS- Supportive Text Group|TXS participants will receive one treatment supportive text message each day for 30 days.These messages will address three domains 1) Recovery oriented messages, 2) Avoiding relapse and sanctions,and 3) Commitment to family, community and the Drug Treatment Court program. After receiving each text message, participants will receive a second message asking them to reply with a rating of how helpful the original message was. Ratings will use a 5-point Likert scale,ranging from 1-not at all helpful to 5-extremely helpful. Participants will also be asked to describe, via text message, what they liked or did not like about the original message, and suggest a better message for those they did not like.
214916758|NCT03668444|BEHAVIORAL|TAU- Treatment As Usual|Participants randomized to the TAU arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive one motivational text message for the 30-days.
214916759|NCT05729789|BEHAVIORAL|Group Written Exposure Therapy|Group Written Exposure Therapy (GWET) is a brief cognitive behavioural therapy for PTSD aimed at allowing patients to process their traumatic experiences in a safe environment. GWET will consist of 6 group sessions (1 orientation session and 5 weekly group sessions). Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience. The written exposure will be followed by a guided discussion about the experience of writing the exposure. There is no homework assigned between sessions. However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
215060663|NCT05006976|OTHER|NSAC health only|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only."
215060664|NCT05006976|OTHER|NSAC health + MBW|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors."
215077778|NCT00101816|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
214309787|NCT01771146|DRUG|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
214309788|NCT01646515|DRUG|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
214480759|NCT06864182|DRUG|CX2101A placebo tablet|CX2101A placebo tablet
214480760|NCT06864182|DRUG|CX2101A enteric-coated tablet|CX2101A enteric-coated tablet
214480761|NCT06864182|DRUG|CX2101A placebo enteric-coated tablet|CX2101A placebo enteric-coated tablet
214480762|NCT06863831|DRUG|Yishen Qutong Granules|The patent prescription of Professor Feng Li, the head of the Department of Traditional Chinese Medicine at the Cancer Hospital of the Chinese Academy of Medical Sciences.
214480763|NCT06863831|DRUG|Yishen Qutong Simulant Granules|Yishen Qutong Simulant Granules is a preparation with one-tenth the dosage of Yishen Qutong Granules.
214480764|NCT06864767|OTHER|Neuro-sensory Motor Developmental Assessment|The test used to assess children's development levels evaluates the child's development in six parameters: gross motor function, fine motor function, neurological status, infant movement patterns, postural development and sensory-motor function (tactile, proprioceptive, ocular and vestibular systems) on a scale of 1 to 5. High scores are interpreted as motor dysfunction.
214480765|NCT06864767|OTHER|Functional Oral Intake Scale|It is a scale consisting of a total of 7 levels and two sections, developed by Crary et al. to indicate the functional oral intake of patients with dysphagia. A higher score indicates a better nutritional level.
214480766|NCT06864767|OTHER|Behavioral Pediatrics Feeding Assessment Scale|The scale used to determine eating problems in children evaluates both the child's nutritional status and the parents' feelings about the child's nutritional status. It consists of 35 items in total and is scored from 1 to 5. High scores indicate problematic eating behaviors and habits.
214309789|NCT01646515|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
214309790|NCT04242004|DRUG|Docosahexaenoic acid (DHA) capsules|Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).
214309791|NCT04242004|DIETARY_SUPPLEMENT|Soy oil capsules|The placebo was identical looking capsules that contained soy oil
214309792|NCT00142870|DRUG|Bupropion|150 mg, twice a day
214309793|NCT00801125|DRUG|natalizumab|
214309794|NCT01153243|DRUG|Ergocalciferol|"Active Comparator: Ergocalciferol~The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)"
214309795|NCT01153243|DRUG|Placebo pill|The investigators will give control group 12 weeks of 1 placebo pill every week.
214309796|NCT04867265|PROCEDURE|Mout-to-mouth ventilation|we will record the visibility of chest rising
214309797|NCT04867265|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
214309798|NCT02436278|OTHER|4MGS|Usual walking speed measured over 4 metres
214309799|NCT02159664|OTHER|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
214309800|NCT03198741|DRUG|Aspirin + clopidogrel|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
214309801|NCT03198741|DRUG|Clopidogrel monotherapy|After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
214309802|NCT03198741|DRUG|Aspirin monotherapy|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
214309803|NCT02154555|PROCEDURE|debridement|post-operative debridement at 1 week follow-up visit
214480767|NCT06864767|OTHER|Pediatric Quality of Life Inventory|The PedsQL assesses health-related quality of life in children ages 2 to 18 years with chronic illnesses from both the child's and parents' perspectives. It consists of 25 items and 3 categories (About My Child's Neuromuscular Disease, Communication, About Our Family Resources). The Neuromuscular Module was used to assess the quality of life of the children in our study and was answered by the parents only. The scale is scored from 0 to 4, with higher scores indicating better quality of life.
214480768|NCT06864884|DRUG|ARC-001|Gel formulation containing investigational anesthetic.
215077779|NCT06767917|DEVICE|Eyefill® S.C.|Used as viscoelastic devices during cataract surgery
215077780|NCT06767917|DEVICE|Eyefill® M.B.|Used as viscoelastic devices during cataract surgery
214480769|NCT06864884|DRUG|Placebo gel|Gel that contains no active ingredients.
214480770|NCT06863415|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement: Probiotics. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
214480771|NCT06863415|DIETARY_SUPPLEMENT|Placebo|Dietary supplement: Placebo. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
214480772|NCT06863207|DEVICE|Percutaneous electrical nerve field stimulation|Percutaneously nerve stimulator applied to the external auricle weekly for several consecutive weeks of therapy
214480773|NCT06863207|BEHAVIORAL|Hypnotherapy|Gut-directed hypnotherapy delivered via audio recordings
214480774|NCT06864793|DRUG|QL1012D|A single Subcutaneous injection, 225IU
214480775|NCT06864793|DRUG|Gonal-F®|A single Subcutaneous injection, 225IU
214480776|NCT06863493|DRUG|SFA002|SFA002 760mg
214480777|NCT06863493|DRUG|Otezla|Oral Otezla 30mg
215077781|NCT06826677|DRUG|Durvalumab|PATIENTS INCLUDED IN AN EARLY ACCESS PROGRAMME TREATED WITH DURVALUMAB IN COMBINATION WITH PLATINUM AND ETOPOSIDE AS FIRST-LINE THERAPY
214309804|NCT06672874|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Fermented Papaya Preparation (FPP) is administered in this study as a dietary supplement aimed at assessing its potential benefits for cognitive function and driving performance in older adults. Participants consume FPP as a 3-gram powder dose taken orally three times daily (morning, afternoon, evening) for a total of 8 weeks. FPP is known for its antioxidant and anti-inflammatory properties, which may influence cognitive domains essential for safe driving, such as attention, memory, reaction time, and executive function. This intervention is specifically designed to explore FPP's potential impact on reducing driving errors and improving psychomotor skills in a high-fidelity driving simulation environment.
214309805|NCT06122090|DRUG|Bimatoprost|Bimatoprost will be delivered with laser
214309806|NCT06122090|DRUG|Saline|Saline control will be delivered with laser
214309807|NCT00776646|DRUG|hydrochlorothiazide 50 mg tablet|
214309808|NCT04721990|DEVICE|Automatic Sound Management 3.0|The investigational front-end features include those within Automatic Sound Management 3.0 (i.e., Ambient Noise and Transient-Noise Reduction, and Adaptive Intelligence). Automatic Sound Management 3.0 will be accessed in the MAESTRO system software. The investigational front-end features within Automatic Sound Management 3.0 will be programmed in the SONNET2EAS processor.
214309809|NCT02132325|BEHAVIORAL|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
214309810|NCT05102383|DEVICE|Comfilcon A Toric contact lenses|Monthly replacement contact lenses
214309811|NCT05102383|DEVICE|Verofilcon A for Astigmatism Daily Disposable contact lenses|Daily disposable contact lenses
214309812|NCT00620828|OTHER|Placebo saline injection|20 cc of sterile, injectable saline
214309813|NCT00620828|DRUG|Ropivicaine 0.5%|Ropivicaine
214309814|NCT01096810|DRUG|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
214309815|NCT00509782|DRUG|ZIO-101|Starting Dose 78 mg/m\^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
214916760|NCT03681548|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
214916761|NCT04858646|OTHER|Experimental( Group A ): Aerobic exercises|Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities
214916762|NCT04858646|OTHER|Conventional( Group B): Conventional Physical therapy|The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes.Treatment duration for both groups will be 30 minutes. Each subject received total30sessions of the treatment, with 5 treatment sessions per week for 6 weeks
214480778|NCT06863493|DRUG|Placebo|Placebo will be matched to whichever drug is assigned when randomized
214670734|NCT01364610|DEVICE|Bravo|Bravo pH Monitoring System sited manometrically.
214916763|NCT04005404|DRUG|Ropivacaine (sciatic nerve block)|injection of 20 ml ropivacaine 0.375%
214916764|NCT04005404|DRUG|Ropivacaine (lumbar plexus block L2-L4)|injection of 20 ml ropivacaine 0.375%
214916765|NCT04005404|DRUG|Ropivacaine (lumbar plexus block Th12-L1)|injection of 20 ml ropivacaine 0.375%
214916766|NCT06012396|BEHAVIORAL|Stoke complex exercise program|"1. warm-up(5min) flexibility exercise - neck, triceps brachii, biceps brachii, forearm, back, quadriceps, biceps femoris, ankle~2. main exercise(40min) aerobic exercise(20min)- use stepper, treadmill, high intensity HRR60%, RPE 11\~14 low intensity HRR30%, RPE 9\~11 repeated interval training strength and balance exercises(20min)- program1. upper(shoulder press, chest press, biceps curl), lower(hip flexion, knee extension), Core(plank exercise, sit up) program2. upper(seated back row, triceps extension), lower(hip extension, hip abduction, knee flexion, Core(superman exercise, bridge exercise) repeated ever other day program1, program2 clean-up(5min) - same as warm-up"
214916767|NCT05482113|DRUG|Liposomal bupivacaine|Liposomal Bupivacaine (Exparel) Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
214916768|NCT05482113|DRUG|Bupivacaine Hcl 0.25% Inj|Standard 0.25% Bupivacaine Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
214916769|NCT06162949|DRUG|Vonoprazan|an acid suppressor therapy that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner.
214916770|NCT06162949|DRUG|Amoxicillin|An antibiotic of penicillins antibiotic group
214916771|NCT06162949|DRUG|Clarithromycin|An antibiotic of macrolide group
215060665|NCT06151613|DEVICE|continuous eCTG monitoring using the NFMS|Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
215060666|NCT02589028|DIETARY_SUPPLEMENT|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
215060667|NCT02589028|OTHER|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
215077782|NCT03551665|BEHAVIORAL|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
215077783|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
215077784|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
214480779|NCT06864897|DEVICE|Total hip prothesis|Total hip prothesis with a Delta-TT cup, H MAX S Stem and a ceramic liner
214480780|NCT06864897|DEVICE|Total hip prosthesis|Total hip prosthesis with a Delta TT cup, H MAX S stem and polyethylene liner
214480781|NCT06863688|DEVICE|Tourniquet|Tourniquets will be applied to the thigh of the operative extremity during operative fixation of ankle fractures.
214480782|NCT06863688|OTHER|No Tourniquet|No tourniquet will be inflated on the operative extremity during the operative fixation of ankle fractures.
214670735|NCT01364610|DEVICE|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
214670736|NCT03988712|DIAGNOSTIC_TEST|Colonoscopy, gastroscopy, virtual colonoscopy, CT scan|Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
214670737|NCT02253875|DRUG|Tipranavir (TPV)|
214670738|NCT02253875|DRUG|Ritonavir|
214670739|NCT02253875|DRUG|Omeprazole|
214916772|NCT06162949|DRUG|Esomeprazole|An acid suppressor therapy that blocks the proton pump.
214916773|NCT02233387|OTHER|injection with [18F] HX4 and PET imaging|"A standard clinical \[18F\]FDG PET-CT will be performed for the radiotherapy planning.~After a minimum time interval of 24 hours, baseline \[18F\]HX4 PET scans will be performed:~Based on the phase I trial1 444 MBq (12 mCi) \[18F\]HX4 is administrated via a bolus IV injection.~The first image acquisition is started together with the administration of \[18F\]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i"
214916774|NCT02659007|OTHER|yoga|8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
214916775|NCT01694160|DRUG|Paricalcitol|Zemplar (paricalcitol) 2ug daily, oral intake
214916776|NCT01602211|OTHER|Internet-Based Intervention|Receive full access to INSPIRE
214916777|NCT01602211|OTHER|Internet-Based Intervention|Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site
214916778|NCT01602211|OTHER|Medical Chart Review|Ancillary studies
214916779|NCT01602211|OTHER|Quality-of-Life Assessment|Ancillary studies
214916780|NCT01602211|OTHER|Questionnaire Administration|Ancillary studies
215077785|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
215077786|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
215077787|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
215077788|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
214670740|NCT05987670|DEVICE|AI-stethoscope|"Clinicians at practices in the intervention arm will be provided with one session of in-person training in use of the AI-stethoscope within 2 weeks of randomisation, including~1. Delivery and setup~2. Smartphone app installation and login~3. Pairing of all clinician smartphones with all AI-stethoscopes in the same practice~4. Demo of patient examination The AI-stethoscope will be used within its CE/UKCA-marked intended purpose. The clinical guidelines for use have been agreed by the NHS North West London Integrated Care System and Betsi Cadwaladr University Health Board Cardiovascular Executive Groups. Patients will be examined with the AI-stethoscope in accordance with these guidelines, and/or where stethoscope examination is deemed clinically appropriate. Patients will provide verbal consent for examination with the AI-stethoscope as per any physical examination performed by healthcare professionals for direct care, in accordance with UK law and General Medical Council guidelines."
214670741|NCT03129438|DIAGNOSTIC_TEST|continuous EEG (cEEG)|differential use of continuous versus routine EEG
214916781|NCT05022940|OTHER|Usual gold-standard multidisciplinary rehabilitation for TBI|In individual and group interventions within a holistic interdisciplinary rehabilitation program focusing on resumption of daily activities and social roles. Interventions could include physiotherapy or physical training, occupational therapy, speech therapy, and neuropsychology/psychology, which aimed at reducing the impacts of cognitive difficulties in daily life by using self-guided and environmental strategies.
214916782|NCT03038867|DRUG|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
214309816|NCT02970279|BEHAVIORAL|Behavioural Activation Group (BAG) Psychotherapy|Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
215060668|NCT01162824|DRUG|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
214309817|NCT03365310|DRUG|C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk|Polyherbal formulation along with standard of care
214309818|NCT03365310|OTHER|Standard of Care|Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
214309819|NCT01626807|BEHAVIORAL|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
214309820|NCT02918851|BIOLOGICAL|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
214309821|NCT02918851|BIOLOGICAL|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
214480783|NCT06864078|DEVICE|IUD Insertion during Cesarean Section|to evaluate the analgesic effect of diclofenac potassium and lidocaine gel applied to the posterior vaginal fornix before IUD insertion in women who had previously undergone cesarean section. By assessing the efficacy of this pain management strategy, this study seeks to contribute to the optimization of IUD insertion protocols, improving patient comfort and increasing the acceptance of this highly effective contraceptive method.
214480784|NCT06864078|DRUG|lidocaine gel and diclofenac potassium tablets|lidocaine gel and diclofenac potassium tablets
214916783|NCT03038867|DRUG|Placebo|Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
214916784|NCT01464593|DRUG|Lyso-Thermosensitive Liposomal Doxorubicin|Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
214916785|NCT01464593|OTHER|5% Dextrose Solution|Single 30 minute intravenous infusion
215077789|NCT01049165|DRUG|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
214309822|NCT02918851|BIOLOGICAL|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
214309823|NCT03972280|BIOLOGICAL|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody|Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
214309824|NCT02073279|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
214309825|NCT02073279|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
214309826|NCT01428180|DRUG|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
214309827|NCT01428180|PROCEDURE|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
214309828|NCT01428180|DRUG|Ibuprofen|3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
214309829|NCT02206555|DRUG|emtricitabine/tenofovir disoproxil fumarate|
214309830|NCT01311193|OTHER|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
214480785|NCT06864078|DRUG|Placebo|Placebo
214480786|NCT06865378|PROCEDURE|Carbon dioxide (CO2) gas insufflation|Artificial pneumoperitoneum created by the Trendelenburg position and carbon dioxide (CO2) insufflation, which is widely used in laparoscopic procedures, frequently leads to physiological changes such as postoperative nausea and vomiting (PONV) and pain. Therefore, the currently limited usable parameters PI and PVI will be evaluated in correlation with end tidal CO2 in continuous monitoring.
214309831|NCT00304356|DRUG|Nitazoxanide|500 mg bid
214309832|NCT01983527|PROCEDURE|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
214309833|NCT01983527|DRUG|Intra-articular corticosteroid Depo Medrol|Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
214309834|NCT03357692|PROCEDURE|all on four implant rehabilitation|implant insertion after piezoelectric site preparation for trans-sinusal implants
214309835|NCT03207932|PROCEDURE|Central vein catheterisation|ultrasound guided versus landmark central vein catheterisation
214309836|NCT04227821|OTHER|Vasopressor and/inotrope therapy|In pediatric patients admitted to the pediatric intensive care, with the persistent hemodynamic instability after fluid resuscitation, the vasopressor and/or inotrope therapy will be initiated
214309837|NCT04650477|PROCEDURE|Fixation while forearm in extension-pronation position|Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
214309838|NCT00951028|BEHAVIORAL|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
214309839|NCT00951028|BEHAVIORAL|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
214309840|NCT00951028|BEHAVIORAL|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
214309841|NCT04540289|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure"
214309842|NCT04540289|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
214309843|NCT01028157|BEHAVIORAL|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
214480787|NCT06864377|OTHER|Quality of life questionnair|The questionnaire used is the Abdominal Hernia Q, which is specific to ventral hernias. Patients will receive the questionnaire at baseline and at 1, 3, 6, and 12 months after ventral hernia repair. If treated conservatively, the questionnaire will be administered at 1, 3, 6, and 12 months after completing the baseline questionnaire.
214480788|NCT06865261|DIETARY_SUPPLEMENT|Bioarginina C|Bioarginine®C oral vials is a dietary supplement based on L-arginine and liposomal Vitamin C that is useful for making an integrative share of L-arginine and Vitamin C. Liposomal Vitamin C is a particular type of Vitamin C produced through an innovative technology that optimizes and amplifies its absorption.
214480789|NCT06865261|DIETARY_SUPPLEMENT|Placebo|Vials containing placebo were made to be indistinguishable in appearance from active treatment
214480790|NCT06672679|BEHAVIORAL|Juntos|6 week family-based intervention
214480791|NCT06672679|BEHAVIORAL|Resource guide|Active control arm will receive a resource guide
214670742|NCT03129438|DIAGNOSTIC_TEST|routine EEG (rEEG)|differential use of continuous versus routine EEG
214670743|NCT00003270|BIOLOGICAL|anti-thymocyte globulin|IV
214670744|NCT00003270|BIOLOGICAL|filgrastim|IV
214670745|NCT00003270|DRUG|busulfan|IV
214670746|NCT00003270|DRUG|cyclophosphamide|IV
214309844|NCT01028157|BEHAVIORAL|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
214309845|NCT04078685|PROCEDURE|Standard catheter ablation|Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
214309846|NCT04078685|PROCEDURE|Contact Force-sensing-based catheter ablation|Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
214309847|NCT00083681|DRUG|Thalidomide|
214309848|NCT00083681|DRUG|Dexamethasone|
214309849|NCT00083681|DRUG|Cytoxan|
214309850|NCT00083681|DRUG|Etoposide|
214309851|NCT00083681|DRUG|Cisplatin|
214309852|NCT00083681|DRUG|G-CSF|
214309853|NCT03297385|DRUG|Enzalutamide|Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
214309854|NCT04718142|DEVICE|vNEP|Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
214309855|NCT01517672|BEHAVIORAL|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
214309856|NCT04130230|DRUG|Neostigmine|Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.
214309857|NCT04130230|DRUG|Standard therapy|Standard therapy for sepsis and septic shock
214916786|NCT01464593|DRUG|ThermoDox|ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
214916787|NCT00302328|PROCEDURE|macular hole operation|macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
214309858|NCT04941456|OTHER|Open Tracheostomy|Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.
214916788|NCT02183883|DRUG|Afatinib|"40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.~EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade \> 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg."
215060669|NCT01162824|DRUG|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
215060670|NCT04020471|OTHER|Pain Scale/Medication Log|Daily recording of pain level after surgery and recording of medication taken for pain relief.
215060671|NCT00249652|BEHAVIORAL|TAP|12-session motivational interviewing-based telephone intervention.
214309859|NCT04941456|DEVICE|PMV in place|Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.
214480792|NCT06864247|OTHER|No Intervention: Observational Cohort|No intervention
214480793|NCT06863454|DIAGNOSTIC_TEST|Trichoscopy|Trichoscopy will be done on patients with PV disease activity and remission
214480794|NCT06859814|PROCEDURE|urinary catheterization|urine samples for culture and sensitivity will be collected in patients having urinary tract infection and we will use sterile container 50cc for urine sampling culture on blood or macconkey medium for detection type of organism .
214480795|NCT06858969|DRUG|Treatment group|Chidamide+XELOX + Bevacizumab+PD-1
214480796|NCT06858969|DRUG|Standard-of-care control group|XELOX + Bevacizumab+PD-1
214670747|NCT00003270|DRUG|cyclosporine|IV
214916789|NCT05688839|DRUG|Jaktinib hydrochloride tablets|2 doses per day, 100mg Jaktinib
214309860|NCT03082599|DEVICE|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
214309861|NCT01742507|DEVICE|Resolute Integrity Stent|Resolute Integrity Stent
214309862|NCT01742507|DEVICE|Biomatrix stent|Biomatrix stent
214309863|NCT03057665|DEVICE|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
214309864|NCT04803669|PROCEDURE|Intrument-assisted soft tissue mobilization technique|This technique; It is applied with the help of a tool made of stainless steel. The instrument is rubbed on the skin at an angle of about 30 degrees, creating a massage-like effect on the soft tissue (2 sessions per week and 5 minutes per session, 8 sessions in total for 4 weeks).
214309865|NCT04803669|PROCEDURE|Conventional Treatment|Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
214309866|NCT00075426|DRUG|arsenic trioxide|
214309867|NCT01825382|DEVICE|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
214480797|NCT06857097|PROCEDURE|single anastomosis sleeve jejunal bypass|sleeve was created starting devascularization of greater gastric curve 6 cm proximal to pylorus. Devascularization was done via either a harmonic scalpel or a ligasure device. Dissection was continued proximally till reaching the left diaphragmatic crus. Afterwards that the stomach was resected along the greater curvature via an endostapler over a 36-Fr bougie. After creating the sleeve, two meters of the small bowel were counted starting from the ligament of Treitz, and an antecolic isoperistaltic gastrojejunostomy (4-cm wide) was created with the antrum via linear stapler, and the anterior wall defect was closed by sutures.
214480798|NCT06857097|PROCEDURE|One anastomosis gastric bypass|dissection started just distal to the crows' foot till reaching the lesser sac. A long narrow gastric pouch was created by the endostapler. After that, a longitudinal gastrojejunostomy (4-cm wide) was created at 200 cm distal to the Treitz ligament as the SASJ group.
214480799|NCT06859931|DRUG|TQB3702 Tablets|TQB3702 is a selective kinase inhibitor.
214480800|NCT06859931|DRUG|TQB3702 Tablets+TQB3702 Placebo|TQB3702 is a selective kinase inhibitor； A placebo is a simulated drug whose physical properties, such as appearance, size, color, dosage form, weight, taste, and odor are substantially the same as the test drug, but cannot contain the active ingredients of the test drug.
214480801|NCT06859931|DRUG|TQB3702 Placebo|TQB3702 Placebo without drug substance.
214480802|NCT06856096|DIAGNOSTIC_TEST|PET/MRI|PET/MR imaging using an integrated TOF PET/MR scanner (Signa, GE Healthcare, WI, USA)
214670748|NCT00003270|DRUG|methylprednisolone|IV
214670749|NCT00003270|PROCEDURE|bone marrow ablation with stem cell support|IV
214670750|NCT00003270|PROCEDURE|umbilical cord blood transplantation|IV
214670751|NCT00003270|RADIATION|radiation therapy|High energy X-rays
214916790|NCT05688839|DRUG|placebo|2 doses per day, placebo
215060672|NCT00249652|OTHER|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
215060673|NCT05954208|OTHER|Vısual Arts Group Therapy Based On Watson's Human Care Model|VAGT-WHCM was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups.
215060674|NCT05954208|OTHER|Ongoing treatment|The control group participated only in the routine follow-up, treatment and practices in the institution.
215077790|NCT01049165|DRUG|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
215077791|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
215077792|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
215077793|NCT05538312|DRUG|vepdegestrant|Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant
214916791|NCT00435708|BEHAVIORAL|5 portions fruit and vegetables/day|Participants consume \> = 5 portions fruit and veg per day
214309868|NCT03239587|BEHAVIORAL|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
214480803|NCT06854354|BEHAVIORAL|HPV Prevention Vaccine|The educational intervention was implemented through a private Facebook group, facilitating access to HPV vaccine information. A user guide was provided and profiles were verified for authenticity using a non-duplicity algorithm. Prior to access, mothers completed questionnaires to assess their knowledge, beliefs and acceptance. The intervention lasted four weeks and included four modules with videos, handouts and infographics. The first session provided information on HPV, its transmission and prevention. The second highlighted the benefits of the vaccine and debunked myths. The third showed testimonials from mothers who had their daughters vaccinated. The last session was a videoconference with group dynamics to resolve doubts. The sessions were held weekly and access and duration were monitored within the group. After finishing, the group was temporarily closed to avoid biases in the second measurement, allowing free access to the contents.
214480804|NCT06854354|OTHER|Placebo|The CG did not have an educational intervention, nor the use of any placebo, the test instruments were applied and a month after this, they were invited to a virtual platform where they were asked to answer again the measurement instruments, once obtained the filling of the questionnaires they were invited and provided the user guide that allowed them to participate and learn about the Facebook group, as well as view the educational materials, to obtain the same benefits as the GE
214480805|NCT06859151|OTHER|Reproductive tract microbiota|Reproductive tract microbiota
214480806|NCT02926690|DRUG|OTS167PO|Single arm, no competitor
214480807|NCT06860425|OTHER|RestoreMe|Comprehensive mobile device application
214480808|NCT06671041|DRUG|Preservative Free eye drop|Participants were required to use a lubricating eye drop
214480809|NCT06671535|DEVICE|Polymethylmethacrylate membrane|A polymethylmethacrylate hollow fiber membrane (PMMA membrane) has unique properties including the uniform structure and the adsorption property.
214916792|NCT03317314|DIAGNOSTIC_TEST|Lung Biopsy during LVAD Implantation|Lung Biopsy during LVAD Implantation
214916793|NCT02888041|DRUG|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
214309869|NCT03239587|PROCEDURE|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
214309870|NCT03239587|BEHAVIORAL|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
214309871|NCT01424423|DRUG|Placebo|Placebo
214309872|NCT01424423|DRUG|GSK1223249|I.V. Infusion
214309873|NCT05497492|DRUG|propofol|single administration of propofol
214309874|NCT05497492|DRUG|propofol and sufentanil|administration of propofol and sufentanil in combination
214480810|NCT06671535|DEVICE|polysulfone membranes|Dialyzers containing polysulfone membranes are widely used for modern dialysis therapies as they allow efficient removal of a broad spectrum of uremic toxins.
214480811|NCT06861361|DEVICE|Myval balloon-expandable THV Series|Patients receive Myval balloon-expandable THV Series (TAVR)
214670752|NCT02378753|BIOLOGICAL|rVSVΔG-ZEBOV|The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
214916794|NCT02888041|DRUG|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
214916795|NCT05540847|PROCEDURE|Interfascial Injection|Interfascial Injection on Ultrasound-guided Obturator Nerve Block
215077794|NCT05538312|DRUG|Itraconazole|Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
214309875|NCT05497492|DRUG|propofol and esketamine|administration of propofol and esketamine in combination
214309876|NCT05497492|DRUG|propofol and lidocaine|administration of propofol and lidocaine in combination
214309877|NCT00729183|DRUG|Odanacatib|Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
214309878|NCT00729183|DRUG|Placebo|Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
214309879|NCT00729183|DRUG|Vitamin D3|Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
214309880|NCT00729183|DRUG|Calcium supplement|Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.
214309881|NCT04085198|PROCEDURE|Light physics enhanced 'no-touch' hysteroscopy|The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.
214309882|NCT04085198|PROCEDURE|Standard hysteroscopy|Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
214309883|NCT00464425|PROCEDURE|Electroacupuncture|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
214309884|NCT00464425|PROCEDURE|Sham Acupuncture|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
214480812|NCT06861361|DEVICE|Surgical bioprosthetic valve|Patients receive any surgical bioprosthetic valve commercially available at the clinical investigation site (SAVR)
215077795|NCT03637712|DEVICE|Computer Algorithm|This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
214916796|NCT05540847|PROCEDURE|Subpectineal Injection|Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
214916797|NCT04267679|DRUG|Cannabidiol|25 mg full-spectrum CBD soft gel capsules
214309885|NCT00464425|OTHER|No Acupuncture|Control
214916798|NCT01288937|DRUG|Milnacipran|"Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)"
214309886|NCT05106244|OTHER|Real-Time Guidance of Home Care for Patients with PICC or PORT|the experimental group adopted the family self-nursing mode, mainly by the patients' family members to observe the catheter and do regular nursing, and the specialist nurses provided remote real-time online guidance to monitor the family nursing of central venous catheter. The procedures are as follows: (1) make nursing videos recorded by central venous catheter specialist nurses; (2) evaluate the nursing operation ability of the patients' family members and carry out relevant training and health education, repeat until they are qualified; (3) distribute nursing guidance prescriptions and maintenance manuals for central venous catheters; (4) provide online simulated realistic nursing video materials; (5) provide real-time telephone audio and video connection to complete remote nursing guidance. (6) set up a home nursing volunteer service group, establish a doctor-patient exchange group by using Wechat and other media.
214309887|NCT05584865|OTHER|Digital occluar prosthesis|Each patient will receive the full digital fabricated ocular prosthesis. DICOM data from the Computerized Tomography (CT) will be imported into Materializes Interactive Medical Image Control System (MIMICS) software++++ tool for visualizing and segmenting medical images (such as CT and MRI)
214309888|NCT05584865|OTHER|Conventional occluar prosthesis|An accurate impression of the patient's eye socket will be obtained to prepare a suitable wax mod. The wax model will be flasked and processed into heat cured acrylic resin of the same colour of the sclera of the other healthy eye of the patient
214309889|NCT01660854|BIOLOGICAL|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
214309890|NCT01660854|DRUG|Malarone treatment|Three days: 4 tablets 250/100mg per day
214309891|NCT00181012|DRUG|Lidocaine|
214309892|NCT01365390|OTHER|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to \< 6 years) or since birth (for subjects aged \< 1 year) will be recorded in the electronic case report form.
214309893|NCT01365390|OTHER|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
214309894|NCT00267722|DRUG|Visilizumab|
214309895|NCT03976063|DRUG|Nifedipine|Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
214309896|NCT03976063|DRUG|Placebo of Nifedipine|Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
214309897|NCT03027895|DEVICE|Lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage of WON with LAMS
214309898|NCT03027895|DEVICE|Double pigtail plastic stent (DPPS)|Endoscopic Ultrasound-guided Drainage of WON with DPPS
214309899|NCT04500184|OTHER|cardiac rehabilitation|rehabilitation performed by professional trainers
214480813|NCT06860711|DRUG|NSAIDs|IV formulation: ketorolac 0.5mg/kg/dose, 15mg maximum, no more than 8 doses total PO formulation: ibuprofen suspension 10mg/kg/dose, 400mg maximum Total duration (IV + PO) will not exceed 5 days.
214480814|NCT06860711|DRUG|Placebo|IV or PO medication, compounded to have similar look, consistency and taste to the corresponding medications
214916799|NCT01288937|DRUG|Placebo|Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
214916800|NCT02733848|DRUG|Creon|"Creon is a porcine derived pancreatic enzyme supplement that comes in in fixed dose combinations of lipase, protease, and amylase, respectively. Dosing is based on lipase per kilograms per meal (i.e. lipase units/kg/meal). Subjects will be started at a dose of 500 units of lipase/kg/meal and snacks at week 4 and continued until week 8. A follow-up visit at week 6 will assess patient for tolerance to Creon and need for dosage adjustment.~Formulations come in different fixed dose combinations as follows:~Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units~Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units~Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units~Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units~Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units"
214309900|NCT01519882|OTHER|Placebo|"Placebo patches size equivalent to 4, 6 \& 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day."
214480815|NCT06862193|BEHAVIORAL|HealthyMoms4MentalHealth|The intervention is a mobile application targeting women during the perinatal period, aiming to promote mental wellbeing.
214480816|NCT06672315|DIAGNOSTIC_TEST|transesophageal echocardiography|Confirmation of chest compression positioning via transesophageal echocardiography (TEE)
214480817|NCT06864286|BEHAVIORAL|Move for Health|"This multi-domain health promotion intervention utilizes the Community-Based Health Promotion Program for Older Adults - Healthy Exercise Class developed by the Health Promotion Administration (Taiwan). This intervention emphasizes a multi-dimensional health approach, focusing on healthy aging, exercise, and cognitive interventions, supplemented by elements of oral health, nutrition, and social participation. The program aims to promote older adults' health self-management capabilities. This 12-week program meets once weekly for two hours per session. Healthy aging curriculum covers important health issues for older adults, such as fall prevention, healthy eating, oral health, vision care, dementia prevention, medication safety, and knowledge related to healthy lifestyle behaviors including home-based exercise."
214480818|NCT06442774|OTHER|Mobile application|"The intervention that has been developed is a digital tool of a biopsychosocial nature based on the main cognitive-behavioral strategies: psychoeducation, reflection, self-observation, guided visualizations, mindfulness and progressive muscle relaxation.~The intervention consists of 3 main areas of work:~* Programs: Biopsychosocial programs in text and audio format.~* Community: Forum with directed questions and space to share experiences between mothers.~* Diary: Space to record mood and emotional record.~The entire tool works transversally in 4 dimensions: self-care, relationship with perinatal changes, relationship with the baby, social relationship.~The tool itself includes 3 mental health and well-being screening questionnaires: Whooley Questionnaire and the Edinburgh Postnatal Depression Scale (EPDS)."
214480819|NCT06442774|OTHER|Monitoring via wearable|Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).
214670753|NCT02473653|BIOLOGICAL|HER-2/neu Pulsed DC1 vaccine|There will be no exceptions to eligibility, contraindicated treatment/therapies/interventions or safety tests.
214309901|NCT01519882|OTHER|Rotigotine|"Rotigotine patches of 4,6 \& 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day."
214309902|NCT00827879|BEHAVIORAL|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
214309903|NCT00827879|BEHAVIORAL|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
214309904|NCT05687591|DEVICE|Amplatzer Amulet Left Atrial Appendage Occlusion Device|The Amplatzer Amulet LAAO is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constucted from a nitinol mesh and consists of a lobe and a disc connected by a central waist. Polyester patches are sewn into both the lobe and disc to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires that permit visibility during fluoroscopy.
214309905|NCT00323115|BIOLOGICAL|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
214309906|NCT00323115|DRUG|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
214309907|NCT00323115|PROCEDURE|Radiotherapy|RT is standard of care (SOC) post surgery
214309908|NCT00323115|BIOLOGICAL|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
214309909|NCT02062918|DEVICE|Abdominal belt|
214670754|NCT03572634|DRUG|TP-0903|"Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression."
214916801|NCT02733848|OTHER|Diet|A registered dietician will meet with the subject and take a thorough review of the patient's dietary history. The subject will then be counseled on a lower carbohydrate and higher protein diet. This diet will be continued for the entire 12 week of the study. The registered dietician will reinforce dietary recommendations by phone on week 2, 4 and 8, respectively.
214916802|NCT02733848|OTHER|Placebo|Placebo will be given to the patient in single blind fashion with the subject unaware but PI aware of study drug assignment from week 8-12. Placebo tablets will be given with meals and snacks similar to CREON to maintain patient blinding to study drug assignment. A follow-up visit on week 10 to review patient tolerance, side effects and possible drug adjustment.
214916803|NCT03637062|DRUG|Progesterone|progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
214916804|NCT03637062|DEVICE|pessary|pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.
214916805|NCT02695966|PROCEDURE|Whipples Surgery|Whipples Surgery
214309910|NCT05191680|DRUG|Apalutamide Oral Tablet [Erleada]|Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.
214309911|NCT05191680|DRUG|Placebo|Placebo to match apalutamide
214309912|NCT06593522|DRUG|AMG 193|Film-coated tablet
214309913|NCT05656768|OTHER|Constant Routine Protocol|A constant routine protocol is used to directly examine markers of circadian rhythmicity (e.g., melatonin and core body temperature). A constant routine protocol requires an individual to remain in a dimly lit room, in a constant semi-recumbent posture, and remain awake for more than 24 hours. It is one of two gold-standard research protocols for examining circadian rhythms in humans.
214309914|NCT06198556|DRUG|HRS-1167 tablets; rifampicin|HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.
214309915|NCT06494449|OTHER|Higher protein|An acute mixed meal containing higher protein
214309916|NCT06494449|OTHER|Lower protein|An acute mixed meal containing lower protein
214309917|NCT00310583|DRUG|Pregabalin|
214480820|NCT06864039|DIAGNOSTIC_TEST|SF36 test|Assessment of quality of life by administering the SF36 test
214480821|NCT06864039|DIAGNOSTIC_TEST|WAIS IV test|Assessment of cognitive abilities by administering the WAIS IV test
214480822|NCT06864039|DIAGNOSTIC_TEST|SCL-90 psychopathological screening questionnaire|Assessment of any psychopathological conditions by means of the SCL-90 psychopathological screening questionnaire
214480823|NCT06864039|DIAGNOSTIC_TEST|CBCL questionnaire|For patients up to 18 years of age: CBCL questionnaire to be administered to parents to describe the patient's behavior
214480824|NCT06864039|DIAGNOSTIC_TEST|bioimpedance analysis|Assessment of body composition by performing bioimpedance analysis
214480825|NCT06863389|PROCEDURE|Chen's U-suture technique|Initially, an approximately 2 cm cut edge of the pancreas remnant was mobilized and a incision of the jejunal loop was conducted slightly shorter than the pancreatic remnant. Using dual-needle 3-0 prolene suture for anastomosis, needle A went through the entire intestinal wall from the posterior wall about 1.5 cm away from the resection margin of the jejunum loop, then went through the superior boarder of the pancreas from posterior to anterior. To suture the anterior wall of the jejunum loop, the stitch next entered from the resection margin of the jejunum loop and kept it within the seromuscular layer from proximal to distal, and got out from about 1.5 cm away from the resection margin. Needle B repeated the aforementioned procedures with a parallel distance about 1.0 cm between needle A. Generally, the whole anastomosis needed two to four identical stitches. The stitches should overlap each other to reduce pancreatic leakage. Once all the stitches were finished and tighte
214480826|NCT06863389|PROCEDURE|invagination|Firstly, using 3-0 silk sutures, the pancreatic capsule and the serosa of the jejunal loop were anastomosed interruptedly to constitute the posterior outer layer of the anastomosis. Secondly, a jejunotomy with an appropriate size was performed and the inner layer (including posterior and anterior) of invagination was formed by two 5-0 prolene sutures with a continuous running between the pancreatic parenchyma and the full-thickness jejunum. Thirdly, the anterior outer layer was sutured in line with the first step.
214480827|NCT06863389|PROCEDURE|Duct-to-Mucosa|Briefly, Duct-to-Mucosa should make a opening matched to the pancreatic duct and was also performed by two layers. One was the outer layer in both the anterior and posterior walls of the anastomosis which were formed by interrupted 3-0 silk sutures betweent the pancreatic capsule and the jejunal serosa. The other was the inner layer performed in eight to twelve stitches from pancreatic duct to jejunal mucosa with 5-0 prolene sutures.
214480828|NCT06864741|BEHAVIORAL|Virtual reality guided motor rehabilitation|Custom rehabilitation exercises running on a Meta Quest 2/3S/3 head mounted virtual reality display.
214480829|NCT06864117|OTHER|Body position during urodynamics|"The group defines the body position in which the first and second measurements are taken.~Group A: sitting, lying down (s/l). Group B: lying down, sitting (l/s). According to the ICS standard, the third measurement is always taken in a sitting position."
214480830|NCT06863181|DEVICE|Radiofrequency ablation|Genicular nerve neurolysis with heat
214480831|NCT06520072|BEHAVIORAL|Children Eating Well (CHEW) mobile app|"The target users of the CHEW app are parents/guardians of preschool aged children. The purpose of the CHEW app is to provide parents/guardians with easy, practical ways to improve nutrition and wellness among their preschool-aged children. The app provides guided goal setting and tracking tools. Parents/guardians set goals related to their preschool-aged children focused on nutrition, physical activity, sleep behaviors and parenting styles. The parents/guardians can also to set goals for themselves for behaviors related to nutrition, physical activity, sleep, and stress. The app does not have features that target children as users.~The CHEW app was developed by the study team and can be downloaded for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). After downloading the CHEW app, enrolled participants must enter the Access Code provided by the study team in order to unlock the app and use it."
214480832|NCT06520072|BEHAVIORAL|Beanstalk mobile app|"Beanstack is free commercially-available mobile app that provides goal setting and tracking tools similar to the CHEW app, but focused on a different topic, specifically encouraging parents/guardians to read to their preschool children more frequently. In the case that a parent/guardian is not able to successfully download Beanstack to their mobile device, as a backup alternative they will be asked to use a similar free commercially-available mobile application called Bookroo.~Beanstack is available to the public for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). Bookroo is a web-based application that users access via the mobile device's web browser and looks and functions like a regular mobile application. It should work on any mobile device with a browser and data/wifi access,"
214480833|NCT06756841|DEVICE|PEF treatment|PEF energy delivery via endoscope
214480834|NCT02853500|DEVICE|TriNav|TriNav is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
214670755|NCT03572634|COMBINATION_PRODUCT|TP-0903 and ibrutinib combination therapy|"Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period)."
214309918|NCT04166721|DRUG|Atezolizumab|Immunotherapy
214309919|NCT05366803|BEHAVIORAL|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
214309920|NCT06914271|COMBINATION_PRODUCT|Kendall Exercise|The Kendall Exercises focus on correcting posture, strengthening the core, and re-educating muscles to improve spinal alignment and reduce pain .These exercises primarily target specific muscles and joint actions to help patients regain their range of motion.
214309921|NCT06914271|COMBINATION_PRODUCT|Kabat Exercises|The principle of the Kabat exercises is based on a series of neuromuscular facilitation techniques that emphasize dynamic movement patterns, flexibility, and coordination to enhance functional mobility and alleviate pain.
214309922|NCT00001598|DRUG|Dehydroepiandrosterone|
214309923|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 1|1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
214309924|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 2|1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
214309925|NCT06858475|DEVICE|CONTROL-IQ (Tandem™)|interaction with the CONTROL-IQ (Tandem™) hybrid closed-loop (HCL) system in individuals with type 1 diabetes
214309926|NCT06529835|DEVICE|NeuroSpan Bridge|"The implant is used to connect peripheral nerve discontinuities. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap.~The NeuroSpan Bridge is a novel scaffold to support regeneration that mimics the natural bio- architecture, providing multiple channels that are strictly linear so that axonal position is accurately maintained across the full length of the scaffold - over any length - to re-enter the distal nerve stump."
214309927|NCT06529835|DEVICE|NeuroGen Nerve Guide|The NeuraGen Nerve Guide is a resorbable implant for the repair of 0.5-1.0cm peripheral nerve discontinuities. NeuraGen Nerve Guide provides a protective environment for peripheral nerve repair after injury. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap. The semi-permeable type 1 collagen membrane allows for controlled resorption, appropriate nutrient diffusion and retention of representative Nerve Growth Factor.
214309928|NCT06529835|DEVICE|Nerve Autograft|A nerve autograft is a surgical procedure that involves transplanting a segment of a patient's own sensory nerve tissue to repair a damaged peripheral nerve injury measuring 1.1-3.0cm. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap
214309929|NCT06356857|DIAGNOSTIC_TEST|Myocardial perfusion imaging (MPI) using [O15]H2O-PET-CT|Re-scan for comparison with initial scan
214309930|NCT02280941|OTHER|single photon emission computed tomography|Single photon emission computed tomography (SPECT) imaging will be done.
214309931|NCT00721773|DRUG|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
214309932|NCT00721773|DRUG|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
214309933|NCT00721773|DRUG|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
214309934|NCT00721773|DRUG|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
214480835|NCT02853500|DEVICE|Traditional Delivery|Low profile tubing microcatheter for easier access to more peripheral/distal vascular branches for precise targeted delivery of medications.
214480836|NCT02853500|DRUG|Doxorubicin|Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
214480837|NCT06540547|BEHAVIORAL|MomMA Intervention|Parents will receive sessions of CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings. The number and specific content of sessions will be determined based on community partner feedback.
214480838|NCT03817983|DIAGNOSTIC_TEST|MRE review for evidence of axSpA in SIJs|Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease
214309935|NCT06622655|DEVICE|Powered orthosis|Home rehabilitation (2 months, 30 minutes/day, 5 days/week) during which subjects will practice walking with the device at home.
214480839|NCT03817983|DIAGNOSTIC_TEST|Clinical assessment and dedicated MRI of the spine and pelvis|Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA
214480840|NCT01993810|DRUG|Carboplatin|Given IV
214480841|NCT01993810|DRUG|Cisplatin|Given IV
214480842|NCT01993810|BIOLOGICAL|Durvalumab|Given IV
214916806|NCT04242472|BEHAVIORAL|SMS-based Mobile Health intervention|Nutritional related SMS text message mobile health intervention will be provided to Tuberculosis patients.
214916807|NCT02719717|DEVICE|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
214480843|NCT01993810|DRUG|Etoposide|Given IV
214480844|NCT01993810|DRUG|Paclitaxel|Given IV
214480845|NCT01993810|DRUG|Pemetrexed Disodium|Given IV
214916808|NCT05369338|DEVICE|Low Level Light Therapy|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
214916809|NCT05369338|DEVICE|Sham Controll|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
214916810|NCT06969482|BEHAVIORAL|measuring knowledge level|The study group consists of 70 nurses, each consisting of 35 people. After the routine training of the hospital was given to the control and experimental groups, their consents were obtained and the pre-tests were completed, they were divided into experimental and control groups using simple randomization. The first group of nurses in the control group will not receive any intervention other than the routine training given by the hospital.
214916811|NCT06969482|OTHER|educational intervention|the effectiveness of training by making measurements after training and comparing them with pre-training results
214916812|NCT02490371|DEVICE|Low frequency rTMS|1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
214916813|NCT02490371|BEHAVIORAL|structured physiotherapy upper limb training|Structural Physiotherapy upper limb training for 30-minutes
214916814|NCT03067532|PROCEDURE|existed simulation system user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
215077796|NCT03274427|DEVICE|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
214309936|NCT06626269|DIAGNOSTIC_TEST|Blood sample|"In cohort A: 3 or 4 blood samples (for plasma and PBMC collection) : at baseline (before immunotherapy initiation); at 3 months ; at 12 months; on case of severe or unexpected toxicity.~In cohort B: 3 blood sampes (for plasma and PBMC collection): at baseline (before treatment initiation); at 3 months ; at 12 months~In cohort C: 2 blood samples (for plasma and PBMC collection) : at baseline (at the time of surgery); at 3 months (after surgery)"
214309937|NCT06626269|OTHER|Tumor tissue|Cohort A and B: 1 tumor block in paraffin at diagnosis + 1 tumor block in paraffin at progression (optional) Cohort C: Fresh tumoral tissue fragments for TIL and CAF + 1 tumor block in paraffin at time of surgery.
214309938|NCT01502423|BIOLOGICAL|Adalimumab|Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
214309939|NCT02208609|OTHER|Day 1: Maize Tortillas with 20% Amaranth|Subjects received Maize tortillas with 20% Amaranth added.
214309940|NCT02208609|OTHER|Day 2 Maize Tortillas without 20% Amaranth|Maize tortillas without Amaranth.
214309941|NCT05903378|OTHER|Relational touch practice|Relational touch practice during the first bedside session. Touch in care aims to improve the patient's perception of potentially painful or anxiety-provoking acts of care. It is based on techniques of skin contact, developing and deepening.
214309942|NCT00567892|DEVICE|rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
214309943|NCT05650658|DEVICE|His/LBBP|Pacing at the level His-Bundle or left bundle branch is used to correct the underlying conduction abnormality, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular defibrillator endocardial lead for LVEF≤35% and by a right atrial endocardial lead for LVEF 36-50%.
214309944|NCT05650658|DEVICE|BiVP|"Biventricular pacing has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.~For LVEF≤35% a biventricular pacemaker-defibrillator will be implanted while for LVEF 36-50% a biventricular pacemaker will be implanted."
214309945|NCT06636656|DRUG|BI 3032950 intravenous (Part A)|BI 3032950 intravenous (Part A)
214309946|NCT06636656|DRUG|BI 3032950 subcutaneous (Part B)|BI 3032950 subcutaneous (Part B)
214309958|NCT06783309|DRUG|CNP-103|CNP-103
214309959|NCT06783309|DRUG|Placebo|0.9% sodium chloride for injection
214309960|NCT07059182|BIOLOGICAL|Inactivated whole-cell Streptococcus pneumoniae vaccine|Single intramuscular injection of 1 mg protein/0.5 mL wSp vaccine
214309961|NCT07059182|DRUG|Placebo|Single intramuscular injection of 0.5 mL placebo
214480846|NCT01993810|RADIATION|Photon Beam Radiation Therapy|Undergo photon beam radiation therapy
214480847|NCT01993810|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
214480848|NCT01993810|OTHER|Quality-of-Life Assessment|Ancillary studies
214916815|NCT03067532|PROCEDURE|home made simulator user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
214916816|NCT05732571|OTHER|Breathing techniques over 12 sessions / 6 weeks inc yoga|as above
214916817|NCT05623540|DRUG|Bisphosphonates, Combinations|
214916818|NCT06566872|DEVICE|ME-APDS|No Intervention
214916819|NCT06968429|DRUG|NBP Softgel Capsules|take orally on an empty stomach；2 capsules 3/day
214916820|NCT06968429|DRUG|Placebo|take orally on an empty stomach；2 capsules 3/day
214916821|NCT01760031|OTHER|Ischemic preconditioning|Subjects received ischemic preconditioning previous to cardiac catheterization
214916822|NCT03219814|OTHER|The Body Project|The Body Project is a dissonance-based body-acceptance program designed to help high school girls and college-age women resist cultural pressures to conform to the appearance ideal standard of female beauty and reduce their pursuit of unrealistic bodies. The Body Project is supported by more research than any other body image program and has been found to reduce onset of eating disorders.
214916823|NCT03219814|OTHER|Mediapsychoeducation|Mediapsychoeducation is used to educate individuals on psychological issues through the use of various medias, in this study mediapsychoeducation is being used to educate individuals on eating disorders and the thin ideal.
214309962|NCT07057596|DRUG|Tebentafusp|"Patients will receive tebentafusp intravenously (IV) weekly for 6 months with liver directed imaging every 2 months to identify rapid progressors. Tebentafusp will be administered at 20 micrograms on W1D1, 30 micrograms on W2D1, and 68 micrograms once every week thereafter.~After 6 months, patients with complete response (CR) according to RECIST will continue tebentafusp therapy (surgery might be an option if deem appropriate by local PI); while patients achieving partial response or stable disease will be evaluated for tumor resection and will enter into Surgery phase. Surgery will be conducted 7 months (+/- 1 month). If progressioh disease (PD) occurs earlier surgery can happen earlier. After surgery, patients without pCR or R0 surgery will maintain tebentafusp until disease relapse, unacceptable toxicity or patient withdrawal. Patients with pCR and R0 will continue tebentafusp therapy for 1 additional year or until disease relapse, unacceptable toxicity or patient withdrawal."
214309963|NCT06347133|DRUG|Plozasiran Injection|ARO-APOC3 Injection
214309964|NCT06347133|DRUG|Placebo|sterile normal saline (0.9% NaCl)
214309965|NCT06753175|DEVICE|underwater galvanic stimulation by 4-cell bath|"Underwater Galvanic Stimulation:~* Equipment: 4-cell bath~* Procedure: Patients will immerse their affected limbs in the 4-cell bath. Electrical stimulation will be applied at a frequency of 15 Hz and intensity of 20 mA for 20 minutes, 3 times per week (Han et al. 2020)."
214309966|NCT06753175|OTHER|Complete Decongestive Therapy (CDT):|"Complete Decongestive Therapy (CDT):~* Manual Lymphatic Drainage (MLD): 60 minutes per session, 3 days per week.~* Compression Therapy: Multilayer bandaging applied after MLD.~* Exercise: Specific exercises performed with compression in place.~* Skin Care: Routine skin and nail care to prevent infections (Curlett et al. 2020)."
214309967|NCT07066371|BEHAVIORAL|Emotional freedom technique|"Emotional Freedom Technique Application Guidelines~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with SUDS again"
214309968|NCT07066852|RADIATION|x ray|we performed pelvis ap and frog leg x ray to child in 6 month and 1 age
214309969|NCT07066852|DIAGNOSTIC_TEST|ultrasound|we will perform ultrasound in 6 week and 3 month
214309970|NCT06774027|PROCEDURE|Specimen collection|Blood specimens will be collected during regular clinical visits for correlative and exploratory analysis
214309971|NCT06774027|DRUG|Non-Investigational Antibody-Drug Conjugates (ADC)|ADC given under usual care for the treatment of cancer
214309972|NCT06774027|OTHER|Medical Record Review|Prospective and retrospective medical chart reviews will be conducted to obtain data for analysis.
214309973|NCT06771453|OTHER|Video Educational Tool Regarding Prenatal Genetics|Video education about prenatal genetics will include content regarding aneuploidy screening and diagnostic testing options, how to make a values-based choice, and specifics of risks/benefits/limitations of each type of testing option.
214309974|NCT07066384|OTHER|breathing yoga|"Yoga Breathing Exercises:~1. Sama Vritti or Equal Breathing:~2. Abdominal Breathing Techniques:~3. Nadi Shodhana or Alternating Breathing:~4. Kapalabhati or Skull Shining Breath:~5. Progressive Muscle Relaxation:~6. Guided Visualization:"
214309975|NCT07066384|OTHER|PMRTs-Progressive Muscle Relaxation Techniques|While patients are breathing in and out, tightening and releasing exercises are applied to 11 different muscle groups. It is applied for 15-20 minutes.
214309976|NCT07067788|DIAGNOSTIC_TEST|Breast Imaging|Intervention using an FDA-approved mammogram machine.
214309977|NCT06810934|BIOLOGICAL|CoTend-BXBB (SARS2-30404)|Ad35-vectored SARS-CoV-2 RBD (XBB.1.5) vaccine
214309978|NCT06810934|BIOLOGICAL|CoTend-s3BXBB (SARS2-17032)|Ad35-vectored s3-SARS-CoV-2 RBD (XBB.1.5) vaccine
214309979|NCT06810934|BIOLOGICAL|Placebo|Sterile sodium chloride 0.9% for injection, preservative free
214309980|NCT06776926|BEHAVIORAL|Carbetocin|Use of carbetocin
214480849|NCT01993810|OTHER|Questionnaire Administration|Ancillary studies
214480850|NCT06069427|BEHAVIORAL|Sprint interval training (SIT)|The SIT protocol consists of 4 repeated 30-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 4-minute warm-up consisting of unloaded pedalling. Each sprint will be followed by 4 minutes of unloaded pedalling.
214480851|NCT06069427|BEHAVIORAL|Reduced-exertion high-intensity interval training (REHIT|The REHIT protocol consists of 2 repeated 20-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 2-minute warm-up consisting of unloaded pedalling. The first sprint will be followed by 3 minutes of unloaded pedalling, and the second sprint will be followed by 4 minutes of unloaded pedalling.
214480852|NCT06069427|BEHAVIORAL|No-exercise control (CON)|The control condition will involve seated rest for a period equivalent to the other interventions.
214480853|NCT06616597|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg/ day
214309981|NCT07070479|DRUG|Ivonescimab|Ivonescimab 10 mg/kg via intravenous infusion, until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.
214309982|NCT07070479|DRUG|Nimotuzumab|Nimotuzumab 400 mg via intravenous infusion, Q3W, until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.
214309983|NCT07070479|DRUG|Irinotecan liposome|Irinotecan liposome 50mg/m2 via intravenous infusion, D1, D15, Q4W for up to 6 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
214670756|NCT05084989|BIOLOGICAL|Part1:Recombinant two-component COVID-19 vaccine (CHO cell)|2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
214670757|NCT05084989|BIOLOGICAL|Part1: Placebo|2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
214670758|NCT05084989|BIOLOGICAL|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
214670759|NCT05084989|BIOLOGICAL|Part2: COVID-19 Vaccine, mRNA|1 dose. Intramuscular injection, 30 μg/0.3 mL.
214670760|NCT05536648|OTHER|Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial|To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.
214916824|NCT06967623|DEVICE|diaphragm ultrasound|On the day of hospitalization or the first day of mechanical ventilation, the patient's position was elevated by 30°, and the high-frequency linear probe of the ultrasound was placed perpendicular to the skin in the cranio-caudal direction, and the diaphragm apposition zone, where the right anterior and middle axillary line corresponds to the 8th-10th intercostal space, was imaged and measurements were made with B mode.
214916825|NCT00406341|DRUG|Difluprednate Ophthalmic Emulsion|
214916826|NCT06240936|OTHER|Active Cycle of breathing|Active Cycle of Breathing Techniques will be given to group A. In Active cycle of breathing exercises, breathing control, thoracic expansion and forced expiration technique will be applied. 3-4 sets of exercise ,10-15 mint, 4 times per week for 4 weeks.
214916827|NCT06240936|OTHER|Active Cycle of breathing with Acapella|"Acapella device will be used along active cycle of breathing techniques to group B. 3-4 sets ,10 mints foe acapella training ,15 -20 munts ,4 times per week for 4 weeks.~This technique is active form of therapy in which patient uses its own energy on request to aid in treatment."
214916828|NCT00119249|DRUG|sorafenib tosylate|Given orally
215060675|NCT02662504|DEVICE|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
214309984|NCT07070479|DRUG|S-1|S-1, D1-D14, BID, p.o., (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose), Q4W for up to 6 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
214309985|NCT07070479|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone hydrochloride liposome 20mg/m2 via intravenous infusion, Q3W for up to 8 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first
214309986|NCT07070479|DRUG|PD-1 Inhibitors|PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab \<240 mg/cycle\>) , Q3W for two years, or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
214309987|NCT05231473|OTHER|Nurse Enhanced Recovery After Surgery participation|Bellvitge University Hospital will include the NEC participation along Enhanced Recovery After Surgery program.
214309988|NCT07070206|BEHAVIORAL|The health professionals in the capacity building arm will receive in-service training about culturally customized maternal nutrition education.|The health professionals in the routine capacity building arm will receive in-service training given through the health are system.
214309989|NCT02265978|DEVICE|CopeSmart|Participants will use the CopeSmart app at least once per day for four weeks
214309990|NCT06379217|DRUG|[68Ga]Ga-PSMA-11|\[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)
214309991|NCT06379217|DRUG|[68Ga]GA-DOTA-TATE|\[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)
214309992|NCT06379217|DRUG|[68Ga]Ga-NeoB|\[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).
214309993|NCT06379217|DRUG|[177Lu]Lu-PSMA-617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for 6 cycles.
214916829|NCT00119249|OTHER|laboratory biomarker analysis|Correlative studies
214916830|NCT01251419|OTHER|Social Proximity and Conversion to Generic Medications|At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
214309994|NCT06379217|DRUG|[177Lu]Lu-DOTA-TATE|\[177Lu\]Lu-DOTA-TATE will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%) every 6 weeks for 6 cycles.
214309995|NCT06379217|DRUG|[177Lu]Lu-NeoB|\[177Lu\]Lu-NeoB will be administered as an intravenous infusion at a dose of 9.25 GBq (250mCi) every 6 weeks for 6 cycles
214309996|NCT06379217|DRUG|L-Lysine HCl-L-Arginine HCl, 2.5 %,|sterile solution for infusion Lysine HCl-Arginine HCl, 2.5 % (1L)
214309997|NCT06379217|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
214309998|NCT06379217|DRUG|GnRH antagonists|abarelix, degarelix, or relugolix
214309999|NCT06379217|DRUG|Antiemetics & antinauseants|ATC code A04A
214310000|NCT06379217|DRUG|Metoclopramide|ATC code A03FA01
214310001|NCT07089628|OTHER|Assessment|There is no intervention in this study. Participants will only undergo assessments.
214310002|NCT06906822|DRUG|enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg be administered on Days 1,8,22 and 29 of every 6-week cycle by IV infusion given over approximately 30 minutes.
214310003|NCT06906822|DRUG|pembrolizumab|Pembrolizumab 400 mg on day 1 of each 42-day cycle (Q6W)
214310004|NCT06743659|DEVICE|Alert-based computerized decision support|"A program will be designed to run within the Electronic Health Record (EHR) that will identify outpatients with definite, probable, or possible diagnosis of FH. The BPA will calculate the Dutch Lipid Clinic Network score using the following EHR data:~1. Maximum LDL-C level in the laboratory results~2. Abnormal genetic testing for FH in the laboratory results~3. Medical history or problem list entry for tendinous xanthomata or arcus cornealis~4. Medical history, visit diagnosis, or problem list entry of premature CAD, cerebrovascular disease, or PAD~5. Family history of premature CAD, cerebrovascular disease, or PAD~In the Alert phase, an on-screen alert will notify the ambulatory care clinician of record that the patient has a definite, probable, or possible diagnosis of FH. ambulatory care clinician will have the opportunity to proceed to an order template through which a referral for specialty care focused on evaluation and management of FH can be made."
214310005|NCT06913400|COMBINATION_PRODUCT|Stereopsis Recovery|This prospective longitudinal observational study aims to assess stereopsis recovery in strabismic patients at one month and three months post-corrective surgery
214916831|NCT02403479|DRUG|Silver Colloid|Topical silver colloid will be administered for 6 weeks. This will either occur before topical saline nasal spray. Participants are randomized as to the order of sprays. The commercially available silver colloid product, Sovereign Silver Mineral Supplement, will be used.
214916832|NCT02403479|OTHER|Saline|Topical saline will be administered for 6 weeks. This will occur before the topical silver colloidal nasal spray. Participants are randomized as to the order of sprays.
214916833|NCT06967012|DRUG|Oral Zonisamide Therapy|Zonisamide tablets are administered orally with the following dosage schedule: Weeks 1-2: 2 mg/kg/day, Weeks 3-4: 4 mg/kg/day, Weeks 5-6: 6 mg/kg/day. After the initial six weeks, the dosage is adjusted based on the patient's condition, with weekly increments of 1 mg/kg/day. The maintenance dose ranges from 4 to 6 mg/kg/day, administered in 1-2 divided doses daily. For children weighing ≥50 kg, the adult dosage should be used.
214916834|NCT03962777|OTHER|chlorhexidine|patients used chx moutrinses for four days
214916835|NCT03962777|OTHER|oil pulling|patients used oil pulling for four days
214916836|NCT04747353|DEVICE|Catheter ablation procedure with heart 3D model|Device: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
214310008|NCT06917079|DRUG|BBO-11818|Participants will receive assigned dose of BBO-11818 orally (PO)
214310009|NCT06917079|DRUG|Pembrolizumab|Patients will receive IV pembrolizumab
214310010|NCT06917079|DRUG|Platinum chemotherapy (cisplatin or carboplatin)|Patients will receive IV platinum chemotherapy (cisplatin or carboplatin)
214310011|NCT06917079|DRUG|Pemetrexed|Patients will receive IV pemetrexed
214310012|NCT06917079|DRUG|Cetuximab|Patients will receive IV cetuximab
214310013|NCT06932640|DEVICE|- Non-Invasive Near-infrared Spectroscopy (NIRS) device (HEM1 with Foresight Elite Sensor)|Near-Infrared Spectroscopy (NIRS) monitors, provided by Edwards Lifesciences, is a monitoring technique. It will be connected to consented patients, automatically capturing brain oxygen as waveform output, and stored in Sickbay system. The NIRS is a non-invasive monitoring method, in which adhesive pads will be applied to forehead. 4 hours continuous monitoring will be recorded on day 1 after SAH (or on presence to NICU), then every three days from day 3 to day 14 (within the DCI window), to 1 to 2 recordings from day 15 to day 21.
214310014|NCT05078866|BIOLOGICAL|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Given IM
214310015|NCT05078866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214310016|NCT05078866|PROCEDURE|Endoscopic Biopsy|Undergo endoscopy with biopsy
214310017|NCT05078866|BIOLOGICAL|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|Given IM
214310018|NCT05078866|OTHER|Questionnaire Administration|Ancillary studies
214310019|NCT06930885|DRUG|Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)|"Cardiovascular Polypill contains Valsartan, Atorvastatin, Aspirin~1. Valsartan 160 mg + Atorvastatin 40 mg + Aspirin 100 mg~   or~2. Valsartan 160 mg + Atorvastatin 80 mg + Aspirin 100 mg~   or~3. Valsartan 320 mg + Atorvastatin 40 mg + Aspirin 100 mg~   or~4. Valsartan 320 mg + Atorvastatin 80 mg + Aspirin100 mg~   or~5. Valsartan 160 mg + Atorvastatin 20 mg + Aspirin 100 mg\*~   or~6. Valsartan 320 mg + Atorvastatin 20 mg + Aspirin 100 mg\*~   * The use of these formulations of the cardiovascular polypill will be restricted to cases of Statin-Related Muscle Symptoms (SRMS)"
214310020|NCT06930885|DRUG|Colchicine 0.5 mg|Colchicine 0.5 mg once daily
214480854|NCT06616597|DRUG|Dexamethasone|Dexamethasone 0.5mg/day
214480855|NCT06616597|DRUG|Metronidazole|Metronidazole 1500mg/ per day
214480856|NCT03744676|BIOLOGICAL|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
214916837|NCT04774367|DEVICE|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps
214310021|NCT06930885|DRUG|Usual Care Group|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the guidelines. Drugs and doses will be left at the discretion of the treating physicians.
214310022|NCT06930885|DRUG|Colchicine-placebo 0.5 mg|Matching Colchicine-placebo 0.5 mg once daily
214310023|NCT07143370|DEVICE|Thermoformed clear aligner|All participants will receive a thermoformed aligner fabricated from polyethylene terephthalate glycol (PETG) material. This aligner is made from using an intraoral scan to print a 3D model of their maxillary dentition, that is then used for the thermoforming process. This aligner will be worn 20-22 hrs/day for 1 week.
214310024|NCT07143370|DEVICE|3D printed clear aligner TC-85|All participants will receive a 3D printed aligner fabricated from TC-85 resin. This aligner will be made using an Stereolithography (STL) file from their intraoral scan to design the clear aligner and then will be fabricated using the SprintRay Pro 95 S printer. This aligner will be worn 20-22 hrs/day for 1 week.
214480857|NCT03333915|DRUG|Pamiparib|Pamiparib is provided as oral capsules
214480858|NCT06997614|OTHER|Conventional group|The conventional group adhered to conventional nutritional management methods and training
214480859|NCT06997614|OTHER|evidence-based nursing group|The study group implemented the EBN-based protocol alongside structured training
214670761|NCT06856902|BEHAVIORAL|B-COMPASS implementation|The patients in the intervention arm will receive B-COMPASS enhanced engagement in addition to standard care. The enhanced engagement is implemented as educational material to the HCP who is engaging with the patient. The content of the educational material will be based on the patient's B-COMPASS patient description. The engagement will either be in person or via phone call depending on the patient visiting schedule of each recruited patient.
214916838|NCT04774367|DEVICE|Order of forceps : First large capacity biopsy forceps and second standard biopsy forceps|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps
214916839|NCT04633512|DEVICE|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted intestinal anastomoses and patients undergoing laparoscopic or robot assisted cholecystectomy.
214916840|NCT01245959|DRUG|Docetaxel, cisplatin and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
214916841|NCT01245959|RADIATION|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
214916842|NCT05390775|BEHAVIORAL|Written Exposure Therapy (WISE)|WISE consists of five weekly sessions. At session one, the therapist will provide psychoeducation about PTSD, rationale for the proposed intervention, and then instructions for writing about their traumatic experience during each session. Psychoeducation and treatment rationale are scripted to ensure consistency. The participant will be instructed to write about the same trauma memory (their recent MVC) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report SUDs levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
214310025|NCT07143370|DEVICE|3D printed clear aligner TA-28|All participants will receive a 3D printed aligner fabricated from TA-28 resin. This aligner will be made using an STL file from their intraoral scan to design the clear aligner and then will be fabricated using the SprintRay Pro 95 S printer. This aligner will be worn 20-22 hrs/day for 1 week.
214310026|NCT06937177|DRUG|TCMCB07|TCMCB07 is will be provided in single-use vials for subcutaneous administration
214310027|NCT06937177|DRUG|Placebo|Matching placebo
214310028|NCT07142291|DRUG|Riluzole 50 MG|FDA approved standard-of-care treatment, 50 mg BID (100 mg daily).
214480860|NCT01768013|DRUG|LEO 90105|Once daily for four weeks
214955043|NCT04468893|BEHAVIORAL|Online Intervention Mental Health COVID-19|The Online Intervention Mental Health COVID-19 aims to provide to the target population a self-applied intervention based primarily on Positive Psychology, aimed at the recognition and development of strengths and virtues from the well-being approach. In addition, it is supported by elements of Cognitive Behavioral Therapy such as the components of emotion and the Antecedent-Response-Consequence (ARC) model of emotions. Elements of Behavioral Activation Therapy are also included, such as the importance of physical exercise and the relationship between physical anxiety and its effects on anxiety and depression. The intervention is made up of 15 modules that are adapted to the symptoms that the population may suffer from the global contingency caused by the COVID-19 pandemic. In addition to the Positive Psychology modules, a module with psychoeducation on grief and loss was added.
215060676|NCT02662504|PROCEDURE|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
215060677|NCT02662504|DRUG|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
215060678|NCT02269813|OTHER|MammaPrint|
215060679|NCT02269813|OTHER|BluePrint|
215060680|NCT02269813|OTHER|TargetPrint|
215060681|NCT02091362|DRUG|LY2409021|Administered orally
215060682|NCT02091362|DRUG|Placebo|Administered orally
215060683|NCT02091362|DRUG|Metformin|Administered as background therapy.
214480861|NCT05217680|BIOLOGICAL|Bevacizumab|Administration of monthly intravitreal bevacizumab (4-12 injections)
214480862|NCT05217680|BIOLOGICAL|Lucentis®|Administration of monthly intravitreal ranibizumab (4-12 injections)
214480863|NCT06342726|DEVICE|PAX Warming Blanket|Electric resistive active external warming blanket
214480864|NCT06342726|DEVICE|Passive insulation|3-layered wrapping model
214480865|NCT05394857|DRUG|SHR-1314|SHR-1314 subcutaneously
214480866|NCT06664892|RADIATION|Ultra-hypofractionated radiation|RT, delivered via external beam, 5.2 Gy per fraction for 5 fractions following BCS and neoadjuvant or adjuvant chemotherapy. Specific adjuvant/neoadjuvant therapies are at the discretion of the treating Medical Oncologist.
214480867|NCT03967158|DEVICE|Xience Sierra stent|Percutaneous coronary intervention with Xience Sierra stent
214955044|NCT04245917|OTHER|Non-interventional|Non-interventional natural history study
214955045|NCT01675674|OTHER|Dried blood spot test for MPS|The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
214955046|NCT02446548|DRUG|aliskiren|aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
214955047|NCT02446548|DRUG|losartan|losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
215060684|NCT02304887|DRUG|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
214310029|NCT07141303|DRUG|The methylprednisolone sodium succinate|Patients will receive intra-arterial methylprednisolone sodium succinate 40mg immediately after the recanalization from thrombectomy in anterior circulation large vessel occlusion. Then, intravenous administration with methylprednisolone sodium succinate 2mg/kg in the next 3 days.
214310030|NCT07141303|DRUG|Placebo|The placebo group patients will receive intra-arterial and intravenous sterile water for injection.
214310031|NCT07144111|DRUG|Inavolisib|Participants will receive a single oral dose of inavolisib
214310032|NCT06948318|DRUG|Mezagitamab|Mezagitamab injection administered SC.
214310033|NCT06950385|DRUG|eRapa (encapsulated rapamycin)|0.5 mg capsules for oral use; white opaque capsule filled with off-white powder; Trial intervention will be provided in 28-count round high-density polyethylene bottles with a polypropylene child-resistant screw cap and foil induction seal.
214310034|NCT06950385|DRUG|Placebo|Capsules in 28-count round high-density polyethylene bottles with a polypropylene child-resistant screw cap and foil induction seal.
214310035|NCT07150143|OTHER|Exercise|Each exercise session lasts 50 minutes, consisting of a 10-minute warm-up, 30 minutes of stabilization exercises, and a 10-minute cool-down. Stabilization exercises are selected from an exercise pool according to the individual's needs, with progression ensuring throughout the program. The exercises will be administered face-to-face twice a week for eight weeks, and participants will be provided with illustrated brochures and instructed to perform a one-hour home exercise program daily.
214310036|NCT07150143|OTHER|Connective tissue massage|Connective tissue massage will be applied, starting from the basic regions and gradually incorporating other regions.
214310037|NCT07150143|OTHER|Infrared therapy|Infrared therapy will be applied for 20 minutes
214310038|NCT07150143|OTHER|Continuous ultrasound|Continuous ultrasound will be applied to the right and left sides for 7 minutes each at an intensity of 2 W/cm².
214310039|NCT07150143|OTHER|Conventional TENS|20 minutes of conventional TENS will be administered to the painful area.
214310040|NCT07155525|DRUG|Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2)|"* Standard duct-to-mucosa pancreaticojejunostomy performed~* Application of 0.5-1.0 mL modified N-butyl-2-cyanoacrylate around the anastomotic site~* Adhesive applied circumferentially around the pancreaticojejunal anastomosis~* Allow 2-3 minutes for polymerization before proceeding~* Standard placement of peritoneal drains"
214480869|NCT06666725|OTHER|Menu label|Participants will select food items from three restaurant menus, displayed with labels as specified by their assigned group
214480870|NCT06084195|BIOLOGICAL|Blood sample and tissue sample|"During the surgery :~* Tissus sample : primary tumor and metastasis~* blood sample : 3 EDTA tubes~* ex vivo MRI data"
214480871|NCT06388824|DRUG|normal saline|Patients undergoing surgical abortion received a single injection of 5ml 0.9% normal saline after the beginning of surgery
214480872|NCT06388824|DRUG|Esketamine|Patients undergoing surgical abortion received a single injection of 0.2mg/kg esketamine after the beginning of surgery
214480873|NCT06172894|DRUG|APN401|APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.
214480874|NCT06337942|PROCEDURE|Bladder Transplantation|A bladder transplantation will be performed. The bladder will be recovered from a brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the recipient's ureter(s) to the new bladder.
214480875|NCT06337942|PROCEDURE|Combined Kidney and Bladder Transplantation|For patients who qualify for a combined kidney and bladder transplant, both a kidney and a bladder transplant will be performed. Both kidney and bladder allografts will be recovered from the same brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the kidney transplant ureter to the transplanted bladder. If the recipient has continued urine output, new connections between the native ureters and the transplanted bladder will also be made.
214480876|NCT06812052|RADIATION|Radiation Therapy|In this study, patients will receive a hypofractionated course of radiation therapy of 2.85 Gy x 15 fractions (42.75 Gy). If there are 2 or more patients with dose-limiting toxicities, the radiation course will be de-escalated to 2.7 Gy x 15 fractions (40.5 Gy).
214480877|NCT06812052|RADIATION|Hypofractionationed Radiation Therapy|This group is receiving hypofractionated radiation therapy (shorter course of RT)
214480878|NCT06388642|DRUG|Afamelanotide 16mg implant|afamelanotide 16mg implant will be administered to each patient during the study.
214480879|NCT03479255|BEHAVIORAL|Smartphone-enabled structured exercise therapy (SE-SET)|The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patients from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent matters related to their care.
214310041|NCT07155525|PROCEDURE|Standard(duct-to-mucosa) Pancreaticojejunostomy|"* Patients undergo duct-to-mucosa pancreaticojejunostomy without additional adhesive following pancreaticoduodenectomy.~* Standard placement of peritoneal drains~* All other aspects of surgical care identical to experimental arm"
214310042|NCT07158515|BEHAVIORAL|Tailored cardiac rehabilitation|The program will address the core components of CR.21 Each of the program components will have an individualized assessment with plan and goals set at the program intake visit. The 12-week program will alternate between group and individual sessions each week. Individualized plans will be reviewed every two weeks at the participant individual sessions. Group sessions will address physical activity, nutrition, and other program topics. Duration of the program was chosen to resemble a typical 12-week cardiac rehabilitation intervention. However, the program will have a greater emphasis on cultural tailoring, language concordance, lowering burden of real-time in-person attendance, motivational coaching, and addressing psychosocial needs.
214310043|NCT07158515|BEHAVIORAL|Referral to an external cardiac rehabilitation program|Participants will be referred to an external cardiac rehabilitation program outside of the safety net setting. This is the current standard of care.
214310044|NCT07158970|DEVICE|Use of the Pulsenmore home ultrasound device for fetal assessment, guided remotely by a physician.|Standard care
214310045|NCT07164313|DRUG|ZW251|Administered intravenously
214480880|NCT03479255|BEHAVIORAL|Standard exercise therapy|The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
214480881|NCT04905095|OTHER|EWS|Early Warning Score will be implemented in the computer system of the nursing station which belong to this intervention group. When the nurses enter the vital signs of the patients into the system, the EWS will be automatically calculated and an alarm will be displayed if an intervention is necessary, which is protocolized.
214480882|NCT04905095|OTHER|usual clinical care|Nurses perform their clinical monitoring activities as usual. EWS will not be implemented in their nursing station
214480883|NCT03298178|PROCEDURE|TAVR|All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea
214480884|NCT03298178|PROCEDURE|SAVR|All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea
214480885|NCT06613217|DRUG|zelenirstat|Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.
214916843|NCT05390775|BEHAVIORAL|Non-emotional Writing|Following randomization, the first session for the control writing condition will be conducted as follows, which is detailed in a structured manual for therapists. The therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did yesterday from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. As discussed, the participant will self-report Subjective Unites of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
214916844|NCT00183859|DRUG|irinotecan|Intraperitoneal Irinotecan given every three weeks
214480886|NCT04649099|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
214480887|NCT06746519|DRUG|BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine|The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.
214480888|NCT04724928|RADIATION|Metastasis directed therapy (MDT)|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Concurrently, the oligometastasis will be treated with stereotactic body radiotherapy or metastasectomy.
214480889|NCT04724928|DRUG|Immunotherapy|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
214480890|NCT04724928|PROCEDURE|Standard of care|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards regular follow up is performed.
214480891|NCT06827353|DRUG|maintenance therapy with bevacizumab|Maintenance therapy after platine-based chemotherapy in non-mutated advanced ovarian cancer is unclear. Arm of patients that received bevacizumab after chemotherapy.
214480892|NCT06827353|DRUG|maintenance therapy with niraparib|Maintenance therapy after platine-based chemotherapy in non-mutated advanced ovarian cancer is unclear. Arm of patients that received niraparib after chemotherapy.
214916845|NCT00005606|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
214916846|NCT00005606|BIOLOGICAL|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
214916847|NCT01065337|BIOLOGICAL|tissue repair cells (TRC)|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
214916848|NCT01065337|BIOLOGICAL|bone marrow stem cells (BMC)|bone marrow stem cells
214916849|NCT04585256|OTHER|Trendelenburg positioning|Women positioned in the trendelenburg position prior to external cephalic version
214916850|NCT01168778|BEHAVIORAL|Physician Workshop|Physicians that were assigned to the intervention group attended a 3.5 hour intervention workshop where they were trained in skills to communicate information about physical examination findings, treatment, and follow-up that will ultimately facilitate appropriate antibiotic prescribing and increase parent satisfaction with care.
215060685|NCT00924794|PROCEDURE|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
214310046|NCT07164989|BEHAVIORAL|Motivational Interviewing-Based Counseling|Motivational interviewing (MI) is a structured, patient-centered counseling technique that helps individuals explore and resolve ambivalence toward behavior change. In this study, MI sessions will be delivered by trained pediatric dental professionals during routine orthodontic visits. Each session will last approximately 10-15 minutes and will be guided by a standardized MI protocol, focusing on improving oral hygiene behavior and increasing personal motivation and responsibility for oral care among adolescent participants. Sessions will be conducted at multiple time points during the course of treatment.
214310047|NCT07164989|BEHAVIORAL|Standard Oral Health Education|Participants in this group will receive the conventional oral hygiene education typically provided in orthodontic clinics. This includes verbal instructions and printed educational materials on topics such as toothbrushing technique, flossing with braces, and the importance of maintaining oral hygiene during orthodontic treatment. Education will be delivered by pediatric dental staff during scheduled orthodontic appointments at the same time points as the intervention group (baseline, 1-month, and 6-month visits). No motivational interviewing techniques will be used. This approach reflects routine care and serves as the comparator for evaluating the added value of MI.
214310048|NCT07168343|DRUG|One icodextrin exchange|One icodextrin fill volume of 550ml/m2 body surface area which is optimal for most paediatric patients is recommended. The minimum dwell time for an icodextrin exchange will be 7 hours, and range between 7-10 hours.
214310049|NCT07168343|DRUG|Two icodextrin exchanges|In two icodextin exchanges, the dwell times can vary but must be a minimum of 7 hours.
214310050|NCT07168109|PROCEDURE|Enhanced monofocal intraocular lens implantation (monovision strategy)|"Participants will undergo phacoemulsification with the implantation of an enhanced monofocal intraocular lens, targeting -0.5 D in the dominant eye and -2.0 D in the non-dominant eye. The first operated eye will be selected based on the worse corrected distance visual acuity; if both eyes are similar, the eye subjectively perceived by the patient as having worse vision will be chosen. The second eye surgery will be performed within 2 weeks after the first eye surgery. Ocular dominance will be determined preoperatively using the finger method . Intraocular lens power will be calculated using multiple formulas \[Emmetropia Verifying Optical (EVO) version 2.0, Kane, LISA\]."
214310051|NCT07168109|PROCEDURE|Enhanced monofocal intraocular lens implantation (bilateral myopia strategy)|"Participants will undergo phacoemulsification with the implantation of an enhanced monofocal intraocular lens, targeting -2.0 D in both eyes. The first operated eye will be selected based on the worse corrected distance visual acuity; if both eyes are similar, the eye subjectively perceived by the patient as having worse vision will be chosen. The second eye surgery will be performed within 2 weeks after the first eye surgery. Ocular dominance will be determined preoperatively using the finger method. Intraocular lens power will be calculated using multiple formulas \[Emmetropia Verifying Optical (EVO) version 2.0, Kane, LISA\]."
214480893|NCT06119074|OTHER|Gifted Savings|Gifted Savings assets will be in the form of cash, Bitcoin, and/or stock. Participants will receive identical asset portfolios. The asset mix will be determined by Gifted Savings. Participants will not have any control over the assets they receive, nor the proportion of each in their account. After registration on the Gifted Savings website, participants can immediately withdraw $100 USD if they choose. Then, for each of the first two years, participants may withdraw up to $500 USD for an emergency (self-attested) if the value of the account is 50% or more of its value 30 days prior and the account has sufficient funds to fulfill the request. Two years post-enrollment, participants may withdraw the entire value of their GS account or continue holding the assets in their GS account (in perpetuity or until the GS non-profit ceases to exist). GS funds are unconditional; there are no restrictions or limitations on how the money can be spent.
214480894|NCT06371261|OTHER|Biological analyses|"A cytobacteriological examination of the sputum will be carried out and sent to the microbiology laboratory at the University Hospital of La Réunion.~The micro-organisms will be quantified.~The micro-organisms, and more specifically bacteria of the Achromobacter genus, will be identified by MALDI-TOF mass spectrometry using the published database (Garrigos et al.2021)."
214480895|NCT06675240|BEHAVIORAL|MediNF|Over 10-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
214916851|NCT00985387|DRUG|Solifenacin|oral
214916852|NCT06171087|DRUG|Domperidon|oral
214916853|NCT06171087|DRUG|Placebo|oral tablet
214916854|NCT05456178|OTHER|Electrostatic wipe|"The main objective will be to study the feasibility of the quantification of domestic fungal exposure with electrostatic wipe. The interval of environmental fungal exposure quantification values measured by conventional mycology and by NGS will be established, with analysis of the correlation between the quantification obtained by the two techniques.~For this, an electrostatic wipe will be deposited in the living room and another one in the bedroom for 12 weeks. The wipes will be analyzed by the mycology laboratory of the Croix Rousse hospital."
214916855|NCT03084107|OTHER|Questionnaire|The elderly participated in the application of smart devices and requested to complete technology acceptance model (TAM) questionnaires for these devices.
214916856|NCT02476578|OTHER|Email|Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
214916857|NCT02960711|DRUG|Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]|
215060686|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ H.|Vegan Capsules with active product, GutMagnific™ high dose
215060687|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ L.|Vegan Capsules with active product, GutMagnific™ low dose
215060688|NCT04741841|DIETARY_SUPPLEMENT|Placebo|Vegan capsules identical to active product in taste and appearance but without probiotic
215060689|NCT00470262|DRUG|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
215060690|NCT00470262|DRUG|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
215060691|NCT03901625|DEVICE|Manual Toothbrush|A manual toothbrush is used to clean teeth surfaces.
215060692|NCT03901625|DEVICE|Dental floss|A dental floss is used to clean inter-proximal areas.
214916858|NCT02960711|DRUG|Ludipress, mg stereate, micronized hydrated silica, talcum|Tablet
214916859|NCT00523471|PROCEDURE|Blood test|
215060693|NCT03901625|DEVICE|Waterjet|A waterjet is used to clean inter-proximal areas.
214480896|NCT06674811|OTHER|Wearing Smartwatch|Patients and their caregivers will be asked to start wearing a smartwatch prior to surgery and continuing to wear it for one year following surgery at all times except when bathing or swimming, eating, undergoing a procedure, or if refusing to wear them. The smartwatches collect motor activity by minutes spent being sedentary, active, or highly active, heart rate, and sleep duration and stages. Data from the smartwatches syncs with Garmin connect using Fitabase to allow the study team to review the data.
214480897|NCT06674811|OTHER|Patient Report Outcomes|To obtain patient-reported outcomes (PROs), questionnaires will be administered at time of enrollment, in the two weeks prior to surgery if applicable, and at 1, 2, 4, 8, 12, 16, 20, 24, 34, 44, and 54 weeks postoperatively. Questionnaires can be completed electronically, over the telephone or in person. The PedsQL Cancer Module and Patient Health Questionnaire depression scale (PHQ-9) will be utilized for questionnaires.
214480898|NCT06674811|OTHER|Blood Draw|When patients are having blood drawn as part of their regular care, extra blood may be drawn for this study. Participants may opt out of this. Blood draws will occur preoperatively and at intervals postoperatively for proteomic, metabolomic, and exposomic testing.
214480899|NCT06674811|OTHER|Clinical Data Review|Clinical data will be collected and stored in a database by study staff. This includes patient demographics, diagnosis characteristics including staging and risk group, treatment characteristics, and outcomes including length of stay following surgical intervention, readmissions, surgical complications including surgical site infection, time off therapy/time to resumption of chemotherapy.
214670762|NCT06856902|BEHAVIORAL|B-COMPASS implementation|At the first data collection, patients will complete the BEAMER questionnaire and adherence-related measures will be collected. Based on patients' answers, the B-COMPASS will assign them into groups, list their support needs, and predict their relative adherence, forming their B-COMPASS description. Patients will then be randomised into either 1) an intervention arm, or 2) a control arm using stratified randomisation via the Adherence Intelligence Visualisation Platform (AIVP), ensuring balance in B-COMPASS descriptions, gender, and age. The patients in the intervention arm will receive B-COMPASS enhanced engagement in addition to standard care. The enhanced engagement is implemented as educational material to the HCP who is engaging with the patient. The content of the educational material will be based on the patient's B-COMPASS patient description. The engagement will either be in person or via phone call depending on the patient visiting schedule of each recruited patient.
214670763|NCT06586489|BEHAVIORAL|Virtual Reality Natural Landscape Exposure|Participants will view immersive virtual natural landscapes using virtual reality (VR) headsets for 10 minutes, three times a week, over eight weeks. They will choose the natural landscapes they wish to visit and admire, allowing for personalized engagement with the virtual environment.
214916860|NCT06183385|OTHER|Saliva collection|Collection of 2 samples of 1.5 to 2mL of saliva by passive salivation in healthy volunteers
214916861|NCT06183385|OTHER|Vaginal secretion collection|Collection of vaginal secretions with 2 dry swabs in women
214310052|NCT07171320|DRUG|Pregabalin|In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.
214310053|NCT07171320|DRUG|Pregabalin with desvenlafaxine|In the pregabalin with desvenlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Desvenlafaxine will be administered at 50 mg daily with breakfast initially. If the initial dose is well-tolerated, the dose could be further escalated by 50 mg per day after 3 days, up to a maximum of 400 mg per day after 7 days. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and desvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.
214310054|NCT07162207|PROCEDURE|Pinhole surgical technique|A pinhole is created in the site of recession, the grafting material (Bi-layer collagen membrane versus connective tissue graft) is trimmed to fit the size of the recession defect, followed by graft insertion in the tunnel.
214310055|NCT07165951|DRUG|TQB2868 Injection|TQB2868 injection: PD-L1 and Transforming Growth Factor-beta (TGF - β) dual antibody
214310056|NCT07165951|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules
214310057|NCT07165951|DRUG|Gemcitabine Hydrochloride Injection|Gemcitabine Hydrochloride Injection
214310058|NCT07165951|DRUG|Paclitaxel for Injection|Paclitaxel for Injection
214310059|NCT07165951|DRUG|TQB2868 Placebo|TQB2868 Placebo without drug substance
214310060|NCT07164820|OTHER|Su Jok Application|Description: The newborn's hands will be used for the application. Su Jok therapy will be administered by applying massage and seeds to the corresponding reflection points on the hand prior to the he
214480900|NCT05740007|DRUG|IW-3300 rectal foam|IW-3300 rectal foam administered daily for 12 weeks
214480901|NCT05740007|DRUG|Placebo|Placebo rectal foam administered daily for 12 weeks
214480902|NCT06673810|OTHER|Ankle Weighted Cuffs Training Along with Routine Physical Therapy Exercises|Group A will have free ankle weighted cuffs while performing routine physical therapy. These weighted cuffs will be above of the child's ankle and child will be encouraged to perform his/her routine physical activities. Ankle weights will correspond to 2% to 3% of the individual's body weight (sandbags) will be attached at 5 cm above the left and right ankle joints
214670764|NCT06586489|BEHAVIORAL|Tablet Screen Natural Landscape Exposure|Participants will watch immersive virtual natural landscapes on a tablet screen for 10 minutes, three times a week, over eight weeks. Participants can select the natural landscapes they prefer to view during the sessions, providing a personalized experience.
214955048|NCT02446548|OTHER|Placebo|placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
215060694|NCT03901625|DEVICE|Electric Toothbrush|An electric toothbrush is used to clean teeth surfaces.
215077797|NCT03274427|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
214310061|NCT07165106|BEHAVIORAL|Aerobic Exercise|"Participants in this group will receive conventional rehabilitation in combination with supervised treadmill-based aerobic exercise three times per week for 6 weeks. Each exercise session will consist of a 5-minute warm-up, a 15-minute main exercise phase, and a 5-minute cool-down. Walking speed will be individualized based on participant tolerance and progressively increased under clinical supervision. Exercise intensity will be monitored using the modified Borg Rating of Perceived Exertion (scale 6-20).~Weeks 1-2: Main exercise at Borg 10-11 (light-moderate).~Weeks 3-4: Main exercise at Borg 11-12 (moderate).~Weeks 5-6: Main exercise at Borg 12-13 (moderate-high).~Cardiorespiratory responses will be monitored during all sessions, and treadmill speed will be gradually adjusted in accordance with improvements in exercise tolerance while maintaining safety."
214310062|NCT07165106|BEHAVIORAL|Resistance Exercise|Participants in this arm will receive conventional rehabilitation combined with supervised resistance training using elastic bands, 3 times per week for 6 weeks. Exercises target major upper- and lower-limb and hip muscles. Each exercise is performed for 3 sets of 10 repetitions with 60-90 seconds rest. Initial band tension is set at the highest tolerable level and progressively increased. The program includes shoulder press, biceps curl, triceps extension, seated leg extension, calf raise, and lateral band walk. All sessions are supervised, emphasizing correct posture, controlled full range of motion, and avoidance of compensatory movements. Patients are guided with verbal and visual cues when necessary.
214310063|NCT07165106|BEHAVIORAL|Conventional Rehabilitation|Participants in this group will receive conventional rehabilitation only, 5 days per week, 1 hour per day, for 6 weeks. The program includes upper and lower limb range of motion exercises, stretching, walking practice, balance and coordination training, proprioceptive exercises, posture correction, obstacle crossing, and turning in place. All sessions are delivered under clinical supervision, with emphasis on correct posture, safety, and full range of motion
214310064|NCT07168642|BEHAVIORAL|Mothering from the Inside Out|Mothering from the Inside Out (MIO) is an evidence-based individual psychotherapy designed to help caregivers in recovery build stronger relationships with their children. In MIO, caregivers are helped to build their ability to reflect on their own mental states and how they arose. Often, we find that the thoughts and feelings that drive caregiving behavior are actually triggered by early experiences of being cared for. MIO thus aims to provide a safe, therapeutic space where caregivers' internal experiences are taken seriously and clinicians are genuinely interested, curious, and collaborative. MIO also involves helping caregivers to reflect on the possible mental states underlying their children's behavior. We find that by providing some information about child development through an attachment lens, this can help parents see through their children's eyes and feel less stressed.
214310065|NCT07169357|DRUG|Gengigel|The use of Gingigel or 0.2% hyaluronic gel is expected to enhance healing and decrease discomfort in the post-operative period. It exhibits viscoelastic characteristic which serves as osteo-conductive, anti-edematous, antifungal and bacteriostatic effects.
214310066|NCT07169357|DEVICE|LASER|PBMT has markedly been effective in reducing pain, inflammation, edema and postoperative discomfort. It is said to be a natural and effective alternative approach to minimize medicaments prescription such as analgesics, anti-inflammatory or antibiotic drugs. With that said, negative outcomes such as drug side effects, bacterial resistance and post-operative complications can be prevented, thus increasing the success of medical care and assuring a better quality of life
214310067|NCT07167212|OTHER|Diaphragm Training|The diaphragm serves dual roles in respiration and postural control, yet its contribution is often overlooked in core stability exercise (CSE) programs for low back pain (LBP) rehabilitation. Abdominal hollowing, or the 'tummy tuck,' targets TrA and lumbar multifidus. Diaphragmatic breathing (DB) increases intra-abdominal pressure, contributing to lumbar stability. The intervention included four progressive weeks: Week 1-Supine and Crocodile breathing; Week 2-Supine and Crocodile with TheraBand; Week 3-Seated and 90/90/90 breathing; Week 4-Seated and 90/90/90 with TheraBand. Supine emphasized diaphragmatic expansion with resistance at the thoracolumbar junction; Crocodile focused on lateral rib expansion; Seated required upright posture with rib control; 90/90/90 integrated deep breathing with resisted stabilization. This study evaluates DB combined with CSE on pain, disability, muscle activity, and sleep quality in chronic LBP.
214670765|NCT05823168|DRUG|Antiepileptic Drug|we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
214670766|NCT01186432|DRUG|PDS 1.0|
214670767|NCT07030738|BEHAVIORAL|Legume-Based High-Protein Diet + Resistance Training|Participants receive a hypocaloric, high-protein diet primarily based on legumes (e.g., lentils, beans, peas) designed to meet protein goals (\~2g/kg body weight). Diet is combined with a structured home-based resistance training program performed 3 times per week for 12 weeks. The exercise includes progressive resistance exercises focusing on major muscle groups using body weight and resistance bands.
214670768|NCT07030738|BEHAVIORAL|Meat-Based High-Protein Diet + Resistance Training|Participants follow a hypocaloric, high-protein diet emphasizing animal-based protein sources, mainly lean meats, to achieve \~2g/kg body weight protein intake. This dietary intervention is combined with a 12-week, home-based resistance training protocol, performed thrice weekly, targeting major muscle groups with progressive overload using body weight and resistance bands.
214670769|NCT07030738|BEHAVIORAL|Mixed Legume and Meat High-Protein Diet + Resistance Training|Participants adhere to a hypocaloric, high-protein diet combining both legumes and lean meats as protein sources to reach \~2g/kg body weight. The dietary plan is paired with a 12-week home-based resistance training program, performed 3 times per week, emphasizing progressive resistance exercises for all major muscle groups using body weight and resistance bands.
214916862|NCT06183385|OTHER|IP-LC-MS/MS : immunoprecipitation enrichment with liquid chromatography coupled to tandem mass spectrometry|"sample preparation and analysis :~* Impregnation of the tips (absorbent cotton) of sterile dry swabs and vaginal swabs with controlled quantities of saliva.~* Immunocapture of salivary proteins of interest (histatin type 1, cystatin D, PRPs) by protein A affinity purification~* LC-MS/MS analysis of eluted purified peptides (Multiple Reaction Monitoring mode)~Dilutions will be made from 10 to 10 (1/10, 1/100, 1/1000...), then after reaching a detectability threshold, specified by a second more precise analysis (e.g. if no signal at 1/1000, analysis at 1/500 then 1/250 etc.). Analytical sensitivity will be tested on three samples of each type (salivary, vaginal, vaginal + semen) to ensure reproducibility of results.~Operators, unaware of the presence of saliva in the samples, will then carry out saliva-specific protein detection analysis using the IP-LC-MS/MS method."
214916863|NCT03347305|BEHAVIORAL|automated DP|Energy expenditure measurement
214310068|NCT07167212|OTHER|Myofascial Release Technique|The myofascial release technique for the diaphragm was performed with the participant lying supine and limbs relaxed. The therapist, positioned at the head, placed the pisiform, hypothenar, and last three fingers bilaterally under the seventh to tenth rib costal cartilages, forearms aligned toward the shoulders. During inspiration, gentle traction was applied cephalad and slightly laterally, accompanying rib elevation. On exhalation, pressure was directed inward along the costal margin to maintain resistance. With each breath, traction was gradually deepened to improve release. The maneuver consisted of two sets of 10 deep breaths with a 1-minute rest between sets. Figure 1 illustrates the manual diaphragm release technique (source: author's photo). This method, adapted from Rocha et al. (2015), emphasizes progressive traction and controlled resistance to facilitate diaphragmatic mobility and rib cage expansion.
214310069|NCT07171775|PROCEDURE|Experimental - Nanohydroxyapatite|Following selective caries removal under local anesthesia and rubber dam isolation, nanohydroxyapatite paste will be applied directly onto the pulpal dentin surface as the pulp protection material. The cavity will then be restored using a standardized adhesive and resin composite protocol.
214480903|NCT06673810|OTHER|Routine Physical Therapy Exercises|Group B will perform all the routine physical exercises which include jogging, walk/run interval training, treadmill training and cycling . Intervention period will be of 6 weeks comprising of 3 sessions per week of 30 to 45 minutes per session
214480904|NCT05827965|BEHAVIORAL|education and drug adjustement|education of the patients (lifestyle) and adjustement of glucocorticoid replacement schedule
214480905|NCT04599569|DEVICE|indirect calorimetry|indirect calorimetry with and without renal replacement therapy
214480906|NCT06674018|DIETARY_SUPPLEMENT|Indole-3-propionic acid|A dosis of either 50 mg IPA, 120 mg IPA or 500 mg IPA (two capsules) will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
214480907|NCT06674018|DIETARY_SUPPLEMENT|Placebo|Two capsules of placebo will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
214480908|NCT05717725|PROCEDURE|Pulsed-field ablation|Patients will receive catheter ablation, i.e. pulmonary vein isolation by means of pulsed-field energy
214480909|NCT05717725|PROCEDURE|Sham procedure|Patients will receive sham procedure, no ablation.
214480910|NCT05948657|DIAGNOSTIC_TEST|PSMA-PET CT|Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
214480911|NCT05990335|BEHAVIORAL|mHealth application (custom)|Smartphone based application designed to engage user executive functions
214480912|NCT06660602|PROCEDURE|cardiac surgery|All kinds of cardiac surgeries
214916864|NCT03347305|BEHAVIORAL|Calorimetric chamber|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
214916865|NCT04120077|DIETARY_SUPPLEMENT|EyePromise DVS, EyePromise DVS plus EyePromise EZTears|Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements
214480913|NCT06363045|DEVICE|NIDEK TONOREF III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
214480914|NCT06363045|DEVICE|Haag-Streit, PERKINS HAND-HELD APPLANATION TONOMETER|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
214670770|NCT07031037|OTHER|Scales|"Five questionnaires were administered at inclusion, socio-demographic and clinical data were collected during an interview (anxiety-depression, treatments).~The following questionnaires were used: The Revised Ritvo Autism and Asperger Diagnostic Scale (RAADS-R-Fr), the Eating Disorder Examination Self-Report Questionnaire (EDE-Q), the Adolescent/Adult Sensory Profile (AASP), the Coping Inventory for Stressful Situations (CISS), the Hospital anxiety and depression scale (HAD) and the Multidimensional Assessment of Interoceptive Awareness Version 2 (MAIA-2)."
214480915|NCT06363045|DEVICE|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
214480916|NCT06597942|DEVICE|TMS|rTMS Stimulation Parameters Pulse count: 1600 pulses Frequency: 20Hz Pules per train: 40 pulses Inter-train interval: 28 seconds Intensity: 100% Motor Threshold (depth-corrected from MRI) Target: Precuneus using structural MRI navigation with MNI coordinates
214480917|NCT06597942|DEVICE|Transcranial Magnetic Stimulation Sham|Sham coil placed in same location and set with same parameters as active treatment coil. However, this device will not output active treatment and scalp electrodes will mimic the sensation of rTMS for the participant.
214480918|NCT06856278|DRUG|NKG2D CAR-NK with PD-1 Antibody|Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.
214480919|NCT06857786|DRUG|Drug: CT041 autologous CAR T-cell injection|The planned dose of satri-cel in this trial was 2.5 × 108 cells, single infusion. The trial will start with a safety run-in phase, which is defined from the day of infusion to the 28th day after infusion for the first 6 participants. The type, grade, incidence rate, and outcome of adverse events during the safety run-in phase will be summarized and assessed by the investigator and collaborator (CARsgen Therapeutics Co., Ltd). The investigator and collaborator could discuss and assess whether the lower or higher doses should be explored based on the based on the safety and tolerability, cellular metabolic characteristics, and benefit-risk profile. If no dose adjustment is required, satri-cel dose will continue to be 2.5 × 108 cells for the rest of the participants.
214670771|NCT07030647|DRUG|Bupivacaine 0.25%|At the end of gynecologic laparoscopic surgery and prior to trocar removal, 40 mL of Bupivacaine 0.25% is instilled intraperitoneal under direct vision to evaluate its analgesic effect.
214670772|NCT07030647|DRUG|Bupivacaine 0.25%|Before trocar insertion in gynecologic laparoscopic surgery, 5 mL of Bupivacaine 0.25% is infiltrated subcutaneously at each trocar port site to assess its effect on postoperative pain.
214916866|NCT03018080|DRUG|Pembrolizumab|IV (in the vein) on day 1 of a 21 day cycle
214916867|NCT03018080|DRUG|Paclitaxel|IV (in the vein) on days 1 and 8 of a 21 day cycle
214916868|NCT01800929|DEVICE|N6|Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
214916869|NCT03601598|DRUG|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
214916870|NCT03601598|DRUG|SHR6390|SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
214310070|NCT07171775|PROCEDURE|Active Comparator - Biodentine|Following selective caries removal under local anesthesia and rubber dam isolation, Biodentine will be mixed according to the manufacturer's instructions and applied onto the pulpal dentin surface as the pulp protection material. The cavity will then be restored using a standardized adhesive and resin composite protocol. This comparator is distinguished by the use of a calcium silicate-based bioactive material with well-established clinical performance, serving as the reference standard against which nanohydroxyapatite is evaluated.
214310071|NCT07170540|DRUG|Cashew sublingual immunotherapy|Glycerinated cashew extract for use in sublingual immunotherapy
214310072|NCT07170540|DRUG|Placebo sublingual immunotherapy|Glycerinated saline for placebo sublingual immunotherapy
214310073|NCT07171723|BIOLOGICAL|Liver-Expressed Antimicrobial Peptide 2 (LEAP2)|Continuous intravenous infusion of LEAP2 (Liver-Expressed Antimicrobial Peptide 2), an endogenous inverse agonist and competitive antagonist of the ghrelin receptor (GHSR), administered at 40 pmol/kg/min for 6 hours. LEAP2 inhibits ghrelin-mediated signaling involved in hunger regulation, gastric motility, and growth hormone secretion. This intervention enables investigation of the physiological relevance of ghrelin receptor activity during semaglutide-induced appetite suppression
214310074|NCT07171723|OTHER|Placebo (saline)|Continuous intravenous infusion of isotonic saline (0.9% sodium chloride) for 6 hours. This placebo comparator is used to match the volume, rate, and duration of the active intervention (LEAP2) in a randomized, double-blind, crossover design. The placebo enables assessment of the physiological effects of ghrelin receptor blockade by LEAP2 in individuals with obesity treated with semaglutide
214310075|NCT07169929|OTHER|Measurement of fetal transverse thalamic diameter by 2dimensional abdominal ultrasound|"All pregnant women attending the feto-maternal unit with gestational age from 18 weeks to 36 weeks in the obstetrics and gynecology department in the faculty of medicine Cairo university Using curvilinear 2D transabdominal ultrasound probe of ultrasound machine either Voluson E10 GE or Nuewa I9 Elite Mindray.~The investigators will take all the biometry (Biparietal diameter, head circumference, abdominal circumference, femur length and trans-cerebellar diameter) and exclude any congenital anomalies in the scan.~Transverse thalamic diameter is to be measured by 2D ultrasound at the standard axial trans-cerebellar plane. A guitar shape representative structure is presented to demarcate the thalamic diameter.~Calculate the gestational age using transverse thalamic diameter from this equation Transverse thalamic Diameter( in mm)=0.912 x Gestational age in weeks -1.134) ( Sridar P, et al 2020)"
214310076|NCT07173790|OTHER|Patient-Reported Outcomes Survey|Participants will complete validated questionnaires including EORTC QLQ-C30, EQ-5D-5L, and disease-specific modules (QLQ-CLL17, QLQ-NHL). Responses will be used to assess quality of life and psychological distress during watchful waiting.
214310077|NCT07173998|OTHER|Survey|SF-36, TSQM-9, qualitative questions
214310078|NCT07173855|DRUG|Magnesium sulfate administration|Magnesium sulfate is used in both arms for magnesium replacement.
214310079|NCT07173855|DRUG|Magnesium oxide|In the higher-target arm, magnesium oxide 420mg po q12h x 2 is one of the options available for magnesium replacement when magnesium levels lie between 0.75 and 0.95mmol/L.
214310080|NCT07173855|DRUG|Magnesium glucoheptonate|Magnesium glucoheptonate 30mL po q12h x 2 is an oral option for magnesium replacement in the higher-target arm.
214310081|NCT07175831|BEHAVIORAL|Low-Intensity Continuous Training|Participants ran continuously for 30 minutes at 50% of their MAS without rest.
214310082|NCT07175831|BEHAVIORAL|Moderate intensity Interval training|Participants ran continuously for 30 minutes at 70% of their MAS without rest.
214310083|NCT07175831|BEHAVIORAL|High-Intensity Interval Training|Participants ran at 105-110% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 5 minutes, constituting one set. A total of four 5-minute sets were completed, interspersed with 2,5-minute passive rest periods, yielding a total exercise time of 30 minutes.
214916871|NCT02645474|PROCEDURE|PECS block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 30 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.
214916872|NCT02645474|PROCEDURE|Paravertebral block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.
214916873|NCT02645474|DRUG|Ropivacaine|Amidic local anesthetic standardly used for nerve block and infiltration
214916874|NCT03084120|OTHER|Collection of bloods samples for the mother|-During pregnancy, childbirth and after delivery
214310084|NCT07161622|OTHER|Low-Level Laser Therapy (LLLT)|"Participants received LLLT using a gallium-aluminium-arsenide (Ga-Al-As) diode laser device (BTL-5000, UK). The laser operated at a wavelength of 830 nm and a power output of 100 mW. Irradiation was applied at three sites (anterior capsule, posterior capsule, subacromial area) using a stationary-contact technique for 60-90 seconds each, delivering 4 J/cm² per site. Sessions were administered three times weekly for eight weeks.~Conventional Therapy (for both groups):~15 minutes of moist heat (Chattanooga Hydrocollator)~Pendulum exercises~Passive and active-assisted ROM exercises~Isometric strengthening of rotator cuff and scapular stabilizers~Postural correction training"
214916875|NCT03084120|OTHER|Retrieval of umbilical cord blood.|-During childbirth
214916876|NCT03084120|OTHER|Retrieval of placenta.|-During childbirth
214916877|NCT03084120|OTHER|Collection of newborn's and mother's lock of hair.|-During childbirth
214916878|NCT03084120|OTHER|Dietetic Patient Outcomes Questionnaires for the mother.|-During pregnancy and after delivery
214916879|NCT03084120|OTHER|Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire).|-At 2 years of age
214916880|NCT03207048|DEVICE|Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 3-second trains with a 15-second inter-train interval, for 50 trains per session
214916881|NCT03207048|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham Transcranial Magnetic Stimulation
214916882|NCT02458248|BEHAVIORAL|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
214310085|NCT07161622|OTHER|Muscle Energy Technique (MET)|"Participants received MET for major shoulder muscles (internal/external rotators, flexors, extensors). Each contraction was performed at \~20% of maximum effort, sustained for 10 seconds, followed by 5 seconds relaxation, and then passive stretch to new end range. Three to five cycles per muscle group were performed. Sessions lasted \~20 minutes, three times weekly for eight weeks.~Conventional Therapy (same as Arm A):~15 minutes of moist heat~Pendulum exercises~Passive and active-assisted ROM exercises~Isometric strengthening of rotator cuff and scapular stabilizers~Postural correction training"
214310086|NCT07180719|BEHAVIORAL|Dementia anti stigma intervention|The intervention is a train-a-trainer programme contextually developed, for delivery (via demonstrations and role-plays) by lay providers such as community health workers. It includes four sessions that promote: (i) understanding of dementia, (ii) demystifying myths and misconceptions, (iii) empathetic connections using videos of people with dementia and carers (virtual social contact) and (iv) social inclusion through a case vignette and discussions. It is delivered bi-weekly in a group setting and each session ranges between 1.5 to 2 hours.
214310087|NCT07180420|DRUG|naloxone IM|naloxone IM to the EDC/forearm muscle
214310088|NCT07180186|DRUG|Mesalamine|Patients with ulcerative colitis in remission treated with oral mesalamine.
214310089|NCT07180186|DRUG|Probiotics (Bacillus Clausii)|Patients with ulcerative colitis in remission treated with probiotics (Bacillus Clausii).
214310090|NCT07180186|DRUG|Mesalamine and probiotics (Bacillus Clausii)|Patients with ulcerative colitis in remission treated with oral mesalamine and probiotics (Bacillus Clausii).
214310091|NCT07180329|DIETARY_SUPPLEMENT|Myrin P Fort|Patient took Myrin P Fort
214310092|NCT07180329|DIETARY_SUPPLEMENT|Zn + Se supplemented cookies|patients took Zn + Se supplemented cookies
214310093|NCT07180329|DIETARY_SUPPLEMENT|Zn + Se + Myrin P Fort|"patients took Zn + Se~\+ Myrin P Fort"
214310094|NCT07179562|OTHER|"motivational interviewing"|"Randomization for motivational interviewing"
214310095|NCT07181525|DRUG|anti-cytokine antibodies|Different kinds of biologics used to treat inflammatory bowel disease (including anti-cytokine antibodies)
214310096|NCT07181525|DRUG|anti-integrin antibodies|Different kinds of biologics used to treat inflammatory bowel disease (including anti-integrin antibodies)
214310097|NCT07179640|DRUG|ALE1|Specified dose on specified days
214310098|NCT07179640|DRUG|Placebo|Specified dose on specified days
214310099|NCT07180823|DEVICE|Bronchoscopy with Lung Vision navigation system|The procedure begins with inspection of the airways up to the subsegmental branches using a flexible bronchoscope. During the procedure, augmented fluoroscopy will be used as a guidance tool, which is already in use at our operating unit as part of normal clinical practice, and will be combined with radial ultrasound using a mini probe. Once the peripheral lesion has been located, a cytological and histological sample will be taken using a needle and/or forceps and/or cryoprobe under augmented fluoroscopic guidance and with R-EBUS, as per normal current clinical practice. If atypical cells or malignant tumour cells are found during the extemporaneous cytological examination, the FM, acquired specifically for the study, will be positioned to mark the pulmonary nodule. A coil-tailed FM will be used. Enhanced fluoroscopy will be used via the LungVision system.
214916883|NCT01591057|DIETARY_SUPPLEMENT|2 portions of fruit and vegetables per day|Consume 2 portions of fruit and vegetables per day
214916884|NCT01591057|DIETARY_SUPPLEMENT|5 portions of fruit and vegetables per day|Consume 5 portions of fruit and vegetables per day
214310100|NCT07180264|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
214310101|NCT07181694|DRUG|Adalimumab (BCD-057) 100 mg/mL|Single subcutaneous injection
214310102|NCT07181694|DRUG|Adalimumab (BCD-057) 50 mg/mL|Single subcutaneous injection
214310103|NCT07181694|DRUG|Adalimumab (Humira) 100 mg/mL|Single subcutaneous injection
214310104|NCT07180836|OTHER|No Intervention (Observational Study)|This is an observational, cross-sectional study. Patients with suspected or confirmed hemoglobinopathies were evaluated for prevalence and hematological characteristics using laboratory investigations, without any experimental treatment or therapeutic intervention applied.
214310105|NCT07181746|PROCEDURE|leg exercises|The patient in study group will offer 72 planned sessions along 16-week period, each session consisted of 5 minutes walking as a warm-up, followed by 30 to 45 minutes of resistance exercises tolerated by the patient, time maintained until the end of the intervention. Each participant will receive about two to three, personal training session regarding the technique of resistance training until they are perfect in performing the exercises. Participants will receive a booklet with instructions on the Pilates training illustrated by colored pictures. The sessions during the staying the patient's in the hospital will be supervised by the researchers
214310106|NCT07179718|DEVICE|neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) is a treatment method in which electrical conduction via surface electrodes is used to stimulate muscle contraction.
214310107|NCT07179718|DEVICE|bicycle ergometer|Exercise training will be performed using the bicycle ergometer method, under the supervision of a physiotherapist, for 30 minutes a day for 5 consecutive days, at the earliest stage when the patient is clinically stable.
214916885|NCT01591057|DIETARY_SUPPLEMENT|8 portions of fruit and vegetables per day|Consume 8 portions of fruit and vegetables per day
214916886|NCT04712448|DIAGNOSTIC_TEST|Anti-COVID test|No intervention is foreseen by the protocol
214955049|NCT03363308|BEHAVIORAL|training for health care workers supplmented by QI teams|Jhpiego will deliver maternal and newborn health and family planning (MNH+FP) training using evidence-based low-dose, high-frequency (LDHF) learning approaches and support hospital staff-led quality improvement efforts to increase the coverage of facility-based high-impact interventions, including care of the mother and newborn on the day of birth and through the first week postpartum and post abortion services.
214955050|NCT01411319|RADIATION|Lattice Extreme Ablative Dose Radiation Therapy|12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.
215060695|NCT03900728|DEVICE|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
214955051|NCT01411319|RADIATION|Standard IMRT|76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
215077798|NCT03274427|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
214310108|NCT07181018|OTHER|Trial within cohort (TWIC)|"Educational intervention based on a protocol specifically developed for the TWINS.PL cohort, aimed at activating and engaging the participant in the intervention process.~Intervention group: Phenotypically concordant participants from the TWINS.PL STUDY cohort, randomized to receive an educational intervention designed to actively engage them in modifying selected health-relevant endpoints.~Control group: The co-twin of the participant randomized to the intervention arm, serving as the control.~1. TWINS-TWIC HL: Research Question: Does participation in a structured, participant-activating educational intervention program influence health literacy indicators among participants of the TWINS.PL study? Study Design: A randomized controlled trial embedded within a prospective observational twin cohort (TWiC study in a twin cohort).~2. TWINS-TWIC DIET Research Question: Does participation in a structured, participant-activating educational intervention focused on dietary habits influence the"
214310109|NCT07180784|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|An intervention group offered to students that teaches meditation and yoga techniques, stress physiology, and mindfulness practices. Each group includes 5-6 participants and met once a week for 1.5 hours over a period of 8 consecutive weeks.
214310110|NCT07180784|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia (CBT-I)|Traditional CBT-I was offered in small group sessions of 5 to 6 participants and lasted 1.5 hours each. They were held once a week over a period of 8 consecutive weeks.
214310111|NCT07179705|DEVICE|Hypotensive prediction index|The HPI, developed by Edwards Lifesciences and integrated into the HemosphereⓇ hemodynamic monitoring system, is an algorithm-based tool that predicts hypotensive events before they occur, allowing earlier intervention. While this tool has shown benefit in surgical and post-operative settings, it has not been tested in ICU patients undergoing dialysis.
214310112|NCT07179705|DEVICE|Standard of care monitoring|"Standard of Care~* Monitoring via conventional invasive BP and clinical judgment~* Use of physical exam, CVP, PPV, and response-based decisions (fluid bolus, vasopressors)"
214310113|NCT07181421|PROCEDURE|Tissue flossing with Therapeutic exercises|"Isometric Knee Extension - Standing Hamstring Curl - Wall Squats - Leg Press Against Wall. The Red TheraBand from Thera Tool (2m \* 5cm \* 1.3mm) will be used. The band will be wrapped starting from the tibial tuberosity and extending to 5 cm above the femoral epicondyle. Care will be taken to ensure that the patella remains uncovered.~* The band will be wrapped with 50% tension and 50% overlap.~* Flossing Duration: The floss band will be kept on for 2 minutes, and during this time, the patient will perform the exercises mentioned above. The number of repetitions for each exercise will depend on the patient's tolerance level, with a reference of 10 repetitions per exercise (based on similar tissue flossing protocols, though adapted for knee OA patients)."
214310114|NCT07181421|PROCEDURE|Therapeutic Exercises|Isometric Knee Extension - Standing Hamstring Curl - Wall Squats - Leg Press Against Wall.
214310115|NCT07180901|OTHER|Proactive Risk-Based Optimization and Notifications for Treatment and Outcomes (PRONTO)|Post-implementation of PRONTO-HN system: 1. Pre-operative risk stratification of requiring adjuvant therapy using our predictive model, applied at tumor board. Patients stratified as fast-track vs normal-track. 2. High-risk patients receive intensive preoperative and postoperative coordination. Low-risk patients are monitored but escalated rapidly if adverse pathology is detected. This includes: - pre-operative dental consultation for fast-track - pre-operative oncology consultation for fast-track with high-risk features - target pathology results 14 days post-operatively for fast-track 3. Automated reminders and target dates sent to members of the multidisciplinary team.
214310116|NCT07180576|BEHAVIORAL|Nutrition counseling|Weekly standardized nutrition counseling will be provided by a study RDN to promote adherence and address barriers to adherence, acceptability, and adverse events. The RDN will also document any changes to the CRT regimen and hospitalizations.
214310117|NCT07180576|DRUG|Fresubin Supportan|Two bottles per day of Fresubin Supportan, a fish oil-enriched high calorie, high protein oral nutrition supplement.
214310118|NCT07181772|BEHAVIORAL|virtual escape room|Triage training will be taught to students in the experimental group for the first time through a virtual escape room game.
214310119|NCT07181772|BEHAVIORAL|with Power point education|The control group was trained using the traditional method using power point.
214310120|NCT07181811|OTHER|Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments|The cognitive and fatigue assessments administered in this study are not currently part of the standard clinical care for multiple sclerosis patients on Ocrelizumab. By prospectively assigning participants to undergo these additional assessments, this aspect of the study is considered investigational, and findings may contribute to clinical decision-making regarding the incorporation of cognitive and fatigue assessments into routine management of multiple sclerosis conditions.
214310121|NCT07181590|PROCEDURE|Pulsed Field Ablation|Pulsed Field Ablation using the Volt PFA
214310122|NCT07180056|DRUG|CDK4/6 inhibitor|abemaciclib OR ribociclib
214310123|NCT07181915|OTHER|Generic email - control|A generic email delivered to a GP practice alongside a digital feedback report. The generic control email will be the same text each time for all practices within that arm and will contain no suggestions for improving practice.
214310124|NCT07181915|OTHER|Personalised email - Intervention|A personalised achievement email delivered to a GP practice alongside a digital feedback report. The personalised email wording will change based on the achievement of the practice and the content in the feedback reports, which is being distributed as part of the pre-existing quality improvement project, rather than this research study. The recommendations in bullet points within the personalised emails suggesting how to improve care will be informed as relevant succinct summaries of the key guidance contained with the feedback reports, which will be based on either national guidelines or respected published literature. This will be written by the lead researcher for this project (who is the author of the QIP feedback reports themselves) and will be reviewed by the same group that reviews the QIP feedback report content before publication.
214310125|NCT07180160|DRUG|QL1706|QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).
214310126|NCT07180160|DRUG|CDK4/6 inhibitor|palbociclib OR ribociclib OR abemaciclib OR dalpiciclib
214310127|NCT07180160|DRUG|Fulvestrant|SERD
215060696|NCT03900728|DEVICE|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
215060697|NCT03900728|DEVICE|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
215060698|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
214310128|NCT07181057|OTHER|one-meal-a-day (OMAD)|"Arm Title: Morning Meal (08:00)~Intervention: Other: One-meal-a-day (OMAD)~Description: Participants consume a single isocaloric meal at 08:00.~Arm Title: Midday Meal (12:30)~Intervention: Other: One-meal-a-day (OMAD)~Description: Participants consume a single isocaloric meal at 12:30.~Arm Title: Evening Meal (18:00)~Intervention: Other: One-meal-a-day (OMAD)~Description: Participants consume a single isocaloric meal at 18:00."
214310129|NCT07180862|DRUG|BAT3306|One vial of 4 mL of concentrate contains 100 mg of BAT3306
214310130|NCT07180862|DRUG|US-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
214310132|NCT07181356|OTHER|RIPerC|Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles
214310133|NCT07181356|OTHER|RIPC|Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles
214310134|NCT07179796|BEHAVIORAL|Observation|Personalized physical activity program tailored to each participant, with variations in frequency, duration, and type of activity based on their preferences, goals, fitness level, and physical ability.
214310135|NCT07181213|PROCEDURE|Adrenalectomy|Surgical removal of patients with unilateral primary aldosteronism in patients selected by the presence of a genetic variant and hypertension
214310136|NCT07180290|BEHAVIORAL|Psychotherapy|Session 1 : Introduction and awareness of the sleep-wake link Session 2 : Awareness of day/night habits and behaviors Session 3 : Awareness of sleep/wake rhythms and sleepiness signals Session 4 : Awareness of the night/bed/sleep association Session 5 : Awareness of emotions and thoughts related to sleep Session 6 : Awareness of possible alternatives Session 7 : Awareness of one's relationship to sleep Session 8 : Awareness of future benefits
214310137|NCT07180446|BEHAVIORAL|Cardiovascular Exercise|Participants will complete a 12-week supervised cardiovascular exercise program at the TCU Recreation Center. Exercise will occur 5 days per week, beginning with 30 minutes per session and progressing to 60 minutes. Intensity will start at 50% of estimated maximal heart rate and gradually increase to 80% by week 8, remaining at that level through week 12. Exercise modalities may include treadmill walking/running, rowing, elliptical, or cycling, based on participant preference and fitness level. Certified trainers will supervise all sessions to ensure safety, proper technique, and adherence to the intensity targets. Participants will wear ActiGraph heart rate monitors to verify exercise intensity throughout the intervention.
214310138|NCT07180446|DIETARY_SUPPLEMENT|Butyrate|Participants will take a dietary supplement containing sodium butyrate during the final 4 weeks (weeks 8-12) of the 12-week intervention. The supplement will be provided in capsule form, with participants instructed to take six capsules per day-two with each meal. This daily dose is equivalent to 3.6 g of butyric acid, which provides 939 mg of sodium, delivered as sodium butyrate. The supplement is intended to support gut health and potentially enhance insulin sensitivity in individuals who do not respond to exercise alone. Participants will receive a 4-week supply during their 8-week study visit, along with instructions for proper use and monitoring of any side effects.
214310139|NCT07179991|DRUG|Desmopressin after protamine reversal|"Desmopressin will be given to participants at a dose of 0.3mcg/kg after protamine reversal at the end of cardiopulmonary bypass (CPB).~Platelet function will be assessed by TEG (Thromboelastography) platelet mapping at the following points:~1. T1 TEG6s: after arterial line insertion before skin incision.~2. T2 TEG6s: after protamine (baseline function after CPB)~3. T3 TEG6s: 30 minutes after desmopressin~4. T4 TEG6s: 6 hours after (intensive care unit) ICU admission~5. T5 TEG6s: 24hours after ICU admission"
214480920|NCT06857071|BEHAVIORAL|Expanded Social Network Recruitment to HIV Testing (E-SNRHT) Intervention|"The E-SNRHT intervention will recruit people newly diagnosed with HIV as seeds, briefly remind them of HIV transmission risks and how HIV spreads through networks, and ask them to recruit people in their expanded social networks (i.e., anyone they know) who they think might benefit from being tested for HIV, regardless of whether or not they have engaged in any HIV risk behaviors together. By including expanded social networks, E-SNRHT aims to broaden the reach of HIV testing to people who are reluctant to participate in risk partner recruitment and/or to seek clinic testing. Network members recruited by a seed will also be asked to recruit additional people they know using the same education and recruitment instructions provided to seeds. All network members will be tested for HIV and provided with pre- and post-test counseling, all participants diagnosed with HIV will be referred to care, and all participants who test negative will be referred to 3-month follow-up HIV testing."
214480921|NCT06475339|OTHER|30/30 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 30 minutes of rest.
214955052|NCT01214668|DRUG|LY573636-sodium|"Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met."
214955053|NCT01214668|DRUG|Liposomal Doxorubicin|"40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
214955054|NCT01964989|BIOLOGICAL|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
214955055|NCT01964989|BIOLOGICAL|Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
214955056|NCT03014141|OTHER|Oat bran (Oatwell 28)|11 g oat bran containing 3.1 gram oat beta-glucan
214310140|NCT07181486|DRUG|Live Biotherapeutic Product L. jensenii 1153-1666|"The vaginally administered MucoCept-CVN contains Lactobacillus jensenii 1153-1666, a natural component of the human vaginal microbiota that has been modified to continuously express the potent HIV entry inhibitor modified-cyanovirin-N (mCV-N) right at the site of infection.~MucoCept-CVN is supplied as a prefilled vaginal applicator containing Lactobacillus jensenii 1153-1666, a modified strain of L. jensenii 1153 by integrating a modified cyanovirin-N gene into its chromosome to enhance the strain's ability to inhibit HIV. Each applicator contains 200 mg of MucoCept-CVN powder (1 x 109 CFU), and an inactive preservation matrix."
214310141|NCT07181486|DRUG|Placebo|Each placebo applicator contains 200 mg of placebo powder comprising the same inactive ingredients of the preservation matrix as the study product.
214310142|NCT07180355|DRUG|SGT-212|Adeno-associated virus serotype AAVhu68 containing a codon-optimized complementary DNA (cDNA)
214310143|NCT07180940|DRUG|0.9%NaCl|2 x 20ml 0.2% ropivacaine with 2ml of 0.9% NaCl
214310144|NCT07180940|DRUG|Dexamethasone 4mg|2 x 20ml 0.2% ropivacaine with 2mg of dexamethasone
214310145|NCT07180940|DRUG|Dexmedetomidine|2 x 20ml 0.2% ropivacaine with 25ug Dexmedetomidine
214310146|NCT07181317|OTHER|Questionnaires|"Assessment of stress and anxiety and quality of life after myocardial infarct:~* Stress score: Perceived Stress Scale-4 (PSS-4)~* Anxiety score: Generalized Anxiety Disorder-7 (GAD-7)~* Depression score: Patient Health Questionnaire-9 (PHQ-9)~* Quality of life scores: European Quality of Life-5 Dimensions (EQ-5D) and 12-Item Short-Form General Health Survey (SF-12)"
214310147|NCT07181317|OTHER|Major events|Collection of information related to major events occurring since inclusion in the WAMIF study
214310148|NCT07180563|DRUG|Participants were treated with doxycycline + berberin for chronic endometritis (intervention group).|Diagnosed chronic endometritis according to endometrial biopsy pathology , the specific medication plan for the intervention group was to use doxycycline 100mg, bid + berberin 100mg, tid, continuously for 14 days.
214310149|NCT07180563|DRUG|At present, the commonly used clinical treatment for chronic endometritis is oral doxycycline|11After hysteroscopic diagnosis of chronic endometritis, patients received monotherapy with doxycycline hydrochloride capsules for 14 days.
214310150|NCT07181382|DRUG|Placebo|Matching capsule containing placebo
214310151|NCT07181382|DRUG|Seralutinib|Capsule containing seralutinib
214310152|NCT07181382|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib or placebo delivery
214310153|NCT07181239|DRUG|CM336 Injection|Specified dose on specified days
214310154|NCT07181239|DRUG|Standard Of Care( SOC)|Specified dose on specified days
214310155|NCT07180537|BEHAVIORAL|Creating Health Online Course|Immediate access to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
214310156|NCT07180537|BEHAVIORAL|Delayed access to Creating Health Online Course|Delayed access (12-week delay) to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
214310157|NCT07179692|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214310158|NCT07179692|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intrapleural infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214310159|NCT07179692|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214310160|NCT07180095|DRUG|Intranasal dexmedetomidine|intranasal dexmedetomidine 2mcg/kg
214310161|NCT07180095|DRUG|Intranasal ketamine|intranasal ketamine 2mg/kg
214310162|NCT07180043|BEHAVIORAL|Structured Behavioral Therapy|Structured patient education, lifestyle modification counseling, and headache diary maintenance without pharmacological prophylaxis.
214310163|NCT07180043|DRUG|Propranolol|Oral propranolol, 1-3 mg/kg/day in two divided doses, titrated according to response, for 12 weeks.
214310164|NCT07179731|PROCEDURE|subcostal transversus abdominis plane block|Under ultrasound guidance, 30 ml of bupivacaine is injected along the fascia of transversus abdominis muscle.
214310165|NCT07179731|PROCEDURE|External Oblique Intercostal Plane Block|Under ultrasound guidance, 30 ml of bupivacaine is injected between the fascias of external oblique and intercostal muscles.
214310166|NCT07179731|PROCEDURE|external oblique intercostal plane block and subcostal transversus abdominis plane block combination|The combination of the two blocks will be applied in 15 ml of volume for each.
214310167|NCT07181291|PROCEDURE|PVI|pulmonary-vein isolation
214310168|NCT07179679|DRUG|TQB2934 injection (subcutaneous injection)|TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen)double-specific antibody，and the isoform is Native Immunoglobulin G1 ( IgG1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
214955057|NCT03014141|OTHER|Maltodextrin|11 g of Maltodextrin
214310169|NCT07179835|PROCEDURE|Full pulpotomy in adults ≥18 years with restorable mandibular first or second molars diagnosed with irreversible pulpitis, with or without apical periodontitis.|Comparison of full pulpotomy with MTA in teeth with and without apical periodontitis
214310170|NCT07179900|DRUG|QL1706|Apololitovoreli monoclonal antibody (QL1706) 7.5mg/kg intravenous infusion, once every 3 weeks
214310171|NCT07179900|RADIATION|Radiotherapy|41.4-50.4Gy/1.8Gy/23-28F
214310172|NCT07179900|DRUG|Sintilimab|200mg q3w
214310173|NCT07179900|DRUG|Bevacizumab|15mg/kg q3w
214310174|NCT05866237|DEVICE|Patient Engagement tool|The study intervention (PET) aims to increase uptake of vaccines that are already recommended through national guidance.The PET will help educate and inform individuals about the benefits of COVID-19 and Flu vaccinations through culturally adapted educational support, including content, design, mode and timing of delivery of messages (text, video or voice messages).
214310175|NCT05113537|DRUG|Abemaciclib|Given Orally
214955058|NCT03176121|DRUG|Oxycodone|Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
214955059|NCT00214214|DRUG|Campath 1H® (Alemtuzumab)|
214310176|NCT05113537|DRUG|Lutetium Lu 177-PSMA-617|Given IV
214310177|NCT01156285|OTHER|Filling in a patient questionnaire|Filling in a patient questionnaire
214310178|NCT05833165|BEHAVIORAL|Feasibility of a supportive approach|Evaluating reasons for patients to use the approach
214310179|NCT05817136|DIAGNOSTIC_TEST|Eko DUO|Acquisition of a single-lead ECG via patients self-examine themselves twice a week for 12 months.
214310180|NCT06145360|DRUG|Empagliflozin 10 MG|the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM
214310181|NCT06145360|DRUG|Insulin+Metformin+DPP4 inhibitor (DPP4I)|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
214310182|NCT00004888|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
214310183|NCT00004888|DRUG|docetaxel|Given IV
214480922|NCT06475339|OTHER|30/20 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 20 minutes of rest.
214480923|NCT06475339|OTHER|40/30 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 40 minutes of work followed by 30 minutes of rest.
214310184|NCT00004888|BIOLOGICAL|trastuzumab|Given IV
214310185|NCT00004888|OTHER|laboratory biomarker analysis|Correlative studies
214310186|NCT02579265|DRUG|Smoflipid 20% (investigational lipid for parenteral nutrition)|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Smoflipid 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Smoflipid 20% will be infused into a central or a peripheral vein."
214310187|NCT02579265|DRUG|Intralipid® 20%|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein."
214310188|NCT01168635|BEHAVIORAL|Spirometry 360 program - Virtually-delivered spirometry quality improvement program|"The Spirometry 360 program includes:~1. Spirometry Fundamentals™: A basic guide to lung function testing, a computer-based training program that teaches primary care providers how to coach patients to produce high-quality spirometry tests and accurately interpret spirometric data;~2. Spirometry Learning Lab: Case-based teaching of spirometry in practice guides test administrators and interpreters through clinical examples in an interactive virtual classroom setting. These sessions are led by expert clinical faculty and are archived for future reference and review;~3. Spirometry Feedback: Tailored analysis of providers' spirometry testing sessions offers monthly individualized feedback reports by clinical experts on spirometry tests performed in the clinic."
214310189|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
214310190|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
214480924|NCT06475339|OTHER|20/12 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 20 minutes of work followed by 12 minutes of rest.
214480925|NCT06859034|DRUG|injection of dextrose 10% in retrodiscal tissues|group 1 will recieve 10% dextrose in retrodiscal tissues
214480926|NCT06859034|DRUG|injection of dextrose 25% in retrodiscal tissues|group 2 will recieve 25% dextrose
214480927|NCT06856070|OTHER|(Group A: Preformed Bioflx crown)|"prepartion:1.The mesiodistal width of the tooth will be measured using calipers and a closely fitted crown will be selected based on the measurements.~2\. The tooth will be prepared similarly to stainless steel crowns (SSCs):~* Occlusal reduction of approximately 1-1.5 mm will be done using a diamond bur.Mesial and distal reduction of no more than 1 mm will be performed using a No. 169L diamond bur.Depending on the tooth anatomy, either no buccal and lingual reduction will be needed, or a minimal reduction will be done.~  3.All sharp line angles and corners will be smoothed to ensure proper crown fit.~  4.The crown will be checked for proper fit before cementation. It will be positioned to extend 1 mm below the gingival margin.~  5.The crown will be cemented using luting glass ionomer cement (GIC). The crown will be held with firm, constant pressure until the cement sets initially.~  6.The marginal fit will be evaluated, and necessary adjustments will be made. 7.The occlusion will be checked,"
214310191|NCT03493828|PROCEDURE|TAP block using Normal Saline|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
214310192|NCT03087968|DRUG|GS-4997|Experimental drug
214310193|NCT03087968|DRUG|Prednisolone|Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
214955060|NCT04829630|BIOLOGICAL|rabies vaccine|"* day 0 : questionnaire, blood sampling and vaccine booster (a single session of two intradermal doses of 0.1 mL)~* day 7 : questionnaire and blood sampling"
215060699|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
215060700|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
214916887|NCT05560269|BEHAVIORAL|Verbal coaching vs. Constraint based coaching|"* 15 repetitions of kettlebell swings using verbal cues and physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues and physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using verbal cues to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval"
214916888|NCT00649922|BIOLOGICAL|adalimumab|80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29
214916889|NCT00649922|BIOLOGICAL|placebo|2 injections Day 1, 1 injection Days 15 and 29
214916890|NCT00649922|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
214916891|NCT02407925|BEHAVIORAL|Feedback|3-monthly or no 3-monthly feedback on results of optical diagnosis
214916892|NCT03596112|OTHER|application of a polyacrylate wound pad|A sterile polyacrylate wound pad with activated carbon cloth treatment will be applied to chronic wounds in an outpatient clinic from a specialist nurse
214310194|NCT03087968|DEVICE|HepQuant SHUNT Test|"The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples."
214310195|NCT03087968|DRUG|Placebo|Placebo
214310196|NCT02174848|DRUG|Deferiprone oral solution|Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
214310197|NCT03146988|DRUG|RGB-02 or Neulasta® (pegfilgrastim)|Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
214916893|NCT03596112|OTHER|Hydrocellular foam|Active Comparator: hydrocellular foam pad serile hydrocellular standard foam pad will be applied to chronic wounds in an outpatient clinic from a specialist nurse
214916894|NCT05648422|DIETARY_SUPPLEMENT|Probiotics|Saccharomyces Boulardii 200 mg every 12 hours for 6 days at week 1, 5 and 9
214916895|NCT05648422|DIETARY_SUPPLEMENT|NSS Nutritional Support System|Nutritional Support System consists in NSS envelope (glutamine, arginine, folic acid, PUFA-n3, vegetal protein, nicotinic acid, cobalamin, thiamine, pyridoxine, magnesium, zinc, selenium, cholecalciferol, resveratrol, ascorbic acid, Spirulina Máxima, glycine, tryptophan, and inuline) every 12 hours for 12 weeks.
214916896|NCT05648422|DRUG|Deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days
214916897|NCT05648422|OTHER|Specific diet|This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of smoothies at breakfast and dinner, high consumption of fish, five meals during the day, 70% of meals eaten during the day will consist on vegetables, fruits, roots, cereals, and legumes. Red meat, gluten, lactose, junk food, sugar, salt, fast food free.
214916898|NCT05648422|OTHER|Conventional diet (WHO)|This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of general nutricional recommendations.
214916899|NCT00003563|RADIATION|WBRT|3 GY of WBRT daily for a total of 10 days
214670773|NCT07032220|DRUG|carbon suspension|Before primary systemic therapy, a core needle biopsy or fine-needle aspiration of the most suspicious axillary lymph node was performed.22 Sterile black carbon suspension (0.5 mL: 25 mg, Chongqing LUMMY Pharmaceutical Co) was injected in the cortex of the metastatic node under ultrasound guidance using a 25G needle by a trained ultrasonographer at the time of biopsy or during a separate session. The injection volume was recorded and varied depending on node size and operator. The trained ultrasonographer had more than 5 years of puncture experience. Of note, for the patients with multiple abnormal nodes or N3 disease under ultrasound at diagnosis, only the pathologically-proven lymph node is marked with carbon suspension.
214670774|NCT03551522|DRUG|Seladelpar|10 mg, 20 mg, or 50 mg
214670775|NCT03551522|DRUG|Placebos|Matching placebo Capsule
214916900|NCT00003563|DRUG|MGd|5.0 mg /kg MGd plus WBRT
214916901|NCT00601939|BEHAVIORAL|Psychoeducational intervention (PEI)|PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
214916902|NCT00601939|BEHAVIORAL|Enhanced treatment as usual (ETAU)|ETAU contains an adherence protocol plus access to weekly support group and a resource room.
214916903|NCT03244930|DRUG|Plerixafor 0.12 mg/kg|Subcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.
214916904|NCT05251896|PROCEDURE|Plasma-free procedure|Use albumin solution, lactated Ringer's solution, normal saline as replacement fluid
214916905|NCT03068195|PROCEDURE|microwave ablation|KY2000 microwave ablation system was used in the experimental group. A power output of 60 W for 1-3 min for 1-3 cycles to treat the renal cysts according to the cysts size and classification.Percutaneous microwave ablation will be performed under the guidance of ultrasound while the laparoscopic microwave ablation will be performed under direct vision
214310198|NCT04230837|DEVICE|Inmediate abutment height|The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.
214310199|NCT02799758|DRUG|NK-104-CR|NK-104-CR 8 mg for 52 weeks
214310200|NCT02799758|DRUG|Livalo® IR|Livalo® IR 4 mg daily for 52 weeks
214310201|NCT02799758|DRUG|Placebo (for NK-104-CR)|NK-104-CR 8 mg placebo for 52 weeks
214916906|NCT03068195|PROCEDURE|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts
214310202|NCT02799758|DRUG|Placebo (for Livalo® IR)|Livalo® IR 4 mg placebo for 52 weeks
214310203|NCT05442164|BEHAVIORAL|DANAKIR support network|"The DANAKIR intervention will consist of:~* Structured written discharge information~* Invitation to the DANAKIR monthly information meeting DANAKIR meetings The monthly meetings are a core component of the support network. One time each month, a meeting will be held at Herlev Hospital with the participation of an emergency surgeon, an emergency surgery dedicated nurse, a dietician, and a physiotherapist. Each professional (surgeon, nurse, dietician, physiotherapist) will host an informative 15 minute session regarding the postoperative course after major emergency surgery. Following the presentations time for questions in plenum and private with the different experts will be held. Furthermore, there will be an opportunity for networking at the DANAKIR meeting. Each meeting is planned to last 2 hours. At the end of each meeting the patients will be asked to evaluate the meeting and content."
214310204|NCT00644969|DRUG|placebo|Randomization 2:1 treatment to placebo
214310205|NCT00644969|DRUG|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
214670776|NCT05606939|DEVICE|intestinal ultrasound|"All patients will be evaluated using intestinal ultrasound with special emphasis on intestinal wall thickness as well as stratification and Visualization of the vascularization of the bowel using color Doppler sonography also visualization of motility.~Findings of intestinal ultrasound will be compared regrading colonoscopic findings"
214670777|NCT06875089|GENETIC|pGS-NBS|Collection of a second DBS card if the parents accept the pGS-NBS for their newborn
214310206|NCT04226066|BIOLOGICAL|T601|"Part1: T601 is injected once (Day1). Dose range: 1E+7, 3E+7, 1E+8, 3E+8, 1E+9pfu.Trial cycle: Day1-21.~For part1, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
214310207|NCT04226066|COMBINATION_PRODUCT|T601+5-FC|"Part2: T601 is injected once (Day1). Dose range: MTD-2, MTD-1 and MTD of Part1. 5-FC is taken on Day5-18 for 14 consecutive days. Trial cycle: Day1-28.~Part3: T601 is injected 3 times (Day1, 8, 15). Dose range: MTD-1 and MTD, or MTD-2 and MTD-1 of Part2. 5-FC is taken on Day5-7, Day12-14 and Day19-32. Trial cycle: Day1-46.~Part4: Protocol revised based on results of Part1-Part3. Preliminary plan: 30 patients with gastric cancer, pancreatic cancer and hepatocellular cancer who have failed standard therapeutic options are enrolled (10 patients for each indication). Treatment plan is same as Part3.~For part2 and part3, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
214310208|NCT05215743|DRUG|Antioxidant therapy|Active therapy
214310209|NCT05215743|DRUG|NaCl 0.9%|Placebo
214310210|NCT02850458|DEVICE|implant-retained overdentures|patients treated with an implant-retained overdenture in the mandible
214310211|NCT05430490|PROCEDURE|MRI|Multimodal neuroimaging on 3T Prisma Fit MRI
214310212|NCT05430490|OTHER|NeuroPsychological Testing|A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.
214310213|NCT05430490|PROCEDURE|Blood Draw|Laboratory reports (CMP, CBC, Lipids)
214310214|NCT05430490|OTHER|Questionnaires|Life history, current behaviors, and substance use surveys
214310215|NCT05430490|PROCEDURE|Lumbar Puncture|Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back
214310216|NCT04998591|BEHAVIORAL|Fasting|fasting for 7 days (caloric intake \<500 kcal in liquid form)
214310217|NCT02261636|DRUG|mesalazine|
214310218|NCT05883904|DRUG|Fedratinib|Fedratinib administered after AIFA reimbusement approval
214310219|NCT00748475|BEHAVIORAL|Neurofeedback|
214310220|NCT01302574|DIETARY_SUPPLEMENT|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
214310221|NCT01992731|OTHER|Drug: Follitropine Bèta|
214310222|NCT05420246|DRUG|Ainuovirine|The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
214310223|NCT00741481|PROCEDURE|FDG-PET imaging|FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
214310224|NCT00001445|BIOLOGICAL|HIV-1 Immunogen|
214310225|NCT03375541|OTHER|Risk Aversion Calculator|The calculator asks the participant to rate their level of aversion to having a set list of potential medication side effects (0 = no concern; 1 = mild concern; 2 = moderate concern; 3 = moderate to severe concern; 4 = severe concern)
214310226|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
214310227|NCT04411433|DRUG|Favipiravir (3600 mg + 1600 mg)|"Drug: Favipiravir (3600 mg + 1600 mg) Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
214310228|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
214670778|NCT06875089|OTHER|Satisfaction questionnaire|questionnaire on information process of parents informed about pGS-NBS
214670779|NCT06875089|OTHER|interview with HSS researcher|interview with a member of the HSS team on reasons for declining /accepting pGS-NBS
214670780|NCT06875089|OTHER|satisfaction questionnaire|questionnaire on results delivery in parents having accepted the pGS-NBS
214670781|NCT06875089|OTHER|Qualitative and quantitative longitudinal exploration|validated anxiety and depression scales to assess the psychosocial impact and perceived utility for 90 families whose child screened negative among which 30 families will be interviewed. Interviews and validated anxiety and depression scales will be suggested to all families receiving positive screening results
214916907|NCT01288196|DRUG|Placebo IV|A single 30-minute IV infusion of placebo
214310229|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
214310230|NCT04411433|DRUG|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
214670782|NCT06875089|OTHER|Medical follow up|follow-up of true positives and false negatives based on medical records (vital status, care pathways) until 5 years after results delivery
214670783|NCT05135052|DEVICE|Rhenium-SCT|Rhenium-SCT irradiation device
214670784|NCT06925581|DRUG|HRS-6768|HRS-6768
214916908|NCT01288196|DRUG|CNTO 6785 1 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 1 mg/kg
214916909|NCT01288196|DRUG|CNTO 6785 3 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 3 mg/kg
214916910|NCT01288196|DRUG|CNTO 6785 10 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 10 mg/kg
214916911|NCT01288196|DRUG|CNTO 6785 SC|A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
214916912|NCT01288196|DRUG|Placebo SC|A single SC dose of placebo administered in up to 3 SC injections
214916913|NCT03433196|DRUG|HS-25 and Atorvastatin|HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily
214916914|NCT03433196|DRUG|Atorvastatin|Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily
214916915|NCT04828018|OTHER|Coffee Morning|Coffee mornings (a maximum of n=2) will be held to raise awareness of the project and to promote participant recruitment. These will be held remotely via video conference if Covid-19 restrictions prevent in-person attendance by the researcher.
214916916|NCT04828018|OTHER|Recruitment Leaflets|Recruitment leaflets will be hand-delivered to all In-Pensioner residents at Royal Hospital Chelsea. Leaflets will be delivered internally by Royal Hospital Chelsea internal mail-room
215060701|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
214347045|NCT03072901|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
214347046|NCT01407861|OTHER|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
214347047|NCT01407861|OTHER|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
214347048|NCT01870843|DRUG|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
214347049|NCT03710434|DRUG|AZD4635 50 mg nano-suspension (reference)|Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.
214347050|NCT03710434|DRUG|AZD4635 solid oral formulation - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
214347051|NCT03710434|DRUG|AZD4635 solid oral formulation - fed|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
214347052|NCT03710434|DRUG|Lansoprazole and AZD4635 50 mg solid oral formulation|Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.
214347053|NCT03710434|DRUG|AZD4635 solid oral formulation variant 1 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
214347054|NCT03710434|DRUG|AZD4635 solid oral formulation variant 2 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
214347055|NCT03710434|DRUG|[14C] AZD4635 IV microtracer - fasted|Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
214347056|NCT03920917|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
214347057|NCT03920917|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~3. Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~4. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~5. Evaluated the procedure and radiofrequency ablation time.~6. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
214347058|NCT06316362|DRUG|SMOF lipid 20%|SMOF 20%; a blend of (soybean oil, medium chain triglycerides, olive and fish oil) is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
214916917|NCT04828018|OTHER|Consent Form completion|All participants will be asked to complete Consent Forms before engaging in the study. The researcher will be available to answer any questions via phone calls if required.
214916918|NCT04828018|OTHER|Participant Information Sheet|All participants will receive Information Sheets which they will read in their own rooms (or elsewhere for Key Staff). The researcher will be available to answer any questions via phone calls if required.
214916919|NCT04828018|OTHER|New In-Pensioner Resident Information Pack|New In-Pensioner resident information packs will be distributed by a member of RHC staff as part of their 'arrivals' process and six months after residency at RHC. The researcher will be available to answer any questions via phone calls if required.
214916920|NCT04828018|OTHER|Key Staff Interviews|Key Staff interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
214480928|NCT06856070|OTHER|(Group B: Preformed Zirconia crown)|1\. Crown Selection: The mesiodistal dimension of the corresponding tooth will be measured . to select the appropriate size.2. Occlusal Reduction: The marginal ridge of adjacent teeth will be used as a reference point and a 1.5-2 mm of occlusal reduction will be performed to allow proper crown seating.3. Bucco-Lingual Reduction: The bucco-lingual wall will be reduced by approximately 1-1.5 mm using a flame-shaped diamond bur.4. Interproximal Reduction: 1 mm of interproximal reduction will be performed using a flame-shaped diamond bur such as a .368 or .330 tapered carbide bur.5. Feather Margin Preparation: Subgingival reduction of 1-2 mm will be done using a flame-shaped diamond bur, creating a feathered margin to achieve a passive fit.6. Trial Fitting of the Crown: The crown will be tried in to ensure proper adaptation. until the crown fits passively and extends sub gingivally by 1-2 mm wit.7. Glass ionomer cement will be used for cementation.
214916921|NCT04828018|OTHER|In-Pensioner Resident Interviews|In-Pensioner resident interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
214916922|NCT04828018|OTHER|ICECAP-A Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
214916923|NCT04828018|OTHER|WHOQOL-BREF Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
214916924|NCT00640913|PROCEDURE|Reversal of defunctioning stoma|Reversal of defunctioning stoma
214916925|NCT01906216|DRUG|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
214916926|NCT01906216|PROCEDURE|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
214916927|NCT05753020|BEHAVIORAL|CKM Jumpstart Tool|The CKM JumpStart Tool is a 1-page handout that describes the values of a patient and words that a providers can try with the patient to explore the patient' values more and to provide a values-based introduction to CKM. The values described in the CKM JumpStart Tool is based on a patient's response to a single validated question that we will ask the patient at T1, if they had to choose, do they value care directed at longevity or comfort. Using the patient's answer to the values question, study staff will generate a CKM JumpStart Tool prior to their upcoming clinic visit with their nephrologist. Study staff will inform the patient that their response to the values question will be shared with their provider prior to their next clinic visit and that their providers might bring up their values and treatment options for kidney disease, if the situation permits. We will share the CKM Jumpstart Tool with their provider and provide instruction on how to use the Tool.
214916928|NCT03297320|OTHER|In-depth conversation about Goals of Care and ACP|In-depth conversation regarding Goals of Care and ACP by an experienced practitioner
214916929|NCT01831076|DRUG|Exemestane|Given PO
214916930|NCT01831076|DRUG|Exemestane and tamoxifen|exemestane 25 mg po daily and tamoxifen 20 mg po daily given concurrently for 4 months prior to surgery
214916931|NCT01019694|DRUG|Combivent CFC-MDI|36/206 mcg Four times a day (QID)
214916932|NCT01019694|DRUG|Combivent Respimat 20/100 mcg|Open label randomized parallel
214916933|NCT01019694|DRUG|Atrovent HFA 42 mcg + Albuterol HFA 200 mcg|Open label randomized parallel
214310231|NCT04411433|DRUG|Hydroxychloroquine combined with Azithromycin|"Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
214916934|NCT06041360|DIAGNOSTIC_TEST|Pure tone audiometry PTA ,Speech audiometry ,Otoacoustic emission,Auditory evoked potentials including (ABR).|Neurological tests for diagnosis of peripheral neuropathy
215060702|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
215060703|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
214670785|NCT06729216|DIAGNOSTIC_TEST|Antifungal susceptibility testing (AFST)|testing the fungal susceptibility to different drugs
214310232|NCT00277212|DRUG|Lamotrigine + Aripiprazole|"Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~Aripiprazole 10-30 mg/day"
214670786|NCT00476931|BIOLOGICAL|SB-509|60 mg dose
214670787|NCT00476931|OTHER|Placebo|Saline
214670788|NCT06735560|RADIATION|89Zr-TLX250 PET/CT|Patients will receive 89Zr-TLX250 for detection of CAIX-expressing tumor by PET imaging.
214670789|NCT00960557|DRUG|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
214916935|NCT03864679|OTHER|Exercise|Subjects will perform a cycling test with 5 min incremental intensity exercise and 1 h cycling test exercising at a moderate-intensity (load will be selected in incremental intensity exercise).
214916936|NCT04244084|DRUG|MMH-407|Oral use.
214916937|NCT04244084|DRUG|Placebo|Oral use.
214916938|NCT05352464|OTHER|cervical traction with EMG biofeedback|"Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.~Ask the patient to assume sitting position on a comfortable chair. Place surface electrodes of EMG biofeedback at the level of C5-6 Para spinal muscles to pick up the activity of the muscles and convert it to vis-ual and auditory impulses produced from the device. Tell the patient to try to relax the tension of the neck muscles as much as he can by lowering the visual and auditory impulses from the device"
214916939|NCT05352464|OTHER|cervical traction and conventional physical therapy|Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position
214916940|NCT05202067|BEHAVIORAL|pharmaceutical education|The patients who were assigned to the intervention group will receive a didactic talk from the research pharmacist. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
214916941|NCT03713060|DIAGNOSTIC_TEST|Mixed meal test|All women will have mixed meal test, continous glucose monitoring and antenatal ultrasounds performed. The children born of these women will have DXA-scans performed after birth.
214916942|NCT05518240|DEVICE|Stent Retrievers|Procedure: Embotrap device
214916943|NCT05518240|DEVICE|Stent Retriever|Procedure: Solitaire device
214916944|NCT00026494|DRUG|temozolomide|
214916945|NCT00026494|DRUG|vinorelbine tartrate|
214916946|NCT01052194|DRUG|Placebo|tablet, placebo b.i.d. for 12 weeks
214670790|NCT03567187|DEVICE|iovera|The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.
214670791|NCT01843322|PROCEDURE|endoleak repair procedure (navigation technology )|
214916947|NCT01052194|DRUG|VX-509|tablets, 25mg b.i.d. for 12 weeks
214310233|NCT00277212|DRUG|Lamotrigine + Placebo|"Tablets, Oral, once daily, Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~placebo 0 mg/day"
214310234|NCT03606681|DRUG|Calcium Hydroxide|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
214310235|NCT03606681|DRUG|Mineral Trioxide Aggregate|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
214310236|NCT03606681|DRUG|TheraCal LC|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
214310237|NCT01991119|DRUG|Propafenone|
214310238|NCT01991119|DRUG|Dronedarone|
214670792|NCT06843317|BIOLOGICAL|Candidate vaccine, SCB-1019T|SCB-1019T is a novel bivalent recombinant RSV vaccine (CHO Cell) designed to broadly neutralize the two dominant circulating strains of the virus. The SCB-1019T vaccine consists of the PreF protein subunits from the two dominant circulating strains, strain A and strain B, fused to Trimer-Tag™.
214670793|NCT06843317|BIOLOGICAL|AREXVY|positive comparator
214670794|NCT06843317|OTHER|placebo|Placebo Comparator
214916948|NCT01052194|DRUG|VX-509|tablet, 50 mg b.i.d. for 12 weeks
214916949|NCT01052194|DRUG|VX-509|tablet, 100 mg b.i.d. for 12 weeks
214916950|NCT01052194|DRUG|VX-509|tablet, 150 mg b.i.d. for 12 weeks
214916951|NCT02890576|OTHER|telemedicine|Monitoring of patients with cochlear implant with sessions of telemedicine
214916952|NCT03324620|OTHER|Specific program functional and respiratory rehabilitation|It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
214916953|NCT02170974|DRUG|BIBR 1048 MS polymorph II|
214916954|NCT02170974|DRUG|BIBR 1048 MS polymorph I|
214916955|NCT00529620|DRUG|sulfalene-pyrimethamine plus amodiaquine|Monthly treatments during the malaria transmission season
214916956|NCT00529620|DRUG|dihydroartemisinin plus piperaquine|Monthly treatments during the transmission season
214916957|NCT00529620|DRUG|sulfadoxine pyrimethamine plus piperaquine|Monthly treatments during the malaria transmission season
214916958|NCT04941612|DEVICE|Activa IM-Nail|PLGA bioabsorbable intramedullary nail
214916959|NCT04676269|BIOLOGICAL|Amnion only|Patients endometrium will be transplanted with amnion only (without seeded cells)
214916960|NCT04676269|BIOLOGICAL|Amnion - endometrium cells|Patients endometrium will be transplanted with amnion seeded with endometrium cells isolated from the patients themselves
214916961|NCT04676269|BIOLOGICAL|Amnion - amnion epithelial cells|Patients endometrium will be transplanted with amnion seeded with amnion epithelial stem cells isolated from other patients' caesarean sectio amnion membrane (tested HLA-DR negative to prevent rejection)
214916962|NCT04676269|BIOLOGICAL|Amnion-EnSC-AESC|Patients endometrium will be transplanted with amnion seeded with endometrium cells-amnion epithelial stem cells co-culture
214916963|NCT01684423|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
214916964|NCT01684423|DRUG|Active comparator|Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
214310239|NCT03336216|BIOLOGICAL|Cabiralizumab|specified dose on specified days
214310240|NCT03336216|DRUG|Nab-paclitaxel|specified does on specified days
214310241|NCT03336216|DRUG|Onivyde|specified dose on specified days
214310242|NCT03336216|BIOLOGICAL|Nivolumab|specified dose on specified days
214310243|NCT03336216|DRUG|Fluorouracil|specified dose on specified days
214310244|NCT03336216|DRUG|Gemcitabine|specified dose on specified days
214480929|NCT06856304|PROCEDURE|laparoscopic disconnection of the hernia sac|disconnection of the hernial sac at the level of the internal ring using hook diathermy with sweeping the vas and the vessels away till completely separating them from the edges of the sac, then narrowing of the internal ring by appling a vicryl 3/0 suture between the ilipubic tract and the transverse arch of the transversus abdominus muscle
214480930|NCT06856304|PROCEDURE|Percutaneous internal ring suturing|A single umbilical trocar was placed through a supraumbilical incision, and then the surgeon stood on the same side of the hernia. To choose the location for the needle puncture, the position of the IIR was assessed by pressing the inguinal region from the outside with the tip of a forceps. Under laparoscopic-guided vision, the previously prepared 18-gauge injection needle threaded with the monofilament suture was introduced into the abdominal wall through a skin puncture at the lateral edge of the internal ring. With the movements of the tip of the needle, the thread passed under the peritoneum, over the lateral half of the IIR. The thread was pushed through the barrel of the needle into the abdominal cavity and eventually made a loop. The needle was pulled out, leaving the loop of the thread inside the abdomen by hanging the loop on the endoscope this prevented the extraction of the loop with the needle and thus prevented repeating this step. Next, the thread loop was pulled out of t
214480931|NCT06859840|DEVICE|LIDAR|Using the LIDAR model to assist in image interpretation, patients with positive results are recalled for further examination based on the LIDAR output information and the original image interpretation, to obtain pathological results and long-term follow-up.
214670795|NCT06774963|DRUG|LNCB74|LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.
214670796|NCT01225068|DRUG|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
214670797|NCT01225068|DRUG|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
214916965|NCT01684423|DRUG|Rivaroxaban (BAY59-7939) suspension|Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
214916966|NCT04160039|DEVICE|Cycle ergometry|Lower extremity cycle ergometry, passive and/or active, up to 20 minutes per session, up to 5 sessions per week
215060704|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
215060705|NCT06181838|PROCEDURE|Lesion extraction|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
214310245|NCT03336216|DRUG|Oxaliplatin|specified dose on specified day
214310246|NCT03336216|DRUG|Leucovorin|Specified dose on specified days
214310247|NCT03336216|DRUG|Irinotecan Hydrochloride|Specified dose on specified days
214310248|NCT06076694|DRUG|TNP-2198|Group A, TNP-2198 capsules 400mg(4 capsules),BID, 14days Group B, TNP-2198 capsules 600mg(6 capsules),BID, 14days Group C , TNP-2198 capsules 600mg(6 capsules),TID, 14days Group D, TNP-2198 capsules 600mg(6 capsules),TID, 7days
214310249|NCT06076694|DRUG|Rabeprazole Sodium|Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days
214310250|NCT06076694|DRUG|Amoxicillin|Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days
214310251|NCT01023581|DRUG|Alogliptin|Alogliptin tablets.
214310252|NCT01023581|DRUG|Metformin|Metformin capsules
214916967|NCT06130514|DEVICE|Ultrasound|Ultrasound-guided stellate ganglion block with 1% mepivacaine 5 mL
214310253|NCT01023581|DRUG|Alogliptin Placebo|Alogliptin placebo-matching tablets.
214310254|NCT01023581|DRUG|Metformin Placebo|Metformin placebo-matching capsules.
214916968|NCT06130514|DEVICE|Fluoroscopy|Fluoroscopic-guided thoracic sympathetic ganglion block with 1% mepivacaine 3 mL
214916969|NCT03185195|DRUG|AQX-1125 Oral Tablet|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
214916970|NCT03185195|DRUG|[14C]-AQX-1125 IV|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
215060706|NCT06181838|DRUG|Tretinoin|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
214310255|NCT00763074|BEHAVIORAL|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.~\----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30\~35kcal/day"
214310256|NCT00763074|BEHAVIORAL|Diet restriction|"Education for diet and exercise every 2 weeks~\----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
214310257|NCT00763074|BEHAVIORAL|Exercise|"Education for diet and exercise every 2 weeks~\----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
214310258|NCT00763074|BEHAVIORAL|Diet and exercise|"Education for diet and exercise every 2 weeks~\----------- Exercise education like as exercise group and diet education like as diet group"
214310259|NCT00803881|OTHER|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
214310260|NCT02515409|DEVICE|HHHFNC|After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
214310261|NCT02515409|DEVICE|CPAP|CPAP, as a first line treatment in OSAS.
214310262|NCT03339609|DIAGNOSTIC_TEST|Uroflow|Isolated uroflow measurement
214310263|NCT03339609|DIAGNOSTIC_TEST|Uroflow/EMG|Uroflow measurement with superficial EMG testing of the pelvic floor
214310264|NCT03339609|DIAGNOSTIC_TEST|US|Ultrasound of post void residual urine
214310265|NCT02280174|DRUG|linagliptin|linagliptin 5 mg/d for12 weeks
214310266|NCT06312878|OTHER|Describe the anatomy of the IVC in the case of an anatomical variant|Evaluated technique by collecting data from the medical record.
214310267|NCT01231581|DRUG|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
214310268|NCT01231581|DRUG|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
214310269|NCT01231581|DRUG|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
214310270|NCT01044602|OTHER|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
214480932|NCT06859489|DEVICE|Active aGeing And Personalised service's Ecosystem (AGAPE)|"The experimental protocol is structured into two phases:~Phase 1 (pre-pilot) - Preliminary assessment of the functionality and usability of the AGAPE platform by older adults and caregivers, divided into:~Living lab: Three sessions to progressively explore and test the platform and its services, including workshop activities.~Testing phase: Use of the platform in the home environment of older adults for one month.~Phase 2 (pilot study) - Evaluation of the platform's impact on the daily lives of older adults, caregivers, and care organizations, with a 12-month involvement for each user."
214480933|NCT06861972|PROCEDURE|Caesarean Hysterectomy|Caesarean delivery followed by hysterectomy
214480934|NCT06861972|PROCEDURE|Conservative management|Focal myometrium resection of the area of diseased myometrium after delivery
214480935|NCT06862024|BEHAVIORAL|Deep Breathing and Cough Exercise Skills|Ability to apply deep breathing and cough exercise skills will be examined.
214480936|NCT06862024|BEHAVIORAL|Satisfaction with the training method|The level of satisfaction with the training provided will be determined with the PechaKucha presentation.
214480937|NCT06862310|OTHER|yogurt intervention|daily probiotics dose of 3 × 108 CFU (95% confidence interval \[CI\]: 1 × 109 to 3 × 1010 CFU) in 112 mL of fermented milk per day (95% CI: 100-187.5 mL/day)
214480938|NCT06864520|DIETARY_SUPPLEMENT|GAMMA-AMINOBUTYRIC ACID - GABA|Food supplement based on GABA and Melissa extract
214480939|NCT06864520|OTHER|Placebo|Placebo based on microcrystalline cellulose, rice bran, bitter cocoa powder
214480940|NCT05869227|DRUG|Capecitabine/Placebo combined with toripalimab|Combined
214480941|NCT06668909|DEVICE|WaveLight® EX500|Phorcidies Planned Contoura LASIK
214480942|NCT06615661|DEVICE|C-Rex Instrument|The C-Rex Instrument is a manual ophthalmic surgical instrument used for ab interno goniotomy and inner wall trabeculotomy.
214916971|NCT03185195|DRUG|[14C]-AQX-1125 Oral Solution|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
214916972|NCT05822323|OTHER|BTX-A|Vials of 100 U Allergan Botox® (Allergan, Inc., Irvine, California) were diluted with 2 ml of physiological saline and made ready for use. The midline was determined at the mentum region. 5 U of BTX-A was injected into the mental muscle approximately 1 cm away from the chin tip and the midline
214916973|NCT05822323|PROCEDURE|free gingival graft|The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.
214916974|NCT06207097|OTHER|physiotherapy techniques|Dry neeling: invasive physiotherapy technique where an acupuncture needle is used on painful points Elastic taping: physiotherapy technique where elastic bandage is used on the skin Exercise program: physical exercise prescription
214310271|NCT01044602|OTHER|Best Medical Management|Standard of care.
214670798|NCT03121690|DRUG|Prednisone|prednisone 40 mg/day for 7 days
214916975|NCT04890197|DIETARY_SUPPLEMENT|tahini|48 grams tahini
214916976|NCT04890197|OTHER|control|no intervention
215060707|NCT05439343|OTHER|Pain scores (numerical rating scale at rest and motion)|As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
215077799|NCT03614416|DEVICE|EOXY device|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
214310272|NCT01044602|PROCEDURE|Roux-en-Y gastric bypass surgery|Surgical treatment.
214310273|NCT00889954|BIOLOGICAL|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
214310274|NCT04512248|BEHAVIORAL|Quit and Stay Quit Monday Model|Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
214310275|NCT02245256|DRUG|Precedex|infusion of 0.1mcg/kg/hr of precedex
214310276|NCT02245256|DRUG|placebo control|placebo
214310277|NCT06440031|BEHAVIORAL|CaMaPi|CaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months
214310278|NCT06440031|OTHER|TAU|Treatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service.
214670799|NCT03121690|DRUG|placebo|5ml saline / day for 7 days
214670800|NCT00907738|DRUG|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
214916977|NCT05458999|OTHER|Virtual reality headset during percutaneous coronary intervention|Virtual reality glasses during percutaneous coronary intervention
214916978|NCT00441129|DEVICE|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
214310279|NCT00957203|DRUG|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
214670801|NCT02032875|DRUG|Daclatasvir|
214916979|NCT00441129|DEVICE|Minimed Paradigm 512/712 Insulin pump|Minimed Paradigm 512/712 Insulin pump
214916980|NCT01455597|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
214670802|NCT02032875|DRUG|Sofosbuvir|
214670803|NCT02032875|DRUG|Ribavirin|
214916981|NCT00405431|DRUG|Restasis|1 drop in study eye twice a day X 6 months
214916982|NCT00405431|DRUG|Endura (artificial tears)|1 drop in study eye twice a day X 6 months
214916983|NCT03358069|DIAGNOSTIC_TEST|Emergence agitation scale|Emergence agitation scale: PAED scale \> 10 defined as positive for Emergence agitation (EA) Post hospitalize behavioral questionnaire (PHBQ) positive Post operative behavioral changes defines as 10 % change from sum score of PHBQ
214916984|NCT04632069|COMBINATION_PRODUCT|N acetyl cysteine + vagus nerve stimulation|NAC x 14 days, taVNS x 10 days
214916985|NCT04042623|DRUG|AVB-S6-500|AVB-S6-500 is experimental drug
214916986|NCT02443714|DEVICE|Needle-free jet injection with insulin lispro|Subjects injected by jet injectors which deliver insulin lispro
214916987|NCT02443714|DEVICE|Conventional pen injection with insulin lispro|Subjects injected by conventional insulin pens which deliver insulin lispro
214916988|NCT03325634|OTHER|Laboratory Biomarker Analysis|Correlative studies
214916989|NCT03325634|OTHER|Quality-of-Life Assessment|Ancillary studies
214916990|NCT03325634|OTHER|Questionnaire Administration|Ancillary studies
214916991|NCT03325634|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214310280|NCT06332716|OTHER|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. The sending doctor can choose from the following relevant treatment drugs and confirm with the responsible researcher for drug sensitivity testing.
214310281|NCT06127082|DEVICE|Echocardiography|Do echocardiography to obese patient
214310282|NCT02510794|DRUG|Ranibizumab|Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
214310283|NCT03938194|PROCEDURE|Aquablation|a novel minimally invasive water ablation therapy combining image guidance and robotics for the targeted and heat-free removal of prostate tissue
214310284|NCT03068975|DRUG|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
214310285|NCT03068975|DRUG|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
214310286|NCT02224911|DEVICE|Laser Interstitial Thermal Therapy|
214310287|NCT00294164|DRUG|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
214310288|NCT00294164|DRUG|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
214310289|NCT03318991|PROCEDURE|Laser prostatectomy|Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
214670804|NCT06768229|OTHER|Consumption of a freeze-dried strains-mix.|One study group of 20 healthy volunteers will consume freeze-dried strains-mix twice per day diluted in 1 glass of still water during 14 consecutive days.
214670805|NCT06935201|BEHAVIORAL|Get Back|A rehabilitation program, targeting physical activity behavior, with a person-centered approach led by a physical therapist during 12 weeks (1 week before surgery until 12 weeks after surgery) in a digital format.
214670806|NCT02858193|DRUG|SCMC-lys powder 1.35 g|"Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments."
214916992|NCT03412734|DRUG|Chlorhexidine|Chlorhexidine preparation solutions
214916993|NCT03412734|DRUG|Iodine|Iodine-based preparation solutions
214916994|NCT00624936|DRUG|Vidaza|Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
214916995|NCT00624936|DRUG|Velcade|Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
214916996|NCT01519219|RADIATION|Hepatic Irradiation|Patients who take part in this study are required to be scheduled for hepatic irradiation. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy
214916997|NCT02467790|DRUG|PEX168|PEX 168: 200µg,Subcutaneous,one time.
214916998|NCT05732337|DEVICE|Poxclin Coolmousse|cooling mousse for application in the skin
214916999|NCT00423332|DRUG|Cediranib|45 mg oral tablet
214917000|NCT00423332|DRUG|Cediranib Placebo|oral tablet
214917001|NCT00812383|DEVICE|RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System|Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
214917002|NCT04870385|BEHAVIORAL|5-week prevention program|Online modular psychological prevention program featuring integrated elements of Islamic spirituality and Acceptance and Commitment Therapy (ACT).
214917003|NCT04870385|BEHAVIORAL|Control|Control group waitlisted to receive prevention program after completion of final data collection.
214917004|NCT00719485|OTHER|Educational program|Informing patients about their condition, treatment options, prioritization on the wait list, and post-operative care
214310290|NCT00581074|BEHAVIORAL|diet (grapefruit or grapefruit juice)|weight loss diet
214310291|NCT02759068|BEHAVIORAL|sounds and odors|presentation of sounds and odors
214310292|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to modifined points group|Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.
214310293|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to conventional points group|Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
214310294|NCT00017134|DRUG|fenretinide|
214310295|NCT00017134|PROCEDURE|conventional surgery|
214480943|NCT05418478|BEHAVIORAL|Intervention transtheoretical model group|"The Transtheoretical Model is a conscious behavior modification model that focuses on individual decision making and planning processes. It is the only model that examines behavior change as a dynamic process rather than an outcome, and considers behavioral strategies that include the individual's cognitive and behavioral processes in this process.~In the model, it is stated that behavior change is a process and develops gradually. It is reported that the change in the behavior of individuals consists of six stages: 1) not thinking, 2) thinking, 3) preparation, 4) taking action, 5) maintaining and 6) terminating. This model consists of four main constructs called change stages (time-related dimension), change processes/behavior modification methods (independent variable dimension), self-efficacy (levels of change) and decision-making balance (perceptions of harm and benefit of change)."
214480944|NCT06677242|DIAGNOSTIC_TEST|Blood sample (serum) for circulating tumor DNA and cervical smear for genome-wide methylation sequencing|These are additional tests, added to the observational study to collect information on tumor characteristics and to pursue early detection of this diagnosis.
214480945|NCT04661137|DRUG|Selinexor 60 MG|Selinexor 60 mg PO on days 1, 8 and 15
214480946|NCT04661137|DRUG|Selinexor 80 MG|Selinexor 80 mg PO on days 1, 8 and 15
214480947|NCT04661137|DRUG|Selinexor 100 MG|Selinexor 100 mg PO on days 1, 8, 15 and 22
214480948|NCT04661137|DRUG|Carfilzomib|56 mg/m2 IV on days 1, 8 and 15
214480949|NCT04661137|DRUG|Pomalidomide|4 mg PO daily for 21 days
214917005|NCT02304861|PROCEDURE|Viscoat|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision 3% Sodium Hyaluronate, 4% Chondroitin Sulfate (Viscoat, Alcon, Greece) was injected in the anterior chamber
215060708|NCT05439343|OTHER|Secondary outcomes|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.
215060709|NCT00000673|DRUG|Ganciclovir|
215060710|NCT05078515|DIAGNOSTIC_TEST|PREDICT score|Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
215060711|NCT05319899|DRUG|ALXN1840|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
215060712|NCT05319899|DRUG|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
215060713|NCT00848835|DEVICE|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
214310296|NCT00992810|PROCEDURE|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
214310297|NCT00992810|PROCEDURE|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
214310298|NCT01587495|DRUG|Ertapenem|Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
214310299|NCT03090100|DRUG|Guselkumab|Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
214310300|NCT03090100|DRUG|Placebo|Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
214310301|NCT03090100|DRUG|Secukinumab|Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
214480950|NCT04661137|DRUG|Daratumumab|16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on
214480951|NCT04661137|DRUG|Dexamethasone|20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22
214480952|NCT04414215|BEHAVIORAL|Emotional working memory training|Participants will complete an emotional working memory n-back training program that progressively increases difficulty and has been shown to enhance prefrontal activity in a non-psychiatric sample
214480953|NCT04414215|BEHAVIORAL|Placebo working memory training|Working memory training that does not involve emotional stimuli using an N-back training program
214480954|NCT06672588|DEVICE|Magnetic Seizure Therapy (MST)|MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation at 100% machine output. Seizure threshold will follow prior protocols used for frontal MST. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
214310302|NCT06143332|OTHER|Aerobic exercise training|Aerobic exercise training on a cycle ergometer
215060714|NCT05940064|DRUG|Zanubrutinib, Polatuzumab Vedotin, Rituximab|Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m\^2 ivgtt D1
214310303|NCT03674866|DRUG|Insulin degludec|Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
214310304|NCT00271479|BIOLOGICAL|A, C, Y, W135 meningococcal polysaccharide vaccine|
214310305|NCT06457555|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|This study is a mixed method research conducted to determine the knowledge levels and experiences of nurses working in adult intensive care units regarding the prevention of pressure sores. In accordance with the purpose of the study, parallel data type in convergent parallel mixed design will be used as the research design. The quantitative phase will be conducted as a descriptive survey, and the qualitative phase will be conducted as a descriptive case study design. In this mixed design, equal priority, parallel timing and combining results during interpretation are planned.
214310306|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
214310307|NCT00516724|DRUG|Carboplatin|intravenous injection
214310308|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
214310309|NCT00516724|DRUG|Paclitaxel|Intravenous injection
214310310|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
214310311|NCT00516724|DRUG|Paclitaxel + Carboplatin|Intravenous injection
214310312|NCT03253848|OTHER|Simplified Patient Care Strategy|Treatment per Acute Promyelocytic Leukemia (APL) Treatment Guidelines plus discussion between doctors and APL expert
214310313|NCT03253848|OTHER|Laboratory Biomarker Analysis|Correlative studies
214310314|NCT05352815|DRUG|IcoSema|Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
214310315|NCT05352815|DRUG|Insulin icodec|Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
214310316|NCT06315569|BEHAVIORAL|Run 3000 meters|Participants in both groups were asked to do two 3,000-meter runs at different intervals
214310317|NCT02165020|DEVICE|Hyaluronic acid (Macrolane VRF 30®, Q-MED)|"One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.~The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle."
214310318|NCT05719207|DEVICE|Balloon dilation of eustachian tube|Patients in the intervention group would undergo balloon dilation of the eustachian tube under local anesthetic in clinic. The Stryker XprESS LoProfile ENT dilation system or the Stryker Audion ET dilation system will be used.
214310319|NCT05719207|OTHER|Sham procedure|Patients in the sham group will undergo the motions of an in-office dilation of the eustachian tube, without actually dilating the eustachian tube.
214310320|NCT05402657|PROCEDURE|Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy|UBRUL-FP involves ultrabrief right unilateral ECT delivered using a novel frontoparietal montage, where the anterior electrode is shifted frontally to a position above the midpoint of the right eye to avoid temporal lobe stimulation (and reduce memory side effects). UBRUL-FP will be delivered using standard ECT devices.
214310321|NCT05402657|PROCEDURE|Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy|UBRUL-TP is the standard form of ultrabrief right unilateral ECT, using the conventional temporoparietal (d'Elia) electrode placement, where the anterior electrode is placed over the right temporal lobe. UBRUL-TP will be delivered using standard ECT devices.
214310322|NCT05923853|OTHER|FiO2 titration using electronic alert system|In the intervention arm, arterial oxygen saturation (SaO2) and peripheral oxygen saturation (SpO2) will be initially noted. Based on the correlation between the SaO2 and SpO2 the optimal oxygenation range will be determined. E-alerts will then be used to monitor oxygenation for patients in the intervention arm, based on SpO2 values generated by the patient due to the FiO2 given to the patient through the ventilator. Once an e-alert is sent, the respiratory therapist has 45 minutes for adjusting oxygen. Then the e-alert continues to monitor FiO2 and SpO2 values in this manner for every 45 minute period until the ventilator is attached to the patient.
214310323|NCT02759120|DRUG|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight \< 50 kilograms or 100mg twice daily if weight \> 50 kilograms for up to 36 months
214310324|NCT02759120|OTHER|No Intervention: Standard of Care|Standard of care
214310325|NCT02861794|PROCEDURE|Medacta International, GMK Sphere medially stabilized knee|Total Knee Replacement
214310326|NCT04133168|DEVICE|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories"
214310327|NCT04792697|OTHER|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising
214310328|NCT04792697|OTHER|Decrease evening blue light|Participants will wear blue light blocker goggles for 2 hours before bed
214310329|NCT04792697|BEHAVIORAL|Sleep Scheduling|Participants will advance their bedtime by 1.5 hours and regularize their wake time
214310330|NCT04792697|BEHAVIORAL|Monitor sleep, mood, and substance use|Participants will complete smartphone-based sleep, mood, and substance use monitoring
215060715|NCT03196596|OTHER|Computer simulation|In these patients, a computer simulation model will be obtained based on pre procedural CT
214310331|NCT01474044|DRUG|Gastropylor Complex Capsules|3 pills, three times a day, after meal
214310332|NCT01474044|OTHER|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
215060716|NCT02827760|DIETARY_SUPPLEMENT|Synergy1|Inulin type fructans
215060717|NCT02827760|DIETARY_SUPPLEMENT|Maltodextrin|
215060718|NCT01580709|PROCEDURE|Multiple brushings|Seven consecutive brush samples for cytology.
215060719|NCT01580709|PROCEDURE|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
214310333|NCT02657460|BIOLOGICAL|tumor derived microparticles|The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.
214310334|NCT02657460|DRUG|cisplatin|cisplatin is a traditional drug for lung cancer
214310335|NCT02152501|OTHER|Exercise Energy Expenditure 300 kcal/day|
214480955|NCT06672588|DEVICE|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q or MECTA sigma machine will be used. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
214310336|NCT02152501|OTHER|Exercise Energy Expenditure 600 kcal/day|
214310337|NCT04463550|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
214310338|NCT04630951|OTHER|Blood Flow Restriction Strength training with low load|Low Load (20-50% 1RM), 4 set of 30/15/15/15 repetitions, 30 seconds resting between sets.
214310339|NCT04630951|OTHER|High Load Strength Training|High Load (60-80% 1RM) 4 sets of 8 repetitions, 2 minutes resting between sets
214480956|NCT06586164|BEHAVIORAL|Targeted Cognitive Training|TCT is a computer-based cognitive training program in which participants train on progressively more difficult auditory processing exercises in order to improve speed, accuracy and fidelity of auditory information processing in order to generate gains in cognition and functioning.
214480957|NCT06590480|BIOLOGICAL|RP1|Genetically modified Herpes Simplex Type 1 Virus
214480958|NCT06590480|BIOLOGICAL|Nivolumab|Anti-PD-1 Monoclonal Antibody
214480959|NCT06679348|OTHER|walking exercise on treadmill|The study included two intervention groups, consisting of participants who met the inclusion criteria and adhered to the experimental procedures. One group will do treadmill walking exercises, while the other will do treadmill walking exercises using virtual reality (VR). Both interventions were conducted in a single session, with each group participating in a 20-minute walking exercise session at a moderate intensity, as identified by other studies.
214480960|NCT06679348|OTHER|Treadmill walking exercise using VR|Walking on the treadmill with the Free Run game on the Nintendo Wii allows users to walk at 5 miles per hour for 20 minutes. The user gets on the Wii Balance Board and starts walking in the virtual environment after running the application. The application detects the user's movements and controls the progress of the virtual character. During this experience, users increase their motivation by encountering various landscapes while tracking their performance and getting information about the calories they spend. This setup provides a fun, game-like atmosphere for a realistic walking experience.
214480961|NCT06677996|DRUG|varegacestat|Experimental intervention
214480962|NCT06677996|DRUG|Itraconazole (200 mg)|Intervention to evaluate DDI with experimental intervention
214480963|NCT06020027|BEHAVIORAL|Water is K'é|Four-month multi-level, family-based intervention that is grounded in Navajo culture and promotes individual knowledge, motivation and skills; social norms; and environmental changes (access to drinking water). At minimum, the enrolled child and primary caregiver will attend monthly sessions, with an open invitation to other family members. Families will also receive social media posts and develop a family access plan by selecting strategies (if needed) to boost their confidence in their water sources at home. ECE sites will also develop a tailored access plan, selecting strategies to increase confidence in water offered at the ECE site, and implement their access plan with study team support.
214480964|NCT06866769|DIAGNOSTIC_TEST|CTA|The levels of biomarkers are determined before (within 30 days prior to the procedure) and after the implantation of the stent (24-48 hours, 1 month, 3 months, 6 months, and at 1 year), along with the performance of a contrast-enhanced ultrasound. Additionally, a follow-up CT angiography is performed to validate the concordance, that is, to assess if there are changes in the biomarker values determined one month after the implantation of the stent compared to the baseline values that may suggest the presence of complications (endoleaks, infection, thrombosis, etc.).
215060720|NCT05547087|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.
215060721|NCT02808325|DRUG|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
215060722|NCT02808325|DRUG|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
215060723|NCT02110186|DEVICE|Dynamic Stabilization|
214310340|NCT05156879|DRUG|Aspirin|75mg, one time/day
215060724|NCT02110186|PROCEDURE|Discectomy|
215060725|NCT02110186|DEVICE|Instrumentation and fusion|
215060726|NCT00263432|PROCEDURE|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
215060727|NCT01994746|DRUG|Nasal Glucagon|
215060728|NCT01994746|DRUG|Intramuscular Glucagon|
215060729|NCT04358146|OTHER|Experimental Infant formula|Exclusive formula feeding with the new infant formula thickened with fibers
214310341|NCT05156879|DRUG|Drospirenone ethinyl estradiol|1 table/day, 21 consecutive days, 28 days as a cycle of use
214310342|NCT04588649|DRUG|THK-5351|\[18F\]THK-5351 PET Imaging
214310343|NCT04588649|DRUG|AV-45|\[18F\]AV-45 PET Imaging
214310344|NCT04109638|DEVICE|Endonovo SofPulse|The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
214310345|NCT00668941|DRUG|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
214310346|NCT00668941|DRUG|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
214310347|NCT00668941|DIETARY_SUPPLEMENT|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
214310348|NCT00668941|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
214310349|NCT04461015|DRUG|0.4mU Insulin followed by withdrawal period followed by 0.8mU study|Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min
214310350|NCT04461015|DRUG|0.8mU Insulin followed by withdrawal period followed by 0.4mU study|Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
214310351|NCT06490029|DIAGNOSTIC_TEST|Auditory, vestibular and electrophysiological investigations|otoacoustic emissions, electrocochleography, vocal audiometry in noise and high-frequency tonal audiometry, impedancemetry
214310352|NCT06490029|DIAGNOSTIC_TEST|Biologic investigations; seric proteins|seric proteins
214480965|NCT06333223|DIETARY_SUPPLEMENT|Mixture of (Poly)phenols and a probiotic supplement|Mixture of (Poly)phenols and a probiotic supplement
214480966|NCT06333223|DIETARY_SUPPLEMENT|Placebo comparator|Mixture of (Poly)phenols and a placebo maltodextrin comparator
214917006|NCT02304861|PROCEDURE|Visthesia|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision sodium hyaluronate 1.5% and lidocaine hydrochloride 1% ophthalmic viscosurgical device (OVD) (Visthesia, Carl Zeiss, Germany) was injected in the anterior chamber
214917007|NCT05901935|DRUG|DP303c|DP303c injection, 3.0 mg/kg, Q3W.
214917008|NCT05901935|DRUG|Trastuzumab|IV, 6 mg/kg, D1, Q3W
214917009|NCT05901935|DRUG|Vinorelbine Tartrate|IV, 25 mg/m\^2，D1、D8，Q3W
214917010|NCT05901935|DRUG|Capecitabine tablets|PO 1000 mg/m\^2, bid, D1-D14, Q3W
214917011|NCT00169611|DRUG|methylphenidate|
214917012|NCT04156711|PROCEDURE|Remote Ischemic Preconditioning (RIPC)|Cycles of forearm ischemia and reperfusion by the inflation of a blood-pressure cuff over the systemic blood pressure for brief periods
214917013|NCT05137444|BIOLOGICAL|LYB001|The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.
214917014|NCT05137444|BIOLOGICAL|Placebo|Aluminum hydroxide
214917015|NCT01602367|DRUG|BMS-823778|Capsules, Oral, 2 mg, Once daily, 12 weeks
214310353|NCT03899584|DRUG|4-Aminopyridine|Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
214310354|NCT03899584|DRUG|Placebo oral capsule|The placebo arm will include a placebo of microcrystalline cellulose.
214310355|NCT04234282|PROCEDURE|Manual Physical Therapy|Orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment.
214480967|NCT05428852|OTHER|Laboratory Biomarker Analysis|Correlative Studies
214917016|NCT01602367|DRUG|BMS-823778|Capsules, Oral, 6 mg, Once daily, 12 weeks
214917017|NCT01602367|DRUG|BMS-823778|Capsules, Oral, 15 mg, Once daily, 12 weeks
214917018|NCT01602367|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 12 weeks
214917019|NCT02183038|DRUG|Meloxicam low|
214917020|NCT02183038|DRUG|Meloxicam high|
214310356|NCT05257811|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device includes custom-fit earbuds with biometric sensors to detect EEG, motion (via tri-axial accelerometers), and heart rate. A ring laser scanner is used to capture the unique geometry of each participant's ear and external auditory canal. Digital models of the individual ear scans are generated and used to create custom fit, 3D-printed earbuds. This design process allows for consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, cardiac activity, and eye movements.
214310357|NCT00146146|DRUG|testosterone undecanoate alone|1000 mg/12 weeks
214480968|NCT05428852|OTHER|Neurocognitive Assessment|NRG-CC
214480969|NCT05428852|OTHER|Questionnaire Administration|Ancillary studies
214480970|NCT05428852|DEVICE|Fitbit|Fitbit Activity Tracking
214480971|NCT05428852|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo ketogenic diet
214480972|NCT04393350|DRUG|Lenvatinib|Given PO
214480973|NCT04393350|DRUG|Lenvatinib Mesylate|Given PO
214917021|NCT02183038|DRUG|Naproxen sodium|
214480974|NCT04393350|BIOLOGICAL|Pembrolizumab|Given IV
214917022|NCT02183038|DRUG|Meloxicam placebo low|
214917023|NCT02183038|DRUG|Meloxicam placebo high|
214917024|NCT02183038|DRUG|Naproxen sodium placebo|
214917025|NCT04952025|DIAGNOSTIC_TEST|Diagnostic criteria|Diagnostic criteria of ALS
214917026|NCT05847465|OTHER|Bike stress test|This is an incremental exercise under maximal pedaling on an Excalibur® type bike with electromagnetic brake over 36 minutes during which gas exchanges are continuously measured through a face mask (Cosmed®).
214917027|NCT05847465|OTHER|Heat Tolerance Test|"The test consists of a walk on a treadmill in shorts, bare chest or bra for women, at 5 km/h and 2% slope in an environment at 40°C, 40% relative humidity, without convection.~During the test, rectal temperature, heart rate and skin temperature will be monitored continuously.~The blood pressure will be measured manually every 30 minutes during the test."
214917028|NCT05847465|OTHER|Heat nociception test|"This test consists in applying a thermal flux generated by an infrared light source on a beam of 1 cm diameter on 2 areas of the dominant lower limb (glabrous face of the forearm and thenar eminence).~Participants will be instructed to remove their limb as soon as the sensation of heat begins to become uncomfortable.~The time between the beginning of the stimulus and the moment of withdrawal will be recorded."
214917029|NCT04132869|BEHAVIORAL|Sports Readiness Intervention|Sixth graders will participate in a 6 month after-school program in which each daily session will last 90 minutes, 60 minutes of which will be moderate to vigorous physical activity. Two sports tracks will be offered during each 8-week season, and children will choose which they prefer. Coaches will be trained through a one day capacity building session and will receive online training throughout the program. Coaches will integrate sports readiness/physical activity programming, nutrition and healthy eating, and social emotional learning into the program with a focus on habit formation. A text-based platform will be utilized to encourage habits learned in the active portion of the program during June and July as well as on weekends during the intervention. Parents will be sent fliers weekly summarizing concepts addressed, and will be invited to cooking classes to watch students compete.
214310358|NCT00146146|DRUG|testosterone undecanoate plus letrozole|TU 1000 mg/12 weeks Letrozole 2.5 mg/day
214310359|NCT00146146|DRUG|testosterone undecanoate plus dutasteride|TU 1000 mg/12weeks Dutasteride 0.5 mg/day
214310360|NCT02494427|DEVICE|CAD/CAM manufactured fixed unitary dental prostheses|
214310361|NCT02494427|DEVICE|Conventionally manufactured unitary dental prostheses|
214310362|NCT04878523|DIETARY_SUPPLEMENT|multi berries juice|Testing product
214310363|NCT04878523|DIETARY_SUPPLEMENT|Placebo drink|Blank
214310364|NCT02435472|BEHAVIORAL|Exercise|This open-label, two-arm randomized controlled trial (RCT) will investigate the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance) in 76 men with histologically confirmed low-risk prostate adenocarcinoma on active surveillance. The only investigational therapeutic agent being tested in this trial is a behavioral intervention in the form of aerobic training.
214310365|NCT02435472|OTHER|Cardiopulmonary Exercise Test (CPET)|Exercise capacity test to assess peak oxygen consumption (VO2peak)
214310366|NCT04796376|PROCEDURE|combined partial fistulectomy or fistulotomy and cutting seton procedure|Partial excision of fistulous tract or just fistulotomy plus cutting seton procedure which is a rubber band or threads put through fistulous tract
214310367|NCT02347267|BEHAVIORAL|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
214310368|NCT02347267|BEHAVIORAL|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
214310369|NCT02523846|DRUG|morphine|"Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)"
214310370|NCT02523846|BEHAVIORAL|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
214310371|NCT00070265|DRUG|oxaliplatin|Given IV
214310372|NCT00070265|DRUG|capecitabine|Given orally
214310373|NCT00070265|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
214310374|NCT00070265|OTHER|laboratory biomarker analysis|Correlative studies
214310375|NCT00102700|DRUG|ARQ 501 in combination with gemcitabine|
214310376|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (Fast Track)|The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
214917030|NCT04997668|DEVICE|SOLTIVE Thulium Fiber Laser|Patients randomized to Arm A will undergo surgery to remove their kidney stone with FDA approved SOLTIVE Thulium Fiber Laser.
214310377|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (5 weeks)|The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
214310378|NCT05333627|BEHAVIORAL|Wellbeing Course (8 weeks)|The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
214310379|NCT04434131|DRUG|Convalescent Plasma|Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
214310380|NCT03768596|BEHAVIORAL|Nudge|Influenza Vaccine Prescription Form accompanied on the back of telephone numbers of occupational health centers of different hospitals where interns are likely to be on probation.
214310381|NCT03768596|OTHER|vaccination form|a form about vaccination
214917031|NCT04997668|DEVICE|Ho:YAG Laser|Patients randomized to Arm B will undergo surgery to remove their kidney stone with FDA approved Ho:YAG laser.
214917032|NCT00026117|DRUG|BenFin|
214917033|NCT00026117|OTHER|placebo|
214917034|NCT02528110|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
214480975|NCT04393350|OTHER|Quality-of-Life Assessment|Ancillary studies
214480976|NCT04393350|OTHER|Questionnaire Administration|Ancillary studies
214917035|NCT02528110|PROCEDURE|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
214917036|NCT02528110|OTHER|SOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
214917037|NCT02528110|OTHER|XELOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
214917038|NCT04510623|OTHER|ARBs and/or ACE inhibitors|This is an observational study only.
214917039|NCT04510623|OTHER|Usual Care|This is an observational study only.
214917040|NCT03231995|BIOLOGICAL|Collection of nasopharyngeal specimen collected at D0, D1, D2 and D5.|"Analyses will be performed on nasopharyngeal specimen collected at D0, D1, D2 and D5.~Definition and validation of nasopharyngeal microbiome biomarkers (bacterial, viral, transcriptomic signature)"
214917041|NCT02215395|DRUG|NES/EE CVR|Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
214917042|NCT05622838|DIAGNOSTIC_TEST|Alpha1 -Antitrypsin level|measuring alpha1 -antitrypsin level in pregnant women
214917043|NCT05800938|DRUG|Isosorbid mononitrate|Imdur tablets were given twice daily for 4 weeks
214917044|NCT05800938|DRUG|Placebo|Placebo tablets were given twice daily for 4 weeks
214310382|NCT03851042|DEVICE|Virtual Reality Head set in PACU|Use of VR headset to determine post op satisfaction in PACU, decreased pain reduction and opioid consumption
214310383|NCT03851042|OTHER|No intervention|Routine post laparoscopic hysterectomy management (no VR headset)
214310384|NCT04236804|DEVICE|Flowly (TMC-CP01)|TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.
214310385|NCT06567626|OTHER|Decision Support Tool (DECIDE-CAD)|DECIDE-CAD is a decision support tool - designed using mixed methods through this study - which aims to enable shared decision making with people who are considering revascularisation options for coronary artery disease.
214310386|NCT04452331|OTHER|Open Access Audio|Patient obtains secure access to an audio recording of the medical encounter post-visit that is accessible from any internet enabled device.
214917045|NCT01136356|DRUG|buprenorphine|parenteral buprenorphine may be administered at multiple times each day
214310387|NCT04452331|OTHER|No Access, Patient and Provider Aware of Recording|Patient does not obtain access to audio recording but both patient and provider are aware visit is being recorded.
214310388|NCT04452331|OTHER|No Access, Provider Unaware of Recording|Patient does not obtain access to audio recording and provider is unaware visit is being recorded.
214310389|NCT05071183|DRUG|TPX-0005|Oral TPX-0005 capsules
214310390|NCT05071183|DRUG|Trametinib|Oral trametinib tablets
214310391|NCT01904708|OTHER|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
214310392|NCT02256761|DRUG|BIRT 2584 XX - multiple escalating dose|
214310393|NCT02256761|DRUG|Placebo|
214917046|NCT01136356|DRUG|morphine|parenteral morphine may be administered multiple times each day
214917047|NCT01453270|DEVICE|NICOM|Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
214917048|NCT01453270|OTHER|Usual care|Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
214310394|NCT02256761|DRUG|BIRT 2584 XX - single dose|
214310395|NCT02256761|OTHER|high caloric meal|30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
214310396|NCT01371474|DRUG|Paroxetine|
214310397|NCT06834360|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
214310398|NCT06834360|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
214310399|NCT06834360|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
214310400|NCT02981823|PROCEDURE|hip replacement|The patients undergo hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
214310401|NCT02808130|OTHER|hyperlipidemia, periodontitis, gingivitis|GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
214310402|NCT06306573|DEVICE|CardioMEMS HF System|The CardioMEMS HF System provides pulmonary artery (PA) hemodynamic data to monitor and manage HF subjects. The CardioMEMS HF System measures PA pressure which clinicians use to initiate or modify HF treatment.
214310403|NCT01229423|DRUG|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
214310404|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
214310405|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
214310406|NCT01516944|DRUG|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
214310407|NCT05580081|BEHAVIORAL|i-CAN|online support and consultation to providers
214480977|NCT05454514|DEVICE|HiDO medication adherence platform|The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.
214917049|NCT00220688|DEVICE|Acupressure Wristbands|
214310408|NCT06171776|DRUG|RetroMTA|calcium silicate lining material work as dentin substitute
214310409|NCT06171776|DRUG|TheraCal|calcium silicat material light cured
214310410|NCT06171776|DRUG|Fuji IX|filling material bonded chemically to the tooth structure
214310411|NCT03943875|BIOLOGICAL|9-valent HPV vaccine, 2 dose efficacy|Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.
214310412|NCT03943875|BIOLOGICAL|9-valent HPV vaccine, 3 doses standard timing|Will be comparison group for 2 dose efficacy group.
214310413|NCT04609566|DRUG|brentuximab vedotin|1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks
214310414|NCT04609566|DRUG|pembrolizumab|200 mg given intravenously every 3 weeks
214310415|NCT00636909|DRUG|Cyclophosphamide|preparative cytoreduction
214310416|NCT00636909|DRUG|fludarabine|preparative cytoreduction
214480978|NCT05454514|DEVICE|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
214917050|NCT04058093|BEHAVIORAL|Functional Training Program|"Functional training program (FTP) include:~1. Functional training sessions will be oriented by graduates or masters in sport with the supervision of a sports medicine doctor;~2. Group nutrition counseling, in the form of healthy cooking classes direct by nutritionists with the support of culinary students."
214310417|NCT00636909|DRUG|cyclosporine|immunosuppressive therapy
214310418|NCT00636909|DRUG|methotrexate|immunosuppressive therapy
214310419|NCT00636909|BIOLOGICAL|G-CSF|foster engraftment
214310420|NCT05224674|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
214310421|NCT06846710|DRUG|HS-20118|Single and multiple ascending doses of HS-20118 orally
214310422|NCT06846710|OTHER|HS-20118 placebo|Single and multiple ascending doses of HS-20118-matched placebo orally
214310423|NCT05221606|BEHAVIORAL|Nurse AMIE|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, mindfulness, CBT, DBT, soothing music.
214310424|NCT05221606|BEHAVIORAL|Usual Care|Binder of written supportive care materials
214310425|NCT02563678|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen therapy
214310426|NCT02563678|OTHER|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
214310427|NCT02563678|OTHER|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
214310428|NCT05682261|DIETARY_SUPPLEMENT|UNIMMAP-MMS|The study participants in this arm will receive the United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) containing 15 micronutrients including 30 mg of iron and 400 µg of folic acid.
214310429|NCT05682261|DIETARY_SUPPLEMENT|IFA|The study participants in this arm will receive iron-folic acid supplements with 30 mg of iron and 400 µg of folic acid.
214310430|NCT05682261|OTHER|Placebo|The study participants in this arm will receive placebo made of sugar (lactose anhydrous).
214310431|NCT04572230|DEVICE|Endovascular treatment of intracranial aneurysms using a flow-diverting stent|The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.
214310432|NCT04315337|BEHAVIORAL|Virtual Kitchen Training|VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
214310433|NCT00913471|OTHER|blood samples|"Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy."
214310434|NCT05612412|OTHER|Morning Exercise|Standardized treadmill exercise session starting at approximately 0700
214310435|NCT05612412|OTHER|Evening Exercise|Standardized treadmill exercise session starting at approximately 1800
214310436|NCT04591574|BIOLOGICAL|Red Blood Cells (Transfusion)|Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines
214310437|NCT04965545|DIETARY_SUPPLEMENT|low copper diet|All patients with wilson disease should receive low copper diet
214310438|NCT03970590|BEHAVIORAL|CTC Intervention|"An integrated peer narrative-based intervention (VIEW \> SELECT \> GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran\] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
214310439|NCT03970590|BEHAVIORAL|Control|6-month HTN management assessment text messages without narrative component
214310440|NCT03840083|BEHAVIORAL|Sleep|Participants will sleep (either a mid-day nap or normal overnight sleep)
214310441|NCT04196140|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
214310442|NCT05042947|DEVICE|double-loop clips|a new ligation method using the double-loop clips (D-L clips) technique
214310443|NCT05042947|DEVICE|Titanium Clip|the Titanium Clip
214310444|NCT02674971|BEHAVIORAL|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
214310445|NCT05355415|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
214310446|NCT03760796|DEVICE|Corrie Health Digital Platform|The Corrie Health Digital Platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure monitor.
214310447|NCT03774953|DIETARY_SUPPLEMENT|Protein and vitamin supplementation|The intervention group will receive 1.5 g protein/kilo/day during hospitalization and a standard dose of 27 g protein/day in 60 days after discharged together with a daily dose of vitamin/mineral supplement
214310448|NCT06484712|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
214310449|NCT05900440|OTHER|Ultrasound with Artificial Inteligence Engabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
214917051|NCT05320315|DEVICE|Foto Ultra ISDIN® Solar Allergy Fusion Fluid|The tested MD is a very high protection sunscreen
214310450|NCT05900440|OTHER|Ultrasound without Artificial Intelligence Enabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
214310451|NCT06023576|OTHER|antihypertensive medications|"One or more of the following medications may be used in both randomization groups to achieve SBP goals:~* Angiotensin converting enzyme inhibitors (ACEI)~* Angiotensin receptor blockers (ARBs)~* Beta-blockers (BB)~* Thiazide-type diuretics~* Calcium channel blockers~* Aldosterone antagonists~* Alpha1-receptor blockers.~* Direct vasodilators~* Loop diuretics"
214917052|NCT06044415|DRUG|JWH018|A vaporized dose of 7.5 mg of JWH-018 will be inhaled by the participants
215060730|NCT04358146|OTHER|Infant formula thickened with locust bean gum|Exclusive formula feeding with the formula thickened with locust bean
214310452|NCT06023576|DIAGNOSTIC_TEST|Blood pressure measurement|Home BP Monitoring (HBPM)-Throughout the study period, patients will perform HBPM at baseline, month 6, and month 12 (end of treatment). At each of these timepoints, HBPM will be performed for 7 days with 2 morning and 2 evening readings for each day (measured 1-min part).
214310453|NCT06023576|DIAGNOSTIC_TEST|Echocardiogram|At baseline, month 6, and month 12
214310454|NCT06023576|OTHER|Symptom-limited cardiopulmonary exercise test|Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.
214310455|NCT06023576|OTHER|Quality of Life Measures|FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.
214310456|NCT06023576|DIAGNOSTIC_TEST|Biomarkers|Research blood samples will be collected at baseline, 3 months, and 6 months
214310457|NCT05039008|OTHER|Blood flow restriction|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, at the same time. The intervention will last 4 weeks, with a periodicity of 3 weekly sessions. In total there will be 12 sessions that will last between 15 and 30 minutes depending on the number of joints affected.
214310458|NCT02836600|DRUG|LY3039478|Administered orally
214310459|NCT04534010|DEVICE|NACgraft|Patients requiring reconstruction of their nipple and areola have a NACgraft surgically implanted on their breasts. A NACgraft is a novel decellularized cadaveric implant derived from human nipples.
214310460|NCT02532647|DRUG|Remimazolam|
214310461|NCT02532647|DRUG|Midazolam|
214310462|NCT02532647|DRUG|Placebo|
214310463|NCT05757687|DEVICE|Omega device|"The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra."
214480979|NCT05454514|OTHER|Time on Task|"Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score."
214480980|NCT06870357|DRUG|propofol|Fifteen minutes after the subarachnoid block, propofol was pumped in at a rate of 20 mg/kg/h with a micro pump, and the pumping rate was reduced to 10 mg/kg/h after 1 min. The infusion was stopped when the consciousness disappeared, and the time of the disappearance of consciousness was observed (time of the disappearance of eyelash reflex).
214917053|NCT06044415|OTHER|non-active control (no substance)|Participants will inhale from a vaporizer with an empty chamber.
214917054|NCT01308827|PROCEDURE|Blood culture|A baseline blood culture will be obtained in all participants
214917055|NCT01308827|PROCEDURE|Other cultures per Clinical routine practice|Cultures from other sterile sites will be obtained per routine clinical practice
214917056|NCT05259462|BEHAVIORAL|Intervention|Participants will utilize low-cost, consumer available head-mounted displays to meet with peers and coaches online. The program will last 4 weeks and include 2 x 1-hour sessions per week of supervised peer-to-peer gaming. The coaches will utilize behavioral change and mindfulness techniques to promote autonomy, competence, and relatedness through a respectful, cohesive, and positive atmosphere. These strategies will be framed by the Self-Determination Theory and learned from the National Center on Health, Physical Activity, and Disability (NCHPAD) mindfulness coaching workshops. Some of the mindfulness-based strategies will include guided breathing focused exercises, body scanning, meditation, and acceptance of social anxiety and shyness
214310464|NCT05696691|DRUG|Ketamine Hydrochloride|100mg IM ketamine to be administered in conjunction with CRP. The ketamine injection will be administered first. Participants will be observed and have vital signs monitored for the first 45 minutes after administering medication in the ED, observing for immediate reactions. Afterwards, participants will continue to be monitored for potential late-term side effects on the inpatient unit. Ketamine will be given only after initial standard of care (SOC) treatment and screening studies have been initiated.
214480981|NCT06869382|DRUG|Foster BDP/Formoterol|Foster is a combination therapy containing beclometasone dipropionate (an inhaled corticosteroid, or ICS) and formoterol fumarate (a long-acting beta-agonist, or LABA), which is used for managing asthma and chronic obstructive pulmonary disease (COPD).
214955061|NCT00424593|DRUG|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
214955062|NCT00424593|DRUG|Placebo|every day (QD), by mouth (PO), 13 weeks
214955063|NCT01556230|PROCEDURE|Surgical intervention for CNFA|(non-experimental) standard procedure
214955064|NCT01556230|RADIATION|Radiotherapy for CNFA|(non-experimental) standard procedure
214955065|NCT04810910|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 300 mcg per peptide
214955066|NCT04810910|OTHER|GM-CSF|GM-CSF: 40 mcg
214955067|NCT03042910|DRUG|Talazoparib|Talazoparib 1 mg orally once daily.
214310465|NCT05696691|BEHAVIORAL|Crisis Response Plan|"Crisis Response Plan is a brief, empirically-validated, Cognitive-Behavioral Therapy-based one-time therapy, and its administration typically takes 30-60 minutes. It begins with a narrative assessment (allowing patients to tell their story) and concludes with collaboratively constructed plan that outlines strategies for the patient's self-management of future acute suicidal crises. Patients who engage in CRP are given an index card to keep with them that summarizes the emotional management strategies that they collaboratively generate with the CRP provider."
214310466|NCT01820416|RADIATION|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
214310467|NCT01820416|OTHER|Placebo Comparator: Disabled Laser|Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
214310468|NCT06158191|BEHAVIORAL|Lifestyle modification program|Participants will take part in a lifestyle modification program focused on physical activity and diet.
214310469|NCT04877249|BEHAVIORAL|Split-belt treadmill training|1\. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg
214310470|NCT06250972|DRUG|Gemcitabine, Nab-paclitaxel, Irinotecan|continuing chemotherapy using the previous regimen until disease progression
214310471|NCT06250972|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy.
214310472|NCT02492269|DRUG|Dexmedetomidine|
214310473|NCT02492269|DRUG|Placebo|
214310474|NCT06644144|OTHER|No Interventions|No intervention so not applicable.
214310475|NCT05669820|DIETARY_SUPPLEMENT|Salovum|Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
214310476|NCT05669820|DIETARY_SUPPLEMENT|Placebo egg yolk powder|Egg yolk powder derived from hen fed with normal feed.
214310477|NCT02952339|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
214917057|NCT00927862|GENETIC|IWPC adapted genotype-guided dosing algorithm for warfarin|"Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
214310478|NCT02952339|BIOLOGICAL|Placebo|Administered as nose drops
214310479|NCT00003752|DRUG|bexarotene|
214310480|NCT02126956|DRUG|ACT-128800|ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
214310481|NCT06543849|PROCEDURE|Target Temperature Management Treatment|Target Temperature Management Treatment
214310482|NCT03162978|OTHER|HIIT + POE|Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.
214310483|NCT03162978|OTHER|HIIT only|Subjects will participate in high-intensity interval training (HIIT) only.
214917058|NCT00927862|GENETIC|Modified IWPC genetic-guided warfarin dosing algorithm|"Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
214955068|NCT02293239|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
214955069|NCT02082769|DRUG|Febuxostat|
214955070|NCT02082769|DRUG|Allopurinol|
214310484|NCT04493060|BIOLOGICAL|Dostarlimab|Given IV
214310485|NCT04493060|DRUG|Niraparib|Given PO
214310486|NCT05492110|DEVICE|Coronary sinus reducer|The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
214310487|NCT05492110|OTHER|Sham-procedure|Implantation procedure with no device implanted
214310488|NCT05492110|DIAGNOSTIC_TEST|Invasive coronary physiology|Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
214310489|NCT04720976|DRUG|JAB-3312|JAB-3312 will be administered orally, variable dose.
214310490|NCT04720976|DRUG|Binimetinib|Binimetinib will be administered orally.
214310491|NCT04720976|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous infusion.
214310492|NCT04720976|DRUG|Sotorasib|Sotorasib will be administered orally.
214310493|NCT04720976|DRUG|Osimertinib|Osimertinib will be administered orally.
214347059|NCT06316362|OTHER|Standard treatment for carbamazepine toxicity|"Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg).~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube"
214310494|NCT05398432|OTHER|motivational interview|"After the pre-test data were applied to all patients, before starting the motivational interview seans, the patients were informed about the interview intervals, duration, and how many times they would be held. In the second week, motivational interview seans were started with the patients. seans with patients took place during the hemodialysis seans. A total of 6 seans were held, one seans per week. After the first seans of the self-care supported motivational interview, the Self-Care and Adaptation to Disease Training Guide prepared by the researcher in line with the literature was given to the experimental group. Self-care training was given in the first, second and third seans. Motivational interviews were conducted in the fourth, fifth and sixth seans. Motivational interviewing techniques were used for patients to realize their self-care activities. seans were held individually with the patients and each seans lasted approximately 15-20 minutes."
214310495|NCT04606576|OTHER|Placebo|Fish Oil
214310496|NCT04606576|DRUG|ORMD-0801 QD|Oral Insulin once per day
214480982|NCT06869382|DRUG|Omalizimab|Omalizumab is a monoclonal antibody that specifically targets immunoglobulin E (IgE), a key mediator in allergic asthma. By binding to free IgE in the bloodstream, omalizumab prevents it from attaching to FcεRI receptors on mast cells and basophils, inhibiting the allergic inflammatory cascade that contributes to asthma exacerbations and bronchoconstriction. This intervention is particularly useful in patients with severe allergic asthma, who have high levels of IgE and have not responded well to conventional therapies such as inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA).
214480983|NCT06869694|DEVICE|computerized tomography|mpMRI and Photon-counting Detector CT scan
214480984|NCT06868992|PROCEDURE|Bariatric surgery (Sleeve Gastrectomy or Gastric Bypass)|Patients undergoin bariatric surgery with simultaneous liver biopsy to analyze MAMs alterations in liver and PBMCs. Follow-up assessments at 6 and 12 months.
214480985|NCT03715959|PROCEDURE|Aspiration of Breast|Undergo NAF
214480986|NCT03715959|PROCEDURE|Biospecimen Collection|Undergo NAF
214480987|NCT06870318|OTHER|No intervention; Observational study|OptiMoM-NForte is meta-analysis study (observational secondary use of data), the investigators will analyze data from the OptiMoM and NForte trials. No interventions form part of this study.
214917059|NCT00927862|OTHER|Standard of care treatment|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients \>=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
214917060|NCT03839862|DRUG|TNF-inhibition|Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
214917061|NCT06495476|DRUG|Ginkgo biloba extract 50 dropping pills|Composition: Ginkgo ketone ester, excipient polyethylene glycol 6000. Size: 10mg ginkgolides/pill.
214955071|NCT05307003|DRUG|Trazodone|Medication used to treat ICU delirium
214310497|NCT04606576|DRUG|ORMD-0801 BD|Oral Insulin, twice per day
214310498|NCT05608421|BEHAVIORAL|1MoreStep|Cognitive behavioral intervention to reduce HIV and IPV stigma.
214310499|NCT05608421|BEHAVIORAL|1MoreStepControl|This is an equal attention control group.
214310500|NCT01630512|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
214310501|NCT01630512|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
214310502|NCT02567955|BIOLOGICAL|Immunogenicity two doses of Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
214310503|NCT02567955|BIOLOGICAL|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
214310504|NCT06802029|GENETIC|Whole Genome Sequencing Analysis|Laboratory blood analysis
214310505|NCT00017147|DRUG|carmustine|"40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m\^2 IV over 1 hour on day 2 of each cycle for the active comparator arm."
214310506|NCT00017147|RADIATION|radiation therapy|5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
214310507|NCT00017147|DRUG|O6-Benzylguanine|120 mg/m\^2 IV over 1 hour on day 1 of each cycle
214310508|NCT06009263|OTHER|Conventional treatment|"Application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
214310509|NCT06009263|OTHER|Open chain segmental control|"Application of open chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
214480988|NCT06868901|PROCEDURE|Standard angioplasty + drug-eluting balloon technique|Treatment of restenosis of hemodialysis vascular access via the standard angioplasty + drug-eluting balloon technique
214480989|NCT06868901|PROCEDURE|Atherectomy + drug-eluting balloon|Treatment of restenosis of hemodialysis vascular access via the atherectomy + drug-eluting balloon technique
214480990|NCT06870708|PROCEDURE|arthroscopic repair of partial rotator cuff tear using the conversion versus the transtendon technique|arthroscopic repair of partial rotator cuff tear using the conversion versus the transtendon technique
214480991|NCT06869109|DIAGNOSTIC_TEST|serum cxcl10|serum blood sample to measure the cxcl10
214480992|NCT06869109|DIAGNOSTIC_TEST|serum crp|blood sample to measure crp
214480993|NCT06869200|DEVICE|Concentrated Growth Factor (CGF) Intra-articular Injection|"Preparation Method: The CGF is prepared using an autologous platelet-rich preparation kit specifically designed to concentrate growth factors from the patient's own blood. The process involves a specialized centrifugation technique that yields a high concentration of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and other bioactive molecules.~Rationale: This intervention leverages the body's natural healing response by utilizing autologous growth factors to enhance the repair of cartilage and other joint tissues affected by osteoarthritis. The high concentration of bioactive molecules in CGF is believed to provide a more potent therapeutic effect compared to other platelet-rich therapies."
214310510|NCT06009263|OTHER|Closed chain segmental control|"Application of closed chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
214310513|NCT02420691|OTHER|Laboratory Biomarker Analysis|Correlative studies
214310514|NCT02420691|OTHER|Pharmacological Study|Correlative studies
214310515|NCT02420691|DRUG|Ribociclib|Given PO
214310516|NCT03636347|DRUG|Placebo Oral Tablet|twice daily administration
214310517|NCT03636347|DRUG|Alvelestat oral tablet - dose 1|twice daily administration
214310518|NCT03636347|DRUG|Alvelestat oral tablet - dose 2|twice daily administration
214310519|NCT04814576|BEHAVIORAL|Collaborative cares|The intervention consists of the co-design and implementation of therapeutic activities by the nurse and the mental health day hospital users following a collaborative care model. For this purpose, the participatory action research (PAR) method will be used and semi-structured interviews and focus groups will be used as data collection techniques.
214310520|NCT06231212|DRUG|ECa 233|Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.
214310521|NCT06231212|DRUG|Ibuprofen|Ibuprofen group was given capsules containing 200 mg of ibuprofen
214310522|NCT06231212|OTHER|Placebo|Placebo-controlled group received capsules containing 250 mg of lactose
214310523|NCT05552677|OTHER|Multicomponent Training|Participants will perform a multicomponent training that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 12 weeks
214310524|NCT00521768|BEHAVIORAL|Prolonged exposure|
214310525|NCT04415281|DEVICE|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
214310526|NCT04415281|DEVICE|sham THOR® laser system|sham THOR® laser system
214310527|NCT00296933|DRUG|Escitalopram|
214310528|NCT00296933|DRUG|Bupropion XL|
214310529|NCT04404738|PROCEDURE|MicroPort® robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System
214310530|NCT04404738|PROCEDURE|da Vinci robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
214310531|NCT00325754|DEVICE|E-Cylinder|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
214310532|NCT00325754|DEVICE|Lightweight Cylinder|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
214310533|NCT00555607|DRUG|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
214310534|NCT03999190|DRUG|NPA radiotracer|"\[11C\]NPA radiotracer, 2 injection per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
214310535|NCT03999190|DRUG|Raclopride radiotracer|"\[11C\]raclopride radiotracer, 2 injections per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
214310536|NCT03999190|DRUG|Dextroamphetamine|Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
214310537|NCT04361981|OTHER|Deep Venous Disease Diagnostic|Clinical and/or echographic diagnosis of Deep Venous Disease in a patient with COVID-19 infection
214310538|NCT00982709|BEHAVIORAL|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
214310539|NCT01334723|DRUG|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
214310540|NCT01334723|DRUG|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
214310541|NCT01675687|BEHAVIORAL|Follow Up Support|inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
214347060|NCT00005981|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
214917062|NCT06495476|DRUG|Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant|"Composition: The main ingredient is polyethylene glycol 6000 + caramel pigment, placebo and ginkgolide drops are basically the same in color, odor and appearance.~Size: 10 mg analog ingredient/pill."
214917063|NCT00820248|BIOLOGICAL|panitumumab|Given IV
214917064|NCT00820248|DRUG|cisplatin|Given IV
214917065|NCT00820248|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
214347061|NCT00005981|DRUG|carmustine|Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
214347062|NCT04936412|DEVICE|Rehabilitation brace|Rehabilitation brace
214310542|NCT05771233|OTHER|Prevention|"First, an anamnesis is performed to collect information on illnesses, previous and current injuries, medication, sports practice outside of dance, diet, sleep hours and, where appropriate, information on menstruation.~Subsequently, an individual pre-intervention assessment of each participant is carried out, where personal data is collected, motor, elasticity and flexibility, muscle strength and stability tests are performed.~After the initial assessment, group sessions are stablished, divided by classes according to the type of specialty of 6th grade dance. The first session is focused on teaching the different exercises and the importance of muscle strengthening, the subsequent sessions are focused on the correction of the exercises, the resolution of doubts and the incorporation of progressions regarding strength and stabilization.~At the end of the intervention, each participant is re-evaluated and results are compared."
214310543|NCT06297174|DRUG|Racecadotril 100 mg Capsules|Racecadotril 100 mg Capsules (test drug)
214310544|NCT06297174|DRUG|HIDRASEC®|HIDRASEC® (reference drug)
214310545|NCT05517499|DRUG|Dexamethasone|Randomized clinical trial
214310546|NCT04139707|DEVICE|Caring4Dementia|A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
214310547|NCT04139707|OTHER|White Paper|The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
214310548|NCT04777162|DRUG|Tislelizumab|For included participants, tislelizumab would be administrated 200mg q3w iv.
214310549|NCT04777162|DRUG|Anlotinib|Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
214310550|NCT01813669|BEHAVIORAL|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
214310551|NCT01888796|DRUG|Linagliptin|
214310552|NCT01888796|DRUG|placebo|
214310553|NCT03350360|BEHAVIORAL|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
214310554|NCT03350360|BEHAVIORAL|Comparison Task|Neutral- neutral stimuli prior to response task
214917066|NCT00820248|RADIATION|accelerated radiation therapy|Patients undergo accelerated fractionation radiotherapy
214917067|NCT00820248|RADIATION|intensity-modulated radiation therapy|Patients undergo radiotherapy
214310555|NCT00000644|DRUG|Clarithromycin|
214310556|NCT03836963|BEHAVIORAL|cognitive training|Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
214310557|NCT03836963|BEHAVIORAL|active control cognitive training|The active control consists of a set of computerized games played on an iPad. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
214310558|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
214310559|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
214310560|NCT01829776|BEHAVIORAL|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
214310561|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 4 weeks post enrollment
214310562|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 12 weeks post enrollment
214310563|NCT00177970|DRUG|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff .
214917068|NCT05167630|OTHER|prognostic marker|prognostic marker
214917069|NCT05393648|DEVICE|Accelerated Theta Burst Stimulation|Cool B65- A/P - active side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
214917070|NCT05393648|DEVICE|Sham accelerated Theta Burst Stimulation|Cool-B65 A/P - sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
214917071|NCT04112043|BEHAVIORAL|Walking Exercise|Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.
214917072|NCT04112043|DRUG|Nicotinamide Riboside (NR)|Participants randomized to this intervention will receive 1,000 mg/day of NR.
214917073|NCT05184595|OTHER|Carfilzomib delivered in OH only|Patients receive the whole treatment en OH.
214917074|NCT05184595|OTHER|Carfilzomib delivered in OH and HaH combined|Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.
214917075|NCT00018941|BIOLOGICAL|aldesleukin|
214917076|NCT00542009|DRUG|CE-326,597 100 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
214917077|NCT00542009|DRUG|CE-326,597 50 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
214917078|NCT00542009|DRUG|CE-326,597 25 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
214917079|NCT00542009|DRUG|Placebo|Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
214917080|NCT00542009|DRUG|CE-326,597 5mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
214917081|NCT01750697|DRUG|Rituximab|Participants will receive rituximab 375 mg/m\^2 IV infusion on Days 1, 8, 15 and 22. Rituximab infusions will be given at a rate of 25 milligrams per hour (mg/h). This may be escalated at a rate of 25 mg/h increments every 30 minutes to a maximum of 200 mg/h.
214310564|NCT00177970|DRUG|Placebo|Placebo to be given IV to patients with C-Diff
214310565|NCT05235334|DEVICE|MySOLIUS|MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.
214310566|NCT03608514|DRUG|Experimental|Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
214310567|NCT03375021|DRUG|CX717 200 mg|CX717 200 mg capsules BID
214310568|NCT03375021|DRUG|CX717 800 mg|CX717 4 X 200 mg capsules BID
214310569|NCT03375021|DRUG|Placebo|Placebo 200 mg or 800 mg capsules BID
214310570|NCT01733446|OTHER|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
214310571|NCT00703885|DRUG|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
214310572|NCT00703885|DRUG|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
214310573|NCT00703885|DRUG|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
214310574|NCT06482021|DEVICE|Low-intensity extracorporeal shock wave|Acetylcholine iontophoresis• The Iontophoresis comprises of electric impulses from a low voltage galvanic current stimulation unit to drive ions (Ach) (1%) into soft tissue structures.
214310575|NCT02625090|DRUG|UCB0942|"* Active Substance: UCB0942~* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg, 100 mg or 200 mg~* Route of Administration: oral"
214310576|NCT03198377|DEVICE|TENS: Randomized frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds"
214670807|NCT02858193|DRUG|Fluifort® syrup|"Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments."
214670808|NCT04121910|DRUG|Savolitinib|On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
214670809|NCT04121910|DRUG|Itraconazole|Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
214670810|NCT04885049|DRUG|Racecadotril|Anti secretary
214670811|NCT04885049|DRUG|DiaResQ Children's Powder for Suspension|oral immunoglobulins
214670812|NCT00662870|BIOLOGICAL|DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)|0.5 mL, Intramuscular
214670813|NCT00662870|BIOLOGICAL|Pentacel: DTaP-IPV/Hib|0.5 mL, Intramuscular
214310577|NCT03198377|DEVICE|TENS: Scan 6/6 of frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds"
214310578|NCT03198377|DEVICE|TENS: Fixed frequency|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Fixed frequency at 100 Hz Pulse width 200 microseconds"
214310579|NCT03198377|DEVICE|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
214310580|NCT02858219|DRUG|Botulinum Toxin Type A|
214310581|NCT02858219|OTHER|Saline solution|
214310582|NCT02858219|OTHER|Indexes|Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
214310583|NCT02467556|DRUG|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
214670814|NCT00178412|BEHAVIORAL|Care Project for Hospitalized Elders & Family Caregivers|"Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home"
214917082|NCT02384746|DRUG|Fulvestrant|500 mg intramuscular every 28 days
214917083|NCT02384746|DRUG|MLN9708|Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
214917084|NCT02653144|DRUG|Ropivacaine|local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
214917085|NCT02653144|DRUG|Dexmedetomidine|local anesthetics adjuvants. 75mcg of dexmedetomidine. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
214310584|NCT02467556|BEHAVIORAL|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
214310585|NCT02467556|OTHER|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
214310586|NCT00647127|DRUG|Buprenorphine|Buprenorphine: 20microg/h
214310587|NCT00647127|DRUG|Fentanyl|Fentanyl: 25microg/h
214310588|NCT00647127|DRUG|Placebo|Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
214310589|NCT03687203|DIAGNOSTIC_TEST|Functional Activities Questionnaire|The FAQ is an economic and easy to apply activity of daily living scale. We aim to validate the prognostic value of novel FAQ scores, which differentiate cognitive- from motor-driven activity of daily living function.
214310590|NCT06204458|OTHER|mild hyperthermia group|The hyperthermia treatment is carried out in a cycle of two treatments per week, with at least one day in between, over a period of two weeks, according to the manufacturer's instructions. For better tolerability, the application takes place under administration of 10L/min oxygen. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
214670815|NCT00178412|BEHAVIORAL|Comparison Group|"Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center."
214670816|NCT02602873|OTHER|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
214670817|NCT02013934|DIETARY_SUPPLEMENT|Probiotic|
214670818|NCT02013934|DIETARY_SUPPLEMENT|Placebo|
214670819|NCT06316323|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride (SDF) is a topical antimicrobial and remineralizing agent which was cleared by the FDA as a Class II medical device to treat tooth sensitivity. In certain circumstances, SDF may be used as a non-restorative treatment to arrest carious lesions on primary and permanent teeth
214310591|NCT06204458|OTHER|sham group|Within the application, patients in the Sham group will undergo a hyperthermia application with virtually no overheating. To achieve this, the patients are positioned on the hyperthermia device in the same way as the intervention group. An insulating foil applied beforehand prevents direct irradiation with water-filtered infrared-A radiation. This prevents an increase in temperature. Due to the insulating blanket and the natural heat from the device and body, patients in the Sham group experience a gentle warmth that cannot be compared with regular whole-body hyperthermia and an increase in core body temperature of around 1.5°C. The number of treatments, the lighting conditions and procedures including 10L/min oxygen supply, is equal to the treatments in the intervention group.
214670820|NCT06316323|DRUG|Sodium fluoride|Fluoride varnish to apply on tooth surface, so that the tooth becomes more resistant to caries attack. The active ingredient of fluoride varnish is 5% sodium fluoride, (22,600 ppm fluoride)
214670821|NCT03630068|PROCEDURE|Stereotactic percutaneous image-guided microwave ablation|Stereotactic percutaneous image-guided microwave ablation implies the use of computer-assisted navigation technology for 3D trajectory planning and stereotactic placement of ablation probes, before applying local microwave ablation therapy
214310592|NCT02076828|DRUG|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
214310593|NCT02076828|DRUG|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
214310594|NCT02076828|DRUG|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
214670822|NCT05477238|PROCEDURE|walking tasks|The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
214310595|NCT03970863|DIAGNOSTIC_TEST|Prostate Health Index|Use Prostate Health Index for the follow-up after focal therapy.
214310596|NCT04396093|BEHAVIORAL|psychological support|specific questionnaires administration: EORTC QLQ 30, EORTC- PAN 26, HADS, Millon Clinical Multiaxial Inventory
214310597|NCT03000699|BEHAVIORAL|Cognitive Bias Modification|Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.
214310598|NCT03493984|OTHER|Ginger exosomes|Naturally occurring plant exosomes from ginger
214310599|NCT03493984|OTHER|Aloe exosomes|Naturally occurring plant exosomes from aloe
214310600|NCT03493984|OTHER|Placebo|Exosome placebo tablet
214310601|NCT03524807|DEVICE|Electrophysiologic therapy|Pelvic floor electrophysiological therapy is used after common gynecologic surgery to record anal exhaust time and micturition time after surgery and endometrium recovery of intrauterine adhesions.For intrauterine adhesions patients, Drug: Aspirin(low dose of Aspirin after operation)Device: intrauterine balloon (insert intrauterine balloon after operation)
214310602|NCT02439320|DRUG|Lasmiditan 100 mg|
214310603|NCT02439320|DRUG|Lasmiditan 200 mg|
214310604|NCT02439320|DRUG|Placebo (matches lasmiditan doses)|
214670823|NCT04646317|DRUG|Dexmedetomidine injection|Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
214670824|NCT04646317|DRUG|Normal Saline|0.9% as placebo
214955072|NCT05307003|DRUG|Quetiapine|Medication used to treat ICU delirium
214310605|NCT01100099|DIETARY_SUPPLEMENT|Gluten challenge.|The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
214310606|NCT02928510|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
214310607|NCT02928510|PROCEDURE|Colonoscopy|Undergo colonoscopy
214310608|NCT02928510|PROCEDURE|Colposcopic Biopsy|Undergo colposcopic biopsy
214310609|NCT02928510|DRUG|Idelalisib|Given PO
214310610|NCT02928510|OTHER|Laboratory Biomarker Analysis|Correlative studies
214310611|NCT02928510|OTHER|Pharmacological Study|Correlative studies
214310612|NCT02928510|PROCEDURE|Physical Examination|Undergo physical examination
214310613|NCT02928510|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
214310614|NCT01238614|OTHER|CHICA PSF plus JIT|
214310615|NCT01238614|OTHER|CHICA maternal depression PSF|
214310616|NCT01238614|OTHER|Control|
214310617|NCT02972632|DRUG|Vortioxetine|Vortioxetine tablet
214917086|NCT02653144|DRUG|Dexamethasone|local anesthetics adjuvants. 4mg dexamethasone. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
214917087|NCT02235844|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|
214917088|NCT00208169|DRUG|Aripiprazole|
214917089|NCT03674112|DRUG|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).
214917090|NCT03674112|DRUG|Pertuzumab IV|Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
214917091|NCT03674112|DRUG|Trastuzumab IV|Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
214917092|NCT04724538|RADIATION|99mTc-pertechnetate aerosol|99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
214917093|NCT04724538|DRUG|99mTc-pertechnetate aerosol|99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
214310618|NCT03857087|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
214310619|NCT03857087|PROCEDURE|Magnetic Resonance Imaging (MRI)|Given PET/MRI
214310620|NCT03857087|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET/MRI
214310621|NCT02245841|DRUG|H.P. Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
214480994|NCT06869200|DEVICE|Platelet-Rich Plasma (PRP) Intra-articular Injection|"Preparation Method: The PRP is prepared using a disposable PRP preparation device that separates and concentrates platelets from the patient's blood. This process enriches the plasma with platelets and associated growth factors.~Rationale: PRP has been widely used in clinical practice for its ability to promote tissue healing and reduce inflammation in osteoarthritis. It serves as an active comparator in this study, allowing for a direct comparison of the therapeutic efficacy and safety profile of CGF against a well-established treatment modality."
214480995|NCT06871332|OTHER|Progressive relaxation exercise group|Patients in the intervention group performed progressive relaxation exercise for 20 minutes before femoral sheath removal.
214917094|NCT00862823|DRUG|tenofovir, emtricitabine and efavirenz fixed dose tablet|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
214917095|NCT00862823|DRUG|tenofovir, emtricitabine and efavirenz tablet added to solution|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
214917096|NCT06258499|COMBINATION_PRODUCT|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is manually placed into the joint fusion space during fusion surgery.
214917097|NCT04820699|OTHER|post isometric relaxation and muligan bent leg raise|6 week intervention
214917098|NCT04820699|OTHER|muligan bent leg raise|muligan bent leg raise
214917099|NCT05174299|DEVICE|magnetic stimulation|For Experimental Arm, active magnetic stimulation on motor cortex followed by active magnetic stimulation on spinal cord, patients underwent ten sessions of double active magnetic stimulation with low frequency repetitive transcranial magnetic stimulation (rTMS) over the bilateral primary motor cortex of the lower leg followed by low frequency repetitive magnetic stimulation over the spinal cord. For Active Comparator Arm, active magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord. For Sham Comparator Arm, sham magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord.
214917100|NCT05794776|DEVICE|BurstDR stimulation|BurstDR spinal cord stimulation
214310622|NCT03307733|BEHAVIORAL|walking and behavour change techniques|a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
214310623|NCT02032147|DRUG|NGF group|This group will be treated with NGF 18u per day im for 60 days
214917101|NCT05794776|DEVICE|Tonic stimulation|Tonic spinal cord stimulation
214917102|NCT05794776|DEVICE|No stimulation|Stimulator is switched off
214917103|NCT02620176|DEVICE|Transcutaneous vagal nerve stimulation|Trans-auricular vagal nerve stimulation
214310624|NCT04362917|OTHER|There is no intervention|There is no intervention
214310625|NCT05723562|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
214310626|NCT01363596|OTHER|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
214310627|NCT01936935|OTHER|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
214310628|NCT01936935|OTHER|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
214310629|NCT02609022|BIOLOGICAL|CV-MG01|"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose."
214310630|NCT02609022|BIOLOGICAL|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
214310631|NCT03688412|DEVICE|Cook lead extraction devices|The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
214310632|NCT04609410|PROCEDURE|Neuromuscular blockade|Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring
214310633|NCT01202825|DRUG|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
214310634|NCT01202825|DRUG|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
214310635|NCT01202825|DRUG|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
214310636|NCT01202825|DRUG|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
214310637|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
214310638|NCT01202825|DRUG|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
214310639|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
214310640|NCT01202825|DRUG|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
214310641|NCT01202825|DRUG|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
214310642|NCT01202825|DRUG|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
214310643|NCT02030379|BEHAVIORAL|QPL-CT|Use the QPL-CT to prioritize questions
214310644|NCT01960946|DIETARY_SUPPLEMENT|Modified Citrus Pectin (MCP) vs placebo|5 grams by mouth three times a day
214670825|NCT02887846|DEVICE|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 \< 0,40, Pa CO2 \< 65 mmHg, pH\> 7.20, MAP (mean airway pressure) \<7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is\<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 \< 0.30 at 24 hours and above, free oxygen will be introduced.
214917104|NCT01985191|DRUG|SAR405838|"Pharmaceutical form:capsule~Route of administration: oral"
214310645|NCT02735161|OTHER|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
214310646|NCT02735161|OTHER|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
214310647|NCT00100243|DRUG|Plenaxis|
214670826|NCT00217477|DRUG|gemcitabine hydrochloride|Given IV
214670827|NCT00217477|DRUG|paricalcitol|Given IV
214670828|NCT01918215|DEVICE|ICD|
214310648|NCT02196285|BIOLOGICAL|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
214310649|NCT03532997|OTHER|ELOS|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel web-based application called ELOS (stands for extra layer of support) in a prospective cohort study."
214670829|NCT01918215|DEVICE|ILR|
214670830|NCT02089737|DRUG|Panitumumab|Panitumumab for intravenous infusion
214670831|NCT04463160|OTHER|"prevention program for prediabetes Say No to Diabetes"|10 therapeutic education sessions
214310650|NCT06200675|OTHER|Compassion-based intervention|Participants assigned to this intervention will be asked to engage in one brief compassion-focused exercise, where they will be asked to be asked to connect to their inner compassionate self. They will be asked to stay connected to that feeling while rereading what they wrote about their feelings of shame and imagining it was someone else who wrote it. Participants will then be asked to write a compassionate response to themselves. Participants will then be asked to reread this response while remaining connected to their compassionate self.
214310651|NCT06200675|OTHER|Logic-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online logic-based exercise that was adapted from a CBT thought record. Participants will be asked to reread what they wrote about their feelings of shame and chose a thought central to their shame to use for this exercise. Participants will be asked to generate evidence for and against their chosen thought, and then generate a more balanced thought. After the exercise, participants will be asked to reread their newly generated more balanced thought.
214310652|NCT06200675|OTHER|Placebo control condition|"Participants assigned to this intervention will be asked to listen to an audio recording of The Hobbit and then re-read what they wrote about their feelings of shame. They will then be asked to write a reflection about the thoughts and feelings arising from doing so. They will then be asked to re-read what they wrote in this reflection."
214310653|NCT01339728|PROCEDURE|far-infrared ray|The duration of far-infrared ray is 20 minutes.
214310654|NCT02823275|OTHER|Functional mobilisation|functional mobilisation
214917105|NCT01985191|DRUG|Pimasertib|"Pharmaceutical form: capsule~Route of administration: oral"
214917106|NCT05751980|BEHAVIORAL|Med Wise Rx|The program consists of two 120-minute classes led by trained community site-based facilitators, designed to help older adults communicate more effectively with their pharmacists.
214310655|NCT02823275|OTHER|Short term plaster cast fixation|2 weeks cast immobilisation
214310656|NCT04126395|DIAGNOSTIC_TEST|Movement Assessment Battery for Children 2(M-ABC-2)|The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.
214310657|NCT04126395|DIAGNOSTIC_TEST|Developmental Coordination Disorder - Questionnaire (DCD-Q)|The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.
214310658|NCT04126395|DIAGNOSTIC_TEST|Social Responsiveness Scale 2 (SRS-2)|The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
214480996|NCT06870409|DRUG|Bacteriophage|"Complex drug of 3-4 virulent phages to each type of bacteria, active against:~* Staphylococcus spp. \[Staphylococcus aureus, CoNS (S. epidermidis, S. haemolyticus, S. hominis, S. warneri, S. capitis)\].~* Streptococcus spp. \[Streptococcus viridans (Str. mutans, Str. sanguis, Str. mitis, Str. cristatus, Str. gordonii, Str. oralis, Str. salivarius), Gemella hemolysans, Str. bovis (Str. gallolyticus), Str. constellatus, Str. anginosus, Str. agalactiae\].~* Enterococcus spp. \[E. faecalis, E. faecium\].~* Non-HACEK \[E. coli, A. baumanii, K. pneumoniae, P. aeruginosa\]"
214480997|NCT06868407|BEHAVIORAL|Psychoeducation about Suicide Crisis Resources (Control Intervention)|The active control intervention includes psychoeducation about suicide crisis services, with a particular focus on breaking down myths and barriers to using suicide crisis services use.
214670832|NCT00612846|PROCEDURE|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
214670833|NCT00612846|PROCEDURE|Laparoscopic bile duct exploration during cholecystectomy|Laparoscopic bile duct exploration during cholecystectomy
214917107|NCT05896904|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
214917108|NCT05648201|DRUG|Doravirine 100Mg Tab|1 single dose of 100mg taken orally
214917109|NCT05648201|DRUG|Raltegravir 600Mg Tab|1 single dose of 1200mg taken orally
214917110|NCT05648201|DRUG|Biktarvy 50/200/25 Tab|1 single dose of 50/200/25 taken orally
214917111|NCT06046781|OTHER|physical exercise|The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.
214917112|NCT00786981|OTHER|Epidural steroid injection plus physical therapy|Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
214917113|NCT00786981|OTHER|Epidural steroid injection|Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
214917114|NCT02049814|DRUG|Metformin|Metformin tablets
214917115|NCT02049814|DRUG|Voglibose|Voglibose tablets
214670834|NCT01707823|DRUG|acetylsalicylic acid|Given PO
214917116|NCT02049814|DRUG|Acarbose|Acarbose tablets
214310659|NCT04126395|OTHER|Retrospective Video Analysis|Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
214310660|NCT02894177|PROCEDURE|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
214670835|NCT01707823|OTHER|laboratory biomarker analysis|Correlative studies
214670836|NCT00008164|PROCEDURE|umbilical cord blood transplantation|
214670837|NCT00764972|DRUG|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
214670838|NCT00440128|DRUG|Docetaxel|Docetaxel
214670839|NCT00440128|DRUG|Casopitant/Docetaxel|Casopitant/Docetaxel
214670840|NCT00253617|DRUG|porfimer sodium|
214670841|NCT00253617|PROCEDURE|adjuvant therapy|
214670842|NCT00253617|PROCEDURE|laser therapy|
214670843|NCT00253617|PROCEDURE|photodynamic therapy|
214670844|NCT00253617|PROCEDURE|phototherapy|
214917117|NCT00966524|PROCEDURE|Endotracheal intubation|Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
214917118|NCT03781635|DRUG|bolus of intravenous ketamine|low-dose ketamine (0.25mg.kg-1) is administered intraoperatively as bolus at incision (T0) and for each hour of anesthesia untel the end of surgery.
214917119|NCT03781635|DRUG|continuous infusion of intravenous ketamine|An infusion of low-dose ketamine (0.25 mg.kg-1.h-1) is started at T0 (incision) with an infusion pump and is kept at the same rate until the end of surgery
214917120|NCT00835224|DRUG|L-NAME|A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
214917121|NCT00835224|DRUG|Midodrine|To treat low blood pressure.
214917122|NCT00835224|DRUG|Placebo|A pill with an inactive substance that looks like the study drug.
214917123|NCT02766803|DRUG|Simvastatin and micronized trans-resveratrol|
214917124|NCT00172328|BIOLOGICAL|Hepatitis B vaccine|
214917125|NCT05354778|DRUG|Hydrocortisone|Corticosteroid
214917126|NCT05354778|DRUG|Placebo|Normal saline only
214917127|NCT06334328|BEHAVIORAL|Virtual reality based mindful movement therapy|VR-MMT combines VR games, multisensory and cognitive stimulation, hand-eye and full body coordination, creative processes, expressive movement, mindfulness practice, and social connectedness.
214917128|NCT00832611|DEVICE|Arteriovenous Fistula (ROX AC1)|The percutaneous creation of an arteriovenous fistula.
214917129|NCT00006483|BIOLOGICAL|sargramostim|
214917130|NCT03064698|OTHER|Post-partum Doppler ultrasound|Participants will undergo one uterine artery Doppler ultrasound at 6 weeks post-partum.
214917131|NCT06389305|DRUG|peripheral blood lymphocytes|autologous or allogeneic peripheral blood lymphocytes
214917132|NCT06389305|DRUG|CIK cell|autologous or allogeneic cytokine-induced killer (CIK) cells
214917133|NCT00532753|BEHAVIORAL|Community Empowerment|
214917134|NCT02292953|OTHER|Serum Prolactin levels|blood samples will be drawn from patients undergoing ICSI to analyse serum prolactin levels
214917135|NCT05969769|OTHER|Thoracic Sustained Natural Apophyseal Glides|Sustained Natural Apophyseal Glides 3 sets of 10 reps with 1 min rest btw sets.
214917136|NCT05969769|OTHER|Muscle Energy Techniques|Short wave diathermy for 10 to 15 mins Muscle Energy Techniques of following muscles will be performed, Hip flexors muscles, Quadrates lamborum muscles, Erector spinae muscles, Piriformis muscles, PFS technique of METs Isometric hold 5-7 sec, Stretching 15 sec, Rest 30 sec.
214310661|NCT04713098|DEVICE|Peripheral Nerve Stimulation|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
214310662|NCT04713098|DEVICE|Sham|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
214310663|NCT02927379|DRUG|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
214310664|NCT02927379|DRUG|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
214310665|NCT02927379|DRUG|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
214310666|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after overnight fasting for at least 10 h
214310667|NCT01451775|DRUG|Empagliflozin|low dose empagliflozin after overnight fasting for at least 10 h
214917137|NCT04758364|OTHER|measurement of gait speed|Cross sectional, cohort
214917138|NCT04138472|DRUG|dexmedetomidine|intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
214917139|NCT04138472|DRUG|fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
214917140|NCT04138472|DRUG|lidocaine|intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
214917141|NCT06141174|OTHER|disease outcome ( mortality and length of stay )|insertion of intercostal tube to drain pleural collection
214917142|NCT01091857|BEHAVIORAL|STRIDE|
214917143|NCT04777786|OTHER|Physical Therapy|Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning \~4 weeks after surgery (x̄=10 visits).
214917144|NCT00214786|BIOLOGICAL|Islet cell transplantation|Allogenic islet transplantation
214310668|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after a standardised high fat breakfast
214310669|NCT01488097|DRUG|sebelipase alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase.
214310670|NCT00191828|DRUG|olanzapine|
214310671|NCT03999411|DRUG|Nicoderm C-Q Transdermal Product|6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
214310672|NCT03999411|BEHAVIORAL|Adherence to Antiretroviral Therapy Counseling|Brief counseling on adhering to antiretroviral therapy with self-help materials.
214310673|NCT03999411|BEHAVIORAL|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
214310674|NCT03999411|BEHAVIORAL|"Crave-to-Quit app"|"Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention."
214310675|NCT03999411|BEHAVIORAL|"vDOT emocha app"|"Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence."
214310676|NCT00542152|DRUG|CYCLOSPORINE VS INFLIXIMAB|"* Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.~* Infliximab 5mg/kg at weeks 0, 2 and 6"
214310677|NCT00001893|DRUG|TNFR:Fc|
214310678|NCT04264910|BEHAVIORAL|Calm App|Calm is a subscription-based meditation app which provides guided meditations, sleep stories, soundscapes and calming music. Calm offers 7 Days of Calm for those new to meditation, the daily Calm, a meditation posted daily and a library of unique 10-12 minute meditations with topics related to acceptance, anxiety, self-compassion, and physical pain (to name a few).
214347063|NCT03960190|DEVICE|Using Eureka Breast Pump with Expression Kit|Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.
214347064|NCT00648479|DEVICE|The Guiding Star|
214347065|NCT00648479|DEVICE|fluoroscopy (OEC 9800 - General Electric)|
214347066|NCT01556113|OTHER|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
214347067|NCT00424437|DRUG|Inhaled human insulin|
214347068|NCT03021187|DRUG|semaglutide|Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
214347069|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
214347070|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
214347071|NCT03021187|DRUG|placebo|Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
214347072|NCT06352853|OTHER|Skin incision in Cesarean Section by Diathermy|Skin incision by diathermy
214347073|NCT06352853|OTHER|Skin incision in Cesarean Section by Scalpel|Skin incision by scalpel
214347074|NCT01664078|DEVICE|Endovascular AAA repair with InCraft®|
214347075|NCT03034148|DIAGNOSTIC_TEST|Platelet Acetyl Coenzyme A Carboxylase analysis in CAD|
214347076|NCT01631032|DRUG|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
214347077|NCT02959073|OTHER|Symptom Recording|Subjects muss record their allergic symptoms after contact with their cats
214347078|NCT03388580|PROCEDURE|bronchoalveolar lavage (BAL)|clinically indicated, elective BAL
214347079|NCT03399695|PROCEDURE|preoxygenation|spontaneous breathing
214917145|NCT02993250|DRUG|AL-335|Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
214310679|NCT04418986|PROCEDURE|opposite clear corneal incisions (OCCI)|"Coaxial small incision cataract surgery was performed for all cases using a 2.8 mm keratome placed at steep meridian and 1-mm paracentesis was made 90 degrees apart with a 20-gauge microvitrectomy blade. Surgery was performed with a 30-degree, 0.9-caliper phacoemulsification tip (microtip) with a divide and conquer technique.~In the OCCI group, a single penetrating incision was created with 2.8 mm keratome in the clear cornea, 1.5 mm anterior to limbal blood vessels, centered over the steep meridian and opposite the phacoemulsification incision."
214310680|NCT03441633|DRUG|apixaban|current or new medication
214310681|NCT03441633|DRUG|dabigatran|current or new medication
214310682|NCT03441633|DRUG|VKA|current or new medication
214310683|NCT03441633|DRUG|rivaroxaban|current or new medication
214310684|NCT06146582|BEHAVIORAL|Laguna Coach and App Intervention Group|Behavioral, mental and contextual support was delivered through personal interactions with Laguna Coaches via mobile app, phone, video, or web chat. Care interventions were individualized to best match each participant's needs and strengths. Support will be provided to participants through interactions over approximately 90 days.
214310685|NCT04979741|OTHER|No interventions|Observational study, no intervention is required
214480998|NCT06868407|BEHAVIORAL|Experimental: Self-Guided Electronic Safety Plan Intervention|This is a modified version of the E-SPI first created by Methi and colleagues (2024) which was originally adapted from the six primary steps of the Stanely-Brown safety plan (identifying warning signs, internal coping strategies, social distractions, non-professional crisis contacts, professional crisis resources, suicidal means restriction). Modifications to the E-SPI were based on pilot-study participant feedback and feedback from a youth focus group. The intervention was updated in accordance with pilot-study participant feedback and feedback from subsequent youth interviews. Modification examples include updated instruction wording to reduce ambiguity, updated illustrations, and increased accessibility for participants with reading-based learning disabilities.
214480999|NCT06869759|BEHAVIORAL|Implementation strategy - Health Promotion and Education-based intervention|Firstly, three broad strategies will be implemented in the intervention arm (use of advisory boards, sensitization, and linkage to care). The advisory board meetings will be held every month to discuss the progress and receive their feedback. Secondly, orientation and capacity building will be done by onsite coaching to community health workers at the health facility level on BSE. Those trained health workers will frequently capacitate FCHVs during monthly meetings. Then, FCHV will visit the community to be aware of BSE as well as they will be involved in a stigma reduction campaign. Sensitization to FCHVs through orientation and capacity building by providing 3 batch training to selected 3 wards, then FCHVs aware and practice the skills of BSE to the recruited participants during home visit and Thirdly, the suspected and identified cases will be linked by strengthening the referral mechanism of the health system and CHWs reminders for follow-up to cases.
214481000|NCT06869928|OTHER|PIUO Pathway|see arm description.
214917146|NCT02993250|DRUG|Odalasvir (ODV)|Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
214917147|NCT02993250|DRUG|Simeprevir (SMV)|Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
214917148|NCT06574958|BIOLOGICAL|CD38/CS1 injection|"Dosage form and specification: injection, 40mL/ dose, according to the number of positive cells 1×106/kg Properties: Colorless or slightly light white clear liquid Prescription composition: CD38/CS1 CAR T cells, 2.5% human blood albumin, 0.9% sodium chloride injection.~Administration mode: intravenous injection Storage condition: 2-8℃ for 8h Mechanism of action :38WP as a dual-target CAR T cell therapy, compared with single-target CAR T cell therapy, its advantage is that it can reduce antigen escape of tumor cells."
214917149|NCT05582408|DEVICE|Measures of Standard Noise Reduction NR1|Each participant will be fitted with the Standard Noise Reduction (NR1)
214917150|NCT05582408|DEVICE|Measures of Noise Reduction Principle NR2|Each participant will be fitted with the novel Noise Reduction principle NR2 on the same hearing aid
214917151|NCT05582408|DEVICE|Measure of Noise Reduction Principle NR3|Each participant will be fitted with the novel Noise Reduction principle NR3 on the same hearing aid
214917152|NCT02571842|DRUG|Intravenous Rituximab|\- 375 mg/m2 rituximab be prescribed 4 consecutive monthly
214917153|NCT02571842|DRUG|ACEI/ARB and corticosteroids|"* ACEI or ARB will be prescribed as high as tolerable dose.~* Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks"
214917154|NCT02566642|OTHER|educational material|pts coming to preadmission testing will view self administered tutorial on the role of anesthesiologist
214917155|NCT01416974|DRUG|cyclophosphamide|Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
214917156|NCT01416974|BIOLOGICAL|modified T cells|followed by consolidative therapy with the modified T cells in 3 planned cohorts.
214917157|NCT01888445|DRUG|roxadustat|oral
214917158|NCT01888445|DRUG|darbepoetin alfa|iv
214917159|NCT01250574|OTHER|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
214310686|NCT03883932|BEHAVIORAL|Fatherhood Focused FVEP (F3)|F3 is designed to focus specifically on the importance of fathering within a cognitive-behavioral intervention.
214310687|NCT03883932|BEHAVIORAL|Family Violence Education Program (FVEP)|FVEP is a court-mandated program intended to treat those arrested for intimate partner violence (IPV).
214917160|NCT01250574|OTHER|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
214917161|NCT05871944|OTHER|KAlternborn Joint Mobilization|This is a join mobilization technique to reduce the joint stiffness and help in improving joint range of motion
214917162|NCT05871944|OTHER|Post stretch Facilitation Technique|This is a PNF techniques used to relax the muscles and help in getting more free range of restricted joint
214917163|NCT03172923|DEVICE|sliding hip screw|fixation of the fracture with a sliding hip screw
214917164|NCT03172923|DEVICE|intramedullary nial|fixation of the fracture with an intramedullary nail
214917165|NCT02527434|BIOLOGICAL|Tremelimumab monotherapy|IV infusion
214917166|NCT02527434|BIOLOGICAL|MEDI4736 monotherapy|IV infusion
214917167|NCT02527434|BIOLOGICAL|MEDI4736 + tremelimumab combination therapy|IV infusion
214310688|NCT00944151|PROCEDURE|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
214310689|NCT01909596|DEVICE|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
214310690|NCT01909596|DEVICE|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
214310691|NCT01909596|DEVICE|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
214310692|NCT00178841|DRUG|Rosiglitazone and Bexarotene|rosiglitazone added to bexarotene capsules
214310693|NCT04076995|OTHER|Water Intake|Increased water intake during the 11 h protocol
214310694|NCT06050499|DEVICE|Microdialysis catheter + biosensor|"Microdialysis catheter from linton instrumetal 63 MD Catheter"
214310695|NCT01251380|BIOLOGICAL|Botulinum toxin type A|Intramuscular (IM) injection on day 1 of each treatment cycle.
214310696|NCT00311896|DRUG|Bemiparin|
214310697|NCT00311896|DRUG|Placebo|
214310698|NCT04579042|PROCEDURE|cartilaginous batten graft septoplasty|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
214310699|NCT04851795|OTHER|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
214310700|NCT04851795|OTHER|unsupervised physical exercise|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
214310701|NCT01650662|DRUG|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
214310702|NCT06416696|DRUG|Toripalimab|"1. Radiotherapy: Both external beam and brachytherapy, with radiation therapy techniques, target delineation, prescribed doses, and organ-at-risk constraints following established guidelines.~2. Chemotherapy: The preferred regimen is cisplatin at a dose of 40mg/m\^2 administered intravenously once weekly for 5-6 cycles; for patients intolerant to cisplatin or with renal impairment, carboplatin (AUC=2) may be considered, also administered once weekly.~3. Toripalimab concurrent immunotherapy: Following the regimens of phase III RCTs such as JUPITER-02, JUPITER-06, CHOICE-01, NEOTORCH, and RENOTORCH, Toripalimab is administered at a fixed dose of 240mg per infusion, given intravenously once every 3 weeks for three doses.~4. The concurrent chemoradiotherapy and immunotherapy phase does not exceed 8 weeks in duration."
214310703|NCT02122536|DRUG|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
214917168|NCT05654870|DRUG|Valbenazine|Oral treatment
214917169|NCT05654870|DRUG|Placebo|Placebo matching valbenazine
214917170|NCT00014430|BIOLOGICAL|trastuzumab|"Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.~The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation-functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and causes breast cells to reproduce uncontrollably."
214670845|NCT05284006|DIAGNOSTIC_TEST|Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.|This study includes 15 major assessments: clinical assessment procedures; anthropometric measurements; activity of daily living and quality-of-life questionnaires; gait kinematics and kinetics analysis; pulmonary function tests (PFT); skeletal radiographs and dual-energy x-ray absorptiometry (DXA); MRI in cervical spine, temporal bones, and hip; computed tomography angiography (CTA) for tracheal obstruction; CT for temporal bones; anesthetic encounters; joint mobility; hearing function; biochemical analyses; and pathological analyses.
214310704|NCT02122536|DRUG|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
214310705|NCT01212718|DRUG|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
214310706|NCT01212718|DRUG|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
214310707|NCT01167231|DRUG|Acarbose (Glucobay, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
214310708|NCT05067296|OTHER|By TVS|Uses of TVS to diagnosis of Cesarean section niche in patients with abnormal uterine bleeding
214310709|NCT04914390|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
214310710|NCT04914390|DRUG|Tislelizumab|200mg on d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
214310711|NCT04914390|DRUG|Anlotinib|8mg on d1-14 of Cycles 1-5 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
214670846|NCT05108324|PROCEDURE|zygomatic implant|2 zygomatic implants and 2 anterior conventional implant
214917171|NCT00014430|DRUG|vinorelbine ditartrate|Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
214670847|NCT05108324|PROCEDURE|conventional implant|patients will receive 4 conventional dental implant
214917172|NCT03249012|OTHER|Empiric use of Calcium Carbonate and Calcitriol|Empiric calcium carbonate and calcitriol repletion
214917173|NCT03249012|OTHER|PTH based Calcium Carbonate and Calcitriol repletion|PTH based treatment
214310712|NCT01430013|DRUG|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
214310713|NCT04383210|DRUG|Seribantumab|Anti-HER3 monoclonal antibody
214310714|NCT02367703|PROCEDURE|laparoscopic hysterectomy|
214310715|NCT05940480|BEHAVIORAL|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
214917174|NCT00862004|PROCEDURE|VATS|video-assisted thoracoscopic surgery (VATS) major pulmonary resection with systematic node dissection (SND) for clinical stage IIIA non-small cell lung cancer
214310716|NCT05940480|BEHAVIORAL|Health education|Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.
214310717|NCT02280590|DRUG|Rosuvastatin(Cresnon®)|10mg
214310718|NCT02280590|DRUG|Rosuvastatin(Crestor®)|10mg
214310719|NCT05776121|DRUG|ZB001 for injection|Dose Cohort1 (3 mg/kg) ZB001 four IV injections
214310720|NCT05776121|DRUG|ZB001 for injection|Dose Cohort2 (10 mg/kg) ZB001 four IV injections
214310721|NCT02473315|OTHER|cryotherapy|"The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks)."
214310722|NCT03880903|DRUG|normal saline and salbutamol|patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
214310723|NCT03880903|DRUG|hypertonic saline and salbutamol|patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours
214310724|NCT03880903|DRUG|Hypertonic saline|patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
214481001|NCT06868771|OTHER|topical treatment with the pre- and postbiotic study preparation and niacinamide 4% and one with the 10% urea-based preparation.|Application of the topical preparation in both groups will be performed twice a day for a total duration of 3 months.
214481002|NCT06869811|DEVICE|LAA Closurse|LAA Closure + DOAC or OAC
214481003|NCT06870305|OTHER|MBTP : Mindflulness based training for psychosis|The group-based mindfulness programme is called MBTP (Mindfulness based training for psychosis). The MBTP programme consists of 5 sessions over a period of one month (2 sessions in the first week, then one session a week). Each session lasts approximately 1h30 and is carried out in a group of 5 participants. The sessions cover informal and formal mindfulness tasks, elements of psycho-education on emotions, meditation exercises on emotions, and thought defusion and acceptance tasks. Participants are encouraged to meditate at home between sessions.
214917175|NCT02549326|DIETARY_SUPPLEMENT|vitamin D|
214917176|NCT02549326|DIETARY_SUPPLEMENT|Placebo|
214917177|NCT00542399|DRUG|Levemir (insulin detemir)|Levemir once a day
214917178|NCT00542399|DRUG|Levemir twice a day|Levemir twice a day
214917179|NCT05280938|BEHAVIORAL|MAAP|Women randomized to the MAAP intervention will complete an 8 week (2hr/wk) hybrid adapted Kabat-Zinn's MBSR.(Kabat-Zinn, 1990) MAAP intervention includes activities related to spirituality, self-empowerment, interdependence, and story-telling, which are salient to AAW.(Watson-Singleton et al., 2019) Women will receive practice links and a program work book (5th grade level) containing objectives and weekly MAAP activities/. Individual weekly home practice is expected. Type and minutes of home practice will be recorded in weekly logs. Program attendance, type, amount of practice, and changes in mindfulness (Five Facet Mindfulness Questionnaire) will be included in data analysis.
214955073|NCT01496417|DRUG|Belatacept|Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
214955074|NCT04769102|DEVICE|seat cushions|flat versus contoured customized seat cushions
214310725|NCT05210790|DRUG|Placebo|Placebo
214670848|NCT03126136|DEVICE|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
214955075|NCT00493506|DRUG|ProAlgaZyme|
214310726|NCT05210790|DRUG|Rusfertide|Experimental drug
214310727|NCT01986868|OTHER|Coronary MR Angiography (CMRA)|Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.
214310728|NCT03149250|DIAGNOSTIC_TEST|Aggregometry, Monitoring of plasmatic hemostasis|Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
214310729|NCT06254742|DRUG|HHPG-19K Injection|first cycle: Auto-HHPG-19K Injection or HHPG-19K Injection second cycle: HHPG-19K Injection or Auto-HHPG-19K Injection
214310730|NCT05585034|BIOLOGICAL|XmAb®808|Monoclonal bispecific antibody
214310731|NCT05585034|BIOLOGICAL|Keytruda® (pembrolizumab)|Monoclonal antibody
214310732|NCT01748643|DRUG|deep neuromuscular blockade with rocuronium, reversal with sugammadex|after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio \> 0.9.
214310733|NCT01748643|DRUG|normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is \> 0.9.
214310734|NCT05612633|DRUG|zelavespib|Oral zelavespib 100 mg will be administered once daily
214955076|NCT06283433|DIAGNOSTIC_TEST|Finger Prick|Blood sample obtained via drop of capillary blood by finger prick onto filter paper
214955077|NCT06283433|DIAGNOSTIC_TEST|Venipuncture|Blood sample obtained trough venipuncture
214917180|NCT05280938|BEHAVIORAL|Educational Program|"The 8-week Educational Program will be matched in duration, frequency, delivery method, and data collection to the MAAP intervention. Like MAAP, it will be delivered using a hybrid format (virtual Zoom and in person visits).~Sessions will be given in groups by an expert perinatal clinician/educator for all cohorts. Content will be set and delivered consistently across cohorts. Sessions will be audiotaped and rated for achievement of objectives and consistency of delivery. Deviations will be promptly addressed. Subject receipt will be monitored by attendance. Sessions will not include content on stress reduction (yoga, meditation, etc.). Classes will be given in the same setting as the MAAP intervention, at the same time but on a different evening, to avoid crossover (diffusion) of effects."
214917181|NCT05840211|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
214310735|NCT02085187|OTHER|Telemedicine training and counselling|"Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.~There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required."
214310736|NCT02701647|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
214310737|NCT02701647|OTHER|Treadmill training|Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
214310738|NCT01369979|PROCEDURE|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
214310739|NCT03042052|DRUG|detrusor infection of Botulinum toxin|detrusor injection
214310740|NCT06542952|OTHER|seizure|epileptic children
214917182|NCT05840211|DRUG|Paclitaxel|Administered intravenously
214917183|NCT05840211|DRUG|Nab-paclitaxel|Administered intravenously
214917184|NCT05840211|DRUG|Capecitabine|Administered orally
214917185|NCT00568061|DRUG|Nitric Oxide|Nitric oxide for inhalation
214917186|NCT00568061|DRUG|Placebo|Nitrogen gas (placebo) for inhalation
214917187|NCT06198153|OTHER|Stationary Cycling|In addition to the conventional physical therapy, children in this group will receive 10-15 minutes of stationary cycle training, 3 times a week for 6 weeks.
214917188|NCT06198153|OTHER|Progressive Functional Training|In addition to the conventional physical therapy, the training will follow a 6-week progressive functional training program for lower extremities. These exercises will include sit-to-stand exercise, lateral/forward step-up exercise (i.e. climbing a stair or stepping up onto a kerb), and half-knee rise exercise (i.e. rising from the ground). All exercises will be performed in 1-3 sets of 10-15 repetitions, with a 90 second rest in between the sets. Each exercise will be performed within 10-15 minutes. Training session will be given 3 times a week. During the training, intensity will be progressively increased by increasing the repetitions
214917189|NCT05043207|DIAGNOSTIC_TEST|uAud|Patients will receive hearing aid treatment based on an audiometry obtained with an user-operated automated audiometry procedure
214917190|NCT05043207|DIAGNOSTIC_TEST|Traditional audiometry|Patients will receive hearing aid treatment based on an audiometry obtained with an traditional audiometry procedure
214310741|NCT02653807|OTHER|mobilization with movement|manual therapy intervention
214310742|NCT02653807|OTHER|osteopathic mobilization|manual therapy intervention
214310743|NCT00417807|DRUG|Imatinib mesilate|
214310744|NCT06422260|OTHER|Prosthesis superstructure|Prosthesis superstructure for 2 implant supported short span fixed bride constructed from different materials
214310745|NCT02205333|BIOLOGICAL|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
214310746|NCT02205333|BIOLOGICAL|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
214310747|NCT02205333|BIOLOGICAL|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
214310748|NCT02205333|BIOLOGICAL|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
214917191|NCT01896128|DRUG|Armodafinil|
214917192|NCT01896128|DRUG|Placebo|inactive pill manufactured to mimic Armodafinil 150 mg tablet
214917193|NCT03656497|OTHER|Observational|No intervention is conducted as the study aim is to explore the link between pheno- and genetype of trigeminal neuralgia
214917194|NCT02307279|DEVICE|Gelesis100|
214917195|NCT02307279|DEVICE|placebo|
214917196|NCT00003620|DRUG|alvocidib|Given IV
214917197|NCT00003620|OTHER|laboratory biomarker analysis|Correlative studies
214917198|NCT02390921|DRUG|Fisiogen Ferro Forte|The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
214917199|NCT02390921|DRUG|Venofer|The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
214917200|NCT01692379|DEVICE|Solitaire FR device|Mechanical embolectomy in anterior large vessel occlusion
214917201|NCT01692379|OTHER|Medical treatment|Standard of care in acute ischemic stroke including intravenous rTPA
214917202|NCT02173002|OTHER|myIBDcoach|
214917203|NCT02173002|OTHER|Standard care|
214917204|NCT06574490|PROCEDURE|Myofunctional therapy (+)|A series of myofunctional exercises performed in 10-20 sessions over 6 months
214310749|NCT05272904|PROCEDURE|Quilting|Following mastectomy and/or axillary lymph node dissection, the subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin.
214310750|NCT05272904|PROCEDURE|Conventional wound closure|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
214310751|NCT05024500|OTHER|ARDSNet table|The setting of the lowest PEEP level and FiO2 match stated by the table to achieve a goal oxygenation.
214917205|NCT06574490|PROCEDURE|Myofunctional therapy (-)|NO exercises; A series of myofunctional exercises performed in 10-20 sessions over 6 months is delayed by 1 year
214917206|NCT00826397|PROCEDURE|Acupuncture|Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
214310752|NCT05024500|OTHER|Driving Pressure|The setting of the lowest PEEP level by the lowest correspondent driving pressure, which is defined by the difference of plateau pressure, after a modified alveolar recruitment maneuver.
214310753|NCT05024500|OTHER|Electrical Impedance Tomography|The setting of the PEEP level above the intersection of the curves representing relative alveolar overdistention and collapse, after a modified alveolar recruitment maneuver.
214310754|NCT01476696|DRUG|Prasugrel|Administered orally
214310755|NCT03038815|DEVICE|VACOped|restriction of ankle joint motion
214310756|NCT03038815|DEVICE|Ortho Tri|restriction of ankle joint motion
214310757|NCT01187927|BIOLOGICAL|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
214310758|NCT04836299|DRUG|Ivermectin|Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.
214310759|NCT04836299|DRUG|Placebo|Participants will be randomly assigned to receive a single of placebo.
214310760|NCT02447133|DEVICE|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
214310761|NCT04818190|PROCEDURE|Sensory neurotization|The donor nerve is a cutaneous nerve that is identified with the most inferior lateral perforator vessels. The nerve is then dissected for neurotization and divided at the level of the fascia where it is a pure sensory nerve. The recipient intercostal nerve is usually easily identified in the third intercostal space during the dissection of the internal mammary artery and vein. The anterior branch of the third intercostal nerve can usually be found at the junction of the inferior portion of the third rib and the sternum, approximately 80% of the time. The nerve is dissected and transected medially. It is then mobilized to give it the longest length possible in preparation for neurotization. Neurotization is performed by coapting the donor nerve to the third anterior intercostal nerve directly with a 9-0 nylon suture in standard fashion.
214310762|NCT03054870|DRUG|Xe-133|Xe-133 ventilation scintigraphy
214310763|NCT03054870|DRUG|Technegas|Technegas ventilation scintigraphy
214310764|NCT05990400|DRUG|Finasteride|finasteride topical 0,1%
214917207|NCT00826397|PROCEDURE|Sham Acupuncture|The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
214917208|NCT02087488|OTHER|auricular acupuncture(AA)|"Auricular acupoints: Shenmen (TF4), Heart (CO15), Subcortex (AT4), modifying points according to different patterns.~Auricular attachment material: disposable Seirin Pyonex Needle Seirin Pyonex Needle manufacturer: Seirin Corporation, a Japanese company. Medical Device Certification number: No. 15500BZZ00806000.~Treatment frequency: every 3 days.~Duration: 4 weeks."
214917209|NCT02087488|OTHER|placebo AA|"Auricular acupoints: Wrist (SF1), Clavicle (SF6), Shoulder (SF4、5), Tooth (LO1), Tonsil (LO7, 8, 9).~Auricular attachment material: the disposable Pyonex Zero Needle Pyonex Zero Needle manufacturer: Seirin Corporation, a Japanese company.~Treatment frequency: every 3 days.~Duration: 4 weeks."
214917210|NCT02087488|DRUG|Eszopiclone|"Dosage form: tablet.~Dosage: 1 piece (3mg).~Drug manufacturer: Kanghong pharmaceutical limited liability company, Chengdu.~Production license: NO. H20100074 approved by the state.~Treatment frequency: 15 mins before going to bed everyday.~Duration: 4 weeks."
214917211|NCT02329171|DRUG|Imiquimod|Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
214917212|NCT02329171|PROCEDURE|LLETZ|Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
214917213|NCT04067167|OTHER|WB-EMS (Sham-intervention)|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS with low-threshold stimulation during a study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
214955078|NCT05811559|OTHER|No intervention|No intervention
214310765|NCT05990400|DRUG|Minoxidil|minoxidil topical 5%
214310766|NCT05562973|DRUG|Psilocybin|Participants will receive three psilocybin sessions, at least two weeks apart.
214310767|NCT05693285|OTHER|No intervention|No intervention
214310768|NCT02009046|BEHAVIORAL|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
214310769|NCT02009046|BEHAVIORAL|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
214310770|NCT02009046|BEHAVIORAL|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
214310771|NCT02009046|BEHAVIORAL|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
214310772|NCT06516276|DEVICE|Mobile App M.I.O|This mobile app provides patients with access to various resources and therapies focused on nutrition, exercise, and emotional well-being. The main objective is to measure the quality of life of the app users through validated questionnaires in a randomized health education study to evaluate whether a substantial improvement in their well-being is achieved.
214310773|NCT03398720|DRUG|HTI-1066 dose level 1|Starting dose level
214310774|NCT03398720|DRUG|HTI-1066 dose level 2|2nd dose level
214310775|NCT03398720|DRUG|HTI-1066 dose level 3|3rd dose level
214310776|NCT03398720|DRUG|HTI-1066 dose level 4|4th dose level
214310777|NCT00844272|BEHAVIORAL|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education."
214310778|NCT01419548|DRUG|ABT-888|
214310779|NCT01419548|DRUG|Carboplatin|
214310780|NCT01419548|DRUG|Paclitaxel|
214310781|NCT01814306|DEVICE|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
214310782|NCT01814306|DEVICE|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
214310783|NCT02822469|OTHER|Manual Therapy Treatment|"Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.~The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes."
214310784|NCT02822469|DEVICE|Placebo Ultrasound|A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
214310785|NCT03695731|PROCEDURE|cold induced activation of brown adipose tissue|cold exposure wearing a cold life jacket
214310786|NCT04027738|OTHER|PRP|The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
214310787|NCT04112017|DEVICE|YVOIRE Y-Solution 360|Hyaluronic acid
214481004|NCT06871098|OTHER|Hip Hinge Instruction|The participant will be instructed to perform a hip hinge movement based on their current understanding and ability. This initial movement assessment will serve as a baseline measure to analyze the participant's natural hip hinge mechanics before any intervention. The purpose of this assessment is to determine whether the implementation of the Founder Exercise intervention leads to significant changes in the kinematics of the hip hinge movement.
214481005|NCT06869005|OTHER|BARF scale|"BARF Scale, validated in paediatrics, is graduated from 0 to 10 and shows 6 increasingly nauseous faces. A child/adolescent will be considered at risk of NV if he/she declares a score greater than or equal to 4 out of 10 on at least one of the 4 observation times.~This scale can be used by the child him/herself, from the age of 4; or by a close adult, usually present at the child's side during treatment."
214917214|NCT04067167|OTHER|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
214955079|NCT06400485|DRUG|AMT-676|Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
214955080|NCT05799898|OTHER|No intervention for research purposes only|No intervention for research purposes only
214670849|NCT04426630|OTHER|mHealth for heart failure patients in Uganda|Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
214670850|NCT03808207|OTHER|Dietary counseling and DHA dietary increase in breastfeeding mothers|Specific dietary advices in order to increase the daily/weekly intake of docosahexaenoic acid of breastfeeding mothers for the first 3 months after delivery
214310788|NCT03530475|DIAGNOSTIC_TEST|ultrasound and doppler|"• Ultrasound examination (2D gray scale and color doppler )~1\. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3\. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion."
214310789|NCT01324388|BIOLOGICAL|LY2189265|Administered subcutaneously
214310790|NCT01324388|DRUG|Metoprolol|Administered orally
214310791|NCT01324388|DRUG|Lisinopril|Administered orally
214310792|NCT01324388|DRUG|Placebo|Administered subcutaneously
214310793|NCT00924872|OTHER|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
214310794|NCT02730299|DRUG|NiCord® (omidubicel)|
214310795|NCT02730299|OTHER|Cord Blood Unit|Cord blood unit
214310796|NCT00917709|OTHER|Imaging with IBVM|in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol
214310797|NCT00917709|OTHER|Imaging with DATSCAN|in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
214310798|NCT00917709|BEHAVIORAL|neuropsychological evaluation|neuropsychological evaluation using neuropsychological tests
214917215|NCT04067167|OTHER|Free WB-EMS|"Whole-Body Electromyostimulation (WB-EMS) using a mobile system:~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
214917216|NCT04067167|OTHER|Flexi band resistance training|"Flexi band resistance Training:~Training during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform resistance exercises using flexi bands~* flexi band exercises are conceptualized to activate similar muscle groups as EMS exercise~* time-effort per session: \~20 min~* 2 training sessions per week"
214917217|NCT04593511|DRUG|LY03009 F1|a single dose of LY03009 F1
214917218|NCT04593511|DRUG|LY03009 F2|a single dose of LY03009 F2
214310799|NCT00362908|BEHAVIORAL|Moderate Fat and Moderate Carbohydrate Diet|40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
214310800|NCT00362908|BEHAVIORAL|Low Fat and High Carbohydrate Diet|20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
214310801|NCT02687984|DRUG|RBP-7000|A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
214310802|NCT03169465|PROCEDURE|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
214917219|NCT04593511|DRUG|LY03009 F3|a single dose of LY03009 F3
214310803|NCT03169465|PROCEDURE|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
214310804|NCT00973479|DRUG|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
214310805|NCT00973479|OTHER|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
214310806|NCT00973479|DRUG|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
214310807|NCT04311099|DRUG|Active drug|Injection of Ropivacaine
214310808|NCT04311099|DRUG|Placebo|Injection of Saline solution
214310809|NCT04311099|PROCEDURE|Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
214310810|NCT04311099|PROCEDURE|Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
214310811|NCT04311099|PROCEDURE|Injection of placebo - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block with saline solution
214310812|NCT04311099|PROCEDURE|Injection of placebo - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
214917220|NCT04593511|DRUG|LY03009 F4|a single dose of LY03009 F4
214917221|NCT02484456|DRUG|AV 101 (4-Chlorokynurenine)|L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.
214917222|NCT02484456|OTHER|Placebo Comparator|Placebo
214917223|NCT00910533|DRUG|ceftriaxone|ceftriaxone 2 g od i.v. for 14 days
214917224|NCT02023411|DRUG|Teriparatide|recombinant human parathyroid hormone (1-34) subcutaneous every day at 8-9 pm
214310813|NCT05356702|OTHER|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. They will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
214310814|NCT05463796|OTHER|Samples|"Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues"
214310815|NCT00415233|BIOLOGICAL|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
214310816|NCT00415233|RADIATION|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
214310817|NCT01643993|OTHER|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
214310818|NCT01643993|OTHER|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
214310819|NCT02596269|DRUG|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
214310820|NCT02596269|DRUG|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
214310821|NCT00589953|DRUG|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
214310822|NCT00589953|DRUG|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
214310823|NCT02958150|DRUG|Dexmedetomidine|
214310824|NCT02958150|PROCEDURE|Standard Clinical Practice|
214310825|NCT03089606|DIAGNOSTIC_TEST|FDG PET/CT scan|18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).
214310826|NCT03089606|DIAGNOSTIC_TEST|C11-AMT PET scan|11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).
214310827|NCT03089606|DRUG|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
214310828|NCT03089606|DIAGNOSTIC_TEST|CT scan|Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
214310829|NCT01482247|DIETARY_SUPPLEMENT|L-Arginine|Dietary Supplement
214310830|NCT01482247|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary Supplement
214310831|NCT06067386|OTHER|Dissemination of a selective reporting for antibiotic susceptibility testing|For each E. coli positive urine culture analyzed by LabOuest, GPs will receive an antibiotic susceptibility testing report, with the list of antibiotics restricted according to four E. coli susceptibility profiles, with an emphasis on narrower-spectrum antibiotics. The selected antibiotic susceptibility testing was developed following a targeted literature review and consultation with a steering committee including GPs, biologists and infectiologists. At the GP's request, a full antibiogram can be provided.
214310832|NCT06067386|OTHER|Standard antibiotic susceptibility testing report|GPs will receive a standard antibiotic susceptibility testing report for each E. coli positive urine culture.
214917225|NCT02023411|OTHER|Placebo|Placebo
214310833|NCT05891509|PROCEDURE|Minimally Invasive Hematoma Evacuation|Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
214310834|NCT05891509|OTHER|Best Medical Therapy|Best medical therapy
214310835|NCT05641233|RADIATION|Stereotactic radiotherapy|Preoperative radiotherapy delivered in a single fraction of 12 Gy focussed on 4cm pancreas at the intended (i.e. future) anastomotic site.
214310836|NCT00780325|DRUG|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
214310837|NCT00780325|DRUG|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
214310838|NCT00780325|DRUG|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
214917226|NCT01996254|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
214917227|NCT05334953|DEVICE|ESWT|"Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
214310839|NCT00780325|DRUG|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
214917228|NCT05334953|DEVICE|Phonophoresis|"Group 2 ( n=17) will be given five times a week total 10 sessions of diclofenac phonophoresis + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
214310840|NCT00780325|DRUG|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
214310841|NCT00780325|DRUG|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
214347080|NCT04728243|OTHER|WHO QualityRights e-training|The WHO QualityRights online training aims to increase knowledge about the rights of people with psychosocial disabilities and change negative attitudes towards these persons and their role as rights holders. Furthermore, the training provides mental health professionals with the skills necessary to support people with psychosocial disabilities to advocate for their rights. The WHO QualityRights online training includes five core modules: 1) Human rights; 2) Mental health, disability, and human rights; 3) The right to health and recovery; 4) Legal capacity and the right to decide; 5) Free from coercion, violence, and abuse. Each module is composed of presentations, videos, interactive exercises, and forum discussions involving all participants. In the online training forum discussions, particular attention will be given to issues relevant to the Ghanaian context.
214670851|NCT03846362|OTHER|HSCT|allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2\>0,1% and initial intermediate risk
214670852|NCT02242279|DRUG|BEA 2180 BR|
214310842|NCT05876741|DIAGNOSTIC_TEST|history taking , vital signs and labaratory investigations|"1. Complete history taking:~   With stress on age, sex, epigastric pain, comorbidities (ischemic heart disease, diabetes, liver cirrhosis, renal failure, malignancy), syncope, disturbed conscious level, blood transfusion, drug history .~2. Clinical examination:~   Pulse, blood pressure, calculating the shock index, pallor, jaundice, cachexia, purpura, ecchymosis, conscious level, abdominal examination.~3. Laboratory investigations:~   * Complete blood count (CBC).~  * Creatinine and blood urea nitrogen (BUN).~  * liver function tests (serum bilirubin, serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), prothrombin concentration (PC), and international normalized ratio (INR)).~  * Serum electrolytes and arterial blood gases.~  * Fasting blood sugar.~4. Assessment of risk and predicting outcomes by:~   * Pre-endoscopic Rockall score (pRS).~  * Glasgow-Blatchford score (GBS).~  * AIMS65 score.~  * ABC score.~  * Horibe score."
214670853|NCT02242279|DRUG|Tiotropium|
214670854|NCT02242279|DRUG|Placebo|
214310843|NCT00002504|BIOLOGICAL|aldesleukin|
214917229|NCT05334953|DEVICE|Ultrasound|"Group 3 (n=17) will be given five times a week total 10 sessions of ultrasound therapy+ home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
214917230|NCT05334953|OTHER|Control group|Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises
214917231|NCT00813254|BEHAVIORAL|Questionnaire|Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
214917232|NCT01637454|DRUG|Noradrenaline|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
214917233|NCT01637454|DRUG|Terlipressin|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
214310844|NCT00002504|BIOLOGICAL|recombinant interferon alfa|
214917234|NCT03348930|DRUG|Tolcapone 200 MG|All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.
214917235|NCT04974060|DRUG|Remifentanil Injection|Dilute 2mg Remifentanil with normal saline to 50 ml (40ug/ml) and continuously intravenous infused at the doses of 0.02, 0.04, 0.06, and 0.08 μg/kg/min for each lasting 30 minutes.
214310845|NCT01678417|DRUG|131I-rituximab|
214310846|NCT01376271|DRUG|Paroxetine|
214917236|NCT04514874|OTHER|Questionnaire|Self-questionnaire about socio-demographical status, health status and lifestyle habits during and following the COVID-19 pandemic.
214917237|NCT06685263|BEHAVIORAL|Group 1|The development group comprises 385 individuals. Following the data collection phase of the development group, the independent risk factors for the onset of delirium will be identified through statistical analysis. A delirium prediction model will then be constructed using the identified risk factors.
214310847|NCT00922883|DRUG|Eltrombopag|
214310848|NCT01583335|BEHAVIORAL|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
214310849|NCT00142675|BEHAVIORAL|Physical Activity|
214310850|NCT03289507|DIETARY_SUPPLEMENT|Treatment1|Longvida Capsule formulation A
214670855|NCT00156728|DEVICE|Vitatron biventricular pacemaker|
214670856|NCT01960686|BIOLOGICAL|Low dose RSV F Antigen|
214310851|NCT03289507|DIETARY_SUPPLEMENT|Treatment2|Longvida Capsule formulation B
214310852|NCT03289507|DIETARY_SUPPLEMENT|Treatment3|Curcuma longa extract of Rhizomes
214310853|NCT02484963|DRUG|Zolpidem|
214670857|NCT01960686|BIOLOGICAL|High dose RSV F Antigen|
214670858|NCT01960686|BIOLOGICAL|Dose 1 of Aluminum Adjuvant|
214670859|NCT01960686|BIOLOGICAL|Dose 2 of Aluminum Adjuvant|
214670860|NCT01960686|BIOLOGICAL|Dose 3 of Aluminum Adjuvant|
214670861|NCT01960686|BIOLOGICAL|Dose 4 of Aluminum Adjuvant|
214670862|NCT01960686|BIOLOGICAL|Placebo|
214670863|NCT03202121|OTHER|insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
214670864|NCT03202121|OTHER|non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
214670865|NCT03202121|OTHER|normal control|Persons without stroke or insomnia served as normal controls that contained 25 cases.
214670866|NCT04964726|BEHAVIORAL|Real-time fMRI dyadic neurofeedback|Participants will attempt to regulate their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
214670867|NCT01483404|PROCEDURE|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
214670868|NCT03977532|OTHER|Micro-blood sampling|capillary sampling of 40 microliters performed at the fingertip
214670869|NCT00405041|DIETARY_SUPPLEMENT|Dietary supplement GVG 2|2.670 g/day for 14 days
214670870|NCT05555030|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
214670871|NCT05555030|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
214670872|NCT01466751|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
214670873|NCT03471221|BEHAVIORAL|Therapy Dog Visit|"Animal Assisted Activities (AAA) provide opportunities for motivational, educational, recreational, and/or therapeutic benefits to enhance quality of life. AAA are delivered in a variety of environments by specially trained professionals, paraprofessionals, and/or volunteers, in association with animals that meet specific criteria.~Key features of AAA are as follows:~1. Specific treatment goals are not planned for each visit.~2. Volunteers and treatment providers are not required to take detailed notes.~3. Visit content and activities are spontaneous.~4. Visit length can be as long or as short as needed."
214670874|NCT00770185|DRUG|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
214670875|NCT00770185|GENETIC|gene expression analysis|
214670876|NCT00770185|OTHER|immunohistochemistry staining method|
214670877|NCT00770185|OTHER|laboratory biomarker analysis|
214917238|NCT06685263|BEHAVIORAL|Group 2|The validation group comprises 385 individuals. The delirium prediction model created using the data from the development group will be validated by testing the data from the validation group. This will enable the evaluation of the model's fit and calibration in predicting delirium.
214917239|NCT06029413|PROCEDURE|myo + fascial injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as well as for fascial layers as described.
214917240|NCT06029413|PROCEDURE|traditional trigger point injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as described.
214917241|NCT05146518|BEHAVIORAL|Supportive and Dignified Maternity Care|"The core components of intervention would include: capacity-building of a typical maternity team comprising clinical staff (gynaecologists, doctors, nurses) and support staff (ward boys/porters and maids); collaborative care, a team-driven approach, led by gynaecologists (ward in-charge), attempts to integrate care and behaviour practices of staff according to the principles of measurement-guided care-plans, quality improvement and accountability, with a focus on meeting SDMC needs; staff and patient feedback: a complaints register will be maintained by designated staff; and brief exit interviews will elicit, and record, the degree to which care has been supportive and respectful; Accountability and governance (performance review): reports of non-respectful care will be discussed, and remedial actions decided, in periodic meetings.~Note: Since it is a behavioural intervention being administered at health system level so LSHTM has exempted this study to have a sponsor."
214310854|NCT02484963|DRUG|placebo|
214310855|NCT02724475|PROCEDURE|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
214917242|NCT06620172|PROCEDURE|CT-guided Radiofrequency Thermocoagulation (RFT)|Participants in this group will undergo CT-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure involves real-time CT imaging to guide the placement of the needle and monitor the process.
214917243|NCT06620172|PROCEDURE|Fluoroscopy-guided Radiofrequency Thermocoagulation (RFT)|Participants in this group will undergo fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure utilizes fluoroscopic imaging for needle placement and monitoring.
214310856|NCT02724475|PROCEDURE|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
214310857|NCT05721963|DIAGNOSTIC_TEST|No interventions.|No interventions.
214310858|NCT01778933|DRUG|EC17|
214310859|NCT05654155|OTHER|auricular acupressure|Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
214310860|NCT01519453|BEHAVIORAL|Home Based Asthma Education|4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
214310861|NCT05397054|BEHAVIORAL|Education|\- Education: Education about risk of high sodium intake, type of sodium, nutrition ingredients
214310862|NCT05397054|BEHAVIORAL|Reformulation|\- Reformulation: Dietary recommendation in low sodium intake
214310863|NCT05397054|BEHAVIORAL|Environmental change|\- Environmental change: Encourage about low sodium intake in community
214310864|NCT05397054|DEVICE|Salt meter|\- Used salt meter: at least 3 times/wk
214310865|NCT05397054|BEHAVIORAL|standard treatment|standard treatment
214310866|NCT01844609|BEHAVIORAL|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
214670878|NCT04507308|BEHAVIORAL|Single-session sleep intervention drawn from principles of the TranS-C youth protocol|We are providing participants psychoeducation on sleep and will be going over several handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth) to improve sleep.
214670879|NCT01469923|DRUG|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
214670880|NCT01469923|DRUG|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
214670881|NCT04913324|BEHAVIORAL|Virtual Care|Infants randomized at 4 months of age to the intervention arm will participate in virtual care visits for 16 weeks in addition to standard of care in-hospital visits.
214670882|NCT06337851|OTHER|Simultaneous burr hole craniostomy|Patients in group-1 were fixed in supine position with their heads in neutral and flexion position. Bilateral burr holes were made one after another, the dural surfaces were exposed at the same time, then the outer membranes of both sides opened and hematomas evacuated simultaneously. All the patients underwent a drainage system, performed with the insertion of a silicone tube into the subdural space and tunneled under the scalp to the exit point.
214670883|NCT06337851|OTHER|Consecutive burr hole craniostomy|In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated. The contralateral hematoma was evacuated.
215060731|NCT06104007|DEVICE|Genoss® DCB|This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
214310867|NCT01844609|BEHAVIORAL|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
214310868|NCT00446407|OTHER|Collaborative Stepped Care Intervention|Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
214310869|NCT00446407|OTHER|Enhanced Usual Care|Screening plus Antidepressants based on practice guidelines
214310870|NCT05195463|OTHER|Exercise intervention|Women with diastasis recti abdominis will do core stabilization exercises for the transversus abdominis muscle with 10 repetitions 3 days a week for 8 weeks. The exercises include diaphragmatic breathing exercises, core stabilization exercises for the transversus abdominis muscle, and pelvic floor contractions
214310871|NCT05195463|OTHER|Exercise intervention by wearing abdominal corset|In this group, in addition to the first group, core stabilization exercises will be performed by wearing an abdominal corset. Participants will be asked to wear their corsets while performing their exercises.
214310872|NCT05195463|OTHER|Corset intervention|Participants included in this group will be required to wear only this corset all day (except for the bathroom) for 8 weeks.
214310873|NCT02532296|BEHAVIORAL|Transition Coach (TC)|"TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care."
214310874|NCT02532296|BEHAVIORAL|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
214310875|NCT05383547|DRUG|Bortezomib|Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
214310876|NCT02802592|DRUG|Epogen|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
214310877|NCT02802592|DRUG|Normal Saline|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
214917244|NCT06464718|DRUG|Fortibone|Participants were given daily sachet containing 5g of Bio active collagen peptides (Fortibone). Electrolyte mix containing 500 mg calcium as calcium lactate, 4 MCg calcitriol and selenised yeast rich in vitamin D3 (400IU) (Colabone®, Vivapharm SA).
214917245|NCT06464718|DRUG|Chewable Tablet|calcium compound containing 25 g calcium carbonate (500mg elemental calcium) and vitamin D3 400IU taken daily
214917246|NCT01677572|DRUG|Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
214917247|NCT01677572|DRUG|Placebo|Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
214917248|NCT01999699|BIOLOGICAL|HEPLISAV|
214917249|NCT03445546|DIAGNOSTIC_TEST|diagnostic test of platelet function|Light transmittance aggregometry and VerifyNow
214310878|NCT04557657|DRUG|Active bio Activa|Cement that release fluoride
214670884|NCT03426215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Changes in size and severity of the main herniated disc causing radiating pain will be evaluated by radiology specialists and Korean medicine doctors (KMDs) and categorized into three groups (improved, worse or no discernible change) in comparison with the immediate previous MRI to track long-term changes and assess for correlations in subjective clinical symptoms and objective physical evaluation and MRI results.
214917250|NCT03058250|OTHER|Transesophageal echocardiography|
214917251|NCT01327170|PROCEDURE|Subthreshold diode micropulse laser|
214917252|NCT04594070|DRUG|Ferrous sulfate|Iron supplementation
215060732|NCT00776542|DRUG|Minocycline 100mg Tablets|
215060733|NCT05243979|RADIATION|DEXA scan|bone study
215077800|NCT03614416|DEVICE|Gold standard oximeter|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
214310879|NCT04557657|DRUG|Resin Cement|Resin Cement Convinonal
214310880|NCT03604640|OTHER|Physical Training|Physical exercise program and health education
214310881|NCT03274531|BEHAVIORAL|Referral of hypertensive patients to the attending physician|Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
214310882|NCT00039754|DRUG|Holmium-166-DOTMP|
214310883|NCT04288648|DIAGNOSTIC_TEST|ultrasound examination|ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.
214310884|NCT01761656|DRUG|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
214310885|NCT01761656|DRUG|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
214310886|NCT03722550|OTHER|Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides|Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
214310887|NCT03722550|OTHER|Breast-feeding|Exclusive Breast-feeding up to 4 months of age
214310888|NCT03722550|OTHER|Standard Starter Infant Formula, Follow-up Formula, and Growing-up Milk|Standard Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
214310889|NCT03272607|OTHER|Deprescribing opportunities|An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
214310890|NCT00251446|DRUG|Vinflunine|320 mg/m2 as a 20-minute IV infusion
214310891|NCT03541824|BEHAVIORAL|Body Acceptance Program|The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
214481006|NCT06869954|DEVICE|Internal HAART 200 annuloplasty device|For the INTERNAL group, the HAART 200 internal annuloplasty ring (CorCym, London, UK), specifically designed for BAV morphology, will be used for all patients. Intraoperative sizing for the internal ring is based on the geometric orientation and size of the non-fused cusp. A standard ball sizer is used for the measurement of the non-fused cusp to assess commissural orientation and surface area of the non-fused cusp. Sizing typically results in values of 23mm or 25mm, with other sizes being very rare. Both commissural posts of the internal annuloplasty ring are fixed using two subcommissural sutures \[10\]. A modified technique for placement of transannular looping sutures will be used to secure the internal ring in the subannular position, as recently published \[21\]. Cusp maneuvers (i.e., shaving, thinning of the raphe, central plication sutures) will be performed to achieve an effective height of 8-10 mm. When indicated (i.e., for ascending aortic diameter \> 45mm or aiming to achieve th
214917253|NCT00708214|DRUG|BIBW 2992|BIBW 2992 at high and medium dosages
214917254|NCT00708214|DRUG|BIBW 2992|BIBW 2992 at high and medium dosages
214917255|NCT00708214|DRUG|Letrozole|Letrozole at standard dosage
214310892|NCT06493708|OTHER|Trauma focused psychotherapy: EMDR|14 sessions of psychotherapy with EMDR will be carried out with patients. One session per week, lasting 90 minutes. The first two sessions will be used for the description of the EMDR method and for stabilization, then there will be treatment sessions.
214310893|NCT00425867|BEHAVIORAL|PAR1 polymoprhisms and placental invasion|
214310894|NCT02145728|BEHAVIORAL|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
214310895|NCT02145728|BEHAVIORAL|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
214310896|NCT04225299|DRUG|TOOKAD®|TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
214917256|NCT00708214|DRUG|Letrozole|Letrozole at standard dosage
214917257|NCT02295592|PROCEDURE|TSTstarr+|"TSTstarr+ : a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
214917258|NCT02295592|PROCEDURE|PPH|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
214917259|NCT00217373|BIOLOGICAL|Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine|Given SC
214917260|NCT00217373|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given SC
214917261|NCT00217373|BIOLOGICAL|Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine|Given SC
214917262|NCT00217373|BIOLOGICAL|Sargramostim|Given SC
214917263|NCT00557544|DRUG|metoclopramide|metoclopramide 0,15 mg/kg
214310897|NCT01618409|BEHAVIORAL|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
214310898|NCT04408482|DEVICE|Biliary cannulation|Cannulation of biliary duct by sphincterotome
214310899|NCT02136576|DEVICE|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
214310900|NCT02136576|DEVICE|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
214310901|NCT02136576|DEVICE|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
214310902|NCT01656590|OTHER|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|"1. High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age \& gender~2. 500 cc Formula - Nutren Replete with Fiber overnight \[8 hours\] via gastrostomy tube~3. Conditioning Exercise once daily"
214917264|NCT00557544|DRUG|placebo|placebo per os
214917265|NCT00557544|DRUG|ketoprofen|ketoprofen 1 mg/Kg
214917266|NCT06501391|DRUG|PD-L1/PD-1 inhibitor and chemotherapy|Stable brain metastases patients in this arm will receive PD-L1/PD-1 inhibitors and chemotherapy.
214310903|NCT00271089|PROCEDURE|PBSC Collection|
214310904|NCT00271089|PROCEDURE|Bone Marrow Harvest|
214310905|NCT00271089|DEVICE|CliniMacs Cell Selection System|
214310906|NCT04028752|BIOLOGICAL|Blood collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in the arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
214310907|NCT02299986|OTHER|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
214310908|NCT04317911|OTHER|Catheter Ablation|Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.
214310909|NCT00537381|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
214310910|NCT00537381|DRUG|Prednisone|Prednisone 5 mg orally twice daily.
214310911|NCT00537381|BIOLOGICAL|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
214310912|NCT00537381|DRUG|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
214310913|NCT03434847|OTHER|Education|Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
214310914|NCT02266459|DEVICE|Microwave technology (Medfield Diagnostics)|A microwave measurement will be performed. The procedure will take approximately 15 minutes (the duration of the actual measurements is \< 1 minute) and will not interfere with the patient's standard of care at the Stroke Unit.
214310915|NCT02965274|DRUG|Torrent's Fluoxetine Tablets|
214310916|NCT02965274|DRUG|Warner Chilcott LLC's Sarafem Tablet|
214310917|NCT00864149|DRUG|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
214310918|NCT00864149|DRUG|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
214310919|NCT00680433|DRUG|Ketamine|Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
214310920|NCT00680433|DRUG|Saline|Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
214310921|NCT05025111|DEVICE|Entia Liberty|Home monitoring device
214310922|NCT00731770|DRUG|Advair 250|1 puff bid inhaled
214310923|NCT00731770|DRUG|Placebo- matched|1 puff bid inhaled
214310924|NCT00731770|DRUG|Placebo|Placebo 1 puff bid inhaled
214310925|NCT00731770|DRUG|Advair 250 - matched|i puff bid inhaled
214310926|NCT00418132|DRUG|Thalidomide|Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
214310927|NCT00418132|DRUG|Placebo thalidomide|Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
214310928|NCT03817242|PROCEDURE|Tympanoplasty using tragal cartilage graft|tympanoplasty type I is performed using tragal cartilage in arm 1
214310929|NCT03817242|PROCEDURE|Tympanoplasty using temporalis fascia graft|tympanoplasty type I is performed using temporalis fascia in arm 2
214310930|NCT03184350|RADIATION|Adjuvant pelvic proton radiation|Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
214310931|NCT04690504|OTHER|dim light melatonin onset (DLMO)|A series of saliva samples will be collected and assayed for melatonin so that the timing of melatonin secretion onset can be determined.
214310932|NCT05057442|OTHER|Proprioception assessment, functionality assessment|Proprioception assessment, functionality assessment
214310933|NCT05196542|PROCEDURE|patients with apical prolapse who will do Sacro hysteropexy using mersilene tape|comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure
214310934|NCT02694237|BEHAVIORAL|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
214917267|NCT06501391|RADIATION|SRT or WBRT|Stable brain metastases (BM) patients in this arm will receive stereotactic radiotherapy (SRT) and whole brain radiation therapy (WBRT) according to their BM condition.
214917268|NCT06451419|OTHER|Tests on non motor symptoms|Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.
214917269|NCT06682221|DIETARY_SUPPLEMENT|Whey protein supplementation.|Protein supplementation will be provided through isolated whey protein, commonly known as whey protein isolate, which was generously donated by the Heroes Science Institute (HSI), as stated in the attached declaration. This whey protein isolate, with a vanilla flavor, is packaged in 25-gram sachets, each providing a total of 20 grams of protein per dose/sachet.
214917270|NCT06682221|BEHAVIORAL|Resistance training|The resistance training protocol in the study included seven exercises: high pull, leg extension, leg curl, bicep curl, triceps pushdown, lateral raise, and machine bench press, taking about 60 minutes per session. The first week focused on familiarizing participants with the exercises to ensure proper execution before intensive training began. Training occurred three times a week for 12 weeks, with each exercise performed in 3 sets of 8 to 12 repetitions and rest periods of 1 to 2 minutes. The load was progressively increased by 2% to 10% weekly, based on participants\&#39; ability to complete repetitions with full range of motion. Assessments were conducted before training and 24 hours after the final session to evaluate the effects on physical and functional parameters.
214955081|NCT01491841|DRUG|Bendamustine + Rituximab + Pixantrone|Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).
214310935|NCT02694237|BEHAVIORAL|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
214310936|NCT02694237|BEHAVIORAL|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
214310937|NCT04826146|DEVICE|Validation of qCON versus BIS|Correlation between qCON and BIS values (main outcome) and qNOX and MOAA/S scale are determined
214310938|NCT04099160|OTHER|Evaluation|The Turkish version of the Revised Neurophysiology of Pain Questionnaire will be applied to patients with chronic spinal pain at the beginning of the study and a week later. The Visual Analogue Scale and the Short Form-36 (SF-36) questionnaire will be applied to patients only at the beginning of the stuy.
214310939|NCT00798538|OTHER|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
214310940|NCT00798538|OTHER|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
214310941|NCT05837416|DRUG|blue®m Gel|Oxygen will be released after application Oxygen Releasing Oral Gel (blue®m gel) creating a partially high oxygen pressure (pO2), which aids in restoring the micro-environment for a healthy oral cavity
214310942|NCT05837416|DRUG|NBF GINGIVAL GEL®|Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a nano bio fusion gel containing propolis, nano vitamin C, E and herb extract
214310943|NCT05837416|DRUG|COE-PAK™|It is non eugenol periodontal dressing. It is supplied in two tubes, the contents of which are mixed immediately before use. One tube contains zinc oxide, oil, a gum, and lorothidol. The other tube contains liquid coconut fatty acids thickened with colophony resin and chlorothymol
214310944|NCT04745598|BEHAVIORAL|Control group: Dental Model|\- Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
214310945|NCT04745598|BEHAVIORAL|Computer-assisted teaching format group|\- Patients receive a Powerpoint presentation containing:
214310946|NCT04745598|BEHAVIORAL|Plaque-disclosing group|\- Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
214310947|NCT04745598|BEHAVIORAL|Intra-oral camera group|\- An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
214310948|NCT05899907|DRUG|Telitacicept|160mg once a week for 48 weeks
214310949|NCT05899907|DRUG|Standard of Care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
214310950|NCT05188209|DRUG|MRG003|Administered intravenously
214310951|NCT05084573|DRUG|Liposomal bupivacaine|Single bolus injection 10mL 1.33% LB
214670885|NCT04424498|PROCEDURE|Absorbable Rods and Kirschner Wires|A Boyd incision was applied in all patients; olecranon fractures were reduced first and fixed with Kirschner wires. Then, the displaced radial neck fractures were reduced and fixed using absorbable rods.
214917271|NCT06682221|OTHER|Group Control|The control group will not participate in any of the interventions proposed in the study, meaning it will not receive supplementation or undergo resistance training, serving as a reference to compare the results of the other intervention groups.
214310952|NCT05084573|DRUG|Standard bupivacaine|Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr
214310953|NCT03394482|DRUG|Lu AF35700 5 mg clinical formulation|Lu AF35700 tablets 5 mg oral single dose
214670886|NCT04576351|OTHER|Observation|The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.
214310954|NCT03394482|DRUG|Lu AF35700 5 mg commercial formulation|Lu AF35700 tablets 5 mg oral single dose
214310955|NCT03394482|DRUG|Lu AF35700 10 mg clinical formulation|Lu AF35700 tablets 10 mg oral single dose
214310956|NCT03394482|DRUG|Lu AF35700 10 mg commercial formulation|Lu AF35700 tablets 10 mg oral single dose
214310957|NCT03394482|DRUG|Lu AF35700 20 mg clinical formulation|Lu AF35700 tablets 20 mg oral single dose
214310958|NCT03394482|DRUG|Lu AF35700 20 mg commercial formulation|Lu AF35700 tablets 20 mg oral single dose
214310959|NCT03187457|OTHER|Metronidazole|Women with Bacterial Vaginosis treated with Metronidazole for 5 days
214310960|NCT03187457|OTHER|Control: no treatment|Healthy women without Bacterial Vaginosis
214310961|NCT00897988|GENETIC|gene expression analysis|
214310962|NCT00897988|GENETIC|mutation analysis|
214310963|NCT00897988|GENETIC|polyacrylamide gel electrophoresis|
214310964|NCT00897988|GENETIC|polymerase chain reaction|
214310965|NCT00897988|GENETIC|protein expression analysis|
214310966|NCT00897988|GENETIC|reverse transcriptase-polymerase chain reaction|
214310967|NCT00897988|OTHER|flow cytometry|
214917272|NCT01948440|BEHAVIORAL|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
214955082|NCT01491841|DRUG|Pegfilgrastim|6mg administered on Day 2 of each 21 day cycle
214955083|NCT03711136|PROCEDURE|aortic prosthesis|ascending aortic and/or aortic arch prosthesis with linear vascular prosthesis or hybrid prosthesis
214955084|NCT02933528|DRUG|DSXS Topical product|once daily for 28 days
214310968|NCT00897988|OTHER|immunoenzyme technique|
214310969|NCT00897988|OTHER|immunologic technique|
214310970|NCT00897988|OTHER|laboratory biomarker analysis|
214310971|NCT00897988|OTHER|pharmacological study|
214310972|NCT02912234|DRUG|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
214310973|NCT02912234|DRUG|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
214310974|NCT01478126|DRUG|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
214310975|NCT01478126|DRUG|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.
214310976|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.
214670887|NCT03119376|OTHER|COBPEER|At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
214310977|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.
214310978|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 1|Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.
214917273|NCT01163968|BEHAVIORAL|MOMENTUM|The Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM) intervention is comprised of 6 modules, totaling 52 daily sessions promoting weight reduction, and 4 coaching sessions over the duration of the 12 week MOMENTUM intervention. The MOMENTUM intervention will be delivered using telehealth methods (Viterion telehealth device will be used to deliver the module content and coaching sessions). The intervention was purposively designed to overcome access barriers by using delivery modes accessible to patients in rural settings, in their home and at times convenient to their schedule.
214310979|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 2|Intramuscular (deltoid) injections of placebo (0.5 mL).
214310980|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.
214917274|NCT00650247|DRUG|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fed
214917275|NCT00650247|DRUG|Imitrex® Tablets 100 mg|100mg, single dose fed
214310981|NCT04368988|OTHER|Normal saline solution (NSS), Placebo, Day 21 - Phase 1|Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.
214310982|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2|Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).
214310983|NCT00827255|DRUG|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
214310984|NCT04087187|DRUG|Treatment A|Subject will be given AZD5718 Dose A tablet once daily
214310985|NCT04087187|DRUG|Treatment B|Subjects will be given AZD5718 Dose B tablet once daily
214310986|NCT04087187|DRUG|Treatment C|Subjects will be given AZD5718 Dose C tablet once daily
214310987|NCT05004155|DIAGNOSTIC_TEST|24 hour pH & impedance monitoring|24 hour pH impedance monitoring will be done on healthy subjects so that normative data specific to indian population can be generated.
214310988|NCT00735878|DRUG|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
214310989|NCT02662881|DEVICE|PerFuse Percutaneous Decompression System|Core decompression with PerFuse
214310990|NCT02662881|DEVICE|BioCUE Platelet Concentration System|PRP injection through the PerFuse cannula into core decompression site
214310991|NCT05190198|OTHER|Proprioceptive neuromuscular facilitation|"* Weight shifting in each direction (anteriorly, posteriorly, and lateral side) combined with side-to-side head movements (5 times for each direction).~* One-legged stance with slight knee flexion of another leg for 15 seconds (5 times for each leg).~* One-legged stance with increasing knee flexion of the other leg for 15 seconds (5 times for each leg).~* Standing on a balance pad with shifting weight (anteriorly, posteriorly, and lateral side) 10 times in each direction.~* In standing position, moving the weight left and right maximally.~* In standing position, moving the weight forward and backward maximally.~* In standing position, moving both heels of feet up and down.~* In standing position, bending and stretching both knees by squatting as much as possible."
214310992|NCT05190198|OTHER|conventional therapy|"(Dorsiflexion, planter flexion, eversion and inversion) 10 repetitions for each movement.~(A) Sit to stand (5 times). (B) Standing with shifting Weight anteriorly, posteriorly, and sideway (5 times for each direction). (C) Functional reach sideway and anterior for touching targets set by the therapist (5 times for each direction). (D) Standing on heels for 20 seconds (5 times). (E) Standing on toes for 20 seconds (5 times).~(A) Spot marching (2 min). (B) Walking over the heels, toes, lateral border of feet with the preferred speed (6 min). (C) Tandem walking in a straight line (2 min)."
214310993|NCT00104455|DRUG|activated recombinant human factor VII|
214481007|NCT06869954|DEVICE|double external ring annuloplasty|For the EXTERNAL group, all study patients will undergo double external Dacron ring annuloplasty by simultaneous stabilization of the basal virtual ring and the STJ \[22\]. The surgical technique of double external annuloplasty, detailed by the Lansac group \[22\], involves aortic annulus sizing with a Hegar dilator to select the sizes of the external subannular annuloplasty ring and STJ ring (same size). After deep dissection of the aortic root, 6-7 2-0 pledgeted U sutures are placed circumferentially at the level of the virtual basal ring for external subannular ring implantation. Cusp maneuvers are performed similar to those in the INTERNAL group. STJ stabilization is achieved using an external STJ ring or ascending aortic replacement with a vascular tube graft (e.g., in cases with a high offspring of the right coronary artery). Treatment of the tubular ascending aorta is identical to the INTERNAL group.
214955085|NCT04276077|OTHER|High-frequency electrical muscle stimulation training|High-frequency electrical muscle stimulation training with 50 Hertz during 8 weeks
214310994|NCT00352846|DRUG|Zoledronic Acid|4 mg/m\^2 by vein over 30 Minutes at baseline and 6 months.
214310995|NCT00352846|DRUG|Vitamin D|400 mg by mouth daily
214310996|NCT00352846|DRUG|Calcium Carbonate|1200 mg by mouth daily
214310997|NCT01344187|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
214955086|NCT04276077|OTHER|Low-frequency electrical muscle stimulation training|Low-frequency electrical muscle stimulation training with 10 Hertz during 8 weeks
214310998|NCT01344187|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
214310999|NCT01344187|DEVICE|KXL System|30 mW/cm2
214311000|NCT05211713|DEVICE|Opp|Opp is a universal mental health promoting mobile application for adolescents aged 13-25 years.
214311001|NCT02233244|DRUG|CTX-4430|
214311002|NCT02233244|DRUG|Midazolam|
214311003|NCT02213393|DIETARY_SUPPLEMENT|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
214311004|NCT02213393|DIETARY_SUPPLEMENT|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
214311005|NCT01527682|DRUG|Latanoprost, Dorzolamide|"* Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~* Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
214311006|NCT05540834|DRUG|Alteplase|The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
214311007|NCT05572112|DEVICE|Venous access port implantation|Venous access port implantation
214311008|NCT05887882|BIOLOGICAL|Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells|The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.
214311009|NCT05887882|PROCEDURE|Implantation|Undergo placement of Ommaya reservoir
214311010|NCT05887882|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
214311011|NCT05887882|OTHER|Quality-of-Life Assessment|Ancillary studies
214311012|NCT00031889|DRUG|Exemestane|Exemestane
214311013|NCT00031889|DRUG|Exemestane+bicalutamide|Exemestane as in arm I and oral bicalutamide once daily
214311014|NCT01544751|DRUG|Low dose metformin|500 mg twice a day
214311015|NCT01544751|DRUG|Metformin|1000 mg twice a day
214311016|NCT01544751|DRUG|Atorvastatin|20 mg/day
214311017|NCT00433823|DRUG|Atorvastatin, Ezetimibe|
214311018|NCT01203228|OTHER|Reduced Intensity Conditioning|"Busilvex®:~6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available)~Busulfan:~8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Fludarabine:~5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS"
214311019|NCT01203228|OTHER|Myeloablative conditioning|"Busilvex®:~12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available):~Busulfan:~16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Cyclophosphamide:~120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW"
214311020|NCT01296295|BEHAVIORAL|Lifestyle counseling and spirometry|The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
214311021|NCT01296295|BEHAVIORAL|Smoking cessation advice|Brief smoking cessation advice
214311022|NCT04390594|DRUG|Nafamostat Mesilate|"Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant"
214311023|NCT03637803|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
214311024|NCT03637803|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
214311025|NCT03263416|OTHER|Dedicated and coordinated follow-up|"* Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period~* Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist~* Completion of QLQ-C30 and GIRERD questionnaires"
214311026|NCT03263416|OTHER|Standard follow-up|\- Completion of QLQ-C30 and GIRERD questionnaires
214311027|NCT04713826|DRUG|BAY2586116|160 µg, nasal spray administration.
214311028|NCT04713826|DRUG|Placebo|Placebo matching BAY2586116, nasal spray administration.
214311029|NCT00600938|DRUG|Core Study: Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
214311030|NCT00600938|DRUG|Core Study: Deferoxamine|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
214311031|NCT00600938|DRUG|Extension: deferoxamine to deferasirox|40 mg/kg deferasirox once daily administered 30 minutes before taking food.
214311032|NCT00600938|DRUG|Extension: deferasirox to deferoxamine|DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,
214311033|NCT00600938|DRUG|Deferasirox|
214311034|NCT00600938|DRUG|Deferoxamine|
214311035|NCT03803280|PROCEDURE|ERAS program|ERAS pathway according to the Spanish Via RICA
215077801|NCT03614416|PROCEDURE|SaO2 sampling|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
214311036|NCT01034449|OTHER|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
214311037|NCT03054662|OTHER|Education|Education of patients and caregivers about haemophilia and carriers of haemophilia.
214311038|NCT03054662|DIAGNOSTIC_TEST|Improve biological diagnosis and follow-up of haemophilia|train the laboratory to the diagnosis ans follow-up un haemophilia
214311039|NCT03054662|DRUG|Implement haemostatic non substitutive care of haemophilia|Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
214311040|NCT03054662|OTHER|Implement non haemostatic care of haemophilia|Implement regular physiotherapy, develop dental care, promote the regular use of pain killers
214311041|NCT00549562|DRUG|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
214311042|NCT03072615|DIAGNOSTIC_TEST|Stiffness measurement|Transient Elastopgraphy (TE) or Shear-Wave-Elastography
214311043|NCT07110363|DRUG|BT02|monoclonal antibody injection with intravenous administration every 2 or 3 weeks
214481008|NCT06867133|DEVICE|Electrophysiological rehabilitation|"On the basis of treatment in the control group, postoperative electrophysiological rehabilitation services were started for 30 minutes each time, once a day, for 6 consecutive days as one course of treatment, for a total of one course of treatment. The patch is located at the projection site of the lower abdomen uterus as shown in the figure, simulating bioelectric stimulation parameters: biphasic pulse current, frequency 2Hz, pulse width 3ms.~Simultaneously conducting family health education, including but not limited to:~1. Guidance on postoperative physical recovery after abortion: provide advice on postoperative care, nutrition, activity, and personal hygiene;~2. Introduction to contraceptive methods: Introduce the advantages and disadvantages of various contraceptive methods, and help patients choose the most suitable contraceptive method for themselves;~3. Other related health education: including fertility planning and the best time to conceive again."
214311044|NCT07108725|OTHER|Magnetic Resonance Cholangiopancreatography|Patients who are scheduled for magnetic resonance cholangiopancreatography and have undergone conventional imaging
214311045|NCT07110558|RADIATION|Without prophylactic neck irradiation|Intensity-modulated radiotherapy restricted to the primary tumor, omitting prophylactic neck irradiation.
214955087|NCT04699370|OTHER|cognition-targeted exercise|"All Standardized physical therapy exercises will be performed in a time-contingent .~Goal setting is essentially done together with the patient, focussing on functionality instead of fatigue relief. Progression to a next level of (more difficult) exercises will be preceded by an intermediate phase of motor imagery.~The treating physical therapist will be advised to address patients' cognitions about their problems during the cognition-targeted exercise training, so that patients will have positive perceptions regarding their illness and treatment outcome.~The treating physical therapist will be advised to discuss the patient's perceptions about each exercise. This include discussion of the anticipated consequences of the exercises and challenging the patient's cognitions in relation to the exercises"
214311046|NCT07110558|DRUG|PD-1 antibody (Toripalimab)|Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab 240mg every 3 weeks with a total of 8 cycles as adjuvant anti-PD-1 immunotherapy after CCRT
214311047|NCT07110558|DRUG|Cisplatin|Cisplatin 100mg/m2(every three weeks), Day 1, Day 22, Day 43 of intensity modulated radiotherapy
214311048|NCT07109921|BEHAVIORAL|Structured Early Rehabilitation Nursing Program|A protocolized, phased program. Phase 1 (unconscious): passive range of motion and repositioning. Phase 2 (awake/stable): respiratory training (deep breathing, incentive spirometry), bed mobility (bridging, rolling), and progressive mobilization (sitting at edge of bed). Phase 3 (active): in-place stepping and supervised ambulation. Psychological support was provided throughout. Safety criteria were monitored continuously.
214311049|NCT07109921|OTHER|Usual Care|Standard ICU management for SAP as directed by the primary ICU team. Rehabilitation was discretionary, typically limited to passive range of motion exercises by bedside nurses if deemed necessary.
214311050|NCT07109102|OTHER|Moderate-intensity eccentric cycling|"* This group will perform eccentric cycling exercise twice per week for ten weeks using the Cyclus2 standard eccentric ergometer.~* The intensity will start at 60% of the peak power output (PPO) of the incremental concentric cycling test.~* The intensity will progressively increase by 5% of PPO every 2 weeks (60%-80% PPO)."
214311051|NCT07109102|OTHER|High-intensity eccentric cycling|"* This group will perform eccentric cycling exercise twice per week for ten weeks using the Cyclus2 standard eccentric ergometer.~* The intensity will start at 80% of the peak power output (PPO) of the incremental concentric cycling test.~* The intensity will progressively increase by 5% of PPO every 2 weeks (80%-100% PPO)."
214481009|NCT06866795|DRUG|GT-220F capsule|GT-220F capsule for oral administration
214481010|NCT06867276|DEVICE|Excimer laser|Excimer laser patients undergo ultraviolet b phototherapy treatments at a physical medicine clinic twice a week for four weeks. The device uses a 308nm beam of coherent light, with six spot sizes to avoid healthy skin. The radiation exposure time is 10 minutes, with a maximum dose of 0.65 J/cm². Personal protection standards include wearing protective eyewear for the retina and choroid, as they absorb visible light radiation, which can cause keratoconjunctivitis or cataracts. The thermal effect of the laser can cause superficial carbonization of the epidermis, phlyctens, or erythema, so non-flammable gloves are recommended.
214481011|NCT06867276|DEVICE|Bioptron Pro 1|Patients undergone Bioptron light treatment twice weekly for four weeks at a physical medicine clinic. The treatment is administered by a physiatrist following the manufacturer's user guide. Patients sit in a comfortable chair with their hand on an armrest, holding the Bioptron light probe at a 90° angle for 10 minutes.
214481012|NCT06867965|DEVICE|BellySense|BellySense is a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
214481013|NCT06866665|DRUG|Anticoagulation Monotherapy|Participants in the anticoagulation monotherapy group will receive apixaban 5 mg twice daily during the study period.
214311052|NCT07109102|OTHER|Moderate-intensity concentric cycling|"* This group will perform concentric cycling exercise twice per week for ten weeks using the Lode Excalibur sport ergometer.~* The intensity will start at 60% of the peak power output (PPO) of the incremental concentric cycling test.~* The intensity will progressively increase by 5% of PPO every 2 weeks (60%-80% PPO)."
214311053|NCT07110545|OTHER|Acupuncture|Application of acupuncture on specific acupoints
214311054|NCT07108374|OTHER|Implementation strategies to increase use of transfusion recommendations|Five implementation strategies will be employed in this study to enhance use of the blood transfusion recommendations. These include 1) building consensus, 2) provider education, 3) identifying and empowering champions ,4) use of computerized clinical decision support tools, and 5) provide quantitative metric-based feedback. Strategies 1-3 will occur prior to initiation of CCDS tools. All patients admitted to the PICU following the date of CCDS tool initiation will be considered to be part of the post-implementation phase. The investigators will collect data from the EHR on CCDS use and conduct provider surveys and interviews following CCDS tool initiation. Surveys and interviews will be both be conducted at 6 and 12 months post-CCDS tool initiation. Process and outcomes measures will be assessed before an after use of the implementation strategies.
214481014|NCT06866665|DRUG|Combination therapy|Participants in the combination therapy group will receive clopiogrel 75 mg daily and apixaban 5 mg twice daily during the study period.
214670888|NCT03847337|OTHER|Telehealth-Screening Tool for Autism in Toddlers (STAT)|Structured autism screening tool
214670889|NCT03847337|OTHER|Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)|Semi-structured autism screening tool
214311055|NCT07108868|BIOLOGICAL|CAR-T cells targeting CD19 and CD22|"Using the 3+3 design, the following dose levels will be assessed:~Dose level 1: 0.5x10e6 CAR-transduced T cells/kg; Dose level 2: 1x10e6 CAR-transduced T cells/kg; Dose level 3: 2x10e6 CAR-transduced T cells/kg; Dose level 0: 0.25x10e6 CAR-transduced T cells/kg"
214311056|NCT07108517|BEHAVIORAL|IC-Growth ACT-Based Support Program|IC-Growth Psychosocial Group Intervention is a structured, manualized program designed to enhance post-traumatic growth (PTG) in adults diagnosed with breast, colorectal, or head and neck cancer. The intervention is delivered in small groups (8-10 participants) over 6-8 weeks, with weekly 90-minute sessions led by trained health psychologists. The program integrates evidence-based therapeutic approaches, including Acceptance and Commitment Therapy (ACT), mindfulness, cognitive restructuring, narrative exercises, and interpersonal support-building, with the goal of improving psychological flexibility, resilience, quality of life, and overall well-being.
214311057|NCT06506877|BEHAVIORAL|Implementation of Cognitive Risk Calculator (RC) and Brief Assessment of Cognitive Health (BACH)|Enrolled providers will have access to two cognitive screening tools during the active phase. The first tool is a Cognitive Risk-Calculator (RC), integrated into the Electronic Health Record, to help providers identify patients who are at high risk of exhibiting cognitive decline. The second tool is a computerized cognitive screening tool, the Brief Assessment of Cognitive Health (BACH), which patients complete independently. Results are automatically entered into the patient's medical record, along with patient-specific flags for concerns about depression and/or sleep disorder. The purpose of these tools is to facilitate cognitive screening and treatment for factors that may be contributing to cognitive decline.
214311058|NCT03228134|DRUG|Ke Chuan Liu Wei Granule|Traditional Chinese Medicine
214311059|NCT03228134|DRUG|Yang He Ping Chuan Granule|Traditional Chinese Medicine
214311060|NCT03228134|OTHER|Ke Chuan Liu Wei Granule placebo|Placebo
214311061|NCT03228134|OTHER|Yang He Ping Chuan Granule placebo|Placebo
214311062|NCT01698463|OTHER|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|"The intervention was delivered in two visits and two follow-up phone calls.~* Physician identifies that the patient is at risk of falls or fractures~* Visit one: individualized exercise prescription by a physiotherapist.~* Visit two: motivational interviewing (behavioural counselling) by kinesiologist~* Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions."
214311063|NCT04709575|DRUG|REGN5713|Administered subcutaneously
214311064|NCT04709575|DRUG|REGN5714|Administered subcutaneously
214311065|NCT04709575|DRUG|REGN5715|Administered subcutaneously
214311066|NCT04709575|DRUG|Placebo|Placebo that replaces REGN5713-5714-5715
214311067|NCT05771480|BIOLOGICAL|Durvalumab|Participants will receive 1500 mg every 3 weeks, or every 4 weeks (in combination with chemotherapy every 3 weeks, or every 2 weeks, respectively) from cycle 1 to cycle 8 of chemotherapy. Upon completion, participants will receive 1500 mg every 4 weeks (as monotherapy)
214311068|NCT05771480|DRUG|Gemcitabine monotherapy|Gemcitabine monotherapy as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
214311069|NCT05771480|DRUG|Gemcitabine + cisplatin|Gemcitabine plus cisplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab) for WHO/ECOG PS 2 participants only
214311070|NCT05771480|DRUG|Gemcitabine + oxaliplatin|Gemcitabine + oxaliplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
214311071|NCT05771480|DRUG|Gemcitabine + carboplatin|Gemcitabine + carboplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
214311072|NCT05771480|DRUG|Gemcitabine + cisplatin + S-1|Gemcitabine + cisplatin + S-1 as background gemcitabine-based chemotherapy every 2 weeks (i.e, 4 cycles of durvalumab)
214311073|NCT05771480|DRUG|Gemcitabine + S-1|Gemcitabine + S-1 as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
214311074|NCT05771480|DRUG|Gemcitabine + cisplatin + albumin-bound paclitaxel|Gemcitabine + cisplatin + albumin-bound paclitaxel as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
214311075|NCT01050738|PROCEDURE|Position of catheter|Position of catheter for administration of local anestesia.
214311076|NCT05717140|BIOLOGICAL|Aerosol Sargramostim|Given via inhalation with nebulizer
214311077|NCT05717140|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214311078|NCT05717140|PROCEDURE|Computed Tomography|Undergo CT
214311079|NCT05717140|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214311080|NCT05717140|OTHER|Medical Device Usage and Evaluation|Use Aerogen Solo nebulization device
214311081|NCT05717140|BIOLOGICAL|Nivolumab|Given IV
214311082|NCT03392116|BIOLOGICAL|NGM120|Subcutaneous Injection
214311083|NCT03392116|OTHER|Placebo|Subcutaneous Injection
214311084|NCT02857010|BIOLOGICAL|Allogenic mesenchymal stem cells|Cell therapy
214311085|NCT02857010|OTHER|Placebo|Serum without stem cells
214311086|NCT00514267|DRUG|YM 155|IV
214311087|NCT00514267|DRUG|Docetaxel|IV
214311088|NCT00514267|DRUG|Prednisone|Oral
214311089|NCT00433056|OTHER|STI|CD4 guided treatment interruption
214311090|NCT00433056|DRUG|stable HAART|continuous therapy
214311091|NCT01548131|BEHAVIORAL|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
214311092|NCT03567837|OTHER|Fructose + Glucose Beverage|The intervention is an oral sugar challenge with blood sampling over three hours.
214311093|NCT05616858|BEHAVIORAL|Complex exercise program|Stretching exercise, aerobic exercise, strengthening and balancing exercise
214311094|NCT00322192|BEHAVIORAL|Conventional UK Physical therapy|
214311095|NCT00322192|BEHAVIORAL|Increased intensity of UK conventional physical therapy|
214311096|NCT00322192|BEHAVIORAL|UK conventional physical therapy plus functional strength training|
214481015|NCT06866457|OTHER|Audio hypnosis|"Audio hypnosis via a digital recording (Ellis Traumgeschichte) accessible via QR code"
214481016|NCT06865976|PROCEDURE|Non-Surgical Intervention|For non-surgical treatment of peri-implant mucositis, granulation tissues were removed by titanium curettes (Hu-Friedy, Titanium Implant Scaler Mini-Five, Chicago, IL, USA) during mechanical debridement under local anesthesia
214311097|NCT06377397|DRUG|Antibiotics|"In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment"
214311098|NCT01339351|BEHAVIORAL|Therapeutic Group by Teleconference|10 sessions
214311099|NCT05595512|BEHAVIORAL|Naser Al-Husban|depressive symptoms within 6 months of delivery
214311100|NCT04421911|DRUG|Ketoprofen topical|Ketoprofen topical for 21days
214311101|NCT04421911|DRUG|Diclofenac Topical|Diclofenac topical for 21days
214311102|NCT01074164|OTHER|Standard-of-care treatment for AD|Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
214311103|NCT01074164|DEVICE|Accu-patch pellet|The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
214311104|NCT05457374|PROCEDURE|PVE|Portal vein embolization (PVE) mainly embolizes the portal vein of the resected liver lobe, causing the non-tumor lobe to proliferate, and after tumor lobectomy, the volume of the non-tumor lobe proliferates so that patients with hepatocellular carcinoma that could not be directly surgically resected are given the opportunity to be surgically resected
214311105|NCT05457374|PROCEDURE|LVD|Combining PVE and Hepatic Vein Embolization (HVE) in the same procedure
214311106|NCT00544258|DRUG|PEP005|
214311107|NCT03365596|OTHER|Conventional therapy|According to the status of a patient, optimized therapy will be applied.
214311108|NCT05422781|DRUG|ITI-3000|ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
214311109|NCT02342483|DIETARY_SUPPLEMENT|MSM|
214311110|NCT04254978|DRUG|Bomedemstat|Oral administration
214917276|NCT05294692|BEHAVIORAL|Financial Health Incentives|Caterpillar Health (Caterpillar Health Inc., Leeds, UK) is a multi-component healthy living app that includes financial incentive (points redeemable for consumer goods like movies or gym passes) and was made available to Leeds, UK residents on the Apple iTunes/App Store and Google Play app stores on August 8, 2022. The app was later made available to all of the UK as of October 3, 2022. The app uses the smartphone's in-built accelerometer and/or is integrated with Apple Health and Google Fit to promote physical activity through step tracking. To offer a variety of popular incentives, Caterpillar Health formed partnerships with two major UK based companies, Vue Cinema and Hussle (a gym network system), allowing users to redeem points for free movie and gym passes. Additionally, the company collaborated with a UK health agency (Active Leeds via Leeds City Council) to assist in the development and approval of educational health quiz content.
214917277|NCT02865499|DRUG|acarbose|acarbose treatment with meals
214917278|NCT02996123|OTHER|cad/cam maxillary dentures|patients wearing cad/cam designed and milled dentures
214917279|NCT05534919|DRUG|Nefecon|Nefecon is taken orally as capsules once daily for 9 months.
214917280|NCT01910545|DRUG|OTS167IV|
214311111|NCT02993003|DEVICE|Nasopharyngeal probe|nasopharyngeal probe insertion
214311112|NCT03796780|DIETARY_SUPPLEMENT|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks
214311113|NCT03796780|DIETARY_SUPPLEMENT|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks
214311114|NCT04931056|DEVICE|Titanium Facial Plates|The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.
214311115|NCT04931056|DEVICE|Titanium Mandibular Plates|"The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length."
214670890|NCT02004405|OTHER|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
214311116|NCT04931056|DEVICE|Add-on Condyle|The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.
214311117|NCT04931056|DEVICE|HTR-PEKK|The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
214311118|NCT04918212|DEVICE|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
214311119|NCT00211458|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
214311120|NCT00414804|DEVICE|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
214311121|NCT00414804|PROCEDURE|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
214311122|NCT02940171|PROCEDURE|Early Excision of full thickness burn|first excision surgery of full -thickness burn performed within 48 hours from burn injury
214917281|NCT01931995|DEVICE|TMS positively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
214917282|NCT01931995|PROCEDURE|TMS to negatively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
214311123|NCT02940171|PROCEDURE|Late Excision of full thickness burn|first excision surgery of full -thickness burn performed after 48 hours from burn injury
214311124|NCT02166190|PROCEDURE|Radiofrequency Ablation using EndoHPB Probe|Radiofrequency Ablation using EndoHPB Probe
214311125|NCT02166190|PROCEDURE|Stenting only|Stenting only
214311126|NCT06164132|OTHER|Evaluation|Evaluation through PCOS Phenotypes, measurements of Body weight, height, waist and hip circumferences, Dual-energy X-ray absorptiometry, and Sonographic examination.
214311127|NCT04774978|DEVICE|TTE|Transthoracic echocardiography
214311128|NCT06361628|BEHAVIORAL|multicomponent intervention on vaccination awareness|Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.
214311129|NCT05005390|DEVICE|TTIP ventilation|In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.
214311130|NCT05005390|DEVICE|Mask Ventilation|In mask ventilation, a mask is placed over the nose and mouth.
214311131|NCT03239470|BIOLOGICAL|Cohort 1: 1.0 x 10^8 PolyTregs|Each participant will receive a target cell dose of 1.0 x 10\^8 polyclonal Tregs.
214311132|NCT03239470|BIOLOGICAL|Cohort 2: 2.5x10^8 PolyTregs|Each participant will receive a target cell dose of 2.5x10\^8 polyclonal Tregs.
214917283|NCT01700075|DRUG|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
214917284|NCT01700075|DIETARY_SUPPLEMENT|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
214311133|NCT05527431|DEVICE|high flow nasal cannula|high flow nasal cannula
214917285|NCT05011786|PROCEDURE|hernia repair/ligation of the hernial sac|the inguinal hernia sac is ligated using sutures at the level of internal ring throught an inguinal incision in the open group and using laparoscopic instruments in the laparoscopic group
214917286|NCT02347215|OTHER|Quality of Life assessment|Seattle Angina Questionnaire and other questionnaires.
214917287|NCT02347215|PROCEDURE|Stress imaging|Stress imaging
214917288|NCT04685460|OTHER|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images were used in this study.
214917289|NCT01537926|DRUG|N-acetylcysteine|NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
214917290|NCT01537926|DRUG|Placebo|sugar pill manufactured to minic NAC 600mg capsule
214311134|NCT05527431|DEVICE|noninvasive ventilation|noninvasive ventilation
214311135|NCT01347138|OTHER|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
214311136|NCT00666757|DRUG|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
214311137|NCT00666757|DRUG|fluoxetine|20-80 mgs orally daily for 12 weeks
214311138|NCT00666757|DRUG|citalopram|20-40 mgs orally daily for 12 weeks
214311139|NCT00666757|DRUG|paroxetine|20-50 mgs orally daily for 12 weeks
214311140|NCT00666757|DRUG|sertraline|50-200 mgs orally daily for 12 weeks
214311141|NCT05381584|PROCEDURE|laparoscopy|laparoscopy will be done under anesthesia for management for cases with blind vagina
214311142|NCT02353559|BEHAVIORAL|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
214311143|NCT06517147|DEVICE|Cryogenx cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
214311144|NCT06517147|DEVICE|Regular cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
214311145|NCT03883204|DRUG|Aripiprazole|Initial dose: 10 mg.
214311146|NCT03883204|DRUG|Risperidone|Initial dose: 2 mg.
214481017|NCT06865976|PROCEDURE|Surgical peri-implant therapy|In cases requiring surgical intervention for peri-implantitis, mucoperiosteal flaps were elevated on both vestibular and oral aspects after administration of local anesthesia (articaine with epinephrine 1:200,000) to expose the peri-implant defect. Granulation tissue from the bony defect area was meticulously excised using by titanium curettes (Hu-Friedy, Titanium Implant Scaler Mini-Five, Chicago, IL, USA).
214481018|NCT06865976|PROCEDURE|Second stage surgery|Healthy peri-implant mucosa samples were obtained during the second-stage surgery of implant placement procedures. These samples consisted of incisional biopsies of peri-implant mucosa in direct contact with the implant surface.
214917291|NCT04571905|DEVICE|Osteosynthesis with resorbable Material|Osteosynthesis with Magnezix screws in fractures of the Epicondylus ulnaris and Condylus radialis under General anaesthesia
214311147|NCT05855564|BEHAVIORAL|mindfulness matters|Classroom program will be provided to primary one students in eight primary schools and they will receive an 8 session mindfulness matters program, developed by Eline Snel, delivered by their teachers. Each session lasts for 30 minutes. The program includes mindfulness exercises, psychoeducation, discussion and sharing activities. For students with special needs, same programs will be delivered by teachers or social workers in small groups and each groups has 4 to 7 students. Program content is consistent with the classroom program.
214917292|NCT05553990|OTHER|intestinal flora disturbance|To observe the clinical prognosis of stroke patients complicated with tumor after enterobacterial disorder
214917293|NCT05988177|DRUG|Carrimycin tablets|Carrimycin tablets are administered 400mg a day orally for 7 days.
214917294|NCT03028688|DEVICE|High flow nasal cannula oxygen|Participants will receive high flow nasal cannula oxygen delivery during anesthesia. Participants will also have transcutaneous PCO2 measurements performed using a cutaneous electrode.
214917295|NCT06070142|PROCEDURE|TEP Group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
214917296|NCT06070142|PROCEDURE|eTEP Group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
214917297|NCT02175511|DEVICE|Cloud-based home BP monitoring|"a sphygmomanometer-style BP measurement device (Microlife®, WatchBP Home) that stored and transmitted data to a secure cloud BP system directly via a General Packet Radio Service (GPRS) gateway through cell phone network."
214917298|NCT04429789|BEHAVIORAL|Active-Alert Hypnosis|Participants in this arm will receive four one-hour weekly sessions that will include training in a rapid self-hypnosis method. Participants will learn how to use waking hypnosis to manage fatigue using exercises with sensory experiences.
214311148|NCT02142686|DEVICE|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
214311149|NCT02142686|DEVICE|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
214311150|NCT02142686|DEVICE|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
214311151|NCT03897400|OTHER|AMH levels in young women with crohn's disease will be considered.|Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.
214311152|NCT01995695|BIOLOGICAL|Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
214311153|NCT01995695|BIOLOGICAL|Inactivated subvirion H7N9 influenza vaccine|Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
214481019|NCT06868134|BEHAVIORAL|Web-Based Exercise Group|Participants will follow a structured progressive exercise program through the Physitrack web platform, including stretching, strengthening, and aerobic exercises. The program will be assigned to each participant's profile, and they will complete the exercises three times per week with at least one rest day between sessions. Assessments will be conducted at the beginning and at the end of the 8th week.
214917299|NCT04429789|BEHAVIORAL|Traditional Hypnosis|Participants in this arm will receive four one-hour weekly sessions where participants will learn how to use hypnosis along with relaxation. The exercises and suggestions included in the training will be adapted from the protocol used in a series of studies on the efficacy of self-hypnosis training for the management of chronic pain in persons with disabilities, and from a therapist guide of procedures and hypnotic suggestions for chronic pain.
214311154|NCT01414569|DRUG|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
214311155|NCT04242888|OTHER|pragmatic manual therapies|three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.
214311156|NCT02867540|OTHER|MRI enterography|
214481020|NCT06868134|BEHAVIORAL|Supervised Progressive Exercise Program|Participants in this group will receive a supervised progressive exercise program consisting of stretching, strengthening, and aerobic exercises. The intervention will be conducted three times per week with at least one rest day between sessions.
214481021|NCT06868004|BEHAVIORAL|Holistic Nursing|The intervention in this study is based on Holistic Nursing (HN) for patients with Alzheimer's Disease (AD). It involves a comprehensive approach including psychological support, cognitive rehabilitation, memory enhancement, self-care training, and environmental modifications. Psychological interventions focus on personalized communication and emotional support, aiming to reduce negative emotions and improve trust in the healthcare team. Cognitive interventions include activities like painting, card recognition, and storytelling to enhance cognitive function. Memory interventions use personalized memory aids, and self-care interventions aim to improve daily living skills. The ward environment is adjusted to promote safety and comfort. This multi-faceted approach is designed to improve cognitive function, self-care abilities, and emotional well-being in AD patients.
214917300|NCT00149344|RADIATION|Vertical scar versus inferior pedicle reduction mammoplasty|Vertical Scar Reduction Mammoplasty Inferior Pedicle Reduction Mammoplasty
214917301|NCT00735813|DEVICE|Taurolock|When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
214917302|NCT00735813|DEVICE|Heparin|When not in use the childrens tunneled central venous catheters are locked with heparin
214917303|NCT02064816|DRUG|Rebif®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
214917304|NCT02064816|DRUG|Rebif®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
214311157|NCT02410499|DRUG|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
214311158|NCT02410499|DRUG|MLN1202|MLN1202 solution for SC injection
214311159|NCT02967250|DRUG|ursodeoxycholic acid|Subjects will be provided \~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over \~2 weeks to a stable dose for 4 weeks.
214311160|NCT02134132|BIOLOGICAL|Platelet Gel|Application of platelet gel in patients suffering from diabetic foot ulcers.
214311161|NCT02134132|OTHER|Placebo|The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
214311162|NCT04982666|OTHER|Whole-Food, Plant-Based Diet|This diet is focused on nutritional needs with natural, minimally-processed plant foods.
214311163|NCT04982666|OTHER|FODMAP Diet|An elimination diet of fermentable, oligosaccharides, disaccharides, monosaccharides and polyols
214311164|NCT00733109|PROCEDURE|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
214311165|NCT00733109|OTHER|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
214311166|NCT01582997|DRUG|GSK2118436|Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
214311167|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
214311168|NCT01889784|DEVICE|Placebo phototherapy - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
214311169|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
214481022|NCT06867172|DIAGNOSTIC_TEST|computerized tomography|Little is known about the prevalence of pancreatic steatosis in patients with pancreatic cystic lesions therefore this observational study aims to clarify the data.
214481023|NCT06867172|DIAGNOSTIC_TEST|Endosonography (EUS)|EUS can better evaluate all pancreatic cysts, therefore is mandatory in this observational study.
214917305|NCT04129957|PROCEDURE|Placement of dental implants|All the included patients underwent the placement of at least one implant in either upper jaw, or lower jaw, or both.
214917306|NCT06149611|DRUG|[14C] TQB3616|TQB3616 is a new type of cyclin-dependent kinase (CDK) 4/6 inhibitor.
214917307|NCT06237530|BEHAVIORAL|Visceral body scan (VBS)|The VBS consisted of a mindfulness exercise designed to bring awareness to visceral sensations in the cardiac, respiratory, gastrointestinal, and urinary systems. These physiological systems were chosen because most of the paradigms developed in the literature to assess interoception focus on them (Khalsa et al., and they are widely recognized in the literature as interoceptive senses (Nord \& Garfinkel, 2022)
214311170|NCT01889784|DEVICE|Placebo phototherapy - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
214311171|NCT05828277|DRUG|repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
214311172|NCT05925491|DRUG|Pembrolizumab|Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care
214311173|NCT05925491|DRUG|Cisplatin|Cisplatin 75mg/mq in combination with pembrolizumab 200 mg and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses.
214481024|NCT06868043|DEVICE|FiberSense System|FiberSense system, a novel CGM system using interstitial fluid (ISF) glucose as an indicator of blood glucose levels by diabetic patients
214481025|NCT06866743|OTHER|There will be no intervention.|This research focuses on examining seasonal variations in kidney function among postmenopausal females. As an observational study, our approach is non-interventional.
214481026|NCT06868121|OTHER|OMGYES.com|OMGYES.com is an interactive website that offers information, video tutorials, interviews, tips, and resources to explore female sexual pleasure through groundbreaking research that's told through the real-life experiences of women of all ages and life stages.
214670891|NCT02004405|OTHER|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
214311174|NCT05925491|DRUG|Docetaxel|Docetaxel 75 mg/mq in combination with pembrolizumab 200 mg and cisplatin 75 mg/mq every three weeks (Q3W) for 3 courses.
214311175|NCT05925491|DRUG|Carboplatin|Carboplatin AUC 5 alternative to Cisplatin if toxicities occur.
214311176|NCT02047799|DIETARY_SUPPLEMENT|Calcitriol|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
214311177|NCT02047799|DIETARY_SUPPLEMENT|Control|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
214311178|NCT01660711|DRUG|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
214311179|NCT01660711|DRUG|Leucovorin|400 mg/m2 by IV infusion over 2 hours
214311180|NCT01660711|DRUG|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
214311181|NCT01660711|DRUG|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
214311182|NCT05993611|PROCEDURE|Biopsy|Undergo biopsy
214311183|NCT05993611|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214917308|NCT06237530|BEHAVIORAL|Somatosensory body scan (SBS)|The SBS consisted of a mindfulness exercise designed to bring awareness to tactile (e.g., itching) and musculoskeletal (e.g. g., tension) sensations in different parts of the body, namely, the head and neck, back, arms, and legs. Body scan exercises typically focus on these types of bodily cues (in addition to breathing) (Williams, 2010).
214311184|NCT05993611|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD6-CAR Tregs IV
214311185|NCT05993611|PROCEDURE|Computed Tomography|Undergo CT
214311186|NCT05993611|PROCEDURE|Echocardiography|Undergo ECHO
214311187|NCT05993611|OTHER|Electronic Health Record Review|Ancillary studies
214311188|NCT05993611|PROCEDURE|Leukapheresis|Undergo leukapheresis
214311189|NCT05993611|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214311190|NCT05993611|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
214311191|NCT05993611|OTHER|Quality-of-Life Assessment|Ancillary studies
214481027|NCT06865703|OTHER|diaphragmatic release technique|The participant lay in the supine position and the therapist stood at the participant's head, the therapist passed his hands (the hypothenar and the lateral 3 fingers) under the costal cartilage of the seventh to the tenth ribs bilaterally, with the therapist's forearm aligned up toward the subject's shoulder. Then, the therapist quietly drew the diaphragm in and upward during the inspiratory phase. The therapist then went deeply with both hands toward the inner costal margin during the expiratory phase to resist the rebounding movement of the thoracic cage. The depth of this manual contact was progressively increased in subsequent respiratory cycles. The maneuver was repeated in 4 sets, each of which consisted of 5 deep breaths with 2-min intervals in between if needed
214481028|NCT06865703|OTHER|rib raising technique in group A|• The patient is in supine position and therapist hand under the thorax The fingertips take up contact with the angular costae and move it up and in lateral traction and maintained and this will repeated until all ribs on the side are mobilized. This movement will be repeated several times until perceives an improvement in the rib flexibility
214670892|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 10mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
214670893|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 20mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
214917309|NCT06237530|BEHAVIORAL|External control meditation (ECM)|The ECM consisted of a mindfulness exercise designed to bring awareness to external stimuli, including sounds and visual properties of the environment.
214670894|NCT03763487|DIAGNOSTIC_TEST|venous blood sampling|Venous blood samples to determine memory B lymphocytes.
214311192|NCT05993611|BIOLOGICAL|Tafasitamab|Given IV
214311193|NCT05993611|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214311194|NCT03293251|PROCEDURE|Trabeculectomy with MMC|glaucoma surgeries
214311195|NCT03267862|OTHER|there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.
214311196|NCT04333810|DEVICE|Whoop strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).
214311197|NCT03945812|DRUG|Granulocyte Colony Stimulating Factor|Filgrastim, Amgen, California, USA 300 mg/1.0 mL
214311198|NCT03945812|OTHER|Platelet Rich Plasma Arm|Platelet Rich Plasma Arm
214311199|NCT03945812|OTHER|Saline|Saline 9%
214311200|NCT00969787|DRUG|DWP05195|tablets, oral administration, single and multiple administrations
214311201|NCT05955339|OTHER|NOTES|The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
214311202|NCT05955339|OTHER|AUDIO|The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
214311203|NCT01865279|DRUG|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
214311204|NCT01865279|DRUG|placebo|Ascending single doses - 5 dose levels
214311205|NCT01865279|DRUG|insulin degludec|A single dose corresponding to that of isophane human insulin
214311206|NCT01865279|DRUG|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
214311207|NCT06182826|PROCEDURE|Core Stability protocol|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Curl Up Side Planks Bird Dog Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
214311208|NCT06182826|PROCEDURE|Routine exercise therapy|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
214311209|NCT00003075|DRUG|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
214311210|NCT00003075|OTHER|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
214311211|NCT03638310|PROCEDURE|intratympanic application of gentamicin|under local anesthesia is gentamicin instilled through tympanic membrane to tympanic cavity
214311212|NCT03638310|PROCEDURE|microsurgical removal of vestibular schwannoma|surgery under general anesthesia
214311213|NCT01759108|DRUG|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
214311214|NCT06832098|COMBINATION_PRODUCT|Nicotine patches plus nicotine mouth spray|Transdermal HABITROL® patches (21mg/24 hrs) plus NICORETTE® QUICKMIST mouth spray (1mg nicotine/spray dose)
214311215|NCT06832098|OTHER|Nicotine Tapering Plan|Tapering plan based on their current e-juice nicotine concentration and frequency of vaping upon entry to the trial. Participants will use their own vapes and nicotine e-liquid.
214311216|NCT01725425|OTHER|Control|The control is designed to determine average mood.
214311217|NCT01725425|OTHER|Increase Portion Size|The purpose is to determine whether a change in mood will occur.
214311218|NCT01725425|OTHER|Decrease Portion Size|The purpose is to determine whether a change in mood will occur.
214311219|NCT01725425|OTHER|Mixed Portions|The purpose is to determine if a change in mood will occur.
214311220|NCT04608903|DIETARY_SUPPLEMENT|L-sulforaphane 1%|Administration of 4g L-sulforaphane per day, for 2 months
214311221|NCT04608903|DIETARY_SUPPLEMENT|Placebo Group|Administration of 4g corn starch colored with chlorophyll, per day, for 2 months
214311222|NCT06201754|OTHER|Measure air quality|Measure air quality, including PM2.5、PM10
214311223|NCT05616104|DEVICE|FLEX Vessel Prep System|"The FLEX Vessel Prep System to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion.~Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding Instructions for Use. Once advanced into the lesion, the balloon should be inflated according to the site's standard of care."
214311224|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
214311225|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
214311226|NCT00076687|DRUG|saline|Saline injection at Day 1, Week 12, Week 18
214917310|NCT03646864|DRUG|ACT-541468|ACT-541468 will be orally administered as a tablet (50 mg strength) at a once daily (o.d.) dose of 50 mg in the evening.
214311227|NCT05794152|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
214917311|NCT03646864|OTHER|Placebo|Placebo will be orally administered as a tablet matching ACT-541468, o.d. in the evening.
214311228|NCT05794152|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
214311229|NCT05794152|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
214917312|NCT01307592|BIOLOGICAL|rituximab|
214917313|NCT01307592|DRUG|gemcitabine hydrochloride|
214917314|NCT01307592|DRUG|lenalidomide|
214917315|NCT01307592|DRUG|oxaliplatin|
214311230|NCT05553054|OTHER|Quantification of IV drugs wastage|"Drugs are prescribed depending on physician discretion.~Specific collection bins are provided to ICU. Healthcare teams discard syringes labelled with name and dilution which have been used to prepare drugs into these bins. After 24 hours of collection, bins are analyzed by investigators."
214311231|NCT05953428|OTHER|Opioid Sparing Anesthesia Protocol (OSA)|OSA protocol will include boluses of dexmedetomidine and ketamine at anesthesia induction, followed by a ketamine infusion that will continue until PACU discharge. Another bolus of ketamine will be administered upon surgical incision and another dexmedetomidine bolus will be given at surgical closure to reduce the use of opioids.
214311232|NCT05953428|OTHER|Opioid Based Anesthesia Protocol (OBA)|The OBA group will be administered a saline infusion at the same rate of the ketamine infusion (only while in the PACU) up until PACU discharge so that surgeons, patients, and PACU nurses will be blinded. The OBA group will be administered fentanyl 100 mcg IV for anesthesia induction followed by 50 mcg IV boluses when heart rate or systolic blood pressure is 20% above baseline throughout the case.
214311233|NCT00826800|DRUG|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
214311234|NCT01206179|BIOLOGICAL|cell injection|Injection of mesenchymal cells in fractured zone
214311235|NCT04193722|DRUG|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a multiperson hyperbaric oxygen chamber. Standard hyperbaric oxygen therapy provided as reimbursed by insurers.
214311236|NCT06180447|BIOLOGICAL|Hepatitis B vaccine, rabies vaccine, HPV vaccine, influenza vaccine|Exposure was defined as use of the vaccine 90 days before the last menstrual period and during pregnancy.
214311237|NCT00976742|BEHAVIORAL|Endurance exercise training|
214311238|NCT03136003|DRUG|DDAVP|The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
214347081|NCT04728243|OTHER|WHO COVID-19 online training|The WHO novel coronavirus 2019 online training series provides a general introduction to COVID-19 and similar respiratory infections and information on what facilities and professionals should be doing to prevent and respond to COVID-19 cases. The training is similar in length to the WHO QualityRights training (13 h 15 min vs. 19 hours) and is intended for health professionals and other stakeholders.
214347082|NCT06235216|DRUG|Sacituzumab govitecan|Dose of 10 mg/kg intravenously
214347083|NCT05427786|DRUG|Nicorandil|Administer 8cc or more of the prescribed drug according to randomization into the coronary artery before starting balloon therapy. The stent treatment method follows the standard treatment method.
214917316|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 1g|
214917317|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 5g|
214311239|NCT03136003|BEHAVIORAL|Exercise|The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
214311240|NCT06447493|OTHER|Osteopathic Manipulative Treatment-Spencer's Technique (Modified)|Combination OMT approach utilizing Muscle Energy Technique (MET), Articulatory Technique (ART), and Myofascial Release (MFR). It is a series of direct OMT addressing the barrier of somatic dysfunction (SD) with the goal of restoring neurovascular balance and improved motion of the shoulder girdle and glenohumeral joint. Utilizing these three OMT techniques, the practitioner attempts restoration of glenohumeral joint motion using shoulder extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction, external rotation, internal rotation, and distraction in abduction. The study uses a modified version of the Spencer technique, done in the seated position for patient comfort, as well as adding to the treatment sequence: latissimus dorsi, pectoralis minor-major, serratus anterior, and rhomboid major-minor. Adding these muscles into treatment will help to address and correct sternoclavicular joint SD, acromioclavicular joint SD, and scapular SD.
214311241|NCT06447493|OTHER|Rest|10 minute rest period.
214311242|NCT02029001|DRUG|Nilotinib (400 mg BID)|Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
214311243|NCT02029001|DRUG|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).
214311244|NCT02029001|DRUG|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
214917318|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 10g|
214311245|NCT02029001|DRUG|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
214311246|NCT02029001|DRUG|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT\* or amplification /translocation of the genes and/or of the ligands.
214917319|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 15g|
214917320|NCT02260336|DRUG|Celecoxib Capsule 400 mg daily|
214917321|NCT00934336|OTHER|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
214311247|NCT02029001|DRUG|Olaparib (300 mg BID)|"ATM, BAP1 et BRIP1 Mutation only if double hit documented; BRCA2, BRCA1, RAD51C, PALB2, RAD51D Mutation; BRCA1, BRCA2, ATM and BAP1 Loss; BRCA1, BRCA2, ATM and BAP 1 : mutation and heterozygote deletion. except for patients eligible to olaparib's available labels and reimbursements in France.~NOTE : only prostate cancer with RECIST 1.1 evaluable disease are eligible until the French price and reimbursement"
214670895|NCT03763487|PROCEDURE|spleen volumetry|Ultrasound examination of spleen to scaled the size.
214917322|NCT00934336|OTHER|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
214917323|NCT02641418|OTHER|Supervised exercise programme|supervised exercise programme
214917324|NCT05750602|DIETARY_SUPPLEMENT|LIMICOL|Suplementation with LIMICOL, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
214917325|NCT05750602|DIETARY_SUPPLEMENT|PLACEBO|Suplementation with PLACEBO, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
214917326|NCT04341805|PROCEDURE|PrevOmega|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of AGHO depending on the randomization performed.
214917327|NCT04341805|PROCEDURE|Physiological saline|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of SSF depending on the randomization performed.
214917328|NCT01732458|DRUG|Aprepitant|Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.
214311248|NCT02029001|COMBINATION_PRODUCT|Durvalumab + Tremelimumab|Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
214311249|NCT05243654|DRUG|Metformin|Metformin 1000mg XR OD + standard-of-care MDT
214311250|NCT05243654|DRUG|Placebo|Placebo + standard-of-care MDT
214311251|NCT04627701|DEVICE|Omega|Omega Implantation
214311252|NCT03788096|BEHAVIORAL|Peer Support with Motivational Interviewing|Mentors will trained in motivational interviewing and will conduct weekly telephone calls with participants randomized to the PS-PICS peer support intervention arm.
214311253|NCT03788096|BEHAVIORAL|Usual Care Group|Usual care.
214917329|NCT01732458|DRUG|Placebo to Aprepitant|
214917330|NCT01732458|DRUG|Ondansetron|Administered IV at a dose of 4 mg for participants \>40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants \<1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.
214917331|NCT01732458|DRUG|Placebo to match ondansetron|Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
214670896|NCT03388983|OTHER|6-week prehabilitation|Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
214670897|NCT00920465|DRUG|mifegyne and cytotec|One day dosage versus two days dosage
214670898|NCT04498858|OTHER|Patient interview|"Patient will be interviewed :~* tobacco consumption~* reported question asked by the dentist about his/her tobacco consumption~* presence and nature of reported advices given by the dentist~* presence and nature of actions proposed by dentists for patients reporting tobacco consumption, including prescription of NRT~* presence and nature of the actions carried out or envisaged by these patients, including - smoking cessation~* contact with the general practioner~* Fagerstrom score (2 questions)~* demographic variables, age, sex, level of education~* satisfaction"
214670899|NCT01556945|BIOLOGICAL|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
214311254|NCT06576063|DEVICE|Lumoral Treatment|Home-use of photodynamic antibacterial dual-light device, used with a marker substance (indocyanine green)
214311255|NCT06576063|BEHAVIORAL|Standard oral hygiene methods|Best available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic
214311256|NCT05664490|BEHAVIORAL|Youth Friendship Bench SA|The intervention includes: 5 individual counseling sessions; one optional in-person or WhatsApp-based group counseling session; optional remote counseling sessions; and optional one-way SMS messages to provide reminders about upcoming visits. During the initial session, participants will meet with the trained counselor to discuss mental health challenges, identify problems in their life that affect their mental health and PrEP use, generate alternative solutions, make decisions about the alternatives, and collaboratively decide on a plan to implement the solutions. During follow-up counseling sessions, participants will discuss progress in implementing solutions to address the problems they identified in prior sessions with the lay counselor. They will also discuss any other mental health challenges and problems in their life that affect their mental health and PrEP use which they would like to address.
214311257|NCT05414045|PROCEDURE|Autologous testicular tissue transplantation of prepubertal frozen testicular tissue|"Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells (SSCs).~If the patient has a childwish on adult age and in case no spermatozoa are found in the ejaculate, the investigators will perform autologous testicular tissue transplantation with the primary objective being to restore spermatogenesis and fertility."
215060734|NCT03441022|DEVICE|Amiigo Watch Only|Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.
215060735|NCT03441022|DEVICE|Amiigo Watch + BodyGuardian|Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.
214311258|NCT05033288|OTHER|Electronic Health Record Review|Medical records are reviewed
214311259|NCT05033288|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
214347084|NCT06265116|OTHER|One-step universal adhesive|Each patient will receive a class II restoration using the corresponding group adhesive
214347085|NCT00718718|DRUG|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
214347086|NCT00718718|DRUG|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
214347087|NCT00718718|DRUG|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
214347088|NCT00718718|DRUG|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
214347089|NCT00718718|DRUG|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
214347090|NCT03460340|DEVICE|prefrontal deep rTMS of H1 Coil|prefrontal deep rTMS of H1 Coil
214347091|NCT01117116|DRUG|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
214347092|NCT01117116|DRUG|budesonide and formoterol|80/4.5 two puffs twice daily
214347093|NCT02516059|DRUG|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
214347094|NCT02516059|DRUG|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
214347095|NCT02516059|DRUG|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
214347096|NCT02516059|DEVICE|epidural catheter|
214347097|NCT05317468|OTHER|Contraceptive Counseling|Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.
214347098|NCT04335877|OTHER|Private sector component + modified BCC|Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
214347099|NCT03144726|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
214311260|NCT00971347|OTHER|Extra sugar-free chewing gum sticks|90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
214311261|NCT00971347|BEHAVIORAL|nutrition brochure|one-time at baseline visit
214311262|NCT04553432|DEVICE|Amniotic membrane Omnigen[TM]|17mm circular disk of processed amniotic tissue donated by mother after birth with a 6mm laser cut aperture to allow unimpeded vision https://www.nu-vision.co.uk/omnigen
214311263|NCT04553432|DEVICE|Bandage soft Contact Lens OmniLenz[R]|18mm soft silicone-hydrogel contact lens https://www.nu-vision.co.uk/omnilenz
214311264|NCT02939560|DEVICE|NeuroStar® TMS device (Neuronetics, Atlanta, GA)|Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
214311265|NCT06389747|OTHER|BFR technique|For BFR application, Airbands brand, wireless, automatic training cuffs will be used. During application, it will be ensured that the device module faces forward and the cuff will be fixed in the correct position by wrapping the band around the metal ring. There will be a space between the skin and the cuff that can fit two fingers. The cuff will then be paired via Bluetooth with the Airbands app installed on the phone. BFR cuffs will be placed proximal to the biceps brachii muscle and pressure will be applied. The cuff will be inflated to automatically detect limb pressure. BFR application with 80% pressure to one group of participants and 20% pressure to the other group will be applied simultaneously with the exercise.
214311266|NCT01170494|DRUG|ergocalciferol 2000 IU orally, daily|ergocalciferol 2000 IU orally, daily
215060736|NCT05710731|OTHER|Use of simulation in urinary catheterization training|To train students on urinary catheterization by using one of 3 different simulation methods.
214311267|NCT01170494|DRUG|ergocalciferol 25000 IU oraly every 2 weeks|ergocalciferol 25000 IU oraly every 2 weeks
214311268|NCT01170494|DRUG|ergocalciferol 50000 IU orally every 4 weeks|ergocalciferol 50000 IU orally every 4 weeks
214311269|NCT01170494|DRUG|ergocal1000 IU & cholecal 1000 IU orally daily|ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
214311270|NCT01170494|DRUG|cholecalciferol 2000 IU orally daily|cholecalciferol 2000 IU orally everyday
214311271|NCT01170494|DRUG|Cholecalciferol 25000 IU orally every 2 weeks|Cholecalciferol 25000 IU orally every 2 weeks
214311272|NCT01170494|DRUG|Cholecalciferol 50000 orally every 4 weeks|Cholecalciferol 50000 orally every 4 weeks
214311273|NCT01170494|DRUG|placebo orally everyday|placebo orally everyday
214670900|NCT01556945|BIOLOGICAL|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
214670901|NCT01556945|OTHER|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
214670902|NCT01556945|OTHER|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
214670903|NCT01400334|RADIATION|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine \[HED, 20 mCi (740 MBq)\] to quantify sympathetic nerve function, b) 13N-ammonia \[NH3, 20 mCi (740 MBq)\] for regional perfusion, and c) 18F-2-deoxyglucose \[FDG; 6.5 mCi (241 MBq)\] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
214670904|NCT05354284|OTHER|online questionnaire|Questionnaire at three timepoints
214670905|NCT04802356|DRUG|Belantamab mafodotin|"Dose of 2.5 mg/kg/every 8 weeks on day 1, intravenously, Induction: three induction cycles with belantamab mafodotin in combination with VRd.~Consolidation: one cycle after 90 days of transplantation with belantamab mafodotin in combination with VRd.~Maintenance: belantamab mafodotin in combination with lenalidomide until disease progression, patients withdrawal, death or up to two years, whichever occurs first"
214311274|NCT03063892|DRUG|Tranexamic Acid (TXA)|Tranexamic acid is an antifibrinolytic used to control bleeding
214311275|NCT03063892|DRUG|Saline solution|Saline solution is used as the placebo comparator
214311276|NCT04773158|BEHAVIORAL|Clinical Decision Support|The intervention clinic sites will be provided access to a Clinical Decision Support System (CDSS) that incorporates the Rome IV criteria for evidence-based care recommendations for functional gastrointestinal disorders (FGIDs)
214311277|NCT03002012|DRUG|Sertraline|sertraline 400mg/day
214311278|NCT03002012|DRUG|Placebo Oral Tablet|matched placebo tablet
214311279|NCT03002012|DRUG|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
214311280|NCT06113198|BIOLOGICAL|rMenB+OMV NZ|3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.
214311281|NCT02129985|DRUG|Exenatide|Exenatide (10 ug/bid for 3 months)
214311282|NCT02129985|DRUG|Metformin|Metformin 850 mg/bid for 3 months
214347100|NCT03144726|OTHER|Standard dressing|A standard dressing will be applied to the amputations in this arm of the study
214347101|NCT01713803|DRUG|Buprenorphine and naloxone|
214347102|NCT05404438|OTHER|Oral Appliances|A pre-experimental, single-group pretest-posttest design was performed. At stage one, each participant underwent a 2-day general sleeping test and a 2-day sleeping test with mouth tape. At stage two, participants underwent conventional impressions for TPD and TED appliances and were then randomly assigned to wear the TPD or TED; together for two days of sleeping test with their mouth taped. After a 2-day break (washout), with the same procedure, participants wore the other appliance for another 2-day sleeping test and decided accordingly the optimal appliance that had reduced their ODI scores more. At stage three, participants wore their optimal appliance mouth-taped during sleep for 6 weeks. At the end of the intervention, all participants underwent few days sleeping test for final results.
214347103|NCT06573333|PROCEDURE|Umblical Cord Clamping|Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate
214311283|NCT03167879|BEHAVIORAL|safer conception counseling|Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
214311284|NCT00854945|DRUG|ON 01910.Na|1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
214311285|NCT01923415|PROCEDURE|No intervention, skin biopsy|All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).
214917332|NCT05517668|DRUG|Intravenous infusion of N-acetylcysteine|If randomized to Control, the participant will receive only N-acetylcysteine. The dose will be determined by the site investigator. Typical continued infusion rate is 6.25 mg/kg/hr. The control drug (D5W) will be administered using the same schedule as fomepizole.
214917333|NCT05517668|DRUG|Intravenous infusion of Fomepizole (4-MP)|If randomized to fomepizole, the proposed infusion schedule for fomepizole closely mirrors the dosing outlined in the medication's package insert. Specifically, the Antizol (fomepizole) doses (bags) #1-5 allocated for the study will precisely adhere to the manufacturer's recommendations from the package insert. This entails an initial loading dose of 15 mg/kg followed by four subsequent doses of 10 mg/kg. The dose of fomepizole will not be adjusted based on age, presence of liver injury or renal insufficiency.
214917334|NCT05724251|OTHER|healthy|no intervention
214311286|NCT01923415|PROCEDURE|No intervention, blood collection|Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.
214311287|NCT01923415|PROCEDURE|No intervention, urine collection|Urine will be collected from all participants.
214311288|NCT05156866|DRUG|TORL-2-307-ADC|antibody drug conjugate
214311289|NCT04508790|DRUG|Dexamethasone|Given PO
214311290|NCT04508790|DRUG|Leflunomide|Given PO
214311291|NCT04508790|DRUG|Pomalidomide|Given PO
214311292|NCT05457257|DRUG|olaparib|300 mg (2x 150 mg tablets) twice daily
214311293|NCT05457257|DRUG|enzalutamide|160 mg (4 x 40 mg capsules) once daily
214311294|NCT05457257|DRUG|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
214311295|NCT05457257|DRUG|Prednisone|5mg(5mg x 1 tablet) twice daily
214311296|NCT06562296|OTHER|Amnion-Intermediate-Chorion|Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
214311297|NCT06562296|OTHER|Amnion-Chorion-Amnion|Dehydrated human placental trilayer allograft derived from donated human tissue.
214917335|NCT05724251|OTHER|periodontitis|no intervention
214917336|NCT02639650|DRUG|Etoposide|etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle
214917337|NCT02639650|DRUG|actinomycin D|actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle
214917338|NCT02639650|DRUG|methotrexate|methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h\*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
214917339|NCT02639650|DRUG|vincristine|vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle
214311298|NCT06562296|PROCEDURE|Standard of Care|Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
214311299|NCT06370156|DRUG|Adalimumab|To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.
214311300|NCT04045496|DRUG|JAB-3312|JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
214481029|NCT06865703|OTHER|THORACIC LYMPHATIC PUMP TECHNIGUE|"* Patient in the supine position and therapist will stand the participant's head, facing The therapist places the thenar eminence of each hand to the pectoral region and infra clavicular and the other fingers were spread around the thoracic cage and angled toward the body's side to create consistent, compressive force across the thoracic cage The participant was then allowed to breathe in deeply and breath out. The therapist slowly reduced the compressive force and withdrew the participant.~* During breath out rhythmic oscillatory compression in the posterior and caudal direction was applied to the chest wall.~* By the end of the expiratory phase, the compressive force was maintained, and ask to take another deep breath. In this way, the participant encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver was repeated for 5 respiratory cycles, then hands to allow for full inspiration."
214670906|NCT04802356|DRUG|Bortezomib|Dose of 1.3 mg/m2, on days: 1, 4, 8 and 11 of every 28-day cycle. Subcutaneous administration Induction: 6 cycles Consolidation: 2 cycles
214917340|NCT02639650|DRUG|cyclophosphamide|cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
214917341|NCT02639650|DRUG|Paclitaxel|paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle
214917342|NCT02639650|DRUG|Cisplatin|cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle
214917343|NCT02639650|DRUG|Carboplatin|carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin
214311301|NCT05228288|PROCEDURE|Conventional direct laryngoscopy (CDL)|This procedure is considered the gold standard for endotracheal intubation and is routinely used in the peri-operative setting as well as in intensive care and emergency medicine.
214311302|NCT05228288|PROCEDURE|Video assisted laryngoscopy with Macintosh-shaped blade (M-VAL)|This device is implemented in most german hospitals and used when conventional direct laryngoscopy is not sufficient. By positioning the camera at the tip of the blade, the achievable field of view onto the glottic plane is improved.
214311303|NCT05228288|PROCEDURE|Video assisted laryngoscopy with hyper-angulated blade (H-VAL)|The hyper-angulated blades are often used as a backup instrument when a view of the glottic plane cannot be achieved with the Macintosh blade due to anatomic abnormalities, even with a video-assisted laryngoscope.
214311304|NCT00864877|DEVICE|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
214311305|NCT06216041|DRUG|IMM-H014|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
214670907|NCT04802356|DRUG|Lenalidomide|Dose of 25 mg/day on days 1-21 of every 28-day cycle. Oral administration. Induction: 6 cycles Consolidation: 2 cycles Maintenance: 10 mg/day on days 1-21 continuously (may increase up to 15 mg/day) until disease progression, patients withdrawal, death, whichever occurs first
214311306|NCT06216041|DRUG|Placebo|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
214311307|NCT06216041|DRUG|IMM-H014 ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
214311308|NCT06216041|DRUG|Placebo ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
214311309|NCT05694546|BEHAVIORAL|Community Health Worker Post-Discharge Intervention|Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
214311310|NCT03350854|BEHAVIORAL|Patient Preference in Treatment Decision Making|The roles are divided into two active roles, a collaborative (or shared) role, and two passive roles in the Patient Preference scale questionnaire. Once the questionnaire is administered, the patient will then proceed to original surgical appointment. The provider is informed of the patient's preferred role and has a discussion with them patient about this in the intervention group, but not in the control group.
214311311|NCT04682184|DRUG|Propranolol|Administered orally.
214311312|NCT04682184|DRUG|Pseudoephedrine|Administered orally.
214311313|NCT04682184|DEVICE|Wearable Biosensor Patch Device|Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.
214311314|NCT05506852|BEHAVIORAL|Web-based training strategy|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game using specific strategies, in order to optimize the performance."
214311315|NCT05506852|BEHAVIORAL|Web-based regular training (no strategy)|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game under regular game instructions."
214311316|NCT01589445|DRUG|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
214311317|NCT01589445|DRUG|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
214311318|NCT03148418|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
214311319|NCT03148418|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
214311320|NCT01912144|OTHER|Coffee|
214311321|NCT03806439|OTHER|Radical cystectomy.|Adult patients undergoing radical cystectomy.
214311322|NCT05831202|DEVICE|The SEAL™ Saccular Endovascular Aneurysm Lattice System|All adult subjects between 22 and 80 years of age and presenting with an unruptured or ruptured saccular Wide Neck intracranial aneurysm with less or equal to 19 mm in its equatorial width (2mm-19mm range) that in the opinion of the Principal Investigator (PI) requires treatment and suitable candidate for intrasaccular flow diversion treatment, who meet all eligibility criteria, will be considered for study enrollment.
214311323|NCT06080386|DIAGNOSTIC_TEST|UDFF|quantification of liver fat: UDFF (lipid fraction derived from ultrasound) from one of the probes of an ultrasound system
214311324|NCT01835743|DEVICE|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
214311325|NCT01835743|DEVICE|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
214311326|NCT04846725|OTHER|Data collection|"Collect in medical records :~* Filter's retrieval rate~* Complications of vena cava filters~* Predictive factors of attempted inferior vena cava filters retrieval: age, the distance between the patient's home and the hospital, the indication or not given by the therapeutic medicine department, patients referred by external structures, patients whose filter was installed during the medical on-call period, the absence of a written request for filter placement, the presence of active neoplasia at the time of filter placement, a peri-surgical context."
214311327|NCT01505608|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
214311328|NCT01505608|DRUG|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
214311329|NCT01505608|DRUG|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
214670908|NCT04802356|DRUG|Dexamethasone|Dose of 20 mg on days: 1, 2, 4, 5, 8, 9, 11 and 12 of every 28-day cycle. Oral administration Induction: 6 cycles Consolidation: 2 cycles
214917344|NCT04429568|OTHER|Smoked Cannabis|Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.
214311330|NCT00370253|DRUG|Terlipressin|1mg/4 h per day
214311331|NCT00370253|DRUG|Noradrenalin|0,1 mcg/kg/min
214670909|NCT04802356|PROCEDURE|Autologous stem cell transplant (ASCT)|High-dose melphalan (200 mg/m2) and ASCT will be performed as per routine practice
214670910|NCT01369719|DRUG|osveral|receive 20 mg/kg daily orally
214670911|NCT01369719|DRUG|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
214481030|NCT06867770|BEHAVIORAL|Observe the frequency of clinical or paraclinical complications during the hospitalization of these children.|The goal is to collect data on the files of infants hospitalized at the HFME from 2017 to 2021 for monitoring a isolated skull. The data that will be collected are an integral part of the child's care and pre-exist the study. This data will be anonymized and no interaction with the patient is envisaged.
214481031|NCT06870474|BEHAVIORAL|Psychoeducational intervention|The psychoeducational intervention has the aim of improving quality of life, problem-solving and social skills, leisure time, self-efficacy and social support of caregivers; and decreasing their depressive symptomology, dysfunctional thoughts, burden and stress. Both mediator and outcome variables will be contemplated.
214481032|NCT06870474|BEHAVIORAL|Support group|This intervention is a placebo group. It has the typical structure and characteristics of this type of intervention
214481033|NCT06870474|BEHAVIORAL|Control group|Participants were not subject to any intervention. They received the psychoeducational intervention once the study had ended.
214311332|NCT01881659|OTHER|HPV screening|Women who signed informed consent will be screened with HPV testing.
214311333|NCT02812316|DEVICE|HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens|Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.
214481034|NCT06869486|OTHER|Exercise|"A cardiopulmonary exercise test in a treadmill will be performed after an overnight fasting. Gas exchange, heart rate, and muscle oxygen saturation levels will be assessed continuously during the entire test. Blood pressure and rate of perceived exertion will be recorded prior the end of each stage whereas blood glucose concentration will be assessed before and after the test. All the hemodynamic parameters will be assessed at rest to standardize the cardio-metabolic condition of the participants prior to exercise testing.~Maximal exertion will be requested from all participants except elders, in whom a submaximal test will be applied, following the guidelines provided by the American College of Sports Medicine. From this trial, maximal oxygen uptake, ventilatory thresholds/dynamics, chronotropic and inotropic response, and metabolic flexibility will be examined. A trained exercise physiologist will supervise all the tests and validate the obtained data."
214481035|NCT06869486|OTHER|Bioelectrical Impedance|Bioelectrical impedance analysis will be used to estimate body compartments through a mechanism of resistance and reactance (InBody 770, KOR) . The compartments measured include body cell mass, fat mass, extracellular tissue, lean mass, muscle mass, visceral adipose tissue area, phase angle, among others.
214481036|NCT06869486|GENETIC|Micronucleus Assay|The frequency of micronuclei, nuclear buds, basal cells, binucleated cells, condensed chromatin cells, karyorrhexis, karyolysis, and pyknosis will be determined through microscopic examination of exfoliated oral mucosal cells from each participant.
214481037|NCT06869486|BEHAVIORAL|Physical activity and sedentary time|Physical activity and sedentary time will be assessed through the Spanish version of the International Questionnaire of Physical activity. In half of the analyzed subjects a wearable device (Fitbit luxe, Fit bit Inc) will be also used to record daily steps, energy expenditure and heart rate patterns.
214481038|NCT06869486|BEHAVIORAL|Sleep|Insomnia severity index, sleep quality, somnolence and chronotype will be subjectively assessed in all participants, using validated scales such as the Pittsburgh, Epworth and ISI questionnaires. In half of the participants, sleep quality will be tracked by wearing a Fit band luxe device in the wrist.
214670912|NCT01432314|OTHER|Radiation therapy|"A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT."
214917345|NCT04429568|OTHER|Vaped Cannabis|Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
214917346|NCT04429568|OTHER|Tobacco Cigarette|Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
214917347|NCT03625375|OTHER|Exercise|Intervention consist of aerobic, stretchig, pelvic motions, kegels and relaxation exercises
214917348|NCT00092625|DRUG|MK0653, ezetimibe|
214917349|NCT00092625|DRUG|Comparator: ezetimibe, placebo|
215060737|NCT05096975|OTHER|Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED|"The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach \& Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde \& De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children."
214311334|NCT06099977|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
214955088|NCT04699370|BEHAVIORAL|Cognitive behavioral therapy|In the first and second sessions, patients will learn about fatigue-related symptoms as well as Cognitive behavioral therapy and its effectiveness. The third and fourth sessions will be devoted on the introduction of behavioral strategies. The fifth session will introduce cognitive strategies to decrease fatigue. The last three sessions will be about how to adopt the proposed strategies consistently.
215060738|NCT05066750|BEHAVIORAL|Mindful breathing|Participants watch a 10 minute mindful breathing video
214311335|NCT06099977|PROCEDURE|Placebo|Only headphone without sound will be applied.
214311336|NCT02479256|DRUG|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
214311337|NCT02479256|DRUG|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
214311338|NCT02479256|DRUG|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
214311339|NCT02479256|DRUG|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
214311340|NCT01642017|DRUG|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
214311341|NCT05957796|DEVICE|"Novel Snaps Eye Shield"|"Using a novel eye shield, Snaps manufactured in Morgantown, WV by Intermed Labs after cataract surgery that has a different adhesive mechanism that utilizes adhesive and snap-on attachments to the shield."
214311342|NCT05957796|OTHER|Standard Alcon Eye Shield|Use normal Alcon eye shield with tape to adhere to shield to eye postop.
214311343|NCT05446402|COMBINATION_PRODUCT|Geologie Acne Regimen - one side of face|"Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three levels over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes:~1. Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid)~2. Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide)~3. Repairing Night Cream -~   1. Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  2. Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  3. Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)"
214670913|NCT01432314|OTHER|Transarterial chemoembolization|"A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop."
214670914|NCT00849693|DRUG|Placebo|Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
214670915|NCT00849693|DRUG|fluoxetine|20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
214917350|NCT00478803|PROCEDURE|Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty|"Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta."
215060739|NCT05066750|BEHAVIORAL|Control video|Participants watch a 10 minute control video
215060740|NCT03248167|DRUG|Cannabidiol|600 mg daily
215060741|NCT03248167|DRUG|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
214311344|NCT05446402|COMBINATION_PRODUCT|Proactive Acne Regimen - other side of face|"ProActiv is an over-the-counter cosmetic regimen with three products. The~Proactiv Solution 3-Piece System regimen includes:~1. Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)~2. Revitalizing Toner (Glycolic Acid)~3. Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)"
214311345|NCT05004233|BIOLOGICAL|Blood collection before antiplatelet treatment|Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment
214311346|NCT05004233|BIOLOGICAL|Blood collection after antiplatelet treatment|"A follow-up will be carried out 5 to 8 days after the initiation of the treatment.~A blood test will be taken in the NeuroVascular Unit"
214311347|NCT04420156|OTHER|No intervention administered.|Eye exams are standard of care and would be performed regardless of participation in this study.
214347104|NCT03619694|DEVICE|MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology
214347105|NCT02685163|OTHER|Antioxidant ice-cream|Narutal Antioxidant ice-cream
214347106|NCT02685163|OTHER|Control Ice-cream|Natural Control Ice-cream
214347107|NCT05173519|DEVICE|Omnibond Topical Skin Adhesive|Application of Omnibond topical skin adhesive to close incision following surgery
214347108|NCT05173519|DEVICE|Dermabond Advanced Topical Skin Adhesive|Application of Dermabond topical skin adhesive to close incision following surgery
214347109|NCT03294447|BEHAVIORAL|Fall Prevention by the Occupational Therapist|The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
214347110|NCT02952079|DEVICE|Blephex|Lid margin exfoliation
214347111|NCT02952079|DEVICE|MiboFlo|Lid warming treatment
214347112|NCT01803997|BEHAVIORAL|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
214347113|NCT05710068|DEVICE|RF Microneedle|Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
214311348|NCT03226262|DEVICE|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
214311349|NCT06353503|PROCEDURE|autologous bone marrow aspirate concentrate|local knee joint injection of autologous bone marrow
214311350|NCT00805974|BIOLOGICAL|Biological examinations (blood and urinary).|
214311351|NCT06050551|PROCEDURE|uniportal VATS|"1. elective uniportal VATS lung resection, pleural tumor removal or mediastinal lymph node biopsy, etc.~   (exclude the bil. operation, extended wound length over 5 cm, conversion to thoracotomy or multiportal VATS procedure, surgeon's decision for exclusion during operation.)~2. thoracoscopic internal costal nerve block with 10 mL of 1% Ropivacaine at the end of the operation,~3. routinely prescribed with oral Tramadol 37.5mg and Acetaminophen 325mg four times a day postoperatively and intravenous morphine as extra dose if need."
214311352|NCT03464006|OTHER|Online Support Module|The online support module is a computer software program which helps patients monitor factors related to their peripheral artery disease
214917351|NCT00478803|DEVICE|Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots|Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
214311353|NCT03464006|OTHER|Standard of Care|The normal care that patients receive at the institution.
214311354|NCT02822989|DEVICE|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
214311355|NCT02822989|DEVICE|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
214311356|NCT02934906|PROCEDURE|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
214311357|NCT00914862|DRUG|Ramelteon|Ramelteon tablets, orally for one day only.
214917352|NCT00329537|DRUG|Sargramostim (Leukine)|Self-subcutaneous injection
214917353|NCT00329537|DRUG|Placebo|Self-subcutaneous injection
214917354|NCT02557581|OTHER|No training|
214917355|NCT02557581|OTHER|Endurance training|
214917356|NCT02557581|OTHER|Resistance Training|
215060742|NCT00783653|DRUG|Sunitinib|25 mg or 37,5 mg daily dose until DLT
214311358|NCT02319031|DRUG|Daclatasvir|
214311359|NCT02319031|DRUG|Sofosbuvir|
214311360|NCT02319031|DRUG|Ribavirin|
214311361|NCT02168010|DRUG|Analgecine|Analgesic drug under test
214917357|NCT02557581|DRUG|Terbutaline|
214917358|NCT02557581|DRUG|Clenbuterol|
214917359|NCT02557581|DRUG|Placebo|
214917360|NCT03688308|PROCEDURE|Arthroscopic rotator cuff repair with bone marrow aspirate concentrate|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique. Subjects will also be injected with bone marrow aspirate concentrate harvested from the pelvis and centrifuged prior to injection in the shoulder (produced using the Harvest/Terumo BCT system)
214917361|NCT03688308|PROCEDURE|Arthroscopic rotator cuff repair|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique.
215077802|NCT03001700|DEVICE|Serranator™ Alto PTA Serration Balloon Catheter|The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
214311362|NCT02168010|DRUG|Neurotropin|Analgesic drug as positive control
214311363|NCT02168010|DRUG|Placebo|Blank tablet as placebo.
214311364|NCT02356692|DEVICE|enfilcon A|Test lens
214311365|NCT02356692|DEVICE|senofilcon A|Control lens
214311366|NCT03435965|DIAGNOSTIC_TEST|AmnioQuickDuo+|AmnioQuickDuo+ kit for detection of PROM
214311367|NCT03448965|DIAGNOSTIC_TEST|random blood sugar|do random blood sugar at 0 hour - 2 hours- 4 hours and after 6 hours
214347114|NCT05710068|DRUG|Combination cream|5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
214347115|NCT01548690|DRUG|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
214347116|NCT06215638|DRUG|Bortezomib|Bortezomib 2 mg per week subcutaneously, for twelve weeks in total
214347117|NCT05494112|DIETARY_SUPPLEMENT|Celastrol|same dose of Celastrol will be given every day for a period of 90-days to all participants.
214347118|NCT02917109|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
214347119|NCT01108744|DRUG|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
214347120|NCT01108744|DRUG|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
214347121|NCT04592692|DRUG|PEGylated Liposome (PEGLip)|Intravenous co-administration of PEGLip with Simoctocog alfa
214311368|NCT01611987|OTHER|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
214311369|NCT01611987|OTHER|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
214311370|NCT06822907|BIOLOGICAL|Early intervention|"In this arm, patient will receive unique dose of the PCV-20 vaccine (Prevnar 20) as soon as possible and until 72h after apyrexia.~The Prevenar 20 will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults."
214311371|NCT06822907|BIOLOGICAL|Delayed intervention|"In this arm, from 15 days and until 58 days after fever resolution (i.e after the first day with a body temperature \< 37.5°C without paracetamol use in the 6 previous hours) (whether or not the patient has been discharged) in the absence of fever, the patient will receive unique dose of the PCV-20 vaccine (Prevnar 20).~The Prevenar 20 will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults."
214311372|NCT05787314|BEHAVIORAL|Low Glycemic Index Diet|"1. Participants who came to the hospital for control and were interested in the study contacted the study researchers and eligibility was determined through face-to-face interviews. Potential participants were invited to a screening visit to verify eligibility.~2. The LGID program was initiated as an outpatient treatment in patients who applied to a dietitian. 3) Medium and high GI carbohydrates (GI \> 55) were excluded from the diet and only low GI (GI \< 50) foodstuffs were allowed. 4) A list of low glycemic index foods were given to the patients. In addition, a list of foods to avoid (medium and high glycemic index) is provided."
214311373|NCT02495311|PROCEDURE|myomectomy or adenomyomectomy|
214311374|NCT04692961|DEVICE|Elastography|Use elastography to evaluate the stiffness of lower leg muscle after peroneal artery-based free flap harvested
214311375|NCT06030843|DRUG|Empagliflozin 10 MG|Empagliflozin 10 MG
214311376|NCT06030843|DRUG|Placebo|Matching placebo containing Lactose content (0.26 gram)
214311377|NCT02307006|DRUG|Ceftaroline|Surgical prophylaxis
214311378|NCT02307006|DRUG|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
214311379|NCT01899599|DRUG|PankoMab-GEX|start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
214311380|NCT01899599|DRUG|Placebo|start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
214311381|NCT01845285|DEVICE|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
214670916|NCT00849693|DRUG|duloxetine|60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
214670917|NCT00849693|DRUG|duloxetine|30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
214670918|NCT05435248|DRUG|HS-10375|HS-10375 will be administered orally once daily in a continuous regimen
214670919|NCT05344092|BEHAVIORAL|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
214917362|NCT05577988|OTHER|single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.|"* Individuals without genetic loss of function to metabolize clopidogrel: stop DAPT and switch to a single antiplatelet therapy by clopidogrel.~* Individuals with genetic loss of function to metabolize clopidogrel (\*2/\*3, 1/\*3, \*2/\*2, \*1/\*2): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.~* Individuals with fast metabolization of clopidogrel (\*1/\*17 or \*17/\*17): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin."
214917363|NCT04601077|DRUG|Nitric Oxide lozenges, 30 mg|Nitric Oxide lozenge, 30 mg twice a day for 30 days
214917364|NCT04601077|DRUG|Placebo|Placebo for Nitric Oxide lozenge, 30 mg twice a day for 30 days
214917365|NCT06279546|DIAGNOSTIC_TEST|Detection of structures|Pre-recorded videos, cropped according to the different windows (mediastinal, gastric, duodenal) will be analyzed by the AIWorks-EUS model and endoscopists on different times for recognition of the different normal anatomical structures.
214311382|NCT02086942|DRUG|Bortezomib|Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.
214311383|NCT02086942|DRUG|cyclophosphamide|Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
214311384|NCT02086942|DRUG|Dexamethasone|Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
214311385|NCT01514968|DRUG|cyclosporine|Single oral dose
214311386|NCT01514968|DRUG|danoprevir|Single oral dose
214311387|NCT01514968|DRUG|ritonavir|Single oral dose
214311388|NCT01991171|OTHER|Kinesio Taping|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
214311389|NCT06454110|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
214311390|NCT05227794|BEHAVIORAL|Compassion Cultivation Training (CCT)|CCT is a secular, empirically supported 8-week program that integrates meditation practices, interactive discussions, and educational lectures to improve self-compassion and other-oriented compassion, emotion and stress management, and happiness and well-being. It includes a weekly 2-hour educational lecture with discussion and in-class exercises, a recommendation of 15-30 minutes of daily meditation, and real-world assignments to practice compassion. The program is taught by a certified instructor with more than 5 years experience.
214481039|NCT06869486|BIOLOGICAL|blood sampling|"The concentrations of glucose, glycated hemoglobin, and lipid profile will be determined through serum analysis using a blood chemistry analyzer (Spin120, Spinreact, ESP). Serum samples will be obtained by centrifuging peripheral venous blood samples (4-6 mL) collected in Vacutainer tubes at 2500 rpm for 10 minutes. From the same serum samples, circulating levels of insulin, ovarian hormones (estradiol and progesterone), insulin-like growth factor 1 (IGF-1), and vascular endothelial growth factor (VEGF) will be assessed using enzyme-linked immunosorbent assays (ELISA) on a microplate reader (iMark, BIORAD, USA), following the specifications provided by each kit manufacturer (Biotechne, USA; AccuBind, GUA).~Glucose, insulin and triglyceride values obtained from the blood chemistry analyzer and ELISA assays will be used to calculate the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and the triglyceride-glucose index."
214481040|NCT06869486|BEHAVIORAL|psychometrics|Perceived stress will be obtained from the Perceived Stress Scale adapted for Mexican population. Additionally, depression and anxiety scores will be obtained from the Becks Depression Inventory, validated in Mexican adults. Ruminative thinking will be assessed through the short version of the Ruminative Responses Scale and substance abuse will be examined through the 10-items Drug Abuse Screening Test. Social media disorder and screen time will be also investigated from the Social Media Disorder Test and a cell-phone screen capture.
214481041|NCT06869486|BEHAVIORAL|Nutritional Supplement|"A semi quantitative food frequency questionnaire will be applied to collect data about macronutrient intake and supplements consumption. Hierarchical consumption of each food groups will be also assessed.~Last meal consumed prior to exercise testing will be also recorded in conjunction with fasting time."
214481042|NCT06869486|GENETIC|Genotyping|The P10L polymorphism of the OPN4 gene, previously associated with chronic insomnia and severe daytime sleepiness in the Mexican population will be determined using RFLP-PCR assays. DNA will be extracted from previously collected blood samples (4 ml) using the Master Pure DNA purification kit from Epicentre (Illumina Inc., US).
214481043|NCT06783712|PROCEDURE|Adductor canal block|Group I: Patients will receive the ultrasound-guided Adductor canal block (ACB) by the supervisors of the research performed just after skin closure. ACB will be performed under complete aseptic conditions. Using a high frequency (6-15MHz) linear probe of an ultrasound machine (Sonosite turbo M, Bothell, Washington, USA) covered with a sterile sheath and 100 mm needle SonoPlex (B-Braun Medical Inc., Bethlehem, PA, USA). ACB block will be performed while the patient is in a supine position at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the sartorius muscle, 100 mm needle SonoPlex will be advanced with the guidance of ultrasound in an in-plane technique and 20 ml bupivacaine (Marcaine) 0.25% will be injected.
214481044|NCT06783712|PROCEDURE|Adductor Canal Block (ACB) + iPACK Block|Group II: The patients will receive ACB by the supervisors of the research just after skin closure as previously described in group I and then an IPACK block will be performed. IPACK block will be performed under complete aseptic precautions using the ultrasound machine with the high-frequency linear probe covered with a sterile sheath and 100 mm needle SonoPlex. IPACK block will be performed while the patient is in a supine position with slight knee flexion, the probe will be applied to the popliteal fossa for identification of the popliteal artery and femur. Then the probe will be distally slided for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappear and the flat metaphysis appear. A needle will be advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reaches the medial edge of the femur,20 ml bupivacaine 0.25% will be injected incrementally
214670920|NCT04364672|DRUG|18F-labeled DPA-714 PET scan|One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 within 4 weeks after completing NACT including at least 2 cycles administered; before surgery
214917366|NCT03798509|DRUG|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
214917367|NCT06565494|DRUG|midomafetamine (MDMA)-Assisted Therapy|This treatment consists 3 Preparation sessions followed by 3 Experimental sessions at 4-week intervals; after each Experimental session, 3 weekly Integration sessions will be conducted. For the first Experimental Session, the dose of MDMA is 80 mg; for the second and third Experimental Sessions, the dose of MDMA is 120 mg. For all three Experimental sessions, a supplemental dose of 50% of the initial dose will be available. The Preparation, Experimental, and Integration Sessions will involve psychotherapy developed specifically for this trial and population.
214917368|NCT01873404|DRUG|BG00010|As specified in the treatment arm
214311391|NCT05227794|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR is among the most studied mindfulness-based interventions in the literature and is a secular, 8-week psycho-educational group-based intervention. The program structure (slightly modified to match CCT) includes a weekly 2-hour class, a prescription of 15-30-minutes of daily mindfulness practice, and a one-day optional retreat (6 hours) between week six and seven. The program is taught by a certified instructor with more than 5 years experience.
214311392|NCT05774158|OTHER|Physiotherapy assessment|Of the individuals included in the study; Information about age, height, body weight, type of congenital heart disease, surgical history, drug use, comorbid chronic disease, education level and occupation will be obtained. Functional Capacity, Peripheral Muscular Strength, Hand Grip Strength, Fatigue, Physical Activity Level, Quality of Life, Social Participation, Depression Anxiety Stress Level and Physical Activity Barriers will be evaluated
214311393|NCT03887000|OTHER|magnesium|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
214311394|NCT03887000|OTHER|placebo|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
214311395|NCT01075698|DRUG|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
214917369|NCT01873404|DRUG|Placebo|As specified in the treatment arm
214311396|NCT01075698|DRUG|ARB (Telmisartan)|Telmisartan 20-80 mg/day
214311397|NCT03149107|DRUG|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
214311398|NCT03149107|DRUG|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
214481045|NCT06886217|BEHAVIORAL|Collaborative Life Skills dHealth tool (CLS-D)|The purpose of this adapted intervention is to integrate digital health (dHealth) technology into the Collaborative Life Skills Program (CLS), an established, school-based behavioral intervention for students with ADHD, to make the program accessible to schools that serve students from low-socioeconomic (SES) backgrounds. Existing evidence-based interventions for students with ADHD are often inaccessible in schools with limited resources to support implementation. By adapting CLS to include a dHealth tool-CLS-D-researchers aim to improve the feasibility of intervention implementation in schools with limited resources and mitigate disparities in access to evidence-based interventions among students with ADHD who are from low-SES backgrounds.
214481046|NCT05785130|OTHER|white noise|Using sound machine for 3 days at bedtime for 7 hours(11p.m.- 6a.m.) in a decibel of 40-50.
214481047|NCT06607744|DRUG|Pharmacokinetic profiles of Selegiline TDS and EMSAM|Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.
214481048|NCT06873022|DEVICE|neuromuscular electrical stimulation|"NMES: Two electrode pads were placed on the anterior, middle, and posterior deltoid boundary lines and at a distance of 1cm distal to the lateral margin of the acromion. The operator palpated the deltoid muscle contraction and asked the subjects to perform arm elevation task with NMES. (frequency of 35 Hz and a duration of 250 microseconds.) A verbal cue was given during both th~A verbal cue was given during both the sEMG biofeedback and NMES interventions: Lengthen your arm as if you want to touch the ground, the scapula keeps in the neutral position, and then elevate your arm. Each intervention consisted of 3 sets of 10 repetitions per set, with a 1-minute rest between sets."
214481049|NCT06873022|DEVICE|biofeedback|sEMG biofeedback: Subjects were instructed to monitor the sEMG signals of the D/UT balances ratio on the screen and maintain the D/UT balances ratio above the threshold during arm elevation and lowering. The threshold was set at 1 standard deviation of the ratio average at baseline (before intervention).
214481050|NCT06867471|DIETARY_SUPPLEMENT|Ketone Diol, R-1,3-butanediol (Ketone-IQ)|Effect variables will be measured on the last day of treatment with Ketone-IQ
214481051|NCT06867471|OTHER|Placebo drink|Effect variables will be measured on the last day of treatment with Placebo
214481052|NCT03351998|DRUG|Lipitor 20Mg Tablet|20 mg/day pills.
214481053|NCT03351998|DRUG|Lipitor 80Mg Tablet|80 mg/day pills.
214481054|NCT03351998|DRUG|Placebo Oral Tablet|Matching placebo pill.
214670921|NCT03531229|DRUG|Placebo|Placebo to Lu AF76432 oral solution
214670922|NCT03531229|DRUG|Lu AF76432|Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
214670923|NCT04427592|DIAGNOSTIC_TEST|ultrasound|trans-vaginal and trans-abdominal ultrasound using different modalities such as grey-scale, Doppler, multi-planer mode
214917370|NCT02420561|BEHAVIORAL|Motivational Interviewing|"* One in-person motivational interviewing session intervention that lasts for 45-minutes~* Additional two 15-minute telephone booster sessions post in-person 45 minute sessions"
214917371|NCT02420561|BEHAVIORAL|Control (brochure)|Participants received a brochure on alcohol and drug use risks.
214917372|NCT03759587|DRUG|Niraparib|Niraparib capsule
214917373|NCT01657825|DRUG|Isavuconazole|oral
214917374|NCT01657825|DRUG|Warfarin|oral
214917375|NCT06004921|DRUG|AB801|Administered as specified in the treatment arm
214917376|NCT06004921|DRUG|Placebo|Administered as specified in the treatment arm
214917377|NCT03871205|BIOLOGICAL|Neoantigen loaded DC vaccine|Patients will be vaccinated with autologous mature dendritic cells loaded with neoantigen, DC vaccine will be injected subcutaneously 6 times, once a week.
215060743|NCT04413214|DRUG|Carrimycin|The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.
215060744|NCT02122146|DRUG|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
214917378|NCT05932537|PROCEDURE|Preoperative visualization techniques|describe techniques for pre-operative visualization of subcutaneous contraceptive implants
215060745|NCT02122146|DRUG|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
214311399|NCT03149107|BEHAVIORAL|IPPI (Integrated Preventive Psychological Intervention)|IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater)
214311400|NCT03149107|BEHAVIORAL|PSM (Psychological stress management)|PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).
214311401|NCT05336474|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge
214311402|NCT00285597|DRUG|Ursodeoxycholic Acid|
214311403|NCT04136925|OTHER|questionnaire|questionnaire before and after race
214311404|NCT04179695|OTHER|Consulting with PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
214311405|NCT04179695|OTHER|Consulting without PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
214481055|NCT05107518|BEHAVIORAL|Children Participation Assessment Scale|Evaluation is carried out to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
214481056|NCT04730518|BEHAVIORAL|Yoga-based group intervention (YoGI)|see above
214311406|NCT05707117|OTHER|Tendon neuroplastic training (TNT)|Subjects will attend physical therapy for three non-consecutive days per week for a total 4 consecutive weeks. Exercise would involve isolated flexion, extension with a dumbbell. This exercise would be paced with external audio/visual cue on smart phone using proMetronome app. Patients will listen to the sound and track the movement of metronome with the eyes. Pace of metronome will be set at 20 beats per minute such that each beat will be 3 sec apart. This will allow a 3sec concentric and 3 sec eccentric phases.4 sets of 8 repetitions would be completed with a 2-minute rest between each set. Exercise will begin with 3 pounds weight, but it would be made sure that this wouldn't cause pain during exercise (more than 5/10), gradual progression in weight to 5 pounds after 2nd weeks.
214481057|NCT06686927|DRUG|corticosteroids combined with immunoglobulin and romiplostim|"Romiplostim N01, starting dose of 1 µg/kg, subcutaneous injection, given on the third day of IVIG, once a week, for up to one month.~IVIG, 400mg/kg/d, intravenous administration, continuous administration for 3-5 days.~Prednisone, 0.8mg/kg/d, taken orally or intravenously, for up to one month."
214481058|NCT06690060|BEHAVIORAL|Mind-Body Intervention|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
214311407|NCT05707117|OTHER|group B Conventional treatment|Subjects assigned to this group will undergo static stretching of Extensor carpi radialis brevis and myofascial release for 4 weeks, 3 sessions a week. Myofascial release technique will be applied for 5 minutes and 2 reptations per session
214311408|NCT00035854|DRUG|Zyvox® / Linezolid|
214347122|NCT02791048|BEHAVIORAL|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
214481059|NCT02785991|PROCEDURE|Balloon cryoablation|pulmonary vein cryoablation for atrial fibrillation
214481060|NCT06685913|DIETARY_SUPPLEMENT|Ketone supplement|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test
214481061|NCT06685913|DIETARY_SUPPLEMENT|Placebo supplement|Placebo with bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test
214481062|NCT06666465|OTHER|Operating Room Environment Experienced by Patients Wearing Virtual Reality Glasses Before Surgery The Effect of Surgery Experience on Surgical Fear Level and Care Perceptions|The video, which will be shot for patients to experience the operating environment, will include premedication, an operating room and a post-operative care unit. In the video, the operating room environment will be recorded by the researcher with a voice introduction. The image was shot with a 360-degree camera (Insta 360 One X2), edited with an application program (Insta 360 Studio) and then uploaded to the YouTube VR Pro application as a secret video. The video will be shown to the glasses via an Android phone on the internet via YouTube. People wearing glasses at the screening will be able to look in any direction they want thanks to the 360-degree video. They will be able to watch the video again if they want.
214481063|NCT06618651|DRUG|SHR-3821 injection|SHR-3821 injection
214917379|NCT04204109|OTHER|Interprofessional case-based learning|"The trial is an educational intervention where groups of healthcare professionals receive the same case-based learning: one group receives case-based learning with healthcare professionals of various professional backgrounds (experimental) versus another group receiving case-based learning with healthcare professionals exclusively of the same professional background (control).~The educational intervention consists of a case that is developed for the purpose of the intervention.~The participants in the experimental group will be randomised into six teams who will receive interprofessional case-based learning. The experimental group will be made up of healthcare professionals from various groups. The participants in the control group will be randomised in groups of one profession"
214917380|NCT04615403|DRUG|Travoprost|Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision
214917381|NCT02024074|OTHER|Sestamibi (Tc-MBI) scan of the breast|Patients will be given 8mCi of Sestamibi intravenously. following which Sestamibi scan will be performed on the breast. Sestamibi scan will be done prior to any surgical procedure..
214481064|NCT06622668|BIOLOGICAL|Biological NTLA-3001|IV administration of AAV and CRISPR/Cas9 gene editing system
214481065|NCT06875466|DEVICE|Sauna bathing|Finnish sauna bathing, participants will sauna once per week for 8 weeks
214917382|NCT02746978|OTHER|Peer directed education|No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators
214917383|NCT02746978|OTHER|Patient Engagement Portal|No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
214481066|NCT02991313|DEVICE|Endocardial Ablation Procedure|
214481067|NCT06875492|COMBINATION_PRODUCT|HMME-PDT|Twice HMME-PDT, and the treatment interval is 2 to 3 months.
214481068|NCT06875492|DEVICE|PDL|Prior PDL treatment history.
214917384|NCT00256269|DRUG|Oxaliplatin|40 mg/m2 IV over 60 minutes Every 21 days
214311409|NCT05078853|DEVICE|Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"FNA Clinic: When a bloody material is seen in the needle, 100 µL of 0.9% saline is drawn via the needle into the syringe. The aspirate is then transferred into an Eppendorf tube. 40 µL is aspirated from the Eppendorf tube and dripped into the middle of the sample well of the POC-Tg kit. Two drops of the buffer are then dispensed into the middle of the sample well. The result of the POC-Tg is obtained and documented after 10 minutes. To compare the accuracy of the POC-Tg kit to the formal immunoassay for Tg, 0.9% saline is added to the aspirate that was left in the Eppendorf tube to a final volume of 0.6 mL. This volume is transferred into a gel containing tube and sent to the clinical laboratory that performs Tg measurement.~Operating room: When an indeterminate or suspicious LN is found, the LN is dissected and evaluated by both the formal evaluation and the POC-Tg. Following dissection of the LN, the ex-vivo POC-Tg is conducted as described above."
214311410|NCT06850168|DEVICE|SVL|Dispensed to one eye in Year 1
214311411|NCT06850168|DEVICE|SVL with passive red-light emission|Dispensed to the contralateral eye in Year 1.
214311412|NCT06850168|DEVICE|MCL|Dispensed to one eye in Year 2 (if used SVL with passive red-light emission in Year 1).
214311413|NCT06850168|DEVICE|MCL with passive red-light emission|Dispensed to the contralateral eye in Year 2 (if used SVL in Year 1).
214311414|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
214311415|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
214311416|NCT03676881|DEVICE|Computerized cognitive battery: Cognigram (CG)|is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
214311417|NCT03676881|DEVICE|The NeuroCatch™ Platform (NCP)|the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
214311418|NCT00176592|DRUG|Betaseron|Betaseron 250 micrograms injected SQ every other day
214311419|NCT00176592|DRUG|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
214917385|NCT00256269|DRUG|Irinotecan|60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
214917386|NCT02145260|DRUG|Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)|A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
214311420|NCT03414463|BEHAVIORAL|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
214311421|NCT03062956|DRUG|MYK-491 or placebo|Oral suspension
214311422|NCT04028245|DRUG|Spartalizumab|Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion
214311423|NCT04028245|DRUG|Canakinumab|Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion
214311424|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - carbon fibers-based implants|Transpedicular stabilization with carbon fiber and PEEK-based implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
214311425|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - titanium implants|Transpedicular stabilization with titanium implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
214311426|NCT06293157|RADIATION|Stereotactic body radiotherapy|Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.
214481069|NCT06875219|DRUG|Luspatercept (ACE-536)|Luspatercept (ACE-536)
214917387|NCT02145260|DRUG|Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)|A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
214917388|NCT02116933|PROCEDURE|Adipose Derived Stem Cells|Adipose derived stem cells harvested from autologous lipoaspirate
214917389|NCT02116933|PROCEDURE|SVF Enriched Autologous Fat Grafting|Cell assisted lipotransfer
214917390|NCT05573932|OTHER|Leaderboard|De-identified leaderboard showing average durations of exercises completed by all participants in leaderboard group.
214917391|NCT05573932|OTHER|Take-home packet|Take-home packet of exercises.
214917392|NCT03340454|OTHER|Test-and-treat EHR-CHW intervention|a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies
215060746|NCT06365658|DIAGNOSTIC_TEST|Psychological assessment|Psychological assessment of memory, learning and language
215060747|NCT01060904|DRUG|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
215060748|NCT01060904|DRUG|doxorubicin|25 mg/m2 IV every 2 weeks
215060749|NCT01060904|DRUG|vinblastine|6 mg/m2 IV every 2 weeks
214311427|NCT04253288|OTHER|Morbidity Mortality Review (MMR)|"* Standardization of Morbidity Mortality Review (MMR) in radiotherapy centers~* National database from MMR board meetings which include clinical , radiation technique and biological parameters of intrinsic radiosensitivity of patients"
214311428|NCT06558474|BEHAVIORAL|Liberal post-dilatation strategy during PCI|"A liberal post-dilatation strategy for stent optimization during PCI will be implemented in multiple centers in the Netherlands.~This include an increase of post-dilatation use of at least 20% per operator, or a percentage of post-dilatation of at least 85%.~Operators will be asked to enforce a very low threshold for post-dilatation in general, with a mandatory HPNC post-dilatation for the following indications:~* In case of any calcification~* Delta of ≥ 0.5mm between the distal and proximal reference diameter of the treated coronary segment~* Stent length \>24 mm~* Signs of incomplete stentframe-deployment on angiography or StentBoost~* In case of CTO~* In case of bifurcation PCI (Left main and non-left main)~  * Proximal Optimisation Technique (POT) with NC balloon~ * Final Kissing Balloon dilatation (FKB) with preferentially first sequential high-pressure inflations and final low pressure kiss both with NC balloons"
214311429|NCT02635516|DEVICE|Near-Infrared Phototherapy|"The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized."
214311430|NCT03178747|DIAGNOSTIC_TEST|Methylene blue|working solution methylene blue
214481070|NCT03812913|BEHAVIORAL|psychological evaluation|"* Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~* Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning."
214481071|NCT06002386|DEVICE|Vsling|Implantable ventricular repair device
214481072|NCT05938127|DEVICE|Inspiratory muscle strength training|High-resistance inspiratory muscle strength training (IMST) is a time-efficient (\~5 minutes/day) form of exercise that employs an affordable, handheld device which impedes inspiratory breathing to train the diaphragm and accessory respiratory muscles
214481073|NCT05938127|DEVICE|Sham Inspiratory muscle strength training|Low-resistance inspiratory muscle strength training
214481074|NCT05909046|DIAGNOSTIC_TEST|Immediate inpatient postpartum OGTT|The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
214481075|NCT05909046|DIAGNOSTIC_TEST|Standard of care 4-12 week postpartum OGTT|Standard of care is 4-12 week outpatient postpartum OGTT
214481076|NCT06875830|PROCEDURE|collagen membrane|augmentation of the buccal plate of bone with xenograft and collagen membrane
214481077|NCT06875830|PROCEDURE|titanium mesh|augmentation of the buccal plate of bone with xenograft and titanium mesh
214481078|NCT06627036|DEVICE|Dermatoscope|For participants in the dermoscopy group, the marking will also be done preoperatively with a marker pen, but the lesion borders will be determined using a dermatoscope. A peripheral margin based on BAD guidelines will be marked similarly.
214481079|NCT06072924|BEHAVIORAL|Isotonic Endurance Exercise|Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day
214481080|NCT06072924|BEHAVIORAL|Sham Exercise|Pressing tongue against pressure sensor at a low threshold (1-15kPa) 30x/day
214917393|NCT03340454|OTHER|Usual care of EHR-only intervention|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability.
214917394|NCT05235893|PROCEDURE|Reflexology|Reflexology was applied to soles of the babies in the second study group during 5-7 minutes, three minutes before the painful procedure was started by a physiotherapist, certificated in reflexology.
214917395|NCT05235893|PROCEDURE|Sucrose %24|The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
214481081|NCT06693830|DEVICE|Phased Variant Enrichment and Detection Sequencing (PhasED-seq)|PhasED-seq designed to detect minimal residual disease (MRD) as indicated by the presence of circulating tumor DNA (ctDNA) evidenced by an aggregate signal of phased variants (PVs) in the plasma of patients diagnosed with large B-cell lymphoma (LBCL) following first-line therapy.
214481082|NCT06693830|OTHER|Standard of Care Treatment|Standard of Care Treatment for cycles 1-6
214481083|NCT06693830|OTHER|De-escalated Treatment|Standard of Care Treatment for cycles 1-4 and de-escalated treatment for cycles 5 and 6
214917396|NCT05235893|PROCEDURE|Kangaroo care|The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
214917397|NCT05235893|PROCEDURE|Music|"Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music"
214917398|NCT01464164|DRUG|Sotatercept|"Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks"
214917399|NCT01464164|DRUG|Sotatercept with prednisone boost|"Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg)."
214917400|NCT02043444|RADIATION|FDG PET-CT|
215060750|NCT01060904|DRUG|dacarbazine|375 mg/m2 IV every 2 weeks
215060751|NCT01060904|DRUG|bleomycin|10 units/m2 IV every 2 weeks
214917401|NCT06407115|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT in this study will consist of a series of 6-10, 30-45-minute sessions with the care manager. These 1-on-1 sessions will occur every week or every other week virtually. Content will be focus on addressing unhelpful thinking and small behavioral changes that may help participants better manage their pain.
215060752|NCT01060904|DRUG|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
215060753|NCT00000788|DRUG|Methadone hydrochloride|
215060754|NCT00000788|DRUG|Fluconazole|
214311431|NCT03178747|DIAGNOSTIC_TEST|Giemsa stain|working solution Giemsa stain (Wolbach's modification)
214311432|NCT03519971|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
214311433|NCT03519971|OTHER|Placebo|Placebo IV (intravenous infusion)
214311434|NCT03519971|DRUG|Cisplatin/ Etoposide|Cisplatin/ Etoposide, as per standard of care
214311435|NCT03519971|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
214311436|NCT03519971|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
214670924|NCT04427592|PROCEDURE|closure of uterine wall defect|uterine incision above placental bulge by at least 5 mm then complete separation of the placenta starting from areas of least resistance to areas of high resistance leaving a clear defect which will be closed by non locked running sutures from inside the uterus starting from one edge, hitch the bed to the other edge of the defect and controlling placental bed hemorrhage then closing the uterine incision via running sutures in 2 layers with compressing the bed from outwards in the first layer. hemostasis of the abnormal pelvic vasculature if excessive bleeding internal iliac artery may be ligated then insertion of intra-peritoneal drain followed by closing the abdomen.
214917402|NCT06407115|BEHAVIORAL|Enhance Fitness|Participants will be encouraged to enroll in instructor-led exercises classes for up to an hour, 3 days per week. These classes can be accessed from home. Data plans and tablets are available to aid participants that need them to gain access to the classes.
214917403|NCT06407115|OTHER|Care Coordination|Care manager will meet with patient in virtual sessions once a month to create a care plan and monitor progress. Care manager will assess social determinants of health and link participants to resources in the community as appropriate. In addition, participants will take monthly assessments about pain and mood to help guide clinical decision making.
214917404|NCT06568822|OTHER|Asessment|Data prepared by researchers regarding the general characteristics of older adults will be examined.
214917405|NCT06568822|OTHER|The Physical Activity Scale for the Elderly (PASE)|PASE will be used to assess the physical activity levels of older adults.
214917406|NCT06568822|OTHER|Turkish Version of the Satisfaction with Life Scale (T-SWLS)|T-SWLS will be used to assess life satisfaction of older adults.
214917407|NCT06568822|OTHER|Modified Morisky Scale (MMS)|MMS will be used to evaluate medication adherence in older adults.
214917408|NCT00097825|DRUG|Zoledronic Acid|
214917409|NCT01438398|PROCEDURE|Submucosal endoscopic myotomy with mucosal flap technique|Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.
214311437|NCT03519971|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
214311438|NCT03519971|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
214311439|NCT05800470|OTHER|fNIRS-based neurofeedback with motor imagery|A multichannel wearable fNIRS (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NY, USA) will be used to detect the cortical activity in SMA. The HbO concentration will be processed and displayed as a visual feedback during MI training.
214311440|NCT05800470|OTHER|Kinesthetic motor imagery|Prior to each task, participants will watch a video of a person executing balance tasks and walking tasks. The balance tasks will include static and dynamic standing tasks such as sit-to-stand, tandem stance, standing on a balance board, reaching out to different directions and single leg stance. The walking tasks consists of tandem walking, crossing obstacles, sideward walking, backward walking, and turning. The participants will be asked to kinesthetically imagine movements in the first-person perspective, and the researcher will give the explicit instruction encouraging them to focus on the feeling (i.e. tactile, proprioceptive and kinesthetic sensations). Each MI session consists of 10-min of balance tasks and 10-min of walking tasks.
214311441|NCT05800470|OTHER|Motor training|The tasks for balance and gait training are similar to those during the MI training. The difficulty of the tasks will be modified individually for each participant. The researcher will ensure the safety.
214311442|NCT06024603|DIAGNOSTIC_TEST|Drug Sensitivity Test (DST)|Refractory cancer tissue will be collected from participants and subjected to single-drug testing while DNA is simultaneously sent for targeted gene sequencing. Drug sensitivity scores from the tests will become available for a final list of therapeutic options ranked best in order of preference together with suggested doses and schedules.
214311443|NCT05852431|DRUG|Pegozafermin|Subcutaneous injection
214311444|NCT05852431|DRUG|Placebo|Subcutaneous injection
214311445|NCT05331378|DEVICE|Test myopia control lenses|A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.
214311446|NCT05331378|DEVICE|Single vision lenses|A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
214311447|NCT04368247|DIAGNOSTIC_TEST|Skin Fluorescent Imaging|Application of reagents, then imaging and scoring
214917410|NCT01438398|PROCEDURE|Submucosal Endoscopic Mucosal Flap (SEMF) technique|
215060755|NCT04114708|DIAGNOSTIC_TEST|Anterior cruciate ligament Reconstruction (ACLR)|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.
214311448|NCT06276491|BIOLOGICAL|XmAb541|Monoclonal bispecific antibody
214311449|NCT02985307|BEHAVIORAL|Short Message Text Service|A service designed by professionals inside the National Health Service (NHS) to provide support and advice for participants to manage weight loss. It combines the expertise of the healthcare team and the convenience of the participant's own mobile phone to give prompts and advice to act on. It makes use of the familiar and convenient mobile phone text service 'SMS' to communicate directly with participants.
214311450|NCT02985307|BEHAVIORAL|Standard Weight Management Group|A standard Lothian NHS group programme facilitated by a Dietitian
214311451|NCT04242615|OTHER|Prognostic score|
214311452|NCT00210054|DRUG|denufosol tetrasodium (INS37217)|
214311453|NCT01828047|DEVICE|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
214670925|NCT06171217|DRUG|Hydroxyurea|Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression
214311454|NCT05933928|OTHER|Simulation-based electronic fetal monitoring training|"Practices will be carried out with the students in the intervention group with the NOELLA Birth Simulator, which is a high-reality simulator located in the Simulation laboratory of the Department of Midwifery of the Faculty of Health Sciences of Hamidiye. A simulator will be practiced with a separate scenario including early, late, variable deceleration, reactive, sinusoidal and non-reactive trace interpretation and intervention."
214311455|NCT05749042|DRUG|Sintilimab|Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.
214311456|NCT05749042|RADIATION|Radiotherapy|Concurrent Chemoradiotherapy Based of Cisplatin
214311457|NCT06003010|BEHAVIORAL|Yoga|6 yoga videos to be done 2-3x a week for 6 weeks before and after surgery.
214311458|NCT00625677|BIOLOGICAL|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
214311459|NCT00625677|BIOLOGICAL|Menjugate (Meningococcal C conjugate vaccine)|Dosage
214311460|NCT06327958|OTHER|Cormack-Lehane (C&L)|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
214311461|NCT06327958|OTHER|POGO score|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
214311462|NCT00563953|DRUG|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
214311463|NCT02437019|DRUG|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
214311464|NCT05628077|OTHER|No intervention|No intervention
214311465|NCT00129129|BIOLOGICAL|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
214311466|NCT00129129|BIOLOGICAL|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
214311467|NCT00129129|BIOLOGICAL|Pediarix|Primary phase: 3 IM doses
214311468|NCT00129129|BIOLOGICAL|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
214311469|NCT00129129|BIOLOGICAL|Menomune|Primary phase: 1 SC dose
214311470|NCT03345589|DRUG|18-22mg/kg/d Ursodeoxycholic|18-22mg/kg/d Ursodeoxycholic
214311471|NCT03345589|DRUG|13-15mg/kg/d Ursodeoxycholic|13-15mg/kg/d Ursodeoxycholic
214311472|NCT05470699|PROCEDURE|Computed Tomography|Undergo PET/CT
214311473|NCT05470699|OTHER|Fluorine F 18 Piflufolastat|Given IV
214670926|NCT06171217|DRUG|Hydroxyurea|Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
214670927|NCT02018510|BIOLOGICAL|1 mg/kg, single dose IV administration of 3BNC117|1 mg/kg, single dose IV administration of 3BNC117
214917411|NCT06382701|OTHER|aromatherapy|Patients in the intervention group; ten minutes before the needle is inserted into the arterio-venous fistula, clove oil will be applied by the interviewer as a spray between 0.5-1 ml, depending on the length of the patient's fistula. Patients in the placebo group; 10 minutes before the needle is inserted into the arterio-venous fistula, 0.5-1 ml of aromatic cloves, which do not contain active ingredients and dissolved in pure water, will be applied as a spray by the interviewer, depending on the length of the patient's fistula.
214311474|NCT05470699|DEVICE|Positron Emission Tomography|Undergo PET/CT
214311475|NCT01647633|OTHER|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
214311476|NCT03963115|DRUG|Epinephrine or normal saline|epinephreine or normal saline coated syringe before drawing allergen for injection.
214311477|NCT02708147|OTHER|Physiotheraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
214311478|NCT02708147|OTHER|Conventional treatment|Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
214311479|NCT01103687|BIOLOGICAL|Ad26.ENVA.01 (rAd26)|5 x 10\^10 virus particles (VP) vaccine delivered intramuscularly (IM)
214311480|NCT01103687|BIOLOGICAL|Placebo Vaccine|Placebo vaccine delivered IM
214311481|NCT02872779|PROCEDURE|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
214311482|NCT04427774|DRUG|Surufatinib plus Sintilimab|Surufatinib will be given orally. Sintilimab will be given intravenously
214311483|NCT02110342|DRUG|[14C] PF-04449913|Single oral dose of 100 mg PF-04449913 + 100µCi of \[14C\] PF-04449913
214311484|NCT06418841|PROCEDURE|Computer-Assisted Paramedian Approach Technique|Computer-Assisted Paramedian Approach Technique
214311485|NCT06418841|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
214311486|NCT00178035|DRUG|paroxetine|
214311487|NCT00178035|BEHAVIORAL|One night of Total Sleep Deprivation|
214311488|NCT05631405|DRUG|Dexamethasone|Patients treated with dexamethasone
214311489|NCT05631405|DRUG|Placebo|Patients treated with placebo
214347123|NCT01605045|OTHER|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
214347124|NCT01605045|OTHER|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
214347125|NCT01117311|DEVICE|VNB on|The implanted Vagal Nerve Blocker will be on at the time of study.
214347126|NCT01117311|DEVICE|VNB off|The implanted Vagal Nerve Blocker will be off at the time of study.
214311490|NCT06220708|OTHER|dance movement therapy|Our DMT program was adapted from an integrated somatic dance and visual arts program previously applied to the older population (Hsu, 2023). The intervention was scheduled in the afternoon and lasted for approximately 2 h. As previously recommended, rhythmic and contralateral movements on both sides of the body were emphasized in this study to enhance coordination and stimulation between the left and right cerebral hemispheres (Phillips-Silver and Trainor, 2007). The experimental groups were then subdivided into six groups. Balloons half-filled with water were used as the game in this study to guide individual and grouping rhythms and movements. Additionally, painting was incorporated to help participants understand their bodies and psychological states (Tjasink et al., 2023). Finally, group discussions and mutual support, along with verbal sharing after the DMT exercise, were encouraged.
214311491|NCT06220708|OTHER|yoga training|The yoga program included breathing exercises, Asanas, eye focus, body lock, and meditation. Participants were instructed to adjust their positioning based on their skill level to mitigate the risk of injury. The yoga intervention was scheduled at 2 pm and lasted for approximately 2 h.
214311492|NCT00973024|DRUG|JNJ-42160443 3 mg|JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
214311493|NCT00973024|DRUG|JNJ-42160443 1 mg|JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
214311494|NCT00973024|DRUG|JNJ-42160443 6 mg/3mg|JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
214311495|NCT00973024|DRUG|JNJ-42160443 10 mg|JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
214311496|NCT00973024|DRUG|Matching Placebo|Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
214311497|NCT02578927|DIETARY_SUPPLEMENT|GT+Ex|In this session the volunteers ingested capsules with 2g of powder green tea before exercise
214311498|NCT02578927|DIETARY_SUPPLEMENT|PL+Ex|In this session the volunteers ingested capsules with 2g of placebo before exercise
214311499|NCT02578927|DIETARY_SUPPLEMENT|Green Tea|In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
214311500|NCT05627531|BEHAVIORAL|Narrative Medicine|Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
214311501|NCT06385145|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
214311502|NCT06385145|DRUG|PEG-rhGH with present preparation (R)|A single subcutaneous injection of PEG-rhGH with present preparation
214311503|NCT04430010|BEHAVIORAL|BEST in CLASS|BEST in CLASS is a Tier-2 evidence based program (EBP) that has demonstrated effectiveness at reducing children's Disruptive Behavior Problems (DBPs) and risk for Emotional and Behavioral Disorders (EBDs)
214311504|NCT04017936|DRUG|Anakinra|Active Treatment
214481084|NCT06694584|BEHAVIORAL|Tea(m)Time|Tea(m)Time is divided into two phases, starting with the qualification of team leaders. This starts with knowledge transfer about healthy leadership, resilience, occupational health and safety, posture work, psychological empowerment, agile management and the role of the manager. The team leaders also learn various moderation/coaching techniques. The qualification is followed by the implementation of Tea(m)Time. The teams start each hour with self-reflection. This is followed by a stress assessment and prioritization. The teams then work on the problems identified and look for solutions together.
214481085|NCT06695728|OTHER|exercise|It consists of exercises to be done with the exoskeleton. These are; jumping exercise, squat, sit-stand and forward bending exercises.
214481086|NCT06695013|DRUG|zanubrutinib|zanubrutinib 160 mg BID orally
214481087|NCT06695013|DRUG|CAR-T|CAR-T Cell therapy
214917412|NCT06382701|OTHER|placebo|This is the group in which 0.5-1 ml of aromatic clove, which does not contain active ingredients and is dissolved in pure water, is applied as a spray to the arterio-venous fistula area, depending on the length of the fistula, ten minutes before needle cannulation in all hemodialysis sessions for four weeks in individuals receiving standard hemodialysis treatment.
214481088|NCT06695013|RADIATION|Bridging radiotherapy|For patients in the experimental group, the decision regarding radiotherapy will depend on whether the specific lesions are suitable.
214481089|NCT06695013|DRUG|Tislelizumab|200mg IV Q3-4W
214481090|NCT06873399|DIAGNOSTIC_TEST|MS-39|The MS-39 (Costruzione Strumenti Oftalmici, Firenze, Italy) is a device for anterior segment analysis of the eye, which combines Placido disc corneal topography and high-resolution SD-OCT. The device provides information on pachymetry, elevation, curvature, and dioptric power of both corneal surfaces. To obtain corneal topography, 22 Placido disc rings are emanated from a laser emitted diode (LED) light source at 635 nanometres (nm). The central 10 millimetres of the anterior corneal surface are covered. Epithelial thickness maps are calculated for different sectors (central, paracentral inferior/superior/nasal/temporal).
214670928|NCT02018510|BIOLOGICAL|3 mg/kg, single dose IV administration of 3BNC117|3 mg/kg, single dose IV administration of 3BNC117
214670929|NCT02018510|BIOLOGICAL|10 mg/kg, single dose IV administration of 3BNC117|10 mg/kg, single dose IV administration of 3BNC117
214670930|NCT02018510|BIOLOGICAL|30 mg/kg, single dose IV administration of 3BNC117|30 mg/kg, single dose IV administration of 3BNC117
214917413|NCT05871762|OTHER|Registry study, no specific intervention|Registry study, no specific intervention
214670931|NCT02018510|BIOLOGICAL|10 mg/kg, two doses IV of 3BNC117|10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
214311505|NCT01161992|GENETIC|Genetic Analysis|Perform Genome Wide Association Studies.
214311506|NCT05908786|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
214311507|NCT05908786|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.
214311508|NCT05908786|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.
214311509|NCT05908786|DRUG|Tobemstomig|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
214311510|NCT00870571|DRUG|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
214311511|NCT00870571|DRUG|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
214311512|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 24%|transfusion
214311513|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 28%|transfusion
214311514|NCT01524692|DRUG|Dovitinib (TKI258)|500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
214311515|NCT03984591|DRUG|Eplerenone|Eplerenone according to guidelines
214311516|NCT03984591|DRUG|Spironolactone|Spironolactone according to guidelines
214311517|NCT01970111|DRUG|KPS-0373, High dose|
214311518|NCT01970111|DRUG|KPS-0373, Low dose|
214311519|NCT04976634|DRUG|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
214311520|NCT04976634|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
214311521|NCT04976634|DRUG|Lenvatinib|Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
214311522|NCT06369168|DEVICE|auricular acupuncture|two auricular acupuncture methods are compared with each other and with no treatment
214311523|NCT06967181|BIOLOGICAL|CVM150|CVM150- Live PIV5-based MuV vaccine expressing the MuV (Iowa strain/2006) F and HN proteins formulated in 1x sucrose phosphate glutamate (\[SPG\]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.
214311524|NCT06967181|BIOLOGICAL|CVM26|CVM26: A live, attenuated MuV vaccine based on Iowa strain genetically edited to remove the V and SH protein expression. Formulated in 1x sucrose phosphate glutamate (\[SPG\]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.
214311525|NCT06967181|OTHER|Placebo|Placebo: 0.9% normal sterile saline (purchased commercially).
214311526|NCT06970925|DIETARY_SUPPLEMENT|Sucrosomial Iron (SI)|The Sucrosomial Iron (SI) you may receive is a considered a supplement, so it has not been approved by the U.S. Food \& Drug Administration (FDA) for sale. However, it is available for over-the-counter purchase. Sucrosomial Iron (SI) has been developed by PharmaNutra.
214311527|NCT04022772|OTHER|Best Practice|Receive standard of care
214670932|NCT02018510|BIOLOGICAL|30 mg/kg, two doses IV of 3BNC117|30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
214670933|NCT03626753|DRUG|Nefopam 20 MG/ML|given by Oral route the dose of 20mg every 6 hours.
214670934|NCT03626753|DRUG|"Nefopam (Acupan) 20 MG/ML Injectable Solution"|given by intravenous route at the dose of 20mg every 6 hours.
214311528|NCT04022772|OTHER|Medical Chart Review|Ancillary studies
214311529|NCT04022772|OTHER|Quality-of-Life Assessment|Ancillary studies
214311530|NCT04022772|OTHER|Questionnaire Administration|Ancillary studies
214311531|NCT04022772|PROCEDURE|Supportive Care|Participate in PACK Health program
214311532|NCT00310531|DRUG|Menostar (Estradiol, BAY86-5435)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
214311533|NCT00310531|DRUG|Raloxifene|Raloxifene tbl. (60 mg/day)
214311534|NCT06821867|DEVICE|PN + HA (Newest)|"PN+HA (Newest) is a viscoelastic, sterile, single-use gel for intradermal use. PN+HA is a medical device containing the combination of polynucleotides (10 mg/ml) and hyaluronic acid (10 mg/ml).~PN+HA is administered using a fine needle (usually 30 G) by injecting the solution into the dermis. Depending on the medical assessment, different injection techniques such as linear threading, serial punctures, crosslinked, radial fanning or mixed can be used. The injection site must consist of healthy skin. PN+HA can also be administered by means of non-invasive techniques (iontophoresis, electroporation, hydroelectrophoresis, etc.). In all these cases, thoroughly cleanse and disinfect the area to be treated before application. Then remove the disinfectant with sterile saline."
214311535|NCT02335723|DEVICE|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
214311536|NCT02335723|DEVICE|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
214311539|NCT01321268|DIETARY_SUPPLEMENT|dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)|oral, twice daily in morning and evening for 6 months
214311540|NCT01321268|DIETARY_SUPPLEMENT|Viatmin E|oral, twice daily in morning and evening for 6 months
214311541|NCT01649531|PROCEDURE|1 Implant|
214311542|NCT01649531|PROCEDURE|2 Implants|
214311543|NCT03902535|OTHER|Comprehensive Geriatric Assessment|Complete comprehensive geriatric assessment
214917414|NCT05664360|OTHER|Age (young versus older)|Age
214311544|NCT03902535|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
214311545|NCT03902535|OTHER|Questionnaire Administration|Complete questionnaires
214311546|NCT03303378|DRUG|melatonin (Helsinn Chemical Co, Biasca, Switzerland)|"Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention)."
214311547|NCT03303378|DRUG|Placebos|The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
214311548|NCT03675802|DRUG|misoprostol|giving misoprostol to this group
214311549|NCT03675802|DRUG|dinoprostone|giving dinoprostine
214311550|NCT02743650|DIETARY_SUPPLEMENT|Sodium bicarbonate|The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
214311551|NCT05232240|DIAGNOSTIC_TEST|blood pressure variability measured by ambulatory 24-hour blood pressure monitoring|The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.
214311552|NCT01253759|PROCEDURE|TTT + ICG-based PDT|
214311553|NCT01209442|DRUG|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
214311554|NCT01209442|DRUG|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
214311555|NCT01209442|RADIATION|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
214311556|NCT01709695|DRUG|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
214311557|NCT01709695|DRUG|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
214311558|NCT00911261|DRUG|Oxymorphone Extended Release|"* Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~* Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~* Treatment will consist of up to 12 months of dosing with Oxymorphone ER."
214311559|NCT06481514|OTHER|Interpretation of the CTG using FRI score|At each of the components of the score will be assigned a score of 1 if the variable evaluated is considered normal, 0 if classified as abnormal. To encourage a simplified clinical interpretation of the different scores obtained (score from 1 to 8) they will be classified into 3 risk categories: Score 5-8: green zone, Score 3-4: zone yellow, Score 1-2: red zone. An FRI of 1-2 (red zone) is to be considered as anomalous
214311560|NCT06481514|OTHER|Classic interpretation of the CTG|evaluate the CTG of group B patients according to the usual internal management protocols
214311561|NCT04650802|DEVICE|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
214311562|NCT02220933|DRUG|MD1003 100mg capsule|
214311563|NCT02220933|DRUG|Placebo|
214481091|NCT06680271|OTHER|Remote exercise|The intervention group will consist of 25 subjects receiving a multicomponent physical exercise intervention (aerobic, strength, flexibility, and neuromotor) delivered by a physical therapist via the Microsoft Teams platform
214481092|NCT06680271|OTHER|Home exercise|The control group will consist of 25 subjects receiving traditional physical therapy at home from a physical therapist.
214311564|NCT06209151|OTHER|monitor signs of infection|Prospective observational study of 1040 patients admitted to the ICU without any signs of infection. All patients were subjected to one or more of the most used procedures in ICU (Intubation \& mechanical ventilation, Central line insertion and Urinary catheterization) for at least 48 hours. Then, they were followed for any signs of infection either clinically or laboratorial.
214311565|NCT06043076|DEVICE|TMS|Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
214311566|NCT06043076|DEVICE|Sham|Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head
214311567|NCT02605707|DRUG|Intravenous stem cell transplantation|Intravenous injection of autologous endothelial progenitor cells transplantation
214311568|NCT04503759|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
214311569|NCT03817385|DEVICE|repetitive TMS|rTMS x 10 times
214311570|NCT03817385|DEVICE|robotic GT|robotic gait training for 20 times
214311571|NCT02882854|DRUG|Guanfacine|Patients will receive 1 mg of guanfacine to take orally.
214311572|NCT02882854|DRUG|Placebo|Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
214481093|NCT06696677|DIAGNOSTIC_TEST|CT|CT measurment of small bowel
214481094|NCT06696677|PROCEDURE|Measuring the small instestine length using pre-marked laparoscopic graspers|Intra-operatively, the surgeon will assess the length of the small intestine using a 5-cm marked laparoscopic graspers to accurately assess the whole small intestine length.
214670935|NCT03626753|DRUG|"Acetaminophen, (paracetamol) 500Mg Tab"|"2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours."
214670936|NCT03626753|DRUG|"(Acetaminophen paracetamol) IV Soln 10 MG/ML"|Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
214670937|NCT03626753|DRUG|"(Piroxicam piroxan) 20 MG Oral Tablet"|"2 tablets of piroxicam (piroxan) administrated orally once per 24 hours."
214311573|NCT00374881|DRUG|Morphine|Morphine
214311574|NCT00374881|DRUG|Morphine|Morphine low dose
214311575|NCT00374881|DRUG|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
214311576|NCT00374881|DRUG|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
214311577|NCT00374881|DRUG|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
214311578|NCT00788892|DRUG|CPX-351|
214311579|NCT00788892|DRUG|Cytarabine|
214311580|NCT00788892|DRUG|Daunorubicin|
214311581|NCT01278485|DRUG|Sulphonylurea|SU administered according to usual practice.
214311582|NCT01278485|DRUG|Metformn|Metformin administered according to usual practice.
214311583|NCT02039674|BIOLOGICAL|Pembrolizumab|IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
214311584|NCT02039674|DRUG|Paclitaxel|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
214311585|NCT02039674|DRUG|Carboplatin|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
214311586|NCT02039674|BIOLOGICAL|Bevacizumab|IV on Day 1 of each 3-week cycle
214311587|NCT02039674|DRUG|Pemetrexed|IV on Day 1 of each 3-week cycle
214481095|NCT06698107|BEHAVIORAL|Childbirth education programme|"The intervention framework is underpinned by a converging of salutogenic and self-efficacy perspectives, aiming to enhance mothers' ability to adapt to new motherhood life despite stressors, and to address the question, How do teenage mothers stay well despite stressful events of transition to motherhood? The intervention consists of six sessions: three of which will be provided in the antenatal period and the other three in the postpartum period. The sessions contain two individual face-to-face educations (each lasting 60-90 minutes), two phone calls (each lasting 30 minutes), and two group discussion sessions (each lasting 90-120 minutes), as supported by the existing evidence."
214481096|NCT06698107|OTHER|Usual Care|The control group will receive the usual maternity care.
214481097|NCT06697964|OTHER|HRA|High resolution anoscopy to help evaluate anal conditions such as precancerous lesions
214311588|NCT02039674|BIOLOGICAL|Ipilimumab|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
214311589|NCT02039674|DRUG|Erlotinib|Orally tablet once daily
214311590|NCT02039674|DRUG|Gefitinib|Oral tablet once daily
214311591|NCT04097093|OTHER|No intervention|No intervention
214311592|NCT02561637|BEHAVIORAL|Case management|
214311593|NCT02561637|BEHAVIORAL|Control group|
214311594|NCT01358357|DRUG|Lurasidone|Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
214311595|NCT01358357|DRUG|Placebo|20-80 mg flexible dose
214481098|NCT04252482|DEVICE|CPAP|Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 12 weeks
214481099|NCT02461134|DRUG|Ponesimod|Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
214481100|NCT06807892|OTHER|Synergistic management|In synergistic management, exercises are carried out in a synergistic way: 40 minutes of exercises involving both physical and cognitive stimulation.
214670938|NCT03626753|DRUG|"(Piroxicam piroxan) 20Mg/1mL Injection"|"2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours."
214311596|NCT01902264|DRUG|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
214311597|NCT03021850|PROCEDURE|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
214311598|NCT02475551|DRUG|IdeS|Intravenous infusion
214311599|NCT06390969|OTHER|Survey|Cross-sectional online survey
214311600|NCT03098537|DRUG|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
214311601|NCT03098537|OTHER|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
214311602|NCT04405648|BEHAVIORAL|CVS GROUP|the students will respond to CVS-F3 questionnaire to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors.
214311603|NCT05543122|DRUG|either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe|This is a cohort study of pharmacokinetics of drugs in milk. Participants in the group are those breastfeeding women on the listed drugs at steady state, who are prescribed these drugs for clinical reasons outside this study framework.
214311604|NCT01330485|BEHAVIORAL|Affect Regulation Training|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
214311605|NCT01330485|BEHAVIORAL|Common Factor Control Condition|The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
214311606|NCT02590939|DEVICE|CEFALY Active|Active external trigeminal nerve stimulation
214311607|NCT02590939|DEVICE|CEFALY Placebo|Placebo external trigeminal nerve stimulation
214311608|NCT00625976|BEHAVIORAL|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
214311609|NCT00625976|BEHAVIORAL|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
214311610|NCT02273895|DRUG|Scopolamine|0.3 mg/mL, intravenously, once
214311611|NCT06029634|DIAGNOSTIC_TEST|T-bet B cell|The frequency, function, and phenotype of T-bet B cells was tested
214311612|NCT00368654|DRUG|Methotrexate|Initial dose 5 mg, then 15 mg per week
214311613|NCT00368654|DRUG|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
214311614|NCT01285245|DRUG|kineret|once daily 100 mg of kineret subcutaneously for 8 days
214670939|NCT01062399|DRUG|concurrent RAD001 10 mg/day|During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
215060756|NCT04114708|DIAGNOSTIC_TEST|ACLR with lateral extra-articular tenodesis (LET)|All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
215060757|NCT00729911|PROCEDURE|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
215060758|NCT00729911|DRUG|Amiodarone|Taken orally on a daily basis.
215060759|NCT06389344|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
215060760|NCT06389344|DRUG|normal saline|Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
215060761|NCT04351607|DIETARY_SUPPLEMENT|Oleovital® Eisen Forte|60 mg daily oral Supplementation for 3 to 6 weeks
215060762|NCT00330980|DRUG|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
215060763|NCT00330980|DRUG|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
215060764|NCT00330980|DRUG|Placebo|Participants will receive placebo for 6 months.
214311615|NCT00930566|DRUG|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
214347127|NCT00472667|PROCEDURE|Procalcitonin guided strategy|Procalcitonin guided strategy
214347128|NCT01235455|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
214347129|NCT05804058|PROCEDURE|Revision surgery|Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)
214347130|NCT00447863|DRUG|Levonorgestrel/Ethinyl Estradiol|
214347131|NCT01478789|DIETARY_SUPPLEMENT|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
214347132|NCT01478789|DIETARY_SUPPLEMENT|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
214347133|NCT01478789|DIETARY_SUPPLEMENT|placebo|100g/d yogurt with no added plant sterol
214347134|NCT02584049|OTHER|Osteopathy|3 sessions of osteopathy during 60 minutes each
214347135|NCT02584049|OTHER|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
214347136|NCT02458105|BEHAVIORAL|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
214347137|NCT02458105|BEHAVIORAL|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
214347138|NCT00887172|DRUG|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
214347139|NCT00887172|DRUG|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
214347140|NCT00887172|DRUG|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
214347141|NCT06039332|PROCEDURE|Fitting of the audioprocessor with the auditory implant BCI602|to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures
214347142|NCT02067403|OTHER|Pressure-support Eadi optimization|
214347143|NCT05774808|PROCEDURE|Aortic valve replacement|An aortic valve prosthesis is surgically implanted to treat AR
214347144|NCT05774808|PROCEDURE|Mitral valve annuloplasty|Surgical repair of the mitral valve in which a prosthetic ring is implanted to treat MR
214347145|NCT02439346|DRUG|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
214347146|NCT04558346|DRUG|Ghrelin (OXE-103)|40ug/kg twice daily by self-injection
214347147|NCT04558346|DRUG|Placebo|40ug/kg twice daily by self-injection
214347148|NCT00875953|PROCEDURE|standard neck dissection|standard surgical technique
214347149|NCT00875953|PROCEDURE|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
214347150|NCT03494010|OTHER|Observation|There is no intervention. Patients will receive the HCL system as part of their clinical care.
214917415|NCT00570063|DRUG|PF-02545920|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
214311616|NCT00930566|PROCEDURE|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
214311617|NCT02347189|DEVICE|Melody Transcatheter Pulmonary Valve PB1016|
214311618|NCT03384550|BEHAVIORAL|Self-regulation coaching|Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
214311619|NCT03384550|BEHAVIORAL|Planning|A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
214311620|NCT03384550|BEHAVIORAL|Financial Incentives|Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.
214311621|NCT03384550|BEHAVIORAL|Charity Incentives|Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
214311622|NCT03293732|BIOLOGICAL|DCB07010|A protein based adjuvant originated from prokaryotic organism.
214311623|NCT03293732|BIOLOGICAL|HA antigens|HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
214311624|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 1
214311625|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 2
214311626|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 3
214311627|NCT03014323|DRUG|Galantamine|Galantamine 4 mg twice a day for 4 weeks
214311628|NCT03014323|DRUG|Placebo|Placebo 1 capsule twice a day for 4 weeks
214481101|NCT06807892|OTHER|Sequential management|In sequential management, exercises are performed sequentially: 20 minutes of physical exercises and 20 minutes of cognitive exercises.
214481102|NCT06698757|BIOLOGICAL|Sintilimab|Subjects were enrolled and received Sintilimab at a dose of 200 mg, administered via intravenous infusion on the first day of each cycle, with each cycle lasting 3 weeks (Q3W)
214481103|NCT04761198|DRUG|Etigilimab|IV infusion of IV etigilimab every 2 weeks
214481104|NCT04761198|DRUG|Nivolumab|IV infusion of nivolumab every 2 weeks
214481105|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®)|ADM (Novomatrix®) will be used alone
214481106|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®) + L-PRF|ADM in combination with L-Prf will be applied
214917416|NCT00570063|DRUG|Placebo|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
214917417|NCT03082859|BEHAVIORAL|Exercise|This a randomised cross-over study involving three different modes of exercise which will be compared to a no-exercise control.
214917418|NCT06156995|DEVICE|Deep Acupuncture at Zhongliao Point to Stimulate Sacral Nerve|Using 0.30mm × 75mm millineedle (produced by Suzhou Medical Equipment Factory, Huatuo brand) deeply punctures the Zhongliao acupoint to reach the sacral nerve. The acupuncture needle is connected using the MuhiStim Sensor nerve stimulator produced by Pajunk in Germany. Connect the positive pole to the left Zhongliao hole and the negative pole to the right Zhongliao hole. The frequency, current, and pulse width of sacral nerve electrical stimulation are 2 Hz, 5mA, and 0.1 ms, respectively.Electroacupuncture stimulates the sacral nerve for 30 minutes, once a day, five times a week. After the treatment, rest for two days before starting the next treatment. Five sessions are considered as one course of treatment, with a total of four courses for four consecutive weeks.
215060765|NCT05891535|PROCEDURE|Robot assisted radical cystectomy without mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
214311629|NCT01277952|DEVICE|Deep Brain Stimulation|Brain pace maker, implanted in the brain
214311630|NCT00994240|PROCEDURE|Electrodessication & Curettage|Electrodessication \& Curettage 1 or 3 cycles
214311631|NCT04754776|BIOLOGICAL|ChAdOx1 RVF|Single dose of ChAdOx1 RVF
214311632|NCT05735301|PROCEDURE|Endovascular|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA"
214311633|NCT05735301|DRUG|Drug|best drug conservative therapy could be uesd in patients who with no indication of surgery
214311634|NCT01886183|OTHER|Virtual Reality Training|The participants of the study will be trained 8 balance games during 14 sessions
214311635|NCT01886183|OTHER|Physical Therapy|Patients of the control group will be trained with balance exercises.
214311636|NCT03266991|DRUG|Rifapentine|Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
214311637|NCT03266991|DRUG|Isoniazid|Treatment with daily isoniazid in 6 months
214311638|NCT04931433|DRUG|Lignocaine|Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.
214311639|NCT04931433|DRUG|Normal saline|Group B will receive saline of similar volume and rate as Group A
214311640|NCT02038582|OTHER|POC CD4 Testing|Point of Care CD4 testing
214481107|NCT06634160|DIAGNOSTIC_TEST|Fibroscan|Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).
214311641|NCT02038582|OTHER|CD4 Referral|Referral to CD4 testing
214311642|NCT02038582|BEHAVIORAL|Lay Counselor Follow-up|Follow-up from a lay counselor
214311643|NCT02038582|BEHAVIORAL|Clinic Accompaniment|Accompaniment to the clinic by a counselor
214311644|NCT02038582|BEHAVIORAL|Clinic Referral|Referral to clinic
214311645|NCT02038582|BEHAVIORAL|SMS Reminder|SMS reminder for male circumcision
214311646|NCT02038582|BEHAVIORAL|Circumcision Promotion|Promotion of male circumcision at the time of HIV testing
214311647|NCT02038582|OTHER|POC VL|POC VL testing for HIV infected persons on ART
214311648|NCT02038582|OTHER|Laboratory based VL assay|Laboratory based viral load testing for HIV infected persons on ART
214311649|NCT00763165|DRUG|Triclosan|Brush twice daily
214311650|NCT00763165|DRUG|Fluoride|Brush twice daily
214311651|NCT00763165|DRUG|Fluoride|Brush twice daily
214311652|NCT05213923|PROCEDURE|ED Sepsis Tracking Sheet|Implementation of an ED Sepsis Tracking Sheet. This sheet will track time of patient presentation, time of High-Acuity Medical Response (HAMR) page, time of bilateral 18g or larger IV access, time of initial lactate, time two sets of blood cultures were sent, time antibiotics were administered as well as which antibiotics and what dose, time initial IV fluid bolus was completed, time repeat lactate was sent, timing of post-IV-fluid bolus vital signs, as well as the presence of persistent hypotension following this IV fluid bolus and whether or not vasopressors were applied.
214311653|NCT06264206|DIAGNOSTIC_TEST|Killer-cell immunoglobulin-like receptors (KIRs) testing|patients were tested for KIRs, and based on the divided in the 2 arms. Patient from ARM KIR AA received immunomuodulatorc treatment.
214311654|NCT04896710|DEVICE|SD Biosensor|Nasal swab SD biosensor to be self administered
214311655|NCT01457885|DRUG|Clofarabine/Busulfan x 4|"* Clofarabine IV dose level: 40 mg/m2/day x 5 days~* Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
214311656|NCT01457885|PROCEDURE|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
214311657|NCT02770586|DIAGNOSTIC_TEST|Breast PET|imaging of the breast using the Breast PET system
214670940|NCT01062399|DRUG|concurrent temozolomide|During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
214311658|NCT06160063|BEHAVIORAL|Education intervention|Board game was created in line with current literature. In each interview, it is expected that the child's negative behaviors will be transformed into positive behaviors.
214311659|NCT05832333|BIOLOGICAL|VaxigripTetra®|Suspension for injection Injection intramuscular
214311660|NCT02064881|DRUG|Metformin glycinate|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .
214311661|NCT02064881|DRUG|Metformin Hydrochloride|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)
214311662|NCT03379207|OTHER|Blood samples|Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
214311663|NCT03379207|OTHER|Tracheal Aspirates|Only for mechanically ventilated participants.
214311664|NCT03379207|OTHER|Surplus of Broncho-alveolar lavage fluid|Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion
214311665|NCT05768152|DEVICE|RLRL|RLRL will be performed twice per day with an interval of at least 4 hours, each treatment last 3 minutes, in addition to single vision spectacles with power for correcting distance refraction.
214311666|NCT01024907|RADIATION|proton beam radiation therapy|Undergo radiation
214917419|NCT06156995|DRUG|Oral Mosapride Tablets|Mosapride citrate tablets (produced by Lunan Beite Pharmaceutical Co., Ltd., with the national drug approval number H19990317), oral administration, 5mg once, three times a day, taken before meals. 5 days is one course of treatment, with 2 days of rest during the treatment period. The total treatment period is 4 weeks, with a total of 4 courses.
214917420|NCT00697463|DRUG|Teriparatide (PTH 1-34)|20 micrograms subcutaneous injection daily
214917421|NCT05191290|DRUG|unfractionated heparin|standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis
214917422|NCT05191290|DRUG|Sodium Citrate|8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis
214917423|NCT03307252|DRUG|Digoxin|Tablet
214311667|NCT01024907|PROCEDURE|quality-of-life assessment|Ancillary study
214311668|NCT01024907|OTHER|questionnaire administration|Ancillary study
214917424|NCT03307252|DRUG|Furosemide|Oral solution
214917425|NCT03307252|DRUG|Metformin|Oral solution
214311669|NCT01089439|DRUG|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
214311670|NCT01089439|DRUG|Placebo|placebo
214311671|NCT02227342|BIOLOGICAL|Fecal Microbiota Transplant|serial FMT
214311672|NCT03745092|DEVICE|normobaric oxygen|Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
214311673|NCT03745092|DEVICE|room air|The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
214311674|NCT03979638|DRUG|BLU-5937|Four escalating doses of BLU-5937 administered BID over the course of the study
214917426|NCT03307252|DRUG|Rosuvastatin|Film-coated tablet
214917427|NCT03307252|DRUG|Verapamil|Film-coated tablet
214917428|NCT03307252|DRUG|Rifampin|Film-coated tablet
214917429|NCT03307252|DRUG|Cimetidine|Tablet
214917430|NCT03307252|DRUG|Probenecid|Tablet
214917431|NCT03093142|DEVICE|tDCS & neurofeedback|tDCs and neurofeedback
214917432|NCT03093142|DEVICE|neurofeedback|Neurofeedback
214311675|NCT03979638|DRUG|Placebo|Matching placebo for BLU-5937
214311676|NCT04255355|OTHER|Pelvic alignment and forceful expiration|"The participant will be in supine with feet flat on a wall and the knees and hips flexed to 90 degrees. A standard 5 ball will be placed between the knees. The participant will hold a standard 9-inch balloon in the mouth with one hand. The subject will be instructed to isometrically contract the hamstrings to lift the ischium off the table while maintaining a posterior pelvic tilt. In this position, subject will be instructed to perform isometric hip adduction by squeezing the ball placed between the knees. The subject will then be instructed to breathe in through the nose and blow the air out into the balloon with full exhalation to activate the transverse and oblique abdominals. The participant will hold the breath for 3 seconds while maintaining hamstring contraction, adductor contraction, and transverse and oblique abdominal contraction. This process will be repeated four times. This exercise will be performed once daily under the supervision of the therapist for 5 days."
214311677|NCT04255355|OTHER|Pelvic repositioning exercise|The participant will be positioned supine with their feet flat on a wall and the knees and hips flexed to 90 degrees. The subject will be instructed to isometrically contract the hamstrings to allow the ischial tuberosities to lift off the table while also maintaining a posterior pelvic tilt. The tailbone should be slightly lifted off the table, the abdominal muscles should be relaxed, and the low back should be flat on the table. While maintaining the posterior pelvic tilt, the subject will be instructed to perform isometric hip adduction by squeezing the ball that is placed between the knees. The subject will hold for 3 seconds and then relax. This process will be repeated four times. This exercise will be performed daily under the supervision of the therapist for 5 days.
214311678|NCT04255355|OTHER|Diaphragmatic breathing exercise|For diaphragmatic breathing exercise, the subject will be in supine position. The investigator places both hands around the participant's lower ribs and abdominal area. The investigator applies slight manual resistance to the chest and abdominal wall during inhalation phase of breathing.The participant is instructed to apply outward pressure against the investigator resistance and to raise the chest and abdominal wall simultaneously with inhalation. Then participants performs a full exhalation and hold his/her breath for 3 seconds before breathing in again. This process is repeated for 4 breathing cycles. Participants will perform this exercise once a day under investigator supervision.
214311679|NCT01064492|DRUG|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
214311680|NCT00945581|OTHER|Experimental Nutritional Powder Formula|Powder twice a day
214311681|NCT00945581|OTHER|Placebo comparator|Powder twice a day
214311682|NCT04130399|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.
214311683|NCT04130399|DRUG|FOLFIRINOX|Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
214311684|NCT04461782|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Oral food supplement
214347151|NCT05122845|BIOLOGICAL|Blood sample|"Blood test (10 tubes of 5mL) :~\- 6 tubes for : complete blood count, platelets, reticulocyte count, TP-INR, AST, ALT, GGT ferritin, serum iron, CRP, transferrin, soluble transferrin receptors, transferrin saturation coefficient enzymatic creatinine, MDRD, ionogram calcemia, phosphoremia, PTH, 25 (OH) D3, 1.25 (OH) 2D3.~2 dry tubes 2 tube EDTA"
214347152|NCT04461522|PROCEDURE|Ultrasound-guided drug injection|The injection drugs were glucocorticoids and anesthetic drugs (1ml+2% lidocaine hydrochloride 0.5ml+0.9% sodium chloride 0.5ml), and the injection sites were subacromion deltoid bursa/coracoid bursa/biceps longhead tenosynosheath/glenohumeral joint bursa, etc.
214481108|NCT06634160|OTHER|Sample collection|20 mL whole blood sample
214481109|NCT06632990|DRUG|BMS-984923|oral capsules once or twice daily
214481110|NCT06632990|DRUG|Midazolam|midazolam, oral, 2mg administered before study drug and after study drug
214481111|NCT06632990|DRUG|Caffeine|Caffeine, oral, 100mg administered before study drug and after study drug
214481112|NCT06632990|DRUG|dextromethorphan|dextromethorphan, oral, 30mg administered before study drug and after study drug
214917433|NCT03093142|DEVICE|sham neurofeedback|sham neurofeedback
214917434|NCT03444662|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose and Sunflower oil
214917435|NCT03444662|DIETARY_SUPPLEMENT|Citicoline and Omega-3 supplement|Citicoline and Omega-3
214917436|NCT03444662|DIETARY_SUPPLEMENT|Omega-3 supplement|Cellulose and Omega-3
214347153|NCT01462344|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
214917437|NCT00624429|DRUG|Budesonide respules|Budesonide respules 0.5 mg nebulized once a day for 4 months of the study.
214917438|NCT02568189|DEVICE|SonoSite Maxx Series Ultrasound System|Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
214347154|NCT01462344|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
214347155|NCT01462344|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
214347156|NCT01462344|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
214347157|NCT02450994|DRUG|Dexamethasone|
214347158|NCT02450994|DRUG|Placebo|
214347159|NCT00724971|DRUG|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
214347160|NCT00724971|DRUG|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
214347161|NCT00608712|DRUG|Esomeprazole|Esomeprazole 20mg oral tablet
214917439|NCT03166722|OTHER|Control group|SpO2 and HR monitoring and routine treatment during immediate transition
214917440|NCT03166722|DEVICE|Study group|Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
214311685|NCT02576028|OTHER|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
214481113|NCT06632418|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
214481114|NCT03533257|DRUG|AMX0035|Combination Therapy of PB and TURSO
214481115|NCT03533257|DRUG|Placebo|Placebo
214481116|NCT06619717|PROCEDURE|Hyperbaric Oxygen Therapy|"Three treatments with hyperbaric oxygen therapy. The exact parameters of each dive will be left to individual clinicians. Commonly used treatments would be:~Weaver protocol, or similar (i.e. 100% oxygen at 3 atmospheres for 90 minutes with two 10-minute air breaks every 30 minutes. Repeat this every 8 hours until 3 treatments are complete.)"
214481117|NCT06619717|PROCEDURE|Hyperbaric Oxygen Therapy|Single treatment with hyperbaric oxygen. Exact parameters left to treating physician but commonly: 100% oxygen at 2.8 atmospheres for 30 minutes followed by a 10-minute air break, then 100% oxygen at 2 atmospheres for 60 minutes with one 10-minute air break after 30 minutes
214481118|NCT06406452|DEVICE|Bioresorbable Tracheobronchial Splint|"Subjects will have several imaging and bronchoscopic studies and the placement of the splint will require an open-chest surgery to implant the airway splint (s).~The Materialise Bioresorbable Tracheobronchial Splint is designed for an individual subject based on Computed Tomography (CT) scans taken using a specific scan protocol. Based on these 3D models, a pre-operative plan is discussed between the Materialise engineering team and the treating surgeon(s) to determine the locations and required dimensions of the splint(s). Each subject may receive up to four splints positioned on subject's trachea or mainstem bronchi.~Subjects will also have several follow-up visits, and parents will be expected to regularly fill out questionnaires."
214481119|NCT06365099|DEVICE|Single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere while participants rest quietly with their eyes open
214481120|NCT06105164|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher."
214481121|NCT06105164|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
214670941|NCT01062399|RADIATION|Radiation therapy|Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
214670942|NCT01062399|DRUG|concurrent RAD001 2.5 mg/day|During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
214311686|NCT02576028|OTHER|standard active exercises|two sessions of 45 minutes of active exercises
214311687|NCT05112380|OTHER|Performing Xco endurance test|The subjects will perform the test two times, with 7-10 days between the two sessions
214311688|NCT00901758|DRUG|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
214311689|NCT00901758|DRUG|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
214311690|NCT02620514|BEHAVIORAL|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
214311691|NCT02620514|BEHAVIORAL|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
214311692|NCT02620514|BEHAVIORAL|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
215060766|NCT05891535|PROCEDURE|Robot assisted radical cystectomy with mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
214311693|NCT02620514|BEHAVIORAL|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
214670943|NCT01062399|DRUG|concurrent RAD001 5 mg/day|During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
214670944|NCT01062399|DRUG|post-radiation RAD001 10 mg/day|Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
214670945|NCT01062399|DRUG|post-radiation temozolomide|Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
215060767|NCT02672189|BEHAVIORAL|EVA-Online|Internet-based cognitive behavioral therapy
214481122|NCT05159700|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
214311694|NCT00272571|PROCEDURE|External counter pulsation therapy|
214481123|NCT06173973|DIETARY_SUPPLEMENT|Kenetik; Ketone Concentrate|Ketone Supplement
214481124|NCT06173973|DIETARY_SUPPLEMENT|Isocaloric dextrose placebo|Drink that is taste and visually matched to Ketone supplement
214481125|NCT06045819|BIOLOGICAL|Blood sampling for venetoclax drug dosage (venous puncture)|8 blood samples for venetoclax and azole antifungal drugs identification and dosage will be taken by venous and capillary punctures throughout management of patients
214481126|NCT04466241|DRUG|Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|2 tablets morning and evening from Day 1 to Day 10
214481127|NCT04466241|DRUG|Telmisartan 40Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
214481128|NCT04466241|DRUG|Atorvastatin 20 Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
214311695|NCT03465332|OTHER|Doctor's questionnaire|The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
214311696|NCT03465332|OTHER|Subject file|All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
214311697|NCT00713336|DRUG|ZD4054|ZD4054 10mg Tablet
214311698|NCT00713336|DRUG|Moxifloxacin|400 mg capsule
214481129|NCT05886452|DEVICE|DT1fA contact lenses|Subjects will be fitted with DT1fA contact lenses
214481130|NCT06457737|DEVICE|IPS Empress Direct|Resin composite will be heated and used to lute a ceramic partial coverage restoration.
214481131|NCT06457737|DEVICE|Bisco Duo-Link Universal|Dual cure adhesive resin cement will be used to lute a ceramic partial coverage restoration.
214481132|NCT06702371|BEHAVIORAL|Mindset Intervention|"The EMBody intervention contains seven short documentary-style films and paired reflection activities across three modules.~Module 1: Introducing Mindsets (Film 1: A New normal; Film 2: What is a Mindset?; Film 3: Your Body is Capable; Film 4: How to Choose Your Mindset).~Module 2: Challenges and Setbacks (Film 5: Living with Uncertainty; Film 6: The Long and Winding Road).~Module 3: Looking to the Future (Film 7: Opportunities Emerge)."
214481133|NCT06699940|DEVICE|Transcranial Magnetic Stimulation|Patients between the age of 12-21 received TMS treatment for MDD disorder.
214481134|NCT06700928|OTHER|External focus training|External focus training
214481135|NCT06700928|OTHER|Internal focus training|internal focus training
214481136|NCT06700928|OTHER|No attentional focus training|no attentional focus training
214917441|NCT02246400|BEHAVIORAL|eCMP|eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.
214670946|NCT04550546|DRUG|Nystatin|600,000 U/mL of nystatin in a rinse suspension
214670947|NCT04308369|BIOLOGICAL|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
214670948|NCT05573165|OTHER|3 hours of preoperative fasting for breast milk|3 hours of preoperative fasting for breast milk
214670949|NCT05573165|OTHER|4 hours of preoperative fasting for breast milk|4 hours of preoperative fasting for breast milk
214311699|NCT00713336|DRUG|ZD4054 Placebo|3 tablets
214311700|NCT00713336|DRUG|Moxifloxacin placebo|1 capsule
214311701|NCT00713336|DRUG|ZD4054 Placebo|2 tablets
214311702|NCT00713336|DRUG|ZD4054|30mg tablet
214311703|NCT00713336|DRUG|ZD4054|10mg tablet
214311704|NCT05810090|PROCEDURE|Total knee arthroplasty|patient who received a TKA in our hospital
214311705|NCT03341195|BEHAVIORAL|SMS messages and automated calls|The intervention consists of SMS and automated calls based messages
214311706|NCT02790970|DEVICE|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
214311707|NCT02790970|OTHER|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
214311708|NCT06215404|OTHER|Liberal group|Fluid challage to keep stroke volume variation \< 10%
214311709|NCT06215404|OTHER|restrictive group|Fluid challage to keep stroke volume variation \< 18%
214311710|NCT00355862|DRUG|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
214481137|NCT06867614|PROCEDURE|Total laparoscopic hysterectomy|Removal of uterus and cervix by laparoscope
214481138|NCT05399381|DEVICE|Transcranial alternating current stimulation (tACS)|Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.
214481139|NCT03250676|DRUG|H3B-6545|Oral capsules by mouth once daily
214481140|NCT06880120|DEVICE|Seismocardiography (SCG) and Gyrocardiography (GCG) Diagnostic Testing|This intervention involves the use of Seismocardiography (SCG) and Gyrocardiography (GCG) Diagnostic Testing, a non-invasive technique that records mechanical vibrations of the chest caused by heart activity using high-precision accelerometers and gyroscopes. Unlike traditional imaging techniques such as coronary artery calcium computed tomography (CAC-CT), coronary computed tomography angiography (CCTA), and invasive coronary angiography (ICA), this method does not require radiation exposure (unlike CAC-CT and CCTA), is completely non-invasive and does not require contrast agents (unlike ICA), and provides real-time cardiac mechanical activity measurements rather than anatomical imaging.
214670950|NCT00249379|DRUG|Acamprosate|Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
214670951|NCT02136394|OTHER|Gastro-esophageal reflux|This is an observational study. The exposure is the gastro-esophageal reflux.
214670952|NCT03372954|DRUG|BMAC|retrograde administration on non-selected BMAC via coronary sinus
214670953|NCT04841668|DRUG|Metformin|Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
214311711|NCT00355862|DRUG|Sirolimus|Sirolimus based immunosuppression
214311712|NCT01983579|PROCEDURE|Intraocular anti-VEGF injection|
214311713|NCT01983579|DEVICE|SENSIMED Triggerfish|
214481141|NCT00733122|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
214481142|NCT05536726|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W ( 6 cycles) +80 mg Q4W during maintenance period
214481143|NCT05536726|DRUG|608 Q4W|608 160 mg Q4W ( 3 cycles) +160 mg Q8W during maintenance period
214481144|NCT05536726|DRUG|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
214481145|NCT06879925|BEHAVIORAL|QI-GONG and control|QIGONG
214481146|NCT06877000|OTHER|VITIQOL questionnaire|16 questions questionnaire measure effect of vitiligo on quality of life
214481147|NCT05630014|BEHAVIORAL|Aliviado DSD Caregiving Mastery Program|Family caregiver intervention consisting of mHealth-app based educational videos and articles; caregiver-administered assessment tools and care plans; and motivational push notification reminders and encouragements.
214481148|NCT06708663|DRUG|HX009+IN10018|"The 7.5 mg/kg dose group will first enroll 3 to 6 subjects, and if the 7.5 mg/kg dose group is tolerable, then 3 to 6 subjects will continue to be enrolled into the 10 mg/kg dose group; if the 7.5 mg/kg dose group is not tolerable, a decision will be made to add a new, lower dose group after discussion between the sponsor and the investigator; in addition, based on the available study data, the sponsor and the investigator will discuss and decide whether to add an unplanned dose group or an exploratory group and decide on the appropriate recommended dose (RP2D) for the Phase IIa study.~IN10018 is fixed dose at 100mg daily."
214481149|NCT06881199|OTHER|Complete denture with a metallic Co-Cr casted palate|Complete denture with a metallic Co-Cr casted palatal material
214481150|NCT06881199|OTHER|Complete denture with an acrylic palate|Complete denture with an acrylic palatal material
214481151|NCT06880718|DRUG|Brixadi (Injectable Buprenorphine)|Brixadi comes in several doses and can be administered on a weekly or monthly basis. For clinical reasons (i.e., each patient will already be on a stable dose of MOUD in a setting without significant illicit opioid use), the monthly injection will be used. The approximately equivalent to the 300mg Sublocade dose is 96mg of Brixadi. The maximum dose is 128mg. Brixadi can be administered in the abdomen, buttocks, or triceps. Participants in the Brixadi treatment arm will be given one or more Brixadi injections each month prior to release from prison and each month after release. They can continue to receive the medication after the conclusion of the trial. Brixadi is covered by most Medicaid health insurances in the state of Rhode Island.
214481152|NCT06880718|DRUG|Sublocade|Sublocade is a 100mg or 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. Participants in the Sublocade treatment arm will be given monthly Sublocade injections, as clinically indicated, each month prior to release from prison and each month after release. They can continue to receive the medication after the conclusion of the trial. Sublocade is covered by most Medicaid health insurances in the state of Rhode Island. The standard dosing schedule is two months of 300mg followed by monthly 100mg injections. To maximize real-world generalizability, the medication dosing will be determined by clinical indication of the provider who will have the flexibility to provide medication dosing based on their clinical acumen and/or shared decision-making.
214481153|NCT06881706|OTHER|medical nutrition therapy|Medical nutrition treatment was planned for all participants with metabolic syndrome. A diet plan was created considering age, gender, blood findings and nutritional habits. Individuals with MetS were given a weight loss diet planned at the basal energy level calculated with the Harris-Benedict equation and applied for 8 weeks. Individuals who applied the weight loss diet were targeted to lose at least 5% of their initial weight at the end of 8 weeks. Individuals who strictly followed the given medical nutrition treatment and achieved the targeted weight loss formed the intervention group, and individuals who did not follow the medical nutrition treatment formed the control group. At the end of the 8 weeks, all parameters, blood pressure and anthropometric measurements of all individuals who participated in the study and retrospective 24-hour food consumption records were recorded again and the study was concluded.
214481154|NCT06880913|BIOLOGICAL|Nanobody-Based CD19/CD22 Tandem Dual CAR-T|"Phase I: Patients will receive a single infusion of autologous CD19/CD22 dual CAR-T cells at one of three dose levels (0.3 × 10⁶ cells/kg, 1.0 × 10⁶ cells/kg, or 2.0 × 10⁶ cells/kg) following fludarabine (25-30mg/m2\*3d) and cyclophosphamide (250-300mg/m2\*3d) (FC) lymphodepleting chemotherapy.~Phase II: Patients will receive autologous CD19/CD22 dual CAR-T cells at the RP2D following FC lymphodepleting chemotherapy."
214917442|NCT03119870|OTHER|Train|Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).
215077803|NCT05945459|DIETARY_SUPPLEMENT|High-calorie density formula (1 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
214311714|NCT01416727|OTHER|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
214311715|NCT01416727|OTHER|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
214311716|NCT00550095|DRUG|valsartan|
214311717|NCT04010721|DEVICE|Experiment 1|Stimulation of one electrode at a time
214311718|NCT04010721|DEVICE|Experiment 2:|Stimulation in groups of 4, 8 and 12 electrodes
214311719|NCT04010721|DEVICE|Experiment 3|Stimulation total duration from 10 to 600 ms
214311720|NCT04248933|BEHAVIORAL|Peer-Delivered Behavioral Activation (Peer Activate)|The Peer Activate intervention consisted of weekly one-hour BA sessions led by a peer recovery specialist (PRS) for up to 12 weekly sessions, with the first five being the core treatment sessions and content, and the subsequent seven designed to reinforce core content. In these sessions, participants received individualized support in learning skills to assist in their retention and persistence in methadone treatment and were guided through exercises aimed at incorporating substance-free, rewarding activities into their daily life.
214311721|NCT03569332|OTHER|Alarm|"1. Alarm is provided from 9am to 9pm.~2. Alarm is active every 50 minutes if the exercise goal(10 times/hour) hasn't satisfied."
214311722|NCT03569332|OTHER|Nurse's dashboard|"1. Wireless data transmission system~2. The practicing rate of participants on study group is sent to Nurse's Dashboard.~3. It is only to display."
214311723|NCT04391387|PROCEDURE|prone position|a position with the patient lying face down with arms bent comfortably at the elbow and padded with the armboards positioned forward
214311724|NCT01422863|BEHAVIORAL|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
214311725|NCT05004376|BEHAVIORAL|Text Messaging|Text messages based on behavioral theory to encourage scheduling colorectal cancer screening.
214311726|NCT04026607|DIETARY_SUPPLEMENT|Protein Supplementation|Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
214311727|NCT05184374|DRUG|Gonadorelin|GnRH pump pulse subcutaneous injection of gonadorelin in a month
214311728|NCT06162156|OTHER|Back massage|For the intervention group, massage will be given to the participant's back area by the researcher for 20 minutes, 12 hours after the cesarean birth. Preliminary data forms will be filled out by the participant before the massage. One hour after the massage, 'Visual Analog Scala' and 'Physiological Parameter Form' data will be filled in again. The final data forms will be filled out by the participant 24 hours after the cesarean birth, that is, 12 hours after the back massage.
214311729|NCT04666064|DIAGNOSTIC_TEST|Covid19 RT-PCR|patients admitted to ER for suspicion of COVID-19 infection will have a SARS-CoV-2 RT-PCR test
214311730|NCT04666064|OTHER|lung ultrasound|patients admitted to ER for suspicion of COVID-19 infection who has a SARS-CoV-2 RT-PCR test and for whom the emergency doctor decide to perform a lung ultrasound
214311731|NCT00578942|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
214311732|NCT01166477|DRUG|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
214311733|NCT01166477|DRUG|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
214311734|NCT05264194|OTHER|Suturing technique|The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.
214311735|NCT03075670|DRUG|N9-GP|A single dose of 50 IU/kg for intravenous (i.v.) injection
214311736|NCT03075670|DRUG|ALPROLIX®|A single dose of 50 IU/kg for intravenous (i.v.) injection
214311737|NCT04070131|OTHER|Horse-Assisted Rehabilitation|One hour weelky session of hippotherapy.
214311738|NCT03747965|BIOLOGICAL|Mesothelin-directed CAR-T cells|Cells will be infused one day after the completion of conditioning regimen of paclitaxel and cyclophosphamide
214311739|NCT05725512|DRUG|Prednisolone|Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
214311740|NCT05725512|DRUG|Placebo|Placebo identical to prednisolone tablets
214311741|NCT00589316|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given via central line
214311742|NCT00589316|DRUG|Cyclophosphamide|Given IV
214311743|NCT00589316|DRUG|Fludarabine Phosphate|Given IV
214311744|NCT00589316|RADIATION|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
214481155|NCT06876090|DIAGNOSTIC_TEST|Sarcopenia tests (for muscle mass, muscle function, physical performance)|We are not aware of any other study performing sarcopenia tests in GDM (or in pregnancy in general), with the aim of assessing sarcopenia prevalence in GDM/pregnancy, and related possible adverse pregnancy outcomes.
214481156|NCT06876090|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The OGTT, in combination with the sarcopenia tests, will allow to explore the relationships between the glucometabolic condition and the muscle quality in the pregnant women, either with GDM or with normal glucose tolerance.
214311745|NCT00589316|OTHER|Laboratory Biomarker Analysis|Correlative studies
214311746|NCT00589316|DRUG|Mycophenolate Mofetil|Given IV or PO
214311747|NCT00589316|DRUG|Tacrolimus|Given IV or PO
214311748|NCT00589316|RADIATION|Total-Body Irradiation|Undergo TBI
214311749|NCT01249612|OTHER|Thermotherapy|Knee joint icing
214311750|NCT01249612|OTHER|Thermotherapy|Elbow joint icing
214311751|NCT00433563|RADIATION|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
214311752|NCT00433563|RADIATION|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
214311753|NCT01883427|DRUG|Placebo|placebo containing saline+glucose
214311754|NCT01883427|DRUG|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
214311755|NCT00255593|DRUG|rituximab|
214311756|NCT01065519|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
214311757|NCT01065519|DEVICE|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
214311758|NCT05094219|OTHER|No intervention will be offered|No intervention will be offered
214311759|NCT00139828|DRUG|human coagulation Factor IX|
214311760|NCT04697693|DRUG|Escitalopram|The participant will be begun on either escitalopram 10mg or duloxetine 30mg. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the HRSD \>7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study.
214481157|NCT06876090|OTHER|Montreal Cognitive Assessment|The MoCA questionnaire, in combination with the sarcopenia tests, will allow to explore the relationships between the cognitive function the presence of the sarcopenia syndrome in the pregnant women, either with GDM or with normal glucose tolerance.
214481158|NCT06704919|DEVICE|Use of conduit cages and fibergraft BG Putty|Patients who require spine surgery under standard of care and meet the inclusion and exclusion criteria identified, will be recruited from clinic. Consent for participation in study will be signed at the same time as consent for surgery. All PROMs and scans will be done as standard of care and data will be obtained through chart review for this study.
214481159|NCT06705790|BEHAVIORAL|Pelvic Floor Muscle Training|Pelvic floor muscle training 5x/week for 12-weeks
214481160|NCT06705088|DRUG|SUVN-I6107|SUVN-I6107 Tablet
214481161|NCT06705088|DRUG|Placebo|A look-alike tablet with no active ingredient.
214481162|NCT06719856|DRUG|18-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
214481163|NCT06883331|PROCEDURE|intermaxillary fixation using IMF screws|"IMF screws will be placed at the junction of the attached and alveolar mucosa, after verifying the root position on the orthopantomogram (OPG) radiograph. One screw in each quadrant was sufficient; all IMF screws will be placed with the patient under local anesthesia or general anesthesia . Cortical perforation with a 1.5-mm drill bit under copious irrigation will be performed or by self-drilling IMF screws and the IMF screws will be tightened on the drilled hole.~After IMFS placement, intraoperative IMF will be achieved by passing round, stainless steel wires through the screw head to achieve satisfactory occlusion."
214481164|NCT06883331|PROCEDURE|intermaxillary fixation using IMF screws with surgical guide|"The patient's CBCT images in DICOM format will be converted into stereolithographic (STL) images using the segmentation software.~The converted CBCT STL images will be integrated to obtain the exact tooth morphology Virtual surgical planning (VSP) will be carried out using software to select the exact position of IMF screws placement away from any vital, anatomical or tooth structure.~these locations will be incorporated into the patients specific IMF surgical guides as access holes to direct the IMF screws drill.~Guide will be constructed with a thickness of 2-3 mm and printed using Photopolymer Resin® (Form labs) in the CAD/CAM 3- dimensional (3D) printer"
214670954|NCT02350829|OTHER|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
214311761|NCT04697693|DRUG|Duloxetine|Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study.
214311762|NCT00977132|DRUG|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
214311763|NCT00977132|DRUG|Lenalidomide|"5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
214311764|NCT05544838|DEVICE|LMA insertion with standard technique|"Standard LMA insertion technique; LMA held like a pen and index finger placed at the junction of LMA tube and cuff. Index finger used to press LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of hypopharynx. LMA then held with non- dominant hand and index finger removed.~Rotational LMA insertion; LMA inserted like guedel airway insertion: LMA proximally grasped close to anaesthesia circuit attachment. Insertion was conducted with LMA cuff facing towards nose, hard palate and then advanced into the base of hypopharynx until resistance was felt. At this point, LMA rotated at 180 degree anti-clockwise and LMA tube black line positioned and confirmed on the nasal side."
214670955|NCT04317222|DEVICE|eCRRT|"eCRRT was define as:~1. Initiated within the first 24 post-transplant hours;~2. High volume (35-50ml/kg) hemofiltration;~3. Continuous at least 12 hours per day for 3 days;~4. Standard treatment"
214917443|NCT03119870|OTHER|MRI|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
214955089|NCT04699370|OTHER|Standardized physical therapy|The standardized physical therapy will consist of eight half-hour individualized face to face physiotherapy sessions, over a 4-week period. this program will consist of twice-weekly supervised general aerobic, strengthening and flexibility exercise sessions .This exercise program is reflective of the general exercises typically undertaken within routine clinical practice.
214955090|NCT00845936|DRUG|Metformin|Metformin 850 mg bid
214311765|NCT02733536|DEVICE|Standard endotracheal tube|1\) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
214311766|NCT02733536|DEVICE|C-MAC|C-MAC introduced with a h size 3 blade.
214311767|NCT01541137|DRUG|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
214311768|NCT01541137|DRUG|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
214311769|NCT01541137|DEVICE|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
214481165|NCT06884891|DRUG|QL2108 injection|300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W);subcutaneous injection
214670956|NCT03671863|OTHER|Invasive analysis (caryotype, CGH array)|Invasive analysis (caryotype, CGH array)
214917444|NCT03119870|OTHER|EEG|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
214311770|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol low dose|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
214311771|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol high dose|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
214311772|NCT04851899|DIETARY_SUPPLEMENT|Placebo|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
214311773|NCT03762382|DRUG|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
214311774|NCT03762382|DRUG|TFV IVR|TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
214917445|NCT01161511|BIOLOGICAL|XmAb5574|Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22)
214311775|NCT03762382|DRUG|Placebo IVR|Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
214311776|NCT04620083|OTHER|Integrative Learning Program for Old People with Dementia|The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
214311777|NCT03156478|BEHAVIORAL|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
214311778|NCT03156478|BEHAVIORAL|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
214311779|NCT02487212|DRUG|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
214311780|NCT02487212|DRUG|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
214311781|NCT02487212|DEVICE|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
214311782|NCT02704078|DEVICE|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
214311783|NCT02704078|DEVICE|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
214311784|NCT03322215|DRUG|Palbociclib|75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.
214311785|NCT03322215|DRUG|Fulvestrant|500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
214311786|NCT03322215|DRUG|Capecitabine|Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
214917446|NCT01735461|DIETARY_SUPPLEMENT|Calcium Carbonate|There is a regimen for dietary supplement intake that will be provided to study participants.
214311787|NCT00002115|DRUG|Adefovir|
214311788|NCT02363725|DRUG|Colchimax®|
214670957|NCT03671863|OTHER|Prenatal management|Prenatal management
214917447|NCT02824120|OTHER|Comedy|patients will watch comedy film
214917448|NCT02824120|OTHER|Documentary|patients will watch a documentary film
214917449|NCT02157376|DRUG|Esomeprazole|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
214311789|NCT02363725|DRUG|Conventional treatment|
214311790|NCT03858946|PROCEDURE|Simple trapeziectomy|A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch
214481166|NCT06884891|DRUG|Dupixent®|300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W); subcutaneous injection
214481167|NCT06884566|DIETARY_SUPPLEMENT|Taurine supplementation|For the intervention trials participants consumed the following in randomized order: 50mg·kg -1 of taurine diluted in 500ml of a sugar-free lemonade drink or placebo which was a sugar-free lemonade drink with nothing added, 60 minutes before the exercise protocols. Participants wore a nose plug during consumption to confirm that no taste differences were discernible between trials.
214670958|NCT02094079|OTHER|biomedical outcomes|Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
214670959|NCT06504550|OTHER|Schroth Exercises|The patients in the Schroth exercise group will start their exercise program under physiotherapist supervision.Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.These exercises include spinal elongation, de-rotation, de-flexion, stretching, strengthening exercises to maintain vertebral alignment.The participants will be asked to combine these exercises with their daily living activities (ADLs).During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support.Exercises are progressed from lying, sitting, or standing positions and from most to least passive support per a review of the quality of the performance.Decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises will depend on the patient's improvement in exercise performance
214311791|NCT03858946|PROCEDURE|Weilby|The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
214481168|NCT06884566|DIETARY_SUPPLEMENT|Placebo|For the intervention trials participants consumed the following in randomized order: 50mg·kg -1 of taurine diluted in 500ml of a sugar-free lemonade drink or placebo which was a sugar-free lemonade drink with nothing added, 60 minutes before the exercise protocols. Participants wore a nose plug during consumption to confirm that no taste differences were discernible between trials.
214481169|NCT06883474|OTHER|Osteosclerotic Changes on Computed Tomography|Osteosclerotic Changes on Computed Tomography
214481170|NCT06882629|BEHAVIORAL|'Speaking at school, a matter of doing' combined with VR homework exercises|The treatment in this study consists of behavioral therapy for selective mutism (with the protocol 'Speaking at school, a matter of doing') with the addition of the VR homework exercises. The protocol consists of 10 steps that help the child to gain confidence while speaking at school. For every treatment step there are VR homework exercises available. Families receive a VR headset for the duration of the study. Parents are instructed to work on the VR homework exercises at least once a week and encouraged to work on the VR homework exercises several times a week.
214481171|NCT06882304|OTHER|orthodontic treatment|young adult after orthodontic treatment
214481172|NCT06881914|BEHAVIORAL|Intervention group:|There were 5 sessions for the intervention group. All sessions took place in the participant's home. The first 4th sessions involved participant sharing a particular time of their life event, such as childhood, adolescence, adulthood, and the current stage. Transcripts were prepared and compiled following the completion of the interviews. The participants will proofread their life-story book before sending it for printing. In the 5th session, they were given their life storybooks. A self-report questionnaire was used in every session to collect participants' quality of life, life satisfaction, and depression scores.
214481173|NCT06885021|DRUG|HDM1002 200mg, oral, once daily, 52 weeks|HDM1002 200mg, oral, once daily, 52 weeks
214670960|NCT06504550|OTHER|Klapp Exercises|The patients in the Klapp exercise group will be treated with supervised klapp exercises. Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.In each session, a sequence of 8 postures of Klapp Exercises will be carried out. Each posture will be maintained for 4-5 minutes with rest breaks when needed.Positions that will be held are: 1) Lateral crawl, 2) Horizontal sliding, 3) Crawl posture near the ground, 4) Bunny hopping, 5) Arm turn, 6) Big arch, 7) Lateral crawl near the ground, 8) Big curve
214481174|NCT06885021|DRUG|HDM1002 400mg, oral, once daily, 52 weeks|HDM1002 400mg, oral, once daily, 52 weeks
214670961|NCT05414123|DEVICE|CNSide|The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
214481175|NCT06885021|DRUG|HDM1002 placebo, oral, once daily, 52 weeks|HDM1002 placebo, oral, once daily, 52 weeks
214481176|NCT06883799|OTHER|Without intervention.|Without intervention
214481177|NCT06882798|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|SCBT-SB is a manualized psychosocial treatment protocol developed specifically with and for L/H youth with suicidal ideation and behaviors. Clinician, adolescents, and caregivers' manuals are available in both Spanish and English. SCBT-SB protocol's main conceptual framework and strategies are informed by Cognitive Behavioral Therapy concepts, psychoeducation, and adolescent parenting strategies. The intervention involves individual, caregivers, and family sessions. SCBT-SB, while maintaining the basic principles of CBT, was further developed to include developmental (e.g., identity), and cultural elements of L/H families (e.g., family communication, language). The protocol has two main phases. Phase 1, the Crisis Module, includes nine standard core sessions, and Phase 2, which proposes a flexible number of sessions, focused on the delivery of interchangeable coping skills modules and the acquisition of skills that reduce STB.
214481178|NCT06882798|BEHAVIORAL|SCBT-SB + CHW|The New Clinical Model consist of one clinician delivering the SCBT-SB and one CHW per each family. The assigned clinician \& CHW will meet at the beginning of treatment to discuss their assigned case and will have follow-up meetings as needed and at a minimum, once monthly. CHWs will support family engagement in treatment. CHWs will assess each family's social needs and concerns about treatment. The CHW intervention will 1) Assess social determinants of mental health; 2) Provide referrals and serve as a bridge to other community resources; 3) Provide psychoeducation on mental health and services to decrease stigma; and 4) Follow-up and provide support on recommended actions.
214481179|NCT06884787|DRUG|Conventional nanohybrid multishade composite|Teeth will be restored with conventional multi shade nanohybrid Resin Based Composite (RBC) filtek Z350Xt,3M ESPE, San Paul, MN, USA
214670962|NCT03323307|DEVICE|OCT imaging|imaging of retina using OCT device
214917450|NCT02157376|DRUG|Cimetidine|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
214917451|NCT03139474|DRUG|Gonadotropin-Releasing Hormone Analogue|Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
214311792|NCT06219460|OTHER|Ventilation using two types of face masks|ventilation using two types of face mask
214311793|NCT01063595|BIOLOGICAL|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
214311794|NCT01063595|BIOLOGICAL|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
214481180|NCT06884787|DRUG|Single shade nanohybrid composite|Teeth will be restored with One-shade Resin Based Composite (Omnichroma, Tokuyama Dental, Tokio, Japan)
214481181|NCT06879223|BEHAVIORAL|Oral Health Educational Program|Providing the children with an educational program through a data show presentation when and how to brush their teeth, causes of dental caries and how to prevent its occurrence. A flyer will be distributed including simple language about preventive measure of dental caries and schedule of teeth brushing to ensure retention of information.
214481182|NCT06878911|DEVICE|Ultrasound Scans|10 seconds scanning for one block region
214481183|NCT06881121|PROCEDURE|Fast-track protocol for hip fracture fixation|Fast-track protocol implication on mortality and morbidities in hip fracture fixation
214311795|NCT03389464|BEHAVIORAL|computer-based confrontation with dysfunctional beliefs|"Patients will be presented with a virtual agent confronting them with their dysfunctional core beliefs (e.g. You are worthless). Participants will be instructed to contradict these virtual agents (e.g. That's not true, I'm a wonderful person)."
214311796|NCT03152370|DRUG|E7046|oral administration
214481184|NCT06882564|DRUG|resveratrol mouthwash|"the participants where instruct to rinse their mouth twice daily with 10 ml of assigned mouthwash for 60 seconds for 7 days. There is currently no published research on the use of resveratrol as a mouthwash for halitosis treatment.~This study aims to fill this gap by evaluating its effectiveness in reducing oral malodor through antibacterial action and the potential of volatile sulfur compounds ( VSCs)"
214481185|NCT06882564|DRUG|Chlorhexidine mouthwash (0.2%)|The second group will given chlorhexidine 0.2% mouthwash as an active comparator, and will asked to rinse with 10 ml of undiluted mouthwash for 60 seconds twice per day for 7 days, and will instructed to refrain from eating and drinking for 30 min after rinsing.
214481186|NCT06882564|DRUG|Placebo|the third group will given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 seconds twice daily for 7 days and will be instructed to refrain from eating and drinking for 30 min after rinsing.
214481187|NCT06882083|PROCEDURE|paravertebral block|A single-dose bilateral paravertebral block will be administered under ultrasound guidance before the induction of general anesthesia. The block will be performed at an appropriate thoracic level using 20 mL of 0.25% bupivacaine as the local anesthetic.
214481188|NCT06884007|BEHAVIORAL|Telepsychiatric Parent Training Program|This study involves a telepsychiatric parent training program for caregivers of children with ADHD. The program includes 9 sessions, each addressing specific topics related to managing ADHD-related behaviors and enhancing parenting strategies. Sessions are primarily delivered through a telepsychiatric platform, such as video conferencing (e.g., Zoom), with additional support provided through text-based communication via platforms like WhatsApp, and, when necessary, follow-up phone calls. The content covers behavior management techniques, stress coping strategies, and skills for managing emotional and behavioral issues in children with ADHD. This intervention is designed to provide accessible, flexible support to caregivers, enhancing their ability to manage their child's condition.
214481189|NCT06884007|OTHER|Routine Treatment|Routine treatment and services (no intervention, participants continue with their usual care)
214670963|NCT04681287|DRUG|inetetamab and PD-1 inhibitor combined with chemotherapy.|"1. Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~2. The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~3. PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued."
214670964|NCT02185170|PROCEDURE|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
214670965|NCT02185170|DEVICE|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
214311797|NCT03152370|RADIATION|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
214311798|NCT03152370|RADIATION|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
214311799|NCT03152370|DRUG|capecitabine|chemotherapy
214311800|NCT03152370|DRUG|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
214311801|NCT00747435|DEVICE|Electric Acoustic System|Combination of a cochlear implant and a hearing aid
214311802|NCT04318782|DEVICE|Pharmacodynamic thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
214311803|NCT00385242|PROCEDURE|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
214311804|NCT00385242|OTHER|PET imaging|PET viability imaging
214311805|NCT02976974|OTHER|Manual therapy|Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
214311806|NCT02976974|OTHER|Therapeutic exercise|"* Shoulder extension: Elastic bands.~* Shoulder flexion: Elastic bands~* Shoulder external rotation: Elastic bands.~* Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~* Thoracic column movements: Flexion-extension"
214311807|NCT03079323|RADIATION|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
214311808|NCT00457938|OTHER|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
214311809|NCT00457938|OTHER|Diet|10 % versus 35 % fat in diet
214311810|NCT03526419|DRUG|Bupivacaine liposome|blood and milk samples will be obtained from those subjects after TAP block
214311811|NCT00719836|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
214311812|NCT03393156|BEHAVIORAL|Internet-based metacognitive therapy|Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
214311813|NCT02180516|DRUG|Meloxicam|
214311814|NCT02180516|DRUG|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
214311815|NCT06563765|OTHER|FAP-targeting PET/CT imaging will be performed on the enrolled patients.|FAP-targeting PET/CT imaging will be performed on the enrolled patients.
214311816|NCT06977737|DRUG|ATTR-01|Intravenous injection
214311817|NCT06135376|BEHAVIORAL|comprehensive multi-component interventions|It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.
214311818|NCT06348524|DRUG|Ferumoxytol injection|ferumoxytol will assess patency of coronary arteries
214311819|NCT06604039|DEVICE|Central venous catheter|Placement of a medical device to gain entry into the bloodstream, typically through a vein or artery, for the purpose of administering fluids, medications, blood products, or for hemodialysis
214311820|NCT05991557|PROCEDURE|peroneus longus autograft|Peroneus longus tendon graft will be harvested with a longitudinal skin incision at 2 to 3 cm (2 finger-breadths) above and 1 cm (1 finger-breadth) behind the lateral malleolus, followed by superficial fascia incision in line with skin incision followed by incision of the tendon sheath proximal to the retinaculum. The peroneus longus and peroneus brevis tendons will be then identified. The tendon division location marked at 2 to 3 cm above the level of the lateral malleolus.The peroneus longus tendon will be exposed on its posterolateral surface through the incision after carefully incising the fascia
214311821|NCT06987474|DEVICE|Unity DX and SMARTCataract DX (SCDX) Biometer|Unity DX is a CE-marked, noninvasive, noncontact instrument that generates a 3D model of the eye using hyper parallel optical coherence tomography (HP OCT), aberrometry, and topography. The current version of SCDX software will be used in this study.
214311822|NCT06987474|DEVICE|IOLMaster 700 Biometer|The IOLMaster 700 Biometer is a CE-marked, noninvasive, noncontact instrument that captures optical biometry. Data will be collected using standard clinical assessments.
214481190|NCT04768777|BEHAVIORAL|Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and one-on-one video chats with a behavioral coach. The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory. Each course consists of an introduction, the primary content, and a take home message.The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries. The chats are conducted face-to-face through an online videoconferencing platform. There are a total of 12 chats over 16 weeks. Chats occur on weeks 1-8, 10-11, 13 and16.
214481191|NCT06719037|PROCEDURE|Endo-Surgi Plus endoscopic surgery|Endo-Surgi Plus endoscopic surgery, as a new type of percutaneous endoscopic lumbar discectomy (PELD), features a larger working channel and represents an optimized single-channel endoscopic technique. However, it still has the limitations inherent in single-channel endoscopy.
214481192|NCT06719037|PROCEDURE|Unilateral biportal endoscopic surgery|Unilateral biportal endoscopic discectomy (UBE) is characterized by its separate endoscopic and working channels, and the ability to use traditional open instruments, making it a convenient and versatile technique. It is a commonly used spinal endoscopic surgery in clinical practice.
214670966|NCT02185170|DEVICE|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
214670967|NCT00978575|DRUG|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
214670968|NCT00978575|DRUG|Ferrosulfate|200mg daily for 12 weeks
214311823|NCT06987474|DEVICE|Argos with Alcon Image Guidance Biometer|The Argos with Alcon Image Guidance biometer is a CE-marked, noninvasive, noncontact instrument that will capture optical biometry. Data will be collected using standard clinical assessments.
214311824|NCT06402825|BEHAVIORAL|Fit-for-Fertility program|Women in the intervention group had to delay fertility treatments for 6 months and were offered the interdisciplinary lifestyle intervention, which was provided for a maximum of 18 months or until the end of a pregnancy that occurred. The lifestyle intervention consisted of individual meetings with a dietitian and a kinesiologist trained in motivational interviewing, combined with 12 educational group sessions during the first 6 months. Details of the lifestyle intervention are presented in the previously published protocol (Duval et al., 2015).
214311825|NCT06861920|DRUG|Naproxen Sodium 550mg|Participants will receive Naproxen Sodium 550 mg oral tablet, administered twice daily for the first 48 hours of their menstrual period, for 1-year. Naproxen Sodium is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief and inflammation reduction. 550 mg naproxen sodium is the highest FDA-approved starting dosage, equivalent to 500 mg naproxen; the sodium formulation quickens absorption.
214311826|NCT06861920|DRUG|Placebo|Participants will receive a placebo oral tablet, identical in appearance to Drug X, administered twice daily for the first 48 hours of their menstrual period, for 1-year. The placebo contains inactive ingredients with no known therapeutic effect.
214311827|NCT06861920|DRUG|Extended Release Acetaminophen (650 mg)|Participants may take extended release acetaminophen 650mg oral tablet as needed for breakthrough menstrual pain. Participants will be instructed to take 1 dose of acetaminophen after 2 hours of taking a dose of either naproxen sodium or placebo, only if needed for pain relief. They are able to take an additional dose of acetaminophen after 2 more hours have elapsed for continued breakthrough symptoms. Use of rescue medication will be monitored and recorded.
214311828|NCT07006142|OTHER|Modified Fasting Guidelines|Patients will follow a full-liquid diet 48 hours prior to their procedure, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure
214311829|NCT07011810|BIOLOGICAL|Axatilimab|Given IV
214311830|NCT07011810|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214311831|NCT07011810|OTHER|Questionnaire Administration|Ancillary studies
214311832|NCT07011810|PROCEDURE|Skin Biopsy|Undergo optional skin biopsy
214311833|NCT07011810|PROCEDURE|Skin Measurement|Undergo optional skin flexibility assessment
214481193|NCT06719037|PROCEDURE|Microdiscectomy|Microdiscectomy (MD) is a mature minimally invasive technique that uses a microscope to treat lumbar spinal stenosis. As early as 1999, prospective randomized controlled studies confirmed that it has equally excellent clinical efficacy compared to open surgery, with less surgical trauma. It is currently the classic minimally invasive surgical approach for treating lumbar spinal stenosis.
214481194|NCT06716983|DIAGNOSTIC_TEST|fMRI|fMRI in patients with dystonia implanted with deep brain stimulation with neurostimulators capable of recording local field potentials
214481195|NCT06716983|DIAGNOSTIC_TEST|EEG-MEG|EEG-MEG in patients with dystonia implanted with deep brain stimulation with neurostimulators capable of recording local field potentials
214481196|NCT06716983|DIAGNOSTIC_TEST|registration of local field potentials|registration of local field potential in patients with dystonia implanted with deep brain stimulation
214481197|NCT06716983|DIAGNOSTIC_TEST|genetic panel|genetic panel for dystonia
215060768|NCT06385379|DEVICE|WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system|The WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system, the aortic extension stent graft system and the branch stent system.
214311834|NCT07017972|DEVICE|AI evaluation of embryos|AI evaluation of embryos inside a time-lapse incubator.
214311835|NCT06681376|OTHER|Comfort menu and cart|"The comfort menu and cart will be implemented after the pre-intervention data collection phase is completed. The menu will list the items available on the cart and will be presented to eligible patients in printed or digital format (on a tablet). The cart will be placed in an easily accessible area within the ED. Approximated retail prices have been previously reported.~Comfort Cart Contents:~* Hot and cold packs;~* Extra blanket and pillow;~* Face towel;~* Gloves and hat;~* Personal hygiene kit;~* Items for distraction;~* Items to enhance communication.~Comfort Menu Options:~* Physiotherapy assessment;~* Conversation with chaplain, concierge, or social worker;~* List of resources for older adults needing community services;~* Home care assistance."
214311836|NCT04057040|DRUG|PTG-300|Active
214311837|NCT04057040|DRUG|Placebo|Placebo
214311838|NCT06627452|OTHER|Dynamic Neuromuscular Stabilization Training|Patients will be taught how to perform exercises in different developmental positions both manually and verbally by the DNS therapist. In the DNS concept, proper breathing patterns are important alongside stabilization, and elastic bands will be used to regulate intra-abdominal pressure (IAP) and teach correct breathing. The elastic band will be secured around the chest just below the ribcage, and the patient will be asked to expand the elastic band in all directions while inhaling, thereby regulating the IAP. After teaching IAP guidance, exercises will be conducted in developmental positions with IAP regulation. The exercises will be conducted twice a week under the supervision of a physiotherapist, and three days at home, with sessions lasting approximately 30 minutes, for a total of five days a week over a period of 12 weeks.
214311839|NCT06627452|OTHER|Pelvic Floor Muscle Training|Pelvic floor exercises involving both slow and fast muscle contractions will be taught to patients through vaginal palpation. During fast contractions, patients will be instructed to quickly contract and relax their pelvic floor muscles. During slow contractions, patients will be asked to gradually squeeze their pelvic floor muscles, hold for 10 seconds, and then slowly relax. Each set of pelvic floor exercises will consist of 10 fast contractions and 10 slow contractions. Patients will perform pelvic floor exercises twice a week with a physiotherapist and three days at home. The exercises will be done in sets throughout the day, lasting approximately 30 minutes, and will be conducted over a period of 12 weeks.
214311840|NCT06714435|OTHER|Intermittent hypoxia|Intermittent hypoxia during 6 hours in daytime
214311841|NCT06714435|OTHER|Normoxia|Normoxia during 6 hours in daytime
214311842|NCT07042139|PROCEDURE|No reduction|No reduction
214311843|NCT07042139|PROCEDURE|Closed Reduction|Closed reduction
214481198|NCT06718257|DRUG|Gemcitabine combined with cisplatin or oxaliplatin|Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)
214481199|NCT06718257|DRUG|Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors|Gemcitabine (1000 mg/m², day 1 and 8), cisplatin (75 mg/m²; day 1) or oxaliplatin (85 mg/m²; day 1), PD-1/L1 agents (200 mg; day 1), and TKI inhibitors (8 mg; per day)
214481200|NCT06718933|DRUG|SHR-A1811|ADC
214311844|NCT07042139|OTHER|Casting|Dorsal cast
214311845|NCT07039656|DRUG|Toripalimab|Participants will receive Toripalimab (240 mg IV) Q3W for 17 cycles (cycle length=21 days).
214311846|NCT07039656|DRUG|Cisplatin-based chemotherapy|Cisplatin\[75 mg/m\^2 IV Q3W\]/carboplatin\[AUC 5 IV Q3W\]+paclitaxel\[260 mg/m\^2 IV Q3W\] or cisplatin\[75 mg/m\^2 IV Q3W)\]/carboplatin\[AUC 5 IV Q3W\]+ pemetrexed\[500 mg/m2 IV Q3W\],dependent on tumor histology. Participants will receive Chemotherapy for 3-4 cycles
214311847|NCT06469164|DRUG|BNT331|Vaginal insert
214481201|NCT06718933|DRUG|Bevacizumab|bevacizumab biosimilar
214481202|NCT06718933|DRUG|Pyrotinib|anti-HER2 inhibitor
214481203|NCT06695299|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise, balance exercises
214481204|NCT06695299|OTHER|Kinesthetic and Visual Motor Imagery Training|Kinesthetic and Visual Motor Imagery Training During kinesthetic imagery, the participants were asked to feel their body parts without any body motion. During visual imagery, the participants were asked to perform a visual presentation of the motion without any body motion.
214481205|NCT06719778|OTHER|Two-stage nutritional therapy concept|"1. Stabilization phase:~   application of a mostly vegetarian Mediterranean wholefood diet and strategies from a comprehensive lifestyle modification concept.~2. Elimination phase:~additional omission diet avoiding the food that was identified by CLE to induce an intestinal barrier defect."
214481206|NCT00556777|PROCEDURE|axillary lymph node dissection|
214481207|NCT00556777|PROCEDURE|conventional surgery|
214481208|NCT00556777|PROCEDURE|sentinel lymph node biopsy|
215060769|NCT03582046|DEVICE|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
214481209|NCT00556777|RADIATION|intraoperative radiation therapy|
214481210|NCT06722430|DRUG|Icalcaprant|Oral capsule
214481211|NCT06722430|DRUG|Itraconazole (ITZ)|Oral capsule
214311848|NCT06469164|OTHER|Placebo|Vaginal insert
214311849|NCT06745518|DRUG|TS-172|oral administration of TS-172 20\~60 mg/day
214311850|NCT06745518|DRUG|Placebo|oral administration of placebo
214917452|NCT03139474|DRUG|Gonadotropin releasing hormone antagonist|antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach \> 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
214311851|NCT07109479|DEVICE|Intravascular Lithotripsy|study group will receive the investigational devices (Single-Use Coronary Forward Intravascular Lithotripsy Catheter combined with the Intravascular Lithotripsy Therapy Device) for calcified lesion pre-treatment.
214311852|NCT07109479|DEVICE|Rotational Atherectomy|control group will receive the control device (Coronary Rotational Atherectomy System)
214311853|NCT06588738|DRUG|ESK-001|ESK-001
214311854|NCT06588738|DRUG|Placebo|Placebo
214311855|NCT06588738|DRUG|Apremilast|Apremilast
214311856|NCT05906537|DRUG|SKB410 for injection|SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
214311857|NCT07087626|OTHER|Arterial Blood Gas Analysis|Arterial blood gas analysis will be performed at predefined time points: at rest during the preoperative period, before induction and preoxygenation during the perioperative period, two minutes after induction but prior to intubation, within the first 30 minutes in the PACU during the postoperative period, and at the 72nd postoperative hour in the ward
214311858|NCT03889912|DRUG|Cemiplimab|Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery
214311859|NCT05592678|OTHER|Donepezil|Donepezil is administered as a standard of care treatment by the subject's provider.
214311860|NCT07104773|DEVICE|Control Lens (omafilcon A)|15 minutes of daily wear
214311861|NCT07104773|DEVICE|Test Lens (stenfilcon A)|15 minutes of daily wear
214311862|NCT04379999|DRUG|Atorvastatin 20mg|No history of colorectal cancer and no colorectal adenomas within 5 years.
214311863|NCT04379999|DRUG|Atorvastatin 20mg AND Aspirin 325 mg|History of colorectal cancer and/or history of colorectal adenomas within 5 years.
214311864|NCT07101523|BEHAVIORAL|mHealth|"The intervention was carried out over a period of 8 consecutive weeks and was delivered through a mobile application specifically developed for this project, called IDHEApp, which incorporated gamification elements to enhance user engagement and motivation. Participants in the experimental group received a structured mHealth-based program aimed at promoting healthier behaviors in three primary domains: physical activity, sedentary behavior reduction, and dietary improvement. Objective data on physical activity and sedentary behavior were collected using a smartwatch device (Fitbit Versa 3), which was worn by all participants in both the experimental and control groups throughout the study. However, only participants in the experimental group received a daily personalized behavioral challenge targeting one of the following domains:~1. Increasing physical activity (e.g., Walk an additional 1,000 steps today);~2. Reducing sedentary behavior (e.g., Stand up and move for at least 5 minut"
214917453|NCT02885220|OTHER|Conventional Program|No scheduled intermediate weight loss goals provided to patient
214311865|NCT07109076|OTHER|skin-to-skin contact|Uninterrupted skin-to-skin contact between the neonate and the mother will be initiated immediately and maintained for at least 15 minutes following cesarean birth.
214311866|NCT07109076|OTHER|routine care|Current routine neonatal care following cesarean section includes delayed umbilical cord clamping. Afterward, the newborn is dried by a midwife, dressed, briefly shown to the mother, and then handed over to the father.
214311867|NCT07109687|OTHER|HIIT GROUP|Participants will perform a 31-minute protocol on a cycle ergometer consisting of 1-minute high-intensity intervals at 90% of peak workload (W peak) and low-intensity intervals at 30-40% of W peak, twice a week for 8 weeks.
214311868|NCT07109687|OTHER|MICT|Moderate intensity continous exercise
214481212|NCT06887738|DRUG|NM8074|NM8074 will be administered as an intravenous infusion at a dose of 20mg/kg
214917454|NCT02885220|OTHER|Goal-directed Program|Scheduled program with intermediate weight loss targets reinforced to patients during follow up.
214311869|NCT07109999|OTHER|None-placebo|This study is an observational study, and no interventions will be implemented.
214311870|NCT07108582|DRUG|no NSAID|no NSAID but a placebo with identical galenic formulations to maintain blindness at all times during participation in the study
214311871|NCT07108582|DRUG|protocol for administering NSAIDs already used in routine care|"* 100 mg ketoprofen LP orally administered 30 minutes before surgery,~* 50 mg ketoprofen intravenously at the end of surgery~* then 100 mg ketoprofen LP PO twice a day for 7 days following surgery"
214311872|NCT07109622|DIETARY_SUPPLEMENT|LN18178|400 mg, One capsule to be consumed in the morning after breakfast for 12 weeks.
214311873|NCT07109622|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed in the morning after breakfast for 12 Weeks
214311874|NCT07109973|BEHAVIORAL|Culturally Adapted Cognitive Behavioural Therapy (CA-CBT)|CA-CBT is an 8-week manualized therapy program based on core CBT principles, adapted for Arab and Asian adolescents in the UAE. Adaptations followed the Southampton Adaptation Framework (SAF-CaCBT) and the PEN-3 model, including culturally relevant metaphors, integration of religious/spiritual beliefs, family involvement, and emphasis on academic and familial stressors. Sessions were delivered weekly for 60 minutes by trained therapists, with support in English, Arabic, and Tagalog.
214481213|NCT06724705|DIETARY_SUPPLEMENT|Lactose|Participants receive lactose to determine whether it changes gut microbial hydrogen production
214311875|NCT07109973|OTHER|Treatment-as-Usual (TAU)|Participants in the TAU group received standard care available within their community. This included optional access to school counselors, general practitioners, or local mental health clinics. No structured psychotherapy or manualized intervention was provided by the research team. This arm served as a pragmatic comparator to evaluate the added value of the Culturally Adapted Cognitive Behavioural Therapy (CA-CBT) intervention.
214670969|NCT00978575|DRUG|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
214311876|NCT07108712|OTHER|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) Scanner: All imaging will be performed using a 1.5 tesla MRI scanner to ensure high resolution and signal-to-noise ratio.
214311877|NCT07110025|OTHER|designed physical therapy program|a one-hour physical therapy program, focusing on abdominal and back muscle activation and improving balance during standing. The program includes exercises like supine on wedges, prone on wedges, weight shifting, and balance training.
214311878|NCT07110025|OTHER|core stabilization exercise with neuromuscular electrical stimulation|The text describes various exercises for children to improve their physical abilities. These exercises include bridging, crab, plank, superhero, wheelbarrow walk, and kneeling on balls. The placement of electrodes on the gluteus maximus and rectus abdominis muscles is determined using anatomical landmarks. The electric current is generated using a biphasic symmetrical waveform with pulse width and intensity, and the stimulus frequency is adjusted to 35 Hz. The neuromuscular electric stimulation mode is used in a Synchronous mode.
214311879|NCT07109232|OTHER|Position the patient|In addition, prior to the operation and throughout the PCNL procedure, hemodynamic measurements were obtained while patients were positioned in the supine, lithotomy, and prone positions, as necessitated by the surgical protocol.
214481214|NCT06724705|DIETARY_SUPPLEMENT|Sucrose|Participants will consume sucrose which they will consume as a placebo
214481215|NCT06724705|DEVICE|Wear smart underwear|Participants will wear the smart underwear device to measure the microbiome activity index
214481216|NCT06703658|DRUG|AZD5004(Part A)|Single dose of AZD5004 oral on Day1
214311880|NCT05588843|DRUG|SAR443122|oral capsule
214311881|NCT05588843|DRUG|Placebo|oral capsule
214311882|NCT07109258|DRUG|Dexamethasone (Decadron) 8mg IM injection|one dose of IM dexamethasone sodium phosphate 8 mg (2 mL) given at the start of labour induction
214311883|NCT07109258|DRUG|Misoprostol 25 mcg|vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h.
214481217|NCT06703658|DRUG|Placebo(Part A)|Single dose of placebo oral on Day1
214481218|NCT06703658|DRUG|AZD5004(Part B)|AZD5004 will be administered as an oral tablet once daily.
214481219|NCT06703658|DRUG|Placebo(Part B)|Placebo will be administered as an oral tablet once daily.
214481220|NCT06724887|BEHAVIORAL|Brain Health Strategy Training and Education|Initial training strategies cover Strategic Memory Advanced Reasoning Tactics (SMART), and subsequent training extends the SMART principles to other life-applications such as stress management, sleep, and lifestyle. Virtual and in-person workshops will expand on topics such as stress management, sleep, resilience, and mental well-being, with an emphasis on how practicing and implementing brain healthy strategies can impact everyday life. For faculty/staff, we will also offer interactive workshops on how to create a brain healthy environment and classroom, including ways to implement and provide brain-healthy strategies and resources in their everyday operations involving students.
214481221|NCT06882772|DRUG|2 mL SunButyrate-TG|"Participants randomized into the 2 milliliter (mL) SunButyrate-TG will take the supplement once daily for 3 weeks prior to cardiac surgery.~Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated."
214917455|NCT04306731|DIETARY_SUPPLEMENT|Nanotechnology Structured water Magnalife|Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules
214311884|NCT07109258|DRUG|Both Misoprostol 25 mcg & Dexamethasone 8mg IM injection|one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.
214311885|NCT07110428|PROCEDURE|NCgroup|The patients in this group received oxygen therapy via nasal cannula at a flow rate of 5 L/min, with an oxygen concentration of 100%. An end-tidal carbon dioxide (ETCO2) monitoring catheter was placed at the nostril opening to monitor ETCO2, observe whether the waveform was regular, and record the values.
214481222|NCT06882772|DRUG|Placebo|Participants randomized into the Placebo arm will take the oil-based placebo once daily for 3 weeks prior to cardiac surgery
214481223|NCT06882772|DRUG|4 mL SunButyrate-TG|"Participants randomized into the 4 mL SunButyrate-TG arm will take the supplement once daily for 3 weeks prior to cardiac surgery.~Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated."
214481224|NCT06887686|BEHAVIORAL|Swaddled Bath Intervention Wipe Bath Intervention|"Swaddled Bath Intervention:~In the swaddled bath group, infants are gently wrapped in a soft towel or blanket to maintain a flexed position. They are then immersed in warm water at an appropriate temperature to regulate body temperature. This intervention is designed to reduce stress and pain, particularly for premature infants, and helps to relax the baby's muscles, stabilize body temperature, and increase overall comfort. It is expected to show a more significant effect on physiological and behavioral stabilization than less invasive methods.~Wipe Bath Intervention:~In the wipe bath group, infants are gently wiped with a cloth soaked in warm water. This method is less invasive than the swaddled bath, aiming to maintain body temperature while providing a milder level of relaxation. The wipe bath is effective for skin cleansing but may not provide the same comfort or stress-reducing effects as the swaddled bath. The expected physiological effects, such as body temperature stabilizatio"
214481225|NCT06885723|DEVICE|Vibration Anesthesia Device (VAD)|In conclusion, induction of anesthesia with VAD in patients treated with ITS provided pain palliation in a similar way to other local anesthetic techniques. Moreover, the advantage of VAD application over other anesthetic agents was that it eliminated the need to use local anesthetics that may disrupt wound healing. In addition, inducing anesthesia with VAD can be considered as an alternative method in patients allergic to drugs. Our study will shed light on different techniques such as the application of ventilation tube in anesthesia with VAD.
214917456|NCT04306731|DRUG|Trimethoprim|Antibiotic
214917457|NCT04306731|DIETARY_SUPPLEMENT|Ordinary bottled drinking water|Placebo
214917458|NCT01074268|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
214917459|NCT01074268|DRUG|insulin detemir|Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
214917460|NCT01074268|DRUG|insulin aspart|Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
214917461|NCT01598844|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via a transapical access
214311886|NCT07110428|PROCEDURE|SJOVgroup|Gently insert an appropriately sized WNJ tube into one nostril of the subject. Connect one port of the tube to a jet ventilator (Twinstream), with the following SJOV (Synchronized Jet Ventilation) parameters: Driving pressure (DP): 15 psi (1 bar ≈ 15 psi) Respiratory rate: 15 breaths per minute Inspiratory-to-expiratory ratio (I:E): 1:2 Fraction of inspired oxygen (FiO₂): 100% Connect the other port to an end-tidal carbon dioxide (ETCO₂) monitoring catheter to observe the ETCO₂ waveform for regularity and record the numerical values.
214311887|NCT02890589|DEVICE|SYNERGY stent|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
214311888|NCT02890589|DEVICE|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
214311889|NCT06923098|PROCEDURE|PET-CT guided biopsy|PET-CT guided biopsy of lung lesions
214311890|NCT06923098|PROCEDURE|CT guided biopsy|CT guided biopsy of lung lesions
214311891|NCT07108946|OTHER|Black background|Changing the background color during scanning to evaluate its effect on scan quality .
214311892|NCT07108946|OTHER|White background|Changing the background color during scanning to evaluate its effect on scan quality .
214311893|NCT07108946|OTHER|Participant own skin as a background|Changing the background color during scanning to evaluate its effect on scan quality .
214311894|NCT05573555|DRUG|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
214311895|NCT05573555|DRUG|Ribociclib|Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
214311896|NCT04328207|OTHER|No Financial Incentive|Standard of care eye health education
214481226|NCT06885723|DRUG|local anesthetic cream|Prior to each ITS, all the four methods including local anesthetic cream (EMLA® cream, AstraZeneca PLC), lidocaine spray (Vemcain® Spray), VAD (Blaine®, Blaine Labs, Santa Fe, USA), and saline drops (control) were administered in each patient. The order of administration was determined for each patient using the randomization software (random.org/lists/). For the fifth ITS, however, the method of administration was selected by the patient.
214481227|NCT06885723|DRUG|lidocaine spray|Prior to each ITS, all the four methods including local anesthetic cream (EMLA® cream, AstraZeneca PLC), lidocaine spray (Vemcain® Spray), VAD (Blaine®, Blaine Labs, Santa Fe, USA), and saline drops (control) were administered in each patient. The order of administration was determined for each patient using the randomization software (random.org/lists/). For the fifth ITS, however, the method of administration was selected by the patient.
214917462|NCT03006601|OTHER|Office-based accommodative/vergence therapy|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks)
214917463|NCT00966992|DRUG|Zoledronic acid|
214311897|NCT04328207|BEHAVIORAL|Financial Incentive|Patients who are referred for an in-person follow-up exam will receive a financial incentive once the referral visit is completed.
214311898|NCT06941974|BEHAVIORAL|Patient Navigation Program|PATH navigation is an antenatal patient navigator program designed to reduce barriers to care, enhance access, improve self-efficacy and knowledge, and improve multiple perinatal health outcomes. PATH navigation is a flexible, multi-pronged, patient-centered program with the capacity to evolve with patient needs and preferences. Early in pregnancy, navigators will establish themselves as a non-medical resource and will introduce PATH as a program designed to help inform, support, and connect patients during pregnancy. Navigators will review screen and address supportive and adverse non-medical needs, facilitate communication, perform logistical support, provide advocacy and bridge communication with clinical teams, and perform health education. Navigation services will be tailored to individual medical, psychosocial, or logistical complexity.
214311899|NCT06944002|DIETARY_SUPPLEMENT|Milk product|The participants will abstain from consumption of any dairy product for ten days and subsequently drink milk for seven consecutive days (700 ml per day), while concomitant consumption of other dairy products is also allowed.
214311900|NCT03190278|BIOLOGICAL|UCART123v1.2|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab
214311901|NCT05864053|DRUG|Ketamine|Ketamine will be administered over a 45-minute period.
214311902|NCT05864053|DRUG|(2R,6R)-hydroxynorketamine|(2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.
214311903|NCT05864053|DRUG|Saline|Saline will be administered over a 45-minute period.
214311904|NCT04439318|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214311905|NCT01331148|DRUG|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
214311906|NCT01331148|OTHER|Placebo|placebo with daily calcium/Vitamin D soft chews
214311907|NCT06211374|BEHAVIORAL|Communication Bridge|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
214311908|NCT03770572|GENETIC|Low dose CLN-301|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of CLN-301 at low dose
214311909|NCT03770572|GENETIC|High dose CLN-301|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of CLN-301 at high dose
214311910|NCT05384093|DEVICE|High Intensity Stretch Device|High Intensity Stretch and Physical Therapy are used either together or alone to treat study arm.
214311911|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
214311912|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
214311913|NCT02665871|BIOLOGICAL|placebo|
214311914|NCT02665871|BIOLOGICAL|placebo|
214917464|NCT01298804|BEHAVIORAL|Problem Solving Education and Activated Referral to Care|"The intervention represents an integrated identification and intervention system based on the evidence-based construct of screening, brief intervention, and referral to treatment (SBIRT). Within the comprehensive case management services of Head Start, eligible women will be randomized to receive either usual care or the Head Start-based intervention. In our intervention, mothers at risk for depression will receive a problem-solving intervention; depression symptom monitoring; and an Activated referral to more definitive services for those who have worsening symptoms over time."
214311915|NCT01285648|PROCEDURE|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
214311916|NCT06441409|BEHAVIORAL|Lifestyle intervention|"Patients were intervened with lifestyle only and returned to clinic for tests in 6 months.~Lifestyle intervention included the diet and exercise. Diet was an energy-restricted balanced diet. Exercise requires 5 days a week and 30 minutes every day."
214311917|NCT04479956|PROCEDURE|Varicose vein surgery|sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee
214311918|NCT02220270|DEVICE|ASD and PDA closure|
214311919|NCT03509675|DRUG|Ibuprofen suspension 5mg/100ml|Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
214311920|NCT03509675|DRUG|Placebos|Placebo
214311921|NCT04628312|OTHER|Static footprint|The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
214311922|NCT04702087|DIETARY_SUPPLEMENT|OLEP|omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
214311923|NCT04702087|COMBINATION_PRODUCT|Placebo|Isocaloric formula
214311924|NCT02464202|OTHER|stereolithography tooth replica|Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
214311925|NCT02755376|BIOLOGICAL|Cartistem(TM)|ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.
214311926|NCT02755376|BIOLOGICAL|hyaluronic acid|ACL reconstruction and injection of hyaluronic acid under arthroscopy.
214311927|NCT02755376|PROCEDURE|ACL reconstruction only|ACL reconstruction only without any injection under arthroscopy
214311928|NCT03817619|DRUG|Zepatier whole tablet|Single-dose ELB/GZR as a whole tablet in a fasted state.
214311929|NCT03817619|DRUG|Zepatier crushed tablet|Single-dose crushed ELB/GZR in a fasted state.
214311930|NCT02029651|DEVICE|E-glove system|Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
214311931|NCT02029651|PROCEDURE|Conventional occupational therapy|conventional occupational therapy
214311932|NCT00983554|DRUG|Anastrazole|Arimidex 1mg daily
214311933|NCT00983554|DRUG|Testosterone|Testim 10g daily
214311934|NCT00983554|DRUG|Dutasteride|Avodart 2.5mg daily
214481228|NCT06885723|OTHER|saline drops|Prior to each ITS, all the four methods including local anesthetic cream (EMLA® cream, AstraZeneca PLC), lidocaine spray (Vemcain® Spray), VAD (Blaine®, Blaine Labs, Santa Fe, USA), and saline drops (control) were administered in each patient. The order of administration was determined for each patient using the randomization software (random.org/lists/). For the fifth ITS, however, the method of administration was selected by the patient.
214311935|NCT00983554|DRUG|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
214311936|NCT02622828|BEHAVIORAL|Participant-identified community based activity|The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
214311937|NCT01855295|DIETARY_SUPPLEMENT|Protein Supplement|During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
214311938|NCT03171454|PROCEDURE|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
214311939|NCT03171454|PROCEDURE|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
214311940|NCT03303833|OTHER|No intervention, observational study.|
214311941|NCT04760158|OTHER|Exercise|Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
214311942|NCT03592433|BEHAVIORAL|I Can PIC|Participants will be shown (on a computer or via email link) a website called I Can PIC. I Can PIC provides health insurance education, suggests ways to learn about the costs of cancer care and follow-up, shows resources to help offset the high costs of care, and helps individuals estimate (based on national data) how much they might spend on health insurance in the upcoming year.
214311943|NCT02189564|BEHAVIORAL|Feedback about good performance|
214311944|NCT02189564|BEHAVIORAL|Feedback about good performance + money|
214311945|NCT02189564|BEHAVIORAL|Feedback about average performance|
214311946|NCT06197594|OTHER|Proprioceptive neuromuscular facilitation techniques|Proprioceptive neuromuscular facilitation techniques
214311947|NCT06197594|OTHER|Rebound Therapy|Rebound Therapy
214311948|NCT03791866|OTHER|Nutrition|Enteral nutrition
214311949|NCT03568357|PROCEDURE|Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in conservative group was increased at increments of 0.1 per minute to reach an FiO2 target of 40% that was adjusted to maintain an arterial PO2 in the range of 250 mm Hg or less during the bypass, while FiO2 in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 80% adjusted to maintain PO2 in the range of 300 mm Hg or more, on the basis of arterial PO2 level measured via a point of care blood gas analyzer.
214481229|NCT06886750|DRUG|Botulinum toxin type A injection|Injection of toxin
214311950|NCT01468766|OTHER|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
214311951|NCT01468766|OTHER|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
214311952|NCT03095066|DRUG|Placebo|Administered as capsules
214311953|NCT03095066|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
214311954|NCT03095066|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
214311955|NCT06072547|OTHER|Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original)|Access to all varieties of on! 4mg nicotine pouch products (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), throughout the trial.
214311956|NCT06072547|OTHER|Access to Original on! 4mg nicotine pouches|Access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
214311957|NCT06072547|OTHER|Non-Flavored then complete flavor on! nicotine pouches|Access to non-flavored (i.e., Original) on! 4mg nicotine pouch products during the first 3 weeks and then access to all varieties (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) of on! 4mg nicotine pouch products during the rest of the trial
214311958|NCT01015248|DRUG|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
214311959|NCT03171350|DIAGNOSTIC_TEST|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
214311960|NCT02427867|OTHER|Remote ischemic preconditioning|
214311961|NCT02427867|OTHER|no ischemic preconditioning|
214311962|NCT00710320|PROCEDURE|Covered and uncovered anesthesia induction|"We hypothesize that the core temperatures of:~1. the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.~2. both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group."
214311963|NCT02008448|PROCEDURE|Pulmonary vein isolation|
214311964|NCT02008448|PROCEDURE|Linear Lesion Ablation|
214311965|NCT02008448|DRUG|BT injection|
214311966|NCT03483935|OTHER|Microwave treatment|Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
214311967|NCT00613028|DRUG|Temo + Avastin|Patients have progressed/had gr3/\> toxicity related to etoposide, with no had progression/gr 3/\> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
214311968|NCT00613028|DRUG|VP-16 + Avastin|Patients have progressed/had gr3/\> toxicity related to temozolomide, but have not progressed/gr3/\> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
214311969|NCT03667352|PROCEDURE|Unilateral Scalp Block|Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.
214311970|NCT03667352|PROCEDURE|Transversus abdominis plane block|The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).
214311971|NCT03667352|DRUG|Intravenous Fentanyl|Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
214311972|NCT02674620|OTHER|Aerobic Exercise|Patients are treated with progressive exercise
214311973|NCT02693574|DRUG|Clarithromycin|
214311974|NCT02693574|DRUG|Levofloxacin|
214311975|NCT03571087|DRUG|HL140 5/10|"1\) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
214311976|NCT03571087|DRUG|HL140 10/10|"1\) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
214311977|NCT03571087|DRUG|HL140 20/10|"1\) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
214311978|NCT03571087|DRUG|Rosuvastatin 5mg → HL140 5/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~   * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
214311979|NCT03571087|DRUG|Rosuvastatin 10mg → HL140 10/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~   * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
214481230|NCT06887816|DEVICE|silver coated device|Patients who will be implanted with prosthesis with a silver coating to counteract infection relapse
214481231|NCT06887816|DEVICE|not silver coated device|Patients who will be implanted with prosthesis without silver coating
214917465|NCT00880412|DRUG|EHT 0202 etazolate|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
214311980|NCT03571087|DRUG|Rosuvastatin 20mg → HL140 20/10|"1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
214311981|NCT03732053|OTHER|GPR Intervention Research group|The research intervention consisted in the reappointment of three GPR therapeutic postures.
214311982|NCT02242838|DRUG|Telmisartan|
214311983|NCT04377607|OTHER|File scanning|RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
214311984|NCT01277939|BEHAVIORAL|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
214311985|NCT01277939|BEHAVIORAL|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
214311986|NCT02034526|DEVICE|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
214311987|NCT02034526|DEVICE|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
214311988|NCT03751215|PROCEDURE|Cataract surgery|During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye
214670970|NCT05517759|OTHER|Educational program|The sessions were delivered in form of face to face, group disscussion, brainstorming and smart cards. The educational package covered all aspect of knowledge regarding VAP such as definitions, risk factors m cause, manifestation, diagnostic criteria, and nursing care to prevent VAP. A PowerPoint and information pamphlet were used to display the material.
214917466|NCT00880412|DRUG|Placebo|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
214917467|NCT03858972|DRUG|Tesetaxel|Tesetaxel plus reduced dose of capecitabine
214917468|NCT03858972|DRUG|Capecitabine|Reduced dose of capecitabine
214917469|NCT03726372|DRUG|Rocuronium|rocuronium is a neuromuscular blocking agent with a duration of 40 minutes
214917470|NCT03726372|OTHER|continuous infusion|rocuronium is continuously infused
214917471|NCT03726372|OTHER|intermittent injection|rocuronium is intermittently given
214917472|NCT05457686|OTHER|kinesio tape|According to this, the proximal part of the band is located close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate tapes are applied so that the strips cross each other
214917473|NCT05457686|OTHER|Sham taping|In the same procedure and time as kinesiotaping, inelastic tape will be used instead of kinesiotape.
214917474|NCT05457686|OTHER|Exercise|Routine exercise and physiotherapy program applied after knee arthroplasty surgery will be applied
214917475|NCT01578239|DRUG|Octreotide LAR|"In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died."
214917476|NCT01578239|DRUG|177Lu-DOTA0-Tyr3-Octreotate|Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
214917477|NCT02302417|PROCEDURE|Spirometry|Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility
214917478|NCT02302417|OTHER|ACOS clinical questionnaire|The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
214917479|NCT02629939|BEHAVIORAL|course for learning CPR|
214917480|NCT05494710|OTHER|Bleomycin electrosclerotherapy treatment|The combination of Bleomycin and electroporation of the treated area which is called electrochemotherapy (ECT).
214917481|NCT04518241|BEHAVIORAL|MI sessions|"Three counseling sessions lasting less than 60 minutes each to identify goals, factors that promote or impede goals, and increase readiness for ART with high adherence"
214917482|NCT04518241|BEHAVIORAL|TMQQ|Weekly text messages with health information as well as motivational messages. Two days later a true/false quiz question is sent. Participants earn 4 points for answering correctly, 2 points for answering incorrectly, and 0 points for not answering. Participants earn $1 for each point. Messages are sent over 21 weeks.
214917483|NCT04518241|BEHAVIORAL|Type of compensation|Participants who achieve HIV viral suppression at 21 weeks will receive either fixed compensation of $275 or be entered into a lottery where they have a 3/10 chance of winning $500, and a 7/10 chance of winning $175. Those who do not achieve HIV viral suppression receive a $50 participant incentive.
214311989|NCT01847391|DRUG|GS-6615|GS-6615 tablet(s) administered orally once daily
214917484|NCT03000010|DEVICE|Incisional Wound Vac|
214917485|NCT03000010|OTHER|Standard Bandage|
215060770|NCT03582046|DEVICE|Mean Arterial Pressure (MAP)|Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
215060771|NCT04428255|DRUG|HBM9161 Dose A|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
214311990|NCT01847391|DRUG|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
214917486|NCT01731119|DRUG|Latuda©|All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
214311991|NCT00024089|DRUG|gefitinib|
214311992|NCT04920123|DEVICE|Neuro-World|Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.
214311993|NCT05175599|OTHER|Water Birth|The water birth group will use a tub of a water to labor and give birth.
214311994|NCT05828446|DEVICE|MRI|To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
214917487|NCT03828721|OTHER|Rx for Success Smartphone Application|"The Rx for Success (RS) mobile application (app) was developed by the non-profit, Children, Inc. The app is designed to be informational and motivational with both video and cueing content. The app uses a View It, Cue It, Do It model that allows parents to quickly download the smartphone app, view brief videos of age-indexed, research-based language enrichment practices; and regulate a push notification cueing program. Videos embedded in the RS app provide a summary of dialogic reading tailored for the child's age, and suggestions for encouraging verbal interactivity and social-emotional engagement through dialogic reading. Key behaviors reinforced by the app include discussing the story before reading to build interest and enthusiasm, followed by interactive reading modeled by specific types of verbal/behavioral prompts for the parent to make and responses to what the child says or does."
214917488|NCT03828721|OTHER|Control - screen time reduction|Control families will receive a new, specially designed children's book regarding limiting screen-based media use and encouraging healthy/active alternatives (Baby Unplugged: Play, Hutton/Jones, blue manatee press), which lists American Academy of Pediatrics screen time recommendations on the back cover.
214917489|NCT01017536|BIOLOGICAL|AERAS-402|AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.
214917490|NCT01017536|BIOLOGICAL|Placebo|Placebo was the identical buffer solution in which AERAS-402 is formulated.
214311995|NCT03436979|DEVICE|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
214917491|NCT03131752|BEHAVIORAL|Elastic Resistance Intervention in Exacerbated Patients|The intervention protocol will performed during 7 days for all patients and this will begin 24 -48 hours after the start of medication for exacerbation. Those who are hospitalized and discharged before this period will continue their treatment at the Laboratory of Spirometry and Respiratory Physiotherapy (LEFIR) of the Federal University of São Carlos. The intervention will also perform for at least 5 continuous days. The ideal elastic band for the training will be chosen through the test of 10 maximum repetitions. The test and the training will be performed in an ergonomic chair allowing the lower limbs to remain pending. After 24 hours of the test, patients will perform knee extension exercise with the appropriate elastic band. Three sets of 10 repetitions will be done in each exercise, with a minimum rest interval of 1 minute between sets or until heart rate values return to baseline. Patients will be re-evaluated 1 and 3 months after the first contact.
214311996|NCT06450171|OTHER|GRAIL Galleri Test|A multi-cancer early detection (MCED) blood test.
214311997|NCT05537376|BEHAVIORAL|SUicide Prevention by Peers Offering Recovery Tactics|Following the completion of a comprehensive mental health evaluation by a licensed VA provider, which includes a suicide safety plan, if a Veteran is having active thoughts of suicide or made a suicide attempt in past three months, they may be eligible for SUPPORT. In SUPPORT, the Peer Specialist and Veteran co-create a personalized suicide-focused recovery plan (SUPPORT Plan) in flexible, 50-minute weekly encounters. The SUPPORT Plan includes modules that focus on valuing recovery, building a hope kit and daily plan, setting recovery goals, and looking ahead to enhance the Veteran's safety plan. Learning strategies are incorporated into each module to promote salience and recall of intervention material. The Peer Specialist works closely with the Veteran's treatment team and uses the most recent safety plan in the Veteran's chart to help complete the SUPPORT Plan as well as reinforce the usage of the Veteran's safety plan.
214311998|NCT06343311|BIOLOGICAL|EB103|EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene.
214311999|NCT00136149|PROCEDURE|Immediate implants|Immediate implants are used.
214312000|NCT04435015|DRUG|Camostat Mesylate|Participants will be given Camostat mesylate three times daily.
214312001|NCT04435015|DRUG|Microcrystalline Cellulose, NF|Participants will be given Microcrystalline Cellulose (placebo) three times daily.
214670971|NCT05675280|OTHER|Gluten free diet|All subjects initiated a gluten free diet as mandated by their diagnosis of Celiac disease, regardless of the study
214670972|NCT01454089|DRUG|OGX-427 600 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
214670973|NCT01454089|DRUG|OGX-427 1000 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
214312002|NCT02855437|DEVICE|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
214312003|NCT02855437|DEVICE|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm."
214670974|NCT01454089|DRUG|Placebo|Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
214670975|NCT01454089|DRUG|Gemcitabine|Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
214312004|NCT06493214|BEHAVIORAL|Physical activity|Participants will be asked to complete three eight-minute InPACT at Home exercise videos per day, five days a week, for 12 weeks.
214312005|NCT04613024|DRUG|Topamax|Experiment randomized group will be prescribed Topamax before and after surgery with follow up at regular interval
214312006|NCT04613024|DRUG|Gabapentin|Control group will be prescribed gabapentin after surgery with follow up at regular interval
214670976|NCT01454089|DRUG|Cisplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
214312007|NCT05289323|DRUG|Neostigmine Methylsulfate|0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
214670977|NCT01454089|DRUG|Carboplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
214670978|NCT02626052|BEHAVIORAL|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
214312008|NCT05289323|DRUG|Dextrose 5%/Nacl 0.9% Inj|one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
214312009|NCT02306512|PROCEDURE|H&E|Sample will be stained with H\&E according to standard procedures
214670979|NCT02626052|BEHAVIORAL|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
214670980|NCT02626052|BEHAVIORAL|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
214670981|NCT02626052|PROCEDURE|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
214670982|NCT02626052|PROCEDURE|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
214312010|NCT02306512|PROCEDURE|IHC MART-1|Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
214312011|NCT02306512|PROCEDURE|IF MART-1|Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
214312012|NCT02306512|PROCEDURE|IF cocktail|The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
214312013|NCT06639126|DIETARY_SUPPLEMENT|Wild thyme extract|All patients will be randomized (1:1) to receive the active thyme extract (600 mg/capsule/day or 600 mg/capsule/day of microcrystalline cellulose) in the form of capsules, administered orally and daily for 2 months
214312014|NCT06639126|OTHER|Placebo|600 mg/day microcrystalline cellulose
214312015|NCT06038799|BEHAVIORAL|Caregiver Skills Training (CST)|The investigators are comparing the relative efficacy of CST between a CST group led by clinicians trained and supervised remotely versus a group led by clinicians trained an supervised face-to-face.
214312016|NCT06356883|DRUG|IA Carboplatin + IA Caelyx|Intraarterial infusion of carboplatin combined with liposomal doxorubicin
214312017|NCT06356883|DRUG|IA Carboplatin + IA Etoposide Phosphate|Intraarterial infusion of carboplatin combined with etoposide phosphate
214312018|NCT06203639|OTHER|UR Caregiver|The UR Caregiver app was informed by previous research and developed in collaboration with caregiver partners. The app utilizes cognitive behavioural principles and is consistent with models of stress and coping. The app consists of seven modules. The app is available on IOS and Googe Play store. In addition to the didactic information provided in the app, worksheets are available in each module to practice the strategy/skill provided.
214312019|NCT06203639|OTHER|CLEAR Dementia Care|A subset of participants will be randomly assigned to use the CLEAR Dementia Care app as part of an active control group. The app consists of features that primarily address care-related needs (as opposed to stress management strategies) allowing for a comparison with the UR Caregiver app. The app was developed by the Northern Health and Social Care Trust (Northern Ireland) and is freely available on both IOS and Google Play stores. The CLEAR Dementia Care app provides users with information about dementia (e.g., the different types of dementia, how dementia affects the brain, and symptoms associated with dementia). The app offers suggestions and alternative approaches to various care-related situations through illustrations/images that caregivers may experience.
214312020|NCT03679910|DIAGNOSTIC_TEST|CEMIP , CA19-9 ,CEA|CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
214312021|NCT03679910|DIAGNOSTIC_TEST|A) CBC . B) RBG. C)KFT. D) LFT.|A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
214481232|NCT06886971|OTHER|The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access|The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access to that choice through the deployment of the SLAT team. HIV-ASSIST is an interactive tool that offers clinicians comprehensive, individualized validated patient-specific ARV decision support along with evidence-based supporting educational material. The free online, interactive tool is designed to augment interpretation of current HIV clinical practice guidelines (CPG).It will be included in the CHOICE counseling providing participants with patient-centered approach, specifically addresses the patient's expressed needs, problems, issues and concerns with a goal of providing accurate and unbiased information on available choices. After CHOICE counseling, if the participant chooses LAI-ART, the participant is referred to the SAVVY LAI-ART access team (SLAT) to facilitate access.
214670983|NCT02626052|PROCEDURE|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
214670984|NCT01362400|DRUG|IPI 504 plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
214670985|NCT01362400|DRUG|Placebo plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
214670986|NCT01407562|DRUG|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
214670987|NCT01407562|DRUG|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
214917492|NCT02789774|PROCEDURE|Posterior fusion C1-C2|Posterior access and screws in C1 (atlas) and C2 (axis) and fusion with addition of iliac crest bone graft. No postoperative collar.
214312022|NCT06164587|DRUG|K8|sustained released bio-erodible intravitreal implants
214312023|NCT03754894|DEVICE|ready made plastic stent application|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
214312024|NCT03754894|PROCEDURE|simple interrupted sutures|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement and securing the flap with simple interrupted sutures
214481233|NCT06886711|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement: Probiotics. The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
214312025|NCT03395158|DIAGNOSTIC_TEST|Implementation of new alert criteria|The intervention is when the prior alert criteria are replaced by the present alert criteria
214312026|NCT03231787|DIAGNOSTIC_TEST|Platelet function assay|"Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours."
214312027|NCT03343184|PROCEDURE|SEE Strategy and Incremental Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
214312028|NCT03343184|PROCEDURE|SEE Strategy and Bulk Fill Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
214312029|NCT03343184|PROCEDURE|SET Strategy and Incremental Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
214312030|NCT03343184|PROCEDURE|SET Strategy and Bulk Fill Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
214312031|NCT06200727|PROCEDURE|PRF membrane tamponade surgery in macular hole|A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.
214312032|NCT06200727|PROCEDURE|ILM peeling in macular hole|The treatment of the macular hole was ILM peeling.
214312033|NCT06200727|PROCEDURE|PRF membrane grafting in pterygium|Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.
214312034|NCT06200727|PROCEDURE|Autologous conjunctival transplantation in pterygium|Used of autologous conjunctiva to cover exposed sclera after pterygium excision
214312035|NCT06200727|PROCEDURE|autologous PRF membrane grafting in trabeculectomy for glaucoma|Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.
214312036|NCT06200727|PROCEDURE|Amniotic membrane in trabeculectomy for glaucoma|Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.
214312037|NCT06200727|PROCEDURE|PRF membrane grafting incorneal ulcer|After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing
214670988|NCT01407562|DRUG|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
214670989|NCT02897193|DEVICE|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
214670990|NCT02897193|DEVICE|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
214312038|NCT06200727|PROCEDURE|Amniotic membrane in corneal ulcer|After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing
214312039|NCT00278954|BIOLOGICAL|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
214312040|NCT05749094|DIAGNOSTIC_TEST|Optic nerve sheath ultrasound|The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.
214312041|NCT05749094|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assesment, blood test review, temporal/axillary artery ultrasound
214312042|NCT00351260|PROCEDURE|Coronary Angioplasty|
214312043|NCT04471636|DEVICE|Withings ScanWatch|The smart watch is capable of recording SpO2, ECG, and heart rate.
214670991|NCT02897193|DEVICE|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
214670992|NCT02897193|DEVICE|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
214670993|NCT05041764|OTHER|NO INTERVENTION|No INTERVENTION
214670994|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
214670995|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
214670996|NCT02580162|BEHAVIORAL|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
214670997|NCT03163342|BIOLOGICAL|Licensed seasonal influenza vaccine|20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
214917493|NCT02789774|PROCEDURE|Rigid cervical collar|External immobilization of cervical spine in a rigid collar for 12 weeks.
214917494|NCT05337280|DEVICE|Imagio OA/US|Imagio optoacoustic/ultrasound
214312044|NCT01370226|BEHAVIORAL|CBI|"The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
214312045|NCT01370226|BEHAVIORAL|TBI|"Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
214312046|NCT03406858|BIOLOGICAL|HER2Bi-Armed Activated T Cells|Given IV
214312047|NCT03406858|OTHER|Laboratory Biomarker Analysis|Correlative studies
214312048|NCT03406858|BIOLOGICAL|Pembrolizumab|Given IV
214312049|NCT06358105|PROCEDURE|Simulator-based training|A two-day training program will be performed before starting their cath lab period as interventional cardiology fellows
214312050|NCT06358105|PROCEDURE|Standard training|Standard master-apprentice training interventional cardiology fellows' program during their cath lab period
214312051|NCT06317753|BEHAVIORAL|Aerobic Exercise|Participants allocated to the Aerobic condition will be following a 4 month-intervention aerobic exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration
214312052|NCT06317753|BEHAVIORAL|Agility-Cognitive Exercise|Participants allocated to the Agility-Cognitive condition will be following a 4 month-intervention agility-cognitive exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration
214312053|NCT06317753|BEHAVIORAL|Stretching/relaxation|Participants allocated to the stretching control condition will be following a 4 month-intervention protocol of 1 weekly session with a 50 minutes duration
214312054|NCT00324467|DRUG|Cyclophosphamide|"Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
214312055|NCT00324467|DRUG|Doxorubicin|"Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
214312056|NCT00324467|DRUG|Vincristine|"Dose: 1.4 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
214481234|NCT06886711|DIETARY_SUPPLEMENT|Placebo|Dietary supplement: Placebo. The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
214481235|NCT06887478|OTHER|Exercise|A progressive resistance exercise program focusing on strengthening the flexor hallucis longus (FHL) muscle in elderly participants.
214481236|NCT06883188|DRUG|talc powder|intrapleural instillation of talc slurry
214312057|NCT00324467|DRUG|Prednisone|"Dose: 45 mg/m\^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
214312058|NCT00324467|DRUG|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
214312059|NCT00324467|DRUG|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
214917495|NCT01182051|BEHAVIORAL|CBT or relaxation training|8 weeks of CBT or relaxation training.
214312060|NCT00324467|DRUG|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
214481237|NCT06883188|BIOLOGICAL|patient's own venous blood|intrapleural instillation of patient's own venous blood
214481238|NCT06879782|DRUG|Drug placebo|Instill one drop of the eye solution in each eye, twice a day (morning and evening, approximately 12 hours apart), for a treatment period of 12 weeks.
214481239|NCT06882759|OTHER|No intervention (observational study)|This is an observational study. No intervention.
214481240|NCT06881719|DEVICE|The Adventures of Apollo & Rosetta|"The new APP The Adventures of Apollo and Rosetta consists of 7 exercises (1. Explorer; 2. Deciphering codes; 3. Particle accelerator tunnel; and 4. Leaping asteroids, - 5. Galactic art; 6. Stellar Laboratory; 7. Challenge of opposites).~The training program provides for the application of 36 mini-game sessions lasting 15-20 minutes each (alternating the first 4 and the last 3 games) over 12 weeks (the child must practice 3 times a week).~The training via APP can be administered in the first sessions on an outpatient basis, then it can be delegated to parents who take care of the exercises 3 times a week (20-15-20 minutes). A work diary will be kept monitoring the progress of the activities."
214481241|NCT06879951|OTHER|Participants are not assigned an intervention as part of the study.|Participants are not assigned an intervention as part of the study.
214917496|NCT06118931|BEHAVIORAL|Early (7:00 - 16:00) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 7:00 to 16:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 7:00, and not consume anything else for two hours.
214917497|NCT06118931|BEHAVIORAL|Mid (9:30 - 18:30) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 9:30 to 18:30 for 7 days. On the 8th day, they will consume a meal replacement beverage at 9:30, and not consume anything else for two hours.
214917498|NCT06118931|BEHAVIORAL|Late (12:00 - 21:00) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 12:00 to 21:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 12:00, and not consume anything else for two hours.
214917499|NCT01277627|DRUG|Nevirapine|nevirapine: 400 mg a day.
214917500|NCT01277627|DRUG|efavirenz, protease inhibitors|efavirenz: 600 mg a day
214917501|NCT01031680|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
214917502|NCT01031680|DRUG|Placebo|Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
214312061|NCT00324467|DRUG|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
214312062|NCT00324467|DRUG|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
214481242|NCT06887257|OTHER|Telematic cardiac rehabilitation program, that includes exercise, educational and psychological sessions during 3 months|"2 group and telematic exercise sessions/week, 1 educational session/week and 1 psychological session/week, during 3 months.~There are no drugs or devices involved in the intervention."
214481243|NCT06887257|OTHER|Standard recommendations|Standard recommendations about exercise, educational and psychologicla advice
214481244|NCT06886867|OTHER|Exergaming|Exergaming: Participants will perform different exercises through videogames
214481245|NCT06886867|OTHER|Usual physical therapy care|Usual care: Different exercises will be performed
214481246|NCT06886438|PROCEDURE|RVS|Revascularization
214481247|NCT06886438|PROCEDURE|L-PRF|Regenerative endodontic procedure with L-PRF application
214481248|NCT06886438|PROCEDURE|i-PRF|Regenerative endodontic procedure with i-PRF application
214481249|NCT06886386|DEVICE|Trans-spinal direct current stimulation|Patients with a neurological level above T10 will receive cervical tsDCS (anode electrode at C7, and the cathode electrode on the right shoulder). Patients with a neurological level from T10 onwards will receive thoracic tsDCS (anode electrode at T10, and the cathode electrode at the iliac crest). (i) Experimental group (active tsDCS): electrical stimulator (Neuroconn/Germany) connected to a pair of saline-soaked sponge electrodes (35 cm²) with a current intensity of 2.5 mA for 20 minutes. (ii) Control group (sham tsDCS) with electrodes positioned at the same locations as active tsDCS, for 30 seconds (the setup will remain for the full 20 minutes). Thus, patients will experience the initial sensations at the stimulated site, without inducing an effect. Physical therapy will be performed during tsDCS (45 minutes), based on scientific evidence, considering patient preferences, and respecting motor learning theory and neuroplasticity principles, focusing on motor function recovery.
214481250|NCT06718699|OTHER|resistance exercise tests|One 1RM and three RTF tests (5-8RM, 9-12RM, 13-16RM) on seven resistance training devices
214481251|NCT06718179|DRUG|Short duration of aspirin and prasugrel|aspirin 75 mg/day for 1 months plus prasugrel 10 mg/day (5 mg/day) for 1 year, followed by lifelong aspirin 75 mg/day after 1 year
214481252|NCT06718179|DRUG|Conventional duration of aspirin and prasugrel|aspirin 75 mg/day lifelong plus prasugrel 10 mg/day (5 mg/day) for 1 year
214481253|NCT06726343|DEVICE|Fetal Monitoring Device|Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
214481254|NCT06726343|DEVICE|Investigational Fetal Monitoring Device|Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
214917503|NCT06178211|DRUG|Immunotherapy: Adebrelimab|Adebrelimab 1200mg Q3W
214917504|NCT06178211|DRUG|chemotherapy: carboplatin plus nab-paclitaxel|carboplatin plus nab-paclitaxel
214312063|NCT00324467|DRUG|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
214312064|NCT00324467|DRUG|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
214312065|NCT00324467|DRUG|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl\*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~\*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)"
214481255|NCT06706791|DRUG|Empagliflozin 10 MG|participants will be divided in two groups one group will empagliflozin 10mg once daily along with standard treatment secong group receiving placebo once daily along with standard treatment.
214481256|NCT05145881|DIETARY_SUPPLEMENT|Low dose probiotics|Taking 1 package of low dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
214481257|NCT05145881|DIETARY_SUPPLEMENT|Normal dose probiotics|Taking 1 package of normal dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
214481258|NCT06727721|BIOLOGICAL|mesenchymal stem cells with OCN-19|The patient received mesenchymal stem cells with OCN-19 three times
214481259|NCT06727721|BIOLOGICAL|Mesenchymal stem cells|Ordinary mesenchymal stem cells were given
214481260|NCT06727721|BIOLOGICAL|albumin injection|Placebo
214917505|NCT01905527|OTHER|Standard Services of Group A (Group A1)|Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals
214917506|NCT01905527|OTHER|Customized Services of Group A (Group A2)|In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.
214312066|NCT00324467|DRUG|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m\^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
214917507|NCT01905527|OTHER|Group B|Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
215060772|NCT04428255|DRUG|HBM9161 Dose B|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
215060773|NCT04428255|DRUG|Placebo|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
214312067|NCT00324467|DRUG|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m\^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
214312068|NCT00324467|DRUG|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
214312069|NCT00324467|DRUG|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
214312070|NCT00324467|DRUG|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
214312071|NCT00324467|DRUG|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
214312072|NCT00324467|OTHER|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
214312073|NCT06453629|DEVICE|Floreo VR|12 week VR program to help children with ASD to reduce the core symptoms of Autism
214312074|NCT06453629|DEVICE|VR Control|12 week program administered in VR
214312075|NCT06453629|DEVICE|VR Control Crossover|If opt in, this group will crossover at the end of 12 weeks to the Floreo VR program
214312076|NCT02255370|DRUG|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
214312077|NCT06338189|OTHER|The 5Ad Diet|Participants are to follow the 5Ad diet.
214312078|NCT06338189|OTHER|The Low FODMAP Diet|Participants are to follow the active phase of the Low FODMAP diet.
214312079|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 3|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
214312080|NCT02269280|DRUG|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
214312081|NCT02269280|OTHER|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
214312082|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 5|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
214312083|NCT05820893|DRUG|Resistant Potato Starch|MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
214955091|NCT02842008|BEHAVIORAL|Exercise group|This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
214312084|NCT05169385|BEHAVIORAL|Parent SMART|Parent SMART experimental intervention
214312085|NCT05169385|BEHAVIORAL|Treatment as Usual|Residential treatment as usual
214312086|NCT04682626|DIETARY_SUPPLEMENT|Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.|Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
214955092|NCT02155088|DRUG|BYL719|Dose escalation beginning at 250 mg/day
214955093|NCT02155088|DRUG|Gemcitabine|Dose escalation beginning at 800 mg/m\^2
214312087|NCT06244615|DEVICE|Verum (WO 6607)|Mouth and throat rinse and gargle solution
214312088|NCT06244615|DEVICE|Placebo (WO 6608)|Mouth and throat rinse and gargle solution
214312089|NCT01650207|PROCEDURE|acupuncture|"All participants were received regular rehabilitation program, and received different interventions.~treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks"
214312090|NCT01650207|PROCEDURE|TENS|
214312091|NCT01650207|PROCEDURE|sham acupuncture|
214312092|NCT00749372|OTHER|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
214312093|NCT04922320|BEHAVIORAL|Patient Priorities Care|A facilitator will schedule a PPC facilitation encounter 2-3 weeks before an upcoming PCP visit. The facilitator conducts a structured assessment using a written conversation guide that begins with general questions establishing what is most important to Veterans about their health and moves toward establishing specific goals (actionable outcomes), and what patients are willing/not willing to do to achieve these goals (care preferences). The result is a structured patient priorities report delivered to PCPs designed to facilitate changes in the patient's care plan to align it with his/her priorities. In the subsequent visit, the PCP will use one or more of the established PPC decisional strategies to align care with patients' priorities. Education for PCPs about the facilitation process, the patient priorities report, and the decisional strategies occurs prior to the PCP seeing any intervention patients. The PCP will document changes in care made to achieve the identified priorities.
214312094|NCT04922320|OTHER|Usual Care|PCPs will not be alerted when an encounter involves a UC group participant. UC participant visits will appear the same as all other unenrolled patient encounters. PCPs will be trained to address the needs of UC participants based on their typical approach without the use of a facilitator or explicit process for identifying patient priorities. UC participants will not receive any additional preparation
214312095|NCT03149692|OTHER|Penile allograft transplantation|Proof of concept of surgical procedure
214312096|NCT02373787|DEVICE|creos xenoprotect|Implant placement with simultaneous bone augmentation
214312097|NCT02373787|DEVICE|Bio-Gide|resorbable collagen membrane
214312098|NCT02174068|DRUG|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
214312099|NCT05659810|DRUG|Gabapentin 300mg|Preoperative gabapentin before spinal anesthesia
214312100|NCT02121483|DRUG|empagliflozin medium dose|
214312101|NCT02121483|DRUG|empagliflozin high dose|
214312102|NCT02121483|DRUG|empagliflozin low dose|
214312103|NCT00385528|BEHAVIORAL|Multi-faceted psychiatric intervention|
214312104|NCT05292560|OTHER|Training in positivity|The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.
214312105|NCT04924036|DRUG|glycopyrronium cloths|Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
214312106|NCT04924036|DRUG|Placebo|Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
214312107|NCT01817725|BIOLOGICAL|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those \<= 20 years old and 40μg in those \> 20 years old.
214312108|NCT02606188|DEVICE|Modified High-flow nasal cannula|Modified High-flow nasal cannula
214312109|NCT02606188|DEVICE|nasal cannula|Conventional oxygen therap
214312110|NCT05738941|PROCEDURE|radiofrequency ablation|17-G length-adjustable electrode (RITA RF Electrode;) a 200-W RF generator is going to be used,under CT fluoroscopic guidance. The type of the electrode and the length of the active tip will be selected according to the size, location, and shape of the tumor, as well as the operator preference.ablation will be performed with 100 W energy for 30 seconds. The number of electrodes placed, ablation time per electrode, total ablation time, and total energy delivered to targets, as well as the temperature of the lesions, will be recorded. For lesions less than 3 cm, surgery was performed with one electrode , and for lesions of 3 cm or more, two or more electrodes were used . The procedure may be followed by injection of bone cement through the same working cannula, and a long working time will be delivered (STABILIT, Merit Medical Systems, Inc.) for the optimal filling of the bone lesion
214312111|NCT05738941|PROCEDURE|angioembolization|"Use a 4- or 5-French diagnostic catheter for the initial angiogram and either continue to use this catheter for embolization where the feeding vessel is large or add a standard 2.3- to 2.5-French microcatheter as a coaxial technique .~\- Injection of embolizing material in the feeding vessels using gel foam , PVA or histoacryl according to the nature of the bony lesion"
214312112|NCT05447364|DRUG|Pregabalin 75mg|1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo
214481261|NCT06880146|OTHER|Blood sample Truculture|"blood sample added to the standard blood test at visit Inclusion and Month 6. This project will use the TruCulture® Whole Blood Stimulation System to assess the Whole Blood Oxylipin Response (WBOR).~WBOR is the ability of patients to produce oxylipins in response to an immune stimulus. One tube is conditioned with LPS stimulant and a control tube is conditioned with no stimulant (Null)."
214481262|NCT06889272|OTHER|blood transfusion|Red blood cell suspension replacement during surgery
214670998|NCT05881850|OTHER|Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49. The research is carry out as a randomized controlled experimental in a pretest-posttest design.|The education program consisting of three sessions was held once a week and each session lasted approximately 40-50 minutes. In the realization of the education program, a power point presentation consisting of the contents of the education booklet prepared for Osteoporosis awareness, a three-dimensional bone model with Osteoporosis and normal bone tissue, some food samples containing calcium during nutrition education, and measuring cups to show portions and amounts were used. During the training, a question and answer activity was also held. The education booklet was also given to the intervention group at the end of the first session.
214917508|NCT03649932|DIETARY_SUPPLEMENT|Enteral L-citrulline|"L-Citrulline as 10 % solution (100 mg/ml) will be provided to the bedside nurse by the Investigational Pediatric Pharmacy. The drug will be given via gavage feeding by bolus infusions followed by a 0.5 ml water flush twice daily (0900 and 2100). Bolus dosing will be needed due to the small volumes (0.5-1.5 ml per dose in most infants). The volume of nasogastric tubing used in preterm infants (Ameritus 4.0 Fr 50 cm) is 0.48 ml, therefore we will follow the administration with 0.5 ml of saline/water flush to ensure all the study drug is delivered to the patient.~Administration of study drug - Will be given via gavage feeding tube twice daily (0900 +/- 30 mins, 2100 +/- 30 mins). L-citrulline will be given by the bedside nurse as a bolus followed by 0.5 ml water flush. L-citrulline will be given separate from feeds to avoid any confusion.~Study drug will be started when infant has been off of TPN for at least 3 days so that IV arginine in TPN does not interfere."
214312113|NCT05447364|DRUG|Pregabalin 150mg|2 tabs of Pregabalin Brillior 75 mg
214312114|NCT04733651|DRUG|Hospital standard of care for COVID-19|Standard care for COVID-19 as per the hospital guidelines
214481263|NCT06731647|PROCEDURE|pleurodesis procedures|All pleurodesis procedures will be conducted with a general anesthesia. The choice of hypnotic, analgesic and neuromuscular drugs will be at the discretion of the physician. Selective orotracheal intubation will be done for all patients with a double lumen tube or a blocker according to centers habits. Regional anesthesia (serratus block, paravertebral block and erector spinae block) will be allowed and chosen at the discretion of the physician. Multimodal pain management will be allowed with the use dexamethasone, ketamine and antinociceptive drugs (nefopam, tramadol, paracetamol at the discretion of the physician. After the surgical procedure, the pleural production of liquid or air will be monitored with a chest tube connected to pleural drainage device according to centers habits. Pain will be monitored with during the hospital stay every 12 h using the pain rate scale graded from 0 to 10. Neuropathic pain will be screened at 48h, 1 months, 6 months and 1 year after the inclusion
214481264|NCT06731647|DRUG|KETOPROFEN(RP19583)|one intravenous dose of ketoprofen 100 mg followed by 5 doses every 12 h of ketoprofen LP 100 mg (a total regimen of 6 doses of ketoprofen every 12 h for 72h)
214481265|NCT06731647|DRUG|Placebo|placebo of ketoprofen with the schema of administration consisting in the administration of one intravenous dose of 100 ml of NaCl 0.9% following 6 oral intakes of a placebo pill every 12h (a total regimen of 6 doses of placebo of NSAID every 12 h for 72h)
214955094|NCT02155088|DRUG|(nab)-paclitaxel|125 mg/m\^2 dose
214955095|NCT00479115|DRUG|AMD3100|240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
214312115|NCT04733651|DRUG|Isoquercetin|Daily 1000 mg Isoquercetin as 4 capsules
214312116|NCT04773444|BEHAVIORAL|Eccentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
214312117|NCT04773444|BEHAVIORAL|Concentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
214670999|NCT00211523|DRUG|MBI 226 Acne Solutions|
214312118|NCT06452095|DEVICE|Hyperbaric Oxygen therapy|The SECHRIST INDUSTRIES mono-place Hyperbaric Chambers OR Sigma Series mono-place Hyperbaric Chambers
214671000|NCT02817438|BEHAVIORAL|Good Days Ahead|Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
214671001|NCT05977543|OTHER|Functional crackers enriched with grape seed flour|The crackers was enriched with 10% grape seed flour
214671002|NCT05977543|OTHER|Functional crackers with 40% barley flour and enriched with β-glucans|The crackers consisted of 60% wheat flour, 40% barley flour and was enriched with β-glucans.
214671003|NCT04021472|BEHAVIORAL|Text message|Two months of daily text messages to support meeting a health goal
214671004|NCT04562324|DRUG|SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics|Medications to relieve anxiety
214671005|NCT04562324|DEVICE|Neurofeedback system|EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
214312119|NCT06297278|BEHAVIORAL|Moderate Intensity Exercise|Participants randomized to the active (moderate intensity) exercise condition will complete a 3-minute warm-up at low speed on a treadmill. Speed and incline will be increased in 3-minute increments until moderate-intensity exercise, defined as participants staying within a zone of 60-80% AAMHR with the target being to attain and maintain 70-75% AAMHR while briskly walking and/or jogging depending on current fitness status, is reached for a total of 30 min.
214312120|NCT05868486|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214312121|NCT05868486|GENETIC|Genetic Testing for Cancer Risk|Undergo germline testing
214312122|NCT05868486|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy testing
214312123|NCT05868486|PROCEDURE|Magnetic Resonance Imaging of the Whole Body without Contrast|Undergo whole body MRI without contrast
214312124|NCT05868486|OTHER|Survey Administration|Complete surveys
214671006|NCT00793923|DRUG|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
214671007|NCT00793923|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
214671008|NCT03580057|BEHAVIORAL|Breastfeeding promotion intervention|Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.
214312125|NCT02746562|PROCEDURE|Freeze all|Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle
214312126|NCT05109663|DRUG|SKLB1028|SKLB1028, capsule, oral
214312127|NCT05700682|DEVICE|Shoulder/Hip/Knee Embolization with Embozene Microspheres|Fluoroscopically-guided arterial embolization of synovitis in the painful shoulder, hip or knee.
214312128|NCT04381845|DIAGNOSTIC_TEST|COVID19 immunization testing|serological COVID19 test with confirmation at J15 during hospitalization
214312129|NCT00559546|DRUG|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
214312130|NCT04541433|DRUG|AZD9833|AZD9833 taken orally
214312131|NCT01425554|OTHER|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
214312132|NCT01425554|OTHER|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
214312133|NCT01425554|OTHER|Air-plethysmography of the neck|Air-plethysmography of the neck
214312134|NCT01425554|OTHER|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
214671009|NCT03580057|BEHAVIORAL|Diet and weight loss intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
214671010|NCT04649853|OTHER|Standardized nursing care|All patients will receive standardized evidence based nursing care
214671011|NCT01755481|OTHER|Probiotic|
214671012|NCT01755481|OTHER|Whey protein concentrate|
214312135|NCT03412084|BEHAVIORAL|Stand up and move more|4 week behavioral intervention involving the development and implementation of action plans
214312136|NCT01816828|BEHAVIORAL|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
214312137|NCT01816828|OTHER|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
214312138|NCT03601221|OTHER|Sample collection|Collection of one sampling pouch from each blood donor
214312139|NCT01420289|DEVICE|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
214671013|NCT01042301|OTHER|Blood samplings|
214955096|NCT00479115|DEVICE|AmCell CliniMACs|CD34+ cell selection from peripheral collection
214312140|NCT01420289|BEHAVIORAL|Excercise|Treadmill walking 45 minutes once daily
214312141|NCT04127916|DRUG|Bendamustine|To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
214312142|NCT00218673|BEHAVIORAL|Peer mentor intervention|groups sessions, 8
214312143|NCT01360658|DRUG|Intravenous immunoglobulins|Single administration of 2 g/kg intravenous immunoglobulins over 2 days
214312144|NCT03255343|DEVICE|IMDENDRIM|In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
214312145|NCT01512953|DRUG|Lansoprazole|Lansoprazole 30 mg once a day
214312146|NCT03689166|DIETARY_SUPPLEMENT|Probiotic|Reduce preterm birth with this dietary supplement
214312147|NCT03689166|OTHER|Placebo|Placebo
214312148|NCT01912846|BEHAVIORAL|Interactive advance care planning|"The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.~Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.~Facilitating EOL care discussions throughout the dying process.~A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP."
214312149|NCT01912846|BEHAVIORAL|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
214312150|NCT05112692|DRUG|Dydrogesterone Tablets|first arm will be coadministered gonadotrophins with 20mg dydrogesterone till day of trigger second arm will be subjected to fixed GnRH antagonist protocol then will do Freeze All in both arms then frozen embryo transfer next cycle
214312151|NCT05112692|DRUG|cetrorelix 0.25mg|In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3.
214312152|NCT05112692|DRUG|human menopausal gonadotropin|(150-225IU) will be administered daily from menstrual cycle day 3 till day ot trigger
214312153|NCT05112692|DRUG|triptorelin 0.1 mg|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
214312154|NCT05112692|DRUG|human chorionic gonadotropin|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
214312155|NCT05112692|PROCEDURE|cryopreservation|All of the follicles greater than 10mm in diameter will be aspirated. The oocytes are inseminated approximately 4-6hours after follicular aspiration by a conventional IVF method or intracytoplasmic sperm injection, based on the sperm quality On day 3, high quality embryos are cryopreserved by means of vitrification
214312156|NCT05112692|DRUG|Estradiol Valerate and progesterone|Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
214481266|NCT05576129|DEVICE|TGP-tACS|"38 min and 20s of 4mA peak-to-peak theta-gamma stimulation with 75 Hz-gamma coupled to the peak of 6Hz-theta waves. 3s ramp-up at the beginning of stimulation and 3s ramp-down at the end of stimulation.~Administered using a Starstim® device and 5 gel electrodes with a πcm² area."
214481267|NCT05576129|DEVICE|Sham-tACS|38 min and 20s of alternation between 10s of 4mA peak-to-peak TGP- tACS and a 6 min 30s stimulation-free interval. Each stimulation consists of 3s ramp-up, 4s TGP stimulation and 3s ramp-down. Administered using a Starstim® device and 5 gel electrodes with a πcm² area.
214481268|NCT06727058|BIOLOGICAL|Pandemic flu H5 mRNA vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intramuscular (IM)"
214481269|NCT06727058|OTHER|Placebo|"Pharmaceutical Form: Liquid solution for injection~Route of Administration: Intramuscular (IM)"
214481270|NCT06889675|DRUG|YB1-X7 Injection (IT)|Intratumoral injection
214481271|NCT06889675|DRUG|YB1-X7 Injection (IV)|Intravenous infusion
214481272|NCT06886854|DEVICE|Mode of delivery|"Retrieval of delivery data, typically recorded by midwives - retrieval of data per delivery and post-delivery - Consultation of medical data on labor duration, labor onset method, estimated fetal weight, etc.~Data collected for each delivery, identical in both groups."
214481273|NCT04466527|DEVICE|Laser Intervention|Subjects with undergo laser exposure of their active acne vulgaris.
214481274|NCT06733844|DIETARY_SUPPLEMENT|Weekly iron folic acid supplementations|In the intervention arm, adolescent girls will receive weekly iron and folic acid supplements (WIFAS), nutrition education, and group counseling sessions. WIFAS will be delivered quarterly, with each girl consuming one supplement at the facilitation center and the remaining 12 at home, once a week. The supplements contain 60mg of iron and 2.8mg of folic acid. A quarterly cash transfer of PKR 1,000 will be given to the mother, conditional on the girl's WIFAS consumption and attendance at the quarterly education and counseling sessions. The girl will report her supplement intake at each visit and receive 13 more supplements. The intervention will last 18 months.
214312157|NCT06231550|DRUG|FC084CSA tablets|"FC084CSA accelerated doses at 100mg QD, and then started the conventional 3+3 design from 200mg QD."
214312158|NCT05804383|DRUG|BMS-984923|Capsules
214312159|NCT05804383|DRUG|Placebo|Capsules
214312160|NCT03060772|DRUG|Pioglitazone|Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
214312161|NCT05956769|DRUG|Tranexamic Acid|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
214312162|NCT05956769|DIAGNOSTIC_TEST|thromboelastography|thromboelastography (TEG6)
214312163|NCT05956769|DRUG|Placebo|Normal saline injection
214312164|NCT02456831|OTHER|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
214312165|NCT02456831|OTHER|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
214312166|NCT02456831|OTHER|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
214312167|NCT02456831|OTHER|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
214312168|NCT00481195|DRUG|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day \[2 tablets\]) was allowed. The dosage could not be increased after it was decreased.
214312169|NCT00481195|DRUG|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
214312170|NCT04146064|OTHER|Breathprint analysis and patient-reported outcomes|"Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints."
214481275|NCT06735703|DRUG|To provide ampicillin sulbactam to pregnant women with premature rupture of membrane|To provide ampicillin sulbactam tonpregnant women with premature rupture of membrane after 34 wks gestation
214481276|NCT06735963|DEVICE|Meta Quest 3 Virtual Reality|Immersive virtual reality Meta Quest 3 device
214312171|NCT03047109|DRUG|Phenylephrine|30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
214312172|NCT03047109|DRUG|Ephedrine|30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
214312173|NCT02932904|DRUG|Vortioxetine|Vortioxetine Overencapsulated Tablet
214312174|NCT02932904|DRUG|Paroxetine|Paroxetine Overencapsulated Tablets.
214481277|NCT06735963|PROCEDURE|Exercise|Traditional exercise program for knee OA patients
214481278|NCT06735963|DEVICE|Electrotherapy|Electrotherapy including Therapeutic Ultrasound (US) and Transcutaneous Electrical Nerve Stimulation (TENS)
214312175|NCT02932904|DRUG|Placebo|Vortioxetine Placebo-matching Capsules.
214312176|NCT03976427|BEHAVIORAL|Guided Imagery|The guided imagery exercise asks participants to think about positive associations with healthy foods and imagine their future healthy selves.
214312177|NCT05532943|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment.
214312178|NCT05532943|BIOLOGICAL|Control group|Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.
214312179|NCT05785065|DRUG|Mycophenolate Mofetil|"The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
214312180|NCT05785065|OTHER|Placebo|"The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
214481279|NCT03587805|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
214671014|NCT01855555|DRUG|sedation with propofol|"When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported."
214671015|NCT05597046|OTHER|Interview|Interviews
214955097|NCT02547909|PROCEDURE|probe-based Confocal Laser Endomicroscopy|"Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue."
214955098|NCT02547909|DEVICE|Cellvizio|
214955099|NCT02547909|DRUG|fluorescein 10%|
214312181|NCT00702117|DRUG|flecainide|2 mg/kg iv in 10 minutes
214312182|NCT00702117|DRUG|ajmaline|1 mg/kg iv in 10 minutes
214312183|NCT00702117|DRUG|procainamide|10 mg/kg iv in 10 minutes
214312184|NCT00004804|DRUG|interferon alfa|
214312185|NCT01142310|DRUG|Lamotrigine|Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
214312186|NCT01142310|DRUG|Placebo|
214312187|NCT00963261|BEHAVIORAL|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
214312188|NCT02514837|DEVICE|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
214312189|NCT03342742|BEHAVIORAL|Weight Loss|Weight loss behavioral intervention via one of two strategies.
214312190|NCT04839159|OTHER|Blood sampling|Blood sampling at the age of 6 and 12 months, 2-3-4 years
214312191|NCT04839159|OTHER|Blood sampling|Blood sampling before any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
214312192|NCT01485562|DRUG|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
214312193|NCT01485562|OTHER|placebo|4 tablets, administered sublingually if the woman experiences a PPH
214312194|NCT03792672|DRUG|TAK-653|TAK-653 tablets.
214312195|NCT03792672|DRUG|Placebo|TAK-653 placebo-matching tablets.
214312196|NCT03792672|DRUG|Ketamine|Ketamine intravenous infusion.
215060774|NCT03255889|DRUG|Glyceryl Tridecanoate|Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).
214312197|NCT01408121|OTHER|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
214312198|NCT04606979|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
214312199|NCT03095456|DRUG|Revefenacin|Revefenacin administered via nebulization.
214312200|NCT03095456|COMBINATION_PRODUCT|Spiriva Handihaler®|Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
214312201|NCT03095456|DRUG|Placebo for Revefenacin|Placebo administered as double blind, double dummy via nebulization.
214312202|NCT03095456|DRUG|Placebo for Spiriva Handihaler®|Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
214312203|NCT01907828|DEVICE|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
214312204|NCT01907828|DEVICE|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
214312205|NCT00591942|DEVICE|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
214312206|NCT05819164|DEVICE|Masimo oximeter|During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
214312207|NCT05819164|DEVICE|Nellcor oximeter|During this period, the Nellcor oximeter N-600 was used for SpO2 reading
214312208|NCT05819164|DEVICE|Nonin oximeter|During this period, the Nonin oximeter was used for SpO2 reading
214312209|NCT01725191|OTHER|Laboratory Biomarker Analysis|Correlative studies
214312210|NCT01725191|OTHER|Pharmacological Study|Correlative studies
214312211|NCT01725191|DRUG|Tivantinib|Given PO
214312212|NCT05564793|DEVICE|Pre-implantation planning|ECGi mapping using the CE marked Amycard 01C device and a contrast enhanced CT
214312213|NCT05564793|DEVICE|Post-implantation assessment|ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
214312214|NCT02087527|DRUG|Dexamethasone|IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
214671016|NCT00676559|DRUG|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
214312215|NCT02087527|DRUG|Normal Saline|IV normal saline every 6 hours for 48 hours
214312216|NCT00727753|DRUG|Ranibizumab|ranibizumab (0.5 mg) will be injected intraocular
214312217|NCT00727753|DRUG|Bevacizumab|Bevacizumab (1.25 mg) will be injected intraocular
215060775|NCT03255889|OTHER|Placebo|Sunflower oil emulsion of equal calories.
215060776|NCT04650230|DEVICE|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices|
215060777|NCT03835481|DRUG|BI 730357|Film-coated tablet
215060778|NCT03835481|DRUG|Placebo to match BI 730357|Film-coated tablet
215060779|NCT02727816|DEVICE|filcon IV I (BC 8.6)|control lens
214312218|NCT00727753|OTHER|No treatment|No treatment
214312219|NCT00396045|DRUG|Revlimid (CC-5013)|
214312220|NCT06171178|DRUG|ASP1012|Intravenous (IV) infusion
214312221|NCT06171178|DRUG|Pembrolizumab|IV infusion
214312222|NCT00155337|PROCEDURE|photodynamic therapy|
214312223|NCT02570061|BEHAVIORAL|telephone|information given at the primary contact by phone, or at a scheduled later time
214312224|NCT02570061|BEHAVIORAL|consultation face-to-face|information given at a scheduled consultation at the hospital
214312225|NCT04391790|PROCEDURE|Cystectomy and modified urinary conduit|The modified retrosigmoid conduit is extended aorund 5 cm, so the left ureter does not have to cross under the mesentery wheras the presumed more robust ileal segment does.
214312226|NCT04391790|PROCEDURE|Cystectomy and standard urinary conduit ad modum Bricker|The conduit is constructed using approximately 15 cm of terminal ileum and placed in the right side of the abdomen. In order for the left ureter to reach the conduit, it is mobilized behind the sigmoideum to the conduit.
214312227|NCT05434520|PROCEDURE|Preoperative biliary drainage (ERC og PTC-aided)|Placement of biliary stent (plastic, covered SEMS, uncovered SEMS) endoscopic by ERC or placement of plastic catheter by PTC
214312228|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
214917509|NCT02757833|OTHER|A 3 Tesla MRI scanner (Siemens, Erlangen Germany), will be used to measure levels of GSH in the brain.|Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high grey/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl ß-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.
214917510|NCT03319238|OTHER|ketamine|The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
214917511|NCT02976740|RADIATION|SBRT|Stereotactic body radiotherapy A type of radiation therapy to the Metastasis lesion
214312229|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
214312230|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
214312231|NCT04007523|BEHAVIORAL|Family Support System|Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.
214312232|NCT04007523|BEHAVIORAL|HELP Support System|A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
214312233|NCT01821534|OTHER|No Intervention|No treatment (intervention) was administered.
214312234|NCT03906045|DRUG|BGF-MDI|Budesonide, Glycopyrronium and Formoterol Fumarate.
214312235|NCT02197806|DRUG|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
214312236|NCT02197806|DRUG|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
214917512|NCT02976740|DRUG|Immunological Agent|Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
214917513|NCT02976740|DRUG|Immunological Factors|Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
214917514|NCT02934698|DRUG|Ivacaftor|Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
214917515|NCT02654977|DRUG|Metreleptin|MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
214312237|NCT02197806|DRUG|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
214917516|NCT04454047|PROCEDURE|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
214955100|NCT03731208|DEVICE|Telerehabilitation|"The telerehabilitation program equipment consists of the following devices:~* a tablet with a keyboard and a fingerprint sensor~* two wearable sensors~* a wireless modem~* measuring tape"
214955101|NCT03401632|OTHER|Enteral nutrition|Enteral nutrition support
214312238|NCT03352323|DRUG|Oxymetazoline|RLD
214312239|NCT02547610|DEVICE|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
214312240|NCT03487861|DIAGNOSTIC_TEST|observational(urinary biomarker for kidney allograft fibrosis)|After an informed consent is obtained, urine specimens will be collected prospectively before kidney transplantation (if available) and 3rd and 7th day, 1st, 3rd, and 6th month post-transplant. About 35\~50ml of urine sample is collected from each patient. For each urine specimen, 0.5 ml of a protease inhibitor mixture (5mM 4-(2-animoethyl) benzensulfonyl fluoride hydrolchloride, 2 μM Leupeptin-hemisulfate, and 3.3 mM Sodium azide) is added. To remove urinary sediments including whole cells, large membrane particles, and other debris, urine specimens are centrifuged at a rate of 4000 rpm for 15 minutes at 4 ℃. An aliquot of supernatant is stored at -80 ℃ until use. Urinary biomarkers including transglutaminase 2 are quantified using ELISA or CBA. In addition, urinary exosomes are isolated and analyzed. When a for-cause biopsy is done for some patients, the correlation between biomarkers and pathologic diagnosis will be assessed.
214312241|NCT00448474|BEHAVIORAL|Mailed Arthritis Self-Management Education|
214312242|NCT02283047|BEHAVIORAL|DIET|Lifestyle intervention through hypocaloric diet
214312243|NCT02283047|BEHAVIORAL|DIET & MODERATE CONTINUOUS TRAINING|Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
214312244|NCT02283047|BEHAVIORAL|DIET & HIGH VOLUME HIIT|Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
214312245|NCT02283047|BEHAVIORAL|DIET & LOW VOLUME HIIT|Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
214312246|NCT03192943|DRUG|BMS-986205|Specified dose on specified days
214312247|NCT03192943|BIOLOGICAL|Nivolumab|Specified dose on specified day
214312248|NCT00491010|PROCEDURE|radiofrequency catheter ablation|
214312249|NCT03558243|PROCEDURE|Patent Hemostasis arm|Patent hemostasis with TR BAND
214481280|NCT06739642|OTHER|Education|caregivers in the intervention group received an individualized educational program intervention. The content of the educational program was developed by the researcher through a review of the literature and interviews with caregivers. The educational program, during three months, was delivered in 6 sessions of 40 minutes each. The topics of the training content were as follows: 1. General Nutrition Information, 2. Changes Affecting Nutrition During Old Age and Nutrition Principles, 3. Anthropometric Measurements and Scans, 4. Nutritional Problems in the Patient with Dementia, Dementiamendations for Increasing Nutritional Intake in Dementia Patients, 6. Alternatives for Severe Feeding Problems. Covering general topics was held as group education; carried out in two separate groups. Another individual session was planned for caregivers who could not attend the group education program, and the missing topics were completed.
214481281|NCT04626427|DEVICE|WavelinQ™ EndoAVF System|AVF endovascular creations using the WavelinQ™ EndoAVF System
214481282|NCT06741852|PROCEDURE|nCLE assisted endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy via a tunnel|Patients received 2.5mL of 10% Fluorescite intravenously during nCLE. The CLE probe was preloaded into a puncture dilation catheter and locked into position with 2mm being exposed beyond the tip. puncture dilation catheter. The lymph node was punctured and the needle positioned at its center. The probe was advanced and locked, and the needle was advanced to the contralateral edge of the lymph node. Image acquisition began at the lymph node capsule, and then the subcapsular region, followed by the cortical sinus. When the image showed granuloma or malignant characteristics, the location will be recorded in EBUS, and retract the CLE probe, leaving the sheath of puncture dilation catheter as a tunnel between airway wall and target lymph node. Then, a 1.1-mm cryoprobe was inserted into the target lymph node through this tunnel under the EBUS guidance. The probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue.
214671017|NCT00676559|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
214671018|NCT06513715|DIETARY_SUPPLEMENT|Control|This intervention will be made with a placebo
215060780|NCT02727816|DEVICE|filcon IV I (BC 8.7)|control lens
214312250|NCT03558243|PROCEDURE|ULTRA arm|Patent hemostasis protocol plus ipsilateral ulnar compression
214312251|NCT03558243|DEVICE|Hemostatic disc arm|StatSeal disc plus TR Band
214312252|NCT00763347|DRUG|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
214312253|NCT00763347|DRUG|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
214671019|NCT06513715|DIETARY_SUPPLEMENT|Jubanine|This intervention will be made with jubanine or prickly pear extract
214917517|NCT00789945|OTHER|Control|Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.
214917518|NCT00789945|OTHER|Study Arm B|"Study Arm B will include participants with type 1 diabetes which will utilize Timing to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor."
214917519|NCT01921101|BEHAVIORAL|intensive medical nutrition|provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
214917520|NCT01921101|OTHER|control|participants will receive standard care for nutrition received from hospital admission to discharge
214917521|NCT02311127|DEVICE|SecurAcath|Devices secures PICC subcutaneously and remains in place during the complete dwell time of the PICC
214312254|NCT00763347|DRUG|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
214312255|NCT00763347|DRUG|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
214671020|NCT04675346|OTHER|Questionnaire|Questionnaire
214671021|NCT02429648|PROCEDURE|DCC first then PVI|DCC performed prior to PVI
214671022|NCT02429648|PROCEDURE|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
215060781|NCT02727816|DEVICE|ocufilcon D|test lens
215060782|NCT02727816|DEVICE|methafilcon A (BC 8.6)|control lens
215060783|NCT02727816|DEVICE|methafilcon A (BC 8.7)|control lens
215060784|NCT02727816|DEVICE|somofilcon A|test lens
215060785|NCT03076489|OTHER|First Visit|blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
215060786|NCT03076489|OTHER|on-line questionnaires|The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
214312256|NCT00763347|DRUG|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
214312257|NCT00763347|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
214312258|NCT00199355|DRUG|Istradefylline (KW-6002)|
214671023|NCT01309425|DRUG|tapentadol (CG5503) ER two 100-mg TRF|200mg TRF single oral dose
214671024|NCT01309425|DRUG|tapentadol (CG5503) ER 50-mg TRF|50mg TRF single oral dose
214671025|NCT01309425|DRUG|tapentadol (CG5503) ER 25-mg TRF|25mg TRF single oral dose
214917522|NCT02311127|DEVICE|StatLock|Device secures PICC however, device has to be changed weekly
214917523|NCT01483027|DEVICE|TheraSphere|yttrium 90 microspheres
214917524|NCT04453449|DRUG|Midazolam|Midazolam given as a sedative during diagnostic lumbar medial branch block
214917525|NCT00815542|DEVICE|double balloon catheter|cervical ripening using double balloon catheter
215060787|NCT03076489|DEVICE|fMRI|a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
215060788|NCT03763695|OTHER|Measures for the VAP prevention in the PICU|Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
215060789|NCT03763695|OTHER|Evaluation of VAP incidence before the protocol introduction|evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
215060790|NCT00191945|DRUG|Atomoxetine Hydrochloride|
215060791|NCT00191945|DRUG|placebo|
215060792|NCT02725476|BIOLOGICAL|XmAb5871|
215060793|NCT05659043|OTHER|overnight fasting|All blood samples were taken on the day of cardiac catheterization after overnight fasting.
215060794|NCT03955328|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
215060795|NCT01662557|BEHAVIORAL|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
215060796|NCT01662557|OTHER|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
215060797|NCT03034005|DRUG|Budesonide|1600 ug inhaled daily for 6 weeks
215060798|NCT01267864|DRUG|Metoclopramide|10mg IVSS
215060799|NCT01267864|DRUG|Ketorolac|30g IVSS
215060800|NCT01267864|DRUG|Valproate|1gm IVSS
215060801|NCT05404191|DEVICE|low level laser therapy|"Low level laser therapy will be performed for 30 min 3 times per week for 8 weeks on the wound area.~Wound area was irradiated by a red 655 nm light, 150 mW, 2 J/cm2 at the bed of the wound."
215060802|NCT02763813|DEVICE|Herbst (propulsion type oral appliance)|Oral appliance
215060803|NCT02763813|DEVICE|Retention type appliance (ORM)|
215060804|NCT03931850|PROCEDURE|Pudendal nerve block|Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
215060805|NCT00785187|DEVICE|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
215060806|NCT01356498|BIOLOGICAL|pegloticase|8 mg intravenous infusion
215060807|NCT02012855|BEHAVIORAL|Exercise|
215060808|NCT02012855|OTHER|Diet (meal type)|
215060809|NCT03954548|DEVICE|CB-17-08 CADe|CB-17-08 Augmented Endoscopy System with Computer Aided Detection (CADe) function
215060810|NCT00720967|PROCEDURE|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
215060811|NCT00720967|PROCEDURE|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP \>75 mmHg, CVP \> 12 mmHg, Htc \> 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at \~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
215077804|NCT05945459|DIETARY_SUPPLEMENT|Standard formula (0.67 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
214671026|NCT01309425|DRUG|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
214671027|NCT03223727|DIAGNOSTIC_TEST|Blood tests|Blood tests for several bone markers (see summary)
214917526|NCT00815542|DRUG|prostaglandins E2|prostaglandins E2 - Intravaginal Propess for 24 hours
214917527|NCT03327727|DRUG|Investigational Agent: VL-2397|VL-2397
214917528|NCT03327727|DRUG|Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B|Voriconazole, Isavuconazole, or Liposomal amphotericin B
215077805|NCT02333149|DIETARY_SUPPLEMENT|Melatonin|"Children \<40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
215077806|NCT02333149|DRUG|Placebo|Placebo frequency and volume are identical to the experimental arm
214671028|NCT03264638|DRUG|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
214917529|NCT02242682|OTHER|Child passenger safety video|
214917530|NCT00723762|PROCEDURE|Specimen collection|A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
214917531|NCT02017431|OTHER|Allergen|Subject specific allergen is inhaled on day 1 of the triad
214917532|NCT02017431|OTHER|Saline|Saline is inhaled on day 1 of the triad
214312259|NCT03774433|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
214312260|NCT03403959|DEVICE|light therapy|6 weeks morning treatment with bright light therapy in own home.
214312261|NCT05552768|PROCEDURE|Bone level-driven placement|The objective of this study will be to determine if implants placed according to the soft tissue-driving implant placement paradigm, i.e. 4 mm below the tissue margin will have different clinical performance as compared to the bone level-driven placement paradigm.
214312262|NCT05552768|PROCEDURE|Biological width-driven placement guidelines|Biological width-driven placement guidelines
214312263|NCT00108160|DRUG|Mupirocin Ointment [Treatment]|The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
214312264|NCT00108160|DRUG|Polyethylene Glycol Ointment [Placebo]|The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
214312265|NCT01632969|BEHAVIORAL|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
214312266|NCT04341142|DIAGNOSTIC_TEST|Serological tests will be applied on patients blood sampling|Application of tests on patients' serum
214312267|NCT04830787|OTHER|no intervention|there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
214917533|NCT02017431|OTHER|Particle depleted diesel exhaust|High-efficiency particulate filtration of diesel exhaust
214917534|NCT03123445|DRUG|Endostar|Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total
214917535|NCT03123445|DRUG|Gemcitabine|Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total
214917536|NCT03123445|DRUG|Cisplatin|Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total
214917537|NCT03456804|DRUG|ESK981|Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
214917538|NCT04862169|OTHER|educational intervention (SPARK)|"There are 3 modules with 11 chapters. These topics were considered as the most relevant topics for implementation of palliative care for PHC nurses. Also, topics were selected based on our previous literature review of the previous study on the content of PHC nurses training program.~The first module is the introduction. This consists of three chapters: introduction, support system and effective communication. Total reading time is estimated to be one hour. The second module is about the nursing approach in palliative care. It is estimated to be completed in around 2 hours and 15 minutes. The last module is about end of life care.~The participants are expected to access this module before the scheduled synchronous mode. Modules will be provided in the electronic version, so that participants are able to download and read them on their own devices. We are also providing video as trigger for case study discussion"
214917539|NCT04862169|OTHER|electronic version of the modules|electronic version of the modules
214917540|NCT00736164|DIETARY_SUPPLEMENT|selenomethionine|Given orally
214917541|NCT00736164|OTHER|placebo|Given orally
214917542|NCT04786860|PROCEDURE|CPR|Cardiopulmonary resuscitation performed on patients with in-hospital cardiac arrest
214917543|NCT04289155|DRUG|GX-I7|patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks
215077807|NCT04624334|OTHER|Elektro-Entero-Graphy procedure|Fasting, after which pre- and postprandial EEnG measurements are performed.
214312268|NCT06497114|OTHER|ABILHAND-Kids questioner|questioner
214312269|NCT03741660|DIETARY_SUPPLEMENT|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ \[100kcal\] of glucommanan)
214312270|NCT03741660|DIETARY_SUPPLEMENT|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
214312271|NCT01144442|DRUG|Hyperthermic intraperitoneal chemotherapy with Carboplatin|Carboplatin at a dose of 1000mg/m\^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
214312272|NCT01144442|OTHER|Isotonic saline (perfusate)|The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
214312273|NCT01144442|PROCEDURE|Surgery|"The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.~If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach."
214312274|NCT01144442|DRUG|Carboplatin|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
214312275|NCT01144442|DRUG|Paclitaxel|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
214312276|NCT02344030|DEVICE|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
214312277|NCT02344030|DEVICE|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
214312278|NCT02368795|DEVICE|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
214312279|NCT02368795|DRUG|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
214955102|NCT02777424|DRUG|Prothrombin Complex Concentrate|Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
214955103|NCT02777424|BIOLOGICAL|Fresh Frozen Plasma|Pooled collection of plasma from donors
214312280|NCT02368795|DRUG|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
214312281|NCT02368795|DRUG|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
214312282|NCT04119856|OTHER|Affiliation with the outgoing lung team|"The work of the outgoing lung team takes place in the patient's home and involves the following:~* The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~* The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~* The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~* The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~* The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call."
214312283|NCT01682590|PROCEDURE|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output \> 1000ml/24 hr or \>2000ml/24hr with diuretics), RRT is not mandatory."
214312284|NCT04092790|DEVICE|Virtual Gate Device (VGD)|A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
214312285|NCT03978585|DEVICE|high tone external muscle stimulation|Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
214312286|NCT03978585|DEVICE|transcutaneous electrical nerve stimulation (TENS) therapy|Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
214312287|NCT03221920|OTHER|Very Low Carbohydrate Diet|1 : 4 ratio of carbohydrate to fat of the total daily calories intake
214312288|NCT02182531|DRUG|Epinastine|
214481283|NCT06741852|PROCEDURE|Endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy via a tunnel|First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Broncus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
214917544|NCT06940167|OTHER|Myofascial Release Group|myofascial release therapy combined with a home exercise program: Myofascial release techniques will be applied manually to the cervical and upper trapezius regions by a trained physiotherapist. The intervention will be administered three times per week for four weeks, totaling 12 sessions. In addition, participants will follow a standardized home exercise program designed to improve cervical mobility and reduce muscle tension.
214671029|NCT03264638|DRUG|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
214671030|NCT03264638|DRUG|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
214671031|NCT02033980|DEVICE|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
214671032|NCT00750347|DRUG|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
214917545|NCT06940167|OTHER|Kinesiology Taping Group|kinesiology taping combined with a home exercise program : Kinesiology tape will be applied to the cervical region following a standardized taping protocol. The taping will be performed by a trained physiotherapist three times per week for four weeks, totaling 12 sessions. The tape will remain on the skin for 3-5 days per application.
214917546|NCT06940167|OTHER|Home Exercise Program (Control Group)|Home exercise program: The exercise program includes cervical mobility exercises, stretching, and strengthening exercises aimed at improving posture and reducing muscle tension. The intervention will be performed three times per week for four weeks, totaling 12 sessions.
214917547|NCT05124288|OTHER|Observations on Relapsed AML Allogeneic Transplanted patients|This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.
214917548|NCT04161248|DRUG|Venetoclax|"Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP"
214917549|NCT04161248|DRUG|Rituximab Injection|375 mg/m2 - Day 1, cycle 1.
214312289|NCT02182531|DRUG|Pseudoephedrine|
214312290|NCT02182531|DRUG|Epinastine + Pseudoephedrine combination|
214917550|NCT04161248|DRUG|Rituximab SC|1400 mg fixed dose - Day 1, cycle 2 and 3
214917551|NCT04161248|DRUG|Gemcitabine|1000 mg/m2 - Day 1 to day 8
214917552|NCT04161248|DRUG|Dexamethasone|40 mg daily - Day 1 to day 4
214917553|NCT04161248|DRUG|Cisplatin|75mg/m2 - Day 1
214917554|NCT04161248|DRUG|Glofitamab|Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP
214917555|NCT04161248|DRUG|Tafasitamab|Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15)
214312291|NCT05103215|DRUG|Lidocaine HCl 2%|Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
214671033|NCT00003820|DRUG|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
214671034|NCT00312780|DRUG|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
214917556|NCT06776016|DIETARY_SUPPLEMENT|Butyrate|Agent: The dietary supplement contains tributyrin, a pro-drug of butyrate. Method: Participants receive the supplement orally at a dose of 20 ml, 2-3 times daily, 12 weeks.
214917557|NCT06122610|DEVICE|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after first cycle of Lutathera® treatment
214917558|NCT06122610|DEVICE|Photon Emission Tomography / CT (PET/CT)|PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
214917559|NCT06122610|DRUG|64Cu-Dotatate|Standard of care administration of radioactive drug for PET/CT
214917560|NCT06122610|DRUG|177Lu-Dotatate|Standard of care administration of radioactive drug for PET/CT and SPECT/CT
214917561|NCT03548779|BEHAVIORAL|Pre-visit prep|Patient and provider surveys will be used to measure the impact of pre-visit preparation on the primary outcomes of engagement of participants in the clinical interaction and their view of the interaction as patient-centered, in addition to secondary outcomes that may be affected by this intervention (described above). The study investigators will test the hypothesis that patients will benefit from pre-visit preparation by: (1) rating their clinical encounters as more patient-centered and (2) asking more questions during their clinical encounters.
214917562|NCT03548779|DIAGNOSTIC_TEST|usual care + exome seq|Provider surveys will be used to assess impact of exome sequencing on diagnostic thinking and management planning. Health utilization and condition-specific general clinical outcomes will be assessed from health records data.
214917563|NCT00589654|OTHER|Questionnaire|Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
215060812|NCT00720967|PROCEDURE|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs \< 75 kg, and 4 hours if \> 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
214312292|NCT05103215|DRUG|Normal saline|Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
215060813|NCT01230190|DIETARY_SUPPLEMENT|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1\*10\^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
215060814|NCT01230190|DIETARY_SUPPLEMENT|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
215060815|NCT03734926|DRUG|ZSP1241|ZSP1241 tablets for oral administration.
214312293|NCT04563169|OTHER|Video consultation|The first video consultation with a nurse was planned one week after start with CPAP. Three focus points were discussed during the consultations: 1) adherence (\>6 hours per night); 2) rest AHI \< 5 (or \<10 if age \>70), and 3) (improvements in) complaints. If these objectives were achieved after one week, a new consultation was planned three weeks later (four weeks after start). As long as these objectives were not achieved, video consultations were planned weekly (until after four weeks).
214312294|NCT06233487|DIAGNOSTIC_TEST|Repeat hip ultrasound measurements|See earlier
214312295|NCT00100126|DRUG|Amoxicillin Pulsatile Release Multiparticluate Sprinkle|
214671035|NCT05603286|PROCEDURE|Home-monitoring|Questionnaires for home-monitoring will be send to the participants 11 weeks after the baseline visit via e-mail using Castor EDC and can be completed using a computer, tablet or smartphone. Home-monitoring can be done together with a parent or guardian, if needed.
214671036|NCT00893594|DRUG|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
215060816|NCT04739319|OTHER|N/A Observational study|N/A Observational study
215060817|NCT02901249|DRUG|sertraline|
215060818|NCT02901249|DRUG|Nortriptyline|
215060819|NCT02901249|DRUG|Lithium|
215060820|NCT06279117|BEHAVIORAL|therapeutic touch|Individuals who undergo therapeutic touch will receive therapeutic touch for 20 minutes 30 minutes before the exam.
215060821|NCT01541007|DRUG|Cabazitaxel|25 mg/m2 every three weeks
215060822|NCT01541007|DRUG|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
214312296|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- low dose|
214312297|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- High dose|
214671037|NCT00893594|DRUG|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
214671038|NCT00216021|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
214917564|NCT06532500|BEHAVIORAL|CBT-MyOWL|12-sessions of CBT-MyOWL
214917565|NCT06532500|BEHAVIORAL|CBT-as-usual|12-sessions of CBT using Mind Over Mood or Anxiety Phobia
214917566|NCT06959563|BIOLOGICAL|9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use|By the percutaneous route with the multiple puncture device - 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix
215060823|NCT02413476|PROCEDURE|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
215060824|NCT02413476|PROCEDURE|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
215060825|NCT05466084|PROCEDURE|tissue Glue for mesh fixation|one arm of the study had their mesh fixed with tissue glue applied at multiple sites
214312298|NCT01150123|BIOLOGICAL|Placebo- Saline|
214312299|NCT03238638|DRUG|Pembrolizumab|Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.
214312300|NCT03238638|DRUG|epacadostat|Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
214312301|NCT01035944|DEVICE|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
214312302|NCT01035944|DEVICE|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
214312303|NCT03076957|DRUG|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
214312304|NCT01977170|BIOLOGICAL|Hib/PRP-T vaccine|Hib liquid vaccine
214312305|NCT00206869|BEHAVIORAL|exercise|
214312306|NCT00206869|BEHAVIORAL|heat|
214312307|NCT00206869|PROCEDURE|red light illumination|
214312308|NCT05823623|DRUG|Inetetamab|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
214917567|NCT05467930|OTHER|Survey|Survey completion by the participant to collect information about health and social experience
214917568|NCT05467930|OTHER|Medical History Review|Review of the participant's medical history at New York Presbyterian/Columbia University Irving Medical Center
214917569|NCT05467930|OTHER|Sample Collection|Collection of nasal and blood samples
214917570|NCT06466382|OTHER|Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling|The intervention studied is a treatment recommendation by a specialized molecular tumorboard (mTB). This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.
214917571|NCT06466382|DRUG|Carboplatin / Paclitaxel Chemotherapy|2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly
214917572|NCT06132893|DRUG|BHV-7000|BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
214917573|NCT06132893|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
214917574|NCT06132893|DRUG|Placebo|Matching placebo taken once daily
214917575|NCT04432831|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.
214917576|NCT04432831|OTHER|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.
214917577|NCT03731585|BEHAVIORAL|Behavioral Intervention|Participate in psychological sessions
214917578|NCT03731585|OTHER|Educational Intervention|Participate in educational sessions
214917579|NCT03731585|OTHER|Questionnaire Administration|Ancillary studies
214917580|NCT03731585|PROCEDURE|Support Group Therapy|Participate in group sessions
214917581|NCT06052033|PROCEDURE|CO2|CO2 laser treatment is a surgical procedure that employs a high-powered carbon dioxide laser beam to precisely ablate cervical lesions. The laser is applied with a depth of 7-10mm and a width of 3-5mm beyond the lesion area in a single session. This intervention aims to address persistent low-grade cervical lesions associated with high-risk HPV infection.
215060826|NCT05466084|PROCEDURE|Metallic Tackers for mesh fixation|in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
214312309|NCT05823623|DRUG|Pyrotinib|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
214312310|NCT05823623|DRUG|Oral Vinorelbine Tartrate|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
214312311|NCT03571542|OTHER|pulmonary function|The aim of this study is to assess the respiratory function thanks to pulmonary function tests in renal transplanted children in France.
214671039|NCT00216021|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
214312312|NCT01527279|DRUG|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
214312313|NCT01527279|DRUG|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
214312314|NCT04318509|DIETARY_SUPPLEMENT|GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
214312315|NCT00152750|DRUG|APO-clonidine|
214312316|NCT02486042|DRUG|Omegaven|Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).
214312317|NCT02486042|DIETARY_SUPPLEMENT|Standard lipids (primarily omega-6 fatty acids)|Infants will receive nutritional supplementation with standard intralipid, composed primarily of omega-6 fatty acids.
214312318|NCT00298207|BEHAVIORAL|Walking (behavior)|
214671040|NCT02297217|DRUG|Carboplatin and Taxol (paclitaxel)|Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
214917582|NCT06962566|BEHAVIORAL|Morning exercise|Participants performed a 45-minute treadmill brisk walking in the morning between 08:00 to 11:00 AM.
214917583|NCT06962566|BEHAVIORAL|Evening exercise|Participants performed a 45-minute treadmill brisk walking in the evening between 18:00 to 21:00 PM.
215060827|NCT00532311|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
214312319|NCT01466387|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|One dose of typhoid Vi polysaccharide vaccine.
214312320|NCT01466387|BIOLOGICAL|Yellow Fever Vaccine|One dose of yellow fever vaccine.
214312321|NCT01466387|BIOLOGICAL|Japanese Encephalitis Vaccine|Two doses of Japanese Encephalitis Vaccine.
214312322|NCT01466387|BIOLOGICAL|Rabies Vaccine|Three doses of Rabies vaccine.
214312323|NCT01466387|BIOLOGICAL|MenACWY-CRM Vaccine|One dose of MenACWY-CRM vaccine.
214312324|NCT06520930|BEHAVIORAL|breathing exercise therapy|Description: The breathing exercises to be applied were taught to each pregnant woman face to face with one-on-one training. The taught practice was then repeated by the pregnant woman and the researcher together. In the next step, pregnant women were asked to perform the application themselves. In this way, it was determined whether individual breathing exercise practices were performed correctly and effectively. After the one-on-one training was completed, the pregnant women were divided into groups of maximum six people and breathing exercise exercises were performed 7 days a week, once a day and once a week face-to-face for 8 weeks. Each session lasted approximately 45 minutes. For 8 weeks, a short reminder message was sent to pregnant women every morning to ensure that they did not interrupt their daily breathing exercise practices, and they were called in the evening to check whether they had performed the application correctly and whether they had any problems.
214312325|NCT04471389|OTHER|Incidence and risk factors of hypertension|During the follow-up period, General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc). Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness, IMT, FMD) will be collected.
214312326|NCT02522208|DRUG|BiDil XR|fixed combination capsule
214312327|NCT02522208|DRUG|BiDil Immediate Release (IR)|fixed combination tablet
214312328|NCT00374296|DRUG|MGCD0103|MGCD0103 administered orally three-times per week
214347162|NCT01003249|DRUG|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
214347163|NCT01003249|DRUG|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
214917584|NCT05769218|BEHAVIORAL|CHORUS+|The CHORUS+ intervention will include a baseline interview with a peer recovery coach to encourage uptake of HIV PrEP (pre-exposure prophylaxis) and medications for opioid use disorder (MOUD) through motivational interviewing (MI). Participants will also be offered HIV self-testing on the day of recruitment, HIV PrEP (if they are HIV negative) and MOUD. Participants will then receive peer coaching for 6 months to increase adherence to PrEP and or MOUD.
215060828|NCT00532311|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
215060829|NCT05933967|DRUG|Orelabrutinib+R-CHOP|Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
215060830|NCT01245686|BEHAVIORAL|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
214312329|NCT02831166|PROCEDURE|Transradial primary percutaneous coronary intervention|Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
214312330|NCT02831166|PROCEDURE|Transfemoral primary percutaneous coronary intervention|Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
214312331|NCT00566150|DRUG|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
214312332|NCT00566150|DRUG|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
214312333|NCT03486093|DEVICE|"Training and retraining to GAVECELT bundle recommendations plus port protector"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced."
214312334|NCT03486093|BEHAVIORAL|"Training and retraining to GAVECELT bundle recommendations"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed."
214312335|NCT03159481|BEHAVIORAL|Usual Care + Health Promotion Intervention|Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
214312336|NCT04628676|DRUG|tranexamic acid|Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.
214312337|NCT04628676|DRUG|Epinephrine|Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
214312338|NCT05441527|DEVICE|MI Paste, then, Biotene Dry Mouth Gel|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
214312339|NCT05441527|DEVICE|Biotene Dry Mouth Gel, then, MI Paste|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
214312340|NCT05068128|OTHER|Flow MRI|"4 flow acquisitions based on the 2D cine phase contrast sequence (present on all MRI systems) will be performed.~This sequence requires a cardiac synchronization by a plethysmograph put on the patient's finger.~32 cardiac phases are reconstructed per acquisition. The processing of the flow MRIs and the analysis of the flow curves of the LCS and blood during the cardiac cycle will be performed using the Amiens software.~Parameters measured via flow MRI are:~\- Cerebral vascular flow, intracranial LCS dynamic volume, extracranial LCS dynamic volume"
214671041|NCT02297217|RADIATION|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
214917585|NCT05769218|OTHER|Standard of care|Normal protocols for care of participants who inject opioids will be followed.
214917586|NCT04699123|DRUG|NC318 800 mg|NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.
214917587|NCT04699123|DRUG|NC318 400 mg|NC318 will be given intravenously (IV) every 2 weeks.
214917588|NCT04699123|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be given IV every 3 weeks
214917589|NCT06307925|DRUG|HC010|HC010 Q2W/28d intravenous infusion
214917590|NCT06117293|DEVICE|Mosaic|1550 Fractional Laser System
214917591|NCT00004787|DRUG|filgrastim|
214917592|NCT06684054|DRUG|docetaxel, anthracycline, cyclophosphamide|"1. Participants were required to receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy.~2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.~3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study."
214917593|NCT01756794|PROCEDURE|Liver transplantation|
214917594|NCT05567744|OTHER|Registry|Registry
215060831|NCT05561101|OTHER|Caregivers burden|Assessment of caregiver burden after admision at Emergency Department of their elderly relative
214917595|NCT03089268|PROCEDURE|Colonoscopy|A colonoscopy will be performed to all individuals.
214917596|NCT03089268|PROCEDURE|Polypectomy or biopsy|All lesions will be removed or biopsied during the procedure
214917597|NCT03089268|GENETIC|Molecular analysis|"Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion"
214955104|NCT03594799|OTHER|Bed Rest Control Group|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days.
214917598|NCT04191369|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
215060832|NCT06554977|OTHER|Laboratory|CBC Kidney function (Urea, creatine) Platelets to albumin ratio Albumin /creatine ratio CRP Urine analysis Abdominal us Kidney function , CBC , Albumin will be done at the time of admission i
214312341|NCT05068128|OTHER|PERFUSION TEST|"The test will be performed will include:~* Inserting a needle into the lumbar space, Ommaya reservoir or valve pre-chamber, as appropriate~* Connect the needle to the pressure transducer via saline filled manometer lines connected via a 3-way valve. The other end of the 3-way connection will be connected to a saline~* Recording of the opening pressure for 10 minutes~* The infusion test is terminated either when the pressure stabilizes again on a new plateau, or when the average pressure exceeds 40 mmHg, or in case of adverse effects or symptoms such as headache, nausea/vomiting or visual disturbances.~* At the end of the test, a depletion of 30 to 50 mL of CSF will be performed.~* The pressure recording during the test is then used to calculate the parameters of the mechanical properties of the CSF circulation and reported to the neurosurgeon ordering the test."
214312342|NCT01866514|PROCEDURE|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
214312343|NCT01866514|DRUG|2% preservative-free lidocaine|
214312344|NCT01866514|DEVICE|EZ-IO|
214312345|NCT05083793|DRUG|Pregabalin 150mg|The effect of pregabalin on post-operative pain
214481284|NCT06742606|BIOLOGICAL|Group 1 of patients will receive Adalimumab while Group 1 will receive ustekinumab|"All the patients will be treated according to guidelines of ECCO/ESPGHAN and will be followed up regularly for 12 months by assessment~• response to treatment Frequency of relapses,~Regular assessment will be:~Clinically every 2 to 4 weeks at gastroenterology outpatient clinic by using activity scoring systems:~pediatric Ulcerative Colitis Activity Index pediatric Chron's Disease Activity Index~Laboratory follow up will done at weeks 12,24,36,48 of starting or changing to other biological by doing inflammatory markers( CBC, ESR, CRP, albumin. At the end of study(week 48) each patient will be reassessed by:~Disease activity:~Laboratory Endoscopy will be repeated at week 48 of starting or changing to other biological to assess effect of biologicals on reach mucosal healing."
214481285|NCT06133231|DIETARY_SUPPLEMENT|Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|Participants will take 2-4 capsules of EMP+ Advanced per day (max 8 capsules) for eight weeks.
214481286|NCT06743945|DRUG|POLA-R-CHP|Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin
214481287|NCT06744231|OTHER|Usual Care|Prior to implementation of the Thriving Hearts package of services, people living in participating counties will receive usual care for pregnancy, birth, and postpartum services. The study team will quantify existing services using a study-developed usual care assessment instrument.
214671042|NCT03551145|OTHER|Acellular collagen matrix|3D collagen matrix consists of the collagen porcine type I and III
214671043|NCT03551145|OTHER|Autogenous free gingival graft|Autogenous graft harvested from the posterior palate
214917599|NCT04191369|DIAGNOSTIC_TEST|Endoscopic ultrasound|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
214955105|NCT03594799|DIETARY_SUPPLEMENT|Cocktail intervention|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days. In addition subjects are receiving a daily supplementation of a Cocktail. The daily dose of Cocktail consists of 6 pills per day: 2 at breakfast, 2 at lunch and 2 at diner. This will be equivalent to a daily dose of around 741 mg of bioactive polyphenols associated with Omega-3, Selenium and Vitamine E.
214955106|NCT04319653|DEVICE|Dynamic pelvic MRI with intravaginal probe with pressure sensor|Dynamic pelvic MRI with intravaginal probe and intravaginal and intrarectal opacification gel
214955107|NCT02784288|PROCEDURE|Neck Dissection|All patients will undergo neck dissection of the cervical lymph nodes
215060833|NCT03180333|DRUG|PNA|
215060834|NCT03180333|DRUG|PNA placebo|
214312346|NCT05083793|OTHER|Placebo|patients will receive placebo one hour before operation
214955108|NCT02784288|PROCEDURE|Standard-of-Care (SOC) Transoral Surgery of Primary Site|Patients with a single lymph node that measures less than six centimeters, have no extracapsular extension in the lymph node, and have no perineural or perivascular invasion of the primary biopsy will undergo transoral surgery of the primary site.
214955109|NCT02784288|RADIATION|SOC Radiation|Patients who have 2 positive nodes with no extracapsular extension, or have perineural or perivascular invasion of the primary biopsy will undergo radiation.
214955110|NCT02784288|DRUG|SOC Carboplatin|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
214955111|NCT02784288|DRUG|SOC Paclitaxel|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
214955112|NCT02784288|PROCEDURE|Videofluoroscopy|All patients undergo a videofluoroscopy procedure one year after completion of therapy to assess swallowing function.
214955113|NCT02734862|DRUG|CD101|Intravenous antifungal therapy
214955114|NCT02734862|DRUG|Caspofungin|Intravenous antifungal therapy
214955115|NCT02734862|DRUG|Fluconazole|oral antifungal therapy
214955116|NCT02734862|DRUG|intravenous placebo|normal saline
214955117|NCT02734862|DRUG|oral placebo|microcrystalline cellulose
214312347|NCT04891900|DRUG|TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine|"Initial treatment (6 cycles)：~1. TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle"
214312348|NCT04404855|OTHER|NGS + Antibiotic Recommendation|NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist
214312349|NCT04404855|PROCEDURE|Standard of Care treatment|Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.
214312350|NCT03209063|DIAGNOSTIC_TEST|polymerase chain reaction|diagnostic test as Polymerase chain reaction for detection of Prothrombin gene and methylenetetrahydrofolate reductase gene polymorphisms
214312351|NCT00386087|DRUG|Enzastaurin Hydrochloride|
214312352|NCT02064010|DRUG|SNC-102|Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
214312353|NCT02064010|DRUG|Placebo|Placebo tablet, administered orally for 4 weeks
214312354|NCT01085799|BEHAVIORAL|Health Education Intervention|This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
214312355|NCT05870033|DEVICE|Electromyography (EMG) measurement|Electromyography (EMG) measurement of m. quadriceps femoris and semitendinosus muscle during static functional tasks
214312356|NCT02158390|BEHAVIORAL|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
214312357|NCT03320564|DIAGNOSTIC_TEST|F-18 FDG PET|Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.
214312358|NCT01760512|PROCEDURE|Gastric bypass|Gastric bypass
214671044|NCT05717179|DIAGNOSTIC_TEST|Ultrasound|At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint.
214312359|NCT00860782|BEHAVIORAL|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
214312360|NCT00788827|BIOLOGICAL|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
214312361|NCT02331147|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment
214312362|NCT02331147|OTHER|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
214312363|NCT02242708|BEHAVIORAL|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
214312364|NCT01218555|DRUG|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
214312365|NCT01218555|DRUG|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
214671045|NCT05339464|OTHER|Family Wellness program|Weekly one-hour online workshops over an 8 week period. Families will also receive text message reminders as part of the intervention.
214671046|NCT04330508|OTHER|Depression and Cognitive Tests|Health Related Quality of Life, neurocognitive tests, PHES
215060835|NCT00025792|DRUG|Pramipexole|
215060836|NCT04022629|PROCEDURE|Arthroscopic Washout Only|To wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic.
215060837|NCT04022629|PROCEDURE|Arthroscopic Bankart Repair|To repair the torn glenoid labrum in the shoulder, using key-hole (arthroscopic) surgery techniques under general anaesthetic. The Bankart technique is well described and will be performed using suture anchors.
215077808|NCT04624334|OTHER|EEnG Questionnaire|Filling out questionnaire about EEnG procedure.
214312366|NCT03667365|PROCEDURE|aortic valve replacement|aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
214312367|NCT03667365|OTHER|strict clinical surveillance|strict clinical surveillance strategy
214312368|NCT05643261|OTHER|Muscle and technique training|The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.
214312369|NCT05228392|OTHER|listening to music|listening to lullaby or other music types
214312370|NCT03889769|DIAGNOSTIC_TEST|OSNA test|Analysis of lymph node with OSNA
214312371|NCT03630809|BIOLOGICAL|HER2 DC1 Vaccine|Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
214312372|NCT02595086|PROCEDURE|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
214312373|NCT02595086|PROCEDURE|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
214312374|NCT01808430|PROCEDURE|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
214312375|NCT02265055|PROCEDURE|transfer early cleavage embryos|transfer early cleavage embryos
214312376|NCT02265055|PROCEDURE|transfer non early cleavage embryo|
214671047|NCT05806450|BEHAVIORAL|Intervention|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
215060838|NCT01664611|PROCEDURE|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
215060839|NCT01664611|PROCEDURE|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
214312377|NCT01599273|DRUG|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
214312378|NCT01083212|DRUG|AZD1656|Single dose,oral tablet
214312379|NCT01083212|DRUG|Gemfibrozil|Oral tablet bid on day 1 - 5.
214312380|NCT01083212|DRUG|Placebo|Oral tablet bid on day 1-5
214312381|NCT03829748|PROCEDURE|Intermittent aspiration|Endoscopic ultrasound is done for the localization of the lesion and to localize the site of puncture.Prior to the puncture of the lesion the stylet is removed and a vacuum syringe is prepared with 10 cc of vacuum allowing the generation of continous pressure inside and connected to the end of the needle. Once the lesion is punctured 15 movements in and out of the lesions will be made while the syringe is opened and closed on and off for a total of 3 times each pass. A total of 4 passes will be done in each lesion.
214312382|NCT03921697|DEVICE|Werable sensors|Parkinson Disease Patients monitored by werable sensors
214312383|NCT02903186|BEHAVIORAL|SMS|This is an intervention using short mobile messages (SMS)
214312384|NCT03745144|DRUG|Cladribine|Participants received cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
214312385|NCT03745144|DRUG|Placebo|Participants received placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
214312386|NCT03745144|DRUG|Microgynon®|Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.
214312387|NCT03843879|PROCEDURE|Transversus Abdominis Plane Block|Single-injection transversus abdominis plane block with 30 mL of 0.25% Bupivacaine with 1:400,000 epinephrine
214312388|NCT03843879|DRUG|Intravenous Lidocaine|Continuous intravenous lidocaine infusion
214312389|NCT03463746|DEVICE|LYRA® gait trainer|The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.
214312390|NCT03463746|DEVICE|Standard individual physical therapy|The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
214312391|NCT01093911|BIOLOGICAL|CDP7657|Ascending single doses of CDP7657
214312392|NCT01093911|OTHER|Placebo|Placebo: 0.9% sodium chloride aqueous solution
214312393|NCT03295708|DIETARY_SUPPLEMENT|fish oil capsule|N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
214312394|NCT03295708|DIETARY_SUPPLEMENT|soybean oil capsule|placebo capsule
214312395|NCT03125434|OTHER|EOS full-spine, MRI, gait analysis|full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
214312396|NCT01542385|PROCEDURE|Stent|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
214312397|NCT05044455|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|A 9 week CBT group, 2 hours weekly, is delivered by trained Peer facilitators to mothers randomized to this arm.
214312398|NCT01586819|DRUG|Botulinum Toxin|"The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete."
214312399|NCT01586819|PROCEDURE|Chemical Peel Only|After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution \[a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)\] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel \[35% Trichloroacetic acid\] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
214312400|NCT00896337|DEVICE|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
214312401|NCT00896337|DRUG|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
214312402|NCT00896337|DRUG|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
214312403|NCT05696912|GENETIC|Ex-vivo approach concerning 25 patients|Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis
214671048|NCT05806450|OTHER|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
214312404|NCT05696912|GENETIC|In-vitro approach concerning 25 patients|In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay
214312405|NCT01359254|DRUG|Melphalan|Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
214312406|NCT01359254|DRUG|Fludarabine|Fludarabine is given through the vein daily for 5 days.
214312407|NCT01359254|DRUG|Antithymocyte Globulin (ATG)|ATG is given every other day for 4 days.
214312408|NCT01359254|DRUG|Busulfan|Busulfan is given daily for 4 days.
214312409|NCT01359254|DRUG|Total Body Irradiation (TBI)|TBI is given twice on the last day.
214312410|NCT04498728|OTHER|Mobile Health Application for Remote Monitoring|The use of the CATCH application (CATCH App), and any data and images obtained from the use of the CATCH App, will all be performed as standard of care for patients at Children's Mercy Kansas City, and will be for the clinical treatment of patients. Data will be collected for the repository for all patients submitting data through the use of the CATCH App. Clinical care team will follow the patients after discharge home from the hospital.
214312411|NCT05752110|DRUG|Ketamine|0,5mg/kg single dose Ketamine (0.05ml/kg) intravenously administered
214312412|NCT05752110|OTHER|Saline|0.09% Saline (0.05ml/kg) intravenously administered
214312413|NCT04083807|BIOLOGICAL|TISSEEL Lyo|The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.
214312414|NCT04083807|PROCEDURE|Manual compression with surgical gauze pads|Surgical 4x4 inches gauze pads
214312415|NCT01571895|DRUG|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
214312416|NCT01296256|DRUG|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
214481288|NCT06744231|BEHAVIORAL|Thriving Hearts|"Thriving Hearts is a collaboration among LHDs in ten North Carolina counties. At the individual level, pregnant individuals will self-screen for HDP risk during prenatal visits, and those at risk will be provided a Mama Hearts Care Kit, including a home blood pressure monitor, low dose aspirin, and culturally tailored educational materials.~At the healthcare provider level, burnout and compassion fatigue will be addressed through skill-building activities, including training in the Community Resilience and Mindfulness-Based Stress Reduction.~At the community level, Loving Connection will provide proactive material and social support through Community Health Workers, text messaging-based communication, a medical legal partnership, and capacity-building support for community-based organizations."
214671049|NCT06613061|OTHER|Breathing exercise|"The researcher has a breathing exercise certificate. In our study, the breathing exercise application consists of three stages: box breathing, sigh breathing and diaphragm breathing.~Patients will be asked to continue the breathing exercise application for 2 weeks and will be reminded to do the breathing exercises. Box and sigh breathing will be done 3 times a day (morning, noon and evening) every day for 2 weeks. Diaphragm breathing exercise will be applied for 2 minutes in the first week and 4 minutes in the second week."
214671050|NCT06095284|OTHER|Pre-Extraction Phase|This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire
214671051|NCT06095284|OTHER|Extraction Phase|Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire
214671052|NCT06095284|OTHER|Post-Extraction Phase|Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation
215077809|NCT04624334|OTHER|Gold Standard Questionnaire|Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.
214312417|NCT03854422|DEVICE|left position|colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy
214481289|NCT01651000|DRUG|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime.
214481290|NCT01651000|OTHER|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
214481291|NCT06736678|DIETARY_SUPPLEMENT|Oral Immunonutrition|Patients receive enteral immunonutrition, Oral Impact® Nestle for 6 weeks from one week before radiotherapy;
214481292|NCT06743360|DEVICE|Insertion|Twenty orthodontic mini-implants (n=20) (AbsoAnchor SH 1312-08, Dentos, Daegu, South Korea) were randomly chosen (every third screw from a sample of 60) numbered consecutively, and embedded in polivynyl siloxane impression material Variotype heavy putty (Kulzer, Hanau, Germany).
214671053|NCT05227274|OTHER|Items completion with or without a MFM-Play|Patients will completed 3 MFM during the follow-up, two times using the MFM-Play, and one without the MFM-Play Delay between each MFM completion will be 1 month ± 15 days
214955118|NCT02757625|DRUG|Dexmedetomidine hydrochloride|"* 45 weeks CGA to \< 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state~* 6 years old to \< 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state"
214312418|NCT03854422|DEVICE|left supine position|Colonoscopy in the Left supine position
214312419|NCT03854422|DEVICE|dynamic position|Colonoscopy in the Dynamic position
214955119|NCT06043492|OTHER|High Intensity Interval Training|10 x 2 min running at vVO2max, interspersed by 2 min recovery at 40% VO2max
214955120|NCT06043492|OTHER|Coninuous Running|40 min continuous running at lactate threshold
214312420|NCT01673035|BEHAVIORAL|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
214955121|NCT06043492|OTHER|Control Trial|The participants will perform only the baseline and post acute-training evaluations, without performing exercise
214312421|NCT01673035|BEHAVIORAL|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
214312422|NCT00864747|DRUG|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
214312423|NCT00864747|DRUG|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
214312424|NCT04668950|DRUG|Fluvoxamine|Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days
214312425|NCT04668950|DRUG|Placebo|Will take 2 capsules per day as tolerated for approximately 15 days
214312426|NCT04196946|DRUG|25 mcg fentanyl|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
214312427|NCT04196946|DRUG|250 mcg alfentanil|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
214481293|NCT06743360|DEVICE|Scanning|After the planned movement is achieved, the mini-implant will be removed and provided to laboratory analysis. All screws were sputtered (0.6µm CaCO₄) and scanned in blue-light technology, using a 3D optical scanner (Atos III, Triple Scan, GOM, Germany) to the nearest 2 micrometres. Due to regularly performed calibration procedures, recommended by the manufacturer, an error study was superfluous. Subsequently, the scans were superimposed using GOM Inspect Software (GOM, Braunschweig, Germany) in order to verify the shape and size repeatability.
214481294|NCT06741540|OTHER|tDCS|"Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that modulates cortical excitability by applying a weak direct current through electrodes placed on the scalp. This technique usually lasts for 20-30 minutes and can affect brain function by altering cortical excitability, local cerebral blood flow, synaptic plasticity, and the balance of cortical excitation/inhibition.~tDCS is widely used in clinical settings and has shown some clinical efficacy in treating common psychiatric and neurological disorders. It is also used to improve motor, perceptual, and cognitive processes, as well as to treat a variety of neurological and psychiatric diseases."
214481295|NCT03982186|DRUG|JNJ-73763989|JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.
214917600|NCT06621030|DEVICE|MIB Breath Analyzer|Going through visit-specific blood glucose excursions by the administration of glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC IMS and the MIBs (investigational devices). Going through visit-specific blood glucose excursions by consuming a standardized meal, monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices) Imitating the glucose excursion from the meal excursion by infusing glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices).
214917601|NCT03714334|DRUG|DNX-2440 injection|DNX-2440 virus will be injected stereotactically
214917602|NCT04973176|DEVICE|Standard Bougie|Standard Bougie for endotracheal intubation
214481296|NCT03982186|DRUG|Placebo for JNJ-73763989|Placebo for JNJ-73763989 will be administered as subcutaneous injection.
214481297|NCT03982186|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
214481298|NCT03982186|DRUG|Placebo for JNJ-56136379|Placebo for JNJ-56136379 tablets will be administered orally.
214481299|NCT03982186|DRUG|Nucleos(t)ide Analog (NA)|NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
215060840|NCT03279159|OTHER|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
215077810|NCT06370234|RADIATION|Whole body 18F-FDG Positron Emission Tomography|The subjects enrolling and participating this study will have done PET/MR during pre-operation chemotherapy. But, in normal procedure, they will not have done.
214312428|NCT04874974|BEHAVIORAL|Metacognitive and Defusion Training|Module I will give a brief introduction into the rational of the therapy and explain the terms cognitive biases and relational responding and their role in the development of psychological problems (psychosis) in a simple language and with the help of examples and small exercises. The principle of metacognition and cognitive defusion in psychotherapy will be made clear. An outlook on the procedures and the goals of the group therapy will be given. Module II will include interventions adapted from the MCT manual (Moritz et al., 2017) and Module III with consist of defusion strategies taken from the ACT group manual (Dambacher et al., 2020) and existing studies on ACT and psychosis (Bach et al., 2013; Gaudiano \& Herbert, 2006).
214312429|NCT01087047|DEVICE|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
214481300|NCT06741813|PROCEDURE|ASCT|The chemotherapy-based preconditioning regimen was BeEAM, which consisted of bendamustine (120-180 mg·m-2·day-1，days -8 to -7), etoposide (200 mg·m-2·day-1，days -6 to -3), cytarabine (400 mg·m-2·day-1，days -6 to -3), and melphalan (140 mg·m-2·day-1，days -2).
214917603|NCT04973176|DEVICE|Flexi-tip Bougie (P3 Medical Bristol,UK)|Flexi-tip Bougie for endotracheal intubation
214917604|NCT00373620|DRUG|paclitaxel|
214312430|NCT02038595|RADIATION|PET imaging|
214917605|NCT00652626|DRUG|azacitidine|
214917606|NCT06466525|DRUG|LBT-3627|Synthetic peptide
214917607|NCT06466525|DRUG|Placebo|Vehicle
214917608|NCT04189783|DRUG|Liposomal Bupivacaine|Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
214312431|NCT02586896|BEHAVIORAL|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
214312432|NCT02586896|BEHAVIORAL|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
214312433|NCT02897674|DIETARY_SUPPLEMENT|Palm olein|two thirds of the 30% fat calories will come from palm olein
214312434|NCT02897674|DIETARY_SUPPLEMENT|Interesterified palm olein|two thirds of the 30% fat calories will come from interesterified palm olein
214312435|NCT02897674|DIETARY_SUPPLEMENT|soybean oil|two thirds of the 30% fat calories will come from soybean oil
214312436|NCT04894396|DEVICE|Aetrex L2305 Premium Memory Foam Orthotics W/ Metatarsal Support|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. For medium to high arches with forefoot pain, featuring a cupped heel to cushion and stabilize the back of foot and a metatarsal pad to redistribute weight to relieve ball-of-foot discomfort. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
214312437|NCT04894396|DEVICE|Aetrex L2300 Premium Memory Foam Orthotics|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
214312438|NCT01124643|BIOLOGICAL|Replagal|0.2 mg/kg administered intravenously \[IV\] every other week
214312439|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
214312440|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
214312441|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
214312442|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
214312443|NCT04903405|OTHER|No intervention|No intervention is involved in this study
214312444|NCT03215329|PROCEDURE|abdominal or vascular surgery|Intermediate or high risk abdominal or vascular surgery
214917609|NCT04189783|DRUG|Quadratus Lumborum Block|"Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery"
214917610|NCT04189783|OTHER|Questionnaire Administration|Ancillary studies
214917611|NCT00317785|DRUG|cyclophosphamide|
214917612|NCT00317785|DRUG|cyclosporine|
214917613|NCT00317785|DRUG|methotrexate|
214917614|NCT00317785|DRUG|mycophenolate mofetil|
214917615|NCT00317785|DRUG|sirolimus|
214917616|NCT00317785|DRUG|tacrolimus|
214917617|NCT00317785|OTHER|pharmacological study|
214917618|NCT00317785|PROCEDURE|allogeneic bone marrow transplantation|
214312445|NCT04220411|DRUG|AR100DP1|topical ointment
214312446|NCT02719132|DRUG|Dapagliflozin|Dapagliflozin, 10 mg
214312447|NCT02719132|DRUG|Metformin|Metformin, up to 2500 mg
214312448|NCT02028988|DRUG|Enzalutamide|
214312449|NCT02028988|RADIATION|External Beam Radiation|
214312450|NCT02803307|DRUG|TLC599|Single dose via intra-articular injection
214312451|NCT02427321|DEVICE|Video recording of flexible cystoscopic examination|The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
214312452|NCT02680639|DEVICE|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
214312453|NCT05744349|PROCEDURE|K-wires Fixation of Pediatric Shaft Both Bone Forearm Fractures|After administration of anesthesia, surgery will be performed with the patient supine on the operating table and fracture will be analyzed with an image intensifier. In radius, the wire will be inserted by surgical drilling through Lister's tubercle or the radial styloid while in ulna, the wire will be inserted through the tip of the olecranon.
214312454|NCT01663415|DRUG|Enzalutamide|oral
214312455|NCT02678676|OTHER|No Intervention|Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
214312456|NCT02678676|OTHER|No Intervention|Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).
214917619|NCT00317785|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214917620|NCT00317785|PROCEDURE|peripheral blood stem cell transplantation|
214917621|NCT00317785|RADIATION|total-body irradiation|
214917622|NCT06578494|DEVICE|Ultrasound|Ultrasound-guided peripheral intravenous catheter insertion
214917623|NCT02764281|DRUG|MEDA|"Methotrexate, 3.0g/m2/d iv, day 1~Etoposide, 100mg/m2 iv, day 2 to day 4~Dexamethasone, 40mg/d iv, day 1 to day 4~Pegaspargase, 2500IU/m2/d im, day 4~The MEDA chemotherapy will be repeated every 3 weeks."
214917624|NCT02764281|PROCEDURE|Auto-HSCT|Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.
214917625|NCT01623310|DRUG|Fluticasone Propionate|Using Optinose Exhalation Delivery System
214917626|NCT02291666|DRUG|CRCHUM-MT cocktail|
214312457|NCT04059146|OTHER|Pain Education and Exercise|Participants will be randomly assigned to a pain education group, following biopsychosocial model, or standard of care education, following biomedical model. The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain. Participants will be given weekly online exercises to promote engagement with the material, give individual feedback to participants, and assess understanding. In person sessions with the physical therapist will reinforce self-learning and application to a home exercise program.
214312458|NCT04059146|OTHER|Standard Education and Exercise|The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage. The videos, handouts, and exercises will be equivalent to the pain education group in terms of time and learning requirements.
214312459|NCT01978028|DRUG|ferric carboxymaltose|
214312460|NCT01978028|DRUG|placebo|
214312461|NCT04909775|DRUG|Tislelizumab|200 mg per cycle, IV on day 1 of 3-week
214312462|NCT04909775|DRUG|Cisplatin|70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
214917627|NCT02898597|BEHAVIORAL|Cognitive Behavioral Therapy|Received 8 weekly individualized counseling sessions of cognitive behavioral therapy
214917628|NCT02530125|OTHER|Laboratory Biomarker Analysis|Correlative studies
214917629|NCT02530125|BIOLOGICAL|Pidilizumab|Given IV
214917630|NCT03171038|OTHER|Telemonitoring|
214917631|NCT03747523|DRUG|Ergocalciferol|Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D
214917632|NCT02430519|PROCEDURE|Furcation treatment with PRF|PRF Placed into the furcation after flap elevation and debridement
214917633|NCT02430519|PROCEDURE|Furcation Treatment with Allograft and GTR|Allograft and GTR placed into furcation after flap elevation and debridement
214917634|NCT02430519|DEVICE|allograft and guided tissue regeneration (GTR) membrane (DFDBM and Healiguide)|
214917635|NCT02430519|DEVICE|autologous platelet-rich fibrin|
214917636|NCT00356603|DRUG|Sumatriptan Succinate|Sumatriptan Succinate
214917637|NCT03303690|PROCEDURE|Ankle Spacer (AS)|All included patients will be treated by means of surgical implantation of the Ankle Spacer prosthesis in an open manner replacing the talar side of the tibiotalar joint.
214917638|NCT00531115|DRUG|cetuximab 5mg/ml|"Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).~The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment."
214917639|NCT01234870|DRUG|Gadolinium|
214917640|NCT01234870|DRUG|Adenosine|
215060841|NCT03279159|OTHER|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
214312463|NCT04909775|DRUG|Gemcitabine|1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
214917641|NCT03961321|RADIATION|stereotactic mr guided adaptive radiotherapy|Study patients will be treated with an online MR-guided hypofractionated course of radiotherapy in 5 fractions of 7.25 Gy per fraction delivered on the prostate with a simultaneous integrated sparing (SIS) of the urethra with a dose of 32.5 Gy in 5 fractions (6.5 Gy per fraction).
214917642|NCT03298958|DRUG|Rapamycin|Subject will be randomized to one of the 2 arms
214917643|NCT03298958|DRUG|Placebo Oral Tablet|Subject will be randomized to one of the 2 arms
214917644|NCT02802124|RADIATION|carbon-ion radiotherapy for tumor away from GI|
214917645|NCT02802124|RADIATION|carbon-ion radiotherapy for tumor adjacent to GI|
214917646|NCT04947774|RADIATION|Prophylactic Cranial Irradiation|The extensive-stage SCLC patients will receive prophylactic cranial irradiation ±immunotherapy after standard first-line chemotherapy combined with immunotherapy, until disease progression or death
214917647|NCT01010529|OTHER|occupational therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
215060842|NCT00241410|BIOLOGICAL|OralvacB2MPL|Comparison of different dosages of drug
214312464|NCT06327399|DRUG|Dexmedetomidine infusion|patients will receive Dexmedetomidine infusion dose of 1 mcg/kg over 10 min before induction.
214917648|NCT02499367|DRUG|Nivolumab|nivolumab 3 mg/kg, every 2 weeks after induction treatment
214917649|NCT02499367|RADIATION|Radiation therapy|20 Gy to metastatic lesion
214917650|NCT02499367|DRUG|Low dose doxorubicin|15 mg flat dose, once weekly for 2 weeks
214917651|NCT02499367|DRUG|Cyclophosphamide|metronomic schedule, 50 mg daily orally for 2 weeks
214917652|NCT02499367|DRUG|Cisplatin|40 mg/m2, weekly for 2 weeks
214917653|NCT00728468|DRUG|PF-00299804|PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
214917654|NCT01568034|DRUG|BIA 9-1067|BIA 9-1067 - 25 mg single-dose
214917655|NCT01568034|DRUG|BIA 9-1067|BIA 9-1067 - 50 mg single-dose
214917656|NCT01568034|DRUG|BIA 9-1067|BIA 9-1067 - 100 mg single-dose
214917657|NCT01568034|DRUG|Placebo|single-dose
215060843|NCT04188834|DEVICE|Customized version of DAVID device|A customized version of the DAVID device will be used to expose participants to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.
214312465|NCT06327399|DRUG|Dexmedetomidine bolus|patients will receive Dexmedetomidine bolus dose of 0.3 mcg/kg over 60 seconds.
214312466|NCT06327399|DRUG|Atropine Sulfate|If heart rate falls below 45 bpm, rescue dose (500 mcg) of atropine will be given.
214312467|NCT06327399|DRUG|Ephedrine|If mean blood pressure decreases below 50 mmHg, boluses of 10 mg ephedrine will be given
214312468|NCT06327399|DRUG|Propofol|Propofol 20 mg boluses till loss of contact
214312469|NCT04038515|DRUG|Nicotine 0 mg/mL|E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
214312470|NCT04038515|DRUG|Nicotine 6 mg/mL|E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
214917658|NCT01568034|DRUG|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
214917659|NCT01568034|DRUG|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
214917660|NCT06215950|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
214917661|NCT06215950|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
214917662|NCT01597570|DEVICE|Vascular Closure Device|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
214917663|NCT02589132|OTHER|Mobile-Thrive application|Families receive standard of care plus the Mobile-Thrive application
214917664|NCT04088175|OTHER|JUUL ENDS - Virginia Tobacco 5% nicotine strength|JUUL ENDS - Virginia Tobacco 5% nicotine strength
214917665|NCT04088175|OTHER|JUUL ENDS - Virginia Tobacco 3% nicotine strength|JUUL ENDS - Virginia Tobacco 3% nicotine strength
214917666|NCT04088175|OTHER|JUUL ENDS - Menthol 5% nicotine strength|JUUL ENDS - Menthol 5% nicotine strength
214917667|NCT04088175|OTHER|JUUL ENDS - Menthol 3% nicotine strength|JUUL ENDS - Menthol 3% nicotine strength
214917668|NCT04088175|OTHER|JUUL ENDS - Mint 5% nicotine strength|JUUL ENDS - Mint 5% nicotine strength
214917669|NCT04088175|OTHER|JUUL ENDS - Mint 3% nicotine strength|JUUL ENDS - Mint 3% nicotine strength
214917670|NCT04088175|OTHER|JUUL ENDS - Mango 5% nicotine strength|JUUL ENDS - Mango 5% nicotine strength
214917671|NCT04088175|OTHER|JUUL ENDS - Mango 3% nicotine strength|JUUL ENDS - Mango 3% nicotine strength
214917672|NCT02954133|DEVICE|Invisalign (7 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.
214917673|NCT02954133|DEVICE|Invisalign (5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
214917674|NCT02954133|DEVICE|OrthoPulse|Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
214917675|NCT02954133|DEVICE|Invisalign (3.5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 3.5 days.
214917676|NCT01262287|DRUG|Dutasteride|dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
214917677|NCT01262287|DRUG|Placebo|placebo capsules in same number as active drug, daily for 8-week treatment period
214917678|NCT04411511|OTHER|Exposure to the Dutch measures due to the Covid-19 pandemic.|Several measures are taken in The Netherlands, due to the Covid-19 virus and pandemic. For example, closure of schools and sportclubs, and advices to stay at home as much as possible. During the pandemic, several measures also will be scaled down.
214917679|NCT00932373|DRUG|trastuzumab-MCC-DM1|Intravenous escalating dose
214917680|NCT00013338|PROCEDURE|Ambulation Training|
214312471|NCT04038515|DRUG|Nicotine 12 mg/mL|E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
214917681|NCT01637922|DRUG|BI 201335|BI 201335 for 9 days
214312472|NCT04038515|DRUG|Nicotine 24 mg/mL|E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
214312473|NCT04038515|OTHER|'Menthol' flavor|E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
214312474|NCT04038515|OTHER|'Menthol/Mint' flavor|E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
214312475|NCT04038515|OTHER|'Green Apple' flavor|E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
214312476|NCT04038515|OTHER|'Watermelon' flavor|E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
214312477|NCT04038515|OTHER|'Unflavored'|E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
214312478|NCT03454984|DRUG|Guadecitabine|30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
214312479|NCT00109395|DRUG|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
214917682|NCT01637922|DRUG|BI 201335|BI 201335 for 9 days
214917683|NCT01223625|DRUG|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
214917684|NCT01223625|DRUG|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
214917685|NCT02445157|OTHER|4MGS|Measurement of usual gait speed over 4 metres (metres/second)
214955122|NCT04421352|DRUG|CS1001|"low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned."
214312480|NCT00109395|DRUG|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
214312481|NCT00109395|DRUG|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
214671054|NCT01980147|BEHAVIORAL|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
214671055|NCT06470308|OTHER|Medication Reviews and Deprescribing|General Practitioners will be given training and education in deprescribing algorithms and the conduction of medication reviews with the use of validated deprescribing tools such as the Beers Criteria and STOPP/START criteria.
214671056|NCT04523792|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
214671057|NCT05951153|COMBINATION_PRODUCT|Tributyrin|Tributyrin is a nutritional supplement prepared by esterification of glycerin with butyric acid that promotes delivery of free butyrate to distal portions of the gut.
214671058|NCT03183245|BIOLOGICAL|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
214671059|NCT03183245|PROCEDURE|Arteriovenous fistula (AVF)|Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
214671060|NCT03183245|OTHER|Hemodialysis|Procedure that filters a person's blood when their kidneys are no longer functioning properly
214671061|NCT01804205|DRUG|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
214671062|NCT01804205|DRUG|Placebo|100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
214671063|NCT02952547|DRUG|Co-administration of DWC20155 and DWC20156|
214671064|NCT02952547|DRUG|DWJ1366 Tab.|
214671065|NCT02554643|OTHER|Diet|Nutrition intervention, once a week during 12 weeks
214671066|NCT02554643|OTHER|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
214671067|NCT02554643|OTHER|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
214671068|NCT04049188|RADIATION|Single-Fraction Palliative Radiation Therapy|All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
214671069|NCT00593086|PROCEDURE|Pain management|Pain mamagement for burn care procedures.
214917686|NCT02915757|DEVICE|EDOR test|"The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.~The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.~Blood sample and clinical assessment"
214917687|NCT05769075|DRUG|TY-2136b|"Drug: TY-2136b PO, QD or BID~Escalation stage: 7 increased dose cohorts from low dose to MTD (from 40mg QD to 420mg QD)"
215060844|NCT04188834|DEVICE|Blackrock CereStim|The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
214312482|NCT06151587|DRUG|QLM3004 Concentration 1|"Low dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
214312483|NCT06151587|DRUG|QLM3004 Concentration 2|"Medium dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
214312484|NCT06151587|DRUG|QLM3004 Concentration 3|"High dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
214312485|NCT06151587|OTHER|Placebo|Vehicle
214312486|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga
214312487|NCT00492310|BEHAVIORAL|cognitive therapy|cognitive behavioral therapy once weekly
214312488|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga twice weekly with smoking cessation once weekly
214312489|NCT00492310|BEHAVIORAL|wellness|wellness program with smoking cessation
214312490|NCT04694313|DEVICE|OPM|Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
214312491|NCT04445428|BIOLOGICAL|oral polio vaccine + information|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
214671070|NCT00593086|OTHER|Standard of care/no virtual reality game|no intervention for standard of care
214671071|NCT04245124|OTHER|Strategic Memory Advanced Reasoning Training|SMART focuses on three metacognitive strategies: Strategic Attention, Integrated Reasoning and Innovation.
214671072|NCT04245124|OTHER|Traditional Cognitive Rehabilitation|Participants randomized to the TCR condition will participate in a clinician-directed intervention that provides manualized, traditional clinician-directed cognitive rehabilitation that was developed for the SCORE trial (Cooper et al., 2017)
214671073|NCT01260181|DRUG|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
214917688|NCT05769075|DRUG|TY-2136b|"Expansion stage: 4 distinct cohorts~The dose for the Expansion stage will be determined based on results from the Escalation stage"
214917689|NCT04121130|DEVICE|F-ESWT Group|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
214312492|NCT04445428|BEHAVIORAL|Information|Advice regarding how to protect oneself from COVID-19
214917690|NCT04121130|DEVICE|sham F-ESWT|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
215077811|NCT02511600|OTHER|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
214312493|NCT00851799|DRUG|Emtricitabine/tenofovir disoproxil fumarate|"200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC"
214312494|NCT00851799|DRUG|Ritonavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
214671074|NCT03690414|DRUG|Experimental BHVI2|Experimental BHVI2 eye drops
214671075|NCT03690414|DRUG|Atropine sulfate 0.02% eye drops|Atropine eye drops
214671076|NCT03690414|COMBINATION_PRODUCT|Combination eye drops|Combination eye drops with experimental BHVI2 plus 0.02% atropine
214671077|NCT01330446|DRUG|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
214312495|NCT00851799|DRUG|Atazanavir|"300 mg taken orally once daily. A protease inhibitor (PI).~Other Name: ATV"
214671078|NCT01330446|OTHER|Placebo|1 by mouth every morning for a 28 day cycle.
214671079|NCT01330446|BEHAVIORAL|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
214917691|NCT05624021|OTHER|Scapular functional training|The scapular functional training consists of press up and push up plus. Press up was done in sitting position on the training bench, feet on the floor with straight arm and the palms on the edge of the bench fingers pointing forward and then lift off and dip down just in front of the seat by moving the shoulder girdle. Progression is done by placing weight on the thigh. Push-up plus exercise started from a push up position on the hand, feet or knees and keeping the torso rigid by bracing the abdominals followed by protracting the scapula as high as possible. Progression is done moving from knees to the feet or adding resistance on the upper back. The training continued for three sessions per week for four weeks.
215060845|NCT03755219|PROCEDURE|TEP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
215060846|NCT03755219|PROCEDURE|TAPP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
215060847|NCT01030952|DRUG|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
215060848|NCT01030952|DRUG|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
215060849|NCT06421064|PROCEDURE|Perforation repair|All patients were operated with slight difference but all had perforation repaired.
215060850|NCT00389545|PROCEDURE|Intracoronary infusion of autologous bone-marrow derived stem cells|
214312496|NCT00851799|DRUG|Raltegravir|"400 mg taken orally twice daily. An integrase inhibitor (INI).~Other Name: RAL"
214312497|NCT00851799|DRUG|Darunavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
214312498|NCT04751149|PROCEDURE|Removal of Urinary Catheter|Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
214312499|NCT02455271|DRUG|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
214312500|NCT00855491|PROCEDURE|Phaco|AcrySof Single-Piece IOL
214312501|NCT05300295|BEHAVIORAL|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
214312502|NCT04056195|DRUG|SKI-O-703|The SKI-O-703 capsules will contain 100 mg of drug substance.
214312503|NCT04056195|DRUG|Placebo oral tablet|Placebo capsules are filled with microcrystalline cellulose.
214312504|NCT05948202|BEHAVIORAL|Pivotal Response Treatment|Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.
214312505|NCT01599507|DRUG|FG-4592|TIW dosing, capsule
214312506|NCT01599507|DRUG|Placebo|TIW dosing, capsule
214312507|NCT05403879|PROCEDURE|fixation of greater tuberosity fractures|deltopectoral approach for shoulder, then open reduction and fixation of displaced greater tuberosity fractures using hooked Kirshner wires
214312508|NCT01453283|DRUG|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
214312509|NCT00118976|DRUG|Lisinopril|
214312510|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
214312511|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
214312512|NCT00108056|DRUG|Enzastaurin (LY317615) monohydronchloride|
214312513|NCT05133687|DRUG|Bupivacaine Hydrochloride|Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
214312514|NCT01951339|DRUG|Sitagliptin|100 mg sitagliptin
214312515|NCT01951339|DRUG|Glimepiride|"Active Comparator~2mg glimepiride"
214312516|NCT01951339|DRUG|Placebo|2 mg placebo once daily
214312517|NCT01951339|DRUG|Placebo|100 mg placebo once daily for three months
214312518|NCT03190070|DIETARY_SUPPLEMENT|Ingestion of protein|Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
214312519|NCT04457609|DRUG|Oseltamivir|Current standardized treatment for Covid-19
214312520|NCT04457609|DRUG|Azithromycin|Current standardized treatment for Covid-19
214312521|NCT04457609|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Adjuvant therapy on top of current standardized treatment (Oseltamivir + Azithromycin)
214312522|NCT03832374|OTHER|Descriptive|
214312523|NCT04280367|DIAGNOSTIC_TEST|Standardised semi-structured talk|Comprehensive assessment of at-risk mental states (CAARMS) will be used.
214671080|NCT00384280|DRUG|Rifampin|
214671081|NCT05144698|BIOLOGICAL|RAPA-201 Rapamycin Resistant T Cells|Autologous Rapamycin-Resistant Th1/Tc1 Cells
214671082|NCT05144698|DRUG|Chemotherapy Prior to RAPA-201 Therapy|Outpatient Carboplatin + Paclitaxel Regimen (CP Regimen)
215060851|NCT01143363|BEHAVIORAL|resting - control|
215060852|NCT01143363|BEHAVIORAL|Moderate intensity exercise|
215060853|NCT01143363|BEHAVIORAL|High intensity intermittent training|
214312524|NCT04280367|DIAGNOSTIC_TEST|Autistic spectre disorder screening|Autism-spectrum quotient (AQ) auto-questionnaire will be used.
214312525|NCT04280367|DIAGNOSTIC_TEST|Anxiety measuring|An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
214312526|NCT02853240|PROCEDURE|Muscle biopsy|A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
214312527|NCT00392431|DRUG|amiodarone|
214312528|NCT00338910|DRUG|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
214312529|NCT04794790|DRUG|Buprenorphine/naloxone|Buprenorphine/Naloxone induction via a standard dose protocol
214312530|NCT05209022|DIETARY_SUPPLEMENT|Beetroot juice|140 mL of beetroot juice or beetroot juice placebo
214312531|NCT04574804|OTHER|Online training program in weight management for osteoarthritis|"An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~1. Overweight and obesity and osteoarthritis~2. Overview of weight regulation, overweight and obesity~3. Examining weight stigma in physiotherapy and personal beliefs about weight~4. Communication approach for addressing weight management~5. Interventions for weight management~6. Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention."
214312532|NCT00302133|DRUG|Naltrexone hydrochloride|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
214671083|NCT05144698|DRUG|Pembrolizumab (PD-1 Blocking Antibody)|Drug Therapy After RAPA-201 Therapy
214917692|NCT05624021|OTHER|Cervical isometric exercises|The isometric neck exercises taught to all the participants to perform in neutral sitting positions at home thrice a day for 15-days continuously. The sequences of exercises were shoulder circling in clockwise and anticlockwise direction, scapular retraction with cervical retraction, neck flexion, extension, either side of lateral bending/flexion, left and right rotation. Each exercise follows a set of 10 repetition of maximum voluntary contraction with a progressive hold time of 3, 5, 7, and 10 seconds depending on the severity of pain and tolerance of the participants.
214917693|NCT05624021|OTHER|Moist heating|A hydrocollator moist heat packs was applied over back of the neck in supine position to receive optimal heating. It was given for 20 minutes/day, five-day a week for four-week.
214917694|NCT02492984|DRUG|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
214312533|NCT00302133|OTHER|Placebo|Placebo arm
214312534|NCT01852266|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
214917695|NCT04128046|PROCEDURE|PRFM injection|Using a 27-gauge microcannula, a total of 4 mL of PRFM was injected intradermally into the mid-cheek and NLF (2 mL for each site) on one side of the face.
214917696|NCT04128046|PROCEDURE|Saline injection|Using a 27-gauge microcannula, a total of 4 mL of saline was injected intradermally into the mid-cheek and NLF (2 mL for each site) on the contralateral side of the face.
214917697|NCT04042389|BEHAVIORAL|WhatsApp reminder|"The WhatsApp group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
214917698|NCT04042389|BEHAVIORAL|Email reminder|"The Email group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
214917699|NCT04042389|BEHAVIORAL|Control|No messages sent.
214917700|NCT00243295|DRUG|rhBMP-2/CPM|
214312535|NCT01852266|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
214312536|NCT04702490|DRUG|MET409 Active|MET409 Active (50mg)
214312537|NCT04702490|DRUG|MET409 Placebo|MET409 Placebo (50mg)
214312538|NCT04702490|DRUG|Empagliflozin|Empagliflozin (10mg)
214312539|NCT06254053|OTHER|zirconia reinforced glass ionomer|Restorative material
214312540|NCT06254053|OTHER|Glass ionomer cement|Restorative material
214312541|NCT05797493|DRUG|Atezolizumab|Upfront chemo-immunotherapy
214312542|NCT06502743|DRUG|Nesuparib|Nesuparib 150mg or 100mg, QD, PO
214312543|NCT06502743|DRUG|Pembrolizumab|Pembrolizumab 400mg, IV, Q6W
214312544|NCT01001442|DRUG|BT062|intravenous administration
214312545|NCT03774589|PROCEDURE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis will be used to complete the anastomosis during bilioenteric anastomosis.
214312546|NCT03774589|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
214671084|NCT05970055|PROCEDURE|elective surgery|All elective surgical procedures performed under the study period will be included.
214671085|NCT00984659|DRUG|Fluticasone propionate/salmeterol combination product|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
214671086|NCT00984659|DRUG|Salmeterol|Salmeterol 50mcg DISKUS twice a day for 8 weeks
214671087|NCT00984659|DRUG|Placebo|Placebo DISKUS twice a day for 8 weeks
214312547|NCT02522390|OTHER|Research activities|"Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.~The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts."
214312548|NCT01988116|DRUG|Oral Calcitriol 0.5 mcg once daily for 6 weeks|
214312549|NCT01988116|DRUG|Placebo|
214312550|NCT05478070|DEVICE|Dexcom G6|Continuous glucose monitor
214312551|NCT01321775|DRUG|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|"Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)"
214312552|NCT03437109|DIAGNOSTIC_TEST|Laboratory tests|Testosterone HSBG Hb1Ac LH
214312553|NCT00187746|DRUG|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
214312554|NCT02753699|DRUG|Alisporivir|Intervention of interest; follow-up after ALV-active study
214312555|NCT04720196|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
214312556|NCT04720196|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
214671088|NCT05255757|BEHAVIORAL|Script Intervention|This intervention provides language to participants to allow them to discuss kidney transplantation with their social network.
214671089|NCT05255757|BEHAVIORAL|Search Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
214312557|NCT02418858|PROCEDURE|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery awake vs. asleep
214312558|NCT05016388|OTHER|Collaborative Multidimensional Model (CMD)|The teams enrolled in the CMD intervention will have a 22-hour training that integrates current knowledge of depression with skills for the management of functional variables, interpersonal, social, emotional regulation, and history of biographical adversity from childhood considering the trauma informed care paradigm. After the training, the PHC teams will implement the depression treatment according to a collaborative model.
214312559|NCT05016388|OTHER|Standard Model (SM)|The teams enrolled in the SM intervention will have a 22-hour training that integrates the current national clinical guide for Depression in Chile. This guide offers a staggered treatment according to the severity of the depression. After the training, the PHC teams will implement the depression treatment according to the SM.
214312560|NCT05492669|DRUG|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
214312561|NCT05492669|DRUG|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
214481301|NCT06741813|PROCEDURE|Allo-HSCT|"Chemotherapy-based preconditioning regimen consisted of cytarabine 4 g·m-2·day-1 (days -9), busulfan (3.2 mg·kg-1·day-1 administered intravenously on days -8 to -6) (day 0 being the first day of donor cell infusion), cyclophosphamide (1.8 g·m-2·day-1, days -5 to -4), and semustine (250 mg.m-2, day -3). For the patients older than 55 years old or with HCT-CI score of 3 or more, cyclophosphamide can be decreased to 1.0 g·m-2·day-1, days -5 to -4, and added fludarabine (30mg·m-2·day-1, days -6 to -2). Rabbit antithymocyte globulin (thymoglobulin, 1.5 to 2.5 mg/kg, days -5 to -2; Sanofi, France) was administered to the HID and URD groups or MSD HSCT recipients who older than 40 years old (1.5 mg/kg, days -4 to -2).~All MSD, HID, and URD HSCT recipinets received cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate (MTX) for GVHD prophylaxis. CsA (2.5 mg/kg, q12h, intravenous \[i.v.\]) was used from day -9, of which the trough concentration was adjusted to 150-250 ng"
214481302|NCT06893432|DEVICE|hearing aids|Hearing aids are a common intervention method used to address age-related hearing loss, providing amplified sound to improve hearing clarity and communication abilities for elderly individuals.
214481303|NCT06737458|DRUG|Bupivacaine + Dexmedetomidine|Patients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
214671090|NCT06583395|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
214671091|NCT04520698|BEHAVIORAL|UPLIFT-AD|Access to palliative care needs screening, advance care planning conversations, palliative care consultations
214312562|NCT05629832|PROCEDURE|mechanical ventilation strategy guided by transpulmonary pressure|Mechanical ventilation parameters adjust guided by transpulmonary pressure monitoring. For pressure assist control or volumn assit control mode; inspiratory pressure or volumn setting needs to maintain Ppeak less than 25 cm H2O; PEEP was set at such a level that expiratory Ptp stayed between 0 and 5 cm H2O.
214312563|NCT04745403|DRUG|mRNA HBV/TCR T-cells|"Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW."
214312564|NCT00511693|BEHAVIORAL|centralized osteoporosis coordinator|The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
214917701|NCT01497925|DRUG|ADI-PEG 20|Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
214917702|NCT01423396|OTHER|optimal care of VRF|VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
214312565|NCT00511693|BEHAVIORAL|fall prevention|Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
214312566|NCT06404151|DEVICE|monitoring|rc02, ORI , spO2
214312567|NCT03602469|DRUG|Bupivacaine|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline
214312568|NCT03602469|DRUG|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)
214312569|NCT03602469|DRUG|Propofol|Using propofol 1.5-2.5 mg/kg
214312570|NCT03602469|DEVICE|Ultrasound|Ultrasound-guided suprascapular nerve block
214917703|NCT01423396|OTHER|standard care|AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
214917704|NCT01356043|DRUG|S-amlodipine 5mg,Telmisartan 80mg|S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
214917705|NCT01356043|DRUG|S-amlodipine 5mg|S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
215060854|NCT01143363|BEHAVIORAL|Short sprint|
215060855|NCT03932318|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
215060856|NCT03932318|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
214312571|NCT03602469|DRUG|Sevoflurane|Sevoflurane 0.7-1.5 MAC in 40% oxygen
214917706|NCT05500339|OTHER|M-health App|Pregnant women receive the App designed for the support of the first 1000 days of life
215060857|NCT03932318|DRUG|Azacitidine|75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
215060858|NCT05343689|PROCEDURE|Pneumatic compression|Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
214312572|NCT03602469|DRUG|Rocuronium|Rocuronium 0.6 mg/kg
214312573|NCT03904238|BEHAVIORAL|Cognitive-Behavior Therapy for Hypersomnia (CBT-H)|"The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., I cannot live a full life because of my illness), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia."
214312574|NCT01342510|DRUG|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
214481304|NCT06737458|DRUG|Bupivacaine + Dexmedetomidine|Patients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
214917707|NCT05500339|OTHER|Standard care|Pregnant women receive standard supportive and educational methods.
214917708|NCT05172817|DRUG|Advixa (Adalimumab)|Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
214955123|NCT04305860|DIETARY_SUPPLEMENT|Modified starch without flavoring|Each patient of this group receives the thickener during three days of hospitalization
214955124|NCT04305860|DIETARY_SUPPLEMENT|Mofidied starch with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
214955125|NCT04305860|DIETARY_SUPPLEMENT|Xanthan gum without flavoring|Each patient of this group receives the thickener during three days of hospitalization
214955126|NCT04305860|DIETARY_SUPPLEMENT|Xanthan gum with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
214955127|NCT04853966|BEHAVIORAL|Physical activity counseling|Physical activity counseling will be performed using physical activity behavior steps of the transtheoretical model.
214955128|NCT04854057|OTHER|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 4 times per week.
214955129|NCT04854057|OTHER|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 4 times per week.
214312575|NCT01342510|DRUG|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
214312576|NCT01342510|DRUG|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
214312577|NCT01342510|DRUG|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
214312578|NCT05694728|BIOLOGICAL|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|"For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6.~For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6."
214312579|NCT05694728|BIOLOGICAL|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)|A 3-dose regimen administered at months 0, 2 and 6.
214312580|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate and Ipratropium Bromide|
214312581|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate|
214312582|NCT03496142|PROCEDURE|Transperineal prostate biopsy|Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
214481305|NCT06739317|RADIATION|Radiation|Subjects receive Stereotactic Body Radiotherapy combined with Camrelizumab and Apatinib as conversion therapy.
214481306|NCT06739317|DRUG|First line therapy|Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
214481307|NCT06739317|DRUG|First line therapy|Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
214481308|NCT06739317|PROCEDURE|operation|If subjects suitable for hepatic resection after conversion therapy, radical surgery and postoperative adjuvant therapy will be performed.
214481309|NCT06739135|BEHAVIORAL|Visual feedback training|Visual feedback training to modify use of the accelerator pedal when driving in a driving simulator, to reduce the % of time driving with the pedal pushed down more than 9 degrees
214671092|NCT01677689|DRUG|Apomivir®|Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
214671093|NCT01677689|DRUG|Placebo|Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
214671094|NCT06108284|DEVICE|Intervention Arm (Biphasic cuirass ventilation)|Patients in this arm will be placed on Biphasic cuirass ventilation
214671095|NCT04652258|DRUG|Actemra|Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
214671096|NCT01395238|BEHAVIORAL|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
214671097|NCT05026658|DEVICE|Visibly Digital Acuity Product|"The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences:~1. V1, E, V2~2. E, V1, V2~3. V2, E, V1~4. E, V2, V1~Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2.~The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences."
214671098|NCT01777633|RADIATION|Palliative re-irradiation for progressive DIPG in children|
214917709|NCT06642142|PROCEDURE|ESP block|"The ESPB will be performed at the T4 level, monolaterally (according to the surgical side), with 30ml volume of 0.5% Ropivacaine injected with a 20-gauge, 50-mm-long needle. The technique used is the standard ultrasound-guided, sterile procedure.~Soon after performing the block, a timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored."
215060859|NCT02101996|OTHER|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
215060860|NCT01539122|DEVICE|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
214312583|NCT03496142|PROCEDURE|Transrectal prostate biopsy|Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
214312584|NCT04750837|PROCEDURE|debridement of the wound|The edges and the floor of the wound were firstly debrided, and any callosities around the wound were removed. This was repeated if needed when callosities around the wound reappeared. By this technique, the chronic wound was transformed into an acute one
214481310|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 1|Investigational varicella vaccine of Lot 1 administered subcutaneously.
214481311|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 2|Investigational varicella vaccine of Lot 2 administered subcutaneously.
214481312|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 3|Investigational varicella vaccine of Lot 3 administered subcutaneously.
214481313|NCT06740630|BIOLOGICAL|Marketed varicella vaccine_Lot 1|Marketed varicella vaccine of Lot 1 administered subcutaneously.
214481314|NCT06740630|BIOLOGICAL|Marketed varicella vaccine_Lot 2|Marketed varicella vaccine of Lot 2 administered subcutaneously.
214481315|NCT06740630|BIOLOGICAL|MMR vaccine|MMR vaccine co-administered subcutaneously or intramuscularly.
214481316|NCT06740630|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
214481317|NCT06740630|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214481318|NCT06740630|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214671099|NCT03873597|BEHAVIORAL|Tele-coaching + Usual Care|The tele-coaching intervention will be delivered for 3 months following discharge from hospital. This consists of: 1) An interview discussing motivational issues, favourite daily activities and strategies to become more physically active; 2) a step counter 3) a smart phone with tele-coaching application providing activity goals (daily steps), feedback and educational tips on a daily basis. Patients' targets will be automatically revised on a weekly basis, based on performance in the preceding week; (4) a booklet containing home exercises; (5) weekly activity proposals; (6) tele-phone contacts triggered in the case of non-compliance, failure to transmit data or difficulty to progress.
214917710|NCT06383234|PROCEDURE|LG-TAP block with local anesthetic|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
215060861|NCT01539122|DEVICE|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
214312585|NCT04750837|BIOLOGICAL|platelet rich plasma|Part of activated PRP was injected around the wound and under the base of the wound, while another portion of PRP was left over the floor of the wound and let to coagulate and form a gel.
214312586|NCT04750837|PROCEDURE|conventional dressing|The wound was irrigated by normal saline, covered by vaseline gauze then sterile dressing. Repeated dressing every two days till 20 weeks, if the wound failed to heal at that time
214312587|NCT05608876|DRUG|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
214312588|NCT01936116|DEVICE|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
214312589|NCT01936116|DEVICE|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
214312590|NCT01538862|DRUG|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
214312591|NCT02282956|DRUG|Ropivacaine 0,75%|Ropivacaine injection
214312592|NCT02282956|PROCEDURE|posterior tibial nerve block|ultrasound guided posterior tibal nerve block
214312593|NCT02282956|DRUG|morphine and droperidol|i.v PCA
214312594|NCT04470999|OTHER|Leukapheresis|Blood collection and PBMC collection via apheresis machine will be conducted
214312595|NCT02978742|BEHAVIORAL|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
214312596|NCT02978742|BEHAVIORAL|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
214312597|NCT01400516|DRUG|Teriparatide|20 μg, subcutaneous injection, 1 injection per day
214312598|NCT01400516|DRUG|calcium citrate|1000 mg of calcium citrate
214312599|NCT01400516|DRUG|Vitamin D|800 IU of Vitamin D
214312600|NCT01400516|DRUG|TNF antagonist|TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
214312601|NCT01412866|BEHAVIORAL|EDSS with CO feedback and health checklist|Web-based electronic decision support system with CO feedback and health-checklist
214312602|NCT01412866|BEHAVIORAL|EDSS with health checklist feedback alon|Web-based electronic decision support system (EDSS) with health-checklist feedback alone (without CO feedback)
214312603|NCT02280135|BIOLOGICAL|Intravitreal injection of Autologous bone marrow Stem Cell|"We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.~After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
214312604|NCT02280135|OTHER|Subconjunctival injection of saline|"In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
214312605|NCT01500642|BIOLOGICAL|Slit One|slit one sublingual immunotherapy 200 stu
214312606|NCT01500642|BIOLOGICAL|Slit One|slit one vestibular immunotherapy 200 stu
214312607|NCT01500642|BIOLOGICAL|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
214312608|NCT02204748|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|
214312609|NCT03007758|PROCEDURE|open ventral hernia repair|An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
214671100|NCT05422079|OTHER|Non-specific lumbar exercise group|Subjects perform a conventional lumbar exercise program twice a week.
215060862|NCT05533294|DRUG|ARO-RAGE Injection|ARO-RAGE injection for sc administration
215060863|NCT05533294|DRUG|Placebo|normal saline (0.9% NaCl) by sc injection
215060864|NCT01369472|DRUG|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
214312610|NCT03007758|PROCEDURE|robotic ventral hernia repair|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
214917711|NCT06383234|PROCEDURE|LG-TAP block with saline solution|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
214312611|NCT05151263|DRUG|Acetyl Salicylate|Aspirin is an effective antiplatelet agent, exhibiting its action by irreversibly inhibiting platelet cyclooxygenase-1 enzyme, thus preventing the production of thromboxane A2 (TXA2). It has been used in the primary and secondary prevention of thromboembolic vascular events
214312612|NCT05151263|DIAGNOSTIC_TEST|Optical Platelet Aggregation test|The evaluation of platelet aggregation was performed using an optical aggregometer (AggRAM, using fresh citrated blood. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 190 g for 5 min. The platelet count was adjusted to 200,000 to 300,000 platelets/mm3. Platelet-rich plasma (250 μl) was deposited in each equipment channel, and the activators adenosine diphosphate, epinephrine, collagen, and arachidonic acid were used according to the manufacturer's instructions. aspirin resistance was defined as platelet aggregation ≥ 20% with arachidonic acid and ≥70% with adenosine diphosphate.
214312613|NCT00162565|DRUG|beta-blocker treatment|beta-blocker treatment
214312614|NCT06372353|OTHER|Baduanjin Exercise|Baduanjin exercise training program was applied to the subjects in the exercise group, 3 days a week, 5 minutes each with warm-up and cool-down exercises, for a total of 24 sessions, 60 minutes each, under supervision, online, via the ZOOM application, for 8 weeks. In addition, the patients did the exercises unsupervised at home once a week. The patients' first sessions were held in the hospital
214312615|NCT02313753|BEHAVIORAL|CLASP|
214312616|NCT02313753|BEHAVIORAL|SAFE|
214312617|NCT04289116|BEHAVIORAL|We Test|This design tests the added benefits of adjunct intervention components delivered prior to receipt of CHTC-Assertive Communication Training (ACT) videos viewed by the couple separately and individually delivered Motivational Interviewing-based Communication Skills Training (MI-CST). These target the development of communication skills necessary to participate fully in HIV prevention and sexual safety discussions inherent to CHTC.
214671101|NCT05422079|OTHER|motor control lumbar exercises|Subjects perform a lumbar stabilization exercise program.
214917712|NCT06383234|PROCEDURE|Port site infiltration|Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon
215060865|NCT04511143|OTHER|muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.
215060866|NCT05619094|OTHER|Corrective exercise program|"Strengthening exercises for deep cervical flexor muscles and shoulder retractors.~Stretching exercises for cervical extensors and pectoral muscles."
215060867|NCT05279924|DRUG|Prophylaxis with Emicizumab|Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
215060868|NCT02833584|DRUG|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
215060869|NCT02833584|DRUG|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
215060870|NCT04409561|DEVICE|Blood collection|9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
214312618|NCT04289116|BEHAVIORAL|IHTC|Individual HIV Testing and Counseling
214312619|NCT03034993|BEHAVIORAL|Text Messaging|"Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response."
214312620|NCT00005833|DRUG|R115777|300mg P.O. BID.
214312621|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 4 mg|They will take astaxanthin 4 mg 1 capsule once daily for 2 months.
214312622|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 6 mg|They will take astaxanthin 6 mg 1 capsule once daily for 2 months.
214312623|NCT05009810|DIETARY_SUPPLEMENT|Placebo|They will take placebo 1 capsule once daily for 2 months.
214312624|NCT01796197|DRUG|Trastuzumab|
214312625|NCT01796197|DRUG|Pertuzumab|
214312626|NCT01796197|DRUG|Paclitaxel|
214312627|NCT01796197|DRUG|Doxorubicin|
214312628|NCT01796197|DRUG|Cyclophosphamide|
214312629|NCT01796197|PROCEDURE|Mastectomy|
214312630|NCT01796197|RADIATION|Radiation Therapy|
214312631|NCT05721248|OTHER|Cessation of anti-HER2 treatment|Cessation of anti-HER2 treatment with standard treatment described as trastuzumab (Herceptin) with or without pertuzumab (Perjeta) continued as long as it is working or significant side effects occur.
214312632|NCT01380184|DRUG|ridaforolimus|4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
214312633|NCT01660828|OTHER|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
214312634|NCT00016952|DRUG|fluorouracil|
214312635|NCT00016952|DRUG|irinotecan hydrochloride|
214312636|NCT00016952|DRUG|leucovorin calcium|
214312637|NCT04243538|BEHAVIORAL|I-HoME|I-HoME will consist of two components: (1) synchronous live video interactions between patients/CGs and a hospice nurse; and (2) educational videos.
214671102|NCT05422079|OTHER|motor control lumbar exercises with ultrasound echography feedack|Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
214671103|NCT06274138|BEHAVIORAL|haptonomy|Pregnant women in the intervention group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. Information will be given that Haptonomy will consist of five sessions. Haptonomy will be applied by the researcher together with the partner. Each session will last for 40 minutes. The effectiveness and continuity of sessions will be planned between 3 to 7 days. One week after completing the five sessions of haptonomy, pregnant women will again complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
214671104|NCT01713634|OTHER|Preflight|4-d controlled diet sessions will occur twice before flight.
214671105|NCT01713634|OTHER|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
214312638|NCT04300972|DIAGNOSTIC_TEST|Body/weight adaption|contrast media dose is adapted to weight and body type
214671106|NCT05712421|DRUG|North Star|North Star
214671107|NCT05712421|DRUG|Levothyroxine|Levothyroxine
214917713|NCT04020692|BEHAVIORAL|EOPC Intervention|"The issue of drug continuity after hospital discharge has become a major issue in recent years. When patients return home, the drugs taken do not correspond to the treatments prescribed at the end of the hospitalization. This is due to appropriate or inappropriate initiatives of the patients (or their relatives) and/or the physicians accompanying them. Prescribed medications, on the other hand, are almost always dispensed by community pharmacists.~The scope chosen in this project is that the intervention of an operational clinical pharmacy team (EOPC), targeting both patient and health care professionals (inpatient and outpatient), will maintain, in outpatient care, the drugs treatments that have been optimized during hospitalization."
215077812|NCT02511600|OTHER|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
214312639|NCT04300972|DIAGNOSTIC_TEST|Standard dose|a fixed amount of contrast media is used, independently of weight and body type
214312640|NCT00044343|DRUG|lapatinib|
214312641|NCT06968988|DRUG|Zanzalintinib|Zanzalintinib will be supplied by Exelixis, Inc.
214312642|NCT06968988|DRUG|Ipilimumab|Ipilimumab will be commercially sourced.
214312643|NCT06968988|DRUG|Nivolumab|Nivolumab will be commercially sourced.
214312644|NCT05386108|DRUG|Elacestrant|300 mg, 400 mg
214312645|NCT05386108|DRUG|Abemaciclib|100 mg, 150 mg
214312646|NCT05028621|DIAGNOSTIC_TEST|Genetic testing|Genetic testing of blood or tissue sample and limited medical information sent to an outside company. Database will link genome sequence data with human trait information, including cancer and other diseases, to be sent to participant's physician.
214312647|NCT05429892|BEHAVIORAL|Smoking cessation counseling and food delivery|"The community health workers will delivery three 30-minute sessions during intervention months 1 through 6 (1,3,6 months) to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Smokers enrolled in the TRTsocialmot1 arm will be provided with food boxes or grocery store gift card at 1,3, and 6 months. Healthy meal preparation instructions will be included and delivery by project staff and will reduce transportation barriers to food access rural counties.~Participants will receive educational materials at 1, 3, and 6 months."
214312648|NCT05429892|BEHAVIORAL|Smoking cessation counseling|"The community health workers will deliver three 30-minute sessions during intervention months 1 through 6 (1,3,6 months) to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Participants will receive educational materials at 1, 3, and 6 months."
214312649|NCT05429892|BEHAVIORAL|Food delivery|"Smokers enrolled in the TRTsocial2 arm will be provided with food boxes or grocery store gift card at 1, 3, and 6 months Healthy meal preparation instructions will be included and delivery by project staff and will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
214312650|NCT03532295|DRUG|Epacadostat|-All BID doses will be taken in the morning and evening, approximately 12 hours apart
214312651|NCT03532295|DRUG|Bevacizumab|-The first infusion will be over the course of 90 minutes; if tolerated, the second infusion will be over the course of 60 minutes; if tolerated, all subsequent infusions will be over 30 minutes
214312652|NCT03532295|RADIATION|Radiation therapy|-The gross tumor maximum diameter (to be irradiated) to be \</= 6 cm in the first 6 patients. If more than 1 target is irradiated, then the sum of all the target maximum diameters should be \</= 6 cm. No more than 3 separate targets for RT is allowed.
214312653|NCT03532295|DRUG|Retifanlimab|-Will be supplied by Incyte
214312654|NCT03388190|DRUG|Nivolumab|"FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.~Nivolumab: 240 mg flat dose; IV administration every 2 weeks."
214671108|NCT00644579|DRUG|bLAC|bLAC high and low dose and placebo
214671109|NCT00644579|DRUG|Placebo|Placebo
214671110|NCT02261441|OTHER|Observational and noninterventional study|No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
214917714|NCT03104049|DEVICE|Neuromuscular taping|"NMT applications:~1. rhomboid major muscle~2. muscles abdominals~3. spinal muscles~4. pectoralis major muscles~5. gastrocnemius muscle~6. upper trapezius muscle~7. anterior muscles of the neck"
214917715|NCT01564888|PROCEDURE|Ulnar artery compression|Compression of ulnar artery for 2 hours with radial artery hemostasis
214917716|NCT06960603|OTHER|Full pulpotomy|First: Cutting the coronal pulp tissue to the level of the root canal orifices. Second: Followed by taking samples of the pulpal blood Third: Placement of calcium silicate material capping over the pulp
214671111|NCT02951273|OTHER|Study of cerebral blood flow|"Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml."
214917717|NCT06622876|DIAGNOSTIC_TEST|Computed tomography exam of the chest|Computed tomography exam of the chest done for other indications other than pulmonary emboli, in which incidental pulmonary embolism was detected.
214917718|NCT06483178|DEVICE|Attune knee implant|Attune cementless cruciate retaining rotating platform implant (DePuy Synthes) with a standard gap balancing cruciate sacrificing surgical technique
214312655|NCT03388190|DRUG|FLOX|FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.
214312656|NCT05984823|OTHER|Home based body weight type exercises with blood flow restriction|"The participant will be asked to complete blood flow restricted exercises described below three times per week for 6 weeks.~Exercise protocol: Two tourniquets will be placed around the upper part of each thigh, these tourniquets will be inflated to an individualised and maintained for the duration of each exercise (including the inter-set rest period) but deflated during the 5 min rest in between. Five Body weight Exercises will be performed: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand."
214917719|NCT06483178|DEVICE|Triathlon knee implant|Triathlon cementless condylar stabilised implant (Stryker) with a standard gap balancing cruciate sacrificing surgical technique
215060871|NCT04984395|DIAGNOSTIC_TEST|Post-treatment CT-guided bone marrow biopsy|At post-treatment, 12 +/- 3 weeks after initiating treatment, patients will undergo a CT guided bone marrow biopsy of the same lesion as baseline.
215060872|NCT00391430|DRUG|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
214312657|NCT05984823|OTHER|Home based body weight type exercises|The participant will be asked to complete body weight exercises for three times per week for 6 weeks. These exercises include: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand.
214312658|NCT06551701|OTHER|Pharmacist call|Pharmacists will call patients and their providers to discuss benefits of statin use
214312659|NCT03511976|BEHAVIORAL|Tier 1 Classroom Management|The primary teacher for each participating student will receive consultation related to implementing Tier I management strategies at a classroom level for all students including the target child (see Appendix C). Consultation will be provided by trained study personnel and the strategies will be implemented by the general education teacher (i.e., the end user of the intervention)
214312660|NCT03511976|BEHAVIORAL|Daily Report Card (DRC)|Students in the RTI DRC condition will receive Tier II strategies, namely an individualized DRC. Behavioral consultants will meet with teachers to identify appropriate behavioral targets and establish a DRC according to established protocol (see our website for an example http://ccf.fiu.edu/for-families/resources-for-parents/printable- information/). Consultants will also meet with parents to develop a plan for reinforcing the DRC at home using a hierarchical menu of rewards/privileges that will be provided contingent on meeting daily goals.
214312661|NCT03511976|BEHAVIORAL|Enhanced DRC (DRC-E)|"In this condition, students who did not show sufficient response to the Phase 1 DRC will receive additional and more intensive Tier II supports.~Following student assignment to RTI-E, the teacher will have meet with one of the consultants to complete a functional behavior analysis (FBA) to identify remaining target behaviors and ascertain their function. The consultant and teacher will then use the completed FBA to develop a treatment plan for an enhanced DRC (DRC-E).~Tier II enhancements will be chosen to directly map on to the functions of the target behaviors as outlined in the FBA."
214312662|NCT03511976|DRUG|Stimulant|Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician. The prescribed medication will be taken daily.
214312663|NCT04964102|BEHAVIORAL|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
214312664|NCT03999710|RADIATION|Radiation Therapy|Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
214312665|NCT03999710|DRUG|Durvalumab|A dose of 1500mg (for patients \>30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
214312666|NCT04960787|OTHER|Educational Intervention|Watch online educational videos
214312667|NCT04960787|BEHAVIORAL|Patient Navigation|Meet with CENTS counselor and PAF case manager
214312668|NCT04960787|OTHER|Quality-of-Life Assessment|Ancillary studies
214312669|NCT04960787|OTHER|Questionnaire Administration|Complete questionnaires
214312670|NCT06521567|DRUG|Cobolimab|Cobolimab will be administered
214312671|NCT06521567|DRUG|Dostarlimab|Dostarlimab will be administered
214312672|NCT05630859|BIOLOGICAL|NgG low dose investigational vaccine|Two doses of NgG low dose investigational vaccine, administered intramuscularly.
214312673|NCT05630859|BIOLOGICAL|NgG medium dose investigational vaccine|Two doses of NgG medium dose investigational vaccine, administered intramuscularly.
214312674|NCT05630859|BIOLOGICAL|NgG high dose investigational vaccine|Two doses of NgG high dose investigational vaccine, administered intramuscularly.
214312675|NCT05630859|BIOLOGICAL|Placebo|Two doses of placebo, administered intramuscularly.
214312676|NCT05630859|BIOLOGICAL|NgG HTD investigational vaccine|Two doses of NgG HTD investigational vaccine, administered intramuscularly.
214917720|NCT00869102|DRUG|GLP-1|intravenous, 124,5 pmol/kg body weight
214917721|NCT04850417|DRUG|Beta blocker, aspirin, clopidogrel|Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy
214312677|NCT05630859|BIOLOGICAL|NgG below HTD investigational vaccine|Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
214312678|NCT04415944|PROCEDURE|Second look laparoscopy reassessment surgery (SLLRS)|Performed less than 12 weeks after intravenous chemotherapy cycles are completed.
214312679|NCT04415944|DRUG|HIPEC with Carboplatin|"Patient receives HIPEC with CBDCA 800 mg/m2 for 90 minutes.~Patients who exhibit the following will not receive the HIPEC procedure:~* Extraperitoneal disease noted at the time of the second look procedure~* Macroscopic intraperitoneal disease which is not resectable to R1~* Technical problems which prevent continuous, adequate flow to maintain intraperitoneal temperature to 41°C during perfusion~* Intraoperative complications such as cardiac or pulmonary instability precluding HIPEC~Participation will consist of completing surveys regarding their cancer and allowing researchers to use information from their medical records for research."
214312680|NCT04415944|OTHER|FACT-O Quality of Life Questionnaire|Participants will be asked to do this three times (pre-study, 3 months and 6 months). Surveys will be given at follow up visits for surgery. They should take about 10-15 minutes to complete.
214312681|NCT00587886|BEHAVIORAL|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
214312682|NCT00587886|BEHAVIORAL|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
214312683|NCT01356654|DEVICE|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
214312684|NCT01356654|DEVICE|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
214312685|NCT03747874|DIAGNOSTIC_TEST|ventilatory polygraphy|we put a ventilatory polygraphy device on the patient in the evening, they come back home to sleep while the device is recording ventilatory parameters and they come back the morrow to give the device back
214312686|NCT03402009|BEHAVIORAL|Apps|Apps and weblinks to coach self-guided meditation.
214312687|NCT03402009|BEHAVIORAL|EEG neurofeedback|Device provides feedback based on EEG readings.
214312688|NCT06018883|DRUG|Ascorbate|Vitamin C 900 mg/day, three times a day, orally.
214312689|NCT06018883|DRUG|Nab paclitaxel|Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks
214312690|NCT06018883|DRUG|Gemcitabine|Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
214312691|NCT02776917|DRUG|Cirmtuzumab + Paclitaxel|Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
214312692|NCT06015503|DRUG|PLB1004|PLB1004 is a capsule in the form of 80mg and 40mg.
214312693|NCT06571175|DIAGNOSTIC_TEST|High frame rate echocardiography|Conventional transthoracic echocardiography will be performed, with added 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.6) and in validated machine learning algorithms.
214312694|NCT06571175|DIAGNOSTIC_TEST|MRI|Cardiac MRI will be performed. In all patients without contraindications, a gadolinium-based contrast agent will be given.
214312695|NCT06571175|DIAGNOSTIC_TEST|Blood test|Conventional brachial venous blood samples will be drawn. Hematocrit value {in %} will be used to calculate CMR-derived exttracellular volume (ECV)
214312696|NCT06571175|DIAGNOSTIC_TEST|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
214312697|NCT06571175|DIAGNOSTIC_TEST|6 min walking test|6 MWT will be performed, and the findings will be related to findings from CMRI/echocardiography.
214481319|NCT06740630|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214481320|NCT06741319|BEHAVIORAL|Demographic characteristics|"* Gender identity~* Sex assigned at birth~* Age~* Address~* History of study enrollment(s)"
214917722|NCT00474071|DRUG|Remifentanil|See Detailed Description.
214917723|NCT05600231|OTHER|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
214917724|NCT05600231|OTHER|LISTERINE COOL MINT ZERO Alcohol Mouthwash|Participants will use LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 second after brushing teeth twice daily.
214917725|NCT05600231|OTHER|Reach Unflavored Waxed Dental Floss|Participants after brushing for 1 timed minute, will rinse mouth with water and Floss once a day.
214917726|NCT05600231|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
214917727|NCT02259374|PROCEDURE|TAP BLOCK 0.2% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
214917728|NCT02259374|PROCEDURE|TAP BLOCK 0.4% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
214917729|NCT02237469|RADIATION|Prone and supine simulation|Treatment planning in the two positions.
214917730|NCT05455541|DIAGNOSTIC_TEST|AI augmented POCUS examination|Internists will perform POCUS studies as they consider appropriate for patient management. Interpretation of the POCUS exams will be aided by machine learning based analysis of the videos.
214481321|NCT06741319|BEHAVIORAL|Social and sexual behaviors|"* Places where clients go for shopping, dining out, exercise, entertainment~* Places where clients meet their sexual partner(s)~* Places where clients obtain condoms and lubricants~* Social networking and other online services clients regularly use and purposes of using~* Lifetime and current sexual practices and condom use~* Number and types of sexual partners~* Self-perceived HIV risk level~* Disclosure of HIV or sexual orientation status"
214481322|NCT06741319|BEHAVIORAL|Psychosocial characteristics|"* Sexual orientation~* Educational level~* Occupation and income~* Attitude towards and use of HIV testing and sexual health services~* Use of injecting drugs, recreational drugs, and alcohol"
214481323|NCT06741319|BEHAVIORAL|Clinical characteristics|"* Medical history, including gender dysphoria and hormone therapy~* HIV counseling and testing~* Diagnosis and treatment of sexually transmitted diseases (STD)~* Sample collection information~* Laboratory results~* Gender dysphoria and mental health history~* Body hair pattern~* Bridging therapy~* Fertility and reproductive issues~* Gender transition effects"
214671112|NCT00121225|DRUG|vorinostat|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
214671113|NCT04220892|DRUG|Pembrolizumab|200 mg intravenous (IV) every 3 weeks
214671114|NCT04220892|DRUG|Pemetrexed|900 mg/m\^2 IV every 3 weeks. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
214917731|NCT00004043|DIETARY_SUPPLEMENT|calcitriol|
214917732|NCT00317187|BIOLOGICAL|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
214917733|NCT00317187|BIOLOGICAL|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
214917734|NCT05418933|OTHER|Family workshop|Family workshops for 5 courses, with 6-7 families in one course. The workshops were 2 hours per session, one time per week, for a total of 6 weeks.
215060873|NCT00391430|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
215060874|NCT04368299|OTHER|Telemedicine|Videoconferencing for follow-up
214312698|NCT06476886|BEHAVIORAL|Intensive Crisis Intervention (ICI)|ICI is a brief (Average Length of Stay \[ALOS\]: M±SD=4.5±1.4 days), intensive family-centered, skills-based alternative to traditional inpatient psychiatric care. Adolescents participate in 2-3 individual sessions and 1-2 family sessions daily. Based on the cognitive-behavioral model of suicidality, ICI emphasizes that learned, maladaptive cognitive, behavioral, and affective responses to stressors contributing to suicidal behavior can be changed. Master's-level clinicians facilitate this process by engaging adolescents and their families in developing more effective coping skills when faced with potential triggers to suicidal crises.
214312699|NCT06476886|BEHAVIORAL|Adolescent Psychiatric Inpatient Unit (APIU)|APIU provides comprehensive assessment and treatment services to children and adolescents with significant psychiatric difficulties and to their families using a multidisciplinary approach. Symptoms and behaviors that led to admission are targeted through a milieu-based model of care and therapeutic group programming. The multidisciplinary treatment team includes a child and adolescent psychiatrist, often in collaboration with an advanced practice provider, psychologist, psychiatric nursing staff including trained mental health specialists, behavioral healthcare clinicians, care managers, rehabilitative care staff, teachers, and parent partners. Average length of stay is 9-11 days. An individualized treatment plan is developed by the entire treatment team, including the patient and caregivers, and includes initial planning for discharge with the primary treatment goal being stabilization of acute psychiatric symptoms. Programming is based on a trauma-informed biopsychosocial approach.
214312702|NCT05431959|OTHER|balneotherapy|immersion in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l.
214312703|NCT05514509|DRUG|APRETUDE|Available as intramuscular injection.
214312704|NCT05514509|DRUG|Cabotegravir tablet|Available as marketed orally administered tablets.
214312705|NCT06689566|DIETARY_SUPPLEMENT|genistein|the patients will receive genistein 250mg BID orally for complete 3 months. Afterwards, there will be 3 months washout period. Patients would then be followed for outcome measurement.
214312706|NCT07015346|DRUG|Rotigexole 8 mg|Rotigotine 8 mg
215060875|NCT04368299|OTHER|Standard care|Standard in-person outpatient follow-up
214312707|NCT07015346|DRUG|Neupro ® 8 mg|Rotigotine 8 mg
214312708|NCT06461351|OTHER|Inaticabtagene autoleucel Injection|Inaticabtagene autoleucel Injection
214312709|NCT00849160|DRUG|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
214481324|NCT06741319|BEHAVIORAL|Referral and linkage to care for HIV-positive clients|"* Health insurance scheme~* Initiation and continuation of antiretroviral treatment"
214481325|NCT06741319|BEHAVIORAL|Characteristics associated with service implementation|\- Facilitators, barriers, feasibility and acceptability of and satisfaction with service implementation as identified by clients and healthcare providers
214481326|NCT06739200|PROCEDURE|Platelet-Rich Fibrin (PRF) Membrane|The Platelet-Rich Fibrin (PRF) membrane is a biocompatible material derived from the participant's own blood and prepared through centrifugation. It is applied at the surgical site during periapical surgery to promote tissue regeneration, enhance wound healing, and reduce postoperative swelling and pain. Unlike synthetic materials, PRF is autologous and does not require additional chemical additives or processing. This study aims to evaluate its effectiveness in improving recovery outcomes compared to surgery without PRF membrane placement.
214312710|NCT07041918|DEVICE|The study is entirely designed to analyze product performance (analyze only results from whole blood and derived from the PRP tubes), and no interventions will be performed.|The study will evaluate and analyze only the results obtained from whole blood in the hemogram test and the results derived from the PRP tubes. The main objective is to measure the performance of the Vacusera PRP Tube and Vacusera PRP Tube with Gel in obtaining platelet-rich plasma. The study is entirely designed to analyze product performance, and no interventions will be performed.
214671115|NCT04220892|DRUG|Abemaciclib|150 mg twice a day, by mouth.
214671116|NCT00850512|DRUG|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
214917735|NCT06363344|OTHER|Questionnaires : PHQ-9 (Kroenke, 2001), the PSC (Sheldrick, 2012), the ASQ-SE (Squires, 2015), the PedsQL (Varni, 1999)|An advanced practice nurse who is a member of the PICU team monitors patients by questionnaires at 1 and 3 months. Depending on the anomalies detected, whether at the somatic, psychological, emotional or social level, the nurse refers to competent specialists and collaborators and continues monitoring of the family as needed.
214917736|NCT02110758|OTHER|Pilot of Patient-Centered Oncology Care|Patient-Centered Oncology Care addresses six domains: track \& coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track \& coordinate care, and measure and improve performance.
214917737|NCT02604043|OTHER|pH monitoring|After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.
214917738|NCT02604043|OTHER|accelerometer monitoring|Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
214917739|NCT00680095|DRUG|AN2690|AN2690 Solution, 2.5%, Daily for up to 21 days
214917740|NCT00680095|DRUG|AN2690|AN2690 Solution, 7.5%, Daily for up to 21 days
214917741|NCT00680095|DRUG|AN2690|AN2690 Solution, 5.0%, Daily for up to 21 days
214917742|NCT00680095|OTHER|AN2690 Solution, Vehicle|AN2690 Solution, Vehicle, Daily for up to 21 days
214917743|NCT00680095|OTHER|Sodium Lauryl Sulfate, 0.5%|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
214917744|NCT06393309|DRUG|Levetiracetam|Patients with idiopathic generalized epilepsy who were under treatment with levetiracetam
214917745|NCT06393309|DRUG|Sodium valproate|Patients with idiopathic generalized epilepsy who were under treatment with valproate
214917746|NCT01097889|DIETARY_SUPPLEMENT|Fortified blended foods, Corn Soya Bean Flour (CSB) with oil.|A daily ration equivalent of 300g CSB and 32g vegetable oil Bi-weekly distribution of premix of 4.2kg CSB with 0.5L vegetable oil. Estimated 1413 kcal, 47g protein
215060876|NCT02388477|DRUG|Doxycycline|antibiotic used to treat infection
215060877|NCT02388477|DRUG|sugar pill|placebo with no pharmacologic effect
215060878|NCT04044196|PROCEDURE|Rotator cuff repair|Rotator cuff repair performed arthroscopically
215060879|NCT03357029|DEVICE|GammaCore Device|GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
215060880|NCT03357029|DEVICE|Sham Device|Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
214671117|NCT00850512|DRUG|Zevalin|12-week safety period for Zevalin
214312713|NCT06732349|DIAGNOSTIC_TEST|Urinary tubular test panel|The urinary tubular test panel will be applied to urine samples that are collected as part of the routine outpatient follow-up. Its predictive power for CKD progression will be assessed. The results of the tubular test panel will not influence the treatment of the patients. They will remain under standard outpatient treatment throughout the study.
214312714|NCT06788834|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase.~Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effects. The duration of the program will be set at a minimum of three weeks."
214312715|NCT06745531|DRUG|TS-172 20~60 mg/day|oral administration of TS-172 20\~60 mg/day
214312716|NCT06745531|DRUG|Placebo|oral administration of placebo
214312717|NCT06896422|DRUG|Glutathione|Glutathione is administered as an adjunct intervention to the PD-1 inhibitor plus chemotherapy regimen.
214312718|NCT06896422|DRUG|PD1 Inhibitor|e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab
214312719|NCT06896422|DRUG|Chemotherapy|Platinum-based doublet chemotherapy
214312720|NCT06227767|OTHER|spinal stabilization exercise|The exercise program will be implemented in the hospital under the supervision of a physiotherapist for 6 weeks, and the next 6 weeks will be followed as a home program. The first group will be given an exercise program 2 days a week, the second group will be given an exercise program 4 days a week. The exercise program is planned to be 40 minutes and the first 5 minutes of the program will be warm-up and the last 5 minutes will be cool-down exercises.
214671118|NCT03078361|OTHER|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.
214671119|NCT03078361|BEHAVIORAL|LATINOS CARES Toolkit|DVD + photonovella booklet), about colorectal cancer screening (CRCS) targeted for a Latino medically underserved population.
214671120|NCT03078361|BEHAVIORAL|Standard Intervention|Standard intervention (CDC brochure) on colorectal cancer screening in community health clinics.
214671121|NCT01708226|BEHAVIORAL|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
214312721|NCT05525156|DRUG|aspirin enteric coated tablet 75 mg|blister packaged enteric coated tablet of 75 mg aspirin taken once daily for 24 weeks in addition to the conventional antiretroviral drugs
214481327|NCT06739109|PROCEDURE|Therapy-guided internet-based treatment program|eBA is a guided internet-based treatment for problematic alcohol use, based on cognitive behavioural therapy and motivational interview. The patients get access to self-help modules with information, questionnaires, and tools useful in a process of reducing alcohol use. Questionnaires measuring changes in alcohol use, illicit drug use, physical and mental health, and quality of life are frequently answered. These questionnaires are an integrated part of the treatment program and are used by the therapist to monitor and adjust the treatment according to each patient. The patients use the results from the questionnaires to assess whether the treatment is helpful reaching the treatment goal. The patients are guided by a therapist, and they communicate using a system for written messages in the treatment program and/ or guided by telephone.
214481328|NCT06889155|DRUG|Oxytocin|10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.
215060881|NCT02308592|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
214312722|NCT05703763|DIAGNOSTIC_TEST|Applanation tonometry|"Applanation tonometry will be used to measure arterial stiffness in these segments, bilaterally:~* Superficial temporal artery to frontal temporal artery~* Common carotid artery to superficial temporal artery"
214312723|NCT05703763|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assessment, blood test review, high-resolution temporal artery ultrasound using a 24mHz probe.
214312724|NCT05703763|DIAGNOSTIC_TEST|Repeat applanation tonometry (optional)|Repeat index test at month 6 and at disease relapse.
214312725|NCT07101679|DRUG|LICSBR|Participating patients will receive the GnP regimen every 21 days (nab-paclitaxel 125mg/m² ivgtt on days 1 and 8 + gemcitabine 1000mg/m² ivgtt on days 1 and 8, repeated every 21 days) combined with serplulimab (200mg ivgtt Q3W). In the second cycle, patients will receive SBRT targeting the primary tumor and/or retroperitoneal lymph nodes: 6.6Gy×5 fractions, 7Gy×5 fractions, or 8Gy×5 fractions, administered every other day with radiotherapy completed in 5 sessions (specific selection determined by investigators based on lesion size and organs at risk \[OAR\] assessment).
214481329|NCT06887998|DRUG|Gabapentin 600 mg capsules|21 patients will receive 600 mg oral gabapentin one hour before induction.
214481330|NCT06887998|DRUG|Gabapentin 400 mg capsules|21 patients will receive 400 mg oral gabapentin one hour before induction.
214671122|NCT00366236|DRUG|Nitazoxanide|
214481331|NCT06887998|DRUG|Placebo|21 patients will receive placepo one hour before induction.
214481332|NCT06885762|DRUG|efgartigimod|efgartigimod 20 mg/kg was administered via intravenous infusion on day 1 and day 5 of the treatment period only.
214481333|NCT06747286|OTHER|Virtual Game Simulation|A virtual computer game that enables participation in a clinical scenario to measure competence.
214481334|NCT06747078|OTHER|Neurodevelopmental Therapy (NDT) + Core Stabilization Training|In addition to the neurodevelopmental treatment of 30 minutes per day, 3 sessions per week, and a total of 24 sessions, core stabilization training was applied 3 sessions per week for 8 weeks and a total of 24 sessions. The core stabilization training session lasted 30 minutes.
214481335|NCT06747078|OTHER|Neurodevelopmental therapy + Balance Exercises|In addition to NDT, which is 30 minutes per day, 3 sessions per week and 24 sessions in total, balance training was applied 3 sessions per week for 8 weeks and 24 sessions in total. The balance exercise session lasted 30 minutes.
214671123|NCT00635102|DRUG|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
214671124|NCT00635102|DRUG|Placebo D-Cycloserine PO and placebo Glycine IV|Placebo
214671125|NCT00635102|DRUG|Placebo D-Cycloserine PO and Glycine IV|
214917747|NCT01097889|DIETARY_SUPPLEMENT|RUSF (ready-to-use supplementary foods) Supplementary Plumpy®|"Peanut-based fortified supplement~One 92g sachet eaten throughout the day Bi-weekly distributions of 14 sachets 500 kcal and 13g protein"
214917748|NCT00618644|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection
214917749|NCT02617160|DEVICE|MD-Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
214917750|NCT02617160|OTHER|Control Group|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
214917751|NCT01508091|BEHAVIORAL|energy restricted mediterranean-type diet|Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women
215060882|NCT02308592|BEHAVIORAL|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
214671126|NCT00635102|DRUG|D-Cycloserine PO and placebo Glycine IV|
214671127|NCT01598181|DEVICE|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
214671128|NCT01598181|DEVICE|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
214671129|NCT02917590|OTHER|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
214671130|NCT02917590|OTHER|Single-task obstacle crossing training|Obstacle crossing training
214917752|NCT01508091|BEHAVIORAL|25 % calorie restriction|25 % calorie restriction respect total energy expenditure
215077813|NCT02511600|BEHAVIORAL|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
214312726|NCT07102979|DRUG|Ursodeoxycholic Acid (URSO)|Ursodeoxycholic acid (UDCA) was administered orally at a dose of 10 mg/kg/day for 6 months.
214312727|NCT07102979|DRUG|Simvastatin|Simvastatin was administered orally at a dose of 40 mg/day for 6 months.
214481336|NCT06747078|OTHER|Neurodevelopmental therapy|NDT was applied for 60 minutes per day, 3 sessions per week, for 8 weeks and a total of 24 sessions.
214481337|NCT06751290|DRUG|Cyproheptadine|Initiation of Cyproheptadine at 0.25mg/kg once daily by mouth at bedtime and titration up to at most three times daily as per participant's primary gastroenterologist.
214481338|NCT06751290|BEHAVIORAL|Nutritional Counseling|This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic nutritional guidance on high-calorie foods.
214481339|NCT06751290|BEHAVIORAL|Behavioral Counseling|This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic behavioral guidance.
214312728|NCT06635824|DRUG|Acasunlimab|IV infusion
214481340|NCT06751134|DRUG|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3\~34×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
214481341|NCT06748287|DEVICE|iGrow Hair Growth System|has a helmet-design and headphones to allow for hands-free use and music listening capabilities. Treatment is 25 minutes every other day. three to four times per week for 4 months.
214481342|NCT06748287|DEVICE|Capillus352|has a similar design to a salon hair dryer which hovers over the head to allow for hand-free use. Treatment is 12 minutes, three times per week for 4 months.
214671131|NCT04063683|DRUG|Anlotinib Hydrochloride, Paclitaxel, cisplatin|"* anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~* Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~* Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."
214312729|NCT06635824|DRUG|Pembrolizumab|IV infusion
214312730|NCT06635824|DRUG|Docetaxel|IV infusion
214312731|NCT06191315|DRUG|Dupilumab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
214312732|NCT06191315|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
214312733|NCT07109362|DRUG|mild sedation|In this experiment, all subjects were administered remimazolam via a TCI pump until they reached a state of mild sedation, as indicated by a MOAA/S score of 4.
214481343|NCT06748287|DEVICE|HairMax Ultima 12 Lasercomb|is comb-like device with hair-parting teeth to aid in delivery of light therapy directly to the scalp. Treatment is 8 minutes three times per week for 4 months.
214481344|NCT06748287|DEVICE|HairMax Laserband 82|is headband design device which has unique hair-parting teeth to aid in delivery of light therapy directly to the scalp. Treatment is 90-second treatments three times per week for 4 months.
214481345|NCT06744101|RADIATION|Evaluate the effectiveness of Diffusion Weighted MRI (DWI) in detecting breast lesions.|Assess the sensitivity, specificity, and diagnostic accuracy of DWI compared to Ultrasonography (USG) for benign and malignant lesions.
214481346|NCT06744101|RADIATION|Compare Sensitivity and Specificity of DWI and USG|Analyze which modality performs better in lesion detection based on sensitivity and specificity.
214917753|NCT04090060|BEHAVIORAL|Practice Self-/Companion Exams|300 men and 50 couples will be randomized and encouraged to practice anal exams at home before Visit 2. Practice results will be elicited by staff. They will return for Visit 2 (six months after Visit 1). At Visit 2, they will complete a pre- and post-visit computer assisted self-interview. They will receive written instructions. After completing an anal self-exam or anal companion exam at home, they will record the results. At the clinic, they will have a Digital Anal Rectal Exam (DARE) by a clinician who will give the subject his results.
214917754|NCT04090060|BEHAVIORAL|Control Arm|300 individuals and 50 couples will be randomized to this arm. Following Visit 1, they will neither be encouraged nor discouraged from practicing self- or companion exam. They will return for Visit 2 (six months after Visit 1). They will receive written anal exam instructions. They will then complete the self- or companion exam at home, and record the results. At the clinic, they will receive a clinician DARE. Clinicians will give DARE results. Persons will take a post-exam computer-assisted self-interview. Persons in this arm (control) will be asked if they have performed exams between visits.
214917755|NCT02074358|DRUG|Apixaban|
214917756|NCT02074358|DRUG|Cofact (4-Factor PCC)|
214917757|NCT02074358|DRUG|Beriplex P/N (4-Factor PCC)|
214917758|NCT02074358|DRUG|Placebo (Saline solution)|
214917759|NCT01164579|DRUG|Tasocitinib plus Methotrexate|Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
214917760|NCT01164579|DRUG|Tofacitinib plus placebo methotrexate|Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
214917761|NCT01164579|DRUG|Placebo tofacitinib plus Methotrexate|Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
214917762|NCT02535767|DRUG|Primaquine|A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
214917763|NCT06573463|DEVICE|Prefabricated band and loop|Prefabricated space maintainer requires only one visit as it fits into the patient's mouth at the clinic without needing the dental lab. It comes in a kit with different band sizes.
214917764|NCT06573463|DEVICE|Conventional Band and loop|Conventional band and loop is the most widely used space maintainer, It shows high success rate and good patient compliance, but needs more than one visit due to the laboratory work.
215060883|NCT05586906|DEVICE|Multiple Breath Washout (MBW) tests|LCI measurements (EXHALYZER® D with Nitrogen Washout System, ECO Medics AG) will be performed every month during follow-up beginning 3 months after lung transplantation.
214312734|NCT07108452|OTHER|A mobile application that uses AI to deliver behavioral nudges that encourage healthy food choices.|As a mobile application for assessing dietary intake, the app provides a daily report of food intake- a core function that both the gamified and limited app versions have. The gamified version has the added functionality of delivering behavioral nudges that encourage healthy food selections.
214312735|NCT07108452|OTHER|Limited app version for dietary assessment only|This app version provides a daily report of energy and nutrient intake- available to those randomized to the control group
214312736|NCT07108400|PROCEDURE|ultrasound-guided injections of hyaluronic acid plus high-power laser therapy|Received two ultrasound-guided injections of hyaluronic acid into the coxo-femoral joint, 10 sessions of physical therapy specifically targeting hip OA (5 sessions/week for two weeks) lasting 45 minutes, and 10 sessions of active high-power laser therapy using a diode laser.
214312737|NCT07108400|PROCEDURE|"ultrasound-guided injections of hyaluronic acid plus sham high-power laser therapy"|"Received two ultrasound-guided injections of hyaluronic acid into the coxo-femoral joint, 10 sessions of physical therapy specifically targeting hip OA (5 sessions/week for two weeks) lasting 45 minutes, and 10 sessions of sham high-power laser therapy using a diode laser, due to the presence of a light pointer and an acoustic signal of the device, which made it impossible to distinguish the active treatment from the sim-ulated one."
214312738|NCT07110259|OTHER|DeepGEM-guided Molecular Testing and Treatment|Artificial intelligence-based mutation prediction using DeepGEM to guide clinical decision-making for molecular testing and therapy selection.
214312739|NCT07110259|OTHER|Standard Diagnostic Pathway|DeepGEM is used for eligibility screening, but its results are withheld. Clinicians manage patients per standard diagnostic and treatment practices.
214312740|NCT07108829|DEVICE|Renal Artery Radiofrequency Ablation Clamp|This device is a clamp used during a laparoscopic surgical procedure. It is placed on the external surface (adventitia) of the renal artery and is connected to a radiofrequency generator. It delivers targeted radiofrequency energy to ablate the renal sympathetic nerves.
214481347|NCT06418347|DRUG|Alpha lipoic acid|"Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria. It acts as an enzymatic cofactor for various enzymes in the Kreb's cycle. ALA has many beneficial properties making it a potential candidate for various clinical disorders. It is considered the universal or ideal antioxidant as it is both water-soluble and fat-soluble facilitating its passage across membran. ALA has direct as well as indirect anti-inflammatory effects. Being a potent antioxidant leads to a reduction in oxidative stress which in turn reduces inflammation, meaning ALA indirectly has anti-inflammatory effects. To add to ALA's benefits, it has anti-inflammatory properties that are independent of its antioxidant effects."
214481348|NCT06418347|DRUG|Letrozole|Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.
214917765|NCT01605552|BEHAVIORAL|Beating the Blues (BtB)|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
214917766|NCT01605552|OTHER|Usual Care|Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
214917767|NCT06302556|DIAGNOSTIC_TEST|Immune checkpoints analysis|The researcher will analyze immune checkpoint molecules, which will include the lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), besides the canonical PD1 and ligands L1 and L2, T cell immunoglobulin and ITIM domain (TIGIT) and CTLA-4. In addition, Foxp3, GATA3 and TOX will be analyzed as specific lineage markers.
214917768|NCT06302556|DIAGNOSTIC_TEST|Gene expression analysis|Immune cells will be purified from bronchoalveolar lavage; total RNA will be purified and subjected to gene expression analysis by Quantigene multiplex 80-plex Assay, which allows to evaluate simultaneously the follow mRNA targets: CCL2, CCL3, CCL5, CXCL10, CSF2, CSF3, IL1A, IL1B, IL1RN, IL6, IL6R, IL8, IL10, IL12B, IL17A, IL18, IL22, IL28A, TNF, TNFRSF4, IFNA2, IFNB1, IFNG, IFI16, IFITM1, IFITM3, MX1, TLR3, TLR4, TLR7, TLR8, NOD1, NOD2, CASP1, NLRP3, PYCARD, CD44, CLEC4M, CD209, ITGA4, ITGB7, CH25H, ABCA1, HMGCS1, NR1H3, ACAT1, PDCD1, PTGS2, CD274, CD69, MPO, HAVCR2, TAP1, ERAP1, ERAP2, AGTR2, AGTR1, PPARG, CRP, IL7, IL12A, ACE2, ELOVL6, CD38, NOS2
214312741|NCT07108673|DIAGNOSTIC_TEST|MRI|structural MRI imaging and behavioral testing (e.g. Barratt Impulsiveness scale) both performed by skilled physicians.
214312742|NCT07110701|OTHER|Retention of the fissure sealants evaluated|Following classification system was employed for the retention evaluation of the sealants: 1 = complete retention; 2 = partial loss; or 3 = complete loss.
214917769|NCT05726071|DEVICE|Holter|24 hour electrocardiography
215077814|NCT00751283|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
214481349|NCT06738329|OTHER|Carrageenan gummy sweet|Gummy sweet containing carrageenan and agar as the gelling agents.
214481350|NCT06738329|OTHER|Carrageenan and inulin gummy sweet|Gummy sweet containing agar and carrageenan as gelling agents, with added inulin.
214481351|NCT06738329|OTHER|Placebo agar agar gummy|Gummy sweet containing agar as gelling agents.
214312743|NCT07108530|OTHER|Integrated IAV/MA Chemotherapy and Allo-HSCT Protocol for Adult AML|This intervention is distinguished by its risk-adapted, time-compressed, and economically tiered design. It integrates two induction options-IAV (idarubicin + cytarabine + venetoclax) for patients with better economic resources and DAV (daunorubicin + cytarabine + venetoclax) for those with limited resources-followed by consolidation with either the MA regimen (liposomal mitoxantrone + intermediate-dose cytarabine) or intermediate-dose cytarabine alone. Eligible patients proceed directly to allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a FA-BuCy/ATG conditioning regimen and a novel GVHD prophylaxis strategy using anti-CD25 monoclonal antibody combined with delayed oral cyclosporine. The entire treatment is designed to be completed within four months from diagnosis. This protocol is unique in its combination of liposomal chemotherapy, venetoclax-based induction, and tailored transplant strategies.
214312744|NCT07108530|DRUG|First Induction (IAV or DAV Regimen)|"* IAV Regimen:Intravenous Idarubicin (Ida): 6 mg/m²/day on days 1-3 (total cumulative dose ≤ 40 mg)，Intravenous Cytarabine: 100 mg/m²/day on days 1-7，Oral Venetoclax: 8-day schedule（100 mg on day 4, 200 mg on day 5, and 400 mg/day on days 6-11）~* DAV Regimen：Intravenous Daunorubicin (D): 60 mg/m²/day on days 1-3，Intravenous Cytarabine: 100 mg/m²/day on days 1-7，Oral Venetoclax: 8-day schedule（100 mg on day 4, 200 mg on day 5, and 400 mg/day on days 6-11）"
214312745|NCT07108530|DRUG|Consolidation Therapy Options: MA or Intermediate-Dose Cytarabine Regimen|"* MA Regimen (Liposomal Mitoxantrone + Intermediate-Dose Cytarabine):Liposomal Mitoxantrone: 10 mg/m²/day on days 1-2.Cytarabine: 1 g/m² every 12 hours for 3 days (days 1-3).~* Intermediate-Dose Cytarabine Regimen:Cytarabine: 1 g/m² every 12 hours for 3 days (days 1-3)."
214312746|NCT07108530|OTHER|Subsequent Treatment Plan for Transplant-Eligible Patients|"Patients eligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT) should proceed directly to transplant after the above two treatment cycles（The requirement before transplantation is that minimal residual disease should be negative).~* Conditioning Regimen: FA + BuCy (Fludarabine + Busulfan + Cyclophosphamide). For haploidentical transplantation, ATG (antithymocyte globulin) is added.~* Donor Selection Priority:~  1. HLA-matched sibling donor (MSD)~ 2. Matched unrelated donor (MUD)~ 3. Haploidentical donor (Haplo) Selection should consider donor age, health status, and other clinical factors."
214312747|NCT07108530|OTHER|Allogeneic Stem Cell Transplantation Protocol|"Conditioning Regimen: FA-BuCy/ATG~* Fludarabine: 30 mg/m²/day on days -8 to -6~* Cytarabine: 1 g/m²/day on days -8 to -6~* Busulfan: 2.4 mg/kg/day on days -5 to -3~* Cyclophosphamide: 30 mg/kg/day on days -4 to -3~* ATG (Antithymocyte Globulin): 7.5 mg/kg total dose, administered from day -5 to -2"
214312748|NCT07108530|OTHER|GVHD Prophylaxis Regimen|"GVHD Prophylaxis~* Recombinant Humanized Anti-CD25 Monoclonal Antibody: 50 mg on days +1 and +4.~* The GVHD prophylaxis regimen consists of cyclosporine, mycophenolate mofetil (MMF), and short-course methotrexate (MTX).Cyclosporine (CsA):Initiated as a continuous 24-hour intravenous infusion at a dose of 2 mg/kg/day, starting from day -9 before transplantation.Once the patient can tolerate oral intake, cyclosporine is switched to oral administration at a dose of 3-5 mg/kg/day, divided into two daily doses.The target therapeutic trough concentration of cyclosporine should be maintained between 150-250 μg/L.~* Delayed Oral Cyclosporine Protocol:Continue IV infusion until day +20, even if GI symptoms resolve.Switch to oral only if no acute GVHD occurs.If grade II-IV acute GVHD develops, continue IV CsA."
214481352|NCT06048783|BEHAVIORAL|Program of systematic and periodic spiritual accompaniment and care|Systematic and periodic spiritual accompaniment and care
214481353|NCT06747013|DEVICE|Point Ablation Catheter|a point ablation catheter using a pulse field energy
214481354|NCT06747650|BEHAVIORAL|Dialectical Behavior Therapy for Adolescents|Standard of care (SOC) DBT-A includes approximately six weeks of pretreatment, and approximately six months of DBT-A skills group, individual therapy, and 24/7 phone coaching. During pre-treatment, clients are oriented to the DBT-A model and client commitment to treatment is established. After approximately six weeks, the client enters DBT-A skills group along with their caregiver. This skills group meets weekly for 1.5 hours and clinicians explain the five main DBT-A skills (mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path) via PowerPoints and discussion. Clients and their caregivers are assigned weekly homework. At the same time, teens are completing weekly 1-hour individual therapy sessions where they are utilizing the skills learned in group. Both teens and caregivers have access to what DBT-A calls 24/7 phone coaching. This phone coaching is 24/7 access to a therapist when a crisis is arising.
214481355|NCT06588842|OTHER|Cluster Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets and 15-second rests after repetitions three and six.
214671132|NCT04964401|PROCEDURE|Thoracic paravertebral block vs Erector spinae plane block|Thoracic paravertebral block and erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
214671133|NCT03900676|DRUG|VB-1953 - 2%|Topical Gel
214671134|NCT03900676|DRUG|VB-1953 - 0% (Vehicle)|Topical Gel
214917770|NCT02203461|DRUG|Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat|STRIBILD® QD, d1-14
214917771|NCT02203461|DRUG|Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir|Truvada®/ Kaletra® 200/50 mg QD, d1-14
214917772|NCT02203461|DRUG|Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir|Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
214917773|NCT04482361|DIAGNOSTIC_TEST|Presence of specific anti-SARS-CoV-2 antibodies|Presence of specific anti-SARS-CoV-2 antibodies
214917774|NCT04291183|BEHAVIORAL|horticultural therapy|Flowers and vegetables will be planted with the elderly. Growth of plants planted with the elderly will be observed and maintained
214917775|NCT00224068|DRUG|Sodium ferric gluconate, ferrous sulfate, standard of care|
214917776|NCT02041663|BIOLOGICAL|BNP|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
214917777|NCT03005496|DRUG|Zinc|included in intervention arm
214917778|NCT03005496|DRUG|Nifedipine|included in intervention and control arm
214917779|NCT03005496|DRUG|Beta Carotene|included in intervention arm
214917780|NCT03005496|DRUG|Vitamin D3|included in intervention arm
214312749|NCT07108530|OTHER|Subsequent Consolidation Therapy for Transplant-Ineligible Patients|"1. Consolidation Therapy (Two Cycles)~   * Option A Intermediate-Dose Cytarabine-Based Regimen：Liposomal Mitoxantrone: 10 mg/day on days 1-2 (dose-reduced).Cytarabine: 1 g/m² every 12 hours for 3 days (days 1-3).~  * Option B VA Regimen (Venetoclax + Azacitidine)：Venetoclax (V): Dose-escalation starting at 100 mg on day 1, increasing to 400 mg/day by day 6, continued through day 14.Azacitidine (A): 75 mg/m²/day subcutaneously or intravenously on days 1-7.~  * Treatment Cycle:Each regimen is administered for two cycles with a 3-week interval between cycles, followed by maintenance therapy.~2. Maintenance Therapy After Two Consolidation Cycles~   * Pegylated Interferon α-2b (Long-acting Interferon): 180μg subcutaneously every two weeks.~Continued until disease progression or unacceptable toxicity occurs."
214312750|NCT07110038|DRUG|Avelumab|Avelumab, 1,200 mg IV
214312751|NCT07110038|DRUG|enfortumab vedotin|Enfortumab vedotin, 1.25 mg/kg IV
214312752|NCT07110103|DRUG|golidocitinib with PD-1 inhibitors|"Dose escalation: 75/150mg golidocitinib with PD-1 inhibitors as maintenance treatment after 4 cycles of PD-1 inhibitors and chemotherapy.~Dose expansion: Selected dose (75mg or 150mg) of golidocitinib with PD-1 inhibitors as maintenance treatment after 4 cycles of PD-1 inhibitors and chemotherapy."
214312753|NCT07109908|BEHAVIORAL|Wiping Bath|"The babies in this group were given the first bath in the form of wiping baths. The bathing application was carried out by the midwife working in the unit and experienced in bathing newborns.~The newborn's clothes except the diaper are removed, the newborn is wrapped in a towel, the newborn's face and body are wiped clean with a skin cleanser and cotton cloth compatible with the baby's skin, the diaper is removed and the genital area is wiped, the baby's body is wiped with a cloth moistened with water (37-39 oc), the body is dried, the baby's body is wrapped in a dry towel, the baby's head is washed with a shampoo compatible with the baby's skin, the baby's head is dried and a hat is put on, The newborn was dressed in clothes."
214312754|NCT07109908|BEHAVIORAL|Wrapping Bath|"The first bath of the babies in this group was in the form of a wrap-up bath, in which the baby was wrapped and placed in the bathtub. The bathing application was carried out by the midwife working in the unit and experienced in bathing newborns.~The newborn's clothes were removed, the newborn was wrapped in a towel, the newborn was slowly immersed in water wrapped in a towel in a bathtub with a maximum of 7 cm of water at the appropriate temperature (37-39 oC), the towel was gently opened and the baby's body was gently cleaned with a suitable cleansing product and a cotton swab, including the torso, legs and genital area, the baby's head was wetted and washed with a shampoo compatible with the baby's skin, the baby's head was rinsed by pouring water from the hairline, The baby's torso was gently removed from the bathtub and rinsed, the newborn baby was dried and then dressed in clothes."
214481356|NCT06588842|OTHER|Traditional Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets.
214481357|NCT02765412|OTHER|Webinar, Promotion, and Tool Access|All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
214481358|NCT02765412|OTHER|LEAP|Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).
214481359|NCT02765412|OTHER|Audit and Feedback|Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).
214481360|NCT02765412|OTHER|Academic Detailing|All sites will be offered an academic detailing approach to implementation of Lung Decision Precision. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.
214481361|NCT05564130|DRUG|Sodium bicarbonate|Sodium bicarbonate 1 mmol/ml
214481362|NCT05564130|DRUG|Sodium chloride|Sodium chloride 9 mg/mL
214481363|NCT05031494|DRUG|YH003|YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
214481364|NCT05031494|DRUG|Toripalimab|Toripalimab will be administered at a dose of 240 mg every 3 weeks.
214481365|NCT05031494|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
214481366|NCT05031494|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
214481367|NCT06748846|DEVICE|Physiotherapy + Occupational therapy + Focal Muscle Vibration|\- Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. -Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. -SMV (15 minutes): Administered during the last part of each physiotherapy session. Experimental Group: SMV is applied to the trapezius (middle/descending fibers) and quadratus lumborum bilaterally at 80 Hz with an amplitude of 0.5 mm.
214481368|NCT06748846|DEVICE|Physiotherapy + Occupational therapy + Sham Focal Muscle Vibration|Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. SMV (15 minutes): Administered during the last part of each physiotherapy session. Control Group: Sham SMV using disconnected terminals produces sound but no vibration, ensuring blinding.
214481369|NCT06877390|OTHER|conventional drug and exercise rehabilitation|patients in the control group received antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel, once a day), β-blocker (25-100 mg of metoprolol, twice a day, with the dose adjusted based on the patient's heart rate) and statins (10-20 mg of rosuvastatin, every night). In addition, the patients received exercise rehabilitation (e.g. aerobic, resistance and flexibility training) for 30-60 min, 3-5 times/week.
214917781|NCT03005496|DRUG|Dexamethasone|included in intervention and control arm
214312755|NCT07109908|BEHAVIORAL|Showering Bath|"The first bath of the babies in this group was in the form of a shower bath. The bathing application was carried out by the midwife working in the unit and experienced in bathing newborns.~The newborn's clothes are removed, the newborn's body is soaked with water at the appropriate temperature (37-39 oC) under running water, the body is washed with the appropriate skin cleanser and cotton cloth, the head is washed with the appropriate shampoo for the baby's skin, the whole body is rinsed under running water, the whole body is dried with a towel and the clothes are dressed."
214312756|NCT07103551|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma used during clear aligner therapy for acceleration of Orthodontic Tooth Movement
214312757|NCT07109440|DIAGNOSTIC_TEST|FAPI PET/CT|Patient will undergo FAPI PET/CT Prior to surgery
214312758|NCT06923969|OTHER|balneotherapy|
214312759|NCT05254327|DRUG|BMX-001|Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
214312760|NCT00857922|OTHER|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
214312761|NCT01743261|OTHER|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
214312762|NCT01743261|OTHER|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
214312763|NCT05328492|DEVICE|iVAPS-AE|Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
214312764|NCT05328492|DEVICE|ST-mode|Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
214312765|NCT00956410|BIOLOGICAL|CAD106|
214312766|NCT00003739|BIOLOGICAL|filgrastim|
214312767|NCT01870622|PROCEDURE|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
214312768|NCT01870622|PROCEDURE|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
214481370|NCT06877390|DEVICE|EECP-based rehabilitation regimen|Patients in the rehabilitation group received the same medication and exercise rehabilitation as the control group during the trial period after undergoing DCB-based PCI DCBs; in addition, they were provided with EECP treatment after 7 days of medication. The treatment adopted a P-ECP/TI EECP device with a pressure setting of 0.020-0.035 MPa. Based on patients' actual tolerance, the treatment pressure and inflation and exhaust times were adjusted to a diastolic/systolic blood pressure ratio of \>1.2 and a diastolic/systolic pressure area of 1.5-2.0. The treatment was applied daily for 1 hour, 6 days a week, for a total of 36 hours.
214481371|NCT06878521|OTHER|Emotional Regulation Skills|"This intervention is inspired by and incorporates elements of Dialectical Behavior Therapy (DBT). It consists of eight weekly group sessions, each lasting approximately 1.5 to 2 hours, held on school premises. Each group includes 8 to 10 adolescents. The sessions are facilitated by two psychologists and/or senior psychology students who have been specifically trained to deliver the intervention.~The sessions focus on developing various emotional regulation skills, which participants are encouraged to practice both during and between sessions. Some of the key skills covered include Mindfulness, Wise Mind, and Problem-Solving, among others."
214481372|NCT06877260|DIAGNOSTIC_TEST|Computer based task with EEG|Participants will undergo EEG recording while performing a computer based neuropsychological task evaluating cognitive control
214481373|NCT06746376|OTHER|Occupational Therapy|"Description:~Participants assigned to the intervention group will undergo a 8-week supervised hand exercise program designed to improve pain, manual dexterity, and functionality."
214312769|NCT03989297|RADIATION|Radiation|Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
214312770|NCT01285804|OTHER|Cuffed ETT|Kimberly Clark
214671135|NCT03792711|DIETARY_SUPPLEMENT|Ensure® Plus Advance|"Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women."
214671136|NCT01570010|OTHER|Norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
214312771|NCT01285804|OTHER|Uncuffed ETT|Kimberly Clark
214312772|NCT04776967|PROCEDURE|Hyperbaric Compression Profile|A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.
214312773|NCT04865757|DEVICE|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
214312774|NCT00132340|DEVICE|Electrodes|
214312775|NCT01686243|OTHER|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
214312776|NCT01686243|OTHER|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
214312777|NCT00983281|DRUG|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
214312778|NCT02110992|DRUG|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
214312779|NCT02110992|RADIATION|Stereotactic Radiation|SBRT will be given over 5 fractions separated by \> 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
214671137|NCT05015361|DRUG|Remimazolam Tosilate|Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose
214481376|NCT06894251|DIETARY_SUPPLEMENT|LIMICOL® NG|All subjects will consume 2 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V2, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 1 tablet in the evening during dinner. If a dose is missed, 2 tablets can be taken at the next dose.
214481377|NCT06893497|DEVICE|Low Level Laser Therapy|In this study, which had more patients than other studies, different parameters were evaluated to determine the protocol of LLL therapy. These parameters were the cause of IAN injury, number of sessions, time of treatment start and period of follow-up.
214312780|NCT00864474|DRUG|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
214481378|NCT06894732|PROCEDURE|Rotary induced abortion|Rotary induced abortion under ultrasonic monitoring was performed with intravenous anesthesia.
214481379|NCT06751069|BEHAVIORAL|Home-based Pulmonary Rehab|Participants are expected to engage in the home-based PR routine five to six days a week for the entire 12-week study period. The PR routine begins with slow upper body and timed breathing exercises, followed by two slow balance walks for 6 minutes each. The total exercise time is 24 minutes a day followed by a 4-minute mindful breathing meditation/cool down. Exercises may be modified or repeated according to baseline activity level and as conditioning improves.
214917782|NCT02391012|BIOLOGICAL|Fecal microbial l transplantation|infusion of preparation of fecal preparation from a healthy donor to a colitis patient
214917783|NCT04607564|OTHER|Ntombi Vimbela! intervention|Ntombi Vimbela! constitutes a series of ten workshops running for a total 35 hours. The intervention is designed to raise awareness about sexual rights, violence against women and girls and its drivers; sensitise about gender inequality and build more gender equitable beliefs; sensitise about sexual assault; equip participants with skills to assess and act in situations where there is a high risk of sexual assault; build resilience and skills to withstand social and material pressures in college or university ; enable utilisation of health, psycho-social services and access to justice for survivors; enhance communication skills and building healthy sexual relationships; promote mental health and coping and build empathy towards survivors.
214917784|NCT01535521|DEVICE|Sleep Position Trainer (SPT)|
214917785|NCT04988932|DRUG|Inhaled nitric oxide|Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
215060884|NCT04593186|PROCEDURE|Trans-oral magnifying endoscopy with NBI|"Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure."
214481380|NCT06748469|PROCEDURE|The duration of the intervention will be 240 seconds|Dorsal Root Ganglion pulsed radiofrequency 240sec
214481381|NCT06748469|PROCEDURE|Dorsal Root Ganglion pulsed radiofrequency 480sec|The duration of the intervention will be 480 seconds
214917786|NCT01981707|DEVICE|F-Choline-PET|
214917787|NCT06512285|DIAGNOSTIC_TEST|Continuous Pulse Oximetry|The patient will wear a continuous pulse oximeter after their adenotonsillectomy surgery until the following morning. This will record continuous pulse oximetry data to allow for analysis of any desaturations in the first night following the surgery. This study is observational only and this data will not be used to impact any treatment
214917788|NCT00497393|BEHAVIORAL|Clinical Decision Unit|a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
215060885|NCT00989846|OTHER|biomarker|measuring serum-biomarkers
215060886|NCT05007899|DRUG|Ferrous sulfate|Alternate day dosing of ferrous sulfate
215060887|NCT03774043|OTHER|Acute Intermittent Hypoxia|Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
214312781|NCT03057145|DRUG|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
214312782|NCT03057145|DRUG|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
214481382|NCT06748872|DRUG|Lymphodepletion|Cylcophosamide and Fludarabine
214481383|NCT06748872|BIOLOGICAL|TCR-T cells (MDG1015)|TCR-T cells (MDG1015)
214481384|NCT06746740|BEHAVIORAL|Exercise|Adapted with input from phase 1
214671138|NCT05015361|DRUG|Propofol Injection.|Treatment group C: Propofol Injection.
214671139|NCT06076330|BIOLOGICAL|20% Albumin|S. albumin \> 3 g/dl: 20g of 20% iv albumin @10-15 ml/hr S. albumin \< 3 g/dl: 40g of 20% iv albumin @10-15 ml/hr
214671140|NCT06076330|BIOLOGICAL|5% Albumin|5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose In case of failure to attain a sustained MAP \>65 mmHg, Fluid boluses will be administered guided by lung ultrasound and IVC.
214671141|NCT06076330|DRUG|Plasmalyte|Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance
214671142|NCT01938625|DRUG|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
214671143|NCT01938625|DRUG|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
214671144|NCT01938625|DRUG|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
214312783|NCT01945385|BEHAVIORAL|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
214312784|NCT05224492|DRUG|Sulforaphane|40 mg of Sulforaphane powder once daily.
214312785|NCT05224492|OTHER|Placebo|Placebo
214312786|NCT00610532|DRUG|phenytoin|intravenous phenytoin (15 mg/kg) single dose
214481385|NCT06752005|BEHAVIORAL|Intervention Group|One of the investigators created a randomization sequence using a simple random numbers table and determined the groups. Another researcher assigned premature infants to the study groups according to the order of hospitalization in the unit, and the same researcher also applied the intervention. Thus, each infant experienced all three positions in a crossover design by the end of the study. Infants in all three groups were positioned for two hours in each posture, totaling six hours by the end of the study. Immediately after positioning in each posture, and at 1, 30, 60, 90, and 120 minutes, heart rate and oxygen saturation (SpO₂) values were recorded from bedside monitors, and respiratory rate was counted over one minute. Comfort and stress scores were assessed immediately after positioning (1 minute) and at 60 and 120 minutes. The Premature Infant Comfort Scale (PICS) was used to assess comfort, while the Neonatal Stress Scale (NSS) was used to evaluate stress.
214481386|NCT06755528|DRUG|Chitosan|The participants will receive medications for fallopian tube adhesions (Chitosan (glucosamine (GIcN) and N-acetylglucosamine (GIcNAc) units,1 tablet per day) as prescribed by the gynecologist
214671145|NCT01938625|DRUG|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
214671146|NCT01938625|DRUG|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
214671147|NCT04861038|DEVICE|aerSleep II|Continuous negative external pressure (cNEP) system that maintains an open airway by applying negative pressure to the anterior neck via a soft silicone collar
214671148|NCT00300027|DRUG|BMS-582664|
214671149|NCT02088034|BEHAVIORAL|Promotora-led Intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
214671150|NCT02088034|DRUG|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
214671151|NCT02088034|OTHER|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
214671152|NCT04364217|DEVICE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
214671153|NCT05290870|DEVICE|Posterior-chamber intraocular lens|Implantation of a posterior-chamber intraocular lens to correct aphakia after removal of the crystalline lens
214671154|NCT00308620|DRUG|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
214671155|NCT00308620|DRUG|Placebo|Placebo once daily for 8 weeks
214671156|NCT05780281|BIOLOGICAL|VIR-7831|VIR-7831 is a fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibody (mAb) derived from antibody S309 from a survivor of SARS-CoV-1.
214671157|NCT05780281|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
215060888|NCT03774043|OTHER|Sham Acute Intermittent Hypoxia|Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
214312787|NCT00610532|DRUG|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
214671158|NCT05780281|BIOLOGICAL|Remdesivir|Antiviral agent
214671159|NCT02220374|OTHER|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
214671160|NCT00546351|DRUG|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
215060889|NCT05466136|BEHAVIORAL|Mental fatigue condition|In mental fatigue condition, the mental fatigue manipulation will use a modified Stroop task with complete incongruent trials, which is wildly used to induce a mentally fatigued state in previous studies. The Stroop task included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), the color of the word will paint inconsistent with the semantic meaning of the word (e.g., red word printed in green). The task consisted of five 6-minute blocks and 1080 incongruent trials for each block. The total duration will be 30-min.
214312788|NCT04689087|COMBINATION_PRODUCT|TTFields|For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
214312789|NCT05508113|OTHER|ozone autohemotherapy|After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
214671161|NCT02117089|DEVICE|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.
214671162|NCT01689506|DRUG|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
214671163|NCT01689506|DRUG|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
214312790|NCT04119089|OTHER|Gastric ultrasound|"A first gastric ultrasound will be performed in the supine and the right lateral (RLD) decubitus position, allowing a qualitative analysis of the gastric contents (empty, liquid, solid, solid-liquid). The antral area will also be measured in both positions. The volume of gastric fluid content will be calculated according to the following formula: volume (ml) = -7,8 + (0,035 x antral area in RLD (mm²)) + 0,127 x age (month).~This examination will be immediately followed by the aspiration of gastric contents through the nasogastric tube used for enteral feeding, into 50-ml syringes, by a nurse blinded to the result of the first ultrasound examination. A second antral ultrasound examination will then be performed, by the same investigator blinded to the volume aspirated.~The occurrence of regurgitation and / or vomiting occurring within the 12 hours before and after the examination will be recorded."
214312791|NCT00214955|DRUG|ORAVESCENT Fentanyl Citrate|
214312792|NCT03552159|BEHAVIORAL|Behavioral activation|Activity scheduling, monitoring, review and re-scheduling
214312793|NCT03552159|OTHER|Psychoeducation|Education on dementia, caregiving stress, event scheduling and communication skills
214312794|NCT06200181|DRUG|Olanzapine|Given by PO
214312795|NCT06200181|DRUG|Olanzapine|Given by PO
214312796|NCT06200181|DRUG|Placebo|Given by PO
214481387|NCT06755528|DEVICE|shockwave therapy|The participants will receive shockwave with the following parameters: sonic pulses characterized by: high peak pressure, up to 100 mpa (500 bar) or even more, rapid rise in pressure (\<10 ns), short duration (\<10 μs) and a broad range of frequency. The energy flux density was 0.09 to 0.16 mJ/mm2; with a frequency of 5 Hz and 2000 impulses, i session per week for 4 weeks.
214481388|NCT06755008|PROCEDURE|bronchial fibroscopy|2 bronchial biopsies will be taken during bronchial fibroscopy
214481389|NCT06753721|DRUG|Doxorubicin liposome combined with CapOX and Bevacizumab|Bevacizumab (7.5 mg/kg, IV, Day 1) + Oxaliplatin (130 mg/m², IV, Day 1) + Capecitabine (1000 mg/m², oral, twice daily, for 14 days) + Doxorubicin liposome (20 mg/m², IV, Day 1), repeated every 3 weeks.
214481390|NCT06756438|OTHER|Study product|Anti-itching, anti-replapse and repairing treatment. Emollient.
214917789|NCT05958628|OTHER|Conventional physiotherapy|"The treatment program was designed in line with the patients' compliance, functional capacities and rehabilitation goals as neurodevelopmental therapy based on the ability to adapt to change, reorganization and healing in the brain by focusing on neuroplasticity from neurodevelopmental treatment approaches; Proprioceptive neuromuscular facilitation techniques to increase selective and voluntary movement; functional exercises to increase motor control skills, stretching exercises for spasticity and neuromuscular electrical stimulation.~The control group received conventional physiotherapy exercises for 45 minutes and neuromuscular electrical stimulation for 15 minutes."
214917790|NCT05958628|OTHER|Robotic Hand Exoskeleton System|In the treatment applications with the robotic hand exoskeleton system, which is designed to accelerate the healing process of patients in need of hand rehabilitation, to gain motor skills, to provide strength training and to increase participation in treatment, the patient will be asked to allow the system to move the hand at adjusted angles for 10 minutes and to accompany this movement. In the applications, while the patient is sitting comfortably and safely, the patient will be asked to place the stroke-affected hand into the system. The hand of patients who may have difficulty due to the functional status of the upper extremity and the severity of spasticity will be placed with the help of the physiotherapist. The physiotherapist will be with the patient throughout the application.
214917791|NCT00182611|DRUG|cisplatin|
214917792|NCT00182611|DRUG|tegafur-gimeracil-oteracil potassium|
214917793|NCT00182611|PROCEDURE|adjuvant therapy|
214312797|NCT06529991|DEVICE|Occipivot suboccipital pillow self-myofascial release|"Subjects will be instructed in the use of the Occipivot suboccipital pillow and how it should feel. They will be supervised as it is placed. Once verbal verification is obtained regarding the feel and placement of the wedge, the treatment time will begin and continue for 5 minutes."
214312798|NCT06196671|DRUG|H101|H101 15x10\^11vp intratumorally injection starts at day 1.
214312799|NCT06196671|DRUG|Camrelizumab|Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.
214481391|NCT06756438|OTHER|Placebo|Emollient
214481392|NCT06757543|DEVICE|Video laryngoscopy|Video laryngoscopy with C-MAC (Karl Storz, Tuttlingen, Germany)
214481393|NCT06757543|DEVICE|Direct laryngoscopy with standard laryngoscope|Direct laryngoscopy with standard laryngoscope
214481394|NCT06762691|DEVICE|MyCRO Band|A 3D-printed cranial remolding orthosis
214481395|NCT06762691|DEVICE|Traditional CRO|A traditionally manufactured cranial remolding orthosis such as the Orthomerica Starband
214481396|NCT00243087|DRUG|BI 2536|
214481397|NCT06839599|DRUG|CMTS4520 (dietary fiber probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 4 weeks of CMTS4520 daily for chronic diarrhoea.
214481398|NCT06839599|DRUG|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
214481399|NCT06845930|DRUG|Rectal Diclofenac|Rectal diclofenac, 100mg administered immediately after skin closure then 12 hourly for 24 hours.
214481400|NCT06845930|DRUG|Intramuscular diclofenac|Intramuscular diclofenac, 7mg administered immediately after skin closure then 12 hourly for 24 hours.
214917794|NCT00182611|PROCEDURE|conventional surgery|
214312800|NCT04576117|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214312801|NCT04576117|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214312802|NCT04576117|OTHER|Quality-of-Life Assessment|Ancillary studies
214481401|NCT05028387|DRUG|medical abortion|medical abortion
214917795|NCT00182611|PROCEDURE|neoadjuvant therapy|
214917796|NCT00826683|BIOLOGICAL|Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures|
214917797|NCT01156961|DRUG|bevacizumab [Avastin]|10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
214917798|NCT01156961|DRUG|paclitaxel|90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
214917799|NCT02881515|OTHER|Low Sodium Diet|Ten days of low sodium diet
214312803|NCT04576117|OTHER|Questionnaire Administration|Ancillary studies
214312804|NCT04576117|DRUG|Selumetinib Sulfate|Given PO
214312805|NCT04576117|DRUG|Vinblastine Sulfate|Given IV
214312806|NCT06957834|DRUG|Eflornithine hydrochloride cream|Eflornithine hydrochloride cream at 11.5% applied twice daily
214481402|NCT06836791|PROCEDURE|chemical cautrizating agents to stop epistaxis|All procedures were performed as office-based procedures under the influence of local anesthesia.Patients were treated with chemical cauterization. Prior to cauterization, 2 cotton packs soaked in 10% lignocaine spray were introduced into each nostril for 5-10 minutes. Then, a cotton-tipped applicator dipped in chemical cautrizating agents solution was applied to the bleeding point, and the sample was firmly pressed for 1 minute. In the case of bleeding, a second application of chemical cautrizating agents solution was applied to the area, after which a cotton tip applicator was applied to the area for 30 s with cauterization of all the feeding blood vessels around the bleeding point. This was followed by the prescription of an antiseptic soothing cream topically twice daily for 2 weeks.
214481403|NCT06836791|DRUG|Silver Nitrate|silver nitrate is chemical cautrizing agent ,in the study ,the investigators use it in treatment of anterior epistaxis in children by dissolving silver nitrate crystals in normal saline solution before using.
214481404|NCT06836791|DRUG|Trichloroacetic Acid Topical|trichloroacetic acid is well known peeling agent ,in the study the investigators use it as chemical cautrizing agent to treat anterior epistaxis in children .
214671164|NCT05797766|BEHAVIORAL|Fluid Distribution Timetable|a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
214671165|NCT05545397|DRUG|Propofol|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
214917800|NCT02881515|OTHER|Medium Sodium Diet|Ten days of a medium sodium diet
214917801|NCT02881515|OTHER|High Sodium Diet|Ten days of a high sodium diet
214917802|NCT06576609|DEVICE|INJEX [ Needle less anesthesia]|already described
214481405|NCT06857084|DEVICE|Arthroscopic rotator cuff repair with REGENETEN Bioinductive Implant augmentation|Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue.
214481406|NCT06671392|DRUG|DWC202405|5/20mg, 1 tablet, Oral, Once a day
214481407|NCT06671392|DRUG|DWC202405, DWC202314|5/20mg + 1.5mg, 1 tablet, Oral, Once a day
214481408|NCT06671392|DRUG|DWC202405, DWC202314P|5/20mg + 1.5mg, 1 tablet, Oral, Once a day
214481409|NCT06671392|DRUG|DWC202313, DWC202314|10/40mg + 1.5mg, 1 tablet, Oral, Once a day
214312807|NCT06957834|DRUG|Hydroquinone cream|Hydroquinone 2% cream, applied twice daily
214312808|NCT06390046|DRUG|TIVA versus Inhalation|comparing TIVA with genera anesthesia with inhalation agent
214312809|NCT04770896|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
214671166|NCT05545397|DEVICE|EEG montior|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
214917803|NCT02416609|RADIATION|LDR|LDR will be delivered during each cycle of Gem-based doublets
214917804|NCT02416609|DRUG|Gem-based doublets|4 cycles of Gem-based doublets
214917805|NCT02416609|RADIATION|SBRT|SBRT will be administered after the fourth Gem-based doblet cycle, if no progression; three fractions will be administered
214312810|NCT04770896|DRUG|Lenvatinib|Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of \< 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
214312811|NCT04770896|DRUG|Sorafenib|Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
214312812|NCT06001346|BEHAVIORAL|ActiveCBT|Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
214312813|NCT06001346|BEHAVIORAL|CalmCBT|Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
214312814|NCT05400278|OTHER|No intervention|No intervention
214917806|NCT06104254|OTHER|education|we will give an education to experimental group about pain and pain management.
214917807|NCT00439283|DRUG|infliximab|
214917808|NCT00439283|DRUG|methotrexate|
214917809|NCT05697354|PROCEDURE|Cognitive rehabilitation using interactive tablet|the cognitive rehabilitation exercises will be administered using the Khymeia VRRS Home Tablet. Patients will be asked to actively carry out exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
214312815|NCT05694650|BEHAVIORAL|Focus Group|Participants can meet with an interviewer alone. The focus group should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
214312816|NCT05694650|BEHAVIORAL|Interview|Participants can meet with an interviewer alone. The interview should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
214312817|NCT04542707|PROCEDURE|joint manipulation|Thrust manipulation to the spine, hand, and foot
214481410|NCT06671392|DRUG|DWC202313, DWC202314P|10/40mg + 1.5mg, 1 tablet, Oral, Once a day
214481411|NCT06885515|DIAGNOSTIC_TEST|leukocyte telomere length (LTL) will be measured using the Telomere Restriction Fragment (TRF) Analysis method|genomic DNA (2-5 µg) is digested overnight at 37°C with HinfI restriction endonuclease. Fragments are being separated on an agarose gel, transferred to a Hybond N+ membrane. The membrane is being hybridized over night at 50°C with a 5' end-labeled (AACCCT)3 oligonucleotide probe and with ladder probe of 1Kb ladder. Following membrane washes the membrane is exposed to PhosphoImager. The mean telomere length is calculated by the computer program Telotool \[19-20\]. TRF analysis will be conducted at the laboratory of Prof. Yehuda Tzfati at the Hebrew University, which is highly experienced in the field of telomere biology and in telomere length analysis. Blood samples will be taken once from each participant. no genetic sequencing will be performed as part of this study.
214481412|NCT06887790|OTHER|Education method (ARCS)|The control group will not be intervened in the study. The experimental group will be given structured training with the ARCS method.
214481413|NCT06842251|OTHER|Rotary Crown Down Technique|Root canal treatment with rotary instrument is done using crown down approach and post endodontic pain measured after 4,12,24,48 hours.
214481414|NCT06842251|OTHER|Manual Step Back Technique|Root canal treatment with manual instruments using step back technique and post endodontic pain measured at 4,12,24,48 hours .
214481415|NCT06866730|DEVICE|Serious game|Serious game in which participants manipulate instrumented toys
214481416|NCT06888245|OTHER|Non-animated Menstruation Education|Providing menstruation education to female secondary school students with Powerpoint support without animation.
214481417|NCT06888245|OTHER|Animated Menstruation Education|Providing menstruation education to female secondary school students with Powerpoint and animation support.
214481418|NCT06890052|OTHER|Targeted exercise program|Participants in the active comparator group will perform 25 sessions of isolated lumbar extension resistance exercise (ILEX) using a new machine-based device equipped with a pelvic restraint system to ensure targeted conditioning of the paraspinal muscles. The exercise will be supplemented by visual biofeedback displayed on a computer screen. A detailed protocol will be followed, incorporating an individualized, diagnosis-based range of motion and progressive resistance overload. The supervised 16-week program consists of two sessions per week for the first nine weeks, followed by one session per week for the remaining seven weeks.
214481419|NCT06890052|OTHER|Targeted exercise as part of an integrative therapy program|"Participants in the experimental group will perform 25 sessions of isolated lumbar extension resistance exercise (ILEX) using a new machine-based device equipped with a pelvic restraint system to ensure targeted conditioning of the paraspinal muscles. The exercise will be supplemented by visual biofeedback displayed on a computer screen.~A detailed protocol will be followed, incorporating an individualized, diagnosis-based range of motion and progressive resistance overload.~The supervised 16-week program consists of two sessions per week for the first nine weeks, followed by one session per week for the remaining seven weeks.~Each session is supplemented with general exercises for the back and trunk muscles (e.g., lat pulldown, abdominal crunch). In addition, participants will receive at least five sessions of therapy, which may include joint mobilization, tissue treatment, stress management, and other therapeutic modalities."
214481420|NCT06744244|DIAGNOSTIC_TEST|Olfactory Testing|Olfactory Test: Odor stimuli will be administered using a custom-designed olfactometer, developed by engineers specifically for this study. The olfactometer will release different odorants (maternal breast milk, vanilla essential oil, rose essential oil, and water as a control) in a controlled way. Each odor will be presented between 6 and 72 hours of life for 10 seconds (On), followed by a 50-second pause (Off) for a total of 15 cycles (On-Off). A new odor will be presented 5 minutes after the previous one. The first olfactory test will be conducted during the Video-EEG recording, and the second one will take place during the fMRI acquisition.
214481421|NCT06744244|DIAGNOSTIC_TEST|Heart rate (HR), Heart Rate Variability (HRV), Respiratory Rate (RR), peripheral oxygen saturation (SpO2)|Simultaneously with the presentation of odors, heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and peripheral oxygen saturation (SpO2) will be monitored and recorded. The onset of the odor will be recorded using a manual timer.
214481422|NCT06744244|DIAGNOSTIC_TEST|Video-EEG|The infant's Video-EEG, as per guidelines following perinatal asphyxia, will be recorded for approximately 2 hours, including the period preceding odor administration (baseline).
214312818|NCT04542707|PROCEDURE|Exercise|Strength training, bike aerobic training, and yoga exercise
214481423|NCT06744244|DIAGNOSTIC_TEST|fMRI|Newborns will undergo an fMRI, as part of routine clinical practice, to identify any brain injury, its extent, and the structures involved. The use of a custom-built fMRI compatible olfactometer will facilitate these studies.
214312819|NCT04542707|DEVICE|Soft tissue massage|Graston tool
214312820|NCT04517552|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] CS1P1. Participants will then undergo a \[11C\] CS1P1 PET/CT scan.
214312821|NCT06333262|DRUG|Pirtobrutinib|"Initial treatment:~\- Pirtobrutinib 200 mg by mouth (PO) daily from Cycle 1 Day 1 until the end of Cycle 12. Each cycle is 28 days.~Re-treatment:~-Pirtobrutinib 200 mg PO daily continuously"
214312822|NCT06333262|DRUG|Obinutuzumab|"Obinutuzumab is given intravenously from Cycle 7 to Cycle 12, for total 6 cycles during initial treatment only.~Initial treatment:~\- Obinutuzumab intravenous (IV) following the standard schedule from Cycle 6 through Cycle 12 (total 6 cycles: 100 mg on Cycle 6 Day 1, 900 mg on Cycle 6 Day 2, 1000 mg on Cycle 6 Day 8 and Cycle 6 Day 15, 1000 mg on Day 1 of Cycle 7 through Cycle 12)."
214312823|NCT04409821|BEHAVIORAL|Tele-delivered psychological intervention|The intervention consists of two (or one, if preferred by caregivers) weekly tele-sessions during the ICU stay, lasting up to 30 minutes, and two sessions in the month after discharge from or death in the ICU. Sessions will be conducted via phone-calls or video-conferencing. Therapists will 1) validate caregivers' subjective experience, 2) normalize and psychoeducate about emotional reactions, and 3) offer emotion regulation drawing on contemporary cognitive treatment packages of decentering, acceptance and emotion tolerance. Sessions for bereaved caregivers will include psycho-education about grief, assessment of risk for adverse outcomes and information about available support, if needed. The intervention will be performed based on an intervention manual. The content of the intervention will be continually adapted and tailored to the needs of the participating caregivers by involving all caregivers in co-creating the intervention trough brief post-session interviews.
214312824|NCT05062629|GENETIC|Whole Genome Sequencing|Whole Genome Sequencing
214481424|NCT06744244|DIAGNOSTIC_TEST|Neurodevelopment assessment|Between 12 and 18 months, the infants will undergo neurodevelopmental follow-up, during which the Bayley III assessment will be administered to evaluate any potential neurocognitive deficits.
214481425|NCT06744166|DEVICE|TENS-WAA|Patients assigned to the TENS-WAA group will receive transcutaneous electrical nerve stimulation based on Wrist-Ankle Acupuncture theory for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively. According to the principles of WAA, two pairs of TENS-WAA (Wuxi Jiajian Medical Device Co., Ltd.) electrode pads will be placed on the upper area 2 and 3 with the skin of the treatment area exposed, and the upper and lower juxtaposition method will be adopted. Upper area 2 is at the middle of the palmar side of the forearm, between the palmaris longus and flexor carpi radialis. Upper area 3 is between the edge of the radius and the radial artery. Stimulation parameters of TENS-WAA are alternating dense-disperse wave with a frequency of 2Hz and a pulse width of 200μs, and a frequency of 100Hz with a pulse width of 150μs, alternating every 3 seconds ，intensity required to reach the maximum tolerable level without causing pain.
214481426|NCT06744166|DEVICE|Sham (No Treatment)|Patients assigned to the sham TENS-WAA group will receive sham stimulation for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively. Researchers will attach the electrode patches at the same location, set the parameters to the same frequency, pulse width, and minimum current intensity as the TENS-WAA group, but do not activate the device, leaving it in place for 30 minutes at each time point.
214481427|NCT04835935|OTHER|microbiome pattern|microbiome pattern in neonatal period
214481428|NCT03937661|BIOLOGICAL|PRP|Autologous PRP intra ovarian infusion
214481429|NCT03937661|BIOLOGICAL|Placebo|Autologous PFP intra ovarian infusion
214671167|NCT05013528|OTHER|Bal-A-Vis-X training|"Bal-A-Vis-X training Performed thrice a week for 10 minutes after baseline assessment Standard Physical therapy treatment along with following exercises.~1. ball Rectangle~2. ball rectangle and 2 ball drop/pass/catch two-foot jumping forward, tandem walking on ground and tandem walking on the balance beam. ."
214671168|NCT05013528|OTHER|Aerobic Training Group|"Aerobic training group performed exercises thrice a week for 10 minutes after baseline assessment.~Standard Physical therapy treatment along with aerobic training as Running is performed"
214917810|NCT05697354|PROCEDURE|Cognitive rehabilitation using smartphone App Medico Amico|the cognitive rehabilitation exercises will be administered through patients' smartphone using the Medico Amico App. Patients will be asked to observe and concentrate on exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
214917811|NCT03491462|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
214917812|NCT03491462|DRUG|Placebo|2 matched placebo capsules taken 3 times daily
214917813|NCT02262520|DRUG|Apixaban|
214917814|NCT02262520|DRUG|Digoxin|
214917815|NCT02309762|DRUG|FB825|FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
214917816|NCT02309762|DRUG|Placebo|Solution containing no active ingredients
215060890|NCT05466136|BEHAVIORAL|Control condition|Similar to mental fatigue conditions, the modified Stroop task with complete congruent trials will be used, The Stroop task also included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), but the color of the word will paint consistent with the semantic meaning of the word (e.g., red word printed in red) in order to set up the match condition of relative less cognitive demanding for participants. Same with the mental fatigue condition, the task consisted of five 6-minute blocks and 1080 congruent trials for each block. The total duration will be 30-min.
215060891|NCT02894723|DIETARY_SUPPLEMENT|L-arginine|30 ml arginoline contains 5 gr l-arginine
215060892|NCT02894723|DIETARY_SUPPLEMENT|syrup|The same bottle of the experimental group, but without l-arginine
214671169|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.15 mg/m\^2 administered on Days 1, 8, 15 of 28-day cycle.
214917817|NCT00740792|DRUG|azelastine HCl/fluticasone propionate|azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
214917818|NCT00740792|DRUG|azelastine Hcl|azelastine Hcl 548 mcg one spray per nostril BID
214917819|NCT00740792|DRUG|fluticasone propionate|fluticasone propionate 200 mcg one spray per nostril BID
214917820|NCT00740792|DRUG|placebo|placebo one spray per nostril BID
214917821|NCT03900169|GENETIC|Genetic|Lipid profile
214917822|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 1.1 Usage|Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
214917823|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 1.2 Usage|Participants will use their Radicle Calm Active Study Product 1.2 as directed for a period of 6 weeks.
214917824|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 1.3 Usage|Participants will use their Radicle Calm Active Study Product 1.3 as directed for a period of 6 weeks.
214917825|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214917826|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
214917827|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 2.1 Usage|Participants will use their Radicle Calm Active Study Product 2.1 as directed for a period of 6 weeks.
214917828|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
214481430|NCT06871475|BIOLOGICAL|sticky bone with coronally advanced flap|using sticky bone with coronally advanced flap in treating the gingival recession
214481431|NCT06871475|PROCEDURE|coronally advanced flap|using coronally advanced flap alone in treating gingival recession
214312825|NCT06780969|BEHAVIORAL|Green Mother Training|Poster education
214312826|NCT03709264|DRUG|Amino Acids|Patients randomized to experimental arm receive a continuous infusion of a balanced mixture of amino acids in a dose of 2 g/kg ideal body weight/day (to a maximum 100 g/day) from the operating room admission up to either death, start of RRT, ICU discharge or 72 hours after treatment initiation, trough a central venous line
214312827|NCT03709264|DRUG|Placebos|Placebo: standard treatment
214312828|NCT00178659|OTHER|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
214481432|NCT06725186|BEHAVIORAL|RELAX|The RELAX intervention is a social-emotional intervention consisting of 8 weekly, 1.5 hr sessions and a booster session 1 month and 6 months after the completion of RELAX. During the first 60 minutes of RELAX sessions, parents and adolescents meet separately; during the last 30 minutes combined parent-adolescent discussion and problem-solving activities take place. RELAX is structured such that parents learn emotion regulation/coping skills the week prior to them being taught to the adolescents. Group sessions will involve both didactics and discussion of topics including psychoeducation, basic cognitive/behavioral principles, emotional awareness, emotion regulation strategies, parent emotion socialization practices, coping skills, conflict management strategies, and communication skills.
214481433|NCT06725186|BEHAVIORAL|Psychoeducational Materials|Infographics with information on emotion regulation development, emotion regulation strategies, and strategies for managing interpersonal conflict, including when different strategies are more or less effective will be provided to participants via email.
214671170|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.37 mg/m\^2 administered on Days 1 and 8 of 21-day cycle.
214917829|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 3.1 Usage|Participants will use their Radicle Calm Active Study Product 3.1 as directed for a period of 6 weeks.
214917830|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
214917831|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 4.1 Usage|Participants will use their Radicle Calm Active Study Product 4.1 as directed for a period of 6 weeks.
214917832|NCT01709682|DRUG|Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)|propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
214917833|NCT01709682|PROCEDURE|re-ablation procedure|Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
214917834|NCT01709682|PROCEDURE|ILR implantation|"The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events."
214917835|NCT01050582|DRUG|Risperidone|As per local prescribing practices
214917836|NCT01050582|DRUG|Other atypical antipsychotic drugs|As per local prescribing practices
215060893|NCT05912894|PROCEDURE|Videolaparoscopic cholecystectomy|Evaluation of Rouvière's Sulcus Anatomical Variation.
214312829|NCT00060996|DRUG|Remodulin® (treprostinil sodium) Injection|
214312830|NCT00393679|DRUG|amodiaquine-artesunate (ASAQ)|A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
214481434|NCT06869733|OTHER|Scooping Mobilization|Group A treated with only scooping mobilization with frequency of 2 to 3 times in a week for consecutive 4 weeks.
214312831|NCT00393679|DRUG|dihydroartemisinin-piperaquine (DHAPQ)|DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
214312832|NCT00393679|DRUG|artemether-lumefantrine (AL)|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
214312833|NCT00393679|DRUG|Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)|"Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
214481435|NCT06869733|OTHER|Scooping Mobilization with Scapulothoracic mobilization|Group B treated with scooping mobilization with scapulothoracic mobilization, which was given 2 to 3 times in a week for consecutive 4 weeks.
214481436|NCT06856356|PROCEDURE|Robot-assisted surgery|Orthopedic surgeons perform total knee arthroplasty using an orthopedic joint surgery navigation system
214481437|NCT06856356|PROCEDURE|Conventional total knee arthroplasty|Orthopedic surgeons perform total knee arthroplasty using a 4 in 1 osteotomy guide
214671171|NCT03411603|OTHER|Diet and socio-demographic questionnaires|24-hr recall or food diary questionnaires; socio-demographic questionnaires
214671172|NCT02075164|DIETARY_SUPPLEMENT|Fructose|High oral Fructose challenge (150g per day for 56 days)
214671173|NCT02075164|DIETARY_SUPPLEMENT|Glucose|Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
214671174|NCT02424149|DRUG|Phenazopyridine|
215060894|NCT02119429|DIETARY_SUPPLEMENT|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
215060895|NCT02119429|DIETARY_SUPPLEMENT|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
214312834|NCT02373358|BEHAVIORAL|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety \& boundaries, strength \& power, assertiveness, intuition, trust, \& community) using mindfulness, breath work, and physical yoga poses.
214312835|NCT03650010|PROCEDURE|Total ankle replacement|total ankle prosthesis through a lateral or an anterior approach
214312836|NCT02366832|PROCEDURE|Cryoablation|Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
214312837|NCT02366832|DEVICE|17g Galil Medical Ice Sphere cryoablation needle|Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
214312838|NCT02613533|OTHER|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
214312839|NCT04891939|OTHER|Health education lessons (Smart-Kid's program)|The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So \& Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
214312840|NCT04891939|OTHER|School Health and Education Program (SHEP)|The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
214312841|NCT00378313|DRUG|gemcitabine, epirubicin, paclitaxel|
214312842|NCT06358456|DRUG|Artificial tear|Application of low viscosity artificial tears (Artelac EDO). The active ingredient is hypromellose (1.92 mg per 0.6 ml container).
214312843|NCT06358456|OTHER|No artificial tears|Before artificial tear application, 2 baseline measurements were taken of the cornea without any intervention
214312844|NCT06375057|PROCEDURE|laparoscopic cholecystectomy|A blood sample is taken the day after surgery
214312845|NCT03135041|DIETARY_SUPPLEMENT|Fiber-containing dietary supplement|Effects of fiber-containing dietary supplement on weight loss during energy restriction
214312846|NCT03135041|DIETARY_SUPPLEMENT|Placebo|Effects of placebo supplement on weight loss during energy restriction
214312847|NCT02376946|DEVICE|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
214312848|NCT02376946|DEVICE|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
214312849|NCT05140577|OTHER|Maximal voluntary isometric strengthening|The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds
214312850|NCT02558790|DRUG|L-Threonic Acid Magnesium Salt (L-TAMS)|
214917837|NCT04065984|DEVICE|Microstim 2v2 Stimulator|Neuro-muscular electrical stimulator portable device (9v battery) connected to the skin participant over the muscle body of choice using self adhesive electro-gel pads. Treatment devices and placebo devices.
214312851|NCT06492811|DRUG|GAT@F nanoenzyme hydrogel complex|The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
214312852|NCT04490434|DRUG|DWP14012|DWP14012 40mg, bid
214312853|NCT04490434|DRUG|Celecoxib|Celecoxib 200mg, bid
214312854|NCT04490434|DRUG|Naproxen|Naproxen 500mg, bid
214481438|NCT06876701|DRUG|Bevacizumab|Evaluation of the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
214481439|NCT06859021|OTHER|follow up call|A follow-up call is made to the patient 30 days (+ 5 days) after inclusion to check for the occurrence of an Major Cardio Vascular Event.
214917838|NCT03195621|DEVICE|Stent implantation|Stent placement after risk factors assessment plus FFR or ultrasound or OCT detection for critical lesions.
214917839|NCT00795002|DRUG|alvocidib|Given IV
214917840|NCT00795002|DRUG|mitoxantrone hydrochloride|Given IV
214312855|NCT04490434|DRUG|Meloxicam|Meloxicam 15mg, qd
214312856|NCT05477875|DRUG|oral cannabinoid|dronabinol
214312857|NCT05477875|COMBINATION_PRODUCT|oral codeine/acetaminophen|10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
214312858|NCT03961100|DRUG|Entrectinib 600 mg (T1)|Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
214312859|NCT03961100|DRUG|Entrectinib 600 mg (T2)|Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
214312860|NCT03961100|DRUG|Entrectinib 200 mg (R)|Reference formulation (R): entrectinib hard capsules
214312861|NCT03961100|DRUG|Entrectinib 200 mg (T)|Test formulation (T): entrectinib HPMC capsules
214917841|NCT00795002|DRUG|cytarabine|Given IV
214312862|NCT02990169|DEVICE|CATS tonometer prism|IOP tonometer prism for assessment of intraocular pressure
214312863|NCT02990169|DEVICE|Goldmann Tonometer prism|IOP tonometer prism for assessment of intraocular pressure
214312864|NCT02342340|OTHER|Navy Beans (cooked)|One time consumption of 3/4 cup of cooked navy beans.
214917842|NCT00795002|OTHER|pharmacological study|Correlative studies
214917843|NCT00795002|OTHER|laboratory biomarker analysis|Correlative studies
214917844|NCT00943540|DRUG|raltegravir QD|Raltegravir 800mg QD
214917845|NCT00943540|DRUG|atazanavir|atazanavir
214917846|NCT00943540|DRUG|lamivudine (or emtricitabine)|lamivudine (or emtricitabine)
214917847|NCT01605240|DRUG|Acetaminophen and Ibuprofen|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
214312865|NCT02342340|OTHER|Red Kidney Beans (cooked)|One time consumption of 3/4 cup of cooked red kidney beans.
214312866|NCT02342340|OTHER|Pinto Beans (cooked|One time consumption of 3/4 cup of cooked pinto beans.
214312867|NCT02342340|OTHER|Black Beans (cooked)|One time consumption of 3/4 cup of cooked black beans.
214312868|NCT02342340|OTHER|Lentils (cooked)|One time consumption of 3/4 cup of cooked lentils.
214312869|NCT02342340|OTHER|White Rice|One time consumption of 3/4 cup of cooked white rice.
214312870|NCT02311439|DRUG|FOLFIRINOX + CRT|"Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator."
214312871|NCT05929092|PROCEDURE|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, the TFBC regimen (TBI/Flu/Bu/Cy) combined with UCBT is safe and feasible for the treatment of patients with high-risk malignant hematological diseases, which has enormous potential to improve patient outcomes.
214312872|NCT03725189|DEVICE|PPG during exercise|PPG use for pulse waveform evaluation of healthy exercise group
214312873|NCT02985632|DRUG|BMS-986141|
214481440|NCT06876155|PROCEDURE|Arm 1: The anaesthesiologically performed, ultrasound-guided, 4 quadrant-TAP block ( a combination of a lateral with a subcostal TAP block bilaterally)|Injection of a total of 60 ml ropivacaine 0.2% into the target compartment (2x 20 ml laterally, 2x 10 ml subcostally)
214481441|NCT06876155|PROCEDURE|Arm2: The surgically performed, laparoscopic landmark-based assisted TAP block|Injection of a total of 6 x 10 ml = 60 ml ropivacaine 0.2% into the target compartment (at 3 defined puncture sides bilaterally: at the anterior axillary line at 2 different, fixed heights and at the midclavicular line subcostally)
214671175|NCT04708990|DEVICE|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
214917848|NCT01605240|DRUG|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
214917849|NCT02949440|PROCEDURE|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.
214312874|NCT00661076|DRUG|adefovir dipivoxil|10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
214312875|NCT00661076|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 48 weeks
214481442|NCT06760260|DRUG|Human Derived anti-CI135 CAR-T Injection|Autologous genetically modified anti-CI135 CAR transduced T cells
214481443|NCT06815458|OTHER|Nursing education|Mind mapping based learning
214917850|NCT02949440|PROCEDURE|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
214917851|NCT06499038|PROCEDURE|Total Hip Arthroplasty|Surgery for total hip replacement
214917852|NCT05484999|OTHER|Meals|12 weeks of medically tailored meals
214917853|NCT05484999|OTHER|Meals + Social Support|12 weeks of medically tailored meals and12 weeks of social media based support
214917854|NCT05484999|OTHER|Control|Waitlist Control Group (no intervention for first 4 months and then receive MamaMeals between 16-20 weeks postpartum)
214917855|NCT04162431|DIAGNOSTIC_TEST|spectroscopic measurement|measurement of the tissue with spectroscopy
214312876|NCT03425812|DRUG|To withdraw NSAIDs therapy|NSAIDs therapy will be withdrew after washout period.
214312877|NCT03425812|DRUG|To continue NSAIDs therapy|NSAIDs therapy will be continued.
214312878|NCT05413252|OTHER|Practice Facilitation|Practices will be assigned a practice facilitator who will support practices in implementing all practice redesign components associated with TBC for HTN management.
214312879|NCT01166685|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
214312880|NCT01166685|DEVICE|Bare-metal stent|Bare metal stent
214312881|NCT01166685|DEVICE|Biodegradable Polymer-DES|drug-eluting stent with bioabsorbable polymer
214312882|NCT01301872|OTHER|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
214481444|NCT06814535|DRUG|Botulinum Toxin A / Botulinum Toxin A|Botulinum toxin type A
214481445|NCT06814535|DRUG|Platelet rich plasma|Plasma that contains concentrated platelets
214671176|NCT04316481|DEVICE|AngelMed Guardian System|The AngelMed Guardian System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events. The Guardian System is indicated as an adjunct to patient recognized symptoms.
214671177|NCT02283944|DEVICE|TMS|Pulsed non-invasive brain stimulation using electromagnets
214312883|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
214312884|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
214312885|NCT03689361|COMBINATION_PRODUCT|MRI|Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion).
214312886|NCT03689361|DIAGNOSTIC_TEST|MRI control|MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion)
214312887|NCT03689361|OTHER|telephone consultation|telephone consultation
214312888|NCT03898349|OTHER|Annie text messaging system|Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
214312889|NCT03898349|OTHER|Annie text messaging system with Usual implementation|"Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls"
214312890|NCT03898349|OTHER|Annie text messaging system with Augmented implementation|"Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance"
214312891|NCT05620576|DRUG|LY3857210|Administered orally
214312892|NCT05620576|DRUG|Placebo|Administered orally
214312893|NCT00165490|DRUG|Cetuximab|Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
214312894|NCT00165490|DRUG|Cisplatin|Given once per week on weeks 1, 2, 4,and 5.
214312895|NCT00165490|DRUG|Irinotecan|Given once per week on weeks 1, 2, 4,and 5.
214481446|NCT06814535|DRUG|Saline -- placebo comparator|Physiological saline .9 %
214481447|NCT06856967|DRUG|Nirsevimab|Evaluation of drug exposure in cases and controls
214671178|NCT03379350|PROCEDURE|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
214917856|NCT04162431|DIAGNOSTIC_TEST|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
214917857|NCT04162431|DIAGNOSTIC_TEST|histopathology and cytology|Histopathology and cytology will be performed on the samples
214917858|NCT00000945|DRUG|Cidofovir|
214917859|NCT00000945|DRUG|Probenecid|
214312896|NCT00165490|DEVICE|Radiation therapy|Once daily for 28 treatments (5 1/2 weeks)
214312897|NCT00165490|PROCEDURE|Surgery|Surgery performed 4-8 weeks after chemoradiation therapy.
214312898|NCT03367143|DRUG|Lenalidomide|
214312899|NCT03367143|DRUG|Ifosfamide|
214312900|NCT03367143|DRUG|Carboplatin|
214917860|NCT01859169|PROCEDURE|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
214917861|NCT00534781|DEVICE|plasma microdebrider|Coblation of the Achilles
215060896|NCT04751994|DIETARY_SUPPLEMENT|Iron drops/Ferrous sulphate|participant will consume daily drops of iron
215060897|NCT04751994|DIETARY_SUPPLEMENT|Placebo drops|Participants will consume daily drops of placebo
215060898|NCT01455922|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
214312901|NCT03367143|DRUG|Etoposide|
214312902|NCT02262481|DRUG|dydrogesterone|
214312903|NCT02262481|DRUG|placebo|
214312904|NCT01510119|DRUG|Hydroxychloroquine|
214312905|NCT01510119|DRUG|RAD001|
214481448|NCT06735170|PROCEDURE|biologic tuberoplasty|a surgical procedure during which an a cellular dermal allograft is attached to the greater tuberosity to prevent bone-to-bone contact between the greater tuberosity and the acromion with the goal of decreasing pain
215060899|NCT01455922|DRUG|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
214312906|NCT02721316|OTHER|Supported with intensive nursing follow post hospitalization|Intensive nursing follow post - hospitalization
214312907|NCT03721419|DEVICE|High Flow High Humidity device|High Flow High Humidity device has a flow generator built into the body of unit and can deliver flows between 10 to 60 Liters per minute (LPM) with oxygen bled in as needed in order to deliver specified Fraction of inspired Oxygen (FiO2)
214312908|NCT03721419|DEVICE|Low Flow High Humidity device|Standard high humidity trach collar utilizing venturi device bleed in
214312909|NCT00355186|PROCEDURE|intracoronary bone marrow cells infusion|"intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described"
214312910|NCT03476083|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.|All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
214481449|NCT06735170|PROCEDURE|subacromial balloon spacer|a biodegradable balloon is inserted into the subacromial space of the shoulder to increase teh distance between the greater tuberosity and the acromion to reduce pain
214481450|NCT06760299|OTHER|%25 tension Kinesio tape|"I shaped Kinesio tape application with 25% tension"
214481451|NCT06760299|OTHER|75% tension Kinesio tape|"I shaped Kinesio tape application with 75% tension"
214312911|NCT02769416|OTHER|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
214312912|NCT02811939|DRUG|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally
214312913|NCT02811939|DRUG|Active Pregnenolone|1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)
214312914|NCT02811939|DRUG|Placebo Dronabinol|Control: Placebo pill (no active cannabinoids) administered orally
214312915|NCT02811939|DRUG|Placebo Pregnenolone|Control: Placebo given sublingually (under the tongue)
214312916|NCT01735656|DEVICE|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
214312917|NCT06310577|DEVICE|Leak-free bronchoscope adapter|Bronchoscopy using both a standard adapter and a leak-free adapter will be performed.
214312918|NCT05437289|DRUG|AZD7442 IM|In cohort 1, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) administered sequentially as direct gluteal IM injections.
214312919|NCT05437289|DRUG|Placebo IM|In cohort 1, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
214312920|NCT05437289|DRUG|AZD7442 IM|In cohort 2, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) administered sequentially as direct gluteal IM injections.
214312921|NCT05437289|DRUG|Placebo IM|In cohort 2, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
214481452|NCT06813170|DIETARY_SUPPLEMENT|Metarecod|Policaptil Gel Retard: Metarecod®. The medical device will be given as 1 sachet twice daily
214481453|NCT06813170|OTHER|Diet|Diet program will be planned to achieve a ≥8% body weight relative reduction over 12 months and tailored calculating a 20% caloric relative decrease from habitual energy intake, corresponding to an average energy deficit of approximately 500 kcal/daily (approximately a total of 1,200-1,500/daily Kcal for women and 1,500-1,800/daily Kcal for men), with \<30% of total calories from fat (\<10% from satured fats) and at least 15% of total calories from proteins. For carbohydrate intake, low glycemic index food will be preferred to high glycemic index food, to prevent higher post prandial glycemic excursions
214481454|NCT06940739|BIOLOGICAL|IOV-3001|IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting.
214481455|NCT06143046|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
214312922|NCT05437289|DRUG|AZD7442 IV|In cohort 3, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
214312923|NCT05437289|DRUG|Placebo IV|In cohort 3, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
214312924|NCT05437289|DRUG|AZD7442 IV|In cohort 4, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
214481456|NCT06143046|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214481457|NCT06783829|DRUG|SHR4394|SHR4394
214481458|NCT04868877|DRUG|MCLA-129|full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
214481459|NCT04868877|DRUG|Osimertinib|Approved, 3rd-generation EGFR-TKI
214481460|NCT04868877|DRUG|Chemotherapy|administrated by IV infusion
214312925|NCT05437289|DRUG|Placebo IV|In cohort 4, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
214312926|NCT02975921|DRUG|Povidone-Iodine|Intrapleural administration of Povidone-Iodine
214312927|NCT02980965|DRUG|letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel|Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
214312928|NCT02980965|DRUG|fluorouracil, epirubicin, cyclophosphamide, docetaxel|Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
214481464|NCT06628687|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
214312929|NCT04115943|OTHER|Treatment protocol for neck pain|The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
214312930|NCT04115943|OTHER|Protocol for release of tongue muscles|. The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
214312931|NCT05398978|OTHER|e-Registration and mHealth|Registration to the electronic database Counseling through voice calls for facility delivery Text messages to promote facility delivery
214312932|NCT01885091|OTHER|Kinerase|
214312933|NCT05652166|OTHER|telephone interview|telephone call to parents to know the information given following the ingestion of foreign body by their child
214312934|NCT02681549|DRUG|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
214312935|NCT01462669|DRUG|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
214312936|NCT01462669|DRUG|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
214312937|NCT01462669|DRUG|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
214312938|NCT01462669|DRUG|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
214312939|NCT02397863|DRUG|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
214312940|NCT03532464|DRUG|azithromycin|The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
214312941|NCT03532464|DRUG|doxycycline|The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
214312942|NCT03952169|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
214917862|NCT00534781|PROCEDURE|Mechanical Surgical Debridement|Surgical Debridement of the Achilles
214312943|NCT03952169|OTHER|Placebo controls|placebo with a similar appearance to probiotics supplement
214312944|NCT02927028|OTHER|Chewing|"On the first visit, the random nut treatments will include chewing walnuts, almonds and pistachios. The chewing conditions will include: 1) 5 g nuts alone, 2) 5 g nuts with 5 ml water, 3) 5 g nuts with 5 ml apple juice, 4) 5 g nuts with 5 g plain yogurt, 5) 5 g nuts with 5 g sweet yogurt.~On visits 2 and 3 the treatments of either 28 g of walnuts or walnut butter will be presented."
214312945|NCT01421784|OTHER|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
214312946|NCT03666169|OTHER|Survey|Survey
214312947|NCT02965443|DRUG|Dapagliflozin 10 mg + Saxagliptin 5 mg|24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
214312948|NCT02965443|DRUG|Placebo 1 10 mg + Placebo 2 5 mg|24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
214312949|NCT04586803|DRUG|SHR4640|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
214312950|NCT03570866|DIAGNOSTIC_TEST|Positron emission tomography and computed tomography|Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.
214312951|NCT03570866|PROCEDURE|Surgical treatment|Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
214312952|NCT06116331|OTHER|Data collection|Participants will answer questionnaires and submit stool samples.
214312953|NCT01299831|BEHAVIORAL|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
214312954|NCT01299831|BEHAVIORAL|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
214312955|NCT01299831|DRUG|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
214312956|NCT01299831|DRUG|Olbetam|"The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours."
214917863|NCT01156623|PROCEDURE|EBUS-TBNA|All included patients received TBNA for lymph node study via a flexible ultrasonic bronchoscope with a linear scanning probe on the tip (BF-UC206F-OL8, Olympus). The curved-probe scanned parallel to the insertion direction of bronchoscope, and the obtained images were linked to the ultrasound scanner (EU-2000C, Olympus) incorporated with Doppler-flow imaging. Each lymph node greater than 5mm in short axis measured by cursors was selected for subsequent TBNA with a 22-gauge (NA-201SX-4022, Olympus) needle in a condition of real-time EBUS guidance. A cytology examination was sent for pathologist blinded for the clinical history and image result of patients. When a tissue core was obtained by TBNA, the specimen was also sent for pathology study.
214481465|NCT05743231|PROCEDURE|interpectoral area block + serratus anterior area block group|The interpectoral and serratus anterior area blocks will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used for two blocks.
214481466|NCT04198129|DRUG|Antibiotic treatment (Unasyn or Cleocin)|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
214481467|NCT04198129|DRUG|Antibiotic treatment (Augmentin or Cleocin)|the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
214312957|NCT04713124|BEHAVIORAL|R2C-M|R2C-M comprises 12 modules addressing core practice elements and skills from evidence-based cognitive and behavioural interventions. Modules include: (i) self-monitoring, goal setting and behaviour change skills; (ii) identification of strengths and motivational enhancement; (iii) relapse prevention; (iv) psychoeducation and harm reduction; (v) emotion regulation skills; (vi) anger management skills; (vii) urges and cravings management skills; (viii) sleep hygiene skills; (ix) mindfulness skills; (x) interpersonal skills; (xi) anxiety management skills; (xii) depressed mood management skills. The R2C-M workbooks contain psychoeducation and intervention exercises, to facilitate counsellor-delivered exercises within sessions, and between-session practice.
214312958|NCT04713124|OTHER|Self-help booklet|A booklet of information and self-help strategies for methamphetamine use problems.
214312959|NCT01147861|DRUG|GSK256073|5mg in the AM and 5mg in the PM
214312960|NCT01147861|DRUG|GSK256073|10mg in the AM
214312961|NCT01147861|DRUG|GSK256073|50mg in the AM
214312962|NCT01147861|DRUG|GSK256073|25mg in the AM and 25mg in the PM
214312963|NCT01147861|OTHER|Placebo|2 placebo tablets in the AM and 2 placebo tablets in the PM
214312964|NCT06484998|BEHAVIORAL|Dental anxiety level and child's compomer colors selection|Patients without any syndromes or systemic disorders, without mental retardation, who needed restorative treatment for primary molars were included in the study. The examination forms of 275 patients requiring restorative treatment of primary teeth were analysed at the session they came for restorative treatment. To determine the child's anxiety, the Modified Child Dental Anxiety Scale-faces version was administered to the children before restorative treatment. The children were asked to choose from a scale consisting of 9 colours (pink, blue, gold, silver, orange, yellow, green, purple, white) for the compomer restoration color selections. The patients were asked what their favourite color was after the compomer restoration color selection so that the previous question would not have any effect on the child's restoration color selection.
214312965|NCT00946426|OTHER|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
214312966|NCT03930888|DIETARY_SUPPLEMENT|Dietary supplement|Patients with preoperative nutritional support with special nutritional supplements vs. patients without special nutritional support.
214312967|NCT06276959|DIAGNOSTIC_TEST|intraoral scanning|The patients underwent intraoral scanning using an iTero Element 5D imaging system (Align Technology, San Jose, CA, USA). This imaging system uses near-infrared light with a wavelength of 850 nm and provides multiple layers of data in a single scan, including a three-dimensional (3D) model, two-dimensional (2D) color images, and NIRI mapped to the 3D model
214481468|NCT04198129|OTHER|Control Group|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
214481469|NCT03586453|DRUG|Osimertinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~* Osimertinib: Oral, Daily 28 day cycle.~* Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~* Tumor biopsy between C4 and C8 and at disease progression"
214917864|NCT01543035|DRUG|stop statin and switch to an antiretroviral drug with less impact on lipid metabolism|Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
214312968|NCT06276959|DIAGNOSTIC_TEST|clinical oral examination|Under illumination in the dental unit, a UVE of the proximal surfaces of the patient's entire dentition was conducted by clinicians using a mouth mirror, dental probe, and an air-water syringe. Visual and tactile methods were performed according to the guidelines of the American Dental Association. Clinicians assessed the soundness of the proximal surfaces based on the presence of discoloration, surface alterations, or cavitation.
214312969|NCT06276959|DIAGNOSTIC_TEST|cone-beam computed tomography|All enrolled patients underwent CBCT scans because clear aligner treatment required real root/bone visualization features. We would like to clarify that due to the retrospective cross-sectional nature of this study, the patients involved were not subjected to radiation beyond what was initially necessary for their orthodontic treatment.
214312970|NCT05877092|DEVICE|implants with overdentures|two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.
214312971|NCT00455507|DRUG|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
214481470|NCT06562712|PROCEDURE|Conventional management|Patients will be subjected to conventional management for placenta accreta spectrum.
214481471|NCT06562712|PROCEDURE|Bilateral internal iliac artery balloon occlusion|Patients will be subjected to bilateral internal iliac artery balloon occlusion for placenta accreta spectrum.
214481472|NCT06427434|OTHER|Strengthening and stretching exercises to the back and abdominal muscles|Strengthening and stretching exercises to the back and abdominal muscles will be performed for 30 min, three times per week for 4 weeks.
214481473|NCT06427434|OTHER|Modified Lumbar Sustained Natural Apophyseal Glide|Modified Sustained Natural Apophyseal Glide will be applied on the affected lumbar level for 30 sec three times per week for 4 weeks.
214481474|NCT05620875|DIAGNOSTIC_TEST|Cerebral injury markers|Blood tests at given time points perioperatively.
214481475|NCT05620875|DIAGNOSTIC_TEST|Cerebral oximetry index|Cerebral oximetry index measurements with the aid of Near Infrared Spectroscopy
214917865|NCT00912743|DRUG|olaparib|400 mg po bid continuously
214917866|NCT01615406|DRUG|99mTc MIP 1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
214917867|NCT03447561|BEHAVIORAL|Anticipatory + consummatory food reward|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake).
214917868|NCT03447561|BEHAVIORAL|Consummatory food reward|Exposure to consummatory food reward (drinking sips of chocolate milkshake).
214917869|NCT00694083|DRUG|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles)
214917870|NCT00570193|DRUG|verteporfin (Visudyne)|Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
214917871|NCT00570193|DRUG|ranibizumab (Lucentis)|ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33\&37 per study protocol
214917872|NCT00984893|DRUG|zoledronic acid|
214917873|NCT00984893|DRUG|Any oral bisphosphonates marketed in Canada|
214917874|NCT02682693|DRUG|Denosumab|Denosumab 120 mg every 4 weeks for 6 cycles
214917875|NCT02682693|DRUG|nab-Paclitaxel|nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
214917876|NCT02682693|DRUG|Epirubicin|Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
214917877|NCT02682693|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
214917878|NCT02682693|DRUG|Carboplatin|Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
214917879|NCT02682693|DRUG|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
214917880|NCT02682693|DRUG|Pertuzumab|Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
214917881|NCT05708872|BEHAVIORAL|Autohypnosis|Patients in the study group will receive a voice recording with hypnotic instructions with a suggestion to improve the psychophysical state.
214917882|NCT05708872|BEHAVIORAL|Relaxing music|Patients in the control group will receive a recording with relaxing music
214917883|NCT00775801|DEVICE|FLD|Artificial lumbar disc
214917884|NCT00775801|DEVICE|Control|Artificial lumbar disc
214917885|NCT01848912|DEVICE|Zephyr Biopatch Device|
214917886|NCT01672541|BEHAVIORAL|Dating Matters Comprehensive Approach|"The Dating Matters Comprehensive Approach includes:~6th, 7th, and 8th grade Student Curricula; Parent Programs for parents of 6th, 7th, and 8th graders; A communications campaign involving brand ambassadors, a text message campaign, and social media campaign; An online training about teen dating violence for educators; Developmental component: A guidance document for sites on assessing and informing local policies relevant to teen dating violence for comprehensive schools (likely to be substantial cross and within site variation on this component)"
214917887|NCT01672541|BEHAVIORAL|Standard of Care Safe Dates Approach|Safe Dates curriculum for 8th grade students
214917888|NCT04893616|OTHER|Integration of vaccination services into delivery services|The purpose of the work is to integrate readily available birth dose vaccinations (Oral Polio and the Tuberculosis vaccine) currently given in a separate clinic into the maternity delivery services through improved training, checklist, and job aides.
214917889|NCT05894941|OTHER|Corrective Exercises|A total of 6 evidence-based exercises and stretches namely; Upper trapezius stretch, Sternocleidomastoid stretch, pectoral stretch; Chin tuck exercise, YTWL exercise, and resisted/isometric neck extension exercise will be prescribed to the exercise group while the postural education group will follow the guidelines provided by National Institutes of Health (NIH) for using computers and other sources. The control group will receive no intervention.
214917890|NCT05894941|OTHER|Postural Education|Postural guidelines for doing daily activity especially sitting for prolonged periods and using electronic devices like computers and other electronic devices.
214917891|NCT01268618|DIETARY_SUPPLEMENT|Probiotic|"2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of:~1. Lactobacillus acidophilus NAS, 30 billion CFU~2. Bifidobacterium bifidum Malyoth, 120 billion CFU~3. Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU"
214917892|NCT01268618|DIETARY_SUPPLEMENT|Placebo|2 capsules, 3x/day placebo capsules
214917893|NCT06110702|BEHAVIORAL|EMDR|Eye movement Desensitization and Reprocessing (as described in the 8-phases protocol), administered both online or in presence.
214917894|NCT02973503|DRUG|Elbasvir/Grazoprevir Fixed Dose Combination|Evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
214917895|NCT03291184|DEVICE|peripheral neuromuscular monitor|Residual paralysis can only be measured by neuromuscular transmission monitoring of a peripheral nerve, typically the ulnar nerve innervating the adductor pollicis muscle.
214917896|NCT05852275|OTHER|Olive-oil|Participants will add to their usual diet a daily intake of 30 mL of an olive oil rich in polyphenols for 3-months (100 days)
214917897|NCT05082675|PROCEDURE|HLA Matched allogeneic transplant|
214917898|NCT04867642|DRUG|UCB0022|Study participants will receive doses of UCB0022 in a pre-specified sequence during the Treatment Period of Part A, B and C.
214917899|NCT04867642|OTHER|Placebo|Study participants will receive placebo comparator in a pre-specified sequence during the Treatment Period of Part A, B and C.
214917900|NCT00410332|DRUG|Traumeel S|homeopathic remedy
214917901|NCT00410332|DRUG|Placebo|placebo drug, identical in size, form and taste as treatment remedy
214917902|NCT06368271|DIETARY_SUPPLEMENT|Lipidomics|Health beneficial effects of medium-chain fatty acids
214917903|NCT03431831|BEHAVIORAL|Intervention Control|diet recommendations of 1200 calorie limit for women daily and 1400 limit for men daily. Decreased foods that are high sugar, highly processed, low nutrient simple carbohydrates. Increased foods that are whole foods, lean proteins, complex carbohydrates and healthy fats. Switch from high calorie drinks to water for beverages.
214917904|NCT03431831|BEHAVIORAL|Counselling|Usual care as listed in comparator intervention plus motivational interviewing to identify areas of barriers and how to overcome them, to help patient set achievable food, physical activity and beverage goals for themselves weekly and monthly. To identify whether knowledge or confidence counseling is more important for each participant and follow up with them. To help them learn self-management techniques for overeating.
214917905|NCT03431831|DRUG|Contrave|In addition to usual care as described in the comparator intervention, these participants will be prescribed Contrave and raised to the therapeutic dosage within one month. They will be monitored closely for side effects and meds adjusted accordingly.
214917906|NCT03431831|DRUG|Contrave and Counseling|This group of participants will receive a combination of all the above interventions including diet/physical activity prescription, motivational interviewing and Contrave.
214917907|NCT01779128|PROCEDURE|PET-CT|
214917908|NCT01779128|PROCEDURE|MR-PET|
214917909|NCT00179660|DRUG|Lenalidomide|Capsules for oral administration.
214917910|NCT04771221|DIAGNOSTIC_TEST|pH metry|The collection of mucus from the laryngopharynx to determine the acid-base values through pH-metry.
214917911|NCT04771221|DIAGNOSTIC_TEST|Filling out the questionnaire|Completion of the questionnaire index of reflux symptoms. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. Evaluation results range from 0 to 5, where 0 is an indicator of no problem, and 5 is an indicator of a serious problem
214917912|NCT04771221|DEVICE|Endoscopic laryngoscopy|Video laryngoscopy and assessment of the presence / severity of the symptoms. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem
214917913|NCT04771221|DEVICE|Acoustic voice analysis|acoustic analysis of the voice was performed in singers with voice disorders before and after treatment using program of the Lingwaves
215060900|NCT01576939|RADIATION|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to \< 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
214917914|NCT03935425|DEVICE|FitMi Plus|A set of common objects that couple with a wireless sensor platform to allow the performance of functional exercises to be measured by a motivating software platform.
214917915|NCT03935425|DEVICE|FitMi Basic|A wireless sensor platform that allows movement subcomponents and point-to-point exercises to be measured by a motivating software platform.
214917916|NCT06428123|BEHAVIORAL|Mirror Therapy on present Lower Limb|Patients will be seated close to a table on which a mirror will placed vertically. The normal (i.e., no amputated limb) will be placed in front of the mirror and made to perform movements of the different joints while the patient looking into the mirror.
214917917|NCT06428123|DIAGNOSTIC_TEST|Mental Imagery on present Lower Limb|"Mental imagery technique in which patients will be instructed to concentrate on sensations from each area of the body, including the phantom limb. Patients will be advised to imagine comfortable, thorough movement and sensation in the phantom limb, such that they could stretch away the pain, and finally to allow the limb to rest in a comfortable position. The actual therapy of moving and feeling the limb will lasted for 5 minutes. Patients will be asked to perform 40 minutes of meditation and imagery exercises."
215060901|NCT02791035|DRUG|Oral administration of Ipragliflozin|
215060902|NCT06531187|OTHER|Evidence-Based Practice (EBP) Teaching|"The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP)."
214671179|NCT01025336|OTHER|Blood draw|Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
214671180|NCT01025336|OTHER|Blood draw|Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
214671181|NCT03317808|DIAGNOSTIC_TEST|Different exercise|Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
214671182|NCT03063255|DRUG|Obturator block|Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
214671183|NCT03063255|DRUG|Neuromuscular block|Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
214312972|NCT00455507|DRUG|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
214671184|NCT01573468|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
214671185|NCT01573468|DRUG|Placebo|Placebo orally once on Day 1 of each cycle
214671186|NCT01573468|DRUG|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
214671187|NCT05308147|DIETARY_SUPPLEMENT|First Reference product|Dextrose (containing 25 grams of carbohydrates)
214671188|NCT05308147|DIETARY_SUPPLEMENT|Second Reference product|Dextrose (containing 25 grams of carbohydrates)
214917918|NCT03090958|BEHAVIORAL|AllyQuest|AllyQuest is a novel, high impact secondary prevention intervention delivered via mobile phones to improve linkage and engagement in care among newly diagnosed HIV+ YMSM. The development of this intervention is both timely and vital given the urgency of the ongoing HIV epidemic among YMSM. The features of the intervention aim to target previously identified barriers to care among newly diagnosed youth, namely, low HIV health literacy, lack of social support, and internalized stigma related to their diagnosis.
214917919|NCT05312463|DRUG|Tongjiang granule|Tongjiang granules, 1 bag / time, 3 times / day.
214917920|NCT05312463|DRUG|Tongjiang granule simulant|Tongjiang granule simulant,1 bag / time, 3 times / day.
214312973|NCT00455507|DRUG|Placebo|Two placebo tablets orally once daily for 12 weeks
214312974|NCT03875378|DRUG|Transdermal estrogen|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
214312975|NCT03875378|DRUG|Placebos|Placebo weekly patch
214312976|NCT06534892|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)
214671189|NCT05308147|DIETARY_SUPPLEMENT|Third Reference product|Dextrose (containing 25 grams of carbohydrates)
214671190|NCT05308147|DIETARY_SUPPLEMENT|First Concept product|Infant Formula (containing 25 grams of carbohydrates)
214671191|NCT05308147|DIETARY_SUPPLEMENT|Second Concept product|Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
214671192|NCT05308147|DIETARY_SUPPLEMENT|Third Concept product|Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
214671193|NCT02689700|OTHER|Blood samples|Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
214671194|NCT00592683|DRUG|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
214671195|NCT00592683|DIETARY_SUPPLEMENT|fish oil|1600mg (4 capsules) daily for 12 weeks
214671196|NCT00592683|DRUG|Placebo|Placebo
214671197|NCT05466435|OTHER|Heavy Slow Resistance|Heavy slow resistance exercise will be given twice a week for 12 weeks along with traditional physical therapy program
214671198|NCT05466435|OTHER|Control group|Traditional physical therapy program only will be given twice a week for 12 weeks
214671199|NCT00152412|DRUG|Levocetirizine oral solution|
214671200|NCT02162979|DRUG|sildenafil|sildenafil 50mg BID for 2 weeks
214671201|NCT02162979|DRUG|Placebo|
214917921|NCT02035449|DEVICE|McGrath MAC|McGrath MAC is a videolaryngoscope
214917922|NCT00885664|DRUG|Truvada (tenofovir/emtricitabine)|Tenofovir/emtricitabine fixed dose combination once daily
214917923|NCT00885664|DRUG|Kaletra (lopinavir/ritonavir)|Lopinavir/ritonavir 400/100 mg twice daily
214917924|NCT01531621|OTHER|Biomarker sampling|Blood samples every 8-12 weeks
214917925|NCT00685399|DRUG|AIN457|AIN457 subcutaneous dose
214917926|NCT00685399|DRUG|AIN 457|AIN457 low dose (i.v)
214917927|NCT00685399|DRUG|AIN457|AIN457 high dose (i.v)
214917928|NCT01311076|DRUG|TAK-329|TAK-329 50 mg, tablets, orally, single dose, one day.
214917929|NCT01311076|DRUG|TAK-329|TAK-329 200 mg, tablets, orally, single dose, one day.
214917930|NCT01311076|DRUG|Insulin|Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
214917931|NCT01311076|DRUG|Placebo|TAK-329 placebo-matching tablets, orally, single dose, one day.
214917932|NCT05458401|DRUG|Trastuzumab deruxtecan|No drug will be administered during this study.
214312977|NCT06322836|PROCEDURE|Duble current electro cardioversion|Instead of the regular clinical treatment, in this study direct-current electrical cardioversion (DC-ECV) will be performed at the patient's home and will be carried out by well-trained and certified advanced practice providers (APP) on site, i.e. nurse practitioner or physician assistant, supported by an EMS ambulance team containing an ambulance nurse and ambulance driver, both trained advanced life-support (ALS) professionals.
214312978|NCT00225381|DEVICE|connection of measuring device to anesthesia circuit|same as name
214312979|NCT00225381|PROCEDURE|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
214312980|NCT00225381|PROCEDURE|changing operating room bed position (head down and up position)|same
214312981|NCT00225381|PROCEDURE|adding PEEP during anesthesia|same
214312982|NCT00225381|PROCEDURE|placement of esophageal Doppler for cardiac output measurements|same
214312983|NCT00225381|DEVICE|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
214312984|NCT00225381|DEVICE|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
214312985|NCT00225381|DEVICE|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
214312986|NCT00225381|DEVICE|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
214312987|NCT04249037|DRUG|bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)|A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.
214481476|NCT05715255|BEHAVIORAL|Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)|Participants randomized to the adaptive intervention are telephoned weekly and asked to enter by pin-pad or voice the severity of the PRO-CTCAE items on a 0-4 scale, with 0 being none and 4 being very severe. Participants are mailed the Symptom Management and Survivorship Handbook in their preferred language (English or Spanish). Survivors who rated any item at moderate or higher (2-4) will be referred by the ATSM to read the corresponding chapters in the Handbook and given a call back in 24 hours to inquire about the severity of the reported symptom, whether it has improved or worsened, and whether the participant reported it to their HCP, or the HCP has contacted the survivor. Participants that report elevated symptoms for two consecutive weeks are rerandomized to continue the ATSM alone or continue the ATSM with TIP-C added for 8 weeks. TIP-C is delivered by a masters prepared counselor with cancer expertise via weekly 30-minute phone calls using interpersonal techniques.
214481477|NCT05715255|BEHAVIORAL|Active control comparator|Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe.
214917933|NCT06575101|PROCEDURE|Target Temperature Management Treatment|Target Temperature Management Treatment
214312988|NCT04249037|DRUG|Standard initiation of antiretroviral therapy (ART)|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
214312989|NCT06367465|DRUG|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.
214312990|NCT04129788|DRUG|Bisacodyl 5 milligram|three doses taken, one per day on three consecutive days
214312991|NCT04129788|DRUG|Placebo oral tablet|three doses taken, one per day on three consecutive days
214312992|NCT02656108|PROCEDURE|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
214481478|NCT06744504|DRUG|cytarabine|Cytarabine combined with daunorubicin was used for induction therapy. According to the different doses of cytarabine, it was divided into standard dose group and intermediate dose group.In addition, high doses of cytarabine are also used for post-remission treatment.
214312993|NCT02656108|PROCEDURE|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
214312994|NCT03684915|DEVICE|Rotary files|using rotary files in cleaning root canals of infected primary molars
214312995|NCT05806294|BEHAVIORAL|Digital Metabolic Rehabilitation|Digital Metabolic Rehabilitation combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise Protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 20 based on physical ability and stage of COPD. Intervention has 3 phases. In phase 1, weekly videoconferences with the kinesiologist and dietitian and monthly sessions with psychologist and respiratory therapist are held for the first 3 months. Phase 2 lasts from months 4 to 6 and has biweekly videoconferences with health professionals. Phase 3 starts in month 6 and has monthly group sessions with health professionals.
214312996|NCT00640705|DRUG|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
214312997|NCT00640705|DRUG|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
214312998|NCT06424262|DEVICE|CI622D|A dexamethasone-eluting Slim Straight electrode
214312999|NCT06424262|DEVICE|CI622|A standard Slim Straight electrode
214313000|NCT01565330|DRUG|florbetapir F 18|single dose IV injection
214481479|NCT06744504|DRUG|daunorubicin|combined with cytarabine and used for induction therapy
214917934|NCT04891146|OTHER|Systemic inflammatory immmune index|Systemic Inflammatory Immune index calculated from platelet, neutrophil and lymphocyte count
214917935|NCT05494814|OTHER|Child Care Centers Served Meals Prepared by Central Kitchen|The child care centers who are served by the central kitchen will receive meals that include locally sourced fresh fruits and vegetables to serve their staff and children.
214917936|NCT01863199|DRUG|Lucentis (Treat and extend)|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
214917937|NCT01863199|DRUG|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
214313001|NCT01203072|DRUG|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
214313002|NCT01203072|DRUG|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
214313003|NCT01203072|DRUG|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
214481480|NCT06744504|DRUG|idarubicin|combined with cytarabine and cyclophosphamide and used for post-remission treatment
214481481|NCT06744504|DRUG|cyclophosphamide|combined with cytarabine and idarubicin and used for post-remission treatment
214481482|NCT06952777|OTHER|Non-adhesive capacitively-coupled sensors|Non-adhesive capacitively-coupled sensors which can detect signals of the magnitude of the fetal heart rate and information about fetal movements.
214481483|NCT04083534|DRUG|REGN5459|Administered by intravenous (IV) infusion
214481484|NCT03697408|DRUG|Itacitinib|A JAK 1 selective small molecule inhibitor
214481485|NCT03697408|DRUG|Everolimus|A mammalian target of rapamycin (mTOR) inhibitor
215060903|NCT04346173|PROCEDURE|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
214313004|NCT01203072|DRUG|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
214313005|NCT01203072|DRUG|Placebo|Matching placebo oral tablets, once daily for 2 weeks
214313006|NCT05655611|OTHER|first rib mobilization|To perform the first rib mobilization, the patient remained lying supine with the head in the examiner's right hand. Examiner then palpated the left first rib and passively side-bended the patient's head to the left to relieve any muscular tension on the first rib. Patient was then asked to take a deep breath in and out. During exhalation, the examiner applied pressure to depress the first rib, holding it in place at the end of the exhalation. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation. This process was repeated three times in two sets, for a total of six first rib depression mobilizations.
214313007|NCT05655611|OTHER|muscle energy technique|Muscle energy technique for glenohumeral joint restricted abduction-The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the glenohumeral joint to palpate for motion and the subjects are directed to press the elbow towards their body. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for three weeks with each repetition maintained for the duration of 7-1 seconds.
214481486|NCT06752746|DRUG|9MW3011|Multiple dose
214481487|NCT04244175|DRUG|Placebo|Participants received CVL-865 matched placebo tablets orally twice a day (BID) during the Treatment Period.
214481488|NCT04244175|DRUG|CVL-865|Participants received CVL-865 tablets orally twice a day (BID) up to the maximum dose of 7.5 mg BID or 25 mg BID during the Treatment Period.
214481489|NCT05624138|DRUG|Placebo tablets|12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets
214481490|NCT05624138|DRUG|Ketotifen Oral Tablet|ketotifen is a potent anti histaminic drug that may prevent oxaliplatin induced peripheral neuropathy and mucositis and will be administered 2 mg daily along with the 12 cycles of modified Folfox-6 regimen
214481491|NCT06281756|BEHAVIORAL|Cognitive Behavioral Treatment for Insomnia (CBT-I)|Subjects will receive therapy for 8 weeks
214481492|NCT06281756|DRUG|Trazodone|Non-remitting subjects will receive Trazodone (dosage) for 8 weeks
214481493|NCT06281756|OTHER|Placebo|Non-remitting subjects will receive placebo for 8 weeks
214481494|NCT04845529|DEVICE|transcranial direct current stimulation (tDCS)|We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.
214481495|NCT06496061|DRUG|Norepinephrine|Norepinephrine infusion with 0.05 mg/kg/h
214481496|NCT06496061|PROCEDURE|Leg wrapping|Elastic leg wrapping
214481497|NCT04595331|DEVICE|Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection|Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
214481498|NCT03710772|DRUG|Cyclophosphamide|Given IV
214481499|NCT03710772|DRUG|Cytarabine|Given IV
214481500|NCT03710772|DRUG|Dexamethasone|Given PO or IV
215060904|NCT04022525|DRUG|Leflunomide 20Mg Tab|blood samples of rheumatoid patients will be collected for SNPs detection and drug assay
214313008|NCT02089061|DRUG|BMS-919373|
214313009|NCT02089061|DRUG|Rosuvastatin|
214313010|NCT02089061|DRUG|Atorvastatin|
214313011|NCT02153944|DRUG|Propranolol|Propranolol 40 mg was given orally during study visit
214313012|NCT02153944|DRUG|Methylphenidate|Methylphenidate 20mg was given orally during study visit
214313013|NCT02153944|DRUG|Placebo|Placebo was given orally during study visit
214313014|NCT03790826|DEVICE|cystoscopy|Comparison of bladder mucosa via cystoscopy.
214313015|NCT02286193|BEHAVIORAL|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
214313016|NCT02204891|DIETARY_SUPPLEMENT|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
214313017|NCT02204891|DIETARY_SUPPLEMENT|Probiotics|One capsule twice daily for 30 days
214313018|NCT01041872|DRUG|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
214481501|NCT03710772|DRUG|Doxorubicin Hydrochloride|Given IV
214481502|NCT03710772|DRUG|Ibrutinib|Given PO
214481503|NCT03710772|DRUG|Methotrexate|Given IV
214481504|NCT03710772|BIOLOGICAL|Rituximab|Given IV
214481505|NCT03710772|DRUG|Venetoclax|Given PO
214481506|NCT03710772|DRUG|Vincristine Sulfate|Given IV
214481507|NCT05757492|DRUG|CHS-006 (anti-TIGIT)|Arm A participants will receive CHS-006 administered via IV Q3W.
214481508|NCT05757492|DRUG|toripalimab (anti-PD-1)|Arm B participants will receive toripalimab administered via IV Q3W.
214481509|NCT05909644|DRUG|Omaveloxolone|Omaveloxolone Capsules, 150 mg, administered orally
215060905|NCT00979966|DRUG|Temsirolimus|25 mg intravenously, once weekly infusion
214313019|NCT01041872|DRUG|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
214313020|NCT01041872|DRUG|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
214313021|NCT01041872|DRUG|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
214481510|NCT05909644|DRUG|Efavirenz|Efavirenz Tablet, 600 mg, administered orally once daily
214481511|NCT04472897|DRUG|GSK2556286|GSK2556286 will be administered.
214481512|NCT04472897|DRUG|Placebo|Placebo will be administered
214481513|NCT05723835|DRUG|Somapacitan|Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
214481514|NCT05280925|BEHAVIORAL|Episodic Future Thinking|Participants will be prompted three times daily to think vividly about personally meaningful future events.
214481515|NCT05280925|BEHAVIORAL|Healthy Information Thinking|Participants will be prompted three times daily to think about their responses to informational health vignettes.
214481516|NCT04521153|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
214481517|NCT04521153|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
214313022|NCT01041872|DRUG|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
214481518|NCT04521153|PROCEDURE|Radical surgery|Radical surgery
214481519|NCT03781089|DRUG|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K \< 4.0 mEq/L, and patiromer will be discontinued if K \< 3.5 mEq/L. Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
214481520|NCT04092634|DEVICE|Dual mobility implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
214481521|NCT04092634|DEVICE|Traditional, Single-bearing hip implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
214313023|NCT01041872|DRUG|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
214481522|NCT04202835|DRUG|Cyclophosphamide|Post Transplant Cyclophosphamide
214481523|NCT04202835|DRUG|Anti-Thymocyte globulin (rabbit)|Anti-Thymocyte Globulin (rabbit, Thymoglobulin)
214481524|NCT02238808|DRUG|Estradiol|Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
214481525|NCT06957886|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
214481526|NCT06957886|DRUG|Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel|Oral administration of Capecitabine. Administration by intravenous infusion of Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.
214481527|NCT03994471|DRUG|XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght|XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
214481528|NCT03994471|DRUG|1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution|Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.
214481529|NCT06550375|DEVICE|TECNIS Odyssey IOL|Implantation with the TECNIS Odyssey IOL
214481530|NCT06958783|OTHER|Blood lipid monitoring in breast cancer patients during chemotherapy|This intervention is distinguished by its prospective design, enrollment of a clearly defined cohort of adult female patients with newly diagnosed early-stage breast cancer (stage IB-IIIB), administration of a uniform chemotherapy regimen (doxorubicin, cyclophosphamide, paclitaxel), and standardized monitoring of fasting lipid profiles at four precisely scheduled timepoints: pre-chemotherapy, pre-paclitaxel, post-paclitaxel, and three months post-chemotherapy completion
214481531|NCT00756639|RADIATION|Prophylactic Cranial Irradiation (PCI)|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
214481532|NCT00756639|OTHER|Brain X-ray|On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
214481533|NCT05635617|PROCEDURE|Lower Extremity Surgery|Patients 18 years of age or older with high energy lower extremity fractures. Provision of informed consent.
214917938|NCT01863199|DRUG|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
214313024|NCT03881137|OTHER|Geriatric assessment with management|"A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs.~The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT."
214313025|NCT02646579|PROCEDURE|Spinal and Peripheral Dry Needling|Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
214481534|NCT05856968|PROCEDURE|continuous subcutaneous tissue closure|The use of continuous subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
214481535|NCT05856968|PROCEDURE|Interrupted subcutaneous tissue closure|The use of interrupted subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
214671202|NCT03359603|DEVICE|Electro-acupuncture|"Patients will be treated by use of 5 obligatory and 3 customized acupoints. Obligatory points (ST35, EX-LE5, LR8, GB33 and Ashi) will be used in all patients. Other 3 customized acupoints should be chosen by the physicians on the basis of traditional Chinese medicine diagnosis for acupuncture channels related to the individual pain area, with the intent of optimizing efficacy. ST34, ST36, ST32, ST40 and EX-LE2 will be used for pain at stomach meridian. GB31, GB36, GB34, GB39 and GB41 will be used for pain at gallbladder meridian. BL39, BL40, BL57 and BL60 will be used for pain at bladder meridian. LR7, SP9, SP10, KI10, SP4, SP6, LR3 and KI3 will be used for pain at three yin meridians of foot. Needles will be stimulated manually for 10 seconds to achieveDe Qi. Paired alligator clips will be attached transversely to the needle holders at LR8-GB33 and two other customized acupoints. Other needles will be manipulated for 10 seconds during the treatments."
214671203|NCT04439734|DEVICE|Electromyostimulation|WB-EMS once per week 20 min for 16 weeks
214671204|NCT03484026|DIETARY_SUPPLEMENT|BioFe|BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
214671205|NCT05776472|DRUG|Pegcetacoplan|Pegcetacoplan will be prescribed according to the label in patients with PNH.
214671206|NCT02333838|DRUG|IV Thiotepa|IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
214671207|NCT02333838|DRUG|IV Fludarabine|IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
214671208|NCT02333838|DRUG|IV Busulfan|(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
214917939|NCT00178685|BEHAVIORAL|Self-determination Intervention for Tobacco Dependence|autonomy supported behavioral intervention for tobacco dependent individuals
214917940|NCT04400851|DRUG|Sintilimab|Patients were enrolled by the design of phase I study standard. Sintilimab was divided into three dosage levels: 1 mg / kg, 3 mg / kg, and 10 mg / kg. The first level of sintilimab was followed by dose escalation
214481544|NCT04487041|BIOLOGICAL|Standard dose influenza vaccination|Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle
214481545|NCT04487041|BIOLOGICAL|High dose influenza vaccination|4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle
214917941|NCT03223415|OTHER|Detection and isolation of C. difficile carriers|"Screening for C. difficile carriage will be conducted by performing a polymerase chain reaction (PCR) assay detecting the toxin B gene (tcdB) on a rectal swab. Screening will occur within 24 h of admission to the ward. To ensure compliance with the policy, automatic orders will be developed. The patient care nurse will perform the screenings. The results will be reported according to the standard institutional policy.~Isolation precautions for C. difficile carriers: healthcare workers will also follow a set of isolation precaution rules during the care of C. difficile carriers. C. difficile carriers will remain under isolation precaution as long as they remain carriers and on the intervention ward. Precautions would be discontinued upon discharge from the ward."
214481546|NCT06551545|DIETARY_SUPPLEMENT|Tryptophan intake|There are 5 different tryptophan test intake levels ranging from 2, 3, 4.5, 6, 8 mg.kg-1.day.1
214481547|NCT06550986|DEVICE|False Lumen Embolization System, IMPEDE-FX RapidFill|Embolization of the false lumen of an aortic dissection
214481548|NCT04109365|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
214481549|NCT05075759|BEHAVIORAL|Behavioral Intervention|Receive personalized clinician-led self-management telehealth sessions
214481550|NCT05075759|BEHAVIORAL|Behavioral Intervention|Receive personalized goal setting for daily steps and activity and dietary goals
214481551|NCT05075759|BEHAVIORAL|Behavioral Intervention|Remote sessions with a health coach
214481552|NCT05075759|OTHER|Survey Administration|Ancillary studies
214481553|NCT05075759|OTHER|Interview|Ancillary studies
214481554|NCT06257056|DEVICE|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain
214481555|NCT05020353|DEVICE|OraQuick® HIV Self-Test|OraQuick® HIV Self-Test in oral fluid conducted by observed intended users (non-healthcare professional and inexperienced in HIV self-testing) compared to laboratory 4th generation Ag/Ab enzyme immunoassay (EIA) results performed on venous blood.
214481556|NCT05536414|DRUG|Centanafadine|capsule
214481557|NCT05536414|DRUG|Escitalopram|capsule
214481558|NCT05536414|DRUG|Placebo|capsule
215060906|NCT00979966|DRUG|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
215060907|NCT04305509|OTHER|no intervention|no intervention
215060908|NCT05894356|OTHER|Study chart review|Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
215060909|NCT02598869|DRUG|Triamcinolone Acetonide|injection of triamcinolone acetonide
214481559|NCT04945473|PROCEDURE|Endoscopic placement of additional sutures|A new endoscopic suture will be performed in case of a BMI≥30 or total weight loss (TBWL) less than 10%, and relaxation of gastric tubulization during the regular endoscopic follow-up after 6 months from the ESG. The same endoscopic suture technique of the primary ESG will be applied.
214481560|NCT05543512|DEVICE|Algorithm to diagnose food allergens|An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm. Subjects randomized to this group will receive a diet assignment based on results of the algorithm.
214481561|NCT05543512|OTHER|Sham diet|Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
214481562|NCT06212583|DRUG|niraparib/abiraterone acetate|Patients on Arm 2 to receive drug for 6 months
214481563|NCT06212583|RADIATION|Stereotactic ablative radiation therapy (SABR)|Both arms will receive SABR
214917942|NCT00690677|DRUG|LBH589|"LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.~The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study."
214313026|NCT02646579|PROCEDURE|Peripheral Dry Needling|Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
214481564|NCT06212583|DRUG|Androgen deprivation therapy (ADT)|All ADT is provided as best prescribed for patient per their medical oncologist.
214481565|NCT06308380|PROCEDURE|Specific protocol of rehabilitation exercise|Specific protocol of rehabilitation exercise
214481566|NCT06308380|PROCEDURE|Short gastrocnemius surgery.|During surgery, a partial release of the gastrocnemius muscle tendon is performed to relieve tension and allow greater range of motion. This procedure is typically performed on an outpatient basis and under local or regional anesthesia, which allows for a quicker recovery compared to more invasive surgeries.
214481567|NCT05968144|BEHAVIORAL|Dietary recommendations|One-on-one meeting with a nutritionist to discuss and personalize dietary recommendations for patients with prostate cancer undergoing ADT.
214917943|NCT02218047|DRUG|Pegylated-Proline-interferon alpha-2b|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
214481568|NCT05968144|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
214481569|NCT05147597|OTHER|Questionnaire|"Cases diagnosed with Idiopathic pulmonary fibrosis (IPF) in the chest diseases outpatient clinic will be informed about the study, and the informed consent form will be signed by the specialist physician and demographic information will be obtained from the cases who accepted to be included in the study.~The surveys will be contacted by the patient at 1-week intervals and answered by the patient by the responsible researcher and chest diseases physician."
214917944|NCT02218047|DRUG|Best available therapy (BAT)|Best available therapy as selected by the investigator
214481570|NCT04887467|DRUG|Apomorphine|"Assigned Interventions:~* blood sampling~* blood collection~* systolic, diastolic, mean blood pressure and heart rate measure"
214671209|NCT02333838|DRUG|IV Anti-thymocyte globuline|(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
214671210|NCT00545818|DEVICE|OsseoSpeed™ length 6 mm|OsseoSpeed™ dental implant, length: 6 mm
214671211|NCT00545818|DEVICE|OsseoSpeed™ length 11 mm|OsseoSpeed™ dental implant, length: 11 mm
214917945|NCT06459453|OTHER|Kaltenborn|Per participant was randomized to receive low grade Kaltenborn manual mobilization(grade I).Any tightening of the connective tissues surrounding the joint (grade II) or oscillations followed by additional stretching (grade III).Kaltenborm mobilization is performed for wrist flexion,extension,radial and ulnar deviation.The duration of intervention will be 4 weeks,3 sessions per week, a total of 12 sessions will be given to the study participants. Each session will be last for 30 minutes .Conventional physical therapy will be given to the participants along with kaltenborn.
215060910|NCT01709552|BEHAVIORAL|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
215060911|NCT01709552|BEHAVIORAL|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
215060912|NCT05710796|BEHAVIORAL|Difference in gender, response to disease, diagnostic test values|Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
215060913|NCT04643587|BIOLOGICAL|CSL787|Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
214313027|NCT00446719|DRUG|Rellidep|2000 mg P.O. daily for 8 weeks
214313028|NCT02639481|BEHAVIORAL|Standard physiotherapy|Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
214481571|NCT03998657|DEVICE|Exablate Prostate Treatment|The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
214671212|NCT05689827|DRUG|Ethyl methyl hydroxypyridine succinate + Meldonium|Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)
214671213|NCT05689827|DRUG|Placebo|Placebo was used in the same way
214671214|NCT02413515|DRUG|Nifedipine (Adalat GITS, BAY1040)|Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
214313029|NCT02639481|DEVICE|Erigo®Pro group without FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
214313030|NCT02639481|DEVICE|Erigo®Pro group with FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
214313031|NCT01492452|OTHER|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
214313032|NCT00003724|PROCEDURE|surgical procedure|
214313033|NCT02507414|OTHER|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
214313034|NCT02507414|OTHER|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
214313035|NCT02507414|OTHER|Head down tilt|"At three different time points the participants will be head down tilted in 20 degrees.~End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)"
214313036|NCT03636750|DRUG|HB002.1T|HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
214313037|NCT04507932|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
214313038|NCT02781103|OTHER|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
214313039|NCT02781103|OTHER|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
214313040|NCT00889343|DRUG|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
214313041|NCT00889343|DRUG|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
214481572|NCT06288906|OTHER|mechanical thrombectomy of caval and iliofemoral veins|investigate efficacy, safety of mechanical thrombectomy systems used in symptomatic acute and subacute ileofemoral and caval thrombosis
214481573|NCT03357757|DRUG|Valproic Acid|The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.
214481574|NCT03357757|BIOLOGICAL|Avelumab|10 mg/kg IV
214313042|NCT00889343|DRUG|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
214313043|NCT00889343|DRUG|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
214313044|NCT00889343|DRUG|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
214313045|NCT02697162|DEVICE|Antiseptic-coated catheter|Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
214313046|NCT02697162|DEVICE|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
214313047|NCT02697162|DRUG|Octenidine chloride|Antiseptic
214313048|NCT00401765|DRUG|CNTO 328|Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
214313049|NCT00401765|DRUG|Docetaxel|Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
214313050|NCT00783042|DRUG|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
214313051|NCT00783042|DRUG|Placebo|Tablet, oral, once daily for 1 month (double blind)
214313052|NCT05583188|DEVICE|Aliya Pulsed Electric Fields (PEF) ablation|Patients will undergo PEF ablation
214481575|NCT03811405|DEVICE|Active biphasic pulse stimulation---Home Settings|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
214671215|NCT02837172|OTHER|Diffusion Weighted Imaging (DWI)|"MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.~Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS"
214313053|NCT05583188|DRUG|Nivolumab plus Platinum Doublet Chemotherapy|If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
214313054|NCT05583188|DRUG|Standard of care neoadjuvant therapy|Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
214481576|NCT03811405|DEVICE|Active biphasic pulse stimulation---VIN Biphasic|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
214481577|NCT03811405|DEVICE|Active biphasic pulse stimulation---Stimulator Off|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
214313055|NCT05583188|OTHER|Surgical Resection|Patients not eligible for systemic therapy will receive definitive surgery without neoadjuvant therapy as per institutional standard of care post-PEF ablation.
214313056|NCT06008964|OTHER|Ylang Ylang oil with inhalation|Ylang Ylang OIL WILL BE INHALED
214313057|NCT06008964|OTHER|Lavender oil with inhalation|LAVENDER OIL WILL BE INHALED
214313058|NCT01883401|DIETARY_SUPPLEMENT|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
214313059|NCT01883401|DIETARY_SUPPLEMENT|Dietary fiber|4g or 8g dietary fiber blended in water
214313060|NCT02383446|DEVICE|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
214313061|NCT02023151|DRUG|Omalizumab|
214313062|NCT04064294|DRUG|Intravenous Infusion|Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
214313063|NCT01400867|DRUG|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects \< 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
214313064|NCT01400867|DRUG|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
214313065|NCT01400867|DRUG|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
214313066|NCT06328790|OTHER|Multidisciplinary Rehabilitation Training|34 Patients will attend the in-person 5-day rehabilitation program (2 h/day) followed by a 12-weeks telemedicine program (1 h/week).
214313067|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and patients with structural/organic diseases|Each subject will undergo behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and interoceptive domains.
214313068|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and healthy controls (HC)|Each subject will undergo a set of behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and
214313069|NCT04431362|BEHAVIORAL|Self-selected music|Participants will be given iPods and headphones to listen to their music
214313070|NCT03450707|DRUG|Thiamine 500 mg IV|Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
214313071|NCT03450707|OTHER|Placebo|100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm
214313072|NCT03001921|OTHER|No intervention|Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
214313073|NCT02302196|PROCEDURE|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
214313074|NCT02302196|OTHER|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
214313075|NCT02635464|BIOLOGICAL|hUC-MSCs+Injectable collagen scaffold+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
214313076|NCT02635464|BIOLOGICAL|hUC-MSCs+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
214313077|NCT02635464|PROCEDURE|CABG|Patients underwent CABG alone.
214671216|NCT03170284|DRUG|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
214313078|NCT03930706|OTHER|Longer administration of estradiol (Progynova®)|All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
214313079|NCT05715567|OTHER|Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)|Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)
214313080|NCT04828954|OTHER|Immobilization for 2-weeks postoperative|Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks
214917946|NCT06459453|OTHER|Mulligan|Per participant gave concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Mulligan mobilization is performed for wrist flexion and extension(in the form of fist)MCP joint flexion and extension,Thumb IC joint flexion and extension, abduction and adduction of fingers, The duration of intervention will be 4weeks,3 sessions per week ,a total of 12 sessions will be given to the study participants .Each session will last for 30 minutes. Conventional physical therapy will be given to the participants along with conventional physiotherapy.
214917947|NCT01835873|OTHER|Lactated Ringer's|
214313081|NCT04828954|OTHER|Immobilization for 6-weeks postoperative|Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
214313082|NCT03343483|BEHAVIORAL|Volunteering|"Volunteers provide non-medical caregiving for frail seniors-care receivers-to help them maintain their independence and improve their well-being. Friendly visiting is the primary service provided. Structured, intensive training is provided prior to placement. The target expectation is of interactions in person and/or by telephone for at least 16 hours per month. On-going training (booster sessions) as well as volunteer support groups, and educational activities are provided. Participants not interested in serving as peer companions are allowed other volunteer options as long as the activities are deemed 'social' by the volunteer coordinator and are options routinely provided as part of the AmeriCorps Senior RSVP Program. COVID update: due to physical distancing requirements, volunteer placements have transitioned to remote friendly calling/letter writing or activities that can be conducted with physical distancing, such as delivery for Meals on Wheels."
214313083|NCT03343483|BEHAVIORAL|Life Review|Subjects will complete a self-guided life review exercise over 12 months. Subjects will complete one section of the life review (with the self-help book) each month and send 'assignments' once per month to an email 'counselor' who will respond with supportive comments within three days.
214313084|NCT04758377|PROCEDURE|Magnetic resonance imaging (MRI)|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
214313085|NCT03500146|DRUG|Anticholinergic|Patients prescribed medication for OAB
214313086|NCT03500146|PROCEDURE|PTNS|Patients prescribed PTNS for OAB
214313087|NCT03961542|OTHER|Chewing|Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
214313088|NCT02644707|DIETARY_SUPPLEMENT|L-selenomethionine|The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
214313089|NCT02644707|OTHER|Placebo|The group will be randomized to receive placebo (control group) for 6 months
214313090|NCT02699944|DEVICE|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
214313091|NCT05325567|PROCEDURE|Mini open incision CTR|two techniques commonly used for carpal tunnel release are being compared to determine if one vs. the other provides superior patient outcomes.
214313092|NCT00337103|DRUG|Eribulin Mesylate|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
214313093|NCT00337103|DRUG|Capecitabine|Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
214313094|NCT05197842|DRUG|BDB-001 injection|Intravenously administered
214917948|NCT01835873|OTHER|HES 130/0.42|Balanced colloid solution
214917949|NCT00181285|DEVICE|High Frequency Chest Wall Oscillator|High velocity, low amplitude oscillatory airflow applied through a pneumatic vest worn over the thorax
215060914|NCT04643587|DRUG|Placebo|Normal saline (0.9% NaCl)
214313095|NCT05197842|DRUG|Cyclophosphamide|Intravenously administered
214313096|NCT05197842|DRUG|Glucocorticoids|Orally administered
214313097|NCT01577758|DRUG|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
214313098|NCT03981133|BEHAVIORAL|offer a pacifier|offer a pacifier to normal newborn infants the first days of life
214313099|NCT03981133|BEHAVIORAL|no pacifier|not to offer a pacifier at 15 days of life
214313100|NCT05497843|DRUG|Chiauranib|50mg, orally once daily
214671217|NCT00660140|DRUG|Gemcitabine|
214917950|NCT05445505|DEVICE|intermittent theta burst stimulation|iTBS is a new form of excitatory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
214917951|NCT05445505|DEVICE|sham iTBS|The pseudo-stimulation device looks and sounds the same as the iTBS device
214917952|NCT05037045|DRUG|GLP-1 receptor agonist|GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM
214955130|NCT04854057|DEVICE|TESS - Transcutaneous Electrical Spinal Cord Stimulation + Functional Task Practice|Participants will receive transcutaneous electrical stimulation to the cervical spinal cord using the TESCoN device developed by SpineX, Inc. Training will consist of progressive functional task practice for upper extremity motor training. A total of 24 treatment sessions, which will last 45 minutes per session, will be completed in 3 weeks (4 days/week) per crossover arm.
214955131|NCT05969587|COMBINATION_PRODUCT|5% cysteamine cream|5% cysteamine cream (Cyspera®) was acquired from Scientis APAC Pte. Ltd. (Singapore, Singapore).Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. The cysteamine cream was washed off 15 minutes after application
215060915|NCT01295151|DRUG|Etanercept|"Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
214313101|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
214313102|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
214313103|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
214313104|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
214313105|NCT03805022|DRUG|At the discretion of the investigator|Drug at the discretion of the investigator.
214313106|NCT05662579|OTHER|Exercises|"There will be 2 reevaluations of the participants, similar to the initial: at the end of the exercise protocol and in a follow-up of 12 weeks after the end of the protocol.~The contraction phase of each exercise will be 2 concentric seconds, 1 isometric second and 2 eccentric seconds, followed by 1 second of rest; there will be approximately 90 seconds of rest between each set of 10 repetitions, time the other member will be exercising.~At the beginning and at the end of each session, the participants will be asked to point out the pain they feel in the hip at that time. In each of the 8 sessions, the physiotherapist will take note of the presence, lateral pain in the hip at the beginning and end of the therapy (by VAS), number of repetitions performed in each exercise (for the group that will do core exercises, it will be noted the time in seconds of each exercise) and any adverse events. Each series of exercises will be repeated 3 times, all performed bilaterally."
214313107|NCT01865162|OTHER|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
214481578|NCT06174701|BEHAVIORAL|Problem Solving Therapy (PST)|PST intervention in the form of one-on-one coaching in preparation for surgery and post-operative care. This coaching consists of educating and guiding the patient in developing problem-solving skills. Please refer to the PST Handbook for further detail on the therapy sessions.
214481579|NCT06174701|BEHAVIORAL|Enhanced Usual Care|"Participants in the control arm will receive enhanced usual care. They will receive additional mental health education in the form of educational handouts mailed or emailed to them."
214481580|NCT06024642|DRUG|V117957|V117957 1 mg - 1 tablet taken orally at bedtime.
214917953|NCT02382497|DEVICE|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
214917954|NCT02382497|DEVICE|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
215060916|NCT01295151|DRUG|Abatacept|"Abatacept will be administered at a dose determined by body weight:~Body Weight (kg) Dose (mg) \< 60kg = 500 mg~\> or equal to 60kg and \< or equal to 100kg = 750 mg \> 100 kg = 1000mg~The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician."
214481581|NCT06024642|DRUG|Placebo|Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
215060917|NCT01295151|BIOLOGICAL|Rituximab|"Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).~In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.~Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given."
214481582|NCT03785574|OTHER|Follow up|the follow up group would be naturely didived into 2 subgroups depending the hCG regression degree.
214481583|NCT03785574|DRUG|chemotherapy|First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
214481584|NCT06193083|OTHER|Semi-directed individual interviews|Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)
214671218|NCT00660140|DRUG|Carboplatin|
214671219|NCT04133324|DIAGNOSTIC_TEST|C-reactive protein|C-reactive protein at postoperative days four and two.
215060918|NCT01295151|DRUG|Adalimumab|"Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
214671220|NCT00102037|DRUG|eptacog alfa (activated)|
214671221|NCT04673903|OTHER|Copenhagen adduction exercise|The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
214671222|NCT04673903|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
214671223|NCT02830373|DEVICE|LVIS stents|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
214671224|NCT02723630|DRUG|Lenvatinib 10 mg|"Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%"
214671225|NCT02685150|DEVICE|Endoscopic Tri-Modal Imaging|Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
214313108|NCT00203970|BEHAVIORAL|Observation|Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
214313109|NCT03387813|DEVICE|CardioMEMS™ HF System|The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.
214313110|NCT04318496|OTHER|Press Tack Acupuncture|PYONEX Φ0.20×0.6 mm made by Seirin Corporation
214313111|NCT04318496|OTHER|Press Tack Placebo|PYONEX placebo sticker made by Seirin Corporation
214313112|NCT06376253|DRUG|[68Ga]Ga-EVS459|Radioligand imaging agent
214313113|NCT06376253|DRUG|[177Lu]Lu-EVS459|Radioligand therapy
214671226|NCT02685150|DRUG|Omeprazole|Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
214671227|NCT02685150|OTHER|Analysis of gastric juice|Analysis of gastric juice including routine, biochemical and microbiological analysis.
214917955|NCT02382497|DEVICE|BED Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
214917956|NCT02382497|DEVICE|BED Sham tDCS|The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
214917957|NCT04414020|DRUG|Progesteron|intramusculer progesterone
215060919|NCT01295151|DRUG|Certolizumab Pegol|"Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
215060920|NCT01295151|DRUG|Infliximab|"Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.~The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.~Further treatment will be prescribed at the discretion of the treating clinician."
215060921|NCT01295151|DRUG|Golimumab|"Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.~Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.~The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice."
214313114|NCT06096714|DRUG|Nicotine|Nicotine will be infused using a pump.
214313115|NCT06096714|OTHER|Saline|Saline with be used to compare Nicotine, Saline will be infused using a pump
214313116|NCT05820347|DEVICE|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|Estimation of inspiratory muscle pressure by an artificial intelligence algorithm integrated in the mechanical ventilator (FlexiMag, Magnamed, Brazil).
214313117|NCT01399242|DRUG|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
214313118|NCT04762134|DRUG|Doxycycline Hyclate|STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
214671228|NCT04036565|BEHAVIORAL|sunlight therapy|Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
214671229|NCT03811951|DRUG|Novolin R|Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
214671230|NCT02491541|BIOLOGICAL|Changchun Werersai|"A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.~1.0 ml experimental vaccine on day 0,3,7,14,28"
214671231|NCT02491541|BIOLOGICAL|Jilin Maifeng|"A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.~1.0 ml comparator vaccine on day 0,3,7,14,28"
214671232|NCT05357183|DRUG|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
214671233|NCT01161836|DRUG|Iniparib|"Solution for infusion~60-minute intravenous infusion"
214671234|NCT04020874|BEHAVIORAL|HuTT-2x|tackling and blocking training twice/week
214671235|NCT04020874|BEHAVIORAL|HuTT-4x|tackling and blocking training four times/week
214671236|NCT06331949|OTHER|video assisted training|Ebelik bakımının yanı sıra NST konusunda eğitim içerikleri, eğitim videoları ve broşür destekli eğitimler verilecek. NST cihazı takılacak ve standart olarak işlem başladıktan 5 dakika sonra NST kaydı sırasında cihazdan gelen fetal kalp sesinin şiddeti artırılarak fetal kalp sesinin devam etmesi sağlanacaktır. Transfer edilecek hamile kadın yaklaşık 2 dakika kadar dinlenecektir.
214917958|NCT06534489|PROCEDURE|neoadjuvant immuno-chemotherapy and surgery|After enrolled, patients should receive neo-adjuvant immuno-chemotherapy and a re-evaluation will be performed after treatment to decide surgery strategy.
214313119|NCT02259361|DRUG|Sustained-release oral dalfampridine|One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
214313120|NCT02259361|DRUG|Placebo|Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
214313121|NCT02578654|OTHER|Strategies to improve HIV care engagement|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
214917959|NCT05387369|DRUG|Paxlovid|The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
214917960|NCT00747019|BEHAVIORAL|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9. PBPA participants also earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity.
214671237|NCT03838848|DRUG|KN046|3mg/kg, Q2W, intravenous injection (IV)
214671238|NCT03838848|DRUG|KN046|5mg/kg, Q2W, intravenous injection (IV)
214917961|NCT00747019|BEHAVIORAL|Physical Exercise (PE)|The PE condition is a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9.
214917962|NCT01562782|OTHER|Fructose + Glucose Beverage|Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
214917963|NCT06682663|BEHAVIORAL|Live Streaming Exercise|Participants try to achieve 150 minutes of moderate-vigorous training per week. The exercise program includes live streaming exercise by trained health professionals, including pregnancy-specific exercises, with professional pregnancy trainers to provide guidance and support when needed.
214917964|NCT02951208|DEVICE|Active tDCS|Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
214313122|NCT00253383|OTHER|counseling intervention|
214313123|NCT00253383|OTHER|educational intervention|
214313124|NCT00253383|PROCEDURE|psychosocial assessment and care|
214313125|NCT00253383|PROCEDURE|quality-of-life assessment|
214671239|NCT03838848|DRUG|KN046|5mg/kg, Q3W, intravenous injection (IV)
214671240|NCT03838848|DRUG|Carboplatin|AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
214313126|NCT06038201|PROCEDURE|LAMS placement for cholecystostomy|The EUS-guided cholecystostomy entails placing a 10 mm x 10 mm or 10mm x 15mm Electrocautery-Enhanced LAMS for direct cholecystoscopy with a transnasal gastroscope. Then, the cholecystostomy will be performed with an echoendoscope, assisted by fluoroscopy to allow the puncturing of the gallbladder form either the duodenal bulb (cholecysto-duodenoscopy) or the gastric antrum (cholecysto-gastrostomy). Subsequently, from the most optimal anatomic point it will be tutored with a 10mmx10mm or 10mm x 15mm LAMS to create anastomosis between the structures. Then, the stone clearance will be performed by endoscopy (basket catheters) or by cholangioscopy (mechanical lithotripsy with or without basket catheters).
214671241|NCT03838848|DRUG|Pemetrexed|500 mg/m2, Q3W, intravenous injection (IV)
214671242|NCT03838848|DRUG|Ningetinib|Oral, QD
214671243|NCT06244966|DIAGNOSTIC_TEST|HIV diagnostic testing|Finger-prick capillary blood will be tested alongside venous blood
214671244|NCT00479466|DRUG|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
214671245|NCT00479466|DRUG|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
214671246|NCT00479466|DRUG|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
214671247|NCT00479466|DRUG|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
214671248|NCT04170140|OTHER|No intervention|Questionnaire
214917965|NCT02951208|BEHAVIORAL|Active VR Motivation Training|Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.
214917966|NCT02951208|DEVICE|Sham tDCS|Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
214917967|NCT02951208|BEHAVIORAL|Sham VR Motivation Training|Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
214917968|NCT03537976|OTHER|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
214917969|NCT03734289|BEHAVIORAL|Caregiver Coaching|Online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
214917970|NCT03313466|BEHAVIORAL|Internet cognitive behavioral therapy for insomnia (iCBTI)|An internet-based program for providing individually tailored CBTI based on participant responses to questions and performance on weekly guided sleep strategies.
214917971|NCT03313466|BEHAVIORAL|Class in sleeping well and improving insomnia|A group education session providing advice on healthy sleep habits and ways to improve common forms of insomnia.
214917972|NCT02177526|DEVICE|Imaging|15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
214481585|NCT06193083|OTHER|The self-administered questionnaires, rPATD and BMQ|"rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.~This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal). Following the analysis of Phase 1 Qualitative of the protocol, three additional questions~BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .~The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.~It comprises 10 items relating to specific beliefs about prescribed treatments:~A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief."
214481586|NCT06193083|OTHER|The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)|"FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )~Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :~Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations"
214671249|NCT01325493|DRUG|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
214481587|NCT06095271|DIAGNOSTIC_TEST|serum Neurofilament Filament Light chain (sNfL) monitoring|the intervention consist of a blood draw and providing the sNfL information to the treating physician
214481588|NCT05554107|OTHER|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists and/or physicians with special interest in POTS.
214481589|NCT05067348|DRUG|Tocilizumab Injectable Product|Participants will receive IV tocilizumab
214481590|NCT06448312|DRUG|SKB264|IV Infusion
214481591|NCT06448312|DRUG|Pembrolizumab|IV Infusion
214481592|NCT06548698|OTHER|escape room|Nursing students in the intervention group analyzed the breast cancer surgery case with the escape room experience.
214481593|NCT06114680|DEVICE|CochSyn test prototype|The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.
214481594|NCT06114680|DEVICE|Universal Smart Box (USB)|Commercially available EEG system intended for use in the diagnosis of hearing related disorders, hearing threshold detection, and other conditions that may affect the responses to auditory, tactile, or visual stimuli. The USB Box hardware and accompanying software programs can be used with patients of all ages. It is intended for use by trained personnel in a hospital, nursery, clinic, audiologist's office, or other appropriate setting.
214671250|NCT01325493|DRUG|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
214671251|NCT02610283|DRUG|QPI-1002|IV injection
214671252|NCT02610283|DRUG|Placebo|isotonic saline
214671253|NCT00124423|PROCEDURE|Megavoltage CT scan|
214671254|NCT01094899|RADIATION|Radiography|Radiography, microscanner, osteodensitometry
214671255|NCT01094899|OTHER|Urine and Blood sampling|mainly dosage of bones metabolism
214481595|NCT05448014|BEHAVIORAL|Compassion focused group therapy online|Seven sessions of therapist-led online compassion-focused therapy in groups of 4-8 adolescents with mild to moderate symptoms of distress, anxiety, or depression. Trained therapists administer the CFT program in face-to-face meetings.
214671256|NCT01094899|OTHER|Echography|body bones echography
214671257|NCT05602467|DEVICE|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
214671258|NCT05602467|OTHER|Treatment as usual (TAU)|Treatment-as-usual (TAU) in the Hong Kong outpatient clinic without TPS intervention was given. They would receive the standard care for mild NCD including counselling, lifestyle modification, cognitive training and antidementia medications occasionally depending on the case doctor's judgement.
214671259|NCT04976075|OTHER|no interventions|no interventions
214671260|NCT03530163|DEVICE|Respiratory Muscle Training|Subjects will breathe through a custom isocapnic Respiratory Muscle Training method developed in-house. The initial breathing frequency will be 30 breaths per minute. Subsequent sessions will begin with 20 minutes of breathing at the highest rate attained on the previous training day. During the last 10 minutes of each session, breathing rate will increase by 1-2 breaths/min.
214671261|NCT03530163|DEVICE|Sham Breathing Training|Each subject in the sham group will be prompted to hold his breath for 10 seconds every 30 seconds (two times each minute) while breathing on a circuit visibly identical to that used in Respiratory Muscle Training. The subject will breathe ambient air normally after each breath hold. Each sham session will last 30 minutes total.
215060922|NCT01393795|DRUG|Qutenza|8% patch
215060923|NCT01393795|DRUG|Tegaderm|No active drug
214671262|NCT01923610|BIOLOGICAL|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-\~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
215060924|NCT03463863|PROCEDURE|rectus sheath midurethral sling|
215060925|NCT01962428|DRUG|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
215060926|NCT02561481|DRUG|Sulforaphane|See under active arm description
215060927|NCT02561481|DRUG|Placebo|See under placebo arm description
214313127|NCT06038201|PROCEDURE|Laparoscopic cholecystectomy|A laparoscopic biliary exploration along with an elective laparoscopic cholecystectomy will be performed by experienced laparoscopic surgeons (over 100 laparoscopic procedures yearly) by three or four-trocar technique with transection of the cystic duct and artery.
214671263|NCT01458769|DRUG|C-10276|C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose
214671264|NCT01458769|DRUG|C-10276|C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose
214313128|NCT01289847|BIOLOGICAL|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
214313129|NCT05876273|DEVICE|Neural-net Artificial Pancreas|NAP is a neural-net implementation of the previously tested UMPC algorithm (below).
214313130|NCT05876273|DEVICE|University of Virginia Model Predictive Control|A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.
214313131|NCT00908726|DRUG|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
214313132|NCT06470412|OTHER|Control group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
214313133|NCT06470412|OTHER|AI-Guided Group|Participants receive supplement prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
214313134|NCT06373497|DIAGNOSTIC_TEST|18-F-NaF Cardiac PET/MRI and|All eligible subjects will receive 18-F-NaF Cardiac PET/MRI at baseline and 6 months after the completion of radiotherapy where the heart is in the treatment field
214313135|NCT06373497|DIAGNOSTIC_TEST|CT Angiogram|All eligible subjects will receive CT Angiogram at baselin
214313136|NCT04033601|BEHAVIORAL|Non-pharmacological intervention|The non-pharmacological intervention will comprise sleep hygiene education, exercise training and relevant modules of cognitive behavioral therapy.
214313137|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the medial orbitofrontal regions over long periods of time.
214917973|NCT04869774|DEVICE|How2Trak mobile application|Patients will undergo virtual monitoring of their incision and symptoms using the How2Trak application(app). Using the app, patients will be asked to answer a series of questions and photograph their surgical incision on post-operative day 3, 5, 7, 10, 20, and 30. Patient responses and photographs entered into the app will be reviewed within 72 hours by a trained Nurse Specialized in Wound, Ostomy and Continence. If a concern is identified the nurse will contact the patient to arrange a virtual visit using the how2trak app or notify the surgeon team (including colorectal surgeons and physician residents) in accordance with clinical discretion.
215060928|NCT00148486|DRUG|NS 2330|
214313138|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the lateral orbitofrontal regions and networks over long periods of time.
214313139|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus)|CBOT device enhanced with BCP.
214313140|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactory stimuli (i.e., not programmed for short or long burst), and without BCP enhancement.
214313141|NCT02051036|PROCEDURE|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
214313142|NCT05774834|OTHER|No intervention|No intervention
214313143|NCT04809324|PROCEDURE|Gross examination of the resection specimen|measurement of the surgical margin by the operating surgeon using sterile scale, margins \<7mm will be revised on table
214313144|NCT04809324|PROCEDURE|Frozen section|frozen section evaluation of the specimen by the pathologist
214313145|NCT01120613|DRUG|Chronotherapy|"Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:~1. ACE or ARB~2. Calcium Channel Blockers~3. Alpha Blocker~4. Beta Blocker~If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed."
214313146|NCT00579111|DRUG|Campath|10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
214313147|NCT00579111|DRUG|Busulfan|3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
214313148|NCT00579111|DRUG|Fludarabine|30mg/m2/day IV daily for 4 days on Day -5 to D -2
214313149|NCT00579111|PROCEDURE|Hematopoietic stem cell infusion|Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
214671265|NCT01458769|DRUG|C-10297|C-10297 200 mg, oral, single dose
214671266|NCT01458769|DRUG|C-10299|C-10299 200 mg, oral, single dose
214671267|NCT01458769|DRUG|C-10297|C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose
214671268|NCT01458769|DRUG|C-10299|C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose
214671269|NCT01458769|DRUG|C-10276|C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose
214671270|NCT01458769|DRUG|Reyataz®|Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
214671271|NCT02723435|DRUG|Midostaurin|Given PO
215060929|NCT02069821|DRUG|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
215060930|NCT02398136|DRUG|Ketamine|
215060931|NCT02398136|DRUG|Midazolam|
214313150|NCT00579111|DRUG|FK-506|FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
214313151|NCT05548660|OTHER|Pharmacogenetic testing|Genetic testing of CYP2B6, CYP2C19, CYP2C9, CYP2C cluster CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-A, HLA-B, IFNL4, NUDT15, SLCO1B1, TPMT, UGT1A1, and VKORC1.
214313152|NCT05548660|OTHER|Pharmacist note with genotype-guided analgesic recommendations|"CYP2C9 normal metabolizers will be recommended to receive ibuprofen and intermediate and poor metabolizers will be recommended to receive naproxen.~CYP2D6 normal metabolizers will be recommended to receive tramadol and ultrarapid, intermediate and poor metabolizers will be recommended to receive oxycodone."
214313153|NCT05548660|OTHER|Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines|Genotype-guided recommendations for all actionable phenotypes resulted from the 16-gene PGx panel per CPIC guidelines and FDA labeling
214313154|NCT04327999|DRUG|Artificial Tears|Self-Administered - utilizing eye drop preservative free vials
214313155|NCT03990896|DRUG|Talazoparib|"Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells."
214313156|NCT04958057|BEHAVIORAL|SAIL|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
214313157|NCT03943563|DIAGNOSTIC_TEST|Dixon sequences acquisition|Dixon sequences acquisition
214313158|NCT03975647|DRUG|tucatinib|300mg given twice per day by mouth (orally)
214313159|NCT03975647|DRUG|placebo|Given twice per day orally
214313160|NCT03975647|DRUG|T-DM1|3.6 mg/kg given into the vein (IV; intravenously) every 21 days
214313161|NCT05788458|DRUG|Bupivacain|"The blocks will be performed in supine position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) will be initially placed in a transverse plane over the anterior superior iliac spine (ASIS) and then alignes to identify the following landmarks: Anterior inferior iliac spine, ilio-pubic eminence, iliopsoas muscle and tendon, the femoral artery, and Pectineus muscle. Point of injection will be musculo-fascial plane between the psoas tendon and ilio-pubic eminence."
214313162|NCT05836402|DIETARY_SUPPLEMENT|Low carbohydrate diet intervention|"Patients will receive a study kit. The kit will contain the following:~* Instruction sheet containing medical food instructions and food journal and a web link to the weekly online journal~* A 30-day supply of the medical food, KetoCitra, developed by Santa Barbara Nutrients, Inc. KetoCitra® is a ready-to-mix powder to be dissolved in water and taken twice per day with meals. KetoCitra® contains BHB, citrate, and a blend of minerals (potassium, calcium, magnesium) and is flavored with natural lemon flavor and stevia natural sweetener. KetoCitra® is sugar- and sodium-free and is intended to support the metabolic switch aimed for with the low-carbohydrate diet by providing exogenous BHB (Package insert)"
214313163|NCT03903354|OTHER|Incidence of infections within 7 days postoperatively|Measure blood glucose concentration intraoperatively and evaluate incidence of infections 7 days after surgery
214313164|NCT05446883|DRUG|QL1706|Intravenous Infusion
214313165|NCT05446883|DRUG|Placebo|Intravenous Infusion
214313166|NCT05446883|DRUG|Paclitaxel injection|Intravenous Infusion
214313167|NCT05446883|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
214313168|NCT06278324|DEVICE|Nasal Spray HSV Treatment|Nasal treatment with the nasal spray Humer Stop Virus for 7 days, 2-3 puffs per nostril, 3-4 per day, space applications 4 hours apart.
214313169|NCT02872116|DRUG|Nivolumab|Specified dose on specified days
214313170|NCT02872116|DRUG|Ipilimumab|Specified dose on specified days
214313171|NCT02872116|DRUG|Oxaliplatin|Specified dose on specified days
214671272|NCT02270177|OTHER|Telemedicine, videoconsultation|We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
214313172|NCT02872116|DRUG|Capecitabine|Specified dose on specified days
214313173|NCT02872116|DRUG|Leucovorin|Specified dose on specified days
214313174|NCT02872116|DRUG|Fluorouracil|Specified dose on specified days
214313175|NCT04663581|OTHER|Left Sided Colonoscopy|Starting colonoscopy with the patient in left decubitus
214313176|NCT04663581|OTHER|Right Sided Colonoscopy|Starting colonoscopy with the patient in right decubitus
214313177|NCT04828668|DIETARY_SUPPLEMENT|Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)|Hemp seed oil
214313178|NCT05578781|BEHAVIORAL|Music Therapy|Music Therapy is a music session with a live therapist and has been shown to reduce pain and anxiety. If effective the music medicine in this RCT will be used help design a full R01 study
214313179|NCT05578781|BEHAVIORAL|Music Medicine|Music Medicine is an audio recorded music therapy session that will be played for the participant. This will be the same music session that will be played live in the music therapy session.
214313180|NCT05578781|BEHAVIORAL|Control group|Control group will listen to an audio recording of text being spoken by the board certified music therapist
214313181|NCT01460433|PROCEDURE|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
214313182|NCT06026865|DIETARY_SUPPLEMENT|S-Adenosyl-L-methionine (SAMe)|S-adenosyl-L-methionine 1200 mg/daily as 2400mg S-Adenosyl-L-methionine disulfate tosylate
214313183|NCT06026865|OTHER|Placebo|Placebo of identical appearance, smell and taste, with the same schedule.
214671273|NCT02255838|DEVICE|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
214671274|NCT02255838|DEVICE|Bronchoscope disposable (aScope 4)|Bronchoscopy and alveolar lavage
214671275|NCT01367132|PROCEDURE|Doppler ultrasound|Ultrasound using Doppler mode to detect blood flow in umbilical cord vasculature and determine the number of vessels present
214671276|NCT04902248|DEVICE|The OTSC® System Set|The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion
214313184|NCT05346263|DEVICE|Intermittent Abdominal Pressure Ventilation|Patients of experimental group will use IAPV in daytime ventilation. Intermittent abdominal pressure ventilation (IAPV) is a portable ventilator with an internal battery and PneumoBelt corset as an interface.
214313185|NCT05346263|DEVICE|Usual ventilation|NIV
214313186|NCT03588221|PROCEDURE|four sets of hand hygiene measurements per participant|"1. Six-step hand hygiene technique with an application time of 30 seconds~2. Six-step hand hygiene technique with an application time of 15 seconds~3. Three-step hand hygiene technique with an application time of 30 seconds~4. Three-step hand hygiene technique with an application time of 15 seconds"
214313187|NCT05528237|DEVICE|Flocked swab paired with Roche Cobas 4800|Consenting individuals will insert the sterile flocked swab into the vagina, rotate at least once, and store in the provided dry tube. The sample will be stored at ambient temperature and routed to the lab for HPV testing with Roche Cobas 4800.
214313188|NCT04227847|DRUG|SEA-CD70|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
214313189|NCT04227847|DRUG|azacitidine|75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
214313190|NCT04227847|DRUG|Venetoclax|400 mg /day PO, continuously; administered with ramping
214313191|NCT04839614|OTHER|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral|See arm description
214313192|NCT03278964|PROCEDURE|Orbital decompression|
214313193|NCT06042036|OTHER|Spontaneous mode of mechanical ventilation|any mode of mechanical ventilation classified as spontaneous or proportional, mainly pressure support ventilation, but also CPAP, APRV, NAVA, PAV+
214313194|NCT00733863|BIOLOGICAL|Placebo|
214313195|NCT00733863|BIOLOGICAL|CAD106|
214313196|NCT02389504|OTHER|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
214313197|NCT02389504|OTHER|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
214671277|NCT04902248|PROCEDURE|angiographic embolization|Transcatheter selective embolization to bleeding arteries
214671278|NCT03792958|DRUG|CM082|CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
214313198|NCT03437785|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
214313199|NCT03437785|DRUG|CKD-495 150mg|CKD-495 150mg Tab.
214313200|NCT03437785|DRUG|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
214313201|NCT03437785|DRUG|Rebamipide 100mg|Rebamipide 100mg Tab.
214313202|NCT03437785|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
214313203|NCT03437785|DRUG|Placebo of the CKD-495 150mg|Placebo of the CKD-495 150mg Tab.
214313204|NCT03437785|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
214313205|NCT03437785|DRUG|Placebo of the Rebamipide 100mg|Placebo of the Rebamipide 100mg Tab
214313206|NCT03591237|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
214313207|NCT00532285|DRUG|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
214313208|NCT04659278|DIETARY_SUPPLEMENT|Endourage 1200 mg OMD ™ Oral Mucosal Drops|The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
214313209|NCT04659278|DIETARY_SUPPLEMENT|Isolate|The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
214313210|NCT04659278|OTHER|Placebo|Total CBD = CBD + (CBD-A \* 0.877). Total THC = THCA-A \* 0.877 + Delta 9 THC, ND = \<LOQ, T-Caryophyllene = Trans-Caryophyllene, \<LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
214313211|NCT04659278|DIETARY_SUPPLEMENT|Peppermint Oil, masking flavor|Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
214313212|NCT04167007|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days
214313213|NCT04167007|DRUG|FOLFOX|Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
214481596|NCT04149600|PROCEDURE|Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.|Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.
214481597|NCT05425355|DRUG|Intravenous (IV) acetaminophen + oral placebo|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
214671279|NCT04076566|DEVICE|alfapump system|active implantable device for treatment of malignant ascites
214313214|NCT03735667|DEVICE|ACURATE neo2™ Transfemoral TAVR System|ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
214313215|NCT03735667|DEVICE|Medtronic CoreValve TAVR System|Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
214313216|NCT03735667|DEVICE|Edwards SAPIEN 3 TAVR System|Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
214313217|NCT03735667|DEVICE|ACURATE Prime™ Transfemoral TAVR System XL|ACURATE Prime™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
214313218|NCT06564584|DRUG|TLC-2716 Dose 1|Capsules administered orally
214313219|NCT06564584|DRUG|TLC-2716 Dose 2|Capsules administered orally
214313220|NCT06564584|DRUG|Placebo|Capsules administered orally
214313221|NCT05114421|DRUG|Lenvatinib|Given PO
214313222|NCT05114421|BIOLOGICAL|Pembrolizumab|Given IV
214313223|NCT06114758|DRUG|Cytotec 200Mcg Tablet|the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered
214313224|NCT06114758|DRUG|Transamine|1 gram intravenous slow infusion intraoperatively as we start the laparatomy
214313225|NCT04770584|BEHAVIORAL|Fear Conditioning|Participants will be administered increasing intensities of mild electric shock via electrodes connected to the foot. New Biopac stimulators that can deliver higher shock intensity, provided participants agreement will be used to assure adequate conditioning levels. Stimulation is measures in milliamps (mA), and each delivered stimulation will be 0.5 seconds long (500 milliseconds). To colored (blue, red, \& yellow) light stimuli (CS). The light stimulus is followed by a shock or no shock depending on color.
214313226|NCT04770584|OTHER|Avoidance conditioning|Via button pressing. Only one stimulus-CS will enable control over experiencing the shock: the participant can press the button during the first 2 seconds of the light presentation to avoid the shock.
214313227|NCT04770584|OTHER|Pavlovian fear extinction learning|After avoidance conditioning, the CS+ associated with avoidance responding appears with no button to press and no shock is administered.
214313228|NCT04770584|OTHER|Willingness to pay to avoid shock|On the next day, participants receive a monetary stipend to use to pay to guarantee that they are not to receive any shocks if they press a button from the CS+. This and all previously described experimental phases noted above will occur inside of the fMRI scanner.
214313229|NCT05261984|PROCEDURE|Resistance exercise|Knee extensions in flywheel inertia machine in four sets of 10 repetitions.
214313230|NCT05261984|DIETARY_SUPPLEMENT|Oral protein supplementation|24 grams of hydrolyzed whey protein.
214313231|NCT01464658|PROCEDURE|panniculectomy|surgery
214481598|NCT05425355|DRUG|Intravenous (IV) placebo plus oral acetaminophen|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
214917974|NCT06303557|DRUG|Preoperative Erector Spinae Plane Block|Erector spinae plane block will be performed bilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the prone position.
215060932|NCT03790813|DIAGNOSTIC_TEST|Intervention 1|Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
215060933|NCT03790813|DIAGNOSTIC_TEST|Intervention 2|MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
214313232|NCT03552575|DRUG|sacubitril/valsartan|Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
214481599|NCT02354547|GENETIC|SGT-53|The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
214671280|NCT05372315|DRUG|Dextenza 0.4Mg Ophthalmic Insert|(dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.
214671281|NCT01784510|PROCEDURE|distance of dissection of gastrocolic ligament from pylorus|
214313233|NCT03552575|DRUG|Valsartan|is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
214917975|NCT06303557|DRUG|Postoperative Erector Spinae Plane Block|Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the prone position.
214917976|NCT02914704|DEVICE|MRI-HIFU|Treatment of uterine fibroids with MRI-HIFU
214917977|NCT00846001|PROCEDURE|Coronary artery bypass grafting|Standard coronary surgry according guidelines
214313234|NCT03984422|OTHER|Smartphone application|use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
214313235|NCT00790439|DRUG|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
214313236|NCT00790439|DRUG|Heparin|Anticoagulant
214313237|NCT00790439|DRUG|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
214481600|NCT02354547|DRUG|Topotecan|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
214313238|NCT00790439|DRUG|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
214481601|NCT02354547|DRUG|Cyclophosphamide|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
214481602|NCT05965414|DRUG|CS6253 Solution for Injection|Solution for intra-venous injection, 50mg CS6253 /mL. Single-use vials containing 100 mg CS6253 (2 mL of 50 mg/mL concentration)
214481603|NCT05965414|DRUG|Placebo|Physiological saline solution for intra-venous injection
214481604|NCT06070051|BIOLOGICAL|VRON-0200-AdC6|VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector
214313239|NCT00790439|DRUG|Tacrolimus|Calcineurin inhibitor
214313240|NCT00790439|DRUG|Cyclosporine|Calcineurin inhibitor, immunosuppressant
214313241|NCT00790439|DRUG|Daclizumab|Monoclonal IL-2 receptor blocker
214313242|NCT00790439|DRUG|Basiliximab|Monoclonal IL-2 receptor blocker
214313243|NCT00790439|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|
214313244|NCT02533336|DRUG|abamectin and fenpyroximate|
214313245|NCT00729339|DRUG|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
214313246|NCT00729339|DRUG|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
214313247|NCT05278078|OTHER|psychological support|psychological support will be given to the patients in the experimental group.
214481605|NCT06070051|BIOLOGICAL|VRON-0200-AdC7|VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector
214671282|NCT00388739|DRUG|Intervention: Budesonide|Patients 1-5 years of age who are randomly assigned to the treatment arm will be given a one month supply as well as a prescription (for a 6 month supply) for Pulmicort respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
215060934|NCT01574287|DRUG|FACBC|Drug is give intravenously over 2 minutes at time of scan
215060935|NCT02137018|DEVICE|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
215060936|NCT02137018|DEVICE|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
215060937|NCT02470585|DRUG|Veliparib|Capsules for oral administration
215060938|NCT02470585|DRUG|Paclitaxel|Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
215060939|NCT02470585|DRUG|Carboplatin|Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
214313248|NCT05278078|OTHER|nutritional education|nutritional education will be given to the patients in the experimental group.
214313249|NCT05278078|OTHER|psychological support and nutritional education|psychological support and nutritional education will be given to the patients in the experimental group.
214313250|NCT05278078|OTHER|no intervation|No intervention will be applied to the control group
214313251|NCT06219681|BEHAVIORAL|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the repetitive negative thinking (RNT) related brain functional connectivity.
214313252|NCT06219681|BEHAVIORAL|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
214313253|NCT01720433|PROCEDURE|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
214313254|NCT05904717|DRUG|PXS-4728 (A)|Participants will receive once daily (QD) for period of 12 weeks
214313255|NCT05904717|DRUG|Matching Placebo (B)|Participants will receive once daily (QD) for period of 12 weeks
214481606|NCT06070051|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
214481607|NCT06070051|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
214481608|NCT03174314|BEHAVIORAL|Standard object battery and training sequence|Used to examine human localization and identification performance. Object battery will include: trip hazards ('pucks' with various height/width combinations to represent children's toys, street debris, rocks, pets, etc.), furniture (chairs, desks, couches, benches), people, walls, and corridors. Objects will be recorded by placing them to the right or left on the path-of-travel. Raw sensor outputs for single obstacles and walls in isolation (trip-hazard pucks with 8 heights, chair, desk, person, wall) and the same set of single obstacles against a wall. This set of 23 raw sensor traces can be used in various combinations (e.g., encountering a curb and then a person, or a chair) to create a training sequence that will help experimentally naïve subjects to understand the correspondence between tactile stimulation and the real-world scenario it is intended to depict.
214481609|NCT03174314|DEVICE|VIS4ION System|"When in Assistive Mode, participants will navigate campus while receiving navigation assistance (acquiring data and simultaneously providing assistance/audio feedback). When in Passive Mode, participants will navigate campus wearing the backpack without receiving navigation assistant."
214481610|NCT04314544|DRUG|TILD|one 1 mL injection of study medication
215060940|NCT02470585|OTHER|Placebo to Veliparib|Capsules for oral administration
214481611|NCT04314544|DRUG|matching placebo injections|one 1 mL injection of placebo
214671283|NCT00388739|DRUG|Usual care: albuterol + systemic steroids|All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.
214671284|NCT00802477|PROCEDURE|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
214313256|NCT05319444|DEVICE|Off-brand Waterpik®|"Study staff will use the Waterpik® device and brush for approximately two to five minutes on the participant's scalp until all scale and other debris appears to be resolved. Their scalp will then be rinsed and gently dried with a towel.~The off-label design utilizes the Waterpik® device, but with adjustments optimized for scalp health. The device settings are adjustable during the treatment, ranging from settings of 2-10. Study staff plan to utilize the setting of 10 unless the participant indicates discomfort. Investigators attached a small Losophy brush in replacement of the Waterpik® toothbrush. The small Losophy brush was connected to the device via PVC heat shrink and a hole was drilled on the brush in order to deliver water while simultaneously utilizing the brush on the scalp."
214671285|NCT00802477|PROCEDURE|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
215060941|NCT05726331|OTHER|Chiropractic Care|Chiropractic care will be delivered by community-based chiropractors that meet pre-set qualifications. Chiropractic treatment protocol will be multimodal and will follow predefined standard operating procedures including the following 6 components: 1) Posture correction and spinal stabilization exercises; 2) Soft tissue release techniques; 3) Manual spinal manipulation; 4) Condition-specific education; 5) Myofascial strengthening and motor control training; 6) Ergonomic and lifestyle modifications/advice. Subjects randomized to chiropractic treatment groups will receive up to 10 chiropractic sessions over 16 weeks.
214313257|NCT04648865|DRUG|LY3537031|Administered SC.
214481612|NCT06435780|PROCEDURE|DIPRF|Denuded interpositional pedicled rolled flap technique
214481613|NCT05660486|OTHER|Aromatherapy|Participants in this group will receive 2-3 drops of 100% pure Lavandula angustifolia essential oil applied to a surgical mask pre-procedure for aromatherapy.
214671286|NCT04346225|DRUG|Hyperpolarized C13|Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
214671287|NCT04346225|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
214671288|NCT01283620|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
214671289|NCT01283620|OTHER|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
214671290|NCT01231191|DRUG|Intravenous acetaminophen|Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
214671291|NCT01231191|DRUG|Intravenous placebo|Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
214671292|NCT01184989|DRUG|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
214671293|NCT02242396|DRUG|Telmisartan|
214671294|NCT02242396|DRUG|Telmisartan hydrochlorothiazide|
214671295|NCT04970680|PROCEDURE|glossopharyngeal nerve block|glossopharyngeal nerve block either blindly or using the ultrasonic technique
214481614|NCT05660486|OTHER|Placebo|Participants in this group will receive 2-3 drops of water applied to a surgical mask pre-procedure.
214481615|NCT01663831|OTHER|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
214481616|NCT05527418|DRUG|Dasatinib|Dasatinib monotherapy 70 mg/day, during 16 weeks.
214481617|NCT05527418|DRUG|Placebo|Placebo during 16 weeks.
214671296|NCT01570491|OTHER|ultrasound-guided spinal anesthesia|ultrasound-guided technique for block placement
214671297|NCT01570491|OTHER|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
214313258|NCT04648865|DRUG|Placebo|Administered SC.
214313259|NCT02550496|DEVICE|Dermoscopy|
214481618|NCT05564325|DEVICE|SmartGUIDE (deflectable guidewire)|SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
214671298|NCT01606722|DRUG|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
214671299|NCT05575518|DRUG|Optimised rifamycin|optimised dose rifampicin with or without moxifloxacin
214671300|NCT01582724|PROCEDURE|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
214671301|NCT03047213|DRUG|Sapanisertib|Given PO
214917978|NCT00846001|DEVICE|Epicardial implantation of cardiac resynchronization therapy device|During the cardiac surgery, the CABG+CRT arm patients will be implanted with epicardial leads to the right atrium, right and left ventricles. Left ventricle leads will be fixed to the posterolateral wall provided that there is no scar or fat tissue (behind and 2-3 cm apical than obtuse marginal artery). Right atrial and right ventricular leads will be fixed in a traditional way. Then the leads will be guided into a preformed pocket (left subclavian region) and connected with the CRT device.
214313260|NCT01746212|PROCEDURE|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
214313261|NCT01746212|BIOLOGICAL|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
214313262|NCT01746212|DEVICE|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
214313263|NCT04424238|BEHAVIORAL|m-health management|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.
214313264|NCT02984358|OTHER|Animal protein based diet|
214313265|NCT02984358|OTHER|Low-nucleotide mycoprotein based diet|
214313266|NCT02984358|OTHER|High-nucleotide mycoprotein based diet|
214313267|NCT05996107|DRUG|Ribociclib|400 mg daily with a possibly dose reduction to 200 mg daily if required
214313268|NCT05996107|RADIATION|Postoperative Radiation Therapy|50 Gy in 25 fractions or 42.56 Gy in 16 fraction +/- 10 Gy boost including comprehensive nodal
214313269|NCT01271868|BIOLOGICAL|IB1001|
214313270|NCT00125866|BEHAVIORAL|Flavonoid rich or flavonoid depleted chocolate drink|
214313271|NCT05424536|OTHER|Bone measurement by DXA and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites plus femoral neck, one measurement will be performed by DXA to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
214313272|NCT02680821|PROCEDURE|ALL reconstruction (Anterolateral ligament)|
214313273|NCT02680821|PROCEDURE|ACL revision (Anterior cruciate ligament )|
214671302|NCT05434910|OTHER|Changes in mean arterial pressure|MAP set at 65 mmHg for 25 min by infusion of noradrenaline. MAP set at 80 mmHg for 25 min by infusion of noradrenaline. MAP set at 95 mmHg for 25 min by infusion of noradrenaline.
214671303|NCT05561621|OTHER|Voice analysis|Voice analysis
214671304|NCT03656640|DRUG|Gammanorm|Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
214917979|NCT02097563|BEHAVIORAL|High Intensity Training|This is a training method involving a live workshop followed by high intensity technical consultation.
214917980|NCT02097563|BEHAVIORAL|Low Intensity Training|Clinicians complete an online workshop in family-focused therapy, followed by technical consultation sessions after every third session.
214313274|NCT02562651|DRUG|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
214917981|NCT00004863|DRUG|GEM 231|
214917982|NCT00004863|DRUG|paclitaxel|
214313275|NCT02562651|OTHER|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
214313276|NCT05400616|PROCEDURE|Microbiome Transplant|A raw microbiome, is collected from a donor without any sinonasal health problems, as a nasal lavage.
214313277|NCT05400616|PROCEDURE|Placebo|Normal saline.
214313278|NCT05526326|DEVICE|Transplant with normothermic machine perfused (NMP) donor liver|The enrolled recipient will receive a DBD or DCD donor liver that underwent normothermic machine perfusion with the OrganOx metra®
214313279|NCT05372120|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression
214313280|NCT01185873|DRUG|danoprevir|Repeated oral doses
214917983|NCT06094725|DRUG|Relacorilant|Relacorilant 300 mg (3 X 100 mg softgel capsules) for oral administration
214313281|NCT01185873|DRUG|ritonavir|Repeated oral doses
214313282|NCT01379742|DEVICE|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
214313283|NCT01379742|DEVICE|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
214313284|NCT03387449|DEVICE|Bimanual Arm Training|Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
214313285|NCT00165412|PROCEDURE|breast MRI|Repeated once a year for three years
214313286|NCT00165412|PROCEDURE|Mammogram|Repeated once a year for three years
214313287|NCT02772562|BIOLOGICAL|PROSTVAC-V/F|"0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.~0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141."
214671305|NCT03692273|PROCEDURE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
214671306|NCT03692273|PROCEDURE|0.5mm punch biopsy|punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
214671307|NCT01479790|DEVICE|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
214671308|NCT01635569|BEHAVIORAL|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
214671309|NCT01635569|OTHER|Waitlist|Baseline and post-12 sessions
214313288|NCT00006478|BIOLOGICAL|autologous tumor cell vaccine|
214481619|NCT05564325|DEVICE|Standard of care guidewire (different models may be used)|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
214481620|NCT03938090|DEVICE|Optimised MultiSite Pacing|The intervention includes using optimal programming settings with MultiSite pacing configurations via the patient's CRT device. The device in use is the same for each arm, the only changes are the programming settings.
214481621|NCT03938090|DEVICE|Standard biventricular pacing|Conventional programming settings using biventricular pacing will be used
214481622|NCT05294172|DRUG|KL-A167|KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.
214481623|NCT05294172|DRUG|Gemcitabine|4-6 cycles for combined therapy
214481624|NCT05294172|DRUG|Cisplatin|4-6 cycles for combined therapy.
214313289|NCT00006478|BIOLOGICAL|keyhole limpet hemocyanin|
214313290|NCT00006478|BIOLOGICAL|sargramostim|
214313291|NCT00006478|PROCEDURE|adjuvant therapy|
214481625|NCT05294172|DRUG|Placebo|4-6 cycles for combined therapy.Placebo maintenance.
214481626|NCT06238882|COMBINATION_PRODUCT|Nitroglycerin|Patients in the intervention group will receive four 8mg-patches (36 mg final dose) of transdermal nitroglycerin with 10 mg release in 24 hours, for 24 hours with 12-hour rest intervals (to avoid receptor saturation) during treatment with radiation therapy (30 Gy in 10 fractions, or 10 days of treatment).
214481627|NCT05712824|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
214481628|NCT06149624|BEHAVIORAL|upfront advice to walk|Control participants will be given upfront advice to walk and also given the wearable activity monitor (Fitbit) and asked to record the total steps achieved each day in a provided log book.
214671310|NCT01154725|BEHAVIORAL|Patient education and rehabilitation|Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
214671311|NCT01154725|BEHAVIORAL|habitual patient education|habitual patient education
214671312|NCT01522495|DEVICE|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
214671313|NCT01522495|DEVICE|SPY Imaging|SPY Imaging to assess tissue perfusion
214671314|NCT05760937|DRUG|BMS-986447|Specified dose on specified days
214313292|NCT06306456|DRUG|GH21|Oral, 15mg BIW/6mg QD
214313293|NCT06306456|DRUG|Tagrisso|Oral, 80mg QD
214671315|NCT05760937|DRUG|Placebo|Specified dose on specified days
214671316|NCT03887832|OTHER|SMBI digital app|Digital platform on the smartphone for the media package
214313294|NCT02768675|DEVICE|LOADPRO|The Intellirod LOADPRO sensor is a single-use, disposable instrument for the intra-operative measurement of posterior instrumented, spine rod strain.
214671317|NCT03887832|BEHAVIORAL|media package|The SMBI app contains a \<1 minute video of a mother and baby or just mother, a reflection question about the video, a few questions about their mood and stress, and some prompts and suggestions on what to do if they have problems.
214917984|NCT01371110|DRUG|Ketamine|Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.
214313295|NCT06493552|DRUG|SEphB4-HSA|A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.
214313296|NCT06493552|DRUG|Pembrolizumab|Antibody to human PD-1.
214313297|NCT06493552|DRUG|Gemcitabine|A chemotherapy drug used to treat various types of cancer.
214313298|NCT06493552|DRUG|Cisplatin|A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.
214313299|NCT06493552|DRUG|Enfortumab vedotin|Nectin-4-directed antibody and microtubule inhibitor conjugate.
214313300|NCT00265824|DRUG|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
214313301|NCT00265824|DRUG|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
214313302|NCT03243812|BIOLOGICAL|Blood sampling|Blood sampling will be performed to assess hematological and hemorheological parameters
214313303|NCT03243812|OTHER|Maximum Voluntary Contraction (MVC) test force|Maximum Voluntary Contraction (MVC) test force will be performed before and after a localized muscle endurance test
214671318|NCT03887832|OTHER|standard newborn and infant care|Recommended standard pediatric primary care will be provided for infants up to 6 months.
214671319|NCT01015443|BIOLOGICAL|Tecemotide|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 918 microgram (mcg) of tecemotide (L-BLP25) at Week 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at 6-Week intervals, beginning at Week 14 (maintenance phase) until disease progression (PD) is documented or the subject discontinues for any other reason.
214671320|NCT01015443|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
214671321|NCT01015443|DRUG|Placebo|Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
214671322|NCT01015443|OTHER|Saline|A single IV infusion of 0.9 percent (%) sodium chloride (saline) will be given 3 days before first placebo vaccination.
214917985|NCT01371110|DRUG|Midazolam|Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.
214313304|NCT03243812|OTHER|Localized muscle endurance test|Subject will perform 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
214313305|NCT03243812|OTHER|Self-paced six-minute walk test|Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society
214313306|NCT00855088|DRUG|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
214313307|NCT00855088|DRUG|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
214313308|NCT00855088|DRUG|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
214313309|NCT05369858|DRUG|[14C] SKLB1028|A single 150 mg oral dose of \[14C\] SKLB1028 containing approximately 120 microcurie of \[14C\] SKLB1028
214313310|NCT04796246|OTHER|Leap Motion Controller|Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
214313311|NCT04796246|OTHER|Conventional Physiotherapy|The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
214313312|NCT04534764|DEVICE|etafilcon A with cosmetic pattern|TEST
214313313|NCT04534764|DEVICE|1-Day Acuvue DEFINE Vivid Style|CONTROL
214313314|NCT00189748|DRUG|Tacrolimus|
214313315|NCT03583996|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Test|One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
214313316|NCT00164242|DRUG|Galantamine|
214313317|NCT03161483|DRUG|CC-220|CC-220
214313318|NCT03161483|OTHER|Placebo|Placebo QD PO
214313319|NCT01523548|DRUG|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
214313320|NCT05766306|DIETARY_SUPPLEMENT|Probiotic Blend|Participants will be taking 1 sachet a day, 3 billion CFU.
214313321|NCT05766306|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day.
214313322|NCT02767427|DEVICE|Chlorhexidine Wipes|(Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.
214313323|NCT02767427|OTHER|No intervention|Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
214313324|NCT03818165|BIOLOGICAL|CAR2 Anti-CEA CAR-T cells|doses will be delivered by hepatic arterial infusions using pressure enhanced delivery device (PEDD)
214313325|NCT00354445|DRUG|pegaptanib sodium (Macugen)|
214313326|NCT04128683|DRUG|amisulpride|Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
214313327|NCT04128683|DRUG|bromocriptine|Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
214313328|NCT04128683|DRUG|Placebo|Placebo pill with no active drug ingredients
214313329|NCT05984355|OTHER|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential application and captors which suggest a Walking itinerary
214313330|NCT03608488|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 50.000 IU/per week, for 8 weeks
214313331|NCT03608488|OTHER|Exercise|Core stability, balance exercises
214313332|NCT01544530|OTHER|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
214313333|NCT00881946|DRUG|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
214313334|NCT04448899|DRUG|Ivabradine Oral Tablet|Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.
214313335|NCT04448899|DRUG|Blacebo plus standard treatment|Blacebo plus standard treatment
214313336|NCT04081948|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
214671323|NCT01015443|OTHER|Best Supportive Care (BSC)|The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
214671324|NCT01515072|OTHER|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
214313337|NCT04081948|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
214313338|NCT03998553|PROCEDURE|IN VITRO MATURATION AND OOCYTE ACTIVATION|This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.
214313339|NCT02127632|DEVICE|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
214313340|NCT02127632|DEVICE|Laryngeal Mask Airway-Supreme|"Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson \& Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.~Other Names:~LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7"
214313341|NCT00980551|DRUG|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
214313342|NCT00980551|DRUG|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
214313343|NCT00980551|DRUG|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
214313344|NCT00980551|DRUG|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
214313345|NCT04345952|BEHAVIORAL|Calm Meditation Mobile App|The Calm Meditation Mobile App will be used to deliver the meditation intervention to study participants. The Calm app is downloaded onto the participant's smartphone.
214313346|NCT01222975|DRUG|Risperidone|orally disintegrating tablets
214313347|NCT02404350|BIOLOGICAL|Secukinumab|Anti IL-17a monoclonal antibody
214313348|NCT04238728|DEVICE|Silverlon|silver nylon dressing will be applied daily
214313349|NCT05698966|OTHER|we will use reduced dose of acceptable corticosteroids treatment for preterm birth|the two different group will differ in the doses of corticosteroids
214313350|NCT00793338|DRUG|Sildenafil|Sildenafil 20mg three times a day for 3 months.
214313351|NCT02901951|BIOLOGICAL|Engerix-B|Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.
214313352|NCT05727254|BEHAVIORAL|Agility training|Multi-component (strength, balance, cognition) exercise training.
214313353|NCT05727254|BEHAVIORAL|Exercise recommendations|Participants are being given the standard recommendations how much exercise and what type older adults should do.
214313354|NCT05727254|BEHAVIORAL|Exercise diary|Participants are instructed to write down their physical activity and exercises.
214671325|NCT01066416|PROCEDURE|Endoscopic Sinus Surgery|
214313355|NCT05389657|BEHAVIORAL|Web-based training|Web-based training will be divided into training modules that will be completed by participants over the course of 6-8 weeks. Training will include didactic training videos, knowledge checks, example sessions, and a library of resources.
214313356|NCT05389657|BEHAVIORAL|Live training|The live training will be delivered by two trainers over the course of two days via Zoom.
214313357|NCT05228275|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214313358|NCT05228275|OTHER|Survey Administration|Complete survey
214313359|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: control|The control/ sham comparator arm of the Mental Health Toolkit for Veterans (MeT4VeT) smart phone app contains only signposting information around support services available to military veterans
214313360|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: intervention|"The Mental Health Toolkit for Veterans (MeT4VeT) smart phone app has been developed through careful and close collaboration with military veterans and key providers of veterans' mental healthcare services. The aim of this app is to provide both a degree of education to support military veterans' understanding of mental health and foster self-recognition and management of mental health symptoms whilst also encouraging those who need it to seek more formal support.~The elements of the app have been chosen for inclusion as they represent the intersection between:~1. Core components of cognitive behavioural therapy, the theoretical framework underwriting the app~2. Behaviour change constructs"
214313361|NCT01972672|DRUG|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
214671326|NCT01066416|OTHER|medical therapy|Subjects will undergo surgery 6 months after randomization
214671327|NCT01103050|DRUG|QAV680 + Cetirizine Placebo|
214671328|NCT01103050|DRUG|QAV680 + Cetirizine|
214671329|NCT01103050|DRUG|Cetirizine + QAV680 Placebo|
214671330|NCT01103050|DRUG|QAV680 Placebo + Cetirizine Placebo|
214671331|NCT00609128|DRUG|olopatadine|olopatadine one drop in one eye for one week
214671332|NCT00650585|BEHAVIORAL|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
214313362|NCT06065826|OTHER|Assessment|All subjects will be assessed for FHP by taking a lateral view picture to calculate the CVA using the Kinovea software. Each subject with FHP will be examined for myofascial trigger points done by the therapist finger to palpate bilaterally on tender nodules in masticatory and neck muscles. Then using a pressure algometer, the PPT value will be scored for each trigger in each muscle bilaterally. Masticatory muscle endurance will be measured by asking the subject to bite on load sensor for as long as the subject can until exhaustion. Using a stopwatch, the time will be recorded in seconds. Using the craniocervical extension endurance test, the subject will lie prone with their head unsupported and with a bubble inclinometer attached to their head. Using a stopwatch, time in seconds will be recorded to test how long the subject can sustain the neck in neutral position. Finally, a smartphone addiction scale will be answered by the subject to identify how much they are addicted to its use.
214313363|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
214313364|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
214313365|NCT06471426|OTHER|Osteopathic Manipulative Treatment|The following methods of evaluation and treatment will be utilized on all subjects: Indirect myofascial release to the cervical region, osteopathic cranial manipulation, sacral articular technique.
214313366|NCT04237428|BIOLOGICAL|CD19 CAR-T cells infusion|"Biological: CD19 CAR-T cells infusion Biological: CD19 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD19 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD19 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD19 CAR-T cells are infused into patients for one time, the number of infused CD19 CAR-T cells are 0.5-4×10\^6/kg."
214313367|NCT01959152|DEVICE|HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode|
214313368|NCT00464828|PROCEDURE|Internal jugular vein cannulation|
214313369|NCT00464828|DEVICE|ultrasound|
214313370|NCT00906191|DRUG|SAM-531|
214313371|NCT00013117|BEHAVIORAL|Telephone specialist consultation|
214313372|NCT05933161|DEVICE|Freestyle Libre 3 Continuous Glucose Monitor (CGM)|Subjects will be provided a Freestyle Libre 3 CGM for monitoring of blood glucose levels throughout participation in the study (approximately 3 months). CGM data will be uploaded to the LibreLink app on a weekly basis for review of glucose control and consultation with a diabetes-trained provider for any values outside of normal ranges. Adjustments to diet and medication therapy (antihyperglycemic therapy) will be made during consultations to improve episodes of hypoglycemia or severe hyperglycemia that were observed.
214313373|NCT06559111|DEVICE|2-week casting followed by 4-week bracing|Participants in the bracing group had a cast for 2 weeks after the surgery followed by ankle brace for 4 weeks.
214313374|NCT06559111|DEVICE|6-week casting|Participants in the casting group had a cast for 6 weeks after the surgery.
214313375|NCT05844852|DEVICE|P200TE|The P200TE provides OCT imaging including retinatopography and ONH (optic nerve head) scans.
214313376|NCT05384184|PROCEDURE|Tumor /metastases removal|Tumor /metastases removal
214313377|NCT04414553|BEHAVIORAL|Community Active and Healthy Families|"Community-AHF will consist of eight, semimonthly 2-hour group appointments. Community-AHF sessions will target two areas: 1) Practical information regarding importance of healthy behaviors, and 2) Problem-solving skills to overcome barriers to improving diet and increasing physical activity and other related healthy behaviors. Each session covers specific objectives, includes a number of complementary activities and provides participants with take-home materials to facilitate behavior change.~Community-AHF will be delivered by a nurse and a Community Health Worker (CHW) trained by a consultant nutritionist and study investigators. The CHW will contact families between group sessions to discuss challenges and successes regarding lifestyle changes."
214313378|NCT03924830|PROCEDURE|Bulk without surface sealant|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds.
214313379|NCT03924830|PROCEDURE|Bulk with Biscover|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, biscover surface sealant will be applied according to the manufacturer's instructions.
214917986|NCT04042714|DRUG|All patients- TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
214917987|NCT05878002|DEVICE|polysomnography|Sleep study through polysomnographic examination
214917988|NCT04762979|DRUG|Alpelisib|Alpelisib 300mg, PO, days 1-28 of each cycle.
214917989|NCT04762979|DRUG|Fulvestrant|Fulvestrant 500mg, IM, once monthly
214313380|NCT03924830|PROCEDURE|Bulk with Permaseal|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, Permaseal surface sealant will be applied according to the manufacturer's instructions.
214313381|NCT03719313|DRUG|Lonafarnib|Lonafarnib (LNF) 50 mg BID
214917990|NCT04762979|DRUG|Aromatase inhibitor|Aromatase Inhibitor, administered per standard of care
215060942|NCT05726331|OTHER|Tai Chi|Tai Chi (TC) will be delivered by community based Tai Chi schools that meet pre-set qualifications. TC programs will emphasize core principles including biomechanically efficient alignment, relaxed integrated movements, deep breathing, and heightened body awareness. Subjects randomized to TC treatment group will attend at least one TC class per week for 16 weeks.
214313382|NCT03719313|DRUG|Ritonavir|Ritonavir (RTV) 100 mg BID
214313383|NCT03719313|DRUG|PEG IFN-alfa-2a|PEG IFN alfa-2a 180 mcg QW
214313384|NCT03719313|DRUG|Placebo Lonafarnib|Placebo
214313385|NCT03719313|DRUG|Placebo Ritonavir|Placebo
214313386|NCT02941679|DRUG|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
214313387|NCT02941679|DRUG|HGP1011|Boehringer Ingelheim
214313388|NCT02941679|DRUG|HCP0910|GlaxoSmithKline
214313389|NCT06114784|DIAGNOSTIC_TEST|Metagenomics|Clinical metagenomics is used to evaluate pathogens
214313390|NCT03376672|DRUG|Ixazomib|All patients will have similar induction and consolidation treatment with the same regimen.
214313391|NCT03376672|DRUG|Lenalidomide|All patients will have similar induction and consolidation treatment with the same regimen.
214313392|NCT03376672|DRUG|Dexamethasone|All patients will have similar induction and consolidation treatment with the same regimen.
214481629|NCT06149624|BEHAVIORAL|Supervised exercise|The onsite physiotherapist will also be trained in appropriate supervision and monitoring of exercise therapy in participants with HIV. This training will include titration of the exercise prescription to ensure safe progress is achieved. Participants will be scheduled to come to Mildmay 2 times per week for eight weeks to perform treadmill walking exercise. Intensity will be regulated using 40-60% of heart rate reserve. Additionally, ratings of perceived exertion via the Adult OMNI Walk/Run Scale will be used to guide the intensity of exercise subjectively at a moderate level. The exercise dose participants complete are standard prescriptions for participants with HIV, according to the American College of Sports Medicine.19 The physiotherapist will document the total steps achieved, including the supervised treadmill sessions and activity completed outside the supervised exercise setting (provided by participants via a log book).
214481630|NCT05044975|BEHAVIORAL|Sleep restriction|Participants will receive sleep restriction intervention
214671333|NCT04609384|DEVICE|Alcohol rub timer device|A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
214313393|NCT04301414|DRUG|BMS-986218 and Degarelix|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.
214481631|NCT05044975|BEHAVIORAL|Stimulus control|Participants will receive stimulus control intervention
214671334|NCT00231140|DRUG|Thalidomide (drug)|
215060943|NCT05726331|OTHER|Enhanced Usual Care|Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).
214313394|NCT04301414|DRUG|Degarelix|Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy
214313395|NCT03641144|DEVICE|Navigation laser|Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
214313396|NCT03641144|DEVICE|Traditional laser|Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
214313397|NCT06244069|DIAGNOSTIC_TEST|Temporal arterial biopsy|Collection of 30 ml of peripheral blood in ethylenediaminetetraacetic acid (EDTA) tubes performed at baseline, 6 months, 12 months and in case of flare before month 12. In addition, the temporal artery specimen (at least 5 mm in length) exceeding that used for clinical activity (at least 10 mm in length in accordance with current clinical recommendations) will be digested to use for research purposes (about protocols for collecting, processing, storing and sending biopsy, refer to Standard Operating Procedures, SOP).
214313398|NCT06244069|DIAGNOSTIC_TEST|Whole exome sequencing|"Patients with CHIP will be identified and characterized by using whole exome sequencing from the peripheral blood samples. M-CHIP will be further characterized by:~i) clone dimension as defined by Variant Allele Fraction (VAF); ii) mutations in specific genes such as DNMT3A, Tet methylcytosine dioxygenase 2 (TET2), Additional Sex combs (ASXL1), or Janus kinase 2 (JAK2); iii) multiple mutations.~L-CHIP will be further characterized by:~i) clone dimension as defined by the VAF; ii) mutations in specific genes such as Dual Specificity Phosphatase 22 (DUSP22), FAT atypical cadherin 1 (FAT1), (Histone-lysine N-methyltransferase 2D (KMT2D); iii) multiple mutations; iv) co-occurrence of mutations heralding M- and L-CHIP."
214313399|NCT06244069|DIAGNOSTIC_TEST|Single cell transcriptomics|The investigators will identify actively inflamed arterial biopsies from three treatment-naïve patients without CHIP, and three treatment-naïve patients with CHIP driven by the most relevant gene mutation. Arterial wall Cluster of Differentiation (CD) 45+ leukocytes will be isolated after digestion of arterial tissue and characterized by single cell transcriptomics, with a specific focus on wall infiltrating T cells and macrophages and their subsets (eg: Vascular dendritic cells, Th1, Th2, Th17, Treg, M1- and M2-like,…). Frequencies of these subsets and their genetic expression will be compared between wall-infiltrating leukocytes from GCA patients with or without CH, focusing on histological events supposed to be pathogenic in GCA, or known to be dysfunctional in CHIP.
214481632|NCT05044975|BEHAVIORAL|Systematic light exposure|Participants will receive systematic light exposure intervention
214481633|NCT04963803|DEVICE|Active transcranial direct current stimulation (tDCS)|Active transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session for 10 sessions.
214481634|NCT04963803|DEVICE|Sham transcranial direct current stimulation (tDCS)|Sham transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session. Participants in this arm will receive sham stimulation for 10 sessions.
214671335|NCT00690872|BIOLOGICAL|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
214671336|NCT00690872|DRUG|carboplatin|
214671337|NCT00690872|DRUG|gemcitabine hydrochloride|
214671338|NCT00690872|GENETIC|polymerase chain reaction|
214671339|NCT00690872|OTHER|fluorescence activated cell sorting|
214671340|NCT00690872|OTHER|immunoenzyme technique|
214917991|NCT04450082|PROCEDURE|One anastomosis gastric bypass|The linear stapler divides the stomach horizontally at the junction of the corpus and antrum at the level of crow's foot. In cases where the pre-operative study has shown the presence of the gastric fundus, if possible the fundus was dissected and a long, narrow gastric pouch was designed starting from beyond the crow's foot to just lateral the angle of His over a 42-Fr orogastric tube. Gastrojejunostomy was then performed between 200-220 cm distally to the ligament of Treitz using a 45-mm.
214917992|NCT01120015|DRUG|diacerein|Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.
214917993|NCT03711682|DIETARY_SUPPLEMENT|Cinnamon|Participants in this group will receive cinnamon capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of cinnamon powder (Cinnamomum verum), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
214313400|NCT04483024|DIETARY_SUPPLEMENT|Collagen hydrolysate and chicken extract|One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
214313401|NCT02567071|OTHER|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
214313402|NCT02567071|OTHER|clean swab|After planned C-section birth, newborns will suck on clean swab.
214313403|NCT02979743|BEHAVIORAL|Occupational therapy|
214313404|NCT02979743|OTHER|Occupational therapy puls acupuncture and massage methods|
214313405|NCT06277934|DRUG|RGT001-075|Administered orally
214313406|NCT06277934|DRUG|Placebo|Administered orally
214917994|NCT03711682|DIETARY_SUPPLEMENT|Wheat Flour|Participants in this group will receive placebo capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of wheat flour(fortified with iron, niacin, thiamin, riboflavin and folic acid), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
214313407|NCT01219725|BEHAVIORAL|Exercise training|6 months of moderate intensity exercise training 3 times per week
214313408|NCT06135168|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
214481635|NCT04963803|BEHAVIORAL|Language Specific Attention Treatment|This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this treatment.
214481636|NCT05803109|OTHER|AVIVA-PURE-CocoPull-Organic-made in USA|virgin cold pressed coconut oil with Peppermint essential oil
214481637|NCT06959251|DIETARY_SUPPLEMENT|Glycine|Patients will receive for 6 months an oral supplement of 0.5 g/kg/day glycine, up to 25 g/day, divided in three daily intakes.
214481638|NCT06959251|DIETARY_SUPPLEMENT|Magnesium+thiamine|Patients will receive for 6 months an oral supplement of up to 400 mg/day, according to age, of elementary magnesium (formulated as magnesium citrate) plus up to 10 mg/day of thiamine (formulated as benfotiamine), divided in three daily intakes.
214481639|NCT06959251|OTHER|Placebo|Patients will receive for 6 months placebo (sugar glass), in a similar daily amount as in experimental arms, and divided in three daily intakes.
214917995|NCT02994225|DRUG|Indocyanine Green|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
214917996|NCT04219124|DRUG|IMP oral tablet|Dapagliflozin 10 MG
214917997|NCT04219124|DRUG|Placebo oral tablet|Matching placebo tablets
214917998|NCT03753464|PROCEDURE|Gingival biopsy and blood sample collection|Gingival and blood samples will be collected.
214313409|NCT06135168|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
214313410|NCT01633697|BEHAVIORAL|Pranayama|Specific yoga-related breathing method.
214313411|NCT01633697|BEHAVIORAL|Education alone|No special attention to breathing
214313412|NCT00855140|OTHER|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
214481640|NCT06237686|DEVICE|CP363|All subjects will test both Test product A and B, with a minimum of 7 days apart. In total, each subject will be enrolled in the investigation for 8 days +3 days.
214481641|NCT06833034|PROCEDURE|The novel surgical method|Additional bone removal in intended direction for tooth movement
214481642|NCT06833034|PROCEDURE|The conventional surgical method|The conventional method to use surgery
214481643|NCT05980884|DIETARY_SUPPLEMENT|L-carnitine|Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days.
214481644|NCT05773690|OTHER|Movement quality|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing mobility, stability and motor control exercises.
214671341|NCT04407507|DRUG|Ivermectin|ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
214313413|NCT06548191|BEHAVIORAL|Time-restricted eating|Fasting (abstinence from calorie-containing food or drink) during 14 h at night, with no caloric consumption after 8 pm to align with circadian rhythms
214313414|NCT06517888|COMBINATION_PRODUCT|AAVAnc80-antiVEGF via Akouos Delivery Device|AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device
214313415|NCT06283797|DEVICE|OmniPod 5|Participants will be trained to use OmniPod 5 to treat type 1 diabetes for 1 year
214313416|NCT06283797|DEVICE|Dexcom G6|Participants will use Dexcom G6 for continuous glucose monitoring
214313417|NCT06283797|OTHER|PAID questionnaires|At visits 3, 7 and 11, parents/guardians and patients aged between 8 and 17 will complete diabetes-related problem questionnaires (PAID-PR, PAID-Peds)
214313418|NCT00299013|DRUG|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
214917999|NCT04155216|BEHAVIORAL|Relaxation and guided imagery program|Listening to a relaxation and guided imagery program for 25 minutes during hemodialysis treatments.
214313419|NCT00299013|DRUG|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
214313420|NCT00956904|DEVICE|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
214313421|NCT00403247|DIETARY_SUPPLEMENT|Capsule with folate, Vitamin B12 & pyridoxine|
214313422|NCT00403247|OTHER|placebo|placebo capsule
214313423|NCT05137561|PROCEDURE|PSMA PET guided prostate biopsy|PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.
214313424|NCT05137561|PROCEDURE|MRI directed TRUS guided prostate biopsy|TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring
214313425|NCT04012944|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System comprises seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)."
214313426|NCT05481177|DRUG|Ivabradine|Ivabradine is a drug approved to treat tachycardia in volunteers with heart failure. This study is to determine benefit of ivabradine treatment in postural orthostatic tachycardia syndrome (POTS) in participants with Long haul Covid.
214313427|NCT01456104|BIOLOGICAL|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
214313428|NCT05316831|BIOLOGICAL|PCV13|Pneumococcal polysaccharides conjugated to CRM197 carrier protein
214918000|NCT04398589|DRUG|Dexmedetomidine injection|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
214313429|NCT05316831|BIOLOGICAL|PPSV23|Pneumococcal polysaccharides
214313430|NCT01085097|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
214313431|NCT01085097|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
214313432|NCT01085097|DRUG|Prednisolone/Prednisone|Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
214313433|NCT01085097|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
214313434|NCT01085097|DRUG|Methylprednisolone|Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
214313435|NCT06159725|DRUG|CMTX-101|CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
214313436|NCT06159725|DRUG|Placebo|Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.
214671342|NCT04407507|DRUG|Placebo|Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
214671343|NCT00247325|DRUG|Iodixanol(Drug)|
214671344|NCT03701789|DRUG|Baricitinib|Effect of Baricitinib on vBMD measured by HR-pQCT
214671345|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
214671346|NCT00923091|DRUG|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
214918001|NCT04398589|DRUG|Saline injection|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
214918002|NCT03618173|DRUG|Dexamethasone|IV dexamethasone at the dose of 0,2mg/kg = 0,2mL/kg of a solution of 1mg/mL max 8mg
214313437|NCT02037542|BEHAVIORAL|Diet and exercise|Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
214313438|NCT00369512|DRUG|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
214313439|NCT02608554|BEHAVIORAL|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
214313440|NCT02608554|BEHAVIORAL|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
214313441|NCT04652479|DRUG|Avexitide|Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
214313442|NCT03872089|OTHER|Infrared Thermography|Measurements of the temperature of the plantar arch by thermal imaging (Infrared Thermography)
214671347|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
214918003|NCT03618173|DRUG|Placebos|IV saline serum at the dose of 0,2mL/kg maximum 8mL
214313443|NCT03389009|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy of anterior segment of the eye|5150 Vumax (Sonomed, USA) under standard illumination
214313444|NCT03784885|BIOLOGICAL|AD07010|A protein based adjuvant
214918004|NCT00708812|DRUG|Endostar(Recombinant Human Endostatin Injection)|Endostar 7.5mg/m2 on d8-d21 in each 21-day cycle
214313445|NCT03784885|BIOLOGICAL|Inactivated trivalent influenza vaccine|Inactivated trivalent seasonal influenza vaccine
214313446|NCT03477227|DEVICE|Short stocking|Patients in the experimental group will be asked to wear new type of compression stockings for four weeks post-operatively
214313447|NCT03477227|DEVICE|Usual stocking|Patients in the control group will be asked to wear usual type of compression 2 class stockings for four weeks post-operatively
214313448|NCT00056563|DEVICE|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
214313449|NCT00056563|OTHER|best medical therapy|"Participants will initially be randomized to DBS or to 6 months of best medical therapy. BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months."
214313450|NCT04459312|DIAGNOSTIC_TEST|Antibody test (SARS-CoV2)|Antibody test
214313451|NCT00075582|PROCEDURE|conventional surgery|Some patients may undergo second-look surgery
214313452|NCT00075582|DRUG|dactinomycin|Given IV
214313453|NCT00075582|DRUG|cyclophosphamide|Given IV
214313454|NCT00075582|DRUG|vincristine sulfate|Given IV
214313455|NCT00075582|RADIATION|radiation therapy|Undergo radiotherapy
214313456|NCT01920919|DRUG|Dexamethasone|
214313457|NCT01920919|DRUG|Placebo|
214481645|NCT05773690|OTHER|Conventional Resistance Training|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing traditional strength training exercises
214481646|NCT05838066|DRUG|Recombinant Humanized Bispecific antibody against HER2，KN026|IV infusion
214481647|NCT05838066|DRUG|HB1801|IV infusion
214671348|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
214918005|NCT00708812|DRUG|paclitaxel-carboplatin|paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w
214918006|NCT00911612|DRUG|Colesevelam|Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
214918007|NCT00911612|DRUG|Placebo|Inert capsule matching the study drug, given twice daily
214313458|NCT03668626|OTHER|Family-centered intervention program (FCIP)|This program included in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention emphasized modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.
214313459|NCT05045144|COMBINATION_PRODUCT|RSVPreF3(120 μg)|A single dose of RSVPreF3(120 μg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 μg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.
214313460|NCT05045144|COMBINATION_PRODUCT|Flu Quadrivalent influenza vaccine (15 μg HA)|A single dose of Flu Quadrivalent influenza (15 μg HA) vaccine was administrated intramuscular (IM).
214313461|NCT05045144|COMBINATION_PRODUCT|Placebo|One dose of placebo, administered intramuscularly in the deltoid region of the right arm, at Day 1.
214313462|NCT02385084|DRUG|LY2409021|Administered orally
214313463|NCT03099447|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
214313464|NCT03099447|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
214313465|NCT03099447|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
214313466|NCT05113615|DRUG|Tiotropium Bromide|respimat inhaler 2.5mcg/puff
214313467|NCT05113615|DRUG|Matching placebo|matching placebo Respimat inhaler
214313468|NCT00768144|DRUG|Sunitinib|
214313469|NCT02268786|OTHER|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
214481648|NCT05838066|DRUG|Pertuzumab|840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion
214481649|NCT05838066|DRUG|Trastuzumab|8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion
214481650|NCT05838066|DRUG|Docetaxel|75 mg/m\^2, D1 Q3W, IV infusion
214918008|NCT00945035|DRUG|etoricoxib|Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.
214918009|NCT00945035|DRUG|Comparator: etoricoxib|Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.
214313470|NCT04432311|BEHAVIORAL|Binge Focused Therapy (BFT)|The BFT group will be provided Binge Focused Therapy, a group-based, guided-self help intervention. Participants in this group will attend three online group sessions spread over six weeks (Week 1, Week 2, and Week 6) and complete homework between sessions. Following Session 3, there is a four week period where participants complete self-guided check-ins once per week to monitor continued progress and/or signs of relapse.
214313471|NCT04432311|BEHAVIORAL|CBT Unguided Self Help (CBT USH)|The CBT USH group will be provided with the book, Overcoming Binge Eating by C. Fairburn, which is a well-established self-help book used to help individuals understand binge eating and control binge eating behaviours. After participants receive the book, they will have 10 weeks to read it and work through the exercises provided in the book.
214313472|NCT00744627|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets.
214313473|NCT00744627|DRUG|Placebo|Vortioxetine placebo-matching capsules
214313474|NCT04251221|DRUG|Oral Alcohol Challenge|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08
214313475|NCT05180214|DRUG|Bupivacain|analgesic
214313476|NCT05180214|DRUG|Ketorolac|analgesia
214313477|NCT00188019|PROCEDURE|diagnosis methods|
214313478|NCT00323492|DRUG|Truvada|Truvada + NNRTI or PI.
214313479|NCT00323492|DRUG|Current HAART regimen|Maintain baseline regimen
214313480|NCT01092533|DRUG|Myfortic|Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
214313481|NCT01092533|DRUG|Decortin|Maintenance dose 5 mg/d
214313482|NCT02788968|OTHER|MRI|"Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI"
214313483|NCT05049070|DIAGNOSTIC_TEST|Mobile medical application to self administer a subjective refraction test|GoEyes is a software as a medical device and mobile medical application, which is downloaded to a smartphone and is a self-administered subjective refraction test that measures the refractive error of the user's eyes in the home environment without any contact or help from health care professionals
214313484|NCT05049070|DIAGNOSTIC_TEST|Standard of care refraction test|Standard of care subjective manifest refraction test performed by a healthcare professional
214313485|NCT05114135|DEVICE|Osteo3 ZP Putty|Transforminal Interbody Fusion at one spinal level (L2-S1) with instrumented posteriorlateral fusion on at least the contralateral side to the TLIF approach.
214313486|NCT02441933|DRUG|taxane plus carboplatin|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles"
214313487|NCT02441933|DRUG|Taxane|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses"
214313488|NCT03905460|DIAGNOSTIC_TEST|Point-of-care ultrasound|Focused ultrasound of the heart, lungs and pleurae
214313489|NCT01470742|DRUG|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
214918010|NCT04913688|PROCEDURE|bedside ultrasound performed group|If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, an emergency physician performs bedside ultrasound of lower extremities to the patients agreed to participate in this study. The patients also are examined duplex ultrasound by radiologist.
214671349|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
214671350|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
214918011|NCT01498211|PROCEDURE|Biopsy|3 mm punch biopsy of the skin at the distal leg.
214918012|NCT05326178|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
214313490|NCT01470742|DRUG|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
214313491|NCT04241497|BEHAVIORAL|Home-based rehabilitation|1 supervised exercise session at the hospital; 3 weeks of supervised home-based exercise training (3x/week); 9 weeks of unsupervised home-based exercise training (3x/week)
214313492|NCT05602987|PROCEDURE|enema|receiving enema at the night before anal surgery
214313493|NCT05602987|PROCEDURE|no enema|no enema before anal surgery
214313494|NCT06078033|BIOLOGICAL|Mobilization with movement|Sustained neutral apophyseal glide (SNAG) mobilization with movement applied to targeted vertebra while patients performed their painful movement.
214313495|NCT06078033|BIOLOGICAL|Sham mobilization with movement|Manual contact (without any pressure) applied to targeted vertebra while patients performed their painful movement.
214313496|NCT02530450|DEVICE|continuous glucose monitoring (CGM)|All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
214313497|NCT06086028|OTHER|Wrist worn sensor|Biostrap collects biometrics such as the following: (1) sleep pattern/ quality; (2) steps, activity, calories; (3) heart rate/ HRV; (4) respiratory rate. Participants will be randomly assigned to one of two groups.
214313498|NCT04982055|DRUG|Nadroparin (intravenous Infusion)|Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU
214313499|NCT04982055|DRUG|Nadroparin (subcutaneous group)|Subcutaneous route of administration of nadroparin 3800 IU
214313500|NCT05225142|PROCEDURE|Modified minimally invasive surgery|Surgical intervention alone
214481651|NCT05877053|DRUG|CK-4021586|CK-4021586
214481652|NCT05877053|DRUG|Placebo for CK-4021586|Placebo for CK-4021586
214481653|NCT06419257|DEVICE|VRDS|VRDS is an augmented virtual reality driving simulator.
214313501|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative|Surgical intervention with local application of regenerative biomaterial
214313502|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Surgical intervention with local application of regenerative biomaterial and bone replacement graft
214313503|NCT00907985|DRUG|Placebo|Single dose of placebo will be provided.
214313504|NCT00907985|DRUG|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
214313505|NCT00907985|DRUG|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
214313506|NCT02374645|DRUG|Volitinib|600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214313507|NCT02374645|DRUG|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214313508|NCT02488603|BEHAVIORAL|Decision aids (tamoxifen-related educational materials in brochure or mobile app)|Decision aids (tamoxifen-related educational materials in brochure or mobile app)
214313509|NCT02488603|DRUG|tamoxifen|
214313510|NCT04010123|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions of blood vessels in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses.
214313511|NCT05492565|DRUG|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
214313512|NCT04868279|BEHAVIORAL|Web-Based Interactive Nurse Support Program Based on Health Promotion Model|Nursing education will be given on healthy behaviors such as nutrition, exercise, health responsibility and stress management according to the health promotion model. The researcher will make phone calls with the intervention group for 6 months (12 times in total), twice a month. During telephone interviews, individuals will be talking about the use of the website, the points that are not understood or need to be emphasized, their application of health promotion behaviors, the obstacles they experience during the application and the suggestions for this.
214313513|NCT00493584|PROCEDURE|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
214313514|NCT00493584|PROCEDURE|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
214313515|NCT02320500|BEHAVIORAL|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
214313516|NCT02320500|OTHER|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
214313517|NCT02437955|OTHER|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
214313518|NCT02437955|OTHER|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
214313519|NCT02437955|OTHER|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
214313520|NCT02437955|OTHER|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
214313521|NCT03013556|DRUG|Group A, TDF|TDF for 96 weeks
214313522|NCT03013556|DRUG|Group B:TDF then TDF and Peginterferon alfa-2a|Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
214918013|NCT00090493|BIOLOGICAL|MAGE-A3|vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
214918014|NCT00090493|BIOLOGICAL|MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY|Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
214918015|NCT06120088|DRUG|Bubpivacaine|Bupivacaine is a long-acting local anesthetic commonly used to provide pain relief by blocking nerve signals in a specific area. It's often utilized for various medical procedures and surgeries, offering prolonged numbing effects.
214918016|NCT06120088|DRUG|dexamethasone|Dexamethasone is a potent corticosteroid with anti-inflammatory properties. It's frequently employed as an adjunct in medical treatments to reduce inflammation and swelling, and in some cases, to prevent nausea and vomiting associated with certain medications or procedures.
214671351|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
214313523|NCT03013556|DRUG|Group C:TDF and Peginterferon alfa-2a then TDF|Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
214313524|NCT06182644|DIAGNOSTIC_TEST|FAPI PET/CT|The same group of patients underwent FAPI PET/CT and FDG PET/CT examinations respectively
214313525|NCT03560531|DRUG|ZN-c5|ZN-c5 is a study drug
214313526|NCT03560531|DRUG|Palbociclib|Palbociclib (IBRANCE®) is an approved drug
214313527|NCT04297137|DIETARY_SUPPLEMENT|Protein ingestion|Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
214313528|NCT02918149|OTHER|Palpation Landmark Technique|"Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
214313529|NCT02918149|DEVICE|Ultrasound-Assisted Technique LP|"Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
214313530|NCT05864911|DEVICE|the Gastric Bypass Stent System|The Gastric Bypass Stent System is a newly designed endoscopic duodenal-jejunal bypass liner for the treatment of obesity by Hangzhou Tangji Medical Technology Co., Ltd.. It consists of three main parts: a 60-cm polyethylene sleeve fixed into the duodenal bulb by anchors with barbs, a delivery system and a retrieval system. Compared to the Endobarrier, it has several technical adjustments. First, it improved sleeve materials to provide better barrier properties and reduce the breeding of bacteria resulting in hepatic abscess. Second, the barbs on the anchoring system have been modified to reduce duodenal injury. Third, the delivery and retrieval system have been optimized to eliminate the need of fluoroscopic guidance during implantation and explantation.
214313531|NCT00012142|DRUG|temsirolimus|
214313532|NCT01751386|DRUG|Baclofen|
214313533|NCT01751386|OTHER|Placebo|
214313534|NCT00067678|DRUG|soy protein|
214313535|NCT03543592|DIAGNOSTIC_TEST|3 dimensional ultrasonography and Doppler|Three-Dimensional images will be recorded. The volumes will be generated by the automatic rotation of the mechanical transducer 360 degrees. Visualization of the endometrium and myometrium in the three planes will be done to detect endometrial cavity and any lesions. The power Doppler gate will be activated for blood flow mapping of the endometrium and endometrial-myometrial interface (sub-endometrial area). The pulsed Doppler sample volume will be activated to obtain a flow velocity waveform (FVW). Vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) will be automatically calculated from three consecutive FVWs.
214313536|NCT03895983|PROCEDURE|Percutaneous primary coronary intervention|Percutaneous primary coronary intervention
214313537|NCT01200797|DRUG|SJG-136|Given IV
214313538|NCT01200797|OTHER|laboratory biomarker analysis|Correlative studies
214313539|NCT03048656|OTHER|static posturography|The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.
214313540|NCT04174911|DRUG|BOL-DP-o-08|BOL-DP-o-08 sublingual drops
214313541|NCT04174911|DRUG|Placebo|sublingual drops
214313542|NCT04681482|DRUG|Apixaban|Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.
214313543|NCT02609334|DRUG|CRD007|One single dose given 3 hours prior to Mannitol challenge
214313544|NCT02609334|OTHER|Placebo|One single dose given 3 hours prior to Mannitol challenge
214313545|NCT00665977|DRUG|Thermosmart & placebo|a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
214313546|NCT00665977|DRUG|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
214313547|NCT00665977|DEVICE|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher \& Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
214313548|NCT00642668|DRUG|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
214313549|NCT03608774|DRUG|Azithromycin|Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
214671352|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
214671353|NCT02140320|DRUG|RV1729 single dose|Safety and tolerability of single dose
214918017|NCT06120088|DRUG|fentanyl|Fentanyl is a powerful synthetic opioid pain reliever. It acts on the central nervous system to alleviate severe pain. Fentanyl is significantly potent and is used in medical settings for acute pain management, such as during surgeries or for chronic pain in cases where other opioids may not be as effective.
214918018|NCT00892671|OTHER|Simulation|simulation of airway management and vascular access
214918019|NCT02071706|DEVICE|PET/MRI system|Enrolled subject undergoes PET/MR scan
214918020|NCT00179777|DIETARY_SUPPLEMENT|Hydrolysed infant formula|Participants in the Hydrolysed infant formula -group received the test formula, casein hydrolysate (Nutramigen™, Mead Johnson Nutritionals), not containing antigenic CM protein, whenever breast milk is not available.
214671354|NCT02140320|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single dose
214671355|NCT02140320|DRUG|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
214313550|NCT03608774|DRUG|Doxycycline|Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
214313551|NCT03608774|OTHER|Placebo|Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.
214313552|NCT01177540|DRUG|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
214313553|NCT01177540|DRUG|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
214313554|NCT03390881|OTHER|Fasting condition|Subjects will fast over the whole experimental period (480 min)
214671356|NCT02140320|DRUG|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
214671357|NCT02140320|DRUG|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
214671358|NCT02140320|DRUG|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
214671359|NCT00014573|BIOLOGICAL|aldesleukin|
214671360|NCT00014573|BIOLOGICAL|autologous tumor cell vaccine|
214671361|NCT00014573|BIOLOGICAL|filgrastim|
214671362|NCT00014573|BIOLOGICAL|sargramostim|
214671363|NCT00014573|BIOLOGICAL|therapeutic autologous lymphocytes|
214671364|NCT00014573|DRUG|carmustine|
214671365|NCT00014573|DRUG|cisplatin|
214671366|NCT00014573|DRUG|cyclophosphamide|
214671367|NCT00014573|DRUG|paclitaxel|
214671368|NCT00014573|PROCEDURE|autologous bone marrow transplantation|
214313555|NCT03390881|OTHER|Sugar condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% carbohydrate, 15% fat and 15% protein and providing 1.5 X hourly resting energy requirement.
214313556|NCT03390881|OTHER|Fat condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% fat, 15% carbohydrate and 15% protein and providing 1.5 X hourly resting energy requirement.
214313557|NCT01793727|DEVICE|Glidescope videolaryngoscope|
214313558|NCT06386835|PROCEDURE|Collagen Paste|Collagen paste injection
214313559|NCT06386835|PROCEDURE|Mucosal advancement|Mucosal advancement flap
214313560|NCT06456333|DEVICE|High-density surface electromyography|Electromyographic signals were acquired from the paravertebral muscles in apical vertebral in patients with AIS using SAGA High Density Myoelectrics (TMSi International, New Zealand)
214313561|NCT03686410|BEHAVIORAL|Web-based Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
214481654|NCT05825937|DEVICE|ClearSight System|Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.
214481655|NCT06550050|BEHAVIORAL|Radiation|Standard of care
214918021|NCT00179777|DIETARY_SUPPLEMENT|Nonhydrolysed infant formula|Participants in the Nonydrolysed infant formula -group received the CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever breast milk is not available.
214918022|NCT05403853|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
214481656|NCT04028401|DRUG|5% benzoyl peroxide|Application of 5% benzoyl peroxide during 5 days before the procedure
214481657|NCT04198870|DEVICE|MitraClip™ device implantation|Transcatheter repair of the mitral valve using MitraClip™ device
214481658|NCT04198870|PROCEDURE|Mitral Valve Repair Surgery|Surgical repair of the mitral valve
214481659|NCT06962735|DEVICE|real-time continuous glucose monitor|Individuals who switched from using isCGM to rtCGM
214481660|NCT06207071|DIETARY_SUPPLEMENT|DHA|DHA supplementation
214481661|NCT06542419|DEVICE|Brain Cooling|Brain cooling consists of a 30-minute seated period, in a dimly lit, quiet room, while listening to calming natural sounds, during which they will wear an Arctic Cooling Cap V1.30, set at a temperature of 33.0 degrees Fahrenheit. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability. This brain cooling treatment will occur on 7 consecutive days.
214481662|NCT06511219|DEVICE|maxillary segmental distalization|maxillary segmental distalization using skeletal anchored digitally printed appliances
214481663|NCT06313632|DRUG|Bupivacaine injection|Erector spinae plane block with bupivacaine (0.5%) 30 mL once
214918023|NCT05403853|DIAGNOSTIC_TEST|Fingerstick|Capillary Blood Draw
214918024|NCT01214083|DRUG|N-acetylcysteine + high-dose naltrexone (150 mg)|All subjects will be evaluated weekly for 12 weeks.
214313562|NCT03686410|OTHER|Conventional Treatment|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
214313563|NCT06418503|OTHER|Balance Training|Participants will complete 16 sessions of balance training (30 min. each) over one month.
214313564|NCT06418503|OTHER|EMG-Biofeedback Training|Participants will complete 16 sessions of EMG-biofeedback balance training (30 min. each) over one month.
214313565|NCT05697887|DIETARY_SUPPLEMENT|Ketogenic diet|The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
214313566|NCT06528522|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all participants, and comprehensive clinical parameters will be meticulously documented. The Plaque Index (PI) and Gingival Index (GI) will be measured at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be recorded in detail for each tooth at six sites. The percentage of bleeding areas will be assessed within 20 seconds post-probing using a binary scoring system to indicate presence or absence. All clinical parameters will be recorded by a calibrated periodontologist utilizing manual probing techniques.~Following collection, saliva samples will be stored at -80°C until subsequent analysis. Concentrations of IL-39, IL-41, IL-1β, and TNF-α in the saliva samples will be quantified using specific enzyme-linked immunosorbent assay (ELISA) kits."
214313567|NCT01113762|DEVICE|articular surface replacement ASR, DePuy|posterolateral incision
214313568|NCT01113762|DEVICE|ReCap/Magnum modular head, Biomet|posterolateral incision
214313569|NCT01113762|DEVICE|Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet|posterolateral incision
214313570|NCT01113762|DEVICE|28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)|posterolateral incision
214481664|NCT06313632|DRUG|Placebo|ESP with matching saline placebo
214481665|NCT06313632|OTHER|Monitored Anesthesia Care|Standard monitored anesthesia care
214481666|NCT03834818|BEHAVIORAL|COMPAS Participants|"The schedule of events for this study are as follows:~Day 1 Pre-Surgery:~* Download the Medable App~* Register to the study~* Validated Questionnaires~* Active Task~Every Day~* 9:00 a.m. Daily Questions~* 9:00 p.m. Daily Questions~Outcome Surveys and Active Task:~* Day 1 Pre-Surgery~* 1-Week Post Operation~* 2-Weeks Post Operation~* 1-Month Post Operation~* 3-Months Post Operation~* 6-Months Post Operation"
214481667|NCT04549116|DRUG|Progesterone-IBSA Injectable Solution|Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
214918025|NCT01214083|DRUG|High-dose naltrexone (150 mg) alone|All subjects will be evaluated weekly for 12 weeks.
214918026|NCT01214083|DRUG|Low-dose naltrexone (50 mg) alone|All subjects will be evaluated weekly for 12 weeks.
214918027|NCT04289376|OTHER|Gaze tracking - no intervention|Monitor gaze as subjects watch a video
214313571|NCT04993287|OTHER|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and HF care team
214313572|NCT04993287|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
214918028|NCT01908829|DRUG|mirabegron 25 mg|Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
214313573|NCT04662801|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will receive twelve weeks of BWL treatment.
214313574|NCT04662801|BEHAVIORAL|Early Responder: BWL continued|Participants categorized as experiencing early weight loss at the end of the first month of treatment will continue with BWL for the remainder of treatment.
214313575|NCT04662801|COMBINATION_PRODUCT|Early Non-responder: BWL continued with medication added|Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion) for the remainder of treatment.
214313576|NCT01880112|DRUG|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
214313577|NCT02323854|DEVICE|Ablation|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
214313578|NCT02323854|PROCEDURE|Surgical Resection|The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
214313579|NCT01004588|DIETARY_SUPPLEMENT|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
214313580|NCT01004588|DIETARY_SUPPLEMENT|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
214313581|NCT03266120|OTHER|Art|Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
214313582|NCT03266120|OTHER|Gardening|Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
214313583|NCT01999595|DEVICE|Control TENS|Control TENS was the application of electrical stimulation via skin with no current
214313584|NCT01999595|DEVICE|Sham TENS|"Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told TENS is at a turn-on level whether or not you feel it"
214313585|NCT01999595|DEVICE|High frequency TENS with large pads|High frequency TENS was delivered on large electrodes
214481668|NCT04549116|DRUG|Progesterone Vaginal Gel with Applicator|Crinone 8%, 90 mg, QD intravaginally
214481669|NCT04549116|DRUG|Placebo Vaginal gel with applicator|Vaginal gel Placebo, once daily (QD) intravaginally
214481670|NCT04549116|DRUG|Placebo injectable solution|Placebo injectable solution, BID SC Injection every 12 hours
214918029|NCT01908829|DRUG|mirabegron 50 mg|Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
214481671|NCT04310423|DRUG|Placebo|Matched to endotoxin
214481672|NCT04310423|BIOLOGICAL|Endotoxin|Bolus dose of 0.8 ng/kg
214481673|NCT06346860|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
214481674|NCT03664453|DRUG|omaveloxolone|Omaveloxolone 50 mg capsules
214481675|NCT04215952|BEHAVIORAL|Semantic Feature Analysis Treatment|On each treatment trial, the clinician will show the participant with aphasia a pictured object and ask them to name it. The clinician will then guide the participant in verbally generating semantic features for the target, using a chart that specifies five kinds of features: group, use/action, properties, location, and personal associations. When the participant cannot generate a given feature, cueing or other assistance will be provided. After feature generation, the clinician will ask the participant to name the picture again and provide cueing if needed. The clinician will then review the generated features and ask the participant to name the item once more, with cueing if needed. Finally, the clinician will ask the participant to say a sentence containing the target word and provide cueing if needed. Treatment will then proceed to the next item. Participants will receive approximately 20 hours of treatment on each of three 10-item lists, for a total of 60 hours of treatment.
214481676|NCT04850729|OTHER|non-intervention|non-intervention
214671369|NCT00014573|PROCEDURE|conventional surgery|
214671370|NCT00014573|PROCEDURE|peripheral blood stem cell transplantation|
214918030|NCT01908829|DRUG|solifenacin 5 mg|Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
214918031|NCT01908829|DRUG|solifenacin 10 mg|Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
214918032|NCT01908829|DRUG|mirabegron 25 mg matching placebo|Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
214918033|NCT01908829|DRUG|mirabegron 50 mg matching placebo|Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
214918034|NCT01908829|DRUG|solifenacin 5 mg matching placebo|Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
214313586|NCT01999595|DEVICE|Low frequency TENS with large pads|Low frequency TENS was delivered on large electrodes
214313587|NCT01999595|DEVICE|High frequency TENS with small pads|High frequency TENS was delivered on small electrodes
214313588|NCT01999595|DEVICE|Low frequency TENS with small pads|Low frequency TENS was delivered on small electrodes
214313589|NCT01969903|DRUG|Precedex injection|
214313590|NCT04714996|DRUG|ES-481|"Treatment Period Week 1 - 25 mg qd, Week 2 - 25 mg bid, Week 3 - 50 mg bid, Week 4 - 75 mg bid.~Step-down and Washout Period Day 1 - 125 mg, Day 2 - 100 mg, Day 3 - 75 mg, Day 4 - 50 mg, Day 5 - 50 mg, Day 6 - 25 mg, Day 7 - 25 mg, Days 8 to 14 - 0 mg"
214313591|NCT04714996|DRUG|Placebo|Placebo on Week 1, Week 2, Week 3 and Week 4
214313592|NCT04714996|DRUG|Open-Label Extension Study|Dosing will be at the discretion of the Investigator with a minimum dose of 25 mg/day (25 mg qd) to a maximum dose of 150 mg/day (75 mg bid).
214313593|NCT02299557|DRUG|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
214313594|NCT02299557|DRUG|Placebo gel|Placebo gel applied intra-anally once daily
214313595|NCT00787774|DRUG|resume raltegravir|resume raltegravir after 16 weeks of stopping
214313596|NCT02820012|OTHER|Scoliosis|Questionnaires, radiography
214313597|NCT03193411|DEVICE|Visumax femtosecond laser|
214918035|NCT01908829|DRUG|solifenacin 10 mg matching placebo|Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
214313598|NCT03193411|DEVICE|Moria M2 microkeratome (MK)|
214313599|NCT01083095|BIOLOGICAL|Sporozoite Challenge Model for Plasmodium vivax in Humans|Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
214313600|NCT02191228|DRUG|Linagliptin - single dose|
214313601|NCT02191228|DRUG|Linagliptin - Multiple dose|
214313602|NCT01623596|DRUG|Fingolimod|
214313603|NCT01623596|DRUG|Disease Modifying therapy|
214313604|NCT04225169|OTHER|Breathing exercises|The patient was taken to a quiet room and asked to lie on the bed. For the first 5 minutes, the researchers explained how the exercise is done with pictures and demonstrated it to the patient. The patient was asked to perform the exercise for 5 minutes under supervision by the researchers. If the patient performed DBE correctly, practice was discontinued. If not, the patient was asked to practice for another 5 minutes. If the patient still could not perform the exercise correctly at the end of this time, they were excluded from the sample. DBE was performed according to the Cleveland Clinic guideline as follows:
214313605|NCT00373516|DRUG|Vehicle (Placebo) applied BID|
214918036|NCT01481662|DEVICE|Diffusion tensor magnetic resonance imaging of the brain|Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
214918037|NCT02365389|DRUG|MTZ vaginal gel|MTZ vaginal gel once daily for 5 days
214313606|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied QD|
214313607|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied BID|
214313608|NCT04124172|DEVICE|Real rTMS (Magstim)|See arm description
214313609|NCT04124172|DEVICE|Sham rTMS|See arm description
214313610|NCT06486571|OTHER|Electromyography recording with HD-sEMG|Measurement of muscle electrical signal with HD-sEMG sensors, training of a pattern recognition classifier for hand gesture recognition, verification and comparison with state of the art.
214313611|NCT06486571|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application of TENS by means of non-invasive superifical electrodes on the stump skin of the participants to restore multimodal somatotopical sensations of mechanoception, nociception and thermoception.
214313612|NCT03056131|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
214313613|NCT00322335|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
214313614|NCT00322335|BIOLOGICAL|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
214313615|NCT00322335|BIOLOGICAL|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
214313616|NCT00322335|BIOLOGICAL|Engerix-B|Intramuscular injection into the thigh as a birth dose
214313617|NCT00322335|BIOLOGICAL|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
214313618|NCT00322335|BIOLOGICAL|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
214313619|NCT00322335|BIOLOGICAL|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
214313620|NCT06363084|DRUG|Nimotuzumab|Nimotuzumab (400mg) was given weekly
214313621|NCT02384824|PROCEDURE|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
214313622|NCT00013130|BEHAVIORAL|Provision of health status information to patients provider|
214313623|NCT00699972|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
214313624|NCT00699972|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
214918038|NCT02365389|DRUG|Conventional MTZ vaginal gel|Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
214313625|NCT00699972|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
214313626|NCT00160316|DRUG|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
214313627|NCT00126295|DEVICE|'What you need to know about stroke' education package|
214313628|NCT05833503|BEHAVIORAL|Integrative Couple Treatment for Addiction (ICT-A)|Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).
214313629|NCT05833503|BEHAVIORAL|Treatment individual as usually offered|Individual-based treatment as usually offer by the specialized centres in addiction.
214313630|NCT04382638|COMBINATION_PRODUCT|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
214313631|NCT04382638|DEVICE|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
214313632|NCT01545817|DRUG|Pazopanib followed by everolimus|All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
214313633|NCT06319599|BEHAVIORAL|Routine therapy|During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
214313634|NCT06319599|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214313635|NCT06319599|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
214313636|NCT06319599|BEHAVIORAL|placebo injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214481677|NCT06778122|DEVICE|High efficiency particulate air filtration system (nightly administration)|Portable air purifier is programmed to provide a dose of filtered air at 275 m³/h nightly for at least 7 hours consecutive within a time window between 10:00 p.m. and 10:00 a.m. Air purifier is set up with active filters (HyperHEPA technology). Dose adjustments are permitted in the study where noise disturbance is an issue for participants. The air filtration therapy will be delivered in doses decreasing sequentially in terms of speed mode. Participants will be instructed to keep doors and windows of the bedroom closed during each session at night, and to follow a similar bedtime routine.
214481678|NCT06778122|DEVICE|High efficiency particulate air filtration system (nightly and daily administration)|Portable air purifier set up with active filters (HyperHEPA technology) is continuously in operation (24 hours for 14 days) at 275 m³/h in bedrooms with the door and windows closed. During this open-labell phase, the participants will be asked to remain in the bedroom for as long as possible and to keep an activity log for the outdoor locations. Dose adjustments are permitted.
214481679|NCT06778122|DEVICE|Air filtration system without filters (sham)|Portable air purifier is programmed to provide a dose of filtered air at 275 m³/h nightly for at least 7 hours consecutive within a time window between 10:00 p.m. and 10:00 a.m. Air purifier is set up with a sham filter, which is identical in appearance and noise as the HyperHEPA filter (active filter) when the air purifier is in operation. Dose adjustments are permitted in the study where noise disturbance is an issue for participants.
214481680|NCT05036018|DEVICE|ACURATE neo2|The ACURATE neo2 valve will be implanted using a two-step mechanism during transfemoral transcatheter aortic valve implantation (TAVI). Balloon predilatation will be recommended in the ACURATE neo 2 valve group.
214481681|NCT05036018|PROCEDURE|minimalist approach|Isolated local anesthesia. Central venous lines, additional arterial lines for blood pressure monitoring, and urinary catheters will be avoided. Insertion of temporary pacemakers is optional and should be avoided whenever possible, and peri-procedural pacing can then be performed on the left ventricular wire. Patients will be directly transferred to the cardiology ward after the procedure, which can be postponed in case of complications.
214918039|NCT05695014|OTHER|Teach Back Metod|teach-back method is a way of checking understanding by asking patients to state in their own words what they need to know or do about their health. It is a way to confirm that you have explained things in a manner your patients understand.
214918040|NCT05797935|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content
214918041|NCT03391570|DRUG|COX-2 inhibitor|Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery
214918042|NCT03391570|DRUG|Placebo Oral Tablet|Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery
214918043|NCT03391570|PROCEDURE|Preoperative peritoneal biopsy|Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
214918044|NCT03391570|PROCEDURE|Single-port laparoscopic surgery|Single-port laparoscopic surgery with CO2 gas
214918045|NCT03391570|PROCEDURE|Postoperative peritoneal biopsy|Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
214918046|NCT02792192|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in respective arm.
214313637|NCT01536639|DRUG|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
214313638|NCT02059928|DEVICE|Intraosseous Device|
214313639|NCT00571259|DRUG|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
214313640|NCT00571259|DRUG|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
214313641|NCT01007461|DRUG|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started \> 5 minutes but \< 20 minutes (approximately) prior to coronary artery reperfusion.
214313642|NCT01007461|DRUG|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
214313643|NCT03372148|DIAGNOSTIC_TEST|pHRMi|Pharyngeal High Resolution Manometry and Impedance swallowing function evaluation
214313644|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|2 times a day
214313645|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair|2 times a day
214313646|NCT02710604|DRUG|CMX157|tablet
214313647|NCT02710604|DRUG|TDF|300mg tablet
214313648|NCT01713868|BEHAVIORAL|Safe Sleep Nursery Education|Nursery-based program for safe sleep
214313649|NCT01713868|BEHAVIORAL|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
214313650|NCT01713868|BEHAVIORAL|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
214313651|NCT01713868|BEHAVIORAL|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
214313652|NCT05268471|DEVICE|Positional device (PD)|OSA treatment with PD for 6 months
214313653|NCT05268471|DEVICE|Continuos Positive Airway Pressure (CPAP)|OSA treatment with CPAP for 6 months
214313654|NCT00423306|DRUG|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
214313655|NCT00003256|DRUG|alvocidib|
214313656|NCT00353743|DRUG|placebo|placebo
214671371|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder. Probiotic will be prepared under strict Food Manufacturing Regulations. The daily dose of 2x10\^10 cfu will be packed individually in sachets. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic must be stored at 4 degrees Celsius
214918047|NCT02792192|BIOLOGICAL|Bacille Calmette-Guérin|For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
214918048|NCT04591886|BEHAVIORAL|mind. body. voice.|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
214918049|NCT06070181|DEVICE|Enamel matrix derivate|'Applying Enamel matrix derivate in the periodontal pockets after completing the non-surgical periodontal treatment
214918050|NCT06070181|PROCEDURE|Non-surgical periodontal treatment|No additional/adjunctive treatment with Emdogain
214918051|NCT02360150|RADIATION|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
214918052|NCT02320058|DRUG|Ipilimumab|
214313657|NCT00353743|DRUG|doxycycline plus metronidazole|doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
214313658|NCT02498093|BEHAVIORAL|Maximal strength training|
214313659|NCT02498093|BEHAVIORAL|conventional rehabilitation|
214313660|NCT01530971|DRUG|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
214481682|NCT05036018|DEVICE|CoreValve Evolut Pro, Pro+ and FX|The Evolut Pro, Pro+ or FX valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.
214313661|NCT04126928|DIAGNOSTIC_TEST|Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.|
214313662|NCT00973791|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
214313663|NCT00973791|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
214313664|NCT03010787|DRUG|V565|single ascending dose of V565
214313665|NCT03010787|DRUG|V565|Multiple dose
214313666|NCT03010787|DRUG|Placebo|Single and multiple dose
214313667|NCT03010787|DRUG|V565|Open-label single dose
214313668|NCT03010787|DRUG|V565|Open-label single ascending dose
214313669|NCT06483971|DIAGNOSTIC_TEST|Oral Isotretinoin|20 mg/kg/day that affects sebaceous glands and is used to treat severe acne Frequency: Once daily
214313670|NCT06483971|COMBINATION_PRODUCT|Antibiotics|250 mg on laternate day/3 months Frequency: Once or twice daily
214313671|NCT05731401|OTHER|Explanations of the cause of pain|"When analyzing the responses to the question Why do you think you have or have had this pain? two themes emerged from the data: 'explanations associated with damage', and 'explanations not associated with damage'.~The themes were sub-classified into sub-themes, according to the type of explanation"
214313672|NCT01387321|DRUG|BYL719|
214671372|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
214313673|NCT06481956|DRUG|Ribociclib Oral Tablet|Patients with advanced breast cancer with at least one evaluable lesion and histologically proven invasive breast cancer were eligible for inclusion. Histopathologically positive for HER2 (IHC 3+, or IHC 2+ with fluorescence in situ hybridization (FISH) positive, either primary or metastatic. Patients with advanced breast cancer must have previously received first-line therapy or initial rescue therapy and have been treated with trastuzumab against HER2.
214313674|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
214313675|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
214481683|NCT05036018|PROCEDURE|Standard of care|Sedation should be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -2 according to local standard of care.The use of EEG monitoring (i.e. BIS, Sedline) can be applied. Continuous CO2-monitoring via face mask should be established during sedation. All patients will receive supplemental oxygen by face mask to maintain an oxygen saturation of approximately 95%. The use of central venous catheters, additional arterial lines for blood pressure monitoring, and urinary catheters can be implemented according to local institutional standards.
214481684|NCT06150716|DRUG|ION356|Administered as intrathecal (IT) injection.
214481685|NCT06965985|OTHER|Mulligan mobilization therapy|While the mobilization belt is placed around the patient's proximal forearm and looped over the therapist's shoulder, the distal humerus will be stabilized with one hand. A lateral glide will be applied to the forearm through the belt and maintained for approximately 5 to 10 seconds. The patient will perform repeated wrist extensions against the manual resistance provided by the therapist's hand. Once a pain-free wrist extension is achieved, the lateral glide will be released. A total of 6 repetitions will be performed with 15-second rest intervals between repetitions. This protocol will be applied three times per week for two weeks.
214313676|NCT00763659|DIETARY_SUPPLEMENT|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
214313677|NCT05789836|OTHER|Nursing care|Involving the mother in nursing care
214481686|NCT06965985|OTHER|Myofascial release therapy|"The patient will be placed in a supine position with the shoulder internally rotated, the elbow in pronation and approximately 15 degrees of flexion, and the palm resting flat on the table. The therapist will stand beside the table at the level of the patient, facing the patient's ipsilateral arm and shoulder. The treatment will be administered for 10 minutes, three sessions per week for two weeks.~The therapist will begin the treatment from just proximal to the lateral epicondyle, on the humerus, and proceed distally along the path of the common extensor tendon to the extensor retinaculum of the wrist. Using the fingertips, the therapist will engage the periosteum and maintain contact as the technique continues along the common extensor tendon and further distally along the extensor retinaculum of the wrist."
214481687|NCT06965985|OTHER|Exercise Therapy|"All patients will be provided with a home exercise program consisting of eccentric strengthening exercises targeting the wrist extensors, with resistance gradually increased each week. Patients will be instructed in strengthening exercises for the wrist extensors as well as forearm pronation and supination. The home program will consist of 3 sets of 10 repetitions per day.~The exercises will be demonstrated in person by the physician, and each patient will receive a printed handout detailing how to perform the exercises. During weekly treatment sessions and after the treatment period, patients will be contacted by phone to assess adherence to the exercise program and to reinforce the importance of compliance.~Patients with exercise compliance below 75-80% will be excluded from the study."
214313678|NCT02533271|RADIATION|Short-course radiotherapy with neoadjuvant chemotherapy|Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy
214313679|NCT02533271|RADIATION|Long-term chemoradiotherapy|Standard chemoradiotherapy
214918053|NCT02320058|DRUG|Nivolumab|
214918054|NCT03088124|DRUG|Apalutamide|Patients will take orally everyday 240 mg of Apalutamide.
214313680|NCT05728164|BEHAVIORAL|Cinematic Simulation|Comprehensive videos from specific films will be selected as films fitting the needs of participants and the established objectives. The films comprehensively develops several characters enriching the values of positive emotions, resilience and empathy. The intervention film videos will be delivered on 5 sessions for each group (2 sessions per week).
214313681|NCT02567461|DRUG|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
214918055|NCT06062121|DEVICE|Motor-cable-driven Rehabilitation Robotic System|Subjects will wear the motor-cable-driven system and receive 30 minutes (including preparation time) wrist and forearm robot-assisting exercise
214313682|NCT02567461|DRUG|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
214313683|NCT02567461|DRUG|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
214313684|NCT02567461|DRUG|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
214313685|NCT02850536|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells
214313686|NCT06212102|DRUG|Progestin primed ovarian stimulation|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
214313687|NCT06212102|DRUG|GnRH antagonist|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
214313688|NCT06377293|OTHER|Dialysis-specific therapeutic diet|A healthy diet for dialysis patients
214313689|NCT00950534|DRUG|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
214313690|NCT00950534|DRUG|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
214313691|NCT05558228|DEVICE|FloPatch FP120|FloPatch FP120 is an FDA 510(k) cleared device indicated for the non-invasive assessment of blood flow in the carotid artery by medical professionals, such as physicians and nurses. FloPatch uses ultrasound and the Doppler effect to assess blood flow.
214313692|NCT04700748|RADIATION|Brain metastases radiation|Brain metastases radiation according to clinical practice.
214313693|NCT05125939|OTHER|Comparison of ADR|The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
214313694|NCT03893799|DRUG|RBT-1|Single intravenous administration
214313695|NCT01991158|DRUG|High dose of methotrexate|Methotrexate 3.0g/Kg, intravenous drip D1
214313696|NCT01991158|DRUG|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
214313697|NCT01991158|DRUG|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
214313698|NCT01991158|DRUG|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
214313699|NCT01742338|DRUG|Low Dose Corticosteroids|
214313700|NCT01742338|DRUG|High Dose Corticosteroids|
214313701|NCT03249779|DEVICE|Scrambler|Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
214313702|NCT05410327|OTHER|Chokeberry (Aronia melanocarpa) juice|A water-infused chokeberry (Aronia melanocarpa) juice will be used as the intervention. The brand being used is called 'Superberries'.
214313703|NCT06530654|BEHAVIORAL|Distraction by dentist|Dental treatment is carried out with tell-show-do technique as a behavioural guidance technique.
214481688|NCT06966115|BEHAVIORAL|Multiple Sclerosis Vocational Rehabilitation (MSVR)|"MSVR involves an initial assessment (including vocational goal setting), followed by up to 10 hours of individually tailored support over six months according to need. The support will focus on supporting the person with MS to remain at work by addressing topics such as:~* Understanding MS~* Advice on reasonable adjustments~* Support requesting reasonable adjustments~* Fatigue management~* Managing cognition at work~* Information about legal rights~* Disclosure~* Long-term career planning~* Managing mood difficulties~* Signposting to local and national resources. MSVR addresses the individual needs of the person with MS and offers advice remotely (e.g., via telephone, videoconference, or email). The sessions will be arranged at a time convenient for the person, and the support needed will vary according to the complexity of their workplace difficulties."
214481689|NCT06853327|DRUG|Ketorolac|The experimental condition to be examined by this study is the timing of administration of ketorolac prior to IUD insertion. Ketorolac 20mg PO has proven beneficial at certain timepoints during IUD insertion in prior studies, but pharmacokinetics indicate that it could require more time until peak analgesia.
214481690|NCT06853327|DRUG|Placebo|Placebo will be used to control the timing of administration and be used to compare ketorolac to baseline standard pain control regimens
214481691|NCT05650619|OTHER|Biospecimen collection|Specimens that may be collected include urine, blood, saliva, kidney tissue, etc. Biospecimens will be collected to establish the RESOLVE biobank.
214481692|NCT05650619|OTHER|Data collection|Data collection for all groups
214481693|NCT06966427|DEVICE|Dosing Guidance System to be used with both time and amount of insulin as input|Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input
214313704|NCT06530654|BEHAVIORAL|Distraction by cartoon movie|Dental treatment is carried out with showing cartoon movie as a passive distraction during the treatment.
214481694|NCT06966427|DEVICE|Dosing Guidance System to be used with only time of insulin as input|any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input
214481695|NCT06965335|BIOLOGICAL|BIOLOGICAL STUDY aiming at describing clinicophatological features of EO-CRC vs SO-CRC|Description of clinicophatological features of EO-CRC vs SO-CRC
214481696|NCT06965400|DEVICE|Automatic Cuff Pressure Control|he IntelliCuff® system (Hamilton Medical, Switzerland) continuously monitored and automatically adjusted cuff pressure to keep it within the target range of 15-25 cmH₂O. Manual intervention was only required upon system alert.
214481697|NCT06224088|OTHER|VV ECMO|treatment with VV ECMO in the ICU
214481698|NCT03964441|BIOLOGICAL|Invasive fetal sampling, blood sampling of mother and father|to perform an exome sequencing analysis in trio
214313705|NCT06530654|BEHAVIORAL|AG-active distraction group|The active distraction group is treated and interacting with the designed application
214313706|NCT04747340|BEHAVIORAL|Training for Awareness Resilience and Action (TARA)|See arm-description
214313707|NCT04747340|OTHER|Standard treatment|See arm-description
214313708|NCT03314584|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
214313709|NCT03314584|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
214313710|NCT03314584|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Brain imaging will be done via MRI prior to the first rTMS/Sham TMS session. Imaging will allow investigators to target specific areas in the brain.
214481699|NCT03964441|BIOLOGICAL|blood sampling from the mother to recover the circulating cell free fetal DNA|to perform a sequencing analysis of the genome of circulating free fetal DNA
214481700|NCT03964441|OTHER|Parent interviews (optional organizational study)|Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
214918056|NCT04449302|PROCEDURE|Immediate molar implant with customized healing abutment|"Patients will receive an immediate implant with customized healing abutment~1. Atraumatic extraction without flap elevation using periotomes and elevators then sectioning of the roots will be performed to preserve the interseptal bone.~2. The drilling will be performed starting from the pilot drill in the interseptal bone to the twisting drills according to the manufacturer's instructions to the selected implant size. The implant is to be placed immediately then the insertion torque will be measured using a torque wrench. In order to place the customized healing abutment, the insertion torque should be more than 25 ncm.~3. The gap distance will be filled by xenograft, a plastic abutment will be screwed in place then a flowable composie resin will be applied around into small amounts and cured to take the soft tissue contour then finishing and polishing of the customized healing abutment will be done."
214918057|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
214918058|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|2 doses (3.5, 5 months of age) plus booster (11 months of age)
214918059|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|2 doses (6, 8 months of age) plus booster (11 months of age)
214918060|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|2 doses 2 months apart
214918061|NCT01339923|BIOLOGICAL|Meningococcal C oligosaccharide conjugated vaccine|Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
214918062|NCT01339923|BIOLOGICAL|Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.|Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
214918063|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|Schedule 3, 5, 12 rMenB + OMV vaccine
214918064|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|Schedule 13,15 rMenB + OMV vaccine
214918065|NCT02809547|DEVICE|Dried Blood Spot device|
214918066|NCT05717049|DRUG|Theophylline Tablets|12 week oral treatment
214918067|NCT03646526|DRUG|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
214918068|NCT03646526|DRUG|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
214918069|NCT06197230|OTHER|Drawing Intervention|"The primary sections of Drawing Intervention will be the art-making and art-sharing sections. During the art-making segment, the group leader will guide the participants through a paper-warming exercise before assigning them a specific subject to draw freely for 20-30 minutes. The leader will then ask participants to talk about the meaning of their artwork, encouraging them to explore their emotions regarding the theme and their drawing. This procedure will be implemented in each segment of the intervention (6 sessions)."
214918070|NCT00531713|DRUG|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
214918071|NCT03477201|PROCEDURE|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Laparoscopic inguinal hernia repair using a robotic assisted laparoscopic procedure.
214918072|NCT03477201|PROCEDURE|Standard laparoscopic inguinal hernia repair|Laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia.
214918073|NCT06341855|DIAGNOSTIC_TEST|MRD-ctDNA|ctDNA-MRD is a powerful biomarker, and ctDNA-MRD is a reliable predictive biomarker in EC.
214918074|NCT04015635|OTHER|None involved|NO intervention
214918075|NCT01430403|BIOLOGICAL|Omalizumab|Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) \[IU/mL\] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.
214918076|NCT01430403|DRUG|Inhaled Corticosteroid Boost Therapy (ICS)|Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
214918077|NCT01430403|BIOLOGICAL|Placebo omalizumab|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
214918078|NCT01430403|BIOLOGICAL|Placebo fluticasone|Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
214955132|NCT05969587|COMBINATION_PRODUCT|hydroquinone cream group|4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co., Ltd. (Yilan, Taiwan). Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. Subjects in the hydroquinone cream group were told to apply a 2:1 ratio of the hydroquinone and betamethasone creams. The hydroquinone/betamethasone creams were left on the skin until the following morning.
214955133|NCT04755894|DRUG|HDDO-1756|single dose
214481701|NCT03964441|OTHER|parent questionnaire (optional organizational study)|To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results
214955134|NCT04755894|DRUG|HDDO-17561/HDDO-17562|single dose
214955135|NCT02298036|BEHAVIORAL|(Remote) Cognitive Behaviour Therapy|Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
214313711|NCT04302389|BEHAVIORAL|myWW App, Virtual Workshops, and Private Facebook Group|The 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and a private online community. Participants are given a personalized food plan based on expert healthy eating guidelines and the latest nutritional science, an activity plan designed to promote regular physical activity and techniques to help shift members towards a helpful mindset for lasting change all within the WW app. Participants will attend weekly virtual workshops led by an expert WW Coach. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals each week. Participants will be encouraged to participate in a private Facebook group that gives participants an opportunity to receive motivational support from each other. Participants can post about their journey through photos, videos, and comments.
214313712|NCT05987423|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
214313713|NCT05987423|DRUG|Placebo|Placebo will be administered by SC injection
214313714|NCT03250026|BEHAVIORAL|Workplace convergence dialogue|Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
214313715|NCT03250026|BEHAVIORAL|Care Manager|Regular contact Care Manager during around 12 weeks
214313716|NCT01984775|DRUG|GSK2894512 cream|GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).
214313717|NCT01984775|DRUG|Vehicle cream|Vehicle cream does not contain any active pharmaceutical ingredient.
214481702|NCT03964441|OTHER|professional interviews (optional organizational study)|interview to understand how the decision is formed
214481703|NCT03964441|OTHER|Focus group for professionals (optional organizational study)|interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.
214481704|NCT06381739|BIOLOGICAL|ChAd-triCoV/Mac|Clinical-grade, fully certified ChAd-triCoV/Mac produced according to current Good Manufacturing Principles (cGMP) will be provided. A single dose of ChAd-triCoV/Mac diluted in 0.5mL formulated buffer will be aerosolized and inhaled via a mouthpiece and tidal breathing over approximately 2 minutes using the AeroNeb Solo Mesh Nebulizer.
214481705|NCT06381739|OTHER|Control|A single dose of placebo (0.5mL formulated buffer) will be aerosolized and inhaled as the intervention vaccine.
214481706|NCT05912296|DRUG|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
214481707|NCT05912296|DRUG|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
214481708|NCT05912296|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
214481709|NCT05912296|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
214918079|NCT06683885|DRUG|Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone|"For non GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Obutinib, 150mg, QD, P.O.; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Obutinib maintain treatment for 6 months. Obutinib, 150mg, QD, P.O. After 6 cycles of initial treatment, the efficacy was evaluated.~For GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Decitabine, 10mg, QD，D1-5, ivgtt; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Decitabine maintenance treatment for 4 cycles, 21 days per cycle. Decitabine, 10mg, QD，D1-5, ivgtt. Evaluate the efficacy after 6 cycles of treatment."
214918080|NCT06040970|DRUG|Sacituzumab|"Dose 0: Sacituzumab govitecan 7.5 mg/kg~Dose -1: Sacituzumab govitecan 5 mg/kg"
214918081|NCT06040970|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV
214313718|NCT01984775|DRUG|Positive control|Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).
214313719|NCT01984775|DRUG|Negative control|Negative control contains petrolatum.
214313720|NCT00602147|OTHER|laboratory biomarker analysis|Blood or cheek cells wil be collected.
214481710|NCT06156865|BEHAVIORAL|Intervention to address late talking|this intervention is designed to support both speech and language development in children who are toddlers. Given the age group of children their parents are part of the intervention program. Importantly the frequency of the intervention can range from once to twice per week, with timing also designed to complement the particular agency
214481711|NCT06093061|COMBINATION_PRODUCT|CCRT with Maintenance Tislelizumab and Metronomic Capecitabine|"CCRT: Radiotherapy will be delivered once daily, for 5 days per week, over 6 to 7 weeks. During RT, cisplatin will be administered either 100 mg/m2 3-weekly or 40 mg/m2 weekly, IV infusion (physician's choice).~Maintenance: Tislelizumab 200mg, day 1 per 3-week cycle, intravenous (IV) infusion and capecitabine 650 mg/m2, days 1-21 per 3-week cycle, bidaily, oral, for a total of 12 months (17 cycles)."
214481712|NCT04587674|DEVICE|Spinal Cord Stimulation|Lead(s) and Implant Pulse Generator
214481713|NCT06303128|DRUG|Amoxicillin 250 MG|Liquid amoxicillin 250mg PO
214481714|NCT06303128|DRUG|Placebo|Given prior to amoxicillin 250mg in one-dose group
214481715|NCT06303128|DRUG|Amoxicillin 62.5mg|Given first in two-dose group, liquid amoxicillin 62.5mg PO
214481716|NCT06303128|DRUG|Amoxicillin 187.5mg|Given second in two-dose group, liquid amoxicillin 187.5mg PO
214918082|NCT04158102|DRUG|Bupivacaine liposome injectable suspension|Single dose of Bupivacaine liposome injectable suspension 266 mg in 20 mL
214918083|NCT00411242|DRUG|agomelatine|
214313721|NCT03264287|PROCEDURE|3 times per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
214313722|NCT03264287|PROCEDURE|1 time per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
214918084|NCT00411242|DRUG|placebo|
214918085|NCT03995589|OTHER|Walking|Technology-guided semi-supervised walking therapy
214918086|NCT03995589|OTHER|Control|Go Home and Walk advice
214918087|NCT00305955|DEVICE|Spectacles|optimal spectacle correction
214918088|NCT04681911|DRUG|Inetetamab|Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
214918089|NCT04681911|DRUG|Pyrotinib|Pyrotinib: 400mg, oral, every day.
214918090|NCT04681911|DRUG|Capecitabine|Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
214313723|NCT05568680|BIOLOGICAL|SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR|Autologous T cells Transduced with Mesothelin KIR-CAR
214313724|NCT04214288|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally.
214481717|NCT02986087|DEVICE|Fetal Tracheal Occlusion|Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of \<25%, LHR \<1, o/e LHR\<30% (moderate), singleton pregnancy, no known other anomalies, gestational age \< 29 weeks 6 days, no maternal disease, maternal age \> 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center.
214481718|NCT06984276|DRUG|Control|Patients will receive o.5 ug/kg/hr fentanyl infusion all through the whole operation.
214481719|NCT06984276|OTHER|Pectoral nerves (PECS)|This group will receive fentanyl infusion at a dose of (0.5 μg/kg/hr) all through the whole operation, plus ultrasound guided bilateral pectoral nerves (PECS) Block which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .
214481720|NCT06984276|OTHER|Transversus thoracic muscle plane block (TTPB)|This group will receive fentanyl infusion at a dose of (0.5 μg/kg/hr) all through the whole operation, plus Ultrasound guided bilateral transversus thoracic muscle plane block (TTPB) which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .
214481721|NCT06859606|OTHER|Lower molar distalization|"Lower Distalization Protocol included extraction of the lower third molars before starting treatment and a 50% sequential lower distalization with two teeth being distalized at a time. The distalization started with the movement of lower second molars, followed by the first molars halfway through the process, and so on. Once the canine reached the right position, the en masse retraction of the four incisors completed the treatment plan. The protocol comprised the use of Class III intermaxillary elastics to support the distalization movement and to control the proclination of lower incisors"
214481722|NCT06859606|OTHER|Class III elastics|Non-Distalization Protocol featured extraction of the lower third molars before starting treatment, transversal dento-alveolar coordination, strategic interproximal reduction (IPR) in the anterior segment of the lower arch, and the addition of Class III elastics
214313725|NCT04214288|DRUG|Fulvestrant|Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
214481723|NCT06409741|PROCEDURE|Biliary sphincterotomy|"ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge.~The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.~For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary.~If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up."
214481724|NCT06996379|DEVICE|Experimental J-Tip Needle-Free Injection System|This experimental intervention arm will include use of the J-Tip needle-less device to administer a one-time dose of 1% lidocaine during the superficial (intradermal) numbing step of a bedside abdominal paracentesis for adults with cirrhosis of the liver and ascites requiring bedside paracentesis.
214481725|NCT06996379|DEVICE|Control (Standard treatment)|The control intervention arm will include use of a 25-gauge needle (standard of care) to administer a one-time dose of 1% lidocaine during the superficial (intradermal) numbing step of a bedside abdominal paracentesis for adults with cirrhosis of the liver and ascites requiring bedside paracentesis.
214481726|NCT06997354|DIAGNOSTIC_TEST|Questionnaire|The parents have to complete a questionnaire
214481727|NCT06091332|DRUG|Sirolimus|Sirolimus is an mTORC1 inhibitor that has received approval from the U.S. Food and Drug Administration (FDA) and has recently been successfully used to treat lymphatic malformations and venous/lymphatic malformations associated with the same PIK3CA GOF mutations.
214313726|NCT04094701|OTHER|Control Group Regimen|Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills. This is the standard of care prescribing procedure for pain management after hip arthroscopy.
214313727|NCT04094701|OTHER|Opioid reduced regimen|Tylenol extra strength (1000 mg, three times daily for 10 days following surgery), Gabapentin (300 mg at night for 10 days following surgery) and Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
214481728|NCT06091332|DRUG|Starch flake|The placebo is composed of starch material and is formulated at 0.5 grams per tablet.
214313728|NCT05217849|BEHAVIORAL|Tai Chi|Tai Chi is an ancient Chinese form of exercise/martial art that involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
214313729|NCT05217849|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is a gentle, mindful movement exercise program that integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection.
214313730|NCT05217849|BEHAVIORAL|Health and Wellness Education|This on-line class will consist of hour-long lectures/talks about various topics related to healthy aging and wellness.
214313731|NCT06790173|BEHAVIORAL|Strategy training for physical activity|STPA is a home-based rehabilitation that guides stroke participants to implement strategy training for addressing barriers to physical activity engagements. Participants learn and practice meta-cognitive strategies (to set a goal, to make a plan, to do the plan, to check the performance of the plan) throughout the intervention period.
214313732|NCT06790173|BEHAVIORAL|Physical activity|PA program consists of a warm-up for 5 minutes, an aerobic exercise program for 30-40 minutes, a multicomponent exercise program (resistance and balance training) for 10-20 minutes, and finally, a cooling down program for 5 minutes.
214313733|NCT06790173|OTHER|Education|Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequala, and adaptive skills for impaired functions are provided.
214313734|NCT03932409|DRUG|Pembrolizumab|"prior to VCB: 200mg IV given one week (7 days) before radiation~after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy"
214313735|NCT03932409|RADIATION|Vaginal cuff brachytherapy (VCB)|Treatment should commence within 12 weeks of the surgery/hysterectomy
214313736|NCT03932409|DRUG|Paclitaxel|after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
214313737|NCT03932409|DRUG|Carboplatin|after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
214313738|NCT05801679|DRUG|Sugammadex|Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
214313739|NCT05801679|OTHER|Placebo|Fifteen minutes after ICU arrival, subjects will be administered placebo (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
214313740|NCT06364553|DEVICE|Esophageal self-expandable metal stent|The Leufen Esophageal aixstent ® (Leufen Medical GmbH) is indicated for the treatment of malignant esophageal strictures and postoperative stenosis. It is comprised of two components: an implantable metallic stent and the delivery system. After the procedure, the stent remains at the intended location, within the patient while the delivery system is removed.
214313741|NCT04415606|DEVICE|QuikClot Control+|Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
214313742|NCT05002127|DRUG|Evorpacept (ALX148)|IV Q2W
214313743|NCT05002127|DRUG|Trastuzumab|IV Q2W
214313744|NCT05002127|DRUG|Ramucirumab|IV Q2W
214313745|NCT05002127|DRUG|Paclitaxel|IV Days 1, 8, and 15 of a 28-day cycle
214313746|NCT06347523|PROCEDURE|The VR-based preoperative rehabilitation program;|Patients are provided with VR headsets for personalized pre-rehabilitation educational videos prior to surgery. These videos cover psychological counseling, nutritional advice, and exercise instructions. Additionally, patients engage in VR interactive functional training. After surgery, patients continue with VR technology interactive functional training and watch postoperative educational videos. This intervention is initiated upon the patient's admission and continues until their discharge.
214313747|NCT06347523|PROCEDURE|standard nursing care,|Patients in the control group receive traditional preoperative rehabilitation methods, which may include the following interventions: Joint exercises and rehabilitation exercises guided by a physical therapist. Written or verbal rehabilitation educational materials.
214313748|NCT03581240|DRUG|eflornithine HCl|"In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID~Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS."
214313749|NCT05989607|OTHER|Lower sugar flavored water|A commercially available low sugar flavored water (2.88kcal/100ml; 0.57(sugar) +0.03 (stevia)=0.60g/100ml; sodium 7.9mg/100ml).
214313750|NCT05989607|OTHER|Plain Water|Commercially available bottled, spring water.
214313751|NCT06104124|DRUG|Dazodalibep|IV infusion
214313752|NCT06104124|DRUG|Placebo|IV infusion
214313753|NCT01794806|PROCEDURE|Tooth extraction and grafting with allograft|Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane
214313754|NCT01794806|PROCEDURE|Tooth extraction|Minimally traumatic single-rooted tooth extraction
214313755|NCT05100069|DRUG|Brigatinib|Brigatinib Tablets
214313756|NCT01171131|OTHER|Blood/saliva sampling|one-time blood sample (\~ 1 TBS) and saliva sample (\~ 1 tsp)
214313757|NCT04884685|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
214918091|NCT04681911|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle
214313758|NCT04884685|BIOLOGICAL|Placebo|aluminium hydroxide solution only
214313759|NCT04896658|DRUG|Belantamab Mafodotin, Cyclophosphamide and Dexamethasone|Study drug
214313760|NCT02902510|OTHER|Therapeutic yoga for people with Parkinson's Disease|Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
214313761|NCT05087056|COMBINATION_PRODUCT|MenABCWY vaccine|Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.
214313762|NCT05087056|COMBINATION_PRODUCT|Placebo|Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.
214313763|NCT06074380|DRUG|MIST surfactant|Surfactant will be given via MIST while neonate is on CPAP
214313764|NCT06537882|DIETARY_SUPPLEMENT|G-NiiB synbiotics formula (SLP07)|SLP07 consists of a blend of food-grade Bifidobacterium and Lactobacillus as active probiotics, omega 3, and vitamin E.
214313765|NCT06537882|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains 2mg of vitamin C with corn starch filler
214313766|NCT06433596|OTHER|Platelet-rich plasma|3 injections of 10 cc of autologous Platelet Rich Plasma (PRP), weeks 1, 5 and 9
214313767|NCT06433596|OTHER|Shock waves therapy|6 sessions of focal shock waves, 1 per week
214313768|NCT06433596|OTHER|Placebo PRP|3 injections of 10 cc of saline solution, weeks 1, 5 and 9
214313769|NCT06433596|OTHER|Sham shock waves therapy|6 sessions of sham shock waves, 1 per week
214918092|NCT04681911|DRUG|Vinorelbine|Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle
214313770|NCT05914779|OTHER|No use of antibiotics|Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
214918093|NCT04681911|DRUG|Carboplatin|Carboplatin, AUC = 6, 3-week cycle
214918094|NCT04681911|DRUG|Albumin paclitaxel|Albumin paclitaxel, 100 mg/m2, weekly
214918095|NCT04681911|DRUG|Eribulin|Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle
214918096|NCT06968884|OTHER|Protocol based|"Preoperative administration of iron, b12 and folate if criteria is met. Medication to aid in smoking cessation is offered if patient uses tobacco. Nutritional supplements offered pre-operative is patient malnurished and preoperative drink offered to all.~Anaesthetic method adapted with increased use of epidural, blocks and local anaesthesia.~Administration on TXA and fluids according to protocol. Postoperative nutritional drink to increase protein intake. Early mobilisation to reduce risk of VTE."
214955136|NCT00824629|PROCEDURE|Afterloading embryo transfer procedure|Afterloading embryo transfer procedure
214955137|NCT00824629|PROCEDURE|Direct embryo transfer procedure|Direct embryo transfer procedure
214918097|NCT06968884|PROCEDURE|Control (Standard treatment)|"Preoperative bloods including haemoglobin to establish that surgery is safe. Transfusions given if clinically necessary, no other protocol for anaemia treatment other then available clinical guidelines.~Peri- and postoperative treatment given in accordance with best clinical practice, no additional protocol."
214313771|NCT05914779|OTHER|with antibiotics treatment|with antibiotics treatment
214313772|NCT02225522|OTHER|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
214313773|NCT02706509|DRUG|Tramadol|patient will receive oral Tramadol 50 mg an hour before IUD insertion
214313774|NCT02706509|BEHAVIORAL|Verbal anesthesia|patient will receive full explanation about the procedure for five minutes before IUD insertion
214313775|NCT02706509|DEVICE|Jaydess|Patient will go through an insertion of Jaydess intrauterine device.
214313776|NCT06223074|OTHER|IV Methylprednisolone administration|Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse
214313777|NCT06223074|DRUG|Nasal Methylprednisolone (MT)|Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
214313778|NCT03806166|OTHER|Shorter Systemic Antibiotics|Reduced duration of post-operative systemic antibiotic therapy
214313779|NCT03806166|OTHER|Standard treatment|Standard duration of systemic antibiotic treatment
214313780|NCT05303753|OTHER|fermented dairy protein with prebiotic fiber|During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
214313781|NCT03451799|OTHER|Ketogenic Diet|A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
214313782|NCT03451799|RADIATION|Standard-of-care radiation|Patients will receive standard-of-care radiation. Radiation is not protocol directed.
214313783|NCT03451799|DRUG|Standard-of-care Temozolomide|Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
214313784|NCT05642416|DRUG|Continuous Infusion of ropivacaine|Continuous infusion of ropivacaine
214313785|NCT05642416|DRUG|Intermittent bolus of ropivacaine|Intermittent bolus of ropivacaine
214313786|NCT05863676|PROCEDURE|Oophorectomy|Ovary will be removed for fertility preservation.
214313787|NCT05863676|DIAGNOSTIC_TEST|Infectious Disease Testing|Infectious Disease Testing will be done on participants.
214955138|NCT02131233|DRUG|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
214955139|NCT02131233|DRUG|Raltegravir|Raltegravir 400 mg tablet orally twice daily
214313788|NCT03890549|DIAGNOSTIC_TEST|SnoreLab (smart phone application for snoring recording)|The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
214313789|NCT01990495|OTHER|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
214313790|NCT01990495|OTHER|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
214313791|NCT01747109|DEVICE|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
214313792|NCT01747109|PROCEDURE|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)"
214313793|NCT02912026|DRUG|IV F901318|Metabolic profile AUC 0 to infinity
214955140|NCT02131233|DRUG|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
214955141|NCT02131233|DRUG|Placebo to Reformulated Raltegravir|Placebo to reformulated raltegravir 2 tablets orally once daily
214313794|NCT02912026|DRUG|Oral F901318|Metabolic profile AUC 0 to infinity
214313795|NCT02290288|PROCEDURE|vaginal surgery|
214313796|NCT02290288|PROCEDURE|laparoscopic surgery|
214313797|NCT01928862|DRUG|Prepopik® ½ Sachet x 2 (9-12 years)|
214313798|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (9-12 years)|
214313799|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
214313800|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (13-16 years)|
214313801|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
214313802|NCT01478321|DRUG|Temozolomide|Given PO
214313803|NCT01478321|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated radiation therapy
214313804|NCT01478321|BIOLOGICAL|bevacizumab|Given IV
214313805|NCT01478321|OTHER|questionnaire administration|Ancillary studies
214313806|NCT00145665|PROCEDURE|FLT-PET scan|PET scan using FLT
214313807|NCT02888548|PROCEDURE|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
214313808|NCT02888548|PROCEDURE|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
214313809|NCT00983268|DRUG|capecitabine|1000 mg taken by mouth on the days of radiation only.
214313810|NCT00983268|DRUG|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~* Vorinostat,at 100 mg~* Vorinostat,at 200 mg~* Vorinostat, at 300 mg~* Vorinostat, at 400 mg"
214313811|NCT00983268|RADIATION|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
214313812|NCT00983268|PROCEDURE|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
214313813|NCT01731522|BEHAVIORAL|EF condition|
214313814|NCT03168464|DRUG|Ipilimumab|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
214313815|NCT03168464|DRUG|Nivolumab|On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
214313816|NCT03168464|RADIATION|Radiation therapy|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
214313817|NCT04649164|BEHAVIORAL|Peer mentor support and caregiver intervention|Sixteen-week modular curriculum with printed/online workbook, additional resources, and weekly phone discussion with Lewy Body Dementia peer mentor.
214313818|NCT04649164|OTHER|Focus group to provide feedback on educational materials and mentoring program|Participation in a 2-3 hour focus group to review pilot and revised materials and provide feedback
214313819|NCT03352921|OTHER|clinical pilates exercises|servikal, deep flexor muscles, posture exercsises
214313820|NCT03352921|OTHER|home exercises program|stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
214313821|NCT02053753|DRUG|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
214313822|NCT02053753|DRUG|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
214313823|NCT04722796|DEVICE|TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)|Transcatheter aortic valve replacement (TAVR) with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
214313824|NCT04722796|DEVICE|TAVR with Venus A plus using annular sizing and THV implantation technique|Transcatheter aortic valve replacement (TAVR) with Venus A plus using annular sizing and THV implantation technique (Traditional sizing strategy)
214313825|NCT03433664|DEVICE|CO2 laser|Fractional CO2 laser treatment using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping
214313826|NCT01969812|DEVICE|Evie Slow-release Insemination Device|
214313827|NCT01969812|OTHER|Traditional Intrauterine Insemination|
214313828|NCT05210166|DEVICE|Active tSCS and Lokomat|"A symmetrical biphasic 30 Hz current of 1 ms pulse-width with an electro-stimulator will be applied.~For the stimulation intensity, the maximum intensity tolerated by the patient will be selected. The intensity will be increased in case of habituation to the current."
214313829|NCT05210166|DEVICE|Sham tSCS and Lokomat|The protocol and device of sham tSCS combined with Lokomat will be the same as active tSCS except for the stimulus intensity, which will be set at the sensory threshold, maintained for 30 seconds and then slowly will be decreased to zero, being this intensity maintained for the remaining 20 minutes of stimulation.
214313830|NCT03183414|OTHER|echocardiographic measurements|echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
214313831|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
214313832|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
214313833|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
214313834|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
214313835|NCT00634088|DRUG|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
214313836|NCT00634088|DRUG|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
214313837|NCT05360563|OTHER|Home-based physical training|Patients allocated to this group will participate in a 16-week home-based physical training program, structured in three weekly sessions of aerobic and muscle strengthening exercises (which also have components that stimulate flexibility and balance). A third of the weekly physical training sessions will be supervised via telemedicine (with video call) by a clinical exercise specialist, but all patients will have illustrated exercise booklets and a full-time remote support service available for the remaining sessions (via text or voice messages).
214313838|NCT00499096|BEHAVIORAL|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
214313839|NCT03507712|PROCEDURE|Symmetrical IO weakening|Bilateral IO Myectomy / Bilateral equal graded IO Recession
214313840|NCT03507712|PROCEDURE|Asymmetrical IO weakening|IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye
214313841|NCT01578928|DRUG|SOM230|
214955142|NCT02131233|DRUG|Placebo to Raltegravir|Placebo to raltegravir 1 tablet orally twice daily
214313842|NCT04037020|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (extreme dark (90%), dark (70%), milk (38%), and white (0%)).
214313843|NCT00422032|DRUG|Clofarabine|"Group A: 15 mg/m\^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days"
214313844|NCT05102188|COMBINATION_PRODUCT|Assessment of sleep and related factors|Eligible participants will be invited to fill out several forms and wear a watch-like device on their wrist (an accelerometer) for 7 days to assess their sleep habits. They will also be asked to sleep at home with a watch-like device attached to a sleeve which covers their index finger (an oximeter) for one night to assess whether they may have a sleep problem like sleep apnea.
214313845|NCT03142880|COMBINATION_PRODUCT|hyperbaric ropivacaine|We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.
214313846|NCT02245243|DRUG|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
214313847|NCT00886431|OTHER|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
214313848|NCT05656924|DEVICE|digital prosthetic interface technology|Individuals randomized to this group will receive a socket and liner that are manufactured using a novel technique meant to achieve a better distribution of pressure on the residuum. The study is based on the hypothesis that an improvement in pressure distribution on the residuum will enable high adherence to an exercise program meant to improve health status in dysvascular amputees.
214313849|NCT04848935|DEVICE|CURATE.AI|CURATE.AI will be utilised to provide personalised training intensity recommendations (low, medium or high) to the patients during the digital cognitive test battery DI session. The difficulty of each task will be modulated by CURATE.AI by adjusting the frequency of critical events that demand evaluation and/or response.
214313850|NCT03880721|PROCEDURE|Microwave abaltion|Use microwave ablation to treat hepatocellular carcinoma
214313851|NCT06227507|BEHAVIORAL|Front-of-package label|Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.
214313852|NCT00621218|DRUG|tretinoin gel 0.05%|Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
214313853|NCT00621218|DRUG|vehicle|Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
214313854|NCT06267235|OTHER|Dietary protein restriction|The consumption of different diets restricted in protein replaced by either carbohydrate or fat and an habitual diet.
214313855|NCT00343057|OTHER|Patients' questionnaire|
214313856|NCT04760717|DRUG|Spironolactone Pill|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
214313857|NCT02788110|OTHER|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
214313858|NCT02788110|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
214313859|NCT01256593|DRUG|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
214313860|NCT01914484|DRUG|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
214313861|NCT01914484|DRUG|Ruxolitinib|"In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor"
214313862|NCT00259090|DRUG|Fulvestrant|500 mg intramuscular injection
214313863|NCT00259090|DRUG|Anastrazole|oral tablet
214313864|NCT00094965|DRUG|Oxaliplatin (SR96669)|oxaliplatin in combination with FOLFOX4
214313865|NCT02735083|BIOLOGICAL|UCART19 follow-up|UCART19 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19. The roll-over occurs at the end of the parent study, or at any time after UCART19 administration, in case of premature discontinuation from the parent study.
214313866|NCT04524312|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant
214313867|NCT04524312|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
214313868|NCT04524312|DEVICE|NexGen Ps or Bioimplanti K-MOD implant|Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
214313869|NCT03162601|PROCEDURE|Neurovascular percutaneous intervention|Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.
214481729|NCT06543238|OTHER|Breastfeeding card game group|Breastfeeding card game group: Breastfeeding education will be given to 30 primiparous pregnant women in the intervention group using the card game method twice, two weeks apart.
214481730|NCT03338387|DRUG|Acipimox|Acipimox
214313870|NCT04223882|BEHAVIORAL|Management of Stress|"Psychoeducation:~Coronary artery disease, Percutaneous Coronary Intervention, traditional risk factors and emotional stress.~Stress: physiology, triggers, triad (thinking, emotion, action).~Skills training:~Identify warning signs - signs and symptoms; Monitoring of irrational automatic thoughts generating alternative interpretations of situations or unrealistic thinking patterns (Dysfunctional Thinking Records Sheet).~Self-control for stress management:~Assertiveness training, problem solving. Thought-stopping technique, designed for dysfunctional thoughts, such as, I won't do it, It won't work.~Stress Relief / Control Techniques:~Diaphragmatic Breathing: Expansion of the abdomen rather than the chest when breathing.~Progressive Muscle Relaxation: Maximize tension and alternately relax the muscles (legs, abdomen, chest, arms and face)."
214313871|NCT04223882|OTHER|Usual care|outpatient medical appointments
214313872|NCT06481592|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with lifileucel, followed by IL-2.
214313875|NCT00145925|DRUG|Perindopril-indapamide|
214313876|NCT00145925|DRUG|Gliclazide MR-based glucose lowering|
214313877|NCT05835479|DRUG|Co-Trimoxazole|Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
214313878|NCT05835479|DRUG|Rezafungin Acetate / Co Trimoxazole|"Rezafungin for infusion. Intravenous anti fungal therapy~Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication"
214313879|NCT02662127|DEVICE|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
214313880|NCT01841151|BEHAVIORAL|SCP training|
214313881|NCT01841151|BEHAVIORAL|Live Z-score training|
214313882|NCT01841151|BEHAVIORAL|WM training|
214313883|NCT05907096|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
214313884|NCT05907096|OTHER|Placebo|Intravenous administration of placebo
214313885|NCT06157177|DRUG|Metaxalone 640 mg Oral Tablet|Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.
214313886|NCT01883687|PROCEDURE|Septoplasty|
214313887|NCT02689258|DRUG|HTX-011B|HTX- 011B (bupivacaine/meloxicam) via injection
214313888|NCT02689258|DRUG|Placebo|Saline placebo via injection
214313889|NCT02689258|DRUG|HTX-011A|HTX- 011A (bupivacaine/meloxicam) via injection
214955143|NCT05750459|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
214313890|NCT02689258|DRUG|HTX-002|HTX-002 via combination
214313891|NCT02689258|DRUG|Bupivicaine HCl|Bupivacaine HCl via injection
214313892|NCT05251376|DRUG|Levomethadone HCl|One dose given orally on Day 8 of the study.
214313893|NCT05251376|DRUG|Methadone|Daily usual oral dose given on Day 1 and Day 2 of the study.
214313894|NCT05251376|DRUG|Morphine Sulfate|Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.
214313895|NCT05251376|DIAGNOSTIC_TEST|x-ray|Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.
214313896|NCT05251376|DIAGNOSTIC_TEST|blood tests|Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.
214313897|NCT05583396|DIAGNOSTIC_TEST|Acute exercise|The measurement will be repeated within one to seven days.
214313898|NCT00210704|DRUG|Dapoxetine|
214313899|NCT05437978|OTHER|"Cap Sport Santé 83 program"|"In Var department (France), the  Maison Sport-Santé 83  has set up a program called Cap Sport Santé 83 to support patients who received a prescription to practice APA regularly. This program helps long-term illnesses patients to restart physical activity by considering their pathology. The Cap Sport Santé 83 program is composed of 5 stages which aim to encourage adherence to APA practice by relying on the medical prescription system. Throughout the process, the patient is supervised and supported by the program's coordinator."
214313900|NCT01050985|DRUG|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
214313901|NCT03823248|DRUG|MoLuoDan|oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
214313902|NCT03823248|DRUG|Sanchi powder|oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
214313903|NCT03823248|DRUG|Folic Acid Tablet|oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
214313904|NCT03823248|DRUG|MoLuoDan simulation|oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
214313905|NCT03823248|DRUG|Sanchi powder simulation|oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
214313906|NCT03823248|DRUG|Folic Acid Tablet simulation|oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
214313907|NCT06821854|DEVICE|PN20 (Plinest)|"PN20 (Plinest) is a single-use viscoelastic, and sterile gel for intradermal use. PN20 contains polynucleotides (20 mg/ml- 2%), water, sodium chloride, sodium phosphate and disodium phosphate.~PN20 is administered using a fine needle (usually 30 G) by injecting the solution into the dermis. Depending on the medical assessment, different injection techniques, such as linear threading, serial punctures, crosslinked, radial fanning or mixed, can be used. The injection site must consist of healthy skin. PN20 can also be administered by means of modern non-invasive techniques (electroporation, hydroelectrophoresis, etc.). In all these cases, thoroughly cleanse and disinfect the area to be treated before application.~PN20, thanks to its versatility and manageability, can be used in any skin area; in the current clinical investigation the face, neck or décolleté will be treated."
214481731|NCT03338387|DRUG|Placebo|Placebo Other Names: Placebo (for Olbetam)
214481732|NCT05572658|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
214955144|NCT04893187|DRUG|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
214313908|NCT00819988|DRUG|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
214313909|NCT00819988|OTHER|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
214313910|NCT00314236|DEVICE|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
214313911|NCT00314236|PROCEDURE|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
214313912|NCT04499586|COMBINATION_PRODUCT|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) per week. Radiation: 45-55Gy/25-30Fx
214313913|NCT00439556|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
214313914|NCT00439556|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214313915|NCT00439556|DRUG|Bortezomib|Given IV
214918098|NCT00863148|DRUG|Clofarabine in combination with IV busulfan and ATG|A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
214918099|NCT05784324|OTHER|No intervention|No intervention
214313916|NCT00439556|DRUG|Carmustine|Given IV
214313917|NCT00439556|DRUG|Cytarabine|Given IV
214313918|NCT00439556|DRUG|Etoposide|Given IV
214313919|NCT00439556|BIOLOGICAL|Filgrastim|Given SC
214313920|NCT00439556|DRUG|Melphalan|Given IV
214313921|NCT00439556|DRUG|Methotrexate|Given IV
214313922|NCT00439556|BIOLOGICAL|Rituximab|Given IV
214313923|NCT00439556|DRUG|Tacrolimus|Given IV and PO
214313924|NCT03321669|PROCEDURE|Capsule endoscopy|Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
214313925|NCT02371707|DRUG|Idalopirdine 60 mg formulation A (test)|Tablet for oral use, single dose
214313926|NCT02371707|DRUG|Idalopirdine 60 mg formulation B (reference)|Tablet for oral use, single dose
214313927|NCT05751330|PROCEDURE|Transcatheter ablation of cardiac ganglionated plexi|"The ablative procedure involves applying radiofrequency deliveries in the two~Right atrium anatomical sites close to the two main ganglionic plexuses of the right atrium:~* Inferior-posterior area (site of first ablation) corresponding to the right inferior atrial ganglion located between the inferior vena cava, coronary sinus ostium and near the atrioventricular node~* Upper-posterior area (site of second ablation) corresponding to the right superior atrial ganglion located between the superior vena cava and the posterior surface of the right atrium"
214313928|NCT04966676|DIAGNOSTIC_TEST|cfDNA blood test|Blood sample will be taken for cfDNA testing
214313929|NCT04966676|DRUG|Nivolumab|Antineoplastic agent
214918100|NCT02074969|DEVICE|Gamma Nail 3|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.
214313930|NCT04966676|DRUG|Ipilimumab|Antineoplastic agent
214313931|NCT04966676|COMBINATION_PRODUCT|Platinum-based Chemotherapy|May include carboplatin with gemcitabine, or paclitaxel or pemetrexed
214313932|NCT02139566|BEHAVIORAL|Video consent (high-tech)|Consent provided by an animated video with captions
214313933|NCT02139566|BEHAVIORAL|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
214313934|NCT02139566|BEHAVIORAL|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
214313935|NCT02139566|BEHAVIORAL|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
214313936|NCT02139566|BEHAVIORAL|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
214313937|NCT03063996|PROCEDURE|peripheral IV access procedure|standard of care guided IV access into peripheral vein excluding IJ
214313938|NCT03063996|PROCEDURE|Peripheral IJ access procedure|standard of care guided IV access into IJ
214313939|NCT05291364|DRUG|Group 1|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
214313940|NCT05291364|DRUG|Group 2|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
214313941|NCT02086929|DRUG|Trazodone|
214918101|NCT02074969|DEVICE|PFNA|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
215060944|NCT02309658|DRUG|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
214313942|NCT02086929|DRUG|Venlafaxine|
214313943|NCT06089720|DEVICE|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|nine orthodontic patients each one will receive 2 coated zinc oxide nanoparticle molar tubes in split-mouth manner and will assess for antimicrobial effect on s. mutans \& lactobacillus after two weeks, in addition to evaluation of bond failure rate after three months.
214313944|NCT06089720|DEVICE|orthodontic molar tubes (control)|nine orthodontic patients each one will receive two uncoated molar tubes in split-mouth manner and will assess for antimicrobial effect on S. mutans \& lactobacillus after two weeks, also, evaluation of the bond failure rate after three months period.
214481733|NCT05572658|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214313945|NCT05866120|OTHER|Physiotherapy on the ground|Physical therapy will be performed on the ground, in 12 weeks, twice a week. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
214313946|NCT05866120|OTHER|Aquatic physiotherapy|Aquatic physiotherapy will be performed in 12 weeks, twice a week, in shallow water. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
214313947|NCT01758380|DRUG|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
214313948|NCT01758380|DRUG|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
214313949|NCT01758380|DRUG|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
214313950|NCT01758380|DRUG|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
214313951|NCT01758380|DRUG|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
214313952|NCT04962646|PROCEDURE|Carbon dioxide flooding|Once the thoracic cavity is opened a flow of carbon dioxide of 5L/min will be initiated into the surgical wound and proceed until there is no connection between the cardiac or aortic cavity and surrounding air.
214313953|NCT04089787|OTHER|Intervention|Shortened antibiotic treatment of 5 days
214313954|NCT04089787|OTHER|Control|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
214313955|NCT06131554|BIOLOGICAL|batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
214313956|NCT06131554|BIOLOGICAL|batch 2 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
214313957|NCT06131554|BIOLOGICAL|batch 3 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
214313958|NCT06131554|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection
214313959|NCT02832310|PROCEDURE|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
214313960|NCT00400647|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
214918102|NCT04765995|DRUG|HZBio1 0.96mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
214918103|NCT04765995|DRUG|HZBio1 3mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
214313961|NCT00400647|DRUG|Mycophenolate mofetil|
214313962|NCT03615807|PROCEDURE|Surgical debridement (if needed)|Surgical debridement
214313963|NCT03615807|DIAGNOSTIC_TEST|Microbiological sampling|Microbiological sampling
214313964|NCT03615807|PROCEDURE|Revascularisation (if needed).|Revascularisation (if needed).
214955145|NCT04893187|DRUG|Placebo|Matched placebo.
215060945|NCT02309658|DRUG|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
214313965|NCT03615807|DEVICE|Off-loading|Off-loading by Special shoes
214313966|NCT03615807|BEHAVIORAL|Patient's education and instructions|Patient's education and instructions by specialized nurses
214313967|NCT03615807|PROCEDURE|Wound debridement|Regular wound debridement by specialized nurses
214313968|NCT03615807|DRUG|Antibiotic duration|Systemic antibiotic duration according to the study arms
214313969|NCT05889598|OTHER|Ballistic Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40%1RM, the ballistic training group will complete eccentric phase hack squat exercise in approximately 3 seconds and the concentric phase as fast as possible with throwing type contractions. If participants can, participants will be allowed to take off in the concentric phase. To maintain high velocity in this group, lower loads will be used compared to the conventional group. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
214481734|NCT03865992|DIETARY_SUPPLEMENT|Curcumin|Given capsules for oral administration
214481735|NCT03865992|OTHER|Placebo|Given capsules for oral administration
214481736|NCT03865992|OTHER|Nanoemulsion|Given nanoemulsion curcumin PO
214481737|NCT03865992|OTHER|Quality-of-Life Assessment|Ancillary studies
214481738|NCT03865992|BEHAVIORAL|Questionnaire|Ancillary studies
214481739|NCT05985395|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will complete 150 minutes of moderate-intensity exercise a week with help of a virtual exercise coach.
214481740|NCT06865274|PROCEDURE|Blood draw for the laboratory assessment|Blood draw of approximately 5 ml of peripheral venous blood (collected in EDTA) will be collected for DNA extraction and genetic analysis limited to the research of FCG3A polymorphisms
214481741|NCT06865027|OTHER|Ventilation strategy|"The selected PaCO2 targets are:~Normocapnia: PaCO2: 5.0-5.5 kPa Hypercapnia: PaCO2: 6.4-7.0 kPa~The adjustments on the ventilator needed to achieve these targets will be administered by the anesthetic nurse and attending anesthesiologist and held within the following limitations:~Tidal volume: 4 - 8ml ml/kg IBW Inspiratory pressure 5-30 cm H2O Respiration rate 10-18 per minute PEEP 5-10 mmHg~\*IBW: 50 + 0.91 (height in centimeters - 152.4) Peep, I:E ratio, and FiO2 will be administered at the anesthetic nurse's and the anesthesiologist's discretion."
214481742|NCT06864416|DRUG|dexmedetomidine as adjuvant to bupivacaine|the efficacy of addition of dexmedetomidine as adjuvants to bupivacaine in femorosciatic nerve block
214918104|NCT04765995|DRUG|HZBio1 6mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
214313970|NCT05889598|OTHER|Conventional Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at Loughborough University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40% of 1RM, the conventional training group will complete eccentric and concentric phases of hack squatting exercises for approximately 3 seconds each, with appropriate breathing techniques. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
214313971|NCT01066988|OTHER|ORB Ocular Emulsion|lubricant eye drop
214313972|NCT01066988|OTHER|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
214918105|NCT04765995|DRUG|HZBio1 9mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
214313973|NCT06372288|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS using Intermittent theta burst stimulation (iTBS)
214313974|NCT06372288|DEVICE|Sham Transcranial Magnetic Stimulation|Participants will not receive intermittent theta burst stimulation during the sham-TMS sessions
214313975|NCT06140095|DRUG|Evolocumab|See arm description
214481743|NCT06864416|DRUG|Fentanyl as adjuvant to bupivacaine|the efficacy of addition of fentanyl as adjuvants to bupivacaine in femorosciatic nerve block
214481744|NCT06863467|DRUG|Intravenous Gemini|Single ascending intravenous dose infused once over 10-15 minutes.
214481745|NCT06863467|DRUG|Intravenous placebo|Intravenous sugar solution infused in a single dose over 10-15 minutes.
214481746|NCT06864312|DRUG|continuous infusion of levobupivacaine|patients one arm of this study will receive a postoperative continuous infusion of levobupivacaine
214481747|NCT06864312|DRUG|oxycodone|A timed weight appropriate dose of oxycodone will be administered 16 hours postoperatively
214918106|NCT04765995|DRUG|HZBio1 12mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
214918107|NCT04765995|DRUG|Placebo|Matching placebo will be administered intramuscularly.
214918108|NCT04316429|OTHER|Egg included vegan phase|: Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets. Participants will also receive instructions to preserve an isocaloric condition with the addition of 2 eggs in their diets. Counseling of the study participants will be based on the U.S. Department of Agriculture (USDA) healthy vegetarian meal plans, with modifications to exclude dairy products. \[21\] Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet (with the exception of including eggs) will also be provided.
214918109|NCT04316429|OTHER|Vegan Phase|The participants will consume a vegan diet for 6 weeks. The study dietitian will provide counseling and sample meal plans based on the USDA healthy vegetarian dietary pattern, with modifications to exclude eggs and dairy products. Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet will also be provided.
214918110|NCT00403481|DRUG|olmesartan medoxomil|Olmesartan medoxomil tablets, once daily
214955146|NCT03183843|DRUG|Dabigatran Etexilate|Dabigatran Etexilate 150 mg capsules for oral administration twice a day
214481748|NCT06864923|OTHER|Hot foot bath application group|The intervention group will receive hot foot baths for three consecutive nights starting from the second day of hospitalization. The foot bath will be applied one hour before the patient goes to bed at night. The foot tub will be filled with hot water to approximately 20 cm above the patient's ankle and the temperature of the water will be measured with a water thermometer. The temperature of the water will be kept stable at 41-42°C. This application will be done for 20 minutes. The sleep and fatigue levels of the patients will be measured with measurement tools in the morning (3 times) following each application.
214955147|NCT03183843|DRUG|Warfarin|Warfarin 2.5 mg tablets for oral administration once a day
214481749|NCT06863350|DEVICE|patent foramen ovale closure|patent foramen ovale closure
214481750|NCT06863675|DEVICE|HAL lenses for children with strabismus|It has been shown that peripheral segmented defocus spectacles can slow myopia progression. The Essilor® Stellest™ lens has been designed with an exclusive and pioneering technology called HALT (Highly Aspherical Lenslet Target). The HALT technology is made of a constellation of 1,021 invisible lenslets. This constellation creates a signal in front of the retina that acts as a shield against eye elongation and, therefore, myopia progression. Studies suggest that children are tolerable against these glasses, and the lenses can slow down myopia progression by 67% on average, compared to single vision lenses, when worn 12 hours a day. It can be considered as one of the best available myopia control spectacle lens designs, being superior to progressive addition and bifocal lenses.
214481751|NCT06863675|DEVICE|SVL for children with strabismus|SVL for children with strabismus
214481752|NCT06864442|PROCEDURE|Catgut Thread Embedding|Catgut Thread Embedding involved implanting chromic catgut size 4.0 thread, which is attached to a 23G guide needle, into subcutaneous tissue at EX-HN21 acupoint. The guide needle was removed after insertion, while the thread remained and dissolved over 10-15 days to provide continuous stimulation.
214481753|NCT06864442|PROCEDURE|Electroacupuncture|Electroacupuncture was administered using four needles (0.3 × 25 mm, diameter × length) inserted at GV-20, EX-HN21, external EX-HN12, and external EX-HN13 acupoints. Electrical stimulation was delivered via the KWD-808I Multipurpose Health Device (Changzhou Yingdi Electronic Medical Device Co., China) with parameters set at 3 Hz frequency and 0.6 ms pulse width, the intensity was adjusted according to the patient's perception. Electroacupuncture was performed daily, except on Saturdays, Sundays, and Vietnamese national holidays, over a treatment course of 30 days.
214313976|NCT00324064|PROCEDURE|GHRH/arginine stimulation testing|GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.
214313977|NCT01900028|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
214313978|NCT01900028|DRUG|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
214313979|NCT01900028|DRUG|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
214313980|NCT01498640|BIOLOGICAL|Collagenase clostridium histolyticum|up to three 0.58 mg injections
214481754|NCT06864975|DRUG|Advate®|Non-daily dose FVIII 50IU/kg.QoD or 100IU/kg.QoD
214918111|NCT00403481|DRUG|Olmesartan medoxomil plus Hydrochlorothiazide|Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
214918112|NCT04502654|DEVICE|Actiwatch 2 (Philips Respironics, Murrysville, USA)|Actiwatch 2 is an unobtrusive, waterproof, light sensor and wrist-worn device (weight 16.0g, size 4.3 cm\* 2.3 cm\* 1.0 cm), containing a tri-axial accelerometer able to records a digitally integrated measure of gross motor activity (a piezoelectric sensor to detect vertical accelerations at the wrist between 0.5 and 2.0 g with a frequency response range between 0.35-7.5 Hz). Activity counts from the device reflect the peak acceleration detected over each epoch and are used in determining sleep and wake intervals, which can be used to rest-activity patterns, quality of physical activity and sleep for 15-60 seconds/ epoch, 24 hours/ day, 2 weeks.
214918113|NCT05641805|OTHER|PAQ-C (Physical activitiy questionare for children), MoCA (Montreal Cognitive Assessment), PBS (Pediatric Balance Scale), Modified Mini Mental State Examination, BMI (Body Mass Index)|"PAQ-C will use to evaluate physical activity level of participants. MoCA and Modified Mini Mental State Examination will use to evaluate cognitive functions of participants.~PBS will use to evaluate participants' balance responses."
214918114|NCT05974878|OTHER|Exercise|"* Joints targeted by exercise; bilateral wrist, metacarpophalangeal, proximal and distal interphalangeal joints, elbow and shoulder joints.~* The muscles targeted by the exercises; lumbricals, iinterosseals, thenar and hypothenar muscles, forearm flexors, forearm extensors, forearm supinators and pronators, elbow flexors and extensors, and shoulder girdle muscles.~* Content of the exercises; There will be warm-up exercises, pinch grip, full grip, nerve and tendon gliding exercises, exercises that improve proprioception, functional exercises, strengthening exercises and stretching exercises."
214313981|NCT01514695|DRUG|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
214313982|NCT01514695|DRUG|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
214313983|NCT01514695|OTHER|Placebo|One dose of saline (2ml)
214313984|NCT02438202|DEVICE|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
214481755|NCT06864975|DRUG|Advate®|Daily dose FVIII 50IU/kg.QD or 100IU/kg.QD
214481756|NCT06864975|DRUG|Advate®|Low dose FVIII 50IU/kg.QD or 100IU/kg.QoD
214481757|NCT06864975|DRUG|Advate®|Medium and high dose FVIII ≥100IU/kg.QD
214481758|NCT06864975|DRUG|Advate®|Medium and high dose FVIII ≥100IU/kg.QD with immunosuppressant agent(s)
214671373|NCT05165329|COMBINATION_PRODUCT|PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
214918115|NCT05974878|OTHER|Conventional Physiotherapy|For control group there will be aerobic exercise recommendation and resistive exercises focused on upper extremity.
215060946|NCT02309658|RADIATION|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
214313985|NCT06532513|OTHER|Family-Centered Goal-Oriented Physiotherapy and Rehabilitation Application|Family centered goal-oriented physiotherapy and rehabilitation applications aim to enhance the functional level of severely affected children with dyskinetic cerebral palsy children through individualized activities conducted by family members at home. The program focuses on specific goals determined collaboratively by the family, physiotherapists, and physician, with regular monitoring and assessments to track progress.
215060947|NCT03392428|OTHER|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
215060948|NCT03392428|DRUG|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
214313986|NCT04533373|PROCEDURE|DIEP Flap Neurotization|"We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new source) that is being transferred and attaching it to a nerve in the chest wall."
214671374|NCT03407391|OTHER|None - observational|No intervention - observational only
215060949|NCT05183074|DEVICE|MR-linac|1.5-Tesla MR-linac based SBRT
215060950|NCT01970228|DIAGNOSTIC_TEST|68Ga-citrate and 18F-FDG PET/CT imaging|Single-day study of the two PET tracers
215060951|NCT04543916|DRUG|Venetoclax 50 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
215060952|NCT04543916|DRUG|Venetoclax 100 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
215060953|NCT04543916|DRUG|Venetoclax 200 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
215060954|NCT04543916|DRUG|Venetoclax 400|Escalating doses to determine recommended phase 2 dose (RP2D)
215060955|NCT04543916|DRUG|Venetoclax 600|Escalating doses to determine recommended phase 2 dose (RP2D)
215060956|NCT04543916|DRUG|Irinotecan 60 mg/m2|Intravenously (IV), days 1, 8, and 15
215060957|NCT04543916|DRUG|Venetoclax (RP2D)|orally, once per day
215060958|NCT00167375|DRUG|eszopiclone 3 mg qHS|
215060959|NCT00167375|BEHAVIORAL|General cognitive/behavioral interventions for insomnia|
215060960|NCT04181229|PROCEDURE|Deep brain stimulation|Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
214313987|NCT03993678|DRUG|IP-001|Dose and route: Immediately (within 15 - 30 min) after thermal ablation, IP-001 will be injected in and around the ablated lesion. The amount of IP-001 injected depends on the dose level.
214313988|NCT03993678|DEVICE|Thermal Ablation|"The medical device includes a laser unit. The system continuously measures the temperature of the tissue, guiding the user to perform precise and safe treatments.~Treatment time: 30 min"
214313989|NCT04770012|DRUG|Placebo|patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
214313990|NCT04770012|DRUG|aspirin|patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment
214313991|NCT04770012|DRUG|Clopidogrel|patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
214313992|NCT05306418|DRUG|Mim8|"For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin"
214313993|NCT00457782|DRUG|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
214313994|NCT05749575|DRUG|Chidamide Plus Toripalimab Plus Paclitaxel|Each participant receives chidamide plus toripalimab plus paclitaxel
214313995|NCT03922451|DRUG|piperacillin-tazobactam|Administered for infection treatment or prophylaxis per hospital protocol
214313996|NCT03922451|DRUG|Cefazolin|Administered for infection treatment or prophylaxis per hospital protocol
214313997|NCT04879004|DRUG|Ropivacaine injection|Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
214313998|NCT03318354|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
214313999|NCT03318354|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
214314000|NCT04377477|RADIATION|Single fraction whole lung radiotherapy|Participants will undergo irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
214314001|NCT05544786|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
214314002|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
214314003|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
214314004|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
214314005|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
214314006|NCT02306629|BIOLOGICAL|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
214314007|NCT02306629|BIOLOGICAL|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
214918116|NCT05724680|OTHER|cognitive behavior therapy|Psycho-therapeutic intervention
214314008|NCT01907672|PROCEDURE|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
214314009|NCT03065244|DRUG|IVIG|Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
214314010|NCT03065244|DRUG|Infliximab|Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
214314011|NCT03163082|OTHER|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
214314012|NCT03163082|BEHAVIORAL|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
214314013|NCT03163082|OTHER|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
214314014|NCT03163082|OTHER|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
214314015|NCT02988791|DIETARY_SUPPLEMENT|probiotic (BIfidobacterium, BB-12®)|probiotic (Bifidobacterium, BB-12®)
214314016|NCT02988791|DIETARY_SUPPLEMENT|Placebo|Placebo
214314017|NCT00187460|BEHAVIORAL|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
214314018|NCT00694759|DRUG|pioglitazone|30 mg for 2 weeks, then 45 mg daily
214314019|NCT00694759|DRUG|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
214314020|NCT00694759|DRUG|placebo|capsule twice daily
214314021|NCT05275647|DRUG|BOTOX 100U in normal saline|LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
214918117|NCT03635515|DEVICE|Gentlewave|The Gentlewave system from Sonendo is a FDA cleared root canal irrigation device that uses broad spectrum acoustic energy, internally degassed distilled water, 3% NaOCl, and 8% EDTA to allow for a more thorough cleaning within the tooth. The fluids work to remove necrotic tissue, debris, biofilm, and bacteria while leaving dentin intact and preserving tooth structure. The Gentlewave irrigation replaces the NaOCl ultrasonic activation and EDTA steps of the standard endodontic protocol. Use of the Gentlewave system is contraindicated in teeth with immature apices, teeth with insufficient coronal structure, and teeth with root apices extending into the maxillary sinus.
214955148|NCT06052995|DRUG|Elidel 1% Topical Cream|Elidel® 1% is a non-steroid cream for cutaneous use containing pimecrolimus. It is indicated for mild or moderate AD.
214955149|NCT06175039|OTHER|Telerehabilitation exercise program|TRGr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone.
214314022|NCT05275647|DRUG|Normal saline|LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
214314023|NCT05259007|DIETARY_SUPPLEMENT|propolis solved in lactic acid solvent|propolis given as a dietary supplement which was solved in a lactic acid solvent.
214314024|NCT05259007|DRUG|Amoxicillin-Clarithromycin-Lansoprazole|H pylori eradication treatment
214314025|NCT05259007|OTHER|IV saline 0.9%|Physiological serum solution is given as a placebo
214314026|NCT05259007|OTHER|Lactic acid|given to determine if the improvement of the symptoms are due to propolis or the solvent
214314027|NCT02755324|BIOLOGICAL|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
214314028|NCT05486221|OTHER|Extensive cardiologic work-up|Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
214314029|NCT03717480|DEVICE|ClinicMACs|The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to participants
214481759|NCT06863805|DIAGNOSTIC_TEST|4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA|"For each patient enrolled in the present study, 4 EDTA tubes of peripheral blood will be collected to be used to obtain molecular profiling during scheduled laboratory controls as per normal clinical practice according to the following time schedule:~* T0 = basal collection before initiation of systemic treatment;~* T1 = sampling at 1 month after the start of systemic treatment;~* T2 = sampling at 3 months (+/- 1 month) after the start of systemic treatment at the first instrumental re-evaluation of disease;~* T3 = sampling at 6 months (+/- 1 month) from the start of systemic treatment at the time of instrumental disease reassessment;~* T4 = sampling at the time of evidence of instrumental disease progression within 24 months of treatment initiation.~The following analyses will be conducted on the samples thus collected:~* multigenic analysis on ccf-DNA and ccf-RNA at baseline, i.e., before the initiation of systemic treatment;~* isolation, counting and analysis of CTCs at baseline vi"
214481760|NCT06865183|BEHAVIORAL|Positive Parenting Seminar Series|Selected Child Triple P Positive Parenting Seminar Series Delivered Through Telehealth
214481761|NCT06857669|DIAGNOSTIC_TEST|Diffuse reflectance spectroscopy and Photoacoustic imaging,|The photoacoustic imaging/diffuse reflectance spectroscopy techniques used in this study have a broader wavelength spectrum. The photoacoustic set-up can generate an optical and an ultrasound image simultaneously.
214481762|NCT06017973|DIAGNOSTIC_TEST|MRI scan including arterial spin labelling of the brain|Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded
214481763|NCT06017973|DIAGNOSTIC_TEST|CT perfusion scan of the brain|Siemens Naeotom Alpha with quantum technology (photon-counting)
214481764|NCT06017973|DIAGNOSTIC_TEST|FDG-PET scan of the brain|An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)
214481765|NCT03601897|DRUG|Rebastinib|Administered orally
214481766|NCT03601897|DRUG|Paclitaxel|Paclitaxel administered by IV infusion at 80 mg/m\^2
214481767|NCT03518554|DRUG|JAB-3068|JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
214481768|NCT06859658|RADIATION|Functional MRI at 3T|At inclusion
214314030|NCT03647865|PROCEDURE|Osseous Genioplasty|Surgical Procedure that cuts the chin and reposition it in the correct place
214314031|NCT01591876|OTHER|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
214314032|NCT01591876|OTHER|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
214481769|NCT06859658|RADIATION|Functional MRI at 3T|At inclusion and at 2 years for CADASIL patients without severe disability (mRS\<4)
214481770|NCT06859658|RADIATION|Functional MRI at 3T|At inclusion and at 2 years for CADASIL patients without severe disability (mRS\<4)
214481771|NCT06860373|BIOLOGICAL|[18F]MK-6240|\[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection.
214481772|NCT06862284|DRUG|Upadacitinib (ABT-494)|Upadacitinib 15mg Qd for 52 weeks
214481773|NCT06862284|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine 200mg Bid for 52 weeks
214481774|NCT05977751|DEVICE|FemBloc|Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.
214671375|NCT04673409|DIAGNOSTIC_TEST|Novel Cardiac MRI sequences|Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.
214314033|NCT02245074|OTHER|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
214314034|NCT01147705|DRUG|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
214314035|NCT01147705|DRUG|Placebo|Same appearance/dosing as active drug.
214314036|NCT03603444|OTHER|No intervention are provided|
214314037|NCT00277433|OTHER|Buccal Swab|collection of buccal swab
214314038|NCT04448405|BEHAVIORAL|Questionnaire for evaluation of confinement on deviant sexual fantasies|Questionnaire for evaluation of confinement on deviant sexual fantasies. Population already followed for deviant fantasies
214314039|NCT01066754|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
214314040|NCT02861703|BEHAVIORAL|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
214314041|NCT02190812|DEVICE|Forearm supporter|The forearm supporter be use in tennis elbow.
214314042|NCT02190812|DEVICE|Grip ball|
214314043|NCT03168152|RADIATION|Microwave Ablation (MWA)|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
214314044|NCT03168152|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
214314045|NCT06243887|OTHER|Enhanced Recovery After Surgery (ERAS) protocol in minimal invasive esophagectomy|Enhanced Recovery After Surgery (ERAS) refers to patient-centered, evidence-based, multidisciplinary team developed pathways for a surgical specialty and facility culture to reduce the patient's surgical stress response, optimize their physiologic function, and facilitate recovery.
214314046|NCT06243887|OTHER|standard of care approaches in minimal invasive esophagectomy|standard of care approaches other than ERAS
214314047|NCT04573595|DEVICE|Blood Pressure Measurement|The purpose of this study is to provide supporting documentation for Noninvasive blood pressure measurement accuracy claims for Fresenius 5008S BPM Module and Cuffs on the intended population(s). The same arm sequential method with dual observer auscultation will be used to collect data.
214314048|NCT01894152|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
214314049|NCT01708174|DRUG|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
214314050|NCT01708174|DRUG|TMZ|Temozolomide capsules were obtained locally by the Investigator
214671376|NCT00916799|DEVICE|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
214671377|NCT02848846|DEVICE|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand."
214918118|NCT03635515|PROCEDURE|Standard Endodontic Protocol|The tooth will be sufficiently anesthetized with local anesthetic. The tooth will be rubber dam isolated. The pulp chamber will be accessed removing all caries, defective restorations, and defective crowns. EAL and radiographs will be used to determine the working length of each canal, all canals will be cleaned and shaped using rotary files to at least a size 25.04 canal size to within 0.5 to 1 mm of the apical terminus. Between each file 5.25% NaOCl will be used to disinfect and clear the canals of debris. A final passive ultrasonic activation of NaOCl will be done for 30 seconds per canal. Each canal will then soak in 17% EDTA for 1 minute, rinsed in 5.25% NaOCl, and finally undergo a final rinse of 95% ethanol. Canals will be obturated with root canal sealer and gutta-percha.
214918119|NCT02148796|DRUG|Broncho-Vaxom (BV)|Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma, Switzerland (OM stands for Omnia Medicamenta) Storage: Store in the original package
214918120|NCT02148796|OTHER|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
214918121|NCT02099110|DRUG|Matching Placebo to Ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
214314051|NCT02782533|DEVICE|Deep Brain Stimulation V3|
214314052|NCT02922907|DIETARY_SUPPLEMENT|arabinoxylan rice bran|a proprietary product derived from rice bran treated with extracts from three mushrooms
214481775|NCT05003583|BEHAVIORAL|Speaking after viewing pictures with negative and neutral valence|"Speaking Condition 1: 10 age-appropriate pictures from the International Affective Picture System (IAPS; Lang, Bradley \& Cuthbert, 2005) will be shown to participants. These pictures are classified as high arousal, negative valence stimuli. Participants will be asked to repeat a simple phrase between picture presentations.~Speaking Condition 2: A blank screen will be shown to participants in place of pictures. This condition is classified as low arousal, neutral valence. Participants will be asked to repeat a simple phrase between blank screen picture presentations."
214314053|NCT02922907|DIETARY_SUPPLEMENT|Placebo for arabinoxylan rice bran|inactive product
214314054|NCT03891420|DRUG|Galidesivir|Galidesivir IV infusion
214314055|NCT03891420|DRUG|Placebo|Placebo IV infusion
214314056|NCT05533047|PROCEDURE|TURP|Bipolar and monopolar transurethral resection of the benign prostatic hyperplasia
214481776|NCT02456233|PROCEDURE|Conventional AF Ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone
214481777|NCT02456233|PROCEDURE|FIRM-guided ablation plus PVI|Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will also be performed.
214314057|NCT00641407|DRUG|NPL insulin|Starting dose 10 IU bedtime and then titration
214314058|NCT00641407|DRUG|Insulin glargine|10 IU bedtime and then titration
214314059|NCT02401880|DRUG|Linagliptin|22 subjects will receive Linagliptin for 30 days
214314060|NCT02401880|OTHER|Placebo|22 subjects will receive Placebo for 30 days
214314061|NCT02401880|DRUG|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
214314062|NCT03444922|OTHER|Placebo|Ingestion of Placebo
214314063|NCT03444922|OTHER|BPA 4 ug/kg BW|Oral BPA ingestion of 4 ug/kg BW
214314064|NCT03444922|OTHER|BPA 50 ug/kg BW|Oral BPA ingestion of 50 ug/kg BW
214918122|NCT02099110|DRUG|Matching Placebo to Ertugliflozin 10 mg|Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
214314065|NCT04680689|DIAGNOSTIC_TEST|128 Multislice CT coronary angiography|128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium
214314066|NCT04680689|DIAGNOSTIC_TEST|2D Cardiac Transthoracic Echocardiography|2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions
214314067|NCT04680689|DIAGNOSTIC_TEST|Laboratory Blood tests|Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
214314068|NCT01774786|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
214314069|NCT01774786|DRUG|Capecitabine|Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
214314070|NCT01774786|DRUG|Cisplatin|Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.
214314071|NCT01774786|DRUG|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
214314072|NCT01774786|DRUG|Placebo|Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
214918123|NCT02099110|DRUG|Matching Placebo to sitagliptin 100 mg|Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
214314073|NCT01774786|DRUG|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
214314074|NCT01337219|DRUG|Tobramycin|
214314075|NCT04357015|DRUG|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
214314076|NCT04357015|DRUG|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
214314077|NCT04357015|DRUG|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
214314078|NCT04903249|BEHAVIORAL|Core Exercise Promotion Intervention|"Participants are instructed to increase weekly time spent exercising to \>90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period."
214314079|NCT03556579|DEVICE|senofilcon A with new UV blocker|Test Lens
214314080|NCT03556579|DEVICE|senofilcon A|Control Lens
214481778|NCT06865001|OTHER|Conventional treatment|Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
214481779|NCT06865001|OTHER|Graded motor imagery|"Graded motor imagery consists of three stages:~1. limb lateralization task~2. an imaginary limb movement task (motor imagery) and~3. mirror therapy. Each session will consist of 12-15 minutes and 3 sets, with 5 minutes between sessions to rest and relax the limb. The application is planned for 30 minutes."
214918124|NCT02099110|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
214918125|NCT02099110|DRUG|Ertugliflozin 10 mg|Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
214314081|NCT02965703|DRUG|Aspirin|Given PO
214314082|NCT02965703|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, stool, and rectal swab samples
214314083|NCT02965703|OTHER|Placebo Administration|Given PO
214314084|NCT02965703|OTHER|Questionnaire Administration|Ancillary studies
214314085|NCT02965703|PROCEDURE|Rectal Biopsy|Undergo rectal biopsy
214314086|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on stool samples|"The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~* Standard sucrose flotation method~* Optimized sucrose flotation~* Stool processing kit (SPK)~* Simple One-step method (SOS)"
214314087|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on respiratory sample|The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
214314088|NCT02641769|BIOLOGICAL|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
214314089|NCT04395209|OTHER|assesment|muscle strength assessment in stroke individuals
214314090|NCT02378363|OTHER|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
214314091|NCT00962507|DRUG|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
214314092|NCT00962507|DRUG|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
214918126|NCT02099110|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
214314093|NCT00962507|OTHER|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
214918127|NCT02099110|DRUG|Metformin >= 1500 mg/day|Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
214918128|NCT02099110|BIOLOGICAL|Insulin Glargine Rescue Medication|Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
214314094|NCT00962507|OTHER|pharmacological study|Pre-study, day 1 and day 26
214314095|NCT00366600|DRUG|neratinib|HKI-272
214314096|NCT04725760|DEVICE|BrainPort Vision Pro|"Ten hours of training over 3 to 5 days, followed by autonomous use of the device.~It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months."
214314097|NCT06427356|BEHAVIORAL|PREVAIL Interdisciplinary Team|Patient meets simultaneously with an interdisciplinary team (IDT) five pain specialists and develops an individualized treatment plan based on Whole Health. Participants receive five months of coaching calls then return six months later for a follow-up visit with the IDT.
214314098|NCT00632255|DRUG|Imatinib|Conventional therapy with imatinib
214314099|NCT05719805|DRUG|Mavacamten|Specified dose on specified days
214481780|NCT06858228|PROCEDURE|Continuous Ablative Radiofrequency|Continuous ablative radiofrequency is a minimally invasive neuroablative procedure that targets the sensory genicular nerves to manage pain in knee osteoarthritis. Under ultrasound guidance, a radiofrequency probe is inserted percutaneously near the target nerves. The procedure delivers continuous thermal energy at 80°C for 120 seconds, creating a controlled lesion that disrupts pain signal transmission. This technique is distinct from pulsed radiofrequency, as it aims for permanent nerve ablation rather than neuromodulation. The expected outcome is prolonged pain relief and improved function in patients with chronic knee osteoarthritis refractory to conservative treatments.
214481781|NCT06858228|DRUG|Chemical Denervation with Absolute Alcohol|Chemical denervation with absolute alcohol is a minimally invasive neurolytic procedure targeting the sensory genicular nerves to manage chronic knee osteoarthritis pain. Under ultrasound guidance, a percutaneous injection of absolute alcohol 66% is administered near the targeted nerves. The neurolytic effect of alcohol induces axonal degeneration and Wallerian degeneration, leading to prolonged disruption of pain signal transmission. This intervention differs from radiofrequency ablation as it achieves chemical neurolysis rather than thermal ablation, with potential for a distinct duration of analgesia and varying nerve regeneration patterns. The expected outcome is long-lasting pain relief and improved function in patients with knee osteoarthritis who have not responded to conservative treatments.
214481782|NCT06616740|OTHER|Cricoid pressure|Cricoid pressure will be applied during LMA ProSeal insertion.
214918129|NCT02099110|DRUG|Glimepiride Rescue Medication|Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
214918130|NCT01435304|DEVICE|method of returning residual CPB blood ( Hemobag®)|The Hemobag® is a collection reservoir used to facilitate ultrafiltration of the CPB circuit after the patient has been disconnected from CPB).
214918131|NCT04002115|DRUG|Clofarabine|"Clofarabine to be administered pre-stem cell transplant infusion (Day 0) once a day for 5 days total."
214918132|NCT04002115|DRUG|Fludarabine|Fludarabine will be administered once a day for 4 days as part of the transplant conditioning regimen.
214314100|NCT01797289|OTHER|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
214314101|NCT02171260|DRUG|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
214314102|NCT00145873|DRUG|nesiritide, continuous infusion|
214481783|NCT06616740|OTHER|Paratracheal pressure|Pratracheal pressure will be applied during LMA ProSeal insertion.
214481784|NCT02777593|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
214481785|NCT06672900|DRUG|Carbamazepine|Commercially available supply.
214481786|NCT06672900|DRUG|Itraconazole (Sporanox)|Commercially available supply.
214481787|NCT06672900|DRUG|ALG-000184|Study Investigational Product
214481788|NCT06334523|DEVICE|Ventilation with Dead Space Washout via Continuous Tracheal Gas Insufflation (CTGI)|"The intervention involves adding a device which allows CTGI (the CTGI-device) to washout the dead space in preterm mechanically ventilated infants. Dead space washout using the CTGI-device is an option added to standard ventilation, to reduce or even cancel anatomical dead space due to respiratory prostheses in intubated preterm infants."
214481789|NCT05256641|DRUG|Acalabrutinib|Given PO
214314103|NCT02574130|DRUG|Amikacin|400 mg, nebulizer, every 12 hours, 10 days
214481790|NCT05274919|DEVICE|Philips Achieva 7T MRI|Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
214481791|NCT05274919|DEVICE|X-ray (optional)|Optional X-ray scan to assess the safety for undergoing an MR examination.
214481792|NCT05274919|COMBINATION_PRODUCT|Additional contrast injection|Contrast agent administration for the additional 7T scan (optional).
214314104|NCT02574130|DRUG|Placebo|placebo 4 ml, nebulizer, every 12 hours, 10 days
214314105|NCT03893604|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2) 2mA or sham
214314106|NCT00399009|DEVICE|AutoSuture Premium Plus CEEA/Ethicon Proximate ILS|
214314107|NCT05218018|DIETARY_SUPPLEMENT|Lipid drink|100 mls of heavy cream
214314108|NCT02824250|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction (MBSR) is an 8-week classroom based program of mindfulness meditation and gentle yoga.
214314109|NCT01062555|DRUG|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
214314110|NCT01062555|DRUG|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
214918133|NCT04002115|DRUG|Busulfan|Busulfan will be administered once a day for 2 days as part of the transplant conditioning regimen.
214918134|NCT04002115|PROCEDURE|Total Body Irradiation (TBI)|TBI will be administered at a dose of 200cGys on Day -1 prior to transplant
214918135|NCT04002115|DRUG|Cyclophosphamide|Cyclophosphamide will be given once a day for 2 days after the transplant infusion.
214918136|NCT04002115|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF will be administered to subjects starting on Day +5 and will continue as clinically indicated
214918137|NCT04002115|DRUG|Tacrolimus|Tacrolimus will be administered to subjects starting on Day +5 and will continue as clinically indicated
214918138|NCT04002115|DRUG|Cellcept|Mycophenolate Mofetil will be administered to subjects starting on Day +5 and will continue as clinically indicated
214314111|NCT01062555|DRUG|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
214314112|NCT01062555|DRUG|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
214481793|NCT05274919|OTHER|Question list|Questionnaire for contra-indications for an MR examination.
214481794|NCT06678971|OTHER|FIFA 11+|The FIFA 11+ protocol consists of fifteen exercises organized into three segments, with three levels of difficulty. The first segment includes six running exercises, the second focuses on six exercises to enhance lower body strength, balance, and agility, and the third segment involves three running exercises aimed at activating the cardiovascular system.
214481795|NCT06678971|OTHER|Basket-Up|"The Basket-Up warm-up program is developed by a committee of experts, including the medical staff and the Performance Department of Valencia Basket Club, with detailed information previously published. This protocol is specifically designed to address the physiological, functional, and physical demands of basketball training. Like the FIFA 11+ program, it is structured into three phases with progressively increasing levels of difficulty, lasting a total of 20 minutes.~Phase 1 includes three exercises aimed at improving mobility. Phase 2 features six exercises focused on strength, direction changes, and plyometric activities. Phase 3 consists of six exercises designed to enhance agility and neurocognitive skills."
214481796|NCT05656742|DIETARY_SUPPLEMENT|Vitamin D|oral vitamin D3
214481797|NCT06865807|PROCEDURE|PDS 2/0 vs Monomax 2/0|We will include in the study patients who require an emergency midline laparotomy by the General and Digestive Surgery Department of the University Hospital Nuestra Señora de Candelaria. Patients will be randomized based on their medical record number: those with an even number will undergo laparotomy closure using PDS 2/0, and those with an odd number will receive Monomax 2/0.
214481798|NCT06865937|BEHAVIORAL|Mobile Intervention for Social Recovery in Serious Mental Illness|mSITE is a blended intervention that integrates a brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching. Participants will attend weekly, in-person sessions for 8 weeks and then 15-minute, remote coaching sessions for 10 weeks. The intervention begins with setting a meaningful recovery goal and then the generic cognitive model is introduced and a simple thought challenging skill is trained to specifically address social avoidance behaviors and facilitate work toward recovery goals. Defeatist attitudes, social threat and avoidance behaviors that interfere with working on the goal are then modified using CBT skills and practiced using role-plays.
214481799|NCT06865937|BEHAVIORAL|Supportive Contact|The SC arm will match the mSITE arm on the same amount of individual in-person and coaching, and mobile device contact. Coaching sessions will be semi-structured and consist of setting recovery goals, check-in about symptoms and potential crisis management, flexible discussion involving psychoeducation, instructions for accessing community crisis lines and community resources, and symptom management behaviors that grow out of discussions, with only minimal therapist guidance.
214481800|NCT06865794|OTHER|Questionnaire and Physical Exam|Rosenberg self-esteem scale pre-operatively, at 3 and 12 months post-op
214481801|NCT06865794|OTHER|Questionnaire and Physical Exam|FACE-Q psychological sub-scale pre-operatively, at 3 and 12 months post-op
214481802|NCT06865794|OTHER|Questionnaire and Physical Exam|BREAST-Q psychological sub-scale pre-operatively, at 3 and 12 months post-op
214481803|NCT06865794|OTHER|Questionnaire and Physical Exam|BSIQ-SF pre-operatively, at 3 and 12 months post-op
214481804|NCT06865794|OTHER|Questionnaire and Physical Exam|FLZ psychological sub-scale pre-operatively, at 3 and 12 months post-op
214481805|NCT06867796|DRUG|TL-001|Intravenously administered
214481806|NCT06867796|DRUG|Placebo|Intravenously administered
214918139|NCT03243032|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg given 30 minutes prior to beginning of surgery
214918140|NCT03243032|DRUG|Local anesthetic Group 1|0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.
214918141|NCT03243032|DRUG|Placebo oral capsule|Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
214918142|NCT03243032|DRUG|Local anesthetic Control|2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
214314113|NCT04116138|DIETARY_SUPPLEMENT|Salovum|Egg yolk powder enriched for anti secretory factor
214314114|NCT00005955|DRUG|temozolomide|
214481807|NCT06866496|BEHAVIORAL|Motivational interviews|Three short and structured motivational enhancement interviews to aid alcohol cessation.
214481808|NCT06866496|OTHER|Standard of Care (SOC)|Standard of care including medical treatment of decompensation, nutrition support, medical treatment of alcohol withdrawal symptoms and craving
214481809|NCT06865924|OTHER|Use of assembloids as in vitro models to test new pharmacological approaches|Using extracellular vesicles containing the CRISPR/Cas9 genome editing system that by faithfully reproducing the in vivo part will allow a more faithful response than the use of conventional 2D model, organoids or animal model.
214481810|NCT06867016|OTHER|Combined Cognitive & Aerobics Training|The ACT combined training will consist of simultaneous aerobic exercise and cognitive training in a dual-task format, conducted twice a week for 8 weeks. The aerobic training (AT) will consist of twice-weekly sessions that include yoga, brisk walking, pedaling exercises, and step aerobics, alongside cognitive training involving speed processing, memory recall, problem-solving, and visual attention exercises. Each session will last approximately 20 minutes, and assessments will be performed at baseline, 4th week, and 8th week.
214918143|NCT01392924|DRUG|SAR245408|Pharmaceutical form: tablet Route of administration: oral
214918144|NCT02887248|DRUG|nab-paclitaxel|"Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.~Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
214918145|NCT02887248|DRUG|Gemcitabine|Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
214955150|NCT06175039|OTHER|Control program|KGr will be a pulmonary rehabilitation information brochure will be given after the initial evaluation. They will be asked to do the exercises on the brochure.
214955151|NCT00230724|BEHAVIORAL|Exercise Counseling|
214314115|NCT02346084|DRUG|Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)|"Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling)."
214314116|NCT05732649|BEHAVIORAL|Auditory neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound.
214314117|NCT05732649|BEHAVIORAL|Tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of tactile stimulation (i.e., electrical or vibrotactile stimulators applied on both hands and feet).
214314118|NCT05732649|BEHAVIORAL|Auditory and tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound and tactile stimulation.
214314119|NCT05732649|BEHAVIORAL|Neurofeedback|Participants train to decrease the intensity of a sensory stimulation (defined in Experiment 1) that is coupled with the network interaction at a specific brain region.
214314120|NCT00937872|DRUG|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
214314121|NCT00937872|DRUG|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
214314122|NCT05337592|DRUG|BI 1815368 formulation 1|BI 1815368 formulation 1
214314123|NCT05337592|DRUG|Placebo|Placebo
214918146|NCT05383040|PROCEDURE|Percutaneous release|Percutaneous release of A1 pulley release will be performed in the well-managed operation theater set up, using an 18 gauge hypodermic needle, after preparation of the skin and injection of 1ml 2% plain lidocaine. The proper location of the pulley will be defined using surface landmarks in each digit after waiting a few minutes to allow the anesthetic to take effect the 18 gauge needle will be longitudinally moved to keep the level of the needle parallel with the tendon grating sensation will be elucidated confirming the cut of pulley until there is no grating sensation felt and improvement of symptoms. A sterile dressing will be placed.
214918147|NCT03550872|BEHAVIORAL|Physical Training|Participants will perform physical training three times a week on a stationary bicycle. The exercise intensity will be controlled between 14 and 16 by the Borg Scale for 40 minutes
214918148|NCT01166438|DRUG|Botulinum toxin A (Botox A®)|A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
214918149|NCT01166438|DRUG|Solifenacin 5mg|Oral Solifenacin 5mg once a day for up to 6 months
214918150|NCT01166438|DRUG|Solifenacin 10mg|Oral Solifenacin 10mg once a day for up to 4 months
214918151|NCT01166438|DRUG|Trospium chloride|Oral Trospium chloride XR 60mg once a day for up to 2 months
214918152|NCT04321356|DEVICE|Triathlon PCR TKA|Total Knee Arthroplasty System
214314124|NCT05337592|DRUG|BI 1815368 formulation 2|BI 1815368 formulation 2
214314125|NCT05847075|OTHER|Heat Therapy|Participants in the HT group will undertake whole body heat treatment according to previous methods. Participants will be housed in an environmental chamber initially set at 55.0oC on three non-consecutive days of the week during 12 weeks. Each session will last 60 min.
214314126|NCT05847075|OTHER|StrengthTraining|Participants will perform supervised exercise in a gym on three non-consecutive days of the week. Each session will last \~60 min and will consist of a warm up, the resistance training and a cool down. All sessions will be conducted by qualified sport and exercise scientists for 12 weeks.
214314127|NCT05847075|OTHER|Sedentary Control|Participants will not receive any intervention during 12 weeks.
214314128|NCT04996459|DRUG|Tislelizumab|Tislelizumab 200mg iv q3w
214314129|NCT04964128|DEVICE|MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)|The AHCL system with Meal Gesture Dosing evaluated in this study includes a commercial/CE-Marked insulin pump with investigational software, and the Klue Health mobile app with investigational software (installed on Apple Watch) for meal gesture detection and micro dosing.
214314130|NCT01471379|DRUG|Milnacipran|50mg Milnacipran PO, BID, for 6 weeks.
214314131|NCT01471379|DRUG|Milnacipran|Milnacipran, 100mg PO, BID, for six weeks
214314132|NCT01471379|DRUG|Milnacipran|Milnacipran, 50mg PO BID for 12 weeks
214314133|NCT01471379|DRUG|Placebo|Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
214314134|NCT02120794|DEVICE|530G Insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
214481811|NCT06867016|OTHER|Cognitive Training|Cognitive training involving speed processing, memory recall, problem-solving, and visual attention exercises. Each session will last approximately 20 minutes, and assessments will be performed at baseline, the 4th week, and the 8th week.
214918153|NCT04321356|DEVICE|Triathlon PS TKA|Total Knee Arthroplasty System
214918154|NCT04321356|DEVICE|Persona PCR TKA|Total Knee Arthroplasty System
214918155|NCT04321356|DEVICE|Persona PS TKA|Total Knee Arthroplasty System
214918156|NCT03798470|BEHAVIORAL|Peer Addiction Counseling|After identification, a 24/7 on-call FRC was paged and met with the patient in the ED. The patients were offered recovery services at the bedside by the FRC. The research team members offered voluntary participation and obtained informed consent to enrolling a longitudinal study looking into the success of his intervention. Patients did not need to participate to be eligible for counseling and resources from AVOR. The FRCs counselled and engaged the patient along with the family to offer a variety of services including active recovery coaching, group treatment modalities, family support services and transportation. After he initial encounter in the ED, the FAVOR team re-engaged the participant by phone or in person the next day and gradually increasing intervals thereafter.
214918157|NCT04618198|OTHER|Immediate anti-TB therapy|Study participants will receive immediate empiric anti-TB therapy
214314135|NCT05766930|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The relief genital itching evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
214314136|NCT04444609|OTHER|Blood tests sputum, nasal lavage and brushing|Venesection, sputum nasal lavage and brushing if appropriate
214314137|NCT00644293|DRUG|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
214314138|NCT00644293|DRUG|placebo|placebo
214314139|NCT00644293|DRUG|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
214314140|NCT00644293|DRUG|placebo|placebo
214314141|NCT00360464|DRUG|Azithromycin SR|
214314142|NCT01112852|DRUG|pantoloc 40 mg|pantoloc iv. infusion per day
214314143|NCT01112852|DRUG|somatostatin or terlipressin|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
214314144|NCT05121883|DRUG|Edaravone Dexborneol|Edaravone dexborneol (Jiangsu Simcere Pharmaceutical, Co, Ltd) will be initiated within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days (maximum: 14 days)
214314145|NCT00196079|DEVICE|Coronary stent|
214314146|NCT05021367|DRUG|TQB3823 tablets|TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.
214314147|NCT05071885|OTHER|games based exercise|Range of motion and strengthening exercises
214314148|NCT02071524|DRUG|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
214314149|NCT02071524|DRUG|Cristalloid administration|Only Ringer Lactate administration
214481812|NCT06868017|DRUG|Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses|Cohort A will receive initumab at initial load dose of 8mg/kg and maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses. Pyrrotinib 400mg orally once daily; Combined chemotherapy drugs (not limited, according to the actual clinical selection), a total of 4 cycles of administration
214314150|NCT01162382|DEVICE|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
214481813|NCT06868017|DRUG|Cohort B will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 6 doses|The initial loading dose of initumab was 8mg/kg, and the maintenance dose was 6mg/kg, which was administered intravenously on the first day of every three weeks. Pyrrotinib 400mg orally once daily; Combined chemotherapy drugs (not limited, according to the actual clinical selection), a total of 6 cycles of administration
214481814|NCT06866522|DEVICE|Whole-body Photobiomodulation Therapy|Whole-body Photobiomodulation Therapy applied for approximately 10 minutes, being 5 minutes with the red wavelength and 5 minutes with the infrared wavelength.
214481815|NCT06867536|DRUG|Glofitamab + Obinutuzumab|"Obinutuzumab An initial 1000 mg dose of obinutuzumab will be administered as pretreatment 7 days prior to the first glofitamab step-up dose~Glofitamab:~Glofitamab was administered intravenously as step-up doses on day 8 (2.5 mg) and day 15 (10 mg) of cycle 1, followed by a dose of 30 mg on day 1 of cycles 2 through 8, maximum of 12 cycles (Q3W). The efficacy is evaluated after 2 cycles of glofitamab. Those with disease progression will be withdrawn from the study. The remaining patients continue with an additional two cycles of glofitamab (4 cycles in total) and then perform efficacy assessment. If the patients achieve a CR or PR, they will continue to complete the remaining treatment as planned. Patients are recommended to treat for 12 cycles (at least 8 cycles, depending on tumor regression in patients) or until disease progression or unacceptable toxicity, whichever occurs first"
214481816|NCT01960751|OTHER|neurocognitive tests battery|The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
214481817|NCT06878274|RADIATION|Post-operative radiotherapy|Mediastinal post-operative radiotherapy to a dose of 40 Gy in 15 fractions
214918158|NCT04618198|OTHER|Sepsis-specific dose anti-TB therapy|Study participants will receive conventional WHO weight-based dose anti-TB therapy
214314151|NCT06021951|DRUG|Bempedoic Acid 180 MG Oral Tablet|Bempedoic Acid 180 MG Oral Tablet \[Nexletol\]
214314152|NCT06021951|DRUG|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet \[NEXLIZET\]
214314153|NCT01886807|DEVICE|TrueView PCD Video Laryngoscope|
214918159|NCT06468345|BEHAVIORAL|acupressure|Application was made to CV12, ST25, SP6, HT7 and LI4 acupressure areas.
214314154|NCT01802658|DRUG|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
214314155|NCT01802658|DRUG|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
214314156|NCT04988217|DRUG|Interferon-Alpha2B|Nebulized interferon alpha 2B
214314157|NCT04988217|DRUG|Placebo|Nebulized placebo
214314158|NCT01243359|DRUG|sunitinib malate|Given PO
214314159|NCT01243359|BIOLOGICAL|bevacizumab|Given IV
214314160|NCT01243359|OTHER|pharmacological study|Correlative studies
214314161|NCT01243359|OTHER|laboratory biomarker analysis|Correlative studies
214314162|NCT01243359|OTHER|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
214314163|NCT01243359|PROCEDURE|positron emission tomography|Undergo FLT PET/CT
214314164|NCT01243359|PROCEDURE|computed tomography|Undergo FLT PET/CT
214314165|NCT05175066|DRUG|Bisoprolol|For patients who were candidates to start therapy with anthracycline, bisoprolol was administrated as explained before to determine the effect of this drug on the reduction of anthracycline-induced cardiomyopathy.
214314166|NCT05175066|DRUG|Placebo|Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.
214314167|NCT02330796|DRUG|Bucillamine|Bucillamine Tablets
214481818|NCT06675162|OTHER|Pilates Reformer Training|Participants will perform a 60-minute Pilates Reformer muscle-strengthening session. The training will include a 7-10 minute warm-up, 35 minutes of muscle strengthening and mobility exercises and a 5-minute recovery. During the training, the physiological responses and the energy expenditure of the participants will be recorded.
214481819|NCT06673758|OTHER|tai chi exercises|tai chi exercises of three basic levels will be given with sessions of two weeks five time a day and follow efftects of tai chi exercises by 6minute walk test and time up and go test and check the results before and after exercises
214481820|NCT06673758|OTHER|Art and crafts activity|Art and crafts activity will be given to control group and check cardiorespiratory fitness before and after arts and crafts activity
214481821|NCT06673927|DRUG|YZJ-1139|Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg
214918160|NCT06468345|BEHAVIORAL|Area different from acupressure area|Massage application to non-acupressure hand, foot and abdominal areas
214481822|NCT06673927|DRUG|YZJ-1139|Multiple Dosing ，Each oral dose of 10 mg，20 mg，40 mg or 60 mg
214481823|NCT06673927|DRUG|Placebo|Placebo administration
214481824|NCT06615115|OTHER|Exercise|All participants will perform a total body stretching exercise for 10 minutes, followed by 10 minutes of obstacle course navigation, 10 minutes of balance training (including tandem walking, balance board exercises, single-leg balance, and two-legged reaching exercises), and will conclude with 10 minutes of strength training exercises.
214481825|NCT06680141|OTHER|Virtual reality glasses|control group
214481826|NCT05451810|DRUG|Epcoritamab|Subcutaneous Injection (SC)
214481827|NCT06680284|OTHER|Staff Education Program|A staff education and environmental awareness campaign and in-service to highlight strategies to reduce, reuse, and recycle waste, as well as proper waste disposal practice, will be implemented by way of instructional posters, e-learning modules, a grand rounds presentation, journal club discussion, and brainstorming sessions for waste reduction, reuse and recycle and a brief knowledge test at the end.
214481828|NCT06681428|OTHER|Allograft|Placental-based Allografts
214481829|NCT06679816|DRUG|Hormone replacement therapy|Perioperative Hydrocortisone Reduction Therapy
214481830|NCT06679816|DRUG|Placebo|Perioperative placebo Reduction Therapy
214481831|NCT06483256|DIAGNOSTIC_TEST|radiographic control|Radiographic study with standard projections (AP and LL) is used to assess any signs of anchor loosening and/or presence of heterotopic ossifications (which can restrict movement and is one of the main complications).
214481832|NCT05251207|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine-L-tartrate
214918161|NCT03250858|BEHAVIORAL|Personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
214918162|NCT03250858|BEHAVIORAL|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalized dietary advice for improved food choice based on standard population health guidelines.
214918163|NCT02555150|DRUG|PRC-063|Oral extended-release capsule
214918164|NCT02555150|DRUG|lisdexamfetamine dimesylate|Oral capsule
214918165|NCT02555150|DRUG|Placebo|Oral placebo capsule
214314168|NCT02330796|DRUG|Colchicine|
214314169|NCT02146638|DRUG|Morphine|
214481833|NCT05251207|DIETARY_SUPPLEMENT|L-leucine|L-leucine
214481834|NCT05251207|BEHAVIORAL|Change of the circadian cycle|Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)
214481835|NCT05256472|DRUG|AK104|anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
214314170|NCT02146638|DRUG|Fentanyl|
214314171|NCT06167018|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8-12 sessions), were given either in an individual manner or in a group setting.The hypnosis treatment is administered by two nurses specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment was based on the North Carolina protocol. Patients assessed gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
214481836|NCT05256472|DRUG|axitinib|an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally
214481837|NCT04704700|DEVICE|repair of a cuff tear|Group (Treatment): Arthroscopic Implantation of the System InSpace on a repaired rotator cuff tendon
214481838|NCT04704700|DEVICE|repair of a cuff tear|Group (Control): standard Arthroscopic repair of the cuff rotator
214481839|NCT06138184|BEHAVIORAL|Anticoagulation Educational Materials|This includes new web-based patient educational materials that have been developed prior to the start of the study
214481840|NCT06138184|BEHAVIORAL|Control Group: Standard of Care|This will be the current practice for patient education
214918166|NCT01377922|DRUG|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
214918167|NCT01377922|DRUG|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
214918168|NCT04637984|BEHAVIORAL|PREP2 algorithm|A) PREP2. It combines clinical measures and neurological biomarkers in the initial days after stroke: 1) SAFE score (day 3), which is the sum of shoulder abduction and finger extension strength in the paretic upper limb using the Medical Research Council (MRC); 2) NIH Stroke Scale (day 3); 3) transcranial magnetic stimulation (day 3-7) to determine the presence of MEPs in the paretic arm. According with the aforementioned measures, 4 categories of upper limb recovery will be identified: EXCELLENT, GOOD, LIMITED and POOR.
214918169|NCT06017297|DRUG|Durvalumab|Durvalumab 1500 mg via intravenous (IV) infusion every 3 weeks for up to 8 cycles
214314172|NCT04151290|DIAGNOSTIC_TEST|Cognoa ASD diagnostic device|Cognoa device is intended to aid healthcare providers in diagnosing Autism Spectrum Disorder (ASD)
214314173|NCT05972538|DEVICE|Osstell ( Osstell AB, Goteborg, Sweden).|Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery
214314174|NCT05972538|DEVICE|periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein|Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery
214314175|NCT05972538|OTHER|questionnaire for patient satisfaction|A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.
214918170|NCT06017297|DRUG|Tremelimumab|A single dose of tremelimumab at 300mg IV is given on C1.
214918171|NCT06017297|DRUG|Gemcitabine|Gemcitabine is dosed at 1000 mg/m2 IV on day (D)1 and D8 of each cycle.
214314176|NCT03214809|DIAGNOSTIC_TEST|ultrasound protocol|after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
214314177|NCT02051530|DIETARY_SUPPLEMENT|tryptophan depletion|tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
214314178|NCT02196792|DEVICE|E-Poly liner|E-Poly liner with a titanium cup
214314179|NCT02196792|DEVICE|ArComXL liner|ArComXL liner with a titanium cup
214314180|NCT02196792|DEVICE|32 mm femoral head|Stem with a 32 mm CoCr femoral head
214481841|NCT06805188|OTHER|Acupuncture|"The intervention was performed by two licensed acupuncturists with at least 10 years of clinical experience who received two weeks of training in standardized intervention methods prior to the trial. Acupoints location refers to the WHO Standard Acupuncture Point Locations in the Western Pacific Region (WHO Standard)〔41〕.The acupuncture group will receive the following acupoints (Figure 3, Table 2): the affected side of Chize(LU5), Quchi (LI11), Dubi (ST35), Fengshi (GB31), and Xiyangguan (GB33).~Needling was performed with 0.30mm x 40mm disposable Huatuo brand sterile acupuncture needles.After the needles were inserted, needle manipulation was performed at all acupuncture points to achieve the sensations of soreness, numbness, distension, and heaviness.Each acupoint was manipulated for about 30 seconds, and the acupuncture treatment was performed for one 30-minute session."
214481842|NCT06805188|OTHER|Sham acupuncture|The device's sham needling operation mimics real needling through appearance and tactile sensation, making it difficult for patients to distinguish, meeting the requirement of blinding and effectively controlling the patients' cognitive bias towards the type of intervention. Patients in the sham acupuncture group received this sham acupuncture intervention, which was designed to ensure that only the actual biological effects of acupuncture differed between the experimental group and the control group, and to exclude the psychological implication effects caused by the patients' expectation effects or the operation itself, so as to enhance the scientific validity and reliability of the research results.
214481843|NCT04519814|PROCEDURE|selective laser trabeculoplasty (SLT)|Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.
214481844|NCT06174428|DEVICE|Oral/Throat cancer test|The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
214481845|NCT01315106|DEVICE|Magnetic Resonance Image Scanner|Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
214481846|NCT06622720|PROCEDURE|surgery|The colorectal surgery of any type conducted in any approach in the timeframe
214481847|NCT06869473|DRUG|Cetuximab/avelumab|"Study Maintenance therapy: AVEC (each cycle every 2 weeks) Cetuximab will be administered at 500 mg/m2 dose (as a 2-hour intravenous infusion) every 2 weeks until disease progression or unacceptable side effects.~Cetuximab will be administered by IV infusion over 120 minutes. The initial dose should be given slowly and speed of infusion must not exceed 5 mg/min.~Avelumab will be administered at 800 mg flat dose (as a 1-hour intravenous fusion) every 2 weeks until disease progression or unacceptable side effects."
214481848|NCT06869174|DRUG|Pucotenlimab combined with MRG002|Pucotenlimab 200mg iv d1, Q3W MRG002 2.2mg/kg d1, Q3W
214314181|NCT02196792|DEVICE|36 mm femoral head|Stem with a 36 mm CoCr femoral head
214314182|NCT02086669|PROCEDURE|Pneumatic dilatation|
214481849|NCT06869720|DEVICE|Eccentric bike|Received eccentric cycling exercise
214481850|NCT06869720|OTHER|conventional group|Received conventional treatment
214481851|NCT06869291|PROCEDURE|Multi level and multi tunnel puncture treatment|"Multi level and multi tunnel puncture treatment steps~1. Disinfect the area within 1cm outside the edge of the eyelid xanthoma and lesion using iodine and cotton swabs three times;~2. Use a 1ml syringe to extract lidocaine for local anesthesia of the eyelid xanthoma lesion area;~3. Use a 1ml syringe to puncture the area between the epidermis and dermis layers, nipple layer, and reticular layer of the lesion, with the puncture endpoint at the edge of the lesion. Be careful not to penetrate the skin as much as possible, and when withdrawing the syringe, do not let the needle completely leave the puncture hole, leaving only one pinhole as much as possible; Within the same level, the distance between adjacent puncture tunnel ends is 1mm; Arrange the puncture tunnels staggered within adjacent levels;~4. Cover the injection site with gauze and maintain for 6-8 hours."
214918172|NCT06017297|DRUG|Cisplatin|Cisplatin is dosed at 25mg/m2 on D1 and D8 of each cycle.
214918173|NCT06017297|PROCEDURE|Surgical Resection|If the tumor is evaluated to be resectable (as defined as successfully treated stage II (tumor shrink away from vessels), stage IIIA (tumor shrink away from visceral peritoneum), stage IIIB (N1 disease no longer pathologically enlarged) after C4 or C8, then the patient may proceed with surgical tumor resection.
214918174|NCT06035640|OTHER|Interview|Participants will be engaged in a semi-structured interview.
214918175|NCT02046590|DRUG|Propofol|
214918176|NCT02046590|OTHER|General anesthesia|
214918177|NCT04804826|PROCEDURE|Pelvic Reconstructive Surgery|Pelvic Reconstructive Surgery including total vaginal hysterectomy
214918178|NCT06575907|OTHER|no intervention|no intervention
214918179|NCT02269228|DRUG|Asasantin ER|
214918180|NCT02269228|DRUG|Placebo|
214314183|NCT02086669|PROCEDURE|Laparoscopic myotomy|
214481852|NCT06869291|PROCEDURE|Heparin Sodium Injection|"(1) Disinfect the area within 1cm outside the edge of the eyelid xanthoma and lesion using iodine and cotton swabs three times; (2) Prepare heparin sodium and lidocaine in ratios of 1:1, and prepare 0.1ml of liquid per 1cm2 of lesion area; (3) Use a 1ml syringe to insert the needle from the edge of the lesion near the eyebrow, so that it will not cover the field of view with gauze after injection; (4) The injection depth is the gap between the epidermal layer and the dermis layer, forming an orange peel appearance after injection, and completely covering the lesion area; (5) Cover the injection site with gauze and maintain for 6-8 hours."
214314184|NCT05834517|DRUG|Hyaluronic acid|Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts
214481853|NCT06869291|PROCEDURE|Multi Level and Multi Tunnel Puncture Treatment + Heparin Sodium Injection|(1) Disinfect the area within 1cm outside the edge of the eyelid xanthoma and lesion using iodine and cotton swabs three times; (2) Prepare heparin sodium and lidocaine in ratios of 1:1, and prepare 0.1ml of liquid per 1cm2 of lesion area; (3) Use a 1ml syringe to extract lidocaine for local anesthesia of the eyelid xanthoma lesion area; (4) Use a 1ml syringe to puncture the area between the epidermis and dermis layers, nipple layer, and reticular layer of the lesion, with the puncture endpoint at the edge of the lesion. Be careful not to penetrate the skin as much as possible, and when withdrawing the syringe, do not let the needle completely leave the puncture hole, leaving only one pinhole as much as possible; Within the same level, the distance between adjacent puncture tunnel ends is 1mm; Arrange the puncture tunnels staggered within adjacent levels; (5) Cover the injection site with gauze and maintain for 6-8 hours.
214314185|NCT05834517|PROCEDURE|non surgical periodontal therapy|NSPT, with or without adjunctive therapies, is an effective treatment for periodontitis. It reduces PD and results in formation of some new attachment; however, it also has several limitations, and surgical therapy might be required to control inflammation and optimize outcomes. When used for non-surgical scaling and root planing, periodontal curettes can reach a mean PD of up to approximately 5.5 mm. The mean PD in which a plaque-free and calculus-free surface can be established is \<4 mm
214314186|NCT03978364|DRUG|Azacitidine combined HHT|Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
214314187|NCT03978364|DRUG|Azacitidine regimen|Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
214481854|NCT06870448|DRUG|Methyprednisolone sodium succinate|Methylprednisolone at a dose of 2 mg/kg/day for 3 consecutive days, with a maximum daily dose of 160 mg (4 vials, 40 mg per vial, Hanhui Pharmaceutical Co., Ltd.). The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug be administered before arterial access closure.
214481855|NCT06870448|DRUG|Placebo|Placebo for 3 consecutive days, with a maximum daily dose of 4 vials (Hanhui Pharmaceutical Co., Ltd.)
214481856|NCT06869044|DEVICE|omafilcon A lens|Participants will be randomized to wear omafilcon A lens for 15 minutes.
214481857|NCT06869044|DEVICE|Low ADD power somofilcon A lens|Participants will be randomized to wear low ADD power somofilcon A lens for 15 minutes.
214481858|NCT06869044|DEVICE|Medium ADD power somofilcon A lens|Participants will be randomized to wear medium ADD power somofilcon A lens for 15 minutes.
214481859|NCT06869044|DEVICE|High ADD power somofilcon A lens|Participants will be randomized to wear high ADD power somofilcon A lens for 15 minutes.
214918181|NCT04119297|OTHER|Routine care|"* Routine care was applied to the periorbital area by clinical nurses.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale"
214918182|NCT04119297|OTHER|Cold gel pack|"* Cold application was applied to the periorbital area for 20 minutes per hour beginning 3rd hour following craniotomy, except from 10pm-7 am, and for three days using gel pack cooled to -14ºC.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale"
214918183|NCT04119297|DRUG|Heparinoids Topical Cream|"* Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale"
214918184|NCT02858804|DRUG|Etoposide|50 mg/m2, IV d1-4
214918185|NCT02858804|DRUG|Doxorubicin|10 mg/m2, IV, d1-4
214918186|NCT02858804|DRUG|Dexamethasone|30 mg/d, d1-5
214314188|NCT01530321|OTHER|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
214314189|NCT01530321|OTHER|Light Massage|5 minutes of light pressure massage to the neck and upper back
214314190|NCT01449526|DEVICE|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
214314191|NCT01449526|DEVICE|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
214314192|NCT06202742|BEHAVIORAL|cognitive behavioral therapy for insomnia|Online meeting, weekly for 8 weeks, to deliver CBTI by psychologist/ psychiatrist
214314193|NCT06202742|BEHAVIORAL|Health education|Online meeting, weekly for 8 weeks, to deliver general health knowledge
214314194|NCT03005821|OTHER|Chinese pediatric massage therapy + usual care|
214314195|NCT03005821|OTHER|Sham massage therapy + usual care|
214314196|NCT02886390|DEVICE|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
214314197|NCT06284785|PROCEDURE|Bariatric surgery|Patients included in our obese patient group are all scheduled to undergo bariatric surgery
214481860|NCT06869629|PROCEDURE|Targeted axillary dissection|Known metastases are marked before surgery and removed together with a sentinel lymph node biopsy
214918187|NCT02858804|DRUG|Vincristine|0.4 mg/m2, IV, d1-4
214918188|NCT02858804|DRUG|Cyclophosphamide|750 mg/m2 ,d5
214918189|NCT02858804|DRUG|Cytarabine|2g/m2, q12h, d1
214918190|NCT02858804|DRUG|Cisplatin|100mg/ m2,IV, d1
214314198|NCT05796674|DEVICE|Clareon UVA IOL|Clareon UVA IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery to replace the natural crystalline lens. Models CC60WF and CCA0T0 are indicated for the visual correction of aphakia. Models CCW0T3, CCW0T4, CCW0T5, and CCW0T6 are indicated for the visual correction of aphakia and preexisting corneal astigmatism.
214918191|NCT02858804|DRUG|Rituximab|375 mg/m2 IV, d1
214918192|NCT02858804|DRUG|Thalidomide|50-150mg/d, po, d1-28
214918193|NCT02858804|DRUG|Prednisone|0.5mg/Kg, po, qod
214918194|NCT03864757|DEVICE|thyroplasty implant|Short-term implantation of thyroplasty implant, VOIS, and evaluation of voice quality and glottal closure. After evaluation, remove VOIS and perform medialization of vocal folds using conventional thyroplasty.
214918195|NCT03170362|OTHER|Pharmacogenetic Test|The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
214918196|NCT01278004|DRUG|Ethosuximide|Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
214918197|NCT01278004|DRUG|Placebo|Capsule
214918198|NCT01152749|DRUG|Nicotine|Single-dose of new NRT product
214918199|NCT01152749|DRUG|Nicotine Gum|Single-dose of marketed nicotine gum
214918200|NCT04443946|DRUG|Propofol|5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
214918201|NCT04443946|DRUG|1% Sevoflurane|add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
215060961|NCT03497039|DRUG|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
215060962|NCT03497039|OTHER|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
214918202|NCT04443946|DRUG|1% Sevoflurane continue|1% sevoflurane continued to maintain anesthesia after endotracheal intubation.
214918203|NCT04443946|DRUG|Sufentanil|0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
214918204|NCT04443946|DRUG|2% Sevoflurane|2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
214918205|NCT04443946|DRUG|Propofol half|2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
214955152|NCT04386161|OTHER|Scheduled exercise program|45 minutes of stretching, strengthening, and balance-coordination exercises and 20 minutes of balance training on the Balance Master® device twice a week for six weeks
214955153|NCT06274242|DIETARY_SUPPLEMENT|Haruna|Mixed Natural Prebiotic-Fibers (Ginkgo nut, Spinach, Corn, Brown rice)
214955154|NCT06274242|DIETARY_SUPPLEMENT|Placebo Powder|Isolate Soy Protein and Isomalt
214955155|NCT00000548|PROCEDURE|mechanical ventilation|
214955156|NCT04714190|DRUG|RC48-ADC|2.5 mg/kg IV every 2 weeks
214955157|NCT04714190|DRUG|Paclitaxel injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
214918206|NCT01509560|DRUG|Everolimus|"Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.~Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16"
214314199|NCT05796674|DEVICE|WaveTec Optiwave Refractive Analysis (ORA) System|Intra-operative system used during refractive cataract surgery to capture wavefront images of the patient's eye for the purpose of optimizing IOL implantation
214314200|NCT05796674|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon UVA IOL
214314201|NCT00363454|DRUG|Triciribine Phosphate Monohydrate|8 Cycles @ 28 days. Level 1: 15 mg/m\^2; Level 2: 25 mg/m\^2; 35 mg/m\^2; 45 mg/m\^2.
214314202|NCT00199290|DRUG|Trafermin (genetical recombination)|
214314203|NCT05471050|DRUG|TAC|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
214314204|NCT05471050|DRUG|Danazol|Danazol is given at 200mg bid for 12 weeks.
214314205|NCT02190799|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
214314206|NCT00128921|DRUG|VELCADE™|"Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated."
214314207|NCT01132495|OTHER|Stenting plus OMT|FFR guided PCI, plus OMT
214314208|NCT01132495|OTHER|OMT|OMT alone
214918207|NCT05800561|DIAGNOSTIC_TEST|Hepatic venous-portal gradient (HVPG) measurement|preoperative evaluation of Hepatic venous-portal gradient (HVPG) and ICG-retention test
214918208|NCT06061120|DEVICE|Recording of an extended high-resolution ECG|Recording of an extended high-resolution ECG
214955158|NCT04714190|DRUG|Irinotecan Hydrochloride Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
214955159|NCT04714190|DRUG|Apatinib Mesylate Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
214955160|NCT04171193|DRUG|Isoflurane|Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
214314209|NCT01132495|OTHER|Standard of care|FFR \> 0.80; treatment according to local practice
214314210|NCT05210686|OTHER|subgingival re-instrumentation|subgingival re-instrumentation (control)
214314211|NCT00918021|DRUG|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
214314212|NCT00918021|DRUG|placebo|placebo
214314213|NCT00082433|DRUG|Ixabepilone + Capecitabine|Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
214314214|NCT00082433|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
214314215|NCT00443586|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
214314216|NCT00443586|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
214314217|NCT00443586|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
214955161|NCT04171193|DRUG|Sertraline Pill|Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
214955162|NCT00790556|DRUG|MK8245|MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
214955163|NCT00790556|DRUG|Comparator: Placebo|MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
214955164|NCT00270504|DEVICE|Memokath stenting|Urethral Stenting
214955165|NCT04416646|DRUG|Cabozantinib|The regimen will be a single oral dose administered daily on a continuous schedule, taken with or without food. The standard dose is 60 mg per day, which can be reduced to 40 or 20 mg according to the latest version of the Summary of Product Characteristics-SPC available. The treating oncologist will evaluate the opportunity to prudentially start treatment at 40 mg/daily in patients screening positively at G8 screening tool, and then escalate to 60 mg/daily only in case of absence of toxicity ³grade 2 at subsequent cycles. Temporary suspensions of treatment are allowed according to the local practice and will be registered if ³ 7 days.
214314218|NCT00443586|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
214314219|NCT03733171|DRUG|PLATELET RICH PLASMA|PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
214314220|NCT03733171|DRUG|diluted epinephrine|diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
214314221|NCT03733171|DEVICE|hemoclips|diluted epinephrine was injected followed by application of hemoclips
214314222|NCT01076907|OTHER|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
214314223|NCT01076907|OTHER|Control|Air will be used instead of warm water for unsedated colonoscopy.
214314224|NCT06333327|DEVICE|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter
214314225|NCT04097821|DRUG|Ruxolitinib|5 mg tablets for oral use
214314226|NCT04097821|DRUG|Siremadlin|10 mg, 20 mg, or 40 mg capsules for oral use
214314227|NCT04097821|DRUG|Crizanlizumab|100 mg/10 mL concentrate for infusion for intravenous use
214314228|NCT04097821|DRUG|Sabatolimab|100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use
214481861|NCT06865729|BEHAVIORAL|Music therapy|Music therapy will be performed by the researchers for 4 days (average length of stay for inpatients is 4 days), starting from the first day the patients start their inpatient treatment. Music therapy will be performed in the evening hours (between 20:00 and 21:00) and in the patients' own rooms, so as not to disrupt the patients' routine follow-up and treatment. Music therapy will be performed passively using an MP3 music player and headphones provided by the researchers. Therapy time will be limited to 30 minutes. Music therapy will be performed in one session per day for 4 days, and the patients will listen to the same music in each session.
214481862|NCT06870981|OTHER|Opti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study.|
214481863|NCT06870552|DEVICE|Single-pulse TMS|A single pulse TMS is delivered at different time points when processing words or numbers.
214918209|NCT04967482|PROCEDURE|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|The patients will receive DEB-TACE if they choose DEB-TACE as the primary treatment. DC Bead loaded with epirubicin (1 vial of DC Bead loaded with 60 mg of epirubicin) is used for chemoembolization. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. DEB-TACE) for the same patient should be consistent.
214918210|NCT04967482|PROCEDURE|Conventional transarterial chemoembolization (cTACE)|The patients will receive cTACE if they choose cTACE as the primary treatment. An emulsion of epirubicin in lipiodol wiil be injected into the tumor feeding artery. Afterwards, microspheres or polyvinyl alcohol particles mixed with contrast agent will be administered intraarterially until arterial flow stasis was achieved. Generally, the dose of lipiodol and epirubicin should not exceed 30 mL and 60 mg for each procedure. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. cTACE) for the same patient should be consistent.
214955166|NCT02149563|DEVICE|oxygen-enriched air -Normobaric hyperoxia treatment for depression|Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
214314229|NCT04097821|DRUG|Rineterkib|100 mg capsule for oral use
214314230|NCT04097821|DRUG|NIS793|700 mg/7 mL concentrate for infusion for intravenous use
214314231|NCT03688763|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
214314232|NCT03510117|BEHAVIORAL|Mindfulness|Mindfulness
214314233|NCT03159728|BEHAVIORAL|Educative intervention:|"* In the induction of the new group members are present, including caregivers who start the program and those who coordinated.~* In Module I: to strengthen the knowledge of the situation and the people involved in care.~* In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.~* In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self."
214314234|NCT06974968|BIOLOGICAL|Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells|"Description:~XS228 Cell Injection is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs). This advanced therapy medicinal product (ATMP) is being developed for the treatment of spinal cord injury (SCI) and represents a novel approach in regenerative medicine."
214314235|NCT06974968|OTHER|Placebo|Standard rehabilitation protocols
214314236|NCT05500378|OTHER|Head extension and rotation movement|Active exercise of the head
214314237|NCT06573476|BEHAVIORAL|PRC supported text + AI driven CSDH-enhanced text|"In interventional Arm-1, PRC-supported text check-ins to participants (3x/week) will be provided by PRC study staff in addition to automated AI-driven texts. The PRC will personalize text check-ins to participants based on: (a) baseline CSDH needs (e.g., food insecurity, legal aid); (b) initial intake visit in primary care or challenges with service entry; and (c) content outlined in the CSH training addressing emerging participant challenges."
214314238|NCT06573476|BEHAVIORAL|AI driven CSDH-enhanced text only|In interventional Arm-2, participants will receive the AI-driven CSDH-enhanced text messaging only. Participants in this arm will not receive text support from the PRC.
214955167|NCT02628158|PROCEDURE|Vitrectomy with internal limiting membrane removal|Vitrectomy with removal of epiretinal membrane and internal limiting membrane
214955168|NCT03140098|DEVICE|cardiac surgery requiring a collagen membrane COVA™+|At the end of the cardiac surgery, the collagen membrane is implanted on the dissection area in order to prevent the formation of postoperative adhesions.
214314239|NCT06573476|BEHAVIORAL|Treatment as Usual (TAU)|In Arm-3, the control group, individuals randomized to the control arm will receive treatment as usual (i.e., verbal instructions and NYC Dept of Health pamphlets detailing access to OUD and social services). No services will be provided except for social/clinical service referrals given at the end of each REDCap visit.
214314240|NCT06052969|DEVICE|Pulse NanoMED System|The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.
214314241|NCT04134923|DRUG|[11C] Pittsburgh Compound-B (PIB)|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] PIB. Participants will then undergo a \[11C\] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.
214314242|NCT06095141|DRUG|Cisplatin|Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.
214314243|NCT06976801|DEVICE|Intramedullary tibial Nail|Subjects will receive the micromotion MicroMotion Intramedullary tibial Nail
214314244|NCT06976801|DEVICE|Intermedullary nail|The non-micromotion intermedullary nail
214314245|NCT03490513|DRUG|anastrozole (1 mg/day)|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
214314246|NCT03490513|DRUG|Placebo|Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
214314247|NCT05400174|DIAGNOSTIC_TEST|Tilt table (upright position)|Different versions of cognitive assessments will be administered in the supine and upright positions.
214314248|NCT06249321|DRUG|mFOLFIRINOX plus IMRT|Chemotherapy will be administered according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline and a modified FOLFIRINOX regimen will be the first choice. Patients with advanced pancreatic adenocarcinoma will receive the modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of NCCN guideline.
214314249|NCT06355895|DIETARY_SUPPLEMENT|Standardized high-carbohydrate meal|8 ounces of Ensure® nutritional protein shake or a similar meal
214314250|NCT04429217|OTHER|immediate post-operative complete weight-bearing after surgery|"Patients randomized to the experimental post-operative rehabilitation intervention will undergo to immediate complete weight-bearing starting immediately after surgery. Immediate complete weight-bearing consists in the possibility to undergo all the everyday activities without limiting weight-bearing and without the use of walking aids.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED); this will ensure the safety of the early recovery phases, protecting from dangerous movements while allowing the mobilization in the healthy range of movement."
214314251|NCT04429217|OTHER|delayed weight-bearing for 6 weeks after surgery|"Patients randomized to the control post-operative rehabilitation intervention will undergo to delayed weight-bearing starting at 6-weeks post-operatively. Delayed weight-bearing consists in the limitation of the weight-bearing to 20-30% of patient's total weight using crutches for the first 6 weeks after surgery.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED)."
214314252|NCT02818218|PROCEDURE|Liver Transplant|liver transplant recipient surgery
214314253|NCT06535802|OTHER|Focus group|Attend a focus group session
214314254|NCT06535802|OTHER|Clinician Interviews|Participate in clinician interviews
214314255|NCT06535802|OTHER|Intervention testing|Test the virtual health intervention
214314256|NCT06535802|OTHER|Survey|Complete a follow-up survey
214314257|NCT06535802|OTHER|Follow-up Interview|Participate in a follow-up interview
214918211|NCT04744194|OTHER|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
214918212|NCT04744194|OTHER|Assisted nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
214918213|NCT01662817|BEHAVIORAL|Intervention|PCP receives one day training in depression screening guidelines and uses guidelines for six months
214918214|NCT01662817|BEHAVIORAL|Control|PCP manages depression in the usual way for six months
214918215|NCT06382246|OTHER|Exercise snacks|Bodyweight-style exercise snacks lasting 1-minute each performed with vigorous effort 4 times per day on two consecutive days.
214918216|NCT00006351|DRUG|gemcitabine hydrochloride|
214918217|NCT00006351|DRUG|lonafarnib|
215060963|NCT04140786|DRUG|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
214314258|NCT06535802|OTHER|Virtual Health Intervention|Participate in the virtual health intervention
214314259|NCT06982885|DIAGNOSTIC_TEST|artificial intelligence|Artificial intelligence assisted diagnostic system was used to diagnose colorectal lesions
214314260|NCT04473053|DRUG|Nafamostat Mesilate|Nafamostat has been shown to have potential antiviral effects against MERS CoV and is thought to possibly inhibit SARS CoV2 infection via inhibition of viral entry due to inhibition of TMPRSS2. In addition, nafamostat has potent anticoagulant properties which may provide benefit in patients with DIC, a common finding in serious cases of COVID-19. Nafamostat has been broadly well tolerated in clinical trials in patients with DIC and acute pancreatitis.
215060964|NCT02748876|OTHER|His-Ventricular (HV) optimisation|Optimisation of atrioventricular pacing interval
215060965|NCT00434993|DRUG|Albuterol Sulfate|"Albuterol sulfate, USP, solution for inhalation will be diluted as follows:~* The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.~* The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
214314261|NCT04473053|DRUG|TD139|TD139 is a specific inhibitor of galectin-3 which has been investigated in healthy volunteers and patients with IPF. No serious drug related serious adverse events have been reported to date. TD139 had no impact on cardiac, haematological or biochemical measures of safety during trials in humans to date. Beneficial effects on biomarker measures of lung inflammation were observed in patients with IPF. It is the purpose of this investigation to examine the potential for delivery of this inhibitor in pre-ventilator patients hospitalised with COVID-19 to examine whether this may lead to detectable changes in blood biomarkers, reduce viral load and also reduce disease severity such as time to ventilation.
214314262|NCT04473053|OTHER|Standard care|Patients will receive standard care.
214314263|NCT04473053|BIOLOGICAL|Allogeneic SARS-CoV-2 VSTs|The allogeneic SARS-CoV-2 VSTs are manufactured in a single stage process directly from the starting material procured from suitable post COVID-19 recovered individuals. This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs.
214314264|NCT06985498|COMBINATION_PRODUCT|Sandwich stratergy|The patients received blinatumoab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed after blinatumomab. Auto-HSCT was proceeded after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after stem cell reinfusion.
214314265|NCT06653894|PROCEDURE|PENG block with 0.25% bupivacaine.|In the PENG group, patients were placed in the supine position. A convex ultrasound probe was positioned under sterile conditions on the operated side, aligned with the iliac bone below the anterior superior iliac spine (ASIS). The anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), iliopsoas muscle, and its tendon were identified. Using an in-plane technique, a 22G 100-mm peripheral block needle was advanced toward the IPE, targeting the space between the iliopsoas muscle tendon and the IPE. Proper placement was confirmed via hydrodissection. Subsequently, 20 mL of 0.25% bupivacaine was administered slowly, with aspiration performed every 5 mL to avoid intravascular injection. The correct spread of the local anesthetic was verified via ultrasound, confirming elevation of the iliopsoas tendon.
214314266|NCT06653894|PROCEDURE|anterior quadratus lumborum block|"The quadratus lumborum and psoas major muscles, along with the transverse process of the L4 vertebra, were visualized in the midaxillary line using an in-plane technique. A 22G, 100-mm peripheral block needle (Stimuplex® Ultra; B. Braun Melsungen AG, Melsungen, Germany) was advanced into the subfascial plane between the quadratus lumborum and psoas major muscles, and 1-2 mL of 0.9% saline was injected to confirm correct placement via hydrodissection.~Following this, 20 mL of 0.25% bupivacaine (Buvasin® 0.5%, VEM, Tekirdağ, Turkey) was injected incrementally, with aspiration performed every 5 mL. Proper spread of the local anesthetic was confirmed by ultrasound visualization of a hypoechoic distribution between the fascial planes."
214314267|NCT06666491|DRUG|Tafenoquine|A single dose of TQ will be administered orally on Day 1 or Day 2.
214314268|NCT06666491|DRUG|Primaquine|A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).
214314269|NCT06666491|DRUG|Chloroquine|A single dose of CQ will be administered orally, daily, on Days 1 to 3.
214314270|NCT06149689|COMBINATION_PRODUCT|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
214314271|NCT06607718|OTHER|Resistance Training|Resistance training for elderly patients in the acute care unit.
214314272|NCT06607718|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|To receive two daily packs of a hypercaloric and hyperproteic oral nutritional supplement for 3 months.
214314273|NCT06607718|OTHER|Control Group|No intervention
214314274|NCT05409118|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
214314275|NCT05409118|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
214671378|NCT03598231|DEVICE|Sacral neuromodulation|"After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period."
214314276|NCT02722447|DRUG|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
214314277|NCT02722447|DRUG|Placebo|Placebo for 6 weeks
214918218|NCT06684561|DEVICE|PIS|"All subjects will be instructed to change the investigational infusion sets (PIS) every 246 hours (10 days \& 6 hours) or at set failure. Each subject is required to wear the CGM device continuously.~defined as any one of the following: After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of \<6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study.~if study 1 is successful, participants will enter study 2; , the same study designed will be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users"
214314278|NCT06610448|DEVICE|ABPMPro|This is an upper arm, cuff-based intermittent ambulatory BP device. This device has an internal activity and body position sensor which gathers information about sleep-wake estimation.
214314279|NCT06610448|DEVICE|Spacelabs Ambulatory Blood Pressure Monitoring|This is an upper arm cuff-based device with tubing for continuous ambulatory BP monitoring with a unique activity sensor that correlate with patient movement activity with blood pressure changes.
214314280|NCT06610448|DEVICE|Aktiia Blood Pressure|This is a wrist cuff-based device which uses an optical sensor (photoplethysmography sensor) to gather data from the arteries under the skin surface. Aktiia has an upper arm cuff device which is used for calibration once every month to provide a baseline blood pressure reading.
214314281|NCT06610448|DEVICE|LiveMetric|This is a wrist cuff-based applanation tonometry continuous ambulatory BP device. This device has automatic self-calibration and comes in various sizes.
214314282|NCT06610448|DEVICE|Bpro|This is a wrist cuff-based wireless oscillometric, continuous ambulatory BP device. It has applanation tonometry at the wrist with Pulse wave analysis. This device needs calibration with a brachial cuff BP measurement.
214481864|NCT06867211|DIAGNOSTIC_TEST|Use of Ultrasonography for Measuring Achilles Tendon Thickness|Achilles tendon ultrasonography was performed on healthy volunteers included in the study by an emergency physician trained in both basic and advanced ultrasonography techniques. Measurements were conducted using a Butterfly iQ (Butterfly Network, Inc., Guilford, CT) ultrasound device in B-mode with a musculoskeletal preset, using biplane imaging. For Achilles tendon measurement, the image depth was set to 2.0 cm. A linear probe was placed longitudinally and perpendicular to the tendon. The distal portion of the Achilles tendon and the calcaneus were visualized in the long axis, whereas the short axis was used to center the Achilles tendon on the screen for an optimal measurement view. The measurement site was determined as 2 cm proximal to the Achilles tendon insertion at the calcaneus. In biplane imaging, Achilles tendon thickness was measured in the long axis, whereas thickness, width, and cross-sectional area were measured in the short axis. Measurements were performed bilaterally
214481865|NCT06869226|DRUG|Camrelizumab + Nab-paclitaxel + Cisplatin|Three cycles of neoadjuvant therapy with camrelizumab (200 mg/dose D1, IV, Q3W)+Nab-paclitaxel(260 mg/m2 D1，IV，Q3W)+Cisplatin(75 mg/m2 D1，IV，Q3W); for patients with organ preservation intent entered into the watchful waiting strategy group and received radiotherapy (50.4 Gy/28 doses), with camrelizumab maintenance therapy for 4-12 weeks after the end of radiotherapy, and a total of up to one year of camrelizumab.
214481866|NCT06871293|OTHER|Functional and cognitive rehabilitation strategy|"The functional and cognitive rehabilitation strategy is a structured, supervised program, designed to improve physical and cognitive function in patients with Long Covid-19 and chronic diseases. Participants will attend weekly in-person sessions for 8 weeks at study sites.~Each session includes:~* Functional Rehabilitation (60 min): Warm-up, aerobic exercise (elliptical/treadmill), muscle strengthening, and cool-down, all supervised by trained healthcare professionals who monitor effort levels and heart rate.~* Cognitive Rehabilitation (30 min): Memory, attention, and executive function exercises, guided by occupational therapists or speech therapists."
214481867|NCT06871293|OTHER|Evidence-Based Informational Support|"The evidence-based informational support intervention provides structured, research-based health information to patients with Long Covid-19 and chronic diseases. Participants receive weekly digital messages for 8 weeks via email or text, covering key topics such as Covid-19 prevention, treatment, follow-up, and prognosis.~Content is derived from high-quality scientific studies and clinical guidelines.~A total of 24 informational pieces are delivered, ensuring comprehensive coverage of essential health recommendations.~This intervention is remote, accessible, and designed to enhance patient knowledge and self-management, distinguishing it from traditional in-person education programs."
214481868|NCT06885086|OTHER|Control group - 1|Patient data will be collected retrospectively from the records.
214671379|NCT04479501|OTHER|Asthma exacerbation related hospitalization|Evaluate the difference between patients with single and multiple hospitalizations for asthma exacerbation
214918219|NCT06256952|BEHAVIORAL|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
214918220|NCT06256952|BEHAVIORAL|social exclusion (Cyberball task)|Social exclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social exclusion, subjects will be systematically excluded by one co-player, and during social inclusion, ball tosses will be balanced between all three players.
214918221|NCT06256952|DIAGNOSTIC_TEST|Saliva samples|Assessing acute stress effects in AUD and HC subjects
215060966|NCT00434993|PROCEDURE|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
214314283|NCT06991296|DIETARY_SUPPLEMENT|SPM Active®|Participants will take two SPM Active® soft-gel capsules orally each day (total 2 g/day of specialized pro-resolving mediators) for 12 weeks (± 2-4 days). Capsules are provided by Metagenics and contain monohydroxylated n-3 PUFA derivatives (14-HDHA, 17-HDHA, 18-HEPE).
214314284|NCT06340737|DRUG|CD22CART Infusion|Dosing and Administration Participants will be hospitalized to receive treatment with CD22CART, if not previously hospitalized, and will remain hospitalized for approximately 5 to 7 (±2) days. Patients may be discharged once all AEs have resolved to Grade 1 or better, or at the discretion of the treating physician. Participants may be discharged with non critical and clinically stable or slowly improving toxicities (e.g., renal insufficiency, cytopenias) even if \> Grade 1, if deemed appropriate by the investigator.
214314285|NCT04449432|BEHAVIORAL|GROWell (Interactive Obesity Treatment Approach)|Personalized messaging via cell phone to support healthy eating behaviors during pregnancy and through 6 months postpartum
214671380|NCT05634590|DRUG|Fruquintinib|4mg, orally, once daily, 3 weeks on/ 1 week off
214671381|NCT05634590|DRUG|FOLFIRI|Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
214314286|NCT04449432|BEHAVIORAL|Attention Support Control|Personalized messaging via cell phone to support healthy behaviors during pregnancy and through 6 months postpartum
214314287|NCT04477304|BEHAVIORAL|Opioid Naive, OR|Visits where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days and clinician is on the clinic list as a treating member of the clinic
214481869|NCT06885086|DRUG|Observation group -2|In the literature, multimodal analgesia strategies-as recommended by ERAS guidelines and supported by recent studies-are implemented. In the intraoperative period, patients receive paracetamol, NSAIDs, and local surgical wound infiltration analgesia. In the postoperative period, oral paracetamol and NSAIDs are routinely continued, with opioids administered as needed.
214481870|NCT05726929|OTHER|Osteopathic treatment|Osteopathic Manual Treatment
214481871|NCT05726929|OTHER|Capsaicin QUTENZA Patch (TAU)|Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service
214481872|NCT06185777|BEHAVIORAL|Exercise oncology counseling and referal|Identification \& brief consultation Screening: Needs assessment for exercise therapy Information / educational talk Consultation with the patient Risk assessment (with physician clearance) Consultation Referral to exercise therapy
214481873|NCT06867068|DRUG|Midazolam Hydrochloride|Short-acting sedative. Benzodiazepine. Gamma-aminobutyric acid (GABA) inhibitor
214671382|NCT05634590|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
214314288|NCT04477304|BEHAVIORAL|At-risk for long-term use, OR|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days and clinician is on the clinic list as a treating member of the clinic
214481874|NCT06867068|DRUG|Fentanyl|Synthetic opioid drug used as an analgesic.
214481875|NCT06867068|DRUG|Ketamine|General Anesthetic. N-methyl-D-aspartate (NMDA) receptor agonist
214481876|NCT06867068|DRUG|Propofol injection|General Anesthetic. GABA receptor modulator and calcium channel blocker
214314289|NCT04477304|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days and clinician is on the clinic list as a treating member of the clinic
214481877|NCT06867068|DRUG|Nitrous oxide|Modulates a wide range of ligand-gated ion channels and inhibits NMDA receptor-mediated currents
214481878|NCT06869902|BIOLOGICAL|Colostrum|Use of the patient's mother's inhaled colostrum during the frenotomy
214481879|NCT06871566|OTHER|Artificial Intelligence-Supported Occupational Therapy Program|The AI-supported occupational therapy program was individually implemented by an occupational therapist over 8 weeks, with 2 sessions per week, each lasting 45 minutes. A touchscreen tablet, touch pen, and external camera were utilized during the sessions. At the beginning of the program, technological devices and artificial intelligence tools were introduced to the children. For the goals and detailed intervention program of the 8-week schedule
214481880|NCT06869993|DIETARY_SUPPLEMENT|Meal Kit plus Mobile Culinary Medicine Education|This intervention will involve four phases: (1) a baseline assessment; (2) a 7-day monitoring phase, (3) a 30-day intervention phase in which all households receive weekly meal kits delivered to their home in addition to mobile culinary medicine education; and (4) a follow-up assessment.
214481881|NCT06873412|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study will last for 3 months, and each subject will be followed up 3 times (month 0, Month 1, Month 2, month 3).
214481882|NCT06873412|DIETARY_SUPPLEMENT|Placbo|The experimental phase of the study will last for 3 months, and each subject will be followed up 3 times (month 0, Month 1, Month 2, month 3).
214481883|NCT06871969|DIAGNOSTIC_TEST|Dry electrode EEG|"A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. EEG data will be acquired with Strokepointer (TrianecT B.V., Utrecht, The Netherlands).~StrokePointer is a portable EEG acquisition and analysis device. The device consists of three parts: (1) StrokePointer headset with dry electrodes to measure EEG data, (2) Portable StrokePointer suitcase that contains a mobile computing device (Android phone), CE-marked (IIa) EEG amplifier and storage compartments and (3) Software to acquire, analyse and upload EEG data."
214671383|NCT05875935|PROCEDURE|ECoG : electrocorticography|"The skull and the dura are opened under general anesthesia and the two grids of 64 cortical electrodes will be applied to the cortex, one facing the glial lesion, and the other at a distance from the glial lesion in the so-called area. Healthy (non-tumor), before the patient wakes up. They consist of 8 recording slides each comprising 8 electrodes of 2 mm in diameter each spaced 0.5 mm (DispoMed®, USA)."
214671384|NCT01401088|DEVICE|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
214671385|NCT05144295|DRUG|Lubiprostone Pill|Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.
214671386|NCT05144295|DRUG|Lactulose Oral Liquid Product|"Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)"
214671387|NCT05144295|DRUG|Bisacodyl 5 MG|Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for \< 12 years or 3 tab/day for \> 12 years
214671388|NCT05144295|DRUG|Sodium Picosulfate|Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
214671389|NCT00239200|DRUG|Lapatinib|
214671390|NCT05278260|DIETARY_SUPPLEMENT|Hydrogen tablets|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that releases molecular hydrogen, for the duration of the radiation therapy
214314290|NCT02795195|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (51GyE, 54GyE, 57GyE, 60GyE, 63GyE) are planned within the Phase I part. And the started dose level will be 54GyE. Daily fraction of 3 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., maximal tolerated dose, is determined or if the treatments to 63 GyE are safely delivered, the recommended dose (or 63 GyE) will be the prescribed dose in the Phase II part of the study.
214314291|NCT07004686|DEVICE|MGRNOX index-guided analgesia|After anesthesia induction, the remifentanil plasma target concentration was adjusted intraoperatively to maintain the MGRNOX index between 30 and 50,but MAP and HR also were considered .In case the MGRNOX index was below 30 for more than 1 minute, remifentanil target-controlled infusion levels were lowered in steps of 0.5 ng/ml , whereas in case of a value greater than 50 for more than 1 minute, remifentanil target-controlled infusion levels were increased in steps of 0.5 ng/ml.
214314292|NCT07004686|DEVICE|Standard Clinical Care|After anesthesia induction, if hypertension (MAP \> 100 mmHg) or tachycardia (heart rate \> 90 bpm) persists for more than 2 minutes, remifentanil target-controlled infusion levels were increased in steps of 0.5 ng/ml.If there is no response to remifentanil or the MAP and HR exceed a certain threshold, then urapidil or esmolol will be administered.For hypotension (50 mmHg \< MAP ≤ 60 mmHg) persisting for more than 2 minutes, remifentanil target-controlled infusion levels were lowered in steps of 0.5 ng/ml (lowest target plasma concentration that was allowed is 1 ng/ml), and 4μg of norepinephrine were given. If MAP ≤ 50 mmHg, remifentanil target-controlled infusion levels were lowered in steps of 0.5 ng/ml(lowest target plasma concentration that was allowed is 1 ng/ml), and 8μg of norepinephrine were given.
214314293|NCT07108608|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a brief, evidenced based intervention for PTSD. WET is generally delivered individually across 5 sessions in which the therapist guides the patient through writing exercises. Across exposure sessions, participants experience habituation so that their symptoms decrease by the end of treatment. WET has an established evidence base in general outpatient psychotherapy for PTSD, but has not been adapted or tested in residential SUD treatment settings. Further, the investigators have adapted WET for this setting based on stakeholder and expert feedback.
214314294|NCT07108608|BEHAVIORAL|Treatment as Usual|Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)
214314295|NCT07109310|DIAGNOSTIC_TEST|RTImodel001|This model was developed through transcriptome sequencing combined with machine learning to predict the risk of disease progression and clinical outcomes of respiratory tract infections
214314296|NCT07109323|DRUG|BCMA CART|Bcma-cart was reinfused at a dose of 1.0-2.0 × 10 \^ 6 / kg on day +3 (± 1 day) after autologous hematopoietic stem cell reinfusion.
214314297|NCT06867484|RADIATION|Intensity modulated radiation therapy (IMRT)|40 Gy total in 15 consecutive weekday sessions to the partial breast
214314298|NCT07009951|DEVICE|Virtual reality|VR headset provides an immersive environment, such as natural landscapes accompanied by relaxing music. The use of VR will begin at least five minutes before the start of the procedure to allow the patient to acclimate. The headset will remain in use throughout the entire procedure, unless complications arise (e.g., nausea or significant discomfort).
214314299|NCT07016035|OTHER|mPCOSQ-F and SF-36|Questionnaires
214314300|NCT07015762|DRUG|IBI3002|Participants with AD will receive IBI3002 at the corresponding dose and dosing interval.
214481884|NCT06872346|OTHER|Visit-based IT reminders to patients and practitioners|"To identify patients due for CCSM, simplify test ordering/referral, and track follow-up, PREDICT will include: 1) automated updating of a patient's problem list with the current cervical screening finding, 2) automated updating of cervical cancer health maintenance topics to the appropriate time interval and follow-up test/ procedure through the use of modifiers, 3) SmartSets to standardize ordering of procedures/ specialty referrals."
214481885|NCT06872346|OTHER|Population outreach|"Patients will be sent a reminder letter 90 days prior to the due date via the patient portal or mailed if no portal account (Outreach 1). If needed, four weeks later a phone call from the outreach coordinator reminds patients of the follow-up date if scheduled or helps establish follow-up (Outreach 2). The coordinator could also place an order for a referral and send a reminder to the practitioner to sign it if appropriate. The coordinator will review and document any alternative care plans discussed by the PCP and patient."
214481886|NCT06872554|OTHER|Supervised exercise training|The intervention will consist of a 12-week multicomponent training program. This program will include exercises focused on strength training, mobility, stretching, and breathing. Throughout the 12 weeks, there will be a progressive increase in training volume-understood as the number of sets and repetitions performed-and in intensity, defined as the difficulty involved in performing the exercises. After each training session, data will be collected on the perceived effort and the pain in the area affected by the abdominal hernia.
214481887|NCT06872554|OTHER|Non supervised exercise training|The intervention will consist of a 12-week multicomponent training program. This program will include exercises focused on strength training, mobility, stretching, and breathing. Throughout the 12 weeks, there will be a progressive increase in training volume-understood as the number of sets and repetitions performed-and in intensity, defined as the difficulty involved in performing the exercises. After each training session, data will be collected on the perceived effort and the pain in the area affected by the abdominal hernia. This program will be realized for the participants at home, with the use of a specified training App, without the supervision of a sport science professional.
215060967|NCT00434993|DRUG|Placebo|"Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
214481888|NCT06861634|PROCEDURE|Nol index|Morphinomimetics will be administered according to NOL Index values or according to the usual criteria.
214481889|NCT06677138|DRUG|gefurulimab|Participants will receive gefurulimab subcutaneously (SC).
214481890|NCT06625671|DRUG|DB-2304|DB-2304
214314301|NCT07015762|DRUG|Placebo|Participants with AD will receive placebo at the corresponding volume and dosing interval.
214314302|NCT06626048|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia (CBT-I) is a behavioral (psychotherapeutic) intervention for insomnia disorder. Participants will complete digital CBT-I online using the Sleep Healthy Using the Internet (SHUTi) program.
214314303|NCT06626048|DEVICE|Passive Body Heating (PBH)|Passive body heating (PBH) is a body-based treatment that participants will complete using a sauna blanket, which is similar in form factor to an adult-sized sleeping bag (head is not within the heated area). Participants will complete at least three 15-minute PBH sessions per week. Participants will complete PBH sessions in the sauna blanket placed on the floor or on a couch (i.e., not in their bed) at a setting of Level 6, 1-2 hours before bed.
214314304|NCT05425524|PROCEDURE|Care Bundle|Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
214918222|NCT06256952|DIAGNOSTIC_TEST|basic psychological assessment|"* Sociodemographics~* ASSIST~* Quantity Frequency: Alcohol, tobacco/e-cigarette, Cannabis \& other illegal drugs~* SCID: AUD criteria and tabak use disorder life time and last year \& acute depressive symptoms \& symptoms for Mania and psychotic disorder~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Allgemeine Depressionsskala (ADS)~* State-Trait-Anxiety Inventory (STAI-T)~* Alcohol Use Disorders Identification Test (AUDIT)~* Cannabis Use Disorder Identification Test (CUDIT)~* CAS -A (Alkohol)~* Fragebogen zur Sozialen Unterstützung (F-SozU K-14)~* Oslo-3-Items-Social-Support Scale~* Social Skills Rating System (SSRS)~* Trier Inventory for chronic stress (TICS)~* Rejection Sensitivity Questionnaires (RSQ-9)~* Need to belong scale (NTBS)~* Fragebogen zu Gedanken und Gefühlen (FGG-14)~* Internationale Trauma Questionnaire (ITQ)~* Zahlen-Symbol-Test (DST)~* Wortschatztest (verbal intelligence)"
214314305|NCT05084768|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|As mentioned previously
214314306|NCT07023978|OTHER|Some movements in the qigong study called Ba Duan Jin, which will be applied to pregnant women, will be arranged for pregnant women and explained in detail. These are very slow, movements|Ba Duan Jin Qigong
214314307|NCT07022041|DIAGNOSTIC_TEST|conductivity and dieletric constant|collecting blood samples and directly measuring plasma conductivity and dielectric constant using microwave probes already validated for non-invasive glucose monitoring.
214314308|NCT07027644|DEVICE|Dry Cupping Therapy|The patients receive dry cupping therapy for 10 min on the marked trigger point using a plastic set with a hand vacuum pump
214314309|NCT07027644|OTHER|Integrated Neuromuscular Inhibition Technique|The patients receive the Integrated Neuromuscular Inhibition Technique, which consists of ischemic compression, strain-counterstrain, and muscle energy techniques.
214314310|NCT07027644|OTHER|stretching and strengthening exercises|The patients receive stretching and strengthening exercises
214314311|NCT07027644|OTHER|combined integrated neuromuscular inhibition, dry cupping and stretching and strengthening exercises|the patients recive all the three interventions
214314312|NCT06687967|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
214314313|NCT06687967|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
214314314|NCT06007547|DRUG|Poractant Alfa|Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
214314315|NCT06887465|DEVICE|Non-invasive Blood Pressure Monitor|Application of the VeriTrack non-invasive blood pressure monitor
214314316|NCT07044843|OTHER|Oxygen|SSOT and sham air (5l/min) will be applied with the oxygen concentrator EverFloTM via nasal cannula during training
214314317|NCT07044843|OTHER|Standard ambiant air will be breathed during endurance training.|ambiant air
214314318|NCT06736522|BEHAVIORAL|Leadership, Engagement, and youth Action Program with Mindfulness|The Leadership, Engagement, and youth Action Program with Mindfulness intervention (LEAP) was designed and co-created with youth to improve youth well-being by enhancing leadership opportunities and by developing mindfulness in day-to-day life. LEAP seeks to foster these improvements in youth and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
214314319|NCT06736522|BEHAVIORAL|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential skills including digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
214918223|NCT06256952|DIAGNOSTIC_TEST|pre and post cyberball task|Positive and Negative Affect Schedule(PANAS)
214314320|NCT02152254|DRUG|Targeted Therapy Based on Molecular Profiling|Molecular profiling results are used to assign targeted therapy. Patients receive targeted therapy by participating in a Phase I or a Phase II clinical trial. If a clinical trial is not available, and a commercially available targeted therapy exists (Food and Drug Administration \[FDA\]-approved for another indication), patients can receive the FDA-approved drug.
214314321|NCT02152254|DRUG|Standard-of-Care Therapy|Standard-of-care treatment regimen will be left to the discretion of the treating physician.
214314322|NCT05142358|DEVICE|Continuous Positive Airway Pressure|Use of CPAP device at the start of treatment planning.
214314323|NCT05142358|OTHER|Deep inspiratory breath hold|Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments
214314324|NCT05142358|OTHER|Free Breath|Regular breathing
214314325|NCT07058324|DIETARY_SUPPLEMENT|Prebiotic fiber|Chicory root-derived prebiotic fiber
214314326|NCT07058324|DIETARY_SUPPLEMENT|Placebo control|Maltodextrin
214314327|NCT06687980|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
214314328|NCT06687980|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
214314329|NCT06754904|PROCEDURE|Omitting TLND|Omitting TLND in patients who achieve an MPR in the index node following neoadjuvant ipilimumab and nivolumab.
214314330|NCT06754904|PROCEDURE|Index node procedure|Index node procedure
214481891|NCT06625671|DRUG|Placebo|Placebo
214481892|NCT06625671|DRUG|Prednisone|Prednisone
214314331|NCT07063836|PROCEDURE|VST|"atraumatic extraction to the hopeless teeth will be performed using periotomes followed by conventional forceps under local anesthesia.A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth.Using special instruments from the VST kit, the gum tissue is carefully dissected to expose the underlying bone and an immediate implant is placed using a surgical guide. the augmentation is done using A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~A special 0.6 mm thick membrane is inserted through the access incision. the vestibular incision is then sutured and the provisional is inserted."
214314332|NCT07063836|PROCEDURE|contour augmentation and early implant placement|"Teeth extraction : minimally invasive adjacent teeth extraction under anesthesia using periotome and forceps.~the empty sockets will be filled with a special collagen material (BioPlug) to aid healing for 4 to 8 weeks.~flap elevation : a full-thickness flap will be carefully raised using a crestal incision extended one tooth mesial and distal to the extraction location, then connected with two vertical incisions extended through the sulcus forming a trapezoid flap.~Implants Insertion: The two implant is then placed into the prepared sockets using surgical guide.~Bone Grafting: Any bone deficiencies are addressed by grafting. This involves placing a layer of (autogenous bone) directly on the two implants' surface, followed by a layer of a bone-grafting material (Demineralized Bone Matrix).~Membrane Placement: A double-layered collagen membrane is used to cover the grafted area.~Flap Closure: The previously lifted flap is repositioned and sutured back in place."
214314333|NCT06776731|OTHER|Oxygen|Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula during endurance training.
214314334|NCT06776731|OTHER|Room Air (placebo)|Room air (5l/min) will be applied with an oxygen concentrator via nasal cannula during endurance training.
214314335|NCT06813742|DRUG|18F-MFBG|Patients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
214314336|NCT04586699|DEVICE|Medi1TMS|rTMS theta-burst protocol paired with a consistent attention-to-breath task
214314337|NCT04586699|DEVICE|Medi2TMS|rTMS theta-burst protocol paired with an intermittent deep breathing task
214314338|NCT01515527|DRUG|Cladribine|"Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
214314339|NCT01515527|DRUG|Cytarabine|"Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
214314340|NCT01515527|DRUG|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
214314341|NCT06591780|OTHER|Clinical Evaluation|"A clinical evaluation occurs at the first study session. The clinical evaluation assesses walking function and mobility, lower extremity, sensation, health-related quality of life (HRQoL) and foot function.~Session 2 will be a dynamometer-based evaluation of passive ankle stiffness and a 3-dimensional gait analysis to evaluate baseline biomechanics. During Session 3, real-time biofeedback conditions will be used to measure the immediate effects on walking function."
214481893|NCT06440447|OTHER|Adult day program use|Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
214481894|NCT06440447|OTHER|Other community care (non-attendees)|Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
214481895|NCT04832412|DIETARY_SUPPLEMENT|BrainPhyt|BrainPhyt low dose supplementation during 6 months
214918224|NCT06256952|DIAGNOSTIC_TEST|VAS|subjective arousal, subjective stress, valence, perceived ostracisms/loneliness
214918225|NCT06256952|DIAGNOSTIC_TEST|after cyberball task|"* Need Threat Scale~* Manipulation check (VAS scale)"
214918226|NCT06256952|BEHAVIORAL|social inclusion (Cyberball task)|Social inclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social inclusion, ball tosses will be balanced between all three players.
214918227|NCT02151305|DRUG|Propofol, remifentanil|
214481896|NCT04832412|DIETARY_SUPPLEMENT|100 % Maltodextrin|100 % Maltodextrin
214481897|NCT06078891|BIOLOGICAL|BCG vaccine|Three intra-dermal vaccinations over a period of one year.
214918228|NCT02151305|DRUG|Sevoflurane|
214918229|NCT02924285|PROCEDURE|Procedure (Radiofrequency catheter ablation)|Radiofrequency catheter ablation
214481898|NCT06263660|DIETARY_SUPPLEMENT|Keto-like supplement|Participants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.
214918230|NCT02924285|DRUG|Amiodarone|"Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:~Antiarrhythmic Drug Amiodarone"
214918231|NCT01545037|DIETARY_SUPPLEMENT|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®|Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.
214918232|NCT01545037|OTHER|Placebo|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
215060968|NCT06435988|BEHAVIORAL|Training in the pecha kucha technique|Providing labor training to pregnant women with the Pecha Kucha technique
215060969|NCT04170998|DRUG|Evogliptin 5mg|Participants receive Evogliptin 5mg orally once a day
214314342|NCT06591780|OTHER|Plantar Pressure Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map represents the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target is provided using the heat map colors of red and target line on the bar graph. Participants are informed that the target is a measurement of the pressure under their foot, and their goal is to decrease pressure to achieve their target
214314343|NCT06591780|OTHER|Propulsion Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant\&#39;s immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For propulsion biofeedback, a visual display with a marker represents the current propulsion (peak AGRF) and a target provided to modulate propulsion. Participants are informed that the marker is a measurement of how hard they are pushing the ground backward, and their goal is to push-off more to achieve their target.
214314347|NCT07080905|GENETIC|CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua)|Administered as a single IV infusion.
214314348|NCT06734234|DRUG|GSK4771261|GSK4771261 will be administered.
214314349|NCT06734234|DRUG|Placebo matching GSK4771261|Placebo matching GSK4771261 will be administered.
214314350|NCT07083050|DEVICE|Volume stable collagen matrix|Volume stable collagen matrix obtained from porcine collagen after proprietary cross-linking by device manufacturer
214314351|NCT07083050|PROCEDURE|Autologous Connective Tissue Graft from the Hard Palate|Autologous connective tissue surgically harvested from the hard palate and transplanted in the area of gingival recession
214314352|NCT07084064|BEHAVIORAL|Families Moving Together|The Families Moving Together intervention was co-designed with community leaders and caregivers to address these barriers and promote physical activity co-participation among families. This evidence-based curriculum consists of six progressive lessons aimed at helping families learn, practice, and sustain an active lifestyle. The goals of this study are to increase community awareness of the importance of physical activity, create changes in parent and child physical activity, and increase parent physical activity knowledge and self-efficacy for promoting family physical activity.
214314353|NCT06268340|PROCEDURE|ECochG monitored CI surgery incl. corrective action guide|Interventional surgery with surgeon having access to intra-operative ECochG monitoring feedback to deploy ECochG based corrective action guide
214314354|NCT06268340|PROCEDURE|Routine CI surgery without ECochG monitoring|Routine CI surgery with access to ECochG monitoring by surgeon
214314355|NCT07086235|DRUG|self-assembling peptide|According to the instructions of the manufacturer, the lesion will be treated with etch solution (Super Etch, SDI Ltd, Bayswater, Victoria, Australia) for 30 seconds to open up the pores to the subsurface lesion and subsequently will be washed and dried. Curodont Repair Fluoride Plus brush will be rehydrated with 0.05 ml of sterile water and a single drop of the resulting solution will be immediately applied to the lesion surface. Moisture control will be ensured until the Curodont Repair Fluoride Plus solution will be no longer visible (approximately two minutes).
214481899|NCT06263660|DIETARY_SUPPLEMENT|Placebo|Participants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.
214918233|NCT03416426|DEVICE|Amplatzer® PFO occluder or Gore® Septal Occluder|The closure procedure was performed under general anesthesia. After achieving femoral venous access, the PFO was crossed with a 5F multipurpose catheter, which was advanced into the left upper pulmonary vein and then exchanged over a 0.035 inch J-tipped stiff guidewire for an 8F or 9F guiding sheath. Procedural anticoagulation was initiated with 5000 units of intravenous heparin. After then additional heparin was administrated throughout procedure to maintain an activated clotting time of ≥250 seconds. Device size was selected based on TEE measurements of the distance between the PFO and the aortic root.
214918234|NCT00179972|DEVICE|Adhesive and non-adhesive oximetry sensors|A sample of 32 premature infants will be recruited to participate in this study in which an adhesive sensor and a nonadhesive sensor are compared. Both sensors will be simultaneously tested in each subject, for a period of 14 days, with one sensor on the right foot and the other sensor on the left foot. Data will be collected on sensor longevity, skin integrity at the sensor site, reason for sensor replacement and ease of use rating by the clinician. Data will be summarized using descriptive statistics.
214918235|NCT01214967|BEHAVIORAL|Problem Solving Education|psycho-educational intervention
214918236|NCT04167098|OTHER|PRP injection|0.5 ml Platelet-rich Plasma around A1 tendon sheath
214918237|NCT04167098|OTHER|Corticosteroid injection|0.5 ml methylprednisolone around A1 tendon sheath
214314356|NCT07086235|DRUG|S-PRG Barrier Coat|According to the instructions of the manufacturer, after mixing one drop of activator with base, a thin film coating will be applied to the WSL area then will be left undistributed for 3 seconds and finally will be light cured for 10 seconds using LED light-curing unit.
214314357|NCT07085338|DRUG|Temozolomide|IV, Days 1-5
214314358|NCT07085338|DRUG|Irinotecan|IV, Days 1-5
214314359|NCT07085338|DRUG|hu14.18K322A|IV over 4 hours daily times 4 doses, Days 2-5.
214314360|NCT07085338|DRUG|N803|Subcutaneous (SC), Day 6.
214481900|NCT04986631|DRUG|Topiramate Tablets|Topiramate intervention
214671391|NCT05278260|DIETARY_SUPPLEMENT|Control|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that does not release any molecular hydrogen, for the duration of the radiation therapy
214481901|NCT04814654|BEHAVIORAL|CHALO! 2.0|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) on the following topics: HIV testing, prevention, treatment, linkage-to-care; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
214481902|NCT04814654|BEHAVIORAL|Attention-matched control (AMC)|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) only related to general health information; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
214481903|NCT04814654|BEHAVIORAL|Digital coupon only (DCO)|"The components of the intervention are:~Digital coupon for free HIV testing; Webpage listing testing/ care sites; access to online outreach workers."
214481904|NCT05376527|BIOLOGICAL|Double Recombinant Vaccinia Virus VV-GMCSF-Lact|"Intratumoral injections:~1\*107 PFU (calculated at minimal ED on mice); 2\*107 PFU; 4\*107 PFU; 6\*107 PFU; 8\*107 PFU; 10\*107 PFU;"
214481905|NCT04703920|DRUG|Talazoparib|Talazoparib will be administered in increasing doses up to 1 mg orally once a day.
214314361|NCT07085338|DRUG|Sargramostim|Subcutaneous injection (preferred) or IV, Days 7-13.
214314362|NCT04088071|DEVICE|Catheter ablation|Ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF).
214481906|NCT04703920|DRUG|Belinostat|Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.
214481907|NCT05196347|DRUG|Dapagliflozin|In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip \<20%.
214481908|NCT05265520|PROCEDURE|His-CRT implantation|The pathophysiological process is utilized in His-Bundle corrective pacing, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular endocardial lead.
214481909|NCT05265520|PROCEDURE|BIV-CRT implantation|Biventricular cardiac resynchronization therapy has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
214481910|NCT05418647|OTHER|high dialysate Na|high dialysate sodium (Na = 141 mmol/L) for 8 weeks
214481911|NCT05418647|OTHER|low dialysate Na|low dialysate sodium (Na = 136 mmol/L) for 8 weeks
214481912|NCT06336291|DRUG|L19TNF|7 μg/kg
214481913|NCT06336291|DRUG|L19TNF|10 μg/kg
214481914|NCT06336291|DRUG|L19TNF|13 μg/kg
214481915|NCT06336291|DRUG|Lomustine|90 mg/m2
214481916|NCT06336291|DRUG|Lomustine|110 mg/m2
214481917|NCT06679543|OTHER|Partial sleep deprivation|Participants will be asked to come to the lab for testing after a night of partial sleep deprivation. Participants will be asked to fall asleep at their habitual bedtime but wake up early (\~40% of normal sleep duration).
214481918|NCT06871813|BEHAVIORAL|combined the CDIO model with escape room pedagogy|consisting of 16 hours of theoretical instruction delivered in a classroom setting during the first two months, followed by 8 hours of practical skills training in the third month. Practical training covered four core competencies: cardiopulmonary resuscitation (CPR), closed intravenous transfusion, micro-infusion pump operation, and cardiac monitoring operation. The experimental group followed the same syllabus, incorporating an innovative teaching strategy that combined the CDIO model with escape room pedagogy.
214918238|NCT04167098|OTHER|Placebo injection|0.5 ml 0.9% saline around A1 tendon sheath
214918239|NCT02502682|DRUG|Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation|Daily bathing.
214918240|NCT01109953|OTHER|Breath-Hold PET/CT image set|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.
214314363|NCT05086887|DIAGNOSTIC_TEST|Malaria diagnostic tests (RDT and PCR) and serology for malaria and other parasitic diseases|All individuals are tested. Individuals with demonstrated parasitic disease are referred to the Infectious diseases or Pediatric clinic for evaluation and treatment.
214314364|NCT06828848|DRUG|Meropenem plus vaborbactam|Meropenem plus vaborbactam fixed dose combination adjusted by body weight up to 2g/2g
214314365|NCT06622759|PROCEDURE|CTG|Connective Tissue Graft has been widely used around implants to increase either the thickness of the soft tissues or the width of keratinized tissues. It is considered the gold standard for soft tissue grafting. The main drawbacks are the donor morbidity and the limit amount of intraoral donor sites. In this study it will be used in the test 1 group in order to compare its clinical results with the other groups.
214314366|NCT06622759|PROCEDURE|Collagen Matrix|Collagen matrix has been used in several studies in order to evaluate its clinical properties over the last years. In this study, the graft will be placed buccally at the time of implant placement in the aesthetic zone in order to assess its clinical and radiographic properties in terms of buccal bone resorption and soft tissue augmentation. Histological assessment and Patient Reported outcomes will also be evaluated.
214314367|NCT06622759|PROCEDURE|Control group|In the control group, the implant will be placed without any kind of soft tissue graft in order to compare this treatment modality that many clinicians apply at the clinical practice.
214314368|NCT05756790|BEHAVIORAL|Motivational Interviewing|Counseling
214314369|NCT05756790|BEHAVIORAL|Motivational Interviewing plus Breathalyzer|Counseling plus mobile breathalyzer/ app
214918241|NCT00253825|DEVICE|mCIMT combined with or without eye patching|
214918242|NCT03682848|DRUG|DTG + 3TC FDC|DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.
214918243|NCT06080399|OTHER|Continuous subcutaneous apomorphine infusion (CSAI)|the CSAI proposed in the usual healthcare pathway of each PD patients included
214918244|NCT00300560|DRUG|Colistin|
214918245|NCT02724046|DRUG|Ciprofloxacin|Single-dose oral ciprofloxacin
214918246|NCT05069220|DRUG|18F-MFBG|Patients with neuroendocrine malignancies receive 2-4 MBq/kg of 18F-MFBG intravenously followed by PET/CT after 60min of injection.
214671392|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 35%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 35% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
214314370|NCT07084077|OTHER|Narratology education module|At RCSI Dublin, mentioned by James Joyce in Dubliners, a one-week student-choice module Narrative Medicine: lessons from Irish writers and storytellers was offered to those in the second of our five-year undergraduate medical degree program, i.e., students were 18-months into the curriculum, had limited communication skills training, and no real-world clinical exposure. The module used close reading, group viewing, small-group workshops, and whole-group discussions to foster narrative competence. A medically-trained narratology-expert facilitated students' interrogation of classic and award-winning non-healthcare themed works by Irish writers and storytellers, i.e., directors and/or producers.
214314371|NCT07087860|OTHER|Best Practice|Receive standard of care
214314372|NCT07087860|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
214918247|NCT05069220|DRUG|68Ga-Dotatate|Patients with malignant PPGL and NB receive intravenously 68Ga-Dotatate followed by PET/CT after 40min of injection.
214918248|NCT00454363|OTHER|Laboratory Biomarker Analysis|Correlative studies
214918249|NCT00454363|DRUG|Pazopanib Hydrochloride|Given PO
215060970|NCT04170998|DRUG|Evogliptin Placebo|Participants receive placebo to match Evogliptin 5mg orally once a day
214314373|NCT07087860|PROCEDURE|Central Venous Cannula Insertion|Undergo central line placement
214314374|NCT07087860|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214314375|NCT07087860|DRUG|Enfortumab Vedotin|Given IV
214314376|NCT07087860|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214314377|NCT07087860|BIOLOGICAL|Pembrolizumab|Given IV
214314378|NCT07087860|PROCEDURE|Plasmapheresis|Undergo TPE
214918250|NCT00454363|OTHER|Pharmacological Study|Correlative studies
214918251|NCT00548301|DRUG|cyclosporine|
214918252|NCT05988827|DEVICE|NGenuity|Cataract surgery performed under microscope using NGenuity
215060971|NCT04170998|DRUG|Dapagliflozin 10mg|Participants receive Dapagliflozin orally once a day
214314379|NCT07087860|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214314380|NCT07087860|OTHER|Questionnaire Administration|Ancillary studies
214314381|NCT07090681|DEVICE|Active Control Placebo|In this intervention, participants underwent magnetic stimulation at the neck level with a TMS coil. Ten minutes after, they received a high frequency temporal interference stimulation with an overlapping sinusoidal wave at 2KHz, without any interferent pattern.
214314382|NCT07090681|DEVICE|tTIS|In this intervention, participants underwent magnetic stimulation at the neck level with a TMS coil. Ten minutes after, they received active transcranial temporal interference stimulation with a patterned stimulation (intermittent theta-burst) generating temporal interference in the striatum; see Wessel et al., 2023, Nat Neurosci. for details
214314383|NCT07090681|DEVICE|tTIS + TMS|In this intervention, participants underwent cerebellar magnetic stimulation at the level of a predefined individual point in the inferior left cerebellar hemisphere with a TMS coil, receiving a total of 600 pulses organised in an intermittent theta-burst pattern. Ten minutes after, they received active transcranial temporal interference stimulation with a patterned stimulation (intermittent theta-burst) generating temporal interference in the striatum; see Wessel et al., 2023, Nat Neurosci. for details
214314384|NCT07084493|DEVICE|CBD stent either a 7-Fr and 7 cm or a 10-Fr and 7-cm OR double-pigtail stent|prophylactic CBD stent either a 7-Fr and 7 cm or a 10-Fr and 7-cm double-pigtail stent
214314385|NCT07084493|DEVICE|biliary stent|prophylactic CBD stent either a 7-Fr and 7 cm or a 10-Fr and 7-cm double-pigtail stent
214314386|NCT02513407|BEHAVIORAL|Behavioral Dietary Intervention|Attend healthy nutritional education session
214314387|NCT02513407|OTHER|Educational Intervention|Attend EML educational session
214314388|NCT02513407|BEHAVIORAL|Exercise Intervention|Attend exercise educational session
214314389|NCT02513407|BEHAVIORAL|Exercise Intervention|Receive fitness tracker
214918253|NCT05444452|DEVICE|Implanatation of Genoss DES sirolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Genoss stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
214918254|NCT05444452|DEVICE|Implanatation of Xience DES everolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Xience stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
214918255|NCT03482453|DRUG|TAK-788|TAK-788 capsules.
214918256|NCT03482453|DRUG|Placebo|TAK-788 placebo-matching capsules.
214918257|NCT03482453|DRUG|TAK-788|TAK-788 DiC.
214918258|NCT01394731|DRUG|Acetaminophen|
214918259|NCT01394731|DRUG|Meperidine|
214918260|NCT03377231|DEVICE|Stratamark®|Film-forming dressing for the prevention and treatment of stretch marks.
214918261|NCT03747380|OTHER|inspiratory muscle program|pre-operative inspiratory muscular training program
214918262|NCT04927780|DRUG|Leucovorin Calcium|IV
214918263|NCT04927780|DRUG|Fluorouracil|IV
214918264|NCT04927780|DRUG|Irinotecan Hydrochloride|IV
214918265|NCT04927780|DRUG|Oxaliplatin|IV
214918266|NCT04927780|PROCEDURE|Resection|Open or minimally-invasive pancreatectomy.
215060972|NCT04170998|DRUG|Metformin ≥ 1000mg|Metformin are administered at the same dose and formulation.
215060973|NCT00465972|DRUG|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
215060974|NCT00465972|DRUG|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
215060975|NCT00465972|DRUG|Placebo|Placebo capsule nightly for duration of study
214671393|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 6%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 6% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
214671394|NCT05443438|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
214314390|NCT02513407|OTHER|Laboratory Biomarker Analysis|Correlative studies
214314391|NCT02513407|OTHER|Questionnaire Administration|Ancillary studies
214314392|NCT06906341|DRUG|Relacorilant 150 mg once daily (QD)|Relacorilant is administered as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
214314393|NCT06906341|DRUG|Nab-paclitaxel 80 mg/m^2|Nab-paclitaxel is administered as intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle.
214314394|NCT06906341|DRUG|Bevacizumab 10 mg/kg|Bevacizumab is administered as IV infusion on Days 1 and 15 of each 28-day cycle.
214314395|NCT06910839|DRUG|PF-07976016|PF-07976016 oral tablets
214314396|NCT06910839|DRUG|PF-06882961|PF-06882961 oral tablets
214314397|NCT07098559|BEHAVIORAL|Creative drama|This intervention is unique in its integration of the Bystander Intervention Model with creative drama techniques to enhance empathy, self-efficacy, and active intervention behaviors among middle school students witnessing peer bullying. Unlike traditional anti-bullying programs that rely on lectures or cognitive-based approaches, this study uses experiential learning and role-playing scenarios to simulate real-life bullying situations and encourage emotional engagement and behavioral change.
214314398|NCT07091279|DRUG|Propranolol|Propranolol, oral, titrated in weekly increments from 10 mg TID to a maximum of 200 mg TID (total daily dose: 30 mg to 600 mg at 8 weeks), based on tolerability. Participants will continue at the highest tolerated dose for additional 4 weeks. Target doses: 10 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg TID.
214671395|NCT05443438|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
214671396|NCT05443438|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
214918267|NCT04760431|DRUG|Trastuzumab|8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles, administered by IV infusion every week until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
214918268|NCT04760431|DRUG|Taxanes|Docetaxel: 75 mg/m2, administered by IV infusion every 3 weeks Paclitaxel: 175 mg/m2, administered by IV infusion every 3 weeks Paclitaxel (Albumin bound): 260 mg/m2, administered by IV infusion every 3 weeks Paclitaxel Liposome: 135-175 mg/m2, administered by IV infusion every 3 weeks
214918269|NCT04760431|DRUG|Pertuzumab|840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
214314399|NCT07091279|DRUG|Placebo|Placebo for Propranolol
214314400|NCT07099911|BEHAVIORAL|NMES|Acute bout of neuromuscular electrical stimulation during a 3-h OGTT.
214314401|NCT07099911|BEHAVIORAL|Sham (No Treatment)|Sham stimulation during a 3-h OGTT.
214314402|NCT07099300|DIAGNOSTIC_TEST|Abdominal Radiography|Obtain plain film radiographs 3 times after adminstration of WSC
214314403|NCT07096544|DEVICE|CardioMEMS Device|The CardioMEMS device will be implanted during a right heart catheterization procedure. The device will be positioned in the pulmonary artery and calibrated using a Swan-Ganz catheter. After implantation, PAP measurements will be taken daily using the home monitoring system provided to the patient. These readings will be transmitted wirelessly to the clinical team, who will review the data at least once per week. Adjustments to the patient's medical therapy and LVAD speed settings will be made based on the hemodynamic data provided by the CardioMEMS device.
214314404|NCT07101406|OTHER|Türkiye Nutrition Guideline Diet|A diet structured according to the Türkiye Nutrition Guideline (TÜBER) for pregnant women, consisting of 45-60% carbohydrates, 12-20% protein (minimum 70 g), and 20-35% fat. Diets were tailored weekly based on blood glucose levels and individual dietary intake records.
214671397|NCT04911270|DEVICE|Computer Decision Support Tool Intervention Group|Computer Decision Support Tool using Bayesian estimation to dose IV vancomycin in pediatric patients using AUC24/MIC
214671398|NCT04911270|OTHER|Matched Historical Controls|Vancomycin dosing based on standard hospital methods, with dose adjustments based on vancomycin trough targets
214671399|NCT03879668|DEVICE|eIPOS|Electronic version of IPOS
214918270|NCT04760431|DRUG|Tyrosine kinase inhibitor|Pyrotinib: 400mg po within 30 minutes after a meal, QD, every 3 weeks Neratinib: 240mg po QD, every 3 weeks Tucatinib: 300mg po Q12H
214314405|NCT07101406|OTHER|DASH Diet|A dietary plan based on DASH guidelines: 45-60% carbohydrates (≥175 g), 12-20% protein (≥70 g), 20-35% fat (≤6% saturated), ≤2300 mg sodium, ≥4700 mg potassium, ≥1250 mg calcium, ≥500 mg magnesium. Includes low-fat dairy, lean meats, fruits/vegetables, and nuts/seeds.
214314406|NCT07100119|DRUG|LY4256984|Administered IT
214314407|NCT07100119|DRUG|Placebo|Administered IT
214314408|NCT06025513|DEVICE|Embrace Patch|Tension offloading skin patch
214314409|NCT07104825|PROCEDURE|Intraoperative autonomic neural blockade (ANB)|Local anesthetic block of the neurovascular tissue along the lesser curve of the stomach and celiac trunk during sleeve gastrectomy or gastric bypass surgery.
214314410|NCT07104825|PROCEDURE|Laparoscopic Standard of Care Abdominal Wall Block|Administration of local anesthetic to abdominal incisions (standard of care)
214314411|NCT07110194|DRUG|TQB2825 Injection (Subcutaneous Injection)|TQB2825 is a Cluster of Differentiation 3 × Cluster of Differentiation 20 (CD3×CD20) dual antibody, which can simultaneously target the CD20 on tumor cells and the CD3 on T cells. It can induce T cell activation, proliferation and cytokine release, and effectively target and kill tumor cells.
214671400|NCT06964360|BEHAVIORAL|REDOCVR Psychoeducational Program|A clinician-guided, group-based psychoeducational program combining pain neuroscience education, emotional regulation techniques, physical activation, and immersive virtual reality experiences. Delivered in eight weekly 90-minute sessions. Includes structured medication tapering support provided by primary care physicians.
214671401|NCT06964360|BEHAVIORAL|Standard Educational Materials|Participants receive written and audiovisual materials on chronic pain self-management. Materials are used independently without group sessions or virtual reality. No structured tapering support is provided beyond usual care.
214671402|NCT04402502|DEVICE|Ultrasound Imaging|The participant will go to the Rheumatology clinic (St. Joseph's Hospital) and have 3D hand ultrasound performed on their hands.
214671403|NCT06490965|OTHER|Repetitive Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) involves generating a magnetic field with specific spatial and temporal properties, allowing the induction of electric current in conductive material near this field. The electro-physiological principle of TMS is based on placing a coil over the skull that will induce a magnetic field generating action potentials in neuronal tissue in response to each TMS pulse. The repetitive application of TMS pulses (rTMS) allows for the modulation of neuronal excitability for a period after rTMS, ranging from inhibition, in the case of low frequencies (\~1 Hz), or facilitation if high frequencies (equal to or greater than 5 Hz) are used.
214671404|NCT06490965|OTHER|Neuronavigation|Neuronavigation is a non-invasive method that allows the creation of computerized three-dimensional models of brain structures based on neuroimaging exams of each individual (e.g., cranial magnetic resonance imaging). As such, this method has been used for various purposes, such as assisting in neurosurgery or mapping functional regions of the brain, but also in the context of TMS (Transcranial Magnetic Stimulation). In this latter area, its use as support for TMS has been employed for therapeutic, diagnostic, and research purposes. The neuronavigation system consists of several components, namely a locating camera, locators for the TMS coil, an adjustable headband with locators, a calibration system for these elements, and the neuronavigation software, which is installed on a supporting computer.
214918271|NCT00184327|BEHAVIORAL|Intensive family therapy - inpatient|2-4 weeks (5days) family inpatient assessment and treatment
214918272|NCT00184327|BEHAVIORAL|Diagnostic assessment - child and adolescent psychiatry|
214918273|NCT01063192|DRUG|Gemcitabine|Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
214918274|NCT01063192|DRUG|Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)|Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
214918275|NCT00373230|BEHAVIORAL|telemedicine|One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
214918276|NCT02302469|DRUG|Revlimid|Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).
214314412|NCT07108491|BIOLOGICAL|Balance Training with Stroboscopic Glasses|"The difficulty level of intermittent visual occlusion was structured from Level 1 to Level 8 based on frequency. As the flicker speed of the lenses decreased and the frequency lowered, the difficulty increased. For example, a setting of 6 Hz means the lenses flicker six times per second, whereas 1 Hz indicates one flicker per second.~Levels 1 to 5 are suitable for dynamic movements such as catching or hitting a ball, while Levels 3 to 8 are appropriate for balance and proprioceptive training.~In this study, participants wore stroboscopic glasses (Senaptec Strobe, Senaptec, USA, 2016) and began at Level 1 (6 Hz). The difficulty was gradually increased each week, with the setting adjusted to Level 3 (4 Hz) in Week 2, Level 4 (3 Hz) in Week 3, and Level 5 (2.25 Hz) in Week 4 (see Table 5).~The training was conducted using the standard Mode A, in which both lenses flicker simultaneously."
214918277|NCT02174263|BIOLOGICAL|tocilizumab|Given IV
214918278|NCT02174263|OTHER|laboratory biomarker analysis|Correlative studies
214918279|NCT02174263|OTHER|quality-of-life assessment|Ancillary studies
214918280|NCT02369965|DRUG|albuvirtide|albuvirtide 320mg administered intravenously once a week
214918281|NCT02369965|DRUG|lopinavir-ritonavir|lopinavir-ritonavir 400/100mg administered orally twice daily
214918282|NCT02369965|DRUG|tenofovir|tenofovir 300mg administered orally once daily
214918283|NCT02369965|DRUG|lamivudine|lamivudine 300mg administered orally once daily
214918284|NCT05832684|DRUG|ZVS101e|ZVS101e contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human wild type CYP4V2 gene.
214918285|NCT05154045|OTHER|Experimental Formula|Diabetes-specific study formula
214918286|NCT05154045|OTHER|Test Meal|Instant oatmeal
214918287|NCT03404037|DIAGNOSTIC_TEST|serum endostatin level|"An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.~Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA"
214918288|NCT02946554|BIOLOGICAL|HepaStem|
214918289|NCT01616797|BEHAVIORAL|Computerized neurobehavioral intervention|Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
214918290|NCT02461433|DEVICE|Prevena|Prevena Incision Management system
214918291|NCT02461433|DEVICE|Standard Dressing|This involves standard of care dressing including but not limited to gauze.
214918292|NCT01579097|OTHER|Oliclinomel N4|Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated
214918293|NCT01579097|OTHER|Compounded ternary parenteral nutrition admixtures|Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days
214918294|NCT01523782|DRUG|GRASPA|Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
214918295|NCT06575127|DRUG|FOLFOXIRI Protocol|as mentioned in Arm description
214314413|NCT07108491|BIOLOGICAL|Balance Training without Glasses|The exercise program consisted of six types of exercises and was conducted in a 30-minute circuit training format repeated twice per session. Participants took part in two sessions per week for four weeks, totaling eight sessions. The six exercises were completed as a circuit, repeated twice per session. A 30-second rest was provided between exercises and a 2-minute rest between circuits. All exercises were conducted by a licensed physical therapist to ensure safety.
214314414|NCT07110662|DRUG|DARATUMUMAB (DARZALEX®)|A single injection of DARZALEX 16 mg/kg body weight administered by intravenous infusion (day 1) in addition to standard symptomatic treatment of NET until re-epidermalization.
214314415|NCT07109180|PROCEDURE|Robot-assisted lateral pancreaticojejunostomy|Robot-assisted
214918296|NCT06119620|DEVICE|intermitted theta burst stimulation|Participants receive intermitted theta burst stimulation for 3-4 minutes before completing the N-back task.
214314416|NCT07109180|PROCEDURE|Open lateral pancreaticojejunostomy|Open surgery
214918297|NCT05495282|OTHER|Microvideo|Asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted.
214314417|NCT07108699|DRUG|HSK39004 Dry Powder Inhaler-0.75mg|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day
214918298|NCT02547220|BIOLOGICAL|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre \[mL\] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
214918299|NCT02547220|DRUG|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
214918300|NCT00660244|DRUG|anastrozole|Oral
214918301|NCT05498129|OTHER|School meal|School lunch was comprised of rice, ghee and beef
214918302|NCT05498129|OTHER|School meal plus micronutrient powder|School lunch plus micronutrient powder
214314418|NCT07108699|DRUG|HSK39004 Dry Powder Inhaler-1.5mg|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day
214314419|NCT07108699|DRUG|HSK39004 Dry Powder Inhaler Simulant|HSK39004 Dry Powder Inhaler Simulants, administered via oral inhalation, 1 tablet each time, twice daily
214314420|NCT07108933|BIOLOGICAL|Autologous platelet-rich plasma|Guided injection of PRP in bony cavities of maxilla after surgical excision of non-malignant tumors.
214314421|NCT07108959|PROCEDURE|Erector spinae plane block (Group E)|The ultra sound probe will be placed on the paravertebral region in a Sagittal plane about 3 cm lateral to the T5 spinous process on the operating side to locate erector spinae muscle, rhomboid major and trapezius from inward (To reach T5, we used C7 as an anatomical landmark, which is the most prominent vertebrae in the back and count downwards to reach T5. To locate C7, we will use palpation or ultrasound guidance if there is difficulty in palpation). Following visualization of these muscles and the transverse process of T5, the skin will be infiltrated with 5 ml of 2% lidocaine, and then 30 ml bupivacaine 0.25% will be injected in the plane between the erector spinae muscle and transverse process using a 22-G 10-cm nerve block needle.
214314422|NCT07108959|PROCEDURE|Lidocaine (drug)|Patients in group L will receive an initial bolus of lidocaine 1.5mg /kg over 10 minutes immediately before the induction of general anaesthesia then 1.5mg/kg/hr lidocaine infusion in a 50cc syringe pump intra operatively that will be stopped at the end of surgery.
214314423|NCT07108270|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
214314424|NCT07108270|DRUG|Carboplatin|Carboplatin will be administered.
214314425|NCT07108270|DRUG|Paclitaxel|Paclitaxel will be administered.
214314426|NCT07109375|DRUG|pegunigalsidase alfa|Pegunigalsidase alfa is 2 mg/mL concentrate for solution and is administered via intravenous infusion every two weeks.
214314427|NCT07109583|BEHAVIORAL|Early dinner|Consume dinner between 17:30 and 19:00 for a week
214314428|NCT07109583|BEHAVIORAL|Delayed dinner|Consume dinner between 20:30 and 22:00 for a week
215060976|NCT04910529|OTHER|Yoga|Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students.
214314429|NCT07110493|DEVICE|Transcranial Magnetic Stimulation (TMS)|Single-pulse TMS is applied to specific areas of the visual cortex to non-invasively induce the perception of phosphenes (brief flashes of light). Stimulation is delivered using a TMS device, with the operator controlling the intensity and frequency parameters to a level equal to the phosphene-evoking threshold. During stimulation, participants are seated comfortably and asked to report the location of perceived phosphenes on a monitor and a physical grid, helping to map the cortical visual field.
214314430|NCT07110493|DEVICE|Electroencephalography (EEG)|Continuous brain electrical activity is recorded using a 128-channel gel-based EEG system (Skoltech). The EEG cap is fitted to the participant's head to capture neural responses with high temporal resolution throughout the session. The collected data is used to analyze brain activity changes, including the P300 component and other event-related potentials, to identify neural correlates of phosphene perception and the effects of TMS.
214314431|NCT07110493|DEVICE|Eye-Tracking|Eye movements are continuously monitored using a Tobii Defusion 2 eye-tracker (Skoltech) operating at 60 Hz. This device provides high-accuracy measurements of gaze fixation and saccades. Participants are instructed to fixate their gaze on one of five predetermined points on a screen (center, top, bottom, left, right), with the fixation point being determined randomly for each trial. The eye-tracking data is analyzed to assess the influence of gaze position on phosphene localization and to study any stimulation-induced changes in eye movement patterns.
214918303|NCT05498129|OTHER|No school meal|No school meal
214918304|NCT00252291|DRUG|Aridol|
214918305|NCT00252291|DRUG|Methacholine|
214918306|NCT00252291|PROCEDURE|Exercise challenge|
214918307|NCT04527692|OTHER|Questionnaire|semi-structured interviews on the quality of life
214918308|NCT02253589|BEHAVIORAL|modified ASSIST-linked Brief Intervention|Trained counsellors support participant's motivation to reduce or stop khat use in a 20 minute counselling session.
214918309|NCT03093194|OTHER|vaginal preparation before CS with Septal soap and septol.|vaginal preparation before CS with Septal soap and septol.
214918310|NCT03093194|OTHER|No vaginal preparation before CS with Septal soap and septol.|No vaginal preparation before CS with Septal soap and septol.
214671405|NCT06490965|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that generates detailed images of the internal structures of the body using a strong magnetic field and radio waves. It provides high-resolution images of soft tissues, such as organs, muscles, and the brain, helping doctors diagnose and monitor various conditions, including injuries, tumors, and neurological disorders. MRI is particularly useful because it does not involve ionizing radiation, making it safer for patients than other imaging methods like X-rays or CT scans.
214314432|NCT07109401|DRUG|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Neoadjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide; Adjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide (the total cycle of perioperative chemotherapy is four), followed by Tislelizumab monotherapy for one year.
214314433|NCT07110467|PROCEDURE|blinking exercises|The study group was instructed to instill artificial tears and perform blinking exercises three- five times a day for 4 weeks.
214314434|NCT07109167|DRUG|Benmelstobart combined with gemcitabine and cisplatin|Benmelstobart 1200mg, intravenous infusion on Day 1;Gemcitabine 1000mg/m², intravenous infusion over 30 minutes on Day 1 and Day 8;Cisplatin 25mg/m², intravenous infusion on Day 1 and Day 8. Maintenance dose of study medication: Benmelstobart 1200mg, intravenous infusion on Day 1;Gemcitabine 1000mg/m², intravenous infusion over 30 minutes on Day 1 and Day 8
214314435|NCT07109765|DRUG|Secukinumab|secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection
214314436|NCT07109089|OTHER|Race Pace-based training|Participants complete one week of endurance training based on race pace zones individually determined from a 5-km time trial performance. The program includes both low-intensity continuous runs and high-intensity interval training sessions.
214314437|NCT07109089|OTHER|Heart Rate-Based Training|Participants complete one week of endurance training based on heart rate zones individually determined from ventilatory threshold assessments. The program includes both low-intensity continuous runs and high-intensity interval training sessions.
214314438|NCT07110480|DIETARY_SUPPLEMENT|Supplement|The enrolled patient was advised to take 1 to 2 tablets daily at any time, preferably with a sip of water, as directed by the pharmaceutical company. In detail, starting with the distribution of Assonal®️PEA (T0) by the principal investigator, patients took 2 tablets per day (1 in the morning and 1 in the evening) for the first 15 days of treatment (T1). Treatment continued with 1 tablet per day until the end of the clinical study (T3).
214314439|NCT07110415|DRUG|Yangxinshi tablet|"Basic treatment: All patients received a conventional treatment regimen, including outcome-improving drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors (ACEIs)) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Yangxinshi tablet, 3 tablets/3 times a day, taken orally"
214314440|NCT07110415|DRUG|Blank control|"Basic treatment: All patients received a conventional treatment regimen, including prognosis-improving drugs (aspirin, β-blockers, statins, and ACEIs) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Blank control"
214918311|NCT01889329|DIETARY_SUPPLEMENT|RUTF-1|Made from local food ingredients
214314441|NCT07108556|BEHAVIORAL|Mindfulness VR-Typical|Participants first experience mindfulness exercise with virtual reality incorporated, then another mindfulness exercise with only audio-guidance as typically delivered without the technology
214314442|NCT07108556|BEHAVIORAL|Mindfulness Typical-VR|Participants first experience mindfulness exercise with only audio-guidance, then another mindfulness exercise with virtual reality incorporated
214314443|NCT07108998|DRUG|Epcoritamab|Epcoritamab is the investigational product under study in combination with SOC drugs in this protocol. During C1, epcoritamab will be initiated using step-up dosing (SUD) C1D1 .16mg, C1D8 .8mg, C1D15 3 mg, C1D22 24 mg vs 48 mg (full dose) during safety lead in to determine the RP2D. On Cycles 2-3 the RP2D (24mg vs 48 mg) will be administered on Days 1, 8, 15, 22. Then Cycles 4-9 RP2D will be administered on Days 1 \& 15. Then Cycle 10-12 RP2D on Day 1 of each cycle. Epcoritamab is administered subcutaneously. The SOC BTKi are oral medications administered daily during the trial period.
214314444|NCT07108985|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg, taken once daily for 24 weeks.
214314445|NCT07108985|DRUG|Sitagliptin 100 mg + Dapagliflozin 10 mg|Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.
214314446|NCT07108985|DRUG|Sitagliptin 100 mg + Dapagliflozin 10 mg|Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.
214314447|NCT07108985|DRUG|Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg|Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg, taken once daily for 24 weeks.
214314448|NCT07108309|BIOLOGICAL|BCD-236|as an intravenous infusion
214314449|NCT07108309|DRUG|Chemotherapy|CHT (at the investigator's discretion):
214314450|NCT07109466|OTHER|Mulit-modality Balance Intervention|Participants will attend a virtual group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
214314451|NCT07109466|OTHER|Gerofit|Participation in a virtual wellness program that consists of a warm up, aerobic training, and general strength training 3-times per week for up to 12 months
214314452|NCT07109830|DIAGNOSTIC_TEST|Cognitive assessment|Cognitive assessment using BCI-game
214918312|NCT01889329|DIETARY_SUPPLEMENT|RUTF-2|Made from local food ingredients
214314453|NCT07109830|DIAGNOSTIC_TEST|NEPSY-II|Standardized cognitive assessment
214918313|NCT01889329|DIETARY_SUPPLEMENT|Plumpynut|Commercially made from peanut paste
214918314|NCT01925729|BIOLOGICAL|ragweed|ragweed arm only
214918315|NCT01925729|BIOLOGICAL|histamine|histamine arm only
214918316|NCT01925729|DRUG|pseudoephedrine|pseudoephedrine arm only
214918317|NCT01925729|DRUG|Oxymetazoline|oxymetazoline arm only
214918318|NCT03689829|DRUG|MOR106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).
214918319|NCT03689829|DRUG|Placebo|Corresponding placebo s.c. injections.
214918320|NCT03793205|DRUG|Long-acting G-CSF|Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required.
214918321|NCT03793205|DRUG|Short-acting G-CSF|Short-acting G-CSF will be given as required 24 hours after the chemotherapy.
214918322|NCT06182111|PROCEDURE|Intraoperative morphine|Morphine dose = 0,1 mg mg/kg (maximum 10 mg) intravenous given 20 min after start of surgery
214481919|NCT06872918|PROCEDURE|Lever positioning manipulation|The patient was placed in the prone position, and the doctor used one-finger Zen pushing, rolling, pressing and kneading, flicking and plucking methods in the patient's lumbar region and the affected side of the lower limb pain repeated massage treatment for 15min; the patient was placed in the prone open-mouth position, and the operator stood on the right side of his/her body, so that the whole body of the patient's muscles were relaxed. According to the type of herniation, the patient with paracentral lumbar disc herniation performed unilateral triggering mode, and the patient with central lumbar disc herniation performed bilateral triggering mode.
214481920|NCT06872918|PROCEDURE|Cluster of pseudo-manipulators|Sham manipulation treatment was given. Recipients take the prone position, the medical practitioner with a finger Zen push method, rolling method, pressing and kneading method, flicking and plucking method in the patient's lumbar region and the affected side of the lower limbs of the pain in the repeated massage treatment for 15min; patients prone position, with traction rope fixed lumbar disc herniation side of the affected limb, so that the affected limb back to the maximum extent of the extension, and then release the traction rope, simulating the backward extension of the force of the lever positioning manipulation, the medical practitioner does not do any manipulation.
214671406|NCT03711019|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
214671407|NCT03711019|DEVICE|RUL-UB ECT|"In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
214671408|NCT03711019|DEVICE|Bitemporal ECT|"Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
214918323|NCT02913677|DIETARY_SUPPLEMENT|nutrition|Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
214918324|NCT01820598|DEVICE|Multisite NMES training during 6 weeks|
214918325|NCT03114605|BEHAVIORAL|Mindfulness-based Intervention|
214314454|NCT07109934|DEVICE|deep breathing exercises, chest mobilization:|The patients were instructed to engage in deep and gentle inspired breathing, maintain it for 3 seconds, and then exhale gently via the mouth while seated in a semi-sitting posture. During expiration, the patients were instructed to cough twice with maximum efficiency (patients were instructed to maintain a cushion in the incision area during coughing). Thereafter, the patient was provided with an incentive spirometer to be utilized 5 to 10 times daily at intervals of 2 hours. The chest mobilization was conducted five times each set, with three sets assigned to each session Individual participants independently performed chest mobilization under the guidance of a physiotherapist for the first time. The chest mobilization technique involves pulling the arms upwards to their maximum extent while inhaling appropriately during arm movement.
214671409|NCT06097806|OTHER|low and high flow|low and high flow anesthesia are both being used. The effects of different gas flows will be evaluated.
214314455|NCT07100496|COMBINATION_PRODUCT|MIG-SPRAY|"MIG-SPRAY® is a film-forming liquid dressing designed for the preventive treatment of migraine.~Key Features:~* Administration:~  * Applied as 2 sprays per nostril, 3 times daily.~ * Treatment duration: 3 months.~* Mechanism: Forms a protective film on the nasal mucosa, potentially modulating local triggers of migraine.~* Use Case: Prophylactic (preventive) therapy for migraine, intended to reduce attack frequency and severity.~Additional Notes:~* Non-systemic (local action).~* CE-marked as a Class I medical device (under EU Directive 93/42/EEC)."
214671410|NCT04770272|DRUG|Atezolizumab 840 MG in 14 ML Injection|840 mg Day 1 for two weeks
214918326|NCT03891251|OTHER|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
214918327|NCT03390751|OTHER|Data collection|The collection of data will be done by interrogation of the patient and his family / entourage and rereading of medical records
214314456|NCT07108881|DRUG|C|isotonic saline solution infusion (fluid preloading) to achieve correction of hypovolemia before spinal anesthesia using cardiac ultrasoud guidance by measurment of VTI variation after a 250ml saline solution loading, with a maximum of 4 challenges, until hypovolemia complete correction
214671411|NCT04770272|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg Day 1 every 3 weeks for 8 cycles
214918328|NCT02320305|BIOLOGICAL|MART-1 Antigen|Given IM
214918329|NCT02320305|DRUG|TLR4 Agonist GLA-SE|Given IM
214918330|NCT02320305|OTHER|Laboratory Biomarker Analysis|Correlative studies
214918331|NCT03459560|DRUG|PolyPill|After the baseline enrollment and excluding non-eligible participants, we randomized villages to Polypill and control arms. Follow-ups are scheduled for 1, 3, and 6 months after the initial enrollment in the Polypill arm and every six months thereafter. For the minimal care arm, the follow-ups are arranged every six months.
214671412|NCT04770272|DRUG|Carboplatin|Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
214671413|NCT04770272|DRUG|Paclitaxel|Paclitaxel 80 mg/m² IV weekly x 12 cycles
214671414|NCT04770272|DRUG|Epirubicin|90 mg/m2, day 1 for 4 cycles (12 weeks)
214671415|NCT04770272|DRUG|Cyclophosphamide|600 mg/m2, day 1 for 4 cycles (12 weeks)
214481921|NCT06872918|PROCEDURE|Mechanics and kinematics data acquisition of unilateral wrenching patterns in lever positioning manipulation|During the unilateral trigger mode operation of the lever positioning manipulation, the operator wears a mechanics sensing glove to collect the mechanics parameters of the manipulation, including: hand preload force, hand trigger maximum force, elbow compression preload force, and elbow compression maximum force. At the same time, a motion capture system was used to collect the kinematic parameters of the lever positioning manipulation, including: loading backward extension angle, loading backward extension trigger angle, average trigger time, maximum speed, and maximum acceleration.
214481922|NCT06872918|PROCEDURE|Mechanics and kinematics data acquisition of bilateral wrenching patterns in lever positioning manipulation|During the bilateral triggering mode operation of the lever positioning manipulation, the operator wore a mechanics sensing glove to collect the mechanics parameters of the manipulation, including: hand preload force, hand triggering maximum force, elbow pressing preload force, and elbow pressing maximum force. At the same time, a motion capture system was used to collect the kinematic parameters of the lever positioning manipulation, including: loading backward extension angle, loading backward extension trigger angle, average trigger time, maximum speed, and maximum acceleration.
214314457|NCT07108881|DRUG|T|"isotonic saline solution coloading after spinal anesthesia associated with recsue boluses of Ephedrine would be the standard of care in this arm. No correction of hypovolemia is done before spinal anesthesia. parturients receive a cristalloid coloading with saline isotonic solution with rescue boluses of ephedrine if hypotesion happens after spinal anesthesia"
214314458|NCT07109674|DEVICE|adjustable compression device (type circaid® reduction kit, Medi-Bayreuth)|inelastic compression during intensive phase of physical therapy
214314459|NCT07109674|DEVICE|Comparison of inelastic compression efficiency|The effect of compression on volume reduction, physical functioning, disease-related symptoms and comfort
214314460|NCT06912802|OTHER|Non-Intervention|Non-Intervention study
214314461|NCT07108569|OTHER|Lutetia|Lutetia is an AI-based training plattform
214314462|NCT07108478|DEVICE|Transcatheter aortic valve and recyclable delivery system|In this study, the transcatheter aortic valve and its recycling delivery system were VitaFlow Liberty®, a TAVR product independently developed by Shanghai Minimally Invasive Cardiovascular Treatment Co., Ltd. (approved and marketed by NMPA). This product is equipment/consumables routinely purchased by hospitals. For routine clinical use, it is designed for transcatheter aortic valve implantation. The valve is delivered to the intended implantation site via the peripheral artery by retrograde flow through the delivery system, realizing the delivery, positioning and release of the valve. Under the supervision of medical imaging equipment, the valve is delivered to the lesion site of the aortic valve, and marked by the diseased aortic annulus, to release the valve and relieve the stenosis at the lesion site, thereby ensuring smooth aortic flow, improving cardiac function and achieving therapeutic purposes.
214314463|NCT06928337|DEVICE|AI evaluation of oocytes.|AI evaluation of oocytes inside a time-lapse incubator.
214314464|NCT03087201|DRUG|nabiximols|"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks"
214314465|NCT03087201|DRUG|placebo|analogous to experimental intervention
214314466|NCT00947297|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
214314467|NCT00502697|BEHAVIORAL|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
214314468|NCT00502697|OTHER|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
214314469|NCT02804503|BEHAVIORAL|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
214314470|NCT02804503|BEHAVIORAL|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
214314471|NCT02804503|BEHAVIORAL|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
214481923|NCT06872203|DEVICE|Deep brain stimulation|Deep Brain Stimulation programming
214481924|NCT06873503|PROCEDURE|Bracket removal using a Weingart plier with the mouth open|The brackets will be removed using a Weingart plier. The patient will be asked to keep his mouth open during this procedure.
214481925|NCT06873503|PROCEDURE|Biting on a cotton roll during brakcet removal|The brackets will be removed using a Weingart plier. During this procedure, the patient will be asked to bite on a cotton roll.
214918332|NCT03468660|BEHAVIORAL|Auditory training with feedback|Experimental group receives phoneme-level and sentence-level training with feedback
214918333|NCT03468660|BEHAVIORAL|Listening paradigm with no feedback|Active controls listen to acoustic stimuli with no feedback
214481926|NCT06872424|BEHAVIORAL|psychosocial skills-oriented group psychoeducation|A 5-session Psychosocial Skills Focused Group Psychoeducation will be implemented, each session lasting approximately 60-90 minutes. In order to make the training more active and effective, the experimental group will be divided into small groups and divided into 3 groups and each group will be given 5 sessions of Psychosocial Skills Focused Group Psychoeducation once a week.
214918334|NCT02200172|OTHER|Melatonin|Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
214918335|NCT02200172|OTHER|Placebo|
214918336|NCT04299568|DEVICE|Anti gravity treadmill training|Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes
214918337|NCT04299568|PROCEDURE|Physical Therapy|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization
215060977|NCT06374888|DRUG|Neratinib maleate in combination with capecitabine|Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃
214314472|NCT02871843|DRUG|RRx-001 dose escalation with TMZ + RT|Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
214314473|NCT02871843|RADIATION|Radiation|Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
214314474|NCT02871843|DRUG|Fixed dose Temozolomide (75 mg/m2)|Oral temozolomide 75 mg/m2 daily for 6 weeks
214314475|NCT02871843|DRUG|TMZ Maintenance|TMZ maintenance at 150-200 mg/m2
214314476|NCT05857605|OTHER|Exercise for Knee Osteoarthritis|Standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
214314477|NCT05857605|DEVICE|Compact seated elliptical exercise machine- Cubii JR-1|Compact seated elliptical machine exerice program in conjunction with standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
214314478|NCT02041130|DEVICE|Renal Denervation|
214314479|NCT03613506|DRUG|Captopril 12.5 Mg|Taking captopril 12.5mg b.i.d for two months before radiotherapy.
214314480|NCT05724004|RADIATION|SBRT/SRS/radiation therapy|Consolidation radiation therapy (SBRT/SRS/moderately hypofractionated radiation therapy)
214314481|NCT05878613|DEVICE|treadmill training with KT group (TTKT group)|The area to be taped will be cleaned with an alcohol swab, and the I-shaped elastic KT was applied to the four trunk muscles from their insertion to their origin. Patients will then undergo treadmill walking with easy speed control for 20 minutes. The training will be immediately stopped if the subject complain of fatigue during treadmill training; training will be resumed after sufficient rest.
214314482|NCT05878613|DEVICE|treadmill training without KT group (TT group)|General treadmill training without taping will be carried out for the same time as the gait training of the experimental group, and the treadmill speed will also be a comfortable speed in the same manner as in the experimental group.
214314483|NCT02915549|OTHER|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
214481927|NCT06873217|OTHER|Acupuncture|Once a patient with Vertigo and Dizziness came to the emergency department, emergency physicians ask if they were willing to accept acupuncture intervention in addition to the routine western medical care.
214481928|NCT06869083|OTHER|AF application enhancing AF education and drug adhrence|This group will use AF-application. The app will include content related to anticoagulation therapy, such as: medication reminders or intake confirmation for anticoagulants, the importance of anticoagulation therapy in stroke prevention, the role of antiarrhythmic and rate-control medications in symptom management, the necessity of controlling risk factors such as hypertension, diabetes, and hyperlipidemia, and quality of life and cognitive function assessments through questionnaires.
214481929|NCT06869083|OTHER|AF application without enhancing AF education and drug adhrence|This group will use AF-application. However, this application will not contain materials enhancing AF education and adherence.
214481930|NCT06868615|DEVICE|AVAVA|1550nm Non-Ablative Fractional Laser
214481931|NCT06868849|DRUG|JMT203 Injection|"Drug：JMT203 Injection~* Anti-GFRAL monoclonal antibody~* Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1)."
214671416|NCT04770272|PROCEDURE|Biopsy Arm A|1st Biopsy two weeks after Baseline visit. 2nd Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 3rd Biopsy with tumor size greater 10 mm in diameter.
214918338|NCT01171027|PROCEDURE|NOTES Cholecystectomy|The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
215060978|NCT06214676|DEVICE|OCT angiography|Detection of microvascular changes in patients with primary open angle glaucoma by using Optical Coherence Tomography Angiography
214314484|NCT02915549|OTHER|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
214314485|NCT02327429|BEHAVIORAL|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
214314486|NCT04174729|DEVICE|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
214314487|NCT04174729|DEVICE|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
214314488|NCT04174729|DEVICE|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
214314489|NCT04174729|DEVICE|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
214314490|NCT04174729|DEVICE|Linear Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
214314491|NCT04174729|DEVICE|Door Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
214314492|NCT04535596|OTHER|Exercise|12 week long strength training exercises for knee
214314493|NCT04076644|DEVICE|TMS treatment|TMS using either a standard 10hz 20min or 3 min theta burst protocol
214314494|NCT04886167|DRUG|AbobotulinumtoxinA|Injection of platysmal bands.
215060979|NCT04803175|DRUG|Sacubitril-Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
214314495|NCT05124639|BEHAVIORAL|Group self-management support program for anxiety disorders|The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.
214314496|NCT01034917|DRUG|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
214314497|NCT01034917|DRUG|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
214314498|NCT03684200|OTHER|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
214314499|NCT00589108|DEVICE|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
214314500|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
214314501|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
214314502|NCT00002794|DRUG|carboplatin|
214314503|NCT00002794|DRUG|vincristine sulfate|
214671417|NCT04770272|PROCEDURE|Biopsy Arm B|1st Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 2nd Biopsy with tumor size greater 10mm in diameter.
215060980|NCT04803175|DRUG|Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
215060981|NCT05561816|DRUG|Hydroxymethylquinoxalindioxyde|Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
214314504|NCT02707614|PROCEDURE|Robotic vs open prostastectomy|robotic minimal invasive surgery
214314505|NCT04651959|DRUG|AVICOD 200 MG Film Tablet|AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
214314506|NCT04651959|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
214314507|NCT03256552|DRUG|Glycopyrronium MDI 28.8 micrograms|Glycopyrronium MDI 28.8 micrograms
214314508|NCT03256552|DRUG|Glycopyrronium MDI 14.4 micrograms|Glycopyrronium MDI 14.4 micrograms
214314509|NCT03256552|DRUG|Glycopyrronium MDI 7.2 micrograms|Glycopyrronium MDI 7.2 micrograms
214314510|NCT03256552|DRUG|Placebo MDI|Placebo Inhalation Aerosol
214314511|NCT05771428|DRUG|ABBV-552|Oral Capsule
214314512|NCT05771428|DRUG|Placebo for ABBV-552|Oral Capsule
214314513|NCT06270459|DEVICE|HMAN Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
214314514|NCT02283814|DRUG|BIA 2-093|
214314515|NCT02283814|DRUG|Topamax|
214314516|NCT04633408|BEHAVIORAL|STAR-C Virtual Training and Follow-up (STAR-VTF)|STAR-C Virtual Training and Follow-up (STAR-VTF) is adapted from an evidence-based, in-person program that trains family caregivers to manage BPSD (behavioral and psychological symptoms of dementia)
214314517|NCT03722017|OTHER|Deprescribing intervention|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
214314518|NCT06442137|DRUG|Chazhu Xiaozhi decoction|Below is the composition of Chazhu Xiaozhi decoction: Camellia Sinensis Radix 15g, Atractylodis Rhizoma 15g, Herba Gynostemmatis Pentaphylli 15g, Ilicis Cornutae Folium 15g, Alismatis Rhizoma 9g, Nelumbinis Folium 6g, Crataegi Fructus 6g, Polygoni Orientalis Fructus 3g.
214314519|NCT06442137|DRUG|Control placebo|The control placebo is a ten-fold dilution of the Chazhu Xiaozhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug.
214314520|NCT04221295|BEHAVIORAL|Exercise Group|Previously described in the arm/group descriptions.
214314521|NCT06957860|OTHER|Piezotome|Four Intra-lift diamond tips were used for drilling the osteotomy, increasing diameters till a final diameter of 2.8 mm is reached for placement of 3.5 mm diameter and 10-12 mm length implant.
214314522|NCT06957860|OTHER|Densah burs|implant drilling procedures will be done using the surgical drills of the supplier kit of densah burs. Surgical drills of increasing diameters will be used till a final drill diameter of 3 mm for placement of a 3.5 mm diameter.
214314523|NCT05630235|DRUG|CBD/CBD-A|Participants will be administered a one-time dose of 204.6 mg of CBD/CBD-A orally.
214314524|NCT05630235|OTHER|Placebo|The placebo equivalent of the CBD/CBD-A dose administered orally.
214314525|NCT06338345|DIAGNOSTIC_TEST|Therapeutic drug monitoring of beta-lactam|During the 24 first hours after inclusion, 5 blood samples will be collected to mesure plasmatic concentrations of the studied beta-lactam, of creatinin and of albumin
214314526|NCT00003217|BIOLOGICAL|filgrastim|
214314527|NCT00003217|DRUG|cyclophosphamide|
214314528|NCT00003217|DRUG|cytarabine|
214314529|NCT00003217|DRUG|dexamethasone|
214314530|NCT00003217|DRUG|doxorubicin hydrochloride|
214314531|NCT00003217|DRUG|methotrexate|
214314532|NCT00003217|DRUG|vincristine sulfate|
214314533|NCT06193746|DEVICE|non-invasive laser therapy|(diode laser, continuous output, in skin contact mode, 0.005W,0.2cm,beam spot area 0.03cm2, 288j/cm ,1800s) in the morning session, we measured lipid profile and kidney function before and after treatment to measure improvement
214314534|NCT02239250|DEVICE|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
214314535|NCT05253482|PROCEDURE|wet cupping therapy|Vacuum cups will used on different acupuncture points to perform WCT: The one on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra was DU 14 (Dazhui) point; the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra interscapulum region were UB 42 (Pohu) bilateral points; and the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 7th thoracic vertebra were UB 46 (Geguan) bilateral points and additionally the patient's trigger points which we detect during the examination. There will be 5-7 points in total. The technique used will be triple S (Sucking, Scarification, Sucking) in all sessions.
214481932|NCT06870188|OTHER|Composite Restoration|The study included premolar or molar teeth with Class 1 and Class 2 cavity types and a remaining wall thickness of at least 3 mm, which had undergone endodontic treatment from volunteer participants. The teeth randomly assigned were divided into two groups: Group 1: fiber-reinforced composite restoration (FRCR), Group 2: composite restoration (CR). Direct composite restorations with or without fiber reinforced material were applied. The restorations were evaluated at 6 and 12 months using the FDI criteria.
214671418|NCT04770272|PROCEDURE|Surgery|After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.
214314536|NCT05549193|OTHER|Exercises Training|"Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg."
214481933|NCT06870188|OTHER|Clinical evaluation|The restorations were evaluated by two experienced and fully blinded observers according to the functional, esthetic, and biological criteria. The criteria were scored from 1 to 5 (sufficient/acceptable= score 1 to 3, insufficient/inacceptable but repair possible= score 4, and insufficient/inacceptable but repair not possible/reasonable= score 5). Scores of 4 and 5 were considered as failure in the restoration.
214671419|NCT04060992|DRUG|Elagolix 200 MG Oral Tablet [Orilissa]|oral tablet given twice daily
214671420|NCT00467649|DRUG|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
214671421|NCT00467649|DRUG|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
214671422|NCT00467649|DRUG|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
214671423|NCT01851096|DRUG|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
214671424|NCT00807664|DEVICE|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
214671425|NCT00807664|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
214671426|NCT00759629|OTHER|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
215060982|NCT05561816|DRUG|Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium|Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
215060983|NCT03292640|DRUG|DFD-03 (0.1% tazarotene) Lotion|DFD-03 Lotion (0.1% tazarotene) - twice daily application
215060984|NCT03292640|DRUG|DFD-03 (0% tazarotene) Lotion (Placebo)|DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
215060985|NCT02218697|BIOLOGICAL|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
215060986|NCT02218697|BIOLOGICAL|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
215060987|NCT02218697|BIOLOGICAL|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
215060988|NCT05521009|OTHER|Control grup, sticky tube holder|In patients using adhesive tube holders and non-adhesive tube holders, it will be investigated whether there is bacterial growth on the tube.
215060989|NCT04256278|OTHER|Spermotrend|oral administration of antioxidants for three months
214314537|NCT05516251|DEVICE|Transcutaneous Supraorbital Nerve Stimulator|SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
214314538|NCT05516251|DRUG|Topiramate 25Mg Tab|Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
214314539|NCT06329154|DEVICE|Extracorporeal shock wave therapy|The experimental group received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. The control group was only given conventional rehabilitation therapy. According to the patient's tolerance and the specific condition, extracorporeal shock wave therapy was performed twice a week, 2000-3000 times each time, energy parameters of 2.5-3.5Bar, 8-15Hz, treatment interval \> 1 day, consecutive 4 weeks. Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser and wax therapy. Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
214314540|NCT06329154|OTHER|conventional rehabilitation therapy|Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser, and wax therapy (same as the control group). Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
214314541|NCT00741884|DRUG|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
214314542|NCT00741884|DRUG|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
214314543|NCT00741884|DRUG|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
214314544|NCT00741884|DRUG|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
214314545|NCT00741884|DRUG|Placebo|Placebo BID for 7 weeks
214314546|NCT02398552|DRUG|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
214314547|NCT03921710|DRUG|CAPA-IVM|Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin \[SAGE, Denmark\] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
214314548|NCT03921710|DRUG|Standard-IVM|Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
214314549|NCT03289728|OTHER|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with \< moderate ischemia will receive medical treatment only (MT)."
214314550|NCT03289728|PROCEDURE|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
214314551|NCT01195805|DRUG|Spironolactone|1 tablet twice a day for 28 days
214314552|NCT01195805|OTHER|Placebo|1 tablet twice a day for 28 days
214314553|NCT01195805|DRUG|Amiloride|1 tablet twice a day for 28 days
214314554|NCT01398566|BEHAVIORAL|SuperBetter play|average 10 min of game play per day for 6 week period
214671427|NCT00759629|OTHER|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
214671428|NCT02248376|DRUG|Gel|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
214671429|NCT00160927|DEVICE|local heating|
214671430|NCT00160927|DEVICE|iontophoresis|
214671431|NCT00160927|DRUG|actylcholine|
214918339|NCT01171027|PROCEDURE|Laparoscopic Cholecystectomy|This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.
214918340|NCT06450327|OTHER|This is a cross-sectional observational study|There will be no intervention in the study.
214918341|NCT05060276|BIOLOGICAL|STI-3258|Intravenous infusion of STI-3258 will be given (one infusion every three weeks).
214671432|NCT00160927|DRUG|sodium nitroprusside|
214671433|NCT05189899|DEVICE|Virtual reality|One hemodialysis session with virtual reality and one other without it
214314555|NCT03026257|DEVICE|Lotrafilcon B contact lenses with added wetting agent|Silicone hydrogel contact lenses
214314556|NCT03026257|DEVICE|Samfilcon A contact lenses|Habitual silicone hydrogel contact lenses
214314557|NCT03026257|DEVICE|POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Multi-purpose disinfecting solution for contact lens care
214314558|NCT03026257|DEVICE|Hydrogen peroxide-based contact lens solution with added wetting agent|Solution for contact lens cleaning and disinfecting
214314559|NCT03026257|DEVICE|Senofilcon C contact lenses|Habitual silicone hydrogel contact lenses
214314560|NCT03026257|DEVICE|Senofilcon A contact lenses|Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks
214314561|NCT03026257|DEVICE|Comfilcon A contact lenses|Habitual silicone hydrogel contact lenses
214314562|NCT03026257|DEVICE|Habitual Multi-Purpose Solution (HMPS)|Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
214314563|NCT06482931|OTHER|Quality of life questionnaires|Patients will be asked to fill in two quality of life questionnaires: PACT-Q and EQ-5D-5L.
214314564|NCT04489030|OTHER|Magnifying narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
214314565|NCT00649064|DRUG|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
214314566|NCT05692661|RADIATION|proton plus carbon ion radiotherapy|CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels \[10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx \].
214314567|NCT02218333|DIETARY_SUPPLEMENT|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
214314568|NCT02218333|DIETARY_SUPPLEMENT|Placebo|
214314569|NCT04654533|OTHER|COSC|"COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, \& Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study."
214671434|NCT00040534|DRUG|Farnesyl Protein Transferase Inhibitor|
214671435|NCT04655625|BIOLOGICAL|Group A (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 2-week intervals
214671436|NCT04655625|BIOLOGICAL|Group A (Placebo)|Placebo twice at 2-week intervals
214314570|NCT03372512|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Fluid overload will be assessed by bioimpedance spectroscopy
214314571|NCT04380857|DRUG|Dexamethasone ophthalmic insert 0.4 mg|intracanalicular dexamethasone insert
214314572|NCT04380857|DRUG|Topical Prednisolone Acetate Ophthalmic Drops|"Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue"
214314573|NCT00200954|DIETARY_SUPPLEMENT|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
214314574|NCT00200954|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
214314575|NCT03132051|DRUG|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
214314576|NCT05010928|COMBINATION_PRODUCT|mouthwash with tea|Using tea as a base, supplemented with licorice to make mouthwash to relieve stomatitis.
214314577|NCT04259112|PROCEDURE|high pressure|High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
214314578|NCT04259112|DRUG|deep neuromuscular block|Deep neuromuscular block is defined as PTC 1-2.
214314579|NCT04259112|PROCEDURE|low pressure|Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
214314580|NCT04259112|DRUG|moderate neuromuscular block|Moderate neuromuscular block is defined as TOF twitch 1-2.
214314581|NCT03412916|BEHAVIORAL|GetActive|GetActive is a comprehensive, multimodal treatment that was designed to increase quality of life, resiliency and ability to cope with medical symptoms and stress. This program is rooted in the elicitation of the relaxation response, a non-judgmental state of focused attention and increased awareness.
214314582|NCT03412916|BEHAVIORAL|Get Active with Fitbit|The GetActive Program for Pain with a Digital Monitoring Device (GetActive Fitbit) is identical to the GetActive with the addition of a FitBit for recording of physical activity.
214918342|NCT02887976|DRUG|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor
214918343|NCT02887976|DRUG|Methylprednisolone|Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
214918344|NCT00204776|DRUG|Capecitabine and Oxaliplatin|
214918345|NCT03278327|PROCEDURE|Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.|Endoscopic resection treatment
215060990|NCT00192764|DRUG|high-dose cyclophosphamide|
215060991|NCT04136587|OTHER|Colonic fluid collection during endoscopy for analysis of the bacterial secretome|Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
214671437|NCT04655625|BIOLOGICAL|Group B (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 4-week intervals
214671438|NCT04655625|BIOLOGICAL|Group B (Placebo)|Placebo twice at 4-week intervals
214671439|NCT03233048|DEVICE|ORBERA™ Intragastric Balloon|The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
214671440|NCT01309516|BEHAVIORAL|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
214671441|NCT06430320|OTHER|NA- no intervention|NA- no intervention
214314583|NCT05111132|DIAGNOSTIC_TEST|Fluid challenge (cristalloïd, NaCl 0,9%)|A fluid challenge according to group will be administrated by infusion pump
214314584|NCT00838201|DRUG|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
214314585|NCT03424837|BEHAVIORAL|ASCENT|"ASCENT includes the following components:~* Survivorship care plan created through the ASCENT tool~* Online tool which assesses health care needs and facilitates receipt of care~* A national-level navigator who helps the participant to access support services~* Periodic reminders for the participant to pursue recommended survivorship care"
214314586|NCT03638817|DRUG|Eltrombopag|"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"
214314587|NCT00232908|DRUG|ARV regimen|As prescribed
214314588|NCT00232908|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
214314589|NCT03898765|DIAGNOSTIC_TEST|Dry blood spot screening|Dry blood spot measurement of biomarker for screening biliary atresia
214314590|NCT01442363|DRUG|BLI-1300 low dose|topical ointment
214314591|NCT01442363|DRUG|BLI-1300 high dose|topical ointment
214314592|NCT01442363|DRUG|placebo|topical ointment
214314593|NCT06146036|BEHAVIORAL|HIIT snacks|Cycling Exercise. 3 times per day 6 x 1 min at approximately 85-95% of HRmax
214314594|NCT06146036|BEHAVIORAL|Sprint snacks|Cycling Exercise. 3 times per day one ''all out'' sprint
214671442|NCT05195879|DIAGNOSTIC_TEST|XTR004|Single dose intravenous injection of XTR004. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
214671443|NCT00110643|DEVICE|CoolTouch II laser|
214918346|NCT03278327|DEVICE|Endoscopic resection at month 2 and month 4|"System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.~The device the most used in this case is the system COOK Medical Duett of Laboratories.~The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.~The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane."
214918347|NCT06352112|OTHER|Pelvic Floor Muscle Training|PFMT consisted of both slow voluntary contractions lasting 15 seconds each (5-s contraction, 5-s hold and 5-s relaxation) and fast voluntary contractions lasting 2-s each. A set of exercises included 10 slow and 10 fast voluntary contractions. During the first week, women performed five sets of exercises a day, and the exercises were continued for eight weeks by increasing five sets each week. The exercises were performed as home exercises.
214918348|NCT06352112|OTHER|Hypopressive Exercises|"HE program in which different placements of the upper and lower extremities were used in standing, sitting and supine positions, and the participants were asked to perform the exercises with a hypopressive maneuver to maintain apnea and rib cage expansion for approximately 10 seconds. Exercises were started with three repetitions a day, and then the number of repetitions was increased to five and/or 10, depending on the participant's tolerance. The exercises were performed as home exercises."
215060992|NCT05892419|OTHER|No intervention|There is no intervention
215060993|NCT02569424|BEHAVIORAL|Patient's position|Supine or Trendelenburg strict -20°)
214314595|NCT06146036|OTHER|Control|No exercise, sedentary.
214314596|NCT05372276|OTHER|Assessment 1|Mental Toughness Questionnaire in Sport
214918349|NCT00642564|OTHER|Observational study in Epileptic Patients|Observation study in Epileptic Patients with Migraine and Headache
214918350|NCT04050852|DRUG|Nusinersen Treatments|Antisense oligonucleotide, which targets the SMN2 pre-mRNA, particularly exon 7.
215060994|NCT00460460|DRUG|AZD4877|
215060995|NCT01948479|DEVICE|Optimised instant offloading insole|
215060996|NCT04105959|DRUG|RIST4721|RIST4721 oral solution
215060997|NCT04105959|DRUG|Placebo|Placebo oral solution
214314597|NCT05372276|OTHER|Assessment 2|Sport Imagery Questionnaire
214314598|NCT05372276|OTHER|Assessment 3|The Pittsburgh Sleep Quality Index
214314599|NCT05372276|OTHER|Assessment 4|The Perceived Stress Scale (PSS)
214314600|NCT05829759|BEHAVIORAL|Tele-B6|Participants will be part of the Tele-B6 intervention that includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group (first phase) will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
214481934|NCT06870461|PROCEDURE|Liver surgery / ablation|Any type of liversurgery or CT-guidede liver ablation
214481935|NCT06871514|OTHER|2-DECIDE intervention: decision support for cardiovascular risk management|"The 2-DECIDE intervention consists of:~* Training of healthcare providers in implementing shared decision-making during clinical consultations.~* At least one initial extended outpatient consultation with a trained physician to ensure adequate time for actual understanding of treatment options.~* Decision support based on U-prevent~* Clear communication to the patient is provided in an easily comprehensible format, including pre-visit information, and a post-visit handout of the information and decisions made using the U-prevent medical device. Additionally, the general practitioner receives a letter detailing the outcome and rationale of the shared decision, along with the individual estimates that have informed the treatment choice."
214481936|NCT06871514|OTHER|No Intervention: usual care|Usual care
214671444|NCT02756871|OTHER|online guided self-help intervention for perfectionism|"CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony"
215060998|NCT00293228|DRUG|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
215060999|NCT00293228|DRUG|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
215061000|NCT05329753|DEVICE|Mobile health application|Health intervention through a smartphone application that favors the process of learning
215061001|NCT04068948|DRUG|Meperidine|This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
214314601|NCT05829759|BEHAVIORAL|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (preintervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
214481937|NCT06871995|PROCEDURE|spinal block|All patients will receive spinal anesthesia via midline approach with patients in sitting position established by assistant under complete aseptic conditions. A subcutaneous bleb using Lidocaine 1% through the needle of an insulin syringe followed by minor skin scratch to will help avoiding possible intrathecal dermoid implantation . A lumbar puncture will be performed in L4-L5 or L5- S1 interspace using 25-G 25-mm pencil-point spinal needle . Depth of epidural space is anticipated at 0.1 mm/kg . After getting free flow of cerebrospinal fluid (CSF) hyperbaric bupivacaine (0.5%) in a dose of 0.5 mg/kg (0.1 ml/kg) will be slowly injected in the subarachnoid space . The end of the injection will be taken as time zero for further data recording.
214481938|NCT06873490|DEVICE|Electric stimulation removabel device|The device will be used to stimulate orthodontic tooth movement through a specific design used to deliver the current to the mucosa around the teeth being retracted.
214481939|NCT06873490|PROCEDURE|Traditional retraction method.|In this intervention, the upper anterior teeth will be retracted together backward using the traditional retraction method. No acceleration devices will be used in conjunction with this procedure.
214481940|NCT06872164|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based psychotherapy for PTSD that provides education and teaches skills to challenge the trauma-related beliefs that maintain PTSD symptoms. In this study, CPT has been adapted to include content on the relationship between substance use and PTSD and a focus on harm reduction.
214481941|NCT06872879|OTHER|VEMS Simulation|"Students in the VEMS (Visually Enhanced Mental Simulation) group will receive a structured training programme to improve their PPH management skills. This process consists of three main stages: Theoretical training, skills training and simulation practice.~1.1 hour theoretical training will be given to the students to remind them the basic information about PPH management.~2\. PPH management will be mentally visualised step by step using VEMS materials. Students will be individually involved in the scenario and will apply the steps of PPH management in a mental simulation environment. After the scenario is completed, a 30-minute debriefing session will be organised.~3\. Manikin simulation will be used to evaluate students' PPH management skills. Students' PPH management skills will be evaluated using the Postpartum Haemorrhage Management Observation Form. Attitudes towards the learning process will be measured by applying the Student Satisfaction and Confidence in Learning Scale."
214481942|NCT06872879|OTHER|Hybrit Simulation|"Students in the hybrid simulation group will receive a simulation-based training in which the standard patient and part task trainer are used together. This process consists of three main stages: theoretical training, skills training and simulation practice.~1.1 hour theoretical training to remind basic information about PPH management. 2. Standard patient and part task trainers will be used in the skills training of the students. Students will make patient assessment, check vital signs and plan necessary interventions by contacting the standard patient.After the scenario is completed, a 30-minute debriefing session will be organised.~3\. Manikin simulation will be used to evaluate students' PPH management skills. Students' PPH management skills will be evaluated using the Postpartum Haemorrhage Management Observation Form. Attitudes towards the learning process will be measured by applying the Student Satisfaction and Confidence in Learning Scale."
214481943|NCT06873269|OTHER|Baseline assessment|demographic information (age, gender, ethnicity), relevant medical, surgical and oncological history (number and types of previous treatments), clinical assessment (including Child Pugh score, BCLC stage), functional assessment (ECOG performance status), baseline laboratory findings (liver and kidney function, AFP tumor marker,..), date of diagnosis, baseline imaging characteristics (number, size, location of lesions, portal vein thrombosis, TNM stage) and if available histopathological diagnosis (grade of differentiation, microvascular invasion).
214481944|NCT06873269|RADIATION|holmium-166 radioembolization|Characteristics of treatment: treatment date, predicted target dose in Gy, predicted non-target dose in Gy, target volume in mL, whole liver volume in mL, administered activity in GBq, tumor absorbed dose, normal liver-absorbed dose Aim of TARE: palliative or curative/downstaging
214671445|NCT02039557|GENETIC|NiCord®/CordIn™ (omidubicel)|
214314602|NCT04296006|BEHAVIORAL|Money|Three money values offered as alternatives to cocaine.
214671446|NCT00463970|BEHAVIORAL|Brief Intervention|Physical examination, education and follow up by a physiotherapist
214671447|NCT00463970|BEHAVIORAL|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
214671448|NCT00463970|DIETARY_SUPPLEMENT|Seal oil|20 capsules per day for 3 months
214671449|NCT00463970|DIETARY_SUPPLEMENT|Soy oil|20 capsules per day for 3 months
214671450|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
214671451|NCT04788563|DRUG|Original antihypertensive treatment (compulsively randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
214955169|NCT05781022|PROCEDURE|endoscopic repair of iatrogenic esophageal perforation|"For patients in EG, we began with assessment of the site \& size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
214314603|NCT04296006|DRUG|Cocaine HCl|3 mg/70 kg is available as an alternative to money.
214314604|NCT06134817|DEVICE|Embozene Color-Advanced Microspheres.|"Embozene Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer. The microspheres are intended to occlude vasculature for the purpose of blocking blood flow to a target tissue.~In the study, the abnormal vessels will be embolized with 100 μm Embozene Microspheres solution under direct fluoroscopic visualization to prevent reflux and non-target embolization. Multiple geniculate arteries may be embolized until neovascularity is no longer seen."
214314605|NCT05098132|DRUG|STK-012|pegylated alpha/beta-biased engineered interleukin-2
214314606|NCT05098132|DRUG|pembrolizumab|anti-PD-1 humanized monoclonal antibody
214314607|NCT05098132|DRUG|pemetrexed|antifolate chemotherapy
214314608|NCT05098132|DRUG|carboplatin|platinum chemotherapy
214314609|NCT05673486|COMBINATION_PRODUCT|PENG Block|"With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer is then slid medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks.~Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 100 mg of ropivacaine is then deposited in this plane, lifting the psoas tendon."
214481945|NCT06873269|OTHER|Follow-up phase|"The following data on the performed monitoring after the procedure with clinical assessment, imaging modalities and blood samples as determined by the center, will be collected retrospectively:~* Response: tumor response on imaging, tumor marker (AFP levels) at 3, 6 and 12 months after Ho166-TARE, and thereafter every 6 months until last follow-up or death, date of progression, time to progression after treatment~* Toxicity and safety: side effects, adverse events, hepatic function parameters, presence of ascites or hepatic encephalopathy~* Survival: date of last follow-up or death"
214481946|NCT06873555|DRUG|DC05F01|DC05F01 capsule
214481947|NCT05818384|BEHAVIORAL|Wakaya: Rising Up for Choctaw Youth Curriculum|An experiential, outdoor, nature-based program grounded in Choctaw values. It is a multi-level intervention that increases individual motivation and leadership skills to make healthy behavioral choices for behavior and exercise.
214481948|NCT02422147|PROCEDURE|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
214671452|NCT04788563|OTHER|Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
214671453|NCT04788563|DRUG|Original antihypertensive treatment (voluntarily randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
214314610|NCT05673486|COMBINATION_PRODUCT|Multimodal analgesia|Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and Nefopam 20mg/8h. Frequency of morphine administration depends on the assessed pain.
214314611|NCT06051461|DIETARY_SUPPLEMENT|Oral lipid emulsions|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).
214314612|NCT04434768|BIOLOGICAL|UMSC01|There will be one dose of IV administration in patients with acute ischemic stroke, or one dose of IV administration followed by low or high doses of IA infusion for acute ischemic stroke with or without bridging therapy (i.e. Intravenous rt-PA thrombolysis or intraarterial thrombectomy) with 12 months of follow up after the first treatment.
214481949|NCT06683196|OTHER|Kinesio Taping|3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.
214481950|NCT06683196|OTHER|Rigid Taping|3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.
214671454|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
214671455|NCT04788563|DRUG|Original antihypertensive treatment (preference selection arm)|In this group, patients will maintain their original antihypertensive treatment.
214955170|NCT00257738|BIOLOGICAL|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
214955171|NCT00257738|BIOLOGICAL|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
214955172|NCT01488747|DIETARY_SUPPLEMENT|Coromega Omega-3 Squeeze|660 mg EPA, 434 mg DHA
214955173|NCT01488747|DIETARY_SUPPLEMENT|Coromega Nectar|660 mg EPA, 436 mg DHA
214955174|NCT01488747|DIETARY_SUPPLEMENT|Barleans Swirl|660 mg EPA, 660 mg DHA
214955175|NCT01488747|DIETARY_SUPPLEMENT|Nordic Omega-3 Softgel|660 mg EPA, 440 mg DHA
214955176|NCT03000322|DEVICE|Cooling Vest|A cool therapy device intended to provide moderate, controlled cooling (approximately 15C/59F) by absorbing heat. The material in the vest is safe, non-toxic, and eco-friendly.
214955177|NCT06501599|DIAGNOSTIC_TEST|Medical software (AI-based system)|Retrospective analysis of chest CT images with medical software (AI-based system)
214955178|NCT04153955|BEHAVIORAL|Mobilization|Any movement out of bed
214955179|NCT00699023|DRUG|ezetimibe tablets|ezetimibe tablets 10 mg/die
214314614|NCT05379478|DIAGNOSTIC_TEST|Laboratory assessment of antibody profiles|Antibody profiles will be determined on submitted plasma samples
214314615|NCT05530096|DIAGNOSTIC_TEST|Standard of care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy
214314616|NCT05421897|DRUG|Dinutuximab with Chemotherapy|Rapid infusion of dinutuximab in 4 hours or less
214314617|NCT06366399|BEHAVIORAL|Resistance Exercise Timing|1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises
214314618|NCT03224702|DRUG|M6495|Subjects will receive M6495 on Day 1
214314619|NCT03224702|DRUG|Placebo|Subjects will receive placebo matched to M6495 on Day 1
214314620|NCT02000375|DRUG|DHEA|DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
214314621|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
214314622|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
214314623|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 12.5 mcg|1 dose of 0.5 mL
214314624|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 5.0 mcg|1 dose of 0.5 mL
214314625|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 1.25 mcg|1 dose of 0.5 mL
214314626|NCT01193907|BIOLOGICAL|Vi-polysaccharide vaccine|1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
214314627|NCT02151448|BIOLOGICAL|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
214314628|NCT02151448|DRUG|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
214314629|NCT02151448|DRUG|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
214314630|NCT02151448|BIOLOGICAL|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
214314631|NCT01139528|PROCEDURE|Bouquet pinning of the 5th metacarpal bone|The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
214314632|NCT05155228|BEHAVIORAL|Attachment Regulation and Competency|Trauma informed psychotherapy intervention for children with a history of exposure to trauma and their caregivers.
214314633|NCT05155228|BEHAVIORAL|Treatment as usual|Supportive psychotherapy
214314634|NCT03731533|BEHAVIORAL|WellStart|"1. Five weekly automated text messages linked to an online article on health and wellness.~2. Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~3. Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~4. Three group (up to 20 participants) health coach online visits (60 minutes).~5. Two online group visits with a dietitian in groups of 10-12 participants.~6. Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes)."
214314635|NCT05338190|DRUG|Combination of Rituximab with subcutaneous belimumab|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
214314636|NCT05338190|DRUG|Combination of Rituximab with subcutaneous placebo|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
214481951|NCT06681922|DRUG|Cyclophosphamide, Bortezomib, Abatacept|Drug given for prevention of Graft-versus-Host Disease (GvHD) following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
214918351|NCT05823233|OTHER|Cold application+Deep friction+Home exercise+Eccentric stretching|In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. Simultaneously with the electrical stimulation of the affected arm, the patient will be asked to stretch for 5 seconds and rest for 5 seconds, and doing this 15 times will be considered 1 set. After 1 minute of rest, he will be asked to do this practice for 2 more sets, so 3 sets of 15 repetitions will be completed in total. A total of 12 sessions will be applied 3 days a week for 4 weeks. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
214918352|NCT05823233|OTHER|Cold application+Deep friction+Home exercise|In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
214314637|NCT02119065|PROCEDURE|positron emission tomography|Undergo PET/CT scan
214314638|NCT02119065|PROCEDURE|computed tomography|Undergo PET/CT scan
214314639|NCT01987427|DRUG|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
214314640|NCT01987427|DRUG|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
214481952|NCT06682858|BEHAVIORAL|Group Cognitive Behavioural Therapy|Participants will complete 8 group sessions of a CBT-based intervention designed to help self-regulate sensory difficulties in autistic young people
214481953|NCT06682910|DEVICE|Microtech sensor pressure|Microtech sensor implantation
214481954|NCT01652092|DRUG|Alemtuzumab 0.3 mg|0.3 mg/kg intravenously (IV) on days -12 through -10
214314641|NCT01987427|DRUG|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
214314642|NCT05042882|DIETARY_SUPPLEMENT|Early enteral nutrition|Enteral nutrition via nasojejunal tube
214314643|NCT01073865|DRUG|ZD9393 (Zoladex) 10.8 mg|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
214314644|NCT01073865|DRUG|ZD9393 (Zoladex) 3.6 mg|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
214314645|NCT01839448|BIOLOGICAL|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
214314646|NCT05477563|BIOLOGICAL|CTX001|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan
214314647|NCT00805766|DRUG|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
214314648|NCT03493490|DRUG|Neodolpasse|Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
214314649|NCT03493490|DRUG|Diclofenac|Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
214314650|NCT03493490|DRUG|Placebo|Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
214314651|NCT00600756|DRUG|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
214481955|NCT01652092|DRUG|Cyclophosphamide|cyclophosphamide 50 mg/kg IV on days -9 through -6
214918353|NCT00550043|DRUG|INCB018424|
214918354|NCT00550043|DRUG|Placebo|
214918355|NCT02011633|DRUG|HCP1201 500/10mg|500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
214314652|NCT00600756|DRUG|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
214314653|NCT03827278|DRUG|Voriconazole|"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"
214314654|NCT06355427|DRUG|[18F]F-FAPI PET-CT|\[18F\]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing surgery
214918356|NCT02011633|DRUG|Metformin SR 500mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
214918357|NCT02011633|DRUG|Rosuvastatin 10mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
214918358|NCT02354677|OTHER|In vitro experiments on bronchial epithelial cells|
214918359|NCT00634361|DRUG|ethyl-eicosapentaenoic acid|2 mg per day
214918360|NCT01027520|OTHER|application of coban dressing|application of a intraoperative coban dressing with reapplications following dressing removal.
214918361|NCT02550782|DRUG|Bupivacaine|patient- controlled infraclavicular perineural marcaine infusion
214314655|NCT01767922|DIETARY_SUPPLEMENT|Extramel 10 mg - 140 UI SOD|"Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~* visit V1, so-called inclusion visit (D0),~* visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~* visit V3 at 84 days, tolerance of +/- 3 days, (D84)."
214314656|NCT01767922|DIETARY_SUPPLEMENT|Placebo - Excipient only|
214314657|NCT03287388|PROCEDURE|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
214314658|NCT03287388|DRUG|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
214481956|NCT01652092|DRUG|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
214918362|NCT02550782|DRUG|Dexmedetomidine|patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
214918363|NCT05013320|DRUG|Glycopyrrolate + dexmedetomidine|Intravenous glycopyrrolate before anesthetic induction. Dexmedetomidine administration during the surgery.
214918364|NCT05013320|DRUG|Dexmedetomidine|Dexmedetomidine administration during the surgery.
214918365|NCT04215627|DEVICE|non-invasive monitoring|Comparing the PiCCO monitor to the non-invasive BB-613PW device in hemodynamically unstable critically ill patients in the ICU
214918366|NCT05032027|OTHER|probiotics|recieving probiotics at the first day of chemoradiotherapy daily
214918367|NCT01493674|DIETARY_SUPPLEMENT|folic acid|two 5-mg tablets of folic acid
214918368|NCT03771560|DRUG|folinic acid|subject will take folinic acid daily for 12 weeks
214918369|NCT01095562|DRUG|ABT-126|ABT-126 Dose 1, ABT-126 Dose 2
214918370|NCT01095562|DRUG|Placebo|Placebo
214918371|NCT03111680|OTHER|environmental intervention|a multi component environmental intervention
214918372|NCT04145180|OTHER|Manual therapy|40 minutes of physiotherapy, based on manual therapy sessions over 6 weeks. Three times a week.
214918373|NCT04273529|DRUG|thalidomide|100mg，po，qn，for 14 days.
214918374|NCT04273529|DRUG|placebo|100mg，po，qn，for 14 days.
214918375|NCT01106560|PROCEDURE|Minimally Invasive Anterior Approach|Anterior minimally invasive surgery (AMIS)
214918376|NCT01106560|PROCEDURE|Standard postero-lateral approach|
214918377|NCT05504980|PROCEDURE|Repositioning|Patients in the intervention group will be given 30 degrees right lateral, supine, and 30 degrees left lateral positions, 1 hour apart, respectively.
214918378|NCT03917446|DRUG|Propofol bolus|Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.
214955180|NCT00699023|DRUG|simvastatin tablets|simvastatin tablets 20 mg/die
214955181|NCT00699023|DRUG|placebo|placebo
214314659|NCT03287388|DRUG|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
214671456|NCT03518957|BEHAVIORAL|Exercise|"Week 1: Patients will undergo an introductory session where the occupational therapist will assess the general condition and physical fitness of the subjects.~Week 1 to Week 12: Group exercise sessions supervised by a physiotherapist, twice per week, each session lasting 1 hour, with no more than 8 participants in each group exercise session. The exercise regimen for each session will be personally tailored for the subjects, and will include stretching, cardiovascular and strength training, and cooling down exercises.~Week 12 onwards: Patients will receive phone calls- monthly for the first 6 months and then 3 monthly up to the 2-year mark, to encourage them to continue with their exercise regimen at home."
214918379|NCT02744729|DRUG|99mTc-3PRGD2|For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
214918380|NCT01653821|PROCEDURE|Carotid body excision|
214918381|NCT05655364|OTHER|Mobile application|Breastfeeding Supportive Mobile Application
214918382|NCT05510479|OTHER|Software as medical device|At home measurements of visual acuity through a mobile app
214918383|NCT02063477|DIETARY_SUPPLEMENT|Placebo|The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule
214918384|NCT02063477|DIETARY_SUPPLEMENT|Oligopin®|"Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:~\- TOTAL POLYPHENOL CONTENT \> 96~1. MONOMERS + PHENOLIC ACIDS 30~2. DIMERS \>15~3. OTHER OLIGOMERS 50~PROCYANIDINS CONTENT (GPC) \> 67~The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule"
214918385|NCT04124211|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT will be performed through transendoscopic enteral tubing (TET) within one week during treatment period
214918386|NCT02499211|OTHER|Intervention stores|"In-store marketing strategies will focus on placement and promotion of healthier items (lower calorie options) in the milk, frozen food, beverage checkout cooler, bread, salty snacks, and cheese sections of the store.~Intervention efforts in the dairy section promote lower calorie milk (skim, 1%, and 2%), while diminishing the presence of whole milk. The visual order of the milk displays will be changed, and the number of facings, or the fronts of packages the consumer can see, of whole milk will be decreased by 30% while increasing the facings of the lower calorie milk. In the other product categories, target products will be moved to eye level and the number of facings will be increased.~Call-out signs will be placed by the target products that list the name and price of the product. No health information or claims will be included. Signage will be rotated monthly to increase the chances that customers will notice them."
214918387|NCT05586347|DRUG|Nicardipine|Nicardipine 0.2-0.5μg/(kg·min) was infused at the beginning of CPB.
214918388|NCT05586347|OTHER|normal saline|It has the same capacity as group N。
214918389|NCT04412109|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization for postoperative pain control
214918390|NCT02887183|DRUG|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
214918391|NCT05353751|BEHAVIORAL|Kind Minds Program|"The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude."
214918392|NCT04883983|DRUG|Open Label Placebo|Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.
214918393|NCT04883983|DRUG|Patient medication as standardly prescribed|Pain medication will be prescribed per standard treatment for initial prescription. On request for additional pain medication, pain medication will be prescribed as per the standard protocol. Pain assessment surveys will be used at 2, 6, and 12 week followups.
214918394|NCT05294055|DRUG|Etoposide|Etoposide 1.5-1.8g/m2, single dose
214918395|NCT05294055|DRUG|Cyclophosphamide|Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
214918396|NCT05294055|DRUG|Mecapegfilgrastim, day 2|Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
214918397|NCT05294055|DRUG|Mecapegfilgrastim, day 5|Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
214918398|NCT06786195|OTHER|Whole-body vibration and Jumping|The subjects were first asked to jump in place 20 times, as if they were jumping rope. Then, whole-body vibration was applied. While the participants stood upright on the whole-body vibration device, low-amplitude (1.2 mm) vibrations were applied at eight different frequencies (25, 27, 29, 31, 33, 35, 37, 39 Hz), each lasting for 10 seconds, with a 5-second rest period in between. The Achilles tendon will be percussed 10 times with an electronic reflex hammer.
214314660|NCT00757835|DRUG|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
214314661|NCT00757835|DRUG|latanoprost/timolol fixed combination drops|once in the evening
214314662|NCT05300165|DIETARY_SUPPLEMENT|Beer|A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
214314663|NCT03800498|OTHER|DASH Education|DASH health education about general knowledge of DASH diet Plan and lifestyle modification
214314664|NCT06068569|BIOLOGICAL|GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)|Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed. 1st injection - component I, 2nd injection - component II.
214314665|NCT00838227|DRUG|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
214671457|NCT00446212|DRUG|Propofol|target controlled infusion of propofol
214671458|NCT00446212|DRUG|desflurane|Anaesthetic maintenance with desflurane
214314666|NCT04503564|DEVICE|coil-reinforced soft polymer indwelling cannula|This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).
214314667|NCT06001658|DRUG|Gemcitabine|Patients will receive treatment on Day 1 and Day 8 of each cycle. Gemcitabine (1000 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
214481957|NCT01652092|BIOLOGICAL|Stem Cell Transplantation|"Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be \> 5.0 x 10\^7 nucleated cells/kg."
214314668|NCT06001658|DRUG|Cisplatin|Patients will receive treatment on Day 1 and Day 8 of each cycle. Cisplatin (25 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
214481958|NCT01652092|DRUG|Fludarabine phosphate 40 mg|40 mg/m\^2 IV on days -5 through -2 (for children \< 6 months and/or \< 10 kg weight dose at 1.33 mg/kg)
214481959|NCT01652092|DRUG|Melphalan|140 mg/m\^2 IV on day -3
214481960|NCT01652092|DRUG|Alemtuzumab 0.2 mg|0.2 mg/kg intravenously (IV) on days -14 through -10
214314669|NCT06001658|DRUG|Pembrolizumab|Patients will receive treatment on Day 1 of each cycle. Pembrolizumab (200 mg) will be administered IV on Day 1 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery. Pembrolizumab (400 mg) will be administered IV Q6 weeks up to 4 cycles as maintenance.
214481961|NCT01652092|DRUG|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
214481962|NCT01652092|DRUG|Fludarabine phosphate 30 mg|fludarabine 30 mg/m\^2 IV on days -8 through -4
214481963|NCT01652092|DRUG|MESNA|administered as per the standard institutional protocol.
214671459|NCT06038448|PROCEDURE|Urinary catheter balloon size|The investigators will collect 120 participants divided into two groups ,in different procedure(stone procedure, herniarraphy, nephrectomy), and the investigators used different urinary catheter balloon size(10ml and 5ml), tp investigate the patient with the severity of catheter-related bladder discomfort.
214481964|NCT06685146|OTHER|Glucagon Infusion|A 240 minutes infusion of glucagon (10 ng/kg/min)
214314670|NCT05850936|DRUG|Assigned Interventions: IOP-lowering eye drops|IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment.
214481965|NCT06685146|OTHER|Glucose clamp|A 240 minutes infusion of 20 % w/v glucose. The infusion rate of glucose will be adjusted continuously to match the levels of glucose measured on the glucagon study day.
214481966|NCT06682520|OTHER|Postpartum NEST-Rural Program (Hospital based service model)|NEST-Rural services will include 3-5 nurse encounters and, if indicated, up to 3 social work encounters with mothers and their infants in the postpartum period, postpartum remote blood pressure monitoring, breastfeeding support, infant weight checks, linking mothers and infants to needed social, behavioral, and health-related resources, and integration of service delivery with healthcare providers.
214481967|NCT06684119|DEVICE|Electrical Impedance Tomography positive end-expiratory pressure titration|A PEEP titration will occur for the patient with the PEEP increased by 2 cm H2O every 2 minutes until a maximum PEEP of 20 or three steps (+ 6 cm H2O) above the set clinical PEEP. The PEEP will then be decreased by 2 cmH2O every 2 minutes until a minimum PEEP of 6 cmH2O or three steps (- 6 cm H2O) below their clinical PEEP.
214481968|NCT06682273|OTHER|Thread-embedding acupuncture|Thread-embedding acupuncture is performed every week for 4 weeks, using a single Polydioxaone thread inserted into acupoints on the body through the needle. After the thread is inserted, the needle will be immediately withdrawn.
214481969|NCT06682273|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into therapeutic points on the ear. The patches with the needle will remain in place for one week.
214671460|NCT05616234|PROCEDURE|Resistance Exercise|Participants will perform a bout of lower body resistance exercise consisting of leg press, leg extension and leg curls.
214671461|NCT03154450|DEVICE|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
214671462|NCT03154450|DEVICE|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
214918399|NCT06778096|BEHAVIORAL|Postnatal anxiety and depression iCBTprogram|The overarching goal of this stand-alone program is to introduce women to CBT skills to help manage symptoms of anxiety and depression, such as psychoeducation, cognitive restructuring and problem solving, behavioural activation, graded exposure and relapse prevention. Each lesson is accompanied by practical homework and resources (e.g., medication during breastfeeding, attachment and bonding, information for entourage, sleep, self-care, intrusive thought, problem solving), and is built to be easily generalizable to a broad range of women. The three lessons must be completed within a 6-week period, with up to two weeks to complete each lesson. Participants will be notified of new lessons available via email and text message reminders. There is a 5-day lockout between lessons stopping the participants to complete the next session once a session is completed to ensure that the sessions are completed over multiple weeks to allow for revision and practice.
214918400|NCT05262361|BEHAVIORAL|Office-based Vergence and Accommodative Therapy|Office-based Vergence and Accommodative Therapy has four phases which start with gross vergence and accommodation. Disparity vergence is isolated using instruments such as vectograms and accommodation is isolated using near far charts and accommodative rock. The final phase includes the integration of vergence and accommodation to increase range and visual comfort which performing activities close to the person.
214918401|NCT04458545|BIOLOGICAL|Oxy(Gly)4-sKLH vaccine - Low Dose|Oxy(Gly)4-sKLH vaccine - Low Dose
214918402|NCT04458545|BIOLOGICAL|Oxy(Gly)4-sKLH vaccine - High Dose|Oxy(Gly)4-sKLH vaccine - high dose
214314671|NCT02781870|PROCEDURE|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
214918403|NCT04458545|BIOLOGICAL|Placebo Oxy(Gly)4-sKLH vaccine|Oxy(Gly)4-sKLH vaccine - Placebo
214314672|NCT02781870|PROCEDURE|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
214314673|NCT05368987|DEVICE|Transcranial magnetic stimulation (TMS)|Research subjects will undergo non-invasive TMS, with a frequency of 20Hz and intensity of 120% of their resting motor threshold (rMT) at varying time points and locations.
214314674|NCT05368987|BEHAVIORAL|Fear Conditioning and Extinction Paradigm|"Participants will undergo a 3-day experimental paradigm. On day 1, participants will undergo a resting-state and structural scans in the fMRI scanner. The data from this scan will be used to determine the specific location of the TMS target for each participant. And participants will be aversively conditioned to two cues in the fMRI scanner. Task based and resting-state scans will occur on this day.~On day 2, subjects will undergo extinction training outside of the scanner where one of the conditioned cues will be paired with TMS in a temporally and anatomically specific manner. A resting-state scan will occur before and after inside the scanner.~On day 3, conditioned cues will be presented during the extinction recall phase of the study. This phase will be conducted in the fMRI scanner. Task-based and resting-state scans will occur on this day."
214314675|NCT04180761|DRUG|intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)|single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy
214314676|NCT06394544|DIETARY_SUPPLEMENT|Brazil Nut|The intervention, for each participant, is estimated to last a total period of six months , which will be divided into three two-month stages, with data collection after each stage. Volunteers will be monitored to control possible side effects, doubts and check compliance. In addition, the telephone number and an email will be made available for contact during business hours, for possible clarifications.
214314677|NCT04941950|BEHAVIORAL|PlaySmart|PlaySmart is designed to provide players with behavioral skills and knowledge through repetitive and engaging videogame play to target adolescent perception of risk of harm from initiating opioid misuse.
214314678|NCT04941950|OTHER|Video Game Control|Participants in the control group will play another video game with no intended effect similar to PlaySmart.
214314679|NCT06563401|OTHER|prognosis of adult-onset t1d|We are comparing mortality and vascular outcomes in adult-onset T1D to T2D and diabetes-free people
214314680|NCT03699397|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
214314681|NCT03762096|DIETARY_SUPPLEMENT|Trans-resveratrol|1 gram, twice a day by mouth Transmax (Biotivia)
214314682|NCT03762096|DIETARY_SUPPLEMENT|Placebo|Placebo
214314683|NCT02747836|OTHER|Ultrasound of the wrist|using sound waves to create images capturing the movement of the SSCT and flexor tendon and transformation of the median nerve in the wrist
214314684|NCT06367348|BEHAVIORAL|Mlambe|A combined economic and relationship-strengthening intervention. Sessions consist of incentivized savings accounts, financial literacy training, and relationships skills building, including couple communication.
214314685|NCT05407623|BEHAVIORAL|PAX Good Behavior Game|"PAX GBG is packaged into ten specific tools that the teachers are trained to introduce in in their classroom management practice. The program introduces verbal and visual cues that facilitate prosocial and attentive behaviors One of the core elements of the program is the PAX-game, meaning that the children - while focusing on ordinary school tasks like math - get to play a game in teams where each team tries to make as few classroom rules infractions as possible during a certain period of time. The teams that succeed in achieving predetermined goals get a reward (often a fun and desirable activity) that serves as a reinforcer of prosocial and task-oriented behaviors.~Supervision is performed individually with each teacher and included that the PAX-trainer observes a lecture given by the teacher before each supervision session."
214481970|NCT06682273|OTHER|Sham thread-embedding acupuncture|Sham thread-embedding acupuncture is performed every week for 4 weeks, using the needle without thread inserted into acupoints on the body. After insertion, the needle will be immediately withdrawn, and no thread will be left in the body.
214481971|NCT06682273|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into non-therapeutic points on the ear. The patches with the needle will remain in place for one week.
214481972|NCT06684639|BIOLOGICAL|GD2-CAR-T cell|Split intravenous infusion of GD2-CAR-T cells \[dose escalating infusion of (1-100)x10\^6 GD2-CAR-T cells/kg\]
214481973|NCT04107116|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
214481974|NCT04107116|OTHER|Usual Care|Usual care as provided by local oncologists
214481975|NCT06682286|OTHER|NIV mask A|Bridge free face mask
214481976|NCT06682286|OTHER|NIV mask B|Full face mask
214671463|NCT01073072|PROCEDURE|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
214918404|NCT05047965|PROCEDURE|Dixon MRI|Undergo Dixon MRI
214918405|NCT05047965|PROCEDURE|Magnetic Resonance Imaging|Undergo standard MRI
214918406|NCT06050356|BIOLOGICAL|H107e|Participants will receive two i.m. injections of 20 µg unadjuvanted H107e on Day 1 and Day 29
214918407|NCT06050356|BIOLOGICAL|CAF®10b|Participants will receive two i.m. injections of CAF®10b (full adjuvant dose) on Day 1 and Day 29
214918408|NCT06050356|BIOLOGICAL|H107e/CAF®10b - low adjuvant dose|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (low adjuvant dose) on Day 1 and Day 29
214918409|NCT06050356|BIOLOGICAL|H107e/CAF®10b - full adjuvant dose|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
214671464|NCT01073072|PROCEDURE|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
214671465|NCT01411540|DIETARY_SUPPLEMENT|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
214314686|NCT05407623|BEHAVIORAL|Count on Me!|"Count on me! is set in adventure game where the child has an avatar that travels thru different worlds/platforms by using their mathematical skills. The child starts of in the home of the avatar, in a house like environment, where the child discovers a magical map that brings the child into a different world called Numberia. During the adventures in Numberia the child learns that it has certain skills, called the mathemagical powers, that will be used to liberate Numberia from the evil Prince Claw that has captured all the beautiful things (e.g., the birds that used to sing in the forest).~Count on me! was developed within a behavior analytic framework using a nonlinear programming process."
214314687|NCT05407623|BEHAVIORAL|Collegial Learning Community|"Collegial learning community is a feasible way of professional learning for teachers according to the five cyclical steps. The teachers go through the first step that is to assess the skill or knowledge gaps for students, using various data sources (for example testing, grades, surveys, student interviews). The second step is to reflect upon what skills the teacher needs to acquire in order to help the students to meet the goals. The third step is to deepen the professional knowledge and skills. The fourth step is engaging the students in the new practice, and in the fifth step to evaluate the impact the new practice has had on student outcomes.~In Collegial learning community teachers take help from their peers in each of these steps in a structured way. For example, way of deepening tacit or procedural knowledge (in step two) is to visit a colleague during class and make observations on their classroom practice."
214314688|NCT06024668|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
214481977|NCT06684470|DRUG|Mirtazapine|mirtazapine will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.
214918410|NCT06050356|BIOLOGICAL|Low dose intranasal H107e|Participants will receive one i.n. administration of 15 µg H107e (low dose intranasal H107e) on Day 85
214481978|NCT06684470|OTHER|Placebo|Placebo will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.
214481979|NCT06685224|DIAGNOSTIC_TEST|Ultrasound Assessment of the aeration of lung tissue and Parasternal Intercostal Muscle Thickness|Examine the predictive value of lung ultrasound in assessing the success of SBTs and tracheal extubation among patients receiving mechanical ventilation in the intensive care unit (ICU)
214481980|NCT06682702|OTHER|DNS Group|ISST Schroth exercises are a model of exercise aimed at correcting scoliosis in three dimensions. Dynamic neuromuscular stabilization exercises, on the other hand, are designed to achieve sagittal stabilization by utilizing the stabilizing function of the thoracic diaphragm muscle.
214481981|NCT06682702|OTHER|Schroth Group|ISST Schroth exercises are a model of exercise aimed at correcting scoliosis in three dimensions.
214481982|NCT04371081|DEVICE|Amplatzer Piccolo Occluder|Interventional placement of vascular occluder
214481983|NCT05471947|DRUG|15% Trichloroacetic acid + 3% glycolic acid|Treatment of the hand with an over-the-counter chemical peel containing 15% trichloroacetic acid + 3% glycolic acid
214671466|NCT05785338|DIAGNOSTIC_TEST|Posterior angle of the hard palate|Fetal ultrasound
214671467|NCT02712684|PROCEDURE|multiparametric MRI. Multi-parametric ultrasound|The investigators aim to test the hypothesis that multiparametric ultrasound is able to detect clinically significant prostate cancer with an accuracy that is similar to multiparametric MRI. Multi-parametric ultrasound uses different types of ultrasound images to visualise different aspects of the tissue. In other words, the standard grey-scale images shows the gross anatomy, Power Doppler and Contrast enhanced Ultrasound image blood supply (cancers have more blood supply), and Real-Time Elastography images the density of tissue (cancers are more dense).
214671468|NCT01883583|DEVICE|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
214671469|NCT01852344|DRUG|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
214671470|NCT01852344|DRUG|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
214918411|NCT06050356|BIOLOGICAL|Full dose intranasal H107e|Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 85
214918412|NCT06050356|BIOLOGICAL|H107e/CAF®10b|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
214918413|NCT06050356|BIOLOGICAL|i.m. placebo|Participants will receive two i.m. injections of placebo on Day 1 and Day 29
214918414|NCT06050356|BIOLOGICAL|BCG|Participants will receive one i.d. injection of BCG on Day 1
214481984|NCT06683144|BEHAVIORAL|Exposure feedback|"* Determining the actual SHS exposure risk level and providing feedback.~* Determining the urinary cotinine test result and providing feedback.~* Feedback on the consistency or difference between the perceived SHS exposure risk level and the actual SHS exposure risk level."
214671471|NCT01852344|BEHAVIORAL|Easy Behavioral Task|Subjects do an easy version of the Letter E Task.
214918415|NCT06050356|BIOLOGICAL|i.d. placebo|Participants will receive one i.d. injection of placebo on Day 1
214918416|NCT06050356|BIOLOGICAL|Intranasal H107e|Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211
214918417|NCT04722315|DIETARY_SUPPLEMENT|Modified Atkins diet|12 weeks of modified Atkins diet
214918418|NCT04540900|BIOLOGICAL|KB301|non-integrating HSV-1 vector expressing human type III collagen
214918419|NCT04540900|OTHER|Placebo|sterile isotonic saline
214314689|NCT01510678|BEHAVIORAL|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F\&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F\&Vs is perceived cost of these foods, information regarding lower-cost options for F\&Vs will be included in the manual.
214314690|NCT01510678|BEHAVIORAL|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to \< 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
214314691|NCT01510678|BEHAVIORAL|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
214314692|NCT02049242|PROCEDURE|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
214314693|NCT02049242|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
214314694|NCT01424982|DRUG|Cyclophosphamide|Given IV
214314695|NCT01424982|DRUG|Cytarabine|Given IV
214314696|NCT01424982|DRUG|Dexamethasone|Given IV or PO
214314697|NCT01424982|DRUG|Doxorubicin|Given IV
214314698|NCT01424982|DRUG|Doxorubicin Hydrochloride|Given IV
214314699|NCT01424982|OTHER|Laboratory Biomarker Analysis|Correlative studies
214481985|NCT06683144|BEHAVIORAL|Interactive education|Slide presentation, video presentation, Q\&A, evaluation of learning and discussion of results
214314700|NCT01424982|DRUG|Methotrexate|Given IV
214314701|NCT01424982|DRUG|Ponatinib|Given PO
214481986|NCT06683144|BEHAVIORAL|Social media post|Sharing informational materials such as messages, brochures, and videos related to SHS exposure, including ways to protect yourself from SHS exposure and the adverse health effects of SHS exposure.
214481987|NCT06685692|DRUG|ADX-629|125 mg twice daily for 28 days
214918420|NCT02367846|DRUG|Combined Oral Contraceptive (COC)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
214918421|NCT02367846|DRUG|Contraceptive Vaginal Ring (CVR)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
214314702|NCT01424982|DRUG|Ponatinib Hydrochloride|Given PO
214314703|NCT01424982|DRUG|Prednisone|Given PO
214314704|NCT01424982|BIOLOGICAL|Rituximab|Given IV
214314705|NCT01424982|DRUG|Vincristine|Given IV
214314706|NCT01424982|DRUG|Vincristine Sulfate|Given IV
214481988|NCT06685692|DRUG|ADX-629|250 mg twice daily for 28 days
214481989|NCT06685289|DRUG|Donafenib|200mg, oral, twice daily, continuous medication for 6 months
214481990|NCT06685289|DRUG|capecitabine|1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)
214481991|NCT06407700|PROCEDURE|Brugger's exercise.|Participant was in a high sitting position. An elastic resistance band was be wrapped on each hand of the participant leaving the palm open and instructed to abduct and extend of thumb along with fingers, followed by wrist extension and forearm supination, the participant were instructed to perform scapular retraction with chin tucked in ,shoulder external rotation, elbow extension, shoulder abduction, and extension. Intervention was started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time was 30 seconds, 4 sets 12 times repetitions.
214481992|NCT06407700|PROCEDURE|Kendall Exercise.|Kendall exercises with the frequency 5 sets of consisting of 12 repetitions of postures, each taking 30 seconds,3 times a week for total of 6 weeks.
214671472|NCT01852344|BEHAVIORAL|Hard Behavioral Task|Subjects do a hard version of the Letter E Task.
214314707|NCT03611868|DRUG|Phase 1b: APG-115+pembrolizumab|"dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrateddose escalation of APG-115 in combination with label dose of pembrolizumab, Fourfour dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as there are cycles every 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.~Phase II: Combination of APG-115 at 150 mg (RP2D) and pembrolizumab or APG-115 monotherapy alone."
214918422|NCT06188364|OTHER|Standard of Care|The usual Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge, so the the delivery of traditional CHW outreach services such as finding health, community and social determinants referrals, problem-solving, and connecting care partners to long-term supports/services
214918423|NCT06188364|OTHER|Experimental|"Novel aspects of the CHW experimental intervention for TBI care partners include:~1. CHW services begin prior to inpatient rehabilitation discharge;~2. care partners get timely, useful health management materials;~3. encounters focus on unlimited, brief, situation-focused calls to help care partners assess and resolve pressing concerns; and~4. long-term support capacity for care partners is built by establishing a reliable referral network of medical, community, and social services that become foundational resources beyond study completion."
214918424|NCT05398302|PROCEDURE|Image Guided Biopsy|Undergo image-guided biopsy
214918425|NCT00990392|DRUG|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
214918426|NCT00990392|OTHER|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
214918427|NCT05893147|OTHER|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result)~De-escalation group: switched to narrower spectrum antibiotic."
214918428|NCT05893147|OTHER|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.~Non beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime."
214314708|NCT04203381|DEVICE|GnRH Agonist|Forty participants who are transgender and who have been prescribed a gonadotropin-releasing hormone (GnRH) agonist by their physician will undergo magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) scans at baseline, at 12 months and at 24 months after initiation of the GnRH agonist therapy. This longitudinal observational study of two cohorts seeks to identify significant changes in bone marrow adiposity and bone density over 24 months. The same assessments will be obtained in 40 healthy control subjects matched for age, race/ethnicity and body mass index, all factors that are known to influence skeletal outcomes. The evaluations of bone marrow adiposity will be correlated with bone density measurements and the assessments of mood (validated anxiety and depression scales) and health-related quality of life, before and after pubertal blockade.
214314709|NCT05368545|DRUG|High intensity lipid lowering|Two different regimens of drugs with different effects on LDL lowering
214481993|NCT05925621|DRUG|Lecanemab|Observational study
214481994|NCT05473663|DEVICE|Radiofrequency Ablation|Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.
214481995|NCT05473663|DEVICE|Sham|Is performed identically to the active treatment but without the application of the RFA current
214481996|NCT06687590|DEVICE|Peripheral balloon angioplasty|Serration balloon angioplasty of iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries, or dysfunctional native or synthetic arteriovenous dialysis fistula
214481997|NCT06243835|DRUG|Kindolor Tosylate|Kindolor Tosylate enteric coated tablets containing the specified amount of drug product
214481998|NCT06243835|DRUG|Placebo|Placebo enteric coated tablets identically matched to the Kindolor Tosylate tablets with equal amount of Prosolv SMCC replacing the Kindolor Tosylate
214481999|NCT04189146|BEHAVIORAL|Inner Engineering Intervention|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
214482000|NCT06688721|DEVICE|Driving a bus equipped with EDA|Eco-driving assistance (EDA) systems is a technology integrated into vehicles that helps drivers to optimize fuel efficiency and reduce emissions by providing real-time feedback and guidance on driving behaviors. The system typically analyzes several driving behaviours that are measured using different captors and sensors. These systems aim to reduce the overall carbon footprint of driving, leading to cost savings for the public transport company and reduced environmental impact.
214482001|NCT06688214|OTHER|Kinesio Taping treatment|Therapeutic KT application administered to patients in group A. The KT treatment was completed in compliance with Kase's recommended methodology for rotator cuff tendinitis/impingement. Initially, an inhibitory approach was used to apply a supraspinatus Y-strip from its insertion to its origin. The measurement of the strip's length was taken from the acromion to the scapular spine. The base of the strip was later applied to the tuberculum major while the patient was seated; the superior tale of the Y-strip was then terminated at the superomedial angle of the scapula, passing between the middle and superior fibers of the trapezius with light tension (% 15-25); the shoulder was then extended, adducted, and internally rotated with cervical contralateral bending; the final portion of the tape (2.5-5 cm) was applied painlessly.
214314710|NCT06473480|DEVICE|Abbott FreeStyle Libre System 2 Plus|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
214314711|NCT06473480|DEVICE|Abbott Freestyle Libre Pro|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
214314712|NCT05740787|OTHER|No intervention|Observation only
214314713|NCT04598035|DIAGNOSTIC_TEST|Diagnostic Tests|"1. Blood and Urine laboratory tests~2. ECG and blood pressure for cardiovascular measurements~3. Self-report questionnaires about pain"
214314714|NCT05222932|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
214314715|NCT05222932|DRUG|Avelumab|Anti-PDL1 antibody
214314716|NCT02375191|DRUG|fentanyl|
214314717|NCT02375191|DRUG|dexmedetomidine|
214314718|NCT02375191|DRUG|Ropivacaine|
214314719|NCT03261947|DRUG|TAK-931|TAK-931 hard gelatin capsules
214314720|NCT05938751|BEHAVIORAL|TEAm_YOUNG ADULTS program|The TEAm\_YOUNG ADULTS program is an intervention to develop self-determination in young adults with autism. It consists of 20 1.5h weekly sessions. The intervention is conducted by two facilitators with expertise in autism and self-determination promotion. Groups are formed by 4 to 6 participants. The program can be applied online or in person. The first five sessions address specific characteristics and support needs of people with autism. The next ten sessions are focused on the development of self-determination. The last five sessions are focused on working with others and the closure of the group. The individual goals of every participant are considered in the beginning of the group and a weekly follow-up of goals is conducted.
214918429|NCT05893147|OTHER|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is no longer needed."
214918430|NCT05893147|OTHER|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (like Meropenem, Ertapenem etc) at standard doses"
214314721|NCT03969992|DRUG|AeroFact|Aerosolized SF-RI 1
214314722|NCT03969992|OTHER|nCPAP|nCPAP (nasal continuous positive airway pressure) alone
214314723|NCT03967392|DRUG|Xylocaine|TREATMENT
214314724|NCT06110429|DRUG|Lactate, Sodium|Isovolemic and osmotic infusion Comparison of osmotic agent
214314725|NCT06110429|DRUG|Hypertonic saline|Isovolemic and osmotic infusion Comparison of osmotic agent
214314726|NCT04462809|DRUG|Talazoparib|"Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment."
214314727|NCT04244513|DEVICE|Deep brain stimulation|the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
214314728|NCT01141881|DRUG|Tissue Plasminogen Activator,bevacizumab ,follow up|25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
214314729|NCT02487238|BIOLOGICAL|Fecal Microbiota Enema|Active intervention.
214314730|NCT02487238|BIOLOGICAL|Normal Saline Enema|Placebo comparator.
214314731|NCT05951530|OTHER|traditional physical therapy|this group received conventional upper extremity active ROMs and stretches for 30 minutes three to five times a week for 6 weeks without using the app-based cognitive training.
214314732|NCT05951530|OTHER|mobile app-based cognitive training|This group received mobile app-based cognitive training of 30minutes session three to five times a week for 6 weeks which includes a few activities such as the memory, coordination and alertness along with conventional UE exercises for 15 minutes three to five times a week for 6 weeks.
214314733|NCT00929682|DRUG|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
214314734|NCT00525668|DRUG|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
214314735|NCT00525668|DRUG|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
214314736|NCT02758392|DRUG|JNJ-61178104 Intravenous|Participants will receive JNJ-61178104 Intravenously on Day 1.
214314737|NCT02758392|DRUG|JNJ-61178104 Subcutaneous|Participants will receive JNJ-61178104 Subcutaneously on Day 1.
214314738|NCT02758392|DRUG|Placebo|Participants will receive placebo on Day 1.
214314739|NCT02063737|BEHAVIORAL|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
214314740|NCT02063737|BEHAVIORAL|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
214314741|NCT02319005|DRUG|Revusiran (ALN-TTRSC)|
214314742|NCT02319005|DRUG|Sterile Normal Saline (0.9% NaCl)|
214314743|NCT01152463|PROCEDURE|thoracic ultrasound|daily thoracic ultrasound evaluation of the chest
215061002|NCT04068948|DRUG|Hydroxyzine|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
215061003|NCT04068948|DRUG|Midazolam|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
215061004|NCT03306433|DEVICE|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
215061005|NCT04150289|DRUG|Farydak|non-interventional study
215061006|NCT02242058|OTHER|Quantitative sensory testing|
215061007|NCT01769976|OTHER|Periodic fasting|
215061008|NCT01769976|OTHER|Energy restriction|
214314744|NCT00902642|BEHAVIORAL|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
214314745|NCT05464654|DRUG|3 g Polynucleotide vaginal suppositories|3 g polynucleotide vaginal suppositories were administered nightly for 6 days.
214314746|NCT05464654|DRUG|Conjugated estrogens cream 1g Tube|Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
214314747|NCT06522191|OTHER|Physiotherapy Training (PT)|Both groups received the same therapist-led standardized PT for 5 days a week including 2 days of RR plus 3 days of conventional rehabilitation (CR) for 5 weeks. RR training will be given 40 min per session using an intelligent feedback robotic system. The system allows patients to move a cursor to targets on a monitor using a unilateral exoskeleton robotic arm and handle, which supports shoulder, elbow, forearm, and optionally multi-joint movements. The system provides visual and auditory feedback, offering exergame training with 1Dimension (D), 2D, and 3D options adjustable to three levels (low to high). Exergames and their parameters will be customized based on each patient's capacity. The CR protocol consists of joint range-of-motion, correct movement, stretching and balance exercises, gait training (walking on level surfaces, stairs), strengthening of antagonist muscle pattern will be provided. Each CR session will last 45 min of active treatment.
214314748|NCT06522191|DEVICE|Cross-Education Intervention|Participants in the CE group will have the less affected upper extremity undergo game-based, unilateral, repetitive movement training using RR to enhance the effectiveness of the training to be provided to the affected side. Similar therapeutic games (exergames) planned for the more affected upper extremity will be selected through the unilateral exoskeleton RR device. As described in the PT section, upper extremity movements will be performed using the robotic arm and handle during the games. The difficulty level will be adjusted by the supervisor physiotherapist based on the grip threshold on the robotic handle, the game's difficulty level (low to high), workspace arrangement before each session, and suspension level according to the patient's needs. An approximately 20-minute program will be implemented, consisting of 8 games, each lasting about 2.5 minutes, tailored to the patient's capacity.
214314749|NCT06522191|OTHER|Control Intervention|The exercises to be administered in the control intervention will be selected based on the patient's level of impairment but will be planned without progression or intensity increase, and the involvement of the upper extremity will be kept to a minimum. The exercises will include lower limb joint range of motion exercises, weight bearing, weight shifting, and gait training.
214314750|NCT03657355|DRUG|ACT-541468|ACT-541468 will be administered as 50 mg tablets for oral use.
214314751|NCT03657355|DRUG|Suvorexant|Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.
214314752|NCT03657355|DRUG|Zolpidem|Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
214314753|NCT03657355|DRUG|Placebo|Matching-placebo will be used.
214314754|NCT03373383|DRUG|Padsevonil|Padsevonil in different dosages.
214314755|NCT03373383|OTHER|Placebo|Placebo will be provided matching Padsevonil.
214314756|NCT03317431|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
214314757|NCT02261376|DRUG|DS-1971a|DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
214314758|NCT04649775|DEVICE|AirFLO2|Mask device
214482002|NCT06688214|OTHER|Scapular Stabilization Exercises|"Participants in Group B engage in a twice-weekly, supervised SSE exercise program that is based on the clinical decision algorithm that has been recommended by an expert panel. The goal of scapular orientation training was to normalize the scapula's resting posture and enhance proprioception. Subsequently, three scapular control exercises were executed: a closed kinetic chain exercise known as the unilateral bench press, bilateral shoulder flexion up to 60°, and a scapular control exercise including bilateral shoulder retraction and extension in the prone position. There was no discomfort involved in performing the exercises, and each session may consist of no more than four exercises. The dosage and progressions were based on the objectives of each exercise; each exercise was performed 8-10 times with a 5- to 10-second hold in between, and there was a 30-to 1-minute rest period."
214482003|NCT06688955|PROCEDURE|Colonoscopy with Bacteriological Controlled Water|Patient with coloscopy which used Bacteriological Controlled Water : Collection of 250 ml of bacteriologically controlled water from the wash bottle at the end of each water-assisted colonoscopy to test for enterobacteria and fecal streptococci
214918431|NCT05893147|OTHER|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
214918432|NCT04855435|DRUG|MBS8(1V270)|The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
214918433|NCT05582980|DEVICE|HD-tDCS|See detail in arm/group descriptions regarding the intervention.
214314759|NCT02479737|DEVICE|Blood drainage post cardiac surgery using PleuraFlow System|
214482004|NCT06690112|PROCEDURE|Arm I (Drainage tube removal)|During gastrectomy, a drainage tube is placed within the abdominal cavity. In Arm I (the intervention group), the drainage tube will be removed at the bedside. This procedure is a simple intervention that does not require local anesthesia and involves the removal of the drainage tube by cutting the nylon suture.
214482005|NCT06687772|DRUG|Thiotepa|Thiotepa will be given intravenously twice daily on Days -5 and -4 over 120 minutes at a dose of 5 mg/kg.
214918434|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral tablet.
214918435|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral capsule.
214918436|NCT06483191|BEHAVIORAL|Acceptance and Commitment Therapy|A half-day pre-operative virtual ACT group workshop, booster post-operative ACT text messages once a week for 6 weeks and a telephone follow-up with a physiotherapist at 6-8 weeks (all in addition to standard care).
214918437|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
214918438|NCT04015609|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
214314760|NCT04262037|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
214314761|NCT01540058|OTHER|Cancer Type ID test|"CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).~CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York."
214314762|NCT01540058|OTHER|No test Empiric strategy|Empiric strategy
214314763|NCT03184181|OTHER|EPTE® group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
214314764|NCT03184181|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
214314765|NCT03521258|DEVICE|Dehydrated Human Amnion/Chorion Membrane|
214314766|NCT03521258|PROCEDURE|Flap-Based Reconstructive Surgery|Standard of Care surgical intervention
214314767|NCT03616288|DIETARY_SUPPLEMENT|thiamine (as thiamine hydrochloride)|Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).
214314768|NCT04753164|DRUG|ACT-539313|ACT-539313 as capsules at a strength of 100 mg, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
214314769|NCT04753164|DRUG|Placebo|Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
214314770|NCT04602858|DEVICE|Reactive Balance Training|Reactive balance training involves the use of the Trip and Slip walkway that is able to expose participants to unpredictable trips and slips. Trips and slips will occur at random location on the walkway and times within the gait cycle, with the participants receiving 3-monthly retraining sessions along with an educational booklet.
214314771|NCT04602858|OTHER|Control|The control intervention will be receiving an educational booklet as part of standard care. The education component will target a variety of fall risk factors and provide strategies to mitigate these risk factors.
214314772|NCT03774940|DIAGNOSTIC_TEST|peripheric blood count|preoperative peripheric blood count
214482006|NCT06687772|DRUG|Carmustine|Carmustine will be given intravenously on Day -6 over 120 minutes at a dose of 400 mg/m\^2.
214482007|NCT06687772|PROCEDURE|Autologous Stem Cell Transplant|Infusion of autologous peripheral blood stem cells on Day 0.
214482008|NCT06687772|DRUG|Anthracycline-based induction chemotherapy|Standard of care, not dictated by protocol.
214482009|NCT06686992|BEHAVIORAL|Vaccination|The researcher will fill in the questionnaire and scales 5 minutes before the vaccination. During the procedure, the child will be played with roll-and-draw. The scales will be filled in again 5 minutes after the procedure. It will take an average of 5-10 minutes to fill out the forms.
214482010|NCT03087903|DIETARY_SUPPLEMENT|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
214482011|NCT03547271|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular
214482012|NCT03547271|BIOLOGICAL|Meningococcal group A, C, W-135, and Y conjugate vaccine|Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular
215061009|NCT01769976|OTHER|Energy balance diet|
214482013|NCT03547271|BIOLOGICAL|DTaP-IPV-HB-Hib vaccine|Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine
214314773|NCT05019924|DIETARY_SUPPLEMENT|Semaine|The dietary supplement is designed, and marketed commercially to be taken in servings of two capsules per day, up to four times per day (a total of 8 capsules daily). Most consumers, however, will only take a serving three times per day, or one with each major meal (breakfast, lunch and dinner).
214314774|NCT00694369|DRUG|Comparator: etoricoxib|etoricoxib 90 mg; 120 mg (once daily) over three days.
214314775|NCT00694369|DRUG|Comparator: ibuprofen|ibuprofen 2400 mg (600 mg Q6h) over three Days
214314776|NCT00694369|DRUG|Comparator: acetaminophen + codeine|acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
214314777|NCT00694369|DRUG|Comparator: placebo|matching placebo over three Days
214314778|NCT01250587|DRUG|PDC31|This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
214314779|NCT05336058|OTHER|No intervention|In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.
214314780|NCT03960151|DRUG|Rolapitant|Rolapitant 180mg PO, Days 1 and 5
214482014|NCT03547271|BIOLOGICAL|Pneumococcal vaccine (13-valent)|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
214482015|NCT03547271|BIOLOGICAL|Pneumococcal vaccine (10-valent)|Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
214482016|NCT03547271|BIOLOGICAL|MMR vaccine|Measles, mumps, and rubella vaccine
215061010|NCT04951011|DIAGNOSTIC_TEST|Serum beta HCG|Raising numbers of S BHCG or decreasing with different management of tubal Ectopic Pregnancy
214314781|NCT03960151|DRUG|Palonosetron|Palonosetron 0.25 mg IV, Days 1,3, and 5.
214482017|NCT06691191|DRUG|Ticagrelor 90 mg|After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
214482018|NCT06691191|DRUG|Prasugrel 10 mg|After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
214482019|NCT06686173|OTHER|None-placebo|This is one kind descriptive study. The different donor groups made the cohorts different: the parous female donor and young male donor
214314782|NCT03960151|DRUG|Olanzapine|Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
214482020|NCT06686173|OTHER|non-intervention study|This study is one kind of non intervention study
214482021|NCT06686173|OTHER|donor selection|the intervention of this study was the different donor groups: the parous female donor and young male donor. All the patients involved in this study were treated by the combination of ATG and PTCy
214482022|NCT06691282|OTHER|Mindful self-compassion intervention|Participants will receive six weekly sessions of training by a trainer in mindful self-compassion (MSC). Each session lasting around 90 minutes and will be conducted face-to-face at the Hong Kong Metropolitan University. The content of the intervention will include an introduction of mindfulness and self-compassion, practice of body awareness and loving kindness, skills to deal with challenging experiences, and methods for relating to positive aspects of the self.
214482023|NCT04835363|OTHER|Early Occupational Therapy intervention|four-week OT intervention program for patients who have suffered a stroke with the aim of improving the functional result and facilitating the return home by providing knowledge about specific care and neurorehabilitation.
214482024|NCT03048084|DRUG|Levetiracetam|Antiepileptic drug levetiracetam
214482025|NCT03048084|DRUG|Valproic Acid|Antiepileptic drug valproic acid
214482026|NCT03118037|DEVICE|Sonata System|Transcervical access for radiofrequency ablation of uterine fibroids
214482027|NCT06309238|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication
214482028|NCT06309238|PROCEDURE|Bariatric surgery|Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG)
215061011|NCT04224831|COMBINATION_PRODUCT|Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis|"Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment."
214482029|NCT06686537|DRUG|Estradiol Patches|Estradiol patched will be worn for 7 days.
214314783|NCT03960151|DRUG|Dexamethasone|Dexamethasone 20 mg AM, Days 1,2 and 3
214314784|NCT01015586|DRUG|Lamotrigine|Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks
214314785|NCT01015586|DRUG|Placebo|Placebo once daily for 12 weeks
214671473|NCT04098614|BEHAVIORAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
214671474|NCT06488807|OTHER|Olfactory Enrichment|Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, menthol, tangerine, green tea, and bergamot). The choice of odors was guided by (1) pleasantness of the odors, (2) presence of slight trigeminal activation in some of the odors, e.g., peppermint, (3) evaporation characteristics, so that the odors would last for the duration of the experiment, (4) technical issues mostly in terms of compatibility with the odor cartridge, (5) availability, and (6) inspiration from the previous studies.
214671475|NCT06488807|OTHER|Sham|The containers provided to the sham group will be odorless. The odor containers and labels will appear identical to those used in the olfactory enrichment group.
215061012|NCT00277810|DRUG|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
214314786|NCT03152539|RADIATION|MRI|
214314787|NCT03152539|DEVICE|EEG|
214314788|NCT03152539|DEVICE|NIRS|
214314789|NCT00907374|DRUG|benazepril|benazepril 10 mg orally once daily
214314790|NCT00907374|DRUG|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
214314791|NCT02457403|DEVICE|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
214314792|NCT02457403|OTHER|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
214314793|NCT04525612|DIAGNOSTIC_TEST|68Ga-BNU-PSMA|Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
214314794|NCT06003530|BIOLOGICAL|hOMSC200|Human Oral Mucosal Stem Cells
214314795|NCT06003530|OTHER|Placebo|Animal component-free, defined cryopreservation medium with 5% DMSO
214314796|NCT02759666|DRUG|SHR3162|SHR3162 capsule(s) is administered orally QD.
214314797|NCT03317171|DIETARY_SUPPLEMENT|Flavonoids, DHA, EPA|oral administration
214314798|NCT03317171|DIETARY_SUPPLEMENT|placebo compound|oral administration
214314799|NCT00062582|DRUG|Roflumilast|
214314800|NCT03897790|OTHER|Transcranial Doppler (DTC)|Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
214314801|NCT03769272|PROCEDURE|Measurement of electrical delay during LV lead placement|Measurement of electrical signal in the heart during implantation of CRT, by positioning the lead in different places in the heart.
214314802|NCT02871739|BEHAVIORAL|Webinar|1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.
214314803|NCT02871739|BEHAVIORAL|DA viewing|Participants will receive 3 decisions aids to review.
214314804|NCT02871739|BEHAVIORAL|SPI feedback|Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
214671476|NCT06966180|BEHAVIORAL|Alcohol Intervention Program (AIP)|A brief behavioral intervention consisting of six bi-weekly group sessions based on motivational interviewing and cognitive-behavioral strategies. The aim was to reduce alcohol use and related problems and increase motivation to change.
214671477|NCT04640636|DRUG|Ketamine hydrochloride injection|single IM injection of ketamine hydrochloride 0.5 mg/kg
214671478|NCT04640636|DRUG|Midazolam injection|single IM injection of midazolam 0.06 mg/kg
214918439|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
214918440|NCT04015609|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
214918441|NCT05501470|DRUG|Probiotic|Probiotic
214918442|NCT05501470|DRUG|Placebo|Placebo
214314805|NCT00656006|DRUG|Albuferon|
214314806|NCT00656006|DRUG|Ribavirin|
214314807|NCT00849966|DRUG|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
214314808|NCT00849966|DRUG|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
214314809|NCT02438748|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
214314810|NCT03818516|OTHER|Oral Glucose Tolerance Test (OGTT)|Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.
214314811|NCT02189421|DEVICE|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
214314812|NCT03166280|DRUG|Sofosbuvir 400 mg|treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
214314813|NCT03166280|DRUG|Daclatasvir 60 mg/day|treatment for hepatitis c by Daclatasvir 60 mg/day
214314814|NCT01944995|DEVICE|glasses broadband|
214314815|NCT01944995|DEVICE|nasal CPAP|
214314816|NCT04330742|DRUG|lactated ringers|the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.
214314817|NCT01642238|DRUG|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
214314818|NCT01642238|DRUG|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
214314819|NCT02181062|BEHAVIORAL|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
214314820|NCT04372602|DRUG|Duvelisib|-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
214918443|NCT05501470|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan® device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
214918444|NCT06386198|BEHAVIORAL|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
214918445|NCT04806386|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber powder baked into a bar is commonly used as a first line of treatment for patients with fecal incontinence.
214314821|NCT04372602|PROCEDURE|Peripheral blood draw|"* First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29"
214314822|NCT04372602|DRUG|Placebo|-Provided by Verastem
214314823|NCT04065789|DRUG|Carfilzomib|Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
214314824|NCT04065789|DRUG|Daratumumab|Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
214314825|NCT04065789|DRUG|Lenalidomide|Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
214314826|NCT04065789|DRUG|Dexamethasone|Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
214314827|NCT05464004|OTHER|Nintendo Wii balance board|"Experimental group was given Nintendo Wii balance board therapy in combination with conventional physical therapy for 16 sessions/8 weeks~Control group was conventional physical therapy which include stretching of the hamstrings, quadriceps and calf muscles. strengthening of the lower limb. Balance exercises include walk in parallel bar"
214314828|NCT03305510|DIAGNOSTIC_TEST|vitamin D is below 20ng/ml|
214314829|NCT02717481|DEVICE|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
214314830|NCT05157932|BEHAVIORAL|Talk test prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on the Talk test method.
214314831|NCT05157932|BEHAVIORAL|CPET prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on their CPET results completed at baseline
214314832|NCT04360577|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
214314833|NCT01667640|RADIATION|sector irradiation|"Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.~A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.~Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.~Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.~Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported."
214671479|NCT03308630|BEHAVIORAL|Yoga based Energy Alignment and Mantra|"Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated."
214918446|NCT06195306|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214918447|NCT06195306|PROCEDURE|Mammography|Undergo mammography
214918448|NCT06195306|DRUG|Omega-3-Acid Ethyl Esters|Given PO
214918449|NCT06195306|OTHER|Questionnaire Administration|Ancillary studies
214918450|NCT06195306|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
214918451|NCT06195306|DRUG|Tamoxifen|Given PO
214918452|NCT06292546|DRUG|Vonoprazan|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
214918453|NCT06292546|DRUG|Amoxicillin|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
214918454|NCT06292546|DRUG|Bacillus subtilis enteric-coated capsules|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
214918455|NCT04624256|PROCEDURE|Discussion|Patients and physicians engage in discussion
214918456|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo conventional hypofractionated radiation therapy
214918457|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo moderate hypofractionated radiation therapy
214918458|NCT04624256|OTHER|Laboratory Biomarker Analysis|Correlative studies
214918459|NCT04624256|OTHER|Quality-of-Life Assessment|Ancillary studies
214918460|NCT04624256|OTHER|Questionnaire Administration|Ancillary studies
214918461|NCT04624256|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214918462|NCT06568055|OTHER|No Intervention|This is non-interventional study.
214918463|NCT06115720|OTHER|Video assisted consent|The intervention group will also be shown the same pre-recorded standard verbal consent, but following this will additionally be shown a specifically recorded video of the anaesthetic process for both GA and RA. This video will aim to communicate the same information as that found in the traditional verbal consent, using an actor undergoing an anaesthetic to provide context.
215061013|NCT03461549|DEVICE|Pressure and Temperature Sensor|This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
214482030|NCT06690554|OTHER|Education Group|"Women will be given a five-day training in line with the health promotion model.~Information will be provided to women who apply to the hospital. Written consent documents will be obtained from women who agree to participate in the study.~Women assigned to the intervention group will attend classes in groups of 8-10. Women will be given a 60-minute training once a day for five days. The total training duration is five hours. Scales will be applied to women who complete the training at the end of the fifth day.~Women who have completed the training will be contacted by phone at the end of the first and second months, reminded of health promotion behaviors and their questions will be answered and follow-ups will be carried out.~At the end of the third month, women who have received training will be invited to the institution and the Fertility Awareness, Preconceptional Knowledge and Attitude will be filled out face-to-face for the final test."
214482031|NCT06691828|DRUG|NX-5948|NX-5948 will be given once by IV and then given once by mouth.
214482032|NCT06065735|DRUG|Paroxetine|Paroxetine will be administered
214482033|NCT06688162|OTHER|Usual Care|During the study treatment and follow-up periods, patients are to receive usual standard of care according to published guidelines for acute stroke care. It is anticipated that background care may include the use of other treatments including drugs and interventions.
214482034|NCT06688162|PROCEDURE|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)|This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
214482035|NCT02532621|DEVICE|Venous InterGraft Connector|The device is designed for transcatheter delivery within a vein and connection to an AVG that has been tunneled under the skin in a standard manner. The connection is made via a small skin incision.
214482036|NCT02532621|PROCEDURE|sutured arterial anastomosis of an implanted vascular graft for hemodialysis|The arterial anastomosis of the implanted vascular graft for hemodialysis is formed using standard suturing technique.
214482037|NCT02532621|PROCEDURE|hemodialysis|The implanted vascular graft is intended as a vascular access for performing hemodialysis treatments.
214482038|NCT06691594|RADIATION|neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy|"Eligible participants will receive neoadjuvant treatment consisting of:~SBRT: One session of 10Gy radiation to the primary tumor, followed by a 150mg subcutaneous injection of pembrolizumab (PD-1 inhibitor).~Chemotherapy and Immunotherapy: One week after SBRT, participants will undergo 6 cycles of pembrolizumab (400mg), albumin-bound paclitaxel (250mg/m²), and carboplatin (AUC=5).~Surgery: Surgery will be performed 21 days after the last chemotherapy cycle, with either breast-conserving surgery or modified radical mastectomy. Pathological evaluation will assess the treatment response.~Adjuvant Immunotherapy: Four weeks post-surgery, patients will receive pembrolizumab every 3 weeks for up to 1 year."
214482039|NCT06690736|DIAGNOSTIC_TEST|CXCR4 PET/CT Imaging|Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
214482040|NCT06691685|DRUG|ESO-T01 Injection|ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
214482041|NCT06628271|DIAGNOSTIC_TEST|Guidelines|Participant with typical spells will be investigated according to our guidelines. These include that participants with heredity for or signs and symptoms of cardiac disease will be subjected to an ECG and participants with two or more spells should be subjected to blood tests for anemia and iron deficiency
214482042|NCT06366633|BEHAVIORAL|Web-TIRELESS|This is a self-administered web-based intervention that consists of 4 30-45-minute video sessions that teach mind-body skills, cognitive-behavioral strategies (e.g., reframing, pain and substance use urge surfing), activity pacing, acceptance and commitment skills, and psychoeducation on the association between substance use and pain. The program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive substance use behaviors.
214482043|NCT00692939|BIOLOGICAL|autologous CD34-selected peripheral blood stem cells transplant|high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
214482044|NCT00692939|DRUG|Alemtuzumab|Transplant conditioning
214482045|NCT00692939|DRUG|ATG|Transplant conditioning
214482046|NCT00692939|DRUG|Melphalan|Transplant conditioning
214482047|NCT00692939|DRUG|Thiotepa|Transplant conditioning
214482048|NCT00692939|DRUG|Rituximab|Transplant conditioning
214482049|NCT00692939|DRUG|Cyclophosphamide|Mobilization
214482050|NCT00692939|DRUG|G-CSF|Mobilization
214482051|NCT00692939|DRUG|Mesna|Mobilization
214918464|NCT02625532|PROCEDURE|Follicular phase|Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
214918465|NCT02625532|PROCEDURE|Luteal phase|Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
214482052|NCT06619392|DRUG|HRS-2129|HRS-2129
214482053|NCT06619392|DRUG|HRS-2129 Placebo|HRS-2129 Placebo
214482054|NCT06624215|PROCEDURE|Appendectomy|Robotic-assisted or laparoscopic appendectomy for acute appendicitis.
214482055|NCT06623006|BEHAVIORAL|mobile health (mhealth)|The intervention will include a text-based mhealth component, designed using a behaviour change framework (Behaviour Change Wheel). The development process will be further informed by a formative research exploring perspectives of both health service providers and users on use of text based mhealth for supporting self-management in people with type 2 diabetes.
214918466|NCT04817696|OTHER|Patients without chronic pain symptoms|Verbal score \< 3 at 3 months
214918467|NCT04817696|OTHER|Patients with chronic pain symptoms|Verbal score ≥ 3 at 3 months
215061014|NCT01295138|DRUG|Lactulose|Lactulose liquid. 15mls twice daily
215061015|NCT03611816|BIOLOGICAL|Blood taken|Collection of clinical data
214314834|NCT01667640|RADIATION|whole brain irradiation|"For whole brain radiation the entire brain, the base of the skull and the meninges are included.~Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.~The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented."
214482056|NCT06623149|BEHAVIORAL|Non-Surgical Intervention|"After referral from the general practitioner to the orthopedic department, the patient is offered a 3-month non-operative treatment program. The conservative program consists of several elements that are offered on an individual basis. The program consists of 3 main elements:~* Patient education/information~* Specialized exercise supervised by a physiotherapist~* Weight loss counseling with a dietician"
214482057|NCT06623149|PROCEDURE|Current practice|After referral from the general practitioner to the orthopedic department, the patient is assessed by an orthopedic surgeon in the out-patient clinic according to standard practice with a focus on symptoms, history, physical examination, radiography, and an appraisal of the patient's expectations. If an indication for knee arthroplasty is found, the patient is offered knee arthroplasty, and if the patient accepts the offer, he/she is scheduled according to usual practice. If a patient declines the offer, the patient is informed that the hospital cannot offer any additional service, and the patient is referred back to primary care.
214482058|NCT06391372|DRUG|estriol cream|1 g intravaginal estriol via applicator twice a week before going to bed for 4 weeks
214314835|NCT04401917|DRUG|[18F]NOS|Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.
214314836|NCT05723016|OTHER|preimplantation genetic test for aneuploidies (PGT-a)|preimplantation genetic test for embryo aneuploidies after IVF
214314837|NCT03076424|OTHER|no intervention used|Patients will be giving a blood sample after 8 hours of fasting.
214314838|NCT05407246|DRUG|Hemay005|Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
214314839|NCT04130243|OTHER|Blood test|Withdrawal of (extra) blood to measure serum biomarkers with a blood test
214314840|NCT00736801|DRUG|Salmeterol and Salmeterol / Fluticasone|Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
214314841|NCT02205593|BEHAVIORAL|Control|Regular follow-up and treatment WITHOUT behavioural intervention
214482059|NCT02833831|DRUG|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
214482060|NCT02833831|DRUG|Placebo|Matching Placebo will be administered.
214482061|NCT02833831|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
214482062|NCT03522298|DRUG|Paxalisib (GDC-0084)|Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
215061016|NCT03611816|GENETIC|Blood taken|Collection of DNA
214482063|NCT05584202|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
214482064|NCT05584202|OTHER|Placebo|0.9% sodium chloride
215061017|NCT03611816|GENETIC|Blood taken|Collection of plasma
215061018|NCT05572606|BEHAVIORAL|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
215061019|NCT06145035|BIOLOGICAL|umbilical cord-derived mesenchymal stromal cells (UC-MSCs)|The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 3.3 million cells/min. The product will be infused into vein via intravenous line placed in the arm.
214314842|NCT00594464|DRUG|Rotigotine|"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."
214314843|NCT00111969|DEVICE|Celacade™ system|
215061020|NCT06835322|DRUG|Finerenone|50 patients with biopsy proven glomerulonephritis who will receive 10 - 20 mg finerenone once daily orally in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.
214314844|NCT05625035|DRUG|Lianhua Qingwen capsules|Lianhua Qingwen capsules: 4 capsules once, three times daily
214314845|NCT04603729|DRUG|Dexamethasone 2 MG/ML|Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
214314846|NCT04603729|DRUG|Methylprednisolone Injection|methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
214482065|NCT06874062|PROCEDURE|Neoputty MTA Pulpotomy Treatment|"All caries were removed before entering the pulp chamber. Once all caries were removed, a carbide bur was used under copious water spray to expose the pulp chamber.Coronal pulp is removed with a round bur on a slow speed handpiece.~Hemostasis was achieved by applying a cotton pellet moistened with sterile saline for no more than 5 minutes. After achieving hemostasis, Neoputty MTA was placed."
214482066|NCT06874062|PROCEDURE|ProRoot MTA Pulpotomy Treatment|"All caries were removed before entering the pulp chamber. Once all caries were removed, a carbide bur was used under copious water spray to expose the pulp chamber.Coronal pulp is removed with a round bur on a slow speed handpiece.~Hemostasis was achieved by applying a cotton pellet moistened with sterile saline for no more than 5 minutes. After achieving hemostasis, ProRoot MTA was placed."
214482067|NCT06874062|PROCEDURE|Theracal PT Pulpotomy Treatment|"All caries were removed before entering the pulp chamber. Once all caries were removed, a carbide bur was used under copious water spray to expose the pulp chamber.Coronal pulp is removed with a round bur on a slow speed handpiece.~Hemostasis was achieved by applying a cotton pellet moistened with sterile saline for no more than 5 minutes. After achieving hemostasis, Theracal PT was placed."
214314847|NCT04307485|DRUG|Ticagrelor|90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
214314848|NCT03458130|DRUG|AG10|TTR stabilizer
214314849|NCT03458130|DRUG|Placebo Oral Tablet|Nonactive control
214314850|NCT01728025|DRUG|Ranolazine|
214314851|NCT03594162|DRUG|iC9-CAR19 cells|One of two dose levels will be given: 1 x 10\^5 or 5 x 10\^5
214314852|NCT03594162|DRUG|AP1903|Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
214314853|NCT03594162|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
214314854|NCT03594162|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
214314855|NCT00775437|DRUG|Adalimumab|Adalimumab solution for injection for subcutaneous use.
214314856|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
214314857|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
214314858|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
214314859|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
214314860|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
214314861|NCT00949624|DRUG|Docetaxel|Intravenous 100 mg/m2 every three weeks
214314862|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
214314863|NCT00949624|DRUG|AG-013736|Oral tablet 5 mg BID continuous
214314864|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
214314865|NCT05193474|BEHAVIORAL|integrated palliative care|shared decision making with patient, and timely integrated palliative care according to patient's preference
214314866|NCT06442735|OTHER|intrapartum ultrasound|In IPUS group, the patient's labor was observed by intrapartum ultrasound.
214314867|NCT06442735|OTHER|vaginal examination|In VE group, the patient's labor was observed by vaginal examination.
214482068|NCT06874062|PROCEDURE|Stainless Steel Crown Application|After pulpotomy treatment, the pulpotomy material was covered using a capsule-form glass ionomer (EQUIA Forte®, GC, Tokyo, Japan). In the same session, preparation was performed for the placement of a stainless steel crown (SSC), and an appropriately sized SSC (3M ESPE, Seefeld, Germany) was selected based on visual estimation. After trial fitting on the tooth, the crown was cemented using a capsule-form glass ionomer (Riva, SDI Ltd., Victoria, Australia).
214314868|NCT02733510|DRUG|methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
214314869|NCT02842502|PROCEDURE|Collection of supernumerary biopsies during skin graft pellet procedure|
214314870|NCT02907359|DRUG|Guadecitabine|
214314871|NCT02907359|OTHER|Treatment Choice|"* BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~* LDAC: 20 mg/m\^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~* Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m\^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m\^2/day) or idarubicin (9-12 mg/m\^2/day) or mitoxantrone (8-12 mg/m\^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
214482069|NCT06874465|DEVICE|Transcatheter aortic valve implantation|Compare self expendable and balloon expendable valves
214314872|NCT05918991|BEHAVIORAL|Daily Report Card|Behavioral consultants will meet with teachers to review daily report card implementation and effective classroom management. The consultant collaborates with the teacher to identify specific behavioral goal targets for the student's DRC based on a review of teacher ratings and teacher description of key problem behaviors. After establishing the initial DRC, the consultant will review procedures with the teacher for scoring the DRC and, importantly, providing the student with effective and consistent performance feedback. The consultant will also make a plan with the teacher to review DRC progress and revise the DRC as needed. Consultants will also meet with parents to develop a plan for reinforcing the DRC at home. The DRC will be implemented for 18 weeks. The behavioral consultants will be available to teachers and parents throughout the duration of the intervention to assist with implementation and adjustment of target behaviors and goals.
214314873|NCT05918991|OTHER|Language Intervention|The intervention protocol to be provided in each grade level will include 18 weeks of 20-25 minutes of small-group intervention 4 days per week, for a total of 72 lessons. The fifth day per week will be allocated to make-up lessons for students absent earlier in the week to maximize opportunity for each participant to receive the full dosage of lessons. Half of these lessons in each grade will be allocated to Language in Motion implementation and the other half to Dialogic Reading. Dialogic Reading is designed to increase vocabulary knowledge through shared reading of picture books. The content involves reading of 9 children's books with 108 targeted vocabulary words. Language in Motion is designed to increase syntax and grammar knowledge using science manipulatives. Daily lessons are highly scripted to introduce primary syntax targets through narrative text. Manipulation props are used to reinforce syntax targets and basic science topics.
214314874|NCT06378086|DEVICE|RHA® Redensity with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
214314875|NCT06378086|DEVICE|RHA® Redensity with lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
214314876|NCT04974671|RADIATION|Stereotactic Body Radiation Therapy|1-5 fraction Stereotactic Body Radiation Therapy to all sites of progression
214314877|NCT04360018|OTHER|Alcohol beverage|High-proof alcohol (e.g., Everclear) will be mixed with orange juice in an approximately 1:3 ratio and split evenly into two drinks. After splitting the orange juice into two cups, a small amount (approx. 6 ml) of high-proof alcohol will be floated on top of the beverage.
214314878|NCT04360018|OTHER|Placebo beverage|The final drink will have the same volume of liquid as the alcohol beverage.
214314879|NCT01405963|DRUG|Placebo|Administered in a 1-hour intravenous infusion
214314880|NCT01405963|BIOLOGICAL|Tezepelumab|Administered in a 1-hour intravenous infusion
214314881|NCT03139149|PROCEDURE|Adhesiolysis|"Method of video laparoscopic operation:~* Open access in the left upper quadrant of the anterior abdominal wall,~* Installation of trocars, depending on the prevalence of the adhesion process~* Assessment of the peritoneal adhesion index~* Detection of the asleep gut~* Detection of obstacle area~* Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity~If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed."
214314882|NCT03139149|RADIATION|X-ray diagnostics|X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.
214314883|NCT03139149|RADIATION|Computer tomography|Computer tomography of abdomen with iv contrast
214314884|NCT03139149|PROCEDURE|Ultrasound|Ultrasound of the abdomen (2 times)
214314885|NCT03139149|OTHER|General and biochemical blood test|General blood test and biochemical blood test 2 times a day
214314886|NCT01805024|DRUG|Omigapil|Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
214314887|NCT03229824|DEVICE|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
214314888|NCT01011842|PROCEDURE|Radiotherapy|Standard of care
214314889|NCT01011842|PROCEDURE|Align RT|Standard of care
214314890|NCT00195247|DRUG|TTI-237|
214314891|NCT06300333|DRUG|Methotrexate|use low dose of Methotrexate in treatment of un distectopic tubal pregnancy
214314892|NCT00554437|BEHAVIORAL|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
214482070|NCT06874257|BIOLOGICAL|Laboratory tests and in vitro studies|Cell models, co-culture condition set-up and functional validation, Single-cell RNA sequencing and NGS, Metabolomics analysis, metabolomics validation and intracellular metabolomics analysis, Metabolic ImmunoProfiling and epigenetic profile, CyTOF immune and signaling profiling, Monocyte, macrophages and MSCs in vitro assays.
214314893|NCT03606954|COMBINATION_PRODUCT|Combination topical corticosteroid|Comparison of a vasoconstriction index between the 2 study arms
214314894|NCT01391065|RADIATION|MR PET Guided Brachytherapy|
214314895|NCT05167162|DIAGNOSTIC_TEST|State-Trait Anxiety Questionnaire|"The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always"
214314896|NCT05167162|DIAGNOSTIC_TEST|Rating of Perceived Exertion|"The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable"
214482071|NCT04661280|DRUG|Donepezil|Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.
214918468|NCT06316609|OTHER|Gestational Exposure to Emerging Contaminants (ECs)|Levels of Emerging Contaminants (ECs), such as Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics, are assessed in maternal blood and umbilical cord blood during gestation.
214314897|NCT05167162|DIAGNOSTIC_TEST|Motor coordination tests|"The motor coordination tests are divided into three:~1. Jumping with 2 feet together.~2. Throwing 2 balls from a given distance and space.~3. Proprioception turns"
214314898|NCT05167162|PROCEDURE|Physiotherapeutic intervention|Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.
214314899|NCT05167162|OTHER|Data Analysis|The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
214314900|NCT01060033|DEVICE|MR Spectroscopy|
214314901|NCT01060033|DEVICE|Fat-Saturation and Diffusion-Weighted Imaging|
214314902|NCT01060033|DEVICE|Dynamic Contrast Enhancement MRI (MR-DCE)|
214314903|NCT01060033|DEVICE|Diffusion Tensor Imaging (DTI)|
214314904|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Standard dose|"Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
214314905|NCT05387317|BIOLOGICAL|AstraZeneca Standard dose|"Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
214314906|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Fractional dose|"Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
214314907|NCT05387317|BIOLOGICAL|AstraZeneca Fractional dose|"Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
214314908|NCT05387317|BIOLOGICAL|Moderna Standard dose|Standard dose (50ug in 0.25ml)
214314909|NCT05387317|BIOLOGICAL|Moderna Fractional dose|Fractional dose (20ug in 0.1ml)
214314910|NCT01760083|DEVICE|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
214314911|NCT05957783|OTHER|Cerebral palsy Gait analysis technique|Visual gait analysis in cerebral palsy new technique
214314912|NCT06582485|DRUG|iCM012 solution 2 mg/mL|200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
214314913|NCT06582485|DRUG|Placebo|200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
214314914|NCT04820790|OTHER|Mobile applications|Monitoring of patients with home oxygen through a mobile application
214314915|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
214314916|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
214314917|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
214918469|NCT06165510|DEVICE|Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.|2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.
214918470|NCT06165510|PROCEDURE|Standard Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
214918471|NCT05149144|DIAGNOSTIC_TEST|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule
215061021|NCT06835322|DRUG|Placebo|50 patients with biopsy proven glomerulonephritis who will receive placebo once daily in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.
214314918|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose|Injection in the muscle
214314919|NCT03023085|DRUG|BLI4700|BLI4700 bowel preparation
215061022|NCT03702062|DIAGNOSTIC_TEST|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
214314920|NCT00884299|DIETARY_SUPPLEMENT|Diet rich in antioxidants|Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
214314921|NCT05828251|PROCEDURE|Vitrectomy (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
214314922|NCT05828251|PROCEDURE|Combined phako-vitrectomy|Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.
214314923|NCT05828251|PROCEDURE|Phako (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
214314924|NCT02599753|DRUG|18-FDTBZ|"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
214314925|NCT05111977|DEVICE|Vibrant capsule|A capsule delivering mechanical vibrations
214314926|NCT02403908|DEVICE|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery \<2 mm proximal from both ostia of right and left pulmonary arteries.
214314927|NCT02364310|DEVICE|Baroreceptor stimulation with Barostim Neo TM|
214671480|NCT06970431|OTHER|eoperative Education + Intraoperative Music Therapy Arm|The experimental group implemented standardized preoperative education one day before the operation (covering knowledge such as the surgical procedure), headphone fitting one hour before the operation (with a volume of 45-55 decibels), and music therapy throughout the operation and for 30 minutes after the operation (parturients can choose personalized music). Full-time nurses were responsible for the preoperative education, and trained operating room nurses implemented the music therapy. Meanwhile, data such as anxiety scores, pain scores, shivering index, postoperative complications, postoperative recovery status, and satisfaction surveys were collected at multiple time points through standardized tools.
214314928|NCT01871363|RADIATION|chemoradiation|"* radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~* bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
215061023|NCT00294671|DRUG|diflunisal|given twice daily for 24 months
215061024|NCT00294671|OTHER|placebo|an inactive substance given twice daily for 24 months
215061025|NCT01966354|PROCEDURE|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
215061026|NCT01234038|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
214314929|NCT02189057|OTHER|AssureRx GeneSight genotyping results|
214314930|NCT02189057|OTHER|Treatment as usual|
214314931|NCT04915391|DIAGNOSTIC_TEST|Skin biopsy and blood sample for inflammation markers, RNA and proteins|A skin biopsy will be performed at the baseline visit from which primary cell cultures of fibroblasts and keratinocytes will be obtained. Four to six weeks later a second biopsy on the scar will be performed and analyzed anatomically and pathologically. In addition, at the initial visit, blood samples will be drawn for analysis of inflammation markers, RNA and proteins.
214314932|NCT04371380|DRUG|Cabotegravir Tablets|Cabotegravir tablets will be white to almost white oval shaped film coated tablets with a unit dose of 30 mg and will be administered orally.
214314933|NCT04371380|DRUG|Rilpivirine Tablets|Rilpivirine tablets will be off-white, round, biconvex film coated tablets with a unit dose of 25 mg and will be administered orally.
214314934|NCT04371380|DRUG|Cabotegravir extended release suspension for injection (long-acting)|Cabotegravir long-acting will be a sterile white to slightly pink suspension containing 200 mg per mL of GSK1265744 as free acid for administration by intramuscular injection.
214314935|NCT04371380|DRUG|Rilpivirine extended release suspension for injection (long-acting)|Rilpivirine long-acting will be a sterile white suspension containing 300 mg per mL of rilpivirine as the free base for administration by intramuscular injection.
214314936|NCT05270434|PROCEDURE|time interval between ESWL and ERCP is 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12h.
214314937|NCT05270434|PROCEDURE|time interval between ESWL and ERCP is greater than 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP ≥12 h.
214314938|NCT05270434|DRUG|morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
214314939|NCT02444247|OTHER|High Dose Exercise (300 kcal)|Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.
214314940|NCT02444247|OTHER|Low Dose Exercise (150 kcal)|Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.
214314941|NCT02444247|OTHER|No Exercise (0 kcal)|Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.
214314942|NCT02444247|OTHER|Sedentary Option|Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
214314943|NCT05711732|DIAGNOSTIC_TEST|MyCare Oncology Busulfan Assay Kit|This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.
214314944|NCT06088433|DRUG|Ticagrelor|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
214314945|NCT06088433|DRUG|Clopidogrel|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
214314946|NCT06088433|DRUG|Aspirin|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
214314947|NCT02262351|OTHER|30 Second Pulse Check|To detect atrial fibrillation
214314948|NCT02262351|DEVICE|Watch BP Home A|Blood pressure device that detects atrial fibrillation
214314949|NCT02262351|DEVICE|HeartCheck Hand-held ECG device|To detect atrial fibrillation
214314950|NCT05309109|OTHER|Hemodialysis sessions|Patients will receive thrice weekly 4 hours hemodialysis sessions during 12 months.
214314951|NCT05256667|COMBINATION_PRODUCT|RCT-SV|Group 1- Endodontic treatment in a single visit using chemomechanical preparation and passive ultrasonic irrigation, followed by obturation and final restoration.
214314952|NCT05256667|OTHER|RCT-TVWD|Group 2- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by intracanal dressing and temporary restoration for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
214671481|NCT06970431|OTHER|Preoperative Education Alone Arm|"The control group received the same standardized preoperative education by full-time nurses one day before the operation, covering surgical procedures, precautions, anesthesia, and postoperative recovery.~Data were collected at multiple time points using standardized tools, including anxiety scores (before and 6, 12, 24 h after surgery via GAD-7), pain scores (before and 6, 12, 24 h after via VAS), shivering index (before surgery, before wearing headphones, when leaving OR), postoperative complications (wound infection, urinary retention, etc.), postoperative recovery indicators (time to get out of bed, anal exhaust, breastfeeding start, hospital stay), and satisfaction surveys (24 h after surgery).~Importantly, the control group had no music therapy intervention before, during, or after surgery."
214671482|NCT06971627|BEHAVIORAL|Nurse-led Telehealth Monitoring Program|Participants in the intervention group will be included in a structured telehealth monitoring program led by a nurse for 12 weeks.
214671483|NCT06971627|OTHER|No intervention|Participants in the control group will only receive standard care. No additional interventions will be implemented during the 12-week period.
214918472|NCT05149144|BEHAVIORAL|audio signal dataset creation and validation; machine learning analysis, empirical evaluations|The project tests and adapts the technology developed at MIT for vocalization collection and labeling, and contributes to data gathering among Italian subjects (and their quality validation) in order to create a multi-cultural dataset and to enable cross-cultural studies and analyses. Next, the focus is placed on the analysis of harmonic features of the audio in the vocalizations of the dataset to identify recurring individual features and patterns corresponding to specific communications purposes or emotional states. Supervised and unsupervised machine learning approaches are developed and different machine learning algorithms will be compared to identify the most accurate ones for the project goal. Last, an exploratory evaluation of the vocalization-understanding machine learning model is conducted to test the usability and utility of the tool for vocalization interpretation.
214918473|NCT06495242|PROCEDURE|Direct pulp capping and partial pulpotomy|Two types of vital pulp therapy procedures
214918474|NCT06047366|DRUG|Sodium bicarbonate|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
214918475|NCT06047366|DRUG|Lidocaine w/ epi|Septodont's standard formulation of 2% lidocaine with epinephrine
214918476|NCT06047366|DRUG|Articaine w/ epi|Septodont's standard formulation of 4% articaine with epinephrine
214918477|NCT06047366|DRUG|Mepivacaine plain|Septodont's standard formulation of 3% mepivacaine
214918478|NCT05894018|DRUG|Fluzoparib|150mg, orally, bid
214918479|NCT05894018|PROCEDURE|Radioactive particle implantation|Radioactive iodine-125 seeds implantation
215061027|NCT01234038|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
215061028|NCT01234038|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
215061029|NCT01234038|DRUG|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
215061030|NCT01234038|DRUG|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
215061031|NCT05088330|DRUG|Daratumumab|treatment with D-VRD in NDMM
215061032|NCT01047137|BEHAVIORAL|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
214314953|NCT05256667|OTHER|RCT-TVWOD|Group 3- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by temporary restoration for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
214314954|NCT05603416|DIETARY_SUPPLEMENT|Perilla frutescens extract|oral dissolvable powder - dosage 300mg
215061033|NCT01047137|BEHAVIORAL|General Supportive Therapy|There is no focus on stress intervention.
215061034|NCT06089863|OTHER|PAMPERO program|"This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :~* 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object~* 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority~* 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick~* 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture~* 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation"
214314955|NCT05603416|DIETARY_SUPPLEMENT|Placebo|oral dissolvable powder - dosage 300mg no active ingredient
214314956|NCT01113632|DRUG|Ofatumumab|IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
214314957|NCT05183737|DIETARY_SUPPLEMENT|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
214314958|NCT05438264|DRUG|Donepezil|acetylcholinesterase inhibitor
214314959|NCT05438264|DRUG|Placebo|placebo
214314960|NCT03471533|DIETARY_SUPPLEMENT|nutraceutical: experimental product|84 days of consumption
214314961|NCT03471533|DIETARY_SUPPLEMENT|placebo|84 days of consumption
215061035|NCT04367155|DRUG|Tranexamic acid injection|hemostatics use
214918480|NCT04755764|DRUG|Labetalol|Beta blocker
214918481|NCT04755764|DRUG|Atenolol|Beta blocker
214918482|NCT04755764|DRUG|Nifedipine|Calcium channel blocker
214671484|NCT06969846|DEVICE|CSN electrode was implanted around tissue including CSN branches|Using a novel surgical approach, a custom electrode was implanted around tissue including CSN branches in anesthetized adults. Following functional mapping, presumed baroafferent fibers were identified via response and stimulated. Outcome measures included change in systolic BP (SBP), diastolic BP (DBP), and heart rate (HR) during and after stimulation using multi-level modeling. Secondarily, dose dependency was examined.
214314962|NCT03330938|BEHAVIORAL|CBI and Resilience|A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).
214314963|NCT03330938|BEHAVIORAL|Cognitive-behavioral Intervention|Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
214314964|NCT03040635|DRUG|Risdiplam|Single oral doses of Risdiplam will be administered on Day 1.
214314965|NCT03040635|DRUG|Placebo|Single oral doses of Risdiplam matching placebo will be administered on Day 1.
214314966|NCT05644704|OTHER|Lower extremity and core muscle training|Lower extremity training: single leg balance training Core muscle training: pelvic control training
214314967|NCT00738972|DRUG|valsartan|80 mg valsartan. Duration: 12 months. Tablets
214314968|NCT00738972|DRUG|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
214314969|NCT00738972|DRUG|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
214314970|NCT00738972|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
214314971|NCT04988347|COMBINATION_PRODUCT|Spirulina platensis|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
214314972|NCT04988347|OTHER|Placebo comparator|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
214314973|NCT01281748|DRUG|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
214314974|NCT01281748|OTHER|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
214314975|NCT00243308|DRUG|Serine proteinase-1 (Serp-1)|
214314976|NCT05399524|OTHER|Standard of Care|Neuronavigation and intraoperative 5-ALA
214671485|NCT06970795|DRUG|SYS6040 for injection|"Intravenous infusion; including dose escalation and backfilling (5 preset dose groups) and cohort expansion.~Treatment Period: All subjects receive trial treatment until disease progression, death, intolerance of toxicity, loss to follow-up, withdrawal of consent, or end of the trial (whichever occurs first)"
214671486|NCT06971510|DEVICE|Exoskeleton Training|Using EksoNR to train balance control and walking and turning abilities in patients with incomplete spinal cord injury.
214671487|NCT06971510|OTHER|Conventional Physical Therapy|Using conventional physical therapy methods to train the balance control and walking and turning abilities in patients with incomplete spinal cord injury.
214918483|NCT05295693|DEVICE|Correlation of the Quantra with the TEG|"The purpose of this study is to evaluate the efficacy/reliability/validity of the Quantra device in patients with congenital heart disease for cardiac surgery on CPB.~The study if of investigational interest only. No clinical decisions will be made based on the results obtained by the Quantra device."
214918484|NCT04881578|OTHER|continuous cardiac monitoring before and after transcatheter PFO closure|Data will be assessed from patients with cryptogenic stroke and planned PFO occlusion who undergo the contemporary ICM protocols to search for silent AF
214314977|NCT05399524|OTHER|Additional pre- and intra-operative imaging|Additional DTI scan during routine pre-operative tumour MRI scan, additional use of intraoperative ultrasound in addition to normal to standard of care (Neuronavigation and intraoperative 5-ALA)
214314978|NCT04418596|RADIATION|bi-planer radiography (EOS), Conventional radiography (Hip+pelvis)|low dose radiation medical imaging to visualise the hip joint and lumbo-pelvic complex specifically.
214314979|NCT05171972|DRUG|Ofatumumab|This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
214314980|NCT06122636|DIETARY_SUPPLEMENT|The probiotic to be used in the intervention corresponds to PRODEFEN Plus manufactured by ITALFARMACO S.A. laboratory|Each patient should take 1 sachet per day, dissolve it in a glass of water, hold in the mouth for 2-3 minutes and then swallow, for a period of 30 days.
214314981|NCT06122636|OTHER|Placebo|The placebo will be administered in an envelope with the same packaging, size, shape and color of contents as the intervention of interest, except that the placebo will not contain the active ingredient of the intervention.
214314982|NCT06060665|DRUG|Seladelpar 10 mg|Administered orally
214314983|NCT06060665|DRUG|Placebo|Administered orally
214314984|NCT06970353|DRUG|Tunlametinib|Locally advanced or metastatic radioactive iodine refractory NRAS mutant differentiated thyroid cancer
214314985|NCT06970353|DRUG|Tunlametinib+PD-1 mAb|Locally advanced or metastatic NRAS mutant poor-differentiated, undifferentiated thyroid cancer
214314986|NCT06685042|BIOLOGICAL|CAR T cell|"The investigational medicinal product (IMP) CD19-CAR\_Lenti consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis product and processed by using the CliniMACS Prodigy® device (Miltenyi Biotec). CD19-CAR\_Lenti is a suspension of fresh CD4/CD8-enriched CD3+ T cells that have been genemodified with a self-inactivating (SIN) lentiviral vector expressing a CAR directed against human CD19. The SIN lentiviral vector is derived from clinically validated viral vectors described in the literature with a fully characterized sequence."
214314987|NCT04477811|DRUG|Vitamin K1|vitamin k1 tablets
214314988|NCT04477811|DRUG|Vitamin k2|vitamin k2 45 ug tablets twice daily
214314989|NCT04477811|OTHER|placebo|placebo tablets
214482072|NCT06874491|BEHAVIORAL|inhalation treatment|"Moving and 3D Book Group: After the data collector is taken to the environment where the child will receive inhalation treatment, the child and the parent will be introduced and the purpose of the study will be explained and the scales will be filled out. During the inhaler treatment, the child will spend time with a moving and 3D book that will be specially designed for inhalation treatment. After the treatment is completed, the child's reactions will be evaluated and the scales will be filled out again. Filling out the forms will take an average of 5-10 minutes.~Hand Puppet Group: After the data collector is taken to the environment where the child will receive inhalation treatment, the child and the parent will be introduced and the purpose of the study will be explained and the scales will be filled out. During the inhaler treatment, the child will spend time with a hand puppet that will be specially designed for inhalation treatment by the researcher. After the treatment is compl"
214314990|NCT03403816|BEHAVIORAL|Before School Physical Activity Program|BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
214314991|NCT02921048|DIETARY_SUPPLEMENT|omega-3 fatty acids|
214314992|NCT01256112|BEHAVIORAL|Parent Supported Behavioral Intervention|Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
214314993|NCT01256112|BEHAVIORAL|Nutrition/Activity Education (NAE)|
214314994|NCT04217473|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
214314995|NCT04946292|BEHAVIORAL|Theory-derived intervention|The intervention will be delivered through multimedia materials and group activities, as appropriate. Participants will spend approximately 30-45 minutes for the intervention. Intervention materials and activities will be carefully designed to address all the constructs/ domains of the selected theoretical model(s). The effectiveness of the interventions will be evaluated using behavioural outcomes (diet, brushing, flossing) and clinical outcomes (oral hygiene, caries and periodontal conditions).
214314996|NCT04946292|BEHAVIORAL|Conventional health education|The conventional health education will be delivered through an oral health talk and oral health booklet. Topics covered are: (i) common oral diseases and its consequences; (ii) common dental problems among older adults; (iii) importance of oral health measures (healthy diet, toothbrushing and dental flossing); and (iv) proper techniques for toothbrushing and dental flossing.
214314997|NCT03498378|DRUG|Avelumab|Avelumab (IV on days 1 and 15 of 28 day cycle)
214314998|NCT03498378|DRUG|Palbociclib|"Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day."
214482073|NCT04151368|PROCEDURE|Robotic Nipple-Sparing Mastectomy (RNSM)|RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
214482074|NCT02360371|DRUG|Within-subject test of blinded study medication|Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
214482075|NCT06874049|DRUG|Vaginal misoprostol|the vaginal misoprostol solution will be prepared by complete crushing of one misoprostol 200 µg tablet into powder then adding the powder into a clean urine specimen cup then adding 20 cc of KY gel measured by a 20 ml syringe then mix the contents together to ensure adequate distribution of the powder , each patient will receive only 2.5cc of the mixture vaginally (inserted into the posterior fornix,) by using medical 3ml syringes equal to 25 mcg misoprostol 4 hourly according to International Federation of Gynecology and Obstetrics (FIGO2023) and remain recumbent for 10-20 minutes
214482076|NCT06874049|DRUG|Oral misoprostol solution (OMS)|the solution will be prepared by dissolving one 200 µg tablet in 200 ml of tap water , each member will receive 25 cc misoprostol solution equal to 25 mcg misoprostol 2 hourly according to International Federation of Gynecology and Obstetrics (FIGO2023)
214482077|NCT04795245|DRUG|afatinib|afatinib
214671488|NCT06970041|DEVICE|Use of NIV during therapeutic FOB as a respiratory support method in patients with type 2 respiratory failure|The aim of the project is to assess the safety, indications and contraindications for therapeutic bronchofiberoscopy in patients with decompensated respiratory acidosis using: invasive mechanical ventilation (IMV), non-invasive mechanical ventilation (NIV) and high-flow nasal canulla (HFNC). Additionally, we want to determine to what extent the use of respiratory support during bronchofiberoscopy (BF) will avoid complications such as exacerbation of hypoxemia and/or acidosis and the occurrence of hemodynamic instability.
214314999|NCT03498378|DRUG|Cetuximab|"Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min."
214315000|NCT06427018|OTHER|No intervention.|Observational study with no intervention.
214315001|NCT01228357|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
214315002|NCT01228357|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
214315003|NCT05264155|BEHAVIORAL|GameBus (mHealth app)|Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
214315004|NCT00680901|DRUG|Lapatinib|5 pills at 250mg each once daily
214315005|NCT00680901|DRUG|Placebo|5 pills once daily
214315006|NCT00680901|DRUG|Capecitabine|1700mg/m2/day in two daily doses
214315007|NCT00680901|DRUG|Oxaliplatin|130mg/m2 on day 1
214315008|NCT01982851|PROCEDURE|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
214315009|NCT01982851|PROCEDURE|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
214315010|NCT01420445|DRUG|YHD001 dose level 1|three times daily / 7 days
214315011|NCT01420445|DRUG|YHD001 dose level 2|three times daily / 7 days
214315012|NCT01420445|DRUG|Pelargonium sidoides extract|6-9mL three times daily / 7 days
214482078|NCT06875505|OTHER|Dynamic PAPE|In this protocol, the load determined for footballers during knee extension will be applied as 90% of their one repetition maximum (1TM). After a standard warm-up session at the beginning, the protocol will be performed by performing 1 set of 3 repetitions with the previously determined 1TM 90% load without resting between repetitions. Isometric knee extension exercise will be used in the protocol. The movement will be performed sitting, in a position suitable for limb lengths and in a controlled manner using a leg extension machine. At the beginning of the movement, the knees will be flexed 90° and the adjustable lever arm of the machine will be fixed at this angle. Then they will be asked to perform bilateral isometric knee extension until the knees form a 180° angle. They will also be verbally motivated to complete the knee extension exercise.
214482079|NCT06875505|OTHER|Isometric PAPE|Isometric contraction will be used in the protocol. On the leg extension machine, the protocol will be performed by applying 3 sets of 3 seconds against the lever arm only with 1TM 90% load, 2 minutes rest will be applied between sets. Isometric knee extension exercise will be used in the protocol. The movement will be performed sitting, in a position suitable for limb lengths and in a controlled manner using a leg extension machine. At the beginning of the movement, the knees will be flexed 90° and the adjustable lever arm of the machine will be fixed at this angle. Then they will be asked to perform bilateral isometric knee extension until the knees form a 180° angle. They will also be verbally motivated to complete the knee extension exercise.
214482080|NCT06874777|OTHER|Aromatherapy group|It is known that aromatherapy is used in symptom management in chronic diseases. When the literature is examined, it is seen that aromatherapy application is effective in relieving anxiety and fatigue in cardiovascular diseases. Currently, there is no symptom management method other than pharmacological treatment that is widely used or recommended by health professionals for ICD patients. The literature review reveals that there is no study examining the effect of lavender oil aromatherapy in relieving anxiety and fatigue in individuals with ICD implantation. In this context, the aim of this study is to determine the effect of aromatherapy applied by inhaling two drops for two minutes before going to bed for one month on anxiety and fatigue levels in individuals with ICD implantation.
214315013|NCT01420445|DRUG|placebo|three times daily / 7 days
214315014|NCT05020392|DRUG|BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells|BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
214315015|NCT05020392|DRUG|Fludarabine-based chemotherapy + CAR-T-CD19 Cells|Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
214315016|NCT06095323|DEVICE|compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg)|The intervention group will wear compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg) during the day for 12 months.
214315017|NCT00974012|DRUG|Divalproex Sodium|500 mg ER Tablet
214315018|NCT00974012|DRUG|Depakote®|500 mg ER Tablet
214315019|NCT01037387|DRUG|Control|Current treatment according to the ATS/ERS guidelines
214315020|NCT01037387|DEVICE|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
214315021|NCT03559140|PROCEDURE|Applied saline solution at 2.5 oC (Cryotherapy group)|Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
214315022|NCT03559140|PROCEDURE|Applied saline solution at 8oC (Cryotherapy )|Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
214315023|NCT03559140|PROCEDURE|Applied saline solution at room temperature (No cryotherapy)|Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
214315024|NCT02112669|DEVICE|VasQ|
214315025|NCT04576611|OTHER|face-to-face protocol|The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).
214315026|NCT04576611|OTHER|self-managed protocol|Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
214315027|NCT02796040|DEVICE|MRI|
214315028|NCT00426582|DRUG|Patupilone|
214315029|NCT03175328|PROCEDURE|continuous renal replacement therapies|The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
214315030|NCT00581568|OTHER|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
214315031|NCT04544293|DRUG|Molgramostim|Molgramostim 300 µg nebulizer solution
214315032|NCT04544293|DRUG|Placebo|Matching placebo nebulizer solution
214315033|NCT04544293|DRUG|Molgramostim Open-label|Molgramostim 300 µg nebulizer solution
214315034|NCT01951157|DRUG|Docetaxel|Powder for solution for infusion
214315035|NCT01951157|DRUG|Gemcitabine|Powder for solution for infusion
214315036|NCT01951157|DRUG|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
214315037|NCT01200654|DRUG|Linezolid|Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
214315038|NCT04645407|DRUG|Fuzheng Huayu tablet|Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
214315039|NCT05125328|DRUG|Remifentanil|First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate\>100bpm and arterial blood pressure\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
214482081|NCT06875297|DIAGNOSTIC_TEST|FPG500|A cancer genome profiling with FPG500 will be performed on samples available from surgery or biopsy. Specimen are reviewed to assess tumor cell fraction. All H\&E slides are digitized before nucleic acid extraction. Semi-automated process is used for DNA/RNA extraction, DNA fragmentation, quantification, library preparation, and sequencing. Profiling is done with the TruSight Oncology 500 assay, analyzing 523 genes for single nucleotide variants, insertions/deletions, copy number variations, and fusions/splicing variants in 55 genes. It also evaluates genomic signatures like microsatellite instability and tumor mutational burden. Sequencing data are processed using Illumina software and a custom pipeline. Post-sequencing quality control is performed. Variants are classified according to the Human Genome Variation Society and clinical actionability guidelines. Genomic report is reviewed by an institutional Molecular Tumor Board.
214482082|NCT06867978|DEVICE|cCeLL In vivo|Dosage Form: Intravenous injection Dosage: 0.1 - 0.5 mg/kg of Indocyanine Green (ICG) Frequency: Single administration during surgery Duration: Real-time imaging performed immediately after ICG injection and used intraoperatively for tumor margin assessment
214482083|NCT06867978|DRUG|Indocyanine Green|fluorescence dye for staining tissue
214918485|NCT05497518|OTHER|Observational study - registry|The Study is a longitudinal observational cohort study that collaborates with health systems to obtain both electronic healthcare records (EHR) and patient-entered data. Eligible people with a diagnosis of chronic kidney disease at any stage, age 18 years and above, are identified through EHR data review, referral by a provider, or are recruited through the NKF's outreach campaign. Patients self-enroll into the online registry and share their experiences and health data through a secure portal where they can also find education, tips, and support. Research partners can view aggregate data through a collaboration portal.
214315040|NCT03864315|DEVICE|HGM|To Study the Efficacy of Therapeutic Pulsed Ultrasound in the Treatment of Vitiligo: a Randomized, Intra-individual, Left-right Comparison Study
214315041|NCT03398031|DRUG|Magnesium Oxide|After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester
214315042|NCT03398031|DRUG|Placebo Oral Tablet|After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
214315043|NCT04809220|DRUG|Dulaglutide|Administered SC
214315044|NCT04809220|DRUG|Oral antihyperglycemics|Administered orally
214315045|NCT05416983|PROCEDURE|Discussion|Attend discussion
214315046|NCT05416983|OTHER|Questionnaire Administration|Complete questionnaire
214315047|NCT01683981|DRUG|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
214315048|NCT06558240|DEVICE|HERADERM Hydrogel Wound Dressing (Sterile)|HERADERM Hydrogel Wound Dressing (Sterile) is a transparent, composite hydrogel dressing. The outer layer is a waterproof and breathable polyurethane film (PU film), which can prevent external bacterial invasion and reduce the risk of infection. The inner layer is A+ polymer hydrogel, which can keep the wound bed in a moist state and reduce the infiltration problem caused by wound exudate.
214315049|NCT05894876|OTHER|No treatment is given|No treatment is provided to the participants as part of this study.
214315050|NCT03418909|PROCEDURE|Primary Trans Oral Robotic Surgery (TORS)|In the absence of severe mobidity patients with early stage disease (T1-2, N1, M0) were offered TORS, as an alternative to the standard of care (radiotherapy).
214315051|NCT03418909|RADIATION|Radio(chemo)therapy|As the standard of care radiotherapy was offered to all of the patients. Patients that qualified for both TORS and radiotherapy were free to choose between the two.
214315052|NCT01429272|DRUG|Minocycline|100 mg po bid for 6 weeks
214315053|NCT01429272|DRUG|Aspirin|81 mg po bid for 6 weeks
214315054|NCT01429272|DRUG|placebo|placebo for minocycline and/or aspirin
214315055|NCT03234660|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
214918486|NCT04556084|DRUG|Blinatumomab|"Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day"
214918487|NCT06961279|DIETARY_SUPPLEMENT|Resveratrol|Administered orally once every 12 hours
214315056|NCT03234660|OTHER|control|0.9% normal saline continuous infusion
214315057|NCT03035955|DRUG|Azelaic acid|15% gel twice daily for four weeks to one side of face
214315058|NCT00329407|DRUG|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM \& 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM \& 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM \& 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
214315059|NCT03143699|OTHER|Immediate Feedback|Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
214315060|NCT00978068|DRUG|Lopinavir/Ritonavir (LPV/r)|
214315061|NCT00978068|DRUG|Nevirapine (NVP)|NVP will be used for children \< 3 years of age
214315062|NCT00978068|DRUG|Efavirenz (EFV)|EFV for children ≥3 years of age
214315063|NCT00978068|DRUG|2 nucleoside reverse transcriptase inhibitor (NRTI)|The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin \< 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
214315064|NCT03010111|OTHER|QFT-IT Test and other blood sampling|In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
214315065|NCT04153500|OTHER|Anatomy class with Pelvic+ methodology|Teaching of female pelvis anatomy using a interactive training model (Pelvic+ methodology)
214315066|NCT02508025|OTHER|Functional Capacity Evaluation|Assessment of work related physical capacity
214918488|NCT06961279|DIETARY_SUPPLEMENT|Placebo|Administered orally once every 12 hours
214315067|NCT01677975|PROCEDURE|FNA (fine needle aspiration)|
214315068|NCT00721786|BEHAVIORAL|UCSF/SFGH Internet Stop Smoking Study site|Internet stop smoking site in Spanish and English
214315069|NCT00384800|DRUG|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
214315070|NCT01048723|DRUG|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
214315071|NCT03550703|BIOLOGICAL|V3-Myoma|Once daily oral pill of V3-Myoma
214315072|NCT01080898|OTHER|tests|color photographs, FLUORESCEIN angiography and OCT
214315073|NCT05296785|PROCEDURE|intramedullary nail with Limb Reconstruction System|bone transport by Limb Reconstruction System over intramedullary nail on fracture tibia
214315074|NCT00002627|BIOLOGICAL|filgrastim|
214315075|NCT00002627|DRUG|carboplatin|
214315076|NCT00002627|DRUG|cyclophosphamide|
214315077|NCT00002627|DRUG|mesna|
214315078|NCT00002627|DRUG|paclitaxel|
214315079|NCT00002627|PROCEDURE|peripheral blood stem cell transplantation|
214315080|NCT02885961|DRUG|Dabigatran|Anti-coagulant
214315081|NCT02885961|RADIATION|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
214315082|NCT04121260|DRUG|Daratumumab|Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
214482084|NCT06872502|BEHAVIORAL|Mindfulness-Based Meditation (Integral Meditation - IM)|The intervention consists of 12 in-person mindfulness-based meditation sessions over a period of six weeks, with each session lasting one hour, twice per week. The practice, called Integral Meditation (IM), includes focused breathing, body relaxation, emotional awareness, and acceptance exercises.
214918489|NCT04797611|DEVICE|TNM Device|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive tvCVS device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
214918490|NCT03867409|BEHAVIORAL|message delivered via virtual technology|The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.
214918491|NCT04901325|DRUG|Baricitinib|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.
214918492|NCT06163820|DRUG|Bevacizumab|Bevacizumab is a humanised monoclonal antibody with molecular weight 167kD that inhibits all isoforms of the vascular endothelial growth factor (VEGF) and is produced from a Chinese hamster ovary mammalian system. It has high specificity for isoform-A and has a half-life of \~21 days.
214315083|NCT00772499|DRUG|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
214315084|NCT00772499|DRUG|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
214315085|NCT00527930|DRUG|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"
214315086|NCT06083350|DIETARY_SUPPLEMENT|Yeast beta-glucan|Produced by Angel Yeast Co., LTD
214315087|NCT06083350|DIETARY_SUPPLEMENT|Starch|Produced by Angel Yeast Co., LTD
214315088|NCT01315704|DRUG|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
214315089|NCT04695132|BEHAVIORAL|Illness Management and Recovery treatment programme|The Illness Management and Recovery treatment programme is a psychosocial treatment aimed at attaining illness management skills and promoting a sense of personal recovery amongst patients with serious mental illness. The original treatment protocol has been translated to Swedish and adapted to a forensic mental health setting. The treatment consists of ten chapters containing information and practical exercises relating to topics relevant for mental health and mental health recovery. These topics include medication use, stress reduction, problem solving, recovery goals and navigating the forensic mental health system. Participants are assigned practical homework and tasks to be completed outside of treatment sessions. Group sessions are conducted to present and discuss treatment material. Individual sessions are used to rehearse treatment content, personalize the treatment and review progress in achieving tasks agreed upon in the group setting.
214315090|NCT05699083|OTHER|Body Image/Self-Esteem Questionnaires|Pre-operation and post-operation questionnaires to assess factors including but not limited to body image, quality of life, and self-esteem.
214315091|NCT01261182|OTHER|In School Feeding|The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
214315092|NCT01261182|OTHER|Take Home Rations|The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
214315093|NCT02858245|OTHER|No intervention - registry|
214315094|NCT04258605|DEVICE|ASHCOM Shoulder System|Reverse Shoulder Arthroplasty
214315095|NCT03684018|BIOLOGICAL|IgPro10|Normal human immunoglobulin G administered intravenously
214315096|NCT04328831|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
214315097|NCT00648596|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
214315098|NCT00648596|DRUG|placebo|placebo tablet by mouth 1 hour before sexual activity for 12 weeks
214482085|NCT06874569|PROCEDURE|TAP Block:|TAP Block: A linear high-frequency probe (6-13 MHz) was placed transversely along the midaxillary line to visualize the external oblique, internal oblique, and transversus abdominis muscles. Using an in-plane approach, a 21G SonoPlex, STIM (PAJUNK, Germany), was advanced, and after hydro-dissection with 1-2 mL saline, 20 mL of 0.25% bupivacaine (Marcaine, AstraZeneca, Sweden) was injected into the plane between the internal oblique and transversus abdominis muscles.
214315099|NCT01442870|DRUG|Metformin|Metformin
214315100|NCT04717375|DRUG|SAR444881|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
214315101|NCT04717375|DRUG|Pembrolizumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
214315102|NCT04717375|DRUG|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
214315103|NCT04717375|DRUG|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
214315104|NCT04717375|DRUG|Pemetrexed|Pharmaceutical form: Powder for concentrate for solution for infusion or concentrate for solution for infusion; Route of administration: Intravenous
214315105|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
214315106|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
214315107|NCT02881645|BEHAVIORAL|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
214315108|NCT00208936|DRUG|Taxol, Cisplatin, 5-Fluorouracil, G-CSF|
214315109|NCT06250062|DRUG|Recombinant humanized IL-17A Monoclonal Antibody（JS005）|Injection
214315110|NCT06250062|DRUG|Placebo（JS005）|Injection
214315111|NCT04657133|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
214315112|NCT04657133|DEVICE|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
214482086|NCT06874569|PROCEDURE|TFP Block:|TFP Block: With a linear probe, the transversalis fascia was identified between the internal oblique and transversus abdominis muscles. An in-plane technique was used to insert a 21G needle, and following confirmation of correct placement with hydro-dissection, 20 mL of 0.25% bupivacaine was administered bilaterally.
215061036|NCT06468891|OTHER|Incontinence Symptom Severity Index|"* The ISSI consists of eight items that assess different aspects of urinary incontinence symptoms, including emptying difficulties, nocturia, daytime frequency, stress incontinence, urge incontinence, leakage with activity, and pad use.~* Each item is scored on a scale of (0 to 3) or (0 to 4), depending on the severity of the symptom. Higher scores indicate more severe symptoms.~* The total ISSI score is obtained by summing the scores of all eight items, resulting in a range of 0 to 32 or 0 to 40, depending on the version used.~* The severity of urinary incontinence symptoms can be categorized based on the total ISSI score"
214315113|NCT04657133|DRUG|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
214315114|NCT05683119|OTHER|Exercise and blood draw|This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle \[MC\] and oral contraceptive pill \[OCP\] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
214315115|NCT03984786|BEHAVIORAL|Assessment Interview|An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.
214482087|NCT06874569|PROCEDURE|QLB:|QLB: A low-frequency curvilinear probe (2-5 MHz) was used to identify the quadratus lumborum muscle and adjacent structures. The needle was advanced in-plane until it reached the targeted region adjacent to the quadratus lumborum, where after hydro-dissection, 20 mL of 0.25% bupivacaine was injected bilaterally.
214482088|NCT06875869|OTHER|Jones technique|In the Jones technique, pressure will be applied on the tender point and the patient's head will be flexed laterally to the side of the tender point, followed by a shoulder abduction of approximately 90 degrees. This position will be held for 90 s and then patient position will be passively returned to the initial position. This will be repeated three times in each session. Patients will receive two treatment sessions per week for 6 weeks
214482089|NCT06875869|OTHER|Ischemic compression therapy|Patients will receive ischemic compression of the trigger points of the upper trapezius and sternocleidomastoid muscle with hold time varying between 30 seconds to 1 minute repeated 3 to 5 times in each session. Patients will receive two treatment sessions per week for 6 weeks
214315116|NCT03984786|BEHAVIORAL|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
214315117|NCT03984786|BEHAVIORAL|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
214315118|NCT02374879|DEVICE|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
214482090|NCT06873646|COMBINATION_PRODUCT|Tri-Gnate Alginate Dressing|Patient will receive dressing product (Tri-Gnate Alginate) for the management of wound. The product will be put on every alternate day. Wound condition will be monitored from T0 - T6.
214315119|NCT04052542|BEHAVIORAL|Traditional online continuing education|30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV
214482091|NCT06873646|COMBINATION_PRODUCT|Dressing product from Manuka honey|Patient will receive other type of dressing product (Manuka honey product) for the management of wound. The product will be put on every alternate day. Wound condition will be monitored from T0 - T6.
214482092|NCT06873646|COMBINATION_PRODUCT|Bactigras + Dermacyn|Patient will receive standard dressing product (bactigras + dermacyn) for the management of wound. The product will be changed everyday. Wound condition will be monitored from T0 - T6 on alternate day basis.
214482093|NCT06875193|DRUG|DW6012(Dasidiem tab. 10/100mg)|Once a day, Oral administration
214482094|NCT06875661|OTHER|Schroth|Patients in the experimental group exercised for 90 minutes a day, three days a week. Schroth exercises were performed in an asymmetrical position to improve the symmetry of the trunk. These exercises include stretching, flexion, spinal lengthening, derotation, strengthening, and rotational breathing exercises. The respondents combined these exercises with everyday life activities. In the control group, subjects were taught Schroth exercises under the supervision of an authorized physiotherapist, and they were asked to practice the exercises as regularly as possible at home.
214482095|NCT03073395|DRUG|[68Ga]P16-093|Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
214482096|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
214482097|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
214482098|NCT05807958|DEVICE|Skin Prick Automated Test|A skin prick automated test will be performed in each participant.
214482099|NCT06624696|DRUG|Penehyclidine hydrochloride|The penehyclidine hydrochloride will be diluted to a total volume of 5 mL with normal saline, added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
214482100|NCT06624696|DRUG|Normal Saline|The normal saline with a total volume of 5 mL will be added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
214482101|NCT06055686|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test|Electrical stimulation test measures sensory/motor responses
214482102|NCT04874428|DRUG|Rivaroxaban 10 mg Oral Tablet|Administration of one single dose of rivaroxaban (10 mg) in tablet form.
214482103|NCT04874428|DRUG|Apixaban 2.5 mg Oral Tablet|Administration of one single dose of apixaban (2.5 mg) in tablet form.
214671489|NCT06970041|DEVICE|Use of HFNC during therapeutic FOB as a respiratory support method in patients with type 2 respiratory failure|The aim of the project is to assess the safety, indications and contraindications for therapeutic bronchofiberoscopy in patients with decompensated respiratory acidosis using: invasive mechanical ventilation (IMV), non-invasive mechanical ventilation (NIV) and high-flow nasal canulla (HFNC). Additionally, we want to determine to what extent the use of respiratory support during bronchofiberoscopy (BF) will avoid complications such as exacerbation of hypoxemia and/or acidosis and the occurrence of hemodynamic instability.
214671490|NCT06971419|OTHER|intervention is the use of aTriage-Based Patient Redirection Using an Electronic Decision Support Toolin the emergency department (ED)|"Name: Logibec Réorientation software-assisted triage and redirection~Type: Decision support system for emergency triage~Implementation:~* Applied during patient triage in the emergency department~* Assists in identifying low-acuity (SETS 4) and semi-urgent (SETS 3) patients eligible for redirection~* Uses standardized inclusion/exclusion criteria to guide redirection decisions~Comparator: Standard nurse-led triage and redirection based only on the Swiss Emergency Triage Scale (SETS)~Key Distinction:~* The investigated group receives Logibec-assisted triage and redirection.~* The comparator group follows traditional nurse-led triage without electronic support, limiting redirection to SETS 4 patients only."
214918493|NCT06163820|DRUG|Ipilimumab|Ipilimumab is an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Ipilimumab is a recombinant human immunoglobulin monoclonal antibody that binds CTLA4 and blocks the interaction between CD80/86 and CTLA4.
214315120|NCT04052542|BEHAVIORAL|Interprofessional education|One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session
214671491|NCT04901507|DEVICE|The Voutia System|Participants will wear the Voutia System oral irrigation device continuously through the day and night, removing for cleaning and if otherwise necessary, but not for time extending beyond six-eight hours.
214918494|NCT06163820|DRUG|Nivolumab|Nivolumab ia an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Nivolumab is a fully human monoclonal IgG4 antibody targeting PD-1 which demonstrates activity across a range of tumours.
214918495|NCT06163820|RADIATION|Hypofractionated stereotactic radiotherapy|Hypofractionated stereotactic radiotherapy (hSRT) will be delivered to previously untreated brain metastases in eligible participants. hSRT will be delivered to all symptomatic brain metastases, all brain metastases \>1 cm and all brain metastases located in eloquent areas of the brain. hSRT will be commenced after the first cycle of nivolumab plus ipilimumab and completed before the second cycle of nivolumab plus ipilimumab. hSRT should be commenced within 1 week from the planning MRI.
214315121|NCT04052542|BEHAVIORAL|Just-in-time education|"Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV"
214315122|NCT02956733|PROCEDURE|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
214315123|NCT02956733|PROCEDURE|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 \& 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
214315124|NCT00682188|BEHAVIORAL|Counseling Intervention|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
214482104|NCT04618406|DEVICE|PICO VAC|PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.
214482105|NCT04618406|OTHER|Standard care|Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
214482106|NCT04722263|RADIATION|Radiotherapy|15 Gy in 3 fractions
214482107|NCT05933772|DEVICE|Lens A (comfilcon A toric lens)|One month wear
214482108|NCT05933772|DEVICE|Lens B (lehfilcon A toric lens)|One month wear
214482109|NCT06874023|OTHER|Passive heating in hot conditions|Participants performed seated passive heating in 54C conditions
214482110|NCT06874023|OTHER|Active heating + passive heating in hot conditions|Participants performed 30 minutes of biking exercise in 43C + 30 min of passive seated heating in 54C conditions.
214482111|NCT06874023|OTHER|Active heating in hot conditions|Participants performed 60 minutes of biking exercise in 43C.
214482112|NCT06874023|OTHER|Active heating at room temperature|Participants performed active heating through biking exercise for 60 minutes at room temperature.
214315125|NCT00682188|BEHAVIORAL|Information Intervention|Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
214315126|NCT04785274|DEVICE|non-invasive hemoglobin (SpHb)|hemoglobin measuring device
214482113|NCT06874023|OTHER|Cool vest|Cool vest (18°C) with 500 mL (16 fl oz) ice water consumption
214482114|NCT06874023|OTHER|Damp neck towel combined with arm cool water immersion|Damp neck towel (24°C) combined with arm (i.e. hand, forearm and half of upper arm) cool water immersion (15°C) and 500 mL (16 fl oz) ice water consumption
214482115|NCT06874023|OTHER|Combination of cooling interventions|Combination of cool vest (18°C), damp neck towel (24°C) with arm cool water immersion (15°C), and 500 mL (16 fl oz) ice water consumption
214482116|NCT06874023|OTHER|Control in thermoneutral room without cooling|A control with participant sitting in a thermoneutral room (20°C air temperature) without any additional cooling intervention.
214482117|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
214482118|NCT06627088|DRUG|[14C]-LY4100511 (DC-853) Administered oral dose|Administered oral dose
214482119|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
214482120|NCT06627088|DRUG|[14C]-LY4100511 (DC-853)|Administered IV infusion
214482121|NCT06875804|OTHER|baseline physical therapy treatment|Group A focuses on pain relief, muscle relaxation, and strengthening. Hot packs and TENS are applied to the lateral thigh and knee for 20 minutes to reduce pain and muscle tension. Hip strengthening exercises include side-lying hip abduction, clam-shells, prone hip extension, bridging, and lunges. Quadriceps exercises involve straight leg raises, prone terminal knee extension, and mini-squats. Each exercise is done in 2-3 sets of 10-15 repetitions, holding stretches for 5 seconds.
214482122|NCT06875804|OTHER|Compressive myofascial release of vastus lateralis.|The experimental group receives an additional session of Compressive Myofascial Release (CMFR) for the Vastus Lateralis to address lateral patellar tracking in PFPS patients. The patient lies on their side, and the therapist identifies tight areas, applying firm pressure for 20-30 seconds. Deeper pressure is held for 30-60 seconds, followed by 1-2 minutes of cross-fiber friction. The session includes muscle shaking for 30 seconds and stretching the Vastus Lateralis by extending the hip and flexing the knee for 30-60 seconds, repeated 2-3 times. Patient response is documented for progress tracking.
214482123|NCT04951856|DRUG|Evolocumab 140 MG/ML|Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
214482124|NCT04951856|DRUG|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
214482125|NCT06622538|DEVICE|Orotracheal intubation|Patients who meet the inclusion criteria and sign the informed consent form will be intubated with the ORION or King Vision video laryngoscope according to randomisation.
214671492|NCT05066815|OTHER|Vita Enamic (Hybrid dental ceramic)|Vita Enamic (Hybrid dental ceramic) is provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology.
214671493|NCT00729430|DRUG|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
214315127|NCT01452464|BIOLOGICAL|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
214315128|NCT06176950|OTHER|Oral History Interviews|I will ask interview subjects about their educational and career path, their research interests and clinical work in the field of neonatology. I will also ask them about their personal and professional motivations and thoughts about their work. And we will discuss how their interactions with colleagues and patients/caregivers shaped their work experience and decision making.
214315129|NCT06215963|DEVICE|App for Independence-O (A4i-O)|A4i-O is a digital health platform designed to support individuals with opioid use disorders. A4i-O will focus on providing education on treatment options, recovery navigation, social activation and connections to a range of resources. It aims to assist with fostering self-management and recovery through identifying risks for relapse, navigating urges/cravings, coping with shame/guilt, avoiding relapse, moving forward after relapse, and lived experiences. Daily wellness and goal attainment check-ins to highlight mental health trajectories will be prompted. With appropriate consent from both the client and provider, a provider dashboard is accessible to the client's provider prior to their appointment, generating a summary of day-to-day wellness ratings, responses to reminders, goal progressions, and other self-reported measures from the platform.
214315130|NCT03718442|DEVICE|PhotonBlade vs Bovie for lumpectomy shaved surgical margins|For each enrolled patient, six shaved margins will be obtained (superior, inferior, medial, lateral, anterior, and posterior). For each patient, electrocautery will be used to obtain 3 of the shaved margins, and PhotonBlade to obtain the other 3 shaved margins. Once the lumpectomy site shaved margins have been obtained, the shaved surgical margins will be evaluated by a pathologist whom is blinded in regards to the dissection device that was used for each margin. The pathologist will be evaluating each shaved margin and reporting the outcomes (qualitative severity and depth of thermal artifact)
214315131|NCT02029534|DRUG|Atorvastatin 20 mg|
214315132|NCT02029534|DRUG|Atorvastatin 80 mg|
214315133|NCT01070316|DRUG|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
214315134|NCT04347382|DRUG|Honey|1gm/Kg/Day
214315135|NCT04347382|DRUG|Nigella Sativa / Black Cumin|80mg/Kg/day
214315136|NCT04347382|DRUG|Placebos|Empty capsule with 250ml of distilled water
214315137|NCT01500707|DRUG|SCH 900800|SCH 900800, one 20 mg tablet, orally
214315138|NCT01712256|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
214315139|NCT00543764|OTHER|pathway|Comparison of pre and post pathway
214482126|NCT06692920|OTHER|DBS stimulation|"* Standard of care DBS surgery~* stimulation through the DBS lead during their DBS lead surgery, the study team will use 2 sets of stimulation settings on each participant:~  1. Stimulation through the DBS contact whose electrical activity is the MOST similar to the area of the brain that controls movement~ 2. Stimulation through the DBS contact whose electrical activity is the LEAST similar to the area of the brain that controls movement"
214315140|NCT00748215|DRUG|calcium aluminosilicate anti-diarrheal|Given orally
214315141|NCT00748215|OTHER|placebo|Given orally
214315142|NCT02194868|BIOLOGICAL|Recipients|"1. Adult recipient:~   * collected 20 ml pre-transplant~  * collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,~  * collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360~2. Children recipients~   * collected residual blood pre-transplant~  * collected residual blood on day 20 post-transplant at engraftment for cell phenotype,~  * collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"
214315143|NCT02194868|BIOLOGICAL|Donors|"1. Adult donors :~   * collected 20 ml of blood, (if possible before granulocyte colony-stimulating factor (GCSF) administration)~  * collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.~2. Children donors samples~   * collected residual blood~  * 2ml of bone marrow (bottom of tube)"
214482127|NCT06691880|BEHAVIORAL|MindPod Dolphin VGT|"The MindPod Dolphin, is an interactive video game that allows users to engage in non-task-based tasks to motivate the users to play and relearn motor skills. The MindPod gaming platform uses markerless tracking to sense the patient's affected arm. The paretic limb controls Bandit the dolphin underwater in an effort to eat fish. The patient learns to map his/her movements to Bandit in a 3-Dimensional work space to reach the targets. During gaming, the therapist titrates game difficulty. Bilateral gaming components are used (the participant uses a controller with the participant's less-affected limb to control the timing of Bandit's movement) and in-game difficulty can be adjusted to create an immersive, challenging, and engaging experience. In order to be successful, the patient must coordinate both arms to control the temporal and spatial aspects of the game."
214671494|NCT00729430|DRUG|Placebo|Placebo tablets taken orally once per day for 6 months
214315144|NCT01561352|DRUG|activated recombinant human factor VII|If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
214315145|NCT00592566|DRUG|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
214315146|NCT04944901|DRUG|SB-121|SB-121 is a formulation of L. reuteri
214315147|NCT04944901|DRUG|Placebo|Placebo oral formulation
214671495|NCT00863187|BIOLOGICAL|rituximab|b cell depletion
214671496|NCT05347056|DIAGNOSTIC_TEST|Lumbar Spine Magnetic Resonance|Metal artifact reduction sequence (mars), axial t2 sequence
214482128|NCT06691880|BEHAVIORAL|Bimanual Arm Trainer VGT|"The bimanual arm trainer (BAT) is a device that involves hardware that interfaces with a computer game. The BAT promotes shoulder external rotation and elbow extension in the paretic arm by coupling movements of the paretic arm with the less affected limb as the participant matches his/her arm movements to those of a virtual avatar. The less-affected side and paretic limb are placed in the BAT apparatus and the less affected limb drives the impaired limb through passive, symmetrical movements that simulate rowing down a virtual river. The protocol created by the investigators group, leads the patient through an active-passive training progression similar to paradigms used in neural priming studies. Through these series of movements, the goal is to restore balance between the muscles of the upper back and chest to maximize range of motion in preparation for improved quality of movement."
214482129|NCT04194216|DRUG|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."|Treatment Arm A
214482130|NCT04194216|DRUG|"Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days"|Treatment Arm B
214482131|NCT04881110|DRUG|Liraglutide|Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one.
214482132|NCT04881110|OTHER|Control|Patients in this arm will be strictly monitored for atherosclerosis major risk factors, such as hypertension and dyslipidemia, and treated according to current clinical practice.
214482133|NCT02213497|RADIATION|18F-FDG (Fluorodeoxyglucose) PET|
214482134|NCT02213497|DRUG|Carboplatin|
214482135|NCT02213497|DRUG|Paclitaxel|
214482136|NCT06246344|RADIATION|Adaptive Boost Radiotherapy|"The choice of adaptive protocol and delivery system is based on individual tumor characteristics, patient anatomy and institutional capabilities. This approach provides flexibility in treatment planning while adhering to evidence-based dose constraints. Adaptive radiotherapy is delivered using one of the following advanced platforms: the Elekta Unity MRI Linac (MR-guided) or Varian Ethos (CBCT-guided), or the United Imaging uRT-linac 506c (FBCT-guided).~ART Option 1 (simultaneous integrated boost, SIB):~GTVp+GTVn: A total dose of 60-65 Gy delivered in 25 fractions using a simultaneous integrated boost approach.~CTV: A total dose of 45-50 Gy delivered in 25 fractions.~ART Option 2 (sequential boost, SB) GTVp+GTVn: An initial hypofractionated boost with a total dose of either 9-12 Gy delivered in 3 fractions or 10 Gy delivered in 2 fractions.~CTV: Followed by standard fractionation delivering 45-50 Gy in 25 fractions."
214482137|NCT06246344|RADIATION|Long course non-ART radiotherapy|Conventional long-course radiotherapy administered in a non-adaptive manner without dose escalation. Treatment will be targeted to the pelvic lymphatic drainage region only. A total dose of 45-50 Gy will be delivered in 25 fractions over the course of treatment.
214482138|NCT06246344|DRUG|Concurrent chemotherapy|Capecitabine (825 mg/m2, po, twice daily)
214482139|NCT06246344|DRUG|Consolidation Chemotherapy|Following the completion of concurrent chemoradiotherapy, consolidation chemotherapy will commence 7 to 10 days later. Patients will receive two cycles of the CAPEOX regimen. Each cycle comprises: Capecitabine: 1.0 g/m² administered orally twice daily on days 1 through 14, and Oxaliplatin: 130 mg/m² administered intravenously on day 1.
214482140|NCT06246344|PROCEDURE|Total mesorectal excision (TME) surgery|Total mesorectal excision surgery
214482141|NCT06450626|OTHER|Listening Music Intervention|Participants will listen to a music playlist while vitals are monitored, along with completing a pre- and post-assessment survey (both of which are the Edmonton Symptom Assessment Scale). Participants will also be asked a set of qualitative questions about their overall experience with the music therapy session.
214482142|NCT06684691|OTHER|Intervention group|The escape room game will be applied to the students in the intervention group after the theoretical training.
214482143|NCT06684691|OTHER|Control group|The escape room game will not be applied to the students in the control group after the theoretical training.
214482144|NCT05817006|GENETIC|Device|research of the long-COVID-19 in the children
214482145|NCT06683560|DEVICE|": photopolymer resin material graphy Tera Harz 85 will be used to print 3D printed aligners for NAM treatment"|3d printed NAM aligner is made from novel photopolymer resin as a novel device
214482146|NCT06624566|OTHER|Experimental: Implementation of an intensive therapeutic group exercise program in the neurorehabilitation process|Description: The variables will be measured prior to group assignment The age and sex variables and the satisfaction survey will be measured at the beginning of the program, the other variables at 20 sessions, at 40 sessions, at 60 sessions and/or at hospital discharge. Before the patient starts the program, he/she is classified in group A - patients who have seated trunk control for at least 2 minutes (with supervision) and no standing control (Berg scale item 3.3) - or in group B - patients who have standing trunk control for 2 minutes (with supervision) (Berg scale item 2.3). There is a maximum of 4 patients per group with 1 physiotherapist per group.. There is a maximum of 4 patients per group with 1 physiotherapist per group.. The difference with respect to the usual treatment of the neurorehabilitation service of the HMS is that in the EINTER program, strength and endurance exercises will be implemented in addition to the usual care plan
214482147|NCT05645276|DRUG|AK129 IV infusion|AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
214482148|NCT06004440|DEVICE|Ion Endoluminal System|Subjects will under a planned procedure with the Ion Endoluminal System
214918496|NCT05916144|BEHAVIORAL|Interaction-Based Early Education Program|The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
214918497|NCT02917798|BEHAVIORAL|Assessments|
214918498|NCT05872386|BEHAVIORAL|Buprenorphine uptake/retention via Telehealth|Bupe by the Book (BBB) randomly assigns unstably housed library patrons with opioid use disorder to a telehealth to receive buprenorphine (aka, Suboxone) treatment from Father Joe's Villages Health Center.
214918499|NCT05872386|BEHAVIORAL|Control group|unstably housed library patrons with opioid disorder are assigned randomly to a treatment as usual control group (in-person at the clinic)
215061037|NCT06468891|OTHER|Force platform|"Use the provided software or tools to analyze the recorded force data, including Step Cycle Duration (ms), Time of Contact (ms), Swing Duration (ms), Single Step Duration (ms), Double Support Duration (ms), Initial Contact (ms) , Loading Response (ms), Mid Stance (ms), Terminal Stance (ms), Step Cycle Length, Half Step Length for left and right lower limbs.~* Interpret the data to draw conclusions about the forces exerted during the subject's movements or activities."
214315148|NCT01933867|PROCEDURE|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
214315149|NCT01933867|PROCEDURE|Air insufflation insertion|
214315150|NCT05284838|OTHER|Error Management Training (Difficult)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter difficult questions.
214315151|NCT05284838|OTHER|Error Management Training (Easy)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter easy questions.
214315152|NCT05284838|OTHER|Error Avoidance Training|Error Avoidance Training used to teach head computed tomography interpretation.
214315153|NCT02098577|OTHER|Crossover|Crossover cycle
214315154|NCT02098577|OTHER|Stabilometric Platform|This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
214315155|NCT05393557|OTHER|Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury|Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR \< 60, or SBP \<100 mmHg) + 2 cycles of intermittent balloon inflation
214315156|NCT03200899|BEHAVIORAL|MAPSS-MS|MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
214315157|NCT03200899|OTHER|Usual Care plus computer games|"Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website."
214315158|NCT01069133|DRUG|Rifaximin|550mg BID open-label
214315159|NCT01069133|DRUG|rifaximin|550mg PO BID
214315160|NCT04646499|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.
214482149|NCT05960786|DEVICE|Otoband Experimental|Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
214315161|NCT00837707|DRUG|aripiprazole|Flexible dose: 5-30 mg/day
214315162|NCT00012558|DRUG|lithium|
214315163|NCT00012558|DRUG|valproate|
214315164|NCT00012558|DRUG|bupropion|
214315165|NCT00012558|DRUG|paroxetine|
214315166|NCT00012558|DRUG|lamotrigine|
214315167|NCT00012558|DRUG|risperidone|
214315168|NCT00012558|DRUG|inositol|
214315169|NCT00012558|DRUG|tranylcypromine|
214315170|NCT00012558|BEHAVIORAL|Cognitive Behavioral Therapy|
214315171|NCT00012558|BEHAVIORAL|Family-focused Therapy|
214315172|NCT00012558|BEHAVIORAL|Interpersonal and Social Rhythms Therapy|
214315173|NCT03468881|OTHER|Communication Skills Training Package (KEW)|A training package (called KEW: Know, Encourage and Warm-up) for therapeutic radiographers to manage emotional talk with breast cancer patients in treatment.
214482150|NCT05960786|DEVICE|Otoband Sham|Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.
214671497|NCT05347056|DIAGNOSTIC_TEST|Isokinetic trunk flexion-extension trunk muscle strength and endurance test|To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s
214671498|NCT05347056|DIAGNOSTIC_TEST|Lomber Region Range of motion assessment|To evaluate for lomber region ROM with digital inclinometer
214315174|NCT05820971|OTHER|C-short plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~* Outcomes (6a)~* Sample size (7a)~* Sequence generation (8a)~* Allocation concealment (9)~* Blinding (11a)~* Outcomes and estimation (17a/b)~* Harms (19)~* Registration (23)~* Protocol (24)~* Funding (25)"
214315175|NCT03080558|DRUG|Indocyanine green|Use of Indocyanine Green during Rectal shaving by laparoscopy.
214315176|NCT05165212|DRUG|Amoxicillin|Patients will be given 10% of a standard weight-based dose of amoxicillin and observed for signs/symptoms of allergic reaction for 30 minutes. If no reaction occurs, they will given the remaining 90% of the standard dose and observed for an additional 30 minutes.
214315177|NCT00891137|BIOLOGICAL|human myeloid progenitor cells|Single intravenous injection/infusion
214315178|NCT02202733|OTHER|Cooking|The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
214315179|NCT01165866|DRUG|Treatment 1. Metoclopramide|metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.
214315180|NCT01165866|DRUG|Treatment 2 Ondansetron|Single dose of Ondansetron 0.15 mg/kg
214315181|NCT03408015|DRUG|Lifitegrast|Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed.
214315182|NCT05252039|BEHAVIORAL|Goals in Focus|"Goals in Focus (GiF) is a symptom-specific treatment program that targets motivational negative symptoms in patients with schizophrenia-spectrum disorders.~The aim is to improve setting and pursuit of personal relevant goals.~GiF follows a 24-individual-sessions treatment manual. GiF includes five treatment phases: 1) Preparation, 2) Goal-setting, 3) Goal-pursuit, and 4) Reflection and preparation of autonomous goal-pursuit. The interventions include generating positive goals, behavioral activation, training of anticipatory pleasure, challenging demotivating beliefs, training of problem-solving skills and social skills training."
214671499|NCT05347056|DIAGNOSTIC_TEST|Radiograph|spinal radiograph AP/Lateral
214315183|NCT01302912|PROCEDURE|Lymphoma-Biopsy|Patients after biopsy of orbital lymphoma
214315184|NCT02727920|DIETARY_SUPPLEMENT|Energy drink|
214315185|NCT02727920|OTHER|Placebo|placebo drink
214315186|NCT05798416|DRUG|Exercise under inhalation CO2|Participants perform shuttle walk test at high altitude while using the novel portable device for inhalation of CO2
214315187|NCT05798416|OTHER|Exercise under inhalation ambient air|Participants perform shuttle walk test at high altitude while inhaling ambient air
214315188|NCT06256042|PROCEDURE|Occlusal splint|a stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).
214315189|NCT06256042|PROCEDURE|Arthrocentesis|The patient then underwent arthrocentesis of the temporomandibular joint itself, following the Nitzan technique.
214315190|NCT04350151|BEHAVIORAL|no intervention|no intervention
214315191|NCT05145829|DIAGNOSTIC_TEST|Diagnostic Test: Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
214315192|NCT01730183|OTHER|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
214315193|NCT06617975|OTHER|Balneotherapy program in rheumatology indication|"At least 4 balneotherapy sessions per day, 6 days a week during 3 consecutive weeks that may include: 1 whirlpool bath per day, 1 poultice application per day, 1 bath with immersion showers in a pool per day, a local jet shower every other day, a penetrating shower every other day.~Alternative treatments may replace penetrating shower or local jet shower, or other care, e.g., collective jet shower or steam bath. 10-minute air diffusion baths are taken in individual tubs at 37°C. Mud is applied 10 minutes as a poultice to both knees (minimum 2 per knee, 52°C), if necessary, to other painful osteoarthritis areas. 10-minute collective pool bathing takes place in a thermal pool equipped with jet stations immersed in water at 32°C. 3-minute local jet shower is applied to the predefined area using thermal water at 37°C. 10-minute penetrating showers are delivered by an affusion ramp on the patient lying down and directed on the area defined, using thermal water at 37°C."
214482151|NCT06161324|OTHER|PFM exercises program through the Mobile app in cooperation with the superficial sensor|"The mobile app will offer a personalized progressive protocol to the user based on his needs, via 12 levels of games(from the easiest to the hardest).The cooperating PFM superficial sensor will indicate the activity of the PFMs during the contraction.Νο face-to-face meetings will be incurred between participants and therapist.~Participants will follow a program for 12 weeks(3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).Endurance training will involve slow velocity contraction and speed training will involve quick (i.e.1 sec duration) strong contractions.Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)."
214315194|NCT05829928|DIAGNOSTIC_TEST|Infectious Disease Testing|Participants will undergo infectious disease testing.
214315195|NCT05829928|PROCEDURE|Gonadal Tissue Removal|Removal of gonadal tissue will be done through a surgical procedure.
214315196|NCT06587451|DRUG|JPB898 (Induction and Maintenance)|Induction and Maintenance: Intravenous (IV)
214315197|NCT06587451|DRUG|Opdivo-EU (Induction)|Induction: Intravenous (IV)
214315198|NCT06587451|DRUG|Opdivo-US (Induction)|Induction: Intravenous (IV)
214315199|NCT06587451|DRUG|Yervoy-EU (Induction)|Induction: Intravenous (IV)
214315200|NCT06587451|DRUG|Opdivo-EU (Maintenance)|Maintenance: Intravenous (IV)
214315201|NCT03369210|DRUG|red blood cell transfusion trigger|patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
214315202|NCT06995430|BIOLOGICAL|rMenB+OMV NZ vaccine|1 dose in the Primed group or 2 doses in the Naive group.
214315203|NCT04866771|OTHER|Transcranial Direct Current Stimulation (tDCS)|Noninvasive brain stimulation
214315204|NCT04866771|OTHER|Sham tDCS + anodal tDCS|Fake noninvasive brain stimulation or anodal noninvasive brain stimulation
214315205|NCT06684379|DRUG|Placebo comparator|A single dose of saline solution 0.9% for infusion
214315206|NCT06684379|DRUG|PRS CK STORM|A single dose of PRS CK STORM (dose A) for infusion
214315207|NCT06684379|DRUG|PRS CK STORM|A single dose of PRS CK STORM (dose B) for infusion.
214315208|NCT06742736|DRUG|BGF|BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
214315209|NCT07064135|BEHAVIORAL|Prompt Medication Adjustment and Intensive Follow-up|Participants receive prompt adjustment of lipid-lowering therapy perioperatively and 6-8 weeks after carotid endarterectomy to achieve guideline-recommended LDL-C targets, combined with intensive follow-up visits and laboratory monitoring. Intensive follow-up visits and laboratory monitoring of lipid parameters are performed at 6-8 weeks and again at 12-16 weeks postoperatively to optimize lipid management.
214315210|NCT07064135|OTHER|Standard Care|Participants receive standard postoperative care according to guidelines, including lipid management and routine follow-up without additional early intervention or intensive monitoring. Lipid parameters are assessed only once at 12-16 weeks postoperatively.
214315211|NCT06682754|OTHER|Stress|All participants will perform a baseline test in which they will first be asked to visualize low-arousal IAPS images for three minutes while seated in a chair, and then get up, walk to a table with two bottles, transfer liquid from one bottle to the other, return to the starting chair and sit down again. Subsequently, they will perform an experimental test, where they will repeat the same movements as in the baseline test after visualizing high-arousal IAPS images for three minutes. In addition, IAPS images will continue to be projected in the background while participants perform the described motor tasks.
214315212|NCT06902740|DRUG|Recaticimab and Statin|Recaticimab (450mg every 12 weeks subcutaneously) combined with rosuvastatin 10mg qn or atorvastatin 20mg qn
214315213|NCT06902740|DRUG|Statin|Rosuvastatin 10mg qn or atorvastatin 20mg qn
214315214|NCT00209677|DRUG|Gemcitabine|
214315215|NCT00209677|DRUG|S-1|
214315216|NCT07087366|PROCEDURE|ERAS protocol|Procedure: ERAS protocol
214315217|NCT07095959|PROCEDURE|vein of Marshall ethanol infusion|After PFA, the coronary sinus venography will be acquired in search of VOM ostium. Then an over-the-wire balloon will be sent into the VOM and deflated with 4-6 atm. Selective VOM venography will be performed, followed by injection of 10ml 95% ethanol into the VOM.
214315218|NCT07095959|PROCEDURE|PVI using pulsed field ablation|Bilateral pulmonary vein antrum ablation using a pulsed field ablation
214482152|NCT06161324|OTHER|Face-to face PFM exercises program in Healthcare environment|"The therapy will include face-to-face meetings weekly, regarding the progress of the treatment and its smooth transition (intra-vaginally assessment when it needs, correction, encouragement, motivation, etc).~Participants will follow a personalized progressive PFM exercise program for 12 weeks (3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).The endurance training will involve slow velocity contraction and the speed training will involve quick (i.e.1 sec duration) strong contractions. The Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks.It will be followed the order of supine, side, prone, quadruped support, sitting and standing position"
214671500|NCT05347056|BEHAVIORAL|SRS 22|SRS-22 Patient Questionnaire
214315219|NCT07099170|BEHAVIORAL|Brochure-Based Pelvic Floor Muscle Training|Brochure-based pelvic floor muscle training will be conducted by providing participants with a brochure containing information about the anatomy, functions, and importance of the pelvic floor, as well as instructions on how to contract the pelvic floor muscles. All educational content will be delivered solely through the brochure, and no additional verbal or written information will be provided to the participants. The brochure will include detailed explanations of pelvic floor muscle contractions and imagery techniques. Participants will be given 30 minutes to review the brochure and apply the training independently.
214918500|NCT04509193|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)
214918501|NCT04509193|DRUG|Warfarin|Participants receive warfarin (per written prescription, medication administration or self-report of medication use)
214918502|NCT03300505|DRUG|ARRx|Given intravenously (IV)
214918503|NCT03300505|DRUG|Enzalutamide|Given by mouth (PO)
214918504|NCT02905318|DRUG|Palbociclib|125 mg orally on days 1-21 each 28 day cycle
214482153|NCT06161324|OTHER|PFM exercises program via home-leaflet(without suprevision)|"The participants of the CG will be advised to follow a personalized PFM exercise program at home based on their 1st meeting assessment. They will receive a comprehensive leaflet, with instructions and images about the PFM exercises at home. The PFM exercise program will last 12 weeks (3 times weekly, 1-5 sessions daily), without meetings, guidance and supervision by the physiotherapist. Similarly to the other two intervention groups, the program will contain endurance training (slow velocity contraction), speed training (quick contractions), Knack maneuver training (pre-contraction before coughing), and changing positions every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)"
214482154|NCT04157517|DRUG|Modakafusp Alfa|Modakafusp alfa intravenous infusion.
214482155|NCT04157517|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
214918505|NCT06240572|OTHER|no intervention|no intervention
215061038|NCT06468891|OTHER|The STT three-dimensional motion analysis (3DMA) system|The STT three-dimensional motion analysis (3DMA) system (STT Systems Company, Zuatzu Business Park, Easo Building, 2nd Floor, San Sebastián, Spain) was used for the assessment of spatiotemporal characteristics of gait. It is an indoor optical system that consists of four cameras, fifteen markers, and computer software for automatic three-dimensional motion capture and analysis. CLINICAL 3DMA V.6.11 is professional software with highly accurate marker tracking. The STT Helen Hayes protocol was used for the gait analysis in this study.
214482156|NCT06694311|DEVICE|CPAP|"12 cmH2O for 48 hours (at least 10 hours of therapy per day). Nasobucal interface will be the preferred route with complete facial mask being also an acceptable device. If needed, therapy breaks will be delivered with HFNO at 50 L/min.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although CPAP will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more."
214671501|NCT06972108|DRUG|Caffeine citrate|Caffeine citrate loading at 10 mg/kg, followed by daily maintenance of 5 mg/kg PO
214671502|NCT06972108|OTHER|Saline (NaCl 0,9 %) (placebo)|Saline PO for loading and daily maintenance
214671503|NCT03395522|DEVICE|iTind|device implanted for 5-7 days
214671504|NCT05707858|OTHER|Development of the NAPFA score|In subjects with suspected food allergy we will evaluate main anamnestic, and clinical features to develop the NAPFA score
214671505|NCT06511661|PROCEDURE|Complete lymphadenectomy|At least 3 N1 stations and 3 N2 stations are examined during surgery, including station 7.
214918506|NCT04254419|BIOLOGICAL|NK cells|"The universal donor TGFβi NK cells will be cryopreserved until they are delivered bedside for infusion. The trained staff will thaw the product by the bedside. The administration of the cells will be done via an Ommaya intra-cavitary/a programable ventriculoperitoneal (VP) shunt.~Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya/VP shunt in approximately 3 milliliters over approximately 2-5 minutes; followed by 1.5-2 milliliter preservative-free normal saline flush over approximately 1 minute."
214918507|NCT06491927|GENETIC|No Intervention|Observational study
214918508|NCT00209963|DRUG|Gaboxadol|
214918509|NCT00664378|DRUG|CYT997|Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle
214918510|NCT03756623|DRUG|Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
214918511|NCT03756623|DRUG|Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
214918512|NCT03756623|OTHER|Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
214918513|NCT01265745|DRUG|Normal Saline for Injection|Equivalent amounts to subjects weight, once over 120 minutes
214918514|NCT01265745|BIOLOGICAL|MDX1303|a sterile solution at a protein concentration of 25 mg/mL: 20 mM sodium citrate, 50 mM sodium chloride, 3.0% mannitol, 50 µM diethylenetriamine pentacetic acid and 0.06% polysorbate 80 at pH 6.5. A tubular, clear glass vial, filled with a 5 mL dose of colorless to pale yellow solution. The vial is sealed with a 20 mm stopper and white flip-off seal.
214918515|NCT02658474|BEHAVIORAL|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
214918516|NCT06570941|DRUG|Chylobinoid Topical Cream|The topical cream is applied to the effected area to reduce or eliminate the symptoms of restless leg syndrome
214482157|NCT06694311|DEVICE|HFNO 50 L/min|"HFNO 50 L/min for 48 hours. Therapy breaks with oxygen facemask will be allowed as per clinician decision but the protocol will advise against this practice.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although HFNO will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more."
214482158|NCT06695650|OTHER|Mandala Coloring|Students in the intervention group will be provided with mandala templates and coloring materials. They will be asked to color for 15 minutes twice a week over a two-month period
214315220|NCT07099170|BEHAVIORAL|Verbal Instruction-Based Pelvic Floor Muscle Training|Verbal instruction-based pelvic floor muscle training involves providing participants with information about the anatomy, functions, and importance of the pelvic floor, as well as instruction on how to correctly contract the pelvic floor muscles. All explanations will be delivered verbally, and no additional equipment or visual aids will be used. During the training, imagery techniques based on verbal cues will be employed. Commonly used metaphors such as a hammock, a faucet, an elevator, or a ship will be utilized to facilitate imagery. Participants will be asked to focus on their pelvic floor and imagine the contractions, and they will be informed about the potential effects of these contractions during the session.
214315221|NCT07099170|BEHAVIORAL|Visual-Aided Pelvic Floor Muscle Training|Visual-aided pelvic floor muscle training includes providing participants with information about the anatomy, functions, and importance of the pelvic floor, as well as training on how to properly contract the pelvic floor muscles. The training will be conducted using anatomical models, visual materials, and videos. Following the explanation of pelvic floor anatomy with models and visual aids, the function and importance of the pelvic floor will be presented through video demonstrations. During the session, the pelvic floor will be visually represented using common metaphors such as a hammock, a faucet, an elevator, or a ship, and these visuals will support the use of imagery techniques. Participants will be asked to focus on their pelvic floor and imagine the contractions, and they will be provided with information about the expected effects of the contractions.
214315222|NCT07099170|BEHAVIORAL|External Palpation-Aided Pelvic Floor Muscle Training|External Palpation-Aided Pelvic Floor Muscle Training This training involves educating participants on the pelvic floor's anatomy, function, and importance, along with instructions on proper muscle contraction. After an educational session using anatomical models, visuals, and videos, external palpation is used to guide correct muscle activation. In a hook-lying position and fully clothed, participants receive light, transverse pressure from a physiotherapist on key pelvic floor muscles (ischiocavernosus, bulbospongiosus/bulbocavernosus, or perineum). The therapist observes real-time muscle response, provides feedback, and offers verbal cues. Imagery techniques (e.g., hammock, faucet, elevator, ship) may be used to support motor learning and awareness.
214315223|NCT07095621|PROCEDURE|3 days discharge|"Patients scheduled for elective minimally invasive DP, eligible for the study and willing to participate will be asked to sign the consent form in person during the preoperative counseling session.~Participants will receive comprehensive preoperative education and will be enrolled in an ERAS protocol that includes urinary catheter removal, initiation of a solid food diet, cessation of intravenous infusions, and oral pain management starting on postoperative day (POD 1). Following discharge on POD3, patients will receive a daily telephonic follow-up by a nurse navigator for the first 7 days after surgery (POD 7)."
214315224|NCT06826430|DRUG|Inaticabtagene autoleucel Injection|Inaticabtagene autoleucel Injection, the autologous 2nd generation CD19-directed CAR-T cells, will be administered by vein. Before CAR-T infusion，patients will get a 3-4 days lymphodepletion therapy with fludarabine and cyclophosphamide.
214315225|NCT06586112|DRUG|ESK-001|ESK-001
214315226|NCT06586112|DRUG|Apremilast|Apremilast
214315227|NCT06586112|DRUG|Placebo|Placebo
214315228|NCT07109960|OTHER|Isometric exercise and hand reflexology|"Each participant in the isometric exercise group receives included ankle exercises, knee workouts, head exercises, static abdominis exercises, and sustained hand grip exercises. Every contraction lasted for 10 seconds, 10 repetitions, two IE sessions over a period of three days. Each IE session lasted between 25 and 35 minutes.~Each participant in the hand reflexology group underwent two the sessions of hand reflexology. Each session had a duration of 15 minutes, which was then followed by a five-minute period of rest.~While isometric exercise- hand reflexology experimental group was given for the participant, the same intervention of isometric exercise and hand reflexology groups Furthermore, no interventions were done for the control group (received routine care only)."
214315229|NCT07108816|DRUG|Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab|"Patients will receive 4 cycles of neoadjuvant treatment with preoperative Sacituzumab tirumotecan in combination with tagitanlimab, followed by surgery.~After surgery, patients will receive up to 13 cycles of adjuvant tagitanlimab."
214315230|NCT07108634|OTHER|RenalGuard Therapy|The RenalGuard Therapy® is comprised of a console, a single-use sterile IV infusion set, urine collection set and a cart. The console is a microcontroller device that has a means for measuring urine output and automatically controls the hydration infusion pump based on the measured urine output and clinician settings. The system is designed for infusion of hydration solutions only. The patient is connected to the console by the IV Infusion set connected to the patient's peripheral IV cannula and the urine collection set connected to the patient's indwelling Foley urinary catheter. The console continuously monitors urine production by measuring the weight of urine in the collection set, converts the urine weight to volume and then, automatically infuses the pre-set volume of hydration fluid to compensate for this output.
214482159|NCT06629701|DEVICE|External support for vein grafts|Group A will consist of a group of patients who will be sutured with external support for vein grafts.
214918517|NCT06339866|OTHER|The Effect of Two Different Video Interventions on Pain and Anxiety in Children with Adenotonsillectomy: A Randomized Controlled Study|The population of the study will be all patients who had adenotonsillectomy surgery between the ages of 6-12 in the Ear Nose and Throat Service of Zonguldak Bülent Ecevit University Hospital, and the sample will be all patients who had adenotonsillectomy surgery between the specified dates and who meet the inclusion criteria.
214918518|NCT00679029|DRUG|doxorubicin hydrochloride|Given IV
214918519|NCT00679029|DRUG|cyclophosphamide|Given IV
214918520|NCT00679029|BIOLOGICAL|bevacizumab|Given IV
214918521|NCT00679029|DRUG|paclitaxel|Given IV
214482160|NCT06693999|DEVICE|Google-Pixel Watch 3|The participant will wear Google-Pixel Watch 3 for at least 10 hours during the 3-month intervention and will receive goal reminders and motivational and coping messages through those watches. At baseline and after 3-months intervention, demographics (standard questionnaire pertaining to subjects' age, sex, race, education and income), technology literacy (eHealth Literacy Scale pertaining to subjects' ability to perform a number of tasks such as turning on the device, using internet and communication), and wearables affinity (pertains to how the subject currently uses wearable in their daily living tasks) will be measured.
214315231|NCT07109141|PROCEDURE|PFA ablation procedure of atrial arrythmia|PFA ablation procedure of atrial arrythmia accroding to the particular patients needs
214315232|NCT07109752|BEHAVIORAL|eHealth cardiac rehabilitation|A face-to-face interview for goal setting and action planning, as well as learning the use of CR website and accelerometer.
214482161|NCT06693999|BEHAVIORAL|Exercise prompts|The participants will receive goal reminders.
214482162|NCT06694675|DRUG|Sevoflurane (Volatile Anesthetic)|Sevoflurane 1%\~3.5%
214482163|NCT06694675|DRUG|propofol|Propofol 9\~15mg/kg/h
214482164|NCT06694662|DIETARY_SUPPLEMENT|PKU EASY Microtabs Plus|"PKU EASY Microtabs Plus is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in patients from 3 years of age upwards.~PKU EASY Microtabs Plus is a microtablet form, slow-release, phenylalanine-free protein substitute containing a blend of essential and non-essential amino acids, vitamins, minerals and trace elements."
214482165|NCT06630143|OTHER|Combined Virtual and Clinical Simulation|Participants will complete a preeclampsia case scenario through virtual simulation first and then engage in a clinical simulation involving the same case. This sequential intervention is designed to reinforce knowledge and skills.
214482166|NCT06630143|OTHER|virtual simulation|Participants will complete the preeclampsia case scenario using the vSim® platform, allowing them to engage in virtual clinical decision-making.
214482167|NCT06691750|DEVICE|Barbed suture|Size 0 barbed absorbable monofilament suture with unidirectional spikes that includes a loop in one of its ends, not requiring knots.
214482168|NCT06691750|DEVICE|Conventional smooth suture|Size 1 smooth multifilament absorbable polyglactin suture.
214482169|NCT06630611|BIOLOGICAL|NMA-LD regimen|The use of the NMA-LD regimen (cyclophosphamide and fludarabine) prior to cell administration is expected to lead to myelosuppression in all patients.
214482170|NCT06630611|BIOLOGICAL|Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion|On Day 0 (at least 24h after the last dose of fludarabine) patients will be hospitalized in a dedicated unit. Autologous TIL infusion will be administered intravenously.
214482171|NCT06630611|BIOLOGICAL|High dose IL-2|"Only for patients in Arm A.~IL-2 begins between 3 and 24 hours after the completion of the TIL infusion and is given as a bolus administration every eight hours (minimum interval) to 24 hours (maximum interval) with a maximum of six doses from the beginning of each administration."
214482172|NCT06630611|BIOLOGICAL|IL-2 analog|"Only for patients in Arm B~ANV419 will be administered between 3 and 24 hours after the completion of the TIL infusion with a slow IV infusion over 15-30 minutes + 5 minutes once, at 243µg/kg."
214482173|NCT02933489|DIAGNOSTIC_TEST|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
214482174|NCT02933489|DIAGNOSTIC_TEST|Digital Tomosynthesis Mammography|Undergo DBT
214482175|NCT02933489|OTHER|Quality-of-Life Assessment|Ancillary studies
214482176|NCT02933489|OTHER|Questionnaire Administration|Ancillary studies
214482177|NCT06482138|PROCEDURE|Biopsy and Cytobrush|Collection of olfactory cleft biopsies and cytobrushes
214482178|NCT06135506|PROCEDURE|free-hand ridge splitting|Midcrestal incision will be followed by reflection of full thickness flap. Midcrestal cut without vertical osteotomy will be done using piezosurgery unit, and then the cut will be extended deep to the implant length. The ridge will be expanded progressively using bone wedges. Dental implant fixtures will be placed stably with 1 mm minimal thickness of buccal bone plate. Surgical site will be completely closed, and wound edges will be sutured in a tension-free way.
214315233|NCT07108842|PROCEDURE|Conventional Needle Irrigation|Patients in this arm will receive traditional syringe and needle irrigation using a 30-gauge side-vented needle. 2.5% sodium hypochlorite will be used as the irrigant, delivered 1-2 mm short of working length intermittently during root canal instrumentation. No activation device will be used.
214482179|NCT06135506|PROCEDURE|AI/guided ridge splitting|"The patient specific guides will be placed and fixed by monocortical osteosynthesis screws at the pre-planned positions at the labial buccal mucosa.~A midcrestal cut will be performed on the crest of alveolar ridge guided by the guide slits. The cuts will be expanded progressively using bone wedges through the guide slits gradually lateralize and expand the labial alveolar plate of bone, so the labial cortex will move through the intentionally created micro gap till it touches the fitting aspect of the patient specific guide. Implant drills will be inserted through the guiding holes in the surgical guide and the implant osteotomy sites will be prepared. Finally, implants will be inserted in the osteotomy sites using torque-wrench in a self-tapping fashion engaging palatal and basal bone for primary stability."
214482180|NCT05939401|OTHER|Biopsies|Biopsies and blood samples will be taken at time of diagnosis or recurrence
214315234|NCT07108842|DEVICE|Conventional Needle Irrigation (Control Group)|Patients in this arm will receive traditional syringe and needle irrigation using a 30-gauge side-vented needle. 2.5% sodium hypochlorite will be used as the irrigant, delivered 1-2 mm short of working length intermittently during root canal instrumentation. No activation device will be used.
214315235|NCT07108842|DEVICE|endoactivator|in group 2 irrigation done with endoactivator
214315236|NCT07108842|DEVICE|Irrigation Solution|irrigation protocol done with disposable syringe
214482181|NCT06806930|DRUG|Neoadjuvant endocrine therapy|Cohort A: Short duration NET. Patients in this cohort can be treated with NET up to 8weeks (\<= 8 weeks)
214482182|NCT06806930|DRUG|Neoadjuvant endocrine therapy|Cohort B: Intermediate duration NET. Patients in this cohort can be treated with NET \> 8weeks but \<=24 weeks
214482183|NCT06806930|DRUG|Neoadjuvant endocrine therapy|Cohort C: Extended duration NET. Patients in this cohort can be treated with NET \>24 weeks but \<= 52 weeks
214315237|NCT07108842|DEVICE|Irrigation Solution|irrigation protocol done with endoactivator
214315238|NCT07108842|DEVICE|Sonic Irrigation with EndoActivator (Experimental Group)|Patients in this arm will receive sonic activation of the irrigant using the EndoActivator device during root canal treatment. After initial instrumentation and irrigation with 2.5% sodium hypochlorite, the irrigant will be activated using a medium-sized (25/04) EndoActivator tip for 30 seconds per canal at a sonic frequency (\~6000 cycles/min), to enhance cleaning and irrigant penetration.
214315239|NCT07109037|OTHER|Conventional exercise therapy|"Conventional exercise therapy includes four exercises: the little swallow flying exercise, the hip bridge exercise, back muscle stretching, and relaxation. It is performed once a day, 45 minutes ."
214315240|NCT07109037|OTHER|Suspension training and conventional exercise therapy|Suspension training alternates with conventional exercise therapy. It is conducted every other day, 45 minutes each time, 2-3 times a week for four consecutive weeks. Elastic ropes for suspension training are chosen based on patients' body mass: single - strand for those with body mass ≤ 30 kg and double - strand for those with body mass \> 30 kg. Suspension slings are placed on the head, lower back, and pelvis, and non-elastic rope slings on the ankles. Lower the lifting bed so that the vertical distance from the ankles to the bed surface is about 25-30 cm.
214315241|NCT07110506|OTHER|Arterial pressure monitoring|Arterial pressure is monitored and obtained
214315242|NCT07109544|OTHER|Breathing Therapy|The patients in the control group will be receiving breathing therapy by a certificated clinical nurse
214315243|NCT07109115|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Subjects will be supplemented with the following vitamin C doses: 0mg, 200mg, 500mg, 1000mg.
214315244|NCT07109804|DEVICE|Deep Brain Stimulation (DBS)|The DBS system delivers electrical current into deep areas of the brain. In this study, the electrical current will be delivered continuously during the study duration to an area of the brain called the cuneiform nucleus (CnF). Stimulation frequencies are anticipated to be between 20 and 50 Hertz. Participants may choose to continue stimulation following study termination. This area of the brain is associated with the body's ability to start a movement.
214315245|NCT07109804|PROCEDURE|Deep Brain Stimulation (DBS) Device Implant Procedure|Participants will undergo a one-time implantation of Cartesia DBS electrodes (bilateral) including the Vercise pulse generator in a single surgery (up to approximately 6 hours) to implant bilateral directional DBS leads in the cuneiform nucleus.
214315246|NCT07109804|OTHER|Training Sessions|Training sessions occurs 3 times/week at the study center to condition the subjects before DBS implantation and after DBS implantation. Each session may last up to 60 minutes. Training sessions include joint mobility (passive stretching), volitional neuromuscular activation (active hip mobility), task isolation (weight shifting), task integration (stepping), and activity rehearsal (walking).
214315247|NCT07107152|BEHAVIORAL|single GPT generated message|Participants receive a single \~640-word message generated by GPT-4.1. The message is tailored to participants' self-reported demographics (age, gender, political ideology, education, urbanicity, health status, and last PCP visit). The message provides persuasive content encouraging colorectal cancer screening, emphasizing stool and colonoscopy screening options. Participants are required to read the message for a minimum of 3 minutes.
215061039|NCT01893411|DRUG|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
214482184|NCT02994927|DRUG|Avacopan|"Avacopan 30 mg twice daily orally for 52 weeks (364 days):~\- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):~* Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day."
214482185|NCT02994927|DRUG|Prednisone|"Avacopan-matching placebo twice daily orally for 52 weeks (364 days):~\- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone tapering regimen over 20 weeks (140 days):~* Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day."
214482186|NCT02994927|DRUG|Cyclophosphamide|Orally or intravenously administered
214482187|NCT02994927|BIOLOGICAL|Rituximab|Intravenously administered
214482188|NCT02994927|DRUG|Azathioprine|Orally administered
214918522|NCT00679029|DRUG|gemcitabine hydrochloride|Given IV
214315248|NCT07107152|BEHAVIORAL|AI Chatbot|Participants engage in a multi-turn conversation with a GPT-4.1 chatbot trained to emulate motivational interviewing techniques. The chatbot personalizes its conversation based on each participant's demographics (age, gender, political ideology, education, urbanicity, health status, and last PCP visit). Conversations last at least 3 minutes and aim to increase participant motivation to complete colorectal cancer screening.
214482189|NCT06692335|PROCEDURE|High-Intensity Focused Ultrasound (HIFU)|The HIFU treatment will utilize the Haifu JC 200 system under real-time ultrasound guidance, with participants positioned prone in a water-filled generator chamber. Conscious sedation will be administered using fentanyl and midazolam, adjusted based on pain tolerance. Acoustic output power will range from 300 to 400W.
214482190|NCT06692335|PROCEDURE|myomectomy|Laparoscopic or open or hysteroscopic myomectomy will be performed.
214918523|NCT00679029|OTHER|laboratory biomarker analysis|Correlative studies
214918524|NCT00679029|BIOLOGICAL|pegfilgrastim|Given subcutaneously
214918525|NCT03256929|BEHAVIORAL|Personalized Diet-driven microbiota|Based on the results of the individual microbiota profile, the investigators will formulate a specific diet aiming to enrich the distinct microbiota with organisms correlated to better mental health. The dietitian will visit each participant twice a month.
214918526|NCT03256929|BEHAVIORAL|General information on nutrition and health|General information on nutrition and health. The dietitian will visit each participant twice a month.
214918527|NCT05208528|DIETARY_SUPPLEMENT|ES1 group|Participants will intake 2 capsules of 300 mg/capsule with 50 mg of Bifidobacterium longum ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
214918528|NCT05208528|DIETARY_SUPPLEMENT|HT-ES1 group|Participants will intake 2 capsules of 300 mg/capsule with 50 mg of HT-ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
214918529|NCT05208528|DIETARY_SUPPLEMENT|Control group|Participants will intake 2 capsules of 300 mg/capsule with 300 mg of maltodextrin.
214315249|NCT07107152|BEHAVIORAL|Expert-Written Patient Materials|Participants read a 642-word expert-written educational summary from the Journal of the American Medical Association's Patient Page on colorectal cancer screening. The material is designed to provide objective information about screening options and guidelines recommended by the US Preventive Services Task Force. Participants are required to read the material for at least 3 minutes.
214315250|NCT07109986|DRUG|UB-VV410|Treatment with single dose of UB-VV410, intravenous injection at Day 1. Note: Subjects may receive retreatment with UB-VV410 if there are preliminary findings suggesting incomplete improvement and acceptable safety.
214315251|NCT07108439|OTHER|Administration of intra-osseous local anesthesia before the extraction of a first permanent molar under general anesthesia|Intra osseous administration of articain 4% 1/100 000 during general anesthesia for the extraction of a first permanent molar. The administration will be done with Quicksleeper 5.
214315252|NCT07110233|DEVICE|TheraSphere® Yttrium-90 microspheres|Administered intra-arterially
214315253|NCT07110233|OTHER|Health Related Quality of Life Questionnaires (HRQOL)|Surveys administered
214482191|NCT06194227|BEHAVIORAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive in-person high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
214482192|NCT06194227|BEHAVIORAL|Traditional Yoga|Participants will perform in-person controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
214482193|NCT06879496|DRUG|Oral ketamin|Patients will be received oral ketamine before operation
214482194|NCT06879496|DRUG|Oral Midazolam|Patients will be received oral Midazolam
214671506|NCT06511661|PROCEDURE|Incomplete lymphadenectomy|Less than 3 N1 stations or 3 N2 stations are examined during surgery, or those without station 7 lymph node dissection.
214918530|NCT04152772|DEVICE|transcranial direct current stimulation|Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
214918531|NCT03483961|BIOLOGICAL|CHIKV VLP/unadjuvanted|Vaccine consists of virus-like particles of chikungunya virus antigens
214918532|NCT03483961|BIOLOGICAL|CHIKV VLP/adjuvanted|Adjuvanted formulation includes Alhydrogel
214918533|NCT03483961|BIOLOGICAL|Placebo|Placebo is vaccine diluent alone
214918534|NCT05669326|OTHER|NODDI TRACT|"Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without contrast injection will be performed, lasting approximately 40 minutes (including installation and deinstallation).~The operative time, surgical procedures and postoperative follow-up are not modified in this study."
214918535|NCT02313493|BEHAVIORAL|Baby Triple P|
214315254|NCT07108413|BEHAVIORAL|Activ4Brain Program|The Activ4Brain Program consists of 24 sessions, twice a week for 3 months. Participants engage in 50 min exercise sessions of moderate intensity (60-80% of maximal heart rate) including 5 min warm-up, 40 min aerobic exercises, and 5 min cool-down. The warm-up period includes similar body movements as the main part of the exercise and dynamic stretching while the cool down period consists of static stretching. The main part of the exercise session is divided in four blocks. Each block consists of 5 min aerobic exercises and 5 min of cognitive training. Participants are instructed to keep moving, marching in place, while performing the cognitive training tasks to maintain the increased heart rate. Each group class is composed of four participants with as must as possible a narrow age range given the participants' schedule convenience.
214482195|NCT06879496|DRUG|Oral dexmedetomidine|Patients will be received oral dexmedetomidine
214482196|NCT06876831|OTHER|Shared decision making for LDCT (3 potential outcomes LDCT on discharge, scheduled date of LDCT, or Lung Cancer Screening referral)|These interventions will be facilitated as an inpatient
214482197|NCT06876831|BEHAVIORAL|Inpatient Tobacco Cessation Counseling (Handouts, NYC Quits number, Medication Recommendations to primary team, Smoking cessation referral)|Active smokers only will received inpatient tobacco cessation counseling/risk reduction
214482198|NCT06693258|PROCEDURE|thyroidectomy by robotic surgery via axillary approach|thyroidectomy
214671507|NCT06363721|DIETARY_SUPPLEMENT|PerioPull™|PerioPull™ is a natural oil rinse formula to support overall oral/gum health, tooth stains, and natural teeth whitening. PerioPull™ includes Medium Chain Triglycerides (C8, C10, C12) (from coconut oil), Bixa orellana (Annatto) Seed Extract (GG-Gold®), Natural Mint Flavor, Bromelain, Ubiquinone, Delta Tocotrienols.
214671508|NCT03246074|DRUG|Fostamatinib 100 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 100 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
214671509|NCT03246074|DRUG|Fostamatinib 150 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 150 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
214671510|NCT03246074|DRUG|Fostamatinib 200 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 200 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
214918536|NCT03124316|BEHAVIORAL|Anticipated regret|Induce awareness of future regret about the unwanted behaviour
214918537|NCT03124316|BEHAVIORAL|Material incentive|Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours
214918538|NCT03124316|BEHAVIORAL|Problem solving|Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
214918539|NCT00400660|DRUG|GSK615915A|GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.
214918540|NCT00400660|DRUG|Placebo|Subjects will also receive placebo inhaler.
214918541|NCT01468194|OTHER|Breathing procedure 1|inhalation during one step, exhalation during the next step
214918542|NCT01468194|OTHER|Breathing procedure 2|inhalation and exhalation during one step
214918543|NCT02731651|PROCEDURE|open hysterectomy|Hysterectomy with laparotomy incision.
214918544|NCT02731651|PROCEDURE|laparoscopic assisted vaginal hysterectomy|Hysterectomy with laparoscopic assisstance.
214315255|NCT07108413|BEHAVIORAL|Aerobic Exercise Program|The Aerobic Exercise Program consists of 24 sessions, twice a week for 3 months. Participants engage in 50 min exercise sessions of moderate intensity (60-80% of maximal heart rate) including 5 min warm-up, 40 min aerobic exercises, and 5 min cool-down. The warm-up period includes similar body movements as the main part of the exercise and dynamic stretching while the cool down period consists of static stretching. The main part of the exercise session consists of a sequence of four different 5 min blocks of aerobic exercise repeated twice. Each block consists of a combination of three different rhythmic movements. Each group class is composed of four participants.
214315256|NCT07108972|PROCEDURE|Transabdominal pre-peritoneal laparoscopic inguinal hernia repair|laparoscopic inguinal hernia repair surgical technique that it's main principal is placing the mesh pre-peritoneally through transabdominal approach
214315257|NCT07108972|PROCEDURE|Totally extraperitoneal laparoscopic inguinal hernia repair|laparoscopic inguinal hernia repair surgical technique that it's main principal is placing the mesh pre-peritoneally through extraperitoneal approach
214315258|NCT07109128|BEHAVIORAL|The T1D Talks: A Virtual Group for Teens and Tweens with T1D|The T1D Talks intervention is an 11 session, virtual (online), group intervention. The T1D Talks intervention teaches developmentally appropriate emotion regulation (ER) skills and facilitates practicing these skills via role-plays and in-session experiences that are meant to elicit strong emotions. The investigators adapted the content and situations of an established intervention to be relevant for youth with T1D (e.g., practicing ER skills while role playing situations like telling parents about high blood glucose numbers or telling a coach about needing to take a time out from a game because of a low blood glucose level). The intervention also provides basic diabetes education about risky situations (e.g., how physical activity can affect blood glucose).
214315259|NCT07109947|DRUG|Letrozole 2.5mg|to determine the effect of Letrozole as a premedication before misoprostol treatment used to induce missed miscarriage.
214315260|NCT07110649|DEVICE|Virtual Reality Rehabilitation Group|Conducted in three progressive stages using VR games: improving ROM, strengthening shoulder muscles, and simulating game scenarios.
214315261|NCT07110649|OTHER|Traditional Rehabilitation Group|Used conventional physical therapy methods based on established rehabilitation programs.
214315262|NCT07110454|DEVICE|Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)|The Minder System consists of an implanted device containing an electrode lead and telemetry unit. The electrode lead contains four electrodes that are placed under the patient's scalp to record electrical activity (EEGs) from both sides of the brain. The electrode lead is connected to the telemetry until that continuously transmits these signals to the external Minder devices to remotely show EEGs for clinician review.
214315263|NCT07110337|DEVICE|Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)|The Minder System consists of an implanted device containing an electrode lead and telemetry unit. The electrode lead contains four electrodes that are placed under the patient's scalp to record electrical activity (EEGs) from both sides of the brain. The electrode lead is connected to the telemetry unit that continuously transmits these signals to the external Minder devices to remotely show EEGs for clinician review.
214315264|NCT06924593|DEVICE|Trans-Carotid Artery Occlusion Shunt System|To evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System for Carotid Artery Revascularization during Endovascular Treatment
214315265|NCT06923280|DRUG|Pegylated Interferon-alpha (IFN)|pegylated interferon-alpha 180 μg once weekly for 24 weeks
214918545|NCT06288841|DRUG|Ropivacaine injection|Ultrasound-guided bilateral QLB2 was performed using Ropivacaine injection prior to anesthesia induction
214315266|NCT06924255|DRUG|Xanomeline and Trospium Chloride|accelerated titration of Xanomeline and Trospium Chloride
214315267|NCT06924255|DRUG|Xanomeline and Trospium Chloride|slow titration of Xanomeline and Trospium Chloride
214315268|NCT06924710|DRUG|Standard Therapy|Adjuvant chemotherapy or adjuvant chemotherapy combined with immunotherapy
214315269|NCT06924710|OTHER|Adaptive Therapy|Patients will be under close MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
214918546|NCT06288841|DRUG|Bupivacaine liposome|Ultrasound-guided bilateral QLB2 was performed using Bupivacaine liposome injection prior to anesthesia induction
214918547|NCT00479050|PROCEDURE|chemoembolization ,Radiofrequency ablation|
214918548|NCT03100968|PROCEDURE|Palpation|Traditional epidural methods used for the identification of the midline using palpation prior to procedure
214918549|NCT03100968|DEVICE|Ultrasound|Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
214918550|NCT01108341|DRUG|Bendamustine hydrochloride|Bendamustine will be administered at 90 mg/m\^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
214918551|NCT01108341|DRUG|Ofatumumab|Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
214315270|NCT06923254|OTHER|7.0T MRI-Scan|7.0T MRI-Scan
214315271|NCT07108322|OTHER|Intraoral scanning|Adigital impression with intraoral scanning
214315272|NCT07108426|BEHAVIORAL|Educational Intervention via Telemedicine|A structured educational program delivered remotely through WhatsApp®, including a 30-minute online lecture and daily dissemination of educational content (videos, texts, and practical guidance) on hospital hyperglycemia and glycemic management strategies.
214918552|NCT03025932|PROCEDURE|repair of giant hiatal hernia with mesh and anterior fundoplication|
214482199|NCT06693258|PROCEDURE|thyroidectomy by standard conventional surgery|thyroidectomy by standard conventional surgery
214918553|NCT02664467|DEVICE|Philips EnergyUp EnergyLight HF3419/01|Bright light therapy (10'000 lux) for 60 minutes after wake-up
214918554|NCT02664467|DEVICE|Philips EnergyUp EnergyLight HF3419/01|Placebo dim light (500 lux) for 60 minutes after wake-up
214918555|NCT00290134|DRUG|Fispemifene once daily for 4 weeks|
214918556|NCT03780803|OTHER|home cardiac rehabilitation and respiratory rehabilitation|
214918557|NCT05869461|BEHAVIORAL|KP Specific Wellness Sessions|The sessions will include content on yoga, nutrition, legal issues, medical information, and community resources from the original Chetana intervention (further described below). They will also include expanded content informed by our previous studies and focus group discussions with MSM and TGW that addresses the needs for sessions on mental health, financial literacy, substance use, legal rights for key populations and coping skills for interacting with the legal system, and community resources for MSM and TGW. Sessions will include specifically tailored content related to the needs of MSM or TGW.
214315273|NCT07109531|DRUG|ASKC202+ Limertinib|ASKC202 orally once per day (QD) combined with Limertinib orally BID for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
214315274|NCT07109531|DRUG|Pemetrexed + Cisplatin /Carboplatin|The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed on Day 1of 21 day cycles for 4\~6 cycles (every 3 weeks).
214315275|NCT05169658|BIOLOGICAL|Mosunetuzumab|Given SC
214315276|NCT05169658|BIOLOGICAL|Obinutuzumab|Given IV
214315277|NCT05169658|DRUG|Polatuzumab Vedotin|Given IV
214315278|NCT05169658|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET and FDG-PET/CT
214315279|NCT05169658|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
214315280|NCT05169658|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and FDG-PET/CT
214482200|NCT06878105|OTHER|Data collection on interventions performs as per medical routine|No intervention other than routine medical practice
214482201|NCT06876987|OTHER|Routine care|Receiving routine care.
214482202|NCT06876987|OTHER|Retraining Program|Retraining program using a mobile-based training system.
214482203|NCT06878053|PROCEDURE|ethanol sclerotherapy|The originality of this project consists in evaluating the effectiveness of ethanol sclerotherapy of endometrioma(s) in infertile patients before IVF/ICSI, excluding patients who have previously had an ovarian cystectomy. To date, no prospective randomized comparative study between ethanol sclerotherapy of endometriomas and therapeutic abstention has been carried out.
214918558|NCT05869461|BEHAVIORAL|Peer Navigation|Participants will be assigned to a peer navigator (PN) who will be their principal point of contact for the intervention. Within a week, the navigator will set up an initial introductory meeting, either in person or via video chat. This will serve as the first monthly check-in to monitor a participant's progress. During these in-person digital meetings, the navigator will work with a participant to identify their unique barriers that currently affect engagement in care and train participants to identify and break down solutions into manageable steps. Special attention will be paid to barriers associated with intersectional stigma and PNs will draw on their own experiences as members of stigmatized groups in identifying and brainstorming successful coping strategies. While this is not a structural intervention, PNs will work with their clients to develop ways of coping with structural barriers, including transportation and referrals to social services.
215061040|NCT01893411|DRUG|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
214315281|NCT05169658|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214315282|NCT05169658|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214315283|NCT05169658|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214315284|NCT05060393|BEHAVIORAL|Mindfulness-based cognitive therapy|Mobile application, mindfulness-based therapy
214315285|NCT01799356|DRUG|Moxifloxacin|daily 400 mg moksifloksasin
214315286|NCT01799356|DRUG|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
214315287|NCT01799356|DRUG|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
214315288|NCT02787252|DEVICE|Implant procedure, Freedom Spinal Cord Stimulation System|A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
214315289|NCT06019975|DIAGNOSTIC_TEST|FDG-PET|Brain FDG-PET
214315290|NCT05932186|PROCEDURE|Interscalene brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position. Interscalene block will be done as follows. US probe will be placed slightly lower to the level of the cricoid cartilage, followed by scanning of the neck to search for C5 and C6 nerve roots enclosed between the anterior and middle scalene muscles. The needle will be introduced in-plane from lateral to medial through the middle scalene muscle until the tip enters the brachial plexus sheath between the C5 and C6 roots, where LA will be injected.~Patients will be transported to the operation room where general anaesthesia will be induced with tracheal intubation Fentanyl (0.5 μg/kg) will be given to maintain the heart rate and mean blood pressure 20% lower than preinduction values. Intravenous 1 gram paracetamol and 8 mg dexamethasone will be given to all patients as part of multimodal analgesia"
214315291|NCT05932186|PROCEDURE|Upper trunk brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position like the the ISB group~Upper trunk will be visualized distal to the convergence of the C5 and C6 nerve roots but proximal to the departure of the suprascapular nerve (This nerve is a small hypoechoic circle that depart the lateral aspect of the upper trunk and courses posterolateral under the omohyoid muscle). The needle will be introduced in-plane from lateral to medial under the deep cervical fascia and through a very small portion of the middle scalene muscle, until the needle tip lies adjacent to the upper trunk, LA will be distributed below and above the upper trunk. Scanning for the upper trunk can be started from the supraclavicular fossa and moving proximal or opposite to cricoid cartilage and moving distal.~The following steps will be done as in the ISB group"
214482204|NCT06707220|OTHER|Heart failure medication|Treated with optimal guideline-directed medical therapy
214482205|NCT06353269|DRUG|Estring Vaginal Product|estradiol vaginal ring, exchanged every 12 weeks
214482206|NCT06353269|DRUG|Vagifem|vaginal estrogen tablet, used twice per week
214482207|NCT06353269|DRUG|Estrace 0.01% Vaginal Cream|vaginal estrogen cream, used twice per week
214482208|NCT06715436|DIETARY_SUPPLEMENT|Mediterranean Diet|The MedDiet will be planned according to the Mediterranean diet pyramid
214671511|NCT06969924|DEVICE|Cardiac resynchronization therapy|Cardiac resynchronization therapy pacemaker or defibrillator with a transvenous or epicardial systemic ventricle lead
214918559|NCT05246189|OTHER|Telephone Call|"Eligible subjects will be pre-selected by the study investigators on the basis of the medical file. A letter of information about the study will be sent to all the pre-selected eligible patients, with the exception of patients who have expressed an objection to the processing of their data for research purposes during their treatment.~The investigators will contact eligible patients by telephone approximately 2 weeks after the mailing of the information letter. During this telephone call, the investigator will answer any questions the patient may have about the study and will collect the patient's non-objection to participate in the study and their responses to the questionnaire."
214315292|NCT02450214|DRUG|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
214315293|NCT02450214|DRUG|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
214315294|NCT02450214|DRUG|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
214315295|NCT05501106|OTHER|Integrated Improvement strategies|"Integrated improvement strategies include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases.~1. A checklist (named as Risk Assessment and Preparedness for Postpartum Hemorrhage (Traffic Light in Delivery Room)) will be used in each virginal delivery to help obstetric staff and teams identify risk factors after admission, before and during labor, and improve the adherence to all known best practices.~2. The Postpartum Hemorrhage Rescue Format will be asked to be used in each postpartum hemorrhage rescue to record the rescue process.~3. Each case of postpartum hemorrhage exceeding 1000 ml will be reviewed. We will convene a QI Panel and a Task Force to assist the hospitals in postpartum hemorrhage case review and quality improvement strategy development."
214315296|NCT06080152|DEVICE|Mobility Tool|An A-Linker device will be given to 12 patients 3 months before their total knee arthroplasty
214315297|NCT05425290|BEHAVIORAL|Single-session emotion regulation training|The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
214315298|NCT04334642|OTHER|A mindfulness based intervention|It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
214315299|NCT05371600|DRUG|Midazolam|midazolam IV at 0.04 mg/kg
214315300|NCT05371600|OTHER|Saline|an equal volume of saline IV
214315301|NCT05687240|BEHAVIORAL|Qigong/Tai Chi|Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.
214482209|NCT06715436|DIETARY_SUPPLEMENT|Ketogenic Diet|Modified Atkins diet with a maximum of 20 g of carbohydrates per day.
214482210|NCT06715436|DIETARY_SUPPLEMENT|Control group|The control group will be asked to continue their dietary and lifestyle habits
214482211|NCT06714071|DIAGNOSTIC_TEST|CRP and Albumin and coagulation profile|CRP and Albumin and coagulation profile
214482212|NCT06717269|DRUG|NX-5948 capsule|NX-5948 in capsule form
214482213|NCT06717269|DRUG|NX-5948 tablet|NX-5948 in tablet form
214482214|NCT06717269|DRUG|Esomeprazole|Esomeprazole capsule, once daily
214671512|NCT01350700|OTHER|Scars assessment & QOL|Scar assessment and quality of life questionnaires
214671513|NCT01053910|DRUG|Ramipril|tablet of Ramipril once daily
214918560|NCT06619353|DIAGNOSTIC_TEST|Blood Sample|Patients' blood samples are tested at 1 month, and then annually for 3 years post-intervention to assess residual thrombotic, metabolic, and inflammatory risk.
214918561|NCT06619353|OTHER|DICOM Dataset|Patients' DICOM dataset is evaluated using artificial intelligence-based quantitative coronary analysis to assess a procedural risk.
214671514|NCT03708900|DRUG|LCI699|osilodrostat (LCI699) is in the form of tablets 1 milligram (mg), 5 mg, and 10mg or in form of capsules 0.1 mg, 0.2 mg, 0.5 mg, 1 mg or 5 mg, both the formulations for oral administration
214671515|NCT01039207|OTHER|Laboratory Biomarker Analysis|Correlative studies
214671516|NCT01039207|BIOLOGICAL|Rilotumumab|Given IV
214671517|NCT00499265|DRUG|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
214671518|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
214671519|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
214671520|NCT03088150|PROCEDURE|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
214671521|NCT03088150|PROCEDURE|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
214671522|NCT02782715|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).
214918562|NCT06280274|DRUG|Metformin|Metformin 500mg oral once daily for 7 days, increased to 1000mg (500mg twice daily) for another 7 days, taken in morning and evening with meals, for a total of 14 days of treatment prior to surgery. Continue dose on day of surgery and up to post operative day 2, or until time of discharge, whichever happens first.
214315302|NCT05687240|BEHAVIORAL|Heart rate variability biofeedback|"Randomized participants will be coached to practice a breathing technique that focuses attention on the sensations in the heart area, slowing and deepening the breath, and activating through memory or imagery a positive emotion. This practice is used along with a feedback device that provides information on achievement of the heart rate variability target, coherence that represents a neurocardiac state associated with vagal tone, or balance."
214482215|NCT06712992|DEVICE|Trans-spinal Direct Current Stimulation|Physiomed- IONOSON-Expert, Germany will be used to deliver SHAM direct current, The Physiomed- IONOSON-Expert, Germany is Two-channel electrotherapy including 21 currents, including direct current. The tsDCS electrodes will be rectangular pieces of saline-soaked synthetic sponge (7 × 8 cm, 56 cm2), to minimize chemical reactions at the electrode-skin interface. The anode will be placed over the spinous process of the eighth thoracic vertebra (T8) and the cathode will be placed on the second lumbar vertebra (L2) according to a modeling study which demonstrated that this configuration had a relevant impact on the distribution of the induced electric field (EF) in the lumbosacral spinal cord for the efficacy of tsDCS.
214482216|NCT06712992|OTHER|Conventional Exercises|"1. Isometric exercises of spine~   * Hollowing in abdominals.~  * Isometric for back extensors.~2. Bridging exercises.~3. Graded active flexion exercises of spine~4. Graded active extension exercises of spine"
214482217|NCT06712992|DRUG|SHAM Trans-spinal Direct current stimulation|"For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions.~These parameters for sham stimulation were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade usually out in the first 30 s of TsDcs ."
214482218|NCT06713005|PROCEDURE|suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve|suprascapular nerve pulsed rf
214482219|NCT06713005|PROCEDURE|suprascapular nerve block and 9 mins Pulsed radiofreuency application to suprascapular nerve|suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve
214482220|NCT06698835|DIETARY_SUPPLEMENT|Turnip Consumption|Turnip Consumption and Qigong Exercise with educational Program about loss of weight
214482221|NCT05656586|OTHER|observational-- no intervention|observational
214482222|NCT06881160|DIAGNOSTIC_TEST|mi-RNA analysis|To identify biomarkers that could predict the risk of a worsened COVID-19 disease progression.
214482223|NCT06882122|DRUG|Atogepant 60 mg|Atogepant 60 mg daily for 3 months
214918563|NCT06280274|OTHER|Placebo|Placebo tablet
214918564|NCT00343226|DRUG|Basiliximab|
214918565|NCT04441320|DEVICE|Coated metal ureteral stent(CMUS)|Coated metal ureteral stent aims to treat the patients with refractory ureteral stricture, such as radiation induced ureteral stricture. In this study, CMUS is indwelled to observe the efficacy and safety in the treatment of radiation induced ureteral stricture compared with Double-J stent.
214918566|NCT04441320|DEVICE|Double-J stent(DJS)|Double-J stent is commonly used for treatment of kinds of ureteral stricture. In this study, DJS is indwelled as a controlled group.
214918567|NCT04858490|DRUG|Diazepam|Symptom-triggered diazepam treatment: 10 or 20mg, at the clinician's discretion
214918568|NCT06665191|OTHER|No Intervention: Observational study for prevalence of dental wear and its association with quality of life|not applicable as it is an observational study testing the prevalence of dental wear in patients attending Cairo University
214918569|NCT03494231|DRUG|HLX06|recombinant fully human anti-VEGFR2 monoclonal antibody against cancers
214482224|NCT06881186|PROCEDURE|Intra-articular injection|Intra-articular injection of a cell-free collagenic gel matrix into the trapeziometacarpal joint
214482225|NCT06881667|DEVICE|Home PSG Assessment|Testing of the Onera STS in the home environment with the current device shipment method and instructions.
214482226|NCT06881095|PROCEDURE|socket shield technique group (study group)|"immediate implant installation with socket shield technique: After administration of local anesthesia, the root will be sectioned in a mesio-distal direction along its long axis, sectioning divided the tooth root into one facial third and two palatal thirds.~Periotomes will then be inserted between the palatal root section and the alveolar socket wall to sever the PDL and this section of root was then carefully delivered so as not to disturb the facial root section, the remaining root section was then reduced coronally to 1 mm above the alveolar crest.~The tooth socket's palatal wall and apex will be then curetted to remove any tissue or infective remnants, and the root section was checked for immobility with a sharp probe.~After completion of the previous steps, the tooth root here will be known as the socket- shield (SS). An osteotomy was then sequentially prepared according to manufacturer"
214482227|NCT06881095|PROCEDURE|conventional immediate implant without socket shield technique|• After administration of local anesthesia, atraumatic tooth extraction by extraction forceps and Periotomes, an osteotomy was then sequentially prepared according to manufacturer instructions and a suitable implant then inserted and placement of cover screw. However, the soft tissue contour formed after healing may need some modification prior to impression taking. Suturing around the healing abutment, suture will be removed one week post surgically and then healing abutment and final prosthetic loading will be done after 4-6 months.
214918570|NCT01583309|PROCEDURE|online pre-dilution hemofiltration|Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one
214918571|NCT01583309|PROCEDURE|online pre-dilution hemodiafiltration|Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
214918572|NCT04607694|RADIATION|Proton radiotherapy|Proton radiotherapy
214918573|NCT04607694|RADIATION|Photon radiotherapy|Photon radiotherapy
214918574|NCT05177276|DRUG|Selinexor|
215061041|NCT01893411|DRUG|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
214315303|NCT03434756|OTHER|Propioceptive training of the abdominal wall muscles|At the beginning, patients will be in a supine position, the lower edge of the StabilizerTM will be placed between the posterior superior iliac spines, aligned with the sacral base. Abdominal manoeuvre will be developed by the patients until they reach 40 mmHg and hold steadily for 10 seconds. Prior the examination, each subject practiced the abdominal manoeuvre three times with an ultrasound image feedback.
214482228|NCT06881212|BEHAVIORAL|THERAPEUTIC APPROACH TRAINING|"This study focuses on pre- and post-operative training for open-heart surgery patients, aiming to reduce anxiety, agitation, and discomfort during intubation and recovery.~In the meeting phase, the nurse introduces herself, explains the research, and obtains written/verbal consent. The patient's anxiety level is assessed.~In the study phase, patients are informed about the surgical process, breathing exercises, Intensive Care Unit conditions, and postoperative care. They are encouraged to express fears and concerns to improve psychological preparedness.~Key topics include:~Fasting before surgery Breathing exercises to ease extubation Use of mechanical ventilation Intensive Care Unit environment \& pain management Early mobilization \& recovery timeline Patients receive guidance on their role in recovery, ensuring better adaptation and reduced distress post-surgery."
214315304|NCT04250064|DRUG|Bevacizumab Injection|Additional concurrent low-dose Bevacizumab with standard EBRT
214315305|NCT04250064|RADIATION|Ultra-low-dose RT|Ultra-low-dose EBRT instead of standard dose RT
214315306|NCT04453917|BIOLOGICAL|Collection of blood and urine|Collection of blood (47 mL) and urine (5 mL) at PML diagnosis and 1, 3 and 6 months after, for analysis of immune checkpoint molecules expression, detection of antiviral immune responses and virological analyses.
214482229|NCT06878287|OTHER|Light exposure|30 minutes morning exposure to light (10 000 lux) using a light-box device filtering UV (CE marking)
214482230|NCT06878287|OTHER|Placebo light|30 minutes exposure to the same device using a filter inactivating light intensity (\< 10 lux)
214482231|NCT06880003|OTHER|During delivery, blood samples will be collected from the umbilical cord|During delivery, blood samples will be collected from the umbilical cord of pregnant women who agree to participate in the study.
214482232|NCT06879015|PROCEDURE|Tension Band Plate (TBP) Surgery|A guided growth procedure in which a non-locking 8-plate is placed extraperiosteally across the physis (growth plate) with two screws, one in the epiphysis and one in the metaphysis. This allows for gradual correction of coronal angular deformities without causing permanent growth arrest.
214482233|NCT06879015|PROCEDURE|Percutaneous Epiphysiodesis by Transphyseal Screw (PETS) Surgery|A minimally invasive procedure in which a partially threaded cannulated screw is inserted across the growth plate (transphyseal) to slow growth on one side of the bone. This technique allows for gradual correction of genu valgum and genu varum.
214482234|NCT06881485|OTHER|Very Low Calorie Diet|This is a parallel multicentric longitudinal randomized controlled trial in which prospective data will be collected from the electronic health record. The inclusion and exclusion criteria will be checked and afterwards patients will be randomized to (unblinded) medication only or combination with VLCKD. Both arms include NB and lifestyle changes for 26 weeks but the patients belonging to the experimental arm must follow a VLCKD in the first 10 weeks on top of it. Like the other arm, the remaining 16 weeks will consist of NB combined with lifestyle interventions. Afterwards there is a follow-up extension of 26 weeks.
214482235|NCT06881628|DRUG|Tranexamic Acid and vitamin K|"Tranxemic acid (1 g loading dose followed by 3 g maintenance dose over 24- 48 hours) and intravenous injection (10 mg daily of vitamin K for 24-48 h) along with initial management of airway management, hemodynamic stabilization, octreotide analogue, PPI, antibiotics, and endoscopy to control UGIB in cirrhotic patients.~Patients will be followed up after 5 days and 6 weeks to assess the rate of rebleeding, need for blood transfusion, hospital stay, adverse effects, and mortality rate."
214918575|NCT05177276|DRUG|Irinotecan|
214918576|NCT03749746|BEHAVIORAL|Home Blood Pressure Monitoring|Each participant will receive 1:1 training by the project staff in all aspects of home blood pressure monitoring (HBPM). Throughout the study, they will be asked to monitor home blood pressures for the first week of each month with Bluetooth-enabled blood pressure cuffs.
214918577|NCT03749746|BEHAVIORAL|Heart Health 4 New Moms|The intervention is comprised of four key components: (1) The online curriculum consists of 12 modules on healthy eating and physical activity adapted from the Diabetes Prevention Program and specifically targeting postpartum women. (2) Self-monitoring and tracking program, in which participants will be provided with a Bluetooth-enabled blood pressure cuff and digital scale and will be provided real-time feedback on their blood pressure and weight trends. (3) A registered dietitian will act as a lifestyle coach for participants with regular review of progress and provision of coaching notes, support and suggestions. (4) Finally participants will have access to a customized online toolbox, including dietary tracking sheets and recipes from the American Heart Association (AHA).
214918578|NCT03749746|OTHER|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
214918579|NCT00267969|DRUG|ustekinumab|Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
214918580|NCT00267969|DRUG|placebo|Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
214918581|NCT04822792|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
215061042|NCT04354948|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
215061043|NCT04354948|BEHAVIORAL|No pain (Hypotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
215061044|NCT02761473|OTHER|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
215061045|NCT02761473|OTHER|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
215061046|NCT02331589|DRUG|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
214315307|NCT04453917|BIOLOGICAL|Spinal tap|Spinal tap for monitoring of JC viral load at PML diagnosis and 1, 3 and 6 months after, and collection of CSF (2 mL) for virological analyses.
214482236|NCT06881628|DRUG|Placebo|"Intravenous saline over 24-48 hours along with initial management of airway management, hemodynamic stabilization, octreotide analogue, PPI, antibiotics, and endoscopy to control UGIB in cirrhotic patients.~Patients will be followed up after 5 days and 6 weeks to assess the rate of rebleeding, need for blood transfusion, hospital stay, adverse effects, and mortality rate."
214482237|NCT06881615|DEVICE|MTA PLACEMENT FOR PP|MTA PLACEMENT FOR PP
214482238|NCT06881615|DEVICE|PUTTY PLACEMENT FOR PP|PUTTY PLACEMENT FOR PP
214482239|NCT06880887|OTHER|nervus vagus stimulation|Vagus stimulation was applied bilaterally through the ear in a transcutaneous manner. transcutaneous auricular VNS (taVNS) was performed using the Vagustim device. The stimulation was applied for 20 minutes with a pulse width of 300 microseconds, a frequency of 10 Hz, and in a biphasic manner. The electrodes were placed on the concha and tragus parts of the ear, and the current was increased until the participant could feel it.
214482240|NCT06881056|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 45 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.
214482241|NCT06881056|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 90 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.
214482242|NCT06881056|BEHAVIORAL|symptomatic and supportive treatment|symptomatic and supportive treatment
214482243|NCT06876038|DRUG|5-Amino Levulinic Acid|5-ALA (Gleolan) orally (20 mg/kg BW 5-ALA HCl) 2 to 4 hours prior to undergoing image-guided SITOS-based PDT treatment
214315308|NCT04453917|DIAGNOSTIC_TEST|Brain MRI|Brain MRI at at PML diagnosis and 3 and 6 months after
214482244|NCT06879769|OTHER|Metoprolol I.V.|The participant will receive intravenous Metoprolol (up to 15 mg) during the CT examination, administered directly at the CT table prior to CCTA.
214482245|NCT06879769|OTHER|Metoprolol I.V. and 1 hour waiting.|The Participant will rest in the waiting room for 1h and then receive intravenous Metoprolol, up to 15 mg.
214482246|NCT06879769|OTHER|Music Intervention, Seloken (Recordati) orally and Metoprolol I.V.|The participant will receive Seloken (Metoprolol) according to clinical routine (up to 100 mg) and Metoprolol I.V. (up to 15 mg). The participant will also receive noise-canceling headphones and an iPad (or their own device) to select calming music and listen to it one hour before and during the CT scan.
214482247|NCT06878950|PROCEDURE|Early Feeding Protocol|The intervention includes removal of Replogle within 24 hours of abdominal closure and the initiation of introductory feeds within 48 hours of abdominal closure.
214482248|NCT06878781|OTHER|High carbohydrate challenge|Capillary blood samples will be obtained in the morning after an overnight 8-hour fasting; then, an indirect fasting calorimetry will be performed. After the indirect calorimetry, the metabolic and hormonal response to the test meal is performed. The nutritional composition of the standardized meal is shown below. Energy, 479.6 kcal; Carbohydrate, 83.6%; Lipids, 12.4%, and Protein, 4.0% (70 g of hot cake, 100 g of mango, 270 ml of peach nectar, and 40 g of strawberry jam). The food challenge should be consumed within 15 minutes. After 5 minutes of rest, indirect calorimetry will be postprandially, lasting 30 minutes. Capillary blood shall be obtained at the following times: 15-30-45-60-90 and 120 min after ingestion of food.
214482249|NCT06878781|OTHER|High lipid challenge|Capillary blood samples will be obtained in the morning after an overnight 8-hour fasting; then, an indirect fasting calorimetry will be performed. After the indirect calorimetry, the metabolic and hormonal response to the test meal is performed. The nutritional composition of the standardized meal is shown below. Energy, 1043.4 kcal; Carbohydrate, 4.9%; Lipids, 86.8%, and Protein, 8.3% (60 g of manchego cheese, 25 g of egg, white, dried, 24 g of bacon, 5 ml of oil, 65 g of cream cheese, 70 g of cream, and 16 g of poblano pepper). The food challenge should be consumed within 15 minutes. After 5 minutes of rest, indirect calorimetry will be postprandially, lasting 30 minutes. Capillary blood shall be obtained at the following times: 15-30-45-60-90 and 120 min after ingestion of food.
214482250|NCT06878781|OTHER|High proteinchallenge|Capillary blood samples will be obtained in the morning after an overnight 8-hour fasting; then, an indirect fasting calorimetry will be performed. After the indirect calorimetry, the metabolic and hormonal response to the test meal is performed. The nutritional composition of the standardized meal is shown below. Energy, 441.3 kcal; Carbohydrate, 1.6%; Lipids, 5.1%, and Protein, 93.3% (2 scoop Isopure Zero Carb, 180 g of chicken breast, 20 g of lettuce and 24 g of ham turkey breast). The food challenge should be consumed within 15 minutes. After 5 minutes of rest, indirect calorimetry will be postprandially, lasting 30 minutes. Capillary blood shall be obtained at the following times: 15-30-45-60-90 and 120 min after ingestion of food.
214315309|NCT04453917|BIOLOGICAL|Neurological evaluation|Neurological evaluation at PML diagnosis and 1, 3 and 6 months after
214315310|NCT03222375|DEVICE|SQUED™ series 28.1 home-use|"Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!"
214315311|NCT05897879|BIOLOGICAL|Nasopharyngeal swab|"For hospitalized patients :~Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril))~For ambulatory patients :~Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated."
214315312|NCT05897879|BIOLOGICAL|Blood samples|For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling
214482251|NCT05178498|PROCEDURE|Follow-Up|Undergo follow up
214482252|NCT05178498|PROCEDURE|Physical Examination|Complete physical measurements
214482253|NCT05178498|OTHER|Questionnaire Administration|Complete questionnaires
214482254|NCT06881173|DRUG|Bu Zhong Yi Qi Tang|The experimental group took 15g of Buzhong Yiqi Decoction concentrated powder, 3 times a day, 1 packet each time.
214918582|NCT03330704|DRUG|3% Sodium Chloride|3% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
214918583|NCT03330704|DRUG|23.4% Sodium Chloride|23.4% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
214918584|NCT03330704|DRUG|8.4% Sodium Bicarbonate|8.4% sodium bicarbonate will be infused into patients for the treatment or prevention of raised intracranial pressure
214918585|NCT02663063|DEVICE|SSP treatment|SSP treatment 5 times a week
214315313|NCT04445545|DEVICE|High intensity laser therapy (HILT)|Laser application with powers greater than 500 milliwatts (mW) in the myofascial trigger point and muscle belly of the upper trapezius. Laser therapy will be applied to the upper trapezius muscle with a total energy delivery of 1,060J divided into 3 phases will be achieved (phase 1, 500J; phase 2, 60J; phase 3, 500J). It will work with an average power of 3W and an energy density of 50J/cm2. For the application of laser therapy, the 12W BTL-6000 equipment that emits infrared wavelengths of 1064nm will be used.
214315314|NCT04445545|DEVICE|Therapeutic Ultrasound (US)|Application of ultrasound therapy in the myofascial trigger point of the upper trapezius muscle. The ultrasound application will be performed with the person in a seated position. The ultrasound parameters will consist of a frequency of 1MHz, the intensity of 1.5 W/cm2, a Duty cycle of 100%, an ERA of 5cm2, and a treatment time of 6 minutes.
214315315|NCT04445545|PROCEDURE|Stretching exercise|t the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series
214315316|NCT06958432|COMBINATION_PRODUCT|Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor|Patients will receive node-sparing modified short-course radiotherapy, followed by six cycles of CAPOX chemotherapy combined with a PD-1 inhibitor. After neoadjuvant treatment, patients will either undergo total mesorectal excision (TME) surgery or enter a watch-and-wait strategy based on clinical assessment.
214315317|NCT06958432|COMBINATION_PRODUCT|Conventional Radiotherapy plus Chemotherapy and PD-1 inhibitor|Patients will receive conventional-target short-course radiotherapy, followed by six cycles of CAPOX chemotherapy. After neoadjuvant treatment, patients will either undergo TME surgery or enter a watch-and-wait strategy based on clinical assessment.
214315318|NCT06232525|PROCEDURE|transobturator tape operation (TOT)|TOT surgery: With an 18 French Foley urinary catheter, the sling passes through the skin in the groin, the obturator foramen, the back of the adductor longus tendon, and the midurethral vaginal incision; extends 1 cm below the midpoint of the urethra, the tape is held in place without sutures by its interface with the patient's tissue. After the mesh is placed, the incision in the suburethral midline is closed.
214315319|NCT06232525|PROCEDURE|urethral ligament plication|Urethral ligament plication: With an 18 French Foley urinary catheter, a vertical incision of approximately 3 cm is made in the anterior-lateral wall sulcus of the vagina on the right and left lines, 2 cm laterally from the midline, with the urethral meatus remaining in the midline, and external urethral ligaments on both sides inferolateral to the urethra, sutured in the midline by using 2-0 or 3-0 polyester sutures on both sides separately. The incised anterior vaginal tissue is closed one by one with 2-0 rapid Vicryl.
214315320|NCT05026463|PROCEDURE|Inspiratory support level|Inspiratory support is the pressure delivered by the ventilator during pressure support ventilation.
214315321|NCT05083442|DEVICE|Low Level Laser Therapy|Non-surgical cosmetic treatment which can be used by individuals intending to reduce size of the mid-section
214315322|NCT05083442|OTHER|Sham (placebo)|Use of sham (placebo) option
214315323|NCT06376019|PROCEDURE|solitary Implant loading with ball attachment|ball attachment will be attached to the dental implant on the day of implant placement
214315324|NCT06376019|PROCEDURE|splinted Implant loading with intra oral welding|Titanium bar will be welded to the dental implant on the day of implant placement
214482255|NCT06881173|DRUG|caramel dyed starch placebo|The control group took 15 grams of caramel dyed starch placebo, 1 pack at a time, 3 times a day.
214482256|NCT06881394|DEVICE|Polymer Skin Barrier|A cyanoacrylate polymer will be applied topically once or twice a day to the palmar surface of hands to prevent perspiration
214482257|NCT06877286|DIAGNOSTIC_TEST|Sirtuin-1 Level Measurement|Measurement of serum Sirtuin-1 levels using ELISA in hemodialysis patients to evaluate the relationship between Sirtuin-1 levels and erythropoietin resistance
214482258|NCT06881875|BEHAVIORAL|AI-guided breathing practices|Participant will obtain a wristband with a built-in breathing practices program when assigned to the intervention group. Four kinds of breathing practices are included, which are bee breathing, diaphragmatic breathing, box breathing and 4-7-8 breathing. A specially prompted AI chat bot interviews the participant and designs a personalized daily breathing practice plan according to participant's preference and daily stress. Participant follows the plan in the following 28-day intervention period. Plan is adjusted weekly based on participant's feedback.
214482259|NCT06881875|BEHAVIORAL|Progressive muscle relaxation|Participant practices progressive muscle relaxation for 5 minutes daily.
214482260|NCT06881550|DRUG|Shenbailing|Adjuvant therapy with Shenbailing granules, starting from 1 day after surgery.
214315325|NCT06376019|PROCEDURE|complete denture|Mucosa supported conventional complete denture will be fabricated without supporting implants
214315326|NCT03878316|DRUG|Instranasal Oxytocin|Intranasal Oxytocin - concentrated formulation - 35 IU per dose
214315327|NCT05151744|DRUG|Vamikibart|Vamikibart will be administered by IVT injection in the study eye.
214315328|NCT05151744|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
214315329|NCT05151744|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
214315330|NCT04403139|DRUG|Shingrix|All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
214918586|NCT00006068|PROCEDURE|Pancreatic Islet Transplantation|
214918587|NCT06534619|PROCEDURE|Electrotherapy|Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 minutes.
214315331|NCT06135155|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
214918588|NCT06534619|PROCEDURE|Rocabado exercises|6 Rocabado exercises 6 Reps each.
214918589|NCT06534619|PROCEDURE|Maitland oscillatory mobilizations|"Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3.~Techniques used are anterior, lateral and inferior glides"
214918590|NCT04219111|GENETIC|Clariom|Clariom S Assay
214918591|NCT00291876|BIOLOGICAL|Havrix™|2 doses at 12 months interval
214918592|NCT06002451|BEHAVIORAL|WEB-BASED PRECONCEPTİONAL CARE AND COUNSELİNG|A web-based preconceptional care and consultancy training platform has been developed. In line with the literature, a comprehensive preconceptional care and counseling training content was prepared for women between the ages of 18-49. Web-based training consists of a total of 9 modules.The videos created for uploading to the website were shot in a professional studio environment with professional equipment.Each video was shot and recorded by dividing the training content according to its subsections, with an average of at least 6 minutes and a maximum of 16 minutes. Each of the module videos is based on giving the main messages in line with the purpose and objectives of the presentation.women were allowed to watch all the videos within 2 weeks. A dialog box is opened on the website where women can communicate with their midwives 24/7. During and after the training, preconceptional care and counseling training was given in this area for a total of 10 weeks.
214918593|NCT01309360|DRUG|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
214918594|NCT01309360|DRUG|prilocaine 1%|40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block
214918595|NCT01309360|DRUG|prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
214918596|NCT01309360|DRUG|prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
214918597|NCT05101746|DRUG|Nitric Oxide (NO) 20 part per million (ppm)|Nitric oxide will be mixed into the gas flow of the cardiopulmonary bypass (CPB) oxygenator, which will be kept at 1-3 L/min to allow for the desired NO delivery rate. NO levels will be maintained at 20ppm using a NO delivery system (INOmax, Mallinckrodt).
214918598|NCT05101746|OTHER|Standard of care cardiopulmonary bypass|Cardiopulmonary bypass (CPB) will be performed using the departmental guidelines and standards. CPB will be performed using in a nonpulsatile flow with the System 1 Heart Lung Machine (Terumo Cardiovascular Systems, Ann Arbor, Mich). The maximum perfusion flow will be 200 ml/kg/minute. Blood pressure management will be selected based on the patient age and procedure. Temperature management will be to cool the patient 32 celsius (C).
214918599|NCT00239122|BEHAVIORAL|Recovery Therapy (Cognitive Behaviour Therapy for psychosis)|
214918600|NCT05812235|PROCEDURE|esophagectomy|esophagectomy
214918601|NCT00802035|DRUG|Baclofen IR|30 mg; single dose
214918602|NCT00802035|DRUG|Baclofen ER|30 mg; single dose
214918603|NCT01680536|DRUG|maraviroc|
214315332|NCT06135155|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
214315333|NCT00943228|DRUG|mycophenolate mofetil|High dose 4gms daily
214315334|NCT03711162|DRUG|GLPG1690|GLPG1690, film-coated tablets for oral use.
214918604|NCT03083015|PROCEDURE|revascularization|a sterile sharp needle was used to irritate the apical tissue until bleeding occurred apically in the root canal space so as to create a biological scaffold for the regenerative process
214315335|NCT03711162|DRUG|Placebo|Matching placebo, film-coated tablets for oral use.
214315336|NCT03292081|DEVICE|OFDI|PCI under OFDI guidance
214315337|NCT03292081|DEVICE|IVUS|PCI under IVUS guidance
214315338|NCT05161130|PROCEDURE|Lumbar Spinal Fusion|Lumbar Spinal Fusion with or without posterior stabilization
214315339|NCT05609955|DRUG|MgSO4|The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
214315340|NCT03034954|DEVICE|Active HD-tDCS|Participants will receive active HD-tDCS at 3mA for 20 minutes
214315341|NCT03034954|DEVICE|Sham HD-tDCS|Participants will receive sham HD-tDCS
214315342|NCT04727658|RADIATION|Radiosurgical thalamotomy on GammaKnife|fractional radiosurgical thalamotomy on an accelerator (3 sessions of 50 Gy at the isocenter )
214315343|NCT02888847|DEVICE|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
214315344|NCT02888847|DEVICE|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
214315345|NCT03729336|DEVICE|Midstream urine collection device|Non-invasive midstream urine collection device
214315346|NCT03729336|DEVICE|Catheter for urine collection|In-and-out catheter obtains urine through the urethra.
214315347|NCT06343844|DIAGNOSTIC_TEST|cardiac imaging to assess left ventricular volumes and function|non-invasive cardiac imaging (echocardiography and MRI)
214315348|NCT02340299|DEVICE|nHFOV|Extubation to ventilator-derived nHFOV using binasal prongs
214918605|NCT03083015|PROCEDURE|Apexification|a 3-5 mm thickness of MTA using a hand plugger and was verified radiographically.
214918606|NCT02230020|DEVICE|Nasal High Flow|
215061047|NCT02331589|DRUG|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
214315349|NCT02340299|DEVICE|nCPAP|Extubation to ventilator-derived nCPAP using binasal prongs
214315350|NCT05228470|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
214315351|NCT02795390|DRUG|Chinese herbal medicine|
214482271|NCT06879600|DEVICE|High-flow nasal cannula therapy application|Patients will undergo HFNC preoxygenation for 3 minutes with a flow rate of 60 L/min of heated and humidified pure oxygen (100% FiO₂, 37°C - Optiflow; Fisher \& Paykel Healthcare, Auckland, New Zealand). To minimize air contamination, large or medium nasal cannulae will be selected based on the patient's nostril size
214482272|NCT06879600|DEVICE|Traditional facemask|Patients will undergo preoxygenation for 3 minutes using a face mask (sized appropriately to fit the patient and ensure an airtight seal) connected to an Aisys CS2 ventilation system (General Electric, GE Healthcare, Oy, Finland). In this group, the ventilation system will be set with a fresh gas flow of 10 L/min, FiO₂ = 100%, without inspiratory support or expiratory positive pressure. The face mask (Economy, Intersurgical, Fontenay-sous-Bois, France) will be removed after induction to enable intubation.
214315352|NCT02795390|DRUG|Placebo|
214315353|NCT00842660|DRUG|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
214315354|NCT00762398|DEVICE|Masimo hemoglobin-meter|Placing a probe on the finger
214315355|NCT00762398|BIOLOGICAL|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
214315356|NCT01515800|BEHAVIORAL|Text message reminder|Receive text message
214315357|NCT04695938|DIAGNOSTIC_TEST|MRI|MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
214315358|NCT00136084|DRUG|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
214315359|NCT00136084|DRUG|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
214315360|NCT00102232|PROCEDURE|supplementation with phosphatidylcholine|
214315361|NCT02531412|DRUG|Spironolactone|After a major surgery event a time 0, 24h and 48h
214315362|NCT02531412|DRUG|Placebo|After a major surgery event a time 0, 24h and 48h
214315363|NCT03427359|DRUG|cisplatin, capecitabine|Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
214482273|NCT06882343|OTHER|Beautiful Flow Plus X|Shofu's Beautifil Flow Plus X F03 is an advanced injectable bioactive composite that merges the adaptability of flowable composites with the mechanical properties of hybrid composites
214482274|NCT06882343|OTHER|Dentsply Nanohybrid flowable composite|a conventional nano hybrid flowable composite
214482275|NCT06719284|OTHER|HFO&VTV at targeted tidal volumes of 1.5, 2.0 and 2.5 ml/kg in random order|HFO\&VTV at targeted tidal volumes of 1.5, 2.0 and 2.5 ml/kg in random order
214482276|NCT06719284|OTHER|HFOV at the settings applied prior to the study|HFOV at the settings applied prior to the study
214918607|NCT02308540|BIOLOGICAL|SIILPCV10|10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).
214918608|NCT02308540|BIOLOGICAL|Pneumovax 23|23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.
214315364|NCT02117375|DEVICE|spinal cord MRI follow-up|Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
214315365|NCT02117375|OTHER|clinical follow-up|Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
214315366|NCT02117375|OTHER|brain MRI follow-up|
214315367|NCT04445558|DIETARY_SUPPLEMENT|oral nutritional supplementation|Adjunction of oral nutritional supplementation
214315368|NCT04445558|DIETARY_SUPPLEMENT|intradialytic parenteral nutrition|Adjunction of intradialytic parenteral nutrition
214315369|NCT06231303|GENETIC|DNA extraction and PCR amplification|"Microbial community genomic DNA extraction from fecal samples will be done using extraction kit in accordance with the manufacturer's instructions. The DNA extract will be checked on a 1% agarose gel, and the DNA concentration and purity will be determined using the NanoDrop 2000 UV-vis spectrophotometer.~The hyper-variable region V3-V4 of the bacterial 16S rRNA gene will be amplified with the primer pair 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTATCTAAT) on a PCR thermocycler. PCR amplification of the 16S rRNA gene will performed as follows:~Initial denaturation at 95 ℃ for 3 min. 27 cycles of denaturing at 95 ℃ for 30 s, annealing at 55 ℃ for 30 s, and extension at 72 ℃ for 45 s.~Final extension step at 72 ℃ for 10 min and incubation at 10 ℃. The PCR product will then be used to quantify different bacterial species in stool samples of patients and controls using real time PCR."
214315370|NCT00703547|DRUG|GSK586529 capsules|GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
214482277|NCT05876780|GENETIC|SRP-9003|Single IV infusion of SRP-9003
214482278|NCT06715540|DRUG|BCD-261, dose 1|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
214482279|NCT06715540|DRUG|BCD-261, dose 2|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
214482280|NCT06715540|DRUG|BCD-261, dose 3|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
214315371|NCT00703547|DRUG|GSK586529 tablets|GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
214482281|NCT06715540|DRUG|BCD-261, dose 4|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
214315372|NCT00703547|DRUG|Placebo|Placebo tablets and capsules will be provided to subjects.
214315373|NCT02449239|BIOLOGICAL|Vicinium|Intravesical administration
214482282|NCT06715540|DRUG|BCD-261, dose 5|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
214315374|NCT02479152|DEVICE|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
214482283|NCT06715540|DRUG|BCD-261, dose 6|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
214315375|NCT03821558|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
214315376|NCT04898751|DRUG|Immune checkpoint inhibitor (ICI)|Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).
214315377|NCT03244865|DEVICE|LaborView Electronic Fetal Monitor|"Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus."
214482284|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose X|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
214482285|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose X|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
214482286|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose Y|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
214482287|NCT06677957|DRUG|Digoxin|Digoxin will be administered together with Rosuvastatin as a drug cocktail as specified for the respective period
214482288|NCT06677957|DRUG|Divarasib|Divarasib will be administered in combination with Digoxin and Rosuvastatin as specified for the respective period
214482289|NCT06677957|DRUG|Rosuvastatin|Rosuvastatin will be administered together with Digoxin as a drug cocktail as specified for the respective period
214671523|NCT02782715|PROCEDURE|Microwave Ablation (MWA)|Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
214671524|NCT05954754|OTHER|Diaphragmatic Breathing Exercises|Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
214671525|NCT04458857|DRUG|Fremanezumab|Dose A or Dose B subcutaneous
214918609|NCT02308540|BIOLOGICAL|Prevenar 13|13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts
214918610|NCT02285166|DRUG|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
214918611|NCT02285166|DRUG|Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).|
214918612|NCT05130541|BEHAVIORAL|Proning|Rotating on long axis 90 degrees every 30 minutes
214918613|NCT05130541|OTHER|Supportive Care|Usual Care
215061048|NCT04479059|OTHER|follicular fluid flushing|Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
214315378|NCT03222843|DRUG|Hetrombopag Olamine|once daily
214315379|NCT03222843|DRUG|matching placebo|once daily
214315380|NCT02235779|OTHER|Transbronchial lung cryobiopsy|
214482290|NCT06705907|BEHAVIORAL|Achieving Independence and Mastery in School (AIMS)|Intervention targeting academic executive functioning
214482291|NCT06705907|BEHAVIORAL|Building Essential Social Skills for Teens (BESST)|Intervention targeting social skills
214482292|NCT06705426|OTHER|Scapular mobilization with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises|Scapular mobilization with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises
214482293|NCT06705426|OTHER|Posterior capsular stretch with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises|Posterior capsular stretch with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises
214482294|NCT04750616|DRUG|Niacinamide|Niacinamide 3 grams on the day of surgery and post-surgical days one and two
214315381|NCT00394212|DEVICE|Transoral Suturing|suturing of anastomosis
214315382|NCT00394212|OTHER|Sham Endoscopy|suturing not performed
214315383|NCT01902446|DRUG|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
214482295|NCT04750616|DRUG|Placebo|Matched placebo on the day of surgery and post-surgical days one and two
214482296|NCT04281498|DRUG|Ruxolitinib|Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
214482297|NCT04281498|DRUG|Enasidenib|50mg -100mg daily
215061049|NCT01485731|DRUG|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
214315384|NCT00588445|DRUG|Gefitinib|"Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (\> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
214315385|NCT03323528|DRUG|Benzalkonium Chloride-Benzocaine Topical|Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
214315386|NCT03323528|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
214315387|NCT05795894|BEHAVIORAL|STAI-Y|Situational Anxiety and Trait Anxiety Inventory
214315388|NCT05795894|BEHAVIORAL|BDI scale|• Beck Depression Inventory scale
214482298|NCT04701112|DEVICE|Temporary His bundle pacing|"Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration."
214482299|NCT06720168|DEVICE|Erythritol air polisher|Dental prophylaxis with erythritol air polisher in patients with dental black stain
214482300|NCT06720168|DEVICE|Dental prophylaxis with ultrasonic treatment|Dental prophylaxis with ultrasonic treatment in patients with dental black stain
214482301|NCT06720012|DEVICE|Patient specific instrumentation (PSI)|Cutting guides that are manufactured using advanced imaging and modelling techniques to create instruments that align more closely with the unique anatomy of each patient. Custom guides were created based on a preoperative MRI protocol (Zimmer Patient Specific Instrumentation for NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States in collaboration with Materialise NV, Leuven, Belgium) to optimize the placement of the components without the need for intramedullary alignment.
214482302|NCT06720012|DEVICE|Conventional instruments|Instruments specific to the implant that are used to guide bone cutting in reference to the intramedullary canal or using an extramedullary jig.
214482303|NCT06720012|PROCEDURE|Cemented Total Knee Arthroplasty|A cemented TKA (NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States) is used in all cases with a cruciate retaining (CR) or posterior stabilized (LPS) prosthesis as determined by the surgeon.
214482304|NCT06822621|OTHER|Control|Dietary intervention with common white wheat bread in mildly hypecholesterolemic subjects following a hypocaloric diet.
214482305|NCT06822621|OTHER|Intervention|Dietary intervention with white wheat bread enriched with oat beta-glucans in mildly hypecholesterolemic subjects following a hypocaloric diet.
214482306|NCT06810154|BIOLOGICAL|Multi-strain probiotics|Infants will be started on probiotics (Bifidobacterium and Lacticaseibacillus) with enetral feed.
214482307|NCT06825624|DRUG|HS-20093|administered as an IV infusion
214482308|NCT06825624|DRUG|Bevacizumab|administered as an IV infusion
214482309|NCT06825624|DRUG|5-FU|administered as an IV infusion
214482310|NCT06825624|DRUG|Leucovorin|administered as an IV infusion
214482311|NCT06825624|DRUG|Capecitabine|administered orally
215061050|NCT01485731|DRUG|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
215061051|NCT01485731|RADIATION|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
214482312|NCT06825624|DRUG|Oxaliplatin|administered as an IV infusion
214482313|NCT06870097|OTHER|A2 Milk|Cow's milk that contains only A2 β-Casein
214482314|NCT06870097|OTHER|A1/A2 Milk|Cow's milk that contains both A1 β-Casein and A2 β-Casein
214482315|NCT06764030|OTHER|Educational web-based application|BRIDGES is a patient-directed computerized universal education on RC that is delivered within the FP setting, and that does not require the patient to disclose RC experiences to learn about RC.
214671526|NCT04458857|DRUG|Placebo|Matching placebo
214671527|NCT01631162|OTHER|Breath sample in all patients|Breath sample will be collected by a special nylon bag
214671528|NCT00982722|DRUG|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
214671529|NCT00982722|DRUG|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
215061052|NCT01485731|RADIATION|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
214671530|NCT02603575|DRUG|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
214918614|NCT05355584|OTHER|Cryotherapy application|The temperature sense test was applied on the dominant side shoulder of the participants against the risk of sensory loss or decreased sensation. In order to test cold intolerance, a cold pack was placed on the forearm of the individuals. After waiting 2-3 minutes, the region was evaluated. Individuals meeting the inclusion criteria were assigned to the groups according to the randomization list created by the computer. Then, the participants' shoulder isometric muscle strength, shoulder flexibility, shoulder endurance and shoulder balance was evaluated. Except for shoulder endurance, all measurements were repeated three times, with a 30-second rest period between each repetition. A 2-3-minute rest period was given after each test. Then, the cold pack was wrapped in a thin and wet cloth on the shoulders of the participants. The treated area was checked every 5 minutes and the participants were asked to say when they felt any unusual symptoms.
215061053|NCT01485731|PROCEDURE|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
215061054|NCT01485731|PROCEDURE|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
215061055|NCT01485731|PROCEDURE|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
214315389|NCT05795894|BEHAVIORAL|M.I.N.I.Kid|"Suicidal risk module of the Mini-International Neuropsychiatric Interview child/adolescent version"
214315390|NCT05795894|BEHAVIORAL|PCL-5|Post-traumatic Check List Scale
214315391|NCT03240133|DRUG|BCX7353|oral liquid formulation
214315392|NCT03240133|DRUG|Placebo|oral liquid formulation to match BCX7353
214315393|NCT03924258|DIAGNOSTIC_TEST|Iron status testing|Blood sample for iron status testing
214315394|NCT03146234|GENETIC|CAR-GPC3 T cells|"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."
214315395|NCT03278990|BEHAVIORAL|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
214315396|NCT03278990|BEHAVIORAL|Control writing exercise|In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
214315397|NCT00197327|DRUG|Epidural bupivacaine (0.25% versus 0.0625%)|
214315398|NCT02259933|DRUG|KUC 7483 CL|
214315399|NCT02259933|DRUG|Placebo|
214315400|NCT00462319|BEHAVIORAL|Education, weight reduction and physical exercise|
214315401|NCT02511470|OTHER|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
214315402|NCT02511470|OTHER|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
214315403|NCT05935579|DRUG|Durvalumab|Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.
214315404|NCT05935579|DRUG|Lenvatinib Oral Product|The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily.
214315405|NCT05935579|DRUG|Chemotherapy|GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
214315406|NCT05729334|DEVICE|Clinicgram Euclides|"Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~* for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~* for EUCLIDES 3D, a two reference points selected by the investigator."
214315407|NCT04871295|BEHAVIORAL|Noom Healthy Weight|Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
214315408|NCT05385419|DIAGNOSTIC_TEST|Bronchoscopic and thoracoscopic frozen section biopsies|Flexible bronchoscopy for patients with lung endobronchial lesion, the bronchoscopic biopsy will be sent for frozen section and permenant paraffin section Medical thoracoscopy for patients with undiagnosed pleural effusion, the thoracoscopic biopsy will be sent for both frozen section and permenant paraffin section
214315409|NCT05676957|DEVICE|Thermogard XP3|Patients received endovascular hypothermia for 12 hours following endovascular treatment and recanalization.
214671531|NCT02603575|DRUG|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
214671532|NCT02603575|DRUG|Sulfanilamides|1.92g q8h
214671533|NCT00960817|DRUG|Statin, aspirin|
214671534|NCT00960817|DRUG|Dipyridamole|
214671535|NCT00203346|PROCEDURE|Greater Occipital Nerve Block|
214315410|NCT02813343|DEVICE|BlueStar app|BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
214315411|NCT04366622|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
214315412|NCT04055688|DEVICE|Orbeye surgical videomicroscope|The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
214315413|NCT04055688|DRUG|5-Aminolevulinic Acid|5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
214315414|NCT04262895|DRUG|TTI-0102|TTI-0102 is a cysteamine precursor.
214315415|NCT04262895|DRUG|Placebo|Placebo
214315416|NCT06228430|DRUG|Acyclovir 800 mg Tablet|Acyclovir 800 mg Tablet (Test Drug)
214315417|NCT06228430|DRUG|Zovirax™ 800 mg Tablet|Zovirax™ 800 mg Tablet (Reference Drug)
214315418|NCT04770376|OTHER|Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.|Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.
214315419|NCT05905484|DRUG|Bemnifosbuvir (BEM)|A single dose of BEM will be administered.
214315420|NCT05905484|DRUG|Placebo|A single dose of matching placebo will be administered.
214315421|NCT05905484|DRUG|Moxifloxacin|A single dose of Moxifloxacin will be administered.
214315422|NCT01879566|OTHER|No intervention will be done. The study is observational|
214315423|NCT03155009|DRUG|Alectinib|600 mg orally BID with food
214315424|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
214315425|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
214315426|NCT06310512|BEHAVIORAL|Structured drug therapy management|Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment
214315427|NCT01497210|DEVICE|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
214315428|NCT01176292|DEVICE|Rotating Platform High-Flex Cruciate Substituting TKA|
214315429|NCT01176292|DEVICE|Rotating Platform Cruciate Substituting TKA|
214315430|NCT00997503|DEVICE|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
214315431|NCT00997503|DRUG|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
214315432|NCT00997503|DRUG|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
214315433|NCT00997503|DRUG|aspirin|"Oral, as prescribed by physician through end of study.~."
214315434|NCT06163248|OTHER|Chrono nutrition|An integral nutritional strategy involving timing, order and distribution of macronutrients
215061056|NCT01485731|PROCEDURE|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
214315435|NCT06163248|OTHER|Standard|Conventional nutritional strategy involving isocaloric distribution with no specific timing
214315436|NCT00116831|DRUG|Glipizide|oral anti-diabetic medication
214315437|NCT00116831|DRUG|rosiglitazone maleate|oral antidiabetic medication
214315438|NCT01040585|DRUG|Linezolid|Treatment for VAP as indication approved and as physician criterium.
214315439|NCT01933048|DRUG|FluMist|FluMist Intranasal Vaccine
214315440|NCT00110812|DRUG|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
214315441|NCT01790334|OTHER|Ultrasonography|
215061057|NCT01485731|PROCEDURE|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
215061058|NCT01485731|PROCEDURE|Proctoscopy|Optional. Pre-Treatment
215061059|NCT01485731|PROCEDURE|Cytoscopy|Optional. Pre-Treatment
214315442|NCT00380393|BIOLOGICAL|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
214315443|NCT00380393|BIOLOGICAL|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
214918615|NCT05405946|BEHAVIORAL|Computerized Cognitive Remediation Therapy|"Sessions of 45 minutes will be developed 2 times a week, for 4-5 months (performing a total of 40 sessions). The sessions will be led by an experienced clinician with psychotic patients, and trained for the management of CCRT. Each intervention session will be individualized according to the results of the evaluation tests and the computerized program itself will adapt the difficulty of the tasks according to the performance of each patient.~The cognitive remediation NeuroPersonalTrainer platform includes two rehabilitation modules: the cognition module that includes attention, memory and executive functions with different levels of complexity and the Social Cognition module which allows working on different aspects of emotional processing, theory of mind and cognitive biases through 43 tasks based on multiple multimedia materials."
214315444|NCT04941508|BEHAVIORAL|the mother's recorded voice|Children will be assigned to listen to the mother's recorded voice at 2 times (in the holding area 3 minutes before induction of anesthesia till induction of anesthesia is ended) and (during emergence from anesthesia till complete recovery).
214315445|NCT04941508|DRUG|Dexmedetomidine|Children will be given a single bolus of dexmedetomidine 0.2 µ/kg IV at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
214315446|NCT04941508|OTHER|saline 0.9% placebo|Children will be given the same volume of saline at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
214315447|NCT02130063|DRUG|iron isomaltoside 1000 (Monofer®)|
214315448|NCT02130063|DRUG|iron sucrose (Venofer®)|
214315449|NCT03126994|DEVICE|PhysioWave Cardiovascular Analyzer|Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI
214315450|NCT03126994|DEVICE|AtCor XCEL PWA & PWV|Measurement of Pulse Wave Velocity and Pulse Rate
214315451|NCT03126994|DEVICE|Detecto SOLO|Measurement of Body Weight and BMI
214482316|NCT06735339|OTHER|Clinic for Multimorbidity|"The patient is assigned a healthcare coordinator. A review of the patient's medication history and a medication review are conducted. A functional assessment is performed, along with relevant measurements, and the patient consults with a specialist physician. A multidisciplinary team (MDT) conference is held with selected specialists, depending on the patient's needs. This may include a cardiologist, endocrinologist, pulmonologist, gastroenterologist, rheumatologist, nephrologist, geriatrician, clinical pharmacologist, psychiatrist, pain nurse, physiotherapist, occupational therapist, and the patient's GP.~The handover of information to the GP is agreed upon at the time of referral and can be carried out in writing, through virtual MDT participation, or by telephone.~In agreement with the patient, the clinic may initiate follow-up actions, such as counseling on medication or disease management. Additionally, the clinic may facilitate cross-sectoral activities, such as therapy."
214482317|NCT06729385|DIAGNOSTIC_TEST|The blood Proteome Profiling|Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.
214482318|NCT04957576|BEHAVIORAL|Visuo-tactile stimulation|The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.
214482319|NCT01508390|RADIATION|CyberKnife Boost|21 Gy in 7 Gy per day, 3 fractions, Every other day
214918616|NCT05405946|OTHER|Treatment as Usual|Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.
214918617|NCT02713360|BEHAVIORAL|Cognitive Therapy|
214315452|NCT00909948|OTHER|Fludarabine and total body irradiation|The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
214315453|NCT00909948|RADIATION|Total body irradiation|Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
214315454|NCT02353767|PROCEDURE|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
214315455|NCT02780804|DRUG|Entinostat|Given PO
214315456|NCT02780804|OTHER|Laboratory Biomarker Analysis|Correlative studies
214315457|NCT02780804|OTHER|Pharmacological Study|Correlative studies
214315458|NCT01039896|DRUG|Period I : SLM0807, Period II : HKB0701 and SLM0807|
214315459|NCT01039896|DRUG|Period I : HKB0710 and SLM0807, Period II : SLM0807|
214315460|NCT02476968|DRUG|Olaparib|"Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water."
214482320|NCT06315023|DEVICE|DETOUR System|Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System
214482321|NCT04707183|DRUG|Lidocaine IV Infusion|Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
214482322|NCT04707183|DRUG|2% Lidocaine via ESPB|10 ml of 2% lidocaine will be infused through ESPB in treatment group
214482323|NCT06299267|OTHER|dual task conditions|dual task conditions on manual skill tests
214918618|NCT06248372|OTHER|Exercise|Both groups will receive the same exercise program that includes strengthening and stretching exercises except for the verbal instructions which shift attention to the internal or external environment or no attentional instructions for the control group.
214315461|NCT02478138|PROCEDURE|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
214315462|NCT02478138|DRUG|Indocyanine Green (ICG)|
214315463|NCT02478138|DEVICE|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
214315464|NCT01723163|BEHAVIORAL|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
214315465|NCT01723163|BEHAVIORAL|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
214315466|NCT00779012|BIOLOGICAL|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
214315467|NCT04460222|PROCEDURE|Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure|"Rotational Thromboelastometry will be performed pre procedure and blood component will be transfused if~* EXTEM CT more than 80 sec then FFP will be transfused at 15 ml/kg MCF less than 35 mm then Platelet will be transfused at 10 ml/kg~* FIBTEM MCF less than 7 mm then Cryoprecipitate will be transfused at 5 ml/kg"
214315468|NCT04460222|PROCEDURE|Conventional transfusion methods to guide blood product transfusion pre invasive procedure|Transfusion will be given If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
214315469|NCT05677620|RADIATION|Pharyngeal Computed Tomography|To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
214315470|NCT05677620|DRUG|Drug-Induced Sleep Endoscopy (Propofol)|The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
214315471|NCT05677620|DEVICE|Mandibular Advancement Device|A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
214315472|NCT01657110|OTHER|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
214315473|NCT03549702|DRUG|Povidone iodine 1% solution|irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
214315474|NCT00751816|DRUG|systemic chemotherapy|
214315475|NCT00751816|OTHER|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
214315476|NCT00751816|PROCEDURE|adjuvant therapy|
214315477|NCT00751816|PROCEDURE|management of therapy complications|
214315478|NCT00751816|PROCEDURE|musculoskeletal complications management/prevention|
214315479|NCT00751816|PROCEDURE|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
214315480|NCT00751816|RADIATION|radiation therapy|
214315481|NCT03430804|OTHER|Bishop score calculation of modified Bishop score in numbers by digital vaginal examination|Measurement of cervical length by transvaginal ultrasound and digital examination of Bishop score in 320 parturients undergoing labour induction at term
214315482|NCT00382811|DRUG|phenoxodiol|400mg phenoxodiol three times daily in 28 day cycles.
214315483|NCT00382811|DRUG|carboplatin|AUC=2 weekly in 28 day cycles
214315484|NCT00382811|DRUG|placebo|every 8 hours daily in 28 day cycles
214315485|NCT00802022|DEVICE|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
214315486|NCT04855643|DEVICE|home-based active tDCS|Anode and cathode electrodes will be placed over the left and right dorsolateral prefrontal cortexes, respectively, with the use of the Omni-Lateral-Electrode system. Caregivers will set up and administer tDCS for participants with ADRD at home. tDCS will be applied for 30 min at an intensity of 2mA, with 30 s ramping up and down. All sessions will be remotely supervised by trained research staff.
214315487|NCT04855643|DEVICE|home-based sham tDCS|For sham stimulation, electric current will be applied only in the first 30s tDCS. All sessions will be remotely supervised by trained research staff.
214918619|NCT03869840|DEVICE|Sensor to spot check blood levels|Sensor to check blood levels, not used as intervention
214918620|NCT03219840|DRUG|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
214918621|NCT03219840|DRUG|Xylitol only chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
215061060|NCT01485731|PROCEDURE|Renal Ultrasound|Optional. Pre-Treatment
215061061|NCT01485731|PROCEDURE|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
215061062|NCT01485731|PROCEDURE|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
215061063|NCT04510987|DRUG|BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5|Tablet, oral
215061064|NCT04510987|OTHER|BAY2433334 on dialysis treatment day|Tablet, oral
214918622|NCT05702801|DEVICE|Stochastic Vibratory Stimulation (SVS)|Investigators implement stochastic vibratory stimulation (SVS) to alter proprioceptive performance by increasing excitement of type Ia afferents in muscle spindles. Based on previous preliminary data, vibration frequencies around 40Hz may provide adequate noise for enhancing aging-related proprioceptive deficits. To make a subsensory noise investigators set it to 90% of the sensory threshold amplitude, which has been effectively used previously for influencing mechanoreceptor sensation in older adults. Stimulation will be imposed bilaterally on: 1) distal ankle (tibialis anterior, peroneus longus, soleus, gastrocnemius); and 2) proximal hip (quadriceps, gluteus medius, and paraspinals). Investigators use Gaussian noise to reduce the anticipative and preemptive adjustments of muscle spindles to the vibration. For SVS investigators use a magnetic actuator system and a Universal Controller (C-2HDLF Tactor/TDK), to provide programmable frequency ranges.
214315488|NCT04111094|DIAGNOSTIC_TEST|No intervention|No intervention
214315489|NCT05547321|DRUG|OMTX705|The investigational product is OMTX705 administered as monotherapy.
214315490|NCT05547321|DRUG|Pembrolizumab|The investigational product is OMTX705 administered in combination with pembrolizumab.
214315491|NCT04914728|PROCEDURE|mini-invasive lumbar arthrodesis|"* The mini-invasive posterior approach is performed using a trans-muscular Wiltse approach. Pedicle screws, neurological decompression and intersomatic cage placement are performed.~* The mini-invasive anterior approach is performed via a left retroperitoneal pararectal approach. After complete discectomy, an intersomatic cage stabilised by a screwed plate will be placed."
214315492|NCT06221228|BEHAVIORAL|Audio-visual assisted Flipped Classroom (FC) CAPD Training Programme|"FC CAPD programme is a one-week individual intervention, which consists of five sessions (8-hours each).~Pre-class audio-visual tutorials will be provided for self-study prior to face-to-face (F2F) sessions. Six instructional videos, each dedicated to a specific procedure, are accessible for preview and repeated viewing as needed. Such flexibility allows the patients to revise at their own preferred time and pace.~Participants will be asked to take note of any issues or difficulties they encounter while watching the video.~A CAPD education booklet will be prepared and distributed to the patients at the beginning of the F2F training session.~Take-home exercises will allow participants to revise the materials covered in the videos and consolidate their learning."
214315493|NCT05522465|DRUG|Prednisone|Prednisone 4mg/kg.d, d1-4
214315494|NCT05522465|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg.d, d1-4
214315495|NCT03837548|OTHER|Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
214315496|NCT03837548|OTHER|The other Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
214315497|NCT01064895|DEVICE|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
214315498|NCT00820001|BEHAVIORAL|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
214315499|NCT00820001|BEHAVIORAL|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
214315500|NCT00820001|OTHER|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
214315501|NCT00820001|OTHER|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
214482324|NCT04591002|DRUG|Osimertinib 80 MG|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. Osimertinib will be administered orally as one 80 mg tablet once a day (1 cycle is 28 days). Cycles are repeated until disease progression, unacceptable toxicity, or until 1 year after the initiation of osimertinib administration.
214482325|NCT05447078|DRUG|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
214482326|NCT05447078|DIETARY_SUPPLEMENT|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.
214482327|NCT04725383|DRUG|amitriptyline|Amitriptyline is a tricyclic antidepressant being studied off-label here for repetitive behaviors in autism spectrum disorders.
214482328|NCT06208813|DIETARY_SUPPLEMENT|Creatine|Creatine supplementation
214482329|NCT06087783|DIETARY_SUPPLEMENT|Experimental product - Fortifit® Powder|Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
214482330|NCT06087783|OTHER|Standard of care|Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement
214482331|NCT03417284|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HSCT
214482332|NCT03417284|BIOLOGICAL|Filgrastim-sndz|Given SC
214482333|NCT03417284|DRUG|Melphalan Hydrochloride|Given IV
214315502|NCT04133493|DEVICE|Kerecis Omega3 Wound|"The intervention group will receive, in addition, a fish skin graft (KerecisTM Omega3 Wound) secured with Steristrips, sutures or staples, covered with a nonadherent dressing (Adaptic, Systagenix, Yorkshire, UK or equivalent), the product bolstered down to the wound bed with a foam dressing (HydraFoam, DermaRite) and hydrogel as needed to retain adequate moisture balance and padded with stretch gauze and self adherent wrap as needed.~The wound will be dressed by the site investigator 1 day a week."
214315503|NCT04133493|DEVICE|Fibracol|The Standard of Care Group will receive Fibracol covered with DSD. Change three times per week
214315504|NCT03379116|OTHER|enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.
214315505|NCT05274256|PROCEDURE|implant placement with simultaneous soft tissue augmentation|implant placement with simultaneous soft tissue augmentation using De-epithelialized free gingival graft and immediate temporization in the maxillary aesthetic zone .
214482334|NCT05132400|BEHAVIORAL|Psychological-informed Physical Therapy (PiPT) Training|An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
214482335|NCT05954832|DIAGNOSTIC_TEST|Echocardiography|Echocardiography and Clearsight BP measurements before, immediately after anesthesia induction and after intubation (for 20 min)
214482336|NCT06497010|DRUG|Biological: PD-1|Intravenous (IV) infusion
214482337|NCT06497010|DRUG|Biological: InnoPCV|Intramuscular (IM) injection
214482338|NCT05942417|PROCEDURE|Echoguided percutaneous neuromodulation plus exercise|This group is taking the EPNM and the exercise program
214482339|NCT05942417|PROCEDURE|Strength program|This group is taking the exercise program
214482340|NCT05937854|DRUG|Tadalafil|one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
214482341|NCT05937854|DRUG|Placebo|one or two encapsulated tablets of placebo po QD
214482342|NCT06206759|DRUG|administration of vitamin C|administration of vitamin C to ICU patients
214315506|NCT00624962|DIETARY_SUPPLEMENT|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
214315507|NCT00624962|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
214315508|NCT05718635|DIAGNOSTIC_TEST|coloured duplex|colored duplex to locate numbers sites and size of perforators.
214482343|NCT06462651|DIETARY_SUPPLEMENT|L. reuteri|Supplementation with drops containing L. reuteri once daily for 21 consecutive days
214482344|NCT06462651|DIETARY_SUPPLEMENT|Placebo|Supplementation with identical drops without L. reuteri once daily for 21 consecutive days
214482345|NCT00640978|DRUG|RAD001|30 mg orally weekly for 4 weeks
214678613|NCT02367170|PROCEDURE|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
214918623|NCT05540912|DRUG|D064+D701|Reference
214918624|NCT05540912|DRUG|CKD-828 Formulation 1|Test 1
214482346|NCT00640978|DRUG|Erlotinib|150 mg by mouth daily for 28 Days
214482347|NCT06339190|DIAGNOSTIC_TEST|Venepuncture|A single blood draw at the time of presentation to clinic or whilst an inpatient.
214482348|NCT05055011|OTHER|Electronic Health Record Review|Review of medical records
214482349|NCT05055011|OTHER|Survey Administration|Complete survey
214918625|NCT05540912|DRUG|CKD-828 Formulation 2|Test 2
214918626|NCT02710812|PROCEDURE|Local Excision or Wait-and-See|"Local excision can be done both with traditional technique and with endoscopic technique (TEM, TAMIS, etc.).~The following principles should be respected:~1. A gross margin of at least 0.5 cm;~2. full-thickness excision including mucosa, submucosa, muscle and peri-rectal fat;~3. determination of the specimen on the support by pins at the edges in order to facilitate the interpretation of histological pathologist."
214918627|NCT03867812|OTHER|SOBAR|SOBAR is a high protein nutrition bar optimized to delay gastric emptying
214918628|NCT03867812|OTHER|Control food|Chexmix (General Mills Inc.), Honey Nut Flavor
214918629|NCT03867812|OTHER|Full meal|Stouffer's Bistro Crostini 5 cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie
214918630|NCT05569668|DRUG|Paclitaxel- and platinum-based chemotherapy|Neoadjuvant Chemotherapy
214918631|NCT00384839|DRUG|azacitidine for injectable suspension|Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
214315509|NCT05718635|PROCEDURE|supra facial dissection|flap raising in supra facial plane
214315510|NCT03070353|DRUG|Dextran 40|Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
214315511|NCT00358202|DRUG|cefepime|cefepime hydrochloride 1gm IM q24h
214315512|NCT00358202|DRUG|ceftriaxone|ceftriaxone 1 gm IM q24h
214315513|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR placebo|2 placebo combination tablets twice daily for 16 weeks (maintenance period)
214482350|NCT02521103|DEVICE|Triathlon Tritanium Cone Augments|The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
214482351|NCT02076009|DRUG|Daratumumab|Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.
214482352|NCT02076009|DRUG|Lenalidomide|Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
214315514|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR 360 mg/day|2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
214315515|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR placebo|2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
214315516|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR placebo|2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
214315517|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
214315518|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
214315519|NCT01859507|DRUG|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
214315520|NCT01921829|DRUG|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
214315521|NCT00275158|DRUG|L-Arginine Supplementation|
214315522|NCT03621228|DEVICE|MindfulGarden|MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
214315523|NCT01715818|DRUG|Placebo|matching aleglitazar placebo tablet orally daily
214918632|NCT03773250|BEHAVIORAL|Behavioral intervention|The intervention has an intensive phase and a maintenance phase.
214918633|NCT03140410|OTHER|Antibiotic resistance|"Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated"
214918634|NCT02302638|OTHER|embryo culture in different single-step media|Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
214315524|NCT01715818|DRUG|aleglitazar|150 mcg orally daily
214315525|NCT05449925|PROCEDURE|Injectable PRF and Microneedling|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
214482353|NCT02076009|DRUG|Dexamethasone|Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).
214482354|NCT06511804|DEVICE|Intracranial Pressure Noninvasive Monitoring|Mespere sensors will be placed on the temporal areas of the head in patients with invasive intracranial pressure monitoring. Blood pressures, intracranial pressure, and Mespere parameters will be recorded.
214482355|NCT02271828|PROCEDURE|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
214482356|NCT06500208|DRUG|Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide|Adebrelimab 1200mg i.v. q3w combined with nab-paclitaxel 100mg/m2 qw\*12w followed by epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 q3w for 4 cycles
214482357|NCT06632938|DRUG|ABBV-382|Subcutaneous (SC) Injection
214482358|NCT06632938|DRUG|ABBV-382|Intravenous (IV) Infusion
214918635|NCT06576024|BIOLOGICAL|2 doses of HAV|Participants will receive two doses of HAV with a 6-month interval
214918636|NCT06576024|BIOLOGICAL|At least one dose of HAV|Participants will receive the first dose of HAV and will receive the second dose with a 6 -month interval voluntarily.
214918637|NCT05445635|DEVICE|Iriscope|The use of Iriscope to improve the diagnostic yield of bronchoscopy in the setting of peripheral lung nodules
214315526|NCT04197570|DRUG|Opioid Anesthetics|see arm/group description
214315527|NCT04197570|DRUG|Non Opioid Analgesics|see arm/group description
214315528|NCT04476030|DRUG|SAGE-217|Oral capsules
214315529|NCT04476030|DRUG|Matching Placebo|Oral capsules
214315530|NCT04476030|DRUG|Sertraline|Oral tablets
214315531|NCT04476030|DRUG|Escitalopram|Oral tablets
214315532|NCT04476030|DRUG|Citalopram|Oral tablets
214315533|NCT04476030|DRUG|Duloxetine|Oral capsules
214482359|NCT06632938|DRUG|Placebo for ABBV-382|IV Infusion
214482360|NCT06632938|DRUG|Placebo for ABBV-382|SC Injection
214482361|NCT04328740|DRUG|TP-1454 monotherapy|Flat dose once or twice daily, alone
214482362|NCT05023772|PROCEDURE|Stereotactic Laser Ablation|MR Guided laser ablation therapy
214482363|NCT05023772|RADIATION|Stereotactic Radiosurgery|Precise delivery of radiation to spinal tumor
214482364|NCT05023772|DIAGNOSTIC_TEST|MRI guided laser ablation|Surgery will take place in intraoperative suite to include operating room and MRI scanner
215061065|NCT02895672|DRUG|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
214315534|NCT04476030|DRUG|Desvenlafaxine|Oral tablets
214315535|NCT00977067|DRUG|GDC-0152|Intravenous escalating dose
214315536|NCT03395366|OTHER|Multifaceted Educational / Cognitive Behavioral Intervention|The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts \& worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
214315537|NCT05159245|DRUG|Alectinib|ALK
214315538|NCT05159245|DRUG|Cobimetinib|MEK1, MEK2
214315539|NCT05159245|DRUG|Vismodegib|Hedgehog
214315540|NCT05159245|DRUG|Trastuzumab+Pertuzumab|HER2
214315541|NCT05159245|DRUG|Entrectinib|NTRK/ ROS1, ALK
214315542|NCT05159245|DRUG|Atezolizumab|PD-L1
214315543|NCT05159245|DRUG|Vemurafenib|BRAF V600
214315544|NCT05159245|DRUG|Regorafenib|KIT/BRAF, RET
214315545|NCT05159245|DRUG|Apalutamide|AR
214315546|NCT05159245|DRUG|Abemaciclib|CDK4/6
214315547|NCT05159245|DRUG|Tepotinib|MET ex14
214315548|NCT05159245|DRUG|Dabrafenib|RAF
214918638|NCT05923138|DIETARY_SUPPLEMENT|MULTIDOMAIN NUTRITIONAL INTERVENTION: DIET, EXERCISE AND NUTRITIONAL SUPPLEMENTS|"Nutritional intervention (diet, dietetic recommendations and/or supplements). Participants will receive specific recommendations about diet, energetic dietetic supplementation, oral nutritional supplements, exercise... The Nutrition Team (formed by cardiologists, dieticians, nurses...) will closely monitor patients with periodic visits and reassessment of nutritional status and compliance with recommendations."
214918639|NCT05923138|DIETARY_SUPPLEMENT|CONTROL|Standard treatment (usual recommendations in patients with heart failure)
214315549|NCT05159245|DRUG|Trametinib|MEK1, MEK2
214315550|NCT05159245|DRUG|Dabrafenib+Trametinib|RAF, MEK1, MEK2
214315551|NCT05159245|DRUG|Pemigatinib|FGFR2
214918640|NCT02919319|DRUG|ACT-541468 (Formulation A)|Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
214918641|NCT02919319|DRUG|ACT-541468 (Formulation B)|Soft gelatin capsules for oral administration formulated at the strength of 25 mg
214315552|NCT01963390|DRUG|Testosterone Therapy|In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
214315553|NCT04411342|DIAGNOSTIC_TEST|Albumin creatinine ratio|normal range of albumin in urine in patients with type 2 diabetes
214315554|NCT04777890|OTHER|suboccipital inhibition|The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
214315555|NCT04777890|OTHER|INYBI|The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
214315556|NCT04777890|OTHER|INYBI + upper cervical manipulation|The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
214315557|NCT00445510|DRUG|GSK256066|
214315558|NCT03164499|BEHAVIORAL|Individual counselling on lifestyles|Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
214315559|NCT03164499|BEHAVIORAL|Additional group counselling on lifestyles|"Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment."
214315560|NCT01653522|DRUG|Triptan|
214315561|NCT01653522|DRUG|Doxycycline|
214315562|NCT04945434|DEVICE|S53P4 bioactive glass (BonAlive)|Surgical implantation of S53P4 in a bone defect created during debridement for chronic osteomyelitis.
214315563|NCT02163291|DRUG|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
214315564|NCT05455983|BIOLOGICAL|covid19 vaccines|different types of (COVID-19) vaccination
214315565|NCT02243150|DRUG|G1T28-1 (CDK 4/6 Inhibitor)|
214315566|NCT02243150|DRUG|Placebo|
214315567|NCT05526872|OTHER|Best Practice|Receive usual care
214315568|NCT05526872|BEHAVIORAL|Health Education|Receive educational materials
214315569|NCT05526872|OTHER|Interview|Ancillary studies
214315570|NCT05526872|OTHER|Planned Notification|Receive planned reminders to schedule mammogram
214315571|NCT05526872|OTHER|Survey Administration|Ancillary studies
214315572|NCT03015051|DRUG|Oxygen|
214482365|NCT06448208|DIAGNOSTIC_TEST|positron emission tomography (PET) scans|Before and after treatment.
214482366|NCT06208371|PROCEDURE|Surgical resection and/or ablation therapy and/or SBRT|Participants may receive surgical resection and/or ablation therapy and/or stereotactic body radiotherapy
214315573|NCT05439356|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
214315574|NCT05439356|DRUG|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
214315575|NCT02404311|BIOLOGICAL|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and \< 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
214315576|NCT02404311|BIOLOGICAL|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
214315577|NCT02404311|BIOLOGICAL|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
214315578|NCT02404311|BIOLOGICAL|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
214315579|NCT05994729|DIAGNOSTIC_TEST|Invasive Physiological Assessment of Coronary Circulation|After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.
214315580|NCT00864162|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
214315581|NCT00864162|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
214315582|NCT06273176|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
214315583|NCT06273176|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
214315584|NCT06273176|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
214315585|NCT00002882|BIOLOGICAL|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
214315586|NCT00002882|BIOLOGICAL|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
214315587|NCT00002882|DRUG|Cisplatin|IV Days 1-4
214315588|NCT00002882|DRUG|Dacarbazine|IVPB on day 1
214315589|NCT00002882|DRUG|Vinblastine|IVPB on days 1-4
214918642|NCT02919319|DRUG|Placebo (Formulation A)|Hard capsules matching ACT-541468 Formulation A
214918643|NCT02919319|DRUG|Placebo (Formulation B)|Soft capsules matching ACT-541468 Formulation B
214918644|NCT02919319|DRUG|14C-labeled ACT-541468|Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
214918645|NCT02919319|DRUG|Placebo tracer|Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
215061066|NCT05087368|BIOLOGICAL|ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
215061067|NCT05087368|BIOLOGICAL|CoronaVac (Sinovac Biotech)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
214315590|NCT00002882|PROCEDURE|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
214315591|NCT01542515|PROCEDURE|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
214315592|NCT05369910|BEHAVIORAL|Light exposure (Flash)|Light exposure (Flash) is administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source (Dawe stroboscope type 1214B, 5 Hz).
214315593|NCT05369910|BEHAVIORAL|Light deprivation (Dark)|Light deprivation (Dark) is administered for one hour on 7 consecutive days. During the Dark intervention, participants are seated in a room in complete darkness.
214315594|NCT03678142|DIAGNOSTIC_TEST|analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood|blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)
214918646|NCT03486158|DEVICE|CalproSmart™ system|Home test kit for measurement of calprotectin in fecal samples. A new clinical tool for monitoring patients with inflammatory bowel disease, enabling measurement of calprotectin level of rapid test through a specially developed Smartphone application (platforms such as Android o Iphone)
214918647|NCT04387019|DIAGNOSTIC_TEST|blood sampling|blood sampling from peripheral vein
214918648|NCT00443079|DRUG|IdB 1016 (Siliphos)|1 pill 3 times daily x 6 weeks
214918649|NCT00443079|DRUG|Matched placebo|1 pill 3 times daily x 6 weeks
214918650|NCT02619864|DRUG|AZD2014|
214918651|NCT00174564|DRUG|oxaliplatin|
214918652|NCT03710863|DRUG|CM082|Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.The treatment period is tentatively set at 1 year.
214918653|NCT02547142|OTHER|Early Palliative Care|Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
214918654|NCT05443763|OTHER|An interdisciplinary intensive therapy program|Children will receive physical, occupation, and/or speech therapy 1-3 hours/day each for 4-5 days/week x 4 weeks.
214482367|NCT06208371|DRUG|Palliative Chemotherapy|Participants in this group may continue the original systemic chemotherapy regimen. Patients with tumor control after 10-12 cycles can either transition to maintenance treatment or temporarily suspend treatment until disease progression, at which point they switch to a second-line treatment regimen.The selection of second-line and subsequent treatment regimens follows CSCO guidelines and clinical practices.
215061068|NCT05087368|BIOLOGICAL|Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
214315595|NCT02646696|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
214315596|NCT03225612|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.
214315597|NCT02555995|DEVICE|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
214482368|NCT06956950|DRUG|Bupivacaine + Magnesium sulfate|ultrasound-guided transmuscular quadratus lumborum block using 25 ml of 0.25% bupivacaine + 5 ml 10% magnesium sulfate
214482369|NCT06956950|DRUG|Bupivacaine + saline|ultrasound-guided transmuscular quadratus lumborum block using 25 ml of 0.25% bupivacaine + 5 ml normal saline
214482370|NCT05444465|DEVICE|Isolated Bioinductive Repair|Isolated Bioinductive repair with REGENETEN™ Bioinductive Implant
214482371|NCT05444465|PROCEDURE|Completion and Repair|Standard surgical repair using the 'Completion and Repair' technique.
214482372|NCT06848465|RADIATION|Low Dose Radiotherapy|10 Gy in 5 fractions, 15 Gy in 3 fractions, 20 Gy in 10 fractions respectively in three Cohorts from Day1
214482373|NCT06848465|RADIATION|Short course Radiotherapy|25 Gy in 5 fractions from Day1
214482374|NCT06848465|DRUG|XELOX|Oxaliplatin: 130mg/m2 IV Q3W on day 1 of each cycle. Capecitabine: 1000mg/m2 Q3W Dose of 1000mg/m2 on day 1-14 of each cycle.
214482375|NCT06848465|DRUG|Tislelizumab|200mg IV Q3W on day 1 of each cycle.
214482376|NCT06848907|DRUG|ganzhixiao capsule|Ganzhixiao Capsule is mainly composed of Bupleurum chinense, Herba Artemisiae, Polygonum cuspidatum, Rhubarb and Hawthorn.Take 3 capsules each in the morning, afternoon, and evening, and swallow with warm water after meals for 16 weeks.All participants in the trial were required to have a low-fat diet and engage in aerobic exercise for 150 minutes per week.
214482377|NCT06848907|DRUG|placebo capsule|Take 3 palcebo capsule each in the morning, afternoon, and evening, and swallow with warm water after meals for 16 weeks.All participants in the trial were required to have a low-fat diet and engage in aerobic exercise for 150 minutes per week.
214482378|NCT06162091|OTHER|Data collection|"The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~1. The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~2. Cognitive functioning (Levels of Cognitive Functioning, LCF);~3. disability (Disability Rating Scale, DRS);~4. level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months."
214482379|NCT04422743|DIETARY_SUPPLEMENT|Citicoline 500 mg plus Homotaurine 50 mg|Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
214918655|NCT00205556|PROCEDURE|on-line hemodiafiltration|addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
214918656|NCT00205556|PROCEDURE|low flux hemodialysis|standard treatment
214918657|NCT03110406|OTHER|whole-body vibration training|Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.
214918658|NCT04551274|BEHAVIORAL|Music Therapy|Music Therapy interventions involve the use of live music (performed or created by the therapist and/or patient), and a process that includes patient-specific assessment, treatment, and evaluation
215061069|NCT00455091|DRUG|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/\> 105 copies/mL and ALT \> 2.0 x UNL
214315598|NCT05973916|OTHER|Comprehensive intervention|"cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed."
214315599|NCT02752191|DRUG|ferumoxytol|ferumoxytol as an MRI contrast agent infused over several minutes
214315600|NCT02752191|DRUG|gadofosveset|gadofosveset as an MRI contrast agent injected over several seconds
214315601|NCT01536496|BIOLOGICAL|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
214671536|NCT04169607|PROCEDURE|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|"Basic ventilation: Volume-controlled ventilation (VCV) mode with positive end-expiratory pressure (PEEP) of 8cm H2O after induction of anesthesia，~Recruitment maneuver (RM): Pressure-controlled ventilation (PCV) mode increasing PEEP from 10 to 25cmH2O in step of 5cmH2O per 30s.~PEEP-titration maneuver: ventilation parameters reset as basic ventilation with PEEP still 25cmH2O.Decrease PEEP to 5cmH2O in step of 2cmH2O per 10 respiratory cycles to confirm the highest dynamic lung compliance (Cdy).~After titration: A new RM will be performed and the final PEEP will be the one related to highest Cdy plus 2cm H2O.~Randomized after the second RM. Individualized PEEP arm: maintain individualized PEEP; PEEP8 arm: maintain a fixed PEEP of 8cm H2O.~VCV with other ventilation parameters the same as basic ventilation until extubation .~After discharged from postoperative anesthesia care unit (60 to 90 minutes after extubation): chest CT ."
214918659|NCT05038774|OTHER|Face to face Educational Training|"1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension."
215061070|NCT02975739|DEVICE|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
215061071|NCT02681419|PROCEDURE|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
215061072|NCT02681419|PROCEDURE|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
214315602|NCT01536496|BIOLOGICAL|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
214315603|NCT02256891|DEVICE|PRFM|
214315604|NCT02256891|PROCEDURE|Double Row|
214315605|NCT04552938|OTHER|pre-LVA|Venous serum samples were collected from patients before LVA.
214315606|NCT04552938|OTHER|post-LVA|Venous serum samples were collected from patients one-month after LVA.
214315607|NCT01748786|BEHAVIORAL|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
214315608|NCT01748786|OTHER|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
214315609|NCT01344447|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
214315610|NCT06106971|DRUG|Sodium tetradecyl sulfate|Subjects receive sodium tetradecyl sulfate via balloon-occluded retrograde transvenous obliteration at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding.
214315611|NCT06106971|DRUG|Cyanoacrylate|Subjects receive endoscopic cyanoacrylate injection at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding then receive repeated endoscopic cyanoacrylate injection at 1-month intervals until obliteration of gastric varices.
214315612|NCT06026891|DRUG|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
214315613|NCT00724516|DEVICE|Novel Breast Compression Paddle|Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
214315614|NCT00218296|DRUG|Usual Care Group|Nicotine replacement therapy
214315615|NCT00218296|OTHER|Reduction Group|Subject selects preferred method for reduction.
214315616|NCT03094754|PROCEDURE|nevi excision|After general anesthesia, nevi excision in children is performed.
214315617|NCT04218058|PROCEDURE|reduction of zygomatic arch in zygomaticomaxillary complex fracture|ultrasound guided reduction of zygomatic arch
215061073|NCT02358161|DRUG|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
214315618|NCT05044806|OTHER|Ultrasound-guided remote ischemic conditioning|Before conducting RIC, Doppler ultrasound was used to measure the total occlusion pressure (TOP) of brachial artery, which was then determined as the cuff inflation pressure during RIC. The RIC program encompasses four main components of (1) three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2) one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3) three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of RIC with 3 min intervals of reperfusion in between, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning.
214482380|NCT04243759|BEHAVIORAL|Control App Version|"The control version is a smartphone-compatible CGNG. The cued go/no-go (CGNG) tests ability to respond fast to go targets (activation) while withholding response to no-go targets (inhibition)."
214482381|NCT04243759|BEHAVIORAL|Standard App Version|The standard version is the same as the control version with the exception that information about performance (correct or incorrect) is displayed along with RT in ms for a correct response during each inter-trial interval.
214482382|NCT04243759|BEHAVIORAL|Experimental, Feedback App Version|The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.
214918660|NCT05038774|OTHER|Printed Education Material|"1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension."
214918661|NCT00248365|BIOLOGICAL|Theralux extracorporeal photochemotherapy|
214315619|NCT05044806|OTHER|Traditional remote ischemic conditioning|The RIC program encompasses four main components of (1)three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2)one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3)three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of upper limb ischemia on the arm that is opposite to the PCI side with 3 min intervals of reperfusion in between delivered by an automated cuff inflation/deflation device, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
214315620|NCT05044806|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
214315621|NCT03087370|OTHER|No intervention|No intervention
214315622|NCT06579144|DRUG|Efanesoctocog alfa|Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
214315623|NCT05262556|DRUG|NP-101 (TQ Formula)|Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
214315624|NCT05262556|DRUG|Nivolumab (3mg/kg)|Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.
214315625|NCT05262556|DRUG|Ipilimumab (1mg/kg)|Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
214315626|NCT04471844|DEVICE|Optune®|"Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression."
214315627|NCT06448403|DEVICE|MRI Scanning|MRI scanning with volumetric, resting and activity-based sequences.
214315628|NCT06448403|DEVICE|64-channel EEG|EEG to quantifiy electric activity.
214315629|NCT06448403|DEVICE|Polysomnography|A randomized group will undergo polysomnography.
214482383|NCT05280639|DEVICE|Wooden block|Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.
214482384|NCT05280639|OTHER|Formal physical therapy or Home Exercise Program|Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
214671537|NCT03685656|OTHER|Slimming gel|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
214671538|NCT03685656|OTHER|Slimming gel placebo|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
214671539|NCT03515187|DRUG|0.3% sodium hyaluronate ophthalmic solution|one to two drops in eye, four times per day
215061074|NCT06084754|DEVICE|pulsed electromagnetic field|pulsed electromagnetic field will be over the site of osteomyelitis where patient in supine lying position. the treatment parameters will be set as10 HZ frequency , 20 gauss amplitude, duration about 120 minutes.
214315630|NCT06448403|BIOLOGICAL|Blood samples|Analysis of specific blood biomarkers.
214315631|NCT06448403|BIOLOGICAL|Fecal samples|Analysis of bacterial composition.
214482385|NCT05569759|DRUG|zetomipzomib|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
214482386|NCT05569759|DRUG|placebo|Subcutaneous injection of placebo
214482387|NCT05569759|DRUG|zetomipzomib in open-label extension|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
214482388|NCT06462638|OTHER|Neurobehavioral states and physiological parameters evaluation|"Each individual infant included in the study will be assessed 3 times a week for at least two weeks: specifically, two detections of neurobehavioral states in response to interaction with the mother, two detections with the father, and two detections with the nurse(s) will be made.~For each infant involved in the study, an audio/video recording of cradle movements and vocalizations will be made at 3 different consecutive times (5 minutes each): baseline; recording during interaction with either parent or nurse; post-interaction assessment.~The parent or nurse is asked to interact freely with the baby, choosing whether to use voice and touch or only one of the sensory stimulation channels. During the interactions, parents and nurse will in turn be assessed relative to some basic physiological parameters through the use of a band applied to the chest; the infant's physiological parameters during the 3 times will also be recorded."
214671540|NCT03515187|DRUG|0.1% sodium bromide solution|one to two drops in eye, twice per day
214671541|NCT03515187|OTHER|Meibomian gland massage|Physiotherapy
214671542|NCT03515187|OTHER|Placebo|Vehicle
214671543|NCT04618705|BEHAVIORAL|Smoking Cessation|Participants will start a smoking cessation program.
214671544|NCT00968344|DIETARY_SUPPLEMENT|Leucine|3-4g Leucine added to daily meals
215061075|NCT06084754|DRUG|Antibiotics|Vancomycin IV injection 1gm divided 250mg every 6hours
215061076|NCT02403817|BEHAVIORAL|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
215061077|NCT02403817|BEHAVIORAL|Eye Motor Training|Game play will be controlled by the player's eye movements (via an eye tracking device)
214315632|NCT06448403|BEHAVIORAL|Cognitive tests|Interview-based cognitive tests for assesment of cognitive levels.
214315633|NCT03951246|OTHER|Cognitive and Motor Training|"In the first phase of the trial, all participants (patients and healthy children) will complete cognitive and motor functions assessment.~Then the sample of patients who have cognitive/motor impairment will be randomized to an either Intervention or Control group.~In the second phase of the trial, survivors in the Intervention Group will receive 6 sessions of cognitive and motor training during two weeks, and survivors in Control Group will undergo …..~After this treatment phase, motor and cognitive functions assessment will be conducted in all patients once again.~In the third phase, the Control Group will be provided the active intervention (i.e. 6 sessions of cognitive and motor training during two weeks), while the Intervention Group engages in passive reading.~After this, motor and cognitive functions assessment will be carried out in all patients once again."
214315634|NCT01067768|OTHER|Daily review|"Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.~The attending physician decides withdraw or no withdraw the urinary catheter"
214315635|NCT00151814|DRUG|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
214315636|NCT03914560|OTHER|Burn injury|minor burn injury
214315637|NCT00591448|OTHER|Virtual Reality (VR)|See above
214315638|NCT03249285|DRUG|Peri|Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
214315639|NCT03249285|DRUG|HCTZ|Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
214315640|NCT00649896|DRUG|Mylan Estradiol Transdermal System 0.025 mg/day|
214482389|NCT06462638|OTHER|Maternal vocal pitch evaluation to assess depressive/anxious state|"Regarding the assessment of any depressive/anxious states of the mother, as an additional support to the self-report questionnaires the maternal vocal pitch will be specifically assessed through the Talking about software (AI algorithm applied to maternal postpartum depression research)."
214315641|NCT00649896|DRUG|Climara® Transdermal System 0.025 mg/day|
214315642|NCT01071928|DRUG|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
214315643|NCT01071928|DRUG|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
214315644|NCT02712944|DRUG|Testosterone|Testosterone
214482390|NCT05395819|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
214482391|NCT05395819|PROCEDURE|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
214671545|NCT00968344|DIETARY_SUPPLEMENT|Alanine|Powered amino acid
214918662|NCT06264102|OTHER|Physical exercise program|"Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece."
214918663|NCT00528489|BIOLOGICAL|PennVax B|DNA vaccine containing the HIV genes Gag, Pol, and Env
214918664|NCT00528489|BIOLOGICAL|IL-12|Cytokine injection
214918665|NCT00528489|BIOLOGICAL|IL-15|Cytokine injection
214918666|NCT05791539|PROCEDURE|Erector spinae plane block|Patients will be divided into 2 groups group 1 will receive US-guided ESPB and group 2 will receive US-guided ESPB + US-guided Retrolaminar plain block before induction of GA.
214918667|NCT05791539|PROCEDURE|erector spinae plane block + retrolaminar block|Patients will be divided into 2 groups group 1 will receive US-guided ESPB and group 2 will receive US-guided ESPB + US-guided Retrolaminar plain block before induction of GA.
214918668|NCT02171312|DEVICE|iDETECT Assessment|The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
214918669|NCT02171312|BEHAVIORAL|Routine Balance and Vestibular Testing|A clinician will assess balance and vision by standard of care routine tests for neurologic function.
214918670|NCT00691912|DRUG|liposomal Doxorubicin|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
214918671|NCT00691912|DRUG|Myocet / Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
215061078|NCT02403817|BEHAVIORAL|Hand Motor Training|Game play will be controlled by the player's hand movements (via a joystick).
214315645|NCT02712944|DRUG|Saline|Placebo
214315646|NCT00006181|BEHAVIORAL|Team-based intervention|
214315647|NCT00006181|BEHAVIORAL|One-on-one intervention|
214315648|NCT01293240|DEVICE|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
214315649|NCT03666078|PROCEDURE|cesarean delivery|women delivered by cesarean section
214315650|NCT05863897|BEHAVIORAL|e-COGRAT (a blended eHealth intervention)|The blended eHealth intervention for fatigue complaints after ABI, e-COGRAT, is a cognitive behaviorial intervention. It consists of 12 weekly sessions, including 6 individual online sessions, 2 face-to-face group sessions and 4 online group sessions, in 4 groups of 4 patients.
214315651|NCT03594383|DEVICE|ULTRASOUND|Lung ultrasound done through POCUS to diagnose pneumonia
214315652|NCT03283020|DRUG|RemifentanilMNTX|Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
214315653|NCT03283020|DRUG|PlaceboMNTX|Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
214315654|NCT03394768|OTHER|No additional intervention|Patients will be treated as per department protocols and no additional intervention will be performed
214315655|NCT01764568|BEHAVIORAL|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz \& Woodward 2007a; Moritz \& Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8-module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
214315656|NCT01764568|BEHAVIORAL|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
214315657|NCT01023646|OTHER|Carbohydrate + Protein|Light Tuna Packed in water.
214918672|NCT06152146|DEVICE|Shockwave Therapy|Each therapy session will last about 20 minutes, during which 1,440 shockwaves will be applied to the penis via the left and right crus (shaft near the base)
214918673|NCT06152146|OTHER|SHAM shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver 1440 SHAM shockwave therapy applied to the penis via the left and right crus (shaft near the base)
214315658|NCT01023646|OTHER|Carbohydrate + Fat|Butter
214315659|NCT01023646|OTHER|Fiber|Unrefined Carbohydrate
214315660|NCT01023646|OTHER|Carbohydrate load|Carbohydrate
214315661|NCT01108536|DEVICE|adaptive prosthetic socket|trans tibial socket with actuator zones (inflatable fluid bladders)
214315662|NCT02434835|DRUG|[14C]KWA-0711|
214918674|NCT00716014|DRUG|TD101|TD101 is injection into a callus on the bottom of one of the patient's feet
214918675|NCT00716014|DRUG|Normal saline (placebo)|A normal saline solution (placebo) is injected into one of the patient's feet.
214918676|NCT04507386|BEHAVIORAL|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
214918677|NCT01932710|PROCEDURE|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
214315663|NCT00129363|DRUG|Carvedilol|
214315664|NCT06351683|DRUG|MitoQ (mitoquinol mesylate)|MitoQ is an antioxidant molecule designed to target cell stress
214315665|NCT06351683|OTHER|Placebo|Control capsules that contain all inactive ingredients found in the study drug capsules (i.e., placebo capsules do not contain mitoquinol mesylate)
214315666|NCT03726008|BEHAVIORAL|Perinatal health promotion program and regular prenatal care|Regular prenatal care and perinatal health promotion program including health promotion during pregnant period, health promotion during the ritual of Tso-Yueh-Tzu, health promotion during postpartum period, newborn care
214315667|NCT00980395|DRUG|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
214315668|NCT00980395|DRUG|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
214315669|NCT00980395|DRUG|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
214315670|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
214671546|NCT03368404|DEVICE|CBL-102 eye drops|CBL-102 eye drops, 3 to 6 times per day for 3 months
214918678|NCT01560312|DEVICE|Renal denervation (Symplicity® Catheter System™)|4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)
214918679|NCT05218343|BEHAVIORAL|"EHR-based nudge interventions"|Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
214918680|NCT04767555|PROCEDURE|ILM (inner limiting membrane) peeling|The standard technique for the removal of the inner limiting membrane is a dye-assisted ILM peeling established since 20 years as the standard of care to treat vision loss due to epiretinal membranes or macular holes in eyes with an otherwise stable retina, but not during retinal detachment surgery. Other dyes may show a stronger staining effect but since there is evidence of a potential toxicity of ICG the investigators use the well-tolerated and for this purpose approved trypan blue dye Membrane Blue ® (Dorc). This intervention will be performed in addition to standard vitreoretinal re-attachment surgery.
214918681|NCT02649439|BIOLOGICAL|PROSTVAC -V|Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus
214918682|NCT02649439|BIOLOGICAL|PROSTVAC-F|Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
215061079|NCT04699695|OTHER|Biologic therapy versus no biologic therapy|Biologic therapy administered per standard of care
214315671|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
214315672|NCT01094548|DRUG|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
214482392|NCT05014971|BEHAVIORAL|Tele-neurohub|Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.
214482393|NCT00449748|DRUG|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
214482394|NCT05046600|DEVICE|Products listed in cohort description|Depending on approved indication per product
214671547|NCT03368404|DEVICE|Vismed Multi eye drops|Vismed Multi eye drops, 3 to 6 times per day for 3 months
214671548|NCT02983292|DEVICE|PyroTITAN™ HRA|Humeral Resurfacing
214918683|NCT03017378|BIOLOGICAL|TB/FLU-01L|TB / FLU-01L (intranasal application)
214918684|NCT03017378|BIOLOGICAL|TB/FLU-01L|TB/FLU-01L (sublingual application)
214918685|NCT01578473|DRUG|Vitamin D2|oral softgel 2000 IU once daily 9 months
214918686|NCT01578473|DRUG|Vitamin E|"oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily~1 softgel of 200 IU daily 9 months"
214918687|NCT01578473|DRUG|Testosterone Pellets|subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
215061080|NCT03053440|DRUG|BGB-3111|160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
215061081|NCT03053440|DRUG|Ibrutinib|420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
214315673|NCT01094548|DRUG|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m\^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m\^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
214315674|NCT00382538|DRUG|Addition of mifepristone 200 mg 24 hours before induction|
214315675|NCT04916730|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician but will not be required to adopt a 10-hr eating window.
214482395|NCT06307184|PROCEDURE|Natural proliferative phase frozen embryo transfer|When endometrial thickness is above 7 mm, vaginal micronized progesterone will be administered 400mg 12/12h when the dominant follicle is at least 13 mm, serum estradiol (E2) levels are \>80 pg/ml, and serum progesterone levels are \<1.5ng/ml. Embryo transfer will be performed on the fifth day of progesterone.
214482396|NCT02339168|DRUG|Enzalutamide|Given PO
214482397|NCT02339168|DRUG|Metformin Hydrochloride|Given PO
214482398|NCT05266040|DRUG|Valacyclovir 500 MG|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
214482399|NCT05266040|DRUG|Placebo|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
214482400|NCT04276246|DEVICE|dental implants and retentive implant components|retentive components (Group A Test), which are connected to the implants to retain the RPD
214671549|NCT00964795|DRUG|Intravitreal Aflibercept Injection 2mg|
214918688|NCT03884530|DRUG|Ticagrelor (Brilique) 90|Drug name Brilique 90 ml Drug form tablet
214918689|NCT03884530|DRUG|Aspirin 75mg|Drug name Aspirin 75 ml Drug form tablet
214482401|NCT04276246|DEVICE|dental implants and supportive implant components|supportive components (Group B Control), which are connected to the implants to support the RPD
214482402|NCT05583422|GENETIC|DPYD or UGT1A1 variants|any CLIA certified lab can be used for confirmatory testing after patients have been identified through Michigan Genomics Initiative (MGI)
214482403|NCT01932125|DRUG|Bevacizumab|Participants will receive five cycles of bevacizumab 15 mg/kg concurrently with six cycles of the standard chemotherapy every three weeks (q3w), followed by extended cycles of bevacizumab 15 mg/kg q3w as a single agent for additional 16 cycles. A total of 21 cycles of bevacizumab will be administered in this study.
214918690|NCT02451774|DRUG|Pentoxifylline Plus Chemotherapy|Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
214315676|NCT04916730|BEHAVIORAL|Time Restricted Eating|Participants in this arm will adhere to a daily, consistent self-selected 10-hr eating window for the course of the study intervention period as well as receive nutritional counseling from the study dietitian.
214315677|NCT05804266|PROCEDURE|Coventional coagulation|In the conventional group, the haemostasis of vessels will be performed with the conventional coagulation technique under CO2 insufflation. First, submucosal fibres surrounding a blood vessel will be dissected and the vessel will be isolated. After, both sides of the isolated vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until the blood vessel turns white and can be finally cut.
214315678|NCT05804266|PROCEDURE|Underwater coagulation|In the treatment group, the prophylactic haemostasis of vessels will be accomplished by the underwater coagulation technique. First, physiological solution will be instilled until there is no more air around the blood vessel. Then, the vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until it turns white and, after the removal of all the physiological solution, can be finally cut.
214482404|NCT06964880|BEHAVIORAL|Exercise with video on media platform|12-week structured video-guided exercise and peer support program
214482405|NCT06964880|BEHAVIORAL|Printed Educational Handout|12-week printed health education handout program
214482406|NCT06965829|DRUG|Tislelizumab|Neoadjuvant immunotherapy (tislelizumab 200 mg d1, q3w × 2 cycles)
214482407|NCT06965829|DRUG|Carboplatin and Paclitaxel and Radiation Therapy|Neoadjuvant chemotherapy (nad-paclitaxel 260 mg/m2 d1 + carboplatin AUC = 5 d1, q3w × 2 cycles) and node sparing radiotherapy (41.4Gy/23 times: 1.8Gy d1-5, qw × 4-5 cycles)
214482408|NCT06966232|DRUG|Entecavir|anti hepatitis B virus
214482409|NCT04215029|BEHAVIORAL|Exercise Intervention|Receive exercise plan
214482410|NCT04215029|OTHER|Informational Intervention|Receive printed exercise materials
214918691|NCT02451774|DRUG|Placebo Plus Chemotherapy|Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
214918692|NCT05591976|OTHER|Exercise training program|16-week, structured exercise training program including resistance and aerobic exercise
214482411|NCT04215029|OTHER|Informational Intervention|Receive physical activity and healthy eating information/materials
214918693|NCT05012722|DIAGNOSTIC_TEST|Sphygmocor CVMS (Atocr Medical, Sydney Australia) PWV measurement|All patients included in this study will have a pulse wave velocity measurement measured using SphygmoCor cardiovascular management system (CVMS) (Atocr Medical, Sydney Australia) which is a tonometry-based device used to noninvasively obtain vital cardiovascular data.
215061082|NCT05360693|PROCEDURE|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done \& patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
214482412|NCT04215029|OTHER|Interview|Participate in interview
214482413|NCT04215029|OTHER|Nutritional Assessment|Complete nutrition counseling sessions
214482414|NCT04215029|OTHER|Questionnaire Administration|Ancillary studies
214482415|NCT04215029|BEHAVIORAL|Telephone-Based Intervention|Receive coaching calls
214482416|NCT06013241|DRUG|Brensocatib|Film-coated tablet.
214482417|NCT06013241|DRUG|Placebo|Film-coated tablet.
214482418|NCT06013241|DRUG|Mometasone furoate nasal spray (MFNS)|Nasal spray suspension.
214482419|NCT06020040|DEVICE|Heterograft|Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).
214482420|NCT05525676|BEHAVIORAL|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
214482421|NCT05525676|BEHAVIORAL|Co-Located Collaborative Care (CCC)|"The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 \& 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)"
214918694|NCT04141501|DRUG|Psilocybin|single dose of psilocybin (25mg). orally in form of a capsule
214918695|NCT04141501|DRUG|Placebo oral capsule|single dose of mannitol (100%)
214918696|NCT05756816|DEVICE|SurePulse VSP|A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VSP placed on the volunteer.
214315679|NCT02846207|DRUG|Yiqi huoxue|Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
214918697|NCT05756816|DEVICE|SurePulse VS|A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VS placed on the volunteer.
214918698|NCT03593824|PROCEDURE|bilateral cataract removal surgery for dense cataract|Participants were born with dense bilateral cataracts (extreme adversity) will undergo surgery for bilateral cataract removal at an early age, mostly around 3 months of age.
214918699|NCT03593824|PROCEDURE|bilateral cataract removal surgery for non-dense nuclear cataract|Participants were born with non-dense and nuclear bilateral cataracts (watered-down adversity) will undergo cataract removal surgery bilaterally in a compromised timing, mostly around one year old.
214918700|NCT04150744|COMBINATION_PRODUCT|radiofrequency ablation|take advantage of RFA to destroy hepatocellular carcinoma by high temperature
214918701|NCT06166446|DEVICE|subtractive technique|The milled denture teeth are then bonded into the milled recesses using a special PMMA bonding system.
214918702|NCT06166446|DEVICE|additive technique|The denture teeth were printed as one unit using the same method with tooth resin (DENTCA Denture Tooth, Shade A2).
214918703|NCT00776295|BIOLOGICAL|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes|Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin 4, Transfected with Adenovirus Vector (Ad5CMV-p53, Introgen Therapeutics) Expressing Wildtype p53 Gene; Combined with Autologous Expanded T Lymphocytes (CD3+, CD4+, and CD8+), Cultured with OKT3 (Orthoclone) and Anti-CD28 (Repligen) Coated Magnetic Beads
214918704|NCT01958814|DRUG|Salbutamol|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
214918705|NCT01958814|DRUG|Placebo|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
214315680|NCT02846207|DRUG|Yiqi group|Astragalus 60g.Oral administration, twice one day, for 12weeks.
214315681|NCT02846207|DRUG|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
214315682|NCT02846207|DRUG|placebo|Dextrin,oral administration, twice one day, for 12weeks.
214315683|NCT00212953|PROCEDURE|Advanced Life Support|
214315684|NCT06291714|DEVICE|GDT-based hemodynamic management based on Clearsight device|Intraoperative use of a HPI-guided hemodynamic goal-directed protocol based on the non-invasive measurement of HPI (Clearsight system)
214315685|NCT02812758|DEVICE|transthoracic echocardiography|recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
214315686|NCT01257958|DRUG|19 nor vitamin d|
214315687|NCT04426617|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane Block|The patient will lie in the supine position. The transducer will be placed in the axial plane on the mid-axillary. transversus abdominis muscle will be visualized. A skin wheel using 3 ml of lidocaine 1 % is made 2 to 3 cm medial to the medial aspect of the transducer and the 22 gauge is inserted in-plane pointing laterally. Then Injection of local anaesthetic mixure in the right plane.
214315688|NCT00806884|OTHER|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
214315689|NCT00806884|OTHER|Control group measurements|None other than control group measurements
214315690|NCT05514158|DRUG|RC48-ADC|RC48 for injection is a novel antibody-drug conjugate, with a her-2-targeting antibody and a microtube inhibitor
214315691|NCT05514158|DRUG|RC98|RC98 is a recombinant humanized IgG1 monoclonal antibody targeting programmed cell death-Ligand 1 (PD-L1)
214315692|NCT00918515|DRUG|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
214315693|NCT00461695|BIOLOGICAL|Vaccination against TBEV (FSME Immun CC)|Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
214315694|NCT02501980|BIOLOGICAL|Biomarker testing and Ultrasonography|
214315695|NCT05302375|OTHER|iPath*D|Online pathway from screening to treatment for depression in cancer patients.
214315696|NCT05318144|OTHER||
214315697|NCT02791620|DEVICE|a nanofractional radiofrequency device|A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
214315698|NCT05358275|DEVICE|surgical cutting guide with piezo|3D planned lid surgery
214315699|NCT05358275|OTHER|control|ordinary cyst enucleation
214315700|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
214315701|NCT00983216|DRUG|Ketoconazole|one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
214315702|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
214315703|NCT00378066|DRUG|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
214315704|NCT02394080|DEVICE|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
214315705|NCT02550457|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
214315706|NCT02550457|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
214315707|NCT02550457|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
214315708|NCT04067284|BEHAVIORAL|Nutrition education|"Nutrition Education on~* Continued breastfeeding until two years of age~* Food groups~* Balanced diet~* Introduction to locally available nutritious and low-cost foods~* Amount and frequency of complementary feeding~* Safe water, and~* Handwashing with soap before feeding"
214315709|NCT04067284|DIETARY_SUPPLEMENT|Homemade yogurt supplementation|The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding.
214315710|NCT04067284|OTHER|Usual care|No intervention/ control group
214315711|NCT01971853|DRUG|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
214315712|NCT01971853|DRUG|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
214315713|NCT04943965|DIAGNOSTIC_TEST|Ultrasound imaging|"The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~1. Pre-induction.~2. Post-induction / Pre-PAC~3. Post-induction / Post-PAC"
214315714|NCT06159972|DEVICE|EndoFLIP|EndoFLIP is a small balloon catheter that is inserted through the endoscope at the time of endoscopy.
214315715|NCT03688672|DEVICE|Apioc Contact Lens Design|Novel soft contact lens design.
214315716|NCT00987116|DRUG|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
214315717|NCT03522181|OTHER|saline|saline
214918706|NCT02888912|OTHER|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
214918707|NCT02888912|OTHER|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
214315718|NCT03522181|OTHER|Insulin|
214315719|NCT01133691|DIETARY_SUPPLEMENT|clear fluid, light breakfast|clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
214315720|NCT05128175|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
214315721|NCT01772641|OTHER|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
214315722|NCT01772641|OTHER|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
214315723|NCT01772641|OTHER|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
214315724|NCT01772641|OTHER|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
214315725|NCT01973101|DRUG|Cisplatin|50 mg/m2 - Day 1
214315726|NCT01973101|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
214315727|NCT01973101|DRUG|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
214315728|NCT01973101|RADIATION|Radiotherapy|45 Gy
214315729|NCT01973101|RADIATION|Brachytherapy|80 Gy
214315730|NCT02271191|DRUG|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
214315731|NCT01122667|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
214315732|NCT01853033|BIOLOGICAL|ABT-122|Injection
214315733|NCT01853033|BIOLOGICAL|Placebo|Placebo Injection
214315734|NCT03356249|DIAGNOSTIC_TEST|Next-Generation Sequencing|In 500 patients with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions), patients´ characteristics and routine blood parameters will be determined at sepsis onset as well as 72 hours afterwards. At the same time points, 2 sets of blood cultures and one blood tube for Next-Generation Sequencing (NGS)-diagnostics will be collected. An evaluation of outcome will be performed at 28 days after sepsis onset.
214315735|NCT03444974|OTHER|adapted treatment according to the MATRIX-A therapy|cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters
214482422|NCT06510816|DRUG|ANX007|Form: solution for injection; Route of Administration: IVT injection
214315736|NCT05410626|DRUG|prolong-release methylphenidate|This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
214315737|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
214315738|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
214315739|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
214315740|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
214315741|NCT03913481|PROCEDURE|Acute normovolemic hemodilution|In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.
214315742|NCT03913481|PROCEDURE|Standard care|Best available treatment without ANH
214315743|NCT05799001|BEHAVIORAL|Dance therapy|"Patients will be randomized in 2 groups, experimental or control.~The experimental group will have 4 months of dance therapy with a professional dancer and will then resume there usual activities.~The control group will start with their usual activities in the nursing home for the first 4 months and then, they will have dance sessions with a nurse previously trained by the dancer."
214315744|NCT01378793|BEHAVIORAL|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
214315745|NCT01378793|BEHAVIORAL|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
214315746|NCT05054530|DRUG|GMA106 Injection|GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
214315747|NCT05054530|DRUG|GMA106 Matching Placebo|Matching Placebo for GMA106
214315748|NCT03215134|OTHER|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre \& Rimes, submitted) and is now being evaluated in a primary mental-health service.
214315749|NCT05581316|DIAGNOSTIC_TEST|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center.|This patients who were included in this study were assessed for four weeks from the first day of hospitalization and taken to the treatment program. All patients who use peripheral venous catheters in this group.
214315750|NCT01367769|OTHER|No intervention|There will be no intervention in this study.
214315751|NCT03706807|OTHER|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
214315752|NCT03706807|OTHER|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
214315753|NCT04253717|OTHER|Motor control exercise program|Structure physical training aimed at strengthening muscles of the lumbo-pelvic-hip core complex in order to improve stabilization and alignment of the spine and pelvis.
214315754|NCT06485700|OTHER|Peer Delivery of Medications|Door-to-door peer delivery of medications within patients' communities will be implemented.
214315755|NCT06485700|OTHER|Health Information Technology (HIT) Platform|The HIT platform provides: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) medication refill tracking to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data.
214315756|NCT03396614|DIAGNOSTIC_TEST|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
214315757|NCT04923971|OTHER|Purdue Pegboard|Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
214315758|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
214315759|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
214315760|NCT00228917|BIOLOGICAL|Mencevax-ACWY|Meningococcal Serogroups A, C, W-135 and Y Vaccine
214315761|NCT03857984|OTHER|Blood sampling|blood sample before and after a single HD
214315762|NCT04025996|DIAGNOSTIC_TEST|Cardiac Assessments and Eye Assessments|"Cardiac Assessments, include the following:~* transthoracic echocardiography~* computed tomography of coronary arteries~* position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~* pupil dilation~* retinal photography~* dynamic vessel analyser~* IOL master"
214315763|NCT04515342|DIAGNOSTIC_TEST|DXA|Each participant will undergo one DXA scan
214315764|NCT04515342|OTHER|Muscle strength and function assessment|Each patient will have their muscle strength and function assessed with the measurements of handgrip strength, 10 m gait speed and a 30 s sit-to-stand test. They will also fill out a questionnaire assessing Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls (SARC-F questionnaire).
214315765|NCT04515342|OTHER|Blood samples|Each patient will undergo a physical examination and also deliver blood samples.
214315766|NCT02221310|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m\^2/dose given IV over 2 hours once during conditioning
214482423|NCT06510816|OTHER|Sham Administration|Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).
214315767|NCT01573780|DRUG|Smac mimetic TL32711|Given IV
214315768|NCT01573780|DRUG|gemcitabine hydrochloride|Given IV
214315769|NCT01573780|OTHER|laboratory biomarker analysis|Correlative studies
214315770|NCT01573780|OTHER|pharmacological study|Correlative studies
214315771|NCT01573780|PROCEDURE|biopsy|Optional correlative studies
214315772|NCT01327352|DRUG|Oshadi D|oral administration
214315773|NCT00706836|DRUG|Pregabalin 50mg|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
214315774|NCT00706836|DRUG|Pregabalin 200 MG|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
214315775|NCT00706836|DRUG|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
214315776|NCT01094691|PROCEDURE|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
214482426|NCT05852990|COMBINATION_PRODUCT|Glutamine plus L. reuteri|Glutamine plus Lactobacillus reueri twice daily for up to 6 weeks or death
214482427|NCT05807997|OTHER|Refusal of ICU admission.|patients aged 18--99 who were presented to the general intensive care unit from January 2018 to the end of December 2023 and were not admitted.
214482428|NCT05598034|DEVICE|Left DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.
214482429|NCT05598034|DEVICE|Right DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.
214482430|NCT05598034|BEHAVIORAL|Cognitive task|Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS
214918708|NCT02714595|DRUG|Cefiderocol|2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days, or 2 g every 6 hours for participants with creatinine clearance \>120 mL/min.
214918709|NCT02714595|DRUG|Best Available Therapy|Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
214918710|NCT00713258|DRUG|Parathyroid hormone (PTH) (1-84)|100 µg PTH(1-84) daily
214315777|NCT03432806|OTHER|blood draws|Patients will have 10 mL of peripheral venous blood drawn immediately prior to surgery, in the post anesthesia care unit (PACU), and at the first postoperative clinic visit for a total of 30 mL.
214315778|NCT03432806|PROCEDURE|colectomy or hepatectomy|"Three small pieces of otherwise normal-appearing liver of 0.5-1 cm3 collected intraoperatively from patients in all four groups (including Group D). Because liver biopsy is less frequently performed during operations for benign colon lesions or Stage I-III colon cancers, this single aspect of the protocol can be made optional at the discretion of the surgical attending or the patient, however bloods and tissue from pathology will still be collected."
214918711|NCT00713258|DRUG|Alendronate|70 mg alendronate weekly
214918712|NCT01832558|DRUG|Eplerenone|
214315779|NCT03432806|DIAGNOSTIC_TEST|Fibroscan test|This may be done either at a preoperative clinic setting or immediately prior to surgery.
214315780|NCT03131440|BEHAVIORAL|Core|The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
214315781|NCT03131440|BEHAVIORAL|Support Calls|Participants will receive 6 bi-weekly phone calls from study staff.
214315782|NCT03131440|BEHAVIORAL|App+|"Participants will receive deluxe version of smartphone app with additional features."
214315783|NCT03131440|BEHAVIORAL|Online gym|Participants will receive access to online exercise videos.
214315784|NCT03131440|BEHAVIORAL|App notifications|Participants will receive motivational app notifications
214315785|NCT03131440|BEHAVIORAL|Buddy|Participants will choose a buddy to receive a Fitbit and support them during the intervention.
214315786|NCT03710421|PROCEDURE|CS1-CAR T Therapy|Undergo CS1-CAR T therapy
214315787|NCT03710421|DRUG|Cyclophosphamide|Given IV
214315788|NCT03710421|DRUG|Fludarabine|Given IV
214315789|NCT03710421|PROCEDURE|Leukapheresis|Undergo leukapheresis
214315790|NCT03892460|DEVICE|neuromuscular electrical stimulation|bilateral quadriceps exercise with neuromuscular electrical stimulation
214315791|NCT00624676|DRUG|Lipo Hydroxy Acid|Twice a day
214315792|NCT00624676|DRUG|5% benzoyl peroxide gel|Once a day
214482431|NCT06978413|OTHER|Integrated Treatment with Digital Tools|"Patients will undergo a 6-week remote telerehabilitation program. The recommended frequency of treatment is a minimum of 3 sessions per week, but patients may adjust the schedule in agreement with their assigned therapist. If a patient is unable to complete at least 18 sessions due to clinical reasons, they will be considered as a dropout.~Moreover, one session per week will be conducted synchronously, with the therapist remotely supervising the patient's activities in real time, while the remaining sessions will be asynchronous, allowing the patient to complete the exercises independently."
214482432|NCT06978413|OTHER|Home-Based Educational Program|Patients will be monitored over a six-week period through weekly phone calls to assess their progress and overall condition. Additionally, participants are required to maintain an activity diary to document their engagement with the prescribed activities.
214482433|NCT04842149|DIETARY_SUPPLEMENT|Bif195 capsules|1 capsule daily for 8 weeks
214482434|NCT04842149|DIETARY_SUPPLEMENT|Placebo capsules|1 capsule daily for 8 weeks
214918713|NCT01832558|DRUG|Placebo|
214918714|NCT01063621|DRUG|KW-6500|Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
214918715|NCT02896062|BEHAVIORAL|sleep-coaching|Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
214918716|NCT05865574|DRUG|BAT1706 Injection|1 vial/carton, 400 mg/16 mL/vial
214315793|NCT02669368|DRUG|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
214315794|NCT02669368|DRUG|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
214315795|NCT02669368|DRUG|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
214315796|NCT02669368|DRUG|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
214315797|NCT00746941|DRUG|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
214315798|NCT02474095|OTHER|Quality-of-Life Assessment|Ancillary studies
214315799|NCT02474095|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
214315800|NCT04209179|DRUG|PCO371|PCO371 capsule
214315801|NCT04209179|DRUG|Placebo|Placebo capsule
214315802|NCT06528392|BIOLOGICAL|Efgartigimod|Efgartigiomd-hyaluroidase (EFG) is a neonatal Fc receptor (FcRn) inhibitor, which blocks the recycling of Immunoglobulin G (IgG), including pathogenic IgG
214315803|NCT01820754|DRUG|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
214315804|NCT01820754|DRUG|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
214315805|NCT04079478|OTHER|AI|Artificial intellignece colonoscopy
214315806|NCT04209309|DEVICE|repetitive transcranial magnetic stimulation|
214315807|NCT00928928|PROCEDURE|Open colectomy|Open colectomy. Epidural anaesthesia used
214315808|NCT00928928|PROCEDURE|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
214315809|NCT03904407|OTHER|Lactobacillus Probiotic Capsule|"One over-the-counter, probiotic capsule taken by mouth once daily for 4 weeks. Each capsule contains 10 billion cells comprised of:~* Lactobacillus crispatus LbV 88~* Lactobacillus jensenii LbV 116~* Lactobacillus gasseri LbV 150N~* Lactobacillus rhamnosus LbV 96"
214315810|NCT03904407|OTHER|Matching Lactobacillus Probiotic Placebo Capsule|Lactobacillus Probiotic placebo capsules identical in appearance taken by mouth once daily for 4 weeks
214315811|NCT03928951|OTHER|General practitioner reassessment of urinary infection antibiotherapy prescribed by emergency departments|Antibiotherapy will be prescribed by emergency physicians and general practitioners will be contacted 4 to 5 days later to know if antibiotherapy was modified
214315812|NCT02245789|PROCEDURE|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
214315813|NCT02245789|DRUG|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
214315814|NCT02180412|BIOLOGICAL|Panhematin|Glucose loading
214315815|NCT02180412|OTHER|Glucose|Glucose is administered to both groups as routine care.
214315816|NCT06482905|BIOLOGICAL|Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103|"Safety Run-In: Dose:6×10\^7 CAR+ T cells~Cohort A Single delivery route(Multi-dose)、Cohort B Dual delivery route(Multi-dose)： 3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells"
214315817|NCT04654117|OTHER|Consultee-centered administrative consultation|The consultee-centered administrative consultation model expressly focuses on supporting providers to increase EBP implementation within their specific setting.
214315818|NCT04618120|OTHER|Virtual reality-based exercise|"Virtual reality-based exercises with Microsoft Xbox 360 Kinect and breathing exercises.~Patient education"
214315819|NCT04618120|OTHER|Exercise|Shoulder range of motion, stretching, posture and breathing exercises. Patient education
214315820|NCT03200678|OTHER|isokinetic assessment|muscle torque assessement
214315821|NCT06045039|OTHER|Stent-balloon-stent (SBS) technique|Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique. The procedure of this technique is to implant the stent into the side branch at the 1\~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel. The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
214315822|NCT00386867|DRUG|800 mcg misoprostol via oral or buccal administration|
214315823|NCT01624428|DRUG|Varenicline|1 mg bid varenicline titrated over a 2 week period
214315824|NCT01624428|DRUG|Placebo|1 mg bid placebo titrated over a 2 week period
214315825|NCT04154228|DIAGNOSTIC_TEST|PET/MR scan|"Patients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed.~PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI)."
214315826|NCT05363735|OTHER|Ultrasound Elastography|Patients will be examined by ultrasound elastography.
214315827|NCT00184262|BEHAVIORAL|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
214315828|NCT00184262|BEHAVIORAL|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
214315829|NCT02237846|BIOLOGICAL|Human umbilical cord tissue-derived mesenchymal stem cells|
214315830|NCT01914224|BEHAVIORAL|dietary education of low sodium and high potassium consumption|
214315831|NCT01914224|BEHAVIORAL|dietary education of low sodium consumption only|
214315832|NCT02347748|BEHAVIORAL|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
214315833|NCT02347748|BEHAVIORAL|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
214315834|NCT02347748|BEHAVIORAL|Reading 2 scripts|"Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation"
214315835|NCT02386696|OTHER|Ultrasound|Lung ultrasound examination on healthy volunteers
214482435|NCT06603870|DRUG|Apixaban|Apixaban is Health Canada approved for routine treatment and secondary prevention of VTE. Upon enrollment and during follow-up, patients will be managed with a prophylactic dose of apixaban (2.5 mg orally twice daily) as long as either a CVC or active cancer is present. Apixaban will be stopped at the time of CVC removal and when cancer is in remission. Patients will be instructed to contact the study team when their CVC is removed (to determine if apixaban should be continued, based on cancer status at the time), or any thrombotic or bleeding concerns were to occur in between visits. The investigators will record loss to follow-up, drop out, or death during the study.
214482436|NCT03902002|DRUG|Omaveloxolone 50 mg capsules|Capsules containing 50 mg of omaveloxolone
214918717|NCT05454644|OTHER|Person-Centred Prescription Model|"Step 1: Identify patients with advanced chronic condition and limited life expectancy.~Step 2: Interview with patients or closes caregiver.~Step 3: Medication Review~The clinical pharmacist conduct a structured medication review based on the medication appropriateness index (MAI):~* Indication/effectiveness: Product information, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.~* Dosage adjustment: Product Information and Lexi-Comp's Geriatric Dosage Handbook.~* Correct and practical directions: Medication Regimen Complexity Index (MRCI).~* Drug-drug interactions: Bot Plus/Beers Criteria and drug burden index (DBI), which measures dose-dependent anticholinergic and sedative loads.~* Drug-disease interactions: Beers Criteria.~* Duplication, duration and cost-effectiveness: Product information.~Step 4: Treatment Plan"
214918718|NCT06967350|OTHER|CARE & AIDET communication mode|The new communication mode, which incorporates fundamental communication principles (AIDET) and service recovery strategies (CARE)
214482437|NCT06987526|BEHAVIORAL|Mindfulness-Based Relapse Prevention|Renewed Recovery is a web-based Mindfulness-Based Relapse Prevention (MBRP) continuing care intervention adapted from the original MBRP curriculum by Bowen et al. It consists of 8 weekly modules designed to teach mindfulness and relapse prevention strategies for individuals with alcohol use disorder. The intervention includes educational content, guided meditations, and practical exercises. Modules are delivered asynchronously online, supplemented by two live Zoom sessions for group meditation practice. The purpose of the curriculum is to teach mindfulness and relapse prevention techniques to the participants with the aim of reducing the risk for relapse. The module titles are as follows: (1) Automatic Pilot and Relapse, (2) Awareness of Triggers and Craving, (3) Mindfulness in Daily Life, (4) Mindfulness in High Risk Situations, (5) Acceptance and Skillful Action, (6) Seeing Thoughts as Thoughts, (7) Self-Care and Lifestyle Balance, and (8) Social Support and Continuing Practice.
214482438|NCT06455358|DRUG|61Cu-NODAGA-LM3|Single intravenous administration of 61Cu-NODAGA-LM3 at an amount of 20 -40 μg (or 13 - 26 nmol) and an activity range of 150 MBq (±25%) followed by up to three PET/CT acquisitions.
214918719|NCT06967350|OTHER|CARE communication mode|CARE (C: connect, A: apologize, R: repair, E: exceed) is a standard service recovery communication mode in medical services.
214315836|NCT05961215|DEVICE|Penguin Cold Cap|Penguin cold cap: administered 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
214315837|NCT06165835|DEVICE|breathing training|Breathing training for six weeks.
214315838|NCT06779318|DRUG|S-1|Tegafur, Gimeracil, and Oteracil Potassium (S-1) 40-60 mg per dose, orally (p.o.), twice daily (BID), from Day 1 to Day 28, with a 6-week cycle, for a total of 8 cycles; or from Day 1 to Day 14, with a 3-week cycle, for a total of 16 cycles.
214315839|NCT03042858|OTHER|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
214315840|NCT03042858|OTHER|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
214315841|NCT03190889|OTHER|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
214315842|NCT03190889|OTHER|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
214315843|NCT03628612|BIOLOGICAL|AUTO CAR T cell therapy|No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
214315844|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
214315845|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
214315846|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
214315847|NCT05079204|OTHER|Intra oral scan|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.
214315848|NCT05079204|OTHER|No intervention|No intervention
214315849|NCT00405548|DRUG|BNP (nesiritide)|
214315850|NCT00405548|DRUG|Placebo|
214315851|NCT03625245|OTHER|Control Yogurt|125 g/day
214315852|NCT03625245|OTHER|Yogurt Variety 1|125 g/day
214918720|NCT06967350|OTHER|AIDET communication mode|AIDET is a nurse-patient communication mode that contains essential communication principles. Each letter represents a step for communication: Acknowledge, Introduce, Duration, Explanation, and Thank. It describes in detail the application and characteristics of the primary language in communication, logical and procedural.
214315853|NCT03625245|OTHER|Yogurt Variety 2|125 g/day
214315854|NCT00732147|DRUG|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
214315855|NCT00732147|DRUG|Placebo|120 micrograms given subcutaneously before each meal x 3.
214315856|NCT03465618|DRUG|89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging|A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.
214315857|NCT03465618|OTHER|Blood and Urine samples|Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan
214315858|NCT00927433|BEHAVIORAL|Psychoeducational intervention for cancer-related fatigue|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
214315859|NCT01394679|DRUG|(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
214315860|NCT01394679|DRUG|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
214315861|NCT01452607|DRUG|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
214315862|NCT01452607|DRUG|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
214315863|NCT04641611|OTHER|Bicaval cannulation|Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied
214315864|NCT04641611|OTHER|Cavoatrial cannulation|Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
214482439|NCT06455358|OTHER|Comparator|Single intravenous administration of 68Ga-DOTA-TOC and PET/CT acquisitions as part of standard clinical care.
214482440|NCT03931590|DRUG|[14C]-Omaveloxolone|\[14C\]-Omaveloxolone 50 mg capsules
214482441|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM|Experimental subjects will receive the iotaSOFT Insertion System with AIM using robotic controlled stop
214482442|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM Control|iotaSOFT Insertion System with AIM using standard of care insertion techniques
214482443|NCT06990815|OTHER|Kinesio Taping|"In the application over the sacrum, one I-strip of kinesio tape will be applied with 25% tension using the fascia correction technique, which requires oscillatory movements between the tape and the skin.~In the application over the suprapubic region, two I-strips will be applied with 25% tension, also using the fascia correction technique, involving oscillations between the tape and the skin."
214482444|NCT06990815|OTHER|Sham|"In the application over the sacrum, one I-strip will be applied without tension.~In the application over the suprapubic region, two I-strips will be placed without tension."
214918721|NCT00224328|DEVICE|ODISsey Tissue Oximeter|
214315865|NCT02473354|DRUG|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
214315866|NCT02473354|DRUG|Oxygen|Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
214315867|NCT02473354|DRUG|Carbon dioxide|Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
214315868|NCT00844363|PROCEDURE|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
214482445|NCT04984421|BEHAVIORAL|Healthy School Start|The Healthy School Start program is a universal 4-component family support program for children starting school (5-7 years of age) promoting healthy dietary habits and physical activity in the home environment to prevent childhood obesity and parents' risk of developing type 2 diabetes. It is targeting both children and parents.
214482446|NCT03438552|RADIATION|Stereotactic Body Radiotherapy|This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.
214482447|NCT06856239|OTHER|Graphene|The study follows an in-vitro experimental design with 76 specimens divided into two groups (conventional PMMA and G-PMMA). These samples will be further divided into two group, the one which undergo thermocycling (simulating oral temperature changes) and the other which don't undergo thermocycling. Flexural strength and modulus will be tested on all these by using a three-point bending test.
214482448|NCT06855433|DRUG|Colchicine Pill|Colchicine 0.6mg tab, overencapsulated to match placebo capsule, taken by mouth once daily
214482449|NCT06855433|DRUG|Placebo|Placebo capsule, taken by mouth once daily
214482450|NCT06856993|PROCEDURE|standardized medical care of cardiac arrest|The standardized medical care for cardiac arrest includes early cardiopulmonary resuscitation (CPR), defibrillation, advanced cardiac life support (ACLS), post-resuscitation care, and continuous monitoring of the patient's vital functions.
214918722|NCT04104763|BEHAVIORAL|study of osteofibrous dysplasia features|obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.
214315869|NCT01408979|DRUG|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
214315870|NCT01408979|DRUG|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
214315871|NCT03551912|PROCEDURE|Surgery|All patients coming for elective surgery
214315872|NCT00725218|DRUG|Saline|Saline 5 ml injection 10 min prior to propofol administration.
214315873|NCT00725218|DRUG|Flurbiprofen Axetil|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
214315874|NCT02251951|DRUG|nab-Paclitaxel|Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
214315875|NCT02741700|BEHAVIORAL|Gout Storytelling Video Intervention|The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.
214315876|NCT00923559|OTHER|Treatment as Usual at Child Health Centre|Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.
214315877|NCT00923559|OTHER|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
214315878|NCT03189615|DRUG|Lu AF35700|Single oral dose of 10 mg Lu AF35700
214315879|NCT00811577|DRUG|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
214315880|NCT00811577|DRUG|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
214315881|NCT03359642|OTHER|blood sample|14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
214315882|NCT03359642|OTHER|stool samples|Study of the fecal microbiota
214315883|NCT03359642|OTHER|food questionnaire|food questionnaire on the seven days before the collection
214482451|NCT06858098|OTHER|Exercise programme|6 week pre-operative graded prehabilitation programme, delivered by video and performed by participant up to 4 times a week at home or in a gym setting
214482452|NCT06858098|DEVICE|Wearable smart device|Participants will wear a wearable smart device (wrist or ring worn) for a period for 14 weeks; 2 weeks prior to prehabilitation, 6 weeks during pre-operative prehabilitation and 6 weeks post operative monitoring,
214482453|NCT06861985|DEVICE|BOBY|high-frequency multi-band harmonic electromagnetic stimulation device
214482454|NCT06861985|OTHER|Control|placebo group
214482455|NCT06860256|OTHER|Basic Body Awareness Therapy|"In TBFT sessions, physiotherapists improve the patient's contact with self by focusing on basic movement principles while performing simple daily movements such as lying, sitting, standing, walking, use of sound and massage. Mental awareness, postural balance and free breathing are considered key elements. The patient is invited to explore and integrate flow, rhythm and intentionality in coordinated movements in relation to time, space and energy. TBFT is practiced 2 days a week, 60 minutes, 5-12 weeks, depending on the patient."
214482456|NCT06860256|OTHER|High Intensity Interval Training|Tabata exercise protocol is an 8 repetition training program with 20 seconds of work and 10 seconds of rest. Warm-up and cool-down exercises of 5 minutes each should be done to prevent injuries and negativities. Although the application varies according to the patient, YŞİA is applied 2 days a week, 15-30 minutes, in processes ranging between 2-12 weeks.
214482457|NCT06860256|OTHER|Classic Exercise and Lifestyle Tips|Classical Exercise (CE) and Lifestyle Recommendations (LSR), Classical exercises used in PD include abdominal, pelvic floor muscles, hip flexors, whole body stretching. Non-pharmaceutical strategies for pain management in LRS include adopting relaxation (rest, warm-up, massage, music, etc.), antalgic positions, and distraction techniques. Common techniques that facilitate relaxation and thus reduce pain include physical rest, hot showers, various heat applications such as thermal seed bags, electric blankets, and drinking hot herbal teas such as chamomile tea.
214482458|NCT06862661|OTHER|Daily Tips and Advice on the use of LactApp m-health tool throughout the breastfeeding journey.|A tool to track breastfeeding frequency, duration, and baby's weight and offers access to a community forum for peer support along with direct consultations with lactation experts.
214482459|NCT04439032|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
214918723|NCT00216619|DRUG|Topiramate|topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
214918724|NCT00216619|DRUG|Topiramate - Placebo|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
214918725|NCT00204464|PROCEDURE|Exercise|
214315884|NCT03359642|OTHER|colonoscopy|Only for patients with ulcerative colitis (in routine care)
214315885|NCT03359642|OTHER|VOCs profile|Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
214315886|NCT00494832|DRUG|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
214482460|NCT06674486|DRUG|Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)|For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France).
214482461|NCT06674486|DRUG|Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)|For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
214315887|NCT00494832|DRUG|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
214315888|NCT02436421|OTHER|Best Practice Alert based in the Electronic Medical Record|
214315889|NCT00430560|BEHAVIORAL|cognitive rehabilitation|computer training
214315890|NCT00430560|PROCEDURE|work therapy|opportunity to work in carefully supervised hospital job
214315891|NCT00430560|BEHAVIORAL|work therapy|work therapy
214315892|NCT04530006|DIAGNOSTIC_TEST|Amantadine Hydrochloride|"Patients who are eligible for the study will be administered a regular 200 mg dose of FDA approved drug amantadine. This will be done at the following timepoints:~1. Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~2. Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~3. Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
214315893|NCT01625455|DRUG|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
214482462|NCT03032588|BIOLOGICAL|sIPV|Participants will receive single dose (0.5 milliliter \[mL\]) of sIPV as a suspension for intramuscular injection on Day 1.
214315894|NCT01625455|DRUG|Placebo|Placebo will be given orally for a total of 7 days.
214315895|NCT02034461|DEVICE|Utah Slanted Electrode Array|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations or peripheral nerve trauma.
214315896|NCT04244188|OTHER|Collection of datas|Collection of datas: pre- and postoperative scanner and endoprosthesis characteristics
214315897|NCT02120976|DRUG|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
214315898|NCT02120976|DRUG|JTT-252|Subjects will receive JTT-252
214315899|NCT04926532|DRUG|Toripalimab|Toripalimab is a humanized anti-PD-1 monoclonal antibody
214315900|NCT04926532|DRUG|Sorafenib|Sorafenib is a multi-kinase inhibitor
214315901|NCT01822080|DRUG|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
214482463|NCT03032588|BIOLOGICAL|cIPV|Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.
214482464|NCT06746207|OTHER|Informed Consent Process Evaluation|This study does not involve a clinical intervention. Instead, it focuses on evaluating the existing process of informed consent in a surgical setting. Patients and caregivers will be surveyed to assess their understanding, satisfaction, and perceptions of the informed consent process. The study examines factors such as clarity of information provided, patient and caregiver involvement, and overall satisfaction with the process, without altering the current practices. The goal is to identify areas for improvement in communication and documentation, ensuring that patient rights and autonomy are respected.
214482465|NCT06494878|DRUG|Aspirin|75-100 mg taken once daily by mouth.
214482466|NCT06494878|DRUG|Low-molecular-weight heparin|Low-molecular-weight heparin injections daily as prescribed by the treating physician.
214918726|NCT05589688|DRUG|Acyclovir|Subjects will receive a single dose of 5 mg/kg infused over 1 hour. Then, 13 blood samples after placement of a catheter, and 4 urine samples will be taken over the 12 hours following the start of administration
214918727|NCT05575778|DIAGNOSTIC_TEST|computed tomographic perfusion|The recruited patients would complete both pre- and post-operative computed tomographic perfusion
214918728|NCT06682897|BEHAVIORAL|Tai Chi training|60 minutes each session, three sessions per week, lasting 4 weeks for undertaking.
214315902|NCT01822080|DRUG|Placebo|Matching placebo once daily by mouth
214315903|NCT04404647|PROCEDURE|Irreversible electroporation|The IRE procedure will be carried out as ultrasound guided technique either percutaneously or during laparotomy. Needle spacing and electrical pulse delivery will be performed in a standardized way.
214315904|NCT00921180|DRUG|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
214315905|NCT00921180|DRUG|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
214315906|NCT04935411|OTHER|nAMD|patients diagnosed with Neovascular Age-Related Macular Degeneration
214315907|NCT03733821|DEVICE|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation tool
214315908|NCT03836196|RADIATION|LDR Brachytherapy and External Beam Radiation Therapy|Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
214315909|NCT00116441|BIOLOGICAL|Therapeutic Cellular Vaccine, GM-CSF Producing|
214315910|NCT02641379|DRUG|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n
214315911|NCT02641379|DRUG|Ribavirin|Ribavirin is available as 200 mg tablets
214315912|NCT01165138|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
214315913|NCT01165138|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
214315914|NCT01165138|DRUG|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
214315915|NCT02017314|DRUG|Morphine|
214315916|NCT05849103|OTHER|Blood Pressure Control Targets|This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90
214671550|NCT01144273|PROCEDURE|Transversus abdominis plane block|"This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity."
214918729|NCT03216005|DEVICE|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
214315917|NCT05849103|OTHER|Hypertension Management|This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.
214315918|NCT03498742|OTHER|NO Intervention|Routine clinical data; asthma control test and spirometry
214315919|NCT04982250|BEHAVIORAL|Enhanced peer PrEP referral + HIVST delivery|After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
214315920|NCT00411164|DRUG|OROS hydromorphone HCI (slow release)|
214315921|NCT02283710|DRUG|Pentoxifylline|Pentoxifylline 600 mg BD
214315922|NCT02283710|BEHAVIORAL|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
214918730|NCT03128177|DIETARY_SUPPLEMENT|Dietary sodium|High (6 g) versus low (1.5 g) sodium diet
214315923|NCT04863755|BEHAVIORAL|DASH|Patients receive DASH diet orientation and recommended to maintain their usual physical activity
214315924|NCT04863755|BEHAVIORAL|DASHPED|Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
214315925|NCT00176553|DRUG|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
214315926|NCT03777293|DEVICE|ultrasound viscoelasticity|use these devices to do ultrasound examination in chronic liver disease patients
214315927|NCT01148511|DRUG|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
214315928|NCT03365700|PROCEDURE|Radiofrequency Ablation|Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
214315929|NCT03365700|PROCEDURE|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
214315930|NCT02283515|DRUG|Rosuvastatin|Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
214315931|NCT06190431|OTHER|Learning the use of an in-exsufflation device with the guidance of a physiotherapist|Learning to use an in-exsufflation device with the guidance of a physiotherapist
214315932|NCT06190431|OTHER|Using the coaching mode|Learning the use of an in-exsufflation device using a coaching mode (playful visual stimulation) in addition to guidance of a physiotherapist
214315933|NCT05033639|DRUG|Melatonin 6 MG|Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.
214315934|NCT05033639|OTHER|Breast Milk|Naturally occurring milk from the mother of the infant.
214315935|NCT02963337|DRUG|remifentanil|Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
214315936|NCT02963337|DRUG|combined spinal-epidural analgesia|Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
214315937|NCT05282719|DRUG|venetoclax combined with azacitidine|On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
214315938|NCT06376240|DIETARY_SUPPLEMENT|Pyridoxamine 300mg per day|oral supplement
214315939|NCT06376240|OTHER|Placebo 300mg placebo per day|oral supplement
214315940|NCT00446147|DRUG|Pyridoxine|100mg BID/daily, Per oral
214315941|NCT00446147|DRUG|Placebo|placebo 100mg BID/daily, Per oral
214315942|NCT03170973|OTHER|Exercise|After a 12-hour fast, volunteers will collect blood in the antecubital vein to measure basal serum values. 12 after the first blood collection they will perform a physical exercise session on a treadmill. The same will be divided in 3 times: heating, conditioning and cooling. The heating will be of 7 minutes, the cooling of 5 minutes and the time of conditioning will correspond to the energy expenditure of 250Kcal with light intensity based on Borg's perception of effort, that is, in the original scale a value between 9 and 11. After 24 hours after the first blood collection the volunteers will return to the laboratory after a 12-hour fast and blood samples will be collected again.
214315943|NCT05211128|PROCEDURE|Robotic Surgery|Surgical procedure using robotic technologies.
214315944|NCT05211128|PROCEDURE|Open Surgery|Surgical procedure using a large, open cut in the skin.
214315945|NCT05211128|PROCEDURE|Laparoscopic Surgery|Surgical procedure using small incisions and trochars.
214315946|NCT01644175|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
214315947|NCT01644175|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
214918731|NCT04541953|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises and stretching.
214315948|NCT01644175|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
214315949|NCT02177279|OTHER|Visit A high wheat bran|
214315950|NCT02177279|OTHER|Visit B normal wheat bran|
214315951|NCT02177279|OTHER|Follow up normal (8days) and high (1day) bran consumption|
214315952|NCT01002833|BIOLOGICAL|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
214315953|NCT04819555|GENETIC|Blood|a blood sample will be taken during hospitalisation for diagnostic confirmation or during the quarterly multidisciplinary consultations scheduled as part of the standard follow-up set up for these patients in the ALS centres of the FILSLAN network. If the genetic status is not yet known, this sample will be taken (1 tube of 7mL EDTA) and then sent within 24-48 hours at room temperature to one of the 3 participating molecular biology laboratories according to the criteria defined in the manual of samples being taken in the 3 laboratories.
214315954|NCT06973993|OTHER|live music|live music will be played during waiting time in ER room
214315955|NCT06973993|OTHER|recorded music|recorded music will be transmitted during waiting time in ER room
214315956|NCT06973993|OTHER|no music|no music will be played or transmitted during waiting time in ER room
214315957|NCT00265512|BEHAVIORAL|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
214315958|NCT00265512|BEHAVIORAL|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
214315959|NCT04249258|DRUG|Dobutamine|Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
214315960|NCT03821493|DRUG|PF-06651600 10 mg tablets|"On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole."
214315961|NCT03821493|DRUG|Itraconazole Solution 200 mg|"Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.~On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets."
214315962|NCT05392361|DRUG|gabapentin (neurontin® capsule 300mg) treatment|Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment
214315963|NCT05392361|DRUG|baclofen (baclofen Tab. 10mg) treatment|Taking baclofen (baclofen Tab. 10mg, Handok co, Seoul, Korea) medication at night.
214315964|NCT02485106|DRUG|Rifaximin|400mg three times per day for 28 days
214315965|NCT02485106|DRUG|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
214315966|NCT03404479|DRUG|Diacerein|For 12 weeks, administered twice a day by oral.
214315967|NCT03404479|DRUG|Celecoxib|For 12 weeks, administered twice a day by oral.
214315968|NCT00819468|DRUG|Teduglutide|Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
214315969|NCT03462238|PROCEDURE|Blood collection for Ppi assay|A 4.5 ml blood sample will be taken with a citrate vacuum tube.
214315970|NCT03462238|RADIATION|CT Scan|A scanner will be performed
214315971|NCT02402985|OTHER|High animal protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
214315972|NCT02402985|OTHER|High plant protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
214315973|NCT00271349|DRUG|Budesonide|
214315974|NCT06538272|DRUG|ONO-2910|ONO-2910 Tablet will be orally administered once daily.
214315975|NCT06538272|DRUG|Placebo|Placebo Tablet will be orally administered once daily.
214315976|NCT02818777|DRUG|cannabidiol|"Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.~A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties."
214315977|NCT04227106|BIOLOGICAL|EB-101|autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7
214315978|NCT00559520|DIETARY_SUPPLEMENT|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
214315979|NCT00559520|DIETARY_SUPPLEMENT|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
214315980|NCT03627819|DIETARY_SUPPLEMENT|Plant sterol-enriched margarine|Margarine enriched with plant sterol esters
214315981|NCT03627819|DIETARY_SUPPLEMENT|Plant stanol-enriched margarine|Margarine enriched with plant stanol esters
214315982|NCT03627819|DIETARY_SUPPLEMENT|Control margarine|Margarine without any addition
214315983|NCT02459028|BEHAVIORAL|Positive Psychology intervention|"Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
214315984|NCT02459028|BEHAVIORAL|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
214315985|NCT01386736|DRUG|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
214315986|NCT01386736|DRUG|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
214315987|NCT00752882|DRUG|ceftazidime|
214315988|NCT01418937|BIOLOGICAL|CervarixTM (GSK580299)|Three intramuscular injections
214482467|NCT06606405|DIAGNOSTIC_TEST|scapular dyskinesis test|Scapular dyskinesia in athletes will be visually evaluated. It will be considered present if, during 3 out of 5 arm elevation attempts, any of the following are observed: prominence of the medial or upper scapular border, lower scapular angle, excessive clavicular elevation, or rapid downward rotation of the scapula. After the tester demonstrates the required movements, the athletes will practice the movement. The test will begin with the arms at the sides of the body, elbows straight, and shoulders in neutral rotation. Two testers will observe from behind and video record the movements. Participants will be instructed to raise their arms as high as possible simultaneously, using the \&amp;#39;thumbs up\&amp;#39; position, and to maintain this position for 3 seconds before lowering their arms for another 3 seconds. Athletes will perform the arm elevation with a dumbbell weight calculated as 1.4% of their body weight (Kamonseki, Haik, Ribeiro, Almeida, \&amp;amp; Camargo, 2023).
214315989|NCT01976832|BEHAVIORAL|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
214315990|NCT01976832|BEHAVIORAL|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
214315991|NCT04595864|OTHER|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|TAI
214315992|NCT05230212|OTHER|Pecan Breakfast Shake|The pecan breakfast shake contains 68 grams of blended raw pecans. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
214315993|NCT05230212|OTHER|Cream Breakfast Shake|The cream breakfast shake contains 138 grams of heavy whipping cream. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
214315994|NCT04339699|DEVICE|NobleStitch™EL Suture Mediated Closure System|Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System
214315995|NCT04339699|DEVICE|Amplatzer PFO Occluder|Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
214315996|NCT04401696|DEVICE|Bubble CPAP|"The bCPAP will be delivered using an oxygen flow meter as the oxygen source. This inspiratory limb containing oxygen from the flow meter will be connected to humidifier and tubing from humidifier will be connected to short binasal prongs, which would be applied to neonate with the help of adhesive bandage on both cheeks. It will be ensured that binasal prongs make appropriate seal. An orogastric tube will be placed for gastric decompression. A 1000 ml/500ml bottle filled with sterile water be used and marks will be made on it at 1cm distance, with '10' marked at base and '0' mark at the water interface.~The expiratory limb from the nasal prongs was connected to tubing that will be dipped in water up to the desired level to provide positive end expiratory pressure. Pressure is varied by varying the depth of the dipped end of tubing."
214315997|NCT04401696|OTHER|Nasal Oxygen|The oxygen will be delivered from a wall oxygen source, delivered between 1 to 6 L/min and the rate varied via a flow regulator.
214315998|NCT00150046|DRUG|Everolimus|
214482468|NCT06608615|OTHER|Kinesio Taping|"Facilitation (Functional) Technique for Tibialis Anterior Muscle: The patient sits with his leg extended. The ankle is placed in eversion and dorsi flexion. After one end of the I tape is adhered to the upper part of the Tibia, the other end is adhered to the dorsal surface of the foot with almost 100% tension. During the application, origin and insertion points are considered as the beginning and end. Then, plantar fexion is performed on the ankle and the remaining non-stick part is glued.~Functional Correction Technique: Correction technique is used to ensure full contact of the foot with the ground. The subtalar joint is positioned in eversion and taping is applied starting from under the medial malleolus, without tension until the lateral outer edge of the calceneus, and then with 100% tension, continuing until 10-15 cm below the head of the fibula. No tension is applied in the last 5 cm"
214482469|NCT06608615|OTHER|Rigid Taping|"Talus Stabilization Taping: The affected ankle of the person to be taped was placed on a chair and asked to bring this foot to a neutral position by advancing the tibia over the foot through knee flexion while standing. Starting from the talus of the ankle, maximum tension was applied towards the medial and lateral malleolus.~Inversion Lock: This lock looks like an inverted 6 when viewed from the front and is used to restrict inversion movement. After the underwrap and anchor were applied, the tape was applied starting from the outer malleolus level. It was glued on itself by proceeding diagonally in front of the foot, passing it in front of the inner malleolus, passing under the foot and in front of the outer malleolus and closing the subtalar area, and the taping was completed by making an anchor on the upper side."
214482470|NCT06608108|OTHER|Non-intervention|Non-intervention
214482471|NCT00071708|DRUG|Duloxetine Hydrochloride|
214482472|NCT06997380|DEVICE|Injection of the investigational product via needle|A hyaluronic acid solution (concentration 2.2%) with the addition of lecithin in the form of liposomes (concentration 0.08%) via needle
214482473|NCT06997380|DEVICE|Injection of the investigational product via cannula|A hyaluronic acid solution (concentration 2.2%) with the addition of lecithin in the form of liposomes (concentration 0.08%) via cannula
214482474|NCT06997380|PROCEDURE|Clinical assessment|Clinical assessment of facial skin condition
214482475|NCT06997380|PROCEDURE|Ultrasound measurement|Ultrasound measurement of facial skin thickness
214482476|NCT06997380|PROCEDURE|Multispectral imaging|Multispectral imaging and analysis of facial skin
214315999|NCT06484608|DRUG|Isotonic Saline with Dextrose|This clinical trial involves two interventions for maintaining fluid therapy in neonates post-surgery. The first intervention, isotonic saline with dextrose, involves administering 0.9% saline solution combined with 5% dextrose. This isotonic solution aims to maintain serum sodium levels within the normal range and minimize the risk of hyponatremia and hypernatremia in postoperative neonates. The second intervention, hypotonic saline with dextrose, involves administering 0.45% saline solution combined with 5% dextrose. This hypotonic solution is being compared to the isotonic solution to evaluate its effectiveness in maintaining electrolyte balance.
214316000|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Discontinued IST
214316001|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Continued IST
214316002|NCT03483675|OTHER|Survey Administration|Ancillary studies
214482477|NCT05361980|DEVICE|Pediatric orthopaedic implant|Patient receives a pediatric orthopaedic implant as a part of standard clinical care.
214316003|NCT05016232|BEHAVIORAL|PrEP N' Shine: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
214316004|NCT05016232|BEHAVIORAL|PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)|"1. Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~2. Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
214316005|NCT01340092|OTHER|Family Navigator|"Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:~1. Help family identify key issues they need to address to get their child autism-specific services~2. Help family address barriers to obtaining these services and strategize approaches to overcome them."
214316006|NCT00656630|DRUG|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
214316007|NCT00656630|DRUG|Naltrexone|50mg capsule, Once daily, 1 week duration
214316008|NCT00656630|DRUG|Placebo|Matched placebo capsule, 1 week duration
214316009|NCT00181961|DRUG|Maca Root|
214316010|NCT02665416|DRUG|Selicrelumab|Selicrelumab will be provided as concentrate for solution to be administered via SC injection
214316011|NCT02665416|DRUG|Vanucizumab|Vanucizumab will be provided as solution to be administered via IV infusion.
214316012|NCT02665416|DRUG|Bevacizumab|Bevacizumab will be administered via IV infusion.
214316013|NCT01770561|DEVICE|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
214316014|NCT01889316|DEVICE|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
214316015|NCT01889316|DEVICE|AN24|
214316016|NCT04860102|PROCEDURE|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
214918732|NCT04541953|OTHER|In-person Rehabilitation Therapy|Range of motion exercises and stretching
214316017|NCT01667978|DRUG|Norethindrone acetate|
214316018|NCT04407130|DRUG|Ivermectin + Doxycycline + Placebo|"Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5"
214316019|NCT04407130|DRUG|Ivermectin + Placebo|Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5
214316020|NCT04407130|DRUG|Placebo|Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
214918733|NCT03229863|OTHER|Sweet Potatos|Plum Organics, Just Sweet Potato
214316021|NCT00896558|DRUG|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
214316022|NCT00896558|DRUG|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
214316023|NCT00006481|DRUG|Biafine cream|
214316024|NCT00006481|PROCEDURE|quality-of-life assessment|
214316025|NCT00006481|RADIATION|radiation therapy|
214316026|NCT06371742|OTHER|Liquid ingestion during labour|An assessment of the volume capacity of the water glasses was carried out using duly certified 50mL syringes in order to calibrate and control the correct measurement of the amount of water ingested. Water is measured using a graduated cup, which is pre-existing in the BP service, since its water intake policy is governed by the formula 1ml/kg/h of clear liquids (water or tea).
214316027|NCT03119415|BEHAVIORAL|Cooperative Learning|CL is an umbrella term that includes peer tutoring, reciprocal teaching, collaborative reading, and other methods in which peers help each other learn in small groups. CL is not prescriptive but rather is a conceptual framework within which teachers design their own small-group activities. Johnson, Johnson, and Holubec's approach to CL combines positive interdependence with individual accountability, a high degree of face-to-face social interaction among youth, and support for the development of cooperative social skills. The Johnsons' approach offers teachers the combination of specific cooperative activities and the conceptual tools to create their own lesson plans using positive interdependence.
214316028|NCT01324349|DEVICE|Veriset Hemostatic Patch|Topical hemostat
214316029|NCT01324349|DEVICE|Fibrin Sealant (TachoSil®)|Topical hemostat
214316030|NCT04353011|OTHER|questionnaire assesment|questionnaire assesment
214316031|NCT02506504|DEVICE|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
214316032|NCT02506504|DEVICE|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
214316033|NCT02531321|DRUG|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
214316034|NCT03561493|OTHER|zumba exercise|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one hour in length and a recovery period of at least 48 h was taken between classes. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced. The Zumba sessions will be supervised by three certiﬁed Zumba instructors, each responsible for regular sessions per week.
214316035|NCT06044376|COMBINATION_PRODUCT|Formula milk with triple Bifidobacterium probiotic strain|Formula milk with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10\^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10\^7 CFU/serving), Bifidobacterium longum subsp. infantis M-63 (6.9 x 10\^7 CFU/serving).
214316036|NCT06044376|OTHER|Formula milk|Formula milk without any addition of probiotic strain
214918734|NCT03229863|OTHER|Pears|Earth's Best, First Pears
214918735|NCT03000426|PROCEDURE|Free gingival graft|Free gingival graft removal from palate for socket preservation
214918736|NCT03000426|DEVICE|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
214316037|NCT02013167|DRUG|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
214316038|NCT02013167|DRUG|Standard of Care Chemotherapy|"* FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
214316039|NCT02220244|DRUG|MD1003 100mg capsule|
214316040|NCT05066971|COMBINATION_PRODUCT|Self-adjustment of medication|Each week, based on the information provided by HM (heart rate and hours of activity each day), the rate control medication is adjusted to increase the total of activity time.
214316041|NCT03349216|PROCEDURE|Intravenous Regional Anesthesia|in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
214316042|NCT03349216|DRUG|Systemic Analgesia|in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
214316043|NCT04152512|BEHAVIORAL|Questionnaire administration|Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
214316044|NCT01113879|BEHAVIORAL|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
214316045|NCT01113879|BEHAVIORAL|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
214316046|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
214316047|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
214316048|NCT03673163|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
214316049|NCT03673163|DRUG|Control|Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
214316050|NCT01024712|DRUG|carboplatin|
214316051|NCT01024712|DRUG|gefitinib|
214316052|NCT01024712|DRUG|paclitaxel|
214316053|NCT01024712|PROCEDURE|quality-of-life assessment|
214316054|NCT01575184|OTHER|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
214316055|NCT01575184|OTHER|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
214316056|NCT03995212|DRUG|CR845 1.0 mg|Oral CR845 1.0 mg administered twice daily
214482478|NCT06862518|DRUG|Control group|Patients will receive general anesthesia alone
214482479|NCT06862518|DRUG|Serratus Anterior Plane Block (SAPB) group|Patients will receive general anesthesia (GA) with ultrasound guided serratus anterior plane block 0.5 ml/kg 0.25% bupivacaine.
214482480|NCT06862518|DRUG|Erector Spinae Plane Block (ESPB) group|Patients will receive general anesthesia (GA) with ultrasound guided erector spinae plane block 0.5 ml/kg 0.25% bupivacaine
214482481|NCT03343431|DRUG|Anti-HBV antiviral prophylaxis|Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum
214316057|NCT03995212|DRUG|Placebo|Oral Placebo administered twice daily
214316058|NCT03863028|OTHER|Simulation training|It is not a randomized trial - all three groups are exposed to simulation training.
214316059|NCT01894269|DRUG|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
214316060|NCT03146442|BEHAVIORAL|Breakfast|For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
214316061|NCT03439969|DEVICE|Mobile Text Messages|Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.
214316062|NCT03439969|DEVICE|Intra Oral Camera|"SPT - Appointment with Intra-Oral Camera~* Examination and diagnosis (15 min) using Intra-oral camera.~* Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min)."
214316063|NCT04327986|DRUG|M7824|Intravenous (IV) on Days 1 and 15 of every cycle
214316064|NCT04327986|DRUG|M9241|Subcutaneous injection on Day 1 of every cycle
214316065|NCT04327986|RADIATION|SBRT|Radiation therapy will be starting on Day 17 (+5 days) of Cycle 1 and continue for 5 consecutive business days.
214316066|NCT02131402|DEVICE|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
214316067|NCT02131402|DEVICE|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
214316068|NCT02131402|DEVICE|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
214316069|NCT05705063|OTHER|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 6 weeks
214316070|NCT05622045|BEHAVIORAL|Voice data|Recorded response to a question about their participation in a weight loss study.
214671551|NCT03949673|DRUG|Fasinumab|Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
214316071|NCT05794789|BEHAVIORAL|Social Identity|This group will receive the same content as the education+planning as well as two additional sessions. This includes short overviews of the benefits of PA as a family, brainstorming how a family can each assist each other in PA, and an activity for developing a family PA action plan. Behavior change techniques such as identity salience, identity similarity, and identity fit and contrast are included in the coaching session include. This will be supplemented by an organization of fun family PA roles for all members (e.g., activity planner, goal setter, supporter, etc.) to instill involvement as well as items (creation of a family PA t-shirt, family PA photos and display, etc.) to instill distinctiveness, which is a central feature of a social identity. Worksheets and discussion will be included. The second session will involve only the parent(s) to focus on parental support identity and the content is based on the behavior change principles of self-identity theory.
214316072|NCT07109336|DEVICE|Heterogeneous Treatment Effect-Based Decision Model|Heterogeneous Treatment Effect-Based Decision Model
214316073|NCT07064577|DRUG|ROS-scavenging Nanoenzymes|ROS-scavenging nanoenzymes are applied to the treatment area, once daily during radiotherapy.
214316074|NCT07064577|BEHAVIORAL|Standard of care|Standard of care
214316075|NCT06958419|COMBINATION_PRODUCT|Node-Sparing Radiotherapy plus first-line therapy|Patients will receive node-sparing modified short-course radiotherapy, followed by 8 cycles of FOLFOX chemotherapy combined with bevacizumab and a PD-1 inhibitor. After induction therapy, patients will continue with maintenance therapy using bevacizumab, PD-1 inhibitor, and 5-fluorouracil (5-FU), administered every 2 weeks (Q2W).
214316076|NCT06958419|COMBINATION_PRODUCT|First-line treatment|Patients will receive 8 cycles of FOLFOX chemotherapy combined with bevacizumab, followed by maintenance therapy with bevacizumab and 5-fluorouracil (5-FU), administered every 2 weeks (Q2W).
214316077|NCT02684643|OTHER|enhanced individualised therapy|additional dialysis dosage, modification of medication and prescribed dietary plan
214671552|NCT03949673|DRUG|Naproxen|Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
214918737|NCT05934604|OTHER|Functional magnetic resonance imaging (fMRI)|Healthy subjects will complete two fMRI sessions after initial assessment and training in the Rest Focus Task (RFT). The first session will be the localizer session to identify the networks involved in switching in the RFT. The second fMRI session, real time functional magnetic resonance imaging neurofeedback (rtfMRI-NF) session, will use localizer information from the first fMRI session to develop a mask for the rtfMRI-NF, and deliver a neurofeedback (NF) stimulus while simultaneously measuring Blood Oxygenation Level Dependent (BOLD) activity for the STOP\>RECALL contrast.
214316078|NCT02684643|OTHER|non-enhanced individualised therapy|modified medication, prescribed dietary plan and regular three times/week dialysis dosage
214316079|NCT02684643|OTHER|regular intervention|Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
214316080|NCT02283112|OTHER|antivirals, antimicrobials, oral contraceptive, erectile dysfunction agents|
214316081|NCT05235191|DRUG|methadone tablets|The intervention with the active drug (methadone) will start with the dose of 1 tablet (5 mg) twice a day (every 12 hours) and titrated on subsequent visits up to the maximum dose of 6 tablets a day (totaling 30 mg divided into 2 daily doses to facilitate therapeutic adherence).
214316082|NCT05235191|DRUG|Placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
214316083|NCT05595993|DRUG|Cilostazol|Study participants will be allocated to receive oral administration of 200 mg cilostazol.
214316084|NCT05595993|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
214316085|NCT05489315|DEVICE|Positioning with peanut ball|If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.
214316086|NCT05489315|OTHER|Traditional positioning|If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
214316087|NCT01139281|DRUG|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
214316088|NCT01139281|DRUG|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
214316089|NCT00117858|PROCEDURE|Anodal DC polarization of left prefrontal cortex|
214316090|NCT05771259|OTHER|Assessment of knowledge and behaviour|Assessment of knowledge and behaviour
214316091|NCT04055597|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
214316092|NCT04055597|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
214316093|NCT01598792|BIOLOGICAL|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
214316094|NCT03033017|OTHER|Blood Testing|
214671553|NCT03949673|DRUG|Diclofenac|Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
214316095|NCT02150174|BEHAVIORAL|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
214316096|NCT03001570|DRUG|Cetuximab plus Radiotherapy|Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
214316097|NCT04347265|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
214316098|NCT03865329|BEHAVIORAL|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
214316099|NCT02930850|DEVICE|Rad-67 Pulse oximeter|Noninvasive pulse oximeter that measures hemoglobin
214316100|NCT01746784|DRUG|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
214316101|NCT01746784|DRUG|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
214316102|NCT00526058|DEVICE|Secura then Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
214316103|NCT00526058|DEVICE|Futura then Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
214316104|NCT03086174|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
214316105|NCT03516669|DRUG|Clarithromycin|Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
214316106|NCT03516669|DRUG|Amoxicillin, Clarithromycin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
214316107|NCT01714310|DRUG|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
214316108|NCT01714310|DRUG|Placebo|Initiated at end of study week 4 and continued to study week 12.
214316109|NCT01714310|DRUG|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
214316110|NCT05869929|DIETARY_SUPPLEMENT|Vegetables|4-5 servings of vegetables daily, per USDA guidelines.
214316111|NCT02822508|DRUG|BLI801 Laxative|BLI801 oral laxative
214671554|NCT03949673|DRUG|Celecoxib|Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
214671555|NCT03949673|DRUG|Placebo|Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
214671556|NCT01328873|OTHER|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
214918738|NCT01053663|DRUG|Tamiflu|10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
214316112|NCT02822508|DRUG|BLI801 Placebo|BLI801 oral laxative placebo
214316113|NCT00654381|DRUG|BI 1356|5 mg/daily
214316114|NCT00654381|DRUG|BI 1356|10 mg/daily
214316115|NCT00654381|DRUG|voglibose placebo|three times daily
214316116|NCT00654381|DRUG|BI 1356 placebo|once daily
214316117|NCT00654381|DRUG|voglibose|0.6 mg/daily
214316118|NCT01782781|DRUG|ropivacaine, ketorelac and epinephrine|Active group
214316119|NCT01782781|DRUG|Placebo|Placebo group
214316120|NCT06574230|OTHER|TRAINING PROGRAM|Each training session included a structured set of exercises aimed at enhancing these skills. For example, participants practiced precision drills to target specific areas of the dartboard, endurance drills to build stamina for longer games, and competitive exercises to simulate real-game conditions. This combination of theoretical knowledge, practical skill development, and strategic gameplay was designed to comprehensively improve the participants\&#39; dart-throwing abilities over the course of the program. A 12-week dart training program, with sessions conducted three times per week, each lasting 90 minutes. In the first week, participants received comprehensive theoretical and practical instruction covering the rules of the game, proper breathing techniques, and throwing mechanics. This initial phase was designed to ensure a solid understanding of the fundamentals before progressing to more advanced training.
214316121|NCT01919658|PROCEDURE|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
214918739|NCT04871204|DRUG|Octreotide Injection|10 mg Sandostatin LAR intramuscular injection
214918740|NCT00894608|DRUG|letrozole + gonadotropins|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
214316122|NCT02852096|OTHER|Dual or Multiple Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
214316123|NCT02852096|OTHER|One Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With One Tumor Tissue Paraffin Blocks
214316124|NCT03741764|DEVICE|Vivosorb|Resorbable implant device
214671557|NCT04399278|DIAGNOSTIC_TEST|Diagnostic Test: end-expiratory occlusion (EEO) test|"A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~* T0: baseline.~* T1: At the end of the first EEO (15 sec or 30 sec)~* T2: 1 minute after completion of the first EEO. Return to baseline.~* T3: At the end of the second EEO (15 sec or 30 sec)~* T4: 1 minute after completion of the second EEO. Return to baseline.~* T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~* T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.)."
214316125|NCT03668652|DEVICE|Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO"
214316126|NCT03668652|PROCEDURE|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
214316127|NCT00323973|DRUG|Bisoprolol|10 mg qd
214316128|NCT05147896|DRUG|Semaglutide Oral Tablet|Semaglutide Oral Tablets will be introduced to the active arm as per protocol for regular therapy introduction.
214316129|NCT01797328|PROCEDURE|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
214316130|NCT01797328|PROCEDURE|warm arm|To the best of ability avoid feeling cold during 6 weeks
214918741|NCT00894608|DRUG|GnRHa + gonadotropins|patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
214918742|NCT04374123|DIAGNOSTIC_TEST|Serological screening for IgG and IgM antibodies against COVID-19|Serum evaluation for IgG and IgM antibodies against COVID-19 in patients in the endoscopy unit during the COVID 19 pandemic
214316131|NCT01323075|PROCEDURE|Truncal block|Patients will have a truncal block during hand or wrist surgery.
214316132|NCT04883632|COMBINATION_PRODUCT|Saypha Volume Lidocaine|"correction of Nasolabial Folds using injection of Saypha Volume Lidocaine manufactured in 2 different plants at Croma Pharma.~The amount injected depended on the size of the area to be corrected and the desired level of soft tissue augmentation. It was estimated that a maximum volume of 4 mL per treatment was needed but should not have exceeded 10 mL in total per treatment or 20 mL per year. and use in respective indications. The investigational device was administered to eligible subjects on investigation Day 0. A touchup treatment at Week 2 was optional at the investigator's discretion if full correction was"
214316133|NCT00664716|BIOLOGICAL|Baminercept alfa 1|experimental - one dose level
214316134|NCT00664716|BIOLOGICAL|Placebo|Placebo comparator
214316135|NCT00664716|BIOLOGICAL|Baminercept alfa 2|experimental - second dose level
214316136|NCT00664716|BIOLOGICAL|Baminercept alfa 3|experimental - third dose level
214316137|NCT00664716|BIOLOGICAL|Baminercept alfa 4|experimental - fourth dose level
214316138|NCT00664716|BIOLOGICAL|Baminercept alfa 5|experimental - fifth dose level
214316139|NCT06498284|DRUG|HM-002-1005|HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets
214316140|NCT05793944|BEHAVIORAL|SmartMom text messaging|SmartMom is a mobile health program delivered via text messaging that guides participants through each week of pregnancy. Participants receive three messages per week with links to content focused on improving knowledge, providing information about prenatal assessments and screening, and encouraging the adoption of behaviours to support healthy pregnancy and physiologic birth. Messages are consistent with current professional guidelines and peer reviewed prenatal education curricula. SmartMom provides optional supplemental streams for individuals who wish to have additional messages addressing topics such as reducing use of tobacco, alcohol or illicit drugs, depression, obesity, and maternal age over 35.
214316141|NCT05793944|BEHAVIORAL|Control text messaging|Control arm participants will receive weekly text messages with accurate, general-interest information about pregnancy and about progress of the trial. Content is not geared to decision-making during pregnancy that may affect health outcomes.
214316142|NCT04164901|DRUG|Vorasidenib|Vorasidenib oral film-coated tablets
214316143|NCT04164901|DRUG|Matching Placebo|Matching Placebo oral tablets
214316144|NCT05097833|BEHAVIORAL|Enhanced Saint Francis Fatherhood FIRE Program|Fathers receive an enhanced series of pro-parenting, relationship, and economic stability workshops over 16 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success and the Nurturing Fathers enhancement program.
214316145|NCT05097833|BEHAVIORAL|Services as Usual Saint Francis Fatherhood FIRE Program|Fathers receive the services as usual approach which includes a series of pro-parenting, relationship, and economic stability workshops over 13 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success.
214316146|NCT06059404|BEHAVIORAL|Meals + RD services only|Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education
214316147|NCT06059404|BEHAVIORAL|Meals + OT services only|Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies
214316148|NCT06059404|BEHAVIORAL|Meals + RD + OT services|A combination of tailored registered dietitian and occupational therapy services will be provided
214316149|NCT02638298|DEVICE|Prevana Dressing|negative pressure wound therapy (NPWT) dressing
214316150|NCT02638298|OTHER|Standard Dry Gauze Dressing|Standard Dry Gauze Dressing
214482482|NCT06528990|BEHAVIORAL|Telehealth Intervention|This includes the following key components: 1) assignment to a peer ostomate; 2) ostomy self-management skills building delivered through group telehealth sessions and led by trained ostomy nurses and peer ostomates; 3) intervention resource manual.
214482483|NCT06528990|OTHER|Standard of care|standard of care, where patients and family caregivers are managed by the oncology care team. Care may include clinic visits for follow-up, cancer directed treatments, referrals to other medical specialties as needed, and institutional ostomy nurse support before and after surgery as needed.
214482484|NCT06676839|OTHER|the complete ICOPE program|"The participant benefits from a personalized intervention, including 1) a screening to be repeated every 6 months, based on the use of the ICOPE tool, allowing an assessment of the 6 functions necessary for an autonomous lifestyle; 2) a comprehensive assessment step for the 6 functions 3) a personalized intervention step aimed at correcting the trajectory of functional decline, based on the participants' preferences; 4) a follow-up step for this intervention.~Participants will benefit from telephone follow-up 1.5 months after the start of the program and between each annual visit to support them in implementing their personalized intervention plan.~At each contact, the ICOPE nurse reviews the participant's implementation of the personalized intervention plan recommendations and their adherence to the program.~The results of the assessment and the proposed intervention are communicated and discussed with the primary care physician and a summary letter is also sent."
214918743|NCT01544387|OTHER|Bed Rest|"* Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position~* Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed~* Subjects may have limited bathroom privileges"
214918744|NCT01544387|OTHER|Activity|"* Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed~* Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired."
215061083|NCT05360693|PROCEDURE|immediate implant placement with socket bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
215061084|NCT04545866|DRUG|budesonide (Pulmicort nebulizing suspension).|The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.
215061085|NCT04545866|DRUG|surfactant (poractant alfa;Curosurf)|The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
214918745|NCT05758610|DRUG|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
214316151|NCT06398990|OTHER|Cognitive Exercise Therapy Approach|It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).
214316152|NCT06398990|OTHER|Yoga|It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).
214316153|NCT06398990|OTHER|Routine Medical Treatment|Assessments of individuals in this group will be made face-to-face in the relevant clinic.
214482485|NCT06677606|PROCEDURE|PENG block|The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle
214482486|NCT06677606|PROCEDURE|PAI block|LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. The admixture (consisting of 60mL of bupivacaine 0.25% and 30mg of ketorolac) will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.
214482487|NCT06677385|RADIATION|diode laser as adjunctive to conventional scaling and debridement|diode laser as adjunctive to conventional scaling and debridement for old age patients
214918746|NCT01408381|OTHER|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
214316154|NCT06649890|DEVICE|Xperience™ Advanced Surgical Irrigation|Xperience™ solution will be applied twice during reconstruction procedures: first after achieving hemostasis and second just before implant introduction. The solution will be warmed to body temperature before use. Both tissue expanders/implants and mastectomy pockets will be soaked with Xperience™, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of Xperience™ will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout, and no rinsing will occur post-irrigation. Surgical site closure will follow standard procedures.
214316155|NCT06649890|DEVICE|Dilute Povidone-Iodine|5% dilute povidone-iodine solution will be prepared by mixing povidone-iodine solution and normal saline at the appropriate ratio. Both tissue expanders/implants and mastectomy pockets will be soaked with dilute povidone-iodine, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of dilute povidone-iodine will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout. Surgeon discretion will determine rinsing after irrigation. Surgical site closure will follow standard procedures.
214671558|NCT00586690|DEVICE|NK Cell infusion using CD56 monoclonal antibody|The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
214918747|NCT05618938|OTHER|Rocabado's approach|"Group A will be treated with Rocabado's approach. Rocabado' approach will be comprised of six exercises.~1. Rest position of the tongue~2. Control of TMJ rotation~3. Rhythmic stabilization technique~4. Axial extension of the neck The patients will receive Rocabado's approach consisting 6 repetitions six times a day thrice per week for four weeks"
215061086|NCT05236452|OTHER|Training for traditional and modern care providers|The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
214316156|NCT06548061|DEVICE|Visualase Thermal Therapy System|Spine laser interstitial therapy used instead of open decompression followed by spine stereotactic radiosurgery (SSRS).
214316157|NCT01978314|DEVICE|75 mg / 6 mL VFI™|Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
214316158|NCT03855995|PROCEDURE|Whole blood sample|Whole blood samples will be collected from all enrolled children hospitalised and suspected of having an AESI or meningitis.
214316159|NCT04335721|DRUG|Voxelotor|Voxelotor 1500mg once a day
214316160|NCT00915369|DRUG|Nanoxel (Paclitaxel Nanoparticle formulation )|Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
214316161|NCT04390581|DEVICE|Juvéderm® VOLIFT with Lidocaine|Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.
214316162|NCT01226381|DRUG|Von Frey electronic|This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
215061087|NCT04125329|DRUG|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
214316163|NCT00003679|DRUG|cyclophosphamide|
214316164|NCT00003679|DRUG|docetaxel|
214316165|NCT00003679|DRUG|doxorubicin hydrochloride|
214316166|NCT00003679|DRUG|tamoxifen citrate|
214316167|NCT00003679|PROCEDURE|conventional surgery|
214316168|NCT00003679|RADIATION|radiation therapy|
214316169|NCT05133999|BIOLOGICAL|Plasma determination of iron, transferrin and ferritin|Iron, transferrin and ferritin levels in plasma
214316170|NCT05133999|OTHER|Fundus Examination by wide field digital imaging camera (PanocamTM camera)|ROP screening using wide field digital retinal imaging according to current recommendations.
214316171|NCT06089486|DIAGNOSTIC_TEST|ICA|Patients will undergo annual CAV surveillance with ICA
214316172|NCT06089486|DIAGNOSTIC_TEST|PET|Patients will undergo annual CAV surveillance with PET
214316173|NCT00097721|DRUG|E7389|The first cohort of subjects were to receive E7389 1.4 mg/m\^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m\^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
214316174|NCT04927936|BIOLOGICAL|Vaccination once with Janssen vaccine (only priming)|Vaccination (priming) with janssen vaccine. There is no boosting.
214316175|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.
214316176|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.
214316177|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.
214316178|NCT03869450|DEVICE|Restylane Volyme|Hyaluronic based filler
214316179|NCT03869450|DEVICE|Restylane Defyne|Hyaluronic based filler
214316180|NCT03869450|DEVICE|Restylane Lyft Lidocaine|Hyaluronic based filler
214316181|NCT00030563|DRUG|irinotecan hydrochloride|
214482488|NCT06677385|PROCEDURE|conventional scaling and debridement|conventional scaling and debridement
214482489|NCT06676982|BIOLOGICAL|anti-CD19 CAR-T|All subjects were intravenous administrated with CNCT19 CAR-T.
214482490|NCT06524024|BIOLOGICAL|Tumor polypeptide pool induced DC-CTL cell injection|In this study, DC-CTL cells were injected once a day for two consecutive days, 1-2 days after study participants received a conventional antitumor regimen, and subcutaneous injections of DC cells were administered before a second infusion of DC-CTL cells. A total of about 4-6 cycles of cell infusion are required
214482491|NCT06878729|PROCEDURE|CTO PCI using ADR strategy|CTO recanalization using ADR performed as primary or secondary CTO PCI strategy (i.e. in case of unattempted or failed antegrade wiring, respectively).
214482492|NCT06878729|PROCEDURE|CTO PCI using retrograde strategy|CTO recanalization using retrograde approach performed as primary or secondary CTO PCI strategy (i.e. in case of unattempted or failed antegrade wiring, respectively).
214482493|NCT03851640|DRUG|HC-1119|oral
214482494|NCT03851640|DRUG|placebo|oral
214482495|NCT06859411|PROCEDURE|visual acuity comparaison|Data collection
214482496|NCT04178915|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)
214482497|NCT04178915|DIAGNOSTIC_TEST|The cholesterol content of the cell membrane of T-cells and monocytes|The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
214482498|NCT06617299|BEHAVIORAL|Intervention Identifies and Responds|"The treatment of Experimental Group is described, which is made up of eight individual sessions taught over three months. Session one will be in face-to-face format, the content, resources and activities are described in tables 2 and 3. The remaining seven sessions will be follow-up sessions (four sessions by message (WhatsApp®) where motivational messages and reinforcement information will be sent; and 3 sessions by phone call for feedback, see details of time, content, activities and resources in tables 2 and 3.~The design of the intervention is aimed at increasing the practice of Responsive Feeding in mothers with children under 6 months of age, is based on the methodology of Sidani and Braden (2021); on CHW (Bandura, 1986); and behavior change techniques to help people have healthy eating habits (Michie et al., 2011)."
214482499|NCT06671379|DRUG|SHR-A2009 monotherapy|SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously
214316182|NCT00030563|PROCEDURE|adjuvant therapy|
214482500|NCT06671379|DRUG|platinum-based dual-agent chemotherapy|Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously
214316183|NCT00030563|PROCEDURE|conventional surgery|
214482501|NCT06094413|BEHAVIORAL|Multicomponent Training Intervention|The intervention was implemented and supervised by a well-trained, highly experienced professional with post-graduate education in the fields of exercise science and health promotion. Each session consisted of three phases: warm-up/initiation, conditioning, and cooldown. The intervention was composed of aerobic, resistance, balance, and flexibility exercises. At each session subjects werre informed of the program goals and the methods used to document exercise tolerance of the session's training loads. The quality of the intervention was measured by patient compliance, adherence, and feedback such as rates of perceived exertion (RPE) which were monitored during the session to measure immediate effect of the intervention. Progressions were guided by individual responsiveness and measured by RPE. Progressions were based on the training principles of specificity, adaptability, and overload.
214482502|NCT06536764|OTHER|Progressive Muscle Relaxation Exercises|Progressive muscle Relaxation exercises will be performed by this group.Advise women to sit in chair. The therapist's voice will then instruct them to contract and release different muscle groups. They will practice tensing a muscle group until they feel the slight contraction and then release it, simultaneously contracting and relaxing all other muscle groups.Practice will progress in the same manner, starting with the muscles in the feet, then the calf, thigh, gluteal muscles, abdomen, chest, hands, forearms, arms, shoulders, neck, face, and finally the forehead muscles .
214482503|NCT06536764|OTHER|Conventional Therapy(Hot pack,TENS,Patient Education)|Conventional therapy including hot pack and TENS will be applied for 10 minutes each. Meanwhile, patients will be given education to ease back pain and improve sleep.
214482504|NCT01211964|DRUG|LEO 22811|Oral administration of solution and tablet.
215061088|NCT04495530|OTHER|Non-interventional study|semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions
215061089|NCT03419312|DEVICE|Proclaim™ Elite 5: Burst - Washout - Sham|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
215061090|NCT03419312|DEVICE|Proclaim™ Elite 5: Sham - Washout - Burst|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
215061091|NCT04512677|DEVICE|Timed Inspiratory Effort (TIE index)|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
215061092|NCT01502514|PROCEDURE|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
214316184|NCT00030563|PROCEDURE|radiofrequency ablation|
214316185|NCT01752855|BIOLOGICAL|New formulation adalimumab|New formulation adalimumab 40 mg every other week
214316186|NCT01289769|DRUG|Dexmedetomidine|dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation
214316187|NCT01289769|DRUG|Placebo|normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
214316188|NCT02581696|DRUG|Lafutidine|Lafutidine 10mg, 1 tablet, bid
214316189|NCT02581696|DRUG|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
214482505|NCT06054906|DRUG|sintilimab+metronomic PLOF|"Drug: Sintilimab 200mg iv d1 Q3W, 2cycles~Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles~Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles~Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles"
214482506|NCT04559685|COMBINATION_PRODUCT|SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.
214482507|NCT04559685|DEVICE|MR-Guided Focused Ultrasound device (MRgFUS)|MR-Guided Focused Ultrasound device (MRgFUS) alone
214482508|NCT05520749|DRUG|Luspatercept|Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
214671559|NCT00586690|PROCEDURE|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for \>24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
214918748|NCT05618938|OTHER|Kraus exercises|"Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~1. Tongue position at rest~2. Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~3. Nasal-diaphragmatic breathing~4. Tongue up and wiggle~5. Strengthening~6. Touch and bite: Proprioceptive re-education: Lateral deviation The patients will receive Kraus exercises with the frequency of 2 sets and 10 repetitions twice a day three times per week for four weeks"
214918749|NCT03533114|DRUG|JZP-258|Participants randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.
214918750|NCT03533114|DRUG|Placebo Oral Solution|Participants randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.
214918751|NCT02064712|OTHER|Low CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
214918752|NCT02064712|OTHER|High CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
214918753|NCT02423395|DRUG|orphenadrine|Orphenadrine in muscle cramps in cirrhotic patients
214918754|NCT02423395|DRUG|Placebo|calcium in muscle cramps in cirrhotic patients
214482509|NCT05178056|DEVICE|Spinal Cord Epidural Stimulation|Spinal Cord Epidural Stimulation (scES) will be administered by a multi-electrode array (5-6-5 SpecifyTM electrode, MEDTRONIC, Minneapolis, MN, USA) previously implanted in the epidural space over the dorsum of the spinal cord.
214482510|NCT05178056|OTHER|Respiratory Training|Standard threshold Positive Expiratory Pressure Device and standard threshold Inspiratory Muscle Trainer (Respironics Inc., Cedar Grove, NJ) assembled together will be used for respiratory training sessions to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure treshold load.
214482511|NCT06547346|DIETARY_SUPPLEMENT|Alfamino Junior|To recruit 15 children and evaluate the acceptability (including gastrointestinal tolerance), palatability and compliance of a hypoallergenic amino acid powdered formula (neutral and vanilla flavours) with HMO's for the dietary management of presumed cows' milk allergy, multiple food protein allergies and other conditions where an amino acid formula is recommended in children ≥1 year of age.
214482512|NCT04936620|PROCEDURE|Duroplasty|Expansion Duroplasty
214482513|NCT04936620|PROCEDURE|Spinal surgery|Spinal surgery including laminectomy
214482514|NCT06866899|PROCEDURE|Surgery for Dupuytren contracture (DC), DeQuervain tenosynovitis (DQS), carpal tunnel syndrome (CTS), or trigger finger (TF)|All of the patients were operated for Dupuytren contracture (DC), DeQuervain tenosynovitis (DQS), carpal tunnel syndrome (CTS), or trigger finger (TF). The study is two center study, one center has the routine of RAAB (regional anesthesia with axillary block) and the other has the routine of WALANT (wide awake local anesthesia no tourniquet) for the mentioned surgeries.
214482515|NCT06866899|PROCEDURE|Regional Anesthesia|Regional anesthesia with axillary block
214671560|NCT01073189|DRUG|Intra-Renal Fenoldopam|Placement of an intra-renal catheter for infusion of fenoldopam mesylate
214918755|NCT02237612|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
214918756|NCT02237612|OTHER|laboratory biomarker analysis|Correlative studies
214918757|NCT01862250|DRUG|Clonidine (Duraclon®)|"Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~* 10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~* 20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~* HR ≤70/min, sustained for ≥30 min after administration"
215061093|NCT03353038|DEVICE|3D printed pillbox|The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
215061094|NCT04106128|DIAGNOSTIC_TEST|ultrasound examination|Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
215061095|NCT01050023|DEVICE|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
214316190|NCT06092515|DIETARY_SUPPLEMENT|Fermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from fermented high zinc wheat flour.~* The flatbreads will be prepared using traditional fermentation methods.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
214316191|NCT06092515|DIETARY_SUPPLEMENT|Unfermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from unfermented high zinc wheat flour,~* The flatbreads will not undergo a fermentation process.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
214316192|NCT06092515|DIETARY_SUPPLEMENT|Post-Harvest Fortified Whole Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from whole wheat flour fortified post-harvest~* These fortified flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months."
214316193|NCT06092515|DIETARY_SUPPLEMENT|Low Zinc Whole Wheat Flour Flatbread (Control Group)|"* Participants in this group will serve as the control group.~* They will receive flatbreads made from whole wheat flour with a low zinc content~* These low zinc flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months. six days a week over the course of six months."
214316194|NCT02203487|DRUG|BIIF 1149 BS - single rising dose|
214316195|NCT02203487|DRUG|Placebo|
214316196|NCT00203528|DRUG|divalproex sodium ER|
214316197|NCT00203528|DRUG|risperidone|
214316198|NCT00892567|BIOLOGICAL|9 Peptides from Her-2/neu, CEA, & CTA|Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
214316199|NCT01733914|PROCEDURE|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
214316200|NCT01733914|OTHER|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
214316201|NCT02882321|DRUG|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
214316202|NCT02882321|OTHER|Pharmacological Study|Correlative studies
214316203|NCT01849211|DRUG|rocuronium|
214316204|NCT03445624|DRUG|Infliximab|follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy
214316205|NCT00096512|DRUG|sorafenib tosylate|Given orally
214316206|NCT00096512|OTHER|laboratory biomarker analysis|Correlative studies
214482516|NCT06866899|PROCEDURE|Local Anesthesia|Wide awake local anesthesia no tourniquet
214482517|NCT06866951|DRUG|Chemo-immunotherapy|"Post-radical surgery for cervical cancer, the first cycle of PD-1 inhibitor combined with chemotherapy will begin 2 to 3 weeks after surgery. Each treatment cycle lasts 21 days, with a total of 6 cycles. A complete imaging efficacy evaluation will be conducted after every 3 treatment cycles. For patients with lymph node metastasis ≥3 or para-aortic lymph node metastasis, 6 cycles of chemotherapy combined with immunotherapy will be administered. Other patients will receive 3 cycles of chemotherapy combined with immunotherapy.~Treatment regimen:~Day 1:~Paclitaxel (albumin-bound) for injection: 260 mg/m², administered intravenously over 30 minutes.~Day 1 to Day 2:~Cisplatin 75-80 mg/m², administered intravenously at a 1 mg/min rate.~Day 3:~PD-1 inhibitor (Camrelizumab for injection, Aikening): 200 mg per dose, infused over 30 to 60 minutes."
214482518|NCT06866951|RADIATION|CCRT|"The overall chemoradiotherapy (including EBRT and brachytherapy) should typically be completed within 6 weeks (with a maximum extension to 10 weeks in case of anticipated delays). External beam radiotherapy (EBRT) should be at least three-dimensional conformal radiotherapy, with image-guided (CT or MR) intensity-modulated conformal radiotherapy techniques recommended, at a 45-50 Gy dose.~Concurrent Chemotherapy:~Cisplatin (40 mg/m²) is preferred on a weekly schedule (administered before the planned EBRT on the same day, once a week \[±1-day window\], for a total of 5-6 infusions). Carboplatin can be used as an alternative if cisplatin toxicity is not tolerated."
214482519|NCT06862765|PROCEDURE|transcatheter tricuspid valve replacement|The LuX-valve was implanted under fluoroscopic and echocardiographic guidance via the transjugular vein approach. Once the delivery system was introduced, it was adjusted within the right heart chamber to be perpendicular to the tricuspid annulus. The anterior leaflet was grasped using two leaflet graspers, and the ventricular portion of the device component was gradually released. After deploying the atrial disc to ensure the elimination of TR, septal anchoring was performed, and the delivery system was subsequently withdrawn.
214482520|NCT05815043|BEHAVIORAL|Low-sodium intake|Participants will consume less than or equal to 720 milligrams of sodium per day for 3 days.
215061096|NCT01050023|DEVICE|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
214316207|NCT00402675|PROCEDURE|Timing of percutaneous coronary intervention|Immediate, early or selective invasive angiography
214482521|NCT05815043|DIETARY_SUPPLEMENT|High-sodium intake|Participants will supplement their existing diets with 10 salt tablets daily for 3 days.
214482522|NCT06085131|DEVICE|Argos|Argos Biometer
214671561|NCT01073189|DRUG|Furosemide|Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
214671562|NCT03670173|DRUG|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
214671563|NCT00098059|DRUG|Famciclovir|Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
214671564|NCT02167269|DEVICE|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
214316208|NCT02619695|DRUG|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
214671565|NCT00041899|DRUG|CDB-2914|
215061097|NCT00430989|OTHER|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
215061098|NCT00430989|OTHER|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
214316209|NCT04134000|DRUG|Atezolizumab|1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
214671566|NCT00041899|DRUG|COB-2914|
214316210|NCT04134000|DRUG|BCG|1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
214316211|NCT02997033|OTHER|No intervention|No intervention
214316212|NCT04242056|DRUG|18F-PM-PBB3|"18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets."
214316213|NCT06240156|OTHER|3D arch pad design Insole group|3D three-dimensional design that is already available on the market (patent number I315187). Its arch support principle is designed using 3DBS (Three-Dimensional Biomechanics System - 3DBS), which can conform to the user's feet.
214316214|NCT06240156|OTHER|flat Insole group|General Insole without any special features
214316215|NCT03640026|DRUG|Tacrolimus|Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.
214316216|NCT01564303|DRUG|Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine|to evaluate the effect of the above agents on Kidney functioning parameters
214316217|NCT01397175|DEVICE|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
214316218|NCT01397175|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
214316219|NCT01397175|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
214482523|NCT04130789|OTHER|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
214482524|NCT04130789|OTHER|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
214482525|NCT04335682|DRUG|Darolutamide|Patients randomized to darolutamide.
214482526|NCT04335682|DRUG|Enzalutamide|Patients randomized to enzalutamide.
214482527|NCT05257356|BEHAVIORAL|psychophysical tasks|"Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.~Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits."
214482528|NCT03076021|DRUG|Isotretinoin|Drug interaction study
215061099|NCT03531164|OTHER|kAYAK ERGOMETER GROUP|Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.
214316220|NCT00093457|DRUG|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
214316221|NCT00994331|PROCEDURE|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
214316222|NCT03800719|BEHAVIORAL|AWARD advice|"At baseline, brief smoking cessation advice following AWARD model will be delivered to subjects within about 2 to 5 minutes:~* Ask about smoking history and habit~* Warn about the risks of smoking using a leaflet~* Advise to quit smoking as soon as possible and use nicotine replacement therapy (NRT) or SC services~* Refer subjects to free smoking cessation services in Hong Kong if they agree~* Do it again: smokers who have tried to quit but relapsed will be encouraged to quit again and those who have reduced smoking will be advised to further reduce or quit smoking"
214316223|NCT03800719|BEHAVIORAL|Health warning leaflet|At baseline, an A5-sized leaflet will be given to subjects, which includes information about risks of smoking, pictures of smoking-related diseases, and smoking cessation services provided in Hong Kong.
214482529|NCT03076021|DRUG|dextromethorphan|Drug interaction study
214482530|NCT06681233|DEVICE|Comparison of HyperSight CBCT imaging to conventional CBCT imaging.|Participants will receive their daily radiation treatment on a radiation therapy system equipped with HyperSight CBCT imaging. For at least 1 and up to 3 treatment fractions, participants will receive their daily radiation treatment on a system equipped with conventional CBCT imaging.
214482531|NCT02311959|PROCEDURE|Nipple sparing mastectomy|"Standardized surgical procedure by :~* Nipple sparing mastectomy with nipple core histopathology.~* Immediate breast reconstruction (flap and/or implant).~* +/- lymph node evaluation (sentinel node procedure or axillary dissection)."
214671567|NCT01237470|PROCEDURE|Desarda technique|no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
214671568|NCT01237470|PROCEDURE|Lichtenstein technique|hernioplasty with the usage of plain polypropylene mesh
214316224|NCT03800719|BEHAVIORAL|Active referral to smoking cessation (SC) services|At baseline, subjects will be encouraged to seek smoking cessation services in Hong Kong. If subjects agree, their contact information will be sent to the preferred service providers for a quick appointment and follow-up.
214316225|NCT03800719|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of pre-set 26 messages will be sent to subjects through WhatsApp 12 weeks after baseline to remind the quit date and to encourage abstinence. Messages are tailored based on subjects' sociodemographic characteristics and smoking habit following Social Cognitive Theory and Transtheoretical Model. Messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. The schedule will be adjusted according to the quit date and also smokers' requests. The format of regular messages will mainly be text-based but also include pictures, animations and videos.
214316226|NCT03800719|BEHAVIORAL|Psychosocial support and referral to SC services through IM|Personalized interactive text or voice conversation will be provided by trained smoking cessation advisors through WhatsApp for 3 months after baseline. Advisors will periodically proactively send messages to subjects to initiate the conversation (e.g. asking recent progress of smoking cessation) and deliver evidence-based advice. Advisors will also actively refer subjects, if they have expressed the need, to smoking cessation services providers. A standard operation algorithm for advisors used in the pilot feasibility trial will be modified for the use.
214316227|NCT03800719|BEHAVIORAL|Message on general health delivered by short message service (SMS)|After baseline, regular messages using SMS will be sent to subjects with similar frequency to Intervention group. The messages include information on general health and reminders on follow-up surveys and biochemical validation for quitting.
214316228|NCT02852265|DRUG|Etonogestrel contraceptive implant|Place nexplanon
214316229|NCT04050111|BIOLOGICAL|Stromal-vascular fraction|Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
214316230|NCT03073278|RADIATION|Stereotactic Body Radiotherapy|Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
214316231|NCT03348696|DRUG|Dexamethasone tapering dose|dexamethasone standard of care pre-medication + dexamethasone tapering dose
214316232|NCT03348696|DRUG|Dexamethasone physician choice|Dexamethasone standard of care pre-medication + dexamethasone physician choice
214316233|NCT03957538|BEHAVIORAL|Virtual reality angiogram experience video|The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
214316234|NCT06103006|OTHER|Telerehabilitation|The structured telerehabilitation program focused on 4 specific objectives: breathing, stretching, posture, and stability. The duration was between 20-30 minutes. Exercises involving the major muscle groups (upper, lower extremity, and trunk muscle groups) were applied by the physiotherapists. Strengthening and stretching sets and repetitions were started with 1 set of 8-15 reps (progress to \>1 set).
214316235|NCT05313165|DEVICE|LimFlow Stent Graft System|Creation of an arteriovenous fistula in the desired limb location
214316236|NCT05357872|DEVICE|deep anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
214316237|NCT05357872|DEVICE|light anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
214316238|NCT03086785|DRUG|Apatinib|apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
214316239|NCT02340234|DRUG|Lebrikizumab|Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
214316240|NCT02340234|DRUG|Placebo|Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
214316241|NCT02340234|DRUG|TCS Cream|TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
214316242|NCT02187302|DRUG|CRLX101|
214316243|NCT02187302|DRUG|Bevacizumab|
214316244|NCT02187302|DRUG|Standard of Care (Investigator Choice)|
214316245|NCT04619056|DRUG|CEB-01 membrane loaded with SN-38|CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
214316246|NCT06132022|OTHER|Mandala|Mandala work is one of the non-pharmacological approaches and is used to support patients and caregivers in various diseases. Mandala is a method that anyone can apply based on coloring a circular shape.
214316247|NCT06132022|OTHER|Routine care|The clinic's routine information will be given to the caregivers of the control group.
214316248|NCT05660694|DRUG|Triamcinolone|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
214316249|NCT05660694|DRUG|Pentoxifylline with Vitamin E|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
214316250|NCT00202618|DRUG|Valsartan|
214316251|NCT00202618|DRUG|Amlodipine|
214316252|NCT03137693|OTHER|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
214316253|NCT03137693|PROCEDURE|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
214671569|NCT03946566|PROCEDURE|Acupuncture|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
215061100|NCT03531164|OTHER|CONTROL GROUP|Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
215061101|NCT01270932|DRUG|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
214316254|NCT00422331|DRUG|Lithium Carbonate Capsule|
214316255|NCT01389440|DRUG|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
214316256|NCT02174835|DRUG|AVP-786|
214316257|NCT02174835|DRUG|AVP-923|
214316258|NCT01110746|DRUG|Viaject 7|100IU/mL administered subcutaneously
214316259|NCT01110746|DRUG|LISPRO|100IU/mL administered subcutaneously
214316260|NCT01895673|OTHER|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
214316261|NCT03588637|OTHER|No intervention|No intervention
214316262|NCT03144180|DEVICE|Q-cup|This technology is a different way of collecting umbilical cord blood.
214316263|NCT04976036|DRUG|Nintedanib|150 mg oral nintedanib soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
214482532|NCT05227352|BEHAVIORAL|Biophilic design experience|Recharge Rooms are immersive, biophilic private spaces featuring multisensory input that is inspired by nature.
214482533|NCT05254314|DRUG|Semaglutide Pen Injector 2.4mg weekly|Once weekly subcutaneous injection
214482534|NCT05254314|OTHER|Placebo|Once weekly subcutaneous injection
214482535|NCT06676371|PROCEDURE|Conventional hemiarch replacement|Conventional open hemiarch replacement
214482536|NCT06676371|PROCEDURE|E-vita® Open Neo; Artivion|E-vita® Open Neo is a hybrid stent graft system for aortic arch and descending thoracic aorta repair with Frozen Elephant Trunk Technique.
214482537|NCT06676371|PROCEDURE|Thoraflex Hybrid; Terumo|The Thoraflex Hybrid is a device system designed to repair a weakened and bulging section (aneurysm) and/or a tear in the lining (dissection) of the aorta behind the heart (aortic arch). The system includes a polyester graft section that reinforces a weakened section of the blood vessel, a connected stented section (nitinol wire frame on polyester graft material) that holds the artery open, and a delivery catheter that is used to place the device. The polyester graft and stented sections are coated with a protein substance taken from animal body parts (gelatin) to seal the implant and prevent blood from leaking out.
214482538|NCT03856528|OTHER|collection of patient data|Patient data will be obtained using digital patients records systems. The following data will be assessed: Demographics and baseline patient characteristics (e.g., gender, age, hospital admission and discharge dates), diagnoses, comorbidities (history of meningitis and/or encephalitis, epileptic disorders, remote stroke, remote intracranial bleeding, remote autoimmune disease, neurodegenerative disorders), laboratory features (blood cultures, lumbar puncture), features of neuroimaging (e.g., time admission-to-CT), therapeutic features (incl. time admission-to-treatment), Patients' outcome measures (Glasgow Outcome Score)
214918758|NCT05478135|DEVICE|NAVIFY Oncology Hub|NAVIFY Oncology Hub is a platform that aggregates and organizes disparate data into an intuitive, longitudinal view of the patient's cancer care journey. The platform is designed to optimize and support oncology workflows and decision-making by providing quick access to the most relevant data in one place, so that providers can make decisions more efficiently and collaborate more seamlessly.
214918759|NCT03524235|RADIATION|Total Body Irradiation|Pre-Transplantation Total Body Irradiation
214316264|NCT04976036|DRUG|Placebo|150 mg oral placebo soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
214316265|NCT04076774|DEVICE|Wondaleaf Female Condom|Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
214316266|NCT04076774|DEVICE|FC2 Female Condom|FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
214918760|NCT03524235|PROCEDURE|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation
214918761|NCT03524235|BIOLOGICAL|CD56-Enriched Donor Lymphocyte Infusion|CD56-Enriched Donor Lymphocyte Infusion
214918762|NCT03524235|DRUG|Bendamustine|Pre-Transplantation Bendamustine
214918763|NCT03524235|DRUG|Fludarabine|Pre-Transplantation Fludarabine
215061102|NCT01370941|DIETARY_SUPPLEMENT|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
215061103|NCT01370941|DIETARY_SUPPLEMENT|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
215061104|NCT06446375|OTHER|exercise|FIFA 11+ KIDS Training Protocol consists of seven different exercises: three for unilateral, dynamic stability of the lower limbs (hopping, jumping and landing); three for whole body and trunk strength/stability; and one exercise on falling technique.
215061105|NCT06446375|OTHER|Regular daily activity|Regular physical activity
215061106|NCT05724862|DEVICE|Needle-less jet anaesthesia|Infiltration anesthesia without needle depending on injection pressure
215061107|NCT05724862|DEVICE|Conventional Injection Anesthesia|Regular Infiltration local anesthesia
214918764|NCT03524235|DRUG|Rituximab|Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)
214918765|NCT00693238|RADIATION|Low Risk Proton Radiation|
214918766|NCT00693238|RADIATION|Intermediate Risk Proton Radiation|
214918767|NCT01028014|DRUG|Pseudoephedrine|Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
214918768|NCT01028014|DRUG|Tamsulosin|Tamsulosin 0.4mg by mouth daily for 2 weeks
214316267|NCT03891654|DIAGNOSTIC_TEST|Dynamic Contrast Enhanced Computed Tomography|Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
214316268|NCT01466946|BEHAVIORAL|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin \& Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
214316269|NCT04732975|DEVICE|CardioFlux|Non-invasive screening for ACS
214316270|NCT03062475|BEHAVIORAL|lifestyle intervention with dietary and exercise recommendation|"With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.~With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy."
214316271|NCT02351869|DRUG|Nitrous Oxide|
214316272|NCT02351869|DRUG|Midazolam|
214316273|NCT02479711|OTHER|composite restoration|The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.
214316274|NCT02479711|OTHER|glass ionomer cement|The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
214316275|NCT03548766|BIOLOGICAL|Homologous Blood Transfusion|Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
214316276|NCT03548766|BIOLOGICAL|Autologous Blood Transfusion|Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
214316277|NCT06163508|DRUG|Q-Cells®|Long term observational study of patients who received 1 of 3 different amounts of Q-Cells®.
214316278|NCT06466096|OTHER|no intervention|this is an observation study, no intervention
214316279|NCT01161199|PROCEDURE|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
214316280|NCT02410720|OTHER|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
214316281|NCT02410720|OTHER|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
214316282|NCT02410720|OTHER|Explanation of paper and application instructions|The research fellow will explain instructions to patients
214316283|NCT02410720|OTHER|Picoprep solution|
214316284|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
214316285|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
214316286|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
214316287|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
214316288|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
214316289|NCT01504724|DRUG|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
214316290|NCT01838005|BEHAVIORAL|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
214316291|NCT00367068|DRUG|baclofen, intrathecal|
214316292|NCT00367068|DEVICE|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
214316293|NCT02547129|DEVICE|Static Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
214316294|NCT02547129|DEVICE|Articulating Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
214918769|NCT01028014|DRUG|Imipramine|Imipramine 25mg daily by mouth for 2 weeks
214918770|NCT01028014|DRUG|Cyclobenzaprine|Cyclobenzaprine 10mg daily by mouth for 2 weeks
214918771|NCT01028014|DRUG|Lactose capsule|Lactose capsule 1 by mouth daily for 2 weeks
214918772|NCT01028014|DRUG|Solifenacin|Solifenacin 5mg by mouth daily for 2 weeks
214918773|NCT01398618|DRUG|4-month rifampin vs. 9-month isoniazid|In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
214316295|NCT03925324|BIOLOGICAL|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg
214316296|NCT03925324|OTHER|Placebo|1.5 mL/kg Lactated Ringer's Solution
214918774|NCT00089063|BIOLOGICAL|tyrosinase peptide|Given SC
214918775|NCT00089063|BIOLOGICAL|gp100 antigen|Given SC
214918776|NCT00089063|BIOLOGICAL|MART-1 antigen|Given SC
214918777|NCT00089063|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
214918778|NCT00089063|DRUG|Montanide ISA 51 VG|Given SC
214918779|NCT00089063|BIOLOGICAL|sargramostim|Given SC
214918780|NCT00089063|OTHER|laboratory biomarker analysis|Correlative studies
214918781|NCT01539330|DRUG|Voriconazole|"At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po"
214918782|NCT01539330|OTHER|microdialysis|long-term microdialysis over study days 1-4 (visits 1-7)
214918783|NCT03455101|OTHER|There is no intervention.|There is no intervention.
214918784|NCT03999164|DRUG|[18F]DPA-714 Positron Emission Tomography Scan|All patients will undergo a \[18F\]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
214316297|NCT00180024|DRUG|irbesartan (drug)|
214316298|NCT03826758|OTHER|E-DYNAMIC Clinical Decision Support|Clinical decision support system
214316299|NCT02170610|DRUG|BIBR 1048 MS|
214316300|NCT02170610|DRUG|Pantoprazole|
214316301|NCT00753116|DEVICE|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
214316302|NCT04933266|PROCEDURE|Subpectoral plexus block (low dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 10ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (5ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 5ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
214316303|NCT04933266|PROCEDURE|Subpectoral plexus block (High dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 20ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (10ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 10ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
214316304|NCT04227236|OTHER|E-based virtual facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using an e-based virtual trainer on a computer. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
214316305|NCT04227236|OTHER|In-person facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using the standard in-person training method. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
214316306|NCT05461573|DRUG|Drospirenone|LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.
214918785|NCT03789149|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
214918786|NCT00331669|PROCEDURE|deep brain stimulation|high frequency stimulation
214918787|NCT04408742|OTHER|pain|"Lower abdominal and low back pain was questioned. Pain intensity was evaluated with a 0 to 10 cm visual analog scale (VAS): 0 indicated no pain and 10 indicated the worst imaginable pain \[18\]. Pain that developed during the activity was also questioned and stated as pain+ activity. A higher score indicates a more severe pain."
214918788|NCT04408742|OTHER|fatigue|"Fatigue was assessed by the Fatigue Severity Scale (FSS). This is a 9-item questionnaire that assesses the effect of fatigue on daily living. Each item is a statement on fatigue that the subject rates from 1 completely disagree to 7 completely agree. A score of 4 or higher generally indicates severe fatigue."
214918789|NCT04408742|OTHER|anxiety|"The Spielberger State Trait Anxiety Inventory (STAI) was used to evaluate levels of anxiety. The state part of the STAI is a 20-item self-report inventory designed to measure state anxiety (current feelings of apprehension, worry, etc.). The STAI state scale is scored on four levels of anxiety intensity from 1 not at all to 4 very much and with a total score between 20 and 80. A higher total score indicates a more severe anxiety level."
214918790|NCT04408742|OTHER|position sense|Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
214316307|NCT02530983|OTHER|Mayo Clinic Upper Digestive Disease Survey on Paper|Mayo Clinic patients will be asked to complete the Mayo Clinic Upper Digestive Disease Survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
214316308|NCT02530983|OTHER|Upper Digestive Disease (UDD Monitor) App|"Mayo Clinic and non Mayo Clinic patients can participate by loading the app through the app store. Patient consent will be completed in the app. Patients will be asked to complete questionnaires at their 1.5 month surgical or diagnosis follow up and then every three months for 1 year after their surgery or diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime or as long as they want to participate.~for iOS: https://apps.apple.com/us/app/upper-digestive-disease/id6448756724 for Android: https://play.google.com/store/apps/details?id=com.mayoclinic.uddmobile\&pli=1"
214316309|NCT00231348|DRUG|Nefazodone|
214316310|NCT05862766|DRUG|Isatuximab|The dose will consist of isatuximab 10 mg/kg actual body weight given weekly for the first 4 weeks, followed by 10 mg/kg biweekly for an additional 4 doses. Isatuximab is a clear, colorless to slightly yellow solution. It is supplied as 100 mg/5 mL or 500 mg/25 mL single-dose vials.
214316311|NCT05862766|PROCEDURE|bone marrow biopsy|Bone marrow biopsy at the time of lung transplantation and at approximately 1 month following completion of therapy. Initial bone marrow biopsy to be performed during the lung transplant operation and to be collected from the sternum by the operating surgeon. Follow-up bone marrow biopsy to be completed by credentialed hematologist during a regularly scheduled follow-up bronchoscopy with standard procedural anesthesia sedation.
214316312|NCT05383768|OTHER|preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C|"Intervention 1: restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 2: Restoration with five time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 3: Restoration with ten time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020)."
214671570|NCT04138667|OTHER|complex decongestive therapy|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
214918791|NCT04408742|OTHER|balance|The Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used to measure limits of stability. The participants were asked to position themselves in a comfortable position on the platform and their foot position coordinate was recorded. The participants were asked to complete as quickly as possible the directional tasks displayed on a screen, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s. A total score was recorded. The higher the total score, the better the ability of the subjects to transfer the center of gravity.
214955182|NCT02333994|DEVICE|GROUP A education programme as well as balance training exercises|Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
214316313|NCT02596594|DEVICE|fetal nutrition port system|Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
214316314|NCT01952756|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
214316315|NCT01952756|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
214316316|NCT05601206|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
214316317|NCT05601206|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
214316318|NCT02059850|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
214316319|NCT02059850|DRUG|Cyclophosphamide|Given IV
214316320|NCT02059850|OTHER|Laboratory Biomarker Analysis|Correlative studies
214316321|NCT00289809|DRUG|combination of TLC D-99 and Ifosfamide|"* TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~* Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
214316322|NCT00628433|DRUG|Placebo|Placebo
214316323|NCT00628433|DRUG|HE3286|daily for 28 days
214316324|NCT00716911|DRUG|ganciclovir|
214316325|NCT00716911|GENETIC|polymerase chain reaction|
214316326|NCT00716911|OTHER|flow cytometry|
214316327|NCT00716911|OTHER|immunologic technique|
214671571|NCT05824767|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Giapreza) was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
214918792|NCT04408742|OTHER|dual task performance|"The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases."
214316328|NCT00716911|PROCEDURE|allogeneic bone marrow transplantation|
214671572|NCT04726306|DIAGNOSTIC_TEST|Otic Barotrauma Grading System|Otic Barotrauma Grading System Placards for TEED Score and the OGS grading system.
214918793|NCT02701530|BEHAVIORAL|Targeted smoking cessation|Smoking cessation program developed in cooperation with and aimed at smokers with low education.
214918794|NCT06576557|OTHER|KNEE-DEeP intervention- Knowledge translation and exercise for early degenerative knee pain|The intervention for health care professionals (GPs and physiotherapists) will consist of training and education. The two-hour educational workshop for GPs will focus on diagnosis and management of patients with early degenerative knee pain, and enhancing communication skills. Training for physiotherapists will focus on delivery of a 'best practice' session. The patient participant intervention will consist of an 'enhanced consultation' delivered by the GP. This will involve a physical exam, key educational messages, written information and a treatment plan. Patients will receive a single session of physiotherapy within 2 weeks of referral from their GP. This 'best practice' session will focus on self-management skills, targeted patient education, goal setting, action planning and exercise prescription.
214316329|NCT00716911|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214316330|NCT00716911|PROCEDURE|assessment of therapy complications|
214316331|NCT00716911|PROCEDURE|peripheral blood stem cell transplantation|
214316332|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Other Week dosing
214316333|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
214316334|NCT03873389|DRUG|Ocrelizumab|Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
214316335|NCT05106855|RADIATION|Low Laser Radiation|One group will receive laser application to check if there is acceleration of healing.
214316336|NCT05106855|OTHER|Changing the implant surface|Changing the treatment surface of the dental implant to see if osseointegration occurs more quickly.
214316337|NCT05106855|RADIATION|Low Laser Radiation off|This group will receive laser application off.
214316338|NCT05106855|PROCEDURE|Implant placement immediately after tooth extraction|When the last alternative is tooth extraction, this will be done, and in the same surgical intervention the dental implant will be placed.
214316339|NCT05106855|PROCEDURE|Installing the dental crown with early loading|The installation of the dental crowns will be performed in a period of 6 to 8 weeks, after the dental implant has been installed.
214316340|NCT03830554|OTHER|Organic Atlas cedar wood essential oil (Cedrus Atantica)|At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
214316341|NCT00459836|DRUG|PR-104|
214316342|NCT00459836|DRUG|docetaxel|
214316343|NCT00459836|DRUG|gemcitabine hydrochloride|
214316344|NCT00459836|OTHER|laboratory biomarker analysis|
214316345|NCT00459836|OTHER|pharmacological study|
214316346|NCT03282292|PROCEDURE|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
214316347|NCT01144507|PROCEDURE|Abdominal Ultrasound|To establish eligibility and/or markers regarding echo pattern types.
214316348|NCT01144507|OTHER|Sample collection procedures|Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
214316349|NCT02293070|OTHER|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
214316350|NCT02293070|PROCEDURE|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
214316351|NCT00641095|BIOLOGICAL|rituximab|concentrate for solution for infusion
214316352|NCT00641095|DRUG|Cyclophosphamide|Tablets
214316353|NCT00641095|DRUG|Fludarabine|Film coated tablet
214316354|NCT03957512|PROCEDURE|Heart surgery|All invasive procedures
214316355|NCT00669812|DRUG|carmustine|
214316356|NCT00669812|DRUG|cyclophosphamide|
214316357|NCT00669812|DRUG|cytarabine|
214316358|NCT00669812|DRUG|doxorubicin hydrochloride|
214316359|NCT00669812|DRUG|epirubicin hydrochloride|
214316360|NCT00669812|DRUG|etoposide|
214316361|NCT00669812|DRUG|ifosfamide|
214316362|NCT00669812|DRUG|melphalan|
214316363|NCT00669812|DRUG|methotrexate|
214316364|NCT00669812|DRUG|prednisolone|
214316365|NCT00669812|DRUG|vincristine sulfate|
214316366|NCT00669812|PROCEDURE|autologous hematopoietic stem cell transplantation|
214316367|NCT00669812|PROCEDURE|biopsy|
214316368|NCT00669812|PROCEDURE|peripheral blood stem cell transplantation|
214316369|NCT00897065|GENETIC|microarray analysis|
214671573|NCT03983941|DRUG|Ropivacaine injection|Total dose not to exceed 3 mg/kg of ropivacaine.
214671574|NCT03022422|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
214316370|NCT00897065|GENETIC|polymerase chain reaction|
214316371|NCT00897065|GENETIC|protein expression analysis|
214316372|NCT00897065|OTHER|diagnostic laboratory biomarker analysis|
214316373|NCT00897065|OTHER|fluorescent antibody technique|
214316374|NCT00897065|OTHER|immunohistochemistry staining method|
214316375|NCT00897065|OTHER|immunologic technique|
214316376|NCT06352450|DIAGNOSTIC_TEST|Active isolated stretching (AIS)|Active isolated stretching (AIS) is a technique that involves stretching specific muscles or muscle groups while actively engaging the opposing muscles. It typically involves holding a stretch for 1-2 seconds and then releasing. This method aims to improve flexibility, increase range of motion, and enhance muscle function.
214316377|NCT06352450|DIAGNOSTIC_TEST|Myofascial release (MFR)|Myofascial release (MFR) is a technique used to release tension and tightness in the fascia, which is the connective tissue that surrounds and supports muscles and organs. It involves applying gentle, sustained pressure to specific areas of the body to help relax the fascia and alleviate restrictions. MFR aims to improve mobility, reduce pain, and enhance overall movement and function.
214316378|NCT02159521|DEVICE|EkoSonic® Endovascular System|
214316379|NCT02159521|BIOLOGICAL|Alteplase|Recombinant tissue plasminogen activator
214316380|NCT05401955|OTHER|Physical exercise|An adapted physical exercise protocol
214316381|NCT04504383|DRUG|PN-943|Administered by the oral route BID for the duration of the study.
214316382|NCT04504383|DRUG|Placebo|Administered by the oral route BID for 12 weeks.
214316383|NCT00916175|DIETARY_SUPPLEMENT|P1&P2|"* First period (4 weeks) intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from AG\&CC group, 4 weeks intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
214316384|NCT00916175|DIETARY_SUPPLEMENT|P1&CC|"* First period (4 weeks) intake food product P1\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from AG\&P2 group, 4 weeks intake food product P1\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
214316385|NCT00916175|DIETARY_SUPPLEMENT|AG&P2|"* First period (4 weeks) intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P1\&CC group, 4 weeks intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
214316386|NCT00916175|DIETARY_SUPPLEMENT|AG&CC|"* First period (4 weeks) intake food product AG\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from P1\&P2 group, 4 weeks intake food product AG\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
214316387|NCT00916175|DIETARY_SUPPLEMENT|TA (concentrated 5:1 aloe vera gel)|"* First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
214482539|NCT06770335|BEHAVIORAL|THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Full intervention|A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm include the full intervention.
214482540|NCT06770335|BEHAVIORAL|THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Cognitive rehabilitation only|A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm includes the cognitive rehabilitation only.
214671575|NCT03022422|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
214671576|NCT01282814|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
214918795|NCT04446455|OTHER|InVEST: Increased Velocity Exercise Specific to Task|Functional Power Training
214918796|NCT04446455|OTHER|TAPAT: Tonic and Phasic Alertness Training|Computerized cognitive training.
214918797|NCT04835090|OTHER|screening test|using three screening tools
214918798|NCT02423343|DRUG|Galunisertib|Administered orally
214316388|NCT00916175|DIETARY_SUPPLEMENT|P3|"* First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
214316389|NCT06031974|BEHAVIORAL|DISCO Intervention|optimal medical management in accordance with European Society of Cardiology recommendations + dietary intervention based on Dietary Approaches to Stop Hypertension (DASH diet) + strict monitoring of eating and lifestyle behaviors
214918799|NCT02423343|DRUG|Nivolumab|Administered IV
214918800|NCT00177242|DRUG|Gefitinib|
214918801|NCT01180751|RADIATION|[18F]-Fluorodeoxyglucose|With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
214316390|NCT04892238|DIAGNOSTIC_TEST|13-C urea breath test|"Standard urea breath test (UBT) (HELICARB, LLC ISOCARB, reg. cert. #РЗН 2016/3773 issued by Roszdravnadzor on 29.02.2016) with 13C-carbamide of 99% purity used for the study.~Samples of exhaled air obtained before and after 20 minutes after 50 mg 13C-urea intake are analysed for 13C/12C isotope ratio with the use of infrared spectrometer IRIS.Doc (Kibion, Sweden). Delta over baseline (δ) of 13C / 12C is calculated based on the results of the initial and second samples, the results were shown in ppm (‰). The results of the test is negative if δ was \<4.0‰; test results with δ ≥4.0‰ are considered positive."
214316391|NCT03712410|BEHAVIORAL|PISCES|The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
214316392|NCT01308307|DEVICE|photorefraction|photorefraction is a name of device.
214316393|NCT02048020|DRUG|paclitaxel|Given IV
214316394|NCT02048020|DRUG|carboplatin|Given IV
214316395|NCT02048020|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
214316396|NCT02048020|PROCEDURE|quality-of-life assessment|Ancillary studies
214316397|NCT02452151|DRUG|Infliximab-Biosimilar|
214316398|NCT02452151|DRUG|Infliximab-Innovator|
214316399|NCT05920434|OTHER|randomized controlled study|randomized controlled study,no drugs or devices were administered to the participants.
214316400|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) in water|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.
214316401|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) within meal|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.
214316402|NCT06381869|DIETARY_SUPPLEMENT|Whey protein in water|After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.
214482541|NCT06412757|DRUG|Silexan|Participants in the Silexan arm will take two over-encapsulated capsules, each containing 80 mg Silexan, daily orally in the morning in addition to their usual medications. No modifications of allocated interventions will be made for any trial participants; if appropriate (i.e following the emergence of adverse events) participants will be withdrawn from the intervention.
214482542|NCT06412757|OTHER|Placebo|Participants in the placebo arm will take two capsules containing an inert placebo daily orally in the morning in addition to their usual medications. The placebo capsules will contain a sub-therapeutic amount of lavender oil to mimic the odor of the experimental drug (Silexan).
214482543|NCT06014580|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
214482544|NCT04825288|BIOLOGICAL|XB2001 or Placebo|XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
214482545|NCT06621732|PROCEDURE|cutanous biopsy and blood sample|cutanous biopsy and blood sample
214671577|NCT01282814|DRUG|Effexor® XR|150 mg Extended-Release Capsule
214918802|NCT05872555|DRUG|Psychiatric Drugs|Receiving any Antipsychotic, Benzodiazepine, antidepressant, mood stabilizer
214918803|NCT02016105|DRUG|GP2017 Adalimumab|
214482546|NCT06868576|DRUG|Dydrogesterone Oral Tablet|Dydrogesterone 20mg tablets daily in PPOS protocol in ovarian stimulation starting from day 2 or 3 of the menstrual cycle until the triggering day
214918804|NCT02016105|DRUG|Humira ® Adalimumab|
214918805|NCT04635995|BIOLOGICAL|LVGN7409|IV infusion once every 3 weeks (Q3W).
214955183|NCT02333994|OTHER|GROUP B on-platform training|on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
214316403|NCT06381869|DIETARY_SUPPLEMENT|Whey protein within meal|After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.
214316404|NCT00122941|DIETARY_SUPPLEMENT|multiple micronutrients|
214316405|NCT04264468|COMBINATION_PRODUCT|neoadjuvant chemotherapy|This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
214482547|NCT06868576|DRUG|Cetrorelix (Cetrotide)|This will be the conventional antagonist in ovarian stimulation given from day 6 of the menstrual cycle until the triggering day
214482548|NCT06867874|PROCEDURE|Blood sample|Blood sample
214482549|NCT06870240|DRUG|Neurosteroid enantiomer|A non-natural synthetic neurosteroid enantiomer considered a new chemical entity
214671578|NCT01784471|DEVICE|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
214671579|NCT00957372|DRUG|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
214671580|NCT00957372|DRUG|placebo (Part I)|once daily placebo comparator
214955184|NCT02117609|DIETARY_SUPPLEMENT|New DELICAL formula|3 months with the option of continuing until 6 months.
214955185|NCT02117609|DIETARY_SUPPLEMENT|Standard DELICAL formula|3 months with the option of continuing until 6 months.
214316406|NCT03876314|BEHAVIORAL|Physical Activity Condition|Subjects will attend virtual group exercise sessions 3x/week for 1 year. Each subject will be encouraged to walk at a moderate intensity (target heart rate (HR)= 40-59% HR reserve) dependent on resting HR and age. Subjects will perform aerobic exercise on their own and resistance exercises will be completed in virtual exercise sessions with an instructor 1 hour/day for 3 days/week for 1 year. At the exercise sessions, these participants will be asked to record measures of the exercises completed and may be asked to provide measures of heart rate (assessed by palpation for 20-seconds) and rate of perceived exertion (RPE). They will be asked to submit exercise logs providing this information. Data from exercise logs and exercise specialist records will be reviewed for evidence of progression, consistent attainment of moderate intensity, and with respect to the prescribed duration of the aerobic and strength training components.
214316407|NCT06063148|DEVICE|Enrolled Participant|Participant will undergo at most 10 SpO2 measurements paired with at most 10 routine blood gas samples.
214316408|NCT00122343|DRUG|ridaforolimus|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
214316409|NCT01304745|BEHAVIORAL|Physical training in group|Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.
214316410|NCT01304745|BEHAVIORAL|Educational and counseling in group|Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
214316411|NCT01750008|PROCEDURE|Global Fibroid Ablation|
214316412|NCT01750008|PROCEDURE|Myomectomy|
214316413|NCT06541288|DIAGNOSTIC_TEST|AI Prediction Model|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer. Further pelvic lymph node metastasis status was determined by artificial intelligence multimodal fusion prediction modeling
214482550|NCT06874140|DRUG|Chuanhong Zhongfeng capsule|Basic treatment (refer to China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018) + Chuanhong Zhongfeng capsule
214482551|NCT06361238|DRUG|Liraglutide injection|Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
214482552|NCT06361238|DRUG|Placebo injection|Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
214482553|NCT04298216|DIAGNOSTIC_TEST|Ultrasound Analysis of Inferior Vena Cavae (IVC)|Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
214482554|NCT05191862|DRUG|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
214482555|NCT05191862|DRUG|PMR 135 mg|Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
214482556|NCT04817969|DEVICE|Zimmer Biomet Persona Ti-Nidium Total Knee System|Primary Knee Total Arthroplasty
214482557|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (10ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
215061108|NCT04012502|OTHER|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
214316414|NCT06541288|DIAGNOSTIC_TEST|Conventional Imageing Assessment|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer.Further pelvic MRI images are read by a specialized imaging physician to determine pelvic lymph node status.
214316415|NCT03517527|BEHAVIORAL|Exercise|
214316416|NCT04231786|PROCEDURE|Breast ultrasonography findings|Breast ultrasonography findings in patients over 30 years of age diagnosed with polycystic ovary syndrome.
214316417|NCT03519568|BIOLOGICAL|EV71 (inoculation vaccine)|EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
214316418|NCT03316885|DEVICE|Clareon® IOL|Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.
214316419|NCT03316885|PROCEDURE|Cataract Surgery|Routine small incision cataract surgery with unilateral IOL implantation
214316420|NCT00230698|DRUG|topiramate|
214316421|NCT01589081|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
214482558|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)
214482559|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)|2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)
214482560|NCT06871384|DIETARY_SUPPLEMENT|Nonalcoholic red wine group (Intervention group)|Mediteranean diet + nonalcoholic red wine (300 mL wine/day, equivalent to a daily dose of 150 mg red wine polyphenols/day, during meals)
215061109|NCT04012502|OTHER|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
214482561|NCT06871384|DIETARY_SUPPLEMENT|Drinking water group (Control group)|Mediterranean diet + drinking water (300 mL/day, during meals)
214482562|NCT05766631|BEHAVIORAL|DynamiCare Health|"Participants earn incentives for:~1. CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~2. Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~3. Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~4. The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment."
214482563|NCT05766631|DRUG|Methadone Treatment-As-Usual|Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
214316422|NCT01589081|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
214482564|NCT06875284|BEHAVIORAL|Sexual Communication and Consent (SCC)|SCC combines universal classroom instruction with tailored web-based content. Based on sociodemographic characteristics and prior sexual assault experiences, Cadets receive tailored content that addresses either primary victimization prevention, revictimization prevention, or healthy relationships and bystander intervention promotion.
214482565|NCT06875284|BEHAVIORAL|Alcohol eCHECKUP TO GO (eCHECKUP TO GO)|eCHECKUP TO GO is a personalized, online intervention designed to reduce cognitive risk factors for alcohol misuse. eCHECKUP TO GO is brief, self-guided, and provides individualized feedback based on a user's self-reported alcohol use patterns and consequences.
214482566|NCT06875284|BEHAVIORAL|Training as usual (TAU)|TAU involves universal classroom instruction focused on developing knowledge, attitudes, and skills to promote personal resilience, increase potential for success, and develop healthy and rewarding personal relationships.
214316423|NCT01262482|DRUG|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
214316424|NCT01262482|DRUG|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
214316425|NCT01102413|DRUG|Monofer|Infusion or injections
214316426|NCT01102413|DRUG|Iron Sulphate|Oral intake
214316427|NCT06086080|OTHER|Standard care|Bracing and physical therapy
214316428|NCT06086080|OTHER|Taping|The patient is treated with tape in special configuration (McConell modified) for the patella + standard care
214316429|NCT06086080|DEVICE|Sham taping|Taping with no treatment disposition
214316430|NCT03309683|DEVICE|Olympus Quick Clip Pro - Single Use Repositionable Clips|A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
214482567|NCT03124303|PROCEDURE|High Density-Electroencephalogram|EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium
214482568|NCT03124303|PROCEDURE|Magnetic Resonance Imaging|MRI scan of brain
214482569|NCT03124303|PROCEDURE|Blood specimen collection|Blood will be collected from participants
214482570|NCT03124303|DIAGNOSTIC_TEST|Pupillometry|A pupillometer is a device that measures the size of the pupils.
214671581|NCT00957372|DRUG|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
214316431|NCT01335958|DRUG|DMUC5754A|Escalating intravenous dose
214316432|NCT02271633|DIETARY_SUPPLEMENT|Sodium nitrate|
214316433|NCT02271633|DIETARY_SUPPLEMENT|Beetroot juice|
214316434|NCT02271633|DIETARY_SUPPLEMENT|Spinach|
214316435|NCT02271633|DIETARY_SUPPLEMENT|Rocket salad|
214671582|NCT01524289|DRUG|Anacetrapib|One oral tablet, orally once daily for 52 weeks
214671583|NCT01524289|DRUG|Placebo|One oral tablet once daily for 52 weeks
214671584|NCT02104180|DEVICE|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
214316436|NCT01897675|PROCEDURE|Incision and Drainage with packing (wick) placement|
214316437|NCT01897675|PROCEDURE|Abscess drainage with loop placement|
214316438|NCT03216850|DEVICE|Sublingual microcirculation assessment|Non-invasive investigation of the endothelial glycocalyx in the sublingual microcirculation.
214316439|NCT01814735|OTHER|Brown rice|
214316440|NCT01814735|OTHER|White rice|
214316441|NCT02948491|OTHER|Music therapy|Song that the mother sings to the child before birth, recording of the mother's voice.
214316442|NCT05926167|DIAGNOSTIC_TEST|blood tests drawn days 1, 8, 22 and 90 of the study|Blood tests related to Factor VIII activity that are not a part of standard of care
214316443|NCT05568472|OTHER|Best Practice|Standard of care hormone therapy and standard visit with clinician
214316444|NCT05568472|PROCEDURE|Biospecimen Collection|Undergo correlative studies
214316445|NCT05568472|PROCEDURE|Endocrine Drug Therapy|Undergo endocrine therapy
214316446|NCT05568472|BEHAVIORAL|Health Education|Receive list of websites
214316447|NCT05568472|OTHER|Questionnaire Administration|Ancillary studies
214671585|NCT02104180|DEVICE|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
214482571|NCT06691867|BEHAVIORAL|I-STRONG|"I-STRONG is an evidence-based protocol from the FIT Teens program. This intervention combines mind-body and cognitive-behavioral approaches with neuromuscular movement training informed by pediatric sports medicine and injury prevention research. It aims to teach mind-body skills applicable during movement training to enhance psychological coping and reduce fear of pain and activity avoidance.~I-STRONG consists of 16 group-based telehealth sessions held twice weekly over 8 weeks. Each group can accommodate up to 6 patients with SCD. Adolescents are expected to attend all sessions, while parents will attend 6 of the 16. Parents will receive education about I-STRONG, guidance on supporting their teen's behavior change, and opportunities for networking with other parents of youth with SCD. Sessions will include brief daily homework (e.g., using phone apps to practice skills) to facilitate proficiency. Participants will self-report their practice of assigned skills."
214316448|NCT05568472|OTHER|Symptom Specific Assessment Tool|Receive a weblink via email or text message and asked 6 brief questions about symptoms
214316449|NCT02074995|BIOLOGICAL|BVS857|Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
214482572|NCT06691867|OTHER|Enhanced Usual Care (EUC)|The EUC arm is designed to account for potential effects on time and standard medical care outcomes. Patients randomized to EUC will continue with standard care and optimal management of their SCD and chronic pain for approximately 8 months (i.e., time from enrollment through 6-month post-treatment assessment) before starting the intervention program to coincide with the study duration of the ES arm. After completing the 6-month follow-up assessment, patients will have the opportunity to start the I-STRONG for SCD intervention.
214482573|NCT06692426|DRUG|MyoPAXon|MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2
214482574|NCT06692426|DRUG|Tacrolimus|Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus host disease (GVHD) as well as allograft rejection in the setting of allogeneic hematopoietic stem cell transplantation.
214482575|NCT06692361|BIOLOGICAL|FMT capsule|The experimental group will maintain escitalopram treatment and take 1.0 g of FMT capsules orally with breakfast every day for 4 weeks.
214482576|NCT06692361|DRUG|Escitalopram (Lexapro)|Both the experimental group and the placebo group were treated with the maximum tolerated dose of escitalopram.
214482577|NCT06692361|BIOLOGICAL|Corn Starch capsules|The placebo group will maintain escitalopram treatment and take corn starch capsules 1.0 g orally with breakfast every day for 4 weeks.
214482578|NCT04926792|DEVICE|Leadless Pacemaker|Leadless pacemaker implantation
214482579|NCT04893096|DRUG|MOR202|Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
214482580|NCT06279975|DIAGNOSTIC_TEST|non-invasive device-supported, automated pupillometry|non-invasive device-supported, automated pupillometry with a precise quantitative measurement of the pupils within the range of micrometers
214482581|NCT05155605|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
214482582|NCT01897441|DRUG|Cyclophosphamide|Given IV
214482583|NCT01897441|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214482584|NCT01897441|DRUG|Doxorubicin Hydrochloride|Given IV
214482585|NCT01897441|OTHER|Laboratory Biomarker Analysis|Correlative studies
214482586|NCT01897441|DRUG|Paclitaxel|Given IV
215061110|NCT02220803|DRUG|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
214316450|NCT02074995|OTHER|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
214316451|NCT00500292|DRUG|Vandetanib|once daily oral tablet two dose strengths
214316452|NCT00500292|DRUG|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
214316453|NCT01653080|PROCEDURE|dynamic contrast-enhanced MRI|Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
214482587|NCT01897441|BIOLOGICAL|Trastuzumab|Given IV
214482588|NCT01897441|DRUG|Endocrine therapy|Patients with ER-positive, HER2-negative disease may receive neoadjuvant endocrine therapy (NET) with an aromatase inhibitor: (either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily) for 4-6 months prior to surgery (or longer if clinically indicated). Anastrozole for 6 months is the preferred regimen for NET.
214482589|NCT06693934|GENETIC|Risk assessment with biogenetic and clinical test to predict diabetes risk|All participants will undergo genetic test and clinical measurement including body weight, body height, blood pressure, waist circumference and capillary blood glucose to predict diabetes risk with report explanation by doctors (for high risk, IGT and DM) and nurses (low risk). Genetic report will be updated annually for high risk and IGT group using updated clinical factors (e.g. age, BMI, BP).
214482590|NCT06693934|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factors|High risk progressors will undergo OGTT and measurement of CKM factors at baseline. In those without IGT or diabetes, they will undergo OGTT and CKM risk factor assessment annually for 2 years. The IGT group will additionally have measurement of beta-cell function (HOMA indexes) and the DM group will additionally have autoimmune marker measurement.
215061111|NCT02220803|DEVICE|nasal Continuous Positive Airway Pressure (nCPAP)|
215061112|NCT00596674|BEHAVIORAL|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
215061113|NCT00596674|OTHER|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
215061114|NCT04004338|DRUG|Kyprolis|Patients receiving kyprolis (carfilzomib)
214316454|NCT02860715|DRUG|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
214316455|NCT02860715|DRUG|Placebo|This is the placebo of GX-I7 described above.
214316456|NCT04910009|OTHER|Four sessions of practical privacy education|Two sessions of theoretical, four sessions of practical privacy education
214316457|NCT00586183|PROCEDURE|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
214316458|NCT02251795|DRUG|Tipranavir|
214316459|NCT02251795|DRUG|Ritonavir|
214316460|NCT02251795|DRUG|Darunavir|
214316461|NCT02251795|DRUG|Aspirin|single dose on day 2
214316462|NCT05860283|DEVICE|Core stabilization exercise using pressure biofeedback unit|"From crook lying:~* 1st and 2nd weeks LEVEL 1: ADIM and hold for 10 seconds LEVEL 2 : Hold for 5 sec. Repeat 10 times. Opposite lower extremity on plinth; bent leg fall out.~* 3rd and 4th week LEVEL 3 : Opposite lower extremity on plinth a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~* 5th and 6th weeks LEVEL 4 : Hold opposite lower extremity at 90˚ of hip flexion a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~From prone lying:~Extension of each lower extremity. The exercise progression each week will be evaluated.Each exercise session lasted 20 min. The patients had to hold each exercise for 10 seconds, three sets per session and each set 10 repetitions."
214316463|NCT05860283|PROCEDURE|Diaphragmatic release technique|This technique will be given 3 days per week for 6 weeks with total technique duration of 45 minutes. The maneuver will be repeated in 4 sets per session, each set will consist of 5 deep breaths with 2-min intervals in between sets.
214316464|NCT01025427|DRUG|Raltegravir, tenofovir/emtricitabine|16 controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
214316465|NCT04694677|DRUG|women receiving tranexamic acid|women receiving tranexamic acid during myomectomy
214316466|NCT04694677|DRUG|women receiving misoprostol|women receiving misoprostol in myomectomy
214316467|NCT01017237|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
214316468|NCT01017237|DRUG|Midazolam|Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
214316469|NCT01017237|DRUG|Ketamine|Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
214316470|NCT01548612|DRUG|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
214316471|NCT01548612|DRUG|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
214316472|NCT00483964|DRUG|Bacopa monnieri|
214316473|NCT00483964|DRUG|Nardostachys jatamansi|
214316474|NCT00483964|DRUG|Olanzapine|
214316475|NCT04716127|BEHAVIORAL|Proximity-incentive strategy based on vaginal self-sampling for women 50 to 65 years who do not participate to cervical cancer screening|"* Direct offer of a vaginal self-sampling kit with information to perform at home and send back to the laboratory for HR-HPV testing~* The psychosocial determinants involved in decision-making process and compliance to cervical cancer screening will be collected from open questionnaires and by semi-directive phone interviews~* Control ; Receive reminder to send the self-sample to the laboratory : After 3 and 6 months without return, women receive a remind letter to send the vaginal self-sample to the laboratory. We call return the receipt of the vaginal self-sample at the laboratory.~* Control ; Receive reminder to perform cervical smear in case of positive HR-HPV test : In case of a positive HR-HPV test, women are asked to perform a control cervical smear. After 3, 6 months and 12 months without return, women and their health-care professional will receive a remind letter or a call to perform a cervical smear for control. We call return the performance of a pap smear."
214316476|NCT04128163|DRUG|QL1206|"subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
214316477|NCT04128163|DRUG|Placebos|"subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
214316478|NCT01314209|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
214316479|NCT00004065|DRUG|tanespimycin|
214316480|NCT01169506|DEVICE|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
214316481|NCT05415696|PROCEDURE|Prostatic artery embolization|Patients will undergo PAE with 100-300 µm or 300-500 µm Embospheres following standard PAE technique performed by Interventional Radiology at Stanford University
214316482|NCT01747083|DRUG|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
214316483|NCT00005828|DIETARY_SUPPLEMENT|green tea extract|
214316484|NCT01553006|DRUG|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
214316485|NCT00828191|DRUG|Progesterone|25 mg, once a day, SC
214316486|NCT00828191|DRUG|Progesterone|100 mg, twice a day, vaginally
214316487|NCT01511575|GENETIC|RNA analysis|
214316488|NCT01511575|GENETIC|reverse transcriptase-polymerase chain reaction|
214316489|NCT01511575|OTHER|laboratory biomarker analysis|
214316490|NCT02246803|PROCEDURE|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
214316491|NCT02246803|PROCEDURE|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
214316492|NCT04045678|DRUG|LY03003 ( Rotigotine, extended-release microspheres)|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
214316493|NCT04045678|DRUG|Placebo, extended-release microspheres|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
214316494|NCT06221033|DEVICE|manual hyperinflation|Each participant will assume a relaxed comfortable in supine position. Bag valve resuscitation circuit locked at pressure 35 cm H20 will be used. Six sets of six MHI breaths will be applied. MHI breaths had a slow inspiration for three seconds duration, a three second end inspiratory pause (hold) then an uninterrupted expiration as a quick release
214316495|NCT06221033|OTHER|Diaphragmatic proprioceptive neuromuscular facilitation technique|"Rhythmic initiation technique that is derived from the PNF concept will be initiated by four 20-second manual diaphragm stimulations. After every stimulation the patient rested for one minute. Therapist's hands will be placed below the rib cage, just below the costal arches and will support patient's exhalation phase by slight lengthening his diaphragm simultaneously in posterior-superior direction using a verbal cue exhale. At the same time, the patient will verbally be encouraged to take a deep breath"
214316496|NCT06221033|OTHER|traditional physiotherapy|This group will receive the traditional medical treatment and chest physiotherapy only.
214316497|NCT05669456|DEVICE|Halo Alert System|The Halo Alert System consists of an EEG sensor headband and is paired with a data transfer device.
214316498|NCT03030079|DEVICE|Experimental Electrical Stimulation Regimen|The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
214316499|NCT00000514|DRUG|chlorthalidone|
214316500|NCT00000514|DRUG|atenolol|
214316501|NCT00000514|DRUG|reserpine|
214316502|NCT02234921|DRUG|Cyclophosphamide|A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
214316503|NCT02234921|BIOLOGICAL|DRibble Vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
214316504|NCT02234921|BIOLOGICAL|HPV Vaccinations|Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
214316505|NCT02234921|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
214316506|NCT05718232|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients ≥ 60kg)
214316507|NCT05718232|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
214316508|NCT05718232|RADIATION|SBRT|SBRT will be given within 3 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-5000 cGy in 5-8 fractions.
214316509|NCT02621814|DIETARY_SUPPLEMENT|Low glycation formula feeding|Formula feeding on demand for 3 months
214316510|NCT02621814|DIETARY_SUPPLEMENT|Commercially common formula feeding|Formula feeding on demand for 3 months
214316511|NCT05200754|OTHER|Convalescent/Vaccine-boosted Plasma (CP/PVP)|"Plasma from apheresis obtained from donors, who have recovered from SARS-CoV-2 infection or received a successful vaccination against SARS-CoV-2.~CP/PVP infusion is administered on two following days. Each CP/PVP bag contains approx. 238 - 337 ml anti-SARS-Cov-2 CP/PVP for infusion."
214316512|NCT03951922|BEHAVIORAL|Horticultural activity|Therapeutic horticulture activities are plant-related activities that include but not limited to digging, watering, planting, weeding, trimming, fertilizing, mulching, harvesting, learning about organic farming, and exploring options to incorporate horticulture into daily activities
214316513|NCT00799578|DRUG|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
214316514|NCT00856908|DRUG|AZD1656|Tolerable dose given twice daily
214316515|NCT00856908|DRUG|Placebo|Tolerable dose given twice daily
214316516|NCT00962104|DRUG|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
214671586|NCT02991612|DRUG|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
214316517|NCT00962104|DRUG|Placebo|Taken by mouth, once daily for 10 weeks.
214316518|NCT01869283|OTHER|Kinesiotherapy|
214316519|NCT01869283|OTHER|Ultrasound|
214316520|NCT01869283|OTHER|Diadynamic currents|
214316521|NCT03397082|DRUG|Lidocaine gel|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.
214316522|NCT03397082|DRUG|Placebo|5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
214316523|NCT05014022|DIAGNOSTIC_TEST|Multiparametric renal MRI|10 patients in the cohort will undergo MRI scanning at day 30 and 90
214671587|NCT03731715|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
215061115|NCT06093269|BIOLOGICAL|Blood samples|"For all subjects (short kinetics):~* Pre-injection of cefazolin~* Start of next dialysis~* Two hours after start of subsequent dialysis~* End of next dialysis, before cefazolin administration~Only in hospitalized subjects (rich kinetics):~* 30 minutes, 1h and 2h after cefazolin injection, to describe the cefazolin peak and possible post-dialysis rebound~* 12h, 24h and 36h after cefazolin injection, to better describe cefazolin elimination and distribution"
214316524|NCT06072937|DEVICE|IntelliStent|Staged implantation of IntelliStent. The system comprises a nitinol self-expanding stent with a hollow element delivered over-the-wire into the main pulmonary artery or its left and right branches, using an 18 Fr transfemoral introducer sheath. The stent consists of two sections, one with a larger diameter and one with a smaller diameter, available in 6 sizes suitable for vessel sizes ranging from 20mm to 30 mm. Additional smaller sizes are currently under development.
214316525|NCT00842348|DRUG|lanreotide (Autogel formulation)|Autogel 120 mg
214316526|NCT05320991|DRUG|Ketamine|Ketamine is applied with a Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA). Target plasma levels are 100 ng/ml with an initial bolus administered as a 2 mg/ml solution.
214316527|NCT05320991|DRUG|Nacl 0.9%|Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).
214316528|NCT00261742|DRUG|Penicillin versus cefuroxim per os|
214316529|NCT03274986|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL.
214671588|NCT04831944|DRUG|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
215061116|NCT04589572|PROCEDURE|XLIF|the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
215061117|NCT04589572|PROCEDURE|PLIF|open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
215061118|NCT05944588|OTHER|Pulmonary Ultrasound|2 pulmonary ultrasound exams, one before respiratory weaning test, and one other at the end of the respiratory weaning test, before extubation
215061119|NCT01761006|DEVICE|NIOX MINO®|
215061120|NCT01701362|DRUG|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
215061121|NCT01701362|DRUG|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
215061122|NCT00570778|DRUG|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
215061123|NCT00570778|DRUG|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
215061124|NCT00570778|DRUG|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
215061125|NCT06391008|RADIATION|Stereotactic radiotherapy|Targeting primary lung lesions and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy was performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f
215061126|NCT06391008|DRUG|Evoximab|Evoximab (20mg/kg, Q3W)
215061127|NCT06391008|DRUG|Pemetrexed|Pemetrexed (500mg/m2, Q3W)
215061128|NCT06391008|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 260 mg/m2, Q3W
215061129|NCT06391008|DRUG|Carboplatin|Carboplatin (AUC5, Q3W)
215061130|NCT05292495|DRUG|HR17031 injection|HR17031 injection; administered subcutaneously.
215061131|NCT02661386|DEVICE|Motility Procedure|The use of esophageal manometry device during general anesthesia
215061132|NCT01223651|PROCEDURE|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
215061133|NCT01324050|BEHAVIORAL|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
215061134|NCT01324050|BEHAVIORAL|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
215061135|NCT02709460|PROCEDURE|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
215061136|NCT02709460|PROCEDURE|Cervical occlusion|Cervical occlusion of the uterine artery
215061137|NCT01475643|DRUG|Loteprednol etabonate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
215061138|NCT01475643|DRUG|Prednisolones acetate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
215061139|NCT03770208|DRUG|Intervention: Lidocaine|IV Lidocaine bolus plus infusion. Weight based.
215061140|NCT03770208|DRUG|Control: Standard Care + Placebo|Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
214482591|NCT06693934|DRUG|Medication|Nurse and medical consultations and subsidized medications (metformin, statin, ARB) will be provided to the high risk progressor, IGT and diabetes groups as appropriate for control of glucose and CKM risk factors.
214316530|NCT03274986|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
214316531|NCT03274986|PROCEDURE|Cataract surgery|IOL bilateral implantation
214482592|NCT06693934|DEVICE|Continuous glucose monitoring (CGM) devices and/or weighing scale|All high risk progressors will be given subsidized weighing scale and low-intensity laboratory assessments, nurse and doctor consultation, regular WhatsApp messages and webinars for 2 years. The IGT and DM group will receive additional subsidized CGM devices for empowerment.
214482593|NCT06693934|BEHAVIORAL|Visit to family doctor with nurse education|All participants in high risk, IGT and diabetes groups will have regular follow-up by family doctors and nurses.
214482594|NCT06693934|DIAGNOSTIC_TEST|Joint Asia Diabetes Evaluation (JADE) assessment|Participants found to have diabetes on OGTT will undergo annual JADE assessment which include eye/foot/urine/blood tests with issue of a personalized JADE report. The JADE Program is a quality improvement program to improve self management and inform shared decision making between doctor and patient.
214482595|NCT06693934|BEHAVIORAL|Education webinars, workshops and health messages|All participants would join the webinars. High risk progressors, IGT and DM group will receive regular WhatsApp messages, webinars and workshops.
214482596|NCT06630741|OTHER|alternative midwifery units (AMU)|"Alternative midwifery birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative midwifery birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative midwifery birth units named Filière physiologique co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room"
214918806|NCT06097923|DRUG|Active fluid management with BIA monitoring|The participants in active fluid management with BIA monitoring arm received fluid supplementation targeting specific range of ECW ratio by BIA (0.390-0.406). If a patient with dehydrated status indicated by the ECW ratio was less than 0.390, a bolus infusion was performed using 250ml of crystalloid fluid (PlasmaLyte). If a patient with overhydrated status indicated by the ECW ratio was more than 0.406, 10mg of furosemide was administered. Changes in the ECW ratio were measured at one hour after initial intervention for fluid adjustment, and these processes continued until the ECW ratio was within the normal range (0.390-0.406).
214482597|NCT06690658|DEVICE|incorporating robotic system for upper body physical training of people with lower limb orthopedic condition|A training session begins with the robot introducing itself, and the participant sits in front of the robot. The robot will demonstrate upper body exercises and will provide verbal instructions and feedback (e.g, number of successful repetitions, motivational). At the beginning of the session, the participant will be asked to follow the robot's demonstration and simultaneously perform the exercise. At the end of each exercise, the robot will provide feedback. If the participant successfully performed ten repetitions of the required exercise in the demonstration time allocated, positive feedback will be provided. Resistance (strengthening) exercises for the upper body include lifting weights, working with resistance bands in different directions involving the upper extremity and trunk. Flexibility exercises include upper extremity and trunk stretching.
214482598|NCT06688630|DEVICE|The laser acupuncture and artificial tears therapy|"Laser acupuncture therapy is the application of a Reimers \& Janssen LaserPen, with a power of 150mW and a wavelength of 810nm, alternating between Nogier frequencies A and C. The dosage is 2 joules per point, with a therapy duration of 26 seconds per point, targeting bilateral acupuncture points BL2, TE23, ST2, LI4, and ST36. The LaserPen is applied without pressing the laser probe onto the body surface.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC."
214482599|NCT06688630|DEVICE|The sham laser acupuncture and artificial tears therapy|"Laser acupuncture therapy is a procedure using the same device but without activating the laser, so no energy is emitted. Performed at the same points as laser acupuncture therapy.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC."
214918807|NCT06097923|DRUG|Conventional fluid management without BIA monitoring|The participants in conventional fluid management without BIA monitoring arm underwent conventional fluid management without specific targets of ECW ratio by BIA.
214918808|NCT00976976|DRUG|docetaxel, capecitabine, cisplatin|Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
214316532|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
214316533|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
214316534|NCT01536431|DRUG|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
214918809|NCT01600365|DRUG|Ophthalmic gel (placebo)|Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
214918810|NCT01600365|DRUG|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
214316535|NCT03200925|OTHER|"Jumping into Kangaroo Care - a video created by the Ohio Department of Health"|The video is 8 minutes and 52 seconds in length. The video discusses the benefits and logistics of Kangaroo Care from professional's perspectives and from new mother's perspectives.
214316536|NCT03221803|OTHER|OT Vertical attachment|new extra coronal castable attachment
214316537|NCT03221803|OTHER|OT cap attachment|standard extra coronal attachment
214918811|NCT04874662|DIETARY_SUPPLEMENT|NAM/B6|Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.
214316538|NCT04558931|DRUG|CellProtect|In vitro expanded and activated autologous NK cells
214918812|NCT01844648|DRUG|NH004 tropicamide|Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
214316539|NCT04558931|DRUG|Isatuximab|Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
214918813|NCT01844648|DRUG|NH004 Placebo|Intra-oral slow dissolving muco-adhesive thin film
214918814|NCT01002430|BIOLOGICAL|VEGF-D gene transfer|Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
214316540|NCT04977258|OTHER|Treadmill aerobic exercise without water intake|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
214316541|NCT04977258|OTHER|Treadmill aerobic exercise with water intake of a predetermined amount.|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
214316542|NCT04977258|OTHER|Treadmill aerobic exercise with water intake according to the desire to drink|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
214316543|NCT01616485|DRUG|TA-1790|2 TA-1790 100 mg capsules
214482600|NCT06689215|DEVICE|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
214482601|NCT06687564|PROCEDURE|Biopsy|A skin biopsy and a blood sample will be taken to culture the iPS cells and intestinal organoids.
214482602|NCT06632145|OTHER|Cog Fun Ageing intervention|Cog Fun Ageing is a group-based occupation-centered intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 14 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
214316544|NCT01616485|DRUG|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
214316545|NCT01616485|DRUG|Placebo|2 placebo capsules for TA-1790 100 mg capsules
214482603|NCT06688968|BEHAVIORAL|neuropsychologist interview|"It will take place either at the hospital or at the participant's home.~This interview will consist of :~* socio-demographic data collection~* neuropsychological tests:~  * MMSE test (Mini Mental State Examination) cognitive function~ * RL-RI-16 test (16-item free recall/indexed recall test)~ * BECS test (Semantic knowledge assessment battery )~ * WCST test (Wisconsin Card Sorting Test )~ * Musical Cognition Test~ * Help from the participant's relative to answer certain questions, in particular the MuseEQ-24 questionnaire"
214918815|NCT02578381|DEVICE|Boston Scientific Pressure Wire|St Jude Medical Pressure Wire
214918816|NCT02578381|DEVICE|Validation of Boston Scientific pressure wire|
214918817|NCT05924425|DRUG|Daridorexant 50 mg|Patients randomized in the experimental group will receive the treatment every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
214918818|NCT05924425|DRUG|Placebo|Patients randomized in the control group will receive the placebo every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
215061141|NCT06416878|DEVICE|Brief ES at the time of decompression for cauda equina syndrome|In patients operated for acute cauda equina syndrome with autonomic dysfunction epidural ES will be delivered utilising SCS trial electrode. It will be delivered for 10 minutes caudal to compression site and for 60 mins cranial to compression site while the wound is closed and patient recovered.
214316546|NCT01616485|DRUG|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
214316547|NCT03700697|BEHAVIORAL|Family Stress Module Intervention|as above
214316548|NCT01622855|BEHAVIORAL|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
214316549|NCT06095791|DRUG|Immunomodulators with FDA approval on the 1st January 2023.|Disproportionnality analysis studying the association between immunomodulators with FDA approval on the 1st January 2023 and atrial fibrillation in the World Health Organization pharmacovigilance database.
214316550|NCT00603746|DRUG|GW685698X|GW685698X
214316551|NCT01318096|DRUG|raltegravir and tenofovir and lamivudine|raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
214316552|NCT01318096|DRUG|efavirenz+tenofovir+lamivudine|efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
214316553|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
214316554|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
214316555|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
214316556|NCT05516082|DEVICE|Lens A|DDH contact lens for 15 minutes
214316557|NCT05516082|DEVICE|Lens B|DDSH contact lens for 15 minutes
214316558|NCT01299922|DRUG|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
214316559|NCT01299922|DRUG|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
214316560|NCT00965822|OTHER|North American ginseng|3 day, once daily, dosing
214316561|NCT00965822|OTHER|Placebo|3 day, once daily dosing
214316562|NCT04484324|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
214316563|NCT00451867|DRUG|Mycophenolate Mofetil|
214316564|NCT00451867|DRUG|Mycofenolate Mofetil (MMF)|2000 mg per day divided into 2 equal doses.
214671589|NCT02490540|DRUG|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
214671590|NCT02490540|DRUG|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
214918819|NCT05924425|PROCEDURE|Polysomnography|A full-night polysomnography recording with blood pressure and heart rate monitoring will be performed at night in the Sleep Laboratory from 11 p.m. to 7 a.m. at baseline (before the randomization) and at the end of each period (Period A/M1, Period B/M2). The recording procedure consists of an electroencephalogram, two electrooculograms, an electromyogram, an electrocardiogram, and a videographic recording. This examination is painless (the sensors are glued to the skin for the duration of the recording). The advantages of this video-polysomnography are based on the evaluation of sleep architecture, micro-arousals, respiratory events and nocturnal motor behavior.
214918820|NCT05924425|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, M1, M2
214918821|NCT05924425|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems will be performed at inclusion, M1, M2
214316565|NCT00451867|DRUG|Placebo|Placebo
214316566|NCT06133309|BEHAVIORAL|Experiential Phenomenological Interview|"Consciousness fluidity of patients suffering from depressive disorder and treated with Esketamine will be evaluated thanks to Experiential Phenomenological Interview and EQFC Trait questionnaire"
214316567|NCT02098590|BIOLOGICAL|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
214316568|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
214316569|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
214316570|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
214316571|NCT02098590|DRUG|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
214316572|NCT00258076|DRUG|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE|
214918822|NCT05924425|PROCEDURE|Actimetrics|Measurement of actimetrics for seven days in average (with a minimum of three nights required) prior to the inclusion visit, M1 visit and M2 visit.
214918823|NCT05924425|PROCEDURE|24-hour Ambulatory Blood Pressure Monitoring (ABPM|Evaluation of the 24-hour hemodynamic profile of a patient by multiple and regular blood pressure and heart rate measurements. The ABP will be monitored at inclusion, M1 and M2
214316573|NCT04842539|OTHER|Fecal Microbiota Transplantation|In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.
214316574|NCT04842539|OTHER|Standard of care|Nutritional supplementation and other supportive measures as per standard guidelines
214918824|NCT05924425|OTHER|Biomarker assay|Determination of AD biomarkers (Aβ42, Aβ40, Tau, P-Tau, neurofilament) and proinflammatory cytokines (TNFa, IL6) in serum and cerebrospinal fluid (CSF) and dosage of Orexin-A/hypocretin-1 in the CSF
214316575|NCT01499888|PROCEDURE|Allogeneic Non-Myeloablative Stem Cell Transplantation|"Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion"
214316576|NCT01499888|DRUG|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
214316577|NCT01499888|DRUG|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
214316578|NCT02165319|DEVICE|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
214316579|NCT02165319|DEVICE|Tapered|Tapered-shaped tube will be used during general anesthesia.
214482604|NCT06688968|BEHAVIORAL|questionnaire|"The participant answers questionnaires:~* Questionnaire MusEQ-24 self reported (Music Engagement Questionnaire)~* Questionnaire BMRQ (Barcelona Reward Music Questionnaire)~* Questionnaire SHAPS (Snaith-Hamilton Pleasure Scale)~* Questionnaire LARS (Lille's Apathy Rating Scale)~* Questionnaire PHQ-9 (Patient Health Questionnaire 9 items)"
214482605|NCT06688266|OTHER|Nerve Gliding Exercises|"This group will receive 25-minute session of nerve gliding exercises per session five days a week for six weeks. It will include: Warm-Up (5 minutes)~Neural Gliding of the upper quadrant:~Median nerve glide (5 minutes) Ulnar nerve glide (5 minutes) Radial nerve glide (5 minutes) Cool Down (5 minutes)"
215061142|NCT06416878|DEVICE|Brief ES to facilitate mcturition/removal of catheter|In patients who do not fully recover function following decompression, brief ES will be applied before second micturition attempt.
215061143|NCT02978157|DRUG|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
215061144|NCT02978157|DRUG|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
214316580|NCT01524627|DRUG|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
214316581|NCT01524627|DRUG|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
214316582|NCT01787578|DRUG|Sobetirome|50 mcg or 100 mcg once-daily oral
214316583|NCT02360163|PROCEDURE|Traditional Landmark Technique (TLT)|
214316584|NCT02360163|DEVICE|ultrasound guided peripheral intravenous access (USGPIVA)|
214316585|NCT04104009|OTHER|Education|"Following the randomization process, group education of pregnant women will be conducted through four one-hour meetings.~Education program: teaching about the basics of childbirth physiology, visit to the maternity ward with the aim of reducing the fear of childbirth, applying the deep inhale and exhale exercise in the first birth stage, applying the classical music listening technique that will continue until the end of pregnancy daily (in the evenings before bedtime) (for 15 minutes), teaching and applying techniques for successful breastfeeding, maternal and infant health care after delivery. The training program will be implemented so that after 4 workshops a 5-week break will be taken. At the end of the program, the educator arranges with the respondents a weekly telephone check (for the sake of communication quality) to inform them of adherence to the agreed classical music listening.Pregnant women who do not meet expectations will be excluded from the study."
214316586|NCT04104009|OTHER|No education|In the control group there will be no education, no breathing exercises and no listening to classical music.
214316587|NCT05813158|DRUG|Group 1(low concentration-high volume bupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive low concentration-high volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline} for each patient
214316588|NCT05813158|DRUG|Group 2(high concentration-low volumecbupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive high concentration-low volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% } for each patien).
214316589|NCT05172661|BEHAVIORAL|Integrated physical-cognitive training|Perform a postural task and a cognitive task at the same time (dual-task model) 70 minutes/session\*2 sessions/week\*6 weeks
214482606|NCT06688266|OTHER|Hand Grip Strength Exercises|"This group's participants will also receive a 25 -minute session five days per week (for six weeks). Warm-Up (5 minutes) Conventional Grip Strength Exercises (15 Minutes)~* Tendon gliding sequence of exercises for hand~* Squeezing a rubber ball or stress ball~* Dead Hang Cool Down (5 Minutes)"
214482607|NCT06686329|BEHAVIORAL|Control (CON)|Standardized meal with insulin administered 15 minutes before eating
214482608|NCT06686329|BEHAVIORAL|Missed Dose (MISS)|Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM
215061145|NCT05911360|DRUG|DTG/3TC|DTG/3TC FDC will be administered once daily.
214482609|NCT06686329|BEHAVIORAL|Missed Dose + 15min walk (MISS+EX)|Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM with a 15-minute walk performed immediately after insulin administration
214316590|NCT05172661|BEHAVIORAL|Consecutive physical-cognitive training|Perform a postural task and a cognitive task separately for identical durations 70 minutes/session\*2 sessions/week\*6 weeks
214316591|NCT00133874|DRUG|SB-275833 ointment, 1%|
214671591|NCT02490540|DRUG|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
214918825|NCT03737500|DEVICE|B-Lite® light weight breast implant|Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant
214918826|NCT03737500|DEVICE|Standard silicone-based breast implant|Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution
214918827|NCT04800887|DEVICE|TECNIS Eyhance intraocular lens|Cataract surgery and implantation with extended depth of focus intraocular lens
215061146|NCT02120781|BIOLOGICAL|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
215061147|NCT02120781|DRUG|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
214316592|NCT03323658|DRUG|Bexarotene|Given topically
214316593|NCT03323658|OTHER|Questionnaire Administration|Ancillary studies
214316594|NCT03913091|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
214316595|NCT03913091|DRUG|0.5% Bupivacaine HCL|0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
214316596|NCT00969553|DRUG|BI 6727|Dose level 1
214316597|NCT06287073|DRUG|JARDIANCE®|JARDIANCE®
214316598|NCT03173716|PROCEDURE|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
214316599|NCT05677542|DRUG|secukinumab|all patients who received secukinumab
214316600|NCT01137942|DRUG|clarithromycin, metronidazole, proton pump inhibitor|appropriate dose of antibiotics and proton pump inhibitor
214316601|NCT05040581|BEHAVIORAL|1-Day CBT-Based Workshop for Preventing PPD|The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
214316602|NCT01726738|DRUG|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
214316603|NCT05588102|DRUG|Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）|Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)
214316604|NCT02276612|DRUG|E/C/F/TAF|150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
214316605|NCT05987865|BEHAVIORAL|Neurofeedback training|Features related to PD symptoms will be extracted from the brain recordings in real-time and used to drive a visual cursor on a computer screen placed in front of the participant, while the participant will be asked to try to control the cursor by regulating their brain signals.
214918828|NCT04800887|DEVICE|Monofocal intraocular lens Tecnis ZCB00|Cataract surgery and implantation with monofocal intraocular lens
214918829|NCT04093011|PROCEDURE|Congenital Heart Disease Surgery|Patients with congenital heart disease will undergo congenital heart disease surgery.
214918830|NCT02637401|BEHAVIORAL|Dialectical Behaviour Therapy|
214316606|NCT03488979|OTHER|educational interventional group|• Patient Education Tool (Appendix 3) and the patient's own IVC images will be shared with each patient in the intervention group in real time. If feasible, each intervention patient will also receive a printed copy of his or her IVC image.
214316607|NCT04382248|OTHER|Smartphone App|An app for monitoring medications, blood pressure, exercise, healthy eating
214316608|NCT04382248|BEHAVIORAL|Tailored education|in-person coaching
214316609|NCT01672476|DRUG|Placebo|Placebo
214316610|NCT01672476|DRUG|Valsartan|Valsartan 80mg
214316611|NCT01672476|DRUG|Fimasartan|Fimasartan 30mg
214316612|NCT01885312|BEHAVIORAL|Adaptive Tailored Intervention|Adaptive
214316613|NCT01885312|BEHAVIORAL|Consequence-based Intervention|Loss Framed
214316614|NCT01885312|BEHAVIORAL|Tailored, not adaptive, based Intervention|Baseline tailored not adaptive
214316615|NCT01885312|OTHER|Assessment only|EMA only
214316616|NCT05354128|DRUG|Thrombolytic|Standard intravenous thrombolysis.
214918831|NCT04052243|DIAGNOSTIC_TEST|Invasive exercise testing|Invasive hemodynamic exercise testing
214918832|NCT02247440|DRUG|Peg-interferon + ribavirin under HIV physician supervision|Peg-interferon + ribavirin under HIV physician supervision
214316617|NCT05354128|PROCEDURE|percutaneous coronary stenting|Percutaneous coronary stenting
214482610|NCT06685822|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
214482611|NCT06250933|OTHER|Postpartum Maternal Care and Premature Infant Care Training|"Training and counseling were provided. In this context, training consisting of three sessions of 100 minutes in total was provided and counseling was provided in the following weeks by conducting 3-4 telephone interviews.~The intervention involves the provision of a training and counseling program designed to increase women's breastfeeding and maternal self-efficacy and reduce the risk of postpartum depression.~In the training phase, women will receive training on postpartum maternal care and premature infant care."
214482612|NCT04840394|DRUG|BDB018|BDB018 is an immunotherapy agent.
214482613|NCT04840394|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
214671592|NCT01125891|DRUG|gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
214671593|NCT01125891|DRUG|ON 01910.Na|The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
214671594|NCT05349461|PROCEDURE|Complete patellofemoral articular contact|The patellofemoral condition is in constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
215061148|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
215061149|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
215061150|NCT00705445|OTHER|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
214316618|NCT02248090|DRUG|AZD9496|AZD9496
214316619|NCT02248090|DRUG|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
214316620|NCT01153412|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulation to determine balance and stability in elderly
214316621|NCT02196324|DRUG|serlopitant|NK1 receptor antagonist
214316622|NCT02196324|DRUG|Placebo|Placebo
214316623|NCT01542216|BEHAVIORAL|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
214316624|NCT01542216|BEHAVIORAL|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
214316625|NCT05111691|PROCEDURE|Dry needling|Dry needling
214316626|NCT01615471|BEHAVIORAL|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
214316627|NCT00454168|BIOLOGICAL|PR1 leukemia peptide vaccine|Given subcutaneously
214316628|NCT00454168|BIOLOGICAL|sargramostim|Given subcutaneously
214316629|NCT00454168|OTHER|placebo|Given subcutaneously
214316630|NCT00885547|DRUG|tripterygium wilfordii (TW)|90 mg/d for 6 months
214316631|NCT01846975|DRUG|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
214316632|NCT02806050|DRUG|Palbociclib|all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
214316633|NCT02806050|DEVICE|FES PET|all patients will have a FES PET at baseline
214316634|NCT02806050|DRUG|Letrozole|all patients will be treated with Letrozole daily until progression
214316635|NCT00832403|OTHER|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
214316636|NCT01306370|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
214316637|NCT01306370|DRUG|Fibrin glue|Topical administration, before to close the surgical wound. Dosage: 2 mL.
214316638|NCT01306370|BIOLOGICAL|Fibrin glue|Topical administration, before to close the surgical wound.
214316639|NCT01306370|OTHER|Habitual haemostasis|The surgical habitual haemostasis.
214316640|NCT04400903|DEVICE|Activity Monitor|Undergo HRV monitoring via WHOOP device
214316641|NCT04400903|OTHER|Quality-of-Life Assessment|Ancillary studies
214316642|NCT04400903|OTHER|Questionnaire Administration|Complete questionnaires
214316643|NCT05960396|BEHAVIORAL|Diet intervention|investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods
214316644|NCT01385124|DRUG|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
214316645|NCT04384302|OTHER|Visual training|Pre-defined visual training protocol including the optometrical unit exercises
214671595|NCT05349461|PROCEDURE|Incomplete patellofemoral articular contact|The patellofemoral condition is in no constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
214482614|NCT03788369|PROCEDURE|Hybrid Coronary Revascularization|Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
214316646|NCT00690963|PROCEDURE|Radiotherapy|Dose excalation based on normal tissue toxicity using 5 dose bins ranging from 56.8 Gy/ 27 fractions to 67.3 Gy in 27 fractions.
214482615|NCT02933762|DRUG|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
214482616|NCT02933762|DRUG|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
214482617|NCT06868706|BEHAVIORAL|VR-Supported Video Modeling|Participants receive virtual reality (VR) supported video modeling training in addition to traditional swimming training.
214482618|NCT06868706|BEHAVIORAL|Traditional Swimming Training|Participants receive only traditional swimming training. Individuals in this group learn swimming techniques through traditional methods (practising in the water under the supervision of an instructor).
214482619|NCT06871982|BEHAVIORAL|PNF+ PBI|Parents of participating students assigned to the PNF+ PBI condition will receive an email invitation to sign up for a Parent-Based Intervention app. This app features six personalized normative feedback (PNF) quizzes and provides tailored videos and readings based on responses to these quizzes. Parents will create an account and complete the first PNF quiz, after which they will immediately receive their initial set of tailored content. They can then explore additional app content at their convenience, including access to five more quizzes that will yield further customized reading lists and access to a general resource library. For approximately six weeks, parents will receive weekly app notifications and email reminders alerting them to additional unengaged content (e.g., PNF quizzes, readings). Parents in this condition will maintain access to the app throughout their student's first year of college.
214316647|NCT03250468|BEHAVIORAL|CBT-I|Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
214316648|NCT01940926|DRUG|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
214316649|NCT01719185|DRUG|Phentermine and B12|
214316650|NCT01719185|DRUG|Phentermine|
214316651|NCT00692770|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
214316652|NCT00692770|DRUG|Placebo|Placebo 2 tablets twice daily (BID)
214482620|NCT06871982|BEHAVIORAL|SNMC+ PBI|Parents of participating students randomized to this condition will receive a series of 6 emails (delivered weekly) in August and September. Each email will include risk-reducing normative facts and a relevant tip for communicating with students about alcohol-related risks.
214671596|NCT06696417|DRUG|Drug group：vunakizumab (IL-17A inhibitor)|The recommended dose of vunakizumab was 240 mg, administered subcutaneously at weeks 0, 2, and 4, then every 4 weeks, with a final injection at 48 weeks
214671597|NCT04912128|DRUG|Anlotinib|"Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.~Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases"
214671598|NCT06945627|OTHER|This research doesn't involve any kind of intervention on the study participants|This research doesn't involve any kind of intervention on the study participants
214671599|NCT06944925|DRUG|BBT002|BBT002 will be administered.
214316653|NCT04563091|DEVICE|Hemodialysis with online HFR|"1. Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values \> 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~2. Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~3. Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~4. Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment."
214316654|NCT05410470|DRUG|Ruxolitinib|
214316655|NCT01998451|DRUG|Tauroursodeoxycholic acid|patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
214316656|NCT04413084|OTHER|Gaze stability exercises|Business card will be placed at eye level. Begin with simpler exercises and progress toward harder one.
214316657|NCT04413084|OTHER|Brandt-Daroff Exercises|"Brandt-Daroff Exercises~1. Start sitting upright on the edge of the bed.~2. Turn your head 45 degrees to the left, or as far as is comfortable.~3. Lie down on your right side.~4. Remain in this position for 30 seconds or until any dizziness has subsided.~5. Sit up and turn head back to center.~6. Turn your head 45 degrees to the right, or as far as is comfortable.~7. Lie down on your left side.~8. Remain in this position for 30 seconds or until any dizziness has subsided.~9. Sit up and turn head back to center."
214316658|NCT04248816|BEHAVIORAL|Usual care|Subjects will receive outreach through their providers as is standard of care.
214316659|NCT04248816|BEHAVIORAL|Opt-out|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.
214316660|NCT04248816|BEHAVIORAL|Opt-out + Incentive|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.
214316661|NCT00397800|BIOLOGICAL|rituximab|
214316662|NCT00397800|DRUG|cyclophosphamide|
214316663|NCT00397800|DRUG|fludarabine phosphate|
214316664|NCT00397800|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214316665|NCT00175890|DRUG|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
214316666|NCT00175890|OTHER|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
214316667|NCT03325686|DIETARY_SUPPLEMENT|vitamin D supplement|D; received 50,000 IU of vitamin D supplement weekly
214316668|NCT03325686|OTHER|Placebo|placebo
214316669|NCT00262067|DRUG|Bevacizumab|Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
214482621|NCT06871982|BEHAVIORAL|PH+ PBI|Parents of participating students randomized to this condition will receive an email introducing the PBI including a link to access the Handbook online. Parents can explore the Handbook at their own pace.
214482622|NCT06872827|DRUG|Herbal toothpaste|Intervention
214482623|NCT06871644|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|Subjects who sign the informed consent form and meet the inclusion/exclusion criteria will be entered into the 0.25×108, 1×108 and 2×108 CAR-T groups, in order of priority, and will be administered 1 dose of
214482624|NCT06873074|PROCEDURE|anterior long segment cervical fixation|
214482625|NCT06873074|PROCEDURE|posterior long segment cervical fixation|
214482626|NCT06873074|PROCEDURE|combined anterior and posterior fixation|
214482627|NCT06873438|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).
214482628|NCT06873438|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).
214482629|NCT06873425|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement: Probiotics. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
214671600|NCT06944925|DRUG|Placebo|Placebo will be administered.
214671601|NCT05680220|DEVICE|Neurostimulation System (NSS): Active Setting|Exposure to the active device for 1 hour a day for 6 weeks
214671602|NCT05680220|DEVICE|Neurostimulation System (NSS): Sham Setting|Exposure to the sham device for 1 hour a day for 6 weeks
214671603|NCT05963971|BEHAVIORAL|PEDALL|twenty-six hour nutrition education intervention delivered virtually over a six month period
214671604|NCT05963971|OTHER|Standard of care|Nutrition education per institutional standard of care
214918833|NCT06012890|OTHER|Automation of cardiac MRI acquisition|The intervention will consist of the automation of the cMRI examination.
214482630|NCT06873425|DIETARY_SUPPLEMENT|Placebo|Dietary supplement: Placebo. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
214482631|NCT06872177|OTHER|Measurements|On existing identified chart records: measurements on CBCT and panographic radiographs.
214482632|NCT06287268|OTHER|eltrombopag|This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.
214482633|NCT06124664|DIAGNOSTIC_TEST|Radionuclide venography|With the patient in an upright position, 370 MBq of 99mTc pertechnetate is injected into one of the dorsal veins of the foot after applying a tourniquet in the area of the ankle joint. Then, with the help of a gamma camera detector, the movement of the radiopharmaceutical is monitored in the following segments: tibial (muscular-venous pump of the lower leg), popliteal, femoral and iliocaval. To study the evacuation function of the muscular-venous pump (MVP) of the leg, using an analytical computer program, areas of interest are identified in the tendon, muscle parts of the veins of the leg and the popliteal vein. The time of evacuation of the radiopharmaceutical from the MVP of the leg is estimated - the average transport time of the isotope.
214482634|NCT06124664|DIAGNOSTIC_TEST|single-photon emission computed tomography|"SPECT of the pelvic veins with in vivo-labelled red blood cells (RBCs). For radionuclide assessment of the state of the pelvic veins, 2 ml of Perfotech solution is injected into the cubital vein for subsequent labeling of red blood cells in vivo. In 20 minutes. 370 MBq of 99mTc-pertechnetate is injected into one of the veins of the dorsum of the foot and radionuclide venoscintigraphy is performed according to the method presented above. 20 minutes after the administration of the radiopharmaceutical and the venography, SPECT of the pelvic veins is performed. Tomography of the distribution of labeled erythrocytes in the pelvic veins is carried out in a circular orbit with the gamma camera detector rotated 360°. The analysis of the obtained information is carried out using the standard ECT Protocol software package, which allows obtaining sections in 3 projections (sagittal, transversal and coronal) with a slice step of 8 mm."
214918834|NCT02002455|DEVICE|PET/CT, PET/MRI, mpMRI|FACBC dose 370 megabecquerel (MBq)
214918835|NCT00695279|PROCEDURE|Venipuncture|Blood draw
214316670|NCT00262067|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody.
214671605|NCT00288470|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
214671606|NCT02632825|DEVICE|Nasal High Flow|Nasal High Flow Therapy
214671607|NCT01089725|BIOLOGICAL|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
214671608|NCT01089725|BIOLOGICAL|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
214671609|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
214671610|NCT01089725|BIOLOGICAL|Placebo IV|1 ml placebo administered IV every 8 weeks
214671611|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
214671612|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
214671613|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
214671614|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
214671615|NCT01089725|BIOLOGICAL|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
214671616|NCT01089725|BIOLOGICAL|Placebo SC|1ml placebo administered SC every 8 weeks
214918836|NCT06078007|BEHAVIORAL|MyMoodCoach|The MyMoodCoach prevention intervention is an evidence-based online intervention based on cognitive-behavioral therapy principles such as behavioral activation, problem solving and challenging negative thoughts.
215061151|NCT01661751|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
214671617|NCT06499259|OTHER|Mandala coloring|Mandala Pack and Application: The mandala pack is a pack consisting of 7 different patterns suitable for adults and 12 pencils. Mandala patterns will be photocopied by the researcher. Packages will be given to the mothers about mandala coloring and their questions will be answered. The choice of the color of the paint to be used in mandala coloring will be entirely up to the mother. No guidance will be given in this regard.
214671618|NCT05366608|DIAGNOSTIC_TEST|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6|Serum level of 14.0- 3.0- 3.0- η protein and IL\_.6 were estimated for all participants by ELISA.
214671619|NCT05858411|PROCEDURE|SRP+rhPDGF|The infrabony defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in rhPDGF.
214482635|NCT06697405|OTHER|Prolonged ≥ 120 minutes|No intervention, regular therapy
214482636|NCT04296955|OTHER|Motivational interview as a new health communication intervention|Same as intervention name
214482637|NCT06229119|DEVICE|Implantable Collamer Lens|The EVO ICL lens is intended to be placed entirely within the posterior chamber directly behind the iris and in front of the anterior capsule of the human crystalline lens. When correctly positioned, the EVO ICL lens functions as a refractive element to optically reduce moderate to high myopia with or without astigmatism.
214316671|NCT00262067|DRUG|Chemotherapy|"The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle"
214316672|NCT01522066|PROCEDURE|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
214316673|NCT01522066|PROCEDURE|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
214316674|NCT01889680|DRUG|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
214316675|NCT01889680|DRUG|LV|400 mg/m2 IV day 1 every 14 days until disease progression
214316676|NCT01889680|DRUG|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
214316677|NCT01889680|DRUG|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
214316678|NCT00655564|DRUG|Alefacept|"Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose)."
214316679|NCT05702593|PROCEDURE|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles. The physiotherapist flexed the participant's hip to the point where resistance to the movement was first observed, with the knee extended.At this point, after waiting for 40 seconds, it was returned to the previous position. This application was made on both sides \[Bretischwerdt\]. The technique was repeated three times, with a 15-second rest interval between each repetition.
214316680|NCT05702593|PROCEDURE|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms. A foam roller was placed under the hamstring muscles and slowly moved the tuberositas ischii popliteus back and forth with pressure for 4 minutes.
214316681|NCT01461772|RADIATION|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
214316682|NCT01461772|DRUG|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
214316683|NCT01461772|DRUG|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
214316684|NCT04536727|BEHAVIORAL|Fit & Strong!|The 8-week intervention will consist of the Fit \& Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content
214482638|NCT00329836|OTHER|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
214482639|NCT05503030|DRUG|Nintedanib|Nintedanib
214482640|NCT05074056|DRUG|Ketorolac|We will administer intraoperative ketorlac.
214482641|NCT03460665|PROCEDURE|Arteriography|knee arteriography
214482642|NCT05795231|DEVICE|Macintosh Laryngoscope Vs Video Laryngoscope|Evaluate incidence of first trial success and complications
214482643|NCT05696652|BEHAVIORAL|Acute exercise|40 minute moderate intensity exercise bout on a treadmill. This is similar to a single session of cardiac rehabilitation.
214482644|NCT05696652|BEHAVIORAL|Cardiac rehabilitation|12 week program of standard clinical cardiac rehabilitation for patients with symptomatic heart failure. Patients undergo 3-times weekly sessions of monitored exercise for 12 weeks. This is the same cardiac rehabilitation patients would get as part of clinical care.
214482645|NCT03475134|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
214482646|NCT03475134|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
214482647|NCT03475134|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
214482648|NCT03475134|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
214482649|NCT03475134|DRUG|Nivolumab|Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
214482650|NCT05407376|OTHER|Produce prescription (weekly produce delivery)|Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
214482651|NCT06701305|DRUG|Efinopegdutide|Subcutaneous injectable solution
214482652|NCT06701305|DRUG|Placebo|Subcutaneous injectable solution
214482653|NCT06701305|DRUG|Acetaminophen|Oral solution
214316685|NCT04536727|BEHAVIORAL|Wait list|Participants randomized to the wait list group receive the 8-week Fit \& Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
214482654|NCT05908084|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV)|ATEV implantation
214482655|NCT05908084|OTHER|AVF|AVF creation procedure
214482656|NCT06701721|DRUG|THN391 MAD|Route of administration- IVT injection
214482657|NCT06700044|DIETARY_SUPPLEMENT|GutMagnific|Participants will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until gestational week 37
215061152|NCT01661751|BIOLOGICAL|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
215061153|NCT03667807|DEVICE|Repetitive transcranial magnetic stimulation|Non invasive brain stimulation
215061154|NCT02364115|RADIATION|Stereotactic Body Radiotherapy|
215061155|NCT05384106|DIETARY_SUPPLEMENT|(R)-1,3-butanediol|Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
215061156|NCT06162559|DRUG|Tucatinib|Tucatinib 300mg is taken orally twice daily
215061157|NCT06162559|DRUG|Trastuzumab|Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
215061158|NCT06162559|DRUG|Pertuzumab|Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
215061159|NCT02013557|BEHAVIORAL|Text-message reminder|
215061160|NCT05337111|OTHER|Cardiorespiratory fitness test|Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness
214482658|NCT06700044|DIETARY_SUPPLEMENT|Placebo|Participants will take one stick/placebo per day from gestational week 12 until partus.
214482659|NCT05650177|BEHAVIORAL|blended Mindfulness-Based Intervention (bMBI)|The blended Mindfulness-Based Intervention (bMBI) is a 24-week online course 'blended' with therapist support via video link. The entire course is completed online and requires no in person contact. The bMBI follows the general structure of Mindfulness-Based Cognitive Therapy (MBCT) with an added emphasis on the cultivation of self-compassion. The bMBI comprises of 9-themed sessions spread out over the 24-weeks. Each session involves: video instructions, written information, psycho-educational exercises, and guided meditation practices. Participants meditate for 30-minutes each day. Additional homework involves short daily activities designed to incorporate mindfulness into daily life and keeping a journal about experiences within and around the practices and exercises. The therapist sessions are every two weeks and last for 45-minutes and help participants overcome any problems they experience.
215061161|NCT05337111|OTHER|Resting measure of fat oxidation|Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
215061162|NCT05337111|OTHER|Maximum fat oxidation test|Progressive exercise test to determine maximum fat oxidation during exercise
215061163|NCT02912494|DRUG|JR-131|
215061164|NCT02912494|DRUG|Darbepoetin alfa|
215061165|NCT00984165|PROCEDURE|Single fraction radiation|8-Gy fraction of radiation
215061166|NCT00984165|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
215061167|NCT00984165|PROCEDURE|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
214482660|NCT06276387|BEHAVIORAL|Mindfulness Program|Participants will receive eight weekly 2.5-hour group sessions and one day-long silent retreat, delivered online. Intervention content will include the MBSR program, which has been extensively studied with many different chronic conditions, and augmentations for individuals with rheumatic diseases. Each MBSR session will include meditation practices (e.g., sitting meditation, body scan, gentle hatha yoga, walking meditation, mindfulness of daily activities, awareness of pleasant and unpleasant events) and review of home practice. Participants will complete daily home practices for about 45 minutes per day and log their practice.
214482661|NCT06700330|OTHER|no intervention, observational study|Only data from the patient file.
214482662|NCT06699030|DRUG|Functional fatty acids|Days 1-3: Oral Administration of functional fatty acids Days 4-6: Oral Administration of functional fatty acids
214482663|NCT06699030|OTHER|Placebo|Days 1-3: Placebo Days 4-6: Oral Administration of functional fatty acids
214482664|NCT06700460|DEVICE|Laser-assisted in Situ Keratomileusis|LASIK
214482665|NCT06700460|DEVICE|Implantable Collamer Lens placement|EVO ICL
214482666|NCT06627192|PROCEDURE|NSPT, clinical and biochemical assesment|Biochemical assessment using ELISA kit for Endcan and TNF alpha GCF sample
214482667|NCT06627244|DRUG|Tebentafusp|Tebentafusp will be administered intravenously to participants at or within 28 days of their first Y-90 TARE procedure. This 28-day period includes the 14- to 28-day Y-90 TARE Recovery Period. For administrative purposes, one cycle of tebentafusp treatment is 28 days in length. Tebentafusp will be administered on a dose escalation schedule for Cycle 1 starting at 20 mcg on Day 1, increasing to 30 mcg on Day 8, and a final dose of 68 mcg on Day 15, which will be administered once per week until unacceptable toxicity develops, disease progression, or withdrawal of consent, whichever occurs first.
214482668|NCT06627244|RADIATION|TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization|Participants will undergo radiographic and 99mTC-labeled macroaggregated albumin (99mTc-MAA) assessment for suitability prior to Y-90 absorbed glass microsphere treatment per institutional procedures. Y-90 trans-arterial radioembolization (TARE) is a standard of care treatment for intrahepatic metastases of uveal melanoma as indicated in the National Comprehensive Cancer Network (NCCN) consensus guidelines (NCCN Guidelines®, 2023). Y-90 absorbed glass microspheres will be administered at least one time prior to initiating Tebentafusp treatment. After the Y90-TARE procedure, participants will have a 14- to 28-day Y-90 TARE Recovery Period.
214482669|NCT06701526|DRUG|Eptinezumab|Solution for infusion
214482670|NCT06633029|DEVICE|Prismaflex HF20|CRRT fluid management and reduction of uremic toxins.
214482671|NCT06633029|DEVICE|Prismaflex M60|CRRT fluid management and reduction of uremic toxins.
214482672|NCT05846464|DEVICE|Meta Quest 2|The Meta/Oculus Quest (along with the SignWave software) delivers an immersive audio/visual-based game environment where the users hand is created and displayed in the virtual environment and matches target gestures to the beat of the music.
215061168|NCT02939820|DRUG|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
215061169|NCT04883294|DIAGNOSTIC_TEST|Electronic Nose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.
214316686|NCT05540964|OTHER|Antiretroviral Therapy Interruption(ATI)|Study participant that were previously infused with autologous genetically modified cell product will be taken off ART and followed closely by monitoring HIV rebound.
214316687|NCT01867593|DEVICE|C-11 methionine PET|
214316688|NCT01116258|DRUG|AZD5847|oral suspension, 15 days
214316689|NCT01116258|DRUG|Placebo|oral suspension, 15 days
214316690|NCT04160793|DEVICE|Genital Nerve Stimulation|Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
214316691|NCT01939587|DRUG|PBF-680 5 mg|
214316692|NCT01939587|DRUG|PBF-680 20 mg|
214918837|NCT02157285|BEHAVIORAL|Peer Mentor Counseling|Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
215061170|NCT06312410|OTHER|VIA Family 2.0|Multidisciplinary team based preventive intervention. For details, please see arm/group description.
215061171|NCT00500565|DRUG|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
214316693|NCT01939587|DRUG|Placebo|
214316694|NCT02188615|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
214316695|NCT02188615|DRUG|Cisplatin|only Radical Chemoradiotherapy
214316696|NCT02188615|DEVICE|Mckeown MIE|only Mckeown MIE using thoracoscopy and laparoscopy
214316697|NCT00885599|DRUG|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
214316698|NCT00885599|DRUG|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
214918838|NCT03006978|DEVICE|TearCare|
214918839|NCT03006978|DEVICE|Warm Compress|
215061172|NCT00500565|DRUG|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
215061173|NCT03198091|DRUG|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
215061174|NCT00529776|PROCEDURE|Continuous lateral rotation therapy|
215061175|NCT00466947|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
214316699|NCT00885599|DRUG|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
214316700|NCT00885599|DRUG|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
214316701|NCT01109082|PROCEDURE|posterior spine fusion|vertebrae are fused to straighten a spinal curve
214316702|NCT03272919|OTHER|Arm 1: Investigational INF|INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.
214316703|NCT03272919|OTHER|Arm 2: standardized muscle stretching and strength|subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist.
214316704|NCT03127969|OTHER|Fluidotherapy treatment|fluidotherapy and joint protection and exercise
214316705|NCT03127969|OTHER|Joint protection and exercise|joint protection and exercise
214316706|NCT05504629|BEHAVIORAL|Concurrent training order 1|atag
214316707|NCT05504629|BEHAVIORAL|RT+ET|aetaer
214316708|NCT00134212|DRUG|Dopexamine and norepinephrine|
214316709|NCT00134212|DRUG|Epinephrine|
214316710|NCT00343733|DRUG|OraVescent Fentanyl|
214316711|NCT03811795|OTHER|ECG monitoring with a Kardia Mobile monitor|The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.
214316712|NCT02964858|RADIATION|Standard Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT , CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
214482673|NCT06633445|PROCEDURE|botulinum toxin type A injection in lateral pterygoid muscle|"* Needle insertion guide will be placed on upper teeth.~* Needle will be inserted from needle insertion sleeve and 25-30 units of botulinum toxin type A will be injected.~* Aspiration will be done before injection, and then, the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle."
214918840|NCT05328206|OTHER|Standard of care for intubated children|Patient ventilated through a cuffed endotracheal tube and having a cuff leak test prior extubation
215061176|NCT00466947|BIOLOGICAL|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
214918841|NCT03606928|DRUG|docetaxel, oxaliplatin, 5-FU, leucovorin|This is a single-arm study with all patients receiving mFLOT chemotherapy.
214918842|NCT06574698|DRUG|Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy|Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
214316713|NCT02964858|RADIATION|Experimental Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT,CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
214316714|NCT03126097|DRUG|JNJ-64155806 150 mg|JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].
214316715|NCT03126097|DRUG|Ethinylestradiol/drospirenone 0.02 mg/3 mg|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
214316716|NCT03126097|DRUG|COCP Placebo|Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
214671620|NCT05858411|PROCEDURE|SRP+collagen sponge|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in saline solution.
214671621|NCT05858411|PROCEDURE|SRP alone|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
214918843|NCT00127998|DRUG|chloroquine|
214918844|NCT00127998|DRUG|sulfadoxine-pyrimethamine|
214918845|NCT00127998|DRUG|amodiaquine|
214918846|NCT00127998|DRUG|amodiaquine+artesunate|
214918847|NCT00127998|DRUG|amodiaquine+sulfadoxine-pyrimethamine|
214918848|NCT00127998|DRUG|sulfadoxine-pyrimethamine+artesunate|
214918849|NCT00127998|DRUG|artemether-lumefantrine|
214918850|NCT00127998|DRUG|mefloquine|
214918851|NCT03335007|DRUG|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
214918852|NCT03335007|OTHER|Placebo|Placebo tablet given one hour before starting the root canal treatment
214918853|NCT05720715|DRUG|cyclosporine A 0.05% eye drops|"Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months."
214918854|NCT06666530|OTHER|Questionary|Three self-questionnaires, either completed independently or with assistance, will be administered at inclusion (between the first obstetric ultrasound and 28 weeks of amenorrhea), during the third trimester of pregnancy, and at 1 year postpartum
214918855|NCT02073448|DRUG|GK530G|
214918856|NCT02073448|DRUG|CD0271|
214918857|NCT02073448|DRUG|CD1579|
214918858|NCT06580301|DRUG|YK012|The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.
215061177|NCT00466947|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
215061178|NCT00466947|BIOLOGICAL|Infanrix hexa|Intramuscular injection,3 doses
215061179|NCT00466947|BIOLOGICAL|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
214918859|NCT00327769|DRUG|Fulvestrant|250 mg intramuscular injection
214918860|NCT00327769|DRUG|Anastrozole|1 mg tablet
214918861|NCT02141412|DRUG|dexmedetomidine 0.25 µg/kg IV|
214918862|NCT02141412|DRUG|dexmedetomidine 0.5 µg/kg IV|
214918863|NCT02141412|DRUG|dexmedetomidine 1 µg/kg IV|
214918864|NCT02141412|DRUG|Placebo Comparator|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
214918865|NCT00436124|DRUG|oseltamivir [Tamiflu]|
214918866|NCT05730959|DEVICE|Sacral nerve modulation|Implant of nerve stimulator
214918867|NCT06682923|DEVICE|MolecuLight DX Imaging Device|The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
214918868|NCT01540214|OTHER|Pre- and postoperative evaluations|"At baseline before surgery and at 6 and 12 months after surgery: questionnaires, bladder diary, pelvic examination with additional ultrasound (one extra outpatient clinic visit at 6 months compared to standard care).~At baseline before surgery and at 12 months after surgery: urodynamics with additional urine sampling (one extra outpatient clinic visit at 12 months compared to standard care).~At time of surgery: additional cystoscopy."
214918869|NCT03079011|DRUG|Palbociclib 125mg|Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle
214918870|NCT03079011|DRUG|Aromatase Inhibitors|Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
214918871|NCT03079011|DRUG|Fulvestrant Injectable Product|500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
214918872|NCT05339711|OTHER|Robotic Pet Therapy/Robot Cat Group|"İn this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher."
214918873|NCT05339711|OTHER|Pet Therapy/Betta Fish Group|İn this study, two fish and the necessary materials (aquarium, fish food, plastic plant, aquarium stone, etc.) were given to the patients by the researcher to keep pets for eight weeks.
214918874|NCT03817008|PROCEDURE|Ascending aorta replacement with graft|Patient with planned Ascending aorta replacement with graft
214316717|NCT05444361|DEVICE|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
214316718|NCT05444361|DEVICE|Sham Comparator|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
214316719|NCT05196906|PROCEDURE|Modified Broström operation and anatomic reconstruction operation|Patients with CLAI and GJL will accept the Modified Broström operation or anatomic reconstruction operation.
214316720|NCT05537623|BEHAVIORAL|Safe Alternatives for Teens and Youths (SAFETY)|Please see description of experimental arm (arm one)
214316721|NCT05537623|BEHAVIORAL|Supportive Therapy|Please see description of active comparator arm (arm two)
214316722|NCT05855330|DRUG|Arginine Hydrochloride|Arginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes. However, rates may be slowed to over 60 minutes for patients experiencing symptoms of flushing, nausea, vomiting, or headache at the research team's discretion. Pediatric doses will be drawn up by the pharmacy.
214316723|NCT06093100|DEVICE|wearable technology|Three wearable devices
214316724|NCT04965636|DRUG|Mepolizumab|Mepolizumab will be provided in pre-filled safety syringe
214671622|NCT05751005|DIETARY_SUPPLEMENT|Collagen Peptides vs. Placebo|Participants were randomized into one of three treatment groups.
214918875|NCT06321861|DIETARY_SUPPLEMENT|Caffeine|Participants will take one caffeine pill. The dose of caffeine will be calculated based on participants' body mass (3mg/kg body mass). Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
214918876|NCT06321861|DIETARY_SUPPLEMENT|Placebo|Participants will take one pill with no caffeine in it. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
214918877|NCT06321861|OTHER|No substance|Participants will take no substance. They will just wait 60 minutes and then engage in the exercise protocol.
214918878|NCT00266578|DRUG|Fluticasone Propionate|Flovent vs. placebo daily for 3 months
214918879|NCT00438607|DRUG|BIIB014|oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
214918880|NCT00438607|DRUG|Placebo|Matched placebo for MTD or MTD-1
215061180|NCT06442566|DRUG|Buprenorphine Patch|Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
215061181|NCT06442566|DRUG|Placebo|double-blinded randomization to placebo or transdermal buprenorphine
215061182|NCT06442566|DEVICE|Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to REAL intermittent theta burst (iTBS) rTMS
215061183|NCT06442566|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to SHAM intermittent theta burst (iTBS) rTMS
215061184|NCT02755662|DEVICE|Mandibular Retention Device|
215061185|NCT02220192|PROCEDURE|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
215061186|NCT02082444|OTHER|Skipping lunch|
215061187|NCT02540512|PROCEDURE|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
215061188|NCT02540512|DEVICE|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
215061189|NCT02540512|PROCEDURE|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
215061190|NCT02540512|DRUG|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
215061191|NCT02540512|DRUG|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
215061192|NCT03371576|DEVICE|intraocular lenses|
215061193|NCT04833660|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a safe, noninvasive, and effective therapeutic intervention that uses an electromagnetic coil applied to the scalp to produce a magnetic field. rTMS induces changes in cortical excitability at the stimulation site and transsynaptically at distant areas. Cortical excitability is increased by high-frequency (≥5 Hz) stimulation and is decreased by low-frequency (1 Hz) stimulation. The application of high-frequency unilateral rTMS to the motor cortex in patients is reported to have a potential to control various types of pain, such as neuropathic pain, fibromyalgia, and musculoskeletal origin pain (myofascial pain syndrome, shoulder pain, and lower back pain).
215061194|NCT00348738|DRUG|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of \>14g/dl, \<15g/dl is reached or until the end of the radiation therapy.
214316725|NCT06311461|PROCEDURE|Acupuncture|The acupuncturist will swab each point with alcohol. Needles will be inserted and retained for 30 minutes. Each needle will be rotated 3 times to stimulate the qi in the meridian; 10 minutes after insertion, 20 minutes after insertion, and just prior to removal at 30 minutes. Needles will be inserted using the standards of clean needle technique established by the Council of Colleges of Acupuncture and Oriental Medicine. One size acupuncture needle, 0.25 diameter × 40 mm length, will be used. All acupuncture needles are sterile, disposable, and made of surgical stainless steel with stainless steel wound heads. Sessions will be repeated twice weekly (with at least 2 off days in between) for 5 weeks (10 sessions).
214316726|NCT06311461|OTHER|Attention control|Viewing non-pain related TED talk videos over 5 weeks approximately equal to 10 hours of treatment for the acupuncture group.
214316727|NCT06501235|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|An adaptation of the Robles and Peralta's (2010) stress management program will be followed. This program includes key techniques from the CBT approach, such as deactivation techniques, cognitive restructuring, and assertiveness training.
214482674|NCT06633445|PROCEDURE|botox injection in lateral pterygoid muscle|"* A 27- gauge needle electrode will be inserted lateral to the maxillary tuberosity, just above the maxillary molars to inject 25-30 units of botulinum toxin type A under electromyographic guidance.~* Aspiration will be done before injection, and then the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle.~* The intramuscular injection will be confirmed when the electromyographic device produces a distinct loud sound."
215061195|NCT05631171|BEHAVIORAL|Adhera® Fatigue Digital Program|"Adhera® Fatigue Digital Program, that includes an application and a smartwatch, is a digital health solution based on emotional and behavioral change techniques. Patient adaptative self-management content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 3 months to detect biometric and psychometric (patient-reported outcomes) information."
215061196|NCT04797689|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
215061197|NCT04797689|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
215061198|NCT04976790|BEHAVIORAL|Chinese Tuina therapy|Firstly, the patient is in the prone position, and the doctor use the method of rolling or kneading the Bladder meridians on both sides of the spine. The waist will be focused on to manipulate preferentially and then using the same technique on the patient's back, buttocks and lower limbs. Secondly, the physician will perform the manipulation on the patient's waist and the posterolateral side of the lower limbs by pressing, kneading, plucking. The doctors press the acupoints, including Mingmen(DU04),Shenshu(BL23),Yaoyangguan(DU03),Huantiao(GB30), Weizhong(BL40),Chengshan(BL57),and Ashi points, with the elbow or the thumb to achieve Deqi sensation. Thirdly, the The doctor uses the method of pressing acupoints, including Tianshu(ST25),Qichong(ST30),Chongmen(SP12),Daimai(GB26),Jingmen(GB25) on both sides. Fourthly, the patient is required to face the doctor in a lateral position for pulling manipulation on the both sides of lumbar vertebrae.
215061199|NCT04976790|DRUG|Flurbiprofen Cataplasms group (FCG).|One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
215061200|NCT03086616|DRUG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
215061201|NCT03066323|OTHER|Rice with tea extract|Rice with tea extract
215061202|NCT03066323|OTHER|Rice without tea extract|Rice without tea extract
215061203|NCT03850093|DRUG|Gabapentin1200 mg|patients received 1200mg gabapentin 2 hrs preoperative
215061204|NCT03850093|DRUG|bisoprolol 2.5mg|patients received 2.5mg bisoprolol 2 hrs preoperative
215061205|NCT03850093|DRUG|placebo|patients received oral placebo 2 hrs preoperative
215061206|NCT02160249|BEHAVIORAL|Community-based rehabilitation|
215061207|NCT02160249|OTHER|Facility based care|
215061208|NCT03352999|PROCEDURE|Fast track access to vaECMO|"ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed."
215061209|NCT03694340|OTHER|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
215061210|NCT03637361|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
215061211|NCT03637361|DRUG|Placebo|
214918881|NCT01216956|DRUG|Extended-release nicotinic acid versus placebo|Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
214918882|NCT02751450|DEVICE|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
214482675|NCT05357222|BEHAVIORAL|Straw phontion|"Pitch Glides: (1 minute) Vocalize through the straw starting from as low as possible to as high as possible. As the participant you will want to get as much as your vocal range as possible. But, don't let the voice get growly at the bottom or press it into a painful range at the top.~2\. Accents: (1 minute) Vocalize progressive little hills or accents. It sounds like a revving engine of the car.~3\. Song: (1 minute) Pick a favorite song and vocalize it through the straw. Examples: National Anthem, Happy Birthday, Mary had a Little Lamb. These are great songs because they have a range of pitches and one can build some accents in, as well.~4\. Reading passage: (1 minute) Vocalize a reading passage through the straw. Be as dramatic as possible, using a lot of inflection."
214316728|NCT06501235|BEHAVIORAL|Virtue-Based Intervention (VBI)|A Well-being Training based on Contemplative Practices (WTCP) (Cebolla \& Alvear, 2019; Alvear \& Cebolla, 2023) will be followed. WTCP combines mindfulness practices with various activities based on virtues such as gratitude, altruism, or compassion. This program focuses on generative or constructive meditations, and puts special emphasis on virtuous actions, emotion regulation (both positive and negative emotions) and compassion, and includes strategies from positive psychology, such as strengths-based interventions, savoring, kindness, or the three good things.
214316729|NCT05637437|BEHAVIORAL|Peer supported diabetes self-care intervention|"Participants in the intervention group will attend a multi-faceted 8 weeks peer supported diabetes self-care intervention through digital communication.~* Weekly group video telephony meeting facilitated by trained peer supporters.~* Support and assistance through instant messaging services between peer supporters and participants."
214316730|NCT05637437|OTHER|Usual care|Participants in the control group will receive the usual care of the hospital.
214482676|NCT06822322|PROCEDURE|Percutaneous Coronary Angioplasty|"A Percutaneous Coronary Intervention is used in both arms, with the drug Zotarolimus for stenting strategy and Paclitaxel for balloon strategy.~Coronary guide wires are passed into both the distal main vessel (distal MV) and side branch (SB) and predilation of MV on a 1:1 basis is required.~The device component dilates the vessel lumen by Percutaneous Transluminal Coronary Angioplasty (PTCA), while the drug is intended to reduce the proliferative response associated with restenosis."
214482677|NCT06822322|DEVICE|Stepwise Provisional Stent Strategy|In the stepwise provisional stent strategy, stenting of the MV is undertaken with a wire jailed in the SB. Then, non-compliant balloons sized to the diameter of the distal MV and SB are sequentially inflated at high pressure, and then simultaneously at low pressure (kissing balloon inflation ; KBI).
214482678|NCT06822322|DEVICE|Drug Coated Balloon Strategy|In the drug coated balloon (DCB) strategy, SB is prepared with a balloon at a 1:1 diameter, followed with a 1:1 sized DCB inflation for 60 seconds at nominal pressure. Then, MV is re-evaluated and treated with DCB at nominal pressure only, sized 1:1 with the proximal MV, for 60 seconds.
214482679|NCT06822322|DEVICE|Cross-Over Stepwise Provisional Stent Strategy|Following Drug Coated Balloon treatment in the Main vessel (MV) in the Drug Coated Balloon Arm, if the result is unacceptable in the MV, with either TIMI\>3 flow and/or dissection propagation, MV stenting is mandatory followed with Kissing Balloon Inflation (KBI), where non-compliant balloons sized to the diameter of the distal main and side branch are sequentially inflated at high pressure, and then simultaneously at low pressure. If the cross-over stent implantation in the MV is used, a further SB treatment with either DCB or stent implantation is used, according to operator preference.
214482680|NCT03875339|BEHAVIORAL|Navigator Guidance|Use of a dedicated Navigator to determine if follow-up and compliance rates can be improved for those infants initially demonstrating an abnormal hearing result.
214482681|NCT06802939|DEVICE|rTMS|RTMS using pseudo stimulus intervention in weeks 1-2, for a total of 10 days. After resting for 2 weeks, enter the 3-4 weeks of real stimulation, with 5 days of intervention per week for a total of 10 days. Application of rTMS for 1Hz low-frequency intervention, with intervention parameters of 1400 sessions, 100% exercise threshold, and a total of 23 minutes per session. After each target intervention, rest for half an hour to one hour.
214482682|NCT06048068|BEHAVIORAL|Educational Informational Platform|This intervention contains many informational articles for surrogates about cardiac arrest, the subsequent hospitalization, and the emotional journey following cardiac arrest. All articles are available in both English and Spanish.
214316731|NCT00654160|DRUG|fluorouracil|
214316732|NCT00654160|DRUG|irinotecan hydrochloride|
214316733|NCT00654160|DRUG|leucovorin calcium|
214316734|NCT00654160|OTHER|pharmacogenomic studies|
214918883|NCT02751450|OTHER|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
214955186|NCT01460602|DRUG|MTD of Velcade, Nipent and Rituxan established in Part 1|"One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1"
214316735|NCT00654160|OTHER|pharmacological study|
214316736|NCT02241499|RADIATION|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
214316737|NCT02241499|DRUG|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
214316738|NCT00287664|DRUG|terlipressin|
214316739|NCT04277754|OTHER|Observational|To Observe and describe motor and visual development
214316740|NCT04268420|DRUG|FMP013|Falciparum Malaria Protein-13
214316741|NCT04268420|DRUG|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
214316742|NCT05463302|DEVICE|Active sleepgift blanket|Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.
214316743|NCT05463302|DEVICE|Sham Sleepgift Blanket|Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.
214316744|NCT03904888|PROCEDURE|r-TAPP|Robot-assisted repair
214316745|NCT03904888|PROCEDURE|l-TAPP|Laporoscopic repair
214316746|NCT03904888|PROCEDURE|local anesthetics|local anesthetics will be administred
214316747|NCT02437851|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery to remove anal or perianal cancer (SISCCA)
214316748|NCT04231877|DRUG|Polatuzumab Vedotin|Given IV
214316749|NCT04231877|BIOLOGICAL|Rituximab|Given IV
214316750|NCT04231877|DRUG|Prednisone|Given PO
214482683|NCT06054802|DEVICE|eCAP|eCap™ has the look and feel of a regular prescription bottle and records real-time adherence data, tracking each opening with the date and time.
214482684|NCT06118099|DRUG|Amlitelimab|Injection solution SC injection
214482685|NCT06118099|DRUG|Placebo|Injection solution SC injection
214482686|NCT05927142|BIOLOGICAL|Durvalumab|Human anti-PD-L1 antibody
214671623|NCT00922545|OTHER|Implementation of Clinical Practice Guidelines (GPC) and Health Education Program|Intervention: The program includes giving clinical results to the health care workers(doctor and nurse), from the medical records and interview. A training course (20h)that deals with aspects related to GPC, motivational interview and health education (tobacco, inhalers, alimentation, exercise and physiotherapy).
214316751|NCT04231877|DRUG|Etoposide|Given IV
214316752|NCT04231877|DRUG|Doxorubicin|Given IV
214316753|NCT04231877|DRUG|Cyclophosphamide|Given IV
214316754|NCT04231877|BIOLOGICAL|Glofitamab|Given IV
214316755|NCT04231877|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214316756|NCT04231877|PROCEDURE|Echocardiography|Undergo echocardiography
214316757|NCT04231877|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET scan
214316758|NCT04231877|PROCEDURE|Computed Tomography|Undergo CT scan
214316759|NCT04231877|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214316760|NCT04231877|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214316761|NCT04231877|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214482687|NCT05927142|DRUG|Rintatolimod|TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)
214482688|NCT05967416|BIOLOGICAL|SIRPant-M|Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection
214955187|NCT01692522|PROCEDURE|Intubation|visualized blind intubation
214955188|NCT03051438|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi.
214955189|NCT03051438|PROCEDURE|Three-port VATS|The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi
214482689|NCT05967416|RADIATION|External-beam radiotherapy (XRT)|Radiotherapy given by external beam to the IT-injected lesion only
214482690|NCT06242002|PROCEDURE|Set up of sensor|Surgery is performed as usual for patients needing this medical procedure. At the end, the sensor is set up under the surgical dressing.
214482691|NCT06186102|DIETARY_SUPPLEMENT|Spermidine|Spermidine capsule of 8 mg x 3 capsules daily.
214316762|NCT06571110|PROCEDURE|Traditional Acupuncture|Acupuncture is a type of treatment where thin needles are gently inserted into specific parts of your body. It's often used to help with things like pain, headaches, stress, and anxiety.
214316763|NCT06571110|PROCEDURE|Sham Acupuncture|Sham acupuncture in this trial involves the insertion superficially to mimic the procedure of true acupuncture without providing any therapeutic effect. The needles will be similar to those used in the true acupuncture group but will not be stimulated, ensuring blinding and controlling for placebo effects.
214316764|NCT06810076|BEHAVIORAL|Machine Learning-Based Clinical Decision Support: Overdose Prevention Alert (OPA) Intervention|In this study, researchers will pilot test an interruptive, ML CDS tool for opioid overdose risk across thirteen primary care clinics at the UF Health in Gainesville, FL. When a patient is identified by the ML algorithm as having an elevated overdose risk and a PCP signs an opioid prescription for the patient, an Opioid Prevention Alert (OPA) will be triggered. The alert will include the rationale for the patient's elevated risk status and provide three risk mitigation recommendations: optimizing pain treatment and mental health support, reviewing and discussing risks with the patient, and offering naloxone annually if no prior naloxone order is found in the patient's record. PCPs can also select an override reason, such as the patient already has naloxone, declined the intervention, is not present/it is not the right time, or the alert is not relevant/other comments, when appropriate.
214316765|NCT05660824|DEVICE|Stromal Vascular Fraction infiltration|Procedure to prepare SVF: In the operations room and after aseptic technic, local anesthesia is applied in the liposuction incision site with lidocaine 1% without epinephrine subcutaneously. 60 ml of tumescent solution are injected. After 15-20 minutes waiting, 15 ml of lipoaspiration per side are recollected into a double syringe. This is centrifuged for 4 minutes at 2.500 rpm and the remaining fat is separated from the other fractions. Two 1.4 mm GEMS syringes are attached together, and fat is transferred at least 30 times from one syringe to the other. Syringe content is again centrifugated for 4 minutes. The oil is discarded and approximately 1.5ml SVF fraction remains.
214482692|NCT06186102|OTHER|Placebo|Placebo capsule. 3 capsules daily.
214482693|NCT05339269|PROCEDURE|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
214482694|NCT04805814|DIAGNOSTIC_TEST|CMR results disclosed|The results of the CMR are disclosed, and used to guide management
214482695|NCT04805814|DIAGNOSTIC_TEST|CMR performed but results not disclosed|The results of the CMR are not disclosed, and management is angiography-guided
214482696|NCT06439342|DRUG|Maribavir|Maribavir tablets
214482697|NCT05068960|DRUG|Liposomal bupivacaine|Addition of liposomal bupivacaine to the interscalene block for extended pain control following total shoulder arthroplasty
214482698|NCT05068960|DRUG|Bupivacaine|Interscalene block with bupivacaine for pain control following total shoulder arthroplasty
214316766|NCT05660824|PROCEDURE|Plattelet Rich Plasma infiltration|Procedure to prepare PRP: 15 cm of peripheral blood obtained by venipuncture are centrifugated at 1500 RPM during 5 minutes. Using PRP Arthrex kit platelets poor plasma is discarded and 1-3 mm of PRP are ready to be injected
214316767|NCT06653166|DEVICE|bougie (S Guide)|bougie (S Guide)
214316768|NCT06653166|DEVICE|videolaryngoscopy|videolaryngoscopy hyperangulated or Macintosh
214316769|NCT04760275|DRUG|Fluoxetine|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT)."
214316770|NCT04760275|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of weekly CBT implemented with Coping Cat (CC). In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with CBT. All participants who do not remit will be randomized (1:1) to either (1) optimization of CBT (intensifying exposure practice and skills review), or (2) optimization of CBT and addition of the medication fluoxetine."
214316771|NCT02207049|BEHAVIORAL|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
214316772|NCT02207049|BEHAVIORAL|No Snacking|Caloric needs will be provided to preschoolers within three meals
214316773|NCT06200532|OTHER|FOOTSAK (FOOTwear self-assessment kit)|FOOTSAK is a Footwear Self-Assessment Kit intended to empower people with diabetes by providing the necessary tools and instructional materials to enable self-assessment to determine whether footwear has adequate length and width. It includes measuring tools (an internal footwear length gauge, scale dividers for measuring internal footwear width, a slide rule for measuring foot length and width, a ruler and magnifying glass for reading off measurements) and instructional materials (booklet instructions and video materials)
214316774|NCT05377905|DRUG|Microneedle Array Doxorubicin (MNA-D)|The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications
214316775|NCT05804175|DEVICE|Linshom Continuous Predictive Respiratory Monitoring|Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
214482699|NCT06871787|DRUG|Indocyanine Green|Indocyanine green (ICG), administered intravenously at a dose of 2.5 mg/ml, will be used during surgery to evaluate bowel anastomosis perfusion through near-infrared fluorescence imaging.
214482700|NCT06871787|DEVICE|Near-Infrared Fluorescence Imaging System|A near-infrared fluorescence imaging device will be used intraoperatively to visualize indocyanine green (ICG) fluorescence, assessing the perfusion of bowel anastomoses during gynecologic oncology surgery.
214482701|NCT06873750|DEVICE|Transcranial Alternating Current Stimulation|Application of low amplitude alternating electric current across the participant's scalp.
214482702|NCT06875323|OTHER|ECHO-FostrSpace|Six ECHO-FostrSpace session training for CASA volunteers.
214482703|NCT06875323|OTHER|Informational Session|One ECHO-FostrSpace session training for CASA volunteers.
214482704|NCT06011876|OTHER|Acute Intermittent Hypoxia (AIH)|AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
214955190|NCT00177866|DRUG|Celebrex|"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."
214316776|NCT05512507|BEHAVIORAL|Physical Therapy Program|Physical Therapy Program
214316777|NCT05832645|OTHER|Meditation with guided tea consumption|Mindful consumption of tea along with an approximately 10-min guide
214316778|NCT05832645|OTHER|Breathing meditation|10-min breathing meditation
214316779|NCT04917744|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214316780|NCT04917744|OTHER|Laboratory Biomarker Analysis|Ancillary studies
214316781|NCT04917744|OTHER|Medical Chart Review|Review of medical charts
214316782|NCT00938145|PROCEDURE|Specimen Ultra-High field MRI|Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.
214316783|NCT00938145|DRUG|chemotherapy|The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
214482705|NCT06011876|OTHER|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).
214482706|NCT06011876|OTHER|Sham AIH|A single session of sham AIH with episodes of normal room air (21% O2).
214482707|NCT06277141|BEHAVIORAL|Standard message|Participants will receive standard messaging based on the Cancer Association of South Africa (CANSA) recommendation on breast cancer screening and a reminder to screen for breast cancer.
214482708|NCT06277141|BEHAVIORAL|Radiology booking site link.|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site.
214482709|NCT06277141|BEHAVIORAL|Radiology practice telephone numbers|Participants will receive a reminder to screen for breast cancer together with a list and telephone numbers of radiology practices
214955191|NCT00177866|DRUG|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
214482710|NCT06277141|BEHAVIORAL|Radiology site link and telephone numbers|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site and a list and telephone numbers of radiology practices
214482711|NCT04831320|DRUG|nab-paclitaxel|Supplied by Celgene Corporation
214955192|NCT01023425|DRUG|donepezil|from 5mg to 10mg, once a day, 12 months
214316784|NCT00938145|PROCEDURE|Cystectomy and Lymphadenectomy|The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
214316785|NCT04828889|DEVICE|Anal dilators|Anal sphincter training for relaxation
214316786|NCT04828889|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy is a firmly established method for treating anal fissures.
214316787|NCT00256698|DRUG|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
214316788|NCT00256698|DRUG|Anastrozole|1 mg oral tablet
214316789|NCT06856720|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Participants will receive NMES application for 30 minutes, three times a week, over a period of 12 weeks. The sessions will be supervised by a physiotherapist. Large muscle groups (quadriceps) will be used, with the following current parameters: frequency of 5 Hz, pulse width of 400 μs, 4 seconds of stimulation (on) for 12 seconds of rest (off), and intensity adjusted to the maximum tolerable level for the patient. These parameters are based on studies that have shown significant improvements in glycemic control and insulin sensitivity, especially in older adults with type 2 diabetes.
214316790|NCT06856720|BEHAVIORAL|Aerobic and resistance exercise|This group will participate in an exercise program combining aerobic and resistance activities, performed three times per week for 12 weeks. The activities will be adapted to the participants' physical capabilities and supervised by a physiotherapist. The program follows the international recommendations and it includes a 5-minute warm-up with flexibility exercises, 20 minutes of aerobic exercise at 60-75% of maximum heart rate or moderate perceived exertion, 20 minutes of resistance exercise at 50-70% of one-repetition maximum (1RM) focusing on large muscle groups (10-15 repetitions per exercise, 1-3 sets), and a 5-minute cool-down with static stretching and breathing exercises for relaxation.
214316791|NCT06856720|BEHAVIORAL|Health literacy education|Participants will receive educational sessions on diabetes management, the role of exercise in glycemic control, and strategies to enhance adherence to physical activity.
214316792|NCT04399928|DEVICE|Total Hip Arthroplasty|Total hip arthroplasty with the R3 Acetabular Hip system.
214316793|NCT02620046|DRUG|Vedolizumab SC|Vedolizumab SC 108 mg injection
214316794|NCT06826196|DRUG|ALD-102|Treatment every 4 weeks for total of 8-week treatment period.
214316795|NCT06826196|DRUG|Placebo|Treatment every 4 weeks for 8-week treatment period
214316796|NCT05462340|DRUG|[18F]ASEM|\[18F\]ASEM demonstrated excellent imaging properties, as was recently confirmed by others. \[18F\]ASEM is the 1st validated α7 human PET radiotracer to examine α7-nAChR characteristics in the living brain of SCZ patients. Previous α7 studies in the SCZ literature were done using brains harvested post-mortem, and under variable storage conditions. The proposed studies will also determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
214316797|NCT05462340|DRUG|[18F]AZAN|The most widely used PET radioligand for human imaging of α4β2-nAChR is 2-\[18F\]FA. Because 2-\[18F\]FA exhibits very slow brain kinetics, the investigators developed \[18F\]AZAN, a highly α4β2 specific tracer with optimal brain kinetics. Therefore, the proposed studies will utilize \[18F\]AZAN to determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
214316798|NCT02814786|RADIATION|MRI scanner|"This examination is divided in 2 parts:~* Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.~* Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome."
214316799|NCT02814786|OTHER|Gait analysis|For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.
214316800|NCT05365672|BIOLOGICAL|MIC|Single intravenous infusion of 1.5x10exp8 MIC per kg of body weight
214316801|NCT05365672|OTHER|Standard of Care|No application of the investigational medicinal product MIC
214316802|NCT05969314|DRUG|Cannabis capsules|Cannabis capsules containing 5 mg of THC and CBD each or 2.5 mg of THC and CBD each.
214316803|NCT03974750|DEVICE|Bimanual motor skill learning with the REAplan(R) rehabilitation robot|REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
214316804|NCT06586281|DRUG|Guselkumab|This is a longitudinal study consisting of a two-time visit by psoriatic arthritis patients. The aim of the study is to determine the effect of biological therapies in liver disorders in patients with psoriatic arthritis.
214316805|NCT06598124|OTHER|Investigational Product (IP)|1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.
214316806|NCT06598124|OTHER|Comparator Product (CP)|1 single dose of CP consisting in 400 mL of milk with lactose
214316807|NCT04287738|BEHAVIORAL|Navigated Care|Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
214316808|NCT00593671|PROCEDURE|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
214316809|NCT01909349|BEHAVIORAL|self-regulation|Web-based support for behavior change regarding physical activity and fruit \& vegetable consumption
214316810|NCT01184547|BEHAVIORAL|Combex|12 weeks of exercise with a trainer post discharge.
214671624|NCT03741881|OTHER|No treatment given|Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
214671625|NCT00193362|DRUG|Paclitaxel|
214482712|NCT04831320|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
214316811|NCT01184547|BEHAVIORAL|Standard of Care|No exercise training received.
214316812|NCT01653496|PROCEDURE|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
214316813|NCT05659628|COMBINATION_PRODUCT|CD19-7×19 CAR-T combined with Tislelizumab|Participants will receive 2×106/Kg CD19-7×19 CAR-T cells infusion and Tislelizumab 200mg every 21 days for 6 cycle on the 31st day after CAR-T infusion.
214316814|NCT03594097|OTHER|Treatment cookies|Plain flour, Coconut Nourish, Queen Garnet Plum, Unsalted Butter, Artificial Sweetener
214316815|NCT03594097|OTHER|Control cookies|Plain flour, Coconut Powder, Unsalted Butter, Artificial Sweetener, Food Colour
214918884|NCT05946317|PROCEDURE|Lingual nerve function assessed after removal of mandibular third molar with lingual split technique|The lingual split technique is based on using chisel and hammer in bone removing. After the buccal and lingual flaps are raised and retracted. Two buccal bone cutting with horizontal cutting up between them are performed, The disto-lingual bone fragment is fractured inward by placing the cutting edge of the chisel at 45 degrees with the surface of the bone and directed towards the lower second premolar of the opposite side. By maintaining the cutting edge of the chisel parallel to the external oblique ridge, a few light taps with the mallet will separate the lingual plate from the rest of the alveolar bone. And it released from soft tissues, buccally force is applied to roll the whole tooth lingually. The neurological function of the lingual nerve was assessed after the demise of local anesthesia, then the location of the disorder and taste function and healing time are determined by sensory neurological tests on a graphic map that divides the tongue into sextants.
214918885|NCT06666816|OTHER|inapplicable|inapplicable
214316816|NCT06987695|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be administered SC.
214482713|NCT06870136|DIETARY_SUPPLEMENT|Lion's Mane Study Product|The Lion's Mane Study product contains vegetable cellulose (capsules), Certified organic Lion's Mane (Hericium erinaceus) fruiting body and mycelial biomass cultured on certified whole oats (Avena sativa). Screening assessments, scales and surveys during baseline and during the use of the study product/placebo and end of study experience survey data will be collected.
214482714|NCT05567120|OTHER|PATH-Care|Individuals will receive the 8-session PATH-Care intervention, delivered virtually (via videoconference or phone) to mitigate negative emotions and stress experienced by informal caregivers of individuals with ADRD. The therapist in the first session will also guide the participant in the tablet-based exercises (WELLPath).
214482715|NCT06362382|BEHAVIORAL|tele-rehabilitation training|"During their stay in the hospital, the patients were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle of (7 days ± 3 days 1 week/times) standardized training.~After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily （a total of 3 months）training sessions and intensive supervision and management by the online community at least once a week. All patients' routines were monitored by telemetry and data, photographs and video recordings were collected by a specialized agency.~The scheme of rehabilitation is impedance training. A specialized professional team including cardiologists, rehabilitation trainers, psychotherapists and radiologists were involved."
214316817|NCT06987695|DRUG|Placebo|Placebo will be administered SC.
214316818|NCT06854653|DRUG|PTX-100|Peptidomimetic inhibitor of GGTase 1
214316819|NCT03244124|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
214316820|NCT03244124|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
214482716|NCT06362382|BEHAVIORAL|health propaganda and education|"During their stay in the hospital, participants of the control group received health propaganda and education (7 days ± 3 days 1 week/times).~After discharge from the hospital, the control group followed their daily routine."
214482717|NCT05980494|DRUG|normal Saline|normal saline cyrstalloids infusion with rate of 4ml/kg /h for 3 hours
214482718|NCT05980494|DEVICE|lung ultrasound|Lung ultrasound by Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID:1385 will scan For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines for a total of 28 sectors will be identified
214482719|NCT05980494|DEVICE|inferior vena cava measurements|The inferior vena cava was explored in the subxiphoid window in its sagittal view-just below the junction between the inferior vena cava and suprahepatic veins which lie approximately 0.5 to 3 cm from the right atrium, following the American Society of Echocardiography guidelines.; The (IVC distensibility index (dIVC) was calculated as (maximum diameter - minimum diameter)/minimum diameter.
214671626|NCT00193362|DRUG|Carboplatin|
214918886|NCT05639816|PROCEDURE|Saline irrigation group|Normal saline irrigation of common bile duct after complete stone removal
214955193|NCT05765071|BIOLOGICAL|Botulinum toxin A|Botulinum injections will be prepared by diluting 100 units of botulinum toxin A with 5.0mL of saline (20.0U/mL). A total of 100 units (5.0mL) of botulinum toxin A will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
214955194|NCT05765071|BIOLOGICAL|Normal saline|A total of 5.0mL of normal saline will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
214955195|NCT03785314|OTHER|thoracic epidural catheterization|thoracic epidural catheterization with different posture
214316821|NCT03244124|OTHER|Etch&Rinse Dry Application Strategy|In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
214316822|NCT03244124|OTHER|Etch&Rinse Wet Application Strategy|In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
214316823|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
214316824|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
214316825|NCT06329453|PROCEDURE|Colon Tissue Biopsy|Colonoscopy and colon tissue biopsy.
214316826|NCT06275165|OTHER|acupressure|In the experimental group, routine nursing care and acupressure (Neiguan and Zusanli points) were performed from the 1st to the 5th day after the postoperative transfer from the ward to the hospital room. Twice a day, 3 minutes each time, 12 minutes in total.
214316827|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography (Baseline)|Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
214316828|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography ( At the end of surgery)|Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
214316829|NCT06663605|DRUG|PALI-2108|Oral dose
214316830|NCT06663605|DRUG|PALI-2108 Placebo|Oral dose
214955196|NCT05867680|BEHAVIORAL|Online Mothers and Babies Course (eMB)|The eMB is an online, asynchronous, self-administered intervention modeled after the efficacious and in-person Mothers and Babies Course. (4) The eight-week course includes psychoeducational modules containing YouTube videos, vignettes, interactive quizzes, homework, guided meditations, and downloadable resources that teach strategies to promote a healthy outcome for mothers and their newborns: 1) overview, 2) thoughts and my mood, 3) fighting harmful and increasing helpful thoughts, 4) activities and my mood, 5) pleasant activities help make a healthy reality, 6) contact with others and my mood, 7) planning for the future and graduation, 8) relaxation exercises.
214955197|NCT04017871|OTHER|MRI|MRI at baseline and J90
214316831|NCT04116853|BEHAVIORAL|ADAPTIVE Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
214316832|NCT04116853|BEHAVIORAL|STATIC Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
214316833|NCT05778734|BEHAVIORAL|CM-PST|CM-PST is a tailored behavioral intervention that enables young adults with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake.
214316834|NCT05778734|BEHAVIORAL|CM only|CM is a behavior therapy that rewards individuals for evidence of positive change (alcohol abstinence).
214316835|NCT00157378|DRUG|Risperidone, Haloperidol|
214316836|NCT06074107|DRUG|BEBT-908 for injection|The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
214316837|NCT04141995|DRUG|Digoxin|Tablet, Oral: Generic: 0.125 mg, 0.25 mg
214316838|NCT04141995|DRUG|5Fluorouracil|5-FU will be given as a 46 hour continuous IV infusion
214316839|NCT04141995|DRUG|Calcium Leucovorin|IV injection over 90 minutes
214316840|NCT04141995|DRUG|Irinotecan|IV administration over 90 minutes
214316841|NCT04141995|DRUG|Oxaliplatin|IV administration
214316842|NCT03962543|DRUG|Mirdametinib (PD-0325901) oral capsule or dispersible tablet|Mirdametinib (PD-0325901) capsule or dispersible tablet
214316843|NCT06608069|BEHAVIORAL|Educational counselling|Enrolled participants will be counselled and educated by pharmacist on the therapy and benefits of adherence.
214316846|NCT07110350|PROCEDURE|Laparotomy refers to a definitive single-stage exploratory abdominal surgery. Damage Control Surgery refers to a staged surgical approach including initial abbreviated laparotomy followed by planned.|This intervention involves exploratory laparotomy performed for abdominal trauma at a single tertiary care trauma center in Taiwan between 2013 and 2024. Patients are stratified based on whether they received a single definitive laparotomy or staged damage control surgery. Staged surgery is defined as an abbreviated initial laparotomy followed by planned reoperation(s), regardless of whether physiological indications were strictly met. This study specifically investigates the discrepancy between guideline-based indications and actual surgical practice.
214671627|NCT00193362|DRUG|Gemcitabine|
214671628|NCT00193362|DRUG|Vinorelbine|
214671629|NCT03968861|DRUG|Xenon|Inhaled xenon gas given via purposely designed ventilator
214316847|NCT06676657|DEVICE|iPancreas automated insulin delivery system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The MPC has a new feature called hyperglycemia pattern detection and dosing algorithm that will analyze problem patterns associated with high blood sugar and automatically calculate and deliver a correction dose.
214316848|NCT06866548|DRUG|anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)|"Drug: Teprotumumab/IBI311 Given by IV infusion Initiate dosing with 10 mg/kg for first infusion, followed by 20 mg/kg every 3 weeks.~Drug: Tislelizumab Given by IV infusion 200 mg every 3 weeks"
214316849|NCT06689436|DRUG|5 mg Apixaban Oral Dissolving Film (fasting)|Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally after at least 10 hours overnight fast
214316850|NCT06689436|DRUG|5 mg Apixaban Oral Dissolving Film (fed)|Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that is preceded by at least 10 hours overnight fast
214316851|NCT06689436|DRUG|5 mg Apixaban Oral Tablet (US RS/RLD)|Single dose of 5 mg Apixaban Oral Tablet (US RS/RLD) will be administered orally after at least 10 hours overnight fast
214316852|NCT06689436|DRUG|5 mg Apixaban Oral Tablet (EU product)|Single dose of 5 mg Apixaban Oral Tablet (EU product) will be administered orally after at least 10 hours overnight fast
214316853|NCT06869135|OTHER|Saliva collection, longitudinal|1 ml of saliva will be collected with Salivette swabs. Subjects will undergo assessments and saliva sampling at enrollment time (T0) and one year after (T12).
214316854|NCT06884267|OTHER|standard hyperkalemia management implementation|The interventions include HK disease management and quality audits for health care professionals (HCPs) and patients (Figure 1). The main contents of HK disease management in CKD include a standardized clinical pathway based on guideline adoption and medical trainings to educate HCPs and patients.
214482720|NCT05980494|DIAGNOSTIC_TEST|passive leg raising test (PLRT)|"Regardless of CVP (i.e., during blind PLR), noninvasiveΔPLR systolic arterial pressure (SAP) more than 17% reliably identify fluid responders. During CVP-guided PLR, in case of sufficient change in CVP (at least of 2 mmHg), noninvasiveΔPLR SAP perform better (cutoff of 9%). These findings, in sedated patients who had already undergone volume expansion and/or catecholamines, have to be verified during the early phase of circulatory failure (before an arterial line)."
214482721|NCT05980494|DEVICE|pulse pressure variation|patients will be temporarily sedated and paralyzed and on fully controlled mechanical ventilation. No spontaneous breathing effort will be detected on the mechanical ventilator waveform monitor ensuring that the respiratory changes in arterial pressure reflected only the effects of positive pressure ventilation. Modes of ventilation is selected to volume or pressure controlled ventilation, depending on the decision of the primary physicians. A tidal volume will be not less than 8 ml/ kg (predicted body weight). The preset respiratory rate will be at 14 breath/min. Positive end expiratory pressure (PEEP) will be between 8 and 10 cmH2O. The plateau pressure was kept at below 30 cmH2O. In all patients, radial artery cannulation will be done for invasive blood pressure monitoring (using a 20 G cannula), PPV is calculated directly on Nihon Kohden monitores at base line.
214482722|NCT06692244|PROCEDURE|Guided Bone Regeneration Surgery Using Additive-Manufactured Personalized Titanium Mesh|Preoperative CBCT datas of participants are obtained to design and manufacture personalized titanium meshes.Use additive-manufactured personalized titanium meshes for guided bone regeneration.In the bone grafting surgery, the additive-manufactured personalized titanium mesh is used to secure the bone substitutes, with fixation screws used to secure the titanium mesh.
214482723|NCT06692244|PROCEDURE|Guided Bone Regeneration Surgery Using Prefabricated Titanium Mesh|In bone grafting surgery, prefabricated titanium mesh is used to fix the bone substitutes, and fixation screws are used to secure the titanium mesh.
214482724|NCT06693895|BIOLOGICAL|Investigational varicella vaccine|1 dose of investigational varicella vaccine administered subcutaneously.
214482725|NCT06693895|BIOLOGICAL|Marketed varicella vaccine|1 dose of marketed varicella vaccine administered subcutaneously.
214482726|NCT06693895|BIOLOGICAL|Measles, mumps, and rubella vaccine|1 dose of measles, mumps, and rubella vaccine co-administered subcutaneously or intramuscularly.
214482727|NCT06693895|BIOLOGICAL|Hepatitis A vaccine|1 dose of hepatitis A vaccine co-administered intramuscularly.
214482728|NCT06693895|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|1 dose of 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214482729|NCT06693895|BIOLOGICAL|PCV 20|1 dose of 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214671630|NCT00266110|BIOLOGICAL|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
214671631|NCT00266110|BIOLOGICAL|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
214955198|NCT04017871|OTHER|Electro-Encephalography-High Density (children with unilateral PC only)|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
214955199|NCT04017871|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
214955200|NCT04017871|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
214316855|NCT04754347|DEVICE|Computer Aided Detection device|The Computer Aided Detection device, Skout, is designed to help endoscopists detect potential colorectal polyps during colonoscopies. The system performs automated real-time analysis on endoscopic video data to identify potential polyps and produces an informational visual aid around the appropriate sections of the video frames on a display monitor.
214316856|NCT07047612|DRUG|ICP-332 Tablets|ICP-332 will be administered as tablet
214316857|NCT07047612|DRUG|ICP-332 Placebo Tablets|ICP-332 Placebo will be administered as tablet
214918887|NCT06622616|DIETARY_SUPPLEMENT|EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS|"The study will have two arms, the functional group with A. domesticus powder (n=60) and a placebo group that will take a vegetable protein powder with a similar macronutrient composition (n=60). This population will be classified according to sex and BMI, and their nutritional-metabolic status (insulin resistance or not).~The study will include analysis of phenotypic data collection (medical history, lifestyle, diet, etc.); biochemical data: glucose, lipid, iron profile, blood count, and analysis of inflammation markers; genotyping, epigenetic analysis (methylation and mi-RNAs), targeted metabolomics (glycome and tryptophan) and metagenomic analysis of stool (16s rRNA sequencing for taxonomic identification study). Using continuous monitoring devices (glucose monitoring using a sensor and physical activity using an activity bracelet), lifestyle parameters (physical activity, circadian rhythms, sleep, stress, etc.) and blood glucose will be evaluated."
214918888|NCT06619496|BEHAVIORAL|Human-led fall prevention program|Human-led evidence-based fall prevention programs include Matter of Balance, Tai Chi Moving for Better Balance, Walk with Ease, or Arthritis Exercise
214918889|NCT06619496|BEHAVIORAL|Avatar-led fall prevention program|The avatar-led fall prevention program consists of the Otago Exercise Program
214918890|NCT01757938|PROCEDURE|Shang Ring Guided Circumcision|
214918891|NCT01757938|PROCEDURE|Forceps Guided Circumcision|
214955201|NCT04017871|DEVICE|Accelerometers|During 5 days a sensor at each wrist to quantify their movement.
214316858|NCT06841692|DIAGNOSTIC_TEST|Diuretic Testing|The administration of hydrochlorothiazide and bumetanide is used to stimulate and assess tubular function.
214316859|NCT06770322|PROCEDURE|Conventional|According to the clinician's own practice, the cuff of the endotracheal intubation tube will be manually inflated with the help of a syringe and the pressure will be measured with manometry and a note will be taken.
214316860|NCT06770322|PROCEDURE|manometer|The cuff pressure will be measured by manometry and the cuff of the endotracheal intubation tube will be inflated with 25-30 cmH2O.
214316861|NCT07101289|BEHAVIORAL|Personal health planning and nutritional coaching|Behavioral support will be offed by ZealCare, an evidence-based, virtual coaching behavioral support program for patients with chronic conditions.
214316862|NCT07101289|OTHER|Prescription Produce|Eat Well is a prescription produce program that provides a reloadable, restricted use debit card to participants to purchase fresh, frozen, or canned fruits, vegetables, and legumes at grocery stores.
214316863|NCT07109648|BEHAVIORAL|Access to app|"The intervention is offering a free subscription to a mental health app that combines self-guided digital tools with AI-powered support. The app features functions such as an emotional diary and structured courses on topics including managing anxiety and stress regulation. A personalized chatbot, powered by large language models (LLMs) and trained on content grounded in cognitive behavioral therapy, delivers evidence-based strategies such as cognitive restructuring, behavioral activation, and emotion regulation. The chatbot also guides users through these resources using natural, supportive conversations.~Participants were randomly assigned to one of two groups:~A treatment group offered free access to the app for three months, or A control group, which will receive free access to the app for one month at the end of the study"
214316864|NCT07108504|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m², d1, 8, 15, q4 week
214316865|NCT07108504|DRUG|LM-302|LM-302, 1.8 mg/kg, d1, q2 week
214316866|NCT07108348|GENETIC|Adenosine deaminase acting on RNA1|Previous studies have demonstrated that increased ADAR1 expression is associated with poor survival in gastric and metastatic colon cancer. In rectal cancer, however, the relationship between ADAR1 levels and TNT response in locally advanced disease has not been investigated. Another point is that ADAR1 can also be studied using immunohistochemistry; however, its sensitivity and specificity are low, so in our study, RNA will be isolated and analyzed using real-time PCR.
214316867|NCT07108790|OTHER|Concentrated growth factors, collagen membrane and xenograft bone graft|Ten sites were treated by concentrated growth factors (CGF), collagen membrane, and xenograft bone graft.
214316868|NCT07108790|OTHER|Collagen membrane and xenograft bone graft|Ten sites were treated with a collagen membrane and a xenograft bone graft.
214316869|NCT07109284|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan 5 mg/kg, intravenously (iv), Q2W
214316870|NCT07109284|BIOLOGICAL|Tagitanlimab|Tagitanlimab 900mg, intravenously (iv), Q2W
214316871|NCT07108764|DRUG|Lidocaine|Patients will receive an IV bolus (50 ml) of lidocaine (1mg/kg) diluted with saline over 10 min before induction of anesthesia. This will be followed by intraoperative lidocaine infusion in a dose of 1.5mg /kg/hr till the end of surgery.
214316872|NCT07108764|DRUG|Dexmedetomidine|Patients will receive an IV bolus (50 ml) of dexmedetomidine in dose 0.5 μg/kg over 10 min before induction of anesthesia. This will be followed by intraoperative dexmedetomidine infusion in a dose of 0.3 μg/kg/hr till the end of surgery.
214316873|NCT07110402|PROCEDURE|Autogenous transplant of fragmented adipose tissue taken from abdominal integuments|Treatment of chondromalacia of the cartilage in the knee joint by arthroscopic technique with the use of autogenous graft of fragmented adipose tissue taken from the abdominal wall.
214316874|NCT07110402|PROCEDURE|PRP GF (platelet-rich plasma with growth factors)|Treatment of chondromalacia of the cartilage in the knee joint by arthroscopic technique with the use of PRP GF (platelet-rich plasma with growth factors)
214316875|NCT07110402|PROCEDURE|Mesenchymal cells centrifuged from bone marrow cells taken from the iliac crest|Treatment of cartilage chondromalacia in the knee joint by arthroscopic technique using mesenchymal cells centrifuged from bone marrow cells taken from the iliac crest
214316876|NCT07110402|PROCEDURE|Hyaluronic acid - low molecular weight|Treatment of chondromalacia of the cartilage in the knee joint with the use of Hyaluronic Acid - low molecular weight
214316877|NCT07110402|PROCEDURE|Hyaluronic acid - cross-linked|Treatment of chondromalacia of the cartilage in the knee joint by arthroscopic technique with the use of cross-linked Hyaluronic Acid Arti Aid Plus, Synovial, Durolain, StavOn, Collagenu
214316878|NCT07100678|PROCEDURE|Porcelain-Fused-to-Metal Fixed Dental Prosthesis|This prosthesis consists of a metal substructure for strength and a porcelain coating for improved aesthetics. The treatment will be planned and delivered by prosthodontic specialist. The intervention is non-surgical
214316879|NCT07101471|DRUG|Tofacitinib|Tofacitinib with a suggested dose of 5 mg twice daily with or without adjuvant prednisolone.
214316880|NCT07108738|PROCEDURE|Pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline will be performed by sterile #330 high speed bur using water spray. Caries will be removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber will be removed by low speed round bur. Haemostasis will be obtained by applying pressure with a moist cotton pellet with saline. Then the test materials will be applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material, then the tooth will be restored with a preformed stainless steel crown
214316881|NCT07108738|PROCEDURE|Radiation|Radiographic evaluation will be performed immediately after teeth restoration (baseline radiograph), then after three, six, and twelve months for the furcation radiolucency area and bone radiodensity. A photo-simulated phosphorus plate sensor was used to take direct standardized digital radiographs. The parallel periapical technique was obtained by Rinn, which is attached to the X-ray tube with its arm fastened to the film holder that contained a coated PSP (photo-stimulated phosphorus plate). To ensure standardization during radiographic film retakes, condensation rubber base impression material will be positioned on the outside of the film holder, and the child is told to bite on it while the material is set. The sensor wil exposed to an X-ray machine (Planmeca ProX, Helsinki, Finland) with a central ray perpendicular to the sensor at 70 kVp, 6 mA, and 0.8 s. Radio-densitometric and radiometric analysis of the radiographs will be performed by RadiAnt software.
214316882|NCT03928288|DRUG|Cabergoline 0.5 MG|Medication
214316883|NCT03928288|DRUG|Placebo - Cap|Placebo capsule
214316884|NCT07109245|DRUG|Haloperidol|The oral investigational agent haloperidol (Generic Brand: TEVA-HALOPERIDOL) will be self-administered, at night, over 7 days. Haloperidol will be titrated up to 2 mg.
214482730|NCT06693895|BIOLOGICAL|Vaxneuvance|1 dose of 15-valent pneumococcal conjugate (Vaxneuvance) vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214918892|NCT06260410|DIAGNOSTIC_TEST|Blood draw for ctDNA and circulating tumor cell collection.|During routine blood sample collection, additional blood will be drawn for analysis of ctDNA and to collect Circulating Tumor Cells.
214918893|NCT01535508|DRUG|Liquid Vitamin D|300 IU/Kg/day not to exceed 10,000 IU/day.
214316885|NCT07109245|DRUG|Placebo|Oral placebo, encapsulated and to be taken at an equivalent titration schedule to Haloperidol.
214316886|NCT07109245|DRUG|Insulin Lispro|A total of 160 IU of intransal insulin (=1.6 mL) will be administered on MRI scanning visits (80 IU = 0.8 mL delivered per nostril). Humalog; Eli Lilly Canada
214316887|NCT07109245|OTHER|Saline|A total of 1.6 mL of intranasal saline will be administered on each MRI scanning visit (0.8 mL delivered per nostril).
214316888|NCT07108647|OTHER|Progressive Hip Strengthening Program|"This 12-week, in-season exercise intervention is designed for athletes with FAI syndrome and consists of three progressive phases.~Phase 1 (Weeks 1-4): Focus on neuromuscular re-education and motor control using low-load exercises to improve hip and core activation, alignment, and stability.~Phase 2 (Weeks 5-8): Targeted strengthening with increased load and movement complexity, emphasizing single-leg control, endurance, and pelvic stability.~Phase 3 (Weeks 9-12): Integration of dynamic control, proprioception, and sport-specific movement patterns to support return to performance.~Exercises target gluteus medius, gluteus maximus, core musculature, and functional movement systems. Participants complete the program \>=3 times per week. Weekly questionnaires will monitor symptoms, adherence, and other management (e.g., physiotherapy)."
214316889|NCT07108647|OTHER|Progressive Muscle Relaxation|Participants in the time and attention control group will complete a 12-week, three-phase progressive muscle relaxation (PMR) program based on the Jacobson method. Phase 1 introduces isolated muscle tensing and relaxing to build awareness of muscle tension and promote body-mind connection. Phase 2 focuses on sequential relaxation of muscle groups, enhancing control and reducing stress. Phase 3 transitions to full-body relaxation through guided breathing and visualization techniques. Sessions are practiced 2-3 times per week using audio guides, with weekly check-ins from study staff. Symptom response, adherence, and participant experience are tracked throughout the season.
214316890|NCT07110077|OTHER|Young First Aiders Traing of Early Secondry School children|Training Young First Aiders in Early Secondary School Children with a pre-, immediate post- and final post-tests to determine knowledge change.
214316893|NCT07109882|DRUG|Chlorzoxazone|This group will receive Chlorzoxazone twice daily for two weeks
214316894|NCT07109882|DRUG|Orphenadrine Citrate|This group will receive Orphenadrine Citrate twice daily for two weeks.
214316895|NCT06008288|DRUG|JAB-21822|800mg, orally QD with 21 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
214316896|NCT06924489|PROCEDURE|Colonoscopy after bowel cleansing with 2D imaging device|participants will undergo colonoscopy examination using 2D imaging colonoscope to detect potential adenomas or polyps. The classification of the detected lession will be determined by the edoscopic diagnosis based on the JNET classification system or by the pathological diagnosis with tissues from biopsy or polypectomy.
214918894|NCT05050123|BEHAVIORAL|iPhone Google Cardboard virtual reality meditation/relaxation app|Virtual reality meditation/relaxation app that has 6 scenes of 360° visual imagery with soothing music. The patient can spend about 15 minutes exploring the app.
214918895|NCT05050123|BEHAVIORAL|Standard relaxation training|"15 minute sessions of guided imagery using Mayo Clinic Patient Education CD-ROM Relaxation for Your Mind and Body"
214918896|NCT06684938|DRUG|sacroiliac injection|sacroiliac injection with local anaesthetic and corticosteroids
214955202|NCT05890014|DIETARY_SUPPLEMENT|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
214955203|NCT00771940|DRUG|Ghrelin|Solvent, cont. infusion
214316897|NCT06924489|PROCEDURE|Colonoscopy after bowel cleansing with 3D imaging device|participants will undergo colonoscopy examination using 3D imaging colonoscope to detect potential adenomas or polyps. The classification of the detected lession will be determined by the edoscopic diagnosis based on the JNET classification system or by the pathological diagnosis with tissues from biopsy or polypectomy.
214316898|NCT06923371|BEHAVIORAL|Direct Cash Support for Maternal and Infant Health (High fee)|The high fee group will receive direct cash assistance to pregnant women and mothers of infants to improve access to healthcare, alleviate financial strain, and facilitate healthier lifestyle choices. This group will receive a higher level of financial support compared to the low fee group, with the aim of examining how larger amounts of financial assistance affect maternal and infant health, healthcare access, and well-being.
214316899|NCT06923371|BEHAVIORAL|Behavioral: Direct Cash Support for Maternal and Infant Health (Low fee)|The low fee group will receive direct cash assistance to pregnant women and mothers of infants to improve access to healthcare, reduce financial strain, and support healthier lifestyle choices. This group will receive a lower level of financial support compared to the high fee group, allowing us to compare the effects of varying levels of financial assistance on maternal and infant health outcomes.
214316900|NCT07108595|DRUG|T- Dxd|T-DXd based therapy
214316901|NCT07108855|DRUG|Indocyanine Green (IC-Green)|Systemic administration of indocyanine green during the endoscopic procedure.
214316902|NCT07108855|DIAGNOSTIC_TEST|Fluorescence guided identification using indocyanine green|Near-infrared quantified fluorescence molecular endoscopy (qFME) will be used during the endoscopic procedure.
214316903|NCT07110246|DRUG|Dabrafenib|Given orally (PO)
214316904|NCT07110246|DRUG|Trametinib|Given PO
214482731|NCT06693362|DRUG|Placebo|The Menstrual blood derived mesenchymal stem cells（Men-MSCs）Placebo is administered via intravenous infusion, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5).The placebo must be thawed, and 3 vials of placebo must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
214482732|NCT06693362|DRUG|Drug therapy|The Menstrual blood derived mesenchymal stem cells（Men-MSCs) injection (SC01009) is administered via intravenous infusion, with a total dose of 9×10\^7 cells, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5), with each infusion consisting of 3×10\^7 cells.Before the infusion, SC01009 injection must be thawed, and 3 vials of SC01009 must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
214482733|NCT06693362|OTHER|Standard Treatment|"Anti-infective and anti-inflammatory drugs: For hospitalized patients with CAP, it is recommended to use β-lactams alone or in combination with doxycycline, minocycline, macrolides, or respiratory quinolones alone.~Corticosteroids: For patients with septic shock, hydrocortisone hemisuccinate 200 mg/day is recommended. The medication should be discontinued promptly after the correction of septic shock, and the duration of use should generally not exceed 7 days.~Antiviral drugs: Oseltamivir, acyclovir, etc.~Antipyretic drugs for those with high fever: such as aspirin, acetaminophen, indomethacin, sulindac, naproxen, etc.~Cough and expectorant drugs for cough and phlegm: ambroxol hydrochloride, acetylcysteine tablets, bromhexine, nacetylethylenediamine, pentedonate, etc.~Low molecular weight heparin: For elderly hospitalized CAP patients, the risk of deep vein thrombosis should be assessed, and low molecular weight heparin should be applied for prevention when necessary."
214482734|NCT06872710|OTHER||There are no interventions. Samples were collected by the Biobank since 2013.
214482735|NCT06872528|OTHER|Recording the amount of medication and the number of complications according to observational follow-up|Observational monitoring of patients and recording data for 24 hours
214482736|NCT06872411|OTHER|HealthyDads Digital Intervention|HealthyDads is a prototype bilingual self-guided psychoeducational Digital Intervention with accurate and easily accessible information on topics related to mental health, parenting and health behaviors, along with strategies to optimize each.
214316905|NCT07110246|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo imaging by MRI
214316906|NCT07110246|PROCEDURE|Specimen Collection|Under collection of blood and optional CSF samples
214316907|NCT07110246|PROCEDURE|Optional Lumbar puncture|Undergo optional lumbar puncture
214316908|NCT02090127|DRUG|ficlatuzumab|humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
214316909|NCT04634084|PROCEDURE|Experimental group(Bursa Implantation)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.In the experimental group, instead of being discarded, this minced bursal tissue will be collected via a sterile filtration device attached to the oscillating shaver. The bursal tissue is then placed into a sterile syringe, and reimplanted back onto the bursal surface of the rotator cuff repair at the completion of the case. The arthroscopic fluid is turned off, and fluid is evacuated from the shoulder prior to reimplantation of the bursa.. Nothing is added to the bursa prior to reimplantation. There are no reagents. The bursa tissue is purely the minced bursa tissue removed from the patient, and never leaves the sterile field.
214316910|NCT04634084|PROCEDURE|Control Group(Standard of Care)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.The current standard of care procedure is to discard this tissue, and then proceed with the rotator cuff repair
214316911|NCT05112393|OTHER|Development of new estimating Glomerular Filtration Rate (eGFR) equation|"Development Cohort:~A new estimating Glomerular Filtration Rate(eGFR) equation will be developed by using a nonlinear regression model utilizing a generalized least squares algorithm."
214316912|NCT05112393|OTHER|Validation of new estimating Glomerular Filtration Rate (eGFR) equation|"Validation Cohort:~Internal validation will be performed by comparing bias, precision and accuracy of the new equations and the other established equations to the measured GFR."
214316913|NCT04784585|BEHAVIORAL|Enhanced Education|"The Enhanced Education intervention option seeks to: 1) enhance understanding of personal health-behavior links, 2) improve health literacy by checking the adequacy of participant understanding, and 3) remind participant of important elements of Behavioral Obesity Treatment (BOT) dietary goals."
214316914|NCT04784585|BEHAVIORAL|Self-Efficacy|"This intervention option is based on a previously established self-efficacy intervention for weight loss, which is a multi-component intervention for increasing self-efficacy. To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either prompt: 1) attainable intention setting related to dietary adherence (e.g., I will focus on eating mostly fruits/vegetables in my next meal/snack in order to take back control of my eating); 2) barrier identification for adhering to dietary goals along with a brief problem-solving exercise; 3) devising a small self-reward; OR 4) self-assessment of thoughts/behaviors that could interfere with dietary adherence in the next several hours with coping strategies (e.g., stimulus control, social support)."
214316915|NCT04784585|BEHAVIORAL|Motivation|"To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either: 1) guide participants in identifying values related to weight control (e.g., longevity, quality of life, being a role model) and connect those values to their behavior in the current moment.; 2) use a collaborative non-judgmental approach to explore the consequences of letting barriers drive behavior (e.g., Take a moment to consider the effect on your longevity if you let your preference for sweets determine your behavior.); 3) prompt participants to identify reasons for change, thereby eliciting change talk; OR 4) engage participants in a brief self-assessment of motivation for dietary adherence (i.e., On a scale of 1-10, how important to you is it to stick to your dietary goals today)."
214316916|NCT04784585|BEHAVIORAL|Self-Regulation|"There are 4 independent modules that prompt self-monitoring and self-awareness efforts: 1) advise participants to record everything that they eat before they eat it, with attention to eating in the subsequent few hours; 2) use the traffic light model to enhance awareness of dietary intake. This module provides the traffic light categories of foods (i.e., green=healthiest choices, yellow=sometimes choices, and red=rare choices), and asks participants to check-off foods that they intend to eat vs. stay away from in the next few hours; 3) advise participants to track portion sizes carefully and provide a portion size guide that is available to them until the following EMA survey; OR 4) provide a tutorial on noticing hunger/satiety cues and slowing down rate of eating, with an experiential exercise for use during their next eating episode."
214316917|NCT04784585|BEHAVIORAL|Generic Risk Alert (Active Comparator)|"Participants will be notified that the JITAI algorithm has determined heightened lapse risk in the following 2-3 hours (i.e., We have detected that your risk of lapsing from your weight loss diet is higher than usual and may require attention.)."
214316918|NCT04784585|BEHAVIORAL|Online Behavioral Obesity Treatment|The online BOT consists of: (a) 12 weekly multimedia lessons for training in behavioral weight loss skills; (b) online tools for self-monitoring weight, diet, and physical activity; and (c) weekly automated text-based feedback on progress to date. Participants are given a goal of losing 1-2lbs per week to achieve a total weight loss of ≥10% of initial body weight. Participants are prescribed a calorie goal of 1200-1800 kcal/day tailored on initial weight. Participants are given guidelines to follow a lowfat or Mediterranean diet to meet the prescribed calorie goal. Participants are given a physical activity goal tailored on initial activity level that gradually increases to 200 min/wk of activity, emphasizing brisk walking as the primary form of activity. They also receive a primer in self-monitoring weight, diet, and physical activity. Participants are instructed to self-monitor and follow the prescribed diet for the 6-month study period.
214316919|NCT05195489|OTHER|Family Connectors|The Family Connectors Program is a manualized program that uses a time-limited parent-to parent (i.e. peer parent) support and education program delivered by phone to families of youth with serious mental health difficulties, assisting family members in becoming fully engaged with provider teams who coordinate and provide care. Family Connectors is delivered weekly by phone over the course of between three and six months.
214316920|NCT01345279|DRUG|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
214316921|NCT01345279|DRUG|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
214316922|NCT01345279|DRUG|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
214316923|NCT06090110|DEVICE|Vagal Nerve Stimulation|Transcutaneous Auricular Vagal Nerve Stimulation
214316924|NCT06090110|DEVICE|Sham stimulation|Sham stimulation with a non-conduction electrode
214316925|NCT05849402|DEVICE|Active Comparator: Active aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
214316926|NCT05849402|DEVICE|Sham Comparator: Sham aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
214482737|NCT05153421|DEVICE|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
214482738|NCT04365114|DIAGNOSTIC_TEST|Breast Screening Mammography with single reader|One clinician examined each woman's mammograms for signs of cancer
214482739|NCT04365114|DIAGNOSTIC_TEST|Breast screening mammography with two readers|Two clinicians seperately examined each woman's mammograms for signs of cancer
214482740|NCT04365114|DIAGNOSTIC_TEST|Test threshold|Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled
214482741|NCT06684418|DIAGNOSTIC_TEST|chest enhanced CT|This is an observational study and patients will receive routine clinical treatment according to the corresponding guidelines. We will collect the enrolled patient's chest enhanced CT and clinicopathological parameters.
214482742|NCT06695390|OTHER|Nursing students' humanistic care competence|A cross-sectional study with nursing students
214482743|NCT06695702|OTHER|the effect of work-based learning on the level of knowledge|The benefit of workbased learning on nursing students' knowledge of oncology symptom management
214482744|NCT06686745|DRUG|SIM0508 Tablets|Every 28 days is one cycle. Multiple dose levels of SIM0508 will be explored in dose escalation, and determine the maximum tolerated dose.
214482745|NCT06686745|DRUG|SIM0508 in combination with olaparib|Every 28 days is one cycle.Multiple dose levels of SIM0508 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
214316927|NCT03252522|COMBINATION_PRODUCT|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
214316928|NCT03252522|DIETARY_SUPPLEMENT|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
214482746|NCT06686745|DRUG|SIM0508 in combination with olaparib|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0508 combination with olaparib established from SIM0508 combination dose escalation.
214918897|NCT03779750|DIAGNOSTIC_TEST|s.creatinine|All ESRD patients on regular hemodialysis in dialysis unit of Assiut university Hospital duing one year. will be subjected to 3- Routine investigations including complete blood picture ,blood urea , s.creatinine,urine analysis , calcium, phosphorus, and parathyroid hormone.
214918898|NCT01579838|DRUG|Eculizumab|PNH and or atypical TTP classical protocols
214316929|NCT03059381|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
214316930|NCT00276718|BIOLOGICAL|bleomycin sulfate|
214316931|NCT00276718|DRUG|carboplatin|
214918899|NCT06441838|BEHAVIORAL|Surah Inshirah|The effects of Surah Al-Inshirah on patients' depression, anxiety, stress and mental well-being will be evaluated during hemodialysis in the experimental group.
214918900|NCT03374917|DRUG|ABBV-951|powder for solution
214918901|NCT06684834|OTHER|5:2 carbohydrate restriction|Carbohydrate ingestion restricted to \<8% of energy intake on 2 self-selected consecutive days each week over 28-30 days. Ad libitum dietary amount, type and pattern followed on the remaining 5 days each week.
214918902|NCT06684834|OTHER|Early time-restricted carbohydrate intake|Carbohydrate intake restricted to \<8% of energy intake after 4pm each day for 28 days. Ad libitum dietary amount, type and pattern followed before 4pm.
214316932|NCT00276718|DRUG|etoposide|
214316933|NCT00276718|PROCEDURE|conventional surgery|
214316934|NCT02181556|DRUG|FOLFIRI Protocol|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
214316935|NCT02181556|DRUG|Aflibercept Injection|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
214482747|NCT06688292|DRUG|Taneasy 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
214482748|NCT06688292|DRUG|Actein effervescent 600mg|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, pulmonary emphysema, mucoviscidosis and bronchiectasis.
214482749|NCT04093869|BEHAVIORAL|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX condition has two integrated components: the CST component will systematically train patients in the use of coping skills for stress reduction and promote key transplant-specific health behaviors. The exercise component of the intervention will progressively increase participants exercise and promote daily physical activity through motivational interviewing strategies.
214482750|NCT04093869|BEHAVIORAL|Standard of Care plus Education (SOC-ED)|The SOC-ED condition provides support and enhanced post-transplant education. Participants will be given detailed educational information about post-transplant care, the importance of medication adherence, and maintenance of physical activity.
214918903|NCT01290679|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
214316936|NCT00363974|DRUG|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
214316937|NCT01572038|DRUG|Docetaxel|Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
214316938|NCT01572038|DRUG|Nab-paclitaxel|Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
214316939|NCT01572038|DRUG|Paclitaxel|Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
214316940|NCT01572038|DRUG|Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
214918904|NCT01290679|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
214316941|NCT01572038|DRUG|Trastuzumab|Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
214316942|NCT00065533|DRUG|pemetrexed|
214316943|NCT03523559|GENETIC|bladder tissue of Interstitial Cystitis and normal bladder tissue|Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
214316944|NCT03662100|BIOLOGICAL|LY3074828|Administered SC
214316945|NCT03662100|DRUG|LY3074828|Administered SC
214316946|NCT03662100|DEVICE|Auto-injector (AI)|AI to administer LY3074828
214316947|NCT03662100|DEVICE|Prefilled syringe (PFS)|PFS to administer LY3074828
214316948|NCT05602415|DRUG|Anlotinib|Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles). The dose could be reduced to 8-10 mg once daily for patients who had grade 3 or 4 treatment-related toxicities, or for patients with intolerable grade 2 toxicity, despite maximum supportive care measures. If dose reduction was necessary, then the dose of anlotinib was reduced to 10 mg once daily. If further dose reduction was necessary, the dosage was reduced to 8 mg once daily. If the dosage of 8 mg once daily was not tolerable, then the patient stopped receiving anlotinib.
214316949|NCT05602415|RADIATION|Radiotherapy|Postoperative radiotherapy would be performed. Postoperative intensity-modu¬lated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). No boost dose would be added if the margin was negative, a boost dose of 10-16 Gy would be added if the margin was microscopically positive, and a boost dose of 16-18 would be added if the margin was gross positive.
214316950|NCT05602415|PROCEDURE|Surgery|Surgery
214316951|NCT01275066|DRUG|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
214316952|NCT01275066|DRUG|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
214316953|NCT01275066|DRUG|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
214482751|NCT06673745|OTHER|IASTM|"Group A received IASTM treatment, which will be given by the Edge tool, that is an ergonomically designed stainless steel instrument and offers several different hand holds, eliminating operator fatigue. Prior to the treatment, the IASTM therapeutic effects will be explained. The scanning assessment will be done to identify areas of restrictions directed by the gritty sensations using the Edge tool. Each restriction will be treated with the tool for 30-60 sec and given. This treatment will be given for 30 minutes for 3 days per week for 4 weeks"
214316954|NCT06438042|DEVICE|Use of a powered low air pressure motorised therapeutic mattress that combines the motorised and static technologies|Patients with a high risk of pressure injury, without pressure injury, lying more than 20 hours a day, will ly a on a XTECH®25 mattress
214316955|NCT00816699|OTHER|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
214316956|NCT01170728|DEVICE|Coloplast Virtue® Male Sling|The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
214316957|NCT00222456|BEHAVIORAL|Sensitizing parents|
214316958|NCT04585516|PROCEDURE|endoscopy|Colonoscopy or gastroscopy
214316959|NCT05794256|OTHER|No interventions are planned|No interventions are planned
214316960|NCT02313610|DRUG|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
214316961|NCT02313610|DRUG|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
214316962|NCT04679077|OTHER|Cytocam-IDF imaging device|Observation of the microcirculation
214316963|NCT01661712|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
214316964|NCT01661712|DEVICE|Sham stimulation|Sham stimulation for one night (no electrical stimulation)
214316965|NCT04763499|OTHER|freeze dried strawberry powder|approximately 24 strawberries that have been freeze dried into a powder
214316966|NCT01200875|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
214316967|NCT01200875|PROCEDURE|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
214316968|NCT06432530|OTHER|C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.|Patients' hematological parameters were recorded, and hematological inflammatory indexes (NLR: neutrophil/lymphocyte; MLR: monocyte/lymphocyte; PLR: platelet/lymphocyte; NLPR: neutrophil/(lymphocyte\*platelet); SII (neutrophil\*platelet/lymphocyte): systemic inflammatory index; SIRI (neutrophil\*monocyte/lymphocyte): systemic inflammatory response index; AISI (neutrophil\*platelet\*monocyte/lymphocyte): aggregate index of systemic inflammation. ) were derived from baseline CBC tests.
214316969|NCT03561974|DEVICE|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
214316970|NCT03702478|OTHER|Questionnaire|No intervention only observational
214316971|NCT06192225|BEHAVIORAL|pre-trained guided slow paced breathing (~6 breaths per minute)|Slow PACE breathing
214316972|NCT05717595|DIETARY_SUPPLEMENT|fructose|oral ingestion of fructose vs dextrose
214316973|NCT04858958|DRUG|Furmonertinib 160mg|randomized to 160mg QD
214316974|NCT04858958|DRUG|Furmonertinib 240mg|randomized to 240mg QD
214316975|NCT04933591|DRUG|Diosmin / Hesperidin|Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
214482752|NCT06673745|OTHER|Dynamic cupping therapy|On the contrary, group B the patient will be seated in a chair with the elbow flexed on the plinth to relax the forearm muscles. The area around the elbow joint will be cleaned with alcohol to remove any foreign bodies from the treated area. Dynamic cupping therapy for elbow stiffness will begin with an assessment of the patient\&amp;#39;s condition, where factors such as the extent of stiffness and range of motion in the elbow joint will be evaluated. Following this assessment, lubricant will be applied to the skin surrounding the elbow to facilitate smooth movement of the cups. Cups of suitable size and material will then be strategically placed around the elbow joint, and suction will be created inside each cup to create a vacuum effect. Once thesecurely attached, the practitioner will move them around the elbow area using gentle techniques such as gliding or pumping motions.
214482753|NCT06687304|DEVICE|Light enhancement|Light recipe that mimics the varying daylight of the day
214482754|NCT06688201|OTHER|Other neurosurgical techniques|Those include open craniotomy, small skull window microsurgery, and endoscopic surgery. The attending clinician is required to consider which type of craniotomy or other procedure according to the expertise and availability at the hospital.
214316976|NCT01191710|OTHER|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
214316977|NCT01026870|DRUG|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
214316978|NCT01026870|DRUG|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
214316979|NCT00515307|PROCEDURE|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
214482755|NCT06688201|PROCEDURE|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation|This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
214918905|NCT01290679|DRUG|Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
214918906|NCT01290679|DRUG|Ribavirin (RBV)|200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
214918907|NCT00562302|DEVICE|Bio-Seal Plug|Deployment of the Bio-Seal plug in needle track
214316980|NCT00383838|BEHAVIORAL|brief, voluntary substance use intervention|
214316981|NCT01870128|DRUG|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
214316982|NCT01870128|DRUG|Methotrexate|Methotrexate 15 to 25 mg PO per week
214316983|NCT01870128|DRUG|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
214316984|NCT01435291|DRUG|Advagraf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
214918908|NCT01219764|DRUG|Rabeprazole, metronidazole, Clarithromycin, Amoxicillin|"Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days."
214918909|NCT01413750|DRUG|Carboplatin|Given IV
214918910|NCT01413750|OTHER|Laboratory Biomarker Analysis|Correlative studies
214918911|NCT01413750|DRUG|Paclitaxel|Given IV
214918912|NCT01413750|OTHER|Placebo Administration|Given PO
214918913|NCT01413750|DRUG|Vorinostat|Given PO
214918914|NCT02905981|DRUG|Fer-In-Sol|Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.
214918915|NCT02905981|DRUG|Shohl's solution|Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
214316985|NCT01435291|DRUG|Prograf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
214918916|NCT02905981|DRUG|Triferic|Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
214316986|NCT03328689|OTHER|Physical activity program|This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.
214316987|NCT03328689|OTHER|Control group standard care|"Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.~Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement"
214316988|NCT02514356|BEHAVIORAL|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
214316989|NCT02514356|BEHAVIORAL|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
214316990|NCT05148481|DRUG|BIIB104|Administered as specified in the treatment arm
214316991|NCT05148481|DRUG|Placebo|Administered as specified in the treatment arm
214316992|NCT05010889|PROCEDURE|Peroral endoscopic myotomy (POEM)|POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
214316993|NCT02623803|DRUG|Lidocaine|
214316994|NCT02623803|DRUG|Placebo D5W|
214316995|NCT02413827|DRUG|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
214316996|NCT02413827|DRUG|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
214316997|NCT05763888|OTHER|No drug will given|No intervention will be given to the subject
214316998|NCT01715103|PROCEDURE|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
214316999|NCT04155515|DRUG|TG-2349|TG-2349 400mg
214317000|NCT04155515|DRUG|DAG181|DAG181 200mg
214317001|NCT04155515|DRUG|Ribavirin|Ribavirin 1000mg/1200mg
214671632|NCT00266110|BIOLOGICAL|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
214671633|NCT00266110|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
214671634|NCT01990599|OTHER|Nasopharyngeal Tube|
214671635|NCT06447181|DEVICE|3D visualization technology ; ICG fluorescence technology .|"Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step.~ICG fluorescence technology is a fluorescent laparoscopic technology that can detect extrahepatic biliary duct misalignment, improving surgical precision and safety."
214317002|NCT02148328|BIOLOGICAL|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
214317003|NCT02148328|BIOLOGICAL|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
214317004|NCT02148328|BIOLOGICAL|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
214317005|NCT02148328|BIOLOGICAL|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
214317006|NCT00850200|RADIATION|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
214317007|NCT00850200|RADIATION|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
214317008|NCT00850200|RADIATION|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
214317009|NCT00839839|PROCEDURE|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
214317010|NCT04342104|OTHER|Monitoring for aggravation|"Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~* lymphopenia~* thrombocytopenia~* CRP~* ferritin~* LDH~* troponin I~* NT-ProBNP~* Liver enzymes~* D-dimers~* radiologic aggravation  1 day and 1 week after starting NIV or CPAP"
214317011|NCT04342104|OTHER|Evaluate HACOR score effectivity in this patients|Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
214317012|NCT02981381|DEVICE|NEST-1|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.
214317013|NCT02981381|DEVICE|SHAM|The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.
214317014|NCT02981381|DEVICE|NEST-2|The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.
214317015|NCT06414174|DEVICE|Split septum needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
214317016|NCT06414174|DEVICE|Mechanical valve needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
214317017|NCT04070300|BEHAVIORAL|Interval exercise|Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
214317018|NCT02098161|OTHER|Laboratory Biomarker Analysis|Correlative studies
214317019|NCT02098161|OTHER|Questionnaire Administration|Ancillary studies
214317020|NCT02098161|DRUG|Smac Mimetic LCL161|Given PO
214317021|NCT05780671|OTHER|oxygen|inhaled oxygen 10L/min with face mask for 1 hour
214317022|NCT03740438|DIAGNOSTIC_TEST|Hemoglobin concentration|Perioperative hemogloin concentration
214317023|NCT06833229|PROCEDURE|FDG-PET|PET scan are performed within 28 days before the start of immunotherapy, then at week 6 and week 12 of follow-up. Various metabolic parameters extracted from the standard PET image (ΔSUVmax, ΔTLG, appearance of new visceral lesion(s)), parametric (metabolic glucose rate (Ki), volume of distribution (VD)) and tumor response based on PERCIST criteria (adapted to immunotherapy) are assessed.
214317024|NCT02046148|BIOLOGICAL|GBS trivalent vaccine|Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein
214317025|NCT02046148|BIOLOGICAL|Placebo|Intramuscular injection - Normal saline
214482756|NCT06873464|OTHER|Three cycles of tDCS combined with motor tasks|"Three cycles of 2 weeks duration each combining tDCS and motor task.~Initial Assessment (V0): Collect demographic data and EDSS, MFIS, MSQOL-54, and BBS results.~First Cycle: 2 weeks, Monday to Friday, with a weekend break. Post-First Cycle Assessment (V1): Reassess MFIS, MSQOL-54, and BBS. Washout Period: 1 month without tDCS. Second Cycle: 2 weeks, Monday to Friday, with a weekend break. Final Assessment after Second Cycle (V2): Reassess MFIS, MSQOL-54, and BBS. Washout Period: 1 month. Third Cycle: 2 weeks. Final Assessment after Third Cycle (V3): Reassess MFIS, MSQOL-54, and BBS."
214918917|NCT03124407|DRUG|Capsaicin Topical Solution|Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin
214918918|NCT03124407|OTHER|Drug product vehicle|This is the vehicle for the active treatment drug product, but without capsaicin
214918919|NCT02690298|DEVICE|ExSpiron|Non-Invasive respiratory volume monitoring
214918920|NCT02113098|OTHER|Treadmill, ankle load|The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
214918921|NCT02113098|OTHER|Treadmill|The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
214918922|NCT06667206|BIOLOGICAL|Licenced Measles-Rubella vaccine|Licenced Measles-Rubella vaccine provided by the Ugandan EPI programme
214317026|NCT04176094|OTHER|16h overnight duty|schedule observed by participating ICUs.
214317027|NCT04176094|OTHER|24h overnight duty|schedule observed by participating ICUs.
214317028|NCT04176094|OTHER|Handover training|Formal handover training for residents in both interventions. ICUs with a pre-existing standardized handover training and process will be asked to continue handover practices throughout the study. In ICUs without a pre-existing standardized handover training and process, ICU education directors will be provided with materials to include in orientation of residents to the ICU and local training to ICU staff physicians at least once per year.
214317029|NCT06505525|PROCEDURE|Extra-articular reconstruction with the Anterolateral Ligament|Anatomical ACL reconstruction combined with extra-articular reconstruction with the Anterolateral Ligament
214317030|NCT01283126|PROCEDURE|euglycemic and hypoglycemic clamp|Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
214317031|NCT01781442|DRUG|Temsirolimus|"The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.~Treatment will continue until disease progression or unacceptable toxicity.~The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity."
214317032|NCT01115595|BIOLOGICAL|Intervention|Dermatophagoides pteronyssinus from ALK company
214317033|NCT01115595|OTHER|Control|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid)
214317034|NCT00014365|DRUG|MKC-1|
214317035|NCT00181207|DEVICE|pneumatic vest|
214918923|NCT03660189|OTHER|Two bag system|The two IV fluid bags have identical fluids and electrolytes, except one has 10% dextrose and the other has no dextrose. The two fluid bags run simultaneously and their rates are adjusted according to the patient's blood sugar.
214317036|NCT00181207|OTHER|placebo pneumatic vest|
214317037|NCT03194451|OTHER|non-interventional study|teeth collection
214317038|NCT06423547|OTHER|no intervention|this is an observation study,no intervention
214317039|NCT05087654|OTHER|Combination of 3D VR and Hands-on Horticultural Activities|The intervention program consisted of 8 two-hour sessions that were conducted once a week for 8 consecutive weeks.
214317040|NCT01627938|DRUG|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
214317041|NCT01627938|DRUG|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
214317042|NCT01110421|DRUG|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
214317043|NCT01110421|DRUG|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
214317044|NCT01110421|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
214317045|NCT01110421|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
214317046|NCT01110421|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
214317047|NCT00006890|DRUG|prednisone|Prednisone 50mg on alternate days
214317048|NCT00006890|DRUG|thalidomide|THALIDOMIDE 200 mg qhs
214317049|NCT04682821|OTHER|Artificial intelligence assistant system|The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
214317050|NCT04849156|OTHER|Sperm selection by thermotaxis|Selection of healthy sperm by thermotaxis procedure
214317051|NCT01649258|DRUG|granisetron transdermal system|Given granisetron transdermal system patch
214317052|NCT01649258|DRUG|fosaprepitant dimeglumine|Given IV
214317053|NCT01649258|OTHER|laboratory biomarker analysis|Correlative studies
214317054|NCT02877628|OTHER|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
214317055|NCT01229475|PROCEDURE|Ablation with stepwise approach|Stepwise approach for repeat AF ablation
214317056|NCT01229475|PROCEDURE|Linear ablation|Linear ablation for AF ablation
214317057|NCT03365206|OTHER|Questionnaire on practices and knowledge in terms of oral hygiene|Questionnaire on practices and knowledge in terms of oral hygiene during a dental consultation
214317058|NCT05428475|DIAGNOSTIC_TEST|[18F]FDG-PET Scan|185 MBq of \[18F\]FDG will be administered IV 30 minutes prior to PET scan. Images will be acquired for 30 minutes. Resulting images will be evaluated for patterns of FDG-uptake to support the diagnosis of the participant symptoms of cognitive impairment.
214482757|NCT06873464|OTHER|Two cycles of tDCS combined with motor tasks|"Initial assessment (V0): Prior to the first tDCS cycle, demographic data and results from the EDSS, MFIS, MSQOL-54, and BBS scales will be collected.~First cycle: 2 weeks Post-first cycle assessment (V1): Reassess MFIS, MSQOL-54, and BBS scales. Washout period: 1 month without tDCS treatment. Second cycle: 2 weeks, with sessions from Monday to Friday and a weekend break. Final assessment (V2): After the second cycle, reassess MFIS, MSQOL-54, and BBS scales.~Follow-up assessment (V3): 45 days after treatment completion."
214671636|NCT02717767|OTHER|Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages
214671637|NCT00296348|DRUG|tacrolimus|immunosuppression
214317059|NCT04943731|DEVICE|Provox Life|Phase 1: Like for like transition, Phase 2: Provox Life day/night regimen
214317060|NCT03384251|BEHAVIORAL|comprehensive sex education|A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
214317061|NCT06353490|DEVICE|Infrared Forehead Thermometer (GE-TF03)|Infrared Forehead Thermometer (GE-TF03) is an investigational device intended to measure body temperature on the forehead. GE-TF03 took three measurements for each subject.
214317062|NCT06353490|DEVICE|Infrared Ear Thermometer (GE-TE06)|Infrared Ear Thermometer (GE-TE06) is an investigational device intended to measure body temperature in the ear canal. GE-TF06 took three measurements for each subject.
214317063|NCT06353490|DEVICE|Electronic Thermometer (MT-B321FB)|Electronic Thermometer (MT-B321FB) is an investigational device intended to measure body temperature on the temporal artery. MT-B321FB took three measurements for each subject.
214317064|NCT06353490|DEVICE|Electronic Thermometer (MT-B231)|Electronic Thermometer (MT-B231) is a reference device that measured axillary temperature one time for each subject.
214317065|NCT00235872|BIOLOGICAL|adalimumab|40 mg eow, sc
214317066|NCT01389180|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
214317067|NCT01389180|BEHAVIORAL|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
214317068|NCT01389180|BEHAVIORAL|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
214317069|NCT01446965|DEVICE|wearable defibrillator|LifeVest wearable defibrillator
214317070|NCT05678335|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 200mg twice daily for 12weeks.
214482758|NCT06875557|BEHAVIORAL|Digital Mental Health Intervention (DMHI)|In the current study, the impact of Digital Mental Health Intervention (DMHI) would be examined through Insight Timer application, focusing on just its one aspect (Reiki healing techniques). Through the usage of DMHIs in the young population, youth would be better able to express their psychological issues with the healthcare professionals instead of the fear of being labelled or stigmatization.
214482759|NCT06875557|BEHAVIORAL|Digital Mental Health Intervention (DMHI)|Digital Mental Health Intervention (DMHI) was provided to the sample of young adults who were experiencing psychological distress. DMHI was being given through Insight Timer application that only focused on reiki healing techniques. Insight Timer is a mobile app that provides guided meditations to calm the mind, alleviate anxiety, manage stress, achieve deep sleep, and enhance well-being and happiness. Additionally, it offers calm and soothing music, educational courses, live events, and workshops in multiple languages. (Insight Network, Inc., n.d.). The app is FREE to download with an email allowing access to their collection of meditation recordings. Insight Timer's free-to-use feature is most suitable for community groups.
214482760|NCT04873323|DRUG|TS-142|Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
214482761|NCT04873323|DRUG|Moxifloxacin|Single dose of moxifloxacin 400 mg in the morning under fasting in each period
214317071|NCT05678335|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
214482762|NCT04873323|DRUG|Placebo|Single dose of TS-142 placebo in the morning under fasting in each period
214671638|NCT00296348|DRUG|mycophenolate mofetil|oral
214918924|NCT04274244|DRUG|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"Regenerative periodontal therapy + Cross-linked hyaluronic acid 1.8%:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Hyadent BG® 1,8% filling the bone defect from the bottom upwards in the test group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks."
214918925|NCT04274244|DRUG|Enamel Matrix Proteins (Active comparator group)|"Regenerative periodontal therapy + Enamel matrix proteins:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Emdogain® filling the bone defect from the bottom upwards in the active comparator group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks."
214918926|NCT01860040|DRUG|Cisplatin|Alkylating antineoplastic agent (Chemotherapy)
214317072|NCT01790464|DRUG|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
214317073|NCT01790464|DRUG|placebo|
214317074|NCT04212585|DIAGNOSTIC_TEST|Serology test|"Serology for Helicobacter pylori (immunoglobulin G for all sites, immunoglobulin M optional, immunoglobulin A optional) will be collected from all participants. 90 samples (immunoglobulin G, immunoglobulin M and immunoglobulin A) at least needed from each site.~Stool antigen for Helicobacter pylori"
214317075|NCT05379296|BEHAVIORAL|Diabetes Prevention Program Plus (DPP+)|The DPP+ includes the CDC-approved DPP lifestyle program expanded to include a CDC-approved module on hypertension prevention and treatment
214317076|NCT05379296|BEHAVIORAL|Diabetes Prevention Program (DPP)|CDC-approved DPP lifestyle program
214317077|NCT01127750|DRUG|FTY720|
214317078|NCT01232296|DRUG|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
214317079|NCT01232296|DRUG|sorafenib|400 mg p.o. b.i.d.
214317080|NCT02871375|DEVICE|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
214317081|NCT02871375|DEVICE|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
214482763|NCT05761769|OTHER|no intervention|no intervention
214482764|NCT04271189|DRUG|Metformin-Sitagliptin-Empaglifozin-Pioglitazone|1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
214671639|NCT00296348|DRUG|daclizumab|oral
214671640|NCT00296348|DRUG|steroids|oral
214671641|NCT04304222|DEVICE|3D Printed Denture Framework|The Denture Framework is 3D printed from the digital image obtained from the denture mold.
214671642|NCT06554457|DRUG|Multimodal analgesia with oral strong opioids|Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics
214671643|NCT04713917|DEVICE|Hyaluronique Acid Gel|Vaginal gel based on HA with liposomal structure applicated 2 times a week
214671644|NCT04713917|DEVICE|Laser CO2|The laser energy delivered along the vaginal wall heats the tissue without damaging it.
214317082|NCT03592121|DRUG|AB-101|Apply approximately 1 hour prior to sexual activity
214482765|NCT04271189|DRUG|Standard of care|Usual medical care to treat diabetes.
214482766|NCT06699056|DEVICE|15-minutes of sitting during COR ECG Acquistion|"Participants will follow a standardized protocol during a 15-minute seated session using the Peerbridge COR™ device. Participants will sit comfortably in an upright chair with a straight back; armrests are optional. Their feet must remain flat on the floor with legs uncrossed to ensure unobstructed blood flow and a stable posture. Arms should be relaxed and placed in their lap, on a flat surface (e.g., table), or on the armrest, ensuring they are not tensed or elevated. Participants will maintain a straight back with relaxed shoulders throughout the session.~To begin, participants will press the Event Button on the Peerbridge COR™ mobile device, marking the start of the session. They will remain seated in this position for 15 minutes. At the end of the session, participants will press the Event Button again to mark the conclusion of the seated event. This protocol ensures consistent data collection across all participants."
214317083|NCT03592121|DRUG|Placebo|Apply approximately 1 hour prior to sexual activity
214317084|NCT02233010|OTHER|The level of NGAL after pre op,post op 4hr, post op 12hr|
214317085|NCT04122482|BEHAVIORAL|Psychoeducation Course|The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.
214317086|NCT06067594|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement|Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
214317087|NCT04054687|DRUG|Tranexamic Acid|Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
214317088|NCT04054687|OTHER|Placebo|This group will receive pledget soaked in saline. Protocol will continue as with TXA group.
214482767|NCT06699654|OTHER|Placebo gel|A gel without active Spirulina components applied as a control intervention.
214317089|NCT00534235|PROCEDURE|Decompression|Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain
214482768|NCT06699654|DIETARY_SUPPLEMENT|Spirulina Gel|A conventional Spirulina gel formulation applied as a periodontal therapy.
214918927|NCT01860040|DRUG|Pemetrexed|Antimetabolite antineoplastic agent (Chemotherapy)
214918928|NCT01860040|DRUG|Gemcitabine|Antimetabolite antineoplastic agent (Chemotherapy)
214918929|NCT05037357|DIAGNOSTIC_TEST|Plasma EBV DNA qPCR test|Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.
214918930|NCT04423770|OTHER|No intervention|No intervention; this is a purely observational study
214918931|NCT03339193|DEVICE|Left atrial appendage closure|Percutaneous insertion of a Watchman FLX left atrial appendage closure device under general anesthesia with transesophageal echo guidance.
214918932|NCT03941054|OTHER|Pressure Release|Subjets receive digitopressure during 90 seconds for the treatment of the Myosfascial Trigger Points
214918933|NCT02821754|DRUG|Durvalumab|Flat dose of 1500 mg every 4 weeks.
214918934|NCT02821754|DRUG|Tremelimumab|Flat dose of 75 mg every 4 weeks for up to 4 doses.
214918935|NCT02821754|PROCEDURE|Trans-arterial Catheter Chemoembolization (TACE)|TACE will be performed on Day 36 (+/-96hrs).
214317090|NCT00534235|DEVICE|Posterolateral Fusion and Implantation of Pedicle Screws|
214317091|NCT00534235|DEVICE|Implantation of coflex Interlaminar Technology|
214317092|NCT02151708|DRUG|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
214317093|NCT02151708|DRUG|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
214317094|NCT05001243|DRUG|Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac|PBOHB to improve uncorrected near vision in healthy presbyopic patients
214317095|NCT05001243|DRUG|Pilocarpine Hydrochloride|Apply in the fellow eye
214317096|NCT05001243|DRUG|Brimonidine Tartrate|Apply in the fellow eye
214317097|NCT02479854|DRUG|Asmakast|1 chewable tablet contains 5 mg montelukast
214317098|NCT02479854|DRUG|Singulair|1 chewable tablet contains 5 mg montelukast
214482769|NCT06699654|DIETARY_SUPPLEMENT|Spirulina Nanoparticles Gel|A novel Spirulina nanoparticles gel formulation applied as a periodontal therapy.
214482770|NCT06700850|DEVICE|Prototype dressing rectangle|Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 30x10cm. Topical application. Single use.
214482771|NCT06700850|DEVICE|Marketed dressing rectangle|CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 30x10cm. Topical application. Single use
214482772|NCT06700850|DEVICE|Prototype dressing square|Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 7.5x7.5cm. Topical application. Single use.
214918936|NCT02821754|PROCEDURE|Radiofrequency Ablation (RFA)|RFA will be performed on Day 36 (+/-96hrs).
214918937|NCT02821754|PROCEDURE|Cryoablation|Cryoablation will be performed on Day 36 (+/-96hrs).
214918938|NCT00514215|BIOLOGICAL|sargramostim|250 μg, inhaled, two times a day, on days 4-10 and days 36-42
214918939|NCT00514215|OTHER|flow cytometry|Days 1 \& 32
214918940|NCT00514215|OTHER|immunoenzyme technique|Days 1 \& 32
214317099|NCT05072353|DEVICE|SEFFICARE|"The SEFFI is a 5-step technique:~1. Preparation: the lower/lateral abdomen is chosen as the donor site.~2. Anesthesia: the donor site is injected with a local anesthetic.~3. Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~4. Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~5. Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound."
214317100|NCT00805116|DIETARY_SUPPLEMENT|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
214317101|NCT00805116|DIETARY_SUPPLEMENT|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
214317102|NCT00005861|DRUG|pegylated liposomal doxorubicin hydrochloride|
214317103|NCT00884234|OTHER|Vehicle Control|Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2
214317104|NCT00884234|DRUG|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 at Baseline (Day 0) and Week 2
214317105|NCT00001442|DRUG|paclitaxel concurrent with radiation therapy|
214317106|NCT02530112|OTHER|Survey|
214317107|NCT04930887|DRUG|Exparel (Bupivacaine Liposome)|Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
214317108|NCT04930887|DRUG|Saline|Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
214317109|NCT06225726|PROCEDURE|urethral bladder resection|urethral bladder resection. Per-operative bladder ultrasound elastography and simultaneous cystometry
214317110|NCT02667483|DRUG|DS-5141b|DS-5141b, Subcutaneous injection
214317111|NCT04259957|DEVICE|Immersive Virtual Reality|Immersive virtual reality games and mindfulness in Oculus Quest Virtual Reality headset
214918941|NCT00514215|PROCEDURE|biopsy|CT guided biopsy on days 1 \& 32
214317112|NCT03121326|DIAGNOSTIC_TEST|blood and urine sampling|Ten mL blood and 15mL urine are collected.
214482773|NCT06700850|DEVICE|Marketed dressing square|CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 7.5x7.5cm. Topical application. Single use.
214482774|NCT06699810|DEVICE|Continuous Glucose Monitoring|After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
214317113|NCT04079985|OTHER|Animal-assisted therapy|The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.
214317114|NCT03829371|DRUG|Velcade|Subcutaneous use
214317115|NCT03829371|DRUG|Melphalan|Oral use
214317116|NCT03829371|DRUG|Prednisone|Oral use
214317117|NCT03829371|DRUG|Lenalidomide|Oral use
214317118|NCT03829371|DRUG|Dexamethasone|Oral use
214317119|NCT03829371|DRUG|Daratumumab|Subcutaneous Injection
214317120|NCT06647030|DEVICE|CURATE.DTx sessions|"Participants will interact with CURATE.DTx twelve minutes per day, three days a week, for ten weeks.~CURATE.DTx is a cognitive training DTx developed by our research team in The N.1 Institute for Health (N.1) and The Institute for Digital Medicine (WisDM). CURATE.DTx is comprised of CURATE.AI and a modified version of the Multi-Attribute Task Battery (MATB), Online MATB.~CURATE.AI is a small data AI-derived platform that can dynamically personalize treatment by modulating drug dose or therapy intensity. We previously implemented CURATE.AI into Online MATB - the modernized, online version of MATB, a flight deck simulator program developed by NASA and the United States Air Force."
214317121|NCT06647030|BEHAVIORAL|Interview|After the last DTx session (regardless of study completion by the participant), a 60-minute interview session will be conducted by a team member, either at the Institute for Digital Medicine (WisDM) in person or via Zoom. All responses will be audio-recorded and transcribed verbatim. We will use thematic analysis of anonymized transcripts to identify emerging or recurring themes. Data will be analyzed using NVivo. The analysis will begin with open/primary coding, where we will descriptively label data. Subsequently, we will group the labels into categories based on literature (i.e., secondary coding). These categories will then help create broader themes/assertions.
214482775|NCT06699810|DRUG|Insulin|Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.
214482776|NCT06702241|OTHER|Continuous Phototherapy with a irradiance of 40 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific to the device's wavelength.
214918942|NCT00514215|PROCEDURE|cryosurgery|Days 1 and 32
214918943|NCT03496896|OTHER|TARGET|The pre-discharge component includes mainly patient information, medication reconciliation, patient education, planning of a first post-discharge primary care physician visit with a timely discharge summary sent to the primary care physician. Two follow-up phone calls are made by a nurse, at D3 and D14, and include the assessment of the general health condition, the verification of the follow-up care plan, a reinforcement of the patient education, and review with the patient of the medication list with assessment of potential adverse drug events.
214918944|NCT02464943|DEVICE|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
214918945|NCT03278223|DEVICE|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
214918946|NCT03278223|DEVICE|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
214918947|NCT05693064|OTHER|wait-list|wait-list
214317122|NCT03341988|DRUG|Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram|To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
214317123|NCT05296603|DRUG|IBI-322 Plus Lenvatinib|"IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg"
214317124|NCT02250196|DRUG|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
214317125|NCT02250196|DRUG|SPMC 2|received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
214317126|NCT05515848|OTHER|No intervention|There is no intervention in this retrospective study.
214317127|NCT00802412|DRUG|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
214317128|NCT00802412|DRUG|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
214317129|NCT05289596|BEHAVIORAL|Sleep Healthy Using the Internet (SHUT-i)|SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
214482777|NCT06702241|OTHER|Continuos Phototherapy with a irradiance of 55 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
214482778|NCT06702241|OTHER|Continuous Phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
214482779|NCT06702241|OTHER|Cycled phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
214482780|NCT06699875|OTHER|Trak exercise prescription protocol at home|Online exercise protocol using the TRAK software. The patient will undergo 4 weeks of an exercise prescription protocol based on shoulder mobility exercises.
214918948|NCT05693064|PROCEDURE|chiropractic adjustments|chiropractic adjustments
214482781|NCT06699875|OTHER|Conventional rehabilitation plan at home|Treatment is based on therapeutic exercise following a conventional rehabilitation plan on paper. The patient will undergo 4 weeks of an exercise prescription protocol based on mobility exercises.
214918949|NCT02099890|DIETARY_SUPPLEMENT|Omega-3|
214482782|NCT06504043|DRUG|HST101|HST101 is a novel anti-PCSK9 fusion protein
214482783|NCT04177771|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD) - Pre-COVID Population|Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments
214918950|NCT02099890|DIETARY_SUPPLEMENT|Vegetation Protein Powder|
214918951|NCT02099890|DIETARY_SUPPLEMENT|InflanNox|
214918952|NCT02099890|DIETARY_SUPPLEMENT|Anti-oxidant Network|
214918953|NCT02099890|DIETARY_SUPPLEMENT|Chlorella|
214317130|NCT00606892|DRUG|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
214317131|NCT00606892|DRUG|Placebo|Sugar Pill
214317132|NCT00606892|DRUG|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
214317133|NCT06105385|OTHER|Suboccipital Myofascial Release Technique|With the patient in a supine position, the therapist sits behind the patient with his or her forearms on the treatment table. The therapist places his fingers between the occiput and axis, with his fingers in semi-flexion (2nd, 3rd and 4th fingers), and continues to hold his hands on the occiput until relaxation is achieved in the suboccipital muscles. A light traction is applied at the end of the technique. Average application time is 4-5 minutes.
214317134|NCT05930665|DRUG|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin|Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks
214317135|NCT06456281|DIAGNOSTIC_TEST|A noninvasive cfDNA multi-omics assay|Peripheral venous blood samples will be collected from pancreatic cancer patients, individuals with precancerous lesions, and healthy controls. Subsequently, cfDNA will be extracted and subjected to low-pass whole genome sequencing (LP-WGS) and hybrid capture-based targeted methylation sequencing (TMS).
214482784|NCT04177771|DEVICE|SofPort LI61AO IOL|Control treatment group will receive SofPort LI61AO IOL
214482785|NCT04177771|DEVICE|Tecnis ZCB00 or ZTC150 IOL|Control treatment group will receive Tecnis ZCB00 or ZTC150 IOL
214482786|NCT04274361|DRUG|Ketamine|Ketamine infusion
214918954|NCT02324504|DEVICE|C3 Wave ECG-based PICC Tip Confirmation System|The C3 Wave PICC tip detection system will be used to identify catheter tip location during the procedural placement of the catheter. This system includes an ECG monitor that will be connected to the guidewire used for catheter placement. The changes in the ECG tracing will guide correct catheter placement.
214918955|NCT04781283|DEVICE|measurement of endothelial cell density by specular microscopy|"During this first appointment (T0), in addition to the usual treatment, measurement of the endothelial cell density by specular microscopy will be carried out on the affected eye (basal cell density). To overcome the variability linked to the machine, three consecutive measurements will be taken; the average of the three measurements will be used.~As part of his post-operative follow-up, the patient will be reviewed at one month, one year, two years, three years, four years and five years after the operation. During these consultations and as part of the research, a new determination of the cell density (3 consecutive measurements) by specular microscopy of the operated eye and an evaluation of the position of the XEN implant will be carried out each time. ® by OCT scan for patients having undergone this surgery."
214482787|NCT04274361|DRUG|Placebo|Placebo infusion
214482788|NCT02806726|DEVICE|iDesign 1.3-PRESBY treatment|Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
214317136|NCT02144740|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
214482789|NCT02806726|DEVICE|iDesign 1.3 treatment|Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
214482790|NCT01159782|OTHER|Rhinovirus infection|All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
214482791|NCT03966586|BEHAVIORAL|Active outreach|Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.
214482792|NCT03966586|BEHAVIORAL|Appointments|Participants in the enhanced-care intervention will be given specific appointment times/dates.
214482793|NCT03966586|BEHAVIORAL|Financial support|Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.
214317137|NCT02144740|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
214317138|NCT04307628|OTHER|Walnut|Study participants will eat 2 ounces of walnuts each day.
214317139|NCT04307628|OTHER|Nut-Free|Study participants will not eat nuts.
214317140|NCT03007394|DRUG|Lorcaserin|Lorcaserin Capsule
214317141|NCT03007394|DRUG|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
214317142|NCT04277091|OTHER|High-intensity interval training|Arm-cranking exercise
214317143|NCT04277091|OTHER|Moderate-intensity continuos training|Arm-cranking exercise
214317144|NCT03662438|OTHER|Home-based physiotherapy program|The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
214317145|NCT03662438|DEVICE|Prescription of a Portable Oxygen Concentrator (POC) device|Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device \[Philips SimplyGo Mini\] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
214317146|NCT00899691|GENETIC|protein expression analysis|
214482794|NCT03966586|BEHAVIORAL|Microenterprise|YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.
214482795|NCT03966586|BEHAVIORAL|Enhanced counseling|Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.
214482796|NCT03966586|BEHAVIORAL|Usual clinical care and counseling|Usual clinical care and counseling
214482797|NCT03443791|DIAGNOSTIC_TEST|Women Enrolled|Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.
214482798|NCT03443791|DIAGNOSTIC_TEST|Newborns of Female Study Participants|Newborns will be tested after birth as soon as possible for CMV positivity.
214482799|NCT06877182|DIAGNOSTIC_TEST|Magnetic Resonance Imaging with Contrast|To evaluate the possibility to improve the neuroradiologic workflow with AI models
214482800|NCT06880289|DRUG|Cisplatin IV on days 1, 22, 43, at a dose of 100 mg/m2|Chemoradiotherapy will be performed from day 1 to day 49 regardless of the arm.
214482801|NCT06879691|DRUG|Nimotuzumab|nimotuzumab group nimotuzumab, 200mg/w, for 6 weeks
214317147|NCT00633191|DRUG|Anti-pseudomonas IgY gargle|Gargle (solution), \> 5FKU, every night after toothbrushing, life-long
214317148|NCT02073422|DEVICE|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
214317149|NCT02073422|OTHER|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
214317150|NCT05874180|DRUG|DW6013|"Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition"
214317151|NCT01469468|DRUG|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
214317152|NCT01469468|DRUG|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
214482802|NCT06879691|DRUG|cis-platinum|30mg/m2/w, for 6 weeks
214482803|NCT06879691|RADIATION|IMRT combine with cisplatin concurrent chemotherapy|IMRT, 66～70Gy (2Gy/F, 35F), for 6 weeks
214671645|NCT04713917|DEVICE|Hyaluronique Acid Injection|HA injection performed under the mucosae (2-3mm in depth) following one injection point every 5mm on the 3 first cm of the vagina and on the posterior part of the introitus.
214671646|NCT00144105|DRUG|TPV500mg/RTV200mgBID|
214317153|NCT04590547|DRUG|GLS-1027|GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
214671647|NCT00144105|DRUG|TPV500mg/RTV100mgBID|
214671648|NCT00144105|DRUG|LPV400mg/RTV100mgBID|
214918956|NCT05783167|DIAGNOSTIC_TEST|Self-sampling for HPV infection|After informed consent has been provided, the woman will be asked to collect firstly a first-void urine sample using the Collipee device and secondly to collect a vaginal self-sample using the dry Evalyn® Brush device. Socioeconomic, demographic and clinical data will be collected in the Bissau HIV Cohort database and through study questionnaires to collect background information on risk factors for HPV persistence and development of cervical cancer (HIV genotype, immune status, parity). Questionnaires will collect additional information on the acceptance of cervical screening measures to better evaluate the feasibility of implementing self-collected screening among HIV infected women in Guinea-Bissau.
214918957|NCT06211686|OTHER|Protein powder and Resistance exercise|"1. Protein powder supplementation 25-30 g/day~2. Resistance exercise 2 time/week"
214918958|NCT06578325|OTHER|Thai dance meditation|Thai dance meditation training program will be based on aerobic Thai dance exercise combined with Buddhist meditation. The participants will perform aerobic Thai dance meditation while concentrated on hand movements through counting the numbers 1 2 3 4 5 6 7 1 on the 1st round and continuing on the 2nd round, counting as 1 2 3 4 5 6 7 2…. Repeat for 8 rounds. Thai dance meditation will be conducted at mild to moderate intensity (40-60% heart rate reserve) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (50-60% heart rate reserve). In both phases the training will be performed foe 50 minutes, 3 times per week.
214918959|NCT06578325|OTHER|No intervention|No intervention
214918960|NCT06577402|DIETARY_SUPPLEMENT|nutritional support|nutritional support
214317154|NCT04590547|DRUG|Placebo|Placebo looks like GLS-1027
214317155|NCT00981006|PROCEDURE|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
214317156|NCT01163994|DRUG|ceftriaxone|intravenously, 2 g, qd, 15 days
214317157|NCT01163994|DRUG|doxycycline|orally, 100 mg, bid, 15 days
214671649|NCT00004154|DRUG|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
214671650|NCT00004154|OTHER|Placebo|Two placebo capsules for 25 days of 28 day cycle.
214671651|NCT04021784|DEVICE|SDS|The patient is implanted with SDS.
214671652|NCT04021784|DEVICE|NEMOST|The patient is implanted with NEMOST.
214918961|NCT05099185|BIOLOGICAL|Water-soluble vitamins and trace elements measures|We would like to measure water-soluble vitamins (B1, B6, B9, B12, C) and trace elements (zinc, selenium) in blood and dialysate for the patients treated by online post-dilution hemodiafiltration patients. There measures on blood are done systematically during the half-yearly report of our patients in our hemodialysis center. Only results are collect for the study.
214671653|NCT02016157|DRUG|Moxifloxacin|TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
214918962|NCT01959464|DRUG|Crinone vaginal progesterone gel|Crinone vaginal progesterone gel is inserted in the female vaginal using the pre-filled applicator.
214918963|NCT01959464|DRUG|Placebo vaginal gel|Placebo vaginal gel is inserted in the female vagina using the pre-filled applicator.
214918964|NCT00002435|DRUG|Thymic Humoral Factor|
214918965|NCT00002435|DRUG|Zidovudine|
214317158|NCT01163994|OTHER|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
214317159|NCT02944318|BEHAVIORAL|The Movement Program|The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
214317160|NCT05935241|BEHAVIORAL|mPATH|The active mPATH intervention takes 6 months including (1) The physical activity education session , (2)mHealth learning and practice; (3)Personalized physical activity training, plan, and biweekly phone calls over 24 weeks (4) mHealth strategies to encourage physical activity and facilitate intervention adherence (5) (5) mPATH during 6-12 months: mPATH will be delivered mainly in 24 weeks before the 6-month data collection. During 6-12 months, the participants will have access to study mHealth strategies, and exercise videos. No additional physical activity training by staff will be supported.
214671654|NCT02495077|BIOLOGICAL|Infliximab|A single dose, of 3mg/kg infusion
214671655|NCT02495077|DRUG|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
214671656|NCT02495077|DRUG|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
214671657|NCT02495077|DRUG|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
214671658|NCT02495077|BIOLOGICAL|Thymoglobulin®|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
214671659|NCT02495077|DRUG|Acetaminophen|"30 to 60 minutes prior to the start of the infusion~* Tylenol, 600 to 1000mg by mouth or~* Suppository form"
214671660|NCT02495077|DRUG|Loratadine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
214671661|NCT02495077|BIOLOGICAL|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
214918966|NCT00880113|PROCEDURE|Non-contrast CT, CT-perfusion and CT-angiography|Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
214918967|NCT03146949|DEVICE|Sorin Inspire Oxygenator|This is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator.
214918968|NCT03146949|DEVICE|Medtronic Affinity Fusion|This is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator.
214482804|NCT06879691|DRUG|painkiller|three ladders pain analgesic( First step: For mild pain, non-opioid agents (excluding nonsteroidal anti-inflammatory drugs \[NSAIDs\]) combined with adjuvant analgesics are administered; Second step: For moderate pain, weak opioids combined with NSAIDs and adjuvant analgesics are prescribed;Third step: For severe pain, strong opioids combined with NSAIDs and adjuvant analgesics are used.)
214482805|NCT06880380|BIOLOGICAL|HIV-CAR-T|Intravenous Infusion of CAR-T Cells
214317161|NCT05935241|OTHER|Attention Control|A registered nurse from the study team will provide 6 monthly home visit (approximately 55-60 minutes each) to provide physical activity education, physical activity safety at home evaluation, feedback, and social activity (meaningful or enjoyable activities as identified by the participants, such as playing cards, doing arts and crafts, listening to music, talking about life history, etc.).
214317162|NCT03452592|DRUG|Alflutinib|Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
214317163|NCT00005770|DEVICE|Acupuncture|
214317164|NCT06262841|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
214317165|NCT06262841|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
214482806|NCT06879366|DRUG|Aloe vera gel|10% aloe-vera gel will be prepared under well-controlled laboratory checks
214482807|NCT06879366|DRUG|Benzydamine Hydrochloride 0.15% Oral gel|Benzydamine Hydrochloride 0.15% Oral gel
214482808|NCT06878469|DEVICE|RehaCom|Participants will receive a personalized neuro-cognitive rehabilitation program using the RehaCom software. Sessions will last approximately 30/40 minutes and will be held twice a week for 8 weeks. The rehabilitation will be aimed at enhancing and/or recovering cognitive functions that may have been compromised by the neurosurgical intervention.
214482809|NCT06877312|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"A light electrical current with zero frequency (tDCS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
214482810|NCT06877312|DEVICE|30 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 30 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
214482811|NCT06877312|DEVICE|50 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 50 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
214482812|NCT06877312|DEVICE|70 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 70 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
214482813|NCT06877312|DEVICE|90 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 90 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
214482814|NCT06877312|DEVICE|Transcranial Random Noise Stimulation (tRNS)|"A light electrical current with random noise waveform (tRNS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
214317166|NCT00144586|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
214317167|NCT01007695|DRUG|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
214317168|NCT00138983|DRUG|Alendronate versus alfacalcidol (1-alpha OH vitamin D)|
214317169|NCT05432310|COMBINATION_PRODUCT|A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme|Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan
214317170|NCT03799484|DRUG|Botulinum toxin type A|Botulinum toxin type A will be administered to both sides
214317171|NCT03799484|DRUG|2.5% lidocaine/2.5% prilocaine|2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead
214317172|NCT03799484|DEVICE|petrolatum ointment|petrolatum ointment will be applied to one side of the forehead
214317173|NCT00794196|BEHAVIORAL|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
214317174|NCT01411878|BEHAVIORAL|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
214317175|NCT01411878|BEHAVIORAL|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, \& Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
214317176|NCT01667666|DRUG|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
214317177|NCT00310908|DRUG|Tramadol Hcl|Active Comparator
214317178|NCT04564625|OTHER|Vitamin D Assessment|index admission vitamin D assessment
214317179|NCT04564625|OTHER|Fracture|rate of nonunion (i.e., failure of a fractured bone to heal)
214482815|NCT06877481|OTHER|Geriatric Pain Measurement Short Form|Geriatric Pain Measure - Short Form (GPM-SF) is a validated pain assessment tool designed specifically for older adults. It is a 12-item questionnaire that evaluates pain intensity, interference with daily activities, and emotional impact of chronic pain in geriatric patients. The short form provides a quick and reliable assessment of pain-related disability in older populations.
214482816|NCT06880224|BEHAVIORAL|Testing Peer navigation|Peer navigators will promote HIV testing in YMSM and linkage to care if HIV-positive
214918969|NCT03280602|PROCEDURE|Tension band wiring (TBW)|2 x K-wire fixation (1.6 mm) and wire cerclage.
214918970|NCT03280602|PROCEDURE|Plate fixation|Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
214482817|NCT06880224|BEHAVIORAL|PrEP Intervention|Motivational-interviewing to promote uptake of PrEP among those who test HIV-negative
214482818|NCT06880224|BEHAVIORAL|Treatment Peer Navigation|Peer navigators will provide assistance and support to youth with HIV to optimize adherence to ART
214482819|NCT06880224|BEHAVIORAL|Social Media Outreach|Social media outreach to identify youth at risk for HIV
214671662|NCT02495077|DRUG|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
214317180|NCT05817396|BEHAVIORAL|Promotion of Physical Activity-related Health Competence (PAHCO)|"Intervention for the curriculum content PAHCO at nursing schools in Bavaria"
214317181|NCT02254538|DRUG|BILR 355 BS|
214317182|NCT02254538|DRUG|PEG 400|
214317183|NCT06203457|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
214317184|NCT05575141|PROCEDURE|incisional hernia repair|Incisional hernia repair for the treatment of wide ventral incisional hernias.
214317185|NCT02771496|OTHER|Other: observational only- no intervention|Other: observational only- no intervention
214317186|NCT06145971|BEHAVIORAL|brief Cognitive Behavioural Therapy for Insomnia (bCBTi)|Two sessions of Cognitive Behavioural Therapy for Insomnia, encompassing a cognitive therapy technique and a behavioural technique as a minimum.
214317187|NCT04240145|DEVICE|MSCT Abdomen|Visceral fat volumetry using MSCT and it's relation to NASH
214317188|NCT02129803|DEVICE|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
214317189|NCT02129803|DEVICE|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
214317190|NCT01655017|PROCEDURE|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
214671663|NCT02495077|DRUG|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
214918971|NCT02638584|DRUG|Ilaprazole|Ilaprazole 10mg 2tablets once a day(1 times / day), before breakfast
214918972|NCT02638584|DRUG|Rabeprazole|Rabeprazole 20mg 1tablets once a day(1 times / day), before breakfast
214918973|NCT00800995|DIETARY_SUPPLEMENT|SOD|
214918974|NCT00800995|DIETARY_SUPPLEMENT|Sham|
214918975|NCT05411783|PROCEDURE|Low tie of IMV|The IMV will be tie under the left colic vein
214918976|NCT02660567|PROCEDURE|Amr maneuver|sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
214918977|NCT01368705|DIETARY_SUPPLEMENT|Standard protein delivery|Protein delivery of 1.5 g/kg/day.
214482820|NCT06880224|BEHAVIORAL|SMS Test messaging|Text (SMS) messages to remind and encourage youth to adhere to their ART
214482821|NCT06880224|OTHER|Adherence standard of care|Standard of care HIV treatment adherence
214918978|NCT01368705|DIETARY_SUPPLEMENT|Intervention 1 (2.2g/kg/day)|protein delivery of 2.2g/kg/day
214918979|NCT01368705|DIETARY_SUPPLEMENT|Intervention 2 (3.0 g/kg/day)|protein delivery of 3.0 g/kg/day
214918980|NCT05271149|OTHER|Routine Physical Therapy|Routine physical therapy and orthosis
214918981|NCT00994461|DRUG|Celecoxib|Celecoxib 100mg tablet twice a day with meal for 2 weeks
214918982|NCT00994461|DRUG|Loxoprofen|Loxoprofen 60mg tablet three times a day with meal for 2 weeks
214918983|NCT00994461|DRUG|Placebo|Placebo tablet three times a day with meal for 2 weeks
214918984|NCT03193372|DRUG|Azelaic Acid (Finacea Foam, BAY39-6251)|Finacea Foam, Active substance Azelaic acid
214918985|NCT04074369|DIAGNOSTIC_TEST|CRISPR-based Test|CRISPR-based Test performed on sputum or BALF in TB suspects.
214918986|NCT03348007|OTHER|Taking two kinds of mineral water|1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).
214918987|NCT02764372|BEHAVIORAL|Serious games|Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113
214918988|NCT02764372|BEHAVIORAL|Exergames|Participants played exergames existent in the Wii game console
214918989|NCT01830868|DRUG|Zonisamide tablets|The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
214918990|NCT04835610|DEVICE|pvi|The Plethysmographic Variability Index (PVI) can be measured with both finger and forehead probes. Vasoconstriction may reduce the reliability of PVI measurements in pediatric surgical patients prone to hypothermia. The vascular structure of the forehead area is resistant to changes in vasomotor tonus. The aim of our study is to compare the efficacy of PVI values measured at the finger and forehead areas to predict fluid responsiveness in these patients.
214918991|NCT02336568|DRUG|Oxytoine|In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
214918992|NCT02336568|DRUG|PLACEBO|In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
214918993|NCT05921292|COMBINATION_PRODUCT|Omeza Products Used in Combination|"Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza® combination therapy which includes the use of the following products:~* Omeza® Lidocaine Lavage~* Omeza® Complete Matrix (OCM™)~* Omeza® Skin Protectant At each treatment (on days 0, 7, 14, 21; +/- 3 days each), the patient's intact skin around the wound/ulcer will be prepped with Omeza® Lidocaine Lavage. OCM™ will be applied directly to the wound/ulcer and Omeza® Skin Protectant will be applied to the periwound and surrounding intact skin. Treatments may be repeated during an optional 7 additional weeks (on days 28, 35, 42, 49, 56, 63, and 70; +/- 3 days each). Final assessment will be made at week 12."
214918994|NCT02653781|BEHAVIORAL|Realistic simulation|The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.
214918995|NCT02653781|BEHAVIORAL|control group|The control group will have contents exposed solely from the dialogue-exhibition.
214918996|NCT02653781|BEHAVIORAL|Simulation workshop|Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
214918997|NCT02653781|BEHAVIORAL|Test realistic simulation|Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
214918998|NCT01599533|OTHER|blood samples|
214918999|NCT05312762|DEVICE|MaxioCel|Microfiber wound dressing
214919000|NCT05312762|DEVICE|AquaCel Extra|Hydrofiber dressing
214919001|NCT02348645|PROCEDURE|Spinal fusion|
214919002|NCT02348645|PROCEDURE|Spinal decompression|
214919003|NCT06449430|DRUG|Sedation with propofol|Sedation with propofol
214919004|NCT06449430|DRUG|Spinal analgesia with bupivacaine|Spinal analgesia with bupivacaine
214919005|NCT02251418|DEVICE|Extracorporeal shockwave therapy|
214919006|NCT02567123|BEHAVIORAL|Experimental|
214919007|NCT02948751|DEVICE|OncoCEE|The CSF sample will be to delivered to Biocept's laboratory for processing, and it will be evaluated for CTCs using OncoCEETM microchannel technology. This CSF sample will also be tested for cell-free circulating tumor DNA (ctDNA).
214919008|NCT01463189|BEHAVIORAL|painACTION: Arthritis|"Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute booster sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs."
214919009|NCT03618394|DIETARY_SUPPLEMENT|MCT/ω-3-PUFA|lipid emulsion
214919010|NCT03618394|DIETARY_SUPPLEMENT|Soybean Based|lipid emulsion
214919011|NCT02256124|DRUG|Lamotrigine|
214919012|NCT02256124|DRUG|Placebo|
214919013|NCT02347813|DRUG|Pioglitazone|15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
214919014|NCT00899119|PROCEDURE|leukapheresis|
214919015|NCT01385137|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given orally
214919016|NCT01385137|OTHER|placebo|Given orally
214919017|NCT01159405|RADIATION|Radiolabeled (99mTc) GP (Glycopeptide)|one injection of Technetium Glycopeptide to yield a target activity of 20-25 mCi to be given by slow IV push (over 3-5 minutes) 5 mg, 10 mg \& 20 mg of GP will be injected
214919018|NCT02837731|DEVICE|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness will be performed at every clinical decision point for the first 72 hours of study enrollment. Fluid responsiveness will be assessed using a passive leg raise (PLR) and Starling SV hemodynamic monitor to guide corresponding treatment.
214317191|NCT02979145|OTHER|No intervention involved|
214317192|NCT06304090|BEHAVIORAL|routine rehabilitation treatment|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
214317193|NCT06304090|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214317194|NCT06304090|DRUG|Lidocaine Hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214317195|NCT03917420|DRUG|Tenofovir 300Mg Oral Tablet|Once daily dose of the combo tab x 5 days pre-sampling
214317196|NCT03917420|DRUG|Emtricitabine 200 MG|Once daily dose of the combo tab x 5 days pre-sampling
214317197|NCT03504696|OTHER|Non-interventional|Non-interventional
214317198|NCT00149747|BEHAVIORAL|Moderate-Intensity Aerobic Physical Activity|Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity
214317199|NCT00149747|BEHAVIORAL|Health Education Class|2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
214317200|NCT00217360|BEHAVIORAL|a customised multifactorial falls prevention program|
214317201|NCT05077943|BEHAVIORAL|Breathing and chest mobilization exercises|Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.
214317202|NCT05077943|BEHAVIORAL|Second phase cardiac rehabilitation|Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.
214317203|NCT00500422|DRUG|Doxil|Starting dose of 20 mg/m\^2 IV over 2 hours on Day 1, 21 day cycle
214317204|NCT00500422|DRUG|Gemcitabine|500 mg/m\^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
214317205|NCT00500422|DRUG|Velcade|Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
214317206|NCT01440738|BEHAVIORAL|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
214317207|NCT02508636|DRUG|Enzalutamide|Given orally
214317208|NCT02508636|DRUG|Leuprolide|Given via intramuscular injection
214317209|NCT02508636|RADIATION|Intensity-Modulated Radiation Therapy|A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
214482822|NCT06877325|BEHAVIORAL|PFMT|The training is divided into three phases. The first phase is the foundation phase (Weeks 1-4), which primarily activates the pelvic floor muscles. Strengthening Phase (Weeks 5-8): Builds muscular endurance and control by increasing contraction duration. Consolidation Phase (Weeks 9-12): Enhances overall stability and strength through functional movements.
214317210|NCT01874262|DEVICE|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
214317211|NCT01874262|DEVICE|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
214317212|NCT03423732|DRUG|CardioCell|"Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion."
214317213|NCT03423732|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
214317214|NCT05037838|PROCEDURE|Longitudinal strain obtained thanks to transesophageal ultrasound data recorded during liver transplantation|Longitudinal strain of Left Ventricule and longitudinal strain of Right Ventricule free wall obtained thanks to TransEosophagal Ultrasound performed during the Liver Transplant
214317215|NCT01262014|DRUG|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
214317216|NCT06495918|DRUG|OTX-TKI|Intravitreal Injection of OTX-TKI
214482823|NCT06877325|BEHAVIORAL|QGPFMT|The training is divided into three phases: Foundation Phase (Weeks 1-4): Focuses on breath regulation and activation to promote energy flow and awaken the pelvic floor muscles. Strengthening Phase (Weeks 5-8): Combines core stability training to enhance muscle strength and flexibility. Consolidation Phase (Weeks 9-12): This phase strengthens core control while incorporating standing meditation and breathing exercises to harmonize body and mind, improving overall stability and endurance.
214919019|NCT03573973|OTHER|Improved product placement of fresh fruit and vegetables|The intervention includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the placement (availability and position) of fresh fruit and vegetables.
214317217|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 2mg of aflibercept
214317218|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 8mg of aflibercept
214317219|NCT02595853|OTHER|Non interventional study|All upper gastro-intestinal bleeding need endoscopic hemostasis. Endoscopic hemostasis conventional methods are injection of saline with epinephrine, placement of hemoclips and thermic or plasma coagulation. Hemospray™ will be sprayed onto bleeding lesions seen in endoscopy after failure of conventional methods or in salvage therapy at the discretion of endoscopists. Retrospective analysis of prospectively cellected data.
214317220|NCT02388984|DRUG|Compound danshen dripping pills|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
214317221|NCT02388984|DRUG|Placebo|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
214317222|NCT04734496|OTHER|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
214317223|NCT04231500|DIAGNOSTIC_TEST|Skin swabs|Pre-moistened skin swabs will be collected before the patient starts the conditioning regimens (before conditioning; start of HSCT = day 0, on the day of the transplantation an the repeated in week 4, 12, 24, 36 and 52 after allo-HSCT. The first swab serves as baseline reference (ideally taken at the earliest one week after a systemic antibiotic treatment). Swabs will be taken from the neck, back, right hip, buccal oral cavity and the genital mucosae. In patients who develop acute or chronic skin-GVHD additional swabs will be taken from affected skin at the time of diagnosis and then again according to the schedule of the non-lesioned skin swabs.
214317224|NCT04231500|DIAGNOSTIC_TEST|Skin punch biopsies|During the first visit, a single skin punch biopsy will be taken to state the skin condition and microbiome before allo-HSCT. Further biopsies will only be taken in case of acute or chronic cutaneous GVHD. A 4-6 mm punch biopsy will be taken from the affected skin area and a second one from a nearby unaffected part of the skin. Before the biopsy, skin disinfection will be performed to avoid contamination with surface bacteria.
214317225|NCT04231500|DIAGNOSTIC_TEST|additional blood sampling|an additional tube of blood (2.7ml) and an additional tube of serum (6ml) will be taken and frozen during visits 1, 2, 3 and 7 in the course of blood collection, in order to be able to carry out any later laboratory tests that may prove to be useful depending on the course of the study.
214317226|NCT00575744|PROCEDURE|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
214317227|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
214317228|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
214317229|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
214317230|NCT00281203|PROCEDURE|blood drawing|blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
214482824|NCT06877325|BEHAVIORAL|Qigong|"The training is divided into three phases. The first phase (Weeks 1-4) focuses on breathing regulation and relaxation to enhance blood circulation and promote body recovery. Strengthening Phase (Weeks 5-8): Utilizes Dao Yin techniques to improve flexibility and stimulate energy flow. Consolidation Phase (Weeks 9-12): Emphasizes overall enhancement and core strengthening and incorporates extended deep breathing meditation to harmonize body and mind."
214919020|NCT03573973|OTHER|Sham comparator|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
214919021|NCT04323163|BEHAVIORAL|Physical Activity|3 sessions per week, 60 minutes per session for 6 months
214919022|NCT00375414|PROCEDURE|PEG-Gastropexy|
214919023|NCT01779843|DRUG|Cytarabine|
214919024|NCT01779843|DRUG|Idarubicin|
214919025|NCT01779843|DRUG|Alisertib|
214317231|NCT00281203|PROCEDURE|fiberoptic bronchoscopy|A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
214317232|NCT05518149|DRUG|Aticaprant|Aticaprant 10 mg tablet will be administered orally.
214317233|NCT03758196|DEVICE|Radiofrequency ablation instruments|Renal Sympathetic Denervation from the adventitia of renal artery
214919026|NCT04841395|DIAGNOSTIC_TEST|Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)|Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.
214919027|NCT01352195|BEHAVIORAL|Forever Free Booklets|Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
214919028|NCT05616195|OTHER|3D printed bone prosthesis replacement surgery|To report the postoperative complications and limb function of patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital.
214919029|NCT01119859|DRUG|Tocilizumab|The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
214919030|NCT01119859|DRUG|Adalimumab|
214919031|NCT01119859|DRUG|Placebo to tocilizumab|
214919032|NCT01119859|DRUG|Placebo to adalimumab|
214919033|NCT03053752|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
214919034|NCT04736147|BIOLOGICAL|JNJ-64300535|JNJ-64300535 injection will be administered intramuscularly.
214919035|NCT01881477|PROCEDURE|kinetics modalities|"The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.~The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.~Additionally, it promotes the adoption and sitting positions long and short legged and walk."
214919036|NCT00603473|DRUG|gabapentin|Orally administered gabapentin
214317234|NCT00853554|DRUG|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
214317235|NCT00853554|DRUG|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
214317236|NCT01845792|DRUG|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
214317237|NCT01845792|DRUG|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
214317238|NCT03863613|DEVICE|Pessary|A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix.
214317239|NCT03863613|PROCEDURE|Cervical cerclage|Cervical cerclage using Mc Donald technique, under anaesthesia
214317240|NCT03863613|DRUG|Vaginal progesterone|Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
214317241|NCT00045747|DRUG|7-hydroxystaurosporine|
214317242|NCT00045747|DRUG|fluorouracil|
214317243|NCT01087086|BEHAVIORAL|Crononutrition|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
214317244|NCT01087086|BEHAVIORAL|American Heart Association|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
214317245|NCT04027166|DRUG|Methadone|Methadone will be administered before study procedures
214317246|NCT04027166|DRUG|Methadone|Methadone will be delayed (4 hours) until the end of the procedures
214317247|NCT00850395|DRUG|maraviroc|No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
214317248|NCT06016452|DRUG|Chlorophyllin|Chlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food coloring agent.
214317249|NCT04365868|DRUG|belapectin|intravenous
214317250|NCT04365868|DRUG|Placebo|intravenous
214317251|NCT03676530|DEVICE|Pro-Tec Shin Splint Compression Wrap|EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
214317252|NCT05883137|DEVICE|Optiflow Switch|High flow nasal oxygen with the Optiflow Switch device
214317253|NCT04344873|OTHER|Placebo|Placebo injection at day one and day fourteen.
214317254|NCT04344873|DRUG|Abatacept 10 mg/kg|Abatacept injection at day twenty eight and day forty two.
214317255|NCT00765310|DIETARY_SUPPLEMENT|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
214317256|NCT00765310|DIETARY_SUPPLEMENT|Placebo|two capsules once daily in morning on empty stomach
214317257|NCT06049043|OTHER|Intervention to Help Orient Men to Excel (IN-HOME)|A multi module online training
214317258|NCT06049043|OTHER|"AARP's English Care at Home resource webpage"|Caregiver information from the American Association of Retired Persons
214317259|NCT02992782|BEHAVIORAL|Standard Care|Home program of decongestive exercise and daily use of a compression sleeve
214317260|NCT02992782|BEHAVIORAL|Exercise and Compression Garment|Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
214317261|NCT02992782|BEHAVIORAL|Exercise and Adjustable Compression Wrap|Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
214317262|NCT03217747|DRUG|Avelumab|Given IV
214317263|NCT03217747|BIOLOGICAL|Ivuxolimab|Given IV
214317264|NCT03217747|RADIATION|Radiation Therapy|Undergo radiation therapy
214317265|NCT03217747|BIOLOGICAL|Utomilumab|Given IV
214317266|NCT06475768|DIAGNOSTIC_TEST|Stress Echocardiogram|Exercise testing via treadmill with simultaneous gas exchange analysis and pre- and post-exercise transthoracic echocardiography.
215061212|NCT03839225|OTHER|Community intervention|"Community intervention will be built depending on contextual factors and will contain the following elements:~* Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~* The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~* Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions."
215061213|NCT02830854|OTHER|Molecular Hydrogen|
214317267|NCT06475768|DIAGNOSTIC_TEST|Cardiovascular Magnetic Imaging (cMRI)|Non-invasive imaging scan used to examine function and structure of the heart
214317268|NCT06475768|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Elastography (cMRE)|Non-invasive imaging scan used to measure myocardial stiffness
214317269|NCT06247514|BEHAVIORAL|The BEET Diabetes Program|The BEET Diabetes program is an adapted CBT program specifically designed to treat disordered eating and improve diabetes self-management. Participants receive support from BHPs to guide them through the program, maintain motivation, and facilitate appropriate goal setting.
214317270|NCT06247514|BEHAVIORAL|Cognitive Behavioral Therapy Guided Self-Help|"6-session cognitive behavioral therapy delivered through the self-help book Overcoming Binge Eating Self-help by Christopher G. Fairburn.~The manual focuses on reducing binge-eating episodes. Guided support sessions can be provided by personnel with no background training or knowledge of CBT or disordered eating behaviors, as the book acts as the expert."
214317271|NCT06029699|DEVICE|high flow nasal cannula|device are used for weaning patients after mechanical ventilation extubation
214317272|NCT06029699|DEVICE|non invasive positive pressure ventilation|device are used for weaning patients after mechanical ventilation extubation
214317273|NCT05898295|OTHER|no intervention|No intervention: only observation of the child behavior
214317274|NCT00233051|DRUG|Salmeterol or Salmeterol/Fluticasone|
214317275|NCT02859649|BEHAVIORAL|neuropsychological test|neuropsychological test
214317276|NCT04685564|DRUG|RBD1016|"Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission."
214317277|NCT04685564|DRUG|Placebo|the same as RBD1016
214317278|NCT02574871|OTHER|Psychological and biological data collection|Psychological and biological data collection for identification of the chronic stress presence
214317279|NCT05923892|DRUG|OPS-2071|There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
214317280|NCT05923892|DRUG|placebo|Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
214317281|NCT05257538|OTHER|FMT|Fecal microbiota transfer from a healthy and tested volunteer
214317282|NCT05257538|OTHER|placebo enema|colored water enema
214317283|NCT05239273|OTHER|Complex Decongestive Therapy|Phase 1 of CDT will be applied. This application consists of manual lymph drainage, skin care, compression bandage and exercises.
214317284|NCT05239273|OTHER|Control|No intervention
215061214|NCT04242576|DEVICE|Right Left Judgement|It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.
215061215|NCT04242576|OTHER|Action Observation|Videos of cervical movements.
215061216|NCT04242576|BEHAVIORAL|Exercise|Evidence based exercises for the neck.
215061217|NCT01308645|DRUG|SB injection|Infusion SB injection of 21.87 ml/m\^2, IV route, 24 times for 4 months
215061218|NCT03577340|OTHER|implant of cardiac device as per guidelines|Observation of performance to validate matrix
215061219|NCT04970823|DEVICE|The somatosensory interactive game for preschool children|The somatosensory interactive game, an independent nursing intervention, promotes pain relief for preschool children.
215061220|NCT04970823|DEVICE|A VR (virtual reality) game for school-age children|A VR (virtual reality) game environment promotes pain relief for school-age children.
215061221|NCT03570242|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
215061222|NCT02807389|DRUG|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
215061223|NCT03638050|OTHER|Functional Capacity Assessment|Individuals will be assessed on the third day after acute myocardial infarction. The six-minute walk test will be performed according to the norms of the American Thoracic Society.
215061224|NCT05290506|DRUG|Dipeptidyl-Peptidase IV Inhibitors|All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
215061225|NCT04384705|OTHER|research specific blood sample|"* one blood sample before the epidemic phase~* one blood sample during epidemic phase~* one blood sample after epidemic phase"
215061226|NCT03226249|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
215061227|NCT03226249|DRUG|Dacarbazine|Given IV
215061228|NCT03226249|DRUG|Doxorubicin Hydrochloride|Given IV
215061229|NCT03226249|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
215061230|NCT03226249|OTHER|Laboratory Biomarker Analysis|Correlative studies
215061231|NCT03226249|BIOLOGICAL|Pembrolizumab|Given IV
215061232|NCT03226249|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
215061233|NCT03226249|DRUG|Vinblastine Sulfate|Given IV
214317285|NCT00262509|DEVICE|Egress Badge|Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
214317286|NCT05907850|DRUG|Riboflavin|Commercially available source of riboflavin capsules
214317287|NCT05907850|DRUG|Placebo|Placebo capsule compounded to be similar in appearance to the active intervention
214317288|NCT01425879|DRUG|Akt Inhibitor MK2206|Given PO
214317289|NCT01425879|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214317290|NCT01425879|OTHER|Pharmacological Study|Correlative studies
214317291|NCT04090554|DEVICE|Cytosponge™|The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
214317292|NCT01820455|DRUG|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
214317293|NCT01820455|DRUG|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
214317294|NCT02361255|OTHER|no intervention|
214317295|NCT04352751|OTHER|convalescent plasma|"* Plasmapheresis, 900 - 1000 mL each time.~* Standard apheresis plasma collection protocol using Haemonetics MCS+ intermittent blood flow system or Terumo Optia, Cobe-Spectra, Trima or Fresenius continuous flow system to be used.~* Isovolumic saline replacement should be done.~* Each donor can donate convalescent plasma again after an interval of every 2 weeks"
214671664|NCT01176396|OTHER|Caries prevention active intervention|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.~High Caries Risk The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office."
214317296|NCT02679859|OTHER|BNP guided medical therapy optimisation|
214317297|NCT05450471|DRUG|Corticosteroid Topical|The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
214317298|NCT05450471|OTHER|Placebo|Placebo
214482825|NCT06875999|BEHAVIORAL|animal assisted therapy|The Children's Emotional Indicator Scale (Facial expression, Vocalization, Activity, Interaction and Cooperation Level) will be used to provide a simple, objective and consistent method to determine children's emotional behavior during stressful medical procedures. The FLACC scale will be used for pain. In addition, all physiological parameters including pulse rate, saturation value and respiration will be measured and recorded with a pulse oximeter device. Animal assisted therapy will be applied to the participants in the study group to reduce the stress of the children. In animal-assisted therapy, the child will be shown a fish in a glass bowl and a red fish song will accompany the process. In the study, participant children will be randomly assigned to intervention and control groups.
214482826|NCT06878599|COMBINATION_PRODUCT|Hyaluronic Acid (HA)|Adding Hyaluronic acid to dexamethasone as intratympanic injection
214482827|NCT06878599|DRUG|Dexamethasone|Intratympanic injection of Dexamethasone
215061234|NCT03018197|OTHER|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
215061235|NCT03540706|DIAGNOSTIC_TEST|Care with C-reactive protein assay in micro method|Care with C-reactive protein assay in micro method
214317299|NCT04291339|PROCEDURE|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
214317300|NCT04291339|PROCEDURE|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
214317301|NCT03480334|OTHER|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
214317302|NCT06300164|DIETARY_SUPPLEMENT|Unripre Carob|The standard cookies and test cookies (with carob addition) to be used in the study will be produced by Dr. Lecturer Özlem ÖZPAK AKKUŞ at Toros University Nutrition Principles Laboratory. Prof. Dr. Özlem ÖZPAK AKKUŞ will produce the cookies. For standard cookies, 1 egg, 325 g gluten-free flour (Söke flour), 75 grams butter, 50 grams sugar, 10 grams baking powder, 10 grams vanilla will be added and the prepared bread mixture will be divided into 50 equal parts. To make cookies with the addition of unripe carob, the same recipe as the standard cookie will be used to make the test cookie with the addition of unripe carob fruit flour, divided into 50 equal parts, and the amount of unripe carob fruit flour will be added by calculating the daily fiber consumption amount of the patients participating in the study to be 25 g.
214317303|NCT06390228|PROCEDURE|Major hepatectomy|the extent of liver resection
214482828|NCT06877143|DIETARY_SUPPLEMENT|100% of individual calory requirement|Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.
214482829|NCT06877143|DIETARY_SUPPLEMENT|120% of individual calory requirement|Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.
214317304|NCT02739269|OTHER|Serum AMH measurement|Serum AMH is measured one month before the IVF treatment
214317305|NCT02739269|OTHER|AFC measurement|Early follicular phase AFC is measured one month before the IVF treatment
214317306|NCT04360564|OTHER|Recurrent pregnancy loss|As described before.
214317307|NCT05049148|OTHER|Platelet count in excised tumors|Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
214317308|NCT01354496|DRUG|LY2409021 Reference Form|Administered orally
214317309|NCT01354496|DRUG|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
214317310|NCT01354496|DRUG|LY2409021 Test-High Formulation (high particle size)|Administered orally
214317311|NCT01354496|DRUG|LY2409021 Test-Low Formulation (low particle size)|Administered orally
214317312|NCT06446947|OTHER|blood sampling|Blood sampling (6ml) on admission and a second on discharge from intensive care.
214317313|NCT03327610|OTHER|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
214317314|NCT03327610|OTHER|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
214317315|NCT03327610|OTHER|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
214317316|NCT03327610|OTHER|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
214317317|NCT03327610|OTHER|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
214317318|NCT03327610|OTHER|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
214317319|NCT04766242|OTHER|Spiritual healing|"The spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient's body, known as power points, outside the patients clothing. The consultation might also include possible life-style advice. The treatments will last for 45-60 minutes each time."
214317320|NCT04766242|OTHER|Usual care|The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.
214317321|NCT01100411|DEVICE|Air Optix Aqua|Contact lens material: Lotrafilcon A
214317322|NCT01100411|DEVICE|Biofinity|Contact lens material: Comfilcon A
214317323|NCT01100411|DEVICE|Proclear|Contact lens material: Omafilcon A
214317324|NCT01100411|DEVICE|Acuvue Oasys|Contact lens material: Senofilcon A
214317325|NCT01100411|DEVICE|Acuvue 2|Contact lens material: Etafilcon A
214317326|NCT01100411|DEVICE|Purevision|Contact lens material: Balafilcon A
214317327|NCT01391481|DRUG|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
214317328|NCT01391481|DRUG|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
214317329|NCT00228345|PROCEDURE|Optical coherence tomography,Fluorescein angiography|
214317330|NCT04307212|OTHER|50% heart rate reserve (HRR) low intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)
214317331|NCT04307212|OTHER|75% HRR moderate intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
214482830|NCT06880315|BEHAVIORAL|Pre-Generated Personalized LLM Coaching Impact|After the initial 7 days, participants will switch to the other type of prompting for another 7 days. This means that participants who initially received personalized LLM-generated prompts will then receive generic activity prompts, and vice versa. This crossover design allows for each participant to experience both types of interventions, providing a within-subject comparison of the effectiveness of personalized versus generic prompts in increasing physical activity levels.
214482831|NCT06880237|OTHER|Singing|"The programme consists of nin 75-min-long singing sessions spread across 8 weeks (8 sessions are practice sessions and 1 session is a full dress rehearsal), and a final performance. The final rehearsal session and showcase performance will be held at a concert venue, while the 8 practice sessions will be conducted at the nursing home.~Each session will kick off with a Hello song, followed by warm-up activities and vocal exercises. Participants will then sing different songs to explore and rehearse as a group, before concluding with a Goodbye song. All sessions throughout the programme are similarly structured to provide consistency for participants."
214482832|NCT06876571|DIAGNOSTIC_TEST|IdentiClone Dx TRG Assay|"The IdentiClone Dx TRG Assay (Assay) is an in vitro diagnostic product intended for qualitative capillary electrophoresis based-detection of clonality in T-cell receptor gamma chain (TRG) gene rearrangements in Formalin-Fixed Paraffin-Embedded (FFPE) specimens as an adjunctive method for the diagnosis of T-cell lymphoproliferative disease. This qualitative, non-automated Assay is for use on the ABI 3500xL Dx and ABI 3500xL Genetic Analyzers."
214482833|NCT06876805|DIAGNOSTIC_TEST|CEUS or Contrast enhanced Ultrasound|CEUS performed as normal clinical practice
214955204|NCT00217581|BIOLOGICAL|Bevacizumab|Must be administered 1st before Docetaxel \& Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
214317332|NCT04307212|OTHER|Control no exercise|Trained and untrained participants will have a no exercise control day
214317333|NCT02306135|OTHER|n/a- this is an observational study|
214317334|NCT03554291|DRUG|Famotidine 20 MG|Famotidine 20 mg capsule taken daily for 24 weeks.
214317335|NCT03554291|OTHER|Placebo|Placebo capsule taken daily for 24 weeks.
214317336|NCT03518385|DIAGNOSTIC_TEST|ultrasound,transvaginal scan|The presence of fluid in the uterine cavity during hormonal stimulation.
214317337|NCT00947479|OTHER|continuous positive airway pressure (CPAP)|After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
214317338|NCT01228747|DRUG|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
214317339|NCT01228747|DRUG|Placebo|Matching oral placebo tablets twice daily for 28 weeks
214482834|NCT06877871|OTHER|WBV utilizes mechanical vibrations to excite muscle, nerves. Abdominal binders are to help patients who have suffered abdominal trauma to stabilize core muscles, reduce pain, and improve mobility|(WBV) is a therapeutic modality that utilizes mechanical vibrations to excite muscle, nerve and tissue structures in the body. WBV was developed initially for fitness and physical rehabilitation and has been moving into other areas of healthcare such as pain management and neurological recovery and improving circulation.However, this activation can help to elevate intestinal motility, reduce bloating and help overall digestion.
214482835|NCT06877754|BEHAVIORAL|Self-Acupressure|Both groups received general health education videos. The experimental group performed SP6 acupressure starting one week before menstruation, 10 minutes per session, twice daily, until the fifth day of menstruation. The control group maintained their usual routines.
214482836|NCT06874907|PROCEDURE|Glucose monitoring|Glucose monitoring
214482837|NCT06684275|PROCEDURE|Pulsed Radiofrequency (PRF)|Participants will receive pulsed radiofrequency (PRF) treatment targeting the trigeminal nerve to manage pain associated with trigeminal neuralgia. This non-ablative technique uses electrical pulses to modulate nerve function, aiming to provide pain relief without creating a thermal lesion.
214482838|NCT06684275|PROCEDURE|Pulsed and Thermal Radiofrequency (PRF + TRF)|Participants will receive a combination of pulsed radiofrequency (PRF) and thermal radiofrequency (TRF) treatments targeting the trigeminal nerve. This approach combines the non-ablative effects of PRF with the thermal lesioning of TRF to provide long-term pain relief for trigeminal neuralgia.
214482839|NCT03527537|DRUG|Insulin|Insulin may be administered base on glucose log values. The dosing of the insulin will be determined by the provider using typical management of gestational diabetes.
214482840|NCT06526663|BEHAVIORAL|vignette exposure|"Participants will be randomized to be exposed to one of 16 written vignettes that vary four elements of the primary care experience. The four attributes can take two levels.~In the second round, individuals will be randomized to only 4 different vignettes."
214482841|NCT06706440|OTHER|no intervention, observational study|Only data will be taken of patient's file.
214482842|NCT04135300|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
214482843|NCT06707610|DRUG|ALK202|Administered intravenously, once every 3 weeks
214482844|NCT06712329|OTHER|extracorporeal shock wave therapy|ESWT (Inceler Medical, Modus Focused ESWT, Turkey) was conducted by a single investigator in accordance with a standardised protocol. The patients were positioned prone on the examination table, with the affected limb placed in a supported position. The focused shockwave was applied in a circular motion along the insertion site of the plantar fascia and over the plantar fascia itself. The participants received 1,800 to 2,000 focused shock waves (0.15-0.25 mJ/mm² session with a frequency of 3-4 Hz). The frequency of the pulses was increased in a gradual manner, in accordance with the maximum tolerable degree of pain for each patient. A minimum dose of 1,000 mJ/mm² was administered. The ESWT was conducted in three sessions, with a two-week interval between each session.
214482845|NCT06712329|OTHER|Prolotherapy|The solution employed for dextrose prolotherapy comprised 1.5 ml of 30% dextrose and 1.5 ml of 0.9% isotonic sodium chloride solution, resulting in a total of 3 ml of 15% dextrose solution. . All procedures were conducted by the same investigator. A dextrose solution was infused into the centre and around the damaged area using a peppering technique. Following the procedure, patients were advised to remain in a supine position with their feet restrained for a period of 15 minutes.. Prolotherapy was repeated on three occasions, with each session occurring at a two-week interval
214482846|NCT06707987|DRUG|Non-immunogenic staphylokinase|Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®
214482847|NCT06712121|DRUG|decitabine plus venetoclax|decitabine 20mg/m2 for 7 days venetoclax 400mg daily for 21 days
214955205|NCT00217581|DRUG|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
214955206|NCT00217581|DRUG|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
214317340|NCT05567289|PROCEDURE|Blood sample collection|"Enrolled patients will undergo sequential blood collection beginning prior to conditioning, then on the day of transplant (day 0), followed by days 7, 14, 21, 28, 56 (2 months) and 90 (3 months) post-transplant.~Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.~The study will also collect an additional blood sample at the onset of treatment for aGvHD for those who receive systemic corticosteroids (PO or IV steroid equivalent to ≥0.5mg/kg prednisolone)."
214317341|NCT05567289|PROCEDURE|Bone marrow aspirate|Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.
214317342|NCT02036502|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
214317343|NCT02036502|DRUG|Lenalidomide|Oral capsule
214317344|NCT02036502|DRUG|Dexamethasone|Oral tablet IV infusion
214317345|NCT02036502|DRUG|Carfilzomib|IV infusion
214317346|NCT06056050|BIOLOGICAL|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)|1 dose of Tdcp vaccine (0.5ml) on Day 0
214317347|NCT06056050|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）|1 dose of PPV23 vaccine (0.5ml) on Day 0
214317348|NCT06056050|BIOLOGICAL|Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)|1 dose of DT vaccine (0.5ml) on Day 0
214317349|NCT00546611|DRUG|PEP005|
214317350|NCT04416087|OTHER|Exercise|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
214317351|NCT06496009|DRUG|PD-1 Inhibitors|advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice
214482848|NCT06712888|DRUG|TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy|"Drug: Toripalimab 240mg will be given every 3 weeks for 3 cycles, started on day 1 of induction chemotherapy.~Other Names:~JS001 PD-1 antibody~Drug: Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation~Other Names:~DDP~Radiation: intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 70 Gy will be given in 33 fractions.~Other Names:~IMRT"
214482849|NCT06712888|DRUG|GP plus placebo induction therapy|"Drug: Placebo 240mg will be given every 3 weeks for 3 cycles, started on day 1 of induction chemotherapy.~Drug: Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation~Other Names:~DDP Radiation: intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 70 Gy will be given in 33 fractions.~Other Names:~IMRT"
214482850|NCT06713707|OTHER|Manuel dexterity|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using 9-HPT, and JTHFT.
214482851|NCT06713707|OTHER|Manual Dexterity (only MMDT)|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT on a predetermined day.
214482852|NCT06713577|DEVICE|CEREC Cercon 4D|"One investigational medical device is a new generation of a full contour zirconia restorative material (CEREC Cercon 4D/Dentsply Sirona) for chairside computer assisted design/computer assisted machines (CAD/CAM) restorations. It has an internal core of 4 mol% (4Y) zirconia transitioning to an external layer of 4/5 mol% (4/5 Y) zirconia with a three-dimensional gradient of shade from an inner chromatic layer to an external translucent layer that replicates the natural structure and appearance of a tooth. It is indicated for crowns, bridges, veneers, inlays and onlays and implant crowns Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations The other investigational medical devices are a universal bonding agent (Prime and Bond Active/Dentsply Sirona) and dual-cure, self-adhesive resin cement (Calibra Universal~+/Dentsply Sirona). They are used in combination to deliver ceramic and zirconia restorations."
214482853|NCT05379855|DRUG|0.01% atropine eye drops|using 0.01% atropine eye drops for both eyes every night
214482854|NCT05379855|DRUG|placebo eye drops (0.1% sodium hyaluronate ophthalmic solution)|using placebo eye drops (0.1% sodium hyaluronate ophthalmic solution) for both eyes every night
214482855|NCT05379855|DRUG|0.05% atropine eye drops|using 0.05% atropine eye drops for both eyes every night
214482856|NCT05129501|BEHAVIORAL|Experimental|The Tiwahe Wicagwicayapi seven-session program is for children ages 10 to 14 who are Native American and/or living in poverty and their caregivers. The program begins with a traditional Lakota meal followed by family time and break-out time for caregivers only and children only. The program includes skill-building activities as well as the integration of Lakota language, history, and culture. The program is facilitated by diverse individuals, predominantly Native Americans in Rapid City and surrounding tribal communities.
214955207|NCT04399889|BIOLOGICAL|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University or University of Miami.
214317352|NCT03254186|DRUG|Propranolol Hydrochloride|Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
214317353|NCT03254186|DRUG|Placebo Oral Tablet|Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
214317354|NCT01068509|BIOLOGICAL|Cvac|Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.
214317355|NCT05465382|DEVICE|Saline Lavage|Three rounds of 10cc of sterile 0.9% normal saline will be injected into the injured ankle joint and withdrawn from the joint using an anteromedial 16-gauge needle attached to a 10cc syringe.
214317356|NCT05465382|OTHER|No intra-articular saline lavage|Subjects in group 2 will not undergo normal saline lavage.
214317357|NCT05465382|DRUG|Lidocaine - intra-articular injection|Intra-articular injection of 10cc of 1% lidocaine without epinephrine via the existing anteromedial 16-gauge needle.
214955208|NCT04399889|OTHER|Placebo|Placebo will be comprised of 40-80 mL of Plasmalyte-A + 1% Human Serum Albumin (HAS) prepared in an identical container to the one used for cell administration. The placebo product will undergo the same process of sterility testing including release inspection, transport and product custodian.
214955209|NCT04412798|OTHER|orange juice concentrate|250mL of 100% orange juice made from concentrate
214955210|NCT04412798|OTHER|Sugar-sweetened orange-flavoured beverage|Sugar-sweetened orange-flavoured beverage, energy-matched to the orange juice condition
214955211|NCT04412798|OTHER|Whole orange juice with skin removed|Whole orange pieces with skin removed, energy-matched to the orange juice condition
214955212|NCT04407143|DIAGNOSTIC_TEST|IgG test|IgG+ blood test by ELISA method.
214955213|NCT06373055|OTHER|neoadjuvant chemotherapy followed by radical cystectomy|combination of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) or combination of gemcitabine and cisplatin (GC) followed by radical cystectomy
214955214|NCT01357395|DRUG|Amuvatinib|Amuvatinib 300 mg PO TID
214317358|NCT05465382|OTHER|Synovial Fluid Aspiration|Aspiration of ankle joint via standard anteromedial approach. Performed using sterile technique using 16-guage needle attached to 10cc syringe.
214317359|NCT02442778|DRUG|AVP-786-18|18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)
214317360|NCT02442778|DRUG|Placebo|Administered as capsules.
214317361|NCT02442778|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
214317362|NCT02442778|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
214482857|NCT04166513|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the targeted region.
214482858|NCT04166513|DEVICE|Active Control Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the active control region.
214482859|NCT04166513|BEHAVIORAL|Phonologic-Focused Speech Therapy|Participants are asked to generate or choose from a list phonologic information about a target picture.
214317363|NCT02482025|OTHER|SMMRT|Includes My HealtheVet registration and enrollment
214317364|NCT05518968|BEHAVIORAL|Acceptance and commitment therapy|8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
214317365|NCT02213211|DRUG|Artemether lumefantrine|
214317366|NCT05046041|DRUG|Mifepristone + Misoprostol|A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.
214482860|NCT04166513|BEHAVIORAL|Semantic-Focused Speech Therapy|Participants who have difficulty retrieving an object name are given hierarchical clues or asked questions about the objects function as a way of activating the semantic network for that object, leading to eventual retrieval of the target word.
214482861|NCT01543659|DRUG|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11-100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
214482862|NCT04429347|DRUG|Gabapentin|Friday night: 1 capsule of 300 mg, Saturday night: 2 capsule of 300 mg (total 600 mg), Sunday night: choice of 1 or 2 capsule of 300 mg (total of 300 or 600 mg)
214482863|NCT04429347|DRUG|Placebo|Friday night: 1 capsule, Saturday night: 2 capsule, Sunday night: choice of 1 or 2 capsules
214482864|NCT04429347|DRUG|Tizanidine|Friday night: 1 capsule of 2 mg, Saturday night: 2 capsule of 2 mg (total 4 mg), Sunday night: choice of 1 or 2 capsules of 2 mg (total of 2 or 4 mg)
214482865|NCT06881576|OTHER|Compare VCI scale|Compare VCI scale
214482866|NCT06877936|PROCEDURE|EOS exam|The EOS procedure will consist of taking 3 x-rays per side (6 in total) while the patient is standing (oriented at 35° to the x-ray) with the arm in position 0°, then at 45° and finally at 90° elevation in the frontal plane for 20 seconds per position.
214482867|NCT06877936|OTHER|Questionnaires Constant et ASES|There will be 2 questionnaires : Constant and American Shoulder and Elbow Surgeons to determine their pain level and functional limitations.
214482868|NCT06879613|DIETARY_SUPPLEMENT|Breastmilk|Breastmilk from the mother of the infant was given for pain
214482869|NCT06879613|PROCEDURE|Massage|The spot that was vaccinated was massaged by the mother/carer of the infant
214482870|NCT06881082|PROCEDURE|endoscopic band ligation with cross-section technique|Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the cross-section banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment.
214482871|NCT06881082|PROCEDURE|Endoscopic band ligation using stepladder technique|Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the stepladder banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment
214482872|NCT06882694|BEHAVIORAL|Pelvic Floor Imagery Questionairre|This intervention consists of a questionairre
214482873|NCT06879262|BIOLOGICAL|CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）|Administer a single infusion of CAR1922T2 T cells to this group of patients following fludarabine plus cyclophosphamide (F+C) lymphodepletion
214482874|NCT06880029|OTHER|Morning pembrolizumab infusions|Patients will be randomized 1:1 to receive all three neoadjuvant pembrolizumab cycles in the morning (before noon) or in the afternoon (after noon).
214482875|NCT06882499|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy
214482876|NCT06882499|OTHER|Physician's choice of systemic treatment|Physician's choice of systemic therapy does not mandate a change in systemic therapy, however, SABR is not permitted for management in this arm
214482877|NCT06882070|OTHER|Vaccine|Trivalent P2-VP8 subunit rotavirus vaccine
214955215|NCT01537835|OTHER|Antimicrobial Scrubs|Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
214955216|NCT01343537|OTHER|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
214955217|NCT05055154|DEVICE|Very low calorie diet|In hospital patients will eat prepared diet with 567 kcal a day during 3 weeks
214955218|NCT01345214|DRUG|ONO-7746|10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
214919037|NCT04121559|BEHAVIORAL|School Interventions|"1. Classroom lessons on nutrition, dietary diversity, healthy food choices and handwashing.~2. Principals provide messages on nutrition, dietary diversity, healthy food choices and handwashing at flag events or school assemblies.~3. Selected adolescent girls are mentored by science teachers as peer mentors and hold weekly group discussions with other girls to discuss nutrition, dietary diversity, healthy food choices and handwashing.~4. Trained science teachers take anthropometric measurements of adolescent girls to calculate BMI and provide nutrition counseling.~5. Parent-teacher meetings to inform and encourage parents about adolescent nutrition, dietary diversity, healthy snacks, and handwashing."
214317367|NCT04246606|DIAGNOSTIC_TEST|IHC4 score|"The IHC4 score is a prognostic tool that incorporates immunohistochemical parameters of ER (H-score), PR (% of positive cells), HER2 (positive or negative status), and Ki67 (% of positive cells).~IHC4 score, combined with nodal status and tumor grade, age, and the type of endocrine therapy (tamoxifen or aromatase inhibitors) provides a clinical score IHC4+C.~IHC4+C provides a prognostic risk of distant recurrence at 10 years for patients who underwent endocrine therapy for 5 years. IHC4+C defined three distinct risk categories:~* \<10%: low risk~* \[10-20%\]: intermediate risk~* \>20%: high risk"
214317368|NCT03532620|DRUG|Pitavastatin Calcium|"In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
214317369|NCT03532620|DRUG|Atorvastatin Calcium|"In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
214317370|NCT04109664|PROCEDURE|laparoscopic sleeve gastrectomy|The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.
214317371|NCT03920631|DRUG|Nivolumab|Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule
214317372|NCT03920631|BIOLOGICAL|Microtransplantation|HLA-mismatched peripheral blood stem cells
214317373|NCT02692677|DRUG|JNJ-42756493|Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.
214317374|NCT01485211|DRUG|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
214317375|NCT05832957|BEHAVIORAL|Drive fun|"The Drive Fun intervention program aims to promote the development of adaptive self-awareness and facilitate the acquisition of management strategies that foster safe and confident driving among participants. The program utilizes a driving simulator to provide a guided learning experience, which incorporates various sources of information, as well as games and thinking tasks. Additionally, participants will engage in reflective exercises that draw upon their occupational experiences and their driving performance within the simulator. Parental involvement is also incorporated to ensure ongoing support for the continued practice of learned skills."
214482878|NCT06882538|OTHER|awareness-based psychoeducation|The aim of psychoeducation is to create a change in knowledge and behaviour towards healthy lifestyle behaviours (1- Self-actualisation, 2- Health responsibility, 3- Exercise, 4- Nutrition, 5- Interpersonal support, 6- Stress management) by reducing internalised stigma. Therefore, it will be evaluated whether the applied psychoeducation programme creates the intended change in knowledge and behaviour.
214482879|NCT06881303|OTHER|preoperative stoma identification and education|The guide to good stoma therapy practice recommends that the site of the future stoma should be marked out preoperatively, in the lying, sitting and standing positions, so that the patient can see the stoma. What's more, the psychological impact of the stoma is such that preoperative and regular postoperative education is essential. This identification and initiation of education is carried out by stoma nurses and/or surgeons.
214482880|NCT06881355|DIAGNOSTIC_TEST|Bruxism diagnosis|The presence of bruxism was determined based on the participant's self-reported statements and intraoral findings.
214482881|NCT06881355|DIAGNOSTIC_TEST|Clinical evaluation|The PCRs on the relevant teeth were evaluated according to the revised FDI criteria
214482882|NCT06881108|OTHER|CHAT Core Functions|CHAT is a virtually delivered patient-level intervention designed to improve health insurance and cost-related literacy
214482883|NCT06881108|OTHER|LIFT Core Functions|LIFT (Lessening the Impact of Financial Toxicity), an intervention developed to coordinate access to existing financial assistance programs.
214482884|NCT06881108|OTHER|Member-Checking Process|Based on the findings from Steps 1 and 2, investigators will develop a document that outlines the points of overlap, harmony, or conflict identified by participants.
214671665|NCT01176396|OTHER|control treatment|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk Control group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).~High Caries Risk The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding)."
214919038|NCT04121559|BEHAVIORAL|Community Interventions|"1. Home visits by HEWs and/or community volunteers to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing.~2. Community gatherings by HEWs and meetings with religious leaders to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing."
214317376|NCT05832957|BEHAVIORAL|educational intervention|7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
214317377|NCT05832957|OTHER|No intervention|one-time short guidance on safe driving at the end of the study.
214317378|NCT01770288|OTHER|Anaerobic wingate test|
214317379|NCT03467087|DEVICE|Myopuls 2000D|Device: Myopuls 2000D (Curatec Services GmBH, 47443 Moers, Germany)
214317380|NCT05233566|DRUG|Ketamine|NMDA antagonist
214317381|NCT05233566|DRUG|Normal saline|IV fluid acting as a placebo
214317382|NCT04974970|DRUG|Peanut Immunotherapy|Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
214317383|NCT00764270|DIETARY_SUPPLEMENT|R-alpha lipoic acid|300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
214317384|NCT05712408|BEHAVIORAL|800g Challenge|The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
214317385|NCT04210752|DRUG|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
214317386|NCT04210752|DRUG|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
214317387|NCT04210752|DRUG|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
214317388|NCT04210752|DRUG|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
214317389|NCT04210752|DRUG|Treatment 5|"Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection"
214671666|NCT03726671|OTHER|25% Cho diet|Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
214671667|NCT03726671|OTHER|50% Cho diet|Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
214919039|NCT04121559|BEHAVIORAL|School System Interventions|"1. Workshop on the adolescent nutrition interventions for school principals, science teachers, HEWs, supervisors, and woreda officers.~2. Biweekly supportive supervision on adolescent nutrition activities for schools and HEWs by school supervisors or woreda health/education office."
214919040|NCT00852059|DRUG|Immediate release methylphenidate (Medikinet®)|Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
214317390|NCT02603835|DEVICE|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
214317391|NCT00456716|DRUG|sorafenib|400mg po bid
214317392|NCT02572466|OTHER|Hemodialysis|ESRD group received long-term hemodialysis
214317393|NCT06108505|OTHER|Lacticaseibacillus with oats|Subjects will receive 7.5 gr of oats containing Lacticaseibacillus
214317394|NCT06108505|OTHER|Plain oats|Subjects will receive 7.5 gr of plain oats
214317395|NCT03080259|BEHAVIORAL|Stimulant Diversion Prevention (SDP)|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
214317396|NCT03864874|DIAGNOSTIC_TEST|Intraoperative intracavitary lung ultrasonography|Ultrasonography on the deflated lung for detection of lung nodules
214317397|NCT00022321|DRUG|gemtuzumab ozogamicin|
214317398|NCT05817019|DRUG|Sugammadex Sodium|Sugammadex Sodium 2mg/kg when TOF \>= 2, postoperative period
214317399|NCT05817019|DRUG|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg when TOF \>= 2, postoperative period
214317400|NCT03098342|PROCEDURE|Methylene blue-mediated photodynamic therapy|Using the 2% MB aqueous solution as a photosensitiser. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
214482885|NCT06882707|OTHER|Median Nerve Mobilization|"Passive neuromobilisation of the median nerve and functional self-exercises. The procedure started with the patient in the supine position. The following steps were taken in sequence: shoulder girdle depression; slight abduction of the elbow extension with arm lateral rotation and forearm supination; wrist, finger and thumb extensions were added; and the shoulder was taken into further extension.~To apply maximum stretch opposite cervical side flexion was done, and, in the end, the wrist was repeatedly moved into and out of stretch by performing a few degrees of flexion and extension at the wrist.~This mobilization technique will be performed by an experienced physician/physiotherapist three times a week for 3 weeks, and the patients will be given 3 sets of 15 cycles with a 1-minute rest period in each set."
214482886|NCT06882707|OTHER|Ultrasound therapy|In control group, patients will received only ultrasound therapy. The patient will be in a sitting position with his/her face facing the physiotherapy technician, elbow in 90 degree flexion, forearm in supination, wrist in neutral position and supported by placing a towel under the patient's extremity and will be applied in Us intermittent mode with an intensity of 0.8 W/cm2 in 1 MHZ frequency in 1:4 mode for 10 minutes, moving in a way to draw an infinity sign for 10 seconds. Treatment will be given 5 days a week for 3 weeks and a total of 15 sessions.
214317401|NCT03098342|DRUG|Amorolfine 5% Nail Lacquer|Patients will be detailed instruction regarding the use of 5% Amorofine Nail Lacquer (Loceryl®) as its recommended protocol.
214317402|NCT04248595|DRUG|Homoharringtonine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
214317403|NCT04248595|DRUG|Azacitidine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
214317404|NCT00062465|DRUG|TwHF|
214317405|NCT03073590|COMBINATION_PRODUCT|Intervention factory with hot lunch|A nutritionally enhanced lunch meal program (increased dietary diversity plus inclusion of multi-nutrient fortified rice), provision of once weekly iron/folate supplement to female workers, and a BCC program conducted in the factory setting focused on improving health and nutrition for women and children, with a focus on anemia prevention.The BCC program will be enhanced to include modules on nutrition (balanced diets/dietary diversity, iron/folate rich foods), infant and young child nutrition (IYCN), and an overview module on anemia prevention, hand-washing with soap and dietary diversity at the very beginning of the intervention.
214317406|NCT03073590|COMBINATION_PRODUCT|Intervention factory without lunch program|In a selected garment factory that does not have a lunch program, the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.
214317407|NCT03073590|COMBINATION_PRODUCT|Control factory with lunch program|One control factory who provides regular lunch meal and a nutrition and health behavior change communications (BCC) program.
214317408|NCT03073590|BEHAVIORAL|Control factory without lunch program|One control factory was selected where only the standard Behavior change communication (BCC) was implemented.
214317409|NCT02472938|DRUG|dimethyl fumarate|dimethyl fumarate 120 mg capsules
214317410|NCT02472938|OTHER|Placebo|Placebo for BG00012
214482887|NCT06881771|DIAGNOSTIC_TEST|Clinical phenotyping|"* Visual acuity assessment~* Contrast sensitivity evaluation~* Slit-lamp photography~* Specular microscopy~* Scheimpflug tomography~* Anterior segment optical coherence tomography~* In vivo confocal microscopy~* Spatio-temporal optical coherence tomography"
214482888|NCT06881771|GENETIC|CTG18.1 Expansion Status Genotyping|"Genotyping for trinucleotide repeat in the TCF4 gene (CTG18.1) and other genetic biomarkers using blood or saliva derived genomic DNA. This includes:~* Short tandem repeat - PCR~* Triplet-repeat primed - PCR~* Genome-wide single nucleotide polymorphism genotyping~* Ultra-deep locus-specific next-generation sequencing"
214482889|NCT06691386|OTHER|Test Product A|Use of Test Product A in controlled use and ad libitum use sessions
214482890|NCT06691386|OTHER|Test Product B|Use of Test Product B in controlled use and ad libitum use sessions
214919041|NCT00852059|DRUG|Extended release methylphenidate (Medikinet retard®)|Treatment: methylphenidate applied with breakfast(once daily), extended release
214919042|NCT04530188|DRUG|Sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
214919043|NCT04530188|DRUG|Propofol|Intravenous sedation with propofol, as already used in our ICU
214317411|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
214317412|NCT00615056|DRUG|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
214317413|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
214482891|NCT06691386|OTHER|Test Product C|Use of Test Product C in controlled use and ad libitum use sessions
214482892|NCT06691386|OTHER|Test Product D|Use of Test Product D in controlled use and ad libitum use sessions
214482893|NCT06691386|OTHER|Test Product E|Use of Test Product E in controlled use and ad libitum use sessions
214919044|NCT04745533|DIAGNOSTIC_TEST|Antigen detection test|To compare the results of the antigen detection test against the polymerase chain reaction in the study of contacts of COVID-19 patients during quarantine.
214919045|NCT05899777|OTHER|Yizhi Baduanjin|Yizhi Baduanjin is a newly compiled routine developed on the foundation of the traditional Baduanjin, aiming at the mental and cerebral health of middle-aged and elderly population, which combining the preliminary research result and principles of the traditional routine. It could be practiced in long term to prevent MCI and AD, or simply as a general health exercise for elders.
214919046|NCT00105547|DRUG|MPC-7869|oral 800 mg BID
214919047|NCT00105547|DRUG|MPC-7869|Oral BID dosing
214919048|NCT02590497|PROCEDURE|Diffusion Weighted Imaging|Undergo diffusion weighted MRI
214317414|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
214317415|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
214482894|NCT06691386|OTHER|Reference Product F: Subjects' OBMST|Use of Reference Product F in controlled use and ad libitum use sessions. The subjects' Own Brand Moist Smokeless Tobacco (OBMST) reference products used in this study were commercially available and had been reported by the subjects as the brands they usually consume.
214317416|NCT00615056|DRUG|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
214317417|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
214317418|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
214482895|NCT06715384|DIAGNOSTIC_TEST|Polyp size measurement using autonomous AI measurement or AI-assisted human measurement with the CAM system|The study of real-time polyp size measurement using the CAM system will be conducted in two phases. Phase I (pilot phase, n=24 polyps, about 27 patients) will be used to assess the feasibility of applying the CAM system in real-time in a clinical video in order to obtain pilot data on the relative accuracy of assessing polyp sizes using autonomous AI measurement and AI-assisted human measurement and to determine the relative accuracy of assessing polyp size in Phase II of the study ( Randomized Controlled Trial) to assess the sample size and reference standards for the CAM system. The sample size for the second phase of the randomized controlled trial (comparing AI-assisted human measurement to non-scaled device) will be based on pilot data in order to compare the relative accuracy of polyp size measurement with AI-assisted human measurement versus non-scaled device in clinical practice.
214482896|NCT06264245|OTHER|Audiological profile|Video otoscopy Tympanometry High-frequency tonal audiometry
214482897|NCT06264245|OTHER|Hearing self-assessments|Hearing skills questionnaire Subjective assessment of tinnitus using a visual analogue scale Self-questionnaire on the impact of tinnitus Hyperacusis self-questionnaire
214482898|NCT06264245|OTHER|Objective and subjective audiological tests|Acoustic Omission Measurement of the stapedial reflex by tympanometry High-frequency tonal audiometry - exposed ear only Speech audiometry in noise Tinnitus and subjective discomfort thresholds Psychoacoustic intensity perception test
214482899|NCT06264245|OTHER|Self-assessment of exposure sound quality|A self-assessment of the sound quality of the manipulated sounds heard during the exhibition will be carried out during the second follow-up visit. The elements on which the participant will be asked to make a qualitative judgement will relate to intelligibility difficulties or not; background noise (these two items in the form of a mark between 0 and 10); the clear, muffled or shrill nature of the sounds, their resonant or saturated side.
214482900|NCT06712836|DRUG|MET097|MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
214919049|NCT02590497|DRUG|Gadolinium|Undergo gadolinium-enhanced MRI
214919050|NCT02590497|OTHER|Laboratory Biomarker Analysis|Tissue genetic analysis
214919051|NCT02590497|PROCEDURE|Magnetic Resonance Imaging|Undergo gadolinium-enhanced MRI
214919052|NCT02590497|PROCEDURE|Magnetic Resonance Imaging|Undergo 3D volumetric T1-weighted sequence
214919053|NCT02590497|PROCEDURE|Magnetic Resonance Imaging|Undergo FLAIR sequence
214317419|NCT02231346|DRUG|Berodual® Respimat® - inhaler|
214317420|NCT03139890|OTHER|High-fat (HF-LC-LP) milkshake|During this experimental day, men will receive a high-fat milkshake
214482901|NCT06712836|DRUG|Placebo|Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
214482902|NCT06716242|PROCEDURE|Peripheral blood collection|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.
214671668|NCT03726671|OTHER|100% Cho diet|Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
214671669|NCT00872716|DRUG|Quetiapine XR|100 mg single-dose Quetiapine XR
214671670|NCT00872716|OTHER|Placebo|Placebo
214919054|NCT02590497|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo perfusion MRI
214919055|NCT02278445|RADIATION|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
214919056|NCT02278445|DEVICE|Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)|
214919057|NCT05391347|OTHER|Orange oil aromatherapy|5 minutes before the invasive procedure, 3 ml of orange oil were dripping onto the sponge, and the patient was told to breathe slowly at a distance of 3 cm and to smell during the process.
214919058|NCT00104780|BIOLOGICAL|EP-2101|
214919059|NCT00104780|BIOLOGICAL|incomplete Freund's adjuvant|
214919060|NCT05204680|BEHAVIORAL|Aerobic Exercise|The participant will work with the physical therapist on an exercise regimen.
214919061|NCT04663529|OTHER|contact lens|daily disposable soft contact lens
214919062|NCT02644668|DRUG|Placebo|Granules for oral suspension (placebo)
214919063|NCT02644668|DRUG|Reldesemtiv 150 mg|Granules for oral suspension, 18.7% reldesemtiv
214919064|NCT02644668|DRUG|Reldesemtiv 450 mg|Granules for oral suspension, 56.0% reldesemtiv
214317421|NCT03139890|OTHER|High-carbohydrate (LF-HC-LP) milkshake|During this experimental day, men will receive a high-carbohydrate milkshake
214317422|NCT03139890|OTHER|High-protein (LF-LC-HP) milkshake|During this experimental day, men will receive a high-protein milkshake
214317423|NCT02876965|PROCEDURE|Muscle Stretching|Subjects completed one stretching session on the main muscle groups of the body weekly.
214317424|NCT02876965|PROCEDURE|Physical Exercise|Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
214317425|NCT05096936|OTHER|Pilates|"The solo Pilates method will be applied twice a week for 12 weeks using the following exercises:~20 Breaths, Double leg stretch, Single leg stretch, Leg circles, Hip lift on ball, Abdominal tightening on ball, Alternating two supports, Side bend, Side kick - side kick, Side kicks, Shell and Swan and Neck pull stretches; in the tenth session, we evolved some exercises: The saw, Swan dive, Book close series, Hip lift on the ball and Front pulls; in the eighteenth session we changed again some exercises for: Leg pull back, Rolling like a Ball, Swimming, Roll over and Leg pull front."
214317426|NCT05096936|OTHER|Photobiomodulation|Applications of FBM or placebo (MR4 ACTIVet PRO Laser Shower Portable, MRM, USA) will last for 115s and will deliver 60 J at each point. The mode of application, with the patient supine on a stretcher, with the grouping probe held stationary in contact with the skin, at a 90-degree angle, in the pubic mound and in the perineum region.
214317427|NCT06208436|OTHER|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (5-FU-based or gemcitabine-based regimens) or underwent surgery alone
214317428|NCT05040633|DEVICE|BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))|Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
214317429|NCT05040633|OTHER|Standard Exercise Therapy|Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
214317430|NCT00831532|DRUG|Dimebon|Dimebon 5mg in healthy controls
214919065|NCT04553601|DIAGNOSTIC_TEST|18F-FDG PET/CT and PET/CT-guide targeted biopsy in another group of participants|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time
214317431|NCT00831532|DRUG|Dimebon|Dimebon 5mg in mild hepatic impairment patients
214317432|NCT00831532|DRUG|Dimebon|Dimebon 5mg in moderate hepatic impairment patients
214317433|NCT00831532|DRUG|Dimebon|Dimebon 5mg in Severe Hepatic Impairment
214317434|NCT05071703|DRUG|Trilaciclib|"* Carboplatin combined with Etoposide (ES-SCLC patients)~* plus Topotecan (second/third line ES-SCLC patients)"
214317435|NCT03026465|DEVICE|Polymer-free stent|PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
214317436|NCT03026465|DEVICE|Biodegradable-polymer stent|PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
214317437|NCT05811611|BEHAVIORAL|WeChat Mini Program plus tailored online health promotion videos|Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
214317438|NCT05811611|BEHAVIORAL|WeChat Mini Program Only|Participants only have access to a WeChat Mini Program.
214317439|NCT01385475|BEHAVIORAL|RT|8 week RT Intervention
214317440|NCT04124107|DEVICE|multiparametric MRI and 68Ga-PSMA PET/MRI|All participants will undergo multiparametric MRI examination. If mpMRI is unfavorable for prostate cancer, participants will undergo 68Ga-PSMA PET/MRI examination
214317441|NCT04124107|PROCEDURE|Prostate biopsy|Participants with unfavorable mpMRI but favorable 68Ga-PSMA PET/MRI will undergo both 68Ga-PSMA PET/MRI-ultrasound-fusion targeted biopsy and transperineal ultrasound guided 12-core systematic biopsy
214317442|NCT00316979|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
214317443|NCT00571506|DRUG|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
214317444|NCT00571506|DRUG|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
214317445|NCT02382081|PROCEDURE|Patient-initiated shared care|
214317446|NCT01303575|BEHAVIORAL|HIV, STI and Pregnancy Prevention Curriculum|"A complete internet-based, It's Your Game...Keep It Real Intervention Program"
214317447|NCT01303575|BEHAVIORAL|Control Curricula|A computer-based, science education program that does not contain elements of sexual health education
214317448|NCT04049656|DEVICE|HFVI|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
214317449|NCT03476304|DEVICE|Endocrown restoration|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement
214671671|NCT04297384|OTHER|Informational Intervention|Receive standard chemotherapy educational materials
214317450|NCT03476304|DEVICE|Post retained composite restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.
214317451|NCT03476304|DEVICE|Post retained ceramic restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
214317452|NCT04425746|DRUG|Afamelanotide|
214317453|NCT04425746|DRUG|Placebo|
214317454|NCT03034785|DEVICE|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
214317455|NCT04932785|OTHER|Regular diet|Regular diet
214317456|NCT04932785|OTHER|Clear Liquid Diet|Clear Liquid Diet
214317457|NCT04010266|DEVICE|RelieVRx headset|RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
214317458|NCT04010266|DRUG|multi-modality pain management|combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
214317459|NCT04640948|DEVICE|High flow nasal therapy|Controlled oxygen administration using at least 20 L/min of flow rate and titrated up as tolerated. Titration of supplemental oxygen to an arterial saturation between 88 - 92%.
214317460|NCT04640948|DEVICE|Low flow oxygen|Controlled oxygen administration using (venturi mask or nasal cannulae) titrated to an arterial saturation between 88 - 92% as the initial oxygen administration method with a flow rate of \<20 L/min.
214482903|NCT06373250|BEHAVIORAL|Membrane stripping group|An information form will be filled in for admission to the Primipar participating maternity unit. Membrane stripping will be performed during a vaginal examination at least once during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the visual analogue scale and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.
214482904|NCT06373250|OTHER|Control group|You will be asked to fill in an information form to be admitted to the Primipar participating maternity unit. No membrane stripping are applied and no cervical interventions are made during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the VAS and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.
214482905|NCT06281327|DRUG|Avatrombopag|"After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L."
214482906|NCT06704516|DRUG|Menopausal hormone therapy|"Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen.~Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)"
214482907|NCT06706908|OTHER|Health questionnaires|Participants are expected to complete a series of health questionnaires (i.e. numerical rating scale, Oswestry Disability Index) relevant to their treatment using a SI-BONE implant.
214482908|NCT06704477|OTHER|Survey|Eight questions about protein intake
214482909|NCT06721208|BEHAVIORAL|"use the Move for Knee APP"|"The mobile APP called Move Your Knee allows the collection of data entered by patients, useful for understanding their lifestyle habits and daily physical activity level, and information relating to KOA pathology.~At the end of the questionnaire, the algorithm integrated into the APP's computer code will allow the calculation of the patient's presumed level of physical activity. This will then be followed by the assignment of a specific form which includes the exercises and the related execution parameters (i.e. weekly frequency), and useful advice for safely carrying out the exercises to achieve the specific functional objectives."
214482910|NCT05317819|DRUG|ADI-PEG20|Treatment for hepatocellular carcinoma
214482911|NCT05317819|OTHER|Placebo|Treatment for hepatocellular carcinoma
214482912|NCT04454203|DRUG|Mepivacaine|An infiltration of mepivacaine superomedially to the femoral artery via perineural catheter.
214317461|NCT02679911|DRUG|Loceryl NL|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
214317462|NCT02679911|DRUG|Ciclopirox NL|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
214317463|NCT02258204|DRUG|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
214317464|NCT02258204|DRUG|Placebo|
214317465|NCT01693328|DRUG|PecFent® (fentanyl) nasal spray|
214317466|NCT02933177|BEHAVIORAL|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
214317467|NCT02933177|BEHAVIORAL|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
214317468|NCT00454090|DRUG|AZD8330|oral tablet
214317469|NCT05242081|DRUG|S-ketamine|S-ketamine 0.5mg/kg for induction and 0.2mg/kg/h for maintenance
214317470|NCT05242081|DRUG|Sufentanil|Sufentanil 0.2-0.3μg/kg for induction and remifentanil 0.05-0.15μg/kg/min for maintenance
214482913|NCT04454203|DRUG|Saline|An infiltration of saline superomedially to the femoral artery via perineural catheter.
214482914|NCT04454203|PROCEDURE|Perifemoral Injection of Local Anesthetic|Infiltration of mepivacaine superomedially to the formal artery via perineural catheter in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
214482915|NCT04454203|PROCEDURE|Perifemoral Injection of Local Anesthetic|Infiltration of saline superomedially to the formal artery via perineural catheter that should NOT numb the nerves that contribute to tourniquet hypertension intraoperatively.
214482916|NCT06880172|BEHAVIORAL|WeCare|"Individual level: Problem identification, Linking Mental health and minority stress, medication adherence, developing an action plan, complementing the plan, and follow-up.~Group level: Social support and self acceptance in MSM, coping with stigma and minority stress, support for medication adherence"
214482917|NCT06880172|BEHAVIORAL|Standard of Care|Access to services offered at the POP INN Wellness Clinic including psychoeducation for all individuals who enroll in PrEP or ART services, free medication, and enrollment in their standard drop-in. Mpowerment support groups, as well as referrals to mental health services on request
214482918|NCT06884020|BEHAVIORAL|EMOTIONAL REGULATION PROGRAMME|"This programme works on early identification and implementation of strategies to improve self-awareness and facilitate children's emotions.~This intervention is designed to be delivered in the educational setting by the tutor in the form of a learning situation with 8 sessions plus 1 family session.~The topics covered are:~* Embarking on an emotional journey~* Recognising our emotions~* Emotions have a voice~* Identifying different emotions~* How do I make decisions?~* Emotion, action, and consequence~* Learning to self-regulate~* Celebrating our learning"
214482919|NCT06882291|OTHER|Intermittent fasting diet|Women in the first experimental group will follow an intermittent fasting diet, where they eat for 8 hours and fast for 16. They can skip breakfast or have an early dinner. Meals will include 500-800 calories of high-fiber and protein-rich foods. Participants can start with 2-3 fasts per week and increase gradually. They must drink 2-3L of water daily and can consume zero-calorie beverages. Weekly assessments will track progress.
214482920|NCT06882291|OTHER|Resistive exercise program|Women in the second experimental group will receive medical treatment and follow an 8-week resistive exercise program (30 min, 5 days/week). Exercises target the upper body, abdomen, and lower limbs, starting with a 10-min warm-up, followed by 30 min of resistance training (biceps curls, triceps exercises, chest press, plank, crunches, squats, lunges, hamstring, and quadriceps curls), and ending with a 10-min cool-down. Repetitions are logged weekly for assessment.
214317471|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:200,000|
214482921|NCT06882291|DRUG|Medical treatment|Each woman in the three groups will receive medical treatment (metformin tablets) for eight weeks and the dose will prescribed by the gynecologist during the first visit. Patients will be asked to attend the clinic each month for routine monitoring.
214482922|NCT06883682|OTHER|No intervention|No intervention is conducted in this study.
214482923|NCT06884982|DRUG|QL1706 Plus Lenvatinib|All enrolled subjects will receive QL1706 5 mg/kg intravenously plus lenvatinib 8/12mg on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
214482924|NCT06552130|OTHER|Spiroergometer test with intranasal insulin spray|Participants will undergo a 60 min bicycle spiroergometer test and intranasal insulin spray. Intranasal insulin will be administered 30 minutes prior to the start of the physical activity.
214317472|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:80,000|
214671672|NCT04297384|OTHER|Informational Intervention|Receive personalized information about cancer, treatment, and side effects
214317473|NCT02849548|DRUG|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
214317474|NCT02849548|OTHER|placebo|Pill with inactive ingredients
214317475|NCT01317238|DRUG|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
214317476|NCT03195959|OTHER|Hypoxia and Hyperoxia|10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
214317477|NCT06052774|PROCEDURE|Non-Surgical periodontal therapy|Supra and Subgingival debridement for all patients except periodontally healthy individuals
214317478|NCT06272877|OTHER|Fluidotherapy|Fluidotherapy is a dry environment created by mobilizing solid particles using heated air flow. Fluidotherapy will be applied 20 minutes a day, 5 days a week for 4 weeks.
214317479|NCT06272877|OTHER|conventional rehabilitation program|The conventional rehabilitation program determined before the study will be implemented by a physiotherapist in the hospital for 6 weeks.
214317480|NCT06055023|DRUG|ZL-82 12.5mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317481|NCT06055023|DRUG|ZL-82 25mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317482|NCT06055023|DRUG|ZL-82 50mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317483|NCT06055023|DRUG|ZL-82 100mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317484|NCT06055023|DRUG|ZL-82 200mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317485|NCT06055023|DRUG|ZL-82 300mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317486|NCT06055023|DRUG|ZL-82 450mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214482925|NCT06552130|OTHER|Spiroergometer test with intranasal placebo spray|Participants will undergo a 30 min bicycle spiroergometer test and intranasal placebo spray. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over 15 minutes 30 minutes prior to the start of the physical activity on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
214317487|NCT06055023|DRUG|ZL-82 600mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317488|NCT06055023|DRUG|zL-82 placebo 12.5mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317489|NCT06055023|DRUG|ZL-82 placebo 25mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214482926|NCT06883266|DEVICE|transcranial direct current stimulation (tDCS)|2 mA will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
214482927|NCT06883266|DEVICE|Sham (No Treatment)|For 30 seconds, the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex
214482928|NCT06883435|PROCEDURE|closed reduction and percutaneous ﬁxation of medial malleolus|No incision is made for fracture reduction, a pointed reduction clamp is applied to reduce the fracture, two 4 mm partially threaded cannulated cancellous screws are inserted over guide wires through stab incisions. Fluoroscopy is used to assess reduction.
214482929|NCT06883435|PROCEDURE|open reduction and screw fixation of medial malleolus|An incision is made over the fracture; the MM fracture is reduced under direct vision. fixation is performed with two 4mm cannulated partially threaded cancellous screws. fluoroscopy is used to confirm reduction.
214482930|NCT06889363|DRUG|MTA|The indirect pulp capping will be applied using MTA using an MTA carrier, then glass ionomer will be applied, then composite restoration above
214482931|NCT06889363|BIOLOGICAL|PRF|The indirect pulp capping will be applied using PRF on a membrane, then glass ionomer will be applied , then composite restoration above
214919066|NCT00691444|DIETARY_SUPPLEMENT|Melatonin|"Subjects will be given up to 0.5 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
214919067|NCT00691444|DIETARY_SUPPLEMENT|Melatonin|"Subjects will be given up to 10 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
214919068|NCT00691444|BIOLOGICAL|Melatonin|"Subjects will be given up to 20 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
214919069|NCT04771286|DRUG|BI 1015550 (C-14)|BI 1015550 (C-14)
214919070|NCT02240212|DRUG|Afuresertib|The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
214317490|NCT06055023|DRUG|ZL-82 placebo 50mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214482932|NCT06885489|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) based psychoeducation program|This study implements an ACT-based psychological intervention designed to enhance psychological well-being and reduce depression, anxiety, and stress among university students. The intervention consists of structured sessions focusing on psychological flexibility, mindfulness, acceptance, and value-driven actions. Participants engage in experiential exercises, cognitive defusion techniques, and behavioral commitment strategies. The intervention is delivered over 8 weeks, with weekly sessions lasting approximately 40 minutes. The sessions are conducted in groups by trained professionals.
214317491|NCT06055023|DRUG|ZL-82 placebo 100mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214671673|NCT04297384|OTHER|Quality-of-Life Assessment|Ancillary studies
214671674|NCT04297384|OTHER|Survey Administration|Complete surveys
214671675|NCT04898907|DRUG|ANG-3777 (Therapeutic Dose)|Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
214671676|NCT04898907|DRUG|ANG-3777 (Supra-therapeutic Dose)|Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
214671677|NCT04898907|DRUG|Placebo|Arms assigned to this intervention will receive normal saline, IV, Fasted
214671678|NCT04898907|DRUG|Moxifloxacin Hydrochloride|Arms assigned to this intervention will receive 400 mg, Oral, Fasted
214919071|NCT02240212|DRUG|Paclitaxel|Paclitaxel sourced locally will be administered IV
214919072|NCT03102996|DRUG|Nephrotrans|Sodium hydrogen carbonate, ATC-Code: A02AH
214919073|NCT03102996|OTHER|Placebo|Identical capsules without active substance.
214317492|NCT06055023|DRUG|ZL-82 placebo 200mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317493|NCT06055023|DRUG|ZL-82 placebo 300mg|1 case,The starting dose,Take the medicine once on D1,D1-7. Edit
214317494|NCT06055023|DRUG|ZL-82 placebo 450mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317495|NCT06055023|DRUG|ZL-82 placebo 600mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
214317496|NCT05460494|BEHAVIORAL|RELOAD-C|RELOAD-C is a web-based platform that centralizes 6 brief videos of our MCP expert (Dr. Applebaum) discussing sources of meaning, links to virtual group meetings facilitated by a social worker trained in MCP to promote discussion of MCP concepts, and written content providing guidance on homework and exercises referenced in the MCP videos
214317497|NCT04171856|DEVICE|REAplan(R)|motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm
214317498|NCT06346782|BEHAVIORAL|Internet-Based Parent-Child Interaction Therapy|I-PCIT consists of two phases. The first phase is designed to enhance positive parent-child interactions. The second phase is designed to enhance parents' behavior management parenting behaviors.
214482933|NCT06737731|DRUG|SHR-1681|SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.
214671679|NCT03983876|DRUG|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease"
214482934|NCT06738563|OTHER|Collection breast milk|Collection of a milk sample taken as part of women's donation
214482935|NCT06735391|DRUG|JMT101|JMT101 is a recombinant humanized anti-EGFR monoclonal antibody.
214671680|NCT02742649|DRUG|Fixed Combination|Continuous elution from the ocular insert.
214919074|NCT04846712|OTHER|Collect data of medical record|Collect data of medical record: initial physical examination, ultrasound (US), Magnetic Resonance Imaging (MRI), physical examination at 30 days, physical examination at 3 months, physical examination at 6 months and final examination at 12 months.
214919075|NCT04347369|OTHER|other|clinical diagnosis
214919076|NCT03292666|DRUG|Oral Anticoagulant|Oral anticoagulants used to treat or prevent venous thromboembolism
214919077|NCT00733421|DRUG|etoricoxib|90 mg once daily
214317503|NCT05673408|DEVICE|Philips IntelliVue X3 Patient Monitor|All subjects enrolled in this study will receive one Philips non-invasive blood pressure cuff. This cuff will be connected via compatible hose to the Philips IntelliVue X3 monitor hosting the released or investigational NIBP algorithm. The invasive blood pressure from the radial arterial line will also be connected to the Philips IntelliVue X3 monitor. The Philips IntelliVue X3 monitor will in turn be connected to a laptop for data collection.
214317504|NCT06446713|RADIATION|Image guided hybrid hyper-fractioned dose escalation with proton therapy|"Radiation: Image-guided hybrid hyper-fractioned dose escalation with proton therapy~The investigational radiation regime will be administered in a two-part schedule:~* The first 4 weeks (i.e. first 20 fractions) of the radiation treatment of the pathological tumor will be according to the conventional clinical standard with proton therapy: 20x 2 Gy to the CTV70 and 20 x 1.55 Gy to the CTV54.~* In week 4 (\~ fraction 16) GTV80 will be determined on conventional weekly CT and additional MR imaging (conventional clinical protocol). Only this adapted tumor volume, the so-called GTV80, will receive the dose escalation (i.e., 80.5 Gy).~* In the last 3 weeks (last 15 fractions) patients will be radiated twice per day (i.e. hyperfractionation). The GTV80, CTV70 and CTV54 will receive 1.55 Gy in the morning, and the GTV80 and CTV70 will receive additional dose in the afternoon."
214919078|NCT00733421|DRUG|tramadol|100 mg twice daily
214919079|NCT03832764|DEVICE|ANSPEC-PRO|Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU
214482936|NCT06735391|DRUG|Osimertinib|EGFR TKI
214482937|NCT03769506|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|Use of ASP-1929 PIT therapy
214482938|NCT03769506|DRUG|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
214482939|NCT06742970|COMBINATION_PRODUCT|Telematic intervention|Telematic intervention will be performed by a specialized company hired by the investigational team. Trained nurses will contact patients assigned to the intervention groups by videocalls at weeks 1,3,5,7,9,11 and 12 after the admission. The specialized nurses will supervise the exercise program sessions (based on an adaptation of he VIVI FRAIL program), correcting potential mistakes and recommending the optimal way for performing the training program. Patients will take a 200 ml dose of hyperproteic, hypercaloric nutrition supplements daily one hour after performing the exercise session. Information about the optimal diet adapted to the clinical profile of patients will be also provided. Additionally, health information about the disease, the importance of adherence to treatments and recommendations and the best measures for controling cardiovascular risk factors, comorbidities and avoiding clinical complications will be also provided
214919080|NCT00616265|DEVICE|CPAP|Pressure device on airway to maintain it open
214671681|NCT02742649|DRUG|Bimatoprost|Continuous elution from the ocular insert. This is an active control arm.
214671682|NCT02742649|DRUG|Timolol|Continuous elution from the ocular insert. This is an active control arm.
214671683|NCT02742649|DEVICE|Placebo Segment|One segment of placebo (no drug product)
214671684|NCT02742649|DRUG|Timolol 0.5%|0.5% timolol drops twice daily.
214919081|NCT06485921|OTHER|Ischemic compression|Participants will received a total of 12 treatment sessions over 6 weeks, with 2 sessions per week.
214919082|NCT06485921|OTHER|Instrument assisted soft tissue mobilization Group|Participants will received a total of 12 treatment sessions over 6 weeks, with 2 sessions per week.
214919083|NCT06485921|OTHER|Exercise and workplace modifications|Participants will receive stretching and strengthening exercises for neck and scapular stabilizer muscles as a 6-week home program.
214919084|NCT00251238|DRUG|Ginkgo biloba extract EGb 761|daily Ginkgo biloba extract EGb 761
214919085|NCT02313311|OTHER|time-lapse imaging|Embryos are observed using time-lapse imaging (Primo Vision®). It is an incubator with a compact, sealed, and digitally inverted camera unit which can automatically acquire images.The system can record the actual developmental stage of the embryos, all the recorded images can be saved to be analyzed later using a special software program.
214919086|NCT01494883|BEHAVIORAL|Mindfulness Based Stress Reduction|A weekly training of eight sessions lasting two and a half hours.
214919087|NCT04309383|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
214317505|NCT06550700|PROCEDURE|laparoscopic hybrid surgery (LHS)|First performed the laparoscopic exploration of the entire abdominal-pelvic cavity to determine the resectability of the primary and metastatic lesions. After the blood vessel detachment and bowel detachment, the distal bowel of the tumor was severed and the pneumoperitoneum was closed. The liver metastases were then removed in both cohorts by open resection through the right subcostal incision.
214317506|NCT06326424|DEVICE|Empatica EmbracePlus|wear a biosensor watch to passively collect biosensor data over 48 hours. The EmbracePlus will collect heart rate variability, accelerometry, and electrodermal activity.
214317507|NCT06239844|OTHER|Experimental: Nav-Team|Participants in this arm will receive additional assistance related to asthma, log encounters, complete surveys.
214317508|NCT05370287|OTHER|oxygen inhalation|Subjects will breath 100% oxygen through a mask.
214317509|NCT05370287|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
214317510|NCT05527080|OTHER|physiotherapy|Some infants will receive physiotherapy as a part of their clinically indicated care.
214317511|NCT05527080|DEVICE|brace|Some infants in the hip dysplasia group will receive brace and/or cast as a part of their clinically indicated care
214317512|NCT01732523|DIAGNOSTIC_TEST|Contrast enhanced carotid ultrasound|
214317513|NCT06466083|OTHER|no intervention|this is an observation study,no intervention
214317514|NCT04731987|BEHAVIORAL|Beverage consumption|"Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal."
214317515|NCT01785979|DRUG|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
214317516|NCT01785979|DRUG|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
214317517|NCT04478357|DRUG|4 mg Fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
214317518|NCT04478357|DRUG|4 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
214317519|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
214317520|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
214317521|NCT01271088|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
214317522|NCT00196560|DEVICE|Immobilization in External Rotation|
214317523|NCT02357147|DRUG|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
214317524|NCT02357147|DRUG|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
214317525|NCT02357147|DRUG|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
214482940|NCT06891521|PROCEDURE|Electroacupuncture|"Patients received electroacupuncture on the day before and the first day of each ICIs treatment cycle. The electroacupuncture points selected Zusanli (ST36), Quchi (LI11), and Hegu (LI4). Patients will be positioned supine, and the acupuncturist will disinfect the local skin at the acupuncture points using 75% ethanol on cotton balls. A disposable acupuncture needle (0.3mm × 40mm) will be inserted using either a single-hand or double-hand needling technique, with rapid, direct insertion. Once the needle reaches a depth of approximately 0.5 cun, the technique of lifting, thrusting, twirling, and rotating will be applied. After obtaining de qi, the needles will be retained for 30 minutes. Needling will be performed once every 10 minutes, and the needling technique used will be a balanced reinforcing and reducing method. Electroacupuncture will be applied using a dense-wave form, with a frequency of 2 Hz and an intensity not exceeding 10 mA."
214482941|NCT06891638|DEVICE|Schedule of tDCS administration|This study evaluates the combined effects of Phono-Motor Treatment (PMT) and transcranial direct current stimulation (tDCS) for reading rehabilitation in post-stroke aphasia. Unlike standard speech therapy, this intervention integrates non-invasive brain stimulation to enhance language recovery by modulating neural activity in perilesional areas. We hypothesize that active tDCS will enhance PMT efficacy, leading to greater improvements in reading competence and phonological processing compared to sham tDCS. Through systematic testing across the 3 study arms, we expect to identify the most effective stimulation timing.
214482942|NCT06736327|DRUG|SKB500|The administration route of SKB500 is intravenous infusion, with a dosing frequency of Q3W.
214317526|NCT02357147|DRUG|Cisplatin|Combination Phase - Cisplatin 75 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
214317527|NCT04829487|DRUG|Ergocalciferol Capsules|Given to subjects 50,000 IU per week for 8 weeks
214482943|NCT06744387|DIAGNOSTIC_TEST|clinical assessments and tissue oxygenation monitoring by Near Infrared Spectroscopy|Flap failure will be identified, based upon gold standard monitoring (flaps skin color, temperature, tissue turgor and capillary refill time) along with Doppler technique during a postoperative period of five days. In all patients Near Infrared Spectroscopy (NIRS) by FORE-SIGHT ELITE will be applied to obtain continuous tissue oxygenation measurements. NIRS values and trends from patients with flap failure (case group) will be compared to NIRS values and trends from patients with no flap failure(control group).
214482944|NCT06743984|OTHER|Polychromatic resin composite|Polychromatic layering resin composite (enamel and dentin shades).
214482945|NCT06743984|OTHER|Monochromatic resin composite|Monochromatic resin composite (opaquer and dentin shades)
214919088|NCT04344483|DRUG|2% Lidocaine and 1:100,000 Adrenaline|Topical application of 2% Lidocaine and 1:100,000 Adrenaline in the form of dressing will be applied over skin graft donor site of thigh for 10 minutes.
214919089|NCT04344483|DRUG|Normal saline|Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.
214919090|NCT06217705|BEHAVIORAL|Project Calm|Project Calm is a \~30-minute self-guided digital intervention designed to teach children and adolescents empirically supported emotion regulation skills to facilitate self-calming when faced with intense negative emotions. Project Calm uses vignettes, interactive activities, and engaging graphics to teach youth calming skills.
214919091|NCT00274274|DRUG|insulin detemir|
214919092|NCT00274274|DRUG|insulin aspart|
214919093|NCT04955353|DIETARY_SUPPLEMENT|AVC-H2|A total of 2.5g AVC-H2 daily (2 tablets in the morning and 2 in the evening)
214919094|NCT04955353|DIETARY_SUPPLEMENT|Placebo|A total of 2.5g placebo daily (2 tablets in the morning and 2 in the evening)
214919095|NCT01456754|DIETARY_SUPPLEMENT|low feeding frequency (3x)|3 meals a day
214919096|NCT01456754|DIETARY_SUPPLEMENT|High feeding frequency (14x)|14 meals a day
214919097|NCT03830697|OTHER|Acupuncture intervention|Patients in the experimental group were given acupuncture treatment for 12 weeks prior to COH. If the patient has a good COH timing during acupuncture treatment, he or she will enter the COH cycle at any time.The acupuncture intervention program of the test group is as follows:Acupoint group 1: Baihui（DU20）, Zhongyu（RN12）, Tianshu （ST25）(bilateral), Guanyuan（RN4）, uterus (bilateral)（EX-CA1）, Dahe（KI12） (bilateral),Zusanli （ST36）(bilateral), Sanyinjiao（SP6） (bilateral), Taichong （LR3）(both sides).
214919098|NCT05308953|DRUG|NVG-291|NVG-291 is a drug injected under the skin (subcutaneous).
214919099|NCT05308953|OTHER|Placebo|Salt water is being used as a placebo and will be injected under the skin (subcutaneous).
214919100|NCT05822076|PROCEDURE|Paravertebral block (ropivacaine) left|Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
214919101|NCT05822076|PROCEDURE|Paravertebral block (ropivacaine) right|Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
214919102|NCT00937976|PROCEDURE|Periodontal Scaling and Root Planing|Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
214919103|NCT05453227|DRUG|Zinc|To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
214919104|NCT02746965|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
214919105|NCT02746965|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
214919106|NCT02746965|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
214919107|NCT02000960|DRUG|Triheptanoin|Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid heptonate.
214919108|NCT00404391|DRUG|Hydrocodone/Acetaminophen Extended Release|1 tablet every 12 hours
214919109|NCT00404391|DRUG|Hydrocodone/Acetaminophen Extended Release|2 tablets every 12 hours
214919110|NCT00404391|DRUG|Placebo|2 tablets every 12 hours
214317528|NCT04829487|DRUG|Placebo|Placebo capsules
214317529|NCT01220258|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
214317530|NCT04656067|DRUG|Oxytocin ,Tranexamic acid and Ethamsylate|Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
214919111|NCT02434146|DRUG|Topical Phenylephrine Solution|Given topically via spray
214919112|NCT02257073|BEHAVIORAL|Cognitive-behavioral treatment|
214919113|NCT02257073|BEHAVIORAL|Waiting List|
214919114|NCT04044040|BEHAVIORAL|Symptom screening with Targeted Early Palliative care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
214919115|NCT04823273|BEHAVIORAL|General improvement|Changes to interface to be more intuitive.
214919116|NCT04823273|BEHAVIORAL|In-line help text|General improvement + in-line help text
214919117|NCT04823273|BEHAVIORAL|Interruptive alert|General improvement + interruptive alert
214317531|NCT02925546|DRUG|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
214317532|NCT02925546|DRUG|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
214919118|NCT04492176|DEVICE|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times
214919119|NCT05945940|OTHER|no intervention|no intervention
214671685|NCT01666236|OTHER|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light \[wavelength of 689 nm\] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
214919120|NCT03283657|BEHAVIORAL|DiRECT|DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.
214671686|NCT05127096|DIAGNOSTIC_TEST|FirstSight blood test|FirstSight blood test for colorectal cancer screening
214919121|NCT03283657|BEHAVIORAL|Usual care (UC)|Standard care with routine medical care.
214919122|NCT01983540|BIOLOGICAL|DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine|DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study
214919123|NCT01983540|BIOLOGICAL|DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine|DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age) and a booster dose of Infanrix hexa vaccine with Prevnar at 12 to 24 months of age in a previous study.
214919124|NCT01983540|BIOLOGICAL|Infanrix hexa + Prevenar + Rotarix vaccine|Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster dose of DTaP-IPV-Hep B-PRP\~T vaccine concomitantly with Prevenar vaccine concomitantly with Prevenar at 12 to 24 months of age in a previous study.
214919125|NCT05103982|BEHAVIORAL|Coping with Infertility Program|6 10-minute videos with assigned homework
215061236|NCT04238091|DRUG|Fecal material transfer therapy|"Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not."
215061237|NCT04238091|PROCEDURE|4mm Punch Biopsy of Scalp|For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
214317533|NCT02925546|DRUG|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
214317534|NCT01179971|DIETARY_SUPPLEMENT|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
214317535|NCT05294848|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
214317536|NCT05294848|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
214317537|NCT05294848|BEHAVIORAL|Neutral Control|Dot-probe task using only neutral stimuli with no training toward threat
214482946|NCT06744309|BEHAVIORAL|Heat Literacy Intervention|The behavioral intervention aims to improve heat literacy among participants through an 8-12 week education and training program. It includes three main modules: enhancing community awareness of hot weather, recognizing and responding to heat-related illnesses, and teaching personal cooling strategies. Participants will use SwitchBot meters to monitor indoor temperature and humidity, access real-time weather information, and learn about heat wave warnings. They will receive educational materials, including infographics, videos, and one-to-one training from field staff. The content of intervention and delivery methods will be refined through co-design workshops with stakeholders and community members to ensure they are practical and culturally appropriate. The goal is to equip participants with the knowledge and skills to protect themselves from extreme heat, resulting in better heat adaptation behaviors and improved health outcomes.
214482947|NCT06744309|OTHER|Structural (Cool Roof) Intervention|The structural intervention in this study involves implementing cool roofs to reduce indoor temperature and mitigate the effects of extreme heat in rural Malaysian communities. Selected households will have their roofs painted with UV-resistant paint, which reflects direct sunlight and reduces thermal absorption. This intervention aims to decrease the amount of solar energy absorbed by the roof, thereby lowering indoor temperature and reducing the physiological heat strain on residents. By maintaining cooler indoor environment, the cool roof intervention seeks to alleviate the health risks associated with prolonged exposure to high temperature.
214482948|NCT06745167|PROCEDURE|Pulsed field ablation|Utilizing pulsed field ablation (PFA), combining pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation.
214671687|NCT01709799|BEHAVIORAL|Exercise|"Participants will do physical activity that raises heart rate to a target heart rate (THR)zone which is pre-calculated using the Karvonen Formula:~(THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Participants begin exercise regimen starting at 50% THR for intensity and gradually increase by 5% up to a maximum of 75% THR.~Activity duration begins at 10 mins./day and increases 5 mins. every week following to a maximum of 40 mins. Polar Heart Rate monitors are used to measure THR and save resulting data."
215061238|NCT04238091|DIAGNOSTIC_TEST|Blood draw|Blood will be collected by a standard venipuncture procedure. 60-80cc of blood will be drawn from a patient per blood draw occurrence. Blood samples will be transferred to the research facility. Samples will be used to either stained with cell surface antibodies for fluorescence acquisition cell sorting (FACS) analysis (FACS experiments will allow for assessment of the subset and activation status of immune cells involved in AA or other cutaneous disorder pathology) or to extract DNA for the purposes of exome or genomic sequencing or genotyping of disease associated genes
215061239|NCT04238091|PROCEDURE|Skin Microbiome sampling|Skin microbiome will be collected using skin swabs at the time of recruitment according to established protocols outlined by the Human Microbiome Project. Sterile (germ-free) techniques will be used for collection of all specimens, with careful avoidance of contamination of collection area by gloved hands. The sites that will be sampled are (in sequence): Lesional AA skin, non-lesional scalp skin, retro-auricular crease, ante-cubital fossa, and anterior nares. Skin surface specimens will be collected with a Catch-All Sample Collection Swab swab that looks similar to a q-tip and is, moistened with sterile solution. Skin will be swabbed approximately 50 times along the scalp, behind your ear and on your arm, and twisted 2 times around the front of the nose.
215061240|NCT04238091|PROCEDURE|Hair Microbiome Sampling|Hair follicle microbiome (bacteria that live in the hair follicle) will be collected as follows: several hairs will be plucked from the scalp at a time using tweezers, once plucked the bulbs of the hairs will be cut using sterile surgical scissors and processed. Approximately 10-15 hairs will be plucked for processing. The number of hairs plucked may be increased depending on the number of hairs containing bulbs. Up to 50 hairs may be plucked, as long as the subject is able to tolerate it. Only several hairs will be plucked at a time in order to minimize pain and discomfort of the procedure.
215061241|NCT04238091|DRUG|Pre-FMT Antibiotic Cocktail|For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
214317538|NCT02105610|DRUG|desflurane, isoflurane, sevoflurane|
214317539|NCT02105610|DRUG|total intravenous anesthetics|
214317540|NCT03480672|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|intravenous application, 12 months, in 3-week cycle (q3w) 200 mg
214317541|NCT03480672|OTHER|adjuvant radiochemotherapy|adjuvant radiochemotherapy with cisplatin
214317542|NCT06670053|DRUG|Testosterone|"Clinical testosterone therapy~No research interventions will be used as a part of the study since the research is observational. Testosterone treatment will be prescribed and followed by participant's clinical physician."
215061242|NCT04238091|DRUG|Bowel Prep|The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
215061243|NCT01562392|DIETARY_SUPPLEMENT|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
215061244|NCT01562392|DIETARY_SUPPLEMENT|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
215061245|NCT00496678|BEHAVIORAL|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
215061246|NCT00496678|BEHAVIORAL|Standard of Care|Cancer patients receive standard of care for their cancer treatment
215061247|NCT02402504|OTHER|Control|Non pulse extruded snack
215061248|NCT02402504|OTHER|Small particle size pea flour|Pulse extruded snack
215061249|NCT02402504|OTHER|Large particle size pea flour|Pulse extruded snack
215061250|NCT02402504|OTHER|Lentil flour|Pulse extruded snack
214317543|NCT03176186|COMBINATION_PRODUCT|Xenon|50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
214317544|NCT06666387|DIAGNOSTIC_TEST|PET-MR examination|PET-MR examination
214317545|NCT05863637|OTHER|Intensive Short-Term Dynamic Psychotherapy|A dynamic and intensive psychotherapy with eight therapeutic sessions
214317546|NCT02417051|BEHAVIORAL|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
214317547|NCT04476537|DEVICE|OncoTreat|OncoTreat is a computational pipeline that begins with a tumor expression profile and ends with a list of several candidate regimens.
214317548|NCT05283538|DIAGNOSTIC_TEST|Coronary Artery Calcification Realization|Coronary Artery Calcification Realization
214482949|NCT06745167|PROCEDURE|Radiofrequency ablation alone|Using conventional radiofrequency ablation technology, combines pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation
214482950|NCT06739889|DIAGNOSTIC_TEST|Elongation longitudinaux articular vertebral and columnar decoaption osteo-articulaire also known as ELDOA|ELDOA targtes cervical and upper thoracic spine. ELDOA exercises involves spicific postural holds that improve forward neck posture.The goal of ELDOA is to help reduce stress and increase space in the vertebral joints so that muscles can move freely. The benefits of these stretches include joint mobility, increased fluid absorption in the discs of the spine, flexibility, improved muscle tone, postural alignment, body-mind connection, and coordination. The tension and release created by these stretches helps normalize the posture.
214482951|NCT06739889|DIAGNOSTIC_TEST|upper thoracic mobilization|Upper thoracic mobilization, often known as joint mobilization, is a common technique in manual therapy. In order to preserve or restore joint mobility, this approach glides and uses distraction on the joint surfaces.
214482952|NCT06737848|PROCEDURE|Single catheter adrenal vein sampling|The clinical invasive procedure involves inserting a single catheter into the right and left adrenal veins to collect blood samples from both adrenal veins.
214482953|NCT06737848|PROCEDURE|Double catheters adrenal vein sampling|The clinical invasive procedure involves inserting double catheters into the right and left adrenal veins to collect blood samples from both adrenal veins.
214317549|NCT06863766|DIETARY_SUPPLEMENT|fortified formula milk powder group|Fortified formula milk powder is supplemented with fiber, bitter gourd powder,mulberry leaves extract, whitekidney beans extract, and probiotics, and packaged in 25-gram sachets. The milk powder is consumed orally, two sachets per day for a duration of 8 weeks.
214317550|NCT06863766|DIETARY_SUPPLEMENT|regular milk powder group|Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
214317551|NCT02734602|DRUG|Ketamine|Ketamine will be administered after the initial PET scan for subjects participating in the ketamine aim.
214919126|NCT03843489|DEVICE|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
214919127|NCT03843489|DEVICE|Reference CO-oximetry sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
214919128|NCT03478644|DEVICE|Experimental Denture Wipe|Participants were instructed to use the experimental wipe to clean their dentures, external to their mouth, up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days. Participants were instructed to use one wipe per denture.
214919129|NCT03478644|OTHER|Tap Water|Participants were instructed to use running tap water to clean their dentures up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days.
214919130|NCT04580940|DEVICE|SpyGlass™ Discover Digital System|Observational, prospective, registry study for the clinical utility of the SpyGlass Discover digital catheter during a PTCS procedure.
214919131|NCT03640533|BEHAVIORAL|Nanit-Insights|Nanit-Insights is an app-based intervention that provides personalized sleep tips to parents.
214919132|NCT02913183|DRUG|young Fresh Frozen Plasma|Blood plasma from healthy male donors aged 18-30 years old.
214919133|NCT02913183|DRUG|old Fresh Frozen Plasma|Blood plasma from healthy male donors aged 40-55 years old.
214919134|NCT00330993|DRUG|mifepristone, misoprostol|
214919135|NCT03955705|DRUG|Nefopam 20 mg/ml|Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
214919136|NCT03955705|DRUG|Normal saline|0.9% Sodium chloride (normal saline or NSS)
215061251|NCT02402504|OTHER|Navy bean flour|Pulse extruded snack
215061252|NCT02402504|OTHER|Pinto bean flour|Pulse extruded snack
214317552|NCT05277311|DRUG|LongShengZhi capsule|LongShengZhi capsules, orally, 5 capsules each time, three times a day.
214317553|NCT05277311|DRUG|LongShengZhi capsule placebo|LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
214317554|NCT06527144|DRUG|3mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
214317555|NCT06527144|DRUG|6mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
214671688|NCT01709799|BEHAVIORAL|Exergames|"Participants experience Wii Video Games in a standardized format, beginning with 15 mins of seated play per day on week one, and then increasing 5 mins./week on each week following up to a maximum of 40mins. of play.~Participants are made aware of the Target Heart Rate Zone for the week, but are not required to reach that zone during play. The THR is calculated by the Karvonen Formula:~THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Polar Heart Rate monitors are used to measure THR and save resulting data."
214671689|NCT01709799|BEHAVIORAL|Cognitive Training|"Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.~INSIGHT Assessments are done at baseline, the start of each training week and at week 28."
214317556|NCT06527144|DRUG|Placebo TQC3721 suspension for inhalation|Placebo without active drug substance.
214317557|NCT05832086|BEHAVIORAL|Fasting Mimicking Diet (FMD)|Consume the FMD (Xentigen, L-Nutra, Los Angeles, CA) for 5 days every monthly cycle for 6 cycles total in 6 months.
214317558|NCT05832086|BEHAVIORAL|Standard Anti-Cancer Diet|Will receive standard of care diet and exercise recommendations from the study dietitian. The diet advice will be consistent with the American Cancer Society for cancer survivors and exercise recommendation of a goal of 150 minutes/week of cardiovascular exercise and weight resistance training at least twice a week.
214317559|NCT05627492|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 2 years. Participants and their treatment providers will decide on the frequency of sessions collaboratively. This may include individual and/or skills sessions in addition to phone coaching for those who attend individual sessions at least once per month. DBT consultation will also remain a component of the treatment. Participants may choose skills training, conducted in approximately 60 minute meetings, and individual therapy conducted in approximately 60 minute sessions. Family participation in skills training is highly encouraged. Skills training may include: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets.
214317560|NCT06917378|PROCEDURE|Percutaneous coronary intervention of coronary chronic total occlusion|Coronary CTO was identified by coronary angiography, and its revascularization was attempted by either antegrade, retrograde or both approach.
214671690|NCT00067522|BEHAVIORAL|User-independent contraception program|
214482954|NCT06738732|DRUG|CBD: GT4 Transdermal Delivery System|CBD: GT4 Transdermal Delivery System
214671691|NCT00067522|BEHAVIORAL|Future Planning Perspectives program|
214671692|NCT02189330|DRUG|Tafamidis|20 mg of current commercial formulation.
214671693|NCT02189330|DRUG|Tafamidis|12.2 mgA free acid tablet.
214671694|NCT02189330|DRUG|Tafamidis|20 mg new soft gelatin capsule.
214671695|NCT02189330|DRUG|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
214671696|NCT02189330|DRUG|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
214919137|NCT03515005|BEHAVIORAL|Lay Health Advisor|Patients will meet regularly Lay Health Advisors who will address the social context of their hypertension.
214919138|NCT06576947|OTHER|Virtual reality|Participants receive virtual reality treatment, 8 weeks of treatment/ 2 times a week
214919139|NCT06576947|OTHER|Neuromodulation of the tibialis posterior nerve|Participants receive neuromodulation of the tibialis posterior nerve8 weeks of treatment/ 2 times a week/ 30 minutes
214317563|NCT03101137|DRUG|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
214482955|NCT06741306|BEHAVIORAL|Group1|Current chemsex users Men who have sex with men, Aged 16-35 years (defined as last chemsex used within 3 months), Able to communicate in Thai fluently.
214482957|NCT06891742|DRUG|OriC902|Whole peripheral blood mononuclear cells are extracted from patients (or donors) through leukocyte separation, and then the required T cell subsets are isolated, which will become the basis for the subsequent preparation of CAR T cells
214482958|NCT06735287|PROCEDURE|bladder sparing set|after neoadjuvant chemotherapy combined with immunotherapy, maximal TURBT and a re-TURBT shall be performed then mitomycin C bladder instillation therapy will be administered
214482959|NCT06735287|PROCEDURE|RC|Radical cystectomy performed immediately after three cycles of neoadjuvant therapy.
214482960|NCT06734845|PROCEDURE|Total Knee Arthroplasty|Total Joint (Knee or Hip) Arthroplasty
214482961|NCT06734845|PROCEDURE|Total Joint Arthroplasty|Participants will be patients undergoing first total knee or total hip replacement
214482962|NCT06734403|OTHER|Bladder Augmentation|Bladder Augmentation using bowel loop (ileal or sigmoid loop)
214482963|NCT06736054|DRUG|Copper 61-PSMA PET/CT|TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATION: Subjects will undergo imaging with 100-300 MBq (2.7-8.1 mCi) of 61Cu-NODAGA-PSMA intravenously (IV), followed by PET/CT imaging 60 (+/- 10) minutes post radiotracer administration.
214482964|NCT06735144|DRUG|FH-006|Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days
214482965|NCT06735144|DRUG|FH-006|administered once every 3 weeks (Q3W), with a treatment period of 21 days
214482966|NCT06734286|OTHER|CogMed|CogMed which is a computerized working memory training program developed by Karolinska University.
214482967|NCT06737913|PROCEDURE|HAI Adebrelimab|Hepatic arterial infusion (HAI) of Adebrelimab (ADE) (1200mg, IA, Q3W)
214482968|NCT06737913|DRUG|intravenous infusion (IV) of Adebrelimab (ADE)|intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)
214482969|NCT06737913|DRUG|intravenous infusion (IV) of Bevacizumab (Bev.)|intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)
214482970|NCT06737913|PROCEDURE|HAIC with FOLFOX regimen|HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W)
214919140|NCT06576947|OTHER|Pelvic floor muscle training|Participants receive pelvic floor muscle training 5 times a day for 9 weeks
214919141|NCT05871047|DEVICE|tragus to wall distance (TWD), craniovertebral angle (CVA) by smart phone application|Applying photogrammetric method for CVA by smart phone application and measure nerd neck objectively from both sitting and standing positions. Also, tragus to wall distance method was used to detect degree of nerd neck from the standing position.
214919142|NCT02768727|DRUG|Xenon|drug given in concentrations of 0% to 60% over period of 2 hours
215061253|NCT04715828|OTHER|Cryopreserved semen|sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
214317564|NCT03101137|DRUG|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
214317565|NCT03101137|DRUG|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
214317566|NCT07110181|BEHAVIORAL|a blended version of the Unified Protocol for Adolescents (UP-A)|The blended UP-A includes 8 weekly modules, 6 of which (Modules 2 - 7)are online self-guided sessions. The online self-guided sessions will last approximately 45 minutes each. Over the course of these 6 weeks, participants will also have 6 therapist-guided online sessions via videoconference, each lasting 30 minutes. Two face-to-face individual sessions are scheduled, one at the beginning of each (Module 1) and one at the end (Module 8), each with an expected duration of 90 minutes.
214482971|NCT06737913|DRUG|Adebrelimab and bevacizumab maintainance treatment|The two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity
214482972|NCT06744686|DRUG|HT-102|50mg, 150mg, 300mg, 600mg
214482973|NCT06744686|DRUG|HT-102|50mg, 150mg, 300mg
214919143|NCT01521832|DRUG|SEN0014196|5 mg single oral dose
215061254|NCT04715828|OTHER|Acute and low irradiation|sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
215061255|NCT04715828|OTHER|Long and low irradiation|sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
214482974|NCT06744686|DRUG|Placebo|Placebo
214482975|NCT06739577|DIAGNOSTIC_TEST|Evaluation of walking abilities (manual Timed-Up & Go - TUG and automatic -OpenTUG))|"To evaluate walking abilities, participants performed the Timed-Up \& Go (TUG) f our times (practice trial, normal, slow and fast speed). Patient's performances are videorecorded with an Intel RealSense depth camera D435i to capture their movements, and manual time recording of time taken (in seconds) and number of steps are carried out by the experimenters.~Complementary to manual experimenter recording, a 2D human pose estimation method (OpenTUG) is applied to automatically extract the time and the number of steps taken by the participant during the TUG task."
214919144|NCT01521832|DRUG|SEN0014196|25 mg single oral dose
215061256|NCT04715828|OTHER|Long and medium irradiation|sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
214919145|NCT01521832|DRUG|SEN0014196|75 mg single oral dose
214919146|NCT01521832|DRUG|SEN0014196|150 mg single oral dose
214919147|NCT01521832|DRUG|SEN0014196|300 mg single oral dose
214919148|NCT01521832|DRUG|SEN0014196|600 mg single oral dose
214919149|NCT01521832|DRUG|SEN0014196|300 mg single oral dose (females)
214919150|NCT01521832|DRUG|SEN0014196|100 mg multiple oral dose
214919151|NCT01521832|DRUG|SEN0014196|300 mg multiple oral dose
215061257|NCT01513187|DRUG|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
215061258|NCT04741321|OTHER|VascuQol-6 questionnaire Spanish version|VascuQol-6 questionnaire was translated by two professional translators into Spanish.
215061259|NCT05245110|BEHAVIORAL|tele-exercise training|a 12-week tele-exercise training program
214317567|NCT07110181|DRUG|Standard psychiatric treatment|Participants in the control group will receive treatment as usual, including pharmacotherapy and routine clinical follow-up, as determined by their treating psychiatrists.
214317568|NCT05717777|OTHER|There is no intervention, only observational study|There is no intervention, only observational study
214919152|NCT01521832|DRUG|SEN0014196|100 mg BID multiple oral dose
214919153|NCT01521832|DRUG|SEN0014196|100 mg BID multiple oral dose (females)
214919154|NCT00789698|DRUG|Lurasidone HC1|Lurasidone 40-160 mg/day flexibly dosed.
214919155|NCT00789698|DRUG|Quetiapine XR|Quetiapine XR 200-800 mg/day flexibly dosed.
214919156|NCT00360061|BEHAVIORAL|Cognitive Behaviour Therapy|
214919157|NCT01945840|PROCEDURE|Roux en Y Gastric Bypass Surgery|
214919158|NCT01945840|OTHER|Gut hormone infusion|
214919159|NCT01945840|OTHER|Placebo infusion|
214919160|NCT01945840|OTHER|Very low calorie diet|
214919161|NCT00596817|DRUG|Placebo|capsules, daily, orally
214919162|NCT00596817|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
214919163|NCT03653962|BEHAVIORAL|video assisted group|
214919164|NCT03653962|BEHAVIORAL|non-video group|
215061260|NCT03338478|DIAGNOSTIC_TEST|Wii Balance Board|Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
214482976|NCT06739577|DIAGNOSTIC_TEST|Neuropsychological assesment is provide to measure objective and subjective cognition/emotional aspects.|Neuropsychological evaluation assess attention (Test for Attentional Performance -TAP-) and quality-of-life (DHI, HADS, and NVI).
214919165|NCT05161260|BEHAVIORAL|Yoga Breathing|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Yoga Breathing group will practice a breathing exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their breathing activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
214919166|NCT05161260|BEHAVIORAL|Attention Control|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Attention Control group will practice a mindfulness exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their mindfulness activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
214919167|NCT05915247|DRUG|HER-096|Administered as a single dose via s.c. injection
214919168|NCT05915247|DRUG|Placebo|Administered as a single dose via s.c. injection
215061261|NCT01222988|DIETARY_SUPPLEMENT|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
215061262|NCT03652766|BEHAVIORAL|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
215061263|NCT03186443|DRUG|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
215061264|NCT03186443|DRUG|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
215061265|NCT05143528|DRUG|Nilotinib BE 84mg|84 mg capsule
215061266|NCT05143528|DRUG|Nilotinib BE 112 mg|112 mg capsule
215061267|NCT05143528|DRUG|Placebo|placebo capsule
215061268|NCT01032434|DRUG|sertraline|sertraline: 50-200mg/day
215061269|NCT04693702|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
214317569|NCT06118346|BEHAVIORAL|Female-Specific Cognitive Behavioral Therapy (FS-CBT)|FS-CBT is a unique 12-session weekly group CBT treatment designed for women Veterans with AUD and/or risky drinking, and provides (1) AUD interventions, (2) general female-specific content, (3) female-Veteran content, (4) wellness and self-care, and (5) a novel 24/7 social support for abstinence discussion mobile app.
214317570|NCT06118346|BEHAVIORAL|Usual Care|Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.
214317571|NCT06869837|OTHER|Group EOİPB|Bilateral external oblique intercostal plane block under USG guidance will be applied 45 minutes before cholecystectomy surgery.
214317572|NCT05165615|DEVICE|Insulin Pump t:slim X2 with Control-IQ technology|Usage of Insulin pump t:slim X2 with Control-IQ technology in previous users of AndroidAPS
214317573|NCT06165861|OTHER|Experimental (with VR-G)|Watching video with using VR-G before undergoing open heart surgery
214317574|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management in in person group Format|The CBSM sessions will be delivered to participants in groups of ten, totaling eight sessions, each focused on a specific theme related to stress management. All participants will attend the complete sessions in person.
214317575|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management Hybrid Format|The CBSM (hybrid) sessions will be offered to participants online, including a total of eight video modules, each dedicated to a specific theme related to stress management. Participants will also have access to three interactive virtual sessions, summary sheets in PDF format, and audio recordings for relaxation.
214317576|NCT04927390|DRUG|Mycophenolate Mofetil 500mg|Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
214317577|NCT06022185|DIAGNOSTIC_TEST|Web Based Training on E-health Literacy, Digital Literacy and Healthy Lifestyle Behaviors.|"In the trainings planned for elderly individuals, digital literacy and e-health literacy levels will be improved, knowledge and awareness levels of elderly individuals will be increased and they will be provided with information in this direction. healthy lifestyle behaviors.~Personal information form, E-Health Literacy Scale, Acquisition and Confirmation of Health Information in Digital Environment Scale, Healthy Lifestyle Behaviors Scale-II will be used in the research."
214317578|NCT03027869|DEVICE|transcranial direct current stimulation|15 minute anodal stimulation 1.5mA
214317579|NCT06303115|OTHER|Nicotine Pouch P1312914, 4 mg nicotine|P1312914 pouch product
214317580|NCT06303115|OTHER|Nicotine Pouch P1312915, 8 mg nicotine|P1312915 pouch product
214482977|NCT06739681|OTHER|Routine Intervention|These routine exercises used in archery training will be applied to all participants. Exercise sessions will be planned 2 days a week, every other day, for 8 weeks. It will progress progressively according to the athlete's tolerance.
214482978|NCT06739681|OTHER|Mental Imagery Intervention|Mental Imagination will be done with Recording Audio. An audio recording will last 5 minutes. The audio recording will be listened to 3 times in one session. The total visualization session will last 15 minutes in a dark and quiet room.
214482979|NCT06739681|OTHER|Breathing Exercise Intervention|Participants participating in Pranayama training will practice in a comfortable position in a quiet room at a temperature of 25 ± 2°C. The slow pranayama technique chosen is alternate nasal breathing (Nadishodhana Pranayama).
214482980|NCT06735326|DRUG|Fluzoparib|Fluzoparib capsule (50mg per capsule) 150mg po BID
214482981|NCT06735326|DRUG|Bevacizumab|Bevacizumab injection (100mg per vial) 7.5mg/kg ivdrip Q3W
215061270|NCT02096952|DRUG|Methylphenidate extended-release liquid formulation|
214317581|NCT06303115|OTHER|Nicotine Pouch P1013215, 8 mg nicotine|P1013215 pouch product
214317582|NCT06303115|OTHER|Nicotine Pouch P1013218, 10 mg nicotine|P1013218 pouch product
214317583|NCT06303115|OTHER|Nicotine Pouch P1012919, 12 mg nicotine|P1012919 pouch product
214317584|NCT06303115|OTHER|Smoking Abstinence|No tobacco/nicotine
214317585|NCT06303115|OTHER|Continued UB cigarette smoking|Usual Brand Cigarette
214317586|NCT00003055|DRUG|cisplatin|
214317587|NCT00003055|DRUG|irinotecan hydrochloride|
214317588|NCT00560950|BIOLOGICAL|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
214317589|NCT06629311|DEVICE|Autotransfusion device|Standard cardiac surgery using I-SEP and SAME™ autotransfusion device
214317590|NCT03521986|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
214317591|NCT03521986|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
214317592|NCT03114462|RADIATION|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
214317593|NCT03114462|BEHAVIORAL|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
214317594|NCT06696690|DEVICE|MNS|The MNS treatment group use the NeuroTrac™ Multi-TENS transcutaneous electrical stimulator to provide an asymmetric biphasic pulse train with a frequency of 35 Hz, an amplitude of 20 mA and a pulse width of 300 ms, which is on for 20 seconds and off for 50 seconds. The treatment lasts for 8 hours per day and the treatment course lasts for one week.
214317595|NCT06696690|DEVICE|Sham stimulation|The sham stimulation treatment group utilized the same stimulation device and was subjected to a safe yet ineffective stimulation protocol for sham stimulation. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.
214317596|NCT04568161|PROCEDURE|Physical Characteristics|Body weight, height and waist circumference
214317597|NCT04568161|PROCEDURE|Muscular Sympathetic Nervous Activity|Microneurography technique.
214317598|NCT04568161|DIAGNOSTIC_TEST|Cardiac Function|Echocardiography.
214317599|NCT04568161|DIAGNOSTIC_TEST|Heart rate|Electrocardiography
214317600|NCT04568161|DIAGNOSTIC_TEST|Blood pressure|Non-invasive photoplethysmography.
214317601|NCT04568161|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.
214317602|NCT04568161|DIAGNOSTIC_TEST|Muscle blood flow|Venous occlusion plethysmography
214317603|NCT04568161|DIAGNOSTIC_TEST|Endothelium-dependent vascular function|Brachial ultrasound
214317604|NCT04568161|DIAGNOSTIC_TEST|Vascular intima-media thickness|Carotid ultrasound
214482982|NCT06735326|DRUG|Paclitaxel|Paclitaxel injection 135-175mg/㎡ ivdrip Q3W
214482983|NCT06735326|DRUG|Carboplatin|Carboplatin injection AUC=4-5 ivdrip Q3W
214919169|NCT00288405|DEVICE|Cordis Self Expanding Stent|
214317605|NCT04568161|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary exercise test
214317606|NCT04568161|DRUG|Anthracycline & Cyclophosphamide treatment scheme|Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
214317607|NCT05695495|DRUG|N,N-Dimethyltryptamine (5mg)|Intravenous bolus application over 45 seconds
214317608|NCT05695495|DRUG|N,N-Dimethyltryptamine (10mg)|Intravenous bolus application over 45 seconds
214317609|NCT05695495|DRUG|N,N-Dimethyltryptamine (15mg)|Intravenous bolus application over 45 seconds
214317610|NCT05695495|DRUG|N,N-Dimethyltryptamine (20mg)|Intravenous bolus application over 45 seconds
214317611|NCT05695495|DRUG|N,N-Dimethyltryptamine (25mg)|Intravenous bolus application over 45 seconds
214317612|NCT05695495|DRUG|Placebo (saline)|Intravenous bolus application over 45 seconds
214317613|NCT06701513|DRUG|Deucravacitinib|As prescribed by treating clinician
214317614|NCT03004833|DRUG|Nivolumab|Infusion of Nivolumab
214317615|NCT03004833|DRUG|Adriamycin|Infusion of Adriamycin
214317616|NCT03004833|DRUG|Vinblastine|Infusion of Vinblastine
214317617|NCT03004833|DRUG|Dacarbazine|Infusion of Dacarbazine
214317618|NCT06875024|BEHAVIORAL|Intelligent intervention programs|The intervention involves a structured exercise program, with participants in the experimental group engaging in cycling exercises three times per week, each session lasting 30 minutes during hospitalization. After discharge, they will follow a walking program, increasing their daily step count by 1,000 steps above the average recorded during hospitalization, for a total of 12 weeks. Structured questionnaires and medical records will be used for data collection at four time points: the first week of enrollment (T0), hospital discharge (T1), the eighth week post-enrollment (T2), and the twelfth week post-enrollment (T3). Additionally, a tri-axial accelerometer-equipped smart wristband will be used to monitor and record participants' heart rate, respiration, blood pressure, daily step count, and sleep quality.
214317619|NCT07027631|DEVICE|Magnesium Sulfate Iontophoresis|Magnesium Sulfate iontophoresis utilizing an iontophoretic drug delivery system
214317620|NCT07027631|DEVICE|Shock Wave Therapy|using Shock Wave Therapy Device
214317621|NCT07027631|OTHER|stretching and strengthening|stretching and strengthening exercises
214317622|NCT04846673|DRUG|Pregabalin 150mg + Alpha-lipoic acid 480mg|Pregabalin qd + alpha-lipoic acid qd
214317623|NCT04846673|DRUG|Pregabalin 150mg|pregabalin qd
214317624|NCT04846673|DRUG|Alpha-Lipoic Acid 480mg|alpha-lipoic acid qd
214919170|NCT06577077|DRUG|Product CM9241GRU|01 tablet in the morning and 01 tablet in the evening for 14 days
214919171|NCT06577077|DRUG|Placebo|01 tablet in the morning and 01 tablet in the evening for 14 days
214317625|NCT06688175|DRUG|IMRT combined with lobaplatin-based concurrent chemotherapy|IMRT combined with two cycles of lobaplatin-based concurrent chemotherapy
214317626|NCT06286735|DIETARY_SUPPLEMENT|cinnamomum|60 capsules of 500 mg of powdered cinnamomum bark (Cinnamomum verum; 40% polyphenols). Participants in this group will be instructed to consume two capsules per day, one after lunch and one after dinner for 3 months.
214317627|NCT06286735|OTHER|Placebo|60 capsules with 500 mg of corn starch per month, until the end of the three months of intervention. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
214317628|NCT06697496|DEVICE|QuitBot Smoking Cessation Chatbot Program|Participate in Quitbot chatbot program
214317629|NCT06697496|DEVICE|QuitBot Smoking Cessation Text Messaging Program|Participate in Quitbot texting program
214317630|NCT06697496|OTHER|Survey Administration|Ancillary studies
214317631|NCT06697496|OTHER|Interview|Ancillary studies
214317632|NCT06697496|PROCEDURE|Carbon Monoxide Measurement|Ancillary studies
214919172|NCT06835465|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective period.
214919173|NCT06835465|DRUG|Rifampin|Rifampin will be administered QD on Days 1 to 7 and Days 9 to 13 and as a single oral dose on Day 8 as specified for the respective period.
215061271|NCT05790044|DRUG|Bupivacaine|intra-oral infra-orbital nerve block with bupivacaine alone
215061272|NCT05790044|DRUG|Clonidine|intra-oral infra-orbital nerve block with bupivacaine and clonidine
215061273|NCT00920361|DRUG|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
215061274|NCT06400589|DRUG|tanfanercept|TNF inhibitor
215061275|NCT06400589|DRUG|Vehicle|Same composition as tanfanercept but without the active ingredient
214317633|NCT06877520|DEVICE|Pivot Extend Tricuspid Regurgitation Spacer Device|The Pivot Extend Tricuspid Regurgitation Spacer Device is an investigational implant designed to reduce tricuspid regurgitation (TR) by occupying the regurgitant orifice and improving leaflet coaptation. The device is implanted via a transcatheter procedure under imaging guidance. Following implantation, participants will undergo post-procedural monitoring for at least 24 hours to ensure safety and device stability. The device is intended for long-term placement, with scheduled follow-up assessments at designated intervals over a 12-month period to evaluate its safety and efficacy. Device removal may be performed if adverse events occur or if deemed necessary by the investigator.
214317634|NCT06879106|OTHER|Intervention group|"The Mindfulness-Based Cognitive Therapy (MBCT) intervention is an educational program consisting of the themes Mindfulness and Autopilot, Living in Our Mind, Focusing the Distracted Mind, Recognizing Hate, Allowing, Thoughts Are Not Real, How Can I Best Take Care of Myself, and Sustaining and Expanding New Learning."
214317635|NCT07030322|DEVICE|Overground Robotic Exoskeleton|Participants will have received training on their personal exoskeleton device prior to data collection. There is no required use dosage of the Ekso Indego Personal for this observational study.
214317636|NCT06880601|DRUG|Teclistamab|"Participants are planned to receive Te monotherapy during the first 5 cycles of treatment (1 cycle= 28 days) Participants will receive Te sc monotherapy consisting of 2 step-up doses (0.06 and 0.3 mg/kg) followed by a weekly treatment dose of 1.5 mg/kg for the first 2 cycles From cycle 3 Day 1, participants will receive Te sc Q2W at the dose of 3 mg/kg- From cycle 7 Day 1, participants will receive Te sc Q4W at the dose of 3 mg/kg.~After cycle 5, participants in PR or better will continue treatment with Te in combination with 4 Ali infusions (cycles +6, +9, +12, +15). The four doses of ALI will be administered with increasing dosage during Te treatment as follows:~* before Te Cycle 6: ALI 10 x 10\^6/kg~* before Te Cycle 9: ALI 20 x 10\^6/kg~* before Te Cycle 12: ALI 30 x 10\^6/kg~* before Te Cycle 15: ALI 40 x 10\^6/kg~Teclistamab single agent will be continued until progression, unacceptable toxicity or patients refusal."
214317637|NCT06685887|DRUG|HIPEC|HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery.
214317638|NCT06685887|DRUG|SOX|Oxaliplatin, 130 mg, i.v. + S-1 (40 mg per dose for BSA \<1.25; 60 mg per dose for BSA 1.25 to 1.5; 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle d1-14, q3w
214317639|NCT06685887|DRUG|Immune Checkpoint Inhibitors|Tislelizumab, 200 mg, q3w
214317640|NCT06709456|PROCEDURE|Ultrasonography-guided pleural drainage|Ultrasonography-guided pleural drainage with insertion of a small-bore intrapleural catheter. Contralateral and repeated drainage conducted as specified during ICU stay until day 90.
214317641|NCT06880861|OTHER|Non-Interventional Study|Non-Interventional Study
214317642|NCT06699797|DEVICE|Acclaim Cochlear Implant|Participants with the Acclaim CI device will be tested during follow-up with their hearing results compared to baseline (before the device implant procedure).
214317643|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine low dose formulation 1|Candidate UTI vaccine low dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
214317644|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine low dose formulation 2|Candidate UTI vaccine low dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
214317645|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine medium dose formulation 1|Candidate UTI vaccine medium dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
214317646|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine medium dose formulation 2|Candidate UTI vaccine medium dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
214317647|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine high dose formulation 1|Candidate UTI vaccine high dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
214317648|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine high dose formulation 2|Candidate UTI vaccine high dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
214317649|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine HTD formulation 2|Candidate UTI vaccine HTD formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
214317650|NCT06702449|COMBINATION_PRODUCT|Placebo|Placebo administered intramuscularly according to a 0, 2 months administration schedule.
214482984|NCT06893159|DEVICE|INSTI HIV-1/2 Antibody Test|The INSTI HIV-1/HIV-2 Antibody Test is a single use, rapid, in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus Type 1 and/or Type 2 (HIV-1/HIV-2) in human venipuncture whole blood, fingerstick blood, or plasma specimens. The test is intended for use by trained personnel in point of care and laboratory situations to aid in the diagnosis of HIV infections. If multiple rapid HIV tests are available, this test is suitable for use in appropriate multi-test algorithms.
214482985|NCT06893159|DEVICE|INSTI Multiplex HIV-1/2 Syphilis Antibody Test|The INSTI MULTIPLEX HIV-1/2 Syphilis Ab Test is a single use, rapid, flow-through in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus Type 1/ Type 2 and Treponema pallidum in human fingerstick blood and serum. The INSTI Multiplex Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and Syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than one minute. Although suitable for near-patient point-of-care (POC) testing, the INSTI Multiplex Test is not suitable for self-testing.
214317651|NCT06703125|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
214482986|NCT06893159|DEVICE|Multiplo Complete Syphilis (TP/nTP) Antibody Test|"Multiplo Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) is a single use, manually performed, visually interpreted, qualitative immunoassay based on Rapid Vertical Flow Technology® for the detection of antibodies to Treponema pallidum (TP), the causative agent of syphilis, and to nontreponemal (nTP; \[RPR titer ≥ 1:8\]) antigens in human serum, plasma, or fingerstick whole blood specimens. Nontreponemal antibodies are called reagins and they are generated after the tissue damage caused by syphilis infection.~Multiplo® TP/nTP is intended for use by healthcare professionals as an aid in the diagnosis of active syphilis infection."
214482987|NCT06741137|PROCEDURE|inhaled nitric oxide combined with prone position ventilation|inhaled nitric oxide combined with prone position ventilation
214482988|NCT06893692|OTHER|Otago exercise program|Experimental group: Group A will perform the Otago Exercise Program. The training protocol consisted of ten repetitions, with a 60-second rest interval between sets. The training protocol consisted of three sessions per week for 12 weeks.
214482989|NCT06893692|OTHER|Balance Training Exercises|Controlled group: Group B will perform Balance Training Exercises for 12 weeks of three sessions per week. BT included exercises such as a single-leg stance with eyes open and closed, standing on heels or toes, tandem and semi-tandem foot stance, tandem walking, walking backward and forward, and weight shifting.
214482990|NCT06042153|DRUG|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
214482991|NCT06042153|DRUG|Placebo|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
214482992|NCT06746636|DEVICE|High velocity nasal insufflation|• HVNI was supplied using a Vapotherm Precision Flow \[Precision Flow Plus, Vapotherm, INC. U.S.A. device\].
214482993|NCT06786624|DRUG|NBI-1065845|NBI-1065845 tablets
214482994|NCT06786624|DRUG|Placebo|Matching placebo tablets
214482995|NCT06794320|OTHER|NF Protocol|The daily practice of physicians in evaluating and treating patients with sNF.
214482996|NCT06794320|OTHER|ASTERIC protocol|i. Risk-assessment tools
214482997|NCT06794320|OTHER|ASTERIC protocol|ii. Fast track absolute neutrophil counts turnaround service
214671697|NCT00917410|BEHAVIORAL|SMS support|"The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.~1. Remember to take your preventive asthma medication (sent at 8.00 am).~2. Were you awakened during the night due to your asthma? Answer YES or NO.~3. How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.~4. What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study)."
214919174|NCT06829771|DRUG|TQB2825 injection +R-CHOP regimen|"R-CHOP is a cancer treatment regimen that uses a combination of five drugs to treat non-Hodgkin lymphoma, e.g., Rituximab+Cyclophosphamide+Doxorubicin Hydrochloride+Vincristine+Prednisone (R-CHOP).~TQB2825 Injection: TQB2825 is a bispecific antibody targeting the cluster of differentiation 20 (CD20) receptor on tumor cells and the cluster of differentiation 3 (CD3) receptor on T cells.~Rituximab: A monoclonal antibody that binds to the CD20 antigen on the surface of B cells.~Cyclophosphamide: An alkylating agent that inhibits the synthesis of DNA and proteins in cancer cells.~Doxorubicin Hydrochloride: An antineoplastic antibiotic that inhibits the synthesis of DNA and RNA.~Vincristine: A microtubule inhibitor that blocks the normal function of microtubules during cell division.~Prednisone: A corticosteroid drug with anti-inflammatory, anti-allergic, immunosuppressive, and anti-cancer effects.~TQB2825 injection + GemOx (Gemcitabine + Oxaliplatin)"
214919175|NCT06829771|DRUG|TQB2825 injection + GemOx|"TQB2825 Injection: TQB2825 is a bispecific antibody targeting the CD20 receptor on tumor cells and the CD3 receptor on T cells.~Gemcitabine: A nucleoside analog that inhibits DNA synthesis. Oxaliplatin: A platinum-based chemotherapy drug that forms cross-links with DNA, inhibiting DNA replication and transcription."
214919176|NCT06787196|DRUG|Dexamethasone|Dexamethasone, single-dose, 8 mg IV administered intraoperatively
214919177|NCT02331914|PROCEDURE|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
214482998|NCT06794320|OTHER|ASTERIC Protocol|iii. A decision tool for patient management and initial antibiotic use
214317652|NCT04629417|DEVICE|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.
214482999|NCT06794320|OTHER|ASTERIC Protocol|iv. A decision tool for patient management and subsequent antibiotic use
214483000|NCT06794320|OTHER|ASTERIC Protocol|v. An educational package
214317653|NCT06722521|DRUG|Pitavastatin 4mg and ezetimibe 10mg, taken once daily|Intensive lipid-lowering therapy without aspirin
214317654|NCT06722521|DRUG|Pitavastatin 2 mg with aspirin 100 mg, taken once daily.|Moderate-intensity lipid-lowering therapy with aspirin
214317655|NCT06886295|DEVICE|Prosthetic controller|The intervention includes an upper limb prosthesis composed at the minimum by skin-surface electrodes for myoelectric signals, a vibrotactile actuator, a multi-articulated and instrumented hand prosthesis and a centralized control system. The centralized prosthetic controller processes the myoelectric signals acquired at the residual limb to enable the movements on the multi-articulated prosthesis.
214317656|NCT05177198|PROCEDURE|M-MIST + Clindamycin augmented PRF|modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
214317657|NCT05177198|PROCEDURE|M-MIST + PRF|modified minimally invasive surgical technique with platelet-rich fibrin alone.
214919178|NCT02331914|PROCEDURE|Tumor biopsy|Tumor biopsy after disease progression
214919179|NCT04662905|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|ECAP-controlled, closed-loop SCS
214919180|NCT06953141|DIAGNOSTIC_TEST|Ultrasound|Transabdominal and transvaginal imaging will be performed to eligible women following gynecological surgery within 24 - 48 hours.
214919181|NCT06163469|DEVICE|Bladder instillation with Irrisept|9 months of bladder instillations (3 months of saline and 6 months of chlorohexidine gluconate)
214919182|NCT05214859|BEHAVIORAL|The Dyadic Expressive Arts Group Therapy|This therapy utilizes different art modalities, such as visual art, music, movement, dance, drama, and writing, as therapeutic means. With multiple sensory stimulations from different art forms, the therapy facilitates communication, expression, perception, and interactions. The therapy consists of 8 weekly 90 minutes sessions, with 3-4 mother-child dyads in each therapy group. Each session will follow the basic structure of Expressive Arts Therapy, including check-in, warm-up, core art-making, sharing, and closure. The following themes related to the mother-child relationship will be included, such as communication, relationship, expression, empathy, interaction, love, gratitude, and connection.
214919183|NCT03582774|OTHER|Best Practice|Undergo standard of care
214483001|NCT06794320|OTHER|ASTERIC Protocol|vi. A decision tool for patient disposal - discharge or emergency department ward observation
214483002|NCT05417165|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|Given IM
214483003|NCT05417165|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM
214483004|NCT05866926|DRUG|FAB122|FAB122 Daily dose 100 mg
214483005|NCT01815359|PROCEDURE|Cytoreductive Surgery|Optimal Surgical Debulking
214919184|NCT03582774|PROCEDURE|Computed Tomography|Undergo PET/CT
214919185|NCT03582774|RADIATION|Gallium Ga 68-labeled PSMA-11|Given IV
214919186|NCT03582774|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214317658|NCT06728072|DRUG|Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin|Metronidazole, ciprofloxacin, aspirin is initiated Cycle 1 Day 1 of chemotherapy. May be initiated any time from 7 days before Cycle 1 Day 1 up to and including Cycle 1 Day 3
214317659|NCT06888804|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms.
214317660|NCT06888804|OTHER|Control Group|No intervention
214317661|NCT06716138|DRUG|ANS03|ANS03 is a rationally next generation TKI targeting both ROS1 and NTRK developed by Shenzhen Avistone Biotechnology (the sponsor).
214317662|NCT07044180|DRUG|pipecuronium bromide|Investigation of muscle relaxation with pipecuronium bromide
214317663|NCT07044180|DRUG|Rocuronium bromide|Muscle relaxation with rocuronium as a control
214317664|NCT06740344|PROCEDURE|Two-handed facemask hold|Two-handed mask hold technique while giving facemask ventilation, with another operator designated to deliver PIP via the T-piece.
214317665|NCT06740344|PROCEDURE|Control: One-handed facemask hold|One-handed mask hold technique while giving facemask ventilation, with the same operator holding the mask and delivering PPV via the T-piece.
214317666|NCT06736808|OTHER|Handout Written at Below a Sixth Grade Reading Level|Participants randomized to this experimental arm will read a simplified handout on pelvic organ prolapse written at below a sixth grade reading level.
214483006|NCT01815359|DRUG|HIPEC with Mitomycin-C|
214483007|NCT01815359|DRUG|EPIC with FUDR and Leucovorin|
214483008|NCT06755320|OTHER|mechanical ventilation (MV)|Mechanical ventilation APRV mode ( Airway Pressure Release Ventilation )
214483009|NCT06755320|OTHER|mechanical ventilation (MV)|Mechanical Ventilation in BiPAP mode (Bi-Level Positive Airway Pressure Ventilation )
214483010|NCT06754592|DEVICE|Ultrasound|evaluate the effectiveness of dynamic high-resolution ultrasonography in identifying various abnormalities of the shoulder impingement syndrome, especially the subacromial type, and to determine the added value of dynamic ultrasonography compared to static examination of such cases. Furthermore, we will compare these findings to MRI
214919187|NCT05859568|DEVICE|Pinna-located microphone|Sound processors using a pinna-located microphone
214919188|NCT05859568|DEVICE|Pinna-simulated microphone algorithm|Sound processors using a pinna-simulated algorithm
214919189|NCT06022848|PROCEDURE|occipital nerve stimulator|Quantitative sensory testing
214919190|NCT02636231|DRUG|Endostatins|Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
214919191|NCT02636231|RADIATION|IMRT|IMRT is to give GTV 60Gy in 27 fractions.
214919192|NCT04200443|DRUG|Cabozantinib|Given PO
214483011|NCT06766474|DRUG|Bupivacain|to our knowledge, this study is the 1st to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus subcutaneous infiltration for postoperative donor site pain control for patients undergoing STSG procedures.
214317667|NCT06736808|OTHER|Handout Written at Above a Sixth Grade Reading Level|Participants randomized to this control arm will read a standard handout on pelvic organ prolapse written at above a sixth grade reading level.
214317668|NCT06891300|DRUG|ketamine hydrochloride|Participants will undergo intravenous (IV) ketamine infusions (0.5 mg/kg infused over 40 minutes) under medical supervision. Treatments will be administered twice weekly for two weeks, for a total of four infusions.
214317669|NCT00366990|BEHAVIORAL|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics with a focus on lowering sodium intake.
214317670|NCT00366990|BEHAVIORAL|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics.
214317671|NCT07109661|BEHAVIORAL|Rational Positive Parenting Program (rPPP)|The Rational Positive Parenting Program (rPPP) is a structured cognitive-behavioral group intervention based on Rational Emotive Behavior Therapy (REBT). It comprises 8-10 weekly sessions focused on addressing irrational parenting beliefs, improving emotion regulation, and teaching positive behavior management strategies for children with disruptive behaviors. Participants in the control group will not receive the intervention during the active phase, but will be offered the rPPP after final assessment to ensure ethical treatment.
214317672|NCT07108543|PROCEDURE|Antegrade versus retrograde cross k-wire|\> Closed reduction of distal radius fracture followed by percutaneous insertion of two or more K-wires in an antegrade direction (from proximal to distal), crossing the fracture site under fluoroscopic guidance. The wires are introduced from the radial metaphysis and directed distally to stabilize the fracture.
214483012|NCT04490057|DRUG|Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler|Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.
214483013|NCT04490057|DRUG|Varenicline or bupropion|Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).
214483014|NCT04490057|BEHAVIORAL|Contingency Management|Participants will be financially rewarded for abstinence to tobacco.
214317673|NCT06895811|BIOLOGICAL|PSMA-UCAR T (BRL-302)|"Three patients will be firstly enrolled at a dose level (DL) of 5.0 × 10\^6cells/kg in the DL1 group, following lymphodepleting chemotherapy which will be given under instruction of protocol and investigators' assessment;~Based on preliminary safety data, efficacy information, and PK/PD parameters obtained at DL1 cohort, the investigator may enroll another three patients in a decreased dose level group of DL-2: 3 × 10\^6 cells/kg or DL-1:1 × 10\^6 cells/ kg, after thorough discussions between the investigators."
214317674|NCT06776965|OTHER|Dietary Questionnaire|Self administered dietary questionnaire at baseline, 6 and 12 months.
214317675|NCT06776965|OTHER|Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)|Self administered questionnaire of disease activity at baseline, 6 and 12 months.
214483015|NCT06761014|OTHER|Instrumental assisted soft tissue mobilization|instrument will be held at 45° angle and the IASTM treatment will be administered for about 20 seconds in a direction parallel to the muscle fibers being treated with deep strokes
214483016|NCT06761014|OTHER|Sustained stretching|The therapist will apply the pressure or ask to maintain the stretch. A total of thirty seconds, divided into three sets of stretches at each intervention, with ten seconds of rest in between
214919193|NCT04200443|OTHER|Quality-of-Life Assessment|Ancillary studies
214919194|NCT04200443|OTHER|Questionnaire Administration|Ancillary studies
214317676|NCT06844331|DEVICE|Thoracic ultrasound|The investigators want to investigate that TUS/US can use to identify and to monitir the disease progression in the patients with F-ILD
214483017|NCT06772649|OTHER|Compression sleeve|The Bauerfeind compression sleeve is a fabric sleeve designed to support the ankle during movement. It's made of a compressive knit material that increases sensorimotor feedback, enhances blood circulation, and stimulates metabolism. The design helps reduce ligament strain, activates the foot's stabilizing muscles more quickly, and improves joint coordination.
214483018|NCT06758557|DRUG|HB0025|HB0025 IV every 3 weeks (q3w)
214483019|NCT06758557|DRUG|Pemetrexed|500 mg/m² iv d1
214483020|NCT06758557|DRUG|Paclitaxel|175 mg/m² iv d1
214483021|NCT06758557|DRUG|Carboplatin|AUC 5 iv d1
214483022|NCT06761989|DRUG|Intrathecal morphine injection|A single dose of intrathecal morphine is administered prior to induction of general anesthesia. The patient is placed in the lateral decubitus position on the bed and a 25 guage quincke spinal needle is inserted intrathecally at the L4/5 median or paramedian approach to administer 0.2 mg of morphine.
214483023|NCT06761989|DEVICE|Continuous wound infiltration|Prior to closure of the abdominal wall, a catheter is placed in the preperitoneal space lateral to the surgical incision through the tunneler. The catheter is connected to a prepared infusion pump (275 ml of 0.5% ropivacaine, 4 ml/hr/catheter), and the remaining catheter protruding from the abdomen is secured with a catheterization dressing. The preperitoneal catheter is removed in the afternoon of postoperative day 3.
214483024|NCT06761027|DRUG|Anlotinib combined with Sintilimab|Based on the mFOLFIRINOX chemotherapy regimen, combined with the safe dose of anlotinib determined in phase Ib and sintilimab.
214671698|NCT05574816|DEVICE|Phi-Bra prototype measurements|"The bra prototype will be placed on the patient's breast. The patient will stay in a half-lying position during 15 min, the time duration of the measurements. Measurements will not be painful.~Measurements will only be realized one time during the first and unique visit of the patient."
214919195|NCT04200443|DRUG|Temozolomide|Given PO
214919196|NCT06963047|DIAGNOSTIC_TEST|Ultrasound|The purpose of the test is to diagnose and assess the amount of blood loss.
214919197|NCT06963047|OTHER|Standard care|Routine management
214919198|NCT02822378|DIETARY_SUPPLEMENT|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
214919199|NCT02822378|DIETARY_SUPPLEMENT|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
214919200|NCT02822378|DIETARY_SUPPLEMENT|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
214317677|NCT06898658|BEHAVIORAL|Mindfulness Intervention|"Hybrid MAPs course will be delivered by a Spanish-speaking Latina certified mindfulness instructor, with a blend of in-person instruction, online instruction and asynchronous (audio-recorded) content instruction over 6-wks. There will be three live-2hr classes (2 in-person, 1 online) and three 3 weeks of 1-hr self-guided audio/week asynchronous content (1hr/wk). Additionally, the instructor will invite the intervention group to join optional weekly via Zoom 1x/wk for 30-min sessions for time to encourage questions, dialogue, and brief group mindfulness practice opportunities.~Class attendance and engagement with audio-recorded materials will be tracked. The study team will call or text participants weekly to maintain engagement, remind about any upcoming scheduled classes, and answer any questions. Participant attendance in classes (in-person and zoom) will be monitored."
214317678|NCT05491551|BEHAVIORAL|Mindfulness-Based Treatment-Regulation of Craving|"Participants will be trained in using the MBT-based mindfulness strategy as described above (notice craving and accept the feeling without judgment or reaction). Participants will then be instructed to think of accepting and non-reactive responses when they see the instruction ACCEPT during ROC-T. On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see ACCEPT and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale."
214317679|NCT05491551|BEHAVIORAL|Cognitive-Based Therapy-Regulation of Craving|"Participants will be trained in using the CBT strategy by first considering and reading about the negative consequences of drinking. Participants will then be instructed to think of those negative consequences (Focus on the negative consequences associated with drinking) when they see the instruction REFRAME during ROC-T.On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see REFRAME and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale"
214317680|NCT05716139|PROCEDURE|Natural Cycle|The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH \< 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.
214317681|NCT05716139|PROCEDURE|Artificial Cycle|Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
214317682|NCT06874452|DRUG|Xanax|The patients will each receive a single tablet of 0.5mg XANAX 30 minutes before surgery. Patients older than 65 years or with liver disease will receive a reduced dose of 0.25 mg rather than 0.5 mg of oral XANAX 30 minutes before surgery.
214317683|NCT06874452|OTHER|Placebo Tablets|The patients will each receive a single tablet of placebo 30 minutes before surgery.
214317684|NCT05535777|BEHAVIORAL|Enhanced texts with Callback by a Person|"Enhanced texts - Callback by a person: Patient randomized to this study arm will receive a phone call back by a call center agent if they press 1 in response to a question on the original text message. The call center agent's job is to schedule patients for clinical visits. These call center agents will be trained by our faculty and staff and will have the usual HIPAA and other patient confidentiality training."
214483025|NCT05997784|OTHER|Performing lung function tests (spirometry and fraction of exhaled nitric oxide (FeNO))|"Performing lung function tests and FeNO following European Respiratory Society (ERS) standardized guidelines, through the MIR portable spirometer and the NIOX Vero®, respectively.~Spirometry is performed using a portable spirometer. All manoeuvres are performed according to the American Thoracic Society and European Respiratory Society (ATS/ERS) standards.~FeNO test is a quick and non-invasive test that is easy for children to do. To take the test, the child have to blow into a handheld device (NIOX Vero®). More in detail, children are asked to inhale ambient air through a nitrogen oxide scrubber to total lung capacity, and then exhale for 10 seconds. The test results are available right away."
214483026|NCT05997784|OTHER|Filling of standardized questionnaires|"(Baseline, Follow-up, Quality of life and Final) allowing to collect data on sociodemographic characteristics, health outcomes, potential risk factors, lifestyle and living environment.~Health outcomes will consider general health (general status, infections, allergies), respiratory health (asthma symptoms, diagnosis, control, triggers, medications, etc.), perception of health and well-being."
214671699|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
214671700|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
214671701|NCT00435539|DRUG|Sham Comparator|Intravitreal sham injection
214919201|NCT05173831|DRUG|Midomafetamine|Initial dose of 120 mg midomafetamine HCl and optional supplemental dose of 60 mg 1.5 to 2 hours later
214919202|NCT05173831|BEHAVIORAL|Therapy|Manualized therapy performed by therapist team
214919203|NCT05817539|PROCEDURE|Fluid balance negativation|"During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .~When the patient's baseline body weight is reached the UF net will be settled to maintain it.~In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min and without tissue hypoperfusion."
215061276|NCT02739386|BIOLOGICAL|Ipilimumab|Intravenous monoclonal antibody injection
214671702|NCT01248806|RADIATION|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
214919204|NCT05817539|PROCEDURE|Body weight Stabilization|"During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.~In case of weight stabilisation failure ( variation \>3% after 24h), the UF net can be increased to 1,5 ml/kg/h, as long as high intakes require UFnette at 1.5mL/kg/h to stabilize water balance, with daily reassessment.~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min."
214919205|NCT01364688|DRUG|oral alfacalcidol|Oral alfacalcidol 0.5 microgram per day
215061277|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
214317685|NCT05535777|BEHAVIORAL|Enhanced Bidirectional Texts|"Patients randomized to this study arm will receive a text message from a call center agent if they press 1 in response to a question on the original text message. The bidirectional texts will have an agent who can answer questions and schedule an appointment through text message back-and-forth conversations with the patient."
214317686|NCT06803797|BEHAVIORAL|Behavior Change Technique Package|"Behavior Change Technique 1: Goal setting (Behavior) (BCT 1.1). Goal setting for behavior is defined as setting a goal for the behavior to be achieved.~Behavior Change Technique 2: Action planning (BCT 1.4). Action planning is defined as detailing the plan of where, for how long, and at what time taking medication is going to be performed.~Behavior Change Technique 3: Self-monitoring of behavior (BCT 2.3). Self-monitoring of behavior is defined as monitoring and recording behavior.~Behavior Change Technique 4: Prompts/Cues (BCT 7.1) This BCT is defined as prompt rehearsal and repetition of the behavior in the same context repeatedly, so that the context elicits the behavior."
214317687|NCT06832137|OTHER|CMTS4520 (dietary fiber probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 2 weeks of CMTS4520 daily for chronic constipation.
214317688|NCT06832137|OTHER|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
214317689|NCT06904599|DRUG|Human chorionic gonadotropin (hCG)|2500 IU intramuscular on days 1, 3, and 5 of the protocol. Patients who have at least a partial response by day 7 will receive 3 weekly doses for an additional 4 weeks.
214317690|NCT06904599|DRUG|Prednisone|Oral prednisone 1 mg/kg/day for 14 days
214317691|NCT06904599|DRUG|Dexamethasone|IV dexamethasone 0.15 mg/kg/day for 14 days
214317692|NCT04009655|OTHER|music|music selected by musician
214317693|NCT03642691|BIOLOGICAL|Ryplazim|Plasminogen IV replacement therapy
214317694|NCT07096518|OTHER|ChatGPT-Integrated Lecture|This group received a structured and interactive educational lecture integrated with ChatGPT, an AI language model, enabling students to learn collaboratively through guided activities related to endotracheal suctioning. Students compared the information obtained from ChatGPT with evidence-based, up-to-date clinical guidelines and discussed the comparison results together in the classroom. The instructor provided guidance throughout the process.
214317695|NCT06499350|DRUG|FC084CSA+Tislelizumab combination (dose escalation)|Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy
214317696|NCT06499350|DRUG|RP2D of FC084CSA+Tislelizumab combination (dose expansion)|RP2D of FC084CSA+fixed dose Tislelizumab combination therapy
214317697|NCT05550623|DEVICE|Tourniquet|Tourniquet use in transfemoral amputation.
214317698|NCT07108751|DEVICE|Endoscopy|Endoscopy will be performed to all patient
214317699|NCT06924515|PROCEDURE|Intercostal suture|止血完成后使用结扎缝合引线器夹持1-0规格的PDS可吸收缝线在主操作口的头侧上一肋间穿入，于副操作空使用双关节分离钳在胸腔内抓持缝线后将缝线从结扎缝合引线器脱离，此时在主操作口足侧下一肋间穿入结扎缝合引线器，在胸腔内由分离钳夹持缝线经结扎缝合引线器钩爪夹持后将缝线牵拉出胸腔外，以此依次行连续缝合共5次缝合引线操作后拉拢缝线将主操作口闭合，打结结束缝合完成肋间肌及壁层胸膜的缝合。
214317700|NCT06924892|BEHAVIORAL|Music Therapy|Independent music therapy 45-minute sessions provided weekly for 3 months
214317701|NCT06924892|OTHER|Wellness Concerts|Wellness Concerts provided at partner sites (Carnegie Hall Weill Music Institute, Cooper Union College, Third Street Music Settlement).
214317702|NCT06924554|BEHAVIORAL|Motivational Training Program|This study presents the protocol for a non-randomized controlled trial evaluating a motivational-based training program for pre-service Physical Education teachers, grounded in Self-Determination Theory and the circumplex model. The program, embedded in a Master's in Physical Education Teacher Education, consists of theoretical and practical training to foster motivating teaching styles and minimize demotivating ones. The study will involve at least 38 pre-service teachers, divided into an experimental group (n = 19) and a control group (n = 19). The experimental group will participate in a 14-hour training program combining theoretical and practical components. The control group will follow the standard Physical Education Teacher Education curriculum.
214317703|NCT06924203|PROCEDURE|AmaIgam|(AmaIgam group): 30 carious moIars, wiII be restored with (amaIgam).
214317704|NCT06924203|PROCEDURE|Stainless steel|A pre-formed stainless steel crown will be cemented over the carious molar without extensive tooth preparation or caries removal.
214671703|NCT00601289|DRUG|temozolomide|
214671704|NCT00601289|GENETIC|DNA methylation analysis|
214671705|NCT00601289|GENETIC|microarray analysis|
214671706|NCT00601289|GENETIC|protein expression analysis|
214671707|NCT00601289|GENETIC|proteomic profiling|
214671708|NCT00601289|OTHER|laboratory biomarker analysis|
214919206|NCT01364688|DRUG|no drug|no drug
214919207|NCT06144125|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
214919208|NCT06144125|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
214919209|NCT06337890|PROCEDURE|Zero contrast FEVAR|Use of automated CO2 angiographies with Fusion Imaging for zero contrast FEVAR
214919210|NCT06290843|PROCEDURE|Schroth method|Exercises from Schoth method
215061278|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
214919211|NCT06600126|BEHAVIORAL|Coping Skills Training|The Coping Skills Training arm will consist of 12 weekly 30-minute sessions via videoconferencing or phone. A trained research staff member will deliver sessions that focus on building coping skills for patients with COPD, such as progressive relaxation training, pleasant activity scheduling, and building communication skills. Caregivers will also participate, learning how to support the patient in using these skills. Participants will complete assignments between sessions to reinforce their learning. Additionally, participants will receive a Coping Skills Training workbook.
214919212|NCT06600126|BEHAVIORAL|COPD Education|The COPD Education arm will consist of 12 weekly 10-minute sessions via videoconferencing or phone. A trained research staff member will provide scripted general support and encouragement without using specific psychoeducational techniques. Caregivers will also participate. Additionally, participants will receive a COPD Education workbook with material from The COPD Foundation, which is also available on the Foundation's website. This program augments usual care, providing an attention control for comparison.
214919213|NCT00129688|DRUG|cloxacillin and amikacin (once or twice daily dosage)|
215061279|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
214317705|NCT06924216|PROCEDURE|alveolar bone grafting|"cancellous iliac crest bone will be harvested following the usual surgical procedure. For patients of group a-PRF, it was mixed with 1 cc of the supernatant previously collected, in order to obtain a cohesive bone graft, easier to manipulate.~The oral mucosal lining will be closed, and a membrane of PRF (PRF group) will be put over the suture line. The alveolar cleft will be then filled with cancellous iliac crest bone along its entire height. A new membrane of PRF will be placed over the bone graft, in order to enclose and protect it. Finally, muco-periosteal flaps will be advanced and sutured without tension over the alveolar crest"
214483027|NCT05997784|OTHER|Using an App on a device|"Children will have to answer a daily questionnaire on cell phone, tablet, computer...), with the help of parents/caregivers.~To encourage children to answer the questions, the questionnaires will be incorporated into a game that will also teach them about environmental challenges and pollutants in Europe.~There will be a general health questionnaire with 3 questions assessed on a Likert scale.~The application will also include 2 questions on respiratory health, with Yes/No answers. If the answer is Yes to one of the questions, the intensity of symptoms will be assessed on a visual analog scale from 0 to 100 (0 almost no symptoms and 100 the most intense symptoms imaginable)."
214671709|NCT06024577|BEHAVIORAL|Walking|Prescribed 150 minutes per week of moderate to vigorous walking.
214671710|NCT06024577|BEHAVIORAL|Variety|Prescribed 150 minutes per week of moderate to vigorous variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training.
214671711|NCT06024577|BEHAVIORAL|Progressive|Prescribed 150 minutes per week of moderate to vigorous progressive variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training. Participants can choose which exercise they want to do, and can do as much or little as they want.
214919214|NCT04807309|DRUG|Danazol Pill|Danazol 200 mg orally twice a day
214919215|NCT04807309|DRUG|Placebo|Placebo twice a day
215061280|NCT02350335|DRUG|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
215061281|NCT05941208|PROCEDURE|continuous fascia iliaca compartment block|ultrasound Patients were in supine position and the puncture site was selected at 1 cm below the junction point at 1/3 of the connection of anterior superior spine and pubic tubercle. An ultrasound apparatus (Sonosite) high-frequency probe was placed in parallel to the inguinal fold to distinguish the femoral fascia and fascia iliaca, the needle was inserted with out-of-plane technique at an angle of 45° and the tip of the needle was pointed to the head. Once needle-tip placement under the fascia iliaca by hydrolocation was confirmed, the probe was rotated 90° into a longitudinal parasagittal orientation to visualize the needle tip in-plane and to track cephalad spread of the injectate under fascia iliaca, identification of the fascia iliaca plane through the linear probe and introducing epidural catheter 18 G , continuous infusion of bupivacaine 0.25% by a set rate of 7 ml per hour for 24 hours,
215061282|NCT00066222|DRUG|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
215061283|NCT00066222|DRUG|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
215061284|NCT00066222|RADIATION|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
215061285|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
215061286|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
215061287|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 3|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
214317706|NCT06924216|PROCEDURE|alveolar bone grafting Plus Platelet rich fibrin|"the PRF group: centrifugation at 1300 rpm during 5 minutes, collection of 1 cc of the supernatant, and centrifugation at 1300 rpm during 3 minutes. Careful removal of the clot and separation from the red blood cell fraction with scissors.~the Platelet-rich fibrin will be added to the surgical site mixed with the iliac crest bone graft and it will also be used as a membrane before closure of the mucoperiosteal flap"
214317707|NCT06923228|DRUG|CGB-500 Ointment with 1% tofacitinib|experimental drug
214317708|NCT06923228|DRUG|Ruxolitinib 1.5% Cream QD|topical cream
214317709|NCT05238883|DRUG|HFB200301|Participants will be administered HFB200301 as described in the experimental arm.
214671712|NCT00000451|DRUG|sertraline|16 week outpatient study
214671713|NCT00000451|DRUG|naltrexone|16 week outpatient study
214671714|NCT03955029|OTHER|Progressive Interval training|heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session).
214317710|NCT05238883|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
214317711|NCT01076712|OTHER|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
214317712|NCT01076712|OTHER|Education Classes|Education Classes
214317713|NCT05774847|OTHER|No intervention|No intervention
214317714|NCT01090726|DEVICE|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
214317715|NCT01090726|DEVICE|Airtraq|Airtraq being used for the actual intubation
214317716|NCT01119911|OTHER|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
214317717|NCT05626036|DEVICE|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
214671715|NCT03955029|OTHER|Conventional Interval training|warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session)
214919216|NCT06280144|BIOLOGICAL|Influenza Vaccine, Live, Nasal, Freeze-dried|The titer of live attenuated influenza virus containing A (H1N1) and A (H3N2) should not be less than 6.9 lg EID50, and the titer of live attenuated influenza B virus should not be less than 6.4 lg EID50
214317718|NCT05626036|DEVICE|Synthes Fibulink|High-tensile strength suture syndesmosis repair
214317719|NCT00283660|DIETARY_SUPPLEMENT|10 mg zinc oxide|10 mg zinc oxide
214317720|NCT00283660|OTHER|Placebo|Placebo pill taken five days a week for six months.
214317721|NCT00301405|DRUG|Thalidomide|Open label drug
214919217|NCT06280144|OTHER|Sterile water for inhalation|Sterile water for inhalation
214919218|NCT02857400|OTHER|current standard of care|connection documentation faxed to GP (General practitioner) on the day of patient's discharge
214317722|NCT03833076|DEVICE|Medical device Procto|Medical device Procto presents itself as a translucent green gel with a typical smell.
214317723|NCT03833076|DEVICE|Matching placebo|IP placebo presents itself as a translucent green gel with a typical smell.
214317724|NCT04623164|DRUG|Cocktail from complex phytoadaptogens (CFA)|Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
214317725|NCT04623164|PROCEDURE|Standard non-surgical periodontal treatment (NSPT)|Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
214317726|NCT04311034|DRUG|RC48|Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
214317727|NCT04302571|BEHAVIORAL|combined aerobic and resistance physical activity|Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
214317728|NCT04302571|BEHAVIORAL|sham exercise|general recommendation to perform regular aerobic physical activity
214317729|NCT02460640|PROCEDURE|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
214317730|NCT02460640|PROCEDURE|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
214317731|NCT02460640|DRUG|Morphine|
214317732|NCT02460640|DRUG|Ropivacaine|
214317733|NCT01457872|BEHAVIORAL|Strength-based case management|Strength-based case management
214671716|NCT03743558|BEHAVIORAL|smartphone homemade video|value of a video recording of the child sleep on smartphone made by the parents
214671717|NCT04221074|PROCEDURE|PECS II versus ESP|compare between :ultrasound guided Pectoralis nerve(pecs) II block or erector spinae plane (ESP) block in surgical treatment for gynecomastia patients under general anaesthesia.
214671718|NCT03249896|BEHAVIORAL|Habits-GDM mobile app|The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
214317734|NCT01457872|BEHAVIORAL|Control condition - referral only|Referral only
214483028|NCT05997784|OTHER|Urine sample|On a voluntary basis, a urine sample will be collected, as well.
214483029|NCT05997784|OTHER|Sensors and devices will be used to assess air pollutants in classrooms during the survey|"* Particulate matter (PM) will be assessed with a counter as a well as a remote sensor (Canarin) .~* Volatile Organic Compound (VOCs) with a passive sampler (Radiello).~* Virus and bacteria will be collected with a pump.~The devices will be attached to the classroom wall.~In addition, dust pollution will be assessed by collecting dust with a vacuum cleaner in order to assess phthalates (Dimethyl phthalate, diethyl phthalates, Di(2-ethylhexyl) phthalate)."
214671719|NCT06111573|DIETARY_SUPPLEMENT|Vitamin D|"Study group using Vitamin D for myofascial pain treatment. Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Study group usind Vitamin D for myofascial pain treatment. Medical treatment with Vitamin D (10,000 IU/day) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
214671720|NCT06111573|DRUG|Diclofenac Sodium|"Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Control group using Diclofenac Sodium for myofascial pain treatment. Medical treatment with Diclofenac Sodium (Voltaren 75 mg, 2x1 ) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
214671721|NCT05370248|OTHER|Tidal volume 6 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
214919219|NCT02857400|OTHER|CREDO standard of care|"organized consultation return home between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP"
214919220|NCT06621758|OTHER|questionnaire|Questionnaire regarding biomarker counseling and diagnostic disclosure
214919221|NCT01648725|PROCEDURE|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
214919222|NCT01648725|PROCEDURE|usual care|Standard care before induction of anesthesia
214919223|NCT04402138|DRUG|Acalabrutinib|Acalabrutinib 129 mg will be self-administered orally twice daily (BID) starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, until the patient has reached approximately 2 years post-BMT.
214919224|NCT06613854|DRUG|Oral semaglutide|Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.
214919225|NCT06613854|DRUG|Empagliflozin 10 mg|Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.
214919226|NCT05215275|BEHAVIORAL|exercise|"the exercise consists of two different modalities: moderate-intensity continuous training (MICT): the main MICT program will be designed to last 30 minutes. The MICT will be designed to involve core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).~high-intensity interval training (HIIT): The HIIT motions will be a mix of spiderman mountain climbers, standing oblique crunches, squats, froggers, jumping jacks, foot fire, jump squats, and mountain climbers. A total of four sets will be performed with 1-minute rests between sets. Each set comprises eight motions, with each motion lasting 30 seconds and a rest interval of 10 seconds between motions. Participants in the HIIT group will perform the most repetitions possible within 30 seconds."
214919227|NCT04938284|DEVICE|PAS|Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)
215061288|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 4|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
215061289|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 5|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
215061290|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
215061291|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
214317735|NCT02586701|OTHER|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
214317736|NCT04962568|DIAGNOSTIC_TEST|DTEE|endexpiratory diaphragm thickness in mm
214317737|NCT04962568|DIAGNOSTIC_TEST|DTEI|endinspiratory diaphragm thickness in mm
214317738|NCT04962568|DIAGNOSTIC_TEST|DEx|diaphragm excursion during rest and diaphragmatic excursion during maximal inspiration in mm
214317739|NCT00794872|OTHER|blood sampling|
214317740|NCT02020668|OTHER|Physiotherapy|
214317741|NCT02020668|OTHER|Wait list control|
214317742|NCT05545852|PROCEDURE|GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
214317743|NCT05545852|PROCEDURE|COT(Conventional Open Thyroidectomy)|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
214483030|NCT05039697|OTHER|oxygen|deliver high flow oxygen (10L/min)
214483031|NCT06814587|DIAGNOSTIC_TEST|Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI)|HP-13C MRI is a metabolic imaging technique that enables real-time assessment of myocardial substrate utilization by tracking the conversion of hyperpolarized \[1-13C\] pyruvate to metabolic intermediates such as bicarbonate and lactate. This imaging modality provides insights into oxidative metabolism and mitochondrial function, facilitating the identification of metabolically active and ischemic myocardial regions in patients with ischemic cardiomyopathy.
214317744|NCT03264404|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks until progression
214317745|NCT03264404|DRUG|Azacitidine|50 mg/m2 subcutaneous daily for 5 days every 28 days
214317746|NCT05653960|OTHER|EMR or ESD|Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms
214317747|NCT06237140|OTHER|PNF+ biofeedback exercise group|Neurorehabilitation will be applied to this group, 5 sessions a week for 4 weeks, to increase balance and walking skills and reduce the risk of falling.
214317748|NCT02914496|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a specific form of Cognitive behavior therapy (CBT) which will be given as a course consisting of seven sessions where each session is two hours long.
214317749|NCT03036566|DEVICE|Lithium disilicate ceramic (Ivoclar)|Three unit high strength ceramic bridges replacing a single tooth.
214317750|NCT05512221|OTHER|GBAT+I, GBAT+E - Phase I|Phase I is the development phase, which is informed by the study team's previous pilot study and autistic advisors. It will include the development of engagement booster materials. Booster materials will be tested in 2 groups (GBAT+I and GBAT+E) of six participants each. Groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions) and GBAT+Engagement Booster (GBAT+E; supplemental materials). The first 4-6 eligible adults recruited will participate in GBAT+I and the second 6 eligible adults recruited will participate in GBAT+E. Both groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities).
214483032|NCT06814587|DIAGNOSTIC_TEST|[¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)|FDG-PET is a molecular imaging technique used to assess myocardial viability by quantifying glucose uptake in cardiac tissue. This method differentiates viable myocardium, which retains metabolic activity, from non-viable scar tissue. FDG-PET is widely used in ischemic cardiomyopathy for viability assessment to guide revascularization decisions.
214483033|NCT06766773|PROCEDURE|Compound heating strategy|After the surgery begins, a temperature monitoring device (disposable medical temperature sensor provided by the limited company) is inserted into the patient's nasopharynx to record the core temperature, while activating the water blanket and forced air heating system.
214483034|NCT06766773|PROCEDURE|perioperative mandatory warming measures|perioperative mandatory warming measures
214483035|NCT06862687|OTHER|Cooling Spray|"A cooling spray containing propan-butane-pentane was applied 25 cm from the cannulation site until mild whitening/frosting appeared.~The standard AVF cannulation procedure was performed. Pain levels were measured immediately after the procedure using VAS."
214919228|NCT04938284|DEVICE|VNS|Non-invasive vagus nerve stimulation delivered through cymba concha \& cymba cavum of the ear.
214919229|NCT05802472|OTHER|Polyphenolic beverage from extract of Vachellia farnesiana|During Visit 2. A single infusion of the polyphenolic extract was administered orally. The dose (1.2 mg/kg body weight) of lyophilized extract, which was diluted in water, was calculated considering each participant's weight.
214919230|NCT05959031|DEVICE|kTMP|a new non-invasive brain stimulation tool
214919231|NCT05959031|DEVICE|Sham kTMP|a new non-invasive brain stimulation tool with sham setting selected
214919232|NCT03960008|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
214919233|NCT03960008|PROCEDURE|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation
214919234|NCT03960008|DRUG|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
214919235|NCT02646475|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
214919236|NCT02646475|DRUG|Saline|Normal saline will be used as a placebo comparator.
214919237|NCT03056638|DRUG|Degarelix|Degarelix monthly for 6 months
214919238|NCT03056638|RADIATION|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
214919239|NCT06330129|DEVICE|CTT Pegasus|The intervention aims to assess the construct validity of trunk flexor, extensor, and rotator muscle strength using the CTT PEGASUS isometric dynamometer (Leipzig, Germany). This involves correlating muscle strength measured isometrically with its physiological determinants: MRI-based anatomical cross-sectional area (CSA) in the lumbar region and muscle activation measured via surface electromyography (EMG) of spine and trunk muscles. Additionally, the intervention will assess the test-retest reliability of isometric strength of trunk flexors, extensors, and rotators.
214483036|NCT06862687|OTHER|Cold Aloe Vera Gel Application|1 ml of cold aloe vera gel was applied to a 5x5 cm area over the fistula site. The standard AVF cannulation procedure was conducted. Pain levels were assessed post-procedure using VAS.
214919240|NCT02464423|BEHAVIORAL|Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)|
214919241|NCT06544135|DEVICE|FLIR One Pro LT|Thermal imaging camera used to measure temperatures of the lower limb.
214919242|NCT00415818|BIOLOGICAL|MVA-MUC1-IL2|"MVA-MUC1-IL2:~Dose of 10exp8 plaque forming units (pfu).~Chemotherapy:~Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first."
214317751|NCT05512221|OTHER|Watchful Waiting and Groups - Phase 2|"Phase 2a will include a watchful waiting (WW) condition and assignment to 1 of 2 treatment conditions: GBAT+I or GBAT+E.~Participants will be assigned to WW for 10 wks. They will not receive specific therapeutic services during WW, but a member of the study team will contact them at weeks 1, 2, 4, 6, and 8 to maintain engagement and monitor for clinical deterioration.~After WW, participants will be randomly assigned to one of the treatment conditions (GBAT+I or GBAT+E). All groups will consist of 10 weekly 60-90-minute GBAT group sessions. GBAT+I participants will attend four 30-minute individual booster sessions. GBAT+E participants will be asked to use booster materials between group sessions (e.g., worksheets, goal trackers, interactive learning activities)~WW group size is based on study feasibility and availability of resources. Additional participants will also be recruited at the end of the WW period to supplement group sizes."
214317752|NCT05512221|OTHER|GBAT+IE|"Phase 2b will include assignment to GBAT+IE, which includes components of both GBAT+I (individual sessions) and GBAT+E (supplemental materials)~All groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities). Participants in GBAT+IE will participate in both the individual sessions and use of booster materials."
214919243|NCT00415818|DRUG|1st line Chemotherapy|
214317753|NCT05898646|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214317754|NCT05898646|BIOLOGICAL|Daratumumab|Given SC
214317755|NCT05898646|PROCEDURE|Echocardiography Test|Undergo echocardiography
214317756|NCT05898646|OTHER|Questionnaire Administration|Ancillary studies
214317757|NCT05898646|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214483037|NCT06862687|OTHER|Standard Procedure (Control Condition)|"No additional pain-relief intervention was applied. The nurse performed the standard AVF cannulation procedure, including hand hygiene, thrill assessment, and site disinfection.~Pain levels were assessed immediately after cannulation using the Visual Analog Scale (VAS)."
214483038|NCT06742814|DEVICE|stress ball|Stress ball: It is a ball with moderate hardness and softness, about 6 cm, which can be held and pressed by hand.
214919244|NCT03076034|DEVICE|Reference Point Indentation|"The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (\~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of \~375 µm."
214919245|NCT04290715|OTHER|no intervention|no intervention
214919246|NCT05498441|DEVICE|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4\*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.
214919247|NCT05498441|DRUG|Antipsychotics, mood stabilizers, etc.|During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
214919248|NCT02119793|DEVICE|YVOIRE contour|YVOIRE contour injection into the anteromedial malar region
214919249|NCT03485807|BEHAVIORAL|Mindfulness Training (MT)|2 week SmartPhone-based mindfulness training
214919250|NCT03485807|BEHAVIORAL|Active Coping Training (CT)|2 week SmartPhone-based structurally equivalent coping training
214919251|NCT03508726|DRUG|Ascorbate|"Phase 1 dose escalation:~75gm IV three times a week~Phase II portion:~75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV"
214919252|NCT04544202|DRUG|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~* Dabrafenib, 150 mg, twice daily (BID);~* Trametinib, 2.0 mg, once daily (QD)"
214919253|NCT04544202|DRUG|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
214919254|NCT04544202|DRUG|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
214919255|NCT03578796|DIAGNOSTIC_TEST|ECAS-N|assessing ALS-specific cognitive impairment
214919256|NCT03578796|DIAGNOSTIC_TEST|MoCA|assessing cognitive impairment
214317758|NCT05898646|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214317759|NCT04926961|DEVICE|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
214483039|NCT06835582|DRUG|Methadone|Comparing methadone point of care test to LC-MS to evalutate methadone and its metabolite levels pre dosing and after dosing using the patient's current methadone prescription.
214483040|NCT06840145|DEVICE|repetitive transcranial magnetic stimulation|Intermittent theta Burst stimulation will be performed as detailed in the Real arm description
214483041|NCT06845176|DEVICE|Tendon vibration (TV)|We use the VIBRAMOOV PHYSIO device which delivers local muscle vibrations at frequencies of 80 Hz and an amplitude of 1 mm.
214919257|NCT03578796|DIAGNOSTIC_TEST|CDR|assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
214919258|NCT03578796|OTHER|Questionnaire|Questions related to work situation and car driving
214919259|NCT05314322|PROCEDURE|Deep brain stimulation with high frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
214919260|NCT05314322|PROCEDURE|Deep brain stimulation with low frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
214919261|NCT01604928|DRUG|YM178|Oral
214919262|NCT01604928|DRUG|tolterodine|Oral
214919263|NCT01604928|DRUG|Placebo|Oral
214317760|NCT04926961|DEVICE|Real transcranial magnetic stimulation (TMS)|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
214483042|NCT06845176|OTHER|Kinesthetic motor imagery (kMI)|kMI is a mental technique in which an individual visualizes performing a movement without physically executing it. This process involves the internal representation of the sensations associated with the movement, engaging neural pathways similar to those activated during actual physical movement. kMI stimulates key motor and sensory areas in the brain, promoting neuroplasticity and enhancing motor performance.
214483043|NCT06756672|DEVICE|HPI guidance|patients with HPI guidance
214483044|NCT06756672|DEVICE|No HPI guidance|patients without HPI guidance
214483045|NCT06824337|OTHER|mobilization training and targeted mobilization|In the first interview with the patients, the content of the early mobilization training given to the patients, what early mobilization is, why it is important, what benefits it provides, what the mobilization goals determined for the patient within the scope of the research, the benefits of walking and the expected results will be explained. It will be explained how to benefit from the smartphone during the mobilization process. In addition to all the training, the patients in the intervention group will be given detailed information about what they need to record in the mobilization diary (total time they walked, how many steps they took in the pedometer application after each mobilization, positive/negative situations they experienced while standing up and walking) and all the forms that will be used in the data collection phase.
214483046|NCT06754891|DRUG|TQH3906 capsules|TQH3906 is an allosteric inhibitor targeting kinase.
214483047|NCT06866821|OTHER|SMWAM's and PNF C-R Technique|"Treatment provided 3 days every week in 6 total weeks with 1 meeting per day, 3 bunches of 10 times repeat and resting period of one minute among bunches. This group received Mulligan's spinal mobilization with arm movement and proprioceptive neuromuscular facilitatin contract-relax technique. Previous to mobilization, all patients got hot pack (10 minutes) and active range of motion warm up exercises (2 sets of 10 repetitions) and did isometric neck exercise as a home plan of care.~Mobilisation (22) was done depending on the side of involvement, the corresponding spinous process would be mobilised combined with different movements of shoulder (flexion/ abduction/ horizontal abduction/ horizontal adduction).~Proprioceptive neuro-muscular facilitation contract relax technique performed with 3 repetitions in each cervical movement (flexion, extension, lateral flexion and rotation) (27)."
214919264|NCT05567211|OTHER|Free use of the virtual platform.|Access to the virtual platform + general healthy eating and physical activity recommendations. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
214919265|NCT05567211|OTHER|Personalized nutritional planning based on the Mediterranean diet + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning based on the Mediterranean diet + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
214919266|NCT05567211|OTHER|Personalized nutritional planning with an extra intake of berries + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning with an extra supply of antioxidants using red berries + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
214317761|NCT03564340|DRUG|Ubamatamab|Administered per the protocol
214919267|NCT03520153|PROCEDURE|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
214919268|NCT03520153|PROCEDURE|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
214317762|NCT03564340|DRUG|Cemiplimab|Administered per the protocol
214919269|NCT03520153|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
214317763|NCT03564340|DRUG|Sarilumab|Administered per the protocol
214919270|NCT06683456|BEHAVIORAL|eMOTE|The intervention combines psychoeducation, mindfulness skills, emotion regulation skills, and distress tolerance skills, along with self-monitoring of meals, behaviours and feelings.
214919271|NCT04115475|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of subcellular muscle components
214919272|NCT04392375|DRUG|Nifedipine 30 MG|Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.
214317764|NCT03564340|DRUG|Tocilizumab|Administered per the protocol
214317765|NCT06416748|PROCEDURE|Minimally invasive simple hysterectomy|Patients with SHAPE inclusion criteria (FIGO 2018 stage IA2 and IB1 up to 2 cm, with limited stromal invasion: \&amp;amp;lt; 10 mm on LEEP/cone and \&amp;amp;lt; 50% depth on imaging) should undergo conization with surgical margins free from invasive disease or conization with involved surgical margins followed by MRI scan or expert ultrasound scan showing no residual disease. In case of residual disease at post conization imaging still fitting inclusion criteria, another conization is recommended. After these steps minimally invasive (laparoscopy or robotic) simple hysterectomy is performed with sentinel lymph node biopsy algorithm. Adjuvant therapy is given only in case of positive surgical margins, metastatic lymph nodes, and extensive LVSI with depth of stromal infiltration over 2/3.
214317766|NCT04625803|DRUG|Camrelizumab , apatinib and chemotherapy|"Camrelizumab 200 mg, IV infusion on Days 1 each 14-day cycle~Apatinib 250mg oral administration once a day, for two months~mFOLFOX6 oxaliplatin 85 mg/m\^2 IV infusion on Day 1 of each14-day cycle. Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2. The loading dose is then followed by a 46-hour 5-fluorouracil infusion of 2,400 mg/m2 via a pump programmed to provide a constant drug infusion rate."
214317767|NCT03783507|BEHAVIORAL|Order 1|"Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)"
214919273|NCT04392375|DRUG|Placebos|At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.
214919274|NCT05331443|DIAGNOSTIC_TEST|Reactive hyperemia-peripheral arterial tonometry Index (RHI )|RHI was assessed by RH-PAT using the EndoPAT2000 system .
214919275|NCT00122993|BEHAVIORAL|Healthful eating and food choices behavior change programs and changes in worksite food availability and prices|Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.
215061292|NCT02220153|BIOLOGICAL|Intravenous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: intravenous infusion"
214317768|NCT03783507|BEHAVIORAL|Order 2|"Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)"
214317769|NCT03783507|BEHAVIORAL|Order 3|"Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)"
214671722|NCT05370248|OTHER|Tidal volume 10 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
214919276|NCT00122993|BEHAVIORAL|Physical Activity|Physical activity programs are offered at the intervention garages for an 18 month period.
214317770|NCT03783507|BEHAVIORAL|Order 4|"Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)"
214317771|NCT06365827|OTHER|observational study|no intervention of interest
214317772|NCT04249128|DIETARY_SUPPLEMENT|Vegetarian Collagen|Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.
214317773|NCT04249128|DIETARY_SUPPLEMENT|Keratin|Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.
214317774|NCT04249128|DIETARY_SUPPLEMENT|Ceramides|Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.
214919277|NCT00122993|BEHAVIORAL|Environment|Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
214919278|NCT03722563|PROCEDURE|total laparoscopic hysterectomy with sacrocolpopexy|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
214919279|NCT03722563|PROCEDURE|total laparoscopic hysterectomy with lateral suspension|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
214919280|NCT05377502|DIAGNOSTIC_TEST|OGTT|OGTT
214919281|NCT01847339|DRUG|bupivacaine|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
214919282|NCT01847339|OTHER|saline solution|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure
215061293|NCT02220153|BIOLOGICAL|Subcutaneous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: subcutaneous infusion"
214671723|NCT01998646|DRUG|ASP4058|Oral tablet
214671724|NCT01998646|DRUG|Placebo|Oral tablet
214671725|NCT01978912|DRUG|KTP-001|KTP-001 is one time dose intradiscally.
214671726|NCT06512766|DRUG|Hydroxychloroquine|Patients in this group were treated with hydroxychloroquine (HCQ), a systemic medication commonly used as a first-line treatment due to its ease of use and established safety profile. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
214919283|NCT03329703|BEHAVIORAL|Project UPLIFT|A group, telephone-based intervention for depression that uses techniques from mindfulness-based therapy and cognitive therapy. The intervention consists of 8 sessions occurring at the same time and day every week.
215061294|NCT01157338|PROCEDURE|diagnostic cardiac catheterization|coronary intervention: angiography
215061295|NCT01157338|PROCEDURE|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
215061296|NCT04325295|PROCEDURE|Laparoscopic ovarian drilling|LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached \> 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
215061297|NCT04325295|DRUG|Recombinant FSH (rFSH)|A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
214919284|NCT04953689|BEHAVIORAL|Conscientiousness Coach|Participants will use the Conscientiousness Coach app to organize their goals and assist them in engaging in more conscientious behaviors. The participant will also be educated about Conscientiousness as it relates to healthy living and accomplishing life goals and values. Participants will receive brief phone calls during weeks 1, 2, 6, and 10 from the research assistant, tracking progress, answering queries, and return visits to the clinic/teleconference will be scheduled for further assistance during week 4 and week 8. These mid-study visits (or 'Booster Sessions') will last approximately 50 minutes and will involve a brief discussion of goal and value progress and app usage; at this in-person meeting/teleconference, similar questions and topics will be covered as in the bi-monthly phone calls. At week 12, there is a treatment termination visit with the principal investigator and research assistant.
215061298|NCT02684617|BIOLOGICAL|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
215061299|NCT02684617|DRUG|dinaciclib|dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
215061300|NCT02579421|DRUG|Progesterone|generic progesterone
215061301|NCT02579421|DRUG|placebo|placebo
215061302|NCT02767869|DRUG|Banaba|Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
215061303|NCT02767869|DRUG|placebo|Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
214317775|NCT04249128|DIETARY_SUPPLEMENT|Astaxanthin|is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.
214317776|NCT04902495|OTHER|MTA Pro Root|pulp therapy
214317777|NCT04902495|OTHER|MTA HP Repair|pulp therapy
214317778|NCT04902495|OTHER|Biodentine|pulp therapy
214317779|NCT06141629|DEVICE|accu chek Aviva Expert|This bolus calculator estimates the dose of insulin to be administrated on the basis of the following parameters: current blood glucose, grams of carbohydrate, carbohydrate to insulin ratio, insulin sensitivity, target blood glucose and quantity of insulin previously administered.
214317780|NCT06141629|DEVICE|Accu Chek Aviva Nano|This meter is a normal glucometer without bolus calculator.
214317781|NCT00470288|PROCEDURE|bladder flap during cesarean section|
214317782|NCT03960502|DRUG|AG-881|Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of \[14C\]AG-881.
214317783|NCT03960502|DRUG|[13C315N3]AG-881|Single IV microdose of approximately 100 μg.
214317784|NCT05036993|BEHAVIORAL|Coaching|Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
214317785|NCT02248129|DRUG|Telmisartan and hydrochlorothiazide|
214317786|NCT02085564|PROCEDURE|Peritoneal washing cytology|The methode is describes in the detailed study description
214317787|NCT04320940|DRUG|Phenobarbital Sodium Injection|The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
214919285|NCT02363413|OTHER|IniVAH|Initiation of the NIV during a 3 days hospitalization as usual.
215061304|NCT05952973|BEHAVIORAL|SkillTalk|Online Educator Mircoskill Training and Parent Microskill Training
215061305|NCT04301934|DEVICE|Mona Lisa Touch|Fractional CO2 LASER
215061306|NCT04301934|DRUG|Conjugated estrogen|Current standard treatment for recurrent UTIs in postmenopausal women
215061307|NCT04301934|DRUG|Estradiol|Current standard treatment for recurrent UTIs in postmenopausal women
215061308|NCT03125031|DEVICE|Rainbow adhesive adult/pediatric sensor|
215061309|NCT03125031|DEVICE|Rainbow adhesive adult/neonatal sensor|
215061310|NCT00146016|DRUG|Amantadine|
215061311|NCT00235235|PROCEDURE|Biopsy|core biopsy
214317788|NCT00849368|DRUG|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets"
214317789|NCT01914666|DRUG|Duloxetine|Administered orally
214317790|NCT04655716|DRUG|Sodium Bicarbonate 150Meq/L/D5W Inj|Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.
214317791|NCT04520425|PROCEDURE|Osteopathic manipulative therapy|"1. Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~2. Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~3. Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~4. Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~5. Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck."
214317792|NCT00896545|BEHAVIORAL|5-keys counseling|5-session small group intervention
214317793|NCT00896545|BEHAVIORAL|Lifestyle counseling|5-session small group behavioral intervention
214317794|NCT02492906|OTHER|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
214317795|NCT02492906|OTHER|Healthy|Healthy and non-symptomatic volunteers.
214317796|NCT03824197|OTHER|EVOO|Extra-virgin olive oil that is rich with oleocanthal and other phenols.
214317797|NCT03824197|OTHER|OO|Olive oil low in oleocanthal and other phenols.
215061312|NCT00235235|PROCEDURE|Serum Collection|serum collection
215061313|NCT00235235|PROCEDURE|Urine Collection|urine collection
215061314|NCT00235235|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
215061315|NCT00235235|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
215061316|NCT00235235|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
215061317|NCT00235235|DRUG|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
215061318|NCT00235235|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
214919286|NCT02363413|OTHER|IniVAD|Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
214317798|NCT03262948|DRUG|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
214317799|NCT03262948|DRUG|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
214317800|NCT03262948|DRUG|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
214317801|NCT06719973|DRUG|M9466|Participants will receive an escalating doses of M9466 orally in 21-day cycles until disease progression, intolerable toxicity, death, withdrawal of study or study consent, lost to follow-up, or end of study.
214317802|NCT06719973|DRUG|Carboplatin|Carboplatin will be administered intravenously on Day 1 of each 21-day cycle.
214317803|NCT06719973|DRUG|Etoposide|Etoposide will be administered intravenously as per standard of care.
214317804|NCT06719973|DRUG|Atezolizumab|Atezolizumab will be administered intravenously as per standard of care.
214317805|NCT06719973|DRUG|M9446|M9446 dose will be further investigated in Module 2 Part A of the study.
214317806|NCT06719973|DRUG|M9446|M9446 recommended Dose for Expansion (RDE) will be further investigated in Module 2 Part B of the study.
214317807|NCT06719973|DRUG|Carboplatin|Carboplatin will be administered intravenously as per standard of care.
214317808|NCT03561857|DEVICE|Confocal Laser Endomicroscopy|"The study is divided in 2 parts.~1. Ex vivo study~   * Prostate specimens will be stained using Fluorescein~  * Images/sequences of normal and abnormal prostatic tissues, and peri-prostatic tissues will be acquired.~2. In vivo study~   * Intravenous injection of contrast agent~  * pCLE imaging every 5mm of the NVB dissection zone."
214317809|NCT03592615|PROCEDURE|cataract surgery|Cataract surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than cataract, e.g., treatment for lens dislocation. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating astigmatism.
214317810|NCT03592615|PROCEDURE|Corneal refractive surgery|Corneal refractive surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than refractive error, e.g., treatment for corneal scar. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating severe astigmatism.
214317811|NCT00779454|DRUG|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
214317812|NCT00779454|DRUG|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
214919287|NCT04015089|DIETARY_SUPPLEMENT|Partially hydrolyzed formula (pHF)|Infant formula with partially hydrolyzed protein
214919288|NCT04015089|DIETARY_SUPPLEMENT|Standard formula (SF)|Infant formula with intact protein
214317813|NCT04112433|DEVICE|PURE EP 2|Enrolled patients receiving cardiac ablation treatment using the current standard of care with additional monitoring and intracardiac electrogram signal collection via the PURE EP 2 system.
214317814|NCT02550327|DRUG|Nab-paclitaxel|125 mg/m2
214317815|NCT02550327|DRUG|Gemcitabine|1000 mg/m2
214317816|NCT02550327|DRUG|Cisplatin|25 mg/m2
214317817|NCT02550327|DRUG|Anakinra|100 mg
214317818|NCT02317302|DEVICE|FDG-PET/MR|
214317819|NCT02317302|DEVICE|FDG-PET/CT|
214317820|NCT05144152|DIAGNOSTIC_TEST|M3|A panel of four bacterial gene markers (Fn, m3, Ch and Bc)
214317821|NCT05144152|DIAGNOSTIC_TEST|FIT|faecal immunochemical test
214317822|NCT03919175|DRUG|Umbralisib|Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
214317823|NCT03919175|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
214317824|NCT01940120|DEVICE|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
214317825|NCT05371314|DIAGNOSTIC_TEST|P/FP ratio|PaO2/FiO2 X PEEP, SpO2/FiO2 X PEEP
214317826|NCT00427635|DRUG|Esomeprazole|
214317827|NCT03277846|DEVICE|Nexalin Based Trans-Cranial Electrical Stimulation|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
214919289|NCT00747370|PROCEDURE|movement of midurethra, bladder neck, cervix and rectum|
214919290|NCT03826264|PROCEDURE|TAVR|transcatheter aortic valve replacement (TAVR)
214919291|NCT06665126|DIETARY_SUPPLEMENT|Prebiotic + Probiotic Supplement|This intervention includes a combination of prebiotics and probiotics designed to promote vaginal and digestive health. The supplement contains Biotin, Lactobacillus acidophilus (as LA-14®), Bifidobacterium lactis (HN019™), Lactobacillus rhamnosus (as HN001™), Lactobacillus crispatus (as CCFM1110™), Lactobacillus gasseri (as HLG13™), Lactobacillus reuteri (as HR7™), Bacillus subtilis (as DE111®), PreforPro®, White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
214483048|NCT06866821|OTHER|PNF C-R Technique and PT Protocol|"Treatment provided 3 days every week in 6 weeks with 1 meeting per day, 5 clusters of 3 times repeat and resting period of one minute among clusters. Regime of training involved PNF (proprioceptive neuromuscular facilitation) contract-relax method along with the standard physical therapy protocol which includes passive stretching (3 sets of 10 repetitions) and isometric strengthening exercises (2 sets of 10 repetitions).~Proprioceptive neuro-muscular facilitation contract relax technique performed with 3 repetitions in each cervical movement (flexion, extension, lateral flexion and rotation) (27)."
214483049|NCT06764966|DRUG|Atorvastatin 20 mg|Atorvastatin 20 mg Once Daily with previously prescribed Non Selective Beta-Blocker
214483050|NCT06764966|DRUG|Placebo|Placebo Once Daily along with previously prescribed Non Selective Beta Blocker
214483051|NCT06883253|BEHAVIORAL|treadmill walking|all participants walking at increasing speeds on a treadmill
214919292|NCT06665126|DIETARY_SUPPLEMENT|Active Placebo Supplement|The active placebo supplement contains similar probiotic strains without the prebiotic component. Ingredients include Biotin, Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus reuteri, Bacillus subtilis, Inulin (from Chicory Root), White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
214317828|NCT01088646|DEVICE|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.~Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.~The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
214317829|NCT04490993|DRUG|APL-1202 in combination with Epirubicin|"* Induction period: APL-1202 is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
214317830|NCT04490993|DRUG|Placebo in combination with Epirubicin|"* Induction period: placebo is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
214317831|NCT05448690|PROCEDURE|Two different approaches|Please refer to Groups
214317832|NCT05448690|PROCEDURE|Non-combined approach|Either transnasal, transcranial or a staged approach
214317833|NCT01888497|DRUG|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
214919293|NCT06665126|DIETARY_SUPPLEMENT|Excipient Placebo Supplement|The excipient placebo supplement contains no active ingredients related to prebiotics or probiotics. It includes White Rice Flour, Magnesium Stearate (Vegetable Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
214919294|NCT03209622|PROCEDURE|Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge|when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B
214919295|NCT03209622|DRUG|Nicotine patch|Arm A
214317834|NCT01888497|DRUG|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
214317835|NCT01888497|DRUG|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
214317836|NCT01888497|DRUG|Placebo|Oral, prior to bedtime on the night before performance testing
214317837|NCT01598116|PROCEDURE|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
214317838|NCT01598116|PROCEDURE|Urine collection|Bagged urine collection
214317839|NCT02412969|PROCEDURE|Lumbar Epidural|control group will receive lumbar puncture epidural
214317840|NCT02412969|PROCEDURE|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
214317841|NCT04152447|DEVICE|VR device|Patients use a VR device
214483052|NCT05578963|OTHER|Schaeffer's Test for palmaris tendon|After demographics, Schaeffer's Test will be used to check the presence or absence of palmaris longus muscle. In this test, students will maintain the forearm at 90 degrees first followed by moving the thumb in opposition towards the little finger with the wrist partially flexed. If the tendon bulges out, it will reflect presence of palmaris longus and vice versa. This finding will be recorded. After that, students will perform Phalen's test. In this test, researcher will ask them to press the backs of their hands and fingers together with their wrists flexed and fingers pointed down. they'll stay that way for a minute or two. If fingers tingle or get numb, it will indicate carpal tunnel syndrome. The reading will be recorded.
214671727|NCT06512766|DRUG|Methotrexate|This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
214919296|NCT03209622|OTHER|the external consultation|without patch
214919297|NCT02669901|BEHAVIORAL|Naloxone Auto-Injector|Naloxone auto-injector is FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
214919298|NCT06666062|OTHER|implant placement and low level laser therapy|Laser biomodulation with low level laser therapy around delayed implant
214317842|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
214317843|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
214317844|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
214317845|NCT00827411|DEVICE|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
214317846|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
214317847|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
214483053|NCT05002439|OTHER|Multicomponent physical exercise program and a nutritional intervention|The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
214483054|NCT06748586|DEVICE|Hyperbaric Oxygen Therapy|The HBOT protocol is 90 minutes, 5 times/week, for at least 40 sessions, 100% oxygen at 2 ATA with five-minute air breaks every 20 minutes. Investigational product: Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel.
214483055|NCT06759870|OTHER|Collection of saliva|An unstimulated saliva sample will be obtained for 1 minute before implant surgery and immediately after implant surgery.
214483056|NCT06759870|OTHER|Collection of gingival samples|Gingival samples will be obtained by punch biopsy 3 months after implant surgery.
214483057|NCT06759870|OTHER|ISQ registration|ISQ value will be record in placement dental implant.
214483058|NCT04546230|PROCEDURE|Low-Thoracic Epidural Anesthesia|"Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle \& a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later \& continued throughout the procedure."
214483059|NCT04546230|PROCEDURE|General Anesthesia|General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen \& infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
214483060|NCT06841744|OTHER|Diaphragmatic Breathing Exercise|Diaphragmatic breathing exercises will be performed twice a day, completing 3 sets of 10 repetitions, 5 days a week for 6 weeks, as instructed by the researcher physiotherapist.
214483061|NCT06841744|OTHER|Information brochure|An information brochure on ergonomic strategies for managing low back pain during pregnancy will be provided.
214671728|NCT06512766|DRUG|Cyclosporine A|Patients in this group were treated with cyclosporine A (CsA), a potent immunosuppressive agent used for its effectiveness in controlling severe inflammatory responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
214317848|NCT00827411|DRUG|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
214317849|NCT04047082|DIAGNOSTIC_TEST|Quantitative aortogram (videodensitometry)|Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)
214317850|NCT03998124|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
214317851|NCT03998124|OTHER|Usual care|Staff-led social activity
214317852|NCT04013191|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
214317853|NCT01396863|PROCEDURE|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
214317854|NCT01396863|PROCEDURE|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
214483062|NCT06812117|OTHER|No Drug|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on mirogabalin will be enrolled in this study.
214483063|NCT03328026|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM inoculation intradermally at 4 sites.
214483064|NCT03328026|DRUG|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
214483065|NCT03328026|DRUG|Interferon Inoculation|Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.
214483066|NCT03328026|DRUG|retifanlimab|retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
214671729|NCT06512766|DRUG|Retinoids|This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
214671730|NCT00731445|DRUG|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
214671731|NCT03378401|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
214671732|NCT03378401|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
214671733|NCT04220866|DRUG|Ulevostinag|IT injection
214671734|NCT04220866|BIOLOGICAL|Pembrolizumab|IV infusion
214483067|NCT05019495|BEHAVIORAL|PrOMOTE|This is an opt-out, proactive approach to tobacco treatment by a clinical pharmacy specialist. The pharmacist will call patients and offer an individualized pharmacotherapy prescription. The patient must opt-out for it not to be sent to their pharmacy. The patient will also receive brief motivational interviewing and behavioral counseling from the pharmacist.
214317855|NCT02335138|BEHAVIORAL|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
214483068|NCT06826118|DRUG|Axicabtagene Ciloleucel|"Pre-treatment chemotherapy: Cyclophosphamide 500 mg/m² and Fludarabine 30 mg/m² will be administered intravenously on Days -5, -4, and -3 (with the day of Axicabtagene Ciloleucel Injection infusion being Day 0).~Axicabtagene Ciloleucel Injection infusion: A single dose of autologous T cells transduced with chimeric antigen receptor (CAR) in the form of Axicabtagene Ciloleucel Injection will be administered to the subject intravenously. The target dose is 2.0×10\^6 anti-CD19 CAR-T cells/kg body weight. The minimum dose that can be used is 1.5×10\^6 anti-CD19 CAR-T cells/kg body weight. For subjects with a body weight of ≥100 kg, the maximum total dose is 2.0×10\^8 anti-CD19 CAR-T cells"
214483069|NCT05758766|DIETARY_SUPPLEMENT|Plant-based omega-3-FA|Plant-based omega 3 Fatty Acids
214483070|NCT05974904|OTHER|high-sensitivity C-reactive protein to albumin ratio|High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.
214483071|NCT06503198|BEHAVIORAL|Virtual care|"Through Cloud DX, intervention group participants will receive:~Remote Automated Monitoring: measurement of: blood pressure, heart rate, respiratory rate, oxygen saturation, temperature and weight.~Frailty-tailored daily symptom survey: The recovery survey consists of questions related to infection, bleeding, pain, appetite, dehydration, appetite, syncope and falls.~The tablet will prompt the participant to complete a Katz Index of Independence in Activities of Daily Living (IADL) survey. The FAM-CAM survey will also be pushed by Cloud DX to be completed.~Virtual RN assessment: a virtual RN assessment will be scheduled at a minimum of every 2 days for the first 7 days. The virtual RN will also perform the 4AT Delirium Assessment.~Medications: the virtual RN will undertake medication review and reconciliation. In addition, they will provide counselling regarding analgesic support and monitor for drug interactions."
214483072|NCT06596772|DRUG|MB04 (proposed biosimilar to etanercept)|MB04 50 mg/week via subcutaneous injection
214483073|NCT06596772|DRUG|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
214483074|NCT06825013|DRUG|Bronchodilators inhalation|Salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg)
214483075|NCT06825013|DRUG|Placebo|Nebulized saline
214483076|NCT06808438|DEVICE|Esophageal pressure catheter|Esophageal pressure was monitored with an esophageal pressure catheter
214483077|NCT06818123|OTHER|Education Intervention along with the doctor's consultation|This educational intervention will assess the improvement menstrual hygiene knowledge and practices among women at slums who are illiterate and can empower individuals to manage their periods with dignity and comfort.
214483078|NCT06818123|OTHER|Control group with doctor's consultation only|Baseline Knowledge will be assessed in this arm about the menstruations hygiene and practices.
214483079|NCT05939336|DIETARY_SUPPLEMENT|Mannooligosaccharides yeast extract|15 g per day of mannooligosaccharide yeast extract.
214483080|NCT06856837|DRUG|Fruquintinib|highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3
214483081|NCT06856837|DRUG|Tislelizumab|humanized immunoglobulin G4 (IgG4)-variant monoclonal antibody (mAb) against human programmed cell death-1 (PD-1)
214483082|NCT06856837|DRUG|Trifluridine/tipiracil|trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor
214483083|NCT06856837|DRUG|Bevacizumab|recombinant humanized anti-VEGF monoclonal antibody composed of human IgG1 framework regions and antigen-binding, complementarity-determining regions from a murine monoclonal antibody (muMAb VEGF A4.6.1)
214483084|NCT05706766|BEHAVIORAL|PARE|Aerobic and resistance exercise program via Zoom platform.
214483085|NCT05706766|BEHAVIORAL|Waitlist Control Group|Normal Activities.
214483086|NCT06481995|DRUG|Fibrogammin|Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing
214483087|NCT06811207|DRUG|Vonoprazan|Vonoprazan (20 mg bid, for 14 days)
214483088|NCT06811207|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg tid, for 14 days)
214483089|NCT06811207|DRUG|Amoxicillin|Amoxicillin (750 mg qid, for 14 days)
214483090|NCT06878183|OTHER|Routine laboratory tests of the patients were examined (such as hemogram, biochemistry, bleeding parameters).|Data obtained from routine examinations, laboratory tests and hospital reports were evaluated.
214671735|NCT05187338|DRUG|ipilimumab +pembrolizumab +durvalumab|"This study has 3 subgroups:~1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
214671736|NCT04804956|PROCEDURE|Stool sample|One stool sample will be taken at baseline for microbiota characterization
214671737|NCT04804956|PROCEDURE|Rectal mucosa sample|Characterization of tissue microbiota before and after surgery.
214919299|NCT06666062|PROCEDURE|implant placement|Delayed implant placement restoring missed tooth
214317856|NCT02335138|BEHAVIORAL|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
214317857|NCT00001720|DRUG|Alendronate|
214317858|NCT02159547|DRUG|Dexketoprofen|50 mg intravenous arveles in 50 ml saline in 5 minutes
214483091|NCT05016791|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~1. Routinely once per day from the day of randomisation till the 12-month visit after AF CA (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~2. If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~3. If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
214919300|NCT05419180|DRUG|Stiripentol|Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
214919301|NCT06664983|DRUG|TPC chemotherapy|The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle
214483092|NCT06881524|DRUG|First-line licorice and lotus root powder combined with low-dose amoxicillin|For first-line experimental group, patients would receive vonoprazan 20mg twice daily, amoxicillin 0.75g three times daily for 10 days, licorice and lotus root powder 5.0g twice daily for an additional 6 weeks
215061319|NCT02290496|BEHAVIORAL|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
214317859|NCT02159547|OTHER|Normal Saline|50 ml normal saline
214317860|NCT00200226|DRUG|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
214483093|NCT06881524|DRUG|First line high-dose amoxicillin|For first-line active comparator group, patients would receive vonoprazan 20mg twice daily, amoxicillin 1 g three times daily for 10 days
214483094|NCT06881524|DRUG|Rescue licorice and lotus root powder combined with low-dose amoxicillin|For rescue experimental group, patients would receive vonoprazan 20mg twice daily, amoxicillin 0.75g three times daily for 10 days, licorice and lotus root powder 5.0g twice daily for an additional 6 weeks
214671738|NCT04804956|PROCEDURE|Mesorectal adipose tissue sample|Characterization of tissue microbiota and dysfunction
214671739|NCT04804956|PROCEDURE|Subcutaneous adipose tissue sample|Characterization of tissue microbiota and dysfunction
214919302|NCT06664983|DRUG|cadonilimab combined TPC chemotherapy|Cadonilimab was intravenously given at dose of 10 mg/kg on day 1. The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle
214317861|NCT00200226|DRUG|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
214671740|NCT04804956|PROCEDURE|Visceral adipose tissue sample|Characterization of tissue microbiota and dysfunction
214919303|NCT00053157|BIOLOGICAL|sargramostim|
214919304|NCT04863781|BEHAVIORAL|Mobile cognitive-behavioral stress management intervention|Each weekly module will consist of a cognitive component and a relaxation component. The cognitive component during the first 3 weeks will educate users about the Transactional Model of Stress, that discrimination is a type of stressor, and the impact of stress on health. Building on this information, users will then learn how to match coping responses to the changeability of stressors during weeks 4 and 5. The cognitive component will conclude by focusing on the four most common coping strategies used by African American women in response to stress. Modules 2 through 4 will teach progressive muscle relaxation through a series of tension and relaxation cycles. Modules 5 through 8 will train users in diaphragmatic breathing. Finally, users will be trained in three types of mindfulness mediations.
214317862|NCT02009410|DRUG|Creon|Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
214317863|NCT02009410|DRUG|Creon 25000 matching Placebo|Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
214317864|NCT02904057|DEVICE|Radiesse (+) Injectable Implant|Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.
214317865|NCT04175093|DIAGNOSTIC_TEST|asymmetric dimethylarginine|measurement by ELISA of asymmetric dimethylarginine
214317866|NCT01581463|DRUG|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
214317867|NCT00938483|OTHER|Nutramigen Lipil (Infant formula)|
214317868|NCT02579746|BEHAVIORAL|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
214317869|NCT02579746|BEHAVIORAL|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
214483095|NCT06881524|DRUG|Rescue high-dose amoxicillin|For rescue active comparator group, patients would receive vonoprazan 20mg twice daily, amoxicillin 1 g three times daily for 10 days
214671741|NCT04804956|BEHAVIORAL|Dietary assessment|Dietary assessment will be taken at baseline
214671742|NCT02138110|DEVICE|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
214671743|NCT00338936|DRUG|Valsartan + Hydrochlorothiazide|
214317870|NCT02310178|PROCEDURE|Bariatric surgery|all of the current bariatric surgeries are allowed in this prospective cohort study
214317871|NCT01404091|DRUG|LY2940094|Administered orally
214317872|NCT01147991|BIOLOGICAL|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
214317873|NCT01147991|OTHER|laboratory biomarker analysis|
214317874|NCT01147991|OTHER|pharmacological study|
214317875|NCT05092555|DIAGNOSTIC_TEST|Nasopharyngeal swap for Reverse transcription polymerase chain reaction|Nasopharyngeal swap and Blood sample is taken for doing previous tests and CT chest is done for all patients
214483096|NCT06881134|DEVICE|SCS+EXS|Eligible participants will undergo implantation of the spinal cord stimulation (SCS) system. Intraoperative electrophysiological monitoring will be used to adjust stimulation parameters. SCS will be tested postoperatively to assess the patient's tolerance to stimulation and its therapeutic effects. Parameters designed to improve sensory function and bladder/bowel control will be established. All parameters will be integrated into a sequential stimulation protocol. Additionally, the simultaneous activation of the SCS and the robotic exoskeleton will be tested to ensure smooth integration. Exoskeleton-assisted training will be conducted for no less than 1 hour per day (divided into two 30-minute sessions). Other rehabilitation interventions will be provided for at least 3 hours per day. Follow-ups will be conducted at 1, 2, 3, 6, and 12 months postoperatively.
214483097|NCT06811649|DIAGNOSTIC_TEST|Ultrasound guided injection with local anaestethic|"Experimental treatment consists of ultrasound assessment combined with palpatory assessment to identify the most suitable space for epidural catheter insertion.~The conventional neuroaxial technique relies on palpation of the spinous processes and iliac crests to recognize the midline and height of the lumbar interspace to be used to perform a neuroaxial block.~With the echo-assisted technique, in aid of the conventional technique, a preprocedure (Prepuncture) is performed for the purpose of combining classic anatomical findings with useful sonographic findings that should improve the success of the neuroaxial technique."
214483098|NCT06811818|OTHER|complete denture with bilateral balanced occlusion|Participants in this group will be given complete dentures with bilateral balanced occlusion
214483099|NCT06811818|OTHER|complete denture with lingualized occlusion|Participants in this group will be given complete dentures with lingualized occlusion
214483100|NCT05920330|OTHER|Nasal Plug|Please see the arm description for details.
214483101|NCT06654128|DIAGNOSTIC_TEST|artificial intelligence|patients will undergo tandem colonoscopy with artificial intelligence
214483102|NCT06750640|DIAGNOSTIC_TEST|Infrared thermography|A thermograph (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) was used to record thermal images. The infrared camera was fixed on a tripod 1 m away from the subject to ensure that no shaking movements or vibrations occurred during the recording of thermal images. MDD related acupoints on the inner and outer sides of the limbs were detected. Appropriate body position was selected according to the different parts to be detected. Using the automatic interval saving shooting mode, one thermal picture was taken at 10-s intervals, 3 pictures were taken for each subject.
214483103|NCT06762639|BEHAVIORAL|Personalized Sleep Prehabilitation (PSP)|"Sleep prehabilitation will consist of usual care prehabilitation (exercise, nutritional support, psychosocial support, education, smoking cessation support, and/or medical care) with the addition of sleep support. This support will consist of:~* Brief behavioural treatment for insomnia~* Sleep hygiene~* Behaviour change support (e.g., goal-setting, use of a wearable tracker to modify behaviour)"
214483104|NCT06762639|BEHAVIORAL|Standard of Care Prehabilitation|Exercise, nutritional support, psychosocial support, education, smoking cessation support, and/or medical care delivered by regulated health professionals included Kinesiologists, Dietitians, Clinical Psychologists, etc.
214483105|NCT06859463|DEVICE|Muscle function|Functional evaluation First, the patients will fill the Fysisk Aktivitet Questionnaire, the o Klinisk Oral Fysiologi (KU) Questionnaire and the Harvard Trauma Questionnaire. Then, the evaluator will applicate the Total Tenderness Score (TTS) for evaluating their tenderness in different spots of the head and neck regions. The next evaluation comprehends the evaluation of the maximal voluntary isometric contraction (MVIC) for the different neck movements and the rate of force development (RFD) of the shoulder elevation. After this, patients will perform the cranio-cervical flexion test (CCFT), and, finally, the Ito test to evaluate the lumbar endurance.
214483106|NCT06817018|DIETARY_SUPPLEMENT|Placebo|Placebo (Sabinsa)
214483107|NCT06817018|DRUG|Ginger|Ginger root extract
214483108|NCT06876870|DRUG|Anesthesia Maintenance Agent|Difference in renal blood flow (RBF) between Propofol and Sevoflurane groups. Quantified by specific Multiparametric MRI metrics (e.g., (Renal blood flow by phase contrast imaging) (regional perfusion by Arterial Spin labeling (ASL) and global and regional oxygenation by Blood oxygen dependent signal (BOLD))
214483109|NCT06879847|PROCEDURE|Salvage Allogeneic Hematopoietic Stem Cell Transplantation|"1. TBI+BUMEL (IBM) Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally, Day -7; Day -6: Total Body Irradiation (TBI) 4Gy, in two parts, Day -6; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion~2. Donor Stem Cell Infusion (Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."
214483110|NCT06625619|OTHER|Non-Interventional Study|Non-interventional study
214483111|NCT06751836|OTHER|Infection and no infection|No intervention apart from the dengue infection
214919305|NCT04863781|BEHAVIORAL|Control|The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
214317876|NCT01308190|DRUG|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
214317877|NCT01308190|RADIATION|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
214317878|NCT01308190|PROCEDURE|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
214317879|NCT01308190|PROCEDURE|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
214317880|NCT01427088|DEVICE|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
214483112|NCT06754722|OTHER|App to guide self-acupressure|The intervention is delivered via a mobile health app. EnergyPoints app, on iOS and Android, educates and guides use of acupressure rituals to self-manage fatigue and sleep disturbances. The intervention involves using the app daily for 6 weeks. A follow-along format guides correct point stimulation for two acupressure rituals (stimulating and relaxing). The app synchronizes symptom self-reports with fitness tracker (e.g., an Apple Watch or Fitbit) sleep and activity data, allowing evaluation of response to acupressure. The dashboard provides options to tailor the rituals and pressing time (½, 1 or 2 min. per point) according to symptom experience, lifestyle, and schedule. Individuals can choose to use enhancements such as aromatherapy (including an instructional safety video), relaxing music, and/or visuals during each ritual and connect with other users via the social engagement feature.
214919306|NCT05030194|OTHER|Electronic Cigarette|Participants engage in 30 minutes of an oral nicotine product. In those 30 minutes the product can be used as much or as little as preferred.
214483113|NCT06753539|DEVICE|ILM forceps - membrane grasping|grasping the epiretinal membrane at the starting location, using pinch peeling, is performed with an ILM forceps.
214483114|NCT06876389|DIETARY_SUPPLEMENT|Probiotic|In group A, children with iron deficiency received standard therapy. This group was given standard therapy in the form of elemental Fe 3 mg/kgBB/day/orally and L Bio as 2 packs per day and Saccharomyces boulardii given 2 capsules per day (dose 2 x 250 mg or 2 x (2.5 x109 cells/cfu)) for ages 1 year - 18 years for 30 days.
214317881|NCT04501731|OTHER|Transcranial Magnetic Stimulation (TMS)|With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.
214317882|NCT04501731|OTHER|Magnetic Resonance Imaging (MRI)|With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.
214483115|NCT06876389|OTHER|Placebo|In group B, children with iron deficiency received standard therapy with placebo. This group was given standard therapy in the form of elemental Fe 3 mg/kgBB/day/orally and placebo for 30 days.
214483116|NCT06740474|DRUG|ABI-6250|Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
214483117|NCT06740474|DRUG|Placebo|Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
214483118|NCT06739096|DEVICE|Short Wave Diathermy|Shortwave diathermy (SWT) is a form of electromagnetic therapy that causes the movement of ions, the disruption of molecules, and the generation of eddy currents, which ultimately produce heat in deep tissue. Its claimed mechanism of action includes inducing an anti-inflammatory response, reducing joint stiffness, stimulating connective tissue repair, and reducing muscle spasm and pain.
214483119|NCT06739096|OTHER|Exercise|range of motion, strengthening and stretching exercises
214317883|NCT04501731|OTHER|Motor assessment|"The motor assessment includes a pegboard game, a grab the alien nose game and measure of your maximum grip force. In total it will last around 30 minutes."
214317884|NCT04501731|OTHER|Questionnaires|Feasibility, tolerability of such intervention as well as quality of life of PFT survivors will be assessed thanks to questionnaires.
214317885|NCT03093675|DEVICE|TELELAP ALF-X Robotic Surgical System|The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
214317886|NCT00913744|DRUG|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
214317887|NCT00913744|DRUG|Sham injection|Sham injection
214317888|NCT01041716|OTHER|None - Observational study|None - Observational study
214483120|NCT06739096|DEVICE|Sham Short Wave Diathermy|Sham protocol
214483121|NCT02129244|OTHER|NCM-Plus|"The NCM will follow the domains of the chronic care model by:~1. Assuring effective, efficient clinical care and self-management support~2. Promoting clinical care consistent with scientific evidence and patient preferences~3. Organizing data to facilitate efficient, effective care~4. Empowering and preparing patients to manage their health and health-care needs~5. Mobilizing community resources to meet the needs of patients"
214483122|NCT05486585|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
214483123|NCT05778591|DRUG|Placebo|Placebo.
214483124|NCT05778591|DRUG|Buprenorphine 0.15 MG [Belbuca]|Buprenorphine
214483125|NCT06776679|DRUG|[14C]-BGB-16673|Administered orally as suspension in lipid vehicle
214483126|NCT05900895|DRUG|Olaparib|Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
214483127|NCT05900895|DRUG|17b-estradiol|17b-estradiol will be taken orally three times per day.
214919307|NCT05030194|OTHER|Oral Nicotine Pouch|Participants will be instructed to place a 6mg nicotine pouch in their mouth between gum and lip for up to 30 minutes.
214919308|NCT06966518|DRUG|Ketamine and Magnesium Sulfate|Patients will receive a bolus of 0.5 mg/kg of ketamine given over a period of ten minutes followed by a constant infusion of 0.25 mg/kg/hr and a bolus dose of 30 mg/kg of magnesium sulfate during a 10-minute period followed by a continuous infusion of 9 mg/kg/hr.
214317889|NCT04780386|DRUG|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)
214317890|NCT04780386|DRUG|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
214919309|NCT06966518|DRUG|Saline 0.9%|Patients will receive saline 0.9% as a control group.
214919310|NCT04629911|DEVICE|THRIVE|Patients will receive HFNO therapy during laryngomicrosurgery. Patients will undergo a gastric ultrasound examination after HFNO therapy.
214919311|NCT06576453|BEHAVIORAL|Self-questionnaire WHOQOL-bref|Parents must complete the self-questionnaire WHOQOL-bref after the first and the last session of the Pepps program.
214317891|NCT02142166|PROCEDURE|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
214919312|NCT06576453|BEHAVIORAL|Self-questionnaire Evaluation Inventory - Parent|Parents must complete the self-questionnaire Evaluation Inventory - Parent after the last session of the Pepps program.
214317892|NCT02142166|PROCEDURE|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
214483128|NCT05267639|DEVICE|Power Knee|Newest version of the commercially-available Power Knee developed by Ossur.
214483129|NCT02620852|OTHER|Complete a health questionnaire|Complete a health history questionnaire.
214483130|NCT02620852|DEVICE|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
214483131|NCT02620852|OTHER|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
214671744|NCT06365333|PROCEDURE|Fluoroscopic-guided air-enema reduction (FGAR)|A hand-held pump facilitated the delivery of atmospheric air, while pressure was monitored using a digital gauge. A two-way Foley's balloon catheter, ranging from 18oF to 24oF in diameter depending on age, was inserted rectally to introduce air. Following insertion, the balloon was filled with 10cc of saline to prevent air leakage, with patient immobilization ensured by leg straps and hand positioning above the head for abdominal exposure. Under intermittent fluoroscopy, the surgeon operated the pump with the right hand, inflating the catheter to 80 to 120 mmHg, simultaneously palpating the intussusceptum with the left hand, employing a deep gliding motion for deep and fixed cases. Successful reduction, indicated by air entry into the small bowel, was confirmed under fluoroscopy, with a subsequent brief rotating abdominal massage ensuring uniform air distribution throughout the small intestine, confirming complete reduction.
214919313|NCT06576453|BEHAVIORAL|quiz of knowledge|Parents must complete the quiz of knowledge after the first and the last session of the Pepps program.
214919314|NCT06576453|BEHAVIORAL|semi-structured interviews (qualitative)|In the month following the last session of the program, the semi-structured interviews (qualitative) will be carried out with parents who have followed either all or part of the sessions of the band.
214919315|NCT03520777|OTHER|Art Intervention|Type of artist intervention will be determined by the subject and the assigned artist.
214919316|NCT06231888|DEVICE|Aligner|Orthodontic alginer
214919317|NCT04411810|DEVICE|Nevisense 3.0|Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in the US. Nevisense 3.0 will be used as a one-time exposure of \<8 seconds per lesion. Disposable electrodes that contact the participant are 5mm x 5mm in size. Nevisense 3.0 measures electrical impedance of skin lesions and provides an output called the electrical impedence spectroscopy (EIS) score. Electrical impedance is a measure of a material's overall resistance to the flow of alternating electric currents of various frequencies. The principle is that electrical impedance is different in normal versus abnormal tissue.
215061320|NCT02290496|BEHAVIORAL|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
215061321|NCT01933698|DRUG|amoxicillin|Comparison of pharmacokinetics of both formulations
215061322|NCT04102800|DRUG|Benralizumab|subcutaneous injection
215061323|NCT02766439|DRUG|etanercept|25-mg etanercept injection subcutaneously twice a week
215061324|NCT03575663|DIAGNOSTIC_TEST|Indirect bronchial challenge|Mannitol dry powder inhalation
215061325|NCT03575663|OTHER|Sham bronchial challenge|Mock dry powder inhalation
215061326|NCT05996965|OTHER|HemoVista|additional attatchment of non-invasive hemodynamic monitoring HemoVista with FloTrac
214317893|NCT00963573|DRUG|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
214317894|NCT00963573|DRUG|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
214317895|NCT00805935|DRUG|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
214317896|NCT00805935|DRUG|Progesterone vaginal insert|100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
214317897|NCT00805935|DRUG|Follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
214483132|NCT02620852|OTHER|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
214483133|NCT05515497|DEVICE|BMT4me 2.0 app|The BMT4me app was designed by AWRI RISI developers and has been through multiple phases of stakeholder testing. The app is a virtual assistant for caregivers, allowing for medication record keeping, medication and refill reminders, symptom tracking, and a word and picture journal. All data is secured on the individuals password protected phone.
214483134|NCT06525363|DRUG|Chitosan|chitosan nanoparticles 1%w/w will be formulated in form of spray for oral application twice daily
214483135|NCT02111538|OTHER|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
214483136|NCT06200896|DEVICE|Self Forming Magnets used to Create A Compression Anastomosis|Self Forming Magnets used to Create A Compression Anastomosis connecting the Duodenum to the ileal in Post Sleeve Gastrectomy Patients and Jejunum to jejunum in Roux-en-Y patients.
215061327|NCT02293967|DRUG|MT-1303|
215061328|NCT01823159|DRUG|retigabine|Single oral administration of a 400 mg tablet.
215061329|NCT01823159|DRUG|placebo|Single oral administration of a tablet
215061330|NCT06644833|DEVICE|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (rTMS) sessions, targeting the dorsolateral prefrontal cortex, at a frequency of 10 Hz. Each session will last approximately 30 minutes, with 5 sessions per week for 4 to 6 weeks.
214483137|NCT02047500|DRUG|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
214483138|NCT02047500|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
214483139|NCT02047500|DRUG|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
214483140|NCT03323944|BIOLOGICAL|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.
214483141|NCT05782374|DRUG|Ibrutinib|ibrutinib alone or in combination with R-CHOP or R-CHOP like
214483142|NCT06960759|BEHAVIORAL|Behavioral cough suppression therapy combined with inactive inhaled drug (BCS+Sham)|Behavioral cough suppression therapy plus inactive inhaled drug. Treatment given twice per week for 12 sessions.
214483143|NCT06960759|COMBINATION_PRODUCT|Behavioral cough suppression therapy combined with capsaicin inhalation (BCS+CAP)|Behavioral cough suppression therapy combined with inhaled capsaicin (cough stimulant). Treatment given twice per week for 12 sessions.
214483144|NCT06960759|DRUG|Inhaled capsaicin (CAP)|Repeated inhalation of diluted capsaicin in increasing concentrations. Treatment given twice per week for 12 sessions.
214483145|NCT05190679|OTHER|None/Observational Studies|This is an observational study and there is no intervention.
214483146|NCT04220203|DRUG|Tucatinib|300 mg orally two times per day
214483147|NCT04220203|DRUG|Capecitabine|1000 mg/m\^2 orally two times per day on Days 1-14 of each 21-day cycle
214483148|NCT04220203|DRUG|Trastuzumab|Loading dose of 8 mg/kg into the vein (IV; intravenously), followed by 6 mg/kg IV once per 21-day cycle
214483149|NCT01473485|DEVICE|ExAblate Transcranial System|MR Guided Focused Ultrasound
214483150|NCT06356584|DRUG|Immunotherapy (Sintilimab)|Sintilimab
214483151|NCT06356584|DRUG|Targeted Therapy Agent (Fruquintinib)|Fruquintinib
214483152|NCT06356584|RADIATION|Radiotherapy (SBRT and LDRT)|SBRT and LDRT
214483153|NCT06476496|PROCEDURE|Acupuncture|A licensed acupuncturist will insert sterile disposable acupuncture needles in the selected body and ear acupoints aiming to alleviate long COVID related pain symptoms. Needles will be removed after 20 minutes of retention. After all the needles are removed, the acupuncturist will insert Pyonex press tack needles (0.3mm) in the participants' left ears and suggest the participants retain them in their ears for up to 5 days.
214483154|NCT05941988|PROCEDURE|pre grafting partial maxillary expansion with post grafting expansion|pre grafting partial maxillary expansion then anterior iliac grafting followed by 2 months period for consolidation then post grafting expansion till full arch alignment
214483155|NCT05419856|DRUG|4P-004|single intraarticular administration in the knee joint
214483156|NCT05419856|DRUG|Placebo|single intraarticular administration in the knee joint
214483157|NCT06677879|RADIATION|Proton radiotherapy|"Lumpectomy group: The total dose was 40.05Gy (RBE) , 2.67Gy (RBE) per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy (RBE) , 2.66Gy (RBE) per fraction with 16 fractions. Once a day, five times a week."
214919318|NCT04411810|DEVICE|Dermlite Cam|Dermlite Cam is a digital camera that captures images of the skin under cross-polarized and non-polarized light and is 510(k) exempt. The DermLite Cam device appears as a single piece camera with a charging cable and USB computer cable. As part of the camera unit, an extensor arm exists to allow for the capture of standardized clinical images. The DermLite Cam will be used to acquire 3 images of \<5 seconds per lesion (one clinical, one polarized dermoscopic, and one non-polarized dermoscopic). NOTE - for the purposes of this study, teledermatology images (dermoscopic and clinical - at approximately 6 inches, 12 inches, and 18 inches) were taken using the Barco Demetra after technical issues arose that prohibited the continued use of the Dermlite Cam.
215061331|NCT06644833|DRUG|Antidepressant|Selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, SNRIs
214483158|NCT06677879|RADIATION|Photon radiotherapy|"Lumpectomy group: The total dose was 40.05Gy, 2.67Gy per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy, 2.66Gy per fraction with 16 fractions. Once a day, five times a week."
214483159|NCT06687369|DRUG|MB12 (Proposed Pembrolizumab Biosimilar)|200mg IV, every 3 weeks on Day 1
214483160|NCT06687369|DRUG|EU-sourced Keytruda®|200mg IV, every 3 weeks on Day 1
214483161|NCT06687369|DRUG|US-sourced Keytruda®|200mg IV, every 3 weeks on Day 1
214483162|NCT06687369|DRUG|Pemetrexed|500 mg/m2 IV, every 3 weeks on Day 1
214483163|NCT06687369|DRUG|Carboplatin|Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.
214483164|NCT06687369|DRUG|Cisplatin|75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles
214483165|NCT06802653|DIAGNOSTIC_TEST|not provided|
214483166|NCT06390657|OTHER|Planning CT, MRI|"SBRT-PATHY and CARBON-PATHY planning is performed for study purposes only. Patients will be treated according to standard radiotherapy as per institutional policies.~The planning images (CT, MRI) will be anonymized and used for planning purposes only."
214483167|NCT05900557|DIAGNOSTIC_TEST|ECoG monitoring|Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.
214483168|NCT05961436|PROCEDURE|PENG block|Using ultrasound-guided technique, a total of 20ml of 0.25 % bupivacaine will be injected after negative aspiration.
214483169|NCT05961436|PROCEDURE|FN block|Using ultrasound-guided technique, after negative aspiration, 20 mL of 0.25 % bupivacaine will be administered.
214483170|NCT06986070|BIOLOGICAL|Stem cells|The suspension of stem cells will be put in a medical nebulizer machine, commonly used to deliver medicines into the lungs through inhalation. This means that the participants will breathe in the mist containing the SMS cells, produced by the nebulizer machine. This is a Phase I First-in-Human study, which indicates that this treatment is being studied for the first time in humans.
214483171|NCT06098716|BEHAVIORAL|Self Regulation|How to plan for Family PA
215061332|NCT00000149|DRUG|Beta Blocker|
215061333|NCT00000149|PROCEDURE|Trabeculectomy|
215061334|NCT00000149|PROCEDURE|Argon Laser Trabeculoplasty|
214483172|NCT06098716|BEHAVIORAL|PA Support & Family Social Identity|"Exercises that strengthen parents' PA-support identity and a shared active-family identity through values reflection, role-modelling, visualization, and visible active family cues."
214483173|NCT06098716|BEHAVIORAL|Education|Information about healthy living (e.g., PA, sleep hygiene and healthy eating)
214483174|NCT03816397|BIOLOGICAL|Adalimumab|Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody, a biologic, immunomodulatory drug. Adalimumab 20mg/0.8 mL and 40mg/0.8 mL is a clear, colorless solution provided in a pre-filled syringe for subcutaneous injection. The formulation is adalimumab, mannitol, polysorbate 80, and water for injection Each pre-filled syringe has a fixed 29-gauge thin wall and ½ inch needle with black protective cover and is intended for a single dose to a single patient.
214483175|NCT03816397|OTHER|Placebo|The placebo solution is a clear, colorless solution provided in a single-use, pre-filled syringe for subcutaneous injection. The volume-matched (0.8mL) placebo is designed to match the characteristics of the citrate-free adalimumab during injection.
214483176|NCT06987734|DRUG|Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab|Patients will receive 3-4 cycles of neoadjuvant treatment with preoperative suglizumab in combination with chemotherapy, followed by surgery. After surgery, patients will receive 1-4 cycles of platinum-containing adjuvant chemotherapy，followed by 1 year of adjuvant sugemalimab.
214483177|NCT06997874|PROCEDURE|Phacovitrectomy|Participants will undergo phacovitrectomy to remove the lens (phacoemulsification and intraocular lens implantation) and to repair the RRD (vitrectomy). Although a phacovitrectomy is done in the same manner whether the condition to be treated is macular hole or RRD, the calculations required for the surgeon to select which intraocular lens should be implanted are different if there is a RRD with a detached macula. For this reason, a Standard Operating Procedure (SOP) will be prepared for the phacovitrectomy group to guide surgeons on how to best determine the intraocular lens under these circumstances (17). Vitrectomy with any gauge size (e.g.23g, 25g, 27g) will be allowed for the surgery, as per standard care at the participating site. The choice of the tamponade agent will be at the discretion of the treating vitreoretinal surgeon, as per standard care.
214483178|NCT06997874|PROCEDURE|Vitrectomy|Participants will receive vitrectomy to repair their RRD. The vitrectomy would be done as per standard care. Vitrectomy with any gauge size (e.g.23g, 25g, 27g) will be allowed for the surgery, as per standard care at the participating site. The choice of the tamponade agent will be at the discretion of the treating vitreoretinal surgeon, as per standard care. Then, if a cataract develops, phacoemulsification and intraocular lens implantation will be done as per standard clinical practice.
214483179|NCT06996743|OTHER|reformer pilates group|Reformer Pilates exercises were applied to the pilates group twice a week for a total of 8 weeks.
214483180|NCT06996743|OTHER|Mat pilates group|Mat Pilates exercises were applied to the pilates group twice a week for a total of 8 weeks.
214483181|NCT06996743|OTHER|Lifestyle change group|After the doctor's check-up, routine application continued. The patient was informed about physical activity. In addition; a physical activity-based brochure prepared by the Specialist Physiotherapist was distributed to the participants in this group.
214483182|NCT06993922|OTHER|Scalp block|Patients will receive a scalp block with bupivacaine alone.
214483183|NCT06993922|OTHER|Scalp block + Dexmedetomidine|Patients will receive a scalp block with dexmedetomidine as an adjuvant to bupivacaine.
214483184|NCT06997510|BEHAVIORAL|Personalized lifestyle recommendations based on artificial intelligence (AI) and polygenic risk scores (PRS)|"Personalized lifestyle intervention that integrates artificial intelligence (AI), polygenic risk scores (PRS), and real-time behavioral and environmental data. MyBETTER4U dynamically adapts to individual needs by combining genetic and biological profiling (e.g., PRS, microbiome, metabolomics), behavioral determinants (e.g., eating habits, physical activity, sleep patterns), sociodemographic and environmental context, technology-assisted self-monitoring through wearable devices and digital tools, and AI-driven decision-support systems that generate ongoing, individualized recommendations.~Intervention group participants will receive personalized recommendations via the Better4U Platform, based on the AI model and, when available, their PRS and genetic data. Since genotyping results depend on sample processing timelines, baseline visits should be scheduled when results are available or expected within 1.5 months to ensure inclusion in the next visit."
214483185|NCT06997510|BEHAVIORAL|Standard care: lifestyle counselling, healthy eating leaflet, and hyocaloric diet targeting ≥5% weight loss in 6 months.|"Participants will receive feedback and counselling from the implementers on their weight status and lifestyle behaviours, based on their measurements/responses during the screening assessment. This counselling will be based on the general healthy eating (based on the Mediterranean diet) and healthy lifestyle recommendations for physical activity, sedentary time, and sleep (based on WHO recommendations) and will be considered the standard care. Those recommendations will also be handed in to them in the form of a standard care leaflet to take home. Participants will also be provided with a standard hypocaloric diet based on their needs for weight loss, aiming for a ≥ 5% reduction in body weight at the end of the 6-month intervention period."
214483186|NCT06996912|DRUG|HSK44459|HSK44459 will be administered orally twice daily
214483187|NCT06996912|DRUG|Placebo|Placebo will be administered orally twice daily
214671745|NCT00844298|DRUG|Nilotinib+mVPD|"1. Induction:~   * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~  * Vincristine 2 mg iv push (d1, 8, 15, 22)~  * Prednisolone 60 mg/m2/day po (d1-28)~  * Nilotinib 400mg bid/d (d8-)~2. Consolidation A (cycle1)~   * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~  * Vincristine 2 mg iv (d1, 8)~  * Prednisolone 60 mg/m2/day po (d1-14)~  * Nilotinib 400mg bid/d~3. Consolidation B (cycles 2\&4)~   * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~  * Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~  * Nilotinib 400mg bid/d~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~  * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~  * Nilotinib 400mg bid/d~5. Maintenance~   ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~6. Consider alloHCT"
214671746|NCT00270920|BEHAVIORAL|Lactation counseling|
214671747|NCT05134974|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
215061335|NCT05578989|DEVICE|Virtual reality glasses|watching a video with music with virtual reality glasses.
215061336|NCT01861691|PROCEDURE|Open surgery|Conventional technique
215061337|NCT01861691|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
214317898|NCT00805935|DRUG|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
214317899|NCT00805935|DRUG|leuprolide acetate|Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
214317900|NCT04683991|PROCEDURE|Subepithelial connective tissue graft|A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
214317901|NCT00838266|DRUG|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
214483188|NCT05374109|BEHAVIORAL|SYV: Sauti ya Vijana (The Voice of Youth intervention)|Mental health is associated with ART adherence and HIV outcomes. SYV was designed to address the specific challenges of young people living (YPLWH) with HIV in Tanzania. SYV includes 10 group sessions (two sessions held jointly with caregivers) lasting approximately 90 minutes and two individual sessions delivered by trained young adult group leaders who use a manualized protocol that is designed to scale in low resource settings. The intervention is applied to the Social Action Theory (SAT), a theoretical framework used to determine factors that influence health behavior. Building off a SAT resilience framework for YPLWH, components of evidence-based treatment models to influence cognitive, self, and social regulation to improve behavioral health outcomes will be strategically used.
214483189|NCT06996041|OTHER|Chocking first aid management program|Power point presentation , Video demonstration, and Practical demonstration of chocking first aid management
214483190|NCT06996938|DIAGNOSTIC_TEST|Rapid diagnostic orientation tests (TROD) HIV, Hepatitis, syphilis|"The following information will be collected :~* Socio-demographic characteristics~* Lifestyle~* Health status~* Access to care and support in care~* Life events/violence~Knowledge of HIV prevention will be assessed~It will be proposed to screen for potentially serious STIs in the absence of specific management. If one of these infections is detected, the women will be referred and accompanied to a specialized consultation in the medical centers participating in the study~Women's needs in terms of health and access to care will be assessed: infections, gynecology, psychology, management of individual violence, sexual in particular, prophylaxis with regard to HIV"
214483191|NCT06997237|BEHAVIORAL|Music Listening Intervention|Participants listened to a playlist of 5-6 music tracks they personally selected before surgery. The music was played continuously for 30 minutes through Bluetooth headphones during liver transplantation. Volume was kept at 65 decibels.
214483192|NCT06997237|BEHAVIORAL|Silence with Headphones|Participants wore Bluetooth headphones during the surgery, but no audio was played. This intervention was designed to control for the effect of wearing headphones and isolating ambient operating room sounds.
214483193|NCT06996587|PROCEDURE|Robotic-Assisted Flexible Ureteroscopy|Use of the ILY® robotic system to perform flexible ureteroscopy.
214483194|NCT06996587|PROCEDURE|Manual Flexible Ureteroscopy|Conventional flexible ureteroscopy performed manually by the surgeon.
214483195|NCT06997185|OTHER|Statement communicating uncertainty with a single arm trial|Because Zenova has not been compared to other treatments, it is unknown if Zenova is better, the same, or worse than other treatments for non-small cell lung cancer.
214483196|NCT06997185|OTHER|Statement communicating uncertainty with limited study duration|Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.
214483197|NCT06997185|OTHER|Statement communicating uncertainty with a limited study population|Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.
214483198|NCT06997185|OTHER|Statement communicating uncertainty with an unvalidated surrogate endpoint|Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.
214919319|NCT04411810|PROCEDURE|Skin biopsy|A skin biopsy is a small procedure that removes a sample of skin from the surface of the body. The method utilized will be either a shave or punch technique. The maximum size of a punch biopsy will be 6mm and these wounds are generally closed with no more than 2-3 sutures. A skin biopsy takes \<15 minutes including preparation time, administration of intradermal anesthesia using lidocaine 1% with epinephrine 1:100,000, removal of the skin sample, achievement of hemostasis, dressing the wound, and providing instructions for home care. Samples will be placed formalin for routine processing.
214317902|NCT00838266|OTHER|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
214317903|NCT00347295|DRUG|Brotizolam|
214317904|NCT00347295|DRUG|Estazolam|
214483199|NCT06997185|OTHER|Statement communicating uncertainty with treatment effect size|It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
214671748|NCT05134974|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
214671749|NCT02917863|DRUG|L-Thyroxine (tablet, per os)|
214671750|NCT02917863|DRUG|L-Thyroxine (oral drops, solution)|
214317905|NCT00072150|DRUG|bortezomib|Given IV
214317906|NCT04607993|BEHAVIORAL|Prone position ventilation technique|"1. Inform the children's family members of the purpose and method of prone position ventilation~2. Assess the fixation of various catheters~3. Suspend feeding before placing prone position~4. Confirm the time to start prone position ventilation under the joint assessment of medical staff~5. Place the child in a prone position with the participation of researchers, doctors and nursing staff, with the child's head tilted to one side to avoid damage to the eyes and nose due to compression, and the arms are bent upward to form a W . Bend both lower limbs downward to form an M shape, and use a soft pillow cushion to measure the knee joints to avoid compression~6. The whole process ensures the smooth fixation of tracheal intubation and various catheters~7. Proper sedation during prone position ventilation to achieve good human-machine synchronization~8. At least 6-8 hours in prone position every day"
214317907|NCT02945410|OTHER|Caloric Restriction|Participants will consume 30 kcal/kg FFM/day.
214317908|NCT02945410|OTHER|Protein|Participants will consume 1.7 g protein/kg BW/day.
214671751|NCT01408537|BIOLOGICAL|JEVAC|Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
214671752|NCT03287297|DIAGNOSTIC_TEST|OGTT & HBA1c|oral glucose tolerance test \& HBA1c: by measuring glycated hemoglobin
214671753|NCT01878006|DRUG|Morphine|
214919320|NCT04411810|DEVICE|Barco Demetra|Barco Demetra is a non-invasive skin imaging system, which acquires multispectral and white light dermoscopic images and clinical photographs of the skin which can then be stored, retrieved, displayed, and reviewed by medical practitioners. The Barco Demetra received 510(k) Premarket approval (K192829). The system involves a hardware imaging device and a stand-alone software application. The hardware device is a portable, battery-powered medical device for acquiring and visualizing images of the skin and uploads all images to cloud storage. The software application is cloud software with an associated web application; it can be used to visualize images and related data and can generate consultation reports. For the purposes of this study, teledermatology images (dermoscopic and clinical - at approximately 6 inches, 12 inches, and 18 inches) were taken using the Barco Demetra after technical issues arose that prohibited the continued use of the Dermlite Cam.
214919321|NCT03981926|OTHER|Team-Based Connected Health (TCH)|TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
214919322|NCT02656004|OTHER|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
214671754|NCT01878006|DRUG|Placebo|
214671755|NCT04792151|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
214671756|NCT04908137|DRUG|2-octyl cyanoacrylate|Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet No. 2. It is provided as a single use applicator in a blister package
214671757|NCT05385614|BEHAVIORAL|de:)press|Patients will receive de:)press for the duration of six weeks. They will be encourages to use the app at least three times a week, up to once per day.
214919323|NCT02656004|OTHER|Control Session|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
215061338|NCT06114914|DIAGNOSTIC_TEST|Tap Talk online program|Online hand and speech motor testing
215061339|NCT03689608|OTHER|Intermittent Fasting (IF)|Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
215061340|NCT03689608|OTHER|Daily Restriction (DR)|Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
215061341|NCT03689608|OTHER|standard care (SC)|Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.
214317909|NCT02945410|OTHER|Exercise|Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
214317910|NCT02945410|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
214317911|NCT02945410|OTHER|Maltodextrin|Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
214317912|NCT05156580|OTHER|No intervention|This is an observational study without any intervention
214317913|NCT04441333|DEVICE|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum
214317914|NCT01095588|DRUG|200 mg Avanafil|2 X 100mg tablets avanafil
214317915|NCT01095588|DRUG|Placebo|2 tablets
214317916|NCT01344369|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
214317917|NCT01344369|DRUG|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
214317918|NCT03227887|OTHER|Two samples of saliva|"1. Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~2. With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation"
214317919|NCT03227887|OTHER|Chewing behaviour|Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
214317920|NCT03227887|OTHER|Study of the food bolus|"2 tests:~1. Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~2. The bolus will be analysed visually"
214317921|NCT03227887|OTHER|Mouthfeel|Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
214317922|NCT04287907|DEVICE|Monitor Group|Use of colorimetric end tidal CO2 to guide provider during provision of mask ventilation, where colour change indicates effective breaths
214317923|NCT03848845|DRUG|belantamab mafodotin|belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
214317924|NCT03848845|DRUG|Pembrolizumab|Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
214317925|NCT01746758|BEHAVIORAL|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
214671758|NCT00212238|BEHAVIORAL|internet behavioral weight loss program|
214671759|NCT00052429|DRUG|cisplatin|
214671760|NCT00052429|DRUG|fluorouracil|
214671761|NCT00052429|PROCEDURE|adjuvant therapy|
214671762|NCT00052429|RADIATION|radiation therapy|
215061342|NCT00851331|GENETIC|genome analyzes (genetic defects and pathophysiological mechanisms )|
214317926|NCT01454726|OTHER|Diaoshi Jifa therapy plus the Western medical treatment.|Diaoshi Jifa treatment
214317927|NCT01454726|OTHER|drug|the Western medical treatment alone.
214317928|NCT04200248|DRUG|RBM-007 Injectable Solution|RBM-007 Injectable Solution
215061343|NCT03763812|PROCEDURE|Endovascular Aneurysm Repair (EVAR)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
215061344|NCT03763812|PROCEDURE|Endovascular Aneurysm Sealing (EVAS)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
215061345|NCT06346431|COMBINATION_PRODUCT|DSPT - Digital Support for Problem-solving Therapy|Mobile app breaking major treatment and social needs into subtasks, providing information, prompts and in-app payment to complete those tasks.
215061346|NCT03133819|DEVICE|Q-Sense_QST (TSA II)|QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
215061347|NCT05474703|OTHER|SF-36 Scores|"From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied."
215061348|NCT03078543|DEVICE|ANTHEM™ PS Total Knee System implant|"The ANTHEM™ PS Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ PS Total Knee System consists of the following components:~* Cobalt-Chrome (Co-Cr) femoral components - Posterior stabilised~* Titanium primary tibial components~* Posterior-stabilised ultra-high molecular weight polyethylene (UHMWPE)~* Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications."
215061349|NCT06435416|OTHER|No intervention|No intervention
215061350|NCT04999384|DRUG|AN4005-dose level 0|50mg BID
215061351|NCT04999384|DRUG|AN4005-dose level 1|100mg BID
214317929|NCT04200248|DRUG|Aflibercept|EYLEA® (aflibercept) Injection, for Intravitreal Use
214317930|NCT04200248|DRUG|Sham|Sham intravitreal injection
214317931|NCT05262634|OTHER|Data collection (laboratory and obstetric results)|"Maternal data: age, pregnancy, parity, singleton or multiple pregnancy, BMI, obstetric history data, and ethnicity.~Laboratory chemical results: hemoglobin (Hb), number of erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), number of hypochromic erythrocytes (HRC), erythrocyte distribution width (EBW), ferritin, C reactive protein (CRP).~Maternal pregnancy outcomes and complications: Hb before and after delivery, mode of delivery, placenta abruption, preeclampsia/eclampsia, gestational diabetes, gestational cholestasis, pregnancy-induced hypertension, bacteriuria or urinary tract infections, peripartum and postpartum hemorrhage, puerperal infections, uterine subinvolution.~Perinatal outcomes: gestational age, birth weight, intrauterine growth retardation, preterm birth, macrosomia, premature rupture of membranes, Apgar score, intrauterine fetal death, pH values, admission to neonatology"
214317932|NCT02332551|DEVICE|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
214919324|NCT05670665|OTHER|Threatened preterm labor|Presence of uterine contractions and cervical shortening between 24+0 and 36+6 weeks of gestation and/or rupture of the membranes between 24+0 and 36+6 weeks of gestation.
214919325|NCT02149979|DEVICE|Temperature Controlled Laser Soldering|This study had a prospective within-subject design. Patients allocated to laparoscopic cholecystectomy procedure were enrolled. After the completion of the laparoscopic cholecystectomy surgical procedure, 4 trocar port sites were randomly either sutured or laser soldered by employing the temperature-controlled laser soldering system.
214919326|NCT01920958|OTHER|TachoSil®|TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and tissue sealing in surgery.
214919327|NCT02323542|OTHER|Nutrition intervention with cereal products|acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
214671763|NCT00683189|DRUG|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
214919328|NCT06966674|DRUG|Intracoronary tirofiban|Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
214919329|NCT06966674|DRUG|Saline 0.9%|Patients will receive intracoronary saline 0.9% solution as a control group.
214919330|NCT03911063|BEHAVIORAL|CBT sessions|weekly 20-40 min CBT sessions during 8 weeks; Both the talking sessions (i.e., placebo) and CBT sessions will be performed via telemedicine either via a HIPAA secure telemedicine platform or the telephone based on the preference of the individual patient.
214919331|NCT03911063|BEHAVIORAL|Talking Sessions|20-40 min talking sessions (i.e., placebo) for 8 weeks; The placebo talking sessions will be performed by an acute care and palliative care board certified, New York State licensed nurse practitioner at the NYU Dysautonomia Center who is familiar with each FD subject enrolling in the study and an expert in familial dysautonomia. The NP will focus the 20-40 minute conversation on typical medical questions and concerns that the FD patient routinely calls the Center to discuss.
214317933|NCT01784783|BEHAVIORAL|HOPE Intervention|"If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.~Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session."
214317934|NCT01784783|BEHAVIORAL|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
214483200|NCT06997861|OTHER|Medication Review Type III|The MR arm will receive four MR interviews. In the first MR, information about the patient's personal and medical history, along with current health problems, relevant lab exams and medication will be gathered. This will be used to proceed with medication review process and assessment of Drug Related Problems (DRP) that may lead to negative medication results. A personalized care plan will be developed to correct any detected DRP, delivered in writing/e-mail to the patient and carefully explained. Some DRP's may need the physician's intervention to correct. In these cases, a detailed recommendation will be sent to the patient's physician via email. All physicians' recommendations acted upon or not, will be recorded. Subsequent interviews will assess patient compliance with the care plan and if necessary, adjustments will be made accordingly.
214483201|NCT06997861|OTHER|Usual Care|The UC arm will receive an intervention by the investigator at the same time frame defined for the MR arm. The intervention will also consist of interviews, although MR will not be conducted. The investigator will ask questions to the patient about is drug therapy in a similar fashion to what would happen in the community pharmacy. Simple advice and information will be carried out (i.e., reinforcement of adherence, explanation about indication of drugs etc.)
214483202|NCT06996093|DRUG|4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy|4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
214483203|NCT06996093|DRUG|aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor|aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
214483204|NCT06997588|DRUG|Alpelisib|"Oral Film-Coated Tablet (FCT):~* Group 1: 250 mg once daily~* Group 2, 6 to \<18 years: 125 mg once daily (starting dose)~Granules:~• Group 2, 2 to \<6 years: 50 mg once daily (starting dose)"
214483205|NCT06618417|DEVICE|sleep apnea home-evaluation|Participants will receive a home-monitoring device by mail to test for sleep apnea at home
214483206|NCT03283137|DRUG|TGR-1202|TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.
214483207|NCT03283137|DRUG|Pembrolizumab|Pembrolizumab will be given at 200 mg every 3 weeks. The dose will not be adjusted throughout the course of the study.
214483208|NCT06685536|OTHER|Safety and efficacy assessments|Safety evaluations,disease-specific assessments,and assessments to monitor for long-term complications of autologous transplant
214483209|NCT05292404|DRUG|alirocumab|In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months
214483210|NCT05292404|OTHER|conventional treatment|conventional treatment were given according to international uniformguidelines
214483211|NCT05812781|DRUG|VTX2735|Dose A
214483212|NCT05812781|DRUG|VTX2735|Dose B
214483213|NCT06430177|BEHAVIORAL|Su Jok|Su Jok will be done
214483214|NCT05930860|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
214483215|NCT05301881|PROCEDURE|Surgery|resection of the oligometastatic lesion(s)
214483216|NCT05301881|RADIATION|Radiotherapy|radiation of the oligometastatic lesion(s)
214483217|NCT05301881|OTHER|Radiofrequent ablation|radiofrequent ablation of the oligometastatic lesion(s)
214483218|NCT05145868|BEHAVIORAL|Alcohol Skills and Emotion Regulation Intervention|The text-based intervention will provide alcohol reduction strategies and emotion regulation skills.
215061352|NCT04999384|DRUG|AN4005-dose level 2|200mg BID
215061353|NCT04999384|DRUG|AN4005-dose level 3|400mg BID
214317935|NCT05022758|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|One of NOAC (Non-vitamin K antagonist oral anticoagulants)
214317936|NCT05022758|DRUG|Warfarin|One of OAC (Oral anticoagulation therapy)
214483219|NCT05145868|OTHER|Attention Control|Text-messages will be sent that include no intervention content to serve as an attention control
214483220|NCT04809363|OTHER|CDPATH™|Crohn's disease risk prediction tool.
214483221|NCT04809363|OTHER|Blood Draw|Three blood samples will be drawn.
214483222|NCT04254484|BEHAVIORAL|SIESTA Rehab Education|Staff nurses will be trained on how to improve sleep in stroke patients in the acute rehabilitation setting.
214483223|NCT04254484|DIAGNOSTIC_TEST|ApneaLink|Stroke patients on the SIESTA Rehab unit will be screened for sleep disordered breathing using ApneaLink monitors. Results will be interpreted by a sleep specialist who will then advise the clinical team at SRALab.
214483224|NCT06689943|DRUG|Tylenol|Tylenol for children
215061354|NCT04999384|DRUG|AN4005-dose level 4|600mg BID
215061355|NCT04999384|DRUG|AN4005-food effect|Dose to be determined upon the MTD determination
214483225|NCT06688279|OTHER|Plyometric Exercise|". The session will last for 60 minutes and 3 times per week. 5 minutes warm up with dynamic stretching and 5 minutes cool down period with static stretching and 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set (total 3 sets).~Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step. Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
214317937|NCT04210635|OTHER|ZEN cart|essential oils + relaxing music + dim light
214317938|NCT00743912|DRUG|rifaximin|550 mg TID
214317939|NCT04761068|DEVICE|VEST|Venous External Support for vein grafts in CABG
214317940|NCT06255652|DRUG|Cephradin|Velosef
214483226|NCT06688279|OTHER|Standard exercises protocol|"The session will last for 60 minutes and 3 times per week. Following exercises would be performed.~* Push ups.~* Sit ups.~* Lunges~* 500 m running.~* Squats Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
214483227|NCT05190341|DRUG|Ibuprofen 800 mg oral|1 hour before HSG
214483228|NCT05190341|DRUG|Ketorolac 30mg oral|1 hour before HSG
214483229|NCT04198701|DEVICE|Medtronic PulseSelect Pulsed Field Ablation (PFA) System|Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.
214483230|NCT04733183|DRUG|Dacarbazine|Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
214483231|NCT04733183|DRUG|onfekafusp alfa|L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
214483232|NCT06679829|DRUG|Siltuximab|11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).
214483233|NCT06679829|DRUG|Melphalan|"Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2"
214483234|NCT06681246|OTHER|Antibiotic treatment|10 days of either antibiotics- Augmentin (amoxicillin+clauvonate), 875mg, 2 /day
214483235|NCT06681246|OTHER|Placebo|consist of a combination of agarose in normal saline/glycerol
214483236|NCT06681701|PROCEDURE|Combined Manual Therapy and Pulmonary Exercises|"Diaphragmatic breathing exercise:~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia.~Rib mobilization from sitting:~Rib mobilization from supine:~Central Posterior-Anterior (PA) mobilization of thoracic facet joints:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:"
214483237|NCT06681662|DRUG|Ephedrine Hydrochloride 30 mg/ml|0.15 mg/kg during induction.
214483238|NCT06681662|DRUG|Saline (NaCl 0,9 %) (placebo)|1 ml during induction.
214483239|NCT05797480|OTHER|Real Dry needling|Real dry needling will be applied to the pelvic floor, hip and lower back muscles.
214483240|NCT05797480|OTHER|Non penetrating dry needling|Sham non penetrating dry needling (fixed needle in an introducer tube) will be applied to the pelvic floor, hip and lower back muscles.
214483241|NCT04752696|DRUG|Onvansertib|Oral capsule
214919332|NCT06576986|DIETARY_SUPPLEMENT|Symbiotic|The synbiotic used will be Simbioflora® (commercial preparation containing 5.5g of FOS added with four species of probiotic, Lactobacillus paracasei LPC-31; Lactobacillus rhamnosus HN001; Lactobacillus acidophilus NCFM; Bifidobacterium lactis HN019, at a concentration of 109 UFC per strain) supplied by Farmoquímica S.A. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.
214317941|NCT05909371|OTHER|exercise|Application of two different exercises to liver transplant individuals.
214317942|NCT04908254|DEVICE|Crossover Device (PCD or Dayspring - alternate to first group)|Cross over arms after a month of use and a month of washout period
214317943|NCT02155335|DRUG|Prefilled Syringe delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using prefilled syringe
214317944|NCT02155335|DRUG|Smartject Device delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using Smartject Device.
214317945|NCT01819805|DRUG|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
214317946|NCT01456325|DRUG|Erlotinib|Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
214317947|NCT01456325|DRUG|Onartuzumab (MetMab)|Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
214317948|NCT01456325|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
214317949|NCT01358318|OTHER|Satiety|Single consumption of snack bars to determine satiety and food intake at next meal.
214317950|NCT00934544|DRUG|Ruxolitinib|5 mg tablets packaged as 60-count in high-density polyethylene bottles
214317951|NCT00934544|DRUG|Best Available Therapy (BAT)|Prescribing and usage per respective package inserts
214317952|NCT03793907|DEVICE|FitBit|Wear Fitbit
214317953|NCT03793907|OTHER|Quality-of-Life Assessment|Ancillary studies
214317954|NCT03793907|OTHER|Questionnaire Administration|Ancillary studies
214317955|NCT03793907|OTHER|Resistance Training|Complete strength training
214317956|NCT03793907|BEHAVIORAL|STEPS to Enhance Physical Activity|Complete a walking program
214483242|NCT04752696|DRUG|Nanoliposomal irinotecan|Intravenous infusion
214483243|NCT04752696|DRUG|Leucovorin|Intravenous infusion
214483244|NCT04752696|DRUG|Fluorouracil|Intravenous infusion
214919333|NCT06576986|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin, used as control, will be purchased from the company PRODIET® under the trade name Carboch®. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.
214919334|NCT06969092|OTHER|Oral Frailty|The exposure factor is the presence of oral frailty in patients before surgery, and oral frailty is evaluated using a scale.
214919335|NCT04059614|PROCEDURE|HFNC; COT|"HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy"
214919336|NCT00610155|DRUG|Placebo|BID
214919337|NCT00610155|DRUG|Pregabalin|Dose 75 mg titrated to 150 mg, bid
214919338|NCT00610155|DRUG|Tramadol SR|Dose 50mg titrated to 200 mg, bid
214919339|NCT01560234|DRUG|AZD8848|Single dose, oral inhalation (nebuliser solution)
214919340|NCT01560234|DRUG|Placebo|Single dose, oral inhalation (nebuliser solution)
214919341|NCT06578858|BEHAVIORAL|Application of questionnaires|Application of SOC-13 and BRS questionnaires in patients after gastric cancer surgery
214317957|NCT00189046|BEHAVIORAL|driving and laboratory tests|
214317958|NCT02781636|DEVICE|Device: StimGuard Protect System|Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
214317959|NCT00482495|BIOLOGICAL|bevacizumab|
214317960|NCT00482495|GENETIC|gene expression analysis|
214317961|NCT00482495|GENETIC|protein expression analysis|
214317962|NCT00482495|OTHER|laboratory biomarker analysis|
214317963|NCT00302003|RADIATION|radiation therapy|Undergo radiation therapy
214317964|NCT00302003|DRUG|doxorubicin hydrochloride|Given IV
214317965|NCT00302003|DRUG|vincristine sulfate|Given IV
214317966|NCT00302003|DRUG|prednisone|Given orally
214317967|NCT00302003|DRUG|cyclophosphamide|Given IV
214317968|NCT00302003|DRUG|ifosfamide|Given IV
214317969|NCT00302003|DRUG|vinorelbine tartrate|Given IV
214317970|NCT00302003|DRUG|dexamethasone|Given IV
214317971|NCT00302003|DRUG|etoposide phosphate|Given IV
214317972|NCT00302003|DRUG|cisplatin|Given IV
214317973|NCT00302003|DRUG|cytarabine|Given IV
214317974|NCT00302003|BIOLOGICAL|filgrastim|Given IV or subcutaneously
214317975|NCT01218516|BIOLOGICAL|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
214317976|NCT01218516|OTHER|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
214317977|NCT01218516|DRUG|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].
214317978|NCT01218516|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 will be administered intravenously.
214317979|NCT01218516|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously.
214317980|NCT01218516|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously.
214317981|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules with 1 pack of Omethyl cutielet
214317982|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules
214317983|NCT05365438|DRUG|Atorvastatin-Ezetimibe|ezetimibe/atorvastatin 10/20 mg
214317984|NCT06441734|DIAGNOSTIC_TEST|cbc serum ferritin serum iron|by using sample of blood to do cbc and serum ferritin and serum iron during 1year
214317985|NCT02042924|RADIATION|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
214317986|NCT02042924|DEVICE|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
214317987|NCT00283439|BIOLOGICAL|AMG 531|"Planned Cohorts:~1. 100 mcg,~2. 300 mcg,~3. 700 mcg,~4. 1000 mcg;~   Optional Cohorts:~5. cohort expansion,~6. schedule change,~7. new dose"
214317988|NCT03111420|DRUG|P2Y12 inhibitor|Administration of P2Y12 inhibitor antiplatelet therapy
214317989|NCT03111420|DEVICE|Platelet function test|Blood is drawn for testing of platelet aggregation activity
214317990|NCT02183441|DRUG|BI 1356|
214317991|NCT02183441|DRUG|Ritonavir|
214317992|NCT06096415|DRUG|ABX-101 1mg|ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
214317993|NCT06096415|DRUG|ABX-101 2mg|ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
214317994|NCT05419102|PROCEDURE|peri-implantitis surgery with enamel matrix derivative|surgical procedures around dental implants with peri-implantits to remove infectious material and apply enamel matrix derivative to the implant.
214317995|NCT02761811|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
214317996|NCT05802693|DRUG|Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection|Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule
214317997|NCT04033003|BEHAVIORAL|Group ANC|Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
214317998|NCT01023165|PROCEDURE|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
214317999|NCT03038464|DIAGNOSTIC_TEST|Synovial biopsy|Biopsy of jint prior reimplantation of new joint prosthesis
214318000|NCT01563575|OTHER|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
214318001|NCT04657536|DEVICE|high frequency fulguration equipment|All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
214318002|NCT04657536|DRUG|promestriene vaginal soft capsules|Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
214318003|NCT05957133|PROCEDURE|Multicomponent exercise without action observation.|Different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
214318004|NCT05957133|PROCEDURE|Multicomponent exercise associated with action observation|Different exercise modalities are integrated: aerobic, mobility, strength, balance and coordination exercises carried out at all times by the physiotherapist and observed by the participants.
214318005|NCT02611258|DRUG|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
214318006|NCT00028756|DRUG|doxorubicin hydrochloride|Given IV
214318007|NCT00028756|DRUG|gemcitabine hydrochloride|Given IV
214318008|NCT00028756|DRUG|vinblastine sulfate|Given IV
214318009|NCT00028756|DRUG|methotrexate|Given IV
214318010|NCT00028756|DRUG|cisplatin|Given IV
214318011|NCT00028756|BIOLOGICAL|filgrastim|Given SC
214483245|NCT06874582|DEVICE|silicone hand or finger prosthesis|To the best of the author's knowledge, no previous studies have evaluated and compared customised finger and partial silicone prostheses in both extremities. This feature distinguishes the present study from other studies.
214318012|NCT02240381|PROCEDURE|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
214318013|NCT02240381|PROCEDURE|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
214318014|NCT02240381|OTHER|laboratory biomarker analysis|Correlative studies
214318015|NCT04550624|DRUG|Pembrolizumab Injection [Keytruda]|200mg IV on day 1 of each cycle
214318016|NCT04550624|DRUG|Lenvatinib Mesylate|20mg PO daily days 1-21 of each cycle
214318017|NCT01932216|PROCEDURE|Cholecystectomy|Gallbladder removal
214318018|NCT01034410|DRUG|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
214318019|NCT01034410|DRUG|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
214318020|NCT03377946|BIOLOGICAL|probiotics|the probiotics group was taking probiotics 4 packets a day
214318021|NCT03377946|BIOLOGICAL|placebo|the placebo group was taking placebo 4 packets a day
214318022|NCT02825069|OTHER|Early introduction of solid foods|Early introduction of solid foods
214318023|NCT03193606|OTHER|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
214318024|NCT00774033|DEVICE|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
214318025|NCT00774033|PROCEDURE|classic skin grafts|classic skin grafts used for the treatment of acute burn
214318026|NCT00430092|DRUG|Difluprednate|
214318027|NCT00430092|DRUG|Difluprednate|
214318028|NCT00430092|DRUG|Placebo|
214318029|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 1
214318030|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 2
214318031|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 3
214318032|NCT01529424|DRUG|Placebo|Dose 1
214318033|NCT01529424|DRUG|Placebo|Dose 2
214318034|NCT01529424|DRUG|Placebo|Dose 3
214318035|NCT00882531|DRUG|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
214318036|NCT00882531|DRUG|placebo|
214483246|NCT06874582|DEVICE|silicone foot and foot toe prosthesis|To the best of the author's knowledge, no previous studies have evaluated and compared customised finger and partial silicone prostheses in both extremities. This feature distinguishes the present study from other studies.
214483247|NCT06875531|OTHER|Creative Drama trainings|"* The experimental group will be trained with the creative drama method and the control group will be trained with the traditional teaching method in line with the learning objectives on the topics of human dignity, responsibility, taking action, safety, autonomy.~* Creative Drama trainings will be carried out by the creative drama leader and the trainings will be continued in line with the creative drama training steps, starting with the warm-up phase, and continuing with the game, activity, improvisation and evaluation phases. Creative drama methods will be used in accordance with each topic. For each stage of the training, students will be divided into equal groups so that group members will change. Each session of creative drama training; 10 minutes for the warm-up stage, 30 minutes for the game activity stage, 30 minutes for the improvisation stage, 20 minutes for the formation and evaluation stages, and each topic will be carried out for a total of 90 minutes."
215061357|NCT02692768|OTHER|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
215061358|NCT02692768|OTHER|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
214483248|NCT06874920|OTHER|No intervention (observational study)|No intervention (observational study)
214318037|NCT00401011|DRUG|Perifosine|"Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks."
214318038|NCT00401011|DRUG|Bortezomib|Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
214318039|NCT00401011|DRUG|Dexamethasone|Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
214318040|NCT03930316|DEVICE|NOX T3|portable sleep study device
214318041|NCT00909636|DRUG|ABT-333|See arm description for more information
214318042|NCT00909636|DRUG|Placebo|See arm description for more information
214318043|NCT00706966|DRUG|dutasteride|6 months of dutasteride 3.5 mg daily
214483249|NCT06874725|DRUG|Rifapentine and Isoniazid for 3 months|tuberculosis preventive therapy (TPT) with 3 months of weekly rifapentine plus isoniazid (3HP)
214483250|NCT06874725|DRUG|Isoniazid (INH) daily for 9 months|tuberculosis preventive therapy (TPT) with 9 months of daily isoniazid (9H)
214483251|NCT06874166|OTHER|Electroencephalography (EEG)|Recording of resting state EEG will be collected
214318044|NCT02995915|OTHER|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
214318045|NCT02995915|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
214318046|NCT02995915|BEHAVIORAL|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
214318047|NCT02995915|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
214318048|NCT02995915|BEHAVIORAL|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
214318049|NCT03123159|DIAGNOSTIC_TEST|DxN HBV Assay|Molecular diagnostic test to detect Hepatitis B
214318050|NCT00556855|OTHER|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
214318051|NCT00556855|OTHER|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
214318052|NCT03076138|DEVICE|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
214318053|NCT02567396|OTHER|Laboratory Biomarker Analysis|Correlative studies
214318054|NCT02567396|OTHER|Pharmacological Study|Correlative studies
214318055|NCT02567396|DRUG|Talazoparib|Given PO
214318056|NCT04400097|PROCEDURE|suture|suture methods of autograft conjunctival transplantation
214318057|NCT01715506|BEHAVIORAL|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
214318058|NCT00003589|DRUG|cisplatin|
214318059|NCT00003589|DRUG|gemcitabine hydrochloride|
214318060|NCT00003589|DRUG|paclitaxel|
214483252|NCT06874166|OTHER|Social Cognition Tasks|Comfort-Distance Task: it will be used to measure the interpersonal comfort distance, the task will be implemented in immersive virtual reality environment Interoception will be measured through an auditory match task based on participants heart-beat A measure emotion processing will be collected through the emotion priming visual task, participants will be asked to detect trial by trial the target emotion which could be preceded by a congruent or incongruent visual priming
214483253|NCT06875726|BEHAVIORAL|Sidekick|Sidekick is a just-in-time adaptive intervention that sends behavior change messages based on personalized sleep and physical activity goals.
214483254|NCT06871202|OTHER|Manual Therapy Protocol|The techniques were divided into three main groups: first, those carried out in cervical, thoracic and upper limbs; second, lumbar, pelvic and lower limbs; and finally, only spine. The techniques are carried out by physiotherapists with more than 15 years of healthcare experience and trained in manual therapy with more than 10 years of experience in this field.
214483255|NCT06871202|OTHER|Sham Protocol|The placebo protocol places the hands on the same areas as the experimental one and for the same application time but without making a manipulative intervention.
214483256|NCT06871202|OTHER|Control-no treatment|Control group without treatment or manual contact
214483257|NCT06868784|OTHER|Evaluations|Evaluations of executive functions and occupational performance
214483258|NCT06870656|OTHER|Low-intensity group|Firstly, they received the same health education as the control group. Subsequently, the elderly individuals with Knee Osteoarthritis (KOA) underwent five interventions per week targeting the quadriceps femoris muscle. For each intervention, the quadriceps performed an isometric contraction and relaxation for 1 second each. The intervention consisted of 10 repetitions per set of Muscle Isometric Contraction (MIC), guided by a rhythmic timer, for a total of 10 sets, with a 30-second rest between sets. The entire intervention lasted for 16 weeks.
214483259|NCT06870656|OTHER|Medium-intensity group|Firstly, they received the same health education as the control group. Subsequently, the elderly individuals with Knee Osteoarthritis (KOA) underwent five interventions per week targeting the quadriceps femoris muscle. For each intervention, the quadriceps performed an isometric contraction and relaxation for 1 second each. The intervention consisted of 20 repetitions per set of Muscle Isometric Contraction (MIC), guided by a rhythmic timer, for a total of 10 sets, with a 30-second rest between sets. The entire intervention lasted for 16 weeks.
214483260|NCT06870656|OTHER|High-intensity group|Firstly, they received the same health education as the control group. Subsequently, the elderly individuals with Knee Osteoarthritis (KOA) underwent five interventions per week targeting the quadriceps femoris muscle. For each intervention, the quadriceps performed an isometric contraction and relaxation for 1 second each. The intervention consisted of 30 repetitions per set of Muscle Isometric Contraction (MIC), guided by a rhythmic timer, for a total of 10 sets, with a 30-second rest between sets. The entire intervention lasted for 16 weeks.
214483261|NCT05755113|DRUG|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
214483262|NCT06872216|PROCEDURE|cupping therapy|After the initial vascular occlusion test and a subsequent 10-minute rest period, the plastic therapy cup was placed on the forearm, 5 cm away from the medial and lateral epicondyles by a certified cupping therapist. The size of used cup was determined according to the size of the volunteer's forearm which cover 50% of the area. The cup was vacuumed two times full pumping with a manual hand pump and remained in place for 5 minutes. And then the air was removed by releasing the cups through the release valve.
214483263|NCT06872216|DIAGNOSTIC_TEST|Vascular occlusion test|A blood pressure cuff was placed on the upper arm. The adult probe of the NIRS device (Covidien INVOS™ 5100C Cerebral/Somatic Oximeter, Dublin) was placed on the thenar region of the ipsilateral hand and the regional oxygen value was recorded during all study term. Baseline arterial pressure and oxygen saturation were monitored (GE Healthcare Oy, Helsinki, Finland) from the side of dominant hand and recorded. After a 3-minute stabilization period, the vascular occlusion protocol was started. The blood pressure cuff was rapidly inflated within 3-4 seconds to 50 mmHg above baseline systolic blood pressure and kept at this pressure during 3 minutes. Following this, the cuff was deflated within 1 second. Five minutes after cupping therapy this protocol had done again.
214483264|NCT06874972|DEVICE|Music played|Music is played in the study group, and no music is played in the control group.
214483265|NCT06874946|BIOLOGICAL|CD5-targeted CAR-T cells|"Phase I: Eligible patients will receive a single infusion of CD5-targeted CAR-T cells at one of three dose levels (0.5 × 10⁶ cells/kg, 1.0 × 10⁶ cells/kg, or 2.0 × 10⁶ cells/kg) following fludarabine and cyclophosphamide (FC) lymphodepleting chemotherapy. A 3+3 dose-escalation design will be used to determine the recommended Phase II dose (RP2D) based on safety, dose-limiting toxicities (DLTs), and preliminary efficacy.~Phase II: Patients will receive CD5-targeted CAR-T cells at the RP2D following FC lymphodepleting chemotherapy."
214483266|NCT06875401|PROCEDURE|Abdominal cerclage (open or laparoscopic)|Participants who have had either an open transabdominal cerclage or laparoscopic abdominal cerclage procedure performed.
214919342|NCT06966921|DEVICE|CES|Currently, most CES intervention studies are applied to the general public, and a few studies focus on athletic performance. There are no related studies on residents of psychiatric nursing homes, nor are there any research designs for improving cognitive impairment. Therefore, this study explores the use of CES programs to improve the cognition, anxiety, depression, and other conditions of residents of psychiatric care homes, with the goal of improving their quality of life.
214919343|NCT06314113|DIETARY_SUPPLEMENT|Epigallocatechin Gallate|Oral treatment with Epigallocatechin Gallate 200 mg per day
214919344|NCT06968559|DRUG|Dexamethasone|Dexamethasone 0.2 mg/kg of ideal body weight (IBW) IV (at a maximum of 20 mg per day) will be blindly infused from day 1 to day 5;
214919345|NCT06968559|DRUG|Placebo|Placebo: one IV administration per day from day 1 to day 5.
214318061|NCT00265616|DRUG|propofol|liquid, mg/kg.h, titrated after EEG
214318062|NCT00265616|DRUG|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
214318063|NCT02090452|DEVICE|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
214318064|NCT02607514|BEHAVIORAL|hyperthermic yoga|heated yoga, 90-minutes
214318065|NCT00141063|DRUG|Focalin XR|
214318066|NCT03100825|DRUG|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
214318067|NCT01437553|DEVICE|iMAP|IVUS and iMAP analysis for acute coronary syndromes
214483267|NCT06874738|DRUG|Liuwei Dihuang pills|Conventional treatment （Hormones, selective 5-hydroxytryptamine reuptake inhibitors, etc.）+ Liu Wei Di Huang Pills
214483268|NCT06875583|DEVICE|Radiation|The use of RAMPART radiation protection device
214483269|NCT06873685|OTHER|Rehabilitation|"After surgery, patients will undergo a personalized rehabilitation program incorporating both conventional and robotic-based approaches. Depending on tumor location, rehabilitation will focus on either the upper or lower limbs.~For lower limb rehabilitation, robotic or technological devices will be utilized for gait training with bodyweight support, as well as for balance and proprioception training. Upper limb rehabilitation will involve robotic or sensor-based devices enabling passive, active, and active-assistive movements of the shoulder, elbow, and hand.~Treatment will be provided in various settings- inpatient, outpatient, or home-based- tailored to each patient's specific needs. Sessions will be conducted daily for 45 minutes, five days per week, over a two-month period."
214483270|NCT06873932|DEVICE|Arm 1: Beveled Attachments|Beveled attachments applied to 20 teeth in each subgroup (horizontal, vertical, and rotational movements).
214483271|NCT06873932|DEVICE|Conventional Rectangular Attachments|Conventional rectangular attachments applied to 20 teeth in each subgroup (horizontal, vertical, and rotational movements).
214483272|NCT06099873|DRUG|ZX-7101A|Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
214483273|NCT06099873|DRUG|Placebo|Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
214483274|NCT06873854|DRUG|LM-108|Q3W, Intravenous Drip
214483275|NCT06873854|DRUG|Toripalimab|Q3W, Intravenous Drip
214483276|NCT01466478|DRUG|Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
214483277|NCT01466478|DRUG|Ointment B: LEO 29102 2.5 mg/g ointment|once daily application, 4 weeks
214483278|NCT01466478|DRUG|Ointment C: Calcipotriol 50 µg/g ointment|once daily application, 4 weeks
214483279|NCT01466478|DRUG|Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
214483280|NCT01466478|DRUG|Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
214483281|NCT01466478|DRUG|Daivonex® ointment|once daily application, 4 weeks
214483282|NCT01466478|DRUG|Diprosone® ointment|once daily application, 4 weeks
214483283|NCT05545878|DEVICE|Super enhanced single vision lens 01 for spectacles|This is a spectacle lens designed to have a small amount of positive power towards the bottom of the lens as this is the area that is in line with the eye when downwards for near tasks such as looking at a digital device.
214483284|NCT01833039|DRUG|Ibrutinib|Ibrutinib
214483285|NCT06395740|OTHER|Enteral nutrtion|enteral nutrition via nasogastric tube.
214483286|NCT06395740|OTHER|TPN|of NPO strategy except for medications to be given via nasogastric tube till 14 days from day of stroke with fulfilment of nutrition requirement by parenteral route
214483287|NCT06864715|BEHAVIORAL|Tele-delivered Behavioral Activation by lay counselors after Stroke (Tele-BA-S)|The Tele-BA-S intervention will comprise 5 weekly video-conferenced BA sessions delivered by trained lay counselors, homework, and 2 monthly follow-up booster calls.
214483288|NCT06864715|BEHAVIORAL|Treatment as Usual|Participants will receive an educational packet and blood pressure (BP) monitor prior to hospital discharge. They will be contacted by a Licensed Clinical Social Worker (LCSW) at 48-72 hours to determine if they have received their medications and appointments. The stroke practitioner will evaluate patients at 7-14 days and 3 months ±14 days, according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities.
214483289|NCT03412058|PROCEDURE|Biopsy|To be performed prior to anti-PD1/PD-L1 treatment initiation
214483290|NCT03412058|PROCEDURE|Biopsy|To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
214483291|NCT03412058|PROCEDURE|Biopsy|To be performed at disease progression if medically feasible
214483292|NCT06624878|DRUG|esketamine|0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.
214483293|NCT06624878|DRUG|placebo|a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.
214483294|NCT06624657|OTHER|vitamin D supplements fo 16 weks|subjects exercised by HIIT-exercise for 16 weeks
214483295|NCT05613426|DRUG|Rosuvastatin 20 mg|Very early use of Rosuvastatin before primary PCI in anterior STEMI
214483296|NCT05613426|DRUG|Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]|Very early use of Evolocumab before primary PCI in anterior STEMI
214483297|NCT06343688|OTHER|"Assessment of Balance and Lower Extremity Gross Motor Function with and without DAFO"|"Measurements will be conducted with the child's custom-made DAFO (Dynamic Ankle-Foot Orthosis) and barefoot."
214483298|NCT05751226|DRUG|BI 1820237|BI 1820237
214483299|NCT05751226|DRUG|semaglutide|semaglutide
214483300|NCT05751226|DRUG|Placebo|Placebo
214483301|NCT05751226|DRUG|BI 456906|BI 456906
214483302|NCT02415933|BEHAVIORAL|Trickle Up|"Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~* Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~* Provision of seed grants to assist in business start-ups through microfinance loans;~* One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~* Trainings on financial planning and household livelihoods."
214919346|NCT01488136|DRUG|Diazoxide|Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
214919347|NCT01488136|DRUG|Placebo|Lactose Ph capsules (Placebo)
214919348|NCT01718535|DEVICE|Spartan FRX CYP2C19 Test System|
214318068|NCT03624868|BEHAVIORAL|Tai Chi|See above description
214318069|NCT03624868|BEHAVIORAL|Wellness Education|See above description
214318070|NCT04809688|DIETARY_SUPPLEMENT|Saskatoon berry|Freeze dried Saskatoon berry (30 g) will be orally administrated daily for 10 weeks.
214318071|NCT04809688|DIETARY_SUPPLEMENT|Dried Saskatoon berry|Prediabetic patients (fasting glucose 5.6-6.9 mM/L, HbA1c 5.7-6.9%, or OGTT 2 h glucose 7.8-11 mM/L) will be randomized in two groups. One group participants will take 40g of dried Saskatoon berry/day for 12 weeks. Another group will take 40g of dried Saskatoon berry/day for 12 weeks,
214483303|NCT02415933|BEHAVIORAL|Trickle Up Plus|"In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage)."
214318072|NCT03357484|PROCEDURE|Leukocyte- and platelet rich fibrin|Prior to surgery, two 9 ml glass-coated tubes (Intra-Spin, Intra-Lock International, Boca Raton, USA) of patient venous blood were collected. Tubes were transferred to a centrifuge (Andreas Hettich GmbH \& Co.KG, Tuttlingen, Germany) and processed for 12 minutes at 2800 rpm to prepare L-PRF.
214318073|NCT03357484|PROCEDURE|Blood clot|Natural blood clot formed within extraction socket
214483304|NCT04955990|OTHER|PAH Therapies|No Drug will be administered as part of this study. Real world data will be collected in participants who newly initiate PAH therapies in routine clinical setting or have already been receiving macitentan 10 mg for at least 3 months prior to the index date.
214483305|NCT06031025|OTHER|Questionnaire, clinical examination|At each follow up visit, a clinical examination and anthropometric evaluation will be performed. Parents will fill a structured questionnaire to describe the occurrence and characteristics of functional gastrointestinal disorders.
214483306|NCT05718687|DRUG|GBT021601|Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
214483307|NCT05323591|DRUG|Filgotinib|Tablets are administered in accordance with the product label
214483308|NCT06442956|OTHER|Rapid Heat Condition|The heat condition is the intervention. Personal protective equipment will be used to create the rapid heat stress condition, resulting in a rapid rise in core temperature. This will be in combination with the physiological heat produced by the treadmill protocol.
214483309|NCT06442956|OTHER|Gradual Heat Condition|The gradual heat condition is the control. Physiological heat will be produced by exercise on a treadmill, and light exercise clothing will help moderate the rise in core temperature.
214483310|NCT03628677|DRUG|Domvanalimab|Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
214483311|NCT03628677|DRUG|Zimberelimab|Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
214483312|NCT06502951|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
214483313|NCT06502951|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
214483314|NCT01611896|DIETARY_SUPPLEMENT|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
214483315|NCT01611896|OTHER|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
214483316|NCT06690957|DIAGNOSTIC_TEST|68Ga/18F-TATE/JR11/LM3|Each subject receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3, and undergo PET/CT imaging within the specificed time.
214483317|NCT03255434|DRUG|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
214483318|NCT03255434|DRUG|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
214483319|NCT01106183|DIETARY_SUPPLEMENT|transfer factor|capsules, 2 per day by mouth for 7 weeks.
214483320|NCT01106183|DIETARY_SUPPLEMENT|Placebo|cornstarch, 2 capsules per day by mouth.
214919349|NCT03293979|DIAGNOSTIC_TEST|Test A i Flu A&B implemented in emergency service|Test A i Flu A\&B implemented in emergency service
214483321|NCT06701422|PROCEDURE|Intraoperative stimulation of the cervical spinal cord|The surgeon will place spinal cord electrodes on the epidural surface, with stimulation sites identified using preoperative MRI. Recruitment curves will be generated by systematically increasing the stimulation intensity across various parameter combinations, including frequency, pulse count, pulse shape, and electrode-specific properties such as size, separation, and arrangement.
214919350|NCT00589615|BEHAVIORAL|multidisciplinary osteoporosis prevention educational program|The program includes individualized counseling aimed at improving diet, muscle strength, balance, and informing individuals about home hazards and the use of medicine.
214318074|NCT04509843|BEHAVIORAL|socioeconomic status|it is a cross-sectional study for assessment the impact of socioeconomic status on periodontal health through using a definite scale mentioned in the protocol related to the middle east people.
214483322|NCT06627959|DEVICE|Statseal|This is a vascular closure device which works independently of the clotting cascade to seal access sites
214483323|NCT06627959|DEVICE|Figure of eight suture|The figure of eight suture is commonly used for vascular access closure
214483324|NCT02459717|OTHER|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
214483325|NCT02459717|OTHER|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
214483326|NCT06633562|DRUG|Nezavist SDD|Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.
214483327|NCT06633562|DRUG|Placebo|Formulated in a diluent that matches the Nezavist SDD suspension in appearance.
214483328|NCT00077584|DRUG|Bosentan 62.5 mg|Oral tablets containing 62.5 mg of bosentan
214483329|NCT00077584|DRUG|Bosentan 125 mg|Oral tablets containing 125 mg of bosentan
214483330|NCT00077584|DRUG|Placebo|Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
214318075|NCT03758638|BEHAVIORAL|Healthy Eating & Active Living Taught at Home|PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum, which includes training materials, an \~8 hour training delivered through a synchronous web-based experience, and ongoing consultation. Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits. In addition to the usual care PAT curriculum content, goal setting related to healthy weight, and the importance of parental modeling of healthy eating and physical activity are incorporated throughout the discussion and visit. HEALTH will be delivered over 24 months via a (1) core and (2) maintenance phase. The visits begin with greater frequency, and taper. Consistent with PAT practice, the frequency and number of visits are determined by the family's needs and preferences.
214318076|NCT03758638|BEHAVIORAL|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
214318077|NCT04693585|BEHAVIORAL|MESSSSAGE - live|mHealth education and social support intervention, synchronous via call
214318078|NCT04693585|BEHAVIORAL|MESSSSAGE - asynchronous|mHealth education and social support intervention, asynchronous via text
214318079|NCT04422145|BEHAVIORAL|Structured nurse led intervention programme|A diabetes research nurse, over a period of 12 months, provided a structured education programme to participants focussing on the avoidance of hypoglycaemia and the treatment of this if/when it occurred.
214318080|NCT04422145|OTHER|Standard care|Participants continue on their current diabetes care plan and are looked after by their usual diabetes care provider
214318081|NCT03221595|DEVICE|Operative|This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
214318082|NCT01091792|DRUG|Bevacizumab|Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
214318083|NCT05372796|OTHER|IASTM|instrument-assisted soft tissue mobilization
214318084|NCT05372796|OTHER|home exercise|home exercise
214483331|NCT06871709|COMBINATION_PRODUCT|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
214318085|NCT05372796|DEVICE|Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom)|OTES (Occipital Transcutenous Electric Stimulation)
214671764|NCT04770168|BEHAVIORAL|Cognitive Behavioral Therapy Curriculum|"The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient."
214671765|NCT05952219|DRUG|CKD-379|2 tablet administration under fed condition
214671766|NCT05952219|DRUG|D759+D745+D029+D150|4 tablet co-administration under fed condition
214671767|NCT05784792|OTHER|Lugol -|Patients that undergo total thyroidectomy without Lugol solution pretreatment
214671768|NCT03140254|DRUG|Chlorhexidine gluconate|
214318086|NCT01515683|BEHAVIORAL|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
214318087|NCT01515683|BEHAVIORAL|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
214318088|NCT01515683|BEHAVIORAL|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
214318089|NCT01515683|BEHAVIORAL|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
214318090|NCT02079688|DRUG|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
214671769|NCT03140254|DRUG|N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride|
214671770|NCT03140254|DRUG|Placebo|
214671771|NCT06639347|DRUG|SHR-A2102|SHR-A2102
214671772|NCT06639347|DRUG|Adebrelimab injection|Adebrelimab injection
214671773|NCT06639347|DRUG|SHR-8068 injection|SHR-8068 injection
214671774|NCT03465800|BEHAVIORAL|self-monitoring|self-monitoring of physical activity
214671775|NCT03465800|BEHAVIORAL|daily incentives|daily incentive payments for physical activity
214671776|NCT03465800|BEHAVIORAL|delayed lump sum incentives|delayed lump sum payments for physical activity
214671777|NCT01676480|BEHAVIORAL|Endurance training|12 weeks of endurance training 3 times per week
215061359|NCT02692768|OTHER|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
215061360|NCT00191399|DRUG|Olanzapine|
214318091|NCT02079688|DRUG|Multiple W/O/W formulation, active ingredient-free vehicle|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
214318092|NCT02146482|OTHER|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
214318093|NCT02212587|DRUG|TOBI|New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
214318094|NCT04400396|DIETARY_SUPPLEMENT|standard HM fortification|Based on the assumed energy and macronutrient composition of HM, the commercial multi-component HM fortifier was added, in order to compensate identified nutritional deficits.
214318095|NCT04400396|DIETARY_SUPPLEMENT|target HM fortification|Based on the measured energy and macronutrient composition of HM, modular protein and fat supplements are added, in addition to the commercial multi-component HM fortifier, in order to correct identified specific nutritional deficits. For this purpose, an Excel program to calculate modular protein and fat supplements to be added to fortified HM was developed and registered (Nona R, Cardoso M, Portuguese Directorate of Intellectual Property Services, IGAC-DSPI, nº 480/2020, 26 February 2020)
214318096|NCT06287346|DEVICE|dental implant|ceramic dental implant
214318097|NCT04632251|DEVICE|SENSEI®|SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
214318098|NCT02750891|DRUG|DSP-7888|Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
214318099|NCT01909661|OTHER|Damira/Celia peptide hydrolyzed casein|
214318100|NCT01909661|OTHER|Picot riz/Celia rice/Sanutri arroz|
214318101|NCT03002051|DEVICE|EUS-guided drainage|"* Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.~* EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.~* After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).~* After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.~* After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance."
214318102|NCT01675882|BIOLOGICAL|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
214318103|NCT01675882|BIOLOGICAL|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
214318104|NCT01675882|BIOLOGICAL|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
214318105|NCT01675882|BIOLOGICAL|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
214318106|NCT02795559|OTHER|Glucose|75g glucose dissolved in 300ml water
214318107|NCT02795559|OTHER|Inulin|75g glucose plus 24g inulin dissolved in 300ml water
214318108|NCT02795559|OTHER|Resistant starch|75g glucose plus 28g resistant starch in 300ml water
214318109|NCT05080452|DIAGNOSTIC_TEST|Dynamic infrared thermography (DIRT)|Visualizing hot spots
214318110|NCT05017194|DRUG|Emodepside|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.
214318111|NCT02561975|OTHER|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~* Alveolar volume (VA)~* Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~* Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
214318112|NCT00810953|DRUG|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
214318113|NCT00420524|DRUG|Patupilone/EPO906|
214318114|NCT04508270|BEHAVIORAL|Early mobilization|Mobilization as soon as patients can, which is not limited on walking
214318115|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
214318116|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
214318117|NCT05983718|DEVICE|Surgical Guide|For this case, after the patient is given anesthesia, the guide will be placed on the teeth. All the drillings will be performed through the guided path. There will be no need for raising flap according to flapless surgery. At the end of the operation, the operation site will be checked and hemostasis will be provided. The operator will record the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
215061361|NCT00191399|DRUG|Fluoxetine|
215061362|NCT01946633|DEVICE|magnetic-controlled capsule endoscopy(Navicam)|
214318118|NCT05983718|PROCEDURE|Guide-pin-assisted Freehand surgery|The regular protocol of the implant surgery will be followed. Before the surgery begins, the patient will be given anesthesia to ensure they are comfortable and pain-free during the procedure. Doctors will go through the digital planning to understand the desired angulation. Then the bony bed will be prepared raising flap from targeted area. Then a guide-pin will be inserted by drilling and through radiographic image the direction will be confirmed. Following the hole of the guide-pin, the implant will be inserted. At the end of the operation, the raised flap will be sewn and hemostasis will be provided. The operator records the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
214318119|NCT02984384|DRUG|Acetylsalicylic acid|The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
214318120|NCT02984384|DRUG|Low Molecular Weight Heparin (LMWH)|The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
214318121|NCT00688480|DRUG|Placebo|1 capsule, orally for 9 months
214318122|NCT00688480|DRUG|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
214318123|NCT00542750|DRUG|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
214318124|NCT01554566|DIETARY_SUPPLEMENT|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
214318125|NCT00735371|DRUG|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
214318126|NCT00735371|DRUG|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
214483332|NCT06871709|OTHER|MTA-Anglus|Mineral Trioxide Aggregate (MTA) has been the gold standard material for primary tooth pulpotomy. MTA has antimicrobial properties, excellent sealing ability, is biocompatible and has a dentinogenic effect on pulp tissue by stimulating the release of cytokines from bone cells, which promotes hard tissue formation. Furthermore, MTA maintains pulp tissue integrity while having no cytotoxic effects. Nevertheless, the clinical application of MTA has been limited due to some properties such as its long setting time, difficulty in its handling, being washed out, discoloration, and increased cost. These urged the search for an alternative pulpotomy material to MTA
214483333|NCT06875622|BEHAVIORAL|Automated online weight loss program|Participants receiving this program are given a daily calorie intake goal of 1200-1800 kcal/day based upon their starting weight and a moderate-intensity aerobic exercise (e.g., walking) goal which progresses to 250 min/week. They are instructed to self-monitor body weight, calorie intake, and exercise minutes daily over 12 months, and are provided with a smart scale for electronic transmission of weight data. Computer-generated, personalized feedback is based upon self-monitoring data, and provided weekly during months 1-3, twice per month during months 4-6, and monthly thereafter. Participants are also instructed to view a new multi-media video lesson weekly during months 1-3, 2x/month during months 4-6, and monthly thereafter (24 lessons in total). These videos are 10-15 minutes in duration and are intended to teach behavioral principles for losing weight, healthy eating, and exercise.
214483334|NCT06875622|BEHAVIORAL|Individual coaching|Participants will receive monthly, one-on-one coaching sessions (12 in total) throughout the 12-month intervention period. Coaching sessions will be conducted via videoconference and the initial coaching session will be approximately 30 minutes and all remaining sessions will be approximately 15 minutes. The structure of the coaching sessions will be similar across participants, but the content will be tailored to the individual. Coaches will use goal setting, problem solving, and motivational interviewing to help facilitate adherence and achievement of weight loss program goals.
214483335|NCT06875622|BEHAVIORAL|Group-based, videoconference-delivered weight loss|Participants receiving this program will be instructed to attend interactive group videoconference sessions (60 minutes each) focused on behavioral strategies for changing diet and exercise to promote weight loss. Classes will be weekly during months 1-3, twice per month during months 4-6, and monthly during months 7-12. These classes are designed to allow participants to interact with, support, and learn from one another. Participants are also given a daily calorie intake goal of 1200-1800 kcal/day based upon their starting weight and a moderate-intensity aerobic exercise (e.g., walking) goal which progresses to 250 min/week. They are instructed to self-monitor body weight, calorie intake, and exercise minutes daily over 12 months, and are provided with a smart scale for electronic transmission of weight data. Semi-automated, personalized feedback, based on self-monitoring data, is provided by the group instructor at the same frequency as group sessions are held.
214919351|NCT06048861|DEVICE|KForce Sens|The device was attached to the middle of the wrist joint with the help of Velcro for all movements. Starting position of the extremity was determined and this position was introduced to the device as the reference position. Then, the participant was asked to perform the movement.
214919352|NCT06048861|DEVICE|Baseline Electrıgoniometer|The pivot point of the goniometer was placed next to the ulnar styloid for 30° and 60° wrist flexion and extension, and also it was placed in the middle carpometacarpal joint for radial and ulnar deviation. A passive movement was made to the extremity in a predetermined amount and direction. The participant was asked to remember this position. Then, the participant was asked to return the extremity to this position when their eyes were closed.
214919353|NCT05369065|COMBINATION_PRODUCT|Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
214919354|NCT05369065|DIAGNOSTIC_TEST|Arterial Angiography Only|Arterial Angiography Only without Intervention
214919355|NCT05369065|COMBINATION_PRODUCT|Single Arm non-Randomized Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
214919356|NCT02547792|BIOLOGICAL|VXA-BYW.10 (Low Dose) Oral Vaccine|Enteric coated tablet for oral delivery
214919357|NCT02547792|BIOLOGICAL|VXA-BYW.10 (High Dose) Oral Vaccine|Enteric coated tablet for oral delivery
214483336|NCT06874881|OTHER|Aquatic Exercises|The aquatic exercise intervention consists of structured, supervised, water-based exercises designed and delivered by an experienced physiotherapist specifically for individuals with chronic low back pain. Sessions are conducted in a temperature-controlled swimming pool with proper warm-up and cool-down. The intervention follows a progressive intensity approach with easy, medium, and hard approaches.
214483337|NCT06874881|OTHER|Land Exercises|The land-based exercise intervention mirrors the aquatic exercise protocol regarding exercise type, duration, frequency, and progression but is performed on land.
214919358|NCT02547792|OTHER|Placebo Tablets|Enteric coated tablet for oral delivery
214919359|NCT02008695|BEHAVIORAL|adult microfinance|"Female piglet provided to household member. Participants agrees to repay participants' loan by giving two piglets (one to repay the loan and one for the interest on the loan) to the association from the first litter of piglets (on average 6-12 piglets). These piglets are then given to other village member households"
214919360|NCT02008695|BEHAVIORAL|Youth microfinance only|One child (10-15 years) receive rabbits loan. The child is mentored by microfinance and community mentors. The child repays the loan to program and other children in the family and community are provided a loan from the repayment.
214919361|NCT02008695|BEHAVIORAL|youth and adult micro finance|One child and adult member of household receive animal loan. The child and adult are mentored and repayment of the loan to the program is provided and the repayment animal is provided to other members of the community
214483338|NCT06875258|DRUG|Sildenafil|Taken daily or on demand. First two weeks dosage of 75mg to manage side effects. If side effects are bearable, dosage will be adjusted to 100mg
214919362|NCT00845221|DRUG|Imatinib mesylate 100 mg (Glivec)|260 mg/m2/day tablets
214919363|NCT02337608|DRUG|GLPG1205|GLPG1205 daily dosing in the morning for 12 weeks
214919364|NCT02337608|DRUG|Placebo|placebo daily dosing in the morning daily for 12 weeks
214919365|NCT01482637|OTHER|CAS|All clients will be asked to complete the CAS instrument.
214919366|NCT05453188|DEVICE|Experimental|Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
214919367|NCT05453188|GENETIC|Control|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
214483339|NCT06875258|DEVICE|Erectile vacuum device|5 days a week, generating 5 erections per day
214483340|NCT06875414|BEHAVIORAL|Nursing care model|Describe relation between resilience, quality of life and depression and marital adaptation in the population considered from diagnosis to 24 months later.
214483341|NCT06592482|DRUG|AZD0780|"A single A dose of AZD0780 will be administered in the morning on Day 1 under fasted condition. Study intervention will be administered orally with approximately 240 mL of water."
214483342|NCT06868498|OTHER|A semester-long course for training of students as CHWs with additional EMPOWER training for delivering a brief trans-diagnostic psychosocial intervention.|Students will participate in a special topics course resulting in a CHW certification with the state of Texas. The course will focus on behavioral activation interventions. Undergraduate Bachelor of Social Work (BSWs) students will then be deployed to the health system as certified CHWs with mental health training to provide a sufficient level of care for many, and an entry point to clinical care for those who have needs that are currently unaddressed.
214483343|NCT03493542|BIOLOGICAL|V501|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
214483344|NCT05485935|DEVICE|Investigational device - intermittent catheter with micro-hole zone|Intermittent male catheter with micro-hole zone for urinary drainage
214483345|NCT05485935|DEVICE|Comparator - standard intermittent catheter|SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.
214483346|NCT03865160|DRUG|Atropine eye drops, 0.01%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
214483347|NCT03865160|DRUG|Atropine eye drops, 0.02%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
214483348|NCT03865160|DRUG|Placebo (NaCl 0.9%) eye drops|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
214483349|NCT06753981|DRUG|Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs|Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.
214483350|NCT06781645|OTHER|The system involves a digital table with a tactile and interactive surface, providing several play areas. It simulates a village and offers different types of serious cognitive games: semantic memory|Each patient included will benefit from a series of 6 sessions of cognitive stimulation with the interactive digital table of cognitive games 'Le Village de Verdurable'©, and a series of 6 sessions of 'classic' weekly cognitive stimulation at the rate of one session per week, i.e. without the digital table and using the methods of cognitive stimulation normally used in the department. The weekly session used as a comparator in the usual condition will be a session based on concentration and attention with target finding or error finding. The order in which these 2 series of 6 sessions will be carried out will be defined randomly (by drawing lots) before the start of the trial.
214919368|NCT00648115|OTHER|Basic Vocational Services|Vocational services
214919369|NCT00648115|OTHER|Self-Study|Veteran receives self-study resources
214919370|NCT00648115|OTHER|Group Program|Veteran participates in group vocational program
214919371|NCT02739009|DRUG|MOR106 single ascending doses, intravenous|
214919372|NCT02739009|DRUG|Placebo single ascending doses, intravenous|
214919373|NCT02739009|DRUG|MOR106 multiple ascending doses, intravenous|
214919374|NCT02739009|DRUG|Placebo multiple intravenous administrations|
214919375|NCT06047678|BEHAVIORAL|Cardiovascular fitness|A randomized single-blind controlled trial tested the hypothesis that different variants of resistance training (antagonistic lower and upper body training, agonistic lower and upper body training, and aerobic training) have different effects on blood pressure (systolic and diastolic), aortic pulse wave velocity (PWVao), and augmentation index (Aix) values and compared subjects with normotension and hypertension during and after exercise session.
214919376|NCT01073605|DRUG|Genotonorm|0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
214919377|NCT01073605|DRUG|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
214919378|NCT01073605|DRUG|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
214919379|NCT00001997|DRUG|Interleukin-2, Polyethylene Glycolated|
214919380|NCT00001997|DRUG|Zidovudine|
214919381|NCT00001997|DRUG|Didanosine|
214919382|NCT01871129|DRUG|Dexmedetomidine|Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.
214919383|NCT01871129|OTHER|Saline (placebo)|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
214919384|NCT00806273|DEVICE|Vista Ultrasonic Bleach Bypass System|The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
214919385|NCT00806273|DEVICE|Needle Irrigation|irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
214919386|NCT04652531|OTHER|Autologous extracellular vesicles from serum|Peri-wound injection of the vesicles will be performed in a sterile environment. Sterile gauze and an elastic-compression bandage will be applied.
214318127|NCT00735371|DRUG|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
214318128|NCT00735371|DRUG|Placebo|Placebo will be identical to test product.
214318129|NCT03941522|OTHER|Early discharge from hospital|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
214318130|NCT02492139|DEVICE|Pumping CE-marked Symphony Pumpset|Pumping with the CE-marked Symphony Pumpset
214318131|NCT02492139|DEVICE|Pumping BrownieForSymphony Pumpset|Pumping with the the BrownieForSymphony Pumpset
214318132|NCT00994448|DRUG|Bupropion SR 150mg tabs|Bupropion SR 150mg tabs (Zyban) twice daily
214318133|NCT00994448|DRUG|Placebo tablets|One placebo tablet twice daily
214318134|NCT02182375|DRUG|BI 201335 NA|
214318135|NCT02182375|DRUG|Raltegravir|
214318136|NCT04891848|OTHER|inflammation|inflammatory values in complete blood count (CBC)
214318137|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
214318138|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
214318139|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
214318140|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
214318141|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
214318142|NCT03405142|DRUG|Panitumumab-IRDye800|Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.
214318143|NCT03405142|DRUG|Lymphoseek|Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
214318144|NCT03995381|OTHER|Decision aids|Shared decision making with decision aids
214318145|NCT00749983|DIETARY_SUPPLEMENT|Creatine supplementation|
214318146|NCT00749983|DIETARY_SUPPLEMENT|Dextrose supplementation|
214318147|NCT01811095|OTHER|Training|"Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score."
214318148|NCT00820612|DRUG|Indomethacin|100 mg PR once at the time of ERCP
214318149|NCT00820612|OTHER|Placebo suppositories|2 placebo suppositories at the time of ERCP
214318150|NCT00436748|DRUG|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
214318151|NCT00436748|DRUG|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
214318152|NCT01610791|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
214919387|NCT00726973|DRUG|Ranibizumab|Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab. For 2 months injected intravitreal Ranibizumab will be given. At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab. If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness \>100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.
214919388|NCT00726973|DRUG|Ranibizumab monotherapy|3 monthly intravitreal injections of Ranibizumab monotherapy. After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
214318153|NCT03949829|DIAGNOSTIC_TEST|Cardiovascular CT|Cardiac and cardiovascular non-contrast and contrast CT
214318154|NCT04560634|DRUG|Norepinephrine|Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
214318155|NCT04560634|DEVICE|ClearSight®, Edwards Lifescience, Irvine, CA|"All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis."
214318156|NCT05892627|DIETARY_SUPPLEMENT|PoZibio|PoZibio (50 x 10\^9 CFUs/ CAPSULE)
214318157|NCT05892627|DIETARY_SUPPLEMENT|Placebo|Placebo
214318158|NCT05459064|DEVICE|Motiva Flora TE|This is a retrospective, observational study - collecting data on patients who have gone through the staged procedure with the Motiva Flora Tissue Expander / Long-term breast implant.
214318159|NCT00003255|DRUG|carboplatin|
214318160|NCT00003255|DRUG|topotecan hydrochloride|
214318161|NCT06679634|DRUG|Chemoplaque also referred to as Episcleral Topotecan|Sustained Release Episcleral Topotecan
214318162|NCT06087172|DIAGNOSTIC_TEST|Six Minutes Stepper Test (6MST)|Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
214318163|NCT04758767|DRUG|CID-103|anti-CD38 antibody
214318164|NCT04905316|DRUG|Canakinumab|Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
214318165|NCT04905316|DRUG|Durvalumab|Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
214318166|NCT04905316|RADIATION|Radiation therapy|Radiation therapy will be performed with external beam ionizing radiation as per standard of care in accordance with institutional practice. Intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist. Patients will be simulated in the treatment position with standard immobilization techniques for thoracic radiotherapy. The prescription dose will be 60 Gy (±10%) in 2Gy fractions to fields encompassing gross tumor and lymph nodes, as per institutional guidelines. The dose must satisfy institutional guidelines and minimize risk to adjacent organs at risk.
214318167|NCT04905316|DRUG|Chemotherapy|Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
214318168|NCT05232851|BIOLOGICAL|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
214318169|NCT05232851|BIOLOGICAL|Pembrolizumab|Given IV
214318170|NCT05232851|PROCEDURE|Computed Tomography|Undergo CT, FDG-PET/CT
214318171|NCT05232851|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
214318172|NCT05232851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214318173|NCT05232851|PROCEDURE|Biopsy|Undergo biopsy
214318174|NCT06639698|DIETARY_SUPPLEMENT|Diosgenin|Patients will take a tablet containing diosgenin (120 mg), alpha-lactalbumin (100 mg) and vitamin D (50 mcg) - two times per day for six months
214318175|NCT05816525|PROCEDURE|Partial removal of carious tissue|Nonselective carious tissue excavation will be performed in the periphery of the cavity to achieve a good marginal seal. In the pulpal wall selective, partial carious tissue excavation is performed to the soft dentin, removing tissue only the amount that is necessary for placing the restoration. The tooth is restored with high-viscosity glass-ionomer cement.
214318176|NCT05816525|PROCEDURE|Final restoration|The teeth will be restored with composite resin after 12 months follow up, if the tooth is asymptomatic, responds to sensibility tests and there are no periapical changes radiographically. Glass ionomer cement will be only partially removed to create space for the final restoration.
214318177|NCT02279186|DRUG|Tranexamic Acid|Intravenous Injection
214318178|NCT01069055|OTHER|Sterile Saline|Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
214318179|NCT01069055|DRUG|Intravenous lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
214318180|NCT01069055|DRUG|Intravenous paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
214483351|NCT05007847|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF Catheter Ablation (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
214483352|NCT06693284|DRUG|mirdametinib and vorinostat|short course of the combination of mirdametinib and vorinostat prior to the most appropriate standard of care treatment for the patient's specific tumor (typically localized radiation followed by surgical resection).
214483353|NCT06692270|DRUG|Tislelizumab|Tislelizumab 200mg Q3W, D1 ; 2 cycles
214483354|NCT06687785|PROCEDURE|Entire Papilla Preservation Technique|A buccal intrasulcular incision was made in the tooth with the defect and a vertical incision was made extending from the buccal center of the tooth to the mesial papillary crest and crossing the mucogingival line. Then, using a micro periosteal elevator, a full-thickness mucoperiosteal flap was lifted from the incision site to the defect under the papilla. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the vertical incision was sutured with 6/0 polypropylene suture using simple suture technique.
214483355|NCT06687785|PROCEDURE|Conventional Flap Surgery Technique|After buccal and lingual intrasulcular incisions were made to eliminate the teeth and papillae adjacent to the defect, a full-thickness mucoperiosteal flap was raised in the vestibular and lingual direction with a periosteal elevator. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the papillary incisions were sutured with 5/0 polypropylene suture using simple suture technique.
214483356|NCT04212234|DEVICE|ultrasound propagation velocities, ultrasound fetal quality|"Obese pregnant women will be included before the second trimester fetal ultrasound examination.~Women will be allocated to one intervention group or to the control group. In the intervention group, the ultrasonographer will be able to use several ultrasound propagation velocities to perform the exam.~In the control group, exam will be performed using the conventional ultrasound velocity.~An exam will be considered to be complete if all the images recommended by national guideline are acquired. If ultrasound images are missing, other ultrasound exams may be performed until completeness is reached.~The protocol will be applied for the second and the third fetal ultrasound examination which are recommended by national guideline.~All scans will be evaluated by two independent experts who do not have performed any of the exams. They will evaluate the completeness of each exam. Each scan will be quoted using the quality score proposed by Salomon et al."
214483357|NCT06876922|OTHER|Thoracic mobility exercises Group|Thoracic mobility exercises Group: Conventional physiotherapy exercises were given to individuals participating in the control group. Conventional physiotherapy exercises included warm-up, stretching, strengthening, posture and breathing exercises integrated between them. These exercises were performed in 30-40 minute sessions, 3 days a week and for 6 weeks. Thoracic mobility exercises were applied to individuals participating in the study group in addition to conventional physical therapy exercises.
214483358|NCT06876922|OTHER|the Conventional physiotherapy exercises Group|the Conventional physiotherapy exercises Group: Conventional physiotherapy exercises were given to individuals participating in the Conventional physiotherapy exercises group. Conventional physiotherapy exercises included warm-up, stretching, strengthening, posture and breathing exercises integrated between them. These exercises were performed in 30-40 minute sessions, 3 days a week and for 6 weeks. Use this module to add descriptions of each arm in the study and to list the interventions being studied.
214483359|NCT06880497|PROCEDURE|total knee arthroplasty|Replacement of knee articulating surface for patients with end-stage osteoarthritis.
214483360|NCT06827873|DIETARY_SUPPLEMENT|ARA (Arachidonic Acid) Supplementation|Oral ARA (Arachidonic Acid) dietary supplement capsules, dosage 1000 mg/person/day. Capsule composition includes: C14:0 (0.15%), C16:0 (6.08%), C16:1 (0.15%), C18:0 (4.57%), C18:1 (19.65%), C18:2 (38.46%), C18:3 (0.87%), C20:0 (0.50%), C20:3 (2.00%), C20:4 (18.66%), C22:0 (1.81%), C24:0 (4.05%). Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue supplementation until Day 24.
214483361|NCT06827873|DRUG|TUDCA (Tauroursodeoxycholic Acid) Supplementation|Oral Double Wood brand TUDCA (Tauroursodeoxycholic Acid) dietary supplement capsules, dosage 1000 mg/person/day. Capsules primarily contain TUDCA, with 500 mg per serving (two capsules), other ingredients include gelatin and rice powder. Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue supplementation until Day 24.
214483362|NCT06827873|DIETARY_SUPPLEMENT|Placebo Supplementation|Oral placebo capsules identical in appearance and smell, dosage 1000 mg/person/day. Placebo capsule composition includes: C14:0 (0.09%), C16:0 (6.12%), C16:1 (0.03%), C18:0 (3.50%), C18:1 (28.06%), C18:2 (59.40%), C20:0 (0.27%), C22:0 (0.76%), C24:0 (0.26%). Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue taking placebo until Day 24.
214483363|NCT06827873|BIOLOGICAL|Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine|Administer Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine, produced by Shanghai Biological Products Research Institute Co., Ltd. , specification 0.5ml/dose, containing 15.0 μg hemagglutinin (for each influenza virus strain), suitable for intramuscular injection in individuals 6 months and older. Administer one dose to all study participants on Day 3. Closely observe and record any potential adverse reactions after vaccination.
214671778|NCT03999567|OTHER|Pen and Paper Digit Symbol Substitution Test (DSST)|The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
214919389|NCT03052231|DEVICE|caremessage|Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
214483364|NCT06758414|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
214318181|NCT02386111|DRUG|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg."
214483365|NCT06758414|BEHAVIORAL|Health & Wellness (H&W)|Health \& Wellness (H\&W) was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health \& Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
214483366|NCT06686576|BIOLOGICAL|QL1706|Phase Ib/Ⅲ： QL1706 will be administered
214483367|NCT06686576|DRUG|CAPEOX|Phase Ⅲ：CAPEOX will be administered
214483368|NCT06691087|BEHAVIORAL|Influence of the parameters of the sound timbre on the perception of a sound|"The experiment consists of evaluating the sound level of n complex stimuli, then equalising them in loudness, in order to measure a loudness curve in function of timbre descriptors.~The stimuli will then be listened to again in pairs. The task is there to compare the stimuli using a VAS to indicate how different the two sounds are."
214483369|NCT06691087|BEHAVIORAL|Complex sound scene comprehension test|The experiment consists in identifying the parameters of the sound timbre that most disturb the understanding of complex sound scenes, by asking the participants to identify sounds whose timbre has been modified.
214671779|NCT03999567|OTHER|Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)|Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
214671780|NCT01943123|DIETARY_SUPPLEMENT|probiotic drink|comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
214671781|NCT01943123|DIETARY_SUPPLEMENT|Placebo Comparator: plain, unsweetend, unflavored pasturised milk|comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
214919390|NCT00643474|DEVICE|Accu-Chek Aviva Meter|4-point daily glucose monitoring profile 3 times per week
214919391|NCT00643474|DEVICE|Accu-Chek Aviva Meter|Frequency and timing of SMBG not specified
214919392|NCT04713631|DRUG|Artesunate|Artesunate is approved for the treatment of malaria and is on the World Health Organization list of Essential Medicines. Artesunate has a hemisuccinate group which confers substantial water-solubility and high oral bioavailability and therefore a convenient oral route of administration. Artesunate has a good safety and tolerability profile, having been used to treat millions of adults and children globally.
214919393|NCT04713631|DRUG|Curcumin|Curcumin has been used in Indian cuisine and traditional medicine for centuries. It has low solubility in aqueous solution and yields low serum levels following oral administration. In the setting of inflammatory bowel disease where the required site of action is the bowel, systemic absorption may be less relevant. Curcumin and its reduced metabolites undergo conjugation in the liver. Curcumin has a half life of 6-7 hours. It has been found to be safe at oral doses of 2 gm and 3 gm a day in patients with ulcerative colitis, for up to 1 year. In a dose titration study conducted in children with inflammatory bowel disease 2 gm twice daily of curcumin was well tolerated
214919394|NCT04713631|DRUG|Placebo A|Artesunate looking placebo
214919395|NCT04713631|DRUG|Placebo C|Curcumin looking placebo
214919396|NCT05952869|DRUG|Enlicitide Decanoate|Oral tablet
214919397|NCT05952869|DRUG|Placebo|Placebo
214919398|NCT01284348|DRUG|Sotatercept 15 mg|Sotatercept 15 mg SC injection once every 42 days, up to four doses
214318182|NCT00025285|DRUG|carboplatin|
214318183|NCT00025285|DRUG|irinotecan hydrochloride|
214318184|NCT00025285|DRUG|thalidomide|
214318185|NCT01664143|DRUG|Placebo|Multiple doses of placebo
214318186|NCT01664143|DRUG|RO5508887|Multiple doses of RO5508887
214318187|NCT04900077|DEVICE|Carriere® Motion™ Appliance|class II malocclusion corrector
214318188|NCT01768390|OTHER|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
214318189|NCT01768390|OTHER|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
214318190|NCT06471647|DRUG|delta-9-tetrahydrocannabinol (THC) (5)|5 mg of THC
214318191|NCT06471647|DRUG|Placebo|Placebo - dextrose
214671782|NCT03842709|DRUG|Pramipexole Oral Tablet|Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
214483370|NCT06691087|BEHAVIORAL|Complex sound scene comprehension test with hearing aids|The experiment will be identical to intervention 2. This time, the modification of the stimulus timbres will focus on the most problematic dimensional modifications, i.e. those where the difference between normal-hearing and hearing-impaired listeners is greatest. We will then modify the signal processing parameters of the hearing aid simulator (for example, the size of the averaging window or the gain balance of the filters), to observe their impact on the salience of certain stimuli.
214483371|NCT05495984|BEHAVIORAL|ERPs with electroencephalography (EEG)|E-Prime 2.0 software will present visual and auditory stimuli in an experimental paradigm lasting approximately 30 minutes (ERPs). Visual stimuli will include photographs of color photographs of unfamiliar infants (aged 5- 10 months) balanced for ethnicity (Black/White) and gender (male/female) displaying happy neutral, and sad affective expressions. Auditory stimuli will include 2-second audio clips of high-distress and low-distress infant cries. Experimental procedure: Trials will consist of a central fixation cross (jittered 400-600ms), stimulus presentation (500ms faces, 2000ms cries), and blank screen (1000ms). Continuous electroencephalography (EEG) will be recorded using Net Station 4.2.1. A 128 Ag/Silver Chloride (AgCl) electrode net will be soaked in a warm potassium chloride solution, and net electrodes will be spaced evenly and symmetrically on each participant's head to cover the scalp.
214483372|NCT05495984|BEHAVIORAL|MIO|A 12-week, manualized, individual parenting psychotherapy developed specifically for mothers with addictions administered by the Principal Investigator. It is designed to foster a mother's capacity for mentalization or reflective functioning (RF). MIO is offered in conjunction with standard addiction treatment.
214483373|NCT06705465|BEHAVIORAL|video conference|video conference
214483374|NCT06705010|DEVICE|Application of new pulse sequence package SIGNATURES2023 to healthy controls|One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 100 healthy subjects to determined reference metabolite maps of the whole brain
214483375|NCT06705010|DEVICE|Application of new pulse sequence package SIGNATURES2023 to 4 groups of patients (pilot)|One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 4 time 10 patients with AD, MCI, DM and HGCS to determine metabolite maps of the whole brain.
214483376|NCT06705140|BIOLOGICAL|Low Dose (LD) RSVt vaccine|"Pharmaceutical form:~Liquid for nasal spray~Route of administration: Intranasal"
214483377|NCT06705140|BIOLOGICAL|Standard Dose (SD) RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
214483378|NCT06705140|BIOLOGICAL|High Dose (HD) RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
214671783|NCT03842709|OTHER|Placebo|Administration of placebo
214318192|NCT06471647|DRUG|delta-9-tetrahydrocannabinol (THC) (10)|10 mg of THC
214318193|NCT05790252|DRUG|Buprenorphine Transdermal Matrix Patch|Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
214318194|NCT05790252|OTHER|Sham patch|Bandage applied at time of induction initiation and removed at 48 hours.
214483379|NCT06705140|BIOLOGICAL|Placebo|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
214919399|NCT01284348|DRUG|Sotatercept 30 mg|Sotatercept 30 mg SC injection once every 42 days, up to four doses
214919400|NCT05533268|OTHER|Mental training|Mental training (guided mindfulness meditation by Jon Kabat-Zinn for 20 minutes, 3 times per week.
214919401|NCT05533268|OTHER|Physical training|Physical training (continuous moderate-intensity training at 40-60% of participants' heart rate reserve for 20 minutes excluding warm-up/cool-down, 3 times per week.
214919402|NCT05533268|OTHER|Mental & physical training|Mental and physical training (combination of mindfulness mediation for 20-minutes, 3 times per week and continuous moderate-intensity training for 20 minutes, 3 times per week.
214483380|NCT06704945|PROCEDURE|No axillary surgery|BCS only. Ommission of axillary surgery. No axillary surgery after neoadjuvant chemotherapy.
214919403|NCT05533268|OTHER|DASH diet|DASH diet ( (more vegetables, fruits and low-fat dairy foods and moderate amounts of whole grains, fish, poultry and nuts; and less than 3 grams of sodium daily) for 6-weeks.
214318195|NCT01241903|DRUG|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
214318196|NCT01241903|DRUG|placebo|frequency and duration
214318197|NCT05942248|OTHER|No Intervention|No Intervention
214318198|NCT03319927|BEHAVIORAL|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
214483381|NCT06704945|PROCEDURE|Axillary surgery|BCS with SLNB(+/-ALND)
214671784|NCT06092398|OTHER|PRP and PRFG in treatment of anal fistula|The tract fistula was cleaned with betadine 10% before PRP and PRFP were applied. Then, 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. The operation time was about 20-30 minutes, the clot formation usually takes about 8 minutes, but the anesthesia was extended to 20 minutes to make sure a complete clot in the place of fistula
214919404|NCT04769518|PROCEDURE|Advanced Recovery Room Care (ARRC)|High acuity care
214483382|NCT04731233|BIOLOGICAL|Plasma Rich in Growth Factor (PRGF) Supplementation|After rinsing the joint, the TMJ will be injected with blood plasma rich in growth factors (PRGF). PRGF supplementation which is an autologous platelet-enriched plasma obtained from patient's own blood, which after activation with calcium chloride allows the release of a pool of biologically active proteins that influence and promote a range of biological processes.
214318199|NCT05837130|OTHER|Blood sample collection and an optional cerebrospinal fluid (CSF) collection|No study drug will be administered to study participants.
214483383|NCT04731233|DRUG|Triamcinolone Acetonide|After rinsing the joint, the TMJ will be injected with 40 mg of triamcinolone acetonide with 5 mg bupivacaine.
214483384|NCT05259605|OTHER|Observational|The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
214318200|NCT05837130|OTHER|Blood sample collection|No study drug will be administered to study participants.
214318201|NCT06957808|DRUG|Diroximel fumarate (DRF)|Diroximel fumarate is an immunomodulating drug licensed for use in multiple sclerosis. It has been found to cross the blood brain barrier and increase brain glutathione levels.
214483385|NCT05292027|RADIATION|low-dose radiotherapy|On the first and second days of induction chemotherapy, lymph nodes were irradiated with 0.5Gy bid for 4 times.
214483386|NCT06708702|DRUG|Copaíba mouthwash|"A 15% aqueous solution of copaíba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula of copaíba oil (Copaifera Officinalis Resin) 15%, liquid mint aroma 5%, tween 80 1%, aqueous solution (Distilled water + Nipagin 0.1%) qsp 100%.~Patients will receive the solution once a week. They will be instructed to shake the bottle before use for homogenization, to use 10mL of the solution for each mouthwash (which should be measured in the 10mL measuring cup that comes with each bottle), 4 times a day, rinsing vigorously for 1 minute and discarding all the solution after use."
214483387|NCT06708702|DRUG|Placebo mouthwash|"Placebo will be used, under the formula of liquid mint flavor 5%, Nipagim 0.1%, and distilled water qsp 60 ml, packed in packaging compatible with that of the product under investigation, maintaining the same physical characteristics to maintain blinding. The product will be stored at room temperature and stored in the INCA pharmacy.~Patients will receive the solution once a week. They will be instructed to shake the bottle before use for homogenization, to use 10mL of the solution for each mouthwash (which should be measured in the 10mL measuring cup that comes with each bottle), 4 times a day, rinsing vigorously for 1 minute and discarding all the solution after use."
214483388|NCT03839446|DRUG|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
214483389|NCT06704217|DIAGNOSTIC_TEST|Six Spot Step Test|The Six-Spot Step Test (SSST), which evaluates balance and functional ambulation, will be performed in an area 5 meters long and 1 meter wide. Five wooden cylinders will be arranged in a zig-zag pattern within this space, with the last cylinder positioned at the centerline. The participant will be asked to strike the wooden cylinders with the medial or lateral side of the same foot and push them outward. The test will be repeated twice with the dominant foot and twice with the non-dominant foot. A trial will be conducted before the test to familiarize participants with the procedure. A two-minute rest period between the test and trials will be provided to minimize fatigue effects. The test's inter-rater reliability will be assessed by two physiotherapists with more than 5 years of clinical experience, who will administer the test twice at 5-minute intervals.
214483390|NCT06704217|DIAGNOSTIC_TEST|Oxford Hip Score|The Oxford Hip Score will be used for functional level assessment.
214483391|NCT06704217|DIAGNOSTIC_TEST|Berg Balance Scale|The Berg Balance Scale (BBS) will be used to assess dynamic balance, which is reliable and commonly used within the orthopedic setting.
214483392|NCT06707376|OTHER|Early Kangaroo Mother Care|"* Initiation of KMC within 24 hours of birth.~* Continuous skin-to-skin contact for at least 8 hours per day, with gradual increase based on infant tolerance.~* Support for exclusive breastfeeding or expressed breast milk feeding.~* Ongoing assessment and support from trained neonatal nurses and lactation consultants."
214318202|NCT06957808|DRUG|Placebo|A placebo pill given to participants.
214318203|NCT05040152|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary recommendations
214318204|NCT05040152|OTHER|Exercise Intervention|Complete home exercises
214483393|NCT06712667|OTHER|Caffeine content|Participants will drink the same volume of water or coffee with different amounts of caffeine.
214483394|NCT06709040|DRUG|Somapacitan|Participants will be treated with commercially available somapacitan according to routine clinical practice at the discretion of the treating physician.
214318205|NCT05040152|OTHER|Informational Intervention|Receive education brochures
214318206|NCT05040152|OTHER|Questionnaire Administration|Ancillary studies
214318207|NCT05040152|BEHAVIORAL|Telephone-Based Intervention|Receive telephone-based weight loss intervention
214318208|NCT01539187|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
214318209|NCT00485316|PROCEDURE|Laparoscopic assisted resection of colorectal carcinoma|
214318210|NCT02266056|DRUG|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
214318211|NCT02266056|DRUG|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
214318212|NCT03905785|BEHAVIORAL|Samarthan|Samarthan intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
214318213|NCT00726570|DEVICE|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
214318214|NCT00726570|DRUG|Dalteparin|"* 2500 UI qd if ≤ 50 kg body weight~* 5000 UI qd if \> 50 kg"
214919405|NCT03789760|DRUG|SaiLuoTong capsule|500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
214318215|NCT00726570|PROCEDURE|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~* Patient admission (before SCD start)~* 40-60 min after admission~* Morning after surgery"
214318216|NCT01917071|OTHER|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
214318217|NCT03948685|DRUG|Carvedilol SR|blood pressure, heart rate based titrated carvedilol SR for 24 weeks
214318218|NCT03948685|DRUG|Placebo|Placebo
214318219|NCT04140461|DRUG|Amphotericin B|The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
214318220|NCT04140461|DRUG|Flucytosine|The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
214318221|NCT06292715|PROCEDURE|microwave ablation of the spleen|Ultrasound-guided percutaneous puncture for splenic ablation treatment
214318222|NCT06292715|OTHER|Splenic artery balloon implantation|Splenic artery balloon implantation
214318223|NCT05398640|BIOLOGICAL|OOS AMTAGVI|Patients will undergo preparative lymphodepleting chemotherapy. Infusion of lifileucel is then given and is followed by administration of IL-2.
214318224|NCT00748267|OTHER|questionnaire administration|
214318225|NCT00748267|PROCEDURE|hypnotherapy|
214318226|NCT00748267|PROCEDURE|therapeutic conventional surgery|
214318227|NCT01295515|DRUG|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
214919406|NCT03789760|DRUG|placebo|500 subjects are randomly divided into two groups by 3:1. 125 subjects in the control group take two pills(120mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
214919407|NCT02166060|DRUG|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
214919408|NCT00248742|BEHAVIORAL|Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods
214919409|NCT02417142|DRUG|Exenatide|Exenatide SQ 2mg/week for 24 weeks.
214919410|NCT02417142|DRUG|Placebo|Placebo SQ 1x/week for 24 weeks.
214318228|NCT04570085|DRUG|Caffeine|100mg caffeine capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks (by 100mg stages) until 400mg aim dose per day in 2 doses during 27 weeks, and finally interrupt according to the same negative titration.
214318229|NCT04570085|DRUG|Placebo|Placebo capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks until 2 doses aim dose per day during 27 weeks, and finally interrupt according to the same negative titration.
214318230|NCT05850169|OTHER|Creative Dance Therapy|"After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015)."
214318231|NCT01434524|DRUG|LIVACT|LIVACT contains 13.0 g of free amino acids
214318232|NCT06007183|BIOLOGICAL|CHIKV VLP vaccine booster|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.
214318233|NCT06007183|BIOLOGICAL|Placebo booster|Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.
214318234|NCT04998136|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
214318235|NCT04998136|DRUG|Placebo (semaglutide 2.4 mg)|Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
214318236|NCT01012011|DRUG|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
214318237|NCT05932095|BEHAVIORAL|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 12-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
214318238|NCT05932095|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
214318239|NCT05083988|DEVICE|virtual reality glasses|a system composed of a head-mounted wide view display placed in front of the eyes and headphones placed in ears, it has the ability to block the real-world stimuli. This could distract the patient from the dental environment, which helps reduce anxiety
214318240|NCT05083988|DEVICE|music|Music can be used to distract patients from the anxiety provoking stimulus. It helps the patient to escape from the stressful reality as it activates imaginary. Psychosocially music can offer peace and comfort to patients during dental treatment as it helps in making the environment less threatening.
214318241|NCT00843921|DRUG|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
214318242|NCT04308317|DRUG|Tetrandrine|Tetrandrine 60mg QD for 1week
214671785|NCT04729530|DEVICE|Dyson Pure Cool - Active Purifier|Free standing air purifier
214671786|NCT04729530|DEVICE|Dyson Pure Cool - Placebo purifier|Placebo air purifier
214671787|NCT00791128|DEVICE|GI Liner|Medical device placed endoscopically in the duodenum, nutritional counseling
214671788|NCT03300453|DRUG|rAAV2/5-hNAGLU|one-time brain intraparenchymal gene therapy dose
214671789|NCT04260724|DEVICE|TMS|"* stimulation intensity : motor threshold 100%~* stimulation frequency : 1600 pulses for 20 minutes~* stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )"
214483395|NCT06712069|DEVICE|Multimodal Intraoperative Neurophysiologic Monitoring (MIONM)|"Multimodal Intraoperative Neurophysiologic Monitoring (MIONM) is a real-time, device-based intervention used during neurosurgical procedures to monitor and preserve the integrity of neural pathways. It combines the following modalities:~Somatosensory Evoked Potentials (SSEP): Monitors sensory pathways by stimulating peripheral nerves and recording cortical responses.~Motor Evoked Potentials (MEP): Assesses motor pathways via transcranial stimulation and muscle response evaluation.~Electromyography (EMG): Detects nerve irritation and monitors muscle activity during surgery.~This intervention provides critical real-time feedback to the surgical team, enabling immediate adjustments to prevent neurological damage and enhance surgical outcomes. The Cascade IOMAX system is the primary device used in this study for implementing MIONM."
214483396|NCT06709131|DRUG|CAR-T cells（ chimeric antigen receptor T cells）|CAR-T cells（ chimeric antigen receptor T cells）
214483397|NCT06708026|BEHAVIORAL|Action Observation and Motor Imagery (AOMI) training|Participants will watch home-based exercise videos and simultaneously imagine themselves performing these exercises in their minds by following verbal instructions in the videos, without actual execution.
214483398|NCT06708026|BEHAVIORAL|Basic wheelchair exercises|A set of low-intensity warm-up wheelchair exercises developed specifically for survivors with spinal cord injury
214483399|NCT06708026|BEHAVIORAL|Watch landscape videos|A set of landscape videos
214919411|NCT03397498|BEHAVIORAL|CogniFit™|The program utilizes 21 tasks, which may develop 14 cognitive domains: awareness, inhibition, spatial perception, visual short term memory, working memory, hand-eye coordination, visual scanning, response time, divided attention, time estimation, visual perception, shifting, naming, and planning.
214483400|NCT06710834|DEVICE|Hemoadsorption cartridge|HA 130 cartridge
214483401|NCT06710834|DEVICE|Hemodiafiltration|Postdilutional hemodiafiltration
214483402|NCT06708286|BIOLOGICAL|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp))|1 dose of Tdcp vaccine (0.5ml) on day 0
214483403|NCT06708286|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (PPV23)|1 dose of PPV23 vaccine (0.5ml) on day 0
214483404|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
214483405|NCT06708286|BIOLOGICAL|PPV23|1 dose of PPV23 vaccine (0.5ml) on day 0
214671790|NCT04260724|DEVICE|sham coil stimulation|no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
214318245|NCT01213979|DRUG|500 mg iron isomaltoside 1000|500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
214318246|NCT01213979|DRUG|1000 mg iron isomaltoside 1000|1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
214318247|NCT05457569|OTHER|Focus group (FC) - WP1|"3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk"
214318248|NCT05457569|OTHER|Child Neurodevelopment Questionnaires - WP2|during the 4th month of corrected infant age
214318249|NCT05457569|OTHER|Evaluation of compliance for the acquired skills in terms of development support - WP2|during the 4th month of corrected infant age
214483406|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
214483407|NCT06708286|BIOLOGICAL|PPV23|1 dose of PPV23 vaccine (0.5ml) on day 0
214483408|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
214483409|NCT06708286|BIOLOGICAL|PPV23|1 dose of PPV23 vaccine (0.5ml) on day 0
214483410|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
214483411|NCT06708286|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine (DTaP)|1 dose of DTaP vaccine (0.5ml) on day 0
214483412|NCT06710028|DEVICE|NORA|NORA app will be downloaded on the patient's mobile device, tablet or computer for clinical monitoring after discharge from the hospital at 3, 6 and 12 months after stroke. At the time of discharge, the patient will be provided with all the information and training necessary for its use. This application has been clinically validated in stroke patients, demonstrating to improve communication between professionals and patients. It improves the adherence of patients to prescribed therapy and their control of cardiovascular risk factors, with the the goal of preventing new episodes. Stroke patients have actively participated in the development of NORA, its use is simple and intuitive, and there are no age restrictions for its use. Through NORA patients will receive questionnaires to evaluate their clinical outcomes after stroke (Patient Reported Outcome Measures- PROMs and Patient Reported Experience Measures- PREMs).
214483413|NCT06708156|DRUG|Atropine sulfate eye drops 0.01%|Drug: 0.01% atropine sulfate eye drops Dosage form and strength: 0.01% (0.4 mL: 0.04 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
214483414|NCT06708156|DRUG|Atropine sulfate eye drops 0.02%|Drug: 0.02% atropine sulfate eye drops Dosage form and strength: 0.02% (0.4 mL: 0.08 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
214483415|NCT06708156|DRUG|Placebo eye drops|Drug: placebo eye drops Dosage form and strength: 0.4 mL eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
214483416|NCT06708559|OTHER|Breast-fed infants|Immune system characterization via blood and stool samples collection
214483417|NCT06707753|DRUG|AL-001|Administered via suprachoroidal space injection.
214671791|NCT03324256|OTHER|energy drink|16 oz cold commercially-available energy drink
214318250|NCT05457569|OTHER|Evaluation of physiotherapist satisfaction with the follow-up and the time spent at the consultation - WP2|at the end of the study
214671792|NCT03324256|OTHER|caffeinated drink|16oz cold commercially-available caffeinated drink
214671793|NCT03324256|OTHER|Energy gum|2 pieces of commercially-available energy gum
214671794|NCT03324256|OTHER|placebo gum|2 pieces of commercially-available placebo gum
214671795|NCT03324256|OTHER|Control drink|16oz cold control drink
214671796|NCT03324256|OTHER|Total sleep deprivation|24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
214671797|NCT06498063|OTHER|Glucagon|Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.
214318251|NCT05457569|OTHER|4 Focus Group (FC) - WP2|"* Parents who accepted the follow-up~* Parents who have partially completed the programme~* Maternal and Child Protection \& CAMSP professionals~* Physiotherapists in a private practice"
214318252|NCT04938232|DRUG|Nivolumab|Intravenous infusion
214318253|NCT04938232|DRUG|Ipilimumab|Intravenous infusion
214318254|NCT05960747|OTHER|Simulation group|Specific training for medical students by using an augmented virtual reality simulator for thoracentesis
214318255|NCT05915767|DIETARY_SUPPLEMENT|Olive leaf tea|Fresh olive leaves will be procured from Chakwal, Pakistan. The leaves will be rinsed to remove dust and debris and dried at 40℃ in the oven. The leaves will be ground into powder form and then incorporated in tea bags containing 1.8 g leave powder/tea bag. Participants in treatment group will be instructed to dip the tea bag in 200-250 ml boiling water for 3-5 minutes.
214318256|NCT05351424|OTHER|Audiovisual Intervention- Radiation Therapy Education|A video with educational information will be shown regarding radiation therapy.
214318257|NCT05351424|OTHER|ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure|Brochure with written information will be given to the subject regarding radiation therapy.
214318258|NCT05351424|OTHER|Audiovisual Intervention- Cancer Clinical Trials Education|A video with educational information will be shown regarding cancer clinical trials.
214318259|NCT05351424|OTHER|NCI Taking Part in Cancer Research Studies Brochure|Brochure with written information will be given to the subject regarding cancer clinical trials.
214318260|NCT06247046|DRUG|Live SK08 powder|Oral Powder
214318261|NCT06247046|DRUG|Placebo|Oral Powder
214318262|NCT03754959|DRUG|BI 1358894|Film-coated tablet
214318263|NCT03754959|DRUG|Placebo|Film-coated tablet
214318264|NCT03754959|DRUG|Midazolam|Solution for injection
214318265|NCT06425055|DRUG|Vonafexor|"* One tablet of a low dose of vonafexor QD from Day 1 to Week 4~* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8~* One tablet of a high dose of vonafexor QD from Week 9 to Week 24"
214318266|NCT03914196|DIAGNOSTIC_TEST|Liver Stiffness Ultrasound|Research imaging will include liver assessments of stiffness (ultrasound shear wave elastography), tissue attenuation (if available), and blood flow (gray-scale and Doppler imaging).
214318267|NCT03616353|PROCEDURE|Perineural Hydrodissection|The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.
214483418|NCT06707805|OTHER|Traditional Physical therapy|Conventional treatment protocol including moist Heating pad for low back pain for 15 minutes. TENS for pain for 10 minutes. Stretchings of tight muscles would be 1 set of 5-7 reps with 5 sec. hold 3 times a week. Strengthing of weak muscles would be 2-3 times a weak with 10-15 reps.Stretching protocol will be followed for Iliopsoas and erector spinae muscles. Strengthening protocol will be followed for weak abdominals and Gluteus maximus muscles
214483419|NCT06707805|OTHER|lumber SNAGS|": Lumber mobilizations with conventional treatment protocol.~* Lumber Mulligan(SNAGs) technique~* Technique applied at L4-L5, L5-S1 level.~* Techniques applied for flexion ,extension, side bending and rotation 6 to 8 cycles per session"
214318268|NCT03616353|PROCEDURE|Corticosteroid Injection|The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.
214318269|NCT01524861|DRUG|Placebo|a placebo tablet bis in die for 12 months
214318270|NCT01524861|DRUG|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
214318271|NCT01524861|DRUG|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
214318272|NCT04963582|PROCEDURE|Acupuncture|LI4 is located on the dorsum of the hand, midway between the 1st and 2nd metacarpal bones, approximately in the middle of the 2nd metacarpal bone on the radial side. Acupuncture is practiced by using 0,25x25mm sized needles. LI4 point is punctured perpendicularly 2cm in the direction of the palm center.
214318273|NCT04653779|DRUG|Evogliptin 5mg/Metformin 1000mg|Size reduction of a tablet formulation
214318274|NCT04329312|RADIATION|Thoracic computed tomography|Patients undergo contrast-enhanced thoracic computed tomography as part of their routine clinical work up.
214318275|NCT00063869|DRUG|Etanercept|
214318276|NCT04196478|DEVICE|doppler ultrasound|a 7.5 MHz ultrasound (US) linear probe is needed, grey-scale ultrasound and Color Doppler and a minimum display facility of the Doppler velocity spectrum for blood flow calculation are mandatory tools.
214318277|NCT04263974|OTHER|Smartphone Application|Exercises and recommendations, based on current scientific evidence, and delivered through the app for Smartphone called CareHand. The intervention protocol is based on strengthening and stretching recommendations for rheumatoid arthritis and osteoarthritis in hands, transferred to an application format through explanatory videos together with tools to improve the autonomy, motivation and adherence of the patient
214318278|NCT04263974|OTHER|Conventional treatment|Conventional approach provided by the Andalusian Public Health System in Primary Care settings. This approach consists of routine visits to the general practitioner specialist, and the delivery of an exercise sheet and recommendations. This general mobility and stretching worksheet contains detailed images, as well as a description of how to perform the exercises and the dose to be taken. While most exercises are intended for the wrist and hands, this sheet also includes basic exercises for the elbow joint.
214671798|NCT06498063|OTHER|Placebo|Placebo (0.9% NaCl).
214671799|NCT06498063|OTHER|Glucagon and exendin 9-39|Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).
214919412|NCT03397498|BEHAVIORAL|Control-games|The program utilizes classic computer games, which may develop cognitive domains. Games will be used over 8 weeks. The participants will use the program 3 days a week, with one rest day between each session. Each session lasts approximately 20 minutes. The participant will use the program for a total number of 24 sessions.
214483420|NCT06706739|OTHER|Online art game intervention group|The researchers conducted a prospective randomized controlled trial in which elderly patients with mild cognitive impairment combined with subthreshold depression who met the inclusion exclusion criteria were randomized into an online art game intervention group and a health education control group, with each group receiving an individualized intervention for 12 weeks. Participants in the experimental group created comic strips through an art game platform developed by the researchers' research team.
214483421|NCT06707662|DEVICE|Pacemaker and defibrillator|Pacemaker implantation, which can be a regular right ventricle apical lead or a LBBAP lead (LBBP or LVSP dependint on the criteria accomplished).
214483422|NCT06708000|DIAGNOSTIC_TEST|Clinical Likelihood (CL) Model-Based Diagnostic Strategy|The Clinical Likelihood (CL) model-based diagnostic strategy utilizes two models: the RF-CL model and the CACS-CL model. These models assess the pre-test probability of obstructive coronary artery disease (CAD) based on patient factors such as age, sex, symptoms, and traditional cardiovascular risk factors like smoking, diabetes, and hypertension. The CACS-CL model incorporates coronary artery calcium scoring to further refine the risk assessment. Patients identified with a low likelihood of CAD may avoid unnecessary diagnostic testing, such as cardiac CT, while maintaining diagnostic accuracy and safety. This approach aims to optimize resource use, reduce patient burden, and focus on other potential causes of symptoms when CAD is unlikely.
214483423|NCT06708000|DIAGNOSTIC_TEST|Standard of care treatment|Patients will follow the standard diagnostic pathway, which includes the use of cardiac CT and other advanced diagnostic procedures based on clinical guidelines. This approach is the current standard of care for patients with suspected obstructive coronary artery disease (CAD). The control group allows for comparison of outcomes with those in the intervention arm, particularly in terms of resource utilization, patient safety, and diagnostic accuracy.
214483424|NCT06707636|BEHAVIORAL|Experimental: Black Women's Stress and Wellness (B-SWELL) arm|The B-SWELL arm consists of 8-weekly sessions. Sessions last 90 minutes and focus on stress reduction, heart disease, and healthy lifestyle changes. The American Heart Association's Life's Essential 8 metrics are leveraged and culturally tailored in the B-SWELL materials. Participants will also receive personalized health coaching.
214483425|NCT06707636|BEHAVIORAL|Active Comparator: Wellness (WE) arm|This is an attention control group. Participants placed in his arm will receive 8-weekly sessions focused on the Life's Essential 8 metrics.
214483426|NCT06707233|PROCEDURE|SIRT|The patients will receive 1-2 sessions of SIRT.
214483427|NCT06697782|DRUG|Ondansetron 8mg|Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
214483428|NCT06697782|DRUG|Aprepitant 125 mg|Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
214483429|NCT06715904|OTHER|Womens with Morton´s Extension|Morton extension application
214483430|NCT06713408|OTHER|Experimental (Music)|Audio recordings consisting of pentatonic music and neva makam will be uploaded to the patients' phones by the researcher. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
214483431|NCT06713408|OTHER|Experimental (Affirmation)|Patients in this group will be asked to listen to the audio recording with pentatonic music and neva makam in the background, along with the affirmation sentences provided in the appendix. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
214483432|NCT06713304|BEHAVIORAL|A community-based Protective Behavioral Strategies program|"A 5-week group program delivered in a healthcare setting to teach and practice protective behavioral strategies. The objectives of each session are:~Session 1: Setting Safe Drinking Limit: The participants can identify the risk related to their drinking behavior, calculate a standard drink, and set a safe drinking limit.~Session 2: Choosing Nonalcoholic Drinks: The participants can understand the benefits of using nonalcoholic beverages and identify and select nonalcoholic beverages.~Session 3: Planning Ahead: The participants can make a plan to stop using during drinking events and know how to say no to alcohol use.~Session 4: Slowing down drinking: The participants can understand the benefits of slowing down drinking and know how to slow down their drinks.~Session 5: Avoid Risky Drinking Situations: The participants can understand the negative effects of excessive drinking and know how to avoid excessive drinking."
214483433|NCT06877858|DRUG|Methadone hydrochloride|Methadone loading dose initiation (vs. standard initiation in the TAU arm)
214483434|NCT06702384|DIAGNOSTIC_TEST|biopsy|Baseline biopsy and biological specimens
214483435|NCT06707909|DRUG|Menaquinone|the socket will be filled with crushed capsule of vitamin k2 menaquinone in study group
214483436|NCT06711510|OTHER|Clinical, behavioral and cognitive evaluation|Questionnaries and tests
214483437|NCT06711510|OTHER|blood sampling|blood sampling (56ml max)
214483438|NCT06711510|OTHER|brain MRI|brain MRI (35 to 70 minutes)
214919413|NCT03674346|OTHER|Hypnoanalgesia group|"The running of a hypnosis session is protocolized and is based on three times:~* The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability.~* The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged,~* The time of return. It is time that allows the patient to regain his classic state of consciousness."
214483439|NCT06711510|OTHER|olfactory swab sampling with nasal brush|olfactory swab sampling with nasal brush
214483440|NCT06711510|OTHER|skin punch biopsy|skin punch biopsy (optional intervention)
214483441|NCT06711510|OTHER|lumbar puncture for CSF sampling|lumbar puncture for CSF sampling (optional intervention)
214483442|NCT06381453|DRUG|Belimumab Auto-Injector [Benlysta]|Belimumab 200 MG/ML \[Benlysta\] will be given once a week as single-dose autoinjector
214483443|NCT06714344|DEVICE|KITGuideMe: W61-MD41-AIT, version 1.0.0|"We are planning to conduct a prospective, 1:1 randomized study within the HM program.~Randomization occurs at the level of network physicians. Network physicians participating in the study are randomly assigned to either the AMPEL group (access to the module) or the non-AMPEL group (no access to the module) using a permuted block randomization scheme to ensure that there are the same number of patients in each study arm. Logical checks within the module ensure that once a network physician is assigned to an arm, he or she remains in that arm for the remainder of the stud"
214671800|NCT03045484|DRUG|Controlled-release oxycodone|CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
214318279|NCT04972019|DEVICE|Telerehabilitation Experimental Group|"Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals and subjective pain level being measured and logged.~They will wear a computer system modified with biosensors, then do motor and cognitive baselines. Subsequently, participants will play an increasing number of games, targeted at cognitive domains of executive function (primary), memory and attention. At the end of every session vitals and subjective pain will be measured and logged.~Clinical Coordinator will call homes weekly to ascertain general health and issues with participation.~At the end of week 4 and 8 participants and their caregivers in the experimental group will fill a subjective evaluation questionnaire to gauge perceived benefits and technical difficulties when using the experimental system. Questions will be scored on a 5-point Likert scale."
214483444|NCT06719635|PROCEDURE|Laparoscopic Presacral Neurectomy|Laparoscopy will be performed under general anesthesia. Then, nerve plexuses will be identified and freed from their underlying tissue, which contains the left common iliac and middle sacral veins. This will be followed by cauterization and cutting of the nerve plexuses.
214483445|NCT06719635|PROCEDURE|Fluoroscopically guided Superior Hypogastric Plexus Neurolysis|The patients will receive fluoroscopically guided Superior Hypogastric Plexus Neurolysis using 3 mL of 75% ethanol and Radiofrequency of the Sacral nerve Roots 2-4.
214483446|NCT06719752|OTHER|Placebo|Placebo intervention; the therapy will mimic exceptional mobilization.
214483447|NCT06719700|DRUG|Chemotherapy|Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.
214483448|NCT06719700|DRUG|Immunotherapy|Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.
214483449|NCT06719700|DRUG|Angio-immuno kinase inhibitor|Oral surufatinib 200 mg once daily (q.d.), given on days 1-14 of each chemotherapy cycle.
214483450|NCT06719700|RADIATION|radiotherapy|Thoracic radiotherapy will begin no later than the start of the third chemotherapy cycle.
214483451|NCT06719700|RADIATION|Prophylactic Cranial Irradiation|PCI is recommended after the completion of chemoradiotherapy.
214483452|NCT06719700|DRUG|Consolidation Therapy with Toripalimab and Surufatinib|Patients achieving complete response (CR), partial response (PR), or stable disease (SD) following chemoradiotherapy will receive consolidation therapy. Toripalimab: 240 mg intravenously on day 1, every three weeks. Surufatinib: 200 mg orally on days 1-14, every three weeks.
214483453|NCT06721611|DEVICE|Optical Blood Pressure Monitoring Device (Aktiia G1)|"Non-hypertensive Nucor employees that accept to wear an optical blood pressure monitoring device (Aktiia 24/7 device) to screen for and identify potential undiagnosed hypertension.~100 participants. Each participant will wear the device continuously for 28 days."
214483454|NCT05359263|DRUG|Dapagliflozin 10 mg|The intervention arm consists of dapagliflozin 10 mg orally once daily
214483455|NCT05359263|DRUG|Placebo|The comparator arm consists of placebo orally once daily
214671801|NCT03045484|OTHER|Chemoradiotherapy|Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
214671802|NCT03897712|DEVICE|Custom Samfilcon B Contact Lenses|Contact lens
214919414|NCT03674346|OTHER|Meopa Group|"The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure.~For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study."
214919415|NCT04543149|DIAGNOSTIC_TEST|Flow cytometric immunophenotyping|To evaluate T cell subsets and monocyte
214919416|NCT00060242|DRUG|fosbretabulin disodium|Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
214919417|NCT05654961|OTHER|Use of telemedicine|Use of telemedicine (any type: telephone only, non-invasive, implantable-cardioverter-defibrillator-based, invasive) in heart failure management
214919418|NCT05235412|OTHER|Not applicable: Observational study without any interventions.|Exposures of interest: Maternal diet and lifestyle, demographics, anthropometrics, infant's health outcomes
214671803|NCT03897712|DEVICE|Alden Optical HP Sphere Contact Lens|Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
214671804|NCT03897712|DEVICE|ReNu MultiPlus Lubricating and Rewetting Drops|For use as needed during the study.
214671805|NCT03897712|DEVICE|Biotrue Multi-Purpose Solution|For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
214671806|NCT04578145|DIAGNOSTIC_TEST|HIV self-testing among female sex workers|"Barriers faced by FSWs in terms of undergoing HIV blood test seemingly overcome through the implementation of alternative strategy of testing, by using OFT self-testing (Ora-Quick).~Ora-Quick test used in this study measures antibody in oral fluid of participants. The oral fluid is collected used a test swab from participant's gum by wiping upper and lower gums once. The specimen mixed with buffered developer solution in test tube. Test result will appear in a short time, by 20 to 40 minutes and leading to interpret."
214671807|NCT01810367|DRUG|ABX Combined With Cisplatin|
214671808|NCT01810367|DRUG|Gemcitabine Combined With Cisplatin|
214671809|NCT05923905|DRUG|FB1006|30mg/day
214671810|NCT05923905|DRUG|Placebo|30mg/day
214318280|NCT04972019|OTHER|Telerehabilitation Sham Control Group|"Sham control group will train playing web games while wearing a biosensor connected to a laptop provided, showing the web games. However biosensor data will not be used to control game difficulty.~Sham group controls will start every session with vitals and subjective pain levels being measured and logged. Then participants will play the same frequency and duration of sessions, however those will consist of web games training the same domains (memory, focusing, executive function). Interaction will be through a mouse, and data will be downloaded to a server maintained by the company doing the web games. Data will then be transferred to the research team.~At the end of every session vitals and subjective pain levels will again be measured and logged.~Once a week the Clinical Coordinator will call the home to ascertain general health and determine is there were issues with that week participation."
214483456|NCT06883773|BEHAVIORAL|Multipurpose Online Tool|The intervention consists of 6 psychoeducational modules, on the Canvas teaching platform. They are automated, requiring no interaction with others (except for communication between participants and the team). Participants go through the psychoeducational modules, then do the corresponding exercise, and then access their rewards (if they belong to the experimental or comparative groups).
214318281|NCT04183556|DRUG|Naproxen|use of naproxen twice a day orally in mens time
214318282|NCT04183556|DIETARY_SUPPLEMENT|Turmeric|Use of turmeric orally (1 gram powder formula) in mens time
214483457|NCT06883773|OTHER|No intervention|The participants will be assessed but without any intervention
214483458|NCT06883760|COMBINATION_PRODUCT|Probiotic tablet candy group|40 volunteers were randomly divided into two groups (n=20): Group A (probiotic → washout → placebo) and Group B (placebo → washout → probiotic). Each group took 1g of tablets (0.5g/tablet, 2 tablets) twice daily for 1 week, followed by a 2-week washout, then switched interventions. Fecal samples were collected at baseline, Day 7, and Day 28. Alcohol tests were conducted on Days 7 and 28 after fasting; participants consumed alcohol (1 mL/kg, 40% v/v) with a standard meal. Serum and saliva were collected post-meal. Body weight was measured, and alcohol dosage was adjusted accordingly. Participants maintained their usual diet and avoided alcohol-detoxifying or liver-protecting drugs. Medication during alcohol tests: 2 pills before tolerance test (after lunch), 2 pills before drinking, and 2 pills after waking.
214483459|NCT06884774|PROCEDURE|Hemorrhoidectomy with lateral internal sphincterotomy|Patients undergoing Hemorrhoidectomy with lateral internal sphincterotomy.
214483460|NCT06884774|PROCEDURE|Hemorrhoidectomy|Patients undergoing Hemorrhoidectomy without lateral internal sphincterotomy.
214483461|NCT06883058|BEHAVIORAL|Caregivers-patients support intervention for advanced cancer (CASA)|The Caregivers-Patients Support Intervention for Advanced Cancer (CASA) will be delivered to patients and caregivers. The sessions follow a protocol and will be held weekly or bi-weekly for a total of 5 sessions.
214483462|NCT06883058|BEHAVIORAL|Placebo|Usual care will be provided to participants in the control group. The usual care consists of symptom management once a week and 5 sessions.
214483463|NCT04342260|OTHER|Active Monitoring|The participants randomized to active symptom monitoring will have alerts sent to their clinicians when their PRO symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported.
214483464|NCT04342260|OTHER|Passive Monitoring|Participants randomized to the passive PRO monitoring arm will complete the same PROs as participants in the active monitoring arm, but will not have alerts sent to their clinician.
214483465|NCT06883942|PROCEDURE|prosthetic group performs the entire protocol with their own prosthesis|"The 1st session is the enrolment and functional evaluation one. The following 2 we test the algorithm functionality verification; one session for both platforms. The last 2 sessions are necessary to acquire prognostic markers for falls; one session for both platforms.~The balance disturbance tests will take place on two platforms:~* The sliding platform consists of a metal supporting structure and a wooden cover, which has a manual release mechanism that allows the activation of the tile responsible for simulating the events that occur during sliding.~* The stumbling platform consists of a metal supporting structure and a wooden cover, which features an electronically activated plastic and foam tripping mechanism that simulates the sequence of events that occur during a stumble."
214483466|NCT06883942|DEVICE|Experimental Group|The fall detection algorithm will be evaluated first. In a second step, the experimentally obtained prognostic markers of fall risk will be studied. The markers thus obtained shall be validated by comparison with markers already established in clinical practice or in the literature.
214483467|NCT06882590|OTHER|Compassionate-focused therapy|A 9-session therapy intervention targeting negative thinking, feelings of guilt and shame, and cultivating compassion for self and others.
214483468|NCT06882915|DRUG|Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab|"TAS-102: Use at the recommended dose of 35 mg/m² each time, twice a day on the 1st to 5th day and the 8th to 12th day every 28 days, with meals.~Bevacizumab: Once a day on the 1st and 15th day every 28 days, at the recommended dose of 5 mg/kg each time, with meals.~Putlimumab: At the recommended dose of 200 mg/time, intravenous drip, infusion time is 60 minutes, once every 28 days."
214483469|NCT06703203|BIOLOGICAL|26-Valent pneumococcal conjugate vaccine|As an experimental group. The active ingredient of 26-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 26 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
214483470|NCT06703203|BIOLOGICAL|23-Valent pneumococcal polysaccharide vaccine|As a control group. The effective ingredients of 23-valent pneumococcal polysaccharide vaccine are 23 serotypes of pneumococcal capsular polysaccharides. Administer one dose of 0.5mL each time.
214483471|NCT06703203|BIOLOGICAL|13-Valent pneumococcal conjugate vaccine|As a control group. The active ingredient of 13-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 13 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
214671811|NCT01414088|OTHER|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
214671812|NCT01414088|OTHER|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
214671813|NCT01414088|OTHER|glucose 5%|infusion, 23 ml/kg, during 50 minutes
214671814|NCT05926089|DIAGNOSTIC_TEST|Blood sampling|blood sampling to measure APR
214919419|NCT00600912|DRUG|SMOFlipid®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
214483472|NCT06884345|DRUG|METR-NK cells combined with Solvatinib|"Sorafenib 250mg po qd, 3 weeks as a course, a total of 3 courses, the drug was stopped 3 weeks before cytoreduction of intermediate tumor.~Dilute METR - 200 mL of NK cells in 37 ℃ 1500 mL of 0.9% sodium chloride physiological saline, intraperitoneal infusion, flow rate \> 150 drops/min, each METR - venous back to the throughput of NK cells is lower than 2 x 107 cells/kg, abdominal cavity to throughput of no less than 4 x 107 cells/kg, Three days of continuous infusion was taken as a course of treatment, and four courses of continuous infusion (the first course of infusion did not use METR-NK cells) were given, with an interval of 14 days for each course. The position was switched every 15 min after the completion of each infusion to ensure uniform distribution of cells to the tumor surface."
214483473|NCT06879990|BEHAVIORAL|Retrograde normal saline irrigation|Retrograde normal saline irrigation during supine Mini percutaneous nephrolithotomy
214483474|NCT06879990|BEHAVIORAL|Without Retrograde normal saline irrigation|Without Retrograde normal saline irrigation during supine Mini percutaneous nephrolithotomy
214483475|NCT06882551|DRUG|Intravitreal Bevacizumab IVB|Intravitreal bevacizumab alone
214919420|NCT00600912|DRUG|2-ClinOleic 20%®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
214919421|NCT03770754|PROCEDURE|Clean and shape Control group|"For the control group the root canals were prepared manually with K-files and step back technique up to size #35. For this group were administered Tylenol"
214483476|NCT06882551|DRUG|intravitreal bevacizumab and suprachoroidal triamcinolone acetonide|Combination of Intravitreal bevacizumab and suprachoroidal triamcinolone acetonide
214318283|NCT00314574|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
214318284|NCT00314574|DRUG|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
214483477|NCT06884748|DRUG|Ursodiol 500 MG|Standard of care treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID for 8 weeks. UDCA to be started while patient is on antibiotics for C. difficile and continue for 8 weeks total.
214483478|NCT06688344|OTHER|fESWT|fESWT will be applied for 1 session between weeks 4-9. The device will be set to low intensity at 0.20 mJ/mm2 - 4 Hz, 500 pulses will be applied from the tibiofemoral interval to the center of the tibiofemoral joint, and 1000 pulses will be applied to the soft tissues around the patella.
214483479|NCT06688344|OTHER|Conventional Physiotherapy|"Participants will be included in the traditional physiotherapy program for the first 9 weeks, and exercise progression will be provided in the form of weekly checks in the 10-12 week period. Between the 12-24th weeks, the exercise program will continue with face-to-face follow-up twice a month.~The traditional physiotherapy program to be applied in the first 9-week period will be as follows :~Week 1 Weight Transfer as Tolerable, NMES, Elevation, Cold Application, Ankle Pumping Exercises, Heel Slide Exercises, Isometric Quadriceps Exercises, Straight Leg Raise Exercises, Extension Brace~Week 2-3 Weight Transfer, Gait Training, NMES, Heel Slide Exercises, Straight Leg Raise, Quadriceps and Adductor Isometric Exercises, Extension Brace, Bicycle, Hip Abduction-Adduction Exercises~Week 4-8. week Mini Squat, Leg Press, Soft Ground Walking, Neuromuscular Training on Balance Board, Functional Strengthening with Elastic Band, Stair Climbing Up and Down"
214483480|NCT06688344|OTHER|shamfESWT|Participants in the control group will receive sham fESWT once a week in weeks 4-9. Participants will be prepared in the same way as the fESWT procedure, but the application will be done with a sham device.
214483481|NCT06884735|OTHER|exposure to virtual reality|exposure to virtual reality
214483482|NCT03830918|BIOLOGICAL|Atezolizumab|Given IV
214483483|NCT03830918|DRUG|Niraparib|Given PO
214483484|NCT03830918|OTHER|Quality-of-Life Assessment|Ancillary studies
214483485|NCT03830918|OTHER|Questionnaire Administration|Ancillary studies
214483486|NCT03830918|DRUG|Temozolomide|Given PO
214483487|NCT05808218|OTHER|Community-Led Total Sanitation|"The community-led total sanitation intervention is implemented across an entire Traditional Authority and includes the following village-level activities:~1. Triggering:~   * Village transect walks and open defecation site mapping~  * Demonstrations of food contamination and medical expense calculations~2. Development of a Community-Action Plan and identification of natural leaders~3. Post-triggering: routine follow-up by selected natural leaders to track and monitor progress against the Community Action Plan~In addition to the activities above, the WASH for Everyone team will:~* Train a cadre of local masons on sanitation construction~* Support the District Health office in the implementation of existing sanitation and hygiene promotion at village markets and other public spaces"
214919422|NCT03770754|PROCEDURE|Cleand and shape Group 1|For the Group 1, LightSpeed LSX rotary instruments (Discus Dental, Culver City, CA, USA) were used to complete the canal preparation to a size #50 for the anteriors and molars to size #40. After procedures were administered Tylenol
214318285|NCT00314574|DRUG|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
214318286|NCT00314574|DRUG|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
214318287|NCT02815748|DRUG|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
214318288|NCT06049056|OTHER|Invitation|During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
214318289|NCT05561842|PROCEDURE|mHealth US-breast biopsy|During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
214318290|NCT01334658|PROCEDURE|Phacoemulsification cataract surgery|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
214318291|NCT01334658|DRUG|Glucose-bicarbonate-Ringer Lactate (GBRL)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
214318292|NCT01334658|DRUG|Balanced Salt Solution (BSS®)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
214318293|NCT00449956|DRUG|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
214318294|NCT00449956|DRUG|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
214318295|NCT00449956|DRUG|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
214318296|NCT00046735|DRUG|Lenalidomide|The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
214318297|NCT05888129|PROCEDURE|surgery after neoadjuvant chemotherapy|surgery after neoadjuvant chemotherapy
214318298|NCT01373749|DRUG|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
214318299|NCT01373749|DRUG|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
214483488|NCT05808218|OTHER|Care Groups|"* Orientation and training of village-level Care Group members on CLTS, latrine construction, and hygiene promotion~* Routine house-to-house follow-up of Care Group members to provide peer-to-peer counselling and support on sanitation and hygiene behaviours."
214919423|NCT03770754|PROCEDURE|Clean and shape Group 2|"For the group 2 the root canals were instrumented with ProTaper ﬁles using X1, X2 (21mm) to X3 (21mm). 0.5% NaOCl was used for irrigation, the original protocol suggested by ProTaper for permanent teeth was simplified for this study.~After clinical procedures Tylenol were administered"
214318300|NCT00712465|DRUG|AZD1305|Extended Release tablet, repeated administration
214318301|NCT00712465|DRUG|Digoxin|Tablet, repeated administration
214318302|NCT01253252|RADIATION|[18F] Fluorodeoxyglucose PET Scan Imaging|"Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.~The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.~The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations."
214318303|NCT01253252|RADIATION|CT scan|Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
214919424|NCT00249132|DRUG|risperidone|
214919425|NCT04138537|OTHER|OB volume|The mean OB volume was calculated in cubic millimeters and compared between the two groups.
214919426|NCT04138537|OTHER|CCCRC test|CCCRC test was done for olfactory function assessment and compared between the two groups.
214919427|NCT02362802|DEVICE|Implantable Cardioverter Defibrillator|
214919428|NCT01620190|OTHER|Laboratory Biomarker Analysis|Correlative studies
214919429|NCT01620190|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
214919430|NCT03039530|BEHAVIORAL|Group Cognitive Behavioral Therapy|9 weekly 2-hour group CBT sessions delivered by 2 trained Public Health Nurses.
214919431|NCT03039530|BEHAVIORAL|Postnatal Care As Usual|Postnatal care as usual will involve treatment from their family physician and midwife or obstetrician, and voluntary participation in programs offered by Niagara Region Public Health and in the community.
214318304|NCT01253252|BIOLOGICAL|Blood sampling for biological investigations|A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
214318305|NCT02363465|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
214318306|NCT05747144|DIAGNOSTIC_TEST|Biometry|Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
214318307|NCT05747144|DIAGNOSTIC_TEST|Retinography (Color) + Autofluorescence (AF)|Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)
214318308|NCT05747144|DIAGNOSTIC_TEST|OCT B-scan and OCT angiography (OCTA)|"OCT B-scan:~2 scans (6 mm)~1 cross line~OCTA:~3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve"
214318309|NCT05747144|DIAGNOSTIC_TEST|Microperimetry|1\) fixation pattern 2) retinal sensitivity map
214318310|NCT05747144|DIAGNOSTIC_TEST|Electrophysiological exams|Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus \< 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.
214318311|NCT04637958|DEVICE|THA|Total hip arthroplasty
214318312|NCT02086110|DIETARY_SUPPLEMENT|Synbiotic|
214318313|NCT02086110|DIETARY_SUPPLEMENT|Prebiotic|
214318314|NCT05999006|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
214318315|NCT04013620|DRUG|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
214318316|NCT05992506|DIAGNOSTIC_TEST|POD risk estimation using PEUMA|A software will analyze intraoperative EEG recording for the estimation of a POD Risk Index
214318317|NCT02462967|DRUG|GR-MD-02|GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
214318318|NCT02462967|DRUG|Placebo|Placebo for GR-MD-02
214318319|NCT02455310|BEHAVIORAL|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
214318320|NCT02844296|BEHAVIORAL|Video about exercise|Video about short-bout exercise will be played for the participants.
214318321|NCT02844296|BEHAVIORAL|App about exercise|A smartphone App about exercise will be installed in participants' mobile phone.
214318322|NCT02844296|BEHAVIORAL|Leaflet about exercise|A leaflet about exercise will be provided for the participants.
214318323|NCT02844296|BEHAVIORAL|Video about diet|Video about healthy diet will be played for the participants.
214318324|NCT02844296|BEHAVIORAL|App about diet|A smartphone App about healthy diet will be installed in participants' mobile phone.
214318325|NCT02844296|BEHAVIORAL|Leaflet about diet|A leaflet about healthy diet will be provided for the participants.
214318326|NCT05155384|OTHER|Pain Neuroscience Education|main topics of pain neuroscience education; neurophysiology of the nervous system, protective mechanism of pain, acute pain formation and chronic pain, factors that increase/reduce pain, central sensitization mechanism, neuroplasticity and treatment strategies in chronic pain.
214318327|NCT05155384|OTHER|Relaxation exercises|Relaxation exercises are a training based on deep relaxation techniques and visual imagery. Relaxation exercises will be applied at the end of the training sessions.
214318328|NCT05155384|OTHER|Cognition target exercise|Cognition target exercises are a time-based approach that is not symptom-conditioned (not based on fatigue or pain). It includes functional and dynamic exercises.
214318329|NCT05155384|OTHER|Pelvic floor stretching exercises|Pelvic floor stretching exercises; consists of stretching exercises involving the pelvic floor muscles and surrounding group muscles (such as piriformis, hamstring, adductor group muscles and lumbar extensors).
214318330|NCT05155384|DEVICE|Transcutaneous electrical nerve stimulation|It will be used with superficial electrodes attached to the suprapubic region of the patients for 20 minutes in each session.
214318331|NCT03764722|DRUG|Levosimendan|"The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP \<90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months."
214318332|NCT06469255|OTHER|Diet Treatment|4 weeks low calorie diet treatment
214318333|NCT02432716|DRUG|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
214318334|NCT02432716|DRUG|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
214318335|NCT00197379|DRUG|roxithromycin|
214318336|NCT01828034|DRUG|Gemcitabine|
214318337|NCT01828034|DRUG|Cisplatin|
214318338|NCT01828034|DRUG|MEK162|
214318339|NCT03101475|DRUG|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
214919432|NCT01521286|OTHER|Data collection|HZ and PHN booklet questionnaire and zoster brief pain inventory (ZBPI) questionnaire.
214919433|NCT06093516|DEVICE|Tinted Lenses|Tinted coloured lenses with UV protection within spectacle frames with the intension to help reduce the symptoms of Visual stress.
214483489|NCT04380454|DEVICE|Functional electrical stimulation (FES)|Functional electrical stimulation (FES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. An electrical stimulator will be used to deliver stimulation during walking (Grass S8800 stimulator with SIU8TB stimulus isolation unit; UDel stimulator). A customized, real-time system will be used to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains 170 will be delivered during gait. The intervention comprises 3 training sessions per week for a total of 12 training sessions. FES intensity is determined at the start of every training session as motor-level stimulation that elicits appropriate functional movements.
214318340|NCT03101475|DRUG|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
214318341|NCT03101475|RADIATION|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
214483490|NCT04380454|OTHER|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention where no specific instructions are provided to target practice to the paretic leg or specific ankle deficits. The intervention comprises 3 training sessions per week for a total of 12 training sessions. Each training session includes six 6-minute walking bouts with 5-minute breaks between bouts.
214483491|NCT06715462|DRUG|N0750|N0750 caps + Cymbalta placebo caps + Lyrica placebo caps
214483492|NCT06715462|DRUG|Cymbalta®|Cymbalta® caps + N0750 placebo caps + Lyrica placebo caps
214483493|NCT06715462|DRUG|Lyrica®|Lyrica® caps + N0750 placebo caps + Cymbalta placebo caps
214483494|NCT06716645|DRUG|Robitussin Maximum Strength Cough and Chest Congestion DM|Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg
214483495|NCT06716645|DRUG|Robitussin Maximum Strength Cough and Chest Congestion DM|Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg
214919434|NCT00478816|BIOLOGICAL|Fluad H5N1 Pandemic Influenza Vaccine|Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.
214919435|NCT00204217|DEVICE|endotracheal intubation|
214919436|NCT05026112|DIAGNOSTIC_TEST|ECG-Imaging|ECG imaging acquisition
214483496|NCT06716645|DRUG|Robitussin Maximum Strength Nighttime Cough DM|Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg
214919437|NCT05026112|DIAGNOSTIC_TEST|Cardiac MRI scan|Cardiac MRI scan
214919438|NCT02196441|DRUG|2% tetracaine local anaesthetic drops|topical anaesthetic drops
214919439|NCT02196441|DRUG|0.5% bupivacaine|was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
214483497|NCT06718907|BEHAVIORAL|Simulated stimuli|Participants will be exposed to a video stimuli in order to assess biophysiological and physiological responses to the stressor and relaxant.
214919440|NCT02220036|DIETARY_SUPPLEMENT|Magnesium Oxide|Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
214919441|NCT05416021|DRUG|dapivirine|dapivirine vaginal ring
214919442|NCT02035202|BEHAVIORAL|CBT2go|CBT administered using mobile intervention.
214919443|NCT02035202|DEVICE|Smartphone|A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
214919444|NCT00952159|BIOLOGICAL|Monitoring seric concentrations of O-demethyl-tramadol and tramadol|The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
214919445|NCT00083759|DRUG|natalizumab|
214919446|NCT00083759|DRUG|placebo|
214919447|NCT05230706|OTHER|Cephalic helmet|An acrylic headgear (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm) was placed on the patient's head. The helmet was covered with surgical cloth (green or blue) folded into 50x60cm rectangles, leaving the front part open to maintain adequate airflow.
214318342|NCT03101475|OTHER|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
214318343|NCT01100008|PROCEDURE|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
214318344|NCT03444142|DRUG|Exenatide LAR|2 mg, once weekly subcutaneously before breakfast during 4 weeks.
214318345|NCT03444142|DRUG|Dulaglutide|.75 mg once weekly subcutaneously before breakfast during 4 weeks.
214318346|NCT01567488|DRUG|Everolimus|Everolimus 10mg/day
214318347|NCT01567488|DRUG|octreotide LAR|30 mg each 28 days
214318348|NCT00253565|DRUG|capecitabine|
214318349|NCT00253565|DRUG|imatinib mesylate|
214318350|NCT02103829|BEHAVIORAL|Brief Intervention #1|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
214318351|NCT02103829|BEHAVIORAL|Brief Intervention #2|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
214318352|NCT02103829|BEHAVIORAL|Brief Intervention #3|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
214318353|NCT04099862|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
214318354|NCT04099862|PROCEDURE|EUS-BD|Endoscopic UltraSound Biliary Drainage
214483498|NCT06718907|BEHAVIORAL|Stress Management|Participants will practice stress management and stress reduction at home, independently.
214483499|NCT06716034|OTHER|Personalized Nutrition Plan and Support|The intervention is a virtually-delivered, personalized nutrition plan and support to improve dietary intake of healthy food (fruit, vegetables and whole grains), based on the principles of a Mediterranean-style diet. Components of the intervention include nutrition counselling, menu planning and the provision of groceries, delivered biweekly, face-to-face, by a registered dietitian over 8 weeks, using a virtual platform. The nutrition counselling structure is grounded in evidence-based behaviour change theory for dietary interventions. Youth and parents will co-develop a personalized menu plan. In addition to biweekly nutrition counselling, participants will receive a food pantry basket, and weekly grocery deliveries to support the menu plan.
214483500|NCT06715111|DEVICE|Laser acupuncture|A study used a laser acupuncture device to deliver treatment to 27 participants in Group A. The device, was designed for high power, non-thermal treatment. The device had a Class IV- high power, non-thermal laser with a wave length of 808-905 and a 650 nm wavelength. It had an ergonomic handpiece, high efficiency aiming beam, and adjustable emission intensity range. The device also included two laser safety goggles, a touchscreen stylus, and a retractable banner. Participants were instructed to relax and accurately detect acupoints before application. The device was adjusted for safety and both participants and researchers wore laser goggles.
214483501|NCT06715111|OTHER|conventional pelvic floor exercise|The study involved participants from groups A and B who underwent conventional pelvic floor exercises for four weeks. The exercises targeted the pubococcygeus, sphincter ani, and urethral musculatures. Participants underwent a warm-up phase with 3-5 minutes of breathing and circulatory exercises, followed by 10 repetitions, 3-5 sets, a 3-5 minute warm-up, 30 minutes of exercises, and a cool-down in five minutes. The exercise program was repeated three times per week for four weeks. Participants were instructed to ensure bladder emptiness, relax, perform contractions and relaxations, squeeze pelvic floor musculatures around the anus and vagina, and maintain contact with the plinth. The cool-down phase involved supervised training for 3-5 minutes of breathing and circulatory exercises.
214483502|NCT06718634|DRUG|BL-M08D1|Administration by intravenous infusion for a cycle of 3 weeks.
214483503|NCT06717659|OTHER|probiotic supplementation intervention|probiotic supplementation will be administered, while participants continue undergoing routine pulmonary rehabilitation therapy
214483504|NCT06717659|OTHER|standard pulmonnary rehabilitation|undergo routine pulmonary rehabilitation without probiotics intervention
214483505|NCT06718946|BIOLOGICAL|IDOV-SAFE|Intravenous administration of oncolytic virus every 3 weeks until tumor progression
214483506|NCT06710223|DRUG|SD-101|Toll-like receptor 9 (TLR9) agonist
214483507|NCT06710223|DEVICE|Cryotherapy|Cryoablation of liver
214483508|NCT06710223|DRUG|Tremelimumab|Anti-CTLA4
214483509|NCT06710223|DRUG|Durvalumab|Anti-PDL1
214483510|NCT07039240|PROCEDURE|Dry needling|The dry needling intervention will follow the fast-in and fast-out technique using disposable stainless-steel needles (0.35 × 40 mm). After insertion with a quick thrust, the needle will be manipulated in multiple directions to elicit at least one local twitch response (LTR). Once the first LTR is obtained, the needle will be moved vertically within a range of 3-5 mm, without rotation, until a total of three LTRs are elicited. The intervention is expected to last approximately 25-30 seconds.
214483511|NCT06709898|OTHER|Cognitive job accommodation|Job accommodation focused on the cognitive aspects at work
214483512|NCT06721910|DRUG|Tocilizumab|Blockade of the interleukin-6 receptor
214483513|NCT06721910|OTHER|Placebo|Infusion of 100 ml normal saline
214483514|NCT06723626|DRUG|Metabolic resuscitation agent|Intervention group will receive intravenous hydrocortisone (200mg every 24 hours), vitamin C (1.5g every 6 hours), and thiamine (200 mg every 12 hours).
214483515|NCT06723626|DRUG|Hydrocortisone|Placebo group will receive intravenous hydrocortisone 200mg every 24 hours.
214483516|NCT06722326|DIETARY_SUPPLEMENT|Dietary Supplement: Hydrogen-rich water|Hydrogen-rich water with 12 mg of hydrogen per serving
214919448|NCT05353842|BEHAVIORAL|WOWii Program|Workout on Wheels Internet Internvention (WOWii) which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
215061363|NCT06264908|BEHAVIORAL|Integrated self-management programme|"8 weeks integrated management programme with three educational sessions. Group therapy sessions (6-8 participants per group) delivered by occupational therapists and rheumatology nurses.~1. Disease pathology and Pain management~2. Joint protection and stretching exercise~3. Psychosocial education~4. Aids prescription Each session will consist of education session, exercise session and group sharing sessions."
214483517|NCT06722326|DIETARY_SUPPLEMENT|Dietary Supplement: Control water|Control water with 0 mg of hydrogen per serving
214318355|NCT01150214|PROCEDURE|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
214318356|NCT01296516|BEHAVIORAL|Non-intervention group|A pedometer and written material on a healthy lifestyle.
214318357|NCT01296516|BEHAVIORAL|Face to face|Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
214318358|NCT01296516|BEHAVIORAL|Telehelath Group|Participants will speak to Trestletree personnel once a week via phone.
214318359|NCT02850874|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
214318360|NCT02850874|PROCEDURE|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
214318361|NCT02850874|DRUG|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
214318362|NCT03633981|OTHER|clinical examinations|"Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery:~* right and left pupillometry (3 times)~* BIS values~* right and left NIRS values~* right and left transcranial Doppler~* neurological clinical examination"
214483518|NCT06723665|DRUG|18F-PSMA-1007|18F-PSMA-1007 is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
214483519|NCT06723665|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
214483520|NCT06722209|OTHER|polyethylene glycol (Protocol I)|Intestinal preparation protocol with polyethylene glycol (Protocol I)
214483521|NCT06530238|PROCEDURE|Russian Currents|Currents are delivered in rectangular bursts. The electrode placement will be at the Tibialis Posterior muscle. Treatment will be given for 10 minutes, 30 minutes during the 3 consecutive days / 4 weeks.
214483522|NCT06723340|DEVICE|Scar gel|Scar gel (medical device - topical application)
214483523|NCT06885450|PROCEDURE|Perforator Pedicled Flaps|Perforator Pedicled V-Y Advanced Flaps
214483524|NCT06722417|DRUG|Icalcaprant|Oral capsules
214483525|NCT06885944|DIETARY_SUPPLEMENT|Probiotic mix preparation|Bifidobacterium containing supplement with vitamin D will start after preterm infants reaches full enteral feeding
214483526|NCT06885944|DIETARY_SUPPLEMENT|Bifidobacteria|Rather than early period we will start probiotics after infant receive full enteral feedings
214483527|NCT06885567|DRUG|BEY2153|Participants administer once daily, PO, 26 weeks
214483528|NCT06885567|DRUG|Placebo|Participants administer once daily, PO, 26 weeks
214483529|NCT06887712|DRUG|Oral midazolam|The intravenous formulation Midazolam Braun 5 mg/ml (B. Braun Melsungen AG, Germany) diluted and mixed with orange juice for oral administration at doses of 0.3 mg/kg , administered approximately 30 minutes before pediatric dental procedures. Sedation and amnesic effects, behavioral cooperation during treatment, sedation onset time, vital signs, recovery duration, safety, and adverse events are systematically monitored and compared between the two dosing groups.
214483530|NCT06887712|DRUG|Oral midazolam|The intravenous formulation Midazolam Braun 5 mg/ml (B. Braun Melsungen AG, Germany) diluted and mixed with orange juice for oral administration at doses of 0.6 mg/kg, administered approximately 30 minutes before pediatric dental procedures. Sedation and amnesic effects, behavioral cooperation during treatment, sedation onset time, vital signs, recovery duration, safety, and adverse events are systematically monitored and compared between the two dosing groups.
214483531|NCT06886243|PROCEDURE|Direct Posterior Composite Restoration|"Description: Composite restorations performed using Clearfil Majesty Posterior (Kuraray, Japan) and Clearfil Universal Bond Quick (Kuraray, Japan) in self-etch mode.~Inferior alveolar nerve block (IANB) administered with articaine hydrochloride with epinephrine (1:100,000) (Maxicaine)."
214483532|NCT06885138|DEVICE|active transcranial Direct Current Stimulation|"Patients will undergo repeated sessions of active transcranial Direct Current Stimulation (tDCS) (anodal polarity). The active electrode (35 cm²) will be placed over the left dorsolateral prefrontal cortex (DLPFC), while the reference electrode (35 cm²) will be positioned over the contralateral area, with a stimulation intensity of 2mA.~Patients will undergo a tDCS session on days 1, 2, 3, 4, 5, 12, 19, and 26 of the study. Each session will last 20 minutes."
214483533|NCT06885138|DEVICE|sham transcranial Direct Current Stimulation|"Patients will undergo repeated sessions of sham tDCS. The electrodes will be placed over the left DLPFC and the contralateral area, as in the active stimulation condition. However, the current will be delivered only for the first 5 seconds, preventing the participants from detecting the placebo condition while ensuring that no neuromodulation occurs in the underlying brain areas. Patients will undergo a tDCS session on days 1, 2, 3, 4, 5, 12, 19, and 26 of the study. Each session will last 20 minutes."
214919449|NCT05171842|BEHAVIORAL|Observe the prognosis after stent implantation|Observe the prognosis of patients after undergoing specific operations. Specific surgery: Use femoral artery or brachial artery to implant naked stent (stent with diameter ≤7mm, stents with \>7mm are not restricted) to restore the blood flow of the true lumen superior mesenteric artery. If the false cavity is large, it can be combined with a spring coil to assist embolization. Anticoagulant therapy should be performed for at least 1 day after surgery. Anticoagulant drugs are not restricted. After discharge from the hospital, the double antibody should be taken for 3 months, and the monoclonal antibody should be maintained for at least 1 year.
214919450|NCT01476878|DEVICE|Frameless Stereotactic Radiosurgery with radiation mask|Linac-based radiosurgery using a thermoplastic mask (single treatment)
214919451|NCT05510193|DEVICE|Aktio prosthesis|Transradial myoelectric prosthesis
214318363|NCT03633981|OTHER|neurological assessment when a neurological event occurs|"next neurological event:~* seizures~* pupillary asymmetry~* myoclonias~* brain stem reflex abnormalities~* osteotendinous reflex abnormalities"
214318364|NCT03633981|OTHER|mortality assessment|to 28 days
214318365|NCT01988571|DRUG|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
214318366|NCT01988571|DRUG|Placebo|One placebo tablet taken each morning orally for 24 months.
214318367|NCT03460522|DRUG|Inotuzumab ozogamicin|Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
215061364|NCT04482777|DRUG|Corticosteriod for treated patients|Drug given to some patients with autoimmune disease
214318368|NCT00004412|DRUG|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
214318369|NCT00004412|OTHER|Standard local care dressing|To heal leg ulcers.
214483534|NCT06887699|OTHER|AI-ECG P4P program|The AI-ECG system will conduct a real-time analysis of the ECG. When the system identifies potential OMI cases, it will immediately send short message service notifications to the on-duty cardiologists. This will enable the cardiologists to promptly review and confirm the diagnosis.
214671815|NCT06051253|DRUG|TDM-based infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously given as an induction therapy at a dose of 5 mg/kg at week 0, 2, and 6. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
214671816|NCT06051253|DRUG|Standard infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
214671817|NCT06151756|BEHAVIORAL|Video Supported Mobile Application|The video-supported mobile application was developed to be interactively utilized on smartphones. T
214318370|NCT05301205|DRUG|oral gabapentin|will be received oral gabapentin capsule 2 HOURS pre-operatively.
214483535|NCT06886334|OTHER|exercise|Ultrasound (4 minutes), TENS (100 Hz, 20 minutes), heat application (15 minutes), and home exercises will be applied. Treatment will be conducted three times a week for four weeks.
214671818|NCT05043610|BIOLOGICAL|Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)|cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.
214919452|NCT00983060|DRUG|NIM811|BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
214483536|NCT06886334|OTHER|mobilization|In addition to heat application (15 minutes) and home exercises, the Cox technique will be used. The patient will be placed face down on a specialized table, and traction will be applied to the lumbar spine for 10 minutes.
214671819|NCT05043610|OTHER|Conventional Treatment|Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
214919453|NCT00983060|DRUG|Placebo BID + SOC|Placebo BID + SOC (PEG IFN and RBV)
215061365|NCT02201329|DRUG|Azacitidine|Azacitidine (subcutaneous)
214671820|NCT06372639|DEVICE|Trans-Cranial Magnetic Stimulation|Brain stimulation by the TMS device will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, the target area will be determined based on an fMRI scan in the resting state of the subject.
214919454|NCT01480466|OTHER|Obesity tools in the electronic health record|The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
214919455|NCT05506566|DRUG|68Ga-FAP-CHX|The dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging
214919456|NCT05506566|DRUG|68Ga-FAP-CHX|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging； 68Ga-FAPI-04, the dose will be 1.8 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging； 18F-FDG, the dose will be 3.7 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging；
214919457|NCT01168466|BEHAVIORAL|QEEG-based Neurofeedback Training|EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.
215061366|NCT02201329|DRUG|Volasertib|Volasertib escalating doses (intravenous)
215061367|NCT06425913|OTHER|Kinesio Taping (KT)|KT was applied to the symptomatic shoulder at the end of the baseline assessment by a certificated physiotherapist with over ten years of experience in Kinesio taping. After three days, participants were re-evaluated. KT application has been made according to the protocol for rotator cuff impingement or tendonitis including inhibition and correction techniques.
215061368|NCT06425913|OTHER|Cold Therapy (CT)|The initial application was administered by the physiotherapist. In a sitting position, a pack was wrapped in a thin towel and placed on the affected shoulder joint, including the painful locations. During the application, the participant was closely observed for discomfort or adverse reactions (redness, burning, numbness, itching, …). The cold application was continued for 20 minutes.After the first application, participants were instructed to apply ice for 20 minutes five times a day for three days at home or work.
214318371|NCT05190042|DEVICE|Cotinuous suture|Cotinuous suture using surgery thread
214318372|NCT05190042|DEVICE|Clips|Hemostatic clips
214318373|NCT00643370|OTHER|CT scan of the chest under deep inspiration breath hold|computed tomography scan of the chest under dep inspiration breath hold conditions
214318374|NCT02128295|DEVICE|Electric breast pump - A|
214318375|NCT02128295|DEVICE|Electric breast pump - B|
214318376|NCT05005858|PROCEDURE|Alveolar ridge splitting|Patients with Kennedy Class I. and II. mandibles with insufficient bone width were included in this study. Ridge splitting was carried out with the use of a piezoelectric surgery device by preparing osteotomies and after mobilization of the buccal cortical by placing an autologous bone block harvested from the retromolar region as a spacer between the buccal and lingual cortical plates. Block-grafts were stabilized by osteosynthesis screws. Implant placement was carried out after a 3-month healing period.
214318377|NCT05005858|DEVICE|Creating osteotomies with piezoelectric device|Osteotomies were carried out with piezoelectric surgery device (NSK Variosurg3 Ultrasonic Bone Surgery System, NSK Europe GmbH, Eschborn, Germany)
214318378|NCT06291142|DEVICE|Observation - Nailfold capillaroscopy|Nailfold capillaroscopy examination
214919458|NCT06048328|BEHAVIORAL|Game Changers for Family Planning|Game Changers for Family Planning (GC-FP) intervention. The intervention will consist of 6 group sessions. The sessions will focus on stigma reduction, disclosure decision making, knowledge, and building skills for advocacy. The 2-hour, weekly sessions will be facilitated by 2 trained peers who are MC users, and conducted in Luganda using a structured manual, and group format to facilitate: sharing of experiences to build support, modeling and motivation; group problem solving and role playing to build skills and self-efficacy; and homework between sessions to practice skills and generate experiences to be processed in the group.
214919459|NCT02702557|OTHER|Elastic Band Exercises|
214919460|NCT04210063|OTHER|Inspiratory Muscle Training (IMT)|IMT is a breathing training technique customized to participant's breathing capacity. Using a handheld electronic manometer (Pro2Fit from Smithfield), a study personnel will initiate training at 40-60% maximal inspiratory pressure. Adjustments will be customized to where the participant reports a difficulty of training between 4-6 out of 10. Training sessions will be performed about 30 minutes a day for 28 consecutive days.
215061369|NCT06425913|OTHER|standardized home exercise program|All participants performed standardized home exercise program, including shoulder isometric and stretching exercises were . A physiotherapist taught the exercise program until the participants were able to exercise accurately on their own. All participants were instructed to perform the exercises three times a day for three days.
215061370|NCT04280016|BEHAVIORAL|Exercise|Participants will participate in an exercise session with non-weight-bearing exercise that the participant is able to perform with off-loading (e.g. total contact cast) intact. They will also be instructed in a home exercise program so that exercise can be performed three days per week with no more than two days between sessions. These participants will also receive standard wound care with off-loading.
215061371|NCT05178836|DRUG|F520+F007|"Drug: F007~F007 is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).~Drug: F520~F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)."
215061372|NCT03629223|DRUG|Tepotinib TF2|Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
215061373|NCT03629223|DRUG|Tepotinib TF3|Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
215061374|NCT02024425|DIETARY_SUPPLEMENT|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
215061375|NCT02024425|DIETARY_SUPPLEMENT|Control supplement|
215061376|NCT04949516|DRUG|Aspirin|Aspirin is discontinued the day after drug-eluting stent implantation
214318379|NCT06482008|DRUG|Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib|HAIC every 3 weeks until 6 treatments have been completed, or HAIC therapy is terminated if patients have not reached 6 treatments and experience intolerable adverse effects; adebrelimab, fixed dose 1200 mg, IV, D1, every 21 days (Q3W), in combination with apatinib, 250 mg (0.25 g), orally, once daily (QD), consecutively dosing in 3-week (21-day) treatment cycles. Study treatment will continue until the subject develops an intolerable toxic reaction, withdraws informed consent, and progresses according to RECIST v1.1 as confirmed by the investigator (after the subject develops disease progression as defined by RECIST v1.1, if the investigator assesses that the subject is still clinically beneficial and can tolerate the study treatment, the subject may continue to receive the study drug; if it is considered that the subject no longer has clinical benefit, then treatment may be terminated), or other termination criteria specified in the protocol, whichever occurs first.
214318380|NCT02308735|OTHER|N/A - No intervention|
214318381|NCT00453999|DRUG|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
214318382|NCT00453999|DRUG|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
214318383|NCT00453999|DRUG|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
214318384|NCT03087656|DRUG|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
214318385|NCT03087656|DRUG|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
214318386|NCT04619706|DRUG|FSD201|Tablets for oral administration.
214318387|NCT04619706|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
214318388|NCT04619706|OTHER|Standard of Care for Covid-19|Standard of care for Covid-19 as determined by site PI
214318389|NCT05360836|OTHER|Conservative treatment via telerehabilitation|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks."
214671821|NCT00719173|DRUG|aprepitant|Given orally
214671822|NCT00719173|DRUG|cyclophosphamide|Given IV
215061377|NCT04949516|DRUG|Colchicine|Colchicine is started the day after drug-eluting stent implantation
215061378|NCT01534351|DRUG|Finasteride|Finasteride 5 mg oral tablet taken once daily.
215061379|NCT01534351|DRUG|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
215061380|NCT01534351|DRUG|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
215061381|NCT01534351|DRUG|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
215061382|NCT03522415|DRUG|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
215061383|NCT03522415|DRUG|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
215061384|NCT02702609|DEVICE|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
215061385|NCT02702609|DEVICE|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
215061386|NCT06341595|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1, 4-6 cycles
214318390|NCT05360836|OTHER|Conservative treatmen + motor imagery|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images."
214318391|NCT01140763|DEVICE|Sysmex's 5-blade lymph node cutter|"A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin \& eosin (H\&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed."
214318392|NCT03471364|DRUG|Ketoconazole|Applied topically
214318393|NCT03471364|OTHER|Laboratory Biomarker Analysis|Correlative studies
214318394|NCT03471364|OTHER|Placebo Administration|Applied topically
214318395|NCT03471364|OTHER|Quality-of-Life Assessment|Ancillary studies
214318396|NCT03471364|OTHER|Questionnaire Administration|Ancillary studies
214318397|NCT04213456|DIETARY_SUPPLEMENT|Nutritional Sport Formula|Powder added to water,high protein and multi vitamins and minerals
214318398|NCT04213456|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
214318399|NCT01358227|DRUG|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
214318400|NCT06470659|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW
214318401|NCT02381912|OTHER|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
214318402|NCT05008991|DEVICE|Spirometry|Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity \[TLC\]) to maximal expiration (residual volume \[RV\]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
214318403|NCT01391728|BEHAVIORAL|Active Lifestyle all your Life|"Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves."
214318404|NCT01039181|DRUG|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
214318405|NCT00782262|DIETARY_SUPPLEMENT|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
214318406|NCT01632202|DEVICE|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
214318407|NCT01632202|DEVICE|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
214318408|NCT05179733|DRUG|six courses of zanubrutinib, rituximab and lenalidomide|Patients in ZR2 group will receive 6 cycles of zanubrutinib 160mg bid, day 1-21, orally, lenalidomide 25mg qd, day 2-11, orally, rituximab 375mg/m², day 1, intravenously, every 21 days.
214318409|NCT05179733|DRUG|six courses of rituximab combined with low-dose CHOP|Patients in R-miniCHOP group will receive rituximab 375 mg/m² on day 1, cyclophosphamide 400 mg/m², doxorubicin 25 mg/m², and vincristine 1 mg on day 2, and prednisone 40 mg/m² on days 2-6, every 21 days.
214483537|NCT06886906|BEHAVIORAL|Intermittent light walking|The participant will remain seated throughout the 1 hour experimental period. During this 1-hour period, participants will complete six bouts of 2.5-minutes of light intensity walking. Overall, the bouts will occur on six occasions, providing a total of 15 minutes of light intensity activity.
214483538|NCT06886906|BEHAVIORAL|uninterrupted sitting|The participant will remain seated throughout the experimental period and will be instructed to minimize excessive movement, only rising from the chair to void. This experimental condition is designed to mimic prolonged uninterrupted sedentary behavior.
214483539|NCT06887452|OTHER|Pharmacist-Led|Pharmacist will conduct regular telehealth visits with Veterans during dose escalation phase of gout treatment
214671823|NCT00719173|OTHER|placebo|Given orally
214671824|NCT02797561|OTHER|5 year Follow-up|
214919461|NCT02390596|DRUG|Anakinra|The dose of Anakinra will be 2mg/kg (patients \<10kg and/or \<8 months: 4mg/kg). If the patient remains febrile (fever \>38°C), he will receive a double dose of anakinra 4mg/kg (patients \<10kg and/or \<8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients \<10kg and/or \<8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
214919462|NCT02361463|DEVICE|3D vision|Laparoscopic simulator training to proficiency under 3D conditions
214483540|NCT06885606|DEVICE|Active tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that involves brief (e.g., 20-min) application of weak electric current (e.g., 2 mA) to the scalp. Active tDCS intervention increases excitability of neurons at the anode with 20-30% of the current going through the brain from anode to cathode so that both cortical and subcortical structures are stimulated. The procedure is very safe, convenient, and fast-acting with well-established parameters. It has the ability to modulate plasticity in specific brain areas and has established efficacy in human laboratory models of addictive motivation and has been shown to decrease craving for cigarettes when the anode is placed over the left dorsolateral prefrontal cortex (DLPFC).
214318410|NCT02101502|OTHER|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
214318411|NCT04185233|OTHER|Games on an iPad|Many games will be programmed on the iPad and organized by age. The child will choose one game and play it during all the procedure time.
214318412|NCT04185233|DRUG|Nitrous Oxide|Nitrous oxide will be provided to the child by a mask 3 minutes before the intervention and during all this one.
214318413|NCT03766100|BEHAVIORAL|Cognitive behavioural therapy (CBT-i)|CBT-i aims to alter behaviours that sustain or add to insomnia and correct cognitions that drive these behaviours. The behavioural components of CBT-i are stimulus control (SC) and Sleep Restriction Therapy (SRT). SC works through the extinction of a conditioned arousal that emerges when bed and bedroom have become associated with wakefulness. With SRT time in bed is reduced to build up sleep pressure. When wakefulness is decreased, time in bed is gradually increased until optimal sleep is attained. With the cognitive component, insomnia is treated by identifying and changing unhelpful or inaccurate thinking regarding sleep and distressing emotional responses to insomnia. The last component of CBT-i aims to reduce hyperarousal with relaxation techniques, scheduled worry time, creating a time to unwind, and employing cognitive therapy strategies.
214483541|NCT06885606|DEVICE|Sham tDCS|Sham tDCS applies a 2mA current for the initial 30 seconds, followed by 0 mA for the remaining 19.5 minutes to simulate active tDCS stimulation. The cathode electrode is placed on the right dorsolateral prefrontal cortex (DLPFC), and the anode is positioned on the left DLPFC, aligned with the electrode placement used in active tDCS.
214483542|NCT06885632|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each patient will have 3 visits (week0, week4, week8).
214483543|NCT06885632|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each patient will have 3 visits (week0, week4, week8).
214483544|NCT06887556|DIAGNOSTIC_TEST|ELISA|Mpox-specific antibody ELISA
214671825|NCT03952650|DRUG|Chloroquine Phosphate|Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
214671826|NCT03952650|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
214671827|NCT03952650|DRUG|Pyrimethamine|"Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses."
214919463|NCT02361463|DEVICE|2D vision|Laparoscopic simulator training to proficiency under 2D conditions
215061387|NCT06341595|RADIATION|Extraperitoneal radiation therapy|Radiotherapy using extraperitoneal radiation therapy, once a day, 5 times a week, 1.8-2 Gy/f, a total of 45-50.4 Gy (lymph node lesion radiation dose of 60-66 Gy)
215061388|NCT06341595|DRUG|Oxaliplatin|oxaliplatin: 130mg/m\^2, D1, Q3W, 4-6 cycles
214318414|NCT02202447|DRUG|EC1169|"PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule."
214318415|NCT02202447|OTHER|EC0652|PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
214318416|NCT02731872|DEVICE|Airvo humidifier|"The Airvo humidifier has adjustable flow settings for delivery of fully saturated breathing gases at 37 °C, 100% humidity.~Flow rates are adjustable between 15 and 45 l/min. Ambient air is drawn in by a low-capacity motor. When coupled to a medical oxygen supply, the regulation of delivered oxygen concentration is ensured."
214483545|NCT06887556|DIAGNOSTIC_TEST|Lateral flow assay|Dried blood spot lateral flow assay for Mpox antibody
214483546|NCT06887309|DIAGNOSTIC_TEST|MRI|MRI : anatomical (3DT1, 3D-FLAIR), functional (task-based and resting-state) and tractographic (multiband diffusion imaging) at three time points: one week, three months and twelve months after the spinal cord injury (SCI)
214483547|NCT06887309|BEHAVIORAL|Neuropsychological tests|The following tests will be performed: the Montreal Cognitive Assessment (MOCA), the Montgomery-Åsberg depression rating scale (MADRS), the Medical Outcome Study Short Form 36 (SF-36)
214483548|NCT06883578|DIETARY_SUPPLEMENT|Short-term continuous normal meal replacement|The normal meal replacement intake is calculated at 25kcal/kg body weight per person per day, with the calorie ratio for breakfast, lunch and dinner being 1:2:2. A meal replacement diet is given for 2 consecutive weeks.
214671828|NCT03952650|DRUG|Coartem|Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
214919464|NCT04366843|OTHER|chair massage|Chair massage was performed useing only traditional methods of Swedish massage were used, consisting of stroking (smooth, continuous movements to relax and calm the sympathetic nervous system), kneading (consisting of wringing, squeezing muscles, compressing pressure points for the relaxation of soft tissues, i.e. muscles, tendons, fascia), stretching combined with swaying and passive movements of the upper limbs (to mobilize the joints of the upper limbs) and final stroking combined with slapping and shaking percussion, vibration.
214318417|NCT03618264|DRUG|Miscible liquid of dexamethasone and ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
214318418|NCT03618264|DRUG|Ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
214318419|NCT00594061|DEVICE|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
214318420|NCT04964453|DRUG|Placebo|Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
214318421|NCT04964453|DRUG|BI 474121|Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
214318422|NCT04869072|DRUG|Convalescent plasma|"Convalescent plasma will be delivered as FFP. Three units of 200ml CP/FFP harvested from one donor will be transfused to one recipient, i.e. there will be a match between donor and recipient and each recipient will receive CP/FFP only from one donor.~CP/FFP will be administered intravenously at the infusion rate of 100ml/hour, starting from day 0, with a new transfusion every 24 hours, for a total of 3 transfusions (see scheme)."
214318423|NCT06466174|DIETARY_SUPPLEMENT|Placebo 1 to Probiotic A|42 day Crossover study design between Placebo 1 and Probiotic A (n = 25)
214318424|NCT06466174|DIETARY_SUPPLEMENT|Probiotic A to Placebo 1|42 day Crossover study design between Probiotic A and Placebo 1 (n = 25)
214318425|NCT06466174|DIETARY_SUPPLEMENT|Placebo 2 to Probiotic B|42 day Crossover study design between Placebo 2 and Probiotic B (n = 25)
214318426|NCT06466174|DIETARY_SUPPLEMENT|Probiotic B to Placebo 2|42 day Crossover study design between Probiotic B and Placebo 2 (n = 25)
214318427|NCT05540366|OTHER|Physical therapy combined with aerobic exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.
214318428|NCT05540366|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
214318429|NCT02254707|DRUG|BILB 1941 ZW|
214318430|NCT02254707|DRUG|Placebo|
214919465|NCT04366843|OTHER|the exercise program|The original set of exercises was developed based on the knowledge and clinical experience of the authors of the study and based on EBP (Evidence Based Practice). The program consisted of 14 strengthening and stretching exercises involving the muscles of the trunk and limbs whose main goal was to mobilize the joints and strengthen the weakened muscles and relax overloaded muscle groups.
214919466|NCT03272295|OTHER|Reference cigarette|The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
214919467|NCT03272295|OTHER|Cigarette with carob bean extract|Based on reference cigarette with added ingredient
214919468|NCT03272295|OTHER|Cigarette with cocoa powder|Based on reference cigarette with added ingredient
215061389|NCT06341595|DRUG|S-1|S-1: 40mg/m\^2, bid, d1-14, 4-6 cycles
214318431|NCT04138875|DRUG|Rituximab|Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a \>10% change in weight dosing will be readjusted.
214318432|NCT04138875|DRUG|Brentuximab Vedotin|Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
214318433|NCT04138875|DRUG|Bendamustine|Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
214318434|NCT04046185|DRUG|PD-1 inhibitor combined progesterone|Toripalimab combine with progesterone
214318435|NCT04046185|DRUG|progesterone|progesterone
214318436|NCT05378139|DEVICE|Vital signs measurements with new app|Patients vital signs are monitored through an app for the nurses to use
214318437|NCT04152889|DRUG|Camrelizumab|Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
214318438|NCT04152889|DRUG|S-1|Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
214671829|NCT03952650|DRUG|ibuprofen|Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
214318439|NCT04152889|DRUG|Docetaxel|Docetaxel: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
214318440|NCT00696137|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
214483549|NCT06883578|DIETARY_SUPPLEMENT|Short-term continuous low-valine meal replacements|The low valine meal replacement intake is calculated at 25kcal/kg body weight per person per day, with the calorie ratio for breakfast, lunch and dinner being 1:2:2. A meal replacement diet is given for 2 consecutive weeks.
214483550|NCT06883578|DIETARY_SUPPLEMENT|Long-term intermittent normal meal replacement|The normal meal replacement intake was calculated at 25 kcal/kg body weight per person per day, with the calorie distribution ratio of 1:2:2 for breakfast, lunch and dinner. A meal replacement diet was used for 2 consecutive days per week for 16 consecutive weeks.
214483551|NCT06883578|DIETARY_SUPPLEMENT|Long-term intermittent low valine meal replacement|The low valine meal replacement intake was calculated at 25 kcal/kg body weight per person per day, with the calorie distribution ratio of 1:2:2 for breakfast, lunch and dinner. A meal replacement diet was used for 2 consecutive days per week for 16 consecutive weeks.
214483552|NCT06883552|DRUG|Tislelizumab Injection|During treatment cycles 1-18, Tislelizumab Injection will be administered in combination with Tislelizumab Injection. From cycle 19 onward, treatment will continue with Tislelizumab Injection monotherapy. The specific regimen is as follows: Tislelizumab Injection: 600 mg (initial dose) - 300 mg (subsequent doses), subcutaneously (SC), every 3 weeks (Q3W), for a total of 18 doses (1 year). Tislelizumab: 200 mg, intravenously (IV), every 3 weeks (Q3W).
214483553|NCT06884059|BEHAVIORAL|Time Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
214671830|NCT04915521|OTHER|erector spina plane block (ESPB) group|"An experienced anesthesiologist performed ESPB in all patients in sitting position bilaterally.~A linear ultrasound probe (6-13 MHz) was used for ultrasound guidance. Injection was done using in-plane technique. A 22G block needle (100mm, B-Braun, Germany) was inserted 3- cm lateral to the T9 spinous process and advanced in cranio-caudal direction. To separate erector spina muscle from the transverse process, initially 1-2 ml saline was injected; then 20 ml 0.5% bupivacaine and 5 ml 0.2% lidocaine were injected following separation. Diffusion of the drugs in erector spina plane at cranio-caudal line was ensured. No analgesic or sedative was used during the procedure."
214671831|NCT02757547|DEVICE|Transcranial magnetic stimulation - Placebo Arm|Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
214919469|NCT03272295|OTHER|Cigarette with fenugreek extract|Based on reference cigarette with added ingredient
214919470|NCT03272295|OTHER|Cigarette with fig juice|Based on reference cigarette with added ingredient
214919471|NCT03272295|OTHER|Cigarette with glycerol|Based on reference cigarette with added ingredient
214919472|NCT03272295|OTHER|Cigarette with guaiacol|Based on reference cigarette with added ingredient
214318441|NCT05483946|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - for each participant, a pre-defined number of measurements will be conducted per leg and forearm
214318442|NCT03621878|OTHER|Neural mobilization exercises -Tensioner technique|Exercise aiming to lengthen the neural structure using more than one joint.
214318443|NCT03621878|OTHER|Neural mobilization exercises -Slider technique|Exercise aiming to slide/glide the neural structure using more than one joint.
214318444|NCT03621878|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device aiming to decrease patient's symptoms.
214318445|NCT03999307|RADIATION|Low-Level Laser Therapy (LLLT)|LLLT will be applied in this group
214318446|NCT03999307|PROCEDURE|Flapless Corticopunture|Small holes in the cortical bone will be achieved using 1-mm diameter round surgical Tungsten bur
214318447|NCT03999307|OTHER|Control|Typical orthodontic treatment with no LLLT or flapless corticopuncture
214318448|NCT06391463|OTHER|Carriage of MRB ou BC|Study of the epidemiology of the carriage of BMR and BC germs in patients in the neonatology department
214318449|NCT02508571|OTHER|Direct swallowing training (DST)|The DST consists of placing a bolus of 0.05-0.2 mL of formula milk (if the parents refuse, distilled water) via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
214483554|NCT06878482|DRUG|Botulinum toxin A|subcutaneous injection of Botulinum toxin A
214483555|NCT06885060|DEVICE|BGaze ADHD Diagnostic Test|The BGaze Clinic ADHD diagnostic test will be administered to all participants. This involves a computer-based task, where an eye-tracker will be recording their eye-movements.
214483556|NCT06885060|DEVICE|Oddball/Alerting Computer Task|Oddball/Alerting Computer Task will be completed by all participants while an eye-tracker records their eye movements.
214483557|NCT06885060|DEVICE|Facical Emotion Computer Task|The Facial Emotion Computer Task will also be completed by all participants while their eye movements are recorded using an eye-tracker.
214671832|NCT02757547|DEVICE|Transcranial magnetic stimulation - Active Arm|Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
214671833|NCT00475449|PROCEDURE|percutaneous coronary intervention|
214671834|NCT00475449|PROCEDURE|coronary artery bypass grafting|
214919473|NCT03272295|OTHER|Cigarette with liquorice extract powder|Based on reference cigarette with added ingredient
214919474|NCT03272295|OTHER|Cigarette plus I-menthol|Based on reference cigarette with added ingredient
214483558|NCT06886815|PROCEDURE|Popliteal Nerve Block|Popliteal sciatic nerve blocks will be performed with the patient in prone position, with the popliteal fossa of the surgical leg marked and sterilized. A high-frequency 10-12 MHz linear array ultrasound transducer will be positioned transversely at the level of the popliteal crease and moved proximally to identify the bifurcation of the sciatic nerve into the tibial and common peroneal nerves. Under ultrasound guidance, a 22-gauge, 80-mm echogenic needle will be inserted using an in-plane lateral-to-medial approach. 15 mL of 0.5% ropivacaine with 2.5 µg/ml of epinephrine will be deposited between tibial and common peroneal nerves within the paraneural sheath. Adequate spread of local anesthetic will be confirmed by visualization of paraneural spread.
214919475|NCT03272295|OTHER|Cigarette with propylene glycol|Based on reference cigarette with added ingredient
214318450|NCT02508571|OTHER|Oral sensorimotor stimulation (OSMS)|The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
214318451|NCT02508571|OTHER|Sham intervention|The sham intervention consisted of the therapists placing his/her hands into the incubator or bassinet for 15 minutes without touching the infants. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
214318452|NCT03742141|DEVICE|Intraoperative Video Laryngoscopy|The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.
214318453|NCT03742141|DRUG|Glycopyrrolate|0.004mg/kg as per routine prior to intubation
214318454|NCT00190801|DRUG|pemetrexed|
214318455|NCT00190801|DRUG|cisplatin|
214919476|NCT03272295|OTHER|Cigarette with sorbitol|Based on reference cigarette with added ingredient
214919477|NCT03272295|OTHER|Cigarette with multiple ingredients|Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
214919478|NCT01517763|DEVICE|Conventional CPAP Therapy|HC244 devices without Thermosmart or SensAwake
214318456|NCT04283643|OTHER|Transcranial Focused Ultrasound|Non-invasive brain stimulation technique
214318457|NCT04283643|OTHER|Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
214318458|NCT00003294|BIOLOGICAL|filgrastim|
214318459|NCT00003294|DRUG|amifostine trihydrate|
214318460|NCT00003294|DRUG|carboplatin|
214483559|NCT06886815|PROCEDURE|Sham Block|Sham blocks will be performed using a 25G needle to inject 1 mL of saline subcutaneously in the popliteus of the surgical knee. Sterilization and ultrasound scanning will mirror that of a popliteal nerve block. The ultrasound screen will be blinded from the patient's vision for all patients in the trial to prevent unblinding by patients with knowledge of the technique.
214318461|NCT00003294|DRUG|paclitaxel|
214318462|NCT03766178|DRUG|Nimotuzumab + SHR-1210|"SHR-1210: 200 mg/time, intravenous injection, q2W continuous medication, a course of treatment needs 28 days. The cumulative longest medication period is 2 years.~Nimotuzumab: 200 mg/time, intravenous injection, administered on the 1st and 8th days of each cycle, every 2 weeks is one cycle."
214318463|NCT00565279|DRUG|ASF1057|Twice daily, topical
214318464|NCT00565279|DRUG|ASF1057|Twice daily, Topical
214318465|NCT00409383|DRUG|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
214318466|NCT00409383|DRUG|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
214318467|NCT00409383|DRUG|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
214318468|NCT01779193|DIETARY_SUPPLEMENT|lactic acid bacteria|oral lactobacillus capsule (dose of 2 \* 10\^9 cfu per capsule), one pill daily
214318469|NCT01779193|DIETARY_SUPPLEMENT|cranberry|oral cranberry capsule, one pill daily
214318470|NCT01779193|DIETARY_SUPPLEMENT|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
214318471|NCT06407466|OTHER|taping|"Kinesiology taping; In order to facilitate the muscle, while the subject is standing and his body is flexed to ensure hip flexion, both I bands will be applied from the origin to the insertion, with 30% stretching from the medial and lateral, starting from the Ischial Tuberositas to the border of the Popliteal Fossa."
214318472|NCT06407466|OTHER|Control|The routine training program will continue without intervention.
214483560|NCT06716567|BIOLOGICAL|Influenza vaccine|Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.
214919479|NCT01517763|DEVICE|Fixed pressure ICON™ without ThermoSmart™|Fixed pressure CPAP therapy using ICON™ without ThermoSmart™ or SensAwake™
214919480|NCT01517763|DEVICE|Auto ICON™ with SensAwake™ and ThermoSmart™|APAP therapy using Auto ICON™ with SensAwake™ and ThermoSmart™
214919481|NCT02915900|OTHER|Gonadotropin removal test|Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
214919482|NCT02915900|OTHER|Routine IVF method|Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
214919483|NCT00704600|DRUG|nelfinavir|"Phase I:~* take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 0: PET-CT~Phase II:~* take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 7 biopsy~* day 7, 21 and week 15 :PET-CT + perfusion CT"
214919484|NCT04623099|DRUG|Escitalopram|Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.
214919485|NCT02506556|DRUG|BYl719|"Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days"
214919486|NCT00444756|PROCEDURE|J-tip jet injection of 1% buffered lidocaine|
214919487|NCT02875613|DRUG|Avelumab|Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
214919488|NCT05969015|BEHAVIORAL|Prochaska and DiClemente transtheorical model|The Prochaska and DiClemente model will be combined to a self-management program in patients with T2DM within 18 months. They will be classified accordingly to their readiness for changing. A care provider will manage the group towards an optimal self-management, aiming to improve their glycemic control and other outcomes of relevance. We will conduct 1 session per week until the end of 12nd intervention month. After, the sections will be conducted each 2 weeks until the end of the trial. Healthcare professional will provide support to the care provider. The recommended processes to progress the patients will be used to trigger them accordingly to their stage, at the discretion of the care provider. We will also consider individualities and non-anticipated problems as a part of the process of behavior changing.
214919489|NCT00452582|DRUG|Sildenafil (Viagra)|Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
214919490|NCT00452582|OTHER|Usual care|Physical therapy, occupational therapy, speech therapy
214919491|NCT00005580|DRUG|bryostatin 1|
214919492|NCT00005580|DRUG|fludarabine phosphate|
214919493|NCT03462160|OTHER|Placebo control group|Placebo will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal. The placebo appearance will be similar to the probiotic.
214919494|NCT03462160|DIETARY_SUPPLEMENT|Probiotic experimental group|Probiotic UroLact containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal.
214919495|NCT00232362|DRUG|Pioglitazone (Actos)|
214919496|NCT00232362|DRUG|Anti-diabetic agent other than pioglitazone or rosiglitazone|
214318473|NCT06407466|OTHER|mobilization|Instrument-assisted soft tissue mobilization; The subject is in a prone position on a bed, with the lower extremity in a neutral position, and a hazelnut-sized amount of lubricant will be applied to the working surface, and will be applied to the skin on the back of the upper leg for 5 minutes, targeting the tissue structures. (Hamstring and deep fascia covering this muscle) Pressure and speed will be adjusted according to the subject's tolerance so as not to cause pain.
214318474|NCT04060056|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
214318475|NCT04060056|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
214318476|NCT04060056|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
214318477|NCT02979340|PROCEDURE|MRI|non-invasive assessment of hepatic fibrosis and steatosis
214318478|NCT00328913|DRUG|5-hydroxytryptophan (food supplement)|
214318479|NCT02376166|DRUG|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade \> 1 toxicities)
214318480|NCT04180020|OTHER|ID/LAB|ID/LAB is the new model in which OUD is managed by Infectious Disease (ID) specialists and/or Hospitalists concurrent with management of the infectious diseases, using long-acting injectable buprenorphine (LAB).
214318481|NCT04180020|OTHER|TAU|TAU is designed to systematize what is the current practice at the participating hospitals and in most U.S. hospitals while offering a minimum standard of care. TAU will constitute recommendation for MOUD initiation and consultation for addiction medicine when available; in practice, it is typically detoxification from opioids and referral to community-based addiction treatment after hospital discharge.
214318482|NCT03447665|BEHAVIORAL|Bedtime routine|Tailored bedtime routine
214671835|NCT02426307|PROCEDURE|TAVR|TAVR: Transcatheter Aortic Valve Replacement
214318483|NCT03447665|BEHAVIORAL|Sleep schedule|Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.
214318484|NCT03447665|BEHAVIORAL|Intervention (bedtime)|Parents implement behavioral sleep intervention at bedtime.
214318485|NCT03447665|BEHAVIORAL|Intervention (after night wakings)|Parents implement behavioral sleep intervention following each night waking.
214318486|NCT00037921|PROCEDURE|Bacterial colonization|
214318487|NCT01297868|OTHER|exercise|
214318488|NCT03729531|PROCEDURE|Conventional vein harvesting technique|Long incision will be used to expose the vein, the perivascular tissue will be dissected carefully by scissors, to check for leakage, the vein will be distended by injecting saline.
214318489|NCT03729531|PROCEDURE|no-touch vein harvesting technique|The vein will be harvested by low-frequency electrotome, about 5mm surrounding tissue will be preserved with the vein, distention should be avoided, the vein will not be cut off until being anastomosed.
214318490|NCT01051128|DEVICE|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
214318491|NCT03862391|DRUG|Analgesics|while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
214318492|NCT03862391|DRUG|Antiemetics|while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
214318493|NCT04832373|DEVICE|Interaction with humanoid robot|A humanoid robot will be installed for 30 days in children. It has a touchscreen tablet, allowing manual interaction complementing the voice interaction. The robot speaks, hears, and has facial and voice identification.
214318494|NCT03247166|DEVICE|TOPS™ System|The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
214318495|NCT02482103|PROCEDURE|Renal denervation|Catheter based renal nerve ablation
214318496|NCT02953379|DRUG|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
214318497|NCT02953379|DRUG|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
214318498|NCT06539117|OTHER|Early feeding post caesarean section|In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
214318499|NCT00363779|DRUG|Cyclosporine|An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
214318500|NCT00363779|GENETIC|Gene expression analysis|A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
214318501|NCT00363779|GENETIC|Microarray analysis|Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
214318502|NCT00363779|OTHER|Laboratory biomarker analysis|Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
214318503|NCT03828812|BEHAVIORAL|Breakfast promotion|Recommendation of having breakfast daily
214318504|NCT03828812|BEHAVIORAL|Nighttime snack reduction|Recommendation of reducing frequency of nighttime snacking
214318505|NCT00256152|DEVICE|AF Suppression Pacing Algorithm|
214318506|NCT03387163|DRUG|Sacubitril/Valsartan|commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
214318507|NCT02829593|OTHER|hypoglycemia (low blood sugar) and MRI|hypoglycemia (low blood sugar) and MRI
214318508|NCT03861260|PROCEDURE|Rigid cystoscopy with urethral dilatation|Patients will have a general anaesthetic and a rigid cytoscopic examination of the bladder dilated with sterile water. The urethra will be dilated from FR20 in incremental diameter increases of 2 to French 32 if possible.
214483561|NCT06886555|PROCEDURE|Epidural analgesia for labour pain|Patients were divided into two groups according to repertorised cervical dilatation at the start of analgesia: Group A \< 4 centimetres (latent stage according to National Institute for Health and Care Excellence guidelines) and Group B between 4 and 6 centimetres.
214318509|NCT03861260|PROCEDURE|Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)|Patients will undergo flexible cystoscopy and intravesical installations of Hyaluronic acid (HA) + Chondroitin Sulphate (CS) (GAGs) weekly for 4 weeks and then at 8 weeks and 12 weeks.
214318510|NCT05507983|DRUG|Tranexamic acid|Tranexamic acid 1500 mg
214318511|NCT05507983|DRUG|Placebo|Placebo, sodium chloride 0.9%
214483562|NCT06717789|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device|"Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device, using the following pain management program,~• High Intensity TENS (50-150 Hz)"
214671836|NCT02426307|PROCEDURE|SAVR|SAVR: surgical Aortic Valve Replacement
214318512|NCT04693390|PROCEDURE|Acupuncture|Application of acupuncture
214318513|NCT04306809|BEHAVIORAL|Internet-delivered ACT for PTSD and chronic pain|The participants will go through an active internet-based ACT treatment focused on education about PTSD, value-based exposure for the traumatic memory and avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
214318514|NCT01810029|BEHAVIORAL|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
214483563|NCT06717789|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device|"Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device, using the following pain management program,~• Low Intensity TENS (5 Hz)"
214318515|NCT04832464|OTHER|RACE Protocol: Balance training along with resistance, aerobic and cognitive exercises.|therapy for the preservation, enhancement, or restoration of movement and physical function impaired or threatened by disease, injury, or disability that utilizes therapeutic exercise, physical modalities (such as massage and electrotherapy), assistive devices, and patient education and training.
214318516|NCT03942978|OTHER|Longitudinal Equity Action Plan|Patients admitted to general medicine pod randomized to intervention will receive a Longitudinal Equity Action Plan (LEAP), which will include a program manager to ensure they are on appropriate medical therapy, that cardiology is consulted when appropriate, that patient is set up with appropriate follow-up appointment with cardiology, that transportation is set up for follow-up visits, and a post-discharge follow up call to remind patients of the appointment and identify any post-discharge issues. This is in addition to standard of care, and there will not be any drug or device interventions.
214318517|NCT02676531|OTHER|Exercise|Walking meditation exercise program
214318518|NCT03226340|DRUG|S-amlodipine 2.5mg + Chlorthalidone 25mg|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
214318519|NCT03226340|DRUG|S-amlodipine 2.5mg + Telmisartan 40mg|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
214318520|NCT02023450|DRUG|saquinavir and ritonavir|micro and low dose
214318521|NCT02023450|DRUG|saquinavir and ritonavir|standard dose
214318522|NCT03639766|DRUG|AbobotulinumtoxinA|AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
214318523|NCT03639766|OTHER|Saline solution|Non-bacteriostatic saline solution
214318524|NCT05041790|DRUG|Choline Alfoscerate|Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
214483564|NCT06886685|OTHER|Near Infrared spectroscopy (NIRS)|NIRS is used as a non-invasive light-based optical technology to measure placental oxygenation and metabolism
214483565|NCT06718010|OTHER|No intervention (observational study)|The study respects the investigator's choice of treatment, without specifying which drugs should be used, the dosage, the administration mode (including monotherapy, combination therapy, or sequential therapy), or the duration of treatment.
214919497|NCT04305457|DRUG|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the subject.
214919498|NCT00627965|DRUG|Sildenafil citrate|50mg tds
214919499|NCT00627965|DRUG|Placebo|Placebo tds
214919500|NCT00036972|BIOLOGICAL|cintredekin besudotox|
214919501|NCT00036972|PROCEDURE|adjuvant therapy|
214919502|NCT00036972|PROCEDURE|conventional surgery|
214919503|NCT00036972|PROCEDURE|neoadjuvant therapy|
214919504|NCT00746746|BIOLOGICAL|HyperAcute vaccine|1.8 mL weekly
214919505|NCT00746746|DRUG|Pegylated Interferon-Alpha 2b|6.0 mcg/kg weekly
214919506|NCT02917291|DRUG|FAB117-HC|(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)
214919507|NCT02917291|OTHER|Control group|(Ph 2) No treatment will be administered
214919508|NCT02917291|DRUG|FAB117-HC|(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)
214919509|NCT02678169|DEVICE|Penumbra Aspiration System|Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain
214483566|NCT06727110|DEVICE|PILP Cement|PILP cement liner.
214919510|NCT04210401|OTHER|Duodenoscope Culture|Culture of reusable duodenoscopes following each use.
214919511|NCT05121701|DEVICE|Videolaryngoscope|C-MAC PM-Karl Storz
214919512|NCT05121701|DEVICE|Macintosh Laryngoscope|Laryngoscope
214919513|NCT02857257|BIOLOGICAL|ACHIM|After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM
214919514|NCT01566539|DRUG|Intranasal Oxytocin (OT) 24 IU|Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.
214919515|NCT01566539|DRUG|Intranasal Vasopressin (AVP)|Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).
214919516|NCT01566539|DRUG|Intranasal Placebo|Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
214919517|NCT01566539|DRUG|Intranasal Vasopressin (AVP) 40 IU|Participants will self-administer a 0.5 ml solution containing 40 international units (IU) of AVP. 5 puffs in total, each with 4 International Units (IU) AVP.
214919518|NCT01566539|DRUG|Lorazepam|Subjects will take 1.0 mg of lorazepam orally 60 minutes prior to fMRI scan.
214919519|NCT00004063|BIOLOGICAL|recombinant interferon alfa|
214919520|NCT00004063|DRUG|cisplatin|
214919521|NCT00004063|DRUG|gemcitabine hydrochloride|
215061390|NCT05719779|DEVICE|Ronco-Onco and MAD|Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.
215061391|NCT03003754|BEHAVIORAL|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
214318525|NCT05041790|DRUG|Placebo|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
214318526|NCT03044405|DIAGNOSTIC_TEST|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
214318527|NCT03044405|DIAGNOSTIC_TEST|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
214318528|NCT01209910|OTHER|Water|Subjects in this arm will be able to drink water with some conditions.
214318529|NCT02769702|DRUG|Acthar|Acthar 80 IU SC twice a week
214318530|NCT00816101|OTHER|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
214318531|NCT00816101|OTHER|Mepilex® Border Lite|Self-adherent foam dressing
214318532|NCT00816101|DEVICE|Adhesive Bandage|Adhesive bandage
214483567|NCT06727110|DEVICE|PILP Conditioner|PILP solution.
214919522|NCT00004063|PROCEDURE|hyperthermia treatment|
214919523|NCT01811810|RADIATION|Radiation therapy (XRT)|
214919524|NCT01811810|OTHER|Androgen Deprivation Therapy (ADT)|
214919525|NCT01811810|OTHER|Chemotherapy|
214919526|NCT03296410|BIOLOGICAL|EV71 and two measles attenuated live vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with two measles attenuated live vaccine at 8 months old.
215061392|NCT03003754|BEHAVIORAL|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
214318533|NCT02355327|DEVICE|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
214318534|NCT02355327|BEHAVIORAL|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
214318535|NCT05861791|DRUG|Fentanyl|opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug
214318536|NCT05861791|DRUG|ketorolac tromethamine with nefopam hydrochloride|non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
214483568|NCT06726369|DRUG|MK-6204 (SKB535) for Injection|MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
214483569|NCT06427447|COMBINATION_PRODUCT|Adjuvant chemoradiotherapy|Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)
214483570|NCT06427447|DRUG|Adjuvant chemotherapy|Chemotherapy (gemcitabine plus capecitabine)
214919527|NCT03296410|BIOLOGICAL|EV71 and attenuated Japanese encephalitis vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with attenuated Japanese encephalitis vaccine at 8 months old.
214919528|NCT03296410|BIOLOGICAL|two measles attenuated live vaccine|infants vaccined with one dose two measles attenuated live vaccine at 8 months old.
214919529|NCT03296410|BIOLOGICAL|live attenuated Japanese encephalitis vaccine|infants vaccined with one dose attenuated Japanese encephalitis vaccine at 8 months old.
214919530|NCT03296410|BIOLOGICAL|EV71 vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).
214483571|NCT06726889|BEHAVIORAL|Standard care|Patient will not receive any additional interventions
214671837|NCT02608164|DIETARY_SUPPLEMENT|3000IU(75μg) vitamin D3|
214919531|NCT00321295|DEVICE|Atrial synchronous bi-ventricular pacing|
214919532|NCT01097590|DEVICE|Active TLA Gut™ column|Five consecutive treatment sessions. The therapy will be administrated every second day.
214919533|NCT01097590|DEVICE|Placebo|Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
214919534|NCT02944695|OTHER|audit|Practice adherence to guidelines
214919535|NCT03892395|DIETARY_SUPPLEMENT|B-vitamin supplementation on bone health|An intervention study to investigate the effect of B-vitamin supplementation for 2-years on bone health
214919536|NCT03892395|DIETARY_SUPPLEMENT|Control group; Vitamin D, a daily capsule containing 10 µg/day vitamin D|Vitamin D, a daily capsule containing 10 µg/day vitamin D
215061393|NCT05538377|OTHER|Focal Vibration|This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
215061394|NCT05538377|OTHER|Control Group|This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
214318537|NCT05452395|OTHER|Post-acute care|"A personalized care program, focusing on managing geriatric syndromes and improving functional performances.~Strength training, activities of daily living (ADL) and instrumental activities of daily living (IADL) practice, basic mobility training, reconditioning exercise, and home environment assessment and modification."
214318538|NCT03689556|DIAGNOSTIC_TEST|FLT PET/CT|Patients will receive 3'-deoxy-3'-\[18F\]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
214483572|NCT06726889|BEHAVIORAL|Decision Support System (DSS)|DSS will be used to deliver educational material through a web-page (in Italian language) accessible through a link
214919537|NCT05214443|PROCEDURE|POEM + F|POEM would first be performed as per usual technique. Upon completion of the myotomy, a 2cm incision would be created over the adventitial layer at the level of gastro-esophageal junction (GEJ), allowing scope entry into the peritoneal cavity. The anterior part of the gastric fundus would be located, grasped with endoscopic forceps and pulled towards the esophageal myotomy site. The intended anterior fundus would then be anchored to the edge of the muscle at the GEJ, with the use of X-TackTM system. After confirming adequate hemostasis and secure anchorage of fundus to the esophagus, the mucosal entry site for the submucosal tunnel would be closed with endoscopic clips as per usual POEM technique.
214483573|NCT06726889|BEHAVIORAL|Reminders|Personalized reminders will be delivered to patients through a common messaging application (WhatsApp)
214483574|NCT06726889|BEHAVIORAL|Feedback|Feedback message will be delivered by physician to patients, through WhatsApp, after medication diary revision
214919538|NCT01199835|OTHER|High Calcium intake from dairy products|High dietary intake of calcium from dairy products (\~1200 mg/d)
214919539|NCT04124835|OTHER|Swiss Ball|"Top narrow (DeLee Plan -5 to -1 or Hodge Plan 1-3) Retroversion, lateralization and pelvic circumference exercises with abducted hips and external rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and external rotation.~Lower Narrow (DeLee Plan +1 to +5 or Hodge Plan 3-4) Pelvic anteversion, tilt, and circumference exercises with abducted hips and internal rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and internal rotation."
214919540|NCT04124835|OTHER|Control Grup|Habitual Care of the Service.
214919541|NCT00410735|DRUG|Placebo|0 mg BID for 12 weeks
214483575|NCT06705712|BEHAVIORAL|Use of activity trackers and motivational conversations to enhance focus on physical activity among women trying to conceive.|"All participants will receive a wrist-worn activity tracker (Garmin VívoSmart 5) which will be connected with an application, Fitrockr. Data from the devices will be linked to data from the Snartforældre-questionnaires. The participants are asked to wear the tracker 24/7 during preconception and during the first trimester of their pregnancy if they conceive within 12 months.~Participants will receive information material and be asked to set goals for their PA level. To follow-up on the goal setting, they will receive two phone calls, where the conversations will be inspired by motivational interviewing."
215061395|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
215061396|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
215061397|NCT02441907|DRUG|aflibercept|
214483576|NCT06707389|BIOLOGICAL|autologous blood monocyte vesicles (lower dose)|20 ml peripheral venous blood was extracted from each patient, anticoagulated with heparin and diluted with PBS. Peripheral blood mononuclear cells were isolated by Ficoll stratified solution. Extracellular vesicles of mononuclear cells were extracted by gradient centrifugation (800g centrifugation at 4 ℃ for 10 minutes, then 2000g centrifugation at centrifuged at 4 ℃ for 10 minutes and then 16000g centrifugation at 4 ℃ for 30 minutes. The precipitate was taken as monocyte vesicle and stored in refrigerator at 4 ℃. For intratympanic injection, precipitate was dissolved in 0.2 ml of lidocaine and 0.8 ml of sterilized injection water. Intratympanic injection of apoVs was performed three times a week.
214483577|NCT06707389|DRUG|Methylprednisolone|40mg of methylprednisolone was dissolved in 0.2 ml of lidocaine injection and 0.8 ml of sterilized injection water. Intratympanic injection of methylprednisolone was performed three times a week.
214671838|NCT04100525|BEHAVIORAL|Neuropsychological testing intervention plus follow up|Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
214919542|NCT00410735|DRUG|Pranlukast hydrate|225 mg BID for 12 weeks
214919543|NCT00034242|DRUG|high-dose intravenous immunoglobulin (IVIG)|
214919544|NCT02299232|DRUG|Dexmedetomidine|Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
214919545|NCT01443585|DEVICE|Progressive Addition Lens (Shamir PrimeIITM) Spectacles|A pair of progressive addition lenses manufactured according to the subject's personal prescription.
214919546|NCT04141683|DIAGNOSTIC_TEST|Stress Echocardiography|Dynamic stress echocardiography using a cycle ergometer on a semi supine exercise table.
214919547|NCT04141683|DIAGNOSTIC_TEST|Pressure volume loop analysis|Pressure volume loop analysis unsing conductance catheter measurements during right heart catheterization.
215061398|NCT05879393|DIETARY_SUPPLEMENT|OMNi-BiOTiC® Active|Multistrain probiotic
215061399|NCT05879393|OTHER|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
215061400|NCT00003587|DRUG|carboplatin|AUC=5.5 day 1 every 21 days X 3
215061401|NCT00003587|DRUG|cisplatin|IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3
215061402|NCT00003587|DRUG|docetaxel|IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3
215061403|NCT00003587|DRUG|gemcitabine|IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3
215061404|NCT00003587|DRUG|paclitaxel|IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3
215061405|NCT00003587|DRUG|vinorelbine|IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3
215061406|NCT02853552|DRUG|Misoprostol|800mcg misoprostol taken sublingually
214318539|NCT05111366|DRUG|TQB2450 injection|TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
214318540|NCT05111366|DRUG|Anlotinib hydrochloride capsules|Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
214318541|NCT04073706|PROCEDURE|TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted|"Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the sentinel node. These one or two nodes are thought to be first involved with cancer spread."
214671839|NCT03289715|DEVICE|On Demand Humidification system Mark 2|The on demand humidification humidifier is set up to alternate between periods of humidification and no humidification totaling 6 periods of 30 minutes duration each. Thus, the test will consist of 3 cycles of disabled humidification and enabled humidification. Each cycle will be with a different humidification setting to assess which setting is most comfortable. In the second phase, the patient will be treated with the dose they had the best experience with in the first test.
214919548|NCT04141683|PROCEDURE|Tricuspid valve repair or replacement|Tricuspid valve repair or replacement using a surgical or interventionale approach according to local heart team recommendation and patients' preference.
214919549|NCT04054115|DRUG|Alprostadil 5 MCG Injection|During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.
214919550|NCT03596593|DIAGNOSTIC_TEST|SPANOM (identifying MSI status from ctDNA)|SPANOM technique, which has been developed by 3D Medicines Inc. Shanghai, China and made it possible to identify MSI status from blood samples, will be used in patients with refractory advanced solid tumors.
214919551|NCT05393856|DRUG|CG-549|"PART A (open-label)~Period 1: single oral dose. Period 2: After PK evaluation of period 1. Period 3: After PK evaluation of period 2.~PART B (randomized)~* Period 1: a single oral dose of ZZ mg CG-549 on Day 1 in fed or fasted state.~* Period 2: a single oral dose of ZZ mg CG-549 on Day 1 in fasted or fed state."
214919552|NCT03533153|BIOLOGICAL|WJ-MSC cells implantation|Laboratory of Stem Cell of Drum Tower Hospital, Nanjing University Medical School, is able to provide types of Good Manufacture Practice (GMP) level stem cells and stem cell-based medicinal products. Clinical-grade WJ-MSC primary cells are cultured to 4\~ 8 passages, and the surface markers (CD90+, CD105+, CD45-, CD31-, CD117-) are identified by flow cytometry. WJ-MSC cells are trypsinized and resuspended in the wash buffer of CTSTMD PBS (+Ca2+, +Mg2+). Within 2 hours after enzyme digestion, WJ-MSC cells are shipped to coronary care unit (CCU) and injected into the body.
214919553|NCT03533153|DRUG|CTSTMD PBS without WJ-MSC|For Case-control study only.
214919554|NCT03533153|DRUG|Conventional drug therapy|All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
215061407|NCT03246516|OTHER|Questionnaire|"Auto and hetero questionnaires:~* STAI Y B, State-Trait Anxiety Inventoriage~* Brief COPE~* RHHI-24, Revised Health Hardiness Inventory~* IPQ-R, Illness Perception Questionnaire"
215061408|NCT04093193|PROCEDURE|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
215061409|NCT06436222|DEVICE|HVNI|Preterm infants with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. The infant has moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth.
215061410|NCT05503706|OTHER|1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo|dandruff shampoo
215061411|NCT06233162|DRUG|Febuxostat-Test product|Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India
215061412|NCT06233162|DRUG|Febuxostat-Reference product|Febuxostat 80 mg tablets Manufactured by: Patheon France, France
215061413|NCT03256669|PROCEDURE|umbilical incision|exploration through umbilical incision
215061414|NCT03287882|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
214318542|NCT04073706|PROCEDURE|TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted|Removal of uterus, tubes and ovaries without retroperitoneal node dissection
214318543|NCT05608824|DEVICE|Shear wave elastography and microvascular flow imaging.|Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
214318544|NCT06714292|PROCEDURE|Endoscopic Clipping|localization of colon lesion with fluorescent clip
214318545|NCT06714292|PROCEDURE|ICG injection|localization of colon lesion with ICG(indocyanine green) through endoscopic tattooing
214318546|NCT07027865|BEHAVIORAL|Sip & Snack Better (SSB) Intervention|Participants (teens 12-16 years) and their parent or legal guardian will participate in a 12-week health coaching intervention to reduce added sugar intake. Parents and teens will participate in 6 health coaching sessions (in weeks 1, 3, 5, 7, 9, and 12; 30-45 minutes, online via Zoom). Teens will participate in four in-person groups sessions (in weeks 2, 4, 6, and 8) and receive text-messages to reinforce intervention content.
214318547|NCT07027865|OTHER|Sip & Snack Better (SSB) Tech-Only Comparison|Participants (teens 12-16 years) and their parent or legal guardian will participate in a 12-week technology-only comparison arm. Parents and teens will receive information about added sugar intake and healthy eating once via email or text message (based on preference) in weeks 1, 3, 5, 7, 9, and 12. Teens will receive informational text messages 3 times per week .
214671840|NCT01644045|DEVICE|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
214483578|NCT06707389|BIOLOGICAL|autologous blood monocyte vesicles (higher dose)|50 ml peripheral venous blood was extracted from each patient, anticoagulated with heparin and diluted with PBS. Peripheral blood mononuclear cells were isolated by Ficoll stratified solution. Extracellular vesicles of mononuclear cells were extracted by gradient centrifugation (800g centrifugation at 4 ℃ for 10 minutes, then 2000g centrifugation at centrifuged at 4 ℃ for 10 minutes and then 16000g centrifugation at 4 ℃ for 30 minutes. The precipitate was taken as monocyte vesicle and stored in refrigerator at 4 ℃. For intratympanic injection, precipitate was dissolved in 0.2 ml of lidocaine and 0.8 ml of sterilized injection water. Intratympanic injection of apoVs was performed three times a week.
214483579|NCT06709196|DRUG|Pivmecillinam|Orally administered pivmecillinam 400mg
214483580|NCT06709196|DRUG|Pivmecillinam|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214483581|NCT06709196|DRUG|Amoxicillin clavulanic acid|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214483582|NCT06709196|DRUG|Amoxicillin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214483583|NCT06709196|DRUG|Cefuroxime|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214671841|NCT02672956|PROCEDURE|Ten mm trocar|
214919555|NCT04017351|OTHER|Artificial Intelligence Virtual Assistant|Virtual assistance application for subjects to ask questions and get information regarding planned surgery
214318548|NCT06722443|DIETARY_SUPPLEMENT|Probiotic|Treatment with capsules with 10\^9 CFU/ day of Limosilactobacillus fermentum CECT5716 during 6 months
214318549|NCT06722443|DIETARY_SUPPLEMENT|Prebiotic|Treatment with capsules 500 mg/capsule/day of olive leaf extract, containing 35% oleuropein during 6 months
214318550|NCT06722443|DIETARY_SUPPLEMENT|Synbiotic|A pill with a combination of prebiotic and probiotic at the same doses during 6 months
214318551|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
214318552|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
214318553|NCT06884254|DRUG|EG1206A|EG1206A 420mg is ongoing to be administered after 840mg loading dose.
214318554|NCT06884254|DRUG|Perjeta|Perjeta 420mg is ongoing to be administered after 840mg loading dose.
214318555|NCT04413162|OTHER|Kinect motion tracking system|Kinect motion tracking system is used to measure shoulder range of motion compared to goniometric measurement.
214318556|NCT05427695|DRUG|Lactobacillus sakei proBio65|Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
214318557|NCT05427695|OTHER|Isotonic Saline Solution|Saline sinus irrigations (SAL group): NeilMed® Isotonic Sinus Rinse™ is marketed as a saline sinus irrigation formula. Subjects will be given instructions to mix one unlabeled packet (containing NeilMed® premixed buffered salt powder) with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
214483584|NCT06709196|DRUG|Ciprofloxacin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214483585|NCT06709196|DRUG|Linezolid|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214483586|NCT06709196|DRUG|Nitrofurantoin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214483587|NCT06709196|DRUG|Trimethoprim|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214483588|NCT06709196|DRUG|Sulfamethoxazole trimethoprim|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214483589|NCT06709196|DRUG|Fluconazole|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
214483590|NCT06709495|DRUG|PEEL-224|Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.
214483591|NCT06709495|DRUG|Temozolomide|Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.
214483592|NCT06709495|DRUG|Vincristine|Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.
214483593|NCT06709495|BIOLOGICAL|Pegfilgrastim|Myeloid growth factor administered per institutional standards.
214483594|NCT06709495|BIOLOGICAL|Filgrastim|Myeloid growth factor administered per institutional standards.
214483595|NCT06711796|DEVICE|emg measurement in adductor pollucis|EMG measurement from adductor pollucis and dorsal interosseus muscles in supination and pronation using increasing stimulation current
214483596|NCT06713421|DRUG|Dimethicone+Pronase|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3.
214671842|NCT01738399|DIETARY_SUPPLEMENT|Coffee|
214671843|NCT01738399|DIETARY_SUPPLEMENT|Placebo|
214671844|NCT01215630|BEHAVIORAL|Aerobic Interval Training|One interval training session
214671845|NCT04901897|DEVICE|kalifilcon A|kalifilcon A daily disposable contact lens
214671846|NCT04901897|DEVICE|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
214671847|NCT04901897|DEVICE|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
214919556|NCT05508698|BEHAVIORAL|Precommitment Nudge|Ask participants to commit to a decision about getting a flu shot
214919557|NCT05508698|BEHAVIORAL|Salience|Additional text and icon in the flu shot alert makes the pre-visit questionnaire response salient to the clinician, which could facilitate action or further discussion with the patient
214919558|NCT01473433|PROCEDURE|Pericardial adipose pedicle (adiFLAP) transposition.|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.
214919559|NCT01473433|OTHER|Control|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
214919560|NCT00879476|DRUG|Ramipril 10mg capsules|
214318558|NCT06127511|OTHER|Food (peanut)|After the recruitment, the participants will follow a peanut-free diet for two weeks.
214318559|NCT06899516|OTHER|The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992)|The LAPS is a established tool for measuring the emotional bond between humans and their animal companions. Animal attachment is assessed according to three factors: the bond between owners and their dogs or cats, the closeness of the human-animal relationship, and the importance of the animal in the owner's life (Johnson et al., 1992). Higher scores indicate greater attachment.
214318560|NCT03037398|DEVICE|Vercise Deep Brain Stimulation System|
214318561|NCT06750783|DRUG|Xuezhikang|The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;
214318562|NCT06750783|DRUG|Atorvastatin|The atorvastatin group takes atorvastatin 20mg once a day, orally after meals.
214483597|NCT06713421|DRUG|Dimethicone|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder.
214483598|NCT06713421|BEHAVIORAL|with Postural Exercise|After the premedication is administered orally approximately 15-20 minutes before EGD, patients are asked to take a 3-minute postural exercise.
214919561|NCT03443362|PROCEDURE|Punch Biopsy|A 3 mm punch biopsy will be taken from lesional and non-lesional skin as a routine procedure.
214919562|NCT03443362|PROCEDURE|Blood sampling|Blood sampling
214919563|NCT01557374|DRUG|Tocilizumab, Abatacept|Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
214919564|NCT01557374|DRUG|Decrease Tocilizumab, Abatacept|"The decrease pattern is established on 4 consecutive stages :~IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):~Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop~SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):~Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop~* If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.~* If DAS 28 \> 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage~* If DAS 28 \> 3,2 : return to previous stage, (relapse according to European expert consensus)~In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study."
214919565|NCT02159157|BEHAVIORAL|Exercise prescription|A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
214919566|NCT03645395|DRUG|MT-3724|Experimental treatment with MT-3724 in combination with LEN therapy.
214919567|NCT02694926|OTHER|Education|During a session of 90 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings.
214919568|NCT06478966|BEHAVIORAL|Experimental|Stoma care training was delivered using the PechaKucha method for the intervention group.The presentation format involves 20 slides (usually containing images only) that are shown for 20 seconds each, for a total presentation length of 6 minutes and 40 seconds.
214919569|NCT00324025|DRUG|Mycograb|
214919570|NCT00324025|DRUG|placebo|
214919571|NCT04001296|BEHAVIORAL|21 day Brush Day and Night school programme|Children participating in the 21 day Brush Day and Night school programme are provided with toothpaste and a toothbrush each and enjoy brushing instruction, supervised brushing, and the singing of songs to facilitate learn the importance of brushing day and night, and stickers and calendars to track progress. A celebration is held at the end of the programme with certificates and rewards. The programme is supported by colourful and attractive materials with bespoke cartoon characters. Parents are provided with educational leaflets.
214318563|NCT06885645|DRUG|KH815 for injection|KH815 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting TROP2 antigens.
214318564|NCT02917031|DRUG|Saxagliptin|5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
214318565|NCT02917031|DRUG|Sitagliptin|50 mg or 100 mg, gray capsule
214318566|NCT02917031|DRUG|Placebo to match saxagliptin|2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
214318567|NCT02917031|DRUG|Placebo to match sitagliptin|50 mg or 100 mg, gray capsule
214318568|NCT06924320|DRUG|MET233 and MET097|For subcutaneous administration
214318569|NCT06924320|DRUG|Placebo|Sterile 0.9% (w/v) saline for subcutaneous administration.
214483599|NCT06713421|BEHAVIORAL|without Postural Exercise.|After the premedication is administered orally approximately 15-20 minutes before EGD, patients sit quietly awaiting examination.
214483600|NCT06697223|DEVICE|INTERCEPT Blood System for Platelets with LED Illuminator|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) using the LED Illuminator and stored for 5 days at 20 to 24°C with continuous agitation.
214483601|NCT06711705|DRUG|Elranatamab|Subcutaneous injection of elranatamab. If patient achieves MRD negative remission, patient would enter treatment-free observation period with MRD monitoring.
214671848|NCT01046188|OTHER|Knowledge Questionnaire|Administered before and after teaching intervention
214671849|NCT01046188|OTHER|Perceived Stress Scale|Administered before and after teaching intervention
214919572|NCT04946435|COMBINATION_PRODUCT|Antibiotic Irrigation|The first 30 patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group. The following 30 patients will be assigned to the experimental group. Immediately following surgery, the control group will receive nasal packing alone and the experimental group will receive nasal packing with antibiotic irrigation
214919573|NCT01057810|DRUG|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
214919574|NCT01057810|DRUG|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
214919575|NCT01861652|DEVICE|Venous Health Systems Vasculaire Leg Compression Device|Leg (calf) compression device used to alleviate symptoms of restless legs
214919576|NCT05297370|BEHAVIORAL|Mixed and match Intervention|Participants will receive a brief 15-minute counselling session based on the 5A's' and '5R's' models by our trained research assistant. Participants will be able to choose their smoking cessation treatment options from our menu.
214318570|NCT06924320|DRUG|MET233|For subcutaneous administration
214318571|NCT06924567|DIAGNOSTIC_TEST|Implant motion provocation CT|Implant Movement Analysis. A low dose CT scan is performed with the hip fixed in external rotation. Then another low dose CT scan is performed with the hip fixed in internal rotation.The CT scans are then overimposed to each other and implant motion in relation to host bone is visualized,
214318572|NCT06923020|OTHER|Exposure: Nutritional Status|The assessment of nutritional risk screening (NRS) and nutritional assessments were conducted using NRS 2002 and Patient-Generated Subjective Global Assessment (PG-SGA).
214318573|NCT06923020|OTHER|Exposure: Nutritional Status|The assessment of nutritional risk screening (NRS) and nutritional assessments were conducted using NRS 2002 and Patient-Generated Subjective Global Assessment (PG-SGA).
214318574|NCT06918353|DIAGNOSTIC_TEST|Diagnosis and Severity Grading of AECOPD Disease|Diagnosis and severity grading of AECOPD disease, as well as assessment of traditional Chinese medicine syndromes
214318575|NCT04620681|BIOLOGICAL|CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes|Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent
214318576|NCT04620681|DRUG|Standard of Care Chemotherapy|Standard of care cytarabine-based chemotherapy
214318577|NCT03271736|BEHAVIORAL|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
214318578|NCT03271736|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
214318579|NCT06399146|DEVICE|Picterus App|Take a photo off the patient's skin (sternum).
214318580|NCT02411331|DRUG|Ethanol 40% + Enoxaparine 400UI/ml|
214318581|NCT02411331|DRUG|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
214318582|NCT05758740|BEHAVIORAL|E-health enhanced behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, a conventional behavioural change intervention will begin following a standardized intervention implementation manual and the physical activity amount will be logged by the participants using a logbook. Physical activity counselling will be conducted by a trained research assistant face-to-face at the elderly community centre. Each counselling session lasts for one hour and is once per week for 12 weeks.
214318583|NCT05758740|BEHAVIORAL|Conventional behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, e-health enhanced behavioural change intervention will begin following a standardized intervention implementation manual and using participants' own smartphones installed with two Apps (i.e., Samsung Health and WhatsApp). The physical activity amount will be logged by the smartphone using Samsung Health. Physical activity counselling will be conducted by a trained research assistant remotely using a smartphone. The remote counselling sessions totally last for accumulatively 1 hour per week for 12 weeks.
214318584|NCT00224211|BEHAVIORAL|Music|
214318585|NCT00403273|DRUG|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
214318586|NCT00403273|DRUG|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
214318587|NCT06316414|BIOLOGICAL|Omalizumab|Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.
214318588|NCT05597007|BEHAVIORAL|VPICS Clinic|Participants will complete a mix of mandatory synchronous and asynchronous sessions with their Health Group to address PICS. Participants will spend 15 minutes daily on physiotherapy, and 15 minutes on cognitive therapy. There are also 2h time slots everyday for participants to join for an optional check-in with their health coach, who can support them in their individual activities. Participants will spend 15 minutes weekly responding to journal prompts about nutrition and general challenges.
214318589|NCT00213174|BEHAVIORAL|school playgrounds|
214318590|NCT04467827|DIAGNOSTIC_TEST|examining group|Posture assessment in young healthy people depending on their level of physical activity
214318591|NCT03265093|OTHER|Platelet Rich Fibrin Injection|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.
214318592|NCT03265093|DRUG|Corticosteroid|Corticosteroid injection
214318593|NCT05091567|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
214318594|NCT05091567|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
214318595|NCT05091567|DRUG|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
214318596|NCT05091567|DRUG|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
214318597|NCT02041598|OTHER|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
214318598|NCT05368207|DRUG|Pembrolizumab|Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
214919577|NCT05297370|OTHER|Control|Participants in the control group will receive a self-help quitting leaflet issued by the TACO
214318599|NCT05049161|DRUG|Temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
214318600|NCT05049161|DRUG|Temelimab 36mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
214318601|NCT05049161|DRUG|Temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
214318602|NCT04884516|DIETARY_SUPPLEMENT|Retinol gummy|Participants take one retinol gummy per day
214318603|NCT02344368|OTHER|0.2 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
214318604|NCT02344368|OTHER|0.5 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
214318605|NCT04041869|BEHAVIORAL|MapTrek|Participants will receive a Fitbit activity monitor and access to the MapTrek game which will be visible on monitors set up in the residential facility.
214318606|NCT05939739|BIOLOGICAL|Blood samples|Samples collected during blood sampling for array CGH (1 EDTA tube for index case and 2 biological relatives)
214318607|NCT05939739|OTHER|Consultation for results delivery|at 4 months
214318608|NCT05939739|OTHER|Study Humanities and Social Sciences|Interview offered to 20 families with positive results and 10 families with negative results
214318609|NCT05087875|BEHAVIORAL|TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. Participants set goals for reducing their drinking and learn strategies to help them achieve those goals. It requires four 30-minute sessions with a counselor using mobile phones.
214318610|NCT05087875|OTHER|No intervention|The comparison group will be evaluated based on daily self-monitoring data.
214318611|NCT04844554|OTHER|Active HD-tDCS 3mA|This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.
214318612|NCT04844554|OTHER|Sham HD-tDCS|This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
214318613|NCT05024565|BEHAVIORAL|prolonged intravenous infusion of β-lactams Antibiotics|(1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
214318614|NCT02584751|DRUG|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
214483602|NCT06713148|BIOLOGICAL|IDOV-SAFETM|Each patient received intratumoral injection on the first day, 14 days as a course of treatment, and the follow-up investigator decided whether to continue the second (D14) and third (D28) course of administration according to the comprehensive evaluation of the subjects' conditions
214318615|NCT02584751|DEVICE|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
214318616|NCT02584751|PROCEDURE|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
214318617|NCT02584751|PROCEDURE|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
214318618|NCT02584751|PROCEDURE|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
214318619|NCT02584751|PROCEDURE|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
214318620|NCT02584751|PROCEDURE|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
214318621|NCT05531162|OTHER|Cognition and emotional neuropsychologicl evaluations|Cognitive ans sensory performances during repetitive micro and partial gravity exposure
214318622|NCT02534792|OTHER|Revalvulation|
214318623|NCT01852292|DRUG|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
214318624|NCT01852292|DRUG|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
214318625|NCT01852292|DRUG|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
214483603|NCT06719674|PROCEDURE|Professional mechanical plaque removal and Laser|A diode laser will be used as an adjunct to mechanical plaque removal.
214671850|NCT01046188|OTHER|Satisfaction questionnaire|Administered after the intervention and at study completion
214919578|NCT05931042|DRUG|Trastuzumab|Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)
214919579|NCT00281788|DRUG|capecitabine|
214919580|NCT00281788|DRUG|carboplatin|
214919581|NCT00281788|DRUG|paclitaxel|
214919582|NCT00281788|RADIATION|radiation therapy|
214483604|NCT06719674|PROCEDURE|Professional mechanical plaque removal|The patients will be treated in accordance with treatment guidelines for Stage III periodontitis issued by the European Federation of Periodontology (13). At baseline, oral hygiene instructions were given together with supra- and subgingival professional mechanical plaque removal (PMPR) using a combination of the ultrasonic scaler and hand instruments, according to the clinical situation. After completing treatment, patients will be asked to return at 1 month for review and again at 3 months to repeat the measurement of clinical parameters and collection of the saliva samples.
214318626|NCT03935035|BEHAVIORAL|internet-delivered Cognitive Therapy for PTSD (iCT)|Participants will receive 10 hours of Cognitive Therapy for PTSD over 12 weeks, with a baseline assessment at the beginning and follow up interview at the end of treatment. The treatment consists of online modules (9 core modules, 11 optional modules and parent/carer modules) and a weekly phone call with a qualified and trained therapist.
214318627|NCT04452266|OTHER|questionnaire assesment|Each patient will to answer questions about their medical history.
214318628|NCT04491162|OTHER|Body weight support treadmill training + conventional therapy|"Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.~Patients in intervention arm were additionally trained with a 40% body weight support and a comfortable walking speed on treadmill for twenty minutes. The training, which was conducted three times a week, for period of two weeks."
214318629|NCT04491162|OTHER|Conventional therapy|Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.
214318630|NCT05953077|BEHAVIORAL|Conversational recasting|The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.
214318631|NCT04700514|DRUG|Dexmedetomidine|Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia
214318632|NCT01670357|DRUG|DA-6034 3%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
214318633|NCT01670357|DRUG|DA-6034 5%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
214318634|NCT01670357|DRUG|DA-6034 Placebo|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
214318635|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
214318636|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
214318637|NCT02586012|DRUG|rFVIII|Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].
214483605|NCT06633146|BEHAVIORAL|Therapies in nature|Therapeutic tasks in nature specifically designed for the study
214919583|NCT06353685|RADIATION|Continuous, hyperfractionated, accelerated radiotherapy(CHART)|high-risk CTV area (CTV1), 45Gy in total, fraction dose of 1.5Gy, twice a day, bioequivalent dose (BED) of 51.75Gy; Low-risk CTV area(CTV2), 39Gy in total , fraction dose of 1.3Gy, twice a day, BED of 44.07Gy; A total of 30 radiotherapy fraction were performed 10 times a week for 3 weeks.
214919584|NCT04560985|OTHER|Hydrophilic fissure sealant|Hydrophilic fissure sealant on first molars
214919585|NCT04560985|OTHER|Hydrophobic fissure sealant|Hydrophobic fissure sealant on first molars
214919586|NCT05973305|DRUG|Dorzol 20 mg/ml|dosing schedule t.i.d.
214919587|NCT05973305|DRUG|Trusopt 20 mg/ml|dosing schedule t.i.d.
214318638|NCT05686681|BEHAVIORAL|Brief Behavioral Activation for Improving Social Connectedness|"Brief Behavioral Activation for Improving Social Connectedness (BBAISC): BBAISC was developed to address social connectedness. Grounded in Behavioral Activation (Lejuez et al., 2011), BBAISC is a structured, 6-session skill-building intervention that has 4 key elements (Pepin et al., 2020):~1. Psychoeducation: Psychoeducation focused on homebound status, social connectedness, and associated changes in behavior.~2. Behavioral Activation intervention rationale: Framing how changing behavior can positively impact social connectedness (i.e., improve social connectedness and reduce loneliness).~3. Exploration of life areas, values, and activities: Focused on identifying life areas and values most relevant to the participant. Then, these values are used to generate activities that are aligned with those values.~4. Activity monitoring and planning: Participants are encouraged to schedule and organize their day based on what is important rather than their current mood or feeling state."
214483606|NCT05016895|DRUG|Single-dose azithromycin|Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.
214483607|NCT06729164|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods guided by cognitive, sociocultural, and linguistic theories that are applied to interventions supporting sign language development among deaf children.
214483608|NCT06729164|BEHAVIORAL|Business-As-Usual Instruction|Teachers will teach business-as-usual without the inclusion of SISI.
214671851|NCT01046188|OTHER|Web-based IVF teaching|Web-based IVF teaching
214919588|NCT02088905|BEHAVIORAL|Parent Child Interaction Therapy|Parent-Child Interaction Therapy (PCIT) is a research-supported parent coaching intervention that has been found to be highly effective among typically developing preschoolers presenting with a range of mental health concerns, especially defiance and noncompliance.6 PCIT holds considerable promise as a potentially effective treatment for children with ASD because it directly addresses the behaviors parents of children with ASD report to be most problematic for them - defiance, stubbornness, and temper tantrums. PCIT is theoretically consistent with other approaches that have shown promise in treating ASD (i.e., behaviorally-based); however, PCIT is unique in that it incorporates a socially-based initial phase which may have some unique benefits for children with ASD.
214919589|NCT05690607|OTHER|Doctors Laboratory TINIES small volume blood testing kit|Doctors Laboratory TINIES small volume blood testing kits comprise microcontainers manufactured by BD Diagnostics designed for sample collection from skin puncture, along with home testing pack with lancets, instructions and Royal Mail postal packs.
214919590|NCT06448507|DEVICE|INJEX [Needle less anesthesia]|already described
214318639|NCT01462903|BIOLOGICAL|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
214671852|NCT01046188|OTHER|Didactic lecture|Didactic lecture
214671853|NCT01357239|DRUG|AFQ056|
214671854|NCT01357239|DRUG|Placebo|
214671855|NCT02743637|DRUG|SDX-7320|SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
214919591|NCT06448507|DEVICE|Syringe Needle [ Traditional technique]|described
214919592|NCT00827905|DEVICE|RSpot Non-Contact Respiratory Rate Spot Check|The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
214483609|NCT06728631|DRUG|Candonilimab and ATRA|Candonilimab at a dose of 6mg/kg IV Q3W will be administered until a maximum treatment duration of 1 year. All-trans retinoic acid will be administered at a dose of 25mg/m² twice daily on days 1-14, with a treatment cycle of 21 days, until a maximum treatment duration of 6 months, or until the occurrence of oral cancer or other malignancies, death, intolerable toxicity, withdrawal of informed consent, or any other reasons specified in the protocol.
214483610|NCT06728631|OTHER|other treatment or observation|other treatment other than Candonilimab/ATRA or observation
214483611|NCT05416697|DRUG|CBD oil|The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.
214483612|NCT05416697|DRUG|Placebo|The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
214483613|NCT06729021|DEVICE|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
214919593|NCT06178029|OTHER|Acupuncture|20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation and acupuncture treatment.
214318640|NCT05581212|OTHER|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack|Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
214318641|NCT01195467|DRUG|Truvada/Raltegravir|All subjects currently on Atripla® will switch to Truvada/Raltegravir
214318642|NCT02886377|BIOLOGICAL|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
214483614|NCT06729021|DRUG|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
214483615|NCT06728228|OTHER|Amnioinfusion|A 20- or 22-gauge spinal needle (routinely used obstetrics and gynecology needle) will be used by an expert in fetal procedures with sterile technique to access the amniotic cavity under real-time ultrasound guidance to infuse isotonic fluid (Lactated Ringers with 1g/L of Oxacillin). This fluid will act as replacement amniotic fluid. Regular monitoring of fluid levels may suggest serial infusion, which will be completed as deemed necessary by the study doctor.
214483616|NCT06727812|DRUG|HRS-6208|HRS-6208.
214483617|NCT06729112|DIAGNOSTIC_TEST|pan immune inflammation value|Using the ratio of neutrophil, monocyte, and platelet counts to lymphocyte count, NLR, MLR, and PLR were calculated. The pan immune inflammation value (PIV) was calculated by multiplying the neutrophil count by the platelet count and the monocyte count, and then dividing the result by the lymphocyte count.
214483618|NCT06728020|OTHER|Active Comparator: Conventional rehabilitation (Group A)|The conventional group will undergo standard rehabilitation treatment according to the rehabilitation plan developed by the rehabilitation team. This group will undergo 3 hours of rehabilitation per day and will carry out face-to-face rehabilitation following an impairment-based approach aimed at the treatment of motor-cognitive functions.
214483619|NCT06728020|DEVICE|ROOMMATE 1st|In addition to Group A, this group will have the bedside multimedia monitor apparatus to access informative, rehabilitation, and entertainment content. Additionally, this group will have a digital and innovation coach to receive support in using the technology.
214483620|NCT06728020|DEVICE|ROOMMATE 2nd|Once the first RCT of the cmRCT is completed, a pilot RCT will be initiated, randomizing 60 cases between Group A and this group. In addition to conventional treatment, this group will have a version of the ROOMMATE system integrated with inertial sensors worn on the hands and fingers to guide the serious games on the platform.
214483621|NCT06727513|PROCEDURE|A single-operator technique for GlideScope intubation.|A single-operator technique where the senior resident will insert the GlideScope and perform the endotracheal intubation using an angulated stylet.
214483622|NCT06727513|PROCEDURE|A double-operator technique for GlideScope intubation|A double-operator technique where the senior resident will insert the GlideScope until visualizing an optimal glottic view, then the attending physician will take over the GlideScope keeping it in the same fixed position, while the resident performs the endotracheal intubation using an angulated stylet.
214483623|NCT04686799|DRUG|Doxycycline Hyclate 20 MG|Subjects will receive doxycycline 20 mg BID
214919594|NCT06178029|OTHER|Conventional Rehabilitation|20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation
214919595|NCT01585740|DRUG|0.9% Normal Saline|Crystalloid fluid
214919596|NCT01585740|DRUG|Ringer's Lactate|Crystalloid fluid
214483624|NCT06884839|PROCEDURE|Therapeutic resection|Patients with colorectal cancer underwent therapeutic resection with pathologically positive tumor deposits (TDs) to determine distant metastasis occurrence and the effect of TDs on survival.
214483625|NCT06882616|OTHER|surgery|All patients will be perform laparoscopic sleeve gastrectomy. Carotid intima-media thickness will be analyzed preoperatively and at the end of the first postoperative year.
214919597|NCT02317276|DRUG|Triamcinolone 0.1%|Topical ointment
214318643|NCT00324779|BIOLOGICAL|rituximab|
214318644|NCT03407326|DIETARY_SUPPLEMENT|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
214483626|NCT06883916|BEHAVIORAL|Virtual reality tour|The glasses have a pre-loaded video containing nature images in their memory. The patient feels like they are walking in the natural environment shown in the video.
214483627|NCT06883916|BEHAVIORAL|Massage|A hand massage was applied by the researcher for 5 minutes for each hand. The massage, which was performed using baby oil and a paper towel, lasted 10 minutes in total for both hands.
214483628|NCT06883721|BEHAVIORAL|Pilates|Participants in this group performed Pilates exercises twice a week for 8 weeks. The exercises included mat and equipment-based exercises, focusing on core stabilization, breathing control, and postural alignment. Exercise difficulty was progressively increased throughout the intervention period.
214483629|NCT06883721|BEHAVIORAL|Cervical stabilization exercise|Participants in this group performed cervical stabilization exercises at home twice daily for 8 weeks. The exercises included chin tucks, cervical extensions, shoulder elevations, and scapular retractions.
214483630|NCT06885866|BEHAVIORAL|Emotion regulation treatment|Emotion regulation intervention in two phases. Phase A focus on establishing normalised eating patterns, and in phase B the emotion regulation interventions are added. Participants will get access to treatment modules every third day over a time period of 8.5 weeks, each module consist of psychopedagogical material, excercises and home work.
214483631|NCT06886113|DEVICE|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs
214919598|NCT02459912|PROCEDURE|Unilateral Nerve-Sparing Cryoablation of the Prostate|The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
214483632|NCT06886113|DEVICE|CorVad|Control group treated with Impella CP for a minimum of 48 hrs
214483633|NCT06879808|OTHER|Color therapy|In the experimental group, color therapy was applied 3 days a week for the first two weeks, while no intervention was performed in the third and fourth weeks. In the fifth and seventh weeks, color therapy was applied for 15 minutes each day, while no intervention was performed in the sixth week.
214483634|NCT06890104|OTHER|Mouthrinse with Coconut oil pulling|Using mouth rinse with coconut oil for two weeks to treat halitosis
214919599|NCT02459912|DEVICE|Precise Cryoablation System with IceRod Needles|Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
214919600|NCT04281758|OTHER|Beverage|16 oz (473.2 ml)
214919601|NCT04666701|DRUG|Escócia association|Escócia association tablet
214919602|NCT04666701|OTHER|Placebo Ketorolac|Placebo Ketorolac tablet
214919603|NCT04666701|OTHER|Placebo Scopolamine|Placebo Scopolamine dragee
214919604|NCT04666701|DRUG|Ketorolac Tromethamine|Ketorolac tablet
214919605|NCT04666701|DRUG|Scopolamine|Scopolamine dragee
214919606|NCT04666701|OTHER|Placebo Escócia association|Placebo Escócia association tablet
214919607|NCT02283996|OTHER|Physical Therapy|"The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.~Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:~http://www.brighamandwomens.org/Patients\_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf"
214919608|NCT02283996|DRUG|Depot Methylprednisolone|40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
214919609|NCT01587846|DIETARY_SUPPLEMENT|Administration of L.reuteri in children with abdominal pain|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
214919610|NCT01587846|DIETARY_SUPPLEMENT|Administration of placebo in children with abdominal pain|Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
214919611|NCT01587846|DIETARY_SUPPLEMENT|Administration of L.reuteri in children with constipation|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
214483635|NCT06890104|OTHER|Mouthrinse with Chlorhexidine 0.12%|Using mouthrinse with 0.12% chlorhexidine for two weeks to treat halitosis
214483636|NCT06889610|DEVICE|MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer|MTT combined with Pucotenlimab, Sacituzumab Govitecan, Eribulin, and Gemcitabine
214483637|NCT06889610|DEVICE|MTT(Multimodal Tumor Thermal Therapy System)- Melanoma|MTT combined with Pucotenlimab, with other specific drugs determined based on first-line treatment regimen and classification.
214483639|NCT06888713|OTHER|Telemonitoring of ADL|Telemonitoring of ADL is based on smart environments sensors (non wearables) and gathers information about activity of daily living routines for a better understanding of homecare services needed.
214671856|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
214919612|NCT01587846|DIETARY_SUPPLEMENT|Administration of placebo in children with constipation|Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
214919613|NCT04606394|DRUG|Trelegy Ellipta 100/62.5/25Mcg Inh 30D|Administration of Trelegy in all patients
214919614|NCT04606394|DRUG|Ventolin 90Mcg/Actuation Inhalation Aerosol|2 hours after the administration of Trelegy, administer Ventolin in all patients
214919615|NCT04067726|DRUG|Denosumab|Denosumab is commercially available and will be provided at no cost to participants.
214919616|NCT04067726|DRUG|Placebo|Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
214919617|NCT04067726|DRUG|Calcium|-Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
214919618|NCT04067726|DRUG|Vitamin D3|Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
214919619|NCT04067726|PROCEDURE|Core needle biopsy|Baseline and 12 months
214919620|NCT04067726|PROCEDURE|Blood draw|Baseline and 12 months
214919621|NCT03397368|DIAGNOSTIC_TEST|Transperineal Ultrasound -|Every women with stress incontinence witll be subjected to urodynamics to confirm genuine stress incontinence then will be subjected Transperineal US
214919622|NCT01231724|DEVICE|Allstate Nasal Spray|Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.
214318645|NCT03407326|DIETARY_SUPPLEMENT|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
214318646|NCT05705908|OTHER|Hot Foot Bath 1|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water)."
214318647|NCT05705908|OTHER|Hot Foot Bath 2|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~* 3 drops of lavender essential oil were dripped in the water"
214318648|NCT02388737|DRUG|Vonoprazan|Vonoprazan tablets
214318649|NCT02388737|DRUG|Lansoprazole|Lansoprazole capsules or tablets
214318650|NCT02388737|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
214318651|NCT02388737|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
214318652|NCT05862025|DIAGNOSTIC_TEST|Echocardiography evaluation|"Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset."
214318653|NCT05510323|DRUG|Prednisolone|RAS blockade as much as tolerated or allowed
214318654|NCT05510323|DRUG|Prednisolone plus Cyclophosphamide|RAS blockade as much as tolerated or allowed
214318655|NCT05498194|DIAGNOSTIC_TEST|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
214318656|NCT00431171|DRUG|Lithium carbonate|
214318657|NCT04734340|PROCEDURE|EIT-guided PEEP setting|Ventilator parameter setting by EIT
214318658|NCT04734340|PROCEDURE|ARDS-net PEEP setting|Ventilator parameter setting according to ARDS-net table
214318659|NCT00002510|BIOLOGICAL|filgrastim|
214318660|NCT00002510|DRUG|cyclophosphamide|
214318661|NCT00002510|DRUG|etoposide|
214318662|NCT00002510|DRUG|mesna|
214671857|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
214318663|NCT00002510|PROCEDURE|peripheral blood stem cell transplantation|
214318664|NCT00002510|RADIATION|radiation therapy|
214318665|NCT01627613|DRUG|AP301|"AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."
214318666|NCT01627613|DRUG|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
214318667|NCT04270500|BEHAVIORAL|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
214318668|NCT03018392|DEVICE|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
214318669|NCT04661345|OTHER|Proteomic analysis of synovial fluids|Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
214318670|NCT04661345|OTHER|Proteomic analysis of the isolated coagulase-negative Staphylococci|Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
214318671|NCT00422565|DEVICE|Endeavor, Medtronic|Zotarolimus-eluting stent
214318672|NCT00422565|DEVICE|Cypher, Cordis|Sirolimus-eluting stent
214318673|NCT00422565|DEVICE|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
214919623|NCT01231724|DEVICE|Placebo Nasal Spray|2 sprays in each nostril
214483640|NCT06723301|BEHAVIORAL|Chatbot-base problem-solving skills training(PSST)|The intervention incorporates eight sessions: Session 1 involves rapport building, understanding relevant personal and medical history, and introducing the Chatbot-based program and worksheet; Session 2 focuses on maintaining brightness and optimism when faced with a specific obstacle; Sessions 3-7 involve the continued application of problem-solving skills training(PSST) to identify problems and the promotion of problem-solving strategies and skills in vivo, including (a) identifying the problem, (b) determining the options, (c) evaluating and choosing the best option, (d) acting according to the best option, and (e) seeing if it works; and Session 8 involves a review of PSST principles and termination.
214483641|NCT06889961|DIETARY_SUPPLEMENT|Mixed spices|Mixed spices 4.00 g capsules of spice mixture contain 1.0 g (25%) turmeric, 1.5 g (37.5%) cinnamon, 0.5 g (12.5%) oregano, 0.5 g (12.5%) black pepper, 0.3 g (7.5%) sage and 0.2 (5%) thyme
214483642|NCT06889961|OTHER|Placebo|4.00 g maltodextrin capsules
214483643|NCT06888661|BIOLOGICAL|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
214919624|NCT06966219|OTHER|Intracytoplasmic sperm injection|• All patients will commence controlled ovarian hyperstimulation (COH) on day 2 or 3 of their menstrual cycle. The initial treatment will be a daily administration of either highly purified human menopausal gonadotropin (hMG) or recombinant FSH (rFSH, Gonal-F 150 IU, Merck Serono, S.P.A, Italy) administered subcutaneously and intramuscularly for a duration of 10-12 days. The treatment will be continued until the final oocyte maturation. The starting dosage will be tailored based on the patient's age, antral follicle count (AFC), body mass index (BMI), serum FSH and AMH levels on days 2-3, as well as the patient's previous response to COH.
214919625|NCT01797861|PROCEDURE|Half-dose photodynamic therapy (PDT)|"At exactly 15 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will take place. The area that has to be treated with the PDT laser is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (approximately 3 minutes) fluorescein angiogram. The spot size will be defined based on diameter of the hyperfluorescent area on ICG angiography plus 1mm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds."
215061415|NCT03287882|BEHAVIORAL|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
214318674|NCT06183684|DEVICE|Laplace TTVR System|Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation
214318675|NCT06284096|BEHAVIORAL|Psychoeducation|The study is planned to consist of 7 sessions, occurring once a week, with approximately 60-70 minutes allocated for each session. Considering the attention span of the participants, the sessions will be divided into two parts, with a session lasting 30-40 minutes followed by a 15-minute break.
214318676|NCT04167774|DRUG|Camrelizumab|Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
214318677|NCT04167774|DRUG|nb-Paclitaxel|nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
214318678|NCT00820742|DRUG|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
214318679|NCT00752583|PROCEDURE|Peritoneal dialysis|Blood, urine and dialysate sampling
214318680|NCT00752583|PROCEDURE|Haemodialysis|Blood, urine and dialysate sampling
214318681|NCT05742880|DIAGNOSTIC_TEST|6 Minute Walking Test|6 Minute walking test
214483644|NCT06886633|BEHAVIORAL|Breathing exercise|"Patients participating in the breathing exercise group will be trained to apply the breathing exercise at least 1 hour before starting the debridement process. 5 minutes before starting the debridement procedure, the researcher will start breathing exercises in the patient's room. The exercise duration will be approximately 15-20 minutes, and the environment will be quiet, at room temperature and well ventilated during the exercise.~The gel part of the pressurized cold therapy bandage will be removed and kept in the refrigerator for at least 2 hours to make it ready for application. The cold gel pack removed from the freezer section of the refrigerator will be placed inside the pressurized cold therapy bandage before application. Pressurized cold will be applied to the patient 10 minutes before starting the debridement procedure."
214671858|NCT04519554|DEVICE|Endometrial sampling|Endometrial sampling with 2 different forceps
214671859|NCT05071339|DRUG|Ganirelix Acetate, Cetrolix Acetate|3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
214318682|NCT05742880|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analyisis
214318683|NCT05742880|PROCEDURE|Wearing a Surgical Facemask|Wearing a Surgical Facemask
214318684|NCT05742880|PROCEDURE|Wearing a FFP2- Facemask|Wearing a FFP2- Facemask
214318685|NCT05742880|PROCEDURE|Wearing no Mask|Wearing no Mask
214318686|NCT04406064|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.
214318687|NCT03299842|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
214318688|NCT00960518|DRUG|adefovir|adefovir at 10 mg daily for 48 weeks
214318689|NCT00960518|PROCEDURE|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
214318690|NCT05960591|DEVICE|ADEPTH|ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
214919626|NCT01797861|PROCEDURE|Micropulse laser (ML) treatment|"The following ML treatment settings will be used: a power of 1800 mW\*, a duty cycle of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, spot size: 125 µm, minimal distance of spot from fovea: 500 µm.~\* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment has to be seen in the retina. In virtually all patients, a power of 1800 mW wil not produce a visible discoloration of the retina after application of a laser spot with the aforementioned settings. If retinal discoloration is seen at a power of 1800 mW the power will be reduced with steps of 300 mW until there is no visible reaction. The first laser test spot will always be applied just outside the macular area."
214919627|NCT06349993|BEHAVIORAL|Digital Intervention|game-based digital intervention app
214318691|NCT02659215|DEVICE|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
214318692|NCT02659215|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
214318693|NCT03127397|BEHAVIORAL|Praise message phone call|Praise message phone calls after each completed ART appointment, up to two calls per month.
214318694|NCT05605262|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
214318695|NCT01816139|DRUG|Vehicle|Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
214318696|NCT01816139|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
214483645|NCT06886633|DEVICE|Experimental: Pressurized Cold Application Group|The gel part of the pressure cold therapy bandage will be removed and kept in the refrigerator for at least 2 hours to make it ready for application, and the cold gel pack taken from the freezer section of the refrigerator before application will be placed inside the pressure cold therapy bandage. Pressure cold will be applied to the patient 10 minutes before starting the debridement procedure. The patient will be assessed and recorded by a nurse independent of the research on the State Anxiety Scale before and after debridement, and the Visual Comparison Scale before, during and after debridement.
214483646|NCT06889051|PROCEDURE|Flexible & Navigable Suction Ureteral Access Sheath (FANS)|The Flexible \& Navigable Suction Ureteral Access Sheath (FANS) is used during retrograde flexible ureteroscopy (FURS) for renal stones (1.5-2 cm). It allows continuous active suctioning, improving stone fragment evacuation, reducing operative time, lowering intrarenal pressure, and optimizing stone-free rates (SFR). The procedure involves inserting the Navigator 10F, 55 cm YIGAOMED FANS over a guidewire, followed by flexible ureteroscopy with PUSEN® 9.2 Fr ureteroscope and laser lithotripsy using Holmium Laser (JenaSurgical® MultiPulse HoPLUS™ 150W).
214483647|NCT06889051|PROCEDURE|Antegrade Suction via Percutaneous Nephrostomy|This technique involves antegrade suction from the kidney during flexible ureteroscopy (FURS) without the use of a ureteral access sheath. A percutaneous nephrostomy (PCN) tract is created using an 18G needle, and a 6F renal dilator is placed and fixed to the skin, allowing for direct suctioning from the collecting system. Following this, retrograde flexible ureteroscopy (FURS) is performed using the PUSEN® 9.2 Fr ureteroscope and Holmium Laser (JenaSurgical® MultiPulse HoPLUS™ 150W) for stone fragmentation. This technique aims to improve stone clearance while minimizing ureteral trauma associated with access sheaths.
214483648|NCT06731608|BEHAVIORAL|OPTIONS|OPTIONS is a multimodal intervention approach that includes providing clinical decision support (CDS) for healthcare providers, patients, and their caregivers focused on exercise, nutrition, and bone-enhancing medications using CDS in SNFs that use the same electronic health record system (PointClickCare).
214483649|NCT06731608|BEHAVIORAL|Enhanced usual care|Enhanced usual care includes access to the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) toolkit, a fall prevention program from the CDC.
214483650|NCT06731023|DRUG|Bismuth|Bismuth 0.6g bid
214483651|NCT06731023|DRUG|Vonoprazan|vonoprazan 20mg bid
214483652|NCT06731023|DRUG|Amoxicillin|Amoxicillin 1g bid
214483653|NCT06731023|DRUG|Rifabutin|Rifabutin 0.15g bid
214483654|NCT06731023|DRUG|Metronidazole|Metronidazole 400mg qid
214483655|NCT06731023|DRUG|Other antibiotics|The selection of other antibiotics is based on the results of drug susceptibility testing.
214483656|NCT06731049|OTHER|Treadmill-based Training Group|The walking speed will start at 75% of the walking speed calculated from the 10-meter Walk Test at normal walking pace, and the treadmill training will begin at this speed. Every two weeks, the speed will increase by 5%, and by the end of the 8th week, it will reach 100% of the normal walking speed. The aim of gradually increasing the walking speed is to progressively make the motor component of the exercise more challenging. Throughout the 8 weeks, a body weight support system will be used, and the support from the treadmill bar will be gradually reduced.
214483657|NCT06731049|OTHER|Dual-Task Treadmill-based Training Group|In the Dual-Task Treadmill-based Training Group, the same walking training protocol as the Treadmill Training Group will be applied with added second tasks to create a dual-task walking protocol. The second tasks will consist of both cognitive and motor tasks. The difficulty of the tasks and the total duration of the dual-task training will be increased over time.
214483658|NCT06873321|DRUG|rivaroxaban 2.5 mg bid + aspirin 100 mg|rivaroxaban 2.5 mg bid + aspirin
214483659|NCT06873321|DRUG|clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures|comparator
214483660|NCT06715488|DIAGNOSTIC_TEST|AI assisted smartphone diagnosis|Patients will examination and clinical photographs for convolutional networks to diagnose inflammatory arthritis
214483661|NCT06716203|DRUG|Drug: 5 mg BGM0504 Administered SC|Drug: BGM0504 Administered SC
214919628|NCT06349993|BEHAVIORAL|Health Education|traditional health education app
214919629|NCT04399213|PROCEDURE|50 µg Histamine|Skin prick through 50 µg/5 µL histamine diHCl
214919630|NCT04399213|PROCEDURE|15 µg Histamine|Skin prick through 15 µg/5 µL histamine diHCl
214318697|NCT01231763|OTHER|No intervention (not applicable)|No intervention (not applicable)
214318698|NCT04916184|OTHER|aerobic exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
214919631|NCT04399213|PROCEDURE|5 µg Histamine|Skin prick through 5 µg/5 µL histamine diHCl
214919632|NCT04399213|PROCEDURE|Placebo (saline)|Skin prick through 5 µL saline (0.9% NaCl)
214919633|NCT04545151|DRUG|Verapamil SR 120 mg|"For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily"
214318699|NCT04916184|OTHER|combined exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
214318700|NCT03661814|DEVICE|Prevena|The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
214318701|NCT04782908|DEVICE|Transcatheter tricuspid valve edge-to-edge repair|Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.
214318702|NCT02649881|PROCEDURE|The heart subject will undergo OCT|
214318703|NCT04667403|OTHER|Telemedicine|"In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~* If necessary within 24 hours of the connection if it is a weekly connection,~* Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention."
214318704|NCT02311465|OTHER|Palliative Care|"Components of the palliative care service intervention are expected to include:~* Establishment of a palliative care plan~* Care coordination by palliative care team~* Informational, patient friendly materials supporting Palliative Care~* Communication by palliative care team to all providers and teams involved in patient's care~* Systematic collection of information, including identification of surrogate or health care proxy and advance care planning~* Questionnaires capturing health related quality of life at regular intervals throughout the intervention period"
214318705|NCT00000735|DRUG|Ampligen|
214318706|NCT02285231|DIETARY_SUPPLEMENT|Arginyl-fructose|
214483662|NCT06716203|DRUG|Drug: : 10 mg BGM0504 Administered SC|Drug: BGM0504 Administered SC
214483663|NCT06716203|DRUG|Drug: Placebo Administered SC|Drug: Placebo Administered SC
214318707|NCT02285231|DIETARY_SUPPLEMENT|Placebo|
214318708|NCT03240575|DRUG|Tiotropium|Fixed Dose Combination
214318709|NCT03240575|DRUG|Olodaterol|Fixed Dose Combination
214318710|NCT03240575|DRUG|Fluticasone propionate|Fixed Dose Combination
214318711|NCT03240575|DRUG|Salmeterol|Fixed Dose Combination
214318712|NCT03837262|COMBINATION_PRODUCT|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
214318713|NCT04561076|DRUG|HLX70|Single-dose, intravenous infusion
214318714|NCT04561076|OTHER|Placebo|Single-dose, intravenous infusion
214318715|NCT04223076|DRUG|Chlorhexidine 0.2%, Corsodyl|Comparison of Corsodyl and Curasept
214318716|NCT04223076|DRUG|Chlorhexidine 0.2%, Curasept|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
214318717|NCT02208791|DRUG|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
214318718|NCT02208791|DRUG|No intervention|
214318719|NCT01720459|DIETARY_SUPPLEMENT|Micronized trans-resveratrol|
214318720|NCT01720459|DIETARY_SUPPLEMENT|Placebo|
214318721|NCT02595736|DRUG|Placebo (SC)|Administered SC
214318722|NCT02595736|DRUG|LY3200327 (SC)|Administered SC
214318723|NCT02595736|DRUG|LY3200327 (IV)|Administered IV
214318724|NCT02595736|DRUG|Placebo (IV)|Administered IV
214318725|NCT02431754|DRUG|Tadalafil|Administered orally
214318726|NCT02431754|DRUG|Placebo|Administered orally
214318727|NCT02431754|DRUG|Alpha1 Blocker|Administered orally
214483664|NCT06726954|DEVICE|High-frequency real-time rTMS DLPF cortex protocol|It was planned to apply the dorsolateral prefrontal cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
214318728|NCT00728377|BEHAVIORAL|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
214318729|NCT00728377|BEHAVIORAL|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
214318730|NCT06132607|DEVICE|Preoperative 3D lung reconstruction created with open-source software|Preoperative 3D lung reconstruction created with open-source software 3D Slicer
214318731|NCT00784511|DIETARY_SUPPLEMENT|cholecalciferol|4000 IU/d
214318732|NCT00784511|OTHER|microcrystalline cellulose|1/d
214318733|NCT00506090|PROCEDURE|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
214318734|NCT05785364|DEVICE|Mpact 3D metal MONOCER cup|adult patients requiring a total hip arthroplasty under 75 years old, will receive the Mpact 3D metal cup, as acetabular sheel device implanted
214483665|NCT06726954|DEVICE|High-frequency real-time rTMS M1 motor cortex protocol|It was planned to apply the M1 motor cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
214919634|NCT04545151|DRUG|Placebo|"The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily"
214919635|NCT00066794|BIOLOGICAL|filgrastim|5 mcg/kg/d IV or SC starting apx day 15
214919636|NCT00066794|BIOLOGICAL|sargramostim|250 mcg/kg/d IV or SC starting apx day 15
214318735|NCT03125512|DEVICE|Night Shift positional device|Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
214318736|NCT03125512|DEVICE|continuous positive airway pressure|Automated adjusting continuous positive airway pressure
214318737|NCT03856437|BEHAVIORAL|HPV vaccination messages|Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
214318738|NCT01290848|BEHAVIORAL|Take TIME Health Campaign|"1. Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.~2. Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.~3. Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children."
214919637|NCT00066794|DRUG|cyclosporine|ind: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-74 consol: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-50
214483666|NCT06726954|DEVICE|Sham rTMS Protocol|It was planned to apply the daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
214919638|NCT00066794|DRUG|cytarabine|ind: 200 mg/m2/d cont IV days 2-74
214919639|NCT00066794|DRUG|daunorubicin hydrochloride|ind: 45 mg/m2/d cont IV days 2-74
214919640|NCT06501378|DRUG|PD-1/PD-L1 inhibitor plus chemotherapy|Active brain metastases patients will receive PD-L1/PD-1 inhibitors and chemotherapy.
214919641|NCT06501378|RADIATION|SRT/WBRT|Active brain metastases (BM) patients will receive stereotactic radiotherapy (SRT) and whole brain radiation therapy (WBRT) according to their BM condition.
214919642|NCT00887848|OTHER|Lokomat training|15 sessions of Lokomat training within 5 weeks (3 trainings/week)
214919643|NCT04061512|DRUG|Dexamethasone, cyclophosphamide, rituximab|DRC Arm (chemotherapy) consists of dexamethasone, cyclophosphamide and rituximab treatment
214919644|NCT04061512|DRUG|Rituximab, ibrutinib|RI Arm (chemotherapy free) consists of rituximab and ibrutinib treatment
214919645|NCT05364281|OTHER|Intracuff pressure measurement|The intracuff pressures were measured and noted after each position (neck extension and placement of mouth gag), at every 5th minute while the operation and before the extubating.
214919646|NCT02516514|PROCEDURE|Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia|Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
214919647|NCT00244114|DRUG|blood draw|Single blood sample collected to perform histamine release assay.
214919648|NCT00244114|PROCEDURE|Blood draw|Single blood sample collected to perform histamine release assay.
214919649|NCT02122705|DEVICE|VPIA remifentanil|Vital signs controlled patient assisted intravenous analgesia using remifentanil
214919650|NCT02478866|DRUG|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
214318739|NCT05572619|DEVICE|1st Reading|The medical team visually checks the non-contrast CT without cELVO and diagnose the large vessel occlusion.
214318740|NCT05572619|DEVICE|2nd Reading|The medical team visually checks the non-contrast CT with assistance from the cELVO and diagnose the large vessel occlusion.
214318741|NCT02934230|BEHAVIORAL|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
214318742|NCT00554671|OTHER|Algorithm driven medication titration|Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
214318743|NCT00554671|BEHAVIORAL|Monitoring|Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
214318744|NCT00554671|BEHAVIORAL|Group support|Peer support are provided in the group setting
214318745|NCT00554671|BEHAVIORAL|Self efficacy|Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
214318746|NCT01665274|DRUG|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
214318747|NCT01665274|DRUG|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
214318748|NCT01665274|PROCEDURE|D2 resection|D2 resection
214318749|NCT00764621|PROCEDURE|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
214318750|NCT00764621|PROCEDURE|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
214318751|NCT00764621|PROCEDURE|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
214318752|NCT00721695|DRUG|OMS302|OMS302 Irrigation Solution
214318753|NCT00721695|DRUG|OMS302-PE|OMS302-PE HCI Irrigation Solution
214671860|NCT05728801|DIAGNOSTIC_TEST|Ageing|Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.
214671861|NCT03702933|DIETARY_SUPPLEMENT|D-serine|dosage
214919651|NCT03997565|PROCEDURE|TKR|No intervention provided, but investigation of the ability to modulate motor performance during specific and functional tasks in subjects undergoing TKR compared with healthy subjects.
214919652|NCT01077037|OTHER|Decision Aid|Chest pain choice decision aid
214919653|NCT03734328|PROCEDURE|connective tissue graft|"* anesthesia of the palatal mucosa~* subepithelial connective tissue graft harvesting~* suturing (5/0 silk suture)"
214318754|NCT00721695|DRUG|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
214919654|NCT03734328|PROCEDURE|connective tissue graft&PRF|"anesthesia of the palatal mucosa subepithelial connective tissue graft harvesting~-suturing (5/0 silk suture)"
214919655|NCT03734328|OTHER|connective tissue graft&PRF|"* taking blood from patient~* centrifuging blood~* obtain PRF"
214919656|NCT06665061|DEVICE|PCV|Patients were randomly assigned to receive PCV mechanical ventilation, with consistent ventilation parameters.
214318755|NCT02030171|OTHER|functionnal reeducation|Specific functionnal reeducation for chronic low back pain
214318756|NCT02061969|DRUG|linagliptin|5mg linagliptin tablets
214318757|NCT02061969|DRUG|insulin glargine|
214318758|NCT05737472|DIETARY_SUPPLEMENT|High-protein RUTF|The high-protein RUTF is isocaloric to the standard RUTF. To have a higher protein quantity and quality, the recipe has greater proportions of milk powder plus whey protein and vegetable oil. A total of 15% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS )of the high protein, RUTF is 1.18 which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 1.19
214318759|NCT05737472|DIETARY_SUPPLEMENT|Standard RUTF|The standard RUTF was manufactured according to WHO recommendations, with at least 50% of protein-sourced dairy, mainly skim milk. A total of 10% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS) of the standard RUTF is 0.76, which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 0.86.
214318760|NCT02342704|DRUG|natalizumab|Administered as specified in the treatment arm
214318761|NCT02342704|DRUG|fingolimod|Administered as specified in the treatment arm
214671862|NCT03133481|PROCEDURE|Adductor Canal Nerve Block|Adductor Canal never technique
214671863|NCT03133481|DRUG|Femoral Nerve Block|Traditional technique
214671864|NCT00577590|DRUG|Metformin|Metformin is taken alone
214671865|NCT00577590|DRUG|Rosiglitazone|Rosiglitizone is taken with Metformin
214671866|NCT00577590|DRUG|Lovaza|Lovaza is taken with Metformin
214671867|NCT03402763|BEHAVIORAL|Educational Video|The intervention is an educational video presented to patients in the ED with the intent to promote ACP among older adults.
214671868|NCT03402763|BEHAVIORAL|Primary Care Provider Email|For intervention patients, an email will be sent to primary care providers explaining that the patient has seen a video about advance care planning, providing a synopsis of the video, and giving instructions about how to document end-of-life care preferences in the electronic health record.
214919657|NCT06665061|DEVICE|VCV|Patients were randomly assigned to receive VCV mode mechanical ventilation, with consistent ventilation parameters.
214919658|NCT06665061|DEVICE|PRVC|Patients were randomly assigned to receive PRVC mode mechanical ventilation, with consistent ventilation parameters.
214919659|NCT03554148|OTHER|No intervention|This is purely an observational study. Groups SSI/No SSI are defined by the occurence of a surgical site infection.
214919660|NCT03522714|DEVICE|Fluid Immersion Simulation System|Dolphin Fluid Immersion Simulation® System Mattress will be used
214919661|NCT03522714|DEVICE|Air Fluidized Bed System|Air Fluidized Bed (Clinitron) will be used.
214919662|NCT00565877|OTHER|Ultrasound inspection|post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
214919663|NCT04564378|OTHER|This is an observational study. There is no therapeutic intervention.|This is an observational study. There is no therapeutic intervention.
214318762|NCT05886569|DEVICE|DIGIPREDICT Physiopatech|Application of the DIGIPREDICT Physiopatch investigational device
214919664|NCT04228146|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|"Immediate access to the self-help CBT-I treatment, content of which is based on the translated Chinese version of a well-established CBT-I treatment manual entitled Insomnia: A Clinician's Guide to Assessment and Treatment. CBT-I aims at changing dysfunctional cognitive beliefs and maladaptive behaviors that contribute to the maintenance of insomnia. The self-help CBT-I treatment is delivered in Chinese language in six consecutive weekly modules via a smartphone application known as proACT-S. Duration of each module is around 45 to 60 minutes."
214919665|NCT04228146|OTHER|Waitlist Control|Delay access to the self-help CBT-I treatment.
214318763|NCT00614913|RADIATION|Proton radiation therapy|A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.
214318764|NCT02347527|BEHAVIORAL|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
214318765|NCT02347527|BEHAVIORAL|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
214318766|NCT03106207|PROCEDURE|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
214318767|NCT05225896|GENETIC|Description of clinical characteristic and genetic tumors|"This is a non-interventional study involving clinical data and biological samples (DNA). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
214318768|NCT01878539|DEVICE|coagulometer|
214318769|NCT01878539|BEHAVIORAL|training programme|
214318770|NCT01632891|DRUG|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
214483667|NCT06710873|DEVICE|TYRX Absorbable Antibacterial Envelope|All enrolled patients will receive the TYRX Absorbable Antibacterial Envelope implanted simultaneously during the CIED surgery.
214483668|NCT05773833|BEHAVIORAL|"Go Healthy program"|Weekly food boxes of fresh fruits and vegetables for 16 weeks; healthy eating and traditional foods curriculum available inside the box; monthly in-person healthy eating and traditional Indigenous foods cooking workshop; Indigenous cooking demonstration video website links to accompany recipes; and a kitchen starter kit with kitchen cooking supplies
214483669|NCT06730360|PROCEDURE|MTA Pulpotomy without photobiomodulation|This intervention involves the application of Mineral Trioxide Aggregate (MTA) to the pulp chamber after the removal of the coronal pulp tissue in first permanent molars with irreversible pulpitis. The procedure is performed without the use of photobiomodulation (low-level laser therapy). The MTA is placed as a seal to preserve the vitality of the remaining radicular pulp.
214483670|NCT06730360|PROCEDURE|MTA Pulpotomy with Photobiomodulation (LLLT)|This intervention combines MTA pulpotomy with photobiomodulation (low-level laser therapy). After performing the MTA pulpotomy, low-level laser therapy is applied to the pulp stumps to reduce inflammation, promote healing, and modulate pain. The laser therapy uses specific wavelengths of light to stimulate cellular activity and enhance the regeneration of pulp tissue.
214483671|NCT06889649|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|Radiation dose of 6-10 Gy per fraction, administered in 5 fractions for peripheral lesions. For lesions near organs at risk, partial-SABR will be used. If neither SABR nor partial-SABR is feasible, moderate hypofractionated radiotherapy (MHFRT) with curative doses will be applied.
214483672|NCT06889649|DRUG|TORIPALIMAB INJECTION(JS001 )|"Toripalimab (intravenous infusion):~Dosage: 240 mg intravenously every 3 weeks. Frequency: Administered every 3 weeks for the duration of the study, until progression or unacceptable toxicity occurs or reach 2 years."
214483673|NCT06889649|DRUG|Axitinib (VEGF-TKI)|"Axitinib (oral, tablet):~Dosage: 5 mg orally twice daily. Frequency: Daily, for the duration of the study, with continuation during progression or until intolerable side effects occur."
214483674|NCT06888518|DIETARY_SUPPLEMENT|OMNi-BiOTiC® FLORA plus+|specially selected probiotic strains for the diatary treatment of Lactobacillus deficiencies in women
214483675|NCT06888518|DRUG|antibiotic|regular antibiotic treatment against bacterial vaginosis
214919666|NCT00971464|BEHAVIORAL|eccentric viewing (EV) training|Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.
214671869|NCT03461926|BEHAVIORAL|(SB-related planning + daily text messages)|Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions/coping plans specifying when, where, how, and for how long they would reduce workplace sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will focus on increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing standing and light-intensity PA time, during work hours. Participants will receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions.
214671870|NCT04132726|OTHER|Massage therapy|Massage therapy performed by a physiotherapist
214671871|NCT04132726|OTHER|non-effective treatment|non-effective treatment
214919667|NCT00971464|DEVICE|Closed circuit television (CCTV)|A CCTV is an electro-optical device mainly used for reading.
214318771|NCT01632891|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
214318772|NCT01632891|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
214919668|NCT04168502|DRUG|Gemtuzumab Ozogamicin|Patients will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
214483676|NCT06888167|OTHER|Study setting|"The subjects in the study will undergo two days of visits, in random order.~1. Following a fasting period of at least 4 hours, the study participants will undergo a PET-CT examination with Ga-exadin-4. Fasting will reduce the endogenous secretion of GLP-1 by the small intestine, which can otherwise compete with exendin-4 for binding to GLP-1R. Blood glucose will be measured before the injection of the tracer and monitored at each time point.~2. On a fasting basis, the anthropometric data of the enrolled subjects will be collected and they will undergo a short interview on their lifestyle. Subsequently, at time 0, the subjects will ingest a standard mixed meal consisting of 2 commercially available ABC Parmareggio snacks. Venous blood samples will be taken at specific time intervals (from -20 to 300 minutes) to measure glucose, C-peptide, insulin, glucagon, GLP-1 and glucose-dependent insulinotropic (GIP) curves. An additional blood sample will be taken at time -10 in order to isolate"
214483677|NCT06881069|BEHAVIORAL|Clinic Level: AAC - SDOH, AAC - Tobacco|Ask-Advise-Connect (AAC) is a health information technology (HIT) implementation strategy that consists of EHR-based point-of-care supports for the assessment of tobacco use and Social Drivers of Health (SDOH).
214483678|NCT06881069|BEHAVIORAL|Non-Bundled|All patient level strategies will address only the content of increasing reach of the Utah Tobacco Quit Services.
214483679|NCT06881069|BEHAVIORAL|Bundled|All patient level strategies will address the content of increasing reach of the Utah Tobacco Quit Services and SDOH.
214483680|NCT06881069|BEHAVIORAL|Dose 1|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 1 opportunity for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
214483681|NCT06881069|BEHAVIORAL|Dose 3|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 3 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
214318773|NCT01632891|DRUG|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
214318774|NCT01632891|DRUG|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
214318775|NCT04188262|COMBINATION_PRODUCT|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
214318776|NCT05498558|OTHER|No intervention.|No intervention.
214318777|NCT04915781|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
214318778|NCT02919670|DIETARY_SUPPLEMENT|Enterade|
214318779|NCT02919670|DIETARY_SUPPLEMENT|Placebo|
214318780|NCT02919670|OTHER|Standard Supportive Care|
214318781|NCT01457495|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix-hexa™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
214318782|NCT01457495|BIOLOGICAL|DTPa-IPV/Hib (Infanrix-IPV/Hib™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
214671872|NCT04575350|GENETIC|reinterpretation of CNV|Reinterpretation of CNV of unknown significance
214919669|NCT04481789|DRUG|MT-1186|Suspension
214919670|NCT04481789|DRUG|Rosuvastatin|Tablets
214318783|NCT01457495|BIOLOGICAL|HBV (Engerix™-B)|3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
214318784|NCT01466270|DRUG|donepezil hydrochloride|Given PO
214318785|NCT01466270|DRUG|Placebo|Given PO
214318786|NCT06026904|DEVICE|transcutaneous auricular vagus nerve stimulation|taVNS was developed as a non-invasive variant of VNS where the vagus nerve is stimulated through the skin of the auricle, which has become a promising avenue for research and, potentially, treatment of various disorders. Commonly, taVNS is applied via the ear targeting the auricular branch of the vagus nerve, where the stimulation elicits far-field potentials. In line with preclinical studies, acute taVNS enhances invigoration of effort and response inhibition capability.
214318787|NCT00004923|DRUG|docetaxel|
214318788|NCT00004923|DRUG|irinotecan hydrochloride|
214318789|NCT00917332|BEHAVIORAL|"relaxation (breathing and muscles) and guided imagery (safe place)"|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
214318790|NCT01556672|DRUG|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
214318791|NCT01556672|DEVICE|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
214318792|NCT01459172|OTHER|limonene containing massage oil|daily massage application to the breast for 4 weeks
214318793|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D|Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol
214318794|NCT04070833|DRUG|Fish oil|Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
214318795|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
214318796|NCT04070833|DRUG|Fish oil placebo|Fish oil placebo
214919671|NCT04481789|DRUG|Sildenafil|Tablets
214919672|NCT04481789|DRUG|Furosemide|Tablets
214919673|NCT04411277|DEVICE|Application of the FreeStyle Libre Flash Glucose CGM.|Assessment of glycemic control and hypoglycemia, adherence to therapy and CGM use.
214318797|NCT00962130|DEVICE|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
214318798|NCT00846118|DRUG|Pitavastatin|1-4mg/day
214318799|NCT02118428|DEVICE|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
214318800|NCT02118428|BIOLOGICAL|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
214318801|NCT06196567|DEVICE|PEMF|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions
214483682|NCT06881069|BEHAVIORAL|Dose 6|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 6 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
214483683|NCT06881069|BEHAVIORAL|Dose 9|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 9 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
214483684|NCT06881069|BEHAVIORAL|Dose 12|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 12 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
214483685|NCT06881069|BEHAVIORAL|RPN|Reactive Patient Navigation Only (RPN): Patient can request to speak to a CHW, over 12 months following a patient's initial clinic visit, at any time.
214483686|NCT06881069|BEHAVIORAL|PPN|Proactive Patient Navigation (PPN): Patient is proactively called, over 12 months following a patient's initial clinic visit, by a CHW up to 4 times.
214483687|NCT06882941|DIETARY_SUPPLEMENT|Fermented Black Soybean and Adlay Supplement|The preparation of the fermented black soybean and adlay supplement involves autoclaved black soybean and dehulled adlay, which are inoculated with Bacillus subtilis natto (1.3 × 10⁶ CFU/g) and incubated for 43 hours at 28°C. Participants assigned to the experimental group will take the Fermented Black Soybean and Adlay Supplement daily for 12 weeks.
214483688|NCT06882941|DIETARY_SUPPLEMENT|non-fermented black soybean and adlay supplement|The placebo product was prepared using uninoculated autoclaved black soybean and dehulled adlay. The samples were provided as frozen food and required microwaving for 30 seconds before serving. Participants assigned to the placebo group will take the non-fermented black soybean and adlay supplement daily for 12 weeks.
214483689|NCT06882369|PROCEDURE|TAP Block|The transabdominal plane (TAP) block is a regional anesthesia technique used for postoperative pain management in abdominal wall procedures, providing somatic analgesia to the anterior and lateral abdominal walls
214919674|NCT04411277|DIAGNOSTIC_TEST|InBody 270 multifrequency bioimpedance|analysis of body composition to calculate appendicular skeletal muscle.
214919675|NCT01871493|DRUG|LY2605541|Administered subcutaneous (SQ)
214318802|NCT06196567|OTHER|exercise|do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
214318803|NCT04019691|DEVICE|Mix-and-Match|Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
214318804|NCT04019691|DEVICE|EDOF|Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
214318805|NCT04019691|DEVICE|Trifocal|Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
214318806|NCT02191189|DRUG|Nevirapine suspension, into Enterion™ capsule|
214483690|NCT06882369|DRUG|Intrathecal morphine injection|Intrathecal injection of morphine plus 20 mg hyperbaric bupivacaine in spinal anesthesia
214483691|NCT06882369|DRUG|spinal anesthesia|intrathecal injection of bupivacaine
214483692|NCT06883708|BEHAVIORAL|iSupport-Malaysia Web-Based Intervention|"iSupport-Malaysia web-based intervention is a website version of the culturally adapted iSupport for Dementia into the Malaysia context (in local Malay language).~The 23 lessons is arranged under the 5 modules in the same way as the original iSupport manual. Each lesson is delivered in bite-sized knowledge, using engaging videos, interactive quizzes with feedback, and reflection exercises. Each lesson takes an average of 10-20 minutes to complete. At the end of each lesson, a completion batch is given. The lesson plan can be personalised by the caregivers themselves according to individual needs. Caregivers will also have the option to receive a course completion certificate if they completed all 23 lessons in the program. Additionally, in each lesson, participants are encouraged to post comments in response to the prompt questions, and also reply to others' comments."
214919676|NCT01871493|DRUG|Insulin Lispro|Administered SQ
214919677|NCT02051140|DIETARY_SUPPLEMENT|Freeze-dried Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
214919678|NCT02051140|DIETARY_SUPPLEMENT|Strawberry Placebo|12g blue, strawberry-flavored powder, twice daily with water, for 90 days
214919679|NCT03761030|DRUG|L-DOPA|We will be using generic sinemet 25/100 tablets in this study.
214919680|NCT03761030|DRUG|Placebo Oral Tablet|25/100 placebo tablets
214919681|NCT00811330|DRUG|Atorvastatin 80 mg|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
214318807|NCT02191189|DRUG|Nevirapine suspension|
214318808|NCT03057691|OTHER|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
214318809|NCT02580370|BIOLOGICAL|Botulinum toxin type A|Topical botulinum toxin type A
214318810|NCT02580370|BIOLOGICAL|Placebo comparator|Topical placebo comparator
214318811|NCT01776983|DEVICE|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
214671873|NCT01333618|DEVICE|curving introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
214919682|NCT05896566|DRUG|Giredestrant|Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
214483693|NCT06883708|BEHAVIORAL|iSupport-Malaysia eBook|"iSupport-Malaysia eBook is the Malay-translated, culturally adapted version of the iSupport for Dementia manual in PDF format. This eBook is approximately 275 pages long, containing comprehensive text-based details for the 5 modules and 23 lessons. The modules and lessons are similar to the iSupport-Malaysia web-based program. The main lesson content is delivered in text-based format. Each lesson includes at least one case 1 scenario(s) presented in a quiz format. Some lessons offer additional worksheets for caregivers to reflect on their own caregiving experiences and apply the strategies learned to their caregiving journey. A completion batch is given at the end of each lesson. The lesson plan can be personalised by the caregivers themselves according to individual needs."
214919683|NCT05896566|DRUG|Triptorelin|Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
214483694|NCT06884683|DRUG|Metformin|"Drug: metformin tablet 500 mg, 1 tablet twice a day (total dose 1000 mg daily), administered orally continuously~\+~Biological: Nivolumab 240 mg via IV infusion every 14 days~Other Names:~Opdivo®"
214318812|NCT06317493|OTHER|Stimuli|"Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras."
214483695|NCT06716151|DRUG|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
214483696|NCT06716151|DRUG|HB0034 matching placebo|HB0034 matching Palcebo
214483697|NCT06889376|DRUG|Intranasal midazolam administration via the DART™ intranasal atomization device along with routine comfort care.|"Intervention: Intranasal midazolam (0.2 mg/kg) administered 10 minutes before ROP screening via the DART™ intranasal atomization device.~Comfort Measures:~* 1 ml of 20% glucose solution orally with a pacifier, 5 min before screening.~* Swaddling and placement under the radiant warmer.~Monitoring:~* Vital Signs (heart rate, respiratory rate, blood pressure, oxygen saturation monitoring before drug administration until 2 hours after).~* Pain assessment (PIPP scale) conducted before, during, and 10 and 30 min post-procedure.~* Modified N-PASS to assess the level of sedation conducted before, during, 10, 30 minutes 1 hour and 2 hours post-procedure~Observations for signs of:~* Respiratory Distress (apnoea, desaturation, increased work of breathing)~* Cardiovascular Instability (Bradycardia, tachycardia, hypotension)~* Neurological Symptoms (Lethargy, seizures, abnormal tone)~* Gastrointestinal Issues (Feeding intolerance, NEC-like symptoms)"
214671874|NCT01333618|DEVICE|straight introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
214671875|NCT03045380|OTHER|Game based physical activity training|Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with motion sensor (Microsoft) and a 50'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades of the games and types of the games will be changed. A game based physical activity training session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
214919684|NCT05896566|DRUG|Anastrozole|Anastrozole: 1 mg daily, PO from day 1 until the day of re-biopsy/surgery.
214919685|NCT06968299|DIETARY_SUPPLEMENT|ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules|Product ingredients: microcrystalline cellulose, corn starch, SWP-CGPA01 Pediococcus acidilactici powder (1.0 x 10\^10 CFU); Capsule shell composition: HPMC (hydroxypropyl methylcellulose), pure water, titanium dioxide, gelatin.
214919686|NCT06968949|BEHAVIORAL|Unadapted Brief Intervention for School Clinicians (BRISC; BR-O)|BRISC is a four-session, individual engagement, assessment, brief intervention and triage strategy for youth age 13-18. BRISC provides a research-based approach to improving structure, efficiency, and effectiveness of school mental health via five elements: (1) Stepped care/tiered structure; (2) Culturally-informed engagement and motivation strategies;(3) Systematic problem-solving framework; (4) Modularized common elements approach; and (5) Structured assessment and monitoring.BRISC is hypothesized to operate on specific mechanisms that influence improvements in efficiency and clinical outcomes.
215061416|NCT02492308|PROCEDURE|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
214318813|NCT04171414|BIOLOGICAL|CT-P17 SC AI (adalimumab)|Subcutaneous Injection of Adalimumab 40mg once every two weeks
214671876|NCT03045380|OTHER|Conventional physiotherapy|A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented. A conventional physiotherapy session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
214671877|NCT06046508|OTHER|blood samples collection|patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention
215061417|NCT02492308|DRUG|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
215061418|NCT03116906|DRUG|BI 685509|to be given for a total of up to 15 days
215061419|NCT03116906|DRUG|Placebo|to be given for a total of up to 15 days
215061420|NCT04277546|DRUG|Brazikumab Maintenance Dose|Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
214318814|NCT05697900|DIETARY_SUPPLEMENT|Creatine Monohydrate|The CrM group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The CrM supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
214318815|NCT05697900|DIETARY_SUPPLEMENT|Placebo|A placebo group intakes five grams of maltodextrin daily throughout the study. The placebo supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
214318816|NCT05697900|DIETARY_SUPPLEMENT|Creatine Hydrochloride|The Cr-HCl group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The Cr-HCl supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
214318817|NCT04900896|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
214318818|NCT05905588|DIETARY_SUPPLEMENT|Hydrogen-rich water|Patients drink 600mL hydrogen-rich water per day by applying hydrogen-rich water cup (Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks. The dissolved hydrogen concentration is 5 ppm.
214318819|NCT05905588|DIETARY_SUPPLEMENT|placebo|Patients drink 600mL tap water per day by applying analogue cup for 12 weeks. This cup has the same appearance as the hydrogen-rich water cup, and the hydrogen-rich water and placebo water were indistinguishable. The dissolved hydrogen concentration is 0 ppm in placebo water.
214318820|NCT02299050|DRUG|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
214318821|NCT00675857|DRUG|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
214318822|NCT00675857|OTHER|placebo|Dosage: 4 capsules BID for 26 weeks
214318823|NCT06262360|PROCEDURE|General anesthesia with mask ventilation|Randomization to General anesthesia with mask ventilation
214318824|NCT06262360|PROCEDURE|General anesthesia and spontaneous laryngeal mask ventilation|Randomization to General anesthesia and spontaneous laryngeal mask ventilation
214483698|NCT06889987|DRUG|Intramuscular quadratus lumborum block|Patients will receive bilateral ultrasound-guided intramuscular quadratus lumborum block with an injection of 0.4 ml/kg bupivacaine 0.25% after induction of general anesthesia
214483699|NCT06889987|DRUG|Lateral quadratus lumborum block|Patients will receive bilateral ultrasound-guided lateral quadratus lumborum with an injection of 0.4 ml/kg of bupivacaine 0.25 after induction of general anesthesia.
214483700|NCT06889987|DRUG|General anesthesia|Patients will receive only general anesthesia without any block.
214919687|NCT06968949|BEHAVIORAL|Brief Intervention for School Clinicians (BRISC) with Implementation Strategies Adapted for School-Employed Practitioners (BR-A)|BR-A is a version of the Brief Intervention for School Clinicians with implementation strategies (IS) adapted for delivery by in the education sector by school-employed practitioners. Although IS modifications will be determined by Study 1 activities, we anticipate that BR-A may include changes to training pacing or format (e.g., asynchronous e-learning modules and videos); adaptations to format/content of consultation; and/ or addition of other ISs to enhance skills development (e.g., development of a learning collaborative) and/or overcome organizational or system barriers (e.g., educational outreach, changes to regulations). Core components of BRISC will be retained in the BR-A condition.
214919688|NCT06327503|OTHER|saliva samples collecting|non-invasive collection of unstimulated whole saliva by spitting method into sterile plastic container
214483701|NCT06725433|PROCEDURE|Nissen fundoplication|Hiatal hernia repair and Nissen fundoplication
214483702|NCT06725433|PROCEDURE|Dor fundoplication|Hiatal hernia repair and Dor fundoplication
214671878|NCT02330029|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
214318825|NCT06262360|PROCEDURE|General anesthesia with spontaneous laryngeal mask ventilation with pressure support|Randomization to General anesthesia with spontaneous laryngeal mask ventilation with pressure support
214318826|NCT02619409|DRUG|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
214318827|NCT02619409|DRUG|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
214318828|NCT02619409|DRUG|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
214318829|NCT02619409|DRUG|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
214318830|NCT02619409|DRUG|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
214318831|NCT02884089|DRUG|Abemaciclib|Administered orally
214483703|NCT06732258|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5 fractions over five days, starting from Day 1 in the first cycle.
214483704|NCT06732258|DRUG|Tifcemalimab injection|100 mg or 200 mg q3w until disease progression or intolerable toxicity;
214483705|NCT06732258|DRUG|Toripalimab|240 mg q3w until disease progression or intolerable toxicity;
214483706|NCT06732258|DRUG|Cisplatin|75 mg/m2 q3w for 4-6 cycles;
214483707|NCT06732258|DRUG|Carboplatin|AUC = 5, q3w for 4-6 cycles;
214318832|NCT02884089|DRUG|Metformin|Administered orally
214318833|NCT02884089|DRUG|Iohexol|Administered intravenously (IV)
214318834|NCT02884089|DRUG|Placebo|Administered orally
214318835|NCT01631474|DRUG|CB-03-01|Topical cream, applied once a day
214318836|NCT01631474|DRUG|Vehicle|Topical cream, applied once or twice a day
214318837|NCT01631474|DRUG|CB-03-01|Topical cream, applied twice a day
214318838|NCT00789282|OTHER|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
214318839|NCT00789282|OTHER|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
214318840|NCT00789282|OTHER|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
214318841|NCT00004881|BIOLOGICAL|MVA-MUC1-IL2 vaccine|
214318842|NCT03465293|OTHER|Bacterial composition and activity after bowel preparation|Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
214318843|NCT03217929|DEVICE|Active-taVNS|Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
214318844|NCT03217929|DEVICE|Sham-taVNS|Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
214318845|NCT04571112|DEVICE|NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)|This will either be turned on or off depending on the arm which the patient is randomized to. After 8-weeks, the subject will switch arms for another 8-weeks.
214483708|NCT06732258|DRUG|Etoposide|100 mg/m2, d1, d2, d3, q3w for 4-6 cycles;
214318846|NCT01196767|DRUG|Ropivacaine (in one arm); catheterization (in both).|"Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine."
214318847|NCT02624284|DEVICE|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
214318848|NCT00392613|PROCEDURE|Strict versus lenient rate control|
214318849|NCT02487394|PROCEDURE|Exhaled Breath Condensate (EBC)|Collection of EBC condensate
214483709|NCT06404827|OTHER|Horseback riding simulator|Horseback riding simulator (HRS) will be applied in addition to routine Physiotherapy and Rehabilitation.
214483710|NCT06404827|OTHER|Routine Physiotherapy and Rehabilitation|Routine Physiotherapy and Rehabilitation within a spesific programme
214483711|NCT06885437|OTHER|Pain and sedation assessment with the N-PASS scale by each nurse|After a painful procedure, the infant's N-PASS pain and sedation scores were assessed simultaneously by three observers (two researchers and the patients' head nurses) independently and blinded.
214318850|NCT02575781|DRUG|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
214318851|NCT03722329|DRUG|Eculizumab|Eculizumab Injection. 300 mg, single dose
214483712|NCT06739772|BEHAVIORAL|HPV Self-Sampling and Behavior Intervention|Participants in the intervention group will receive HPV self sampling and behavioral intervention
214483713|NCT06739772|BEHAVIORAL|Participants in the intervention group will receive HPV self sampling and behavioral intervention|Received enhance standard care
214483714|NCT06883487|OTHER|No intervention|Observational study without intervention
214483715|NCT06886984|BEHAVIORAL|Social media motivation|Reminding the oral hygiene instructions using social media tools to keep their oral hygiene stable
214671879|NCT02330029|DEVICE|Atractylodes|Atractylodes (\~10-15g)
214671880|NCT02330029|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
214671881|NCT02330029|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
214671882|NCT02330029|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
214483716|NCT06887075|BIOLOGICAL|Blood sample|"* Immunophenotyping of peripheral lymphocytes, with a focus on proportions of naïve / central memory / effector memory / TEMRA cells, and markers of activation and senescence~* Serum inflammatory markers : CRP, IL-6, MCP-1, TNF, sTNFR1~* Single Molecule Array for IL1 and LUMINEX for IL18 in patient's sera~* RT-qPCR for inflammasomes genes (NLRP3, NLRC4, NLRC5, AIM2, ASC, casp1, IL1b, IL18) expression among peripheral blood mononuclear cells~* Assembly of the inflammasome platform will be measured in monocytes using intra-cellular staining of the ASC protein and flow cytometry"
214483717|NCT06887075|BEHAVIORAL|Geriatric assessment standardized|"* Exhaustion (2 standardized questions)~* Physical activity \<383 kcal/week (men) or \<270 kcal/week (women), measured using a standardized questionnaire (IPAQ)~* 4-meters gait speed, with sex and height-specific cutoffs~* Handgrip strength, measured using a dynamometer, with sex and BMI-sp Comorbidity (CIRS-G score )~* Screening for intrinsic capacity decline (first step of ICOPE program, adapted to the study, )~* Physical performance (SPPB score )~* Cognitive functions (MoCA score ),~* Depression (GDS-15 score ),~* Nutrition (MNA score )~* Sensory functions (Snellen test for vision, HHIES questionnaire for hearing) -- Dependency in activities of daily living (ADL and IADL scores)"
214483718|NCT06884228|DEVICE|Vibrating mesh nebulisation|Vibrating mesh nebulisation (VMN) uses a mesh membrane that oscillates at high frequency (typically 128kHz) to produce a stream of drug-carrying droplets of pre-determined size to be inhaled
214483719|NCT06884228|DEVICE|Jet nebuliser|Jet nebulisers use the flow of a gas (air or oxygen) to draw medication up through a capillary tube to generate small particles to be inhaled.
214483720|NCT06884085|DRUG|Co-administration of AD-227A and AD-227B|Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral
214483721|NCT06884085|DRUG|Administration of AD-227|Administration of AD-227 1Tab., Per Oral
214483722|NCT06885164|OTHER|Continuous monitroing|Continuous monitoring for 30 days with a small combined SCG and 1-lead ECG sensor
214483723|NCT06886789|BEHAVIORAL|Text Messaging|On 3 days/week they receive a text about 1 of the 3 behaviors (weight maintenance or loss, physical activity, and medication adherence) in randomized order with guidance for maintaining or improving these behaviors to reach program-provided goals. The system compares their last week's adherence to the responder criteria. They receive feedback praising adherence and instructions for a theory-driven behavioral strategy (e.g., stimulus control) to increase adherence. Feedback is tailored to the patient's adherence or existence of self-monitoring data.
214483724|NCT06886789|BEHAVIORAL|Fully Automated Online Program|Patients receiving the fully automated online program will select a weight loss or a weight maintenance curriculum based on their goals. Patients will receive 8 weeks of fully automated lessons covering the 3 key behaviors: weight (management or loss), physical activity, and medication adherence. All 3 behaviors are discussed weekly, but the lessons first prioritize PA, then weight management, and then medication adherence to mimic the emphasis in Phase II. Total weekly lesson time is 20-30 minutes. Patients retain access to lessons. They self-monitor calories, weight, moderate-to-vigorous physical activity, and medication adherence. Tracking data are seamlessly integrated into the system. They manually enter their medication adherence data and receive encouraging feedback on each of the behaviors the next week.
214483725|NCT06886789|BEHAVIORAL|Low-Intensity Cardiac Rehabilitation Maintenance Program|Patients are instructed to log in 3 times weekly to view lessons, sync their Fitbit data, and complete a home-based workout video. They track weight, PA, and medication adherence daily. Patients have access to an extensive CR resource library made and curated by the platform provider plus resources on maintaining heart healthy behaviors during Phase III created by the research team. They are reminded to log in if they log in less than twice weekly.
214483726|NCT06886789|BEHAVIORAL|High Intensity Cardiac Rehabilitation Maintenance Program|Patients are instructed to log in 3 times weekly to view lessons, sync their Fitbit data, and complete a home-based workout video. They track weight, PA, and medication adherence daily and attend a once weekly virtual meeting with a CR case manager. Meetings are modeled after Phase II and focus on tailored exercise prescription, addressing cognitive, behavioral, and environmental adherence barriers, and support. Patients have access to an extensive CR resource library made and curated by the platform provider plus resources on maintaining heart healthy behaviors during Phase III created by the research team. They are reminded to log in if they log in less than twice weekly.
214483727|NCT06736873|OTHER|Light intervention|Light intervention
214483728|NCT06886360|DRUG|norucholic acid|500 mg norucholic acid film-coated tablets; 3 tablets/day
214671883|NCT02330029|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
214671884|NCT02330029|DRUG|Radix curcumae|Radix curcumae (\~10g)
214671885|NCT02330029|DRUG|Fingered citron|Fingered citron (\~10g)
214671886|NCT02330029|DRUG|Tuckahoe|Tuckahoe (15g)
214671887|NCT02330029|DRUG|Placebo|Placebo is blindly given to patients.
214919689|NCT00049465|PROCEDURE|fatigue assessment and management|
214919690|NCT00049465|PROCEDURE|management of therapy complications|
214919691|NCT00049465|PROCEDURE|psychosocial assessment and care|
214919692|NCT05896501|DEVICE|Fractional Flow Reserve|Functional assessement of anatomical stenosis of coronary artery
214919693|NCT01937910|BEHAVIORAL|TRAIT Task|Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
214919694|NCT06574594|DRUG|Methotrexate|methotrexate discontinuation group : stop MTX for 2 weeks after each shingrix vaccination
214919695|NCT06574594|DRUG|Methotrexate|methotrexate continuation group : keep methotrexate
214919696|NCT00435682|DRUG|Botox (Allergan Inc., US)|
214919697|NCT03271281|DRUG|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
214919698|NCT03271281|DEVICE|PET/CT|Following injection of 68Ga-NODAGA-E\[c(RGDyK)\]2 the patients will be subjected to whole body PET/CT
214919699|NCT02602990|DEVICE|SQUID™|
214919700|NCT02713932|DEVICE|Transcatheter aortic valve implantation|
214919701|NCT03139578|DEVICE|Test 8.5BC|senofilcon A contact lenses with 8.5 base curve
214318852|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
214318853|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
214318854|NCT01010282|DRUG|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
214318855|NCT01010282|DRUG|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
214318856|NCT01010282|DRUG|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
214483729|NCT06584292|PROCEDURE|caudal block|Caudal Block (CB) Procedure: The sacral hiatus was identified using an out-of-plane transverse ultrasound view at the level of the sacral cornua. The probe was then rotated longitudinally to visualize the sacrococcygeal ligament and sacral bone. A block needle was inserted through the sacrococcygeal membrane into the sacral canal using the in-plane technique, and 0.125% bupivacaine was administered at a dose of 1 mL/kg, with a maximum limit of 20 mL per side.
214483730|NCT06584292|PROCEDURE|Retrolaminar block|Retrolaminar Block (RL) Procedure: The RL block was performed with the patient in a lateral decubitus position. The ultrasound probe was positioned at the L4 vertebral level in a paramedian sagittal plane. The probe was moved medially until the vertebral laminae were visualized. The needle was inserted using the in-plane technique, advancing from the cephalad to caudal direction until it contacted the L4 lamina. A dose of 0.1 mL/kg of 0.25% bupivacaine was then injected into the retrolaminar space.
214483731|NCT06739330|DEVICE|Fibroscan|Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.
214483732|NCT06737692|OTHER|Exercise|"Supervised Aerobic Exercises: Conducted every two weeks, three days a week (on days 11-13 post-systemic treatment). The supervised aerobic exercises will consist of 20 minutes on a treadmill at a heart rate corresponding to 55-75% of the Karvonen formula. Warm-up and cool-down will be performed at 30-40% of the Karvonen heart rate for 5 minutes.~Supervised Resistance Exercises: Conducted every two weeks on consecutive days (days 11 and 13 post-systemic treatment).~Resistance training will involve 12 different exercises targeting major muscle groups, using body weight and resistance bands, at an effort level of 5-7 on the Borg scale, with 8-12 repetitions and 1-3 sets. The intensity will be progressively adjusted based on the individual's perceived exertion.~On weeks without supervised exercises, participants will follow a home exercise program that includes breathing exercises, walking for 20-30 minutes, and resistance exercises."
214483733|NCT06737055|BEHAVIORAL|Education about behavioral strategies to improve sleep|In collaboration with direct care workers, the investigators are developing an intervention to help home visitors support clients who experience sleep difficulties in the perinatal period. The intervention consists of a series of educational videos about promoting healthy sleep and addressing sleep difficulties during pregnancy and the postpartum period.
214483734|NCT06889402|PROCEDURE|Neoadjuvant therapy with PD-L1 inhibitor|During neoadjuvant treatment, patients may receive neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, or neoadjuvant chemotherapy combined with immunotherapy during the perioperative period.
214483735|NCT06881758|BEHAVIORAL|Exercise|The investigators will investigate the differences between high and low intensity training
214483736|NCT06739252|COMBINATION_PRODUCT|Gemcitabine Oxaliplatin and 5FU|The perioperative treatment plan includes neoadjuvant therapy and adjuvant therapy. Neoadjuvant therapy consists of three cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), while adjuvant therapy includes two cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), along with additional capecitabine or tegafur as auxiliary maintenance treatment for three cycles. The total treatment duration for the perioperative period is six months. HAIC regimen: gemcitabine (1,000 mg/m2, 2h, d1) + oxaliplatin (35 mg/m2, 2h, d1-2) + 5-FU (0.75g/m2, 22h, d1-2); atezolizumab (PD-L1 inhibitor): 1200 mg, intravenous infusion, administered within 24 hours before HAIC treatment; bevacizumab: 7.5 mg/kg, intravenously infused before HAIC treatment (bevacizumab use is paused during the third neoadjuvant treatment). Each cycle lasts for three weeks.
214483737|NCT06779461|DEVICE|Magnesium Microspheres|Biodegradable Magnesium Embolic Microspheres
214318857|NCT01641367|DRUG|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])
214483738|NCT06779461|PROCEDURE|cTACE|cTACE
214483739|NCT01527188|DRUG|100 IR house dust mites allergen extract tablet|One sublingual tablet daily during 6 months
214318858|NCT01641367|DRUG|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
214318859|NCT01641367|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
214483740|NCT01527188|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily during 6 months
214483741|NCT01527188|DRUG|500 IR house dust mites allergen extract tablet|One sublingual tablet daily during 6 months
214483742|NCT01527188|DRUG|Placebo tablet|One sublingual tablet daily during 6 months
214318860|NCT01641367|DRUG|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
214318861|NCT01641367|DRUG|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
214318862|NCT01641367|DRUG|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
214483743|NCT06735274|DIAGNOSTIC_TEST|Cerebral Autoregulation (CAR)|Cerebral Autoregulation (CAR) is the mechanism capable of maintaining cerebral blood flow constant despite fluctuations in blood pressure. The evaluation of dynamic CAR (dCAR) with spontaneous blood pressure variations allows it to be applied in acute and non-collaborating patients
214318863|NCT01641367|OTHER|SOC adherence versus SOC+CPI adherence|"* not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence."
214318864|NCT04634292|BEHAVIORAL|EEG|EEG + walking task + auditory task
214318865|NCT05851352|DIAGNOSTIC_TEST|serum anti-endometrial antibodies|\- Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .This assay employs the qualitative enzyme immunoassay technique
214318866|NCT04462042|RADIATION|Proton radiotherapy|Proton radiotherapy
214318867|NCT04462042|RADIATION|Photon radiotherapy|Conventional photon radiotherapy
214318868|NCT01894828|DIETARY_SUPPLEMENT|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
214483744|NCT06735274|DIAGNOSTIC_TEST|Neurovascular coupling (NVC)|Neurovascular coupling (NVC) is the relationship between neural activity and cerebral blood flow, allowing this activity to be evaluated in spatiotemporal terms .
214483745|NCT06735274|DIAGNOSTIC_TEST|Microembolic signals (MES)|Microembolic signals (MES)
214483746|NCT06735274|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|Montreal Cognitive Assessment (MoCA)
214483747|NCT06735274|DIAGNOSTIC_TEST|Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)|Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
214483748|NCT06735274|DIAGNOSTIC_TEST|Instrumental Activities of Daily Living Scale (IADL)|Instrumental Activities of Daily Living Scale (IADL)
214483749|NCT06735274|DIAGNOSTIC_TEST|Modified Rankin Scale for Neurologic Disability (mRS)|Modified Rankin Scale for Neurologic Disability (mRS)
214483750|NCT04549792|DRUG|Ustekinumab|Each subject will receive ustekinumab at Baseline (Day 0) and Months 1, 3, 5, 7, 9, and 11. During the LTE, subjects will receive injections every 8 weeks for one year: Month 13, Month 15, Month 17, Month 19, Month 21, and Month 23. Subjects will come back in for a follow-up visit at Month 25 for an end of study visit (no drug administration).
214483751|NCT06742437|DEVICE|Standard sperm preparation|Sperm samples in the control group will undergo traditional processing
214483752|NCT06742437|DEVICE|HyperSperm|Sperm samples in the experimental group will undergo product-specific processing
214483753|NCT06892158|OTHER|Massage therapy|Participants in IA will receive a 20-30-minute massage five days per week for 21 days.
214919702|NCT03139578|DEVICE|Test 9.0BC|senofilcon A contact lenses with 9.0 base curve
214919703|NCT03139578|DEVICE|Control 8.5BC|narafilcon A contact lenses with 8.5 base curve
214919704|NCT03139578|DEVICE|Control 9.0BC|narafilcon A contact lenses with 9.0 base curve
214919705|NCT00461773|DRUG|Letrozole|Letrozole 2.5 mg po qd
214483754|NCT06892158|OTHER|Standard of care|Institutional standard of care treatment
214483755|NCT06890806|OTHER|Foot Core Stabilization Exercise Group (FCSEG)|"Exercise Group (Foot Core Stabilization Exercises)~Exercise Group will perform foot core stabilization exercises under the supervision of a physiotherapist, three times a week for five weeks. The exercises will include:~Short foot exercise Towel curl exercise Big toe press exercise Toe splay exercise Calf raise to big toe press exercise Leg swings Backward tandem walking Each exercise will be performed in three sets of 15 repetitions."
214919706|NCT00461773|DRUG|Bevacizumab|bevacizumab 10 mg/kg IV
214919707|NCT02312089|DRUG|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
214919708|NCT04504214|OTHER|Upper limb repeated multi-site tendon vibrations|Upper limb tendon vibration protocol will be added to the usual rehabilitation protocol performed during hospitalization
214919709|NCT04216836|DIETARY_SUPPLEMENT|Magnesium oxide|Magnesium capsule
214919710|NCT04216836|DIETARY_SUPPLEMENT|Placebo|Cornflour capsule manufactured to mimic the 166.6 mg magnesium capsule.
214919711|NCT02552069|DEVICE|Tritanium® cup|
214318869|NCT02421458|RADIATION|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
214318870|NCT02421458|RADIATION|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
214318871|NCT03237728|DRUG|0.06mg/kg,KB|0.06mg/kg,Q8h,Day1-Day7
214318872|NCT03237728|DRUG|0.12mg/kg,KB|0.12mg/kg,Q8h,Day1-Day7
214318873|NCT03237728|DRUG|0.24mg/,KB|0.24mg/kg,Q8h,Day1-Day7
214318874|NCT03237728|DRUG|Placebos|Placebos,Q8h,Day1-Day7
214318875|NCT02586493|DRUG|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
214318876|NCT02586493|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
214318877|NCT01188408|DRUG|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
214318878|NCT02033733|DRUG|Cisatracurium infusion|"This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group)."
214919712|NCT04657198|BIOLOGICAL|RSVPreF3 OA investigational vaccine (GSK3844766A)|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).
214318879|NCT02033733|DRUG|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
214318880|NCT01471548|DRUG|TKI258|
214318881|NCT01117727|DEVICE|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
214318882|NCT02244333|DRUG|ALNA®|
214318883|NCT02711800|DRUG|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
214318884|NCT04736459|PROCEDURE|Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination|The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure
214318885|NCT06641856|OTHER|Sample Collection|All participants will provide nasal and pharyngeal swabs for virome analysis. A subset of 30 elderly volunteers will also provide peripheral blood samples and undergo bronchoscopy under general anesthesia to collect upper and lower respiratory tract samples.
214318886|NCT03900533|BEHAVIORAL|Adjunctive group emotion regulation skills training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual
214318887|NCT03900533|BEHAVIORAL|Treatment as usual|Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
214318888|NCT03266328|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
214318889|NCT01250470|OTHER|Laboratory Biomarker Analysis|Correlative studies
214318890|NCT01250470|DRUG|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
214318891|NCT01250470|BIOLOGICAL|Sargramostim|Given SC
214318892|NCT00191503|DRUG|Pemetrexed|
214318893|NCT00191503|DRUG|Gemcitabine|
214318894|NCT02252627|DRUG|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
214919713|NCT03793842|OTHER|Usual care|Intervention is the standard basic lung protective ventilation strategy used at the University Hospital Respiratory Care at Michigan Medicine.
214318895|NCT02252627|OTHER|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
214318896|NCT02252627|OTHER|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
214318897|NCT02252627|DRUG|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
214318898|NCT01869192|DRUG|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
214318899|NCT01869192|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
214318900|NCT01869192|DRUG|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
214318901|NCT01869192|DRUG|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
214318902|NCT01869192|RADIATION|Radiation Therapy|Standard dosing, fields depending on clinical findings
214318903|NCT04582851|OTHER|some risk factors correlated with TMD|exposure factors causing TMD
214318904|NCT05180136|DIETARY_SUPPLEMENT|Rice bran extract group|Rice bran extract 1,000 mg/day for 8 weeks
214318905|NCT05180136|DIETARY_SUPPLEMENT|Control group|Placebo 1,000 mg/day for 8 weeks
214318906|NCT03376178|COMBINATION_PRODUCT|lidocaine and ropivacaine injection through catheters|injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
214318907|NCT03844126|OTHER|Transition classes|90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
214318908|NCT02393963|DRUG|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
214318909|NCT02393963|OTHER|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
214318910|NCT00004066|BIOLOGICAL|filgrastim|
214318911|NCT00004066|DRUG|docetaxel|
214318912|NCT00004066|DRUG|gemcitabine hydrochloride|
214483756|NCT06890806|OTHER|Extracorporeal Shock Wave Therapy Group (ESWTG)|Extracorporeal Shock Wave Therapy Group (ESWTG) One group will receive Extracorporeal Shock Wave Therapy (ESWT) once a week for five weeks. The ESWT sessions will be performed using the Gymna Shockmaster 500 device at a frequency of 15 Hz and a pressure of 3 bar, delivering a total of 1800 pulses per session.
214483757|NCT06743464|DRUG|Rifaximin 550 MG|Preoperative Rifaximin supplementation 550 mg twice daily from preoperatively 2 weeks to post op POD 1 to 7
214483758|NCT06743464|OTHER|SOC|SOC means Standard of care which means that the patient will revieve standard post op care followed at our insitute and other hospitals in India.
214483759|NCT06744179|DIAGNOSTIC_TEST|echocardiography, chest x-ray, full blood count , SGPT, lipid profile, HbA1C, AQ20 questionnaire, mmRC dyspnoea scale, Duke activity status index, COPD assessment test, Age and stage questionnaire|Participants from both exposed and non-exposed groups will be assessed using different standardized questionnaire and a number of investigations to identify any cardiac and pulmonary complications over time. Individuals will be matched for age and sex to ensure comparability. This study aims to evaluate these complications and analyze any significant differences between the groups over the defined follow-up period.
214483760|NCT06743841|DIETARY_SUPPLEMENT|Nutritional supplement|60g of a nutritional supplement powder, divided into 2 daily intakes, one in the morning and one in the afternoon
214483761|NCT06743841|DIETARY_SUPPLEMENT|Control supplement|60g of a placebo supplement powder, divided into 2 daily intakes, one in the morning and one in the afternoon
214483762|NCT06744699|OTHER|Infants fed goat milk-based infant formula|Type of infant feeding during the age of 0-12 months
214483763|NCT06744036|OTHER|Therapeutic Exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises.
214483764|NCT06744036|DEVICE|Interferential Current|However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee. The parameters used were as follows: carrier current frequency of 4000 Hz; amplitude modulated frequency of 50 Hz; sweep frequency of 50 Hz; oscillation pattern of 1:1 second, and the amplitude of the current will be increased until the research participants report strong but comfortable and non-painful stimulation paresthesia. The interferential current will be applied for 30 minutes.
214483765|NCT06744036|DEVICE|placebo interferential current|However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee. The parameters used were as follows: carrier current frequency of 4000 Hz; amplitude modulated frequency of 50 Hz; sweep frequency of 50 Hz; oscillation pattern of 1:1 second, and the amplitude of the current will be increased until the research participants report strong but comfortable and non-painful stimulation paresthesia. The device will only be turned on in the first minute
214483766|NCT06745713|OTHER|Turkish- Computer System Usability Questionnaire Short Version|Developed in 1995 by Lewis at IBM, the Computer System Usability Questionnaire (CSUQ) is one of the widely used questionnaires in the field of usability. The scale, which was adapted into Turkish by Erdinç in 2013, consists of 13 items in total. It has 4 sub-dimensions: system usefulness (items 1-6), information quality (items 7-9), interface quality (items 10-12) and general satisfaction (item 13). Each item is scored as 1 (Strongly agree) - 7 (Strongly disagree). The Cronbach α of the scale is \> .70 and the Cronbach α value for each sub-dimension varies between .73 and .92. A minimum score of 13 and a maximum score of 91 can be obtained from the scale. A low score is defined as good usability, and the higher the score, the lower the usability quality of the system (Erdinç \& Lewis, 2013).
214483767|NCT06745713|OTHER|Student Information Form|In the form developed by the researchers in line with the literature, a total of 12 questions were included to determine the socio-demographic characteristics of the students (such as age, gender, academic average, whether they provide care to patients with chest tubes, whether they receive training on chest tube care). All participants in the experimental and control groups were applied once as a pre-test.
214318913|NCT05103124|DEVICE|Hydral|The investigational product GUM Hydral will be administered for a 30-days treatment period
214318914|NCT05103124|OTHER|Placebo|The placebo product will be administered for a 30-days treatment period
214318915|NCT02150668|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|
214318916|NCT02150668|BEHAVIORAL|Homework Support Intervention (HSI)|
214318917|NCT06113952|DEVICE|Sharps bin to collect used needles/injections|Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.
214318918|NCT02009033|DRUG|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
214318919|NCT02009033|DRUG|Hydroxyethylstarch|
214318920|NCT04088682|BEHAVIORAL|Quality improvement strategies and tools|Quality improvement strategies and tools
214318921|NCT04055857|OTHER||There is no Intervention.
214318922|NCT00011089|DRUG|Tenofovir disoproxil fumarate|
214318923|NCT00555984|DRUG|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
214318924|NCT00555984|DRUG|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
214318925|NCT05614245|BIOLOGICAL|VBI-2901e|Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants
214318926|NCT00423891|DRUG|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
214318927|NCT04886011|COMBINATION_PRODUCT|placebo gel|just methyl cellulose gel was applied to the ulcer
214318928|NCT04886011|COMBINATION_PRODUCT|camel whey protein gel|camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
214318929|NCT01996969|DRUG|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
214318930|NCT00414661|DRUG|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
214318931|NCT03031288|DEVICE|A|standard bottle
214318932|NCT03031288|DEVICE|B|vented base bottle
214318933|NCT00357370|DRUG|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
214483768|NCT06745713|OTHER|Clinical Reasoning Readiness Scale for Nursing Students|It is a comprehensive assessment tool developed by Huang Huiman (2018) to determine the clinical reasoning readiness levels of nursing students in Taiwan (Ho et al., 2021; H.-M. Huang et al., 2018). 'Clinical Reasoning Readiness Scale for Nursing Students' consists of 4 sub-dimensions. These sub-dimensions are 'awareness of clinical clues' (4 items), 'verification of clinical problems' (4 items), 'action determination and implementation' (4 items) and 'evaluation and reflection' (4 items). Each sub-dimension contains four items to assess students' clinical reasoning readiness levels. The lowest score that can be obtained from the scale is 16 and the highest score is 80. Responses to the scale are evaluated on a 5-point Likert scale (5=strongly agree, 4=agree, 3=decided, 2=disagree, 1=strongly disagree). Cronbach's α ranged from 0.894 for the total and 0.78 to 0.89 for each sub-dimension. The corrected item-total correlation is between 0.627-0.728. Higher scores indicate higher levels
214483769|NCT06745713|OTHER|Self-directed Learning Scale|The original Self-Managed Learning Scale was used as a self-report scale by Lounsbury et. al. (2009). The Turkish adaptation and validity and reliability study of the scale, which shows the extent to which individuals learn autonomously with a one-dimensional structure, was conducted by Demircioğlu, Öge, Fuçular, Çevik, Nazlıgül, and Özçelik in 2018. The scale is 5-point Likert-type and consists of 10 items. For each item, participants are expected to respond according to 1 (Strongly disagree), 2 (Disagree), 3 (No opinion), 4 (Agree) and 5 (Strongly agree). Cronbach's alpha coefficient of the scale is 0.85. In line with the scores obtained from the scale, above average self-directed learning skill means high and below average self-directed learning skill means low (Demircioğlu et al., 2018). Both groups were applied as pre-test and post-test.
214318934|NCT00357370|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
214318935|NCT04999631|DRUG|Squaric Acid Dibutyl Ester|Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.
214318936|NCT04999631|DRUG|Ethanol Solution|Control
214318937|NCT06452524|DEVICE|axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)|Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.
214483770|NCT06745713|OTHER|Chest Tube Care Management Knowledge Test|It was created by the researchers in line with the evidence in the literature (Abuejheisheh et al., 2021; Basler, 2020; Bertrandt et al., 2019; Charnock \& Evans, 2001; El-Senousy, Mahrous, Abd-Al Salam, \& Zedan, 2020; Ho et al., 2021; Tarhan et al., 2016; Zisis et al., 2015). The 'Chest Tube Care Management Knowledge Test' was initially prepared as a total of 43 multiple-choice questions, including the headings and subheadings in each session (Abuejheisheh et al., 2021; Malone, 2015). Expert opinions were obtained from 5 faculty members with clinical experience and studies on chest tube care. The experts gave suitability scores to the knowledge test questions one by one on a 4-point Likert-type scale (1: The item is not suitable, 2: The item should be seriously revised, 3: Suitable should be slightly revised, 4: Suitable). In line with the suggestions from the experts, the questions were reorganised and 9 questions were removed. For the remaining 34 multiple-choice questions in the kno
214483771|NCT06744218|PROCEDURE|Standard Treatment|Patients who will be assigned to the control group and subjected to standard treatment (usual care at our clinic) will undergo a physiotherapy treatment of 8 in-person sessions for 4 post-operative weeks
214318938|NCT01389297|BEHAVIORAL|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
214318939|NCT01389297|BEHAVIORAL|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
214318940|NCT03096522|DRUG|Phenytoin 2% spray|Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
214318941|NCT03096522|PROCEDURE|Anal fistulotomy|Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
214318942|NCT02108821|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
214318943|NCT06493630|BEHAVIORAL|Hypnobreastfeeding Education|Hypnobreastfeeding Education: Monitoring breastfeeding myths, breastfeeding expectations and breastfeeding self-efficacy with hypnobreastfeeding education
214318944|NCT00638703|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks
214318945|NCT00638703|DRUG|Placebo|placebo
214318946|NCT03365674|DEVICE|Vibration|Vibration applied with vibrator switch-on state (100Hz)
214318947|NCT03365674|DEVICE|Placebo vibration|Vibrator applied with switch-off state
214318948|NCT04951934|DEVICE|EmoLED|This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
214318949|NCT04951934|PROCEDURE|Standard treatment|"The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging."
214318950|NCT00617682|BIOLOGICAL|PNCRM9|0.5 mL IM at 30-35 wks gestation
214318951|NCT00617682|BIOLOGICAL|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
214318952|NCT06207539|DRUG|hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
214318953|NCT06207539|DRUG|misoprostol under the generic name of misotac tablets|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
214318954|NCT02078804|PROCEDURE|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
214318955|NCT02790346|PROCEDURE|arthrodesis talonavicular|
214318956|NCT02790346|PROCEDURE|tendon gestures|
214318957|NCT02963493|DRUG|Melphalan flufenamide (Melflufen)|
214318958|NCT02963493|DRUG|Dexamethasone|IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
214318959|NCT00620594|DRUG|BEZ235|
214483772|NCT06744218|PROCEDURE|Experimental Treatment|patients who will be assigned to the experimental group and subjected to the experimental treatment will undergo a physiotherapy treatment of 8 sessions in telerehabilitation for 4 post-operative weeks
214483773|NCT06891092|DEVICE|RayOne EMV|non-diffractive monofocal IOL
214318960|NCT00797082|DEVICE|MRI|MRI = Myocardial Perfusion Stress
214318961|NCT00797082|DEVICE|MPS|MPS = Myocardial Perfusion Scintigraphy
214318962|NCT05039346|OTHER|Phone interviews|Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
214318963|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
214318964|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
214318965|NCT00404352|DRUG|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
214318966|NCT03849820|DEVICE|Robotic-assisted partial nephrectomy|Application of the da Vinci surgical robot to assist the partial nephrectomy
214318967|NCT03849820|OTHER|Open partial nephrectomy|Open surgery to conduct the partial nephrectomy
214318968|NCT03663283|DRUG|Liposomal Bupivacaine|Interscalene Nerve Blocks
214318969|NCT03663283|DRUG|Bupivacaine Hydrochloride|Interscalene Nerve Blocks
214318970|NCT04838314|PROCEDURE|regional analgesia|Peri operative regional analgesia by bilateral ESP catheter for 72h
214318971|NCT04486846|OTHER|eVisit|electronic surveillance program in lieu of in-person clinic visit
214318972|NCT06213402|OTHER|Data collection from EHR.|Collection of clinical and laboratory data. Reviwe of the electronic health record
214318973|NCT06646029|DEVICE|RMO flexion orthosis (splint)|RMO flexion is an orthosis fabricated by hand therapists made of thermoplastic material design to position the involved finger in relative flexion at the metacarpal joint compared to adjacent fingers to facilitate PIP extension during daily activity use.
214318974|NCT06646029|OTHER|Standard of care|Treatment includes finger stretches, active range of motion (AROM), passive range of motion (PROM), thermal modalities, LMB finger extension orthosis.
214483774|NCT06891092|DEVICE|Vivinex Impress|non-diffractive monofocal IOL
214483775|NCT06890494|DRUG|BiTE-EV|Thi product organically combines extracellular vesicles with BiTEs, and enables stable expression of the bispecific antibody on the surface of mesenchymal stem cells. By collecting the culture supernatant, the bispecific vesicles BiTE-EV, which express both CD3 and CD19 antibodies on their surface, are enriched and isolated.
214318975|NCT06571981|DEVICE|TUP ultraportable US with teleradiology capacities|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
214483776|NCT06891118|PROCEDURE|Stellate gangion blockade %1 5 mL|"SGB is performed under sterile conditions in the operating room, with the patient's intravenous line established, monitored during the procedure, and ultrasound guidance used simultaneously. The patient is positioned supine, with the neck slightly hyperextended and the head slightly turned to the opposite side. After the skin is cleaned with an antiseptic solution and the probe is sterilized, a linear ultrasound probe is placed transversely at the level of the sixth cervical vertebra (C6).~The relevant anatomical landmarks, including the internal carotid artery, internal jugular vein, thyroid tissue, longus colli muscle, prevertebral fascia, C6 transverse process (Chassaignac's tubercle), C6 nerve root, and vertebral artery, are visualized. Avoiding vascular structures and thyroid tissue, a 25-gauge 38 mm sterile needle is advanced with a lateral approach using the in-plane technique, ensuring the needle tip is just below the surface of the longus colli m"
214318976|NCT06571981|DEVICE|CUS conventional ultrasound|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
214318977|NCT02346136|BEHAVIORAL|Tai Chi training|
214318978|NCT02346136|BEHAVIORAL|Educational Control|
214318979|NCT03539835|OTHER|Resistance training (RT)|Resistance training (RT) will include 15 repetitions for two sets and to exhaustion on the third set for seven major muscle groups: the leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl. Resistance is gradually increased to account for strength gains when subjects are able to complete 20 repetitions on the third set.
214318980|NCT03539835|BEHAVIORAL|Cognitively-based compassion training control (CBCT)|Cognitively-based compassion training control (CBCT) classes will be performed in a group setting for 1.5-2 hours per week, and consist of didactics, class discussion, and guided meditation practice. Each class will begin with a period of meditation to calm and focus the mind, followed by analytical practices designed to challenge unexamined assumptions regarding feelings, and actions toward others with a focus on generating spontaneous empathy and compassion for themselves and others.
214318981|NCT05203263|DEVICE|(810A-v1) device prototype|Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).
214318982|NCT05203263|DEVICE|(810B-v1) device prototype|Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).
214318983|NCT05203263|DEVICE|(810C-v1) device prototype|Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
214318984|NCT05026684|OTHER|Personalized cost handout|Patients will be given a personalized cost handout to make transparent the full costs to Veterans of different types of ambulatory visits in order to optimize the value of their health care investments.
214318985|NCT01052545|BEHAVIORAL|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
214318986|NCT05539482|BEHAVIORAL|Community-based Health Education based on core intervention package|"Community-based Health Education will potentially include the following three components:~1. A manual of emergency preparedness and self-protection against COVID-19 infection. The main content will include hand washing, mask wearing and social distancing guidelines.~2. Early testing. Participants will be trained on how to recognize the early symptoms of COVID-19 and appropriate practice to take in a response, and they will be provided with testing resources.~3. Knowledge of vaccines and their benefits and resources for vaccination.~Collaborators should design and implement health programs based on the core intervention package."
214318987|NCT05539482|BEHAVIORAL|Health Information Sharing Group|Collaborators are encouraged to collect and share health information to the participants. Shared information should be previewed by researchers.
214318988|NCT05137873|OTHER|Dunn-2 infant Sensory Profile (PS2-N)|The Dunn-2 infant Sensory Profile evaluates the child's sensory integration process
214318989|NCT03088176|DRUG|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
214318990|NCT03088176|DRUG|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
214318991|NCT03088176|DRUG|Dabrafenib|150mg PO qday
214318992|NCT03088176|DRUG|Trametinib|2mg PO qday
214318993|NCT04226482|DEVICE|New Device|Laparoscopic appendectomy using new ultrasonic shears.
214318994|NCT04226482|DEVICE|Used Device|Laparoscopic appendectomy using reprocessed ultrasonic shears.
214318995|NCT05372692|DRUG|mesothelin-specific chimeric antigen receptor T cell injection|Autologous T cell injection
214483777|NCT06891014|OTHER|Combine Exercise|The participants in the exercise group will be individuals over the age of 65 who applied the same exercise programs 2-3 days a week for 8 weeks under the control of two different physiotherapists independent of the study. The exercise session will be applied for one hour, including a warm-up phase, a combined exercise program including strengthening, stretching, balance and proprioceptive exercises, and a cool-down phase.
214919714|NCT03793842|DEVICE|PEEP titration by EIT|PEEP Titration procedure involves two phases: a recruitment phase followed by a gradual reduction in the end-expiratory pressure phase (Decremental PEEP).
214919715|NCT04024345|DIAGNOSTIC_TEST|Barratt Simplified Measure of Social Status (BSMSS)|Questionnaire that evaluates cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)
214919716|NCT04024345|DIAGNOSTIC_TEST|Global Assessment of Functioning scale (GAF)|Used to measure overall levels of functionality of an individual
214919717|NCT04024345|DIAGNOSTIC_TEST|General Self-Efficacy Scale (GSES)|Psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life
214919718|NCT04024345|DIAGNOSTIC_TEST|Perceived Stress Scale (PSS)|To assess the perceived stress
214919719|NCT04024345|DIAGNOSTIC_TEST|Coping Orientation to Problems Experienced (Brief COPE),|It evaluates the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations
214919720|NCT04024345|DIAGNOSTIC_TEST|Multidimensional Scale of Perceived Social Support (MSPSS)|to explore the subject's social support system
214318996|NCT04736238|PROCEDURE|Arthroscopy surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. Establish an anteromedial channel at the inner side of the tibial anterior tibial tendon at the level of the tibiotalar joint, and establish an anterolateral channel at the lateral angle of the talus. Exploring and clearing the ankle joint and dealing with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then observe the lateral sulcus through the anterior medial channel, clean the synovium in the lateral sulcus, and explore the anterior talofibular ligament. A double-line anchor was inserted into the fibula side stop of the anterior talofibular ligament through the anterolateral channel. The anterior talofibular ligament was sutured using an outside-in technique in the anterior inferior safety zone of the distal end of the fibula. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
214318997|NCT04736238|PROCEDURE|BrostrÖm surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. The first ankle arthroscopy is performed to deal with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then, open surgery was performed, and an arc incision was made at the anterior edge of the lateral malleolus to the tip of the fibula. After separating the subcutaneous tissue, the anterolateral joint capsule and talofibular ligament are exposed. A double-line anchor was placed at the fibular side stop of the anterior talofibular ligament. Tighten and suture the anterior talofibular ligament, anterolateral joint capsule, and extensor support belt with an anchor band. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
214318998|NCT06095466|DEVICE|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
214483778|NCT06733207|OTHER|Pupil examination|Pupil assessment : bilateral clinical examination of the patient's pupils, assessed in qualitative data : mydriasis, myosis, pupillary light reflex, anisocoria or isochoria.
214483779|NCT06741332|DEVICE|Methinks software|Introduction in the stroke code workflow the Methinks AI software capable of detecting LVO on NCCT and CTA, and ICH on NCCT.
214483780|NCT06741332|OTHER|Normal CT scans evaluation|The control group is obtained from a historical cohort at each participating center. We include consecutive suspected acute stroke patients who meet the same inclusion/exclusion criteria defined above, except for Methinks image processing.
214483781|NCT06741124|PROCEDURE|Channel Esophagogastrostomy|Channel Esophagogastrostomy
214483782|NCT06741124|PROCEDURE|Double Tract Reconstruction|Double Tract Reconstruction
214483783|NCT06737224|OTHER|Fasting + Exercise (FAST+EX): fasting + exercise condition|Participants will complete a 48-hour fast. One hour of exercise will be performed on each morning of the fast.
214483784|NCT06737224|OTHER|Fasting only (FAST): Non-exercise fasting condition|Participant will complete a 48-hour fast. No structured exercise will be performed during each of the fasting days.
214483785|NCT06737042|DRUG|GZR18|GLP-1
214483786|NCT06737042|DRUG|Tirzepatide|Active Comparator
214483787|NCT06738758|DRUG|PCSK9 inhibitor|The patient used PCSK9 inhibitor (with or without statins ± Ezetimibe/Hybutimibe) in the early hospitalization, and patients continually prescribed or stopped PCSK9 inhibitors treatment during the follow-up visit, which depend on physician's clinical decision and patient preference. PCSK9 inhibitors include Evolocumab, Alirocumab, Tafolecimab, Recaticimab, and Inclisiran, among others.
214671888|NCT03619915|DIAGNOSTIC_TEST|Spirometry|The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
214671889|NCT03619915|OTHER|Functional Independence Measure|Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
214671890|NCT02446782|DRUG|Cefazolin|Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
214671891|NCT02446782|OTHER|saline|100 mL normal saline 15-30 minutes before the start of the procedure
214671892|NCT03385668|DRUG|Pirfenidone|Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
214671893|NCT00637728|DRUG|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
214671894|NCT00637728|DRUG|Placebo|Placebo oral suspension, 5 mL once daily
214318999|NCT06095466|DIAGNOSTIC_TEST|Histopathology and Immunohistochemistry|"In patients who do not survive, we will take a trucut core biopsy from the ventricular myocardium, using ultrasound guidance. Cardiac tissue slices preserve the heterogeneous structure and multicellularity of the myocardium and allow its functional characterization. However, in this protocol, only those patients who consent to autopsy or those who consent to most mortem biopsy will be sampled for cardiac histology in CCM. Thus samples for histology and immunohistopathology will be available in only a few patients.~For the immunohistochemistry study, the sections will be collected on the poly-L-lysine covered slides and dried in a thermostat, at 37°C, for 24 hours, for increasing the adherence of the biological material to the histological slide."
214319000|NCT04631939|DEVICE|Metacognitive training game|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The intervention consists of 4 different puzzles. Unbeknownst to the player, the first pieces of evidence of each puzzle are often misleading, i.e. indicate the wrong solution, such that hasty decisions are punished. Players receive immediate feedback and are shown the correct response after submitting their solution, as well as explicit cues that educate them on the value of making adequately informed decisions. The order of the puzzles is fixed for each player, but different per session."
214319001|NCT04631939|DEVICE|Control games|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The control intervention consists of 4 different puzzle games requiring exclusively dexterity and accuracy (i.e., not including any metacognitive elements). The order of the puzzles is fixed for each player, but different per session."
214319002|NCT00615563|BEHAVIORAL|NO BI Drug administered|
214483788|NCT06738758|DRUG|Statin+Ezetimibe/Hybutimibe compound|The patient used statins and Ezetimibe/Hybutimibe in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
214319003|NCT04845607|DRUG|Amiodarone Injection|Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
214319004|NCT05824806|BIOLOGICAL|PRP Protocol A|Platelet rich plasma protocol A
214319005|NCT05824806|BIOLOGICAL|PRP Protocol B|Platelet rich plasma protocol B
214483789|NCT06738758|DRUG|Statin|The patient used statins in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
214919721|NCT03359759|OTHER|Conected objects|"Every week, each patient report her symptoms and answer ten questions on the i-PAD. The connected watch reports the performance status (activtiy and time spent in bed or sitting), and the falls.~If nurses or doctors detect any problem, they ask the patient for a telemedicine to try to help her. During the same time, nurses or doctors send a message on a secure plateform to the local team (nurse, General Practitioner, and pharmacists) and they reserve a place for an hospitalization if necessary."
214919722|NCT05538364|BIOLOGICAL|platelet rich plasma injection|Platelet rich plasma will be injected to the epidural space under light sedation using target-controlled infusion of propofol to an effect site concentration of between 0.5 to 1.5mcg/ml.
214919723|NCT03173664|DEVICE|KAMRA Inlay|Unilateral implantation of the KAMRA inlay in the corneal stroma.
214319006|NCT05824806|DEVICE|Hyaluronic acid|Hyaluronic acid
214483790|NCT06739603|OTHER|pharmaceutical analysis|pharmaceutical analysis
214483791|NCT06739187|DEVICE|Virtual reality platform on head mounted display|Enhance Virtual Reality platform on a Meta Quest head mounted display
214483792|NCT06740045|BIOLOGICAL|Tezepelumab|10 patients will receive teszpire
214483793|NCT06741176|BEHAVIORAL|Experimental|The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The mothers in the experimental group will be asked to write messages to their babies on the milk bags they bring in the mornings for 3 days. They will be asked to write on the paper attached to the milk bag what they want to tell their baby that the investigators will read the message to them and to return it every morning. The post-test of all surveys will be conducted at the end of the 3rd day.
214319007|NCT04201561|DRUG|sodium selenite pentahydrate|High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.
214319008|NCT04201561|DRUG|Normal saline|Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
214319009|NCT04201561|DRUG|Chemotherapy|Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
214483794|NCT06741176|BEHAVIORAL|Control|The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The post-tests will be conducted 3 days after the pre-test without any messages being requested from the mothers in the control group.
214483795|NCT06741098|BIOLOGICAL|NCR100|Subjects will receive multiple intra-articular NCR100 injections.
214919724|NCT00944242|DRUG|Sertraline|
214919725|NCT00944242|DRUG|Sertraline Hydrochloride|
214919726|NCT06250920|DEVICE|Virtual reality visual training|Children in intervention group were administered at home under the supervision of parents for 20 minutes per session every day with virtual reality visual training
214919727|NCT04844749|DRUG|VERU-111|Based on the safety and antitumor activity of VERU-111 in the Phase 1b/2 clinical study, VERU-111 is initiating this Phase 3 clinical study of VERU-111 for the treatment of metastatic castration resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent
214483796|NCT06741098|OTHER|0.9% Normal saline|Subjects will receive multiple intra-articular 0.9% Normal saline injections.
214319010|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
214319011|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
214319012|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
214319013|NCT04120610|DIAGNOSTIC_TEST|FlowMet-R|FlowMet-R is a noninvasive blood flow measurement.
214319014|NCT04120610|DIAGNOSTIC_TEST|ABI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the ankle and arm.
214319015|NCT04120610|DIAGNOSTIC_TEST|TBI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the toe and arm.
214319016|NCT03837899|DRUG|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
214319017|NCT04990960|OTHER|Physiotherapy|During each session (45 minutes)the patient was assessed and trained in self-treatment exercises assigned to treat their cords. This later method was chosen to ensure regular participation in their exercises and early correction of any inaccuracies in the implementation of the exercises regarding AWS treatment . Or the Physiotherapist worked actively on cords with soft or vigorous stretching.
214319018|NCT06142721|OTHER|3D Gait Analysis|3D gait analysis was applied to children. Static, kinematic and kinetic walking parameters were evaluated
214319019|NCT01194947|DEVICE|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
214319020|NCT05585970|DIAGNOSTIC_TEST|procalcitonin|The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens
214319021|NCT06447090|DRUG|Mitoxantrone hydrochloride liposome|Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7; Mitoxantrone Liposomal 30 mg/m2, d1; Cytosine arabinoside(Ara-C) 100 mg/m2/d, d1-7; Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5); After 1 day of rest, cryopreserved donor stem cells MNC1-2X10\^8 /kg infusion, add low-dose (25 mg Bid) and short-course treatment (stop 2-3 weeks after DLI) oral cyclosporine (CSA) to prevent graft-versus-host disease (GVHD) 3 days before cryopreserved stem cell infusion.
214483797|NCT06740266|BEHAVIORAL|Promoting First Relationships in Primary Care (PFR-PC)|"Promoting First Relationships® in Primary Care is based on attachment theory and is strengths-based. The intervention is delivered in 10 home visits, with 2 additional clinic visits. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
214483798|NCT06737237|PROCEDURE|cervical plexus block|local anesthetic (10ml of bupivacaine 5mg/ml)
214483799|NCT06737237|PROCEDURE|Local Infiltration Analgesia (LIA)|local anesthetic (20ml of bupivacaine 2.5mg/ml)
214919728|NCT04844749|DRUG|Enzalutamide, Abiraterone|Enzalutamide and abiraterone were chosen as active comparators are both are FDA approved for the treatment of metastatic castration resistant prostate cancer
214919729|NCT01558557|OTHER|Gluten Free Diet|Participants will be given a Gluten Free Diet for 2 weeks
214919730|NCT05960916|PROCEDURE|Densah® burs|Osseodensification is a non-excavating implant site preparation technique, it creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects.
214319022|NCT03364296|OTHER|Blood Samples|Blood sample retrieved for biological assessment and biobanking
214319023|NCT05961566|DEVICE|Use of collagen matrix after subepithelial connective tissue graft harvest|A collagen matrix is placed under the overlying flap after the subepithelial connective tissue graft harvesting.
214319024|NCT03588364|OTHER|Osteopathic Manipulation|Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
214319025|NCT04384965|DEVICE|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~3 minutes) at a target of 110% of the subject's resting MT.
214319026|NCT04514601|OTHER|Standard Operating Protocol|This was a written protocol on how the handover process should be conducted.
214319027|NCT03007511|DEVICE|Fidmi enhanced enteral feeding device|Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.
214319028|NCT05749081|DRUG|Lacidophilin tablets in combination with vonorazan dual therapy|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
214483800|NCT06737237|PROCEDURE|cervical plexus block|placebo (10ml of 0.9% sodium chloride)
214483801|NCT06737237|PROCEDURE|Local Infiltration Analgesia (LIA)|placebo (20ml of 0.9% sodium chloride)
214483802|NCT06742164|DRUG|Ivabradine 5mg Tab|Ivabradine (5 mg twice daily) orally or via nasogastric tube
214483803|NCT06742164|DRUG|control|Patients didn't receive Ivabradine .
214919731|NCT05960916|PROCEDURE|Conventional Burs|Conventional burs is the gold standard that used to prepare the osteotomy site by drilling of the bone and creating a bed for implant placement, it is used according to the manufacturer instructions.
214319029|NCT05749081|DRUG|Placebo in combination with vonorazan dual therapy|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
214319030|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class A
214919732|NCT01377350|DEVICE|"Pneumedicares monitoring system."|50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.
214319031|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class B
214319032|NCT00651027|DRUG|PF-868554|200 mg, healthy volunteers
214483804|NCT06742489|DEVICE|Percutaneous tibial nerve stimulation device|T-PTNS primarily delivers electrical stimulation to the sacral voiding center via the tibial nerve through the S2-S4 sacral plexus via skin-surface electrodes to improve patients' symptoms of urinary frequency, urgency, and urge incontinence.
214483805|NCT06742489|DEVICE|Sham group device|The device in the sham group is manufactured by the same company and has the same appearance, display interface, and operation method as the device in the treatment group. These devices have the output circuit disconnected and no actual current output.
214483806|NCT06835621|PROCEDURE|Restricted inverse kinematic alignment Total Knee Arthroplasty|Restricted inverse kinematic alignment (restricted iKA) total knee arthroplasty is an alignment technique of total knee replacement surgery, aim to maintain the native coronal alignment within a HKA angle safe zone of 177° to 183°. This technique aims to 'resurface' the femur maintaining the native femoral joint line obliquity, with the flexion and extension gaps balanced by adjusting the tibial resection first. It is considered a more personalized approach because it aims to replicate the knee's pre-arthritic alignment and movement, believing that each patient's knee has a unique alignment.
214483807|NCT06835621|PROCEDURE|Adjusted Mechanical alignment Total Knee Arthroplasty|The adjusted Mechanical Alignment (aMA) technique is an adaptation of the conventional MA technique but with undercorrection of constitutional coronal deformity, within a limit of ± 3°. The femoral resection is adjusted to preserve mild constitutional deformity and/or reduce more severe deformity while leaving the tibial component mechanically aligned. The tibial component was positioned with the aim to be perpendicular (90°) to the mechanical tibial axis.
214483808|NCT01265537|DRUG|Tacrolimus|"Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4"
214671895|NCT00345111|PROCEDURE|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
214919733|NCT01377350|DEVICE|"Pneumedicares monitoring system"|Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
214919734|NCT01506102|DEVICE|Thromboelastography|Thromboelastography during labor and after delivery
214919735|NCT04797702|COMBINATION_PRODUCT|Glumetinib combined with Toripalimab|"Ib：All enrolled subjects received Glumetinib combined with Toripalimab on a 21-day cycle, starting with 200mg/ day continuous Glumetinib and 240mg/ 3 weeks Toripalimab.~II：The SMC will determine the dose group for the Phase II study based on the safety and initial efficacy data of the Phase Ib subjects. Approximately 62 evaluable subjects will be enrolled in the study to receive the recommended dose of Glumetinib once daily and continuous treatment with Toripalimab 240mg every 3 weeks."
214919736|NCT05357703|DEVICE|Standard treatment + Active B-Cure laser|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/minute.
215061421|NCT04277546|DRUG|Brazikumab Induction Dose|Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
214319033|NCT05551143|OTHER|LiftKit|"The LiftKit contains 7 tools that could assist EMS providers when lifting/moving patients. These tools are:~1. Simple Strap - A sling to lift a seated patient~2. Strap and slide stick - A strap system for raising a supine patient to a sitting posture.~3. Slip Preventer- An envelope that goes over the patients feet with high friction straps for the EMS providers to stand on that prevent the patient from sliding forward when lifted.~4. Drag Straps - straps with handles that can be clipped on tarps used to drag patients~5. The Binder Lift - a vest with handles that allow EMS providers to easily get hold of patient they need to lift.~6. Patient Turning Straps - a way to log-roll a patient that in on the floor while in a standing posture.~7. The ELK - an inflatable seat cushion that can raise a patient who in the floor to chair level"
214319034|NCT03525197|DIETARY_SUPPLEMENT|Whey protein-based supplement|High quality protein supplement to be consumed twice daily
214319035|NCT03525197|DIETARY_SUPPLEMENT|Collagen protein-based supplement|Lower quality protein supplement to be consumed daily
214319036|NCT01465464|DRUG|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
214319037|NCT01465464|DRUG|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
214319038|NCT06073925|DRUG|VIT D|50000 IU per week of VIT D
214319039|NCT06357637|DIAGNOSTIC_TEST|Measure of abdominal circumference|Measure of abdominal circumference preoperatively in both sitting and lying position
214319040|NCT04871243|OTHER|Qualitative Interview|Individual semi-structured interviews
214319041|NCT02505633|DEVICE|Stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL."
214319042|NCT02505633|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
214319043|NCT00785486|DRUG|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
214319044|NCT00785486|DRUG|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
214483809|NCT01265537|DRUG|Tacrolimus|"Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8."
214919737|NCT02442570|BIOLOGICAL|recombinant human alpha B-crystallin|intravenous injections
215061422|NCT03786224|BEHAVIORAL|Contingency Management|Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
214319045|NCT00785486|DRUG|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
214319046|NCT02513524|PROCEDURE|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
214319047|NCT01465646|DRUG|levothyroxine|
214319048|NCT01465646|DRUG|levothyroxine|
214483810|NCT06829290|DIAGNOSTIC_TEST|Ultrasound|Sonographisch measurement of muscles Blood muscle markers
214671896|NCT06073314|DIAGNOSTIC_TEST|Quantitative MRI|Patients will be asked to remain in the scanner for an additional 10 minutes while we acquire additional quantitative MR images
214671897|NCT06073314|DIAGNOSTIC_TEST|Reproducibility study|A subset of patients will be invited back for a repeat MRI scan (prior to any treatment for their condition) to help measure reproducibility of our Artificial Intelligence model
214919738|NCT02442570|OTHER|Placebo comparator|intravenous injection
215061423|NCT02968446|DIETARY_SUPPLEMENT|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
215061424|NCT02968446|DIETARY_SUPPLEMENT|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
215061425|NCT02968446|DRUG|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
215061426|NCT01442337|DRUG|ASP8597|one time IV dose
215061427|NCT01442337|DRUG|Placebo|one time IV dose
214483811|NCT06746909|OTHER|Multidomain cognitive training and physical training|"The cognitive training programme will be based on 8 cycles composed by 18 sessions of exercises and activities aimed at stimulating multiple cognitive functions. Each cycle will last 3 weeks, after which the same kind of cognitive stimulation sessions will be restarted, with exercises and activities of increased complexity. Each cycle will be structured in sessions aimed at stimulating specific cognitive domains and in sessions focused on multimodal activities (music-therapy, cineforum, etc.).~The physical training will include aerobic exercise on an ergometer cycle, whose duration will be increased gradually from 10 to 20 minutes followed by exercises targeted to improve muscle strength, physical function, neuromuscular control and flexibility."
214319049|NCT02699294|OTHER|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
214483812|NCT05719909|BEHAVIORAL|Cognitive Training|8 sessions of web-based cognitive training
214483813|NCT05719909|BEHAVIORAL|Sham Training|8 sessions of web-based sham training
214483814|NCT06396949|DIAGNOSTIC_TEST|Fibromyalgia study form|Fibromyalgia study form, consisting of clinical measurement, Fibromyalgia impact questionnaire (FIQ), Beck Anxiety Questionnaire and Beck Depression Questionnaire, Short-Form (SF)-36, who applied to the outpatient clinic with fibromyalgia will be filled in detail.
214483815|NCT06396949|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken."
214483816|NCT06396949|DIAGNOSTIC_TEST|Ultrasonographic Diaphragm Thickness Measurement|Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity) (millimeter-mm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
214483817|NCT06754449|OTHER|Art therapy group|Application of different applications of art therapy such as painting, drawing, cutting to children
214483818|NCT06752954|DEVICE|Viabahn endoprosthesis group|Viabahn endoprosthesis group：Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
214483819|NCT06752954|DEVICE|Drug-coated balloon group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
214483820|NCT06738095|DEVICE|daily low-level red-light|Daily low-level red-light is a kind of myopia intervention. Red-light typically using 650-nm wave of length. The treatment duration last 3 minutes each time, every day children were anticipated to use two times, at home.
214483821|NCT06770803|PROCEDURE|High Pressure Pneumoperitoneum|The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
214483822|NCT06770803|PROCEDURE|Low Pressure Pneumoperitoneum|The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
214483823|NCT04974268|OTHER|Specific supervised exercise and weight loss program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal, manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
214483824|NCT04604418|OTHER|No intervention. It is observational|No intervention. It is observational
214671898|NCT00325572|DRUG|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
214671899|NCT00325572|OTHER|oral Placebo|Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
214919739|NCT06160115|DEVICE|Flow cytometry|"1. Profiling of NK cells using flow cytometry on peripheral blood and bone marrow aspirate samples.~2. Isolation and identification of pathogens causing BSI and bacterial drug susceptibility testing using VITEK compact fully automatic microbial identification instrument."
214319050|NCT02699294|OTHER|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
214319051|NCT02699294|OTHER|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
214919740|NCT06661954|DEVICE|Bed A - supine|Hercules dream air surface in supine position
214319052|NCT06340035|OTHER|TENS|The TENS group is subjected to transcutaneous current. Two surface electrodes are inserted at the level of the superior gluteal and inferior gluteal nerve tract. A protocol of 10 stimulations x 10 seconds of stimulations x 10 times is performed with a 10 second rest between each repetition. A maximum contraction evoked without pain is sought.
214319053|NCT06340035|OTHER|Percutaneous Peripheral Nerve Stimulation|In the pPNS group, the superior gluteal nerve and inferior gluteal nerve are stimulated percutaneously. The nerves are localized at an ultrasound-guided level and with respect to the vascular-nervous package two acupuncture needles are inserted, one for each nerve. The stimulation is the same as the TENS group: 10 stimulations x 10 times x 10 seconds, evoking the maximum contraction without pain.
214319054|NCT00544076|DRUG|sildenafil citrate|Given orally
214319055|NCT00544076|DRUG|alprostadil|Given intraurethrally
214319056|NCT00544076|PROCEDURE|robotic-assisted laparoscopic surgery|Undergo prostatectomy
214319057|NCT00544076|PROCEDURE|quality-of-life assessment|Ancillary studies
214319058|NCT00544076|OTHER|questionnaire administration|Ancillary studies
214319059|NCT05640570|DRUG|The individualized Jade Wind-Barrier Herbal Tea Bag|The individualized Jade Wind Barrier Herbal Tea Bag is composed of Astragali Radix (Zhi Huangqi) 4g, Saposhnikoviae Radix (Fangfeng) 2g, Atractylodes macrocephala Koidz (Baizhu) 2g, Nelumbinis Folium (Heye) 1g, Chrysanthemum morifolium Ramat (Juhua) 1g.
214319060|NCT02052921|PROCEDURE|Rectal resection|Surgical rectal resection
214319061|NCT02052921|OTHER|Observation|
214919741|NCT06661954|DEVICE|Bed B - supine|Oncare Skinguard surface
214319062|NCT03637465|BEHAVIORAL|Hydrate Philly|"Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods)."
214319063|NCT05534477|DEVICE|Verily Clinical Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
214319064|NCT05534477|DEVICE|Vivalink ECG Patch|The Vivalink ECG Patch is a continuously recording ECG monitor and will be used as a reference device for measuring participants' pulse rate, pulse rate variability, and pulse rate coverage. The Vivalink ECG Patch is a medical device manufactured by VivaLNK Inc. and has been cleared by the FDA.
214319065|NCT05534477|DEVICE|Modus StepWatch 4|Modus StepWatch 4 is an ankle-worn wearable medical device, and will be used as a reference device for measuring participants' ambulatory time and daily step count. The Modus StepWatch 4 is FDA listed.
214319066|NCT00624533|BEHAVIORAL|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
214671900|NCT02348567|OTHER|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
214671901|NCT02348567|OTHER|announced hospital surveys|
214671902|NCT01050062|DRUG|Telmisartan 80mg|Combination tablet
214919742|NCT06661954|DEVICE|Bed A - head of bed at 30 degrees|Hercules dream air surface with head of bed at 30 degrees
214919743|NCT06661954|DEVICE|Bed B - head of bed at 30 degrees|Oncare Skinguard surface with head of bed at 30 degrees
214919744|NCT01152346|DRUG|Azacitidine for Injection|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
214919745|NCT01152346|DRUG|Vidaza®|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
214919746|NCT02880475|DRUG|OXN PR tablet|Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
214319067|NCT00624533|BEHAVIORAL|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
214319068|NCT01603446|DRUG|L-Arginine|NOW® L-Arginine powder
214319069|NCT02889640|OTHER|SAGA Innovations|An intensive math tutoring program
214319070|NCT02889640|OTHER|Scale-up tutors|Tutors who have been selected for hire via the one in three-and-a-half randomization process
214319071|NCT02889640|OTHER|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
214483825|NCT06831318|BEHAVIORAL|Community Health Worker (CHW) Guided Support|"The CHW conducts a family assessment, which identifies caregiving stressors, social support, and needs as related to social determinants of health, dementia education, care navigation, caregiver health and burden. Closer to discharge, dyads receive an individualized dementia caregiving toolkit including the post-discharge care planning checklist, tracking sheets for patient medications, tests, and procedures, and info on local resources. All meetings will be done in person, telephone, or zoom.~Within one week of discharge, the CHW meets the dyad via phone or Zoom to review their goals and to identify any additional needs for coaching, education, or navigation support. In the first month after discharge, the CHW provides weekly or bi-weekly check-ins. For the next two months, the CHW provides about four additional bi-weekly check-in sessions. Each check-in session will last approximately 30-45 minutes. The exact number of meetings will be determined by need and caregiver availability"
214483826|NCT05589402|DRUG|Lidocaine Cream 5%|Ebanel 5% Lidocaine Topical Numbing Cream Maximum Strength 1.35 Oz, Numb520 Pain Relief Cream Anesthetic Cream Infused with Aloe Vera, Vitamin E, Lecithin, Allantoin, Secured with Child Resistant Cap
214483827|NCT05589402|OTHER|Rehabilitation Movement Training|reaching tasks, hand exercises (e.g., putty, grip exerciser, resistance bands, etc).
214483828|NCT06581900|OTHER|Vitamin B12|Quantification of Vitamin B12
214483829|NCT06735781|DRUG|Nivolumab|As prescribed by the treating clinician
214483830|NCT06871436|OTHER|Aerobic Exercice and muscular reinforcement|Aerobic exercise and muscle strengthening to increase weekly physical activity at moderate and vigorous intensities
214483831|NCT06745999|DRUG|Ameluz 10% Topical Gel|Paired with device intervention of red light PDT
214483832|NCT06745999|DEVICE|Red Light PDT|Paired with drug intervention of Ameluz 10% topical gel
214483833|NCT06745999|PROCEDURE|Cryotherapy|Liquid Nitrogen
214483834|NCT06746610|DIAGNOSTIC_TEST|Genetic Screening for Monogenic Diabetes|"This intervention involves genetic testing for monogenic diabetes (MDM) in recruited participants. The testing includes either a panel test specifically targeting genes associated with monogenic diabetes or whole exome sequencing (WES) to comprehensively identify genetic variants linked to MDM.~Precise diagnosis and treatmen：~1. The clinical trial of individualized treatment was carried out for the individuals with diabetes with HNF1A mutation.~2. The research team will closely follow up individuals with GCK mutation diabetes after suspending the current hypoglycemic drugs, and evaluate their clinical glucose metabolism related indicators.~3. Observe the dosage of sulfonylurea drugs used in individuals with different disease course and pancreatic function, and observe the impact of disease course and pancreatic function on the success rate of oral drug replacement."
214483835|NCT06746844|DEVICE|ViewMind Atlas™|The intervention involves the use of ViewMind Atlas™, a novel digital tool for cognitive assessment, and traditional cognitive tests. The ViewMind Atlas™ device evaluates cognitive performance through eye-tracking technology and advanced analytics, providing objective measurements of cognitive function. Traditional cognitive tests are used as the standard comparator to validate the device's diagnostic performance
214483836|NCT06757972|COMBINATION_PRODUCT|Tele Rehab|Tele rehabilitation intervention is 6 months standardized program aimed to provide special rehabilitation services to patients with mobility impairments in rural areas without the need for them to travel to healthcare facility in big cities. The program consists of standard exercises addressing key components of mobility impairments.
214319072|NCT00437684|DRUG|LPV/r|200/50 mg 2 cpr bid monotherapy
214319073|NCT00437684|DRUG|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
214483837|NCT06757972|DIAGNOSTIC_TEST|Formal Rehab|After formal rehabilitation is completed, some impaired mobility victims re-access services; no attempt will be made to stop the control group from accessing further care, in either a public or private setting. However, physical activity participation will be assured during monthly phone call by a blinded -research assistant. Participants in this group will undergo three assessments at baseline, 6 and 12 months
214671903|NCT01050062|DRUG|Telmisartan 40mg|Combination tablet
214671904|NCT01050062|DRUG|Hydrochlorothiazide 12.5mg|Combination tablet
214671905|NCT03940781|BEHAVIORAL|comprehensive rehabilitation|oropharyngeal rehabilitation, cardiopulmonary rehabilitation, and therapeutic exercise
214919747|NCT06218940|DRUG|HY1272|Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily
214319074|NCT00437684|DRUG|Ribavirin|Ribavirin 1-1.2 g/day
214319075|NCT00437684|DRUG|NUCS|Nucleoside Reverse Transcriptase Inhibitors
215061428|NCT00758693|DRUG|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
215061429|NCT00758693|DRUG|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
215061430|NCT02697981|BEHAVIORAL|nutrition counseling|nutrition counseling and guidance.
215061431|NCT03571360|OTHER|PD-L1 positive vs PD-L1 negative NSCLC patients|Genomic analyses of PD-L1 positive vs PD-L1 negative NSCLC patients
214319076|NCT03561415|OTHER|Universal Posaconazole Prophylaxis|All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.
214319077|NCT03561415|OTHER|Pre-emptive Posaconazole Therapy|Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.
214319078|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
214319079|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
214319080|NCT01590407|DRUG|ALS-002200|ALS-002200
214319081|NCT01590407|DRUG|Placebo|Placebo
214319082|NCT04328974|PROCEDURE|lumbar CSF drainage|We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg \[14, 15\].
214319083|NCT01554618|DRUG|Exenatide Once Weekly|2 mg exenatide once weekly
214319084|NCT01554618|DRUG|Placebo|Placebo
214319085|NCT01566448|DRUG|Ketamine|20mg/5ml swish and spit four times daily
214319086|NCT02131480|DRUG|Doxorubicin|60 mg/m²
214319087|NCT02131480|DRUG|Trabectedin|1,1 mg/m²
214319088|NCT01528241|DRUG|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
214319089|NCT05310110|DRUG|10% lidocaine spray|10% lidocaine spray 3 puff for the throat before induction
214319090|NCT05310110|DRUG|Placebo of lidocaine spray|Normal saline spray 3 puff for the throat before induction
214319091|NCT05310110|DRUG|Cisatracurium|Intravenous cisatracurium 0.12 mg/kg during induction
214319092|NCT05310110|DRUG|Placebo of cisatracurium|Intravenous normal saline during induction
214319093|NCT05310110|DRUG|Propofol|The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.
214319094|NCT05430828|DRUG|Repatha (evolocumab); Praluent (alirocumab)|Dosage form: Injection
214319095|NCT04759625|OTHER|Novel biscuit enriched with mushroom powder containing 3g of β-glucans|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
214319096|NCT04759625|OTHER|Placebo biscuit|Daily consumption of placebo biscuit
214319097|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for three months|period of treatment
214319098|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for six months|period of therapy
214319099|NCT01020071|PROCEDURE|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
214319100|NCT04686864|BEHAVIORAL|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
214319101|NCT03175094|BEHAVIORAL|Holistic Health Recovery Program for HIV+|Holistic Health Recovery Program for HIV+ (HHRP+) is a CDC-recommended, evidence based behavioral (psychoeducational) group intervention focused on harm reduction principles. The investigators systematically adapted HHRP+ using findings from qualitative interviews with the target population of adult women living with and at-risk for HIV who are justice-involved (on probation, parole, or recently released from prison or jail).
214319102|NCT01116232|BIOLOGICAL|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
214483838|NCT06757491|DEVICE|repeated transcranial magnetic stimulation treatment|"IBS patients received repetitive transcranial magnetic stimulation at~1 Hz/s for 20 minutes for 2 weeks."
214319103|NCT01116232|BIOLOGICAL|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
214319104|NCT01116232|DRUG|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
214319105|NCT01116232|DRUG|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
214319106|NCT01116232|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214319107|NCT01116232|PROCEDURE|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
214319108|NCT01116232|PROCEDURE|management of therapy complications|management of therapy complications
214483839|NCT03782116|DEVICE|Transcutaneous electrical stimulation (Elitone)|Transcutaneous perineal area electrical stimulation
214483840|NCT06754215|BEHAVIORAL|Focus Group|Participate in focus group
214483841|NCT06754215|OTHER|Interview|Participate in semi-structured interview
214319109|NCT01116232|PROCEDURE|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
214319110|NCT06139159|OTHER|Outreach/navigator|"* Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct informal screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues to clinics for triage.~* Document outreach, screening, and referral activities in LHW database"
214319111|NCT06139159|OTHER|Auxiliary to care|"* Arrange consultation for those at-risk, suspected, or affected individuals at clinics for triage.~* Introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit.~* Support patients in attending their clinic visits; help patients address barriers through education, referral, and navigation to ancillary community services (SAVAME, legal, housing, economic, etc);~* Engage, activate, and empower patients to participate in the care process~* Frequent contact with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Assist with group sessions: affinity groups~* Identify community-based resources.~* Document outreach, screening, referral, and auxiliary care activities in LHW database"
214319112|NCT06139159|OTHER|Stepped care and task shifting|"* Support counselling initiated by the psychologist~* Reinforce patient education about depression, anxiety, trauma, and other syndemic conditions.~* Work with patients' families and peers to reduce stigma, address syndemic factors and social conditions.~* Contact frequency with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Co-lead group sessions: affinity groups~* Provide Mental Health First Aid to members of the community.~* Document outreach, screening, referral, auxiliary and stepped care activities in LHW database"
214319113|NCT02357940|DRUG|Experimental Product|1% Colloidal Oatmeal Balm
214319114|NCT03304847|OTHER|ablation|radio-frequency applications on arrhythmogenic substrate
214319115|NCT02275481|DRUG|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
214319116|NCT02275481|DRUG|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
214319117|NCT06363565|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Folic acid, vitamin B6, vitamin B12, and betaine per day orally for 12 weeks.
214319118|NCT06363565|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste, and weight are same with the tablet of supplement.
214319119|NCT05223855|OTHER|Physiotherapeutic hydrotherapy treatment|"Physiotherapeutic hydrotherapy treatment The intervention consists of physiotherapeutic one-on-one treatment in a 34-36 degrees centigrade hot water, where the participants are placed supine in the water supported by the physiotherapist as well as buoyant aqua noodles. The physiotherapist supports and moves the participants in the water and adapts to the participant's reaction.~The combination of heat, water, movement and touch affects the musculoskeletal and neuromuscular systems and thus has a depth-relaxing effect (Schoedinger, 2010)."
214319120|NCT02338765|BEHAVIORAL|mHealth Physical Activity|
214319121|NCT02338765|BEHAVIORAL|Buddy-partnered exercise|
214319122|NCT06032312|OTHER|description|no intervention, just description of the groups
214319123|NCT02661360|BEHAVIORAL|Swaddling Intervention for Preterm Infants|Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
214319124|NCT02661360|BEHAVIORAL|Unswaddled Control|Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
214319125|NCT01495585|DRUG|Lonafarnib|Commercially approved products used to test the research hypothesis
214319126|NCT01495585|OTHER|Placebo|Placebo control
214319127|NCT05769959|DRUG|RO7515629|RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
214483842|NCT06754215|BEHAVIORAL|Smoking Cessation Intervention|Participate in feasibility study of intervention components
214319128|NCT05769959|DRUG|tocilizumab|Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).
214319129|NCT01991002|BEHAVIORAL|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
214483843|NCT06754215|OTHER|Survey Administration|Complete survey
214671906|NCT05225532|OTHER|Radiofrequency ablation|Radiofrequency ablation of ganglionated plexi located in the left or right atrium
214671907|NCT03172650|DIAGNOSTIC_TEST|glomerular filtration rate|collection of blood sample 5 milliliter for calculation of glomerular filtration rate
214671908|NCT05886192|DRUG|norepinephrine+vasopressin|Norepinephrine combined with vasopressin to maintain blood pressure
214671909|NCT05886192|DRUG|Norepinephrine|norepinephrine
214919748|NCT06062589|RADIATION|Iodine-125 particle brachytherapy|All enrolled patients' relapsed or metastatic lesions underwent image-guided radiation I-125 particle implantation brachytherapy (single implantation, half-life of 60 days, 99% of total dose given after 90 days). The prescribed dose is above 130Gy. Technical process: positioning and preoperative planning design; Template reset and particle implantation under the guidance of image system; Rapid and real-time intraoperative optimization; Postoperative dose validation.
214319130|NCT00694967|PROCEDURE|McDonald cerclage placement|Transcervical McDonald cerclage placement
214919749|NCT06062589|DRUG|AK104|AK104 treatment (6mg/kg Q2W) starting within 1 week of particle implantation, for a total of 6 cycles or until disease progression, intolerable toxicity, investigator decision, withdrawal of informed consent, death, or other reasons as specified in the protocol.
214483844|NCT06756048|PROCEDURE|Rhomboid Intercostal Nerve Block|"Following standard ASA monitoring, patients were positioned on the surgical table with their backs facing the operator. Skin antisepsis was achieved using povidone. A high-frequency 8-18 MHz linear ultrasound probe was used.~After palpating the rhomboid muscles and intercostal spaces at the T6-T7 levels, the medial border of the scapula and the vertebral column were identified. The ultrasound probe was placed horizontally along the medial border of the scapula. Using ultrasound guidance, the ribs, rhomboid muscles, intercostal muscles, and pleura were visualized. Once these anatomical structures were clearly identified, a 50 mm, 22G regional block needle was advanced in-plane from caudal to cranial under ultrasound guidance until the interfascial plane beneath the rhomboid muscles was reached and total of 20 ml of 0.25% bupivacaine (Marcaine® 0.5%, AstraZeneca PLC, London, UK) was injected."
214483845|NCT06756126|DRUG|AK120|AK120 subcutaneous injection
214671910|NCT05361096|OTHER|Educational approach (Flipped learning)|"In the intervention group, the out-of-class stage started one week before the in-class stage of the relevant week. The researchers covered the topic of the week asynchronously in the virtual classroom in the learning management system. Students have been able to log into the system at anytime and anywhere and study the course video and other course materials repeatedly.~The in-class stage is the session in which the students in the intervention group come together with the researcher synchronously and conduct an online lesson. It was conducted one session per week for four weeks. The course was carried out synchronously on the Zoom platform during the in-class stage."
214919750|NCT00638222|OTHER|Carvedilol and Placebo|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
214919751|NCT03806725|DIAGNOSTIC_TEST|Intravenous administration of iodinated contrast medium for coronary CT angiography|Administration of iodinated contrast medium for coronary CT angiography
214919752|NCT00427921|BIOLOGICAL|adalimumab|160 mg loading dose, 80 mg at week 2, 40 mg every other week
214919753|NCT05389930|DRUG|THC-dominant cannabis|Smoked cannabis with 9.53% THC and 0.09% CBD
214919754|NCT05389930|DRUG|CBD-dominant cannabis|Smoked cannabis with 0.35% THC and 11.27% CBD
214919755|NCT05389930|DRUG|Cannabis placebo|Smoked placebo cannabis plant material
214319131|NCT00694967|DRUG|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
214319132|NCT04617691|DRUG|Guselkumab|Guselkumab will be administered as IV solution derived from FVP or PFS-U.
214319133|NCT03975907|BIOLOGICAL|CAR-BCMA T Cells|The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
215061432|NCT00858728|BEHAVIORAL|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
214319134|NCT05768477|OTHER|Consultation|Consultation with the pain specialist, which might entail prescription of medication of vitamins.
214319135|NCT05768477|PROCEDURE|Interventions|Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation
214319136|NCT05768477|DRUG|Baxter therapy|Ketamine or Linisol baxter therapy
214319137|NCT05768477|BEHAVIORAL|Interdisciplinary therapy|Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
214319138|NCT04162028|DRUG|Nebutlized Ketamine|The PK-BAN package will be opened and weight -based dose of ketamine will be administered to the patient via BAN. The medication will be delivered with a minimum time of 5 min and maximum time of 15 min.
214319139|NCT00704028|DRUG|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
214919756|NCT05389930|DRUG|Alcohol|Drink containing 0.3 g/kg of alcohol
214919757|NCT05389930|DRUG|Alcohol placebo|Placebo beverage contains only juice and a negligible trace of alcohol for masking
214919758|NCT05796466|BEHAVIORAL|How-to talk so kids will listen and listen so kids will talk|The How-to Parenting Program focuses on how expectations, rules, and values are better communicated (vs. what rules ought to be). It includes skills related to the three components of authoritative parenting, namely affiliation, structure, and autonomy support. 1) Affiliation: Parents learn how to listen and respond to their children in a way that helps them feel accepted unconditionally. 2) Structure: Parents learn how to communicate expectations, give feedback, follow through, and use joint problem-solving in a factual, non-judgmental way. 3) Autonomy support: Parents learn how to validate emotions, encourage initiatives, and free children from roles. Finally, the How-to program can be endorsed by parents of various cultural backgrounds, as suggested by the large number (\> 30) of languages in which the material is translated. This advantage is crucial in ethnically diverse regions such as Canada.
215061433|NCT00858728|BEHAVIORAL|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
214319140|NCT00704028|DRUG|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
214319141|NCT02883296|OTHER|Pelvis Magnetic resonance imaging|
214919759|NCT05796466|BEHAVIORAL|Nobody's Perfect|Nobody's Perfect is delivered in family resource centers across Canada to support parents of infants and preschoolers. Its focus is on developing parents' capacity to problem solve, providing child development information, and helping parents recognize their strengths and find their own positive ways to interact with their children. It thus does not teach specific parenting skills and does not suggest specific rules to put into practice in the home-environment.
214483846|NCT06754527|BEHAVIORAL|ON-TRAC|Online tablet-based intervention that teaches youth emotion regulation skills and integrates substance use prevention content
214483847|NCT06751628|DEVICE|Insides system|The miniaturization of the pump proposed by Insides System enables the patient to perform CR independently and to carry the pump anywhere, thus facilitating outpatient implementation of CR.
214483848|NCT06758375|DRUG|Low-dose teclistamab|NDMM patients will receive VRd 3x cicles followed by low dose teclistamab.
214483849|NCT06758180|BEHAVIORAL|verbal basic life support training|"Both groups will be given verbal adult basic life support training simultaneously, on a day and time that will not conflict with the students' class schedules. The Adult Basic Life Support Training presentation published by the Ministry of Health in 2021 will be used in the training and will last approximately 40 minutes.~A week after the verbal training, a basic life support application for adults will be held in the Faculty of Medicine Skills Laboratory."
214483850|NCT06758180|BEHAVIORAL|Interactive game intervention|"The interactive game group will be given reinforcement training before the laboratory application. Here, each student will play the game accompanied by a researcher.~Lifesaver is an educational game developed by the Resuscitation Council (UK), offered in English and completely free of charge. The game can be downloaded to computers, phones or tablets from Google Play or the App Store. Lifesaver includes four different interactive video scenarios to help users develop their lifesaving skills. The Harry scenario to be used in this research is based on a real case. In the scenario, Harry, a high school student who has a sudden heart attack while playing football, is given heart massage, CPR and defibrillation by his friends.~The game offers different options at each stage to improve the players' knowledge and skill levels. If a wrong choice is made, the same section is played again until the correct step is performed. The completion time of the game may vary average 15 minutes."
214319142|NCT06244264|PROCEDURE|Autoblood transfusion|Through a negative pressure suction device, the patient's blood that flows out during surgery is collected into a blood storage filter. During the suction process, it is mixed with an appropriate anticoagulant and passed through multiple layers of filters. When the volume of recovered blood reaches a certain level, it is continuously (or intermittently) centrifuged. Using a high-speed centrifugal blood recovery tank, the red blood cells are separated, and the plasma, waste, cell fragments, anticoagulants, and harmful components are diverted into a waste bag. A large amount of saline is used to repeatedly wash, purify, and concentrate the red blood cells. Finally, the concentrated red blood cells are prepared into a 70% red blood cell suspension with saline and stored in a collection bag for transfusion back to the patients. Open surgery is considered as the standard procedure for metastatic spinal cord compression
214319143|NCT05129878|PROCEDURE|scaling and OHI|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive scaling and oral hygiene instructions
214319144|NCT05129878|PROCEDURE|oral Hygiene instructions|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive oral hygiene instructions only
214319145|NCT05129878|PROCEDURE|Scaling and oral hygiene instruction|Systemically Healthy (age and BMI matched) females with gingivitis will receive with OHI and Scaling
214483851|NCT06758180|BEHAVIORAL|video training|"One week after all students are given verbal adult basic life support training, a video titled Adult Basic Life Support will be shown to the students in the video training group before the laboratory application. The video will be shown by the researcher using a projector. After the video watching process is completed, each student will apply basic life support on the adult training model in turn and the applications will be evaluated individually. In the video training, the video titled Basic Life Support and AED Use - Adult (TYD), which was published as open access on the 'paramedic online' YouTube channel on May 31, 2023 and prepared in accordance with the 2021 ERC guideline, will be used (Paramedic online, 2023). This video covers the topics of heart massage, artificial respiration and automatic external defibrillator use within the scope of basic life support."
214483852|NCT06757101|OTHER|Vojta Therapy|Exercises will be performed in supine, lateral, decubitus and reflex crawling. Exercises will include Stretching's, ROMs Exercises, Stimulation of 10 different zones for locomotion \& gentle pressure applied to stimulation areas. Frequency of exercises will be 2 times a week, duration 40 minutes per day.
214483853|NCT06757101|OTHER|Bobath Therapy|Exercises will be performed in supine, lateral, prone and standing position. Exercises includes stretching Exercises, ROMs, Quadruped imbalance exercise, Imbalance from the kneeling exercise, Cervant Knight exercise, Tandem walk, Kicking a ball, Step climbing, marching at one place with alternate foot Frequency of exercises will be 2 times a week, duration 40 minutes per day.
214671911|NCT04084392|OTHER|Bridge Clinic|Referral to the Bridge Clinic for temporary outpatient addiction treatment while the bridge clinic identifies an outpatient addiction treatment provider to accept the patient for long term treatment.
214671912|NCT04084392|OTHER|Usual Care|Referral to an outpatient provider for addiction treatment.
214671913|NCT03419702|DIETARY_SUPPLEMENT|Almonds|During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
214919760|NCT00119717|DEVICE|NeuroFlo™ catheter|45 minute treatment
214919761|NCT00119717|OTHER|Control|ASA Guidelines
214919762|NCT05304416|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
214483854|NCT06757101|OTHER|Combined Vojta and Bobath Therapy|Combined Vojta and Bobath exercises along with the conventional treatment. Frequency of exercises will be 2 times a week, duration 40 minutes per day.
214483855|NCT04084496|DRUG|Folfirinox|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
214483856|NCT06570018|PROCEDURE|Post operative enhanced recovery elements|According to the study group the researchers collaborated with surgeons, nurses, and anesthesiologists to implement post operative enhanced recovery protocol that defined clearly in the following elements Early nutrition, Early mobilization, Non-opioid analgesia. Early removal of abdominal drains and tubes throughout the patients' hospital stay up to their discharge.
214319146|NCT04508842|BIOLOGICAL|CD19/CD22-Dual-STAR-T|Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
214319147|NCT04118309|BEHAVIORAL|Exercise|
214319148|NCT04118309|OTHER|Placebo|
214483857|NCT06753500|PROCEDURE|Autonomic neural blockade|"Autonomic nerve block performed with:~* Bupivacaine: 20 mL of 0.5%.~* Dexamethasone: 8 mg."
214483858|NCT06752200|DEVICE|Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.|Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.
214483859|NCT06752200|DEVICE|Occlusal splints fabricated using a combined digital workflow using a conventional bite technique|upper and lower arches will be scanned intraorally. The bite will be registered at centric by using rubber base bite registration material after patient deprogramming with Lucia jig. Then the bite will be scanned. The splint will be designed and printed in the same workflow as the intervention group.
214483860|NCT06809673|OTHER|blood sampling|"blood sampling at baseline, 1,3,6 months after surgery and eventually when recurrence is detected.~If adjuvant treatment is planned, blood sampling at baseline, 1 month after surgery, 1,3,6 months after the last fraction of RT and eventually when recurrence is detected."
214483861|NCT06773442|OTHER|Rehabilitation Practices Group|"Evidence-Based Training Program:Develop a structured training program for rehabilitation professionals focusing on evidence-based shoulder rehabilitation practices.~Clinical Mentorship and Supervision:Implement a mentorship program where experienced rehabilitation professionals provide guidance and support to junior staff members.~Standardization of Rehabilitation Protocols:Review and standardize rehabilitation protocols for common shoulder conditions based on current evidence and best practices.~Patient-Centered Care Approach:Adopt a patient-centered approach to shoulder rehabilitation, emphasizing shared decision-making and individualized treatment plans Outcome Monitoring and Quality Improvement:Use standardized outcome measures to evaluate improvements in pain, function, range of motion, and patient satisfaction."
214483862|NCT06773442|OTHER|Documentation Protocols Group|"Training and Education Program:Develop and implement a training program for rehabilitation professionals aimed at enhancing their knowledge and skills in shoulder rehabilitation practices and documentation protocols.~Standardization of Protocols:Review and update existing rehabilitation protocols to ensure alignment with current evidence-based guidelines and best practices.~Quality Assurance Measures:Establish a system for ongoing monitoring and evaluation of shoulder rehabilitation practices and documentation protocols.~Patient Education and Engagement:Develop educational materials and resources for patients undergoing shoulder rehabilitation to enhance their understanding of treatment goals, exercises, and self-management strategies.~Outcome Monitoring and Evaluation:Implement a system for monitoring and evaluating patient outcomes, including pain levels, range of motion, functional status, and satisfaction with rehabilitation services."
215061434|NCT05600361|DRUG|hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
214483863|NCT06672068|DRUG|TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin|TY-9591 80mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
214483864|NCT06672068|DRUG|TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin|TY-9591 160mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
215061435|NCT02284256|DRUG|Fibrocaps|
215061436|NCT02284256|DRUG|TachoSil|
214319149|NCT01139333|GENETIC|gene expression analysis|
214319150|NCT01139333|GENETIC|western blotting|
214319151|NCT01139333|OTHER|flow cytometry|
214319152|NCT01139333|OTHER|laboratory biomarker analysis|
214319153|NCT06040021|OTHER|standardized treatment|Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
214319154|NCT02445495|DEVICE|GenesisPlus 1064 nm Nd:YAG laser|Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis
214319155|NCT05904457|DRUG|bevacizumab|Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.
214319156|NCT05904457|DRUG|erlotinib|Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.
214319157|NCT02653742|DRUG|Ketorolac|Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
214319158|NCT02653742|DRUG|Fentanyl|Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
214319159|NCT03738943|DRUG|Adenosine Triphosphate|See arm/group descriptions
214319160|NCT03738943|DRUG|Acetylcholine|See arm/group descriptions
214319161|NCT03738943|DRUG|Sodium Nitroprusside|See arm/group descriptions
214319162|NCT03738943|DRUG|Adenosine Diphosphate|See arm/group descriptions
214319163|NCT03738943|DRUG|Adenosine Monophosphate|See arm/group descriptions
214319164|NCT03738943|DRUG|Uridine Triphosphate|See arm/group descriptions
214319165|NCT03738943|DRUG|Adenosine|See arm/group descriptions
214319166|NCT03738943|DRUG|Vitamin B 6|See arm/group descriptions
214319167|NCT03738943|DRUG|Pyridoxal 5'-Phosphate|See arm/group descriptions
214319168|NCT06148922|OTHER|Brief Mental Health First Aid Workshop|a 2-hour workshop delivered by a registered nurse with a MHFA training certificate
214319169|NCT06148922|OTHER|Semi-structured interviews|One-to-one, face-to-face semi-structured interviews will be conducted by a research assistant. The duration would be around 30 minutes.
214319170|NCT06497049|DRUG|GP40221|Solution for Subcutaneous Administration 1.34 mg/ml
214319171|NCT06497049|DRUG|ozempic|Solution for Subcutaneous Administration 1.34 mg/ml
214319172|NCT06104501|DEVICE|RadiHeart|The participants' blood pressure will be measured multiple times by both the mercury sphygmomanometer and RadiHeart, by using the same arm sequential method.
214319173|NCT04813796|BIOLOGICAL|mRNA-1283|Sterile liquid for injection
214319174|NCT04813796|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214319175|NCT04813796|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214319176|NCT01020058|PROCEDURE|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
214319177|NCT05134207|DIETARY_SUPPLEMENT|oral carbohydrate solution|Patients in the intervention group; Preop oral carbohydrate solution was ingested orally twice within 10 minutes, as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the surgery.
214319178|NCT02259309|DRUG|Misoprostol - buccal|buccal administration
214319179|NCT02259309|DRUG|Misoprostol - vaginal|vaginal administration
214319180|NCT02232581|DRUG|Alovudine - low|
214319181|NCT02232581|DRUG|Alovudine - medium|
214319182|NCT02232581|DRUG|Alovudine - high|
214319183|NCT02232581|DRUG|Placebo|
214319184|NCT03258827|PROCEDURE|Exercise with a towel|Exercise program composes with warm-up, strengthening exercise, cold-down, 60 minutes/time, 3 times/week. A towel is an important tool for exercise. Total duration of the program is 3 months.
214319185|NCT03258827|PROCEDURE|Home-based exercise|Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times. The total duration is 3 months.
214319186|NCT04366167|OTHER|Cardiac surgery|Cardiac surgery during the COVID-19 pandemic
214319187|NCT05606042|DEVICE|IM Implant|Patients that have had surgical interventions with one or more IM Implant as part of standard of care for a pelvic and/or acetabular fracture
214319188|NCT03337282|PROCEDURE|Protocolized general anesthesia|Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
214319189|NCT05041933|DRUG|outsourcing of chemotherapy to Hospital at Home|outsourcing of chemotherapy to Hospital at Home
214319190|NCT03214627|DEVICE|Anemia Control Model (ACM)|The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
214319191|NCT03214627|DRUG|IV iron|IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
214319192|NCT03214627|DRUG|Erythropoiesis-Stimulating Agent (ESA)|ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
214319193|NCT04925011|DRUG|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
214319194|NCT05420558|DIAGNOSTIC_TEST|Fibroblast activation protein inhibitor PET/CT imaging|All participants will receive a 68Ga-labelled fibroblast activation protein inhibitor PET/CT imaging
214319195|NCT03533387|DRUG|MN-166|an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
214319196|NCT04605328|OTHER|Two dimension and three dimension ultrasound|Patient will undergo 2D and 3D ultrasound evaluation after CS for detection of CSD
214319197|NCT01010048|DRUG|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
214319198|NCT04338464|BEHAVIORAL|Psychosocial therapy for South Asian women experiencing mood disorders|"The 12 week intervention has four major components:~* Relational theory (Belgrave, 2002) \& South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~* Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek \& Ehrenriech-May, 2012; Ritschel, Noriel \& Lindsay, 2015).~* Psychoeducation on mental health, sexual health, and substance use.~* Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support."
214319199|NCT00370474|DEVICE|Bi-ventricular lead placement|
214319200|NCT02094001|RADIATION|Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
214319201|NCT03385252|OTHER|Eggs|Eggs provided as complementary food for the infant
214319202|NCT03385252|BEHAVIORAL|Visits|Twice weekly household visits by study staff
214319203|NCT03402438|DRUG|Fulacimstat (BAY1142524)|single oral dose of 25 mg immediate-release tablet BAY1142524
214319204|NCT03413059|DRUG|Morphine Sulfate|Thoracic Epidural morphine
214319205|NCT03413059|DRUG|Triamcinolone Acetonide|thoracic epidural triamcinolone acetonide
214319206|NCT03411876|DEVICE|Oxymizer® pendant nasal cannula|Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
214319207|NCT03411876|DEVICE|conventional nasal cannula|Supplemental oxygen is provided by a conventional nasal cannula.
214319208|NCT05145166|BIOLOGICAL|Safety group|All of the participants(N=10000) received one dose of live attenuated mumps vaccine.Vaccine will given by single intramuscular injection(0.5 ml) on day 0.
214319209|NCT02529384|OTHER|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
214319210|NCT02752932|OTHER|Drug testing on PDX per Investigator's choice (upto 4)|Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
214319211|NCT06058195|PROCEDURE|Quadratus lumborum plane block|QLB (quadratus lumborum plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
214319212|NCT06058195|PROCEDURE|Transverse abdominis plane block|TAPB (transverse abdominis plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
214319213|NCT06058195|PROCEDURE|Intravenous analgesia|IVA (Intravenous analgesia): These patients will be administered 1000 mg paracetamol intravenously in the preoperative waiting room in the operating room approximately 20-30 minutes before induction of anaesthesia. No block procedure will be performed. Patients will not be given any analgesic medication before awakening from anaesthesia.
214319214|NCT02273219|DRUG|AEB071|Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
214319215|NCT02273219|DRUG|BYL719|Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
214319216|NCT04908670|BEHAVIORAL|Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI|Watching pain neuroscience education video
214319217|NCT04908670|PROCEDURE|PA manipulation|Low grade PA manipulation on the cervical, thoracic and lumbar spine
214319218|NCT06357611|OTHER|Simulated technique|"The participant was in a supine position, with her upper limbs at her sides and her neck in a neutral position.~The researcher sat in a cephalic position, making contact with the participant's shoulders, without any movement, until 5 minutes had elapsed."
214319219|NCT06357611|OTHER|Muscle energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~The researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. He then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively until the motor barrier was reached, and instructed her to perform an isometric contraction of the hamstrings. She was asked to perform three 7-second contractions with a 2 to 3-second interval, using approximately 20% of her maximum strength, gaining a new motor barrier between each set, for a total of three sets."
214319220|NCT06357611|OTHER|4th ventricle technique and muscular energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~For CV-4, the researcher contacted the squamous portion of the occiput laterally, bringing it close to the posterior convexity of the occiput, bringing the skull into extension, changing the compression movement with decompression, until 3 minutes had elapsed.~For the MET, the researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. She then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively to the motor barrier, having been instructed to perform an isometric contraction of the hamstring. A total of 3 7-second contractions with a 2-3 second interval were requested, using approximately 20% of her maximum strength, and with a new motor barrier being gained between each series, for a total of 3 series."
214319221|NCT02265822|DRUG|melatonin in children premedication|
214319222|NCT02265822|DRUG|midazolam in children premedication|
214319223|NCT02110316|OTHER|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
214319224|NCT01251588|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
214319225|NCT01251588|PROCEDURE|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
214319226|NCT00006211|DRUG|Capravirine|
214319227|NCT00006211|DRUG|Nelfinavir mesylate|
214319228|NCT00089570|DRUG|terlipressin|
214319229|NCT00089570|DRUG|Placebo|
214319230|NCT01581632|DEVICE|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
214319231|NCT01274403|DRUG|Melphalan, Prednisone and Thalidomide|
214319232|NCT03350503|DEVICE|AcrySof IQ Toric A-code IOL|Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
214319233|NCT03350503|PROCEDURE|Cataract surgery|Removal of cataractous lens and implantation of IOL
214319234|NCT01750580|DRUG|Lirilumab|
214319235|NCT01750580|DRUG|Ipilimumab|
214319236|NCT05240846|PROCEDURE|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
214319237|NCT05240846|PROCEDURE|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on ultrasound assistance paramedian spinal. Spinal anesthesia with a paramedian approach was performed based on the optimum puncture point, suggested puncture angles, and puncture depth. The suggested puncture angles included the cephalad angle measured by the built-in angle program of the ultrasound and the medial angle measured by a 180° protractor (Deli). The puncture depth, the distance from the skin to the posterior complex, was measured utilizing the ultrasound clipper tool.
214319238|NCT00098111|DRUG|azathioprine|
214319239|NCT04752501|OTHER|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
214319240|NCT04752501|OTHER|Biomedical Education (Control)|This arm will provide education of basic knee anatomy, lower extremity mechanics, and simple exercises and will not address maladaptive psychological behaviors
214319241|NCT02199405|OTHER|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
214319242|NCT02199405|OTHER|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
214319243|NCT02199405|OTHER|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
214319244|NCT02199405|OTHER|Cervical traction|
214319245|NCT01166828|BEHAVIORAL|TELLEPUPPS|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
214319246|NCT05687435|DRUG|Changyanning tablet|"Changyanning Tablet is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd，composed of Euphorbia humifusa, golden ear grass, camphor tree root, Elsholtzia splendens and maple leaves. It is mainly used for the treatment of acute and chronic intestinal diseases caused by various reasons.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
214319247|NCT05687435|OTHER|Changyanning tablet placebo|"Changyanning Tablet placebo is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd. Changyanning Tablet placebo has the same appearance, smell, taste, specifications and packaging with Changyanning Tablet, but does not contain active pharmaceutical ingredients.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
214319248|NCT04492891|DRUG|Cyclosporine|2.5 mg/kg PO BID 7 days
214319249|NCT04492891|OTHER|Standard of Care Treatment|Standard of Care Treatment, N= 25 Patients, 7 days
214319250|NCT04953533|OTHER|no intervention|
214319251|NCT06071455|OTHER|Platelet-rich fibrin|injected distal to the canine on the experimental side.
214319252|NCT06071455|OTHER|Vitamin D3|injected distal to the canine on the experimental side.
214319253|NCT02986620|GENETIC|IDH mutation test performed at diagnosis or relapse until January 31st, 2019.|Observation of the test result.
214319254|NCT05625763|DIAGNOSTIC_TEST|sonoclot signature analysis|Investigate the value of global hemostasis studies (Sonoclot signature analysis) in cases of pre-eclampsia and if there a correlation between it and the specific traditional assays of hemostasis.
214319255|NCT05595317|DEVICE|Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. In the non-immersive virtual reality application, Microsoft Kinect Xbox 360 Adventures games will be applied at the light level exercise level under the supervision of a physiotherapist. The participant will play a game in which he stands in a standing boat in a boat going on a flowing river and has to overcome obstacles by jumping, crouching and stepping left and right (River rush game).
214319256|NCT05595317|DEVICE|Sham Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. As a sham application, the participants will sit in a chair in front of the screen and try to prevent the balls sent from the opposite direction by using their upper extremities while their bodies are fixed with the help of a belt, under the supervision of a physiotherapist (Rally ball game).
214319257|NCT03420703|OTHER|erector spinae plane block|ultrasound guided erector spinae plane block will be administered to this group.
214483865|NCT06792513|DEVICE|Clear Aligner|In this intervention, clear aligners were digitally designed using three-dimensional models for the upper jaw. Attachments were applied to the patients, specifically placed on the incisors exhibiting a crossbite relationship and on the permanent first molars in the posterior region. The series of clear aligners were replaced every 10 days. The aligners were used full-time, except during meals and tooth brushing.
214483866|NCT06792513|DEVICE|Labiolingual Spring Hawley Appliance|In this intervention, a custom-made labiolingual spring Hawley appliance was designed for the upper jaw. It included two Adams clasps, a vestibular arch, and an active labiolingual spring positioned on the palatal side of the incisor in crossbite. The spring was activated every 10 days. The appliance was used full-time, except during meals and tooth brushing.
214319258|NCT03420703|DEVICE|Intravenous morphine patient controlled analgesia device|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
214319259|NCT04915404|DRUG|Berubicin Hydrochloride|Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
214319260|NCT00344773|DRUG|Gefitinib|250mg tablet oral tablet once daily
214319261|NCT00684853|DRUG|bevacizumab|1.25 mg of bevacizumab intravitreal
214319262|NCT00684853|DRUG|vetaporfin|full fluence of vetaporfin
214319263|NCT02152410|DEVICE|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
214319264|NCT02152410|DRUG|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS\> 30).
214319265|NCT02299531|OTHER|Varying meal energy density and portion size|
214319266|NCT03672695|COMBINATION_PRODUCT|S 64315 (also referred as MIK665) and venetoclax|"The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy."
214319267|NCT02766244|DEVICE|ICG/SPY|indocyanine green fluorescence imaging
214319268|NCT02766244|DRUG|Antibiotic Ointment|Antibiotic ointment
214319269|NCT00347724|DRUG|Tramadol HCl ER|
214319270|NCT06125821|OTHER|questionnaire|questionnaire
214319271|NCT02510911|DRUG|Caffeine (100 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
214319272|NCT02510911|DRUG|Caffeine (200 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
214319273|NCT02510911|DRUG|corn starch (250 mg approx.)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
214319274|NCT02510911|OTHER|Radiopaque marker|"On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%)."
214319275|NCT02141074|DRUG|nonacog beta pegol|For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
214319276|NCT01194206|RADIATION|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
214319277|NCT06848686|BEHAVIORAL|Prevention Ambassadors|Delivery of prevention supplies and information on local services plus training to build the capacity of PWUD to distribute HIV self-testing (HIVST) kits with information and referrals to other PWUD in their social networks to promote HIV testing and HIV service engagement among PWUD.
214319278|NCT06848686|BEHAVIORAL|SSP Standard of Care|Delivery of prevention supplies and information on local services.
214319279|NCT05844163|OTHER|observation|observation
214483867|NCT04997525|DRUG|Estradiol Tablets|Combined with progesterone
214483868|NCT04997525|DRUG|Progesterone|Combined with estradiol
214319280|NCT05942326|BEHAVIORAL|Sleep GOALS|Web-based interventions
214319281|NCT05942326|BEHAVIORAL|Education|Brochures from the American Academy of Sleep Medicine (e.g., sleep hygiene, sleep in women) and SNAP education connection (e.g., family-friendly activities, meal planning)
214319282|NCT05756972|DRUG|PM8002|IV infusion
214319283|NCT05756972|DRUG|Carboplatin|IV infusion
214319284|NCT05756972|DRUG|Pemetrexed|IV infusion
214483869|NCT04997525|DRUG|Follitropin Alfa|Combined with hCG
214483870|NCT04997525|DRUG|Chorionic Gonadotropin, Alpha|In either natural cycle or combined with Follitropin Alfa
214483871|NCT06858020|PROCEDURE|Prophylactic polypropylene onlay mesh|The patients in the mesh group are closed with small bites technique and in addition receiving an onlay polypropylene mesh when closing the fascia in midline laparotomies.
214483872|NCT06855784|BEHAVIORAL|Time-Restricted Eating 16h/8h|Participants will be advised to eat only during a self-selected window of 8 hours over the 24-hour cycle, with a 1-hour allowance according to their daily routine.
214483873|NCT06855784|BEHAVIORAL|Active Control|Participants will be advised to eat 2 to 3 meals every day according to their eating habits and social activities
214483874|NCT05155943|DEVICE|KALPA X™|Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver. 1.0.229-0 Source control ID: 65f1dbf7) in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
214483875|NCT06769217|DEVICE|Drug Eluting Coronary Stent|The Drug Eluting Coronary stent is indicated for the treatment of de novo coronary artery lesions in patients with symptomatic ischemic heart disease.
214319285|NCT05007561|DRUG|Naltrexone Hydrochloride|oral naltrexone
214319286|NCT05007561|DRUG|Placebo|oral sugar pill
214319287|NCT05028205|BEHAVIORAL|Prevention Plus|Families will receive a behavioral intervention for childhood obesity provided by a BHC. This will consist of three, in-person meetings (months 1, 3, and 5), and three, 20-minute phone calls (months 2,4, and 6). During in-person visits, child height and weight will be taken, and BMI will be plotted on the BMI-for-age growth chart. During these sessions, families will receive feedback on child growth and weight status. Prevention Plus materials and child and caregiver energy balance behavior goals will be reviewed. The phone calls will be with the caregiver, where caregivers will be asked to measure the height and weight of their child, calculate BMI, and plot on the BMI-for-age growth chart. The BHC will discuss the family's progress on achieving child and caregiver goals and implementation of behavioral parenting strategies. Families will receive a fruit and vegetable prescription (FVx) in addition to the standard Prevention Plus family-based behavioral weight loss treatment.
214483876|NCT06858657|DRUG|HSK44459|Dose 1 to Dose 5
214483877|NCT06858657|DRUG|placebo|dose 1 to dose 5
214483878|NCT06861569|PROCEDURE|Positive end expiratory pressure|Positive end-expiratory pressure (PEEP) is a value that can be set up in patients receiving invasive or non-invasive mechanical ventilation. 5cmH2O PEEP will be applied to the PEEP group participants.
214483879|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month pre-intervention visit
215061437|NCT01279811|OTHER|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
214319288|NCT03133650|DRUG|WST 11-mediated VTP therapy|Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
214319289|NCT01232101|DEVICE|covered or uncovered stents|Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
214319290|NCT05669508|DEVICE|RISES-T System|Non-invasive closed-loop electrical stimulation of the spinal cord through the skin
214319291|NCT05669508|OTHER|Occupational/Physical Therapy|Exercise therapy to improve function of upper and/or lower limbs
214319292|NCT06591429|RADIATION|Radiotracer [11C]-CS1P1|Radiotracer used in PET/CT scans of the head and neck Dose range: 12-17 mCi
214319293|NCT06591429|RADIATION|Radiotracer [11C]-DPA-713|Radiotracer used in PET/CT scans of the head and neck Dose range:15-20 mCi
214319294|NCT06591429|DRUG|anti-CD20 MS treatment|MS treatment taken indepenently after initial testing
214319295|NCT06591429|RADIATION|Radiotracer [12F]-FDG|used in PET/CT scans of the head and neck Dose: 5-7 mCi
214319296|NCT06589440|DRUG|SR-8541A|SR-8541A administered orally in combination with intravenous botensilimab and balstilimab
214319297|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Adductor Canal Block|0.25% 15-20ml bupivacaine (local anesthestic) delivered as part of the adductor canal block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the adductor canal block
214319298|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block|10 ml of 0.25% bupivacaine (local anesthetic) delivered as part of the anterior femoral cutaneous nerve block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the anterior femoral cutaneous nerve block
214319299|NCT06809049|BEHAVIORAL|Dalcroze music education|Dalcroze is a type of music education which focuses on free and improvised movement, as well as structure and choreographed sequences. It has been successfully applied to similar populations as an effective, accessible, and sustainable intervention. We hope to use Dalcroze music education to employ a holistic approach to improve the brain-heart symptoms of children with congenital DM1.
214319300|NCT05938790|OTHER|Continuous Fetal Monitoring|Fetal doppler used to monitor fetal heart rate in triage
214319301|NCT05938790|OTHER|Point of Care Handheld Ultrasound|Point of Care Handheld Ultrasound
214319302|NCT01719887|DEVICE|Conservative treatment|Conservative treatment with functional brace.
214319303|NCT01719887|PROCEDURE|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
214319304|NCT01719887|OTHER|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
214319305|NCT05965349|BEHAVIORAL|Healthy Mind, Healthy Living|A telephone, 8-week MBCT workshop series including: (1) learning mindfulness skills; (2) practicing mindfulness skills in class and at home; and (3) dialogue and inquiry.
214319306|NCT04814225|OTHER|Test Product 1|Pea Protein powder
214319307|NCT04814225|OTHER|Test Product 2|Pea \& Oat Protein Powder
214319308|NCT04814225|OTHER|Test Product 3|Oat Protein Powder
214483880|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month post-intervention visit
214319309|NCT04814225|OTHER|Comparator|Whey Protein Isolate
214483881|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 3-months post-intervention visit
214483882|NCT06857149|OTHER|Human milk|"In accordance with the physiology of breastfeeding, mothers will be asked to milk and deliver their milk to the ICU once every 3 hours. The mother will be asked to completely empty her breast with a milking machine. Before milking, the mother will wash her hands, and the parts of the milking machine that come into contact with the milk will also be boiled and disinfected after it is provided to be used. The mother will put the milk she has milked into a milking bag and deliver it to the researcher by writing the date and time on it. Feeding will be initiated by the neonatal specialist with the determination that the newborn is stable. During the period when mothers' babies are in the neonatal intensive care unit, the feeding of the babies in the circadian rhythm group will be carried out taking into account the date and day/night practice.~The milk that the mother expresses at night will be given to her baby at night, and the milk that she expresses during the day will be used for dayt"
215061438|NCT01995500|DEVICE|BioNIR|drug-eluting stent
215061439|NCT01995500|DEVICE|Resolute|drug-eluting stent
215061440|NCT04071431|OTHER|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
214319310|NCT00368264|DRUG|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
214319311|NCT00368264|DRUG|placebo|azathioprine (2 mg/kg) plus four placebo infusions
214319312|NCT06045091|DRUG|Human BCMA targeted CAR-NK cells injection|Allogenic genetically modified anti-BCMA CAR transduced NK cells
214319313|NCT00975533|DEVICE|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
214319314|NCT00975533|DRUG|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
214319315|NCT06660238|OTHER|No interventions|No interventions
214319316|NCT06923956|DRUG|Bempedoic Acid Film Coated Tablet|1 tablet of 180 mg Bempedoic Acid
214319317|NCT06923956|DRUG|Nilemdo® (Bempedoic Acid) Film-coated tablets|1 tablet of 180 mg Bempedoic Acid
214483883|NCT06857149|OTHER|Control Group|"The application in the control group is similar to the application in the cycadian rhythm group (mother's milking technique, collection method, storage and appropriate transportation, etc.) instead of the milk expressed first is given first condition used in routine practice, without taking into account the day and night characteristics of the expressed breast milk. will be brought. The routine practice of the clinic will continue. In line with the practice of the Turkish Neonatology Association (2018) and the clinic, the information of babies given breast milk fortifiers in the expressed breast milk of enterally fed babies will be recorded. In order to ensure that the data is collected safely and to facilitate monitoring, it will be recorded in the Breastfeeding Follow-up Form, as in every feeding intervention group. The monitoring of babies is the same as in the circadian rhythm group. For the first month, the baby's weight and height will be measured and recorded twice a week."
214483884|NCT06887946|OTHER|Medical couching and traditional|"The control group received traditional OHI using the tell-show-do method, which was personalized based on the individual PCR and GBI. The recommendations were tailored to each participant, based on personalized instructions to improve plaque control, decrease of gingival inflammation and facilitate optimal patient compliance, contributing to oral hygiene performance.~The intervention group was actively engaged in an iterative, collaborative process, based on the following steps:~Definition of the goals of oral hygiene and lifestyle styles according to the SMART model (Specific, Measurable, Achievable, Realistic, Timely):"
214483885|NCT06750510|BEHAVIORAL|Digitally Delivered Parent Training|The intervention is a universal, digitally delivered parenting program, including 5 themes with recommended length of 1 week each. The total length of the intervention is 8 weeks. The program focuses on positive parenting, encouraging to develop parenting skills that strengthen their relationships and communication with their children.
214483886|NCT06749639|GENETIC|PUMCH-E101 Injection（Low dose）|Single intravitreal injection
214483887|NCT06749639|GENETIC|PUMCH-E101 Injection（High dose）|Single intravitreal injection
214483888|NCT06753682|BEHAVIORAL|Healthy Plant Based Diet|Registered Dietician will assist in modifying the patient's diet
214483889|NCT06753630|BEHAVIORAL|Extensor Muscle Strengthening Exercise|A series of exercises aimed at strengthening the extensor muscles of the forearm to alleviate symptoms of lateral epicondylitis.
214483890|NCT06753630|PROCEDURE|Extracorporeal Shockwave Therapy|A non-invasive procedure that uses shockwaves to promote healing and reduce pain in the affected area.
214483891|NCT06753630|DRUG|Saline injection (Octreotide LAR placebo)|A 3mL injection of saline solution used as a placebo in the study.
214483892|NCT06753630|DRUG|Polydeoxyribonucleotide Injection|A 3mL injection of polydeoxyribonucleotide (5.625mg/3mL) used to enhance the healing process and improve outcomes in lateral epicondylitis treatment.
214483894|NCT06752057|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
214483895|NCT06752057|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
214483896|NCT06752057|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
214483897|NCT06869681|DRUG|Topical Sertaconazole 2%|After cleaning the identified lesions, the patients will topically self-apply the both products/creams using a cotton swab applicator, where the applied amount will be able to make the lesions be covered with a thin layer of medication. Both the creams will be applied topically twice daily for 4 weeks.
214483898|NCT06869681|DRUG|Clotrimazole 1%|Same as above
214483899|NCT06875375|DIETARY_SUPPLEMENT|probiotic LH76|Intervention with LH76 (30 billion CFU/ day, 3g) was administered daily for 8 weeks. Store in a cool, dry place.
214483900|NCT06875375|DIETARY_SUPPLEMENT|Placebo|Every day to give 3 g maltodextrin intervention for 8 weeks. Store in a cool and dry place.
214483901|NCT06763965|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.
214483902|NCT04750551|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
214483903|NCT04750551|DEVICE|EStim|EStim will applied for 10 to 20 minutes.
214919763|NCT05304416|DIAGNOSTIC_TEST|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like a moving x-ray of the participant swallowing foods and liquids (barium).
215061441|NCT04508933|DEVICE|Extravascular Lung Water Index|Measurement of the EVLWI
215061442|NCT04508933|DEVICE|Pulmonary Vascular Permeability Index|Measurement of the PVPI
215061443|NCT01301287|DRUG|Chlorella|
215061444|NCT05777668|RADIATION|Volumetric modulated radiotherapy|
214319318|NCT06108349|DRUG|Cannabidiol|Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa that is emerging as a treatment to mitigate pain, numbness, and tingling associated with peripheral neuropathy. CBD acts through multiple receptors to modulate central and peripheral neuropathic signaling pathways to alleviate pain.
214319319|NCT04909632|DIAGNOSTIC_TEST|Liquid chromatography-mass spectrometry (LC-MS) analysis|The data were acquired by UNIFI software (Waters) and processed by UNIFI and Progenesis QI software. Omics analysis methods, such as principal component analysis (PCA), partial least squares-discriminate analysis (PLS-DA), and orthogonal partial least squares-discriminate analysis (OPLS-DA), were employed to identify the biochemical patterns in tongue coating samples and suggest variables that can be used as biomarkers for diabetes and pre-diabetes.
214319320|NCT06412978|PROCEDURE|absorbable subcuticular polyglycolic acid staples (INSORB)|Insorb absorbable staples are used for skin closure
214319321|NCT06412978|PROCEDURE|subcuticular, polyglecaprone suture (Monocryl)|Monocryl absorbable staples are used for skin closure
214319322|NCT06867913|DIETARY_SUPPLEMENT|Supplement groupx|"Selenomethionine (e.g., 100 µg/day)~* Myo-inositol (e.g., 600 mg/day or higher)~* Patients on levothyroxine will maintain their current dose (if clinically indicated)."
214319323|NCT06867913|DIETARY_SUPPLEMENT|Supplement groupx|"Selenomethionine (e.g., 100 µg/day)~* Myo-inositol (e.g., 600 mg/day or higher)~* Patients on levothyroxine will maintain their current dose (if clinically indicated)."
214319324|NCT06865885|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|The intervention arm will receive subcutaneous injection of inclisiran 284mg at the baseline visit, 3 months and 9 month visit.
214319325|NCT05886296|BEHAVIORAL|Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process.|To evaluate the effect of the implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution of functionality, quality of life, empowerment and self-efficacy in the three months of the surgical intervention.
214319326|NCT06872697|OTHER|whole body vibration|In the group receiving whole-body vibration in addition to conventional treatment, the whole-body vibration will be performed with the patient's hips and knees in approximately 20° flexion, and the bed inclined to 25-30°. The vibration platform will be fixed at the end of the bed, and the patients will apply pressure with their feet on the platform. The whole-body vibration will be administered for 3 minutes, 1-4 sets, at a frequency of 20-25 Hz, 5 days a week, for 4 weeks, depending on the protocol, in addition to conventional physiotherapy.
214319327|NCT06872697|DEVICE|Neuromuscular Electrical Stimulation|In this group, neuromuscular electrical stimulation (NMES) will be applied to the targeted muscle groups. The application will be carried out with the patient in a comfortable seated or lying position. Stimulation parameters will be set as follows: a frequency of 35-50 Hz, a pulse duration of 200-400 microseconds, and an intensity adjusted to elicit visible muscle contractions without causing discomfort. NMES will be applied for 20-30 minutes per session, 3-5 times a week, for 4-6 weeks, depending on the protocol, in addition to conventional physiotherapy.
214319328|NCT06872697|OTHER|Conventional Physiotherapy|The conventional treatment program will include normal range of motion, airway clearance techniques, breathing exercises, and mobilization.
214319329|NCT04813159|DEVICE|Remote Ischaemic Conditioning (RIC)|The RIC protocol will comprise inflation of the automated RIC device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
214319330|NCT04813159|DEVICE|Sham-control|The sham protocol will comprise low-pressure inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff used in the active arm. The sham control protocol will be repeated daily for the next 2 days.
214319331|NCT04305951|PROCEDURE|Comprehensive acupuncture therapy (CAT)|"CAT will be conducted for 2 sessions per week for 12 consecutive weeks.~The following 14 body acupoints with only manual stimulation will be used: HT7 (Shenmen), LI4 (Hegu), TH5 (Waiguan), ST36 (Zusanli), ST40 (Fenglong) and SP6 (Sanyinjiao) in two sides, and CV12 (Zhongwan) and CV4 (Guanyuan) in midline. Electrical stimulation will be conducted on the following frontal acupoints: GV20 (Baihui), EX-HN3 (Yintang), GB15 (Toulinqi), GB8 (Shuaigu), EX-HN5 (Taiyang), and ST8 (Touwei) on two sides, and left and right EX-HN1 (Sishencong).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation is additionally delivered on the 6 pairs of the frontal acupoints. Each session of treatment will last 30 minutes."
214319332|NCT04305951|PROCEDURE|Comfy Acupressure for the Elderly (CAE)|"CAE intervention will be conducted for 3 times per week for 12 consecutive weeks.~CAE consists of 12 steps which need about 15 minutes to complete and mainly concentrates on the acupoints on face, head, neck, and shoulder. The detailed CAE Operation Guide will be provided for the provider and the video demonstration is accessible at https://www.youtube.com/watch?v=pAqNIZPKmnM."
214319333|NCT06816940|OTHER|CONTROL GROUP:|will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated before any intervention is carried out
214319334|NCT06816940|OTHER|EXPERIMENTAL GROUP|will be provided therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks, and rurgery was also performed using the dry needlig
214483904|NCT06734221|DEVICE|Paclitaxel Coated Peripheral Angioplasty Balloon Catheter|"Paclitaxel coated peripheral angioplasty balloon catheters are catheters of over the wire (OTW) type. Distal part of the catheter consists of two channels. External channel is used for inflating the balloon, and internal channel is the guide wire. Catheter has two markers enabling precise determination of balloon position in the vessel. The balloon is covered with a coating POLIGRADE® and drug paclitaxel an amount to 2.5 µg/mm2 , which is eluting during balloon inflation. Paclitaxel belongs to alkaloids group from taxanes group. It is cytostatic and it inhibits the cell cycle in G2/M phase. By inhibiting division of cells and their migration, paclitaxel allows for limiting restenosis phenomenon. Paclitaxel selectively inhibits smooth myocytes proliferation, while the endothelium cells show higher resistance to its action. In addition, paclitaxel restricts inflammatory conditions in walls of the arteries after balloon angioplasty."
214319335|NCT05724134|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
214319336|NCT05724134|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
214919764|NCT05304416|DIAGNOSTIC_TEST|Videofluoroscopy instrumental swallowing exam (VFSS)|This is like a moving x-ray of the participant swallowing foods and liquids (barium).
214483905|NCT06760429|PROCEDURE|Pectoral Nerve Block Type II|In the PECS II group,once the needle tip reached the fascial plane between the pectoralis minor and serratus anterior muscles and there was no blood aspiration, 15 mL of 0.375% ropivacaine was injected. Then the needle was withdrawn until the needle tip reached the fascial plane between the pectoralis major and pectoralis minor muscles, and another 15 mL of 0.375% ropivacaine was injected. After the nerve block was implemented, the area of sensory block was marked, and the spread of the local anesthetic was monitored by ultrasound. Alcohol swabs and pinprick tests were used to detect cold and pain sensations.
214483906|NCT06760429|PROCEDURE|Subserratus Plane Block|In the RISS group,the linear ultrasound probe was placed in the sagittal plane at the level of the 5th to 6th thoracic vertebrae (T5-6), just medial to the scapula, to identify the trapezius, rhomboid major, and intercostal muscles. A 21-gauge puncture needle was inserted in a cranial-to-caudal direction into the plane between the rhomboid major and intercostal muscles. When there was no blood aspiration, 20 mL of 0.375% ropivacaine was injected. After that, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for performing the subserratus block at the level of the 8th to 9th thoracic vertebrae (T8-9). The puncture needle was advanced from the previous position, and when there was no blood aspiration again, an additional 20 mL of 0.375% ropivacaine was injected.
214483907|NCT06786793|DEVICE|Computer-aided detection (CADe)|Endo-Aid CADe system is an AI-assisted computer-aided lesion detection application on ENDO-AID hardware. It uses a complex algorithm created via a neural network developed and taught by Olympus. With this new app, the sophisticated machine learning system can alert the endoscopist in real-time when a suspicious lesion appears on the screen. The image from the vision processor is transferred to the CADe device. The computer application recognizes the shape of the polyps and marks their place on the monitor screen.
214483908|NCT06786702|PROCEDURE|Laparoscopic TAPP (Trans Abdominal Pre-Peritoneal) hernia repair: Round Ligament Preservation|Group 1 (Round Ligament Preservation): Patients will undergo laparoscopic TAPP surgery with the round ligament preserved. The preservation will be achieved using a longitudinal incision technique in the peritoneum.
214483909|NCT06786702|PROCEDURE|Laparoscopic TAPP (Trans Abdominal Pre-Peritoneal) hernia repair: Round Ligament Cutting|Group 2 (Round Ligament Cutting): Patients will undergo laparoscopic TAPP surgery with the round ligament cut close to the peritoneum using an energy device.
214319337|NCT05724134|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
214483910|NCT06788392|OTHER|reminiscence therapy|Reminiscence Therapy is a supportive care model that has been used in recent years and increases life comfort.
214483911|NCT03105336|BIOLOGICAL|axicabtagene ciloleucel|A single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered intravenously.
214483912|NCT03105336|DRUG|Cyclophosphamide|Administered intravenously
214483913|NCT03105336|DRUG|Fludarabine|Administered intravenously
214919765|NCT05304416|OTHER|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
214919766|NCT05304416|OTHER|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
214919767|NCT05304416|OTHER|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
214483914|NCT06872372|DRUG|N-Acetylcysteine (NAC) Treatment|Participants in this group received N-Acetylcysteine (NAC) at a dose of 140 mg/kg orally or via a nasogastric tube every 4 hours for the first 16 hours, followed by the same dose at intervals of 6-8 hours for a total of 3 days, alongside standard supportive care for acute liver failure.
214919768|NCT05304416|DIAGNOSTIC_TEST|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
214919769|NCT01338402|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
214919770|NCT01338402|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
214319338|NCT05724134|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
214319339|NCT05724134|OTHER|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
214319340|NCT05724134|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
214319341|NCT05724134|DIETARY_SUPPLEMENT|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp."
214319342|NCT05724134|DIETARY_SUPPLEMENT|CORE Bar|Energy bar used as a standardized snack on the day before the pancreatic clamp.
214919771|NCT01338402|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color
214919772|NCT00900159|DRUG|eszopiclone|3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
214919773|NCT00900159|DRUG|matching placebo|matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
214919774|NCT04229654|OTHER|Questionnaire|A written questionnaire was used to capture demographic data, obstetric history, knowledge, expectations, and perception of anomaly scans.
214319343|NCT05724134|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
214319344|NCT05724134|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
214319345|NCT06122246|BEHAVIORAL|Community Health Worker (CHW)|Participants will receive the additional support of a Community Health Worker (CHW).
214319346|NCT06122246|OTHER|Remote Blood Pressure (BP) Management Program (RBPM)|Participants will receive a medical model of remote BP management (RBPM).
214319347|NCT06878872|BEHAVIORAL|T1DAL Program|T1DAL is a 16-week behavioral program. Teens meet in virtual groups and individually with a health coach throughout the program. Teens learn healthy lifestyle behaviors specific to living with type 1 diabetes and get opportunities to connect with other teens who are living with type 1 diabetes.
214319348|NCT06881693|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|The Wellbeing Course for New and Expecting Parents (WCNEP) is an adaptation of the Wellbeing Course (developed and evaluated at Macquaire University, Australia) and the Wellbeing Course for New Moms (a Canadian adaptation of the Wellbeing Course for new moms). The WCNEP is a transdiagnostic ICBT intervention designed for perinatal parents experiencing depression and/or anxiety, and will be offered by the Online Therapy Unit, a unit providing routine care ICBT services in Canada. The WCNEP will be evaluated in phases; phase 1 will evaluate the course for birthing parents only and phase 2 will evaluate the course for birthing and non-birthing parents. Therapist support will be offered for 8 weeks, with the possibility to extend the support to 12 weeks. Therapists will spend \~15 minutes/week communicating with each client, via secure messages. Phone calls will only be made if there is a significant clinical issue requiring attention that the therapist feel cannot be addressed in messages.
214319349|NCT03216447|DRUG|Advagraf|Tacrolimus prolonged-release hard capsules (QD)
214319350|NCT03216447|DRUG|Prograf|Tacolimus capsules (q12h)
214319351|NCT06727344|OTHER|Blood Flow Restriction|Exercise with restriction of blood flow supply
214319352|NCT06727344|OTHER|Brace|Knee brace to restrict range of motion
214319353|NCT06886373|DRUG|Systane Complete|Systane COMPLETE is an artificial tears that contain nano-emulsion of mineral oil and phospholipids.
214319354|NCT06923709|DRUG|amiloride|5mg twice daily for 7 days
214319355|NCT06923709|DRUG|Placebo|1 tablet twice daily for 7 days
214319356|NCT06589505|DEVICE|Software as a Medical Device|The subject will undergo treatment using the Software as a Medical Device
214319357|NCT02940431|OTHER|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
214319358|NCT02940431|OTHER|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
214319359|NCT05109234|DRUG|Brivaracetam Film-coated tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses."
214319360|NCT05109234|DRUG|Brivaracetam oral solution|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses."
214319361|NCT05732506|DRUG|Edoxaban|There are not intervention.
214319362|NCT06760039|DRUG|R-CMOP Regimen|Rituximab intravenous drip, Cyclophosphamide intravenous drip, Liposomal Mitoxantrone intravenous drip, Vincristine intravenous drip, Prednisone orally
214319363|NCT06760039|DRUG|R-CHOP Regimen|Rituximab intravenous drip, Cyclophosphamide intravenous drip, Doxorubicinin intravenous drip, Vincristine intravenous drip, Prednisone orally
214319364|NCT06767228|BEHAVIORAL|Reformer Pilates|This intervention involves a structured reformer pilates program designed to enhance core endurance, posture, and body awareness. The program includes exercises such as Footwork Series, Pelvic Lift, Arm Circles, Leg Circles, Frog Series, Long Box Series, Short Box Series, Elephant, Knee Stretch Series, Stomach Massage, and Side Stretch. The program emphasizes progressive resistance, controlled movements, and professional supervision to ensure safety and effectiveness. Sessions are conducted twice weekly for six weeks.
214319365|NCT06900621|OTHER|ice water|Patients who apply SPTM are given a semifowler position with the head of the bed at least 45°, if there is no contraindication. The water temperature (5-9 °C) will be measured with a calibrated digital thermometer. After VAS scoring, patients are sprayed with 5 ml of ice water placed in spray cans every 30 minutes until all the water is used up in the mouth, tongue, palate, floor of the mouth, inside the right and left cheeks, depending on the group. A total of 5 rounds are made with 5 ml of water in one round (0.2 ml is sprayed on the tongue, palate, floor of the mouth, inside the right and left cheeks) and each round is planned to be completed in 1 minute and last at most 5 minutes. This application is applied to the intervention groups 5 times in total (30th min- 60th min- 90th min- 120th min- 150th min). The first oral intake of the patients is routinely started at the 180th minute.
214483915|NCT06872372|OTHER|Standard supportive care|Participants in this group received only standard supportive care for acute liver failure, without N-Acetylcysteine (NAC). Standard supportive care included measures to prevent hypoglycemia, administration of broad-spectrum antimicrobials, proton pump inhibitors, fluid and electrolyte balance maintenance, and supportive treatment for hepatic encephalopathy.
214483916|NCT06922214|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT ( 25 Gy single fractions at isodose 80%) on the area responsible of ventricular tachicardia
214919775|NCT02555787|DRUG|Tacrolimus|oral
214919776|NCT03443622|DRUG|SC-43 Oral Solution|SC-43 Oral Solution has drug substance of 1-\[4-chloro-3(trifluoromethyl)phenyl-3-\[3-(4-cyanophenoxy)\] urea, or SC-43. SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings. As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells. The anti-tumor activity of SC-43 was also investigated in a variety of xenograft tumor models. Administration of SC-43 provides the tumor-bearing animals survival benefits, including the reduction of tumor volume and prolonged lifespan. SC-43 has been proposed to be evaluated as an anticancer therapeutic in in subjects with refractory solid tumors in the phase I trial.
214319366|NCT06900621|OTHER|room temperature water|Patients who apply SPTM are given a semifowler position with the head of the bed at least 45°, if there is no contraindication. The water temperature (15-24 °C) will be measured with a calibrated digital thermometer. After VAS scoring, patients are sprayed with 5 ml of room temperature water placed in spray cans every 30 minutes until all the water is used up in the mouth, tongue, palate, floor of the mouth, inside the right and left cheeks, depending on the group. A total of 5 rounds are made with 5 ml of water in one round (0.2 ml is sprayed on the tongue, palate, floor of the mouth, inside the right and left cheeks) and each round is planned to be completed in 1 minute and last at most 5 minutes. This application is applied to the intervention groups 5 times in total (30th min- 60th min- 90th min- 120th min- 150th min). The first oral intake of the patients is routinely started at the 180th minute.
214319367|NCT04145778|OTHER|6-minute walk test|The 6-minute walk test is performed as part of routine practice for patients with BMDS to assess patients' overall endurance. In order to compare patients' global endurance with controls, this walking test will also be offered to 50 of the healthy subjects already recruited in the study.
214319368|NCT06877364|BIOLOGICAL|GcMAF|GcMAF is an immunomodulatory protein derived from vitamin D-binding protein via enzymatic deglycosylation. In this study, GcMAF will be administered (e.g., subcutaneously) once or twice-weekly for 12-16 weeks, followed by a 4-8-week observation period. The primary objectives include assessing clinical efficacy in chronic inflammatory conditions and confirming safety. GcMAF activates macrophages and dendritic cells, modulates M1/M2 profiles, and may reduce inflammatory markers such as CRP and ESR.
214319369|NCT06877364|OTHER|Placebo Injection (Saline)|Participants in the placebo arm will receive a visually matching injection of normal saline (placebo) on the same schedule as the GcMAF arm (e.g., once or twice-weekly for 12-16 weeks). This allows for double-blind comparison of safety and efficacy endpoints. The placebo is designed to be identical in appearance and administration route to maintain blinding for investigators and participants.
214319370|NCT06023394|DEVICE|Laryngeal Mask Airway|Laryngeal mask airway will be used as an airway device for Cohort A in the standard fashion.
214319371|NCT06023394|DEVICE|Endotracheal Tube Device|Endotracheal tube airway will be used as an airway device for Cohort B in the standard fashion.
214319372|NCT05023811|DRUG|[14C]RIST4271|\[14C\]RIST4271 oral solution
214319373|NCT06901778|BEHAVIORAL|DEAR weight management|"In the DEAR weight management model:~D (Diet) refers to dietary management, primarily based on a calorie-restricted balanced diet; E (Exercise) refers to exercise management, guided by the 10th edition of the ACSM Exercise Testing and Prescription Guidelines and the 2017 National Fitness Guidelines. Exercise prescriptions are tailored to the patient's daily activity levels (light, moderate, and vigorous) to match the corresponding intensity levels; A (Accompany) refers to peer education, which involves using peer education methods to provide health education for patients, build confidence, and alleviate anxiety; R (Refresh) refers to rejuvenation, which involves correcting unhealthy dietary and exercise habits and establishing good lifestyle practices."
214319374|NCT06901778|BEHAVIORAL|Standardized discharge care plan and follow-up schedule|Standardized discharge care plan and follow-up schedule providing patients and their families with professional and feasible pre-discharge education on disease-related knowledge, dietary and exercise recommendations, daily living advice, and psychological support to help patients establish healthy behaviors. Patients are provided with printed health education materials and a handbook on health and disease knowledge. A WeChat communication group is established to promptly answer patients' questions, encourage peer-to-peer experience sharing, and conduct regular telephone follow-ups and questionnaire surveys after discharge.
214483917|NCT06736002|OTHER|Vitamin D|Vitamin D
214483918|NCT06736002|OTHER|Placebo|Placebo oral solution
214483919|NCT06861309|DEVICE|ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS)|All study participants, regardless of arm, will receive a combine ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS) research exam with the Verasonics Vantage 256 (Verasonics, Inc, Kirkland, WA) every three weeks from their routine growth ultrasound until delivery.
214483920|NCT06760013|BEHAVIORAL|Su Jok Therapy|The researcher, who has a Su-Jok practitioner certificate, applied pressure for 1-2 minutes on the active point on the meridian (the area between the 3rd and 4th fingers pointing to the uterus) that provides energy flow in the palm in 20-minute periods, with the help of a diagnostic probe (diagnostic stick). The point will be determined. Once this point is detected, a massage will be performed on the point. The massage will be applied with a 10-minute rest period between each two periods.
214919777|NCT02580617|BIOLOGICAL|ALLO-ASC|Infusion for Crohn's disease
214919778|NCT01075256|DEVICE|5% calcium sodium phosphosilicate toothpaste|Low concentration calcium sodium phosphosilicate tubule occlusion agent
214919779|NCT01075256|DEVICE|7.5% calcium sodium phosphosilicate toothpaste|High concentration calcium sodium phosphosilicate tubule occlusion agent
214919780|NCT01075256|DEVICE|Placebo toothpaste|Placebo toothpaste
214919781|NCT00184132|PROCEDURE|Psychiatric intensive care unit in Norwegian home style|
215061445|NCT06285045|DRUG|Roujin Formula|48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
214483921|NCT06917950|DRUG|Roxadustat|Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Administered orally three times per week. Dosage will be initiated and adjusted according to prescribing guidelines for treating anemia associated with chronic kidney disease in patients on dialysis based on hemoglobin levels.
214483922|NCT06917950|DRUG|Conventional Anemia Management|Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron supplementation. Dosing and specific agents used are per standard clinical practice at the study site and adjusted based on hemoglobin levels and iron status according to prevailing guidelines.
214483923|NCT06817629|OTHER|Effects of ventilation with tidal volume adjusted on driving pressure on ventilation/perfusion ratios and hemodynamics in ARDS|To ventilated patients with ARDS with an objective of driving pressure than a tidal volume set on predicted body weight
214919782|NCT00184132|PROCEDURE|Psychiatric intensive care unit sparsely furnished and not decorated|
214319375|NCT06901778|BEHAVIORAL|Implementation of the weight management mobile health application|Patients undergoing weight management are instructed to download the app from the app store (compatible with both iOS and Android platforms). Users in the control group can independently register and log in using their mobile phone numbers to access and use the app. The app will create an electronic health record for weight management for each user. Users can input their weight-related information, and the app features a data analysis function that displays weight trends through charts (e.g., BMI calculation and personal weight change curves). The app interface also provides professional guidance on diet and exercise, such as food calorie information, customized nutritional meal plans, and specialized exercise programs with training courses. By offering educational articles and instructional videos, the app aims to promote correct weight management concepts, disseminate scientific health knowledge, and enhance self-efficacy in weight loss.
214319376|NCT06901778|BEHAVIORAL|Implementation of the weight management mobile health application + Enhance the regular interaction, feedback, and supervision mechanism between medical teams and apps|Based on the intelligent app's comprehensive coverage on the user side and integrating the ABI concept, the app dynamically adjusts intervention strategies. This is achieved by real-time collection and analysis of user behavior data, providing users with all around and personalized weight management support across diet, exercise, psychological support, etc., thereby enhancing the effectiveness and sustainability of interventions. The research team has formed a professional and experienced medical team. All members hold a bachelor's degree or above and possess rich clinical weight management experience. Through the app, they provide users with scientific and rigorous supervision and guidance. During weight loss, users can obtain accurate, professional answers and personalized adjustment advice in real-time via the app's question-asking column if they encounter any problems.
214319377|NCT06908408|DIAGNOSTIC_TEST|Corrrelation between metabolic acidosis severity in patients on admission to the ICU and platelet count trend in 2 days following admission was investigated|The aim of the study was to investigate if there exists any correlation between metabolic acidosis severity in patients upon admission to the ICU and platelet count trend in 2 days, following admission.
214319378|NCT06909643|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model|Collect magnetic resonance imaging and pathological slides of resected tumor of the enrolled patients. Analyze the data using the AI model to generate diagnostic results (sensitive or insensitive to the neoadjavant therapy). No intervention to patients would be performed in this diagnostic test study.
214319379|NCT06909747|BEHAVIORAL|Posture Training|Training program consists of three sessions. It will cover proper body posture, the importance of spinal health, and targeted exercises to support spinal well-being.
214483924|NCT06819423|DEVICE|AI fundus photography|In the dark room, Canon CR-2AF automatic mydria-free fundus camera was used to collect images of both eyes of the patients, and one fundus photo was taken with macula as the center of each eye
214483925|NCT06879444|OTHER|Core Muscle testing and patient reported outcome measures|These are the situation evaluation parameters. It presents the data of the participants at the time of evaluation.
214483926|NCT06870084|OTHER|Ultrasonography|The masseter muscle thickness measurements were performed in B mode of ultrasound, midline between the zygomatic arch and mandibular plane, parallel to the mandibular plane and perpendicular to the mandibular ramus. Prior to the examination being performed in the resting position, the patient was instructed to make minimal contact between the lips without the teeth touching each other.The first USG image was recorded in this position. The patient was then requested to clench their teeth as firmly as possible, after which a second USG image was recorded from the same area. The thickness of the muscles was measured again on second recorded images. To ensure the reliability of the measurements, these procedures were repeated by the same researcher after the patients rested for five minutes.
214483927|NCT06870084|OTHER|Lateral cephalometric radiography|Standard lateral cephalometric radiographs were obtained from the patients.
214483928|NCT06870084|OTHER|Facial photograph|Standard facial photographs were taken from a distance of 1.5 metres.
214483929|NCT06870084|OTHER|Weigth and Heigth|The Body Mass Index is calculated by measuring with a standardised scale and height chart.
214483930|NCT06870084|OTHER|Electronic caliper|The intermaxillary distance is measured from the cervical level of the palatal surfaces of the first permanent molars to their mesial corners using an electronic caliper.
214483931|NCT06952985|DIETARY_SUPPLEMENT|Sugar free chew gum|Chew gum has a role in ERAS protocol which is significant in early post operative recovery as compared to normal routine care methods
214483932|NCT06952985|OTHER|Nil Per Oral|According to classic protocols patient were kept nil per oral till bowel sounds were audible
214919783|NCT04630236|DIAGNOSTIC_TEST|Ultrasound|Using ultrasound control, the central vein catheter is injected with saline solution and the time to detect the saline bolus in the ultrasound is measured.
214919784|NCT05184569|DRUG|Verdiperstat|Oral, extended release (ER) tablet
214919785|NCT01296945|OTHER|Kiosk|Touchscreen computer containing three educational modules in Spanish on infant/toddler juice intake, milk, and solid/foods
214919786|NCT01296945|OTHER|paper|Participants will receive a paper handout with nutrition educational information.
214919787|NCT01296945|OTHER|Kiosk PLUS paper|Individuals will use the 3 computer modules on a touchscreen and receive the information on a paper handout.
214483933|NCT04201184|BEHAVIORAL|Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules|Caregivers will receive 12 lessons, weekly, over a period of 12 weeks. Full curriculum contains: 4 lessons on cultural connection and traditions, 4 lessons on parenting adapted from Family Spirit intervention, and 4 lessons on stress and trauma adapted from CETA. modules
214319380|NCT06903117|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
214319381|NCT06903117|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
214319382|NCT06908837|DRUG|Bupivacaine|Applied perineurally using a 22-gauge, 80-mm block needle (Temena, Felsberg, Germany) under ultrasound guidance.
214319383|NCT06909474|BIOLOGICAL|Anti-CD5 CAR NK cells|Each patient will initially receive a single infusion of CAR-NK cells on Day 0. If a suboptimal response is observed after the first infusion (assessed by Day 28) and the safety profile remains acceptable, a second infusion may be administered as a remedial dose after Day 28. CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion.
214319384|NCT06915662|DEVICE|Tulavi allay Nerve Cap|"The Tulavi allay Nerve Capfirst and only fully absorbable in situ forming technology designed to protect transected nerves, prevent axonal escape, and reduce the risk of neuroma formation.~https://tulavi.com/allay-nerve-cap/"
214319385|NCT06922968|PROCEDURE|TRUS-Guided TURP and enucleation|realtime TRUS guidance during the procedure (TURP and enucleation)
214319386|NCT06922968|PROCEDURE|Standard TURP and enucleation|No TRUS guidance during the procedure (TURP and enucleation)
214319387|NCT06924359|DIAGNOSTIC_TEST|Multimodal Ophthalmic Imaging and plasma biomarker|Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.
214919788|NCT01296945|OTHER|Kiosk PLUS web|Participants will utilize the 3 modules on the touchscreen computer and be given a piece of paper that includes information on how to see this information again on the internet. Participants will be asked to view the modules on the web.
214319388|NCT06924775|OTHER|Weighted jump rope training|Unlike isolated jump rope studies, this intervention was embedded within the participants' habitual CrossFit routine, enhancing ecological validity. Performing the jump rope protocol immediately prior to regular training-rather than as a stand-alone session-was intended to promote warm-up and neuromuscular priming benefits. The use of a weighted rope introduced a resistance stimulus that is rarely incorporated in jump rope interventions.
214319389|NCT06923397|BEHAVIORAL|Interrupted Sedentary Time Intervention|A 12-week, semi-supervised exercise intervention comprised of reminder prompts, counseling, and activities of walking, cycling, and resistance band exercise for at-home and in-clinic settings. Supervision will be under an exercise trainer. Resistance bands, Libre Pro continuous blood sugar monitor, and Fitbit and ActivPAL trackers will be provided to participants.
214319390|NCT06924372|OTHER|Taking saliva samples of unstimulated saliva will be collected in sterile containers, salivets.|Subjects will sit in a filiological position in a dental chair. Samples of unstimulated saliva will be collected in sterile containers, salivets. A prerequisite for taking saliva samples will be that subjects do not take water and food until two hours before the examination, according to the manufacturer's instructions. SARSTED Salivette will be used. In a sterile manner, the swab will be removed from the salivette with sterile tweezers and applied to the patient's mouth on the buccal mucosa. The tampon will be held for a minimum of 2 minutes in the patient's mouth (with buccal mucosa). After the elapsed time, the tampon will be removed from the mouth, using sterile tweezers and sterile gloves and will be inserted into the saliva and closed. After sampling, the salivates will be transported to the Department of Microbiological Diagnostics of the Institute for Pulmonary Diseases of Vojvodina. Transport should be done in the shortest possible time.
214319391|NCT06924372|OTHER|Dental status|Dental status in both groups of subjects will be assessed by clinical visual examination by determining the prevalence of caries of deciduous and permanent teeth using the KEP and KEPS indexes. The clinical examination will be carried out in a dental chair using artificial light-reflectors, using a dental mirror and a dental probe on all surfaces of the tooth, which are dried with air from the puster. On the basis of a dental examination, the prevalence of caries of deciduous and permanent teeth will be determined.
214483934|NCT04201184|BEHAVIORAL|Active nutrition control|The active control condition will receive nutrition information, weekly food boxes and recipes. Recipes will be developed based on seasonal foods and a shopping list for making future meals will be included.
214483935|NCT06954376|OTHER|Hyperbaric oxygen therapy|Patients received hyperbaric oxygen therapy (HBOT) using a monochamber hyperbaric chamber in addition to conventional rehabilitation.
214483936|NCT06954376|OTHER|Conventional rehabilitation|Patients received conventional rehabilitation alone.
214919789|NCT02115581|DRUG|Coenzyme Q10|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
214919790|NCT02115581|DRUG|Placebo|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
214919791|NCT06198491|BEHAVIORAL|Misbeliefs about HPV training|Intervention trainings mentioned false beliefs before or after the current knowledge
214919792|NCT03763825|BEHAVIORAL|Mini-AFTERc|Structured 30-45 minute telephone discussion based on health psychology theory and CBT principles.
214919793|NCT05935397|DEVICE|percutaneous coronary intervention|patients with CAD undergoing PCI with second generation DES
214919794|NCT04793308|OTHER|Endodontic files|Engine-driven nickel titanium Ni-Ti instruments
214919795|NCT03719781|DIAGNOSTIC_TEST|standardized minimental testing|To diagnose postoperative cognitive dysfunction
215061446|NCT06493643|OTHER|Measurement of perfusion index after supraclavicular brachial plexus block at blocked & unblocked limb|The PI (Perfusion Index) was measured using Masimo SET pulse oximetry applied on the index finger. The PI was recorded at baseline and at 10 , 20 , and 30 min after local anaesthetic injection in both the blocked limb and the contralateral unblocked limb using two separate oximeters. The PI ratio was calculated as the ratio between the PI at 10min after injection and the baseline PI. In every patient, a comparison between the blocked and unblocked limb was performed .
214919796|NCT05300009|COMBINATION_PRODUCT|topical methotrexate hydrogel 1% coupled with microneedling.|Microneedling will be performed on each wart for a maximum 5 lesions per patient using dermapen (Ostar rechargeable dermapen, OB-DG 03N, Ostar Beauty Sci-Tech Co, Beijing, China) supplied with 12 needles arranged in rows. The penetration depth was adjusted at 2-mm, endpoint was pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the wart. Then topical methotrexate 1% gel will be applied on the lesions every session.
214919797|NCT05300009|OTHER|Liquid nitrogen|"The wart is frozen for 10 to 30 seconds until a 1- to 2-mm ice ball halo surrounds the targeted area.~The sessions were performed every 2 week until complete clearance for a maximum of six sessions."
214319392|NCT06924372|OTHER|Periodontal status|The assessment of the presence of dental plaque will be determined visually using the Silness and Loe plaque index, while the condition of the gingiva will be determined using the gingival index Loe and Silness . Before the examination, the subject will be advised to rinse his mouth with water to remove food residues and dental plaque. Performed in the dental chair using artificial light-reflectors, by gently pulling the dental probe over the vestibular, oral, mesial and distal surfaces of all crowns of the present teeth. Four values will be entered for each tooth. The result will be obtained by adding up all the values.
214919798|NCT06035146|PROCEDURE|Mechanical energy monitoring|Monitoring of the mechanical energy acting on the lung parenchyma during mechanical ventilation.
214919799|NCT06035146|PROCEDURE|Conventional mechanical ventilation|The conventional procedure of mechanical ventilation controlled according to the physician's decision.
214319393|NCT06923566|PROCEDURE|Targeted muscle reinnervation|"In 1ry TMR ,after the amputation is performed by the standard method , transected nerves will be replanted micro surgically to motor entry points (MEPS)in the hand as predetermined by Daugherty et al , Motor branches in the recipient muscles could be determined by a nerve stimulator intraoperatively.~In 2ry TMR , neuroma site will be explored and it will be excised ,the distal end of the transected nerve will be connected micro surgically to the nearest MEPS"
214319394|NCT06924411|DEVICE|Direct Intubation|Direct laryngoscopy intubation
214319395|NCT06924424|DRUG|Aponermin, pomalidomide, dexamethasone|Three drugs combination for R/R MM. Aponermin, 10mg/kg d1-5 Pomalidomide 4mg d1-21 Dexamethasone 20mg d1,d8,d15 Each treatment cycle is 28 days.
214319396|NCT06924307|DEVICE|Executive Function Intervention|The intervention is an in-home cognition training system that provides parents with a modular series of short, easy-to-follow, collaborative cognitive training activities they will share with their child to address the needs of families with young children identified with deficits in executive function (EF), a critical cognitive process associated with self-control. The system employs a novel two-generational training model that views parental involvement as a critical component of the intervention process. In this model, an engaging, parent-facing smartphone application will deliver personalized daily training activities consisting of both traditional hands-on activities as well as collaborative, parent-controlled, child-facing video games. This approach supports multiple pathways for learning and building strong personal relationships between parent and child.
214319397|NCT00004733|DRUG|levodopa|
214319398|NCT04743661|DRUG|Irinotecan|"Irinotecan is a semisynthetic water-soluble analog of camptothecin (a plant alkaloid isolated from Camptotheca acuminata). Irinotecan is available in single-dose amber glass vials in 40 mg (2 mL) and 100 mg (5 mL), 300 mg (15 mL), and 500 mg (25 mL).~Patients on Stratum 1 will be given irinotecan at 50 mg/m2/day IV on Days 1 through 5 of each chemotherapy course."
214483937|NCT06744452|BEHAVIORAL|harmony|Use of the app-based digital self-help intervention harmony over a 12-week-period. The app was designed for stress management and the preventive promotion of mental health. Harmony provides users with access to a wide range of psychological self-help content, including video episodes, audio sessions, texts, and downloadable materials. Utilizing artificial intelligence, Harmony offers personalized content suggestions tailored to the user's individual situation and preferences, ensuring the content remains relevant and updated. Content is delivered through a combination of psychoeducation, guided exercises, relaxation techniques, meditations, practical tasks, self-reflection activities, and everyday application tasks.
214483938|NCT05598957|DIAGNOSTIC_TEST|Vitamin D Binding protein|Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels
214483939|NCT05738486|DRUG|Donanemab|Administered IV
214483940|NCT05738486|DRUG|Placebo|Administered IV
214483941|NCT05738486|DRUG|Dexamethasone|Administered IV
214483942|NCT01564056|DRUG|HORMONOTHERAPY|"Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
214919800|NCT03231072|DEVICE|Electrical Impedance Tomography record|Monitoring of pleural effusion evacuation by means of EIT
214919801|NCT02909712|DRUG|sulfadoxine-pyrimethamine (SP)|"Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:~3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing."
214919802|NCT02909712|DRUG|dihydroartemisinin-piperaquine (DHA-PQP)|Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
214919803|NCT03175705|BIOLOGICAL|HCC antigens-specific CD8+ T lymphocytes|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10\^7/m2 Loading Dose 2: 6x10\^7/m2 Loading Dose 3: 9x10\^7/m2 The doses are calculated according to the actual number of GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytes (CTLs)"
214919804|NCT03175705|DRUG|IL-2|IL-2 will be given at a dose of 25000 IU/kg/day for 5-14 days.
214919805|NCT03175705|DRUG|Tegafur|Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
214919806|NCT01417247|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
214919807|NCT02858583|PROCEDURE|CC+SI|chest compression will be delivered during sustained inflation (CC+SI). The duration of each sustain inflation is 20sec. After 20sec a pause of 1sec id done before the next sustained inflation is delivered for another 20sec. Chest compressions are given continuously. This approach is continued until return of spontaneous circulation.
214919808|NCT02858583|PROCEDURE|3:1 C:V|During 3:1 C:V. 3 chest compressions are given, then stopped and then 1 inflation is given. This approach is continued until return of spontaneous circulation.
214919809|NCT03483233|OTHER|fMRI and EEG study|fMRI and EEG study
214483943|NCT01564056|DRUG|CHEMOTHERAPY then HORMONOTHERAPY|"CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~* Docetaxel 75 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~* Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin \[Myocet®\]+ cyclophosphamide)~* Myocet® 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
214919810|NCT00347009|DRUG|adefovir dipivoxil|10mg once daily
214919811|NCT06091917|DIETARY_SUPPLEMENT|Betaine supplementation in infant formula|Infant formula will be supplemented with betaine to provide a final concentration of 100 µmol/L in the reconstituted milk. The intervention will last for 12 weeks.
214483944|NCT02790853|PROCEDURE|Biopsy|Undergo brush biopsy and incisional biopsy
214919812|NCT06091917|DIETARY_SUPPLEMENT|Regular infant formula|Regular (unmodified) infant formula . The intervention will last for 12 weeks.
214919813|NCT06252558|DIETARY_SUPPLEMENT|Symbiotic|One-a-day administration of a capsule supplement containing:15 billion CFU probiotic blend (Lactobacillus acidophilus La-14, Bifidobacterium longum BB536, Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus GG, Lactobacillus gasseri Lg-36) and 250mg of chicory root inulin.
214919814|NCT06252558|DIETARY_SUPPLEMENT|Placebo|Daily fiber capsule containing microcrystalline cellulose
214319399|NCT04743661|DRUG|Temozolomide|"An orally administered alkylating agent, a second generation imidazotetrazine. A prodrug of MTIC, temozolomide spontaneously decomposes to MTIC at physiologic pH. Exerts its effect by cross-linking DNA. Temozolomide capsules are available in six different strengths (5, 20, 100, 140, 180, 250 mg). The capsules vary in size, color, and imprint according to strength. In the US, capsules are packaged in 5-count and 14-count bottles.~Patients on Stratum 1 will be given temozolomide at 150 mg/m2/dose PO on Days 1-5 of each chemotherapy course."
214319400|NCT04743661|DRUG|Bevacizumab|"Bevacizumab is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody. Bevacizumab is supplied as a clear to slightly opalescent, sterile liquid ready for parenteral administration. Each 400 mg (25 mg/mL, 16 mL fill) glass vial contains bevacizumab with phosphate, trehalose, polysorbate 20, and Sterile Water for Injection.~Patients on Stratum 1 will be given bevacizumab at 10 mg/kg/day IV on Days 1 and 15 of each chemotherapy course, with the exception of the last course of Induction Chemotherapy (i.e., Course 2 or 4) where it will be administered on Day 1 only."
214319401|NCT04743661|DRUG|Omburtamab I-131|"Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276) manufactured by in vivo growth of the hybridoma cell line without the use of animal-derived components. Omburtamab will be radiolabeled with iodine-131 at a designated radiolabeling facility. 131I-omburtamab is supplied as a sterile, injectable, radioactive product in a vial. Each supplied vial will contain enough radioactivity to prepare 50 mCi of 131I-omburtamab, formulated in 3.5-4 mL of solution. 131I-omburtamab should be administered via an intraventricular access device (i.e., Ommaya catheter or programmable VP shunt). Radioimmunotherapy consists of 56 days.~Patients on Stratum 1 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 8 and 36 of Radioimmunotherapy.~Patients on Stratum 2 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 1 and 29 of Radioimmunotherapy."
214319402|NCT04743661|DRUG|Liothyronine|Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight \< 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
214319403|NCT04743661|DRUG|SSKI|SSKI (potassium iodide) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. SSKI (potassium iodide) will be administered as 7 drops (\~0.35 mL) PO, NG, or G-tube daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
214483945|NCT02790853|PROCEDURE|Fluorescence Imaging|Undergo PS2.1/PS3 imaging
214483946|NCT02790853|PROCEDURE|High-Resolution Microendoscopy|Undergo HRME imaging
214483947|NCT02790853|DRUG|Proflavine Hemisulfate|Applied on mucosa
214483948|NCT04879342|BEHAVIORAL|VIP Program|This intervention will engage the participants with psychoeducational material once a week. This material will include didactic instruction as well as participant engagement in developmentally appropriate activities.
214483949|NCT06087237|DRUG|Pentoxifylline|"Two 400 mg extended-release pentoxifylline oral tablets are administered 2 hours before surgery, then one tablet three times per day after surgery, and continued for four weeks after the surgery.~Standard of care for pain management, including paracetamol 1g IV every 8 hours and Ketorolac 30 mg IV every 12 hours."
214483950|NCT06087237|DRUG|paracetamol +ketorolac|"Patients receive the usual treatment only:~paracetamol 1g IV every 8 hours and Ketorolac 30 mg IV every 12 hours"
214483951|NCT06954480|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Patients will receive Dato-DXd 6.0mg/kg, which will be administered by infusion on day 1 of each 21-day cycle.
214919815|NCT00006178|DRUG|Sirolimus|
214919816|NCT00006178|DRUG|Thymoglobulin|
214919817|NCT02283684|PROCEDURE|Greenlight laser PVP|Vaporization of the prostate adenoma using 532nm laser with 180W XPS system using Moxy fiber
214919818|NCT02283684|PROCEDURE|Bipolar TUVP|Bipolar energy is used for generation of plasma that ends up by vaporization of the prostate adenoma
214919819|NCT00928291|OTHER|procalcitonin|plasma PCT measurement
215061447|NCT05454462|DRUG|IMP Application KM-001|KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
215061448|NCT05454462|DIAGNOSTIC_TEST|Chemistry|patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
214319404|NCT04743661|DRUG|Dexamethasone|Dexamethasone will be given as premedication for 131I-omburtamab to prevent possible meningeal inflammatory reaction. Starting within 24 hours prior to each 131I-omburtamab injection, dexamethasone will be administered orally at 0.5 mg (if weight \< 15 kg) or 1 mg (if weight ≥ 15 kg) twice-daily doses for a total of 6 doses to alleviate infusion-related AEs: Two doses starting 24 hours pre-131I-omburtamab injection, two doses on the day of the injection (can be given before or after), and two doses 24 hours post-131I-omburtamab injection.
214319405|NCT04743661|DRUG|Antipyretic|An antipyretic (e.g., oral acetaminophen \[15 mg/kg, 650 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
214319406|NCT04743661|DRUG|Antihistamine|An antihistamine (e.g., IV diphenhydramine \[1 mg/kg, 50 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
214319407|NCT04743661|DRUG|anti-emetics|An anti-emetic (e.g., IV ondansetron \[0.25 mg/kg, 16 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
214319408|NCT04036500|DRUG|Estradiol|Patients will be given estradiol: 1 mg oral and 1 mg sublingual.
214483952|NCT06954480|DRUG|Durvalumab|Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.
214319409|NCT02283788|DRUG|BIA 2-093|
214319410|NCT02283788|DRUG|Moxifloxacin|
214319411|NCT02283788|DRUG|Placebo|
214319412|NCT02177240|DEVICE|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
214319413|NCT02177240|DEVICE|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
214319414|NCT01305031|OTHER|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
214483953|NCT03512301|DEVICE|CAMCI|CAMCI is a computerized screening tool for the assessment of cognitive status. CAMCI accurately assesses cognitive performance using standard neuropsychological tests of memory, attention, and executive ability modified for computer administration, and an innovative Virtual Environment task, testing domains such as incidental memory, not easily assessed using paper-pencil tests. Computer-administered tasks ensure standard administration and scoring, avoiding inter-site and inter-examiner variability. The CAMCI battery consists of tasks testing multiple aspects of cognitive function, and a series of self-report questions administered via tablet computer. Using touchscreen technology for response input, CAMCI takes approximately 15-20 minutes to complete.
214483954|NCT03512301|DIAGNOSTIC_TEST|MoCA|"The Montreal Cognitive Assessment (MoCA) is a rapid screening tool used to detect mild cognitive impairment (MCI), assessing cognitive domains (visuospatial skills, executive function, memory, attention, language, and orientation). Individual test scores are summed into a total score from 0 (worst) to 30 (best). Individuals may achieve any score within that range. Individual test scores are not reported.~Scores:~26-30 considered Normal; 19-25 may suggest Mild Cognitive Impairment (MCI); 10-18 can suggest moderate impairment; \< 10 may indicate severe impairment"
214919820|NCT00928291|DRUG|antibiotic therapy|antibiotic therapy use
214919821|NCT02903940|DEVICE|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
214919822|NCT05219591|DEVICE|EPR|application of EPR technology during CPAP treatment
214919823|NCT02295826|DRUG|Dabigatran|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
214919824|NCT02295826|DRUG|Acetylsalicylic acid|participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
214919825|NCT03894189|DRUG|Doxapram Hydrochloride|the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
214919826|NCT03894189|DRUG|Theophylline|the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
214919827|NCT01029782|DRUG|IV cefazolin plus oral probenecid and placebo cephalexin|Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
214319415|NCT01305031|OTHER|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
214319416|NCT03734120|OTHER|cryopreservation|Samples were frozen with a programmable freezing unit. Each semen sample was divided into two aliquots. One aliquot was plunged into liquid nitrogen and the other was stored in dry-phase nitrogen for 3 or 6 month. Thawing was performed at room temperature
214319417|NCT06107491|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
214319418|NCT06107491|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
214319419|NCT00802217|DRUG|Civamide|5 mg liquid filled softgel capsules
214919828|NCT01029782|DRUG|Oral cephalexin and saline IV plus probenecid placebo|Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
214919829|NCT00896792|OTHER|counseling intervention|
214919830|NCT00896792|OTHER|questionnaire administration|
214919831|NCT00896792|OTHER|survey administration|
214919832|NCT00896792|PROCEDURE|end-of-life treatment/management|
214919833|NCT00896792|PROCEDURE|psychosocial assessment and care|
214919834|NCT03963492|OTHER|Walking|Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
214919835|NCT02318446|DRUG|Folic Acid|Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
214319420|NCT00802217|DRUG|Civamide|5 mg x 2 liquid softgel capsules
214319421|NCT05402527|DIETARY_SUPPLEMENT|Fish nutrients|Intake of fish protein, omega-3 fatty acids, and vitamin D
214319422|NCT05402527|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
214319423|NCT05402527|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
214919836|NCT02318446|DRUG|Saccharine|Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
214319424|NCT06276634|OTHER|Acute Intermittent Hypoxia|During each AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles: one with lower oxygen concentration (9-10% Oxygen) than that at sea level (\~21% Oxygen) lasting between 30 and 60 seconds, followed by a similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
214319425|NCT06276634|OTHER|Sham-Acute Intermittent Hypoxia|During each Sham-AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the Sham-AIH intervention. The Sham-AIH intervention involves alternating breathing cycles: both with oxygen concentrations of \~21% Oxygen lasting between 30 and 60 seconds, followed by another similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
214319426|NCT06476223|DRUG|Artificial saliva containing cumin and ginger extract|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
214319427|NCT06476223|DRUG|Placebo|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
214319428|NCT04376645|PROCEDURE|Mandibular Setback with maxillary impaction|Occlusal bite force will be measured after surgery to correct vertical disproportions
214319429|NCT04376645|PROCEDURE|Mandibular setback only|Occlusal bite force will be measured after surgery without changing vertical disproportions.
214319430|NCT02359266|DIETARY_SUPPLEMENT|Vitamin D|Given to patients with existing vitamin D deficiency
214319431|NCT00214994|DRUG|Gabitril|
214319432|NCT00000826|DRUG|Clarithromycin|
214319433|NCT00000826|DRUG|Rifabutin|
214483955|NCT03512301|DIAGNOSTIC_TEST|Clinical Adjudication|"Cognitive status assessed by traditional neuropsychological tests measuring visuospatial skills, executive function, memory, attention, language, orientation. Results compared to age-adjusted norms, reviewed by expert neuropsychologists for consensus classification, per Univ of Pittsburgh Alzheimers Disease Research Ctr and Ntl Alzheimers Coordinating Ctr, and Alzheimer's Assoc criteria. Final classification adjusted per clinical judgment.~Impaired: ≥3 scores ≥2SD below norms Indeterminate: ≤2 scores \>1SD below norms Normal: Neither criteria met. Total and domain scores not reported."
214919837|NCT01226784|BEHAVIORAL|Physcial activity|Strenght training Relaxation exercise
214919838|NCT04620837|DRUG|Tislelizumab|Tislelizumab：200mg Q3W IV. There will be no dose reduction for Tislelizumab ， if there is no disease progression or serious Treatment Related adverse events(TRAE) , patients will receive Tislelizumab (200mg,Q3W) until progression or death
214919839|NCT04620837|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated. Depending tolerated dose reduction. Medication process: disease control and patients can tolerate the side effects, continued drug use; researchers believe the patient is not fit to continue medication or efficacy evaluation at the end of the clinical progression of medication.
214919840|NCT04438837|DRUG|Hydroxychloroquine|Hydroxychloroquine post exposure prohylaxis
215061449|NCT05454462|DIAGNOSTIC_TEST|Hematology|patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
214319434|NCT00000826|DRUG|Sulfamethoxazole-Trimethoprim|
214319435|NCT00000826|DRUG|Dapsone|
214319436|NCT00000826|DRUG|Fluconazole|
214319437|NCT05628740|DRUG|3 mg NOC-100 (via nebulizer)|Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
214319438|NCT05628740|DRUG|1 mg NOC-110 (via DPI) [1x 1 mg capsule]|Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
214319439|NCT05628740|DRUG|3 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
215061450|NCT05454462|DIAGNOSTIC_TEST|Urinalysis|Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
214319440|NCT05628740|DRUG|Placebo (via DPI)|Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
214319441|NCT05628740|DRUG|6 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
214319442|NCT05628740|DRUG|Placebo (via DPI) [2x Placebo capsules]|Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
214319443|NCT04986059|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
214319444|NCT06207682|DRUG|Avacopan|Orally via capsules
214319445|NCT06207682|DRUG|Simvastatin|Orally via tablets
214919841|NCT06125652|DRUG|anti Tim-3/CD123 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
214919842|NCT06535152|DEVICE|Lifelight|Lifelight is a artificial-intelligence software application that enables completely contactless spot measurements (i.e., one-off measurements without prior calibration) of PR and BP. Based on the science of remote photoplethysmography (rPPG), Lifelight works by detecting tiny changes in the colour of facial skin that occur every time the heart beats. All that is required to generate PR and BP measurements is that the software application is downloaded onto a computer device (e.g., smartphone or tablet) with a standard camera, and that the patient's face stays in the line of sight of the camera for up to 60 seconds.
214919843|NCT06535152|DEVICE|Manual sphygmomanometer|Blood Pressure Measurement
214919844|NCT02067845|BEHAVIORAL|Adapted Many Men, Many Voices (3MV) group level intervention|"The intervention will adapt the Many Men, Many Voices (3MV) group level intervention for MSM to address individual and social determinants of HIV/STI risk and vulnerability. This intervention involves 6 consecutive 2-3 hours sessions conducted at a weekend retreat. We will have 1 retreat in Calgary and 1 retreat in Toronto; each retreat will include 20 persons.~Based on the 3MV format, a draft template includes: Session 1: Intersectionality; Session 2: STI/HIV Prevention Among WSW and LBQ Women; Session 3: STI/HIV Risk Assessment and Prevention Options; Session 4: Relationship Issues; Session 5: Self-efficacy, Resilient Coping and Capacity for Change; Session 6: Social Support and Problem Solving to Maintain Change.~Delivery methods include discussion, role-plays and risk-reduction planning."
214319446|NCT02565381|DRUG|Transdermal nicotine patch|"* ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
214319447|NCT02565381|BEHAVIORAL|In-person smoking cessation counseling|\- One-on-one 15-minute counseling sessions once per week for 8 weeks
214319448|NCT02565381|BEHAVIORAL|Contingent financial rewards for smoking abstinence|\- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide \<8ppm
214319449|NCT02565381|BEHAVIORAL|Text messages to support smoking abstinence|\- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
214319450|NCT06358391|DEVICE|TS-RF Transseptal Needle|Apply radiofrequency energy to the electrode tip via the TS-RF Generator and puncture the atrial septum
214319451|NCT06358391|DEVICE|BRK Transseptal Needle|Cross and puncture the atrial septum with the BRK Transseptal Needle
214319452|NCT04160273|DIAGNOSTIC_TEST|patient questionnaire and telephone follow-up|PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
214319453|NCT03100786|DRUG|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
214319454|NCT03100786|OTHER|Placebo|Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
214319455|NCT03369717|DRUG|Amoxi Clavulanate|Postoperative antibiotics
214319456|NCT05929235|DRUG|FX-909|FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.
214319457|NCT01696435|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
214319458|NCT01696435|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
214319459|NCT01696435|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
214319460|NCT01696435|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
214319461|NCT04569123|DEVICE|real stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver vibration for the treatment group.
214319462|NCT04569123|DEVICE|No stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver no vibration for the control group during therapy.
214319463|NCT03031912|BIOLOGICAL|V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine|The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
214319464|NCT03031912|OTHER|Saline|Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
214319465|NCT03732911|BEHAVIORAL|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
214483956|NCT04823247|DRUG|Tildrakizumab|As provided in real world clinical practice.
214483957|NCT05927649|DRUG|Omaveloxolone|Omaveloxolone capsules
214919845|NCT02067845|BEHAVIORAL|A group-based HIV/STI prevention intervention for women who have sex with women|
214319466|NCT03356210|BEHAVIORAL|Neurofeedback|The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
214319467|NCT04975334|DRUG|Naloxone|One bolus of naloxone
214319468|NCT03344185|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention consisted of three low GI meals.
214483958|NCT05927649|DRUG|Moxifloxacin|Moxifloxacin capsules
214319469|NCT03344185|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention consisted of three meals, all with a high GI value.
214319470|NCT05466019|DRUG|Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)|FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.
214319471|NCT04522297|DRUG|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
214319472|NCT04522297|DRUG|Nor-epinephrine|Intravenous infusion norepinephrine
214319473|NCT04677946|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 9g of linoleic acid) 1 per day for 8 weeks
214483959|NCT03496181|BEHAVIORAL|Multilingual Aphasia Examination|"For patients only prior to MRI scans.~The MAE contains eleven subtests in five categories which may be used to assess both languages in bilinguals and the participant's primary language in monolinguals: Oral Expression, Spelling, Oral Verbal Understanding, Reading, and Rating Scales. Subtests are scored for accuracy of individual items on a three-point scoring system (0, 1, 2). Contained within these domains are The Token Test, Aural Comprehension of Words and Phrases and Visual Naming which naturally parallel fMRI and direct cortical stimulation behavioral assays already in place for clinical use (phonemic fluency, auditory responsive naming and confrontation naming respectively). The MAE is expected to take under 50 minutes."
214319474|NCT02400723|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
214319475|NCT02400723|BEHAVIORAL|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
214319476|NCT02400723|OTHER|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
214319477|NCT00004258|DRUG|cilengitide|dose escalation of cilengitide
214319478|NCT06323252|DIETARY_SUPPLEMENT|MastihaOil|1 soft gel capsule of Mastiha oil every day for 3 months
214319479|NCT06323252|BEHAVIORAL|nutritional counsel|nutritional counsel
214483960|NCT03496181|DIAGNOSTIC_TEST|Language paradigms + RS fMRI|10 monolingual patients: 2 language paradigms + RS fMRI = 7x3 = 21 minutes 10 early bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes 10 late bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes
214483961|NCT03496181|DIAGNOSTIC_TEST|Language paradigms + RS fMRI + one anatomical sequence|"10 monolingual English volunteers: 2 task language paradigms\* + 1 Resting State fMRI + one anatomical sequence for a total of approximately 25 minutes.~10 late bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes.~10 early bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes."
214319480|NCT05669079|DRUG|decitabine|15 mg/m2 daily intravenously for consecutive 3 days
214319481|NCT05669079|BIOLOGICAL|umbilical cord blood|MNC ≥ 3\*108 cells; HLA compatibility ≥ 5/6
214483962|NCT05515705|DEVICE|EUS navigation system|Incorporation of the EUS navigation system to the EUS scope
214483963|NCT05714384|DEVICE|CeraSeal (Calcium Silicate-based Root Canal Sealer)|A calcium silicate-based root canal sealer will be used in cases requiring root canal retreatment.
214483964|NCT01825226|OTHER|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
214483965|NCT06184880|BEHAVIORAL|behavioral|International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,
214483966|NCT06184880|OTHER|Sedentary|Actimetry (cumulative time without movement over 24h, prolonged sedentary periods \>30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
214319482|NCT05669079|DRUG|Granulocyte-colony stimulating factor|Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
214483967|NCT06421012|PROCEDURE|Experimental : Patients without additional preoxygenation|Throughout the entire period of their mechanical ventilation, patients will not receive additional preoxygenation before any endotracheal suctioning; their FiO2 value will be maintained constant
214919846|NCT05930054|DEVICE|skeletal anchorage and rapid palatal expansion|Eighteen patients were randomly divided into 2 groups through a free randomization program (Random Allocation Software 2.0). Baseline demographic characteristics were matched in both groups. All appliances were fabricated by the same technician in the orthodontic lab. All individuals were treated by a single practitioner.
214319483|NCT05669079|DRUG|Recombinant human thrombopoietin / thrombopoietin receptor agonist|Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
214319484|NCT05669079|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
214319485|NCT01331616|DRUG|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
214483968|NCT06421012|PROCEDURE|Active Comparator : Patients with additional preoxygenation|Throughout the entire period of their mechanical ventilation, patients will receive additional preoxygenation at 100% FiO2 for a systematic 2-minute duration prior to any endotracheal suction. Subsequently, the FiO2 will be reset to the previous default value.
214483969|NCT00447980|DRUG|NT-501|Low Dose
214483970|NCT00447980|DRUG|NT-501|High Dose
214483971|NCT05325424|PROCEDURE|Laparoscopic splenectomy|The laparoscopic splenectomy was performed by the same surgical team.
214483972|NCT05963997|DRUG|Samuraciclib|Samuraciclib capsules by mouth once a day
214483973|NCT05963997|DRUG|Elacestrant Dihydrochloride|Elacestrant tablets by mouth once a day
214483974|NCT06134921|DEVICE|transcranial direct current stimulation (Active)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Active-tDCS group, participants will receive real tDCS with intensity 2.0 mA for 30 minutes, with a 30-second ramp-up and ramp-down."
214919847|NCT00459277|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|
215061451|NCT05454462|DIAGNOSTIC_TEST|Serelogy|Patients will provide a blood sample for serelogy test at day -14 (screening visit)
215061452|NCT05454462|DIAGNOSTIC_TEST|12-Lead ECG|patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
214319486|NCT04217486|OTHER|Patient will be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will then be shown a photograph of their knee at 2 weeks postoperative.
214319487|NCT04217486|OTHER|Patient will not be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will not be shown a photograph of their knee at 2 weeks postoperative.
214319488|NCT02674412|DRUG|Buspirone|
214319489|NCT02674412|DRUG|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
214319490|NCT02203864|BIOLOGICAL|BIBW2 component A|BIBW2 without IL-2 secreting cell line
214319491|NCT02203864|BIOLOGICAL|BIBW2 component B|BIBW2 with IL-2 secreting cell line
214319492|NCT04515303|OTHER|Diverse Intervention Participation in DASH|A qualitative examination of barriers and facilitators of the DASH dietary pattern, and quantitative investigation of the types of recruitment methods effective for black adults entering a digital DASH-promoting intervention.
214483975|NCT06134921|DEVICE|transcranial alternating current stimulation (active)|Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.
214319493|NCT00698269|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214319494|NCT00698269|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214319495|NCT00698269|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214483976|NCT06134921|DEVICE|transcranial electrical stimulation (sham)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for applied the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Sham group, participants will receive sham stimulation with intensity 2.0 mA for 1 minute, with a 30-second ramp-up and ramp-down, and no stimulation until the end of 30 minutes of stimulation. Electrodes will remain for 30 minutes."
214319496|NCT00749463|DRUG|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
214483977|NCT06134921|OTHER|Conventional physical therapy program|A conventional physical therapy program will be provided after 30 minutes of stimulation immediately. The program will be provided for both upper and lower limbs which consist of stretching exercise, active exercise, and functional exercise.
214483978|NCT03952520|OTHER|Standard Approach (SA)|The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.
214919848|NCT06224647|BEHAVIORAL|Mobile Transdiagnostic Emotion Regulation Intervention|"The intervention aims to provide a tailored and engaging way for users to manage and comprehend their emotional well-being.~It consist of 5 components:~1. Daily tracking of emotions~2. A suite of exercises placed in six categories facilitating adaptive emotion regulation skills (i.e., upregulation of positive effect, self-compassion, cognitive defusion and cognitive restructuring, mindfulness, breathing techniques),~3. A self-assessment module where users can complete surveys evaluating their states (e.g., wellbeing) and traits (e.g., perfectionistic tendencies),~4. A personal toolkit area (i.e., each exercise is represented by an object commonly found in a student's room. Users can collect objects of favoured exercises in the virtual ROOM, enabling them quick access to exercises they liked / found helpful),~5. A recommendation system linking users to the content based on their specific needs or preferences"
214919849|NCT06383754|DEVICE|Clareon|Monofocal intraocular lens
214919850|NCT06383754|DEVICE|Tecnis 1|Monofocal 1 Piece intraocular lens
214319497|NCT00749463|DRUG|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
214319498|NCT02889094|OTHER|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
214919851|NCT04659954|OTHER|Application O'DIDE|The intervention is the use of an application that aimed to favorize contact between the patient and the care team between the consultations.
214919852|NCT04798053|BEHAVIORAL|Questionnaire|14-item Perceived Stress Scale (PSS-14), 9-item Patient Health Questionnaire (PHQ-9 questionnaire), State Trait Inventory Anxiety questionnaire (STAI questionnaire), Post-traumatic Stress Disorder Checklist Scale (PCL-S questionnaire)
214919853|NCT04798053|BIOLOGICAL|blood sample and salivary sample|10 ml whole blood for Peripheral blood and 2 ml saliva sample. Only for 100 cases.
215061453|NCT05454462|DIAGNOSTIC_TEST|Pregnancy test|Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
215061454|NCT05454462|DIAGNOSTIC_TEST|Blood PK sampling|PK test will be performed on day 1, 7, 28, 35 and on ET visit
215061455|NCT05454462|PROCEDURE|Physical Examination|patients will undergo a physical examination on all the clinical visits
215061456|NCT05454462|PROCEDURE|Vital signa|patient's vital signs will be measured on all the clinical visits
215061457|NCT05454462|DIAGNOSTIC_TEST|Investigator's Global Assessment|patient's disease evaluations will be evaluated on all the clinical visits
214319499|NCT03641378|OTHER|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
214319500|NCT03641378|OTHER|Standard Transplant Care|Standard care per hospital guidelines
214319501|NCT02880982|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
214319502|NCT02880982|OTHER|Placebo|Weekly oral placebo softgel capsule
214319503|NCT04914910|DEVICE|Minimed 780G insulin pump|This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
214319504|NCT02530424|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
214319505|NCT02530424|DRUG|Pertuzumab|Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
214319506|NCT02530424|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
214319507|NCT02530424|DRUG|Fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
214319508|NCT04297930|DEVICE|Paul Glaucoma Implant Surgery|This group of patients had glaucoma surgery with the Paul Glaucoma Implant
214319509|NCT03221933|BIOLOGICAL|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses
214919854|NCT03512054|PROCEDURE|Standardized 5-step weaning procedure|"Weaning process in 5 steps (0-4), by a multi-professional team (neurosurgeon, physiotherapist, nurse, caregiver…) Stability criteria are defined for each person, after validation pass the next step. Stability criteria degradation return to the previous step. Weaning process can take back after stability criteria renormalization.~Step 0: cuff deflate. Step 1: occlusion test. Steps 0 and 1 can assess the freedom and protect capacity airway. In failure process, we can propose a nasofibroscopy.~Step 2: Phonatory Valve. Respiratory rehabilitation/ swallowing, limiting breathing effort. The valve ought to stay 12 hours before going to the step 3.~Step 3: Plug. Finish the Respiratory rehabilitation/ swallowing. The plug ought to stay 24hours minimum before going to the step 4.~Step 4: Decannulation"
214319510|NCT03221933|BIOLOGICAL|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided dose
214319511|NCT00726219|OTHER|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
214319512|NCT05690737|BEHAVIORAL|Tai Chi training|The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.
214319513|NCT05690737|DRUG|Standard prophylactic medication|Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
214319514|NCT02588924|OTHER|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
214319515|NCT02588924|OTHER|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
214483979|NCT03952520|OTHER|Tailored Approach (TA)|The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.
214483980|NCT03635567|BIOLOGICAL|Pembrolizumab|IV infusion
214483981|NCT03635567|DRUG|Paclitaxel|IV infusion
214483982|NCT03635567|DRUG|Cisplatin|IV infusion
214483983|NCT03635567|DRUG|Carboplatin|IV infusion
214919855|NCT01803750|BEHAVIORAL|in-depth, semi-structured interviews|In-depth interviews will be conducted by the Principle Investigator and will use a combination of open-ended and closed, fixed response questions. Interviews will be audio recorded if the participant agrees, and answers to fixed response questions will be marked for complete analysis. The data collection portion of the study is estimated to take approximately 8 months. Areas to be addressed in the open-ended portion of the interview include: 1) Knowledge, attitudes and beliefs toward evidence-based cancer screening and prevention approaches 2) Barriers to implementing evidence-based cancer screening practices in the individual provider's clinical setting 3) Preferences for mechanisms of information dissemination and implementation and 4) Ideas and methods to facilitate evidence-based practices to improve cancer screening in the Latino population. A community-based participatory committee (CBPC) will be formed with 5-7 key informants identified during the interview process.
214919856|NCT00687544|BIOLOGICAL|Peginterferon alfa-2b (SCH 054031)|Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
214919857|NCT00687544|DRUG|Ribavirin (SCH 018908)|Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is \<65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is \>85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
214919858|NCT00511745|DRUG|Rabeprazol|As prescribed
214919859|NCT01487122|RADIATION|Continuous microwave|Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
214483984|NCT03635567|BIOLOGICAL|Bevacizumab|IV infusion
214483985|NCT03635567|DRUG|Placebo to pembrolizumab|IV infusion
214319516|NCT06441383|OTHER|Pittsburgh Sleep Quality Index|"The the Pittsburg Sleep Quality Index (PSQI) questionnaire is a standardized tool for the subjective assessment of sleep. Sleep is described according to 7 components: subjective sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disorders, medication use and daytime dysfunction. The sum of the scores for these 7 components gives an overall score of 21 points maximum.~The presence of sleep disorders will be defined according to the results of the PSQI, with a value above 5 defining the presence of sleep disorders."
214319517|NCT01749722|DEVICE|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
214319518|NCT01791738|PROCEDURE|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
214483986|NCT06953063|DRUG|DA-302168S|A small molecule GLP-1R agonist tablet, orally administration, once daily，16weeks.
214483987|NCT06953063|DRUG|Placebo of DA-302168S|Matching placebo tablet will be provided
214919860|NCT01487122|RADIATION|Pulsed microwaves|Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
214919861|NCT01487122|PROCEDURE|Sham microwaves|Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks
214919862|NCT05729360|DRUG|GamCoviMab|A total of 30 people will be randomized and receive the study drug (GamCoviMab) in a hospital setting (7 days of hospitalization).
214319519|NCT01433107|DRUG|Terbinafine|1% single application
214319520|NCT01433107|DRUG|Terbinafine Placebo|single application
214319521|NCT03643562|DRUG|Adrabetadex|Administered via lumbar puncture (LP) and IT infusion
214483988|NCT06563622|PROCEDURE|Pericapsular Nerves Group Block|USG-guided single-shot PENG in a dose of 0.5 ml/kg of 0.25% bupivacaine per side.
214483989|NCT06563622|PROCEDURE|Caudal Epidural Block|USG-guided single-shot CEB in a dose of 0.5 mL/kg of 0.25% bupivacaine.
214919863|NCT04858776|COMBINATION_PRODUCT|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
214919864|NCT04858776|COMBINATION_PRODUCT|Perivascular sham|Saline delivery around target vein segment(s)
214919865|NCT03915327|DRUG|Intravenous iron isomaltose anhydride|Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
214919866|NCT01788527|DEVICE|CGM|Real Time Continuous Glucose Monitoring
214919867|NCT04153760|DRUG|Aspirin 81 mg|Aspirin 81 mg p.o. daily
214919868|NCT04153760|DRUG|Placebo|Placebo p.o. daily
214919869|NCT00917176|DEVICE|Occipital nerve stimulation|
214919870|NCT02195869|DRUG|Ibrutinib|
214919871|NCT01095380|OTHER|Locomotor training|Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping
214919872|NCT05944744|DRUG|Adenosylcobalamin|The drug contains Cobamamide / Adenosylcobalamin with dose of 3000 mg.
214919873|NCT05944744|DRUG|Placebo|The drug doesn't contain any properties or substances for treatment.
214919874|NCT03525275|DEVICE|Battlefield Acupuncture|Battlefield Acupuncture uses ASP semi-permanent needles inserted into their ears for pain attenuation in 5 known points. Both groups receive their respective post-surgical rehabilitation protocols
214919875|NCT03525275|PROCEDURE|Post-surgical shoulder protocol|Surgery specific post-surgical physical therapy protocol
214919876|NCT02402387|PROCEDURE|Neutral head position|
214919877|NCT02402387|PROCEDURE|Flexed head position|
214919878|NCT02402387|PROCEDURE|Extended head position|
214919879|NCT02402387|PROCEDURE|Rotated head position|
214919880|NCT02402387|DEVICE|Air-Q SP Airway|
214919881|NCT05527275|DRUG|Mitoxantrone liposome combine with Chidamide|"Mitoxantrone Hydrochloride Liposome Injection： Grade 1: 14mg/ m2, D1; Grade 2: 17mg/ m2, D1; Grade 3: 20mg/ m2, D1; Chidamide：20mg twice a week (D1 and D4 or D2 and D5 or D3 and D6) Every 28 days for a cycle, a maximum of 6 cycles of treatment. Mitoxantrone Hydrochloride Liposome Injection RP2D was determined in the phase I trial, and the combination regimen will be used to in the phase II study, with a cycle of every 28 days and a maximum of 6 cycles of treatment.~Subsequently, maintenance treatment was performed: Chidamide, 20mg twice a week, for 1 year."
214919882|NCT00949559|DRUG|EP-100|as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)
214919883|NCT04591366|OTHER|Barrier dressing|A barrier dressing will be applied either pre or post implant prior to a culture swab and closing the incision.
214919884|NCT04463147|DEVICE|Needle-pilotTM device|The main objective aims to compare the procedure time between conventional real time ultrasound guidance and guidance with Needle-pilotTM device.
214919885|NCT02812069|DEVICE|ThermaZone® Device|The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
214319522|NCT01417403|DRUG|hydroxychloroquine|Given PO
214319523|NCT01417403|RADIATION|radiation therapy|Undergo radiotherapy
214319524|NCT01982253|DRUG|Fasiglifam|Fasiglifam tablets
214319525|NCT01982253|DRUG|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
214319526|NCT04025528|PROCEDURE|Bariatric Surgery|Weight loss surgery with either gastric sleeve or gastric bypass surgery
214319527|NCT02809430|DEVICE|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
214319528|NCT00291122|DRUG|celecoxib 400 mg BID|
214483990|NCT05717842|RADIATION|Nuclear Medicine Scan|Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
214483991|NCT00730509|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
214483992|NCT05157841|DRUG|Bupivacaine liposome injectable suspension 266 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
214483993|NCT05157841|DRUG|Bupivacaine HCl|Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
214483994|NCT05157841|DRUG|Bupivacaine liposome injectable suspension 133 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
214483995|NCT02662907|PROCEDURE|Barium Swallow|Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
215061458|NCT05454462|DIAGNOSTIC_TEST|Itch Assessment via PP-NRSj|patient's disease evaluations will be evaluated on all the clinical visits
214319529|NCT06290310|DEVICE|EIT|continuous electric impedance tomography measurement
214319530|NCT06290310|DEVICE|patient-ventilator asynchrony assessment|patient-ventilator asynchrony assessment by flow/time curve and machine learning
214319531|NCT01080313|OTHER|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
214319532|NCT05160428|BIOLOGICAL|COVID-19 vaccination|different types of covid-19 vaccinations.
214319533|NCT05940935|PROCEDURE|Arterial Blood Gas Base Deficit|The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.
214319534|NCT03383328|DRUG|NSAID + prednisolone, preoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
214319535|NCT03383328|DRUG|NSAID + prednisolone, postoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
214319536|NCT03383328|DRUG|NSAID, preoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
214319537|NCT03383328|DRUG|NSAID, postoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
214919886|NCT03424057|PROCEDURE|Asymmetric Primary Closure and Additional Skin Excision Technique|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume.
214919887|NCT03424057|PROCEDURE|Standard Karydakis technique.|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method
214919888|NCT04613921|OTHER|Observational Protocol|The cohorts will be followed for one year after LT transplantation except for group 3 (1-year follow-up after inclusion)
214919889|NCT06915610|OTHER|Invitation of all participants to CCS according to the standard of care (active comparator)|Invitation of all participants to CCS according to the standard of care
214319538|NCT03383328|DRUG|Drop-less surgery|A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
214319539|NCT01364090|DRUG|Pegylated interferon alfa 2b|Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
214319540|NCT01364090|DRUG|Ribavirin|Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
214319541|NCT02244203|DRUG|BI 60732|
214319542|NCT02244203|DRUG|Placebo|
214319543|NCT00712088|BEHAVIORAL|Project ICARE|Group-level intervention (Project ICARE)
214319544|NCT00712088|BEHAVIORAL|HCT|Offer of HIV counseling and testing
214319545|NCT02204254|DEVICE|Radiofrequence|Associated to arm radiofrequence
214319546|NCT02204254|DRUG|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
214319547|NCT01163409|PROCEDURE|exercise training|exercise training comprises aerobic and strength training
214319548|NCT01163409|PROCEDURE|acupuncture|acupuncture involves two sessions per week, during 14 weeks.
214319549|NCT01163409|PROCEDURE|Exercise, Acupuncture and Fibromyalgia|Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
214319550|NCT03316833|DEVICE|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score \<33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
214319551|NCT01127503|DRUG|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day \[2000 mg/day if metyrosine\]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
214319552|NCT01127503|DRUG|Placebo|Placebo capsules were identically matched to Metyrosine.
214319553|NCT01606046|DEVICE|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
214319554|NCT01606046|DRUG|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
214319555|NCT01262885|DRUG|GSK2251052|500 mg tablet, dose levels detailed in Arm description
214319556|NCT01262885|DRUG|Placebo|matching placebo tablet
214483996|NCT02662907|BEHAVIORAL|Questionnaires|Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
214483997|NCT02662907|DEVICE|Expiratory Muscle Strength Training (EMST) Device|Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
214483998|NCT02662907|DEVICE|Digital Manometer|Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
214483999|NCT02662907|BEHAVIORAL|Neurocognitive Exams|Participants given neurocognitive exams at baseline.
214484000|NCT02662907|DRUG|Barium|Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
214484001|NCT05768958|OTHER|Exercise|45 min exercise bout performed on bicycle ergometer. The exercise bout will consist of a 10 min warm-up period at 40 % Watt max followed by 4 cycles of 4 min at 85 % Watt max and 3 min at 50 % Watt max. A cool-down period (7 min) will be performed at 40 % Watt max.
214484002|NCT05768958|OTHER|Control|45 min rest during the same time period as the exercise bout on exercise study visits.
214484003|NCT04889417|BEHAVIORAL|Comprehensive training program|The COPE-iOS program is a pragmatic comprehensive training program that combines computerized cognitive training and progressive supervised video conference physical exercise sessions performed 2-4 weeks prior to surgery and for 3 months after discharge.
214484004|NCT04889417|BEHAVIORAL|Active control|The active attention control will include control computer games and supervised video conference stretching exercises performed 2-4 weeks prior to surgery and for 3 months after discharge.
214484005|NCT01242228|DRUG|ipragliflozin|oral
214484006|NCT01242228|DRUG|DPP-4 inhibitor|oral
214919890|NCT06915610|OTHER|Invitation of all participants to CCS through self-sampling|"A self-sampling kit mailed to the participants, with a prepaid envelope for returning them after sample collection. Participants may also return the kits by depositing them in a container that will be available in their Health Care Center.~The invitation for CCS through self-sampling is accompanied by written instructions, SMS reminders and navigation support (dedicated telephone line, WhatsApp, website)"
214919891|NCT06915610|OTHER|Invitation of all participants to CCS, asking them to choose between self-sampling and the standard of care|In a telephone contact, prompted by an SMS, participants will be given the opportunity to schedule CCS according to the standard of care or to ask for a self-sampling kit to be mailed to them. Depending on their choice, the procedure will be similar to what is described for arm SOC or for arm SS, as applicable
214919892|NCT06915610|OTHER|Invitation of all participants to CCS according to the standard of care, followed by invitation of those non-adherent to CCS through self-sampling|Participants not adhering to CCS after the first invitation (SOC) will be additionally invited for CCS screening through self-sampling (as in SS)
214319557|NCT06277804|DRUG|LTC004 in Combination With Cyclophosphamide and Fludarabine|LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable
214319558|NCT00219674|BEHAVIORAL|Group I: Video training|"Participants will receive the AED with a video that provides instructional training."
214319559|NCT00219674|BEHAVIORAL|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
214319560|NCT00219674|BEHAVIORAL|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
214319561|NCT00219674|BEHAVIORAL|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
214319562|NCT04168177|PROCEDURE|PCA|Patient controlled analgesia
214319563|NCT04168177|PROCEDURE|ESP|erector spinae plane block
214319564|NCT04169867|BIOLOGICAL|Collection of stool samples|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
214319565|NCT04026906|DEVICE|Cyanoacrylate glue|One drop of cyanoacrylate glue will be applied to the intravenous (IV) insertion site and another drop under the hub of the IV catheter
214319566|NCT04026906|OTHER|Transparent polyurethane dressing|The IV will be secured in the usual manner with tape and a transparent dressing.
214319567|NCT02829749|DEVICE|NeoChord beating heart mitral valve implantation|The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
214319568|NCT02829749|PROCEDURE|Control|traditional mitral valve repair performed under cardiac arrest
214319569|NCT00847496|DEVICE|AWBAT|One-time application of dressing over partial-thickness burns
214319570|NCT00847496|DEVICE|Biobrane|One-time application over partial-thickness burns
214319571|NCT02481895|BEHAVIORAL|E-neurocognitive module|The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
214319572|NCT00254995|BIOLOGICAL|None administered in this study|N/A in this study
214319573|NCT03298828|BIOLOGICAL|CD19 CAR and PD-1 knock out engineered T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
214319574|NCT03298828|BIOLOGICAL|CD19 CAR T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
214319575|NCT01470846|PROCEDURE|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
214319576|NCT01470846|PROCEDURE|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
214319577|NCT01489969|DRUG|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
214319578|NCT01911507|DRUG|INC280|Given PO
214319579|NCT01911507|DRUG|erlotinib hydrochloride|Given PO
214319580|NCT00853177|PROCEDURE|MEOPA inhalation|N2O of 50% and 50% O2
214319581|NCT00853177|PROCEDURE|xylocaine|Ampoule-bottle of 20 ml
214319582|NCT02223767|DEVICE|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and intertrial interval (ITI) of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
214319583|NCT02223767|DEVICE|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
214319584|NCT04702373|OTHER|passive range of motion exercise therapy|Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
214319585|NCT06305533|DEVICE|LASER disinfection|In test group 1, the diode Laser will be used to disinfect the inner layer of the pockets and thus reducing the microbial load. Diode laser (Biolase, EpicX, BIOLASE, Inc, USA) settings will be as follows: wavelength: 940nm; power: 1W; 300μm uninitiated fibers; continuous radiation mode; and energy level: 80 J/s. The laser fibers then will be inserted into the pockets in such a way that they will be in contact with the soft tissue wall of the pockets and parallel to the root surface and then will be moved to the apical surface through a horizontal sweeping motion (1mm/s) while remaining in contact with the soft tissue wall of the pockets.
214919893|NCT06915610|OTHER|Invitation of all participants to CCS through self-sampling, followed by invitation of those non-adherent to CCS according to the standard of care|Participants not adhering to CCS after the first invitation for self-sampling (SS) will be additionally invited for CCS screening according to the standard of care (as in SOC)
214919894|NCT06915610|OTHER|Invitation of all participants to CCS, asking them to choose between self-sampling and the standard of care; this mode of invitation is repeated when participants do not adhere to the first invitation|Participants not adhering to CCS after a first invitation for screening through a method of their choice (CHOICE) will be invited again, also being given the opportunity to choose between the standard of care or self-sampling (as in the first CHOICE invitation). Depending on the participants' choice, the procedure will be similar to what is described for arm SOC or for arm SS, as applicable, both in the first and in the second CHOICE invitations
214919895|NCT05272111|OTHER|DBM fasciatherapy+ conventional physical therapy|DBM fasciatherapy (3 sessions per day). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the fasciatherapy. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks
214919896|NCT05272111|OTHER|fascial manipulation+ conventional physical therapy|Fascial manipulation (3 sessions per day). This technique involves the identification of specific, localized areas of the fascia with limited movements. Once it is identified, then a specific point on the fascia is targeted and through the appropriate manipulation of this precise part of the fascia, movement can be restored. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks
214919897|NCT04444011|DRUG|Anaprazole Sodium|Anaprazole Sodium isthePPI inhibitor
214919898|NCT04444011|DRUG|Amoxicillin|antibiotic
214319586|NCT06305533|DEVICE|Photodynamic therapy|the second test group will receive additional adjunctive aPDT using a ICG photosensitizer activated with diode laser. In details, pockets will be irrigated by a syringe loaded with an ICG photosensitizer solution (Verdye, Diagnostic green, Germany) at a concentration of 5mg/ml. The ICG solution will be allowed to stay in the pockets for 2min, and washing out excess solution from the pockets before laser irradiation. Afterwards, a 300μm bulb optical fibre of the 810nm diode laser unit (QuickLase, United Kingdom) set at 300mw in pulsed mode (100ms ON/100ms OFF) will be inserted along the pocket and activated for 30s with continuous vertical movements from the bottom of the pocket to the gingival margin
214319587|NCT06305533|PROCEDURE|Root surface debridement|For all groups, sites with initial PPD 4-6 mm will be treated with RSD using area specific (Graecy) curettes.
214319588|NCT06249282|PROCEDURE|Biopsy|Undergo biopsy
214319589|NCT06249282|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214319590|NCT06249282|DRUG|Carfilzomib|Given IV
214319591|NCT06249282|PROCEDURE|Computed Tomography|Undergo CT
214319592|NCT06249282|PROCEDURE|Echocardiography|Undergo ECHO
214319593|NCT06249282|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214319594|NCT06249282|DRUG|Sotorasib|Given PO
214919899|NCT04444011|DRUG|Clarithromycin|antibiotic
214919900|NCT04444011|DRUG|Bismuth|Bismuth is to protect the gastric mucosa
214919901|NCT00869622|DRUG|Risedronate|35 mgs/week + calcium and vit d
214319595|NCT00614796|BEHAVIORAL|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
214319596|NCT05932446|DRUG|LY3819469|Administered SC.
214919902|NCT00869622|DRUG|Placebo + Calcium and Vitamin D|sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
214919903|NCT03063437|BIOLOGICAL|Encapsulated fecal microbiota preparation|30 capsules
214919904|NCT03063437|BIOLOGICAL|Encapsulated placebo|30 capsules
214919905|NCT04166942|DRUG|KD025|Single dose of 200 mg KD025 orally
215061459|NCT05454462|OTHER|E-diary data|The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
215061460|NCT02096250|OTHER|NaFeEDTA|
215061461|NCT02096250|OTHER|Ferrous fumarate|
215061462|NCT02096250|OTHER|NaFeEDTA + ferrous fumarate|
215061463|NCT00069134|DIETARY_SUPPLEMENT|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
215061464|NCT04769271|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
215061465|NCT04769271|DRUG|Scaling and Root Planing with tea tree oil|Supra- and sub-gingival calculus and debris were removed and 5% tea tree oil was applied
214319597|NCT01654965|OTHER|Laboratory Biomarker Analysis|Correlative studies
214319598|NCT01654965|BIOLOGICAL|Pegfilgrastim|Given SC
214319599|NCT01654965|OTHER|Pharmacological Study|Correlative studies
214319600|NCT01654965|DRUG|Tivantinib|Given PO
214319601|NCT01654965|DRUG|Topotecan Hydrochloride|Given IV
214319602|NCT02403505|BIOLOGICAL|CEA protein antigen plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix"
214319603|NCT04782778|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
214319604|NCT01674686|DRUG|Sarpogrelate|Sarpogrelate 100mg twice a day
214319605|NCT01674686|DRUG|Atorvastatin|Atorvastatin 80mg daily
214319606|NCT01041625|DRUG|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
214319607|NCT03672435|DRUG|Topical Solution|proparacaine 0.5% eye drop
214319608|NCT02040662|PROCEDURE|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
214319609|NCT02040662|PROCEDURE|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
214319610|NCT02040662|PROCEDURE|Patient-Controlled Analgesia with Morphine|"Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:~* patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)~* paracetamol 1000 mg iv every 8 hrs~* ketoprofen 100 mg iv every 12 hrs"
214319611|NCT01410734|DRUG|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
214319612|NCT04488029|OTHER|PCT|PCT is designed to deliver similar therapy as is conventionally provided in-clinic by a Speech Language Pathologist (SLP), which the patient can access from any location using the application installed on a supported tablet. The device functions by allowing clinicians to create a personalized therapy program for each patient from 75 categories of clinical therapies, which patients may access from their tablet device remotely. The PCT software is comprised primarily of authentication and an algorithm that suggests advancement of the therapy program based on observed patient deficits and progress.
214319613|NCT04488029|OTHER|Workbooks|Subjects in this group will be provided with a standard regime of paper workbooks (e.g. Workbook for Aphasia: Exercises for Expressive and Receptive Language Functioning; Brubaker, 2006) that are typically used by clinicians to practice therapy tasks with individuals. Notably, the control procedure employed here is similar to that employed on a large-scale study examining technology as a treatment option and involved usual care control group by Palmer and colleagues (2015).
214319614|NCT06291558|OTHER|Exercise|The first 5 minutes of heating in the exercise program are planned to be implemented for 8 weeks, and the last 5 minutes are a cooling period. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. As respiratory exercise, diaphragmatic respiratory exercise will be applied to heating and cooling peryots with 5 repetitions. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, and hip exercise. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
214319615|NCT03692546|DRUG|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
214319616|NCT03607916|DRUG|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
214319617|NCT03607916|DRUG|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
214319618|NCT03607916|DRUG|Morphine|100µg morphine
214671914|NCT03681860|BIOLOGICAL|ChAdOx185A|ChAdOx1 85A is an adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A. Adenoviruses are attractive candidates for use as viral vectors and have been used as vaccine vectors for a number of conditions; however, the use has been limited by the high level of anti-vector immunity present in humans in whom adenovirus is a ubiquitous infection. This has led to the consideration of simian adenoviruses, which are not known to cause pathology or illness in humans and to which the prevalence of anti-vector antibodies is low. The ChAdOx1 vector has been developed by the University of Oxford and been used with different inserts for vaccination, for example the vaccine ChAdOx1 NP+M1 has demonstrated an excellent safety profile in the Influenza trial FLU004. A BCG - ChAdOx1 85A - MVA85A prime boost regime is more protective than BCG alone in mice.
214919906|NCT06922695|OTHER|Pill-in-pocket anticoagulation|Participants will stop their oral anticoagulation after a 30-day period free of AF episodes. After this, they will only take their anticoagulation in response to an episode of AF detected by their implantable cardiac monitor. The participants will receive an automated smartphone alert instructing them to commence their anticoagulation as soon as AF is detected.
214919907|NCT04326361|PROCEDURE|Neonatal surgeries|Current practices of neonatal surgeries in India
214919908|NCT02375360|OTHER|Oral immunotherapy|
214919909|NCT06923163|BEHAVIORAL|Exercise intervention|"Exercise prescription for participant，~* 150Kcal for Weeks 1-4 (gradually increase to 150Kcal in the first two weeks as familiar stage),~* 250Kcal for Weeks 5-8,~* 350Kcal for Weeks 9-12."
214919910|NCT00117273|DRUG|Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]|1 tablet daily
214919911|NCT00117273|DRUG|Seasonique (LNG/EE and EE)|1 tablet daily
214919912|NCT00117273|DRUG|Portia (LNG/EE)|1 tablet daily x 28 days
214484007|NCT06836388|PROCEDURE|ultrasound guided bougie insertion|The anesthesiologist will use a high-frequency linear ultrasound probe at the level of the suprasternal notch to identify the tracheal rings. The probe will then be moved cephalad and placed over the cricothyroid membrane to visualize the vocal folds in the transverse view with the patient in the supine position. Using a C-mac laryngoscope, the intubator will assess the difficulty of visualization using the Cormack Lehan score; if the score is three or more, the bougie will be gently inserted with the curved tip anteriorly into the trachea and assess the real-time visualization of the bougie on the ultrasound screen as a linear echogenic structure moving through the hypoechoic lumen of the trachea then the tube will railed on the bougie and connected to the capnograph for endotracheal positioning confirmation when the square waveform will be maintained for five breaths.
214484008|NCT06836388|PROCEDURE|Conventional methods for bougie insertion|The anesthesiologist will perform the bougie insertion using a C-mac laryngoscope, and he will assess the difficulty of visualization using the Cormack Lehan score; if the score is three or more, the bougie will be gently inserted with the curved tip anteriorly into the trachea while feeling the tracheal clicks as a sign of correct its placement, the intubator will advance it gently till feel resistance then withdraw 2-3 centimeters. If the depth of the bougie reaches 30 centimeters from the angle of the mouth without feeling the resistance, the bougie will be removed and reinserted. Then, the tube will be railed on the bougie and connected to the capnograph for endotracheal positioning confirmation when the square waveform is maintained for five breaths.
214319619|NCT03479866|OTHER|Dietary intervention|To carry out an interventional dietary study using standardised meals to predict for an individual their metabolic response to certain foods using the gut microbiome and their metabolic profile. Responses will include post-prandial appetite, levels of satiety, circulating glucose, insulin, ketone bodies and lipid levels.
214319620|NCT01167062|DRUG|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
214484009|NCT06352840|BEHAVIORAL|My Pelvic Plan Website|This is a self-directed program which integrates patient education about conditions that frequently contribute to pelvic pain, as well as instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Participants will have open access to the program over the 6-month intervention period. The intervention will be comprised of an active (12-week) phase and a maintenance (3-month) phase. Participants will receive a weekly text or email prompt directing patients to a specific module. All participants will receive prompts to the same modules for the first four weeks of the study, then during the next 8 weeks, participants will receive prompts to modules that corresponded to the most impactful symptoms on participant's baseline questionnaires. Following 12-week active phase, all participants will enter the maintenance phase.
214919913|NCT00602836|BIOLOGICAL|Rituximab|Cycle 1: 100 mg by IV on day 1, 375 mg/m\^2 by IV on day 2 Cycle 2-6: 375 mg/m\^2 by IV on day 1 (every 21 days)
214919914|NCT00602836|DRUG|Cyclophosphamide|600 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
214319621|NCT01167062|OTHER|Placebo|One tablet OD for a maximum of 28 days
214919915|NCT00602836|DRUG|Lenalidomide|Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
214319622|NCT06391866|OTHER|extracorporeal circulation|extracorporeal circulation during cardiosurgical operation
214319623|NCT03310424|OTHER|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
214319624|NCT02129075|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
214319625|NCT02129075|DRUG|Poly ICLC|Given SC
214319626|NCT02129075|BIOLOGICAL|Recombinant Flt3 Ligand|Given SC
214319627|NCT00333229|DRUG|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
214319628|NCT00333229|DRUG|Placebo|Matching Placebo
214319629|NCT00348556|DRUG|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
214319630|NCT02720926|DRUG|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
214319631|NCT02720926|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
214319632|NCT02720926|DRUG|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
214319633|NCT03161561|OTHER|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
214319634|NCT00240071|DRUG|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
214319635|NCT00240071|DRUG|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
214319636|NCT03744377|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
214319637|NCT03294603|DRUG|CC-220|1mg \[14C\]-CC-220 will be administered as a single dose
214319638|NCT03294603|RADIATION|[14C]|Single dose of \[14C\]-CC-220 will contain approximately 1.4 μCi of radioactivity
214319639|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL QD: RAL 800 mg/24 hs
214319640|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID 400 mg/12 hs
214319641|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID to QD
214319642|NCT03646721|DRUG|DA-1241|"\[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)"
214319643|NCT03646721|DRUG|Placebo|\[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.
214319644|NCT03646721|DRUG|Sitagliptin|\[Part2\] Administration of Sitagliptin 100mg once daily for 56 days.
214319645|NCT04723199|DEVICE|Electrocautetery LAMS|Electrocautetery LAMS
214319646|NCT01332617|DRUG|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"1. Simvastatin 80 mg PO daily starting day -2 through day 10.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
214319647|NCT02457533|BEHAVIORAL|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
214319648|NCT01944059|DRUG|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
214319649|NCT01944059|OTHER|Placebo (l-alanine)|Theramine like placebo comparator
214319650|NCT03645629|DIAGNOSTIC_TEST|skin test with food at different storage times|Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
214319651|NCT06099262|BEHAVIORAL|GenPMTO|GenPMTO is a parenting programme which involves trained practitioners using active teaching approaches (such as group problem-solving, role-play, and video modelling) to support caregivers in using positive parenting strategies at home. The programme is designed to improve parenting practices, as well as a range of outcomes for young people, including improving academic performance, reducing school exclusions, and reducing offending and criminal behaviour. The version of the programme investigated in this project is delivered to groups of parents.
214319652|NCT00049062|DRUG|anastrozole|
214319653|NCT00049062|DRUG|gefitinib|
214319654|NCT04514575|BIOLOGICAL|Plasma transfusion|Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
214319655|NCT03219060|BEHAVIORAL|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
214319656|NCT03219060|BEHAVIORAL|Brief advice|Brief advice based on 5As
214319657|NCT02633956|DRUG|Obeticholic Acid|Once a day (QD) by mouth (PO)
214319658|NCT02633956|DRUG|Atorvastatin|"Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated."
214319659|NCT02633956|DRUG|Placebo|Once a day (QD) by mouth (PO)
214319660|NCT01166594|DRUG|Bevacizumab|Intrableb injection
214319661|NCT01166594|DRUG|Control|intrableb BSS injection
214319662|NCT02157766|BEHAVIORAL|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
214319663|NCT02157766|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
214319664|NCT02157766|BEHAVIORAL|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
214319665|NCT03373175|DEVICE|Basal record|Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.
214919916|NCT00602836|DRUG|Pentostatin|2 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
214319666|NCT03373175|DEVICE|PS 10 record|PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
214319667|NCT03373175|DEVICE|PS 15 record|PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
214319668|NCT03373175|DEVICE|PS 20 record|PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
214319669|NCT04118010|DRUG|Vitamin D3|High-dose vitamin D3 50,000 IU /week for 12 weeks
214319670|NCT04118010|DRUG|Placebo vitamin D3|Matching to Vitamin D3 placebo capsules for 12 weeks
214319671|NCT04118010|DRUG|Inulin|Chicory-derived prebiotic inulin 12 g/day for 12 weeks
214319672|NCT04118010|DRUG|Placebo Inulin|Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
214319673|NCT04301167|BEHAVIORAL|befriending|Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
214919917|NCT02745431|DRUG|Oxytocin|
214919918|NCT02745431|DRUG|Placebo|
214919919|NCT04018131|DRUG|Cimetidine|Antihistamine 2 antagonist
214319674|NCT01304485|DRUG|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
214319675|NCT00024362|DRUG|BBR 3464|
214919920|NCT04018131|DRUG|Placebos|Placebo drug
214919921|NCT06014190|DRUG|HS-20089|All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
214919922|NCT03386591|DRUG|Naloxone|Comparing pharmacokinetics of naloxone
214919923|NCT03386591|DEVICE|Mucosal atomization device and syringe|Injection
214919924|NCT03386591|DEVICE|Narcan|Nasal Spray
214919925|NCT03386591|DEVICE|Intramuscular Auto Injector|Intramuscular injection
214919926|NCT00516672|DRUG|pazopanib|Pazopanib oral tablet
214919927|NCT00516672|DRUG|Lapatinib|Lapatinib oral tablet
214319676|NCT06034054|OTHER|nursing counceling|"* Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~* Answering the information and questions that the patient needs in addition, and receiving contact information in October.~* Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive."
214319677|NCT04400721|DRUG|Erector spinae plane block with ropivacaine 3.75mg/ml|Single shot erector spinae block
214319678|NCT03106727|BEHAVIORAL|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
214319679|NCT03125369|PROCEDURE|Sleeve gastrectomy + duodeno-jejunal bypass|
214319680|NCT03125369|PROCEDURE|Roux-Y gastric bypass|
214319681|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
214319682|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
214319683|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
214319684|NCT01489046|DRUG|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
214319685|NCT01489046|DRUG|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
214319686|NCT01489046|DRUG|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
214319687|NCT01489046|DRUG|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
214319688|NCT01586468|DRUG|WF10|0.5 mg/kg B.W.
214319689|NCT01586468|DRUG|NaCl Solution|NaCl Solution
214319690|NCT05525819|DRUG|Control group|The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
214319691|NCT05525819|DRUG|Intrathecal group|The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
214319692|NCT05525819|DRUG|Intravenous group|The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
214319693|NCT04206293|DEVICE|Juvederm® VOLITE|1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).
214319694|NCT00996762|DRUG|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
214319695|NCT04127760|RADIATION|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
214919928|NCT00086177|DRUG|8% progesterone vaginal gel|Progesterone 8% Vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
214919929|NCT00086177|DRUG|Placebo Vaginal Gel|Placebo vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
214919930|NCT06940440|DRUG|IFx-Hu2.0|"Therapeutic Classification:~• Innate immune agonist~Route of Administration:~• Intralesional"
214919931|NCT06940440|DRUG|Pembrolizumab|"Therapeutic Classification:~• Immunotherapy (Immune checkpointinhibitor)~Route of administration:~• Intravenous (IV) infusion"
214919932|NCT06939634|DEVICE|Hands-free exoskeleton|Having undergone at least on session with Atalante exoskeleton. Clinical, safety and session data are collected retrospectively.
214919933|NCT06939101|BEHAVIORAL|self-efficacy training|The principal investigator will supervise students and build this program to increase occupational, physical, and speech therapy student participation. There are two one-hour briefing meetings for onboarding to promote self-efficacy preparation and six 1-2 hours of debriefing after each clinical day.
214919934|NCT06941246|PROCEDURE|Non Surgical Periodontal Treatment|the intervention includes Non Surgical Periodontal Therapy( scaling and root planning ),performed to reduce periodontal inflammation .Gingival Crevicular fluid samples will be collected before and after treatment to assess changes in prolactin hormone levels.
214919935|NCT06941246|DEVICE|paper points|we use paper point to collect GCF sample
214919936|NCT06941246|DEVICE|ELISA Kits|The samples are analyzed by ELISA kits to measure prolactin levels
214319696|NCT06288516|DRUG|Benralizumab 30 mg/ml|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
214319697|NCT00599937|DRUG|ATRA|early introduction of ATRA
214319698|NCT00599937|DRUG|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
214319699|NCT04587934|DEVICE|iRes Warmer with ResusView|Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
214319700|NCT04587934|OTHER|iRes Warmer without ResusView|Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
214319701|NCT02773043|DEVICE|CZT SPECT camera|
215061466|NCT04930120|OTHER|Inter ICU long distance patient transfer|Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
214319702|NCT01454934|DRUG|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
214319703|NCT01454934|DRUG|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"* Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~* Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~* Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~* Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
214484010|NCT06352840|BEHAVIORAL|Control Group website|Patients in the control group will undergo an active control intervention in which participants receive open access to a separate website that contains only the Monitoring Progress symptom tracker subpage over the 6-month study period. Control group participation will also be divided into an active (12-week) phase and a maintenance (3-month) phase. Similar to the intervention group, the control group will receive a weekly text (first 12 weeks) or email prompt directing them to a specific module or portion of the respective website. During the maintenance phase of the study, participants will receive monthly prompts to the Monitoring Progress subpage (without prompting to a specific symptom or activity).
215061467|NCT00690430|DRUG|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
215061468|NCT00690430|DRUG|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
215061469|NCT04094493|DRUG|vit D|preoperative intra muscular vit D injection
215061470|NCT01967797|BEHAVIORAL|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes \& team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners \& teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
215061471|NCT00617097|DRUG|lidocaine|paracervical block with lidocaine
215061472|NCT00617097|DRUG|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
215061473|NCT04807088|PROCEDURE|Tactile-kinesthetic Stimulation|
215061474|NCT04807088|OTHER|Placebo|
215061475|NCT04322331|OTHER|no intervention|no intervention
215061476|NCT01430143|BEHAVIORAL|Exercise|Daily exercise for 12 weeks.
215061477|NCT04963855|DRUG|GT300|SIngle oral dose
215061478|NCT04963855|DRUG|Microcrystalline cellulose|placebo
215061479|NCT03933683|DEVICE|Pudendal nerve terminal motor latency assessment|After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
215061480|NCT05641012|OTHER|data collection|helioderma evaluation
214319704|NCT02227485|DRUG|Punica granatum Pleniflora (Golnaar) mouth rinse|"All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks."
214319705|NCT02227485|DRUG|Chlorhexidine (0.2%)|All the patient in control group use 10 ml of chlorhexidine (0.2%) for 2 minutes every night for 2 weeks.
214319706|NCT02227485|PROCEDURE|Tooth bleaching|Tooth bleaching for both groups one time after using mouth rinses.
214319707|NCT01079871|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
214484011|NCT02937662|DRUG|Idarubicin|Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
214484012|NCT02937662|DRUG|Cytarabine|Cytarabine at a dose of 100mg/㎡/d on days 1-7.
214484013|NCT02937662|DRUG|Cyclophosphamide|Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
215061481|NCT00244868|OTHER|counseling intervention|
215061482|NCT00244868|OTHER|educational intervention|
215061483|NCT02030769|DRUG|Pronase|use pronase to improve visibility during endoscopical iodine staining
215061484|NCT02030769|DRUG|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
215061485|NCT05247450|DEVICE|Functional electrical stimulation therapy (FES-t)|Functional electrical stimulation therapy (FES-t) that will use a multichannel device (MyndSearch device).
215061486|NCT05247450|OTHER|Conventional physiotherapy|Conventional physiotherapy is the current standard of care for rehabilitation of C5 palsy
215061487|NCT02125838|DEVICE|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
215061488|NCT02125838|DEVICE|Endotracheal Tube|ETT
215061489|NCT04227626|DEVICE|GlucoSTAT|Closed-loop blood glucose control using intravenous insulin and dextrose
215061490|NCT01088204|PROCEDURE|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
215061491|NCT01088204|PROCEDURE|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
215061492|NCT05195086|DRUG|endoxan|Immunosuppressant
215061493|NCT05195086|DRUG|cellcept|Immunosuppressant
215061494|NCT00787839|OTHER|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
214484014|NCT02937662|DRUG|Physician-Directed Regimens without Cyclophosphamide|Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
214319708|NCT04966338|BIOLOGICAL|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) will be administered via intravenous (IV) infusion.
214319709|NCT04966338|BIOLOGICAL|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) will be administered via intravenous (IV) infusion.
214319710|NCT02021591|BEHAVIORAL|Mobile Diabetes Detective (MoDD)|MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
214319711|NCT02312232|DRUG|levodopa, carbidopa, ODM-104|
214319712|NCT04877262|OTHER|weight maintenance diet (WMD)|A diet meeting the participant's weight maintenance energy needs will be provided.
214319713|NCT01352390|BEHAVIORAL|Planning Prompt|A prompt to have their child their health test reminder mailing to color
214319714|NCT01352390|BEHAVIORAL|Control Condition|A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
214319715|NCT02848976|OTHER|Re-training to effort (RE)|The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
214484015|NCT03237377|DRUG|Durvalumab|1500mg via IV infusion every 4 weeks for up to 3 doses/cycles
214319716|NCT02378844|DEVICE|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
214319717|NCT02378844|DEVICE|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
214484016|NCT03237377|DRUG|Tremelimumab|75mg via IV infusion every 4 weeks
214484017|NCT03237377|RADIATION|Thoracic Radiation|5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction
214484018|NCT03237377|PROCEDURE|lobectomy|patients may proceed to surgery post drug and radiation intervention for lung lobectomy
214484019|NCT03237377|DRUG|Standard of care adjuvant chemotherapy|patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery
214919937|NCT06939595|DRUG|CT-P51|CT-P51 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks
214484020|NCT03278119|DIAGNOSTIC_TEST|PET Scan and nocturnal polysomnography|Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables
214484021|NCT05354531|PROCEDURE|anterior subcutaneous internal fixator ( INFIX)|INFIX was invented based upon the same biomechanical principle as the traditional external fixator, but it is placed subcutaneously. It proved to be stiffer than the traditional external fixator, and at the same time eliminates the open pin tracts, which increased the infection rate and nursing care
214484022|NCT05583513|DIAGNOSTIC_TEST|MLHFQ (Minnesota Living with Heart Failure Questionnaire)|The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL
214484023|NCT05583513|DIAGNOSTIC_TEST|KCCQ (the Kansas City Cardiomyopathy Questionnaire)|The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
214484024|NCT04363853|DRUG|Tocilizumab 20 MG/ML|We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
214484025|NCT05909709|DRUG|Alocyte low dose|"Low dose containing 0.2 - 1.0 x 10\^11 particles and 3-10x10\^6 cell in 2mL which will be administered intra-facet into a single facet joint.~Preparation of low dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 2ml of the diluted product will be used."
214484026|NCT05909709|DRUG|Alocyte medium dose|"Medium dose containing 0.6 - 3.0 x 10\^11 particles and 9-30x10\^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used."
214919938|NCT06939595|DRUG|EU-approved Keytruda|Keytruda 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks
214484027|NCT05909709|DRUG|Alocyte high dose|"High dose containing 1.0 - 5.0 x 10\^11 particles and 15-50x10\^6 cell in 10mL which will be administered intra-facet into five facet joints delivering 2ml/facet joint.~Preparation of high dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, 10ml of diluted product will be used."
214919939|NCT06939881|OTHER|"11 for Health training group"|"The 11 for Health intervention consisted of two 45-minute sessions per week for 11 weeks, implemented during school hours. Each week included one session focused on football-related physical activities (e.g., passing, dribbling, shooting) and another on health education topics (e.g., hygiene, nutrition, mental well-being), both delivered in an engaging and inclusive format. The program emphasized social interaction, autonomy-supportive teaching, and real-life applicability through take-home tasks."
215061495|NCT00787839|OTHER|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
215061496|NCT03201575|DEVICE|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
214319718|NCT04254614|DEVICE|Personalised mobile application for IBD patients|"Patients will use a mobile application for ±6months (exact period depends on interval of biologic treatment) with the following functionalities:~* Personal interactive timeline to prepare for biologic treatment with reminders for blood tests, a questionnaire to exclude contra-indications for biologic treatment (e.g. current infection) and a message from the gastroenterology nurse when blood tests results and the questionnaire have been checked. Only in case of abnormal results or answers patients will be contacted by telephone by their gastroenterology nurse, which is currently standard care.~* Information about the patients' diagnosis and biologic treatment.~* General information on e.g. IBD treatment, vaccinations, frequently used medical terms, preparing for outpatient visits, what to do in case of disease symptoms.~Patients will fill in a questionnaire to measure study outcomes at baseline and at the end of the study period."
214319719|NCT00854503|DRUG|Simvastatin|20 mg/day in one oral administration
214319720|NCT00854503|DRUG|Rosuvastatin|20 mg/day in one oral administration.
214319721|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* on pre-operative d-1/d, post-operative d1 and d5(+/-2),~* one month post-operative,~* at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
214319722|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* before starting the therapy~* at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~* at the end of the study or at the date of disease progression."
214319723|NCT03696524|DEVICE|tunneled pleural catheter|Placement of a tunneled pleural catheter through the chest wall into the pleural space to drain the patient's chronic pleural effusion. The catheter is an indwelling device that will be drained from home three times per week by nursing care, the patient, or patient's family.
214319724|NCT06187545|DEVICE|Minimum viable prototype|Deep sedation in critical ill patients using minimum viable prototype
214319725|NCT06187545|DEVICE|Usual care|Deep sedation without minimum viable prototype
214319726|NCT04322396|DRUG|Azithromycin|Azithromycin
214319727|NCT04322396|DRUG|Hydroxychloroquine|Hydroxychloroquine
214319728|NCT04322396|DRUG|Placebo oral tablet|Placebo Azithromycin
214319729|NCT04322396|DRUG|Placebo oral tablet|Placebo Hydroxychloroquine
214319730|NCT04061694|PROCEDURE|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
214319731|NCT04061694|PROCEDURE|Immediate loading|Only subjected to immediate loading. Conventional procedure.
214319732|NCT01225445|DRUG|Ramipril|2.5 mg daily
214319733|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
214319734|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
214919940|NCT06939868|DIETARY_SUPPLEMENT|Shatavari Root Extract, oral capsule|"This intervention consists of a proprietary, standardized extract of Asparagus racemosus (Shatavari), formulated specifically for women's health and cognitive support. The supplement is provided in oral capsule form and standardized to a specific concentration of shatavarin IV, the primary active compound. Participants will take one capsule daily for 30 days.~This formulation, known as SheVari4™, is patent-pending and manufactured by Cepham, designed to address vasomotor symptoms (hot flashes) and other menopausal concerns. It is distinct from other Shatavari supplements in its standardization and use in a placebo-controlled, double-blind trial targeting postmenopausal women."
214919941|NCT06941142|DRUG|Sirolimus (albumin - bound)|Dose escalation, intravenous infusion
214319735|NCT01406821|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
214319736|NCT01406821|PROCEDURE|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
214319737|NCT00748644|DRUG|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
214319738|NCT00748644|DRUG|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
214319739|NCT00280254|PROCEDURE|Hemodynamically Oriented Echocardiography-based Strategy|
214319740|NCT04313920|OTHER|Nutritional Supplement|50 g Carbohydrate
214319741|NCT00846924|DEVICE|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
214319742|NCT00846924|DEVICE|24-hour Holter|Repeat standard 24-hour Holter Monitor
214319743|NCT01123538|DRUG|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
214319744|NCT01123538|DRUG|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
214319745|NCT04338711|DRUG|tofacitinib modified release (MR)|"Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution"
214319746|NCT01248026|OTHER|Buttermilk|"Consumption of the 2 experimental periods~1. buttermilk (45 g/d)~2. placebo (45 g/d,)"
214319747|NCT00004436|DRUG|leuprolide|
214319748|NCT00004436|DRUG|prednisone|
214319749|NCT03374826|DIAGNOSTIC_TEST|Dedicated axillary hybrid PET-MRI|All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.
214319750|NCT06218004|DRUG|Envafolimab combined with chemotherapy|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
214319751|NCT01993108|DRUG|Methylphenidate|One dose 40mgs of methylphenidate one hour before fMRI scanning.
214319752|NCT01993108|DRUG|Naltrexone|One dose 40mgs of naltrexone one hour before fMRI scanning.
214319753|NCT01993108|DRUG|Placebo|One dose of placebo one hour before fMRI scanning.
214319754|NCT03995576|OTHER|thoracic sympathetic ganglion block|thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
214319755|NCT01697657|DRUG|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
214319756|NCT01697657|DRUG|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
214319757|NCT01697657|DRUG|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
214319758|NCT03160963|OTHER|Power Testing|Chair stand, vertical jump, computerized squat
214319759|NCT00628290|DRUG|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
214319760|NCT00628290|DRUG|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
214319761|NCT01802775|DRUG|edoxaban|
214319762|NCT01802775|DRUG|Clopidogrel|75mg tablet
214319763|NCT01802775|DRUG|Aspirin|
214319764|NCT04433897|OTHER|Questionnaire|"All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale"
214319765|NCT00386256|DEVICE|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
214319766|NCT00386256|OTHER|Telephone counseling|
214319767|NCT00052845|DRUG|docetaxel|70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
214319768|NCT00052845|DRUG|estramustine phosphate sodium|280 mg PO tid Days 1-5 of ea cycle
214319769|NCT00052845|DRUG|exisulind|Two 125 mg capsules PO bid Days 1-21 of ea cycle
214319770|NCT04269967|OTHER|Receiving routine rehabilitation care via tele-rehabilitation system|Drain care education, self-massage techniques and exercise (PT and OT)
214319771|NCT05429450|DRUG|Methotrexate|Three periocular injections of methotrexate at week 0, week 3 and week 6.
214319772|NCT05429450|DRUG|Triamcinolone Acetonide|Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
214319773|NCT06278675|DEVICE|Acupuncture needles|"1. Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.~2. Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days."
214319774|NCT03438435|DRUG|QRH-882260 Heptapeptide|Imaging agent
214319775|NCT03019276|DRUG|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
214319776|NCT01375218|OTHER|Pavlik Brace|Pavlik Brace
214319777|NCT01375218|OTHER|Plastizote Brace|Plastizote Brace
214319778|NCT05928650|OTHER|Evaluation of menstrual function|Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
214319779|NCT03897972|BEHAVIORAL|Non-personalised diet advice delivered via the eNutri app (control)|Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).
214319780|NCT03897972|BEHAVIORAL|Personalised diet advice delivered via the eNutri app (intervention)|Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
214319781|NCT04935151|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser
214319782|NCT04935151|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
214319783|NCT01285206|DEVICE|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
214319784|NCT02994342|DEVICE|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
214319785|NCT06189456|DEVICE|BLUgel A|BLUgel A: Hyaluronic Acid Eye Drops 0.30%
214319786|NCT06189456|DEVICE|BLUyal A|BLUyal A:Hyaluronic Acid Eye Drops 0.15%
214319787|NCT05329597|GENETIC|Genotyping|Genotyping is performed using the subjects' blood cells
214319788|NCT05227924|DEVICE|Total hip arthroplasty (primary or revision)|Total hip arthroplasty with at least one medical device from the SYMBOL range
214319789|NCT02897596|DRUG|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
214319790|NCT02897596|DRUG|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
214319791|NCT02897596|DRUG|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
214319792|NCT02897596|DRUG|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
214319793|NCT01529359|DIETARY_SUPPLEMENT|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
214319794|NCT01529359|DIETARY_SUPPLEMENT|Placebo|Placebo 2 gelules per days for 6 weeks
214919942|NCT06941142|DRUG|Palbociclib tablet|The dosage is 125 mg, orally once a day. Taken continuously for three weeks followed by a one - week break, with a treatment cycle of four weeks
214671915|NCT03681860|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly-attenuated strain of vaccinia virus which cannot replicate in human cells. It is known to be highly immunogenic in UK adults but has been less immunogenic in African children and infants. It is suitable for use as a viral vector in a prime-boost regime in new vaccine development. It has an excellent safety record as it was administered intradermally to approximately 120,000 people during the smallpox eradication campaign, and has since been used in numerous clinical trials of candidate vaccines against viral, mycobacterial and protozoal infections.
214671916|NCT03681860|BIOLOGICAL|BCG|BCG is the only vaccine currently approved for use against Tuberculosis.
214671917|NCT01525394|DRUG|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
214671918|NCT01525394|DRUG|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
214671919|NCT01525394|DRUG|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
214671920|NCT04180592|PROCEDURE|CT Fusion + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
214671921|NCT02282761|DRUG|ITI-007|
214671922|NCT02282761|DRUG|Placebo|
214671923|NCT00955240|BIOLOGICAL|cetuximab|
214671924|NCT00955240|DRUG|cisplatin|
214671925|NCT00955240|DRUG|fluorouracil|
214671926|NCT00955240|OTHER|laboratory biomarker analysis|
214671927|NCT00955240|RADIATION|radiation therapy|
214671928|NCT05355012|OTHER|5A organizational innovation|"This project is based on three strategic axes:~* A gradation of the care offer allowing to adapt the means and resources mobilized on the territory~* Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman~* Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population."
214671929|NCT03246269|DIAGNOSTIC_TEST|MoCA|
214319795|NCT04766749|OTHER|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
214319796|NCT01691027|BEHAVIORAL|Visuo-motor training|Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
214319797|NCT03341052|OTHER|Normal Diet|The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
214319798|NCT03341052|OTHER|High Fat Diet|The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
214671930|NCT06399081|OTHER|Observational|Observational
214671931|NCT00299377|DRUG|Abciximab i.v.|
214671932|NCT00299377|DRUG|Abciximab i.c.|
214671933|NCT03196713|BEHAVIORAL|Early Intensive Behavioral Intervention|
214671934|NCT04652024|DEVICE|Anorectal manometry|, patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
215061497|NCT03201575|DEVICE|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
215061498|NCT01389726|BEHAVIORAL|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
214671935|NCT03244371|OTHER|blood draw|4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
214671936|NCT01585389|GENETIC|gene expression analysis|
214671937|NCT01585389|GENETIC|genetic linkage analysis|
214671938|NCT01585389|GENETIC|microarray analysis|
214671939|NCT01585389|OTHER|immunohistochemistry staining method|
214671940|NCT01585389|OTHER|laboratory biomarker analysis|
214671941|NCT00060892|GENETIC|HGF plasmid|Intramuscular injections into index leg on Days 0, 14, and 28
214671942|NCT00001081|DRUG|Nitazoxanide|
214671943|NCT02348047|DEVICE|Hamilton T1|
214671944|NCT03992235|OTHER|Chest physiotherapy|"All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation."
214671945|NCT03992235|OTHER|Educational material|Exercise brochure with photos and explanations
214671946|NCT05896176|DIAGNOSTIC_TEST|a clinical examination and anamnesis|The investigators compare the results of the PSQ alone with the elements provided by the clinical examination regarding the referral of patients to the Otolaryngologist (ENT) consultation.
214671947|NCT00893607|DRUG|NRL001|10mg NRL001 was administered as a slow release suppository
214671948|NCT03280329|OTHER|Generalized Music therapy|Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge
214671949|NCT03280329|OTHER|Personalized Music therapy|Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
214671950|NCT00670111|DEVICE|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
214671951|NCT05123287|DRUG|PD-1 immune checkpoint blockades|intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
214671952|NCT05861947|DRUG|AUR106|Once or twice daily
214671953|NCT03988751|BEHAVIORAL|Ambulation|Variation in ambulatory intensity.
214671954|NCT01277146|DRUG|OMP-59R5|IV infusion
214919943|NCT06941142|DRUG|Fulvestrant injection|The dosage is 500 mg, intramuscular injection. It is given on the 1st and 15th days of the first cycle, with a treatment cycle of four weeks. After that, it is administered once every four weeks.
214319799|NCT03341052|OTHER|Low Fat Diet|The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
214319800|NCT01209897|BEHAVIORAL|Smoking cessation booklet|
214319801|NCT02385812|PROCEDURE|Low-dose computed tomography Annual scan x3|Annual scan x3
214319802|NCT02385812|PROCEDURE|Low-dose computed tomography Baseline scan only|Baseline scan only
214319803|NCT03848546|BEHAVIORAL|PDA|"Subjects receive personal dietary fiber advice to increase their fiber intake. This advice will be provided using an online web-portal, where subjects can choose high-fiber alternatives that closely match their own intake. The aim is to swap product for low in fiber for a high fiber alternative (such as white bread, whole wheat bread)."
214319804|NCT03848546|OTHER|Control (no intervention)|No intervention
214484028|NCT04933474|BEHAVIORAL|painTRAINER®|PainTRAINER is among the most widely-validated mHealth interventions for pain management.18-25 Originally developed by members of our team at Duke and Northwestern University under NIH funding, the app teaches evidence-based pain coping skills using a self-administered, home-based software program. The system delivers eight sessions via any web-connected platform, including Android or iOS smartphones, tablets, or personal computers. The digital curriculum covers progressive muscle relaxation, activity/rest cycling, pleasant activity scheduling, recognizing negative automatic thoughts, pleasant imagery/distraction, problem solving, and monitoring for maintenance. Patients complete one session per week in a pre-determined order. The program can be completed in a flexible manner to accommodate life and medical events.
214484029|NCT04933474|DEVICE|Skills-Based VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx+ software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
214919944|NCT06941350|BIOLOGICAL|NCR102 injection|Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.
214919945|NCT02716168|OTHER|Shared video consultation between patient, general practitioner and oncologist|At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
215061499|NCT01389726|BEHAVIORAL|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
215061500|NCT01389726|BEHAVIORAL|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader \& 1 peer leader over the course of 11 weeks.
215061501|NCT02383186|PROCEDURE|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
215061502|NCT02383186|PROCEDURE|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
215061503|NCT01591434|DEVICE|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
214319805|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
214319806|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
214319807|NCT00782210|DRUG|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
214319808|NCT06466954|OTHER|Evaluating spinopelvic alignment parameters|Evaluation of thoracic kyphosis, lumbar lordosis, pelvic tilt, and pelvic torsion
214319809|NCT06466954|OTHER|Measuring uterine dimensions|Measurement of corpus length, corpus width, cervix length, and cervix width
214484030|NCT06305143|DRUG|Conbercept|participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.
214484031|NCT05709782|PROCEDURE|Spine Radiosurgery|scan
214484032|NCT05709782|DEVICE|Magnetic Resonance imaging|scan
214484033|NCT05709782|RADIATION|MR-LINAC|scan
215061504|NCT01591434|DEVICE|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
215061505|NCT06071598|OTHER|Surgical specimens of CRC-affected patients|Specimens of CRC-affected patients will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
214319810|NCT04447092|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
214319811|NCT04447092|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
214319812|NCT04447092|DRUG|Pembrolizumab|Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
214319813|NCT04447092|DRUG|Oxaliplatin|Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
214319814|NCT04447092|DRUG|Leucovorin|Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
214319815|NCT04447092|DRUG|Irinotecan|Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
214319816|NCT04447092|DRUG|5FU|5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
214319817|NCT02627859|DEVICE|Durolane SJ|1ml single intra-articular injection in ankle
214319818|NCT01018420|DRUG|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
214319819|NCT01018420|DRUG|Moxifloxacin|400 mg capsule at the 6 hour point
214319820|NCT04895384|DEVICE|Edwards ClearSight and Masimo SET|Placement of Edwards ClearSight and Masimo SET on the patient intraoperatively.
214319821|NCT00964808|DRUG|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
215061506|NCT01693198|PROCEDURE|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
215061507|NCT04826263|OTHER|Home Exercise Program|All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.
214319822|NCT00964808|DRUG|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg \* 2 pr. day until time to discharge from the Hospital or latest at day 12.
214319823|NCT05015491|BEHAVIORAL|Noom Healthy Weight Program|"The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Users are encouraged to log their weight (Weight Logging) at least 1x/week and log their food and beverages (Food Logging) daily. Exercise logging (steps via automatic collection or manually added) is done daily. The Noom Food color grading system is founded on calorie-density (Volumetrics diet, Barbara Rolls) and is a simple and effective method for creating long lasting changes in diet and food choice. Coaches are contacted via In-app messaging or phone communication."
214319824|NCT02053727|DRUG|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
214319825|NCT02053727|DRUG|Placebo|
214319826|NCT06457022|OTHER|Modified Constraint Induced Movement therapy|patient wears a restraint instrument in his unaffected hand, then applying massed practice to his affected upper extremity. The patient wears padded glove in his unaffected upper extremity for restraining the patient from using his unaffected upper extremity for about 3 hours per day including the treatment session and the home program. So, by this way the patient is reinforced to use his affected upper extremity during this period of time to achieve his activities of daily living. Finally, the total time, the patient spends it during the day wearing the glove should be recorded each day.
214319827|NCT06457022|OTHER|Dual task training in the form of cognitive - motor task|Verbal fluency: Ask the hemiparetic patient to title many words of specific type as fruits, vegetable or animals. Mental tracking: as the hemiparetic patient to subtract serial 3 between number 90 and 100.
214319828|NCT06457022|OTHER|Conventional physiotherapy rehabilitation program|Ultrasound on shoulder. Graduated active exercises for shoulder. Prolonged stretching for spastic muscles
214319829|NCT05668767|DRUG|Surufatinib Durvalizumab EP/EC|Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
214319830|NCT05298852|DIAGNOSTIC_TEST|High resolution computed tomography of the chest|All participants were subjected to High resolution computed tomography of the chest.
214319831|NCT04210154|DEVICE|Haemodiafiltration|pre-dilution and post-dilution Haemodiafiltration
214319832|NCT00613600|DIETARY_SUPPLEMENT|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
214319833|NCT00613600|DIETARY_SUPPLEMENT|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
214319834|NCT06032624|PROCEDURE|combined ultra-sound guided femoral and sciatic nerve block.|Femoral nerve block, The femoral area will be scanned behind the midpoint of the inguinal ligament and the depth of the image will be set at 3-5 cm, and a linear high frequency 8-12MHz) probe will be placed perpendicular to the course of the femoral nerve., the volume of 15 ml of bupivacaine will be injected to perform the block. Sciatic nerve block, A curvilinear low-frequency (3-9 MHz) probe will be used to do a scan of the sub-gluteal region below a line from the ischial tuberosity and greater trochanter which are seen as two hyperechoic bony prominences,A volume of 25 ml of bupivacaine will be injected to perform the block.
214319835|NCT03683134|BEHAVIORAL|Mediterranean diet|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
214319836|NCT03683134|DIETARY_SUPPLEMENT|Olive oil and mixed nuts|Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.
214319837|NCT03683134|BEHAVIORAL|American Heart Association|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
214319838|NCT00826267|DRUG|lapatinib|lapatinib tablets 1500 mg daily
214319839|NCT00826267|DRUG|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
214319840|NCT00826267|DRUG|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
214484034|NCT05239169|DRUG|Durvalumab|Durvalumab at a fixed dose of 1500 mg as an IV infusion over 1 hour, on day 1 together with the Tremelimumab infusion. Durvalumab only infusion to be repeated every 4 weeks for a maximum of 12 months on day 1 of each cycle.
214484035|NCT05239169|DRUG|Tremelimumab|Tremelimumab at a fixed dose of 300 mg as an IV infusion over 1 hour on day 1 of cycle 1.
214484036|NCT05239169|DRUG|Capecitabine|Capecitabine at 1250 mg/m² p.o. twice a day on days 1 to 14 of a 3-weekly cycle (eight cycles).
214484037|NCT05451043|BIOLOGICAL|Durvalumab|It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1. Durvalumab is known as a checkpoint inhibitor drug
214919946|NCT06539403|BEHAVIORAL|Memory tasks|"Naturalistic Episodic Memory encoding: Participants will play short sessions of 3 board games with the researcher. The board games include Ludo, Snakes \& Ladders and Solitaire. Participants will play each boardgame for around 5 min. They will wear a head camera while playing the games.~Later participants will be tested on their memory of the naturalistic episodic memory task, a semantic memory task (memory of facts) and a perceptual task. Each task will consist of 2-3 sub-tasks of around 30 trials. These tasks will all take place on the computer and will take 30-40 minutes in total. In each trial participants will choose between two options. For example: Which of these two images is taken from your head camera? What colour piece did you use in 'snakes and ladders'?. After they choose their answer, they will report how confident they are in their choice. At the end of each task, they will be asked to report how well they think they performed on the task overall."
214319841|NCT04019912|OTHER|Gait Training plus music|GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
214919947|NCT04672577|OTHER|Observational study|No intervention is planned
214919948|NCT01069198|DRUG|Albendazole, Iron, Zinc and Vitamin A|single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged \<5 and \>=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.
214319842|NCT04019912|OTHER|Traditional Gait Training|The traditional training will be provided by a conventional treadmill.
214319843|NCT04987073|PROCEDURE|skin biopsy|A skin biopsy to cultivate fibroblasts.
214319844|NCT00044954|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214319845|NCT00044954|DRUG|cyclosporine|
214319846|NCT00044954|DRUG|fludarabine phosphate|
214319847|NCT00044954|DRUG|mycophenolate mofetil|
214319848|NCT00044954|PROCEDURE|allogeneic bone marrow transplantation|
214319849|NCT00044954|PROCEDURE|peripheral blood stem cell transplantation|
214319850|NCT00044954|RADIATION|radiation therapy|
214319851|NCT00134381|DRUG|Green Tea|Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
214319852|NCT00134381|DRUG|Placebo|Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
214319853|NCT04066426|DRUG|naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol|NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
214319854|NCT03962335|BEHAVIORAL|Vegetarian diet|7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months
214319855|NCT03962335|BEHAVIORAL|Mediterranean diet with butyrate|7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months
214319856|NCT03962335|BEHAVIORAL|Mediterranean diet|7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
214319857|NCT04888546|DRUG|Anlotinib hydrochloride capsules＋ TQB2450 injection|"Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
214319858|NCT05188352|OTHER|Chest physiotherapy|The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.
214319859|NCT05188352|OTHER|Aerobic exercise training|"A treadmill was used for aerobic exercise. Training intensity was used at 60-75% of maximal VO2.~Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period."
214319860|NCT04037202|OTHER|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
214319861|NCT00003082|BIOLOGICAL|monoclonal antibody A27.15|
214319862|NCT00003082|BIOLOGICAL|monoclonal antibody E2.3|
214919949|NCT01069198|OTHER|Placebo|Placebo
214919950|NCT06940791|DRUG|Tirabrutinib|Tirabrutinib (480 mg) taken orally daily at fasting condition
214919951|NCT06940791|DRUG|Placebo|Placebo taken orally daily at fasting condition
214919952|NCT06941090|OTHER|sampling stool|Participants will receive a self-sampling stool kit with detailed instructions by mail to their home address. Samples will be mailed back by the participant to the treatment laboratory, which will determine the characteristics of their intestinal microbiota.
214919953|NCT04936750|OTHER|Analysis of body composition|The cross section of the third lumbar spine in the CT scan images of the patients was analyzed to obtain the parameters related to the body composition of the patients
214319863|NCT06051058|BEHAVIORAL|Care Transitions App|Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.
214484038|NCT05451043|DRUG|Gemcitabine|Gemcitabine is a nucleoside analog and a chemotherapeutic agent. As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells
214319864|NCT00004903|BIOLOGICAL|filgrastim|
214319865|NCT00004903|BIOLOGICAL|recombinant interferon alfa|
214319866|NCT00004903|DRUG|cisplatin|
214319867|NCT00004903|DRUG|cyclophosphamide|
214319868|NCT00004903|DRUG|cytarabine|
214319869|NCT00004903|DRUG|etoposide|
214319870|NCT00004903|DRUG|melphalan|
214319871|NCT00004903|PROCEDURE|peripheral blood stem cell transplantation|
214319872|NCT00554827|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
214319873|NCT00554827|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
214319874|NCT00554827|DRUG|Pralatrexate|Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or
214319875|NCT01885481|DRUG|Dexamethasone|epidural steroid injection using dexamethasone
214319876|NCT01885481|DRUG|Betamethasone|epidural steroid injection using betamethasone
214319877|NCT02837536|OTHER|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
214319878|NCT02837536|OTHER|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
214319879|NCT05263999|BIOLOGICAL|Itolizumab|Itolizumab \[Bmab600\]
214919954|NCT01733667|DEVICE|MediENT|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
214319880|NCT05263999|DRUG|EQ001 Placebo|EQ001 Placebo
214319881|NCT04400513|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart sounds using electronic stethoscopes
214319882|NCT05229224|OTHER|Osteo fluidic Sensitive méthod|Manual therapy, without manipulative treatment, based on rebalancing of the body with manual pressures on specific body areas.
214319883|NCT05229224|OTHER|Placebo method|Soft Manual pressures at specific points that are defined as non-effective and non-deleterious for patients.
214319884|NCT00219128|DRUG|aliskiren|
214319885|NCT01105247|DRUG|PCI-32765|420 mg daily or 840 mg daily
214319886|NCT00651482|DRUG|Everolimus|
214319887|NCT00651482|DRUG|Bevacizumab|
214319888|NCT00154453|PROCEDURE|obtain surgical specimen for analysis|
214319889|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo + MTX|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
214319890|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
214319891|NCT00048542|DRUG|OLE BSA Adalimumab +/- MTX|Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
214319892|NCT00048542|DRUG|OLE FD Adalimumab +/- MTX|Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
214319893|NCT00234988|DRUG|sibutramine hydochloride monohydrate|10 mg QD with the option to increase dose to 15 mg QD up until Week 4
214319894|NCT00578175|BIOLOGICAL|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
214319895|NCT00578175|BIOLOGICAL|ProQuad®|One subcutaneous injection.
214319896|NCT00578175|BIOLOGICAL|Havrix®|Two intramuscular injections.
214319897|NCT00578175|BIOLOGICAL|Prevnar®|One intramuscular injection.
214319898|NCT05126927|BIOLOGICAL|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
214319899|NCT03751085|DEVICE|AW frame|AW stereotactic frame for intracranial lesion biopsy
214319900|NCT05358496|DIAGNOSTIC_TEST|Data collection|Clinical data collection
214319901|NCT05243212|BIOLOGICAL|CAR-BCMA|CAR-BCMA T-cells are genetically modified autologous T-cells directed to the B-cell maturation antigen (BCMA). CAR-BCMA T-cells identify and eliminate BCMA-expressing malignant plasma cells. Upon binding to BCMA-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, persistence and elimination of malignant plasma cells.
214484039|NCT05451043|DRUG|Nab paclitaxel|Nanoparticle albumin-bound (nab) paclitaxel is a form of paclitaxel which works as an antimicrotubule agent. Paclitaxel, the active ingredient in nab-paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This interferes with the normal dynamic reorganization of the microtubule network required for interphase and mitotic functions
214484040|NCT05451043|BIOLOGICAL|Tremelimumab|Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker.
214484041|NCT05451043|DRUG|Propranolol|Competitively blocks both β1 and β2 adrenergic receptors.
214319902|NCT06448936|OTHER|Patient-reported outcome measures (PROMs)|Administration of questionnaires investigating the impact of facial difficult-to-treat basal cell carcinoma treated by surgery on patient's quality of life over the course of one year. The questionnaires will be submitted at baseline (i.e., before surgery) and at 3-months follow up.
214319903|NCT03129672|PROCEDURE|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
214319904|NCT00577512|DRUG|DTPACE|"* Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~* Thalidomide 200 mg by mouth (PO) Days 1-7~* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~* Adriamycin 15 mg/m2 Days 1-4~* Cyclophosphamide 600 mg/m2 Days 1-4~* Etoposide 60 mg/m2 Days 1-4"
214484042|NCT05451043|DRUG|Cisplatin|cisplatin has been associated with ability to crosslink with the urine bases on the DNA to form DNA adducts, preventing repair of the DNA leading to DNA damage and subsequently induces apoptosis within cancer cells.
214484043|NCT04174170|DRUG|Brexpiprazole|3 mg pill
214484044|NCT04174170|DRUG|Sertraline|150 mg pill
214484045|NCT04174170|OTHER|Placebo|Pill
214484046|NCT04174170|DRUG|Brexpiprazole|2 mg pill
214484047|NCT06217276|OTHER|Respiratory muscle fatigue protocol|It will be performed using a powerbreath device at 60% of the maximum inspiratory pressure (MIP) amount obtained by measuring mouth pressure. The protocol includes 7 sets consisting of 2 minutes of inspiratory effort and 1 minute of rest. To further confirm the occurrence of fatigue, the patient will score fatigue using the modified Borg scale, and the score will be 5 or above11. During the application, heart rate, blood pressure and peripheral oxygen saturation will be monitored. The measurement will be performed once for each case.
214484048|NCT05556967|DRUG|Immulina|Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
214484049|NCT00324415|BIOLOGICAL|cetuximab|400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
214484050|NCT00324415|DRUG|cisplatin|75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
214484051|NCT00324415|DRUG|fluorouracil|1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
214484052|NCT00324415|RADIATION|radiation therapy|Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy \[5 weeks if given on schedule and without interruption\], maximum 54.0 Gy \[6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
214484053|NCT06635486|BEHAVIORAL|Adapted cognitive-behavioral (CBT) intervention|The intervention is 6-12 sessions, depending on the symptom presentation of the participant. The weekly sessions last 60 minutes and will be delivered remotely and individually via Meet or a similar platform by trained lay providers. Intervention methods include cognitive re-structuring, behavioral activation, exposure to memories and situations, problem solving, and emotional regulation.
214484054|NCT04867525|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
214484055|NCT05178849|OTHER|Hypnosis|Hypnosis
214484056|NCT05178849|DRUG|Local anesthetic|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
214919955|NCT01733667|DEVICE|MeroPack|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
214919956|NCT01583062|DRUG|Amoxicillin/clavulanic acid|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
214919957|NCT01583062|DRUG|Amoxicillin plus placebo|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
214919958|NCT03299660|DRUG|Avelumab|Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT
214919959|NCT03299660|DRUG|5 Fluorouracil|5FU continuous infusion 225mg/m2/day during radiotherapy
214319905|NCT04419688|DRUG|STT-5058|Monoclonal Antibody STT-5058
214319906|NCT04419688|DRUG|Placebo|Matching placebo to STT-5058
214319907|NCT02272413|DRUG|BI 695502|
214319908|NCT02272413|DRUG|Avastin|
214319909|NCT01968018|DRUG|Tramadol HCI/acetaminophen|Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
214319910|NCT00963339|DEVICE|Foresee Home|Home Monitoring
214484057|NCT04793750|DIAGNOSTIC_TEST|Cepheid GeneXpert HIV-1 Qual POC HIV VL test|POC Nucleic acid-based test for HIV RNA.
214484058|NCT04793750|DIAGNOSTIC_TEST|DPP HIV-Syphilis test system|POC Tests for antibodies to HIV 1/2 and Treponema pallidum.
214484059|NCT04793750|DIAGNOSTIC_TEST|OraQuick|POC oral fluid swab test for HIV 1/2 antibodies.
214484060|NCT03358446|OTHER|A group|"The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval."
214484061|NCT03358446|OTHER|S group|B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
214319911|NCT04780425|BEHAVIORAL|DESMOND|as previously described
214319912|NCT04780425|OTHER|usual care|usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
214319913|NCT04061603|DEVICE|Adagio AF Cryoablation System (iCLAS™)|Endovascular ablation of the left and right atrium
214319914|NCT01450410|DRUG|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
214319915|NCT01450410|DRUG|Placebo|Placebo treatment will last for 12 weeks.
214319916|NCT01164449|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
214319917|NCT02126969|RADIATION|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
214319918|NCT02126969|DRUG|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
214319919|NCT04729166|BEHAVIORAL|Structured education and follow-up|This structured educational material was developed by the authors on the basis of the literature. Interventions of the study were carried out in the 32nd-42nd week of pregnancy, 3rd-7th day postpartum, and at the 1st month. At first stage, a 15-20-minute education was given to the pregnant women in the study group in the breastfeeding room of the facility, educational booklets were distributed. The main emphasis parts of the education were repeated with a standard summary information form at each follow-up.
214319920|NCT01965808|DRUG|LY2157299|Administered orally
214319921|NCT03003975|DEVICE|PVI by single cryoballoon application guided by Achieve Mapping Catheter|Pulmonary vein isolation by single cryoballoon application guided by recorded electrogram signals from an internal Mapping Catheter and by temperature drop if mapping of signals is not possible (temperature cutoff \< or = -40 degrees C)
214319922|NCT03003975|DEVICE|PVI by 2 routine cryoballoon applications|Pulmonary vein isolation by 2 cryoballoon applications guided by degree of occlusion and by temperature drop according to discretion of physician
214319923|NCT04671459|COMBINATION_PRODUCT|TTFields and SRS|SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.
214319924|NCT02908113|BEHAVIORAL|collection data|
214319925|NCT02908113|BEHAVIORAL|IRM|
214319926|NCT01533246|DRUG|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
214319927|NCT01533246|OTHER|laboratory biomarker analysis|Correlative studies
214319928|NCT00091299|DRUG|warfarin|
214484062|NCT05325437|PROCEDURE|Laparoscopic splenectomy and azygoportal disconnection|The laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
214919960|NCT03299660|DRUG|Capecitabine Pill|Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy
214319929|NCT05180903|OTHER|X-tra base & GrandioSO reinforced by Ribbond|The missing peripheral tooth structure will be built up via 2-mm wedge-shaped a universal hybrid resin composite, GrandioSO . Then the polyethylene fibers will be wetted with an unfilled resin first . After removing the excess resin, fibers will be covered with a very thin layer of flowable composite X-tra base . After that, fibers will be bonded immediately against the peripheral missing walls and cured for 20 seconds. Then a bulk-fill flowable resin composite lining X-tra base will be applied in approximately 4 mm thick in bulk increments as needed to fill the cavity 2 mm short of the occlusal cavosurface and each increment will be light cured for 20 s. The remaining occlusal part of the cavity will be restored with a universal hybrid resin composite, GrandioSO . The shade of the composite will be selected according to the teeth to be restored. All cavities will be restored with open-sandwich technique (Deliperi, et al. 2017).
214319930|NCT02018289|PROCEDURE|Triclosan coated suture|Suture of the abdominal wall with triclosan coated suture
214319931|NCT02018289|PROCEDURE|No triclosan|Suture of the abdominal wall with suture without triclosan coat
214319932|NCT04949269|DRUG|Deucravacitinib|Specified dose on specified days
214319933|NCT04949269|DRUG|Famotidine|Specified dose on specified days
214319934|NCT00198016|DEVICE|Coil|
214319935|NCT05645822|OTHER|Screen&treat|Study participants will be tested with an RDT to prove the presence of antibodies against Trypanosoma brucei gambiense. Should the RDT be positive, they will be offered the 10-day treatment with fexinidazole, and an additional blood sample will be taken for the post hoc confirmation of the disease.
214319936|NCT03597581|DRUG|ompenaclid|RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.
214919961|NCT03299660|RADIATION|Radiotherapy|50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week
214919962|NCT03299660|PROCEDURE|Surgical Resection|Surgical resection of tumour mass post radiotherapy and chemotherapy
214919963|NCT00664768|DIETARY_SUPPLEMENT|Neocate Infant|minimum of 8 fl. oz daily
214919964|NCT00664768|DIETARY_SUPPLEMENT|new Neocate|minimum of 8 fl oz daily
214919965|NCT06030297|PROCEDURE|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fib"
214919966|NCT06030297|DRUG|ZTlido 1.8 % Topical System|ZTLI(diethylamino)-N-(2,6-dimethylphenyl), has an octanol:water partition ratio of 43 at pH 7.4. Each ZTLIDO contains 36 mg of lidocaine (18 mg per gram adhesive) in a non-aqueous base and also contains the following inactive ingredients: butylated hydroxytoluene, dipropylene glycol, isostearic acid, mineral oil, polyisobutylene, silicone dioxide, styrene/isoprene/styrene block copolymer, and terpene resin. DO (lidocaine topical system) 1.8% is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of ZTLIDO is 10 cm × 14 cm × 0.08 cm. Lidocaine, an amide local anesthetic, is chemically designated as acetamide, 2-
214319937|NCT03597581|DRUG|FOLFIRI|FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
214319938|NCT03597581|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor.
214319939|NCT03597581|DRUG|FOLFOX regimen|The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines
214319940|NCT04720365|DEVICE|play-based rehabilitaion|usual re-education treatment by their physiotherapist
214319941|NCT00250211|PROCEDURE|Functional MRI imaging and tomotherapy|
214319942|NCT04570293|DRUG|5% lidocaine medicated plaster|The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
214319943|NCT04570293|DRUG|vehicle plaster|Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
214319944|NCT05787951|DIAGNOSTIC_TEST|Bone marrow aspirite for diagnosis|Routine investigation of acute myeloid leukemia such as bone marrow aspirite for diagnosis ,cbc
214319945|NCT04931901|DEVICE|EMG TOF device|Use of Stimpod NMX450X as an electromyographic neuromuscular monitor
214319946|NCT03775668|DRUG|1 µCi of 14C-AAI101 + 500 mg AAI101|Single dose open label
214319947|NCT04498962|DRUG|Danzhu Fuyuan Granule|Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
214319948|NCT01143090|DRUG|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
214319949|NCT03145441|DEVICE|CytoSorb®|CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
214319950|NCT06298175|BEHAVIORAL|Self management training|The self-management training programme for the study group consisted of eight sessions. Each session lasted between 40 and 50 minutes and followed a structured format: a 5-minute introduction, a 5-minute summary of the previous session, and a 30-40 minute presentation on the session's topic. Training plan on cognition, emotion regulation and self-management was implemented
214319951|NCT06174324|DEVICE|PreserFlo Microshunt|The PreserFlo MicroShunt was invented to create a minimally invasive glaucoma drainage device, that comes close to the eye pressure reduction and safety profile of the current gold standard, the trabeculectomy. Reference: Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, Palmberg P, Parrish RK 2nd, Weber BA, Kwon Y, Parel JM. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017 Jan;105(1):211-221. doi: 10.1002/jbm.b.33525. Epub 2015 Sep 18. PMID: 26380916; PMCID: PMC5215625.
214319952|NCT01211028|BIOLOGICAL|Expanded autologous ASCs|Drug: Expanded autologous adipose-derived adult stroma/stem cells
214319953|NCT02304224|OTHER|eye masks|eye masks from 21:00 to 6:00 each night during admission
214919967|NCT06030297|DIAGNOSTIC_TEST|PeriCam PSI NR|It is a method that visualizes tissue blood perfusion in real time. LASCA provides new means to study the microcirculation in ways that were not possible in the past. PeriCam PSI System combines dynamic response and high spatial resolution in one instrument, providing both real-time graphs and video recordings of the tissue being studied. To further enhance its usability, dedicated application software, PIMSoft, has been developed.
214919968|NCT06030297|DIAGNOSTIC_TEST|Medoc Quantitative Sensory Testing|"Quantitative sensory testing (QST) is a method through which sensory nerve function is quantitatively measured, based on responses of the subject. The peripheral sensory nervous system responds to specific stimuli of specific modality and intensity in a specific manner, which is well-known through many decades of research into human sensation. Thermal QST provides information about the function of small diameter unmyelinated (C fibers) and thinly myelinated (A-delta fibers) nerve fibers for which no nerve conduction test, or other objective tests exist.~Small fiber nerve damage can manifest itself in thermal hypoesthesia (raised perception thresholds) or hyperalgesia (lowered pain thresholds)."
214919969|NCT06030297|OTHER|Inactive Topical System|Inactive, non-medicated topical system comprised of an adhesive material containing, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of the system is 10 cm × 14 cm × 0.08 cm.
214319954|NCT01245855|DRUG|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
214319955|NCT03926234|OTHER|Four-level Chinese Emergency triage scale|a four-level category system, i.e. life-threatening (Level I), emergent (Level II), urgent (Level III) and semi-urgent (Level IV) . This system contains critical indicators (cardiac arrest, shock, and apnea), high risk indicators (ACS and DKA), single objective indicators (SBP, RR, HR, and SpO2) and MEWS (synthesis indicator). According to patients' health care problems, patients are rated by nurses into one of the four mentioned levels.
214319956|NCT00548860|DRUG|Ferric Carboxymaltose|
214319957|NCT00548860|DRUG|Standard Medical Care (SMC)|
214319958|NCT01148953|DRUG|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
214319959|NCT01148953|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
214319960|NCT02719158|DRUG|6 mg ciprofloxacin|Single administration of OTO-201
214319961|NCT02719158|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
214319962|NCT02719158|OTHER|Sham|
214319963|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
214319964|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
214319965|NCT02612532|DEVICE|ReCIVA breath sampler|Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva
214319966|NCT03068299|OTHER|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
214319967|NCT03068299|OTHER|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
214919970|NCT06940453|DEVICE|CONDUIT|Arm Description: Group/Cohort Description: This cohort is composed of patients who will be prospectively enrolled (35 total). These patients will undergo spinal stabilisation for lumbar degenerative disease using the CONDUIT ALIF cage system with supplemental posterior fixation. This device is FDA approved thus this is post market observational intervention.
214319968|NCT04616807|DRUG|Mexiletine|Observational Study
214319969|NCT01414335|DIETARY_SUPPLEMENT|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
214319970|NCT01414335|OTHER|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
214319971|NCT01461096|BIOLOGICAL|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
214319972|NCT01461096|BIOLOGICAL|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
214319973|NCT01461096|BIOLOGICAL|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
214319974|NCT04089540|PROCEDURE|New intubation method|
214319975|NCT04089540|PROCEDURE|Conventional intubation method|
214319976|NCT04634149|DRUG|BMS-986036|Specified dose on specified days
214319977|NCT04892576|OTHER|Physical Therapy|"The control group recieved the standard physical rehabilitation program conducted for 45 minutes, twice a week for eight consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.~The SSC group received the same program in addition to the SSC exercises for 30 minutes, two times per week for eight successive weeks"
214319978|NCT03348358|BEHAVIORAL|quiet music|playing quiet music during labor
214319979|NCT03348358|BEHAVIORAL|Rhythmic music|playing rhythmic music during labor
214319980|NCT03348358|BEHAVIORAL|control|No music during labor
214319981|NCT00660062|DRUG|escitalopram|10 mg daily
214319982|NCT00660062|DRUG|escitalopram|20 mg daily dosage
214319983|NCT00660062|DRUG|escitalopram|30 mg daily dosage
214319984|NCT00660062|DRUG|nortriptyline|100 mg daily dosage
214319985|NCT05724849|DRUG|Venlafaxine|See arm/group description.
214319986|NCT05724849|DRUG|Placebo|See arm/group description.
214319987|NCT00852709|DRUG|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
214319988|NCT00852709|DRUG|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
214319989|NCT01783951|BIOLOGICAL|DC-CIK|Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
214319990|NCT01783951|DRUG|S-1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
214319991|NCT01783951|DRUG|Cisplatin|Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
214319992|NCT01044082|PROCEDURE|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
214319993|NCT01044082|PROCEDURE|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
214319994|NCT02162290|OTHER|Interval exercise training|Exercise bouts in low and high intensities
214319995|NCT02162290|OTHER|Continuous exercise training|
214484063|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
214484064|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
214484065|NCT06128356|DRUG|Dexmedetomidine Sublingual|Dexmedetomidine 120 mcg on two thin dissolvable films for sublingual administration
214484066|NCT05255926|DRUG|68Ga-pentixafor|All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq/kg body weight).
214955219|NCT05457179|BEHAVIORAL|Park-based physical activity|The experimental arm will optimize a 12-week intervention 3 days/wk, last approximately 60 minutes, and consist of 10 minutes of warm up, 15 minutes of simple strength training activities, 25 minutes of moderate to vigorous aerobic activities (e.g., walking), and 10 minutes of cool down. The eight full-body strength training exercises will use body weight and/or elastic bands and will include a circuit of chest press, seated row, squat, shoulder press, biceps curl, triceps extension, calf raise, and reverse crunch. Sessions will include education and skill building activities focused on Social Cognitive Theory mechanisms of change including self-efficacy, goal setting, and social support. Under the guidance of trained research staff, certified peer specialists who have experience working with peer groups, will be selected to help deliver the intervention.
214319996|NCT00389116|DRUG|gastrograffin|ingestion
214319997|NCT00389116|DRUG|water|oral water ingestion
214319998|NCT03504358|PROCEDURE|Liver resection|Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.
214319999|NCT01112293|DRUG|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
214320000|NCT02006277|DRUG|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
214320001|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
214320002|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
214320003|NCT02006277|DRUG|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
214320004|NCT02006277|DRUG|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
214320005|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
214320006|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
214320007|NCT02006277|DRUG|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
214320008|NCT02006277|DRUG|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
214320009|NCT02838212|DRUG|adverse drug reaction|drug-related death
214320010|NCT01666756|DIETARY_SUPPLEMENT|Chinese herbal formulation PHY906|Given PO
214484067|NCT05255926|DEVICE|PET/CT|PET/CT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.
214484068|NCT03932032|BEHAVIORAL|Attention Bias Modification Treatment|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
214484069|NCT03932032|BEHAVIORAL|Neutral Control Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
214484070|NCT05701098|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an ultrasound imaging system and a therapy probe driven by a high voltage generator. The probe will be placed on the patient's skin, the stone located via diagnostic ultrasound and up to 30 minutes of therapy will be delivered to the stone. The therapy probe accommodates coaxial alignment of an ultrasound imaging probe for treatment guidance.
214484071|NCT06364423|BIOLOGICAL|Autologous HuCD19 ( Anti-CD19)CAR T cells|1.0x10\^6 CAR+T-cells - 12x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
214484072|NCT06364423|DRUG|Cyclophosphamide|500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
214484073|NCT06364423|DRUG|Fludarabine|30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
214484074|NCT06364423|DRUG|Rituximab|500 mg/m2 IV infusion over 30 minutes on day -5; 375 mg/m2 IV infusion over 30 minutes on days 2-9 prior to apheresis
214919971|NCT04736498|OTHER|Inferior venacava Ultrasonography (IVC USG) guided fluid management|The IVC will be visualized using a paramedian long-axis view via a subcostal approach. A two-dimensional image of the IVC as it enters the right atrium will be first obtained. Variations in IVC diameter with respiration will be assessed using M-mode imaging performed 2 to 3 cm distal to the junction of right atrium and IVC. Maximum and minimum diameter will be measured from inner wall to inner wall and collapsibility index(CI) will be calculated using formula: CI = \[(dIVCmax - dIVCmin)/dIVCmax\] x 100% CI of ˃36% will be accepted as predicted fluid responder and ≤36% will be regarded as predicted fluid non responders. Predicted fluid responders will receive a bolus of 500 ml of Ringer's lactate over a time period of 15 min, after which the IVC diameter variation will be reassessed. Additional 250ml of Ringer's lactate bolus will be applied until a non fluid responder pattern is observed during IVC USG. Thereafter,spinal anaesthesia will be performed.
214919972|NCT02227498|DEVICE|Effect of Argus II on Functional Vision|To evaluate the safety and effectiveness of the Argus II Retinal Prosthesis in subjects with AMD.
214484077|NCT06463691|DRUG|BGB-11417|Sonrotoclax, orally, 320 mg once daily following a weekly ramp-up schedule
214955220|NCT05457179|BEHAVIORAL|Active Control|The active control group will receive information about the importance of park-based PA and a map of local park locations but will not participate in structured park-based PA sessions. Participants in the control group will be invited to participate in park PA sessions after they have completed posttest.
214955221|NCT02829047|DEVICE|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
214320011|NCT01666756|DRUG|sorafenib tosylate|Given PO
214320012|NCT01666756|OTHER|laboratory biomarker analysis|Correlative studies
214320013|NCT01666756|OTHER|pharmacological study|Correlative studies
214320014|NCT03715608|OTHER|Psychological Intervention|The patients in the intervention group received psychological counseling and corresponding medication after the operation. Psychotherapy was based on the clinical expertise of the psychosocial specialist from Peking University Sixth Hospital, who selected the most appropriate plan for each patient.
214320015|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
214320016|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
214320017|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
214320018|NCT02838264|DRUG|PF-06463922|Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
214320019|NCT02838264|DRUG|Itraconazole|200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
214320020|NCT06321874|PROCEDURE|Oxygen|
214320021|NCT02117037|OTHER|blood sample|
214320022|NCT03778151|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
214320023|NCT01807052|OTHER|laboratory biomarker analysis|Correlative studies
214320024|NCT00233727|PROCEDURE|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
214484078|NCT06463691|DRUG|BGB-3111|Zanubrutinib, orally, 320 mg total daily dose
214484079|NCT06463691|DRUG|CD20|CD20mab is recommened as Rituximab as per the protocol, other CD20mab is also allowed.
214484080|NCT05836688|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
214484081|NCT05836688|BEHAVIORAL|Individual Supportive Listening|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
214320025|NCT00233727|PROCEDURE|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
214320026|NCT05243095|OTHER|Computer assited, game-based cognitive training|"After recording the demographic information of the participants, the Stroop Test was applied to evaluate attention. After the stages of the test were explained to the participants in detail, they were shown once in practice.~The training group received 20 minutes of cognitive training every day for 8 weeks. No training was applied to the control group. Groups were evaluated at baseline and after 8 weeks."
214320027|NCT05706688|PROCEDURE|Anesthetic technique (regional versus general)|Anesthetic technique (regional versus general)
214320028|NCT04446065|DRUG|Previfenon®|Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.
214320029|NCT04446065|DRUG|Placebo|Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
214320030|NCT05440292|DEVICE|Transcranial magnetic stimulation|For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.
214320031|NCT00112242|BIOLOGICAL|Melan-A ELA + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
214320032|NCT00112242|BIOLOGICAL|Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
214320033|NCT00112242|BIOLOGICAL|Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
214484082|NCT05816343|DRUG|Orlistat|Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
214484083|NCT05816343|DRUG|Placebo|Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
214484084|NCT03857490|BEHAVIORAL|Lower leg heat therapy|Home-based 8 weeks of lower leg repeated heating.
214484085|NCT06148077|OTHER|Manual Therapy|3 times a week, for 6 weeks.
214484086|NCT06148077|OTHER|Motor control exercises|3 times a week, for 6 weeks.
214484087|NCT04991129|DRUG|WJ01024|5mg QD: WJ01024, Q4W, once per day
214484088|NCT04991129|DRUG|WJ01024|5mg BID: WJ01024, Q4W, twice per day
214484089|NCT04991129|DRUG|WJ01024|10mg BID: WJ01024, Q4W, twice per day
214484090|NCT04991129|DRUG|WJ01024|40mg BIW: WJ01024, Q4W, twice per week
214484091|NCT04991129|DRUG|WJ01024|60mg BIW: WJ01024, Q4W, twice per week
214484092|NCT04991129|DRUG|WJ01024|80mg BIW: WJ01024, Q4W, twice per week
214484093|NCT04991129|DRUG|WJ01024|60mg QW: WJ01024, Q4W, once per week
214484094|NCT04991129|DRUG|WJ01024|80mg QW: WJ01024, Q4W, once per week
214484095|NCT04991129|DRUG|WJ01024|50mg QW: WJ01024, Q4W, once per week
214484096|NCT04991129|DRUG|WJ01024|40mg QW: WJ01024, Q4W, once per week
214484097|NCT06248125|BEHAVIORAL|Singing intervention|The goal of this intervention is to improve the frequency and quality of active parent-infant interaction via infant-directed singing.
214484098|NCT06248125|BEHAVIORAL|Music listening intervention|This intervention follows the same structure as the singing intervention but focuses on the use of passive music listening rather than live singing.
214484099|NCT06248125|BEHAVIORAL|Book reading intervention|This intervention follows the same structure as the singing intervention, but without the musical elements, while emphasizing enriched parent- infant interaction in non-musical (or less-musical) contexts.
214484100|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous quadriceps tendon graft|Surgical reconstruction of anterior cruciate ligament with autologous quadriceps tendon graft
214955222|NCT02865694|OTHER|Cascade|
214955223|NCT05161845|BIOLOGICAL|Measles, Mumps and Rubella Combined Vaccine, Live|0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.
214955224|NCT00428428|DRUG|Isoproterenol|ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
214320034|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
214320035|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
214919973|NCT03211884|BEHAVIORAL|Problem-Solving Thearpy|"The problem-solving therapy (PST)-based intervention consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet \& greet session, participants received written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7-steps to solve at least one problem together before ending the training. Participants keep a record of their problem-solving efforts between sessions and questions they had related to the application of PST. These records were used as a basis for discussion during the PST training sessions."
214320036|NCT01734551|DRUG|Morphine|"Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.~Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is \<0.1mg/kg/day, may discontinue."
214320037|NCT01734551|DRUG|Clonidine|Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
214320038|NCT06366880|OTHER|Parenteral nutrition cycling|"This study is a single-centre, non-blinded RCT in the NICU of Pediatric Hospital of Sinaloa, Northwest, Mexico.~A total of 66 infants born ≥34 weeks of gestation who have a high likelihood of intolerance to enteral nutrition (EN) for at least 10 days will be randomised to PNC o PNT after informed parental consent. In both groups, EN will be commenced as early as clinically feasible."
214320039|NCT02048553|DEVICE|Tablet-guided ventriculostomy|"In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand )."
214320040|NCT02048553|PROCEDURE|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
214320041|NCT01503827|RADIATION|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
214320042|NCT02885155|OTHER|Echocardiography|planned at regular intervals
214484101|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous bone patellar tendon bone graft|Surgical reconstruction of anterior cruciate ligament with autologous bone patellar tendon bone graft
214919974|NCT04017507|DEVICE|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
214919975|NCT04017507|DEVICE|Side-to-side electric toothbrush|Side-to-side electric toothbrush used twice daily
214919976|NCT04017507|DEVICE|Manual toothbrush|Manual toothbrush used twice daily
214919977|NCT00924495|DEVICE|transcranial magnetic stimulation|rTMS therapy daily for two weeks, five times per week each lasting for half an hour
214919978|NCT05321238|OTHER|High agency and immediate threat|Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
214919979|NCT05321238|OTHER|High agency and distant threat|Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
214955225|NCT02020135|DRUG|PSMA ADC|Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
214320043|NCT02885155|OTHER|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
214484102|NCT06323512|DEVICE|Pulmonary artery denervation (PADN)|Combining invasive angiography with pulmonary artery CTA is frequently employed to determine the final size of the PADN catheter, aiming for an expected ratio of distal ring/vessel diameter between 1.1 and 1.2. The PADN system comprises a radiofrequency generator, connecting tubing and control handle, and the PADN catheter. The main interface of the radiofrequency generator offers multiple language options and displays parameters such as temperature, impedance, energy, and ablation time. The generator features three control modes: temperature control, power control, and a combination of both.
214484103|NCT03529019|DRUG|Ensure Surgery Immunonutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
214320044|NCT05880849|DRUG|Choline|Eight 275mg capsules taken orally twice daily (4 capsules with breakfast \& 4 capsules with dinner) x 180 days
214320045|NCT03522766|OTHER|urine sample|The subjects are asked to give a maximum of 15 urine samples during the study
214320046|NCT03602937|DIETARY_SUPPLEMENT|Renastep|Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.
214320047|NCT01556529|PROCEDURE|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
214320048|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
214320049|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
214320050|NCT01072851|BEHAVIORAL|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
214320051|NCT01072851|BEHAVIORAL|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
214320052|NCT01072851|BEHAVIORAL|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
214320053|NCT01753635|DEVICE|supraglottic airway placement and use|
214484104|NCT03529019|DRUG|Ensure Enlive Advanced Nutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered 2 weeks prior to and 2 weeks post surgical procedure for a period of one week. .
214484105|NCT06447376|DRUG|Siltuximab|Single dose of prophylactic siltuximab, 11mg/kg, started 1 hour prior (+/- 60 minutes) to the infusion of epcoritamab.
214484106|NCT06447376|DRUG|Epcoritamab|"Epcoritamab dosing for Diffuse Large B-cell Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 48mg~* Cycle 1, Day 22 = 48mg~* Cycles 2 \& 3, Day 1 = 48mg~* Cycles 2 \& 3, Day 8 = 48mg~* Cycles 2 \& 3, Day 15 = 48mg~* Cycles 2 \& 3, Day 22 = 48mg~* Cycles 4-9, Day 1 = 48mg~* Cycles 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg~Epcoritamab dosing for Follicular Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 3mg~* Cycle 1, Day 22 = 48mg~* Cycle 2 \& 3, Day 1 = 48mg~* Cycle 2 \& 3, Day 8 = 48mg~* Cycle 2 \& 3, Day 15 = 48mg~* Cycle 2 \& 3, Day 22 = 48mg~* Cycle 4-9, Day 1 = 48mg~* Cycle 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg"
214484107|NCT05276388|OTHER|biological bank|biological bank of subjects vaccinated against SARS-CoV-2 infection
214919980|NCT05321238|OTHER|Low agency and immediate threat|Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
214919981|NCT05321238|OTHER|Low agency and distant threat|Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
214919982|NCT00765518|BIOLOGICAL|Ixmyelocel-T|CRCs will be administered via direct injection into the heart muscle.
214919983|NCT00765518|OTHER|Standard of Care|Because the eligible patients had no other cardiac surgery or percutaneous cardiac interventions that were likely to produce clinical improvement, SOC was limited to pharmacologic therapy, heart transplant, or ventricular assist device therapy.
214919984|NCT00003446|DRUG|fluorouracil|
214919985|NCT00003446|DRUG|leucovorin calcium|
214919986|NCT00003446|DRUG|trimetrexate glucuronate|
214955226|NCT02680171|BEHAVIORAL|Prism Goggles|Patients in the experimental condition will wear prism goggles while completing a computerized aiming task. This prisms will shift the patients' vision 10 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out over several days.
214955227|NCT02680171|OTHER|Non-Shifting Goggles|Non-shifting goggles are worn instead of prism goggles, while completing the same computerized aiming task as those assigned to the prism adaptation.
214955228|NCT03513666|COMBINATION_PRODUCT|Drug intervention|anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin
214955229|NCT04504578|PROCEDURE|contact lens assisted corneal cross linking|40 eyes of 30 patients underwent CACXL. The central 9 mm of corneal epithelium was abraded , Iso-tonic riboflavin 0.1% was applied every 2 minutes for 10 minutes on the debrided cornea. A disposable soft Contact lens without an ultraviolet filter (Soflens, Bausch \& Lomb) was placed in the inferior fornix during soaking of the stroma with riboflavin for 10 minutes. The contact lens was applied on the corneal surface and the cornea was exposed to ultraviolet-A irradiation at fluence of 3.0 mW/cm2 for 30 minutes The uncorrected (UDVA) and best corrected (BDVA) visual acuity, and maximum (K max) keratometric values, were assessed before, and after 9 months CXL. Endothelial cell count was assessed before and 3 months after CXL. Anterior segment OCT was done 1 month after CXL to evaluate the presence and depth of the corneal stromal demarcation line.
214320054|NCT04225923|DRUG|NPC-21 Low dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
214320055|NCT04225923|DRUG|NPC-21 High dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
214320056|NCT04225923|DRUG|NPC-21 Placebo|Placebo will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
214320057|NCT01113125|DRUG|Betamethason-17-valerate and fusidic acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
214320058|NCT01113125|DRUG|Fusidic Acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
214320059|NCT01874834|OTHER|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
214320060|NCT04576533|BEHAVIORAL|walk out from operating room|After the surgery of laparoscopic colectomy or laparoscopic rectectomy surgery (Dixon technique), patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
214320061|NCT01417481|DIETARY_SUPPLEMENT|Glycine|Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
214919987|NCT03617614|BEHAVIORAL|Collaborative Care Model|"Trained care managers (CM) work collaboratively with patients, caregivers, and primary care providers to provide education, care navigation and behavioral activation. The latter includes a stepped psychotherapy intervention called ENGAGE, that focuses on reward exposure engagement in meaningful, rewarding activities for patients. Patients (home) visits are delivered over a period of 6 to 16 weeks. Progress is assessed with standardized measures for depression (PHQ-9), anxiety (GAD-7) and functioning (WHO-DAS). Furthermore, patients are presented by the CM at Systematic Case Review meetings where an integrated team of medical, psychiatric and allied health professionals work collaboratively to review the patient's goals and treatment to formulate a care plan and recommendations."
214919988|NCT03617614|BEHAVIORAL|Mood Consultation|A meeting with a psychiatrist to do assessment, provide education and make recommendations regarding the care of the patient for the Primary Care Provider.
214320062|NCT01417481|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
214320063|NCT00855309|DRUG|acyclovir sodium|Given IV
214320064|NCT00829296|DRUG|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
214320065|NCT00829296|DRUG|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
214320066|NCT05272930|DRUG|Dienogest|Assessment of fibromyalgia effects after the use of dienogest
214320067|NCT00577083|DEVICE|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
214320068|NCT00914030|OTHER|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
214320069|NCT04630093|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.
214320070|NCT05047991|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
214320071|NCT05047991|DRUG|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
214320072|NCT05047991|DRUG|Leucovorin|Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
214320073|NCT05047991|DRUG|Oxaliplatin|Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
214320074|NCT05047991|DRUG|Nab paclitaxel|Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
214320075|NCT05047991|DRUG|Gemcitabine|Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
214320076|NCT05349162|DEVICE|Implantable cardioverter defibrillator use|Implantation of an implantable cardioverter defibrillator (epicardial or transvenous)
214320077|NCT05411510|PROCEDURE|Densah bur|Surgical treatment
214320078|NCT02808845|OTHER|microalbuminuria|
214320079|NCT04102475|OTHER|Eatline|"After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~* Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
214320080|NCT04102475|OTHER|Control|"After discharge from the first hospitalization:~* No specific phone calls~* TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
214320081|NCT04116710|BIOLOGICAL|HS-110 (viagenpumatucel-L)|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
214320082|NCT04116710|BIOLOGICAL|HS-130|Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
214919989|NCT00741676|PROCEDURE|laparoscopy-assisted distal gastrectomy|10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3\~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
214320083|NCT01194024|OTHER|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
214320084|NCT05017610|DRUG|Liothyronine|Given PO
214320085|NCT05017610|DRUG|Lomustine|Given PO
214320086|NCT05017610|DRUG|Methimazole|Given PO
214320087|NCT03002168|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.
214320088|NCT03002168|DIETARY_SUPPLEMENT|Placebo|Placebo tablets identical in appearance to the active comparator
214320089|NCT03002168|RADIATION|Triolein radiolabeled with 100 microcuries of 3^Hydrogen|A MicroCurie (µCi) is a measure of radioactivity.
214320090|NCT03002168|RADIATION|Tripalmitin radiolabeled with 20 microcuries of 14^Carbon|A MicroCurie (µCi) is a measure of radioactivity.
214320091|NCT06373679|BEHAVIORAL|Switching to E-Cigarette|Participants will receive eleven weeks of e-cigarette products with instructions to switch completely at switch date
214320092|NCT06373679|BEHAVIORAL|Switching using Medication|Participants will receive eleven weeks of FDA approved medication, either varenicline or combination NRT, with instructions to quit smoking cigarettes at quit date
214320093|NCT04296396|DRUG|0 to 20 tablets of oxycodone 5mg|Individualized opioid prescription protocol (IOPP) that includes shared decision making
214320094|NCT04296396|DRUG|Fixed opioid prescription|20 tablets of oxycodone 5mg
214320095|NCT04818359|BEHAVIORAL|MoviS Training|Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).
214320096|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 1 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
214320097|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 2 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
214320098|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - Without Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps.~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
214320099|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
214320100|NCT03857633|DIAGNOSTIC_TEST|Peripheral Whole Blood Samples|20ml EDTA whole blood samples - collected sequentially during study - max 8 time points
214320101|NCT01077960|BIOLOGICAL|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
214484108|NCT06082986|DRUG|Ustekinumab|No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.
215061508|NCT04826263|OTHER|Low-Level Laser Therapy (LLLT)|Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.
215061509|NCT04826263|OTHER|Extracorporeal Shockwave Therapy (ESWT)|Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
215061510|NCT04929353|OTHER|Systematic symptom assessment|"* Systematic symptom assessment~* Conventional symptom assessment"
215061511|NCT02812238|DIETARY_SUPPLEMENT|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
215061512|NCT02812238|DRUG|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
215061513|NCT04342676|DEVICE|k ras|K ras
215061514|NCT04342676|DRUG|Panitumumab|vectibex in stage iv
215061515|NCT01008761|DRUG|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
214320102|NCT05323955|DRUG|Trastuzumab|Administer per current package insert based on site standard of care guidelines
214320103|NCT05323955|DRUG|Trastuzumab Emtansine (T-DM1)|Administer per current package insert based on site standard of care guidelines
214320104|NCT05323955|DRUG|Pertuzumab|Administer per current package insert based on site standard of care guidelines
214320105|NCT05323955|DRUG|Tucatinib|300 mg orally twice daily (21 Day Cycle)
214484109|NCT02399124|DEVICE|PROSENSE™|single arm, open label, PROSENSE™ treatment
214484110|NCT06241352|DRUG|statin addition to chemotherapy|Chemotherapy was administered along with 80mg of atorvastatin per day. Atorvastatin was discontinued when CA19-9 levels (with CA19-9 negative patients referenced against CEA or CA-125) rose more than 20% above baseline.
214484111|NCT06157996|DRUG|lenvatinib and tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
215061516|NCT01008761|DRUG|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
215061517|NCT02303210|DEVICE|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
214484112|NCT06157996|DRUG|tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
214320106|NCT04120532|BEHAVIORAL|Perioperative Rehabilitation|Physical therapist will be consulted one day before and after the operation (OP) day. On the day before the OP day, they focus on education, including how to get up from bed and stand up from a chair. Five rehabilitation exercises are also demonstrated: 1) ankle flexion and extension, 2) knee flexion and extension, 3) hip joint abduction and adduction, 4) hip joint flexion and extension, and 5) drawing-in maneuver. The participants will be required to repeat each component to confirm that they can do it correctly. Each exercise is suggested to be done 10 times per day following MI-TLIF, and the number will be recorded 3 days (pre-OP day, post-OP day, and post-OP day 2).
214484113|NCT04227379|BEHAVIORAL|Intervention 1- DSMS+|Participants in this group were signed up for an interactive, patient-centered, and customizable diabetes self-management support texting intervention (DSMS+). This arm received the same daily educational content as the DSMS arm augmented by the following: regular two-way check-in messages about diabetes self-management behaviors, an invitation to receive messages written by other Veterans living with diabetes on demand, and a menu of optional and customizable modules (e.g., medication reminders, blood sugar and blood pressure monitoring,: physical activity reminders, weight management, and goal setting) from which participants could select messaging th
215061518|NCT02303210|DEVICE|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
215061519|NCT05793359|DRUG|Methylprednisolone|methylprednisolone applied as intravenous infusions or intramuscularly
215061520|NCT03102450|DRUG|Benzalkonium Chloride Spermicide Cream|"One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.~Duration of treatment : 6 months (12 months optional)"
215061521|NCT03204604|DIETARY_SUPPLEMENT|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
215061522|NCT03204604|DIETARY_SUPPLEMENT|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
215061523|NCT03204604|PROCEDURE|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of \[11C\]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using \[11C\]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post \[11C\]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
215061524|NCT03204604|BEHAVIORAL|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
215061525|NCT03204604|BEHAVIORAL|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
215061526|NCT03204604|BEHAVIORAL|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
215061527|NCT03204604|BEHAVIORAL|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
214484114|NCT04227379|BEHAVIORAL|Comparison - DSMS|"Participants in the comparison condition were signed up for a one-way education-only protocol called Diabetes Self-Management Support (DSMS), comprised of 6 months of once daily one-way text messages covering standard diabetes self-management education content. Starting with the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, created in alignment with VA/DoD diabetes guidelines, we enhanced the educational content by incorporating Veteran input through a co-design process with Veterans living with diabetes and expert clinician review. DSMS messages could not be customized. There was no interactive content for the DSMS arm other than a once monthly message asking whether the messages had been helpful."
214484115|NCT05970562|DEVICE|Ambulatory Voice Monitoring with Biofeedback (AVM-B)|AVM-B is software on the Voice Health Monitor that uses a neck-placed accelerometer to sense neck skin vibrations during voicing in daily life. The AVM-B consists of cues every time the patient exceeds a subject-specific threshold, \[100% frequency AVM-B\] and/or summary statistics every 2 minutes of voicing \[Summary AVM-B\].
215061528|NCT00068315|DRUG|bortezomib|Given IV
215061529|NCT00068315|DRUG|fludarabine phosphate|Given IV
215061530|NCT00068315|BIOLOGICAL|rituximab|Given IV
215061531|NCT03400046|DRUG|Nutritional Product Supplementation|Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
215061532|NCT00335738|DRUG|liposomal vincristine sulfate|Given IV
215061533|NCT00335738|DRUG|carboplatin|Given IV
215061534|NCT00335738|DRUG|etoposide|Given IV
214484116|NCT05970562|BEHAVIORAL|Conversation Training Therapy|CTT is a 4-week (1 45-minute session per week) evidence-based voice therapy for patients with VH, developed primarily to maximize the amount and speed of generalization outside the therapy session. It consists of 3 required targets: Decreased overall auditory-perceptual voice severity, improved discrimination between baseline and improved voicing, and adherence to CTT recommendations in daily life. The three optional targets are decreased overall auditory-perceptual severity across an increased pitch range, loudness range, and decreased rate of speech. All voice-related targets are modified through practicing voicing with increased forward resonance and mean airflow in spontaneous speech/conversation.
214484117|NCT02089880|DEVICE|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
214484118|NCT02089880|DEVICE|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
214484119|NCT06644131|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate
214484120|NCT06644131|DIETARY_SUPPLEMENT|Sugar Pill (Placebo)|Placebo - sugar pill
214484121|NCT06557980|OTHER|toothpaste|group of patients with hypersensitive areas will use the calcium silicate toothpaste twice per day (morning and bedtime) the toothpaste will be applied uniformly using medium toothbrush to the hypersensitive surfaces for 30seconds. After that, the patient will rinse their mouth with plain water. the other group of patients will use the sodium fluoride toothpaste twice per day (morning and bedtime). The toothpaste will be applied uniformly using a medium toothbrush to the hypersensitive areas for 30 seconds after that the patients will rinse their mouth with plain water
214484122|NCT04160494|DRUG|D2C7-IT (6920 ng/mL via convection-enhanced delivery)|dual-specific mAB
214484123|NCT04160494|DRUG|Atezolizumab (1200 mg every three weeks)|programmed cell death ligand 1 (PD-L1) blocking antibody
214484124|NCT04160494|DRUG|D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)|dual-specific mAB
214484125|NCT06964945|BEHAVIORAL|Auricular Acupressure with Vaccaria Seeds|Auricular Acupressure with Vaccaria Seeds Participants in this group receive auricular acupressure using 2 mm Vaccaria seeds adhered to five specific auricular acupoints (TF4, CO15, Extra5, LO4, LO4) with 7 mm × 7 mm adhesive patches. Each session lasts 10-20 minutes, with seeds left in place for 5-7 days. A total of 12 weeks, along with standardized sleep hygiene education.
214484126|NCT06964945|BEHAVIORAL|Sham Auricular Acupressure (No Seeds)|Participants in this group receive sham auricular acupressure using identical adhesive patches without Vaccaria seeds, applied to the same five auricular points. Procedures, duration, frequency, and sleep hygiene education are identical to those in the experimental group to maintain blinding.
214484127|NCT06966362|DRUG|Motivation-Phase Varenicline|Varenicline reduction dosing will start when participants initiate Motivation-phase treatment: 0.5mg once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the duration of the 12-week reduction regimen.
214484128|NCT06966362|DRUG|Motivation-Phase Nicotine Mini-Lozenge|NRT mini-lozenge reduction dosing will start when participants initiate Motivation-phase treatment: 2-mg mini-lozenges in place of cigarettes (5-15/day).
214484129|NCT06966362|DRUG|Cessation-Phase Combination Nicotine Replacement Therapy (NRT)|Combination NRT (nicotine patch + nicotine mini-lozenge) cessation dosing will begin on the target quit day: if smoking \>10 cigarettes/day = 8 weeks of 21-mg, 2 weeks of 14-mg, and 2 weeks of 7-mg nicotine patches; if smoking 10 cigarettes/day = 10 weeks of 14-mg and 2 weeks of 7-mg nicotine patches. All participants will receive 2 or 4 mg mini-lozenge for the 12-week cessation period (9/day, 1 piece every 1-2/hours).
214484130|NCT06966362|DRUG|Cessation-Phase Varenicline|Varenicline cessation dosing will start one week prior to their TQD: 0.5mg once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the remainder of the 12-week cessation regimen.
215061535|NCT02688270|DRUG|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
215061536|NCT02688270|DRUG|Vehicle Cream (placebo)|Vehicle administered topically
215061537|NCT04047615|OTHER|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
215061538|NCT02538536|DRUG|PBI4050|
215061539|NCT00745290|DRUG|Bupivacaine HCl|200 mg bupivacaine HCl
215061540|NCT00745290|DRUG|SKY0402|600 mg SKY0402 (study drug).
215061541|NCT05070312|BIOLOGICAL|MEDI3506|MEDI3506
215061542|NCT05070312|DRUG|Placebo|Placebo
215061543|NCT04646252|OTHER|Perfused Boundary Region of sublingual microvessels|Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx Measurement of Pulse Wave Velocity to quantify arterial stiffness
214320107|NCT01520129|OTHER|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
214320108|NCT01371656|DRUG|levofloxacin|Given PO or IV
214320109|NCT01325779|DRUG|heparin|subcutaneous heparin 5000 units every 8 hours
214320110|NCT01325779|DRUG|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
214320111|NCT05991102|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
214320112|NCT03812965|DRUG|Botulinum toxin type A|2 units/point of botulinum toxin type A
214484131|NCT06966362|BEHAVIORAL|Motivation-Phase Counseling|All participants receive motivation-phase counseling. Motivation-phase counseling involves 5, 10-15-minute counseling calls. The counselor will work with participants on smoking control skills selected by the participant, such as avoidance of smoking cues, reducing smoking heaviness/contexts, developing urge coping skills, or finding support from friends and family. Counseling will emphasize setting realistic and achievable smoking control goals. Counseling will also emphasize competence and self-efficacy, which will be linked to success in smoking control.
214484132|NCT06966362|BEHAVIORAL|Cessation-Phase Counseling|All participants who enter cessation treatment will be offered 4, 10-15-minute counseling calls. The first counseling session involves pre-quit preparation, and can occur any time before the target quit day. The other 3 counseling calls will be scheduled for 1 day, 1 week, and 4 weeks after the target quit date. Cessation counseling will be based on treatment guidelines and will review instructions for when to start cessation medication, the timing of the quit day (relative to medication start), and medication adherence. Counseling will involve problem solving and skill development.
214484133|NCT06965179|OTHER|Jenga game|In the Jenga game group, participants will complete the Elderly Information Form and Mini-Mental State Examination (MMSE) before the intervention. As pre-tests, the Life Satisfaction Scale (LSS) and the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) will also be administered. Participants will play Jenga in pairs for at least 30 minutes once a week over four weeks. Grouping will consider participant preferences and promote social interaction. After the intervention, the same scales (LSS and WEMWBS) will be re-administered as post-tests to evaluate changes in life satisfaction and mental well-being.
214484134|NCT06965179|OTHER|Bocce game|In the Bocce game group, participants will first complete the Elderly Information Form and Mini-Mental State Examination (MMSE), followed by pre-tests including the SF-36, Life Satisfaction Scale (LSS), and the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS). Bocce sessions will take place once a week for four weeks, with each session lasting at least 30 minutes. Games will be played in pairs to enhance social interaction and psychomotor skills. Participants will be randomly assigned to six groups of two, considering individual preferences. Pairings will rotate weekly based on game outcomes to encourage diverse interaction. After the final week, the LSS and WEMWBS will be re-administered as post-tests by the researcher.
214484135|NCT02760537|BEHAVIORAL|Lay Health Worker Intervention|Lay Health Worker Phone Intervention The second phase addressed phone intervention training, where LHWs who had completed the first phase and were willing to participate in the second phase learned the process for calling participants to remind them to complete a series of HBV vaccinations. The LHWs assigned to the intervention group conducted phone interventions by reminding participants about completing a series of vaccinations at Months 1, 2, and 6, and also provided accompanying resources and support.
214484136|NCT02760537|BEHAVIORAL|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
214484137|NCT03944915|DRUG|Carboplatin|Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
214484138|NCT03944915|DRUG|Paclitaxel|"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."
214484139|NCT03944915|DRUG|Nivolumab|Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
215061544|NCT01970241|DRUG|NPH|NPH given per study table based on steroid dose and patient weight in kg.
215061545|NCT01970241|DRUG|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
215061546|NCT04700085|DEVICE|ReMotion Knee|The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
214320113|NCT03979443|PROCEDURE|Discharge on the day of surgery|Patient discharge on the day of the surgery, usually within 6-8 hours after procedure
214320114|NCT01443247|DRUG|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
214320115|NCT02797847|DRUG|ALN-TTRSC02|Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection
214320116|NCT02797847|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
214320117|NCT01537783|DRUG|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
214320118|NCT01537783|DRUG|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
214919990|NCT00741676|PROCEDURE|open distal gastrectomy|Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
214919991|NCT04134429|DEVICE|Everion|The Everion® device, by Biovotion, Zurich, is a on-skin wearable device measuring health data.
214919992|NCT06274073|PROCEDURE|Dorsal digital block|Dorsal regional digital block anesthesia (No drug or device is being investigated here; the two digital block procedure mentioned are compared)
214919993|NCT06274073|PROCEDURE|Palmar digital block|Palmar regional digital block anesthesia (No drug or device is being investigated here; the two digital block procedures mentioned are compared)
214919994|NCT00875108|DRUG|VIAject™|Subcutaneous injection 25 IU/mL
214919995|NCT01515865|DRUG|Midodrine HCl|dose at subject's current dose level
214919996|NCT01515865|DRUG|Placebo|single dose of matching placebo
214919997|NCT05251831|DRUG|Intradermal injection|Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.
214919998|NCT00185263|GENETIC|AdF5FGF-4 vs. Placebo|Intracoronary infusion
214919999|NCT01470963|OTHER|Implementation of referral template|Implementation of referral template at the GP office
214920000|NCT00417924|BEHAVIORAL|Patient education|
214920001|NCT05771324|OTHER|Baby-Led Weaning (BLW)|BLW trainings given to mothers for 6-12 month old babies
214920002|NCT05771324|OTHER|Traditional Complementary Feeding (TCF)|TCF trainings given to mothers for 6-12 month old babies
214920003|NCT06158984|DEVICE|IPL|Intense pulse light (IPL) therapy is used for the treatment of drug-related dry eye in glaucoma patients.
214920004|NCT04687046|DEVICE|JUVÉDERM VOLUX®|JUVÉDERM VOLUX® injectable gel
214920005|NCT06502600|PROCEDURE|surgery time|This study is a retrospective observational study, with surgery time being one of the exposure factors under investigation.
214920006|NCT06502600|PROCEDURE|surgeon|This study is a retrospective observational study, with surgeon being one of the exposure factors under investigation.
214920007|NCT06502600|PROCEDURE|surgical procedure duration|This study is a retrospective observational study, with surgical procedure duration being one of the exposure factors under investigation.
214920008|NCT06502600|PROCEDURE|operating room|This study is a retrospective observational study, with surgical procedure duration being one of the exposure factors under investigation.
215061547|NCT03807050|DIETARY_SUPPLEMENT|Astaxanthin|Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
215061548|NCT01769664|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
215061549|NCT01769664|DRUG|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
215061550|NCT01769664|DRUG|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
214320119|NCT06492161|DEVICE|Physical activity measure|After surgery, patients patients will be fitted with GT3X ActiGraph's activity monitor to capture and record continuous physical activity.
214320120|NCT06261268|PROCEDURE|Strip graft with Mucograft|"An apically repositioned flap is made in the vestibular region. The flap is then elevated with a split-thickness preparation, and the mucogingival junction will be repositioned apically and fixed with periosteal-anchored sutures. Then, a free epithelialized gingival strip graft will be harvested from the molar area of the palate. The Strip graft is sutured to the apical end of the recipient bed. The remaining uncovered part of the periosteal bed will be covered with a xenogeneic collagen matrix (Mucograft®. Geistlich Pharma AG, Wolhusen, Switzerland) fixed with simple interrupted and crossed sutures. The edges of the palatal wound (donor area) will be approximated with crossed sutures."
214320121|NCT06261268|PROCEDURE|Free gingival graft|The preparation of the apically repositioned flap and the recipient bed with its apico-coronal design and dimension is performed as in the test group. Subsequently, an epithelialized free gingival graft with the size of the entire recipient area with a thickness of 2 mm will be harvested from the molar area of the palate. The graft is sutured to the recipient periosteal bed using simple interrupted and crossed sutures. In the donor area, a collagen sponge is sutured to the wound by means of crossed sutures.
214320122|NCT02067377|DIETARY_SUPPLEMENT|Serum bovine immunoglobulin (SBI) medical food|Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
214320123|NCT02067377|DIETARY_SUPPLEMENT|Placebo (for serum bovine immunoglobulin)|
214920009|NCT06502600|PROCEDURE|type of surgery|This study is a retrospective observational study, with type of surgery being one of the exposure factors under investigation.
214920010|NCT03928899|PROCEDURE|New procedure|An optimal management on the timing and mode of delivery of pregnant women with GDM, by a comprehensive assessment and consideration of their fetal weight, gestational age, and cervical ripeness.
214920011|NCT05965180|DEVICE|Fine Needle Photoacoustic Probe|Fine Needle Photoacoustic Probe guided by the standard biopsy system without tissue core extraction
214920012|NCT05802407|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
214920013|NCT03691207|DRUG|AL101|"AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenously"
215061551|NCT01009970|DRUG|Rituximab|375 mg/m2 day 1
214484140|NCT03944915|RADIATION|Radiation|Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
214484141|NCT03944915|DRUG|Hydroxyurea Pill|One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
214484142|NCT03944915|DRUG|5-fluorouracil|5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
214920014|NCT06468878|BEHAVIORAL|Exposure Intervention Plus Music Induction|VR exposure for acrophobia with background music.
214920015|NCT06468878|BEHAVIORAL|Exposure Intervention With No Music Induction|VR exposure for acrophobia with no background music.
214920016|NCT06496685|OTHER|psychoeducational|A structured AAT program and usual treatment in Experimental group.
214920017|NCT01113385|DRUG|D-Galactose|Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
215061552|NCT01009970|DRUG|Cyclophosphamide|750 mg/m2 day 2
215061553|NCT01009970|DRUG|Vincristine|1,4 mg/m2 (max 2 mg) day 2
215061554|NCT01009970|DRUG|Prednisone|40 mg/m2 day 2-6
215061555|NCT01009970|DRUG|Doxorubicin|50 mg/m2 day 2
215061556|NCT03578926|DEVICE|fanfilcon A toric lens|contact lens
215061557|NCT03578926|DEVICE|senofilcon A toric lens|contact lens
215061558|NCT05127408|PROCEDURE|Interventional Endoscopy|correct defects of the gastrointestinal tract.
215061559|NCT01786382|DRUG|PPI-668|
215061560|NCT01786382|DRUG|Midazolam|
215061561|NCT01786382|DRUG|Omeprazole|
215061562|NCT01786382|DRUG|Telaprevir|
215061563|NCT01290042|DRUG|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
215061564|NCT01290042|OTHER|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
215061565|NCT01930422|DEVICE|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
215061566|NCT01930422|DEVICE|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
215061567|NCT06378333|PROCEDURE|patients who underwent coronary angiography|All patients included in the ICAR project (Montpellier - Nîmes) benefit from a consultation at one year (12+or - 2 months), as they are systematically reviewed in our department: data will therefore be collected in the patient's medical record. Clinical biological parameters and events during the hospital phase are also collected in the patient's computerized record. Normal patient management remains unchanged.
215061568|NCT00992056|DRUG|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
215061569|NCT00992056|DRUG|Metoprolol|Metoprolol 50 mg titrated to 100 mg
215061570|NCT00075855|DRUG|therapeutic testosterone|
215061571|NCT00075855|OTHER|placebo|
215061572|NCT02700620|BEHAVIORAL|Internet-delivered CBT|Guided internet treatment
215061573|NCT01483235|BEHAVIORAL|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
214320124|NCT00000796|DRUG|Cycloserine|
214320125|NCT00000796|DRUG|Ethionamide|
214320126|NCT00000796|DRUG|Capreomycin sulfate|
214320127|NCT00000796|DRUG|Aminosalicylic acid|
214320128|NCT00000796|DRUG|Streptomycin sulfate|
214320129|NCT00000796|DRUG|Ethambutol hydrochloride|
214320130|NCT00000796|DRUG|Amikacin sulfate|
214320131|NCT00000796|DRUG|Isoniazid|
214320132|NCT00000796|DRUG|Pyrazinamide|
214320133|NCT00000796|DRUG|Pyridoxine hydrochloride|
214320134|NCT00000796|DRUG|Levofloxacin|
214320135|NCT00000796|DRUG|Rifampin|
214320136|NCT00000796|DRUG|Clofazimine|
214320137|NCT03661437|DEVICE|Actigraph|Wear Actiwatch
214320138|NCT03661437|OTHER|Questionnaire Administration|Ancillary studies
214320139|NCT03661437|PROCEDURE|Systematic Light Exposure|Undergo BWL treatment
214320140|NCT03661437|PROCEDURE|Systematic Light Exposure|Receive DWL treatment
214320141|NCT00847288|OTHER|Monthly Review Arm|Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
214320142|NCT00847288|OTHER|Quarterly Review Arm|Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
214320143|NCT05091008|DRUG|Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet|proper history was taken. HCV genotyping was done revealed GT 4 in all included patients. Basic ECG and abdominal US were performed prior to treatment. Concomitant HBV infection was excluded by HBs Ag and anti-HBc antibody HIV screening was done prior to treatment. Basic investigations were done prior to therapy. All included patients received Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks. Regular visits were arranged at 4, 8, and 12 weeks with easy access to the pediatric hepatology unit and the treating physician if any urgent problem in between the visits. Every visit, laboratory investigations were checked. Adverse events (after excluding other possible causes) were reported for the safety profile of the drug. The efficacy of the drug, HCV-RNA was assessed by quantitative real-time PCR at 4 weeks and after the end of the treatment course (12 weeks)
214320144|NCT06410144|BEHAVIORAL|Program A|Subjects in the Control group will receive 1) National Kidney Foundation information, and 2) support from a kidney therapy educator.
214320145|NCT06410144|BEHAVIORAL|Program B|Subjects in the intervention group will receive 1) a video and paper decision aid, and 2) coaching from a decision support specialist. The visits will be aimed at supporting patients with kidney therapy decision-making.
214320146|NCT03553732|OTHER|Registry|Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
214320147|NCT03530579|BEHAVIORAL|Educational group trainings|"Participants will receive 6 two and a half hour educational group training's over the course of 6 months. These sessions will be led by a trained CHW in your language and will be held on a monthly basis in a community based location.~Session 1: What is Diabetes~* Why is Prevention Important~Session 2: Nutrition Session 3: Physical Activity Session 4: Cardiovascular Disease \& Diabetes Complication Session 5: Stress Management Session 6: Access to Service"
214320148|NCT03530579|BEHAVIORAL|Community Health Care Worker|A community health care worker answer your questions about diabetes and refer participant to a physician. Survey will be completed at the start of the study and during the 3rd, 6th and 12th months
214320149|NCT04448210|BEHAVIORAL|DigiKnowIt News: Teen|Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
215061574|NCT01483235|BEHAVIORAL|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
215061575|NCT03628066|DRUG|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
215061576|NCT03628066|DRUG|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
215061577|NCT03628066|DRUG|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
215061578|NCT03628066|DIAGNOSTIC_TEST|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
215061579|NCT05965050|DIAGNOSTIC_TEST|Myofascial Release Technique|myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
214320150|NCT05715372|BEHAVIORAL|Mediterranean diet|12-week structured program for Mediterranean diet.
214320151|NCT05715372|BEHAVIORAL|AHA walking program|12-week structured AHA walking program.
214320152|NCT05715372|BEHAVIORAL|Mindfulness-based stress reduction|8-week structured mindfulness-based stress reduction (Cabot).
214320153|NCT05715372|BEHAVIORAL|Unstructured Mediterranean diet|Unstructured 12-week program with basic outline for Mediterranean diet.
214320154|NCT05715372|BEHAVIORAL|Unstructured walking program|Unstructured 12-week walking program.
214320155|NCT05715372|BEHAVIORAL|Unstructured stress reduction|Unstructured program using mobile application for stress reduction.
215061580|NCT05965050|OTHER|Ultrasound Therapy|Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
215061581|NCT04803864|DRUG|Roxadustat|Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.
215061582|NCT05082766|DRUG|enhanced DefenAge 8-in-1 BioSerum|DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
214320156|NCT00291668|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
214320157|NCT00291668|OTHER|Placebo|"* Active Substance: isotonic sodium chloride solution~* Pharmaceutical Form: Solution for injection~* Concentration: 1 mL~* Route of Administration: Subcutaneous use"
214320158|NCT00313612|DRUG|oxaliplatin|Given IV
214320159|NCT00313612|DRUG|topotecan|Given IV
214320160|NCT05913895|OTHER|hydrogen water|To investigate whether the intervention of hydrogen water adjuvant therapy can improve oral mucositis, oral frailty, pain and Quality of Life with head and neck cancer who have received radiation therapy or combined chemotherapy.
214320161|NCT00451035|DRUG|LBH589|
214320162|NCT01965288|DEVICE|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
214320163|NCT01965288|DEVICE|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
214920018|NCT04056533|BIOLOGICAL|CMV CTLs|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when their donors are sero-positive for CMV-DNA 21 days after transplant. The CMV-DNA levels will be monitored weekly for at least 100 days after the HAPLO. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive a CMV specific antiviral drug.
215061583|NCT04819529|BEHAVIORAL|Early and Intensive Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 1 one session each 48 h and SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: daily visits by trained family members and health staff about the intervention process"
214920019|NCT05170152|PROCEDURE|ultrasonography-guided injection|ultrasonography-guided injection
214920020|NCT05170152|PROCEDURE|pullae A1 release|ultrasonography-guided pullae A1 release
214320164|NCT01625143|OTHER|laboratory biomarker analysis|Correlative studies
214320165|NCT04675216|PROCEDURE|Posterior fossa intracranial pressure measurement|Measurement of posterior fossa pressure in an invasive way
214320166|NCT00218517|DRUG|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
214320167|NCT00218517|DRUG|Placebo|Matching placebo capsules using blue 00 capsules
214920021|NCT02881489|OTHER|Biological: Cell-based therapy|Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.
214920022|NCT04689373|DIAGNOSTIC_TEST|VAS Score|"The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain and worst pain.~The Mini-Mental State Exam (MMSE) is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills."
214920023|NCT03449329|PROCEDURE|SIP|The intervention group will receive a SIP block
215061584|NCT04308655|OTHER|Interview|Semi-structured interviews
214320168|NCT02752009|PROCEDURE|Axillary Lymph Node Sampling Clip|
214320169|NCT05107258|DIAGNOSTIC_TEST|The Pine Trees Health Test System|Consists of the Pine Trees Health Reader and the Pine Trees Health COVID-19 Test Kit, which contains the Pine Trees Health Cartridge, Pine Trees Health Sample Vial containing Sample Lysis Buffer and the Pine Trees Health Nasal Swab (anterior nares) for collection. The Test System is a point-of-care test used for the qualitative detection of nucleic acid from SARS-CoV-2 viral RNA in nasal swabs taken from individuals who are suspected by a healthcare professional of having COVID-19. The COVID-19 test is a rapid molecular, in vitro diagnostic test using isothermal nucleic acid amplification technology and detection of the resulting amplicon using CRISPR-mediated collateral reporter unlocking.
214320170|NCT02510378|RADIATION|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
214320171|NCT03887364|OTHER|Group A-Diaphragmatic breathing|Patient was in casual and agreeable position in which gravity helped the stomach, for example, a semi fowler's position. Hand was put on the rectus abdominis just beneath the foremost costal edge and requested that the patient take in gradually and profoundly through the nose. Persistent was told to keep the shoulder casual and upper chest very, enabling the belly to rise marginally. At that point persistent was guided to remain loose and breathed out gradually through the mouth. The patient rehearsed this 3 to 4 times and the rest time frame was given so patient couldn't hyperventilate.This group was given 10 reps of 3 sets with 4 weeks of follow up
214484143|NCT03944915|DRUG|Filgrastim Injection|Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
214920024|NCT00713791|DRUG|ZD4054|Treatment period 1: 10mg oral solution
214920025|NCT00713791|DRUG|ZD4054|Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
214320172|NCT03887364|OTHER|Group B-Icing and Airflow Stimulation|"Patient was lying comfortable in semi fowler position. Facial muscle icing was given using ice pack wrapped in cloth over cheeks and nose in butterfly pattern and over forehead for 5 minutes. Ice pack was applied on the patients face (around the cheek \& nose) and accessory muscles (sternocleidomastoid muscles, upper trapezius) for single session of 5 to 10 minutes.~After that airflow stimulation was given with the help of table fan. Table fan was placed on the central area of face. Duration of the fan for the patient was at least 5 minutes to relive dyspnea and distance kept approximate of 60 centimeter (2 rulers)."
214320173|NCT05830474|PROCEDURE|Continuous intra-airway monitoring and intervention during surgey|Continuous monitoring was performed by visual double lumen bronchial catheter. Once sputum or blood gushing into the tracheal carina was found in the distal bronchus on the surgical side, the above secretions were sucked out with a sputum suction tube under video monitoring until the removal was complete
214484144|NCT03944915|DRUG|Cisplatin|Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
214920026|NCT00713791|DRUG|ZD4054|Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
214920027|NCT00713791|DRUG|ZD4054|Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
214920028|NCT04065971|DRUG|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
214920029|NCT04065971|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
214920030|NCT03836183|DIAGNOSTIC_TEST|Pleuropulmonary ultrasound with clinical examination|Pleuropulmonary ultrasound associate with a clinical examination
214320174|NCT01393405|DRUG|Methotrexate|"Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine"
214320175|NCT03664752|DRUG|IDP-120 Gel|IDP-120 Gel, once-daily application
214320176|NCT03664752|DRUG|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
214320177|NCT01358604|GENETIC|polymerase chain reaction|
214320178|NCT01358604|GENETIC|protein expression analysis|
214320179|NCT01358604|GENETIC|western blotting|
214484145|NCT06064812|DRUG|FWD1802|"Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days."
215061585|NCT04308655|OTHER|Surveys|Validated surveys on pain, fear, anxiety, depression, beliefs
215061586|NCT03235882|DIAGNOSTIC_TEST|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
215061587|NCT05799703|DEVICE|electrical stimulation device|the device has 2 channels ,4 electrodes with multiple ems programs
214920031|NCT01736397|DRUG|Ferric Citrate|Dose depends on serum phosphorus levels collected at each study visit.
214320180|NCT01358604|OTHER|flow cytometry|
214484146|NCT06064812|DRUG|palbocilib|"The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days."
214920032|NCT01736397|DRUG|Placebo|
215061588|NCT05799703|OTHER|kinesio taping|kinesio tape a therapeutic tape that's applied strategically to the body to provide support, lessen pain, reduce swelling, and improve performance
215061589|NCT04812782|DIETARY_SUPPLEMENT|EVOO supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO
215061590|NCT04812782|DIETARY_SUPPLEMENT|Butter supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter
215061591|NCT02279368|BEHAVIORAL|Family Counselling and safeguarding|
215061592|NCT02959294|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
215061593|NCT02959294|DEVICE|Centricyte 1000|Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
215061594|NCT02959294|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
215061595|NCT06365255|OTHER|questionnaires|filling in questionnaires
215061596|NCT00682903|DEVICE|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
215061597|NCT02585986|DIETARY_SUPPLEMENT|Probiotic|daily intake of 1 capsule probiotic
215061598|NCT02585986|DIETARY_SUPPLEMENT|Placebo|daily intake of 1 capsule containing placebo
215061599|NCT01294111|BEHAVIORAL|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
215061600|NCT04796272|OTHER|Adapted and individualized physical training program|Physical training program adapted and individualized according to each patient in this group
215061601|NCT04796272|OTHER|traditional training program|Same training program for all patients in this group
215061602|NCT00191568|DRUG|Gemcitabine|
214320181|NCT01358604|OTHER|immunohistochemistry staining method|
214484147|NCT03796793|PROCEDURE|Wound Edge Debridement|Wound debridement is performed using a sharp, circular disposable curette to remove the slough, non-viable tissue and any fibrous tissue down to the vascular base.
214484148|NCT03796793|OTHER|Standard of Care Treatment|Standard of Care treatment will include foam dressing and 4 layer compression therapy, changed weekly.
214920033|NCT02954692|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
214920034|NCT02954692|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
214920035|NCT02954692|DRUG|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
214920036|NCT02954692|DRUG|meglitinides|"Pharmaceutical form: tablet~Route of administration: oral"
214484149|NCT06968091|OTHER|Trendelenburg position|After the loss of consciousness during general anesthesia, the 10° Trendelenburg position is adopted.
214484150|NCT06968091|OTHER|Supine Horizontal Position|After the loss of consciousness during general anesthesia, the Supine Horizontal Position is adopted.
214320182|NCT01358604|OTHER|laboratory biomarker analysis|
214320183|NCT01203592|DRUG|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
215061603|NCT00191568|DRUG|Oxaliplatin|
215061604|NCT00191568|PROCEDURE|Radiotherapy|
214484151|NCT06967246|COMBINATION_PRODUCT|Kinesio tape|Kinesio tape applied to one surgical site
214484152|NCT06967246|COMBINATION_PRODUCT|non-elastic tape|The non-elastic tape with only adhesive properties was used as the placebo tape on the other side
214484153|NCT05772533|PROCEDURE|Serratus anterior plane block|The latissimus dorsi muscle between the midaxillary line and the posterior axillary line will be located under ultrasound guidance. The needle will be inserted into the plane from top to bottom until the serratus anterior surface, and the injectate will be slowly administered.
214484154|NCT05772533|PROCEDURE|PENG block|"Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed Between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
214484155|NCT06238297|DIAGNOSTIC_TEST|MRSA nasal swab based de-escalation|Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
214484156|NCT06965283|BEHAVIORAL|Providing training and Mentoring|The intervention packages are providing postpartum family planning training at each MCH units, Using WHO PPFP counseling toolkit, mentoring health care provider to fill knowledge and skill gap, contraceptive logistic availability, and regular supportive supervision
214920037|NCT02954692|DRUG|thiazolidinediones|"Pharmaceutical form: tablet~Route of administration: oral"
214920038|NCT02954692|DRUG|alpha-glucosidase inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
214920039|NCT02954692|DRUG|GLP1 Receptor Agonist|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
214920040|NCT02954692|DRUG|Dipeptidyl peptidase-IV (DPP-IV) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
214920041|NCT02954692|DRUG|Sodium-glucose transport-2 (SGLT-2) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
214920042|NCT03815799|PROCEDURE|Bilateral Erector Spinae Block|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. 40 ml bupivacaine/lidocaine mixture will be injected into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
214920043|NCT03815799|OTHER|Control|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive meperidine 0.5 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
214320184|NCT00717769|DRUG|SUN13834|Low dose, orally 3 times a day (tid) for 28 days of SUN13834
214320185|NCT00717769|DRUG|Placebo|Placebo, orally (tid) for 28 days of SUN13834
214320186|NCT02724904|PROCEDURE|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
214320187|NCT02724904|DRUG|Fludarabine|Standard Treatment
214320188|NCT02724904|DRUG|Thiotepa|Standard Treatment
215061605|NCT03141125|OTHER|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
214320189|NCT02724904|DRUG|Methotrexate|IV Bolus
214320190|NCT05233436|DRUG|PF-07265028|PF-07265028 will be administered orally
214320191|NCT05233436|BIOLOGICAL|Sasanlimab|Administered subcutaneously
214320192|NCT03496688|PROCEDURE|Sinus floor augmentation|
214320193|NCT01519856|DRUG|piribedil (Clarium)|oral tablets, 50 mg
214320194|NCT03096665|DIAGNOSTIC_TEST|blood test|Point of care blood analysis obtained from skin puncture
214920044|NCT02828046|BIOLOGICAL|M281|
215061606|NCT03141125|OTHER|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
215061607|NCT00057759|DRUG|sildenafil citrate|
215061608|NCT00057759|OTHER|Placebo|Placebo
215061609|NCT01564212|OTHER|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
214320195|NCT03814954|DRUG|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
214320196|NCT03814954|DRUG|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
214484157|NCT06965959|BEHAVIORAL|Exergaming Intervention Group|A behavioral intervention involving the use of motion-based digital games such as table tennis, boxing, skiing, and bowling. Participants performed exergaming sessions twice per week for eight weeks. Each session lasted approximately 15 minutes and was conducted in pairs under supervision. The intervention aimed to promote physical activity, cognitive engagement, and social interaction among older adults in a nursing home setting.
214484158|NCT06965959|BEHAVIORAL|Autogenic Relaxation|A behavioral mind-body intervention in which participants practiced standardized verbal relaxation techniques focused on passive concentration and bodily awareness. Sessions were conducted in quiet rooms in small groups, twice per week for eight weeks, each lasting approximately 15 minutes. The goal was to enhance psychological well-being and reduce emotional tension in institutionalized older adults.
214484159|NCT05381766|OTHER|CSA Model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided weekly for 20 weeks to community members in Sunset Park and surrounding neighborhoods. Brooklyn Grange in Sunset Park will grow and provide Chinese specific produce for a fee ranging from $7 to $31 depending on the participant's self-identified situation and Angel Family Farm will grow and provide Mexican specific produce for a fee of up to $15. Participants that receive SNAP benefits can use their EBT card to cover their produce box fees. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
214484160|NCT06156774|OTHER|Chimeric Antigen Receptor T-cells (CAR-T) therapy|Patients will be treated with CAR-T cell product as per routine clinical practice.
214920045|NCT02828046|OTHER|Placebo|
214920046|NCT03648437|DRUG|Paracetamol 10Mg/mL|Experimental drug
214920047|NCT03648437|DRUG|0.45% Sodium Chloride|Placebo comparator
214920048|NCT03648437|DRUG|Ibuprofen|Standard therapy
214920049|NCT03648437|DRUG|Indomethacin|Standard therapy
214920050|NCT00220428|BIOLOGICAL|T-Cell Vaccination|
214920051|NCT03396315|DRUG|Alendronate|oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis
214920052|NCT03396315|DRUG|Zoledronic Acid|single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
214920053|NCT04146493|DIAGNOSTIC_TEST|Blood samples for Heparin-binding protein measurement|Blood samples before and after given heparin
214920054|NCT02448537|DRUG|PM01183|
214920055|NCT02448537|DRUG|Doxorubicin|
214920056|NCT02448537|DRUG|Gemcitabine|
214920057|NCT00262132|DRUG|Mycophenolate|
214920058|NCT06660381|DRUG|Psilocybin|Participants will receive a moderately high dose (25mg) of psilocybin in week 5 of the 12-week counseling, and either another moderately high dose (25mg) or a high dose (35mg) in week 7.
214920059|NCT02524886|DEVICE|GPi DBS with Medtronic electorde and Activa PC pulsegenerator|The electric stimulation of 2 leads implanted in the Globus Pallidus internus
214920060|NCT04563975|DRUG|Toripalimab|Toripalimab，240mg，d1，Intravenous Infusion，q3w
214920061|NCT04563975|DRUG|Docetaxel|Docetaxel，60-75mg/m2，d8 and d15，Intravenous Infusion，q3w
214920062|NCT04563975|DRUG|nab-paclitaxel|nab-paclitaxel，125mg/m2，d1 and d 8，Intravenous Infusion，q3w
214920063|NCT00798668|DIETARY_SUPPLEMENT|Liquid Supplements|Liquid supplement that provides 12.5% of the subjects total energy requirement.
214920064|NCT00798668|DIETARY_SUPPLEMENT|Solid Supplement|Solid supplement that provides 12.5% of the subjects total energy requirement.
214920065|NCT05108350|DRUG|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment T1 followed by 7 days washout and then receive treatment R1+R.
214920066|NCT05108350|DRUG|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment R1+R followed by 7 days washout and then receive treatment T1.
214920067|NCT05108350|DRUG|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment T2 followed by 7 days washout and then receive treatment R2+R.
214320197|NCT04522037|OTHER|No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups|Respiratory rate is analyzed with the scope (approved by the French national medical authorities)
214320198|NCT00917891|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
214320199|NCT00917891|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
214920068|NCT05108350|DRUG|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment R2+R followed by 7 days washout and then receive treatment T2.
214920069|NCT04112602|OTHER|Sputum|Sputum will be collected after a respiratory physiotherapy session, scheduled as part of routine care.
214920070|NCT04112602|OTHER|Tracheal aspiration|Tracheal aspirations will be collected in intubated patients (intubation for surgery under general anesthesia).
214920071|NCT01046279|DRUG|Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
214920072|NCT04106895|DRUG|Fibryga|Fibryga
214920073|NCT03644823|DRUG|Atezolizumab|PDL1- inhibitor
214920074|NCT03644823|RADIATION|Radiotherapy|6 Gy x 3
215061610|NCT01564212|OTHER|laminar airflow with surgical drapes|
215061611|NCT01564212|OTHER|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
215061612|NCT01564212|OTHER|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
214484161|NCT06805214|OTHER|post tracheostomy fever|incidence of post tracheostomy fever and whether retrospectively the increased temperature indicated development of sepsis or not (no intervention)
214484162|NCT05441683|PROCEDURE|horizontal extending incision|a papilla preserving incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Then horizontally extending incisions will be added to each side of the initial incision, extending one to two teeth beyond the defected area, before a full-thickness flap is lifted.
214484163|NCT05441683|PROCEDURE|vertical releasing incision|a papilla preserving incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Vertical releasing incisions will be made on each side of the initial incision before a full-thickness flap is lifted. The incision formed an oblique trapezoidal flap with a wider base.
214484164|NCT06501495|OTHER|video polysomnography|video polysomnography during 2 nights
214484165|NCT06501495|OTHER|Attention task|Attention task : SART Test (Sustained Attention to Response Task)
214484166|NCT05826860|BEHAVIORAL|Mindfulness Practice|Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
214320200|NCT04361461|DRUG|Hydroxychloroquine Sulfate|400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
214484167|NCT05826860|BEHAVIORAL|Storytelling Workshop|Participants attend 2 (90 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
214484168|NCT06853041|DRUG|Esketamine|A single slow intravenous injection of low-dose esketamine (0.15 mg/kg) over 10 minutes using an infusion pump.
214320201|NCT04361461|DRUG|Hydroxychloroquine Sulfate + Azythromycin|400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
214320202|NCT01892696|DEVICE|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
214320203|NCT00974714|DRUG|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
214484169|NCT06853041|DRUG|Ketamine|A single slow intravenous injection of low-dose ketamine (0,3 mg/kg) with an infusion pump, during 10 minutes
214484170|NCT02960555|BIOLOGICAL|Isatuximab|Given IV
214484171|NCT02960555|OTHER|Laboratory Biomarker Analysis|Correlative studies
214920075|NCT02926729|DEVICE|nonlinear microscopy imaging of excised surgical margins|Following standard lumpectomy excision, excised tissue will be imaged with NLM. If invasive cancer or ductal carcinoma in situ (DCIS) is detected on or close to the margin, additional excision may be performed. Following surgery, final margins will be evaluated using paraffin embedded histopathology as per standard procedure. Paraffin embedded histopathology will be used to make a final margin determination.
214320204|NCT00974714|OTHER|placebo|oral placebo 2 g twice a day for 14 weeks
214320205|NCT01371097|OTHER|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
214320206|NCT01153581|DRUG|Ganirelix acetate|Ganirelix acetate: .25 ml/day by subcutaneous injection
214484172|NCT03528447|OTHER|Pulmonary Rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band."
214484173|NCT00942734|DRUG|Erlotinib|One tablet (150 mg) by mouth every day of each 28 day study cycle.
214484174|NCT00942734|DRUG|RAD001|1 tablet (5 mg) by mouth every day of each 28 day study cycle.
214484175|NCT06649266|DRUG|RBD1016|RBD1016, active drug.
214484176|NCT06649266|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
214920076|NCT02926729|PROCEDURE|standard lumpectomy without nonlinear microscopy imaging|Lumpectomy with postoperative paraffin embedded histopathology to make a final margin determination.
214920077|NCT06667531|PROCEDURE|Implant|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 3 mm.
214320207|NCT01153581|DRUG|17β-Oestradiol|17 beta estradiol: 0.2 mg/day (patches)
214320208|NCT01153581|DRUG|Progesterone|progesterone, 200 mg day-1 oral
214320209|NCT01399593|DRUG|Eculizumab|
214320210|NCT02214277|DEVICE|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
214320211|NCT02214277|DEVICE|TAVR|
214320212|NCT00587379|DRUG|Atorvastatin|40 mg atorvastatin pill daily
214320213|NCT00587379|DRUG|placebo|40 mg pill per day
214320214|NCT03302728|DRUG|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
214484177|NCT05456698|DRUG|Inotuzumab ozogamicin|"Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.~Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity."
214920078|NCT06667531|PROCEDURE|Implant|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 2 mm.
214920079|NCT06667531|PROCEDURE|Implant|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 1.5 mm.
214484178|NCT02971046|OTHER|varying protein intakes|"In healthy school-aged children: Four randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are 0.95, 1.3,1.55, and 2.0 grams per kilogram of bodyweight per day.~In healthy young and old adults: Up to six randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are : 0.66, 0.8, 1, 1.2, and 1.5 grams per kilogram of bodyweight per day."
214320215|NCT03302728|DRUG|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
214320216|NCT01358617|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214320217|NCT02366078|BEHAVIORAL|SMART|Paced breathing meditation with cognitive training
214320218|NCT02957175|OTHER|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
214320219|NCT00244712|DRUG|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
214320220|NCT00244712|DRUG|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
214320221|NCT06242210|OTHER|pursed lip|pursed lip breathing technique for group A through videos on smart phones and a brochure given to patients. Each session takes 15-20 minutes until researchers ensure that patients understand how to perform exercises and re-demonstrate them. • Each group applied it twice per day for a period of 4 weeks. Telephone follow-up was used for patients in both groups
214484179|NCT06815029|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
214484180|NCT06815029|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells intracranially
214320222|NCT06242210|OTHER|Stacked Breathing|The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed
214320223|NCT02953899|BEHAVIORAL|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
214320224|NCT02953899|BEHAVIORAL|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
214320225|NCT05967962|BEHAVIORAL|The Trauma Film Paradigm|"Trauma film paradigm is a well-known, validated and established procedure that produces reactions similar to those generated by trauma, and that is often used in research to predict susceptibility for peritraumatic and posttraumatic reactions. In this study the trauma film paradigm will be utilized to simulate combat exposure. The two groups of participants will undergo the trauma film paradigm by watching 16 min traumatic combat scenes vs. non-traumatic movie scenes, respectively. Participants will be given standardized instructions (i.e., ''Imagine you are present at the scene; Do not close your eyes)."
214484181|NCT06815029|PROCEDURE|Echocardiography|Undergo echocardiography
214320226|NCT05967962|BEHAVIORAL|non-traumatic (neutral) film|non-traumatic (neutral) film
214320227|NCT02582853|PROCEDURE|Lumbar puncture|Lumbar puncture for spinal fluid
214320228|NCT02582853|PROCEDURE|Blood Sample|Blood sample
214320229|NCT06858696|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
214320230|NCT06386497|DEVICE|Nocturnal translational vestibular stimulation|Nocturnal (overnight) translational vestibular stimulation applied by the rocking bed (Somnomat Casa) for two months in patients familiar home environment.
214320231|NCT05798286|OTHER|Quantra|The study plans to collect 2 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts.
214320232|NCT05798286|OTHER|Control|The study plans to collect 1 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts at each time.
214484182|NCT06815029|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
214320233|NCT02777125|DEVICE|Metered Dose Inhaler|A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.
214320234|NCT02777125|DEVICE|Breath Actuated Nebulizer|The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
214484183|NCT06815029|PROCEDURE|Intracranial Catheter Placement|Undergo placement of Rickham catheter
214484184|NCT06815029|PROCEDURE|Leukapheresis|Undergo leukapheresis
214484185|NCT06815029|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214484186|NCT06815029|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
214484187|NCT06815029|PROCEDURE|Resection|Undergo surgical resection
214484188|NCT03267498|DRUG|Nivolumab|Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.
214484189|NCT03267498|DRUG|Cisplatin|Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
214484190|NCT03267498|RADIATION|Radiation Therapy|2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
214484191|NCT03614533|BIOLOGICAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
214484192|NCT03614533|BIOLOGICAL|Inactivated Poliovirus Vaccine (IPV)|Single 0.5-ml intramuscular injection
214484193|NCT05511649|DEVICE|continuous electronic monitor|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University will receive 24-hour continuous cardiac monitoring until discharge.
214320235|NCT06923553|BEHAVIORAL|NDBIs|Caregivers will meet with clinicians virtually weekly to (a) watch the newly developed NDBI videos that demonstrate the strategy use, (b) discuss how this might be applied to their own child, (c) receive individualized homework planning, (d) record and upload videos of their practice of strategy use with their own child, and (e) review the videos with clinicians to receive individualized feedback on their strategy use. This will occur for 10 weeks. Each session will be video recorded to assess the clinicians' intervention fidelity. After 10 weeks, pre-post tests will be conducted to assess parents' confidence on implementing these strategies, their child's social communication, and satisfaction of providers and caregivers.
214320236|NCT04949750|OTHER|Paper - based cognitive training|Cognitive training
214320237|NCT06903546|DRUG|Propolis drops|The intervention given is propolis drops that are approved by Indonesian Food and Drug Authority
214320238|NCT06903546|OTHER|Placebo|The given placebo are look-alike substance with no effect
214320239|NCT00006028|DRUG|cisplatin|
214320240|NCT00006028|DRUG|gemcitabine hydrochloride|
214320241|NCT06923722|DIETARY_SUPPLEMENT|High-flavonoid grape intervention|High-flavonoid grape powder: 60 g, equivalent to 300 g fresh grapes. Total polyphenols: 437 mg/100g).
214320242|NCT06923722|DIETARY_SUPPLEMENT|Low-flavonoid grape intervention|60 g powder isocaloric-matched control (Total polyphenols: \< 60 mg)
214320243|NCT06924125|DIAGNOSTIC_TEST|Motor function scales|Evaluation of patients motor function using motor scales (MFM32, CHOP)
214320244|NCT06924125|DIAGNOSTIC_TEST|MUSCLE ULTRASOUND|Ultrasound guided evaluation of 28 muscles evaluated accross different body regions, assessed using the Heckmatt gradinf system (semiquantitative scale).
214320245|NCT06924125|DIAGNOSTIC_TEST|Muscle Elastography|Assess the mechanical properties of muscles, such as stiffness and elasticity.
214320246|NCT06924125|OTHER|Complete physical examination|Complete physical evaluations including muscle power and goniometry measurements
214320247|NCT06924125|OTHER|Ventilatory/ respiratory and other support assessment|Assessment of ventilatory, respiratory, and other support needs to evaluate the necessity of assistive devices
214320248|NCT06924125|OTHER|Oromotor function and nutrition|Assessment of bulbar funcionality: feeding devices, nutritional status.
214320249|NCT06924125|OTHER|Motor Milestone Assessments|Motor milestones age of acquisition and loss
214320250|NCT06923696|BEHAVIORAL|Diet therapy|One of the groups will follow a gluten-free diet therapy, while the other will follow a LOW FODMAP diet.
214320251|NCT03120065|OTHER|Electronic Dose Monitoring (MEMS)|The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
214320252|NCT00001368|PROCEDURE|cytokine and leukocyte activation profile|
214320253|NCT06000878|OTHER|first aid e-book|interactive first aid e-book interventions
214320254|NCT03460184|DIAGNOSTIC_TEST|G.A Group A:|"G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage."
214320255|NCT03675958|OTHER|Johnstone's Pressure Splint|the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching
214320256|NCT03675958|OTHER|Stretching|the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
214320257|NCT02782897|DRUG|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
214320258|NCT02782897|OTHER|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
214320259|NCT02064452|OTHER|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
214320260|NCT02064452|BEHAVIORAL|Placebo Comparator|Enhanced Usual Community Care-Waitlist
214320261|NCT00574405|DRUG|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
214320262|NCT00574405|DEVICE|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
214320263|NCT02049489|BIOLOGICAL|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
214320264|NCT00405574|DRUG|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
214320265|NCT02828839|PROCEDURE|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
214320266|NCT05361044|BIOLOGICAL|Blood samples Donnor|Additional samples will be preleved in the Normothermic Regional Reperfusion at 30 min, and blood sample will be collected at the end of the Normothermic Regional Reperfusion (4 samples of 5ml).
214320267|NCT02594722|DEVICE|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
214320268|NCT02594722|DEVICE|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
214320269|NCT01336738|DRUG|Placebo|Tablets (n=6), 0 mg, once daily for 84 days
214320270|NCT01336738|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
214320271|NCT01336738|DRUG|450 mg PF-04991532|Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
214320272|NCT01336738|DRUG|750 mg PF-04991532|Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
214320273|NCT01336738|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
214320274|NCT06285539|DRUG|Filgotinib|Filgotinib
214320275|NCT05492084|OTHER|without Intervention|without Intervention
214320276|NCT05567991|BEHAVIORAL|Comprehensive Mindulness-Based Intervention (C-MBI)|C-MBI, was administer online via Zoom and included: 10 Integral Meditation classes lasting approximately 35 minutes each, given twice a week (Monday and Wednesday); 10 minutes of yoga exercises focused on breathing and posture before each IM class; and dietary advice. Regarding this latter, the participants received via email a document which entailed non-mandatory dietary suggestions to promote healthy nutrition, sleep and stress-relief. An online lecture held by the nutritionist with a question-and-answer format was also organized. The degree to which to follow this advice was left to the discretion of each participant. The core of our intervention was represented by the IM training, that is a MBI intervention, that simultaneously uses breathing, focusing attention, releasing of physical tensions, thoughts and feeling sensations through internal senses and imagery, allowing a quick relaxation and more deeply a physical, energetic, and spiritual well-being.
214320277|NCT02383667|DEVICE|Electrocardiogram holter|
214320278|NCT02355132|OTHER|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
214320279|NCT03041259|DRUG|Rejuveinix Low Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
214320280|NCT03041259|DRUG|Rejuveinix High Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
214320281|NCT02970968|DRUG|VLY-686 (Tradipitant)|oral capsule
214320282|NCT02970968|OTHER|Placebo|placebo oral
214320283|NCT03003520|DRUG|Durvalumab|"Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection.~Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion."
214484194|NCT06845631|DEVICE|PNS device, observational study, no intervention during study|PNS device, observational study, no intervention during study
214484195|NCT06985784|OTHER|Interview|Ancillary studies
214320284|NCT03003520|DRUG|Rituximab|Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.
214320285|NCT03003520|DRUG|Doxorubicin|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
214320286|NCT03003520|DRUG|Vincristine|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
214320287|NCT03003520|DRUG|Cyclophosphamide|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
214320288|NCT03003520|DRUG|Prednisone|"Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle.~Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm."
214320289|NCT03003520|DRUG|Lenalidomide|Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.
214320290|NCT01332149|DRUG|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
214320291|NCT01332149|DRUG|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
214320292|NCT03976921|DIAGNOSTIC_TEST|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
214320293|NCT03976921|DIAGNOSTIC_TEST|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
214320294|NCT06118294|DIETARY_SUPPLEMENT|probiotics|\>30 billion CFU/capsule
214320295|NCT06118294|DIETARY_SUPPLEMENT|Placebo|Placebo
214320296|NCT01558700|DRUG|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
214320297|NCT01558700|DRUG|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
214484196|NCT06985784|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit
214484197|NCT06985784|OTHER|Questionnaire Administration|Ancillary studies
214484198|NCT06985784|OTHER|Virtual Technology Intervention|Receive 3D mindfulness VR headset
214484199|NCT06985784|OTHER|Virtual Technology Intervention|Receive 2D non-immersive VR headset
214920080|NCT06667531|PROCEDURE|Implant|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 3 mm.
214920081|NCT06667531|PROCEDURE|Implant|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 2 mm.
214320298|NCT04996303|DRUG|Routine steroid administration group|Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
214920082|NCT06667531|PROCEDURE|Implant|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 1.5 mm.
214920083|NCT02175394|DRUG|Microgynon®|
214920084|NCT02175394|DRUG|BI 1356|
214920085|NCT03611777|DRUG|Inhaled corticosteroid|Drug
214320299|NCT04996303|DEVICE|Steroid pulse therapy group|Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg \~ 1g) pulse 3 days -\> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
214920086|NCT02741674|PROCEDURE|Roux-en-y gastric bypass (RYGB) - historical|Participant has had RYGB, as identified using existing data
214920087|NCT02741674|PROCEDURE|Adjustable gastric banding (AGB) - historical|Participant has had AGB, as identified using existing data
214920088|NCT02741674|PROCEDURE|Sleeve gastrectomy (SG) - historical|Participant has had SG, as identified using existing data
214920089|NCT05431530|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery including resection of tumors involving rectosigmoid colon.
214920090|NCT05019196|DEVICE|GE 3.0T MRI|using GE 3.0T MRI to obtain anatomical and functional MR images and DTI images
214320300|NCT05565287|COMBINATION_PRODUCT|ultra early physiotherapy intervention|"* NBAS / NBO and GMs based guidelines in explaining neonatal signs into the NICU (lasting 15-30 minutes)~* NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention upon hospital discharge (lasting one hour)~* NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention every 15 to 20 days until the 3rd month of life (corrected age)."
214320301|NCT05724602|DRUG|Xevinapant|3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
214320302|NCT05724602|DRUG|Placebo|3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
214320303|NCT03205085|RADIATION|magnetic resonance imaging|assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
214484200|NCT06980259|RADIATION|Spatially Fractionated Radiotherapy|SFRT builds on CRT, administered at 3.0 Gy per fraction for 15-20 fractions, with the addition of weekly high-dose vertices of 8-15 Gy per fraction for 3-4 fractions. It employs Intensity-Modulated Radiation Therapy (IMRT), Intensity-Modulated Proton Therapy (IMPT), or Volumetric Modulated Arc Therapy (VMAT) to create a grid-like pattern of alternating high- and low-dose regions. Target volume delineation includes the gross tumor volume (GTV), clinical target volume (CTV, expanded 0.5-1.0 cm from GTV), and planning target volume (PTV, expanded 1.0 cm from CTV). Prior to each treatment session, cone-beam CT (CBCT) or kilovoltage cone-beam CT (kV-CBCT) is used for Image-Guided Radiation Therapy (IGRT) to verify patient positioning.
214484201|NCT06980259|RADIATION|Conventional Radiotherapy|CRT is delivered at 3.0 Gy per fraction for a total of 15-20 fractions, utilizing Intensity-Modulated Radiation Therapy (IMRT) or Intensity-Modulated Proton Therapy (IMPT) techniques, ensuring a target volume dose coverage of at least 90%. Target volume delineation includes the gross tumor volume (GTV), clinical target volume (CTV, expanded 0.5-1.0 cm from GTV), and planning target volume (PTV, expanded 1.0 cm from CTV). Prior to each treatment session, cone-beam CT (CBCT) or kilovoltage cone-beam CT (kV-CBCT) is used for Image-Guided Radiation Therapy (IGRT) to verify patient positioning.
214484202|NCT06985277|DIAGNOSTIC_TEST|Urgent endoscopy strategy|Patients will undergo colonoscopy within 24 hours of diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) followed by same-session video capsule endoscopy (VCE) will be performed immediately
214484203|NCT06985277|DIAGNOSTIC_TEST|Standard colonoscopy with standard VCE group|Patients will undergo colonoscopy within 24-48 hours after diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) will be performed immediately. If EGD shows no bleeding source, video capsule endoscopy (VCE) will be performed within 24 hours of the preceding endoscopies
214920091|NCT04498689|DRUG|Camrelizumab|Patients firstly receive camrelizumab 200 mg per time (iv, no less than 20 minutes and no more than 60 minutes, rinse time included) on Day 1 and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
214920092|NCT04498689|DRUG|Nab paclitaxel|Patients secondly receive nab-paclitaxel 100 mg/m2 (iv, at least 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
214920093|NCT04498689|DRUG|Gemcitabine Injection|At last, patients receive gemcitabine 1000 mg/m2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
214920094|NCT04696055|DRUG|Pembrolizumab|Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).
214920095|NCT04696055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.
214320304|NCT03205085|PROCEDURE|2D and 3D trans-thoracic echocardiography|assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
214320305|NCT03205085|OTHER|Blood samples|Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
214484204|NCT06985745|OTHER|Standard Cleanser, Investigational emulsion, Standard moisturizer, Standard Sunscreen|"Products Application and Usage Instruction:~Wash out: T-2W \~ T0~Frequency:~AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer Caution: All the products should be applied to full face. No any other skincare or facial make up products are used except provide products.~b. Mode of application : 4-week Treatment T0 \~ T4W~Frequency:~AM: Standard cleanser + test emulsion (FLA#2039180 68) + standard sunscreen PM: Standard cleanser + test emulsion (FLA#2039180 68) Caution: All the products should be applied to full face. No other skincare or facial make up products are used except provide products.~c. Mode of application : 2-week relapse T4W \~ T6W AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer~Usage Instruction： Test emulsion (FLA#2039180 68): Self-application 0.6 ml for full face by hand every day (2x/day)."
214484205|NCT02347254|DEVICE|Transcranial ExAblate|Transcranial ExAblate MRgFUS
214484206|NCT02765854|DRUG|Dexamethasone|Given PO
214484207|NCT02765854|DRUG|Ixazomib|Given PO
214484208|NCT02765854|DRUG|Lenalidomide|Given PO
214920096|NCT06557629|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of gastric residual volume
214920097|NCT00116818|DRUG|GW685698X aqueous nasal spray|
214320306|NCT05910580|BEHAVIORAL|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment. Procedures for SBIRT delivery will be adapted to the flow of telemedicine visits.
214320307|NCT02517034|OTHER|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
214320308|NCT02517034|OTHER|Quality-of-Life Assessment|Ancillary studies
214320309|NCT02517034|OTHER|Questionnaire Administration|Ancillary studies
214320310|NCT02517034|OTHER|Survey Administration|Ancillary studies
214320311|NCT01516190|BEHAVIORAL|Exercise|Supervised exercise sessions and independent exercise
214320312|NCT01516190|BEHAVIORAL|Surgical preparation program|Book, tapes, CD
214320313|NCT04615949|DRUG|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
214320314|NCT04615949|DRUG|Placebo|Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
214320315|NCT02722694|DRUG|Subcutaneous(SC) Abatacept|Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.
214320316|NCT02722694|OTHER|Placebo|Subjects received weekly SC placebo injections for 24 weeks
214320317|NCT02722694|DRUG|Methotrexate|All Subjects received backup Methotrexate treatment.
214484209|NCT06986603|DRUG|Glucagon for Injection (Fresenius Kabi USA)|We are assessing response to glucose, including incremental glucose values as well as changes in endogenous glucose production, insulin secretion, and glucagon levels.
214920098|NCT02767024|DRUG|Sodium nitroprusside|Sodium nitroprusside is a medication used to lower blood pressure.
214920099|NCT02767024|DRUG|Dobutamine|Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ÃŸ receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.
214920100|NCT02767024|DRUG|Furosemide|Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
214920101|NCT03688867|BEHAVIORAL|Prehabilitation regimen|"The intervention targets individual behavior, specifically a patient's proclivity to exercise prior to pancreatic resection. The prehabilitation program is tailored to the three most commonly used objective frailty metrics currently available and will be implemented during the initial consultation visit in the surgery outpatient clinic, where patients will undergo baseline testing and then provided with a fitness tracker and stress ball.~Additionally, they will be provided with an activity log to keep track of their daily activity. Shown below is the activity log."
215061613|NCT06158464|OTHER|Functional Capacity Evaluation|In a FCE, an occupational therapist will evaluate a patient's ability to perform work-related tasks, using a battery of tests. Depending on the circumstances, he/she will for instance test fatigue, ask the patient to kneel, lift objects, or assess concentration. This assessment lasts ± 4 hours and includes physical tests and tests related to the (previous or reference) profession of the client. This means that an explicit match is made between the functional capacities of the patient (what is he/she capable of) and the demands of a certain job (what is he/she expected to do). Following this assessment, the occupational therapist will explain the results of this assessment to the patient. The evaluation will therefore take place during one or two visits.
214320318|NCT05458856|DRUG|Triptorelin embonate 22.5 mg|A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
214320319|NCT02882282|OTHER|Laboratory Biomarker Analysis|Correlative studies
214484210|NCT06664684|OTHER|Energy-restricted dietary intervention|The diets were planned based on current guidelines, manuals, systematic reviews, and meta-analyses published in recent years on MAFLD \[5-6, 27-28\]. In this diet, carbohydrates constituted 50%-55% of total energy intake, proteins constituted 10%-20%, and fats constituted 25%-35%. The content of the diets was tailored to each patient, considering various factors such as sex, age, and physical activity status.
214320320|NCT02882282|OTHER|Patient Observation|Undergo observation
214320321|NCT02882282|BIOLOGICAL|Pembrolizumab|Given IV
214320322|NCT06581835|DEVICE|Observational|The study objective requires placement of a jugular venous bulb catheter in the right or left jugular venous bulb with ultrasound guidance. A venous and radial arterial line will be placed. Two INVOS™ sensors (PMSENS71-A) will be placed bilaterally on the subject's forehead. The INVOS™ device will be evaluated for a targeted range of 70-100% SpO2 levels. Hypoxic mixtures of gas are delivered, and data are collected at approximately (\~) 5-minute intervals during steady periods of increasing and decreasing oxygen concentration.
214320323|NCT06484153|DRUG|Pirfenidone|Two doses of pirfenidone (200 mg,tid,po;500 mg,tid,po) were set up. Using the 3+3 design, the DLT observation period is 28 days.
214320324|NCT06484153|DRUG|Fruquintinib|3mg, orally, qd
214320325|NCT06484153|DRUG|Pembrolizumab|200mg iv every 3 weeks
214320326|NCT05061160|OTHER|Interval Aerobic Exercise training Group|"Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
214320327|NCT05061160|OTHER|Continuous Aerobic Exercise training Group|"Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
214320328|NCT05996081|BEHAVIORAL|Adherence toolkit|The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.
214320329|NCT02252887|DRUG|Gemcitabine|
214320330|NCT02252887|DRUG|Trastuzumab|
214320331|NCT02252887|DRUG|Pertuzumab|
214484211|NCT06664684|OTHER|Energy + time-restricted dietary intervention|Patients in the energy + time-restricted diet group followed the same dietary intervention and a 16:8 eating pattern where they were instructed to restrict their energy intake to an 8-h time window and not to consume energy-containing foods or drinks during the remaining 16 h. Participants were allowed to consume energy-free beverages such as water, coffee, and tea during fasting. The timing of the eating window during the day varied according to participants' lifestyles and habits. However, considering the importance of nocturnal fasting, the eating window in all patients started at 10:00-12:00 in the day and ended at 18:00-20:00 in the evening. The energy-restricted diet group did not follow any time restriction in the planning of main meals and snacks.
214484212|NCT06664645|PROCEDURE|LHB tendon reinforcement|complete repair with LHB tendon reinforcement
214920102|NCT04495972|DIETARY_SUPPLEMENT|Intestinimonas-capsules|Capsules containing microbiota (Intestinimonas)
214920103|NCT04495972|DIETARY_SUPPLEMENT|Placebo-capsules|Placebo capsules are identical to the active treatment
214920104|NCT06123169|DRUG|Antibioprophylaxis (Piperacillin-tazobactam)|antibiotic prophylaxis during surgery
214920105|NCT06123169|DRUG|5 days Antibiotherapy (Piperacillin-tazobactam)|5 days Antibiotherapy from surgery
214920106|NCT05462938|DRUG|Continuous infusion of propofol|Sedation under continuous infusion of propofol. Small doses of fentanyl will be administered if needed.
214920107|NCT05462938|DRUG|Continuous infusion of dexmedetomidine|Sedation under continuous infusion of dexmedetomidine. Small doses of fentanyl will be administered if needed.
214920108|NCT06968013|BEHAVIORAL|Well-Being Therapy|Participants will undergo Well-Being Therapy (WBT) sessions once daily for 50 minutes over a period of six weeks. The core elements of WBT include prompting participants to identify instances of well-being, contextualize these experiences using a structured diary, and recognize as well as restructure thoughts, beliefs, and behaviors that prematurely disrupt well-being. Additionally, the specific components of the six dimensions of the Psychological Well-Being (PWB) scale-autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance-are systematically integrated into different therapy sessions
214920109|NCT06968013|BEHAVIORAL|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
215061614|NCT06398002|OTHER|Dialysate calcium 1.50 mmol/L|Increased dialysate calcium of 1.50 mmol/L (as compared to standard dialysate calcium of 1.25 mmol/L)
215061615|NCT00641355|PROCEDURE|No intervention|No intervention
215061616|NCT03776318|DRUG|Long-Term Safety Follow-up|STX-015-18-01 long-term safety follow-up
214484213|NCT06664645|PROCEDURE|complete repair without reinforcement|conventional rotator cuff complete repair without reinforcement
214920110|NCT06969170|DRUG|Psilocybin (drug)|Psilocybin 3mg Po (oral solution) administered daily for 28 days (Open-Label Run-in Phase) followed by Psilocybin 3mg Po (oral solution) OR Placebo for 28 days (Double-Blind Treatment Phase) in patients with Generalized Anxiety Disorder(GAD)
214920111|NCT06969170|OTHER|Placebo|Sucralose 0.2% oral solution
215061617|NCT04875455|DEVICE|POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
215061618|NCT04053972|DRUG|Lenvatinib|oral lenvatinib after hepatectomy
215061619|NCT04077489|PROCEDURE|cataract surgery|To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
215061620|NCT05640050|OTHER|Audit Implementation|The feasibility of establishing and implementing an acceptable and robust audit system with community representation at secondary health facilities to improve maternal and perinatal outcomes. The implementation phases follow the standard World Health Organization (WHO) audit system.
215061621|NCT06246838|DIAGNOSTIC_TEST|Ga-68 V/Q PET/CT|Head-to-head comparison of Ga-68 V/Q PET/CT vs Tc-99m V/Q SPECT/CT
215061622|NCT00005097|DRUG|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
215061623|NCT01111734|DIETARY_SUPPLEMENT|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
215061624|NCT01111734|DRUG|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
214320332|NCT02837432|DRUG|Hydrocortisone acetate|
214320333|NCT02837432|DRUG|Placebo|
214320334|NCT04737642|PROCEDURE|Papillary ballon dilatation|Trans cystic papillary ballon dilatation during cholecystectomy
214320335|NCT01920932|DRUG|brentuximab vedotin|Given intravenously (IV).
214320336|NCT01920932|DRUG|etoposide|Given IV.
214320337|NCT01920932|DRUG|prednisone|Given orally (PO).
214320338|NCT01920932|DRUG|doxorubicin|Given IV.
214320339|NCT01920932|DRUG|cyclophosphamide|Given IV.
214320340|NCT01920932|DRUG|Dacarbazine(R)|Given IV.
214320341|NCT01920932|DRUG|filgrastim|Given subcutaneously (SQ) as clinically indicated.
214320342|NCT01920932|OTHER|quality of life assessment|Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
214320343|NCT01920932|RADIATION|radiation therapy|At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
214320344|NCT00134875|DRUG|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
214320345|NCT02227524|OTHER|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
214320346|NCT02227524|DEVICE|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
214320347|NCT02227524|DEVICE|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
214320348|NCT02227524|DEVICE|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
214320349|NCT05436470|DEVICE|PK Papyrus|The PK Papyrus is a balloon mounted stent that will be administered during standard of care treatment of pseudoaneurysms.
214320350|NCT00196950|BIOLOGICAL|Meningococcal (vaccine)|
214320351|NCT04429009|DEVICE|ZEPHYRx Respiratory Therapy (RT) System|A breath controlled video game system for respiratory therapy
214320352|NCT04429009|DEVICE|Standard Incentive Spirometer|A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
214320353|NCT01140477|DEVICE|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
214320354|NCT01140477|DEVICE|Accommodating Lens|Accommodating lens implanted after cataract extraction
214320355|NCT06955338|PROCEDURE|Music intervention|The music for the study will be the 'MusiCure® 9 Scandinavia' compositions specially developed by Inge Eje and Niels Eje (Gefion Records, Copenhagen, Denmark) (MusiCure, 2024). The compositions include melodies with harp, cello, strings and sounds from nature (birds, forest and night sounds) in a soft rhythm between 60-80 bpm for relaxation, based on research into the acoustic environment of hospitals and shown to have a positive effect on patients' symptoms such as pain, fear and anxiety. Two minutes after the child starts listening to the music, oral mucositis care will be started. Five minutes after the end of the procedure, the Child Anxiety Scale-Conditioning (CAS-D), Child Fear Scale and Visual Comparison Scale will be applied and the duration of the procedure will be recorded.
214484214|NCT05708443|OTHER|LL group|"The program will include daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 60 minutes on a stationary bike for the lower limbs (2 sessions per day of 30 minutes) at moderate-high intensity;~2. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist."
214320356|NCT06955338|PROCEDURE|Virtual reality|In this group, children will be shown a short film with virtual reality glasses. In the study, the short film 'MusiCure® The Journey' specially developed by Inge Eje and Niels Eje (Gefion Records, Copenhagen, Denmark) will be preferred in the virtual reality group. The duration of the film is 16 minutes (MusiCure, 2024). Two minutes after the child starts watching the film, oral mucositis care will be started. Five minutes after the end of the procedure, the duration of the procedure will be recorded by applying the Child Anxiety Scale-Conditioning (CAS-D), Child Fear Scale and Visual Comparison Scale.
214320357|NCT04535284|BEHAVIORAL|Coaching|"Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching."
214320358|NCT06097234|DEVICE|Pelex Upp|Biofeedback-mediated pelvic floor trainer. It captures contraction and relaxation of the pelvic floor muscles during use by the subject, and represents these contractions and relaxations back to the subject to improve conscious control of the muscle groups.
214320359|NCT06097234|BEHAVIORAL|Pelvic Floor Physical Therapy|A form of physical therapy whereby the subject is given instructions on how to identify the pelvic floor, how to coordinate the pelvic floor contractions and relaxations, as well as counseling on dietary changes that affect pelvic floor and pelvic organ function
214920112|NCT06969300|DEVICE|Gold micro needles|The treatment (with gold microneedles) was administered on the day of enrollment after the completion of the detection items. Follow-up visits were conducted at 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks. The follow-up contents included visia photography, camera photography, non-invasive skin examination, questionnaire assessment, etc. The study duration was 12 weeks.
215061625|NCT00626886|DRUG|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
214320360|NCT03252821|BEHAVIORAL|High-intensity interval training|High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
214320361|NCT03252821|BEHAVIORAL|Resistance training|Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
214320362|NCT03285373|DRUG|NOAC|New Oral Anticoagulant
214320363|NCT06139913|OTHER|aerobic exercise|moderate intensity aerobic exercise using treadmill
215061626|NCT00626886|DRUG|placebo collagen sponge|collagen
215061627|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
215061628|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks"
215061629|NCT02761681|BEHAVIORAL|ACT-CL Web-based guided self-help|
215061630|NCT02761681|BEHAVIORAL|Control Web-based guided self-help|
214320364|NCT05822869|PROCEDURE|EIT-guided mechanical ventilation strategy|During prone ventilation, the PEEP level is adjusted based on EIT monitoring. The optimal PEEP is the lowest sum of collapse and overdistension percentages
214920113|NCT06969300|DRUG|Gold micro-needles combined with salicylic acid|On the day of enrollment, the treatment was administered (gold microneedle + 30% salicylic acid on half of the face) after the completion of the detection items. A site follow-up was conducted one week later, and a follow-up was carried out two weeks later with the second acid brushing treatment. A follow-up was conducted four weeks later with the third acid brushing treatment. Follow-up was also conducted at the eighth and twelfth weeks. The follow-up contents included: Visia photography, camera photography, non-invasive skin examination, questionnaire assessment, etc. The study duration was 12 weeks.
214920114|NCT05406479|DRUG|BE-PEP (Bedaquiline)|Single dose of Bedaquiline
214920115|NCT05406479|DRUG|SDR-PEP|Single dose of Rifampicin
214920116|NCT05406479|DRUG|BE-PEP (Rifampicine)|Single dose of Rifampicin
215061631|NCT04239261|DIETARY_SUPPLEMENT|SBI|Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
215061632|NCT04239261|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed gelatin 10.0 g once daily
214320365|NCT05822869|PROCEDURE|Lung protective ventilation group|Lung-protective ventilation strategy during prone positioning that continues the supine position.
214320366|NCT01823029|DRUG|erythropoietin|
214320367|NCT01823029|DRUG|enteral nutrition.|
214320368|NCT01823029|DRUG|injection of iron|
214320369|NCT04400279|BEHAVIORAL|Yoga group|At-home yoga exercise instruction provided by a mobile/tablet app or through a computer web browser
214320370|NCT04400279|BEHAVIORAL|High Intensity Interval Training group|At-home HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
214320371|NCT04400279|BEHAVIORAL|Combination|At-home yoga \& HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
214320372|NCT03871127|PROCEDURE|Percutaneous coronary intervention|Using sirolimus eluting stent
214320373|NCT03871127|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
214320374|NCT01550419|DRUG|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
214320375|NCT01550419|DRUG|Placebo|The smell and shape of placebo are the same as atorvastatin
214320376|NCT01945489|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
214320377|NCT01945489|DRUG|Normal saline|Normal saline (placebo) injected into the detrusor.
214320378|NCT00829322|DRUG|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
214320379|NCT00829322|DRUG|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
214320380|NCT02084771|DRUG|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
214320381|NCT02084771|BIOLOGICAL|Oral Salt and Water|Oral salt capsules and water, based on patient weight
214320382|NCT00697346|DRUG|Alisertib|Alisertib (MLN8237) PIC or ECT
214320383|NCT01381861|BIOLOGICAL|Carotuximab (TRC105)|Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
214320384|NCT03569371|DRUG|INCB054707|INCB054707 administered once daily orally with water without regard to food for 8 weeks.
214320385|NCT04114253|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214320386|NCT06402188|DEVICE|ColoSeal ICD Device|The subject will undergo scheduled resection per the surgeon's preferred technique. Following completion of the anastomosis, the Intraluminal Colonic Diversion (ICD) Device will be inserted, advanced and positioned with the ICD Delivery System transanally. The ICD Device will remain in place for 10± 2 days. Anastomotic leak testing will be performed prior to scheduled removal.
214320387|NCT00876473|PROCEDURE|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator"
214320388|NCT01515969|DRUG|Erlotinib hydrochloride|Given PO
214320389|NCT01515969|DRUG|Dovitinib lactate|Given PO
214320390|NCT03611569|DRUG|Lu AF82422|Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
214320391|NCT03611569|DRUG|Placebo|placebo - concentrate for solution for infusion, single dose
214320392|NCT00017706|BEHAVIORAL|physician-delivered weight control|
214320393|NCT01236755|DEVICE|single-vision glasses|Daily wear of glasses to correct vision in the first seven months of the study
214320394|NCT01236755|DEVICE|ortho-k lenses|Nightly wear of lenses to correct vision in day time in the second seven months of the study
214320395|NCT01388829|DRUG|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
214320396|NCT01388829|DRUG|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
214320397|NCT06336369|DIAGNOSTIC_TEST|analyzing brown adipose tissue, body composition and metabolic health|cooling procedure, PET-CT imaging, MR imaging, blood sampling, indirect calorimetry, thermograpy, impedance analysis
214320398|NCT03567850|BEHAVIORAL|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
214320399|NCT03780842|DEVICE|NAVA level|"A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV."
214320400|NCT00202904|DRUG|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
214320401|NCT00202904|DRUG|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
214320402|NCT02300324|DIETARY_SUPPLEMENT|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
214320403|NCT02300324|DIETARY_SUPPLEMENT|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
214320404|NCT02300324|DIETARY_SUPPLEMENT|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
214320405|NCT04409782|OTHER|Electronic portal education|Participants will receive education via an electronic portal covering the key messages pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
214320406|NCT04409782|OTHER|Online educational video|Participants will receive online education via a video and written web content. Key messages will include information pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
214320407|NCT03212703|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale
214484215|NCT05708443|OTHER|L+UL group|"These patients will attend a rehabilitation program with daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 30 minutes on a stationary bike for the lower limbs (1 session of 30 minutes per day) at moderate-high intensity;~2. 30 minutes with arm-ergometer (1 daily session of 30 minutes) at moderate-high intensity;~3. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist."
214484216|NCT05800717|BEHAVIORAL|SCI Self-Management for AIS D|An individually administered, self-management intervention for Veterans with AIS D spinal cord injury.
214484217|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (low dose)|Inject 1 dose of low-dose vaccine
214484218|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (low dose)|Inject 1 dose of low-dose placebo
214484219|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (high dose)|Inject 1 dose of high-dose vaccine
214484220|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (high dose)|Inject 1 dose of high-dose placebo
214920117|NCT05801783|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
214920118|NCT06969222|PROCEDURE|Robotic TKA|Total knee replacement of arthritic knees either with robotic-assisted Skywalker device
214920119|NCT06969222|PROCEDURE|Conventional TKA|Total knee replacement of arthritic knees performed manually
214920120|NCT06564675|DIAGNOSTIC_TEST|C-Trend Index|C-trend-Index is collected blinded from the patients using Brainstatus device. The device shows and collects also cEEG. These are analyzed retrospectively after all study patients have their 6-month follow-up data collected. The intervention does not affect clinical management or decision-making.
214920121|NCT02915770|PROCEDURE|cholangiojejunostomy|Half of participants will receive hepatectomy, cholangiojejunostomy and T-tube Drainage,while the other half will receive hepatectomy and T-tube Drainage
214920122|NCT02915770|PROCEDURE|hepatectomy|
214920123|NCT02915770|DEVICE|T-tube|T-tube Drainage
214320408|NCT03212703|OTHER|Waitlist control (WLC)|Observation surveys at baseline, mid-point and end-point of an 8-week period
214320409|NCT02881294|DRUG|SUVN-G3031|
214484221|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|Inject 1 dose of positive control vaccine
214484222|NCT06015191|BEHAVIORAL|Remote Cardiac Rehabilitation|Participants will engage in a ramp-up period (weeks 0-2) where participants will attend 1-on-1 live, remote in-home exercise sessions (20-35 min./session, 3-days/wk.) delivered by a health coach via telehealth video conferencing. Participants will be provided a tablet computer and a small set of equipment. Following the ramp-up period, participants will be asked to attend live, in-home, group-based exercise sessions (weeks 3-12, 3-5 participants/group, 45-min, 3-days/wk. minimum). Sessions will be offered 4-days/wk. in the afternoons and early evenings allowing participants to select the most convenient 3 days per week to attend. Sessions will include a variety of dynamic aerobic and anaerobic (resistance) exercises with a target heart rate corresponding to 60-75% of VO2peak. In the group-based exercise sessions, participants will be able to see, hear, and verbally interact with the health coach and the other participants, allowing for supervision and encouraging social support.
214920124|NCT05220449|OTHER|Cross-frequency dual-site tACS|Dual site transcranial alternating current stimulation over the primary visual cortex (V1) and the mediotemporal cortex (MT/V5) using two different stimulation frequencies (Alpha and Gamma)
215061633|NCT05561283|DIAGNOSTIC_TEST|Self-questionnaires|Self-questionnaires on satisfaction, burn-out, depression, anxiety, relational skills and sleep quality
214320410|NCT04020302|BEHAVIORAL|Self-monitoring shopping intervention|Intervention will occur once per week for a duration of 8 weeks. The intervention format will alternate between individual and group sessions, so that the first week of intervention will be provided in a group format, the second week will be provided in an individual format, and so forth. Sessions will be 90 minutes in duration. Data will be collected during individual sessions, which will occur every other week. During individual sessions, each participant will meet at the facility for the first 15 minutes, will travel to a local grocery store for 45 minutes, and then reconvene at the facility for the final 30 minutes. Group sessions will follow the same structure; however, all ten participants will be present. Each of the 8 sessions will consist of the following: awareness training; facilitation of strategy generation; facilitation of error detection; reinforcement of self-monitoring techniques; and opportunity for participants to practice self-monitoring techniques.
214320411|NCT03779412|BEHAVIORAL|The Happiness Trap|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
214320412|NCT03779412|BEHAVIORAL|A Mindfulness-Based Stress Reduction Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
214320413|NCT02515266|OTHER|nutrition: protein intake|additional protein fortification of human milk
214320414|NCT03843684|DEVICE|3D-printed foot orthoses|3D printed foot orthoses with arch support
214320415|NCT03843684|DEVICE|5 degrees lateral wedge insoles|Insoles with a lateral inclination set at 5 degrees
214320416|NCT00104533|DEVICE|Magnets|
214320417|NCT03202004|DRUG|GSK2894512 1% cream|1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
214320418|NCT03202004|DRUG|Vehicle cream|Vehicle cream will be provided in tubes labeled in compliance with country requirements.
214320419|NCT00895739|BIOLOGICAL|alemtuzumab|
214320420|NCT00895739|DRUG|cyclosporine|
214320421|NCT04976491|DIETARY_SUPPLEMENT|CD-C-Food|CD patients combined with the characteristics of Chinese diet, remove the refined food, and combined with food intolerance detection method to check the corresponding food
214320422|NCT04976491|DIETARY_SUPPLEMENT|EEN|EEN goup received EEN continuously for 6 moths
214484223|NCT06015191|BEHAVIORAL|Active Control|Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
214484224|NCT02343991|DEVICE|Transcranial ExABlate|MR Guided Focused Ultrasound
214484225|NCT06988254|OTHER|Animation-based breathing therapy|The animation-based breathing therapy includes breathing exercises for children, such as lion, crab, and rainbow breathing. The intervention will continue for six weeks (two sessions per day, five days per week).
214484226|NCT06990360|DIAGNOSTIC_TEST|CBCT Scanning|The Styrofoam mandibles were scanned using CBCT, which was performed for each mandible pre-operatively, the raw DICOM data set obtained from the CBCT scanning were imported to a special third-party software\* for secondary reconstruction.
214320423|NCT03857802|BEHAVIORAL|Sleep hygiene intervention|"An individual education will be carried out following a bidirectional feedback method. It is intended to develop skills to make conscious and autonomous decisions. The explanation will consist:~1. Information and reading with discussion of the educational sheet: The 9 tips for a healthy sleep will be read, point by point. The nurse will be open to discuss those that generate doubt.~2. Confrontation: even if the patient does not ask any questions about it, it will be necessary to ask if he has understood the advice.~3. Participated information: Questions will be asked to the patient such as: Did you already know any of these tips?.~A telephone call per month will be made as an educational reinforcement to the intervention."
214320424|NCT03734848|DRUG|Bilateral Ultrasound Guided Pectoralis Nerve Block.|Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
214320425|NCT04633096|BEHAVIORAL|tailored feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
214320426|NCT04633096|BEHAVIORAL|standardized feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
214320427|NCT05291299|BEHAVIORAL|Anti-inflammatory diet|Patients randomized to the intervention group will work with a registered dietitian to create an individualized diet program to help reduce inflammation and Rheumatoid arthritis related symptoms.
214320428|NCT05291299|OTHER|Control/Standard of Care|Patients randomized to the control group will be following standard of care where their doctor will instruct them to follow a Mediterranean diet and provides them with an instructional sheet.
214320429|NCT01539226|COMBINATION_PRODUCT|Placebo Vaginal Ring|Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
214320430|NCT01539226|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
214320431|NCT03904459|OTHER|no intervention|
214484227|NCT06989203|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
214320432|NCT00514410|DRUG|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
214320433|NCT00514410|DRUG|Placebo|Matching placebo taken once a day for three months
215061634|NCT04180098|BEHAVIORAL|C-mill intervention|A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
215061635|NCT04180098|OTHER|No intervention|Participants in the control group are placed on a waiting list.
215061636|NCT01906411|DIETARY_SUPPLEMENT|Dopamine depletion vs. Balanced aminoacid drink|
215061637|NCT01113177|DEVICE|Distraction splint therapy|After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
215061638|NCT01116466|DEVICE|ActiGait|ActiGait - implantable drop foot stimulator
214320434|NCT01099085|DRUG|Simvastatin|simvastatin 40 mg qd daily
214320435|NCT01099085|DRUG|Placebo|Placebo
215061639|NCT04657705|PROCEDURE|High power ablation|High power ablation parameters (50-55 W)
215061640|NCT04657705|PROCEDURE|Standard ablation power|Standard ablation power parameters (40-45 W)
214320436|NCT00667238|BEHAVIORAL|Questionnaire|
214320437|NCT02643251|DRUG|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
214320438|NCT02643251|DRUG|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
214320439|NCT05372016|BIOLOGICAL|Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9vHPV vaccine ,0.5mL, three doses, 0,2,6 months
214320440|NCT05372016|BIOLOGICAL|Active Comparator: GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
214320441|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
214320442|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
214320443|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
214320444|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
214920125|NCT04520542|OTHER|Acupressure Application|Acupressure was administered in a semi-sitting or supine position where the woman felt comfortable and the researcher could perform the practice comfortably to the acupressure points. The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention.
214320445|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
214320446|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
214320447|NCT03112161|OTHER|Eucaloric Feeding Period|
214320448|NCT03112161|OTHER|Overfeeding Feeding Period|
214320449|NCT03112161|OTHER|Underfeeding Feeding Period|
214320450|NCT00839293|DRUG|ABT-335|Once, see arm description for more information
214484228|NCT06989203|BEHAVIORAL|Calorie-restricted balanced diet|Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes and APP-connected scale will be used to monitor their weight changes during interventions.
214920126|NCT03021083|DEVICE|IONSYS Patch|Patient controlled transdermal fentanyl patch, IONSYS, applied to patient in place of a PCA.
214920127|NCT05461001|OTHER|Warm Up Exercises|The daily warm up exercises for male football players include full body stretch, high knees, lunges, squat and burpees.
215061641|NCT05713981|PROCEDURE|Meibomian gland (MG) expression|The procedure is performed with a sterile cotton tip applicator once in the upper and lower eyelids of the subject's choosing.
214320451|NCT01506531|PROCEDURE|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
214320452|NCT01506531|PROCEDURE|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
214320453|NCT00077168|DRUG|anastrozole|
214320454|NCT00077168|DRUG|tamoxifen citrate|
214320455|NCT00077168|PROCEDURE|adjuvant therapy|
214484229|NCT06989203|DRUG|semaglutide|Participants will receive semaglutide as medically prescribed
215061642|NCT00140712|DRUG|Ropinirole Immediate Release|Ropinirole Immediate Release
215061643|NCT05293600|DRUG|Placebo|Placebo capsule 30 min before bedtime
214320456|NCT00077168|RADIATION|radiation therapy|
214320457|NCT01057043|DEVICE|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
214320458|NCT03246867|OTHER|Isolytic stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.
214320459|NCT03246867|OTHER|Static stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.
214484230|NCT06989203|DIETARY_SUPPLEMENT|Dietary protein supplementation|participants will receive 30 g/day of dietary protein supplementation
214671955|NCT00249561|BEHAVIORAL|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
214920128|NCT05461001|OTHER|Endurance Based Exercises|Sport-specific endurance-running (duration \[in minutes\], total distance \[in meters\], mean speed \[in meters per minute\], high-speed running \>15 km·h-1, and relative high-speed running \[\>75% and \>85% of maximal velocity\]) will be given to the experimental group. Athletes will run in excess of 15 km of total distance (TD) and 4 km of high-speed (\>15 km·h-1) distance per session 3 to 4 running-based endurance sessions per week for 6 weeks.
214920129|NCT04956601|RADIATION|vaginal brachytherapy/pelvic external beam radiotherapy|high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy
214920130|NCT03951883|OTHER|Increased Egg Consumption|Subjects will be instructed to use a weekly food purchase supplement for inclusion of 2 additional eggs per day to be added to subject's typical daily diet.
214920131|NCT03951883|OTHER|Typical diet|Subjects will be instructed to maintain their current dietary patterns.
214920132|NCT02763137|DRUG|Standard LD/CD|LD/CD will be administered at patient's usual dose and frequency during 8 hours interval
215061644|NCT05293600|DRUG|Acetazolamide|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
214320460|NCT03246867|OTHER|Control group|Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
214320461|NCT04869735|OTHER|Data collection: DTPolio vaccine delivery|"with information about booster vaccination group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS without information about booster vaccination group: no intervention"
214320462|NCT02993575|DRUG|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
214320463|NCT03863210|OTHER|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
214484231|NCT04643769|DRUG|ORIN1001|Oral tablet - ORIN1001
214484232|NCT04643769|DRUG|Placebo|Oral tablet - placebo
214484233|NCT04242992|BEHAVIORAL|CETA|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based CBT elements so providers can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include SMS reminders of their HIV care appointments, similar to the active control group.
214484234|NCT04242992|OTHER|Short Message Service (SMS) text reminders|Short Message Service (SMS) text reminders for upcoming appointments will be sent monthly.
214484235|NCT06990919|OTHER|Saliva collection|Pre-operative saliva collected before the full mouth treatment under general anesthesia while, post-operative saliva collected at 1-month follow-up after general anesthesia.
214920133|NCT02763137|DRUG|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of standard LD/CD at a dose equal to the total dose of standard oral LD/CD that patients would normally consume over 8 hours period.
214920134|NCT04724083|DIAGNOSTIC_TEST|biomarkers|new diagnostic biomarkers
214920135|NCT03567005|DEVICE|Nelfilcon A digital contact lenses|Silicone hydrogel digital contact lenses
214920136|NCT03567005|DEVICE|Nelfilcon A contact lenses|Silicone hydrogel spherical contact lenses
214920137|NCT02780453|DEVICE|Negative pressure dressing|
214920138|NCT02780453|DEVICE|Standard wound dressing|
214920139|NCT00820053|DRUG|epirubicin and lipiodol|using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
214920140|NCT05206253|DIETARY_SUPPLEMENT|Whole egg powder|Nutritional supplementation during a 12 week resistance training program
214920141|NCT05206253|DIETARY_SUPPLEMENT|Whey protein powder|Nutritional supplementation during a 12 week resistance training program
214920142|NCT05206253|DIETARY_SUPPLEMENT|Maltodextrin placebo|Nutritional supplementation during a 12 week resistance training program
214920143|NCT01781845|PROCEDURE|AFRI-SVI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI)a new ultrasound technology in which unique sound waves create the images/pictures of the kidney beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
215061645|NCT05293600|DRUG|Trazodone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
214920144|NCT02132182|BIOLOGICAL|Blood draw|The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
214320464|NCT02365636|DRUG|TV-45070|TV-45070 is an ointment applied topically twice daily to area of pain.
214920145|NCT04245631|DIAGNOSTIC_TEST|Recombinase aided amplification (RAA) assay|We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.
214920146|NCT01511029|DRUG|Dexpramipexole|300 mg - Oral Tablets
214920147|NCT01511029|DRUG|Dexpramipexole|600 mg Oral Tablets
214920148|NCT01511029|DRUG|Dexpramipexole Placebo|Placebo - Oral Tablet
214920149|NCT01511029|DRUG|Moxifloxacin|400 mg - Oral Tablet
214920150|NCT03117660|DRUG|Vitamin A|vitamin A daily X3-4 weeks
214920151|NCT02868489|DIETARY_SUPPLEMENT|LactoWise®|blend of bacillus coagulans and galactomannans
214920152|NCT02868489|OTHER|Placebo|Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium citrate)
214920153|NCT05484089|DEVICE|CapFlex PIP implant|Patients receive the CapFlex PIP implant based on regular care. During surgery tantalum markers are placed in the bone surrounding the implant.
214920154|NCT02533050|DEVICE|CPAP treatment|Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
214920155|NCT04431258|DRUG|ABTL0812|ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.
214320465|NCT02365636|DRUG|Placebo|The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
214320466|NCT04750122|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning|The choice of chemotherapy is based on the PTC drug sensitivity results.
214320467|NCT04379167|DRUG|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
214320468|NCT02111252|DRUG|TAK-850|TAK-850 injection
214320469|NCT03427658|BEHAVIORAL|Sweet food consumption|Comparison of the impacts of sweet and non-sweet food consumption
214320470|NCT04403321|DRUG|Tacrolimus|Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.
214320471|NCT04403321|DRUG|Placebo (for Tacrolimus)|placebo will be given at 1mg bid.
214320472|NCT00148603|DRUG|montelukast|
214320473|NCT05098639|BEHAVIORAL|BASICS|In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.
214484236|NCT06989177|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
214484237|NCT06989177|BEHAVIORAL|Energy-restricted nutritional and lifestyle intervention|Participants will receive dietary advice, behavioral guidance and nutritional and lifestyle education by dietitian and physicians. App-connected wearable devices will be utilized to monitor their dietary intakes and App-connected scale will be used to monitor their weight changes during interventions.
214484238|NCT06989177|DIETARY_SUPPLEMENT|Placebo|Participants will receive one bag (2 g; 1 × 10¹² CFU) daily of LC-19.
214484239|NCT06989177|DIETARY_SUPPLEMENT|Probiotic|participants will receive daily one bag of LC-19 (10\^12 cfu/bag).
214484240|NCT06989177|DRUG|semaglutide|Participants will receive prescibed semaglutide therapy
214484241|NCT06021769|OTHER|Observational only|No intervention
214484242|NCT06782035|DEVICE|Ora-Aid-Oral Wound Dressing|Intended as a physical barrier for temporary protection of oral mucosal tissue and to provide pain relief. This product is a non-eugenol protective material applied to intraoral wounds. Ora-Aid is a new concept of pasting intra-oral patch to protect the affected area such as post implant, extraction, orthodontic, and ulcers. This new concept of pasting intra-oral wound dressing is designed to protect the affected area and aid natural healing.
214484243|NCT06782035|BIOLOGICAL|Platelet rich fibrin|"It has been reported that the use of Platelet-Rich Fibrin (PRF) to cover palatal wounds accelerates healing and reduces postoperative morbidity. Studies have demonstrated that PRF supports key processes in wound healing, such as immunity, angiogenesis, and cellular proliferation. Its use has garnered significant interest, particularly in non-healing wounds and areas left to heal by secondary intention after surgery. Leukocyte and Platelet-Rich Fibrin (L-PRF) is frequently used in periodontal surgical applications. The platelets and growth factors it contains accelerate the healing process and facilitate tissue repair."
214484244|NCT06782035|DEVICE|Palatal Stent|Palatal stents help prevent complications such as infection or excessive discomfort. These plates are typically customized to fit the patient's palate by taking impressions before the surgery. Once placed, they serve as a barrier, especially during the early stages of healing. Additionally, they may reduce the need for postoperative interventions, such as the use of strong painkillers.
214920156|NCT04431258|DRUG|Folfirinox|"FOLFIRINOX will be dosed according to the standard following regimen:~* oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~* leucovorin 400 mg/m2, administered as 2-hour iv infusion~* irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~* fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities."
214320474|NCT05098639|BEHAVIORAL|Deviance Regulation Theory (DRT)|The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.
214320475|NCT04355962|DRUG|Sevoflurane|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
214320476|NCT04355962|DRUG|Intravenous drug|Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
214320477|NCT00968591|DRUG|Everolimus|
214320478|NCT03906669|DRUG|Letrozole|PO daily for 14 days
214320479|NCT03906669|DRUG|Letrozole and Prometrium|PO daily for 14 days
214320480|NCT03906669|DRUG|Tamoxifen and Prometrium|PO daily for 14 days
214320481|NCT03182348|PROCEDURE|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
214320482|NCT01163604|DRUG|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
214320483|NCT01163604|DRUG|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
214320484|NCT00006219|DRUG|clarithromycin|
214320485|NCT00006219|DRUG|prasterone|
214484245|NCT06996054|BEHAVIORAL|Multifaceted School-Based Mental Health and Suicide Prevention Program|Pupils will receive a four-session psychoeducational programme, delivered weekly by trained psychologists during school hours, covering mental health literacy, emotion regulation, identification of suicide risk, and help-seeking skills. Concurrently, parents and teachers will access a digital co-intervention through a custom-designed platform with four multimedia modules.
214320486|NCT06366971|OTHER|The Patient Education|The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.
214320487|NCT06366971|OTHER|The Pelvic Proprioceptive Neuromuscular Facilitation Techniques Training|The content of the pelvic proprioceptive neuromuscular facilitation techniques training will include the application of the anterior depression pattern with the rhythmic initiation technique and the application of the posterior elevation pattern with the contract-relax stretch technique. All PNF techniques will be performed in 3 sets of 10 to 12 repetitions. The pelvic proprioceptive neuromuscular facilitation techniques training will be delivered face to face 3 days a week for 6 weeks by an experienced and trained physiotherapist.
214320488|NCT04917094|DEVICE|Compression stocking|"A below-the-knee compression stock will be worn daily for 2 weeks from waking up to before sleep.~Bioelectrical impedance will be performed before and 2 weeks after wearing the stocking to assess the total body water content.~Measuring the calf and neck circumference will be done before and after wearing the compression stocking. After 2 weeks, the patient will return back to the clinic for calf and neck circumference measurement.~Sleep test will be done the night before and 2 weeks after wearing the compression stocking. Oxygen Desaturation Index(ODI) will be assessed through a level 4 home sleep apnea testing device.~Patients recruited will have mild excessive to severe excessive daytime sleepiness and/or STOP-Bang score of 3 or more, with underlying conditions such as type II diabetes and hypertensive patients using the Epworth sleepiness scale. Epworth sleepiness scale will be assessed again 2 weeks after to assess for increase sleep efficiency."
214320489|NCT05897177|BEHAVIORAL|Subjective Scale of Stigma and Discrimination (SISD).|"Subjective Scale of Stigma and Discrimination (SISD) A sixdimension self-administered scale will be used that included statements with which the participants agreed or disagreed. The scale consists of 23 Likert-type items and responses range from 1 (completely in disagreement) to 5 (completely in agreement), grouped together to represent the six indicators making up this part of the scale"
214320490|NCT03431116|RADIATION|ultrasound|to detect the placental site
214484246|NCT06996405|OTHER|Access to dietary treatment|Dietary treatment using current nutrition guidelines, dialogic communication and Nutrition Care Process repeatedly by weekly access to a dietitian for four month.
214484247|NCT06997653|BIOLOGICAL|TURKOVAC|Inactive COVID-19 Vaccine - TURKOVAC
214920157|NCT04431258|DRUG|Placebo|Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
214920158|NCT04008719|OTHER|Thymic history|This interview concerns mainly the nature of the previous psychiatric and psychological care
214920159|NCT04008719|OTHER|Evaluation of the psychiatric disorders|Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.
214920160|NCT04008719|OTHER|Cognitive evaluation|They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.
214320491|NCT05349448|DRUG|Hylase plus Triamcinolone plus sterile isotonic saline|transforaminal fluroscopic epidural injection
214320492|NCT05349448|DRUG|Hylase plus Dexmedetomidine plus Triamcinolone|transforaminal fluroscopic epidural injection
214484248|NCT06997666|PROCEDURE|Prone Position|Patients assigned to the Prone Position Group were placed in the prone position (lying face down) for 30 minutes once daily over two consecutive days while hospitalized in the ICU for COVID-19-induced ARDS. The intervention was performed between 12:30 and 13:00 under nurse supervision. Oxygen saturation, blood gas parameters (SaO₂, PO₂, PCO₂, pH, lactate, sodium), and respiratory rate were measured before and after each prone positioning session. The procedure was standardized across patients and no additional treatments were introduced during the intervention period.
214484249|NCT06059378|DEVICE|Artificial intelligence-assisted classification (CADx)|CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.
214320493|NCT00463060|DRUG|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
214320494|NCT00463060|PROCEDURE|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
214320495|NCT05121584|PROCEDURE|Placement of an anterior crown restoration as a final restoration|Placement of an anterior crown restoration as a final restoration
214320496|NCT01782313|DRUG|tivozanib|Given PO
214320497|NCT01782313|OTHER|laboratory biomarker analysis|Correlative studies
214320498|NCT01993407|BEHAVIORAL|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
214320499|NCT01993407|BEHAVIORAL|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
214320500|NCT05963542|BEHAVIORAL|ACT for tinnitus|The intervention will be based on the ACT model and adjusted for tinnitus.
214320501|NCT05963542|OTHER|Customized sound therapy|The music will be modulated through a smartphone app using a set program to generate customized tinnitus relieving sound.
214320502|NCT05018572|BEHAVIORAL|I AM|"I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks."
214320503|NCT05599035|DEVICE|repititive transcranial magnetic stimulation|a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
214320504|NCT03199703|DEVICE|Baylis transseptal system group|
214320505|NCT03199703|DEVICE|Standard conventional transseptal group|
214484250|NCT06747663|PROCEDURE|Needle Depth Measurement Using MRI, Ultrasound, and Fluoroscopy|This intervention involves cervical epidural steroid injection (CESI) for patients with chronic neck and radicular pain. Needle depth is measured pre-procedurally using MRI and ultrasound to predict the ideal needle placement. Fluoroscopy is used during the procedure to confirm and compare these measurements, aiming to evaluate the accuracy of imaging techniques and minimize radiation exposure.
214484251|NCT06996470|OTHER|- Cervical Vestibular-Evoked Myogenic Potential (cVEMP) along the Sternocleidomastoid|Endurance time during gazing
214484252|NCT05292222|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
214484253|NCT05966766|OTHER|Mozart selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections by Mozart of previously studied and shown to reduce anxiety.
214320506|NCT02506816|DRUG|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
214484254|NCT05966766|OTHER|Patient-preferred music selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections of patient choice.
214320507|NCT04038489|DRUG|Aspirin|325 mg aspirin daily during AC-T chemotherapy
214484255|NCT05522517|DRUG|Cosentyx|Cosentyx injection will be administered subcutaneously.
214484256|NCT05522517|DRUG|Candin|Candin will be administered interadermally along with NaCl solution.
214484257|NCT06613828|BEHAVIORAL|Mnemonic-Based Educational Training for Stroke Symptom Recognition|"This is a Culturally Adapted Mnemonic-Based Educational Strategies for Rapid Stroke Symptom Recognition in the Spanish-Speaking Population.~It uses five distinct mnemonic strategies (RAPIDO, CORRE, DALE, CAMALEON, ICTUS 911), each specifically tailored for a Spanish-speaking audience.~Aims to improve the recognition of early cerebrovascular disease symptoms, differentiating it from other clinical studies that might focus on different health conditions or target populations.~Emphasizes its focus on rapid action by educating participants about stroke symptoms and the importance of contacting emergency services (911)."
214484258|NCT06526520|DRUG|Exposure to progesterone or HRT medication|to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
214484259|NCT04908930|BEHAVIORAL|On-field activity group - Aim 3|Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
214484260|NCT06676345|PROCEDURE|Surgical treatment|Surgical repair of post-infarction mechanical complications (e.g. sutureless or sutured repair for LVFWR, David or Daggett technique for VSR, mitral valve repair or replacement for PMR)
214320508|NCT04038489|DRUG|Tamoxifen Pill|Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
214320509|NCT04038489|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
214320510|NCT04038489|DRUG|Cyclophosphamide|Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
214484261|NCT06676345|PROCEDURE|Percutaneous treatment|Percutaneous approach for the management of post-infarction mechanical complications (e.g. percutaneous closure with device for VSR, Mitraclip for PMR, PIFIT for LVFWR)
215061646|NCT05293600|DRUG|Atomoxetine and eszopiclone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
214320511|NCT04038489|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
214320512|NCT05627895|OTHER|Neurofeedback|Participants will be shown their brain activity measured in real-time using an MRI scanner. They can then use mental strategies, such as imagination to influence and regulate this activity.
214484262|NCT06677320|OTHER|Exercise|Patients with rotator cuff disease will receive exercise treatment for two months.
214484263|NCT04586244|DRUG|retifanlimab|retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,
214484264|NCT04586244|DRUG|epacadostat|epacadostat will be administered daily twice daily orally up to and including day of surgery.
214484265|NCT04586244|DRUG|INCAGN02385|INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
214484266|NCT04586244|DRUG|INCAGN02390|INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
214484267|NCT06670911|DRUG|Low-dose Pembrolizumab Plus Chemotherapy (Paclitaxel plus Carboplatin or Cisplatin)|Patients will receive pembrolizumab 100mg IV every 3 weeks plus chemotherapy (paclitaxel 175 mg/m² + carboplatin AUC 5 or paclitaxel 175 mg/m² + cisplatin 50 mg/m² for cisplatin-naïve patients).
215061647|NCT02674113|DRUG|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
215061648|NCT02674113|DRUG|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
215061649|NCT03775824|DRUG|MTX start|Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
214320513|NCT02616224|OTHER|No intervention|No intervention was administered in this study.
215061650|NCT03775824|DRUG|TNF start|Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
215061651|NCT05330390|DRUG|Levetiracetam|Epilepsy, treatment with levetiracetam
215061652|NCT01632592|DRUG|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
215061653|NCT01632592|DRUG|Placebo|placebo given by injection 2mg subcutaneously daily
214320514|NCT00115596|OTHER|Formal Curriculum; Low-Fidelity Simulation|The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
215061654|NCT02295696|BEHAVIORAL|EMMA|Consultations using dialogue tools
215061655|NCT00333411|DRUG|BIRT 2584 XX|
215061656|NCT00333411|DRUG|Placebo|
215061657|NCT01723046|DEVICE|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
215061658|NCT05822947|OTHER|Active manual therapy|Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).
215061659|NCT05822947|OTHER|Control manual therapy|Light touch and a breathing exercise (3 to 4 minutes).
215061660|NCT05793801|OTHER|Dressing change|"The patient circuit corresponds to that of usual care.~Not part of usual patient management:~* The rhythm of PICCline dressing changes, which differed between the two groups.~* The collection of pain on a visual analog scale at each dressing change."
215061661|NCT04031898|OTHER|Non Interventional|This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
215061662|NCT06041009|DIAGNOSTIC_TEST|Pancreatic elastase-1 in blood serum|Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.
215061663|NCT00958347|DEVICE|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
215061664|NCT04767581|DRUG|KHK7791|oral administration
215061665|NCT04767581|DRUG|Placebo|oral administration
215061666|NCT05139953|OTHER|No intervention|No intervention
215061667|NCT02723916|BEHAVIORAL|ezParent Program|Tablet-based behavioral parent training program.
215061668|NCT02723916|BEHAVIORAL|Health-e Kids Control App|Tablet based health promotion information App
215061669|NCT06367166|DRUG|"Venarus® (diosmin and hesperidin)"|"Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months"
214320515|NCT06319326|OTHER|Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.|This is an observation study involving measurement of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. No intervention is given to study participants.
214320516|NCT01369875|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
214320517|NCT01369875|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
214320518|NCT01369875|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
214320519|NCT01369875|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Intravenous (IV) over 30 minutes on day 0
214320520|NCT04989049|DRUG|Folic Acid 5 MG|folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
214320521|NCT04989049|OTHER|placebo|an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
214484268|NCT06870565|DRUG|paclitaxel and platinum|After the start of External Beam Radiation Therapy (EBRT), paclitaxel (150-175 mg/m2) or paclitaxel (albumin-bound) 222-260 mg/m2 + cisplatin (60-75 mg/m2) or carboplatin \[Area Under Curve (AUC) = 4-5\], Q3W (every 3 weeks is a dosing cycle), administered on the first day of each cycle, for a total of 4 cycles. Adjuvant chemotherapy started 4 weeks after the end of external irradiation therapy, and chemotherapy-related adverse reactions dropped to grade 2 or below before chemotherapy began. If not met, it can be postponed for 2 weeks.
214484269|NCT06870565|DRUG|platinum|During EBRT, cisplatin (40 mg/m2) or carboplatin (AUC = 2) was used for concurrent chemotherapy once a week for a total of 5 times. On the day of cisplatin infusion, radiotherapy should be performed after cisplatin or carboplatin.
214320522|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
214320523|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
214484270|NCT06679400|BEHAVIORAL|Massage|"Participants will have one massage that will last 30 minutes and focus on the chest and shoulder of the side that received the cancer treatment. There will be certain techniques applied during the intervention (per protocol). The timing and order of each element will be varied based on tissue response and patient feedback.~All participants will have ultrasounds and complete surveys prior and after the massage."
214484271|NCT06886945|OTHER|Audio-Visual Perceptual Tasks|"Around 75 participants will be recruited for this study (25 per each group), and asked to perform two distinct audiovisual tasks (run via Matlab-based automated routines, and presented using a CRT monitor and a pair of loudspeakers) :~1. TOJ task, in which a white flashing dot, and a basic auditory stimulus, will be presented in close temporal proximity at several stimulus onset asynchronies (SOAs, from 30 to 540 ms in steps of 30 ms), with participants asked to report ( after each trial), which stimulus occurred first (task duration estimate: 25 minutes, 30 trials per each SOA)~2. A modified version of the SIFI (mSIFI), in which the presentation of paired (and temporally close) auditory stimuli will be coupled with the occurrence of either 1 or 2 flashing dots, at several different SOAs (from 30 to 250 ms in steps of 10 ms), with participants asked to report (after each trial), whether they saw 1 vs 2 flashes (task duration estimate: 25 minutes, 30 trials per each SOA)"
214484272|NCT06864936|DRUG|Ublituximab|ublituximab
215061670|NCT06367166|PROCEDURE|Endovenous laser ablation (EVLA) with miniphlebectomy|Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.
215061671|NCT06367166|OTHER|Elastic compression|All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment
214320524|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
214320525|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
214320526|NCT01236196|BEHAVIORAL|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
214320527|NCT01236196|BEHAVIORAL|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
214320528|NCT06445335|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement.
214484273|NCT06864936|OTHER|Other disease modifying therapies|Other disease modifying therapies for MS (not ublituximab)
214484274|NCT06867042|DRUG|Tacrolimus Lipid Suspension for enema|Tacrolimus Lipid Suspension for enema 4 mg/vial
214484275|NCT06867042|DRUG|Identical Tacrolimus-free Lipid Suspension for Enema|Identical Tacrolimus-free Lipid Suspension for Enema
214920161|NCT04557241|BEHAVIORAL|Brief informational infographic|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process. Infographics are preferable to narratives or text because they center visuals as part of the storytelling process and facilitate cognitive information processing, knowledge absorption, and enhanced persuasion. The study's infographic design will follow best practices in health communication. The message will be simple and jargon free. Visuals will include individuals (scientists), charts, text, and numbers. Attention will be paid to images, color, frames, representation, and composition (e.g., how the elements in the infographic are organized to show their relationship to each other).
214920162|NCT04557241|BEHAVIORAL|Placebo control (non-behavioral infographic)|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (e.g., about cats), but that is developed using the same communication and graphical style."
214320529|NCT01827657|DRUG|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
214920163|NCT06221241|DRUG|JMKX000623|tablets for oral administration.
214320531|NCT02104089|DEVICE|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
214320532|NCT02820194|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
214320533|NCT02820194|PROCEDURE|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
214320534|NCT03261349|DRUG|Ledipasvir and sofosbuvir|To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
214320535|NCT04176159|OTHER|MOTOR IMAGERY AND TASK-ORIENTED TRAINING|"The intervention will be divided into two modules. A first module will include activities of activation and relaxation of the body, prediction and sequencing of movement and motor imagery. The second module, task-oriented training, will be divided into analytical work phase (visual coordination, balance, muscular strength, fine motor skills ...), a second phase of integration into specific tasks and, at end, the inclusion of the free (and supervised) practice of a sport.~The investigators will apply 20 sessions of 40 minutes."
214484276|NCT05475600|BEHAVIORAL|Classical APA group:|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
214484277|NCT05475600|BEHAVIORAL|APA with Exergaming device|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
214484278|NCT05475600|BEHAVIORAL|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à Exergaming device 3 - Cool down: 20min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
214484279|NCT03861676|RADIATION|Focal brachytherapy with PSMA PET imaging|Focal brachytherapy with PSMA PET imaging. Focal (partial prostate gland) brachytherapy following 18F-DCFPyl PET/CT radiotracer imaging. Patients will also undergo pre-treatment transperineal mapping biopsy.
214484280|NCT03861676|DRUG|(18F)DCFPyL|18F-DCFPyl PET/CT scan
214484281|NCT04494958|DRUG|Combination, Palbociclib + Binimetinib|"Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily."
214484282|NCT05826002|BEHAVIORAL|Digital self-guided psychological intervention for insomnia|A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.
214484283|NCT05035316|DRUG|acetylsalicylic acid|Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day
214484284|NCT05035316|DRUG|Calcium|Oral tablet: calcium, 1 tablet/day
214484285|NCT06701890|OTHER|Blood sample collection|16 mL at inclusion 16 mL at 1 month after return from travel
214484286|NCT06701890|OTHER|Fecal sample collection|"1 sample at inclusion~1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel"
214484287|NCT06692153|DEVICE|An AID System.|The embecta Automated Insulin Delivery (AID) System is a closed loop system comprised of 3 components: the embecta insulin pump, a Smartphone with the Tidepool Loop app, and the Dexcom G6 CGM
214484288|NCT06692153|OTHER|Standard of Care (SC)|Participants will continue to use their current therapy for T2D.
214484289|NCT06686433|OTHER|Novel infant formula|Infants are fed with the novel infant formula from the date of enrollment to the age of 6 months.
214484290|NCT06686433|OTHER|Standard infant formula|Infants are fed with the standard infant formula from the date of enrollment to the age of 6 months.
214484291|NCT06700278|BEHAVIORAL|auricular acupressure|auricular acupressure was performed three times daily, with each acupoint massaged for three minutes at an optimal pressure level that induced sensations of soreness, numbness, distension, or mild pain. This was conducted five days a week for three weeks, in addition to regular rehabilitation therapy provided five days per week.The selected auricular acupoints include Shenmen (TF4), Subcortex (AT1), Liver (CO12), and Sympathetic (AH6a).
214920164|NCT06221241|DRUG|Pregabalin|capsules for oral administration.
214920165|NCT06221241|DRUG|Placebo|matched to JMKX000623 and Pregabalin
214920166|NCT01985841|DRUG|Bevacizumb|Avastin
214920167|NCT01985841|DRUG|5-Fluorouracil|5-FU
214920168|NCT01985841|DRUG|Epirubicin|Farmorubicin
214920169|NCT01985841|DRUG|Cyclophosphamide|Endoxan
214920170|NCT01985841|DRUG|Docetaxel|Taxotere
214920171|NCT05299554|DRUG|Chronocort|Hydrocortisone modified-release capsule 5 mg and 10 mg
214920172|NCT05029375|BEHAVIORAL|PEERS® for Preschoolers|P4P is a 16-week manualized social skills treatment program, adapted from an existing empirically supported social skills intervention for young children with autism
214920173|NCT02910206|DRUG|Etomidate|etomidate is given intravenously
214920174|NCT02910206|DRUG|propofol|propofol is given intravenously
214320536|NCT05925517|OTHER|Graded Motor Imagery (GMI)|"GMI includes three stages. Each session will be 30 minutes, and the GMI program will span over 8 weeks. The first 3 weeks will focus on lateralization, followed by 3 weeks of motor imagery, and the final 2 weeks will involve mirror therapy.~Lateralization: Patients will be asked to differentiate whether the extremities shown in the Recognise™ Knee application belong to the right or left side of their body.~Motor Imagery: Patients will be instructed to imagine slowly and smoothly moving their affected extremities to the posture depicted in the photos in the Recognise™ Knee application and then returning to the starting position.~Mirror Therapy: Using a mirror measuring 90x60 cm² placed between the lower extremities, patients will be instructed to progressively move only their unaffected extremity, then their affected extremity, and finally both extremities."
214320537|NCT05925517|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes. The current will be applied to the most painful area of the affected knee. The four self-adhesive electrodes will be positioned in a square pattern, approximately 5 cm apart, centered over the pain point. Conventional TENS will be applied for 30 minutes at a frequency of 100 Hz, pulse width of 100 μs, and intensity below 10% of the motor threshold.
214320538|NCT05925517|OTHER|Conventional Physiotherapy Program|The routine 60-minute program for OA patients in conventional physiotherapy includes warming up, core stability, pelvic and hip stability, gluteus medius strengthening, knee control and stability (knee flexion and extension control, lunge exercises), knee strengthening exercises (wall-assisted leg press with a ball, step-ups with elastic bands), and functional exercises.
214320539|NCT05925517|OTHER|Home Exercise Protocol|The home exercises will include a warm-up consisting of a 10-minute walk at a normal pace on a flat surface while gently stretching the hamstring and calf muscles. The exercises will also involve straight leg raises, terminal knee extension, isometric contractions of the quadriceps femoris and adductor muscles using a pillow for support, toe raises, single-leg standing, toe taps, and quadriceps strengthening exercises included in the session.
214320540|NCT05415267|BIOLOGICAL|diphtheria and tetanus toxoids (adsorbed) vaccine|The diphtheria/tetanus toxoids vaccine will be given to participants enrolled into Group 1 as a comparator vaccine to the mRNA COVID-19 booster vaccine with the aim of determining whether the results related to COVID-19 vaccine timing also apply to more traditional protein-based vaccines.
214320541|NCT05415267|BIOLOGICAL|COVID-19 vaccine|All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm
214484292|NCT06700278|BEHAVIORAL|body acupoint massage|The control group will receive acupoint massage three times daily, with each acupoint being massaged for three minutes. The applied pressure will be adjusted to induce sensations of soreness, numbness, fullness, or mild pain. The intervention will be conducted five days per week for a total of three weeks. The selected body acupoints include Quchi (LI11), Hegu (LI4), Sanyinjiao (SP6), and Zusanli (ST36).
214484293|NCT03624790|BIOLOGICAL|rRSV A/Maryland/001/11|10\^5 PFU; delivered intranasally
214671956|NCT00249561|BEHAVIORAL|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg \& Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
214671957|NCT05651087|DRUG|LACUDY|LACUDY:Insert 2mL twice a week for 4 weeks before going to bed
214671958|NCT02849769|DEVICE|Implant of an MR-conditional Tachy device system|
214671959|NCT02220881|DEVICE|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
214671960|NCT02220881|OTHER|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
214671961|NCT00844883|DRUG|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
214671962|NCT00844883|PROCEDURE|LC Bead-TACE|"LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"
214671963|NCT02623361|DRUG|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
214920175|NCT02910206|DRUG|Sufentanil|sufentanil is given intravenously
214920176|NCT02910206|DRUG|Cisatracurium|Cisatracurium is given intravenously
214920177|NCT02339532|DRUG|FEC100|"3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²"
214920178|NCT02339532|DRUG|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV
214920179|NCT02339532|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
214320542|NCT06274398|DRUG|TAF/EVG rectal insert|Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
214320543|NCT06274398|DRUG|Matching placebo rectal insert|Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
214320544|NCT02036034|DEVICE|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
214320545|NCT02036034|DEVICE|warming blanket|warming blanket placed on torso of patient under the drape.
214320546|NCT04589676|BEHAVIORAL|Naloxone training|The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
214484294|NCT06878794|COMBINATION_PRODUCT|Using medical biological glue for filling And Using the meniscus suture system|Using medical biological glue for filling And Using the meniscus suture system
214484295|NCT06878794|PROCEDURE|Using the meniscus suture system|Using the meniscus suture system
214671964|NCT02623361|DRUG|Sham Block|Sham Block by saline injection
214671965|NCT01673061|DRUG|Lidocaine|See associated Arm Description
214671966|NCT01673061|DRUG|Vapocoolant|See associated Arm Description
214671967|NCT00177346|DEVICE|CAS with cerebral protection|
214484296|NCT06878157|BEHAVIORAL|ontological coaching|Group session: This session will provide an overview of coaching and the following topics will be covered: 1) Experience coaching in teams, 2) The Ideal Life, 3) The Coaching Distinction, 4) Introduction to Body, Emotions, Language (BEL), 5) Deeper understanding of BEL, 6) Applying BEL to clinical scenarios, 7) The coaching perspective in Nursing, 8) Re-visit the Ideal Life, 9) Explore mental/emotional/physical challenges in practicing nursing, 10) Time and stress management, work-life balance; Individual Session: This individualized session will cover the discussions on the topic brought up by novice nurses. The aim of this session is to: 1) Help novice nurses design the steps in their journey towards what they care about, 2) Explore the nurses' world by asking encouraging and evoking questions, 3) Collaborate with nurses in a stimulating and imaginative manner that help them to optimize their potential, 4) Co-create with nurses the professional and personal identity they strive for
214320547|NCT02711423|DRUG|Gantenerumab|Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
214320548|NCT02711423|DRUG|Placebo|Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
214320549|NCT02902198|DIETARY_SUPPLEMENT|Placebo|Tap water 200ml
214320550|NCT02902198|DIETARY_SUPPLEMENT|Glucose|25g Glucose in 200ml tap water
214320551|NCT02902198|DIETARY_SUPPLEMENT|Monosodium glutamate|1g monosodium glutamate in 200ml tap water
214484297|NCT06876948|DIAGNOSTIC_TEST|Psychological tests, EEG, Magnetic Resonance|Patients are administered some psychological tests, if they are positive they move on to the next stage, otherwise the patients leave the practice. If they are positive, EEG, MRI and other psychological tests are also administered.
214484298|NCT06876116|DRUG|Fluorometholone 0.1% ophthalmic solution|After induction therapy with fluorometholone 0.1% four times a day for 4 weeks, patients continued with fluorometholone 0.1% once a day for 8 weeks.
214484299|NCT06876116|DRUG|Cyclosporine 0.05% eye drops|After induction therapy with fluorometholone 0.1% four times a day for 4 weeks, patients continued with cyclosporine 0.05% twice a day for 8 weeks.
214484300|NCT04569942|DRUG|Vasopressor|Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.
214484301|NCT04569942|OTHER|Fluids|An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
214671968|NCT00177346|DEVICE|CAS without cerebral protection|
214671969|NCT03511339|DEVICE|TecTraum device|"A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck."
214671970|NCT00000960|DRUG|Zidovudine|
214671971|NCT03894540|DRUG|IPN60090|Oral capsules given daily
214671972|NCT03894540|DRUG|pembrolizumab|An intravenous solution in single-use vial to be diluted for infusion.
214671973|NCT03894540|DRUG|paclitaxel|An intravenous solution in single-use vial to be diluted for infusion.
214920180|NCT02339532|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
214920181|NCT02339532|DRUG|Carboplatin|CARBOPLATIN AUC 6 IV q3w
214320552|NCT02902198|DIETARY_SUPPLEMENT|Quinine|17mg quinine in 200ml tap water
214671974|NCT03894540|DRUG|IPN60090 single administration|Oral capsules given once
214671975|NCT01938170|BIOLOGICAL|FluMist|Subjects receiving Flumist vaccine
214671976|NCT02718846|DRUG|Meniace|6 mg of Meniace tablets were administered 3 times per day after meals
214671977|NCT02718846|DRUG|Isobide|an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
214920182|NCT03612661|BEHAVIORAL|Group Intervention|Participants in the group intervention will attend eight weekly, 90-minute sessions involving group activities and discussions. They will complete homework between sessions to reinforce learning. The intervention focuses on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
214320553|NCT06800170|DIETARY_SUPPLEMENT|myo-Inositol plus DIoscorea Villosa|myo-Inositol + alpha-lactalbumin + folic acid once daily, Dioscorea Villosa + alpha-lactalbumin + Vitamin D twice daily
214320554|NCT01892631|OTHER|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
214320555|NCT01892631|OTHER|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
214320556|NCT02493738|DRUG|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
214320557|NCT02493738|DRUG|Sporanox 100mg|Sporanox 100mg single dose under fed condition
214320558|NCT01407913|PROCEDURE|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
214320559|NCT01531946|PROCEDURE|MRI Scan|"Patients will have to spend additional 10min in the scanner.~Additional scan modalities used:~1. Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.~2. Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.~An overall 20min scan period."
214320560|NCT00413725|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
214671978|NCT00990015|DRUG|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
214920183|NCT03612661|BEHAVIORAL|Guided Self-Help|Participants in the GSH condition will follow the intuitive eating content through self-guided study, with eight weekly scheduled phone calls with an interventionist (\~20 minutes each). Interventionists will review homework assignments, answer questions, and reinforce adherence. The intervention materials are the same as the group and also focus on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
214920184|NCT00156611|PROCEDURE|Balloon Angioplasty|
214920185|NCT00156611|DRUG|ReoPro|
214320561|NCT00413725|OTHER|Placebo|Placebo
214320562|NCT01289925|DIETARY_SUPPLEMENT|Selenium|200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
214320563|NCT01289925|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
214320564|NCT05680766|OTHER|Cardiovascular endurance training|Based on the results of a maximal effort test, investigators will provide a personalised training program. Results of a submaximal effort test after 6 weeks, will allow for adaptation of the training program for the remaining training period.
214320565|NCT06037746|OTHER|Graston|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 10 minutes in the longitudinal, vertical and oblique directions.
214320566|NCT06037746|OTHER|Percussive massage|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 5 minutes in all directions without being bound to a single direction.
214484302|NCT06878963|PROCEDURE|PENG Block|The PENG block will be performed on the patient with the injection of local anesthesia under ultrasound guidance in the femoral region, beneath the biceps tendon.
214484303|NCT06878963|PROCEDURE|SIFICB Block|The SIFIB block will be performed on the patient with the injection of local anesthetic between the iliac fascia and iliac muscle in the femoral region, under ultrasound guidance.
214484304|NCT06877741|OTHER|Group A (Heavy Slow Resistance exercises)|Pre - assessment will be taken. Heavy slow resistance exercises will be given to group A and exercises of 4 sets of 10-20 repetitions will be given
214484305|NCT06877741|OTHER|: Group B (Eccentric exercises)|Sessions should be conducted 2 times per week, similar to Group A, in 3 sets of 10-20 repetitions. Exercises focus solely on eccentric loading, such as eccentric squats, eccentric leg presses, and step-down exercises.
214920186|NCT02582060|OTHER|Thromboelastography/Thromboelastometry-Guided Treatment Regimen|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
214484306|NCT06692842|DEVICE|CONEMO App|The CONEMO application has three protocol, aimed to improived symptoms of depression, insomnia and anxiety. It is based on cognitive behavioral therapy (CBT) and contextual behavioral therapy (activation behavioral theraphy, mindfulness) and adapted considering broader contexts of mental health care, which involves a low-intensity intervention administered without any or minimal professional guidance and widely accessible. In a brief and structured format, CONEMO involves offering the intervention through texts, audios and videos. Based on the principles of CBT and contextual thrapies, CONEMO is organized into structured sessions that promote psychoeducation and teach basic behavioral skills, often through interactive exercises. Each journey was developed based on scientific evidences. The CONEMO journeys comprise seven weekly modules.
214484307|NCT06692517|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
214484308|NCT06879743|OTHER|Suboccipital release|"The ptients in this group recieve suboccipital release. The patient is positioned in a supine (lying on their back) position, allowing full relaxation of the cervical spine.~The therapist places their fingertips or hands under the patient's occiput, making contact with the suboccipital muscles.~Using gentle, sustained pressure, the therapist allows the weight of the head to create a release, often holding for 1-5 minutes.~Subtle adjustments may be made, such as slight traction or rocking, to facilitate myofascial release and relaxation."
214484309|NCT06878885|BEHAVIORAL|Acute psychological stress task (Paced Auditory Serial Addition Task)|Volunteers will complete a 4-minute Paced Auditory Serial Addition Task which is a standardized laboratory challenge that is widely used to monitor cardiovascular, neuroendocrine, and inflammatory responses in the laboratory.
214484310|NCT06880471|BIOLOGICAL|TheraCal PT pulpotomy|After the coronal pulp tissue is removed using a high-speed sterile diamond bur and bleeding control is achieved, TheraCal PT material will be placed. According to the manufacturer's instructions, the irradiation time is 10 seconds. It is dual-cure. Its content is based on calcium silicate modified with resin.
214671979|NCT00990015|DRUG|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
214671980|NCT01588301|BEHAVIORAL|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
214671981|NCT01588301|BEHAVIORAL|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
214920187|NCT00379080|PROCEDURE|conventional surgery|Undergo surgery
214920188|NCT00379080|DRUG|tandutinib|Given orally
214920189|NCT00379080|OTHER|pharmacological study|Correlative studies
214920190|NCT00379080|OTHER|Tissue samples|Correlative studies
214920191|NCT04690231|DRUG|Apatinib Mesylate|apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3
214920192|NCT04690231|DRUG|ifosfamide and etoposide|ifosfamide and etoposide
214920193|NCT00245973|DRUG|Bifeprunox|
214920194|NCT02901067|DRUG|Aspirin and Rosuvastatin|Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
214320567|NCT02796807|DRUG|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
214320568|NCT03023865|PROCEDURE|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
214320569|NCT05414643|OTHER|Standard care|No interventions were used, as this is an observational study.
214320570|NCT01310322|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
214320571|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
214320572|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
214484311|NCT06880471|BIOLOGICAL|MTA pulpotomy|After the coronal pulp tissue is removed using a high-speed sterile diamond bur and bleeding control is achieved, ProRoot MTA material will be placed. After waiting for 15 minutes for it to set, the restorative treatment will be performed. MTA consists of the main components: tricalcium silicate, dicalcium silicate, tricalcium aluminate, tricalcium oxide, silicate oxide, and calcium sulfate dihydrate.
214484312|NCT06880471|BIOLOGICAL|Biodentine pulpotomy|After the coronal pulp tissue is removed using a high-speed sterile diamond bur and bleeding control is achieved, Biodentin material will be placed. After waiting for 12 minutes according to the manufacturer's instructions for it to set, the restorative treatment will be performed. Biodentin is a two-component material. The powder primarily consists of tricalcium silicate.
214484313|NCT06876493|OTHER|Aerobic Exercise Programme|The aerobic exercise programme was shown to female students with premenstrual syndrome on the first day by the researcher (D.A.) at the sports centre. Participants were advised to drink water and wear running shoes during exercise. Warm-up exercises were performed for 10 minutes before the exercise. Exercise intensity was determined by the Karvonen formula (HRmax=220-age, HRR=HRmax-HR rest, 60% THR=(0.60xHRR)+HR rest). .According to the pulse rate of the exercise, pulse values are monitored on the treadmill and km/hour speeds are adjusted according to pulse values. The exercise programme started with low aerobic exercise intensity on the treadmill, gradually increased at 5-minute intervals and completed at 40-60% of the heart rate, and finally 5 minutes of light stretching movements were performed to return to the initial state. In the following sessions, the participants performed the exercise programmes individually at the sports centre for 45 minutes (10 min warm-up, 30 min walk,
214920195|NCT02901067|DRUG|Placebo (for Aspirin and Rosuvastatin)|Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.
214920196|NCT01184820|BIOLOGICAL|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.
214671982|NCT01850381|DRUG|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
214920197|NCT01184820|BIOLOGICAL|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))|Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.
214920198|NCT02355964|BEHAVIORAL|Exercise|Aerobe exercise 3 times a week in 8 weeks
214920199|NCT02355964|BEHAVIORAL|Diet|Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
214920200|NCT00313326|PROCEDURE|Adaptative Support Ventilation|Adaptive Support Ventilation (ASV) is a new protocol of weaning of the tracheal prosthesis after surgery which maintains a preset ventilation by an operator, and this whatever the activity of the patient
214320573|NCT01310322|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
214920201|NCT00288366|DRUG|ziprasidone vs. aripiprazole|ziprasidone vs. aripiprazole dosed according to package insert
214920202|NCT00288366|DRUG|aripiprazole vs. ziprasidone|aripiprazole vs. ziprasidone dosed according to package insert
214920203|NCT02461069|DRUG|Dimethyl fumarate|Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
214320574|NCT00699010|DRUG|Acurox 5/30mg taken first|followed by oxycodone 5mg with 48 hour washout
214920204|NCT00000825|DRUG|Aldesleukin|
214320575|NCT00699010|DRUG|Oxycodone 5mg taken first|followed by Acurox 5/30mg with 48 hour washout
214320576|NCT01263548|DRUG|lisdexamfetamine dimesylate|Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
214320577|NCT05130567|DRUG|LP-128 capsules|Oral dosing with LP-128 capsules
214320578|NCT05130567|OTHER|Matching Placebo|Oral dosing with placebo capsules to match LP-128 capsules.
214920205|NCT00857896|DRUG|Fesoterodine|4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
215061672|NCT06367166|OTHER|Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores|The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment
215061673|NCT00229697|DRUG|Gefitinib|
214320579|NCT03274479|DRUG|PBF-1129|PBF-1129 once a day by oral administration
214320580|NCT04370691|DEVICE|JETi lower extremity arterial thrombosis|The JETi System is is a hydro-mechanical aspiration system, intended for the removal of intravascular thrombus. The system comprises of the JETi Catheter (6F or 8F), JETi Pump Set, JETi Saline Drive Unit (SDU), JETi Accessory Cart, JETi Suction tubing and JETi Non-Sterile Canister Set. The JETi System is designed to continuously aspirate thrombotic material into the catheter, where a high-pressure stream of saline within the catheter tip macerates the thrombus as it is aspirated.
214320581|NCT02973763|DRUG|Alflutinib|
214320582|NCT04152226|DRUG|Janthinobacterium lividum|Investigational Product
214320583|NCT06116149|BEHAVIORAL|In-person health coach delivery of the GLB|"Delivery of 24 health coaching sessions in-person by health coaches over 1 year.~Standard delivery of 24-sessions of the Group Lifestyle Balance (GLB) behavioral intervention in WIC clinics. The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
214320584|NCT06116149|BEHAVIORAL|Technology-assisted health coach delivery of the GLB|"Delivery of 12 health coaching GLB sessions in-person by health coaches over one year; supplemental technology support, including tools for self-monitoring, health coach monitoring, asynchronous delivery of intervention materials, and asynchronous coach and group connection.~The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
214320585|NCT00217542|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
214320586|NCT00217542|DRUG|amifostine/azacitidine|Given SC
214320587|NCT01653093|PROCEDURE|3-Tesla magnetic resonance imaging (3T MRI)|Undergo 3T MRI
214320588|NCT01653093|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
214320589|NCT01653093|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
214320590|NCT01653093|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MR spectroscopy
214320591|NCT04552691|DRUG|Pegunigalsidase Alfa|Pegunigalsidase alfa is a recombinant ERT (enzyme replacement therapy) used to treat Fabry disease (dosage: 1 mg/kg body weight every 2 weeks).
214320592|NCT04374890|DEVICE|CP308|3 weeks of baseline followed by 2x3 weeks use of the test device
214484314|NCT06876493|OTHER|Whole Body Vibration Training Programme|The WBV programme used a frequency of 25 Hz and an amplitude of 2 mm (low amplitude). The Power Plate® (pro5TM) machine provided the device's vibration. This device provides a three-plane oscillatory motion. The programme lasted eight weeks and was performed three days a week. There was at least one day's rest between each session. Before and after each vibration, stretching exercises (warm-up and cool-down programme) were performed for 5 minutes, particularly for the quadriceps and trunk extensors
214484315|NCT06879288|DRUG|Bupivacaine|Patients received intraperitoneal bupivacaine only at the end of the operations.
214484316|NCT06879288|DRUG|Dexmedetomidine|Patients received intraperitoneal bupivacaine plus dexmedetomidine at the end of the operations.
214484317|NCT06879288|DRUG|Magnesium sulfate|Patients received intraperitoneal bupivacaine plus magnesium sulfate at the end of the operations.
214671983|NCT01850381|DRUG|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
214320593|NCT02486380|DEVICE|Toffee full face mask/toffee nasal mask|Toffee full face mask/toffee nasal mask
215061674|NCT00229697|DRUG|Tamoxifen|
215061675|NCT03334708|DIAGNOSTIC_TEST|Blood Draw|"If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:~Patients and controls weighing 50kg or more~* For draw amounts up to 50mL, there is no required hemoglobin threshold.~* For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.~Patients and controls weighing \< 50kg~* For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time."
215061676|NCT03334708|DIAGNOSTIC_TEST|Tumor Tissue Collection|Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
215061677|NCT03334708|DIAGNOSTIC_TEST|Cyst Fluid|Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
215061678|NCT04116411|DRUG|Valganciclovir Tablets|Valganciclovir treatment of glioblastoma
215061679|NCT04116411|DRUG|Temozolomide 120 mg|Chemotherapy
215061680|NCT04116411|RADIATION|Radiotherapy 60 Gy|Radiation therapy
215061681|NCT04116411|DRUG|Placebo oral tablet|Placebo treatment of glioblastoma
215061682|NCT05529082|OTHER|Opioid Attitudes|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
215061683|NCT05529082|OTHER|Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
215061684|NCT05305898|DRUG|Metformin|"Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation."
215061685|NCT03374735|DEVICE|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
215061686|NCT02332785|OTHER|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
215061687|NCT01596712|DRUG|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
215061688|NCT01596712|DRUG|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
215061689|NCT00153595|DRUG|EWO1|
215061690|NCT01423695|DRUG|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
215061691|NCT00631813|DRUG|Prucalopride|0.5 mg bid
215061692|NCT00631813|DRUG|Prucalopride|1 mg bid
215061693|NCT00631813|DRUG|Prucalopride|2 mg bid
215061694|NCT00631813|DRUG|Placebo|bid
215061695|NCT02881411|OTHER|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
215061696|NCT02881411|OTHER|Fibromyalgia coping skills programme|Exercise, education programme
214671984|NCT01479049|DRUG|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
214920206|NCT06575764|OTHER|The Heart Priority Programme|The programme is delivered by the Cardiac Rehabilitation (CR) team. It consist of two main parts: 1) an evidence-based identification form to identify patients at risk of dropout due to being in a vulnerable situation and 2) an add-on intervention to standard CR targeted these patients. The add-on intervention encompasses three core elements: 1) Assigning a contact person with specific responsibilities, 2) Systematically communicating patient information to colleagues in the CR team and 3) Systematic follow-up
214920207|NCT04819516|PROCEDURE|high-intensity focused ultrasound therapy|Patients will receive high-intensity focused ultrasound therapy in local site.
214320594|NCT04889742|DEVICE|loco-regional hyperthermia|loco-regional hyperthermia by the use of microwave, capacitive, or superficial hyperthermia devices.
214320595|NCT05081856|OTHER|mobilization with moduler medical equipment carring vehicle|Mobilization of the patients was carried out with the vehicle in their modular vehicle.
214320596|NCT00886210|PROCEDURE|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
214320597|NCT00886210|PROCEDURE|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
214320598|NCT00144365|DRUG|Antiretroviral therapy|
214320599|NCT05520008|OTHER|Game-based exercise|Patients in the active group will put on a sensor connected to a tablet to play a game-based foot/ankle exercise twice a day for 5 minutes for four weeks.
214320600|NCT06186778|PROCEDURE|secondary colonoscopy|After the routine colonoscopy, a repeat colonoscopy of the sigmoid colon is performed
214320601|NCT06186778|PROCEDURE|conventional colonoscopy|It starts from the rectum and progresses forward to the cecum, with observations made during withdrawal: from the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon to the rectum.
214484318|NCT06880185|OTHER|Connective Tissue Graft|Implant treatment was performed in 20 patients with a single tooth deficiency and soft tissue deficiency in the horizontal direction in the edentulous site. All patients received bone-level titanium implants. Soft tissue augmentation was performed simultaneously with implant treatment. The group were divided into CTG , and 10 patients were randomly assigned to group.
214484319|NCT06880185|OTHER|Ribose Cross-Linked Thick Collagen Membrane|Implant treatment was performed in 20 patients with a single tooth deficiency and soft tissue deficiency in the horizontal direction in the edentulous site. All patients received bone-level titanium implants. Soft tissue augmentation was performed simultaneously with implant treatment. The groups were divided into RCCM, and 10 patients were randomly assigned to group.
214671985|NCT01479049|DRUG|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
214671986|NCT01625169|DRUG|Etravirine pharmacokinetics in breast milk and plasma|HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
214920208|NCT04819516|DRUG|Toripalimab|Toripalimab plus regorafenib
214920209|NCT02907918|DRUG|Palbociclib|Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.
214920210|NCT02907918|DRUG|Letrozole|Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.
214920211|NCT02907918|BIOLOGICAL|Trastuzumab|"* Or FDA approved biosimilar~* Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery."
214920212|NCT02907918|DRUG|Goserelin|Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.
214920213|NCT02907918|PROCEDURE|Breast surgery|Standard of care
214920214|NCT02907918|PROCEDURE|Research tumor biopsy|Baseline, cycle 1 day 15, and surgery
214320602|NCT06210087|OTHER|Spontaneous pushing technique|Pregnant women selected for the experimental group were trained on spontaneous pushing technique in the first stage of labor. During the second stage of labor, the women were encouraged and supported in this direction.
214320603|NCT02626143|OTHER|Investigational nutrient-rich whey protein formula|
214320604|NCT02626143|OTHER|Cow's milk based formula|
214320605|NCT05551806|BEHAVIORAL|Internet-based self-help cognitive behavioural therapy|The online CBT-I course will consist of an introductory module, followed by 6 weekly modules, incorporating the key CBT-I components, including sleep hygiene education, stimulus control, sleep restriction, relaxation training, and cognitive therapy.
214320606|NCT03013543|DRUG|Setmelanotide|RM-493 QD SC injection
214320607|NCT00006484|DRUG|carboplatin|
214320608|NCT00006484|DRUG|paclitaxel|
214320609|NCT00006484|DRUG|tirapazamine|
214320610|NCT03635632|GENETIC|C7R-GD2.CART cells|"Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10\^7 on day 0 and day 7~Dose Level 3b = 1 x 10\^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI."
214920215|NCT02907918|PROCEDURE|Research bone marrow (OPTIONAL)|Baseline and surgery
214920216|NCT02907918|PROCEDURE|Research blood sample|Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
214320611|NCT05510869|PROCEDURE|"Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally"|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
214320612|NCT05510869|PROCEDURE|Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
214320613|NCT05510869|PROCEDURE|Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.|small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
214320614|NCT05181111|DEVICE|Wearable Sensor|The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
214320615|NCT05181111|OTHER|Usual Care|Usual Care Monitoring
214320616|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
214320617|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
214320618|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
214320619|NCT01561768|BIOLOGICAL|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
214320620|NCT01561768|BIOLOGICAL|cTIV|Preconfigured dose; intramuscular injection, deltoid
214320621|NCT00004028|DRUG|carmustine|
214320622|NCT00004028|PROCEDURE|conventional surgery|
214320623|NCT04960228|BEHAVIORAL|Altruism Video|The video provides three vignettes about a diverse set of people who may be more vulnerable to serious health consequences from COVID-19. In each of the stories, high vaccine uptake of those around these vulnerable individuals serves to protect them. This communicates that getting the COVID-19 vaccine can be done for prosocial reasons and to foster a sense of community, as it provides protection not only to oneself, but also to others.
214484320|NCT06878378|OTHER|Investigation of Factors Influencing Bowel Preparation Quality|Observed parameters include BMI, history of abdominal surgery, history of diabetes, history of diarrhea and constipation, stool characteristics, and specific bowel preparation protocols.
214484321|NCT06880328|DRUG|Ralmitaront|Participants were given a once 150 mg daily dose of Ralmitaront orally during the 14 day treatment period.
214484322|NCT06880328|OTHER|Radiolabeled PET tracer [18F]-DOPA|\[18 F\]-DOPA solution for injection is manufactured by the PET imaging centers according to specifications established for the tracer at the site. The injection will happen prior to the scan being done and will last for approximately 30 seconds.
214484323|NCT06880328|DRUG|Placebo|Participants were given a daily dose of the placebo during the 14 day treatment period.
214484324|NCT06879509|DIAGNOSTIC_TEST|Thromboelastography|All participants will receive this intervention. Thromboelastography (TEG) is a blood test that provides a detailed assessment of the clotting process, measuring how blood clots form, strengthen, and dissolve. It offers real-time insights into a patient's coagulation status, helping to identify clotting disorders and guide treatment decisions.
214484325|NCT06880211|OTHER|physical activity recommendations|The participants (bus and tram drivers) in the control group will receive the latest World Health Organization recommendations for physical activity in written form.
214484326|NCT06880211|OTHER|activitysnippets|Participants (bus and tram drivers) in the intervention group will receive the ActivitySnippets toolbox. The toolbox was developed through collaborative workshops with the target group, sports scientists and physiotherapists to create a sustainable, occupation-specific and evidence-based physical activity promotion. The toolbox, which provides simple incentives to integrate physical activity into everyday working life, consists of 30 to 40 activity snippets (exercise cards). The design of the toolbox allows for individualization and variation of the exercise cards. The aim of the exercises is to improve muscle strength, increase physical activity levels at work and reduce stress. All exercises can be performed for between 10 and 60 seconds, allowing for realistic implementation in everyday working life. Participants are encouraged to incorporate the exercises into their daily work routine as often as possible.
214920217|NCT02907918|GENETIC|Research blood for germline DNA|Baseline
214320624|NCT04960228|BEHAVIORAL|COVID-19 Informational Text|The topics included in the text are how COVID-19 spreads, hygiene, physical distancing, and travel restrictions. Participants will complete three comprehension questions, one after each of the following sections: hygiene, physical distancing, and travel restrictions.
214320625|NCT06121271|DRUG|Lu-177 DOTATATE (Lutathera®)|Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
214320626|NCT03671902|DEVICE|Fluid shift|We are using lower body negative and positive pressure to create a fluid shift in the body. This study is investigating if there are changes in phonocardiographic parameters related to changes in blood volume caused by this fluid shift
214320627|NCT00544596|DRUG|R-(-)-gossypol acetic acid|Given orally
214320628|NCT00544596|DRUG|cisplatin|Given IV
214320629|NCT00544596|DRUG|etoposide|Given IV
214320630|NCT04388579|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
214320631|NCT02757079|DRUG|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
214920218|NCT02907918|PROCEDURE|Blood for detection of circulating tumor cells|Baseline
214920219|NCT02325388|DEVICE|ForeSite PT™ system|"XSENSOR Technology Corporation's ForeSite PT™ Patient Turn System (referred to as the ForeSite PT™ system) continuously monitors interface pressure and provides CPI that quantifies real-time interface pressure information. It also provides patient turn tracking to assist with management of the patient turn schedule by alerting healthcare providers and/or caregivers to the location of body areas that have experienced the greatest exposure, and when the next turn/repositioning is due as per pre-set alerts."
214920220|NCT01006876|DRUG|Coumadin|Continuous oral Coumadin therapy through the catheter ablation procedure
214920221|NCT01006876|DRUG|Coumadin|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
214320632|NCT05853133|OTHER|Erector Spinae Plane Block|Group E (ESP block), before the operation, the ESP block will be applied to the patients in the prone position under sedation by same anesthesiologist. ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level. All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
214920222|NCT01006876|DRUG|Coumadin|Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
214920223|NCT05371015|PROCEDURE|quadratus lumborum nerve block (ropivacaine )|Echo guided quadratus lumborum nerve block with ropivacaine
214484327|NCT06876961|OTHER|Arm cycling exercise|The study involves a 20-minute arm cycling exercise twice daily for five days, starting with a warming-up and ending with a cooling-down. The workload is gradually increased to 60-70% of maximal heart rate, with patients sitting on a back support chair with 20 degrees backward inclination.
214484328|NCT06876961|OTHER|The traditional physical therapy program|The patient undergoes 10 minutes of deep diaphragmatic breathing exercises, 10 minutes of spirometer training, 3-set ankle pump and heel slide exercises, 10-minute sitting on the bed edge, 5 minutes of walking in the intensive care unit, and 3-set active free range of motion exercises.
214484329|NCT05357105|OTHER|Numerical Pain Scales|Patients who are about to receive regional nerve blocks will be administered a numerical pain scale (NRS) before, during and after the offset of the nerve block.
214484330|NCT06879561|PROCEDURE|Angiography-guided angioplasty|Balloon angioplasty will be performed on the target infrapopliteal artery lesion to achieve an optimal procedural result, as determined by angiography. Optimal results are defined as antegrade blood flow without residual stenosis \>50% or any flow-limiting dissection.
214484331|NCT06879561|PROCEDURE|Pressure wire-guided angioplasty|Balloon angioplasty will be performed on the target infrapopliteal artery lesions to achieve an optimal procedural result, as determined by the pressure gradient across the target lesion. An optimal procedural result is defined as pressure gradient less than 10 mmHg, measured using a Pressure Wire.
214484332|NCT06880133|DEVICE|Seismocardiography (SCG) and Gyrocardiography (GCG) Screening|"This intervention involves the use of SCG/GCG diagnostic testing, a radiation-free, non-invasive technique for assessing cardiac function. SCG/GCG utilizes high-precision accelerometers and gyroscopes to record and analyze cardiac-induced microvibrations on the chest.~Participants will undergo SCG/GCG testing before their scheduled coronary artery calcium computed tomography (CAC-CT) or coronary computed tomography angiography (CCTA). The study aims to evaluate the diagnostic performance of SCG/GCG in identifying CAD, particularly in hypertensive patients and those with mild CAD.~Data collected from SCG/GCG will be compared with CAC-CT and CCTA findings to determine its predictive value for CAD severity and coronary artery stenosis."
214484333|NCT06877351|DRUG|Amoxicillin|Participants randomized to the intervention group will receive oral amoxicillin at a dose of 40-50 mg/kg/day (maximum 1500 mg/day), administered in three doses daily for 14 days for early syphilis and 21 days for late syphilis or syphilis of unknown duration.
214671987|NCT04165265|DEVICE|Constant-Care|"Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients"
214671988|NCT03000452|DRUG|DARATUMUMAB|DARATUMUMAB
214671989|NCT03000452|DRUG|DURVALUMAB|DURVALUMAB
214920224|NCT05371015|PROCEDURE|quadratus lumborum nerve block (normal saline)|Echo guided quadratus lumborum nerve block with normal saline
214920225|NCT05498844|BEHAVIORAL|Medical Nutrition Therapy (counselling)|Participants will receive nutrition counseling to enhance adherence to the principles of the Mediterranean diet and support the achievement of adequate levels of lipid control, blood pressure and weight.
214920226|NCT03997240|PROCEDURE|Chiropractic Applied Clinical Neuroscience|Chiropractic Applied Clinical Neuroscience makes use of chiropractic care in addition to application of therapies designed to stimulate multisensory reintegration and cerebellar coordination. The multisensory reintegration and cerebellar therapies make use of the body's own sensory receptors as a target, with the purpose of realigning the brain's interpretation of different afferent signals. Observation of motor and autonomic output patterns during and after sensory stimulation afford the clinician real-time feedback, providing for adaptation of the sensory based protocol.
214920227|NCT01091662|DRUG|Eslicarbazepine acetate 1600 mg|1600 mg once per day
215061697|NCT05013021|OTHER|Sprint Interval Training|"The Sprint Interval Training (SIT) training consists of 3 successive blocks of 5 training sessions each. The sessions are 24 to 48 hours apart.~. One block lasts two weeks. After the end of one block, the following block begins the day after.~The Sprint Interval Training lasts 6 weeks.~Each session consists of a series of sprints, the number of which varies from 8 to 14. Thus a session will last from 30 to 45 min approximately~So, the time frame of this study is Baseline, Block 1, Block 2 and Block 3 (Not in day or week or month)"
215061698|NCT01735734|DEVICE|Air cooling to CM site|
214920228|NCT01091662|DRUG|Eslicarbazepine acetate 1200 mg|1200 once per day
215061699|NCT03144336|BEHAVIORAL|Information provision|All study participants will receive weekly messages with HIV prevention information.
214320633|NCT05853133|OTHER|Wound Infiltration|Group W, at the end of the operation,wound infiltration will be administered under general anesthesia in supine position by same surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each). All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
214320634|NCT05105308|BEHAVIORAL|Family Assisted Diet (FAD)|A behavioral intervention consisting of helping parents renourish their child and conduct food exposures with new foods.
214320635|NCT05105308|BEHAVIORAL|Feeling and Body Investigator_ARFID Division (FBI-ARFID)|A sensory and somatic focused intervention that educates children about feelings and bodily sensations, in-session exposures to body and food sensations, different strategies to improve generalization while at home, and strategies to help them understand and track experiences exploring food.
214320636|NCT00816725|BEHAVIORAL|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
214320637|NCT01353378|DRUG|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
214320638|NCT04412330|OTHER|ICU Recovery + Physical Therapy|Physical therapy interventions will be supervised by a physical therapist (\>20 years of experience in ICU and pulmonary rehabilitation). Potential interventions include endurance/aerobic training (treadmill training, upper and lower extremity ergometer, and recumbent step machine), upper and lower extremity resistance strength training, balance training, functional movement training, and education. If the interventions are providing in the home environment the exercises will be completed through Zoom, video communications app. Home-based interventions will include seated and standing exercise including resistance exercises (such as lifting small weights) and endurance (e.g. marching or stepping in place, repetitive sit-to-stand training). Physical therapist will provide verbal instructions for motivation and adherence to exercise interventions.
214484334|NCT06877351|DRUG|Penicillin G, Benzathine|Participants randomized to the control group will receive intramuscular procaine benzathine penicillin (PGB) at a dose of 50,000 IU/kg (maximum 2,400,000 IU/day), administered as a single dose for early syphilis and as three consecutive weekly doses for late syphilis or syphilis of unknown duration.
214320639|NCT04733963|DRUG|Fruquintinib Plus Capecitabine|Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
214320640|NCT04733963|DRUG|Bevacizumab Plus Capecitabine|Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
214671990|NCT03083951|PROCEDURE|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
214320641|NCT02471521|OTHER|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
214320642|NCT02471521|DRUG|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
214320643|NCT00169650|OTHER|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
214320644|NCT05162872|DRUG|Niraparib，Sintilimab|Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W
214320645|NCT02235376|OTHER|weaning trial of mechanical ventilation|
214320646|NCT05180461|DRUG|emodepside|emodepside tablet
215061700|NCT03144336|BEHAVIORAL|Weekly quizzes|Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
214320647|NCT05180461|DRUG|matching placebo of emodepside|emodepside matching placebo tablet
214320648|NCT05180461|DRUG|ivermectin|ivermectin tablet (overencapsulated for blinding)
214320649|NCT05180461|DRUG|matching placebo of ivermectin|matching placebo of overencapsulated ivermectin tablet
214320650|NCT03343769|OTHER|BERG scale|Complete the BERG balance scale
214320651|NCT03343769|OTHER|Functional tests|timed up and go, Mini motor test, retropulsion test
214320652|NCT03343769|OTHER|Measurement of balance on a force platform|4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
214320653|NCT03343769|OTHER|Measurement of maximal moment of the plantar flexor and dorsiflexor muscles|5-second repetitions
214320654|NCT03343769|OTHER|Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements|3 10-second repetitions
214484335|NCT06757868|DRUG|Amobarbital|Amobarbital 1mg/kg is given prior to cardiopulmonary bypass
214484336|NCT06757868|DRUG|Midazolam|midazolam 0.1mg/kg is given prior to cardiopulmonary bypass
214484337|NCT06703060|BEHAVIORAL|Peer Navigation Group|Participants randomized to the intervention will receive behavioral lifestyle education on topics related to biomedical HIV prevention. This will include 4 group sessions and 4 one-on-one sessions with a peer navigator.
214320655|NCT02396836|OTHER|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
214320656|NCT02396836|OTHER|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
215061701|NCT03144336|BEHAVIORAL|Rewards for testing HIV-negative|Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
214920229|NCT02276989|DRUG|acetazolamide|"On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.~On Day 1, pregabalin PK measures will be collected.~On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.~On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On the mornings of Days 7-8 subjects will receive their PGB dose only."
214320657|NCT04950777|BEHAVIORAL|patient education document|The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
214320658|NCT02897128|OTHER|Observational Only - Transcutaneous Oxygen Measurement|The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.
214320659|NCT03524703|OTHER|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
214320660|NCT06190730|OTHER|Voice-Assisted Remote Symptom Monitoring System (VARSMS)|Utilizing an Alexa Skill activated via an Amazon Echo Dot device, this system will administer two patient-reported outcomes measures to subjects. This will not be used as basis for diagnosis, nor for any clinical intervention.
214320661|NCT04705285|DEVICE|Erbium Yag Laser|Subjets in the laser arm will undergo 2 sessions of vaginal erbium-yag laser, separated by a month
214320662|NCT04705285|BEHAVIORAL|Pelvic Floor Training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist
214320663|NCT04359368|OTHER|collection of patient data|Data collection (history, clinical presentation, medication, complications, laboratory testing) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs.
214320664|NCT00013663|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214320665|NCT00013663|DRUG|Aldesleukin|
214320666|NCT04332289|OTHER|Heavy water experiment|3 times daily heavy water (deuterated-water) and mixed meal administration for one week
214920230|NCT02276989|DRUG|Quinine|"On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.~On Day 11, PK testing of QUIN and PGB will be repeated.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.~On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week."
214920231|NCT02276989|DRUG|Riboflavin|"All subjects will receive riboflavin on the following days of the study:~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected."
214320667|NCT03240627|DRUG|LH-8|LH-8 cutaneous solution
214320668|NCT03240627|DRUG|Placebo|Placebo cutaneous solution
214320669|NCT05180084|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory, self-determination theory and self-compassion therapy for low self-esteem among young adults.
214320670|NCT03768115|DRUG|Autologous Plasma Eye Drop|Autologous plasma crimped segments
214320671|NCT03767218|COMBINATION_PRODUCT|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH \> 10 IU/L, till day of trigger.
214320672|NCT03767218|COMBINATION_PRODUCT|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
214320673|NCT05210127|PROCEDURE|Scarf osteotomy for Hallux Valgus deformity|An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol
214320674|NCT04725435|BEHAVIORAL|Kangaroo care|Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.
214320675|NCT04725435|BEHAVIORAL|Facilitated Tucking Position|"Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
214320676|NCT05832346|BEHAVIORAL|Laughter yoga programme|"Intervention for intervention group:~This is a 4-week laughter yoga programme (8 sessions) to help adolescents with intellectual and physical disabilities bring more happiness, laughter and joy to promote their mental health status. As laughter yoga therapy can reduce people's levels of stress, anxiety, depression, loneliness, strengthen the immune system and keep the mind positive. Each laughter yoga session will last for 15 minutes and in total there will be 8 sessions for four weeks (two sessions per week). Each laughter yoga session consists of hand clapping warming-up exercise, followed by deep breathing exercise, childlike playfulness exercise, and then laughter exercise. The intervention group also receives routine care provided by special school."
214320677|NCT05309603|OTHER|Loaded Walking High|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried high on the back
214320678|NCT05309603|OTHER|Loaded Walking Mid|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried on the mid-back
214320679|NCT05309603|OTHER|Walking|Walking three miles on a treadmill at a self-selected speed
214320680|NCT01289808|DRUG|Glucose 25%|1ml of glucose 25% once
214320681|NCT01289808|DRUG|Glucose 25%|1ml glucose once per os
214484338|NCT06874309|DEVICE|home-based tDCS stimulation|stimulation parameters: 20 sessions of tDCS over lDLPFC (anode over F3, based on the 10:20 system, and cathode over the right supraorbital area), 2 mA intensity, 20 min duration (30 s fade in/fade out)
214320682|NCT03569670|DEVICE|Posterior stabilized all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
214320683|NCT03569670|DEVICE|Cruciate retaining all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
214484339|NCT06874309|DEVICE|home-based tDCS stimulation - sham|20 sessions of tDCS over lDLPFC (anode over F3, based on the 10:20 system, and cathode over the right supraorbital area), the electric current will flow for only 15 s, with similar fade in/fade out, at the beginning and at the end of 20 min, to mimic the subjective sensations that occur during active tDCS.
214484340|NCT06874309|PROCEDURE|Bariatric surgery|The operation itself is not a study-related procedure and thus the indicated patients would undergo the surgery regardless of their participation in this study. The operating surgeons will perform either Roux-en-Y or gastric sleeve resection.
214484341|NCT06703333|COMBINATION_PRODUCT|Extracorporeal photopheresis (ECP)|"* Months 1-3: One ECP cycle (two-consecutive days) every other week for 3 months (12 procedures).~* Months 4-6: One ECP cycle every month for 3 months (6 procedures).~* Total: 18 procedures (within 6 months \~24 weeks)."
214320684|NCT03283423|DEVICE|Image-guided Lymphadanectomy in AMIGO|Image guided laparoscopic lymph node biopsy
214320685|NCT00913809|DRUG|Desipramine HCL 100 mg Tablets Cord Laboratories|
214320686|NCT00913809|DRUG|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
214320687|NCT02242851|DRUG|Telmisartan|
214320688|NCT04100707|PROCEDURE|Genicular block was applied|This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
214320689|NCT05812014|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
214320690|NCT05812014|DRUG|0.9% sodium chloride solution|One dose was administered by intramuscular injection, 1.0ml/dose
214320691|NCT05931328|DRUG|thiotepa combined with pomalidomide|thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
214320692|NCT03811756|DIETARY_SUPPLEMENT|Test syrup containing CoQ10 and collagen|Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
214320693|NCT03811756|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
214320694|NCT00732810|DRUG|SCH 727965|SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.
214320695|NCT00732810|DRUG|Capecitabine|Capecitabine 1250 mg/m\^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
214320696|NCT00732810|DRUG|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
214920232|NCT04190940|BEHAVIORAL|Behavioral Assessment|"Patients will be asked to complete the behavioral assessment before and after their HIFU treatment or on and off their DBS treatment."
214320697|NCT02630784|PROCEDURE|Non-Invasive Ventilation with Homecare ventilator|
214320698|NCT02630784|PROCEDURE|Non-Invasive Ventilation with ICU ventilator|
214320699|NCT04328376|DIAGNOSTIC_TEST|ECG coupled to phonocardiography|"A standard ECG is recorded along with a phonocardiographic recording. The phonocardiographic recording is obtained by using a specific electronic stethoscope plugged into the auxiliary port of the ECG machine. The recording takes less than 30 seconds. The two recording methods are concomitant.~QT interval is measured on the ECG recording, EMW is measured with ECG coupled to phonocardiography."
214320700|NCT02281552|DRUG|Tofacitinib|tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
214320701|NCT02281552|DRUG|Tofacitinib|tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
214671991|NCT03083951|PROCEDURE|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
214920233|NCT01532960|BIOLOGICAL|poly-ICLC|poly-ICLC
214920234|NCT01532960|BIOLOGICAL|9 Peptides from Her-2/neu, CEA, & CTA|9 synthetic peptides derived from Her-2/neu, CEA \& CTA derived breast cancer proteins.
214920235|NCT01532960|BIOLOGICAL|Peptide-tet|A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
214920236|NCT04109391|BIOLOGICAL|TX05 (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
214920237|NCT04109391|BIOLOGICAL|Herceptin (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
214920238|NCT01222520|DRUG|Telmisartan and amlodipine|Telmisartan 80 mg and amlodipine 5 mg once a daily
214920239|NCT01222520|DRUG|Telmisartan|80 mg once a daily
214920240|NCT01329874|PROCEDURE|Type of block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
214920241|NCT00259948|PROCEDURE|Aerobic exercise training|
214920242|NCT00758173|GENETIC|polymorphism analysis|
214920243|NCT00758173|OTHER|laboratory biomarker analysis|
214920244|NCT00758173|OTHER|questionnaire administration|
214920245|NCT02571101|DRUG|CDFR0812-15/25mg|Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
214920246|NCT02571101|DRUG|CDFR0812-15/50mg|Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
214920247|NCT02571101|DRUG|Condencia|Contains chlomipramine HCl 15mg.
214920248|NCT02571101|DRUG|CDFR0812-Placebo|Placebo tablet of CDFR0812.
214320702|NCT03900299|PROCEDURE|oncoplastic breast surgery|oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
214484342|NCT06877130|OTHER|Aerobic exercise with BFR|"To prescribe BFR training, Systolic blood pressure (SBP) will be measured using an automated oscillometer BP device.~Blood pressure will be measured according to the recommendations of the American Heart Association. A bilateral restriction of 50% of the measured SBP will be applied to each lower limb for the application of BFR of lower limbs using the equipment. A wide cuff (18 cm wide) will be placed in the proximal portion of the thigh (inguinal fold region) and will be inflated until the absence of the tibial artery blood pulse. Thus, a 50% restriction of SBP will be applied in both legs during lower body exercises."
214320703|NCT00331175|DRUG|Peptide YY3-36|
214484343|NCT06877130|OTHER|Aerobic training|"HR max = 206.9 - (0.67 x age).~Moderate intensity aerobic exercise: the rate of heart reaches 64-76 percent of their age predicted peak hearty rate"
214484344|NCT06877039|OTHER|Observational studies did not involve any interventions|
214484345|NCT06879158|DRUG|BR3409|One tablet administered alone
214484346|NCT06879158|DRUG|BR3409-1|One tablet administered alone
214484347|NCT06879158|DRUG|BR3409-2|One tablet administered alone
214671992|NCT01803165|PROCEDURE|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
214320704|NCT04365699|DRUG|AT-001|Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team
214320705|NCT06392243|DEVICE|Intracardiac ultrasound imaging system|The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention
214320706|NCT05839457|BEHAVIORAL|Empowerment Pilot|The Empowerment Pilot is a school-based program aimed to raise awareness and change attitudes around SRGBV among students and teachers and promote gender equality. This intervention includes training provided by Teacher Mentors to other teachers in school, learning sessions delivered via safe spaces for student learners, and guidance for engaging parent-teacher committees.
214484348|NCT06878508|DEVICE|DuoCor Ventricular Assist System|The DuoCor VAS is used to provide hemodynamic support by shareing some or all the workload of the left and right ventricles during the support period.
214484349|NCT06880614|DIAGNOSTIC_TEST|Oral Glucose Tolerance test (75g 2-hour)|The participants are required to drink a glucose solution containing 75 g of glucose dissolved in 250 mL of water
214484350|NCT06880614|DIETARY_SUPPLEMENT|Whey|Supplemented with whey protein isolate masked with a chicken-flavored soup
214484351|NCT06880614|DIETARY_SUPPLEMENT|House cricket|Supplemented with house cricket powder masked with chicken-flavored soup
214484352|NCT06880614|DIETARY_SUPPLEMENT|Placebo|Placebo consists of chicken-flavored soup without any supplement inside
214484353|NCT06879938|DEVICE|High-concentration vaginal oxygen therapy (Caress Flow) with topical hyaluronic acid|five treatment sessions of high-concentration vaginal oxygen therapy (Caress Flow) with topical hyaluronic acid 2 weeks apart with a duration of approximately 15 minutes
214484354|NCT06879938|DEVICE|hyaluronic acid-based gel (Hydeal-D®)|hyaluronic acid-based gel (Hydeal-D®) applied once every three days for 12 weeks
214484355|NCT06879652|OTHER|Increasing Dairy intake|The prediabetic and overweight participants aged 14-17 and 60-75 years consuming ≤1 serving of dairy per day who are assigned to the intervention group will consume 3 servings of dairy (milk, yogurt, cheese) before each meal throughout a day for 24 weeks.
214484356|NCT06880432|OTHER|Collection of fluid samples|\- Blood sampling, urine sampling and tissue sampling
214484357|NCT06879132|DRUG|BR3409|One tablet administered alone
214484358|NCT06879132|DRUG|BR3409-1|One tablet administered alone
214920249|NCT02571101|DRUG|Condencia-Placebo|Placebo tablet of Condencia
214920250|NCT05976269|DEVICE|Dry needling|Dry needling will be performed by licensed physical therapists who are formally trained in dry needling and meet all of the requirements of the state of Ohio and agree to participate as key personnel in this study. These therapists will receive specialized training in the study protocol including appropriate documentation, standardized dry needling technique/procedures, and study communication. Dry needling will be performed in a clean field using sterile acupuncture needles of appropriate length to pierce muscle bellies based on patient size and muscle mass.
214920251|NCT02412163|DEVICE|Ellipse IM HTO Nail|
215061702|NCT00508105|PROCEDURE|subscapularis peel|"Detachment of the subscapularis tendon from its insertion on the lesser tuberosity the peel."
214320707|NCT02540954|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|A dose of 2 mg aflibercept injected intravitreally
214320708|NCT04300569|OTHER|Non-interventional|No intervention will be administered.
214320709|NCT01005004|BIOLOGICAL|HuCNS-SC cells|intracerebral transplantation
214484359|NCT06879132|DRUG|BR3409-2|One tablet administered alone
214484360|NCT06877832|OTHER|Static Stretching (SS)|For the SS, participants will be instructed to stand and place their dominant foot on a wedge with a 35° incline, stretching the plantar flexor muscles.
214484361|NCT06877832|OTHER|Foam Rolling (FR)|For the FR, participants will be instructed to position the muscle belly of the PF on the roller. Thirty rolls (15 proximal and 15 distal) will be performed on the muscle belly while maintaining compression on the muscle.
214484362|NCT06877832|OTHER|Foam rolling with dynamic movement (FR-DM)|The FR-DM will involve positioning the muscle belly of the PF on the roller and, without moving the roller, performing 15 plantar flexions and 15 dorsiflexions of the ankle for a period of 30 seconds while compressing the dominant leg with the contralateral leg.
214671993|NCT01538173|DRUG|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
214671994|NCT01538173|DRUG|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
214320710|NCT05667233|OTHER|Resistance Training Program|Participants will undergo a high exertion machine-based resistance training protocol.
214320711|NCT01388842|DRUG|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
214320712|NCT01388842|DRUG|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
214320713|NCT03160053|DEVICE|NB-UVB|NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
214320714|NCT01933906|DRUG|P1101|
214320715|NCT04023877|DRUG|E2027|E2027 oral capsule.
214320716|NCT02800330|DRUG|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
214320717|NCT02800330|DRUG|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
214920252|NCT03766867|DRUG|Vortioxetine infusion 25 mg|1 mg/mL, concentrate for solution for infusion, 25 mL (25 mg) administered in 250 mL saline over 2 hours as single dose for 7 days
214320718|NCT02800330|DRUG|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
214320719|NCT01652391|DEVICE|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
214320720|NCT01794091|DRUG|Eplerenone|Eplerenone 25 mg daily for 6 months
214320721|NCT01794091|DRUG|Placebo|
214320722|NCT02832869|OTHER|short message service based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
214320723|NCT02832869|OTHER|Wechat based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
214320724|NCT05949138|DEVICE|ECG-Less Cardiac CT using SmartPhase|"Administration of medications and biologic products (such as contrast agent administration, and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational workflow on an existing CT device that has regulatory clearance. The investigational workflow includes preforming the CT acquisition according to the hospital's usual care with the exception that the ECG signal which triggers the scan will be coming from an ECG simulator based on an estimate of the patient's heart rate, rather than through ECG leads connected to the subject. Clinically-indicated Cardiac CTs take approximately 30-60 minutes. No additional imaging is needed as part of the study."
214320725|NCT00903812|OTHER|No intervention|No intervention as observational study
214320726|NCT01393743|DRUG|Perampanel|
214484363|NCT06880484|DEVICE|Far-Infrared Radiation (FIR) Socks|Participants in the experimental group will receive two pairs of Far-Infrared Radiation (FIR) emitting socks, designed to be worn for at least 8 hours per day over a 3-month period. These socks utilize FIR technology, which is hypothesized to improve circulation, reduce neuropathic pain, and enhance quality of life in patients with diabetic peripheral neuropathy (DPN). Participants will be educated on the proper use of the socks, provided with a usage protocol, and monitored for adherence via three follow-up phone calls assessing compliance and comfort using the Visual Analog Scale (VAS). At the end of the study, participants will undergo a follow-up Electroneuromyography (ENMG) evaluation, and pain and quality of life will be reassessed using the LANSS Scale and NePIQoL forms.
214320727|NCT01393743|DRUG|Placebo comparator|
214920253|NCT03766867|DRUG|Vortioxetine tablets 10 mg/day|10 mg, tablets, oral administration once daily
214920254|NCT03766867|DRUG|Placebo infusion|concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose
214920255|NCT03766867|DRUG|Placebo tablets|oral administration once daily
214920256|NCT03857217|DEVICE|Extra-Corporeal Membrane Oxygenation|ECMO is implanted in cardiac surgery patients.
214920257|NCT04850430|PROCEDURE|Gastric venous reconstruction|Patients will be assigned to study after intraoperative evaluation of gastric venous drainage after coronary vein resection during TP, and the gastric venous outflow will be reconstructed after TP.
214920258|NCT03468686|DEVICE|Bilateral rTMS|The coil will locate on F3 and F4 in accordance with the 10-20 international system. bilateral rTMS include stimulate the right DLPFC at 1 Hz for a 10 seconds train of stimulation, and a total of 150 pulse trains. Immediately after that, the stimulation was carried out on the left DLPFC at 10 Hz, 5 seconds of stimulation, with 10 second inter-train interval and 75 pulse trains.
214920259|NCT03468686|DEVICE|Sham rTMS|The same parameters will use in the sham rTMS. However, the coil adjust at an angle of 90º vertically on the skull in a way that one wing place on the head.
214920260|NCT03468686|DEVICE|Unilateral rTMS (High frequency)|The coil will locate on F3 in accordance with the 10-20 international system. Unilateral rTMS include stimulate the Left DLPFC at 10Hz for a 5seconds train of stimulation, 10 seconds inter-train interval, and a total of 75 pulse trains. .
214920261|NCT02975986|OTHER|123I-BMIPP|Uptake of radioactive isotope by the kidney
214320728|NCT04246385|BEHAVIORAL|CO-OP Group|"Participants in the intervention group will attend one 1:1 session where one goal will be selected from their COPM results to focus on during the group, group expectations will be reviewed, caregivers will be invited, and questions answered. The group will run six sessions as supported by the literature (Chan, 2007; Lee, Fischer, Zera, Robertson, \& Hammel 2017).~Day Rehab CO-OP Group Curriculum Session Content~Introduction One on one session. COPM, introduction to group, education for caregiver. Session 1 Introduction to group and CO-OP approach, homework. Session 2 Review CO-OP approach, practice, homework. Session 3 Review CO-OP approach, plan outing, homework. Session 4 Review CO-OP approach, experiential learning according to participants' alternate COPM goals, homework. Session 5 Review CO-OP approach, outing, homework. Session 6 Review CO-OP approach, focus group, lessons learned, final COPM, homework"
214320729|NCT02581384|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
214320730|NCT01076504|DRUG|Amrubicin|30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
214320731|NCT01076504|DRUG|Carboplatin|AUC=5 IV, Day 1 of each 3-week treatment cycle
214320732|NCT01076504|DRUG|Pegfilgrastim|6 mg SQ on Day 4 of each 3 week treatment cycle
214320733|NCT00915512|DRUG|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
214320734|NCT03738371|OTHER|In situ simulation|Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
214320735|NCT02165046|DRUG|Budesonide|
214320736|NCT02165046|DRUG|Procaterol|
214320737|NCT03571919|DRUG|Lidocaine infusion|Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr
214484364|NCT06880484|DEVICE|Placebo Socks|Participants in the placebo group will receive two pairs of non-FIR socks, which are visually identical to the FIR socks but lack FIR-emitting properties. They will follow the same 8-hour daily usage protocol for 3 months and receive the same education on sock usage. Compliance and comfort will be monitored through three follow-up phone calls, and assessments will be conducted using the VAS, LANSS Scale, and NePIQoL forms. At the end of the study, participants will undergo a final ENMG evaluation.This study aims to determine the effect of FIR socks on neuropathic pain, nerve conduction, and quality of life, using both subjective (pain scales) and objective (ENMG) measures.
214484365|NCT00216827|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
214920262|NCT02975986|OTHER|99mTc-MAG3|Uptake of radioactive isotope by the kidney
214920263|NCT03146455|OTHER|no intervention|no intervention
214320738|NCT03571919|DRUG|Saline infusion|Intravenous bolus of saline and then infusion
214320739|NCT02321462|DRUG|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
214320740|NCT02321462|DRUG|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
214320741|NCT04434885|OTHER|Clinical and imaging examination of symptoms and signs suggestive of axial involvement|Clinical and imaging examination including X-rays and magnetic resonance imaging of sacroiliac joints and spine
214320742|NCT04082988|DIAGNOSTIC_TEST|18F-FDG PET-CT|18F-FDG PET-CT scan
214320743|NCT02469116|DRUG|Docetaxel|
214320744|NCT02469116|DRUG|Carboplatin|
214320745|NCT02469116|DRUG|Pegylated G-CSF|
214320746|NCT01183169|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
214320747|NCT01183169|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
214320748|NCT01183169|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
214320749|NCT01183169|DRUG|Placebo|ALV placebo soft gel capsules administered orally
214320750|NCT01514396|DEVICE|Surgiseal|surgical glue
214320751|NCT00161707|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
214320752|NCT05019222|DRUG|Sevoflurane based inhalation anesthesia|Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.
214320753|NCT05019222|DRUG|Remimazolam based total intravenous anesthesia|Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.
214320754|NCT06424080|PROCEDURE|laparoscopic partial nephrectomy|cases amenable for partial nephrectomy
214320755|NCT06424080|PROCEDURE|robotic partial nephrectomy|cases amenable for partial nephrectomy
214320756|NCT03044197|DEVICE|MRI/ultrasound transperineal prostate biopsy|3-6 targeted biopsy cores from each prostate region of interest
214320757|NCT03044197|DEVICE|transrectal ultrasound-guided prostate biopsy|12 systematic biopsy cores
214320758|NCT01221961|DEVICE|Masimo Radical-7|The Masimo device will be placed on one finger of the patient. To see whether or not the hemoglobin values recorded at the same time matches between the standard clinical practice (CSMC Lab and outside Lab) and the Masimo device
214320759|NCT05409235|DRUG|OTT166|Participants will receive OTT166 ophthalmic solution
214920264|NCT02156908|DRUG|D-serine|D-serine 60 mg/kg
214320760|NCT05409235|DRUG|Vehicle control|Participants will receive vehicle control
214920265|NCT06192381|OTHER|Web-Based Learning Module (WBL)|To ensure a uniform starting point, the participants were recruited via faculty website and students' academic counseling services. At the baseline, after the initial assessment, the participants were randomized at a 1:1 allocation ratio into the following groups: 1) traditional health education group (control group) (n = 68) who received health education with traditional face-to-face method; 2) web-based health education group (intervention group) (n = 68) who received health education with Web-Based Learning Module (WBL).
214920266|NCT04685824|DEVICE|Biofeedback Training|Audiovisual stimulation
214920267|NCT04685824|DEVICE|Immersive Virtual-Reality|Audiovisual stimulation
214920268|NCT04415034|OTHER|VAS and 5-D itch pruritus assessment|All subjects were evaluated for presence of pruritus using VAS and 5-D itch scale
214920269|NCT00001741|DRUG|Losartan|
214671995|NCT05518591|BEHAVIORAL|Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)|Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
214671996|NCT03043365|DRUG|control fish oil|4 capsules, 3 times a day after meals
214320761|NCT04697979|OTHER|Questionnaire|"Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary."
214320762|NCT03657472|DRUG|CJ-30061|Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
214320763|NCT03657472|DRUG|Exforge® 5/160mg & Lipitor® 20mg|Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
214484366|NCT06185595|OTHER|Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.|9.3 oz (273 ml) aliquot of one of the study beverages every 15 min for a total of 28 oz (828 ml) over a 45-min period, followed by 15 min of rest. Flavored water matched for sweetness, color. flavor, but cannot be matched for saltiness. All sodium-containing drinks will include a base blend of other electrolytes (potassium 15 mmol/L, magnesium 8 mmol/L, and calcium 5 mmol/L).
214671997|NCT03043365|DRUG|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
214671998|NCT00168012|DRUG|Immunoglobulins Intravenous (Human)|
214920270|NCT01089608|DRUG|Azithromycin|"Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
214920271|NCT01089608|DRUG|Povidone|"Eye drops Single dose unit~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
214920272|NCT06185179|DRUG|Metformin|Metformin will be distributed in 500mg pills.
214920273|NCT06185179|OTHER|Placebo|Placebo will be distributed in pill form
214671999|NCT03455543|DEVICE|Active Provant Therapy System|Treatment with active Provant Therapy System
214672000|NCT03455543|DEVICE|Inactive (sham) Provant Therapy System|Treatment with inactive Provant Therapy System
214920274|NCT00599287|DRUG|Haloperidol|Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
214920275|NCT00599287|DRUG|Methylphenidate|Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
214920276|NCT00599287|DRUG|Rivastigmine|Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
214920277|NCT01492374|DRUG|BMS-241027|Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
214672001|NCT05667519|PROCEDURE|Additional guidance of lead implantation by transesophageal echocardiography|Transesophageal echocardiography guidance of lead implantation targeting a stable lead position in a tricuspid valve commissure (preferentially postero-septal) and an apical ventricular lead position
214920278|NCT01492374|DRUG|BMS-241027|Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
214920279|NCT01492374|DRUG|BMS-241027|Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
214320764|NCT00834912|DRUG|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
214672002|NCT02884115|DRUG|benzathine penicillin|
214672003|NCT01917825|DRUG|MDT-15|
214920280|NCT01492374|DRUG|Placebo matching BMS-241027|Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
214920281|NCT00279682|BEHAVIORAL|treatment guidelines and depression care management|
214920282|NCT06194370|OTHER|Training by BOPPPS Teaching Model|Training by BOPPPS Teaching Model
214672004|NCT05418361|DRUG|ACE inhibitor ,angiotensin receptor blockers|patients taking ACEI or ARBs with cardiovascular disease
214672005|NCT05858502|BIOLOGICAL|Blood sample collection|Blood sample collection between inclusion and 3 months max 55 ml at each visit
214672006|NCT05858502|OTHER|Saliva sample collection|Saliva sample collection between inclusion and 3 months
214672007|NCT05858502|OTHER|Nasopharyngeal and nasal sample collection|Nasopharyngeal and nasal sample collection between inclusion and 3 months
214672008|NCT05858502|OTHER|Exhaled Breath Condensate (EBC)|Exhaled Breath Condensate (EBC) between inclusion and 3 months
214672009|NCT02873221|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
214672010|NCT02873221|DRUG|Placebo-matching Ubrogepant|Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
214672011|NCT02873221|DRUG|Usual Care|Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
214672012|NCT01776099|DIETARY_SUPPLEMENT|Dietary supplement (4 arms, 2 active, 2 placebo)|
214920283|NCT06194370|OTHER|Training Regularly|Training Regularly
214920284|NCT05616351|OTHER|Data collection in patients with diabetic foot syndrome and infections in the area of the foot|Data collection: on (surgical and antibiotic) treatment and implementation of the recommendations published 2019 with regard to the duration of antibiotic therapy.
214920285|NCT03320382|DEVICE|Multiple breath washout testing|Multiple breath washout testing will be completed on different devices over time
214920286|NCT03364374|BEHAVIORAL|Postural counseling|A therapist will provide verbal/physical cues to improve the participants posture
214920287|NCT04109274|BEHAVIORAL|Exercise|Exercise component: Aerobic exercise, using recumbent bikes, delivered within the cancer institution. Participants will take part in up to 30-minutes of moderate intensity (50-70% HRmax or 4-6/10 on Rate of Perceived Exertion scale)6 exercise for eight sessions during chemotherapy. An exercise specialist with experience in cancer rehabilitation will supervise the exercise component.
214320765|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
214320766|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
214320767|NCT00053794|DRUG|perifosine|
214484367|NCT07033520|BEHAVIORAL|Online Mindfulness-Based Cognitive Therapy|The intervention consists of an 8-week Online Mindfulness-Based Cognitive Therapy (MBCT) program for adults with chronic migraine and adverse childhood experiences. Participants attend one 90-minute virtual group session per week via video conferencing, led by a trained therapist. Daily home practice is encouraged, including 20-30 minutes of guided mindfulness exercises provided as audio files. The program includes cognitive restructuring, body scans, breathing awareness, and acceptance-based techniques. The intervention is fully remote and requires no in-person contact.
214920288|NCT04109274|BEHAVIORAL|Self-Management|Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines
214320768|NCT01416168|OTHER|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
214320769|NCT03376243|OTHER|LIPIKAR BAUME AP+ emollient|Structured education on prevention guidelines
214320770|NCT00350766|PROCEDURE|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
214320771|NCT03200782|DRUG|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
214484368|NCT06705153|OTHER|laughter yoga|Patients who come to the outpatient clinic will be met, informed about the study and written informed consent will be obtained from patients who agree to participate in the study. Patient information form will be applied, baseline measurements will be made (IBS-SSS, DAS-42, PSQI and IBS-QOL) and IBS type will be determined according to Bristol stool scale. Type 1-2 constipation, Type 6-7 diarrhea, Type 1 or Type 2 at the same time with Type 6 or Type 7 will be considered as mixed type IBS and those who do not fit any of the scales will be considered as unclassifiable IBS. A total of 8 sessions will be held with the patients in the intervention group in the form of meetings via zoom with the help of a smart cell phone/computer (2 weekly sessions). The meetings will be in 3 groups.
214484369|NCT06000254|DEVICE|High energy density pulse electromagnetic field|The treatment coil is positioned over the area of the shoulder that experiences the most pain, and it remains in place for a duration of 9 minutes. The patient is subjected to a high-energy high-PEMF with a frequency of 3 pulses per second during the session.
214484370|NCT06000254|OTHER|physiotherapy|Physiotherapy includes a range of activities such as passive and active-assisted shoulder range of motion (ROM) exercises, Pendulum exercises, Codman's exercises, and Cross-body reach exercises. These exercises are conducted under the supervision of a physiotherapist and each training session lasts approximately 30 minutes.
214672013|NCT00636623|OTHER|Pilates exercises|15 FM patients participated in the PE programme three times a week during a 4-week period
214920289|NCT04109274|BEHAVIORAL|Booster Sessions|Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.
215061703|NCT00508105|PROCEDURE|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
215061704|NCT00375505|DRUG|Zoledronic acid|
215061705|NCT00375505|DRUG|Placebo|Placebo
215061706|NCT04491435|DIAGNOSTIC_TEST|Summated Xerostomia Inventory|structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)
215061707|NCT04491435|DIAGNOSTIC_TEST|Sialometry|unstimulated whole saliva (UWS) flow measurement
214320772|NCT03200782|DRUG|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
214320773|NCT03200782|OTHER|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
214320774|NCT03200782|OTHER|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
215061708|NCT03329625|BEHAVIORAL|Pathways Triple P|Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.
215061709|NCT03329625|BEHAVIORAL|Services as Usual|Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
215061710|NCT04173286|PROCEDURE|antibiotherapy|\< 7 days
214320775|NCT05768932|DRUG|BAL0891|BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
214320776|NCT05768932|COMBINATION_PRODUCT|Carboplatin|Carboplatin is an Antineoplastic agent
214320777|NCT05768932|COMBINATION_PRODUCT|Paclitaxel|Paclitaxel is a natural product with antitumor activity
214320778|NCT01885390|DEVICE|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
214320779|NCT00004918|BIOLOGICAL|PR1 leukemia peptide vaccine|Given SC
214320780|NCT00004918|DRUG|Montanide ISA 51 VG|Given SC
214320781|NCT00004918|BIOLOGICAL|sargramostim|Given SC
214320782|NCT00004918|OTHER|laboratory biomarker analysis|Correlative studies
214320783|NCT01971658|DRUG|Thalidomide®|
214320784|NCT01971658|DRUG|Cyclophosphamide|
214320785|NCT01971658|DRUG|Velcade®|
214484371|NCT06000254|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is positioned over the area of the shoulder where maximum pain is experienced, and it remains in place for a duration of 9 minutes. The parameters are consistent with those used in the experimental group. The key distinction lies in the fact that the energy output is not delivered to the patient.
214484372|NCT06453421|OTHER|Pulmonary rehabilitation|Enrolled patients are subjected to a personalized respiratory rehabilitation treatment aimed both at weaning from the tracheostomy tube and at functional recovery
214484373|NCT04717102|DRUG|0.5 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.
215061711|NCT03092999|DRUG|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
214320786|NCT01971658|DRUG|Dexaméthasone|
214320787|NCT00749931|DEVICE|MarginProbe|Device use to assess margin status of the excised specimen surface.
214320788|NCT00749931|PROCEDURE|Lumpectomy|Standard of care lumpectomy procedure
214320789|NCT03671291|BEHAVIORAL|self-administrated questionnaire|Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
214320790|NCT03829046|DRUG|Placebo|12 weeks of treatment
214484374|NCT04717102|DRUG|0.75 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.
214484375|NCT04717102|DRUG|1.0 MAC desflurane|On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
214320791|NCT03829046|DRUG|Evolocumab|12 weeks of treatment
214320792|NCT05112666|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Clinical Practice Research Datalink (CPRD) GOLD and Aurum Hospital Episode Statistics (HES)-linked datasets in UK.
214484376|NCT05172180|DRUG|Reamberin|the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)
215061712|NCT06299865|OTHER|Ungrouped|Ungrouped
215061713|NCT01131806|DRUG|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
215061714|NCT01131806|DRUG|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
214320793|NCT05112666|DRUG|other DOACs|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
214320794|NCT05112666|DRUG|LMWH|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
214320795|NCT01037946|BEHAVIORAL|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
214320796|NCT04518007|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel."
214320797|NCT05962411|OTHER|Dress in Professional Attire|"Adolescents pretend to be adult e-cigarette buyers by dressing in professional attire."
215061715|NCT00002050|DRUG|Thymopentin|
214320798|NCT04709666|PROCEDURE|Endsocopic Retrograde ColangioPancreatography (ERCP)|
214320799|NCT00326664|DRUG|Cediranib Maleate|Given orally
214320800|NCT01930292|DRUG|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
214320801|NCT01930292|DRUG|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
214320802|NCT01930292|DRUG|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
214320803|NCT01930292|DRUG|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
214320804|NCT01166308|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
214320805|NCT01166308|RADIATION|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
214320806|NCT00424151|DRUG|Rituximab|
214320807|NCT01886248|DRUG|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
214320808|NCT05624346|OTHER|Deep-Breathing Exercises|In addition to routine care in the hospital, the patient will be taught pre-operative breathing exercises. After surgery the patients do deep-breathing exercises every hour.
214320809|NCT01638962|DRUG|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
214484377|NCT05172180|DRUG|Ringer's solution|Ringer's solution at an average daily dose of 8.1 ml/kg/day
214484378|NCT06713226|DEVICE|Hativ P30 and 12-lead ECG comparator device|"The purpose of this study is to compare the clinical equivalence and diagnostic ability of the Hativ P30 against the 12-lead ECG comparator device.~Electrocardiograms of all participants will be obtained using both the Hativ P30 and a 12-lead ECG comparator. That is, all participants will get the same intervention."
214320810|NCT01638962|OTHER|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
214320811|NCT00924911|DRUG|GSK1322322|Four different formulations of 1000mg of GSK1322322
214320812|NCT00924911|DRUG|GSK1322322|GSK1322322 1000mg
214320813|NCT02201303|DRUG|Danirixin|Powdered form for in-vitro administration to blood sample
214320814|NCT02201303|OTHER|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
214320815|NCT00895791|DEVICE|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
214320816|NCT00895791|DEVICE|culotte stenting (Xience V)|implantation of stent
214320817|NCT01470391|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
214320818|NCT01470391|PROCEDURE|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
214320819|NCT00989833|DRUG|budesonide|400 yg x 1
214320820|NCT00989833|DRUG|terbutaline|0.4 mg as-needed
214320821|NCT00989833|DRUG|budesonide/formoterol|160/4.5 yg as-needed
214320822|NCT02518477|OTHER|exercise|progressive resistance training
214320823|NCT00563238|DRUG|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
214320824|NCT00858871|DRUG|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
214320825|NCT00858871|DRUG|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
214320826|NCT00858871|DRUG|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
214320827|NCT00858871|DRUG|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
215061716|NCT00801073|PROCEDURE|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
214320828|NCT04990934|BEHAVIORAL|Semistructured Interview|Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
214484379|NCT06876350|OTHER|Woodcasting Splint|This is the experimental group so we could see the outcomes and preference for patients using surveys and compliance scores
215061717|NCT03907176|DRUG|HTX-011|300 mg
214320829|NCT01228630|DRUG|Cloratadd-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
214320830|NCT01228630|DRUG|Allegra-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
214320831|NCT00249470|BEHAVIORAL|Abstinence & Work|Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
214320832|NCT00249470|BEHAVIORAL|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
214320833|NCT04859868|DEVICE|Galvanic Vestibular Stimulation|Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.
214320834|NCT04436523|DEVICE|Blood flow restriction (Delfi Personalized Tourniquet System)|The Delfi Personalized Tourniquet System will be utilized to apply the blood flow restriction protocol.
214320835|NCT04436523|OTHER|Standard rehabilitation|Post-operative physical therapy as guided by a standardized protocol for patients undergoing meniscus repair.
215061718|NCT03907176|DEVICE|Luer lock applicator|Applicator for instillation
214320836|NCT00624806|BEHAVIORAL|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
214320837|NCT00624806|BEHAVIORAL|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
214320838|NCT00684606|DRUG|Oxytocin IV|5 miu/1000ml Glu/Saline
214320839|NCT02361710|PROCEDURE|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
214320840|NCT00500370|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
214320841|NCT00500370|DRUG|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
214320842|NCT01616186|DRUG|Everolimus and sorafenib|"* Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~* Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
214320843|NCT01616186|DRUG|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
214320844|NCT06577493|DRUG|Phenazopyridine Hydrochloride 99.5 MG|Experimental arm to take two 99.5 mg phenazopyridine hydrochloride by mouth for a total of 199mg immediately prior to start of urodynamic testing
214320845|NCT00436943|DRUG|nicotine replacement therapy and bupropion|3-6 months
214320846|NCT00436943|BEHAVIORAL|smoking cessation counseling and referrals|Organizational counseling and referrals
214320847|NCT03771833|DEVICE|MARIA scan|The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
214320848|NCT00132015|DRUG|tanespimycin|
215061719|NCT03907176|DRUG|Ibuprofen|600 mg
215061720|NCT03907176|DRUG|Acetaminophen|1 g
214320849|NCT01282424|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
214320850|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
214320851|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
214320852|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
214484380|NCT06876350|OTHER|Control (Standard treatment)|Thermoplastic splints are standard of care treatment for patients after CMC arthroplasty. We will use the data from this group as the comparator to the experimental group.
214484381|NCT06876675|DRUG|Lorlatinib|To study hyperlipidemia frequency, levels, impact on cardiovascular events after use of Lorlatinib in NSCLC patients.
214484382|NCT06880926|DRUG|Krill oil|Antarctic krill oil was used for intervention in the experimental group.
214484383|NCT06880926|DIETARY_SUPPLEMENT|Olive Oil|Olive oil was used for intervention in the placebo group.
214484384|NCT06733753|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radio frequency ablation, laser ablation
214484385|NCT06721143|BIOLOGICAL|AION-301|AION-301 Infusion
214484386|NCT06721143|DRUG|Placebo|Placebo Infusion
214484387|NCT06720350|DRUG|Romosozumab and Denosumab Combination Therapy|Romosozumab 210mg per month and denosumab 60mg per 6 months will be applied
214484388|NCT06720350|DRUG|Romosozumab Prefilled Syringe [Evenity]|Romosozumab 210mg subcutaneously per month
214484389|NCT06720350|DRUG|Denosumab (Prolia)|Denosumab 60 mg subcutaneously per 6 months
214484390|NCT06884046|OTHER|Personalized support project|"1. Presence of a child nurse at the consultation of the anesthesiologist-resuscitator.~2. Antenatal paramedical consultation conducted by a child nurse composed of a semi-structured interview and an evaluation of Parental Stress by the ISP-4 self-questionnaire.~3. Implementation of the personalized support project~4. Self-assessment of parental stress using the ISP-4 self-questionnaire (child admitted to intensive care or resuscitation unit)~5. Application of the personalised support project~6. Self-assessment of parental stress using the ISP-4 self-questionnaire (child discharged from intensive care)~7. Paramedical follow-up consultation with parents (semi-directive interview, ISP-4 self-questionnaire) and assessment of the child's psychomotor development in the child's 6th month of life"
214484391|NCT06884709|OTHER|Mirror Therapy|"During mirror therapy, participants will sit in an arm chair with a mirror placed in their mid-sagittal plane so that their non-paretic lower limb is reflected and their paretic lower limb is hidden. They will be asked to complete activity-based exercises with their non-paretic limb whilst watching the reflection in the mirror and imagining the reflection is their paretic limb.~The activity-based exercises consist of rocker board dorsi/plantarflexion, rocker board in/eversion, step ups, wiping floor (or ball rolling) in/external hip rotation, wiping floor ab/adduction, ball kicking, and picking up marbles with the toes. Participants will do these exercises for 15 minutes, three days per week for four weeks.~Participants will also receive 45 to 60 minutes of usual personalized conventional physiotherapy such as neurodevelopmental facilitation, sensory motor re-education, active/active-assisted exercises, and balance/gait training, five days per week."
214484392|NCT06883968|BEHAVIORAL|Therapeutic exercise during hemodialysis session|"Participants in the intervention group will receive a therapeutic exercise program during hemodialysis sessions at the hospital. The physiotherapist, after assessing the participant, will plan a program with the sets and number of repetitions for the prescribed exercises based on the participant's condition.~In this exercise program, the lower and upper extremities will be worked on with the aim of improving strength, balance, as well as contributing to the improvement of the participant's quality of life and mood."
214672014|NCT00636623|OTHER|Connective tissue massage|21 patients received CTM, three times a week during a 4-week period
214672015|NCT05109390|DRUG|Danicopan|Oral tablet.
214672016|NCT05109390|DRUG|Cyclosporine|Oral capsule.
214672017|NCT05109390|DRUG|Tacrolimus|Oral capsule.
214672018|NCT05109390|DRUG|Calcium Carbonate|Chewable tablet.
214672019|NCT05109390|DRUG|Aluminum/Magnesium Hydroxide/Simethicone|Chewable tablet.
214672020|NCT05109390|DRUG|Omeprazole|Oral, delayed-release capsule.
215061721|NCT04174859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment dose is following the description of physicians.
214320853|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
214320854|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
214320855|NCT00714259|DRUG|Fludarabine|Fludarabine 30 mg/m2/day x 3 days
214320856|NCT00714259|RADIATION|Total Body Irradiation|TBI 200cGy x1 dose on transplant day
214672021|NCT01421849|PROCEDURE|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months."
214672022|NCT03570229|OTHER|Hyperbaric oxygen treatment|"Participants in this study will receive hyperbaric oxygen treatment (HBOT) but the investigators do not assign this specific intervention to the study participants. Thus, the patients in this study will receive HBOT as part of routine medical care. Consequently, we regard this as an observational study because the patients will get HBOT independently of the study and they are NOT assigned prospectively to HBOT according to a protocol to evaluate the effects.~HBOT for pelvic radiation injury typically involves a treatment pressure of 2.4 ATA (Atmospheres Absolute) breathing oxygen for 90 minutes. The treatment is delivered as series treatment, usually daily treatment up to 30 dives."
214320857|NCT00714259|OTHER|Infusion of Stem Cells|On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight.
214320858|NCT02729649|DEVICE|ArmAssist robotic training|
214320859|NCT02729649|OTHER|Conventional therapy|
214320860|NCT02729649|OTHER|Extended conventional therapy|
214320861|NCT04441294|BEHAVIORAL|ACE-Plus|
214320862|NCT01902485|OTHER|Timing of Contraceptive Initiation in Medical Abortion|
214320863|NCT04209088|OTHER|Pulmonary ultrasounds|"Two ultrasounds will be performed by the same pediatrician for each child included: the first at nine days of life +/- two days, the second at fifteen days of life +/- two days.~A blind replay of ultrasound images to calculate the score will be performed by a another investigator."
214320864|NCT00874068|OTHER|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
214320865|NCT00874068|OTHER|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
214672023|NCT02797873|OTHER|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
214672024|NCT02797873|OTHER|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
214672025|NCT02797873|BEHAVIORAL|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
214672026|NCT02797873|OTHER|SCID-II|See Detailed Study Description.
214672027|NCT02797873|OTHER|SDQ|See Detailed Study Description.
214672028|NCT02797873|OTHER|ASRS|See Detailed Study Description.
214672029|NCT02797873|OTHER|AQ|See Detailed Study Description.
214672030|NCT02797873|OTHER|TAS-20|See Detailed Study Description.
214320866|NCT05709184|COMBINATION_PRODUCT|Lyophilized fecal microbiome transfer|Five days of vancomycin followed by five days of lyophilized fecal microbiome transfer, administered in a loading dose of 15 capsules, and a daily maintenance dose of 10 capsules.
214320867|NCT05709184|DRUG|Vancomycin|Ten days of oral vancomycin 125 mg four times daily
214672031|NCT02797873|OTHER|Raven's SPM|See Detailed Study Description.
214672032|NCT02797873|OTHER|Reading ability|See Detailed Study Description.
214672033|NCT02797873|OTHER|Ishihara's tests for colour deficiency|See Detailed Study Description.
214672034|NCT02797873|OTHER|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
214320868|NCT02753894|DRUG|ASP1585|Oral
214320869|NCT02459392|OTHER|Epiduroscopy|"Epiduroscopy has two main uses in the pain clinic:~Releasing epidural adhesions for the relief of chronic sciatica. Adhesions can form around the lower lumbar nerve roots after decompressive surgery for disc disease or after a bad bout of inflammatory sciatica in the absence of surgery. Epidural adhesions can usually be identified on an enhanced magnetic resonance scan using intravenous gadolinium. They also cause uneven spread of X-ray contrast when performing an epidurogram.~Injecting mixtures of local anesthetic and depot steroid around inflamed nerve roots when epidural injections / nerve root blocks have been unsuccessful. The presence of adhesions can prevent epidurally injected drugs from reaching the inflamed nerve roots."
214320870|NCT02459392|DRUG|Hyaluronic Acid|Drug administration
214320871|NCT02459392|DRUG|DepoMedrol|Drug administration
214320872|NCT05039970|OTHER|WellQuest™|WellQuest™ is a mobile device-based serious health game.
214320873|NCT01589432|DRUG|ABT-639|two 50 mg oral capsules
214320874|NCT01589432|DRUG|Placebo|2 placebo capsules
214320875|NCT01589432|DRUG|Lidocaine|3mg/kg infusion over 30 minutes
214320876|NCT05891938|OTHER|H2 gas inhalation|H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
214320877|NCT06354907|BEHAVIORAL|The Kids' Empowerment Program|The 12-session KEP provides support and information while teaching children self-management skills based on techniques derived from a combination of best, evidence-based practices (e.g., using elements of cognitive behavioral therapy, behavioral activation, brief behavioral activation, and interpersonal therapy. Adjustment is enhanced with a comprehensive approach that strengthens cognition (how to think about things), changes behavior (problem solving or planning actions), and focuses on emotions (identifying and expressing feelings), social relationships (peers, parents, siblings), and physical health (de-stressing, exercise). Group leaders follow a training manual with developmentally appropriate scripts, instructions for behavioral applications in (e.g., craft or game activities) and practice plans.
214672035|NCT02797873|OTHER|Brown-ADD|See Detailed Study Description.
214672036|NCT02797873|OTHER|MFQ|See Detailed Study Description.
214672037|NCT02797873|OTHER|STAI-T|See Detailed Study Description.
214672038|NCT02797873|OTHER|BIS|See Detailed Study Description.
214672039|NCT02797873|OTHER|DAWBA|See Detailed Study Description.
214320878|NCT06239779|OTHER|Education|The education intervention will involve a PowerPoint presentation delivered individually by a physician to each participant in intervention group, covering an overview of fibromyalgia, coping strategies, and the potential impact of smart phone addiction on fibromyalgia.
214320879|NCT04793360|DEVICE|LiverCare|The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.
214320880|NCT04804813|DRUG|Cabozantinib|Cabozantinib tablets
214320881|NCT05627518|DRUG|Linaprazan glurate|100 mg
214484393|NCT06882239|OTHER|SPINEPASS Physical Therapy|SPINEPASS consists of a core set of three daily exercises integrated into daily activities to improve/restore overall spinal and dural mobility and or stability. It also provides training in the use of specific tools to be used as needed to address symptoms as they occur. Treatment can also include spinal manual therapy and other exercises to enhance the tools, but the emphasis is on self-management.
214672040|NCT02797873|OTHER|STAI-S|See Detailed Study Description.
214672041|NCT02797873|OTHER|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
214920290|NCT06176404|DRUG|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with SGB, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for SGB. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214920291|NCT06176404|BEHAVIORAL|Rehabilitation therapy|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
214920292|NCT06023446|DIAGNOSTIC_TEST|Optical Coherence Tomography|The retina is imaged using infrared light. Images collected in light are compared to those collected in darkness to extract information about function.
214920293|NCT00445172|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin twice a week.
214920294|NCT06437795|DIAGNOSTIC_TEST|Dry Needling Group|Participants in this group will receive dry needling therapy. This involves inserting thin needles into trigger points in the piriformis muscle to relieve pain and muscle tension. The therapy will be administered twice a week for 4 weeks, with each session lasting approximately 30 minutes.
214920295|NCT06437795|OTHER|Cupping Therapy Group|Participants in this group will receive cupping therapy. This involves placing cups on the skin to create suction, which is believed to improve blood flow and reduce muscle tension. The therapy will be administered twice a week for 4 weeks, with each session lasting approximately 30 minutes.
214920296|NCT06387212|DRUG|35 kDa hyaluronan fragment HA35 injection|First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).
214920297|NCT06575114|OTHER|Self-determination theory-based health education measures|In the control group, a conventional intervention will be used, and health education brochures on the COVID-19 vaccine will be distributed for the study participants to read on their own time. The intervention group will receive self-determination theory-based interventions, with targete interventions proposed based on the self-determination theory-including health-related talks and sharing sessions. To ensure that older individuals with varying levels of literacy understood the intervention, the process will be conducted in the local native dialect.
214320882|NCT05747066|OTHER|No intervention|No intervention
214320883|NCT04976530|DEVICE|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
214484394|NCT06882239|OTHER|Standard Physical Therapy|The cervical therapy for standard Physical Therapy will be based on impairments found but could include cervical and or thoracic manual therapy, exercises to improve segmental range of motion, exercises for cervical and axioscapular neuromotor retraining, and specific cervical related sensorimotor control exercises such as proprioceptive retraining. A home program of exercises tailored for the individual will be provided.
214484395|NCT06884475|PROCEDURE|Implantoplasty|Following clinical and radiographic examinations and thorough case planning, surgical procedures were performed under local anesthesia by a operator. After, anesthesia, surgical access will be performed for debridement and implantoplasty of the affected dental implant.
214484396|NCT06884475|PROCEDURE|Surgical access|Following clinical and radiographic examinations and thorough case planning, surgical procedures were performed under local anesthesia by a operator. After, anesthesia, only surgical access will be performed for debridement without implantoplasty of the affected dental implant.
214484397|NCT06881407|DEVICE|Robot|This robot will serve as a cheerleader and coach to provide encouragement and feedback.
214484398|NCT06881407|DEVICE|Virtual Reality|Our developed Super Pop VR system will be used to provide virtual reality intervention.
214672042|NCT02797873|OTHER|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
214672043|NCT02797873|BEHAVIORAL|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
214320884|NCT04976530|DEVICE|Sham comparator|Sham comparator in similar position to the investigative device, but NOT integrated into the cardiopulmonary (CPB) circuit
214920298|NCT06524934|DEVICE|Use of virtual reality during the hysteroscopic procedure|In VR group patients underwent hysteroscopy with standard care but the addition of VRT provided by a VR headset and headphones with the use of a Hypno VR software.
214920299|NCT03507322|OTHER|Ultrasound texturization|Along several visits to the clinic, the patients will be subjected to 2D/3D ultrasound scanning.
214920300|NCT03854825|PROCEDURE|Cardiac surgery|
214920301|NCT05423535|DEVICE|test group: collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland)|Following tooth extraction and wound debridement, the alveolar socket was filled with collagen-enriched deproteinized bovine bone mineral (C-DBBM, Bio-Oss Collagen® 100 mg or 250 mg, Geistlich Pharma AG, Wolhusen, Switzerland) up to the level of the oral bone crest. Subsequently, a collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland) or gelatin spons (Spongostan Dental® 1x1x1 cm, Ethicon, Johnson \& Johnson, New Brunswick, VS) was sutured on top with 4 to 6 single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to protect the underlying C-DBBM.
214920302|NCT00665262|DRUG|tramacet|2 tablets every 6 hours for 5 days
214920303|NCT06348030|DEVICE|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
214920304|NCT06348030|DEVICE|Vessel Sealer Extend Energy Device and SureForm Stapler|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
214920305|NCT01892410|OTHER|Cetaphil Restoraderm Skin Restoring Body Wash|Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
214920306|NCT02337439|BEHAVIORAL|Sensory Information Processing Training|Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
214920307|NCT02337439|BEHAVIORAL|Active Control Training|Commercially available educational software
214920308|NCT02696538|OTHER|Functional Gait Assessment|Balance assessment
214920309|NCT02696538|OTHER|mini-Balance Evaluation Systems Test|Balance assessment
214920310|NCT02696538|OTHER|Berg Balance Scale|Balance assessment
214920311|NCT05938764|BEHAVIORAL|MICRA|see earlier description
214920312|NCT05938764|BEHAVIORAL|TAU|see earlier description
214320885|NCT05791461|BEHAVIORAL|MARS (Measures Against Work-related Stress)|"The stress management intervention is based on cognitive behavioral therapy and aims to change the way patients perceive and cope with stressful situations at work.~It is group sessions over 3 months with approximately 9 participants. Participants meet 9 times (once a week the first 3 weeks and once every second week the last 5 times) and for a follow-up session 3 months after the intervention has ended. Each session lasts for 3 hours and is led by a trained psychologist. The participants perform tasks at home between the sessions. In the first session the rationale behind the intervention is introduced. In session 2 and 3 the patients work with enhancing self-regulation. In session 4 and 5 the focus is on modifying intermediate beliefs. In session 6 the focus is on improving interaction. Session 7 and 8 focuses on consolidation of learning and strategies to prevent relapse, and session 9 is a follow-up session 3 months after the intervention has ended."
214320886|NCT06183320|PROCEDURE|Restoration with Incremental Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, proximal wall will be completely restored with Vittra APS composite resin, using the triangular incremental traditional technique described for classe II restorations. Then, Opus Bulk Fill Flow APS will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
214320887|NCT06183320|PROCEDURE|Restoration with Bulk Fill Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, Opus Bulk Fill Flow APS resin will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
214320888|NCT04561986|DRUG|Tocilizumab|Tocilizumab is a recombinant humanized monoclonal antibody directed against the human interleukin-6 (IL-6) receptor
214320889|NCT06775678|RADIATION|Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy|Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy
214320890|NCT06775678|RADIATION|Conventional fractionated radiotherapy|Conventional fractionated radiotherapy
214320891|NCT05545735|DRUG|Standard of Care Antibiotic Therapy|Antibiotics will be administered as per the standard of care orally via tablet
214320892|NCT05462600|OTHER|Position change|Distribution of ventilation, respiratory drive, pulmonary mechanics and gas exchange will be measured in 3 unique positions: prone, head of bed (HOB) flat (i.e. 0 degrees) and HOB elevated (i.e. 30 degrees).
214320893|NCT04448717|DIAGNOSTIC_TEST|COVID-19 Antibody testing|COVID-19 Antibody testing in venous blood and/or saliva samples.
214320894|NCT02983383|PROCEDURE|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
214320895|NCT02983383|PROCEDURE|spinal anesthesia|Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
214320896|NCT05847569|BIOLOGICAL|Belantamab Mafodotin|Given IV
214320897|NCT05847569|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214320898|NCT05847569|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
214320899|NCT05847569|PROCEDURE|Bone Marrow Biopsy|Undergo biopsy
214320900|NCT05847569|PROCEDURE|Computed Tomography|Undergo CT scan
214320901|NCT05847569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
214484399|NCT06879821|OTHER|high intensity functional training|The pillar of rehabilitation will be based on high intensity functional training. 45-minute sessions divided into 5 minutes of warm-up, 35 minutes of functional exercises, and 5 minutes of going back to bed and cooling down. The 35 minutes of exercises were divided into 3 categories: lower extremity exercises, upper extremity exercises, and static and dynamic coordination and balance exercises. Each category will consist of 3 exercises per session, performing 2-3 series with a maximum of repetitions of 10-RM. The progression of the load will be progressively increased in weeks 3, 5 and 8 between 40-60% of the 1-RM.
214484400|NCT06887127|DRUG|TLL-018|TLL-018 20 mg BID for 78 weeks
214484401|NCT06886074|DRUG|Short course of blinatumomab|"Patients will receive 175 mcg of blinatumomab trough out seven days in a 24-hours infusion.~Blinatumomab therapy will be assigned 17.5 mcg per day for the first 2 days. Then blinatumomab 28 mcg per day for 5 days (completing 7 days). A single intravenous 20 mg dose of dexamethasone will be applied one hour before starting dose."
214484402|NCT06885541|DIAGNOSTIC_TEST|Detection of objective internal tremors|head-mounted motion sensors
214920313|NCT05021679|OTHER|AMP Implementation|Each study site will implement the Johns Hopkins AMP program at different times. The AMP program includes nursing staff training on the goals of AMP, how to complete mobility-focused outcome measures, set mobility goals, and to safely mobilize/ambulate patients. The AMP program also includes embedding these outcome measures and mobility goals into electronic medical records and producing weekly/monthly reports that show how often nursing staff score patient mobility and help patients meet daily activity goals.
214920314|NCT06389760|DRUG|Nimotuzumab|When combined with the mFOLFIRINOX regimen, nimotuzumab (nimo) will be administered at a dose of 400mg on Day 1 and 15 of a 28-day cycle (6 cycles). When combined with the GX regimen, nimotuzumab will be given at 400mg on Day 1 and 8 of a 21-day cycle (8 cycles).
214320902|NCT05847569|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214320903|NCT05524545|DRUG|Evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
214320904|NCT05524545|DRUG|Enfortumab Vedotin|Nectin-4 directed antibody and microtubule inhibitor conjugate
214320905|NCT04744454|DRUG|Isauvuconazole group|Patients who are treated with Isavuconazole according to its protocol label.
214320906|NCT06068582|BEHAVIORAL|Strenghtening the brain|Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.
214672044|NCT02797873|OTHER|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
214920315|NCT06389760|DRUG|mFOLFIRINOX|Patients will receive mFOLFIRINOX as follows: Oxaliplatin 65 mg/m2 on Day 1 and 15 of a 28-day cycle; Irinotecan 130 mg/m2 on Day 1 and 15 of a 28-day cycle; Leucovorin(LV) 200 mg/m2 Day 1 and 15 of a 28-day cycle; 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day 1 and 15 of a 28-day cycle (6 cycles).
214920316|NCT06389760|DRUG|GX|Patients will receive GX regimen as follows: Gemcitabine 1000 mg/m2 on Day 1 and 8 of a 21-day cycle; capecitabine 2000 mg/m2 on d1-14 a 21-day cycle(8 cycles).
214920317|NCT02587390|DRUG|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
214320907|NCT06068582|BEHAVIORAL|Strengthening the mind|Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
214320908|NCT00931749|DEVICE|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
214320909|NCT00931749|DEVICE|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
214672045|NCT02797873|OTHER|Structural T2 MRI scan|See Detailed Study Description.
214672046|NCT02797873|OTHER|DTI MRI scan|See Detailed Study Description and Outcome Measures.
214672047|NCT02797873|OTHER|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
214672048|NCT03990948|OTHER|Blood sampling|Blood sample collection
214920318|NCT02587390|DRUG|Simvastatin 80 mg|2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
214920319|NCT03137472|DEVICE|Transcranial Magnetic Stimulation (TMS)|The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
214920320|NCT06413901|PROCEDURE|TIP|TIP hypospadias repair
214920321|NCT00970840|DIETARY_SUPPLEMENT|LNS-20gM or LNS-P&L|Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P\&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
214672049|NCT01508676|DRUG|Pennsaid|
214920322|NCT03095560|DEVICE|NIRVANA|Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.
214672050|NCT01508676|DRUG|Placebo (2.3% DMSO solution)|
214672051|NCT02333539|BEHAVIORAL|Adherence behaviors and recommendations for improvement.|
214672052|NCT02333539|BEHAVIORAL|Adherence behavior that needs improvement is targeted|
214672053|NCT06289725|DRUG|antiviral treatment|The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019
214672054|NCT05087186|BEHAVIORAL|Guided imagery and FLASH technique|"Five virtual group sessions delivered by psychological therapists;~* Sessions 1 and 2: Guided imagery~* Sessions 3 and 4: FLASH technique~* Session 5: Refresher on guided imagery and FLASH technique"
214320910|NCT05798390|DRUG|Bempedoic acid and/or its fixed dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided as part of this protocol to the patients. Medications will be as prescribed by the treating physician in line with clinical practice.
214320911|NCT04741165|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
215061722|NCT05771129|DEVICE|Pulse electric field ablation system developed by Zhouling (Shanghai) Medical Appliance Co., Ltd.|Pulsed electric field ablation instrument is a therapeutic instrument based on the irreversible electroporation (IRE) mechanism. The high frequency short duration energy is delivered via a disposable pulse ablation catheter through the bronchoscope and act on the bronchial mucosa, through which goblet cell hyperplasia and airway mucus secretion will be alleviated. The entire treatment consists of two procedure sessions that will be performed one month apart. The first treatment procedure consists of a baseline biopsy of the airway mucosa followed by the treatment of the right lung. The second procedure consists of a biopsy of the treated airway, followed by the left-side treatment. A third bronchoscopy will be performed three months following the first treatment and mucosa-biopsy will be conducted to evaluate the histopathological change in mucus producing cells after treatment. Subjects will also be required to fill questionnaire and complete several examinations during follow-up.
214672055|NCT02532543|BIOLOGICAL|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
214920323|NCT06683326|DEVICE|ROKOKO smart-glove|ESD expert hands and fingers motion broadcasted by the ROKOKO smart-glove to trainees
214672056|NCT02532543|BIOLOGICAL|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
214672057|NCT02532543|BIOLOGICAL|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
214672058|NCT02532543|BIOLOGICAL|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
214672059|NCT00994565|BEHAVIORAL|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
214672060|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
214672061|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
214672062|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
214920324|NCT05040204|DIETARY_SUPPLEMENT|Monosaccharide Powder|Monosaccharide powder dissolved in water.
214920325|NCT05040204|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo (glucose powder)
214920326|NCT02924168|DEVICE|Active Radial Shockwave|Four weekly sessions of active radial shockwave treatment.
215061723|NCT02146131|DEVICE|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
214320912|NCT04741165|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
214320913|NCT04741165|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle
214320914|NCT05702216|OTHER|Rehabilitation|Hybrid approach in cardiac telerehabilitation. Patients underwent 20 cardiac rehabilitation sessions: alternatively, patients underwent 10 classical cardiac rehabilitation sessions in the clinic and 10 cardiac telerehabilitation sessions at home.
214920327|NCT02924168|DEVICE|Sham Radial Shockwave|Four weekly sessions of sham radial shockwave treatment.
214320915|NCT04222738|DIETARY_SUPPLEMENT|GINOFF1|The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
214320916|NCT06842875|BEHAVIORAL|RI-SPHERES|Participants assigned to the RI-SPHERES group will be introduced virtually or in-person to the care manager (CM), who demonstrate how to communicate directly with patients through the app for medical or non-medical needs. Each participant will learn how to obtain SMBP, sync the LTE-enabled BP cuff to the RI-SPHERES app, and respond to adaptive messaging pertaining to BP measurements, which include the ability to receive on-demand education on postpartum topics (e.g., HDP, breastfeeding, mood disorders) per participant preference. During the study period, the CM will respond to needs elicited from the SDoH screening by facilitating referrals to community resources. After six weeks, the focus of RI-SPHERES will transition to preventive care in addition to SMBP. The CM will engage monthly with each study participant to ensure they have a primary care provider and to facilitate preventive care visits or specialist appointments, if needed.
214320917|NCT06842875|BEHAVIORAL|Standard self-measured blood pressure program|Participants assigned to the routine care group meet virtually or in-person with a member of WIH's existing SMBP program and enroll in WIH's EPIC MyChart Portal to allow the SMBP program to receive patient-entered BP measurements and respond to messages. Participants will be provided with BP cuffs and taught how to obtain SMBP and report their BP through MyChart. At six weeks postpartum, WIH SMBP staff send a MyChart message to recommend BP ascertainment once per month and to describe the importance of attending a clinical visit with a primary care provider within a year of birth.
214320918|NCT00945503|DRUG|GSK1018921|GSK1018921 is a GT1 recepor antagonist
214320919|NCT03750903|BEHAVIORAL|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
214320920|NCT03750903|BEHAVIORAL|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
214320921|NCT06820203|DRUG|Fentanyl and Bupivacaine|Patients will receive premixed intrathecal fentanyl and bupivacaine in the same syringe.
214320922|NCT06820203|DRUG|Fentanyl and Bupivacaine|Patients will receive intrathecal fentanyl and bupivacaine in separate syringes.
214320923|NCT06820203|DRUG|Fentanyl and Bupivacaine|Patients will receive manually mixed intrathecal fentanyl and bupivacaine in the same syringe.
214320924|NCT06985901|PROCEDURE|Persistent atrial fibrillation ablation using Pulsed-field ablation|Pulmonary vein isolation with pulsed-field ablation coupled with 3D electroanatomic mapping. Follow-up with insertable cardiac monitor.
214320925|NCT05364008|DRUG|Green Tea Extract|Green tea extract 1650 mg/day (45% EGCG) along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
214320926|NCT05364008|OTHER|Placebo|Placebo 1650 mg/day along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
214320927|NCT06335407|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the Sub Lingual (SL) space.
214920328|NCT06968247|PROCEDURE|PROMise Model of Care|Patients will go for blood tests and be sent PROMs questionnaire prior to planned clinic appointments. The results of the blood tests and questionnaire will be reviewed by a physician. The physician will postpone patient's appointment if the patient is assessed as stable. Any physician-endorsed medication will be sent via a medication delivery service.
214920329|NCT02827825|OTHER|No intervention|No intervention. It's a study on retrospective Data
214920330|NCT06684158|DRUG|Mecapegfilgrastim|6 mg,HD d3,every 2weeks (Q2W)
214920331|NCT06684158|DRUG|Adebrelimab|Adebrelimab：1200 mg，iv d1，every2 weeks (Q2W)
214920332|NCT06684158|DRUG|Docetaxel|Docetaxel：50 mg/m2 iv gtt d1，every 2 weeks (Q2W)
214920333|NCT06684158|DRUG|Oxaliplatin|Oxaliplatin ：85 mg/m2 iv gtt d1，every2 weeks (Q2W)
214920334|NCT06684158|DRUG|5-Fluorouracil (5-FU)|5-FU ：2600 mg/m2 ，intravenous infusion， 24h ，d1，every 2 weeks (Q2W)
214920335|NCT06684158|DRUG|Leucovorin (LV)|LV：200 mg/m2 iv gtt d1，every 2 weeks (Q2W)
214920336|NCT05171036|OTHER|Adapted Physical Activity|"* Group 1 Maintenance of autonomy: Patients in group 1 have no cardiovascular disorders, possibly some cognitive deficits but do not reside in a protected unit.~* Group 2 Prevention of the risk of falls: Patients in group 2 have no cardiovascular problems, possibly some cognitive problems, but can finally follow the indications of the cognitive assessment in the form developped for the study.~* Group 3 Prevention of the risk of falls and monitoring of cardiovascular disorders in the absence of cognitive impairment: Patients in group 3 have had a recent, and currently stabilised, cardiovascular event that may justify exercise reconditioning.~* Group 4 Prevention of the risk of falls and disorientation in a context of cognitive deficit: Patients in group 4 have moderate to severe cognitive disorders, or have Alzheimer's disease or a related disease at a stage of the disease requiring special attention."
214920337|NCT05040425|DRUG|Zi-Yin-Liang-Ge-San|Zi-Yin-Liang-Ge-San is composed of five herb ingredients, namely Rx. Scutellariae (Huang Qin), Rx. Glycyrrhizae (Gan Cao), Hb. Dendrobii (Shi Hu), Rx. Ophiopogonis (Mai Men Dong), and Hb. Menthae Haplocalycis (Bo He). It is orally administrated trice daily from the first day to the end of RT in the treatment group, aiming to prevent and manage the OM. ZYLGS is manufactured as a concentrated herbal extract, constituted 4 g per packet, and origin from pharmaceutical companies in Taiwan with good manufacturing practice (GMP).
214920338|NCT04485325|DRUG|Tofacitinib|5 mg twice daily, p.o.
214920339|NCT04485325|BIOLOGICAL|Etanercept|50 mg once per week, s.c.
214920340|NCT00002943|DRUG|carboplatin|
214920341|NCT00002943|DRUG|cyclophosphamide|
214920342|NCT00002943|DRUG|etoposide|
214920343|NCT00002943|PROCEDURE|autologous bone marrow transplantation|
214920344|NCT05272293|BIOLOGICAL|NK cell infusions|Three doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).
214920345|NCT06968143|DEVICE|Smart Knee Implant|"An important advancement in objective recovery data occurred when the first ever 'smart' knee implant for remote therapeutic monitoring (RTM) after total knee arthroplasty (TKA) was released in 2021. The implant includes both a prosthesis for TKA and a stem, the latter of which records the following metrics: step count, distance traveled, tibial range-of-motion (ROM), functional ROM, average walking speed, stride length, and cadence. The implant sends the recordings to a mobile platform. Additionally, it collects and analyzes patient across the entire population of users and creates percentiles for each metric based on patient age, gender and time since surgery. These recovery curves provide more objective data for practitioners and patients to evaluate recovery progress and make adjustments to their care plans accordingly."
214920346|NCT06967038|BIOLOGICAL|CAR-NK cell|Chimeric Antigen Receptor Natural Killer Cell
214484403|NCT06883136|DRUG|Sintilimab+Cis-platinum/Carboplatin with Pemetrexed or Gemcitabine|"1. Sintilimab, 200mg, intravenous infusion on day 1 of each cycle, every 3 weeks as a cycle (Q3W), until disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new anti-tumor therapy, or termination of treatment for other reasons specified in the protocol; The longest treatment time of sintilimab was 24 months.~2. Chemotherapy regimen:~1\) Pemetrexed combined with platinum regimen (non-squamous cell carcinoma) : pemetrexed 500mg/m2, intravenous infusion on day 1 of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W) for a total of 4-6 cycles.~2\) Gemcitabine plus platinum regimen (squamous cell carcinoma) : gemcitabine 1000mg/m2 intravenously on days 1 and 8 of each cycle, cisplatin 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W) for 4-6 cycles."
214320928|NCT06335407|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space
214320929|NCT06636084|PROCEDURE|Guided bone regeneration (GBR)|A composite graft composed of a 50:50 proportion of autogenous bone and a demineralized bone mineral will be positioned around the bony defect or placed in the membrane, depending on the group randomization. The selected membrane will then be secured with screws to ensure a complete and stable coverage of the grafted area.
214320930|NCT06608758|BEHAVIORAL|Electonic health record prompts with education|"1). A baseline audit of diagnostic processes (including data from the Safer DX Checklist and CPT E/M code usage) for patients aged ≥ 3 to 89 years with one or more of 26 diagnoses prone to error to compare cases of PWD with specific disabilities (major mobility impairments,1 mental health concerns,2,3 severe visual impairments/ blindness,4 severe hearing loss/deafness,5 and IDD6,7) versus without the disabilities.~Using analyses of data, chart reviews, staff interviews and mock tracers, a frame of themes underlying increased risk of DE will be co-produced to develop algorithms to identify patients with the specified disabilities at risk. Case studies for education on DE, and EHR prompts, alerts, and decision supports related to the algorithms will be co-produced along with education on the EHR materials. Evaluate for change in use of diagnostic processes among PWD post implementation of algorithms and EHR prompts, alerts and decision supports will be conducted post-intervention."
214320931|NCT06608758|OTHER|Standard of care|Patients without disabilities will receive standard care related to electronic health record prompts, alerts, and decision supports.
214320932|NCT06592586|BIOLOGICAL|GBS-NN/NN2 vaccine|0.5 mL (50 μg GBS-NN +50 μg GBS-NN2 adsorbed to 0.5 mg aluminium as Alhydrogel®)
214320933|NCT00705107|BIOLOGICAL|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
214320934|NCT00705107|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
214320935|NCT01284283|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|For total ankle replacement
214320936|NCT00665600|DRUG|Levalbuterol HCl|Levalbuterol 0.63 TID
214320937|NCT00665600|DRUG|Levalbuterol HCl|Levabuterol 1.25 mg TID
214320938|NCT00665600|DRUG|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
214320939|NCT00665600|DRUG|Placebo|Placebo TID
214320940|NCT00417443|DRUG|Clonidine|
214484404|NCT06886724|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
214484405|NCT06886724|DIETARY_SUPPLEMENT|Placebo|The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
214484406|NCT06888440|PROCEDURE|scaling and zinc stents|this group will receive scaling and zinc containing stents
214484407|NCT06888440|PROCEDURE|scaling and placebo stents|this group will receive scaling and placebo stents
214672063|NCT06408831|BEHAVIORAL|Classroom Teaching University Students Intervention Group|Web-based cyber sexual violence training and counseling will be provided to female classroom teaching students, who are the intervention group, and the effect of the intervention on cyber sexual violence experience, sensitivity and cyber security will be examined.
214672064|NCT06002581|DEVICE|rTMS real stimulation stage1|In the first stage, the early treatment group use low-frequency rTMS real stimulation,
214920347|NCT05263271|DRUG|Gentulizumab|Gentulizumab will be administered by intravenous infusion once a week, with every 28 days as a dosing cycle .
214920348|NCT04418128|DRUG|Nafamostat Mesylate|The Nafamostat mesilate group received continuous intravenous infusion of 0.1-0.2 mg/kg/h of nafamostat mesilate mixed with 5% DW.
214920349|NCT05007028|DRUG|EMONO|Exposure to 1 hour of EMONO via facial mask
214920350|NCT05007028|DRUG|Medical Air|Exposure to 1 hour of Medical Air via facial mask
214920351|NCT05348291|DEVICE|ventilation tubes|Transtympanic pressure equalising devices.
214920352|NCT04203602|PROCEDURE|telepresence discharge|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
214920353|NCT04203602|OTHER|Conventional discharge|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
214920354|NCT05984940|DEVICE|Ortho MTA cement|Ortho MTA has a fine granularity for only 2 microns. It penetrates into dental tubules and fuses itself to the surface where it is applied. In addition, it prevents micro-leakage by forming an interfacing layer of hydroxyapatite (Hap) between the OrthoMTA and the canal wall.
214920355|NCT05984940|DEVICE|GP and AH Plus sealer|AH Plus Sealer is a calcium silicate-based root canal sealer. Tricalcium Silicate interacts with body fluids to release calcium and hydroxide ions that promote hydroxyapatite (HA) formation.
214920356|NCT05633940|BEHAVIORAL|Implementation of the service delivery model primary care behavioral health|The research project will study a real-world implementation of PCBH in routine primary care. The implementation is facilitated by a regional implementation group of psychologists with special training in PCBH. The active implementation period for each intervention center is 12 months, where continuous support, materials and training are offered by the implementation group.
214920357|NCT03265951|DRUG|Ramelteon|8 mg once daily administered within 30 minutes of bedtime
214920358|NCT03265951|OTHER|Usual Care|education brochure about sleep hygiene
214920359|NCT01437254|DRUG|CPERT|Single 340 MBq CPERT scan in first 10 subjects
214920360|NCT01437254|DRUG|GPERT|Single 340 MBq GPERT scan in up to 20 case-matched controls
214672065|NCT06002581|DEVICE|rTMS shame stimulation stage1|In the first stage, the control group (delayed treatment group) all use sham stimulation.
214672066|NCT06002581|DEVICE|rTMS real stimulation stage 2|In the second stage, both the early treatment group and the control group (delayed treatment group) will be treated with true stimulation low-frequency rTMS.
214672067|NCT03186469|BEHAVIORAL|Safety Baby shower|"A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged."
214920361|NCT00955955|OTHER|6(S)-5-MTHF(Deplin)|Deplin is a medical food. Patients will take 15 mg/day of deplin.
214920362|NCT00955955|OTHER|Placebo|Inactive substance
214920363|NCT01312883|BEHAVIORAL|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
214920364|NCT05169242|PROCEDURE|Endoclip|In the intervention arm, one or more endoclips will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
215061724|NCT02146131|DEVICE|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
215061725|NCT04895930|DRUG|Furmonertinib|80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).
215061726|NCT04895930|DRUG|Anlotinib|10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).
215061727|NCT02567799|DRUG|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
215061728|NCT02567799|DRUG|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
215061729|NCT02567799|DRUG|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart."
215061730|NCT02567799|RADIATION|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
214920365|NCT01385969|DEVICE|Standard inflation of LMA cuff|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.
214920366|NCT01385969|DEVICE|Pressure check with syringe recoil|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil
214920367|NCT01385969|DEVICE|Pressure check by pressure transducer|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
214920368|NCT04046770|DEVICE|Drug administration and Flushing procedure using Double-Chamber Syringe|The new device will allow the professional to conduct all the procedure (assure the patency/enables the pre-flushing), drugs administration and flushing, using only one device.
215061731|NCT01656707|BEHAVIORAL|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
215061732|NCT01656707|BEHAVIORAL|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
215061733|NCT05449041|DEVICE|Bulbicam|Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size
215061734|NCT00364650|DRUG|Probiotic Supplement|2 capsules twice daily
215061735|NCT00364650|OTHER|Placebo|placebo
215061736|NCT03221465|BEHAVIORAL|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
215061737|NCT03221465|BEHAVIORAL|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
215061738|NCT02781571|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
215061739|NCT00348998|BIOLOGICAL|bevacizumab|
215061740|NCT00348998|DRUG|bicalutamide|
215061741|NCT00348998|DRUG|goserelin acetate|
215061742|NCT00348998|RADIATION|radiation therapy|
215061743|NCT00311025|PROCEDURE|intensive endurance, strength and balance exercises|
215061744|NCT04476446|DRUG|Esketamine|Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
215061745|NCT00349349|DRUG|ofatumumab|Intravenous infusion
214920369|NCT04046770|DEVICE|Drug administration and Flushing procedure using Classic Syringe|To fully complete the intravenous drug administration with rigor, nurses should flush the catheter pre, post and inbetween drug administration. This implies the use of two or three syringes.
214920370|NCT03973411|DRUG|Prophylactic ondansetron|Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
214920371|NCT03973411|DRUG|Placebo|Pacients will receibe standard spinal anesthesia
214920372|NCT03703583|OTHER|There is no intervention in this observational study.|There is no intervention in this observational study.
214920373|NCT03423173|BIOLOGICAL|TAK-003|TDV subcutaneous injection
214920374|NCT03423173|BIOLOGICAL|Placebo|TDV Placebo-matching normal saline (0.9% NaCl) subcutaneous injection
214920375|NCT02920008|DRUG|guadecitabine|In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m\^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.
214920376|NCT02920008|DRUG|Treatment Choice (TC)|"* High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).~* Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.~* Best Supportive Care (BSC)."
214920377|NCT01553604|PROCEDURE|augmentation mammaplasty|Dressing is removed on the first postoperative day
214920378|NCT01553604|PROCEDURE|augmentation mammaplasty|Dressing is removed on the 6th postoperative day
214920379|NCT02737930|DRUG|Fluoxetine|
214920380|NCT02737930|DRUG|Placebo|
214920381|NCT02041117|DRUG|Rosuvastatin|Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
214920382|NCT03169881|DRUG|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
214920383|NCT03169881|DRUG|Placebo|normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
214920384|NCT03852264|BEHAVIORAL|Pet dog|Children will interact freely with their pet dog for 25 minutes.
214920385|NCT03852264|BEHAVIORAL|Unfamiliar dog|Children will interact freely with an unfamiliar dog for 25 minutes
214920386|NCT03852264|BEHAVIORAL|Nonsocial control|Children will play with age-appropriate toys/games for 25 minutes.
214920387|NCT00795470|DRUG|Antimicrobial|Appropriate antimicrobial based on urine culture results
214920388|NCT00795470|DEVICE|Catheter change|Change urine catheter
214920389|NCT01094158|DRUG|Aramchol|100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
214920390|NCT01094158|DRUG|Aramchol|300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
214920391|NCT01094158|DRUG|Placebo|tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
214920392|NCT04246216|PROCEDURE|Percutaneous Electrical Nerve Stimulation|Experimental: Percutaneous Electrical Nerve Stimulation The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
214920393|NCT04246216|PROCEDURE|Endoscopic surgery of the carpal tunnel|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
214920394|NCT01631149|DRUG|Surgical block (rocuronium; atracurium/mivacurium)|The surgical block will be varied by either induction of a deep block (via rocuronium infusion) or a moderate/normal block (using atracurium/mivacurium infusion)
214920395|NCT01631149|DRUG|Surgical block (rocuronium; atracurium/mivacurium)|A surgical block will be induced by infusion of either rocuronium (deep block) or atracurium/mivacurium (normal/moderate block)
214920396|NCT02181582|DRUG|Emapunil|Single peroral administration
214920397|NCT02181582|DEVICE|PET|Positron emission tomography, which creates images by detecting radioactivity.
214920398|NCT02557802|BIOLOGICAL|Fluenz Tetra|Intranasal spray, 0.2 ml dose
214920399|NCT02557802|BIOLOGICAL|Fluarix Tetra|Intramuscular injection, 0.5 ml dose
214920400|NCT04614181|DIETARY_SUPPLEMENT|Nestle Resource drink|Beverage (Nestle RESOURCE). Each serving is 237ml containing 53.6g of carbohydrate and 9g of protein. Intervention group will consume two servings of the carbohydrate beverage (53.6g each, total of approximately 100g) on the day before surgery and one serving up to 6 hours prior to scheduled surgery time.
214920401|NCT04614181|OTHER|Usual care|Usual fracture care as determined by clinical team
214920402|NCT01665950|DRUG|Simvastatin|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
215061746|NCT02991898|BIOLOGICAL|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion."
215061747|NCT02840942|BEHAVIORAL|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
215061748|NCT02840942|BEHAVIORAL|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
215061749|NCT00861692|DRUG|argatroban|
215061750|NCT01543282|DEVICE|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
215061751|NCT00061854|DRUG|soblidotin|
215061752|NCT02122666|PROCEDURE|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
215061753|NCT06291337|DRUG|Inhibition of Sweet Taste by Ibuprofen Oral Rinses|Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
214320941|NCT06988332|BEHAVIORAL|Problem Management Plus (PM+)|"Problem Management Plus (PM+) will be delivered according to the Spanish version of the WHO protocol (OMS, 2016).~PM+ is a low-intensity, transdiagnostic psychological intervention based on Cognitive Behavioral Therapy (CBT). The protocol incorporates evidence-based strategies, including problem-solving, stress management, behavioral activation, and accessing social support.~The intervention consists of five individual 90-minute sessions provided by healthcare professionals without previous expertise in mental health care (WHO, 2018). PM+ helpers will be supervised by master trainers specifically trained for Chile.~Two systematic reviews have demonstrated the effectiveness of PM+ in reducing symptoms of common mental disorders, such as depression and anxiety (Schäfer et al., 2023) and specific symptoms of post-traumatic stress (Akhtar et al., 2022)."
214920403|NCT01665950|DRUG|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
214920404|NCT05635435|OTHER|Detection of Immune and Inflammatory Indices in Peripheral Blood|We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.
214920405|NCT01581242|DRUG|Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil|Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15
214320942|NCT05651711|DRUG|Rocatinlimab|Rocatinlimab will be administered through a subcutaneous (SC) injection.
214320943|NCT05651711|OTHER|Placebo|The matching placebo will be administered through a SC injection.
214320944|NCT06992726|DIETARY_SUPPLEMENT|Fish oil intervention|The diet was based on the principles of a balanced diet, and subjects in this group were additionally supplemented with n-3 PUFA (provided as 1.36 g fish oil capsules), with the rest of the intervention being the same as in the control group.
214320945|NCT06992726|OTHER|Placebo intervention|Diet based on the principles of a balanced diet, taking placebo capsules with the same appearance and odor as the fish oil capsules.
214320946|NCT02132585|PROCEDURE|Speckle tracking echocardiography|
214320947|NCT06923319|DEVICE|Odòn, Kiwi, Simpson skills|time 0, time 1 month and 2 months
214320948|NCT05255588|DEVICE|EarlyTect® CRC test|A highly accurate and sensitive real time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE/qMSP) for measuring SDC2 methylation in stool DNA to detect CRC.
214320949|NCT01168024|DEVICE|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
214920406|NCT01581242|DRUG|Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;
214920407|NCT01581242|DRUG|Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15
214920408|NCT03961958|DRUG|Propofol reduction|Reduction of propofol target concentration
214920409|NCT06140758|DRUG|Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
215061754|NCT06291337|DRUG|Inhibition of Sweet Taste by Naproxen Oral Rinses|Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
215061755|NCT05441215|DRUG|nirmatrelvir|nirmatrelvir/ritonavir
215061756|NCT05441215|DRUG|ritonavir|nirmatrelvir/ritonavir
215061757|NCT05602454|OTHER|Digital Heart Failure Medication Titration|Story Health Platform, which is a remote, digital tool that provides treating clinicians collected data to make clinical decisions regarding heart failure medication titration.
215061758|NCT05111002|DRUG|Lefamulin|600mg tablet orally twice daily
215061759|NCT05111002|DRUG|Doxycycline|100mg tablet orally twice daily
215061760|NCT04380753|DRUG|AMG 510|Subjects will be enrolled and will receive AMG 510 PO QD.
215061761|NCT03644225|DEVICE|Measurment with Aspirational Medical Device|The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
214320950|NCT01168024|OTHER|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
214320951|NCT06625047|BEHAVIORAL|Assessment|Complete in-person assessment visits
214320952|NCT06625047|OTHER|Questionnaire Administration|Ancillary studies
215061762|NCT03644225|DEVICE|Measurment with Cutometer MPA 580|The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
215061763|NCT05964348|PROCEDURE|CT-Scan|semi-automated analyse by anatomical landmarks with a dedicated fully automated software
215061764|NCT03913013|BEHAVIORAL|Family-Focused Treatment with MCC App|12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
215061765|NCT05148650|DIAGNOSTIC_TEST|Standard laboratory coagulation tests and rotational thromboelastometry measurements|"Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM."
215061766|NCT00972517|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Three intramuscular injections
215061767|NCT00542126|DRUG|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
215061768|NCT04486547|BEHAVIORAL|Information-Motivation-Behavioral Skills model-based intervention|Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
215061769|NCT05712980|DEVICE|Implanted pulse generator for SCS with different programming modalities|"Surgical technique~Patients recruited will be scheduled for the implantation of the SCS system in two phases. The implant procedure will be performed following our standardized clinical practice under local anesthesia and moderate sedation.~Clinical parameters~Clinical evaluation of study subjects shall include, in addition to demographic parameters, the assessment of parameters related to pain experience, disability, quality of life, as well as other psychological variables. All these parameters will be evaluated at different times of the study.~Sample processing~10 ml of peripheral blood will be obtained per venopuncture at different moments, always at the same time of day and in the same anatomical location.~Expression arrays~After a manual removal of RNA the expression arrays and the scanning of the crystals will be carried out after hybridization"
215061770|NCT00132990|DEVICE|Deep brain stimulation|
215061771|NCT03841851|PROCEDURE|sub epithelial connective tissue graft|"* Local anesthesia will be injected intra-orally at the implant site.~* Atraumatic extraction of badley decayed teeth in the aesthetic area traditional drilling for immediate implant placement .~* immediate temporization .~* subepithelial connective tissue graft from the palate"
215061772|NCT02229708|BEHAVIORAL|Healthy Lifestyle Group|
215061773|NCT00851890|DRUG|ABT-333|50 mg capsules
215061774|NCT00851890|OTHER|Placebo for ABT-333|Capsule
215061775|NCT00851890|DRUG|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
215061776|NCT00851890|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
215061777|NCT05963243|OTHER|Ultrasound Scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
215061778|NCT04171505|DRUG|HPV vaccine|". Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account."
215061779|NCT03135431|PROCEDURE|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
215061780|NCT03135431|PROCEDURE|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
215061781|NCT01941381|PROCEDURE|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
214320953|NCT06625047|OTHER|Telemedicine Visit|Complete telehealth assessment visits
214320954|NCT06625047|DRUG|Temozolomide|Given PO
215061782|NCT00002108|DRUG|Lamivudine|
215061783|NCT00002108|DRUG|Zidovudine|
215061784|NCT02518165|DIETARY_SUPPLEMENT|Proprietary spearmint extract|Water extracted spearmint extract
215061785|NCT02518165|OTHER|Placebo|Microcrystalline Cellulose
214320955|NCT06875908|OTHER|Turkish Validity and Reliability of The GSDS-T in patients with multiple sclerosis|The aim of this study is to investigate the validity and reliability of the Turkish version of general sleep disturbance scale (GSDS-T) in patients with multiple sclerosis. It has 21 questions. This study will be conducted on patients with multiple sclerosis. In order to evaluate the validity of the GSDS-T, the Pittsburgh Sleep Quality Index (PSQI) which can evaluate sleep quality and has been validated in Turkish, will be used. Scales will be repeated after 15 days to assess test-retest reliability.
215061786|NCT00482040|DEVICE|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
215061787|NCT02997696|DRUG|ONO-4474|
215061788|NCT02997696|DRUG|Placebo matching ONO-4474|
215061789|NCT04054921|DRUG|PTG-300|PTG-300 is a hepcidin Mimetic
215061790|NCT02709577|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
214320956|NCT02198911|OTHER|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
214320957|NCT02198911|OTHER|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
214320958|NCT02198911|OTHER|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
214320959|NCT04436042|DEVICE|MyHand Device|These subjects may be asked to attend 1-40 sessions (approximately 90 mins) to trial a variety of device controls and/or components.
214320960|NCT06880679|DEVICE|Point of Care Ultrasound|Point of Care Ultrasound during hospitalization
214320961|NCT06890481|DEVICE|Upper-limb planar robotic intervention|"The training sessions consist of three phases.~In the first, the therapist provides the patient with the necessary information for the session.~In the second, patients undergo a pre-scenario phase, in which the parameters of the robot (ratio between virtual and physical space, viscosity, and weight) are adjusted.~In the third phase, the scenario is used for motor and cognitive exercise.~Specifically, the scenario consists of a reaching exercise involving sequential stimuli placed in different spatial areas. The scenario has adaptive characteristics regarding:~* Type of stimuli~* Size of the stimuli~* Visual and auditory cues~* Number of stimuli, related to the space in which they are displayed.~Each of these characteristics is adjusted differently according to the scenario's difficulty level. Regardless of the difficulty level, the scenario provides assistance as needed through a guided path (both visual and movement-based) toward the target."
214320962|NCT06735222|DIETARY_SUPPLEMENT|Hydroxytyrosol acetate (HT-Ac)|Hydroxytyrosol acetate (15 mg) orally co-administered with 2 g EPA
214320963|NCT06735222|DIETARY_SUPPLEMENT|Hydroxytyrosol eicosapentanoate (HT-EPA)|Oral intake of hydroxytyrosol eicosapentanoate (15 mg) solubilized in an EPA-enriched oil matrix.
214320964|NCT06735222|DIETARY_SUPPLEMENT|Oleacore®|Oleacore® (containing 15 mg of hydroxytyrosol) orally co-administered with 2 g EPA
214320965|NCT06893627|BEHAVIORAL|Body Project|Dissonance-based, online, peed-led eating disorder prevention intervention, consisting of 4 x 1 hour with a week a part.
214920410|NCT06140758|DRUG|Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
214920411|NCT06140758|DRUG|Toms of Maine 0 ppm Fluoride Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
214920412|NCT06140758|DRUG|Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
214920413|NCT06140758|DRUG|1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
214920414|NCT06140758|DRUG|1100 ppm (0.454% Stannous fluoride) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
214920415|NCT00116155|BIOLOGICAL|CV787 (CG7870)|
214920416|NCT00878202|DEVICE|SCAD information system|Clinical follow-up and continuation of therapeutic education by telemedicine during 3 months
214920417|NCT04879121|DRUG|Larotrectinib Sulfate|Given PO
214920418|NCT05265442|DRUG|Methadone|titration of Zoryon (methadone): increase of posology untill pain relieved is reached
214920419|NCT05334485|DRUG|Pyridostigmine Bromide|Oral 60mg pyridostigmine bromide
214920420|NCT05334485|OTHER|Placebo|Oral starch placebo
214920421|NCT00832871|DRUG|Mifepristone|Mifepristone 200 mg will be administered orally
214920422|NCT06685328|PROCEDURE|minimal posterior pole vitrectomy combined with a sodium hyaluronate gel-covered internal limiting membrane(ILM) flap with balanced saline filling and postoperative supine position|Vitrectomy of the posterior pole within the vascular arch was performed by a standard 25G ciliary flattening three-way tract procedure, followed by injection of a small amount of tretinoin suspension (TA) to mark the posterior vitreous cortex, which was excised. The inner limiting membrane (ILM) of the macular surface was stained with indocyanine green (ICG, 2.5 mg/ml), and the ILM around the hole was peeled off, leaving a semicircular piece of ILM attached to the hole, and then the single ILM flap was folded and covered with MH. 0.2 to 0.3 mL of hyaluronic acid gel (Bausch \& Lomb, Iviz) was injected over the inverted ILM flap using perfluorocarbon liquid for complete coverage. The perfluorocarbon liquid was aspirated. Postoperatively, the patient was advised to remain in a non-emergent supine position for 24 hours.
214920423|NCT06685328|PROCEDURE|Conventional vitrectomy combined with inner limiting membrane flap flip coverage with sterile air filling and postoperative prone position|A standard 25G ciliary flattening three-way tract procedure was taken to perform posterior and midperipheral vitrectomy, followed by injection of a small amount of tretinoin (TA) to label the posterior vitreous cortex and excision of the posterior vitreous cortex within the vascular arch. The ILM on the macular surface was stained with indocyanine green (ICG, 2.5 mg/ml), and the peripapillary ILM was peeled off with forceps, leaving a semicircular piece of ILM attached to the foramen ovale, and the individual ILM flaps were then turned over and covered with MH. Air-liquid exchange was then performed and subsequent surgery was routinely performed according to existing surgical concepts. Ultrasonic emulsification and IOL implantation were selectively performed depending on the extent of the cataract and the patient's surgical needs. Antibiotic ointment is applied at the end of the procedure. After surgery, patients were advised to remain in strict prone position for 3 days.
214920424|NCT04762615|DIAGNOSTIC_TEST|AMH level measurement|AMH level measurement using ELISA test from blood samples
214920425|NCT06083961|DRUG|Alirocumab|Initial alirocumab, single dose of 300mg, subcutaneous injection
215061791|NCT02709577|OTHER|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
214920426|NCT05214183|DRUG|Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma|Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab
215061792|NCT04453826|DRUG|Camrelizumab plus chemo-radiotherapy|"1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.~2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~3. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~4. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
215061793|NCT04453826|DRUG|Chemo-radiotherapy alone|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
214320966|NCT06893627|BEHAVIORAL|Expressive writing|Participants are encouraged to write about their body 40 min. per week
214320967|NCT06894836|BEHAVIORAL|Third wave VR therapy|All participants in this trial will receive the VR intervention which is adapted from third wave CBT protocols (including mindfulness and Acceptance and Commitment Therapy) and focuses on decentering-the ability to step back and view thoughts and emotions as temporary, objective events rather than identifying with them. Decentering has been linked to improved emotional regulation, reduced rumination, and better psychological flexibility, which in turn can lead to improvements in depression and anxiety symptoms. The intervention is clinician-delivered in a clinical setting, one-on-one, over 4-5 sessions (60 min each) across 10-12 weeks. Each session includes psychoeducation, a 15-minute VR experience, and debriefing. Sessions cover three core techniques targeting improvement in decentering ability: 1) arousal reduction via controlled breathing, 2) sitting with discomfort without reacting, and 3) cognitive defusion by changing perception of negative thoughts.
214672068|NCT03186469|BEHAVIORAL|Standard of Care|Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
215061794|NCT05799391|DRUG|SJC|Soothing cream jel
215061795|NCT05799391|OTHER|Placebo|Placebo cream jel
215061796|NCT02477917|BIOLOGICAL|Allergovac depot with Parietaria judaica pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
214672069|NCT00002208|DRUG|Indinavir sulfate|
215061797|NCT03538886|PROCEDURE|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
215061798|NCT03538886|PROCEDURE|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
215061799|NCT02044224|DRUG|Dexmedetomidine|"Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required"
214672070|NCT00002208|DRUG|Lamivudine|
214920427|NCT06683066|DRUG|Triprorelin for injection|Specification: Triprorelin for injection 3.75mg. Produced and supplied by Qilu Pharmaceutical Co.
214920428|NCT06683066|DRUG|Diphereline|Specification: Diphereline 3.75mg. Produced by Ipsen Pharma Biotech and supplied by Qilu Pharmaceutical Co.
214920429|NCT00729157|RADIATION|Fludeoxyglucose F-18|Correlative studies
214920430|NCT00729157|OTHER|Laboratory Biomarker Analysis|Correlative studies
214920431|NCT00729157|OTHER|Pharmacological Study|Correlative studies
214920432|NCT00729157|PROCEDURE|Positron Emission Tomography|Correlative studies
214920433|NCT00729157|BIOLOGICAL|Ziv-Aflibercept|Given IV
215061800|NCT02509364|OTHER|No intervention|
215061801|NCT03226327|DIETARY_SUPPLEMENT|formula salt with very low sodium (Brand name: Manlikang)|hypertension patients will use the formula salt with very low (\<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
215061802|NCT00375674|DRUG|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
215061803|NCT00375674|OTHER|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
214920434|NCT04644926|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
214920435|NCT05708157|DRUG|concomitant intranasal antihistamine and corticosteroid|concomitant intranasal administration with antihistamine and corticosteroid
214920436|NCT01335048|DRUG|atorvastatin and clopidogrel|Atorvastatin 80 mg daily + clopidogrel 150 mg daily
214920437|NCT01335048|DRUG|Clopidogrel|Clopidogrel 150 mg daily
214920438|NCT02217410|BIOLOGICAL|CFZ533|
214920439|NCT02217410|DRUG|Tacrolimus (Tac)|
214920440|NCT02217410|DRUG|Mycophenolate mofetil (MMF)|
214920441|NCT02217410|DRUG|Corticosteroids (CS)|
214920442|NCT02217410|BIOLOGICAL|anti-IL2 Induction|
214920443|NCT01895881|DRUG|Estradiol|
214920444|NCT01895881|DRUG|Placebo|
214920445|NCT04703361|BIOLOGICAL|Placebo NaCl|Placebo
214920446|NCT04703361|BIOLOGICAL|Niacin|B3 vitamin, Niacin
214920447|NCT04703361|BIOLOGICAL|Na-3-OHB|Na-3-OHB
215061804|NCT03269539|OTHER|MRI Imaging|
215061805|NCT00298441|DRUG|chondroitin sulfate-iron colloid|
214320968|NCT06893393|DEVICE|Virtual travel-into-nature application Toujours Dimanche|The use of the virtual travel-into-nature application which features real natural environments from the Eastern Canada area.
214320969|NCT05677425|OTHER|Temperature measurement|Temperature measurement in the renal pelvis during ureteroscopic laser activation.
214320970|NCT06895759|DEVICE|Soda lime|Respiration into a snow air pocket through an experimental rebreathing circuit with the integration of a soda lime canister.
214320971|NCT06895759|DEVICE|Sham|Respiration into a snow air pocket through an experimental rebreathing circuit without the integration of a soda lime canister.
214320972|NCT06828419|DEVICE|Domestic single-port laparoscopic surgery system|The minimum distance of the single-port surgical system from the port is 5-7cm to obtain the instrument bending space. The load capacity of surgical tools is increased from 2N to 5N, which greatly improves the structural reliability. At the same time, it can realize 6 degrees of freedom movement。
214320973|NCT06897579|DRUG|Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule|Carboplatin for injection inhibits DNA synthesis, thereby preventing cancer cell division and reproduction/Cisplatin for injection binds to DNA, interfering with DNA replication and transcription processes, Thus inhibiting tumor cell proliferation/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Bemosubebezumab injection is a humanized recombinant anti-Programmed cell death ligand 1 (PD-L1) monoclonal antibody/Anlotinib hydrochloride capsule is a tyrosine kinase inhibitor.
214920448|NCT03055897|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
214920449|NCT03158480|BIOLOGICAL|DC-CIK immunotherapy|Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
214920450|NCT03758222|DEVICE|XFLO Expander System|Implantation and retrieval of the XFLO Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)
214920451|NCT06684210|PROCEDURE|Intercostal plane block of the external oblique muscle|Under ultrasound guidance, a single dose of 0.25% ropivacaine 20ml was given for bilateral intercostal muscle plane block of external oblique muscles
214920452|NCT06670508|PROCEDURE|Transversus Abdominis Plane block|Group A, The patient was in the supine position then; the TAP block was given by a high frequency linear ultrasound transducer (Siemens acuson x300 3-5MHz ultrasound). After skin preparation and isolation, the transducer was placed 2 cm sub-xiphoid, then moved along the subcostal edge to identify the rectus abdominis muscle and the transversus abdominis then, a blunted tip, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) was introduced in-plane 2-3 cm lateral to the transducer, under direct ultrasound visualization. After confirming the correct placement of the needle and the negative aspiration probe, the rest of the anaesthetic substance was injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine on each side after aspiration to avoid intravascular placement, and the dissection of the plane was observed. The block was performed bilaterally.
214920453|NCT06670508|PROCEDURE|Erector Spinae Plane block|Group B, the patient was placed in the prone position. Then, the Erector Spinae block was given by same ultrasound transducer . It was sagittaly placed against the target vertebral level (T7 transverse process) in the prone position and moved in approximately 3-cm lateral to the spinous process.. The Erector Spinae muscle and transverse process was identified, and a same blunted tip , 20-gauge, short bevel needle was advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane. The block was performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally.
214920454|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 0.25 µg/kg
214920455|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 0.5 µg/kg
214920456|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 0.75 µg/kg
214920457|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 1 µg/kg
214920458|NCT06685081|DRUG|lidocaine and triamcinolone|2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection
214920459|NCT06392113|BEHAVIORAL|ACTION FALLS|Falls prevention advice including booklet and videos
214920460|NCT00845208|BEHAVIORAL|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
214920461|NCT05229523|OTHER|repeated assessments|validity and reliability of the Modified Four Square Step Test (mFSST) in children with cerebral palsy with the tests of Pediatric Berg Balance Scale (PBSS), Timed Up and Go Test (TUG), Pediatric Functional Reaching Test (PFUT)
214920462|NCT00661609|DRUG|AZD4877|Intravenous (IV)25mg/weekly
214920463|NCT03025815|OTHER|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
214920464|NCT03025815|OTHER|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
214920465|NCT05940376|DRUG|rapid acting insulin|Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2°C) and, was provided by the cornea specialist and was self-administered by patients at a dosage of 1 eye drop 4 times daily. Treatment continued until NK healed and then tapered accordingly. Patients would discontinue topical insulin if the condition did not improve or worsen within 4 weeks. Patients were followed up daily and slit-lamp photographs were captured with and without fluorescein corneal staining.
214955230|NCT01909973|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
215061806|NCT03038971|BIOLOGICAL|Dose Level 1|Short and Tall Ragweed Mix
215061807|NCT03038971|BIOLOGICAL|Dose Level 2|Short and Tall Ragweed Mix
214320974|NCT06897579|DRUG|Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection|Carboplatin for injection inhibits DNA synthesis and thus prevents the division and reproduction of cancer cells/Cisplatin for injection binds to DNA and interferes with the DNA replication and transcription process, thereby inhibiting the proliferation of tumor cells/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Tislelizumab injection is a humanized recombinant anti-PD-1 monoclonal antibody.
214320975|NCT05980572|DRUG|Glenohumeral joint and subacromial space triamcinolone injections|"All patients will receive both glenohumeral joint and subacromial space injections. The injections will consist of a solution containing 1 ml of 40 mg/ml triamcinolone acetonide and 1 ml of 1% lidocaine in each site. The glenohumeral joint injection will be performed blindly using an anterior approach. The needle will be inserted medially to the head of the humerus, located approximately 1 cm lateral to the coracoid process, and directed posteriorly at a slight superior and lateral angle.~Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds."
214320976|NCT05980572|DEVICE|App-assisted exercise|Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds. Then the APP group will suggest performing the exercise from APP education The APP intervention group will be guided through the exercises using the mobile app, while the conventional group will be provided with a printed pamphlet illustrating the exercises.. Each set exercise will have 10 repetitions and investigators recommend 4 sessions per day.
214320977|NCT05980572|DRUG|Nonsteroidal anti-inflammatory drugs (aceclofenac)|All patients will be prescribed two weeks of nonsteroidal anti-inflammatory drugs (aceclofenac) .
215061808|NCT03038971|BIOLOGICAL|Placebo|Saline with 0.4% Phenol
215061809|NCT01922362|DEVICE|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
215061810|NCT01922362|DEVICE|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
215061811|NCT02474576|PROCEDURE|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
215061812|NCT04301661|OTHER|Blood collection|Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.
215061813|NCT04301661|DRUG|Abacavir/lamivudine|Participants who are already taking abacavir/lamivudine as part of standard HIV care will continue taking their therapy.
215061814|NCT04301661|DRUG|Tenofovir alafenamide/emtricitabine|Participants who are already taking tenofovir alafenamide/emtricitabine as part of standard HIV care will continue taking their therapy.
215061815|NCT04301661|DRUG|Switch|Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
215061816|NCT01312025|PROCEDURE|conventional laparoscopic cholecystectomy|
215061817|NCT01312025|PROCEDURE|modified laparoscopic cholecystectomy|
215061818|NCT03744910|BIOLOGICAL|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
215061819|NCT03744910|DRUG|Physiologic saline solution|Normal saline
215061820|NCT05631769|DRUG|Dual antiplatelet agent duration|"Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria)."
215061821|NCT05322512|DRUG|18F-FDG|All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
215061822|NCT04234529|DIETARY_SUPPLEMENT|AMATEA™|"AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).~Total of 1.35g of AMATEA containing 270mg of caffeine."
214320978|NCT06867939|DIETARY_SUPPLEMENT|liposomal curcumin|Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.
214320979|NCT06867939|DIETARY_SUPPLEMENT|Liposomal Curcumin|Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.
214320980|NCT06791850|BEHAVIORAL|HF-FamPALhomeCARE|Participants in HF-FamPALhomeCARE Intervention group receive standard care plus 2 home visits, 3 bi-weekly telephone call on HF home EOLPC care, and follow-up telephone calls at 3, 6, 9, and 12 months.
214672071|NCT00002208|DRUG|Stavudine|
214672072|NCT00002208|DRUG|Zidovudine|
215061823|NCT04234529|DIETARY_SUPPLEMENT|Caffeine|1.08g of microcellulose and 270mg of caffeine.
215061824|NCT04234529|OTHER|Placebo|1.35g of microcellulose
215061825|NCT04328753|DRUG|Super Oxide water|Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
215061826|NCT04328753|DRUG|Chlorhexidine mouthwash|CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
215061827|NCT04328753|OTHER|Distilled water|act as a negative control in this study
215061828|NCT00064259|BIOLOGICAL|oblimersen sodium|Given IV
215061829|NCT00064259|DRUG|cisplatin|Given IV
215061830|NCT00064259|DRUG|fluorouracil|Given IV
215061831|NCT02953093|DRUG|Acarbose|see arm description
214320981|NCT06889545|OTHER|Assessment of frailty using multiple tools|This is an observational study without any intervention. Frailty is assessed using multiple tools and postoperative outcome is compared.
214320982|NCT06901726|DRUG|Human insulin enteric coated capsules in dose 32mg|Single oral administration of human insulin enteric coated capsules in dose 32mg (16 mg per capsule, two capsules).
214320983|NCT06901726|DRUG|Human Insulin Injection in dose 5IU|Single subcutaneous administration of Human Insulin Injection in dose 5IU.
214320984|NCT06924047|OTHER|Beautifil Flow Plus X|Shofu's Beautifil Flow Plus X F00 a advanced bioactive injectable composite
214320985|NCT06924047|OTHER|EverX Flow|Short fiber reinforced composite
214320986|NCT06922864|OTHER|thermal stimulation|contact heat stimulation at 54℃
214320987|NCT06922864|OTHER|itch|itch the sole of the foot
215061832|NCT02953093|OTHER|Placebo|See arm description
215061833|NCT01132651|OTHER|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
215061834|NCT01132651|OTHER|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
215061835|NCT06257667|OTHER|Respiratory Support|Treatment with High Flow Nasal Cannula
215061836|NCT06034873|DRUG|Propofol injection and fentanyl|The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
214320988|NCT06813235|BEHAVIORAL|iDream2Heal|iDream2Heal (iD2H) is an unsupervised, self-guided web-based version of the cognitive behavioural therapy for insomnia (CBT-I).
214320989|NCT06813235|BEHAVIORAL|Easy Exercise|Easy Exercise (eEX) is an unsupervised, self-guided web-based exercise intervention.
214320990|NCT06813235|BEHAVIORAL|Dream2Heal|Dream2Heal (D2H) is a manualised, multi-component intervention which is grounded with core CBT-I elements of stimulus control, sleep restriction, sleep hygiene, relaxation training, and cognitive restructuring.
214320991|NCT06813235|BEHAVIORAL|iDream2Heal & Easy Exercise|The augmented iDream2Heal \& Easy Exercise (iD2H \& eEX) intervention is a combined, unsupervised, self-guided web-based intervention that covers the content of iD2H and eEX interventions.
214320992|NCT06904885|BEHAVIORAL|Implementation of a guideline-based model of care for hip and knee osteoarthritis|Guideline-based model of care including GLA:D (Good Life with osteoArthritis from Denmark) -program that includes training for physiotherapists and group based education and exercise for patients with hip and knee OA.
214320993|NCT06923904|OTHER|Trial group, treated with a 980 nm diode laser and desensitizing topical gel|The study aims to evaluate the actual efficacy of diode lasers in laser desensitization by comparing the topical gel Emoform Actisens, containing 5% potassium nitrate, alone and in combination with a diode laser.
214320994|NCT06924749|DRUG|EGCG|"EGCG (high pressure liquid chromatographic purity~≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day."
214320995|NCT06923475|DRUG|Pembrolizumab|Patients will initiate with 2 sets of 3 cycles of neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab (up to total of 1 year immunotherapy treatment)
214320996|NCT06923475|DRUG|Gemcitabine, Cisplatin|Patients will initiate with 2 sets of 3 cycles of neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab (up to total of 1 year immunotherapy treatment)
214920466|NCT04859790|BEHAVIORAL|Social Concerns Appraisal Retraining|"SCAR consists of an hour-long intervention session, followed by a 2-week-long EMI. During the hour-long intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety), discuss popular misconceptions they may have about publicly observable anxiety symptoms (e.g., people can tell I'm anxious by looking at me), and complete exposure exercises (e.g., practicing facing feared physical sensations such as sweating). During the EMI, participants will report on their social anxiety symptoms four times per day. When participants endorse elevated social anxiety during this time, they will receive a targeted message reminding them of the topics covered in the intervention session."
215061837|NCT06034873|DRUG|Bupivacain|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
215061838|NCT00721760|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
214672073|NCT00846612|DRUG|Doxil|1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle
214672074|NCT00846612|DRUG|Bevacizumab (Avastin)|1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
215061839|NCT00721760|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
214672075|NCT02614794|DRUG|tucatinib|300 mg orally twice daily
215061840|NCT00721760|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
215061841|NCT05742516|DIETARY_SUPPLEMENT|Bimuno Daily|Galactooligosaccharide supplement within Bimuno Daily
215061842|NCT05742516|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder
215061843|NCT03983265|OTHER|Bilateral Sagittal Split Osteotomy|after BSSO condyle will be re positioned by using computer guided device
215061844|NCT00948857|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|25 mg PO TID
215061845|NCT00948857|DIETARY_SUPPLEMENT|Placebo|Blinded placebo
215061846|NCT03900104|PROCEDURE|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
215061847|NCT03900104|PROCEDURE|Cervical injection of technetium 99 m-labeled human albumin colloid particles|Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
215061848|NCT02897037|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
215061849|NCT02897037|DRUG|heparin|heparin monotherapy
215061850|NCT04331340|OTHER|Pharmacist review of LUTS|Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications
214672076|NCT02614794|DRUG|capecitabine|1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
214320997|NCT06923540|DRUG|IV Acetaminophen|This intervention will be administered to patients undergoing abdominal surgery who are nil per os (NPO) directly after surgery. This patient group has not been properly studied in other clinical studies using IV Acetaminophen. The study aim is to determine if patients who have an altered enteral route may benefit from IV Acetaminophen.
214320998|NCT06924580|OTHER|ECG screening|Each subject is subjected to ECG assessment.
215061851|NCT04331340|OTHER|Pharmacist Provision of healthy aging leaflets|Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
215061852|NCT04739553|DEVICE|His Pacing|The patients will receive a pacemaker implant with a traditional right ventricular pacing lead and an additional His pacing lead in a basal high septal position at the level of the proximal electrical conduction system (His). An atrial lead is implanted if dual chamber pacing is needed. All leads are connected to a biventricular pacemaker with the His lead in the LV port.
214320999|NCT06924112|OTHER|Isometric exercises|The three isometric exercises were performed without the addition of BFR following the best evidence recommendations. Each exercise was performed for 10 repetitions, with isometric contraction of 15 seconds followed by a rest period of 15 seconds, intensity with a load at 20-25% of the maximal voluntary isometric contraction (MVIC), rest period after each exercise of 2 minutes, and pain level below 5 on the verbal Numeric Pain Rating Scale (NPRS).
214672077|NCT02614794|DRUG|trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
215061853|NCT03541967|DEVICE|ADHEAR and PONTO 3 SUPER POWER on softband hearing aids|Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
215061854|NCT00006447|PROCEDURE|Social Support|
215061855|NCT02753907|DIETARY_SUPPLEMENT|Low LA|Individuals who replaced 10 mL soy oil with one apple
215061856|NCT02753907|DIETARY_SUPPLEMENT|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
215061857|NCT00585442|DRUG|calcitriol|1.0 mcg daily
215061858|NCT00585442|DRUG|Placebo|Placebo
215061859|NCT06355947|OTHER|Cognitive cycling training|Cycling training conducted with cognitive tasks
215061860|NCT06355947|OTHER|Cognitive treadmill training|Treadmill training conducted with cognitive tasks
215061861|NCT02973204|DRUG|Sorafenib|
214920467|NCT02125942|BEHAVIORAL|Central Meditation and Imagery Therapy|mindfulness, guided imagery, meditation
214920468|NCT04308499|BEHAVIORAL|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions accessed using either a computer or a smartphone
214920469|NCT04308499|BEHAVIORAL|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions comprised of comprise a website and a downloadable booklet
214920470|NCT01455272|PROCEDURE|prophylactic GPBPCI|A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
214920471|NCT03747757|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBT
214920472|NCT03747757|OTHER|Quality-of-Life Assessment|Ancillary studies
215061862|NCT02973204|PROCEDURE|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
215061863|NCT02973204|DRUG|Everolimus|
215061864|NCT02973204|DRUG|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
215061865|NCT03871101|PROCEDURE|Scalpel|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with scalpel for placing the healing abutment.
215061866|NCT03871101|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
215061867|NCT05205538|OTHER|Sprint interval exercise training|A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.
215061868|NCT02156284|BEHAVIORAL|Empathic behaviour by nurses|"Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse."
215061869|NCT05151432|DEVICE|Pulsed Ultrasound|Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W
215061870|NCT05151432|DEVICE|Pulsed Electromagnetic field|The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.
214672078|NCT02614794|DRUG|placebo|Oral dose twice daily
214920473|NCT03747757|OTHER|Questionnaire Administration|Ancillary studies
214920474|NCT05018403|DRUG|Intravenous AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
214920475|NCT05018403|DRUG|Intravenous placebo|Isotonic glucose solution identical in appearance to AON-D21.
214920476|NCT02067884|PROCEDURE|dynamic contrast-enhanced ultrasound imaging|Undergo CEUS
214920477|NCT02067884|PROCEDURE|shear wave elastography|Undergo SWE
214920478|NCT02067884|DRUG|Definity, (Lipid Microspheres) Intravenous Suspension|Participant will receive contrast agent by intravenous administration
214920479|NCT02067884|DEVICE|Philips Shear Wave Elastography|Equipment used for SWE
214920480|NCT00767728|DRUG|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
214920481|NCT00767728|DRUG|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
214920482|NCT00585845|BIOLOGICAL|CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin|2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10\^8 cfu to 1x10\^10 cfu.
214920483|NCT00938847|DEVICE|PCI|Stent implantation after acute myocardial infarction
215061871|NCT05151432|OTHER|Traditional exercise program|Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening
215061872|NCT05151432|DEVICE|Sham Pulsed US & Electromagnetic field|The patients will receive Sham Pulsed US \& Electromagnetic field.
215061873|NCT02727387|DRUG|TEMIRI|Window therapy frontline for VHR patients
215061874|NCT02727387|DRUG|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
215061875|NCT02727387|DRUG|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
215061876|NCT02727387|DRUG|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
214484408|NCT06890169|BEHAVIORAL|OneSTOP program|The OneSTOP program will incorporate at least 50% (4 out of 8 sessions) of the doctor and dietician consults over the 26-week study as teleconsults, which may be scheduled as joint or asynchronous consults. The exercise prescription and calorie restriction will be tailored to each subject's individual needs as in the F2F structured weight management program in the control group. In addition, participants will be taught to use the EMPOWER app will be used to enable them to upload their weight, blood pressure and glucose, food and exercise duration records. The app also has the capability to co-ordinate visits and investigations, deliver intelligent health nudges and reminders on adherence to treatment which can be individualized to their progress, and provide information on their conditions curated by their doctors and dieticians.
214484409|NCT06890169|BEHAVIORAL|Standard of care weight management program|The standard face-to-face weight management program consists of 4 doctor and 4 dietician consults over 26 weeks, at 2-4 weekly intervals in the first 3 months, and 6-8 weeks in the next 3 months. At the baseline visit, participants are provided with an aerobic and resistance exercise prescription individualized to each subject's fitness and comorbidities to target at least 180 minutes/week of moderate-intensity physical activity (with exercise on at least 3 days/week), and dietary advice based on a calorie-deficit diet (400-600 kilocalories less than the calculated daily caloric requirement, based on the Mifflin-St Jeor equation) which emphasizes reduction in sugar-sweetened beverages, refined carbohydrates and saturated fats. Subjects will be provided with a list of fitness resources such as gyms and fitness corners with advice on use of the equipment, and specific guidance on increasing intensity and duration of exercise and monitoring for injury.
214484410|NCT06731166|BEHAVIORAL|self-care|Videomonitoring provide by cardiovascular nurses
214484411|NCT06731556|DRUG|Intravenous paracetamol|Paracetamol was administered intravenously at a dose of 20 mg/kg/day, twice daily.
214484412|NCT06731556|DRUG|Intranasal Paracetamol|Paracetamol at a concentration of 1.25 mg/mL was administered intranasally.
214484413|NCT06731556|DRUG|Intranasal Diclofenac Sodium|Diclofenac sodium at a concentration of 0.0625 mg/mL was administered intranasally.
214484414|NCT06731556|DRUG|Intranasal Ibuprofen|Ibuprofen at a concentration of 0.375 mg/mL was administered intranasally.
214484415|NCT06730399|DEVICE|Computed-assisted-cryotherapy|cryotherapy device
214484416|NCT06730906|DEVICE|PACTAID App|The PACTAID app will provide real time decision support during exercise for patients with type 1 diabetes.
214484417|NCT06731036|BIOLOGICAL|CD34+ cell enriched stem cell graft|Patients will receive a peripheral blood stem cell graft that has been CD34+ cell enriched using the Miltenyi CliniMACS Prodigy® system.
214484418|NCT06716216|DRUG|Drug: 5 mg BGM0504 Administered SC|Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
214484419|NCT06716216|DRUG|Drug:10 mg BGM0504 Administered SC|Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
214484420|NCT06716216|DRUG|Drug: Semaglutide Administered SC|"Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week"
215061877|NCT02727387|DRUG|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
215061878|NCT02727387|DRUG|BUMEL|Consolidation phase
215061879|NCT02727387|DRUG|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
215061880|NCT06035575|BEHAVIORAL|Educational video|Development of the original video used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script will typically be shown to the patient within 48-72 hours of the acute care visit, with a maximum window of 5 days post visit.
215061881|NCT03430843|DRUG|Tislelizumab|200 mg administered intravenously (IV)
215061882|NCT03430843|DRUG|Paclitaxel|135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
215061883|NCT03430843|DRUG|Docetaxel|75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
215061884|NCT03430843|DRUG|Irinotecan|125 mg/m\^2 administered IV
215061885|NCT06040918|DRUG|N-803|fixed dose of 1 mg by subcutaneous (SC) injection
215061886|NCT03608371|DRUG|BTRX-246040|oral capsule
215061887|NCT03608371|DRUG|Placebo|oral capsule matching BTRX-246040 capsule
215061888|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 5 mg subQ once weekly
215061889|NCT03415594|DRUG|FE203799 Placebo GLP-2 analogue|Placebo subQ once weekly
215061890|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 10 mg subQ once weekly
215061891|NCT06067685|OTHER|Observation|Prospective Observation only. Will record serum triglyceride, fingerstick blood triglyceride measurements, cord c-peptide, and neonatal body fat composition measurements in the first 6 months.
215061892|NCT05244603|BEHAVIORAL|Ideal binary mask|Speech in noise processed by ideal binary mask to reduce background noise
215061893|NCT06349343|BIOLOGICAL|CD19/BCMA CAR-T cell therapy|CD19/BCMA CAR-T cell will be infused intravenously at 3 doses: Dose A, Dose B, Dose C.
214484421|NCT06727045|OTHER|Mandala Coloring|"A literature review was conducted to determine the frequency and number of mandalas to be applied to the patients in the intervention group, and the average of the number of mandala sessions applied to different patient groups was obtained, and mandala application was performed during a total of eight hemodialysis sessions, every other day. Mandala painting was performed approximately 30 minutes after the start of HD treatment, considering the art therapist's recommendation and the symptoms that may develop during HD. Each mandala painting was performed with a structured and different mandala pattern. Since it was stated that the use of round patterns instead of square patterns was effective in increasing the comfort level, the booklet called Mandala Booklet, consisting of 8 structured mandala patterns with round shapes and containing general information about mandala, was used in the study. The group was informed about the content of the booklet face to face. Dry pencils were prefer"
214484422|NCT06705881|OTHER|Eccentric exercise program (EEP)|All participants will perform a 6-week single-leg eccentric squat exercise. It will be performed on an incline board with a 25° incline. It will consist of a single-leg squat, with the downward component (eccentric phase) of the EEP performed using the symptomatic leg and the upward component (concentric phase) using the contralateral leg primarily. If pain occurs during the exercises, athletes will be asked to continue the exercise if they score ≤5 out of 10 on the Visual Acuity Scale (VAS). The exercises will be attempted in the first session of each week, and if no or very little pain is felt, the weight will be increased by 2.5% to increase the intensity of the exercise. Three sets of 15 repetitions per session will be performed twice a day. It will be performed 5 days a week. Participants will be asked to fill out an exercise diary (sets, repetitions, and daily frequency) and return it to the researchers at each follow-up session.
214484423|NCT06705881|OTHER|ESWT (Extracorporeal Shock Wave Therapy)|ESWT is a therapy method routinely used in private and public hospitals. Tendinopathy therapy parameters approved by the International Society for Medical Shock Wave Therapy (ISMST) for focused ESWT treatment are: 0.10-0.25 mJ/mm (dosing appropriate to pain), up to a maximum of 5 Hz, 1500-2500 pulses per session, 1-2 weeks apart. Accordingly, in our study, the focused ESWT dosage of the ESWT group will be applied as; 0.10-0.25 mJ/mm (dosing appropriate to pain), 4 Hz, 2000 pulses, 1 session per week for 3 weeks. No exercise will be done on the day of ESWT.
214484424|NCT06710249|DIETARY_SUPPLEMENT|Salovum/SPC flakes|Egg yolk powder and specially processed cereals
214484425|NCT06727864|DRUG|4-month regimen (2HERZ/2HRE)|4-month (2HERZ/2HRE)
214484426|NCT06727864|DRUG|6-month (2HERZ/4HRE)|2 months of HREZ followed by 4 months of HR/HRE
214484427|NCT06728592|DEVICE|Portable Magnetic Resonance Imaging|0.23T Low-field Magnetic Resonance Imaging
214484428|NCT06803147|OTHER|Discontinued endoscopic surveillance|Endoscopic surveillance is discontinued for eligible patients in line with the new guideline revision, and patients are then followed in this prospective cohort
214920484|NCT03468166|OTHER|Chronic stroke|The data for motor function and gait pattern analysis was obtained.
214920485|NCT04448522|RADIATION|reduced dosage IMRT|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：63.6Gy/30Fr/2.12Gy; PTVnd：63.6Gy/30Fr/2.12Gy; PTV1：54Gy/30Fr/1.8Gy; PTV2：49.2Gy/30Fr/1.64Gy"
214920486|NCT04448522|RADIATION|conventional dosage IMRT|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：69.96Gy/33Fr/2.12Gy; PTVnd：69.96Gy/33Fr/2.12Gy; PTV1：59.4Gy/33Fr/1.8Gy; PTV2：54Gy/33Fr/1.64Gy"
214920487|NCT02100995|BEHAVIORAL|Intervention Simultaneously Targeting Obesity and Pain|
214920488|NCT02100995|BEHAVIORAL|Weight Loss/Weight Self-Management|
214920489|NCT02100995|BEHAVIORAL|Chronic Pain Self-Management|
214920490|NCT04515706|DRUG|Iguratimod|Iguratimod is an anti-rheumatic drug that approved for treating rheumatoid arthritis in East Asia. Recent data reveal its independent anti-fibrosis effect.
214920491|NCT04515706|DRUG|Placebo|Placebo of Iguratimod
214920492|NCT00637000|DRUG|Buprenorphine soluble film|Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
214920493|NCT00637000|DRUG|Buprenorphine/naloxone film strip|Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
214920494|NCT00637000|DRUG|Placebo|Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
214920495|NCT03604679|DRUG|SyB C-0501|Specified dose on specified days
214920496|NCT06293508|BEHAVIORAL|Standard Health Communication Intervention|Participants in this group will receive links and materials related to breast cancer screening from official sources (e.g. MOH, Non-governmental organizations (NGOs), etc.) that is already readily available and accessible by the Malaysian public. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
214920497|NCT06293508|BEHAVIORAL|Behavioural Change Health Communication Intervention|Participants receive health communication materials designed using persuasive behavioural change communication principles and behavior science to promote breast cancer screening. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
214920498|NCT06220175|DRUG|Strepsils Intensiv plus Xilocaine spray Arm|After Stepsils Intensiv ingestion, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
214920499|NCT06220175|DRUG|Xilocaine Spray Arm|After Xilocaine Spray pharyngeal topical anestesia, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
214920500|NCT01281670|OTHER|vibration|8 week vibration
215061894|NCT01373008|DRUG|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
214321000|NCT06924112|DEVICE|Isometric exercises with BFR|Participants will perform three isometric exercises with BFR. An auto-regulated portable BFRT SmartCuffs® 3.0 Pro system with a 17-inch long and 5-inch-wide cuff (Smart Tools Plus, United States), placed on the most proximal part of the arm, will be used. The session will begin with a maximal occlusion test to personalize the occlusion pressure to the participant. The limb occlusion pressure (LOP) will be set at 60% of the maximum occlusion pressure. Each exercise was performed for 10 repetitions, with isometric contraction of 15 seconds followed by a rest period of 15 seconds, intensity with a load at 20-25% of the MVIC, rest period after each exercise of 2 minutes with cuff deflated (reperfusion), and pain level below 5 on the NPRS.
214321001|NCT06923085|OTHER|Observational Assessment Only|This is an observational study examining bilateral sensorimotor function in patients with cervical radiculopathy. No interventional procedures were applied. Participants underwent comprehensive assessments including pain evaluation (VAS), neck disability (NDI), upper extremity functionality (DASH), muscle strength measurements, sensory function testing, hand performance evaluation, kinesiophobia (TAMPA), and emotional status assessment (Beck Inventory). The study compared findings between different cervical radiculopathy groups and a control group with non-specific neck pain.
214321002|NCT06923852|BEHAVIORAL|Smoking cessation support that World Health Organization (WHO) 5A model (Ask, Advise, Assess, Assist, Arrange).|Smoking cessation support that World Health Organization (WHO) 5A model (Ask, Advise, Assess, Assist, Arrange).
214321003|NCT06924463|OTHER|None AHT|This study does not involve any interventions. It analyzes pre-existing biological samples (FFPE tumor tissue) and clinical data from patients with rhabdomyosarcoma.
214484429|NCT06888336|BEHAVIORAL|Yoga nidra (full)|"The intervention consists of remotely delivered audio recordings (\~30 minute length) of iRest yoga nidra meditation instructions that participants will be asked to listen to daily for 8 weeks, for a total listening time of about 3.5 hours each week. The yoga nidra practices will be in the tradition of iRest. They will include the following sections: intention setting, articulating a heartfelt desire, inner resource, body sensing, breath sensing, emotion and cognition sensing and opposites, welcoming joy, witnessing awareness, and integration. Each week includes an additional brief (\~2-5 minute) introduction to one of the iRest yoga nidra sections. Participants will be asked to lie on a lightly cushioned surface when listening to the practices.~Participants are informed that they may opt to listen to the recordings more often but are instructed to listen to the recordings at least once per day."
215061895|NCT00800696|PROCEDURE|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
214484430|NCT06888336|BEHAVIORAL|Yoga nidra (brief)|"The intervention will consist of remotely delivered audio recordings of yoga nidra meditation instructions. Participants will be asked to listen to one \~30-minute practice and six \~10-minute practices per week (total listening time of \~1.5 hours each week) for 8 weeks. The yoga nidra practices will be in the tradition of iRest. They will include the following sections: intention setting, articulating a heartfelt desire, inner resource, body sensing, breath sensing, emotion and cognition sensing and opposites, welcoming joy, witnessing awareness, and integration. Each week includes an additional brief (2-5 minute) introduction to one of the iRest yoga nidra sections. Participants will be asked to lie on a lightly cushioned surface when listening to the practices.~Participants are informed that they may opt to listen to the recordings more than once a day but are instructed to listen to the 30-minute recording once per week and the 10-minute meditations the other 6 days of the week."
214672079|NCT00906789|BEHAVIORAL|Software|This is an observer performance study. Radiologists will interpret chest radiographs without and then with the Riverain software, both SoftView (TM) OnGuard (TM) CADe Software with be tested
214920501|NCT04764370|DEVICE|WeFlow-Ach Moduler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
214920502|NCT03457116|DRUG|Norco|20 tablets of Hydrocodone 5mg-Acetaminophen 325mg (Norco)
214920503|NCT03457116|DRUG|NSAID|Ibuprofen 400mg for post-operative pain
214920504|NCT06341907|BIOLOGICAL|Neoantigen polypeptide vaccine|Completion of polypeptide neoantigen polypeptide vaccine (day 1, 4, 8, 15, 22, 54, and 84)
214920505|NCT00467727|OTHER|Phase Contrast Mammography|Standard and magnification views
214920506|NCT00839527|DRUG|placebo to match albiglutide|albiglutide matching placebo weekly subcutaneous injection
214920507|NCT00839527|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
214920508|NCT00839527|DRUG|metformin|metformin
214920509|NCT00839527|DRUG|glimepiride|glimepiride
214920510|NCT00839527|DRUG|pioglitazone|pioglitazone
214920511|NCT00839527|DRUG|placebo to match pioglitazone|pioglitazone matching placebo
214920512|NCT04599348|DIETARY_SUPPLEMENT|HRG 80 Red Ginseng|A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.
214920513|NCT05230368|DRUG|Decitabine cycle 1|Decitabine administration (5mg/m²) at days 1, 2, 3
214920514|NCT05230368|DRUG|Romidepsin cycle 1|Romidepsin administration (5mg/m²) at days 4, 11, 18
214920515|NCT05230368|DRUG|Decitabine cycle 2|Decitabine administration (5mg/m²) at days 35, 36, 37
214920516|NCT05230368|DRUG|Romidepsin cycle 2|Romidepsin administration (5mg/m²) at days 38, 45, 52
214920517|NCT05230368|DRUG|Decitabine cycle 3|Decitabine administration (5mg/m²) at days 70, 71, 72
214920518|NCT05230368|DRUG|Romidepsin cycle 3|Romidepsin administration (5mg/m²) at days 73, 80, 87
214920519|NCT05230368|DRUG|Decitabine cycle 4|Decitabine administration (5mg/m²) at days 105, 106, 107
214920520|NCT05230368|DRUG|Romidepsin cycle 4|Romidepsin administration (5mg/m²) at days 108, 115, 122
214920521|NCT01243216|DEVICE|Ultrasound|Ultrasound examination of the lumbar spine. The level of the lumbar interspace will be determined by the oblique/sagittal method. The transverse method will be used to determine the best lumbar interspace and the distance from the skin to the target (epidural space or intrathecal space)
214920522|NCT03566914|DRUG|Tadalafil 10 MG|Tadalafil 10 mg per oral once daily for 3 months
214672080|NCT03425110|OTHER|Modified Ketogenic Diet|
215061896|NCT03944564|BEHAVIORAL|Sitting|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
215061897|NCT03944564|BEHAVIORAL|Static standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
215061898|NCT03944564|BEHAVIORAL|Dynamic standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
215061899|NCT03162744|BEHAVIORAL|Post-suicidal crisis interview|Protective factor exploration during post-suicidal crisis interview
215061900|NCT06440122|DIAGNOSTIC_TEST|FDG-PET Scan|Positive for activated brown adipose tissue (SUVmax \>1.5) FDG-PET scan
215061901|NCT02407080|DRUG|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
215061902|NCT02407080|DRUG|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
215061903|NCT06429046|OTHER|LIDOCAINE GEL|To LG group patients, 20 ml lidocaine gel will be applied intrarectally (double application: 5cc to the perianal region, covering the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed in the rectum.
215061904|NCT06429046|OTHER|COLD LIDOCAINE GEL|In CLG group patients, 20 ml of cold lidocaine gel kept in the refrigerator at +4 0C will be applied intrarectally (double application: 5cc to the perianal region, including the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed into the rectum.
215061905|NCT00002848|PROCEDURE|psychosocial assessment and care|
215061906|NCT00002848|PROCEDURE|quality-of-life assessment|
215061907|NCT01827436|BEHAVIORAL|Conventional physical therapy|
215061908|NCT01827436|BEHAVIORAL|Asymmetrical gait training|
215061909|NCT01581229|PROCEDURE|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
215061910|NCT01581229|PROCEDURE|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
214321004|NCT06922838|OTHER|Virtual Reality intervention|The head-mounted virtual reality device is used to provide patients with relaxing videos of nature scenes accompanied by calming music and guided meditations.
214321005|NCT06922838|OTHER|Aromatherapy|The cotton ball soaked in lavender essential oil is placed near the patient's pillow.
214321006|NCT05686642|DRUG|LT3001 Drug:high dose|Administered by intravenous infusion.
214321007|NCT05686642|DRUG|Placebo|Administered by intravenous infusion.
214321008|NCT05686642|DRUG|LT3001 Drug:low dose|Administered by intravenous infusion.
214321009|NCT03420885|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines the traditional Chinese medicine and traditional Chinese philosophy and embrace the body, breath and spirit. Ba Duan Jin consists of eight main movements. According to traditional theory, every movement has unique effect to different Zang-fu organs.
214321010|NCT03420885|BEHAVIORAL|Health Education|Health education includes work, rest, diet and other basic programs according to the different conditions of participants.
214321011|NCT03163368|RADIATION|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant stereotactic radiosurgery
214672081|NCT04928365|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 therapy
214920523|NCT03566914|OTHER|Placebo|TPlacebo tablet per oral once daily for 3 months
214920524|NCT04287855|DRUG|Isatuximab|Isatuximab by IV route - Cycle 1 : 10mg/kg on days 1, 8, 15 and 22 per 28 days cycle. After cycle 1 : 10mg/kg on days 1 and 15 per 28 days cycle
214920525|NCT04287855|DRUG|Carfilzomib|Carfilzomib by IV route - Cycle 1 : 20/27 mg/m² on days 1-2, 8-9, 15-16 per 28 days cycle. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
214920526|NCT04287855|DRUG|Pomalidomide|Pomalidomide by oral route - Cycle 1-2 : 3mg on days 1 to 21 per 28 days cycle. After cycle 2 : 4mg on days 1 to 21 per 28 days cycle.
215061911|NCT04491682|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
215061912|NCT04491682|DRUG|Rosuvastatin|At a dosage of 10 mg/day
215061913|NCT01380678|DRUG|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
215061914|NCT01380678|DRUG|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
215061915|NCT03993444|BEHAVIORAL|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
215061916|NCT03993444|BEHAVIORAL|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
215061917|NCT00590122|DRUG|Parcopa|at subjects current stable dose of comparator
215061918|NCT00590122|DRUG|carbidopa-levodopa (Sinemet)|at subjects current stable dose
215061919|NCT03050450|DRUG|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
215061920|NCT03050450|DRUG|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
215061921|NCT03050450|DRUG|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
215061922|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
215061923|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
215061924|NCT02653443|BIOLOGICAL|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
215061925|NCT02653443|BIOLOGICAL|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
215061926|NCT06288308|DIAGNOSTIC_TEST|fibronigin to albumin ratio|"To investigate the association of fibrinogen to albumin ratio (FAR) with LN in different classes.~b. Secondary (subsidiary):~To prove the possible role of FAR as a novel diagnostic biomarker to predict LN progression"
215061927|NCT06520696|BEHAVIORAL|MILC application|Eligible Hispanic participants in their third trimester will be recruited for the study. Intervention group will receive standard WIC services plus the MILC application. Standard WIC support includes on-site lactation consultation, bilingual peer counseling, weekly peer support meetings, free breast pump, and enhanced food package for BF mothers. If a participant has trouble with breastfeeding, she will be referred to a home-visiting breastfeeding peer counselor in the area. Participants will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months along with demonstrating breastfeeding via MILC app. Participants will send in 1 BF video per month using the MILC app to verify continued BF and fill out monthly self-report to verify EBF. Participants in the incentive group will receive escalating monthly points as incentives for every additional month of continued BF and EBF.
215061928|NCT06520696|BEHAVIORAL|Usual care|"Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months. Participants in the control group can receive financial compensation for the completion of assessments. This is necessary to maximize retention and adherence to the monthly assessment schedule, provide comparable remuneration as the incentive group, and minimize demoralization of control group participants following treatment assignment. All participants are informed of the differential group procedures during the randomization consent process. In addition to the follow-up assessment, control group will also complete a monthly self-report on BF status (both for EBF and any BF). For attention control purposes in this group, participants will be referred to a mobile app for tracking the baby's milestones called Baby Connect."
215061929|NCT01687543|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
215061930|NCT01687543|OTHER|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
215061931|NCT04347512|DRUG|Hydroxychloroquine and azithromycin treatment arm.|"Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
215061932|NCT04347512|DRUG|Hydroxychloroquine|"Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
215061933|NCT04347512|DRUG|Control arm|In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
214321012|NCT03163368|PROCEDURE|Neurosurgical resection|Surgical resection of newly diagnosed brain metastases
214321013|NCT03395769|BIOLOGICAL|AB-SA01|AB-SA01 is an investigational bacteriophage therapeutic for treatment of Staphylococcus aureus infections
214321014|NCT03787992|DRUG|Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo|"The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
214321015|NCT03787992|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214321016|NCT03787992|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
214321017|NCT03787992|DRUG|Placebo AST2818 80mg//40 mg|The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214321018|NCT00008346|DIAGNOSTIC_TEST|Full Field Digital Mammography|Radiologic test to screen women for Breast cancer using digital detectors
215061934|NCT01738815|DRUG|Valproic Acid|500 mg orally, once daily for up to 30 days
215061935|NCT05524857|DRUG|Fedratinib Oral Capsule 300 mg|300 mg by mouth, once daily
214484431|NCT06883955|COMBINATION_PRODUCT|Disease education, pharmacological treatment, Non-pharmacological treatment|"Disease education: Provide patients with education on knowledge related to primary headache, including the causes, pathogenesis, symptoms, treatment methods, and preventive measures of headache, etc., to help patients better understand their own diseases and improve their self-management ability.~Non-pharmacological treatment: Although specific non-pharmacological treatment methods are not elaborated in detail in the research protocol, they may include psychotherapy, physical therapy, etc. For example, biofeedback therapy, relaxation training, transcranial magnetic stimulation, etc. These can all be recorded as possible intervention measures.~Pharmacological treatment: Record the medications used for the treatment of acute episodes and preventive treatment by patients during the research process, including the types of medications, dosages, frequency of use, etc. For instance, non-steroidal anti-inflammatory drugs and triptan drugs used during acute episodes, and β-blockers."
214484432|NCT06889623|PROCEDURE|Immediate postoperative chemotherapy|Systemic chemotherapy with cisplatin/gemcitabine intravenous infusion within 24 hours after TURBT
214484433|NCT06704763|DRUG|Orforglipron|Administered orally
214484434|NCT06704763|DRUG|Midazolam|Administered orally
214321019|NCT00008346|DIAGNOSTIC_TEST|Screen Film Mammography|Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
214321020|NCT02929576|DRUG|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
214321021|NCT02929576|DRUG|Placebo|
215061936|NCT05524857|DRUG|Decitabine 20 mg/m2|20 mg/m2 for injection, for intravenous use
215061937|NCT05524857|DRUG|Fedratinib Oral Capsule 400 mg|400 mg by mouth, once daily
215061938|NCT00711594|DRUG|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
215061939|NCT00711594|DRUG|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
215061940|NCT00711594|DRUG|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
215061941|NCT00711594|DRUG|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
215061942|NCT00443872|DRUG|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
214484435|NCT06704763|DRUG|Quinidine|Administered orally
214484436|NCT06734455|OTHER|Robot-Assisted Pyeloplasty|Pyeloplasty in Children using robotic surgery
214484437|NCT06735508|DRUG|mRNA Neoantigen Vaccine|mRNA Neoantigen Vaccine
214484438|NCT06735508|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
214484439|NCT06081127|OTHER|MOve-ABC|"The intervention is called Moving On After Breast Cancer (MOve-ABC) and includes:~1. Three in-person visits for clinical measurements~2. Enhanced usual care (EUC)~3. Pre-hab ((Pre-Treatment) PT evaluation and individualized home therapeutic exercise prescription with safe progressions).~4. Teach Back (HEP, post-op movement precautions)~5. Self-management education with reinforcement check-ins via text messaging and phone calls at regular intervals."
214484440|NCT06081127|OTHER|Enhanced Usual Care|"All patients will receive EUC. However, half of our sample will have only EUC consisting of~1. Three in-person visits for clinical measurements~2. Planned oncology treatment (surgery, chemotherapy, radiation)~3. Nursing education on surgical site and drain care, post-operative movement precautions, pain management~4. If needed, laboratory and radiological testing to rule out disorders that interfere with treatment outcomes~5. Monthly monitoring with Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF) surveys beginning at baseline with alerts from scores = or \< 45 (indicating moderate or severe impairment) for physical therapy referral"
214484441|NCT06349889|DRUG|Adebrelimab|"Drug: Adebrelimab Adebrelimab 1200mg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.~Other Names:~PD-L1 antibody~Drug: Gemcitabine Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Other Names:~GEM~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation~Other Names:~DDP~Radiation: Intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.~Other Names:~IMRT"
214484442|NCT03535142|PROCEDURE|Bariatric surgery|Roux en y gastric bypass or gastric sleeve operation
215061943|NCT06516081|DIETARY_SUPPLEMENT|Micronutrient powder (Sprinkles®)|
214484443|NCT06375941|OTHER|Observational|Observational
214484444|NCT06886880|DEVICE|endoscope|findings in upper GIT Endoscopy
215061944|NCT02437630|PROCEDURE|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
215061945|NCT02437630|PROCEDURE|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
214321022|NCT02929576|DRUG|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
214321023|NCT05099328|BEHAVIORAL|Recast Therapy|Recast therapy is when a interventionist uses the child's own productions as a platform for restating or recasting the child's speech with corrections or alterations to focus on a particular syntax target.
214321024|NCT05099328|BEHAVIORAL|Syntax Stories|Syntax stories are specially constructed stories read verbatim designed to teach a syntax target.
214321025|NCT05836597|DEVICE|Virtual reality|Virtual reality
214321026|NCT03332238|DEVICE|Autologous Stomal Vascular Fraction Material|Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
214321027|NCT03332238|DEVICE|Ringer's solution|Ringer's solution
215061946|NCT02437630|OTHER|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
215061947|NCT02437630|PROCEDURE|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
214321028|NCT03057626|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine
214321029|NCT03057626|OTHER|Laboratory Biomarker Analysis|Correlative studies
214321030|NCT03057626|OTHER|Quality-of-Life Assessment|Ancillary studies
215061948|NCT02437630|PROCEDURE|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
215061949|NCT02437630|OTHER|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
214484445|NCT06733896|OTHER|trigger point pressure|The midpoint of the sternocleidomastoid muscle with abundant nerve distribution and the onset and endpoint of the sternocleidomastoid muscle were used as acupoints, which can relieve localised muscle spasms and promote nerve nutrition.
214484446|NCT06733896|OTHER|neck exercises|Manual Cervical Traction Technique and others
214321031|NCT05084053|DRUG|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
214321032|NCT04626518|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
214321033|NCT04626518|BIOLOGICAL|MK-4830|Administered via IV infusion at a dose of 800 mg Q3W
214321034|NCT04626518|DRUG|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
214321035|NCT04626518|DRUG|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
214321036|NCT04626518|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
214321037|NCT04626518|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
214321038|NCT05448664|BEHAVIORAL|Family HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students and their parents in the following 24 weeks.
214484447|NCT06885528|DIAGNOSTIC_TEST|Complete Blood Count with differential|First CBC w/diff test ordered within 12 hours of presentation to ED as part of standard medical care. The MDW result will be used as diagnostic marker to predict the risk of developing sepsis.
215061950|NCT04387006|OTHER|OMT|OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
215061951|NCT04387006|OTHER|MP|MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
214321039|NCT05448664|BEHAVIORAL|Adolescent HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students in the following 24 weeks.
215061952|NCT03102827|DRUG|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
215061953|NCT03102827|OTHER|Placebo|Ambient air without high-flow therapy administered during first night
215061954|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at home|LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
215061955|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at facility|LHWs will identify SAM as per 'Standard CMAM program' (MUAC \< 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
215061956|NCT00301392|OTHER|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
215061957|NCT00301392|DRUG|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
215061958|NCT04693273|OTHER|Decision Aid for Surgical Modality Choice|A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
215061959|NCT04685720|DEVICE|LungFit|LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
215061960|NCT06259487|BIOLOGICAL|Coordinated Vaccination|Coordinated Vaccination against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e., during cardiology visits)
215061961|NCT06259487|BEHAVIORAL|Following recommendations|Guidance on following the standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
215061962|NCT03890354|PROCEDURE|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
215061963|NCT06329752|PROCEDURE|Ultrasound-guided Sciatic Nerve block (20 mL of 2% Lidocaine)|Patients will be scanned with the ultrasound machine to determine the technical feasibility of sciatic nerve blocks. If feasible, one of the following techniques will be performed a) popliteal sciatic nerve block, with either lateral or posterior approach; b) CAPS (crosswise approach to popliteal sciatic) block, with either lateral to medial or anterolateral to posteromedial approach; c) subgluteal sciatic nerve block; d) transgluteal sciatic nerve block. In all cases, 20 mL of 2% Lidocaine will be used.
215061964|NCT05030519|DRUG|Pyrotinib|Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)
215061965|NCT06513039|DRUG|Erythropoietin carried on chitosan carrier|Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing
214920527|NCT04287855|DRUG|Dexamethasone|Dexamethasone by oral route - Cycle 1-13 : 40/20 mg on days 1, 8, 15 and 22. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
215061966|NCT06513039|OTHER|chitosan carrier|inert scaffold agent
214321040|NCT05448664|BEHAVIORAL|Adolescent e-pamphlets|The contents of e-version of three pamphlets, published by Department of Health (http://www.toothclub.gov.hk/en/en\_index.html) will be distributed in an electronic form and sent via a mobile message.
214321041|NCT06784882|DEVICE|continuous peripheral nerve block with OnQ pump|For continuous nerve blocks, the infusion pump that will be used are OnQ pumps (Avanos, Alpharetta, GA) and pre-filled with ropivacaine 0.2% and provided by UCSD's Investigational Drug Services.
214321042|NCT06784882|DRUG|single injection nerve block|An adductor canal single injection nerve block will be performed per standard of care. The adductor canal will be identified by ultrasound in the short-axis view. The distal aspect of the femoral triangle (and beginning of the adductor canal) will be identified distal to the mid-thigh in the ipsilateral limb. Using ultrasound guidance, a standard Tuohy block needle will be advanced through a skin wheal of lidocaine until its tip is in the hypoechoic area immediately distal saphenous nerve adjacent to the femoral artery. Twenty milliliters of ropivacaine 0.5% will be injected in divided doses with repeated negative aspiration.
214920528|NCT06685510|OTHER|the score of UPDRS item|The score of MDS-UPDRS item 3.1 greater or equal to 2 during the drug-off period at baseline
214920529|NCT06685510|OTHER|the score of UPDRS item|The score of MDS-UPDRS item 3.3 greater or equal to 2 during the drug-off period at baseline
214920530|NCT06685510|OTHER|the score of UPDRS item|The score of MDS-UPDRS item 3.10 greater or equal to 2 during the drug-off period at baseline
214920531|NCT06685510|OTHER|the score of UPDRS item|Any one of the MDS UPDRS 3.15-3.17 scores greater or equal to 2 during the drug-off period at baseline
214920532|NCT06685510|OTHER|the score of UPDRS item|Sum of MDS UPDRS 4.1-4.2 scores greater than or equal to 3
214920533|NCT00978081|DRUG|aminolevulinic acid hydrochloride|Patients undergo continuous or fractionated photodynamic therapy.
214920534|NCT00719238|BEHAVIORAL|Nutrition plus education|Nutritional instruction in small groups plus education
214321043|NCT00071812|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
214321044|NCT00071812|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
214321045|NCT00071812|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
214321046|NCT00071812|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
214321047|NCT01253616|DEVICE|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
214321048|NCT00222469|DRUG|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
214321049|NCT00222469|DRUG|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
214321050|NCT00222469|DRUG|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
214321051|NCT05226286|DEVICE|Medtronic Implantable Tibial Neuromodulation (TNM) System|Stimulation of the tibial nerve using Medtronic's tibial neuromodulation device.
214321052|NCT01589822|BIOLOGICAL|EVICEL Fibrin Sealant|Intraoperative
214321053|NCT05168475|BIOLOGICAL|Rituximab|Hospital stock of rituximab used as intervention; biosimilars are allowed
214321054|NCT05168475|BIOLOGICAL|Infliximab|Hospital stock of infliximab is used in the trial; biosimilars are allowed
214321055|NCT05168475|BIOLOGICAL|Tocilizumab|Hospital-supplied stock.
214920535|NCT00719238|BEHAVIORAL|Education only|Educational video and pamphlets
214920536|NCT06666010|DRUG|PEX010-Assisted Therapy|The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
215061967|NCT06035952|DIAGNOSTIC_TEST|3D topographical scan|Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.
215061968|NCT06090812|OTHER|Ultrasound evaluation|Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
215061969|NCT01138085|DRUG|GSK1120212|MEK inhibitor
215061970|NCT01138085|DRUG|GSK2141795|AKT Inhibitor
215061971|NCT03684837|DIETARY_SUPPLEMENT|Vitamine D supplementation|a vitamine D dose for week
215061972|NCT03684837|OTHER|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
215061973|NCT05377476|OTHER|Motor Imagery training|Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation.
215061974|NCT05377476|OTHER|Action Observation training|Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation.
214321056|NCT01735292|DEVICE|Automatic Respiration Transfer System- Timer|
215061975|NCT05377476|OTHER|standard rehabilitation|40 minutes of standard rehabilitation.
214321057|NCT05444309|PROCEDURE|Quadratus lumborum (QL) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the quadratus lumborum block approach
215061976|NCT05594485|DEVICE|Carebot AI CXR|Carebot AI CXR is a deep learning-based software that assists radiologists in the interpretation of chest radiographs in posterior-anterior (PA) or anterior-posterior (AP) projections. The solution with artificial intelligence automatically detects abnormality based on visual patterns for the following findings: atelectasis, consolidation, cardiomegaly, mediastinal widening, pneumoperitoneum, pneumothorax, pulmonary edema, pulmonary lesion, bone fracture, hilar enlargement, subcutaneous emphysema, and pleural effusion.
215061977|NCT05648877|DEVICE|Ureteroscope|Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
215061978|NCT06019039|DRUG|Normal Saline Flush|Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
214321058|NCT05444309|PROCEDURE|Pericapsular Nerve Group (PENG) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the Pericapsular Nerve Group (PENG) block
214920537|NCT06666010|DRUG|PEX010(01)|The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
214920538|NCT06685419|OTHER|Propolis containing gum|Patients with moderate gingivitis will be asked to use gum containing propolis 5 times a day for a total of 3 weeks.
214920539|NCT03152838|GENETIC|DNA methylation and Real-time Polymerase Chain Reaction Analysis|"Fasting blood samples will be collected from both autism and controls for DNA extraction. Peripheral blood (2ml) will be drawn from the cubital vein intoplastic syringes. Lymphocytes will be isolated from blood samples. We will examine the gene methylation in the peripheral blood lymphocytes of drug-naı¨ve autism patients and control subjects.~DNA will be isolated from lymphocytes, purified and processed for bisulfate modification. Bisulfate treatment of genomic DNA will be performed using DNA methylation kit according to the manufacturer´ instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, but leaves methylated 5'Cytosines unchanged. Quantitative real time Polymerase chain reaction will be used to determine the DNA methylation status of the Brian derived neurotrophic factor and glia fibrillary acidic protein genes using primers specific to the human genes."
214920540|NCT03152838|DIAGNOSTIC_TEST|Gilliam Autism Rating Scale Arabic version|"An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score. The Arabic version has been validated with good reliability and validity and used in many studies before. The lower the scores are, the worse the condition is.~The scale will be done by trained and certified psychologist. The protocol and informed consent for this study will be reviewed and approved by the ethics committee at the Faculty of Medicine, Assiut University, Egypt."
214920541|NCT04313179|OTHER|Music therapy|Mozart lullaby music
214920542|NCT04313179|OTHER|Sucrose|0.5 ml of 24% Sucrose
214484448|NCT06887400|OTHER|Point of care ultrasound (POCUS)|In this study, POCUS was performed by the same emergency medicine physician who had basic and advanced USG training and at least two years of POCUS experience, in accordance with ACEP imaging protocols. A portable USG device with B-Mode, M-Mode, Color Doppler, Power Doppler, Pulsed Wave Doppler modes, and which can be used in all clinical modes with a single probe was used during the protocol application (Butterfly iQ+™, Burlington, United States). Eight abdominal points (epigastric region, right upper quadrant, right side, right lower quadrant, suprapubic region, left lower quadrant, left side and upper quadrant, umbilical region) were scanned with POCUS, the findings were recorded on the previously prepared form, the triage categories of the patients (cl) were updated and the patients were directed to the area where they would be examined with the form.
214484449|NCT06883864|PROCEDURE|Catheter ablation plus medication|All patients will receive atrial fibrillation catheter ablation. They also should receive guideline-directed medical therapy, anticoagulation, and rate control with medications according to the guidelines.
214484450|NCT06883864|DRUG|Medication|Patients will receive guideline-directed medical therapy, anticoagulation, and rate control according to the guidelines for the management of AF and heart failure.
214484451|NCT06883864|PROCEDURE|(ELEVATE-AF X) experimental group|Subsequent ablations may be considered for patients with recurrence，and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.
214484452|NCT06883864|PROCEDURE|(ELEVATE-AF X) control group|All patients could receive catheter ablation if the procedure is needed, and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.
214484453|NCT06885008|OTHER|Active video game|The participants played the video game using an Xbox 360 Kinect console connected to a 55-inch Full HD television. The video games were planned with the assistance of a physiotherapist, 3 days per week, with 8 repetitions during the first 4 weeks and 12 repetitions during the final 4 weeks. The warm-up and cool-down periods were designed and applicated.
214920543|NCT01666743|DRUG|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
214920544|NCT01855243|DRUG|regular insulin|
214920545|NCT01855243|DRUG|70/30 insulin|
214920546|NCT01855243|DRUG|Glargine|
214920547|NCT01855243|DRUG|glulisine|
214920548|NCT02126423|OTHER|Conjunctival and nasopharyngeal swabs|For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.
215061979|NCT06019039|DEVICE|Doppler|"All color flow Doppler images will be performed with a Phillips CX50 ultrasound machine using a 5.0 MHz a low frequency curvilinear US probe. A two-dimensional transverse interspinous view was used to visualize the posterior complex (ligamentum flavum, epidural space and dura). After loss of resistance to normal saline, the color flow Doppler function will be turned on to examine flow through the epidural needle tip.~The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space ."
215061980|NCT01826539|PROCEDURE|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
215061981|NCT00853710|OTHER|PSA assay|rapid prostate specific antigen assay.
215061982|NCT00135330|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
215061983|NCT00135330|DRUG|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
215061984|NCT01132846|OTHER|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
215061985|NCT01132846|DRUG|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
214920549|NCT05928429|DEVICE|Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA|Patients in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).
214920550|NCT05133089|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
214920551|NCT04068129|DEVICE|photoscreen|Determine amblyopia risk factors
215061986|NCT01132846|DRUG|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
215061987|NCT03075306|BEHAVIORAL|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
215061988|NCT04920071|DEVICE|Visual acuity and contrast sensitivity measurement|Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
215061989|NCT04099355|DRUG|Dronabinol 5mg Cap|1 QAM and 2 QHS PO 14 days
214321059|NCT04256616|OTHER|This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.|"urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC."
215061990|NCT04099355|DRUG|Non-active comparator|1 QAM and 2 QHS PO 14 days
215061991|NCT04512820|DEVICE|TRUCLEAR tissue removal system|evacuation of POC using the TRUCLEAR tissue removal system
215061992|NCT00163241|DRUG|celecoxib|
215061993|NCT05780008|BEHAVIORAL|Eat My ABCs|"The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home."
214321060|NCT01002144|OTHER|blood sampling|
214321061|NCT01931267|BEHAVIORAL|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
215061994|NCT04505319|DEVICE|DEFINISSE CORE FILLER|"DEFINISSE CORE FILLER volume will be injected between 4.0 of 5.0 ml on the whole face (at the discretion of the treating physician to achieve an optimal aesthetic result).~A touch-up will be possible at the first follow-up visit (after one month) with a amount of product between 4.0 and 5.0 ml on the whole face"
215061995|NCT02644252|DRUG|Day 1: Cisplatin 75 mg/m2|
215061996|NCT02644252|DRUG|Day 1: Vinorelbine 25 mg/m2|
215061997|NCT02644252|DRUG|Day 8: Capsule vinorelbine 50 mg/m2|
215061998|NCT02644252|DRUG|Day 1: Carboplatin AUC=5|
215061999|NCT02644252|DRUG|Day 1: Vinorelbine 30 mg/m2|
215062000|NCT02644252|DRUG|Day 8: Capsule vinorelbine 60 mg/m2|
215062001|NCT02644252|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily until progression|
215062002|NCT02644252|DRUG|Placebo 1 capsule x 3 daily until progression|
215062003|NCT01720589|DIETARY_SUPPLEMENT|Melt (test oil)|
215062004|NCT01720589|DIETARY_SUPPLEMENT|Corn oil (control)|
215062005|NCT06273722|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
215062006|NCT05289492|DRUG|EOS884448|EOS884448 will be administered in arm A,B and C
215062007|NCT05289492|DRUG|Iberdomide|Iberdomide will be administered in arm B and C
214920552|NCT06666140|OTHER|Ultrasonic elastography|"The measurement of diaphragmatic stiffness by shear waves is performed with a high-frequency linear ultrasound probe, intercostally, during apneas lasting a few seconds.~After quantitative diaphragm thickness measurements, the ultrasound probe positioning is unchanged and regions of interest are placed in the patient's diaphragm thickness as well as in the adjacent liver or spleen (baseline). A stiffness result is obtained in kPa.~The elastography measurement extends the duration of the ultrasound scheduled as part of patient care by only 10 minutes.~The examination is painless and non-invasive."
215062008|NCT05289492|DRUG|Dexamethasone|Dexamethasone will be administered in arm C
215062009|NCT05689918|OTHER|No intervention|No intervention
215062010|NCT03387709|BEHAVIORAL|Pistachio-enriched diet|Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
215062011|NCT03387709|BEHAVIORAL|General dietary guidance diet|During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
215062012|NCT00004215|BIOLOGICAL|filgrastim|
215062013|NCT00004215|BIOLOGICAL|leridistim|
215062014|NCT00004215|DRUG|cytarabine|
214321062|NCT01931267|BEHAVIORAL|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
214321063|NCT01086592|OTHER|No intervention|Daily life activities
214920553|NCT00730795|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)
215062015|NCT00004215|DRUG|daunorubicin hydrochloride|
215062016|NCT05432596|DRUG|ATI-1777 2.0% w/w|ATI-1777 topical solution 2.0% w/w
214321064|NCT01086592|OTHER|Strong progressive strengthening exercises of lower limbs|Lower limb weight
214920554|NCT00943150|DEVICE|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
214920555|NCT00943150|PROCEDURE|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
214920556|NCT04582058|BEHAVIORAL|Mobile Health of lifestyle|Mobile health of lifestyle with an orientation about daily activities and necessary care to patients with CEID, and protocol of exercise training with images and guidelines to execute five days per week, with a duration of 50 minutes, and space for doubts which patients could send message to researcher.
215062017|NCT05432596|DRUG|ATI-1777 1.0% w/w|ATI-1777 topical solution 1.0% w/w
214484454|NCT06885008|OTHER|Aerobic exercise|Aerobic exercise training was performed on a stationary bike, 3 days per week, for 20 minutes per session. The intensity of the aerobic exercise was determined using the Karvonen method. For the first 4 weeks, the intensity was set at 30-50% of the maximum heart rate (MHR), corresponding to light intensity, and was then increased to 50-70% (moderate intensity) for the following 4 weeks. A pulse oximeter (ChoiceMMed, China) was used to monitor the target heart rate. During both the warm-up and cool-down phases of the aerobic exercise, participants performed hip abduction and adduction, hip-knee flexion, heel raises, and mini squats while standing for 3-5 minutes.
214484455|NCT06885008|OTHER|Conventional treatment|Convetional treatment included Hotpack, Transcutaneous Electrical Nerve Stimulation (TENS), and Ultrasound (US) modalities, were applied to the symptomatic knee(s) for a total duration of 30 minutes. Following this, the exercise program outlined below was performed with 3 sets of 10 repetitions each. The session lasted approximately 45 minutes.
214484456|NCT06886503|OTHER|Inspiratory Warm-Up - 60% MIP|Inspiratory Muscle Warm-up Protocols In addition to athletic warm-up an athletic warm-up protocol, participants performed inspiratory muscle warm-up (IMW) using the POWERbreathe® Plus Blue Medium Resistance (POWERbreathe International Ltd., Warwickshire, England UK). In the IW60 arm, inspiratory muscle warm-up was performed at 60% of maximal inspiratory pressure (MIP). Each protocol consisted of two sets of 30 repetitions (Marostegan et al., 2022; Demirkan et al., 2025).
214484457|NCT06886503|OTHER|Inspiratory Warm-up - 40% MIP|Inspiratory Muscle Warm-up Protocols In addition to athletic warm-up an athletic warm-up protocol, participants performed inspiratory muscle warm-up (IMW) using the POWERbreathe® Plus Blue Medium Resistance (POWERbreathe International Ltd., Warwickshire, England UK). In the IW40 arm, inspiratory muscle warm-up was performed at 40% of maximal inspiratory pressure (MIP). Each protocol consisted of two sets of 30 repetitions (Marostegan et al., 2022; Demirkan et al., 2025).
214484458|NCT06886503|OTHER|Sham|In addition to athletic warm-up an athletic warm-up protocol, participants performed inspiratory muscle warm-up (IMW) using the POWERbreathe® Plus Blue Medium Resistance (POWERbreathe International Ltd., Warwickshire, England UK). In the sham arm, inspiratory muscle warm-up was performed at 15% of maximal inspiratory pressure (MIP). Each protocol consisted of two sets of 30 repetitions (Marostegan et al., 2022; Demirkan et al., 2025).
214484459|NCT06884280|DRUG|Monofer (iron isomaltoside 1000)|Intravenous iron infusion, administered in this study up to every 3 months. Dosage determined by haemoglobin and weight.
214920557|NCT00067301|DRUG|Polyunsaturated Fatty Acids (PUFA)|
214920558|NCT00067301|DRUG|Citalopram|
214920559|NCT04431908|DEVICE|olfactory device|A quantitative non-biased olfactory device intended for the rapid identification of SARS-CoV-2 infected subjects (as identified by PCR).
214920560|NCT05842447|DIETARY_SUPPLEMENT|367 mg Pomanox group|Treatment with 367 mg Pomanox®P30 during 12 weeks
214920561|NCT05842447|DIETARY_SUPPLEMENT|700 mg Pomanox group|Treatment with 700 mg Pomanox®P30 during 12 weeks
214920562|NCT05842447|DIETARY_SUPPLEMENT|Control group|Treatment with maltodextrin during 12 weeks
214920563|NCT01704651|DRUG|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.
214920564|NCT01704651|DRUG|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
214920565|NCT00543972|DRUG|AVE9633|Intravenous Infusion
214955231|NCT01963507|BEHAVIORAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
214955232|NCT04192890|DEVICE|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
214955233|NCT04724603|OTHER|patients having had avderse event after phagotherapy for bone or joint or implant infection|to determine the accountability of adverse effects in having had avderse event after phagotherapy for bone or joint or implant infection
214955234|NCT01042821|PROCEDURE|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
214955235|NCT01042821|PROCEDURE|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
214955236|NCT00836446|OTHER|physical activity|physical activity routines 5 times a weeks for 12 weeks.
214955237|NCT02247882|OTHER|Patient Education|"The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.~The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain."
214955238|NCT02247882|OTHER|Aquatic Physical Therapy|The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
214920566|NCT05555524|OTHER|Baby oil|"Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool baby oil will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks"
215062018|NCT05432596|DRUG|ATI-1777 0.5% w/w|ATI-1777 topical solution 0.5% w/w
214920567|NCT05555524|OTHER|Placebo|"Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool distilled water will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks"
215062019|NCT05432596|DRUG|Vehicle|Vehicle topical solution
215062020|NCT02466477|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
215062021|NCT02466477|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
215062022|NCT02466477|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
215062023|NCT05349968|DRUG|Lipovirtide for injection|Multiple dosing of Lipovirtide
215062024|NCT00005987|DRUG|carmustine|
215062025|NCT00005987|DRUG|cyclophosphamide|
215062026|NCT00005987|DRUG|dexamethasone|
215062027|NCT00005987|DRUG|etoposide|
215062028|NCT00005987|DRUG|filgrastim|
215062029|NCT00005987|DRUG|mitoxantrone hydrochloride|
215062030|NCT00005987|DRUG|recombinant interferon alfa|
215062031|NCT00005987|DRUG|sargramostim|
215062032|NCT00005987|PROCEDURE|bone marrow ablation with stem cell support|
215062033|NCT00005987|PROCEDURE|peripheral blood stem cell transplantation|
215062034|NCT00005987|PROCEDURE|radiation therapy|
215062035|NCT01482806|BEHAVIORAL|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
215062036|NCT01482806|BEHAVIORAL|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
215062037|NCT00104416|DRUG|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
214321065|NCT01086592|OTHER|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
214321066|NCT01086592|OTHER|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
214321067|NCT02041026|DIETARY_SUPPLEMENT|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
214321068|NCT04275128|DEVICE|Cooled radiofrequency ablation|Cooled radiofrequency thermal treatment uses the electrical current produced by radio waves to destroy a part of nerve tissue and relieve pain.
214484460|NCT06884280|DRUG|Ferrous Sulfate|Oral iron tablet taken once daily for duration of study.
214920568|NCT02136212|BEHAVIORAL|Approach-positive AAT|
214920569|NCT02136212|BEHAVIORAL|Control AAT|
214920570|NCT04322019|OTHER|Data record|Data record
214920571|NCT02791321|OTHER|ADS severity|Evaluation of the ADS severity with the CARS scale
214920572|NCT02791321|OTHER|Adaptative and intellectual functioning|Evaluation with IQ and Vineland II scale
214920573|NCT02791321|OTHER|Psychiatric and somatic comorbidities|Evaluation with the Reiss, DSQIID and CIRS Scales
214920574|NCT06620640|DEVICE|Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.|Nigth stimulation
214920575|NCT03315286|DEVICE|SHADE Ultraviolet Sensor|Patients will wear device for 6 months in addition to their own method of photo-protection.
214920576|NCT03315286|BEHAVIORAL|Standard of care counseling|Patients will use their own method of photo-protection
215062038|NCT00104416|DRUG|Placebo|Placebo control
215062039|NCT00909441|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
215062040|NCT02047422|DRUG|Furosemide|furosemide (doubling previous furosemide dose)
215062041|NCT02047422|DRUG|metolazone|metolazone (add 2.5mg qod)
214484461|NCT06888063|COMBINATION_PRODUCT|Hepatic Arterial Infusion Pump chemotherapy with floxuridin|Participants in this arm will receive in addition to standard care (surgery) a chemo pump. This pump will provide participants with 4 cycles of treatment with chemotherapy (Floxuridin), each lasting 4 weeks. Total treatment with chemotherapy will last 16 weeks (approx. 4 months)
214484462|NCT06888739|PROCEDURE|MR4|The study is a clinical retrospective study and does not involve any interventional measures.
214484463|NCT06887673|OTHER|No Interventions|No study treatment other than the standard of care management.
214484464|NCT06887673|DIETARY_SUPPLEMENT|Sports Pro Resolve 4 g|Sports Pro Resolve 4 tabs (2 g) twice daily
214484465|NCT06887673|DIETARY_SUPPLEMENT|Double Wood SPM 4 g|Double Wood SPM 4 tabs (2 g) twice daily
214484466|NCT06887673|DIETARY_SUPPLEMENT|20 California Sweet Almonds|10 California Sweet Almonds twice daily
214484467|NCT06887673|DRUG|Montelukast 10 Mg Oral Tablet|Montelukast 10 Mg Oral Tablet daily
214484468|NCT06887673|COMBINATION_PRODUCT|Montelukast 10 Mg Oral Tablet and SPM 4 g|Montelukast 10 Mg Oral Tablet and SPM 4 g
214484469|NCT06887673|DIETARY_SUPPLEMENT|Cold- Pressed Almond Oil 30 mL|Cold- Pressed Almond Oil 30 mL every morning
214484470|NCT06885476|BIOLOGICAL|Infusion of alloreactive NK cells|Infusion of alloreactive NK cells for acute leukemia patients harboring minimal residual disease after conventional chemotherapy and prior to allogeneic stem cell transplantation
214484471|NCT06890182|DRUG|Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed|furmonertinib 80mg/d for 12 weeks and carboplatin AUC5 d1 iv / cisplatin 75mg/m2 d1 iv+ pemetrexed 500mg/m2 d1 iv at 21 day cycles for 4 cycles
214920577|NCT03003039|BIOLOGICAL|GB241|Single intravenous infusion (IV) 375 mg/m2
214920578|NCT03003039|BIOLOGICAL|Rituximab|Single intravenous infusion (IV) 375 mg/m2
214920579|NCT02604498|DRUG|Nemonoxacin|Single dose 500mg oral
214920580|NCT02076893|DRUG|gabapentin|The active comparator arm will receive gabapentin as per dosing specifics listed in the study arm description.
214920581|NCT02076893|DRUG|Tramadol|Both study arms will receive tramadol per dosing details listed in the study arm descriptions.
214920582|NCT02076893|DRUG|Ibuprofen|Both study arms will receive as needed (PRN) ibuprofen to take home.
214920583|NCT02076893|DRUG|Placebo|Simple syrup suspension
214920584|NCT06620120|DEVICE|Insoles|"At the D0 visit, if the patient is assigned to the arm with insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
214920585|NCT06620120|OTHER|Without insoles|"At the D0 visit, if the patient is assigned to the arm without insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
214920586|NCT03075891|DRUG|Ivermectin 1% cream|Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
214920587|NCT03075891|DRUG|Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|1 Capsule once-daily for 12 weeks
214920588|NCT03075891|OTHER|Oral placebo capsules|1 Capsule once-daily for 12 weeks
214920589|NCT01084317|OTHER|medical documentation and telephone interview|medical documentation analysis supplemented by telephone interview conducted with parents of the child
214920590|NCT03391869|BIOLOGICAL|Ipilimumab|Given IV
214920591|NCT03391869|PROCEDURE|Local Consolidation Therapy|Undergo radiation and/or surgery
214920592|NCT03391869|BIOLOGICAL|Nivolumab|Given IV
214920593|NCT03391869|OTHER|Quality-of-Life Assessment|Ancillary studies
214920594|NCT03391869|RADIATION|Radiation Therapy|Undergo radiation
214920595|NCT03391869|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214920596|NCT05852717|PROCEDURE|AutoSCT OR CAR T-cell Therapy|Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP
214920597|NCT05852717|DRUG|GDP|Gemcitabine Cisplatin Dexamethasone
214920598|NCT05852717|DRUG|Epcoritamab|Epcoritamab
214920599|NCT06967766|BEHAVIORAL|health education based on the Metaphor-Embedded Integrated Behavioral Model|In each intervention scenario, health education information is set to target key behaviors in the scenario. In the main scenarios for obtaining antibiotics, such as township health centers, village clinics, and community pharmacies, scenario-driven interventions are carried out for two key behaviors: patients actively asking for antibiotics (led by doctors in township health centers) and customers buying antibiotics without prescriptions (led by community pharmacy staff).
214920600|NCT06968936|DRUG|Sucrose Iron，subcutaneous recombinant human erythropoietin，intravenous vitamin C|Patients in the experimental group will receive a combination therapy consisting of intravenous sucrose iron (200 mg), subcutaneous recombinant human erythropoietin (150 IU/kg), and intravenous vitamin C (2 g), administered once daily for three consecutive days within the week prior to surgery.
214920601|NCT06968936|PROCEDURE|Routine perioperative management|Routine perioperative management based on clinical judgment, including observation, monitoring, and standard nursing practices.
214920602|NCT06967688|OTHER|Smartwatch-Supported Caregiver Intervention|This intervention involved informal caregivers of people with dementia using smartwatches to monitor and manage their own health parameters over an 8-week period. The primary goal was to enhance caregivers' self-efficacy and overall well-being by providing real-time health data through wearable technology. Caregivers were introduced to the smartwatch features, which included heart rate monitoring, inactivity alerts, sleep tracking, stress level monitoring, weight tracking, water intake reminders, and blood oxygen level measurements. Caregivers were instructed to track these parameters using the smartwatch and record their health behaviors in provided diaries.Weekly phone consultations lasting no more than 5 minutes were conducted throughout the 8-week intervention, where caregivers' use of the smartwatch and diaries was reviewed, and general discussions about their health and caregiving experiences took place. The intervention aimed to integrate health self-monitoring into the caregi
214920603|NCT06968338|BIOLOGICAL|ARGX-213|Intravenous or subcutaneous administrations of ARGX-213
214484472|NCT06889454|DRUG|GLP-1 receptor agonist|30 women will receive lifestyle modification and GLP-1 receptor agonists
214484473|NCT06889454|DRUG|Oral contraceptive|30 women will receive lifestyle modification and oral contraceptive
214484474|NCT06889454|DRUG|Metformin|30 women will receive lifestyle modification and metformin
214484475|NCT06889454|OTHER|Lifestyle modification|30 women will receive only lifestyle modification
214484476|NCT06737991|OTHER|Range of motion exercises|Range of motion Exercises, soft tissue massage, positioning to prevent pressure sores, stretch pole for 20 minutes
214484477|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (low dose)|Administered intravenously. For phase I: single infusion, 1.0×10\^6 cells/kg. For phase II: 1.0×10\^6 cells /kg once a week for a total of 4 times.
214920604|NCT06968338|OTHER|Placebo|Intravenous or subcutaneous administrations of placebo
214920605|NCT05326243|BIOLOGICAL|CD19-targeted chimeric antigen receptor T-cell|"Drug: Fludarabine~patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Drug: Cyclophosphamide~patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Biological: CD19 CAR-T~CD19 CAR-T cells will be administered using as a single dose at 0.1-9\*10\^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis."
214484478|NCT06740149|DRUG|Solvent of CG-BM1|Administered intravenously, once a week for a total of 4 doses.
214484479|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (medium dose)|Administered intravenously. For phase I: single infusion, 2.0×10\^6 cells /kg. For phase II: 2.0×10\^6 cells /kg once a week for a total of 4 times.
214484480|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (high dose)|Administered intravenously. For phase I: single infusion, 4×10\^6 cells /kg.
214920606|NCT04957615|BIOLOGICAL|Nivolumab|Given IV
214955239|NCT04919603|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
214955240|NCT04919603|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to \< Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)
214955241|NCT05916807|OTHER|Stabilization Exercises|It consists of 26 patients who will receive stabilization exercises which will be divided in three components in lying posture, sitting, standing, rolling and kneeling positions to treat posterior, inferior muscles of scapula for 35-45 min for 3 days a week for 4 weeks.
214955242|NCT05916807|OTHER|Posture Training|It consists of 26 patients who will receive postural training and breast-feeding patterns for the mother and child for 35-45 min in 3 days a week for 4 weeks.
214955243|NCT00460239|DRUG|Buprenorphine|Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
214955244|NCT00460239|DRUG|Morphine|Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
214955245|NCT00460239|DRUG|Placebo|Intramuscular; double blind; once per week
214955246|NCT03055910|DIAGNOSTIC_TEST|Fractional Flow Reserve Measurement|Wire-based invasive measurement of the fractional flow reserve in the context of coronary angiography and percutaneous coronary intervention in order to assess the hemodynamic relevance of coronary artery stenoses
214955247|NCT00348335|DRUG|Cyclosporine 0.05%|
214955248|NCT00348335|DRUG|Ocular lubricant|
214955249|NCT01462305|DEVICE|goLITE|goLITE at 30 minutes per day, within 30 minutes of waking in the morning
214955250|NCT01462305|DEVICE|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
214955251|NCT03668665|DRUG|Ready Medical Post Treatment|"Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed"
214955252|NCT03668665|DEVICE|Conventionell Treatment|Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively
214955253|NCT02225808|BEHAVIORAL|CBT for anxiety in autism|
214955254|NCT02455453|DRUG|18F-FFNP|
214955255|NCT02455453|DEVICE|CTI/Siemens Biograph 40 PET/CT Scanner|"* Will include (1) 18-FDG-PET/CT scan~* Will include (2) 18F-FFNP-PET/CT scans"
214955256|NCT02455453|DRUG|Estradiol|
214955257|NCT02455453|DRUG|18F-FDG|
214955258|NCT06014164|DIAGNOSTIC_TEST|Interview|An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes
214955259|NCT03169907|RADIATION|Mid trimesteric fetal ultrasonography|"Venous and arterial Doppler indices:~1. Middle cerebral artery (MCA) peak systolic velocity (PSV):~2. Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):~3. Ductus venosus (DV) Doppler:~Cardiac functions:~1. Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):~2. Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:~3. Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)"
214955260|NCT04141397|GENETIC|Initiation of POG-related WGTA|POG-related WGTA generally involves collecting biopsy samples, applying whole-genome and transcriptome sequencing, and using bioinformatics analysis to interpret sequence data and inform clinical decision-making.
214955261|NCT04141397|GENETIC|Usual care|Usual care, not involving the initiation of POG-related WGTA
214955262|NCT00649792|DRUG|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
214955263|NCT05569369|PROCEDURE|angioplasty and stenting|dilatation of stenotic arteries and insertion of stent
214955264|NCT00032500|DRUG|Echinacea|
214955265|NCT01996150|DRUG|bleach bath (sodium hypochlorite)|Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
215062042|NCT02047422|DRUG|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
215062043|NCT02047422|DRUG|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
215062044|NCT04597645|OTHER|Therapeutic elastic band resistance training|A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
214920607|NCT01131169|DRUG|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.
214484481|NCT06739018|OTHER|pentacam scheimpflug tomography|"Pentacam tomography is not radiation-based. It uses Scheimpflug imaging, which involves a rotating camera that captures multiple images of the anterior segment of the eye. The system employs light-based technology to measure the front and back surfaces of the cornea, along with the anterior chamber and lens, creating a 3D model of the anterior eye structures.~it uses light instead of ionizing radiation (like X-rays), it is considered safe and non-invasive for routine use in ophthalmology.~* It was used to assess 23 parameters from topographic maps and 15 parameters from Belin-Ambrosio enhanced ectasia (BAD) display maps.~* Parameters included keratometry readings, anterior and posterior sagittal curvature, corneal thickness, anterior chamber volume, and several indices from the BAD display map.~* These parameters were analyzed to discriminate between keratoconus and high myopic astigmatism using Receiver Operating Characteristic (ROC) curves for diagnostic accuracy."
214484482|NCT06738706|DEVICE|intermittent hypoxia-hyperoxia treatment|The intermittent hypoxia-hyperoxia training refers to 4 cycles of 10-minute hypoxia inhalation interspersed with 20-minute hyperoxia, which is performed once daily for 14 days within 2 to 3 weeks.
215062045|NCT03493061|DRUG|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
215062046|NCT03493061|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
214920608|NCT01131169|DRUG|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.
214920609|NCT03626402|BEHAVIORAL|Planning for the Care You Want|25-minute culturally specific educational video informing viewers about advance care planning options, palliative care, and hospice care and meeting with a lay health advisor to discuss content of the video.
214920610|NCT00828568|DRUG|Imiquimod 5% manufactured by Taro|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
214920611|NCT00828568|DRUG|Aldara - Imiquimod 5%|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
214920612|NCT00828568|DRUG|Imiquimod Vehicle manufactured by Taro|Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
215062047|NCT03493061|DRUG|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
215062048|NCT01309997|DRUG|imatinib mesylate|Given PO
215062049|NCT01309997|BIOLOGICAL|rituximab|Given IV
215062050|NCT01500785|DRUG|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
215062051|NCT01500785|DRUG|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
215062052|NCT00243945|DRUG|Rotigotine|
215062053|NCT03462641|DRUG|Flumazenil|1mg in 10cc normal saline
215062054|NCT03462641|DRUG|Placebo|10 cc normal saline
215062055|NCT05130385|DEVICE|High-resolution optical coherence tomography (High-Res-OCT)|Imaging with high-resolution optical coherence tomography
215062056|NCT05130385|DEVICE|Standard spectral domain OCT (SD-OCT)|Imaging with standard spectral domain OCT
215062057|NCT05509647|DRUG|Unfractionated heparin|Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
215062058|NCT04075006|DRUG|Ketamine|standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
215062059|NCT00752934|DRUG|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
215062060|NCT00752934|DRUG|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
215062061|NCT00954564|OTHER|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
215062062|NCT00954564|OTHER|medical chart review|Observational only
215062063|NCT00954564|OTHER|questionnaire administration|Observational only
215062064|NCT00954564|PROCEDURE|assessment of therapy complications|Observational only
215062065|NCT02051751|DRUG|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
215062066|NCT02051751|DRUG|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
215062067|NCT00372619|DRUG|clofarabine|Given IV for 5 days
215062068|NCT00372619|DRUG|cytarabine|Given IV
214484483|NCT05039411|BIOLOGICAL|PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.
214484484|NCT06713889|BIOLOGICAL|Biocollection|"At each sampling time, 2 dry tubes of 4 ml, 1 EDTA tube of 4 ml, and 1 heparinised tube of 4 ml, i.e. a total of 16 ml per sampling time.~Group A patients will be sampled at inclusion, before, during and after the TAVI procedure, at 1 month follow-up and at 1 year follow-up, for a total of 120 ml. Patients in groups B and C will be sampled at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up, for a total of 80 ml."
214484485|NCT06713889|BEHAVIORAL|Quality of life questionnaires|EQ-5D-5L and HAD questionnaire at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up
215062069|NCT00372619|DRUG|methotrexate|Given intrathecally or IT age based dosage
215062070|NCT00372619|OTHER|laboratory biomarker analysis|
215062071|NCT00437957|DRUG|Temozolomide|75 Mg/m2/day for all Cohorts
215062072|NCT00437957|DRUG|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
215062073|NCT00437957|PROCEDURE|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
215062074|NCT03394651|DRUG|Oral medications to treat lower urinary tract symptoms|Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
215062075|NCT03394651|PROCEDURE|Minimal invasive transurethral prostate procedures|Patients in this group will receive surgical treatment.
215062076|NCT02553200|DEVICE|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
215062077|NCT02553200|DEVICE|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
215062078|NCT02553200|DEVICE|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
215062079|NCT01748461|BEHAVIORAL|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
215062080|NCT01748461|BEHAVIORAL|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
215062081|NCT03729583|BEHAVIORAL|Pulmonary Rehabilitation|A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
215062082|NCT01555853|DRUG|Abraxane|
215062083|NCT02888691|OTHER|Low carbohydrate diet|
215062084|NCT02888691|OTHER|High carbohydrate diet|
215062085|NCT03037359|BIOLOGICAL|Bivigam|Human immune globulin
215062086|NCT03037359|BIOLOGICAL|Other|Human immune globulin
215062087|NCT03122678|DRUG|Thiamine|
215062088|NCT03122678|DRUG|Placebos|
215062089|NCT04534179|PROCEDURE|Vacuum myofascial therapy and physical activity program.|"This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program"
215062090|NCT04534179|OTHER|Physical activity program.|Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
215062091|NCT05398159|DEVICE|Trim II|"Eligible subjects will receive 3 bi-weekly treatments (once in 2 weeks) with Trim II hands-free applicator belt according to the study protocol.~Trim II hands-free applicator composed of 4 units applied to the abdominal area, using a single-use belt.~Each treatment duration will be 45-60 minutes. Study duration for each subject is approximately 6 months (including screening, 3 treatments and 2 follow-up visits at 1 and 3 months post last treatment)."
215062092|NCT03525301|RADIATION|standard treatment|3000 cGy in 10 daily fractions
215062093|NCT03525301|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
215062094|NCT00332020|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
214920613|NCT00597610|OTHER|Transrectal ultrasound 3-D (TRUS)|Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
214920614|NCT01155908|DRUG|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
214920615|NCT01096719|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|12 week standard behavioral weight loss intervention including a physical activity goal and behavioral weight control strategies
214920616|NCT01096719|BEHAVIORAL|Dietary Goal: Reduction in Energy Density of Dietary Intake|Consume low ED foods (ED \< 1.0) for at least 10 items consumed per day and limit high ED foods (ED \> 3.0) to two items consumed per day.
215062095|NCT00332020|DRUG|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
214920617|NCT01096719|BEHAVIORAL|Dietary Goal: Reduction of Energy Intake|Limit energy intake to 1200 to 1500 kcals/day and \< 30% kcals from fat.
214920618|NCT03864224|BEHAVIORAL|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
214920619|NCT02279654|DRUG|Lenalidomide|Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
214484486|NCT05871151|DEVICE|taVNS|Trans-auricular Vagus Nerve Stimulation is a non-invasive method of stimulating the auricular branch of the vagus nerve through the inner ear. Trans-auricular Vagus Nerve Stimulation will be provided using a commercially available device. The investigators will use custom earbuds that will make the experience significantly more comfortable than traditional transauricular Vagus Nerve Stimulation.
215062096|NCT02659033|DRUG|ceftriaxone|ceftriaxone (1 gram per day)
215062097|NCT02659033|DRUG|Cefotaxime|cefotaxime (1 gram every 8 hours)
215062098|NCT03235895|OTHER|Educational material|Educational material given as a part of CME activity as through enhanced internet method
215062099|NCT00101920|DRUG|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
215062100|NCT03960060|BIOLOGICAL|CCT301-59|Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
215062101|NCT02427386|DRUG|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
215062102|NCT02427386|DRUG|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
215062103|NCT04461873|OTHER|Reiki|Reiki by touching
215062104|NCT04461873|OTHER|Sham Reiki|Sham reiki by gesturing and mimic imitation through touching
215062105|NCT01624961|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
214920620|NCT00634803|BEHAVIORAL|CBT|Cognitive behavioral therapy
215062106|NCT04975984|DIAGNOSTIC_TEST|qualitative hCG levels and ultrasound criteria|detect upper limit of qualitative hCG levels associated with successful expectant management of ectopic pregnancy
214920621|NCT00634803|DRUG|Buprenorphine|buprenorphine/naloxone
214920622|NCT00634803|OTHER|Educational Counseling|Didactic, lecture-discussion format to supplement information and advice provided by physicians
214920623|NCT00634803|OTHER|Physician Management|Brief physician counseling
215062107|NCT01834950|OTHER|Blood test|
215062108|NCT03748706|DRUG|PTI-125, 100 mg tablets|PTI-125, 100 mg tablets taken twice a day for 28 days
215062109|NCT05634694|OTHER|No interventions.|No interventions.
215062110|NCT01370200|PROCEDURE|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
215062111|NCT04356846|DRUG|LP-108 tablet|Taken orally within 30 minutes after a meal at the designated dose, once daily.
214920624|NCT00396656|DRUG|Atenolol|100 mg tablets orally once a day (od) in the morning.
214920625|NCT00396656|DRUG|Hydrochlorothiazide (HCTZ))|12.5 or 25 mg tablets orally once a day (od) in the morning.
214920626|NCT00396656|DRUG|Valsartan|80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
214920627|NCT05747326|DRUG|oral vinorelbine and capecitabine|The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
214920628|NCT00841113|DRUG|Abarelix|100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter
214920629|NCT00841113|DRUG|Goserelin plus Bicalutamide|Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
214920630|NCT00552643|DEVICE|Suspension of polystyrene beads (POLYHEAL 1)|Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle
214920631|NCT00552643|DEVICE|Saline (0.9% NaCl)|Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
215062112|NCT03096639|DEVICE|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
215062113|NCT00422877|DRUG|Taxoprexin|DHA-paclitaxel
215062114|NCT05621122|OTHER|This is an observational study|This is an observational study. The control group (omnivours) will be compared with all otgher groups
215062115|NCT05294484|DRUG|Indapamide 1.5 MG SR|the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
215062116|NCT00952861|DRUG|Doxycycline|200 mg QD in 5 days
215062117|NCT00952861|DRUG|Placebo (matching)|Placebo QD i 5 days
214484487|NCT05871151|BEHAVIORAL|Exercise|All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations. The exercise intervention proposed involves the supervision of a licensed PT at all times during the treatment session. Exercise will be provided in a clinical setting, 45 minutes per session, up to 3 sessions/week, for 4-6 weeks total.
214484488|NCT06734494|DEVICE|Laparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation|Airseal is a constant and low-pressure insufflation device. Standard insufflation is a variable pressure insufflation device.
214484489|NCT06736236|OTHER|Inspiratory muscle warm-up|This study will use a respiratory muscle warm-up protocol set at 40% of the maximal inspiratory pressure (MIP) using the POWERbreath® device, as this intensity has been shown to optimally stimulate respiratory muscles. The protocol involves two sets of 30 breaths with a 60-second rest between sets, performed with participants sitting and using a nose clip. Participants will be trained in this technique during the familiarization session and monitored throughout the tests to ensure proper execution.
214484490|NCT06736236|OTHER|General warm-up (Control)|The general warm-up (Control) protocol will include exercises such as running and dynamic, active, and passive movements tailored to the diverse sports disciplines in the study. These movements will follow the principles of elevation, activation, and mobilization, focusing on increasing mobility from the arms and shoulders to the lower back and legs. Each session will involve demonstrations emphasizing proper technique and speed, with participants completing a consistent number of repetitions. Researchers will monitor participants closely to ensure correct form and execution throughout the intervention.
214484491|NCT06736236|OTHER|Inspiratory muscle warm-up placebo (IMW %15)|The respiratory muscle warm-up protocol will be conducted at 15% of maximal inspiratory pressure (MIP) using the POWERbreath® device. This placebo protocol will involve two sets of 30 breaths, separated by a 60-second rest, with participants seated and wearing a nose clip. Training for the technique will occur during a familiarization session, and participants will be observed during tests to ensure proper execution. The purpose of this protocol is to serve as a placebo, masking the actual aim of the study to enhance data reliability.
214484492|NCT06736067|BEHAVIORAL|Exercise|Thirty minutes of exercise on a treadmill, including a 5-minute warm-up followed by increments in speed until reaching optimal moderate to high intensity (60-80% of age-predicted maximal heart rate), which will be maintained for 20 min, followed by a 5-minute cool-down. Age-predicted maximal HR will be defined as 220 beats-per-minute (BPM) minus age in years.
214484493|NCT05771467|DIAGNOSTIC_TEST|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)
214484494|NCT06079216|BEHAVIORAL|Volunteer Led Making Connections Thru Music|Volunteer led Group music therapy-based intervention
214484495|NCT06079216|BEHAVIORAL|Staff Led Making Connections Thru Music|Staff led Group music therapy-based intervention
214484496|NCT02232386|DRUG|Ibrutinib|Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
214484497|NCT02232386|DRUG|Rituximab|Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
214920632|NCT00175149|DRUG|Alfacalcidiol|Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
214920633|NCT03825029|PROCEDURE|Pillow|A pillow to lessen the angle differences between hips so that the acetabular component can be placed in an optimal position.
214920634|NCT03177005|BIOLOGICAL|CSL830|
214920635|NCT03208998|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
214920636|NCT00364923|DRUG|Pralatrexate Injection|Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
214920637|NCT01965340|OTHER|Systematic Therapeutic Drug Monitoring for the intervention group|
214920638|NCT06575010|DRUG|Liposomal bupivacaine|20 mL Liposomal bupivacaine (Exparel) will be given in the shoulder block prior to surgery
214920639|NCT06575010|DRUG|Bupivacaine Hcl 0.5% Inj|0.75% bupivacaine will be given in the shoulder block prior to surgery
214920640|NCT06575010|DRUG|Dexamethasone|10 mg Dexamethasone will be given in the shoulder block prior to surgery
214920641|NCT05603611|DEVICE|Pulmonary vein isolation|Local electrical isolation of PV ostia to prevent recurrence of AF due to ectopic PV-triggers
214920642|NCT03474731|BEHAVIORAL|Diabetes Self-Management Program (DSMP)|"The the Diabetes Self Management Program (DSMP) in a group setting: participants will attend a six week, evidence-based diabetes home self-management program. The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization."
214920643|NCT03474731|BEHAVIORAL|Tailored Patient Navigation (PN) only|"Tailored Patient Navigation (PN) only: trained Community Health Workers (CHW) will meet one-on-one with participants to assess the barriers experienced in adhering to medical appointments and will implement a navigation program accordingly.~The goal of this arm of the project is to try to get participants to attend recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs."
214920644|NCT03474731|BEHAVIORAL|DSMP AND Tailored Patient Navigation|DSMP AND Tailored Patient Navigation : patient navigation followed by 6 weeks of DSMP classes after the 3 month post-test interview.
214920645|NCT03474731|BEHAVIORAL|Diabetes Self-Management Program (DSMP) Delayed|"Groups randomized to DSMP Delayed will receive 6 weeks of DSMP classes after the 3 month post-test interview.~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization."
214920646|NCT02432612|DRUG|Sativex|Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
214920647|NCT00766636|DRUG|Gemcitabine|"Arm A:~1000 mg/M\^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.~Arm B:~400 mg/M\^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day."
215062118|NCT05616546|BIOLOGICAL|Influenza Vaccine|The vaccine used in this study will be a licensed seasonal inactivated influenza vaccine for intramuscular injection that is approved by the FDA. Enrolled subjects will receive licensed seasonal inactivated influenza vaccine (administered as a part of the study).
215062119|NCT04903574|BEHAVIORAL|NEAT!2 sedentary behavior app|This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.
215062120|NCT04903574|OTHER|Pregnancy smartphone app|This is a commercially available general pregnancy smartphone app
215062121|NCT01959178|DEVICE|LD127025 MF|At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
215062122|NCT01959178|DEVICE|Air Optix Aqua MF|At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
215062123|NCT00091741|DRUG|Etanercept (Enbrel)|
215062124|NCT04010656|PROCEDURE|PVR-based self-catheterization|Home self-catheterization based on standard of care
215062125|NCT04563403|BEHAVIORAL|Projection-based augmented reality therapy (P-ARET)|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
215062126|NCT01094977|DRUG|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
215062127|NCT01094977|DRUG|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
215062128|NCT01094977|DRUG|Saline Placebo|
215062129|NCT05252494|OTHER|animal assisted therapy|In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
215062130|NCT04545424|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
215062131|NCT04545424|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
215062132|NCT04545424|DEVICE|Standard of care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
215062133|NCT04923633|DEVICE|Quantifiable Soft Tissue Manipulation (QSTM)|Quantifiable soft tissue manipulation (QSTM) is a force sensing device system that can be used by a clinician to apply a massaging force while the system monitors objective metrics, i.e., the amount, rate, and angle of force applied.
215062134|NCT03517371|OTHER|mHealth delivered exercise program|"Participants in the mobile health condition have up to 8 in-person visits with a physical therapist over 12 months. The exercise program, consisting of walking, strengthening and stretching exercises, is prescribed through an app and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week."
214484498|NCT03520114|DEVICE|RP sling placement|A 1.5 cm incision will be made at the mid-urethra through a separate vaginal incision with lateral dissection with Metzembaum scissors. After placement of both trocars, cystoscopy with a 70-degree scope will be performed to assess for bladder and urethral injury. Surgeons will set the tension of the tension-free vaginal tape (TVT) slings so that a spacer can be placed between the sling and the urethra. Sling tensioning will be performed after anterior and apical prolapse is corrected.
214920648|NCT00766636|RADIATION|Radiation Therapy|1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy.
214920649|NCT00766636|DRUG|Erlotinib|100 mg daily by mouth on days 1-42.
214920650|NCT00766636|PROCEDURE|Surgery|Surgical removal of the pancreas and duodenum
214920651|NCT05686135|OTHER|90Second IBD|Patients will receive 90SecondIBD weekly at no charge via text message or email linked to a website.Each 90SecondIBD letter has an attractive photo, 250 words of targeted information on a specific topic and 3 specific action suggestions on the first page. The second page is a seven-item quiz on attitudes and behavior on the designated topic. The reader gets immediate feedback and advice. The third page is a personal story of someone with IBD about this topic. Finally, there is an evaluation of the specific 90SecondIBD issue and an opportunity to recommend topics.
214920652|NCT05743348|BEHAVIORAL|Telepsychotherapy|Remotely delivered psychotherapy sessions
214484499|NCT03520114|DEVICE|SIS placement|The sling is introduced through a single anterior vaginal incision of 1.5 cm at the mid-urethra. The sling/needle assembly is advanced behind the ischiopubic rami in a transobturator trajectory toward the obturator space bilaterally. The needle is then removed by simply sliding the fixating tip back out. The other side is then completed in an identical fashion. After the fixation of the two anchors at the 2 and 10 o'clock positions, the patient's bladder is filled with 250 mL of Sodium Chloride (NaCl). Afterward, an intraoperative crede maneuver is performed and the tension adjustment suture is pulled, when necessary, to achieve the desired continence. The mesh will lie in direct apposition to the urethra. The adjustment thread is then cut short and the vaginal incision is closed with an absorbable suture.
214484500|NCT06742541|DEVICE|Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively|Planned surgery to receive a spherical Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively
214484501|NCT04629547|DRUG|Suvorexant 20 mg|Suvorexant 20mg will be taken nightly for 24 months.
214321069|NCT04275128|DEVICE|Conventional radiofrequency ablation|Genicular nerve ablation involves using radiofrequency to heat up the genicular nerve until it dies, causing relief of pain. This is a minimally invasive treatment that does not require any medication.
214321070|NCT05593224|DEVICE|Intracranial Stent (Tonbridge)|The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
214321071|NCT03612167|BEHAVIORAL|cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
214484502|NCT04629547|DRUG|Placebo|Placebo will be taken nightly for 24 months.
214484503|NCT06741631|BEHAVIORAL|MyPEEPS Mobile|An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence.
214484504|NCT01220531|BIOLOGICAL|Cultured Thymus Tissue|Potential recipients of cultured thymus tissue are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted under general anesthesia in the operating room. Cultured thymus tissue is placed into the subject's quadriceps. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one-year post-implantation. At approximately year 2 post-implantation, subjects are contacted for data collection.
214920653|NCT05542784|PROCEDURE|Modified LERV|"Patients routinely underwent LC. The ligature clamp clamps the distal end of the capsule tube. In this case, you need to perform two steps:~Laparoscopic operation: proximal incision, anterograde placement of guide wire into the duodenum. The catheter was removed and the balloon dilated. The balloon was released and removed when the ERCP was initiated for cannulation. After successful ERCP retrograde placement, the anterograde guide wire was pulled out and the gallbladder was removed.~ERCP procedure: After the anterograde guide wire was observed by duodenoscope, duodenal papilla was placed through a retrograde incision along the anterograde guide wire, and a retrograde cannula was inserted into the common bile duct. Remove stones by dragging them with a net basket or/and balloon. Angiography confirmed that there was no filling defect in the extrahepatic bile duct, and ENBD was indwelled."
214920654|NCT06353984|DIETARY_SUPPLEMENT|Minimeal product|Intervention product consisting of bioprocessed oats and chickpeas
214321072|NCT03612167|BEHAVIORAL|nutritional group|12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
214920655|NCT06353984|DIETARY_SUPPLEMENT|Reference product|Reference product mimicking available soups and fruit drinks
214920656|NCT01474473|DEVICE|CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.~CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days"
214920657|NCT01474473|DEVICE|Placebo and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.~Placebo is applied on the wound for 10 minutes every 3 to 4 days"
214920658|NCT02477332|BIOLOGICAL|QGE031|
214920659|NCT02477332|BIOLOGICAL|Omalizumab|
214920660|NCT02477332|OTHER|Placebo|
214920661|NCT02549287|BEHAVIORAL|SafeCare|An evidence-based home visiting program
214920662|NCT02549287|BEHAVIORAL|Supportive Case Management|Child welfare services as usual
214920663|NCT05321043|OTHER|Vitamin B2 labeling|Using medical non-toxic fluorescent agents, VB2 solution, to mark the patient's hands before endoscopy examination.
214920664|NCT05131438|DRUG|sugemalimab|sugemalimab (Anti-PD-L1 antibody)
214920665|NCT00250952|DRUG|Botox Cosmetic™|
214920666|NCT02420730|DRUG|AGN-232411|AGN-232411 topical ophthalmic solution
214920667|NCT02420730|DRUG|AGN-232411 Vehicle|Vehicle for AGN-232411 topical ophthalmic solution.
214920668|NCT04164108|DIETARY_SUPPLEMENT|Intermittent Enteral Nutrition Protocol|Patients will receive total recommended nutrition divided into four equal meals, delivered at a rate of 400 cc/hr at 8:00, 12:00, 16:00, 20:00. Titration schedule will include administering 50% of volume for first two feeds, then 75%, and then 100%.
214321073|NCT02837887|BEHAVIORAL|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
214321074|NCT01815281|DEVICE|Foot Mechanical Stimulation (GONDOLA)|
214321075|NCT03759093|DRUG|Bortezomib|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
214321076|NCT03759093|DRUG|Cyclophosphamide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
214321077|NCT03759093|DRUG|Dexamethasone|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
214484505|NCT06890572|DEVICE|HEPA + VOC collecting filter purifier|Subjects operate HEPA + VOC collecting filter purifier
214484506|NCT06890572|DEVICE|fake air purifier|Subjects operate fake air purifiers
214484507|NCT05903859|DRUG|Probenecid 500 Milligrams (mg)|Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
214321078|NCT03759093|OTHER|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen
214321079|NCT03759093|DRUG|Thalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
214321080|NCT03759093|DRUG|Bortezomib|Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
214484508|NCT05903859|DRUG|probenecid 250 Milligrams (mg)|Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
214484509|NCT05903859|DRUG|Placebo|Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
214484510|NCT06890299|DRUG|BR3006|One tablet administered alone
214484511|NCT06890299|DRUG|BR3006A|One tablet administered alone
214321081|NCT03759093|DRUG|Cyclophosphamide|Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
214321082|NCT03759093|DRUG|Thalidomide|Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
214321083|NCT03759093|DRUG|Dexamethasone|40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
214484512|NCT06890299|DRUG|BR3006B|One tablet administered alone
214484513|NCT06890299|DRUG|BR3006C|One tablet administered alone
214484514|NCT04873232|BIOLOGICAL|Engensis|Injections with Engensis in study VMDN-003-2
214484515|NCT04873232|OTHER|Placebo|Injections with Placebo in study VMDN-003-2
214920669|NCT05929768|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214920670|NCT05929768|DRUG|Carboplatin|Given IV
214920671|NCT05929768|DRUG|Cyclophosphamide|Given IV
214920672|NCT05929768|DRUG|Docetaxel|Given IV
214920673|NCT05929768|DRUG|Doxorubicin|Given IV
214920674|NCT05929768|DRUG|Paclitaxel|Given IV
214920675|NCT05929768|BIOLOGICAL|Pembrolizumab|Given IV
214920676|NCT05929768|OTHER|Quality-of-Life Assessment|Ancillary studies
214920677|NCT05929768|OTHER|Questionnaire Administration|Ancillary studies
214920678|NCT05929768|PROCEDURE|Surgical Procedure|Undergo surgery
214920679|NCT00765336|DRUG|minocycline extended release|1 mg/kg extended release minocycline HCL, once daily for 84 days.
214920680|NCT00765336|DRUG|Placebo|placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
214920681|NCT04549090|DRUG|QL (quadratus lumborum) block administration|Fo the QL block group, they will be receiving bilateral QL block. A total of 40ml of 0.25% bupivacaine (Marcaine) and 10ml of liposomal bupivacaine (Exparel) will be administered
214920682|NCT05000554|PROCEDURE|Neoadjuvant Therapy|"Drug:~Camrelizumab 200mg,d1，Repeat every 21 days for 3 courses； Oxaliplatin 130mg/m² ,d1;S-1 40-60mg,Bid, d1-14; S-1: bsa\<1.25m2,40mg/time，twice a day；bsa1.25\~1.5m2，50mg/time，twice a day；bsa≥1.5m2,60mg/次，twice a day，d1-d14；~Procedure: Gastric cancer resection Distal gastrectomy combined with D2 lymph node dissection"
214920683|NCT04455087|OTHER|sensitization|sensitization of doctor to decrease the prescription of abuse exams
214920684|NCT01082705|DRUG|artemether-lumefantrine|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
214920685|NCT01082705|DRUG|Dihydroartemisinin-piperaquine|once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
214920686|NCT05954195|OTHER|high intensity interval training|high intensity interval training through ergometer, with whole treatment session between 20 - 30 minutes divided into 3 parts, the 1st is warming up (40% of HRmax intensity for 2/3/5 minutes then the active training part (intervals of 85-90% of HRmax for 1 minute then rest period of 1 minute of 40 % of HRmax and so on for nearly 20 minutes ) then the last part is cooling down (30 % of HRmax for 3/5 minutes).
214920687|NCT00502970|DRUG|16 weeks Interferon Tiw with Ribavirin|16 weeks Interferon Tiw
214920688|NCT00502970|DRUG|24 weeks Interferon|24 weeks Interferon Tiw with Ribavirin
214920689|NCT04042688|DRUG|intraarticular administration of tranexamic acid|Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
214920690|NCT04459000|BEHAVIORAL|STARS + maternal Attachment Biobehavioral Catchup home visiting model|Mothers receive up to 12 home visits from a licensed therapist focused on attachment and positive parenting in substance exposed babies. This includes 1 prenatal home visit and up to 11 postnatal visits.
214920691|NCT04459000|BEHAVIORAL|STARs Only|Participants receive prenatal care in the STAR clinic (a clinic specifically designed to support mothers with substance abuse who are at risk of losing their children to child welfare at birth).
215062135|NCT03517371|OTHER|Exercise only|Participants in the control group have up to 8 in-person visits with the intervention physical therapist over 12-months. Participants are instructed by the physical therapist to engage in walking and perform progressive resistance and stretching exercises (tailored to their needs and provided in written format) 5 days per week.
214321084|NCT03759093|DRUG|Lenalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
215062136|NCT05358886|DRUG|BPN14770/ zatolmilast|25mg BID BPN14770
215062137|NCT05358886|DRUG|Placebo|Placebo
215062138|NCT05689671|DRUG|Atezolizumab|1200 mg i.v. q3w
215062139|NCT05689671|DRUG|Nab paclitaxel|100 mg/m² i.v. qw
214920692|NCT03706378|OTHER|Glucose Reference 1|Glucose contains 50g of available carbohydrates
214920693|NCT03706378|OTHER|Glucose Reference 2|Glucose contains 50g of available carbohydrates
214920694|NCT03706378|OTHER|Glucose Reference 3|Glucose contains 50g of available carbohydrates
214920695|NCT03706378|OTHER|Wheat Yellow Noodle|Wheat Yellow Noodle will contain 50g of available carbohydrate
214920696|NCT03706378|OTHER|Beta-glucan yellow Noodle|Beta-glucan yellow noodle will contain 50g of available carbohydrate
214920697|NCT03706378|OTHER|Rice Roll|Rice Roll will contain 50g of available carbohydrate
215062140|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
215062141|NCT05689671|DRUG|Pembrolizumab|200 mg i.v. q3w
215062142|NCT05689671|DRUG|Cisplatin|75 mg/m² i.v. q3w
215062143|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
215062144|NCT05689671|DRUG|Pemetrexed|500 mg/m² i.v. q3w
215062145|NCT06544785|DRUG|Zanubrutinib Oral Product|"Zanubrutinib drug product is supplied as 80 mg strengths in capsules for oral administration.~In both arms A and B, zanubrutinib 320 mg will be taken qDay with or without food. Patients will take zanubrutinib with water at approximately the same time every day."
214321085|NCT03759093|DRUG|Lenalidomide|Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
214321086|NCT04418206|OTHER|patients COVID 19|Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
214321087|NCT03186118|BIOLOGICAL|T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)|Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
214321088|NCT05543928|DRUG|CTAP101|CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
214321089|NCT05543928|DRUG|Placebo|Placebo
214321090|NCT05143970|DRUG|IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB|"Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD)."
214321091|NCT06003556|DIAGNOSTIC_TEST|PSMA-1007 Positron Emission Tomography (PET) scan|Additional staging PET scan prior to focal therapy to focal therapy.
214321092|NCT02401568|DEVICE|Dynamic CT|Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
214321093|NCT02401568|PROCEDURE|Arthrography|percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
214321094|NCT00204620|DRUG|Bendamustin|
214321095|NCT00869739|BEHAVIORAL|telephone-based intervention|
214321096|NCT00869739|OTHER|educational intervention|
214321097|NCT00869739|OTHER|partner-assisted coping skills training|
214321098|NCT00869739|OTHER|questionnaire administration|
214321099|NCT00869739|PROCEDURE|psychosocial assessment and care|
214321100|NCT00869739|PROCEDURE|quality-of-life assessment|
214321101|NCT03422393|DRUG|Venetoclax|On cycle 1, day 1, patients will initiate venetoclax. The dose of venetoclax will ramp-up from 20 mg PO daily to 400 mg PO daily over a 5 week period.
214321102|NCT03422393|DRUG|Ibrutinib|"During the screening period, patients will continue on ibrutinib at their previous tolerated dose, unless required to stop (e.g.: by a preceding clinical trial).~On cycle 1, day 1, the dose of ibrutinib will be assigned based on the dose cohort. Patients in cohort 1 will receive ibrutinib 420 mg PO daily. Patients in cohort 2 will receive ibrutinib 560 mg PO daily. Cohort 3 will be 840 mg PO daily."
214321103|NCT03645668|DRUG|Meropenem Injection|Different administration types between two groups
214321104|NCT02636465|OTHER|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
214321105|NCT03568942|DRUG|Gepotidacin|Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
214920698|NCT03706378|OTHER|Rice Roll with resistant starch|Rice Roll fortified with resistant starch will contain 50g of available carbohydrate
214920699|NCT03706378|OTHER|Sucrose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of sucrose
214920700|NCT03706378|OTHER|Isomaltulose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of Isomaltulose
215062146|NCT06544785|DRUG|Obinutuzumab|"Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg)."
215062147|NCT05352516|BIOLOGICAL|HLX14|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14."
215062148|NCT05352516|BIOLOGICAL|Prolia®|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14."
215062149|NCT06444880|DRUG|Ubamatamab|Given by IV
214321106|NCT02978287|DRUG|BAVU Solution|Tissue preservation solution for transplantation
214321107|NCT02526069|BEHAVIORAL|Acceptance and Commitment Therapy|An application based on Acceptance and Commitment Therapy
214321108|NCT00107458|DRUG|valproic acid|
215062150|NCT06444880|DRUG|Cemiplimab|Given by IV
215062151|NCT04771299|DRUG|Cariprazine|Cariprazine is a novel atypical antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I disorder.
215062152|NCT04771299|OTHER|Placebo|Placebo is an inactive substance that looks identical to the study medication that contains no therapeutic ingredient.
215062153|NCT05300477|DRUG|Acetazolamide|Carbonic Anhydrase Inhibitor
215062154|NCT05300477|DRUG|Erythropoietin|Hormone for red blood cell
215062155|NCT06406400|DRUG|AZD4041|"Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7."
215062156|NCT06406400|DRUG|Itraconazole|Healthy participants will receive itraconazole orally from Days 6 to 8 in Period 2 and Days 9 to 21 in Period 3.
215062157|NCT06406400|DRUG|Buprenorphine|Participants with OUD will receive buprenorphine (as standard of care treatment) on Day 4.
215062158|NCT06406400|DRUG|Buprenorphine / Naloxone|Participants with OUD will receive buprenorphine + naloxone (as standard of care treatment) on Days 4, 5, 6 and 7
215062159|NCT06406400|DRUG|Hydromorphone|Participants with OUD will receive hydromorphone (as a replacement opioid) on Days 1, 2 and 3.
214321109|NCT02843945|DEVICE|Directional Brachytherapy Source Implant|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
215062160|NCT06406400|DRUG|Placebo|"Part 1b: Healthy participants will receive matching placebo orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive placebo daily from Days 1 to 7."
215062161|NCT05420961|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
215062162|NCT05420961|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
214321110|NCT02380651|PROCEDURE|Limb salvage|Local or free flaps
214321111|NCT02203812|DRUG|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
214321112|NCT02203812|DRUG|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
214321113|NCT04216862|OTHER|Exercise|Different type of exercises for treatment of Forward Head Posture
214321114|NCT02686346|DRUG|Brentuximab Vedotin|"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
214321115|NCT02686346|DRUG|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
214321116|NCT02686346|DRUG|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
214321117|NCT02686346|DRUG|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
214321118|NCT01267396|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
214321119|NCT01076985|DRUG|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
214321120|NCT00398853|DIETARY_SUPPLEMENT|chromium picolinate 1000 mcg daily vs placebo|chromium picolinate 1000 mcg daily vs placebo
214321121|NCT00398853|OTHER|Placebo|Placebo
214321122|NCT03466502|DRUG|Oral Vancomycin|Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
214321123|NCT02547662|DRUG|Dexamethasone|Given PO
214321124|NCT02547662|DRUG|Ixazomib Citrate|Given PO
214321125|NCT02547662|OTHER|Laboratory Biomarker Analysis|Correlative studies
214321126|NCT02547662|DRUG|Pomalidomide|Given PO
214321127|NCT00937638|DIETARY_SUPPLEMENT|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
214321128|NCT00937638|DIETARY_SUPPLEMENT|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
215062163|NCT05420961|BIOLOGICAL|PPSV23|Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
214321129|NCT00937638|DIETARY_SUPPLEMENT|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
214321130|NCT01024543|DRUG|Angiotensin II|Angiotensin II
214321131|NCT01024543|DRUG|Phenylephrine|Phenylephrine
215062164|NCT06378918|PROCEDURE|puncture|Local anesthesia is previously carried out with 2-5 cc of 1% lidocaine. The puncture is then carried out using a 16 gauge needle. Antibiotic coverage will be offered. A work stoppage is recommended until the day after the puncture/aspiration but the duration is left to the discretion of the surgeon. A visit is systematically realised 15 days after the puncture/aspiration with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. In the event of fistulization following the puncture, associated with discharge and skin necrosis, local nursing care is recommended. The definitive resection procedure is then planned 4 to 6 weeks after the puncture/aspiration if the evolution is favorable.
215062165|NCT06378918|PROCEDURE|incision of the abscess|This is carried out according to the habits of the department: in the operating room under general or local anesthesia or in consultation (or emergencies) under local anesthesia. The procedure is carried out on an outpatient basis but, if necessary, short-term hospitalization is carried out. Daily drying is then carried out with nursing care at home until healing. A work stoppage is recommended for a period of approximately 10 days. A visit is systematically realised 15 days after the incision with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. The definitive resection procedure is then planned 4 to 6 weeks after the initial operation if the evolution is favorable.
215062166|NCT05735704|DIAGNOSTIC_TEST|Blood sampling for HemaChip screening/diagnostic testing|"Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA, and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom-targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed."
215062167|NCT05014646|DRUG|Cholestyramine|Given PO
215062168|NCT05014646|DRUG|Leflunomide|Given PO
215062169|NCT04283656|DRUG|Doravirine/Lamivudine/Tenofovir|100mg/300mg/300mg orally for one dose, daily
215062170|NCT04283656|DRUG|Spironolactone 100mg|200mg orally for two doses, twice-daily
215062171|NCT04283656|DRUG|Estradiol 2mg|4mg orally for two doses, twice-daily
215062172|NCT04283656|OTHER|Placebo|Placebo for one dose, daily
215062173|NCT04896047|PROCEDURE|Meal test and muscle biopsies|"The FGF19 parameters will be assessed in fasting and in postprandial period after the consumption of a hyper-carbohydrate and hyper-lipidic test meal called Flexmeal.~A muscle biopsies by a needle will be performed before and after the Flexmeal."
215062174|NCT06484179|BEHAVIORAL|Targeted Self-Help|In addition to usual care participants will receive a self-help booklet specific for their cancer type. There are five booklets available, written at a 5-6th grade reading level and targeted by cancer type, that explain the connection between smoking and each cancer type, describe the benefits of quitting smoking after cancer, and address some of the barriers cancer patients face to quit smoking when fighting cancer. Each booklet also includes four testimonials inspired from conversations with patients.
215062175|NCT06484179|BEHAVIORAL|Usual Care|Participants will receive the standard care typically offered for smoking cessation.
214321132|NCT01024543|DRUG|Placebo|
215062176|NCT05279040|DRUG|Trikafta|Elexacaftor/Tezacaftor/Ivacaftor combination therapy
215062177|NCT04754269|BEHAVIORAL|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
215062178|NCT04754269|BEHAVIORAL|Reading Intervention|Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
215062179|NCT03393897|OTHER|Trans oesophageal echocardiography|Transoesophageal echocardiography : it's a standard practice for this patient
214321133|NCT00733720|DRUG|Suboxone|4/1mg, 8/2mg 16/4mg
214321134|NCT02170584|DRUG|BIBR 953 ZW IV|
214321135|NCT02170584|DRUG|BIBR 1048 MS tablet|
214321136|NCT02170584|DRUG|BIBR 1048 MS oral solution|
214321137|NCT02170584|DRUG|BIBR 953 ZW IV Placebo|
214321138|NCT00178945|DRUG|Botulinum Toxin Type A|
214321139|NCT00129233|DRUG|Valsartan|valsartan 80 to 160 mg daily
214321140|NCT00129233|DRUG|Amlodipine|Amlodipine 5 to 10 mg daily.
214321141|NCT03899610|DRUG|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"1. Neoadjuvant treatment:~   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~2. Interval debulking surgery~3. Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
214321142|NCT06355869|OTHER|repeated 3D gait-analysis|An observational 3D gait-analysis was performed with a period of 1-14 days is foreseen between the two measurements.
214321143|NCT03228810|OTHER|Blood draw|(2) 10 mL tubes will be collected
214321144|NCT03228810|PROCEDURE|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
214484516|NCT06890949|OTHER|(Group A: Preformed Bioflx Crown)|"Crown Selection \& Tooth Preparation~Measure the mesiodistal width using calipers to select an appropriately sized crown.~If a mesial or distal wall is missing, use the contralateral tooth for size selection.~Choose the crown that closely matches the measured mesiodistal width. Select the smallest crown that preserves proximal contacts using a trial-and-error approach.~if crimping is necessary use Howe's pliers.~Tooth Preparation Perform 1-1.5 mm occlusal reduction using a tapered diamond bur. Reduce proximal areas by approximately 0.5 mm to clear the contact area.~Crown Placement \& Cementation Ensure a snug fit of the selected crown. Apply a thin layer of glass ionomer cement inside the crown. Seat the crown firmly using finger pressure. Have the child bite down gently to ensure proper seating.~Final Adjustments \& Cleanup Remove excess cement with floss or an explorer. Verify the crown's fit, occlusion, and stability."
214484517|NCT06890949|OTHER|(Group B: Preformed Zirconia crown)|"Crown Selection~Measure the mesiodistal width using calipers to select the appropriate crown. If a mesial or distal wall is missing, use the contralateral tooth for size selection.~Choose the crown that closely matches the measured width. Select the smallest crown that preserves proximal contacts.~Tooth Preparation~Reduce the occlusal surface by 1.5-2 mm using a tapered diamond bur. Reduce interproximal areas by 1-1.5 mm, ensuring a feather-edge finish. Perform a 1-2 mm subgingival preparation using a tapered fissure bur.~Crown Placement \& Passive Fit Check~Place the selected crown and check for passive fit.~Cementation of the Crown~Apply a thin layer of glass ionomer cement inside the crown. Seat the crown with passive finger pressure. Have the child bite down gently to ensure proper seating.~Final Adjustments \& Cleanup~Remove excess cement using floss or an explorer. Verify fit, occlusion, and stability"
214484518|NCT05047952|DRUG|Vortioxetine|"Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician."
214321145|NCT00640510|DRUG|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
214321146|NCT00640510|DRUG|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
214321147|NCT00989729|DRUG|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
214484519|NCT05047952|DRUG|Placebo|A placebo pill will be taken once daily.
214484520|NCT06892249|DIETARY_SUPPLEMENT|Renalive® LP, flavour Vanilla|flavour Vanilla
214484521|NCT06892249|DIETARY_SUPPLEMENT|Renalive® LP, flavour Cappuccino|flavour Cappuccino
214484522|NCT06745492|DRUG|Neostigmine + Glycopyrrolate|a 20 mcg/kg of neostigmine and 4 mcg/kg of glycopyrrolate were administered at a TOF ratio of 0.7.
214920701|NCT04499144|PROCEDURE|modified buccal flap and subepithelial connective palatal flap|The connective flap was harvested from the deeper area of the palatal mucosa. Pedicle flap dimensions were reported using the periodontal probe. The flap was then rotated to cover the oro antral communication (OAC) area. The rotation could be in mesial or distal direction, related to OAC position and for the convenience of the donor site. The connective palatal flap was sutured to the buccal periostium using mattress sutures.
214920702|NCT02619630|DRUG|nelarabine|"Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil \>1 Giga/Liter~for a maximum of 5 blocks"
214920703|NCT02580409|BEHAVIORAL|Exercise Intervention|Investigators are proposing an innovative rehabilitative care program for older primary care patients at risk for mobility decline. The program targets newly identified risk factors for mobility decline and utilizes mobile health technology to deliver patient centered care more efficiently. Study participants will receive exercise instruction with a licensed physical therapist for an average of 8-10 training sessions, with the possibility of up to 16 sessions. some at home and some in the clinic. The exercise training sessions will focus on improving mobility, balance and ability to get up from a chair with the use of an exercise application (Wellpepper) being used on a study issued iPad.
214920704|NCT00466388|DRUG|Cevimeline|
214920705|NCT01972438|DRUG|ASEDs|Experimental Intervention
215062180|NCT03393897|OTHER|Trendelenburg test|Trendelenburg test : it's a standard practice for this patient
214920706|NCT01972438|DRUG|Saline|Control Intervention
214920707|NCT00606385|PROCEDURE|Liver resection|Laparoscopic or Open hepatectomy
214920708|NCT04490291|OTHER|chronic pain team|enrollment in chronic pain team at study site
214920709|NCT04490291|OTHER|chiropractic team|enrollment in chiropractic team/intervention at study site
214920710|NCT02594982|OTHER|intervention bundle (sedation, pain, mobilization and sleep)|"Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.~Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night"
214920711|NCT06575829|DRUG|Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks|The interval of ERT with alglucosidase alfa will be extended from once every 2 weeks to once every 4 weeks. The dose of 20 mg/kg per infusion remains the same.
214920712|NCT00511914|BIOLOGICAL|cTIV|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
215062181|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
214321148|NCT00989729|DRUG|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
215062182|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
215062183|NCT00394329|DRUG|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
215062184|NCT02014662|OTHER|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
215062185|NCT04482439|DEVICE|Vivity Extended Depth of Focus intraocular lens (IOL)|Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.
214321149|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
214484523|NCT06744738|BEHAVIORAL|Pharmacist led behavioral change technique|"The intervention was developed based on the behavior change technique taxonomy (v1). This intervention was designed to improve adherence to all therapeutic aspects of hemodialysis patients, including the dialysis program, medications, diet, and fluids. Additionally, the effect of the pharmacist intervention on physiological indices (serum potassium, total calcium, phosphate, IDWG, and hemoglobin) was examined.~The program was explicitly created for implementation in an actual setting, ensuring that the time allocation for participants and facilitators (the party responsible for conducting the PL-BCT) remained reasonable in most contexts.~The BCT components were developed after the identification and coding of the BCTs from previous interventional studies that contain behavioral components and result in positive effects on one or more hemodialysis patients' adherence domains toward their therapeutic regimen (dialysis program, medications, diet, and fluid)."
214484524|NCT06743802|DRUG|Coenzyme Q10|Coenzyme Q10 was administered from admission to one month after discharge at a dose of 200 mg per day (200 mg/qd).
214920713|NCT01001273|OTHER|Hyperinsulinemic Normoglycemic Clamp|The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
215062186|NCT01184677|DEVICE|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
215062187|NCT01184677|DEVICE|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
215062188|NCT04764097|DRUG|Dapagliflozin|SGTL2 Inhibitor
215062189|NCT04764097|DRUG|Placebo|Placebo
214321150|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
214321151|NCT01647867|OTHER|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
214484525|NCT06743802|OTHER|Placebo|The placebo was administered from hospital admission until one month after discharge.
214920714|NCT02581280|OTHER|Residual blood|Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
214920715|NCT00047073|DRUG|Rapamycin|"Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.~Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.~Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same."
214920716|NCT00047073|PROCEDURE|Surgery|Surgical resection.
214920717|NCT00047073|PROCEDURE|Supportive Care|"Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.~Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.~If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented."
214920718|NCT03901820|DEVICE|Medication Interaction System of Dr App (SIMDA)|A module for the electronic clinical records allowing detection of the potential drug interactions
214920719|NCT01030289|DEVICE|real tDCS|transcranial direct current stimulation
214920720|NCT01030289|DEVICE|sham tDCS|transcranial direct current stimulation
214920721|NCT03321500|OTHER|Versacryl soft liner|Versacryl has been used to construct different parts of complete and partial dentures . It can be used as thermo-elastic liner which consistency can be controlled to tailor the reline to each individual case, by adding or subtracting drops of liquid B, as explained in the directions for use. The reline can be re-adapted repeatedly, even by the patient if necessary.
214920722|NCT03321500|OTHER|Silicone-based soft liner|gold standard for denture relining material
214920723|NCT05282537|BEHAVIORAL|In person academic activities|All participants will perform academic activities in person from March to December, 2022
214920724|NCT00003853|DRUG|4'-iodo-4'-deoxydoxorubicin|
214920725|NCT04515654|OTHER|IDEAS (Identity Evolution and Sharing) Performance|60 minute webinar depicting first-hand stories of transgender and gender non-conforming individuals followed by expert panel/talk-back
214920726|NCT01538277|PROCEDURE|Contact Force during ablation|Radio Frequency Ablation procedure with real-time contact force information known to the operator
214920727|NCT01538277|OTHER|Standard ablation procedure|Standard ablation procedure
214920728|NCT06482398|DRUG|Sericin extract and turmeric extract cream|Apply the sample 2 times a day for 8 weeks
214920729|NCT06482398|DRUG|Triamcinolone acetonide 1% Cream|Apply the sample 2 times a day for 8 weeks
214484526|NCT06744907|BIOLOGICAL|10% Povidone-Iodine Arm|A second application of surgical antisepsis with a topical povidone-iodine in the subdermal layer after making an incision.
215062190|NCT03136653|BIOLOGICAL|MP0250 plus BOR+DEX|"6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops."
214321152|NCT05765968|PROCEDURE|Double Stimulation Protocol|cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle
214321153|NCT05765968|PROCEDURE|Antagonist Stimulation Protocol|cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
214321154|NCT02677090|DRUG|Placebo (including Maltodextrin)|
214321155|NCT02677090|DRUG|Dose 1 - Promitor®|
214321156|NCT02677090|DRUG|Dose 2 - Promitor®|
214321157|NCT02677090|DRUG|Dose 3 - Promitor®|
214321158|NCT05850156|PROCEDURE|basal blood collection|blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
214321159|NCT05850156|PROCEDURE|blood collection M6|6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
214920730|NCT03162653|DRUG|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
214321160|NCT05850156|PROCEDURE|blood collection M12|12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
214321161|NCT03270046|PROCEDURE|Water enema|Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
214321162|NCT05393375|OTHER|No intervention|No intervention
214321163|NCT04731844|DRUG|Curcumin plus Piperine|Curcumin with piperine is a well-tolerated over-the-counter supplement.
214321164|NCT01479907|DIETARY_SUPPLEMENT|Synbiotics|12 gr in 250 cc of water once daily X 15 days
214321165|NCT01479907|DIETARY_SUPPLEMENT|Placebo|12 gr in 250 cc of water once daily X 15 days
214484527|NCT06744907|PROCEDURE|Saline Arm|An application of saline in the subdermal layer after making an incision.
214484528|NCT06743971|BEHAVIORAL|ocean sound concert|intervention group listened to the ocean sound, the control group continued their daily care routines
214484529|NCT06743789|RADIATION|Radiation Therapy|"Group 1 (3 participants) - will receive a dose of 20 Gy (Gray, a measurement of radiation) in a single study intervention (one study intervention day)"
214920731|NCT03162653|DRUG|Mannitol|Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
214920732|NCT01186692|DEVICE|Melody® Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
214920733|NCT00957320|DRUG|Sirolimus|Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
214920734|NCT00957320|DRUG|PEG-asparaginase|Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
214920735|NCT05421182|OTHER|Revised Impact of Event Scale|to measure the affect of routine life stress,everyday traumas and acute stress
214920736|NCT05421182|OTHER|Hospital Anxiety and Depression scale|to measure anxiety and depression
214920737|NCT05421182|OTHER|36-Item Short Form Survey|SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
214920738|NCT05421182|OTHER|satisfaction survey|satisfaction survey of the trusted person about the communication with ICU personal
214920739|NCT05421182|OTHER|semi-directed interview with trusted person on the general experience of the patient's medical evacuation|interview of the trusted person about the medical evacuation : evacuation announcement;organization of the medical evacuation,; concerns related to evacuations;reception and information by the center admitting the evacuated patient; arrangements of visit, patient repatriated
214920740|NCT05421182|OTHER|semi-directed interview with trusted person on the general experience of hospitalization in intensive care|interview of the trusted person about ICU hospitalization: reception in ICU; ICU organization; concerns related to ICU hospitalization, information and communication with ICU staff, arrangements of visit, context of ICU discharge
214920741|NCT02989038|OTHER|Very Low Nicotine Content Cigarettes|cigarettes with 0.03 nicotine yield with 0.4 mg/g nicotine content and 9.0 mg tar yield
214920742|NCT02989038|OTHER|Intermediate Nicotine Content Cigarettes|cigarettes with 0.12 nicotine yield with 2.4 mg/g nicotine content and 9.0 mg tar yield
214920743|NCT02989038|OTHER|Normal Nicotine Content Cigarettes|cigarettes with 0.8 nicotine yield with 15.8 mg/g nicotine content and 10.5 mg tar yield
214920744|NCT01040637|DRUG|TD-1211|Dose level 1
214920745|NCT01040637|DRUG|TD-1211|Dose level 2
214920746|NCT01040637|DRUG|TD-1211|Dose level 3
214920747|NCT01040637|DRUG|TD-1211|Dose Level 4
214920748|NCT01040637|DRUG|TD-1211|Ascending doses
214920749|NCT01040637|DRUG|TD-1211|Ascending doses
214920750|NCT01040637|DRUG|TD-1211|Ascending doses
214920751|NCT01040637|DRUG|TD-1211|Ascending doses
214920752|NCT01040637|DRUG|TD-1211|Ascending doses
214920753|NCT01040637|DRUG|Placebo|Ascending doses
215062191|NCT03410719|OTHER|Hi GI|subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be \<55 (Low-GI group) or \>70 (Hi-GI group).
215062192|NCT04491903|PROCEDURE|REBOA|Endovascular balloon occlusion of the aorta
214920754|NCT04463251|BIOLOGICAL|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
214321166|NCT00859170|DEVICE|Accordion device|an antiretropulsion device
214321167|NCT02777762|BEHAVIORAL|Fun First|8 weekly interactive small-group sessions with a health coach
215062193|NCT03018535|DRUG|Rituximab|Rituximab,1 g IV, day 1 and day 15
215062194|NCT03018535|DRUG|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
215062195|NCT03018535|DRUG|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
215062196|NCT01976702|BEHAVIORAL|Enhanced Behavioral Skills Training|
215062197|NCT02318368|DRUG|Ficlatuzumab|
214920755|NCT04463251|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
214920756|NCT03811548|DRUG|Janagliflozin 25mg|Tablets, Oral, 25 mg, Tablets, Oral, 50 mg
214920757|NCT03811548|DRUG|Janagliflozin 50mg|Tablets, Oral, 25 mg, Once daily, 52 weeks
214920758|NCT03811548|DRUG|Placebo/Janagliflozin|Tablets, Oral, 25 mg, Once daily, 52 weeks
214920759|NCT01055691|DRUG|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
214920760|NCT01055691|DRUG|Dapagliflozin|dapagliflozin tablet 2.5 mg Oral Single dose
214920761|NCT01055691|DRUG|Metformin|metformin IR tablet 850 mg Oral Single dose
215062198|NCT02318368|DRUG|Erlotinib|
214920762|NCT01055691|DRUG|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
215062199|NCT02318368|DRUG|placebo|
215062200|NCT03440515|DRUG|Prednisone|Prednisone treatment for severe skin rash induced by imatinib
214321168|NCT02777762|BEHAVIORAL|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
214321169|NCT02922452|DRUG|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
214321170|NCT02922452|DRUG|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
214321171|NCT02178033|DRUG|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
214321172|NCT05466578|DRUG|abrocitinib|
214484530|NCT06743789|RADIATION|Radiation Therapy|Group 2 (3 participants) - will receive a dose of 15 Gy in a single study intervention (one study intervention day)
214484531|NCT06743789|RADIATION|Radiation Therapy|Group 3 (3 participants) - will receive a dose of 10 Gy in a single study intervention (one study intervention day)
214484532|NCT06743789|RADIATION|Radiation Therapy|Group 1 (3 participants) - will receive a dose of 12 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 36Gy)
214484533|NCT06743789|RADIATION|Radiation Therapy|Group 2 (3 participants) - will receive a dose of 10 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 30Gy)
214484534|NCT06743789|RADIATION|Radiation Therapy|Group 3 (3 participants) - will receive a dose of 8 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 24Gy)
214484535|NCT06743867|DRUG|Pressurized Intraperitoneal Aerosol Chemotherapy|"The comprehensive therapeutic strategy will be modified based on the integrated 2- or 3-week systemic chemotherapies. In the interim, a total of three PIPAC procedures will be conducted for all qualifying patients.~1. PIPAC combined with 2-week systemic chemotherapies:~   PIPAC therapy will occur every four weeks, while systemic chemotherapies will be administered during the first and third weeks following the initial and second PIPAC procedures respectively.~2. PIPAC combined with 3-week systemic chemotherapies:~(1) Scheme 1: PIPAC therapy will occur every 6 weeks, with systemic chemotherapies administered during the 1st and 4th weeks following the first and second PIPAC procedures, respectively.~(2) Scheme 2: PIPAC therapy will occur every 6 weeks, while systemic chemotherapies will be administered in the 2nd and 5th weeks following the initial and second PIPAC procedures, respectively."
214920763|NCT01055691|DRUG|Dapagliflozin|dapagliflozin tablet 5 mg Oral Single dose
214484536|NCT06745141|PROCEDURE|Periodontal surgery|"In the intervention group, patients underwent a comprehensive periodontal evaluation conducted by periodontists at a dental clinic. All permanent teeth, except for third molars, were assessed using dental mirrors and periodontal probes. Each tooth was examined at four sites (vestibular, distal, lingual, and mesial) to evaluate visible plaque, probing depth, probing bleeding, and attachment loss.~During the first treatment session, patients were provided with information about periodontal disease, emphasizing the importance of controlling supragingival bacterial biofilms for successful treatment. Plaque-retentive factors (calculus) were removed. Temporary materials were used to restore carious lesions, root remnants were extracted, and maladaptive restorations were adjusted. Supragingival calculus was removed using periodontal scalers, followed by cleaning with a rubber cup, prophylaxis paste, dental floss, and/or interdental brushes. No prophylactic antibiotics were used prior to the"
214321173|NCT02310191|PROCEDURE|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
214321174|NCT00952094|DRUG|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
214484537|NCT06743919|DRUG|Magnesium sulfate 50% - 1g/h|magnesium sulfate group 20 ml bupivacaine 0.25% plus 500 mg magnesium sulfate in 5ml normal saline on both sides.
214484538|NCT06743919|DRUG|dexmedetomidine 0.5 µg/kg IV|dexmedetomidine group 20 ml bupivacaine 0.25% plus o .5 microg per kg dexmedetomidine in 5 ml normal saline on both sides.
214484539|NCT06743919|DRUG|Bupivacaine|20 ml bupivacaine 0.25% plus 5 ml normal saline on both sides.
214484540|NCT06745219|DRUG|herombopag|receive harombopag for the prevention of thrombocytopenia in the next cycle of chemotherapy
214484541|NCT06743607|BEHAVIORAL|Immediate Intervention|Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences immediately after enrollment.
214484542|NCT06743607|BEHAVIORAL|Waitlist control|Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences 12 weeks after enrollment.
214484543|NCT06890325|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment (CGA)|The intervention will consist of a total of 3 sessions which will take place in different areas of the Faculty of Health and Welfare Sciences (FCSB) at the University of Vic - Central University of Catalonia. In Session 1, a comprehensive geriatric assessment (CGA) will be conducted to the users (by students supervised by health professionals).
214484544|NCT06890325|BEHAVIORAL|Health education|A report with the results of the CGA and health recommendations will be delivered to the users. They will receive health education including specific recommendations and community health resources based on their health status and CGGA.
214484545|NCT06891430|PROCEDURE|Procedure: Anatomical Single-Bundle ACL Reconstruction|Patients undergo anatomical single-bundle ACL reconstruction with femoral and tibial tunnel drilling.
214484546|NCT06891430|PROCEDURE|Procedure: Central Axial Single-Bundle ACL Reconstruction|Patients undergo central axial single-bundle ACL reconstruction with optimized tunnel positioning.
214321175|NCT01872871|DRUG|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
214321176|NCT01872871|DRUG|Topical anaesthetic drop with placebo|
214484547|NCT06891430|PROCEDURE|Procedure: Double-Bundle ACL Reconstruction|Patients undergo double-bundle ACL reconstruction targeting AMB and PLB footprints.
214484548|NCT06888492|BIOLOGICAL|EXG202|EXG202 is a gene therapy product for the treatment of wet (neovascular) age-related macular degeneration（wAMD） with a single intravitreal injection and administration.
214484549|NCT06891196|OTHER|Long-term Follow-up Surveys|Patients will be given surveys, including validated PRO measures such as the Hip Disability and Osteoarthritis Outcomes Score (HOOS), Short-Form 12 (SF-12), Visual Analog Scale (VAS) for pain, and Marx activity scores.
214484550|NCT06890442|DEVICE|CT|"Thickened Medial Pterygoid Plates In bony atresia, excessive thickening of the medial pterygoid plates is common. Narrowing or Fusion of the Posterior Choanae Complete bony or membranous obstruction at the choanal opening. Abnormal Sphenoid Bone Development Hypoplasia or deformity in the sphenoid sinus, affecting adjacent structures. Vomer Deviation or Hypertrophy The vomer bone is often displaced or abnormally thickened, contributing to obstruction.~Abnormal Development of the Hard Palate"
214484551|NCT06892470|OTHER|No intervention|No intervention
214920764|NCT01055691|DRUG|Metformin|metformin IR tablet 1000 mg Oral Single dose
214920765|NCT00725361|DRUG|Ambrisentan|
214321177|NCT05374811|OTHER|Neuropathic Pain|Neuropathic pain degrees of the patients will be evaluated with the Douleur Neuropathic-4 (DN4) questionnaire.
214321178|NCT05664997|BEHAVIORAL|playing assessment|Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
214920766|NCT04384042|OTHER|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
215062201|NCT03323216|DIAGNOSTIC_TEST|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the intervention and 6 months after the intervention."
214484552|NCT06732479|BEHAVIORAL|Behavioural Skill Training Programme|"BST was administered in 3 sessions in a week on alternate days, each session lasting for an hour. Training was given in small groups consisting of 4-6 members. Parents were involved as co-therapists, and observed the training given by the researcher and practiced it at home with their children.~The training was carried out through the following steps:~1. Instruction- Involved teaching the location of private parts, difference between appropriate and inappropriate touch, safe and unsafe secrets, sexuality, self-protection skills (saying NO, move from situation, tell trusted person, report the person and situation.~2. Modelling- researcher, modelled, correct responses, and instructed to act in the unsafe situation using role play. Situations were presented using video.~3. Rehearsal-researcher presented situations using video and instructed to rehearse the skills until able to demonstrate the skill independently"
214484553|NCT06740110|DEVICE|Bone replacement composite vs standard of care|"Bone replacement composite: Before application the Bone replacement composite (size 10 mm) will be mixed with autogenous blood or a saline solution and modelled. Next, the medical device will be applied to the place where teeth extraction is performed.~Standard of care: Before application standard of care (Bio-Oss) will be mixed with autogenous blood or a saline solution and modelled. Next, the standard of care will be applied to the place where teeth extraction is performed. Subsequent application of a collagen membrane (Bio-Gide) will be conducted."
214321179|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
214321180|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
214321181|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
214321182|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
214484554|NCT06733116|OTHER|Delphi method survey|This intervention involves a Delphi method study, where a panel of experts in isokinetic testing will collaborate to reach a consensus on best practices for standardizing the reporting of isokinetic test data. Unlike other clinical studies, this intervention focuses on gathering expert opinions iteratively to establish a unified framework for data reporting, without direct clinical or experimental treatment. The process includes multiple rounds of feedback, refining key elements related to testing protocols, measurement parameters, and result presentation, ensuring broad expertise from various fields such as medicine, rehabilitation, and biomechanics.
214484555|NCT06736717|DRUG|Onvansertib|"20 or30mg flat dose - depending on results from safety lead-in. Administered concurrently with NALIRIFOX.~Once daily on D1-5 of each 14-day cycle."
214484556|NCT06736717|DRUG|NALIRIFOX|"Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.~Intravenously on Day 1 of each 14-day cycle."
214484557|NCT06738979|DRUG|TQF3510 (Semaglutide Injection)|Semaglutide injection is a long-acting Glucagon-like peptide-1 (GLP-1) receptor agonist.
214484558|NCT06738979|DRUG|Wegovy®|Active Comparator
214484559|NCT06738940|DEVICE|CPAP|Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 48 weeks
214484560|NCT06880068|DIAGNOSTIC_TEST|Dual Task Impact on Daily-living Activities Questionnaire|This questionnaire makes us assess dual-task performance while performing daily-living activities.
214484561|NCT06736730|BEHAVIORAL|Hospital-Linked Violence Intervention Program|Activation of Operation Good, our community partner with a history of direct violence interruption in the streets and longitudinal health and wellness services to firearm injured patient (i.e. linking and aiding those who have suffered from violent injury to mental healthcare, job services, educational services)
214484562|NCT06736730|BEHAVIORAL|Mobile Community Event Support|A menu of services provided to the community in an activated cluster where funding will be provided to assist that community in holding events that support overall health and wellness (community clean-up, legal advisory services, pop-up clinic for blood pressure checks).
214321183|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
214321184|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
215062202|NCT03323216|DIAGNOSTIC_TEST|Study specific questionnaire|"Study specific questionnaire~The questionnaire is performed prior and 6 months after the intervention."
215062203|NCT03323216|PROCEDURE|Blood collection|"Blood collection during surgery:~* coronary sinus~* arterial~* peripheral venous~Blood collection 6 months after surgery:~\- peripheral venous"
214321185|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
214321186|NCT06097884|OTHER|Main study intervention-Salt substitute|replacing regular salt with salt substitute in school meals
215062204|NCT04002050|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness Course|The Cognitive Behaviour Therapy with Mindfulness (CBTm) Course for Public Safety Personnel is a brief psychoeducational course consisting of 5 classes (90 minutes each) occurring on a weekly basis. The CBTm course addresses the fundamentals of CBT and provides participants with practical strategies for managing stress (such as relaxation strategies, cognitive restructuring, goal setting, behavioural activation, and exposure therapy).
215062205|NCT04744948|DEVICE|Treadmill exercise|high intensity interval training
214321187|NCT06097884|OTHER|Main study control-Usual salt|Use usual salt in school meals
214321188|NCT06097884|OTHER|Ancillary study intervention-Meal trays|Replacing bowls with trays in school cafeteria
214321189|NCT06097884|OTHER|Ancillary study control-Bowls|Use bowls in school cafeteria
214321190|NCT00481728|DRUG|Tolterodine|Single dose per patient as determined by protocol.
214321191|NCT00481728|PROCEDURE|Filling cystometry|This is a procedure.
214321192|NCT00481728|PROCEDURE|Intravesical neurostimulation|This is a procedure.
214321193|NCT01298024|OTHER|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
214321194|NCT01726010|DEVICE|22-G Procore Needle|
214321195|NCT01907633|DRUG|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
214321196|NCT05488899|DIAGNOSTIC_TEST|Half iodine Spectral CT|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 keV.
214321197|NCT05488899|DIAGNOSTIC_TEST|Standard iodine conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kv Polychromatic CT acquisition.
214484563|NCT06736730|BEHAVIORAL|Unrestricted Cash Assistance|A participant in an activated cluster after firearm injury will receive two disbursements of 500$. One at the time of initial hospital evaluation and a second disbursement \~1 month later to offset the financial burden associated with firearm injury on the individual.
214484564|NCT06738576|DRUG|allogeneic mesenchymal stem cells|"Cell implantation is carried out in the following steps:~1. \- Patient anesthesia~2. \- Identification of the external urinary sphincter and the incompetent area responsible for incontinence through intraurethral cystoscopy.~3. \- Resuspension of the cells by gentle manual shaking of the vials. Once the cells are resuspended, they will be used immediately.~4. \- Injection of the cell suspension with a long, fine needle (those usually used in endoscopic puncture, \<22G) at 2 points of the sphincter that will coincide with the 3 o'clock and 9 o'clock position of the hands of a clock). The injection will be superficial, trying not to go deeper than 2 mm to create a wheal in each injection visible endoscopically.~5. \- Cellular remains, if any, and the vials used will be eliminated following the usual procedures used for the management of hospital surgical waste."
214484565|NCT06738576|DRUG|Placebo|Placebo implantation is carried out in the same way as the drug implantation
214484566|NCT06736119|BEHAVIORAL|Task Oriented Intervention|Intervention group will recieve task oriented interventions.Throwing and catching balls of different sizes and weights will be done. For writing, a task-oriented approach has 4 phases that will involve writing,correcting and fun writing 30-minute per session. Interventions provided 3 days per week for 3 months.
214920767|NCT04266327|RADIATION|3D-printing Template-assisted CT-guided I-125 Seed Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seed implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume;Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc.Regular follow-up was conducted after treatment.
214920768|NCT03512444|DEVICE|Negative Pressure System|Negative Pressure System is a non-invasive system that applies sub-atmospheric(Negative) pressure, through a foam and an air-tight film dressing which is connected by suction tubes to a controller unit by which the primary negative pressure can be adjusted.
214920769|NCT06085469|BEHAVIORAL|Temporal Adaptation Approach|the temporal adaptation: It includes giving importance to the use of time, choosing meaningful activities, adjusting the time used during these activities and improving it. Such adaptation serves to improve an individual's quality of life, health, and occupational participation.
214920770|NCT05577208|DEVICE|"Symplicity Spyral multi-electrode renal denervation catheter and Symplicity G3 generator (Renal Denervation System)"|Minimally invasive percutaneous interventional therapy aimed to modulate the sympathetic nervous system through endovascular ablation of both renal arteries
214920771|NCT02083432|BEHAVIORAL|5 session of CBT performed by specially trained dentists|"A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.~The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV)."
214920772|NCT06363370|DRUG|Human interferon α1b Inhalation Solution|Participants will receive Human interferon α1b Inhalation Solution
214920773|NCT06363370|DRUG|Inhalation Solution Placebo|Participants will receive Inhalation Solution Placebo
214920774|NCT03439761|DRUG|PT-112 Injection|PT-112 Injection 28 days constitute a period. The drug is intravenously dripped for 60 minutes at the 1st, 8th and 15th day of each period.
215062206|NCT04744948|OTHER|low caloric diet|low caloric diet (1200ca/lday)
215062207|NCT03449563|COMBINATION_PRODUCT|Open TPVB|In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
215062208|NCT03449563|COMBINATION_PRODUCT|Ultrasound-guided TPVB|In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
214672082|NCT02562196|DEVICE|tdcs|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
214672083|NCT02334267|DEVICE|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
214321198|NCT02821884|DEVICE|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
214920775|NCT00530127|DRUG|placebo|Same dose and frequency as treatment
214920776|NCT00530127|DRUG|deferiprone|100 mg/mL
214920777|NCT00530127|DRUG|deferiprone|100 mg/mL
214920778|NCT00530127|DRUG|placebo|Same dosage and frequency as study drug
214920779|NCT00530127|DRUG|deferiprone|100 mg/mL
214920780|NCT02118727|DRUG|Memantine|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
214920781|NCT02118727|DRUG|Placebo (for Memantine)|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
214920782|NCT02519998|OTHER|Concussion|Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
214920783|NCT00831298|OTHER|Analysis of sleep disturbance|Behavioral Questionnaire Sleep Recordings Genetic analysis
214920784|NCT00065754|DRUG|placebo|
214920785|NCT05931341|DIETARY_SUPPLEMENT|Rosemary extract|Softgel capsule including rosemary extract
214920786|NCT02863445|DRUG|Levonorgestrel-based emergency contraception 1.5 mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
214920787|NCT02863445|DRUG|Levonorgestrel-based emergency contraception 3.0mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
214920788|NCT06024798|DIAGNOSTIC_TEST|Photon-Counting-Computed-Tomography|Initial and follow up (after 4 weeks) PCCT acquisition of the affected area of the lower extremity. Image acquisition will be performed on the PCCT
214920789|NCT04520997|DEVICE|Restylane Defyne|Up to 2 milliliters (ml) of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at baseline, up to 2 ml of Restylane Defyne per NLF and ML at week 3 and optional up to 2 ml of Restylane Defyne per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
214920790|NCT04520997|DEVICE|Restylane Defyne|Up to 2 ml of Restylane Defyne per NLF and ML at baseline, up to 2 ml of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at week 3 and optional touch-up of up to 2 ml per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
214920791|NCT03439592|DIAGNOSTIC_TEST|collection of fecal material|in study population we will collect fecal material to analyze the microbiotic flora by genetic techniques.
214920792|NCT02981082|DRUG|Dimethyl Fumarate (DMF)|Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.
214920793|NCT02981082|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
214920794|NCT01023945|DRUG|ASP1941|oral
214920795|NCT01023945|DRUG|Placebo|oral
214920796|NCT05367973|DEVICE|IVR Dose 1|Estradiol 80 ug/day + progesterone 4 mg/day
214920797|NCT05367973|DEVICE|IVR Dose 2|Estradiol 160 ug/day + progesterone 8 mg/day
214920798|NCT03098654|DIAGNOSTIC_TEST|Blood glucose and blood pressure testing|Diabetes will be assessed using a 6-question risk assessment on a 10-point scale (based on a field-tested and culturally adapted International Diabetes Federation formula on DM risk factors and symptoms) and a random blood glucose test with a portable finger stick glucose monitor. Those with either: (1) a risk score of 5 or more, or (2) a random blood glucose with a value greater than 140 mg/dl, will be asked to return after fasting for at least 8 hours to have a fasting glucose test taken. Blood pressure will be assessed using a portable battery operated automatic BP cuff. The BP test will include three values taken at least 5-minutes apart and the 3 will be averaged to determine the final value.
215062209|NCT03449563|OTHER|placebo|In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
214321199|NCT02821884|DEVICE|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
215062210|NCT05151159|OTHER|immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3|
215062211|NCT00574392|DEVICE|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
215062212|NCT02429193|DRUG|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
215062213|NCT02429193|DRUG|Enzalutamide|Enzalutamide (160 mg/day p.o.)
215062214|NCT00442494|DRUG|intravenous hydrocortisone|
215062215|NCT01060748|BIOLOGICAL|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
215062216|NCT01060748|BIOLOGICAL|Placebo|Placebo
215062217|NCT01926951|DEVICE|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
215062218|NCT03715140|DRUG|Crucumin|Evaluation of the effect of Crucumin in patients with osteoarthritis
215062219|NCT03715140|DRUG|Placebo|Placebo
215062220|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
215062221|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
215062222|NCT01555073|DRUG|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
215062223|NCT01555073|DRUG|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
215062224|NCT01555073|DRUG|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
215062225|NCT01555073|DRUG|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
215062226|NCT04475523|DRUG|CI-8993|CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
215062227|NCT04817475|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
215062228|NCT01741233|GENETIC|VitDgen|
215062229|NCT02463396|BEHAVIORAL|MBCT for ADHD|
215062230|NCT04660552|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.
215062231|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
215062232|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
215062233|NCT03490292|COMBINATION_PRODUCT|Avelumab combined with Chemoradiation|Co-administration of avelumab with chemoradiation in pre-operative period.
215062234|NCT03490292|DRUG|Carboplatin|Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
215062235|NCT03490292|DRUG|Paclitaxel|Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
215062236|NCT03490292|RADIATION|Radiation|Radiation therapy \[23 fractions, M-F, estimated completion day 35\]
215062237|NCT04334135|DIETARY_SUPPLEMENT|MitoQ|Four to eight 20mg capsules (depending on body mass)
215062238|NCT03335904|OTHER|Hyperoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
215062239|NCT03335904|OTHER|Hypoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
215062240|NCT03335904|OTHER|Repeated Hypoxic Apneas|Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
215062241|NCT03335904|OTHER|Hypoxic Sleep Study|Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
215062242|NCT03335904|DRUG|Losartan|Losartan, 50mg, BID
215062243|NCT03335904|DRUG|Placebo|Placebo, 50mg, BID
215062244|NCT04291690|OTHER|Physical Component of the Intervention|We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
215062245|NCT04291690|OTHER|Cognitive Component of the Intervention|We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
214484567|NCT06894966|DEVICE|low intensity transcranial focused ultrasound stimulation (TUS)|Low-intensity transcranial focused ultrasound (TUS) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. TUS is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth. Low intensities of focused ultrasound (TUS) are used so that tissue damage does not occur, but neural activity can be modulated by mechanical effects.
214484568|NCT06894472|OTHER|Electromyography biofeedback|Participants in the experimental group will receive surface electromyography (SEMG) feedback training, targeting the Masseter muscle, for 40 minutes per session according to the Evidence-Based practice since longer practice may become counterproductive due to fatigue and loss of focus. The frequency of the sessions will be 3 sessions/week for 4 weeks.
214484569|NCT06894472|DRUG|Pharmacotherapy|Pharmacotherapy will be received by all participants in the two groups in the form of multi relaxant (cyclobenzaprine) 10 MG twice daily for 4 weeks \& anti inflammatory (non steroidal anti-inflammatory drugs).
214920799|NCT03098654|BEHAVIORAL|Diet and lifestyle counseling|All participants with elevated glucose or BP will receive personalized lifestyle counseling by trained counselors informed by lab results and that includes education on diabetes, hypertension, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose, BP, and adjust their diet, activity level, as needed. Personalized risk reduction plans will be negotiated with the client during their scheduled visits.
214920800|NCT03098654|DRUG|DM/HTN medications as needed|Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
214920801|NCT01961154|DRUG|Asthma medication reduction|The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
214920802|NCT05892276|BEHAVIORAL|Trauma Memory Reactivation|Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.
214920803|NCT05892276|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Broad-Spectrum Oil|300mg CBD broad-spectrum oil.
214484570|NCT06720727|RADIATION|craniospinal irradiation|Delivering radiotherapy to brain, spinal cord and its covering membrane.
214484571|NCT06742242|PROCEDURE|lymphaticovenous anastomosis|supermicrosurgical lymphatic vessel to recipient ven lumen-to-lumen coaptation
214920804|NCT05892276|DIETARY_SUPPLEMENT|Placebo Oil|3ml oral dose of medium-chain triglycerides (MCT) coconut oil.
214920805|NCT03647579|DRUG|midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine|midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
214920806|NCT03647579|DRUG|Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine|Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
214920807|NCT02705300|DRUG|Irinotecan 165 mg/m2 iv|Max. 4 months
214484572|NCT06739408|DIETARY_SUPPLEMENT|Lean red meat|30g of protein from lean beef.
214484573|NCT06739408|DIETARY_SUPPLEMENT|Whey protein|Whey protein to provide 30g protein
214484574|NCT06739408|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin, to provide 0g protein but matched isocalorically
214920808|NCT02705300|DRUG|Oxaliplatin 85 mg/m2 iv|Max. 4 months
214920809|NCT02705300|DRUG|Calcium folinate 200 mg/m2 iv|Max. 6 months
214920810|NCT02705300|DRUG|5-fluorouracil 3200 mg/m2|Max. 6 months
214920811|NCT02705300|DIETARY_SUPPLEMENT|Tocotrienol|Max. 2 years or at the discretion of the investigator
214920812|NCT02705300|DRUG|Placebo|Max. 2 years or at the discretion of the investigator
214920813|NCT02923453|DIETARY_SUPPLEMENT|CNT 2000 American ginseng extract|
214920814|NCT02923453|DIETARY_SUPPLEMENT|Placebo|
215062246|NCT04291690|OTHER|Nutritional Component of the Intervention|We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
215062247|NCT04291690|OTHER|Iron-Deficiency Anemia (IDA) Component of the Intervention|We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin \<130g/L in men or \<120g/L in women with (ii) a Ferritin \<100μg/L or a Ferritin \<300μg/L with a Saturation \<20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
214321200|NCT02821884|DEVICE|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
214321201|NCT02304042|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
214321202|NCT02304042|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
214321203|NCT04921930|DRUG|Artesunate Oral Product|Dose escalation intake of artesunate
214484575|NCT06749834|DRUG|Intravenous thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
214484576|NCT06750614|DEVICE|intermittent theta-burst stimulation (iTBS)|In each visit, the intensity of the iTBS applied to the participant will be set at 70% of their individual resting motor threshold (rMT), with one session specifically targeting the left DLPFC.
214484577|NCT06750523|DIAGNOSTIC_TEST|Cord blood sampling|A cord blood sample will be taken at birth for analysis of oxidative stress markers, endocrine disruptors, and microRNAs.
214920815|NCT04138953|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation, also known as repetitive transcranial magnetic stimulation, is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction.~It will be used to create a 'virtual lesion,' disrupting neural activity in a specific brain region to identify whether it is causally involved in a specific behavioral process."
214484578|NCT06750523|DIAGNOSTIC_TEST|urine sampling|At one month of age, urine samples will be collected from newborns to analyze oxidative stress markers and endocrine disruptors.
214484579|NCT06750523|BEHAVIORAL|Life style questionnaire|At the time of enrollment, mothers will complete a specialized questionnaire designed to assess potential exposure to endocrine disruptors (EDCs) through diet, clothing, and the use of cosmetics and detergents.
214672084|NCT02334267|DEVICE|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
214672085|NCT01420640|BEHAVIORAL|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
214672086|NCT01420640|BEHAVIORAL|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
214672087|NCT01420640|BEHAVIORAL|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
214920816|NCT04138953|OTHER|Sham TMS|Sham Transcranial Magnetic Stimulation (TMS)
214920817|NCT03685253|DRUG|Niagen|Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
214920818|NCT03685253|DRUG|Placebo|Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
215062248|NCT00140153|DRUG|testosterone gel (Androgel)|
214672088|NCT01420640|BEHAVIORAL|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
214672089|NCT01420640|BEHAVIORAL|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
214672090|NCT00244205|PROCEDURE|Identifying genes methylated in urine|
214672091|NCT02984878|DEVICE|Revanesse Ultra|Nasolabial Fold correction
214672092|NCT06094712|DRUG|CORT125134|CORT125134 150-mg capsule
214672093|NCT02019381|DIETARY_SUPPLEMENT|Endocrine Society UL Dosage Vitamin D|Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
214321204|NCT02007928|OTHER|Rispéridone, aripiprazole, olanzapine|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
214321205|NCT05028374|DRUG|"A single booster dose of the Moderna mRNA COVID-19 vaccine"|All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
215062249|NCT01111383|DRUG|tobramycin|"300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period."
215062250|NCT02565147|PROCEDURE|PPCI|PPCI for treatment of participants presenting with large STEMI.
215062251|NCT02565147|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.
215062252|NCT02565147|DRUG|Heparin|Heparin is an anticoagulant.
214321206|NCT03490266|PROCEDURE|Robotic Repair|The surgeon will be utilizing a robotic system to repair the hernia.
214321207|NCT03490266|PROCEDURE|Laparoscopic Repair|The surgeon will be repairing the hernia laparoscopically.
214321208|NCT03706235|OTHER|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
214672094|NCT02019381|DIETARY_SUPPLEMENT|Institute of Medicine Dosage Vitamin D|IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
214920819|NCT01955278|DEVICE|Definitive end colostomy with mesh|In the mesh group, a synthetic prosthetic mesh low weight type Ultrapro (15x15 cm) will be used. It will be placed in a sublay position between the rectus abdominis muscle and the posterior rectus sheath, will be sutured to the posterior rectus sheath with absorbable multifilament stitches. Once positioned and fixed the mesh the bowel will be brought out through a cross cut in the center of the mesh Finally, colon will be fixed by colocutaneous end to end absorbable multifilament sutures.
214920820|NCT01955278|OTHER|Conventional definitive end colostomy|
214920821|NCT06920940|OTHER|Ketogenic Therapy|During the keto therapy (16 weeks), the youth will participate in a strict ketogenic diet, with adjustments made as necessary from weekly dietitian coaching sessions.
214920822|NCT01554462|DIETARY_SUPPLEMENT|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA + 650 mg DHA daily
214920823|NCT01554462|DIETARY_SUPPLEMENT|Placebo dietary intervention (MUFA) in ADHD group|Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
214920824|NCT01554462|DIETARY_SUPPLEMENT|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA and 650 mg DHA daily
214920825|NCT01554462|DIETARY_SUPPLEMENT|Placebo dietary intervention (MUFA) in healthy control group|Placebo contains MUFA in stead of PUFA, same energy value
215062253|NCT03443856|DRUG|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
215062254|NCT03443856|OTHER|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
215062255|NCT00750035|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
215062256|NCT00750035|PROCEDURE|Subtotal abdominal hysterectomy|
215062257|NCT03063723|DRUG|Ledipasvir-Sofosbuvir|8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
215062258|NCT03063723|DRUG|Daclatasvir-Sofosbuvir|7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
215062259|NCT06137885|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a comprehensive model of care involving prescribed exercise, medication management, lifestyle modification, and psychosocial counseling to help people with heart diseases resume and enhance their psychosocial and vocational status.
214672095|NCT02019381|DIETARY_SUPPLEMENT|Calcium|1200mg of CaCO3 supplementation will be given to each participant in both groups
214920826|NCT04552990|DRUG|Jet injection of ALA|The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).
214920827|NCT04552990|PROCEDURE|Surgical excision|In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).
214920828|NCT04552990|PROCEDURE|Illumination|For patients 5-16,after 3h incubation (+/- 30 min), the tumor will be illuminated with red light corresponding to a dose of 75 J/cm2 570- 670 nm or equivalent dose of narrowband red light. The intervention will be repeated at after 14 days in patient 5-16. If the wound is not healed at two weeks, the treatment may be postponed to allow healing (patient 5-16).
214920829|NCT04552990|OTHER|Incubation|After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).
214920830|NCT06926387|DRUG|YHP2407|Test drug: YHP2407, Comparator: YHR2502
214920831|NCT06926387|DRUG|YHR2502|Test drug: YHP2407, Comparator: YHR2502
214920832|NCT05025176|DEVICE|Non invasive arterial pressure monitoring|Non invasive arterial pressure monitoring
214920833|NCT00006160|BEHAVIORAL|home based worker|
214321209|NCT00614016|DRUG|Sodium ST20|single administration of oral dosage form
214321210|NCT04150081|PROCEDURE|Surgery or Endoscopic treatment|All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
214484580|NCT06748508|DRUG|Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib|Patients were randomized in a 1:1:1 ratio to three treatment groups: control group A: pembrolizumab combined with XELOX regimen, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles. Group B: treatment regimen was pembrolizumab combined with Nab-POF regimen, the regimen was repeated every 2 weeks, and tumor efficacy was evaluated every 3 treatment cycles. Group C: treatment regimen was pembrolizumab combined with XELOX regimen and lenvatinib, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles.
214920834|NCT02727946|OTHER|optimal resuscitation|optimal resuscitation to achieve mean arterial blood pressure above 65 mmHG , Central venous pressure more than 8 mmHg , urine out put more than 0.5 ml /Kg/hour
214920835|NCT01314872|DRUG|Vibegron|Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.
215062260|NCT06137885|OTHER|Active post-market surveillance of devices|Active post-market surveillance of devices is an essential and ongoing process that involves systematic monitoring and assessment of medical devices once they are available on the market. It involves continuous data collection and analysis, early detection of issues, risk assessment, compliance with regulatory requirements, adaptive decision-making, and transparent communication with healthcare professionals and patients.
215062261|NCT06137885|OTHER|Multi-omics approach to precision medicine|Multi-omics analysis refers to the collective analysis of extensive biological data from multiple omics sources to gain a holistic understanding of an individual's health status, disease susceptibility, and response to therapies. By considering a broad spectrum of genetic and molecular information, multi-omics precision medicine aims to deliver more accurate diagnoses, predict disease risks, select optimal treatment options, and monitor therapeutic responses with a high degree of specificity, ultimately improving patient outcomes and minimizing adverse effects.
215062262|NCT06137885|OTHER|The prescription pattern analysis|The prescription pattern analysis refers to the systematic examination and evaluation of the types, dosages, frequencies, and trends in medications prescribed to patients with cardiovascular conditions. By scrutinizing prescription patterns, researchers and healthcare professionals can identify prevalent medications, assess adherence to treatment guidelines, uncover potential gaps or areas for improvement in patient care, and gain insights into the evolving landscape of cardiovascular therapies.
215062263|NCT04784793|OTHER|App-based group|"Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
215062264|NCT04784793|OTHER|Control group|"Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
214920836|NCT01314872|DRUG|Tolterodine ER|Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
214920837|NCT01314872|DRUG|Placebo matching vibegron|Participants received placebo matching vibegron tablets, taken orally each morning.
214321211|NCT05187416|DIAGNOSTIC_TEST|two-dimensional shear wave elastography|Preoperative ultrasound elastography examination
214321212|NCT01595360|DRUG|Placebo|It is applied directly to the bleeding site after tooth extraction
214321213|NCT01595360|DRUG|TT-173|It is applied directly to the bleeding site after tooth extraction
214321214|NCT02985294|OTHER|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
214672096|NCT03718494|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.
214920838|NCT01314872|DRUG|Placebo matching tolterodine ER|Participants received placebo matching tolterodine ER capsule, taken orally each morning.
215062265|NCT04186533|BEHAVIORAL|Default Option|The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
214484581|NCT06750133|BIOLOGICAL|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells(6-10×10\^7 CNK+ cells/kg). The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
214484582|NCT05066503|DIETARY_SUPPLEMENT|260279 active study product|The active study product (20g per serving) contains 13.6g of amino acids and natural flavors, citric acid, malic acid, and stevia for flavoring.
214484583|NCT06745089|DEVICE|Intense pulsed light|Intense pulsed light exerts photothermal, photochemical effects, and photobiomodulation on meibomian glands.
215062266|NCT04186533|BEHAVIORAL|Nutrition Education|The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
215062267|NCT05582356|DIETARY_SUPPLEMENT|Carbohydrate group (Group OC)|Carbohydrate group (Group OC)
215062268|NCT05582356|DIETARY_SUPPLEMENT|Placebo group (Group OP|Placebo group (Group OP
214672097|NCT03718494|DIAGNOSTIC_TEST|F-18 Florbetapir Positron Emission Tomography (PET) Imaging|After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.
214920839|NCT03286556|DRUG|Autoantibody Reductive Therapy|TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.
214920840|NCT03286556|DRUG|Treatment as Usual (TAU)|Antibiotics and steroids
214920841|NCT06252545|BEHAVIORAL|semistructured interviews|Black subjects with pancreatic cancer will provide insight on their experience discussing clinical trials and preferences for communicating clinical trial information
214920842|NCT06252545|BEHAVIORAL|feedback|Black subjects with pancreatic cancer will provide feedback on mHealth app prototype.
214920843|NCT06001307|BEHAVIORAL|Program STARS (Supporting Trans Affirmation, relationships, and Sex)|See description to the left.
215062269|NCT06030973|BEHAVIORAL|Filling in an online survey|Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.
215062270|NCT00295334|DRUG|alcohol|
215062271|NCT00002032|DRUG|Rifabutin|
215062272|NCT00124163|PROCEDURE|Imaging procedure of CT colonography|
215062273|NCT00763295|OTHER|T-Spot.TB test|diagnostic test
215062274|NCT03777046|BEHAVIORAL|Standard of Care (SOC)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
215062275|NCT03777046|BEHAVIORAL|SOC with Psychology Therapy (CBT)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
214920844|NCT06001307|BEHAVIORAL|Relaxation and Stress Reduction|See description to the left.
214920845|NCT04211675|BIOLOGICAL|Natural Killer Cells|NK cells dose 1x 108 cells/ kg on day 8 of each cycle
214920846|NCT04211675|DRUG|Temozolomide|Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is \<0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.
214920847|NCT04211675|DRUG|Irinotecan|Irinotecan 50mg/m2/dose IV daily on Days 1-5
214920848|NCT04211675|DRUG|Dinutuximab|Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5
214920849|NCT04211675|DRUG|Sargramostim|Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12
215062276|NCT03358420|DIAGNOSTIC_TEST|Immunohistochemical staining|Pathological liver slides to be immunohistochemically stained for alpha-defensin
215062277|NCT01001767|DRUG|Lovaza|Lovaza one gram twice a day for 24 weeks
215062278|NCT01001767|DRUG|Placebo|Placebo
215062279|NCT06162273|DEVICE|IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
215062280|NCT01888783|OTHER|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
215062281|NCT05076773|PROCEDURE|Ultrasound guided block|Giving one regional block
215062282|NCT05076773|DRUG|IV morphine|given when VAS\>3
215062283|NCT04523623|DRUG|Oxycodone|oxycodone 0.2mg/kg, max 10mg to be administered, randomized between that and Ibuprofen
215062284|NCT04523623|DRUG|Ibuprofen|ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
215062285|NCT01878578|DRUG|Eslicarbazepine acetate|Tablets containing ESL 600 mg
215062286|NCT01878578|DRUG|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
215062287|NCT01878578|DRUG|Placebo|Tablets containing matching placebo
215062288|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Non-obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
214321215|NCT00394966|DRUG|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
214321216|NCT00394966|DRUG|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
214321217|NCT00394966|DRUG|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
214321218|NCT00394966|DRUG|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
214484584|NCT06745089|DEVICE|thermal pulsation therapy|Thermal pulsation therapy utilizes local heating and massage on the eyelids.
214484585|NCT06745089|DRUG|Ocular lubricant|Ocular lubricants moisturize the ocular surface.
214484586|NCT05144516|BEHAVIORAL|Behavioral: COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
214484587|NCT06784518|OTHER|Clinical scores and functional MRI|Motor evoked potentials between Day 3-Day 7 of the stroke, for a equal distribution of patients into three prognostic groups according to the PREP2 algorithm (good, limited and poor). Longitudinal follow-up with clinical scores and functional MRI at Day 7-Day 10, Day 30, Month 3 and Month 6 of stroke.
214920850|NCT03232931|BEHAVIORAL|Therapist skin-to-skin Care|"Skin-to-skin (STS) holding is part of the multisensory intervention where the therapist will wear a clean 100% cotton T-shirt with a clean hospital gown on top of the shirt and wrap the kangaroo positioner securely over the gown. A gauze square scented with parent's skin will be used to provide olfactory stimulation. Therapist STS sessions occur with simultaneous playing of mother's voice contingent on infant pacifier sucking."
214920851|NCT03232931|DEVICE|Contingent parent's voice exposure|The Pacifier Activated Lullaby® (PAL®) device, is a digital music delivery system that integrates a sensor, a pacifier routinely used in the NICU, and a receiver. It delivers a predetermined 10 seconds of recorded parent's voice singing lullabies upon detection of a suck that meets a preset pressure threshold. The original systems were modified for research use by decreasing the lower limit of activation thresholds for delivering the recording. Minimal effort is required to trigger the device. However, the settings ensure that regular attempts are needed to continue to receive continual presentation of the recording of mother's voice by requiring another suck after 10 seconds. The auditory stimulation with PAL will be provided when the infants are still awake (i.e., at the beginning of the session).
214920852|NCT03232931|BEHAVIORAL|Parental skin-to-skin care|The standard of care includes parental skin-to-skin care and exposure to parent's voice. During parental skin-to-skin care, infants are placed in a prone position with head positioned over the sternum, allowing transmission of breath and heart sounds to the developing ear. Deeper pressure is applied to offer support and feedback to the child's bottom. Session length is set to a minimum of 45 minutes per unit protocols.
214920853|NCT03232931|DEVICE|Recorded parent's voice|Per standard of care, preterm infants in the NICU currently receive noncontingent recorded parents' voice during two 20 minute sessions per day. Recordings are standardized and are played through a sterilizable device (DINO-egg).
214920854|NCT04594980|PROCEDURE|lumbar fusion|Transforaminal Lumbar Interbody Fusion will be performed using minimally invasive approach or traditional open technique.
214920855|NCT04294979|OTHER|Physical Therapy|The rehabilitation program will consist of both passive and active therapeutic exercises specifically aimed at restoring or maintaining muscular flexibility, range of motion, balance, coordination of movements, postural passages and transfers, and ambulation. . Furthermore, advanced robotic therapy such as Lokomat® exoskeleton (Hocoma AG, Volketswil, Switzerland), Biodex® Stability System (BSS, Biodex, Inc, Shirley, NY), G-EO System™ (Reha Technology AG, Olten, Svizzera) and Indego® Therapy (Parker USA), will be used to personalize rehabilitation treatment.
214484588|NCT06767475|OTHER|Best Practice|Receive usual care
214484589|NCT06767475|OTHER|Discussion|Attend a focus group
214484590|NCT06767475|OTHER|Health Promotion|Participate in group discussion with exercises and activities
214484591|NCT06767475|OTHER|Interview|Attend a one-on-one interview
214484592|NCT06767475|OTHER|Questionnaire Administration|Ancillary studies
214484593|NCT06787560|BIOLOGICAL|CD7 CAR-T cells injection|Each subject receive CD7 CAR T-cells by intravenous infusion
214484594|NCT06787560|PROCEDURE|Allo-HSCT|allogeneic hematopoietic stem cell transplantation
214321219|NCT00394966|DRUG|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
214321220|NCT00033384|DRUG|CI-1040|
214321221|NCT01441193|BIOLOGICAL|HIV-1 Tat/delta-V2 Env combined vaccine|
214321222|NCT01441193|BIOLOGICAL|HIV-1 delta-V2 Env vaccine|
214321223|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 7.5 microg|
214321224|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 30 microg|
214321225|NCT01467076|DRUG|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
214321226|NCT01467076|DRUG|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
214321227|NCT02866838|DRUG|Tranexamic acid|intravenous
214321228|NCT02866838|DRUG|Saline 0.9%|intravenous
214321229|NCT00981500|PROCEDURE|gastric bypass|Roux-en-Y gastric bypass
214672098|NCT03718494|DIAGNOSTIC_TEST|F-18 AV-1451 Positron Emission Tomography (PET) Imaging|Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449). PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.
214672099|NCT03718494|OTHER|Neuropsychological Testing|A comprehensive battery of standardized neuropsychological tests administered by trained personnel.
214321230|NCT00981500|PROCEDURE|gastric banding|laparoscopic adjustable gastric banding
214321231|NCT00981500|PROCEDURE|sleeve gastrectomy|vertical sleeve gastrectomy
214321232|NCT00901940|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
214321233|NCT00901940|BIOLOGICAL|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
214321234|NCT04751591|PROCEDURE|Endoscopic resection|Endoscopic submucosal dissection (ESD) or endoscopic full-thickness resection (EFTR) for patients with 2-5cm gastric GISTs
214321235|NCT04751591|PROCEDURE|Laparoscopic partial gastrectomy|Laparoscopic partial gastrectomy for patients with 2-5cm gastric GISTs
214321236|NCT01753453|DRUG|Plerixafor|240mcg/kg, solution, subcutaneous injection
214321237|NCT01753453|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
214321238|NCT04555135|DEVICE|EndoVigilant Software|While using this device, colonoscopy will continue to be performed in the standard manner as is done without the use of this device. The video signal from the colonoscope will be fed into a computer running the EndoVigilant software in addition to the standard video output to the procedure monitor. The gastroenterologist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the augmented video on the second monitor. The gastroenterologist may rely on the second monitor (with augmented video generated from EndoVigilant software) for polyp detection, but the standard procedure monitor with the original feed will always be operational and available for maneuvers such as fast insertion, polypectomy etc.
214321239|NCT03304899|DRUG|RiaSTAP Injectable Product|"RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))"
214321240|NCT02093572|OTHER|3 standard meals/day|
214321241|NCT02093572|OTHER|2 meals/day (omit breakfast)|
214321242|NCT02744846|DRUG|Antibiotics exposure|
214672100|NCT02297893|BEHAVIORAL|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
214321243|NCT02548988|OTHER|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
214321244|NCT02900820|OTHER|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
214321245|NCT02900820|OTHER|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
214321246|NCT05052424|DIAGNOSTIC_TEST|Analysis of cytokines and immun cell related markers|blood samples
214321247|NCT04942275|DRUG|Pre-therapeutic imaging test|The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
214321248|NCT00418691|DRUG|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
214321249|NCT00418691|DRUG|Modafinil|200 mg PO Once Daily x 4 Weeks
214321250|NCT00418691|DRUG|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
214321251|NCT04894981|DEVICE|Immersive condition (CAVE)|Driving course with obstacles in a CAVE system
214321252|NCT04894981|DEVICE|Immersive condition (HMD)|Driving course with obstacles with a virtual reality headset
214321253|NCT04894981|DEVICE|Non Immersive condition (Screen alone)|Driving course with obstacles on a screen with physical simulator
215062289|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Mild obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
214321254|NCT04894981|DEVICE|Non Immersive condition (Screen with physical simulator)|Driving course with obstacles on a screen only
214321255|NCT05118594|BEHAVIORAL|Pre-treatment psychotherapy recommendations|After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.
214321256|NCT01518075|OTHER|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
214321257|NCT01518075|OTHER|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
214321258|NCT03337633|BEHAVIORAL|Menu design|Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
214321259|NCT04199429|BEHAVIORAL|Relationship-Based Care|
214484595|NCT06741215|OTHER|Hand Rehabilitation|"Passive mobilization exercises were initiated for these patients in the first postoperative week.~Flexor tendon repair patients were immobilized for 3-4 weeks postoperatively. During this period, passive mobilization exercises were with controlled movement. After removing the splint in the third or fourth week, tendon-gliding exercises were initiated, followed by isolated tendon-gliding exercises in the fifth week. Electrotherapy was started in the sixth week (5 days a week, for 15 sessions).~For extensor tendon repair patients, immobilization lasting 3-6 weeks was applied based on the injury level. During immobilization, passive range of motion (ROM) exercises were performed for adjacent joints while the hand remained in the splint. After splint removal, active and passive ROM exercises, and tendon-gliding exercises with gradually increasing intensity were started according to the injury level. Electrotherapy was started in in the sixth week."
214672101|NCT02297893|BEHAVIORAL|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
214920856|NCT05868005|OTHER|Clinical decision support system for screening of migrants using the ISMiHealth software tool.|"The implementation of the screening programme will be facilitated using a simple and user-friendly software tool (ISMiHealth).~When an individual attends the PCC for any reason, the tool will generate an alert for health professionals in the EPR system, with recommendations on the conditions that should be considered for screening, based on this patient's characteristics (country of birth, age and sex). Health professionals will decide what diseases/conditions should be screened for, supported by the recommendations of the digital software (intervention centres) or based on their knowledge on the epidemiological background of the diseases (control centres). In any case, health professionals will be responsible for requesting serology tests, chest radiographies and/or referrals to specialists."
214920857|NCT06957574|DRUG|Bubpivacaine|ESPB using local anesthetic 20 ml 0.25% bupivacaine on each side
214920858|NCT06957574|DRUG|Normal Saline (Placebo)|ESPB using normal saline 20 ml 0.25% bupivacaine on each side
214920859|NCT06225011|DRUG|Fluoxetine|Receive PO
214321260|NCT03025724|DRUG|Levulan Kerastick|Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
214321261|NCT03025724|DEVICE|blue light source|At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
214321262|NCT03025724|OTHER|participant satisfaction survey|Participants will be asked to fill out a satisfaction survey.
214321263|NCT01297673|PROCEDURE|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
214321264|NCT03641573|DRUG|[14C] ASN002|\[14C\] ASN002
214920860|NCT04556266|BIOLOGICAL|CAR T-Cell Infusion|Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg
214920861|NCT05646784|DRUG|Cerebiome|Evaluate the effect of oral intake of a probiotic agent on plasma inflammatory markers, gut bacterial profile and depressive state in a subgroup of target patients versus a subgroup treated with placebo
214321265|NCT00774098|DRUG|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
214321266|NCT00774098|DRUG|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
214920862|NCT05646784|DRUG|Placebo|Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment for 12 weeks
214920863|NCT06433921|DRUG|Salbutamol HFA-152a|A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
214920864|NCT06433921|DRUG|Salbutamol HFA-134a|A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
214920865|NCT06433921|DRUG|Placebo|A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
214920866|NCT04925557|DRUG|Mayzent|PET imaging to evaluate the effects of Mayzent on the microglia of the brain.
214920867|NCT04925557|DRUG|Ocrevus|PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.
214920868|NCT04201288|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|Acceptance-Based Behavior Therapy (ABBT) In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified barriers to retention in care. Interventionists will help participants identify potential challenges to acceptance, including disclosure concerns. At the second session, participants will practice acceptance-based coping skills and a behavioral plan will be developed to target barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage their HIV.
214321267|NCT00774098|DIETARY_SUPPLEMENT|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
214321268|NCT00774098|DRUG|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
214321269|NCT01067352|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
214321270|NCT04995640|PROCEDURE|open cardiovascular repair or endovascular treatment (TEVAR)|Surgery type: open cardiovascular repair and endovascular treatment (TEVAR)
214321271|NCT00002275|DRUG|Fat Emulsion 2%|
214321272|NCT00002275|DRUG|Fat Emulsion 20%|
214321273|NCT02090816|PROCEDURE|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
214321274|NCT01096784|DRUG|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
214321275|NCT03052582|OTHER|Milk type|
214321276|NCT06410872|DIAGNOSTIC_TEST|BART Task|The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)
214321277|NCT03761628|DEVICE|pHyph generation I|A vaginal tablet for the treatment of VVC to be administered every 48 hours
214321278|NCT04515004|DRUG|leucoselect phytosome|A standardized grape seed procyanidin extract complexed with soy phospholipid.
214321279|NCT05275777|DRUG|ADG106|Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
214321280|NCT05275777|DRUG|Doxorubicin|Administered as an intravenous infusion.
214321281|NCT05275777|DRUG|Cyclophosphamide|Administered as an intravenous infusion.
214321282|NCT05275777|DRUG|Paclitaxel|Administered as an intravenous infusion.
214321283|NCT05235074|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
214321284|NCT04541017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214321285|NCT04541017|PROCEDURE|Computed Tomography|Undergo PET/CT or diagnostic CT
214321286|NCT04541017|BIOLOGICAL|Magrolimab|Given IV
214321287|NCT04541017|BIOLOGICAL|Mogamulizumab|Given IV
214321288|NCT04541017|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214321289|NCT04541017|PROCEDURE|Punch Biopsy|Undergo skin punch biopsy
214672102|NCT02796144|DRUG|Lorcaserin|Max dose of 10 mg BID
214484596|NCT06790914|BEHAVIORAL|Flurbiprofen axidate combined with noise-cancelling headphones music|30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After general anesthesia induction, noise-cancelling headphones (Sony WH-1000XM3) were fully covered with both ears, and MP3 (GoGear, Philips) was connected to play music continuously until the headphones were removed after the operation.
214484597|NCT06790914|BEHAVIORAL|Flurbiprofen axidate combined with noise-cancelling headphones|30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After induction of general anesthesia, noise-cancelling headphones (Sony WH-1000XM3) were applied to cover both ears completely until the headphones were removed at the end of the procedure.
214484598|NCT06790914|OTHER|Flurbiprofen exate on a drip|30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline at 60 drops /min.
214484599|NCT06793514|DRUG|Probiotic|The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophiles) alongside with fructooligosaccharide (FOS), which is prepared in the concentration of 109 cfu by Bisot Khimr and is in the form of an edible sachet that can be dissolved in cold water, which is consumed once a day for one month. Sachets should be stored at a temperature of 2 to 8 degrees Celsius (in the refrigerator), which increases the useful life of probiotic bacteria and makes them more effective.
214484600|NCT06793514|DRUG|Placebo Drug|The placebo is also prepared in the form of probiotic supplement in the form of sachets with similar packaging by the bio-fermenting pharmaceutical company.
214484601|NCT06793995|DRUG|LY03017|single dose，administered orally for each period
214484602|NCT06793995|DRUG|LY03017|single dose，administered orally
214484603|NCT06791655|DEVICE|Stock Abutment Implant|Participants in this intervention group receive a two-piece dental implant that utilizes a stock abutment. The stock abutment is a prefabricated component that connects the implant to the prosthetic suprastructure. This intervention aims to evaluate the standard outcomes of using stock abutments in the restoration of teeth in esthetic zones after immediate implant placement.
214484604|NCT06791655|DEVICE|Customized CAD CAM Titanium Milled Abutment Implant|Participants in this intervention group are treated with a two-piece dental implant that includes a customized CAD CAM titanium milled abutment. These abutments are tailor-made using computer-aided design and manufacturing to fit the specific contours and needs of the patient's dental structure. This customized approach is hypothesized to offer superior integration with the soft and hard tissues, leading to better aesthetic outcomes and tissue health around the implant area.
214484605|NCT04270786|PROCEDURE|Early de-escalation|In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.
214484606|NCT04270786|PROCEDURE|Standard|In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.
214920869|NCT04201288|BEHAVIORAL|Enhanced-Treatment-as-Usual (ETAU)|ETAU will consist of two brief sessions lead by study interventionists, performed at the same times and by same methods as ABBT. Topics of education include safe sex practices, review of treatment options, and review of HIV-related indices of health.
214920870|NCT06356025|DRUG|botulinum toxin type A|Botulinum toxin type A 75U dissolved in 3mL physiological serum injection in the upper esophageal sphincter
214920871|NCT06356025|DRUG|Sodium Chloride 0.9% Inj|Placebo: physiological serum 3mL injection in the upper esophageal sphincter
214920872|NCT05488470|DEVICE|LINQ/LINQ II|Algorithm developed and validated to continuously measure QT intervals for every beat using LINQ/LINQ II ECG. This study is aimed at determining if QT interval changes can be detected during antiarrhythmic drug loading by the designed QT detection algorithm from LINQ/LINQ II ECG.
214920873|NCT05221554|PROCEDURE|Computer-navigated THA surgery|Navigation software coupled with real-time modeling software will be used to plan optimal acetabular cup for patients undergoing THA.
214920874|NCT05221554|PROCEDURE|Standard of care THA surgery|Patients already underwent THA procedure with manual placement of acetabular cup with conventional instrumentation.
214920875|NCT05639088|BEHAVIORAL|Transition preparation program|"AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach."
214920876|NCT05639088|OTHER|Educational materials|AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
214484607|NCT06829186|DIETARY_SUPPLEMENT|Curcumin (Longvida™)|patients will be suplemented during 3 months with longvida, 2 cap /8 hours
214920877|NCT03431090|DEVICE|CliniMACS® TCRαβ/CD19 Combined Depletion System|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
214484608|NCT06829186|DRUG|Placebo|one capsules every 8 hours during 12 weeks
214672103|NCT02796144|DRUG|Metformin|Max dose of 1,000 mg BID
214672104|NCT02796144|DRUG|Placebo|Matching placebos will be administered for each drug.
214672105|NCT05378789|PROCEDURE|Nap|"ICU nurses can take a 20-mn nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair."
214920878|NCT03524326|DRUG|Lenvatinib Pill|24 mg oral daily
214920879|NCT03524326|DRUG|Lenvatinib Pill|20 mg oral daily
214920880|NCT03524326|DRUG|Lenvatinib Pill|14 mg oral daily
214920881|NCT03524326|DRUG|Cetuximab|400mg/m2 IV, then 500mg/m2 IV weekly
214920882|NCT03524326|DRUG|Lenvatinib Pill|10 mg oral daily
214920883|NCT03524326|DRUG|Lenvatinib Pill|4 mg oral daily
214920884|NCT05707637|OTHER|Ablation|Unipolar and bipolar ablation
214672106|NCT01252888|DEVICE|iStents|Implantation of two iStents through a small temporal clear corneal incision
215062290|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Moderate obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
214920885|NCT02966730|DRUG|Ibrutinib|Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
215062291|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Severe obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
214484609|NCT06840626|OTHER|Series of breathing exercises|During the intervention, participants perform respiratory exercises, including deep breathing, belly breathing, exhalation with vocalization, and forced exhalation. Each exercise is repeated five times, three times per day: twice in the morning and once in the afternoon. The exercises are conducted in a seated, corrected position, guided by rehabilitation specialists or special needs teachers who provide instructions and demonstrations. Teachers are provided with the exact protocol for the breathing exercises series. Each breathing exercise focuses on maintaining a specific rhythm, with inhalation lasting approximately 3-4 seconds, holding for 1-2 seconds, and exhalation for 5-6 seconds. Forced exhalation is facilitated using playful motivational tools such as windmills and balloon blowing. The protocol includes instructions for the breathing exercises in first-person singular. The entire session lasts approximately 5 minutes, resulting in a total of 15 minutes of training per day.
214920886|NCT04730011|BEHAVIORAL|Short and Intensive Treatment|Intensive Treatment Week with behavioural psychotherapy
215062292|NCT05092997|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
215062293|NCT05092997|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
214321290|NCT02416427|DRUG|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
214321291|NCT03903627|OTHER|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
215062294|NCT04306458|PROCEDURE|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
215062295|NCT04306458|DEVICE|daVinci Xi system|robot assisted minimally invasive esophagectomy
215062296|NCT02578134|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
215062297|NCT02578134|OTHER|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
215062298|NCT02942836|DEVICE|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
215062299|NCT03098433|DRUG|Liothyronine|Single dose
215062300|NCT03098433|DRUG|Levothyroxine|Active comparator
214920887|NCT05917587|DRUG|Metformin Hydrochloride|12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.
214920888|NCT05917587|OTHER|placebo|12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.
214920889|NCT06569602|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
215062301|NCT03098433|DRUG|Placebos|Placebo
214321292|NCT00007033|DRUG|magnesium gluconate|
214321293|NCT00007033|DRUG|magnesium sulfate|
214321294|NCT04264286|DRUG|Prophylactic esmolol|Patients will receive prophylactic esmolol after the end of the surgery
214321295|NCT04264286|DRUG|Placebo|Patients will prophylactic placebo after the end of the surgery
214321296|NCT01505686|PROCEDURE|MRI scan|MRI scan with a 1,5 T MRI scanner
214321297|NCT01474642|DRUG|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
214321298|NCT01474642|DRUG|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
215062302|NCT04315727|GENETIC|WGS Diagnostic Blood take for genetic diagnostic.|Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).
215062303|NCT04315727|GENETIC|Hair collection|Hair including root will be collected from the scalp (\~15-20) and transferred to cultivation medium for the organoid cultivation
215062304|NCT04748679|BEHAVIORAL|Worry Intervention|The worry intervention is weekly individual therapy with a trained therapist
215062305|NCT04748679|BEHAVIORAL|Befriending|The worry intervention is weekly individual therapy with a trained therapist
215062306|NCT05684692|DRUG|Siltuximab|A chimeric immunoglobulin G mAb, via intravenous infusion.
215062307|NCT05684692|DRUG|Erenumab-Aooe|Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
215062308|NCT05684692|DRUG|Siltuximab Matching Placebo|Dextrose 5% in water, via intravenous infusion.
215062309|NCT05684692|DRUG|Erenumab-Aooe Matching Placebo|0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
215062310|NCT02371785|DEVICE|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
214484610|NCT06840457|BEHAVIORAL|Mindfulness + Tailored Messages|"Tailored Messages (TM) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Messages will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual messages.~The study will use an app designed to train the user in mindfulness practices."
214484611|NCT06840457|BEHAVIORAL|Mindfulness without Tailored Messages|The study will use an app designed to train the user in mindfulness practices.
215062311|NCT01667133|DRUG|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
215062312|NCT01667133|DRUG|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
215062313|NCT02548910|PROCEDURE|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
215062314|NCT02548910|DEVICE|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
214484612|NCT06840457|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) + Tailored Messages|"Tailored Messages (TM) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Messages will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual messages.~The study will use an app designed to deliver cognitive behavioral therapy."
214484613|NCT06840457|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) without Tailored Messages|The study will use an app designed to deliver cognitive behavioral therapy.
214484614|NCT06837064|DEVICE|Chatbot supporting system|"The intervention tool is the automated chatbot supporting system, which contains:~A) educational information (therapeutic education and psychoeducation); B) symptom monitoring (stool quality and frequency, assessment of mood, sleep quality, physical activity, and dietary adherence on a scale of 0 to 10); C) behavioral distraction techniques, and body tension reduction techniques."
214484615|NCT06120608|BEHAVIORAL|Novel dietary approach focused on restricting the intake of highly bioavailable potassium|Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.
215062315|NCT04483193|DIAGNOSTIC_TEST|Duplex ultrasound|Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
215062316|NCT04695470|DRUG|Fruquintinib and Sintilimab|"fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w"
214484616|NCT06120608|BEHAVIORAL|Traditional approach|Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.
215062317|NCT01104545|DRUG|MK-3614|
214484617|NCT06485297|OTHER|questionnary|questionnaire in word format, sent by email and in paper version, which was established by the two main investigators (Diana Neponoceno, Pr Sophie-Myriam Dridi)
214484618|NCT02325154|DEVICE|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
214484619|NCT02531932|DRUG|Carboplatin|Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k
214484620|NCT02531932|DRUG|Everolimus|The study drug Everolimus will be self-administered (by the patients themselves).
214484621|NCT05144633|DEVICE|Auscultation|This study will be to determine if the addition of Eko AI-assisted lung auscultation examination to a standard of care Pulmonary POCUS + assists with acute respiratory failure diagnosis.
214484622|NCT06485752|BIOLOGICAL|tNIV 1 and Matrix-M Adjuvant|tNIV will be administered as a single 0.5 mL IM injection Day 0
214484623|NCT06746272|PROCEDURE|Serratus Anterior Plane Block|Ultrasound guided Serratus anterior block will be performed according to the analgetic standard in our department using an ultrasound guided transducer to inject 2mg/kg of 0.5% ropivacaine with an adjuvant. A sterile plaster will be placed on the puncture site after performing the block. Patients will receive i.v. analgesia according to the analgesic standard of care in our department.
214484624|NCT00709956|DRUG|iloprost (5 µg)|Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
214484625|NCT00709956|DRUG|placebo|Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
214484626|NCT06201611|DRUG|Nebivolol+ Standard care arm|This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
214484627|NCT06201611|DRUG|Epalrestat + Alpha Lipoic Acid +Standard care|This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
214484628|NCT06201611|DRUG|Standard care alone|Patients in this arm will receive standard care as judged by their treating physicians which is generally pain modifying treatment.
214484629|NCT06117670|COMBINATION_PRODUCT|posterior colporrhaphy using gamma-irradiated amniotic membrane as a graft|Posterior colporrhaphy with application of the gamma-irradiated amniotic membrane graft will be done
214484630|NCT06843395|BEHAVIORAL|ACT-based ecological momentary intervention|The intervention is based on Acceptance and Commitment Therapy (ACT) and includes the six core processes (being present, acceptance, defusion, self-as-content, values, and taking action). It is delivered in the form of an ecological momentary intervention (EMI), lasting for 7 days with two sessions per day. The intervention aims to enhance mental health, well-being, and psychological flexibility.
214484631|NCT06843395|OTHER|Mood monitoring|Participants do not receive any intervention. During the intervention period, they only need to complete ecological momentary assessments twice a day.
214484632|NCT04245085|DRUG|Atezolizumab|"Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit."
214484633|NCT04245085|DRUG|Bevacizumab|Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
214484634|NCT04245085|DRUG|Carboplatin|Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.
214484635|NCT04245085|DRUG|Paclitaxel|Patients in treatment Arm A will receive paclitaxel, 175-200 mg/m2 (at the investigators' discretion), every 3 weeks for 4-6 cycles.
214484636|NCT04245085|DRUG|Pemetrexed|Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
214484637|NCT06578156|DEVICE|Nasal High Flow Cannula|High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times
214484638|NCT06578156|DEVICE|Nasal Low Flow Cannula|Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times
214672107|NCT02069782|OTHER|Home visiting|Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
215062318|NCT01104545|DRUG|Comparator: Placebo|
215062319|NCT05053074|DEVICE|Nasal High Flow (NHF)|Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.
215062320|NCT04397367|DRUG|Ruxolitinib 10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
215062321|NCT04397367|DRUG|Ruxolitinib 5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
215062322|NCT04397367|DRUG|Ruxolitinib 5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
215062323|NCT04397367|DRUG|Ruxolitinib 2.5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
215062324|NCT01550406|DEVICE|Tachocomb|"A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
215062325|NCT01550406|DEVICE|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
214321299|NCT06060574|DEVICE|Platelet rich fibrin device|"Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes."
214321300|NCT04655911|BIOLOGICAL|ABO-101|Gene therapy rAAV9.CMV.hNAGLU
214321301|NCT02489747|DIETARY_SUPPLEMENT|WBE|wheat bran extract (3 g/day)
214321302|NCT02489747|DIETARY_SUPPLEMENT|Placebo|Placebo
214321303|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 weekly for 4 doses
214321304|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 weekly for 4 doses
214321305|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|1 μg vaginal dose of AZU-101 weekly for 4 doses
214321306|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 twice-weekly for 8 doses
214321307|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 twice-weekly for 8 doses
214321308|NCT06308991|OTHER|Yakson touch|Yakson touch method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The Yakson method continued for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes).
214321309|NCT06308991|OTHER|Gentle Human Touch|Gentle Human Touch (GHT) method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The GHT method continued for 15 minutes.
214321310|NCT06308991|OTHER|Routine care|Infants in the Routine care will be applied swaddling. It will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.
214321311|NCT03140202|DEVICE|CPRmeter (feedback device) with feedback|Participants have a real time feedback and record.
214321312|NCT03140202|DEVICE|CPRmeter (feedback device) without feedback|Participants have a real time record without feedback.
214321313|NCT04117126|BEHAVIORAL|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
214321314|NCT02956213|OTHER|HEPA portable air filter|A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
214321315|NCT02956213|OTHER|Sham Control/Active Comparator|A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
214321316|NCT06572475|DIAGNOSTIC_TEST|USPIO enhanced MRI|Ferumoxytol (Feraheme©, AMAG pharmaceuticals, US) enhanced MRI
214321317|NCT03756220|DRUG|Combination therapy of vitamin C and thiamine|Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
214321318|NCT03756220|DRUG|Normal saline solution|Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
214321319|NCT06579573|DRUG|Cenobamate|Cenobamate will be orally administered once daily.
214321320|NCT04314089|DRUG|GT103|intravenously (dose depending)
214672108|NCT01943279|OTHER|Remote Follow-up (RFU)|Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
214920890|NCT04308278|DRUG|2LEBV® / 2LXFS®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
214920891|NCT04308278|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
214920892|NCT01763580|DRUG|Tacrolimus|Oral
214321321|NCT05572983|DRUG|Chidamide combined with CHOP|A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po
214321322|NCT05572983|DRUG|Chidamide|Chidamide: 20mg，qw（d1,d4）,po
214321323|NCT01835249|OTHER|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP \<120 mmHg.
214920893|NCT01763580|DRUG|Prednisolone|Oral
214920894|NCT05849415|DIAGNOSTIC_TEST|Periodontal Screening and Recording, periodontal evaluation.|Periodontal probing for the evaluation of bleeding on probing and Periodontal Screening and Recording
214920895|NCT05204862|DRUG|TU2218|orally administered
214920896|NCT05204862|DRUG|Anti-PD-1 antibody|Intravenously administered
214920897|NCT05272228|DIETARY_SUPPLEMENT|Dietary supplement - standard product|Single dose intervention with Standard product Coenzyme Q10 (ubiquinone) 2 capsules - 100 mg total coenzyme Q10
214321324|NCT01835249|OTHER|Standard BP arm|Participants in the Standard BP arm have a goal of SBP \<140 mmHg.
214920898|NCT05272228|DIETARY_SUPPLEMENT|Dietary supplement - Investigational product IP1|Single dose intervention with Investigational product IP1; Q10 MICROENCAPSULATED 2 capsules - 100 mg total coenzyme Q10
214920899|NCT05272228|DIETARY_SUPPLEMENT|Dietary supplement - Investigational product IP2|Single dose intervention with Investigational product IP2; Final formulated product BQSM® 2 capsules - 100 mg total coenzyme Q10
214920900|NCT00068393|DRUG|Doxorubicin|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
214920901|NCT00068393|DRUG|Gemcitabine|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
214920902|NCT00068393|DRUG|G-CSF (granulocyte-colony stimulating factor)|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
215062326|NCT04834193|PROCEDURE|Endoscopic ultrasound-guided fine-needle biopsy|Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)
215062327|NCT04107740|DRUG|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
214321325|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
214321326|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
214321327|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
214321328|NCT04865497|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.
214321329|NCT05418725|DEVICE|PVI and Linear lesion using PEF|PVI and Linear lesion using PEF
214321330|NCT05418725|DEVICE|PVI and Linear lesion using CFRF|PVI and Linear lesion using CFRF
214321331|NCT02350205|BIOLOGICAL|Self assembled skin substitute (SASS)|All patients in Phase B will receive Self assembled skin substitute (SASS)
214321332|NCT04321876|BEHAVIORAL|Collaborative Behavioral Health Program|Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.
214321333|NCT03118492|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
214321334|NCT03118492|DRUG|Cyclophosphamide|Given IV
214321335|NCT03118492|DRUG|Fludarabine|Given IV
214321336|NCT03118492|BIOLOGICAL|Glycosylated Recombinant Human G-CSF AVI-014|Given IV
214321337|NCT03118492|OTHER|Laboratory Biomarker Analysis|Correlative studies
214321338|NCT03118492|DRUG|Melphalan|Given IV
214321339|NCT03118492|DRUG|Mycophenolate Mofetil|Given PO
214321340|NCT03118492|DRUG|Tacrolimus|Given IV or PO
214321341|NCT03118492|RADIATION|Total-Body Irradiation|Undergo TBI
214321342|NCT03064126|DEVICE|RANGER™ Paclitaxel Coated Balloon|"A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
214321343|NCT03064126|DRUG|Paclitaxel|The RANGER™ Balloon is coated with the drug Paclitaxel.
215062328|NCT04107740|DRUG|Placebo|BID, 10mg per day, for 24 weeks
215062329|NCT01590745|DEVICE|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
215062330|NCT02038972|GENETIC|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
215062331|NCT06269692|DEVICE|MRI screening|Cardiac Magnetic Resonance imaging for the quantification of the infarct intramural scar
215062332|NCT06269692|DEVICE|Implantable Loop Recorder|Inplantation of the Implantable Loop Recorder (ILR) for the patients assigned to the experimental group
215062333|NCT06269692|DEVICE|Implantable Cardioverter Defibrillator|Inplantation of the Implantable Cardioverter Defibrillator (ICD) for the patients assigned to the control group, according to the current guidelines
214672109|NCT01943279|OTHER|Standard Follow-up (SFU)|Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
214672110|NCT00178321|DEVICE|earplugs|
214672111|NCT05898503|BEHAVIORAL|Walking exercise + resistance training|Walking exercise and resistance training for 12 weeks
214672112|NCT05898503|BEHAVIORAL|Resistance training|Resistance training for 12 weeks
214672113|NCT05898503|BEHAVIORAL|Walking exercise|Walking exercise for 12 weeks
214672114|NCT05898503|BEHAVIORAL|Health promotion|Health promotion for 12 weeks
214321344|NCT03064126|PROCEDURE|Standard Balloon Angioplasty|"A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
214672115|NCT05638386|PROCEDURE|Bone plug|The investigational treatment is the use of a bone plug in the two drill-holes in the tibia, made by two pins for securing the tibial array to the bone. The pins that are used for this, are 4.0mm wide. The bone plug that is used to fill the drill-holes of tibia, is obtained from the bone that is removed during the operation to make place for the new prosthesis. A piece as wide as the drill-hole is cut off the recessed bone and put into this hole. After this, the wound is closed using surgical staples.
214321345|NCT01888198|BEHAVIORAL|(EORTC QLQ-C30) questionnaire|
214321346|NCT01888198|BEHAVIORAL|EuroQol EQ-5D 7-item questionnaire|
214321347|NCT04126785|OTHER|High Intensity Interval Exercise in Heated Water-Based|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
214321348|NCT04126785|OTHER|Continuous Moderate Exercise in Heated Water-Based|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.
214321349|NCT04126785|OTHER|Control Group|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
214321350|NCT04508725|DIAGNOSTIC_TEST|Doppler Ultrasound|Power Doppler measurements will be made
214321351|NCT04508725|DEVICE|SIEMENS S3000 and Verasonics Vantage 256|Vantage 256 used for power Doppler ultrasound, manufactured by Verasonics
214321352|NCT04508725|DRUG|Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)|Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI).
214321353|NCT04508725|DRUG|Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI|Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI
214321354|NCT06799403|BEHAVIORAL|Therapist-assisted online stress management|Participants gain access to an online program comprised by 14 modules covering psychoeducation on stress, sleep, and communication, cognitive behavioral restructuring, and exercises and tools for dealing with stress and preventing relapse. Participants are followed by a therapist providing feedback on exercises and progress. The program extends over approx. 12 weeks.
214672116|NCT04990544|BIOLOGICAL|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
214672117|NCT04990544|BIOLOGICAL|202-CoV low antigen dose|low dose of 202-CoV with CpG / alum adjuvant
214672118|NCT04990544|BIOLOGICAL|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
214672119|NCT04990544|BIOLOGICAL|Placebo|Normal saline solution
214672120|NCT00992303|OTHER|biologic sample preservation procedure|
214672121|NCT00992303|OTHER|medical chart review|
214672122|NCT00992303|OTHER|questionnaire administration|
214672123|NCT05221294|DRUG|Modified Del Nido Versus Custodiol Cardioplegia|Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
214672124|NCT06135597|OTHER|This is a blood test without regarding to intervention nor diagnostic tests|This is a blood test without regarding to intervention nor diagnostic tests
215062334|NCT02846792|BIOLOGICAL|Nivolumab|Given IV
215062335|NCT02846792|DRUG|Plinabulin|Given IV
215062336|NCT01849393|OTHER|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
215062337|NCT05944068|BEHAVIORAL|midfulness training|For this study we chose for a mindfulness based intervention. Mindfulness is defined as the ability to notice and observe details about one's present internal and external environment with the goal of non-judgemental and non-elaborative awareness of cognitions, emotions and physical sensations. The goal of the mindfulness intervention will be to teach patients a way of coping with negative emotions without acting on them, letting patients take control of their disease related behaviour and come to better disease acceptance. Where medical treatments fail to take away all disabling symptoms, psychological interventions like mindfulness could offer patients a coping method through which symptoms are experienced as less disabling and patients regain their quality of life. This research may further strengthen the need for a multidisciplinary approach in patients with Crohn's disease.
215062338|NCT00116038|DEVICE|Femoral implant (Versys Fiber Metal Taper®)|
215062339|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
215062340|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
215062341|NCT02676895|BIOLOGICAL|Menveo|One injection of Menveo was administered in subjects in the Control Group.
215062342|NCT02676895|BIOLOGICAL|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
215062343|NCT02784158|DRUG|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.
215062344|NCT00289289|DEVICE|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
214321355|NCT06799403|BEHAVIORAL|Group-based face-to-face stress management|The group-based format consists of 8 sessions of each 3 hours spread across 12 weeks. The sessions cover psychoeducation on stress, sleep, and communication, cognitive behavioral restructuring, and exercises and tools for dealing with stress and preventing relaps. A group includes 8-9 participants
214321356|NCT05778188|DRUG|RLS-0071|RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3 or 10 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
214321357|NCT05778188|DRUG|Placebo|Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3 or 10 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
214321358|NCT03856658|DRUG|Floxuridine (FUDR)|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
214321359|NCT03856658|DEVICE|Hepatic Artery Infusion Pump|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. The primary tumor will be resected or ablated with irreversible electroporation at the time of HAI pump placement. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
214321360|NCT03856658|DRUG|Heparinized Saline|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
214321361|NCT06249438|BIOLOGICAL|CD20/BCMA-directed CAR-T cells|Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
214321362|NCT05403697|PROCEDURE|Individualized MAP|Hemodynamic optimization beginning after general anesthesia induction, and ending at the 24th hour postoperatively, which consists in obtaining a mean arterial pressure (MAP) which is at least 90% of the usual MAP of the patient.
214321363|NCT03806309|DRUG|FOLFIRI|Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2
214321364|NCT03806309|DRUG|OSE2101|subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
214321365|NCT04522323|BIOLOGICAL|MEDI5752|MEDI5752
214321366|NCT04522323|DRUG|Axitinib|INLYTA
214321367|NCT04522323|DRUG|Lenvatinib|LENVIMA
214321368|NCT04156815|RADIATION|1,565nm NAFL|1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
215062345|NCT04905524|DIETARY_SUPPLEMENT|VIOME Precision Nutrition Program|Diet and supplements recommendations
215062346|NCT01642056|DRUG|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
214321369|NCT04156815|DRUG|Oral isotretinoin|Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
214321370|NCT04156815|OTHER|Pricking blood therapy|Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
215062347|NCT01642056|DRUG|Placebo|
215062348|NCT04166370|OTHER|Control|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
214321371|NCT04388943|OTHER|Observation|Physiological Measurements Patient reported questionnaire Blood sampling
214321372|NCT04176003|OTHER|Qualitative interview|Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies
214321373|NCT04176003|OTHER|Member checking|Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.
214321374|NCT02465528|DRUG|Ceritinib (LDK378)|Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
214321375|NCT06959901|BEHAVIORAL|PATHS-UP Mobile Phone Application|Youth in the intervention will be given access to a health-based mobile phone application and a remote bluetooth scale. The app is focused on promoting health education and self-monitoring. For 30 days youth will be asked to engage with content focused on promoting healthy sleep, physical activity, and dietary habits every day. Youth will also be asked to self-monitor health behaviors using the app as it pulls in data on daily steps from the accelerometer embedded within the smartphone, information on weight from daily weigh-ins using the remote scale, sleep via a weekly survey within the app, and caloric intake using a daily food log that is powered through artificial intelligence within the app.
214321376|NCT00769847|PROCEDURE|Endoscopic strip craniectomy|Surgery
215062349|NCT04166370|OTHER|Strengthened (Services and SBCC)|"Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior."
214321377|NCT00645333|DRUG|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
214321378|NCT03907683|BEHAVIORAL|Short Message with Text and Optional Image|"Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
214321379|NCT06058598|OTHER|Exercise Training|6-months supervised exercise training + 6 months unsupervised exercise training
214321380|NCT06058598|OTHER|Lifestyle Counselling|12-months of lifestyle counselling
214321381|NCT04965792|OTHER|Screening|Blood test
214321382|NCT05657470|DRUG|Tenecteplase|intra-arterial tenecteplase
214321383|NCT02975934|DRUG|Rucaparib|Rucaparib will be administered daily.
214321384|NCT02975934|DRUG|Abiraterone acetate or Enzalutamide or Docetaxel|Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
214672125|NCT03291197|DRUG|Suprascapular and median nerve blocks|Ultrasound guided injection of the median and suprascapular nerve of the affected side.
214672126|NCT00887692|BEHAVIORAL|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
214672127|NCT03630640|DRUG|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
214672128|NCT04626219|OTHER|Imaging|Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
214672129|NCT04626219|BEHAVIORAL|fast|hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
214672130|NCT04626219|BEHAVIORAL|regulated meals|standardized diet from noon until 9 a.m. the next day
214672131|NCT02183545|DRUG|BI 1060469|single rising doses given as tablet
214672132|NCT02183545|DRUG|Placebo|given as tablet (matching placebo of BI 1060469)
214672133|NCT02460822|DEVICE|MyChemoCare iPad application|
214672134|NCT06069531|DIETARY_SUPPLEMENT|Lactobacillus johnsonii, Placebo Comparator: White pomegranate extract|Group A: Placebo; Group B: heat-killed Lactobacillus johnsonii TCI250; Group C: White pomegranate extract, dosage of 500mg for 8 weeks.
214672135|NCT04967430|DRUG|Peginterferon Lambda-1A|"Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose."
214672136|NCT04967430|OTHER|Placebo|The placebo will be 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
214672137|NCT05758038|PROCEDURE|Radiofrequency ablation/Microwave ablation|thermal ablation by radiofrequency and Microwave
214672138|NCT01633060|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
214672139|NCT01633060|DRUG|BKM120|BKM120 100 mg once daily
214672140|NCT01633060|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
214920903|NCT00068393|DRUG|Neulasta|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
214920904|NCT01941745|DRUG|Half normal saline|2 ml/kg
214920905|NCT01941745|DRUG|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
214920906|NCT01941745|DRUG|High dose rhCC10|5 mg/kg in 2 ml/kg
214672141|NCT04068883|OTHER|Q collar|An externally-worn medical device that applies mild jugular compression
214672142|NCT05004012|DEVICE|Magnetically Controlled Capsule Endoscopy|This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
214672143|NCT04332549|DRUG|PICS (Reconstitution Method 1 or 2)|dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
214672144|NCT04924725|PROCEDURE|Endoscopic ultrasound-guided fine needle biopsy|Endoscopic ultrasound-guided fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions
214672145|NCT03597906|PROCEDURE|topography guided ablation|using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
214672146|NCT03597906|PROCEDURE|manifest refraction|using for ablation the exact manifest refraction
214672147|NCT03597906|PROCEDURE|full topography modified refraction|full topography modified refraction means changing both sphere and cylinder power in the ablation profile
214672148|NCT03597906|PROCEDURE|partial topography modified refraction|partial topography modified refraction means changing only cylinder power and axis in the ablation profile
214672149|NCT04970706|PROCEDURE|ACL reconstruction|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
214672150|NCT04460027|OTHER|Woebot Substance Use Disorder|Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
214672151|NCT05895851|RADIATION|head and neck radiation|RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
214672152|NCT03146312|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 4 weeks
214672153|NCT03146312|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
214672154|NCT00576914|DRUG|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
214920907|NCT02586610|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Days 1, 22 and 43
214920908|NCT02586610|DRUG|Capecitabine|Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
214920909|NCT02586610|RADIATION|Radiation Therapy|Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)
214920910|NCT05509465|DEVICE|Ergonomic chinrest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting.
215062350|NCT04166370|OTHER|Strengthened (Services and SBCC) + CCT|Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
215062351|NCT06414343|OTHER|Observational - no intervention|Observational - no intervention
215062352|NCT01471769|BEHAVIORAL|Pain management video|6-minute video
215062353|NCT01471769|BEHAVIORAL|Falls Prevention Video|6-minute video
214321385|NCT02075840|DRUG|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
214321386|NCT02075840|DRUG|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
214321387|NCT04798352|OTHER|6-minute walk test|6-minute walk test
214321388|NCT04798352|OTHER|WIQ functional questionnaire|WIQ functional questionnaire
214484639|NCT06882109|OTHER|Five-in-two ankle block|"The FIT block is a new approach for regional anesthetic block of the ankle. We use an optimized ultrasound guided approach for the FIT Block, based on optimal nerve anatomical locations. A one puncture proximal approach for the fibular nerves is used, while maintaining the benefit of preserved extrinsic motricity. Another one puncture approaches the sural nerve laterally, after the block of the tibial nerve during the same puncture and then the subcutaneous infiltration of the saphenous nerve. An anatomical proof of concept study has been done before the exploratory clinical study.~These approaches permit a surgical anesthetic block for foot surgery using 2 punctures (instead of 5) with a single patient's body position, compatible with sedation."
214484640|NCT06747325|DRUG|Fei Re Qing Granules|Fei Re Qing Granules (Ingredients: Scutellaria baicalensis \[Huang Qin\], Trichosanthes kirilowii \[Gua Lou\], Forsythia suspensa \[Lian Qiao\], Fritillaria thunbergii \[Zhe Bei Mu\], etc.)
214484641|NCT06747325|OTHER|Routine standard treatments|Routine standard treatments
214484642|NCT06747325|DRUG|Placebo granules|The placebo granules are prepared using 5% of the active drug, ensuring consistency in appearance, weight, color, and odor with the Fei Re Qing Granules
214672155|NCT04881539|DIETARY_SUPPLEMENT|Cannabidiol (CBD)|This group will receive an oral dose of CBD (Six Degrees Wellness).
214484644|NCT06741774|DEVICE|Trabecular Meshwork Microstent Drainage System|The device is implanted on the functional trabecular meshwork with head in schlemm canal and tail in anterior chamber. There is a hollow tube connecting schlemm canal and anterior chamber. The device can promote external drainage of aqueous humor to reduce intraocular pressure.
214484645|NCT06741774|PROCEDURE|phacoemulsification|Eyes with OAG and cataracts randomly divided into control group that were planned for phacoemulsification alone.
215062354|NCT04175340|DEVICE|BL-300-PFM04|Preservative Free Lubricating and Rewetting Drops for use during contact lens wear
215062355|NCT04175340|DEVICE|OPTI-FREE|Replenish Rewetting Drops
215062356|NCT03353987|BEHAVIORAL|Cognitive training|"Procedure~1. A therapist will go through the daily routine of the participants at home before starting the intervention~2. Selections of exercise items based on familiar items/ activities at home~3. Given a memory logbook with list of household items, names and numbers and newspaper cuttings from the previous week~4. Taught on how to perform the exercises~5. Perform at least one hour per day~6. Both spatial and visual memory strategies will be used for memory training: simple mnemonics, associations, visualisations, rhymes~7. Advised to follow-up with the therapist to review on the progress and compliance of exercises weekly~8. The difficulty of the exercise will be adjusted weekly~List of exercises:~1. Memorizing a set of lists, household items, names and numbers~2. Summarising the contents of newspaper cuttings within a set of time~3. Searching and listing sets of words from newspaper cuttings"
214321389|NCT04798352|OTHER|quality of life questionnaires (EQ5D5L and SF-36)|quality of life questionnaires (EQ5D5L and SF-36)
214321390|NCT04621890|BEHAVIORAL|LOAN2DOSE and COIN2DOSE|This is a behavioral economics intervention designed to help improve meal time bolusing behaviors in youth with type 1 diabetes.
214484646|NCT06735573|OTHER|the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes|"Primary Objective The primary objective is to measure the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes, in older female participants with clinically diagnosed COPD.~Secondary Objectives The secondary objective is to investigate whether the level of inflammation (plasma CRP) is associated with the intake of total, plant-based and animal-based protein, with the prevalence of sarcopenic obesity, and with lung function outcomes."
214484647|NCT06728761|BEHAVIORAL|Standardised test meal|"Ingestion of a 1850 Kcal standardised 'Christmas meal' identical for each session. It will consist of the following elements Assortment of Picard Mini-Puff Pastry Aperitifs: 70g = 210 Kcal 1 glass of white wine = 85 Kcal with the aperitif~1 slice of vacuum-packed foie gras = 50 g = 230 Kcal~1 portion of turkey leg 200 g = 250 Kcal 50 g turkey cream = 130 Kcal~1 portion of steamed potatoes = 200 g = 160 Kcal~1 glass of red wine = 85 Kcal to accompany the main course~1 slice of white bread (30 g) = 55 Kcal to eat with the main course Blind test or control drink (trou normand or placebo = water) / 1 scoop of apple sorbet~1 portion 30 g camembert = 90 Kcal + White bread 1 slice (30 g) = 85 Kcal with the cheese~1 portion crumble 100 g = 250 Kcal The different elements will be weighed for each participant."
214484648|NCT06728761|BEHAVIORAL|Ingestion of test drink|Ingestion of 2,5 cl Calvados 40° at the 70th min of the meal (before cheese and dessert)
214484649|NCT06728761|BEHAVIORAL|Ingestion of Control drink|Ingestion of 2,5 cl water at the 70th min of the meal (before cheese and dessert)
214672156|NCT05133986|OTHER|Onion Feeding|The intervention includes feeding individuals a 120g portion of onions (experimental condition).
214672157|NCT05133986|OTHER|Couscous Feeding|The intervention includes feeding individuals a 120g portion of couscous (control condition).
215062357|NCT01014936|DRUG|MSC2156119J|
215062358|NCT03028129|DRUG|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
214672158|NCT05133986|OTHER|Onion Supplementation Period|Three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised.
214672159|NCT05593601|DRUG|Neomycin|Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
214672160|NCT00084786|DRUG|docetaxel|
214672161|NCT00084786|DRUG|gefitinib|
214672162|NCT01293669|DRUG|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
214672163|NCT01293669|DRUG|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
214672164|NCT05643300|OTHER|Survey|Data collection from participants via questionnaire
214920911|NCT05509465|DEVICE|Ergonomic chinrest used with a low Super Kun shoulder rest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
214920912|NCT04699110|DRUG|Adrenaline|Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow
214672165|NCT03471910|DRUG|Diosmin|Diosmin 600mg tablet, once daily
214672166|NCT03471910|DRUG|Diosmin / Hesperidin|Diosmin 900 mg / Hesperidin 100mg tablet, once daily
214672167|NCT04507750|DRUG|Camrelizumab|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
214672168|NCT00765583|DRUG|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
214672169|NCT04291014|DEVICE|SunRay Light Boxes|SunRay light boxes will be used to administer the light therapy.
214672170|NCT02404506|DRUG|Eribulin mesilate|Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
214672171|NCT03321812|PROCEDURE|decalcification bone scaffold|Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
214672172|NCT03321812|PROCEDURE|microfracture|Microfracture is the surgical option for conventional treatment of cartilage defects.
214920913|NCT04699110|DRUG|Adenosine|Control group will receive adenosine (100 to 400 mcg)
214920914|NCT00893997|BIOLOGICAL|PR-1 vaccine|0.5 mg injections under the skin once every 3 weeks for a total of 4 vaccinations.
214920915|NCT04543097|BEHAVIORAL|Vocational Support|"Participants randomised to receive vocational advice will all be offered:~Step 1, contact by phone to undertake an assessment with a trained Vocational Support Worker (VSW) to identify obstacles to Return to Work (RTW) and support RTW planning.~Step 2, face-to-face (in person or by videoconference) in-depth discussion of obstacles to RTW and further support for RTW planning.~Step 3, contact by the VSW (with participant consent) with the participants' workplace.~The frequency of contact will be individualised to the needs of participants and the offer of support continued until sustained RTW (defined as return to any work for at least 4 weeks) or until 6 months of absence, after which participants will be signposted to other services."
215062359|NCT03028129|DRUG|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
215062360|NCT05370027|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.
215062361|NCT00768846|DEVICE|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
214321391|NCT00846742|DRUG|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
214321392|NCT00846742|RADIATION|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
215062362|NCT00768846|DEVICE|Xience V Stent|Everolimus-eluting Xience V Stent
215062363|NCT03522935|DRUG|Elafin|Elafin subcutaneous.
215062364|NCT03522935|DRUG|Placebo|Placebo subcutaneous.
215062365|NCT04982315|PROCEDURE|Standard Acupuncture|The standard acupuncture intervention is based on classical Chinese acupuncture therapy. Participants randomized to standard acupuncture will receive up to 15 acupuncture treatments over 3 months with the total number being determined by the patient and acupuncturist together. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
215062366|NCT04982315|PROCEDURE|Enhanced Acupuncture|The enhanced acupuncture intervention includes the 3 months of standard acupuncture plus an additional 3 months of maintenance acupuncture. Participants randomized to enhanced acupuncture will receive up to 21 acupuncture treatments over 6 months. The maintenance acupuncture treatment sessions are expected to consist of the same intervention used in the first 3 months of care described in the standard acupuncture arm, plus up to 6 treatments during the maintenance phase. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
214920916|NCT06466681|OTHER|All included subjects|Administration of the subtest of divided attention of the Test of Attentional Performance (TAP), recording of the event related potentiels N200 and P300, measure of the variation of power in several frequency bands (theta, alpha and beta) and measure of the high-resolution EEG connectivity during an attentional task at several time-points : a first time during interictal period (no seizure for more than 24 hours) and 1, 3, 6 and 24 hours after a focal seizure.
214321393|NCT05563064|DRUG|Karika Syrup|To evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets) collected from blood samples of patients after treatment of 15 days long period.
214321394|NCT05237258|BEHAVIORAL|Specialty Palliative Care|Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
214321395|NCT05237258|BEHAVIORAL|Primary Palliative Care|Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
214321396|NCT04703218|OTHER|olfactory rehabilitation|Olfactory rehabilitation consists of smelling 4 scents twice a day using scent sticks, for 12 weeks
214321397|NCT05748340|PROCEDURE|Unilateral cleft lip repair|Surgical repair unilateral cleft lip
214321398|NCT05292378|OTHER|2500 ppm Carbon Dioxide|2.5 hour exposure to 2500 ppm carbon dioxide
214321399|NCT05292378|OTHER|600 ppm Carbon Dioxide|2.5 hour exposure to 600 ppm carbon dioxide
214321400|NCT02775344|DEVICE|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
214321401|NCT05703022|OTHER|Aerobic interval training|The intervention will start between 7 and 21 days after heart valve surgery. While hospitalized the participants will perform supervised aerobic interval training comprised 4x4 minute, 3 times per week. Intensity will start at 60% of maximum heart rate in the first week, around 13-14 in Borg RPE-Scale. The workload will be gradually increased as the participant tolerance improves, but not above 85% of maximum heart rate or 16-17 in Borg RPE Scale.
214321402|NCT04848571|COMBINATION_PRODUCT|Fetal Protection Pill|A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa.
214920917|NCT05946798|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
214920918|NCT05946798|DRUG|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
214920919|NCT03318094|DRUG|Phentolamine|Intrabrachial phentolamine will be given on the blocked day
214920920|NCT03318094|OTHER|Saline|Intrabrachial saline will be given this day
214920921|NCT03318094|DRUG|Sodium Nitroprusside|Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine
214321403|NCT04205760|COMBINATION_PRODUCT|Nutrition + exercise|Patients will receive preoperative optimization consisting of oral nutrition support (Fresubin 3.2 kcal) and bed-cycling (50 minutes per day) for 5-14 days before surgery.
214321404|NCT02650986|DRUG|Cyclophosphamide|Given IV
214321405|NCT02650986|DRUG|Decitabine|Given IV
214920922|NCT05839067|BEHAVIORAL|Care-HF|Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
214920923|NCT05795244|DRUG|Nivolumab|\- Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles
214920924|NCT06566820|DRUG|Aroxybutynin and Atomoxetine|Fixed Dose Combination
214920925|NCT04286386|OTHER|Hyperpolarized Carbon C 13 Pyruvate|Given IV
214920926|NCT04286386|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
214920927|NCT04286386|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
214920928|NCT06372834|DEVICE|piTBS being delivered using the Magstim Rapid2 stimulator|Magstim Rapid2 stimulator (Magstim Company, Ltd, Whitland, Wales, UK, SA340HR). See detail in arm/group descriptions regarding the intervention.
214920929|NCT06255522|PROCEDURE|Fully guided implant placement|Through guided surgery, previously planned and designed based on CBCT study and CAD/CAM scanning, implant placement of Conelog Progressive line implants (Biohorizons Camlog, Iberia) will be performed in maxilla or mandibula in a one stage surgery. Postoperative CBCT in ECO mode (35μSv) will be taken after the implant placement to assess the final position and comparing with the initial digital planning.
214920930|NCT03486444|DIAGNOSTIC_TEST|Phillips Lumify Diagnostic Ultrasound System|portable ultrasound device
214920931|NCT03486444|OTHER|Surveys|surveys assessing perception of ultrasound
214920932|NCT01653015|BIOLOGICAL|Trivalent Inactivated Vaccine|Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
214920933|NCT01653015|BIOLOGICAL|Live Attenuated Influenza Vaccine|Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
214920934|NCT04876131|DRUG|Benzylpenicillin - single dose|"Participants will receive a single dose of IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours."
214920935|NCT04876131|DRUG|Benzylpenicillin - three days|"Participants will receive three days of this IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours. For severe infections, use up to 60 mg/kg (maximum 2.4 g) every 4-6 hours."
214920936|NCT04876131|DRUG|Gentamicin - single dose|"Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)"
214920937|NCT04876131|DRUG|Gentamicin - three days|"Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)"
215062367|NCT01674049|DIETARY_SUPPLEMENT|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
214484650|NCT06728761|DIAGNOSTIC_TEST|Ultrasound measurement of the antral area|Ultrasound measurement of the antral area in the volunteers lying in the 45° semi-recumbent position using an ultrasound machine (Venue Go™, GE Healthcare, Chicago, IL, USA) fitted with an abdominal transducer (probe C1-5, 1.5 to 5 MHz) to obtain a sagittal cross-section of the antrum in a plane including the left lobe of the liver and the aorta. This will be performed during the intake visit, immediately before the test drink ingestion (70th min of the meal) and 15, 45, 60, 90, 120, 150, 180 min after the end of the meal
215062368|NCT01674049|DIETARY_SUPPLEMENT|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
214484651|NCT06728761|DIAGNOSTIC_TEST|Breathalyser for measurement of the level of exhaled ethanol|Breathalyser performed during the intake visit, and 15, 90, 180 and 300 min (if the exhaled alcohol level measured at 180 minutes was greater than 0.25 mg/l of breath) after the end of the meal.
214484652|NCT06728761|BEHAVIORAL|Discomfort|discomfort will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
214920938|NCT04876131|DRUG|Cefalexin - post single dose of IV antibiotics for the remaining two days|Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
214484653|NCT06728761|BEHAVIORAL|Appetite|Appetite will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
214484654|NCT06728761|DIAGNOSTIC_TEST|Pregnancy urine test carried out during the intake visit on the day of the protocol|Pregnancy urine test carried out during the intake visit on the day of the protocol for exclusion of pregnant woman.
214484655|NCT06885411|OTHER|metal-on-metal hip arthroplasty|Cobalt and chromium release from metal-on-metal hip arthroplasties.
214484656|NCT06741163|DIETARY_SUPPLEMENT|Pre-activity shot|Water-based shot containing olive leaf extract (100mg Oleuropein), vitamins, and other active ingredients. The product will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the test product before their training session on each intervention day (Day 5, Day 6, and Day 7).
214484657|NCT06741163|DIETARY_SUPPLEMENT|Placebo|Water-based shot with similar appearance and taste but without the active ingredients of the test product. The placebo will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the placebo before their training session on each intervention day (Day 5, Day 6, and Day 7).
214672173|NCT03797443|DRUG|Ascorbic Acid|"Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid."
214920939|NCT01527695|DRUG|ER tablet 25 mg AZD3241|2 tablets twice daily for Day 1
214920940|NCT01527695|DRUG|ER tablet 100 mg AZD3241|1-6 tablets twice daily from Day 2 until Day 56±3 days
214920941|NCT01527695|DRUG|Placebo for AZD3241 25 mg|2 tablets twice daily for Day 1
214920942|NCT01527695|DRUG|Placebo for AZD3241 100 mg|1-6 tablets twice daily from Day 2 until Day 56±3 days
214920943|NCT04101682|DRUG|Bupivacaine|Administered by an anesthesiologist or certified nurse anesthetist, under ultrasound guidance a catheter placed overlying the nerve sheath. This catheter is then connected to a device with a reservoir that administers local anesthetic at a set rate.
215062369|NCT01674049|OTHER|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
215062370|NCT00940290|OTHER|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
215062371|NCT01889264|OTHER|Observational|Observational, Translational non-treatment study
215062372|NCT00601614|DRUG|temozolomide|
215062373|NCT00601614|DRUG|vandetanib|
215062374|NCT00601614|OTHER|immunoenzyme technique|
215062375|NCT00601614|OTHER|laboratory biomarker analysis|
215062376|NCT05971368|PROCEDURE|thoracic paravertebal block|"o Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~A high-frequency linear ultrasound probe will be placed between transverse processes from the T4 level (the level of port introduction) in the paramedian plane while patients is in the lateral decubitus position. The transverse processes, superior costotransverse ligaments, and pleura will be well visualized. The block needle (22 gauge) will be advanced until it crosses the superior costotransverse ligament. The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) in the thoracic paravertebral space. Depression of the pleura will be observed as a result of the spread of local anesthetic."
214321406|NCT02650986|OTHER|Laboratory Biomarker Analysis|Correlative studies
214321407|NCT02650986|PROCEDURE|Leukapheresis|Undergo leukapheresis
214321408|NCT02650986|BIOLOGICAL|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
214321409|NCT03601806|OTHER|Laboratory Biomarker Analysis|Correlative studies
214321410|NCT03601806|DRUG|Pomalidomide|Given PO
214321411|NCT03817320|DRUG|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
214321412|NCT03817320|DRUG|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and \< 1 year: 1.2mg/m2/dose~\< 6 months: 1mg/m2/dose"
214321413|NCT03817320|DRUG|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and \< 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~\< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
214920944|NCT05770271|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild senile groin eczema, neurodermatitis and psoriasis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
214321414|NCT03817320|DRUG|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose"
214321415|NCT03817320|DRUG|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose"
214321416|NCT03817320|DRUG|Methotrexate (IT)|For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
214321417|NCT03817320|DRUG|Triple IT (Methotrexate, Hydrocortisone, Cytarabine)|For patients with CNS 3, on Days 1, 8, 15, 22, and 29
215062377|NCT05971368|PROCEDURE|serratus anterior muscle block|"Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~While the patient is in the supine position, a high-frequency linear ultrasound probe will be placed horizontally on the mid-axillary line at the level of 4th or 5th ribs on the side of the block. The serratus anterior, latissimus dorsi, and intercostal muscles will be identified. The block needle (22-gauge) will be advanced below the serratus anterior muscle (SAM) towards the fifth rib (using in-plane technique). The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) between the SAM and the rib. It will be observed that the solution of local anesthesia will spread between the SAM and the rib."
215062378|NCT02669394|BEHAVIORAL|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
214321418|NCT03817320|DRUG|Leucovorin|For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
214321419|NCT04166487|DRUG|Pembrolizumab|predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
214321420|NCT04166487|DRUG|PEMETREXED|administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
214321421|NCT04166487|DRUG|CARBOPLATIN|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
214321422|NCT04166487|DRUG|PACLITAXEL|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
214321423|NCT04166487|DIAGNOSTIC_TEST|InVision|Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
214321424|NCT03909165|DRUG|Sugammadex 2 mg/kg|For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.
214321425|NCT03909165|DRUG|Sugammadex 4 mg/kg|For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
214321426|NCT03909165|DRUG|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
214321427|NCT03909165|DRUG|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
214321428|NCT04609020|DEVICE|JUVÉDERM|JUVÉDERM VOLBELLA with Lidocaine Treatment of any fine lines and medium-sized skin depressions. Can also be used for enhancement and pouting of the lips to correct structural defects such as asymmetry, contour deformities, volume loss. JUVÉDERM VOLIFT with Lidocaine Intended for the treatment of any deep skin depressions due to conditions such as premature aging. Can also be used for face contouring and volume restoration to correct facial structural defects such as asymmetry, contour deformities, volume loss in the lips, cheeks, chin, lower face. JUVÉDERM VOLUMA with Lidocaine Intended to restore volume of the face JUVÉDERM VOLITE with Lidocaine Intended for treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity. JUVÉDERM VOLUX with Lidocaine Intended to restore and generate facial volume in chin and mandible areas
214321429|NCT04609020|DRUG|BOTOX|Indicated for the treatment of hyperkinetic facial lines.
214321430|NCT04609020|DEVICE|HArmonyCA Lidocaine|HArmonyCa Lidocaine injectable gel is a dermal filler intended for facial soft tissue augmentation.
214321431|NCT03804359|DRUG|Rituximab|"In the personalized arm, the patient will be treated in function of the CysR activity result during the inclusion visit."
214920945|NCT02986282|DEVICE|ABI measurement using both doppler and oscillometric method|
214920946|NCT06435143|DEVICE|Prelivia|Pad applied to skin provide electrical stimulation for 10 seconds every 10 minutes
214484658|NCT06887985|DRUG|JY231 Injection|"This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo chimeric antigen receptor T-Cell (CAR-T cell) therapy in patients with relapsed refractory B-cell leukemia.~Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 15 years to determine if the disease is under control."
214484659|NCT06748339|OTHER|no intervention|no intervention
215062379|NCT02669394|BEHAVIORAL|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
215062380|NCT01099748|DRUG|Methadone|Methadone 50 - 150 mg QD (Day 1)
214484660|NCT06893354|DRUG|lorlatinib|Subjects will be registered to receive oral lorlatinib 100mg qd for 3 cycles of 4 weeks each (12 weeks total), and then underwent surgery.
214484661|NCT06893354|DRUG|lorlatinib plus chemotherapy|Subjects will be registered to receive oral lorlatinib 100mg qd for 3 cycles of 4 weeks each (12 weeks total) plus chemotherapy, and then underwent surgery.
214484662|NCT06893952|DEVICE|TREO Endograft|Post Market collection data in use of TREO modular endografts
214484663|NCT06739954|COMBINATION_PRODUCT|Mulligan's Two Leg Rotation technique|The participants will undergo Mulligan's Two Leg Rotation technique, performing 10 repetitions with a 30-second hold for each repeat. There will be a 1-minute rest period between each stretch. The therapist positions themselves on the affected side of the supine patient lying on the treatment table and holds onto the side of the table with their hand on the opposite side. Both legs will be bent so that the feet are raised from the plinth. Maintaining the subject's shoulders on the bed, he gradually moves the subject's legs to the side, considering the restricted flexibility of the hamstring muscles. Once the patient reaches their maximum, the therapist applies extra pressure to sustain the posture for 30 seconds. Then, the legs are lowered to the plinth. A 1-minute interval was provided between each stretch, and the stretches were performed for a total of 10 repetitions. The identical technique is performed on the opposite side to address insufficient flexibility in the hamstrings.
214920947|NCT03295240|DRUG|BR-I (bendamustine, rituximab, ibrutinib)|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
214920948|NCT03295240|DRUG|VEN (Venetoclax)|The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
215062381|NCT01099748|DRUG|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
215062382|NCT05970536|OTHER|Apple vinegar or EDTA 17%|Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.
215062383|NCT02910752|DRUG|CLAM+PBSC|Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
214484664|NCT06739954|DIAGNOSTIC_TEST|Dry Needling|The DN technique, based on previous research, involved slowly inserting and removing the needle in the muscle or tendon to elicit a specific response. This response could be a local twitch, a dull ache, a feeling of heaviness or distension, or the reproduction of the participant's symptoms. The needle is manipulated in and out of the targeted tissue five times every five minutes for a total of fifteen minutes. After the treatment, sterile gauze is applied and pressed on the DN site, and sterile non-stick pads are used to cover the treated areas. The number of needles used varied depending on the participant's condition. The knee muscles that will be included in the dry needling intervention are the Quadriceps and Hamstrings .
215062384|NCT04393597|DRUG|DWJ1458 (fasted)|Subjects take single dose of DWJ1458 on a fated condition
215062385|NCT04393597|DRUG|DWJ1458 (fed)|Subjects take single dose of DWJ1458 after high-fat diet
214484665|NCT06746571|DIAGNOSTIC_TEST|complete blood count|measure cbc and blood ratios to compare their values with respone of patients to treatment
214484666|NCT06752265|BEHAVIORAL|Peran sadar application|The PERAN SADAR application is an android-based SACA prevention application containing material related to SACA prevention which is given in a series for nine days using multimedia video stories and songs, documents, and tiktok in an attractive package, so that it attracts someone's interest in listening to the contents of the message. Social media applications are educational methods that are popular with all ages
214484667|NCT06741930|DRUG|Ketamine|The Ketamine group received IV ketamine at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
214484668|NCT06741930|DRUG|Midazolam|The Midazolam group received IV midazolam at a titrated dose of 0.15-0.40 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
214484669|NCT06741930|DRUG|Propofol|The Propofol group received IV propofol at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
214672174|NCT03797443|DRUG|nab paclitaxel|30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
215062386|NCT05542095|DRUG|Simvastatin|Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
215062387|NCT02443246|DRUG|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
214484670|NCT06748963|BEHAVIORAL|Fasted Exercise|Participants will complete three sessions of combined resistance-aerobic exercise per week. Sessions will always start with resistance training followed by aerobic training, and will increase in duration throughout the intervention period, so that by the final three weeks of the intervention, all participants accumulate 150 minutes per week of moderate intensity aerobic exercise and 75 minutes of resistance exercise per week. Participants will complete three distinct resistance exercise sessions per week, which will increase in load, but decrease in repetition range throughout the trial. The aerobic component of the exercise sessions will increase in duration from 35 to 50 minutes per session. Participants will walk on a treadmill at a speed and incline that corresponds to 70-80% of ventilatory threshold.
214484671|NCT06748963|BEHAVIORAL|Postprandial Exercise|Participants will complete three sessions of combined resistance-aerobic exercise per week. Sessions will always start with resistance training followed by aerobic training, and will increase in duration throughout the intervention period, so that by the final three weeks of the intervention, all participants accumulate 150 minutes per week of moderate intensity aerobic exercise and 75 minutes of resistance exercise per week. Participants will complete three distinct resistance exercise sessions per week, which will increase in load, but decrease in repetition range throughout the trial. The aerobic component of the exercise sessions will increase in duration from 35 to 50 minutes per session. Participants will walk on a treadmill at a speed and incline that corresponds to 70-80% of ventilatory threshold.
214484672|NCT06755645|OTHER|Lifestyle intervention|A technological smart platform (app) that integrates diets, physical activity programs, sleep habits and other lifestyle interventions
214321433|NCT00952107|DEVICE|FLARE imaging system|Testing of operation of imaging system
214321434|NCT02018458|BIOLOGICAL|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
214484673|NCT06755333|BEHAVIORAL|Oral hygiene motivation|the patient underwent a professional oral hygiene session before starting chemotherapy, as part of the routine pre-transplant procedure. Patients then received oral hygiene instructions.
214672175|NCT03797443|DRUG|Cisplatin|60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine
214672176|NCT03797443|DRUG|Gemcitabine|30 minute IV infusion on days 1 and 8 repeated every 21 days
214920949|NCT03725592|OTHER|Standard Treatment|Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
214920950|NCT03725592|BEHAVIORAL|Intensive Education|Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
214920951|NCT05127330|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge. Other mental health treatment is unrestricted.
214920952|NCT05127330|BEHAVIORAL|Treatment as Usual|Individuals will receive unrestricted routine mental health care in the community as appropriate for their condition.
214920953|NCT04981470|DEVICE|baroloop System|vagal nerve stimulation
214920954|NCT03226821|DRUG|Tesamorelin|Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
214920955|NCT05599646|BEHAVIORAL|traditional pedometer based walking intervention|Participants were recommended to monitor their step count using traditional pedometer and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
214920956|NCT05599646|BEHAVIORAL|gamified pedometer based walking intervention|Participants were recommended to monitor their step count using gamified pedometer, earn money, compete friends and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
214920957|NCT03045744|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
214920958|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|Subconjunctival daily or bid
214920959|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|topical and systemic
214920960|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|topical systemic
214920961|NCT06483711|OTHER|Lifestyle Kit|The investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.
214920962|NCT05162417|OTHER|Methylene Blue|1mg/ml of Methylene as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
214920963|NCT05162417|OTHER|Toluidine Blue O|1mg/ml of Toluidine blue o as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
214920964|NCT04973423|RADIATION|MRI|2 additional MRI will be done for the CALM + MRI group
214920965|NCT02926157|BEHAVIORAL|Life Style and Sleep Intervention|
214920966|NCT05034211|PROCEDURE|Programmed intermittent bolus epidural|one arm will receive programmed intermittent boluses of local anesthetic via the epidural catheter on fixed time intervals. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
215062388|NCT02443246|DRUG|Placebo|
215062389|NCT00429676|DRUG|Haloperidol|
215062390|NCT00602225|DRUG|clofarabine|Given IV
215062391|NCT00602225|DRUG|cytarabine|Given IV
215062392|NCT00602225|BIOLOGICAL|filgrastim|Given subcutaneously
215062393|NCT03657134|DIAGNOSTIC_TEST|CoVa-2 Monitoring System|Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
215062394|NCT00009880|BIOLOGICAL|filgrastim|
215062395|NCT00009880|DRUG|cisplatin|
215062396|NCT00009880|DRUG|fluorouracil|
215062397|NCT00009880|DRUG|paclitaxel|
215062398|NCT00009880|RADIATION|radiation therapy|
215062399|NCT04667598|DRUG|Modified Wenxin Decoction|Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
214484674|NCT06738043|DRUG|Dexmedetomidine infusion|A bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg/kg/h until 10 minutes before the end of surgery.
214484675|NCT06738043|DRUG|Ketamine infusion|A bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg/kg/h until 10 minutes before the end of surgery.
214484676|NCT06738043|DRUG|Normal Saline Infusion (Placebo)|A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.
214484677|NCT06768073|DEVICE|Sham (No Treatment)|The Sham device is identified to the Active device with the exception that it has a black connector component, part number 10531-02, to block the vacuum from reaching the vaginal tissue with vacuum pump activation. In this manner, the control procedure has been designed to mimic the active therapy to the extent practicable allowing for subject blinding.
214484678|NCT06768281|DIAGNOSTIC_TEST|Headache Impact Test-6 (HIT-6)|Patients who had injections were asked to mark their headache severities with a survey includes six questions about their past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.
214484679|NCT06768281|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Patients who had injections were asked to reply some questions about their sleeping habits for past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.
215062400|NCT06326359|PROCEDURE|autologous stromal vascular fraction|autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
215062401|NCT00670618|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
214484680|NCT06768281|DIAGNOSTIC_TEST|Visual Analogue Score (VAS)|Patients who had injections are asked to state their pain with a 10 cm visual analogue scale preoperatively and postoperatively 1st,2nd weeks and 1st and 3rd months.
214484681|NCT06768281|OTHER|Masseter muscle injection|1 ml of insulin needle with a 27-gauge ½ inch 13 mm needle tip will be injected into up to 4 trigger points in the taut bands that cause the most pain in the masseter muscle. Injections were done at most 3 times. As the control group, the first group was injected with isotonic saline; the second group was injected with 2% lidocaine without vasoconstrictor; the third group with ozone gas; and the fourth group with ozonated isotonic saline.
214484682|NCT06768112|DEVICE|Non-Invasive Vagus Nerve Stimulation|Using non-invasive vagus nerve stimulation at the ear to stimulate the adrenergic and serum hormone pathways, activating the frontal lobe system, sensory-motor nervous system, and cerebellum, to investigate the effects and neural mechanisms of dynamic posture training and learning.
215062402|NCT00670618|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
215062403|NCT00670618|DEVICE|Fluoride (Elmex Medical Gel)|Fluoride
215062404|NCT01894724|DEVICE|NeuroSave device|
215062405|NCT02040350|DRUG|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
215062406|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
215062407|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
215062408|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
215062409|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
215062410|NCT01541904|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
215062411|NCT05322291|BEHAVIORAL|Mobil Application|The mobile application developed will be installed on the phones of hemodialysis patients
215062412|NCT01271907|DRUG|fludarabine|Fludarabine 25 mg/m\^2 x 5 days
215062413|NCT01271907|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
215062414|NCT01271907|DRUG|Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Up to 1x10e10 CTL-05 cells
215062415|NCT01271907|DRUG|Aldesleukin|Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
215062416|NCT00603096|DEVICE|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
215062417|NCT00003321|PROCEDURE|psychosocial assessment and care|
215062418|NCT00003321|PROCEDURE|quality-of-life assessment|
215062419|NCT04467229|BEHAVIORAL|Focus group|5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.
215062420|NCT04620772|DRUG|Cyclophosphamide injection|Cyclophosphamide vs placebo
214484683|NCT06768112|BEHAVIORAL|balance training|Participants will be asked to stand on a soft-platform and hit on blaze-pod LED within 60 seconds.
215062421|NCT00564902|DRUG|3R 3'R Zeaxanthin|8 mg per day during 12 months
215062422|NCT00564902|DIETARY_SUPPLEMENT|Lutein|9 mg of Lutein during 12 months
215062423|NCT00564902|DIETARY_SUPPLEMENT|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
215062424|NCT03539393|DRUG|Fremanezumab|For patients who enter this program, the monthly dose of fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the patient's weight every 3 months.
215062425|NCT06643858|OTHER|No intervention|This study does not involve any interventions.
215062426|NCT05613322|DIAGNOSTIC_TEST|Resistell Phenotech|Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.
215062427|NCT03583359|DEVICE|Radiesse (+)|Radiesse (+) for jawlines.
215062428|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
215062429|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
215062430|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
215062431|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
215062432|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
215062433|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
215062434|NCT02473094|DRUG|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
215062435|NCT02473094|DRUG|Metformin|Metformin up to 2500mg/d
215062436|NCT02473094|RADIATION|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
215062437|NCT02473094|DRUG|Placebo|Placebo up to 2500mg/d
215062438|NCT03148379|DEVICE|Customized patient instruments|Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
214484684|NCT06768112|BEHAVIORAL|Mini-Mental State Examination|The mini-mental state examination (MMSE) or Folstein test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment.
215062439|NCT03148379|DEVICE|Traditional Metal Instruments|Traditional metal instrument will be used to make bone cuts and size the components in this control group.
215062440|NCT02886507|DIETARY_SUPPLEMENT|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
215062441|NCT02886507|DIETARY_SUPPLEMENT|Placebo|The placebo capsules contain microcrystalline cellulose.
215062442|NCT05083611|OTHER|GraMI|The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
215062443|NCT04979026|DEVICE|active ankle pumping with a regular watch alarm|In addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge.
215062444|NCT04979026|DEVICE|intermittent pneumatic compression|In this group, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
215062445|NCT04776720|BEHAVIORAL|Yoga Practice Program|3 month group yoga classes
215062446|NCT04776720|BEHAVIORAL|Physical Conditioning Program|3 month group physical conditioning classes
215062447|NCT02147730|PROCEDURE|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
215062448|NCT02147730|PROCEDURE|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
214920967|NCT05034211|PROCEDURE|Provider administered analgesia on patient request|one arm will receive bolus of local anesthetic via the catheter upon patient request. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
215062449|NCT05053399|DEVICE|Model Series ZXT|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
214920968|NCT04917822|BEHAVIORAL|Emotion regulation|Emotion regulation arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics include raising awareness of emotions (e.g., learning emotions theories), developing skills to manage emotions (e.g., attention deployment, cognitive changes, response modification), and facilitating parent-child relationship (e.g., gratitude). For children, the main topics are similar to that in parents' intervention. In this arm, we give more specific examples and simple explanations to the children.
214321435|NCT02018458|BIOLOGICAL|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
215062450|NCT06399315|DRUG|ZE46-0134 or placebo|The patients will receive ZE46-0134 or placebo
215062451|NCT06399315|DRUG|Rabeprazole, 20mg oral|Rabeprazole 20 mg daily will be administered for 2 prior ZE46-0134 and 7 co-administered
215062452|NCT06399315|DRUG|Itraconazole (200 mg)|Itraconazole 200 mg BID
215062453|NCT05356910|BEHAVIORAL|OPPEN|OPPEN training sessions (three small-group and two one-on-one sessions) build skills for effective peer PrEP outreach through didactic instruction, group discussions, role-play exercises, and goal planning and problem-solving activities.
215062454|NCT05356910|BEHAVIORAL|Control Condition|Control sessions (three small-group and two one-on-one sessions) build skills for diet and nutrition behavior change through didactic instruction, group discussions, and goal planning and problem-solving activities.
214321436|NCT06049888|BEHAVIORAL|Restricted Social Media|Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.
214321437|NCT04364529|OTHER|The pit crew model|The pit crew model
214321438|NCT00403000|DRUG|dutasteride|Oral
214321439|NCT03584269|DEVICE|NIV Device + LTOT|Respiratory assistance by a facial mask without intubation or tracheotomy
214920969|NCT04917822|BEHAVIORAL|Information provision|Information provision arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics in these four sessions include learning the general information about Hong Kong such as education and medical care, housing condition, employment and training. For children, the main topics include learning the general information about Hong Kong, such as education, community facility, and learning method.
215062455|NCT03377179|DRUG|ABC294640|Two 250 mg capsules of ABC294640 will be taken twice daily
214321440|NCT03584269|DEVICE|LTOT|Long term oxygenatory tyherapy without NIV
214321441|NCT00354172|BIOLOGICAL|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If \< 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
214321442|NCT00354172|BIOLOGICAL|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
214321443|NCT00354172|BIOLOGICAL|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
214321444|NCT00354172|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
214321445|NCT00354172|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of \>200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
215062456|NCT03377179|DRUG|Hydroxychloroquine Sulfate 200 MG|HCQ tablets will be taken at a dose that will be determined
215062457|NCT05060016|DRUG|Tarlatamab|Intravenous (IV) infusion
215062458|NCT06107530|OTHER|semi structured interview|Women fulfilling the inclusion / exclusion criteria will be asked to participate to a semi structured interview with a psychiatrist or a psychologist
215062459|NCT04196530|DRUG|BDB001 (EIK1001)|BDB001 (EIK1001) is an immunotherapy agent.
215062460|NCT04196530|DRUG|Atezolizumab|Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
215062461|NCT00000325|BEHAVIORAL|Gonadorelin|
215062462|NCT02599311|DEVICE|transvaginal synthetic mesh|transvaginal synthetic mesh
215062463|NCT02599311|DRUG|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
215062464|NCT02606071|DEVICE|CRT-D|HF patients treated in clinical practice with a CRT-D device
215062465|NCT05761808|OTHER|exercises|Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. First of all, exercises to learn transversus abdominis activation will be performed in patients. They will then be included in the stretching and strengthening exercise program. Stretching and strengthening exercises were planned as dynamic abdominal bracing, finding and maintaining neutral position, and exercises on all fours. Exercise therapy will be applied by the same physiotherapist 3 days a week for 5 weeks. Patients will continue to exercise for 7 more weeks as a home program. During this period, they will be called once a week by phone.
214321446|NCT00354172|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
214321447|NCT00354172|DRUG|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
215062466|NCT05761808|OTHER|neuromuscular electrical stimulation|NMES intensity will be planned individually according to the patients. Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. NMES application will be applied by a specialist physiotherapist 3 days a week for 5 weeks, for a total of 15 sessions. Exercises will be applied 3 days a week for 5 weeks, accompanied by a physiotherapist. Patients will continue to exercise for 7 more weeks as a home program. In this process, patients will be called once a week by phone.
214920970|NCT04849468|DRUG|Declofenac|evaluating the preemptive effect of intramuscular declofenac on postoperative analgesia in patients undergoing perianal surgeries under saddle block
214920971|NCT04849468|DRUG|saline|evaluating the preemptive effect of intramuscular saline on postoperative analgesia in patients undergoing perianal surgeries under saddle block as control
215062467|NCT05123989|BEHAVIORAL|Personalized move goals|Personalized move goals delivered by the Welltory mobile app
214920972|NCT04325568|BEHAVIORAL|PsyGist and Clinician Manual|This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
214920973|NCT01811641|OTHER|season, dietary intake|
214920974|NCT04390503|BIOLOGICAL|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2.
215062468|NCT05123989|BEHAVIORAL|Constant move goals|Static move goal delivered by the Welltory mobile app
215062469|NCT05553769|OTHER|Resistance training, detraining, retraining|Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
215062470|NCT00803595|DRUG|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
214920975|NCT04390503|BIOLOGICAL|Control (albumin 5%)|Albumin (Human) 5% is a sterile aqueous solution for intravenous use containing the albumin component human plasma.
215062471|NCT00803595|DRUG|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
214321448|NCT00354172|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (\<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9 /L)."
214321449|NCT00354172|PROCEDURE|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
214321450|NCT00354172|RADIATION|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
214321451|NCT01427205|DRUG|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
214321452|NCT01427205|DRUG|OSI-906|150 mg by mouth twice a day.
214321453|NCT01427205|OTHER|Placebo|Placebo taken by mouth twice daily.
214321454|NCT06218147|BEHAVIORAL|Nutrition-behavior lifestyle program|The 15 participants randomized to the intervention group will complete the activities described in the arm/group description.
214321455|NCT01800916|DEVICE|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
214321456|NCT01800916|DEVICE|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
214321457|NCT01800916|DEVICE|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
214321458|NCT01800916|DEVICE|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
214321459|NCT02431858|DEVICE|E-Catheter (Pajunk)|
214321460|NCT02431858|DEVICE|Sonolong Catheter (Pajunk)|
214321461|NCT02093546|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor
214321462|NCT00610493|DRUG|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
214321463|NCT00610493|DRUG|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
214321464|NCT00610493|PROCEDURE|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
214321465|NCT00610493|PROCEDURE|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
214321466|NCT00610493|PROCEDURE|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
215062472|NCT00803595|DRUG|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
215062473|NCT00984594|OTHER|Primary injury site|Autograft will be placed in the primary defect site.
214321467|NCT00556595|PROCEDURE|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
214321468|NCT00556595|PROCEDURE|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
215062474|NCT00984594|OTHER|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
214321469|NCT00325234|DRUG|Pemetrexed|600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
215062475|NCT04118075|DRUG|PT-CY-FK +/-ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
215062476|NCT05461586|DEVICE|Refractive Technique (MR #1)|Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.
215062477|NCT05461586|DEVICE|Refractive Technique (MR #2)|Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths
215062478|NCT04083703|PROCEDURE|Interbody cage insertion in lumbar disc prolapse|Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
215062479|NCT05582512|OTHER|sequelae tracking|"An integrated outpatient clinic for Long COVID-19 Syndrome in Children will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection"
215062480|NCT05052944|DEVICE|Cochlear implantation|Patients who receive cochlear implant for single-sided deafness
215062481|NCT05317026|PROCEDURE|Vertebroplasty|"SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~* Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~* Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~* Decubitus position for 2 hours following procedure, then hospital discharge on the same day."
214321470|NCT00325234|DRUG|Carboplatin|AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
214321471|NCT00325234|DRUG|Gemcitabine|1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
214321472|NCT00325234|DRUG|Vinorelbine|30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
214321473|NCT01234467|DRUG|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
214321474|NCT01234467|DRUG|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
214321475|NCT02142127|DRUG|14C-labelled GFT505 120 mg|
214321476|NCT02679586|DEVICE|Diffusion weighted MRI|
214321477|NCT05657028|DRUG|Dexmedetomidine|-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
214920976|NCT04606004|OTHER|Stool application|Application of stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time. However, with the stool application no barrier cream will be applied to the skin in order for the stool to achieve penetrance to the skin. Stool application will include removing any barrier creams gently, applying a thin layer of stool with a surface area shown in illustration to ensure consistent coverage, and placing a diaper on the subject. Depending on the type of the participant's ostomy, a medication cup, syringe, and/or tongue blade provided by the researchers, may be used to aid in the application of stool. After 10 minutes of application, the caregiver or inpatient healthcare provider will remove the entire thin layer of stool gently without excessive friction, just enough to remove the stool, a dabbing motion is preferred.
214920977|NCT04606004|OTHER|Standard of care skincare|"Standard of care for skin care pre-operatively: which is either no application of barrier cream, or an application of an over the counter (OTC) skin barrier such as Aquaphor, Desitin, or Vitamin A\&D if the patient is experiencing skin redness from urine incontinence.~Standard of care skin creams post op: 3M no-sting immediately post op, once begin stooling- stoma powder, 3M no-sting, Critic-aid thick barrier paste will be applied to the skin."
214920978|NCT00468481|DRUG|Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
214920979|NCT00468481|DRUG|Drospirenone/Ethinylestradiol (Yaz)|0.020 mg ethinylestradiol with 3.0 mg drospirenone
215062482|NCT05317026|PROCEDURE|Stereotactic Body Radiation Therapy only|SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
215062483|NCT02848456|PROCEDURE|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
215062484|NCT02848456|PROCEDURE|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
215062485|NCT02848456|PROCEDURE|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
215062486|NCT06140251|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.
215062487|NCT01042587|OTHER|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
215062488|NCT01042587|OTHER|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
214672177|NCT01305369|DRUG|Prasugrel|"Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment A will be allocated to treatment B, and vice versa."
214672178|NCT01707875|OTHER|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
214672179|NCT03178461|OTHER|Body temperature parenteral fluids|2 study groups shall receive the same parenteral fluids but at different temperatures.
214672180|NCT00691574|DIETARY_SUPPLEMENT|Melatonin|up to 3 mg, daily, for up to 1 year
214672181|NCT00691574|DEVICE|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
214672182|NCT00806117|RADIATION|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks~* Lateral: 2 cm lateral to the bony margin of the pelvis~* Superior: Between L5 and S1~* Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
214920980|NCT05472129|OTHER|self-administered questionnaires|The validation process of a linguistic translation must maintain conceptual and technical equivalence between the source and the target language.The questionnaire was submitted to women during a gynecological medical interview and they were asked to evaluate their perceived degree of difficulty in understanding each question item. After that, the final Italian version of the questionnaire was obtained
214920981|NCT00833495|DRUG|Prednisolone Acetate 0.12% (Pred Mild®)|Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.
214920982|NCT00833495|DRUG|FOV1101-00|This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
214920983|NCT00833495|DRUG|Prednisolone Acetate 1% (Pred Forte®)|PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
214920984|NCT00833495|DRUG|Placebo|The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
214321478|NCT05657028|DRUG|Lidocaine IV|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
214321479|NCT03869125|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
214321480|NCT05310266|PROCEDURE|Transversus abdominis plane block|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
214321481|NCT05310266|PROCEDURE|Quadratus Lumborum Block|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
214321482|NCT04462705|PROCEDURE|Usual physiotherapeutic intervention and Abdominal Massage|Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
214321483|NCT04036656|DRUG|SYHA136 0.5 mg|oral tablet
214321484|NCT04036656|DRUG|SYHA136 1 mg|oral tablet
214321485|NCT04036656|DRUG|SYHA136 2.5 mg|oral tablet
214321486|NCT04036656|DRUG|SYHA136 5 mg|oral tablet
214321487|NCT04036656|DRUG|SYHA136 10 mg|oral tablet
214321488|NCT04036656|DRUG|SYHA136 20 mg|oral tablet
214321489|NCT04036656|DRUG|SYHA136 35 mg|oral tablet
214672183|NCT00806117|OTHER|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
214672184|NCT00806117|OTHER|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135\~175mg/m2 over 3 hours Cisplatin 60\~75mg/m2
214672185|NCT06331585|RADIATION|low dose radiotherapy|LDRT (5Gy/5f) of oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy
214672186|NCT00900432|OTHER|immunoenzyme technique|
214672187|NCT00900432|OTHER|laboratory biomarker analysis|
214672188|NCT05914272|DRUG|Osmotic drugs|Patients had used osmotic drugs within 72 hours of admission.
214920985|NCT04657029|BEHAVIORAL|Treadmill|30 minutes of moderate-high intensity treadmill training.
215062489|NCT04504344|DEVICE|Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)|We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
215062490|NCT02254044|DRUG|bivatuzumab mertansine|
214321490|NCT04036656|DRUG|SYHA136 50 mg|oral tablet
214321491|NCT04036656|DRUG|Placebo matching SYHA136 0.5 mg|oral tablet
214321492|NCT04036656|DRUG|Placebo matching SYHA136 1 mg|oral tablet
214321493|NCT04036656|DRUG|Placebo matching SYHA136 2.5 mg|oral tablet
214321494|NCT04036656|DRUG|Placebo matching SYHA136 5 mg|oral tablet
214321495|NCT04036656|DRUG|Placebo matching SYHA136 10 mg|oral tablet
214321496|NCT04036656|DRUG|Placebo matching SYHA136 20 mg|oral tablet
214321497|NCT04036656|DRUG|Placebo matching SYHA136 35 mg|oral tablet
214321498|NCT04036656|DRUG|Placebo matching SYHA136 50 mg|oral tablet
214321499|NCT02459977|DRUG|Basiliximab|Basiliximab induction therapy
214321500|NCT02459977|DRUG|No basiliximab|No basiliximab induction therapy
214321501|NCT02459977|PROCEDURE|Kidney transplantation|kidney transplantation
214321502|NCT04026919|OTHER|OK EN CASA-ZAINDOO|Intervention based on cognitive- behavioural techniques offered in an online format.
214321503|NCT00113659|DIETARY_SUPPLEMENT|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
214321504|NCT00113659|DIETARY_SUPPLEMENT|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
214321505|NCT01639040|DRUG|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
214920986|NCT03187418|DEVICE|MicroPulse® P3 Glaucoma Device (MP3)|"Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time-0.5ms; micropulse off time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s)."
214321506|NCT01639040|DRUG|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
214321507|NCT01639040|OTHER|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
214321508|NCT01479621|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
214321509|NCT01479621|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
214321510|NCT01479621|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
214920987|NCT00593684|DEVICE|Silver Alginate|This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
214920988|NCT00409136|BEHAVIORAL|Human Alert|An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
214920989|NCT05571475|OTHER|Simulated competition|During a competition, athletes will typically compete for a reward, against opponents and in the presence of others. This will be replicated in the laboratory.
214920990|NCT01934049|PROCEDURE|hip arthroplasty|Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
214321511|NCT01479621|DRUG|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
214321512|NCT02140034|PROCEDURE|Extensive Peritoneal Lavage|
214321513|NCT06094270|DEVICE|EndoMind|Withdrawal time is calculated and an image report is generated using the EndoMind system.
214920991|NCT01934049|DRUG|Total Intravenous Anesthesia and Peripheral nerve blocks|Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
214920992|NCT01808599|DRUG|Chlorambucil|
214920993|NCT01808599|DRUG|Rituximab i.v.|
214920994|NCT01808599|DRUG|Rituximab s.c.|
214920995|NCT03554733|BEHAVIORAL|ReInventing Yourself after SCI|6-week, manualized, cognitive-behaviorally based group educational intervention
214920996|NCT04324970|DEVICE|Tookie Vest|Tookie Vest
214920997|NCT03055312|DRUG|TPC|"Conventional chemotherapy(choose a):~TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.~GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 \& days 8)every 3 weeks.~GC:(Gemcitabine 1000mg/m2 on days 1 \& days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 \& days 8) every 3 weeks"
214920998|NCT03055312|DRUG|Bicalutamide 150 mg|Bicalutamide 150mg/day,every 28 days
214920999|NCT01451528|BIOLOGICAL|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
214921000|NCT00734162|DRUG|Tenofovir disoproxil fumarate (TDF)|TDF administered as a 300-mg tablet once daily
214921001|NCT00734162|DRUG|Placebo|TDF placebo tablet once daily
214921002|NCT02076724|DEVICE|Biological mesh|
214921003|NCT02076724|DEVICE|Synthetic mesh|
214921004|NCT00596687|DRUG|Insulin glargine|Insulin glargine once daily SQ
214921005|NCT00596687|DRUG|Regular insulin|Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
214921006|NCT00596687|DRUG|Insulin glulisine|scheduled glulisine given SQ at mealtime TID; none given if patient NPO
214921007|NCT00653133|DEVICE|Ultrasound imaging|Ultrasound guided techniques for placement of peripheral nerve block catheters for continuous infusion of local anesthetic
214921008|NCT00653133|DEVICE|Peripheral nerve stimulator|either stimulating needle or stimulating catheter used for placement of catheter for continuous infusion of local anesthetic
215062491|NCT01949571|DRUG|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
215062492|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
215062493|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
215062494|NCT00777595|DRUG|Placebo|Inhaled solution, single dose of placebo
214321514|NCT05634278|BEHAVIORAL|Preoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
215062495|NCT00777595|DRUG|Moxifloxacin|Tablet, oral, 400mg, single dose
215062496|NCT01147159|OTHER|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
215062497|NCT00998452|BEHAVIORAL|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
215062498|NCT02510469|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
214321515|NCT05634278|BEHAVIORAL|Postoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
214321516|NCT05634278|BEHAVIORAL|Mind wandering|"A timed, seven-minute mind wandering period during which participants are instructed: For the next 7 minutes, allow your mind to wander."
214321517|NCT00046033|DRUG|Lopinavir/ritonavir|
215062499|NCT03021655|BEHAVIORAL|Adventure-based intervention group|One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
215062500|NCT03021655|BEHAVIORAL|WhatsApp intervention group|A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.
215062501|NCT03021655|BEHAVIORAL|Control group|Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
214672189|NCT01396525|DEVICE|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
215062502|NCT01637532|DRUG|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
215062503|NCT01637532|DRUG|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
214672190|NCT04265989|DEVICE|Single BMS|Single bare metal stent covered the coronary artery aneurysm
214672191|NCT04265989|DEVICE|Single or Double BMS|Single or double layer bare metal stents covered the coronary artery aneurysm
214921009|NCT00527293|PROCEDURE|adjuvant therapy|If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.
214921010|NCT00527293|RADIATION|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
214921011|NCT00527293|RADIATION|brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
214921012|NCT02644993|RADIATION|Proton therapy|
214921013|NCT05142631|DRUG|Fruquintinib|To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma.
215062504|NCT03122145|DRUG|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
214321518|NCT00046033|DRUG|Ritonavir|
214321519|NCT00046033|DRUG|Saquinavir|
214321520|NCT00046033|DRUG|Tenofovir disoproxil fumarate|
214321521|NCT00046033|DRUG|Amprenavir|
214321522|NCT04622553|DRUG|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts.~Cohort 1 - (patients aged 12 to \< 18 years):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2- (patients aged 6 to \< 12 years,):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Enrolment for Cohort 2 will begin after initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, of patients in Cohort 1"
214321523|NCT05255770|DEVICE|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
214672192|NCT04265989|DEVICE|Single or Double BMS|Treated with single or double layer bare metal stents
214672193|NCT04265989|DEVICE|BMS+DES|Treated with bare metal stent combined with drug eluting stent
214921014|NCT02008474|BEHAVIORAL|Online weight loss + incentives for behavior 3 months|Participants will receive monetary incentives for submitting their behavior change information into a study website
214921015|NCT02008474|BEHAVIORAL|Online weight loss + incentives for weight loss at month 3|Participants will receive an incentive for meeting their weight loss goal at month 3.
214921016|NCT02008474|BEHAVIORAL|Online weight loss + Incentives for behavior 12 months|Participants will receive incentives for submitting behavior change information over the course of 12 months.
214921017|NCT02008474|BEHAVIORAL|Online weight loss + Incentives for weight loss 12 months|Participants will be receive monetary incentives for reaching their weight loss goal at months 3 and 12.
214321524|NCT05255770|DEVICE|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
214321525|NCT05255770|DEVICE|Control NRL condom|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
214321526|NCT05581979|DIAGNOSTIC_TEST|68-Ga PSMA PET scan|"On the scheduled visit date for the study,~* An intravenous cannula (plug) will be inserted in a vein in the participant's arm, through which the 68-Ga PSMA radiotracer for the scan will be injected. The infusion will take about 1-2 minutes.~* PET imaging will be performed with a dedicated PET/CT scanner. 2.5-6.0 mCi (depending on weight of the patient) of PSMA radiotracer will be injected intravenously."
214921018|NCT05918887|DEVICE|NJOY ACE commercial e-cigarette|"The NJOY ACE is the commercial version of the Standardized Research E-Cigarette (SREC), which was developed by NIDA with NJOY for research purposes.~Nicotine pods:~* Sealed, pre-filled, non-refillable~* 1.9 mL e-liquid with 5% w/w nicotine~* Approx 300 (280-330) puffs/pod~Nicotine liquid characteristics:~* Volume of liquid per pod 1.9 mL~* Active (nicotine USP 5% wt/wt)~* Propylene Glycol USP \& Vegetable Glycerin USP - PG/VG Ratio 0.77~* Lactic Acid USP~Battery characteristics:~* USB Rechargeable~* Storage Capacity \~ 400 mAh~* Approx 200 (3s) puffs / charge~* 300 charge cycles to \> 80% initial capacity~* Time to full charge 75 - 85 min~* Voltage / Temperature settings not user adjustable"
214921019|NCT05898932|OTHER|Medical Management|Participants will be managing condition with medication
214921020|NCT05898932|OTHER|Surgical Management|Participants will be managing condition with a surgery
214921021|NCT04050878|DEVICE|Facial scanner (Bellus3D) to assess perioral alterations|Use of a digital caliper for conventional measurements and a facial scanner (Bellus3D) to analyse the modifications induced by the use of implant supported dental prostheses in the lip support
214921022|NCT03831113|DRUG|Magnitude Group|Dose reductions will alternate between 1mg or 2 mg weekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
214321527|NCT02180282|DEVICE|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
214321528|NCT00319826|OTHER|No intervention|This is an observational study with no intervention
214321529|NCT05162911|BEHAVIORAL|Ask, advise, Assist and refer to the Quitline|A nurse will ask, advise, assist and refer patient to the Quitline
214321530|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor|A nurse will ask, advise, assist and refer patient to a counselor
214321531|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor and NRT|A nurse will ask, advise, assist and refer patient to a counselor and provide nicotine replacement therapy in the form of gum
214321532|NCT01216475|PROCEDURE|Femtosecond LASIK|LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.
214321533|NCT01216475|PROCEDURE|Small incision lenticule extraction (SMILE)|Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.
214321534|NCT04797260|GENETIC|Gene therapy|Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
215062505|NCT03122145|DEVICE|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
215062506|NCT01872975|RADIATION|regional nodal XRT|
214321535|NCT05949996|OTHER|A nurse-led symptom distress screening program|Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
215062507|NCT01872975|RADIATION|chestwall XRT|
215062508|NCT01872975|RADIATION|WBI|
215062509|NCT03934580|OTHER|hallucinated meal|a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis
215062510|NCT03934580|OTHER|Real meal|A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
215062511|NCT01186887|DRUG|Celecoxib|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
214321536|NCT05992792|BEHAVIORAL|App message|Participantes push App message cancer prevention from the recomendations ECAC. 2 SMS notifications (push) per week or frequency of app notifications per week.
214321537|NCT05992792|BEHAVIORAL|SMS message|Participants push SMS message cancer prevention from the ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
215062512|NCT01186887|DRUG|Placebo|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
215062513|NCT03794427|OTHER|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
215062514|NCT03794427|OTHER|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
214321538|NCT05992792|BEHAVIORAL|Internet|Internet connection in their mobile phone and WI-Fi. Participants push message cancer prevention from the recomendations ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
214321539|NCT05992792|BEHAVIORAL|Whithout internet|Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
214321540|NCT00639834|BIOLOGICAL|MDX-1342|One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
214321541|NCT03616990|BEHAVIORAL|TASC Service Linkages - Discharge Area Only|Individuals will meet with TASC Care Coordinators in the discharge area of the Cook County Jail. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
214484688|NCT06759675|OTHER|group based exercise with Cognitive functional therapy|"1. Cognitive functional therapy CFT A cognitive functional therapy is the behavioral approach which is used to treat low back pain. This approach has 3 components Making sense of pain Exposure with control Lifestyle changes~2. Group exercises Group exercises will be the exercises that perform on all individuals. It is performed in a group session having 3 components Pain education Exercises Relaxation"
214484689|NCT06759675|OTHER|Group based exercise|Group exercises Group exercises will be the exercises that perform on all individuals. It is performed in a group session having 3 components Pain education Exercises Relaxation
215062515|NCT03794427|OTHER|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
214672194|NCT02742740|BEHAVIORAL|Chemo Buddy|The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates.
214672195|NCT03114969|DEVICE|Relvar ELLIPTA|ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
215062516|NCT03794427|OTHER|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
215062517|NCT01597908|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily orally
214672196|NCT03114969|DEVICE|Symbicort TURBUHALER|TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
214321542|NCT03616990|BEHAVIORAL|SRC Overnight Stay|Individuals receiving SRC services will have the option to stay at the SRC overnight. At the SRC, individuals will be able to rest, have a meal, receive a change of clothes, and take a shower in a therapeutic, non-coercive environment.
215062518|NCT01597908|DRUG|Vemurafenib|Vemurafenib 960 mg twice daily orally
214321543|NCT03616990|BEHAVIORAL|TASC Services Linkages - SRC Onsite|While at the SRC, individuals will meet with TASC Care Coordinators. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
214321544|NCT03616990|BEHAVIORAL|APN Appointment|Individuals at the SRC will be able to meet with an Advanced Practice Nurse. As part of that visit, the APN will be able to prescribe medications or reroute prescriptions previously administered by the Cook County Jail's hospital, Cermak, to a participant's desired location as needed.
214672197|NCT03114969|DEVICE|Seretide DISKUS|DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
214672198|NCT03114969|DEVICE|Spiriva HANDIHALER|HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
214672199|NCT03114969|DEVICE|BREEZHALER|BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
215062519|NCT01597908|DRUG|Trametinib|Trametinib 2 mg once daily orally
214321545|NCT04291885|DRUG|Avelumab|Avelumab IV infusion
214321546|NCT04291885|DRUG|Placebo|Placebo IV infusion
214321547|NCT05117411|DIAGNOSTIC_TEST|OCTA and pseudophakin cystoid edema|Patients underwent OCT angiografia after cataract surgery
214321548|NCT03067805|BEHAVIORAL|Sexual Infidelity Condition|
214321549|NCT03067805|BEHAVIORAL|Emotional Infidelity Condition|
214321550|NCT03067805|BEHAVIORAL|Neutral Condition|
214321551|NCT03067805|BEHAVIORAL|Player in Jealousy Condition|
214321552|NCT03067805|BEHAVIORAL|Player in Non-Jealousy Condition|
214321553|NCT06159764|PROCEDURE|Cardioneuroablation|radiofrequency ablation to destroy cardiac ganglionated plexi located in epicardial fat pads around the atrias
214321554|NCT02596646|PROCEDURE|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
214321555|NCT02596646|PROCEDURE|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
214321556|NCT00486265|DRUG|AZD4877|intravenous infusion administered on days 1, 2 and 3
214321557|NCT01452412|DRUG|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
214321558|NCT01452412|DRUG|Placebo|To be taken on the same schedule as the active arm
214321559|NCT06297707|OTHER|aquatic high intensity resistive training|The experimental group participants will involve in aquatic high intensity resistive training sessions. The participants in the intervention group will receive 1 h of supervised lower limb aquatic resistance training three times a week for 12 weeks, for a total of 36 training sessions.
214321560|NCT06297707|OTHER|usual care|The control group will maintain usual care and will be asked to continue their usual leisure time activities. They will be offered the possibility of participating in two sessions consisting of 1 h of light stretching and relaxation during the 3-month intervention period.
214321561|NCT03296306|DRUG|Treatment duration of cisplatin based chemotherapy|"* GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~* GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~* MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~* HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks"
214321562|NCT05286190|DRUG|Bupivacaine 0.25% Injectable Solution|Bupivacaine 0.25% Injectable Solution
214321563|NCT00353678|DRUG|YM150|
214672200|NCT03114969|DEVICE|Incruse ELLIPTA|ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
215062520|NCT02384044|DEVICE|Crest® Sensi-Stop™ Strips|
215062521|NCT02384044|DEVICE|Colgate® Sensitivity Relief Pen|
215062522|NCT06231875|DEVICE|Press|Fabrication of clear aligners using press machine (Mini-star)
215062523|NCT04822818|DRUG|BEVA+SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
215062524|NCT04822818|DRUG|SOC|patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
215062525|NCT00593177|DRUG|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
215062526|NCT00837161|DEVICE|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
214484690|NCT06759857|DRUG|FHND9041|FHND9041 is a novel therapeutic agent targeting EGFR mutations. Participants will take an 80 mg oral dose once daily until disease progression, intolerable toxicity, or meeting other study-defined discontinuation criteria.
214484691|NCT06759857|DRUG|Afatinib|Afatinib is an approved, second-generation, irreversible EGFR tyrosine kinase inhibitor used as a standard first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, such as L858R and Exon 19 deletions. Participants in this arm will take a 40 mg oral dose once daily. Afatinib serves as the active comparator in this study to evaluate the efficacy and safety of FHND9041.
214484692|NCT06761391|DIAGNOSTIC_TEST|Pain Pressure Threshold|A hand-held pressure algometer will be used to record the pressure pain threshold (PPT), defined as the level at which gradually increasing pressure becomes painful. Pressure algometry has shown high intratest reliability in asymptomatic individuals over the suboccipital area and upper trapezius. PPT levels will be measured bilaterally over the neck angle over the middle of the anterior surface of the upper trapezius; and over the rectus capitis posterior major (RCPM) muscle. The physiotherapist will use an increasing pressure of approximately 1 kg/cm²/s. The average of three measurements with a 30-second rest period will be taken for analysis. Two measurements will be taken, before and after.
214321564|NCT03862664|PROCEDURE|Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation
214321565|NCT00099463|PROCEDURE|Blood Test|
214321566|NCT00099463|PROCEDURE|Urine Test|
214321567|NCT00099463|PROCEDURE|Physical Exam|
215062527|NCT02082964|OTHER|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
215062528|NCT02082964|OTHER|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
214321568|NCT00099463|DRUG|Vaccine|
215062529|NCT06006936|BEHAVIORAL|Coping with Infertility Self-Help Program|"The CWI program consists of seven 10-minute videos, each with accompanying homework assignments.~The first module, cognitive restructuring, includes instructions on challenging extreme or unhelpful automatic thoughts. The second module, challenging negative core beliefs, includes looking for patterns in thinking that illustrate core beliefs. The third module features behavioural activation techniques and emphasizes the importance of regular pleasure and skill-based activities. The fourth module highlights coping with grief and factors that contribute to grief, such as individual differences in grieving style. The fifth module supports strengthening relationships through responding to requests for affection and outlines several common relationship mistakes. The sixth module demonstrates how to identify and use values to make decisions and guide behaviour. The seventh module summarizes how thoughts, actions, and interactions can contribute to well-being when experiencing infertility."
215062530|NCT03069833|DIAGNOSTIC_TEST|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
215062531|NCT05457153|OTHER|Well-Being Process Program (WEBEPROP)|Technology-Based Well-Being Process Program (WEBEPROP)
215062532|NCT05275088|DEVICE|Prizvalve® system|Transcatheter atrioventricular valve replacement
215062533|NCT05170477|PROCEDURE|apical patency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
215062534|NCT05170477|PROCEDURE|Non-apical surgery|in Gp B apical patency will not be maintained. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration
214484693|NCT06761391|DIAGNOSTIC_TEST|Cervical Range of Motion|The degrees obtained as a result of the Range of Motion (ROM) measurements are made with a universal manual goniometer. Goniometer is still the most commonly used method for ROM measurements. For all ROM measurements to be performed, the necessary measurements can be taken based on the American Academy of Orthopaedic Surgeons (AAOS) guidelines . The flexion, extension, right and left rotation angles of the cervical region will be measured and recorded with the goniometer in the sitting position of the person. The measurement will be made twice, before and after the application.
214672201|NCT03114969|DEVICE|Anoro ELLIPTA|ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
214672202|NCT00949650|DRUG|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
214672203|NCT00949650|DRUG|BIBW 2992|BIBW 2992 once daily until progression
214672204|NCT00949650|DRUG|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
214672205|NCT04601272|BEHAVIORAL|Decision aid|Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.
214672206|NCT00851110|PROCEDURE|stem cell reinfusion|hematopoietic stem cell reinfusion
214321569|NCT00099463|DRUG|VRC-SRSDNA015-00-VP|
214321570|NCT03029624|DEVICE|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
214321571|NCT00062569|BEHAVIORAL|Bathing Support Intervention (BSI)|Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
214321572|NCT00062569|BEHAVIORAL|Caregiver reminiscence with coaching|"BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a crib sheet for caregiver use conversationally prior to and during the bath"
214672207|NCT00851110|DRUG|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
214921023|NCT03831113|DRUG|Frequency Group|Dose reductions of 2 mg will occur alternate between once weekly to biweekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
215062535|NCT02353013|DIETARY_SUPPLEMENT|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
214321573|NCT03610243|BEHAVIORAL|Self-administered acupressure|Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
215062536|NCT02353013|DIETARY_SUPPLEMENT|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
215062537|NCT04893317|DEVICE|Ablation in the ventricles with the Adagio Medical VT Cryoablation System|The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias
215062538|NCT04192669|DEVICE|Heart rate monitoring|The heart rate will be recorded and calculated by a heart rate monitor (Polar H10, Finland) located on the chest. The recording is done over a period of 5 minutes, the patient being in a sitting position, without any particular stimulus, in a quiet room. The recording is transferred via the HRV Logger application. Any ectopic beats and artifacts are automatically identified and replaced by values interpolated by the investigator, if necessary. The Kubios HRV Premium Software is used for all calculations.
215062539|NCT01142050|BIOLOGICAL|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
215062540|NCT04114071|BEHAVIORAL|TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women|See arm description
215062541|NCT01465880|OTHER|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
215062542|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
215062543|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
215062544|NCT01659996|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
215062545|NCT03530254|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
215062546|NCT03530254|DIAGNOSTIC_TEST|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
214321574|NCT04891029|DIAGNOSTIC_TEST|DOvEEgene test|Women participating in the study will undergo a genomic uterine pap test, DOvEEgene test, for the screening of ovarian and endometrial cancers. Clinical tests will also be administered as a comparator (CA-125 blood test and TVUS).
214321575|NCT01619033|DRUG|BF2.649|single dose 20 mg
214672208|NCT00027131|BIOLOGICAL|Heat Shock Protein 70-peptide complexes (HSP70)|
214672209|NCT03576677|DRUG|Levosimendan|"Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.~Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min."
214672210|NCT03576677|DRUG|Placebo|"The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group."
214672211|NCT01210937|PROCEDURE|CEA and TCD monitoring|All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
214672212|NCT00414440|DRUG|Placebo|placebo comparator
214672213|NCT00414440|DRUG|Everolimus|experimental
214921024|NCT01838564|OTHER|Routine Data collection|"Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.~Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST."
214921025|NCT01838564|OTHER|Feedback of patient-reported outcomes|Patients, parents and primary providers received printed reports summarizing patient/parent reported outcomes for last five visits. When child reported moderate-severe distress an email was automatically sent to primary providers (oncologist, nurses and psychosocial clinicians), as well as to the pain and palliative care services.
214921026|NCT03484663|DEVICE|central venous catheter (small catheter drainage)|Insertion central venous catheter ( small catheter drainage ) after uniport vats to decrease hospital stay and to easy drainage after procedure
215062547|NCT06197152|OTHER|Nasopharyngeal swabs and biological collection|"* Nasopharyngeal PCR~* Blood and virological samples taken as part of the research will be included in a biological collection"
214321576|NCT05269693|OTHER|Brief Hope Intervention|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions
215062548|NCT00479102|DRUG|Ferripel-3 - iron polysaccharide complex for prevention|
214921027|NCT04414969|DRUG|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1, PEG-ASP 2500U/m2 im d1, Chidamide, 30mg, po, on d1，d5，d8，d12，d15，d19. The regimen was repeated every 3 weeks for 4 cycles followed by involved-field radiotherapy after got CR and PR (patients with efficacy of SD and PD withdrew from the study). Intensity-modulated radiation treatment was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 54-56 Gy. During the radiotherapy, the anti-PD-1 antibody is administrated (200mg ivdrip, every 3 weeks) for 2 cycles. After the completion of radiotherapy, the subsequent 2 cycles of anti-PD-1 antibody + Peg-Asparaginase + Chidamide are administrated. After the end of all the above induction treatments , anti-PD-1 antibody (200mg ivdrip, every 3 weeks for up to 9 cycles) is given as maintenance therapy for 6 months (the total cycles of anti-PD-1 antibody is 17）.
214921028|NCT01259362|PROCEDURE|Transcranial Magnetic Stimulation|5 Hz, 120 % motor threshold, intertrain interval 20s, number of pulses in train 50.
214921029|NCT01259362|PROCEDURE|Transcranial Magnetic Stimulation|Cocaine addicted will receive 20 sham TMSr
214921030|NCT01980459|DIETARY_SUPPLEMENT|magnesium lactate|Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.
214921031|NCT00477399|BEHAVIORAL|Long term follow up after intensive lifestyle intervention|
214921032|NCT02547415|OTHER|questionnaires and psychological testing|"Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.~Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:~* Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires~* Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview."
214921033|NCT01068730|DRUG|metformin (Diabex)|Tablets, Oral, 500 mg, Once daily, single dose
214921034|NCT01068730|DRUG|metformin (Glucophage™)|Tablets, Oral, 500 mg, Once Daily, single dose
214921035|NCT01068730|DRUG|metformin (Glucophage™)|Tablets, Oral, 1000 mg, Once daily, single dose
214921036|NCT01068730|DRUG|metformin (Diabex)|Tablets, Oral, 1000 mg, Once daily, single dose
215062549|NCT06658509|BEHAVIORAL|HIIT|High-intensity interval training
215062550|NCT06658509|BEHAVIORAL|SIT|Sprint interval training
215062551|NCT04608383|OTHER|Additional and minimal collection of products of the human body carried out during a sample for standard of care|"* Swab of the peritoneal fluid for traces of COVID19. The collection of peritoneal fluid is a standard care practice.~* Swab from the laparoscopy filter"
215062552|NCT00675623|DRUG|Dimebon|Dimebon, 5 mg orally three times daily for six months
215062553|NCT00675623|DRUG|Dimebon|Dimebon 20 mg orally three times daily for six months
215062554|NCT00675623|DRUG|Placebo|Placebo three times daily for six months
214321577|NCT02739191|DEVICE|PICO, Smith & Nephew|Direct application of negative pressure wound therapy following Foot and Ankle surgery
214321578|NCT05871073|DRUG|Ropivacaine 0.75% Injectable Solution|WOUND INFILTRATION AFTER SPINAL SURGERY
214321579|NCT05871073|DRUG|dexamethasone 8mg|WOUND INFILTRATION AFTER SPINAL SURGERY
214321580|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U.~≈ bolus protocol: From 6 pm until 6 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm~1 dose/h + 50 % s.c. (≈ bolus)."
214321581|NCT00497536|DRUG|Insulin Aspart (IAsp).|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
214321582|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
214321583|NCT06115538|OTHER|Levodopa|Levodopa benserazide (100+25 mg) will be given to one group of study patients, and levodopa carbidopa entacapone (100+25+200 mg) will be given to the other group of study patients. Just before the drugs are given (0th minute), at 90 and 180 minutes after the drugs are given, a total of 3 doses will be given.
214321584|NCT01771432|DRUG|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
214321585|NCT01771432|OTHER|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
214321586|NCT02180334|DRUG|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
214321587|NCT02180334|DRUG|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
214321588|NCT02180334|DRUG|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
214321589|NCT06481722|OTHER|cerebral palsy|no intervention
214321590|NCT00847444|DRUG|Drug-based intervention|Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
214321591|NCT00847444|BEHAVIORAL|Lifestyle-based Intervention|"All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:~Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention."
214321592|NCT00006412|DRUG|Pravastatin sodium|
214321593|NCT00006412|DRUG|Fenofibrate|
214321594|NCT03397290|DEVICE|Ultrasound (US) Imaging|Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
215062555|NCT03828760|BEHAVIORAL|Music listening|Patients will be asked to either use their personal phones to listen to preferred music which is already on their device, or if they do not have a phone or other personal device capable of playing music of their choice, we will use a device (e.g. iPod) to load music of their choice. While in the waiting room, participants will listen to music through headphones/earphones, however they will need to remove their headphones/earphones during the initial consultation with the family physician (explaining risks, etc.), and resume listening to music through the phone speakers once in the examination room as patients will need to be able to hear instructions from the physician during the procedure.
215062556|NCT06007508|DRUG|Insulin Glargine|Long-acting insulin
215062557|NCT02282072|DEVICE|Deep brain stimulation：PINS Stimulation System|
215062558|NCT06536543|OTHER|Acute Respiratory Distress Syndrom (ARDS) treated with Prone Position (PP) equipped with Electrical Impedance Tomography (EIT)|Positive End-Expiratory Pressure (PEEP) will be titrated with PEEP-EIT method as it is already done in usual care. A classical low flow Pression Volume (PV) curve will be done in order to detect airway closure and measure compliance, the acquisition of EIT data during PV curve will be analysed secondary with a dedicated software. Reconstruction of EIT derived PV curve will determine the regional airway opening pressures and compliances of the 2 lungs. Two decremental PEEP-EIT titrations will be compared, one in supine and the other just after turning in prone.
215062559|NCT05598853|DRUG|intrathecal nivolumab and intrathecal ipilimumab|Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
214321595|NCT05148312|DRUG|Budesonide Inhalant Product|Single-dose of budesonide solution administered by nebulization.
214321596|NCT04594850|BIOLOGICAL|Cellgram-ED|Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
215062560|NCT06221943|BEHAVIORAL|Group-based Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in a group setting.
215062561|NCT06221943|BEHAVIORAL|One-on-one Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in an one-on-one setting
215062562|NCT06221943|BEHAVIORAL|ASD Diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
215062563|NCT00325260|BIOLOGICAL|Influvac; subunit influenza vaccine|
214321597|NCT01049724|OTHER|Tear collection|Tear collection
214321598|NCT00892164|DEVICE|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
214921037|NCT03573557|DEVICE|Pink Pad|Pink Pad made by Xodus Medical Inc. used for patients in steep Trendelenburg position during surgery.
214921038|NCT03573557|DEVICE|Bean Bag|Vac-Pac Bean Bag made by Olympic used for patients in steep Trendelenburg position during surgery.
214921039|NCT03573557|DEVICE|Gel Pad|Gel Pad used for patients in steep Trendelenburg position during surgery.
214921040|NCT00465296|DRUG|rosiglitazone|
214921041|NCT02288845|DRUG|ITI-007|
214921042|NCT05284799|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1
214921043|NCT05284799|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)|One single administration intramuscularly at Day 1
214921044|NCT05284799|BIOLOGICAL|Placebo|One single administration intramuscularly at Day 1
214321599|NCT00892164|DEVICE|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
214321600|NCT05986890|PROCEDURE|Roux-en-Y Bypass|laparoscopic Roux-en-Y
214921045|NCT04136379|DIAGNOSTIC_TEST|INR monitoring using a CoaguChek POC device|INR monitoring using a CoaguChek POC device
214321601|NCT05986890|PROCEDURE|gastrojejunostomy|surgical gastrojejunostomy
214321602|NCT02157987|DRUG|bevacuzimab spray|
214321603|NCT04683185|DRUG|E6742|E6742 tablets.
214321604|NCT04683185|DRUG|Placebo|E6742-matched placebo tablets.
214321605|NCT02109328|DRUG|Alisertib|"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."
214921046|NCT01760915|OTHER|NC100182 Hyperpolarized 3He|Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.
214921047|NCT03170531|DIAGNOSTIC_TEST|Custom Designed Spine Coil|During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
214921048|NCT03170531|DIAGNOSTIC_TEST|FDA approved spine coil|During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging. Volunteers may receive up to 3 scans to allow for comparisons of changes to the calibration files as we continue to test the coil and improve its performance.
214484694|NCT06761391|DIAGNOSTIC_TEST|Balance Error Scoring|"Balance performance will be assessed using the Balance Error Scoring System (BESS), known in Turkish as DHPS. Subjects must maintain test positions for 20 seconds under 6 conditions with eyes closed and no support: 2 surfaces (flat and foam) and 3 stance positions (double-foot, single-foot, tandem). A laboratory floor will serve as the flat surface, and an exercise mat will serve as the foam surface. All subjects will perform the conditions in this sequence: double-foot flat, single-foot flat, tandem flat, double-foot foam, single-foot foam, tandem foam, both pre-test and post-test. Each 20-second period will be timed with a stopwatch, and each error within this period will count as 1 point. Each test condition has a maximum error score of 10. Errors include:~1. Lifting hands above the iliac crest,~2. Opening eyes,~3. Taking a step,staggering, falling,~4. Flexing or abducting the hip joint beyond 30°,~5. Lifting the forefoot or heel off the ground,~6. Leaving the test position"
215062564|NCT02297711|PROCEDURE|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
215062565|NCT02297711|PROCEDURE|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
214321606|NCT02109328|DRUG|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
214321607|NCT02109328|DRUG|Placebo|Placebo oral tablets
214321608|NCT06240897|DEVICE|CURATE.Dtx|CURATE.Dtx is a self-guided digital multitasking game that involves a combination of four subtasks played simultaneously, targeting different cognitive domains.
214321609|NCT06240897|DEVICE|Optional games|The patient will first be asked how he/she feels and what they have done that day. The patient then selects a digital local pet (dog, cat, bird) and can customize its appearance, name and background location. The player can interact with their pet via several actions such as feed, bathe, train and accessorize. Playing with digital pets can help reduce stress and anxiety in the elderly. It can be a positive distraction in alleviating the elderly's worries and discomforts. In order to purchase accessories for their digital pet, they are encouraged to play short games that include Grocery Snap, Down Memory Lane and Pet Escape. These games are aimed at improving memory and reduce cognitive decline.
214321610|NCT00548704|DRUG|Dexrazoxane|
214321611|NCT01640366|DEVICE|PICO|Single-use Negative Pressure Wound Therapy System
214321612|NCT02045511|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
215062566|NCT00993863|DRUG|Placebo|single dose
215062567|NCT00993863|DRUG|ADL5859 30 mg|single dose
214321613|NCT02045511|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
214484695|NCT06761391|DIAGNOSTIC_TEST|Cervical Joint Position Sense|The sense of joint position in the cervical region will be evaluated in four positions: flexion, extension, right rotation, and left rotation, using a goniometer. Participants will sit upright with arms at their sides, looking ahead. The physiotherapist will passively move the participant's head to 65% of the maximum joint range of motion, previously determined, minimizing vestibular function effects. After holding the head in position for three seconds, participants will be asked to remember the position. Subsequently, they will be instructed to return their head to the neutral position and then actively move it to the previously determined point. The degree of error between the target and achieved positions will be measured.
214672214|NCT02291380|DRUG|Botulinum Toxin Type A for Injection|In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
214921049|NCT04299061|DIAGNOSTIC_TEST|International Physical Activity Questionnaire|"This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. Walking = 3.3 METs Moderate Intensity = 4.0 METs Vigorous Intensity = 8.0 METs Total MET-minutes/week = Walk (METs\*min\*days) + Mod (METs\*min\*days) + Vig (METs\*min\*days)~1\. Low: • No activity is reported OR • Some activity is reported but not enough to meet Categories 2 or 3. 2. Moderate: • 3 or more days of vigorous activity of at least 20 minutes per day OR • 5 or more days of moderate-intensity activity and/or walking of at least 30 minutes per day OR • 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of at least 600 MET-minutes/week. 3. High: • Vigorous-intensity activity on at least 3 days and accumulating at least 1500 MET-minutes/week"
215062568|NCT00993863|DRUG|ADL5859 100 mg|single dose
215062569|NCT00993863|DRUG|ADL5859 200 mg|single dose
215062570|NCT00993863|DRUG|ibuprofen 400 mg|single dose
215062571|NCT01760616|DRUG|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
215062572|NCT00978419|DRUG|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
215062573|NCT00978419|DRUG|Placebo|Placebo administered every day for up to 28 days
215062574|NCT03297684|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
215062575|NCT00475085|DRUG|aprepitant|Given orally or IV
215062576|NCT00475085|DRUG|dexamethasone|Given orally or IV
215062577|NCT00475085|DRUG|granisetron hydrochloride|Given orally or IV
215062578|NCT00475085|DRUG|palonosetron hydrochloride|Given orally or IV
214672215|NCT02291380|DRUG|Placebo|In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
215062579|NCT00475085|DRUG|prochlorperazine|Given orally or IV
215062580|NCT00475085|DRUG|placebo|Given orally
215062581|NCT06625138|DEVICE|Latex Band|Hemorrhoid banding with latex band
215062582|NCT06625138|DEVICE|Non-Latex Band|Hemorrhoid banding with non-latex bands
214321614|NCT02722928|OTHER|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
214321615|NCT03377777|OTHER|No intervention|
214321616|NCT00006125|DRUG|doxorubicin hydrochloride|
214321617|NCT00006125|DRUG|topotecan hydrochloride|
214321618|NCT00838565|DRUG|Placebo|intravenous infusion on three consecutive months
214321619|NCT00838565|DRUG|dose level 1|intravenous infusion on three consecutive months
214321620|NCT00838565|DRUG|dose level 2|intravenous infusion on three consecutive months
214672216|NCT00112138|DRUG|gabapentin|
214672217|NCT00294346|DRUG|AV608|
214321621|NCT00838565|DRUG|dose level 3|intravenous infusion on three consecutive months
215062583|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
214321622|NCT00838565|DRUG|dose level 4|intravenous infusion on 3 consecutive months
215062584|NCT01059864|DRUG|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
215062585|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
215062586|NCT01059864|DRUG|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
214321623|NCT06566443|DRUG|Honokiol|Honokiol will be given orally at a starting dose of 1 capsule (250 mg/ capsule) per day for 2 weeks. Dose levels will escalate based on dose-limiting toxicity occurrence. We will start at one capsule (250 mg) once daily, dose 0 would be one capsule (250 mg) twice daily, dose +1 would be 500mg in the AM and 250mg in the evening, and +2 would be 500 mg twice daily.
214321624|NCT06368544|OTHER|lower-body positive-pressure|By increasing the chamber in the lower body around Pressure acts as a counterweight to gravity
214321625|NCT03571516|DRUG|Teduglutide|SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
214321626|NCT03571516|OTHER|Standard Medical Therapy|Standard medical therapy will be administered for 24 weeks.
214321627|NCT03571516|DEVICE|Syringe|Teduglutide will be administered using syringe (510k number: K980987).
215062587|NCT03267784|BIOLOGICAL|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
215062588|NCT00343005|BIOLOGICAL|AMA1-C1|
215062589|NCT00343005|DRUG|AMA1-C1/alhydrogel Malaria Vaccine|
215062590|NCT00451958|DRUG|Degarelix 80 mg / Degarelix 80 mg|
215062591|NCT00451958|DRUG|Degarelix 160 mg / Degarelix 160 mg|
215062592|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 80 mg|
214321628|NCT03571516|DEVICE|Needle|Teduglutide will be administered using needle (510k number: K021475).
214672218|NCT02583750|BEHAVIORAL|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
214672219|NCT02583750|BEHAVIORAL|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
214672220|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
214672221|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
214672222|NCT01158898|DRUG|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
215062593|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 160 mg|
215062594|NCT04720755|DEVICE|Low-Intensity Extracorporeal Shock Wave Therapy|Twice-weekly treatments for 6 weeks, of 0.2mL/mm\^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
215062595|NCT06659120|DRUG|Fremanezumab|Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
215062596|NCT04912089|BEHAVIORAL|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
215062597|NCT07061496|BEHAVIORAL|Moderately intense exercise|Structured moderate-intensity aerobic activity (e.g., brisk walking) for 30-45 minutes/day, 5 days/week, for 12 weeks.
215062598|NCT07061496|DRUG|MetFORMIN 500 Mg Oral Tablet|Participants will receive oral metformin 500 mg twice daily for 12 weeks.
215062599|NCT06895863|DEVICE|MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.|"Intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) will be administered over five consecutive days.~On each intervention day, patients will undergo five high frequency iTBS sessions (each lasting approximately 10 minutes, excluding preparation) with about 50 minutes of rest between sessions. Each iTBS session delivers 1,800 pulses, resulting in a total of 25 sessions and 45,000 pulses over the course of a standard work week."
215062600|NCT06895863|DEVICE|Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.|Intermittent theta burst stimulation (iTBS) targeting the left inferior parietal lobule (IPL) will be administered over five consecutive days using the stimulation pattern described in the active DLPFC arm.
215062601|NCT06895863|DEVICE|Sham stimulation of the MagVenture MagPro XP Orange Edition Prototype flipping the active side of the MagVenture Cool-B65 coil|"Device: Sham stimulation of the left DLPFC or IPL will be administered using the same stimulation duration and repetition as the active iTBS.~To match the subjective experience of iTBS, the sham CoMPACT uses a dedicated (Active/Placebo) stimulation coil that has both active and sham functions, generating the same sound level regardless of the type of stimulation."
215062602|NCT07062549|DRUG|111In-XYIMSR-01|Unite Dose: 10.5±1 mCi of 111In-XYIMSR-01 Route of administration: Intravenous catheter placed in an antecubital vein or an equivalent venous access
215062603|NCT07073456|DIAGNOSTIC_TEST|Viscoelastic Coagulation Monitoring measurements|Peripheral venous blood samples will be obtained for the assessment of the eight following parameters utilizing the VCM (Viscoelastic Coagulation Monitor) device: clot time, clot formation time, alpha angle, amplitude at 10 minutes, amplitude at 20 minutes, maximum clot formation, lysis index at 30 minutes, and lysis index at 45 minutes. These parameters will be measured at the Emergency Department and subsequently on a daily basis for three consecutive days, if the patient is hospitalised.
215062604|NCT07071454|BEHAVIORAL|Patient intervention|Patient intervention has 2 components. 1) The investigators will send patients a letter that promotes screening and contains targeted messages based on the individual's demographic characteristics. 2) Study staff who is trained in patient navigation will call each patient up to 3 times to confirm receipt of the letter and conduct one-on-one education about screening using a standardized script.
215062605|NCT07071454|BEHAVIORAL|PCP intervention|PCP intervention has 2 components. 1) PCPs of patients who are randomized to this group will receive an initial email that provides a list of all patients assigned to the PCP who are randomized to the PCP intervention. PCPs will be specifically informed which patients are high-risk. The email will also include a personal report card with the percentage of patients assigned to the provider who are up-to-date with CRC screening in two age groups: 45-49 years and 50-75 years. Subsequently, PCPs will receive weekly emails with a list of patients randomized to the PCP intervention who are scheduled for a clinic visit with them. 2) The investigators will design a local clinical dashboard using Microsoft Power BI that allows PCPs to view a list of their patients who are randomized to the PCP intervention as well as provide a link to this in each email. High-risk patients will be specifically marked.
215062606|NCT01070134|BEHAVIORAL|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
215062607|NCT01070134|BEHAVIORAL|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
215062608|NCT05629312|PROCEDURE|Maxillary expansion|The upper jaw is expanded with a removable expansion plate
215062609|NCT05629312|PROCEDURE|Extraction of deciduous upper canines|Both deciduous upper canines are extracted in this group
215062610|NCT03262805|DIETARY_SUPPLEMENT|Lanconone|. Lanconone® is a joint pain supplement containing natural herbs such as Shyonak, Ashwagandha, Shunthi, Guggul, Chopchini, Rasna and Shallaki in therapeutic quantities and documented in the ancient scriptures as pain relievers.
215062611|NCT03262805|OTHER|Placebo|Microcrystalline cellulose
214321629|NCT06414057|OTHER|Offering opportunistic HPV vaccine during routine sexual health clinic visits|Investigators will offer Gardasil-9 and HPV self-swab screening to up to 500 individuals across the three study sites, aiming to recruit 120-180 individuals within each of the three participating health boards over a 6-9 month timeframe. Participants will be asked to provide a vaginal swab sample for baseline HPV testing.
214321630|NCT06259331|DRUG|SPN-812 (600mg, QD)|Viloxazine ER
215062612|NCT06896058|OTHER|Written and verbal training given to caregivers|Education was provided with a brochure containing information on practices regarding care of stroke patients with PEG, prepared by the researcher in line with literature information.
215062613|NCT01308840|DRUG|Panitumumab|Day 1 and 15 = 6 mg/kg IV
214321631|NCT04122573|DIAGNOSTIC_TEST|Coronary angiography|Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.
214321632|NCT04122573|DIAGNOSTIC_TEST|CT angiography of aorta|Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.
215062614|NCT01308840|DRUG|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
215062615|NCT01308840|DRUG|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
215062616|NCT00526539|OTHER|Total hip replacement, Spectron and Taperloc|
214321633|NCT04122573|DIAGNOSTIC_TEST|CT angiography of pulmonary arteries.|Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.
214321634|NCT04122573|DIAGNOSTIC_TEST|Electrocardiogram|All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.
214321635|NCT04122573|DIAGNOSTIC_TEST|Cardiac Troponin|Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
215062617|NCT06196996|PROCEDURE|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
215062618|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
215062619|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - medium|
215062620|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
215062621|NCT01706653|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
215062622|NCT01088295|DRUG|Telmisartan|
215062623|NCT03281629|DEVICE|Active TMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
215062624|NCT03281629|DEVICE|Sham TMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
215062625|NCT01084343|BIOLOGICAL|MYM-V101|"* Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~* Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks."
215062626|NCT06926946|OTHER|Intervention Arm- Cerebral Oximetry + Treatment Guideline|if the cerebral oximeter shows low values, a pre designed treatment guideline will be followed and corrective actions taken.
215062627|NCT06928545|DEVICE|Side-to-side duodenal-ileal anastomosis|Side-to-side duodenal-ileal anastomosis formed by magnetic compression using the GT Metabolic MagDI System.
215062628|NCT00939887|DRUG|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
215062629|NCT00652275|BIOLOGICAL|MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP|189 children will receive 3 doses of experimental vaccine
215062630|NCT00652275|BIOLOGICAL|Verorab vaccine|189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
215062631|NCT02175277|DRUG|Darbepoetin Alfa|The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
215062632|NCT01968538|RADIATION|Radiation Therapy|
215062633|NCT03833557|PROCEDURE|Nanohydroxyapatite Pulpotomy|Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic
215062634|NCT03833557|PROCEDURE|MTA pulpotomy|Angleus grey MTA
215062635|NCT03833557|PROCEDURE|Formocresol Pulpotomy|Buckley's Fromocresol. diluted full strength foromocresol
215062636|NCT03815448|DRUG|Methotrexate|Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
214321636|NCT06451042|DIAGNOSTIC_TEST|FET-PET/MRI|Radiation planning target volume (PTV) when planned with FET-PET/MRI to PTV when planned with conventional (Standard of Care) MRI only. 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) 180-200 megabecquerel (MBq) administered intravenously prior to PET/MRI imaging.
214321637|NCT06361823|DRUG|Semaglutide|Giving Semaglutide via subcutaneous injections on a weekly basis for a duration of 3 months. The dosage is 0.25 mg for the initial month, then upped to 0.5 mg for patients who could handle it in the second month, and eventually escalated to 1.0 mg for patients who continued to tolerate it in the third month.
214321638|NCT06361823|DIETARY_SUPPLEMENT|Low calorie diet|Low calorie diet (max 1200 kcal/day)
214321639|NCT02372851|DEVICE|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
214321640|NCT04011410|DRUG|Hydroxychloroquine Sulfate 200Mg Tab|Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
214672223|NCT02875288|DRUG|liposomal bupivicaine|"1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration"
214672224|NCT06130384|DRUG|Use of bromfenac 0.09% to reduce intravitreal injection pain|The eyedrop (bromfenac) will be given to the assigned eye.
214672225|NCT06130384|DRUG|Use of artificial tears to reduce intravitreal injection pain|The eyedrop (artificial tears) will be given to the assigned eye.
215062637|NCT03815448|OTHER|Placebo|Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
215062638|NCT03501901|DIAGNOSTIC_TEST|Antibiotic susceptibility test|
215062639|NCT01163396|DRUG|Bevacizumab|
215062640|NCT01163396|DRUG|Irinotecan|
215062641|NCT01163396|DRUG|Oxaliplatin|
215062642|NCT01163396|DRUG|5-fluorouracil/leucovorin|
215062643|NCT06008262|OTHER|Cold Application|An ice pack will be applied to the posterior upper neck regions of patients with nausea in Group-I, with an interval of 5 minutes. The vital signs of the patients will be recorded. The severity of nausea and pain of the patients will be evaluated with a numerical rating scale. The effectiveness of its application as perceived by the patient will be evaluated.
215062644|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids Supplementation|
215062645|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
215062646|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 1.
215062647|NCT03974932|DRUG|Ibuprofen|NSAID.
215062648|NCT03974932|DRUG|Acetaminophen|Analgesic.
215062649|NCT03974932|DRUG|Celecoxib|NSAID.
215062650|NCT03974932|DRUG|+/- Bupivacaine HCl|Local anesthetic.
214321641|NCT02653651|DRUG|Ketamine|Ketamine infused at 0.1 mg/kg/hour
214321642|NCT02653651|DRUG|Lidocaine|Lidocaine infused at 1 mg/kg/hour
214321643|NCT02653651|DRUG|Placebo|An equal volume of saline
214321644|NCT05231265|OTHER|Walking task|Treadmill walking task with study of fractal variability (complexity) for 10 minutes.
214321645|NCT01838642|DRUG|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
214321646|NCT00259506|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|
214321647|NCT04643262|PROCEDURE|Sleeve Gastrectomy|Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or \_\_\_\_\_proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.
214321648|NCT03748199|DRUG|POL6014|"DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)"
214321649|NCT03748199|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
214321650|NCT03806920|DIETARY_SUPPLEMENT|Intervention A|
214321651|NCT03806920|DIETARY_SUPPLEMENT|Intervention B|
215062651|NCT03974932|DEVICE|Luer Lock Applicator|Applicator for instillation.
215062652|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 2.
215062653|NCT04001439|DRUG|Experimental drug|All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
215062654|NCT04122846|BEHAVIORAL|Emotional Awareness and Expression Therapy|"Very much based on Unlearn your pain by Howard Schubiner."
215062655|NCT00922246|DEVICE|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
215062656|NCT04051294|DIETARY_SUPPLEMENT|Commercial kombucha tea|Commercially-available kombucha tea.
215062657|NCT04051294|DIETARY_SUPPLEMENT|Brewed kombucha tea|Kombucha tea brewed
215062658|NCT04051294|OTHER|Control: Tea|Tea brewed in our lab.
214484696|NCT06761391|OTHER|Suboccipital manual therapy|The procedure will be conducted with the patient lying on their back. The practitioner will be seated on a stool at the top of the examination table, their forearm in contact with the surface. After locating the occipital condyles through palpation, the practitioner will position their fingers in the slightly concave region between the occiput and the second cervical vertebra's spinous process. The patient's head will be gently elevated by the practitioner flexing their metacarpophalangeal joints. With the patient's skull base resting in the practitioner's palm, pressure equivalent to the weight of the patient's head will be applied to the rectus capitis posterior and obliquus capitis superior muscles using the practitioner's second, third, and fourth fingers for a duration of 5 minutes. To prevent eye movements from influencing suboccipital muscle tone, patients will be instructed to keep their eyes closed during the procedure.
214921050|NCT04299061|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index|"The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep. It differentiates poor from good sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month.The client self rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of 5or greater indicates a poor sleeper."
214921051|NCT04299061|OTHER|Physical Activity Awareness Questionnaire - prepared by the researchers|It consists of 13 questions to assess the physical activity level awareness of students. The questionnaire was prepared by the researchers therefore it does not have a validation.
214921052|NCT04299061|DIAGNOSTIC_TEST|Perceived Stress Scale|The Perceived Stress Scale (PSS) is a classic stress assessment instrument that helps understand how different situations affect feelings and perceived stress. The questions in this scale ask about feelings and thoughts during the last month. It consists of 14 questions.
215062659|NCT04051294|OTHER|Control: Water|Tap water
215062660|NCT04090957|DRUG|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
215062661|NCT04090957|DRUG|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
215062662|NCT00284635|PROCEDURE|Fast track vs conventional|
214321652|NCT03806920|DIETARY_SUPPLEMENT|Intervention C|
214321653|NCT03806920|DIETARY_SUPPLEMENT|Intervention D|
214921053|NCT05993897|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|10 mg of Dapagliflozin orally once daily
214921054|NCT05993897|DRUG|Rhythm control and anticoagulation|"In acute stage: Cardioversion with D.C shock if haemodynamically unstable, after failure of pharmacological cardioversion or participant preference.~or pharmacological cardioversion with either IV cordarone in structurally abnormal heart (150mg over 10 minutes followed by1 mg/min infusion for 6 hours followed by 0.5 mg/min not exceeding 2.4 grams over 24 hours till restoration of sinus Rhythm. Then maintenance dose of 200 mg tab orally every 8 hours for 3 weeks then 200 mg tab orally once per day.~or Propafenone (Rytmonorm) 600 mg single oral dose in structurally normal heart then maintenance dose of 150mg tab orally every 8 hours.~\+ Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females."
215062663|NCT05455580|BEHAVIORAL|Nurses Taking On Readiness Measures (N-TORM)|The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
214921055|NCT01828983|BEHAVIORAL|Telephone support groups|
214921056|NCT01828983|OTHER|Education webinars|
215062664|NCT06785454|DRUG|Lorundrostat|Lorundrostat tablet.
215062665|NCT06785454|DRUG|Placebo|Lorundrostat matching placebo tablet.
214321654|NCT01557400|DRUG|Ataluren|Oral powder for suspension
214321655|NCT02453958|DEVICE|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
214321656|NCT03437122|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
214321657|NCT06162286|DRUG|Omadacycline|Omadacycline IV/PO
214321658|NCT06162286|DRUG|Moxifloxacin|Moxifloxacin IV/PO
214321659|NCT00153400|BEHAVIORAL|Enhanced Lifestyle Intervention|Three face-to-face counseling sessions for nutrition and physical activity. Used a Spanish culturally tailored materials. These interventions were delivered by community health workers (CHWs) who are trained.
214321660|NCT02745964|DEVICE|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
214321661|NCT02745964|DEVICE|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
214321662|NCT01434290|RADIATION|36.25 Gy IMRT|36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.
214321663|NCT01434290|RADIATION|51.6 Gy IMRT|51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.
214321664|NCT03488212|BEHAVIORAL|Training to Identify Eligible Patients and Direct them to Online Obesity Treatment Program|Primary care clinic staff are trained to identify patients who meet study inclusion and exclusion criteria. They are then trained to provide patients with the information necessary to enroll in the study and access the online behavioral obesity treatment.
214321665|NCT03488212|BEHAVIORAL|Training to Motivate and Support Patients' Weight Loss|Primary care clinic staff are trained in psychological and behavioral strategies for: talking to patients about weight and weight loss in a way that patients find acceptable and helpful, increasing motivation for weight loss, overcoming common barriers to weight loss, and persevering with a weight loss attempt. They are trained in strategies to provide this support by telephone in addition to during clinic visits.
214321666|NCT03488212|BEHAVIORAL|Online Behavioral Weight Loss Intervention|For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
214321667|NCT03488212|BEHAVIORAL|Control Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online newsletters with educational information pertaining to healthy weight, diet, and physical activity habits.
214321668|NCT03488212|BEHAVIORAL|Monthly Lessons and Feedback Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; monthly feedback on the self-monitoring record.
214321669|NCT03488212|BEHAVIORAL|Refresher Courses for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive two month-long refresher courses with weekly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record; weekly challenges focuses on specific behavior change and weight loss goals.
214321670|NCT05939492|BEHAVIORAL|Mindfulness-Based Intervention|"Participants in the mindfulness-based intervention (MBI) group will be asked to use the Headspace app to sequentially complete the Basics, Basics 2, and Basics 3 courses. Each of these courses lasts 10 days, and participants have the ability to choose how long daily sessions last. Participants can choose between 3, 5, or 10-minute sessions for the Basics course; 10 or 15-minute sessions for the Basics 2 course; and 10, 15, or 20-minute sessions for the Basics 3 course. These daily sessions are audio recordings that prompt users to engage in a variety of mindfulness techniques, including focusing on their body and breathing, as well as acknowledging thoughts and emotions in a non-judgmental manner."
214321671|NCT02583932|DRUG|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
215062666|NCT00708136|BEHAVIORAL|water based training program to improve balance|
215062667|NCT02752919|DRUG|Galunisertib|Administered orally
215062668|NCT02679937|BEHAVIORAL|Fit4Duty|Small (\<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
215062669|NCT02679937|OTHER|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
215062670|NCT05984745|DRUG|Coenzyme Q10 Forte® capsules|Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
215062671|NCT06358573|DRUG|INT230-6|"INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate.~The IMP is without marketing authorization in Switzerland and anywhere in the world."
214321672|NCT02583932|BEHAVIORAL|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
214321673|NCT05970315|BEHAVIORAL|PPC|Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.
214321674|NCT05970315|BEHAVIORAL|Usual care|Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.
214321675|NCT02803918|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214484697|NCT06761508|BEHAVIORAL|Intervention study for Arm one using video|A 3 Arm randomized control trial, using video as the first Arm of intervention to assess the behaviour change of the community in hypertension prevention.
214321676|NCT02803918|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214321677|NCT02803918|DRUG|Basal Insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214321678|NCT02803918|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
214484698|NCT06761508|BEHAVIORAL|intervention 2:using infographics|A 3 Arm randomized control trial,that involves the use of infographics in Arm to assess the behaviour change of the community in hypertension prevention.
214484699|NCT06761508|BEHAVIORAL|intervention 3: use of pamphlet|A 3 Arm randomized control trial,that contains the use of pamphlet for the 3rd Arm which is the control group to assess the behaviour change of the community in hypertension prevention.
214672226|NCT02924753|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
214921057|NCT00522106|BEHAVIORAL|Behavioral graded activity|The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
214921058|NCT00522106|OTHER|Exercise therapy|Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
214321679|NCT01224639|BIOLOGICAL|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10\^3 PFU, TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, and TDV-4: 2 x 10\^5 PFU, total virus per dose 2.2 x 10\^5 PFU
214672227|NCT02924753|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
214672228|NCT02924753|BIOLOGICAL|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
214672229|NCT02143271|DRUG|KHK7580|Oral administration
214672230|NCT02168946|DRUG|Vabomere|Vabomere for IV injection, administered as a 2 g/2 g dose
214672231|NCT02168946|DRUG|Best Available Therapy|Antibiotic(s) chosen by Investigator
215062672|NCT06358573|OTHER|neoadjuvant immuno-chemotherapy|Standard of care
215062673|NCT06788106|BEHAVIORAL|high-intensity aerobic exercise + synchronous music|This group will be intervened under high-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
214672232|NCT02846077|OTHER|No intervention. Observation only|No intervention. Observation only
215062674|NCT06788106|BEHAVIORAL|medium-intensity aerobic exercise + synchronous music|This group will be intervened under medium-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
215062675|NCT06788106|BEHAVIORAL|low-intensity aerobic exercise + synchronous music|This group will be intervened under low-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
215062676|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 1|"Participants will complete 4 cycles. For each cycle they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Inulin."
215062677|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 2|"Participants will complete 4 cycles. For each cycle they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Resistant Starch."
215062678|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 3|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Inulin."
215062679|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 4|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Beta-Glucan."
215062680|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 5|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Resistant Starch."
215062681|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 6|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Beta-Glucan."
215062682|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 7|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Inulin."
215062683|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 8|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Resistant Starch."
214321680|NCT01224639|BIOLOGICAL|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, and TDV-4: 3 x 10\^5 PFU, total virus per dose : 4.7 x 10\^5 PFU. TDV administered intradermally.
214321681|NCT01224639|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
214321682|NCT03919461|DRUG|Propranolol and etodolac|A perioperative combined drug regimen
214321683|NCT03919461|OTHER|Placebo|Placebo
214321684|NCT03465878|DRUG|LY900014|Administered via SC injection
214321685|NCT03465878|DRUG|Insulin Lispro|Administered via SC injection
214321686|NCT05970432|DRUG|TQH2722 injection 300mg-150mg|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
214321687|NCT05970432|DRUG|TQH2722 injection 600mg-300mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
214321688|NCT05970432|DRUG|TQH2722 injection 900mg-450mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
214321689|NCT05970432|DRUG|TQH2722 injection matching Placebo|Placebo without active substance.
214321690|NCT04625751|OTHER|CO2-enriched air|To assess cardiovascular reactivity
214321691|NCT04625751|OTHER|Meal response test|Meal response test to assess changes in splanchnic blood flow.
214321692|NCT01433432|DRUG|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
214321693|NCT01411163|DRUG|Creatine monohydrate|Up to 30 grams daily creatine monohydrate
214321694|NCT06310850|DRUG|Ketamine|Patients will be administered 0.15 mg kg-1 intravenous ketamine (The sample provided contains equal proportions of two enantiomers, S and R ketamine hydrochloride.) 3 minutes before thoracic epidural catheter placement.
214321695|NCT06310850|OTHER|Placebo|Intravenous saline will be administered to patients 3 minutes before the thoracic epidural catheter is placed.
214321696|NCT03531216|OTHER|Rosemary essential oil|Topically-applied oil to both dorsal and palmar aspects of the hands
214321697|NCT03531216|OTHER|Placebo|Topically-applied oil to both dorsal and palmar aspects of the hands
214321698|NCT04395937|OTHER|exercises|One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises
214321699|NCT04656132|BEHAVIORAL|Physical activity assessment, promotion and monitoring in a preventive cardiology clinic|physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
215062684|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 9|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Arabinoxylan."
214672233|NCT03332953|OTHER|E-cigarettes with varying concentrations of nicotine & flavor|Subjects will be asked to vape various e-cigarettes containing e-liquids at three concentrations of nicotine and sweet flavor (9 stimuli per subject).
214672234|NCT02067221|DEVICE|RIRS|"* RIRS arm~* Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract"
214672235|NCT02067221|DEVICE|MPCNL|"* MPCNL arm~* A new technique that reduced the size of percutaneous tract to make renal stone into small pieces."
215062685|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 10|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Inulin."
214321700|NCT01876069|DEVICE|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
214321701|NCT01876069|DEVICE|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
214321702|NCT06018558|GENETIC|OCU410|Subretinal administration of OCU410
214321703|NCT03773731|BEHAVIORAL|High intensity interval training (HIIT)|Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals
214321704|NCT03773731|BEHAVIORAL|Moderate intensity continuous training (MICT)|Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)
214321705|NCT04887662|OTHER|Fermented vegetable|Participants will be asked to consume 100 g of fermented vegetables per day, at least 5 days per week, for 8 weeks
214321706|NCT00542581|DEVICE|The Acrysof toric SN60T3 IOL|Intraocular Lens
214321707|NCT01184274|DRUG|SB939|"Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~1. (starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~2. \- 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~3. \- 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"
214321708|NCT03517709|OTHER|Primary Care Physician Management of blood pressure|"* You will receive a 30-minute education session about your blood pressure medications and the need to take them every day.~* Your primary care physician will make recommendations on your optimal target blood pressure range and medication recommendations. ."
214321709|NCT03517709|DEVICE|Withings Smart Blood Pressure Monitor|We will use the Withings Smart Blood Pressure Monitor for daily blood pressure measurements.
214321710|NCT03493334|OTHER|Visual feedback|Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.
214321711|NCT03493334|OTHER|No visual feedback|Participants will be asked to perform active movements of their neck with the mirrors covered.
214321712|NCT06097208|BEHAVIORAL|community-based health promotion and obesity prevention intervention|The intervention involving measurements of children aged three- to four-years old in kindergartens, parents of the children had the opportunity of individual contact with a community health nurse, and education to kindergartens manager and employees e.g. pedagogues and kitchen staff. as well to parents of children in kindergartens.
214321713|NCT02022228|DRUG|triptorelin|0.2 mg triptorelin, ih
214321714|NCT02022228|DRUG|hCG|1000 IU hCG, im
214321715|NCT02022228|DRUG|hCG|500IU hCG, im
214321716|NCT03946397|OTHER|Mulstisensory massage|7 minutes of hand massage followed by multisensory immersion (lights and music) for 23 minutes
214321717|NCT01970839|DEVICE|tourniquet, sensory nerve conduction abnormality|
214321718|NCT02394938|OTHER|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
214321719|NCT00677807|DRUG|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
214321720|NCT00677807|DRUG|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
214321721|NCT04224766|PROCEDURE|Suprascapular Nerve Block with 5ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
214321722|NCT04224766|PROCEDURE|costoclavicular Block 10ml bupivicaine 0.5%|transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
214672236|NCT04634162|DRUG|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
214672237|NCT04634162|DRUG|Placebo|Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
214321723|NCT04224766|PROCEDURE|Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
214321724|NCT00607763|DRUG|Micafungin (Mycamine)|IV
215062686|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 11|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Resistant Starch."
215062687|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 12|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Arabinoxylan."
215062688|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 13|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Arabinoxylan."
215062689|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 14|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Beta-Glucan."
215062690|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 15|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Beta-Glucan."
215062691|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 16|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Inulin."
214321725|NCT01224249|DIETARY_SUPPLEMENT|Fish and shellfish|Intake of 1000 grams of fish and shellfish per week for six months.
214321726|NCT00754754|PROCEDURE|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
214321727|NCT01336686|DRUG|Arhalofenate|Arhalofenate 400 mg once daily for 4 weeks
215062692|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 17|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Arabinoxylan."
215062693|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 18|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Inulin."
215062694|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 19|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Beta-Glucan."
215062695|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 20|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Arabinoxylan."
215062696|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 21|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Arabinoxylan."
215062697|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 22|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Resistant Starch."
214321728|NCT01336686|DRUG|Arhalofenate|Arhalofenate 600 mg once daily for 4 weeks
214321729|NCT01336686|DRUG|Placebo comparator|Matching placebo once daily for 4 weeks
214321730|NCT01336686|DRUG|Colchicine|0.6 mg colchicine daily for flare prophylaxis
214321731|NCT04019041|DRUG|bermekimab|bermekimab 2 mL (200 mg/mL) pre-filled syringe
214321732|NCT04019041|DRUG|placebo|placebo 2 mL pre-filled syringe
214321733|NCT00189735|DRUG|FK778|
214321734|NCT01618357|RADIATION|Radiation|Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.
214321735|NCT01618357|PROCEDURE|Lumpectomy/Mastectomy|Resection of breast cancer.
214672238|NCT05067660|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SABR) is a highly focused radiation treatment that concentrates an intense dose of radiation on the recurrent tumorous lesion while limiting the dose to healthy surrounding tissues.
215062698|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 23|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Resistant Starch."
215062699|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 24|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Beta-Glucan."
215062700|NCT05355909|PROCEDURE|Individualized high intensity preoperative fitness training|The individualised training program consists of stamina training, interval training and strength training. The personalised fitness training will be designed based on the FITT-VP (frequency, intensity, time, type, volume, progression) of the American College of Sports Medicine (ACSM) and will contain 6 training session within 2 weeks under supervision of professional sport physicians.
215062701|NCT05275608|DIETARY_SUPPLEMENT|VLCKD diet with replacing meals|Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (\<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.
215062702|NCT05275608|BEHAVIORAL|Hypocaloric mediterranean Diet|Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry \* physical activity score).
215062703|NCT06320678|OTHER|Nursing Students Education|Effect of Concept Mapped Blended Learning Self-Directed Learning
215062704|NCT00497419|PROCEDURE|fast track|
215062705|NCT05056805|OTHER|Aerobic Exercise|Receive aerobic exercise encouragement
214321736|NCT01618357|DRUG|Veliparib|Pills to be taken twice a day during radiation and for one week after completion of radiation for a total of 29 days.
214484700|NCT06761287|PROCEDURE|Endoscopic resection|Eligible patients will undergo endoscopic submucosal dissection (ESD) or endoscopic intermuscular dissection (EID) after two to eight weeks of nCRT completion, depending on the used neo-adjuvant regimen. Procedures will be performed using the GIF EZ-1500 endoscope (Olympus America, Center Valley, PA, USA) and an electrosurgical unit (VIO 300 D; Erbe, Germany) to power the electrosurgical knife (1.5-mm DualKnife J, Olympus America). For mucosal incision, Endocut or Drycut mode will be used, while Precise, Swift or Spray Coagulation modes will support submucosal dissection and hemostasis. An initial submucosal lift will be created by Glycéol Gel injection. The ERBE Flushing Pump (Erbe, Germany) will supply further submucosal lift during dissection through foot pedal-controlled, pressurized injections of methylene blue and saline solution delivered via the DualKnife J's ceramic-tipped tubing.
214484701|NCT06761287|BEHAVIORAL|Short interval restaging|"Close follow-up and endoscopic re-evaluation four to eight weeks after the initial evaluation\*.~\*Defined as the first endoscopic evaluation after completion of the neoadjuvant treatment"
214484702|NCT06761287|PROCEDURE|Total mesorectal excision|This technique consists of the surgical complete removal of the rectum, together with the surrounding mesorectum lymphovascular fatty tissue (mesorectum).
214484703|NCT06763874|DEVICE|EMG-based FES device|One session of one hour to execute task-oriented exercises with the upper limb while wearing the EMG-based FES device. Submission of questionnaires related to usability, acceptance and satisfaction of the device.
214484704|NCT06771297|OTHER|nursing education|Nursing training will be given before rhinoplasty surgery. As a result, patients' involuntary thoughts and quality of recovery will be questioned.
214484705|NCT06341062|OTHER|Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound|Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound before hospital discharge
214484706|NCT03008382|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
214484707|NCT03008382|DRUG|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
214484708|NCT03008382|OTHER|No intervention- observational sub-study|Participants did not receive placebo or metoprolol during the entire duration of the study.
214484709|NCT06857565|DIETARY_SUPPLEMENT|Lactobacillus crispatus M247|CRISPACT® (Lactobacillus crispatus M247), Pharmextracta, S.p.A
215062706|NCT05056805|OTHER|Dietary Intervention|Consume high protein snack/meal/shake
214484710|NCT06857565|DIETARY_SUPPLEMENT|iNatal-duo® (containing Bifidobacterium animalis subsp. lactis BB-12 and Enterococcus faecium L3)|iNatal-duo®, PharmExtracta S.p.A
214672239|NCT05067660|RADIATION|Current standard template-based salvage therapy|In the group receiving salvage radiotherapy according to current standard of care, radiation will be directed to the prostatic bed and pelvic lymph nodes according to the radiation oncologist's discretion.
215062707|NCT05056805|OTHER|Nutritional Intervention|Receive nutritional consultation and guidelines
215062708|NCT05056805|OTHER|Quality-of-Life Assessment|Ancillary studies
215062709|NCT05056805|OTHER|Questionnaire Administration|Ancillary studies
214321737|NCT03603795|DRUG|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
214321738|NCT03603795|DRUG|Placebo|Placebo concomitant with induction chemotherapy patients with AML
214321739|NCT04278521|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
214321740|NCT05530122|BIOLOGICAL|infliximab, adalimumab, golimumab, vedolizumab, ustekinumab|
214321741|NCT00881192|PROCEDURE|IABP|preoperative IABP placement
214321742|NCT00314366|BIOLOGICAL|Stem Cell Therapy|Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
214321743|NCT00314366|OTHER|Control (plasma)|Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
215062710|NCT05056805|OTHER|Resistance Training|Complete strengthening exercise
214321744|NCT02825303|OTHER|Workplace consisting of two height-adjustable desks|Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
214321745|NCT01495845|OTHER|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
214321746|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SAPB
214321747|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
215062711|NCT01152125|OTHER|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
215062712|NCT01905943|DRUG|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
215062713|NCT01905943|DRUG|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
215062714|NCT01905943|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
215062715|NCT01905943|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
215062716|NCT01905943|DRUG|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
214484711|NCT06867679|OTHER|Recreational Soccer Training (Boys Group)|This group will have 3 training sessions per week, with each session lasting 60 minutes (13). The session will include: Warm-up (10 minutes): Light jogging, Dynamic stretching (Arm circles, Leg swings, Hip circles), Mobility exercises (Ankle roll, Trunk rotations),Technical Skills Training (20 minutes):Dribbling, passing, and shooting drills, Small-Sided Games (20 minutes): 3v3 or 4v4 games emphasizing teamwork, passing, and movement off the ball.Cool Down (10 minutes):Light jogging, Static stretching, Breathing exercises. Training Progression: Weeks 1-2: Basic skills and small-sided games, Weeks 3-5: Increased drill complexity, Weeks 6-8: Enhanced tactical awareness and structured gameplay.
214484712|NCT06867679|OTHER|Recreational Soccer Training (Girls Group)|This group will have 3 training sessions per week, with each session lasting 60 minutes (13). The session will include: Warm-up (10 minutes): Light jogging, Dynamic stretching (Arm circles, Leg swings, Hip circles), Mobility exercises (Ankle roll, Trunk rotations),Technical Skills Training (20 minutes):Dribbling, passing, and shooting drills, Small-Sided Games (20 minutes): 3v3 or 4v4 games emphasizing teamwork, passing, and movement off the ball.Cool Down (10 minutes):Light jogging, Static stretching, Breathing exercises. Training Progression: Weeks 1-2: Basic skills and small-sided games, Weeks 3-5: Increased drill complexity, Weeks 6-8: Enhanced tactical awareness and structured gameplay.
214484713|NCT06866990|DIETARY_SUPPLEMENT|Lactobacillus johnsonii|The investigational product is a probiotic containing Lactobacillus johnsonii. It is recommended to be stored under refrigerated conditions at approximately 4°C. Participants are instructed to take one sachet twice daily, dissolved in warm water, with a total daily oral dose exceeding 1×10¹¹ colony-forming units (CFU).
215062717|NCT02574078|DRUG|Nivolumab|
215062718|NCT02574078|DRUG|Bevacizumab|
215062719|NCT02574078|DRUG|Pemetrexed|
215062720|NCT02574078|OTHER|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
215062721|NCT02574078|DRUG|nab-Paclitaxel|
215062722|NCT02574078|DRUG|Paclitaxel|
215062723|NCT02574078|DRUG|Docetaxel|
215062724|NCT02574078|DRUG|Gemcitabine|
215062725|NCT02574078|DRUG|Erlotinib|
215062726|NCT02574078|DRUG|Crizotinib|
215062727|NCT02574078|DRUG|Carboplatin|
215062728|NCT00193011|DRUG|Docetaxel|Docetaxel
215062729|NCT00193011|DRUG|Cyclophosphamide|Cyclophosphamide
215062730|NCT00193011|DRUG|Methotrexate|Methotrexate
215062731|NCT00193011|DRUG|5-Fluorouracil|5-Fluorouracil
214921059|NCT02062164|PROCEDURE|bariatric surgery|The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.
214484714|NCT06866990|OTHER|Placebo|The placebo product contains the same excipients as the investigational product, except for the absence of Lactobacillus johnsonii. It is identical to the investigational product in appearance, color, weight, and taste. It is recommended to be stored under refrigerated conditions at approximately 4°C. The administration method is the same as that of the experimental group.
214484715|NCT06693986|BIOLOGICAL|Replicative Adenovirus Vector (RGDCRAdCOX2F)|"RGDCRAdcox2F (RGD) is a local product and is provided through this study."
214921060|NCT02062164|OTHER|conservative care|Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
214921061|NCT06048562|DIAGNOSTIC_TEST|echocardiography|evaluation idm for cardiomyopathy by echo
214921062|NCT01575652|OTHER|Group using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level with use of ACEIs
214921063|NCT01575652|OTHER|Group not using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level without usage of ACEIs
214921064|NCT01270464|DRUG|Reslizumab|3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
214921065|NCT01270464|DRUG|Placebo|Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
214921066|NCT05061277|DRUG|Recifercept|A lyophilized powder for solution for injection
214921067|NCT04262323|DEVICE|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the mobile phone application and the non-invasive reference method (upper arm cuff).
214921068|NCT03727048|DRUG|Ketorolac|the investigators aimed to evaluate the effect of postoperative ketorolac after ankle fracture surgery on postoperative opioid consumption, pain control, an patient satisfaction.
214921069|NCT03727048|OTHER|No ketorolac|standard of care post operative pain management protocol
214921070|NCT02796066|DRUG|Vehicle|Applied once a day
214921071|NCT02796066|DRUG|TSN2898|Applied once a day
214921072|NCT02796066|DRUG|TSN2898|Applied once a day
214921073|NCT02796066|DRUG|TSN2898|Applied once a day
214921074|NCT05201963|PROCEDURE|Serratus Anterior Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the patient's midaxillary line in the longitudinal plane (lateral position with arm abduction), at the level of 5th rib, the indicator oriented toward the operator's left. With the rib, pleural line, overlying serratus anterior and latissimus dorsi muscles visualized, then, a 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the 5th rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.6-13-MHz, linear transducer set for small parts and a depth of 1-4 cm is used for this block(15-16).
214921075|NCT05201963|PROCEDURE|Erector Spinae Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which skin, subcutaneous tissue, trapezius and erector spinae muscle will be visible superficial to T5 transverse process. Echogenic block needle will be inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1 ml normal saline . After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% will be performed. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used
214921076|NCT01369030|OTHER|Deplin®|Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
214921077|NCT06320236|DIAGNOSTIC_TEST|Adjust-Unlikely|"Pulmonary embolism will be excluded during emergency department assessment by the combination of:~1. 'Pulmonary embolism is the most likely diagnosis' as per the treating physician AND a D-dimer result \< 500 ug/L fibrinogen equivalent units;~2. 'Pulmonary embolism is not the most likely diagnosis' AND D-dimer \< age-adjusted threshold; or,~3. A negative computed tomography scan, planar ventilation perfusion scan or ventilation perfusion-SPECT.~Emergency departments will use their local laboratory D-dimer assay."
214921078|NCT01311375|DIETARY_SUPPLEMENT|w3 supplement in SCI|"supplements(Mor DHA and Ca 500 mg -D200 micro g )( will be given in this group"
214921079|NCT01311375|OTHER|placebo|placebo+ capsule CA-D
214921080|NCT04057547|DRUG|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
214921081|NCT04216199|DEVICE|Point of care Ultrasound|Point of care Ultrasound
214321748|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
214321749|NCT00571129|PROCEDURE|DCR with no tubes or mitomycin|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
214321750|NCT01831232|DRUG|pravastatin sodium|Given PO
214321751|NCT01831232|DRUG|idarubicin|Given IV
214484716|NCT06703281|PROCEDURE|Interscalene Nerve Block|Patients assigned to the Interscalene Nerve Block would have spirometry and ultrasound-guided diaphragm excursion measurements both pre and post-blok 30 minutes.
214921082|NCT03201770|DRUG|pyronaridine artesunate|Antimalarial treatment
214921083|NCT05473572|BEHAVIORAL|Fluency shaping exercises|Training for prolonged speech, easy onset, light contact and abdominal breathing moving from the level of single words till using short sentences describing pictures
214321752|NCT01831232|DRUG|cytarabine|Given IV
214321753|NCT01831232|OTHER|laboratory biomarker analysis|Correlative studies
214321754|NCT00819416|DRUG|5% albumin|5% albumin for the first 7 days of care in the ICU
214321755|NCT00819416|DRUG|Normal Saline|Normal Saline for the first 7 days of care in the ICU
214321756|NCT04527861|PROCEDURE|Single-incision Laparoscopic Surgery|In this group，the surgery is performed through a single incision. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
214321757|NCT04527861|PROCEDURE|Conventional Laparoscopic Surgery|In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
214921084|NCT01728662|PROCEDURE|ELVR Procedure|Lung Volume Reduction Procedure
214921085|NCT00276991|DRUG|"Kallunk oxide (Immunotherapy) "|"The study was assigned only one Arm \>450 cu/mm\^3 of baseline CD + T cells. HIV type-1 subjects were received one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine(Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 0.100 mg and 0.200 mg Kallunk oxide molecules with 199.900 mg, and 499.800 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 200 mg for children and 500 mg for adults. This powder form sample size product was administered once daily dose on 5 days treatment. The Botanical name of the antidote is Piper Longum."
214921086|NCT00532194|DRUG|cediranib|Once-daily oral tablet starting dose 20mg
214921087|NCT00308594|DRUG|Dexamethasone|
214921088|NCT01603745|DRUG|Zoely|1 pill every day
214921089|NCT01603745|DRUG|Yasmin|1 pill every day
214921090|NCT05793879|BEHAVIORAL|Video 360|Patients will undergo 12 sessions, 3 per weeks, 4 weeks
214921091|NCT05793879|BEHAVIORAL|Standard videos|Patients will undergo 12 sessions, 3 per weeks, 4 weeks
214921092|NCT04471233|OTHER|Multimodal analgesia including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal. Patient will be provided with an preoperative pregabalin dose and will continue medication two weeks postoperatively.
214921093|NCT04471233|OTHER|Multimodal analgesia not including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal.
214921094|NCT06317194|DEVICE|kTMP|A new non-invasive brain stimulation tool
214921095|NCT06317194|DEVICE|Sham kTMP|A new non-invasive brain stimulation tool with sham setting selected
214921096|NCT04725812|DRUG|Eculizumab|Eculizumab Intravenous Solution
214921097|NCT06036043|DRUG|Botulinum toxin type A|"The treatment will be administered either as a) subcutaneous infiltration with BoNT, covering the painful area, identified as allodynia during sensory examination, or b) perineural injection corresponding to the peripheral nerve(s) innervating the area where the pain is localized.~1. 100 IU Xeomin is mixed with 4 ml NaCl. Injections are performed with a 1.5 cm spacing. Maximum of 40 injections (200 IU).~2. 100 IU of botulinum toxin is mixed with 10 ml NaCl. For administration around multiple nerves, 50-100 IU per nerve (maximum 300 IU).~The treatment will primarily be provided by the principal investigator, or an anesthesiologist specializing in nerve blocks.~The specific method will be determined on an individual basis.~If there is no effect after one to two treatments, the treatment will be considered ineffective and discontinued. A treatment interval of 3 months has been established in accordance with a previous larger study."
214921098|NCT00915486|PROCEDURE|Good Standard of Care (GSoC)|Procedural treatment twice per week
214921099|NCT00915486|BIOLOGICAL|Vehicle|Topical fibrin as an adjunct to GSoC twice per week
214921100|NCT00915486|BIOLOGICAL|I-020201|Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
214921101|NCT03147131|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
214921102|NCT02977325|OTHER|water cure|
214921103|NCT04536038|BEHAVIORAL|Opt-out|A study coordinator will call the patient unless they opt-out. See arm description for more details.
214921104|NCT05359016|BEHAVIORAL|HPV testing of women for cervical cancer screening|Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
214921105|NCT06620445|BEHAVIORAL|Interventiion or CBT Group|This RCT aims to evaluate the effect of Cognitive Behavioral Therapy (CBT) compared to usual care (UC) in pediatric oncology patients. We hypothesize that those receiving CBT will report lower depression and anxiety and improved QoL six months post-enrollment.
215062732|NCT04089670|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention|"The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week."
215062733|NCT02351063|DRUG|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
215062734|NCT04806061|DRUG|Sodium bicarbonate|sodium bicarbonate 8.4% to achieve urinary pH \>7.5
215062735|NCT04806061|DRUG|standard care|standard care
215062736|NCT03195218|DEVICE|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
215062737|NCT05516797|DEVICE|Continuous Glucose Monitoring (CGM)|Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring
215062738|NCT05641961|BEHAVIORAL|Survivorship mobile application|Mobile phone application
215062739|NCT05641961|OTHER|Questionnaires|Questionnaires assessing cancer knowledge and system usability will be delivered to participants via Survivorship App
214321758|NCT03806582|DRUG|Norepinephrine|intervention with norepinephrine to reach a MAP of 85 mmHg
214321759|NCT01806896|DRUG|PF-02545920|"* Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Treatment for 28 days."
215062740|NCT06844058|BEHAVIORAL|Islamic-Oriented Ericksonian Hypnotherapy (IEH)|"This intervention involves 12 weekly sessions (60 minutes each) of Ericksonian hypnotherapy integrated with Islamic religious elements. Sessions incorporate:~Quranic metaphors and Islamic imagery Spiritual affirmations to enhance relaxation and emotional regulation Faith-based guided hypnosis adapted to cultural and religious beliefs Techniques such as indirect suggestions, therapeutic storytelling, and guided imagery The intervention is designed for Muslim participants with mild to moderate anxiety and depression."
214321760|NCT01806896|DRUG|Placebo|"\- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
215062741|NCT06844058|BEHAVIORAL|Standard Ericksonian Hypnotherapy (SEH)|"Participants receive 12 weekly sessions (60 minutes each) of standard Ericksonian hypnotherapy, which includes:~Metaphorical storytelling and guided imagery Indirect hypnotic suggestions to promote psychological flexibility Relaxation techniques to reduce anxiety and depressive symptoms Unlike the Islamic-Oriented Hypnotherapy (IEH), this intervention does not integrate religious or faith-based elements."
215062742|NCT04113044|OTHER|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.
215062743|NCT04119804|DIAGNOSTIC_TEST|cellular neural networks-genetic algorithm|Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
215062744|NCT06040008|GENETIC|blood collection|"* 3 blood collections over a period of 6 weeks~* V0 - Inclusion~* V1 - 3 weeks ± 14 days~* V2 - 3 weeks ± 14 days~* 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~* Clinical information obtained at each visit"
215062745|NCT04433741|DRUG|Oxytocin|Oxytocin administered intravenously
215062746|NCT04433741|DRUG|Placebo|Placebo administered intravenously
214321761|NCT01806896|DRUG|PF-02545920|"* 5mg dose~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
214321762|NCT01806896|DRUG|Placebo|"* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
214484717|NCT06703281|PROCEDURE|Superior trunk block|Patients assigned to the Superior Trunk Nerve Block would have spirometry and ultrasound-guided diaphragm excursion measurements both pre and post-blok 30 minutes.
214484718|NCT06870890|DIAGNOSTIC_TEST|muscle evaluation|The investigators will evaluate the muscle mass and muscle strenght for all patients included
214484719|NCT06870890|BIOLOGICAL|Dosage|Evaluation of the cinetic of biomarkers during exercise
214484720|NCT06870890|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|CPET
214484721|NCT06870890|COMBINATION_PRODUCT|Questionnaire and Physical Exam|Evaluating dyspnea, anxiety, sleep, physical activity, quality of life
214484722|NCT06756295|BIOLOGICAL|individualized tumor FAST vaccine combination (including adjuvant)|Using the patient's individual tumor tissue, an autologous FAST (Fragmented Autoantigen Stimulated T-cell Immunotherapy) vaccine is prepared.
214484723|NCT06873828|DEVICE|ATP-C135|A wearable long-term electrocardiogram monitoring device that monitors electrocardiograms by attaching it for up to 14 days.
214484724|NCT06873828|DEVICE|ATP-C75|A wearable long-term electrocardiogram monitoring device that monitors electrocardiograms by attaching it for up to 7 days.
214484725|NCT06882486|PROCEDURE|nephrectomy|Nephrectomy scheduled within 3 months of inclusion. Patients may continue their systemic treatment at the usual rate until D-5 prior to surgery. Treatment will not be resumed after surgery. Surgery may consist of partial or enlarged nephrectomy, with or without associated lymph node dissection, depending on technical possibilities and at the surgeon's discretion.
214484726|NCT06889337|OTHER|head elevated laryngoscopy position by Oxford pillow|ramped position, also known as head elevated laryngoscopy position,
215062747|NCT06525402|OTHER|Sodium Bicarbonate Group (Usual care)|In the clinic where the research was conducted, a guideline is routinely applied for the care of oral mucositis in line with the stages of oral mucositis. Sodium bicarbonate is used in line with this guideline. The first group, the control group, will receive routine oral care in the clinic with sodium bicarbonate. Oral care will be applied 4 times a day for 14 days.
215062748|NCT06525402|OTHER|Saline Group|The second group, the experimental group, will first receive oral care routinely applied in the clinic. Then, oral care will be given in the form of 5 ml mouthwash with saline. Oral care will be applied 4 times a day for 14 days.
215062749|NCT06525402|OTHER|Black Mulberry Syrup Group|The third group, the experimental group, will first receive oral care routinely applied in the clinic. Then black mulberry syrup will be applied. Then, oral care will be given in the form of 5 ml mouthwash with black mulberry syrup. Oral care will be applied 4 times a day for 14 days.
214321763|NCT04642729|PROCEDURE|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery|Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
214921106|NCT06959706|DRUG|TGW101|TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) and a corresponding small molecule chemical trigger (TRG001) administered separately.
215062750|NCT04150640|DRUG|Nal-IRI|chemotherapy drug
214321764|NCT02311491|DEVICE|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
214484727|NCT06889077|OTHER|QR Code Group|Students will receive support in their clinical practice through QR Code-supported perioperative education materials.
214484728|NCT06750172|DIAGNOSTIC_TEST|The oral sodium loading test|The subjects underwent an oral high-salt diet test with an additional 10g of salt per day for 3 consecutive days, and 24-hour urine measurements of aldosterone, sodium, potassium and creatinine were obtained on days 2 and 3
214484729|NCT06761248|DEVICE|Fluorescent Starch Nanoparticles Caries Detection Rinse|The fluorescent starch nanoparticles caries detection rinse is an innovative diagnostic tool designed to enhance the early detection of active dental caries. It contains proprietary fluorescent starch nanoparticles that infiltrate the porous enamel of active caries lesions. Upon illumination with a standard dental curing light, the nanoparticles fluoresce, allowing clinicians to differentiate active caries from inactive lesions and other enamel conditions. This rinse is evaluated as a non-invasive, highly sensitive, and specific diagnostic device.
214484730|NCT06757166|PROCEDURE|endotracheal intubation|endotracheal intubation for invasive mechanical ventilation
214484731|NCT04912596|DRUG|Albuterol Sulfate inhalation aerosol 108 mcg per actuation|equal to albuterol 90 mcg/puff, MDI
214672240|NCT03647943|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation, involving low-levels of electrical stimulation applied to the right and left DLPFC will be used in conjunction with cognitive training for 46 minutes.
214484732|NCT04912596|DRUG|Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation|equal to albuterol 90 mcg/puff, MDI
215062751|NCT04150640|DRUG|Oxaliplatin|chemotherapy drug
214672241|NCT03647943|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation, involving no electrical stimulation will be used in conjunction with cognitive training for 46 minutes.
215062752|NCT04150640|DRUG|5-FU|chemotherapy drug
214484733|NCT04912596|OTHER|Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo|MDI
215062753|NCT04150640|DRUG|Trastuzumab|immunotherapy
214484734|NCT04912596|OTHER|Albuterol Sulfate inhalation Placebo|MDI
214672242|NCT00477373|DRUG|depakine chrono|Depakine Chrono 500 mg
215062754|NCT04150640|DRUG|Pembrolizumab|immunotherapy
215062755|NCT04150640|DRUG|Nivolumab|immunotherapy
215062756|NCT04071340|DEVICE|non-contrast MSCT|non-contrast multi-slice computed tomography
215062757|NCT04071340|DEVICE|Abdominal ultrasonography|Abdominal ultrasonography
215062758|NCT04071340|DIAGNOSTIC_TEST|Urine analysis|Urine analysis
215062759|NCT04071340|DIAGNOSTIC_TEST|Urine culture|Urine culture
214672243|NCT02457897|DRUG|Liothyronine|Oral supplement given every 8 hours
214672244|NCT04222725|DRUG|TRS01 eye drops|Dosed 4 times a day (QID)
214672245|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
214672246|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
214672247|NCT04222725|DRUG|Placebo eye drops|Dosed QID
214672248|NCT00985452|OTHER|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
214921107|NCT00527644|DEVICE|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
214921108|NCT06731140|DRUG|Retinoic Acid|Retinoic acid 20mg tid, p.o.
214921109|NCT06731140|DRUG|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
215062760|NCT04012827|DRUG|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
215062761|NCT05936840|DEVICE|Mira Monitor tracking|Using the Mira monitor to track the menstrual cycle
215062762|NCT02805634|OTHER|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
215062763|NCT02805634|DEVICE|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
215062764|NCT06254092|PROCEDURE|tourniquet binding of cervical|The procedure will be performed by surgeons with rich experience in clinical work
215062765|NCT01255839|DEVICE|Double Balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
215062766|NCT01255839|DRUG|Minprostin|The prostaglandin 2 minprostin (3mg) was applied vaginally
215062767|NCT06300749|OTHER|Chiropractic Cervical Manipulation|"In the chiropractic cervical manipulation group, the patient was placed in the supine position. The therapist moved to the patient's head, identified the C5-C6 segment by palpation, and manually performed spinal manipulation from the right side using the cervical rotary break/index push technique since the dominant side of the patients was the right extremity. In the cervical rotary break/index thrust technique, the lateral aspect of the practitioner's index finger was placed in contact with the posterior aspect of the participant's C5 facet joint, and a rotational thrust was performed between the C5-C6 vertebrae."
214321765|NCT00745914|DRUG|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
214321766|NCT00745914|DRUG|Placebo comparator|Placebo comparator
215062768|NCT06300749|OTHER|Sham Technique Practice|The sham technique can be defined as a technique that does not have any therapeutic effect and is preferred to determine whether the efficacy of another technique is superior. The patient was placed in the supine position. The therapist moved to the patient's head, and the C5-C6 segment localized in the lower cervical region was detected by palpation. The C5-C6 segment was positioned to perform chiropractic cervical manipulation and waited for 30 seconds without any pushing force.
215062769|NCT05663177|DRUG|Almonertinib and metronomic oral vinorelbine|Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
215062770|NCT05031338|DEVICE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.
215062771|NCT05031338|PROCEDURE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.
215062772|NCT01544101|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
214484735|NCT04912596|OTHER|Methacholine|Methacholine 100 mg/vial
214484736|NCT06887868|PROCEDURE|Mobilization with movement|Manual application of a sustained translational or rotational glide force, either medial or lateral, on the tibia, while an active partial weight-bearing lunge movement was performed.
214484737|NCT06887868|PROCEDURE|Sham mobilization with movement|The physiotherapist mimicked the pain-reducing glide direction without applying glide force while the participants performed the active lunge movement. To achieve this, the physiotherapist's hands lightly touched the knee skin, with one hand on the tibia and the other on the femur over the joint surfaces.
214484738|NCT06876545|DIAGNOSTIC_TEST|systematical screening of at risk patients based on predefined hemorrhagic criteria|"Patients selected if condition present:~Hematuria (blood in urine)~Macroscopic hematuria (visible blood in urine) Hematuria detected by urine dipstick or microscopic analysis Ecchymoses (bruising)~Epistaxis (nosebleeds)~Petechiae (small pinpoint hemorrhages on the skin)~Gastrointestinal bleeding~Upper GI bleeding: Hematemesis (vomiting blood) Lower GI bleeding: Melena (black tarry stools) Positive fecal occult blood test (FOBT) Cerebral hemorrhage (brain bleeding)"
215062773|NCT01544101|DIETARY_SUPPLEMENT|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
215062774|NCT04435301|DEVICE|DC-Stimulator, NeuroConn, Germany|Neurostimulation device
214484739|NCT06879275|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|2 self administered questionnaire for diagnosis of dismorphophobia will be administered
214484740|NCT06886321|DEVICE|Prostate Irreversible Electroporation|The Prostate Irreversible Electroporation procedure was performed in our institution by a single urologist using an Prostate Irreversible Electroporation device and 18-gauge electrodes (Nanoknife®; Angiodynamics, Queensbury, NY, USA). All patients were positioned in lithotomy position under general anesthesia. A transrectal ultrasound was used to visualize the prostate and a brachytherapy grid was used to place the electrodes. An indwelling catheter was placed to empty the bladder. Four to six electrodes were placed through the perineum via the template grid to surround the targeted lesion. The lesion was defined based on prostate biopsy and MRI images. The active tip varied between 15- and 20-mm exposure. The distances between the electrodes were measured using TRUS and entered into the Nanoknife system. An initial ten pulses were delivered to ensure sufficient current was delivered between the electrodes (20-40 A). If sufficient then the remaining 80 pulses were given.
215062775|NCT02492191|DEVICE|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
214321767|NCT02444091|DRUG|Cyclophosphamide|Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
214321768|NCT04516265|PROCEDURE|neurodevelopmental treatment|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
214321769|NCT04516265|PROCEDURE|video-based trunk training|Games developed for the use of children with cerebral palsy will be used for trunk training.
214321770|NCT04516265|PROCEDURE|Video-based trunk training will apply with Theratogs|Video-based trunk training will apply with Theratogs
215062776|NCT03620136|DRUG|locoregional analgesia by a block on the adductor channel|"The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision."
214321771|NCT05733143|OTHER|cardiopulmonary exercise stress test (CPEST)|The study is observational and purely exploratory. We will utilise cardiopulmonary exercise stress testing to assess levels of fitness and causes for symptoms in proposed groups.
214321772|NCT06227377|DRUG|QTX3034|QTX3034 will be administered at protocol defined dose
214321773|NCT06227377|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
214484741|NCT06887270|OTHER|Continued DOAC|The continued DOAC group will continue their DOAC peri-procedurally as routine without interruption.
214484742|NCT06887270|OTHER|Interrupted DOAC|The interrupted DOAC group will take their last DOAC dose on Day -2, unless their DOAC is Dabigatran and their creatinine clearance is \< 50mL/min (Cockcroft-Gault equation), in which their last dose will be on Day -3. The DOAC will be resumed on Day +1.
215062777|NCT03620136|DRUG|locoregional analgesia by periarticular local infiltrations|"A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure."
215062778|NCT03694769|OTHER|Semi-structured interview|One-hour interview with researcher
215062779|NCT03694769|OTHER|Drop attack diary|Diary of any drop attacks experienced within an 8 week period
215062780|NCT05421169|DIAGNOSTIC_TEST|diastolic hyperemia-free ratio (DFR)|diastolic hyperemia-free ratio uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure
215062781|NCT00025064|BIOLOGICAL|bleomycin sulfate|
215062782|NCT00025064|DRUG|chlorambucil|
215062783|NCT00025064|DRUG|cisplatin|
215062784|NCT00025064|DRUG|dacarbazine|
215062785|NCT00025064|DRUG|doxorubicin hydrochloride|
215062786|NCT00025064|DRUG|etoposide|
215062787|NCT00025064|DRUG|ifosfamide|
215062788|NCT00025064|DRUG|melphalan|
214484743|NCT06816771|DRUG|pazopanib|Given PO The dosage will be determined according to the participant's body surface area, with body surface area less than 0.75, 1 tablet, and 2 tablets for body surface area greater than 1. 0.75-1,1.5 tablets.
215062789|NCT00025064|DRUG|prednisolone|
215062790|NCT00025064|DRUG|procarbazine hydrochloride|
215062791|NCT00025064|DRUG|vinblastine sulfate|
215062792|NCT00025064|DRUG|vincristine sulfate|
214484744|NCT06816771|DRUG|TGI chemotherapy|TGI chemotherapy (nab⁃Paclitaxel+ gemcitabine + ifosfamide)
214484745|NCT06816771|DRUG|CIV chemotherapy|CIV chemotherapy (cyclophosphamide +Irinotecan + vinorelbine)
214484746|NCT06726811|DRUG|Droperidol injection|2.5 mg
215062793|NCT00025064|PROCEDURE|peripheral blood stem cell transplantation|
215062794|NCT00025064|RADIATION|radiation therapy|
215062795|NCT05129657|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
215062796|NCT05129657|OTHER|Product B|P1012914, A nicotine pouch product with 4 mg of nicotine
215062797|NCT05129657|OTHER|Product C|P1012915, A nicotine pouch product with 8 mg of nicotine
214484747|NCT06878339|BEHAVIORAL|A social robot KaKa-assisted intervention|A social robot KaKa-assisted intervention (SRAI) to provide auditory rehabilitation and physical activity program
214672249|NCT00985452|OTHER|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
215062798|NCT05129657|OTHER|Product D|P1012919, A nicotine pouch product with 12 mg of nicotine
215062799|NCT05129657|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
215062800|NCT02931643|OTHER|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
214484748|NCT06694181|OTHER|AI-PERSONALIZED CLINICAL DECISION SUPPORT|AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT
214484749|NCT06442995|DRUG|Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
214672250|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
214672251|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
214672252|NCT01176851|DRUG|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
215062801|NCT02931643|OTHER|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
214321774|NCT06854081|COMBINATION_PRODUCT|EluPro Antibiotic-Eluting BioEnvelope|Utilization of an EluPro Antibiotic-Eluting BioEnvelope with the CIED during the participant's CIED implant procedure.
214321775|NCT01454921|BEHAVIORAL|Evolution: Young Women Taking Charge and Growing Stronger|The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
214321776|NCT06658041|BEHAVIORAL|Cognitive behavioural therapy (CBT)-based intervention with stepped-care|"After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]).~Mild symptoms (PHQ-9=5-9) without major risks (\*see above): 4 weekly CBT-informed intervention sessions led by trained Emotional Support Assistants (Peer Supporters with 80hrs mental health training + 15hrs intensive clinical training).~Mild symptoms (PHQ-9=5-9) with major risk factors or moderate-to-moderately severe symptoms (PHQ-9=10-19): 6 weekly CBT-based intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Individual CBT-based intervention will be provided to those unsuitable for group interventions.~In cases of non-remission (PHQ-9≥5): a second intervention trial will be provided. Those needing additional support will be referred to a partnered General Practitioner (if PHQ-9=10-19) or referred to more intensive psychological or psychiatric services as needed."
214321777|NCT06658041|OTHER|Care-as-usual|Following an initial interview session with research assessments, participants continue with their usual care at their primary care setting.
215062802|NCT00301262|DRUG|Viagra (Sildenafil citrate)|
214484750|NCT06442995|DRUG|Injection of Isotonic saline + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies
214484751|NCT06680635|DIETARY_SUPPLEMENT|Flavonoid-enriched juice and a low-calorie diet|Orange juice enriched in flavonoids (14%: nobiletin, sinensetin, tangeretin) (200 ml/day) and low calorie diet
214484752|NCT06680635|DIETARY_SUPPLEMENT|Food supplement: placebo juice and a low calorie diet|Placebo juice (200 ml/day) and a low calorie diet
214484753|NCT06679803|BEHAVIORAL|Physical Activity Chats after Stroke (PA-ChatS)|"PA-ChatS consists of (1) self-monitoring step count using a Fitbit Inspire, and (2) behavioral activation for stepping activity delivered via the telephone and guided by the PA-ChatS workbook.~Participants will receive education regarding the physical activity after stroke, American Heart/Stroke Association guidelines for post-stroke physical activity levels, and an overview of the intervention activities. They will then use the Fitbit data to monitor average daily step counts, set a new step count goals (increasing by 5 to 10% of the daily average step count from the prior week), and create a specific plan for achieving the new step count goal. The interventionist will collaboratively problem solve with the participant to identify strategies to overcome barriers to stepping activity and maintain safety."
214484754|NCT06748092|DEVICE|iCare IC1000|Measurement of Intraocular Pressure (IOP) in sitting and supine position
214484755|NCT06748092|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP) in sitting and supine position
214484756|NCT06748092|DEVICE|GAT|Measurement of Intraocular Pressure (IOP) in sitting position
214484757|NCT06748092|DEVICE|Perkins|Measurement of Intraocular Pressure (IOP) in supine position
214484758|NCT06869421|OTHER|Questionnaire|group of questions about the predictors (age, type of diabetes, level of education) and about the outcomes: knowledge and awareness of the link between diabetes and oral health, and attitude towards maintaining their oral health as diabetics
214484759|NCT06870292|PROCEDURE|Posterior nasal nerve combined with anterior ethmoid neurotomy|"First, a vertical incision was made in the posterior portion of the middle nasal turbinate. Dissection was performed along the bone to elevate the mucosal flap to expose the thick orbital process of the vertical plate of the palatine bone and the sphenopalatine foramen. The 3-4 mm of mucosal and submucosal neurovascular bundles surrounding the sphenopalatine foramen were subjected to full radiofrequency ablation, directly to the bone. The mucoperiosteal flap is reposited back. The bilateral nasal cavity was packed with Merocel nasal pack and hemostasis was achieved.~The anterior ethmoidal nerves of the lateral nasal branch and septal branch of the nasal cavity were cut off with a plasma treatment needle. Below 30°, the mucous membrane of the posterior lateral wall of the nasal colliculus was cut down to the bone surface using the needle of the nasal endoscope plasma therapy instrument. The contralateral side was then treated in the same way, with an arc cut line and a length of 2cm."
215062803|NCT04520152|DEVICE|FreeFlowMedical Lung Tensioning Device|Bronchoscopic lung tensioning device implantation
214484760|NCT06870292|DRUG|Drug therapy group|Subjects will be treated with medication according to guideline recommendations when nasal-related symptoms occur. Oral antihistamines or nasal antihistamines are preferred, and nasal hormones (budesonide nasal spray), or a combination of two or three drugs, may be used in severe cases.
214484761|NCT06881316|OTHER|Caffeine|Participants' solutions were prepared in separate Falcon Sterile Tubes: LSPTCAFF (1.2% w/v caffeine solution, Nature's Supreme). An MRI was performed before the LSPT. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The caffeine solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before LSPT and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz.
214484762|NCT06881316|OTHER|CHO|Participants' solutions were prepared in separate Falcon Sterile Tubes: LSPTCHO (6% w/ v glucose solution, Protein Ocean, Turkey) An MRI was performed prior to LSPT. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The CHO solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before LSPT and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz.
214484763|NCT06881316|OTHER|Control|For the control condition, no supplements were taken and only exercise was performed.
214672253|NCT02232438|BEHAVIORAL|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
215062804|NCT02524236|DRUG|Botox injection in the prostate|transrectal access of prostatic injection
214484764|NCT06815705|PROCEDURE|Vascularized lymphatic transplantation|"Preoperative ultrasonography was performed to check the distribution, quantity and size of axillary lymph nodes. During the operation, methylene blue was injected subcutaneously into the elbow fossa to make the axillary lymph nodes in area B and D chromogenic, and avoid damage to the arm drainage lymph nodes.~Adjusting the flap design according to the size of the defect. The perforating branches of lymphoid tissue in areas A and C of grade I were located about 3-5cm above the perforating branches of the skin, and moved towards the thoracic side to the lymphatic adipose tissue. Finally, the pedicle of the thoracic dorsal artery was separated, and the blood transport of the flap and the lymphatic adipose tissue was examined by fluorescence imaging and other methods. The lymphoid adipose tissue was placed in the neck area I and II, and fixed by suture. The arteriovenous microvessels in the thoracic dorsal were anastomosed to the vessels in the receiving area of neck."
214484765|NCT06814483|BEHAVIORAL|Experimental: A computer-based multimodal mind and body approach (cbMMBA)|cbMMBA will include three modules: BDJ, acupressure, and relaxation techniques including deep breathing, guided imagery, and progressive muscle relaxation.
214484766|NCT06814483|BEHAVIORAL|A standard cognitive training group|The program uses paper puzzles (Sudoku, crosswords, word-search, etc.) to engage subjects
214484767|NCT06792292|OTHER|conventional colonoscopy procedure|Study subjects in this interventional arm will undergo conventional colonoscopy.
214321778|NCT04633655|OTHER|outcome measures for CIPN testing|questionnaires administration, physician based scales for CIPN data collection
214321779|NCT05466149|DRUG|Furmonertinib|240mg QD on a continuous dosing schedule.
214484768|NCT06792292|OTHER|artificial intelligence-assisted colonoscopy procedure|Study subjects in this interventional arm will undergo colonoscopy done with a commercially-available module that uses artificial intelligence to highlight suspected polyps on the screen during colonoscopy. This module also attempts to characterize the detected polyp as adenomatous or not. The detection and characterization of polyps is in real time, during the procedure.
214321780|NCT02632708|DRUG|AG-120|
214321781|NCT02632708|DRUG|AG-221|
215062805|NCT01940367|DEVICE|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
214484769|NCT06738472|OTHER|home based exercises|given exercises to the participants
214484770|NCT06738069|OTHER|Participants are not assigned an intervention as a part of the study|Participants are not assigned an intervention as a part of the study
214484771|NCT06888401|PROCEDURE|ERCP|
214484772|NCT06862947|PROCEDURE|Rectus Sheath Block|Bilateral rectus sheath block performed under ultrasound guidance using 15 ml of 0.4% ropivacaine on each side
214484773|NCT06862947|PROCEDURE|Placebo|Injection of 15 ml of 0.9% saline as a placebo under the same conditions as the experimental group.
214484774|NCT03698669|BEHAVIORAL|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
214484775|NCT03698669|BEHAVIORAL|Health Education (HE)|Participants randomized to the control HE condition are offered six telephone sessions led by the Behavioral Health Specialists. The first health session is around nutrition. At the remaining sessions, participants choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
214484776|NCT05372042|BEHAVIORAL|CBT Text Messages|CBT skills based text messages delivered 3x per week for four weeks
214484777|NCT04947462|DEVICE|Chronically Implanted Neural and Muscular Interface|Participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
214484778|NCT00983307|DRUG|Erlotinib|Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
214321782|NCT02632708|DRUG|cytarabine|
214321783|NCT02632708|DRUG|daunorubicin|
214321784|NCT02632708|DRUG|idarubicin|
214321785|NCT02632708|DRUG|mitoxantrone|
214321786|NCT02632708|DRUG|etoposide|
214321787|NCT06915493|OTHER|General Anesthesia|Blood glucose measurements during general anesthesia
214321788|NCT07018973|OTHER|GAISMA|After the pre-test and randomization, the experimental group will first start the morphological analysis application. After completing a certain period of time, copies of the matrix and suggestion studies will be taken and they will be allowed to use the generative artificial intelligence application. At the end of the application, a post-test will be applied. In addition, an opinion form will be given and their opinions about the morphological analysis method, the use of generative artificial intelligence and the use of artificial intelligence with the morphological analysis method and how it affects them will be taken.
214321789|NCT07018973|OTHER|Control|In the control group, morphological analysis will be applied. Post-tests will be applied at the end of the application. Finally, their opinions about the morphological analysis method and how it affects them will be taken by giving an opinion form.
214321790|NCT02030860|DRUG|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
214321791|NCT02030860|DRUG|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
214484779|NCT00983307|RADIATION|Hypofractionated Radiotherapy|Patients undergo hypofractionated thoracic RT 5 days a week for approximately 2.5 weeks beginning on day 0. Patients also receive erlotinib hydrochloride PO daily beginning on day -5 and continuing for up to 24 months in the absence of disease progression or unacceptable toxicity.
214484780|NCT01612351|DRUG|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
214321792|NCT02030860|DRUG|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
214321793|NCT04471168|DEVICE|Cryo-Auriculotherapy|3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
214321794|NCT04471168|DEVICE|Sham comparator|3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
214321795|NCT07025278|BEHAVIORAL|Medium difficulty fixed priority group|During the intervention process, participants carried out cognitive and motor tasks simultaneously. They were told to divide attention equally between them and not prioritize one over the other.
214321796|NCT07025278|BEHAVIORAL|Medium difficulty variable priority group|During the intervention process, participants performed medium-difficulty cognitive and motor tasks simultaneously. Participants alter focus between the motor task and the cognitive task every half of the intervention time.
214321797|NCT07023887|OTHER|6-12-25 Training Regimen|A conditioning regimen involving three exercises performed consecutively with minimal rest. Includes 4-6 repetitions at 4-0-1-0 tempo, 10-12 repetitions at 3-0-1-0 tempo, and 20-25 repetitions at 2-0-1-0 tempo.
214321798|NCT07023887|OTHER|8x8 Training Regimen|A conditioning regimen optimizing high volume with short rest periods. Six exercises are performed consecutively with a 2-0-1-0 tempo and no rest between sets.
214484781|NCT01612351|DRUG|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
214484782|NCT01612351|DRUG|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
214484783|NCT01612351|DRUG|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
214484784|NCT01612351|DRUG|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
214484785|NCT01612351|RADIATION|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
214921110|NCT04012749|BEHAVIORAL|Advance directive|Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.
214484786|NCT01612351|RADIATION|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
214484787|NCT01612351|PROCEDURE|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
214484788|NCT06957730|DEVICE|Phonak Audeo Infinio Hearing Aid|Commercially available receiver-in-canal (RIC) style hearing aid manufactured by Sonova.
214921111|NCT04012749|BEHAVIORAL|Prepare|Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.
214484789|NCT06953791|DIETARY_SUPPLEMENT|aCDED + Modulen|"Unique diet + partial enteral nutrition (PEN): This group will receive as follows:~* Weeks 1-6: 50% of dietary needs from PEN (Modulen, ModuLife phase I) and 50% from a limited whole food diet~* Weeks 7-12: 25% of dietary needs from PEN (Modulen, ModuLife phase II) and 75% from a limited whole food diet~* Weeks 12-48: liberal diet and Modulen as needed"
214484790|NCT06953791|DRUG|Prednisolone|1 mg/kg, tapering scheme
214484791|NCT06952634|DRUG|ESK-001|Single oral dose of ESK-001 in participants from all cohorts
214672254|NCT05362162|PROCEDURE|cervical plexus block|local anesthetic agent injection into the either Superficial or intermediate area
214921112|NCT04012749|BEHAVIORAL|Facilitator|Facilitator engages patient to activate advance care planning and to carry out navigation and facilitation aspects of advance care planning. Facilitator can tee up advance care planning activities with the primary care physician.
214484792|NCT06061939|OTHER|Blood Flow Restriction training with Oclussion Cuff.|A strength training program with blood flow restriction will be performed for 12 weeks, with 30-45 minute sessions on Mondays, Wednesdays and Fridays. Each session includes a warm-up, the main part with specific exercises and a cool-down with stretching.
214484793|NCT06953895|PROCEDURE|Mulligan's Mobilization With Movement|The Mulligan's MWM group received mobilization with movement in the glenohumeral joint, as described by Mulligan. The participant was seated, and the physiotherapist was placed on the opposite side to the affected shoulder with the thenar eminence of one hand over the anterior aspect of the humeral head, and the other hand over the spine of the scapula posteriorly of the affected shoulder. The hand over the humeral head performed a posterolateral glide, while the other hand stabilized the scapula. This maneuver was sustained while the participant asked to raise the arm in scapular plan (as explained above) without pain. The physiotherapist previously determined the amount of posterolateral pressure which was the best to abolish the pain during shoulder scaption for each participant. The participants performed three sets of 10 trials with a resting time of 30 seconds between each set. After intervention was allowed a resting time of three minutes.
214484794|NCT06953895|PROCEDURE|Active Mobilization|"In the Placebo group, no effective intervention was performed, the participant was asked to raise the affected arm in scapular plane without pain, while the physiotherapist placed their hands-on shoulder, with the same manual contacts described in Mulligan's MWM group, but without performing any pressure.~The participants performed three sets of 10 trials with a resting time of 30 seconds between each set. After intervention was allowed a resting time of three minutes."
214484795|NCT01134172|BEHAVIORAL|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status. A member of the study team will call a subset of patients who have completed both baseline and follow-up surveys to clarify responses to previous questions. Patients will be considered lost to follow- up if surveys A or C have not been completed two years from the participant's consent date (participants who enroll but do not complete survey A are not prompted for survey C). Deviations will not be filed until the end of the study, as there are opportunities over the course of study follow- up to collect previously missing information.
214484796|NCT01134172|BEHAVIORAL|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. All three follow-up contact methods (email, postcard, call) contain the same question regarding current employment status with minor modifications in formatting. However, the employment question asked in all three follow-up contact methods is shown in the Postcard\_Template document. Due to the recent COVID-19 pandemic study staff will be working from home. Therefore, calls will be made via MSK-approved platforms (e.g. Jabber, etc.). Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs. The data collected for these internal tracking logs will be managed through a REDCap database.
214484797|NCT04522544|DRUG|Tremelimumab|300 mg Tremelimumab C1D1
214484798|NCT04522544|DRUG|Durvalumab|1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
214484799|NCT04522544|PROCEDURE|Y-90 SIRT|Locoregional therapy will be performed as a standard-of-care procedure
214484800|NCT04522544|PROCEDURE|DEB-TACE|Locoregional therapy will be performed as a standard-of-care procedure
214484801|NCT06952764|OTHER|Seizure risk forecast|Participants are provided with daily risk estimates about upcoming seizure likelihood.
214484802|NCT06952764|OTHER|Control seizure risk forecast|Participant receive uninformative control forecast
214921113|NCT04271540|DRUG|Tildrakizumab|"Tildrakizumab, a p19 inhibitor which blocks IL-23 and Th17 mediated inflammation, will be given for 6 months. As below, a baseline cardiac PET scan will be performed prior to initiation and after 6 months of treatment.~Radiation: A cardiac PET scan will be performed at baseline and at 6 months"
214921114|NCT05006443|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|a non-invasive assessment to determine severity of tricuspid regurgitation
214921115|NCT00742963|DRUG|TH-302|"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"
214921116|NCT04697563|DEVICE|Laser|real laser beam administered
214921117|NCT04697563|DEVICE|Placebolaser|no laser beam admitted
214921118|NCT06024109|DEVICE|Closure of the Vaginal Cuff after Total Hysterectomy|Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
214921119|NCT06295276|OTHER|teletherapy-guided exercise programme|"Exercise program guided by online sessions. Subjects perform this exercise program three times a week at home, so that they complete four sessions per week for six weeks. The duration of a session is approximately twenty minutes. There are six exercises with three sets and about fifteen repetitions. Subjects in the treatment group also receive an instructional video. The subjects keep a diary in which they record their adherence to the treatment protocol at home.~At the beginning of the intervention and after the sixth week, participants are assessed with ODI, NDI and SF36-Short and NRS-11 scales. At the end, we use the Global Rating Scale."
214921120|NCT06295276|OTHER|Waiting list/control intervention/delayed teletherapy intervention|Subjects in the control group will be advised to maintain their daily routine but will be asked to refrain from other treatments to avoid co-interventions during the 6-week study period. However, the use of painkillers such as non-steroidal anti-inflammatory analgesics (NSAIDs) taken by study participants in all groups for more than 3 months is allowed and will be documented (taking a pragmatic approach). Any change in medication will be monitored and documented by the PT at each visit.
214921121|NCT03269994|DRUG|Cefoxitin|Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
214921122|NCT03269994|DRUG|Piperacillin-tazobactam|Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
215062806|NCT01940367|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:~* Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~* The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~  * Mode: Burst~ * Cycle: 10 seconds~ * Frequency: 10 Hz~ * Pulse Width: 250 µs~ * Intensity: to subject comfort level"
214321799|NCT07023887|OTHER|5/5/5 Cluster Set Training Regimen|A hypertrophy regimen where an individual performs 5 repetitions at a tempo of 4 seconds during the eccentric movement of the exercise, while performing the concentric motion in 1 second then resting for 20 seconds and repeating the sequence two additional times to total three clusters of 5 repetitions.
214921123|NCT04862117|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
214921124|NCT03969901|DRUG|IMI/REL|"Age-based dosing:~* 12 to \<18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~* 6 to \<12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 2 to \<6 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 3 months to \<2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* Birth to \<3 months, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention."
215062807|NCT05315674|DIAGNOSTIC_TEST|Frequent assessment of biomarker panel|During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
215062808|NCT00368745|DRUG|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
215062809|NCT00368745|DRUG|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
215062810|NCT06169787|PROCEDURE|sentinel lymph node biopsy|sentinel lymph node biopsy
215062811|NCT06169787|PROCEDURE|comprehensive pelvic lymphadenectomy|comprehensive pelvic lymphadenectomy
214321800|NCT07023887|OTHER|Double Training Regimen|A hypertrophy regimen adding an additional set of lesser repetitions for a specified exercise at the end of a tri-set of exercises.
214321801|NCT06921512|BEHAVIORAL|TCM Daoyin exercise|"Participants will receive a 12-week, group-based TCM Daoyin intervention consisting of two 90-minute sessions per week (total: 24 sessions), led by qualified physicians. Each session integrates movement regulation, breath regulation, and mind regulation, aiming to alleviate anxiety and depression symptoms. Each session includes a 10-minute warm-up and a 10-minute cool-down.~Compliance and Analysis:~Per-protocol analysis will include participants who attend ≥80% of sessions (≥19/24 sessions). Safety analyses will be conducted on all enrolled participants (n=20) following the intention-to-treat (ITT) principle."
214321802|NCT06897293|PROCEDURE|Modified Broström procedure + Suture tape augmentation operation|Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation
214321803|NCT06897293|PROCEDURE|Modified Broström procedure operation|Patients with CLAI and GJL will accept the Modified Broström procedure operation
214321804|NCT06832813|DEVICE|cTBS|"Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 40s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.~1. Enhanced phase：participants received cTBS treatment for a total of 5 times a week for 2 weeks；~2. Consolidation phase：participants received cTBS treatment for a total of twice a week (at least 24 hours apart) for 8 weeks；~3. Maintenance phase：participants received cTBS treatment for a total of once a week for 8 weeks."
214321805|NCT06245473|DIAGNOSTIC_TEST|blood sample|During the blood test planned as part of the care an additional blood tube with a volume of 6mL will be takeń in an EDTA tube.
214321806|NCT06741735|DEVICE|INVU fetal monitoring system|INVU fetal monitoring system allows for at-home non-stress testing as opposed to the typical in-clinic testing
214321807|NCT06777355|OTHER|Transthoracic and Transesophageal echography within 24 hours post cardiac surgery|Transthoracic and Transesophageal echography within 24 hours post cardiac surgery in patients at risk for postoperative complications
214321808|NCT07079072|DEVICE|Acupuncture|"The main acupoints include Guanyuan (CV4), Zhongwan (CV12), Shangyintang (EX-HN3), bilateral Tianshu (ST25), bilateral Zusanli (ST36), bilateral Hegu (LI4), and bilateral Taichong (LR3). The patient adopts a supine position, and after disinfecting the acupoints, sterile cotton pads are affixed to secure needles.~In the experimental group, filiform needles measuring Φ0.30×40mm are inserted into the skin to a depth of 0.5-1 cun, achieving De Qi sensation. Needles are retained for 30 minutes. At each acupoint (except Shangyintang), manual stimulation including lifting, thrusting, twisting, and plucking is performed once every 10 minutes. The participants received 12 acupuncture sessions over a 4-week period, with three sessions per week scheduled every other day."
214321809|NCT07079072|DEVICE|Sham Comparator|The acupoints are same with those in the experimental group. The patient adopts a supine position, and after disinfecting the acupoints, sterile cotton pads are affixed to secure needles. The control group use dull needles measuring 0.30 × 25 mm, which are inserted vertically through the fixed pad until reaching the skin surface. The needles are gently lifted, twisted, and rotated slightly three times each, without piercing the skin. The needles are retained for 30 minutes, with no manipulation during this period. The participants received 12 sham acupuncture sessions over a 4-week period, with three sessions per week scheduled every other day.
215062812|NCT01162954|DRUG|DA-6034|
215062813|NCT01162954|DRUG|Placebo|
214484803|NCT06952569|OTHER|IKE System|Age-gate the access and activation of a device to authorized users of legal age
214484804|NCT06953518|DIETARY_SUPPLEMENT|Qualia Senolytic|Qualia Senolytic manufactured by Qualia Life Science
214484805|NCT06744777|DRUG|Ribavirin|Ribavirin is an antiviral medication administered as part of the intervention arm. It will be provided orally in a dosage of 15 mg/kg body weight twice daily (BD) for a duration of 7 days. The drug has demonstrated efficacy in vitro and in vivo against RNA viruses, including dengue, through mechanisms such as inosine monophosphate inhibition and immunomodulation.
214484806|NCT06744777|OTHER|Standard Treatment|"The standard treatment for dengue fever includes supportive care measures aimed at managing symptoms and preventing complications. These measures typically involve:~Intravenous (IV) fluid therapy for rehydration and maintaining hemodynamic stability.~Platelet transfusion as needed, based on clinical assessment and platelet counts.~Antipyretics for fever management (excluding non-steroidal anti-inflammatory drugs to prevent bleeding risks).~Continuous monitoring of vital signs and blood parameters, including platelet counts and hematocrit levels.~No antiviral drugs or additional pharmacological interventions are included in the standard treatment protocol."
214484807|NCT03520374|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography use for the evaluation of gastric contents
214484808|NCT04660526|OTHER|Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators|EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
214484809|NCT04660526|OTHER|Systematic bystander resuscitation instruction by 911 operators|911 operators will be able to describe how to administer CPR over the phone.
214484810|NCT04660526|OTHER|Comprehensive community training of lay people in CPR and AED use.|Training of lay people regarding CPR and AED use.
214484811|NCT04660526|OTHER|Optimized first responder performance including earlier use of AEDs.|First responders will recognize where AEDs are located and use them appropriately
214672255|NCT01142648|DRUG|Sugammadex|Sugammadex 200 mg iv, single dose, bolus.
214672256|NCT01142648|DRUG|Neostigmine and glycopyrrolate|Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
214672257|NCT03401177|DRUG|Naproxen 500 Mg|Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
214921125|NCT03969901|DRUG|Active Control|"All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents."
214921126|NCT03969901|DRUG|Oral Switch|All oral switch medications will be investigator's choice from a list of acceptable approved agents for infection types cIAI, and cUTI and will be given per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines. Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.
215062814|NCT00779428|DRUG|Tanespimycin|"Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"
215062815|NCT00395824|PROCEDURE|anticoagulation procedure|
215062816|NCT03574376|DRUG|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
215062817|NCT03574376|DRUG|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
214672258|NCT03401177|DRUG|Placebo Oral Tablet|Placebo is used, to provide a control to the active group.
214672259|NCT03401177|OTHER|Heavy resistance training|Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
214672260|NCT05259046|DIETARY_SUPPLEMENT|Menaquinone-7 (MK-7) tablet (333 µg)|One MK-7 tablet containing 333 µg MK-7 per day
214672261|NCT05259046|DIETARY_SUPPLEMENT|Placebo tablet|One placebo tablet per day
214672262|NCT04813679|DIAGNOSTIC_TEST|Bed side Ultrasound Sonography|Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
214672263|NCT03134963|OTHER|Transcranial doppler ultrasonography|Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
214672264|NCT03134963|OTHER|Blood pressure monitoring|Continuous blood pressure recording
214672265|NCT03134963|OTHER|Heart rate monitoring|Continuous heart rate monitoring
214672266|NCT03134963|OTHER|End tidal CO2 monitoring|Continuous ETCO2 monitoring
214672267|NCT03134963|OTHER|Addenbrooke's cognitive examination|Performance of a memory test
214672268|NCT04962165|DEVICE|Mandibular Advancement Device|The device maintain opened upper airway by moving the lower jaw slightly forward while sleeping.
215062818|NCT04547634|OTHER|Therapeutic Exercise and Education|The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
215062819|NCT03695614|OTHER|Cognitive Remediation Therapy|Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
214321810|NCT07079124|BEHAVIORAL|Multi-level Social Participation Intervention|The intervention will span 12 weeks and comprises five core components: (1) a health education manual, (2) a resource information package, (3) a structured library of social activities, (4) a motivational incentive kit, and (5) a training toolkit for staff.
215062820|NCT02321787|PROCEDURE|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
215062821|NCT06036355|DRUG|Oral NMN combined with DC cell vaccine|The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
215062822|NCT03079934|DEVICE|Absorb-BVS|BVS patients undergoing optical coherence tomography examination at follow-up
215062823|NCT04413656|OTHER|ablation|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
215062824|NCT04413656|OTHER|surgery|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
215062825|NCT02305589|DRUG|Sugammadex|Muscle relax reversing agent
215062826|NCT01193634|DEVICE|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
215062827|NCT01882556|DRUG|onabotulinumtoxinA|
215062828|NCT01882556|DRUG|Placebo|
214321811|NCT07079124|BEHAVIORAL|Health Education|Standardized Health Education Materials
214321812|NCT06898398|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
214484812|NCT04050280|DRUG|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)|"Induction:~G-CSF 300 mcg subcutaneously daily on days 0-5.~Cladribine 5 mg/m2 in normal saline given intravenously over 2 hours daily on days 1-5.~Cytarabine 2000 mg/m2 in normal saline given intravenously over 4 hours daily on days 1-5.~Gemtuzumab ozogamicin 3 mg/m2 intravenously over 2 hours on days 1 and 4, prior to cladribine and cytarabine.~Consolidation:~If CRMRD-, CR or CRi is confirmed by bone marrow biopsy and aspirate after induction chemotherapy, patients may receive one cycle of consolidation chemotherapy (at the discretion of the investigator) with the same CLAG-GO regimen at the same doses given for induction. In addition, the investigator has the option of giving CLAG alone without GO if there is concern for increased risk of sinusoidal obstruction syndrome.~Patients who remain in CRMRD-, CR or CRi after consolidation chemotherapy may receive up to eight infusions of GO 2 mg/m2 approximately every 28 days."
214321813|NCT06898398|PROCEDURE|Surgery|The surgical plan was based on the tumor size, tumor location, and liver function. We applied Pringle's maneuver with cycles of clamping and unclamping times of 1-10 and 5 min, respectively, and maintained the central venous pressure below 4 mmHg during parenchymal dissection to control intraoperative bleeding.
214321814|NCT06853015|DRUG|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose twice a day.
214484813|NCT06237270|PROCEDURE|Nerve transfer surgery for elbow flexion|A functioning but less important nerve (e.g. spinal accessory nerve, phrenic nerve, fascicle of median nerve, or fascicle of ulnar nerve) was transferred to nerves innervating biceps or brachialis muscle to restore elbow flexion.
214921127|NCT06959914|OTHER|Training group|Patients in the intervention group will receive AVF care training. The training will last for 8 weeks and is planned to be given once a week. In the first session, the patients in the intervention group will be introduced. Afterwards, general information will be provided about the purpose and applications of AVF training and the importance of participation in training will be emphasized. Afterwards, patients who agree to participate in the study will sign an informed consent form. In addition, the Patient Information Form, SF-12 Quality of Life Short Form, the Comfort Scale for Hemodialysis Patients and the Scale for Assessing Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients will be given and asked to answer. For those who cannot read or write, the researchers will read the survey forms. In the first session, the pre-test data of the patients will be collected and then the training books will be given.
215062829|NCT02715830|PROCEDURE|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
215062830|NCT04771416|BIOLOGICAL|PBKR03|Single dose of PBKR03, via intra cisterna magna
215062831|NCT04990063|DRUG|Chemotherapy|Standard chemotherapy drug
215062832|NCT04990063|BIOLOGICAL|Adoptive TKC transfer therapy|TKC: co-cultured autologous NK cells and γδT cells
215062833|NCT02371577|DRUG|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
215062834|NCT05156099|DEVICE|Ultrasound Scanning|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
215062835|NCT05156099|DEVICE|Ultrasound Scanning - 2 months later|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
215062836|NCT03037476|BEHAVIORAL|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
215062837|NCT03037476|BEHAVIORAL|Assessment Only|The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
214484814|NCT06548009|DIAGNOSTIC_TEST|Metabolomics and other blood samples|Blood samples taken with the objective of identifying a diagnostic test
214484815|NCT05134142|OTHER|Electronic Health Record Review|Undergo medical record review
215062838|NCT00758368|DRUG|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
214484816|NCT05134142|OTHER|Physical Performance Testing|Undergo physical performance testing
214484817|NCT05134142|OTHER|Quality-of-Life Assessment|Complete assessments
214484818|NCT05134142|OTHER|Questionnaire Administration|Complete questionnaire
214484819|NCT04773834|OTHER|Digital diabetes prevention program (dDPP)|The digital diabetes prevention program is through the Noom app, and the three devices (Fitbit physical activity tracker, Fitbit weight scale, and self-check hemoglobin a1c kit). This is a one year diabetes prevention program where participants will be expected to participate in 5 to 7 interviews over a 18 month period.
214484820|NCT04773834|OTHER|Adapted dDPP-EHR tool|This is a product of Phase 1 and 2 of this study where participants will receive detailed text messaging regarding their engagement levels in Noom app.
214484821|NCT05222984|DRUG|Decitabine|Given IV
214484822|NCT05222984|BIOLOGICAL|Navitoclax|Given PO
214484823|NCT05222984|DRUG|Venetoclax|Given PO
214484824|NCT05896163|DRUG|maplirpacept (PF-07901801)|Intravenous infusion
214484825|NCT05896163|DRUG|Glofitamab|Intravenous infusion
214484826|NCT05896163|DRUG|Obinutuzumab|Intravenous infusion
215062839|NCT04622891|DRUG|Clarithromycin 500mg|clarithromycin 500
215062840|NCT04622891|DRUG|Azithromycin|azithromycin group
215062841|NCT04622891|DRUG|Placebo|control group
215062842|NCT00005643|DRUG|pegylated liposomal doxorubicin hydrochloride|
215062843|NCT05010486|PROCEDURE|rectal surgery|
215062844|NCT03023579|OTHER|The star excursion balance test|
215062845|NCT04379479|DRUG|Dialyzable Leukocyte Extract|Experimental Intervention. Dialyzable Leukocyte Extract
215062846|NCT04379479|DRUG|Placebo oral|Placebo
214321815|NCT06853015|DRUG|Placebo|The placebo provided by the SRAL pharmacy that looks identical to the 4-AP, will be administered twice a day.
214321816|NCT06853015|OTHER|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
214321817|NCT06853015|BEHAVIORAL|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
214321818|NCT06774274|DRUG|Ketamine infusion|"A 10% ketamine solution will be prepared in a 250 cc bag of 0.9% saline (1 mg/cc) using 5 cc from a vial of ketamine that has a concentration of 50 mg/cc. The infusion will be initiated at the time of surgical site closure and will proceed as follows: a bolus of 0.35 cc/kg (equivalent to 0.35 mg/kg) will be administered, followed by a continuous infusion of 0.1 cc/kg/h (equivalent to 0.1 mg/kg/h) for up to 48 hours postoperatively.~Patients in this group will have access to a PCA pump with morphine for analgesic rescue and to monitor daily opioid consumption."
214321819|NCT06774274|DRUG|PCA Ketamine|"A mixture of 5% ketamine and 5% morphine will be prepared in a 100 cc bag of 0.9% saline. This will be achieved by using 1 cc of a ketamine vial (50 mg/cc) and 5 cc of a morphine ampule (10 mg/cc). This results in a final concentration of 0.5 mg of ketamine and 0.5 mg of morphine per cc in the 100 cc saline bag.~The pump settings will be configured as follows:~* PCA (Patient-Controlled Analgesia) dose: 2 cc (which delivers 1 mg of ketamine and 1 mg of morphine)~* Lockout interval: 6 minutes~* Maximum dose limit: 15 doses over a 4-hour period~The pump will be available for patient use for up to 48 hours postoperatively."
214321820|NCT05321758|BIOLOGICAL|Fecal Microbiota Transplantation|In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
214321821|NCT05321758|DRUG|Immunosuppressive Agents|hormones, azathioprine, thalidomide
214321822|NCT06903572|OTHER|the clinical pharmacists interventions about medication related information during transition of care|the intervention is the clinical pharmacists ' interventions regarding medication related information during transition of care .This includes reviewing medications regimen and treatment plan , documenting patients' drug history, drug related adverse events and detecting medication discrepancies.
214321823|NCT06902142|DEVICE|Adherence measured by MEMS caps|The methodological choices made in this study are justified by the need to assess the effectiveness of bictegravir, taking into account the varying levels of adherence among PLHIV. The use of electronic antiretroviral caps (MEMS caps: https://aardexgroup.com/medication-event-monitoring-system/ ) and the intra-cellular TAF assay to measure drug concentrations will enable a combined, precise and objective assessment of treatment adherence, and constitute the originality of this research.
214321824|NCT02416882|OTHER|Aerobic Exercise|Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
214321825|NCT02416882|OTHER|Resistance Exercise|Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
214321826|NCT02416882|OTHER|Sedentary Option|Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
214321827|NCT06923995|OTHER|AI-driven clinical interview|AI-driven clinical interview
214321828|NCT06922981|BEHAVIORAL|resistance training program|"Thirty-eight male and female patients aged 18-45 years, diagnosed with NSCLBP will be recruited through direct referrals from orthopedic surgeons, based on their availability to participate, thus a sample of convenience will be used, Participants will be randomly assigned as follows:~Group A:~Patients in group (A) (n=19) will receive a periodized resistance exercise program.~Group B:~The patients in group (B) (n=19) will receive a periodized aerobic exercise program"
214321829|NCT06923813|OTHER|caloric intake measurement|Detailed daily tracking of the enteral feeding provided to each patient, inclusing the type and amount of nutritional formula administered. Apart from the enteral intake, supplemental calories provided by infusion (e.g. glucose) will be recorded to ensure accurate measurement of caloric intake.
215062847|NCT02136758|BEHAVIORAL|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
214321830|NCT06923813|PROCEDURE|stool sample collection|"* a nonabsorbable blue dye marker will be administered at the start and end of the stool collection period to precisely indentify the stool produced within a specific time frame.~* stool will be collected for three days. Each sample will be collected, weighted and labeled with the date and time, then stored at -20°C.~* only stool samples from the appearance of the first dye marker to the appearance of the second dye marker will be saved and analyzed.~* bomb calorimetry preparation~  * blending and dilution: each stool sample will be put into a blender and mixed with an equal amount of water~ * freeze dying: the diluted stool will be placed into freeze-dye flasks and frozen at -20°C. The next day, the flasks will be placed into a freeze dryer for 48hours.~ * pellet formation: the freeze-dried samples will be formed into 1-gram pellets and stored until calorimetry~ * calorimetry analysis: the Parr 6200 isoperibol calorimeter will be used to measure the energy content of the stool pellets"
215062848|NCT04043403|DEVICE|Open Loop DBS|Standard DBS therapy at a constant frequency and voltage
215062849|NCT04043403|DEVICE|Adaptive (Closed Loop) DBS|DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state
215062850|NCT04043403|DEVICE|Intermittent Open Loop DBS|Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
214321831|NCT06923813|OTHER|energy expenditure measurement|performing indirect calorimetry to measure the REE of each patient
214321832|NCT06924723|PROCEDURE|tear duct probing|"In-office tear duct exploratory surgery was performed on the study participants, and the children were closely monitored for healing after the procedure.~The children were closely monitored for healing afterward, and the patients were also examined at 1 week, 1 month, and 2 months after the start of treatment."
214321833|NCT06924723|PROCEDURE|Lacrimal sac massage|At the time of the visit, the patient's parents (one of them) were given Standardized tear duct massage (Crigler massage)Teaching and hands-on practice were performed, with the researcher confirming the standardization of movements.Subsequent massages were performed by the family member who received the training, and the child's family swiped the card to access the program.completed by the family member of the child, who scanned the code to enter the small program punch card group, according to the standardized process of massage (the frequency of massage was not less than 3 times/day, each time no less than 4 eight beats)And complete the punch card on time (each punch card interval should be greater than 2 hours).(each clock interval should be more than 2 hours).
214321834|NCT03632187|DRUG|Abatacept|Subcutaneous abatacept every weeks during 3 months
214321835|NCT03632187|DRUG|Placebos|Subcutaneous placebo every week during 3 months
214484827|NCT06166563|BEHAVIORAL|Exercise Program|The intervention includes an individualized exercise program in Frequency, Intensity, Time, and Type (FITT).
214484828|NCT05805436|DRUG|Polyethylene Glycol 3350|Patients in the intervention arm will take polyethylene glycol 3350 for three days before robotic urologic surgery. Patients in the control arm will not.
215062851|NCT00002249|DRUG|Levofloxacin|
215062852|NCT05655559|OTHER|Questionnare|Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
215062853|NCT05655559|DEVICE|Moxy Muscle Oxygen Monitor|Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
215062854|NCT06272838|OTHER|Biodex balance system|In addition to the conventional exercise program, it will be applied on a platform with the Biodex balance system for 4 weeks, 5 days a week, in a total of 20 sessions.
215062855|NCT06272838|OTHER|The conventional balance exercise program|The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
215062856|NCT02603237|OTHER|Glucose tolerance test|Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
215062857|NCT02603237|OTHER|Fat tolerance test|Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
215062858|NCT03863470|BEHAVIORAL|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
215062859|NCT03277430|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
215062860|NCT03277430|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
215062861|NCT03277430|DRUG|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
215062862|NCT01675297|DRUG|Risedronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination once a week
215062863|NCT01675297|DRUG|Risedronate|Risedronate once a week
215062864|NCT06641115|BEHAVIORAL|HOPE Therapy|Helping Opioid Use and PTSD with Exposure (HOPE) therapy is an integrated 10-12 week treatment for opioid use disorder and trauma/posttraumatic stress disorder
215062865|NCT03388866|DRUG|Mite extract sublingual immunotherapy (SLIT)|Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
215062866|NCT03388866|OTHER|Placebo|Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
215062867|NCT05935657|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.1\~1.0 mg/kg/h continuous infusion
215062868|NCT05935657|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
215062869|NCT05204576|BEHAVIORAL|CBT4CBT COPES|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily IVR assessment calls
214484829|NCT04665908|OTHER|Assessment by PT/Orth surgeon|Assessment by orthopaedic surgeon or a PT
214921128|NCT06090916|OTHER|Best Practice|Receive standard nutrition care
215062870|NCT01568151|BEHAVIORAL|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
214321836|NCT06889142|DIETARY_SUPPLEMENT|Nicotinamide Mononucleotide|The dietary supplement NMN \[1,000mg\] will be taken orally by participants daily for a total of 12 weeks
214321837|NCT06908863|OTHER|Tasks learning and MRI scan|"\- 2-week learning and training phase of motor tasks and oral and facial language (OLF) tasks.~Manual fine motor tasks will correspond to activities requiring increasing precision and different types of grip (crushing a ball, modelling clay with the palm of the hand, sorting round coins with thumb/index pliers).~The OLF praxis tasks will correspond to coordinated movements of different parts of the face (cheeks, lips and tongue).~\- MRI (magnetic resonance imaging) exam, During this exam, the investigator will give to the subject instructions for a task to be carried out. These tasks will correspond to the motor tasks previously trained."
214321838|NCT06909344|DEVICE|577 nm Diode laser|All patients will be treated with sessions of the 577 nm Diode laser on one side of the face and on the other side serve as a control
214321839|NCT06909604|RADIATION|HER2 expression of PET imaging|Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with neoadjuvant therapy
214321840|NCT06908434|DRUG|GenSci128 tablets|GenSci128 tablets have three specifications, including 50mg, 200mg, 500mg, and are taken in combination with the doctor's advice in different dose levels. GenSci128 will be orally administrated daily (except single dose in Cycle 0) with no interruptions until occurrence of unacceptable toxicity, or progressive disease, or withdrawal of consent, or death, or contact lost, or starting a new anticancer therapy, etc. (whichever occurs first).
214321841|NCT06908213|PROCEDURE|Posterior vertebral fusion surgery with Enhanced Recovery After Surgery (ERAS) procedure|"This will include at least:~* A one-day hospitalization to visit the surgical unit and to provide therapeutic education to patients and their parents.~* A transition to morphine based treatments per os from intravenous morphine on the second day following surgery~* Phone calls from a surgery unit nurse 2 times a day during 5 days~* A teleconsultation with the surgeon between D3 and D5 following surgery"
214321842|NCT06908213|PROCEDURE|Posterior vertebral fusion surgery with standard of care procedure|"Patients in this group will undergo posterior vertebral fusion surgery without the set of procedures for ERAS.~They will have a first consultation with the anesthesist and the surgeon then the surgery will be planned. The discharge from hospital after surgery will not happen early and the standard of care procedures will be followed during and after surgery.~Patients will receive 2 phone calls at D1 and D5 after surgery. The patient will also have 2 appointments at the hospital for post-surgical follow-up at D45 and M12."
214321843|NCT06908772|DRUG|Glumetinib Tablets|An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
214321844|NCT06908772|DRUG|Osimertinib Mesylate Tablets|3rd EGFR-TKI
214321845|NCT06908772|DRUG|Glumetinib Tablets Placebo|Placebo
214321846|NCT06909721|DRUG|Misoprostol|to compare Misoprostol and Dinoprostone as regarding to cost-effectiveness and safety in induction of normal Labor
214321847|NCT06909084|PROCEDURE|Myringotomy with ventilation tube|Under microscope tympanic membrane was visualized after cleaning the external auditory canal and myringotomy incision was given with the help of myringotome in anteroinferior quadrant of tympanic membrane. Secretions from middle ear were drained by suction. A tympanostomy tube (Shepard tube) of appropriate size was placed in the incision and canal was packed with bismuth iodoform paraffin paste which was removed after 24 hours.
214321848|NCT06909084|PROCEDURE|Myringotomy alone|Under microscope tympanic membrane was visualized after cleaning the external auditory canal and myringotomy incision was given with the help of myringotome in anteroinferior quadrant of tympanic membrane. Secretions from middle ear were drained by suction. NO FURTHER PROCEDURE WAS DONE and canal was packed with bismuth iodoform paraffin paste which was removed after 24 hours.
214321849|NCT06908902|PROCEDURE|partial nephrectomy with main or branch renal artery clamping|Robotic-assisted laparoscopic or laparoscopic partial nephrectomy with main or branch renal artery clamping
214321850|NCT06908902|PROCEDURE|partial nephrectomy with zero renal artery clamping|Robotic-assisted laparoscopic partial nephrectomy with zero renal artery clamping
214321851|NCT06908642|DRUG|Hemay005 tablet|Hemay005 is a small molecule PDE4 inhibitor.
214321852|NCT06908642|DRUG|Placebo|Placebos are the same as drugs, but contain no Hemay005.
214321853|NCT06907979|DEVICE|TMS - Sham|Trains consisting of bursts of three stimuli at 50 hertz (Hz) repeated at 5 Hz frequency delivered at 20% of maximum stimulator output (MSO) in 20 x 2-second trains with 8-second intertrain intervals (192 seconds total)
214484830|NCT03801616|DEVICE|Virtual Reality|Virtual Reality in controlling pain
214484831|NCT04332744|DRUG|Enzalutamide|Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
214921129|NCT06090916|OTHER|Dietary Intervention|Participate in weekly support sessions with diet prescription
214921130|NCT06090916|OTHER|Medical Chart Review|Ancillary studies
214921131|NCT06090916|OTHER|Medical Device Usage and Evaluation|Record dietary and physical activity using MyFitnessPal smartphone app
214921132|NCT06090916|OTHER|Nutritional Assessment|Undergo malnutrition screening
214921133|NCT06090916|OTHER|Questionnaire Administration|Ancillary studies
214921134|NCT04680000|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)|BCBT-CP is the standard of care for behavioral management of acute and chronic pain in the Defense Health Agency Stepped Care Pain Pathway. BCBT-CP is a 7-module, CBT-based intervention for the treatment of acute and chronic pain in the primary care setting. The BCBT-CP manual was developed in a collaboration between the Defense Health Agency and the Department of Veterans Affairs as an intervention tailored for use by Behavioral Health Consultants embedded in Military Health System primary care clinics and Patient Centered Medical Homes. Details on BCBT-CP content can be found in the treatment arm description section of this listing.
214321854|NCT06907979|DEVICE|TMS - Active iTBS|Trains consisting of bursts of three stimuli at 50 Hz repeated at 5 Hz frequency delivered at 110% of measured individual motor threshold in 20 x 2-second trains with 8-second intertrain intervals (192 seconds total)
214321855|NCT06907979|DEVICE|TMS - Active cTBS|Trains consisting of bursts of three stimuli at 50 Hz repeated at 5 Hz frequency delivered at 110% of measured individual motor threshold in 1 x 40-second train (40 seconds total)
214321856|NCT06909513|DEVICE|U-shaped Travel Neck Pillow|Participants in the intervention group will receive a U-shaped travel neck pillow immediately after surgery upon arrival to the ward. The pillow will be used only during rest (supine or semi-Fowler's position) for the first 24 hours postoperatively and removed before mobilization begins. After removal, assessments will include cervical comfort using the Visual Analog Scale (VAS), pain scores during neck movements (flexion, rotation, lateral flexion-excluding extension) via VAS, the McGill Pain Questionnaire for pain localization and severity, and cervical range of motion using a universal goniometer. This intervention aims to evaluate the pillow's effectiveness in reducing neck pain, stiffness, and discomfort, and improving mobility after thyroidectomy.
214484832|NCT04332744|DRUG|Talazoparib|Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
214484833|NCT02611687|DRUG|pitolisant|Tablet
214484834|NCT02611687|DRUG|Placebo|Tablet
214484835|NCT03873805|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
214484836|NCT03873805|DRUG|Cyclophosphamide|Given IV
215062871|NCT01568151|BEHAVIORAL|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
215062872|NCT03891914|DRUG|Positron Emission Tomography using 18F-FCH|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
215062873|NCT03891914|DRUG|Positron Emission Tomography using 18F-FDG|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
215062874|NCT06355414|DRUG|Psilocybin|Drug administration under supportive conditions
215062875|NCT06355414|DRUG|Methylphenidate|Drug administration under supportive conditions
215062876|NCT06188598|BEHAVIORAL|Time-restricted eating|Eating is restricted to an 8-hour window that is the same each day (e.g., 10am - 6pm)
215062877|NCT03979469|DRUG|Ketamine, dexmedetomidine|Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively
215062878|NCT03979469|DRUG|fentanyl, remifentanil|Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
215062879|NCT00931125|DRUG|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
215062880|NCT00931125|PROCEDURE|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
215062881|NCT02789358|OTHER|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
215062882|NCT02789358|OTHER|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
215062883|NCT02789358|DEVICE|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
215062884|NCT02789358|DRUG|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
215062885|NCT02789358|DEVICE|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
215062886|NCT01498692|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
215062887|NCT04923737|DRUG|Dexmedetomidine|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
215062888|NCT04923737|DRUG|0.9% sodium chloride|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
215062889|NCT02727595|DEVICE|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
215062890|NCT03956992|OTHER|Mouth gel|Stop using the mouth gel
215062891|NCT00352469|DRUG|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
214484837|NCT03873805|DRUG|Fludarabine|Given IV
214484838|NCT03873805|DRUG|Fludarabine Phosphate|Given IV
214484839|NCT04848974|DRUG|Cladribine|Given IV
214484840|NCT04848974|DRUG|Cytarabine|Given SC
214484841|NCT04848974|DRUG|Uproleselan|Given IV
214484842|NCT01057628|DRUG|ipragliflozin|oral
215062892|NCT04916561|DIAGNOSTIC_TEST|RT-PCR|Detection of Covid-19 in bone, articular fluid and muscle samples using RT-PCR
215062893|NCT02045888|DEVICE|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
215062894|NCT02045888|BIOLOGICAL|Placebo|Placebo is visually matched solution
215062895|NCT04719481|DRUG|Pravastatin Sodium 80 MG|daily oral administration of 80mg
215062896|NCT04719481|DRUG|Placebo|daily oral administration
215062897|NCT03441529|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
215062898|NCT03441529|DRUG|Piperacillin/Tazobactam|Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
215062899|NCT00907322|DRUG|Dimebon|Oral tablet; 20 mg Dimebon, single dose
215062900|NCT00907322|DRUG|Dimebon|Oral tablet; 40 mg Dimebon, single dose
215062901|NCT00907322|DRUG|Dimebon|Oral tablet; 60 mg Dimebon, single dose
215062902|NCT00907322|DRUG|Dimebon|Oral tablet; placebo, single dose
215062903|NCT04300205|DEVICE|High intensity LED light device|Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
214321857|NCT06909370|BEHAVIORAL|peer education|"The training titled The Effect of Peer Education on Human Papillomavirus (HPV) for Students in the Faculty of Health Sciences on Knowledge, Awareness, and Concern Levels includes scientific and up-to-date information about HPV transmission methods, prevention, risk factors, treatment methods, and vaccination. The content of the training aims to provide students with accurate information about HPV, as well as highlight the negative health effects of the virus, particularly its association with serious diseases like cervical cancer. The training seeks to increase students' awareness of HPV and help them manage their levels of concern about the virus. Through the peer education method, students were able to interact with each other, thus providing a more effective learning experience."
214484843|NCT01057628|DRUG|placebo|oral
214484844|NCT04745754|OTHER|Embedded primary care in cancer survivorship model|Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
214484845|NCT00262717|DIAGNOSTIC_TEST|Blood test: genotype testing|
214921135|NCT04680000|OTHER|BCBT-CP Booster|The BCBT-CP Booster is a telephone or videoteleconference-based booster contact designed to extend the benefits of the standard of care BCBT-CP intervention. BCBT-CP Booster contacts are not clinical interventions (i.e., no new clinical content is provided), but are intended to help motivate patients to use BCBT-CP module content, problem-solve BCBT-CP skills practice and offer reminders for future appointments. BCBT-CP Booster content was developed using feedback from focus groups with patients who completed standard BCBT-CP treatment in a military primary care clinic. Details on BCBT-CP Booster contacts can be found in the treatment arm description section of this listing.
214921136|NCT06969131|PROCEDURE|Open Partial Nephrectomy|Patients underwent open partial nephrectomy.
214921137|NCT06969131|PROCEDURE|Laparoscopic Partial Nephrectomy|Patients underwent laparoscopic partial nephrectomy.
215062904|NCT04300205|DEVICE|Sham LED light device|Participants have the light treatment moved off their wound after masking
215062905|NCT00408707|PROCEDURE|local infiltration analgesia|
215062906|NCT01208324|DRUG|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
215062907|NCT01208324|DRUG|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
215062908|NCT01208324|DRUG|Placebo Patch|placebo
215062909|NCT01208324|DRUG|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
215062910|NCT05940857|DEVICE|OCS Liver|The TransMedics® Organ Care System (OCS) Liver is an FDA approved portable extracorporeal liver perfusion and monitoring system.
215062911|NCT01101282|DEVICE|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
215062912|NCT02236234|BIOLOGICAL|HPV vaccine|HPV vaccine
215062913|NCT02448992|RADIATION|hippocampal-sparing WBRT|
215062914|NCT00140179|DRUG|valnoctamide|
215062915|NCT02707965|DRUG|Oxcarbazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
215062916|NCT02707965|DRUG|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
215062917|NCT02707965|DRUG|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
215062918|NCT02707965|DRUG|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
215062919|NCT02707965|DRUG|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
215062920|NCT02707965|DRUG|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
215062921|NCT02707965|DRUG|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
215062922|NCT02707965|DRUG|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
215062923|NCT03970876|BIOLOGICAL|ATGC-100|Clostridium Botulinum Type A
215062924|NCT03970876|BIOLOGICAL|Botox®|Clostridium Botulinum Type A
215062925|NCT01635270|RADIATION|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
215062926|NCT01635270|RADIATION|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
215062927|NCT03862612|PROCEDURE|regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block|Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
215062928|NCT03685474|BEHAVIORAL|Facing Your Fears - School Based|Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.
215062929|NCT03685474|BEHAVIORAL|Usual Care|Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
215062930|NCT04497363|DEVICE|Brainsonix Pulsar 1002|Each participant will undergo 8 consecutive weekly sessions (each session is 10 minutes long) of focused ultrasound with the Brainsonix Pulsar 1002 device.
215062931|NCT00954629|DRUG|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
215062932|NCT00954629|DRUG|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
215062933|NCT03292549|PROCEDURE|Robotic partial surgery|Robotic partial surgery
215062934|NCT00046761|DRUG|ONO-2506|
215062935|NCT02520869|PROCEDURE|swim-up technique|swim-up technique used
215062936|NCT02520869|PROCEDURE|zeta test technique|zeta test technique used
215062937|NCT03487588|DRUG|A-101 Topical Solution|A-101 Topical Solution applied Day 1, Day 15 and Day 29
215062938|NCT04972682|PROCEDURE|Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy|Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy (BSO), and sentinel lymph node (SLN) biopsy are executed by 1 of 5 experienced gynecologic oncologists. SLN mapping utilizes indocyanine green (ICG) at a standard concentration of 2.5 mg/mL - 1 mL is injected into the cervix at the 3 and 9 o'clock positions (total dose - 5 mg) to a depth of 5-10 mm, initiated right after general anesthesia induction. Diagnostic laparoscopy employs the Image 1S equipment (KARL STORZ©, Tuttlingen, Germany). Upon examination, fluorescence in the near-infrared spectrum is observed. Successful mapping is indicated by identifying a lymphatic vessel with at least one LN. Detected SLNs are then extracted, and the total hysterectomy with BSO is completed. SLN frozen section remains at the surgeon's discretion. If metastasis surfaces in the SLN either during the frozen section or routine assessment, the option for systematic LN dissection in a subsequent procedure exists although not mandatory.
215062939|NCT01163357|DRUG|bortezomib|Given IV
214321858|NCT06909032|RADIATION|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) will be delivered using Volumetric Modulated Arc Therapy (VMAT). Treatment will be started within 12 weeks of breast conserving surgery and within four weeks of randomisation. Treatment will occur in five (5) once-daily sessions and should be completed within seven (7) days of starting radiotherapy. Two total doses of APBI will be compared: 30 Gy and 26 Gy. The aim is to determine whether quality of life is no worse when a higher dose of APBI is used compared to a slightly lower dose of APBI. The results of this study will help to guide doctors choose the best dose of APBI for patients with early breast cancer in the future.
215062940|NCT01163357|DRUG|fludarabine phosphate|Given IV
215062941|NCT01163357|OTHER|melphalan|Given IV
214321859|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214321860|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
214321861|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
214484846|NCT06424301|DRUG|Targeting NUDT21 siRNA drugs|It is performed for intravitreal chemotherapy.
215062942|NCT01163357|RADIATION|total marrow irradiation|Undergo TMI
215062943|NCT01163357|DRUG|tacrolimus|Given IV and orally
215062944|NCT01163357|DRUG|sirolimus|Given orally
214321862|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
215062945|NCT01163357|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
215062946|NCT01163357|OTHER|laboratory biomarker analysis|Correlative studies
215062947|NCT00417378|DEVICE|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
215062948|NCT00417378|DEVICE|Intraaortic Balloon Pump|Counterpulsation
215062949|NCT00748618|DIETARY_SUPPLEMENT|Standard vitamin D3 treatment|10,000 I.U./wk of vitamin D3 orally for 6 months
214321863|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
214321864|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
214321865|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.2 Usage|Participants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks.
214321866|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
215062950|NCT00748618|DIETARY_SUPPLEMENT|High dose vitamin D3 treatment|50,000 I.U./wk of vitamin D3 orally for 6 months
215062951|NCT04338178|BEHAVIORAL|Cognitive Remediation Therapy (CRT)|This intervention consists of mental exercises aimed at improving executive function via practice. Simple cognitive tasks that encourage reflective learning and insight into patient's own thinking process are administered. Exercises target set-shifting (i.e., cognitive flexibility), estimating, organization and planning.
215062952|NCT04338178|BEHAVIORAL|Emotional Skills Training (EST)|EST places emphasis on the improvement of inner emotion awareness, facial and body expression recognition and intra- and interpersonal emotion regulation skills. Different modules and interactive exercises are designed to help patients learn about i) the functions and manifestations of emotions, ii) the identification and labelling of own's and others' emotions, iii) tolerating and communicating emotions, and iiii) balancing between negative and positive emotions.
215062953|NCT04338178|BEHAVIORAL|Cognitive Behavioral Therapy|CBT intervention aimed to manage food craving by teaching group members cognitive (e.g., restructuring of urge-related thoughts) and behavioural strategies (e.g., increasing awareness through food diaries, relaxation skills, identification of cues that trigger craving, avoidance of high-risk situations for craving, distraction).
215062954|NCT04338178|PROCEDURE|Multidisciplinary outpatient program|Multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches. Patients are regularly followed and educated about the importance of lifestyle changes including healthy dietary habits and exercise in weight reduction and maintenance. Patients are also usually given information about nutritional value of various foods and few simple exercises for decreasing and maintaining body weight. This program is therefore planned as part of the usual care and responds to the recommendations of good practice for obesity
215062955|NCT05480982|BEHAVIORAL|Cognitive functional therapy via tele rehabilitation|Participants in the CFT group will be treated by a physiotherapist with seventeen years of clinical experience and that has attended six CFT workshops with three of the international tutors of the method. She has completed 212 hours of training including workshops, patient examinations and a pilot study under the supervision of a physiotherapist with more than seven years of clinical experience in CFT. Another two physiotherapists, one with more than fifteen years and the other with more than ten years of clinical experience, and both with more than 106 hours of CFT training including CFT via tele physiotherapy, will complete the staff.
215062956|NCT05480982|OTHER|Pilates via tele rehabilitation|Physiotherapist will have the freedom to judge about the exercises´ progression and the need of adaptation considering both the level of difficulty to perform each exercise according to the original proposal and the individual´s demands. The treating physiotherapists will have at least 2 years of clinical practice in Pilates and clinical experience in Pilates via teleconference.
215062957|NCT00301145|BEHAVIORAL|smoking cessation intervention|
215062958|NCT00301145|DRUG|varenicline|
215062959|NCT00301145|OTHER|counseling intervention|
215062960|NCT00301145|OTHER|internet-based intervention|
215062961|NCT02854436|DRUG|Niraparib|Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.
214321867|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
214321868|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
214321869|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
214321870|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
214321871|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 6|Participants will use their Placebo Control Form 6 as directed for a period of 6 weeks.
214321872|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1 Usage|Participants will use their Radicle Clarity Active Study Product 6.1 as directed for a period of 6 weeks.
214321873|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control 6.1.0|Participants will use their Placebo Control 6.1.0 as directed for a period of 6 weeks.
215062962|NCT06430242|DEVICE|Tele rehabilitation|In the active group, one of the co-investigators will install and demonstrate the use of the mobile app (Rehab App) on participants' mobile phone and explain the use of the software. The participants will be followed up for the duration of their enrolment in the e-health and tele-rehabilitation service, which can last up to 2 months.
215062963|NCT06430242|OTHER|Exercise|Participants in the control group will get the usual treatment from the clinical staff and in-person education, and they will be supervised by one of the assigned research team members every week.
215062964|NCT02676674|DRUG|Dose 1|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
215062965|NCT02676674|DRUG|Dose 2|Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
214484847|NCT06800833|OTHER|Low fat cookies|To determine the effects of low fat cookie consumption on physiological indicators of sexual, mental, skin, and gut health
214484848|NCT06800833|OTHER|Mango|To determine the effects of mango consumption on physiological indicators of sexual, mental, skin, and gut health
214484849|NCT06435260|DRUG|Camrelizumab+chemotherapy|"Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy:~AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles.~Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles."
214484850|NCT06435260|RADIATION|hypofractionated radiotherapy|Hypofractionated radiotherapy:PGTV=30Gy/5F(PTV≥25Gy/5F),
214484851|NCT04700800|OTHER|Exercise|Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake
214484852|NCT04700800|OTHER|Infusion of Amino Acids|Intravenous infusion of mixture of amino acids
214484853|NCT06003153|DRUG|oral semaglutide|Semaglutide is the only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for treatment of type 2 diabetes. Participants will receive 7 mg of oral semaglutide once daily for 14 days in between Visit 1 and Visit 2.
214921138|NCT06967376|PROCEDURE|Corneal Collagen Cross-Linking Solutions|Topical anaesthesia was achieved using 0.4% benoxinate hydrochloride drops. Epithelium was removed up to 9 mm diameter. Corneal thickness of the area to be treated was measured (without epithelium) aiming for a starting thickness of no less than 350μm. Corneas thicker than 500μm were dehydrated to reduce thickness by using 70% Glycerol drops applied topically at intervals of 2-3 seconds for a total of five minutes. A schematic representation of PACK-CXL protocol is provided in Figure 1. Iso-osmolar riboflavin drops were instilled topically on the cornea at regular intervals of 2 minutes for a total period of 30 minutes. Thickness was also re-measured every 5 min to ensure that it remained below 500µm during instillation of riboflavin. The cornea was illuminated using a UVX, UV-A 365 nm with an irradiance of 3 mW/cm2 for 30 minutes and a total dose of 5.4 J/cm2 during which riboflavin was instilled every 2 min and corneal pachymetry performed every 5 min. PACK-CXL was performed in a 9
214921139|NCT06967376|DRUG|Topical Antimicrobial/Antifungal Medications|Initial antimicrobial therapy for both groups consisted of fortified vancomycin eye drops 50 mg/ml, fortified ceftazidime eye drops 50 mg/ml hourly, and the antifungal agent itraconazole 100 mg orally twice per day. This regimen was subject to change according to microbiology culture sensitivities and/or results.
214484854|NCT06003153|OTHER|Mixed Meal Tolerance Test (MMTT)|The MMTT is developed by the Metabolism and Nutrition Metabolic Kitchen at the MGH TCRC. The meal is a high-calorie, high-carbohydrate and moderate-to-high glycemic index challenge composed of commonly consumed breakfast food items. It provides nearly 90 grams of carbohydrates and mimics an oral glucose challenge. The participants will undergo a MMTT at Visit 1 and Visit 2.
214921140|NCT06969365|OTHER|10-pound weighted lap-pad|10-pound weighted lap pad will be placed over the patient's chest and shoulders
214484855|NCT06382844|DIAGNOSTIC_TEST|Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).|Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)
214484856|NCT06580002|DRUG|Riluzole|Given PO
214484857|NCT06580002|DRUG|Placebo|Given PO
214484858|NCT01917942|DEVICE|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
214484859|NCT01917942|OTHER|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
214484860|NCT05442580|DRUG|3x10(6) CART-38 cellls|3x10(6) CART-38 cells via intravenous infusion
215062966|NCT04283955|DRUG|High-dose MTX based chemotherapy|Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6\~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7\~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
215062967|NCT03975335|BEHAVIORAL|Health education|In this health education intervention, emphasis is given on evoking adolescents' internal desire to change, supporting self-efficacy to be changed, guiding self-regulatory ways along with facilitating desired changing process by empowering them with choices and skills.
215062968|NCT03975335|OTHER|Carrier Guidance|Carrier opportunities and counselling
215062969|NCT01977729|DRUG|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S\<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
215062970|NCT01977729|BEHAVIORAL|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
214921141|NCT06969365|OTHER|blanket|A simple, unweighted blanket will be applied to patients during IUD insertion
214921142|NCT06967844|PROCEDURE|Simultaneous motor-cognitive task training|"16 sessions (2 sessions per week) for 8 weeks, 40 min per session~1. walking while counting walk 5, 10 and 15 meters while counting backward by ones, threes and sevens~2. balancing on one foot while naming or solving puzzles stand on one foot for 10, 20 and 30 seconds while naming animals. solving simple and complex puzzles~3. ball toss and recall toss ball at 3, 5 and 7 meters distance while recalling three-word, five-word and seven-word lists"
214921143|NCT06967844|PROCEDURE|Sequential motor-cognitive task training|"16 sessions (2 sessions per week), for 8 weeks, 20+20 min per session with 20 min break in between~motor training~1. Standing on one foot standing on one foot for 10, 20 and 30 seconds~2. Heel to toe walk walking heel to toe for 5, 10 and 15 meters~3. Leg swings 10 swings, 15 swings and 20 swings per leg cognitive training~4. Memory games recall three-word, five-word and seven-word lists~5. Problem solving tasks simple, moderate and difficult arithmetic problems"
214921144|NCT02866292|OTHER|Pelvic floor muscle and sexual function evaluation|"PFM evaluation was performed by vaginal palpation and vaginal squeeze pressure. During vaginal palpation the physiotherapist introduced the index and middle fingers about 4cm inside the vagina, and requested to hold the maximum contraction of the PFM. Muscle function was classified by the Oxford Scale Modified.~The vaginal squeeze pressure was measured through Perineometer.To obtain the measurements, the subjects remained positioning and vaginal sensor was introduced into the vaginal cavity. The women were oriented and motivated verbally to perform three voluntary maximal contractions sustained for five seconds and one minute interval between them.~Sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The questionnaire consists of 19 multiple-choice questions, which involves six sexual response domains: desire, arousal, lubrication, orgasm, satisfaction and pain."
214921145|NCT06969248|BEHAVIORAL|Intervention Group|Fathers will be provided with a total of 8 weeks of training and videos. The training will cover the role of fatherhood and its historical development, the developmental stages and care needs of babies, ways for fathers to participate in baby care and the benefits of participation, father-infant bonding and influencing factors, and paternal depression. Videos on the subject will be shared with fathers.
214921146|NCT06969144|PROCEDURE|cholecystectomy|The indications for elective cholecystectomy were symptomatic cholelithiasis, a GB polyp more than ten millimeters, a history of cholecystitis, biliary pancreatitis, or choledocholithiasis. Patients with cholecystitis and severe or moderately severe pancreatitis were operated on after six weeks of the event. Other patients received surgery at the earliest available date. All patients with choledocholithiasis underwent endoscopic retrograde cholangiopancreatography (ERCP) and stone clearance before cholecystectomy. Patients who underwent laparoscopic cholecystectomy were evaluated by surgical and anesthesia teams in outpatient clinics and co-morbid conditions were optimized. Preoperative antibiotic prophylaxis was given to all the patients before induction of anesthesia.
215062971|NCT04360005|DRUG|Asciminib|Patients receive Asciminib
215062972|NCT01268046|DRUG|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
215062973|NCT01268046|DRUG|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
215062974|NCT01268046|DRUG|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
215062975|NCT01268046|DRUG|placebo oral capsule|placebo oral capsule administered daily for one month.
215062976|NCT01821092|PROCEDURE|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
215062977|NCT01821092|DEVICE|osseointegrated implant|Osseointegrated Implant Insertion
215062978|NCT02378077|PROCEDURE|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
214321874|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1.1 Usage|Participants will use their Radicle Clarity Active Study Product 6.1.1 as directed for a period of 6 weeks.
215062979|NCT02378077|PROCEDURE|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
215062980|NCT02378077|DIETARY_SUPPLEMENT|Fish Oil Supplement|Fish Oil supplementation for three months.
215062981|NCT03366025|DIAGNOSTIC_TEST|Serum progesterone measure|Serum Progesterone will be measured in all donors on the day triggering at 8:00 am, 12:00 p, 16:00 pm and 20:00 pm
215062982|NCT00003065|BIOLOGICAL|filgrastim|
215062983|NCT00003065|DRUG|paclitaxel|
215062984|NCT00003065|DRUG|topotecan hydrochloride|
215062985|NCT06329466|OTHER|intervention (EFT) group|It is the group to which EFT is applied.
215062986|NCT05273814|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d4
215062987|NCT05273814|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
215062988|NCT05273814|DRUG|Bevacizumab|Pemetrexed intravenous infusion 7.5mg/kg，d1
215062989|NCT05233488|DEVICE|Pulsed Ultrasound Therapy|Ultrasound therapy is applied in the pulsed mode.
215062990|NCT05618210|OTHER|regional anesthesia|"in the ESPB group, the linear ultrasound probe was placed in the erector spina muscles were visualized on the side where VATS was planned. block needle can be seen on ultrasound, the skin and erector spina muscles are passed in the cranio-caudal direction. ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.~In the rhomboid intercostal block group, the ipsilateral arm is positioned towards the chest, allowing the scapula to move laterally and the area called auscultation triangle to be opened, and after the skin disinfection of the surgical side; By using a linear ultrasound probe, the rhomboid major and intercostal muscles will be defined in the auscultation triangle region, and T5-6 level with an in-plane approach with 20 ml of 0.5% bupivacaine and local anesthetic injection."
215062991|NCT02140606|DRUG|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
215062992|NCT05476887|DRUG|KP104|KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.
214921147|NCT06967168|BEHAVIORAL|Virtual consultation|Virtual (telephone) consultation with a podiatrist, who will provide self-management advice to the participant including advice on footwear, massage, and stretching. Supplemented by written advice leaflets.
215062993|NCT00224120|DRUG|Silodosin|8 mg daily for 12 weeks
215062994|NCT00224120|OTHER|Placebo|One capsule daily for 12 weeks
214921148|NCT06967168|BEHAVIORAL|Self-help video|Self-help video providing self-management advice to the participant including advice on footwear, massage, and stretching. Available online or as a DVD.
214921149|NCT06967168|DEVICE|Orthotics|"Provision of orthotics following an in-person musculoskeletal assessment by a podiatrist to check foot function, footwear, and position of feet, ankles, knees, and hip.~Podiatrists prescribe, produce, and fit orthotic devices to be worn inside footwear. The devices used in this feasibility study will be selected according to individual patient needs. All will have regulatory certification (CE mark) and will be used in accordance with the manufacturer's Instructions For Use."
214921150|NCT06967168|DEVICE|Shockwave therapy|"A 3-week course of Shockwave therapy following an in-person musculoskeletal assessment by a podiatrist to check foot function, footwear, and position of feet, ankles, knees, and hip.~Extracorporeal shockwave therapy (ESWT) is delivered by a podiatrist in an outpatient clinic. Most patients lie down during the procedure. The machine passes pulses of energy through the skin towards the injured area of the heel. This encourages the body to respond and aims to stimulate the healing process. Participants will need to attend the clinic approximately once a week for three weeks to complete the course of treatment."
214921151|NCT05162924|OTHER|Spinal Manipulation|Manual therapy technique applied by a chiropractor in the form of a high-velocity low-amplitude force to the lumbopelvic spine
214321875|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1.2 Usage|Participants will use their Radicle Clarity Active Study Product 6.1.2 as directed for a period of 6 weeks.
214321876|NCT04132492|OTHER|no intervention|there is no intervention
214321877|NCT06908187|OTHER|Opt-In Early Latinx intervention|Participants will access to the Opt-In Early training program website, but will be able to access the Spanish language version as well. Families will fill out a usage diary to record their experience.
214321878|NCT06908187|OTHER|Opt-In Early Rural Intervention|Participants will access to the Opt-In Early training program website. Parents will be able to interact with the rural community-oriented aspects of the program. Families will fill out a usage diary to record their experience.
214321879|NCT06908668|DRUG|Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy|"1. Recommended Chemotherapy Regimen and Doses:~   Albumin-bound Paclitaxel 260 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles, followed by Epirubicin 90 mg/m² on Day 1 + Cyclophosphamide 600 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles.~2. Recommended Immunotherapy Dose:~   Adebrelimab 1200 mg, repeated every 3 weeks, starting simultaneously with neoadjuvant chemotherapy and continuing for 1 year (including postoperative administration).~3. Radiotherapy:~Preoperative Radiotherapy:~Positioning: Immobilization with a neck-chest integrated frame, combined CT and MRI positioning with image fusion. Diagnostic MRI images can also be fused simultaneously. CT positioning should be performed with a plain scan, with a slice thickness of 3 mm. MRI positioning should include at least three sequences: T1-enhanced, T2 fat-suppressed, and DWI.~Target and Normal Organ Contouring:~GTVp (Gross Tumor Volume - Primary): Define the breast tumor target area based on MRI, CT, physical examination, and ultrasound"
214321880|NCT06908668|DRUG|Neoadjuvant Chemotherapy Combined with Immunotherapy|"1. Recommended Chemotherapy Regimen and Doses:~   Albumin-bound Paclitaxel 260 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles, followed by Epirubicin 90 mg/m² on Day 1 + Cyclophosphamide 600 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles.~2. Recommended Immunotherapy Dose:~Adebrelimab 1200 mg, repeated every 3 weeks, starting simultaneously with neoadjuvant chemotherapy and continuing for 1 year (including postoperative administration)."
214321881|NCT06909149|DRUG|Amniotic membrane extract eye drops|Patients received the amniotic membrane extract eye drops once every two hours during waking time as an adjunctive therapy to the specific treatment.
214321882|NCT06909149|DRUG|Specific treatment|Patients received the specific treatment only.
214321883|NCT06908122|DIAGNOSTIC_TEST|laboratory biomarkers in the diagnosis of NAFLD disease|"All included patients will be assessed as follows:~1\. Questionnaire: different questionnaire variables extrapolated from study published by Xin Li, 2024, Bao et al., 2024 (8), (9).The questionnaire will be divided into six parts: First section includes demographic characteristics of patients as (name , age, gender, occupation, educational level and special habits) The second section includes chronic diseases-related questions and drug administration as if a patient were diagnosed with chronic disease, on treatment and drugs used.~The third section for assessment of dietary lifestyle includes:~nutrition adherence to Mediterranean will be assessed by a validated 17-item MedDiet adherence questionnaire, which all participants will answer. A score will be given for each met objective: 1 (compliance) or 0 (non-compliance).~The counseling session will be about the Mediterranean diet program, and a brochure will be given to each patient."
214484861|NCT05442580|DRUG|7x10(5) CART-38 cells|7x10(5) CART-38 cells via intravenous infusion
214484862|NCT05442580|DRUG|7x10(6) CART-38 cells|7x10(6) CART-38 cells via intravenous infusion
214484863|NCT05442580|DRUG|3x10(7) CART-38 cells|3x10(7) CART-38 cells via intravenous infusion
214484864|NCT05442580|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered at physician discretion
215062995|NCT01707680|OTHER|SOC|Patient are given standard of care
215062996|NCT04566952|DRUG|Anlotinib|Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.
215062997|NCT04566952|DRUG|Olaparib|Olaparib will be treated with a total daily dose of 450 or 300mg.
215062998|NCT05260138|OTHER|Gentle Body message|The intervention group received gentle body massage twice/day and position change from supine to lateral every two hours under the phototherapy for three consecutive days in addition to routine NICU care.
215062999|NCT05260138|OTHER|Routine NICU Care|received the conventional NICU care of infants undergoing phototherapy. Phototherapy was given by single Blue LEDs emitting light in a narrow spectrum (450-470 nm). Initially, phototherapy lamps were checked and adjusted at the height of 30 cm from the neonates who were kept naked in the incubator/crib except for the reproductive organs with shielded eyes. The neonates were positioned supine under the phototherapy. The treatment was given continuously, except while feeding and nursing for 30 minutes every 3 hours. The neonates' skin was cleaned with warm water without applying any sorts of ointments oils or creams. They were also observed for signs of dehydration.
214484865|NCT05442580|DRUG|Fludarabine|Lymphodepleting chemotherapy administered at physician discretion
214484866|NCT04520087|PROCEDURE|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
214484867|NCT04425018|DRUG|Paclitaxel|Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.
214484868|NCT04425018|DRUG|Pertuzumab|Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
214484869|NCT04425018|DRUG|Margetuximab|Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
214484870|NCT04425018|DRUG|Trastuzumab|Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
214484871|NCT05755711|DEVICE|Shockwave Medical Coronary IVL System|Coronary Intravascular Lithotripsy (IVL)
214484872|NCT06241183|DRUG|Intravenous Famotidine|Patients in this group will receive 20mg IV Famotidine.
214484873|NCT06241183|DRUG|Oral Maalox/ Mylanta|Patients in this group will receive 30 ml Maalox/ Mylanta.
214484874|NCT06099665|BEHAVIORAL|Automated alert|Receiving an automated alert via the EHR to highlight that the patient in question presents for severe aortic stenosis or severe mitral regurgitation according to the AHA guidelines and that they are a good candidate for valve intervention. The alert will not list any specific manufacturer's device.
214484875|NCT06463314|DEVICE|Multiplo TP/HIV Antibody Test|"The Multiplo TP/HIV Antibody Test (MedMira Laboratories Inc., Halifax, NS), \[Multiplo TP/HIV Test\] is a single use, rapid, vertical-flow in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus (HIV) Type 1/Type 2 and Treponema pallidum (Syphilis) in human fingerstick blood. The Multiplo® TP/HIV Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than five minutes. The Multiplo TP/HIV Test has not yet sought approval for self-testing. All required pre and post-test counselling guidelines must be followed in each setting in which the Multiplo TP/HIV Test is used. Results are read visually."
214484876|NCT04239157|BIOLOGICAL|Canakinumab|Given SC
214484877|NCT03099681|OTHER|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
214484878|NCT06424249|OTHER|Virtual Reality|A progressive rehabilitation protocol (different levels according to success scores) consisting of several exercises using virtual and augmented reality with mechanical perturbations (pitching of the treadmill), interaction with the virtual environment, interaction with the virtual environment and augmented reality (projection of obstacles on the treadmill), and modification of the gait pattern with visual and/or audio biofeedback
214484879|NCT06424249|OTHER|Standard rehabilitation|A treadmill walking protocol with virtual reality to immerse the patient in a 3 x 5-minute walking session, without visual, mechanical or auditory disturbances, and without prompting the patient to modify their walking pattern.
214484880|NCT05765851|DRUG|DS-1103a|One IV infusion Q3W on Day 1 of each 21-day cycle
214484881|NCT05765851|DRUG|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
214484882|NCT06032988|DIETARY_SUPPLEMENT|LactoLevure|Participants will receive LactoLevure\^R probiotic dietary supplement or matching placebo once a day.
214484883|NCT05373537|BEHAVIORAL|Cognitive behavioral therapy for Insomnia|Caregiver with insomnia will receive CBT-Insomnia and will be trained to implement CBT-I tailored for their child with Autism Spectrum Disorder and Insomnia
214484884|NCT06098170|BEHAVIORAL|Unguided use of the My SCI Toolkit program|Participants will be asked to use the My SCI Toolkit program for 8 weeks (without a coach), following the prompts and guides built into the program.
214484885|NCT06098170|BEHAVIORAL|Coached My SCI Toolkit|Participants will be asked to use the My SCI Toolkit program for 8 weeks, following the prompts and guides built into the program. Participants will also have weekly phone calls (the first is about 30-45 minutes, and the rest are about 15 minutes) with a study coach. The coach can help answer questions and tailor the skills more to the participant's goals and needs. The coaching sessions will be audio recording for fidelity purposes.
215063000|NCT02422693|OTHER|Aquatic Exercises|Exercises performed in the water.
215063001|NCT02422693|OTHER|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
215063002|NCT00282087|DRUG|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
215063003|NCT05556083|DRUG|Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
215063004|NCT05556083|DRUG|Placebo oral tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
215063005|NCT03072394|DRUG|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
215063006|NCT03072394|DRUG|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
215063007|NCT01312805|OTHER|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
215063008|NCT01312805|OTHER|CHICA Control|This is CHICA without the asthma module, and was used as a control
215063009|NCT00861172|PROCEDURE|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
215063010|NCT00740441|DRUG|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
215063011|NCT02788032|OTHER|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
215063012|NCT05330494|OTHER|transcutaneous electrical acupoint stimulation(TEAS)|transcutaneous electrical acupoint stimulation (TEAS), the modern therapies derived from traditional acupuncture, which could activate nerve endings or fibers and generate action potentials.s. TEAS uses self-adhesive electrodes placed on the surface of acupoints, instead of needles for electrical stimulation.The resulting stimulation signals, which are transmitted to the spinal cord and brain, stimulate the central nervous system to generate specific chemical mediators to induce relevant physiological effects.
214484886|NCT03554902|PROCEDURE|Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
214484887|NCT02390869|DRUG|R2-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
214484888|NCT02390869|DRUG|R-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
214484889|NCT06415682|DEVICE|SMA+M1 Transcranial Magnetic Stimulation|"The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). For SMA stimulation, a 5s burst of 10Hz rTMS was repeated 20 times (1000 pulse, 20 minutes' duration).~Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex (M1) of the lower leg and supplementary motor area (SMA)."
214484890|NCT06415682|DEVICE|M1 Transcranial Magnetic Stimulation|The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). Patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral M1 of the lower leg.
214484891|NCT06415682|DEVICE|Sham Transcranial Magnetic Stimulation|Patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on M1 of the lower leg.
214484892|NCT05111093|DEVICE|ARC-IM Investigational System implantation|Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
214484893|NCT03983382|DIAGNOSTIC_TEST|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
214484894|NCT01161732|PROCEDURE|Early surgery|Early surgery is performed within 2 months of randomization.
214484895|NCT06949176|PROCEDURE|Root canal tratment using mecchanical and chemical preparation.|Root canal procedures including access cavity preparation, chemomechanical instrumentation, irrigation with sodium hypoclorite (NaOCl), microbiological sampling and obturation with warm vertical compaction.
214484896|NCT06949176|DRUG|Sodium Hypochlorite.|Sodium Hypoclorite used as the primary irrigant in the root canal treatment at concentrations of 2.5% (Group A) and 5% (Group B).
214484897|NCT06949176|DRUG|Hydrogen peroxide.|Applied to the operating field and tooth as part of initial disinfection prior to cavity access.
214484898|NCT06949176|DRUG|Sodium Sulfate.|Used to inactivate sodium hypoclorite prior to sample collection.
214484899|NCT06949176|DEVICE|Root ZX mini apex locator (Morita).|Used to determine the working length of the root canal.
214921152|NCT05162924|OTHER|Placebo|Placebo spinal manipulation consisting in the application by a chiropractor of a lower-velocity lower-amplitude force to gluteal muscles in a non-intentional direction
214921153|NCT06968364|DEVICE|Cervisense Intravaginal Probe V0.1 cervical stiffness evaluation.|The Cervisense Intravaginal Probe V0.1 measures cervical stiffness. It is an in-vivo predictive technology that, by using torsional waves, quantifies the mechanical properties (specifically the shear modulus, or resistance of the cervix to shear deformation (kPa), of cervical tissue with extremely high precision. Torsional wave is a type of mechanical wave characterized by a rotational motion and low energy levels (it uses 1000 times less energy than other mechanical waves such as ultrasound). These waves propagate through the tissue, and their propagation speed, which is related to the stiffness (waves propagate faster in stiffer tissues), is measured using piezoelectric sensors.
214921154|NCT06968364|DEVICE|Transvaginal ultrasound|Cervicometry measured with transvaginal ultrasound
214921155|NCT06967402|OTHER|Experimental (chlorhexidine)|Test group: administration of experimental antiseptic (CHX 0.12%+CPC 0.05%) for 3 weeks
214484900|NCT06949176|DEVICE|Protaper Gold rotary files (Dentslpy Maillefer).|Used for coronal flaring in root canal instrumentation.
214484901|NCT06949176|DEVICE|Smarttrack and Hyflex totary files.|Used for root canal instrumentation to full working length.
214484902|NCT06949176|DEVICE|Endo-Eze 27G irrigation needle (Ultradent).|Used to deliver irrigant into the root canal.
214921156|NCT06967402|OTHER|Control (chlorhexidine with cetylpyridinium chloride)|Active comparator: administration of control antiseptic (CHX 0.2%) for 3 weeks
215063013|NCT06035406|DRUG|Retagliptin Phosphate Tablet|Retagliptin Phosphate Tablet;100mg
215063014|NCT06318247|PROCEDURE|site preservation|Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
214321884|NCT06908239|OTHER|thermostatic feeding|In the thermostatic feeding group (intervention arm), milk or formula was delivered directly into the stomach via an infusion pump (Model 8713030CN, Shenzhen Shengnuo Medical Equipment Co., Ltd., Shenzhen, Guangdong, China) located within the incubator. The initial temperature of the milk was set at 38°C, and naturally decreased to match that of the incubator, maintaining a stable, thermostatic environment until the completion of feeding, as well as the setting and adjustment of the temperature of incubator according to the Chinese Medical Association guidelines
214321885|NCT06908239|OTHER|control|In the control arm, standard feeding involved delivering breast milk or formula directly into the stomach using an infusion pump (Model 8713030CN) placed on an infusion stand. The initial temperature of the milk or formula was set at 38°C, and the temperature was allowed to naturally decrease to match the ambient air temperature of the NICU until feeding was completed. For both groups, the feeding volume and speed were managed in accordance with the clinical application guidelines for neonatal nutrition support in China.
214321886|NCT06908200|DEVICE|Radiofrequency therapy|Radiofrequency or myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
214321887|NCT06908200|OTHER|myofascial manual therapy|Myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
214321888|NCT06909656|OTHER|Multimodal electrophysiological recordings|"Intervention(s): Multimodal electrophysiological recordings (Local field potentials, High-Resolution Electroencephalogram, Electromyogram) coupled with video analysis, in experimental condition, in uncontrolled tic and voluntary (tic-like) movement."
214321889|NCT06908356|DRUG|30mg PRAX-628|Once daily oral
214321890|NCT06909305|DRUG|Ozone|Patients received intraarticular ozone injection.
214321891|NCT06909305|DRUG|Dextrose prolotherapy|Patients received intraarticular dextrose prolotherapy injection.
214321892|NCT06909305|DRUG|Dexmedetomidine|Patients received intraarticular dexmedetomidine injection.
214321893|NCT06904781|PROCEDURE|Pulpotomy|Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.
214321894|NCT06904781|PROCEDURE|Pulpectomy|Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Vitapex/Metapex)
214484903|NCT04626882|PROCEDURE|Staged in-hospital or Immediate complete revascularization|Patients with ST-segment elevation myocardial infarction and multivessel disease will be randomized after primary PCI for IRA. All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
214484904|NCT04165213|BEHAVIORAL|Care of Older Persons in their Environment (COPE) online module training|An online module version of training for clinicians (OTs and RNs) in the evidence-based dementia caregiving program called Care of Older Persons in their Environment (COPE) is the intervention being tested for non-inferiority against the usual instructor-led COPE training. COPE modules include rich multimedia content, simulated scenarios, interactive assessments to keep the learner engaged The content is packaged into the latest the latest Shareable Content Object Reference Model (SCORM) specifications, which will allow for repurposing and sharing with other institutions. Each of the ten modules last 45-60 minutes.
214484905|NCT06079840|DEVICE|mindfulness-based stress reduction app|mobile application (app) for caregivers
214484906|NCT03760939|OTHER|Clinical and economical evaluation|Evaluation of the clinical and the economical impact of a colorectal surgery
214672269|NCT05684978|DRUG|Perampanel|The purpose of this study is to determine the efficacy of Perampanel, an approved antiseizure medication, in the treatment of refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
214921157|NCT06967090|DEVICE|Implant surgery using surgical guide|Dental implant surgical guides are customized device used to position dental implants to ensure that the implant is placed in the most ideal location, angulation and depth into the bone.
214921158|NCT06966752|OTHER|NIPPV|"NIPPV~* PEEP 6-8 cmH2O~* PIP: 14-16 cmH2O~* Tinsp: 0.3-0.5sec~  * \<28 weeks GA: 0.3 - 0.4 sec~ * \>28weeks GA: 0.4 - 0.5 sec~* Rate: 20-35 breaths per minute."
214921159|NCT06966752|OTHER|CPAP|CPAP pressure of 6-8 mmH2O
214921160|NCT06968806|DRUG|Ketorolac|patients in the experimental group will receive ketorolac treatment for Stanford Type A aortic dissection, consisting of a 60mg intramuscular injection preoperatively followed by 30mg twice daily for two days postoperatively, while maintaining standard baseline therapies including analgesia, blood pressure control, and subsequent cardiovascular surgical management.
214921161|NCT06968806|DRUG|0.9 % saline|0.9% saline
214921162|NCT06968377|DEVICE|A novel airborne pathogen containment device.|The dome is placed over the patient's head during the full duration of a surgery (intubation and extubation included) as a method of preventing infection transmission through airborne aerosols throughout a hospital.
214921163|NCT06969235|BEHAVIORAL|intensive health behavior and lifestyle treatment|the IHLBT will consist of 18 group meetings over 6 months that teens and parents attend. Topics covered during the meetings will include discussions regarding nutrition and physical activity recommendations, family communication, and use of strategies like monitoring, planning, goal setting, and problem solving.
214955266|NCT04339205|OTHER|Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available.|"The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed.~At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium.~The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain.~We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not."
214484907|NCT02978521|OTHER|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
214484908|NCT06207110|BEHAVIORAL|Regulation of Cues|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to improve satiety responsiveness and decrease food cue responsiveness. This arm will include an experiential component, including hunger monitoring during a meal or snack and participating in exposure exercises.
215063015|NCT03707990|DRUG|NNC0165-1875|Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.
215063016|NCT03707990|DRUG|Placebo (NNC0165-1875)|Participants will receive a single dose of s.c. placebo injection.
215063017|NCT03707990|DRUG|Semaglutide|Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.
215063018|NCT02173639|DRUG|BI 1356/metformin|fixed dose combination tablet
215063019|NCT02173639|DRUG|BI 1356|
215063020|NCT02173639|DRUG|Metformin|
214321895|NCT06568211|DEVICE|Virtual Reality|Persons living with dementia (PLwD) will view 360-degree videos using a commercially-available Virtual Reality (VR) head mounted display that has built-in speakers. While wearing the VR headset, PLwD-participant will be able to visually explore the virtual environments by turning their head to face different directions. Care partner-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the VR headset through the \&amp;#34;screen mirroring\&amp;#34; function.
214321896|NCT06568211|DEVICE|Tablet-Only|PLwD and care partner will view 360-degree videos together on a commercially-available tablet that has built-in speakers. They will be able to visually explore the virtual environment using the touch screen (dragging the view around with their fingers).
215063021|NCT01260688|DRUG|cediranib maleate|Given orally
215063022|NCT01260688|DRUG|dasatinib|Given orally
215063023|NCT04919031|DEVICE|Inspiratory muscle trainer|POWER breathe IMT is a drug-free, hand-held breathing training device. The medical term for this type of breathing training is Inspiratory Muscle Training, or IMT. POWER breathe IMT exercises the main muscles you use to breathe in, primarily your diaphragm and intercostal
215063024|NCT04919031|OTHER|diaphragmatic release|diaphragmatic release is a manual technique use for restoring the ability of the diaphragm to go through a full range of motion
215063025|NCT03213132|BEHAVIORAL|SHUTi (Sleep Health Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
214321897|NCT06915675|BIOLOGICAL|Placental Extract|Participants will receive allografts bone substitutes mixed with flowable human placental derived connective tissue matrix in one extraction socket immediately following tooth extraction.
215063026|NCT03213132|BEHAVIORAL|Patient Education|Educational website containing information on insomnia
215063027|NCT02680938|DRUG|oxytocin|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~\- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
215063028|NCT02680938|DRUG|saline|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~\- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
215063029|NCT03621904|DRUG|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
214321898|NCT06915675|PROCEDURE|Allograft|Participants will receive allografts bone substitutes solely in one extraction socket immediately following tooth extraction.
214321899|NCT06919419|BEHAVIORAL|Multicomponent strategy|dentify patients for HIV/STI testing, engage in discussions around PrEP and navigate patients to PrEP after jail incarceration
214484909|NCT06207110|BEHAVIORAL|Family Based Behavioral Treatment|FBT provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.
214484910|NCT06207110|BEHAVIORAL|Regulation of Cues +|ROC+ includes all of the skills provided in ROC but integrates nutrition education and reducing energy intake
214484911|NCT06207110|BEHAVIORAL|Health Education|The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
214484912|NCT06784674|OTHER|No intervention|Observational study
214484913|NCT03131128|BEHAVIORAL|Mindfulness-based Intervention|"1. Keeping mindful when selecting food.~2. Be aware of hunger and satiety by the body clues.~3. Understanding how stress affect diet and life, and learn how to cope with stress in life.~4. Learning to identify overeating caused by mood, social stress and specific food."
214484914|NCT03131128|BEHAVIORAL|Health Education Intervention|"1. Identifying improper diet patterns and attitudes~2. Understanding the impact of irrational cognition and attitudes on dietary behavior~3. Training coping skills for stresses in real life and preventing the recurrence of bulimia."
214484915|NCT06798155|OTHER|Standardized Music Listening Therapy|"Type of Intervention: Pre- and postoperative listening to standardized music sequences designed specifically for relaxation and pain management.~Delivery Method: Sessions are conducted via the Music Care® application, using a tablet and headphones provided during hospitalization. Participants select their preferred music style, tempo, and tracks to tailor the experience to their preferences.~Duration and Schedule:~Pre-surgery: One 20-minute session in a dedicated room before entering the operating theater.~Post-surgery: Daily 20-minute sessions at home for 28 days post-surgery using participants' own devices (smartphone, tablet, or computer).~Purpose: To evaluate the effect of music on reducing postoperative pain, minimizing analgesic use, and improving the quality of life.~Distinctiveness: This intervention uniquely integrates patient-controlled music preferences with a structured listening regimen before and after surgery, offering a personalized approach to enhancing recovery outcom"
214484916|NCT06207253|DRUG|Diclofenac Sodium|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
214484917|NCT06207253|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
214484918|NCT04611880|DRUG|Crizanlizumab|Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. It is administered intravenously.
214484919|NCT05621954|PROCEDURE|Telehealth Monitoring|Connected devices and smartphone apps to measure symptoms and observations at home, with centralisation of results to a staffed hub
214484920|NCT04772911|DEVICE|Optical Coherence Tomography (OCT)|OCT will be performed at baseline and prior to each standard of care laser treatment to characterize the mean diameter and depth of blood vessels.
214484921|NCT04601051|BIOLOGICAL|NTLA-2001|A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
214672270|NCT05448534|DIAGNOSTIC_TEST|Eletroencephalography|We used Sinek and Young Scale to classify electroencephalographic patterns and cognitive outcome with MOCA score.
214672271|NCT01665781|DRUG|Erythropoietin|
214672272|NCT01848444|OTHER|Breastmilk|to measure levels of contaminants in human breastmilk samples
214672273|NCT01556919|PROCEDURE|Standard of care endoscopy|standard of care endoscopy
214672274|NCT01743027|DRUG|AL-4943A ophthalmic solution|
214672275|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
214672276|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.1%|
214672277|NCT01743027|DRUG|AL-4943A ophthalmic solution vehicle|
214921164|NCT06966947|BEHAVIORAL|Risk Early Warning Management|"This intervention involves a perioperative risk early warning management strategy for hip fracture patients. A dedicated team of nurses is responsible for monitoring vital signs (heart rate, blood pressure, respiratory rate, temperature, and consciousness level) to identify and respond to early signs of clinical deterioration.~The intervention follows a structured scoring system that classifies patients into different risk levels based on their vital signs:~Risk Score 0-4: Standard perioperative care and monitoring~Risk Score 5-7 (or single-item score ≥3): Intensive monitoring with vital sign checks every 4 hours and immediate physician notification if condition changes~Risk Score ≥7: Continuous monitoring, with immediate physician availability and ready access to emergency equipment The intervention aims to improve patient outcomes by ensuring early identification of deterioration and more rapid response to clinical changes. A red warning sign will also be placed at the patient's b"
214921165|NCT06966947|BEHAVIORAL|Standard Perioperative Care|"This is the standard care protocol for patients undergoing hip fracture surgery at the study hospital. It includes health education before surgery, regular vital sign monitoring, routine anticoagulation, and infection control management.~Patients will receive standard perioperative management, including preoperative counseling, assistance with rehabilitation exercises, and monitoring of clinical symptoms and vital signs throughout the surgical and recovery process.~There is no specific risk early warning scoring system in this group, and intervention is based on routine clinical monitoring."
214921166|NCT03938844|PROCEDURE|BURCH Colposuspension|stress urinary incontinence surgery ( burch or tot)
214921167|NCT03938844|PROCEDURE|TOT|
214921168|NCT04511520|OTHER|Physical training program|
214921169|NCT04511520|DRUG|Trimetazidine|
214921170|NCT05368220|OTHER|Whole genome sequencing|Each participant will have WGS performed in order to report on clinically actionable genetic variation in diabetes.
214921171|NCT06409598|OTHER|Non-immersive virtual reality home-based exercise.|This intervention aims include some exercises in the form of games to facilitate and improve the upper limb functions and static balance from sitting and standing positions among chronic stroke survivors.
214921172|NCT03510845|PROCEDURE|Arthroscopic ACL Primary Repair|"All patients (in both groups) will undergo diagnostic knee arthroscopy at the start of the procedure; those in the experimental arm repairable ACL tear, whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle."
214921173|NCT03510845|PROCEDURE|Arthroscopic ACL Reconstruction|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
214921174|NCT01469130|DRUG|MEK162|MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
214921175|NCT04481269|DEVICE|Surface-modified composite coated orthopedic implants|The surface-modified composite coated orthopedic implants have the capacity of high binding strength, high tissue-inducing activity and intelligent bacteria-resistance. The implant devices are expected to be used in the prevention and treatment of plant-related infections in orthopedic surgeries.
214921176|NCT04481269|DEVICE|conventional orthopedic implants|conventional orthopedic implants
214921177|NCT02313168|OTHER|observation, inspection|
215063030|NCT03938103|BEHAVIORAL|Enhanced Go NAPSACC|In the Enhanced delivery model, TA coaches will help centers create an implementation team and conduct a needs assessment to identify organizational strengths and challenges. TA coaches will also provide an orientation to Go NAPSACC and its online tools and help the team develop a plan to guide their Go NAPSACC efforts. The team will then work through 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly check-ins incorporating tailored support based on the results from the needs assessment. They will also organize 2-3 meetings among teams from different centers to reflect and share lessons learned.
215063031|NCT03938103|BEHAVIORAL|Basic Go NAPSACC|In the Basic delivery model, TA coaches will provide an orientation to Go NAPSACC and its online tools to the center director. The director will then work 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly brief check-ins.
215063032|NCT02924441|OTHER|Lidocaine|Applied to breast skin
215063033|NCT02924441|OTHER|Calming Music|Played during mammography
215063034|NCT02924441|OTHER|No Music|No music played during mammography
215063035|NCT00851292|DEVICE|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
215063036|NCT01951989|DRUG|Imiglucérase (drug) pharmacokinetics|
215063037|NCT01303718|DEVICE|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
215063038|NCT01303718|OTHER|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
215063039|NCT02569255|PROCEDURE|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
215063040|NCT05792982|BEHAVIORAL|12 hour fasting for 29 days|This study aims to determine the effects of fasting on serum FGF21 levels. For this reason, male adults who fasted during the Ramadan were included in the study.
214921178|NCT05269446|PROCEDURE|percutaneous coronary intervention (PCI)|A family of minimally invasive procedures used to open clogged coronary arteries and restore blood flow. This is also a standard treatment for patients diagnosed with STEMI or SA
214921179|NCT05269446|DEVICE|total body PET/CT scan|all participants will receive a total-body PET/CT scan (uExplorer) after enrolment
215063041|NCT01032408|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
215063042|NCT01032408|BIOLOGICAL|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
214321900|NCT06916429|OTHER|Psychotherapeutic treatment|"The psychotherapeutic treatment will reflect the therapy practices that characterize the Danish primary sector.~Treatment: Clients are referred by their GP to receive up to 12 individual psychotherapy sessions, typically of 50-60 minutes' duration. For clients with depression and anxiety as referral reason, it is possible to get a supplementary referral by the GP ensuring 12 more sessions, totaling 24 sessions of therapy.~Procedure: Due to the Danish primary sector having relative freedom in method of choice, the psychologist carries out the psychotherapy according to the treatment principles they consider the most relevant, without clauses regarding specific models of therapy or manualization. The therapists register the therapeutic approaches and interventions used in each course of therapy on The Multitheoretical List of Therapeutic Interventions (MULTI-30)at the end of each treatment."
214321901|NCT06916429|OTHER|Waiting List for Psychotherapeutic Treatment|"Treatment: During the waiting list period, clients will not receive any psychotherapeutic treatment for their mental health issues in the Danish primary sector. However, their general practitioner may refer them to appropriate psychiatric treatment if their mental condition worsens and requires immediate treatment.~Procedure: Clients in the waiting list group will fill in questionnaires on their symptom development during the waiting period. They will complete the same set of predictor and outcome questionnaires as the psychotherapy group."
214321902|NCT06919159|DIAGNOSTIC_TEST|PSMA PET/CT scan|Different developing agents
214321903|NCT06919159|DIAGNOSTIC_TEST|FDG-PET|Different developing agents
214321904|NCT06776406|DEVICE|Freedom Pursuit Robotic Platform|The Freedom Pursuit Robotic Platform is a robotic head holder device that uses data from the AlignRT system (3D surface imager) to make small movements of a patient's head to stabilize it during radiation therapy.
214484922|NCT06807697|RADIATION|Curative radiotherapy for Head and Neck Cancers|Radiotherapy is a localized, non-invasive, painless therapy, mostly performed on an outpatient basis, capable of causing necrosis or the death of tumor cells through the use of high-energy radiation called ionizing radiation.
214921180|NCT05269446|PROCEDURE|Coronary Angiography (CAG)|A procedure that uses X-ray imaging to visualize coronary arteries.
214921181|NCT05269446|DRUG|TSPO injection|Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer
214921182|NCT01699269|OTHER|peritumoral glial cell infiltration|
214921183|NCT00502112|DRUG|lintuzumab|4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
215063043|NCT01071499|DRUG|Morphine|One dose of morphine (0.1 mg/kg)
215063044|NCT01071499|DRUG|Morphine|One dose of morphine (0.2 mg/kg)
215063045|NCT01071499|DRUG|Morphine|One dose of morphine (0.3 mg/kg)
215063046|NCT02346643|DEVICE|Implantation with the commercially available Axium Neurostimulator|
215063047|NCT05319808|OTHER|Manual therapy|Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
215063048|NCT05319808|DEVICE|Telehealth exercises|A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.
214921184|NCT00502112|DRUG|lenalidomide|10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
214921185|NCT01609855|DRUG|Hyoscine Butyl Bromide 20mg/2 ml i.v.|Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
214921186|NCT01609855|DRUG|Saline 2 ml i.v.|Administration of Saline 2 ml at time of caecal intubation
214321905|NCT06923982|OTHER|virtual reality, experimental group|Socio-demographic characteristics form questions were asked to individuals in the intervention group before care. During the care, patients are given virtual reality glasses (VR box 2.0 virtual reality glasses and 6.5 inch) for a total of 15 minutes, ranging from 3 to 10 minutes, and watch videos that the patient wants to watch, such as park, nature and seaside walks, undersea and museum trips, with a music background. and he was shown videos that he could change at any time. After the maintenance, Visual Analog Scale-Pain (VAS-P) scale, General Comfort Level Scale and Satisfaction Evaluation Scale for Virtual Reality Glasses Application questions were applied. 24 hours after the care, VAS-P and General Comfort Level Scale were administered again.
214321906|NCT06923982|OTHER|control group|A socio-demographic questionnaire was administered to the control group before care. During maintenance, no intervention was applied and standard care in routine practice was applied. After the care, Visual Analog Scale-Pain (VAS-P) scale and General Comfort Scale were applied. 24 hours after the treatment, the Visual Analog Scale-Pain (VAS-P) scale and the General Comfort Scale were applied again.
214321907|NCT06923891|DRUG|Xanomeline/Trospium|Xanomeline/Trospium (titrated dose)
214321908|NCT06923176|DRUG|Biejia-Ruangan compound|Biejia-Ruangan compound have the functions of softening hardness, dispersing lumps, removing blood stasis and detoxifying, and nourishing qi and blood. Used for chronic hepatitis B liver fibrosis, as well as early liver cirrhosis characterized by blood stasis obstructing collaterals, qi and blood deficiency with incomplete heat toxicity.
214321909|NCT06923176|OTHER|Routine medical care|Routine medical care
214321910|NCT06924086|DEVICE|Deep Brain Stimulation|Picostim DBS Device
214321911|NCT06924229|DRUG|Hormonal treatment|hormonal treatment for breast cancer
214921187|NCT04266834|OTHER|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the Hikari DX L-FABP test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the L-FABP test at the clinically-appropriate point in each case."
214921188|NCT05033717|OTHER|Tissue Flossing Technique|"Subjects will receive tissue-flossing intervention on bicep muscle for 30 sec to 2 min with an occlusion pressure of 100 mmHg.~After removal of flossing, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 rep, 4 sets for a single day and 3 days per week for 2 weeks in total."
214955267|NCT00368459|DRUG|raloxifene|Raloxifene is a selective estrogen receptor modulator
214955268|NCT00368459|DRUG|Placebo|Identical appearing placebo
214955269|NCT04452552|OTHER|healthy diet|balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks
214955270|NCT00412126|DRUG|Insulin|
214955271|NCT01373034|DIETARY_SUPPLEMENT|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
214955272|NCT01373034|DIETARY_SUPPLEMENT|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
214955273|NCT03989596|RADIATION|Hypofractionated radiotherapy|"Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.~Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks."
214955274|NCT03989596|OTHER|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
214955275|NCT02855801|OTHER|constant exercise|
214955276|NCT02855801|OTHER|cryotherapy|
214955277|NCT02855801|OTHER|intermittent exercise|
214955278|NCT00094679|DEVICE|Eye patch|adhesive patch to cover the sound eye
214955279|NCT00411723|DRUG|RTL1000 (recombinant T cell receptor ligand)|Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
214955280|NCT00411723|DRUG|RTL1000 Placebo|Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
214955281|NCT00301457|DRUG|Anastrozole|1 mg once daily oral dose
214955282|NCT00248157|DRUG|Octreotide acetate in microspheres|
214955283|NCT04169737|DRUG|Acalabrutinib|Given PO
214955284|NCT04169737|BIOLOGICAL|Obinutuzumab|Given IV
214955285|NCT04169737|DRUG|Venetoclax|Given PO
214955286|NCT02875795|PROCEDURE|automatic speech processing tool|
214955287|NCT05386290|DRUG|Infliximab|A TNFα inhibitor in UC and CD treatment
214955288|NCT05386290|DRUG|Vedolizumab|An integrin receptor antagonist in UC and CD treatment
214955289|NCT05386290|DRUG|Ustekinumab|An IL-12/IL-23 inhibitor in CD treatment
214955290|NCT05386290|DRUG|conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)|Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
214955291|NCT02363712|DEVICE|APOS shoe|"It consists of two shoes each with two large convex rubber balls called Pertupods screwed into the plantar surface of the sole so that a person walks on these balls."
214955292|NCT02363712|DEVICE|Sham-APOS shoe|It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
214955293|NCT05018676|DRUG|ARX788|1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.
214955294|NCT01005901|DRUG|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
214955295|NCT01005901|DRUG|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
214955296|NCT00760487|DEVICE|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
215063049|NCT05319808|OTHER|Non-computer based exercises|Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
215063050|NCT00231686|BEHAVIORAL|Supervised aerobic training|
215063051|NCT00231686|BEHAVIORAL|Supervised strength training|
215063052|NCT00231686|BEHAVIORAL|Unsupervised training|
215063053|NCT00867802|BEHAVIORAL|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
215063054|NCT00338286|OTHER|Standard supportive care (packed RBC transfusion)|Per doctor prescription
215063055|NCT00338286|DRUG|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
215063056|NCT05524623|OTHER|percutaneous microelectrolysis in myofascial trigger points of the trapezius|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
215063057|NCT04607512|DRUG|telaglenastat|glutaminase inhibitor
215063058|NCT04607512|OTHER|telaglenastat placebo|matching placebo for telaglenastat
214484923|NCT06333938|OTHER|Nonpharmacologic Treatment|At least one three nonpharmacologic treatments (Music Medicine, Aromatherapy, Battlefield Acupuncture) will be delivered. Music Medicine is the delivery of personal music players to listen to patient-preferred music before, during, or after surgical or non-surgical procedures. Aromatherapy is the delivery of personally-preferred AromaTabs before, during, or after surgical or non-surgical procedures. Battlefield Acupuncture is the delivery of Auricular Acutherapy by trained providers using acupuncture needles or acupressure beads before, during, or after surgical or non-surgical procedures.
214484924|NCT06333938|OTHER|Standard Care|Patients will receive standard clinical care without the addition of Music Medicine, Aromatherapy, or Battlefield Acupuncture
214484925|NCT05931848|OTHER|Warm-up and Cool-down Program|"Each exercise in the warm-up and cool-down protocols consisting of active movements and static stretching exercises will be performed as 1 set and 10 repetitions. Active movements will be performed for 10 seconds. The detailed protocol is shown below.~Neck flexion/extension/lateral flexion Circles made with the head chin-tuck Backward bilateral shoulder circumduction Shoulder external rotation with hands clasped at neck Circles with wrists clasped clockwise and counterclockwise Reciprocal upper extremity flexion-extension cat-camel Trunk lateral flexion with hands clasped overhead Trunk rotation in both directions Ankle dorsi/plantar flexion with knee extension Static Stretching Exercises Neck lateral flexor stretch Posterior capsule stretching Hands clasped trunk flexion lateral Trunk lateral flexion with hands clasped Trunk rotation in both directions Knee extensor and ankle plantar flexor stretching by reaching for toes"
214484926|NCT05931848|OTHER|Strengthening Exercises|"The progression of the strengthening program will be achieved by gradually changing the number of repetitions, sets, resistance and the number of exercises.~1-6 Weeks Upper extremity strengthening in unilateral PNF D2 pattern, Scapulothoracic strengthening with shoulder extension in elbow extension, Scapulothoracic strengthening with shoulder extension in elbow flexion, hip flexor strengthening, Hip abductor strengthening in knee flexion, when sit on the chair fingertip ups and downs 7-12 Weeks Added exercises Scapular adductor strengthening with shoulders in horizontal abduction position, Shoulder adductor strengthening in elbow extension with trunk lateral flexion in arms overhead position, hip abductor strengthening 13-16 Weeks Added exercises Shoulder abductor/flexor strengthening in the scapular plane, Elbow flexor strengthening, Upper extremity strengthening in unilateral PNF D2 pattern with trunk rotation, Taking a lateral step in a mini-squat position"
214921189|NCT05033717|OTHER|Static Stretching Technique|"Subjects will perform passive static stretching exercises of bicep muscle. Each stretch will last for 30 sec at 100% of stretch intensity with 4 reps for each, 1 set per day and 3 days per week for total duration of two weeks.~After the application of static stretch, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 reps, 4 sets for a single day and 3 days per week for 2 weeks in total."
214921190|NCT01603849|RADIATION|Prophylactic Cranial Irradiation|Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
214921191|NCT00510536|DRUG|Acetaminophen|dose to be determined by investigator
214921192|NCT00510536|DRUG|NSAID|dose to be determined by investigator
215063059|NCT04607512|OTHER|moxifloxicin|positive control
215063060|NCT04829786|DRUG|palovarotene low-dose|oral capsules
215063061|NCT04829786|DRUG|palovarotene high-dose|oral capsules
215063062|NCT05929391|PROCEDURE|Recycling orthodontic brackets|"T0: The adhesive removal will be performed by high-speed hand piece with tungsten carbide bur. the bur will be changed every five attachments. T1: Control group of T0. T2: The adhesive removal will be performed by sandblasting via Micro-etcher.~T3: Control group of T2."
215063063|NCT06537765|DRUG|Medical treatment|All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist.
215063064|NCT06537765|DEVICE|Therapeutic ultrasound (US)|Women will be asked to assume supine lying position, and the lower abdomen will be cleaned thoroughly with alcohol and dried well thereafter. Ultrasound gel will be distributed over the lower abdomen .The device will be adjusted to Frequency of 1MHz, Mode: continuous wave, Intensity: 1.5W/cm, duration of treatment: 15 minutes for the treatment site, then the skin will be cleaned again to remove ultrasound gel.
215063065|NCT06537765|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS electrodes will be placed on specific acupuncture points for women in supine position. These points include VB29, ST36, CV6, CV4, LV3, KD3, SP6, and SP9. The treatment aims to improve blood circulation, remove adhesions, regulate menstrual activity and hormones, and prevent new adhesions and menstrual reflux in endometriosis patients.
215063066|NCT03248531|DRUG|Bimekizumab|Bimekizumab in different dosages (dose 1 and 2).
215063067|NCT03248531|DRUG|Adalimumab|Adalimumab in different dosages (dose 1, 2 and 3).
215063068|NCT03248531|OTHER|Placebo|Placebo will be provided matching Bimekizumab.
214321912|NCT06924762|DRUG|Placebo intramuscular injection|On the basis of background treatment, intramuscular injection of placebo was added.
214484927|NCT05931848|OTHER|Balance Exercises|"Balance exercises will be applied following the strengthening exercises. The exercises will be gradually made more difficult. Participants will be encouraged to complete the balance exercises by standing next to the grab bar and with as little support as possible.~1-6. Week Rising and falling on the heels Hands at waist trunk extension hip abduction 6-9. Week Hip abduction and extension without lowering the foot to the ground, respectively 5 sec stop on tiptoe 5 seconds standing on one leg 10-12. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~5 sec stop on tiptoe 10 sec stop on tiptoe 5 seconds standing on one leg 10 seconds standing on one leg 13-16. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~10 sec stop on tiptoe 15 sec stop on tiptoe 10 seconds standing on one leg 15 seconds standing on one leg"
214484928|NCT05931848|OTHER|Otago Home Exercise Program|"The exercises included in the Otago Home Exercise Program will be taught to the participants after the group exercise session held at the Social Life Center. At the same time, home exercise training will be supported by brochures and videos. In addition to the exercises in the program, participants will be asked to do 30 minutes of moderate-intensity walking 2 days a week. Participants will be asked to record the exercises they did during the week in the exercise diary given to them.~Balance Exercises~1. Knee bend (half squat)~2. Walking backwards~3. Walk and turn around~4. Sideways walking~5. Tandem stance~6. Tandem walking~7. Standing on one leg~8. Walking on the heel~9. Toe walking~10. Tandem walking backwards~11. Sit down~12. Going up and down stairs Strengthening Exercises~1\. Knee extension 2. Knee flexion 3. Hip abduction 4. Ankle plantar flexion 5. Ankle dorsiflexion"
214484929|NCT04340882|DRUG|Docetaxel|Given IV
214321913|NCT06924762|DRUG|Human interleukin-2 (I) intramuscular injection|On the basis of background treatment, intramuscular injection of human interleukin-2 (I) will be added.
214321914|NCT06924268|BEHAVIORAL|Single Art Therapy Session|Each participant will engage in a 30-60 minute structured art therapy session using pre-drawn coloring sheets featuring themes such as mandalas, nature scenes, and inspirational designs. A variety of coloring tools will be provided, including crayons, colored pencils, markers, gel pens, and watercolor paints. Sessions will be facilitated by the primary investigator, who will provide non-directive prompts and engage in casual conversation to foster comfort and engagement.
214321915|NCT06924736|DEVICE|Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter|Randomly assign subjects to the experimental group to treat the lesions with an intravascular shockwave therapy device/disposable coronary artery shockwave catheter.
214484930|NCT04340882|BIOLOGICAL|Pembrolizumab|Given IV
214321916|NCT06924736|DEVICE|Non - compliant balloon dilatation catheter|Randomly assign subjects to the control group to treat the lesions with a non - compliant balloon catheter.
214484931|NCT04340882|BIOLOGICAL|Ramucirumab|Given IV
214484932|NCT02131584|OTHER|Questionnaire Administration|Ancillary studies
214484933|NCT02131584|DRUG|Ruxolitinib Phosphate|Given PO
214484934|NCT03593811|DIAGNOSTIC_TEST|Questionnaires|Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.
214672278|NCT01874782|DEVICE|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
214672279|NCT01275248|DRUG|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
214672280|NCT01275248|DRUG|Placebo|Oral tablet to match the experimental interventions
214672281|NCT06610630|DIAGNOSTIC_TEST|Assessment of Bowel Preparation Using AI-Driven Smartphone Applications|Assessment of Bowel Preparation Using AI-Driven Smartphone Applications
214921193|NCT04404764|DRUG|Nusinersen Injectable Product|The patient´s treatment is provided by SUS. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.
214921194|NCT02913443|DRUG|RO7051790|RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
214921195|NCT01091506|OTHER|Placebo|Placebo once a day for 12 weeks
214921196|NCT01091506|OTHER|L-methylfolate|L-methylfolate 15mg once a day for 12 weeks
214921197|NCT02815332|DRUG|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
214921198|NCT02815332|DRUG|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
214921199|NCT02815332|DRUG|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
214921200|NCT05000671|DRUG|STC314 injection or Placebo(rate=58.3 mg/hr)|To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
214955297|NCT06845865|DIETARY_SUPPLEMENT|enteric dyed solution|Oral administration of 0.5 mg/kg of body weight of food coloring dye
214955298|NCT03689153|DRUG|JNJ-63733657|Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.
214955299|NCT03689153|DRUG|Placebo|Participants will receive matching placebo intravenously.
214955300|NCT02813473|RADIATION|Coronary Angiography|Coronary angiography is an X-ray test to diagnose diseases of the arteries that supply blood to the heart. Coronary angiography can detect weakened blood vessel walls and narrowed or blocked vessels. X-rays are taken after a special dye has been injected into the bloodstream, making the vessels and blood flow through the vessels visible on X-rays.
214955301|NCT02813473|RADIATION|Computed Tomography (CT) scan|A CT scan is an X-ray imaging technique that uses a computer to produce cross-sectional images. It can be used to examine the heart and blood vessels for problems
214321917|NCT06924242|PROCEDURE|total or partial thyroidectomy|Total thyroidectomy is a surgical procedure that involves the complete removal of the thyroid gland. It is performed to treat conditions such as thyroid cancer, large goiters, or severe hyperthyroidism. The surgery is typically conducted under general anesthesia through an incision in the lower neck. Postoperative management may include hormone replacement therapy with levothyroxine to compensate for the loss of thyroid function. Potential complications include hypocalcemia due to parathyroid gland injury and vocal cord dysfunction from recurrent laryngeal nerve damage.
214321918|NCT06923059|OTHER|AI-assisted endoscopy recovery assessment|The intervention group will be assessed by the AI model regularly, which will be installed in a smartphone attached to the head of the stretcher once the patient in this group arrives at the recovery room. After the recovery nurse starts the AI application following the standard-of-care baseline assessment of vital signs, the AI application will prompt an automatic voice alarm to wake up the patient by asking if he/she is awake every 10 minutes.
214321919|NCT06924190|DRUG|Budiair® 200ug/puff inhalation aerosol|The subjects randomly received one puff Budiair®(budesonide inhalation aerosol 200ug/puff )
214484935|NCT03593811|DIAGNOSTIC_TEST|4 channel electrogastrogram (EGG)|EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.
214484936|NCT03593811|DIAGNOSTIC_TEST|36 channel high resolution electrogastrogram (HR-EGG)|HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.
214484937|NCT03593811|DIAGNOSTIC_TEST|Magnetogastrogram (MGG)|MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
214484938|NCT03593811|DIAGNOSTIC_TEST|Electrocardiogram (EKG)|Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin
214484939|NCT03593811|DRUG|Ondansetron|Patients will be administered 4mg or 8 mg ondansetron dependent upon age in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.
214484940|NCT03593811|DRUG|Cyproheptadine Oral Tablet|Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 4mg twice a day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients
214484941|NCT04726410|BIOLOGICAL|Cold Stored Platelets|early infusion of urgent release CSP
214484942|NCT04726410|BIOLOGICAL|Standard Care|standard care including room temperature platelets
214484943|NCT00076310|DRUG|Docetaxel|60 mg/m\^2 IV repeated every 21 days.
214484944|NCT00076310|DRUG|OSI-774|100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
214484945|NCT00076310|DRUG|Cisplatin|75 mg/m\^2 IV every 21 days.
214484946|NCT04838301|DRUG|Allopregnanolone|Allopregnanolone 4mg IV via 30-minute infusion, once per week.
214484947|NCT04838301|OTHER|Placebo|Normal saline solution IV via 30-minute infusion, once per week
214484948|NCT05592093|DRUG|Korean red ginseng capsule (marketed product in Korea)|Korean red ginseng capsule (marketed product in Korea) KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.
214484949|NCT05592093|DRUG|Korean red ginseng capsule(placebo)|"KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group.~The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time."
214484952|NCT04957849|PROCEDURE|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery
214921201|NCT05000671|DRUG|STC314 injection or Placebo(rate=87.5 mg/hr)|To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
214921202|NCT02631122|PROCEDURE|Supraclavicular vs Retroclavicular Nerve Block|An ultrasound-guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% ropivicaine will be performed on patients scheduled for lower arm surgery; 25 ml to be delivered to the brachial plexus and 5 ml to the intercostal nerve
214921203|NCT00005616|PROCEDURE|conventional surgery|
214921204|NCT00005616|PROCEDURE|neoadjuvant therapy|
214921205|NCT00005616|PROCEDURE|radionuclide imaging|
214921206|NCT00005616|RADIATION|iodine I 131 monoclonal antibody F19|
215063069|NCT00815568|DRUG|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
215063070|NCT03815695|DRUG|FT-4202/Placebo|Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
215063071|NCT02446678|DEVICE|PillCam ESO2|Capsule endoscopy
215063072|NCT06637306|DRUG|Dupilumab|Dupilumab 600mg subcutaneous initial loading dose, 300mg for subsequent doses; administered every 3 weeks for 4 cycles. Immunotherapy drug FDA approved to treat patients with eczema, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Investigational/not yet FDA approved to treat patients with breast cancer.
215063073|NCT06637306|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenous every 3 weeks for 4 cycles and one 400mg intravenous dose one week following completion of chemotherapy. Cancer immunotherapy drug FDA approved for the treatment of high-risk, early-stage, triple-negative breast cancer (TNBC).
215063074|NCT06637306|DRUG|Paclitaxel|Paclitaxel 80mg/m2 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
214321920|NCT06924190|DRUG|budesonide 200ug/puff inhalation aerosol|The subjects randomly received one puff budesonide inhalation aerosol(200ug/puff )
215063075|NCT06637306|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
215063076|NCT02891902|OTHER|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
215063077|NCT04075513|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
215063078|NCT04075513|DRUG|Insulin degludec, 100U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
215063079|NCT04075513|DRUG|Background therapy: Rapid acting insulin analogs|Route of administration: SC injection
215063080|NCT05292924|PROCEDURE|Early SCC|Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
215063081|NCT04287309|OTHER|CAR-T cells|CD19 targeted CAR-T treatment
215063082|NCT05749991|DEVICE|Dryshield|"DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)"
215063083|NCT05749991|DEVICE|Cotton roll isolation|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
214321921|NCT01275183|DRUG|raltegravir and cisplatin|"Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles"
214321922|NCT01602276|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
215063084|NCT00690690|BEHAVIORAL|Video (group-delivered video-based intervention)|group-delivered video-based intervention
214321923|NCT01532466|DRUG|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
214321924|NCT00567775|DRUG|human insulin|
214321925|NCT00567775|DRUG|inhaled human insulin|
214484953|NCT04957849|PROCEDURE|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach
214484954|NCT05037305|OTHER|Educational video|The brief educational video provides information about pharmacogenetic testing, the results of pharmacogenetic testing, and how to find these results in the patient portal.
214921207|NCT06106412|DRUG|Ionomycin SIGMA|Oocytes will be activated with Ionomycin SIGMA
214921208|NCT06106412|DRUG|A23187|Oocytes will be activated with A23187
214921209|NCT04437290|DRUG|investigational radiotracer [18F]MK6240|Brain PET scan
214921210|NCT01514539|OTHER|cross-sectional|"Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity."
214921211|NCT00638716|DRUG|CJC-1134-PC|1.5 or 2.0 mg CJC-1134-PC
214321926|NCT02526381|DRUG|Danlou Tablets|Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
214921212|NCT00638716|DRUG|Placebo|Placebo
214921213|NCT03660332|PROCEDURE|Infusion of a liquid meal intraduodenally|Infusion of IL-6/NaCL before a liquid meal intraduodenally
214921214|NCT03028909|DRUG|Oseltamivir|Standard of care for influenza caused by Type A strains
215063085|NCT00690690|BEHAVIORAL|HCT|Offer of HIV counseling and testing
215063086|NCT01031589|DRUG|TMC278 (Rilpivirine) LA; Placebo|
215063087|NCT04707118|DRUG|cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
215063088|NCT04707118|DRUG|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
215063089|NCT00550810|DRUG|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
214484955|NCT06036407|DIAGNOSTIC_TEST|Hearing test|Participants visit a local hearing aid shop to assess their hearing function
214484956|NCT04684524|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214484957|NCT04684524|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
214484958|NCT06070376|DEVICE|Fully Covered Esophageal Prosthesis (FC-SEMS)|The placement of the Fully Covered Esophageal Prosthesis (FC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
214921215|NCT03028909|DRUG|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
214921216|NCT03028909|DRUG|Placebo|Salt-water solution containing no active ingredients.
214921217|NCT02641626|PROCEDURE|Urgent Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
214921218|NCT02641626|PROCEDURE|Deferred Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
214921219|NCT01126814|DRUG|Imatinib (Gleevec)|
214321927|NCT02526381|DRUG|Tongmai Yangxin Pills|Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
214321928|NCT04641923|OTHER|Adhesion barrier|Adhesion barrier application at the time of first surgery
214321929|NCT01083433|BEHAVIORAL|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
214321930|NCT01083433|DEVICE|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
214921220|NCT01859065|BEHAVIORAL|Intensified anticipatory guidance|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
214321931|NCT02023034|OTHER|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
214321932|NCT01581593|BIOLOGICAL|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
214321933|NCT02242877|DRUG|Telmisartan|
214321934|NCT02242877|DRUG|Telmisartan combined with hydrochlorothiazide|
214321935|NCT04722640|DRUG|SKYRIZI|SKYRIZI
214321936|NCT00887900|PROCEDURE|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
214921221|NCT01859065|BEHAVIORAL|Routine|Routine anticipatory guidance (control)
214955302|NCT06229223|BEHAVIORAL|PALOMA|Partnering with Parents of Adolescent Latinos on Mental Health Assistance
214321937|NCT00887900|PROCEDURE|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
214321938|NCT01895894|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 20\~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
214955303|NCT06844045|BEHAVIORAL|Gonorrhea/chlamydia Point-of-Care Testing|Point-of-care testing for sexually transmitted infections.
214955304|NCT05535387|BEHAVIORAL|FamilyNet smart speaker/mobile application|In a 4-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans. The prototype FamilyNet program will guide families in creating and implementing positive behavior plans to foster positive child behavior, consistent parenting, and promote a positive parent-child relationship.
214955305|NCT05471960|OTHER|Natural progression over time|Each subject will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
214955306|NCT05892211|DIAGNOSTIC_TEST|Polysomnography|Polysomnography is performed by 3-channel electroencephalography ((EEG; F4-M1, C4-M1, O2-M1), 2-channel electrooculography (EOG), chin electromyography (EMG), surface EMG recording from tibialis anterior muscles of the right and left leg, body position, oronasal thermal airflow sensor, nasal pressure sensor, thoracic and abdominal respiratory belts for assesing the respiratory effort, electrocardiography (ECG), pulse, recording of respiratory sounds, oxygen saturation and synchronous video recording. The sleep stages are scored by the current criteria of American Academy of Sleep Medicine.
214955307|NCT05892211|DIAGNOSTIC_TEST|Skin conductance|The sympathetic skin response recordings are performed with a four-channel electromyography apparatus (Nihon-Kohden). They are recorded from both sides of the sternum with the active and reference electrodes placed 2 cm apart from the midline.
214955308|NCT05892211|GENETIC|ALU and LINE-1 DNA methylation analysis|2 cc peripheric venous blood is drawn from the participants to the test tubes with EDTA. DNA isolation is done by Nucleospin Blood Kit (REF:740951.250, Macherey-Nagel). Epitect Fast DNA Bisulfite Kit (REF:59824, Qiagen) is used to do DNA bisulfite modification. ALU and LINE-1 site specific methylation primer is designed and the methylation patterns are compared between the groups by Epitect Methylight PCR Kit (Cat. No:59496, Qiagen).
214955309|NCT05892211|DIAGNOSTIC_TEST|The Menopause-Specific Quality of Life Questionnaire (MENQOL)|The Menopause-Specific Quality of Life Questionnaire (MENQOL) is filled by each participant to assess the health related quality of life before the polysomnography test.
214955310|NCT05892211|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is done by each participant to assess the sleep quality and disturbances before thepolysomnography test.
214955311|NCT05520866|BEHAVIORAL|PrehabPal|Web based application
214955312|NCT06360588|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214955313|NCT06360588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214955314|NCT06360588|DRUG|Copanlisib|Given IV
214955315|NCT06360588|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
214955316|NCT01067898|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
214955317|NCT01067898|OTHER|olive oil|10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
214955318|NCT01067898|DIETARY_SUPPLEMENT|calcium carbonate|1000 mg calcium per os every day for one year
214955319|NCT04430088|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
214955320|NCT04430088|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
214955321|NCT00338221|DRUG|alanyl-glutamine|
214955322|NCT00338221|DRUG|glycine|
214955323|NCT02785562|OTHER|Assessment of PDL1 expression|Intervention : 2 biopsy slides will be analyzed in central laboratory.
214955324|NCT05108584|PROCEDURE|PPE Level 3 and Video Laryngoscope|The operator used level 3 PPE and video laryngoscope for the intubation process
214321939|NCT04982029|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|600mg
214321940|NCT04982029|DRUG|Placebo|Matching placebo
214321941|NCT04962815|DEVICE|Electroencephalogram (EEG) Test|EEG test and delirium assessments will be performed on subjects experiencing delirium in the ICU.
214321942|NCT05892068|DRUG|Tucatinib|Standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
214321943|NCT03882606|DEVICE|Scharioth Macula Lens (SML, Medicontur)|magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient
214321944|NCT04988503|DEVICE|Coil embolization|coil embolization for ruptured intracranial aneurysm with bare platinum coils or second-generation hydrogel coils
214321945|NCT05308901|DRUG|Pembrolizumab|200 mg IV every 3 weeks for a maximum of 2 years.
214321946|NCT05308901|DRUG|Lenvatinib|20 mg daily for a maximum of 2 years.
214321947|NCT06956339|PROCEDURE|Early anterior cruciate ligament surgery|Participants randomised to early anterior cruciate ligament reconstruction surgery (ACLR) will be referred to a study orthopaedic surgeon. Participants will have surgery within 8 weeks of randomisation. The ACLR will reflect usual care for each surgeon. Participants will undergo routine preoperative care, including an anaesthetic consultation to assess fitness for surgery and general anaesthesia. Surgeons will choose their preferred surgical technique and graft, and treat concomitant injuries surgically if indicated and aligned with their usual practice. Participants will follow the surgeon's standard recommendations regarding post-operative care and appointments. Participants will be provided with 15 funded physiotherapy consultations within 12 months of surgery and undertake a physiotherapist-supervised goal-oriented exercise-based rehabilitation program.
214321948|NCT06956339|OTHER|Novel bracing protocol|"Participants will undertake the Cross Bracing Protocol under the supervision of a study physiotherapist (23 funded physiotherapy sessions within 12 months). Medical oversight and venous thromboembolism prophylaxis will be provided by the study sports and exercise medicine physician.~A specialised knee brace will be fitted within 21 days of ACL injury. The knee is kept at 90° flexion in the brace at all times for the first four weeks. The brace is then adjusted weekly by the physiotherapist to allow progressive increases in knee range (60-90° flexion at 5 weeks, 45-90° flexion at 6 weeks, 30° to full flexion at 7 weeks, 20° to full flexion at 8 weeks, 10° to full flexion at 9 weeks, unrestricted range at 10 weeks, brace off at 12 weeks). Whilst braced and after brace removal, the participant will undertake physiotherapist-supervised goal-oriented exercise-based rehabilitation within the available knee range."
214321949|NCT01896895|DRUG|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
214321950|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
214921222|NCT04638283|BEHAVIORAL|Goal Attainment Scaling|Individual goals will be formulated and measured by Goal Attainment Scaling (GAS). GAS provides a method for quantifying the attainment of individualized goals, typically set in cognitive rehabilitation. Different levels of outcomes for each goal are operationalized in a five-point scale and given a numeric value. For each individual goal, minus two refers to the goal attainment much less than expected, minus one refers to a little less than expected, zero refers to expected outcome, plus one refers to a little bit better than expected and plus two refers to goal attainment much better than expected. The participants can establish as many goals as desired. Outcomes can be summed within different patient goals, as well as across patients to assess overall outcome of treatment outcomes.
214921223|NCT03290261|OTHER|Hypnosis|3 hypnosis sessions performed at 4 - 6 weeks apart
214921224|NCT03910205|DIAGNOSTIC_TEST|ELISA|Enzim linked immunoabsorbant assay
214921225|NCT02728505|DRUG|SinuSurf irrigation twice daily|
214921226|NCT02728505|DRUG|NeilMed Sinus rinse irrigation twice daily|
214921227|NCT03838289|RADIATION|multimodal magnetic resonance imaging or computed tomography|multimodal magnetic resonance imaging including T1 Flair,T2 Flair, magnetic resonance angiography (MRA), perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), enhanced gradient echo T2 star weighted angiography (ESWAN); multimodal computed tomography including non-contrast CT, volume perfusion CT
214921228|NCT05750329|PROCEDURE|assisted liver transplantation combined with two-stage hepatectomy|"Stage 1 Surgery: Left Hepatectomy, Left Lateral Graft Implantation, Portal Shunt to Graft Intermediate stage: continuous monitoring of liver function indexes and liver transplant donor volume after the first stage of surgery. Until the graft size reaches 0.8% of body weight (GBWR), or 35%-45% of the standard liver volume.~Stage 2 Surgery: Residual Right Hepatectomy"
214921229|NCT01919866|OTHER|Transplantation of CD3/CD19 depleted stem cells|
214921230|NCT05808426|DEVICE|Bonus Winner Mahjong|Bonus Winner Mahjong developed by Bonus Winner Online Entertainment Co., Ltd. The participants in experimental group played three times a week, each time requiring at least lasting 30 minutes, for half of a year.
214921231|NCT02589626|DRUG|empagliflozin 10mg|
214921232|NCT02589626|DRUG|empagliflozin 25 mg|
214921233|NCT02589626|DRUG|Placebo|For blinding purposes
214921234|NCT02467062|DEVICE|MRI|MRI measurement to evualuate for 4D blood flow pattern
214921235|NCT02423330|DEVICE|Strattice-LIFT|Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
214921236|NCT00567658|DRUG|Esomeprazole|Esomeprazole or Nexium 40 mg BID is given for four months.
214921237|NCT01690858|OTHER|blood sample|blood sampling at inclusion and throughout pregnancy when pregnant
214921238|NCT05198024|BEHAVIORAL|Nutrition knowledge|Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'
215063090|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. suturing the nasal conformer in the cleft side
214321951|NCT01896895|DRUG|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214921239|NCT02189343|DRUG|ACY-1215 in combination with pomalidomide and dexamethasone|Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
214921240|NCT02564900|DRUG|DS-8201a (DP1)|DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.
214921241|NCT02564900|DRUG|DS-8201a (DP2)|DS-8201a is to be administered via intravenous (IV) dose. DS-8201a (DP2) was used only used for Dose Expansion Part 2e.
214921242|NCT02564900|DRUG|DS-8201a (DP)|DS-8201a (DP) is to be administered via intravenous (IV) dose.
214921243|NCT04283799|DIETARY_SUPPLEMENT|A new human milk fortifier|Contents of protein, protein/energy ratio, moderate hydrolysis of whey protein, medium-chain fatty acid are increased in the new HMF
215063091|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. No nasal conformers used in this group
215063092|NCT01326884|DEVICE|ZLP|ZLP Graft
215063093|NCT01142778|DRUG|Bevacizumab|Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
215063094|NCT01142778|DRUG|Docetaxel|Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
215063095|NCT01142778|DRUG|Trastuzumab|Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
215063096|NCT01142778|PROCEDURE|Surgery|All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
215063097|NCT01142778|RADIATION|Radiotherapy|All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
214921244|NCT01861899|DEVICE|SI-LOK|Sacro-iliac joint fusion
214921245|NCT04782297|DEVICE|Long term hemodialysis catheter|There will be no interventions in this study. Strictly observational.
215063098|NCT01142778|DRUG|Hormonal Therapy|Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
215063099|NCT02341768|DEVICE|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
215063100|NCT02384473|PROCEDURE|Real-Time CEUS|Undergo real-time CEUS
215063101|NCT02384473|PROCEDURE|SWE|Undergo SWE
215063102|NCT02384473|DRUG|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
215063103|NCT02384473|DEVICE|Philips Shear Wave Elastography|Type of equipment used for SWE
215063104|NCT05221632|DEVICE|Accelerated transcranial magnetic stimulation with real coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation.
215063105|NCT05221632|DEVICE|Transcranial magnetic stimulation with real coil|The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .
214921246|NCT03612609|BIOLOGICAL|blood, urine and semen sample|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 15, 30, 60 and 90 days after. Dengue virus RNA being diagnosed with blood and/or urine sample positive for dengue virus RNA. Dengue virus RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
214921247|NCT05175911|OTHER|golden hour : an initial standardized stabilization|"This is a quality improvement project to evaluate the implementation of Golden hour, a standardized stabilization during the first hour of life in inborn preterm infants younger than 31 weeks of gestational age or weighting less than 1300 g in the NICU of the University of Liege.~There is no comparative arm."
215063106|NCT05221632|DEVICE|Transcranial magnetic stimulation with sham coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
215063107|NCT03467893|DRUG|Antacids|number aof antacids treatment after PPI stop
214321952|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
214321953|NCT03348761|DEVICE|rTMS group|
214321954|NCT02321865|DRUG|NPC-02|
214921248|NCT03217383|DEVICE|MATRx plus|The MATRx plus test is a 2- or 3-night home sleep test that uses temporary titration trays to move the lower jaw in response to respiratory events. The purpose of the test is to predict oral appliance therapy outcome, and to provide a protrusive position for individuals predicted to experience therapeutic success.
214484959|NCT06070376|DEVICE|Partially Covered Esophageal Prosthesis (PC-SEMS)|The placement of the Partially Covered Esophageal Prosthesis (PC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
214484960|NCT06195150|OTHER|Blood collection|15ml of blood are harvested before surgery
214484961|NCT06179485|DRUG|Ketamine|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
214484962|NCT06179485|DRUG|Etomidate|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
214484963|NCT06426004|OTHER|patients will receive NPH education|Patients will benefit from the Hydrocephalus Association's (HA) educational strategy for idiopathic normal pressure hydrocephalus (iNPH) emphasizes patient collaboration in the development of educational materials specifically for this condition. HA has a library of assets that include PowerPoint presentations, videos, and online and print educational materials. There will be also in-person outreach resulting recruitment, website (the study website and HA website), webform (with a symptom of gait, dementia, and bladder symptoms), YouTube videos. The investigators will also go to the communities like senior centers, health fair, and churches, then we will give a talk about iNPH. These resources will be carefully adjusted to suit low-income demographics, guided by feedback from Baltimore audiences and HA's iNPH volunteers.
214921249|NCT05138770|DRUG|VC005 Tablets|VC005 Tablets 1、5、10、25、50、100mg single dose
214921250|NCT05138770|DRUG|VC005 Tablets Placebo|VC005 Tablets Placebo 1、5、10、25、50、100mg single dose
214921251|NCT05138770|DRUG|VC005 Tablets food effects group|VC005 Tablets qd per period, for two periods
214921252|NCT00892151|DEVICE|GLUCOFACTS® Deluxe|Diabetes Data Management Software
214921253|NCT04349345|DIAGNOSTIC_TEST|sperm count|total progressive sperm motile count
214921254|NCT03395145|DEVICE|Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation after tooth extraction
214921255|NCT02040051|BEHAVIORAL|Sound isolation / Music therapy|"Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.~Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)"
214921256|NCT05178160|OTHER|PEEP Standard Protocol|All the patients treated with CPAP receive a PEEP standard of 10 cmH2O with a fixed FiO2
214921257|NCT02807727|DRUG|Intralipid 20%|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
214921258|NCT02807727|DRUG|Modified Ringers Lactate|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
214921259|NCT05131373|DRUG|ORG101 - Experimental 1|C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals
214921260|NCT05131373|DRUG|ORG101PL - Placebo 1|Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals
214955325|NCT05108584|PROCEDURE|PPE Level 3 and Direct Laryngoscope|The operator used level 3 PPE and direct laryngoscope for the intubation process
214955326|NCT05108584|PROCEDURE|PPE Level 2 and Direct Laryngoscope|The operator used level 2 PPE and direct laryngoscope for the intubation process
214955327|NCT03887377|DRUG|Botulinum Toxins|We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.
214955328|NCT03887377|OTHER|Normal saline|Normal saline will serve as the placebo control on the contralateral breast
214955329|NCT05430659|OTHER|observational study|Retrospective observational study
214955330|NCT05885646|DRUG|Sulthiame|Sulthiame add-on according to good clinical practice in these childhood epilepsy syndromes
214955331|NCT06384053|COMBINATION_PRODUCT|Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined|The wIRA device applies hyperthermia by heating the treatment area (with maximum surface temperature set to 43° C), aiming to make cancer cells more sensitive to radiation therapy for non-melanoma skin cancer combined with radiotherapy.
214955332|NCT06384053|RADIATION|Radiotherapy (RT)|Radiotherapy is applied.
214955333|NCT06439524|DRUG|40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate|if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis
214955334|NCT03079973|DRUG|P-3073 (calcipotriene 0.005%)|Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
214955335|NCT03079973|DRUG|Vehicle of P-3073|Once daily for 24 weeks.
215063108|NCT05894135|DRUG|BG2109 100mg|One tablet of BG2109 100mg , oral , once daily
215063109|NCT05894135|DRUG|BG2109 200mg|One tablet of BG2109 200mg, oral , once daily.
215063110|NCT05894135|DRUG|ABT(E2 1 mg / NETA 0.5 mg)|One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
214484964|NCT06426004|OTHER|primary care physicians (PCPs) will receive professional NPH education|A comprehensive professional development program for PCPs and CHWs, featuring presentations, educational videos, webinars, and tools on iNPH diagnosis, treatment, and care management. Provider Continuing Medical Education (CME) credits will be offered for in-person lectures, aiming to equip PCPs with the skills needed to address iNPH in low-income settings effectively
214484965|NCT06426004|OTHER|A community health worker will assist PCP|A community health worker will assist PCP to identify barriers and help overcome these barriers in order for patient to access iNPH care.
214484966|NCT05377411|DEVICE|tDCS|During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
214921261|NCT04925882|PROCEDURE|Erector spinae plane block|"After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
214921262|NCT04925882|PROCEDURE|Erector spinae plane block|"After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
214484967|NCT05377411|BEHAVIORAL|cognitive training|Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
214921263|NCT02699931|DEVICE|Electric3D|Oral-B 3D with orthodontic head
214921264|NCT02699931|DEVICE|Manual|Oral-B orthodontic
215063111|NCT05894135|DRUG|BG2109 100mg Placebo|One tablet of BG2109 100mg Placebo, oral , once daily.
215063112|NCT05894135|DRUG|BG2109 200mg Placebo|One tablet of BG2109 200mg Placebo, oral , once daily.
215063113|NCT05894135|DRUG|ABT Placebo|One tablet of ABT Placebo, oral, once-daily
215063114|NCT05847660|DRUG|Progesterone antagonist|Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.
214484968|NCT05643196|DEVICE|PLIFUS|The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
214484969|NCT05643196|DEVICE|Sham PLIFUS|Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
214484970|NCT05643196|DEVICE|MRI|A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
214484971|NCT04772534|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
214921265|NCT02518282|OTHER|Serum levels of high-sensitivity troponin T|Serum levels of hs-cTn will be measured before surgery, upon arrival at the ICU, as well as every 6 hours for 24 hours, then every 8 hours the following 24 hours and a last blood sample will be taken 72 hours after surgery.
214921266|NCT02518282|OTHER|Twelve-lead ECGs|Twelve-lead ECGs obtained the day prior to heart valvular surgery, immediately upon arrival at the ICU, and then 24, 48 and 72 hours post-surgery will be reviewed by a cardiologist to evidence signs of MI.
215063115|NCT05847660|DRUG|conventional antagonist protocol|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
215063116|NCT06199375|BEHAVIORAL|Routine treatment|The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
215063117|NCT06199375|BEHAVIORAL|Rehabilitation training|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
214321955|NCT03938116|OTHER|Healing Hearts Together|Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
214321956|NCT05357391|DEVICE|The Pressure Injury Prediction and Education model using a mobile application system|Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
215063118|NCT06199375|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
214484972|NCT05267496|DEVICE|oscillating positive expiratory pressure device|Patients randomized to the experimental arm of the study will receive an AEROBIKA oscillating positive expiratory pressure device in addition to the standard pulmonary rehabilitation program. The patient will receive instructions pertaining to the use of the device during the first evaluation visit to the rehabilitation service and this information will be reinforced at each follow-up visit. The patient will receive a log book in order to record date and time of use to assess treatment compliance and an instructions and maintenance booklet will be handed out to ensure adequate use of the device.
214484973|NCT05267496|PROCEDURE|Pulmonary rehabilitation|"Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~* Directed ventilation~* Physical conditioning Post-surgical rehabilitation~* Diaphragmatic mobilization~* Thoracic expansion through incentive flow spirometry"
214484974|NCT05435547|DRUG|Dexamethasone|Will take Dexamethasone pre-operatively
214484975|NCT05435547|DRUG|Placebo|Will take Placebo pre-operatively
214921267|NCT02518282|OTHER|Transthoracic echocardiography (TTE)|A TTE will be also performed by a cardiologist after cardiac valvular surgery to determine the ejection fraction of left ventricle and the occurrence of a new regional wall motion abnormality. This TTE will be compared, by the same cardiologist, with a TTE performed before cardiac valvular surgery.
215063119|NCT02995161|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)
215063120|NCT02995161|DRUG|SPF control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
215063121|NCT01035463|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
215063122|NCT01035463|DRUG|Carmustine|Given IV
214321957|NCT06251700|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonscopy
215063123|NCT01035463|DRUG|Cytarabine|Given IV
215063124|NCT01035463|DRUG|Etoposide|Given IV
215063125|NCT01035463|DRUG|Lenalidomide|Given PO
215063126|NCT01035463|DRUG|Melphalan|Given IV
214672282|NCT06970574|DRUG|Levobupivacaine|to compare the clinical intraoperative effects of intrathecal administration of fentanyl in comparison with dexmedetomidine on shoulder tip pain in patients undergoing laparoscopic cholecystectomy.
214672283|NCT06970015|OTHER|No intervention|No intervention, this is an observational study on patients with suspected acute mesenteric ischemia
214672284|NCT02973672|DRUG|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
215063127|NCT01035463|BIOLOGICAL|Rituximab|Given IV
214672285|NCT00499993|DRUG|lanreotide (Autogel formulation), duration of treatment 46-48 weeks|
214672286|NCT05361512|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
214921268|NCT02954029|DEVICE|ezClot (hemostasis pad)|ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.
214921269|NCT02954029|DEVICE|BloodSTOP ix pad|BloodSTOP® pad is an etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation pathway.
214921270|NCT02954029|DEVICE|Rotary compression device|Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.
215063128|NCT04082845|OTHER|Education|Web-based patient education
215063129|NCT04924101|BIOLOGICAL|Pembrolizumab|IV infusion
215063130|NCT04924101|BIOLOGICAL|MK-4830|IV infusion
215063131|NCT04924101|BIOLOGICAL|Boserolimab|IV infusion
215063132|NCT04924101|DRUG|Lenvatinib|Oral capsule
215063133|NCT04924101|DRUG|Etoposide|IV infusion
215063134|NCT04924101|DRUG|Cisplatin|IV infusion
215063135|NCT04924101|DRUG|Carboplatin|IV infusion
215063136|NCT00737217|BEHAVIORAL|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
214484976|NCT05520515|OTHER|Aquatic Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention is performed at the thermal pool sector of Clube Brilhante in Pelotas city. The pool water temperature is maintained between 30-32°C, with participants immersed in the depth level between the xiphoid process and shoulders. The aquatic training group performs the following water aerobics exercises: stationary running, frontal kick, cross-country skiing, and butt kick during the stimulus and jumping jacks during the active recovery. The training session is collective, with 3 to 6 participants, supervised by two experienced instructors, one outside and one inside the pool. The group also receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
214484977|NCT05520515|OTHER|Land Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention occurs at the School of Physical Education, Federal University of Pelotas. Depending on weather conditions, the land training group will perform aerobic training with walking/running exercises in a flat outdoor environment or inside a multi-sport gym. The training session will be collective, with 3 to 6 participants, supervised by two experienced instructors, one at the starting point and the other following the movement of the participants. In addition, the group receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
215063137|NCT01412450|DEVICE|nitinol stent|implantation of one Protégé EverFlex stent
214321958|NCT04600648|DIAGNOSTIC_TEST|Serum insulin level|Measure levels before and after weight loss related to bariatric surgery
214321959|NCT04600648|DIAGNOSTIC_TEST|Serum Leptin test|Measure levels before and after weight loss related to lifestyle change weight loss
214321960|NCT05891548|DRUG|CLS-AX|CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.
214321961|NCT05891548|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
214321962|NCT04127786|BIOLOGICAL|Purified vero rabies vaccine - serum free - VRVg-2|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
215063138|NCT02746887|OTHER|Preterm/term cohort|
214484978|NCT05520515|OTHER|Health Education|The intervention occurs at the School of Physical Education, Federal University of Pelotas. The intervention consists of an educational program with weekly lectures of approximately 30 min. The lectures are led by a qualified health professional, using expository and interactive approaches on topics that cover basic knowledge related to breast cancer and complementary therapies. Additionally, each participant receives a self-care booklet containing information about the topics addressed during the meetings. Qualified professionals give lectures on the following topics: 1) fatigue and quality of life; 2) anxiety and depressive symptoms; 3) body image and sexual function; 4) self-esteem; 5) self-care; 6) sleep; 7) cognitive function; 8) symptoms in the arm and breast; 9) pain and arthralgia; 10) body composition and bone health; 11) eating habits; 12) physical activity.
214484979|NCT01287871|OTHER|supportive care|
214484980|NCT04194450|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.
214921271|NCT03090529|OTHER|Exercise Group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
214321963|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Verorab®|Pharmaceutical form:Freeze-dried Route of administration: Intramuscular
214321964|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Imovax® Rabies|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
214484981|NCT04194450|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of taste-matched placebo prior to assessment of outcomes.
214484982|NCT05142371|OTHER|Best Practice|Continue current activities of daily living
214484983|NCT05142371|OTHER|Exercise Intervention|Participate in exercise intervention
214484984|NCT05142371|OTHER|Quality-of-Life Assessment|Ancillary studies
214484985|NCT05142371|OTHER|Questionnaire Administration|Complete questionnaires
214484986|NCT02252380|DEVICE|Transcranial ExAblate System|MR Guided Focused Ultrasound
214484987|NCT05890716|DIAGNOSTIC_TEST|AI-powered ECG analysis to detect cardiac arrhythmic episodes|ECG recording and processing by AI platform
214921272|NCT04544657|OTHER|no intervention|No intervention for enrolled patients
214921273|NCT01155440|DRUG|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
214921274|NCT01155440|PROCEDURE|Thoracic epidural block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
214921275|NCT04784429|DEVICE|Kenevo or C-Leg 4|Kenevo fitted to subjects walking slower than 0.8 m/s as measured by the 2-minute Walk Test. C-Leg 4 fitted to subjects walking faster than 0.8 m/s.
214921276|NCT04784429|DEVICE|Non microprocessor controlled knee (NMPK)|NMPK consistent with current standards of care
215063139|NCT01250184|OTHER|Physical therapy|Twelve sessions (3 per week)
215063140|NCT01250184|DRUG|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
215063141|NCT01250184|OTHER|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
215063142|NCT04528017|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
215063143|NCT04528017|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
214921277|NCT02799667|DEVICE|Standard Dressing|Patients are randomized to the standard dressing at the time of fascial closure.
214921278|NCT02799667|DEVICE|Negative Pressure Wound Therapy Dressing|Patients are randomized to the NPWT at the time of fascial closure.
214921279|NCT00003140|DRUG|letrozole|Given orally
214921280|NCT00003140|OTHER|placebo|Given orally
214921281|NCT02729766|OTHER|Induced hypotonic hyponatremia - SIAD model|
214921282|NCT02729766|DRUG|Empagliflozin 25mg Tbl|
214921283|NCT02729766|DRUG|Placebo P-Tablet|
214921284|NCT04075682|OTHER|Inserts with efficacy messages|Four rotating inserts (i.e., small, printed messages) with messages about cessation benefits (i.e., response efficacy) and tips to quit (i.e., self-efficacy messages) will be placed inside cigarette packs.
214921285|NCT04075682|OTHER|Pictorial warnings on packs|Four rotating pictorial warnings illustrating the harms of smoking will be printed on labels that will placed on and cover approximately 50% of the cigarette packs.
214921286|NCT01448772|DRUG|Dronabinol Capsules, 5 mg|Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods
214921287|NCT01448772|DRUG|Dronabinol Oral Solution|Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
214921288|NCT03292328|OTHER|Yoga|Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
214921289|NCT03292328|OTHER|Wait List Control|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
214921290|NCT06409338|DEVICE|Transcutaneous auricular vagus nerve stimulation (active）|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
214955336|NCT02716506|PROCEDURE|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
214955337|NCT02087943|DRUG|Apremilast|Orally twice a day (BID)
214321965|NCT06032780|OTHER|Eccentric Resistive Training + Aerobic training Group|"Eccentric Resistive training includes upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings) 2 sets of 12 repetitions (reps) for each group of muscles in lengthened position for eccentric training in approx. 20 minutes (min). Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair descending training and squatting position and eccentric hamstring curls with weights at ankle for lower limb eccentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain) . (approx. 20 min).~\+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
214321966|NCT06032780|OTHER|Resistance Training + Aerobic training Group|"Resistive training (concentric) includes Upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings), 2 sets of 12 reps for each group of muscles in approx. 30 min. Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair climbing training and quadriceps training + standing hamstring curls with weight at ankle for lower limb concentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain)~\+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
214955338|NCT02087943|DRUG|Apremilast|Orally twice a day (BID)
214955339|NCT02087943|DRUG|Placebo|Orally twice a day (BID)
214955340|NCT02087943|DRUG|Placebo|Orally twice a day (BID)
214955341|NCT01308996|DEVICE|INFUSE® Bone Graft|Implantation of INFUSE® Bone Graft \[recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)\] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device
214955342|NCT01308996|PROCEDURE|Autogenous bone graft from tibia or iliac crest|Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
214955343|NCT05750173|OTHER|Streamlining of the pre-procedural patient pathway|"Pre-TAVI ICA is associated with procedural risk, radiation, costs and requires hospitalization (2d).~Show that CTA is a viable alternative to rule out ≥50% left main coronary artery (LM) / prox. left anterior descending artery (LAD) stenosis.~An implementation of a standardized patient pathway which is reproducible, will help to streamline the pre-procedural workup of patients without compromising patient safety."
214955344|NCT03894033|DEVICE|Ascyrus Medical Dissection Stent (AMDS)|The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
214955345|NCT05526248|DRUG|Darolutamide(BAY1841788, Nubeqa)|tablet, oral
214955346|NCT05526248|DRUG|Enzalutamide|tablet, oral
214955347|NCT04885231|BEHAVIORAL|Perioperative Pain Management Education and Counseling|All patients will receive both verbal postoperative pain management education and counseling as well as a written handout. Multi-modality non-opioid methods of pain control will be thoroughly discussed.
214955348|NCT04977830|DEVICE|Xenon-129|Patients will undergo a hyperpolarized MRI with administered Xenon gas
215063144|NCT01175265|OTHER|respiratory biofeedback|In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
215063145|NCT00178074|BEHAVIORAL|total sleep deprivation|
215063146|NCT00178074|PROCEDURE|PET imaging|
215063147|NCT04145921|PROCEDURE|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
215063148|NCT04145921|PROCEDURE|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
215063149|NCT05541406|BEHAVIORAL|Proud & Empowered|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
214321967|NCT06032780|OTHER|Aerobic training Group|Aerobic training as a control will be given to this group as well for approximately 60 minutes per session. Aerobic training exercise will be completed via a ergometer/stationary cycle; type will be continuous aerobic exercise and intensity of 60% of max HR (or peak VO2) in HF individuals.
214321968|NCT04147312|DRUG|Fufang E'Jiao Jiang|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
214321969|NCT04147312|DRUG|placebo containing low-dose fufang E'Jiao Jiang|placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
214321970|NCT01613781|OTHER|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
214321971|NCT01613781|OTHER|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
214321972|NCT06241027|OTHER|Nerve flossing technique|The nerve flossing technique will be perform actively with the participant sitting on the chair. The participant flexed the knee of the target lower extremity backward beside the chair as far back as possible and flexed the neck at the same time, holding both the flexed knee and neck in thisposition for 5 seconds. The participant in turn extended the neck and knee of the target lower extremity, abducted and flexed the hip until pain will feel and did not push beyond that point. This extended position will be hold for 5 seconds.
214321973|NCT06241027|OTHER|Myofascial release|Myofascial release therapy involved the application of a low load, long duration stretch along the line of maximal fascial restriction. Pressure will be applied directly on the skin toward the direction of restriction until resistance of the tissue barrier will felt, Once found , the collagenous barrier will engaged for 90-120 seconds without sliding over the skin or forcing the tissues until the fascia complex started to yield and a sensation of softening will achieved.This stage will be repeated up to 5 times for new barrier until the sensation of tissue restriction during stretching became weaker.
215063150|NCT00158249|DRUG|citicoline|2 gm/day, 8 weeks treatment
214321974|NCT00004238|DRUG|pralatrexate|
214321975|NCT04992221|PROCEDURE|arterial line|arterial line inserted for invasice mointroing and sampling
214321976|NCT01904604|BIOLOGICAL|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
214321977|NCT01904604|BIOLOGICAL|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
214321978|NCT01904604|BIOLOGICAL|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
215063151|NCT00158249|DRUG|placebo|matched for physical appearance
215063152|NCT05583318|OTHER|Data collection|Data from hematological malignancy registries
214321979|NCT05124665|BEHAVIORAL|Social Support|"The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description."
215063153|NCT05583318|OTHER|Questionnaires|"9 questionnaires were sent out:~1. QLQ-C30 and SF-12 Quality of Life Questionnaire.~2. Oral quality of life questionnaire QLQ-OH15~3. Sexuality questionnaire SHQ-C22~4. Anxiety and depression questionnaire HADS,~5. Rosenberg Self-Esteem Questionnaire~6. RNLI Reintegration to Normal Life Questionnaire~7. Social Support Questionnaire SSQ6,~8. Socio-economic status questionnaire EPICES,~9. Complementary questionnaire collecting data on socio-professional status."
215063154|NCT05103605|DRUG|Osimertinib|Single arm treated by osimertinib
215063155|NCT06477393|OTHER|Regular rehababilitation|Subjects of the experimental and control groups will receive routine procedures applied in the resort sanatorium: physiotherapy (28-32), occupational therapy (12-18), dry hydromassage (7-8), psychotherapy or audiovisual relaxation (3-4), social worker's visit ( 1-2), physiotherapy (magnetotherapy, ultrasound therapy (8-9).
215063156|NCT06477393|OTHER|Heat procedures|"The bath is filled with 200 litres of warm tap water at 36-38°C. The participant lies in the prepared bath, ensuring the chest area remains uncovered. While in the bath, the participant performs gentle movements. The procedure lasts 12-15 minutes. Air is pumped into the water to increase the oxygen saturation in the bath environment.~A prepared gel pack will be placed in another bag and heated to 50-55°C. The heated pack will be delivered to the treatment area using pumps. For applications, the gel pack is used at 40-42°C. Temperature of the gel pack can range between 38-43°C."
214484988|NCT03130244|DEVICE|Magnet Anastomosis System|The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.
214921291|NCT06409338|DEVICE|Transcutaneous auricular vagus nerve stimulation (sham）|In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
214921292|NCT03128138|DRUG|SPH3127|"Drug: SPH3127 Tablet~Drug: Placebo Tablet"
214921293|NCT00179439|PROCEDURE|nasal potential difference testing|
214921294|NCT02673125|GENETIC|MitoGrade|MitoGrade refers to the mitochondrial DNA assessment in embryos.
214921295|NCT00707525|PROCEDURE|Preimplantation Genetic Diagnosis|Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.
214921296|NCT01579422|BEHAVIORAL|social cognitive training|social cognitive training, 8-10 sessions
215063157|NCT06477393|OTHER|Healing mud application|"Therapeutic mud applications: peat brought from the quarry is sifted, ground, and mixed with natural mineralisation of 20-22g/l with mineral water in a ratio of at least 4:1 until the consistency of thick sour cream. The prepared peat mud is heated to 50-55 degrees. The heated mud is fed to the place where the procedures are performed with the help of pumps. Mud mass at 40-42 degrees is used for applications. A mud temperature range of 38-43 degrees is possible.~Before the procedure, it is recommended not to eat, go to the toilet, or take a warm shower. A polyethene film is laid on a special heated couch, and a 2-4 cm thick layer of mud is poured into the area of the hands and feet, covered with a blanket. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel, and rests. Peloids are not reused."
215063158|NCT06477393|OTHER|Mineral water bath|The pearl bath is prepared by a physical method. The bath is filled with 200 l of warm 36-38 C mineral water, the subject lies in the prepared bath, leaving the heart area open, while lying in the bath he performs light movements. The duration of the procedure is 12-15 minutes. Air is blown into the water, which increases oxygen saturation in the bath environment. Before the procedure, it is recommended not to eat, go to the toilet, take a warm shower. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel and rests. Mineral waters are not reused.
214321980|NCT04067362|OTHER|food containing dietary fiber|commercially available chicory root flour and chicory root fiber
214321981|NCT04147442|DEVICE|Hearing aid with fine-tuned and standard programs|A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
214321982|NCT02871128|DIETARY_SUPPLEMENT|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
215063159|NCT05486884|PROCEDURE|Maintain MAP ≥ 90 mmHg|Maintain MAP ≥ 90 mmHg for the 24 hours following inclusion by perfusion of norepinephrine
214321983|NCT02871128|DIETARY_SUPPLEMENT|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
214484989|NCT03130244|DRUG|Best Medical Management|The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
214484990|NCT05858905|DEVICE|Intravascular Lithotripsy|The Shockwave Medical IVL System is intended for lithotripsy-enhanced treatment of lesions, including calcified lesions, to increase luminal diameter, allowing for further treatment (e.g. post-dilatation) in the peripheral arterial vasculature. Not for use in the coronary or cerebral vasculature.
214484991|NCT06495099|OTHER|Russian electrical stimulation|Type of Medium frequency current with 2500 Hz frequency modulated at 50 Hz with 50% Duty cycle training protocol is (10 sec. on time - 50 sec. off time - 10 minutes total time)
214921297|NCT06065917|DIAGNOSTIC_TEST|Measurement of the total small bowel length using CT scan and MRI with 3D reconstruction and AI tool|The intervention consists in performing CT and MR imaging with small bowel length measurement before bariatric/metabolic surgery in obese patients. Then, during surgery the patients will undergo laparoscopic stretched small bowel measurement as the reference gold standard method to measure the small bowel length. The imaging of the training cohort will be used to trained an AI to set up an automatic method of small bowel length measurement via the analysis of CT and MRI imaging.
214921298|NCT05091541|DRUG|Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection|CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
214921299|NCT04421287|DRUG|Zhenyuan capsule|0.25g/ tablets, 2 tablets / TID, for 12 weeks
214484992|NCT05379725|OTHER|Mediterranean Dietary Pattern|The Mediterranean dietary pattern includes whole or minimally processed foods with a high intake of vegetables, fruits, whole grains, fish, and olive oil.
214921300|NCT03768154|PROCEDURE|Supine + spontaneous effort|without muscle paralysis in supine position
214921301|NCT03768154|PROCEDURE|Supine + paralysis|administer muscle paralysis in supine position
214921302|NCT03768154|PROCEDURE|Prone + paralysis|change the patient position from supine to prone with muscle paralysis
214921303|NCT03768154|PROCEDURE|Prone + spontaneous breathing|cease the paralysis in supine position
215063160|NCT05486884|PROCEDURE|Maintain MAP ≥ 65 mmHg|Maintain MAP ≥ 65 mmHg for 24 hours after randomization through the perfusion of norepinephrine
215063161|NCT06248164|OTHER|No intervention|We will not carry out any type of intervention, just observe the behaviors and health parameters of parents and children.
215063162|NCT05764720|RADIATION|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
215063163|NCT03943901|DRUG|Rituximab|Rituximab is a monoclonal antibody
215063164|NCT03943901|DRUG|Cyclophosphamide|Chemotherapy drug, alkylating agent
215063165|NCT03943901|DRUG|Doxorubicin|Chemotherapy drug, anthracycline antibiotic
215063166|NCT03943901|DRUG|Vincristine|Chemotherapy drug, plant alkaloid
215063167|NCT03943901|DRUG|Prednisone|Steroid, anti-inflammatory
215063168|NCT03943901|BIOLOGICAL|Pegfilgrastim|Granulocyte stimulating factor, biologic response modifier
215063169|NCT05646446|BEHAVIORAL|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to harm among bisexual women.
214321984|NCT02871128|DRUG|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
214321985|NCT01453842|DIETARY_SUPPLEMENT|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
214321986|NCT01453842|DIETARY_SUPPLEMENT|Olive oil|Carrot and olive oil and 1½ g of paracetamol
214321987|NCT01453842|DIETARY_SUPPLEMENT|Carrot|Carrot and 1½ g of paracetamol
214321988|NCT01347437|BEHAVIORAL|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
214321989|NCT00895466|BIOLOGICAL|PEP-223/CoVaccine HT|
214321990|NCT04054037|OTHER|No intervention|This is an observation study, no intervention will be indicated during diagnosis and treatment.
214321991|NCT01395940|DRUG|KLH-2109|
215063170|NCT04366830|DRUG|Remestemcel-L|Participants will receive remestemcel-L in two infusions of 2 x 10\^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
215063171|NCT05132179|DRUG|Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution|Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
215063172|NCT05369598|DEVICE|Post-operative ABF followed by fitting according to clinical standard|Cochlear implant will be fitted first with anatomy-based fitting for 6 months and followed by default fitting for 2 months.
215063173|NCT05369598|DEVICE|Fitting according to clinical standard followed by post-operative ABF|Cochlear implant will be fitted first with default fitting for 6 months and followed by anatomy-based fitting for 2 months.
215063174|NCT01407952|DEVICE|HydroCoil Embolic System|HydroCoil Embolic System
215063175|NCT01407952|DEVICE|Control (bare platinum coils)|bare platinum coils
215063176|NCT01062789|DEVICE|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
215063177|NCT01059487|OTHER|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
215063178|NCT04670263|DEVICE|Tear Film Imager|Tear Film Imager recording
215063179|NCT00935493|DRUG|Guanfacine|Guanfacine 0.1 mg po qhs
215063180|NCT00935493|DRUG|Guanfacine|Guanfacine 0.5 mg po qhs
215063181|NCT00935493|DRUG|Placebo|Placebo po qhs
215063182|NCT02281227|PROCEDURE|skin compression|skin compression with an indicator for determination of needle entry point
215063183|NCT03565250|OTHER|self understanding interview|semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model
215063184|NCT04153981|DRUG|Insulin Glargine|Administered SC
215063185|NCT05746013|DIETARY_SUPPLEMENT|Lipid Emulsion|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
215063186|NCT02003794|DRUG|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
215063187|NCT03910790|DEVICE|19 gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
215063188|NCT06343545|BEHAVIORAL|Standard of Care|Standard of Care provided by enrolling hospitals
214321992|NCT01395940|DRUG|KLH-2109|
214321993|NCT02273843|DRUG|High-dose vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
214921304|NCT04420533|BEHAVIORAL|Behavior therapy alone|"1. reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient;~2. moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;~3. use of relaxed and double-voiding techniques;~4. urethral milking to prevent post-micturition dribble;~5. distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms;~6. bladder retraining that encourages men to hold on when they have sensory urgency;~7. reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);~8. providing necessary assistance when there is impairment of dexterity, mobility or mental state;~9. treatment of constipation."
215063189|NCT06343545|BEHAVIORAL|Rehabilitation|An implementation bundle of measures to improve outcomes in intensive care unit, hospital, and after hospital discharge, including rehabilitation at home performed through telemedicine.
214921305|NCT04420533|DRUG|Mirabegron 50 MG Extended Release Oral Tablet|Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
214921306|NCT03661242|BEHAVIORAL|Physical activity|Patients in shared care arm has regular combined visits with Oncologist and Clincal Exercise Physiologist (CEP). Individual physical activity plan developed by CEP for patients in shared care arm.
214921307|NCT00282399|DRUG|Subcutaneous Decitabine|
214921308|NCT00887315|DRUG|Docetaxel and cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV repeated every 21 days for 2 additional cycles. For patients randomized to group 1, the chemotherapy is identical to that administered for the first 2 cycles
214921309|NCT00887315|RADIATION|Docetaxel and cisplatin Plus Hypofractionated Radiotherapy|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV for 2 cycles along with hypofractionated radiotherapy to all known sites of disease
214921310|NCT04830111|DEVICE|heart rate variability biofeedback Application (Eureka iDestressor)|heart rate variability biofeedback protocol duration time is 10 min twice/day for 5days
214921311|NCT00619892|DRUG|quetiapine XR|Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.
215063190|NCT05679596|DIETARY_SUPPLEMENT|ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate|Provided twice a day between meals.
215063191|NCT05679596|DIETARY_SUPPLEMENT|carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)|Provided twice a day between meals.
215063192|NCT00021567|DRUG|Interferon Gamma for Aerosol|
215063193|NCT04037449|PROCEDURE|TAP block|With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
214321994|NCT02273843|DRUG|Conventional-Dose Vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
214321995|NCT00358527|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
214321996|NCT00358527|OTHER|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
214321997|NCT04144166|DEVICE|capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
214321998|NCT02439112|OTHER|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly \>65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
214321999|NCT00145509|DRUG|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
214322000|NCT00145509|DRUG|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
214322001|NCT02959281|OTHER|Providing caring physicians with hemodynamic variables|NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
214322002|NCT02881996|DRUG|IV tylenol|IV tylenol given scheduled in addition to standard PCA
214322003|NCT02881996|DRUG|No IV tylenol|No additional IV Tylenol given
214322004|NCT02881996|DRUG|Ketorolac|both groups receive as part of our standard postop pain protocol after all operations
214322005|NCT01890772|DRUG|Telaprevir|
214322006|NCT01890772|DRUG|Peginterferon alfa-2a|
214322007|NCT01890772|DRUG|Ribavirin|
214322008|NCT01890772|DIETARY_SUPPLEMENT|Vitamin D|
214322009|NCT05473533|DRUG|Placebo|Placebo; formulated as solution for inhalation without active substance.
214322010|NCT05473533|DRUG|PRS-220|PRS-220; formulated as solution for inhalation.
214322011|NCT02376192|DEVICE|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
214484993|NCT05379725|OTHER|High Fermented Food Dietary Pattern|Fermented foods such as yogurt, kefir, fermented cottage cheese, fermented vegetables, vegetable brine drinks, kombucha, other fermented non-alcoholic drinks, and other foods will be recommended.
214484994|NCT04983511|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
214484995|NCT04263038|DRUG|Rivaroxaban|Anticoagulation
214484996|NCT04263038|DRUG|Placebo|Study drug without active agent
214484997|NCT06250673|DIETARY_SUPPLEMENT|Diet experiment|For the isotretinoin users
215063194|NCT04037449|OTHER|Conventional analgesia|"Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)"
215063195|NCT02603458|DRUG|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
215063196|NCT02603458|DRUG|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
215063197|NCT01355679|DEVICE|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
214921312|NCT00619892|DRUG|placebo|Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
214921313|NCT03193320|OTHER|Fluid therapy protocol|Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
214921314|NCT03046667|DIETARY_SUPPLEMENT|Barley β-glucan|The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
214921315|NCT03046667|DIETARY_SUPPLEMENT|Control|The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
214921316|NCT04448444|BEHAVIORAL|Motor Program Activating Therapy|Patients undergo ambulatory physiotherapy - Motor Program Activating Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
214921317|NCT04448444|BEHAVIORAL|Vojta reflex locomotion|Patients undergo ambulatory physiotherapy - Vojta Reflex Locomotion Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
214921318|NCT06161467|DEVICE|Ultrasound devices|Safe , no radiation
214921319|NCT00821964|DRUG|imiquimod|Given topically
214921320|NCT00821964|DRUG|Abraxane|Given IV
214322012|NCT02376192|DRUG|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
214322013|NCT02376192|DEVICE|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
214322014|NCT02376192|DRUG|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
214322015|NCT02376192|DRUG|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
214322016|NCT01836484|DIAGNOSTIC_TEST|Diffusion-weighted MRI|
214322017|NCT01836484|DIAGNOSTIC_TEST|Fluorodeoxyglucose-18-PET/CT|
214322018|NCT01836484|DIAGNOSTIC_TEST|Fluoro-ethyl-coline-PET/CT|
214322019|NCT03422341|DEVICE|Comparison between GenePOC CR and Reference Method|The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
214322020|NCT04145895|OTHER|Postoperative activity restrictions|Recommendations for return to full activity including return to school, sports, exercise, etc.
214322021|NCT03606525|PROCEDURE|subarachnoid block|Vertebral column length and abdominal girth will be measured before routine subarachnoid block is given to recruited patients
214322022|NCT02123199|DRUG|Indacaterol (Onbrez®) /QAB149|
214322023|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided quadratus lumborum block|prospective randomized comparative study between Group (1) : quadratus lumborum block
214322024|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
214322025|NCT01481116|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
214322026|NCT01481116|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
214322027|NCT01481116|DRUG|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
214322028|NCT02808286|BEHAVIORAL|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
214322029|NCT02808286|BEHAVIORAL|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
215063198|NCT05302869|OTHER|None intervention|None intervention
215063199|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|200 mg dose daily for 12 weeks.
215063200|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|400 mg dose daily for 12 weeks.
214921321|NCT00821964|OTHER|laboratory biomarker analysis|Correlative studies
214921322|NCT00821964|GENETIC|RNA analysis|Correlative studies
214921323|NCT00821964|OTHER|immunoenzyme technique|Correlative studies
214921324|NCT05772221|OTHER|Screening|Screening assessments to measure social determinants of health in relation to cardiovascular disease.
214921325|NCT01962766|BEHAVIORAL|Myofunctionnal therapy|
214921326|NCT01962766|BEHAVIORAL|instructions|
214921327|NCT02497820|DRUG|Aspirin|"Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place."
214921328|NCT00387855|BEHAVIORAL|SOS program|screening and didactic programming to raise awareness of depression suicidality
215063201|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|600 mg dose daily for 12 weeks.
215063202|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|800 mg dose daily for 12 weeks.
215063203|NCT00175630|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
215063204|NCT03177512|BEHAVIORAL|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
215063205|NCT02244307|DRUG|alpha-adrenergic blocker|
215063206|NCT01781806|DRUG|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.
214322030|NCT03030027|BEHAVIORAL|Connecting Through Caregiving|The Connecting Through Caregiving intervention focuses on reappraisal exercises on intergeneration relationships in caregiving, involving the following: 1) enhancing self-awareness of the caregiver, 2) developing interpersonal empathy for the care-recipient, 3) help-seeking in caregiving, 4) balancing self-care and caring and 5) negotiating action plans.
214322031|NCT03030027|OTHER|Basic Skills Building|Skill building involves: 1) monitoring activities, 2) pleasant event scheduling, 3) communicating with the care recipient, 4) communicating with family members and 5) review implementation
215063207|NCT00964002|DRUG|efavirenz|
215063208|NCT05700786|BEHAVIORAL|Mindful compassion for perfectionism|The intervention is a 8-week group psychotherapy in a hybrid format: 8 weekly online sessions lasting 2 hours plus an in presence half-day of silence lasting 4 hours.
215063209|NCT02977910|PROCEDURE|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
215063210|NCT04736212|DEVICE|Bed sensor monitoring system|Respiratory patterns in the post-anesthesia care unit will be assessed using a validated, modified under bed weighing scale placed under the patient's bed in the PACU.
214921329|NCT02846155|OTHER|clear water|the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination
215063211|NCT00002297|DRUG|Inosine pranobex|
215063212|NCT06012747|OTHER|Questionnaire|The patients receive a questionnaire every 6 hours during the first 24 hours after their cesarean section, and again after 2, 7, and 30 days.
215063213|NCT04751604|DIETARY_SUPPLEMENT|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks
215063214|NCT04751604|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
215063215|NCT03084094|DEVICE|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
215063216|NCT00904670|DRUG|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
215063217|NCT00904670|DRUG|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
215063218|NCT00904670|DRUG|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
214322032|NCT02072291|DRUG|Nifedipine|PO Nifedipine 5mg single dose
214322033|NCT04904185|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
214322034|NCT04904185|DRUG|Fludarabine Phosphate|Fludarabine Phosphate 30 mg/m2 is administered on day -4 and -3
214322035|NCT04904185|BIOLOGICAL|Multiple Antigen Specific Endogenously derived T cells|Antigen specific, ex vivo expanded T cells derived from peripheral blood T cells
214322036|NCT04904185|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered on day -1 and on day 21. The medicine is administered over 30 minutes
214322037|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 1 for 84 days
214322038|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 2 for 84 days
214322039|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 3 for 84 days
214322040|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
214322041|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 5 for 84 days
214322042|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 6 for 84 days
214921330|NCT02846155|DRUG|simethicone|the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination
214921331|NCT02846155|DRUG|simethicone combined with pronase|the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion)，pronase granules（Deyou；Beijing Tide Pharmaceutical Co，China,containing 20,000iu pronase），and clear water before Magnetic-controlled Capsule Endoscopy examination
215063219|NCT04880746|DRUG|BEAC|Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
214484998|NCT03718130|COMBINATION_PRODUCT|Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
214484999|NCT03718130|COMBINATION_PRODUCT|Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The HTNV vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
214485000|NCT03718130|COMBINATION_PRODUCT|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The PUUV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
214485001|NCT03718130|COMBINATION_PRODUCT|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The PUUV DNA vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
214485002|NCT03718130|COMBINATION_PRODUCT|Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV and PUUV vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
214485003|NCT03718130|COMBINATION_PRODUCT|Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)|The HTNV and PUUV vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
214485004|NCT03021330|DRUG|Daunomycin and Cytarabine (DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
214485005|NCT03021330|DRUG|Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-4 and 1g/㎡/d on day 5-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
214485006|NCT04282109|DRUG|Nivolumab + Paclitaxel|"Combination treatment: Nivolumab 240 mg will be administered via IV infusion every 2 weeks. Paclitaxel 80mg/m2 will be administered via IV infusion weekly. After 12 weeks from the start of the combined treatment paclitaxel will be stopped.~Maintenance treatment with nivolumab 480 mg every 4 weeks will start two weeks after the last administration of nivolumab 240 mg. Once nivolumab is administered at 480 mg, paclitaxel can no longer be administered.~Nivolumab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months."
214485007|NCT04282109|DRUG|Cetuximab + Paclitaxel|"Combination treatment: Cetuximab 250 mg/m2 (first dose of 400 mg/m2) administered via IV infusion weekly plus weekly paclitaxel (80 mg/m2) administered via IV infusion.~After 12 weeks from the start of the combined treatment paclitaxel will be stopped and weekly cetuximab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months."
214485008|NCT01783587|DRUG|Afatinib|Taken orally once per day
214485009|NCT01783587|DRUG|Docetaxel|15 mg/m2, given intravenously once per week
214485010|NCT01783587|RADIATION|Radiation Therapy|Daily, Monday-Friday, for six to seven weeks
214485011|NCT06367192|BEHAVIORAL|The adapted Kids in Transition to School Intervention|An intensive, school readiness intervention designed to improve preschoolers' social skills, early literacy, numeracy, and self-regulation skills at high risk for academic difficulties. The intervention is delivered virtually over 8 weeks with caregivers and intentionally occurs over the summer when there is a gap in preschool services.
214485012|NCT06367192|BEHAVIORAL|Standard school resources|Information about local preschool programs and age appropriate books for children will be provided.
214921332|NCT04111250|PROCEDURE|Maxillary sinus augmentation|Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.
214921333|NCT03992924|PROCEDURE|function or imaging guided PCI|FFR may be good tools to differentiate patients with STEMI who may not need stent implantation from those who need Optical coherence tomography (OCT) can visualize the microstructure of culprit and the OCT characteristics were validated by histology
214921334|NCT03505684|DIETARY_SUPPLEMENT|CTP|1,000 mg of CTP was orally administered per day for 12 weeks.
214921335|NCT03505684|DIETARY_SUPPLEMENT|placebo (starch)|placebo (starch)
214921336|NCT02216942|DRUG|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
214921337|NCT02216942|DRUG|Endodontic treatment using Guedes Pinto|Endodontic treatment using Guedes Pinto paste
214921338|NCT02022280|DRUG|Lansoprazole|
214921339|NCT02022280|DRUG|Placebo|Vitamin pill
214921340|NCT00018876|PROCEDURE|Lumbar nerve root decompression|
214921341|NCT00018876|PROCEDURE|Preoperative low-dose external beam radiation|
214921342|NCT01661101|DRUG|Dabigatran|Dabigatran 110 mg taken twice daily
214921343|NCT01661101|DRUG|Placebo (for Dabigatran)|Dabigatran placebo taken twice daily
214921344|NCT01661101|DRUG|Omeprazole|Omeprazole 20 mg capsule taken once daily
214921345|NCT01661101|DRUG|Placebo (for Omeprazole)|Omeprazole placebo taken once daily
214921346|NCT02595463|DRUG|Lidocaine|Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
214921347|NCT02595463|DRUG|Saline|Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
214921349|NCT01160081|OTHER|Serum sample|Serum samples collected
214921350|NCT04920396|DEVICE|E>Eye IRPL|Regulated intense pulsed light therapy
214921351|NCT04920396|DEVICE|Warm compress|Fabric mask with anti-bacterial coating filled with BodyBeads® heated in a microwave for 30 seconds before application over the eyes for 5 minutes
215063220|NCT04880746|DRUG|Cladribine combined with BEAC|Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
215063221|NCT00083954|DRUG|Quetiapine Fumarate|
214921352|NCT06015074|DRUG|Propofol|patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.
215063222|NCT05449912|OTHER|Collection of environmental exposure data|noise pollution air pollution proximity and accessibility to green spaces, blue spaces
215063223|NCT01599312|DEVICE|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
215063224|NCT06279598|BEHAVIORAL|Prolonged Exposure therapy|This concerns a form of psychotherapy for PTSD.
215063225|NCT06279598|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|This concerns a form of psychotherapy for PTSD.
215063226|NCT06279598|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|This concerns a form of psychotherapy for PTSD.
215063227|NCT05304975|BEHAVIORAL|diet|Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline visit. Participants will then meet online with the study nutritionist for around 90 minutes for personal dietary advice which will be based on the latest evidence from the MIND (Mediterranean-DASH diet Intervention for Neurodegeneration Delay) diet tailored for the target population. The nutritionist will support participants to set personal dietary goals and to monitor progress in changing towards the MIND diet. If weight loss is indicated, the nutritionist will also advise energy intake to facilitate 5-10% body weight reduction. Following the initial appointment, review meetings with the nutritionist will take place monthly in the first four months, either online or by telephone and lasting up to 60 minutes
215063228|NCT05304975|BEHAVIORAL|cognitive stimulation|Cognitive stimulation will be delivered using Brain HQ® (Posit Science), a computer based cognitive training platform, which utilises games to enhance attention, mental processing speed, learning, memory, and low mood. On 2 occasions during the first month participants will receive a 30-60min training. The aim is to familiarise participants with games and program processes to optimise engagement with the programme.The cognitive training application is available to download on a range of devices. Following training, participants will be asked to log in and complete the training session at least 4 days per week. Each session is expected to last 30 minutes. Individual cognitive training performance will be recorded centrally. Participants will receive feedback of percentage improvement in performance. The program allows remote monitoring of frequency of use and engagement. Therefore, performance, frequency, duration, and type of use will be recorded centrally throughout the study period
214921353|NCT06015074|DRUG|Ciprofol|patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.
215063229|NCT05304975|BEHAVIORAL|physical activity|The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise written resource that has been designed for older adults and adapted for the current study. It is expected that participants will begin with a basic level of exercise that will increase in frequency and intensity over the first 4 weeks to reach a core required level. In week one, participants will meet online with the trained exercise instructor for around 60 minutes to plan a personalised exercise programme. The instructor will explain the basics of exercise prescription, the foundations of the personal home programme and safety aspects. The instructor will facilitate appropriate exercise goal setting and demonstrate the exercises within the personal programme. Participants will be advised to wear the study pedometer to record their walking activity and complete the exercise diary to record overall step count and daily exercise.
215063230|NCT05304975|OTHER|risk factor management|Metabolic and vascular risk factor management. At each study visit (baseline, month 4, month 6 and month 9), participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary
214322043|NCT01403038|DRUG|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
215063231|NCT04868097|PROCEDURE|cervix biopsy|large loop electrosurgical cervix biopsy
215063232|NCT00002028|DRUG|Didanosine|
214322044|NCT05159843|BEHAVIORAL|Therapeutic education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
214921354|NCT01262157|DEVICE|Extracorporeal Shockwave Therapy Generator (Vascuspec)|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
214921355|NCT01262157|DEVICE|Low intensity shock wave therapy|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
214921356|NCT04728048|PROCEDURE|Dural puncture epidural|already described
214921357|NCT04728048|PROCEDURE|Standard epidural|already described
214921358|NCT03054155|DEVICE|Alexandrite Laser|Alexandrite 755nm hair removal laser
214921359|NCT00280397|DRUG|E7080|E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.
215063233|NCT00286091|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
215063234|NCT00286091|BIOLOGICAL|Placebo|Same volume subcutaneous injection
215063235|NCT04407156|OTHER|acute kidney injury|AKI in COVID positive cases
215063236|NCT03423238|OTHER|Exercise|Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
215063237|NCT03423238|BEHAVIORAL|Health Education|Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.
214322045|NCT00152217|DRUG|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
215063238|NCT03423238|OTHER|Exercise Compliance|Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
214322046|NCT00152217|PROCEDURE|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
214322047|NCT04101266|OTHER|Interscalene block|30 minutes before anaesthesia induction interscalene nerve block will be applied with ultrasound guidance with %0,25 bupivacain 20 cc .The sham block consisted of after patients were placed in the lateral decubitus position skin preparation, ultrasound scanning of the suprascapular region, and a dry-needling, all performed to preserve patient blinding in the ISB group patients.
214322048|NCT04101266|OTHER|suprascapular and infraclavicular nerve block|30 minutes before anaesthesia induction suprascapular with %0,25 bupivacain 10 cc .and infraclavicular nerve block with %0,25 bupivacain 10 cc will be applied with ultrasound guidance
214322049|NCT02690675|DIETARY_SUPPLEMENT|Iron fortified formula milk|One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
214322050|NCT00140075|DRUG|Epirubicin with Cyclophosphamide, followed by a Taxane|"Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
214322051|NCT00140075|DRUG|Epirubicin with a Taxane|"Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
214322052|NCT04242108|DIAGNOSTIC_TEST|Deep learning algorithm based on AS-OCT scans|The OCT scans of study subjects would be imported into the algorithm. Automated classfication of angle width and detection of synechia would be performed by the algorithm. The diagnostic performance of the algorithm would be compared with gonioscopy records.
214322053|NCT03199378|OTHER|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
214322054|NCT02863978|OTHER|Multimodal signal acquisitions|"Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras."
214322055|NCT06021067|BIOLOGICAL|Death mesenchymal stem cell|A standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10\^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4\~6 weeks.
214322056|NCT05691426|DIAGNOSTIC_TEST|Assessment of pulse wave amplitude (PWA)|Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)
214322057|NCT05691426|DIAGNOSTIC_TEST|Salivary Nitric Oxide|assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,
214322058|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
214322059|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
214322060|NCT01263288|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
214322061|NCT03643003|BEHAVIORAL|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
214322062|NCT03643003|BEHAVIORAL|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
214322063|NCT05402943|BEHAVIORAL|Nursing Care Program for Endometriosis|Nursing Care Program for Endometriosis, developed in line with Health Promotion Model
214322064|NCT05402943|BEHAVIORAL|EHP-5 Endometriosis Health Promotion Model.|EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis
214322065|NCT05402943|BEHAVIORAL|Healthy Life Style Behaviours Scale II.|A questionnaire used to measure the Healthy Life Style Behaviours.
214322066|NCT05402943|BEHAVIORAL|The Satisfaction Questionnaire for Nursing Care Program for women with Endometriosis.|A questionnaire used to measure the satisfaction levels of women with endometriosis who applied the Nursing Care Program for women with endometriosis.
214921360|NCT06383897|DRUG|HS-10398|SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction
215063239|NCT03423238|DIETARY_SUPPLEMENT|Calorie-Restricted Diet|Diet plans will provide a caloric deficit of 500 kcals per day. The lowest calorie level permitted will be 1,100 kcals for women and 1,200 kcals for men. The calorie distribution goal will be 15-20% from protein, \<30% from fat, and 45-60% from carbohydrates. Participants will consume 2 meal replacements per day (Premier Protein shakes and bars); provided by the study)), along with one meal composed of traditional foods (500-750 kcals, low in fat, high in vegetables), and 1-3 snacks as needed (e.g., cereal bar, fruit, or vegetable, providing 100-150 kcals each). For the meal, patients will follow a weekly menu plan and recipes provided by the study. The food plan will be tailored to individual preferences and energy needs.
215063240|NCT03423238|BEHAVIORAL|Behavioral Modification|During months 1-3, participants will attend weekly individual behavioral counseling sessions with the study registered dietitian (RD); individual sessions will be held twice per month during months 4-6. The sessions will focus on self-monitoring, portion control, mindful eating, coping with negative thoughts, eating at regular times, and stress management. The RD will review individual progress, solve problems, answer questions, and set weight loss goals.
214921361|NCT06383897|DRUG|HS-10398 Placebo|SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14
214921362|NCT04821609|BEHAVIORAL|Resistance Training|The resistance training will be for arms and legs, self-loading type, and external weights.
215063241|NCT03423238|OTHER|Weight-Loss Compliance|Participants will be asked to record their food and beverage intake in daily logs which will be reviewed weekly by the RD to verify compliance to the diet. Body weight will be measured weekly to ensure that participants are losing weight at an appropriate rate. If a participant is not meeting weight loss goals, energy intake will be modified accordingly to produce the desired rate of weight loss.
214322067|NCT04508569|BEHAVIORAL|Big Decisions|Big Decisions is a promising teen pregnancy prevention intervention that consists primarily of abstinence-plus sexual health education curriculum. The intended dosage for students is 10 classroom-based sexual health lessons.
215063242|NCT03423238|OTHER|Dietary Counseling|Participants have one meeting with the Rehab dietitian upon starting.
215063243|NCT05135585|OTHER|Blood sample collection|Blood sample collection at 1 month and 6 months after vaccination
215063244|NCT05135585|OTHER|Questionnaires|data collection (health data, vaccination data, etc.)
214322068|NCT05155969|DRUG|Esketamine|esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction
214322069|NCT05155969|DRUG|Normal saline|Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
215063245|NCT05085041|BEHAVIORAL|Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE)|The investigators will provide 8 sessions of a multi-component education intervention to the participants in the intervention group. Each session will address parental nutrition knowledge, self-efficacy, and attitudes around feeding, parental modeling of healthy foods, and skill development to increase success in making behavioral changes. The intervention curriculum will be informed by Social Cognitive Theory to help parents guide young children to engage in healthy eating behaviors through modeling (Curriculum Design). The investigators will deliver the intervention using multicomponent to enhance and maximize the learning experiences of the participants for successful behavior changes. The intervention will be comprised of instructional videos, text messages with key information, online cooking activities, and telephone consultation (Modality).
215063246|NCT05281627|OTHER|Emergency Laparotomy|All patients undergoing Emergency Laparotomy
214921363|NCT04727060|DEVICE|patient with knee arthroplasty|
214921364|NCT04517201|DRUG|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
214921365|NCT04517201|DRUG|Physician based insulin regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
215063247|NCT05032677|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
215063248|NCT05032677|PROCEDURE|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
215063249|NCT02036580|BIOLOGICAL|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
215063250|NCT02036580|BIOLOGICAL|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
215063251|NCT02036580|OTHER|Placebo|
214921366|NCT03033862|DEVICE|Bioresorbable Vascular Scaffold|Bioresorbable Vascular Scaffold
214921367|NCT03033862|DEVICE|Drug Eluting Stent|Drug Eluting Stent
214921368|NCT06244550|DRUG|Ganwei|Capsules
214921369|NCT06244550|DRUG|Metformin|Tablets
214921370|NCT06244550|DRUG|Placebo|Matching capsules
214921371|NCT03757728|PROCEDURE|Haemorrhoidectomy operations|for treatment of symptomatic 2 to 3 degree haemorrhoids
214921372|NCT05485168|OTHER|Sequential Variety|3 different foods served in 3 successive courses
214921373|NCT05485168|OTHER|Single-Food|1 food served in 3 successive courses
214921374|NCT05485168|OTHER|Small Portion|Small meal portion size
214921375|NCT05485168|OTHER|Large Portion|Large meal portion size
214921376|NCT02973724|DRUG|Remifentanil|The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
214672287|NCT05361512|DEVICE|epidural waveform analysis|A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
214672288|NCT06969859|DEVICE|PEMF|The PEMF will be delivered using a BIXEPS device (Quantum Tx, Singapore) ; It is utilised by the patient placing the leg into the machine. This device is operated by participant individualized NFC cards, which will be centrally programmed to deliver either active PEMF (uniform 1mT, 50Hz) or sham PEMF (0mT, 0Hz) for 30 minutes. Because this biophysical intervention is non-invasive, and the electromagnetic fields emitted into the legs do not generate any sensation (e.g. heat, sound), participants will be blinded to the treatment. The protocol will be 180 minutes of PEMF therapy, performed in six 30-minute sessions 3 times a week and completed in 2 weeks.
214921377|NCT02973724|DRUG|Propofol anesthesia|Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
214921378|NCT03562208|BIOLOGICAL|Adult Bone Marrow Stem Cells|Autologous Bone Marrow Stem Cells Transplant
215063252|NCT06482827|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
214322070|NCT04182035|OTHER|patient-tailored therapy|The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
214322071|NCT04182035|OTHER|Non-patient tailored therapy: generalized exercise program|The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
214322072|NCT04182035|OTHER|Education|Education considering neck pain information
214322073|NCT04080765|BEHAVIORAL|HIV-ASSIST|HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.
214322074|NCT04080765|BEHAVIORAL|DHHS guidelines|This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
214921379|NCT02112630|DRUG|P-IFN alfa 2a|P-IFN alfa 2b 0.75 mcg/kg/week
214921380|NCT02112630|DRUG|P-IFN alfa 2b|P-IFN alfa 2a 135 mcg/kg/week
214921381|NCT02112630|DRUG|Ribavirin|200 mg PO once daily or 200 mg PO three times a week
214921382|NCT02112630|DRUG|Boceprevir|800 mg PO three times daily starting at week 4
214921383|NCT04144543|OTHER|White Noise|The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.
214921384|NCT04144543|OTHER|Facilitated Tucking|The baby's arms and legs were held in flexed positions close to the midline of the torso in sidelying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.
214921385|NCT04144543|OTHER|White Noise+Facilitated Tucking|The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position.
214921386|NCT00497289|DRUG|Lipofundin MCT/LCT 20 %|daily i.v. infusion for up to 5 days
214921387|NCT00497289|DRUG|Lipidem 20%|daily i.v. infusion for up to 5 days
214921388|NCT02257489|DRUG|ACE-083|recombinant fusion protein
214921389|NCT03239860|DRUG|GNbAC1 Monoclonal Antibody|Monthly IV
214921390|NCT06967233|OTHER|Multimodal treatment|Surgical resection, locoregional liver-directed treatments and continuous systemic treatment in patients with liver metastatic pancreatic cancer
214921391|NCT01452893|PROCEDURE|Spiroergometry|"At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.~At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP)."
214921392|NCT00863356|DEVICE|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
214921393|NCT04276116|BEHAVIORAL|Pulmonary age|Communication of pulmonary age
214921394|NCT02698332|DEVICE|Algorithm for UTI|The algorithm consists of one sheet of laminated paper with instruction in how to diagnose UTI
214485013|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with hydroxyethylamide|The resection will be performed in three stages using hydroxyethylamide : delimitation, incision and dissection. Initially we will inject the hydroxyethylamide and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
214485014|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye)|The resection will be performed in three stages using Hyaluronic acid (TS-905 Blue Eye) : delimitation, incision and dissection. Initially we will inject the Blue-Eyed and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
214322075|NCT02789176|OTHER|Surveys|Regarding development, epilepsy, and family impact
214485015|NCT03340428|BEHAVIORAL|Transition Community Adherence Club (TCAC)|A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
214485016|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~1 hour, 3 times a week for six weeks."
214485017|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~1 hour, 3 times a week for six weeks."
214921395|NCT03064815|DEVICE|Videocapsule endoscopy|"Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.~Capsule endoscopy helps doctors see inside your small intestine - an area that isn't easily reached with more-traditional endoscopy procedures."
214921396|NCT03064815|PROCEDURE|colonoscopy|Colonoscopy is a test that allows your doctor to look at the inner lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
214322076|NCT02789176|OTHER|EEG|
214921397|NCT03064815|DIAGNOSTIC_TEST|PROMETHEUS® IBD sgi Diagnostic™|This test combines serologic, genetic, and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test helps physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.
214921398|NCT03064815|DIAGNOSTIC_TEST|Fecal calprotectin|A stool test to measure inflammation in the gut.
214921399|NCT06314646|PROCEDURE|Transanal Transection and Single-Stapled anastomosis (TTSS)|Low anterior rectal resection with Transanal Transection and Single-Stapled anastomosis (TTSS)
214921400|NCT06314646|PROCEDURE|Double-stapled Total Mesorectal Excision (TME)|Low anterior rectal resection with double-stapled Total Mesorectal Excision (TME)
214921401|NCT06316232|DEVICE|STIM ON plus|increase of intensity of stimulation of 0.5 mA bilaterally
214322077|NCT02433834|DRUG|Glycopyrronium MDI|GP MDI
214921402|NCT06316232|DRUG|MED ON plus|administration of a 2x levodopa morning dose
214322078|NCT02433834|DRUG|Serevent Diskus 50 μg|
214921403|NCT02557932|DRUG|Standard triple therapy|Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
214921404|NCT02557932|DRUG|Bismuth quadruple therapy|Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
214921405|NCT03200704|COMBINATION_PRODUCT|IC2000 and SPY-PHI|Investigational treatment to assess the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
214921406|NCT03200704|COMBINATION_PRODUCT|Tc-99m radioactive colloid and Gamma Probe|Comparator; standard of care for sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
214322079|NCT02433834|DRUG|Placebo|
214322080|NCT02473068|DEVICE|CPAP|
214322081|NCT03393221|BEHAVIORAL|ER|Emotion regulation content
214322082|NCT03393221|BEHAVIORAL|SBWC|
214322083|NCT00595569|BEHAVIORAL|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
214322084|NCT00968175|PROCEDURE|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
214322085|NCT04675424|DEVICE|ANSwatch|"ANSwatch wrist sphygmomanometer and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients. Two measurements will be obtained:~1. Pulse diagnosis: Pulse diagnosis done on radial artery is recorded by traditional Chinese medicine physician and ANSwatch wrist sphygmomanometer at the same time.~2. Heart rate variability: Heart Rate Variability represents significant information on autonomic nervous system (ANS)'s regulating function and balance status."
214322086|NCT00596011|DRUG|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
214322087|NCT00596011|DRUG|Placebo|Matching placebo BID
214322088|NCT03794843|DRUG|Nimodipine Injection|Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
214322089|NCT03794843|DRUG|Nimodipine Injection (II)|Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
214322090|NCT00820924|DRUG|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
214322091|NCT05018715|DIAGNOSTIC_TEST|Machine learning model diagnosis|Machine learning model diagnosis
214322092|NCT05980546|DRUG|Bupivacaine Injection|The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.
214322093|NCT05980546|DRUG|Dexamethasone injection|The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.
214322094|NCT05980546|DRUG|Fentanyl|This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.
214322095|NCT05980546|DRUG|Mepivacaine|This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.
214322096|NCT02634138|DEVICE|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
214485018|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
214485019|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (twelve weeks: 6 +6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
214485020|NCT06965868|DRUG|Metformin|The Metformin intervention will be self-administred capsules, taken during a 12-week period: Four weeks of dose increase; first and second week 500 mg once daily, third and fourth week 500mg twice daily. Full-dose administration (850 mg twice daily) for eight weeks.
214485021|NCT06965868|DRUG|Placebo|This intervention will be self-administered placebo capsules
214485022|NCT06964919|DIETARY_SUPPLEMENT|Probiotic|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
214485023|NCT06964919|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
214485024|NCT06966206|DRUG|Multiprofen-CC™ plus standard treatment|Standard care pain medications and topical Multiprofen-CC™ (1g TID) for 2 weeks
214485025|NCT06966206|OTHER|Placebo plus standard treatment|Standard care pain medications and visually identical topical placebo (1g TID) for 2 weeks
214485026|NCT06966414|BEHAVIORAL|Morning exercise|Participants performed bodyweight exercise in the morning between 08:00 to 11:00 AM.
214921407|NCT04303520|BIOLOGICAL|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
214921408|NCT04303520|DRUG|Fludarabine|30mg/m2/d
214921409|NCT04303520|DRUG|Cyclophosphamide|500mg/m2/d
214921410|NCT05195255|DIETARY_SUPPLEMENT|Prebiotic|Guar gum (8 g/d) will be administered for 18 days
214921411|NCT01553422|OTHER|Fluid therapy (Saline Normal)|Saline Normal 1 Lit. during 30 minutes
214921412|NCT01553422|OTHER|Fluid therapy (Saline Normal)|saline Normal 1 lit during 30 minutes
215063253|NCT06482827|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2004 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
215063254|NCT05284500|PROCEDURE|Pediatric cardiac surgery with cardiopulmonary bypass|All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
214322097|NCT02661438|DRUG|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
214921413|NCT03107039|BEHAVIORAL|Exercise|A 12 week resistance exercise curriculum
214921414|NCT03107039|BEHAVIORAL|Health Education|A 12 week health education curriculum
214921415|NCT00778869|BIOLOGICAL|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
214921416|NCT02957253|OTHER|risk factors|monitoring risk factors due to deterioration of the liver disease
214921417|NCT02957253|OTHER|self-care|information and motivation to adherence to self-care instructions and medical treatment
214921418|NCT02957253|OTHER|nutrition|nutritional assessment and activities to prevent malnutrition
214921419|NCT02957253|OTHER|lifestyle|motivation of lifestyle changes essential for disease progress and
214921420|NCT02957253|OTHER|psychosocial needs|psychosocial care.
214921421|NCT02957253|OTHER|Nurse-led clinic|compensated disease once yearly, decompensated disease twice a month to every third month
215063255|NCT02584452|DRUG|Mepivacaine|20cc of 2% mepivacaine \<20 minutes prior to in room time.
215063256|NCT02584452|PROCEDURE|adductor canal continuous nerve catheter|Placement of ultrasound guided adductor canal continuous nerve catheter
215063257|NCT02584452|DRUG|Normal Saline as bolus followed by bupivacaine|normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
215063258|NCT02584452|PROCEDURE|adductor canal nerve block|ultrasound guided adductor canal nerve block
215063259|NCT02584452|DRUG|ropivacaine and dexamethasone|10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
214322098|NCT01860261|BEHAVIORAL|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
215063260|NCT02584452|DRUG|Propofol|Anesthesia induction will include a propofol bolus.
215063261|NCT02584452|DRUG|Fentanyl|Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
215063262|NCT02041390|OTHER|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
215063263|NCT02041390|OTHER|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
215063264|NCT00407368|PROCEDURE|Blood Sample|
215063265|NCT00162214|DRUG|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
215063266|NCT02562300|DRUG|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
214921422|NCT03382236|OTHER|osteopathy|osteopathic techniques
214921423|NCT04696822|DRUG|Epinephrine Nasal Product, 1.6 mg|Single dose Nasal powder spray without allergen challenge
215063267|NCT02562300|DRUG|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
215063268|NCT01596140|DRUG|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
215063269|NCT01596140|DRUG|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
215063270|NCT01596140|DRUG|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
215063271|NCT03732716|DIAGNOSTIC_TEST|blood pressure measurement|Intervention: Each patient's supine and standing blood pressure measurements will be recorded
215063272|NCT00923351|DRUG|Tumor Purged/CD25 Depleted Lymphocytes|
215063273|NCT00923351|BIOLOGICAL|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
215063274|NCT00923351|DRUG|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
215063275|NCT00923351|BIOLOGICAL|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
215063276|NCT02016495|DIETARY_SUPPLEMENT|Magnesium plus alpha-lipoic acid|
215063277|NCT02016495|DRUG|Placebo|
215063278|NCT05100355|PROCEDURE|Physiological serum injection|In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray
215063279|NCT05100355|PROCEDURE|Contrast agent injection|In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
215063280|NCT05720052|DRUG|MS-553|MS-553 oral tablet BID x 28-days
215063281|NCT04873258|DIAGNOSTIC_TEST|Bioimpedence Vector Analysis|Bioimpedence vector analysis
215063282|NCT01536561|BIOLOGICAL|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
214322099|NCT02733978|DEVICE|the ozone generator device (Human Pro medic, German)|noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
214322100|NCT01588002|DRUG|danoprevir|multiple oral doses
214322101|NCT01588002|DRUG|efavirenz|multiple oral doses
214322102|NCT01588002|DRUG|ritonavir|multiple oral doses
214921424|NCT04696822|DRUG|Epinephrine nasal product, 1.6 mg + allergen|Single dose Nasal powder spray with allergen challenge
214921425|NCT04696822|DRUG|Epinephrine Injection 0.3 mg|Intramuscular injection
214921426|NCT04696822|DRUG|Epinephrine Nasal Product, 3.2 mg|Twice dose Nasal powder spray without allergen challenge
214921427|NCT04696822|DRUG|Epinephrine Nasal Product, 3.2 mg + allergen|Twice dose Nasal powder spray with allergen challenge
214921428|NCT05495100|DRUG|Mitoxantrone liposome、Chidamide、Azacitidine|Mitoxantrone liposome 20mg/m2, d1; Chidamide 20mg, biw; Azacitidine 100mg, d1\~7; Every 4 weeks is a cycle, with a maximum of 4 cycles of treatment.
214322103|NCT04230096|DEVICE|low level laser therapy|apply low level laser therapy on buccal surface of maxillary jaw on anterior segment for three minutes at every three weeks in fixed orthodontic patients in their regular follow up visits
214322104|NCT05418452|DRUG|Metformin|metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects
215063283|NCT00822159|DEVICE|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
215063284|NCT03583268|OTHER|Exercise|The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
214322105|NCT05322187|DRUG|PD-1 inhibitor|Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance
214322106|NCT04583813|DRUG|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
214322107|NCT04583813|OTHER|Placebo|Empagliflozin matching placebo, once daily, for 24 months
214322108|NCT02229877|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
214322109|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
214322110|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
214322111|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
214322112|NCT00796965|DRUG|AZD7268|Solution/Capsule, Oral, once daily
214322113|NCT00796965|DRUG|Placebo|
214322114|NCT03949075|DRUG|Enalapril|Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.
214322115|NCT03949075|DRUG|Placebo|Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
214322116|NCT05637645|PROCEDURE|Midline Approach|In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
214322117|NCT05637645|PROCEDURE|Paramedian Approach|The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
214485027|NCT06966414|BEHAVIORAL|Evening exercise|Participants performed bodyweight exercise in the morning between 18:00 to 21:00 PM.
214322118|NCT05637645|PROCEDURE|Taylors approach|his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
214322119|NCT05580224|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
214485028|NCT06966245|DRUG|mastalgia-oil|External mastalgia-oil 1 ml/d per breast for 3 consecutive menstrual cycles
214921429|NCT01045811|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
214322120|NCT04024475|OTHER|Observation|
214322121|NCT02821962|BEHAVIORAL|Sedentary prompts from a VTAP device|
214322122|NCT02399150|OTHER|No intervention as observational study|
214485029|NCT06966245|DRUG|Mastalgia-oil placebo|External mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
214485030|NCT01102673|DRUG|PF-04991532|The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
214485031|NCT01102673|DRUG|Placebo|Placebo to match PF-04991532 will be provided
214485032|NCT03819101|DRUG|Acetylsalicylic acid|100mg
214485033|NCT03819101|DRUG|Atorvastatin|80 mg
214485034|NCT05324683|OTHER|No intervention planned|No intervention planned; study is observational
214921430|NCT01045811|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
214921431|NCT06297330|BEHAVIORAL|Sleep|The sleep management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to the sleep and fatigue levels will be recorded to assess the progress of each student.
214921432|NCT05917184|OTHER|Telehealth|Two video telehealth visits will be conducted and recorded within 3 days of one another (+/- 1 day)
214921433|NCT00328211|DIETARY_SUPPLEMENT|Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)|15 mg/kg/day for 18 days
214921434|NCT00328211|DIETARY_SUPPLEMENT|Sphingomyelin|1000mg/day for 19 days
214921435|NCT00328211|OTHER|C13 Stable isotope of Cholesterol|Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
214921436|NCT01270984|DRUG|Luckyvec 400mg film coated tablet|•400mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)
214921437|NCT01270984|DRUG|Glivec 100mg film coated tablet|•100mg/tablet, PO, 4 tablets once daily for Period I \& II D1(crossover)
214921438|NCT03411499|PROCEDURE|Early surgery|Surgery within 72 hours from endocarditis diagnosis
215063285|NCT02231528|DEVICE|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
214322123|NCT03940365|DEVICE|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
214322124|NCT03097653|OTHER|Decision-aid|Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.
214322125|NCT03097653|OTHER|Standard information|Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
214322126|NCT04257682|DRUG|Bupivacaine|Bupivacaine is a long-lasting dense sensory-motor block that can last up to four hours. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 6.75 mg to 8.25 mg for the knee, and 7.5 mg to 9 mg for the hip.
214322127|NCT04257682|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic that is known for its differential sensory-motor block. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 9 mg to 11 mg for the knee, and 10 mg to 12 mg for the hip.
214485035|NCT06685432|BEHAVIORAL|Diet|"The effect of motivational interviewing techniques was examined in addition to diet treatment. The effect of motivational interviewing techniques on anthropometric measurements before and after the study was evaluated. The participants' indecisiveness was investigated and a self-directed change conversation was presented. Behavior change strategies including determining positive and negative aspects, using importance and confidence scales, and setting the agenda were applied by the researcher.~In the interviews that included motivational interviewing techniques:~1. A participant-centered interview was conducted by collaborating with the participant.~2. The researcher was impartial and did not assume the role of an expert.~3. At the beginning of the interview, an evaluation of what was discussed in the previous week was made.~4. First of all, an attempt was made to determine the agenda according to the topic the participant wanted to discuss.~5. The importance scale was used (1-10)."
214485036|NCT06755411|OTHER|OHFCP2|The proposed intervention consists of a two-phase approach for implementing guidelines and evidence-based recommendations: educating healthcare professionals and enhancing clinical activity.
214921439|NCT03411499|PROCEDURE|Conventional therapy|Delayed surgical intervention or medical treatment according to the current guidelines
214921440|NCT04836013|DIETARY_SUPPLEMENT|combined Lactobacilli|1 oral stick per day for 30 days starting the day of antibiotic treatment
214921441|NCT04836013|OTHER|Placebo|1 oral stick per day for 30 days starting the day of antibiotic treatment
214921442|NCT04768413|OTHER|Teleconsultation either by phone or by computer consultation. Quantitative and qualitative approaches to analysis|A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.
214921443|NCT04768413|OTHER|Care modalities. Quantitative and qualitative approaches to analysis|Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.
214921444|NCT00777270|PROCEDURE|repair of episiotomy or second degree tears|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
214921445|NCT00777270|PROCEDURE|repair of episiotomy or second degree tears|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
214485037|NCT04878094|DIAGNOSTIC_TEST|Intravenous Indocyanine Green/ICG injection|Intravenous Indocyanine Green/ICG injection will be administered for visualization
214485038|NCT04878094|DIAGNOSTIC_TEST|PINPOINT endoscopic fluorescence imaging system|After resection the surgeon will use the PINPOINT imaging system to assess perfusion of the colonic stump. The intervention will again be used following establishment of the anastomosis, however this time via a proctoscope to visualize the proximal and distal ends of the rectosigmoid anastomosis.
214485039|NCT04878094|DIAGNOSTIC_TEST|Endoscopy|Standard technique and assessment of anastomosis without the use of NIR angiography
214921446|NCT06063642|DEVICE|Neurofeedback training|Neurofeedback training is a type of non-invasive brain modulation technique that enables individuals to self-regulate brain activity patterns by providing them feedback on specific activity measures. Effective self-regulation is often linked to changes in cognition, behavior, and clinical symptoms.
214921447|NCT06063642|DEVICE|Sham feedback training|A controlled form of neurofeedback training that provides feedback irrelevant to the targeted mental process.
214921448|NCT04091789|DRUG|Pure Femme Tablets|A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
214921449|NCT05107193|DRUG|afatinib|afatinib
215063286|NCT02231528|DEVICE|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
215063287|NCT01924039|BEHAVIORAL|Brief Motivational Enhancement Therapy|The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
215063288|NCT01924039|OTHER|treatment as usual|Treatment as usual includes case management as well as psychiatric appointments.
215063289|NCT05522582|DRUG|Methotrexate tablets|Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
215063290|NCT05522582|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
215063291|NCT05522582|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
215063292|NCT02994472|RADIATION|Gastric emptying scintigraphy using 99mTc-DTPA|
215063293|NCT03305796|RADIATION|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
214485040|NCT06965205|DIETARY_SUPPLEMENT|MCT feeding|"MCT feeds will be initiated using Nutrison Peptisorb 1kcal/ml. Peptisorb has lower fat content, with a higher proportion of MCTs. The feeding protocol for both formulae will be the same, with equivalent rates of enteral feeding:~* Day 1: if no clinical contra-indication, commence feeding either with standard or MCT feeds at 20ml/hr for 24 hours. Feeds to commence at 8am.~* Day 2: if tolerating feeds continue feeds at 20ml/hr for 12 hours, then increase to 40ml/hr for 12 hours~* Day 3: if tolerating feeds increase feeds to 60ml/hr and await dietician review regarding target rate and duration.~By POD6, if there is no chyle leak, all patients will be given standard feeds for discharge home.~For oral feeding, if patients are progressing clinically, they will have restricted fluids on POD3, with introduction of diet in each group from day 4 onwards. This allows a direct comparison of chyle leak rates for 72h of regular vs MCT enteral feeding."
214485041|NCT06965205|DIETARY_SUPPLEMENT|Standard feeds|Nutrison Protein Plus 1.25kcal/ml.
214485042|NCT05151731|DRUG|Vamikibart|Vamikibart will be administered by IVT injection as specified in each treatment arm.
214485043|NCT05151731|DRUG|Ranibizumab|Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
214485044|NCT05151731|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
214485045|NCT03492762|DRUG|Cu-DOTA-ECL1i|Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.
214485046|NCT05770908|OTHER|Therapeutic exercise program|"Therapeutic exercise program based on increasing resistance with elastic bands or weights. The programmes are composed of combinations of the following exercises:~* Scaption with elastic band.~* External rotation at 0º of abduction with elastic band.~* Internal rotation at 0º of abduction with elastic band.~* Shoulder protraction in supine position with weights.~* Low row with elastic band.~* Horizontal adduction stretching."
214485047|NCT05770908|OTHER|Multimedia animation information|Multimedia animation videos (including audio) showing the performance of the prescribed exercises.
214485048|NCT05770908|OTHER|Paper-based information|Paper-based information showing the performance of the prescribed exercises, based on figures and a brief description of the exercise performance.
214485049|NCT01242202|DRUG|ipragliflozin|oral
214485050|NCT01242202|DRUG|alpha glucosidase inhibitor|oral
214485051|NCT04965454|COMBINATION_PRODUCT|Fluorine-18 fluorocholine|18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.
214485052|NCT03049189|DRUG|177Lu-edotreotide PRRT|PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
214485053|NCT03049189|DRUG|Everolimus|Everolimus will be administered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
214485054|NCT03049189|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
214485055|NCT06966466|DEVICE|HuGgy Compression vest|This intervention involves the use of a HUGgy compression vest, a wearable device that provides deep touch pressure (DTP) to pediatric patients undergoing tonsillectomy and adenoidectomy under general anesthesia. The vest is worn by patients immediately after surgery, and pressure is applied to provide calming sensory input. The pressure level is adjusted based on the manufacturer's guidelines, providing a gentle, even compression to reduce emergence agitation (EA) during the recovery period.
215063294|NCT04685005|DIETARY_SUPPLEMENT|"Wake Up"|The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up
215063295|NCT04685005|DIETARY_SUPPLEMENT|Caffeine|Caffeine
215063296|NCT02901587|DRUG|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
214485056|NCT06970483|DRUG|Tranexamic acid|Transamine1 gram was administered intravenously during the lower segment incision.
215063297|NCT02901587|DRUG|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
215063298|NCT02901587|DRUG|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
215063299|NCT04552288|DRUG|Benralizumab|All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
215063300|NCT05285644|DRUG|0.003% AR-15512 ophthalmic solution|Administered via topical ocular instillation
215063301|NCT05285644|DRUG|AR-15512 vehicle ophthalmic solution|Inactive ingredients administered via topical ocular instillation
215063302|NCT00786968|DRUG|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
215063303|NCT03001193|DRUG|DF 01|
214485057|NCT06970483|DRUG|Misoprostol 200mcg Tab|Cytotec 400 micrograms were administered sublingually immediately after delivery of the baby and clamping of the umbilical cord.
215063304|NCT03001193|DRUG|Oxytocin|
214485058|NCT06972927|OTHER|Smoothie containing iron biofortified microgreens|30g of iron biofortified microgreens consumed within a smoothie for 28 days
214485059|NCT06973460|DEVICE|Hunova Robotic-Assisted System|Hunova Movendo Robotic System
214485060|NCT06973460|OTHER|Balance and Mobility Exercise|Balance and Mobility Exercise derived from the Otago Exercise Programme
215063305|NCT03001193|DRUG|Placebo|
215063306|NCT04532294|DRUG|BGB DXP593|Administered intravenously (IV) as specified in the treatment arm
215063307|NCT04532294|DRUG|Placebo|Placebo to match BGB-DXP593
215063308|NCT06853288|BEHAVIORAL|Diet containing 80% ultra processed foods|Very high ultra-processed food diet where 80% of calories are coming from ultra processed food
215063309|NCT06853288|BEHAVIORAL|Diet containing 20% ultra processed foods|Low ultra processed food diet where 20% of the calories are coming from ultra processed food
215063310|NCT04050072|OTHER|Childhood Cancer Survivors (CCSS)|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
215063311|NCT04050072|OTHER|SJLIFE|To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
215063312|NCT04050072|OTHER|Community non-cancer control|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
215063313|NCT04318678|DRUG|CD123-CAR T|To treat relapsed/refractory CD123+ AML/MDS, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.
215063314|NCT04318678|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
214485061|NCT03549442|COMBINATION_PRODUCT|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
214485062|NCT03549442|COMBINATION_PRODUCT|CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive CART-BCMA + huCART19. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
214485063|NCT03549442|COMBINATION_PRODUCT|Single-dose infusion of CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA + huCART19. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
214485064|NCT03549442|COMBINATION_PRODUCT|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
214485065|NCT04098276|BEHAVIORAL|WeWomen Plus technology based intervention|The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
214485066|NCT04846790|BEHAVIORAL|Nature Only|See above for description.
214485067|NCT04846790|BEHAVIORAL|Nature+Mindfulness|See above for description.
214921450|NCT01365078|DIETARY_SUPPLEMENT|Echium oil (SDA-rich oil)|The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner
215063315|NCT04318678|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis
215063316|NCT04318678|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
215063317|NCT04318678|DRUG|Rituximab|Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes
215063318|NCT04295759|DRUG|INCB7839|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
214921451|NCT01365078|DIETARY_SUPPLEMENT|high-oleic acid sunflower oil (HOSO) (low in SDA)|The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
215063319|NCT05054491|BEHAVIORAL|Group Antenatal Care|Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
215063320|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 0.76 g|
215063321|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.15 g|
215063322|NCT02244372|DIETARY_SUPPLEMENT|Placebo|
215063323|NCT00156104|DRUG|Asenapine|5 mg BID
215063324|NCT00156104|DRUG|Asenapine|10 mg BID
215063325|NCT00156104|DRUG|Haloperidol|4 mg BID
215063326|NCT00156104|OTHER|Placebo arm|
215063327|NCT06433154|PROCEDURE|Arthroscopic surgery|Arthroscopic treatment (lysis and lavage) of internal derangement of the temporomandibular joint.
214322128|NCT04257682|DRUG|Mepivacaine|Mepivacaine is an intermediate-acting local anesthetic producing shorting and motor-sparing blocks. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 40 mg to 50 mg for the knee, and 45 mg to 55 mg for the hip.
214485068|NCT02954809|DEVICE|Morning bright light therapy|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
214322129|NCT05114356|DEVICE|TIDAL Cervical Interbody Fusion implant|Cervical interbody fusion device
214322130|NCT00065884|DRUG|Valproate|
214322131|NCT00808288|DRUG|PF-00610355|oral, inhaled, dry powder, 600ug, OD
214485069|NCT02954809|DEVICE|Dim light|Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
214485070|NCT02295891|DEVICE|MiraDry ®|Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
214485071|NCT06490601|DRUG|thalidomide and hydroxyurea|"Thalidomide:~Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor- alpha Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Hydroxyurea:~Hydroxyurea or hydroxycarbamide (HU) lies in the category of antimetabolite. Mechanism of fetal hemoglobin induction includes increase in erythropoietin and nitric oxide production, apoptosis induction and potentiating in granulocyte cycling activity."
214485072|NCT06490601|DRUG|Thalidomide|"Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor -alpha , Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Investigating the impact of thalidomide on transfusion-dependent beta thalassemia patients is essential for discerning its therapeutic efficacy and safety profile."
214485073|NCT03242915|DRUG|Pembrolizumab|200mg IV every 3 weeks
214485074|NCT03242915|DRUG|Carboplatin|AUC 5 IV every 3 weeks
214485075|NCT03242915|DRUG|Pemetrexed|500 mg/m\^2 IV every 3 weeks
214485076|NCT03019263|DIETARY_SUPPLEMENT|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
214485077|NCT03019263|OTHER|Control|Nutritional counseling
214485078|NCT02780024|DRUG|Metformin|Metformin,
214485079|NCT03068819|DRUG|CIML NK Cell Infusion|-Day 0
214485080|NCT03068819|PROCEDURE|CD3+ T Cell Product Infusion|-Day -1
214485081|NCT05497024|BEHAVIORAL|Interviews|"Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material"
214485082|NCT05497024|BEHAVIORAL|Surveys|Participants may answer questions that are sensitive in nature.
214485083|NCT05802602|DEVICE|Porcine Collagen Membrane|Atraumatic tooth extraction with porcine collagen membrane placement
214921452|NCT03512613|DEVICE|c-FLOW 3310-P|"c-FLOW 3310-P is a continuous, non-invasive monitor of cerebral deep tissue blood flow used to measure relative changes in blood flow.~The device monitors regional micro circulatory blood flow in tissues, by using sensors placed near the area of interest."
214921453|NCT05468112|BEHAVIORAL|SKY Meditation and Mindfulness|The intervention is a 3-day in-person meditation and mindfulness workshop using the SKY meditation approach. It utilizes a unique set of standardized breathing techniques to rapidly reduce neuro-endocrine stress responses and the autonomic imbalance due to sympathetic overdrive, thus restoring autonomic homeostasis. These are interwoven with coping and stressor appraisal strategies, and simple stretching exercises. Classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions with an additional 7 consecutive days of online sessions immediately thereafter. In addition, participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. They will complete a follow-up session once per week in the subsequent 8 weeks.
214921454|NCT05478161|DEVICE|(ALLEGRA Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
214485084|NCT05802602|DEVICE|Bovine Collagen Dressing|Atraumatic tooth extraction with bovine collagen dressing placement
214485085|NCT05190211|OTHER|Telerehabilitation exercise program|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
215063328|NCT01696981|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
215063329|NCT01696981|PROCEDURE|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
215063330|NCT02354261|DRUG|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
215063331|NCT03899233|DEVICE|Fractional CO2 laser|Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond
215063332|NCT03899233|DRUG|Tranexamic acid intradermal microinjections|Tranexamic acid 500mg/5ml ampules
214322132|NCT00808288|DRUG|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
214322133|NCT00808288|DRUG|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
214322134|NCT00808288|DRUG|Placebo|oral, inhaled, dry powder, placebo, OD
214485086|NCT05190211|OTHER|Videobased exercise program|After 1 session of online simultaneous exercise training in the company of a physiotherapist via videoconference on the smart phone, an exercise video including the exercises will be sent to them and the patients will be asked to do their exercises 3 days a week. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling them once a week.
214485087|NCT06972771|DIAGNOSTIC_TEST|TTP-ICG incubation solution|Clinical specimens will be incubated with TTP-ICG with different concentrations and times.
214322135|NCT00808288|DRUG|Salmeterol|salmeterol, 50ug, BID
214322136|NCT01405638|BEHAVIORAL|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
214322137|NCT01405638|BEHAVIORAL|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
214322138|NCT06382987|DRUG|Deucravacitinib|According to the product label
214322139|NCT06382987|DRUG|Apremilast|According to the product label
214322140|NCT01956110|DRUG|Follitropin Delta (FE 999049)|
214322141|NCT01956110|DRUG|Follitropin Alfa (GONAL-F)|
214485088|NCT05988398|BEHAVIORAL|READY To Stand Curriculum|Students will receive the RTS programming over six consecutive school days, spread over two weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
214485089|NCT06432725|BEHAVIORAL|JUNTOS|HIV test counselor and Latino MSM participants will be given access to the JUNTOS website/app, which shows information about local HIV and ancillary services. HIV test counselor participants will also be given access to a training video explaining how to use the JUNTOS website/app. HIV test counselors are encouraged to use the website/app for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the website/app to locate HIV and ancillary services as needed.
214485090|NCT06432725|BEHAVIORAL|Referral Sheet|HIV test counselor and Latino MSM participants will be given access to referral sheet, which is a list of local HIV and ancillary services. HIV test counselors are encouraged to use the referral sheet for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the referral sheet to locate HIV and ancillary services as needed.
214485091|NCT06525376|DIAGNOSTIC_TEST|smartphone inclinometer application|an instrument for measuring angles of slope (or tilt), elevation, or depression of an object with respect to gravity.
214485092|NCT04658693|DEVICE|Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode|See arm description
214485093|NCT05109871|OTHER|KForce Link|Traction (pull-type) dynamometer
214485094|NCT06576271|DRUG|GSK4527363|GSK4527363 will be administered to participants.
214485095|NCT06576271|DRUG|Placebo matching GSK4527363|Placebo matching GSK4527363 will be administered to participants.
214485096|NCT06576271|DRUG|Belimumab|Belimumab will be administered to participants.
214921455|NCT04637711|PROCEDURE|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision|Only visible lesions and necrotic tissues, such as abscess cavity, sinus tract and fistula, were removed intraoperatively, while normal glands and fat were retained. Preoperative ultrasound was used to locate the lesion area and then the surgical incision was designed. Intraoperative ultrasound examination of latent small lesions, resection of lesions visible under ultrasound, and then a full breast exploration, one finger page incision interval.Radially cut from the base to the subcutaneous, lesions were found and treated locally. After removal of lesion, fully using the syringe, in turn, use of 3% hydrogen peroxide solution, 1% eniodine, saline water is widely jet pulse washing, and around the lesions base. After rinsing, soak in 1% active iodine for 10min, then rinse with normal saline until the liquid is clear. Breast tumor Surgery (Oncoplastic Breast Surgery, OBS) core technology (volume replacement and volume replacement).
214921456|NCT03710382|OTHER|Walking epidural|Parturients in spontaneous or induced labor will receive combined spinal-epidural analgesia (CSE) using an infusion of bupivacaine 0.0625% and fentanyl 2 mcg/mL and will be encouraged to walk a minimum of 15 minutes every hour during the first stage of labor.
214921457|NCT04411394|OTHER|Questionnaire|Body Perception Questionnaire and Hospitalized Anxiety and Depression Scale
214921458|NCT05679102|DRUG|Amlodipine 5 MG Oral Tablet|one group will be given only Amlodipine 5MG once daily
214921459|NCT05679102|DRUG|Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet|one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily
214921460|NCT00776438|BIOLOGICAL|Inactivated, split-virion, influenza vaccine|0.1 mL, Intradermal
214921461|NCT00776438|BIOLOGICAL|Inactivated, split-virion, influenza vaccine|0.5 mL, Intramuscular
214485097|NCT05436652|DRUG|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
214921462|NCT00776438|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL, Intradermal
214485098|NCT05436652|DRUG|SPI-62 matched placebo|Inactive tablets identical in appearance to SPI-62 tablets
214485099|NCT05436652|DRUG|Prednisolone 10mg|Standard of care prednisolone
214485100|NCT05436652|DRUG|Additional prednisolone|Over encapsulated prednisolone
214485101|NCT05436652|DRUG|Additional prednisolone matched placebo|Inactive capsules identical in appearance to over encapsulated prednisolone
214485102|NCT06995976|DRUG|68Ga-dPNE|Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET/CT will be used to detect tumors.
214921463|NCT00776438|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
214921464|NCT01718678|DRUG|Melatonin|it is kind of drug
214921465|NCT01718678|DRUG|Placebo|It is Placebo
214921466|NCT00650013|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fed
214921467|NCT00650013|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fed
214921468|NCT05707026|OTHER|cross fiber fascial manipulation|The group A received three sessions of fascial manipulation in two weeks. FM applied for 5 to 8 minutes at each point.
214921469|NCT05707026|OTHER|stretching techniques(sleeper stretch and cross body adduction stretch)|Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets.
215063333|NCT00876096|OTHER|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
215063334|NCT02284815|DIETARY_SUPPLEMENT|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
215063335|NCT02299141|DRUG|Nintedanib|
214921470|NCT00850408|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
215063336|NCT05152524|DEVICE|Tigertriever 13|patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.
214921471|NCT02986542|PROCEDURE|Femoral artery catheterization|The intervention will be performed by a single experienced individual.
214921472|NCT02976558|BEHAVIORAL|Clown theatrical Performance|
214485103|NCT06995976|DRUG|18F-FDG|Intravenous injection of 18F-FDG.18F-FDG PET/CT will be used to detect tumors.
215063337|NCT05662540|DEVICE|Positron Emission Tomography/Magnetic Resonance (PET/MR)|18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
215063338|NCT05278845|DRUG|SLC-391|SLC-391 is an AXL inhibitor
215063339|NCT02020798|OTHER|Dietary Intervention|
215063340|NCT05675722|BIOLOGICAL|biologic vaginal-construct implantation|biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.
215063341|NCT04306562|DIETARY_SUPPLEMENT|enteral nutrition supplement|enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day for at least 14 days from a preanesthetic clinic visit to a day of surgery.
214485104|NCT06996236|DRUG|Treatment with brimonidine eye drops 0.025%|Treatment with brimonidine eye drops 0.025%, instilled once a day at night, with simultaneous occlusion of the lower lacrimal punctum to avoid its systemic absorption, for 2 years.
214485105|NCT06997016|DIETARY_SUPPLEMENT|pre-operative carbohydrate drink|50 g of carbohydrate drink 2 hours before surgery
215063342|NCT04566939|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
214485106|NCT06997016|DRUG|Acetaminophen|650mg acetaminophen 30 minutes prior to surgery
214485107|NCT06997016|DRUG|Gabapentin|300 mg gabapentin 30 minutes prior to surgery
214485108|NCT06997016|DRUG|Bupivacaine|intraoperative local anesthetic
214485109|NCT06997016|OTHER|Ambulation|Assisted ambulation 12 hours after surgery
214921473|NCT02976558|PROCEDURE|Acupuncture|Acupuncture according to Traditional Chinese Medicine
214921474|NCT02976558|BEHAVIORAL|Music Therapy TaKeTiNa|
214921475|NCT03706430|DEVICE|Pulse CO-Oximeter sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb), Pulse Rate (PR), Perfusion Index (Pi), Methemoglobin (SpMet), Pleth Variability Index (PVi), RPVi, etc.
214921476|NCT06682104|BEHAVIORAL|Individual intensive short term psychodynamic therapy|ISTDP aims to help patients explore and process unconscious emotions, particularly those linked to past trauma or unresolved conflicts, that may be contributing to their physical symptoms. Patients are guided to identify and express repressed feelings such as anger, grief, or fear. The therapist actively engages the patient in a focused and intensive manner, helping them to recognize emotional defenses, break through resistance, and experience these emotions directly in the therapeutic setting.
215063343|NCT04566939|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the shoulder at the physician's discretion.
215063344|NCT04566939|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Gyunwoo (LI15), Gyunryo(TE14), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
214921477|NCT04694989|DRUG|CKD-386|QD, PO
214921478|NCT04694989|DRUG|D013, D326, D337|QD, PO
214921479|NCT03435536|OTHER|Blood samples|Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
215063345|NCT04566939|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
215063346|NCT04566939|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
215063347|NCT04566939|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
215063348|NCT04566939|PROCEDURE|Herbal hot pack|Herbal hot pack treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
215063349|NCT04566939|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
215063350|NCT04566939|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
215063351|NCT06513390|DEVICE|Exoskeleton of default mode|Default mode: A standard control system offering a conventional assistive function of Exo-H3.
215063352|NCT06513390|DEVICE|Exoskeleton of Intelligent mode|Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.
214485110|NCT06997549|DEVICE|Patients treated with NeuroStar TMS|non-invasive brain stimulation device
214485111|NCT06997549|DRUG|Patients treated with Esketamine|nasal spray for treating depression
214485112|NCT06996600|DEVICE|wireless thermal anisotropy measurement device|Wireless wearable thermal anisotropy measurement device designed for use at home
214485113|NCT06996509|DEVICE|Non-Invasive Ventilation (NIV)|Bi-Level NIV delivers two preset pressure levels-Inspiratory Positive Airway Pressure (IPAP) and Expiratory Positive Airway Pressure (EPAP)-via a tightly fitting mask interface
215063353|NCT00802620|PROCEDURE|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
215063354|NCT03335150|BEHAVIORAL|CogSMART-PD|Cognitive Rehabilitation for persons with PD-MCI
214322142|NCT00003491|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214921480|NCT06667479|OTHER|Cold Water Immersion (CWI) - Cold Tub Immersion (CI)|Once thermoneutral procedures are complete, participants in the CI group will be seated in the cold tub and submerged into the water (10º C). The sternal notch of each participant will be used as the anatomical marker to mark submersion point. Participants will sit with both arms outstretched underwater with their backs not touching the sides of the tub. Participants with a shorter stature will be provided an underwater cushion to meet the submersion requirements. The 4-minute timer will begin once confirmation of the participants submersion level and posture is determined. Once completed, the participant will be instructed to slowly exit the tub and allowed to dry and change as necessary.
214921481|NCT06667479|OTHER|Cold Water Immersion (CWI) - Cold Shower (CS)|Once thermoneutral procedures are complete, participants in the CS group will be instructed to enter the research shower area. Within the shower area, the walls of the shower will be numbered from 1 to 4, with 1 defined as facing the faucet, 2 defined as 90° to the right of side 1, 3 defined as 180° from the faucet, and 4 defined as 270° to the right or 90° C to the left from side 1. Participants will be instructed to turn 90° to the right cycling through sides 1 to 4 and then back to 1 every 15 seconds prompted by the researcher. This will allow the participant to complete four full rotations in the shower during the 4-minute intervention time. The shower faucet is modified and oriented in a way where it only produces cold water (10º C) when turned on. Once completed, the participant will be instructed to slowly exit the shower and is allowed to dry and change as necessary
214921482|NCT06667479|OTHER|Control Group (CO)|Participants will be encouraged to maintain their current diet and exercise across the duration of the 4 week intervention. Participants will still be subjected to the pre- and post-intervention data collection session.
214921483|NCT00478777|DRUG|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
214921484|NCT00478777|DRUG|dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
215063355|NCT03335150|BEHAVIORAL|Supportive Care|Support Group for persons with PD-MCI
215063356|NCT03690986|BIOLOGICAL|VX15/2503|Given IV
215063357|NCT03690986|BIOLOGICAL|Ipilimumab|Given IV
215063358|NCT03690986|BIOLOGICAL|Nivolumab|Given IV
214322143|NCT01857258|DIETARY_SUPPLEMENT|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
214322144|NCT02961907|PROCEDURE|PEPCI|"Both parents will receive:~* consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required~* endocrinologist consultation then dietitian follow-up if required~* actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt."
214322145|NCT02135224|DRUG|Fentanyl|
214322146|NCT02135224|DRUG|Normal saline|
215063359|NCT03838211|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
215063360|NCT03838211|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
214322147|NCT05118841|DRUG|ZX-4081|Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
214322148|NCT00860652|RADIATION|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
214322149|NCT00860652|RADIATION|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
215063361|NCT04648488|OTHER|Experimental early mobilisation|early activ assisted exercises treatment
215063362|NCT04648488|OTHER|Aktive comparator standrad treatmnet|standard treatment with a plaster 3 weeks and then active assisted exercises
215063363|NCT02097719|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
215063364|NCT02097719|DRUG|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
215063365|NCT02097719|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
215063366|NCT02097719|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
215063367|NCT01551654|DEVICE|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
215063368|NCT02406469|DIETARY_SUPPLEMENT|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
215063369|NCT04898348|DRUG|KBL697|3 capsules twice a day dosing of KBL697
215063370|NCT04898348|DRUG|Placebo|3 capsules twice a day dosing of Placebo
215063371|NCT02077829|BEHAVIORAL|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
215063372|NCT02000024|BEHAVIORAL|Weight Watchers|"The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk."
215063373|NCT02000024|BEHAVIORAL|National Diabetes Education Program|
215063374|NCT05086900|OTHER|Non-interventional Cross-sectional Patient Reported Outcome Measure Development|Development of Patient Reported Outcome Measure
214322150|NCT03085329|DEVICE|Seattle-PAP|Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
214485114|NCT06996509|DEVICE|High Velocity Nasal Insufflation|High-Velocity Nasal Cannula therapy delivers heated, humidified gas at flow rates exceeding patients' peak inspiratory demands (35-60 L/min), with precise FiO₂ control up to 100 %
214485115|NCT06996223|DRUG|The Group A received PCSK9 inhibitor plus statin therapy|Subjects randomized to the Group A will be treated with a lipid-lowering regimen based on PCSK9 inhibitors (subcutaneous injection, twice a week) + statins (maximum tolerated dose).
214485116|NCT06997692|DIAGNOSTIC_TEST|Gong's Mobilization with NMES|Gong's Mobilization Technique: The participant will be positioned in a side-lying posture on a height-adjustable bed, with the affected side upward and the head supported by a pillow The therapist will apply an antero-posterior glide to the humeral head while stabilizing the scapula with the other hand. The participant will perform quick, powerful shoulder abduction in the coronal plane without external rotation or elbow flexion while the therapist maintains the mobilization force.
214485117|NCT06997692|COMBINATION_PRODUCT|Comprehensive Conservative Physical Therapy|Thermal Modality Application: Participants will receive either a cold or hot pack (based on individual preference and clinical presentation) applied to the affected shoulder for 10-15 minutes. Cold packs will be wrapped in a thin towel and applied to
214921485|NCT01614717|DEVICE|CRT-P Implant|All patients will be implanted with a CRT-P device, then randomized to Treatment or Control Group
214921486|NCT03334643|DIETARY_SUPPLEMENT|Fiber mix|Participants will test white bread or fiber mix over a span of 2 weeks. During each testing block, each food will be tested twice over two consecutive days. There are 4 testing blocks in total (one for white bread and three for fiber mix).
214921487|NCT04293419|DRUG|Durvalumab (MEDI4736)|6 cycles of mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) followed by long course chemoradiotherapy (50.4 Gy together with capecitabine) followed by surgery. Patients will receive durvalumab 1500 mg every 4 weeks during induction chemotherapy, chemoradiotherapy and waiting period until surgery.
214921488|NCT00183053|DEVICE|BedEx Patient Occupancy Monitoring System|
214921489|NCT04345237|DIETARY_SUPPLEMENT|dietary supplement consumption|"Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training"
215063375|NCT03028415|DEVICE|AMPLEX|A bone graft substitute
215063376|NCT03028415|PROCEDURE|Autogenous Bone Graft (ABG)|Control material administered by surgical implant
214322151|NCT03085329|DEVICE|Conventional bubble nasal CPAP|Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher \& Paykel bubbler device, which is the standard of care at Nationwide Children's.
214322152|NCT00742313|BIOLOGICAL|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
214322153|NCT05353192|DRUG|Recombinant human growth hormone|Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
214322154|NCT01962558|DEVICE|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
214322155|NCT01962558|DEVICE|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
214322156|NCT06153446|DIAGNOSTIC_TEST|Synovasure® Comprehensive Infection Panel|The Synovasure Comprehensive PJI Test Panel (PJI Panel) is a laboratory-developed test (LDT) panel (CD Laboratories, CLIA Registration No.: 21D0216863) intended to aid the diagnosis of PJI.
214322157|NCT04828655|BEHAVIORAL|Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.|Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
214322158|NCT03191539|DRUG|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
214485118|NCT06996106|OTHER|Effect of Platelet Rich Fibrin on Septoplasty|it is a randomized trial of usage of platelet rich fibrin in septoplasty
214485119|NCT06854380|DRUG|Intralesional injection of steroids (betamethasone), (Betafos®) and hyaluronidase (enzyme), (Hynidase®) into benign vocal fold lesions by a naso-fiberscope with a side working channel(Storz 11001UD1)|that this intervention is intralesional injection of glucocorticoid (betamethasone) and enzyme (hyaluronidase) via flexible fiberscope
214485120|NCT07007013|OTHER|Humor therapy|The intervention consists of a cycle of 8 group sessions (one per week) led by trained professionals specialized in humor ('clown doctors'). Each session will last approximately 90 to 120 minutes
214485121|NCT06863129|PROCEDURE|Internal Fixation|Internal Fixation
214485122|NCT06863129|PROCEDURE|Resection and reconstruction|Resection and reconstruction
214485123|NCT06771284|BEHAVIORAL|Function-based assessment and intervention|This intervention will be implemented by the caregiver. The intervention will consist of teaching the child an alternative, appropriate skill (usually communication) to replace the problem behavior. The caregiver will provide reinforcement for the appropriate skill and no reinforcement (i.e., extinction) following problem behavior. The caregiver will also learn and use general strategies for teaching social-emotional skills (e.g., setting appropriate rules) as part of the intervention.
214485124|NCT06868953|DRUG|combination of sumatriptan 85 mg and naproxen 500 mg|combination of sumatriptan 85 mg and naproxen 500 mg
215063377|NCT04922372|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
214322159|NCT01436279|DRUG|Mifepristone|200 mg po 20-24 hours prior to the procedure
214322160|NCT01436279|DEVICE|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
214322161|NCT04541875|OTHER|MAR-Scale|The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
214322162|NCT03160924|OTHER|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
214322163|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 10 days
214322164|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 15 days
214322165|NCT00910715|DRUG|placebo|control subjects without a history of Lyme borreliosis
214672289|NCT06969859|BEHAVIORAL|Alfredson eccentric training program|All participants will be subject to a standardised rehabilitation exercise region consisting of stretching and eccentric exercises following the Alfredson protocol. The 12-week program will be taught by a physiotherapist or athletic trainer and supplemented by video tutorials. The regime begins with three 30-second static stretches for the gastrocnemius (knee extension) and soleus (knee flexion) muscles with 1-minute rest between each stretch. The 2nd part is eccentric exercises to the calves following the Alfredson protocol. This will be three sets of eccentric exercises lasting 12 weeks, with 15 sets twice a day. If participants are unable to complete three sets of 15 repetitions, they can start with fewer repetitions and sets (at least 2 sets of 10 repetitions each) and gradually increase to the total number of sets. Participants will perform the static stretching exercises from Step 1 at the end of each session
214672290|NCT03529214|BEHAVIORAL|Exposed study site|The study sites will pilot the Team Birth Project designed to improve team communication (between providers, as well as providers and patients). The project includes three key implementation steps that involve: preparing local sites for the implementation of the project; training and coaching on the use of the tools; and sustainment through peer coaching and data feedback. A mixed methods approach will be used to assess acceptability and feasibility, including: (1) clinician surveys and interviews, (2) implementation team focus groups, and (3) patient surveys.
214672291|NCT03305250|DEVICE|Implantable Loop Recorder|An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
214672292|NCT00278824|DRUG|Matrix Transdermal Fentanyl/CHADD Drug Delivery System|Patch applied every 3 days for 15 days
214921490|NCT06684886|OTHER|Ankle Brachial Index|"Normal ABI ranges from 1.0 - 1.4~* Pressure is normally higher in the ankle than the arm.~* Values above 1.4 suggest a noncompressible calcified vessel.~* In diabetic or elderly patients, the limb vessels may be fibrotic or calcified. In this case, the vessel may be resistant to collapse by the blood pressure cuff, and a signal may be heard at high cuff pressures. The persistence of a signal at a high pressure in these individuals results in an artifactually elevated blood pressure value.~* An value below 0.9 is considered diagnostic of PAD.~* Values less than 0.5 suggests severe PAD.~* Individuals with such severe disease may not have sufficient blood flow to heal a fracture or surgical wound; they should be considered for revascularization if they have a non-healing ulcer."
214921491|NCT00876655|DRUG|TR-701 di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
214921492|NCT00876655|DRUG|TR-701 free acid phosphate|One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
214921493|NCT01070368|OTHER|Commercial extract and in-house wheat extract|Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.
214921494|NCT00806897|DRUG|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
214921495|NCT04339153|BEHAVIORAL|Parent Training for Disruptive Behaviours|Critically, PT also involves education about autism during the initial sessions, and thus benefits of PT are inferred to come from the specific training.
214921496|NCT02168257|DEVICE|RAM Cannula|
214921497|NCT02168257|DEVICE|Binasal Prong CPAP|
214921498|NCT02406001|DEVICE|Tigran PTG|Open Flap Debridement
214921499|NCT02406001|PROCEDURE|Surgical intervention|Open Flap Debridement
214921500|NCT00144521|DRUG|MRA(Tocilizumab)|8mg/kg/4week(i.v.)for 24 weeks
214921501|NCT00144521|DRUG|MRA placebo|0mg/kg/4week(i.v.) for 24 weeks
214921502|NCT00144521|DRUG|MTX|8mg/week(p.o.) for 24 weeks
214921503|NCT00144521|DRUG|MTX placebo|0mg/week(p.o.) for 24 weeks
214921504|NCT00666822|BEHAVIORAL|compliance monitoring|To examine the relationship between adherence to endocrine therapy and variables from the Health Belief Model (i.e., perceived risk, barriers to and benefits of adherence, and cues to action such as physician recommendation) as well as measures of patient's perceptions of patient- and family-centered care in women with estrogen receptor-positive stage I-IIIA breast cancer.
214921505|NCT00666822|OTHER|medical chart review|Patient's medical records are reviewed for information about the time since diagnosis, tumor characteristics, treatment, and comorbidity.
214921506|NCT00666822|OTHER|questionnaire administration|Patients complete a 15 minute questionnaire on-line or by mail comprising questions of demographic and medical variables (i.e., age, race/ethnicity, marital and educational status, and medication side effects) as well as health beliefs and selected aspects of patient- and family-centered care. Data collected from the questionnaire will be stored in an Excel database.
214921507|NCT06318988|PROCEDURE|Radiofrequency ablation using Closure fast|Thermal ablation technique
214921508|NCT06318988|PROCEDURE|Aethoxysclerol|sclero-or foamsclerose
214921509|NCT06318988|DRUG|Daflon|Venoactive drugs
214921510|NCT06318988|DEVICE|Compression stocking|Compression
214921511|NCT01218087|DEVICE|Cranial cup device and Moldable positioner|The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants
214921512|NCT01218087|DEVICE|Moldable positioner device|This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
214485125|NCT06868693|DRUG|Neoadjuvant Chemotherapy (NAT) Group|This cohort includes elderly patients (≥70 years) with resectable or borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy (NAT). The NAT regimens include 5-FluoroUracil, Irinotecan, Oxaliplatin (FOLFIRINOX), gemcitabine/nab-paclitaxel (GnP), and other standard chemotherapy protocols. The study aims to evaluate the impact of NAT on overall survival (OS), progression-free survival (PFS), R0 resection rates, and postoperative outcomes, as well as the toxicity profile of different NAT regimens.
214485126|NCT04983199|DEVICE|Hexoskin Medical System|Hexoskin is a smart shirt that can detect heart rates, lung function and physical activity of patients before and after radiotherapy.
214485127|NCT07016789|DEVICE|Near-infrared spectroscopy monitoring (NIRS) INVOS 5100C|Continuous bilateral cerebral oxygen saturation monitoring using near-infrared spectroscopy (NIRS) during TAVI. Sensors are placed on the forehead to record rSO₂ values at predefined timepoints. Device used: INVOS 5100C (Medtronic/Covidien).
214485128|NCT06681389|DRUG|NP-201 acetate injection (Part A)|Route of administration- Sub cutaneous. Dosage interval and frequency: MAD1-200mg daily for 5 days; MAD2- 300mg daily for 5 days, MAD3- 400mg daily for 5 days
214485129|NCT06681389|DRUG|Placebo|Matching placebo administered across Part A and Part B
214485130|NCT05588505|BEHAVIORAL|Cognitive-Behavioral Therapy Targeting Executive Dysfunction in College Students with ADHD|The intervention is 12 weeks long, made up of one 2- hour session each week. These sessions are designed to help the participants develop strategies to improve their executive functioning skills including self- care, time management and organizational skills. These skills will also be applied to specific academic tasks such as note-taking during reading and lectures, organizing and conducting research, and writing papers.
214485131|NCT04276779|OTHER|Alcohol administration|Participants in the alcoholic beverage group will be provided a dose of 95% alcohol (0.99g/kg for males and 0.90 g/kg for females body weight) distributed in two equally spaced beverages (mixed with orange juice 1:5 ratio). This dose will produce a breath alcohol content ranging between .08-.10.
214485132|NCT04276779|OTHER|Placebo administration|Individuals in the placebo condition will receive orange juice with 4 ml of alcohol layered on top of the juice. Ethanol will be sprayed on the rims of the glasses.
214485133|NCT04276779|BEHAVIORAL|Positive mood induction|Participants will be randomized to either positive mood induction procedure. Both conditions involve listening to music that reliably induces positive mood, while simultaneously reading self-referent statements that also induce either positive mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
214672293|NCT00278824|DRUG|Placebo Patch|Placebo patch applied every 3 days for 15 days
214921513|NCT03979053|DEVICE|Multiparametric MRI Scan|Patients attending the clinic will have a MRI scan added to their standard of care.
214921514|NCT00552396|DRUG|Anti-KIR (1-7F9)|human monoclonal antibody
214921515|NCT00203619|DEVICE|Wireless capsule endoscopy|wire less capsule endoscopy
214921516|NCT00203619|OTHER|standard care|standard diagnostic evaluation as decided by treating physician
214921517|NCT04402762|DRUG|Ovine Enoxaparin|The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.
214921518|NCT04402762|DRUG|Enoxaparin Prefilled Syringe [Lovenox]|The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.
214921519|NCT00713947|DRUG|during one week for the active treatments|during one week for the active treatments placebo during 25 weeks
214921520|NCT00713947|DRUG|Pantoprazole|6 months at 20 mg
214921521|NCT00713947|DRUG|Placebo Formula 515|26 weeks, one tablet per day
214921522|NCT01323387|DEVICE|Interbody Fusion|allograft spacer + anterior plate
214921523|NCT02313207|DIETARY_SUPPLEMENT|FODMAP|patients will undergo a specific FODMAP diet for a period of 2 weeks.
214921524|NCT05389566|DIAGNOSTIC_TEST|Quantative Sensory Testing|Evaluation of small fiber neuropathy
214921525|NCT05389566|DIAGNOSTIC_TEST|NCStat-DPN-Check|Evaluation of large fiber neuropathy
214921526|NCT05389566|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score 31|Evaluation of autonomic neuropathy
214921527|NCT05389566|DIAGNOSTIC_TEST|Computerized dynamic posturography|Evaluation of dynamic postural control
214921528|NCT05389566|DIAGNOSTIC_TEST|Video Head Impulse Test|Evaluation of vertigo and the vestibular organ
214921529|NCT05389566|DIAGNOSTIC_TEST|Accelerometer|Evaluation of gait pattern
214921530|NCT05389566|DIAGNOSTIC_TEST|Handgrip strength|Evaluation of muscle strength
214921531|NCT05389566|DIAGNOSTIC_TEST|Dual Energy X-ray Absorbtimetry scan|Evaluation of body composition
214921532|NCT05389566|DIAGNOSTIC_TEST|Force Plate Platform|Evaluation of balance while standing still
214921533|NCT05142969|OTHER|2% Chlorhexidine bathing|Eight chlorhexidine-impregnated cloths are used in sequential order to wipe the body surfaces from neck to toe to avoid exposure of chlorhexidine to the mucous membranes of the eyes, ears and mouth.
214921534|NCT03025529|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation or TMS is a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. This magnetic field can pass through the head safely and painlessly. TMS can be used to change activity in the brain.
214921535|NCT03025529|DEVICE|Sham Transcranial Magnetic Stimulation|Sham Transcranial Magnetic Stimulation or sham TMS is like active TMS, a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. TMS can be used to change activity in the brain but in this intervention, the coil will be angled 90 degrees from the scalp, resting on one wing of the coil, and therefore will not be delivering active TMS.
214921536|NCT04185220|DRUG|Recombinant human Interleukin-15 (rhIL-15)|Interleukin 15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation 3 + 3 system with a starting dose of 2 mcg/kg/day and a second dose level of 4 mcg/kg/day on days 1-5 of each of six cycles.
214921537|NCT04185220|BIOLOGICAL|Mogamulizumab|Mogamulizumab (intravenous (IV) over at least 1 hour) will be administered at a dose of 1 mg/kg on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle. Treatment will continue for a maximum of 6 cycles.
214921538|NCT04201574|DRUG|ALY688 0.1%|ALY688 0.1% Ophthalmic Solution
214921539|NCT04201574|DRUG|ALY688 0.4%|ALY688 0.4% Ophthalmic Solution
214921540|NCT04201574|DRUG|Vehicle|Vehicle Ophthalmic Solution
215063378|NCT02907216|BIOLOGICAL|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
215063379|NCT02907216|BIOLOGICAL|Rotarix|Two doses administered orally
215063380|NCT03960567|DEVICE|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
214921541|NCT02097329|DRUG|palbociclib commercial free base|125 mg oral capsule single dose
214921542|NCT02097329|DRUG|famotidine|20 mg oral tablet 10 hours before and 2 hours after palbociclib
214485134|NCT04276779|BEHAVIORAL|Negative mood induction|Participants will be randomized to either negative mood induction procedure. Both conditions involve listening to music that reliably induces sad mood, while simultaneously reading self-referent statements that also induce either sad mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
214485135|NCT01992913|BEHAVIORAL|integrated Cognitive Behavioral Therapy|Novel CBT paradigm for schizophrenia/schizoaffective disorder
214485136|NCT01992913|OTHER|Usual Care|The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)
214672294|NCT06277661|BEHAVIORAL|MOMI PODS|MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.
214921543|NCT02097329|DRUG|rabeprazole|2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib
215063381|NCT03102515|DRUG|USG-TAP block|
215063382|NCT03102515|DRUG|CIC|
214485137|NCT01992913|BEHAVIORAL|Computerized cognitive remediation (CCR)|Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
214485138|NCT05029726|DRUG|Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine|Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB
214921544|NCT02097329|DRUG|palbociclib commercial free base|125 mg oral capsule single dose
215063383|NCT04622501|PROCEDURE|posterior spinal decompression and posterior spinal instrumented fusion|posterior spinal decompression and posterior spinal instrumented fusion performed on a patient with Spinal Epidural Lipomatosis
214322166|NCT05949476|OTHER|ozone therapy|"Ozone in the gaseous state produced by a machine at concentrations for medical use (sssssssssss9) injected after anesthesia in the surgery site and in the post-extraction alveolus after suture.~* Topical ozone in the form of a gel (indicate the brand) to be applied to the post-surgical site 2 times a day for 7 days."
214322167|NCT03930459|PROCEDURE|Static cold storage (SCS)|The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
214322168|NCT03930459|DEVICE|Normothermic machine perfusion (NMP)|During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
214322169|NCT05550155|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment|a 4-month maintenance procedure of active rTMS
214322170|NCT05550155|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|a 4-month maintenance procedure of sham rTMS
214322171|NCT05771155|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, on Weeks 0, 2 and 6, 14, 22, 30, 38 and 46
214322172|NCT01097837|OTHER|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
214322173|NCT06529003|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) unit|All participants in this study will receive the standard of care, which includes oral ibuprofen and a paracervical block at the time of laminaria insertion. Those in the treatment group will receive an adjunctive TENS unit with specific instructions for use in the interval between laminaria insertion and dilation and evacuation the next day. TENS is a non-invasive, inexpensive, over-the-counter, nonpharmacologic option to relieve pain. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
214485139|NCT05029726|DRUG|normal saline|normal saline in 30cc syringes administered using ESPB technique
214921545|NCT02097329|DRUG|antacid|30 mL orally once (2h before palbociclib)
214921546|NCT02097329|DRUG|antacid|30 mL orally once (2h after palbociclib)
214921547|NCT01478776|DIETARY_SUPPLEMENT|omega-3|4 cap 1 gr omega-3 per day for 10 weeks
214921548|NCT01478776|DIETARY_SUPPLEMENT|placebo|patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
214921549|NCT01763060|RADIATION|CT scan|
214921550|NCT01763060|BEHAVIORAL|Cognitive function|
214921551|NCT01763060|RADIATION|MRI|
214921552|NCT01013272|DRUG|Entecavir|Entecavir 0.5mg orally daily
214921553|NCT01013272|DRUG|Lamivudine|Lamivudine 100mg orally, daily
214921554|NCT01045382|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cell injection
215063384|NCT05175430|DRUG|Paroxetine|Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
215063385|NCT05175430|DRUG|Lysergic Acid Diethylamide|LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
215063386|NCT05175430|DRUG|Placebo|Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
215063387|NCT06277856|BEHAVIORAL|Peer interaction/control|This study was planned as a randomised controlled study with a two-group pretest and posttest design.
215063388|NCT06009991|DRUG|Remimazolam besylate|"Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need)."
214322174|NCT06529003|DEVICE|Placebo|Participants in the placebo group will be given a TENS unit without a battery with similar to the intervention group but will be advised that they may or may not feel a sensation from the electrodes. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
214322175|NCT03377335|DRUG|Dapagliflozin 10mg|"The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
214322176|NCT03377335|DRUG|Metformin|"All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
214322177|NCT05923229|BEHAVIORAL|Mindfulness Based Walking Therapy (MBWT)|MBWT is a modified version of the Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking mediations and is acceptable for people with Parkinson disease and freezing of gait.
214485140|NCT06303297|OTHER|REFLEXOLOGY|will receive foot and hand reflexology and stretching. The researcher will administer foot and hand reflexology to the participant for a period of 3 weeks this last for a duration of 10 min on each hand and foot with total duration of 40 minutes. Foot reflexology include general foot massage, including the foot rotation, Achilles stretching, and the foot extension and stretching, will be performed for a minute on each foot. In the right foot, the bottom of the heel will be kept with the left hand, and the metatarsal arch of the same foot will be held with the other hand. Then, the foot will be rotated clockwise and counter clockwise three times each direction. The same technique will be performed on the left foot. On hand lubricated with moisturizer to the dorsal and plantar surface and apply pressure on for 10 minutes. Noninvasive and safe complementary therapy that involves a direct pressure on specific body points connecting specific organs.
214485141|NCT06303297|OTHER|GENERALIZED STRETCHING|will receive Stretching of upper and lower limbs. The stretching program lasts for 3 weeks with 60 min of stretching session 3 times a week. Extension of body include shoulder extension, torso rotation, hip extension, calf stretching (ankle pumps). ten stretches of 30 s each, with 15 s of rest between each stretch
214921555|NCT01045382|OTHER|Isotonic solution|Isotonic solution injection
214921556|NCT01600027|PROCEDURE|Fascia iliaca compartment block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
214921557|NCT01600027|PROCEDURE|Fascia iliaca block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
214921558|NCT03813680|OTHER|Passive Vertebral Mobilization|Posteroanterior glides was given to cervical spine using Maitland method along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
214921559|NCT03813680|OTHER|PNF exercise|The subjects was given PNF exercises comprising PNF diagonal patterns for neck along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
214921560|NCT03813680|OTHER|Routine Physiotherapy|Thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
214921561|NCT05663073|DRUG|Irbesartan/Amlodipine FDC|Irbesartan/Amlodipine FDC
214921562|NCT05663073|DRUG|Irbesartan|Co-administration of Irbesartan and Amlodipine
214921563|NCT05663073|DRUG|Amlodipine|Co-administration of Irbesartan and Amlodipine
214921564|NCT05129865|DRUG|LYT-300|A prodrug of allopregnanolone, a small molecule drug
214921565|NCT05129865|OTHER|Placebo|Placebo for LYT-300
214921566|NCT06349291|DIAGNOSTIC_TEST|Detection of venous thrombosis via US|Detection of venous thrombosis via US in patients after removal of central venous catheter
214921567|NCT00604591|DRUG|Tolcapone|200 mg by mouth three times a day
214921568|NCT00604591|DRUG|Placebo|200 mg by mouth three times a day
214921569|NCT00315133|PROCEDURE|Immunosuppression and autologous stem cell transplantation|Immunosuppression and autologous stem cell transplantation: Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and granulocyte-colony stimulating factor (G-CSF, 10 ug/kg/d), followed by collection and cryopreservation of unselected HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit anti-thymocyte globulin (ATG 4.5 mg/kg).
214921570|NCT01573832|OTHER|integrated client care group|receives integrated client care for wound treatment
214921571|NCT04340037|PROCEDURE|percutaneous nephrolithotomy|percutaneous surgery using nephroscope
214921572|NCT04861727|OTHER|MRPA procedure|The patient will receive the device for BP measurement at home for a week and two daily measurements will be taken, one in the morning (between 6 and 10 am) and one in the afternoon / evening (between 6 pm and 10 pm), for seven days. At the end of the procedure, it is expected to record 14 measurements (representing a total of 42 in seven days), but it is considered feasible when at least 10 results are recorded, respecting the number of two measurements per day, in the periods oriented. Participants who do not reach the satisfactory number of measures or do not check between the times mentioned above, will be invited to repeat the procedure
214921573|NCT04861727|OTHER|Pharmaceutical intervention|The suggestion procedure, for this research, is defined as the pharmaceutical act of forwarding a letter of suggestion to the prescriber, previously agreed with the patient, based on clinical evaluation, review of pharmacotherapy, adherence to treatment and result of the MRPA procedure.
214921574|NCT03271190|BEHAVIORAL|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills (21 hours), leisure activities (music lessons or Spanish lessons) (27 hours), selected videogames to practice variable attention strategies (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by a trained therapist for formal sessions and a professional music or Spanish teacher for leisure sessions.
215063389|NCT06009991|DRUG|Propofol|"Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance"
214322178|NCT05923229|OTHER|Freezing of Gait (FOG) Education|Participants will receive materials to read weekly about FOG and track their usual care regimens.
214322179|NCT06456411|PROCEDURE|Functional Near-Infrared Spectroscopy|Undergo fNIRS
214322180|NCT06456411|OTHER|Questionnaire Administration|Ancillary studies
214322181|NCT06456411|OTHER|Virtual Technology Intervention|Undergo relaxation period using VR
215063390|NCT04822896|BEHAVIORAL|Physical Exercise|"The videos will be prepared by the researchers and will be watched by the physical exercise group, which includes exercises such as shifting the jaw to the side, pushing the tongue forward, jaw opening, sliding the jaw with the tongue, opening the chin with the tongue, opening the chin by pressing the tongue against the palate and shifting the chin with the person's own resistance. Then they will be asked to do the exercises physically. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
215063391|NCT04822896|BEHAVIORAL|Kinesthetic Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as kinesthetic imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
215063392|NCT04822896|BEHAVIORAL|Visual Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as visual imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
215063393|NCT03737955|DRUG|Gemtuzumab Ozogamicin|Receive IV
215063394|NCT03737955|OTHER|Quality-of-Life Assessment|Ancillary studies
215063395|NCT02792309|BEHAVIORAL|MotherWise Program|Healthy Marriage or Relationship Education services for pregnant women.
215063396|NCT01854775|DRUG|E/C/F/TAF|Tablets administered orally with food.
215063397|NCT01854775|DRUG|E/C/F/TAF (Low Dose)|90/90/120/6 mg STR administered once daily orally with food.
214322182|NCT06456411|OTHER|Cold Stimulation|cold stimulation using ice pack
214485142|NCT06186414|DRUG|SIM0237|Several dose levels of SIM0237 will be administered as a single agent for evaluation
214485143|NCT06186414|DRUG|SIM0237 and BCG|Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
214485144|NCT06186414|DRUG|SIM0237|RD level of SIM0237 will be administered as a single agent for evaluation
214485145|NCT06186414|DRUG|SIM0237 and BCG|RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
214485146|NCT05574036|DRUG|Febuxostat 80 MG Oral Tablet|Febuxostat used as 80 mg oral tablet once daily for 6 months
214485147|NCT05574036|DRUG|vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
214485148|NCT02333162|DRUG|Fludarabine Phosphate|Given IV
214485149|NCT02333162|DRUG|Melphalan|Given IV
214485150|NCT02333162|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMTMI
214485151|NCT02333162|RADIATION|Total Marrow Irradiation|Undergo IMTMI
214485152|NCT02333162|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
214485153|NCT02333162|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
214485154|NCT02333162|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
214485155|NCT02333162|DRUG|Tacrolimus|Given IV or PO
214485156|NCT02333162|DRUG|Mycophenolate Mofetil|Given IV or PO
214485157|NCT02333162|OTHER|Laboratory Biomarker Analysis|Correlative studies
214485158|NCT06201403|DIAGNOSTIC_TEST|Determination of biomechanical properties of muscles|All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the muscle body. When the red light on the plexiglass frame of the device probe turns green, the pressure application will be stopped and will remain constant until 5 strokes are made. In every 5 beats, the duration of 1 beat is 15 ms and the time between beats is 8 ms. The SENIAM sensor location guide will be considered as a reference for the estimated motor point determination in the MyotonPRO measurement.
214485159|NCT05648110|BIOLOGICAL|AZD5156 (Parent study Sentinel Safety Cohort)|"600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1"
214485160|NCT05648110|BIOLOGICAL|Placebo (Parent study Sentinel Safety Cohort)|single dose of Placebo (3 mL + 2 mL) IM
214485161|NCT05648110|BIOLOGICAL|EVUSHELD™ (Parent study Main Cohort)|"600 mg EVUSHELD™/AZD7442 consisting of 300 mg AZD1061 and 300 mg AZD8895, both at 100 mg/mL~2 IM injections (thigh) of 3 mL each IM on Visit 1 Day 1 and on Visit 5 Day 181"
214485162|NCT05648110|BIOLOGICAL|AZD3152 (Parent study Main Cohort)|"300 mg AZD3152 at 150 mg/mL~1 IM injection (thigh) of 2 mL of AZD3152 on Visit 1 Day 1 and on Visit 5 Day 181"
214485163|NCT05648110|BIOLOGICAL|Placebo (Parent study Main Cohort)|Single doses of 0.9% sodium chloride 2 mL IM for injection on Visit 1 Day 1 and Visit 5 Day 181
215063398|NCT04450706|OTHER|Precision Medicine|"The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression."
215063399|NCT04450706|OTHER|Physican Decision Making|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
215063400|NCT06649253|OTHER|Sampling bone tissue and blood|Extra tube collection of bone and blood will be collected during routine care sampling interventions at the diagnosis, after the first phase of treatment and after relapse, if it occurs.
215063401|NCT05269771|DRUG|Ruxolitinib|Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.
215063402|NCT02822183|OTHER|Online Survey|
215063403|NCT02091531|DRUG|MLN0128|
215063404|NCT04635371|DEVICE|Non-invasive Monitoring|Wearable, wireless, non-invasive chest-patch devices will be attached to the patients following recruitment and aigning an informed consent form, and from that moment on, vitals will be collected automatically and analyzed retrospectively.
215063405|NCT01633840|OTHER|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
215063406|NCT01633840|OTHER|Elemental E028|Elemental E028 with no added food allergens
215063407|NCT03215719|RADIATION|Standard Radiation Treatment|An interval scan at 4 weeks to assess for a good response defined as \>40% nodal shrinkage will stratify patients into receiving standard treatment (≤40% nodal shrinkage) or a dose-deescalated treatment regimen (\>40% nodal shrinkage). Those with nodal shrinkage and clearance of circulating plasma HPV DNA shall undergo further treatment de-escalation.
215063408|NCT03215719|RADIATION|Dose-Deescalated Treatment|Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation therapy used to treat cancer and noncancerous tumors. IMRT uses advanced technology to manipulate photon and proton beams of radiation to conform to the shape of a tumor. Patients will be treated with intensity-modulated radiation therapy (IMRT) with megavoltage photons
215063409|NCT03215719|DRUG|Cisplatinum|Standard of care chemotherapy
215063410|NCT04312477|DRUG|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
215063411|NCT01896830|BIOLOGICAL|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
215063412|NCT01896830|BIOLOGICAL|0.9% normal saline|0.5 mL, intramuscular
215063413|NCT01162252|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
214322183|NCT05279664|OTHER|Remote ischemic conditioning (RIC) + Standard of Care for NEC|RIC will consist of 4 cycles of limb ischemia (5 min) followed by reperfusion (5 min), repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure. Neonates in this arm will continue to receive standard of care for NEC.
214322184|NCT05279664|OTHER|Standard of Care for NEC|Neonates in this arm (i.e. the control arm) will receive standard of care for NEC.
214322185|NCT06513624|DRUG|ETC-159|ETC-159 will be administered orally.
214921575|NCT03271190|BEHAVIORAL|ENGAGE DISCOVERY|Educational content about brain and healthy aging (21 hours), leisure activities (watching documentaries followed by group discussion and debate) (27 hours), selected non-stimulating videogames (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by the same trained therapist as in the ENGAGE arm.
214322186|NCT06513624|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously.
214322187|NCT06513624|DRUG|Denosumab / Zoledronic Acid|Denosumab will be administrated subcutaneously. Zoledronic Acid will be administered intravenously if denosumab has no response.
214485164|NCT05648110|BIOLOGICAL|AZD3152 (Sub-study)|Single dose of 1200 mg IV at Visit 1 Day 1
214485165|NCT05648110|BIOLOGICAL|AZD7442 - EVUSHELD™ (Sub-study)|Single dose 300 mg IM administered on Visit 1 Day 1
215063414|NCT01162252|BEHAVIORAL|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
215063415|NCT06024551|OTHER|Telerehabilitation|Patients in this arm will be given telerehabilitation three times a week, for four weeks.
215063416|NCT06024551|OTHER|home exercise program|Patients in this arm will receive home exercise program for four weeks
215063417|NCT01433042|DEVICE|capsule endoscopy|capsule endoscopy procedure
214322188|NCT05288556|DEVICE|Placement of stoma site enteral feeding tube accessory|The study stoma site accessory will be attached at the stoma site during an enteral tube replacement procedure the patient is scheduled to have as a standard of care procedure. The study stoma site accessory is compatible with commercially available enteral nutrition feeding tubes ranging from size 16 to 20 French tubing that are adjustable to variable length.
215063418|NCT02059629|DEVICE|Eluna pacemaker family|"New pacemaker generation with new functions, like wandless RF telemetry SafeSync"
215063419|NCT02059629|DEVICE|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
215063420|NCT05620810|BEHAVIORAL|neuropsychiatric symptoms|neuropsychiatric symptoms
215063421|NCT06388746|OTHER|BRIX3000®|A gel that when applied to the tooth completely removes carious tissues in a chemo mechanical way without rotary instruments. It contains an enzyme that has bactericidal, bacteriostatic and anti-inflammatory properties and proteolytic properties that help soften and break down decayed tissue without destroying the underlying healthy collagen fibers.
214322189|NCT04114552|OTHER|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
214485166|NCT05648110|BIOLOGICAL|AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152|Single dose of AZD7442 (EVUSHELD™) 300 mg IM
214485167|NCT02831283|DRUG|11C-PBR28|11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
214921576|NCT04163120|OTHER|Low calorie Mediterranean ketogenic diet with phytoextracts (KEMEPHY)|The KEMEPHY diet (24-29) is a Mediterranean low calories ketogenic protocol (about 1000/1100 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg) Table 1. Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (30). Liquid herbal extracts were used for their draining /toning activity, useful to reduce some commonly reported light side effects of ketogenic diets as constipation, headache and halitosis.
214921577|NCT03007082|DEVICE|Revive SE intracranial thrombectomy device|"1. Intra-arterial mechanical thrombectomy with Revive SE；~2. According to patient condition, the investigator could determine intravenous thrombolysis or not at his/her discretion"
214921578|NCT04769089|PROCEDURE|Treatment with Pulse Dye Laser|Pulse Dye laser treatment will be applied to one randomized area with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s.
214921579|NCT04769089|PROCEDURE|Treatment with CO2 Laser|CO2 laser treatment will be applied to one randomized area with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
214322190|NCT02756793|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
214322191|NCT02756793|OTHER|Standard of Care Treatment|"May include:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment~Palliative radiotherapy is allowed in this arm."
214485168|NCT02831283|DRUG|18F-Florbetaben|18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
214485169|NCT02831283|PROCEDURE|Lumbar puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
214485170|NCT06263686|OTHER|Pasteurised yoghurt|Pasteurised (heat treated) natural yoghurt containing \<15 CFU/g of Lactobacillus delbrueckii bulgacirus and \<15 CFU/g of Streptococcus thermophilus.
214485171|NCT06263686|OTHER|Fresh yoghurt|containing ≥ 108 CFU/g of Lactobacillus delbrueckii bulgacirus and ≥ 108 CFU/g of Streptococcus thermophilus
214485172|NCT06263686|OTHER|Sterilised yoghurt|Not containing viable bacteria
214485173|NCT06631729|BEHAVIORAL|HRV-bio|participants will complete a HRV biofeedback task via the Elite HRV app. In this intervention, participants will learn how to use their HRV data that they will see in real-time via the Elite HRV app to improve their HRV by engaging in an app-guided diaphragmatic breathing exercise. They will complete this exercise twice daily (morning, night).
214921580|NCT04769089|PROCEDURE|Treatment with combination of pulse dye laser and CO2 laser.|Pulse Dye laser and CO2 treatment will be applied to one randomized area. Pulse Dye will be applied with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s followed by the CO2 laser treatment with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
214921581|NCT04769089|OTHER|Control|One area will be randomized to receive no laser treatment.
214921582|NCT04832594|OTHER|AI selection for supplemental breast MRI|An AI tool will generate scores used to determine eligibility. Women randomized to MRI will be examined in an MRI scanner.
214921583|NCT04803344|BEHAVIORAL|Expressive Writing tecnique|Expressive Writing (EW), is a simple, potentially inexpensive, therapeutic intervention which involves writing daily for 15-20 min over 3-4 consecutive days. EW can be completed at home without the need for facilitation, a specialist therapist or a dedicated facility.
214921584|NCT04803344|BEHAVIORAL|Neutral Writing|Participants were asked to write on neutral objects or events.
214921585|NCT02802787|OTHER|Camp Discovery|Activities will include physical, social, emotional, sensory and spiritual activities.
214921586|NCT02092545|OTHER|Ketogenic diet|
214921587|NCT01102868|DEVICE|Needle in acupuncture point Li11|Acupuncture needle in acupuncture point Li11
214921588|NCT01102868|DEVICE|IMS of the musculus pronator teres|Acupuncture needle in musculus pronator teres
214921589|NCT00767455|DEVICE|HP828-101|21 day patches
215063422|NCT06388746|OTHER|Riva Star Aqua, SDI Limited, Australia|A solution that contains 44,800 ppm F and 253,870 ppm Ag. It acts as a fluoride storage for the acid challenges, while inhibites demineralization of hydroxyapatite crystals and preserves collagen from degradation in demineralized tissues.
215063423|NCT03818906|PROCEDURE|Molar extraction - Control Group|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
214322192|NCT05555472|BEHAVIORAL|Halt-intervention|The main aim of the Halt-intervention is to reduce the risk for reoffending. Seven sub-goals are implemented to work towards this main aim: (1) youths gain insight in (the consequences of) their behaviour; (2) strengthening youths' social skills; (3) youths are able take responsibility for the consequences of their behaviour; (4) victim-offender reconciliation; (5) youths are able to access support from own social network and, if necessary, access to formal support; (6) parents gain insight their child's behaviour; and (7) if youths complete the intervention, they do not receive a registration on their criminal record. With a compulsory screening and risk assessment at the start of the intervention, it is determined which sub-goals fit the adolescents' needs. The intervention gives Halt professionals the opportunity to identify adolescents (and families) in vulnerable circumstances and to guide them towards formal support, like youth care organisations or addiction treatment centres.
215063424|NCT03818906|PROCEDURE|aPDT + Molar Extraction - Test Group 1|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.
215063425|NCT03818906|PROCEDURE|Infrared + Molar Extraction - Test Group 2|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion
214485174|NCT06631729|BEHAVIORAL|ED-JITAI|"participants will be prompted to complete focused, guided body scan tasks that will be sent to them via the MindLogger app. These guided tasks will be sent to them in the form of 1 of 3 brief (3-5 minute) videos via the MindLogger app. The body scans will be designed to promote participants' connection with, vs.~distancing/distraction from, feared ED sensations (e.g., hunger, satiety, bloating).~Participants will receive prompts to complete the body scans at times when they report via EMA that they are experiencing worse interoception than usual. Worse interoception than usual will be defined as participants' EMA-reported interoception scores during the intervention period that fall 1 SD or more above their baseline EMA-reported interoception levels."
214485175|NCT06630169|COMBINATION_PRODUCT|Cryopreserved AURN001|Corneal Endothelial Cells and Y27632
214485176|NCT06875063|DRUG|GB5005 CART|Included patients will receive GB5005 chimeric antigen receptor T-cell injection: A sterile syringe will be used to draw the assigned dose volume (calculated based on the patient's weight and converted to volume). The cells will be slowly infused intravenously at a rate of about 10 mL/min.
214672295|NCT06277661|BEHAVIORAL|Enhanced Usual Care (EUC)|Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L\&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.
214672296|NCT03812016|DEVICE|Feedback-enabled magnetic device|The device comprises 1 or 2 matched pairs of one near-infrared light-emitting diode and one sensor, a magnetic actuator, an iron sheet, and a biosignal acquisition module. The efficacy and safety were assessed using the feedback-enabled magnetic device.
214921590|NCT05445362|DEVICE|Diode laser disinfection|\- Disinfection with parameter of Power: 1.5 watt, Mode: pulse: SP: Ton=10ms; Toff10ms 50Hz (50% pulse mode), for 5 seconds in spiral movement in apical to coronal direction no stop with non-initiated endodontic tip 200 micron diameter and 15 mm length three times. Irrigation with NaOCl, irradiation with the laser, then irrigation with E.D.T.A and irradiation with the laser, for three times then final rinse with distilled water with paper point dryness in between irrigations.
214921591|NCT05445362|DEVICE|Diode Laser bio-stimulation.|"\- The diode laser bio-stimulation with Wiser Diode Laser, Irradiation of the periapical area from the labial mucosal surface, day after day day on-day off for one week, two sessions will be applied at the same day with two hours interval, first session immediately after filing (blood induction), with flat top hand piece , diameter 1cm at a distance between 0 and 105 cm, at 1 watt power for 50s with CW continues mode in order to obtain the 5 J/cm2 fluence."
215063426|NCT03818906|PROCEDURE|aPDT + Infrared + Molar Extraction - Test Group 3|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
215063427|NCT05117567|COMBINATION_PRODUCT|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
215063428|NCT04601532|DEVICE|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin.
215063429|NCT04601532|DRUG|Silver Sulfadiazine|Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
214672297|NCT05108376|DEVICE|Visensia Safety Index (VSI)|Enrolled patients will undergo continuous vital sign monitoring, to be used by the Visensia Safety Index (VSI) to identify early deterioration. If early deterioration is identified, the VSI will produce an alert to notify the RACE team.
214322193|NCT05555472|BEHAVIORAL|Youth Initiated Mentoring (YIM) approach|"The YIM approach focuses on strengthening naturally existing relationships between youth and non-parental adults within their own social network (Van Dam \& Schwartz, 2020). It stems from the idea it takes a village to raise a child (Educational Civil Society), which implies that other adults are co-responsible for the development of youth in their environment (Bowers et al., 2015). The YIM approach can be implemented in a formal context; expertise from the own social network is then combined with expertise from professionals (Van Dam \& Verhulst, 2018). Professionals support youth in identifying and positioning a YIM as part of a broader intervention (Van Dam \& Schwartz, 2020). Youths are responsible for asking their YIM and once agreed upon, the YIM is positioned. The YIM offers advice/support and plays a role during the intervention followed by the youth. Youth, parents, YIMs and professionals work together to set expectations and goals for the engagement of the YIM."
214322194|NCT05868707|DRUG|OH2|Oncolytic Type 2 Herpes Simplex Virus
215063430|NCT01138696|OTHER|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
215063431|NCT01138696|OTHER|RX|X-rays and clinical investigation of the knee 20 years after surgery
215063432|NCT02613663|PROCEDURE|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
214322195|NCT05868707|DRUG|Salvage chemotherapy or best supportive care|single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
214322196|NCT03307759|DRUG|Pembrolizumab|Pembrolizumab
215063433|NCT02613663|PROCEDURE|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
215063434|NCT02339844|DRUG|Aripiprazole|6 weeks of individual doses of aripiprazole
215063435|NCT06414135|BIOLOGICAL|Relma-cel|All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells
215063436|NCT00269750|DRUG|OROS® oxybutynin or Ditropan®|
215063437|NCT03082911|OTHER|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention."
215063438|NCT03082911|OTHER|Invitation letter|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
215063439|NCT01141998|DRUG|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
214322197|NCT03307759|RADIATION|Radiotherapy (SABR)|Radiotherapy
214485177|NCT06872229|BEHAVIORAL|Autism Spectum Conditions - intervention|"Initially, participants will participate in a familiarization session in which they will see and hear all pairs of pictures and sounds without any associated task, thus ensuring adequate understanding of the stimuli. Next, each child will be tested for each predicted condition, receiving clear instructions on the task: they will have to indicate whether the picture and sound are related. The main task consists of presenting 40 pairs of image-sound stimuli. For each pair, participants must answer the question, Does what you saw match what you heard? using a keypad with a green key for Yes and a red key for No. Each condition includes 10 trials, distributed randomly, with short breaks between them to keep participants focused."
214921592|NCT05445362|DRUG|Triple antibiotic paste disinfection|-The root canals will be copiously and slowly irrigated with 20 ml of 1.5% (17) sodium hypochlorite (NaOCl) solution for 5 minutes alternatively with 20 ml of 17% ethylene diamine tetra acetic acid (E.D.T.A) solution for 5 minutes with intermediated rinse of distilled water with paper point dryness in between irrigations. The triple antibiotic paste will be prepared using metronidazole , ciprofloxacin and doxycycline . The doxycycline capsule content will be evacuated in a sterile mortar; a tablet of metronidazole and a tablet of ciprofloxacin will be crushed and ground into homogenous powder in the same mortar using a pestle. Saline drops will be added and mixed using the pestle until a creamy paste achieved . The canals Will be dried with paper points and medicated with triple antibiotic paste; the access cavity will be sealed with intermediate restorative material (I.R.M) .
215063440|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. Week 0-10.
214672298|NCT06324097|DIAGNOSTIC_TEST|endocytoscopy|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue.
215063441|NCT01141998|RADIATION|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
215063442|NCT01141998|RADIATION|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
215063443|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. From week 14 to 52.
215063444|NCT02296710|PROCEDURE|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
215063445|NCT06125171|DRUG|Tucidinostat, Apatinib|"Tucidinostat:~age≥18years, 30mg, po., biw, q4w; age≥10years，\<18years，0.5mg/kg, biw, q4w~Apatinib:~BSA≥1.2m\^2, 500mg, qd, q4w BSA\<1.2m\^2, 250mg, qd, q4w"
215063446|NCT02748421|PROCEDURE|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
214485178|NCT06872229|BEHAVIORAL|Typical Development - intervention|"Initially, participants will participate in a familiarization session in which they will see and hear all pairs of pictures and sounds without any associated task, thus ensuring adequate understanding of the stimuli. Next, each child will be tested for each predicted condition, receiving clear instructions on the task: they will have to indicate whether the picture and sound are related. The main task consists of presenting 40 pairs of image-sound stimuli. For each pair, participants must answer the question, Does what you saw match what you heard? using a keypad with a green key for Yes and a red key for No. Each condition includes 10 trials, distributed randomly, with short breaks between them to keep participants focused."
215063447|NCT02748421|PROCEDURE|Conventional Microscope|macular membrane dissection without OCT RESCAN
215063448|NCT06814301|DIAGNOSTIC_TEST|Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV|A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with Letermovir
214485179|NCT06872021|OTHER|Early IABP use|Patients receive IABP for left ventricular unloading within 6 hours after VA-ECMO initiation.
214485180|NCT06872021|OTHER|Conventional approach|Patients do not receive mechanical unloading within 6 hours after VA-ECMO initiation.
214485181|NCT06871423|BEHAVIORAL|distraction|"distraction via virtual reality game named Waltz of the Wizards aka magic bowl."
215063449|NCT06814301|DIAGNOSTIC_TEST|Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV|A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with LTV
215063450|NCT06657599|PROCEDURE|Major Abdominal Surgery|Patients with ASA I-IV, over 18 years of age, undergoing major abdominal surgery, have gynecological and GIS tumor, expected to stay in postoperative care unit for more than 24 hours.
215063451|NCT01114087|DRUG|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
214921593|NCT05445362|PROCEDURE|"revascularization using the standard method Blood Clot"|"\- The root canal Will be over-instrumented using finger plugger size #25 to encourage bleeding up to cemento-enamel junction. The sterile finger plugger size # 25 will be used with sharp strokes into the periapical tissue beyond the apex until bleeding becomes evident at the cervical portion of the canal. Blood column will be left 10 minutes to clot covered by sterile cotton, a collagen orifice plug Collagen plugs will be used as matrix against mineral trioxide aggregate (M.T.A) condensation, M.T.A will be mixed according to the manufacturer's instructions and carried to the cavity with M.T.A carrier (Dovgan M.T.A Carrier) , and then compacted using wet cotton roll on pluggers (S- Kondenser) . Finally the cavity will be restored with a glass ionomer base and light cure composite resin ."
214921594|NCT03046589|DRUG|DP13|dose escalation
215063452|NCT03599778|DRUG|Apatinib|XELOX + apatinib's MTD
215063453|NCT06652412|DRUG|Ultrafractionated RT and CGA Guided systemic treatment.|in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.
215063454|NCT06652412|OTHER|data prospectively collected|in cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.
214921595|NCT03046589|DRUG|placebo|control to dose-escalation
215063455|NCT06652412|RADIATION|Ultrafractionated Radiotherapy|1Fx every 3 or 4weeks
215063456|NCT06652412|DRUG|Sintilimab|200 mg q3w
215063457|NCT06652412|DRUG|Fluorouracil|5-Fluorouracil or capecitabine
215063458|NCT06652412|DRUG|Raltitrexed|Raltitrexed
215063459|NCT06652412|DRUG|Oxaliplatin|Oxaliplatin
215063460|NCT06652412|DRUG|Irinotecan (CPT-11)|irinotecan
215063461|NCT04859101|OTHER|Gum|2 minutes of gum chewing prior to procedure
214921596|NCT01686126|DRUG|Levonorgestrel|Intrauterine device
214921597|NCT01686126|DRUG|Metformin|oral medication
214921598|NCT05101889|DIETARY_SUPPLEMENT|Oral Impact®|3 ready-to-drink bottles/day
214921599|NCT05335980|DEVICE|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
214921600|NCT04756973|BEHAVIORAL|Behavioral weight loss program|A 12 week small group weight loss program delivered via teleconference video technology
214921601|NCT01172925|DRUG|Tiotropium|Inhaler
214921602|NCT01172925|DRUG|Placebo|Inhaler
215063462|NCT04859101|OTHER|Control|2 swallows prior to procedure
215063463|NCT03226847|PROCEDURE|Pulmonary Vein Isolation|Standard antral pulmonary vein isolation using radiofrequency ablation catheters
215063464|NCT00249587|DRUG|Methadone|dosed to effect, every six hours
215063465|NCT05517486|DRUG|GTX-101|Bupivacaine HCl metered spray
215063466|NCT05517486|DRUG|Bupivacaine HCl subcutaneous injection|Bupivacaine HCl, 50 mg/10 mL
215063467|NCT04472481|DRUG|Ergocalciferol 1.25 mg tablet|weekly 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) given orally group II
215063468|NCT04185077|DRUG|Bivalirudin|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
215063469|NCT04185077|DRUG|Heparin|a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
215063470|NCT02855879|OTHER|Collection of biological data|
215063471|NCT02855879|OTHER|Collection of clinical data|
215063472|NCT01489865|DRUG|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
215063473|NCT04303104|OTHER|GeneXpert Edge|Screening intervention: novel diagnostic for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at point-of-contact in a mobile van
214322198|NCT05198791|DRUG|Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets|Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
215063474|NCT04303104|OTHER|GeneXpert Ultra|Screening intervention: novel diagnostic test for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
215063475|NCT00395499|DRUG|Risperidone|
215063476|NCT02783547|DRUG|SyB C-1101 and Azacytidine|"This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up."
215063477|NCT04780802|PROCEDURE|The balloon catheter is placed at the various arterial feeders of the tumor|use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
215063478|NCT01847612|PROCEDURE|indocyanine green fluorescent cholangiography|
215063479|NCT01847612|DRUG|methylene blue|
215063480|NCT06171139|OTHER|Counseling Tool|Non-therapeutic educational intervention
214485182|NCT06697015|OTHER|Pendulum Exercises|In this group, 18 participants will perform pendulum exercises, which involve leaning forward and allowing the affected arm to hang down, swinging it gently in small circular or side-to-side motions. This exercise is designed to enhance shoulder mobility and promote relaxation of the rotator cuff muscles without straining the shoulder joint. The pendulum movement helps improve circulation and relieve tension in the shoulder area, making it a suitable intervention for individuals experiencing rotator cuff pain.
214485183|NCT06697015|OTHER|Serratus Punch Exercises|In this group, 18 participants will engage in serratus punch exercises, focusing on strengthening the serratus anterior muscle. Participants will perform a punching motion by extending the arm forward while maintaining shoulder stability. This exercise activates the shoulder muscles to enhance scapular control, supporting the rotator cuff and improving overall shoulder function. The goal is to build strength in the stabilizing muscles, which can help alleviate pain and enhance mobility in participants suffering from rotator cuff issues.
214485184|NCT06697158|OTHER|Physiotherapy and rehabilitation|"Complex Decongestive Physiotherapy (CDP) Complex Decongestive Physiotherapy (CDP) consists of Manual Lymphatic Drainage (MLD), skin care, compression bandaging, and exercise, which are routinely used in clinical practice (9). CDP sessions will last approximately one hour each and will be administered for 4 weeks, with 5 sessions per week, totaling 20 sessions.~Manual Lymphatic Drainage (MLD) is a massage technique involving rhythmic, gentle pressure movements aimed at reducing the accumulation of lymphatic fluid in conditions such as lymphedema. This therapy facilitates the drainage of lymphatic fluid into the body's primary lymphatic pathways, thereby reducing edema, pain, and tightness, while enhancing range of motion and overall quality of life. MLD typically focuses on areas with a high concentration of lymph nodes, promoting the smooth circulation of lymph fluid. Treatment sessions usually last between 30 minutes to one hour."
215063481|NCT06171139|OTHER|Questionnaires|Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.
215063482|NCT06688006|OTHER|climate change short animation film|For the short animated film, a scenario will be created that describes climate change, risk factors that threaten human health as a result of climate change, adverse health effects of climate change, adverse effects on maternal and foetal health, precautions to be taken to protect against and adapt to the adverse effects of climate change. In the short animation film, visual materials will be created that show the adverse effects of climate change by using developing technology. The created scenario will be prepared as a two-dimensional (2D) animation film with the support of Selçuk University SERATEM (Selçuk University Radio and Television Application Center). All lines, colours, decorations and characters used in the creation phase of the short animation film will be determined by the researchers. Once the drawing and animation phases are complete, the voice-over actors will be selected after a further review. The short animated film should be about 2-3 minutes long.
214672299|NCT00938548|DRUG|Pregabalin|Pregabalin 75 mg orally
214672300|NCT00938548|DRUG|Vitamin Complex (placebo)|Vitamin Complex orally
214672301|NCT04856761|DRUG|S-1|S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
214672302|NCT04856761|DRUG|Capecitabine|Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
214672303|NCT00069121|DRUG|Capecitabine|1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle.
214672304|NCT00069121|DRUG|Oxaliplatin|130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
215063483|NCT02483091|BEHAVIORAL|Multifaceted KT intervention|"The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months."
215063484|NCT06873633|DRUG|Remdesivir|Remdesivir (RDV) has shown potent antiviral activity against RSV A in an animal model. Remdesivir has been also shown to be a safe treatment option in pediatric patients hospitalized with COVID-19. Based on previous clinical evidence and preclinical data, to address the unmet medical need for safe and effective RSV therapy, this study is being conducted to investigate remdesivir in infants and children (aged 0 days to \<2 years) as a potential treatment for RSV infection.
215063485|NCT07020650|PROCEDURE|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and bone graft.
214921603|NCT06577701|DRUG|traditional Chinese medicine (TCM)|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).
215063486|NCT06415760|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
215063487|NCT06440252|DRUG|Grape Seed Extract|One daily dose of 1 capsule containing 600mg grape seed extract
215063488|NCT06440252|DRUG|Maltodextrin|One daily dose of 1 capsule
215063489|NCT06712706|PROCEDURE|Feeding jejunostomy placement|Placement of feeding jejunostomy at staging laparoscopy
215063490|NCT06712706|PROCEDURE|Feeding jejunostomy placement at esophagectomy|Placement of feeding jejunostomy at esophagectomy
215063491|NCT05313607|OTHER|Designed physical therapy|Attention is given to improve motor function, conducted for 30 minutes
215063492|NCT05313607|OTHER|Occupational therapy|included exercises facilitating hand skills, conducted for 30 minutes
215063493|NCT05313607|OTHER|Conventional Therapy|aimed to improve the affected upper extremity function, conducted for 30 minutes
215063494|NCT05313607|OTHER|Plyometric training|basically focuses on upper extremity strength training conducted for 30 minutes
215063495|NCT04784663|BEHAVIORAL|Messaging|Four brief video messages, each approximately 1.5 minutes in length, focused on facilitating treatment seeking by addressing barriers and improving attitudes. Intervention delivered to participant by study mobile app downloaded to participants' own smartphone.
215063496|NCT04784663|OTHER|Wait list control|one push notification each week thanking individuals for participation, informing them that they will receive messages in the near future or reminding them of the length of the study.
215063497|NCT06893224|OTHER|Coastal exposure|"This is a real-life exposure to the coastal environment, in which participants walk to a bench, sit there for 15 minutes, followed by a walk of approximately 30 minutes. After the 15 minute sitting period, a saliva sample is collected. During the walk, participants are equipped with wearable sensors. The walking route is indicated on a map."
215063498|NCT06893224|OTHER|Urban exposure|"This is a real-life exposure to the urban environment, in which participants walk to a bench, sit there for 15 minutes, followed by a walk of approximately 30 minutes. After the 15 minute sitting period, a saliva sample is collected. During the walk, participants are equipped with wearable sensors. The walking route is indicated on a map."
215063499|NCT07071090|DRUG|DC50292A|DC50292A tablet
215063500|NCT06878001|DIETARY_SUPPLEMENT|Carotenoids|CaroRite capsule containing carotenoids with sunflower oil. 1 capsule to be taken each day for 12 weeks.
215063501|NCT06878001|OTHER|Placebo|Placebo capsule containing sunflower oil. 1 capsule to be taken each day for 12 weeks.
215063502|NCT07070765|DRUG|Sodium-glucose transport-2 (SGLT-2) inhibitors|Dapagliflozin 10mg in addition to standard clinical care
215063503|NCT07070765|OTHER|Standard medical treatment|Standard clinical care
215063504|NCT06831851|BEHAVIORAL|Storytelling Sessions|Children will participate in structured storytelling sessions, held once a week for 30 minutes per session. The sessions will use interactive narrative techniques, including voice modulation, gestures, and visual aids, to enhance cognitive, linguistic, and socio-emotional development. The intervention is designed to promote active engagement, stimulate imagination, and improve attention and language skills in early childhood.
214322199|NCT05198791|OTHER|Stratification and standard care|Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
214322200|NCT06034535|BIOLOGICAL|CD62L depleted donor lymphocyte infusion|Intravenous infusion of CD62L depleted donor lymphocytes
214672305|NCT00069121|DRUG|Leucovorin (LV)|Administered by one of two regimens, as specified in the arm description.
214672306|NCT00069121|DRUG|5-Fluorouracil (5-FU)|Administered by one of two regimens, as specified in the arm description.
214672307|NCT04868240|BEHAVIORAL|Concurrent training program|"The experimental group will perform 16-weeks of exercise. The exercise sessions will occur three times/week.~The participants should conduct their daily activities as usual outside of the study and maintain the same diet."
214672308|NCT02806401|DEVICE|landmark|
214672309|NCT02806401|DEVICE|US_Ax|
214672310|NCT05149378|DRUG|Venetoclax combined with azacitidine regimen|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
214672311|NCT00565422|DRUG|Escitalopram|10 mg/day
215063505|NCT06831851|BEHAVIORAL|Music Education Sessions|Children will participate in structured music education sessions, conducted twice per week for 40 minutes each. The sessions will include rhythm exercises, vocalization, body percussion, and instrumental exploration using age-appropriate musical instruments. Activities will be designed to enhance cognitive, motor, and socio-emotional development by fostering auditory discrimination, fine and gross motor coordination, and social interaction. The intervention follows an interactive and play-based methodology, ensuring active engagement and progressive learning.
215063506|NCT06831851|BEHAVIORAL|Parental Guidance Sessions|Parents or guardians will attend 8 biweekly training sessions (60 minutes each) designed to equip them with strategies for cognitive, linguistic, and socio-emotional stimulation in early childhood. The sessions will include practical guidance on storytelling techniques, musical interaction, and play-based learning to reinforce the intervention at home. The goal is to create continuity between structured intervention activities and the home environment, maximizing developmental outcomes for the children. Sessions will be interactive, combining theoretical content with practical exercises and demonstrations
215063507|NCT06831851|BEHAVIORAL|Standard Daycare Activities|Children in this group will participate in regular daycare activities, including artistic and pedagogical tasks such as drawing, painting, and modeling. These activities are part of the standard curriculum and do not include structured storytelling or music education interventions
215063508|NCT05227976|BEHAVIORAL|Patient education (Theory)|"Theory/Lectures (1h/week)~Interventions given once weekly for 10 weeks."
215063509|NCT05227976|BEHAVIORAL|Physical training|"Physical training group (1 hour/week)~Interventions given once weekly for 10 weeks."
215063510|NCT05227976|BEHAVIORAL|Mindfulness and medical yoga in group|"Mindfulness/medical yoga in group (1hour/week)~Interventions given once weekly for 10 weeks."
215063511|NCT03606291|RADIATION|isotoxic hypofractionation|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
215063512|NCT03108521|DRUG|Sitagliptin|100mg.QD for 3 months
215063513|NCT06895473|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
215063514|NCT06895473|DRUG|Cytarabine|Given IT
215063515|NCT06895473|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
215063516|NCT06895473|DRUG|Methotrexate|Given IT
215063517|NCT06895473|DRUG|Therapeutic Hydrocortisone|Given IT
215063518|NCT06895226|BEHAVIORAL|Exercise|Exercise and physical activity program and usual care
214322201|NCT06142448|DEVICE|Cueing app|"All participants that are included come to the movement lab for the baseline measurement. The baseline measurement consists out of extensive clinimetrics (for example MDS-UPDRS) to identify patient characteristics. With the use of an objective gait assessment, the effectiveness of both internal and external cueing is determined. This will divide the participants in three groups; responders, non-responders and in between. Participants who clearly respond to either internal or external cueing (determined as the responders) are asked to apply the working form of cueing in daily life during the six-month follow-up. During this period the participants will use a mobile application that can provide them with a rhythmic auditory stimulus and records the use of this application.~After 6 months, both the responders and non-responders are asked to return to the lab for the follow up measurement in which the baseline measurement is repeated to evaluate the effect of long-term cueing."
214322202|NCT05734105|DRUG|Ripretinib|50 mg tablets
214322203|NCT05734105|DRUG|Sunitinib|12.5 mg tablets
214322204|NCT05677412|BEHAVIORAL|suggestive relaxation|suggestive story before sleep onset
214322205|NCT05677412|BEHAVIORAL|Neutral story|neutral story before sleep
215063519|NCT06895226|OTHER|Usual Care|Usual cara and Exercise and PA recommendations
215063520|NCT06897228|DRUG|PANK-003 cell injection|PANK-003 cell injection
215063521|NCT04088968|BEHAVIORAL|Prehabilitation|Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
215063522|NCT06899737|OTHER|MOMS Postpartum Course|Online professional development training for CHWs on outreach and support for high-risk postpartum mothers
215063523|NCT04235816|DRUG|Azithromycin|Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
215063524|NCT04235816|DRUG|Placebo|Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation
215063525|NCT05225233|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 seconds ramp up/ramp down at the beginning of the session)
215063526|NCT05225233|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
215063527|NCT06308081|OTHER|Tailored|Messages will be in the form of high-quality English-language anti-vaping messages comprising static text and imagery designed to resemble social media posts (e.g., image and a caption). We will create 24 messages based on the top-ranked tailoring features and belief themes tested in Aim 2 to comprise SGM-tailored messages. For the non-tailored message condition, we will create 24 anti-vaping social media messages that mirror the SGM-tailored messages but do not contain SGM identity cues. We will match the belief themes used in the tailored and non-tailored messages such that they represent a range of belief targets (e.g., addiction, physical health effects, mental health effects) as indicated in Aims 1 and 2. We do not utilize a social media platform for the delivery of the message to avoid potential contamination across randomized conditions.
214322206|NCT04565015|BIOLOGICAL|GC5107|Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months
214322207|NCT06006559|DRUG|EYU688|EYU688 administered by oral route
214322208|NCT06006559|DRUG|Placebo|Matching placebo administered orally as capsules
215063528|NCT04732130|BEHAVIORAL|Time-Restricted Feeding|Participants are instructed to limit food intake to maximum 8 hours per day.
215063529|NCT04732130|BEHAVIORAL|Alternate Day Fasting|Participants are instructed to fast every other day.
215063530|NCT01945216|DRUG|Alogliptin|Alogliptin tablets
215063531|NCT01956630|BIOLOGICAL|Genetically modified DCs plus CIK cells|
215063532|NCT01956630|BIOLOGICAL|Donor leukocyte infusions (DLI)|
215063533|NCT03054805|DRUG|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight \> 30 kg
215063534|NCT03054805|DRUG|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight \< 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight \> 30 kg
214322209|NCT00527813|PROCEDURE|prone position|prone position for at least 16 hours per day
214921604|NCT06577701|DRUG|non traditional Chinese medicine (non-TCM)|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).
214322210|NCT03400332|DRUG|BMS-986253|Specified dose on specified days
214322211|NCT03400332|BIOLOGICAL|Nivolumab|Specified dose on specified days
214322212|NCT03400332|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214322213|NCT03400332|OTHER|Placebo|Specified dose on specified days
214322214|NCT00937417|DRUG|docetaxel|
214322215|NCT00937417|DRUG|vandetanib|
214322216|NCT00937417|GENETIC|proteomic profiling|
214322217|NCT00937417|OTHER|laboratory biomarker analysis|
214921605|NCT01725022|OTHER|Home Care|This is the interventional arm where patients receive the transplant care in their homes.
214921606|NCT04771598|OTHER|Breathing exercise with the phone application|"1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home."
214921607|NCT04771598|OTHER|Breathing exercise|"1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week"
214921608|NCT03297645|BEHAVIORAL|School|CHWs will ensure that families submit required health paperwork (e.g., asthma action plan, medication release form) and confirm with school nurses that children have the appropriate medications. School nurses will be given a standardized protocol to follow with clear guidelines for caring for students with asthma. The CHW assigned to the family will work with the school nurse to ensure that communication with the medical provider is occurring.
214921609|NCT03297645|BEHAVIORAL|Asthma education|CHWs will deliver evidence-based asthma education to parents and children. Content is drawn from existing asthma management programs, and adapted for families in Richmond. Between sessions, CHWs will call parents at least monthly to check in and assess family asthma management, including healthcare utilization since the last contact.
214921610|NCT03297645|BEHAVIORAL|Home environmental remediation|Healthy Homes will complete home-based environmental assessments using evidence-based protocols. Healthy Homes will provide real-time education and share information about their findings and recommendations for action. Families are provided with low-cost intervention materials (e.g., filters, pillow covers), as well as behavioral modifications to aid in the reduction of asthma triggers in the home.
214921611|NCT03297645|BEHAVIORAL|Informational mail|Family will be mailed publicly available asthma information every 3 months.
214921612|NCT00022698|DRUG|Capecitabine|
214921613|NCT00022698|DRUG|Irinotecan|
214921614|NCT01343680|DRUG|Heparin|5ml 10 units/ml IV heparin 3 times per week
214921615|NCT01343680|DRUG|Normal saline|10ml normal saline IV weekly
214921616|NCT05342623|DRUG|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
214921617|NCT05342623|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
214921618|NCT03964675|DEVICE|SenseGuard|A single invitational visit with a respiratory rate measurement duration of 30 minutes.
214921619|NCT05072249|DRUG|Naloxone|Take Home Naloxone for reversing opioid overdose
214921620|NCT05198037|DEVICE|Bihemispheric tDCS|The anode and cathode are placed over the ipsilesional and contralesional primary motor cortex (C3 or C4 based on 10-20 system), respectively. The size of the electrode is 5x5 cm.
214921621|NCT05953688|DRUG|ESK-001|Oral tablet
214921622|NCT03425396|DRUG|Omadacycline tablets|Oral Omadacycline
214921623|NCT03425396|DRUG|Nitrofurantoin capsules|Oral Nitrofurantoin
214921624|NCT00301353|DRUG|Isoflavones-enriched foods|
214921625|NCT02428309|BIOLOGICAL|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|
214921626|NCT00003571|GENETIC|mutation analysis|
214921627|NCT00003571|GENETIC|tumor replication error analysis|
214921628|NCT06577064|PROCEDURE|Sacral erector spinae plane block|30 ml of 0.2% ropivacaine will be injected in the plane between the ESM and sacrum on each side
214921629|NCT02893033|DEVICE|repetitive transcranial magnetic stimulation|rTMS
214921630|NCT02274012|DRUG|Afatinib|Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
214921631|NCT02274012|DRUG|Paclitaxel|On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
214921632|NCT03689374|DRUG|Semaglutide|Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.
214921633|NCT03689374|DRUG|Insulin aspart|Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days
214921634|NCT03689374|DRUG|Insulin glargine U100|Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
214921635|NCT04710784|BEHAVIORAL|Sexual health information|We will provide participants with sexual health information, that is basic, accurate, and directly contributes to health-promoting decisions and behavior, once a week at the beginning of the study.
215063535|NCT06833931|DRUG|IV infusion|IV infusion
214322218|NCT00937417|OTHER|pharmacological study|
215063536|NCT06833931|OTHER|Placebo|IV infusion
215063537|NCT01808638|DRUG|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
215063538|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
215063539|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
214322219|NCT05365581|DRUG|ASP2138|Intravenously or Subcutaneously
214322220|NCT05365581|DRUG|Pembrolizumab|Intravenously
214485185|NCT06699303|OTHER|Use of diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g / 100 g for infants in the control group in diaper dermatitis care|In diaper dermatitis care, it was planned to use their mothers' milk for the babies in the experimental group and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g for the babies in the control group. The reason why diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g is preferred is that it is the most frequently used cream in cases of uncomplicated diaper dermatitis. The mothers of the babies in the control group will be asked to wash and dry the baby's diaper with soap and water during each diaper change and then apply diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g. Mothers will be asked to record any new signs and symptoms that develop during the treatment and to inform the investigators will be asked to provide information. Positive and negative effects of treatment will also be recorded.
214485186|NCT06702293|BEHAVIORAL|Digital psychotherapeutic intervention|Mobile app comprising various psychobehavioural tools to educate, enhance self-efficacy and coping and promote wellness in dermatological patients.
214322221|NCT05365581|DRUG|Oxaliplatin|Intravenously
214322222|NCT05365581|DRUG|Leucovorin|Intravenously
215063540|NCT06360900|DEVICE|taVNS|Electrical transcutaneous auricular vagus nerve stimulation
214322223|NCT05365581|DRUG|Fluorouracil|Intravenously
214921636|NCT04710784|BEHAVIORAL|I-TEST branded HIVST package|The I-TEST branded HIVST package will include HIV self-testing (HIVST) kits, referral coupons, condoms, female or male hygiene products, and instructions on how to use the I-TEST photo verification App or USSD (Unstructured Supplementary Service Data) system to verify the HIVST results. Study participants will be referred to a youth-friendly health clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment and PrEP referral.
214322224|NCT05365581|DRUG|Ramucirumab|Intravenously
214322225|NCT05365581|DRUG|Paclitaxel|Intravenously
214485187|NCT06702293|BEHAVIORAL|Healthy365|Mobile application by the Health Promotion Board (HPB) Singapore which aims to encourage users to adopt a healthier lifestyle.
214485188|NCT07030985|RADIATION|CTP scan|Patients with diagnosed aSAH and no evidence of early radiologic vasospasm will receive a CTP scan within 48 hours of aSAH symptom onset.
214921637|NCT04710784|OTHER|Follow-up testing and clinic assessments|Information to encourage routine retesting for HIV every 6 months and linkage to the youth-friendly clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment, and PrEP referral. Additionally, follow-up surveys will be administered to assess HIV testing, sexual behavior history, youth participation experience, and other related outcomes will be collected from enrolled participants.
214921638|NCT06445751|BEHAVIORAL|"Step Up for STEM and Health Careers (Step Up) game"|"Step Up for STEM and Health Careers (Step Up) game is an interactive, digital resource to help high school students understand the importance of diversity in STEM and health careers, attain STEM/health career self-efficacy, and help them create an inclusive learning environment for others."
215063541|NCT06360900|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
215063542|NCT06360900|BEHAVIORAL|Education Control|Education of FD condition
215063543|NCT06360900|DEVICE|Sham taVNS|Sham (no current) transcutaneous auricular vagus nerve stimulation
214322226|NCT05365581|DRUG|Irinotecan|Intravenously
214322227|NCT06423053|BEHAVIORAL|Biology Course with Integrated Mindfulness|The intervention, Mindful Physiology, is an undergraduate-level biology course embedded with mindfulness practices. There will be 19 class sessions, each 1 hour and 50 minutes long, over 10 weeks. Students will be taught human physiology through didactic lectures, laboratory activities, and written quizzes typical for a college course. Each class meeting will have \~20 minutes of mindfulness practice in Thích Nhất Hạnh's Plum Village tradition. Students will also be encouraged to practice mindfulness for 15 minutes daily outside the class. Students will complete a daily log of their mindfulness practice and be given credit for each log completion regardless of the minutes of mindfulness practice. Students will be assigned a weekly written reflection on the physiology course content and/or their mindfulness practice. All students in the class are required to attend a 4.5-hour or a two-day (16-hour) on-campus mindfulness retreat.
215063544|NCT06963905|DRUG|Relatlimab FDC + Nivolumab|Relatlimab: 360 IV Q3W (Dose level 1) and 120mg IV Q3W (Dose level -1) Nivolumab: 360mg IV Q3W
214322228|NCT01188577|DRUG|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
214322229|NCT01188577|DRUG|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
214322230|NCT00643838|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
214322231|NCT06846866|DRUG|BMS-986419|Specified dose on specified days
214322232|NCT06846866|DRUG|BMS-986419 Matching Placebo|Specified dose on specified days
214322233|NCT06846866|DRUG|Moxifloxacin|Specified dose on specified days
215063545|NCT06963905|DRUG|Sacituzumab Govitecan (SG)|10 mg/kg IV D1 \& D8 every 21-day cycles (Dose level 1); 7.5 mg/kg IV D1 \& D8 every 21-day cycles (Dose level -1); 5 mg/kg IV D1 \& D8 every 21-day cycles 21-day cycles (Dose level -2)
215063546|NCT06963905|DRUG|Nivolumab|360mg IV Q3W
214322234|NCT06846866|DRUG|Moxifloxacin Matching Placebo|Specified dose on specified days
214921639|NCT06445751|BEHAVIORAL|Educational PowerPoint Presentation on Diversity in STEM Careers|An educational PowerPoint on Diversity in STEM careers to increase adolescents' STEM/health career self-efficacy, and help them create an inclusive learning environment for others.
214921640|NCT02660957|BEHAVIORAL|self-determination smoking cessation|a self-help quitting leaflet plus a series of brief interventions using the AWARD model
214921641|NCT02660957|OTHER|placebo comparator|suggest a healthy life style as a placebo comparator
214921642|NCT02921932|DIETARY_SUPPLEMENT|Ensure, Resource 2.0 and Glucerna|Preoperative nutritional supplement for undernourished patients
214921643|NCT02921932|OTHER|Cognitive Training, Memory Card Game|Preoperative memory card game
214921644|NCT02921932|DEVICE|'Threshold' Inspiratory Muscle Trainer, Respironics of New Jersey Inc|Inspiratory muscle trainer protocol for strengthening respiratory muscles
215063547|NCT03367962|DRUG|[18F]F-Ara-G|the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
215063548|NCT04591639|DRUG|Dapagliflozin 10 milligrams [Farxiga]|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
214921645|NCT05276375|DRUG|Bronchipret|Bronchipret syrup (3x 5,4 ml daily) until day 14
214921646|NCT05565833|BEHAVIORAL|SHUTi OASIS|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6-9 weeks in a fully automated, interactive, tailored web-based program
214921647|NCT05565833|OTHER|Patient Education|An educational website containing information on insomnia
214921648|NCT02919423|DEVICE|transcranial magnetic stimulation|
214921649|NCT01011530|DRUG|MLN4924|Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
214921650|NCT06433778|OTHER|No Intervention|This is a non-interventional study.
214322235|NCT06846268|DRUG|ADG126|Administered via intravenous infusion on Day 1 only (Q6W) or Day 1 and Day 22 (Q3W).
214322236|NCT06846268|DRUG|Pembrolizumab|Administered via intravenous infusion on Day 1 and Day 22.
214322237|NCT06305299|BIOLOGICAL|iC9-CAR.B7-H3 T cells|iC9-CAR.B7-H3 T cells will then be administered intraperitoneally
214322238|NCT06305299|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
214322239|NCT06305299|DRUG|Fludarabine|fludarabine 30 mg/m2 IV will be given.
214322240|NCT06519734|OTHER|Questionnaire|"Questionnaire intended for patients on contraceptive modalities and use of menstrual hygiene products.~Consultation of the medical records of patients who have reported infectious complications linked to the use of intrauterine devices, tampons or menstrual cups."
214322241|NCT04476017|DRUG|SAGE-718|Oral tablets.
214322242|NCT02704364|BIOLOGICAL|NGM282|
214322243|NCT02704364|OTHER|Placebo|
214322244|NCT02684292|BIOLOGICAL|pembrolizumab|IV infusion
214322245|NCT02684292|BIOLOGICAL|brentuximab vedotin|IV infusion
214322246|NCT05741125|BEHAVIORAL|DSME + ASE intervention (Centering Appetite)|The intervention will enable participants to relearn their stomach's hunger and fullness signals and monitor their appetite. Participants will also learn strategies for glucose monitoring and carbohydrate management. Monthly booster sessions will be devoted to problem-solving, addressing barriers to emotion management, and self-monitoring type 2 diabetes mellitus symptoms. Participants will also receive weekly lessons with interactive activities delivered via a digital app.
214322247|NCT05225935|DEVICE|image-guided VT ablation strategy|Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
214322248|NCT05225935|DEVICE|conventional VT ablation strategy|Catheter ablation will be performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.
214322249|NCT05546697|OTHER|Online- Yoga-based Intervetion|See arms description
214322250|NCT05546697|BEHAVIORAL|Online- BA|See arms description
214322251|NCT04063761|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|Prospective, single center pilot study
214322252|NCT06178341|DEVICE|Kata Inhalations-App|"The Kata Inhalations-App is a digital product that bears a CE mark. The application provides algorithms to run an inhalation trainer. The inhalation trainer shows patients how to improve their inhalation maneuver in a simple and understandable way. For this purpose, the signals from the camera and microphone of the patient's smartphone are used to evaluate the individual steps of the inhalation maneuver in real-time to provide automatic, personalized feedback. Additional functions of the Kata Inhalations-App include the possibility to document health parameters and to receive inhalation reminders.~After set-up, subjects will use the application on their own as an add-on to their usual therapy for asthma. The total duration of application use will be 13 weeks, 1 week use of the Messinstrument (Measurement)-App for all subjects (Baseline period), followed by 12 weeks use of the Kata Inhalations-App (intervention) or the Messinstrument-App (control)."
214322253|NCT04843852|DRUG|Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]|one 0.5ml intramuscular injection on day 0 and week 4.
214322254|NCT06105905|BEHAVIORAL|"Healthy futures (Futuros Saludables)"|The developed intervention will be delivered in a workshop format by facilitators, over 8 sessions for teens and parent/guardian(s). Feedback on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Participants will complete sessions, in either Spanish or English depending on participants' preference, using video conference tools. After the delivery of the intervention, facilitators will take field notes and complete a debriefing questionnaire to assess practicality and fidelity. Teens and parent/guardian(s) will complete a 20-minute survey pre-intervention, immediately post-intervention, three-month, six-month, and twelve-month post-intervention. Surveys will assess acceptability and risk behaviors.
214322255|NCT02178163|OTHER|cytology specimen collection procedure|Correlative studies
214322256|NCT02178163|OTHER|laboratory biomarker analysis|Correlative studies
214921651|NCT06685497|DEVICE|Mobile application follow-up|Colorectal cancer patients enrolled in the 'Internet Plus' post-treatment management platform use the digital medical quality management system based on the 'COLORECTUM+' model for quality evaluation and continuous improvement. The platform integrates AI, using natural language processing and machine learning to analyze patient-reported symptoms, automatically assess severity, and generate alerts. Alerts are classified as yellow, orange, or red. Yellow indicates mild issues with self-care recommendations; consecutive yellow alerts prompt doctor contact within 24 hours. Orange indicates moderate severity, requiring doctor intervention within 24 hours. Red alerts signify serious symptoms or high-risk medication errors, prompting immediate notification of the doctor and emergency team. The system monitors symptom changes and updates alerts to support treatment optimization.
214485189|NCT07030985|DIAGNOSTIC_TEST|Neurological and neuropsychological testing|All enrolled patients will receive neurological and neuropsychological assessment at 12 months after aSAH.
214485190|NCT06878820|BEHAVIORAL|Function Focused Care|FFCiH is an effective nursing approach and focuses on stimulating nurses to promote patients' self-reliance in daily functioning, encouraging the patients' engagement in daily activities and helping patients to attain and maintain their highest level of function and to increase time spent in physical activity.
215063549|NCT04591639|DRUG|Placebo|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
215063550|NCT03062280|DRUG|Hydrocortisone|Modified release hydrocortisone
215063551|NCT04894877|PROCEDURE|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
214485191|NCT06877689|DRUG|Apitegromab|Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.
215063552|NCT04894877|PROCEDURE|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
214485192|NCT06876844|DRUG|combination of Surufatinib and Envolizumab|envolizumab: 300 mg subcutaneously every 3 weeks (Q3W); Surufatinib : 200 mg orally within 1 hour after breakfast, once daily continuously every 3 weeks as a treatment cycle until intolerable toxicity or disease progression. If any ≥ Grade 2 treatment-related adverse event occurs during treatment, the dose may be adjusted to 100 mg according to the investigator 's clinical assessment.
214485193|NCT06877767|OTHER|Graston Technique|"Following the conventional treatment, this technique will be carried out through Graston tool called GT-1 The special Graston Emollient or lubricant will be applied to the hamstrings of the subject then the tool used to find adhesions and break them up for 2.5 minutes per leg. First, the subject will lay prone and bent the knee joint to around 30° to 60°.The Graston instrument will be rubbed on each subject 30 times for 60 seconds from the gluteal line to the popliteal fossa. This treatment technique will be applied twice a week"
214485194|NCT06877767|OTHER|Active Release Technique|Following the conventional treatment, subject received single session of ART on each side. There are 3 steps to perform ART. Step 1:Subject lies supine on the plinth and gentle tension was applied to the hamstring muscle along the entire length while stretching the leg in different positions to better work the muscle. Step 2: Gentle tension will be applied at the origin and insertion of the hamstring muscle. Step 3: The therapist will place tension on the bellies of hamstrings longitudinally at a specific tension \& ask the patient to extend his knee as per ART protocol.• This is done for 2.5 minutes on each leg. • This treatment technique will be applied twice a week.
214485195|NCT06876181|OTHER|Pharmacokinetics of Intra-Articularly Administered TXA: Postoperative Concentration Dynamics in Periarticular Hematoma|As part of the standard total knee arthroplasty procedure, participants receive a 2 g dose of tranexamic acid into the joint space after suturing the joint capsule. Before closing the joint capsule, a silicone drain is inserted into the joint space, through which periarticular hematoma samples are collected aseptically at 0.5, 1.5, 3, 6, and 9 hours post-application.
214485196|NCT07028008|BIOLOGICAL|tumor-infiltrating lymphocyte (TIL)|tumor-infiltrating lymphocyte (TIL): CT-SP 1\~100 x10 9 cells
214672312|NCT02035384|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
214921652|NCT03469128|BEHAVIORAL|Cognitive processing therapy|Psychological treatment for patients suffering from PTSD and SUD symptoms.
214921653|NCT03469128|DRUG|Sertraline|Sertraline for the treatment of post-traumatic stress and SU disorders
214921654|NCT03469128|OTHER|Placebo Control|Placebo Control
215063553|NCT04894877|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
215063554|NCT04894877|BEHAVIORAL|Lifestyle|diet, physical activity, smoking cessation
215063555|NCT04894877|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
214322257|NCT05452993|DEVICE|Analysed Retinophotography|taking 2 retinophotographs per eye, and then analysed by AI software to detect Diabetic retinopathy
214322258|NCT05523765|DRUG|Brepocitinib|Oral Brepocitinib
214322259|NCT03606759|PROCEDURE|Weekly assessment|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)"
215063556|NCT06679192|DEVICE|Milled thickness varied soft upper surface, based on plantar pressure measurement|"This custom made shoe insole is milled, with a thickness varied soft upper surface ranging from 0-6mm in thickness. The base of the insole is 45 shore Ethylene-vinyl acetate (EVA).~This intervention makes the insole from an individual foot scan, a plantar pressure measurement from the individual and the shoe model to mill a finished custom made shoe insole with a soft upper surface. It is difficult in clinical practice of making shoe inserts to create a thickness varied soft upper with different zones all over the insole. Furthermore, a soft upper requires a physical positive model to be made of the foot and staff must spend time to grind the insole to an acceptable shape. A milled version would be more effective since it require no physical foot model, little to no work grinding the insole and enables the use of thickness-variations. It also enables the use of data-based insole-manufacturing, such as data from plantar pressure measurements."
215063557|NCT06679192|DEVICE|3mm soft upper surface|This intervention has a 3mm soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.
215063558|NCT06679192|DEVICE|No soft upper surface|This intervention has a no soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.
215063559|NCT05642455|GENETIC|Afamitresgene autoleucel|Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to \<40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells/kg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion
214485197|NCT06707623|OTHER|Respiratory Physiotherapy|Physiotherapy will include: Progressive breathing retraining, neurosensory training, nose breathing training, activity modification, inhalation-exhalation ratio training, dynamic respiratory control training and instructions for continuing all of the above training at home. Total 5 sessions in 9 weeks time.
214921655|NCT00030394|DRUG|imatinib mesylate|Given orally
215063560|NCT06349954|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
215063561|NCT06349954|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
215063562|NCT01894854|PROCEDURE|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
214322260|NCT03606759|PROCEDURE|Weekly assessment ajusted|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)"
214921656|NCT00030394|OTHER|laboratory biomarker analysis|Correlative studies
214921657|NCT00030394|OTHER|pharmacological study|Correlative studies
214921658|NCT05088603|DEVICE|Clear Mask|The clear mask has a 4.75 x 1.35 inch clear window that allows for clear visibility of the mouth.
214921659|NCT03619239|DRUG|GX-I7|During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.
214921660|NCT05967832|OTHER|7T MRI|Patients and healthy volunteers will have a 7T MRI
214921661|NCT01253551|DRUG|Treatment sequence AB|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
214921662|NCT01253551|DRUG|Treatment sequence BA|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
214921663|NCT02207803|BEHAVIORAL|Transition Assistance Program|
215063563|NCT06788561|DEVICE|Transauricular Nerve Stimulation|Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.
215063564|NCT06788561|DEVICE|s-taVNS|Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.
214322261|NCT03655002|DRUG|Cyclophosphamide|Given IV
214322262|NCT03655002|BIOLOGICAL|Cytokine-based Biologic Agent IRX-2|Given SC
214322263|NCT03655002|BIOLOGICAL|Nivolumab|Given IV
214322264|NCT05080309|DIETARY_SUPPLEMENT|carbohydrate oral intake|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
214322265|NCT05080309|OTHER|free water only|Women will have free access to water only
214485198|NCT06707623|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation will be completed in 16 sessions (2 times a week for 8 weeks). It will combine exercise with breathing retraining guided by CPET findings regarding erratic breathing pattern and/or hyperventilation.
214921664|NCT00594100|DEVICE|GORE Flow Reversal System (GFRS)|Carotid artery angioplasty and stenting with embolic protection
214921665|NCT02372812|DRUG|dexamethasone|12 mg of dexamethasone
214921666|NCT02372812|DRUG|Placebo|
214921667|NCT03981900|DRUG|Tofacitinib|5 mg BID, oral administrtaion
214921668|NCT03981900|DRUG|Tofacitinib|tablet form 11mg once daily oral
214921669|NCT01071980|OTHER|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
214921670|NCT06663280|DEVICE|Digital health assistant ADELE|The digital health assistant ADELE Blood Pressure A0007 (ADELE for short) improves the daily lives of patients with high blood pressure and enhances patient care. Participants in the intervention group were provided with ADELE to use during the study period for voice-based recording, interpretation and classification of their vital signs and body conditions.
214921671|NCT02155673|DRUG|GCS-100|1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.
214921672|NCT02162719|DRUG|Ipatasertib|Participants received ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
214921673|NCT02162719|DRUG|Paclitaxel|Participants received paclitaxel 80 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
214485199|NCT06708260|DRUG|ENN0403, low dose|ENN0403 capsules will be orally administered once a day for 12 weeks.
214485200|NCT06708260|DRUG|ENN0403, high dose|ENN0403 capsules will be orally administered once a day for 12 weeks.
214485201|NCT06303037|DRUG|Remimazolam besylate and low-dose Esketamine|Esketamine was injected intravenously 0.25mg/kg and the initial dose of Remimazolam was 0.3mg/kg
214485202|NCT06303037|DRUG|Remimazolam besylate and Medium dose Esketamine|Esketamine was injected intravenously 0.5mg/kg and the initial dose of Remimazolam was 0.2mg/kg
214485203|NCT06753864|DRUG|Test (T)|Abaloparatide injection, specification :3120 μg/1.56 ml(2000 μg/ml), drug information subject to actual supply, Qilu Pharmaceutical Co., LTD. The test preparations for the subjects are all from the same batch number.
214485204|NCT06753864|DRUG|Reference (R)|Abaloparatide injection (Tymlos®), specification :3120 μg/1.56 ml(2000 μg/ml), drug information is subject to actual supply, provided by Qilu Pharmaceutical Co., LTD. The reference preparations for the subjects were all from the same batch number.
214485205|NCT06882148|DRUG|target therapies (biological drug, small molecules)|describe the drug sruvival rate of the different approved drugs
214485206|NCT06882473|OTHER|Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day|Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day.
214485207|NCT06881680|DEVICE|virtual reality (VR) head mounted display|This group of subjects received immersive and interactive VR training, which combined rich immersive VR scenes with specific interactive tasks, including two VR scenes. Task selection was based on the subjects' upper limb functional performance, and experienced therapists provided guidance and monitoring, and adjusted the tasks when necessary.
214921674|NCT02162719|DRUG|Placebo|Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
214485208|NCT06882200|OTHER|A combined mindfulness and therapeutic scuba-diving protocol|The Bathysmed program is a unique scuba diving program that combines scuba immersion with techniques from mindfulness meditation, psychology and sports mental preparation. The program includes 30 different exercises over ten scuba-diving sessions with mindfulness training, twice a week for five weeks.
214485209|NCT06882200|OTHER|Control group regular follow up in primary care|Standard care includes regular appointments and health education with their general practitioner and monthly appointments with the dietician and psychotherapist at the primary care centre in Montpellier, France throughout the study. This care includes monthly sessions on diet, exercise and general stress management with a registered dietician.
214485210|NCT06706960|DIAGNOSTIC_TEST|measurement of IJV-height|"Protocol 1: IJV tapering portion is portrayed in a transverse view. With a skin marker, the IJV height is marked and measured as soon as IJV is smaller than CCA throughout the whole respiratory cycle.~Protocol 2: IJV tapering portion is portrayed in a transverse view. With a skin marker, the IJV height is marked and measured as soon as IJV is completely collapsed throughout the whole respiratory cycle.~Protocol 3: IJV tapering portion is portrayed in a longitudinal view. With a skin marker, the IJV height at the end of expiration is marked and measured at the following two positions:~1. Measurement 1: at the very end of the tapering portion (collapsing point / top of pulsation).~2. Measurement 2: at the beginning of the tapering portion (taper point)."
214672313|NCT01925521|DRUG|Part1 : OPS-2071|single oral dose under fasted condition
214921675|NCT06666647|PROCEDURE|Treatment by ambulance or helicopter services with response times|Prehospital treatment by ambulance and/or helicopter services personnel of patients in acute conditions
214921676|NCT06667947|PROCEDURE|caudal block|For the caudal block, a caudal needle was used by the same anesthesiologist after the patients were placed in the left lateral decubitus position.
214921677|NCT02042326|DRUG|Sirolimus|For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
214921678|NCT02490787|DRUG|Concizumab|Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
214921679|NCT02490787|DRUG|placebo|Administered subcutaneously (s.c., under the skin)
214921680|NCT02838719|DRUG|Perineural Dexamethasone acetate|
214921681|NCT02838719|DRUG|Intravenous dexamethasone acetate|
214921682|NCT02096757|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
214921683|NCT02096757|OTHER|Pro-Omega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
214921684|NCT04988971|DRUG|a compound glutamine capsule|A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
214921685|NCT04988971|DRUG|a compound glutamine capsule simulated placebo|a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
214921686|NCT02775877|DRUG|Letrozole|
214921687|NCT02775877|DRUG|clomiphene|
214921688|NCT02775877|DRUG|HMG|
214921689|NCT04181606|DRUG|Esmolol infusion|The Esmolol loading dose will be 0.5 mg/kg fat free mass/min administered over the first 3 minutes, followed by a maintenance dose of 0.25 mg/kg fat free mass/min for the remainder of the protocol (maximum of 60 minutes).
214921690|NCT04181606|DRUG|Saline infusion|Saline will be rate/volume matched to the calculated esmolol dose.
214921691|NCT04181606|OTHER|Pre exercise baseline|Subject rests quietly while drug infusion begins (3 min loading dose followed by 10 min of maintenance dose) until heart rate and blood pressure stabilize.
214921692|NCT04181606|OTHER|Isometric handgrip exercise|The subject will grip at 40% of their maximum and maintain that grip for 90 seconds. Once at rest and once during heavy intensity cycling.
214921693|NCT04181606|OTHER|Semi-recumbent cycling|Subjects will pedal for 2-4 minutes at a very light intensity (20W), followed immediately by 5 minutes at a moderate intensity (at a workload intended to elicit 85% of the oxygen consumption observed at the lactate threshold), and 5 minutes of cycling at a heavy intensity (at a workload estimated to elicit oxygen consumption half way between those observed at the lactate threshold and respiratory compensation point). Subjects will then continue cycling at the heavy intensity for 90 seconds while performing isometric handgrip exercise.
215063565|NCT06839131|DRUG|SPH9788|SPH9788 tablets administered orally
215063566|NCT06839131|DRUG|Placebo|Matching placebo administered orally
215063567|NCT05314179|BEHAVIORAL|Doula - Patient engagement|"Ubuntu ambassador/Doula and Patient will decide on details of engagement. The components to be included will be: 1) emotional support, 2) practical assistance, 3) family support, and/or 4) legacy building projects as per study protocols.~The nature and type of visits will be determined by the patient and doula."
215063568|NCT06959264|OTHER|Virtual reality|Patients in the study group will be shown a video with virtual reality glasses during the procedure. Patients will be asked to wear a virtual reality goggles (VR Shinecon G12 3d Virtual Reality Goggles Black 4.5-7.0 Inch) compatible with a mobile phone (Xiaomi Redmi Note 8 Pro 2019 model) with android operating system in supine position and minimizing sound loss. With the virtual reality goggles, nature landscapes with a relaxing music background will be watched by adjusting the volume at the level desired by the patient. Virtual reality goggles will be applied during the urodynamic procedure.
215063569|NCT04299308|BEHAVIORAL|Aerobic Exercise|Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload
215063570|NCT02840435|BEHAVIORAL|Sit to Quit|Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
215063571|NCT02840435|BEHAVIORAL|Quit for Life|"Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills."
214485211|NCT06714708|RADIATION|Experimental|Radiation: 30Gy/15F Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
214485212|NCT06714708|DRUG|Active comparator|Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
214672314|NCT01925521|DRUG|Part1 : Placebo of OPS-2071|single oral dose under fasted condition
214921694|NCT06966687|DRUG|Ulinastatin and Thymosin α1|Ulinastatin (100000U TID for 5 days) and Thymosin alpha 1 (1.6 mg q12h for 5 days) immediately after surgery
214921695|NCT06966687|DRUG|Ulinastatin only|Ulinastatin (100000U TID for 5 days) immediately after surgery
214921696|NCT06968585|DRUG|A166|intravenous(IV) infusion (Q3W)
214921697|NCT06968585|DRUG|T-DM1|intravenous(IV) infusion (Q3W)
214921698|NCT06968507|DRUG|Methylprednisolone (drug)|In our study, we use methylprednisolone as a oral treatment daily for 2 weeks (48 mg for the first 7 days, 32 mg for the following 2 days, 16 mg for the 2 days, and 8 mg for the last 3 days)
214921699|NCT06968507|DRUG|Dexamethasone|In our study we use dexamethasone 8mg/2ml form as intratympanic treatment every other day, totally 4 doses.
215063572|NCT02423525|DRUG|Afatinib|
214322266|NCT03471338|BEHAVIORAL|Cognitive rehabilitation|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
214322267|NCT03471338|BEHAVIORAL|Standard Psychological care|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
214322268|NCT03057639|OTHER|Quality-of-Life Assessment|Ancillary studies
214322269|NCT03057639|OTHER|Questionnaire Administration|Ancillary studies
214322270|NCT06383247|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
214921700|NCT06967207|OTHER|Not applicable- observational study|Not applicable- observational study
214921701|NCT06968598|OTHER|blood sample|blood sample
214921702|NCT06967857|DRUG|DEX IR tablets|tablet twice daily
214921703|NCT06967857|DRUG|DEX XL|capsule once daily
214921704|NCT06967857|DRUG|Placebo|Placebo to either capsule or tablet
215063573|NCT05258890|OTHER|Social Network Group Counseling|Researchers will identify the influential network members based on their network position, driving distance from the patient, speaking frequency, and whether they have high blood pressure. The index patient and social network members will meet with the study nurse on weeks 2, 6, and 12 after initial enrollment. The study nurse will begin the social network counseling session in which she will provide counseling on teamwork and blood pressure control. The teamwork specific topics will include how networks can work together as a team, communication tips for engaging with one another, spreading positive messages, and establishing the roles and responsibilities of each network team member. The blood pressure control specific topics will include the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. Patient and social network members will receive text messages every week in the weeks between sessions.
215063574|NCT05258890|OTHER|Individual Counseling|The index patient will meet individually with the study nurse on weeks 2, 6, and 12 after initial enrollment. The nurse will provide counseling on the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. The patient will receive text messages every week in the weeks between sessions.
215063575|NCT06366789|DRUG|ZE46-0134|oral capsules QD
215063576|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose1|A topical drop of BRM424 ophthalmic solution.
215063577|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose2|A topical drop of BRM424 ophthalmic solution.
215063578|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
215063579|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
215063580|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
215063581|NCT04935697|DEVICE|nVNS|3x daily treatment of nVNS + SOC
215063582|NCT04935697|OTHER|SOC|Standard of care patient management.
214322271|NCT06422767|DRUG|Bepirovirsen|Bepirovirsen will be administered.
214322272|NCT06422767|DRUG|Placebo|Placebo will be administered.
215063583|NCT05077982|DIAGNOSTIC_TEST|Spirometry|Spirometry to assess lung function
214322273|NCT02917083|GENETIC|CAR T Cells|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2."
214322274|NCT04081792|PROCEDURE|Antibiotic therapy|Postoperative randomizations regarding the duration of systemic antibiotics
215063584|NCT05077982|DIAGNOSTIC_TEST|6-minute walk|Exercise tolerance
215063585|NCT02469987|DRUG|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
215063586|NCT02469987|DRUG|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
215063587|NCT02469987|DRUG|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
215063588|NCT04309370|DEVICE|20 Hz rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.
215063589|NCT00559455|DRUG|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
215063590|NCT00559455|DRUG|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
215063591|NCT00559455|DRUG|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
215063592|NCT02805751|DEVICE|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
215063593|NCT02805751|OTHER|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
215063594|NCT02805751|OTHER|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
215063595|NCT03117868|OTHER|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
215063596|NCT05644665|DRUG|Ozanimod|Specified dose on specified days
215063597|NCT05644665|DRUG|Placebo|Specified dose on specified days
214322275|NCT06554327|DEVICE|Multiplex PCR|In the intervention group (Multiplex PCR performed and results communicated to the clinician), bronchoalveolar lavage will be examined directly after Gram staining by the laboratory, followed by quantitative culture. A multiplex PCR will be performed.
214322276|NCT06576830|DRUG|Methadone|Single-dose intraoperative intravenous methadone with initial dose at 0.15 mg/kg in children and 0.2 mg/kg in adolescents.
214322277|NCT06576830|DRUG|Fentanyl/Hydromorphone|Per routine care, given as needed
214672315|NCT01925521|DRUG|Part2 : OPS-2071|multiple twice-daily oral dosing for 5-7days
214322278|NCT06088810|OTHER|CoMPoSER intervention group|Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.
215063598|NCT01321944|OTHER|Direct to Smoker Outreach Program|"Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs."
214485213|NCT06719427|DEVICE|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation that uses magnetic fields to stimulate specific areas of the brain. It is commonly used for the treatment of neurological and psychiatric disorders, such as major depressive disorder (MDD), anxiety, and sometimes ALS.
214485214|NCT06705218|BEHAVIORAL|MINDSET|2.5-hour mHealth intervention consisting of three modules containing brief films and corresponding interactive reflection activities aimed to improves whole patient health (physical, social, emotional, and functional quality of life as measured by the FACT-G) in patients undergoing systemic treatment for cancer with curative intent. Films feature interviews with people living with cancer describing their experience with diagnosis, treatment, and recovery, and the importance of their mindsets during their experience. The films also feature Stanford faculty with expertise in oncology, psychiatry, and psychology who offer a scientific framework for the importance of mindsets during cancer treatment and provide examples from their clinical practices. The reflection exercises that follow the films are designed to help patients craft a personalized strategy (a) for changing maladaptive mindsets and maintaining adaptive ones and (b) for translating ideas from the film into actionable behavior
214485215|NCT06705218|BEHAVIORAL|Digital Information Series for Cancer|This behavioral intervention provides educational information on coping strategies for individuals undergoing cancer treatment through a hybrid of videos and corresponding questions.
214485216|NCT06882967|DEVICE|Thoracic Endovascular Aortic Repair|Placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.
214322279|NCT06088810|OTHER|Sleep Education|Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
215063599|NCT05143749|OTHER|video tutorial|get video tutorial
215063600|NCT05557851|COMBINATION_PRODUCT|Minnelide|Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
215063601|NCT00964665|DRUG|albinterferon alfa-2b|
215063602|NCT00964665|DRUG|albinterferon alfa-2b|
214322280|NCT05329103|DRUG|PEEL-224|Lyophilized powder reconstituted with D5W
214322281|NCT05329103|DRUG|FOLF+B|infusional 5-FU, LV, and bevacizumab
214485217|NCT06884163|GENETIC|comprhensive spatial transcriptomic profile on lesional skin biopsies|Spatial transcriptomics (Visium, 10X Genomics) will be used to analyze gene expression of chronic eczema derived from lesional skin biopsies
214485218|NCT06883786|DEVICE|Virtual reality hypnosis|Virtual reality hypnosis
214485219|NCT06884124|BEHAVIORAL|Experimental|Micro teaching method will be applied for ventrogluteal injection training. Students will be trained with short learning units, multimedia content and feedback sessions.
214485220|NCT06884124|BEHAVIORAL|Control|Routine lectures and practice will be done on the model
214485221|NCT06879379|DRUG|KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation|After post-transplant randomization, patients will receive either KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation then maintenance or no consolidation and maintenance.
214485222|NCT06883734|BEHAVIORAL|Illness Management Skills Training|In this study, in addition to routine outpatient clinic check-ups, 12 sessions of Illness Management Skills Training were applied to the intervention group of 25 patients, each in four separate groups of 6+6+6+7 patients (Group 1, Group 2, Group 3, Group 4), once a week, for 60 minutes each. The training consisted of 1) Introduction-Getting Acquainted, 2) Recovery Goals, 3) Understanding Schizophrenia-1, 4) Understanding Schizophrenia-2, 5) Stress Vulnerability Model and Coping with Stress-1, 6) Stress Vulnerability Model and Coping with Stress-2, 7) Learning About Medication, 8) Using Medication Effectively and Monitoring Treatment, 9) Coping with Persistent Symptoms, 10) Recognizing and Monitoring Warning Signs, 11) Warning Signs My Emergency Plan, and 12) Termination sessions.
214485223|NCT06883890|DRUG|Recombinant LH (Luveris)|In the treatment group patients will receive the pretreatment with rLH, a daily dose of 187.5 IU (75 U in the morning and 112.5U in the evening) rLH treatment for 60 days will be administered.
214485224|NCT06883890|DRUG|No Treatment Added|In the control group, women will not receive any therapy and will be followed up with the same schedule as women in the treatment group
214485225|NCT06703632|DIAGNOSTIC_TEST|blood sampling|PreveCol test based on blood sampling
214485226|NCT06703632|OTHER|Survey using a questionnaire.|Preference questionnaire for colorectal cancer screening methods
214485227|NCT06703632|OTHER|Survey using a questionnaire.|PREMs for colorectal cancer screening programme
214485228|NCT06880094|GENETIC|blood withdrawal|blood withdrawal for genetic testing
214672316|NCT01925521|DRUG|Part2 : Placebo of OPS-2071|multiple twice-daily oral dosing for 5-7days
214672317|NCT01832961|DEVICE|Flutter valve exercises|30 minutes of flutter exercises
214672318|NCT01832961|DEVICE|Flutter Sham exercises|30 minutes of flutter-sham exercises
214672319|NCT01832961|DEVICE|Flutter and bronchodilator exercises|Flutter + bronchodilator exercises with an interval of 3 to 5 days
214672320|NCT06219252|DEVICE|Intraoperative aberrometer|the patient intraocular lens will be optimized during the aphakic period after cataract extraction and before intraocular lens implantation, this will produce a possible change in the dioptric power of the intraocular lens
215063603|NCT00964665|DRUG|albinterferon alfa-2b|
215063604|NCT00964665|DRUG|albinterferon alfa-2b|
215063605|NCT00964665|DRUG|Pegasys®|
215063606|NCT03440736|DRUG|Secukinumab|Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
214485229|NCT06880705|BEHAVIORAL|The TLC Program|Participants randomized to the TLC Program will receive TAU plus the telehealth, peer-delivered group intervention. The TLC Program was adapted from Acceptance and Commitment Therapy (ACT) - an acceptance and mindfulness-based third wave cognitive behavioral therapy. The intervention will be delivered in a group format with peer facilitators via telehealth using videoconferencing. The protocol covers all six ACT core concepts (i.e., contact with the present, acceptance, defusion, self-as-context, values, and committed action) with tailored examples and exercises focused on gender affirmation, internalized stigma, and substance use. Additional sessions are included defining stigma, how stigma affects physical and sexual health and engagement with healthcare, and values-driven self-care goals of substance use reduction and healthcare engagement. Sessions are approximately 1.5 hours each and are delivered over 12 weeks.
214485230|NCT06881654|PROCEDURE|Bleaching teeth|Traditionally, home bleaching has been done with soft silicone trays. Patients now wear aligners, which are rigid trays used for orthodontic treatment. The use of rigid trays for home whitening has not been validated. The aim of this clinical trial is to analyse the effectiveness, comfort and sensitivity perceived by patients when whitening with 0.5 mm rigid aligners.
214485231|NCT06881238|OTHER|History of IBD course and outcome in HBV patients|"Full history taking including:~* Personal history (name, age, sex, occupation, residence, and marital state).~* Complaint.~* Age at diagnosis of IBD.~* Medication history.~* History of hospital admissions and disease flares.~* Disease extent, location, and behavior. (Montreal classification, Truelove-Witts severity index).~* Surgical history (intestinal resection in CD patients and total proctocolectomy in UC patients).~* Follow up duration and mortality.~* Data of endoscopic examination~* Data of laboratory investigations (complete blood picture, HBV serology, liver and kidney function tests, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP))."
214485232|NCT06883838|BEHAVIORAL|Survivorship care delivery intervention|"Guided by the Practical, Robust Implementation and Sustainability Model (PRISM), the intervention includes three evidence-based components:~1. Training: This will include provider-to-provider tele-mentoring using Enhancing Community Health Outcomes (ECHO).~2. Tracking: This includes systematically assessing cancer history and monitoring survivors' care to plan and organize subsequent care.~3. Coordinating care for cancer survivors. Each clinic leader will designate a staff member (or members) as the care coordinator champion after exploring current clinic staff, skills, and capacity of various staff roles."
214485233|NCT06884150|OTHER|Exercise|Participating in schroth exercises for 45 minutes, 2 days a week after receiving the relevant diagnosis
214485234|NCT06724523|BEHAVIORAL|Business-as-usual instruction|Deaf children are receiving business-as-usual instruction in sign language in deaf education programs.
214485235|NCT07038564|OTHER|Immune-Nutritional Scoring and Postoperative Sleep Assessment|Routine preoperative laboratory data (hemoglobin, albumin, lymphocyte, platelet) will be used to calculate immune-nutritional scores (HALP, PNI). Postoperative sleep quality will be assessed with the Richards-Campbell Sleep Questionnaire (RCSQ).
214485236|NCT06703255|DRUG|HX301+/Temozolomide|"Part I: It is planned to firstly explore a dose of 160 mg and enroll approximately 3-6 subjects to receive HX301 monotherapy until disease progression, intolerable toxicity, or other reasons for stopping treatment for up to 24 cycles of 28 days each. Safety evaluation was performed using the traditional 3 + 3 rule, and the DLT observation period was 28 days (C1D1 \~ C1D28). If 160 mg was not tolerated, it was reduced to 120 mg for exploration. Part II: Combination therapy phase: HX301 will be administered in combination with temozolomide approximately 4-6 weeks after completion of chemoradiotherapy. The TMZ dose will follow the first cycle: 150 mg/m 2 qd D1-D5, starting with the second cycle, and if the criteria for TMZ dose increase are met, TMZ will be administered as 200 mg/m 2 qd D1-D5 every 2 8 days for up to 12 cycles. Monotherapy maintain period: Following the end of temozolomide treatment, HX301 monotherapy will be continued for a maximum of 12 cycles of 28 days each."
214485237|NCT06885788|PROCEDURE|To remove the uterine uterine ligament|Both groups underwent laparoscopic inguinal hernia repair. The preservation group retained the uterine round ligament, while the resection group had it removed.
214672321|NCT06219252|OTHER|Preoperative intraocular lens calculation|the intraocular lens in this group will be calculated preoperatively with Barrett Universal II formula
214672322|NCT04617288|OTHER|Ultrasound Therapy, SNAGs|
215063607|NCT03440736|BEHAVIORAL|Life-style intervention|A structured program to guide weight loss and increased physical activity
215063608|NCT03723720|DEVICE|Colonoscopy|Endoscopic examination of large bowel
215063609|NCT00438126|BEHAVIORAL|A lifestyle educational program|
215063610|NCT01791049|DRUG|TD-1607|
215063611|NCT01791049|DRUG|Placebo|
215063612|NCT03307603|RADIATION|yttrium-90 radioembolization|Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
215063613|NCT03307603|DRUG|Phase Ib - nivolumab|240 mg intravenously
215063614|NCT03307603|DRUG|Phase II - nivolumab|nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
215063615|NCT05959447|DRUG|Camlipixant|Camlipixant will be administered
215063616|NCT05959447|DRUG|Dabigatran etexilate|Dabigatran etexilate will be administered
215063617|NCT05959447|DRUG|Gemfibrozil|Gemfibrozil will be administered.
215063618|NCT05049772|BEHAVIORAL|Telerehabilitation-based motor imagery training|10 weeks of motor imagery training and stabilization exercises.
215063619|NCT05049772|BEHAVIORAL|Stabilization exercises group|10 weeks of stabilization exercises.
215063620|NCT05278039|BEHAVIORAL|Respiratory-Swallow Phase Training|Participants will complete 6 respiratory-swallow phase training sessions that will last approximately one hour.
215063621|NCT05278039|OTHER|Swallow Practice|"Participants will complete 6 swallow practice sessions that will last approximately one hour."
215063622|NCT05642234|PROCEDURE|Epidural Ultrasonography|In this study, we measured the intervertebral distance and skin-epidural distance with the help of ultrasonography in the thoracic and lumbar regions in sitting and rider positions.
215063623|NCT06429072|BEHAVIORAL|Mindfulness training|• I-MASS begins with one introductory telephone call by a mindfulness coach within 1 week of the patient scheduling surgery to introduce the participant to the Pattern Health app, discuss the benefits of combining mindfulness and acupuncture, discuss how to access the Healthwise educational content, and lead a brief (\~10 min) mindfulness exercise, as desired. Thereafter, participants will complete 4 self-directed mindfulness modules through the Pattern Health app (1 prior to surgery, 3 following surgery). Each mindfulness module is anticipated to last one week and includes a short (4-5 min) introductory video, daily sessions comprised of a 6-8 min guided mediation, and interactive suggestions for how to apply mindfulness within a daily routine (\~10-12 min total per daily session).
215063624|NCT06429072|OTHER|Acupuncture|This arm also includes up to 8 total acupuncture treatments (1 prior to surgery and up to 7 treatments in the 12 weeks after surgery). Auricular acupuncture will be the preferred form of acupuncture used. This technique involves inserting tiny needles in specific areas of the outer ear to target points believed to influence pain. If participants are unable to tolerate auricular acupuncture, they will have the option to receive peripheral acupuncture.
215063625|NCT06429072|BEHAVIORAL|Enhanced education|• The program consists of education prior to and after surgery for all participants. All of the educational material is delivered via the Pattern Health App. All educational content is from the Healthwise.net Duke Health Library (https://www.healthwise.net/dukehealth/Content) and is carefully selected with input by surgeons to be delivered during the appropriate phase of recovery. Education is in the form of short reading materials or videos, all designed to help safely and effectively recover from surgery. Educational topics include learning how to lift and sit when experiencing pain, proper precautions following surgery, how to ease back into daily activities following surgery, and ways to self-manage pain.
215063626|NCT06245005|DEVICE|Brain exercise gameplay on a portable electronic device|Feasibility is defined as a 70% completion rate for at least 3 of the six brain exercise games in study participants from which a 'first gameplay score' can be determined. Investigators will also assess level of satisfaction with the brain exercise intervention and barriers to playing in the busy preoperative clinical settings as evaluated by a patient-centered questionnaire (Discharge Survey).
214322282|NCT05840146|OTHER|Kinesiotaping|"Two I-strips were used:~1. The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.~2. The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension."
215063627|NCT05756920|DRUG|ABL301|SAD: Participants will receive a single dose of ABL301 IV infusion, MAD: Participants will receive multiple doses of ABL301 IV infusion
214322283|NCT05840146|OTHER|Sham taping|A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.
214322284|NCT06075524|PROCEDURE|Biospecimen Collection|Undergo blood and optional stool/tissue sample collection
214322285|NCT06075524|OTHER|Electronic Health Record Review|Medical records are reviewed
215063628|NCT05756920|DRUG|Placebo|SAD: single Placebo IV infusion, MAD: multiple Placebo IV infusion
215063629|NCT00107432|DRUG|sorafenib tosylate|Given orally
215063630|NCT00107432|OTHER|laboratory biomarker analysis|Correlative studies
215063631|NCT04053855|BIOLOGICAL|Urinary sample|Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
215063632|NCT06223971|DRUG|[11C]CPPC Injection|"A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: \[5-cyano-N-(4-(4-\[11C\]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide\]"
215063633|NCT06223971|DRUG|[11C]CPPC Injection|"A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: \[5-cyano-N-(4-(4-\[11C\]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide\]"
215063634|NCT03154515|DRUG|Ingavirin|
215063635|NCT03154515|DRUG|Placebo|
215063636|NCT02181491|OTHER|[11C]-P943|
215063637|NCT02348034|DEVICE|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
215063638|NCT02876237|OTHER|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
215063639|NCT02876237|RADIATION|Radiotherapy|standard radiotherapy
215063640|NCT06125925|PROCEDURE|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
215063641|NCT06125925|DRUG|Medical Therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
215063642|NCT00070876|BEHAVIORAL|Mental health communication skills training|
214322286|NCT06548412|DRUG|Gemcitabine|Given by IV
214322287|NCT06548412|DRUG|Cisplatin|Given by IV
214322288|NCT06548412|DRUG|Durvalumab|Given by IV
214485238|NCT06885593|DIAGNOSTIC_TEST|Supine Position|All ultrasonography (USG) procedures will be performed by the same anesthesiologist using a Ultrasound device before the start of spinal anesthesia (SA) and after baseline blood pressure and heart rate have been measured. Patients will be placed in supine and left lateral tilt (LLT) positions. After at least 3 minutes in each position, ultrasound of the inferior vena cava (IVC) and femoral vein (FV) will be performed. The oblique probe will be placed below the xiphoid. Anteroposterior diameters and peak velocities of the IVC will be measured 2-3 cm below the IVC-right atrium For standardization purposes, measurements of the right femoral vein will be used in the study. The FV will be visualized with B-mode ultrasound 2-5 cm below the level of the inguinal ligament where the femoral artery is best palpated, without applying any pressure that may affect the FV diameter.
214485239|NCT06885593|DIAGNOSTIC_TEST|Supine Position|All ultrasonography (USG) procedures will be performed by the same anesthesiologist using a Ultrasound device before the start of spinal anesthesia (SA) and after baseline blood pressure and heart rate have been measured. Patients will be placed in supine position. After at least 3 minutes in each position, ultrasound of the inferior vena cava (IVC) and femoral vein (FV) will be performed. The oblique probe will be placed below the xiphoid. Anteroposterior diameters and peak velocities of the IVC will be measured 2-3 cm below the IVC-right atrium For standardization purposes, measurements of the right femoral vein will be used in the study. The FV will be visualized with B-mode ultrasound 2-5 cm below the level of the inguinal ligament where the femoral artery is best palpated, without applying any pressure that may affect the FV diameter.
214485240|NCT06885593|DIAGNOSTIC_TEST|Left Lateral Tilt Position|All ultrasonography (USG) procedures will be performed by the same anesthesiologist using a Ultrasound device before the start of spinal anesthesia (SA) and after baseline blood pressure and heart rate have been measured. Patients will be placed in left lateral tilt (LLT) position. After at least 3 minutes in each position, ultrasound of the inferior vena cava (IVC) and femoral vein (FV) will be performed. The oblique probe will be placed below the xiphoid. Anteroposterior diameters and peak velocities of the IVC will be measured 2-3 cm below the IVC-right atrium For standardization purposes, measurements of the right femoral vein will be used in the study. The FV will be visualized with B-mode ultrasound 2-5 cm below the level of the inguinal ligament where the femoral artery is best palpated, without applying any pressure that may affect the FV diameter.
214485241|NCT06884371|OTHER|physical therapy|ultrasound and TENS for the back
214485242|NCT06886607|BEHAVIORAL|the Mindfulness and Web-Based Physical Activity Program|"The Mindfulness and Web-Based Physical Activity Program consists of two phases: the Mindfulness Skill Development Program and the Mindful Physical Activity Program. In the first phase of the Program, the Mindfulness Skill Development Program was implemented for two weeks, five days a week, from October 23 to November 3, 2023. The program includes activities for individuals to develop mindfulness skills through videos uploaded on the YouTube channel. In the second phase of the Program, The 12-week Mindful Physical Activity Program, implemented between November 2023 and January 2024, consisted of Mindful Walking and Mindful Physical Activity Day sessions held twice a week (Tuesday and Thursday) and three days a week for 50 minutes. Each session began with a 10-minute warm-up exercise, followed by 40 minutes of endurance and strength training sessions, and ended with 10 minutes of cool-down exercises."
214672323|NCT02817607|PROCEDURE|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
214672324|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 5mg
214672325|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 10mg
214672326|NCT05513976|DRUG|febuxostat tablet|febuxostat tablet 40mg or 60mg or 80mg based on prior medication
214921705|NCT06966843|DRUG|Dantrolene|Dantrolene sodium capsule 25 mg orally once daily for 4 weeks. Dose may be titrated to 50 mg daily after 1 week if tolerated. Used to assess impact on muscle pain and biomarkers of muscle injury in patients with statin-induced myopathy.
214921706|NCT06966843|DRUG|Placebo|Oral placebo capsule matching dantrolene in size and appearance, administered once daily for 4 weeks.
214921707|NCT06967532|DIAGNOSTIC_TEST|Blood test|Blood sampling
214921708|NCT06967649|DEVICE|TITANIUM IMPLANT|The surgical technique, type of implant installed, and selected prosthetic components will follow the manufacturer's recommendations (SIN Implant System, São Paulo, Brazil), always considering treatment options for optimal patient rehabilitation.
214921709|NCT03820635|DIAGNOSTIC_TEST|Osteopontin (OPN)|the serum level of Osteopontin (OPN) will be measured in the subject's blood sample
214921710|NCT06270264|DEVICE|the Nociception level index monitoring|Nociception level index (NOL) monitoring (Medasense) is a non- invasive device differentiated from its alternatives by the use of five parameters: heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives.
214322289|NCT06548412|DRUG|CTX-009|Given by IV
214322290|NCT06003127|DEVICE|Transcranial Magnetic Stimulation-Electroencephalography|Transcranial magnetic stimulation of the cerebral cortex and measurement of TMS-evoked potentials in the EEG.
214322291|NCT04664998|DRUG|Daily oral PrEP|All participants will be offered daily oral PrEP at each visit
214322292|NCT04664998|DRUG|Daily oral PrEP|All participants will be offered daily oral PrEP at each visit.
214322293|NCT06491706|OTHER|the was no intervention|there was no intervention in this observational study
214322294|NCT04404777|PROCEDURE|Treatment for local recurrence with surgery or other treatments|All types of treatment for local recurrence will be evaluated
214322295|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 40 Gy
215063643|NCT02251834|BEHAVIORAL|Community Health Worker (CHW)|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
215063644|NCT02251834|OTHER|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
214672327|NCT05513976|DRUG|SHR4640 placebo tablet|SHR4640 placebo tablet 5 or 10mg
215063645|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
214322296|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 43 Gy
214322297|NCT04627064|DRUG|Abemaciclib|Tablet taken orally
214322298|NCT04627064|DRUG|MK-6482|Tablet taken orally
214322299|NCT00676299|DRUG|JNJ-26483327|
215063646|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
215063647|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
214672328|NCT06812156|OTHER|Cardiovascular Health Education|This intervention aims to promote healthy behavioral changes at both individual and community levels by supporting education with virtual reality technology.
214921711|NCT03627026|OTHER|Blood samples will be collected at different time points:|"* Baseline~* Week 6 Day 1~* Week 12 Day 1~If feasible, an optional tumor biopsy specimen will be collected during baseline visit for a maximum of 30 patients included in IUCT-O center."
214921712|NCT01895374|PROCEDURE|laser treatments|
214921713|NCT01895374|OTHER|amniotic membrane application|
214921714|NCT01895374|DEVICE|hydrocolloid application|
214921715|NCT05778968|PROCEDURE|low etco2|Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg
215063648|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
215063649|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
215063650|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
215063651|NCT00368381|DRUG|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
215063652|NCT02110537|PROCEDURE|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
215063653|NCT02110537|PROCEDURE|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
215063654|NCT02110537|DRUG|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
215063655|NCT01525862|DEVICE|Balloon sinus dilation|
214322300|NCT05896293|DRUG|kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
214322301|NCT05896293|DRUG|leuprolide acetate|Single SC bolus
214322302|NCT04339400|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
214322303|NCT03263208|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
214322304|NCT03263208|DRUG|Fludarabine|Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
214322305|NCT03263208|BIOLOGICAL|CD19 CAR-T|CD19 CAR-T cells will be administered after completion of the chemotherapy.
214322306|NCT02857452|OTHER|SLA Questionnaire|
214322307|NCT02857452|OTHER|Lupus Qol Questionnaire|
214322308|NCT02107599|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
214322309|NCT00779103|DRUG|Histrelin Subcutaneous Implant|histrelin subcutaneous 50 mg implant
214322310|NCT03509038|OTHER|Exploratory pathophysiology Study|Urodynamic tests before and after bariatric surgery in obese incontinent women before and after bariatric surgery
214322311|NCT03382483|DEVICE|Low intensity pulsed ultrasound|bone growth stimulator
214322312|NCT02559869|DRUG|[18F] GE-180|PET Tracer Ligand
214322313|NCT03189628|BIOLOGICAL|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
214322314|NCT03189628|DRUG|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
214921716|NCT05778968|PROCEDURE|normal etco2|Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg
214921717|NCT05778968|PROCEDURE|high etco2|Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg
214921718|NCT01559025|DRUG|Vildagliptin|Vildagliptin ( Galvus 50mg twice day) during one year
214322315|NCT02861950|DRUG|Caudal block with ropivacaine|Patients in this arm will receive a caudal block with ropivacaine
214322316|NCT02861950|DRUG|penile nerve block with bupivacaine|Patients in this arm will receive a penile block with bupivacaine
214322317|NCT06801535|DEVICE|Splint|Patients will use the splint at home 3 times daily for 10 minutes per session for 3 months total.
214921719|NCT05899517|DRUG|oral lollipop with oxytocin (24IU)|For oral oxytocin administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after oxytocin administration.
214485243|NCT04000763|DEVICE|superficial peroneal nerve stimulation|A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.
214322318|NCT06385587|DEVICE|Oleena|Oleena™ is a software medical device for patients and their healthcare team which digitalizes some aspects of their supportive care, allows remote monitoring by healthcare professionals (HCP) and supports the management of targeted symptoms in adult cancer patients while they are being actively treated for their cancer.
214322319|NCT04033159|DRUG|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
214485244|NCT06882044|DEVICE|mHealth|The mobile application contains medication and personalised reminders, the screen where blood pressure and pulse are entered, the lifestyle change recommendations information, and the section that allows users to communicate with the researcher. Also, there is a control panel that allows the application to be controlled remotely, patient information to be viewed, data to be monitored, lifestyle information to be uploaded and viewed in the mHealth, personalised reminders to be sent to patients, and communication with patients.
214485245|NCT06882681|DIETARY_SUPPLEMENT|LipoMicel Milk Thistle|A maximum single dose of approx. 140 mg silymarin (in soft gel capsule)
214322320|NCT02020005|OTHER|Non-flavored 2mg nicotine gum|
214322321|NCT02020005|OTHER|Non-flavored 4mg nicotine gum|
214485246|NCT06882681|DIETARY_SUPPLEMENT|Unformulated Milk Thistle Extract|A maximum single dose of approx. 130 mg silymarin (in hard gel capsules)
214322322|NCT02020005|OTHER|Mint-flavored 2mg nicotine gum|
214322323|NCT02020005|OTHER|Mint-flavored 4mg nicotine gum|
214322324|NCT02020005|OTHER|Non-flavored nicotine inhaler|
214322325|NCT02020005|OTHER|Mint-flavored nicotine ihaler|
214485247|NCT06882252|OTHER|Low glycemic index diet|Replacement of typical meal/snack with lean pork containing meal/snack
214485248|NCT06887374|DRUG|Probiotic Bacillus Clausii|Patients were given 2 billion spores of probiotic (Bacillus clausii) every12 hours, contained in a small bottle.
214485249|NCT06717230|OTHER|EverX Posterior|Restoration
214485250|NCT06885255|OTHER|Alternate day fasting|Participants are instructed to alternate between consuming 100% of their usual energy intake on one day and only 25% on the following day.
214485251|NCT06885255|OTHER|Time restricted eating|Subjects are instructed to limit their energy intake to 8 hours a day and to fast for the remaining 16 hours.
214485252|NCT06885255|OTHER|High-intensity interval training|Patients participate in high-intensity interval training.
214921720|NCT05899517|DRUG|oral lollipop with placebo|For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after placebo administration.
214921721|NCT01405339|DEVICE|Mucosal Atomization Device (MAD)|The use of pulmicort via MAD once a day for a total of 30 days.
214921722|NCT01405339|DEVICE|Budesonide via Nasal Syringe|The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
214921723|NCT06475755|DRUG|Immunochemotherapy combined with antiangiogenic|neoadjuvant： Tislelizumab 200mg iv，d1，q3w， Anlotinib 10mg，po，qd1-14，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
214921724|NCT06475755|DRUG|Immunochemotherapy|neoadjuvant：Tislelizumab 200mg iv，d1，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
214921725|NCT01533324|DRUG|S-1 combined with Leucovorin|S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
214921726|NCT04405635|OTHER|No intervention or exposure|No intervention or exposure
214921727|NCT01983696|OTHER|5% oxygen concentration|the oocytes and embryos are cultured in the incubator with concentrations of 6% CO2,5%O2, and 89% N2
214921728|NCT00351702|DRUG|Isoniazid with Ethambutol|Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
214921729|NCT04478721|DRUG|Temocillin|The intervention of experimental arm will be Intravenous administration of temocillin.
214921730|NCT04478721|DRUG|Meropenem|The intervention of comparator arm will be intravenous administration of meropenem.
214921731|NCT02293135|DEVICE|Verum Stendo session on V1 and Phantom Stendo session on V2|On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)
214921732|NCT02293135|DEVICE|Phantom Stendo session on V1 and Verum Stendo session on V2|On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
215063656|NCT04193709|DEVICE|Spinal Cord Epidural Stimulation|For arm 2, optimal stimulation parameters (cathode/anode configuration, stimulation frequency and voltage; placement of electrode from L1 to S1) will be identified for blood pressure and bladder pressure to achieve a bladder capacity in the target normative range of 400-450 mLs. Spinal cord epidural stimulation will then be used in a controlled lab setting for the regulation of blood pressure and heart rate to maintain normative values (target systolic pressure of 110-120 mmHg) and bladder pressure below 10 cmH2O during bladder filling up to the targeted capacity (fill volume of 400 mLs).
214921733|NCT02069808|DRUG|Follistim|Follicle stimulating hormone promotes recruitment of follicles for ovulation.
215063657|NCT00079261|DRUG|CHOP regimen|
215063658|NCT00079261|DRUG|cyclophosphamide|
215063659|NCT00079261|DRUG|doxorubicin hydrochloride|
215063660|NCT00079261|DRUG|gemcitabine hydrochloride|
215063661|NCT00079261|DRUG|prednisone|
215063662|NCT00079261|DRUG|vincristine sulfate|
215063663|NCT00705497|PROCEDURE|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
215063664|NCT00249808|DRUG|Efalizumab - anti-CD11a recombinant human monoclonal antibody|Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
215063665|NCT02789345|DRUG|Ramucirumab|Administered IV
215063666|NCT02789345|DRUG|Necitumumab|Administered IV
215063667|NCT02789345|DRUG|Osimertinib|Administered orally
214672329|NCT05435430|OTHER|PERSPECTIVE, MULTICENTRIC and observational|we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.
214921734|NCT02069808|DRUG|Ganirelix|GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
214921735|NCT02069808|DRUG|Menotropins|Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
215063668|NCT05119374|DEVICE|SenseGuard Investigational Device|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~* RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~* ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~* SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
214921736|NCT02069808|DRUG|Leuprolide|Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
214921737|NCT02069808|PROCEDURE|Transvaginal ultrasound guided needle aspiration of oocytes|
215063669|NCT03139981|DRUG|ASN002|Daily dose of ASN002 for 28 days
215063670|NCT03139981|DRUG|Placebo Oral Tablet|Placebo for ASN002 for 28 days
215063671|NCT02245269|DRUG|Tipranavir|
215063672|NCT02245269|DRUG|Ritonavir|
215063673|NCT02245269|DRUG|Atorvastatin|
215063674|NCT02245269|DRUG|Maalox|Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
215063675|NCT04753346|OTHER|Physical Activity Level|International Physical Activity Questionnaire
215063676|NCT04753346|OTHER|Anxiety and Depression Assessment|Hospital Anxiety and Depression Scale
215063677|NCT04753346|DIAGNOSTIC_TEST|Exercise Capacity|6 Minute Walk Test
215063678|NCT04753346|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry
215063679|NCT04753346|DIAGNOSTIC_TEST|Cardiopulmonary Fitness Level|Cardiopulmonary Exercise Test
214485253|NCT06885242|DEVICE|Microdrop instillation of cyclopentolate 1%|1 drop administered through the Nanodropper device adapted to the commercially available multi-dose dropper bottle
214485254|NCT06885242|DEVICE|Standard drop instillation of cyclopentolate 1%|1 drop administered directly through the commercially available multi-dose dropper bottle
215063680|NCT04753346|OTHER|Cognitive Assessment|Montreal Cognitive Assessment
215063681|NCT06238895|DRUG|Tardyferon|Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
215063682|NCT06410352|DRUG|Semaglutide, Empagliflozin|subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day
214921738|NCT05000008|OTHER|Exercises|Moderate aerobic and resistance exercise programe
214921739|NCT00983203|OTHER|FID 114657 ORB Preserved Ocular Emulsion|1 drop OU
214921740|NCT00983203|OTHER|Soothe XP Lubricant Eye Drops|1 drop OU
214921741|NCT01931475|DRUG|Duloxetine|Administered orally
214921742|NCT01931475|DRUG|Placebo|Administered orally
214921743|NCT03461952|DRUG|Nivolumab|240mg
214921744|NCT03461952|DRUG|Ipilimumab|1mg/kg
214921745|NCT03055299|OTHER|COMEX intervention|Comprehensive Exercise
215063683|NCT06410352|PROCEDURE|Minigastric bypass|Endovideososcopic techniques with the intraperitoneal using of synthetic/biological materials. MGB is performed to reduce the absorption surface of the gastrointestinal tract by shunting the greater part of the stomach, the duodenum and the initial section of the small intestine, which reduces the absorption of food and leads to a decrease in the production of gastrointestinal hormones.
215063684|NCT06410352|DIETARY_SUPPLEMENT|Analimentary detoxication|very-low-calorie-restriction diet ('Analimentary-detoxication') including \<100 kcal/day with fat-free vegetables (tomato/cucumber) and salt intake (5-6 g/day), optimum physical activity, and sexual self-restraint.
215063685|NCT06410352|BEHAVIORAL|Ramadan fast's weight loss|"The participants adhered to fasting on RF season. They strictly adhered to two principles of nutrition during RF: 1) no blood, no smell of fat which means don't eat meat and don't eat fatty foods; 2) the 'Sehri time' (a meal eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (apple, dates, and persimmon). Indeed, the patients followed a diet in which they ate one meal a day - participants have a meal during 'Iftar time' (a meal eaten after sunset)."
215063686|NCT00819000|DRUG|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
215063687|NCT02508584|BIOLOGICAL|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
214322326|NCT00661700|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
214322327|NCT00661700|DRUG|Placebo|10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
214485255|NCT06725121|BIOLOGICAL|Atezolizumab & Bevacizumab|Atezolizumab \& Bevacizumab will be initiated as part of the study, as per standard treatment protocol. Administration of Atezolizumab and Bevacizumab will be performed according to SOC in approx. 21-days intervals. Clinical follow up during treatment will be done as per SOC in medical and surgical oncology clinics at UHN.
214485256|NCT06725121|DRUG|Yttrium-90 (Y-90)|Storage, administration and treatment of Y90-RE will be done according to established treatment protocols and standard of care at UHN.
214485257|NCT06725121|RADIATION|Stereotactic body radiotherapy (SBRT)|Dose and administration frequency of SBRT will be done as per current standards for treating HCC at UHN.
214485258|NCT06704620|DRUG|Diphenhydramine|Diphenhydramine intramuscular injection 20mg qd d0-2 Q3W
214485259|NCT06704620|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d1
214485260|NCT06704620|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
214485261|NCT06704620|DRUG|Albumin paclitaxel|Albumin paclitaxel intravenous infusion 260mg/m2 d1
214485262|NCT06704620|DRUG|Carboplatin|Carboplatin intravenous infusion AUC5 d1
214322328|NCT06437210|DIETARY_SUPPLEMENT|Viusid Oral Solution|Patients in the experimental intervention group will be administered Viusid Oral Solution (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
214485263|NCT06704620|DRUG|Cisplatin|Cisplatin intravenous infusion 75mg/m2 d1
214485264|NCT06879119|PROCEDURE|Localized scalp thread embedding|Volunteers who met the inclusion criteria were enrolled in the trial. All participants underwent treatment intervention in the vertex alopecic area via vertex alopecic area scalp thread embedding. A single thread embedding session was performed upon enrollment, with monthly follow-ups conducted over a total period of 6 months. Operative procedure: After fully exposing and disinfecting the treatment area, threads were inserted into the scalp at an approximately 15-degree oblique angle, with needle tips reaching the subgaleal space at a depth of 2-4 mm. Threads were spaced 1 cm apart. Upon completion, the treated area was disinfected and applied with erythromycin ointment.
214485265|NCT06880952|OTHER|Chlorhexidine Digluconate Mouthwash without Alcohol|In the rinsing group, the patients received a bottle of 0,2% chlorhexidine
214485266|NCT06872567|DEVICE|genicular artery embolization|genicular artery embolization
214485267|NCT06872567|DRUG|Corticosteroid Injection|Corticosteroid Injection
214485268|NCT06888934|DEVICE|Intervention with Lync device.|Treatment of arthritis and/or correction of bone alignement default in the toes (mallet toes, claw toes, hammer toes) with Lync device.
214672330|NCT02696746|OTHER|Observation|No intervention
214672331|NCT00458250|PROCEDURE|Haploidentical hematopoietic stem cell transplantation|
214921746|NCT04453280|DIAGNOSTIC_TEST|Quantitative analysis of anti-SARS-CoV-2-antibodies|Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
214921747|NCT04453280|DIAGNOSTIC_TEST|SARS-CoV-2 diagnostic rapid test|The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
215063688|NCT04925219|BEHAVIORAL|Remotely supervised exercise programme|Electronic walking log Fortnightly video/telephone calls with physiotherapist
214672332|NCT00458250|DRUG|Busulfan|
215063689|NCT04925219|BEHAVIORAL|Self-directed exercise|Electronic walking log and instructions to exercise 4 times per week.
215063690|NCT01804049|DRUG|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
214672333|NCT00458250|DRUG|Cyclophosphamide|
214672334|NCT00458250|DRUG|CAMPATH-1H|
214672335|NCT00458250|DRUG|Cyclosporin A|
214672336|NCT00458250|DRUG|Methotrexate|
214672337|NCT01500174|DEVICE|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
214672338|NCT01500174|DEVICE|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
215063691|NCT01804049|DRUG|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
214921748|NCT06684574|OTHER|Nordic walking program|The intervention is a defined program of Nordic walking and strengthening exercises for 10 weeks in a regimen of two days per week (two 75-minute sessions per week). In these sessions, they did Nordic walking three 5-minute breaks, where strength and proprioception exercises of the lower extremities were performed.
214921749|NCT06684574|OTHER|Educational advise|Patients in the control arm participated in a single session to advise them on the need for self-exercise.
214322329|NCT06437210|DIETARY_SUPPLEMENT|Placebo|Patients in the experimental intervention group will be administered Placebo (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
214485269|NCT07038252|DIETARY_SUPPLEMENT|Oral SPM-enriched marine oil (LIPINOVA)|LIPINOVA is an oral dietary supplement provided by Solutex, consisting of marine oil enriched in specialized pro-resolving mediator (SPM) precursors. Each daily dose (3 g/day) includes 1500 mg of omega-3 free fatty acids and a minimum of 520 mcg of SPM precursors (17-HDHA, 18-HEPE, 14-HDHA). The supplement is administered orally in 6 softgel capsules per day (3 after breakfast, 3 after dinner) over 12 weeks. It is used to investigate its effect on vascular function and inflammation in patients with obesity-related hypertension. The product is over-the-counter and commonly available in the EU, including France.
214322330|NCT02845752|DRUG|Stiolto Respimat|Oral inhalation spray
215063692|NCT01055938|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
214322331|NCT02845752|DRUG|Placebo Respimat|Oral inhalation spray
214322332|NCT00006489|BEHAVIORAL|Cognitive-Behavioral Therapy|Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
214322333|NCT00006489|DRUG|Naltrexone|Daily dosing 100 mg for 24 weeks
214322334|NCT00006489|DRUG|Placebo|Pill Placebo daily dosing 24 weeks
214322335|NCT03172936|DRUG|MIW815|MIW 815 (ADU-S100) is a STING agonist
214322336|NCT03172936|BIOLOGICAL|PDR001|PDR001 is an anti-PD-1 antibody
214485270|NCT07038252|DIETARY_SUPPLEMENT|Placebo|Placebo capsules provided by Solutex, identical in appearance to LIPINOVA, contain refined olive oil with no active omega-3 fatty acids or SPM precursors. The placebo is administered orally in 6 softgel capsules per day (3 after breakfast, 3 after dinner) for 12 weeks, following a randomized, double-blind, crossover design. It serves as a control to evaluate the effects of SPM-enriched marine oil on vascular and inflammatory parameters in patients with obesity-related hypertension.
214485271|NCT06725732|DRUG|Tranexamic Acid (TXA)|To see if nebulised TXA is better to control blood loss in functional Endoscopic sinus surgery
214485272|NCT06725732|DRUG|Tranexamic Acid|To see if intravenous TXA is better to control blood loss in functional Endoscopic sinus surgery
214485273|NCT06725719|DIAGNOSTIC_TEST|18F-DPA714/FDPA|Each subject receive a single intravenous injection of 18F-DPA714/FDPA, and undergo PET/CT or MRI imaging within the specificed time.
214485274|NCT06725953|BEHAVIORAL|Social Cognitive Theory-based, Technology-delivered Physical Activity Program|Participants will engage in a 12-week program of aerobic and muscle-strengthening physical activity. This program will be delivered remotely via two smartphone applications--one for providing health education, goal setting, and journaling features and the other for delivery of the physical activity program in a highly-personalized and HIPAA-compliant manner. Participants will receive a Fitbit to track their activity and resistance bands to use during their resistance training physical activity. All program components will be based in the Social Cognitive Theory and will target improving participants' physiological and psychological health outcomes.
214485275|NCT06726395|DRUG|Penicillin G_1200mg|benzylpenicillin preferred dosing 1gx4
214485276|NCT06726395|DRUG|cloxacillin|cloxacillin 2gx4
214485277|NCT06726057|BEHAVIORAL|Imlementation strategies in conjunction with multicomponent hypertension intervention|In this study, the researchers will develop and test strategies for the implementation and scale-up of a proven multicomponent hypertension intervention (MCHI) programme in Pakistan. Implementation strategies will be devised through an engagement process and will involve the use of implementation frameworks including the Consolidated Framework for Implementation Research (CFIR) to identify barriers and facilitators to the implementation of MCHI\&amp;amp; Expert Recommendations for Implementation Change (ERIC) to identify a set of implementation strategies addressing each barrier. Input for the development of strategies will be sought from the community, public health sector managers, general practitioners and community health workers. The implementation strategies will be used to randomise study clusters while MCHI will be implemented in both intervention and control arms.
214672339|NCT00824694|OTHER|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
214672340|NCT00824694|OTHER|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
214672341|NCT00824694|OTHER|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
214672342|NCT05476692|OTHER|AOFAS score and VAS|Clinical outcome by the Visual analogue scale (VAS) and the American Orthopaedic Foot and Ankle (AOFAS) score.
215063693|NCT02966288|DRUG|Toradol|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
215063694|NCT02966288|DRUG|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
214322337|NCT02888899|BEHAVIORAL|Biofeedback|
214322338|NCT02888899|DRUG|Loperamide|
214322339|NCT02888899|DRUG|Stool bulking agent (sterculia or ispaghula husk)|
214322340|NCT02888899|OTHER|PTNS|
214322341|NCT01617057|DRUG|tiludronic acid|400 mg / day for 3 months
214322342|NCT01617057|DRUG|Placebo|400 mg / day for 3 month
214322343|NCT06123546|OTHER|Patient oriented discharge summary|"The intervention consists of three components: the patient-oriented discharge summary (PODS), the teach-back technique and the involvement of caregivers.~The PODS will be completed with participants over the course of the hospitalisation as teaching content related to the six sections of information is delivered. Participants will take the PODS home at discharge to use it as a reference for relevant and individualized discharge information in the post-discharge period.~Healthcare providers will receive a training refresher on the teach-back technique and will be reminded to use it when they deliver discharge teaching during participants' hospital stay.~Involvement of caregivers will include early identification by the healthcare provider responsible for patient admission of a caregiver who will provide care at home, at least one teaching session during hospitalization and the review of the PODS the day of discharge."
214322344|NCT00722917|DRUG|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
214322345|NCT00722917|DRUG|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
214485278|NCT06726057|BEHAVIORAL|Multicomponent hypertension intervention|"The multicomponent hypertension intervention has four components as follows:~1. Training of community health workers (CHWs) in conducting health education sessions regarding hypertension, its risk factors, prevention, and health-seeking~2. Blood pressure (BP) monitoring and referral of hypertensive individuals by CHWs to general practitioners in primary care facilities~3. Training of general practitioners in primary care settings in BP monitoring and management of hypertension~4. Hypertension care coordination in primary care facilities for the care of referred patients."
214485279|NCT06705595|DRUG|Tracheo-Spray|Participants will receive 2 ml of 10% lidocaine delivered via a Tracheo-Spray device to the tracheal mucosa before anesthesia induction.
214485280|NCT06705595|DRUG|Lidocaine Spray on DLT|Before intubation, participants will receive 10% lidocaine spray applied to the distal surface and cuffs of the double-lumen tube (DLT).
214485281|NCT06705595|DRUG|Saline (Placebo)|Before intubation, participants will receive 1 ml of 0.9% saline applied to the distal surface and cuffs of the double-lumen tube (DLT).
214485282|NCT06725459|DEVICE|Prophylactic ciNPWT|The prophylactic closed incision negative pressure wound therapy (ciNPWT) will be applied to one breast for up to 7 days postoperatively to promote wound healing and prevent complications.
214485283|NCT06725459|OTHER|Standard Adhesive Dressing|The standard adhesive strip dressing will be applied to one breast immediately after surgery. It provides a protective covering for the wound during the initial healing phase and is the standard of care for incision management.
214485284|NCT03872466|DEVICE|GRASP HEP|The GRASP system comprises a sensor package and therapy game software that works with a commercial glove orthosis to enable virtual world-based practice of activities of daily living (ADLs) involving the hand.
214485285|NCT03872466|BEHAVIORAL|Usual Care Treatment (UCT)|Participants in the control group will continue to receive any previously prescribed therapy services. These patients will not receive any treatment services through the study as UCT group participants.
214485286|NCT06707259|BIOLOGICAL|anti-CD19 IL10 CAR-NK|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19-IL10 CAR
214485287|NCT06733350|PROCEDURE|Biopsy of Prostate|Undergo prostate biopsy
214485288|NCT06733350|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214485289|NCT06733350|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214485290|NCT06733350|OTHER|Patient Observation|Undergo standard AS
214485291|NCT06733350|OTHER|Questionnaire Administration|Ancillary studies
214485292|NCT06733350|DRUG|Therapeutic Testosterone|Given via injection, gel, lotion, or transdermal patch
214921750|NCT04003831|DEVICE|Device: P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
214921751|NCT01910480|DRUG|NBI-98854 50 mg capsule once daily|
214485293|NCT06732687|OTHER|Calisthenics|"Calisthenics~Arm Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks."
214672343|NCT03661541|DRUG|Squaric Acid Dibutyl Ester|2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.
214921752|NCT01910480|DRUG|Ketoconazole 400 mg (200 mg twice daily)|
214921753|NCT03935776|BEHAVIORAL|Risk Factors Modification Programme|12- week supervised risk factor modification programme derived from the Euroaction study standards
214921754|NCT03935776|BEHAVIORAL|Standard Healthcare|Patients are advised to adjust lifestyle without the support of the structured supervised programme
214921755|NCT05126394|PROCEDURE|ultrasound guided serratus anterior plane block|the patients receive local anesthetic (20 ml of Bupivacaine 0.25 %), injected superficial to the serratus muscle under ultrasound guidance.
214921756|NCT02547389|BEHAVIORAL|Community support group|
214921757|NCT02547389|OTHER|Printed material Supported|
214921758|NCT00842920|DRUG|Simvastatin 60 mg|60 mg once daily
214921759|NCT00842920|DRUG|Placebo|one tablet once daily
214921760|NCT00842920|DRUG|Simvastatin 20 mg|20 mg once daily
214921761|NCT00115492|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
214921762|NCT00115492|DRUG|Salmeterol|
214921763|NCT01998802|DRUG|Active Comparator EBI-005|
214921764|NCT01998802|DRUG|Placebo Comparator|
214921765|NCT04810000|DEVICE|tourniquet|Tourniquet release before/after wound closure
214921766|NCT05788367|PROCEDURE|The pericapsular nerve group|patients received Ultrasound guided pericapsular nerve group block using 20 ml of bupivacaine 0.5%
214921767|NCT05788367|PROCEDURE|Interscalene brachial plexus block|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia
214921768|NCT01522001|BEHAVIORAL|Shared Care model|"* First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~* Dietary counseling with dietician~* Exercise (1 hour, 2 timer pr week for 12 weeks)~* Smoking cessation if smoker with educated smoking cessation instructor~* Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~* Examination by the patient´s general practitioner 8-12 weeks after discharge."
214921769|NCT02177916|OTHER|Education|
214921770|NCT04240639|DEVICE|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
214921771|NCT05592665|OTHER|Survey Questionnaire|Study participants will complete several questionnaires/assessments via PRO-Core standardized email communication or via telephone with a study team member.
214921772|NCT06223399|OTHER|Imaging-based programming|Preferred contact point(s) and settings for DBS programming will be determined based on the visualization of the electrodes in the patient-specific anatomy and the volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function). This will be determined with help of the software program Brainlab with the GUIDE XT module.
215063695|NCT03758131|BEHAVIORAL|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
215063696|NCT03758131|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
215063697|NCT03758131|OTHER|Waitlist Control|Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
214322346|NCT00722917|DRUG|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
214322347|NCT00722917|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
215063698|NCT06106009|DRUG|PF-07976016|Oral solution, oral suspension or solid oral formulation(s)
215063699|NCT06106009|DRUG|Placebo|Oral solution, oral suspension or solid oral formulation(s)
214485294|NCT06732687|OTHER|Plyometrics|Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
214485295|NCT06732687|OTHER|Combined( Calisthenics+ Plyometrics)|Description: Both exercises would be performed. First Calisthenics will be performed and then plyometrics will be performed.
214485296|NCT06723717|DRUG|Daily infusion of dornase alfa|Daily infusion of dornase alfa at a dose of 125 microg/kg as an intravenous bolus until day 14 after SAH
214485297|NCT06723262|OTHER|Tonotopic cochlear implant fitting FS4T|Comparison of FS4T and FS4noT
214921773|NCT06223399|OTHER|Threshold assessment-based programming|The preferred contact point(s) and settings for DBS programming will be determined according to current clinical practice. During the threshold assessment, the amount of electrical current needed to generate symptomatic improvement and the amount of electrical current needed to generate adverse-effects are determined for every contact point of both DBS leads by increasing current with 0.5 mA steps from 0 to approximately 5.0 mA. With each step, severity of Parkinson symptoms and presence of possible adverse-effects are assessed. For each side (i.e., left and right), the contact point with the most favorable trade-off between clinical improvement and adverse effects will be used for stimulation.
214921774|NCT03750149|DEVICE|EyeTracker|Patients with various ophthalmologic diseases (ERM, glaucoma, AMD, diabetic retinopathy) will undergo reading analysis using the EyeTracker
214921775|NCT01417091|DRUG|BPS804|
215063700|NCT06106009|DRUG|Midazolam|Midazolam oral solution
215063701|NCT00140907|DRUG|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
215063702|NCT00140907|DRUG|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
215063703|NCT04234009|OTHER|Healthy Lifestyle|"The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle."
214322348|NCT00722917|DRUG|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
214322349|NCT05217550|BEHAVIORAL|Veggie Brek|Offering vegetables to children at breakfast alongside their main breakfast food for three consecutive weeks (five days a week) between baseline and follow-up weeks where vegetables are also offered to children at breakfast alongside their main breakfast food for five days a week.
214322350|NCT05583903|OTHER|Virtual Reality Software|The ReCognition virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
214485298|NCT06733051|DRUG|Golidocitinib|150 mg, administered once daily from Day 1 to Day 21 (D1-D21)
214485299|NCT06733051|DRUG|Benmelstobart|1200 mg, administered on Day 1 (D1) of every cycle
214672344|NCT00231478|DRUG|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
214672345|NCT00231478|DRUG|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
214672346|NCT01815398|BEHAVIORAL|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
214485300|NCT06733077|DEVICE|gait with cueing wearable device and neuro-ocular performance|"Participants will be invited to participate in the following sequential phases. Participants can participate in Phases as selected. Control participants will not be invited to Phase 4.~Phase 1. Lab testing \[2 hours\] Validation study of digital technology measures MachineMD and gaitQ to criterion metric of UPDRS.~Phase 2. home/community testing \[2 weeks daily\] Determine feasibility of daily measuring in the home of gaitQ to determine usability, acceptability, and day to day variability of measurement metrics and to determine concurrent validation of home metric to lab metrics to determine, reliability, concurrent validity of change, minimal detectable change and criterion validation to lab-based measures.~Phase 3. Lab retesting \[2 hours\] see Phase 1~Phase 4. Home/community intervention \[2 weeks\] Determine the potential for effect of the gaitQ vibration intervention from a 2-week exposure in the home."
214485301|NCT01778686|DRUG|Citalopram and Pindolol|"Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"
214485302|NCT01778686|OTHER|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
215063704|NCT05757440|OTHER|Icon resin application|Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
215063705|NCT01147250|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
215063706|NCT01147250|DRUG|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
215063707|NCT03588806|DRUG|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
215063708|NCT06497283|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
215063709|NCT01335256|DRUG|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
215063710|NCT03334981|PROCEDURE|Concentrations in Meconium of Buprenorphine and Methadone|buprenorphine or methadone concentration measurement
215063711|NCT05141708|DRUG|Talazoparib|Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
215063712|NCT02319616|DRUG|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
215063713|NCT02319616|DRUG|Placebo|Blinded, daily application to one arm for a period of fourteen (14) days
214485303|NCT01778686|DIETARY_SUPPLEMENT|Acute tryptophan depletion|
214485304|NCT06721520|BIOLOGICAL|Botulinum Toxin A (Botox )|Patients randomized for intrapyloric Botox injection will undergo the following standard procedure: 100 units of Botox are dissolved in 10 mL normal saline. After identifying the pylorus, the 10 mL of Botox solution is injected intramuscularly at the anterior pyloric ring in 2 separate areas and in 1 area on each side of the pyloric ring.
214672347|NCT01815398|BEHAVIORAL|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
214672348|NCT02330991|DRUG|Temozolomide|
214921776|NCT01901601|PROCEDURE|LALAK|"1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
215063714|NCT03985943|DRUG|Placebo|Placebo
215063715|NCT03985943|DRUG|Nemolizumab|Nemolizumab
215063716|NCT05368389|DEVICE|Healthdot attachment|"The wearable health monitoring device Healthdot 5 will be attached to the patient's skin at left lower rib and data like heart rate, respiratory rate, posture and activity will be collected for 10 days.~A questionnaire will be sent to patients to fill out at the 10th day after the device attachment."
215063717|NCT03277898|BEHAVIORAL|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
215063718|NCT03277898|BEHAVIORAL|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
215063719|NCT01060449|OTHER|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output"
215063720|NCT02029755|PROCEDURE|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
215063721|NCT02029755|PROCEDURE|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
215063722|NCT02029755|PROCEDURE|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
215063723|NCT00022763|DRUG|Enfuvirtide|
215063724|NCT04840485|DRUG|SHR-1314|SHR-1314 high dose
215063725|NCT04840485|DRUG|SHR-1314|SHR-1314 low-dose
215063726|NCT04840485|DRUG|Placebo|Placebo
215063727|NCT06110936|DEVICE|Transcutaneous Spinal Direct Current Stimulation|Transcutaneous spinal direct current stimulation (ts-DCS), a neuromodulation technique, is one of the non-invasive brain stimulation techniques. ts-DCS occurs when a continuous and low-intensity electric current passes through electrodes with moist sponges placed on the spinal cord.
215063728|NCT01092780|DRUG|MK-7288|one or two 10 mg capsules, orally, single dose
215063729|NCT01092780|DRUG|Placebo to MK-7288|one or two capsules, orally, single dose
215063730|NCT01092780|DRUG|Modafinil|two 100 mg tablets, orally, single dose
214485305|NCT06721520|PROCEDURE|Pyloromyotomy|Patients randomized for pyloromyotomy will undergo standard pyloromyotomy as follows: after identifying the pylorus, a 2-cm longitudinal incision is made with Metzenbaum or Mayo scissors on the anterior pylorus, centered on the pyloric ring. The incision extends through the serosa and muscular layers to expose the submucosa and mucosa, which is left intact. The cut muscle is spread apart until the submucosa bulges up to the level of the cut serosa. Care is taken to avoid perforation, and the surgeon confirms no mucosal perforation at the end of the procedure. If a perforation is encountered, it will be repaired primarily.
215063731|NCT01092780|DRUG|Placebo to modafinil|two 100 mg tablets, orally, single dose
215063732|NCT02022761|DRUG|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
214322351|NCT06098950|OTHER|Artificial Intelligence model predictions without explanation|During 6 clinical vignettes, participants will see AI model predictions without a corresponding AI explanation. The AI model will provide a score for each diagnosis (heart failure, pneumonia, COPD) on a scale of 0-100 estimating how likely the patient's presentation was due to each of these diagnoses. In 3 of the clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions, with the model specifically biased against one of the three diagnoses.
214322352|NCT06098950|OTHER|Artificial intelligence model predictions with explanation|During 6 clinical vignettes, participants will see AI model predictions with explanation. The AI model will provide a score for each diagnosis on a scale of 0-100. In 3 clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions with the model specifically biased against one of the three diagnoses. If the AI model provides a score above 50 an AI model explanation will be shown as gradient-weighted class activation mapping (Grad-CAM) heatmaps overlaid on the chest X-ray that highlighted which regions of the image most affecting the AI model's prediction.
214485306|NCT06720675|PROCEDURE|Hypothermic Oxygented Perfusion|HOPE start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid (cold Belzer MPS solution) during back-table preparation. Hepatic perfusion was performed through the vein leads to a pressure of 3-5 mmHg. Organ were treated with continuous HOPE until transplant and the perfusion was continuously monitored and data downloaded in a USB memory.
214485307|NCT06720675|PROCEDURE|Static Cold Storage|Liver grafts are stored in sterile organ bags with cold Belzer or Celsior solution and kept in ice at 4°C.
214485308|NCT06720909|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The standard 8-week MBSR program will be led by certified MBSR instructors from the UCSD Center for Mindfulness. The program content will consist of a variety of mindfulness and meditative techniques, such as sitting meditation, body scans, and mindful yoga. Participants will engage in weekly sessions via Zoom, participation in group discussions, and honing their other mindfulness skills. Throughout the program, participants will be instructed to commit to a daily mindfulness meditation practice lasting approximately 45 minutes, at least 6 days a week.
214485309|NCT06720909|OTHER|Open-Label Placebo (OLP)|The placebo pills will be size #1 capsules filled with (1) microcrystalline cellulose, a common inert excipient for pharmaceuticals, and (2) 25 mg riboflavin tracer. Participants will be informed that the placebo pills are inactive substances, like sugar pills, and contain no active medication. Then, they will watch a brief introduction video which will cover four main discussion points: (1) the placebo effect can be powerful and can have beneficial effects for diverse symptoms, (2) the body can respond to taking placebo pills automatically despite the knowledge that it is placebo (e.g., Pavlov's dogs), (3) a positive attitude or expectation can be beneficial but is not necessary, and (4) taking the pills faithfully throughout the intervention period is critical.
214485310|NCT06720909|OTHER|MBSR+OLP|This condition involves a combination of interventions, where participants will receive both MBSR and OLP treatments.
214485311|NCT06720389|RADIATION|peri implant bone loss was assessed by CBCT|using CBCT, vertical bone loss (VBL) was measured at baseline (T0), at1 year(T1), at 3 years(T3)
214485312|NCT06720389|OTHER|posterior ridge resorption was assessed by CBCT|posterior ridge resorption was assessed by CBCT at baseline (T0), at 1 year( T1), at 3 years (T3). By superimposition of pre and post CBCT.
214485313|NCT06720610|DRUG|Vonoprazan 20 mg|Vonoprazan PO, 20mg, once a day, 14 days.
214485314|NCT06720610|DRUG|Esomeprazole|Esomeprazole PO, 40mg, once a day, 14 days
214485315|NCT06729801|DEVICE|IRP-Monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS)|The IRP-Monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS) is a novel device designed to enable real-time monitoring of intrarenal pressure (IRP) during retrograde intrarenal surgery (RIRS). It incorporates a pressure-sensing port connected to a gas conduit embedded in the sheath, which allows the surgeon to adjust irrigation flow and suction pressure based on real-time IRP readings, thereby optimizing stone retrieval efficiency while ensuring safety by maintaining a safe IRP range. The device improves surgical outcomes, particularly in complex cases involving larger renal stones, by reducing operative time and minimizing the risk of complications.
214322353|NCT06098950|OTHER|AI model biased against heart failure|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against heart failure, always predicting that heart failure is present with high likelihood in survey vignette patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses (pneumonia, COPD).
214485316|NCT06729801|DEVICE|Conventional FANS|The Conventional Flexible and Navigable Suction Ureteral Access Sheath (FANS) is a standard device used in retrograde intrarenal surgery (RIRS) for stone retrieval. Unlike the IRP-monitoring version, this device does not provide real-time monitoring of intrarenal pressure (IRP). Irrigation flow and suction pressure are pre-set and adjusted based on clinical protocols. It facilitates the removal of renal stones through a flexible and navigable design, but without the added capability of monitoring and adjusting IRP during the procedure.
214672349|NCT04095416|DEVICE|ACE compression wrap|Bilateral lower extremity ACE compression wraps
214672350|NCT00152373|DRUG|Levetiracetam|
215063733|NCT03220932|PROCEDURE|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
215063734|NCT03220932|DRUG|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
214322354|NCT06098950|OTHER|AI model biased against pneumonia|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against pneumonia, always predicting that pneumonia is present with high likelihood in survey vignette patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses (heart failure, COPD).
214322355|NCT06098950|OTHER|AI model biased against COPD|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against COPD, always predicting that COPD is present with high likelihood in survey vignette patients where a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses (heart failure, pneumonia).
214322356|NCT02567513|BEHAVIORAL|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
214322357|NCT02567513|BEHAVIORAL|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
214485317|NCT06728267|OTHER|Core stabilization training|Exercise training will be given for 6 weeks, 3 days a week, 2 sets of 10 repetitions for the first two weeks, 2 sets of 15 repetitions for the second two weeks, and 3 sets of 12 repetitions for the third two weeks.
214485318|NCT06728267|OTHER|Training|Routine training sessions conducted by coaches specific to the sport of underwater rugby.
214485319|NCT06729645|OTHER|radiotherapy|External beam radiotherapy and endorectal brachytherapy
214485320|NCT04207931|DRUG|Topical steroid class I-II|applied once daily - 18 month duration of the study
214485321|NCT04207931|DRUG|Triamcinolone Acetonide|Intralesional Steroid Injection, 7.5mg/cc. max dose of 3 cc. Scalp injections will be administered every 6-8 weeks, for a total of 8 injections.
214485322|NCT04207931|DRUG|Doxycyline|oral antibiotic twice daily for 6 months
214485323|NCT04207931|DRUG|Minoxidil|5% solution or foam started after month 8
214485324|NCT06727734|DRUG|Levonorgestrel|Levonorgestrel 1.5 mg
214485325|NCT06727734|DRUG|Piroxicam|Piroxicam 40 mg
214485326|NCT06727734|DRUG|Ulipristal Acetate|Ulipristal 30 mg
214921777|NCT01901601|PROCEDURE|IEK|"1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
214921778|NCT01901601|DRUG|Retrobulbar Block or General Anesthesia|
214921779|NCT01901601|DEVICE|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.
214921780|NCT01901601|DRUG|Topical Anesthesia|
214485327|NCT06727734|DRUG|Placebo - LNG|Placebo of levonorgestrel
214921781|NCT01901601|DEVICE|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
214921782|NCT03106363|DRUG|delta 9 tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
214921783|NCT03106363|DRUG|placebo delta 9 tetrahydrocannabinol|A single placebo cannabis cigarette (\<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
214921784|NCT03106363|DRUG|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
214921785|NCT03106363|DRUG|Placebo alcohol|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
214921786|NCT04292912|DRUG|GSK2798745|GSK2798745 will be administered.
214921787|NCT02464774|PROCEDURE|Breast-Conserving Therapy|Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
214921788|NCT02464774|PROCEDURE|Mastectomy|Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
214921789|NCT02464774|DRUG|Adjuvant Chemotherapy|Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
214921790|NCT02464774|RADIATION|Radiation Therapy|N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
214921791|NCT03211260|DEVICE|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
214921792|NCT04786340|DRUG|Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution|WST-057
214921793|NCT04786340|DRUG|Placebo: WST-057 4mL topical solution|Placebo
214921794|NCT06175026|BEHAVIORAL|Health messages|Participants view messages about the health impacts of certain dietary substitutions.
214921795|NCT06175026|BEHAVIORAL|Environmental messages|Participants view messages about the environmental impacts of certain dietary substitutions.
214921796|NCT06175026|BEHAVIORAL|Health and environmental messages|Participants view messages about the health and environmental impacts of certain dietary substitutions.
214921797|NCT06175026|BEHAVIORAL|Neutral messages|Participants view neutral messages unrelated to the health and environmental impacts of certain dietary substitutions.
214921798|NCT05325190|DRUG|Granisetron Transdermal Patch System|Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
214672351|NCT06656728|OTHER|Blood-based liquid biopsy|Venous blood sample will be taken from the patient as part of the routine blood tests taken as part of the work at the Medical Center
214322358|NCT00240370|DRUG|Muraglitazar|
214322359|NCT04145570|DRUG|Erlotinib HCl 150 mg|"Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.~dosing in each period."
214322360|NCT04145570|DRUG|Tarceva®|Tarceva® 150 mg
214322361|NCT01546116|DRUG|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
214322362|NCT06216392|BIOLOGICAL|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
214322363|NCT06216392|BIOLOGICAL|placebo|0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
214322364|NCT00654069|DRUG|Placebo|2 tablets every 6 hours for 48 hours
214322365|NCT00654069|DRUG|Acurox 5/30 mg|2 tablets every 6 hours for 48 hours
214322366|NCT00654069|DRUG|Acurox 7.5/30|2 tablets every 6 hours for 48 hours
214322367|NCT03469921|DRUG|administered therapeutic regimens|administered therapeutic regimens
214322368|NCT00737516|BIOLOGICAL|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
214921799|NCT04081610|DRUG|lagricel ofteno multidose|"* Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic"
214921800|NCT04081610|DRUG|lagricel ofteno single dose|"* Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic"
214921801|NCT01786135|DRUG|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
214921802|NCT06968416|OTHER|Standard cleanser，standard moisturizer，standard sunscreen，Investigational serum|"Products Application and Usage Instruction~1. Mode of application: T-3W \~ T0~   Frequency:~   AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer Caution: No any other skincare or facial make up products are used except provide products~2. Mode of application: T0 \~ T12W~Frequency:~AM: Standard cleanser + Investigational serum (face and eye) \[FLA #774715 21\] + standard moisturizer + standard sunscreen PM: Standard cleanser + Investigational serum (face and eye) \[FLA #774715 21\] + standard moisturizer~Caution: No any other skincare or facial make up products are used except provide products~Usage Instruction： Use serum \[FLA #774715 21\] 8-10 drops (0.3ml) on cleansed face and eye skin 2 times a day (AM \& PM)."
214921803|NCT06967558|BIOLOGICAL|Exendin 9-39|Exendin 9-39 is a competitive antagonist of the GLP-1 receptor
214921804|NCT06967558|BIOLOGICAL|Saline|Saline
214921805|NCT00860197|DIETARY_SUPPLEMENT|Fully torrefied coffee|Fully torrefied coffee
214921806|NCT00860197|DIETARY_SUPPLEMENT|Partially torrefied coffee|Partially torrefied coffee
214921807|NCT00557011|DRUG|NRP104|30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
214921808|NCT00557011|DRUG|Adderall XR|10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg
214921809|NCT00557011|DRUG|Placebo|Placebo capsule taken once daily in the morning
214921810|NCT01765348|BEHAVIORAL|Syntax treatment via sentence-combining method|"Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.~Treatments are conduced by school-speech therapist once two weeks for 8 sessions."
214921811|NCT01765348|BEHAVIORAL|Syntax treatment managed by narrative-based treatment|Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
214921812|NCT02225860|BEHAVIORAL|Diet and water adjustment|The dietary intervention consisted of three elements: low sodium (1500 mg/day), low protein (daily protein dietary allowance of 0.8 gram/kg body weight), and low urea (avoidance of preservatives, food additives, bulking agents, and chewing gum). Protein was factored by measured body weight to mirror the estimated average requirement (EAR) of healthy adults which is set on a grams per kilogram basis
214921813|NCT05323448|DEVICE|Control Group|During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent).
215063735|NCT04654611|DRUG|preservative free tafluprost 0.0015%|preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
215063736|NCT02604602|OTHER|blood exam|laboratory test
214322369|NCT03060746|OTHER|Newly Diagnosed|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
214322370|NCT03491150|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
214322371|NCT01110629|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
214322372|NCT01110629|DRUG|Placebo|daily dose: 3 tablets TID for 8 weeks.
214322373|NCT04019158|DEVICE|Virtual reality headset|All participants will walk in the three conditions described earlier in this form
214322374|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET|At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
214322375|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC|At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
214322376|NCT02271308|BEHAVIORAL|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
214485328|NCT06727734|DRUG|Placebo - Piroxicam|Placebo of piroxicam
214485329|NCT06727734|DRUG|Placebo - UPA|Placebo of ulipristal acetate
214485330|NCT05355441|DRUG|Paracetamol|Routine clinical practice treatments recommended by the medical team involved
214485331|NCT05355441|DRUG|Ibuprofen 600 mg|Routine clinical practice treatments recommended by the medical team involved
214485332|NCT05355441|DRUG|Tramadol|Routine clinical practice treatments recommended by the medical team involved
214485333|NCT05355441|DRUG|Morphine|Routine clinical practice treatments recommended by the medical team involved
214672352|NCT01958567|OTHER|Optical Coherence Tomography|
215063737|NCT01825148|OTHER|radiolabeled Exendin|
214485334|NCT06724796|OTHER|Y4BI|"The yoga classes will follow the Iyengar method, one of the most widely practiced traditional yoga styles, aimed at promoting body alignment and precision in executing poses (asanas) through the use of props such as blankets, straps, cushions, chairs, and blocks, making the poses accessible to all individuals.~The classes will be conducted once a week, in groups, with each session lasting 1 hour. They will be led by a qualified instructor with over 10 years of teaching experience in yoga. The classes will be adapted for beginners who do not practice yoga regularly."
214485335|NCT06724796|OTHER|ACTIVE|The total body classes will take place once a week, with each session lasting one hour. They will be led by a kinesiology specialist in preventive and adapted physical activities.
214485336|NCT06723535|DRUG|BMS-986278|Specified dose on specified days
214485337|NCT06722560|OTHER|GLP-1 hormone|s.c. continuous infusion for 72 hours using an insulin pump
214485338|NCT06722560|OTHER|Placebo|s.c. continuous infusion for 72 hours using an insulin pump
214485339|NCT06723418|OTHER|Malnutriton Screening Tool (PYMS)|In a pilot implementation study, PYMS will be used on children with IBD attending the outpatient and inpatient hospital clinics
214485340|NCT01374984|BIOLOGICAL|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
214485341|NCT06730763|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (TDCS) is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain.
214485342|NCT06730763|OTHER|Exercise|selected traditional physical therapy program for improve balance and decrease risk of falling
214485343|NCT06731699|DRUG|FD-001|"The initial dose was 0.4mg, and subsequent doses of 0.8mg, 1.6mg, 2.4mg, 3.2mg, and 4.0mg were proposed to be administered in a progressive manner using the rapid titration method combined with the traditional 3+3 experimental design. The trial process consists of three periods: screening period, treatment period, and follow-up period. The screening period lasted from D-28 to D-1 for treatment (DLT observation period): during this time frame, there was a single administration period (C0D1-C0D4) where oral administration occurred on day one followed by safety observations on days two to four; as well as multiple administration period one (C1D1-C1D28) where oral administration took place on days one to two and seven to nine with rest periods in between. The drug is available in capsule form."
214485344|NCT06731192|BIOLOGICAL|hUC-MSC|"This group of patients received a total of 2 peripheral intravenous Human umbilical cord mesenchymal stem cells (hUC-MSC) infusions during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days, and the single infusion dose was approximately 2×1000,000 cells/Kg.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."
214485345|NCT06731192|DRUG|Placebo control drug|"This group of patients received a total of 2 intravenous infusions of normal saline (the same volume, specifications and batches used in the experimental group) as a placebo control during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."
214485346|NCT06888310|PROCEDURE|extra blood sampling|search for biomarkers for the prevention of liver disease
214485347|NCT06888349|PROCEDURE|spinal anesthesia|spinal anesthesia using 15 mg 0.5% hyperbaric bupivacaine in the sitting position at L3-4 or L4-5 intervertebral space.
214485348|NCT06888349|PROCEDURE|Adductor Canal Block|local anesthetic spread around the saphenous nerve in the adductor canal ultrasound guided using 22 Gag spinal needle with injection of 15ml 0.25% bupivacaine with addition of 2mg dexamethasone and 2.5mcg /ml epinephrine as an adjuvant to prolong its action.
214485349|NCT06888349|PROCEDURE|interspace between Popliteal artery and capsule of knee (IPACK) block|ultrasound guided Local anesthetic infiltration over the posterior aspect of the femur underneath the popliteal artery targeting the genicular nerves which are the articular branches of tibial and common peroneal nerves, posterior branches of the obturator nerve, and medial genicular nerve using 22Gag spinal needle injecting 20ml 0.25%bupivacaine with addition of 2mg dexamethasone and 2.5mcg /ml epinephrine as an adjuvant to prolong its action.
214485350|NCT06886100|DEVICE|Diode laser|Diode Laser is a semiconductor device similar to a light-emitting diode in which a diode pumped directly with electrical current can create lasing conditions at the diode's junction. It is used in periodontal surgery as melanin depigmentation
214921814|NCT05323448|DEVICE|ARISTA|"During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent). Before surgical wound closure, the corresponding amount of ARISTA-AH will be applied to completely cover the bleeding site :~* 5g for 5 to 8 instrumented vertebra~* 10g fo 9 or more instrumented vertebra"
214921815|NCT00117104|DRUG|Aranesp®|
214921816|NCT02254967|DRUG|Fidaxomicin|oral tablets administered in an extended pulsed regimen
214921817|NCT02254967|DRUG|Vancomycin|oral capsule
214921818|NCT00730860|PROCEDURE|radiofrequency ablation associated with TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
214921819|NCT00730860|PROCEDURE|radiofrequency ablation only|treatment of hepatocellular carcinoma by radiofrequency ablation only
214921820|NCT05323240|OTHER|PM exposure|To determine whether 3-day consecutive exposures to levels of fine particulate matter (PM2.5) that are close to the current 24-hr national standard will cause changes in inflammatory and cardiopulmonary endpoints.
214921821|NCT05323240|OTHER|Filtered air exposure|To determine whether 3-day consecutive exposures to filtered air will cause changes in inflammatory and cardiopulmonary endpoints.
214921822|NCT01141946|PROCEDURE|thoracic ultrasound|All patients will receive pre-operative pleural-based ultrasound during their initial consultation.
214921823|NCT01141946|PROCEDURE|pleural aspiration|Before proceeding to pleural aspiration, a radiography of the chest will be performed in order to ascertain the presence of a pleural effusion.
214921824|NCT02857946|DRUG|Prevaglip (linagliptin)|1 tablet contains 5 mg linagliptin
214921825|NCT02857946|DRUG|Trajenta (linagliptin)|1 tablet contains 5 mg linagliptin
214921826|NCT04954001|DRUG|FCN-159|FCN-159 is administered orally in once daily schedule for 28 days a cycle.
214921827|NCT02022384|OTHER|Blood sample and life quality questionnaires|Blood will be drawn at distinct time points during and after radio(chemo)therapy
215063738|NCT05111431|DRUG|Dexmedetomidine Hydrochloride Nasal Spray|"In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray."
215063739|NCT05111431|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation|"In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
215063740|NCT06281652|OTHER|Go classes|Classes of board games (Go), performed in groups of 6-10 subjects, once a week
215063741|NCT06281652|OTHER|Chess classes|Classes of board games (Chess), performed in groups of 6-10 subjects, once a week
215063742|NCT06075134|PROCEDURE|Botox injection|Botox injection
215063743|NCT06075134|DEVICE|EMG|Quantitative Electromyography
214485351|NCT06886100|DEVICE|Scalpel No 15|The No.15 blade has a small curved cutting edge and is the most popular blade shape ideal for making short and precise incisions.
214485352|NCT06888232|DRUG|Thalidomide|Thalidomide was administered at a dose of 1.5 mg/kg/day, and all patients continued standard iron chelation therapy and other supportive treatments as per institutional protocols.
214485353|NCT01654133|DEVICE|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft|Repair of thoracoabdominal aortic aneurysms
214485354|NCT01654133|DEVICE|Endovascular repair of ascending/arch aortic aneurysm using branched stent graft|Repair of ascending/arch aortic aneurysms
214485355|NCT06889285|PROCEDURE|Continuos epidural infusion|"This group of parturient will be inserted epidural catheter at L3/L4 or L4/L5 depending on anaesthetist-in-charge justification, epidural catheter will be kept 4-5 cm in epidural space and anchored with adhesive tape. Similarly, a test dose of LA Lignocaine 2% 2ml will be given after epidural insertion. Infusion tubing will be primed in advance. Epidural catheter will be connected to epidural cocktail (Bupivacaine 0.1% + Fentanyl 2mcg/ml in 50ml mixture) with the protocol as below: (directly extracted from Malaysia Pain management in Obstetrics and Gynaecology Procedure Guideline 2023)~* Loading dose 10 ml~* Continuous infusion: 10ml/hour"
214485356|NCT06889285|PROCEDURE|Programmed intermittent epidural bolus|"This group patient will be inserted epidural catheter at L3/L4 or L4/L5 depending on anaesthetist-in-charge justification, epidural catheter will be kept 4-5 cm in epidural space and anchored with adhesive tape. A test dose of LA Lignocaine 2% 2ml will be given after epidural insertion. CADD-Solis infusion tubing will be primed in advance. Epidural catheter will be connected to epidural cocktail (Ropivacaine 0.05% + Fentanyl 2mcg/ml in 100ml mixture) with the protocol as below:~* Loading dose: 10ml~* Intermittent bolus: 10ml, bolus interval 1 hour, next bolus 1 hour~* PCEA dose: 10ml, lockout interval 10 minutes"
215063744|NCT06075134|DRUG|Zinc Supplement|To increase efficacy of Botox
215063745|NCT05151692|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
215063746|NCT04424459|DRUG|opioid withdrawal|The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
214322377|NCT03012854|PROCEDURE|short-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
215063747|NCT05822804|DEVICE|Vascular Closure Device (Tonbridge)|Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).
215063748|NCT05822804|DEVICE|EXOSEAL Vascular Closure Device (Codis Corporation)|Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).
214485357|NCT06884644|DIAGNOSTIC_TEST|Death by Airsquat|Increasing number of squats have to be completed every minute (EMOM principle).
214485358|NCT06886594|OTHER|breast cancer education program training|"The first researcher conducted the breast cancer education program for the experimental group, and the researcher completed her doctorate in Obstetrics, Gynecology and Diseases Nursing. The content of the education given to the experimental group was prepared in accordance with the Breast Cancer Prevention, Screening, Diagnosis, Treatment and Follow-up Clinical Guide 2020 (Version 1.0) of the Ministry of Health of the Republic of Turkey. Each woman in the experimental group was given face-to-face individual education in accordance with the education material prepared by the first researcher, and their questions were answered at the end of the education. After the theoretical education was completed, each woman in the experimental group was given BSE practical education using the Wearable Breast Examination Simulator by the first researcher using the demonstration method in accordance with the steps in the Breast Self-Examination brochure by the Cancer Early Diagnosis, Screening"
214485359|NCT06705387|BIOLOGICAL|Dupilumab|Subcutaneous injection of 300mg per week for 16 weeks.
214485360|NCT06705387|DRUG|Fluticasone|Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.
214485361|NCT06707194|BIOLOGICAL|Etanercept|Prefilled syringe, 25mg of hypodermic injection, twice a week
215063749|NCT06479083|OTHER|New Intervention form including|The central element of the new form of care is the implementation of a tele medical evaluation and coordination function, which controls individualized treatment processes within the network. The individualized evaluation and coordination of treatment paths is carried out within the already existing Parkinson's network RheinMain+ by a non-physician medical specialist (APN) specially trained for the indication Parkinson's disease.
215063750|NCT06479083|OTHER|Standard treatment|The standard treatment which all compulsory insured patients get.
215063751|NCT06403098|DEVICE|External Nasal Dilator Strip|Participants will wear an extra strength Breathe Right nasal strip overnight.
215063752|NCT04670523|PROCEDURE|Early postoperative day 0 (POD 0) chest tube removal.|Chest tube removal is a standard bedside intervention after lung resections. Its time point is normally defined according a traditional standard airleak threshold. Traditionally, in our department this threshold will be respected not earlier than 1 day after the operation. The patients of the study group are getting their chest tube removed according to our current airleak protocol (Flow \<20 mL/ min on digital suction device) but already in the operating room after wound closure (POD 0). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
215063753|NCT04670523|PROCEDURE|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).
215063754|NCT04135807|COMBINATION_PRODUCT|Microdevice|"Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus) released by the microdevice reservoirs. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
215063755|NCT06546202|OTHER|No Drug|This is an non-interventional, observational study. No drug was administered during this study.
215063756|NCT06348615|DEVICE|Anti-cellulite cream-gel Medical Device (DEFBODY)|one bottle of 400 ml, twice a day
215063757|NCT05908981|OTHER|sandalwood aromatherapy (Santalum album)|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
215063758|NCT05656222|DRUG|VIA combination treatment|a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
215063759|NCT03402594|DEVICE|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
215063760|NCT03402594|DEVICE|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
215063761|NCT01864148|DRUG|BIIB033|
215063762|NCT01864148|OTHER|Placebo|
215063763|NCT01864148|DRUG|Avonex|
215063764|NCT02889497|BIOLOGICAL|the first batch vaccine|
215063765|NCT02889497|BIOLOGICAL|the second batch vaccine|
214485362|NCT06707194|DRUG|Benzathine Penicillin|Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, 1.2 million units of intramuscular injection, once every two weeks
214485363|NCT06707194|OTHER|Placebo|Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, intramuscular injection, once every two weeks
214672353|NCT01134510|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
214921828|NCT06371495|DRUG|rosuvastatin|"Stude include three groupsof people GroupA: recieve rosuvastatin 40mg Group B :recive rosuvastatin 20mg Group C: recive placebo 2- Follow up will be done using NIHSS at the onset and modified Rankin scale at the onset and after 1 month and 3 months of the onset.~3- Carotid duplex will be done at the onset and after 1 month and 3 months of the onset."
215063766|NCT02889497|BIOLOGICAL|the third batch vaccine|
214322378|NCT03012854|PROCEDURE|long-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
214485364|NCT01499368|DRUG|Lafutidine|Lafutidine 20mg/day
214485365|NCT01499368|DRUG|Famotidine|Famotidine 40mg/day
214485366|NCT01499368|DRUG|Omeprazole|Omeprazole 20mg/day
214485367|NCT06732674|DIAGNOSTIC_TEST|A home monitoring strategy with event driven management|Bi-weekly home monitoring with forced vital capacity (FVC), patient reported outcome measures (PROMs), at-home measures of blood oxygen levels (SpO2) during 1-minute-sit-to-stand test (1MSTS) and temperature with algorithm based risk evaluation of deterioration and infection and consecutive event driven management
214485368|NCT06733389|OTHER|peripheral waveform collection|The peripheral venous pressure is collected by connecting a pressure transducer that is currently in use to the central venous line. In addition, pulse pressure variation and stroke volume variation that can be obtained from the arterial catheter. In addition, the pleth variability index is collected through the oxygen saturation monitoring. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithms' (B-2202-738-401).
214672354|NCT01134510|DRUG|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
214672355|NCT06596447|DEVICE|Deep Brain Stimulation|While most patients with obsessive compulsive disorder (OCD) eventually respond to treatment with medication and/or behavioral therapy, a small minority do not improve following all conventional treatments. Obsessive-compulsive disorder (OCD) can sometimes be difficult to treat with medication and psychotherapy. For these patients, in this study, we employ deep brain stimulation (DBS), an advanced surgical treatment that uses electrical impulses.
214921829|NCT04850352|DIETARY_SUPPLEMENT|Heukcha Extracts|Experimental group: Heukcha Extracts
214921830|NCT04850352|DIETARY_SUPPLEMENT|Placebo|Placebo group
214921831|NCT04679350|DRUG|hzVSF-v13|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
214322379|NCT03012854|PROCEDURE|full-thickness myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
215063767|NCT05657080|DEVICE|Cytosponge-TFF3|Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
215063768|NCT04964505|DRUG|Azacitidine|Given IV or SC
215063769|NCT04964505|DRUG|Uproleselan|Given IV
215063770|NCT04964505|DRUG|Venetoclax|Given PO
215063771|NCT06516146|BEHAVIORAL|Exercise|The intervention will involve online (via University of British Colombia (UBC) Zoom videoconferencing) 1-hour moderate to high intensity exercise classes 3 times a week for 6 months
215063772|NCT06516146|BEHAVIORAL|Meditation|"The intervention will involve 15 minute guided mediation following exercise classes as well as mindfulness classes.~Mindfulness classes will consist of 1.5 hour Mindfulness Based Stress Reduction (MBSR) classes for the first 2 months, followed by 1 month of 1 hour bi-weekly discussions and practice, then MBSR 2.0 for months 4 and 5, and 1 hour bi-weekly discussions and practice for the remaining month of the intervention."
215063773|NCT06516146|BEHAVIORAL|Diet|The intervention will involve biweekly 1-hour nutrition and cooking classes with a dietician.
215063774|NCT00153673|DRUG|celecoxib|Celecoxib 200mg bd
214672356|NCT05387161|OTHER|Nutritional intervention|The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative ungrammatical daily diet plan, which must be followed for the entire period of intervention (6 months).
215063775|NCT00153673|DRUG|Dologesics|Dologesics 2 tablets bd
214921832|NCT04679350|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7
214921833|NCT05429281|OTHER|Pilates-based Core Strengthening Exercises|The PsCS group performed eight Pilates exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the supervision of a physical therapist who had more than 5 years of experience in Pilates.
214921834|NCT05429281|OTHER|Plyometric-based Muscle Loading Exercises|The PlyoML group performed 10 plyometric exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
215063776|NCT03489772|DRUG|ITI-214|Oral
215063777|NCT03489772|DRUG|Placebo|Oral
215063778|NCT01731158|DRUG|Avastin in combination with Roferon-A|
215063779|NCT01731158|DRUG|Afinitor|
215063780|NCT01731158|DRUG|TKI: Sutent, Nexavar or Votrient|TKI
215063781|NCT01437579|PROCEDURE|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
215063782|NCT01437579|PROCEDURE|cystoscopy|cystoscopy under general anesthesia
214322380|NCT03012854|PROCEDURE|circular myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
214322381|NCT04992559|DRUG|Consolidation Toripalimab|Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
214322382|NCT03081416|DRUG|Ketamine|Intranasal ketamine administration
214322383|NCT03081416|DRUG|Normal saline|
214322384|NCT03081416|DRUG|Metoclopramide|Standard therapy
214322385|NCT03081416|DRUG|Ketorolac|standard therapy
214322386|NCT03081416|DRUG|Dexamethasone|Standard therapy
214322387|NCT03081416|DRUG|Benadryl|Standard therapy
214322388|NCT03915288|OTHER|Group continuous training at moderate intensity|70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
214322389|NCT03915288|OTHER|Group high Intensity Interval Training|70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
214485369|NCT06733480|DEVICE|Band Connect|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
214485370|NCT06732115|PROCEDURE|One-step polishing system with nanohybrid resin composite restorations.|one-step polishing system using OneGloss by Shofu
214485371|NCT06732115|PROCEDURE|Multistep system polishing system Super-Snap X-treme (Shofu) with nanohybrid resin composite restorations.|A multi-step polishing system
214485372|NCT06252519|DIETARY_SUPPLEMENT|NAC|1 375 mg capsule containing N-acetyl cysteine
214485373|NCT06252519|DIETARY_SUPPLEMENT|Neuro-NAC|3 capsules containing a total of 375 mg N-Acetyl L-Cysteine Ethyl Ester
214485374|NCT06252519|DIETARY_SUPPLEMENT|Neuro-NAC XS|3 capsules containing a total of 75 mcg Selenium, 150 mcg Molybdenum, 1800 mg Glycine, and 375 mg N-Acetyl L-Cysteine Ethyl Ester
214485375|NCT06059443|BEHAVIORAL|mLab App Plus|Participants will use the mLab Plus app to test for Syphilis and HIV using the DPP HIV/Syphilis Test
214485376|NCT07040059|DRUG|AUR103 Calcium|AUR103 Calcium will be administered with standard dose of Trastuzumab and CAPOX (Capecitabine and oxaliplatin).
214485377|NCT07040059|DRUG|Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)|Standard dose of Trastuzumab and CAPOX (Capecitabine + Oxaliplatin) will be administered in the Control Arm of Phase 2.
214485378|NCT07039201|BIOLOGICAL|CG-102-12C|Chimeric Antigen Receptor Autologous T-cell
214485379|NCT05146297|BEHAVIORAL|Clinical trial match-list|Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.
214485380|NCT05146297|BEHAVIORAL|Match-list intervention|Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.
214672357|NCT03244098|BEHAVIORAL|Transition Assistance Program|TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
214672358|NCT04971590|OTHER|Participant completed survey|Participants will be required to complete the participant survey.
214672359|NCT04971590|OTHER|Medical chart review|Data will be collected from medical charts of participants.
214672360|NCT01098968|BEHAVIORAL|Physical activity program|School intervention program specifically designed to increase health-related physical fitness
214672361|NCT00686751|DRUG|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
215063783|NCT01978054|OTHER|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
215063784|NCT03528122|PROCEDURE|Recurrent opened macular hole|pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
214485386|NCT06721351|DIAGNOSTIC_TEST|Diabetic Retinopathy screening Point of Care Artificial Intelligence|Random assignment of participants to intervention and control groups minimizes confounding variables. This ensures that any observed differences in outcomes are likely due to the intervention itself and not pre-existing differences between the groups. Participants of the DRES-POCAI study will be randomized into two groups: usual care (receive a retinal screening by an optometrist) or intervention group (receive a retinal screening using a special camera and EyeArt® system, an autonomous AI-based DR screening). The randomization will occur after consenting and completing the surveys, prior to conducting the DR screening process (for those randomized to the intervention group).
214485387|NCT06721897|OTHER|Prehabilitation Program|"A prehabilitation programme supervised by a physiotherapist in a ward is proposed, with a frequency of 3 sessions/week on alternate days lasting 30-45 min/session, in addition to a daily physical exercise programme at home.~The programme will consist of a warm-up, strength exercises with progressive loads, proprioception, balance, cardiovascular training aimed at functional work and a cool-down.~The home programme will be complementary to the supervised programme, which will consist of daily sessions of 20-30 min of flexibility and proprioception exercises.~The same prehabilitation protocol will be proposed for those patients awaiting total hip and knee replacement surgery."
214672362|NCT00745316|DRUG|Tonapofylline|Oral Tonapofylline - 2 capsules bid
214672363|NCT00745316|DRUG|Placebo|Oral placebo - 2 capsules bid
215063785|NCT00161837|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
214485388|NCT06721897|OTHER|Non prehabilitation Program|The control group (CG) will carry out a post-operative physiotherapy program in addition to a home exercise program that will be shown by the physiotherapist before hospital discharge.
214485389|NCT06728241|BEHAVIORAL|RecoVRy|A mental health professional (VR therapist) will be together with the patient when VR treatment is provided. The VR therapist will help put on the VR headset, start the program and encourage the patient to apply the learning from RecoVRy to real-world challenges by setting up homework tasks to be carried out between VR sessions. The application will run through Meta Quest 2/3®. RecoVRy is designed as a repeated behavioural procedure in which the main focus is for participants to learn that they are safer than assumed. Participants can proceed at their own pace, allowing for more or less than 8 (+/- 2) sessions of VR treatment. Scenarios and levels may be repeated if necessary
214485390|NCT06728241|BEHAVIORAL|VR Games|Patients randomized to this condition will receive a total of ten sessions of VR games.
214672364|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh no attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with no attachement of posterior mesh
215063786|NCT00161837|BIOLOGICAL|Egg-derived Influenza Vaccine|
215063787|NCT05364970|COMBINATION_PRODUCT|VR_Training_1PP|Immersive VR scenario of physical training with avatar embodiment
215063788|NCT05364970|COMBINATION_PRODUCT|VR_Training_3PP|Immersive VR scenario of physical training without avatar embodiment
215063789|NCT06086158|PROCEDURE|Nordic Reverse Protocol|The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
215063790|NCT00479817|DRUG|AMG 386|10mg/kg
215063791|NCT00479817|DRUG|AMG 386|3 mg/kg
215063792|NCT00479817|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
215063793|NCT00479817|DRUG|AMG 386 Placebo|AMG 386 Placebo
215063794|NCT04181593|DRUG|Omega 3 fatty acid|Omega 3 fatty acid Softgels
215063795|NCT04181593|DRUG|Placebos|Mineral oil Softgels
214322390|NCT03915288|OTHER|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
214322391|NCT01054703|DEVICE|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
214322392|NCT05492058|OTHER|tactile stimulation group|The tactile stimulation group will be asked to touch their own abdomen during the NST procedure.
214322393|NCT05492058|OTHER|listen music|Pregnant women in the music group will listen to a song they want with headphones during the NST procedure.
214322394|NCT05492058|OTHER|virtual reality group|Pregnant women in the virtual reality group will be shown a nature walk video with nature sounds (stream, bird, etc.) during the NST procedure.
214322395|NCT06091553|DRUG|Duloxetine alone|30 mg once daily for 1 week, then 60 mg once daily
214322396|NCT06091553|DRUG|Duloxetine augmented with gabapentin|30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime
214322397|NCT06091553|DRUG|Duloxetine augmented with amitriptyline (as combined therapy)|10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily
214322398|NCT02784301|DEVICE|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
214322399|NCT02784301|BEHAVIORAL|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
214322400|NCT02784301|BEHAVIORAL|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
214322401|NCT01416883|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
214322402|NCT03192839|OTHER|Low dose PUFA|Low dose PUFA
214322403|NCT03192839|OTHER|High dose PUFA|High dose PUFA
214322404|NCT03192839|OTHER|Placebo|Placebo
214322405|NCT03077503|DRUG|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
214322406|NCT03077503|DRUG|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
214322407|NCT03077503|DRUG|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
214322408|NCT03077503|DEVICE|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
214322409|NCT03417661|DRUG|HEXI-PREP By Clinell Wipes|Sterile single sachet wipe containing 3ml solution.
214322410|NCT03417661|DRUG|Chloraprep|Sterile applicator containing 3ml solution.
214322411|NCT03417661|DRUG|Placebos|Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
214322412|NCT01964911|DRUG|Ropivacaïne|"The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN \<3/10 : non opioids, EN 3-5/10 : weak opioids, EN\>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days)."
214322413|NCT01854021|PROCEDURE|intravenous anesthesia|intravenous anesthesia
214322414|NCT01854021|PROCEDURE|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
214322415|NCT01854021|PROCEDURE|inhalational anesthesia|inhalational anesthesia
214322416|NCT05984134|DRUG|NL005 Middle Dose|Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
214322417|NCT05984134|DRUG|NL005 High Dose|Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
214322418|NCT05984134|DRUG|Placebo|30 subjects will be randomly assigned to the placebo for 7 days
214322419|NCT00117143|DRUG|Romiplostim|Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
215063796|NCT05731635|DIAGNOSTIC_TEST|plantar pressure values|Walking enables for extremely accurate and pointwise ground response force measurement because to plantar pressure measurement (pedobarography). It allows for the objective comparison and evaluation of the dynamic pressure put on the ground by the foot in contact with it. It is often used in clinics to assess foot mechanics and associated disorders that affect the foot sole. Additionally, plantar pressure analysis is useful for identifying, treating, and monitoring conditions that impact the lower extremity's axial alignment.
215063797|NCT02575872|BEHAVIORAL|Exercise Intervention|Participate in physical activity behavioral intervention
215063798|NCT05568160|DRUG|Vasopressin|The infusion is started at 5 ml hr-1, increased in increments of 1 ml hr-1 every 5 minutes to reach a maximum target rate of 30 ml hr-1
215063799|NCT05568160|DRUG|Norepinephrine|The infusion is started at 5 ml h-1, increased in increments of 1 ml h-1 every 5 minutes to a maximum target rate of 30 ml h-1
214322420|NCT02803112|PROCEDURE|Emergent craniotomy for traumatic brain injury|Emergent craniotomy for traumatic brain injury (either for removal of an epidural hematoma, subdural hematoma, intraparenchymal hematoma or decompressive craniectomy).
214322421|NCT02117063|BEHAVIORAL|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
214322422|NCT00786695|DRUG|esomeprazole|esomeprazole (40 mg o d) for 14 days
214485391|NCT06727526|OTHER|Acupressure|The literature found that acupressure positively affects child health, but no study was found to determine the effect of acupressure on pain and physiological parameters in children undergoing cardiac catheterization. Therefore, this study was designed to determine the effect of acupressure applied before and after cardiac catheterization on infants' pain levels and physiological parameters.
214672365|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with the attachement of posterior mesh to vagina
215063800|NCT05568160|OTHER|Collection of clinical data|At D1, D2, D7, D30 or D60 and D90
215063801|NCT05568160|OTHER|Quality of Life Questionnaire EQ-5D|At the anesthesia consultation, discharge from intensive care, D7, D30 and D90
215063802|NCT00684710|DRUG|PAZ-417|
215063803|NCT00684710|DRUG|Placebo|
215063804|NCT03587428|DRUG|Zinc-A toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
215063805|NCT03587428|DRUG|Zinc-B toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
214322423|NCT00786695|DRUG|Placebo|Identical looking Placebo, same regimen, for 14 days
214322424|NCT04262336|DRUG|DB-020|Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water
214322425|NCT04262336|DRUG|Placebo|Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
214322426|NCT01103934|DRUG|Vitamin D3|4000 IU once daily
214322427|NCT01103934|DRUG|Placebo|Placebo taken once daily
214322428|NCT01103934|DRUG|Fluticasone Propionate|200 mcg daily, intranasal
214322429|NCT04708327|DRUG|STAT-205|naltrexone hydrochloride capsules 4.5 mg each
214322430|NCT01265446|DRUG|Lidocaine 8mg + CPC 2mg|one single dose
214322431|NCT01265446|DRUG|Lidocaine 1mg + CPC 2mg|one single dose
214322432|NCT02639364|DEVICE|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
214322433|NCT02672735|OTHER|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
214322434|NCT03302702|OTHER|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
214322435|NCT02361567|DRUG|Tramacet|Pain medication commonly used post-operatively
214322436|NCT02361567|DRUG|Percocet|Pain medication commonly used post-operatively
214322437|NCT02735070|DRUG|Resfenol|Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
214322438|NCT02735070|DRUG|Coristina d|Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
214322439|NCT04237961|PROCEDURE|Botox and brow lift|Botox injection
214322440|NCT04237961|PROCEDURE|Injection|Fat injection and botox
214322441|NCT04237961|PROCEDURE|Suture|Suspension suture
214322442|NCT02402452|DRUG|Voxilaprevir|100 mg tablet administered orally
214322443|NCT06802757|DRUG|Posaconazole|Posaconazole 120mg/m2 po bid d1-14 q21d
214322444|NCT06802757|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 d1 q21d
214322445|NCT06802757|DRUG|Carboplatin|Carboplatin AUC=6 d1 q21d
214322446|NCT06802757|DRUG|Anthracycline|Epirubicin 90-100mg/m2 d1 q21d or Doxorubicin 50-60mg/m2 d1 q21d
214322447|NCT06802757|DRUG|Cyclophosphamide|Cyclophosphamide 1000mg/m2 d1 q21d
214322448|NCT06802757|DRUG|Pembrolizumab|Pembrolizumab 200mg d1 q21d
215063806|NCT03587428|OTHER|Mineral water|Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 \[generally 7\] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
215063807|NCT02936869|BEHAVIORAL|Performance-based monetary incentives|
215063808|NCT02764359|DRUG|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
215063809|NCT06351163|PROCEDURE|Laparoscopic reduction|A 1cm longitudinal transumbilical incision was made to insert a 5mm trocar for laparoscope placement. CO2 was injected at 10mmHg and a flow rate of 3L. Two 5-mm working trocars were inserted in the lower right and left abdomen under direct visualization, along with two grasping forceps. The ascending colon was manipulated to locate the intussusception mass. Atraumatic graspers were alternately utilized on the ascending colon to mobilize the intussusceptum, pushing it downward towards the cecum. The first visible part of the terminal ileum was grasped and pulled outward and downward, along with its mesentery, using the right grasper, while the left grasper pulled the intussusceptum's neck in the opposite direction. If resistance was encountered, the terminal ileum could be held with the left hand while the right grasper widened the intussusceptum's neck. After reduction, the intestines were examined for necrosis and possible lead points, followed by routine appendectomy and ileopexy.
214322449|NCT02877784|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
215063810|NCT06351163|PROCEDURE|Transumbilical mini-open reduction|If laparoscopic reduction alone was unsuccessful or if bowel resection was required, the intussusceptum was fixed with grasping forceps and brought to the umbilicus for MOR. A 2cm transumbilical incision was created, and a skin retractor was inserted. The underlying fascia was longitudinally extended upward and downward along the linea alba. Upon division of the peritoneum, the actual opening could be expanded up to 5cm, while maintaining the skin incision at 2cm. If the initial incision site proved insufficient for exploration, lateral division of the rectus muscle around the umbilicus on both sides could be performed without cutting the skin, thereby enlarging the surgical field. Manual reduction of the intussusceptum was subsequently carried out, along with bowel resection and anastomosis as indicated.
215063811|NCT03597204|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for up to five years and follow-up colonoscopy was arranged for those with FIT positive result
215063812|NCT03597204|DIAGNOSTIC_TEST|Colonoscopy|Subjects in the retrospective cohort were allowed to choose one-off colonoscopy for CRC screening
215063813|NCT02483858|DRUG|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
215063814|NCT00056576|DRUG|Zonisamide|
215063815|NCT05631340|OTHER|Discharge education|Researcher's newly prepared discharge education supported by a booklet and mobile app
214322450|NCT02877784|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
214322451|NCT02877784|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
214322452|NCT02889354|BEHAVIORAL|Cognitive-behavioral therapy|
214322453|NCT02462577|DRUG|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
214322454|NCT04277988|DEVICE|Ultrasonography|Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
214322455|NCT02287896|DRUG|ROLEDUMAB|See Arm description
214322456|NCT03448315|DEVICE|tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
214322457|NCT01314924|DIETARY_SUPPLEMENT|Dark chocolate|70% cocoa
214322458|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
214322459|NCT00559962|DRUG|placebo|3 capsules each evening for each 4-week period
214322460|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
214322461|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
214322462|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
214322463|NCT00559962|DRUG|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
214322464|NCT00559962|DRUG|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
214322465|NCT00559962|DRUG|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
214322466|NCT02647034|OTHER|no intervention|no intervention
214322467|NCT05445765|BIOLOGICAL|anti-CD33 CAR T cells|Anti-CD33 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
214322468|NCT01125215|DRUG|0.75% capsaicin nanoparticle cream|0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
214322469|NCT01125215|DRUG|Placebo|Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
214322470|NCT05052190|BEHAVIORAL|Text Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
215063816|NCT04033614|DEVICE|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
215063817|NCT06117033|OTHER|video assisted mobilization training|Preoperative video-assisted mobilization training was given to patients undergoing coronary artery bypass graft surgery
215063818|NCT03556670|BEHAVIORAL|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
215063819|NCT03556670|OTHER|Control|Usual practice control
215063820|NCT05353114|OTHER|3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).|The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
215063821|NCT04742530|BEHAVIORAL|Fasted Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after a 7-hour period of fasting. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
215063822|NCT04742530|BEHAVIORAL|Fed Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
215063823|NCT04742530|BEHAVIORAL|Fed Morning Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 10:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
215063824|NCT05182658|DRUG|Empagliflozin 10 MG|The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
215063825|NCT05182658|DRUG|Placebo|The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
215063826|NCT00506454|DRUG|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
215063827|NCT00506454|DRUG|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
215063828|NCT01264692|DRUG|ACT-280778|10 mg once daily for 28 ± 2 days
215063829|NCT01264692|DRUG|Placebo|Placebo oral capsules matching ACT-280778
214322471|NCT05052190|BEHAVIORAL|Text Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
214322472|NCT05052190|BEHAVIORAL|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period advising them to get the flu vaccine at their upcoming appointment.
214322473|NCT05052190|BEHAVIORAL|Portal Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
214322474|NCT05052190|BEHAVIORAL|Portal Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
214322475|NCT05052190|BEHAVIORAL|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via the portal advising them to ask their doctor for the flu vaccine at their upcoming appointment via text when they schedule a visit during the study period.
214322476|NCT03578510|DEVICE|Hemocontrol hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
214322477|NCT03578510|DEVICE|Standard hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.
214322478|NCT01173302|BIOLOGICAL|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
214322479|NCT06474494|PROCEDURE|Application of one layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive
214322480|NCT06474494|PROCEDURE|Application of double layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying double layer of Scotchbond Universal Plus adhesive
214322481|NCT06474494|PROCEDURE|Etch-and-rinse application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as etch-and-rinse application mode
214322482|NCT06474494|PROCEDURE|Selective enamel etching application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as selective enamel etching mode
215063830|NCT01264692|DRUG|Amlodipine|10 mg once daily for 28 ± 2 days
214672366|NCT04301453|OTHER|Maternal Scent|Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
215063831|NCT06243328|DEVICE|negative wound pressure therapy|nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister
215063832|NCT00654225|DRUG|Rosuvastatin|
215063833|NCT00654225|DRUG|Atorvastatin|
215063834|NCT06180499|DRUG|T-reg depleted DLI|Treg depleted Donor Lymphocytes Infusion
215063835|NCT00851552|BIOLOGICAL|rituximab|Given IV
215063836|NCT00851552|DRUG|bortezomib|Given IV
215063837|NCT00851552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
215063838|NCT00851552|GENETIC|gene expression analysis|Correlative Study
215063839|NCT00851552|GENETIC|polymerase chain reaction|Correlative Study
214322483|NCT04765007|OTHER|mindfulness-based stress reduction|"Eight sessions of two hours and a half, one day per week during eight weeks. In addition, patients will perform a day of intensive silent practice of 6-8 hours of duration.~The content of each session balances three activities: the presentation of a topic, moments of dialogue and group exploration (using appreciative inquiry) and a Mindfulness practice.~The sessions will take place in online format, through the google meet application"
214322484|NCT04765007|OTHER|Minimal intervention|A guided meditation program of eight weeks of duration will be provided to the patients and they will be informed about the procedure and the beneficial effects of the therapy.
214322485|NCT00232310|DRUG|CELIVARONE (SSR149744C)|
214322486|NCT06197789|BIOLOGICAL|TPX-105|Subjects will be administered with autologous fibroblasts through injection
214322487|NCT06197789|BIOLOGICAL|Placebo|Subjects will be administered with Placebo through injection
214322488|NCT01064557|DRUG|all-trans retinoic acid (ATRA)|
214322489|NCT05422053|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.
214322490|NCT05714917|OTHER|Observational study with no interventions|This is an observational study and there will be no clinical interventions.
214322491|NCT05216874|DEVICE|Oclusal Splint|"Cl III Laterognati volunteer group using occlusal stabilization splint before orthognathic surgery~-Splint will be used for at least two months"
214322492|NCT02040610|RADIATION|Hypofractionated Proton Therapy|
214322493|NCT00081614|DRUG|Avastin (bevacizumab)|
214672367|NCT02628730|DEVICE|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
215063840|NCT00851552|GENETIC|polymorphism analysis|Correlative Study
215063841|NCT00851552|GENETIC|proteomic profiling|Correlative Study
215063842|NCT00851552|OTHER|flow cytometry|Correlative Study
215063843|NCT00851552|OTHER|laboratory biomarker analysis|Correlative Study
215063844|NCT03718806|DRUG|Zoliflodacin|oral suspension; oral administration
215063845|NCT03718806|OTHER|high calorie, high fat breakfast|fasted/fed conditions
215063846|NCT06284590|DRUG|L19IL2|Arm 1: The amount of L19IL2 that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13 MioIU/1 mL of L19IL2.
215063847|NCT06284590|DRUG|L19TNF|Arm 2: The amount of L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 400 μg/1 mL of L19TNF.
215063848|NCT06284590|DRUG|L19IL2/L19TNF|Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.
215063849|NCT06284590|DRUG|KEYTRUDA®|KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.
215063850|NCT04346147|DRUG|Imatinib tablets|Imatinib 400 mg QD oral
215063851|NCT04346147|DRUG|Baricitinib Oral Tablet|Baricitinib 4 mg QD oral
215063852|NCT04346147|OTHER|Supportive tratment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
215063853|NCT01281384|OTHER|Advanced Imaging|
215063854|NCT01281384|OTHER|Standard Imaging|
215063855|NCT00003352|DRUG|cyclophosphamide|600 mg/m2, IV, every 3 weeks
215063856|NCT00003352|DRUG|Taxotere|60 mg/m2, IV, every 3 weeks
215063857|NCT00003352|DRUG|Adriamycin|60 mg/m2, IV, every 3 weeks
215063858|NCT02689206|DRUG|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
214322494|NCT00081614|DRUG|Tarceva (erlotinib HCl)|
214485392|NCT06727526|OTHER|Placebo acupressure|In health sciences, placebo refers to an inactive intervention used to relax the patient and assess treatment efficacy. It may involve inert substances (e.g., sugar tablets, saline) or non-therapeutic interventions (e.g., artificial electrical stimulation or conversations). Expectancy theory often explains The placebo effect, which suggests that treatment expectations can induce physiological changes. Factors like age, cognitive development, and previous pain experiences influence children's responses to placebo. Parental belief in an intervention's efficacy can reduce a child's pain expectations and positively influence their perception of pain. Although the sample included young children, our study incorporated the placebo group to account for this effect, especially since the parents evaluated pain scores.
214485393|NCT06728449|DIETARY_SUPPLEMENT|Cumin tea|The preparation involved boiling 200 ml of water with 2 grams of cumin seeds. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
214672368|NCT02628730|DEVICE|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
215063859|NCT02689206|DRUG|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
215063860|NCT05883995|OTHER|Phage therapy requests|Quantification of phage therapy requests received at the Hospices Civils de Lyon from 2015 to 2028
215063861|NCT01712581|OTHER|Magnetic Resonance Imaging|
215063862|NCT00761384|DRUG|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
215063863|NCT04714827|BIOLOGICAL|KQ-2003 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .
215063864|NCT04052750|BEHAVIORAL|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
214322495|NCT02578784|DEVICE|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
214322496|NCT02578784|DEVICE|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
214322497|NCT00885833|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
214485394|NCT06728449|DIETARY_SUPPLEMENT|Ginger Tea|The preparation involved boiling 200 ml of water with 2 grams of ginger. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
214485395|NCT06728449|DIETARY_SUPPLEMENT|Lemon Peel Tea|The preparation involved boiling 200 ml of water with 2 grams of lemon peel. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
214485396|NCT06728449|DIETARY_SUPPLEMENT|Functional Tea|The preparation involved boiling 200 ml of water with 2 grams of functional tisane (0.6 g cumin seeds, 0.6 g ginger, and 0.6 g lemon peel) Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
214485397|NCT06728449|DIETARY_SUPPLEMENT|Conventional therapy|A carbohydrate-controlled diet focuses on limiting refined carbohydrates and sugars and total carbohydrate restriction to 50-70gm per major meal.
214485398|NCT06729437|OTHER|tDCS + Therapeutic eccentric exercise|A direct current of 1.5 mA will be applied for 20 minutes to the primary motor cortex (M1) during each session of eccentric exercises.
214485399|NCT06729437|OTHER|Sham tDCS + Therapeutic eccentric exercise|The current will be interrupted after 30 seconds.
214921835|NCT05429281|OTHER|Combined Pilates and Plyometrics|The combined training group performed the same exercises as the PsCS and PlyoML groups, although with half the number of sets/repetitions over 45 minutes, three times per week for 12 successive weeks. The PsCS and PlyoML were executed within the same session, with a 10-to-15-minute rest interval. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
214921836|NCT05225870|GENETIC|immunohistochemical staining|sections from colorectal carcinoma will be immunohistochemically stained by anti-Cortactin antobody.
214921837|NCT00936143|DRUG|infliximab|100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
214322498|NCT03932396|OTHER|Observational study|No intervention is planned outside of usual clinical practice. Only active screening for hepatotropic virus infection, mainly hepatitis C virus, HIV, and mental illness will be carried out. If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
214921838|NCT02453035|DEVICE|PTCA - Desolve Scaffold|Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold
214322499|NCT02051465|DEVICE|LumenR Retractor|Polyp removal using LumenR Retractor Modified overtube
214322500|NCT02051465|DEVICE|Removal without overtube|Endoscopic removal of polyp without overtube
214322501|NCT03681457|DRUG|LJN452|Dose A single dose
214322502|NCT00323414|DRUG|Polyunsaturated fatty acid (Opti-EPA)|Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
214322503|NCT00323414|DRUG|Placebo|Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
214322504|NCT05521204|DRUG|Olverembatinib|Given PO
214322505|NCT03129516|BEHAVIORAL|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
214322506|NCT02552316|DEVICE|NB-UVB Phototherapy|
214322507|NCT00222547|DRUG|Vitamin A|
214322508|NCT00222547|DRUG|Albendazole|
214322509|NCT04382911|DRUG|18F-fluoroestradiol|Patients will receive the FES tracer during a PET/MRI scan
214322510|NCT00006012|BIOLOGICAL|filgrastim|
214322511|NCT00006012|DRUG|amifostine trihydrate|
214322512|NCT00006012|DRUG|cisplatin|
214322513|NCT00006012|DRUG|etoposide|
214322514|NCT00006012|DRUG|paclitaxel|
214322515|NCT00006012|DRUG|topotecan hydrochloride|
214322516|NCT00006012|RADIATION|radiation therapy|
214322517|NCT06143566|DRUG|Polypill|A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
214322518|NCT06143566|DRUG|Combined prescription of the individual medications|We will initiate participants on an ARB, SGLT2i, and Finerenone if they are not in the polypill arm.
214322519|NCT00327704|DRUG|albumin|albumin 20% 100 ml/8 hours for 3 days
214322520|NCT00327704|DRUG|saline|saline 100 ml/8hours for 3 days
214322521|NCT03904771|BEHAVIORAL|Nutrition counselling + peer support|Behavioral nutrition counselling and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by a nutrition therapist.
214322522|NCT03904771|BEHAVIORAL|Social activation + peer support|Social activation and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by group leader.
214322523|NCT03624621|BEHAVIORAL|Functional Remediation|Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
214322524|NCT03624621|DEVICE|Computerized Cognitive Training (CCT)|12 add-on sessions (20-minute long) after each group session to train cognitive domains.
214322525|NCT03624621|BEHAVIORAL|Psychoeducation|12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.
214322526|NCT03624621|DEVICE|Online games|Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
214322527|NCT00186667|PROCEDURE|high dose chemotherapy and autologous hematopoietic cell transplant|
214322528|NCT01312584|DIETARY_SUPPLEMENT|Processed High-flavanol|
214322529|NCT02995291|DRUG|OraVerse|1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
214485400|NCT06728436|BEHAVIORAL|CuidaTEXT|CuidaTEXT is a multidomain, bilingual 6-month text message intervention that includes delivery and content features tailored to Latino caregivers. All caregivers receive one core daily automatic message on five domains: ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Caregivers can access on-demand automatic messages to expand on the five domains via sending keywords and interact with a coach via a live chat for more personalized help.
214485401|NCT06818903|DRUG|Misopristol|Foley catheter with Misopristol local application
214485402|NCT06818903|DEVICE|Foley catheter|Foley catheter alone
215063865|NCT01558596|PROCEDURE|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
214322530|NCT02995291|DRUG|Saline Water (Control)|1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
214485403|NCT06735079|DRUG|REL1017 (esmethadone HCI) (active drug)|REL-1017 is an investigational drug administered as an oral tablet, once daily. The dosing regimen includes a 75 mg dose on Day 1 (three tablets) in the clinic, followed by 25 mg daily (one tablet) at home from Day 2 to Day 28, with regular safety, efficacy, and tolerability assessments REL-1017 (esmethadone HCl) is under investigation as a novel NMDAR antagonist. Unlike racemic methadone, it lacks opioid-like effects such as dependency or respiratory depression. REL-1017 also lacks dissociative effects seen with more potent NMDAR antagonists such as ketamine. Finally, REL-1017 does not appear to have metabolic or neurological side effects.
214322531|NCT05143177|DRUG|Evogliptin|DA-1229 10 mg, 1 tab
214322532|NCT05143177|DRUG|Placebo|DA-1229 Placebo, 1 tab
214485404|NCT06735079|DRUG|Placebo|"The placebo serves as a control to evaluate the effectiveness and safety of REL-1017. It is an inactive substance that matches the active drug in appearance but contains no active ingredients. The placebo group allows researchers to compare outcomes, such as changes in depressive symptoms, with the active drug group.~The double-blind design ensures neither participants nor researchers know who is receiving the active treatment or placebo, eliminating bias. The placebo also helps assess whether observed side effects are due to the drug or unrelated factors.~Participants are randomly assigned to receive either REL-1017 or the placebo, both administered once daily for 28 days. This helps establish REL-1017's clinical effectiveness and safety in treating Major Depressive Disorder (MDD)."
214485405|NCT03092674|DRUG|Azacitidine|Given SC or IV
214485406|NCT03092674|DRUG|Cytarabine|Given IV
214485407|NCT03092674|DRUG|Decitabine|Given IV
214485408|NCT03092674|OTHER|Laboratory Biomarker Analysis|Correlative studies
214485409|NCT03092674|DRUG|Midostaurin|Given PO
214485410|NCT03092674|BIOLOGICAL|Nivolumab|Given IV
214672369|NCT04596371|OTHER|pure pulmonary ground glass nodules in women preparing for pregnancy|pure pulmonary ground glass nodules in women preparing for pregnancy
214672370|NCT02957773|BEHAVIORAL|Qigong and art activities|Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.
214672371|NCT02957773|BEHAVIORAL|Art activities|Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.
214672372|NCT02957773|BEHAVIORAL|Qigong|Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
214672373|NCT02957773|BEHAVIORAL|Daily activities|Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
214672374|NCT00936949|PROCEDURE|surgical approach|Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
215063866|NCT01558596|PROCEDURE|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
215063867|NCT00652314|DEVICE|Thrombi-Gel|Applicaton of Hemostatic product during surgery
215063868|NCT03617601|DIAGNOSTIC_TEST|MET|Testing of the metabolic equivalent of task before aortic procedure
215063869|NCT01014572|BEHAVIORAL|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
214322533|NCT05876091|OTHER|Vaping|Undergo vape puffing regimen
214322534|NCT05876091|PROCEDURE|Biospecimen Collection|Undergo collection of saliva samples and oral cell samples
214322535|NCT05876091|OTHER|Questionnaire Administration|Administer Quesitonnaire
214322536|NCT01942629|OTHER|their will be no intervention in any of the groups, the study is retrospective|
214322537|NCT02385799|DRUG|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
214322538|NCT02385799|DRUG|Sertraline|Active medication
214322539|NCT00139568|DRUG|Tegaserod|
214322540|NCT02016963|BIOLOGICAL|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
214322541|NCT04688164|DRUG|REL-1017|REL-1017 tablet
214322542|NCT04688164|DRUG|Placebo|Placebo tablet
214322543|NCT02172313|DRUG|semaglutide|For oral administration.
214322544|NCT04464070|DIETARY_SUPPLEMENT|niacin|induce biosynthesis of PGD2
214322545|NCT04464070|DRUG|aspirin|inhibition of cyclooxygenase
214322546|NCT04464070|OTHER|PGD2|labeled precursor
214322547|NCT00696956|DEVICE|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
215063870|NCT01014572|DRUG|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
214921839|NCT03981484|BIOLOGICAL|Prothrombin Complex Concentrate|single dose of 25 IU/kg of 4-PCC at time of enrollment
214485411|NCT06778382|OTHER|Oligometastasis Treatment|"Oligometastatic Radiotherapy Group: Patients will receive radiotherapy to lung lesions, with the lung metastases outlined as the Gross Tumor Volume (GTV). The prescribed dose will be based on a BED (Biologically Effective Dose) of 72-100 Gy, using either conventional split, macrodissected, or SBRT (Stereotactic Body Radiation Therapy) at the investigator's discretion. No systemic therapy will be administered.~Oligometastatic Radiofrequency Ablation Group: For lesions suitable for radiofrequency ablation, this will be performed in consultation with the Department of Interventional Medicine, considering patient and family preferences. Systemic therapy will not be given.~Oligometastatic Surgery Group: For lesions suitable for surgical resection, patients will undergo surgery after consultation with the Department of Surgery. No systemic therapy will be performed."
214485412|NCT06735547|DEVICE|Telerehabilitation|Patients in the Telerehabilitation group will perform an average of three therapy sessions per week, with data collected and monitored by TRAK's physiotherapists. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.
214485413|NCT06735547|OTHER|Conventional therapy group|Patients in the conventional group will be assessed by a professional physiotherapist, scheduling appointments according to their own preferences and disponibility. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.
215063871|NCT01014572|BEHAVIORAL|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
214485414|NCT06735352|OTHER|virtual reality intervention|Evaluated the effect of virtual reality use in elderly people with mild cognitive impairment compared to a control group.
214672375|NCT00936949|PROCEDURE|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
214921840|NCT03981484|BIOLOGICAL|Whole Blood, Plasma, Packed Red Blood Cells|site's standard resuscitation protocol
214921841|NCT04426721|DRUG|Ozone|10 cc of oxygen-ozone
214921842|NCT04426721|DRUG|Hyaluronic Acid|Sinovial forte 32 mg\\2ml
214921843|NCT02379702|OTHER|Metabolic Syndrome|This study will provide important information on the social and economic dimensions of metabolic syndrome
214921844|NCT03807479|DRUG|Ponatinib|2 film-coated tablets à 15mg for oral administration on a daily basis
214921845|NCT05338502|DRUG|Selpercatinib|Administered orally.
214921846|NCT05338502|DRUG|Ranitidine|Administered orally.
214921847|NCT05338502|DRUG|Omeprazole|Administered orally.
214921848|NCT00555464|DRUG|Vincristine|Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
214485415|NCT06216665|OTHER|Continuous Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered continuously during the hyperinsulinemic euglycemic clamp test
214672376|NCT02786862|OTHER|independent ventilation|comparison conventional and independent 1:1 ventilation
214672377|NCT02638246|BEHAVIORAL|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
214921849|NCT00555464|DRUG|Prednisone|Prednisolone given at 3 mg/kg/day by mouth for 12 week
214921850|NCT05410275|DRUG|Rivaroxaban|Experimental group Each patient will receive successively over 3 distinct periods the 3 doses of rivaroxaban to be evaluated, i.e., 5 mg, 10 mg, and 15 mg as a single daily dose (once daily over 3 days for each dose).
214921851|NCT04279470|DRUG|CAR T-cell and Cellular Therapies|Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy
214921852|NCT00436475|DRUG|Vitamin D3 2,000 IU orally once daily|Vitamin D3 2,000 IU orally once daily
214921853|NCT00436475|DRUG|Calcium Carbonate 400 mg orally twice daily|Calcium Carbonate 400 mg orally twice daily
214921854|NCT00436475|DRUG|Vitamin D3-Placebo|Vitamin D3-Placebo
214921855|NCT00436475|DRUG|Calcium-Placebo|Calcium-Placebo
214921856|NCT05043025|OTHER|Identification of the cricothyroid membrane|The cricothyroid membrane is identified using a laryngeal handshake technique in different patient positions.
214921857|NCT06578286|DRUG|ARX788|ARX788，1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle
214921858|NCT00647738|DRUG|Baclofen|Single-dose 20 mg immediate-release oral tablets
214921859|NCT00647738|DRUG|Baclofen|Single-dose 20 mg immediate-release oral tablet
214921860|NCT03024957|DRUG|Morphine Sulfate|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
215063872|NCT00000401|DRUG|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
215063873|NCT04202068|DRUG|Ceftriaxone sodium and Sulbactam Sodium for injection|Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
215063874|NCT00644072|DRUG|SNX-5422|
215063875|NCT02534012|DRUG|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
214485416|NCT06216665|OTHER|Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered every five minutes during the hyperinsulinemic euglycemic clamp test
214485417|NCT05788666|PROCEDURE|GeriKit Mobile Application|Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.
214485418|NCT06726577|DRUG|TP04HN106|During the treatment period, the experimental drug group received intravenous injections of 0.83mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.83mL/kg TP04HN106.
214322548|NCT00696956|DEVICE|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
214347513|NCT05099848|DRUG|Camrelizumab|"Procedure:~1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.~2. On the 2nd day of treatment, intravenous infusion of Camrelizumab 200mg every 3 weeks.~3. On the 3rd to 4th day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX, oxaliplatin 85 mg/m2 in 0-2 hours, folinic acid 400 mg/m2 in 2-3 hours, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 8 times.~The cumulative maximum drug use period is up to 8 cycles. Patient will be administratied radical resection if possible during treatment. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
214485419|NCT06726577|DRUG|Saline|The placebo group received intravenous injections of 0.83mL/kg of saline each time. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.
214485420|NCT06704906|DEVICE|Use of Viper Prime/Expedium system with Fibergraft BG Putty|Patients who require spine surgery under standard of care and meet the inclusion and exclusion criteria identified, will be recruited from clinic. Consent for participation in study will be signed at the same time as consent for surgery. All PROMs and scans will be done as standard of care and data will be obtained through chart review for this study.
215063876|NCT02534012|DRUG|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
215063877|NCT02534012|PROCEDURE|Major abdominal surgery|
215063878|NCT05383781|OTHER|Hip and Knee focused exercises|Exercises which improves muscle strength, ROM
215063879|NCT05383781|OTHER|Short foot exercise|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
215063880|NCT04635254|OTHER|Halophites-based cream 24 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
215063881|NCT04635254|OTHER|Halophites-based cream 48 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
215063882|NCT04635254|OTHER|Vehicle cream 24 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
215063883|NCT04635254|OTHER|Vehicle cream 48 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
215063884|NCT04635254|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
215063885|NCT04635254|OTHER|Cowhage|The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
215063886|NCT05723692|BIOLOGICAL|ALTB-268|monoclonal antibody
215063887|NCT05723692|OTHER|Placebo|formulation buffer
215063888|NCT03097523|DEVICE|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
215063889|NCT00428935|BIOLOGICAL|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
215063890|NCT04299152|COMBINATION_PRODUCT|Stem Cell Educator-Treated Mononuclear Cells Apheresis|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
215063891|NCT04538118|BEHAVIORAL|Shoulder disability|"Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
215063892|NCT04538118|DEVICE|Shoulder Range of Motion|"Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
215063893|NCT04538118|BEHAVIORAL|Pain Intensity|"Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
215063894|NCT01453972|BEHAVIORAL|Long distanse moderate training|Moderate exercise
215063895|NCT01453972|BEHAVIORAL|Long interval training|High-intensity exercise, long duration
215063896|NCT01453972|BEHAVIORAL|Short interval training|High intensity exercise, short duration
215063897|NCT05327075|OTHER|questionnaire|it is in the form of questionnaire and scoring tool
215063898|NCT00595881|DEVICE|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
215063899|NCT02177721|BIOLOGICAL|Sample Collection|"Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to Sponsor for determination of raxibacumab concentrations.~Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to Sponsor for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for lethal factor (LF) levels."
215063900|NCT05535504|DEVICE|Low-frequency rTMS (experimental)|Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / Location: motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: tangential to scalp
215063901|NCT05535504|DEVICE|Low-frequency rTMS (sham comparator)|Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: vertical to scalp
215063902|NCT01479764|DRUG|Sugammadex|sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
215063903|NCT01479764|DRUG|Neostigmine|neostigmine, per usual practice
215063904|NCT01479764|DRUG|Glycopyrrolate|glycopyrrolate per usual practice
214672378|NCT02638246|BEHAVIORAL|Internet-delivered, non-contingent incentives + Motivational Interviewing|
215063905|NCT02916069|DEVICE|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
215063906|NCT02916069|DEVICE|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
215063907|NCT02916069|DEVICE|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
214347514|NCT00252642|DRUG|Peginterferon Alpha-2a|
214347515|NCT04672304|OTHER|Al-Husban University Naser|filling a questionnaire
214485421|NCT05288361|DIAGNOSTIC_TEST|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|"Patients presenting with symptomatic ischemic heart disease (including chronic stable angina or unstable angina) without evidence of myocardial infarction who require elective or urgent cardiac catheterization, and who meet all eligibility criteria will be enrolled.~Participants will undergo routine coronary angiography as well as comprehensive physiologic assessment with intracoronary acetylcholine provocation for diagnosis of vasospastic angina (VSA), coronary thermodilution to evaluate for coronary microvascular dysfunction (CMD), and intracoronary imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) to evaluate for the presence of atheroma, plaque burden, and myocardial bridging."
214921861|NCT03024957|DRUG|Dexmedetomidine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
214322549|NCT06724679|OTHER|Utilisability of an immersive VR device in a functional restoration program (FRP) for patients with chronic low back pain.|"Patients participating will engage in three 20-minute VR sessions per week, in addition to the standard FRP program, for a duration of four to five weeks. The sessions will consist of a series of pre-programmed exercises designed to facilitate various trunk movements (flexion, extension, inclination, rotation) through exergames. Each exercise will last an average of 5 to 7 minutes. These exercises have been developed in collaboration between the company providing the VR device and the rehabilitation teams. Patients will be set up by a healthcare provider in a dedicated room for VR use. The provider will configure the device, assist the patient in donning it, and initiate the program, will remain present throughout the session to monitor for any adverse effect~. While the specific exercises may vary, the total duration of the session will be 20 minutes, consisting of various exercises interspersed with breaks. The principal investigator will propose a standardized series of exercises,"
214322550|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
214921862|NCT03024957|DRUG|Bupivacaine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
214921863|NCT02218099|DRUG|ASP8232|Oral
214921864|NCT02218099|DRUG|Placebo|Oral
214921865|NCT04424706|DIAGNOSTIC_TEST|diagnosed as type 2 diabetes without atherosclerosis|patients diagnosed as type 2 diabetes without atherosclerosis
214921866|NCT04424706|DIAGNOSTIC_TEST|diagnosed as type 2 diabetes with atherosclerosis|patients diagnosed as type 2 diabetes with atherosclerosis
214921867|NCT04424706|DIAGNOSTIC_TEST|people without type 2 diabetes or atherosclerosis|normal people without type 2 diabetes or atherosclerosis
214921868|NCT04046510|DRUG|Ocytocin|Administration of lower doses of Ocytocin in bolus and continuous infusion
214921869|NCT05105542|DRUG|11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor|The radiotracer, \[11C\]EMO, will be administered at the beginning of each PET scan.
214921870|NCT05105542|DEVICE|PET Scan|PET scanner with high sensitivity and resolution available for human brain imaging
214921871|NCT06640257|DRUG|SHR-1314 injection|SHR-1314 injection
214921872|NCT06640257|DRUG|Placebo|Placebo
214921873|NCT04115592|OTHER|Cocoa butter|Consumption of cocoa butter made with chocolate confectionery
214921874|NCT04115592|OTHER|Cocoa butter oleogel|Consumption of cocoa butter oleogel made with chocolate confectionery
214921875|NCT04115592|OTHER|Sal seed oil|Consumption of sal seed oil made with chocolate confectionery
214921876|NCT04115592|OTHER|Sal seed oleogel|Consumption of sal seed oleogel made with chocolate confectionery
214921877|NCT02655991|BEHAVIORAL|Telephone Case Monitoring|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
214921878|NCT02655991|BEHAVIORAL|Treatment as Usual|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
214921879|NCT05200182|DEVICE|Neurofeedback with functional near infra-red spectroscopy|"the neurofeedback protocol will last 15 minutes per session, and during each session, the volunteer will have to increase the brain activity of his/her dorsolateral prefrontal cortex using a visual gauge representing the activity level of his/her own dorsolateral prefrontal cortex. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
214921880|NCT05200182|DEVICE|Sham Neurofeedback|the participants will receive the same instruction but will be shown a random signal
214921881|NCT05200182|OTHER|oral microbiota collection|an examination and oral swab for oral microbiota analysis will be performed by a dentist
214921882|NCT05200182|OTHER|Questionnaires|questionnaires for pre-intervention behavioral characterization
214921883|NCT05200182|DEVICE|resting-state fMRI|characterize the brain function of volunteers by resting-state fMRI
214921884|NCT05200182|DEVICE|Electro gastrogram|Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.
214921885|NCT05200182|BEHAVIORAL|Emotional Stroop task|an emotional Stroop task adapted to food and body image representation
214921886|NCT03575793|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.
214921887|NCT03575793|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-\[\[5-(1,1-dimethylethyl)-1H-imidazol-4-yl\[methylene\]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).
214921888|NCT03575793|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
214921889|NCT06685731|OTHER|Laughter Yoga|"Laughter Yoga Intervention:~Laughter Yoga is composed of four stages: deep breathing exercises, clapping and warm-up exercises, childlike play, and laughter exercises. These stages are designed to remove barriers to laughter, enhance emotional expression through childlike play, and prepare the lungs for laughter exercises.~Before the Laughter Yoga session begins, participants will be introduced to both the practice itself and to Laughter Yoga in general. The session will then proceed according to the following structure:~Deep Breathing Exercises: Participants inhale through the nose for 4-5 seconds, hold their breath for 2-3 seconds, and exhale through the mouth, with lips pursed, for one second longer than the inhalation, while smiling or laughing. This exercise is performed for 10-15 minutes.~Clapping and Warm-Up Exercises: Participants clap with palms and fingertips touching, keeping their hands parallel. This stimulates acupressure points in the hands. To increase group energy, a"
215063908|NCT05034809|DRUG|Melatonin 20 MG|Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
214322551|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
214322552|NCT02946060|OTHER|Audiobooks|iPods with audiobooks
214322553|NCT02946060|OTHER|Tempo-pace synchronized playlists|Playlists with or without RAS
214322554|NCT02946060|OTHER|Usual Care|iPods containing either a silent track or white noise
214322555|NCT02558998|OTHER|Survey|
214322556|NCT05939206|PROCEDURE|rTARUP|robotic assisted transabdominal retromuscular umbilical prosthetic repair
214322557|NCT04568057|DEVICE|NIR Transcranial phototherapy device|1068 nm NIR helmet
214322558|NCT04568057|DEVICE|Placebo Transcranial Device|The placebo device looks like the active device.
214322559|NCT02350309|DRUG|Lemborexant 5 mg|Lemborexant 5 mg tablet.
214485422|NCT06738784|BEHAVIORAL|Perceive, Recall, Plan and Perform (PRPP) evaluation|Passing the PRPP for 2 activities
214485423|NCT06883396|PROCEDURE|Medial Patellofemoral Ligament (MPFL) Reconstruction|For the purposes of this study, isolated MPFL reconstruction is defined as MPFL reconstruction with a tendon graft, with or without additional soft tissue procedure(s) including lateral retinacular lengthening or release, patellofemoral chondroplasty and/or cartilage restoration. No patient in the study will receive a bony realignment procedure to treat patellar instability.
214921890|NCT00790244|DRUG|doxorubicin , ifosfamide|doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
214921891|NCT00790244|DRUG|doxorubicin, ifosfamide|Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
214921892|NCT00790244|DRUG|doxorubicin, ifosfamide|"\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
214921893|NCT00790244|DRUG|doxorubicin, ifosfamide|"\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
214921894|NCT05581940|COMBINATION_PRODUCT|Group A Caudal Epidural Anesthesia with bupivacaine 0.25% and group B with opioid intervenors|(CEB) in group A using drugs bupivacaine 0.25% commonly used in children including neonates in group A In infraumbilical operations, it is used as a supplement to GA and to control postoperative pain It is a safe, easy, and effective type of central neuraxial block.\[ The patient will be intubated and the caudal block will be performed under GA after securing the airway. The patient's position will be turned onto the lateral decubitus then a landmark-based, blind technique will be used. In children, the success rate with the blind technique is above 96% but the occurrence of side effects is reported. Group B uses general anesthesia (GA) alone for intraoperative and perioperative pain control used the opioid intervious without caudal block .
214921895|NCT04594369|DRUG|Brensocatib 10 mg|Oral tablet.
214921896|NCT04594369|DRUG|Brensocatib 25 mg|Oral tablet.
214921897|NCT04594369|DRUG|Placebo|Brensocatib-matching oral tablet.
214921898|NCT03137940|DEVICE|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator.
214921899|NCT03137940|DEVICE|sham tDCS|one-shot of sham tDCS session (20 minutes) with BrainStim Stimulator.
214921900|NCT04805801|DRUG|Emicizumab subcutaneous injection|Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.
214921901|NCT01250873|DRUG|LY2216684|po administration
214921902|NCT01250873|DRUG|Sertraline|po administration
214921903|NCT01983033|BEHAVIORAL|Drop It training session|8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month
214921904|NCT01983033|BEHAVIORAL|treatment as usual|12 weeks of no intervention other than treatment as usual
214921905|NCT03687333|DRUG|ALGLUCOSIDASE ALFA (MYOZYME)|"Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion"
214921906|NCT04342637|OTHER|Practice details|Physicians will report details of their endoscopy practice through answering the questions of the questionnaire
214921907|NCT02510963|DRUG|Tenofovir Disoproxil Fumarate|Use Tenofovir at 24week of gestation
214921908|NCT02510963|DRUG|Tenofovir Disoproxil Fumarate|Use Tenofovir at 28week of gestation
214921909|NCT02510963|DRUG|Tenofovir Disoproxil Fumarate|Use Tenofovir at 32week of gestation
214921910|NCT03788031|OTHER|Acuity training|The intervention will be a vision therapy. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to identify the location of the stimulus.
214485424|NCT06740240|DRUG|68Ga-FAPI-Biotin|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer doses of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT
214921911|NCT03788031|OTHER|Occlusion therapy|Participants will be required to patch the good eye for 20 days, 1 hour per day.
215063909|NCT04889248|OTHER|Inspiratory Muscle Training with Powerbreath IMT device.|"Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax."
215063910|NCT04170088|DRUG|Tranexamic Acid|Tranexamic acid intradermal injections were used for treatment of melasma
215063911|NCT04170088|DRUG|0.9% Normal Saline|Normal saline used for comparision of efficacy of tranexamic acid
215063912|NCT05813184|DRUG|Antibiotics|Any antibiotic therapy administered \> 7 days
215063913|NCT03800537|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
215063914|NCT01814865|DRUG|Abiraterone Acetate|1000 mg PO OD x 2 weeks
215063915|NCT01814865|DRUG|Prednisone|5 mg PO OD x 2 weeks
215063916|NCT01814865|DRUG|Aromatase Inhibitor|1 mg PO OD x 2 weeks
215063917|NCT00254150|PROCEDURE|Increase oxygen extraction rate|
215063918|NCT00902850|DEVICE|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
215063919|NCT00902850|DEVICE|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
215063920|NCT00260832|DRUG|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
215063921|NCT00260832|DRUG|Dacogen (decitabine) only|20mg/m\^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
215063922|NCT00996879|DRUG|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
215063923|NCT00996879|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
215063924|NCT00784888|OTHER|Aromatase inhibitors|non-interventional study
215063925|NCT03745638|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
215063926|NCT03745638|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
215063927|NCT01032603|PROCEDURE|Bilateral lateral rectus recession (BLRc)|Bilateral lateral rectus recession surgery
214322560|NCT02350309|DRUG|Lemborexant 10 mg|Lemborexant 10 mg tablet.
214322561|NCT02350309|DRUG|Lemborexant-matched placebo.|Lemborexant-matched placebo tablet.
214322562|NCT02350309|DRUG|Flurazepam 30 mg|Flurazepam 30 mg capsule.
214921912|NCT05094674|DIAGNOSTIC_TEST|Breath Sample analysis|The participant's breath sample is taken by blowing preferably three times into a disposable tube. Thereafter, the tube is sealed, sterilized, and scanned by the BioSafety Station for analysis. This will take place once during the study.
214322563|NCT03033407|OTHER|Tailored mobile coaching messages|Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
214322564|NCT05685290|OTHER|Pushing with saline technique|Peripheral venous catheter placement by pushing with saline technique
214322565|NCT05685290|OTHER|Traditional method|Peripheral venous catheter placement with the traditional method by nurses in the clinic routinely.
214347516|NCT06429020|BIOLOGICAL|the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.|record the condition of vaccination
214921913|NCT03781362|DRUG|CPI-100|CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
214921914|NCT03781362|DRUG|Capecitabine|Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period
215063928|NCT01032603|PROCEDURE|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
215063929|NCT04470050|DRUG|Dexmedetomidine|Sublingual Film of Dexmedetomidine
215063930|NCT04470050|DRUG|Placebo|Sublingual Placebo film
215063931|NCT01447342|DEVICE|Cryo-Touch II|Percutaneous treatment with the device
215063932|NCT02057640|DRUG|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
215063933|NCT02057640|DRUG|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
215063934|NCT02057640|DRUG|MLN9708|4mg on day 1, 8, 15, 28
215063935|NCT03585764|DRUG|MOv19-BBz CAR T cells|intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
215063936|NCT03585764|DEVICE|Alpha Folate Receptor expression test|Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
214485425|NCT06740240|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
214485426|NCT06884488|DEVICE|repetitive transcranial magnetic stimulation (Magstim Super Rapid stimulator, The Magstim Company Ltd, Whitland, UK)|The paradigm will be applied over the dominant cerebral hemisphere for 10 minutes (600 pulses) over the dominant pharyngeal motor cortex capped at 120% of pharyngeal resting motor threshold.
214485427|NCT06884488|DEVICE|pharyngeal electrical stimulation (Digitimer model DS7; Welwyn-Garden City, Herts, UK)|The PES (0.2-ms pulses, 280 V) was delivered at a set frequency (5 Hz), intensity (75% of maximal tolerated), and duration (10 minutes), which have been reported as the most effective parameters for PES.
214672379|NCT05396118|DRUG|18F-FDG|Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
214921915|NCT00081757|DRUG|Thalidomide|
214921916|NCT06261125|RADIATION|Stereotactic body radiotherapy|Patients in both cohorts will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 33-48 Gy in 6 fractions over 2 weeks.
214921917|NCT06261125|DRUG|Adebrelimab|All patients will reveive adebrelimab 1200 mg every 3 weeks for up to 35 cycles after the completion of SBRT.
214921918|NCT06261125|DRUG|Lenvatinib|All patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight \<60 kg) orally once daily after the completion of SBRT.
214921919|NCT04036435|DRUG|BMS-986165|Specified dose on specified days
214921920|NCT02278939|BEHAVIORAL|Filipinos Fit and Trim Weight Loss Program|This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
214921921|NCT01103258|PROCEDURE|high ligation and stripping (surgery)|surgery consisting of high ligation in combination with long saphenous stripping
214921922|NCT01103258|PROCEDURE|FOAM|duplex guided foam sclerotherapy
214921923|NCT01070212|OTHER|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
214921924|NCT01070212|OTHER|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
214921925|NCT01070212|OTHER|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
214921926|NCT04828213|DEVICE|Rapid Maxillary Expansion Treatment with Tooth-borne RME appliance (Hyrax)|The patients were treated with a expansion appliance containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
214921927|NCT04828213|DEVICE|Rapid Maxillary Expansion Treatment with Hybrid hyrax RME appliance|The patients were treated with a Hybrid hyrax RME appliance containing a Hyrax expansion screw positioned parallel to the second premolars and mini-screws. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
214921928|NCT00839813|BEHAVIORAL|Yoga|10 weeks of a trauma-sensitive yoga class
214921929|NCT03428113|OTHER|Bladder Volume Measurement bladder scanner RN|Measure Urine Volume with Bladder Scanner by RN
214921930|NCT03428113|OTHER|Bladder Volume Measurement Ultrasound APRN|Measure Urine Volume with Point of Care Ultrasound by APRN
214921931|NCT03428113|OTHER|Bladder Volume Measurement bladder scanner APRN|Measure Urine Volume with Bladder Scanner by APRN
214921932|NCT03428113|OTHER|Bladder Volume Measurement Ultrasound MD|Measure Urine Volume with Point of Care Ultrasound by MD
214921933|NCT03428113|OTHER|Intermittent Straight Catheterization|Measure Urine Volume with Intermittent Straight Catheterization
214921934|NCT02669836|PROCEDURE|Posterior fossa decompression|Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
215063937|NCT04307069|DRUG|Oxytocin|The drug wil be adminisrate for augmentation of labor at admission.
215063938|NCT03687294|DEVICE|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
215063939|NCT02746588|OTHER|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
215063940|NCT03953248|DRUG|L-Carnitine|
215063941|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
214672380|NCT05396118|DRUG|Injection of hyperpolarized [1-13C]Pyruvate|Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.
215063942|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
215063943|NCT03280849|OTHER|Implant of bilaminar chitosan scaffold|The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
215063944|NCT05216718|PROCEDURE|Mini-flap|Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
215063945|NCT05216718|PROCEDURE|Conventional flap|Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
214322566|NCT02421133|OTHER|Transitional care program.|"During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.~The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.~During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit."
214322567|NCT02421133|OTHER|standard care program|The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician…) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
214322568|NCT03414346|OTHER|Exclusively ice pack|Each subject will receive an experimental intervention of exclusively 500 grams of crushed ice. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
214322569|NCT03414346|OTHER|Ice pack added 10% of water|Each subject will receive an experimental intervention of ice pack added to 50 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
214322570|NCT03414346|OTHER|Ice pack added 100% of water|Each subject will receive an experimental intervention of ice pack added to 500 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
214322571|NCT05908279|OTHER|Walking test|Walk with and without a metronome
214322572|NCT05908279|OTHER|Disease assessement|Disease stage assessed by a doctor
214322573|NCT04415541|BEHAVIORAL|Psychodynamic Psychotherapy|Intensive psychotherapy that is psychodynamically oriented.
214322574|NCT04415541|BEHAVIORAL|Usual Care|Conventional treatment offered in the community.
214322575|NCT05970224|DRUG|Ir-CPI|Participants receive a single intravenous dose of Ir-CPI during 48 hours
215063946|NCT01563705|PROCEDURE|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
215063947|NCT01563705|PROCEDURE|Manual dexterity assessment|Purdue pegboard test
215063948|NCT02574767|BEHAVIORAL|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet \& Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
215063949|NCT02574767|DIETARY_SUPPLEMENT|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
215063950|NCT02574767|BEHAVIORAL|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
215063951|NCT02574767|DIETARY_SUPPLEMENT|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
215063952|NCT00038090|DRUG|Thalidomide|100 mg capsules by mouth daily each evening
215063953|NCT00038090|DRUG|Dexamethasone|20 mg/m\^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
215063954|NCT03640507|DRUG|Chlorhexidine-alcohol|Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
214485428|NCT06884488|DEVICE|sham repetitive transcranial magnetic stimulation(Magstim Super Rapid stimulator, The Magstim Company Ltd, Whitland, UK)|Sham rTMS is delivered with the coil tilted to its side at 90 degrees and with the identical stimulation conditions as active 1 Hz rTMS.
214322576|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
214322577|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
214322578|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
215063955|NCT03640507|DRUG|Povidine-iodine|Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
215063956|NCT03640507|DRUG|Sterile saline|Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
215063957|NCT04823286|OTHER|Virtual reality health platform during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis. The game will also aim at providing nutritional advice, and improving psychological wellbeing and cognitive function.
215063958|NCT06354530|DRUG|anlotinib|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: anlotinib 8 mg/day orally (from days 1 to 14 in a 21-day cycle) for 2 cycles"
214322579|NCT03521453|OTHER|PEPPER robot|Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
214322580|NCT00058825|BIOLOGICAL|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
214322581|NCT00058825|DRUG|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
215063959|NCT06354530|RADIATION|Thoracic radiotherapy|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Thoracic radiotherapy RT once daily (from cycle 1 \[C1D1\], 41.4Gy/23Fx, 1.8Gy daily, for 4.6 weeks, 5 days/week)"
215063960|NCT06485713|DRUG|trifluridine/tipiracil combined with fufuquitinib|trifluridine/tipiracil combined with fufuquitinib
215063961|NCT06485713|DRUG|fufuquitinib|fufuquitinib
215063962|NCT06485713|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil
215063963|NCT05121298|DRUG|upadacitinib 15mg/day|Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of \<2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
214485429|NCT06884488|DEVICE|sham pharyngeal electrical stimulation (Digitimer model DS7; Welwyn-Garden City, Herts, UK)|For sham pharyngeal stimulation, the same method including the insertion of the catherter will be employed without actual electrical stimulation.
214322582|NCT00058825|PROCEDURE|Stem Cell Transplant|Day 0: Donor stem cells infused.
214322583|NCT00058825|RADIATION|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
214485430|NCT06885502|DEVICE|RGS|The standardized intervention schedule consists of 20-30-minute daily training sessions (including weekends) for 6 weeks, in addition to the prescribed conventional therapy (Standard of Care, SoC). Each session includes 4 to 6 exercises, each lasting approximately 5 minutes. To promote variability and engagement, at least one exercise will be replaced every week based on the participant's progress. Participants are encouraged to train more than the prescribed duration if desired. The RGSapp training will take place at home, and patients will use a smartphone. An optional wearable device (smartwatch) will be used to remotely monitor the use of the paretic upper arm for the duration of the trial. Regular check-ins by clinicians will monitor adherence, adjust the intervention if needed, and ensure the participants' safety.
214485431|NCT06738745|DRUG|HRS-2189|HRS-2189
214485432|NCT06738745|DRUG|HRS-5041|HRS-5041
214485433|NCT06739798|DIAGNOSTIC_TEST|Exp Group|Binocular Spectacle prescription are therapeutic tools used to correct refractive errors in visually impaired patients. They improve Visual acuity as well as other visual functions in Amblyopic and visual impairment patients. They stimulate weaker eye to generate visual impulse and stimulate visual cortex to improve stereopsis and fusion.
214485434|NCT06739798|DIAGNOSTIC_TEST|Control Group|Patching therapy is a gold standard tool used world wide to correct visual acuity in amblyopic patients. This tool is used by occluding stronger eye with a patch or bandage or fogging lens and stimulating amblyopic eye to generate visual stimulus to motivate visual cortex.
214485435|NCT06737367|OTHER|CT radiomic analysis|Radiomic features of tumor and peritumor tissue
214921935|NCT02669836|PROCEDURE|Dural Augmentation|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
214322584|NCT00058825|DRUG|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
214921936|NCT01329042|DRUG|Potassium-sodium citrate|The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment
214921937|NCT05169918|OTHER|Core stabilization|"The progressive core stabilization exercise approach created by Kumar et al. will be used.~* Stage 1; Isolation and facilitation of target muscles~* Stage 2; Trunk stabilization training with increased load under static conditions~* Stage 3; Development of trunk stabilization during slow controlled movement of the lumbar spine.~* Stage 4 and 5; Lumbar stabilization during high speed and dexterous movements. The exercises will last 20-30 minutes in each sessions and twice a week for 10 weeks. The level of stage will be increased when the patients reach the aim of the stage where he/she is at. The duration of the each stage will change depending on the days the patients' need to achieve the aim of the level. For each level, at least four exercise is described."
215063964|NCT04416334|DRUG|Colchicine plus symptomatic treatment (paracetamol)|Colchicine plus symptomatic treatment (paracetamol).
215063965|NCT04416334|DRUG|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
215063966|NCT02819986|BEHAVIORAL|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
215063967|NCT03604172|BEHAVIORAL|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
215063968|NCT03604172|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
215063969|NCT03993886|DEVICE|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
215063970|NCT03993886|OTHER|Activity Monitor|commercially available accelerometer to be worn on wrist
215063971|NCT03993886|OTHER|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
215063972|NCT03993886|OTHER|ECG|Commercially available electrocardiogram machine
214485436|NCT06740851|PROCEDURE|Touch® Trapeziometacarpal Joint Arthroplasty|The intervention involves primary trapeziometacarpal joint (TMJ) arthroplasty using the Touch® prosthesis, a dual-mobility implant designed for the treatment of osteoarthritis in the thumb.
215063973|NCT03993886|OTHER|respiratory rate sensor|Commercially available respiratory rate sensor.
215063974|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine|while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.
215063975|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline|Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
215063976|NCT05192928|DEVICE|Ripple Health Smart Pill Cap|The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
215063977|NCT02168062|BEHAVIORAL|Behavioral Dietary Intervention|Receive individualized nutrition counseling
215063978|NCT02168062|OTHER|Counseling|Receive individualized symptom management service counseling
215063979|NCT02168062|OTHER|Educational Intervention|Review educational modules
214322585|NCT02187328|OTHER|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
214322586|NCT02187328|OTHER|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
214322587|NCT04970758|OTHER||no intervention
214322588|NCT03151759|RADIATION|Neoadjuvant radiotherapy|Neoadjuvant radiotherapy prior to rectal cancer surgery
214322589|NCT04399161|DRUG|Chlorhexidine mouthwash|A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.
214322590|NCT04399161|DRUG|Xylitol|Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.
214322591|NCT04399161|DRUG|Probiotic|Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.
215063980|NCT02168062|BEHAVIORAL|Exercise Intervention|Receive individualized exercise counseling
215063981|NCT02168062|DRUG|Goserelin Acetate|Given SC
215063982|NCT02168062|OTHER|Laboratory Biomarker Analysis|Correlative studies
214672381|NCT05396118|PROCEDURE|PET/MR/MRS/MRSI scanning|Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized \[1-13C\]Pyruvate.
214672382|NCT01347164|BEHAVIORAL|RISE life coaching intervention|6 2-hour sessions
214485437|NCT06740669|BEHAVIORAL|Virtual reality glasses (VR) application|It will be evaluated at 1 and 6 hours after the Caesarean section and a relaxing video called Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ, a video containing nature scenes accompanied by nature sounds) will be shown for a maximum of 20 minutes through virtual reality glasses (Toker and Gökduman Keleş, 2024).
215063983|NCT02168062|DRUG|Leuprolide Acetate|Given SC or IM
215063984|NCT02168062|OTHER|Quality-of-Life Assessment|Ancillary studies
215063985|NCT02168062|DRUG|Triptorelin Pamoate|Given IM
215063986|NCT01270880|DRUG|Hsp90 inhibitor STA-9090|Given IV
215063987|NCT01270880|OTHER|laboratory biomarker analysis|Correlative studies
215063988|NCT01270880|GENETIC|polymerase chain reaction|Correlative studies
215063989|NCT01270880|OTHER|enzyme-linked immunosorbent assay|Correlative studies
215063990|NCT01270880|GENETIC|RNA analysis|Correlative studies
214485438|NCT06740669|BEHAVIORAL|Those who are applied expressive touch|Expressive touch does not require any preparation other than warming the hands to the same temperature as the body temperature. During expressive touch practice; the parts of the body that are touched the most are the hands, arms, forehead, hair and shoulders. The hands are massaged during the touch and the arms and shoulders are lightly touched before and after the massage, so that the expressive touch made on the hands is effective (Pinar and Demirel, 2021; Routasalo, 1999) After the evaluation, the researcher will apply expressive touch to one of the mother's hands for an average of 15-20 minutes
214485439|NCT06740669|BEHAVIORAL|Focus|. The researcher mother will be asked to focus on her baby for 10 minutes (Kiliçli Id and Zeyneloglu Id, 2024; Vamour et al., 2019).
214485440|NCT05252312|BEHAVIORAL|Psycho-acoustic tests|"Listeners' cognitive and biological responses to vocal stimuli will be tested using psycho-acoustic tests. After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?).~These stimuli might be human voices, animal voices or synthetic voices Physiological measures will be simultaneously taken using an array of complimentary, non-invasive techniques such as the Nociception Level (NOL) Index or video pupillometry"
214485441|NCT06739382|COMBINATION_PRODUCT|extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin.|In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin in group (A) of patients.
214485442|NCT06739382|COMBINATION_PRODUCT|two β-lactam antibiotics plus a single non-β-lactam antibiotic|In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to include two β-lactam antibiotics plus a single non-β-lactam antibiotic, or a combination of double β-lactam antibiotics, with the aim of avoiding aggressive and toxic antibiotics in group (B) of patients
214485443|NCT06739382|OTHER|Control group received standard therapy|Treatment was adjusted to the second-line empirical antibiotic according to the hospital's local policy.
214485444|NCT05317364|DRUG|Estradiol 0.01% Vag Cream|1g estradiol vaginal cream 0.01% or placebo will be administered nightly for 2 weeks then twice weekly to complete 6 months therapy
214485445|NCT05317364|DRUG|Placebo vaginal cream|Placebo cream
214485446|NCT06778200|OTHER|client interview|using a data collection form clients voluntarily described services provided by practitioner
214921938|NCT05169918|OTHER|Sensorial Discrimination Training|Training group will be participate in core stabilization exercises (as describe in Control Group). Additionally, Sensorial Discrimination Training (SDT) will be applied on the low back of the patients for 20 minutes before the 20 minutes of core stabilization exercises. SDT is defined as the ability to correctly interpret the characteristics of the stimulus made to a part of the body by the patient. It aims to reverse the cortical reorganization observed in patients with chronic pain. It consists of tactile localization and graphesthesia training, which includes determining the localization and type of stimulus and recognizing the letter/number that drawn in a body part, by the patient. The training consists of five stages progressively, each stage lasting two weeks. As the participants complete the sensory tests at each stage with 90% accuracy, the next stage will be passed. If this accuracy rate is not achieved within two weeks, the stage can be extended for one week.
214921939|NCT00824902|PROCEDURE|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
215063991|NCT01270880|OTHER|spectrophotometry|Correlative studies
215063992|NCT01270880|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
214672383|NCT01347164|BEHAVIORAL|HIV Counseling|Standard one-hour HIV counseling session
214672384|NCT02711371|OTHER|fMRI|
214322596|NCT01248858|DRUG|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
214485447|NCT06778200|OTHER|practitioner responses|completed reflections after each module completion
215063993|NCT01270880|GENETIC|gene expression analysis|Correlative studies
215063994|NCT04637724|DEVICE|transcranial direct current stimulation (tDCS)|10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
214485448|NCT06093438|DRUG|Toripalimab|Patients enrolled in this arm would receive three cycles of induction treatment before receiving definitive chemoradiotherapy. The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d. Patients would receive pelvic MRI to evaluate the regression status of tumor after three cycles of induction treatment. Patients with satisfying tumor regression would receive definitive chemoradiotherapy afterwards. During chemoradiotherapy, patients would receive weekly cisplatin (40mg/m2) and 240mg toripalimab every three weeks. After chemoradiotherapy, patients would receive another three cycles of consolidated treatment (regimen identical to induction treatment).
214485449|NCT06650995|OTHER|Exercise training|exercise intervention will consist of supervised, home-based, combined training with elements of endurance, resistance and respiratory training
215063995|NCT01740921|DRUG|Liraglutide|Administered once daily
215063996|NCT01740921|OTHER|diet|reduction of caloric intake to promote weight loss
214921940|NCT06630364|DRUG|ketamine|Induction: Sevoflurane in N2O/O2, Propofol (1-1.5 mg/kg) Analgesia: Ketamine (0.5 mg/kg) Maintenance: Sevoflurane
214921941|NCT06630364|DRUG|fentanyl|Induction: Sevoflurane in N2O/O2 Analgesia: Propofol (1-1.5 mg/kg), Fentanyl (1 µg/kg) Maintenance: Sevoflurane
215063997|NCT01740921|DRUG|Aspirin|300mg of Aspirin per day
214322597|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
214322598|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
214322599|NCT00477672|DRUG|Placebo|tablet, once daily by mouth, 6 weeks
214921942|NCT06569706|PROCEDURE|Nipple-Sparing Mastectomy, with immediate breast reconstruction|It is an endoscopic approach for mastectomy using an axillary single port
214485450|NCT06734910|BEHAVIORAL|HealthyPregnancy|"A digital care guide comprising of:~1. Information about diet, exercise and mental wellbeing in pregnancy. Presented in text, video and audio material featuring various healthcare professionals.~2. Online exercise. Access to live online structured physical exercise twice a week and to an off line library of exercise videos.~3. Chat function with possibility to chat safely with healthcare professionals.~4. Push-notifications reminding the participants of upcoming antenatal appointments.~In addition an invitation to monthly café sessions focusing on e.g., mental health, parenting skills, breastfeeding and healthy lifestyle."
214921943|NCT01094470|DEVICE|Body weight support system on ground level|Gait training with body weight support on ground level with sessions of 45 minutes, three times a week, on alternating day during six weeks, completing a total of 18 sessions.
214485451|NCT03800017|BIOLOGICAL|Hyperoxia|Participants breathe 60% oxygen during exercise
214485452|NCT06450314|DRUG|Discontinuation of the anti-HER2 maintenance therapy|Heroes is a de-escalation study. Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line setting for their HER2-positive metastatic breast cancer with complete response or partial response at last radiological assessment. Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study
214485453|NCT06450314|DEVICE|Monitoring with signatera test|"ctDNA test will be performed at 1.5 month after inclusion and every 3 months during 2 years.~Note: For the ctDNA negative patients who become ctDNA positive: ctDNA test will be performed once, 3 months after restarting treatment (+/-1 week)."
215063998|NCT00976716|DRUG|Celecoxib|"Day 1~* The first dose: Celecoxib 400mg~* The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~\- Celecoxib 200mg twice daily"
215063999|NCT02386787|DEVICE|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
215064000|NCT03459469|DRUG|Tegavivint|This is an Investigational drug
215064001|NCT04222699|DRUG|Mupirocin calcium ointment, 2%|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
215064002|NCT04222699|DRUG|Topical Chlorhexidine, 4%|"Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury."
215064003|NCT01474005|DEVICE|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
215064004|NCT01890590|DEVICE|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
214485454|NCT06741514|DEVICE|Precice IMLL|Parents or legal guardians of children that previously received the Precice IMLL will complete a survey. No additional or new interventions will be administered.
214485455|NCT06638645|PROCEDURE|VATS/RATS anatomical lung resection|Perioperative care according to the ERAS protocol for lung surgery
214672385|NCT00603044|DRUG|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
214672386|NCT00393458|DRUG|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
215064005|NCT05024253|DRUG|Tranexamic acid injection|. TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)
215064006|NCT05024253|OTHER|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
215064007|NCT03628105|BEHAVIORAL|CR Before Exposure|"Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger \& Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study."
215064008|NCT03628105|BEHAVIORAL|CR After Exposure|Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
215064009|NCT01679678|DEVICE|PolyHeal 2|PolyHeal is a sterile medical device
215064010|NCT01679678|DEVICE|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
215064011|NCT01606176|DRUG|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
215064012|NCT01606176|DRUG|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
215064013|NCT03780621|DIETARY_SUPPLEMENT|Andrographis and Withania|Combination of Andrographis paniculata and Withania somnifera
215064014|NCT03780621|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule
215064015|NCT01473199|DEVICE|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
215064016|NCT01832493|DEVICE|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
215064017|NCT00489320|DEVICE|Cypher Stent|
215064018|NCT05287958|DIAGNOSTIC_TEST|EIT|EIT comprises a chest belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. The chest belt captures EIT data, which is transmitted via the USB or Ethernet cable to the computer. Tomography-like impedance images of the lungs are computed and displayed on the computer. The impedance images will be used to evaluate lung recruitment and other pulmonary function parameters that are currently measured using standard-of-care PFT devices.
215064019|NCT03757624|PROCEDURE|shrinkage|shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
215064020|NCT02993822|DRUG|Orvepitant Maleate|Tablet, once daily, oral
215064021|NCT02993822|DRUG|Placebo|Tablet, once daily, oral
215064022|NCT01545791|DRUG|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
215064023|NCT05525130|DIETARY_SUPPLEMENT|Food supplement|FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
215064024|NCT05525130|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
215064025|NCT03702569|DIAGNOSTIC_TEST|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
215064026|NCT01732510|DRUG|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
215064027|NCT01732510|DRUG|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
215064028|NCT05535023|DRUG|SAR444245|Given by vein (IV)
215064029|NCT05535023|DRUG|Cemiplimab|Given by vein (IV)
215064030|NCT03874741|DRUG|SCT200|"Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200"
215064031|NCT01364454|OTHER|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
214322600|NCT03078946|DRUG|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
214322601|NCT03078946|DRUG|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
214322602|NCT05091905|DRUG|Continuous Infusion of ropivacaine 0.2%|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr popliteal-sciatic and 8 mL/hr infraclavicular, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
214322603|NCT05091905|DRUG|Titratable Automated Intermittent Boluses of ropivacaine 0.2%|"Patients will receive patient-titratable intermittent boluses of Ropivacaine 0.2% (8 mL popliteal-sciatic or 11 mL infraclavicular automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout). In addition, the infusion pump will be set in a pause mode that delays initiation of the automated bolus doses by 5 hours (this can be over-ridden by patients if they would like to initiate their perineural infusion earlier than 5 hours). Lastly, subjects will be able to titrate the volume of their automated bolus up or down within the range of 1-16 mL."
214322604|NCT06223594|OTHER|Intravenous Fluid Therapy|Evaluate the safety and efficacy of the Dallas acute pancreatitis protocol(DAPP) order set on Acute pancreatitis(AP) patients receiving aggressive, goal-directed Intravenous fluid(IVF )therapy.
214322605|NCT05981638|OTHER|group WM|Patients were given 5ml/kg dose of water and patients were mobilized.
214322606|NCT05981638|OTHER|group WR|Patients were given 5ml/kg dose of water and patients were rest.
214322607|NCT05981638|OTHER|Group AR|Patients were given 5ml/kg dose of apple juice and patients were rest.
214322608|NCT05981638|OTHER|Group AM|Patients were given 5ml/kg dose of apple juice and patients were mobilized.
214322609|NCT01398891|OTHER|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
214322610|NCT04427969|BEHAVIORAL|prone position|to lay in prone position at least 12 hour in a day at ICU
214322611|NCT06101979|DEVICE|Fortiva Tissue Matrix|Acellular Dermal Matrix used in hernia surgery
214322612|NCT05431088|DRUG|Osivelotor|Tablets which contain drug substance
215064032|NCT00313144|DRUG|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
215064033|NCT04463186|OTHER|Muscle Static Stretching|Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
215064034|NCT05183516|BIOLOGICAL|tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
215064035|NCT05734911|DRUG|Niraparib|We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
214672387|NCT00393458|DRUG|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
215064036|NCT04701606|DRUG|Artecom® (pyronaridine-artesunate)|"\* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)"
215064037|NCT04701606|DRUG|Placebo|"\* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)"
215064038|NCT05090163|OTHER|PREP Plus|Group based exercise in addition to PREP exercises
215064039|NCT05090163|OTHER|PREP|Group based exercise
215064040|NCT04971239|DRUG|topical methotrexate micoemulsion|The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
215064041|NCT04971239|DEVICE|Excimer light|the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
215064042|NCT04971239|DEVICE|Narrow band ultraviolet B|the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
215064043|NCT01221753|DRUG|docetaxel|
215064044|NCT01221753|DRUG|cisplatin|Given intravenously on day 1 of each cycle
215064045|NCT01221753|DRUG|5-FU|
215064046|NCT01221753|RADIATION|IMRT|
215064047|NCT01221753|DRUG|cetuximab|
215064048|NCT01221753|DRUG|carboplatin|
215064049|NCT04309851|DIAGNOSTIC_TEST|deep learning|the deep learning method is a field of study involving artificial neural networks and similar machine learning algorithms with many hidden layers.
215064050|NCT01628354|DRUG|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of \>5 letters or increase in retinal thickness of \>100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
215064051|NCT04183504|BEHAVIORAL|Brief parenting intervention|Coaching session on positive parenting practices and promoting child development
215064052|NCT04249297|DRUG|Duphaston® (Dydrogesteron)|No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
215064053|NCT00617058|DRUG|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
215064054|NCT00617058|BEHAVIORAL|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
215064055|NCT03071315|OTHER|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
215064056|NCT03071315|OTHER|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
214322613|NCT03841058|DRUG|Abaloparatide|80 mcg delivered SC by a pen
214322614|NCT03841058|DRUG|Placebo|A pen to deliver a SC dose of placebo
214322615|NCT01485523|OTHER|Nasal provocation test|"TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites."
214322616|NCT04233281|OTHER|Kori tofu|16.5 gram Kori-tofu mixed in a high carbohydrate test meal
214322617|NCT04233281|OTHER|Whey protein|high carbohydrate test meal with whey protein, matched in macronutrient content
214322618|NCT02460770|DRUG|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
214322619|NCT02800148|DRUG|Azelaic acid foam|
214322620|NCT02800148|DRUG|Azelaic acid foam|
214322621|NCT02800148|DRUG|Azelaic acid foam - Placebo|
214347517|NCT05234827|OTHER|Virtual Reality|Total time duration for session is 40 minutes which includes 5 min of warm exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 minutes of VR session and 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
214485456|NCT06742827|OTHER|educational intervention based on information and communication technologies.|will be carried out through a mobile application, which will be installed on each person's device, as well as short text messages will be sent and counseling will be available 24/7. The contents of the application will be educational and will be elaborated framed in the following components: understanding of the disease and the consequences of not adhering (comprehensibility) to the treatment, maintaining a balance between the psychosocial resources that the patient has and the demands that the disease places on them (manageability), and the involvement of the person in decision making and the sense of continuing to adhere to hemodialysis treatment (meaningfulness).
214485457|NCT06742320|BEHAVIORAL|Asthma education|There are very few studies examining the asthma knowledge level, quality of life and asthma control of children in Turkey.
214921944|NCT01547143|DRUG|IST and/or alloHCT|"1\) Patients will be categorized by their initial serum ferritin level.~1. Mild ( ferritin\<3,000 μg/L): close observation~2. Moderate (ferritin: 3,000-10,000 μg/L):~   1. Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)~  2. continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.~3. Severe (ferritin\>10,000 μg/L):~   1. initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)~  2. continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.~      2\) AlloHCT for refractory or reactivated cases."
214921945|NCT06041542|DIAGNOSTIC_TEST|10-second hand grip and release test|To grip and release hand in ten seconds
215064057|NCT00371215|BIOLOGICAL|rThrombin|1000 U/mL applied topically
215064058|NCT04142138|OTHER|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
214921946|NCT02810717|DEVICE|theta-burst stimulation using a MagPro X1000|TBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS over left DLPFC: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. Trains will be repeated 20 to reach a total number of 600 pulses per session. cTBS over right DLPFC: cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses per session. Two sessions per day, separated by 60 minutes; 30 Sessions in total over 3 weeks.
214921947|NCT02810717|DEVICE|sham stimulation using a MagPro X1000|Sham TBS with the coil set at 45° against the skull will be performed over left and right dorsolateral prefrontal cortex for a period of three weeks
215064059|NCT02810769|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
215064060|NCT02810769|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
215064061|NCT02810769|DIETARY_SUPPLEMENT|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
215064062|NCT04217811|OTHER|No intervention|No intervention
215064063|NCT06128889|BEHAVIORAL|Supporting Transition and Resilience to Clinical Nursing Education (STRONG) Program|The STRONG program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher. Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics. Overall, the program will be delivered over in one week lasting six hours.
215064064|NCT02083341|DEVICE|Lelo® Siri vibrator|external vibration device
215064065|NCT02083341|DEVICE|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
215064066|NCT02959853|DRUG|Anastrazole|
214485458|NCT06750393|OTHER|Barre exercise along with gym ball exercises|"The Barre exercises will be administer to the participant of Group A for a period of 3 month.~Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. Gym ball exercises program include Knee tucks, leg curls, back extension exercises"
214485459|NCT06750393|OTHER|Barre exercises|"The Barre exercises for a period of 3 month Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. During"
214485460|NCT06890663|OTHER|Nonspecific Hypnotherapy for Relaxation|A therapeutic technique that uses hypnosis for relaxation.
214485461|NCT06890663|OTHER|Gut-Directed Hypnotherapy (GDH)|A therapeutic technique that uses hypnosis and relaxation to help with gastrointestinal (GI) disorders.
214921948|NCT00585832|BEHAVIORAL|DASH-4-Teens|24-week behavioral nutrition intervention emphasizing a diet high in fruits, vegetables and low fat dairy foods and that is low in fat and sodium
215064067|NCT02959853|BEHAVIORAL|weight loss|
215064068|NCT06036602|BIOLOGICAL|cAD3-Sudan Ebolavirus Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
215064069|NCT06036602|OTHER|Placebo|0.9% NaCl solution for injection.
215064070|NCT01976546|DEVICE|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
215064071|NCT00197418|DRUG|rabeprazole, amoxicillin, clarithromycin, metronidazole|
215064072|NCT06045858|DRUG|Anticoagulation Agents|anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
215064073|NCT01262560|DRUG|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
215064074|NCT01262560|DRUG|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
214921949|NCT00585832|OTHER|Routine Care|individual in-person counseling sessions on guidelines consistent with the Fourth Pediatric Report of the National High Blood Pressure Education Program.
214921950|NCT04826965|DEVICE|Wound Vac is applied|A wound vac or wound vac with cleanse choice dressing, track pad duo, and saline irrigation is applied.
214921951|NCT05448963|DEVICE|da Vinci SPⓇ Single-port System|Nipple-sparing mastectomy with or without axillary lymph node dissection using da Vinci SP single-port system
214921952|NCT03477253|PROCEDURE|Laparoscopic cholecystectomy|The use of laparoscopic cholecystectomy in management of acute calculous cholecysitits
214921953|NCT01864070|OTHER|TheraSphere|TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
214921954|NCT01864070|DRUG|Everolimus|"Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.~Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort."
214921955|NCT01864070|OTHER|Phone Call|At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
214921956|NCT05007743|DEVICE|Transcutaneous vagus nerve stimulation|"Frequency of 30 Hz, biphasic, rectangular pulses with a pulse width of 250 µs and an intensity of 20 mA.~Device: Easy Tens+ device (body clock, London, UK)"
214921957|NCT02088671|DRUG|Propofol induction followed by randomized doses of desflurane|Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.
214921958|NCT02088671|DEVICE|Recording of EEG using NeuroSENSE|"The NeuroSENSE NS-701 system is a 2-channel device for brain activity monitoring in the operating room, intensive care unit, emergency room and other clinical settings. The system acquires and processes electroencephalograms (EEGs) via noninvasive electrodes placed on a patient's forehead. The acquired raw EEG signals and processed EEG variables are continuously displayed for interpretation by the clinician.~The proprietary processed variable, WAVcns, quantifies the patient's brain activity, which is typically affected by anesthetic drugs. The system displays processed variables based on 2 bilateral channels (1 per brain hemisphere) for use as a supplement to the anesthesia standard of care.~Note: the indications provided by the NeuroSENSE monitor are not used for anesthesia dosing or patient assessment in this study, and the anesthesia provider is blinded to the monitor readings. The device is used only for acquisition of EEG signals and may be used to log the events of interest."
215064075|NCT01262560|DRUG|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
215064076|NCT04182399|DRUG|Zonisamide Capsules|anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
215064077|NCT03213938|DEVICE|Acupuncture|"For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
215064078|NCT03213938|DEVICE|Sham acupuncture|"For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
215064079|NCT02665663|DEVICE|medical device|
215064080|NCT04368494|BEHAVIORAL|12-week home based exercise|Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
214485462|NCT06890663|OTHER|3-month Follow-Up|A 3-month follow is completed after both intervention phases (general hypnotherapy and Gut Directed Hypnotherapy) are completed for each participant.
214485463|NCT06744764|DEVICE|PEMF (1mT)|1mT of field strength will be given to patients/healthy volunteers for 10 minutes, twice per week for 4 consecutive weeks.
214485464|NCT06744764|DEVICE|PEMF (0mT)|Healthy volunteers will place their legs in the PEMF device, twice per week for 4 consecutive weeks. However, no magnetic stimulation will be given.
214485465|NCT06744803|BEHAVIORAL|Gamified Neuropathy Management Application on Cancer Behavior|"The study will be conducted in three phases:~Phase 1: The content of the gamified neuropathy management application used in the study will be prepared by the researchers using relevant literature.~Phase 2: The developed gamified neuropathy management application will be introduced to patients during one-on-one interviews at the daytime chemotherapy clinic. After collecting pre-test data, the application will be sent to the patients, who will be asked to use it for 8 weeks.~Phase 3: Following the start of the study's implementation, patients will be contacted in the 4th and 8th weeks to collect mid-study and post-test data."
214485466|NCT06740916|DRUG|81-mg aspirin once daily|81-mg aspirin once daily
214485467|NCT06740916|DRUG|81-mg aspirin twice daily|81-mg aspirin twice daily
214921959|NCT02088671|OTHER|Data collection|"Non-invasive blood pressure (BP), heart rate (HR), respiratory rate (RR) and electroencephalogram (EEG) will be recorded during the surgery in all subjects. Also, information about all medically significant events, all study-related events (incl. patient's reactions, responses, observations and assessments) and administered medications (incl. end-tidal (ET) desflurane concentration) will be recorded along with time stamps.~The anesthesia and physiological parameters (e.g., BP, HR, RR, ET agent concentration) outputted from the anesthesia monitor will be recorded electronically during the surgery by the anesthesia monitoring system (data-points will be recorded at least every 3 min for BP and every 10 sec for other variables).~The EEG signal will be continuously recorded by NeuroSENSE NS-701 Monitor (described under a separate intervention).~The CRC will also be present in the Operating Room (OR) to record and manage the recording of all the required information."
214921960|NCT02088671|OTHER|Drug: Emergence by stepping down the desflurane ET|Anesthesia will be reduced to facilitate rapid recovery at the discretion of the anesthesiologist, about 20 minutes before the end of surgery. The desflurane ET will be stepped down from 0.8 MAC by steps of 0.2 MAC approximately every 5 min during the Emergence.
215064081|NCT03026231|BIOLOGICAL|PRIM-DJ2727|Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
215064082|NCT03026231|DRUG|Placebo (for PRIM-DJ2727)|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
215064083|NCT01339819|DRUG|Dabigatran|Patients assigned to this group will receive Dabigatran
214921961|NCT01127451|DRUG|Denileukin diftitox|Denileukin diftitox intravenous infusion over 30-60 minutes.
214921962|NCT00660933|DRUG|Iron sucrose|Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.
214921963|NCT00660933|DRUG|NaCl|NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days
214672388|NCT00393458|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
214921964|NCT00930774|DEVICE|FM system|Frequency modulation assistive device
214921965|NCT00930774|BEHAVIORAL|Auditory training|Participation in computerized auditory training program for eight weeks
214921966|NCT03462394|OTHER|Current Script|This is the version of the phone call script currently used at NYU Langone Health.
214921967|NCT03462394|OTHER|Alternate Script Iterations|Intervention includes various iterations of the phone call script (different wording or script structure).
214921968|NCT03636724|BEHAVIORAL|E-intervention|The 10-week e-health intervention will target HAPA-based social-cognitive variables of PA and FVI. Particularly, Week 1: risk perception and outcome expectancies; Week 2: goal setting; Week 3: development of action plans; Week 4: revision and adjustment of previous action plans; Week 5: development of coping plans; Week 6: revision and adjustment of previous coping plans; Week 7: development of perceived social support; Week 8: revision and adjustment of previous social support. Week 9-10: self-monitoring. Self-efficacy will be a fixed intervention variable involved from week 2 to week 10. Additionally, some behaviour change techniques will be employed in the intervention in order to facilitate the implementation and maintenance of behaviour.
215064084|NCT01339819|DRUG|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
215064085|NCT01594723|DRUG|120 mg LY2784544|Administered orally
215064086|NCT05511610|PROCEDURE|Sevoflurane uptake and supply|"Phase sevo 1)~* Moment 1 (M1): from OTI until end-tidal sevoflurane (etSEVO%) exceeds ettSEVO% by 10%. Deliver of sevoflurane to the system (SEVOdel) carried out by completely opening sevoflurane vaporizer (8%).~* M2) once etSEVO% surpass ettSEVO% by 10%: turn off sevoflurane vaporizer and observe the progressive fall etSEVO%. When etSEVO% approaches ettSEVO% (0.1-0.2 points above ettSEVO%), the investigators will turn on the sevoflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of sevoflurane.~Phase sevo 2) Objective: to maintain etSEVO% = ettSEVO% ±5% When the etSEVO% increases above the mentioned levels \>\> reduce SEVOdel by 0.25-0.5%.~When the etSEVO% decreases below the mentioned levels\>\> increase SEVOdel by 0.25-0.5%."
215064087|NCT05511610|PROCEDURE|Washout phase|The investigators will close the sevoflurane vaporizer and will start the administration of Propofol in intravenous perfusion; the investigators will then open the FGF sequentially at 2\>5\>10 liters per minute (LPM), until the etSEVO% is \<0.2 MAC.
215064088|NCT05511610|PROCEDURE|Desflurane uptake and supply|"Phase desflu 1)~* Moment 1 (M1): from the end of Washout phase until end-tidal desflurane (etDESFLU%) exceeds ettDESFLU% by 10%. Deliver of desflurane to the system (DESFLUdel) carried out by completely opening the desflurane vaporizer (18%).~* M2) once etDESFLU% surpass ettDESFLU% by 20%: turn off the desflurane vaporizer and observe the progressive fall etDESFLU%. When etDESFLU% approaches ettDESFLU% (0.8-1.2 points above ettDESFLU%), the investigators will turn on the desflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of desflurane.~Phase desflu 2) Objective: to maintain etDESFLU% = ettDESFLU% ±5% When the etDESFLU% increases above the mentioned levels \>\> reduce DESFLUdel by 0.25-0.5%.~When the etDESFLU% decreases below the mentioned levels\>\> increase DESFLUdel by 0.25-0.5%."
214485468|NCT06737965|OTHER|Medical abortion|"Medical abortion performed according to standard practice with cord blood sample (1 to 10ml) collected on EDTA tube before injection of foeto toxic agent.~EDTA tube transfered to laboratory on ambient temperature. Blood sample will be centrifuged to isolate the extracellular vesicles once in the laboratory."
214485469|NCT06737965|OTHER|Foetopathology exam|"Foetopathology exam is performed according to standard practice on the day after abortion (H12 to H48 from foetus death).~Investigator will recover 2 horizontal slices (in line with the heart) between 3 and 5 mm thick, including the right and left ventricles put them in a cold physiological saline solution, and transfer them rapidly to the laboratory.~Investigator will also recover segments of the descending aorta (approximately 2cm, between the ductus arteriosus and the celiac trunk) and the left renal artery. The isolated segments will be separated from the fat and connective tissue by the foetopathology team and put in a cold physiological saline solution."
214485470|NCT06737965|OTHER|Outcomes mesurement|"* From the myocardial samples, 10 µm thick sections will be prepared and slides will be incubated with antibodies directed against proteins of interest (adrenergic receptors, protein kinase A, ryanodine receptor, PDE3, troponin). After washing, fluorescent secondary antibodies will be used and slides will be observed under a fluorescence microscope. Rest of the cardiac tissue will be frozen in liquid nitrogen in order to perform Western blots.~* Vessel samples will be put in a myograph to study contractile function. Concentration-response curves will be constructed by cumulative application of noradrenaline or U46619. For the study of endothelial function, arteries with and without functional endothelium will be pre-contracted to 80% of maximal contraction with U46619. When contraction reaches a plate, cumulative addition of different vasodilating agents will be performed. The vessels will also be cannulated on an arteriograph to assess dilation in response to flow and myogenic tone."
214921969|NCT03428672|PROCEDURE|total hip arthroplasty|Bone samples from Hip fracture were collected from the femoral head which has been replaced
214485471|NCT06739265|DRUG|Golidocitinib plus CHOP|Phase 1: dose escalation phase. Drug Golidocitinib: 2 dose level of 150 mg qod and 150 mg qd; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle. Phase 2: dose expansion phase. Drug Golidocitinib: RP2D established in the phase I study; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle.
214921970|NCT03996174|OTHER|Interview|Interview bases on the use of an interview guide, during one hour maximum
214485472|NCT06740448|DIETARY_SUPPLEMENT|Green Tea|200 mL Green Tea
214485473|NCT06740448|DIETARY_SUPPLEMENT|Control (Hot Water)|200 mL hot water
214485474|NCT06737666|DRUG|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang granules were taken 2 bags at a time, 2 times per day at 1h after meal for 4 weeks.
214672389|NCT00393458|DRUG|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
214672390|NCT06346795|OTHER|High-filling flowable dental composite|Class II restorations will be performed with G-aenial Universal Injectable, Grandio Flow, and Clearfil Majesty Flow high-filling flowable composites.
214921971|NCT06668415|PROCEDURE|Hydro dilation|The hydro dilation injections comprises of Depomedrol 80mg and normal saline 0.9%. It is performed under fluoroscopic guidance by the orthopedic surgeon.
214921972|NCT06668415|PROCEDURE|Spencer muscle energy technique|Spencer muscle energy technique is a seven 7 step procedure which consists of shoulder extension with elbow flexed, shoulder flexion with elbow flexed, circumduction with compression, circumduction with traction, Abduction then adduction with external rotation and glenohumeral pump. Following the complete action, patients will be encouraged to use their muscles for 3 to 5 seconds against little resistance provided by the therapist
214921973|NCT06668415|PROCEDURE|Passive Stretching|The low intensity stretches will be given in supine for all the movements ie Flexion ,Abduction , Internal Rotation and External Rotation for 5 repititions with 30 sec hold.
215064089|NCT05511610|PROCEDURE|Final phase|"From the end of Phase desflu 2 until the end of the intervention. Maintenance of anesthesia with desflurane following the principles of MAAS Method.~Between 15-20 minutes before the end of the intervention, the investigators will stop the administration of desflurane, registering the time until the reaching etDESFLU% \< 0.2 MAC."
215064090|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection|Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
214921974|NCT06100263|OTHER|Individualized exercise program|guided exercise program for 12 weeks
215064091|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection|intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
215064092|NCT04837885|DRUG|LUTATHERA® by intra-arterial hepatic (IAH) injection|One treatment dose of LUTATHERA® by IAH injection. The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations
215064093|NCT04837885|PROCEDURE|Scan|Scans after completion of LUTATHERA® treatment injection
215064094|NCT06632587|PROCEDURE|Early cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Early cranioplasty is defined as being performed within 8 weeks following the decompressive hemicraniectomy.
214485475|NCT06736665|DEVICE|Orbital atherectomy|The Diamondback-360 (OAS) (Abbott) device is used to perform this technique, consisting of a bidirectional, diamond-coated orbital crown that utilizes a combination of centrifugal force (creating elliptical orbits) and surface abrasion to modify the calcified plaque and increase distensibility. Additionally, the pulsatile impact of the crown at high speed can create microfractures in deep calcium. As a result, a single 1.25 mm crown can treat vessels ranging from 2.5 to 4 mm in diameter.
214485476|NCT06736665|DEVICE|Intravascular lithotripsy|The Shockwave Medical Intravascular Lithotripsy System (Shockwave Medical) is a balloon that emits pulsatile sonic waves capable of fracturing intracoronary calcium. This therapy is administered by advancing a catheter and inflating the balloon at low pressure to deliver sonic pulses.
214485477|NCT06736665|DEVICE|Optical Coherence Tomography (OCT)|"Optical Coherence Tomography (OCT) is an intravascular imaging modality that uses near-infrared light to provide high-definition, cross-sectional and three-dimensional images of the vessel microstructure.~These images provide additional information on the degree and characteristics of coronary artery disease compared to angiography which doesn't delineate the composition of the coronary artery. With automated, highly accurate measurements, OCT can guide stent selection, placement, and deployment."
214485478|NCT06736665|DEVICE|Percutaneous coronary intervention with stent implantation|All patients will undergo percutaneous coronary intervention with drug-eluting stent implantation after plaque modification using the technique assigned by randomization.
214485479|NCT06737757|DEVICE|Artificial polymer heart valves|The experimental group will use polymer material surgical aortic valves(PoliaValve, Hearthill Medical) for aortic valve replacement
214485480|NCT06737757|DEVICE|Bovine pericardial aortic valve|The control group will undergo aortic valve replacement using bovine pericardial aortic valve
214485481|NCT06738420|DIETARY_SUPPLEMENT|ABB S3|Postbiotic ABB S3 for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
214485482|NCT06738420|DIETARY_SUPPLEMENT|ABB C22|Oral Rehydration Solution containing postbiotics ABB C22 for the management of diarrhoea signs of dehydration
214485483|NCT06738420|DIETARY_SUPPLEMENT|Placebo|Placebo for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
214485484|NCT06738420|DIETARY_SUPPLEMENT|Placebo|Oral Rehydration Solution containing placebo for the management of diarrhoea signs of dehydration
214485485|NCT06739694|BEHAVIORAL|PNE|A manual therapy(Mulligan´s Mobilization with Movement) and 4 sessions of strenght exercises program was administered for both groups. In addition, a pain neuroscience education protocol was administered for the experimental group for a whole period of 4 weeks (1 session/week, 75mins per session).
214485486|NCT06739694|PROCEDURE|Manual therapy|5 sessions of Mulligan´s Mobilization with Movement and 4 sessions of strenght exercises
214485487|NCT06869304|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Preoperative and postoperative MoCA test scores
214485488|NCT06251245|PROCEDURE|Oral Injector|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* • Experimental Group (Giving the medicine orally to the child with an Oral Injector)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
214485489|NCT06251245|PROCEDURE|Spoon|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* Control Group (Giving the medicine orally to the child with an oral medication spoon)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
214485490|NCT06734598|DRUG|Echo-guided Botox injection|Echo-guided Botox injection to the masticatory muscles
214921975|NCT06100263|OTHER|Control Arm|American Cancer Society Physical Activity and the Person with Cancer summary for patients will be provided
214921976|NCT01496963|OTHER|Physician standard-of-care according to ESC/ERS Guidelines|Physician standard-of-care
214921977|NCT05911048|BIOLOGICAL|Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)|boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
214921978|NCT05911048|BIOLOGICAL|Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)|boost with Recombinant COVID-19 vaccine (Sf9 Cell) (WSK-V101)
214921979|NCT01726725|DRUG|desflurane|
214921980|NCT02818985|DRUG|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
214921981|NCT02818985|DRUG|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
214921982|NCT02818985|DRUG|Saline|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
214921983|NCT06364501|DRUG|KH801|KH801 is an injection solution
214921984|NCT06641193|DEVICE|high frequency-repetitive transcranial magnetic stimulation|rTMS involves the repeated application of magnetic pulses to specific areas of the brain. These pulses are delivered using a coil placed on the scalp, which generates a magnetic field that induces electrical currents in the brain tissue.
215064095|NCT06632587|PROCEDURE|Standard-of-care cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Standard-of-care cranioplasty is defined as being performed after 3 months following the decompressive hemicraniectomy.
215064096|NCT04238481|DRUG|Pudexacianinium chloride|Intravenous
215064097|NCT05596461|DEVICE|Transcranial magnetic stimulation|Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.
214485491|NCT06734598|PROCEDURE|echo-guided normal saline injection|echo-guided normal saline injection
214485492|NCT06735794|DEVICE|Compressed iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-30 and Pre-15). Participants will then complete iTBS-c (active comparator), which will be delivered unilaterally to the left motor cortex. Following iTBS-c, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right APB, ADM, and FDI muscles to assess the effects of the stimulation.~The MCF-B65, MCF-P-B65, and/or Cool-B65 A/P TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
214485493|NCT06735794|DEVICE|Spaced iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-30 and Pre-15). Participants will then complete iTBS-s (experimental study intervention), which will be delivered unilaterally to the left motor cortex. Following iTBS-s, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right APB, ADM, and FDI muscles to assess the effects of the stimulation.~The MCF-B65, MCF-P-B65, and/or Cool-B65 A/P TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
214485494|NCT06735794|DEVICE|Sham iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-30 and Pre-15). Participants will then complete iTBS-sh (sham comparator), which will be delivered unilaterally to the left motor cortex. Following iTBS-sh, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right APB, ADM, and FDI muscles to assess the effects of the stimulation.~The MCF-B65, MCF-P-B65, and/or Cool-B65 A/P TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
214485495|NCT06734650|OTHER|peripheral waveform collection|The peripheral venous pressure waveform is collected by connecting a pressure transducer that is currently in use to the placed central venous line. In addition, the pulse pressure variation or stroke volume variation value that can be obtained from the arterial catheter. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithm' study (B-2202-738-401).
215064098|NCT05596461|DEVICE|Transcranial direct current stimulation|Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
215064099|NCT02270528|BEHAVIORAL|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (\~5 minutes)
215064100|NCT02270528|BEHAVIORAL|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
215064101|NCT03815149|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|Neurointerventional procedures to treat intracranial (cerebral) aneurysms are minimally-invasive procedures performed by Interventional Neuroradiologists. The physician accesses the arterial system through a blood vessel in the groin followed by the insertion of a catheter. Pipeline™ Flex Embolization Device(s) with Shield Technology™,a flow diversion device, is implanted under high-magnification subtraction fluoroscopy, requiring the use of ancillary devices, such as micro-catheters and guidewires to complete the procedure under general anaesthetic. Procedural heparinisation and preloading with dual antiplatelet therapy (DAPT) using acetyl-salicylic acid and P2Y12 inhibitors such as clopidogrel or prasugrel are required.
215064102|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
215064103|NCT00673231|DRUG|Dapagliflozin|Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
214485496|NCT06734572|DRUG|18F-FAPIBiotin|The dose will be 148-296 MBq given intravenously.
214672391|NCT06143384|DEVICE|Telemonitoring AirView (ResMed company)|Introduction of AirView telemonitoring of HMV, during a 6-months period.
214672392|NCT05612997|OTHER|Dietary Assessment|Food Frequency Questionnaire and 24h Recalls.
215064104|NCT00673231|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
215064105|NCT00673231|DRUG|Placebo|Placebo
215064106|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
214322622|NCT02403245|OTHER|Psychosocial stimulation|"Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music."
214322623|NCT02264002|DRUG|Cilobradine low dose 1|
214322624|NCT02264002|DRUG|Cilobradine low dose 2|
214322625|NCT02264002|DRUG|Cilobradine medium dose|
214322626|NCT02264002|DRUG|Cilobradine high dose 1|
214322627|NCT02264002|DRUG|Cilobradine high dose 2|
214322628|NCT02264002|DRUG|Metoprolol succinate tablets|
214322629|NCT02264002|DRUG|Placebo|
214485497|NCT06735586|PROCEDURE|neuromuscular control exercise|All of the 17 participants participating in the study will be included in the 6-week exercise program investigators created after the initial evaluations. Exercises will be done 3 times a week, 10 sets of each exercise. And the participants will be given a rest period of 3 minutes between each set.1st and 2nd (5 times) week exercise program: Non-weight bearing exercises will be given in the first week; lateral hip abduction, clam shell exercises, and bridging exercises. 3rd and 4th week (5 times) exercises: This week investigators will give controlled weight lifting exercises:pelvic drop exercise, single leg squat exercise,step down exercise,single leg raise exercise. 4th and 5 th week exercise: lateral band walks, side lunges, forward lunges, and back lunges. 5 th and 6 th week exercise: Plyometric exercises: jump exercise, BOSU single knee scales exercise,resistive single leg squats,resisting vertical bridge.
214485498|NCT06735586|PROCEDURE|neuromuscular control exercise and taping|Exercises and taping will be done 3 times a week, 10 sets of each exercise. Mulligan Knee Taping Application: The application was made with Protape 38mm x 10 m rigid tape. The application will be performed in the participant's foot, with the hip and knee in internal rotation, and the knee in 20º flexion. The tape will be applied starting from the head of the fibula, passing over the tibia anteriorly, passing under the medial joint line of the knee and ending at the back of the knee, bringing the tibia to internal rotation.
214322630|NCT02723149|BEHAVIORAL|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
214322631|NCT01121692|BEHAVIORAL|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
214485499|NCT06742099|PROCEDURE|Intercostal chest tube|the use of chest tubes to drain malignant pleural effusion
214485500|NCT06742099|COMBINATION_PRODUCT|Pleurodesis|the injection of Talc in pleural space to induce inflammation reaction and produce pleurodesis
214485501|NCT06741696|PROCEDURE|Surgical extraction|saline irrigation at different temperatures
214485502|NCT06741696|PROCEDURE|saline irrigations|saline irrigation done after 3rd molar surgery
214485503|NCT06743048|PROCEDURE|Tissue Sparing Laser Implantation|A penile implant will be implanted using the cavernosal sparing technique and assisted by a laser fibre optic
214485504|NCT06742892|DRUG|HLX43 DOSE 1|Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214485505|NCT06742892|DRUG|HLX43 DOSE 2|Dose 2; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214485506|NCT06742892|DRUG|HLX43 DOSE 3|Dose 3; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214921985|NCT06641193|DEVICE|sham stimulation|The sham group receives 10 sessions of rTMS stimulation with a sham stimulation coil, which emits the same sound and vibration as the active coil but does not produce any induced electrical currents.
214921986|NCT02149446|DEVICE|Surgisis (C-SLRA-ECH60) made by COOK Medical|Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
214921987|NCT04296825|DIETARY_SUPPLEMENT|Camel milk containing Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
214921988|NCT04296825|DIETARY_SUPPLEMENT|Camel milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
214921989|NCT04296825|DIETARY_SUPPLEMENT|Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
214921990|NCT04296825|DIETARY_SUPPLEMENT|Cow milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
214921991|NCT06646822|OTHER|questionnaire|observational study
214921992|NCT03727152|DRUG|generic single tablet TAF/FTC/DTG|HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
214921993|NCT05045079|PROCEDURE|Inferior Vena Caval (IVC) Occlusion maneuver|During standard of care right heart catheterization (RHC), a second catheter will be inserted next to the catheter that was placed for the RHC in the jugular vein or femoral vein to assess the degree of pericardial restraint from the severe tricuspid regurgitation that may increase left sided filling pressures.
214485507|NCT06743763|BEHAVIORAL|fNIRS-based neurofeedback|fNIRS-based neurofeedback is provided during a simulated classroom scenario where the child participants are asked to learn to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
214485508|NCT06743763|BEHAVIORAL|Virtual Reality Simulated Classroom|A simulated classroom scenario is integrated in VR setting and children are asked to complete academic tasks in the simulated classroom.
215064107|NCT00673231|DRUG|Dapagliflozin|tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
215064108|NCT01279291|BIOLOGICAL|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
215064109|NCT01279291|DRUG|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
215064110|NCT01279291|DRUG|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
215064111|NCT01279291|DRUG|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
214485509|NCT06744660|DIAGNOSTIC_TEST|Aptitude Medical Systems Metrix COVID Test|The Metrix COVID Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2 via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
214485510|NCT06738992|DRUG|Aspirin|Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg once daily.
215064112|NCT04061824|DRUG|Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))|In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
215064113|NCT04061824|DRUG|Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)|In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
215064114|NCT06170190|BIOLOGICAL|IBI133|"IBI133:~The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the course of the study. Q3W"
215064115|NCT03594747|DRUG|Tislelizumab|Administered intravenously as described
215064116|NCT03594747|DRUG|Paclitaxel|Administered intravenously as described
215064117|NCT03594747|DRUG|Nab-paclitaxel|Administered intravenously as described
214485511|NCT06738992|DRUG|Warfarin|Anticoagulation therapy was initiated on the second day after surgery, starting at 4.5 mg once nightly, with adjustments made based on changes in the INR value.
214485512|NCT06740201|DRUG|Cipepofol|Adjust plasma target-controlled concentration
214485513|NCT06739629|OTHER|Insect porridge|Yellow mealworm porridge
214485514|NCT06739629|OTHER|Maize Porridge|Maize porridge
214485515|NCT06737068|PROCEDURE|Low pressure pneumoperitoneum (8-10mmHg) with AirSeal device|Elective robot assisted hiatal hernia repair with low pressure pneumoperitoneum (8-10mmHg) with AirSeal device
214485516|NCT06737068|PROCEDURE|Standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device|Elective robot assisted hiatal hernia repair with standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device
214485517|NCT06740604|DEVICE|BSD-10CH|The BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
214485518|NCT06740604|DEVICE|Sham BSD-10CH|The Sham BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
214485519|NCT06736145|OTHER|Traditional Physical Therapy|"Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week~Total of 9 sessions were given each consisting of 40 mins."
214485520|NCT06736145|OTHER|Mulligan Glides|"Natural Apophyseal Glides of Cervical spine are given 3 repetitions x 3-6 sets, 3 days/week.~Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week~Total of 9 sessions were given each consisting of 40 mins."
214485521|NCT06735313|DIAGNOSTIC_TEST|Periodontal examination and saliva collection|Before the periodontal examination, saliva samples are collected from each patient participating in the study and periodontal measurements are made.
214672393|NCT02803502|DEVICE|Chronometric method|Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)
214672394|NCT02803502|DEVICE|Chromogenic method|"Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)"
215064118|NCT03594747|DRUG|Carboplatin|Administered intravenously as described
215064119|NCT05882045|DRUG|Retatrutide|Administered SC
215064120|NCT05882045|DRUG|Placebo|Administered SC
215064121|NCT04734860|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
215064122|NCT04734860|DRUG|Placebo|Diluent solution
215064123|NCT01396590|DRUG|Perampanel|6 x 2 mg perampanel once per day
215064124|NCT01396590|DRUG|Perampanel|12 mg perampanel once per day
215064125|NCT04406207|OTHER|Demonstration of T cell responses|"Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest."
215064126|NCT00500461|DRUG|GSK233705|GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
215064127|NCT01310946|OTHER|Database|Database
214672395|NCT02803502|DEVICE|Thrombin generation test (TGT)|"Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used."
215064128|NCT05748509|OTHER|Surface EMG activations|We will try to find out which of the exercises such as pressing the back back, waist extension on the balance ball, lumbar extension in the active prone position, Superman exercises have better lumbar extensor muscle activations. Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
215064129|NCT01925040|DEVICE|Placement of restoration|Placement of restorations
215064130|NCT05107011|DRUG|LBL-015 for Injections|Initial dose - MTD ; Q2W ; intravenous infusion
215064131|NCT06563466|OTHER|The experimental intervention PEGASUS|See arm description.
215064132|NCT06563466|OTHER|Treatment as usual|See arm description
214322632|NCT01121692|BEHAVIORAL|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
215064133|NCT05779241|DRUG|LYN-005|Risperidone long-acting oral capsule
215064134|NCT05779241|DRUG|Risperidone|Risperidone immediate release (IR) oral tablets
215064135|NCT06031285|DRUG|Sintilimab|sintilimab (200 mg intravenous infusion), a bevacizumab biosimilar (15 mg/kg intravenous infusion), and TACE-HAIC (c-TACE, FOLFOX-based HAIC).
215064136|NCT00412295|DEVICE|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
215064137|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
215064138|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
215064139|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
215064140|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
215064141|NCT03669757|DRUG|LEO 134310 vehicle|Active substance: none
215064142|NCT03669757|DRUG|0.1% betamethasone valerate ointment (class III steroid)|Active substance: betamethasone valerate
215064143|NCT02644369|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
215064144|NCT03657784|DRUG|P03277|Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
215064145|NCT01557101|PROCEDURE|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
215064146|NCT01557101|PROCEDURE|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
215064147|NCT03254706|OTHER|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
215064148|NCT03254706|OTHER|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
214322633|NCT01121692|BEHAVIORAL|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
215064149|NCT03254706|OTHER|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
215064150|NCT03254706|OTHER|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
215064151|NCT02740062|DEVICE|NIBS system for evaluation and non invasive current stimulation|
215064152|NCT02082080|OTHER|Education|
215064153|NCT02082080|OTHER|Social support|
215064154|NCT06375473|DRUG|Irinotecan liposome II combination therapy regimen|Irinotecan liposome II combination therapy regimen
215064155|NCT05361720|DRUG|Cabozantinib|Given PO
214322634|NCT04488965|OTHER|Autologous transplant|Autologous transplant obtained from cortical biopsy
214672396|NCT00964418|DRUG|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
214672397|NCT00964418|DRUG|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
214672398|NCT02509546|DRUG|8-Chloroadenosine|Given IV
214672399|NCT02509546|OTHER|Laboratory Biomarker Analysis|Correlative studies
214672400|NCT02509546|OTHER|Pharmacological Study|Correlative studies
215064156|NCT05361720|BIOLOGICAL|Ipilimumab|Given IV
215064157|NCT05361720|BIOLOGICAL|Nivolumab|Given IV
215064158|NCT03533439|DIAGNOSTIC_TEST|Near infrared spectroscopy|Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management
215064159|NCT02199093|OTHER|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
214322635|NCT06028945|DEVICE|HMD: Virtual Reality Exposure Therapy|The virtual reality exposure therapy uses 360-degree videos delivered through a head mounted display (HMD). Participants will be matched with one of three available exposure hierarchies: Social Party Scenario, Subway Scenario, or Shopping Mall Scenario. Each hierarchy comprises seven 5-min scenes ordered in increasing intensity (from low to high anxiety). Participants are gradually exposed to scenes, viewed twice per day for up to 10 days, while rating their anxiety immediately before and after the exposures. Anxiety ratings will inform when participants may advance to the next level intensity in the exposure hierarchy.
214322636|NCT06028945|DEVICE|HMD: Neutral Game|The neutral game is a virtual-reality based game that is not designed to provoke anxiety. Participants assigned to the neutral game will play for 5 minutes twice per day for up to 10 days.
214322637|NCT06016634|DRUG|Alendronate Sodium|Administer oral alendronate 70 mg once a week x 24 weeks to all study participants
214322638|NCT01938274|OTHER|Educational intervention|A 30-minute discussion and slide presentation with a trained member of the research team.
215064160|NCT02199093|OTHER|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
215064161|NCT04304053|DRUG|Treatment and prophylaxis|"Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7."
215064162|NCT04304053|OTHER|Standard Public Health measures|Isolation of patient and contact tracing as per national guidelines.
215064163|NCT01063062|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
215064164|NCT01063062|DRUG|Methotrexate|methotrexate as per standard of care in clinical practice.
215064165|NCT03009162|DRUG|Lasmiditan|200 mg, single oral tablet
214322639|NCT02480556|PROCEDURE|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction \& cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
214485522|NCT06735157|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (intermittent theta burst stimulation) will be delivered using a Magstim Rapid 2 stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby iTBS will be delivered three times during the same study session. Each iTBS session will deliver 600 pulses in 50 Hz bursts of 3 pulses for a total of 1800 pulses delivered each day. iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.
214485523|NCT06735157|BEHAVIORAL|Augmented reality vestibular rehabilitation therapy|Participants will complete the vestibular training through Nreal Air AR Glasses (Nreal, China). The vestibular training task was custom-made in Unity V2021.3.14fI software using C+ script language. Participants will be standing upright for the AR training, with a safety bar positioned directly in front of them should they need to hold onto something. A large cross-shaped target will be positioned approximately 3 feet in front of the participant's head with its vertical center aligned with the participant's midline. This will act as a visual starting point. The training is adapted from clinical vestibular rehabilitation training methods used in PCD. The vestibular training task consists of locating and tracking a series of moving 3-dimensional balls presented at random within the participant's field of view.
214485524|NCT06735157|DEVICE|SHAM repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be delivered using a Magstim Rapid 2 sham stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of sham stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby sham iTBS will be delivered three times during the same study session. Each sham iTBS session will sound and feel identical to real iTBS delivery, but will not deliver a stimulating current. Sham iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Sham stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of sham iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.
215064166|NCT05792007|PROCEDURE|Biological sampling in patients|blood and bone marrow samples from patients with Acute Leulemia.
215064167|NCT05792007|PROCEDURE|Biological sampling in control patients|blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
215064168|NCT01328028|OTHER|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
215064169|NCT01328028|OTHER|Data collection|Log sheet
215064170|NCT01790646|OTHER|intubation|intubation using Glidescope videolaryngoscope
215064171|NCT03137680|BEHAVIORAL|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
215064172|NCT00136695|DRUG|anastrozole|1 mg QD
215064173|NCT02337101|OTHER|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
214322640|NCT02480556|PROCEDURE|Conservative separation of placenta|"Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu \& uterus is massaged awaiting spontaneous placental separation"
214322641|NCT00110058|BIOLOGICAL|recombinant interferon alfa|
214322642|NCT00110058|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215064174|NCT02337101|BEHAVIORAL|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
214921994|NCT06682390|BEHAVIORAL|Hypocaloric anti-inflammatory diet|The anti-inflammatory hypocaloric diet combines the exclusion of pro- inflammatory constituents and inclusion of anti-inflammatory nutrients. Excluded food items will be refined carbohydrates, soda and alcoholic beverages, ultra- processed foods, smoked foods, fatty foods, packaged foods, canned products, preservatives, emulsifiers, and sauces. Reduce or eliminate red/processed meats. Included food items will be a defined minimum diversity of fruits, vegetables, and nuts based on complementary phytonutrient contents, particularly those rich in phenolic compounds such as ellagitannins and sulforaphanes. Selected herbs (e.g., turmeric, ginger, garlic, black pepper, rosemary, cardamon, cinnamon), green tea, fermented foods, fats (e.g., avocado), and oils (e.g., olive oil) will be encouraged. The goal is to have 5 servings of vegetables, 2 fruits per day, and 5 vegetable color groups per week. Participants will also be asked to reduce their kcal by 500/day and walk for 1 gr 3x per week.
214921995|NCT04198038|BEHAVIORAL|Songwriting with licensed music therapist|Song selected by parent-child dyad with recordings of physiologic components (i.e. heartbeat, breathing)
214921996|NCT04128254|DRUG|Apixaban Oral Tablet|Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism
214921997|NCT01663090|DRUG|Ferumoxytol|
214921998|NCT06104761|OTHER|Release group|i will make release for these muscles ( upper trapizius , levator scapulae , strenomastoid ) in addition to sub occipital fascia , then I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
214921999|NCT06104761|OTHER|strength exercises and stretching for upper crossed syndrome|I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
214922000|NCT04443075|DEVICE|faecal sample collector|The frontline medical workers mainly exposed under the stress of fighting against 2019-nCoV
214922001|NCT03119675|DEVICE|GoCheck Kids (iOS)|Photorefraction method is used to screen amblyopia risk factors.
214922002|NCT03119675|DEVICE|GoCheck Kids (Windows)|Photorefraction method is used to screen amblyopia risk factors.
215064175|NCT04635709|DEVICE|biofeedback training and interferential therapy|compare the effect of applying both types of devices on the pelvic floor muscles
215064176|NCT03968029|PROCEDURE|suturing meniscal augmented|meniscal tear sutured + bone marrow injection/collagen membrane
215064177|NCT03968029|PROCEDURE|suturing meniscal|meniscal tear sutured
215064178|NCT02782351|BIOLOGICAL|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
215064179|NCT02015481|DRUG|Cabaletta|
215064180|NCT02485639|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants received vaccine intramuscularly (IM) on Day 0.
215064181|NCT01480583|DRUG|GRN1005|550 mg/m2 IV every 3 weeks
215064182|NCT01480583|DRUG|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
215064183|NCT01480583|DRUG|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
215064184|NCT01457404|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
215064185|NCT01457404|BEHAVIORAL|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
214322643|NCT00110058|DRUG|cyclosporine|
214322644|NCT00110058|DRUG|fludarabine phosphate|
214322645|NCT00110058|DRUG|imatinib mesylate|
215064186|NCT04538300|DIAGNOSTIC_TEST|Abramowitz Emesis Score|Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.
215064187|NCT04538300|DIAGNOSTIC_TEST|Degree of nausea|Degree of postoperative nausea was evaluated.
215064188|NCT04538300|DIAGNOSTIC_TEST|Observer's Assessment of Alertness/Sedation Scale|Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
215064189|NCT04538300|DIAGNOSTIC_TEST|Patient Satisfaction|Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
214322646|NCT00110058|DRUG|mycophenolate mofetil|
214672401|NCT03879590|DRUG|Doxophylline|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
214322647|NCT00110058|PROCEDURE|peripheral blood stem cell transplantation|
214322648|NCT00110058|RADIATION|radiation therapy|
214322649|NCT00925483|PROCEDURE|dialysis|different dialysis schedules for each arm
214322650|NCT00208195|DRUG|Divalproex ER|
214322651|NCT03810274|DEVICE|3DV+TPS；VARIAN TPS；FonicsPlan|
214322652|NCT03322228|OTHER|Music Therapy|Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
214322653|NCT01467999|DRUG|Guanfacine|Guanfacine, 4mg given once daily
214322654|NCT00605046|DRUG|SPECT scan|AV151-01: Evaluation of \[123I\] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
214322655|NCT02787473|DRUG|pemetrexed|Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles
215064190|NCT04538300|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
215064191|NCT04538300|OTHER|Chewing Peppermint gum|Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
215064192|NCT06139614|BEHAVIORAL|PERSIST|PERSIST is adapted from empirically validated treatment of negative affect and low positive emotion. Skills Training 1 includes content across 4 sessions on 1) understanding emotions, 2) present-moment emotional awareness, 3) cognitive flexibility, and 4) countering avoidant and emotion-driven responses. Skills Training 2 includes content across 4 sessions on a) translating values to action, b) lower barriers to action, c) countering avoidance, and d) maintaining actions that support personal resilience. The classes will occur every other Wednesday, resulting in a 16-week intervention period.
214322656|NCT02787473|DRUG|cisplatin|Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles
214322657|NCT02787473|RADIATION|thoracic radiation therapy|Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin
214322658|NCT02787473|DRUG|docetaxel|Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles
214322659|NCT01398956|DRUG|Levetiracetam|"formulation: tablet or dry syrup~strength: 250 mg tablet, 500 mg tablet, dry syrup 50%~dosage: Sb ≥16 years and ≥4 and \<16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and \<16 years (\<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day~frequency: twice daily"
214322660|NCT00882258|DRUG|12.5 mg Proellex|12.5 mg Proellex administered orally daily
214322661|NCT00882258|DRUG|25 mg Proellex|25 mg Proellex administered orally daily
214922003|NCT03813836|DRUG|Pembrolizumab|Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
214322662|NCT00882258|DRUG|Placebo|Administered orally daily
214322663|NCT03585452|DRUG|Dexmedetomidine Infusion|Patients with additional dexmedetomidine infusion
214322664|NCT03585452|DRUG|Propofol based general anesthesia|Patients with typical anaesthetic regimens
214672402|NCT03879590|DRUG|Budesonide|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
214672403|NCT02788539|BEHAVIORAL|Our Whole Lives Website|OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
214922004|NCT02745613|OTHER|8 weeks of combined exercise intervention|The subjects will undergo an 8 week combined exercise intervention
214922005|NCT01335074|DRUG|Temsirolimus + Sorafenib|200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
214922006|NCT06642207|DIAGNOSTIC_TEST|CBC|to compare platelet count in Ankylosing Spondylitis patients in treatment with Anti-TNF- α and patients with IL17 Inhibitor
214922007|NCT04817488|OTHER|Prehospital emergency ultrasound with tele-supervision|Prehospital emergency ultrasound with tele-supervision in patients with acute dyspnoea
214922008|NCT04817488|OTHER|Prehospital emergency ultrasound without tele-supervision|Prehospital emergency ultrasound without tele-supervision in patients with acute dyspnoea
214922009|NCT04544488|PROCEDURE|Recording of expulsive efforts by connection of a pressure sensor to the women's bladder probe|"Using a pressure probe connected to a Foley Catheter, intra bladder pressure wille be registered during the whole duration of expulsive phase.~The device will be inserted into women's bladder using usual guidelines for insertion of Foley catheter"
214922010|NCT01909193|BEHAVIORAL|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
214922011|NCT01909193|BEHAVIORAL|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
214922012|NCT01680861|DRUG|Tacrolimus|Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of \<4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
214922013|NCT01680861|DRUG|Everolimus|Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.
214922014|NCT01680861|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
214922015|NCT01680861|DRUG|Corticosteroids|Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
214922016|NCT06681961|OTHER|squatting with hip adduction (SQU-HA) group|The intervention comprised three sets of 15 repetitions with resting 5-min between sets, followed by IT band stretching for five repetitions. Each participant performed the respective exercise 5 days a week, with 2 days of rest, for 8 weeks.
214922017|NCT02375893|OTHER|No intervention|Collecting blood and feces samples
214922018|NCT02375893|OTHER|Healthy subject|Collecting blood and feces samples
214922019|NCT03403829|DRUG|Gemcitabine|Gemcitabine maintenance chemotherapy
214922020|NCT03403829|RADIATION|standard chemoradiotherapy|standard chemoradiotherapy
214922021|NCT03745729|DRUG|allopurinol sustained-release capsules|allopurinol sustained-release capsules (0.25g), once a day, one pill at a time
214922022|NCT03745729|DRUG|placebo capsules|placebo sustained-release capsules, once a day, one pill at a time
214922023|NCT05342389|DRUG|Camrelizumab|a PD-1 antibody
214922024|NCT05342389|DRUG|Apatinib Mesylate|an oral tyrosine kinase inhibitor
214922025|NCT05801289|DRUG|Quetiapine|Giving the drug to group Q
214922026|NCT00062881|DRUG|Intrathecal Mafosfamide|
214922027|NCT01366235|DRUG|chloroquine phosphate 1000 mg|1000 mg, 1day
215064193|NCT04653090|DIAGNOSTIC_TEST|Xray|Hip AP Xray
215064194|NCT05744778|OTHER|Dry needling|In addition to the physical therapy and exercise program, the dry needling group will consist of patients who have had 3 sessions of dry needling applied to the trigger points in the trapezius muscle, 5 days apart.
215064195|NCT05744778|OTHER|Physical therapy and rehabilitation|The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.
214322665|NCT02239809|PROCEDURE|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
214322666|NCT02239809|PROCEDURE|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
214485525|NCT06734663|PROCEDURE|Clinical outcomes of sutured versus sutureless conjunctival autograft in primary pterygium excision|Studies have concluded that pterygium surgical excision is the main treatment for pterygium. Pterygium excision with superior graft is the procedure followed most commonly at present. This is achieved by many methods, with the result differing from one method to another. The most important difference is the incidence of recurrence(4)But Varioustechniques such as Bare Sclera, Rotational Conjunctival Flap, Limbal Conjunctival Autograft, Amniotic Membrane Graft, and Free Conjunctival Autograft are also used for the removal of pterygium(3 ,4)Of the various possible alternative approaches, conjunctival autograft is usually preferred. Diverse methods for grafting with sutures, glue or autologous serum from the recipient bed are in use (5,6). Many adjunctive therapies like mitomycin C, corticosteroids, thiotepa, interferon-alpha- 2b, beta irradiation, 5-FU are being used to decrease the risk of recurrence after surgical removal of pterygium.
214485526|NCT06734663|PROCEDURE|pterygium excision and conjuctival graft suturing|pterygium is surgically removed, and a conjuctival graft is placed on bare sclera using sutures to surrounding conjuctiva.
215064196|NCT04307368|OTHER|FODMAP diet|8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
214485527|NCT06734663|PROCEDURE|pterygium excision and conjuctival graft placement by autologous blood|pterygium is surgically removed and a conjuctival graft is placed on bare sclera on which the patient's blood remains. the graft is left without sutures, adhering only by autologous blood.
214485528|NCT06306534|OTHER|Auditory Nerve Acute (ANA) Electrode Array|To measure eABRs when stimulating the human auditory nerve
214485529|NCT06743438|DRUG|Tenofovir Amibufenamide（TMF）|Once-daily oral dose of 25 mg TMF were maintained in all participants
215064197|NCT04307368|OTHER|Elimination-rotational diet|During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
214485530|NCT06743139|DIAGNOSTIC_TEST|Echography|Simultaneous performance of an echocardiogram (part of the follow-up assessment for sickle cell heart disease) at rest and then during the cardiorespiratory stress test, and an ear capillary lactatemia analysis (already routinely performed to ensure the safety of the cardiorespiratory stress test) during the cardiorespiratory stress test routinely performed at Mondor University Hospital prior to cardiovascular rehabilitation programs.
214485531|NCT06353334|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP twice daily. Each patient will receive continuous medication for 14 days.
214485532|NCT06353334|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
214485533|NCT05862636|BEHAVIORAL|Mindfulness Training|"All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers."
214485534|NCT04403438|OTHER|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
214672404|NCT00133744|DIETARY_SUPPLEMENT|folic acid|pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
214672405|NCT00133744|DIETARY_SUPPLEMENT|folic acid plus iron|pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
215064198|NCT04307368|OTHER|Classic diet|8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
215064199|NCT03860831|DRUG|Ketamine + midazolam|Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
214322667|NCT01995799|DEVICE|Ferumoxytol enhanced MRI|Ferumoxytol enhanced MRI scan
214322668|NCT00146718|DRUG|Amodiaquine and Sulphadoxine/Pyrimethamine|
214485535|NCT06736392|PROCEDURE|Ultrasound guided Pericapsular Nerve Group Block|"With the patient in the supine position and the leg slightly abducted, a curvilinear transducer (2.5-7.5 MHz) is prepared with sterile conduction gel and covered with a sterile probe cover. The transducer is placed transversely over the anterior superior iliac spine (ASIS), then aligned with the pubic ramus and rotated approximately 45° parallel to the inguinal crease. The probe is slid medially to identify key landmarks: the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), iliopsoas tendon, femoral artery, and femoral nerve. Sliding the probe distally or tilting caudally exposes the femoral head.~A 20-22 gauge echogenic needle (100 mm) is inserted in-plane from lateral to medial, targeting the plane between the psoas tendon and the pubic ramus. the anesthetic agent is deposited to lift the psoas tendon while avoiding tendon puncture."
214485536|NCT06736392|DRUG|Isobaric Bupivacaine 0. 25%|group c will receive PENG block with only 20ml isobaric bupivacaine 0.25%
214485537|NCT06736392|DRUG|20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine|group D will receive PENG block with 20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine
214485538|NCT06736392|DEVICE|the ultrasound machine with curvilinear transducer (high -frequency probe, 2.5Mhz to 7.5Mhz)|the two groups will receive the PENG block under ultrasound guidance
214485539|NCT06736392|DEVICE|a standard echogenic 20-22 gauge 100mm needle|the two groups will receive the PENG block using a standard echogenic 20-22 gauge 100mm needle
214485540|NCT06893744|DEVICE|occlusal splint|
214485541|NCT06893276|BEHAVIORAL|ePSMI|Participants will complete an hour of cognitive behavioral stress management program in person or remote each week for ten weeks. The cognitive behavioral therapy (CBT) skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour. After module completion, participants will have access to modules covered during session.
214485542|NCT06737887|OTHER|Stoma simulation|Patients who will undergo stoma surgery will have an intervention one day before the surgery. The adapter will be cut to an estimated stoma size, heated by rubbing with hands and adapted to the skin by applying stoma paste. The patient will be asked to place their hand on the adapter and apply pressure. Then, the stoma bag filled with tissues and water and the adapter will be combined. The patient will be informed that they should not hesitate to do any activity that they will spend 24 hours with the stoma bag. The patient will be provided with the opportunity to go to the toilet, eat, sleep and experience all their daily activities with the stoma. It allows patients to experience the stoma bag by putting it on 24 hours before the surgery. In this way, patients know that they will not encounter any surprises after the surgery.
215064200|NCT02597452|DEVICE|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
215064201|NCT02620800|DRUG|5FU|5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump
215064202|NCT02620800|DRUG|nab-paclitaxel|nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
215064203|NCT02620800|DRUG|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
215064204|NCT02620800|DRUG|calcium leucovorin|calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15
215064205|NCT02620800|DRUG|oxaliplatin|oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15
215064206|NCT02434549|DRUG|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
215064207|NCT02434549|DRUG|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
215064208|NCT01774669|DEVICE|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
215064209|NCT01774669|OTHER|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
215064210|NCT03375645|DRUG|Any oral opioid|Emergency department patients who receive a prescription for an oral opioid
215064211|NCT03500016|OTHER|High intensity interval training|See under arm description.
215064212|NCT01555970|DRUG|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
214322669|NCT04489706|DRUG|Arsenic trioxide for injection|Arsenic trioxide for injection, 0.16 mg/kg (maximum single dose is 10 mg), daily IV drip, d1 to d14, once every 28 days, for six cycles of treatment or until one of the following events occurs: Initiation of new anti-tumor therapy, disease progression, withdrawal of Informed consent form (ICF) and/or death.
215064213|NCT01555970|DRUG|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
214322670|NCT01742793|DRUG|lenalidomide (Revlimid) and romidepsin (Istodax)|
214322671|NCT01977586|OTHER|Magnetic Resonance Imaging (MRI)|
214322672|NCT01076829|OTHER|Spice polyphenols|spice
215064214|NCT05719857|PROCEDURE|Hepatic vein pressure gradient measurement|HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.
214322673|NCT05534763|BEHAVIORAL|IERGD|A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.
214322674|NCT05534763|OTHER|IER SUPPORT|A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.
214322675|NCT04389411|DRUG|Montelukast 10mg|10mg oral Montelukast will be taken daily for 60 days
214322676|NCT02825836|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
214322677|NCT02825836|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
214485543|NCT06892860|DRUG|Avelumab|Avelumab treatment will be given up to a maximum of 2 years from the end of chemotherapy
214485544|NCT06893991|DIETARY_SUPPLEMENT|SYMBIONIC|"Provision of 100 ml symbiotic beverages daygurt per day for 6 weeks, plus standard dietary advice for dyslipidemia"
214485545|NCT06893991|BEHAVIORAL|Dietary advice|Participants get standard dietary advice for dyslipidemia
214485546|NCT06892873|DEVICE|Comfort-In|Application of Comfort-in Jet Injection Method Comfort-in jet injection method was used for palatal anesthesia of the primary molars. The device was placed 5 mm below the palatal gingival margin, close to the free gingiva, and with a steep angle. 0.2 ml of anesthetic solution was administered by pressing the jet injection system button. 1 mL Articaine Hydrochloride (Ultracaine D-S forte, Hoechst, Canada) containing 1/100,000 epinephrine was used as a local anesthetic agent in the injections. 38 patients were included in this group and the procedure was performed. After waiting for 2 minutes, the anesthetized area was probed with the help of a probe (probing gingiva) to check whether the anesthesia had taken effect. Afterwards, buccal infiltration anesthesia was performed with the help of a traditional dental injector and tooth extraction was performed.
214322678|NCT02677792|BEHAVIORAL|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
214322679|NCT05248516|DIETARY_SUPPLEMENT|Simplified dose of ready-to-use therapeutic food (RUTF)|"In the simplified arm all children receive the same dose: 1 sachet of RUTF/day. This until discharge from treatment.~Recovery from treatment will be defined as WAZ\>= -3 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
214485547|NCT06892873|OTHER|Traditional dental injection|Application of Traditional Dental Injection Method Palatal injection; It was applied 5-10 mm below the palatal gingival margin\*, on the attached gum, and with a 45-degree needle angle. After needle entry, 0.2 mL of anesthetic solution was stored when bone contact was removed. 1 mL Articaine Hydrochloride (Ultracaine D-S forte, Hoechst, Canada) containing 1/100,000 epinephrine and a 27 G dental needle were used as local anesthetic agents for injections. 38 patients were included in this group and the procedure was performed. After waiting for 2 minutes, the anesthetized area was probed with the help of a probe (probing gingiva) to check whether the anesthesia had taken effect. Afterwards, buccal infiltration anesthesia was performed with the help of a traditional dental injector and tooth extraction was performed.
214485548|NCT06744946|PROCEDURE|thoracoscope|bleomycin- tranxemic acid mixture pleurodesis versus thoracoscopic talc poudrage
214485549|NCT06744881|PROCEDURE|CAPA-IVM|On days 2-4 of the menstrual cycle, after patients have consented to CAPA-IVM, they will undergo oocyte aspiration anytime thereafter but no later than day 6 of the cycle. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 or day 5 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transfer
214485550|NCT06893172|OTHER|Warm acupuncture and Gabapentin|This group used gabapentin 300mg per tablet, twice a day, for a treatment period of 4 weeks, combined with warm acupuncture at the Ashi point, EX-B2, LI4, TE6, PC5 and SP6, five times a week for 4 weeks.
214485551|NCT06893172|DRUG|Gabapentin|This group used gabapentin 300mg per tablet, twice a day, for a treatment period of 4 weeks
214485552|NCT06893835|DRUG|Colistimethate Sodium|compare the clinical outcomes and safety between colistin and tigecycline for multi-drug-resistant gram-negative bacteria.
214485553|NCT06893835|DRUG|Tigecycline|compare the clinical outcomes and safety between colistin and tigecycline for multi-drug-resistant gram-negative bacteria.
214485554|NCT06893575|BEHAVIORAL|TTM-Guided Digital Sleep Health Program|This intervention is a TTM-based sleep health improvement program designed for HF patients. It includes three components: (1) Sleep health education sessions (Weeks 1-4) delivered face-to-face and via telehealth, (2) WhatsApp-based sleep hygiene support (Weeks 5-12) with daily reminders, educational messages, and video content, and (3) Follow-up monitoring (Weeks 13-24) with periodic motivational messages. Patients will track their sleep using smartwatches and share data via WhatsApp. The intervention guides behavior change through TTM stages, promoting sustainable sleep hygiene practices.
214485555|NCT06889064|DRUG|BR1400-1|One tablet administered alone
214322680|NCT05248516|DIETARY_SUPPLEMENT|Standard dose of ready-to-use therapeutic food (RUTF)|"In the standard arm, children will receive different doses of RUTF depending on their WHZ category and weight.~1. children with a WHZ\<-3 will receive the equivalent of 200kcal/kg/d of RUTF until discharge.~2. children with a WHZ between -3 and -2 will receive 1 sachet (500kcal) of RUTF per day until discharge.~3. children with a WHZ\>=-2 will receive no nutritional treatment.~Recovery from treatment will be defined as WHZ\>= -2 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
214922028|NCT03921840|BEHAVIORAL|ELDERFITNESS|"In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps \& minutes of moderate activity) using the smartwatch. The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer.~Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans. Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects."
214922029|NCT03921840|OTHER|Control|General education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
214922030|NCT03694964|DRUG|ProteoCIT®|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
214922031|NCT03694964|DRUG|Placebo Oral Tablet|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
214922032|NCT01756781|DRUG|Midazolam|Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
214922033|NCT01756781|DRUG|PD-0332991|Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
214922034|NCT01756781|DRUG|Midazolam|"Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone."
214922035|NCT01756781|DRUG|PD-0332991|Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
214922036|NCT06588751|OTHER|Scalp block|After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.
214922037|NCT04339985|DRUG|ATx201|Topical
214922038|NCT04339985|DRUG|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
214922039|NCT05684575|OTHER|Phone satisfaction questionnaire|Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
214922040|NCT01940887|DRUG|E10030|
214322681|NCT05248516|DIETARY_SUPPLEMENT|No nutritional treatment|no nutritional treatment will be provided to children in the control arm.
214322682|NCT02196272|BEHAVIORAL|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:~\- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
214322683|NCT00386412|DRUG|Valganciclovir|900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
214322684|NCT04155008|DRUG|Dexamethasone|If the patient's prognosis is extremely poor (less than 12 weeks expected survival, based on discussion with the patient's treating physicians) and there is no additional disease modifying therapy planned, the patient will be prescribed 4mg dexamethasone (which is FDA approved), once daily, to be taken orally in the morning.
214322685|NCT04155008|DRUG|Dronabinol|If the patient has a history of marijuana use or has tried it in the past and had a positive experience with it, then the patient will be prescribed dronabinol (which is FDA approved) 2.5mg, twice daily before meals.
214485556|NCT06889064|DRUG|BR1400-2|One tablet administered alone
214485557|NCT06889064|DRUG|BR1400-3|One tablet administered alone
214485558|NCT06894901|BIOLOGICAL|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
214485559|NCT06888362|DRUG|GZ21T|GZ21T cream is intended to be studied as a potential treatment for patients with actinic keratoses and other dermatologic conditions which may be amendable to the study treatment.
214485560|NCT03032627|PROCEDURE|Collection of discarded heart tissue|Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
214485561|NCT06741150|BIOLOGICAL|NWRD09 administered by intramuscular injection|Intramuscular injection administration was carried out according to the protocol design.
214322686|NCT04155008|DRUG|Mirtazapine|If the patient does not have any history of marijuana use, mirtazapine will be prescribed. If the patient is under the age of 70, then the patient would be prescribed 15mg of mirtazapine (which is FDA approved), once daily, to be taken orally at bedtime. For geriatric population (if the patient is over the age of 70), then the patient would be prescribed 7.5mg of mirtazapine, once daily to be taken orally at bedtime.
214322687|NCT04155008|BEHAVIORAL|Nutrition Intervention|"Nutrition intervention will be in accordance with the Academy of Nutrition and Dietetics guidelines. The intervention will involve purposefully planned action(s) designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status"
214322688|NCT01147185|DEVICE|Locomotor training using a robotic device|50min walking time, 3-5 trainings/week.
214922041|NCT01940887|DRUG|bevacizumab or aflibercept|Patients are randomized to receive either bevacizumab or aflibercept
215064215|NCT05719857|PROCEDURE|Ultrasound-guided percutaneous liver biopsy|Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.
215064216|NCT05719857|DIAGNOSTIC_TEST|Multiparametric Abdominal Magnetic Resonance with Elastography|The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
214322689|NCT01147185|DEVICE|Locomotor training using a robotic device|25min walking time, 3-5 trainings/week.
214322690|NCT00256919|DRUG|GW856553|
214922042|NCT01940887|DRUG|E10030 sham injection|Pressure on the eye with a syringe with no needle
214922043|NCT00749307|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|
214922044|NCT00749307|DIETARY_SUPPLEMENT|Placebo|
214922045|NCT01906307|DRUG|LJPC-501|Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
214922046|NCT06622928|DIAGNOSTIC_TEST|Echocardiogram|"Echocardiographic Assessments:~Pre-Hemodialysis Echocardiography:~Before each hemodialysis session, echocardiograms will be performed to evaluate cardiac function and gather baseline data on ventriculo-arterial coupling (VAC) parameters. This will include recording three apical echocardiographic views (4-chamber, 2-chamber, and 3-chamber) by a trained sonographer.~Post-Hemodialysis Echocardiography:~Following the completion of the hemodialysis session, echocardiographic assessments will be repeated to measure changes in VAC parameters and other relevant cardiac metrics."
214922047|NCT04807205|DEVICE|RF Non-Invasive Treatment|Self-controlled single-arm group using the Elite IQ device
214322691|NCT05714488|DEVICE|blue halo coil catheter|device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
214322692|NCT01155895|DRUG|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
214322693|NCT00739752|BEHAVIORAL|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
214322694|NCT00739752|BEHAVIORAL|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
214322695|NCT00739752|BEHAVIORAL|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
214322696|NCT00739752|BEHAVIORAL|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
214322697|NCT00739752|BEHAVIORAL|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
214322698|NCT00739752|BEHAVIORAL|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
214322699|NCT04939285|PROCEDURE|PEEP|The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
214322700|NCT04222582|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
214322701|NCT05289609|PROCEDURE|Liver Transplantation|Individuals with end-stage liver disease will be subjected to liver transplantation from deceased or living donors
214322702|NCT05638646|OTHER|Intervention group|Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease
214322703|NCT05638646|OTHER|control group|Maintain current treatment
214322704|NCT03821012|OTHER|in-hospital process optimization|
215064217|NCT06419556|PROCEDURE|Cervical Plexus Block|"The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt."
214672406|NCT00133744|DIETARY_SUPPLEMENT|supplements with multiple vitamins and minerals|pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
215064218|NCT04848467|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine (CVnCoV)|Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
215064219|NCT04848467|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
215064220|NCT04848467|OTHER|Placebo|One intramuscular injection as normal saline \[0.9% NaCl\].
215064221|NCT06340724|DRUG|Vonoprazan|20 mg tablet twice daily
215064222|NCT06340724|DRUG|Amoxicillin|1 g tablet three times daily
215064223|NCT06340724|DRUG|Banxiaxiexin decotion|100 ml liquid-medicine twice daily
214672407|NCT02127762|BEHAVIORAL|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
214922048|NCT06078774|BEHAVIORAL|Virtual Health Coach|"Dyads first session will be 60-minutes, totaling 1 hour. Dyads will participate in weekly 30-minute sessions for weeks 2-12, totaling 5.5 hours.~Dyads will participate bi-weekly 30-minute sessions for 12 weeks, totaling 3 hours.~Dyads will participate in weekly 30-minute exercise sessions for 24-weeks, totaling 12 hours.~Children will have 3, 30-minute visits with their primary care physician (PCP) every 3 months, totaling 1.5 hours.~Parents will have three, 60-minute individual sessions, totaling 3 hours. Total study duration is 24 weeks, with a total of 26 contact hours.~Sessions follow a behavior therapy approach, including guided goal-setting, self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks, maintenance and relapse prevention. Weight is assessed weekly by coaches, with MI-consistent, autonomy-supportive feedback provided. Parent sessions will focus on ways to support their child's weight management."
214922049|NCT05278546|DRUG|ILB2109|ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214922050|NCT00644410|BIOLOGICAL|Mesenchymal stromal cell|Mesenchymal stromal cells 20 - 40 mill.
214922051|NCT00644410|BIOLOGICAL|Saline|12 injection with 0.2 ml saline
215064224|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Scoliosis specific corrective exercises and physical activity counseling
215064225|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises|Only scoliosis specific corrective exercises
215064226|NCT00924014|DRUG|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
215064227|NCT00924014|DRUG|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
215064228|NCT00924014|DRUG|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
215064229|NCT04259437|OTHER|High Protein, Energy Dense Nutritional Supplement|Ready to drink oral supplement
214322705|NCT03821012|OTHER|PPCI hospital-based regional STEMI transfer network construction|
214322706|NCT03821012|OTHER|the whole-city STEMI care network construction|
214322707|NCT03501095|DIAGNOSTIC_TEST|Vocal analysis and Laryngostroboscopy|"Vocal analysis study the acoustic emission of the pneumo-phono-articulatory system, i.e. the vocal signal. Currently, digital technology instruments enable the processing and analysis of the verbal signal quickly and reliably, also offering graphical products and numerical data. Among the various existing software products for the study of the vocal signal, PRAAT is available. In practice, the vocal parameters are acquired in a non-invasive way with a microphone.~Laryngostroboscopy is one of the most widely used techniques for laryngeal clinical evaluation. This is a non-invasive endoscopic practice performed by means of a flexible fibroscope, which, through a pulsed light source, allows visualization of the chordal movement."
214322708|NCT05882227|BEHAVIORAL|video|The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.
214322709|NCT05882227|BEHAVIORAL|Traditional information|"Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group."
214322710|NCT03761732|BEHAVIORAL|Islamic Trauma Healing|6 session behavioral intervention program designed to reduce PTSD and related symptomatology
214322711|NCT03925727|DRUG|Tavilermide ophthalmic solution|BID topical dosing
215064230|NCT02523092|DRUG|Acthar gel|Acthar gel given IM or SQ as per package insert
215064231|NCT01533337|PROCEDURE|Free dorsal digital flap|The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
214672408|NCT01444391|DEVICE|Tympanostomy tube placement (Acclarent iontophoresis device)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
214672409|NCT01535937|DRUG|Ketamine|0.5 mg/kg IV over 40 minutes
214922052|NCT06610578|DIAGNOSTIC_TEST|fundus imaging|Fundus photography, OCT or OCTA
214922053|NCT01663285|DRUG|Neoadjuvant Cisplatin and Gemcitabine|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
214922054|NCT02475265|DRUG|estradiol 0.045 mg/levonorgestrel 0.015mg|
214922055|NCT04927130|DIAGNOSTIC_TEST|ARNA Breast|A specific DNA fragments and globulins will be detected in blood plasma.
214922056|NCT03783585|BEHAVIORAL|Cognitive behavioral therapy for insomnia|The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
214922057|NCT03783585|BEHAVIORAL|Cognitive behavioral therapy for insomnia + biweekly support|Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
214922058|NCT05571124|BEHAVIORAL|Therapeutic Exercise Intervention|Participants will perform stretching and mobility exercises in short bouts of time.
214922059|NCT06365710|OTHER|Telerehabilitation|Telerehabilitation program
214922060|NCT06365710|OTHER|Traditional physiotherapy|Guided rehabilitation program with physiotherapist appointments
214922061|NCT01598090|BIOLOGICAL|Peginterferon Lambda-1a|Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
214922062|NCT01598090|BIOLOGICAL|Peginterferon Alfa-2a|Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
214922063|NCT01598090|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
214922064|NCT01598090|DRUG|Telaprevir|Tablets, Oral, 750 mg, three times a day, 12 weeks only
214922065|NCT04490603|BEHAVIORAL|Virtual reality experience|Patients are to experice virtual reality with virtual reality experience equipment (headsets, headphones, smartphones) and virtual reality experience programs. The equipments and programs are commercialized products on the market rather than medical products.
215064232|NCT00943098|DRUG|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
214922066|NCT04796506|OTHER|Progressive Resistance Training (PRT)|PD subjects may be randomized (1:1) to PRT with supervised sessions 3 times per week for 12 weeks. Exercise training will consist of a combination of resistance training (RT) and bodyweight functional mobility exercises with limited rest intervals. The full volume exercise prescription will consist of: 1) five movements to improve strength and muscle mass each performed for 3 sets of 8-12 repetitions; 2) trunk exercises to improve postural stability; and 3) 3-4 bodyweight exercises to improve power and balance. Change in slow wave sleep (SWS) from baseline to 12-weeks will be used to determine the assignment in the second 12-week period. Subjects with an increase in SWS by \>24 minutes will continue in PRT for the 2nd 12 weeks of the trial, while participants with \<24 minutes increase in SWS will transition to endurance training (ET).
214922067|NCT04796506|OTHER|Delayed Exercise Training (DE)|PD subjects randomized to the exercise control group (1:1) will not exercise during the first 12 weeks of the study. During that time, they will be asked not to change their physical activity levels or dietary habits. All participants in the delayed-exercise group will begin PRT at completion of the 1st 12-week period.
215064233|NCT00943098|DRUG|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
214922068|NCT04796506|OTHER|Endurance Training (ET)|Non-responders to PRT will transition too ET during 2nd 12 weeks of the study. This intervention is supervised endurance training, 3 times per week for 12 weeks. Each session lasts approximately 75 min., comprised of warm-up, stimulus phase for 50-60 min., and cool-down. Sessions are split between cycle ergometer and treadmill exercise. Participant heart rate is monitored to maintain target exercise intensity of 60-80% (±5%) of heart rate reserve (HRR).
214922069|NCT05015998|OTHER|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
215064234|NCT05073484|DRUG|BAT6021|Ⅳ infusions
215064235|NCT05073484|DRUG|BAT1308|Ⅳ infusions
215064236|NCT05827328|OTHER|Observation|Observe the 30-day mortality and 30-day morbidity.
215064237|NCT04027595|PROCEDURE|Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy|A Nd: YAG laser will be used to open the cloudy posterior capsule of the lens to improve central visual acuity.
215064238|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
215064239|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
215064240|NCT03545087|DRUG|Lanabecestat|Administered orally
215064241|NCT03545087|DRUG|Iohexol|Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
215064242|NCT01510990|DRUG|Gefitinib|gefitinib 250mg/day daily
214672410|NCT01535937|DRUG|Midazolam|0.025 mg/kg IV over 40 minutes
214672411|NCT03400293|OTHER|Functional Assessment of HIV Infection|Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.
214672412|NCT03400293|OTHER|Patient Satisfaction Questionnaire|Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.
214485562|NCT06749002|PROCEDURE|Turning based specific training along with functional Muscle training|"Experimental group will receive Turning based specific training protocol for 6 weeks along with functional muscle training, training will be done on alternate days.~Functional muscle training:~Details: Week 1-6: 3 days a week on alternate days.~Hip Abductors:~Side lying leg raises Single leg squatting Standing leg wall press Progressing to Adding resistance bands~Hip adductors:~Side lying adduction Standing Adduction Progress to adding resistance bands~Hip Flexors:~Standing leg lift Straight leg raises Progress to adding resistance bands~Hip Extensors:~Prone lying raises Standing single leg extension Progress to adding resistance bands~Plantarflexors/ DorsiFlexors:~Plantarflexors:~Plantarflexion against resistance Toe raises~Dorsiflexors:~Dorsiflexion against resistance Heel raises~Hip external rotators:~Sitting-externally rotate hip 0-30° Add resistance bands~Hip Internal rotators:~Sitting-internally rotate the hip 0-30° Add resistance bands."
214672413|NCT03400293|OTHER|Symptom Distress Module|Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.
214672414|NCT03400293|OTHER|Patient Health Questionnaire|Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.
214672415|NCT03400293|OTHER|Internalized Stigma of AIDS Tool|Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.
214672416|NCT03400293|OTHER|Medication adherence visual analogue scale|Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.
214672417|NCT00653315|DRUG|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
214672418|NCT00653315|DRUG|Ultracet|Tablets, 37.5mg/325mg
214672419|NCT01642537|DEVICE|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
214672420|NCT03169283|OTHER|Cereal with B glucan|A cereal high in viscous dietary fiber B glucan
214672421|NCT03169283|OTHER|Cereal without B glucan|Cereal without B glucan
214672422|NCT00949338|PROCEDURE|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
214672423|NCT03331211|DRUG|TKIs|Dasatinib combined with Chematherapy
214922070|NCT02982174|DEVICE|3D OCT-1 Maestro|Image acquisition of the posterior surface of the eye
214922071|NCT02982174|DEVICE|DRI OCT Triton|Image acquisition of the posterior surface of the eye
214922072|NCT05588973|OTHER|MEDISKIN cream|MEDISKIN cream with collagen
214922073|NCT05588973|OTHER|Panthenol cream|Panthenol cream
214922074|NCT00399646|DEVICE|Metricath Gemini System|
214922075|NCT04185012|BIOLOGICAL|Benralizumab|Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
214922076|NCT04185012|BIOLOGICAL|Placebo|Placebo administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
214922077|NCT06665958|DIETARY_SUPPLEMENT|Polyphenol extract|Single dose
214922078|NCT03702075|OTHER|self-administered program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
214922079|NCT00692848|OTHER|Procalcitonin dosage PCT-Q test (Brahms, Germany)|Procalcitonin result available to the attending physician
214922080|NCT01676740|DRUG|Iron Supplement,|Pills to be swallowed
214922081|NCT01676740|DRUG|Placebo|Daily administration of active drug or placebo
214922082|NCT01118260|PROCEDURE|total intravenous anaesthesia|propofol and remifentanil
214922083|NCT01118260|PROCEDURE|spinal anaesthesia|bupivacaine and fentanyl
214922084|NCT02015416|BIOLOGICAL|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
214922085|NCT01789411|OTHER|Drawing blood samples|Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
214922086|NCT01789411|DEVICE|Coronary intravascular ultrasound imaging|Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
214922087|NCT01789411|DEVICE|Coronary near-infrared spectroscopy|Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
214922088|NCT05074121|DRUG|N-acetylcysteine|N-acetylcysteine
214922089|NCT05074121|OTHER|Placebo|Placebo
214922090|NCT01686464|DRUG|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
214922091|NCT01686464|DEVICE|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2\~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2\~3.0 L / min for the same duration during all acupuncture sections.
214922092|NCT04729829|BEHAVIORAL|Social and behaviour change communication|Each SBC treatment community will receive nutrition content and learning through savings groups. The group members will participate in skill-building activities that promote five key behaviours about fish nutrition and household decision making on fish consumption as part of facilitated discussions, interactive learning sessions, and a video-based facilitated dialogue. Increased fish consumption through SBC mass attendance events through marketing of fish vendors, interactive learning, and edu-tainment competitions promoting fish consumption. SBC will raise awareness of the benefits of eating fish as part of a balanced diet, with a particular focus on pregnant and lactating mothers, and children under 5 years of age.
214485563|NCT06749002|PROCEDURE|turning based specific training.|"Week 1:~90 Degrees turns on the spot~Visual cues to follow~Week 2-3:~90 degrees turns on the spot~Figure of 8 walking~Visual cues to follow~Week 4-5:~90 Degrees turns on the spot~Figure of 8 walking~Step across body~Braiding~Week 6:~90 degree turns on the spot~Figure of 8 walking~Step across body~Braiding~Visual cues to follow~Obstacle avoidance"
214485564|NCT06748534|DIAGNOSTIC_TEST|Plus Lens Addition (+0.75 D)|Participants in this group were provided with +0.75 D lenses, designed to assist in alleviating strain caused by accommodative infacility by reducing the demand on the eye's focusing mechanism.
214485565|NCT06748534|COMBINATION_PRODUCT|Vision Therapy Using HART Chart|Intervention Details: Participants in this group underwent vision therapy sessions utilizing the HART chart, aimed at enhancing their accommodative flexibility through repetitive focusing exercises.
214485566|NCT06749795|DRUG|LIV001|Orally administered for 8 weeks
214485567|NCT06749795|DRUG|Placebo|Orally administered for 8 weeks
214922093|NCT04729829|OTHER|Fish aggregating device|This is a moored line attached to buoys in coastal waters that attracts oceanic fish to it, to make it easier for small-scale fishers to catch them using their existing gear and boats. This FAD will work to increase the catch rate and hence, the availability of fish for sale in upland community markets.
214922094|NCT03780881|BEHAVIORAL|Expectation confirmation|Participants receive manipulated feedback indicating that their performance was above average in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
214922095|NCT03780881|BEHAVIORAL|Expectation disconfirmation|Participants receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
214922096|NCT00220610|DEVICE|Transcranial magnetic stimulation|
214922097|NCT05627505|DIAGNOSTIC_TEST|metagenomic next-generation sequencing|Collection of bronchoalveolar lavage fluid
214922098|NCT02449798|DEVICE|"AccuCath 2.25 BC Intravascular Catheter"|Long peripheral IV catheter designed for difficult IV access patients requiring deeper vessel access, often used with ultrasound guidance.
214922099|NCT02209519|DRUG|Metronidazole (male partner)|500 mg PO BID for 7 days
214922100|NCT02209519|OTHER|Placeob (male partner)|matching placebo capsules PO BID for 7 days
214922101|NCT00276887|BEHAVIORAL|Cognitive Behavior Therapy|
214922102|NCT00276887|BEHAVIORAL|Psychiatric Consultation Letter|
214922103|NCT02401048|DRUG|Ibrutinib|
214922104|NCT02401048|DRUG|MEDI4736|
214922105|NCT05622474|DRUG|Induction chemotherapy plus Concurrent chemotherapy|"Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2，D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles）~Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation."
214922106|NCT05622474|DRUG|Concurrent chemotherapy|Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.
214922107|NCT05622474|RADIATION|IMRT|Radical radiation: Intensity-modulated radiotherapy
214922108|NCT06060951|DIAGNOSTIC_TEST|Estimated intraperitoneal pressure|"The following anthropometric measurements are required:~1. Height: measured standing with shoes off~2. Weight: dry weight should be used~3. The distance from the decubitus plane to the mid-axillary line was measured~4. Waist circumference: measured with a tape measure wrapped above the iliac crests around the level of the umbilicus.~The estimated IPP will be assessed using different equations."
214922109|NCT01826513|DEVICE|Standard AutoSet algorithm|An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.
214922110|NCT01826513|DEVICE|Modified AutoSet algorithm|An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
214922111|NCT05094869|BEHAVIORAL|Use of mobile health application|The APP would regularly send messages including the medication reminder, health education knowledge, etc.
214922112|NCT05094869|BEHAVIORAL|Online interaction|The patients would be able to upload their examination results in the APP and then the doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.
214322712|NCT03925727|OTHER|Placebo|BID topical dosing
214322713|NCT06391788|PROCEDURE|thoracoscopic Morrow surgery|minimally invasive trans-mitral Morrow septal myectomy
214322714|NCT06391788|PROCEDURE|modified Morrow surgery|median open modified enlarged Morrow septal myectomy
214322715|NCT03533062|DRUG|botulinum toxin A|botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
214322716|NCT01828372|OTHER|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
214322717|NCT01677091|OTHER|Cervical vibration|Vibration of neck muscles during 10 minutes
214322718|NCT01677091|OTHER|Prism adaptation|Prism adaptation during 10 minutes
214322719|NCT01677091|OTHER|Conventional rehabilitation|conventional rehabilitation
214322720|NCT00558103|DRUG|lapatinib|Oral administration
214322721|NCT00558103|DRUG|Pazopanib|Oral administration
214322722|NCT04947332|PROCEDURE|Auto-inoculation|A wart will be excised from the body, minced and will be inoculated in a subcutaneous pocket on forearm.
214322723|NCT05886959|OTHER|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
214485568|NCT06787794|BEHAVIORAL|Virtual Reality-assisted hypnosis|"The VRH intervention consists of 6 interventional sessions. Every session, first, participants receive hypnotic induction and go through a deepening phase using a hypnotic script and a VR environment designed based on input from individuals suffering from chronic itch. To this end, participants are instructed to close their eyes while they will continue to listen to the recorded hypnotic script developed based on general hypnotic principles as amongst others described by Yapko (2013). Direct antipruritic suggestions are used such as your skin will feel so soft, relaxed and cool, it is fully at ease. After these standardized suggestions, the participants will be alerted again. Home exercises (ca 5 min/day) include guided self-hypnosis records with direct antipruritic suggestions comparable to the ones they listen to during the intervention at location."
214672424|NCT04289883|COMBINATION_PRODUCT|Nano-particulated whey protein vs non-particulated whey protein (control)|Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.
214922113|NCT05094869|BEHAVIORAL|Self follow-up reminders|The APP would regularly send messages including the follow-up reminder (manually set up by the patient on the APP)
214922114|NCT05094869|BEHAVIORAL|Intelligent follow-up reminders|The APP would regularly send messages including the follow-up reminder (automatically set up by the APP)
214922115|NCT00893412|DRUG|Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)|1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
214922116|NCT00893412|PROCEDURE|Hysterosalpingography (HSG)|One HSG using a metal canula or balloon catheter, 30 minutes after tablet
214922117|NCT00893412|DRUG|Placebo|
214922118|NCT04634591|PROCEDURE|Bariatric surgery|Bariatric surgery (Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy) for the treatment of morbid obesity
214922119|NCT03644394|DEVICE|Implantation of IMES sensors|Surgical implantation of IMES sensors during routine surgery to improve prosthetic control
214922120|NCT05217134|PROCEDURE|DPEA|Dural puncture with 27 G Whitacre needle
214922121|NCT03902873|OTHER|Real-time audiovisual feedback|During the chest compressions, doctors receive audiovisual feedback on the depth and speed of the appropriate chest compressions.
214922122|NCT02912975|OTHER|Mirror treatment|The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
214922123|NCT02912975|OTHER|Tactile treatment|In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
214922124|NCT05423496|DIAGNOSTIC_TEST|KidneyCare|Using KidneyCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
214922125|NCT05423496|DRUG|steroid|optimization of steroids
214922126|NCT05423496|DRUG|MMF|optimization of MMF
214922127|NCT01799512|DEVICE|experimental: real-time continuous glucose monitoring|
214922128|NCT01799512|DEVICE|Active comparator: blinded continuous glucose monitoring|
214922129|NCT01217164|DIETARY_SUPPLEMENT|no intervention|received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
214922130|NCT02208713|BIOLOGICAL|Intramuscular injection|Intramuscular injection of stem cells in patients with FSHD.
214922131|NCT04087720|BIOLOGICAL|Pegloticase|intravenous (IV) infusion
214922132|NCT02743936|DEVICE|Nasal cannula|Placement of nasal cannula under non-invasive positive pressure ventilation mask
214922133|NCT02743936|DEVICE|Non-invasive positive pressure ventilation|Non-invasive positive pressure ventilation
214672425|NCT04289883|COMBINATION_PRODUCT|High molecular weight whey protein-alginate coacervates vs calcium alginate (control)|Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
214672426|NCT04259710|BEHAVIORAL|Goal-setting intervention|The participant will meet weekly with the investigator, report steps and set goals for the following week.
214672427|NCT04259710|BEHAVIORAL|Goal setting with implementation intentions|In addition to the standard goal-setting intervention, the participant will fill out a form that directs them to perform implementation intentions at weeks 1, 5 and 9.
214672428|NCT04259710|BEHAVIORAL|Pedometer only|the participant will be given a pedometer and instructed how to use it.
214672429|NCT06292312|OTHER|Craniosacral therapy|Craniosacral therapy is defined as an alternative, massage-like treatment approach using gentle manual force to address somatic dysfunctions of the head and the rest of the body.
214672430|NCT06292312|OTHER|Conventional physiotherapy|Range of motion, stretching, resistance exercises. Spasticity inhibition Balance and coordination exercises Walking training Stabilization exercises Breathing exercises
214922134|NCT03425084|DRUG|Morphine|The study was designed as an open, non-controlled drug trial, with scientists and participants blinded to the patients OCT1 status. Morphine will be given as a single dosis (0,15 mg/kg) at the end of the Surgery and later as boluses of 0,04mg/kg administrated by patient-controlled analgesia, (PCA). Blood samples with drug concentrations will be used to determine a difference in morphine AUC due to the patients OCT1 status. Questionnaire answers will be used to determine the effect of morphine due to the patients OCT1 status
214322724|NCT05886959|OTHER|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214322725|NCT05886959|OTHER|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
214322726|NCT05886959|OTHER|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214322727|NCT05886959|OTHER|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
214322728|NCT05886959|OTHER|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214485569|NCT06807801|BEHAVIORAL|Baby swimming|Participants in the treatment group will be contacted by a researcher and invited to an introductory meeting at the swimming facility, where they will receive information about the baby swimming course from the instructor. The course will take place twice a week for five weeks, totaling 10 sessions of 30 minutes each. During the sessions, mothers will be encouraged to engage in physical contact, maintain eye contact, and respond to their baby's signals. The course will also include water safety exercises.
214922135|NCT05862350|OTHER|aromatherapy inhalation with lavender essential oil|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 50% lavender essential oil，which is diluted with coconut essential oil， on the cotton chip in the diffuser clip for 8 hours each night during sleep
214922136|NCT05862350|OTHER|aromatherapy inhalation with coconut essential oil.|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 100% coconut essential oil on the cotton chip in the diffuser clip for 8 hours each night during sleep
214485570|NCT06747793|OTHER|Virtual Reality|The intervention will consist of relaxing virtual reality stimulation, which will be started after obtaining informed consent. Immersive 360-degree videos (nature environments) will be played inside a head-mounted display, with the video sound played inside headphones. Each virtual reality video will last 30 minutes. The stimulation will be provided two times per day, morning and evening, every day until the patient ICU discharge, or the maximum of 7 days will be reached. The intervention group will also receive standard intensive care unit care, same as in the control group.
214922137|NCT05499754|OTHER|pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL|a SAD was inserted by all anaesthetists participating in the study had at least 3 years experience of airway management and were experienced with both the pLMA, sLMA and I-jel. Inadequate ventilation after two attempts was considered a failed placement, and these patients were excluded, while the practitioner was freed to use an alternative airway device.
214922138|NCT05507385|BEHAVIORAL|IMAGINE-POSITIVE|The intervention will combine aspects of Memory Specificity Training (MeST), which includes information about the links between memories and emotions, with Positive Prospective Mental Imagery (PPMI), to increase vividness and savouring of positive future images, in order to harness positive affect. IMAGINE-PA will follow a treatment manual and delivery will be accompanied by a therapy workbook.
214922139|NCT05507385|BEHAVIORAL|Control|Non-directive supportive therapy (NDST) consists of individual sessions, with an empathetic, emotionally supportive practitioner and provides non-directive problem solving and monitoring. Using NDST will control for factors that may contribute to change, which are not active components e.g. speaking to an empathetic therapist. NDST will follow treatment guidelines.
214922140|NCT00646815|DRUG|growth hormone (genotropin)|Dosage regulation will follow the local recommendations of GHD treatment
215064243|NCT02400606|OTHER|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
214922141|NCT05356949|BEHAVIORAL|Intervention|The participants receive a psychological intervention including six weekly sessions. The intervention is based on methods of cognitive-behavioral therapy and delivered by a psychiatric nurse working in the participant's school.
214485573|NCT01105091|DRUG|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
214922142|NCT05263050|DRUG|Cabozantinib|Cabozantinib initiated at 40 mg daily. Dose-escalate or de-escalate based on pre-specified criteria and at set dosing schedules
215064244|NCT02400606|OTHER|Solving VP cases|See above
215064245|NCT05320354|DIAGNOSTIC_TEST|Microbial ID test|In addition to the standard of care procedure for patients suspected for a periprosthetic joint infection, the MID-test will be performed using the residual synovial fluid. Individual test results of the MID-test are not reported back to the participating sites in order to not interfere with the sites' standard of care approach.
215064246|NCT00348101|DRUG|Combined therapy with enoximone and esmolol|
215064247|NCT02547246|DEVICE|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
215064248|NCT02547246|DEVICE|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
214922143|NCT05263050|DRUG|Nivolumab|Nivolumab injection is to be administered as an IV infusion at a dose of 480 mg on day 1 of each cycle
214922144|NCT05404477|DEVICE|TransAeris System|The TransAeris System includes four TransLoc® intramuscular diaphragm electrodes, the TransAeris external stimulator, and the FrictionLoc® connectors which provide the interface between the TransLoc electrodes and the TransAeris stimulator.
215064249|NCT02052115|BEHAVIORAL|12 month exercise and weight loss intervention|
215064250|NCT05908994|OTHER|Examination|Exmainations including imaging, neurophysiological, kinetic and kinematic measurmetns. Behavioral assessments
214322729|NCT05886959|OTHER|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
214485574|NCT01105091|DRUG|Flolan®|Per Prescribing Information
214485575|NCT06860789|DRUG|AK135|IV infusion, specified dose with specified treatment frequency
214322730|NCT05886959|OTHER|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
214322731|NCT02409862|DRUG|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
214322732|NCT02409862|DRUG|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
214322733|NCT02484703|DRUG|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
214322734|NCT02484703|DRUG|RO5186582|Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
215064251|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
215064252|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
215064253|NCT02177734|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
215064254|NCT00625391|DRUG|Placebo|500 mg medicinal starch pills daily
214322735|NCT03759067|DRUG|clopidogrel 75mg|clopidogrel once daily 75mg
214322736|NCT03759067|DRUG|Clopidogrel 300 mg|clopidogrel 300mg reloading
214322737|NCT03759067|DRUG|clopidogrel 600mg|clopidogrel 600mg loading
214322738|NCT01547416|DRUG|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|"Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
214322739|NCT01547416|DRUG|no epidural drug administered|"Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
214322740|NCT04431791|DRUG|Regorafenib|oral regorafenib
214322741|NCT04431791|DRUG|Fruquintinib|oral fruquintinib
214485576|NCT06860555|DEVICE|Mydriatic Hyperspectral retinal Camera, (MHRC) and Optical coherence tomography (OCT)|Imaging with the MHRC and optical coherence tomography (OCT).
214485577|NCT06866158|BIOLOGICAL|Dendritic cell immunotherapy|DCL (Dendritic Cells+Lymphocytes) previously matured with S-Protein of SARS-CoV-2. The number of cells given depends on individual yields.
214485578|NCT06882135|DRUG|HW071021 Tablets|Administered orally at pre-specified doses once or twice daily.
214672431|NCT01595204|PROCEDURE|Diagnostic laparoscopy|"Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers."
214672432|NCT04467112|DEVICE|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
214672433|NCT00003018|DRUG|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
214672434|NCT00003018|DRUG|fluorouracil|200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle
214672435|NCT00003018|DRUG|leucovorin calcium|30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle
214672436|NCT00003018|DRUG|mitomycin C|10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
214672437|NCT01264003|DRUG|sefazolin|In prophylaxis
215064255|NCT00625391|DRUG|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
215064256|NCT00625391|DRUG|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
215064257|NCT00625391|DRUG|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
215064258|NCT04807608|OTHER|Usability Assessment|A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.
215064259|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor."
214485579|NCT06887361|BEHAVIORAL|MOON Program|The MOON Program aims to contribute to the primary prevention of sexual violence among young university students. The program aims to achieve this goal by promoting bystander attitudes and behaviors through psychoeducation and skills training that enable participants to be active agents in this process. During the sessions, beliefs that legitimize violence will be deconstructed and skills such as communication about consent and empathy will be promoted. The MOON program consists of five online sessions, which are intended to be completed autonomously on a weekly basis. Throughout the sessions, participants will learn on the following topics: SV and consent, gender stereotypes, SV myths and bystander attitudes and behaviors.
214485580|NCT06748430|OTHER|Grape variety control|Reference grape variety
214485581|NCT06748430|OTHER|Grape variety 1|First grape variety to evaluate
214922145|NCT06491875|BEHAVIORAL|Digital Storytelling (DST)|The DST activity emphasized the use of multimedia to bring the stories to life. At the beginning of the workshop, interactive circles were formed for informative interactions. Children with autism and typically developing children were asked to prepare a short video reflecting a personal experience from their own lives. The children's habits and interests were identified and they were made to work on preparing materials such as pictures, photographs, handicrafts, dough toys, etc. to be uploaded to the computer program. It was explained that they could also choose from ready-made photos in the video editing/editing program for their stories, and that they could make short audio recordings if they wished. Digital stories are usually prepared as videos that combine audio, video, and video clips to tell a story. The DST study was conducted for 16 hours over two months. During the DST, the mothers who wanted to participate and watch also participated in the study.
214922146|NCT06491875|BEHAVIORAL|Sensory Integration Therapy (SIT)|Sensory integration training for children with ASD was conducted 2 days per week for 2 months. Taking into account the results of the Dunn Sensory Profile Scale, sensory approach strategies were determined for children with ASD, taking into account low and high neurological thresholds and hyper- and hyposensitive responses in the auditory, visual, tactile, vestibular and kinesthetic sensory systems. Sensory-motor activities with deep pressure and proprioceptive stimuli were used for children sensitive to tactile stimuli, and activities with linear and slow vestibular stimuli and resistive movement were used for children with kinesthetic sensitivity. In the intervention, swings, ball pools, ramps, rotation, and fast motion inputs were used in swing for children with hypersensitivity to motion, and sensory materials with different textures, play dough, and some other sensory materials were used for children with hypersensitivity to tactile sensory system.
214485582|NCT06748430|OTHER|Grape variety 2|Second grape variety to evaluate
214485583|NCT06740643|PROCEDURE|intracanal reinforcement using short composite post|after pupectomy is done flowable composite will be applied 3mm intacanal to make a short compsite post before zircon crown aplicaction
214485584|NCT06740643|PROCEDURE|no intracanal reinforcement|no intracanal reinforcement using resin modified glass ionmer before zircon crown application
214485585|NCT06747598|DIAGNOSTIC_TEST|pregnancy test|POC pregnancy testing using peripheral serum
214485586|NCT06769724|PROCEDURE|Anterior cruciate ligament reconstruction surgery|Anterior cruciate ligament reconstruction surgery with semitendinosus tendon autograft
214485587|NCT06769724|PROCEDURE|Anterior cruciate ligament reconstruction surgery|Anterior cruciate ligament reconstruction surgery with peroneus longus autograft
214922147|NCT01376986|BEHAVIORAL|physical, psychological and social activation|
214922148|NCT04263441|BEHAVIORAL|NICE Intervention|Subjects enrolled in the intervention arm will be offered assistance in enrolling in healthcare coverage and provided assistance on where they can go for care immediately. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review.
214922149|NCT02246543|DIETARY_SUPPLEMENT|Control|Water, Toast \& Egg (Yolk only) + 0.1g 13C Octanoic Acid
214922150|NCT02246543|DIETARY_SUPPLEMENT|HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
214485588|NCT06892613|BEHAVIORAL|Emotion-Focused Couples Therapy (EFCT)|EFCT is a structured approach to couples therapy that focuses on helping partners understand and express their emotions, address attachment insecurities, and strengthen their emotional connection.
214485589|NCT06892613|BEHAVIORAL|Behavioral Couples Therapy (BCT)|BCT is a form of therapy that aims to improve relationship satisfaction through behavioral change, communication training, and problem-solving techniques.
214485590|NCT06739850|COMBINATION_PRODUCT|Identification of Risk Phenotypes of Sarcopenia|Sarcopenia is a condition characterized by progressive loss of skeletal muscle mass, strength, and function, often associated with aging. Traditionally, it is studied in older populations, but your focus is on identifying its early manifestations in young adults, potentially offering a window for prevention.
214485591|NCT06740292|DEVICE|conventional miniplates|conventional miniplates in double configuration
214485592|NCT06740292|DEVICE|InterFlex plates|InterFlex plates in configuration
214672438|NCT04939493|OTHER|Rhythmic Auditory Cueing|"Patients will perform the same movement sequence in time with the metronome beat. The frequency of the rhythmic auditory stimulation will be matched to the participants preferred movement speed, which will be assessed prior to the start of the trial, and participants typically started moving after they had heard the metronome beat two to three times. Participants will be given sufficient practice trials to ensure full understanding before the actual recording of data, and will be given 3-minutes break between trials.~On the 3rd and 5th week, the rhythm frequency was increased by 5%."
214485593|NCT06761001|DEVICE|I-PRF|After local anesthesia is injected, alveolar curettage is performed and the socket is irrigated with saline solution. I-PRF is given to patients in the experimental group.
214485594|NCT06761001|OTHER|Control|After local anesthesia is injected, alveolar curettage is performed and the socket is irrigated with saline solution.
214922151|NCT02246543|DIETARY_SUPPLEMENT|LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
214322742|NCT04935476|DRUG|Dapsone 85 mg PO BID|Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
214322743|NCT04935476|DRUG|Placebo 85 mg PO BID|Placebo oral tablet, twice daily for 21 days.
214322744|NCT06468709|DRUG|Glucocorticoids|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group
214322745|NCT06468709|DRUG|Glucocorticoids+MMF|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group B was the GC+MMF maintenance group
214322746|NCT02069522|OTHER|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
214322747|NCT02069522|OTHER|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
214322748|NCT00040885|BIOLOGICAL|infliximab|
214322749|NCT00040885|DRUG|docetaxel|
214485595|NCT06769737|DRUG|Interventional group#1|"The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) + 3 mcg of Dexmedetomidine HCL, Demexa®, 4mcg/ml (0.75 ml) total volume = 3.55 ml.~The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision. The Bromage score is a clinical scale used to determine motor block during regional anesthesia by evaluating lower limb movement: Grade 0: Full movement of hips, knees, and ankles (no block). Grade 1: Unable to lift the leg but can move knees and ankles (partial block). Grade 2: Unable to bend the knee but can move ankles (near-complete block). Grade 3: No movement in hips, knees, or ankles (complete block). Dermatomal coverage will be assessed simultaneously till it reaches the L1-L2 level. Also, The Ramsay Sedation Scale (RSS) will be used to evaluate the sedation depth, if any."
214922152|NCT02246543|DIETARY_SUPPLEMENT|HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
214922153|NCT02246543|DIETARY_SUPPLEMENT|LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
214922154|NCT05896891|DIAGNOSTIC_TEST|esophagogastroduodenoscopy (EGD), buccal swab, blood withdrawal|During routine EGD, biopsy, blood and buccal saliva samples will be withdraw and stored at San Raffaele Hospital
214922155|NCT03113942|DRUG|Pomalidomide 2 MG Oral Capsule [Pomalyst]|Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
214922156|NCT05956470|BEHAVIORAL|Meditation and breathing program : Sudarshan Kriya Yoga (SKY)|The SKY sessions (3x1,5 h on consecutive days) included online instruction in gentle stretches ('office yoga' in a sitting position), specific breathing exercises and meditation, and discussion of cognitive/behavioral coping skills. After the 3-day program, participants asked to practice the techniques once a day for about 30 min. In addition, there were weekly group exercise sessions of 1 hour where all participants were asked to join.
214922157|NCT05956470|BEHAVIORAL|Stress management education|This control intervention included viewing of educational videos on stress management and group discussions, where the sessions were equal in length to the SKY intervention. There were also weekly follow-up sessions as in the SKY group where the educational points were reviewed and experiences of the subjects during the previous week was discussed.
214322750|NCT00040885|OTHER|placebo|
214322751|NCT00969293|DRUG|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
214322752|NCT00573027|PROCEDURE|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
214322753|NCT06863701|DRUG|Etoricoxib + Betamethasone fixed dose|One tablet of 90 mg / 0.25 mg a day
214322754|NCT06863701|DRUG|Etoricoxib fixed dose|One pill of 90 mg a day
214322756|NCT06769711|PROCEDURE|Surgical procedure using Peroneus Longus for ACL reconstruction.|Surgical procedure using Peroneus Longus for ACL reconstruction.
214922158|NCT02308072|DRUG|Olaparib|50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.
214922159|NCT02308072|DRUG|Cisplatin|35 mg/m\^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m\^2)
214922160|NCT02308072|RADIATION|IMRT|2 Gy delivered in 35 fractions, on days 1-3, 1-4 or 1-5 each week for up to 7 weeks (total overall dose delivered 70 Gy)
214922161|NCT05362396|OTHER|Inspiratory Muscle Training with Powerbreath IMT device.|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 repetitions, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP
214922162|NCT03107884|DRUG|Metformin (Bed Rest)|A clinical oral dose of Metformin will be given to participant daily during bed rest
214922163|NCT03107884|DRUG|Placebo (Bed Rest)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
214922164|NCT03107884|DRUG|Metformin (2 week run-in only)|A clinical oral dose of Metformin will be given to participant daily during a two week run-in period only.
214922165|NCT03107884|DRUG|Placebo (2 week run-in only)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
214485596|NCT06769737|DRUG|Interventional group#2|"The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) total volume = 2.8 ml.~The intravascular mixture consists of 0.5 mcg/kg of Dexmedetomidine HCL, Demexa®, and a maximum of 30 mcg diluted to 4 mcg/ml. According to body weight, the total volume is 7.5 ml or less and given using a syringe pump over 30 minutes. The anesthesiologist will start the infusion once the patient is positioned supine post-spinal anesthesia and has stable hemodynamics. The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision reaches grade 3: No movement in hips, knees, or ankles (complete block). The anesthesiologist will assess dermatomal coverage until it reaches the L1-L2 and calculate the Ramsay Sedation Scale (RSS) of the depth of sedation aiming for level 2: Patient is cooperative, oriented, and calm"
214322757|NCT06769711|PROCEDURE|Surgical procedure using Hamstring tendons for ACL reconstruction.|Surgical procedure using Hamstring tendons for ACL reconstruction.
214485597|NCT06831981|OTHER|Hyperthermia|Additional hyperthermia to radiochemotherapy regime in Arm 1 and radiochemotherapy without additional hyperthermia in Arm 2.
214485598|NCT06831981|RADIATION|Radiotherapy|Radiotherapy of the pelvis
214485599|NCT06831981|DRUG|Chemotherapy with 5-fluorouracil|Chemotherapy with 5-flurouracil is given in parallel to radiotherapy
214485600|NCT06831981|DRUG|Consolidation chemotherapy with FOLFOX|Consolidation chemotherapy with 5-fluorouracil and oxaliplatin
214485601|NCT06757699|OTHER|Walking|"Participants will perform 30 minutes of walking and cycling exercises. During the cycling and walking exercises, heart rate will be calculated using the Karvonen formula based on heart rate reserve.~HRmax (maximum heart rate)=220-age HRR (%)(heart rate reserve)= (HR-HRrest)/(HRmax-HRrest)\*100~Blood samples will be collected from participants before starting the exercise, at the end of the 30-minute exercise session, and twice more at 30-minute intervals. The same participants will perform the cycling exercise half an hour later, and the same procedures will be applied."
214485602|NCT06757699|OTHER|Cycling|Cycling
214485603|NCT06757556|OTHER|Non-starchy vegetables will be provided to the participants as an intervention.|Intervention will consist of provision of vegetables (based on WHO criteria of 2-3 servings) to overweight and obese adults fo weight loss purpose.
214485604|NCT06751511|OTHER|General warm-up|The General Warm-up (Control) protocol will consist of activities such as running and dynamic, active, and passive movements, adapted to suit the varied sports disciplines included in the study. These exercises will align with the principles of elevation, activation, and mobilization, aiming to enhance mobility across key muscle groups, from the arms and shoulders to the lower back and legs. Each session will include clear demonstrations to ensure proper technique and pacing, with participants performing a standardized number of repetitions. Researchers will supervise participants closely to verify accurate form and consistent execution during the intervention.
214672439|NCT04939493|OTHER|Bilateral arm training|Training will consist of 20 minutes of bilateral arm training In each session, patients will be seated comfortably at a table in the following limb positions: ankles in neutral dorsiflexion, knees and hips placed at 90°, shoulders in 0° flexion, elbows in 60° flexion, and wrists in neutral position of flexion/extension
214922166|NCT02398903|OTHER|Blood samples for measurement of drug Css|Blood samples for measurement of drug Css
214322758|NCT07087249|BEHAVIORAL|Ultrasound Visual Feedback|Speech therapy using real-time ultrasound imaging to provide visual feedback on tongue placement and movement. Aimed at improving speech accuracy and motor planning in children with Childhood Apraxia of Speech (CAS). The intervention follows principles of motor learning and includes 12 individual sessions over 6 weeks (twice per week). Practice alternates between ultrasound-assisted and non-assisted phases to promote generalization.
214322759|NCT07087249|BEHAVIORAL|Traditional Speech Therapy|Standard speech motor therapy for children with Childhood Apraxia of Speech (CAS), based on evidence-based motor learning approaches. No visual feedback tools are used. Therapy focuses on blocked and random practice, varied feedback, and increasing speech complexity. Delivered in 12 sessions over 6 weeks (twice per week).
214322760|NCT06924684|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|Tab Rosuvastatin 40mg (weight) at presentation. Tab Rosuvastatin 20mg at night for 30 days.
214322761|NCT06924684|DRUG|Placebo|Placebo caspule
214322762|NCT07086170|OTHER|Psychological First Aid Training|Structured training based on psychological first aid principles. Delivered in six 60-minute sessions over three weeks. Includes theoretical content, interactive methods, and case-based exercises to build disaster response competencies.
214322763|NCT07086898|OTHER|Integrated Neuromuscular Inhibition Technique|Patients will receive integrated neuromuscular inhibition technique in the form of intermittent ischemic compression, strain counterstrain, and muscle energy technique plus postural correction exercises
214322764|NCT07086898|OTHER|Postural Correction Exercise|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction exercises.
214322765|NCT07086547|OTHER|AI-Based Fever Management Education|This intervention consists of a fever management education program developed using ChatGPT 4.0, a large language model by OpenAI. The educational content includes seven pages and eight visuals explaining how to manage fever in children. The content was reviewed by pediatric specialists and revised accordingly. It is delivered as a one-time structured session to mothers in the intervention group.
214322766|NCT03968822|DRUG|Lidocaine 2%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
214322767|NCT03968822|DRUG|Lidocaine 1%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
214322768|NCT03968822|DRUG|Bupivacaine 0.25%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
214322769|NCT03968822|DRUG|Bupivacaine 0.5%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
214322770|NCT03968822|DRUG|Intralipid, 20% Intravenous|a 250ml bag administered intravenously
214322771|NCT03968822|OTHER|Saline intravenously|a 250ml bag administered intravenously
214322772|NCT03968822|OTHER|Saline|3 mL of test solution to a skin area on the thigh, 2cm in diameter
214322773|NCT06909682|DEVICE|Intervention Group (Device Group - AI-Based Remote Monitoring)|This intervention utilizes a mini-invasive wearable device for continuous remote monitoring of chronic heart failure (CHF) patients. Unlike traditional telemonitoring, it integrates AI-driven predictive analytics to track oxygen saturation (SpO₂), heart rate variability (HRV), electrodermal activity (EDA), temperature, respiratory rate, and sleep quality in real time. The system generates automated alerts for healthcare providers, enabling early detection of CHF exacerbation and proactive intervention through teleconsultations, medication adjustments, or in-person evaluations. Data is securely transmitted to a cloud-based platform, allowing continuous risk assessment and personalized care adjustments. This approach aims to reduce unnecessary hospitalizations, enhance patient monitoring, and optimize heart failure management through advanced AI-based digital health technology.
214322774|NCT06909682|OTHER|Standard Clinical Follow-Up|Participants in this group will receive standard chronic heart failure (CHF) management according to current clinical guidelines. Their follow-up will consist of scheduled in-person visits every three months, during which they will undergo routine laboratory tests (including BNP, NT-proBNP, renal function, and electrolytes), as well as echocardiography and ECG evaluations. Treatment adjustments will be made based on clinical assessments and reported symptoms. Unlike the intervention group, these participants will not use a wearable device, and their condition will be monitored exclusively through traditional hospital visits and self-reported health status.
214322775|NCT06909695|OTHER|Blood volume and environmental testing|Testing blood volume measures, iron stores, and physiological responses to acute environmental exposures of heat, cold, and high-altitude (each environment independently)
214322776|NCT06909266|OTHER|OT Hope 0 - 5 ans Therapeutic tool|OT Hope 0 - 5 ans Therapeutic tool for self determination of pediatric goals in occupational therapy
214322777|NCT06909266|OTHER|Qualitative interviews with parents|qualitative interviews to understand how vestibular impairments affect their child's daily life activities, challenges encountered, and strategies used to support participation.
214922167|NCT02398903|OTHER|DXA and impedancemetry|Body composition by DXA and impedancemetry
214922168|NCT01479569|PROCEDURE|Pericardiocentesis|
214922169|NCT02164331|BEHAVIORAL|JNC guideline training|Providers will receive a series of trainings on what the JNC guidelines for treating uncontrolled hypertensives are and strategies for meeting those guidelines.
214922170|NCT00520533|BIOLOGICAL|Chimeric monoclonal antibody cG250|"First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st \& 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (124I-cG250).~Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No 124I-cG250 will be used in the 2nd cycle.~Up to 2 cycles available."
214922171|NCT00520533|DRUG|Sunitinib malate|"First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.~Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.~Up to 2 cycles available on-study."
214922172|NCT02239133|DEVICE|ProVATE vaginal pessary|
214922173|NCT02438826|DRUG|Galcanezumab 300 mg|Administered SC
214922174|NCT02438826|DRUG|Placebo|Administered SC
214922175|NCT02397122|BIOLOGICAL|platelet-rich fibrin|autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods
214922176|NCT02397122|PROCEDURE|connective tissue graft|connective tissue graft was harvested from the palatal region of each patient by single incision method
214922177|NCT02397122|PROCEDURE|coronally advanced flap|buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
214922178|NCT02614742|DRUG|SFX-01|An intervention releasing sulforaphane.
214922179|NCT02614742|DRUG|Placebo|Placebo otherwise identical to Active product
214922180|NCT05694884|DRUG|Placebo|Placebo Comparator
214922181|NCT05694884|DRUG|ASLAN004|ASLAN004
214922182|NCT05193916|DRUG|chiglitazar sodium tablets|the drugs will be given orally once a day
214922183|NCT05193916|DRUG|Placebo|no active drug contained
214922184|NCT03453034|DRUG|TQ-B3233|QD or BID in different stage of this research
214322778|NCT06908915|DEVICE|Nd:YAG laser 1064 nm|The entire face of each patient with rosacea was treated with long-pulse 1064nm Nd:YAG laser. The parameters that been used were spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 mJ and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval.
214322779|NCT06909669|BEHAVIORAL|Group brief transdiagnostic cognitive-behavioral therapy|Eight-session treatment based on Barlow's Unified Protocol. These sessions include: improving motivation and commitment to treatment, understanding the functioning of emotions, emotional awareness training, developing more flexible and adaptive thinking patterns, reduction of emotional avoidance and emotion-driven behaviors; awareness and tolerance of physical sensations; interoceptive and situational emotional exposure; achievement, maintenance and relapse prevention.
214922185|NCT04448834|DRUG|Blinatumomab|liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
214322780|NCT06909669|BEHAVIORAL|Group relaxation|The participants in this group will receive basic training in Jacobson's progressive relaxation with a similar periodicity to the ultra-brief intervention.
214672440|NCT04939493|OTHER|Conventional physical therapy program|Scapular mobilization. Thoracic spine mobilization. Mechanical assisted (active and passive) exercises. Therapeutic positioning as weight bearing on the paretic arm. Opening and closing closed fist. Strengthening exercise. Stretching of spastic muscles.
214672441|NCT03901378|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:
214922186|NCT01004640|GENETIC|DNA analysis|
214922187|NCT01004640|GENETIC|Southern blotting|
214922188|NCT01004640|GENETIC|cytogenetic analysis|Correlative studies
214922189|NCT01004640|GENETIC|polymerase chain reaction|
214922190|NCT00005891|DRUG|cyclophosphamide|
214922191|NCT00005891|PROCEDURE|Allogeneic Bone Marrow Transplantation|
214922192|NCT00598312|DRUG|Leuprolide Acetate for Injectable Suspension|Sustained release injectable microspheres, 22.5 mg, one injection every 84 days, 3-month product
214922193|NCT05379283|DRUG|Lidocaine|effect of lidocaine on sweat production during exercise in the heat
214922194|NCT05379283|OTHER|control|one arm will be pretreated with topical lidocaine, the other arm will not
214922195|NCT01839214|DRUG|VB-201 160mg|
214922196|NCT01839214|DRUG|Placebo|
214922197|NCT01651520|DRUG|PET with 11C-Flumazenil|PET with 11C-Flumazenil.
214922198|NCT00625417|PROCEDURE|breast biopsy|
214922199|NCT00625417|PROCEDURE|histopathologic examination|
214922200|NCT00625417|PROCEDURE|light-scattering spectroscopy|
214922201|NCT00625417|PROCEDURE|therapeutic conventional surgery|
214922202|NCT05615363|DRUG|OPC 131461 10mg group|OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days
214922203|NCT05615363|DRUG|OPC 131461 5mg group|OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days
214922204|NCT05615363|DRUG|OPC 131461 2mg group|OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days
214922205|NCT05615363|DRUG|OPC 131461 1mg group|OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days
214922206|NCT05615363|DRUG|Placebo|Placebo tablet，once-daily oral administration for 14 days
214922207|NCT00000672|DRUG|Didanosine|
214922208|NCT06343415|OTHER|GAIT-assisted training|"GAIT duration starts when walking is started. The participant will walk as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Speed starts at 1 km/h and is adjusted accordingly.~The body weight support (BWS) is kept between 60-100% of total body weight. The BWS is adjusted so the knee flexion in the stance phase does not exceed 10 degrees. The guidance force is kept at 100% and symmetric in all sessions."
214922209|NCT06343415|OTHER|STEP-assisted training|"STEP duration starts when stepping and elevation are started. The participant will step as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Step cadence starts at 40 steps/minute and cadence is adjusted accordingly.~The leg loading starts a 5 kg and is, if possible, increased to a maximum of 40% of total body weight while adjusting knee extension to ≤10 degrees flexion in stance. The guidance force is kept at 100% and symmetric in all sessions."
214922210|NCT05779683|DEVICE|Caretaker Device placement|placement of the device on the postoperative cardiac surgery patient that has a pulmonary artery catheter for comparison readings
214322781|NCT06909669|BEHAVIORAL|Group ultra-brief transdiagnostic cognitive-behavioral therapy|This is a reduction to four sessions of the brief transdiagnostic treatment (Experimental group 1). For this reduction, sessions 1 and 2 of the brief transdiagnostic treatment will be combined, sessions 3 and 6 will be eliminated, and sessions 7 and 8 will be combined. As in experimental group 1, the treatment groups will consist of 8-10 people. Each session will have a duration of 1.5 hours and the intervention will be carried out on a weekly basis, with a maximum duration of four weeks.
214322782|NCT06909669|BEHAVIORAL|Individual ultra-brief transdiagnostic cognitive-behavioral treatment format|Participants of this group, wil receive the same treatment than group 2 (ultra-brief transdiagnostic cognitive-behavioraltreatment in group format) but individual format. Each session will have a duration of 1 hour and the intervention will be carried out on a weekly basis, with a maximum duration of four weeks.
214322783|NCT06923449|OTHER|Multidisciplinary Tumor Board|Institution of Multidisciplinary Tumor Board for Gastric Cancer at Fondazione Policlinico Gemelli in november 2019
214322784|NCT06924645|PROCEDURE|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplantation (FMT) is delivered as a single dose of oral microbiota capsules within 72 hours before starting standard therapy.
214322785|NCT06924645|OTHER|Standard Therapy|Standard Therapy Alone
214322786|NCT06923787|DRUG|Lidocaine|intravenous infusion of lidocaine
214322787|NCT06923787|DRUG|Dexamethasone|intravenous infusion of dexamethasone
214322788|NCT06923787|DRUG|Placebo|saline solution intravenous infusion
214922211|NCT00308191|DRUG|Formoterol Fumarate|
214922212|NCT00308191|DRUG|Tiotropium Bromide|
214922213|NCT04576520|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
214922214|NCT04576520|PROCEDURE|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
214922215|NCT03595514|OTHER|Single injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
214922216|NCT03595514|OTHER|Double injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
214922217|NCT03595514|DRUG|lidocaine, bupivacaine, epinephrine, dexamethasone|lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
214922218|NCT06224816|DEVICE|Custom 3D mask (3DM) application in neonate|Premature infants with a birth weight less than 1500 g r first received 3D mask during 4 hour, then crossed over to traditional mask.
214922219|NCT06224816|DEVICE|Traditional mask (TM) application in neonate|Premature infants with a birth weight less than 1500 g r first received traditional mask during 4 hours, then crossed over to 3D mask.
214922220|NCT05005195|RADIATION|Low dose abdominal computed tomography scan|A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer
214922221|NCT04854512|DRUG|Metformin DR|Delay-Release Metformin
214922222|NCT04854512|DRUG|Metformin IR|Immediate Release Metformin
214922223|NCT04854512|DRUG|Metformin DR Placebo|Metformin DR Placebo
214922224|NCT04854512|DRUG|Metformin IR placebo|Metformin IR placebo
214922225|NCT06032195|DRUG|Custodiol-N|heart will preserved in and will be treated with Custodiol-N solution
214922226|NCT06032195|DRUG|Custodiol|heart will preserved in and will be treated with Custodiol solution
214922227|NCT06045676|DEVICE|ECG|ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.
214922228|NCT06577883|DIAGNOSTIC_TEST|Chest X-ray Tomosynthesis|An imaging device that uses X-rays projected from multiple angles to reconstruct a three-dimensional images of the chest
214922229|NCT04831255|DRUG|triamcinolone acetonide extended-release injectable suspension|ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
214922230|NCT02553499|BIOLOGICAL|MK-1248|IV infusion
214922231|NCT02553499|BIOLOGICAL|pembrolizumab|IV infusion
214922232|NCT05377307|GENETIC|Pell's lentiviral-based gene-edited immune cell therapy|No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.
214672442|NCT02704429|DRUG|PRN1008|"Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks."
214672443|NCT03048448|DRUG|Fevipiprant|Single 450mg dose
215064260|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor."
215064261|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor."
215064262|NCT00252031|BEHAVIORAL|Dialectical Behavioral Therapy|
215064263|NCT05415254|DRUG|Calcitriol|Calcitriol supplementation orally
214485605|NCT06751511|OTHER|Inspiratory muscle warm-up (Placebo - %15)|The placebo inspiratory muscle warm-up protocol will utilize the POWERbreathe® device at 15% of maximal inspiratory pressure (MIP). This placebo protocol will consist of two sets of 30 breaths, separated by a 60-second rest interval, with participants seated and wearing a nose clip. Proper technique will be taught during a prior familiarization session, and participants will be closely monitored during testing to ensure accurate execution. This protocol is designed to function as a placebo, effectively concealing the study's true objective to improve data validity and reliability.
214485606|NCT06751511|OTHER|Inspiratory muscle warm-up (%40 IMW)|This study will implement a respiratory muscle warm-up protocol at 40% of maximal inspiratory pressure (MIP) using the POWERbreathe® device, as this intensity is considered optimal for effectively stimulating respiratory muscles. The protocol will consist of two sets of 30 breaths, with a 60-second rest period between sets, conducted while participants are seated and wearing a nose clip. Training for proper technique will be provided during the familiarization session, and participants will be closely monitored throughout the tests to ensure correct and consistent execution.
215064264|NCT06040424|COMBINATION_PRODUCT|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
215064265|NCT06040424|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
214672444|NCT03703531|PROCEDURE|Cardiopulmonary resuscitation|CPR performed because of out-of-hospital cardiac arrest
214672445|NCT04415138|DEVICE|Robotic-assisted mitral valve repair|Mitral valve repair using robotic technology (DaVinci X platform)
214672446|NCT06207344|DRUG|Dexmedetomidine and propofol|Group 1: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Meantime, propofol was infused at 4-12mg/kg/h intravenously to maintain the depth of anesthesia.
214672447|NCT06207344|DRUG|Dexmedetomidine and desflurane|Group 2: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was inhaled to maintain the depth of anesthesia.
214672448|NCT00392873|BEHAVIORAL|EAMD+Calories|During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
214672449|NCT00104104|DRUG|zoledronic acid|4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
214672450|NCT02163369|DRUG|Peppermint and Lavender Essential Oils|
214322789|NCT04196556|BEHAVIORAL|Active Families|This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
214672451|NCT01786018|DRUG|Thiotepa|
214672452|NCT01786018|DRUG|Busulfan|
214672453|NCT01786018|DRUG|Fludarabin|
214672454|NCT01786018|PROCEDURE|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10\^7 CD3 cells/kg recipient weight and cryopreserved.
215064266|NCT02566785|OTHER|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
215064267|NCT05199636|OTHER|Dragon fruit product|Frozen dragon fruit based beverage
215064268|NCT02544867|BEHAVIORAL|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
215064269|NCT02269553|DEVICE|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
215064270|NCT02269553|DEVICE|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
215064271|NCT02720055|OTHER|Psychological workbook|
215064272|NCT02720055|OTHER|Basic information workbook|Basic rehabilitation information that represents current practice.
215064273|NCT03073317|DIAGNOSTIC_TEST|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
215064274|NCT00281099|DEVICE|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
215064275|NCT01795976|GENETIC|NY-ESO-1 T cells|
215064276|NCT01795976|DRUG|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
215064277|NCT01795976|DRUG|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
215064278|NCT01795976|BIOLOGICAL|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
215064279|NCT03425435|OTHER|QoL and developed questionnaires for healthcare research|Questionnaires
215064280|NCT01049230|RADIATION|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
215064281|NCT03423446|DRUG|Telotristat Ethyl|Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose
215064282|NCT02441153|OTHER|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
215064283|NCT02323685|BIOLOGICAL|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
215064284|NCT02991495|BIOLOGICAL|Stamaril, Sanofi Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
215064285|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Bio-Manguinhos|"1. Full dose~2. Fractional dose: one fifth (1/5)"
215064286|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
215064287|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
215064288|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
215064289|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
215064290|NCT00271921|BEHAVIORAL|Calorie controlled diet|
215064291|NCT06981390|DRUG|Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy)|Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, followed by aspirin monotherapy
214322790|NCT04196556|OTHER|Madrid's Primary Healthcare Standardized Service portfolio|"An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook."
214322791|NCT02516124|PROCEDURE|Autologous HSCT|1st AHSCT
214322792|NCT01046955|DRUG|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
214672455|NCT01786018|RADIATION|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
215064292|NCT06981390|DRUG|Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy)|Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 6 months, followed by aspirin monotherapy
215064293|NCT06981390|DRUG|Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)|Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 12 months, followed by aspirin monotherapy
215064294|NCT06602310|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application. Telematic non-face-to-face preoperative assessment.
215064295|NCT04116437|DRUG|Zanubrutinib|Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
215064296|NCT06982261|OTHER|Voice-activated smart speakers|"Participants will attend a single 90 to 120-minute in-person baseline visit to complete standardized questionnaires and review a list of smart speaker-based tasks. They will select three tasks; all will receive an Echo Show and a Fitbit Versa. Additional digital health devices (e.g., blood pressure monitor, in-home motion sensors) will be provided based on their selections. Participants will learn to interact with Alexa, followed by a second home visit one week later for task-specific setup and device installation.~The team will conduct weekly or bi-weekly check-in calls for two months, with additional home visits as needed. At two months, a home visit will include questionnaires and a 30-60 minute interview on intervention feasibility. Participants will then use the devices independently for one month, with a final home visit at three months for questionnaires and a closing interview."
215064297|NCT06658938|DRUG|Blinatumomab|"Beginning 3 months after transplantation, 1 cycle of blinatumomab was performed every 3 months for a total of 4 maintenance cycles.~Dosage of blinatumomab: 9 ug/d D1-4, 28 ug/d D5-14"
215064300|NCT06658860|PROCEDURE|Modified Socket Shield Technique|The modified socket shield technique involves partial retention of the buccal aspect of the tooth root during extraction to preserve the surrounding alveolar bone and soft tissue. This technique is used to optimize the condition for delayed implant placement by preventing resorption of the alveolar ridge.
215064301|NCT06658860|PROCEDURE|Conventional Tooth Extraction|Conventional tooth extraction involves the complete removal of the tooth without the use of the socket shield technique. This arm served as the control group, with alveolar ridge changes observed and compared with those in the experimental arm over time.
215064302|NCT06658418|PROCEDURE|Erector Spinae Plane Block|dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries.
215064303|NCT06662396|DRUG|MK-6552|Oral Gelatin Coated Capsule
215064304|NCT06662396|DRUG|Diltiazem|Oral Extended-Release Capsule
215064305|NCT06661863|PROCEDURE|alveolar ridge preservation with bioactive glass|Bioactive glass grafted into alveolar preservation.
215064306|NCT06661863|PROCEDURE|alveolar ridge preservation with autologous bone|Autologous bone graft in alveolar ridge preservation.
215064307|NCT06661811|DRUG|CAR-T|CAR-T cells
215064308|NCT06661200|DEVICE|SMC signal recording|SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.
214922233|NCT06147596|OTHER|Head impact exposure|The cohort is exposed to naturalistic head impacts (heading) during voluntary participation in a soccer match. All participants are regular soccer players and are therefore not exposed to excessive head impacts compared to their regular exposure.
214922234|NCT04073888|PROCEDURE|Semen collection|Semen collection for seminogram and spermocytogram
214922235|NCT06684132|OTHER|Inspiratory muscle training|The H-IMT will be performed in seven sets of three-minute cycles consisting of two minutes of training followed by one minute of rest in the training workload. Each session will consist of 14 minutes of loading and seven minutes of rest for a total of 21 minutes.
214672456|NCT01786018|DRUG|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
214922236|NCT06684132|OTHER|Exercise|Stretching exercises for pectoral muscles, neck muscles and back muscles, strengthening exercises for upper extremity and back muscles and posture exercises will be applied.
214672457|NCT01786018|DRUG|Cyclosporine|"CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below."
214922237|NCT05376449|BEHAVIORAL|HealthPartners NeuroWell Exercise Program|A 12-week exercise program geared towards individuals with neurological disorders or injuries run by the Regions Hospital Rehabilitation department at the HealthPartners Neuroscience Center. The exercise programming will be designed by the exercise physiologists and adapted to individuals' abilities. Exercise prescriptions will be designed based on established guidelines, level and completeness of injury, individual functional ability, individual goals, and baseline exercise assessments. Program will consist of strength and endurance adaptive exercise.
214922238|NCT04538781|DEVICE|VASCADE MVP VVCS|The VASCADE MVP Venous Vascular Closure System (VVCS) is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 - 12F inner diameter (maximum 15F OD) procedural sheaths, with single or multiple access sites in one or both limbs.
214922239|NCT00842023|DRUG|Nesiritide|Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
214922240|NCT00842023|DRUG|Nitroglycerin|5-10 mcg/min titrating per protocol based on blood pressure
214922241|NCT06575972|DIETARY_SUPPLEMENT|JoyRise Recovery Powder|JoyRise Recovery Powder is a dietary supplement that contains Dihydromyricetin (DHM) and other natural ingredients. It is designed to mitigate the aftereffects of alcohol consumption. Participants will mix one serving in 8-12 oz of water and consume it the morning after alcohol consumption.
214922242|NCT06575972|DIETARY_SUPPLEMENT|Placebo|A placebo solution that is visually and tastefully similar to JoyRise Recovery Powder but contains no active ingredients. It will be mixed in 8-12 oz of water and consumed the morning after alcohol consumption.
215064309|NCT06662253|DRUG|Anti-Xa Guided Dosing of Low Molecular Weight Heparin|Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
215064310|NCT06662253|DRUG|Standard of Care Dosing|Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
215064311|NCT06660043|OTHER|physical activity|40 min circuit training session
215064312|NCT06660043|OTHER|analgesic physical therapy|physical therapy with massage and Transcutaneous Electrical Nerve Stimulation in a 40min session
215064313|NCT06660043|OTHER|analgesic physical therapy AND physical activity|25 min circuit training session and 15 min physical therapy
215064314|NCT06662110|DIAGNOSTIC_TEST|PSRscore|PSRscore calculated based on baseline serum immune proteomics
214322793|NCT03836092|PROCEDURE|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
214485607|NCT06763497|OTHER|Systematic Oral Feeding Education Program|The experimental group will receive 11 intervention sessions during the study period. The first intervention will occur immediately after the pretest and will involve a systematic oral feeding education program, including guided feeding techniques and practical feeding demonstrations. During the feeding session, caregivers' practices will be recorded on video. These recordings will then be reviewed with the caregiver to identify areas for improvement.The remaining 10 intervention sessions will take place daily on days 2-4, 6-9, and 11-13, during which the researcher will observe the primary caregiver's feeding practices, provide assistance, and offer tailored suggestions. On the 14th day, the experimental group will complete the same posttest assessments as the control group.
215064315|NCT06660160|OTHER|Exercise program supported by audiovisual media|"The intervention group will perform the group exercise protocol during HD sessions. The videos with the exercises will be broadcast on all televisions simultaneously, so that the volunteers perform the exercises along with the person in the video.~* The first level of difficulty includes 5 exercises for the lower limbs and 3 exercises for the upper limbs. One set of 10 repetitions will be performed for each exercise per session.~* The second level includes 3 exercises for the lower limbs and 2 exercises for the upper limbs. These consist of proprioceptive neuromuscular facilitation diagonals for both the lower and upper limbs. One set of 10 repetitions will be performed for each exercise, once per week, for 3 weeks.~* The third level includes 8 combined lower and upper limb exercises performed simultaneously. One set of 20 repetitions will be performed for each exercise.~Exercises will be performed 3 times per week over a 4-week period, for a total of 12 planned exercise sessions."
214672458|NCT01786018|DRUG|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
214672459|NCT01786018|DRUG|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
214322794|NCT00965068|OTHER|Cholesterol|
214322795|NCT03905551|PROCEDURE|Cold Dialysis|Dialysate temperature reduced to 35oC for a period of 7 months.
214322796|NCT03905551|PROCEDURE|Typical Dialysis|Dialysate temperature is set at 37oC for a period of 7 months
214322797|NCT03905551|PROCEDURE|Exercise|Aerobic Intradialytic exercise training
214322798|NCT05010174|DRUG|MDR product|Observation of patients previously receiving MDR product(s)
214672460|NCT01786018|PROCEDURE|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
214672461|NCT01274897|BIOLOGICAL|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
214672462|NCT01274897|BIOLOGICAL|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
215064316|NCT06658327|OTHER|Dynamic stretching|Group A will receive 2\*10 repetitions of dynamic stretching of hamstrings and calf muscles in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
215064317|NCT06658327|OTHER|Static stretching|Group B will receive 2\*10 repetitions of static stretching of hamstrings and quads in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes. The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
215064318|NCT06660680|DRUG|Methylene Blue|Received MBI treatment to their surgical incisions upon completion of surgery
215064319|NCT06660966|PROCEDURE|M TAPA block|Grup M: The patients who underwent M-TAPA block were placed in the supine position. The right upper quadrant of the abdomen was cleaned with antiseptic solution. For the block procedure, 20-30 ml of 0.25% bupivacaine, 22G 8.5 cm stimuplex needle and 10-14 Hz high frequency USG were prepared for the procedure. The USG probe was determined in the costochondral area at the mid-clavicular line, and the internal and transversus abdominis muscles were determined. The needle was advanced with the in plane technique from cephalad to caudal, passing through the skin, subcutaneous, external and internal oblique muscles, respectively, and then over the transversus abdominis fascia. After the target was confirmed with 2 ml of saline, 0.3 mg / kg bupivacaine (20-30 ml) was administered.
214485608|NCT06769035|DIETARY_SUPPLEMENT|Cocoa, amaranth seed and ginger|Sachet with 20gr of cocoa, 10g of amaranth seed and 1g of ginger, one dose per day for 12 weeks
214485609|NCT06769035|DIETARY_SUPPLEMENT|Amaranth seed|Sachet with 10g of amaranth seed one dose per day for 12 weeks
214485610|NCT06769035|DIETARY_SUPPLEMENT|Cocoa|Sachet with 20gr of cocoa one dose per day for 12 weeks
214922243|NCT06388954|DEVICE|True Transcutaneous auricular Vagus Nerve Stimulation (TaVNS)|"Vagus Nerve Stimulation (VNS) consists in the activation of the Vagus nerve using electrical current, Transcutaneous auricular VNS works through the placement of noninvasive electrodes on the neck or auricle for stimulation of the auricular branch of the vagus nerve.~Transcutaneous electrical nerve stimulation (TENS) electrodes will be used to stimulate the auricular branch of the Vagus nerve, The active electrode will be placed on the cymba concha of the left ear. This reduced the risk of taVNS side eﬀect on the heart. The reference electrode will be placed outside the left ear attached to the tragus. TENS parameters used were: 30 minutes treatment time, a pulse width of 300 microseconds, pulse frequency 20 hertz and a duty cycle of 25%. The stimulation intensity was set at super-threshold levels, such as 200% of patient perceptual threshold."
215064320|NCT06660966|PROCEDURE|ESP block group|"In Group E, patients who were to undergo ESP block were placed in the lateral position with the right side up. The T8-T10 dorsal region was cleaned appropriately with antiseptic solution. For the block procedure, 20-30cc %0.25 bupivacaine, 22G 8.5cm stimuplex needle and 10-14Hz high frequency USG were prepared for the procedure.~The USG probe is first determined in the sagittal direction, the spinous process of the T10 thoracic vertebra is then followed 1-2 cm above the transverse process, with the in plane technique, the skin, subcutaneous tissue and erector spina muscle are passed, the needle is touched to the transverse process and the target is confirmed with 2cc saline, then 20-30 cc (0.5 mg / kg bupivacaine) of local anesthetic is administered and the procedure is terminated."
214485611|NCT06769035|DIETARY_SUPPLEMENT|Placebo|Sachet with coloring and flavoring, one dose per day for 12 weeks one dose per day for 12 weeks
214485612|NCT02030964|DRUG|DFMO|
214485613|NCT02030964|DRUG|Celecoxib|
214485614|NCT02030964|DRUG|Cyclophosphamide|
214485615|NCT02030964|DRUG|Topotecan|
214672463|NCT05278793|DRUG|Ferrous fumarate|Ferrous fumarate 200mg oral
214672464|NCT01821677|DRUG|Danazol Capsules|
214672465|NCT01821677|DRUG|Placebo|
214922244|NCT06388954|DEVICE|Sham Trancutaneous auricular Vagus Nerve Stimulation|Sham transcutaneous vagal nerve stimulation will be performed by the same procedures of the study group but without electrical stimulation. The active electrodes will be attached to the left cymba conchae. The taVNS stimulator will be turned on and the stimulation intensity will be increased until the patient perceived the electrical stimulation and then the stimulator will be turned off.
214672466|NCT01188018|BEHAVIORAL|Brief Advice (BA)|Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
214322799|NCT02215070|DRUG|Pasireotide|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
214322800|NCT05489094|COMBINATION_PRODUCT|Nutrition Education and Growing Up Milk for 1 - 3 years old|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories. while Intervention product is formulated to deliver macro- and micronutrients as part of the dietary intake for children at 1-3 years old with Iron-C formula
214322801|NCT05489094|BEHAVIORAL|Nutrition Education|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories.
214322802|NCT05241223|OTHER|Behavior change intervention|This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
214922245|NCT06139198|BEHAVIORAL|Self-MAnagement intervention for Reducing The epilepsy burden among Ugandans|SMART-U sessions are operationalized in written curricula, including an intervention manual, participant manual, slides, and handouts typically delivered over a period of 10-12 weeks.
214922246|NCT01726270|DRUG|tamsulosin|0.4 mg
214922247|NCT03136640|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
214922248|NCT06664970|DRUG|Azacitidine or Ruxolitinib combined with Selinexor|"1. The initial dose of Selinexor combined with Azacitidine for the treatment of MDS patients is 40mg QW, adjusted according to blood tests, with the highest dose ≤ 60mg QW.~   Azacitidine: The initial dose is 75 mg/m ², administered subcutaneously or intravenously, with a cycle of 1-7 days and 28 days until ineffective or intolerant.~2. Selinexor combined with Ruxolitinib for the treatment of patients with MPN symptoms: Selinexor dose: 40mg QW; Adjust according to the blood count, with a maximum dose of ≤ 60mg QW.~Initial dose of Ruxolitinib: platelet count\>100 × 109/L before enrollment, initial dose is 15 mg BID; Platelets range from 50-100 × 109/L, with an initial dose of 10 mg BID. Until ineffective or intolerant."
214922249|NCT01455532|DRUG|Iniparib (SAR240550-BSI-201)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
214922250|NCT01455532|DRUG|Gemcitabine|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
214922251|NCT01455532|DRUG|Carboplatin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
214922252|NCT01455532|DRUG|Placlitaxel|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
214922253|NCT01455532|DRUG|Pegylated liposomal doxorubicin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
214922254|NCT04288687|DRUG|Niraparib Pill|Niraparib 200 mg by mouth daily (2 x 100 mg pills)
214922255|NCT01609647|DRUG|Prasugrel|Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
214922256|NCT01609647|DRUG|Clopidogrel|Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
214922257|NCT02502812|DRUG|Clop F1|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
214922258|NCT02502812|DRUG|Clop F2|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
214922259|NCT02502812|DRUG|Innovator|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
214922260|NCT00996151|DRUG|Testosterone MD-Lotion|Single dose Testosterone MD-Lotion 2%
214922261|NCT02756130|DRUG|Birinapant|Given IV
214322803|NCT05241223|OTHER|Educational program|The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.
215064321|NCT06658639|DEVICE|Ultrasound lipolysis|Ultrasound lipolysis uses a Luvitra device to emit low-frequency ultrasound pulsed waves. The abdominal area is divided into two sections and the patient is placed in a comfortable supine lying position. The cavitation head is applied slowly to each segment in small circular movements. The treatment lasts 30 minutes on each side, with each session lasting 60 minutes. The same abdominal area is treated every two weeks for three months. The procedure involves cleaning the skin with alcohol cotton.
215064322|NCT06658639|DEVICE|Cryolipolysis|The study utilized Lipocool, a cryolipolysis apparatus from Korea, with a thermoelectric cooling element. Participants were treated with thermal coupling gel on their abdomen, and the tissue was drawn into the applicator with a moderate vacuum. The device was used for 40-50 minutes, with energy extraction controlled by sensors. The system stopped cold exposure and the clinician released the vacuum. Participants underwent cryolipolysis sessions every 2 weeks for 3 months.
214322804|NCT02904252|OTHER|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F\>2).
214322805|NCT04041505|BEHAVIORAL|(feeding modality)|The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
214485616|NCT06860074|BEHAVIORAL|Sustainable Environmental Health Programs|"* Sustainable Future: Environment, Ecological Balance and Health,~* Ecological Balance and Pollution: Protecting Environmental Health~* Ecological Balance and Environmental Health~* A New Life for Waste: A Sustainable Future with Recycling~* Environmental Behaviors~* Recycling for Street Animals: A Shed Construction Project"
214485617|NCT06858644|DIAGNOSTIC_TEST|BUB1-Integrated Deep Learning Model for Gastric Cancer Metastasis and Cachexia Prediction|This intervention utilizes a deep learning model that integrates BUB1 gene expression, radiopathomics (quantitative imaging features), and histopathological data to predict peritoneal metastasis and cachexia in gastric cancer (GC) patients. Unlike traditional approaches, this model combines genomic, imaging, and pathological data to enhance early detection and improve prognostic accuracy. The model aims to identify key patterns in multi-modal data to offer personalized predictions for GC progression. By leveraging artificial intelligence, it seeks to support clinicians in decision-making, improving patient outcomes through earlier interventions and tailored treatments. This approach offers a novel, comprehensive method for predicting GC metastasis and cachexia, providing a unique tool compared to existing interventions.
214485618|NCT06930443|OTHER|Oxygen consumption measurement|After arrival to the ICU, prior to cessation of iv anaesthetics and extubation, indirect calorimetry will be performed by connecting a metabolic monitor to the ventilator during a minimum of 20 minutes.
214485619|NCT06924281|BEHAVIORAL|Brief motivational interviewing with personalized feedback|The manualized intervention is delivered individually in two phases by an interventionist trained in motivational interviewing. The intervention includes liver health information and explains connections with weight-related behaviors. The enhanced (experimental) group receives personalized feedback, i.e., a summary of self-reported drinking patterns and results of liver imaging with Fibroscan®, i.e., steatosis (liver fat) and fibrosis (liver scaring) scores. The feedback is used to develop discrepancies between a goal of halting or reversing health risks associated with consuming alcohol versus continuing to drink. The sessions are matched in duration and interventionist skill level with the standard (control) group.
214922262|NCT02756130|DRUG|Carboplatin|Given IV
214922263|NCT02756130|OTHER|Laboratory Biomarker Analysis|Correlative studies
214922264|NCT02756130|OTHER|Pharmacological Study|Correlative studies
214922265|NCT06747364|OTHER|Alcohol (Ethanol)|Alcohol will be administered to participants by research staff. In Phase 1, participants will consume alcohol designed to produce a targeted blood alcohol concentration (BAC) of 0.06% using the modified Widmark equation.
214922266|NCT03691311|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Two injections on days 1 and 8 previous to surgery breast cancer excision
214922267|NCT06181084|DRUG|LY3410738|Administered orally.
214322806|NCT02718105|GENETIC|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
214322807|NCT02381392|DEVICE|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
214322808|NCT03732092|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
214922268|NCT06181084|DRUG|Esomeprazole|Administered orally.
214922269|NCT01397877|DRUG|BKM120|per os, 60mg/j, until progression or unacceptable toxicity
214922270|NCT00404001|DRUG|MD-0727|
215064323|NCT06658639|OTHER|Low Caloric Diet|A low-calorie diet is a structured plan that restricts daily caloric intake, often used for weight loss. It involves consuming 1,200 to 1,500 calories daily, creating a calorie deficit. However, it requires discipline and safety. The diet is low in fat (20-25%), high in complex carbohydrates (60%), and sufficient in protein (25-50%).
214322809|NCT05078736|OTHER|Moderate intensity intermittent training|In group A participants will receive moderate intensity intermittent training including running of 5 km with 1-min at 70% of maximal aerobic speed with interval of 1-min passive recovery, exercises will be performed by gym trainer for 5 weeks including 3 days/week
214322810|NCT05078736|OTHER|Moderate intensity continuous training|In group B participants will receive moderate intensity continuous training ran continuously the same 5 km at 70% of maximal aerobic speed, exercises will be performed by gym trainer for 5 weeks including 3 days/week.
214322811|NCT00931905|DRUG|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
215064324|NCT06657963|DIETARY_SUPPLEMENT|Opuntia ficus-indica Supplementation|Participants are required to consume oral supplementation of OFi fine powder packaged in individual sachets (LifeGreenTM, LifeTree Asia, Selangor, Malaysia) at the dosage of 1500 mg once daily for 3 months.
215064325|NCT06659913|BEHAVIORAL|Exercise training|Session 1: Consist of high intensity interval training performed on spinning bikes. An exercise physiologist will supervise the participants to perform a light 10 min warm-up, followed by 4 min working periods (intervals) interspersed by 3 min active breaks. The intensity should be 85-95% of estimated peak heart rate, corresponding to approximately 16 on the Borg scale (17). There will be a maximum of 10 participants in each group, depending on how many patients who are recruited for each of the two inclusion periods.I In addition, participants are encouraged to participate in the physical education at school and encouraged to perform exercise during the weekend, either with their family or friends.
214322812|NCT00931905|OTHER|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
214322813|NCT02502786|BIOLOGICAL|humanized anti-GD2 antibody|
214322814|NCT02502786|DRUG|GM-CSF|
214322815|NCT04386967|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
214322816|NCT04386967|DRUG|Keytruda|Anti-PD-1 antibody
214322817|NCT00978731|DRUG|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~* 5 days on, 2 days off~* 6 days on, 1 day off~* Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
214322818|NCT05991037|BIOLOGICAL|Blood sampling for psychoactive drugs dosage|4 blood samples for psychoactive drugs identification and dosage will be taken on arrival at the emergency room during fall management
214322819|NCT05593653|DRUG|Suvorexant|20mg taken at bedtime for 4 weeks
214322820|NCT05593653|DRUG|Placebo|placebo taken at bedtime for 4 weeks
214922271|NCT06383910|BEHAVIORAL|Square Stepping Exercise|The exercise is performed on a thin exercise mat divided into 40 small squares. Participants are shown specific step patterns on this mat and are instructed to repeat the same step pattern until the end of the exercise mat. Once a pattern is completed on the exercise mat, its mirror-image pattern is also performed. The basic pattern is repeated 3-5 times, followed by the same number of repetitions for the mirror-image pattern. However, if participants struggle with the pattern, it is repeated until they learn it. Individuals execute the demonstrated pattern on the exercise mat and return to the beginning of the mat after completing it.
214922272|NCT02171234|DRUG|Placebo|
214922273|NCT02171234|DRUG|BIA 2-093|
214922274|NCT02036073|DRUG|recombinant human erythropoietin|rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
214922275|NCT00048386|BIOLOGICAL|autologous neuroblastoma vaccine|A vaccine dose of 0.3 x 108 IL-2 secreting cells/patient/injection will be used. Injections will be given twice monthly for two months, then monthly for four months, for a total of eight vaccine injections over six months.
214922276|NCT02819973|OTHER|Educational Video1|
214922277|NCT02819973|OTHER|Educational Video 2|
214922278|NCT02819973|OTHER|Usual Care 3|
214922279|NCT03012997|OTHER|Fraction of inspired oxygen 40%|
214922280|NCT03012997|OTHER|Fraction of inspired oxygen 100%|
214922281|NCT05914597|OTHER|Setting up home delivery of Colon capsule endoscopy|Feasibility study of home delivery of CCE
214922282|NCT03767153|DEVICE|Venus Viva|"The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.~Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits."
214922283|NCT04977427|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dexamethasone inserted into lower punctum at the end of cataract surgery in order to control inflammation in the eye for the following 30 days after surgery.
214922284|NCT04977427|DRUG|Prednisolone Acetate 1% Oph Susp|Standard Prednisolone taper following cataract surgery, QID for one week, followed by TID for one week, BID for one week, and QDaily for one week, then stop.
214922285|NCT01610882|DEVICE|Panda first followed by manual pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Panda will be used first, manual method 5 mins later.
214922286|NCT01610882|DEVICE|Manual first followed by Panda pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Manual method will be used first, Panda 5 mins later.
215064326|NCT06661070|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
215064327|NCT06661070|OTHER|Dry Needling|A dry needle with size 0.30 × 40 (Agupunt, Barcelona, Spain)
215064328|NCT06661499|OTHER|establish an artificial neural network model|to establish an artificial neural network model for pathogen diagnosis in ICU pneumonia
215064329|NCT06660797|OTHER|Group1: A matching gutta-percha master cones will be used in up and down motion 2mm amplitude at a frequency of 100 strokes during approximately 1 min in each prepared canal.|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by matching gutta percha master cone , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
215064330|NCT06660797|OTHER|Group2: XP-endo Finisher activation: The XP-endo Finisher instrument will be used in continuous rotation for 1 mintute|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by XP-endo Finisher used in continuous rotation for 1 minute , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
215064331|NCT06660797|OTHER|Group 3:EasyClean system activation : EC instrument coupled to the countrangle handpiece and operated with a micromotor at approximately 20,000 rotations per minute in continuous rotation.|after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by EasyClean system activation , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
214922287|NCT06192862|BEHAVIORAL|Assessment of screening intention and Transtheoretical Model stages for CRC screening|"Screening Intentions will be measured by asking the subject, How much do you agree or disagree: I am intending to have colon cancer screening within the next 6 months. Subjects who strongly disagrees or somewhat disagrees are considered not having screening intention. Subjects who somewhat agrees or strongly agrees are considered having screening intention. For subjects who has screening intention, they will be asked if they have plan to arrange a consultation with primary care physician to collect FIT kits in next 3 months."
214922288|NCT05596929|DIAGNOSTIC_TEST|Artificial intelligence|After the patients under triage classification to which randomly allocates in two groups. The group with AI intervention and the other without AI intervention.
214922289|NCT04304430|DRUG|Dapagliflozin|Initiation of dapagliflozin according to clinical indication
214922290|NCT04304430|DRUG|DPP-4 inhibitor|Initiation of DPP-4i according to clinical indication
214322821|NCT04389216|DEVICE|Cool-tip electrode for Radiofrequency Ablation|Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
214322822|NCT06259409|DEVICE|Regenn® Negative Pressure Therapy System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
214322823|NCT06259409|DEVICE|Prevena™ Incision Management System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
214322824|NCT06783361|DEVICE|Transcranial Magnetic Stimulation with figure-eight coil|A total of 50 sessions will be applied for 2 weeks, 5 sessions a day, 5 days a week. There will be at least 30 minutes rest time between each session. It includes first an intermittent theta burst (iTBS) protocol at a frequency of 5 Hz with 1800 pulses to the left DLPFC at 90% motor threshold, followed by a continuous theta burst (cTBS) protocol at a frequency of 5 Hz with 600 pulses to the right DLPFC at 80% motor threshold.
214485620|NCT06924281|BEHAVIORAL|Brief motivational interviewing with standard health information|The manualized intervention is delivered individually in two phases by an interventionist trained in motivational interviewing. The intervention includes liver health information and explains connections with weight-related behaviors. The standard (control) group does not receive personalized feedback. The sessions are matched in duration and interventionist skill level with the enhanced (experimental) group.
214922291|NCT01965366|BEHAVIORAL|Virtual reality exposure therapy|Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
214322825|NCT06783361|DEVICE|Transcranial Magnetic Stimulation with figure-eight coil|A total of 50 sessions will be applied for 2 weeks, 5 sessions a day, 5 days a week. There will be at least 30 minutes rest time between each session. One session will consist of a high frequency (5 Hz) intermittent theta burst (iTBS) of 1800 pulses at 90% motor threshold to the left DLPFC followed by a pseudo continuous theta burst (cTBS) of 600 pulses at 5 Hz frequency at 80% motor threshold to the right DLPFC. The sham cTBS treatment will be applied by placing the coil at a 45-degree angle to the application site.
214322826|NCT00256659|BEHAVIORAL|Early assessment and referral to ancillary care services vs. standard care|
214672467|NCT01188018|BEHAVIORAL|Motivational Interviewing (MI)|Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
214672468|NCT01188018|BEHAVIORAL|Health Education (HE)|Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
214922292|NCT01965366|DRUG|0.5 mg DEX|A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
214922293|NCT05424848|OTHER|Ultasonographic measurement|Ultrasonographic measurements of the patients will be evaluated by Dr. Merve Damla Korkmaz. Patients will be positioned in a semi-dark room with the knees fully flexed. Ultrasonographic measurements will be made to evaluate the femoral cartilage thickness of both knees, with images taken from the suprapatellar axillary position. Images of the intercondylar area, lateral and medial femoral condyles of the right and left knees will be taken and the measurements will be made from these areas, 3 measurements will be taken from each knee and the average of these measurements will be taken.
214922294|NCT00982332|DRUG|Betamethasone|betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
214922295|NCT00982332|DRUG|isotonic sodium chloride solution (placebo)|4 ml intramuscular
214922296|NCT01416493|DRUG|s.c. injections of bovine intestinal Alkaline Phosphatase|daily subcutaneous treatment with two injections of 2000IU bIAP for three days
214922297|NCT03204994|DRUG|Indocyanine Green|Fluorescence guided lymphatic mapping using indocyanine green.
214922298|NCT04892329|OTHER|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
214922299|NCT04968080|DEVICE|Infrared Cameras Inc. (ICI) FMX 400 Infrared (IR) Camera System|Infrared thermal camera
214922300|NCT04968080|DEVICE|Welch Allyn SureTemp Plus 690|Oral thermometer
214922301|NCT04968080|DEVICE|Welch Allyn ThermoScan PRO 6000|Ear thermometer
214922302|NCT04968080|DEVICE|Infrared Cameras Inc. (ICI) HotSpot Infrared (IR) NonContact Infrared Thermometer|Forehead temperature gun
214922303|NCT03258294|DRUG|Melatonin(Circadin®)|
214922304|NCT03258294|DRUG|Placebo Oral Tablet|
214922305|NCT02073929|DRUG|Liraglutide for 26 weeks|GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
214922306|NCT02073929|DRUG|placebo|Placebo s.c. daily for 26 weeks
214922307|NCT06577480|OTHER|No intervention|No intervention
214922308|NCT04528940|DIAGNOSTIC_TEST|PD-1/PDL-1 staining|Every endometrial or ovarian carcinoma will be stained for PD-1/PDL-1. The stage and grade of the tumor will be determined and correlation between tumor grade and stage and PD-1/PDL-1 staining will be made.
214922309|NCT03198312|DEVICE|CathiportTM|fully implanted
214922310|NCT03198312|DEVICE|Implant Port|fully implanted
214922311|NCT01736644|DEVICE|Electrocautery|Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
214922312|NCT01736644|DEVICE|Bipolar sealer Aquamantys|Aquamantys use in tourniquet and tourniquetless total knee replacement.
214922313|NCT01710579|PROCEDURE|Anorectal 3D-high resolution manometry|Anorectal probe is used with a single-use protective sheath with an inflation balloon Control of balloon deflation Patient in left lateral decubitus position with hips flexed to 90° (this position is the most commonly use and the most convenient) Transanal insertion 2 minutes resting period: resting anal pressure will be evaluated the second minute of rest Sustained voluntary maximal squeeze for at least 30 seconds; the maneuver will be repeated once Valsalva Bear down maneuver; the maneuver will be repeated once Anorectal reflexes evaluation with 20-, 40- and 60-ml intra-rectal balloon inflation Probe removal
214922314|NCT01710579|PROCEDURE|Anorectal radial endosonography (rotative 360° probe)|Patient in left lateral decubitus position with hips flexed to 90° Transanal probe insertion Evaluation of internal and external anal sphincter integrity and puborectalis muscle at rest
214922315|NCT01710579|PROCEDURE|Dynamic anorectal endosonography (sagittal and radial)|Patient in left lateral decubitus position with hips flexed to 90° Rectum is filled with 50-ml water Probe is covered with a water-filled balloon to maintain the acoustic window for the ultrasound wave Transanal probe insertion Slow and manual rotation of the linear probe through 360° to identify the various layers constituting the anal wall (mucosa, IAS, EAS), the layer forming the rectal wall and the perirectal tissues (puborectalis muscle, bladder, and vagina or prostate) After the initial examination, the patient will be asked to make a defecation effort with the probe left in the same position
214322827|NCT05953480|BIOLOGICAL|Redasemtide|Lyophilized white powder reconstituted in 0.9% saline for injection
214322828|NCT05953480|DRUG|Placebo|Lyophilized white powder reconstituted in 0.9% saline for injection
214322829|NCT02488785|BEHAVIORAL|Virtual Diabetes Self-Care and Education Program|Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
214322830|NCT02488785|DEVICE|Fitbit|Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
215064332|NCT04621240|BEHAVIORAL|Online SMART & Stress Solutions|1\. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
215064333|NCT06078527|DEVICE|Cheung-Bearelly Aesthesiometer|The Cheung-Bearelly Aesthesiometer will be used to deliver a range of calibrated stimuli through the channeled flexible laryngoscope to assess sensation of the laryngopharynx.
215064334|NCT06078527|PROCEDURE|Transnasal Laryngoscopy|A procedure to examine your larynx (voice box)
215064335|NCT06078527|OTHER|Questionnaires|Patient-reported health and behavioral outcomes measures will be administered
214322831|NCT02488785|DEVICE|Smartphone|All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
214322832|NCT05839665|DEVICE|Humidified high-flow nasal oxygen|Humidified high-flow oxygen delivered via the Optiflow device
215064336|NCT05978674|BEHAVIORAL|rocking bed group|Babies assigned to the intervention group first will be placed on a rocking bed after routine care such as feeding and diaper changes and when the newborn is stable. A rocking attempt will be applied to the baby placed in the rocking bed for 30 minutes. After 30 minutes, the baby will not be lifted from the bed and will lie in bed for 90 minutes. After a period of two hours in total, the babies will be cared for and fed. Then, babies will be quota and control group measurements will be made.
215064337|NCT06018077|BEHAVIORAL|Dietary İntake, Biochemical parameters, Antropometric measuruments|Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.
215064338|NCT05894889|BIOLOGICAL|Pembrolizumab 200 mg IV infusion|"Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion"
214485621|NCT06878573|DRUG|Intravitreal Aflibercept Injection|After instillation of topical anesthesia (0.4% oxybuprocaine hydrochloride and lidocain; own production), sterilization of the eyelid (Betaisodona solution 11% povidone-iodine, Mundipharma, Limburg, Germany), and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) will be injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions.
214322833|NCT05839665|DEVICE|Standard nasal cannula|Oxygen delivered with high flows via a standard nasal cannula
214322834|NCT05839665|DEVICE|Facemask|Oxygen delivered with facemask
214322835|NCT02685774|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
214322836|NCT02685774|DRUG|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
214322837|NCT01368575|PROCEDURE|CABG|CABG
214322838|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
214322839|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
215064339|NCT01821066|DRUG|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
215064340|NCT01821066|DRUG|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
214322840|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
214485622|NCT06878573|DEVICE|Laser speckle flowgraphy|"The RetFlow consists of a fundus camera equipped with a diode laser at a wavelength of 830 nm and a digital charge-coupled device camera (750 x 360 pixels). A total of 118 images are acquired at a rate of 30 frames per second over a 4-second measurement period. The main output parameter of LSFG, mean blur rate (MBR), is calculated from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. MBR was calculated for the total ONH area, defined by a ellipsoid region of interest (ROI). By using the on-board software, the MBR will be calculated in the large vessels within the ONH (ONH-MV, mean MBR of vascular area) and the tissue area containing the microvasculature (ONH-MT, mean MBR of tissue area)"
214485623|NCT05860452|OTHER|ropivacaine|single shot bilateral TAP block
214485624|NCT05860452|OTHER|normal saline|single shot bilateral TAP block
215064341|NCT01821066|DRUG|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
215064342|NCT01821066|DRUG|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
215064343|NCT00025207|DRUG|gefitinib|Given orally
215064344|NCT00025207|OTHER|laboratory biomarker analysis|Correlative studies
215064345|NCT02106572|DRUG|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
215064346|NCT02106572|DRUG|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
215064347|NCT06842381|OTHER|Telerehabilitation Program|A support system for the treatment of cervical pain based on Web technologies will be used, accredited as a health website. This system has a structure based on 4 sections: database treatment, database user profiles, recommendations, and feedback/biofeedback procedures. This system allows the registration and introduction of a subject, and modification of a treatment with electroanalgesia and exercises, according to the symptomatic evolution of the pain. It is based on an initial patient assessment system.
215064348|NCT06842381|OTHER|Face to Face Program|Electroanalgesia therapy and the McKenzie exercise protocol will be applied by six therapists with more than 10 years of experience in both procedures. This program will be developed in the Health Sciences clinical units of the Universities of Almeria, Granada and Malaga.
214322841|NCT01368575|PROCEDURE|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
215064349|NCT06290505|DRUG|Durvalumab|"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."
214322842|NCT00293384|DRUG|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
215064350|NCT02686632|BEHAVIORAL|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
214322843|NCT00293384|DRUG|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
214322844|NCT00293384|DRUG|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
214322845|NCT00293384|DRUG|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
214322846|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
214322847|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
214322848|NCT05120219|DRUG|FDC tablet|single and multiple doses of HR20033 FDC tablet
214322849|NCT00888303|DRUG|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
214322850|NCT00888303|DRUG|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
214322851|NCT00888303|PROCEDURE|Thyroidectomy, total or partial|Surgical standard intervention
214322852|NCT02333578|PROCEDURE|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
214322853|NCT00773175|DRUG|recombinant human hyaluronidase|150 Units in 1 mL
214322854|NCT02984176|DRUG|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
214322855|NCT02984176|DRUG|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
214322856|NCT05422248|DEVICE|Series Topical Oxygen Therapy|Standard care provided to the whole wound followed by intervention device care to the whole wound.
214322857|NCT05422248|DEVICE|Paired Topical Oxygen Therapy|Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
214322858|NCT01302964|DRUG|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
214322859|NCT01302964|DRUG|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
214322860|NCT04820283|BEHAVIORAL|Care manager intervention (nurse)|In this intervention, a primary care nurse provides the participant with self-management support to manage stress-related problems. The participant meets with the nurse face-to-face for typically 2 to 6 sessions.
215064351|NCT06659653|DRUG|PRG2302|Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
215064352|NCT06658925|DRUG|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
215064353|NCT06868641|BEHAVIORAL|TAIL-PrEP|The TAIL-PrEP intervention is comprised of two components: (1) monthly cab-LA monitoring with specimens self-collected by patient and mailed to a lab for processing; and (2) monthly HIV prevention coaching with personalized cab-LA feedback.
215064354|NCT01526941|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
215064355|NCT01526941|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
215064356|NCT07081321|BEHAVIORAL|Lithotomy position|Participants in the lithotomy decubitus position group were in the lithotomy position at the second stage of labor of delivery.
215064357|NCT07081321|BEHAVIORAL|Lateral Position|Participants in the lateral position group were in the lateral position at the second stage of labor of delivery.
215064358|NCT07081321|BEHAVIORAL|Upright Position|Participants in the upright position group were in the upright position at the second stage of labor of delivery.
215064359|NCT07080502|OTHER|Application for the creation of a questionnaire on alterations in vaginal penetration|"Development of domains and items:~Through the judgment of 10 experts, the set of items of each domain will be identified.~Development of the scale:~A pilot will be carried out to guarantee the viability and feasibility of what was created in the previous stage; The questionnaire will be applied to 30. participants.~Evaluation of the scale:~At this stage, the Questionnaire will be applied to a larger sample: 10 participants for each item create. In the same way as the previous stage, the Female Sexual Function Index will be applied together with the created questionnaire."
214672469|NCT03939910|DEVICE|Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.|Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
214322861|NCT04820283|BEHAVIORAL|CBT|In this intervention, the participant receives therapist supported self-help CBT. The participant randomized to this arm can choose to receive the treatment via an online treatment platform or via bibliotherapy, i.e., a self-help book.The treatment is comprised of 12 modules or chapters, which entail information about stress management techniques including behavioral activation and exposure. The participant that chooses online CBT is guided by a therapist who provides feedback on homework assignments through written asynchronous text messages; the patient who chooses bibliotherapy is guided by a therapist in typically 2 to 5 face-to-face sessions at a primary care clinic.
214672470|NCT00162877|DRUG|Rabeprazole vs. Esomeprazole|
215064360|NCT07079501|OTHER|Test Eye Cream (Formula# 899675 44A)|A white cream formulated as eye cream (Formula# 899675 44A) provided by L'Oréal R\&I China. Participants will apply 1ml of the product on the full face and neck twice daily for 8 weeks. The aim is to evaluate its efficacy on facial wrinkles, eye bags, dark circles, and other skin aging signs in healthy Chinese women.
215064361|NCT07081750|BEHAVIORAL|Dyadic tailored home-based activity program intervention|"1. During hospitalization, caregivers receive health education on managing behavioral and psychological symptoms of dementia. Patient-caregiver dyads participate in structured ward activities to assess activity preferences and capabilities, forming the basis for co-developing individualized home activity plans with training for caregivers.~2. A customized home activity kit is provided at discharge.~3. Post-discharge, a 12-week tailored home intervention is implemented, using a patient-centered model with caregiver support. Caregivers record participation and behavioral responses, which inform dynamic adjustments to activity content, difficulty, and methods."
215064362|NCT07081750|OTHER|Routine care|Participants will receive routine care consisting of standard hospitalization treatment, basic caregiver education on behavioral and psychological symptoms of dementia (BPSD), routine discharge instructions (including general home activity recommendations without personalized intervention assessment, planning or implementation), and routine post-discharge follow-up for 12 weeks.
215064363|NCT07081503|DRUG|ADX-626|siRNA duplex oligonucleotide
215064364|NCT07081503|DRUG|Placebo|Saline
215064365|NCT07081269|OTHER|observation alone|No interventions will be conducted during the observation period, maintaining participants' normal daily living conditions.
215064366|NCT07080801|DRUG|RAG-21|Intrathecal bolus administration of RAG-21 will be initiated at a dose of 120 mg, prepared with a dedicated solvent into a 10 mL sterile aqueous solution. Dosing will occur every 2 weeks, with the dose escalating to 180 mg after 3 administrations. Subsequently, the dosing interval will be extended to every 4 weeks. The investigator will then select an optimal dose from the completed dose cohorts or continue dose escalation until the maximum tolerated dose (MTD) is reached, with a predefined maximum dose of 210 mg. For continued treatment, the investigator-determined optimal dose will be administered as a fixed dose every 4 weeks, with a total treatment duration of 6 months (8 administrations).
215064367|NCT07080840|BEHAVIORAL|Nursing education A+1|Dietary education once
215064368|NCT07080840|BEHAVIORAL|Nursing education A+2|Dietary education twice
214322862|NCT06533969|PROCEDURE|Epidural Spinal Cord Stimulation|"This will be a one time surgery lasting no more than 2 hours where ESCS electrodes will be connected to an external stimulator approved for human research. Stimulation intensity and parameters will be configured before each session for optimal upper extremity motor function.~The ESCS approach will include surgical implantation of temporarily placed leads in the cervical epidural space and connection cables tunneled percutaneously through the skin for \<30 days"
215064369|NCT07080840|BEHAVIORAL|Nursing education A+3|Dietary education three times
215064370|NCT07080840|BEHAVIORAL|Nursing education B+1|Medication education once
215064371|NCT07080840|BEHAVIORAL|Nursing education B+2|Medication education twice
215064372|NCT07080840|BEHAVIORAL|Nursing education B+3|Medication education three times
214322863|NCT06533969|DEVICE|Electrocorticographic|Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
214322864|NCT06533969|DEVICE|Electroencephalographic|Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
214322865|NCT06629220|OTHER|Tools|In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of men with suicidal thoughts/behavior.
215064373|NCT07080840|BEHAVIORAL|Nursing education AB+1|Combined dietary and medication education once
215064374|NCT07080840|BEHAVIORAL|Nursing education AB+2|Combined dietary and medication education twice
215064375|NCT07080840|BEHAVIORAL|Nursing education AB+3|Combined dietary and medication education three times
215064376|NCT07080892|PROCEDURE|distal iPACK|● In the distal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the most distal part of the thigh, between the femoral condyles.
215064377|NCT07080892|PROCEDURE|proximal iPACK|● In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).
215064378|NCT07080463|PROCEDURE|vasculens and cta|using vasculens and cta for one group and cta for the second group (control)
214322866|NCT04718870|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
214322867|NCT06268613|DRUG|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
214322868|NCT06268613|DRUG|EU sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
215064379|NCT07080658|DRUG|[14C]-WPV01|Single oral dose of 600 mg \[14C\]-WPV01
215064380|NCT07081126|DRUG|Daratumumab (Subcutaneously)|Kidney transplant recipients with late ABMR and de novo DSA treated with daratumumab (1800mg subcutaneous, weekly x 4, then monthly x 6).
215064381|NCT07081126|OTHER|control group|Kidney transplant recipients with late ABMR and de novo DSA treated with standard therapies (IVIG, plasmapheresis, rituximab, etc.) prior to the start of the daratumumab study.
215064382|NCT02147197|DRUG|Ulipristal acetate (UPA)|UPA tablet
215064383|NCT02147197|DRUG|Placebo|Matching placebo tablet.
215064384|NCT00119028|PROCEDURE|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
215064385|NCT01762774|DRUG|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
215064386|NCT01762774|DRUG|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
215064387|NCT05579509|DRUG|Midazolam and Fentanyl|Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
215064388|NCT05579509|BEHAVIORAL|Educational Reassurance|Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
215064389|NCT02744612|DRUG|Brentuximab Vedotin|Given IV
215064390|NCT02744612|DRUG|Ibrutinib|Given PO
215064391|NCT06482203|OTHER|Trunk Extensor Endurance training & Scapular mobilization|"Trunk Extensor Endurance Training Level 1:Prone shoulder extension or prone shoulder raises Level 2: Prone back extension Level 3: Prone Ys or Y raises Level 4:Super man pose Level 5:Super man or prone cobra~(The given position should be hold for 10 seconds and performs 25 repetitions with 3 sec rests in between the efforts)~Scapular Mobilization:~Intervention program includes, supero-inferior, medio-lateral along with circumduction movements).~3 sets of 10-15 repetitions of each of the supero-inferior ,medio-lateral, and circumduction movements Between each session, there was a10 or 30-second break. The length of rests was adjusted depending on the patient's endurance"
215064392|NCT06786780|COMBINATION_PRODUCT|Drug: Cisplatin|Organoids were constructed prior to simultaneous radiochemical therapy
215064393|NCT04956731|OTHER|Pharmacist Provision of Medication Abortion|Pharmacists providing start to finish medication abortions
215064394|NCT05215808|DRUG|RBN-3143|Oral Administration of tablets
215064395|NCT02712983|DRUG|TIP|TIP dose regimen
215064396|NCT02712983|DRUG|TIP and placebo|TIP and inhaled placebo dose regimen
215064397|NCT02712983|DRUG|Placebo|Inhaled placebo dose regimen
215064398|NCT01045148|RADIATION|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
215064399|NCT01045148|RADIATION|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
215064400|NCT00628472|DRUG|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
215064401|NCT06489158|DIAGNOSTIC_TEST|Detect VOCs in exhaled gas|The exhaled gas of the patients should be collected within one week before surgery and be tested within 24 hours after enrollment. Then receive treatment according to the existing diagnosis and treatment process.
215064402|NCT03947164|OTHER|biopsy|"For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.~Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination."
215064403|NCT03381365|DEVICE|CuraSeal Percutaneous Intraluminal Closure System|
215064404|NCT05360966|DRUG|0.003% AR-15512 ophthalmic solution|Administered via topical ocular instillation
215064405|NCT05360966|DRUG|AR-15512 vehicle ophthalmic solution|Inactive ingredients administered via topical ocular instillation
215064406|NCT06506903|DEVICE|Medtronic Avalus Ultra|Surgical aortic valve replacement with the Medtronic Avalus Ultra bioprosthesis for management of aortic stenosis and regurgitation.
215064407|NCT04823858|PROCEDURE|Lumbar Interbody Fusion|The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
215064408|NCT02891148|DRUG|BI 690517|
215064409|NCT03522246|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
215064410|NCT03522246|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
215064411|NCT03522246|DRUG|Placebo Oral Tablet|Placebo tablets will be administered twice daily
215064412|NCT03522246|DRUG|Placebo IV Infusion|IV placebo will be administered once every 4 weeks
215064413|NCT06194604|DEVICE|Instrument-assisted soft tissue mobilization|Instrumented soft tissue mobilization is a type of manual therapy method.Istrumented soft tissue mobilization aims to reduce fascial limitations by increasing circulation. Increases in localized blood flow and soft tissue realignment promote muscle function, increased normal joint movement, and decreased pain.
215064414|NCT06194604|OTHER|Routine rehabilitation programe|Routine rehabilitation programe consisting of stretching and strengthening exercises will be applied.
214922316|NCT05056259|DEVICE|18F-FDG PET/CT|"The PET/CT procedure will be performed according to the institutional standard with 18F-FDG (0.8-1.2 mCi /kg) injection following 6 h fasting. Blood glucose was controlled to be \<150 mg/dl. PET/CT from the vertex to the middle femur will be obtained 60 min after FDG injection.~MDCT examination without IV contrast will be done for attenuation correction and anatomic localization followed by PET images from the skull vault to the mid-thigh region.~Images of CT and corresponding functional PET images are displayed in axial, coronal and sagittal planes.~PET/CT data will include tumor size and extension, LN invasion\& distant metastasis SUVmax will be calculated for all positive lesions, Metabolic parameters including SUVmax, SUVmean, TLG \& MTV will be calculated for primary tumor.~Data of PET will be compared with other diagnostic imaging and postoperative pathologic data."
215064415|NCT04683029|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered intravenously.
215064416|NCT04683029|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered subcutaneously.
215064417|NCT04683029|DRUG|Placebo|Placebo will be administered intravenously or subcutaneously.
215064418|NCT06027255|DIAGNOSTIC_TEST|IL-6|"Compare IL-6 level , as a marker of inflammation in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae."
215064419|NCT06027255|DIAGNOSTIC_TEST|cytokines (IL-17, and IFN-ɣ)|"Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae"
215064420|NCT06027255|BEHAVIORAL|Compass 31|Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients
215064421|NCT06782932|DRUG|AGEN2373|"1. Up to 3 doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) will be tested in Phase I to determine the dose to be used in Phase II. AGEN2373 will be administered as a 60 minute IV infusion (-5/+15 min) on Day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 1 mg/kg, 3 mg/kg, and 10 mg/kg IV"
215064422|NCT06782932|DRUG|Balstilimab|"1. 450 mg will be administered as a 30 minute IV Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV"
215064423|NCT06782932|DRUG|Cyclophosphamide|"1. 200 mg/m2 will be administered as a 30 minute IV infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 200 mg/m2 IV"
215064424|NCT06782932|DRUG|GVAX|"1. Vaccine (5 × 108 cells) will be administered on Day 2 of each cycle for a total of 6 cycles of treatment. Six intradermal injections will be given in the upper thighs and non-dominant arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: GVAX"
215064425|NCT06782932|DRUG|AGEN2373 (RP2D)|"1. Drug: Up to 3 doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) will be administered as a 60 minute IV. Infusion (-5/+15 min) on Day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 1 mg/kg, 3 mg/kg, and 10 mg/kg IV"
215064426|NCT06782932|DRUG|Balstilimab|"1. 450 mg will be administered as a 30 minute IV. Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV"
214322869|NCT06268613|DRUG|US sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
214322870|NCT05149742|BEHAVIORAL|Cognitive and audiometry evaluation|"For both Patients and controls:~* Cognitive functions evaluation~* Tonal and vocal audiometry~* Self questionnaires"
214322871|NCT06843980|DEVICE|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
214322872|NCT06843980|OTHER|Non-Surgical Treatment|The non-surgical arm includes assist devices, physical conditioning, prescription or nonprescription medications, creams, vitamins, or supplements, intra-articular Injections, physical therapy and weight loss.
215064427|NCT06782932|DRUG|mKRASvax|"1. mKRASvax will be administered on Day 1 of each cycle and on Day 8 of Cycle 1 only. mKRASvax is given as 5 subcutaneous injections administered in the upper thighs and arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
215064428|NCT06438120|BEHAVIORAL|Chatbot-based positive psychology intervention|Eight positive psychology exercises will be delivered, including positive introduction, personal strengths, using strengths, three good things, gratitude, hope and optimism, active/constructive responding, and savoring.
215064429|NCT05929703|BEHAVIORAL|HELP|This is usual (standard) care across hospitals in this trial. A multidisciplinary team of nurse specialists, social workers, and volunteers implement daily protocols focused on orientation, cognitive stimulation, early mobilization, sleep enhancement, support with visual and hearing aids, mealtime assistance, hydration, reduction in polypharmacy, and nursing-based delirium prevention protocols.
214322873|NCT06146569|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.
214322874|NCT06146569|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
214322875|NCT03323489|RADIATION|Celiac Plexus Radiosurgery|patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
214322876|NCT06333795|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Treatment is given as capsules.
214922317|NCT01019759|PROCEDURE|pulmonary vein isolation|The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
214922318|NCT01006187|DRUG|Liposomal lidocaine|4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection
215064430|NCT05929703|BEHAVIORAL|FAM-HELP|Family members and care partners will provide daily emotional and social support during hospitalization. Additionally, family members and care partners will engage in HELP-based protocols throughout the day. The rationale for this protocol augmentation is two-fold: (1) HELP may not consistently have available volunteers (e.g., short-staffing) during a hospital stay, and (2) patients may be more likely to engage in therapeutic activities with a family member given the connection and comfort level.
214922319|NCT01006187|DRUG|Vapocoolant spray|medium stream spray on arm for 4-10 seconds prior to injection
214922320|NCT01006187|OTHER|Rubbing adjacent to the injection site|rubbing adjacent to the injection site before and during injection
215064431|NCT06830889|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
215064432|NCT06830889|DRUG|T-DM1|Administration by intravenous infusion for a cycle of 3 weeks.
215064433|NCT06119971|DEVICE|ACUPRESSURE|Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
215064434|NCT04493424|DRUG|Spesolimab|Spesolimab
215064435|NCT00814580|DRUG|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
215064436|NCT00814580|DRUG|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
215064437|NCT02739763|BIOLOGICAL|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
215064438|NCT02482428|DRUG|Investigational Treatment|Applied twice daily for up to 12 weeks
215064439|NCT02482428|DRUG|Aldara|Applied 3 times a week for 16 weeks
215064440|NCT01910324|BEHAVIORAL|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
215064441|NCT01910324|BEHAVIORAL|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
215064442|NCT05658627|OTHER|active release technique|Hamstring active release technique-
215064443|NCT05658627|OTHER|conventional therapy|ultrasound therapy - stretching Exercise - Strengthening Exercise -
215064444|NCT04314024|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
215064445|NCT00039780|DRUG|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
214322877|NCT06333795|PROCEDURE|Placebo|Treatment is given as capsules.
214922321|NCT01006187|OTHER|Distraction|By means of self-selected reading material or video
214922322|NCT05027659|OTHER|virtual reality glasses|Virtual reality (VR) glasses have a detachable screen frame compatible with smartphones. A VR headset has earphones and sensors that track the user's head movements, giving them the impression that they are moving around in a virtual environment. The investigators used a smartphone and VR glasses to perform the intervention. They connected the phone to the VR headset via a 360 degree VR video app. Experimental participants wore the VR glasses and watched a 360 degree VR video of nature scenes with ambiance music during colonoscopy. They put on the VR glasses right before the procedure and took them off right afterward.
214322878|NCT03535220|COMBINATION_PRODUCT|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
214322879|NCT02337244|DEVICE|Zimmer Persona Total Knee System|No Intervention
214922323|NCT03319732|DRUG|Arbaclofen|Arbaclofen is the active R enantiomer of baclofen.
214922324|NCT03887442|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
214922325|NCT03887442|DRUG|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
214922326|NCT02948660|DRUG|Zolpidem Tartrate Tablets|All participants were administered 10 mg of zolpidem tartrate tablets either via a feeding tube (for patients with prolonged disorders of consciousness) or orally.
215064446|NCT00039780|DRUG|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
215064447|NCT02431780|DEVICE|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
214922327|NCT05334693|BIOLOGICAL|Expanded haploidentical NK cells|Two doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).
214922328|NCT02075931|OTHER|Physical activity feedback with group meetings|Physical activity feedback
214922329|NCT02075931|OTHER|Control|No intervention
215064448|NCT03409705|DIETARY_SUPPLEMENT|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
215064449|NCT03409705|DIETARY_SUPPLEMENT|Control group|2,000 mg of starch was orally administered per day for 12 weeks.
215064450|NCT04837703|DRUG|Eltrombopag|Eltrombopag should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cation (e.g. aluminum, calcium, iron, magnesium, selenium and zinc). Eltrombopag may be taken with food containing little (\< 50 mg) or preferably no calcium.
215064451|NCT02079116|OTHER|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
215064452|NCT02079116|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
215064453|NCT01824654|OTHER|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
215064454|NCT01824654|OTHER|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
215064455|NCT00093197|DRUG|KAI-9803 for Injection|0.05 mg
215064456|NCT00093197|DRUG|KAI-9803 for Injection|0.5 mg
215064457|NCT00093197|DRUG|KAI-9803 for Injection|1.25 mg
215064458|NCT00093197|DRUG|KAI-9803 for Injection|5 mg
215064459|NCT00093197|DRUG|Placebo|
214922330|NCT03855527|DRUG|Silver Diamine Fluoride|SDF will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
214922331|NCT03855527|DRUG|Chlorhexidine|Chlorhexidine will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
215064460|NCT05247957|BIOLOGICAL|CAR-NK cells|NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
215064461|NCT00945347|DRUG|Miglustat|Nasal instillation of miglustat
215064462|NCT00945347|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
215064463|NCT03278717|DRUG|Olaparib|Olaparib is a PARP inhibitor, targeting DNA repair processes.
215064464|NCT03278717|DRUG|Cediranib|Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.
215064465|NCT02782052|DRUG|Nebulized ipratropium bromide|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
214922332|NCT03855527|PROCEDURE|Atraumatic Restorative Treatment without Disinfection|Atraumatic Restorative Technique will be performed without cavity disinfection
214922333|NCT04301869|DRUG|Antibiotics|Oral versus intravenous therapy
214922334|NCT06170476|DRUG|HSK21542-60μg|HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
214922335|NCT06170476|DRUG|HSK21542-120μg|HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
214322880|NCT01570023|BEHAVIORAL|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
214322881|NCT05789732|DRUG|Placebo|Patients will receive placebo treatment once daily.
214322882|NCT05789732|DRUG|Silodosin|Patients will receive Silodosin 8 mg once daily.
214322883|NCT05789732|DRUG|Tadalafil|Patients will receive Tadalafil 5 mg once daily.
214922336|NCT06170476|DRUG|HSK21542-180μg|HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
214922337|NCT06170476|DRUG|Placebo|A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
214922338|NCT00454376|OTHER|questionnaire administration|
214922339|NCT00454376|PROCEDURE|quality-of-life assessment|
214922340|NCT00430573|DRUG|D-cycloserine|Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
215064466|NCT02782052|DRUG|Nebulized combination ipratropium bromide with salbutamol|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
215064467|NCT02782052|DRUG|Nebulized Placebo|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
215064468|NCT06447623|DRUG|Apatinib|Apatinib is a kind of TKI inhibitor.
215064469|NCT06447623|DRUG|CDK4/6 Inhibitor|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
214922341|NCT00430573|DRUG|Placebo|Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
215064470|NCT06447623|DRUG|Aromatase inhibitor and Fulvestrant|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
215064471|NCT00467545|DRUG|telbivudine|
215064472|NCT06562166|RADIATION|online adaptive radiotherapy|Patients in ART group received daily online adaptive radiotherapy with a prescription dose of 50.4Gy/28f.
215064473|NCT04451564|BEHAVIORAL|Mindfulness oriented recovery enhancement|8- week psychological program based on mindfulness techniques
215064474|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZFR00|IOL replaces the natural lens removed during cataract surgery.
215064475|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZYR00|IOL replaces the natural lens removed during cataract surgery.
215064476|NCT03372434|DEVICE|TECNIS Multifocal Intraocular Lens: Model ZLB00|IOL replaces the natural lens removed during cataract surgery.
215064477|NCT06326450|BEHAVIORAL|Augmented Reality simulation|Augmented simulation of medical crisis scenarios
214322884|NCT05789732|DRUG|Silodosin and Tadalafil|Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
214322885|NCT05476562|OTHER|Tyrosine Kinase Inhibitors (TKIs)|The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.
214322886|NCT00192075|DRUG|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
214322887|NCT00192075|DRUG|avastin|5 milligrams per kilogram (mg/kg)
214922342|NCT00433589|DRUG|anthracycline-based|
214922343|NCT00433589|DRUG|docetaxel and capecitabine|
214922344|NCT00433589|DRUG|tamoxifen|
214922345|NCT00433589|DRUG|Letrozole|
214922346|NCT03972189|DRUG|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
214922347|NCT06576492|OTHER|RV4986A lotion|"* Application between Month -0.5 and Month 0 (before hair transplant): once a day on the entire scalp~* From 4 days after hair transplant and until Visit 4 (Month 0,5 post transplant): once a day on the recipient area~* Between Month 0.5 and Month 12: once a day on the entire scalp"
214922348|NCT06576492|OTHER|RD0057H shampoo|"* Application between Month -0.5 and Month 0 (before hair transplant): at usual frequency when required on the entire scalp~* From 2nd day after hair transplant and until the 7th day after hair transplant: application on the recipient area with a spray containing mixture of water and shampoo. For the rest of the head application with the same modalities than before hair transplant~* From the 8th day after hair transplant to the 15th day: application with a sponge on the recipient area~* From the 16th day after hair transplant and for the next 12th months: application with the same modalities than before hair transplant"
214922349|NCT00031629|DRUG|Docetaxel|Given IV
214922350|NCT00031629|BIOLOGICAL|Filgrastim|Given SC
214922351|NCT00031629|DRUG|Gemcitabine Hydrochloride|Given IV
214922352|NCT00031629|BIOLOGICAL|Pegfilgrastim|Given IV
214922353|NCT00613964|DRUG|Carperitide heart failure therapy|carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
215064478|NCT06326450|BEHAVIORAL|In Person simulation|In Person simulation of medical crisis scenarios
215064479|NCT06425887|DIAGNOSTIC_TEST|Smart watch|not interventional
215064480|NCT04585542|DRUG|Polyethylene Glycol 3350|Nonspecific laxative comparison group.
215064481|NCT04585542|DRUG|Sodium Polystyrene Sulfonate Oral Suspension [SPS]|Potassium binder to treat hyperkalemia.
215064482|NCT04585542|DRUG|Patiromer|Potassium binder to treat hyperkalemia.
215064483|NCT04585542|DRUG|Sodium zirconium cyclosilicate|Potassium binder to treat hyperkalemia.
215064484|NCT04545164|DIAGNOSTIC_TEST|CAD4TB|CAD4TB is a Computer Aided Diagnosis (CAD) image processing algorithm that can aid interpretation of Chest X-ray images to accurately detect tuberculosis.
215064485|NCT04545164|DIAGNOSTIC_TEST|FujiLAM|Fujifilm SILVAMP TB LAM is a high sensitivity test for mycobacterial lipoarabinomannan (LAM) in urine samples.
215064486|NCT04904471|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified by antigen isolation and added with aluminum hydroxide adjuvant for the prevention of COVID-19.
215064487|NCT04904471|OTHER|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate) are consistent with the study vaccine and have been tested and qualified by National Institutes for Food and Drug Control.
215064488|NCT05844618|DRUG|Triamcinolone Acetonide (Aristocort® C)|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
215064489|NCT05844618|DRUG|Vehicle|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
215064490|NCT05924165|DRUG|5mg Oxycodone, Q6 PRN|Oxycodone is an opioid that is used to relieve moderate to severe pain.
215064491|NCT05924165|DRUG|10mg Ketorolac, Q6 PRN|Ketorolac is an NSAID used to relieve moderately severe pain.
215064492|NCT04075292|DRUG|Acalabrutinib|acalabrutinib 100 mg twice daily orally
215064493|NCT04075292|DRUG|Rituximab|Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
215064494|NCT04075292|DRUG|Chlorambucil|Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
214322888|NCT00192075|DRUG|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
215064495|NCT06006702|DRUG|TYRA-300-B01|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
215064496|NCT06059612|PROCEDURE|injection|steroid injection into superior cluneal nerve
214922354|NCT00613964|DRUG|Standard heart failure therapy|Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
215064497|NCT03665766|DRUG|Cycloserine,Tacrolimus|
215064498|NCT03026296|BEHAVIORAL|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
215064499|NCT02516995|DEVICE|Functional magnetic resonance imaging|
215064500|NCT02516995|DEVICE|Ultrasound|
214322889|NCT00192075|DRUG|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
214322890|NCT00779675|BIOLOGICAL|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
214322891|NCT06210529|DEVICE|a high-intensity focused ultrasound tumor treatment system (Super Knife)|All participants will be randomly divided into groups A and B. Participants in group A will receive a high-intensity focused ultrasound tumor treatment (Super Knife) once, and participants in group B will receive treatment twice (4 weeks, one cycle).. Breast cancer surgery was performed at 3 months ± 1 week after the Super Knife treatment.
214922355|NCT04559100|RADIATION|chest radiography|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
214922356|NCT04559100|RADIATION|thoracic computed tomography scan|6 and 12 months after hospital discharge, if the patient had a CT scan upon admission to the hospital. If the study is normal at 6 months it will not be repeated at 12 months.
214922357|NCT04559100|DIAGNOSTIC_TEST|spirometry|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
214922358|NCT04559100|DIAGNOSTIC_TEST|Diffusing capacity of carbon monoxide|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
214922359|NCT04559100|DIAGNOSTIC_TEST|6 minute walk test|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
214922360|NCT04559100|DIAGNOSTIC_TEST|saint george respiratory questionnaire|6 and 12 months after hospital discharge.
214922361|NCT02767466|PROCEDURE|Physical therapy and robotic assisted gait training|
214922362|NCT02642120|DEVICE|"Dental device Laboraide"|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
215064501|NCT01140594|PROCEDURE|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
215064502|NCT01140594|PROCEDURE|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
215064503|NCT05960578|DRUG|Apalutamide|Given PO
215064504|NCT05960578|PROCEDURE|Biopsy|Undergo tumor biopsy
215064505|NCT05960578|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215064506|NCT05960578|PROCEDURE|Computed Tomography|Undergo CT scan
215064507|NCT05960578|DRUG|Golimumab|Given SC
215064508|NCT05960578|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215064509|NCT05960578|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
215064510|NCT05960578|PROCEDURE|Bone Scan|Undergo bone scan
215064511|NCT03608241|DRUG|PF-06651600|200 mg by mouth (PO) Once daily (QD) for 11 days
215064512|NCT03608241|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
215064513|NCT03724383|BEHAVIORAL|Risk Factor Management Consult|Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.
215064514|NCT03724383|BEHAVIORAL|Diet Classes|Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.
215064515|NCT03724383|BEHAVIORAL|Stress Management Classes|Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.
215064516|NCT03724383|OTHER|Exercise Classes|Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.
215064517|NCT03724383|OTHER|Home based exercise program|The interval and resistance training program will mirror the supervised exercise.
215064518|NCT04308239|BEHAVIORAL|Reactive balance training|Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.
215064519|NCT04308239|BEHAVIORAL|Otago Balance Training|Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
214322892|NCT00649116|DRUG|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
214322893|NCT00649116|DRUG|Lopressor® Tablets 100 mg|100mg, single dose fed
214672471|NCT02773992|BEHAVIORAL|The IoT|"For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform."
214672472|NCT01855789|DRUG|Tocilizumab (TCZ)|TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).
214672473|NCT01855789|DRUG|Methotrexate (MTX)|MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
214672474|NCT01855789|DRUG|Placebo (PBO)|PBO matching to MTX will be administered orally.
214672475|NCT03067311|BEHAVIORAL|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
214672476|NCT03067311|BEHAVIORAL|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
214672477|NCT04102774|DEVICE|Over-night treatment with myAIRVO2|"Gas flow will be set between 20 and 30 l/min, according to patient's comfort, and administrated via nasal canula.~Temperature will be set at 37°C. If the patient was already in nocturnal oxygen therapy FiO2 will be set according to the prescription."
215064520|NCT02643615|DEVICE|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
215064521|NCT02643615|DEVICE|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
215064522|NCT02643615|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
215064523|NCT02643615|DRUG|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
214322894|NCT01829932|DIETARY_SUPPLEMENT|Factor Altered Diet|
214322895|NCT03237234|OTHER|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
214322896|NCT03237234|DEVICE|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
214322897|NCT01341184|DRUG|Rifabutin|Rifabutin 300 mg orally on days 20-41
214322898|NCT01341184|DRUG|Rifampin|Rifampin 600 mg orally on days 20-41
214322899|NCT01341184|DRUG|TMC207|TMC207 400 mg orally on days 1 and 29
214322900|NCT00004091|OTHER|Papanicolaou test|
214322901|NCT00004091|OTHER|cytology specimen collection procedure|
214322902|NCT00004091|OTHER|fluorescent antibody technique|
214322903|NCT00004091|PROCEDURE|colposcopic biopsy|
214322904|NCT00004091|PROCEDURE|study of high risk factors|
214322905|NCT03693768|BEHAVIORAL|Health coaching|Health coaching
214322906|NCT01818804|DIETARY_SUPPLEMENT|n-3PUFA|
214322907|NCT01818804|DIETARY_SUPPLEMENT|olive oil|
214322908|NCT01569529|BEHAVIORAL|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
214322909|NCT02224872|PROCEDURE|Bone marrow transplant|Day 0
214322910|NCT02224872|DRUG|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
214322911|NCT02224872|DRUG|Fludarabine|30 mg/M2 IV on days -6 to -2
214322912|NCT02224872|DRUG|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
214322913|NCT02224872|RADIATION|TBI|200 cGy on day -1
214322914|NCT02224872|DRUG|Mesna|40 mg/kg IV on days 3, 4
215064524|NCT03241680|DIAGNOSTIC_TEST|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
215064525|NCT05790798|OTHER|occupational therapy-based instrumental daily living activities intervention|Occupational therapy-based instrumental activities of daily living intervention were applied to 9 people with disabilities in the intervention group, with sessions consisting of 45 minutes twice a week (totally 8 weeks/16 sessions). While the activity intervention program was being created for the intervention group, the problem areas in the ADL and IADL determined by the evaluations made before the intervention were identified. Ten occupation kits including 2 ADLs (dressing and feeding nutrition), and 8 IADLs (laundry, meal preparation, light cleaning, paperwork, use of technology, lifting and carrying, fine motor and gross motor leisure groups) were used as interventions. Various materials (jar, shirt, spoon, teapot, play dough, stapler, plastic bag, sponge, etc.) were prepared to be used in each occupation kit and to simulate daily activities.
215064526|NCT05790798|OTHER|Quite recreation activity|For the control group, information about the scope, duration and requirements of the research was shared throughout the process. During this period, reading activities continued. The final evaluation of all participants was made at the end of the 8th week of the study and the study was completed.
215064527|NCT00561158|BEHAVIORAL|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~* Rate Your Plate: determining high fat foods~* Label Reading: reading food labels~* Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~* Recipe Modification: preparing old recipes in new ways to reduce fat~* Eating Out: order healthier fast foods~* Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~* Substituting fat-modified foods for high fat foods~* Avoiding fat as a seasoning or flavoring~* Avoiding fried foods~* Modifying meat~* Replacing high fat foods with fruits, vegetables, grains and breads"
215064528|NCT05598125|DEVICE|electronic cigarette (e-cigarette)|
214322915|NCT02224872|DRUG|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
214322916|NCT02224872|DRUG|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
215064529|NCT05598125|DEVICE|conventional tobacco cigarette|
215064530|NCT03938766|DIAGNOSTIC_TEST|PSMA PET/CT|Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
215064531|NCT03239951|DEVICE|iTind|temporary implant
215064532|NCT00361868|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
215064533|NCT00361868|DRUG|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
214322917|NCT01813981|DIETARY_SUPPLEMENT|Low roast coffee|Instant coffee
214322918|NCT01813981|DIETARY_SUPPLEMENT|High roast coffee|Instant coffee
214322919|NCT01813981|DIETARY_SUPPLEMENT|Control (Caffeine dissolved in water)|Caffeine dissolved in water
214322920|NCT04608266|DRUG|Camostat Mesylate|Camostat mesylate, oral administration 600mg/day (2 x 100mg tablets every 8 hours) for 14 days
214322921|NCT04608266|DRUG|Placebo|Placebo tablets, oral administration 2 tablets every 8 hours for 14 days
214322922|NCT00355238|DRUG|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
214322923|NCT02821585|BEHAVIORAL|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
214322924|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
214322925|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
214322926|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
214322927|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
214322928|NCT02407106|DIETARY_SUPPLEMENT|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
215064534|NCT02479087|DRUG|Plasma-derived FVIII/VWF concentrate|"The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of \> 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma)."
215064535|NCT02719964|OTHER|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
215064536|NCT02719964|OTHER|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
215064537|NCT02719964|OTHER|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
215064538|NCT00178165|PROCEDURE|Skill Training Condition - problem solving training|
214322929|NCT00072865|DRUG|Pemetrexed|
214322930|NCT00072865|DRUG|Carboplatin|
215064539|NCT00178165|PROCEDURE|REACH for TLC (Telephone Linked Computer) system|
214322931|NCT00460941|DRUG|Placebo|sc weekly
215064540|NCT00459875|DRUG|sunitinib malate|
215064541|NCT03680781|DEVICE|Intermittent theta-burst stimulation (iTBS)|"Participants will receive iTBS to the left DLPFC or bilateral DLPFC, to the right and left DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device."
215064542|NCT03898297|RADIATION|[18F]FPEB|Radiotracer: \[18F\]FPEB
215064543|NCT03898297|RADIATION|[11C]APP311|Radiotracer: \[11C\]APP311, \[11C\]UCB-J
214322932|NCT00460941|DRUG|Taspoglutide 20mg|sc weekly
214322933|NCT00460941|DRUG|Taspoglutide 20mg-30mg|sc weekly
215064544|NCT01210248|OTHER|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
215064545|NCT03735628|DRUG|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
215064546|NCT03735628|DRUG|Nivolumab|Nivolumab: concentrate for solution for infusion
215064547|NCT02720380|OTHER|Buteyko|Intervention will be held twice a week during 3 weeks.
214322934|NCT00460941|DRUG|Taspoglutide 20mg-40mg|sc weekly
214322935|NCT03755024|DEVICE|ultrasound|"The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~* Biparietal diameter~* Head circumference~* Abdominal circumference~* Femur length~* Humerus length"
214485625|NCT06190600|OTHER|High Intensity Interval Training (HIIT)|HIIT training twice a week throughout the chemotherapy: treadmill, elliptical, stationary bicycle and indoor rower. The intensity of physical activity will be increasing during consecutive mesocycles. Each training session will begin with a 10-min. wole-body warm-up session at 50-60% hear rate (HR) max. Mesocycle 1 - one month with 4 sets of 1 min. 45 sec. of exercise at a maximal intensity of 75% HR max. Mesocycle 2 with exercises at 80% to 90% HR max divided into 3 periods: 1/ one month, session of 5 sets 1 min. 30 sec. each; 2/ two months, sessions of 5 sets 1 min. 45 sec. each; 3/ two months, sessions of 5 sets 2 min. each. Moreover patients will be instructed to individually perform- a 45-min. aerobic training session (e.g.: walking, jogging, roller skating, swimming) once a week, in patient's own time.
215064548|NCT02720380|OTHER|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
214322936|NCT04240899|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
215064549|NCT02687685|OTHER|Skin to skin contact immediate|Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
214485626|NCT06190600|DRUG|neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)|Patients aged 18 to 40 in good physical condition (Eastern Cooperative Oncology Group (ECOG) scale 0-1) who are set to receive neoadjuvant chemotherapy will be selected. Criteria for entry into the study include proper liver, kidney and bone marrow function as well as heart ejection fraction of ≥ 50%. Treatment will be carried out according to 4 x AC regimen (doxorubicin 60 mg/ m2 cyclophosphamide 600 mg/ m2 i.v. every 21 or every 14 days + pegfilgastrim) followed by 12 x paclitaxel 80 mg/ m2 every 7 days and in the case of HER2 positive tumors trastuzumab ± pertuzumab (according to SPC).
214485627|NCT06190600|OTHER|Standard Supportive Care|Patients will be asked to perform 150-300 min. of moderate-intensity aerobic activity or 75-150 min. of vigorous aerobic activity. Each participant will be monitored by an activity watch worn at all times by the patient.
214485628|NCT05897047|COMBINATION_PRODUCT|Additional interventional telemedical management|Predefined additional telemedical management including regular telemedicine visits and automatic data transfer (e.g. vital signs, well-being, medication plan laboratory data and chat) between the patient at home and KTC through a certified smartphone application.
215064550|NCT02687685|OTHER|skin to skin contact early|Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
215064551|NCT00504517|OTHER|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
215064552|NCT04717297|BEHAVIORAL|Medication Management Remote Intervention|First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.
215064553|NCT04717297|BEHAVIORAL|Waitlist Control|A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.
215064554|NCT04717297|BEHAVIORAL|Medication Management In-Person Intervention|Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
215064555|NCT04509518|OTHER|Exercise therapy program plus TENS therapy|All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
215064556|NCT01771692|OTHER|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
214922363|NCT03194880|DEVICE|AlereCOMBO and Alere q Detect|"The feasibility assessment will comprise of two components:~1. User's perspective: A questionnaire will be developed and used to assess the level of satisfaction among community health workers performing the two new tests, using a 5 point Likert scale. We will assess the training and manual, the use of the test, the user's confidence, troubleshooting and technical support components and resolving problems.~2. The laboratory component: For each test we will evaluate:~   * The percentage of assays completed~  * The percentage of assays incomplete (i.e. invalid result on two attempts)~  * Reasons for incomplete assays, e.g.~     * The sample could not be delivered to the strip or cartridge correctly~    * Invalid control~    * Results could not be interpreted~    * Others"
215064557|NCT01771692|OTHER|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
215064558|NCT03300154|BEHAVIORAL|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
215064559|NCT03300154|BEHAVIORAL|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
215064560|NCT00501592|DRUG|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
214322937|NCT02573610|DRUG|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
215064561|NCT00501592|DRUG|Placebo|Placebo
215064562|NCT00919750|OTHER|Cytology Specimen Collection Procedure|Correlative studies
215064563|NCT02180256|PROCEDURE|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
214922364|NCT00020865|DRUG|cefepime hydrochloride|
215064564|NCT01432145|DRUG|6-Mercaptopurine|6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.
214322938|NCT02573610|DRUG|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
214322939|NCT04613180|DRUG|Montelukast Sodium|Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
215064565|NCT01432145|DRUG|Methotrexate|Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
214322940|NCT04613180|DRUG|Placebo|placebo containing no active substance
214922365|NCT00020865|DRUG|levofloxacin|
214922366|NCT00072280|BIOLOGICAL|dactinomycin|Given Slow intravenous (IV) push over 1-5 minutes, dose \< 1yr 0.025 mg/kg \> or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64
214922367|NCT00072280|DRUG|cyclophosphamide|Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
214922368|NCT00072280|DRUG|etoposide|Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
214922369|NCT00072280|DRUG|ifosfamide|Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
214922370|NCT00072280|DRUG|vincristine sulfate|Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
214922371|NCT00072280|PROCEDURE|Conventional Surgery|"Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections."
214922372|NCT00072280|BIOLOGICAL|MESNA (mercaptoethane sulfonate)|Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.
214485629|NCT05968703|DEVICE|Combined STN+NBM DBS|This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)
215064566|NCT05946044|BEHAVIORAL|Diet and Exercise|Group and individual weight loss and weight maintenance sessions combined with exercise throughout the 48 months.
214922373|NCT00072280|BIOLOGICAL|Filgrastim|Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
214922374|NCT05020665|DRUG|Entospletinib|400 mg, Orally as tablets
214922375|NCT05020665|DRUG|Placebo|Orally as tablets
214922376|NCT05020665|DRUG|Cytarabine|Continuous infusion
215064567|NCT05417451|OTHER|Acupuncture|All participants will receive a semi-standardized acupuncture protocol (standardized points for pain, fatigue, depression, anxiety, sleep disturbance, with additional points for patient's particular pain location)
215064568|NCT05844943|DEVICE|ReHeal glove with Negative Pressure Wound Therapy (NPWT)|ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).
215064569|NCT04898894|DRUG|Venetoclax|Given orally (PO)
215064570|NCT04898894|DRUG|Selinexor|Given Orally (PO)
215064571|NCT04898894|DRUG|Cytarabine|Given in to the vein (IV) or intrathecal (IT)
215064572|NCT04898894|DRUG|Fludarabine|Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.
214922377|NCT05020665|DRUG|Anthracycline|Either daunorubicin or idarubicin was administered via slow intravenous (IV) push
215064573|NCT04898894|BIOLOGICAL|Filgrastim|Given subcutaneous (SubQ, SC)
215064574|NCT04898894|DRUG|Methotrexate|Given intrathecal (IT)
215064575|NCT04898894|DRUG|methotrexate/hydrocortisone/cytarabine|Given intrathecal (IT)
215064576|NCT01436656|DRUG|LGX818|
215064577|NCT02102685|PROCEDURE|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
215064578|NCT02102685|PROCEDURE|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
215064579|NCT04667676|DEVICE|acupoint TENS|TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
215064580|NCT02636504|DEVICE|Laser Doppler Flowmetry|Pulp vitality of teeth is tested with three pulp vitality testing including laser Doppler flowmetry, cold testing, and electric pulp testing.
215064581|NCT01292122|DEVICE|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
215064582|NCT04729972|COMBINATION_PRODUCT|NT-501 CNTF implant|Single implantation of CNTF-secreting NT-501 device into fellow (untreated) eye
215064583|NCT02535013|DEVICE|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
215064584|NCT00241176|DRUG|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS \& CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
215064585|NCT02321917|DEVICE|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
215064586|NCT00576628|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
215064587|NCT03871309|DEVICE|Tigertriever|Mechanical Thrombectomy
215064588|NCT06057597|PROCEDURE|Laparoscopic OAGB|It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
214922378|NCT03384030|OTHER|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
214922379|NCT06576245|DEVICE|Quantum Molecular Resonance (QMR) Therapy|Quantum Molecular Resonance (QMR) therapy will be administered using the RexonEye® device (Resono Ophthalmic, Trieste, Italy). The device delivers low-intensity, high-frequency electrical waves ranging from 4-64 MHz through specialized contact electrodes. Participants will receive 4 QMR treatment sessions over 6 weeks. Each session lasts for 20 minutes, with a 30-second alternation between the eyes. The goal of QMR therapy is to stimulate cellular regeneration and improve tear production by targeting the lacrimal gland.
215064589|NCT06057597|PROCEDURE|Laparoscopic RYGB|A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
215064590|NCT01934712|DRUG|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
215064591|NCT01934712|DRUG|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
215064592|NCT03206970|DRUG|Zanubrutinib|Administered as specified in the treatment arm.
215064593|NCT01762384|PROCEDURE|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
214485630|NCT06953726|DRUG|Apixaban|Study participants will be randomized to twice daily oral administration of apixaban 5mg. Reduced dose apixaban (2.5 mg twice daily) will be given to participants who meet 2 of the 3 criteria: age 80 years, body weight 60 kg, and serum creatinine 1.5 mg/dL.
214485631|NCT06953726|DRUG|Rivaroxaban|Study participants will be randomized to daily oral administration of rivaroxaban 20mg. Reduced dose rivaroxaban (15 mg once daily) will be given to participants with a creatinine clearance 15-50 mL/min.
215064594|NCT01762384|PROCEDURE|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
215064595|NCT01762384|DEVICE|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
215064596|NCT03379948|DIAGNOSTIC_TEST|blood culture|blood culture to diagnose blood stream infection
215064597|NCT03702959|DRUG|Betamethasone|Corticosteroids
215064598|NCT06553118|PROCEDURE|Total knee arthroplasty|Patients already admitted for total knee arthroplasty for knee osteoarthritis will have the procedure as planned
215064599|NCT02516982|OTHER|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
215064600|NCT02516982|OTHER|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
215064601|NCT02516982|OTHER|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
215064602|NCT02516982|OTHER|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
215064603|NCT04136548|DRUG|Fentanyl|Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
215064604|NCT04136548|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
215064605|NCT05139719|DRUG|HEC585 dose A|taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
215064606|NCT05139719|DRUG|HEC585 dose B|taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage
215064607|NCT05139719|DRUG|Placebo|taking Placebo orally once daily, up to 24 weeks in main stage
215064608|NCT03800524|DRUG|Tauroursodeoxycholic Acid|"* Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
215064609|NCT03800524|DRUG|Placebo|"* Placebo 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
215064610|NCT04964648|DEVICE|shear wave elastography|Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second
215064611|NCT04362488|PROCEDURE|Preoperative evaluation|"Preoperative evaluation using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
215064612|NCT04362488|PROCEDURE|Postoperative evaluation|"Postoperative evaluation at 4 months of follow up after surgery using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
215064613|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
215064614|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
215064615|NCT01129765|DEVICE|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
215064616|NCT05081518|DRUG|Lu AG06466|Lu AG06466 - capsule
215064617|NCT05081518|DRUG|Placebo|Placebo - capsule
215064618|NCT01050920|BIOLOGICAL|Blood collection|
215064619|NCT03093207|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
215064620|NCT03093207|OTHER|Placebo|Placebo pills over a period of 180 days
214922380|NCT06576245|DEVICE|Intense Pulsed Light (IPL) Therapy|Intense Pulsed Light (IPL) therapy will be performed using the OptiLIGHT® device (Lumenis Be Ltd., Yokneam, Israel). IPL treatment involves the application of high-intensity, non-coherent, polychromatic light within the 500 to 1200 nm wavelength spectrum. Participants will receive 3 IPL sessions over 6 weeks, with sessions targeting the periocular area and upper eyelids to improve meibomian gland function. Each session includes the application of 50 light pulses to the periocular area and upper eyelids using specified parameters (e.g., fluence 14 J/cm² for the periocular area, fluence 11 J/cm² for the upper eyelids).
215064621|NCT03093207|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
215064622|NCT03093207|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
215064623|NCT00962741|DRUG|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
215064624|NCT01326156|DEVICE|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
214322941|NCT04125108|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
214322942|NCT00165971|PROCEDURE|BIS monitoring|
214322943|NCT05835453|OTHER|Whitening|Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each tray, completing a total of 4 weeks of whitening procedure.
214322944|NCT00393055|DIETARY_SUPPLEMENT|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
215064625|NCT03397433|OTHER|Information Technology physician assist|The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
215064626|NCT05761106|OTHER|Oculomotor Therapy|It will consist exercise of a convergence technique and an accommodative technique.
214922381|NCT06576245|DRUG|Tear Substitute Treatment (Supportive Therapy)|"All participants will also receive supportive therapy with tear substitutes throughout the study period. This includes:~Idroflog® (0.2% Hyaluronic Acid with 0.001% Hydrocortisone): Applied 3 times per day.~VisuXL gel® (Cross-linked Carboxymethyl Cellulose with Coenzyme Q10): Applied once a day.~Artelac® Nighttime Gel (0.24% Sodium Hyaluronate with Carbomer): Applied before sleeping. These tear substitutes are intended to provide symptomatic relief and support tear film stability during the treatment period."
215064627|NCT05761106|OTHER|Therapy for Temporomandibular Disorder|It will consist exercise of a ATM and cervical spine.
215064628|NCT01630928|PROCEDURE|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
215064629|NCT05658159|DIAGNOSTIC_TEST|Vitamin D|Finger stick capillary blood sampling using test from ZRT Laboratories, Beaverton, OR
215064630|NCT05658159|DIAGNOSTIC_TEST|DXA scan|10 minute scan using scanner by GE Lunar, Madison, WI
215064631|NCT05658159|OTHER|Nutrition analysis|Analysis of 24-h recalls will be conducted by a registered dietician using Nutritionist Pro software by Axxya Systems, Redmond, WA
215064632|NCT01807559|DEVICE|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
215064633|NCT03242564|DEVICE|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
214322945|NCT00393055|DIETARY_SUPPLEMENT|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
215064634|NCT00760942|DIETARY_SUPPLEMENT|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
215064635|NCT00760942|DIETARY_SUPPLEMENT|Similac human milk fortifier|Powdered human milk fortifier.
215064636|NCT01814878|DRUG|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
215064637|NCT01814878|DRUG|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
215064638|NCT02186379|BEHAVIORAL|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
215064639|NCT02186379|BEHAVIORAL|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
215064640|NCT04167059|BEHAVIORAL|Telehealth-delivered participation strategies to increase physical activity|Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
215064641|NCT03645421|DRUG|MEDI0382 100 μg|Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
214922382|NCT02504827|DRUG|Ceftazidime/avibactam|Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
214922383|NCT05248373|BIOLOGICAL|Gam-COVID-Vac|two-component combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus
214922384|NCT05248373|OTHER|Placebo|solution with same composition as for vaccine formulation except rAds
214322946|NCT03169491|DEVICE|Continuous positive airway pressure (CPAP)|CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
214322947|NCT04300296|DRUG|secukinumab 300 mg Q4W|secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
214322948|NCT04300296|DRUG|secukinumab 300 mg Q2W|secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
214922385|NCT06308692|DIAGNOSTIC_TEST|ARES PCR|"Real time PCR assays will be used for the identification of infecting microorganisms and the drug resistance they carry that allow their identification, such as KPC, VIM, IMP, NDM, Acinetobacter OXA, Oxa48, MCR.~The validation of the method will be carried out in 100 (based on availability in Tropica Biobank) clinical samples: blood n=50 (positive, as for the negatives reference will be made to those already provided in the GENRES study) and rectal swabs ( positive n=40 and negative n=10) provided by the DITM. Sensitivity and specificity will be analyzed. As a reference for positivity and negativity data, reference will be made to routine diagnostic data obtained through standard operating procedures at the DITM laboratories."
214922386|NCT05053620|DEVICE|Calculation of the arcuate intrasomal incisions|All patients participating in the study will undergo femtosecond laser treatment for the correction of astigmatism through arcuate intrastromal incisions with the Catalys laser (Johnson \& Johnson, USA, CE marked). The calculation of intrastromal arcuate incisions will be carried out using the following nomogram indicated on the laser: 9.0 mm optical zone and symmetrical incisions of 50 degrees for 0.50D, 55 degrees for 0.75D, 60 degrees for 1.00D and 65 degrees for 1.25D of corneal astigmatism. After the incisions, conventional cataract surgery will be performed using the Centurion phacoemulsifier equipment (Alcon, USA, with CE marking) in the ZCB00 monofocal intraocular lens (IOL) implant (Johnson \& Johnson, USA, with CE marking). All patients will be treated according to standard clinical practice.
214922387|NCT00245089|BIOLOGICAL|dactinomycin|
214922388|NCT00245089|DRUG|cyclophosphamide|
214922389|NCT00245089|DRUG|vincristine sulfate|
214922390|NCT01267565|OTHER|dosage of amylase|4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
214922391|NCT00322231|BIOLOGICAL|zoster vaccine live (ZOSTAVAX™)|1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
215064642|NCT03645421|DRUG|MEDI0382 200 μg|Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
215064643|NCT03645421|DRUG|MEDI0382 300 μg|Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
215064644|NCT03645421|DRUG|PlaceboA|1.0 mL liquid formulation per Vial
214922392|NCT00322231|BIOLOGICAL|Comparator: Placebo|1 dose 0.65 mL/dose subcutaneous injection of placebo.
214922393|NCT02965729|BEHAVIORAL|Family-based weight management|"The Our Lifestyles, Our Lives family-based weight management intervention consisted of 10 weekly 90-minute group sessions focused on physical activity, nutrition, and behavioral modification. Parents and siblings were encouraged to join the participant in these sessions. Sessions were interactive and included cooking demonstrations, light to moderate intensity physical activity that engaged all family members, and behavioral counseling sessions in both mixed (parent and child) and parent-only format."
214922394|NCT02965729|BEHAVIORAL|Pedometer|In addition to participating in the family-based weight management intervention, participants were given a pedometer (Omron HJ-324U, Omron Healthcare, Lake Forest, IL) and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10.
215064645|NCT03645421|DRUG|MEDI0382 50 ug|Solution for injection, 1.0 mL per vial, 50 ug
215064646|NCT03645421|DRUG|PlaceboB|Solution for injection in 1.0 mL pre-filled syringe.
215064647|NCT00428571|PROCEDURE|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
215064648|NCT00428571|PROCEDURE|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
215064649|NCT00428571|PROCEDURE|Intensive Medical Management|lifestyle, diet, medication optimization
214322949|NCT04300296|OTHER|Placebo|Matching placebo administered via a pre-filled syringe
214322950|NCT00193401|DRUG|Topotecan|
215064650|NCT03048890|BEHAVIORAL|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
215064651|NCT03894982|OTHER|Group Classes|Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
215064652|NCT01216709|DIETARY_SUPPLEMENT|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
215064653|NCT01216709|OTHER|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
214322951|NCT03325166|DRUG|Ferumoxytol|Given IV
214322952|NCT03325166|OTHER|Laboratory Biomarker Analysis|Correlative studies
214322953|NCT03325166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214322954|NCT03325166|BIOLOGICAL|Pembrolizumab|Given IV
214322955|NCT03268616|DEVICE|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
214322956|NCT06263335|OTHER|Mindfulness Based Stress Reduction Intervention|During an eight-week intervention period, clients were to engage in mindfulness practices lasting between 45 minutes to an hour each session. The intervention would incorporate various components of the Mindfulness-Based Stress Reduction (MBSR) program, including mindfulness of the present moment, body scans, mindful eating, walking meditation, yoga exercises, and discussions on applying mindfulness to everyday experiences and stress management. Sessions would typically range from 30 to 90 minutes per week, with an additional full-day retreat session towards the end of the program. In addition to mindfulness practice, participants were to receive teachings on stress management and its application to interpersonal and daily life situations.
214322957|NCT01633944|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
214322958|NCT01633944|DRUG|Placebo|Matching Placebo Buccal Film twice daily
214322959|NCT04347486|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
214322960|NCT04347486|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
215064654|NCT01216709|OTHER|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
215064655|NCT00694837|DRUG|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
215064656|NCT04220463|OTHER|Hypnosis + NIV|For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.
214922395|NCT02965729|BEHAVIORAL|Individualized step goals|In addition to participating in the family-based weight management intervention, participants were given a step goal to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
214922396|NCT03019601|BEHAVIORAL|Group Education|Structured group education on family planning facilitated by Peer Champions
214922397|NCT00998647|DEVICE|modified ultrafiltration using Maquet haemoconcentrator, BC 20 plus|usage of modified ultrafiltration following extracorporeal circulation; filtration about 1,5 liters and re-fill with colloids
214922398|NCT01726907|DEVICE|Robotic SMG resection|The surgical procedure and the considerations for surrounding neurovascular structures were similar to that of the endoscope-assisted SMG resection. The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA) including a 30° dual channel endoscopic arm and two instrument arms was introduced. The SMG was retracted using the 5-mm Maryland forceps on the left and the dissection was conducted using a 5-mm spatula monopolar cautery or a Harmonic curved shears on the right. A Yankauer suction handled by a bed-side assistant could be used for counter traction of the gland which facilitated the dissection procedure.
214322961|NCT04347486|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
214922399|NCT01726907|DEVICE|Endoscopic SMG resection|An assistant held a 10-mm 30° rigid endoscope allowing the operating surgeon to use both hands. Surgical resection tools such as dissector and Harmonic scalpel (Harmonic Ace 23E®; Johnson \& Johnson Medical, Cincinnati, OH, USA) was held in the right hand and a Yankauer suction or a Debakey forcep was held on the left for traction of the SMG. The dissection plane between the capsule of the SMG was conducted under magnified endoscopic view using the the blade of the Harmonic scalpel and the endoscopic dissector. Routine identification of the marginal mandibular branch of the facial nerve was unnecessary in SMG resection, since the dissection plane was always deep to the middle layer of the deep cervical fascia which includes the fascia of the gland. The Wharton's duct, facial artery and vein were ligated using the Harmonic scalpel or vascular clip.
214322962|NCT04347486|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
214322963|NCT00054561|BIOLOGICAL|recombinant interferon alfa|
214322964|NCT00054561|DIETARY_SUPPLEMENT|vitamin E|
214322965|NCT00054561|DRUG|isotretinoin|
214322966|NCT00054561|PROCEDURE|adjuvant therapy|
214922400|NCT00819845|DRUG|carvedilol|carvedilol vs ramipril
214922401|NCT00819845|DRUG|ramipril|carvedilol vs ramipril
214922402|NCT04574908|DEVICE|ViSi device|Mobile patient monitoring system for vital signs.
214922403|NCT04182308|OTHER|dissection|Dissection of lisfranc ligament from 30 aldult Vietnamese cadavers's foot
214922404|NCT00877487|DRUG|SPD489 (Lisdexamfetamine dimesylate)|1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.
214922405|NCT00877487|DRUG|Placebo|1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
214922406|NCT04846283|PROCEDURE|Elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure|We considered all the procedures that required an intestinal anastomosis in colo-rectal surgery
214922407|NCT02752061|OTHER|Potlako intervention|"Multicomponent intervention including:~* provider training on early detection and diagnostic approaches to cancer~* patient education on importance of obtaining timely cancer diagnosis~* provision of a patient navigator to facilitate diagnosis and entry into care~* provision of transportation support to vulnerable patients"
214922408|NCT05362877|DEVICE|Earplug|Using earplugs to reduce the symptoms of temporomandibular disorder
214922409|NCT05362877|DEVICE|occlusal splint|Using occlusal splints to reduce the symptoms of temporomandibular disorder
214322967|NCT02096458|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
214322968|NCT02694224|DRUG|vismodegib|Smo inhibitor
214322969|NCT02694224|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
214322970|NCT02694224|DRUG|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
214322971|NCT02694224|DRUG|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
214322972|NCT01988870|RADIATION|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
215064657|NCT04220463|OTHER|NIV|In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
215064658|NCT05096247|DEVICE|TempSure|This device is an RF device.
215064659|NCT05096247|DEVICE|Icon|This device works with IPL (Intense Pulsed Light) handpieces.
215064660|NCT05359874|DRUG|Bevacizumab-IRDye800CW|In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
214322973|NCT03142503|DIETARY_SUPPLEMENT|Diet + supplementation|Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
214922410|NCT05362877|OTHER|exercise|Applying exercise to reduce the symptoms of temporomandibular disorder
214922411|NCT03070002|BIOLOGICAL|Denosumab|Given SC
215064661|NCT01343186|DRUG|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
215064662|NCT01343186|DRUG|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
215064663|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
215064664|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
214922412|NCT03070002|OTHER|Laboratory Biomarker Analysis|Correlative studies
214922413|NCT05664152|BIOLOGICAL|MG1111|BARYCELA inj.
214922414|NCT00151242|DRUG|Cytarabine|100mg/m² kont. i.v. day 1-7 (induction therapy) 3g/m² 2x/die i.v. day 1,3,5 or day 1,2,3
215064665|NCT05047939|DRUG|remimazolam-based TIVA|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
215064666|NCT05047939|DRUG|propofol-based TIVA|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
214322974|NCT03142503|DIETARY_SUPPLEMENT|Diet + placebo|Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
214922415|NCT00151242|DRUG|Idarubicin|12mg/m² i.v. day 1,3,5 (first induction cycle) 12mg/m² i.v. Tag 1,3 (second induction cycle)
214922416|NCT00151242|DRUG|Etoposide|100mg/m² i.v. day 1-3 (induction therapy)
214922417|NCT00151242|DRUG|All-trans retinoic acid|45mg/m² p.o. day 6-8 (induction therapy) 15mg/m² p.o. day 9-21 (induction therapy) 15mg/m² p.o. day 6-21 (consolidation therapy)
214922418|NCT00151242|DRUG|Pegfilgrastim|6mg s.c day 10 (cohort 1), 6mg s.c. day 8 (cohort 2)
214922419|NCT00016432|DRUG|exemestane|25 mg for 5 years
214922420|NCT00016432|DRUG|Placebo|Placebo
214922421|NCT05972486|DEVICE|Muse-S™ headband system|Clinical grade, headband-style wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (a smartphone or tablet). The device is a soft, stretchy band that fits around the forehead to the back of the head.
215064667|NCT00328887|GENETIC|CD40 Gene Transfer|gene transfer, intratumoral administration
215064668|NCT04985201|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 60 mg/m\^2 on Day 1,8 of each 21-day cycle.
214922422|NCT02754427|BEHAVIORAL|Prospective Surveillance Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.
214322975|NCT03142503|DIETARY_SUPPLEMENT|Placebo|Supplementation of 1g soybean oil, 3 times a day.
214322976|NCT03913078|BEHAVIORAL|Group Fitness|Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.
215064669|NCT04985201|DRUG|Simvastatin|Simvastatin 40 mg daily oral tablet taken.
215064670|NCT03692754|DRUG|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 month
215064671|NCT03692754|DRUG|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 month
215064672|NCT03692754|DRUG|Dexamethasone|Dexamethasone will be given in 40mg po qd for 4 days
215064673|NCT04030546|DRUG|Ivabradine|Ivabradine capsule
215064674|NCT06523608|OTHER|Standard survillance protocol|Patients will be followed every 6 months. They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.
214322977|NCT03913078|BEHAVIORAL|PlayFit|Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
214322978|NCT06388551|DRUG|LY03017|single dose, administered orally
215064675|NCT06523608|OTHER|Stratified survillance protocol|"Based on PLEASE and M10LS20 scores, patients will be followed every 3 or 12 months. Low-risk patients will be followed once per year, and high-risk patients every 3 months.~They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification."
215064676|NCT03060915|DEVICE|Polysomnography|Patient's undergo a polysomnography
215064677|NCT03060915|DEVICE|Actigraphy|Patient's wear an actigraphy while doing the polysomnography
215064678|NCT01496053|DIETARY_SUPPLEMENT|AndoSan|AndoSan 30 ml x 2 for 21 days
215064679|NCT01496053|DIETARY_SUPPLEMENT|Sugar Extract|Sham comparator
215064680|NCT00232999|DRUG|Nebulized IVX-0142|
215064681|NCT06547645|OTHER|Sub-Acute Rehab at Home|Patients randomized to the intervention group will receive skilled nursing and rehabilitative care at home upon discharge from the hospital, or when eligible for skilled-nursing facility care when requiring a step up in services at home. Home care will be delivered and overseen by a multidisciplinary clinical team, which will develop individualized care plans based on diagnosis, specific rehabilitation objectives, and broader goals of care.
214322979|NCT06388551|DRUG|LY03017-Placebo|single dose, administered orally
214322980|NCT05706363|PROCEDURE|Quadriceps graft|Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
215064682|NCT05445921|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
215064683|NCT04748328|PROCEDURE|ACL Reconstruction surgery and Rehabilitation Treatment|ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
215064684|NCT03171584|DRUG|Terbinafine|oral antifungal drugs
215064685|NCT01746381|DEVICE|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
215064686|NCT03357796|DRUG|LY03005|80 mg, oral tablets, single dose
214322981|NCT06368063|DRUG|Huaier granule|Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
214347518|NCT05234827|OTHER|Control|Control group receive endurance exercise testing in which stationary cycle is used for 30 min per session. It includes lower extremity strengthening i.e., increases hamstring and quadricep strength. Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
214922423|NCT02754427|BEHAVIORAL|Education Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
214347519|NCT00618475|BEHAVIORAL|Cognitive behavioral therapy|"10 sessions~1 hour per week"
215064687|NCT03357796|DRUG|Pristiq|50 mg, oral tablets, single dose
215064688|NCT04005469|DRUG|Treprostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
214922424|NCT04781608|BEHAVIORAL|English: In It Together (IIT)|Digital intervention program that consists of 4 modules, to be completed 1 week apart. The modules consist of psychoeducation, as well as acceptance and commitment therapy-inspired activities.
214922425|NCT05908721|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
214922426|NCT04043533|BEHAVIORAL|Exercises|The women in the experimental group were given information about the benefits of exercises done in the postpartum period, the time to start these exercises, and the exercises to be conducted in three different phases (mild, medium, severe). The first physical exercise practice was done in the FHC together. In line with the recommendations by ACOG (2015), the women were told to do mild and medium level exercises in the first two weeks, at least five days in a week and at least half an hour daily (ACOG, 2015). They were also told that they should do medium and severe level exercises in the following two weeks. They were asked to mark on the form what time, how long, and at what level they did the exercises every day. The education booklet that included this information and the visuals of the exercises were given to the women in the experimental group. In addition, the women were called once a week in order to check whether the training was applied.
215064689|NCT02688699|PROCEDURE|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
215064690|NCT03415425|OTHER|Current Version of the Influenza Alert|Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
215064691|NCT03415425|OTHER|Alternate Modifications of the Influenza Alert|Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
215064692|NCT01557543|OTHER|Cell Therapy|Intramyocardial Injection of BMSCs
215064693|NCT03919084|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
214922427|NCT00389532|BIOLOGICAL|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
214922428|NCT00389532|BIOLOGICAL|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
214922429|NCT03686228|PROCEDURE|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and wound care and pain killer drug
214922430|NCT03686228|DRUG|No-PB-MNC therapy|Patients will receive ASA 81 mg once daily and wound care and pain killer drug
214922431|NCT03231202|PROCEDURE|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist."
214347520|NCT00467870|DRUG|Testosterone Undecanoate 750 mg|
214347521|NCT00467870|DRUG|Testosterone Undecanoate 1000 mg|
214922432|NCT05386017|OTHER|Anthropometric measurements and sociodemographic and health data collection|"Anthropometric measurements : weight, height, abdominal circumference, abdominal circumference, percentage of fat mass, percentage of lean body mass, and estimated visceral fat level, visceral fat.~Sociodemographic and health data collection : Collect over a 7-year period changes in physical activity practices, eating habits and behaviours and the motivations for these changes or the initiatives to change the weight, Perceived stress and control, Life courses, events and impact perception Status, level of education, social background, place of residence, relationship with family Diet, tobacco and alcohol consumptions Physical activity behaviour and barriers, sedentary behaviour, quality of life perceived, exploring possible behavioural eating disorders, anxiety, depression"
215064694|NCT03919084|OTHER|Pharmacy Care Program services|Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
215064695|NCT03919084|OTHER|Patient Navigation Services|In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
214322982|NCT06368063|DRUG|chemotherapy drugs|"Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)~· Gemcitabine combine with capecitabine~Gemcitabine 1000mg/m\^2 intravenous infusion for more than 30 minutes, day 1, 8, 15,repeat every 4 weeks for a total of 6 cycles.~· mFOLFIRINOX solution~Oxaliplatin 85mg/m\^2 intravenous infusion for 2 hours, day 1 Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1 Leucovorin calcium 400mg/m\^2 intravenous infusion for 2 hours, day 1 5-FU 2400mg/m\^2, continuous intravenous infusion for 46 hours, repeated every 2 weeks, administered until 24 weeks.~* Gemcitabine monotherapy~  1000mg/m\^2 intravenous infusion, day 1 qw x 7, rest for 1 week Afterwards, qw × 3, take a week off, and administer medication for 6 months.~* Tegio capsules monotherapy~Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months."
214322983|NCT02412631|DRUG|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
214322984|NCT02412631|DRUG|Varenicline|Chantix is an FDA approved medication for smoking cessation
214322985|NCT02412631|DRUG|Placebo|Placebo for lorcaserin
215064696|NCT03919084|OTHER|Motivational Interviewing|Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
215064697|NCT03919084|OTHER|Linkage to Community Partner Organization|The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
215064698|NCT02253433|OTHER|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
215064699|NCT02253433|OTHER|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
215064700|NCT04113356|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
215064701|NCT01756573|DRUG|Dexamthsone|
215064702|NCT01756573|DRUG|Bupivacaine|
215064703|NCT00296049|DRUG|daptomycin|
215064704|NCT00296049|DRUG|vancomycin|
215064705|NCT03444103|DRUG|Clazakizumab / Clazakizumab|Humanized monoclonal anti-IL-6 antibody
215064706|NCT03444103|DRUG|Placebo / Clazakizumab|0.9% Saline
215064707|NCT00807586|DRUG|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
215064708|NCT00807586|DRUG|Placebo|Normal saline (1.6 cc)
215064709|NCT02008942|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
215064710|NCT02008942|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
215064711|NCT00759876|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight
215064712|NCT00969605|PROCEDURE|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
215064713|NCT04894838|PROCEDURE|Distal gastric bypass|Distal gastric bypass, revisonal surgery after failed RYGB
215064714|NCT00742222|RADIATION|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
215064715|NCT00742222|RADIATION|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
214322986|NCT05729620|DEVICE|Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
214322987|NCT05459493|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
214322988|NCT03025022|DRUG|14C-JNJ-42847922 40 mg|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
214485632|NCT06532097|BEHAVIORAL|Physical and behavioral smartwatch-based activation|We used smartwatches to provide an interactive tool for delivering a mixed intervention of physical and behavioral activation, with the former addressing physical activity level and the latter pleasant activities including and beyond physical activity (e.g., social, relaxing activities). Moreover, given the relationship with physical activity level, we additionally incorporated digital insomnia exercises that have also shown large effects in the amelioration of depression.
214485633|NCT01837693|PROCEDURE|Experimental: immediate colposcopy|A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
214485634|NCT06286670|PROCEDURE|Single Implant Fixation|Single implant fixation with either a precontoured lateral locking plate or an intramedullary nail.
214922433|NCT05010252|BEHAVIORAL|Cycled light Experimental|The preliminary plan of this study is to carry out empirical evidence and expert advice to confirm precise lighting and develop care intervention strategies for preterm infants based on evidence. It is planned to be in the Neonatal Intermediate Care Nursery, National Taiwan University Children's Hospital, and the subjects are premature babies born 32 weeks old. Divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-weeks and three-months delay effect.
214922434|NCT04740827|DRUG|Atogepant 60 mg|Atogepant tablets.
214922435|NCT04740827|DRUG|Placebo|Atogepant matching placebo tablets.
214922436|NCT06152874|OTHER|consumption of glucose solution 1|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
214922437|NCT06152874|OTHER|consumption of glucose solution 2|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
214922438|NCT06152874|OTHER|consumption of Bread A and oral processing|bread made with 95% durum wheat fine semolina (\< 400 micrometer) + 5% of gluten + 1.2% of yeast + 1% of salt + 59%of water) (portion corresponding to 50 g available carbohydrates) + 250 mL water
214922439|NCT06152874|OTHER|consumption of Bread B and oral processing|bread made with 80% durum wheat fine semolina (\< 400micrometer) + 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
214922440|NCT06152874|OTHER|consumption of Bread C and oral processing|bread made with 80% durum wheat coarse semolina (\> 500micrometer)+ 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
214922441|NCT02063945|DRUG|Methylphenidate|As stated in arm/group
214922442|NCT02063945|DRUG|Risperidone|As stated in arm/group
214922443|NCT02380833|BEHAVIORAL|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
214922444|NCT02380833|BEHAVIORAL|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
215064716|NCT04792788|PROCEDURE|Weaning from mechanical ventilation|Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.
214322989|NCT06126484|PROCEDURE|transcatheter cardiac intervention|Balloon atrial septostomy, PDA stent implantation, Pulmonary valvuloplasty, Aortic valvuloplasty, Balloon angioplasty of coarctation, PDA closure in preterm neonates
214322990|NCT04465045|PROCEDURE|Laparoscopy-hysteroscopy|Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
214322991|NCT00958776|DRUG|Peramivir+SOC|"* Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~* Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
215064717|NCT01863069|DRUG|Interferon beta 1a|
215064718|NCT01863069|DRUG|(IM) AVONEX®|
215064719|NCT06412835|OTHER|cooperative learning|Students working in groups
215064720|NCT00086983|DRUG|becatecarin|Given IV
215064721|NCT00086983|DRUG|oxaliplatin|Given IV
215064722|NCT00086983|OTHER|pharmacological study|Correlative studies
214322992|NCT00958776|DRUG|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
215064723|NCT02514811|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
215064724|NCT02836717|DEVICE|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
215064725|NCT00268944|BIOLOGICAL|Myozyme|20 mg/kg qow
215064726|NCT03636893|DRUG|FLOT Chemotherapy|5-FU+Leucovorin+Docetaxel+Oxaliplatin
215064727|NCT03636893|DRUG|SOX Chemotherapy|Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
215064728|NCT03087877|DEVICE|Acetaminophen Challenge (G6 CGM)|Evaluation of acetaminophen effect on CGM glucose sensing
214322993|NCT05380661|PROCEDURE|Self-catheterization|Participants will perform self-catheterization, following the same routine for intermittent catheterization at home
214347522|NCT00108225|OTHER|LoBag Diet - test phase|A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
214922445|NCT02380833|BEHAVIORAL|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
214922446|NCT02380833|BEHAVIORAL|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
215064729|NCT00824252|BEHAVIORAL|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
215064730|NCT04808726|BEHAVIORAL|Teach Back Method|Effect of Breastfeeding Training on Breastfeeding Success Using The Teach Back Method: Randomized Controlled Study
215064731|NCT02654821|BIOLOGICAL|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
215064732|NCT02654821|PROCEDURE|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
215064733|NCT02654821|PROCEDURE|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
215064734|NCT00612378|DEVICE|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
215064735|NCT00438360|DRUG|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
214922447|NCT03691051|DRUG|Pyrotinib plus Capecitabine|Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.
215064736|NCT00438360|DRUG|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
215064737|NCT01844297|DRUG|TDF+3TC+EFV|
215064738|NCT05842434|DEVICE|Felix|Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
215064739|NCT06471699|DEVICE|Continous Glucose Monitoring|The aim is to examine if the use of CGM will give the participants a significant support to implement lifestyle improvements in individuals with new on-set type 2 diabetes
215064740|NCT06471699|OTHER|Self monitoring blood glucose|Capillary testing as in standard procedure
215064741|NCT05690347|BEHAVIORAL|Back At work After Surgery (BAAS)|see protocol
215064742|NCT03797963|DEVICE|PBM+ACB|Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone
215064743|NCT03797963|DEVICE|ABB+ACB|Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
215064744|NCT01207609|PROCEDURE|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
215064745|NCT01719458|DRUG|(S,S)-[11C]MRB|PET radioligand
215064746|NCT06071663|PROCEDURE|Single and two visits pulpectomy|Comparison of clinical and radiographic outcome of Single and two visits pulpectomy
215064747|NCT02455804|DEVICE|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
214922448|NCT02556073|OTHER|Smartphone action|Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
214922449|NCT02556073|DRUG|usual care|fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
214922450|NCT02060058|DRUG|Stop trial intervention for boceprevir, PEG-IFN and RBV|"Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped."
214485635|NCT06286670|PROCEDURE|Dual Implant Fixation|Dual implant fixation with either a lateral locking plate plus an intramedullary nail or a lateral locking plate plus a supplemental medial plate.
214485636|NCT06493461|BIOLOGICAL|HS135|HS135 is dosed subcutaneously
214922451|NCT01993901|OTHER|CSRT led telephone follow up|Patients in the intervention group will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms. A second follow up telephone call will be made at 12 weeks post treatment if required in order to address treatment related side effects that were identified during the first call and any interventions that were recommended
214922452|NCT02460250|PROCEDURE|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
214922453|NCT01976650|DRUG|dexamethasone 700 ㎍ intravitreal implant|dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
214922454|NCT06803121|OTHER|Traditional treatment|Traditional exercises for scoliosis include breathing exercises, posture training, spinal flexibility exercises, stretching exercises for the involved muscles (especially for the concave side of the curve), and general strengthening exercises for the main muscle groups of trunk, pelvis, and shoulder girdle muscles (especially for the convex side of the curve).
214922455|NCT06803121|OTHER|Core stability exercises|The CS training program includes local muscle stability training (transverses abdominis, multifidus, and diaphragm), global muscle stability training (oblique abdominal muscles, psoas major, quadratus lumborum, and pelvic floor muscles), global muscle mobility training (rectus abdominis, back extensors, and hamstring muscles), and strength training of the core muscles through the thoracolumbar fascia by maintaining the neutral spine position. Diaphragmatic breathing technique will be used during exercises.
214922456|NCT06179017|OTHER|Experimental group:Intervention Group|Intervention Group:Interventionist choose the optimal endovascular treatment (EVT) strategy and device based on the patient's condition and local guidelines. The patient will receive the best medical treatment according to the local guidelines.
214922457|NCT06179017|OTHER|Control group:best medical treatment|Best medical treatment:Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.
214922458|NCT00453531|PROCEDURE|Limb Ischemia|
214922459|NCT00453531|DRUG|Acetylcholine|
215064748|NCT04560816|DRUG|ALXN1840|ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
215064749|NCT04560816|DRUG|Placebo|Placebo will be administered orally.
215064750|NCT04560816|DRUG|Moxifloxacin|Moxifloxacin (400 milligrams) will be administered orally.
215064751|NCT00780767|DEVICE|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
214485637|NCT05354323|BIOLOGICAL|NECVAX-NEO1|Oral Ty21a based T-cell vaccination, personalized patient-individual NECVAX-NEO1 constructs containing a eukaryotic expression plasmid encoding for a series of selected neoantigen epitopes
214485638|NCT05468827|PROCEDURE|lymphatic mapping with indocyanine green|subserosal injection of indocyanine green near the primary tumour with subsequent assessment of the dye spread along lymphatics
214485639|NCT03934931|OTHER|Streamlined weekly DOT visits|Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects
214485640|NCT03934931|OTHER|Weekly DOT visit reminders|Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits
214485641|NCT03934931|OTHER|Cost reimbursement DOT|Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)
214485642|NCT03934931|OTHER|99DOTS|99DOTS-based digital adherence technology to monitor and promote adherence
214485643|NCT03934931|OTHER|Weekly SAT dosing reminders/check-ins|Weekly SMS or IVR phone call dosing reminder/check-in for side effects
214922460|NCT03976167|DEVICE|Oxygen administration with Common nasal cannula|Oxygen administration during elective flexible bronchoscopy in children with high flow nasal cannula with inspired oxygen fraction 1.
214922461|NCT03976167|DEVICE|Oxygen administration with high flow nasal cannula, device Airvo2 Fisher and Pykel|
214485644|NCT03934931|OTHER|Cost reimbursement SAT|Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
214485645|NCT04232085|DRUG|Alemtuzumab|Preparative regimen
214485646|NCT04232085|DRUG|Fludarabine|Preparative regimen
214485647|NCT04232085|DRUG|Melphalan|Preparative regimen
214485648|NCT04232085|RADIATION|Low Dose Total Body Irradiation|Preparative regimen
214922462|NCT00006617|DRUG|Abacavir sulfate|
214922463|NCT00006617|DRUG|Amprenavir|
214922464|NCT00006617|DRUG|Lamivudine|
214922465|NCT00006617|DRUG|Zidovudine|
214485649|NCT04232085|DRUG|Cyclophosphamide|GVHD prophylaxis
214485650|NCT04232085|DRUG|Tacrolimus|GVHD prophylaxis
215064752|NCT05570656|DEVICE|XSENS-Awinda|"The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day."
215064753|NCT02029456|DRUG|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
215064754|NCT02277691|DRUG|TAK-536TCH tablet|TAK-536TCH tablets
215064755|NCT02277691|DRUG|TAK-536CCB tablet|TAK-536CCB tablets
215064756|NCT02277691|DRUG|HCTZ 12.5 mg tablet|HCTZ tablets
215064757|NCT04416152|PROCEDURE|Pelvic reconstruction surgery|Pelvic reconstruction surgeries, such as anterior/posterior colporrhaphy, sacrospinous ligament fixation, transvaginal mesh repair and sacrocolpopexy.
215064758|NCT05739396|OTHER|core stabilization|The treatment session lasted one hour with short breaks of around 10 minutes and will be conducted three times per week for twelve successive weeks
215064759|NCT03818607|DRUG|ABP 959|intravenous infusion
214485651|NCT04232085|DRUG|Mycophenolate Mofetil|GVHD prophylaxis
214485652|NCT04801797|DRUG|Cytarabine|Intravenous infusion
214485653|NCT04801797|DRUG|Idarubicin|Intravenous infusion
214485654|NCT04801797|DRUG|Daunorubicin|Intravenous infusion
214485655|NCT04801797|DRUG|Liposomal daunorubicin and cytarabine|Intravenous infusion
214485656|NCT04801797|DRUG|Venetoclax|Orally by mouth
214485657|NCT04801797|DRUG|Azacitidine|Intravenous infusion
214485658|NCT04115007|RADIATION|Stereotactic Body Radiotherapy (SBRT) + Standard of care|"Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).~SBRT is delivered using the following regimen: 30 Grays (10 Gy x 3 fractions) for axial and appendicular bones and lymph node metastases if present. In case the dose cannot be safely delivered while maintaining a safe dose to the organs at risk, an alternate regimen (35 Gy in 5 fractions of 7 Gy) can be used."
214485659|NCT04115007|DRUG|Standard of care|"Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel)."
214922466|NCT02118649|BEHAVIORAL|Game|
214922467|NCT01435018|DRUG|Etoposide (ET)|"Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade \>= 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade \>= 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.~Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
215064760|NCT03818607|DRUG|Eculizumab|intravenous infusion
215064761|NCT02691910|DRUG|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
215064762|NCT02691910|DRUG|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
215064763|NCT02697760|RADIATION|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
215064764|NCT05314543|OTHER|Hypoxia|Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
214922468|NCT01435018|DRUG|Bleomycin and Vincristine (BV)|"BV was administered on day one of each chemotherapy cycle.~Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below.~Bleomycin sulfate was administered at a dose of 15 units/m\^2 over 10 minutes every 3 weeks.~Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
215064765|NCT03560102|DEVICE|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
215064766|NCT01761799|BEHAVIORAL|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
215064767|NCT03863379|DIAGNOSTIC_TEST|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
215064768|NCT03089333|DRUG|Dapagliflozin 10mg|Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
215064769|NCT03089333|DRUG|Glibenclamide 5Mg Tablet|Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
214922469|NCT01435018|DRUG|Paclitaxel (PTX)|Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m\^2 body surface area (BSA) every 3 weeks.
214922470|NCT01435018|DRUG|Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)|"The following ART regimens were used:~1. EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~2. FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~3. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~4. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~5. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing"
214922471|NCT05287919|OTHER|Patients received the standard physical therapy (SPT) programme (passive mobilization) twice a day.|All participants have received standard physical therapy (SPT) sessions based on a passive range of motion mobilization protocol for the lower limbs. It consisted of a bilateral series of 10 repetitions of hip flexion, knee flexion and extension, and ankle flexion and extension. The procedure was performed twice a day: a morning (between 8am - 12pm) and an afternoon session (between 2pm - 6pm).
214922472|NCT05287919|OTHER|Patients received the low-frequency neuromuscular electrical stimulation (NMES)|Electrical stimulation was performed twice a day after SPT. Two electrodes were attached to each thigh at the motor points of the quadriceps muscle. The point halfway between the anterior superior iliac spine and the base of the patella was used as reference and electrodes were placed 15 cm apart each other, 5 cm proximal and 10 cm distal from the reference point. After the first measurement, semi-permanent markers were used to indicate the position of electrodes. Electrical stimulation was performed using a 4-channels device (Sonopuls 492, series 4, Enraf-Nonius®, Rotterdam, Netherlands). The low-frequency protocol consisted of 100 Hz and 400 ms width pulses, delivered in trains of 5 s ON (ramp-up time: 1 s, plateau: 3 s, ramp-down time: 1 s) and 10 s OFF. Sessions had 20 min of duration (total of 40 min/day) and the current amplitude (mA) was adjusted to the identification of visible and palpable contractions and was rectified every 3 min to sustain the initial level of contraction.
215064770|NCT01643265|DIETARY_SUPPLEMENT|Whey Milk Protein|20 grams of Whey Milk Protein
215064771|NCT01643265|DIETARY_SUPPLEMENT|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
215064772|NCT05059301|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
215064773|NCT02924246|BIOLOGICAL|cholera vaccination|Oral cholera vaccination on day 0 and day 14
215064774|NCT02924246|OTHER|raw milk|raw milk
215064775|NCT02924246|OTHER|pasteurized milk|pasteurized milk
215064776|NCT02924246|OTHER|UHT milk|UHT milk
215064777|NCT00733070|DEVICE|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
215064778|NCT00434447|DRUG|Zoledronic acid|
215064779|NCT02767089|DRUG|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
215064780|NCT02767089|DRUG|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
215064781|NCT01164891|DRUG|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
215064782|NCT05051670|PROCEDURE|da vinc SP gastrectomy|radical subtotal gastrectomy performed by da vinci SP
215064783|NCT00610350|DRUG|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
215064784|NCT00610350|DRUG|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
215064785|NCT06792760|OTHER|Physiotherapy|The intervention will consist of 10 individual physiotherapy sessions delivered by a single physiotherapist trained in FMD. The physiotherapy programme will include education, movement retraining and a self-management plan.
215064786|NCT06792760|OTHER|Specific Breathing Techniques|The intervention will include education and training in specific breathing techniques, which will be exercised by the patient as a self-management plan for over 5-10 minutes daily.
215064787|NCT00441142|DRUG|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
215064788|NCT00441142|DRUG|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
215064789|NCT00441142|RADIATION|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
215064790|NCT01140997|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
215064791|NCT01140997|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
214672478|NCT06674382|PROCEDURE|Haploidentical hematopoietic stem cell transplantation|"This is a single-arm study in which all patients will undergo haploidentical hematopoietic stem cell transplantation for the treatment of myelofibrosis.~Pre-transplant Evaluation:~Evaluation includes status of primary Disease, donor specific antibodies (DSA), organ function (assessments for heart, liver, lungs, kidneys, and the nervous system), and Spleen size.~Transplantation Protocol:~Conditioning Regimen:~Dac/TT/Bu/Flu/ATG regimen:~Decitabine 100 mg/m², on day -12. Thiotepa (TT) 5 mg/kg/day, on days -11 and -10. Busulfan 0.8 mg/kg body weight, every 6 hours, on days -8 to -6. Fludarabine 30 mg/m², once daily, on days -6 to -2. Anti-thymocyte globulin (ATG) 2.5 mg/kg body weight, once daily, on days -5 to -2.~Transplant Donor: Haploidentical donor. GVHD (Graft-versus-Host Disease) Prophylaxis Regimen: Cyclosporine, mycophenolate mofetil, and short-course methotrexate for GVHD prevention.~Graft:~Target MNC (Mononuclear Cells): 6-8 × 10⁸/kg. Target CD34+ stem cells: 5 × 10⁶/kg"
214922473|NCT05287919|OTHER|Patients received the medium-frequency neuromuscular electrical stimulation (NMES)|Electrical stimulation was performed twice a day after SPT. Two electrodes were attached to each thigh at the motor points of the quadriceps muscle. The point halfway between the anterior superior iliac spine and the base of the patella was used as reference and electrodes were placed 15 cm apart each other, 5 cm proximal and 10 cm distal from the reference point. After the first measurement, semi-permanent markers were used to indicate the position of electrodes. Electrical stimulation was performed using a 4-channels device (Sonopuls 492, series 4, Enraf-Nonius®, Rotterdam, Netherlands).The medium-frequency protocol had similar parameters, but a carrier frequency of 2500 Hz and burst frequency of 100 Hz. Sessions had 20 min of duration (total of 40 min/day) and the current amplitude (mA) was adjusted to the identification of visible and palpable contractions and was rectified every 3 min to sustain the initial level of contraction.
214922474|NCT06684366|DRUG|Statins (atorvastatin or simvastatin)|A resting transthoracic echocardiogram Non-invasive functional imaging for myocardial ischemia or coronary computed tomography angiography (CCTA) is recommended as the initial test for diagnosing CAD in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone
214922475|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - baseline|Baseline laboratory values will be obtained
215064792|NCT05206188|BEHAVIORAL|Mastering the World of Work (MWW)|Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
215064793|NCT06394479|OTHER|Outcome after bariatric surgery in patient with T1D|Retrospective evaluation of clinical data
215064794|NCT01597765|DRUG|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
214485660|NCT05734495|DRUG|Pirtobrutinib|Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.
214485661|NCT05734495|DRUG|Venetoclax|Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.
214485662|NCT02446457|OTHER|Laboratory Biomarker Analysis|Correlative studies
214485663|NCT02446457|DRUG|Lenalidomide|Given PO
214485664|NCT02446457|BIOLOGICAL|Pembrolizumab|Given IV
214485665|NCT02446457|BIOLOGICAL|Rituximab|Given IV
214485666|NCT05922657|DEVICE|Cerene|Real world use of Cerene.
214672479|NCT07013175|PROCEDURE|Choosing wisely protocol|Se arm description
214672480|NCT06940401|DRUG|JS111 capsules (AP-L1898)|In Phase I, approximately 3-12 subjects will be enrolled in each dose group (160 mg QD or 240 mg QD) and receive oral JS111 capsules once daily until any treatment discontinuation criteria are met. After all subjects have completed at least 21 days observation following the first dose, the Safety Monitoring Committee (SMC) will review safety and pharmacokinetic data to make decisions. Phase II will continue enrollment at the RP2D dose level until approximately 30 subjects have been treated at that dose.
214922476|NCT05538234|OTHER|Medical information 12 hours before organ harvesting|"* average hourly diuresis~* hypotension MAP\<65 Torr longer than 30 minutes (YES/NO)~* Furosemide administration (YES/NO)~* Mannitol administration (YES/NO)~* administration of anti-diuretic hormone (YES/NO)~* administration of vasopressors (YES/NO)~* polyuria \>3ml/kg/h (YES/NO)~* nephrotoxic agents during hospitalization (YES/NO)"
214922477|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 12 hours after reperfusion|Laboratory values will be obtained 12 hours after reperfusion
214922478|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 48 hours after reperfusion|Laboratory values will be obtained 48 hours after reperfusion
214922479|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 7 days after reperfusion|Laboratory values will be obtained 7 days after reperfusion
214922480|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 90 days after reperfusion|Laboratory values will be obtained 90 days after reperfusion
214922481|NCT05538234|OTHER|Medical information during organ harvesting/transplantation|"Medical information during organ harvesting/transplantation~* hypotension MAP 65 Torr \> 5 minutes (YES/NO)~* vasopressor support (YES/NO, duration in minutes)"
214922482|NCT05538234|PROCEDURE|Organ harvesting|Organ harvesting for transplant
214922483|NCT05538234|PROCEDURE|Organ transplantation|Transplantation of the harvested organ
214922484|NCT02114944|DEVICE|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
214922485|NCT02114944|DEVICE|CPAP|Patient treated, as per attending physician's decision, with CPAP
214922486|NCT02114944|DEVICE|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
214922487|NCT02114944|DEVICE|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
214922488|NCT04069832|BEHAVIORAL|Single-Session Consultation|A single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
214922491|NCT06272318|OTHER|Blood Pressure Cuff, EKG, PPG|A blood pressure cuff, an EKG, and a PPG will be utilized to collect subject vitals.
214922492|NCT03806933|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).
215064795|NCT01597765|DRUG|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
215064796|NCT04098419|BEHAVIORAL|Science for Life|The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
215064797|NCT03670654|OTHER|Pilates|The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
215064798|NCT03670654|OTHER|Muscle stretching|The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
214322994|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant blinded to time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting blood pressure and heart rate will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be draped and they will be not aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
214322995|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant aware of time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting BP and HR will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be visible to participant and they will be fully aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
214672481|NCT03366311|PROCEDURE|holding position|two types of holding positions plus two types of shapes of stylet, with or without epiglottis lift
214672482|NCT00883194|DRUG|PRF-108|Ropivacaine
214672483|NCT00883194|DRUG|Placebo|PRF-108 Placebo
214922493|NCT06124950|BEHAVIORAL|Gender-transformative intervention|"A multidisciplinary team of experts, including 8-10 experts in reproductive medicine, nursing, social work, psychiatry, family law, and evidence-based medicine, will be established to support the development of the intervention.~Five 60-minutes intervention sessions will be delivered by trained nurses and social workers throughout participants' fertility treatment cycle. Intervention will be carried out at the 5 critical windows of opportunity for infertility treatment: (1) before entering the cycle; (2) during follicular monitoring; (3) before oocyte retrieval; and (4) 2 weeks after the embryo transfer; and (5) 28-30 days after the embryo transfer.~The intervention components will equip couples with educational information on health and relationship and skills obtained from interactive activities designed with an explicit focus on challenging gender stereotypes, all of which could incite reflection on sociocultural norms and gender-related power inequality."
214922494|NCT04108468|DRUG|Golimumab|Simponi
215064799|NCT03294044|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
215064800|NCT03294044|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
215064801|NCT05105581|BEHAVIORAL|Quality of life scale|"1. To assess the quality of life of patient~2. To assess the degree of OCD"
215064802|NCT03455933|OTHER|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
214672484|NCT00883194|DRUG|Ropivacaine|Solution
214672485|NCT00883194|DRUG|PRF-110|
214672486|NCT01582282|DIETARY_SUPPLEMENT|placebo|fiber-free placebo
214922495|NCT04108468|DRUG|Methotrexate|Methotrexate
215064803|NCT03455933|OTHER|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
214922496|NCT00078767|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|12 weeks of Trauma-Focused CBT (TF-CBT)for youth and parent
215064804|NCT03455933|OTHER|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
214322996|NCT05195320|BEHAVIORAL|Reinvention with MS|A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
214922497|NCT00078767|DRUG|Sertraline Pill|12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT
214922498|NCT00078767|DRUG|Placebo Oral Tablet|12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
214922499|NCT01957436|DRUG|abiraterone acetate|abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
214922500|NCT01957436|RADIATION|radiotherapy|74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
214922501|NCT01957436|OTHER|Androgen Deprivation Therapy|The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
214922502|NCT01957436|DRUG|Docetaxel|6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
214922503|NCT02841670|DEVICE|InFo - Instant Focus (c) lens implantation|
214922504|NCT02282631|BEHAVIORAL|Incentive scheme|Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
214922505|NCT04082572|BIOLOGICAL|Pembrolizumab|Given IV
214322997|NCT00020111|DRUG|arsenic trioxide|
214322998|NCT04894617|DRUG|Amantadine|200 mg Amantadine daily for a total of 5 days.
214322999|NCT04894617|DRUG|Lactose monohydrate|Lactose monohydrate two tablet daily for a total of 5 days.
214323000|NCT02105077|DRUG|Anesthesia with inhalative application of xenon gas|
214672487|NCT01582282|DIETARY_SUPPLEMENT|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
214672488|NCT01582282|DIETARY_SUPPLEMENT|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
214323001|NCT02285985|DRUG|Saxagliptin|Tablets: 5 mg
214323002|NCT02285985|DRUG|Placebo|Tablets: 5mg
214323003|NCT03732898|DEVICE|Novel Programming (nDBS)|The commercial CP installed with the investigational DBS programming software will be used to set up Novel Programming (nDBS) therapy on the IPG.
214323004|NCT03732898|DEVICE|Conventional Programming (cDBS)|The commercial CP installed with commercial software will be used to set up standard cDBS therapy on the IPG.
214323005|NCT00175903|DRUG|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
214323006|NCT00175903|DRUG|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
214323007|NCT00175903|DRUG|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
214323008|NCT04181346|DRUG|Pregabalin|antipsychotic
214323009|NCT04181346|DRUG|Placebo|Placebo
214323010|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
214323011|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
214323012|NCT03366350|PROCEDURE|Allogeneic hematological stem cell transplantation|Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
214323013|NCT03215355|DRUG|Primovist|"Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety."
214323014|NCT03977571|PROCEDURE|Cytoreductive nephrectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach.
214323015|NCT03977571|OTHER|Tissue sampling|Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
214347523|NCT00108225|OTHER|LoBAG Diet - control phase|A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
214672489|NCT03920852|DRUG|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
214922506|NCT05749978|BEHAVIORAL|Asana adjustment|Adjust the operating table to 15° head height and foot low in advance. The patient is then slowly turned over from the transport table to the operating table and completed in the prone position. After the patient's hemodynamic stability is smooth, adjust the operating table to the level.
214922507|NCT04662281|DRUG|Placebo|LX9211 matching-placebo, tablets will be administered orally.
214922508|NCT04662281|DRUG|LX9211|LX9211, 200 mg, tablets will be administered orally.
214922509|NCT03427099|BEHAVIORAL|Rehabilitation with a biopsychosocial focus|Rehabilitation with a biopsychosocial focus
214922510|NCT03427099|BEHAVIORAL|Control group|usual care
214922511|NCT05908032|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
214922512|NCT05908032|BIOLOGICAL|Placebo|Placebo
214922513|NCT00082446|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
214922514|NCT00082446|BIOLOGICAL|MVA Smallpox Vaccine|Imvamune/MVA-BN 1x10\^8 will be administered intramuscularly to Group F on day 0 and day 28.
214922515|NCT00082446|BIOLOGICAL|MVA Smallpox Vaccine|Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.
214922516|NCT00082446|OTHER|Placebo|Group E will receive sterile saline placebo for injection via scarification on day 112.
214672490|NCT01812304|OTHER|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
214672491|NCT01812304|OTHER|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
214672492|NCT02076672|DRUG|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
214672493|NCT05280015|DIETARY_SUPPLEMENT|microbiotherapy (GynMDD)|multi-target microbiotherapy add-on venlafaxine
214672494|NCT05280015|OTHER|placebo|placebo add-on venlafaxine
214922517|NCT00082446|OTHER|Placebo|Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
214672495|NCT05782218|DIETARY_SUPPLEMENT|Almonds|Participants will receive 2.2 oz (62 g) of almonds to ingest within 15 minutes.
214672496|NCT05782218|DIETARY_SUPPLEMENT|Coconut|Participants will receive 1 oz (30 g) of a coconut-chocolate bar and 1.4 oz (40 g) of 100% dried coconut chips to ingest within 15 minutes.
214672497|NCT01486316|DEVICE|Reveal XT® Insertable Cardiac Monitor|If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
214323016|NCT05366660|OTHER|Interrogation/programming|As the study investigates remote programming, we will describe two locations: local (patient side) and remote (expert side). Local support is defined by a physician or a technician under the direct responsibility of a nearby physician who connect the patient to the remote programming system. Similar to a conventional check-up, an external defibrillator will be located in the near vicinity of the patient. The patient will first be connected to the programmer as during a conventional follow-up. The programmer will then be connected to a local PC which captures the programmer VGA video output and controls the programmer through a mouse emulator. This local PC will be remotely controlled by the remote PC using Cisco Webex, a communication software used worldwide to support telemedicine.
214323017|NCT05634811|BIOLOGICAL|VLA15|6-valent OspA-based Lyme disease vaccine
214672498|NCT01486316|OTHER|Heart Failure Risk Status Diagnostic|"The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High."
214672499|NCT00112151|DRUG|LowT|Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
214672500|NCT00112151|BEHAVIORAL|Resistance Training|Weight training 45-60 minutes 3 times per week
214672501|NCT00112151|DRUG|Placebo|2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
214672502|NCT00112151|DRUG|HighT|High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
214922518|NCT01421628|OTHER|Fitness exercise program|Exercise program, daily frequency, duration of 6 weeks.
214672503|NCT00830453|PROCEDURE|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
214672504|NCT02137434|OTHER|Dietary calcium|Dietary calcium from skimmed milk
214672505|NCT02137434|DIETARY_SUPPLEMENT|Supplementary calcium|Supplementary calcium from calcium carbonate
214672506|NCT03020810|DRUG|Dupilumab|The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
214672507|NCT02031380|DEVICE|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
214672508|NCT03177135|DEVICE|AmnioSense|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.
214922519|NCT02819752|DRUG|Pembrolizumab|Pembrolizumab
214922520|NCT02819752|RADIATION|Radiotherapy|Radiotherapy - Standard Treatment
214922521|NCT02819752|DRUG|Chemotherapy|Chemotherapy - Standard Treatment
214323018|NCT05634811|OTHER|Normal Saline|0.9% sodium chloride solution for injection
214323019|NCT06138756|DEVICE|Nerivio|Nerivio is a remote electrical neuromodulation (REN) device for the treatment of migraine
214672509|NCT00664274|BEHAVIORAL|Cognitive remediation therapy|36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
214672510|NCT00664274|GENETIC|COMT Genotyping|One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
214672511|NCT05645666|BEHAVIORAL|Well-being therapy|Well-being therapy is a short-term, organized and problem-oriented treatment program that is based on Riff's psychological well-being model. Its purpose is to help patient in order to improve His/her functions in six dimensions; personal growth, environmental mastery, purposefulness of life, and autonomy, self-acceptance and positive relationships with others Therapists help patients find well-being experiences in their present and past lives and pay attention to these experiences, no matter how small or short they are.
214672512|NCT01792986|BEHAVIORAL|water-only 24-hour fasting once per week for 6 weeks|
214672513|NCT02002078|DRUG|methylprednisolon|
214672514|NCT05099601|COMBINATION_PRODUCT|Silymarin|The patients will use topical silymarin 0.7% cream on the face twice daily(home use).
214922522|NCT04950270|BIOLOGICAL|Blood copeptin monitoring|Blood copeptin monitoring during the first 6 days of ICU stay with PRES
214922523|NCT04950270|OTHER|phone interview|Structured phone interview at 3 months to collect vital status and modified Rankin Scale score
214922524|NCT02718989|DEVICE|Transcutaneous Electrical Stimulation|TENS transcutaneous electrical stimulation over the back the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214922525|NCT02718989|DEVICE|10Kilohertz (KHz)|10 KHz transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214922526|NCT02718989|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214922527|NCT05902273|DIAGNOSTIC_TEST|hemodynamic monitoring|Baxter Starling Monitor for measuring cardiac output and systemic vascular resistance (SVRI) which is using bioreactance technology. We need to place four electrodes on chest wall (upper left, upper right, down left, down right) and input monitor demographic parameters. Also enter mean arterial pressure (MAP) for calculating SVRI so we input MAP every minute.Patient bed set as 45 degree head elevated and legs 0 degree. Just after start measuring, monitor needs to synchronize itself for patient. After synchronisation we start fluid challenge with passive leg raising option. This test has two stages. First stage calculating baseline parameters which takes 3 minutes and second stage is measuring difference with fluid challenge which also takes 3 minutes. At the end of first stage monitor shows to perform passive leg raise and we perform trendelenburg maneuver till head comes to 0 degree. After second stage measurement has finished.
214922528|NCT05902273|DIAGNOSTIC_TEST|resistive index|We use ultrasonography at the same time with cardiac output monitor in both stages. First we determine the location of radial artery at wrist snuffbox at 1.5 centimeters depth with linear probe and confirm pulsatile flow with color mode. In Starling's baseline stage we measure and calculate resistive index with doppler P-mode in triplex setting 3 times. When received 3 same result successively we noted as SBRI-1. Second measurement is initiated at last 30 seconds of passive leg raising as described before and we noted our measurement as SBRI-2
214922529|NCT05902273|DIAGNOSTIC_TEST|Pleth variability index|During all stages Masimo Rad-87 rainbow probe is placed patients index or middle finger and we note PVI-1 and PVI-2 at the same time with SBRI-1 and SBRI-2
214922530|NCT01058993|DRUG|AMD3100 or plerixafor|The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
214922531|NCT00849511|DRUG|melatonin|Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
214922532|NCT00831311|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular
214922533|NCT00831311|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine|0.5 mL, Intramuscular (right and left thighs, respectively)
214922534|NCT02993328|DRUG|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
214922535|NCT02993328|DRUG|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
214922536|NCT05856383|DRUG|Inetetamab Combined With Pyrotinib and Vinorelbine|Inetetamab Combined With Pyrotinib and Vinorelbine
214922537|NCT06084845|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214922538|NCT06084845|DRUG|Carboplatin|Given IV
214922539|NCT06084845|PROCEDURE|Chest Radiography|Undergo chest x-ray
214922540|NCT06084845|DRUG|Cisplatin|Given IV
214922541|NCT06084845|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
214922542|NCT06084845|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
214922543|NCT06084845|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214922544|NCT06084845|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214922545|NCT06084845|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
214922546|NCT06084845|DRUG|Xevinapant|Given PO
214922547|NCT03603145|PROCEDURE|Immediate insertion|Immediate insertion of intrauterine contraception within 48 hours of medical abortion
214922548|NCT06133751|DRUG|black chokeberry (Aronia melanocarpa)|Black chokeberry capsules standardized for anthocyanin compounds
214922549|NCT06133751|DRUG|Placebo|Chokeberry fiber placebo capsules
214922550|NCT03620123|DRUG|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
214922551|NCT03620123|DRUG|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
214922552|NCT01728818|DRUG|Gemcitabine|1000 mg/m² d1,8,15 q4weeks
214922553|NCT01728818|DRUG|Afatinib|40mg flat dose, po, once daily
214922554|NCT01728818|DRUG|Gemcitabine|1000 mg/m², d1,8,15 q4weeks
214922555|NCT05557643|DRUG|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the issues that arise in this participant population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
214922556|NCT05557643|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) is a well-established evidence-based mindfulness training program initially developed by Jon Kabat-Zinn that has been shown to reduce symptoms of depression, anxiety, and burnout. The 8-week MBSR curriculum provides training in formal meditation practices including body scan techniques, mindfulness meditation, and yoga. Mindfulness can be understood as the non-judgmental acceptance and investigation of present experience, including body sensations, internal mental states, thoughts, emotions, impulses and memories, in order to reduce suffering or distress and to increase well-being.
214922557|NCT01713114|OTHER|Acute measures of satiety and food intake at next meal|
214922558|NCT01024868|DRUG|Ropivacaine 0,5%|Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
214323020|NCT05100745|DEVICE|Therapeutic Device|This device delivers ultrasound energy to the targeted area of the lower limb.
215064805|NCT04952753|DRUG|NIS793|Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.
214922559|NCT00730730|DEVICE|Complete SE Iliac Stent|Iliac stenting
214922560|NCT00730730|DEVICE|Complete SE Iliac Stent|Self-expanding stent
214323021|NCT05159999|OTHER|Dry weight target adjustment|Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.
214323022|NCT05159999|DRUG|Anti-hypertensive medications|Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.
214323023|NCT03795610|DRUG|IPI-549|40mg by mouth (PO) every day (QD) for at least 14 days
214485667|NCT04274881|PROCEDURE|Catheterization of internal jugular vein|"The right internal jugular vein will be cannulated under transesophageal echocardiographic (TEE) guidance in order to place the catheter tip in the mid-SVC.~The length of the catheter required to place the tip at the mid-SVC as guided by TEE will be regressed on the C-length or on the distance from the entry point to the surface point corresponding to the mid-SVC on the chest wall in order to obtain a predictive equation.~The accuracy of either equation will be assessed by estimation of the standard error of the estimate (SEest)."
214485668|NCT05615311|DIETARY_SUPPLEMENT|Vitamin D supplementation|Study participants assigned to the intervention group will receive 800 IU/ day of vitamin D plus 200-300 IU/day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
214485669|NCT05615311|OTHER|No additional vitamin D supplementation|Study participants assigned to the control group will receive 200-300 IU/ day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
214922561|NCT04845919|DRUG|5-Aminolevulinic Acid|"SDT treatment with 5-ALA using the ExAblate Model 4000 Type-2 Neuro-System."
214922562|NCT01841762|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily
214922563|NCT06565026|GENETIC|CS-206|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
215064806|NCT04952753|DRUG|Bevacizumab|Bevacizumab will be administered IV
215064807|NCT04952753|DRUG|Modified FOLFOX6|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
215064808|NCT04952753|DRUG|FOLFIRI|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
215064809|NCT04952753|DRUG|Tislelizumab|Investigational drug tislelizumab will be administered intravenously (IV).
215064810|NCT06169943|OTHER|mHealth social support program|This is a 3-month program comprises mobile app, group discussion, individual telephone contact, and reminders.
215064811|NCT06169943|OTHER|Control|The same mobile app as the intervention group but with limited function.
215064812|NCT01242839|DEVICE|CACICOL20|CACICOL20 is a solution of dextran \& poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
215064813|NCT01242839|DEVICE|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
215064814|NCT04952597|DRUG|Ociperlimab|Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle
215064815|NCT04952597|DRUG|Tislelizumab|Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle
214323024|NCT05491083|DRUG|Pembrolizumab & ADG106 (Phase Ib)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
214323025|NCT05491083|DRUG|Pembrolizumab & ADG106 (Phase II)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
214323026|NCT02509065|DEVICE|Bionic Pancreas|Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
214323027|NCT02509065|OTHER|Usual Care|Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
214347524|NCT02630264|DRUG|Endostatins|"Specification: 1mL/division, 1×1012 VP/1.0mL~E10A preparation:~1. Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.~2. Swirl gently. Do NOT shake.~Method of administration~1. E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.~2. After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.~3. Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding."
214347525|NCT02630264|DRUG|Paclitaxel injection|"Specification:~30mg/5mL,~Usage:~160mg/m2 on day 3, according to instruction."
215064816|NCT04952597|DRUG|Concurrent Chemoradiotherapy|"Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
215064817|NCT00167141|DRUG|injection of hormonal male contraceptive|testosterone injections 4 times
215064818|NCT05563311|OTHER|Exercise on High-intensity interval training|3 times a week, for 8 weeks
215064819|NCT05731817|OTHER|Observational study|N/A - observational study.
215064820|NCT05358522|OTHER|Opioid Prescribing Report Cards|"Initial comparison: Clinicians will receive an initial peer comparison feedback report by email in which their post-operative opioid prescribing for patients undergoing their top 3 procedures is compared to the guideline recommended doses and the mean prescribing doses by other University of Pennsylvania Health System (UPHS) prescribers for each of those 3 procedures since the start of the baseline period.~Furthermore, in an attached report, for each of the 3 procedures, the mean patient reported ability to manage pain one week at home after the procedure will be displayed for those who received guideline compliant dosages of opioids relative to those who received higher than guideline recommended amounts.~Monthly comparison: On a monthly basis clinicians will get a report providing similar peer comparison feedback as above but with a monthly trend line of their performance since the start of the intervention."
214922564|NCT06683417|DEVICE|Vestibular Rehabilitation Aid|"The tablet-based VestAid system was developed to repair, restore and maintain vestibular-ocular function that is impaired in patients post-mTBI.~Each participant\&amp;#39;s treating physical therapist will develop their own personalized exercise prescription. The physical therapist will be asked to recommend that the patients complete a home exercise program at least 2-3 times per day for 6 weeks. The exercise prescription will be placed on the VestAid by the physical therapist for the patient to follow. The patient is not able to modify the exercise, only the physical therapist can modify the exercises. Exercises will be modified based on patient\&amp;#39;s response and symptom reports. The physical therapist and study coordinator will receive an alert on the VestAid online dashboard if the patient\&amp;#39;s symptoms are greater than or equal to 8/10."
215064821|NCT03515135|BEHAVIORAL|Metacognitive Executive Function Training|Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
214485670|NCT04765098|DRUG|Tamoxifen|Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
215064822|NCT01885884|BEHAVIORAL|Embedded Supportive Care|
215064823|NCT04277325|BEHAVIORAL|Emotionally Focused Therapy|Emotionally Focused Couples Therapy (EFT) is an empirically supported, attachment-based model of couples therapy that combines experiential, systems, and attachment theories with the goal of fostering the development of safe contact, accessibility, and responsiveness in both partners.
215064824|NCT05318469|DRUG|Ivermectin|Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).
215064825|NCT05318469|DRUG|Balstilmab|Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
215064826|NCT05318469|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle
215064827|NCT03260374|DEVICE|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
214485671|NCT04765098|DRUG|Etoposide|etoposide 50mg/m2 daily
214485672|NCT04996875|DRUG|bezuclastinib|Bezuclastinib is administered as tablets to be taken orally, continuously in 28-day cycles.
214485673|NCT05594498|DEVICE|StrataXRT|StrataXRT is a silicone-based film-forming topical gel that may help in reducing radiation dermatitis.
214922565|NCT06683417|OTHER|Standard of care vestibular rehabilitation|Vestibular rehabilitation to include gaze stabilization exercises, optokinetic training, smooth pursuits and saccades
214922566|NCT03576690|BIOLOGICAL|REGN3470-3471-3479|
214922567|NCT01868438|DRUG|Pyronaridine-artesunate granules|
214922568|NCT01868438|DRUG|Pyronaridine-artesunate tablets|
214922569|NCT04996602|DRUG|2.0 GBq of 177Lu-EB-PSMA|Patients were intravenous administrated with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA every 8 weeks (±1 week) for a maximum of 3 cycles.
215064828|NCT03260374|DEVICE|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
214485674|NCT05583344|DRUG|GSK4532990|GSK4532990 will be administered.
215064829|NCT03260374|DEVICE|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
215064830|NCT05730335|DEVICE|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
215064831|NCT06264089|PROCEDURE|Preservation Rhinoplasty Nasal Valve Angle and Area|The same group of patients who underwent Preservation Rhinoplasty will be followed and the nasal valve angles before and after surgery will be compared.
215064832|NCT03468751|DRUG|HLX10|recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
215064833|NCT00073736|DRUG|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
215064834|NCT00073736|DRUG|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
215064835|NCT00073736|DRUG|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
215064836|NCT00073736|DRUG|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
215064837|NCT00073736|DRUG|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
215064838|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
215064839|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
215064840|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
215064841|NCT01749124|DEVICE|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
215064842|NCT00883168|DRUG|Placebo|Placebo
214672515|NCT05099601|PROCEDURE|Microneedling|Patients will be subjected to microneedling sessions on one side of the face. Three consecutive sessions, 4 weeks apart (0, 4, 8 weeks), will be performed by dermapen. Sessions will be done by well trained physician.
215064843|NCT00883168|DRUG|azelastineHcl|azelastine hydrochloride 548 mg
215064844|NCT00883168|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
215064845|NCT00883168|DRUG|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
215064846|NCT00262886|BIOLOGICAL|anti-thymocyte globulin|
214485675|NCT05583344|DRUG|Placebo|Placebo will be administered.
214485676|NCT06167486|DRUG|SG2918|The SG2918 will be administrated by intravenous infusion every 3 weeks
214922570|NCT03843749|DRUG|Pyrotinib|Pyrotinib in Combination With Trastuzumab
214922571|NCT06665867|OTHER|Video consultation|Participants will have their follow-up consultation with the physician via video. The consultation takes place via the participant's/parent's own device.
214922572|NCT06665867|OTHER|Face-to-face consultation|The follow-up consultation with the physician will take place at the hospital.
214922573|NCT06526143|BEHAVIORAL|M2VA Pain Care Pathway (M2VAPCP)|M2VAPCP is a manualized Motivational Interviewing-based intervention, designed to motivate Veterans to engage in multimodal nonpharmacological pain care and reduce substance misuse when present. The first session includes empathic exploration of the Veteran's MSD, pain experiences, and motivations for pain care; psychoeducation about the benefits of multimodal pain care and judicious use of non-opioid medications; information about available pain management services and treatments for conditions that might exacerbate chronic pain; screening for substance misuse, including prescription medications, and motivational enhancement to change behaviors related to positive screens; and for those interested, making plans to achieve these goals. Over 12 weeks, case managers will hold up to two additional sessions with participants to check on their goal achievement and continue motivational enhancement for multimodal pain treatment and reduced substance misuse.
215064847|NCT00262886|BIOLOGICAL|graft-versus-tumor induction therapy|
215064848|NCT00262886|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215064849|NCT00262886|DRUG|cyclophosphamide|
215064850|NCT00262886|DRUG|fludarabine phosphate|
214922574|NCT06526143|BEHAVIORAL|Implementation Facilitation|"Implementation facilitation teams consisting of internal and external facilitators will conduct activities for two purposes:~1. to build working relationships within the pain and addiction care pathways to achieve the shared goal of implementing high-quality M2VAPCP; and~2. to promote constructive, problem-solving oriented communication based on indicators of M2VAPCP implementation progress.~Activities will include Virtual Site Visits, all-side facilitation team meetings, local facilitation team meetings, M2VAPCP consultation groups, learning collaboratives, case identification reports and audit and feedback."
215064851|NCT00262886|DRUG|mycophenolate mofetil|
215064852|NCT00262886|DRUG|tacrolimus|
215064853|NCT00262886|PROCEDURE|allogeneic bone marrow transplantation|
215064854|NCT00262886|PROCEDURE|peripheral blood stem cell transplantation|
215064855|NCT04332536|OTHER|Exercise with and without Codeine|This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
215064856|NCT02502292|BEHAVIORAL|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
215064857|NCT03674073|BIOLOGICAL|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
215064858|NCT03674073|PROCEDURE|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
215064859|NCT04548934|DEVICE|Personal protective equipment (PPE)|Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
215064860|NCT04548934|DEVICE|No Personal protective equipment (PPE)|Standard CPR without wearing PPE
215064861|NCT03438279|OTHER|Non-Interventional|Non-Interventional
214347526|NCT02630264|DRUG|Cisplatin injection|"Specification:~20mg~Usage:~Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction."
214347527|NCT00692172|DRUG|Alefacept|intramuscular injection (IM)
214347528|NCT01466998|OTHER|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
214922575|NCT06546956|BEHAVIORAL|Integrative Breathwork Intervention|GRMT has three core components: respiratory regulation (i.e., sustained conscious connected breathing pattern into the upper chest where there is no pause between inhale and exhale), mindfulness of somatic sensations while breathing (i.e., interoceptive awareness with acceptance), and relaxation of physical tension. These components are the primary focus in every breathwork session. The intervention is delivered 1-on-1 in-person with a trained facilitator. Participants lay supine throughout the 60 minute session. The facilitator observes the participant's breathing pattern and guides the participant to apply the three core components. Each session ends with spontaneous, relaxed breathing and an opportunity to briefly share what happened during the session.
215064862|NCT01243372|GENETIC|mutation analysis|
215064863|NCT01243372|OTHER|laboratory biomarker analysis|
215064864|NCT04027803|BIOLOGICAL|BCD-148|single intravenous infusion of BCD-148 (900 mg)
215064865|NCT04027803|BIOLOGICAL|Soliris|single intravenous infusion of Soliris (900 mg)
215064866|NCT05047029|PROCEDURE|Transjugular intrahepatic portosystemic shunt implantation|Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)
215064867|NCT05047029|DIAGNOSTIC_TEST|Magnetic resonance imaging|Multiparametric cardiac and hepatic magnetic resonance imaging
215064868|NCT05286658|BEHAVIORAL|MEG/EEG|"The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete."
215064869|NCT05286658|BEHAVIORAL|MRI|An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.
215064870|NCT05286658|BEHAVIORAL|Speaking Tasks|The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
215064871|NCT01612286|DRUG|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle \*4cycles
214347529|NCT01466998|OTHER|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
215064872|NCT00660413|DEVICE|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
215064873|NCT01714037|DRUG|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
214323028|NCT06034613|BEHAVIORAL|internet-based mindfulness intervention for emotional distress(iMIED）|The iMIED program integrates the rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from MBIs. In addition, the iMIED program selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks. In total, it took about 30 min per day to finish all the tasks. The program lasted for 49 days.
214323029|NCT01718756|DRUG|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
214922576|NCT03260244|PROCEDURE|cardiac mapping and radiofrequency ablation procedure|"It is a minimally invasive procedure which can be performed using either general or conscious sedation. During catheter ablation, catheters (narrow, flexible tubes) are inserted into a blood vessel, often through a site in the groin (upper thigh) or neck, and guided through the vein until they reach the heart. Small electrodes on the tip of the catheters stimulate and record the heart's activity. This test, called an electrophysiology study (EPS), allows the doctor to pinpoint the exact location of the short circuit. Another word for pinpointing the exact location of the short circuit is 'mapping', for which precision is a key requirement to maximize a successful outcome.~Once the location is confirmed, the short circuit is either destroyed (to reopen the electrical pathway) or blocked (to prevent it from sending faulty signals to the rest of the heart)."
214922577|NCT05445232|DRUG|LY3437943|Administered SC.
214485677|NCT05247801|BEHAVIORAL|Psychoeducational intervention for safe medication use at home + Medication dosing device|"The intervention is yet to be defined. Psychoeducational intervention based on virtual reality, demonstrations, and psychoeducational content using virtual reality. Contents:~Most frequent medication errors at home. Approaches to risk management in the home. Correct use of the most common medications in different patient profiles. Strategies to avoid medication errors. Guidance to alleviate the burden of responsibility suffered by women as a result of the gender bias derived from assuming the caregiver role.~Other."
214485678|NCT05247801|DEVICE|Medication dosing device|Use of medication dosing device.
214922578|NCT05445232|DRUG|Midazolam|Administered orally.
214922579|NCT05445232|DRUG|Warfarin|Administered orally.
214922580|NCT05445232|DRUG|Caffeine|Administered orally.
214922581|NCT06525805|OTHER|Long Abstract|"The intervention and control group will be provided with a structured abstract of the review by Soderberg et al., entitled Percutaneous nephrolithotomy vs. retrograde intrarenal surgery for renal stones. This review was published once in the Cochrane Database of Systematic Reviews and once in the journal BJU International. The length of the abstract differs significantly depending on the journal.~The participants assigned to this study arm will be presented with the longer version published in the Cochrane Database, comprising 771 words (PMID: 37955353)."
215064874|NCT01714037|DRUG|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
214922582|NCT06525805|OTHER|Short Abstract|The participants assigned to this study arm will be presented with the shorter version published in BJU International, comprising 277 words (PMID: 37942649).
214922583|NCT03473366|DEVICE|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
214922584|NCT03473366|DEVICE|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
214922585|NCT00870636|DRUG|Bevacizumab (Avastin)|Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.
215064875|NCT01714037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
215064876|NCT01714037|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
215064877|NCT01714037|DRUG|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
215064878|NCT03949452|OTHER|Subcostal Transversus Abdominis Plane catheter|"Prior to surgery, an ultrasound guided unilateral Subcostal Transversus abdominis plane bolus dose (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) will be given on the same side of the surgical incision.~At the end of surgery, A Transversus abdominis plane catheter will be inserted unilaterally by surgeon during wound closure. Then postoperatively, Transversus abdominis plane infusion of a solution mixture prepared in multiple 50 cm syringes each syringe contain 20 ml bupivacaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivacaine is 0.2%). This solution mixture will be infused through Transversus abdominis plane catheter at a rate of 6 ml/hour for 72 hours postoperatively."
215064879|NCT03949452|OTHER|Epidural catheter|"Prior to surgery, we will site an epidural catheter in the thoracic T7-T9 region, and inject an epidural bolus dose same as described above (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) for intra operative analgesia.~Postoperatively, patients will receive epidural infusion of the solution mixture (same as described above) prepared in multiple 50 cm syringes each syringe contain 20 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivaccaine is 0.2%). This solution mixture will be infused epidurally at a rate of 6 ml/hour for 72 hours (3 days) postoperatively."
215064880|NCT00849355|DRUG|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
215064881|NCT03926923|OTHER|no intervention|There will be no intervention. The blood sample is taken while a routine blood sampling.
214323030|NCT01718756|DRUG|Continuous infusion|"The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery"
214323031|NCT01718756|DRUG|Scheduled|"The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia."
214323032|NCT01970683|DIETARY_SUPPLEMENT|VSL #3 BID|
214672516|NCT05791825|BEHAVIORAL|Cultivating Healthy Intentional Mindful Educators|The 8-week, manualized, CHIME intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Each CHIME session focuses on a specific mindfulness technique, such as mindful breathing, mindful listening and bringing attention to current states and surroundings to support optimal responsiveness, emotion regulation, and compassion. Social emotional learning is promoted by focusing on five broad competencies: self-awareness, social awareness, responsible decision-making, self-management, and relationship skills and these competencies are practiced and developed through small group discussions, storytelling, journal reflections, modeling, and guided awareness (e.g., meditations), and implementation activities (e.g., gratitude necklace).
214672517|NCT03191396|DRUG|Semaglutide|Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any
214672518|NCT03191396|DRUG|Liraglutide|Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
215064882|NCT06351345|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).
215064883|NCT05221840|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
215064884|NCT05221840|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
215064885|NCT05221840|DRUG|Monalizumab|Monalizumab IV (intravenous infusion)
215064886|NCT05221840|OTHER|Placebo|Placebo IV (intravenous infusion)
214347530|NCT04824404|BEHAVIORAL|CBT4CBT-Buprenorphine + Recovery Coach|This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professionalCBT4CBT-Buprenorphine is an 8-session (module) system for teaching a wide range of CBT skills (understanding and changing patterns of substance use; coping with craving; refusing offers of drugs and alcohol; problem-solving skills; identifying and changing thoughts about drugs and alcohol; and improving decision-making skills)
215064887|NCT05411822|DEVICE|Lighting Intervention Blue light|Custom made lighting fixture that will deliver the blue lighting intervention. Blue light (λmax = 451 nm) on axis and off axis.
215064888|NCT05411822|DEVICE|Lighting Intervention Green light|Custom made lighting fixture that will deliver the green lighting intervention. Green light (λmax = 522 nm) on and off axis
215064889|NCT05411822|OTHER|Dim-light control condition|(\< 5 lux at the eye) for 30 min
215064890|NCT03352141|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
215064891|NCT06269185|DRUG|Infliximab|Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
215064892|NCT06269185|DRUG|Adalimumab|Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
214347531|NCT06203509|BEHAVIORAL|Thrive Intervention|• The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals being managed for both chronic diseases and serious mental illness following hospitalization.
214922586|NCT01089764|BEHAVIORAL|Couplelinks.ca website|Participation in the Couplelinks.ca program, an online intervention.
214922587|NCT06259903|DRUG|MD-18|Subcutaneous Administration of MD-18 in Healthy Subjects.
214922588|NCT03526536|DRUG|IV Novolin R human insulin|Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
214922589|NCT03403296|GENETIC|nProfiler I Stomach Cancer Assay Kit|qPCR by nProfiler I Stomach Cancer Assay Kit
214922590|NCT01265979|PROCEDURE|Whole body diffusion MRI|These studies will be performed on a 3 Tesla (T) MR system. A major advantage of 3T compared to 1.5T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
214922591|NCT02729363|BEHAVIORAL|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention.
214922592|NCT02729363|BEHAVIORAL|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute computer-administered sickle cell disease experience discussion.
214922593|NCT02171338|OTHER|PCT-level|PCT-level is available to the treating doctor.
214922594|NCT02171338|BEHAVIORAL|Antibiotic treatment based on PCT-level|"PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.~The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above."
214922595|NCT02735525|DEVICE|Smartphone monitoring|Patients will be trained to use the smartphone and the wound surveillance app prior to discharge. Patients will use the app from home to take send digital images of their postoperative wounds and answer a short survey, all of which will be transmitted to a secure database maintained by the UW Department of Surgery and accessible only to UW-employed study personnel. These data will be evaluated by one of three vascular surgery service nurse practitioners (NPs) daily. Patients who have concerning findings either in their images or in their survey answers will be contacted for further evaluation.
214922596|NCT02364323|BEHAVIORAL|Personalized Risk Counselling|Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
215064893|NCT04715568|DRUG|Losartan|50 mg tablets taken orally
215064894|NCT04715568|DRUG|Placebo|Tablets taken orally
215064895|NCT04058561|DEVICE|MAGEC® Spinal Bracing And Distraction System|The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
215064896|NCT05726032|DRUG|Empagliflozin 10 MG|Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
215064897|NCT05726032|DRUG|Matching Placebo|Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
215064898|NCT06401694|OTHER|Home-delivered meals|Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines
215064899|NCT06401694|OTHER|Wellness check and socialization visit|At-home delivery with opportunity for driver observation and interaction
214922597|NCT02364323|OTHER|Normal usual care|General education on diabetes and diabetic complications
214922598|NCT03932175|BEHAVIORAL|Intervention group|Behaviorial intervention on non-invasive ventilation use and adherence alongside lifestyle changes recommendations supported by an mHealth tool (MyPathway app)
215064900|NCT06401694|BEHAVIORAL|Community Health Worker calls|Calls from a certified Community Health Worker (CHW) to assess needs, identify gaps in care and resources, and then support health and resource coordination
215064901|NCT06401694|OTHER|Supplemental grocery bag|Monthly delivery of a grocery bag containing a variety of nutritionally balanced foods and educational materials
215064902|NCT06212063|BEHAVIORAL|Cadet Health|Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
215064903|NCT05270941|PROCEDURE|COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT|In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.
215064904|NCT01732029|OTHER|Normobaric hypoxia chamber|
215064905|NCT05033184|BEHAVIORAL|Brief Action Planning Exercise|The Brief Action Planning exercise is a previously developed goal-setting exercise which has been designed to incorporate aspects of motivational interviewing such as compassion, acceptance, evocation, and partnership. It is a tool that allows participants to identify an aspect of their life they would like to improve upon and guides them through the process of making a specific, measurable, achievable, realistic, and timely (SMART) goal. It also assesses their confidence in achieving this goal so as to assist with making alternative plans if confidence is low.
214347532|NCT02813850|DEVICE|oxygen therapy|Oxygen therapy early in the night (2L/min) during 4hours per days
215064906|NCT05033184|BEHAVIORAL|Goal Setting Exercise|The Goal Setting exercise allows participants to identify an aspect of their life they would like to improve upon without incorporating aspects of motivational interviewing components or providing any guidance on how to set this goal.
215064907|NCT04728360|DRUG|BAT2206|45 mg/0.5 mL
214485679|NCT05227417|BEHAVIORAL|SMS|Weekly text messages that will be sent automatically by a web-based system to participants' cell-phones. Participants will be able to respond and messages will reach the system. The health providers will be in charge to respond (from the web system) to participants who reply asking for support or any other request.
214485680|NCT01243814|DEVICE|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
214485681|NCT01243814|DEVICE|placebo injection|joint injection with saline solution for placebo
214485682|NCT05252468|DEVICE|TaffiX™|Personal nasal powder spray.
215064908|NCT04728360|DRUG|Stelara (EU-sourced)|45 mg/0.5 mL
214323033|NCT04098458|BEHAVIORAL|NDURE|NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.
214323034|NCT05409027|DRUG|SPI-62|SPI-62 is supplied as 1 mg tablets for oral dosing.
214323035|NCT05409027|DRUG|Cortisone-d8|Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion
214323036|NCT02983006|BIOLOGICAL|DS-8273a|"* Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~* Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
214323037|NCT02983006|BIOLOGICAL|Nivolumab|5 mg/kg IV Q 3 weeks
214323038|NCT05851729|OTHER|Kegal exercises with postural correction|Kegal exercises with postural correction
214323039|NCT05851729|OTHER|Kegal exercises without postural correction|Kegal exercises without postural correction
214485683|NCT06775665|OTHER|No interventions were applied to the patients.|No interventions were applied to the patients.
215064909|NCT02798224|BEHAVIORAL|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
215064910|NCT02798224|BEHAVIORAL|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
215064911|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.
214323040|NCT01552239|RADIATION|IMRT/IGRT, Tumor resection, Brachytherapy|"All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection"
214323041|NCT02656641|BEHAVIORAL|Continuous Client Feedback|Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
214323042|NCT02656641|BEHAVIORAL|Continuous Self Feedback|Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
214323043|NCT04151602|BEHAVIORAL|Smoked illicit drug use|The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
214323044|NCT00951431|DRUG|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
214323045|NCT00951431|DRUG|Placebo|Placebo in the form of study drug
214323046|NCT01307566|DEVICE|Continuous Positive Airway Pressure CPAP|CPAP treatment
214323047|NCT02605668|BEHAVIORAL|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
214323048|NCT02605668|BEHAVIORAL|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
214672519|NCT01025245|DRUG|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ \& Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
215064912|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
215064913|NCT03456349|DRUG|HTL0018318|HTL0018318
215064914|NCT03456349|DRUG|Placebo|Placebo
214323049|NCT05912699|OTHER|Slimbiotics Postbiotic|"SlimBiotics postbiotic formula contains the following ingredients:~* Heat-inactivated L. fermentum K8 Postbiotic.~* Microcrystalline cellulose."
215064915|NCT02192892|DIETARY_SUPPLEMENT|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
215064916|NCT02192892|DIETARY_SUPPLEMENT|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
215064917|NCT02192892|DIETARY_SUPPLEMENT|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
215064918|NCT02192892|DIETARY_SUPPLEMENT|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
215064919|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
215064920|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
215064921|NCT02192892|DIETARY_SUPPLEMENT|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
214323050|NCT05912699|OTHER|Placebo|The placebo capsules contain microcrystalline cellulose only.
214323051|NCT05775978|BEHAVIORAL|Más Presente, the UGRComp program|Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life.
215064922|NCT02192892|DIETARY_SUPPLEMENT|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
215064923|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge flour|Porridge from commercial porridge flour
215064924|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge bar|Porridge from commercial porridge bar
215064925|NCT02192892|DIETARY_SUPPLEMENT|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
215064926|NCT04004221|DRUG|Tislelizumab|200mg intravenously (IV) every 3 weeks (Q3W)
215064927|NCT01754246|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
215064928|NCT03520686|DRUG|N-803 + Pembrolizumab|"The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~* Pembrolizumab (200 mg intravenous infusion \[IV\])~* N-803 (15 μg/kg subcutaneously \[SC\])"
215064929|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|"The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV)~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)~Day 8:~* Nab-paclitaxel (100mg/m² IV)~Day 15:~* Nab-paclitaxel (100mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
215064930|NCT03520686|DRUG|N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~* N-803 (15 μg/kg SC)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
215064931|NCT03520686|DRUG|Pembrolizumab|"Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)"
215064932|NCT03520686|DRUG|Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|"The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)~* Pembrolizumab (200mg IV)~Day 8:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Day 15:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
214922599|NCT05212662|DRUG|TTI-0102|"The study treatment is a precursor to cysteamine, TTI-0102 (cysteamine-pantetheine disulfide). Each molecule of TTI-0102, after reduction and metabolism in the digestive tract, allows the absorption of 2 molecules of cysteamine and one molecule of pantothenic acid (Vit B5). Each dose of TTI-0102 comes in a vial as a powder to dissolve in water and absorb orally. Each vial contains 5.5g of TTI-0102, corresponding to the equivalent of 2.4g of cysteamine base. This single dose is less than the maximum daily dose authorized with other formulations of cysteamine (Cystagon or Procysbi, 1.95 g/m2/day) for patients over 1.25 m2 or 40 kg (88 lbs).~This dose of 5.5 g is justified by the need to maintain a thiol/disulfide ratio in favor of cysteamine over 24 h. It has been tested in healthy volunteers and has no side effects due to the specific pharmacokinetics of cysteamine after administration of TTI-0102."
214922600|NCT05212662|DRUG|Placebo|Placebo comparator supplied in vials identical to the active intervention, TTI-0102
214922601|NCT05200013|BIOLOGICAL|BAT7104|Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage
214922602|NCT04286581|DEVICE|I-Gel Laryngeal Mask Airway|The I-Gel Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
215064933|NCT03520686|DRUG|Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
215064934|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab|The treatment plan for the experimental arm of Cohort D will consist of repeated 6-week cycles for a maximum of 18 cycles (approximately 2 years). Nab-paclitaxel and Carboplatin will only be administered in cycle 1.
215064935|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-in technique|This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.
214922603|NCT04286581|DEVICE|Ambu Auragain Laryngeal Mask Airway|The Ambu Auragain Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
215064936|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-out technique|This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
215064937|NCT00862758|DRUG|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
215064938|NCT01648244|OTHER|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
215064939|NCT00000696|DRUG|Interferon alfa-2a|
215064940|NCT00000696|DRUG|Zidovudine|
215064941|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
215064942|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
215064943|NCT01153711|DRUG|Ketoconazole|400 mg tablet
214323052|NCT05775978|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
215064944|NCT01153711|DRUG|Ketoconazole|400 mg tablet
215064945|NCT03222362|OTHER|Surgery|
215064946|NCT00800527|DRUG|Gabapentin|Gabapentin 800 mg one a day up to 30 day
215064947|NCT00800527|DRUG|Diclofenac|Diclofenac 75 mg one a day up to 30 day
214323053|NCT05775978|BEHAVIORAL|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
214323054|NCT00984581|DRUG|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
214323055|NCT00984581|DRUG|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
215064948|NCT01814397|DRUG|Anastrozole|1 mg orally daily
215064949|NCT01814397|DRUG|exemestane|25 mg orally daily
215064950|NCT01814397|DRUG|letrozole|2.5 mg orally daily
215064951|NCT03305588|DEVICE|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
215064952|NCT01178944|OTHER|Laboratory Biomarker Analysis|Correlative studies
215064953|NCT01178944|DRUG|Oxaliplatin|Given IV
215064954|NCT01178944|DRUG|Pralatrexate|Given IV
215064955|NCT00640809|DRUG|Celecoxib|200 mg oral capsule twice daily for 2 weeks
215064956|NCT00640809|OTHER|Placebo|Matched placebo for 2 weeks
215064957|NCT00640809|DRUG|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
214323056|NCT00984581|DRUG|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
215064958|NCT03445377|DEVICE|Real-time continuous glucose monitoring|Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
215064959|NCT03445377|DEVICE|Self-monitoring of blood glucose|Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
215064960|NCT00799630|DIETARY_SUPPLEMENT|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
215064961|NCT06549166|OTHER|Experimental: VR and exercise|Participants will perform a 20-minute exercise program consisting of neck joint mobility exercises, neck and scapulothoracic muscle strengthening exercises, and stretching exercises. Then, for the next 20 minutes, they will engage in active neck movements using the Oculus Quest2 headset with the Ocean Rift game.
215064962|NCT06549166|OTHER|Sham Comparator: exercise|The control group will perform a 40-minute same neck exercises.
215064963|NCT00404378|DRUG|ketoconazole|Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
215064964|NCT00404378|DRUG|casopitant 100 mg|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
215064965|NCT00404378|DRUG|Casopitant 50 mg|Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
215064966|NCT00982046|DEVICE|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
215064967|NCT00982046|DEVICE|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
215064968|NCT00982046|DEVICE|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
215064969|NCT00982046|DEVICE|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
215064970|NCT00982046|DEVICE|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
215064971|NCT00982046|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
215064972|NCT05446038|BEHAVIORAL|Multi-Family Guided Self-Help FBT|Previous research has shown that Family-Based Treatment (FBT) is an effective treatment for Anorexia. We hope to learn whether an adaptation of Family-Based Treatment (FBT), called online Multi-Family Guided Self-Help FBT, is feasible and acceptable for families of young people with Anorexia. The 'Self-Help' aspect of the treatment consists of a series of educational videos for parents about how to help their child with Anorexia, which parents watch on an online platform. The 'Multifamily' and 'Guided' aspects of the treatment consists of weekly meetings by Zoom for a group of parents of young people with Anorexia, with a facilitator present to guide a group discussion around whether parents feel they understood the content of the videos and whether the content is helpful.
215064973|NCT05456997|PROCEDURE|Muscle biopsy|Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
215064974|NCT04087941|BIOLOGICAL|VM-202|VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
215064975|NCT01939977|DRUG|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
215064976|NCT01939977|DRUG|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
215064977|NCT01849692|DRUG|ESBA1008 solution|Intravitreal injection or infusion
215064978|NCT01849692|DRUG|Ranibizumab|Intravitreal injection
215064979|NCT00856596|DRUG|Sertaconazole nitrate cream 2%|Once a day topical cream
214922604|NCT03793673|BEHAVIORAL|CoYoT1 Care|Selected providers will be trained in the CoYoT1 Care protocol for completing medical appointments (both telehealth/standard appointments). There are three key components: (1) Shared decision making: Providers and YA will mutually agree on priorities for each medical visit using a shared decision making tool completed by both the provider and patient. (2) Autonomy supportive care: Providers will be trained in communication strategies, such as motivational interviewing, designed to support YA autonomy and intrinsic motivation. YA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach YA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate.
215064980|NCT05129280|DRUG|RO7444973|RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
214323057|NCT03762083|DEVICE|pHyph generation I|A vaginal tablet for the treatment of BV with administration every 48 hours.
214922605|NCT03793673|OTHER|Standard Care|"Providers selected for the Standard Care group will complete medical appointments in their usual manner, without specific training or guidelines regarding how to deliver care.~NOTE: Per COVID-19 hospital policies, current clinic appointments consist of telehealth appointments."
215064981|NCT05129280|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
215064982|NCT01253148|DEVICE|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
215064983|NCT05533307|DIAGNOSTIC_TEST|observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth|ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
214323058|NCT00002524|BIOLOGICAL|Bleomycin Sulfate|
214323059|NCT00002524|BIOLOGICAL|Filgrastim|
215064984|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff."
215064985|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
215064986|NCT03987802|DRUG|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
215064987|NCT06452641|OTHER|Jones technique|Strain counter strain technique also known as Jones technique will be performed with the patient lay supine on the treatment table, taking them to a position-of-comfort by extending, side-bending, and rotating the head away (ESARA) from the TP until the TP pain has reduced. Continues to monitor, maintaining the patient's position for 90 seconds. After 90 seconds has elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks. In essence, the TP should be relieved by placing the patient in a position of comfort, holding this position for 90 seconds, and slowly returning the patient to a neutral position.
215064988|NCT06452641|OTHER|Cross-friction massage|Group B will get cross friction massage for 15-20 mins. Participants will be treated 3 times per week for 6 weeks. Pre and Post-treatment readings will be taken in 1st session and 6th week respectively.
215064989|NCT04636840|DEVICE|Space From Body and Eating Concerns- Teen|Mobile application with coaching component
214323060|NCT00002524|DRUG|Cisplatin|
214922606|NCT03528369|DRUG|CGS-200-1|CGS-200-1 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 1% for this study.
214922607|NCT03528369|DRUG|CGS-200-5|CGS-200-5 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
214922608|NCT03528369|DRUG|CGS-200 Vehicle|CGS-200 Vehicle contains all of the ingredients in CGS-200-1 and CGS-200-5 except for capsaicin.
214922609|NCT06277882|BIOLOGICAL|HAVRIX|intramuscular injections
214922610|NCT01542723|DRUG|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
214323061|NCT00002524|DRUG|Cyclophosphamide|
214323062|NCT00002524|DRUG|Cytarabine|
214323063|NCT00002524|DRUG|Doxorubicin Hydrochloride (DOX)|
214323064|NCT00002524|DRUG|Etoposide|
214323065|NCT00002524|DRUG|Fluorouracil|
214323066|NCT00002524|DRUG|Ifosfamide|
214323067|NCT00002524|DRUG|Leucovorin calcium|
214323068|NCT00002524|DRUG|Methotrexate|
214323069|NCT00002524|DRUG|Methylprednisolone|
214323070|NCT00002524|DRUG|Pentamidine|
214323071|NCT00002524|DRUG|Prednisone|
214323072|NCT00002524|DRUG|Trimethoprim-Sulfamethoxazole|
214323073|NCT00002524|DRUG|Vincristine Sulfate|
214323074|NCT00002524|DRUG|Zidovudine (AZT)|
214323075|NCT00002524|RADIATION|Radiation Therapy|
214922611|NCT00160706|BIOLOGICAL|Certolizumab Pegol (CDP870)|"Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.~Up to 84 months of therapy in this study."
214323076|NCT04107571|PROCEDURE|A type of operation for coranary heart disease patients.|A type of operation for coranary heart disease patients.
214323077|NCT00116558|DEVICE|Early NIPPV|Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).
214323078|NCT00116558|DEVICE|Standard NIPPV|Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
214323079|NCT02027844|BEHAVIORAL|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
214323080|NCT02027844|BEHAVIORAL|parental presence|parental presence during inhalational induction of sevoflurane
214922612|NCT00004875|DRUG|enoxaparin|
214323081|NCT00378014|DRUG|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
214922613|NCT00004875|DRUG|heparin|
214922614|NCT03214380|DRUG|LY900014|Administered SC
214922615|NCT03214380|DRUG|Insulin Lispro|Administered SC
214922616|NCT03214380|DRUG|Insulin Glargine|Administered SC
214922617|NCT03214380|DRUG|Insulin Degludec|Administered SC
214922618|NCT03214380|DRUG|Metformin|Administered orally.
214922619|NCT03214380|DRUG|SGLT2 inhibitor|Administered orally.
214922620|NCT01872598|DRUG|Masitinib|
214922621|NCT01872598|DRUG|Placebo|
214922622|NCT01872598|DRUG|Standard of care|stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
214922623|NCT01159366|PROCEDURE|percutaneous coronary intervention|early timing
214922624|NCT06666374|BEHAVIORAL|OHL program|This program used OHL as its core structure and incorporated elements of experiential learning and self-efficacy to enhance patient engagement and understanding. The program comprised seven steps designed to guide patients through key aspects of oral health care, enabling them to progressively build their skills and confidence. These steps included personalized education on oral health, hands-on practice of proper oral hygiene techniques, self-assessment exercises, and strategies for overcoming barriers to good oral health.
214922625|NCT06666374|BEHAVIORAL|Traditional program|Program primarily focused on providing information without the OHL components, self-efficacy strategies, or the interactive elements of the intervention program.
214922626|NCT02402257|BEHAVIORAL|CVC Train the Trainer|Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
214922627|NCT04836026|DEVICE|HF20™|HF20™ will be used for CRRT
214922628|NCT00697086|DRUG|Dronedarone (SR33589)|
214922629|NCT00697086|DRUG|Placebo|
214922630|NCT03438604|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
214922631|NCT06666868|BEHAVIORAL|Sustained CARD|This group is using CARD for the 2nd year in a row in participating pharmacies as the vaccination delivery framework (It was used in the 2023-2024 fall/winter vaccination season and is now being sustained in the 2024-2025 fall/winter vaccination season).
214922632|NCT06666868|BEHAVIORAL|First-time CARD|CARD is being used for the 1st time in participating pharmacies as the vaccination delivery framework (2024-2025 fall/winter vaccination season).
214922633|NCT02053142|DRUG|Acyclovir|Single dose of acyclovir 200mg was given for pk study
214922634|NCT02053142|DRUG|Placebo|
214922635|NCT03555565|DRUG|Alogliptin and Metformin hydrochloride|Alogliptin and Metformin hydrochloride combination tablets
214922636|NCT03329170|BEHAVIORAL|educational intervention using motivational interviewing|A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is \<12 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
214922637|NCT04804748|OTHER|No intervention|no intervention
214922638|NCT00394836|DRUG|Ofatumumab|Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
214922639|NCT00394836|DRUG|Ofatumumab|followed by 7 weekly infusions of 1000mg ofatumumab
214922640|NCT02593526|DRUG|Bumetanide|Diuretic
214922641|NCT02593526|OTHER|Cool Dialysate|Cool dialysate (35°C)
214922642|NCT00977704|DEVICE|Restylane and Perlane|
214922643|NCT05906173|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
214922644|NCT06967883|DIAGNOSTIC_TEST|Ultrasonographic assessment of Cervical Multifidus and Longus Colli Muscle Thickness, Postural Balance and Limit of Stability using the balance platform,Cervical Flexion and Extension Strength|"Intervention Description~Participants in both groups will undergo ultrasonographic measurement of cervical multifidus and longus colli muscle thickness. Postural sway, Limits of Stability (LOS), and a 6-direction balance test (ABC-6) will be assessed using the HUR SmartBalance BTG4 platform under stable and unstable conditions with eyes open and closed. Functional balance will be evaluated with the Berg Balance Scale (BBS), Timed Up and Go (TUG) Test, and Single-Leg Stance Test. Isometric cervical flexion and extension strength will be measured bilaterally using a hand-held dynamometer. Ankylosing Spondylitis patients will additionally complete BASFI, BASMI, BASDAI, and ASQoL questionnaires."
214922645|NCT06968130|BEHAVIORAL|routine hemodialysis|Patients will receive routine hemodialysis without any additional intervention. The same scales will be administered at baseline and during two follow-ups one week apart.
214922646|NCT06968130|BEHAVIORAL|Breathing Exercise|Patients will perform deep breathing exercises guided by the researcher: 1 minute normal breathing, 3 minutes chest breathing, 3 minutes diaphragmatic breathing, 2 minutes pursed-lip breathing, and 1 minute normal breathing. Exercises will be conducted for 10 minutes before and after hemodialysis, repeated in two follow-up sessions one week apart, with post-session scale completion.
214922647|NCT06968130|DEVICE|Virtual Reality|After completing the initial scales, patients will watch a 20-minute nature simulation via virtual reality glasses before and after hemodialysis. This will be repeated in two follow-up sessions one week apart, followed by scale administration.
215064990|NCT01636336|OTHER|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
215064991|NCT01636336|OTHER|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
214485684|NCT02056236|DRUG|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
214922648|NCT06966869|DRUG|Transdermal fentanyl patch|The fentanyl patch will be applied as per standard ICU protocol for pain management. Blood levels will be monitored every 4 hours for 48 hours. Patients in this group require norepinephrine (\>5 drops/hour of 4 mg/50 mL) to maintain MAP ≥ 65 mmHg.
214922649|NCT06966869|DRUG|Transdermal fentanyl patch|The fentanyl patch will be applied as per standard ICU protocol for pain management. Blood levels will be monitored every 4 hours for 48 hours. Patients in this group maintain MAP ≥ 65 mmHg without norepinephrine infusion.
214922650|NCT01163851|BIOLOGICAL|4 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
214922651|NCT01163851|BIOLOGICAL|0.5 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
214922652|NCT06968169|BEHAVIORAL|Supportive learning|All interventions are manipulations to the stimuli that the child hears with the goal of discovering which manipulations support verbal learning.
214922653|NCT06968169|BEHAVIORAL|Cascades|The intervention is a manipulation of word instruction with the goal of discovering whether weaker word learning results in cascading effects on semantic category memory and sentence comprehension.
215064992|NCT03244709|DRUG|Tocilizumab|Intravenous Tocilizumab followed by subcutaneousTocilizumab
215064993|NCT00740753|DEVICE|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
215064994|NCT02952313|DEVICE|Nasal Implant|
215064995|NCT06517069|OTHER|TEAS|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction
215064996|NCT06517069|DRUG|Oxycodone|Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
215064997|NCT06040684|DIAGNOSTIC_TEST|Level of antibodies|The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
215064998|NCT05838950|OTHER|high-intensity interval training intervention|Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.
215064999|NCT05893225|DRUG|Metformin Hydrochloride 850 mg Oral Tablet|Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.
215065000|NCT05893225|DRUG|Placebo|Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.
215065001|NCT00295009|DEVICE|ProDisc|Total disc replacement with ProDisc
215065002|NCT00295009|PROCEDURE|Spinal Fusion|A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
215065003|NCT00767663|DRUG|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
215065004|NCT00767663|DRUG|placebo|placebo twice daily, minimal three days pretreatment
215065005|NCT02095873|DIETARY_SUPPLEMENT|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
215065006|NCT02095873|DIETARY_SUPPLEMENT|Placebo|Mannitol, 108 mg
215065007|NCT00945529|DRUG|inhaled nitric oxide (iNO)|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
215065008|NCT06146751|DRUG|Superparamagnetic Iron Oxide Nanoparticles|Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
214485685|NCT02056236|OTHER|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
214485686|NCT03479411|DRUG|Itraconazole Powder|Itraconazole administered as a dry powder for inhalation (PUR1900)
214485687|NCT03479411|DRUG|Itraconazole 200 mg|Sporanox® Oral Solution
214485688|NCT05521386|DRUG|Caffeine|Single pill in an acute dose of 5 mg per kg of body mass
215065009|NCT00418704|DRUG|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
215065010|NCT00418704|DRUG|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
215065011|NCT00792740|DRUG|ITF2357|ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
214485689|NCT05521386|DRUG|Placebo|Single pill in an acute dose of 5 mg per kg of body mass
214485690|NCT05002738|DRUG|Desogestrel and Ethinyl Estradiol Tablets|Combined oral contraceptive pill
214485691|NCT05494762|DRUG|BGB-B167|Intravenous administration
214485692|NCT05494762|DRUG|Tislelizumab|Intravenous administration
215065012|NCT00792740|OTHER|Placebo|Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
215065013|NCT05658250|DEVICE|CRE8 polymer-free Amphilimus-eluting stent, Cre8 evo stent|Percutaneous coronary intervention using a Cre8 stent, Cre8 evo stent for long lesions
215065014|NCT03935178|DIAGNOSTIC_TEST|Measuring Right Ventricular Size and Function|This study focuses on evaluating different approaches to evaluation of right ventricular size and function using the Upper Valley Right Ventricle Algorithm and novel imaging modalities
215065015|NCT03042429|DRUG|Cycles N8, N5 and N6|two chemotherapy cycles N8 followed by standard arm therapy
215065016|NCT03042429|DRUG|Cycles N5 and N6|Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin
215065017|NCT03349138|DEVICE|Conventional Therapy|
215065018|NCT03349138|DEVICE|Robotic Glove|
215065019|NCT03349138|DEVICE|Electrical Stimulation|
215065020|NCT04062864|DEVICE|Pupil size|Measures the diameter of pupil before and after painful stimuli
215065021|NCT03612063|DEVICE|Fitbit Iconic HR and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
215065022|NCT03612063|DEVICE|Fitbit Iconic HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
215065023|NCT03612063|DEVICE|Garmin Vivosmart HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
214323082|NCT00378014|DRUG|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
214323083|NCT00378014|DRUG|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
214323084|NCT02748577|OTHER|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
214323085|NCT02748577|OTHER|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
214323086|NCT01262313|BEHAVIORAL|Lifestyle Counseling|"Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes."
214323087|NCT04495114|OTHER|40g carbohydrate load (Apple juice)|A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
215065024|NCT03612063|DEVICE|Fitbit Iconic HR and Apple Watch III|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
214485693|NCT03443999|DEVICE|Supraflex Family Sirolimus-eluting Coronary Stent System|Patient implanted with at least one Supraflex Family sirolimus-eluting stent as a part of planned clinical care
215065025|NCT03612063|DEVICE|Apple Watch III and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
215065026|NCT03612063|DEVICE|Apple Watch III and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
215065027|NCT01546233|BEHAVIORAL|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
215065028|NCT01546233|BEHAVIORAL|standard education|standard education before and after chemotherapy
215065029|NCT04236050|DRUG|Rocuronium|Rocuronium administered in continuous infusion or multiple bolus doses
215065030|NCT01320852|OTHER|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
215065031|NCT02748499|OTHER|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
215065032|NCT02748499|OTHER|Control|Participants maintain their daily acitvities.
215065033|NCT02263196|OTHER|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
215065034|NCT02263196|OTHER|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
215065035|NCT02072252|BEHAVIORAL|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
214323088|NCT05888168|PROCEDURE|CABG|All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.
214323089|NCT00001839|DRUG|Antithymocyte globulin|
214323090|NCT00001839|DRUG|Cyclosporine|
214485694|NCT04227899|DEVICE|Esprit BTK Device|Participants will receive Esprit BTK Device
214485695|NCT04227899|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
215065036|NCT00712686|DRUG|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
215065037|NCT00712686|DRUG|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
215065038|NCT05007418|BIOLOGICAL|STI-1492|Anti-CD38 A2 KOKI DAR T cells
215065039|NCT06553105|DIAGNOSTIC_TEST|ct scan|use ct scan for diagnosis fistula
215065040|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
215065041|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
215065042|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
215065043|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
215065044|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
215065045|NCT00396786|DRUG|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
215065046|NCT02216916|DRUG|HM781-36B|
215065047|NCT05492227|DIAGNOSTIC_TEST|Left-overs|Totally nasal swab leftovers were stored from the biobank of Hospital Puerta del Hierro. The coded specimens were kept at -80°C and analyzed using the SARS-CoV-2 NAD Kit. Previously these specimens were analyzed using the gold-standard RT-PCR.
215065048|NCT02094209|DEVICE|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
215065049|NCT02553551|DRUG|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
215065050|NCT02553551|DRUG|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
215065051|NCT04818216|DRUG|Placebo|Placebo capsule containing inert ingredient
215065052|NCT04818216|DRUG|Nicotinamide riboside|250 mg Nicotinamide riboside capsules
215065053|NCT03101488|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
215065054|NCT00444483|BEHAVIORAL|Structured diabetes teaching and treatment program|
214672520|NCT02980835|DRUG|Normal Saline|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
214922654|NCT06967363|PROCEDURE|Nerve Block|"The nerve block intervention in this study involves the targeted administration of anesthetic agents and corticosteroids to specific nerves or nerve roots to alleviate pain associated with low back pain. This procedure is performed under imaging guidance (e.g., fluoroscopy or ultrasound) to ensure precise delivery of the medication to the affected nerve. It aims to temporarily block the transmission of pain signals from the affected area to the brain, providing relief and allowing for a better assessment of the underlying pain mechanism. The nerve block is distinguished from other interventions in this study by its localized approach, focusing on pain modulation through direct neural targeting, rather than systemic pain management methods. The procedure may be used either as a standalone treatment or in conjunction with other therapies (e.g., physical therapy, medications) based on the patient's individual needs and response to treatment."
214672521|NCT02980835|DRUG|Ropivacaine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
215065055|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
215065056|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
215065057|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
215065058|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
215065059|NCT01642498|DEVICE|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
214672522|NCT02980835|DRUG|Epinephrine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
214922655|NCT06967363|PROCEDURE|endoscopic spinal disecetomy|"The Endoscopic Lumbar Discectomy is a minimally invasive surgical procedure designed to treat symptomatic lumbar disc herniations by removing the protruding or damaged disc material that is pressing on the nerve roots. This intervention is distinguished by the use of endoscopic technology, which allows for a smaller incision, real-time visualization of the affected area via an endoscope, and the removal of herniated disc tissue with minimal disruption to surrounding structures. Unlike traditional open discectomy, which requires larger incisions and muscle dissection, endoscopic discectomy involves the use of a small tubular retractor and specialized instruments, leading to reduced blood loss, shorter recovery times, and less postoperative pain.~This procedure is typically performed under local anesthesia, and the patient is often able to go home the same day. It is specifically designed for patients with lumbar disc herniations who have not responded to conservative way."
215065060|NCT05083208|DRUG|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II: Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks (including the treatment received in Phase Ib).~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
215065061|NCT05083208|DRUG|Chidamide|"Phase Ib: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast until disease progression, death or unacceptable toxicity developments."
215065062|NCT06981143|BEHAVIORAL|Quantitative study|A validated questionnaire will be used to investigate the knowledge and perceptions of physical activity and exercise of specialists and residents in Pathological Oncology
215065063|NCT04212013|DRUG|Ibrutinib|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.
214323091|NCT01507285|DRUG|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
214323092|NCT01507285|DRUG|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
214323093|NCT03912727|DIETARY_SUPPLEMENT|Alpha-Lipoic acid plus renal replacement therapy|Alpha lipoic acid (ALA) is a vitamin-like antioxidant
214323094|NCT03912727|OTHER|renal replacement therapy|standard renal replacement therapy
214323095|NCT06448741|OTHER|Replantation of amputated penis|Replantation of the amputated penis done macroscopically, but testicular replantation was not done because of lack of microsurgical access
214922656|NCT06967363|DRUG|Medication|The treatment of lumbar pain typically involves a multimodal approach combining medications based on the specific type of pain and patient needs. NSAIDs, acetaminophen, and muscle relaxants are often first-line treatments for nociceptive pain, while opioids and anticonvulsants like pregabalin are used for more severe or neuropathic pain. The choice of medication is guided by the severity of the pain, its underlying causes, and the patient's response to treatment. Each class of medication has its strengths and limitations, and the decision to use them must take into account factors like patient safety, the risk of side effects, and long-term efficacy.
215065064|NCT04212013|DRUG|Rituximab|Will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 of cycle 1
215065065|NCT04212013|OTHER|Placebo|Placebo capsules will be similarly dosed at 4 capsules daily.
214323096|NCT01217918|DRUG|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
214323097|NCT01217918|DRUG|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
214323098|NCT01217918|DRUG|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
214323099|NCT06442501|OTHER|routine care|routine care
214323100|NCT04333680|DIAGNOSTIC_TEST|Focused Assessment of Sonography for Trauma Exam|Speed and image quality of ultrasound exams performed with either transducer specified in the arms.
214922657|NCT06967363|BEHAVIORAL|Psychotherapy|"Cognitive Behavioral Therapy (CBT): This structured, goal-oriented therapy focuses on identifying and changing negative thought patterns, cognitive distortions, and maladaptive behaviors associated with chronic pain. CBT equips patients with coping strategies to reframe thoughts, reduce pain-related anxiety, and enhance emotional regulation, thereby improving overall function and quality of life. CBT can include techniques such as cognitive restructuring, relaxation training, and behavioral activation.~Acceptance and Commitment Therapy (ACT): ACT encourages individuals to accept pain and distressing emotions rather than avoiding them. It emphasizes mindfulness, acceptance, and values-based living, helping patients focus on behaviors that align with their values, despite ongoing pain."
214323101|NCT02493634|PROCEDURE|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
214323102|NCT02493634|DEVICE|MRWire|
214323103|NCT01178892|DIETARY_SUPPLEMENT|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
214485696|NCT06562218|PROCEDURE|isokinetic strengthening exercise|"Participants' isokinetic strength measurements will be assessed using the Cybex II Humac Norm isokinetic dynamometer. A strengthening programme will be performed for a total of 12 sessions, 3 days a week for 4 weeks, at 20 degrees of flexion, 20 degrees of extension, 60-90 and 180 degrees/s speed.~At the beginning and end of the 12th session, isokinetic and isometric muscle performance tests will be performed on the healthy wrist, and isometric wrist flexor and extensor strength measurements will be performed in neutral position 1 week after removal of the cast on the fractured wrist."
214485697|NCT06562218|PROCEDURE|conventional exercise programm|The immobilised limb was given finger grip exercises.
214922658|NCT06966739|OTHER|MSOT of musculature|All measurements using multispectral optoacustic tomography (MSOT) are performed on the paraspinal muscles as well as the trapezius, rectus abdominus and the proximal and distal limb muscles in a right vs. left comparison (leg proximal: quadriceps and ischiocrural muscle, leg distal triceps surae muscle, tibialis anterior muscle; arm proximal: M. biceps, distal: forearm flexors).
214922659|NCT06968910|DEVICE|CANNEFF® SUP rectal suppositories|CANNEFF® SUP suppositories with cannabidiol (CBD = 100 mg) and hyaluronic acid (HA = 6.6 mg) as active ingredients
214922660|NCT06966895|DEVICE|a parent-child collaboration game app|This application is utilized throughout the entire behavioral process of a museum visit; it serves as an auxiliary tool to facilitate the parent-child groups\&#39; experience in the museum in a more targeted manner.
214922661|NCT06966895|OTHER|traditional text-based panels group|A traditional museum visitor\&#39;s manual, containing knowledge of similar content to that in the game.
214922662|NCT06968923|BEHAVIORAL|in person treatment|The group undergoes a 5-week treatment, twice a week, for a total of 10 rehabilitation sessions. Each session lasts approximately 60 minutes. The treatment follows standard in-person clinical practice.
214922663|NCT06968923|BEHAVIORAL|Telerehabilitation|The group undergoes a 5-week treatment, with 2 hours per week, for a total of 10 hours at home. Each session lasts approximately 20 minutes. The treatment consists of a sequence of exercises performed using the Euleria Home® device, a medical software that enables the delivery of personalized exercise therapy programs designed by a healthcare professional.
214922664|NCT06967155|DRUG|• Drug: Dabrafenib • Drug: Trametinib • Drug: Cetuximab • Drug: Рanitumumab • Drug: Oxaliplatin • Drug: Irinotecan • Drug: Leucovorin • Drug: 5-FU|"Irinotecan + Dabrafenib + Trametinib and Cetuximab or Panitumumab in the second line of therapy Dabrafenib 150 mg twice orally daily Trametinib 2 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks or Panitumumab 6 mg/kg (60-minute IV infusion) every two weeks Irinotecan 90 mg/m2 (90-minute IV infusion) weekly.~Second-line treatment is administered until disease progression or intolerable toxicity. It may be possible to switch to a regimen of dabrafenib, trametinib, cetuximab or panitumumab if irinotecan is intolerable."
214922665|NCT06968754|OTHER|Intervention Group|Pharmaceutical care will be provided by a clinical pharmacist in addition to conventional care. This includes assessment and resolution of drug therapy problems (DTPs) related to indication, effectiveness, safety, and compliance. Infection control interventions involve: patient education for early AV fistula use, topical antimicrobials at the catheter exit site (e.g., Mupirocin), antiseptic/antibiotic lock solutions to prevent bloodstream infections, and antimicrobial selection based on culture sensitivity. Patients will receive ongoing follow-up and support throughout the study period.
214922666|NCT06967506|DEVICE|Blowing exercise group|Maximum effort exhalation exercises using the AirOFitPRO will be performed three times daily. Each session will be conducted for a minimum duration of five minutes, with 30-second intervals between each effort.
214922667|NCT03364465|OTHER|change of ventilatory settings|change of tidal volume during one-lung ventilation
214922668|NCT04000425|COMBINATION_PRODUCT|AVENIO ctDNA surveillance kit|AVENIO circulating tumor DNA (ctDNA) Analysis Kits is a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit.
214922669|NCT03267082|OTHER|Laparoscopic management of perforated appendicitis|"1. Insertion of Ports~2. Exposure of the Appendix~3. peritoneal toilet and aspiration of pus after abdominal exposure~4. Isolation of Mesoappendicular Artery~5. Clipping and Dividing of the Artery~6. Application of 3 x Endoloops~7. Division of the Appendix~8. Retrieval of the Appendix in an Endobag"
214922670|NCT00140244|DRUG|r-metHuLeptin|
214922671|NCT00140244|DRUG|Placebo|
214922672|NCT03192306|DRUG|Merlin|glycolic acid/ethanol solution
214922673|NCT03192306|DRUG|Ethanol|Ethanol solution
214323104|NCT01178892|DIETARY_SUPPLEMENT|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
215065066|NCT03939962|DRUG|SHR1210 combined with FOLFOX|"1. SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~2. FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication."
214323105|NCT01178892|BEHAVIORAL|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
214323106|NCT01178892|BEHAVIORAL|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
214485698|NCT06102421|DEVICE|BTL-6000 FSWT|Low-energy focused extracorporeal shockwave therapy will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy can vary between 0.12-0.20 mJ/mm2 based on the pain toleration, frequency 5 Hz, total number of shocks 2x2000. The application of the first set of shocks will be semi-static at the location of the largest USG defined pathology in the patellar tendon and the second set of shocks will be performed dynamically to the proximal tendon. These parameters were selected in accordance to ISMST guidelines.
214485699|NCT05453084|BEHAVIORAL|Exercise Program|The intervention includes an individualized exercise program in terms of Frequency, Intensity, Time, Type, Volume and Progression (FITT-VP).
214485700|NCT06442579|OTHER|Walking on a treadmill|Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible.
214922674|NCT01975142|DRUG|Trastuzumab - Emtansine|
214922675|NCT04932655|DRUG|simufilam|Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.
214922676|NCT04866758|OTHER|Survey|All data gathered will be quantitative in nature. In addition to participant completed surveys, additional demographic, and diagnosis/treatment related information will be collected from the patient's electronic medical record via Health Data Compass. Subsequent data collected as part of the patient's standard psychosocial and cancer related care (i.e., health outcomes, future utilization of UCCC psychosocial services) will also be gathered. This subsequent data collection will not include further participation, but continued access to the patient's medical record. Protected health information collected for this project will include dates (e.g., birth dates, date of diagnosis, date since last treatment, death dates) and participant zip codes. No other identifiable data will be collected. A separate survey emailed to the participant at the end of the study will collect information regarding the participant's completion status of the survey.
214922677|NCT00447824|PROCEDURE|Introduction of better conditions during blood sampling|
214922678|NCT03409289|DEVICE|RUSH Exam|Within two hours of return of spontaneous circulation, the following elements of the RUSH exam will be performed: focused evaluation of the heart, inferior vena cava, abdomen and aorta with the addition of evaluation for DVT and ocular ultrasound.
215065067|NCT06661135|PROCEDURE|TLPD total laparoscopic pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the laparoscopy
215065068|NCT06661135|PROCEDURE|OPD open pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the open technique
215065069|NCT06659185|DIETARY_SUPPLEMENT|Exercise|The effects of placobo mouth rinsing on softball batting performance
215065070|NCT06659484|DIAGNOSTIC_TEST|Assessment|"Evaluation carried out during a day hospital at T0 (initial assessment) and T3 (after the exercise program at around 3 months) including:~1. Clinical assessment by a geriatrician~   * Medical history; systematic search for symptomatic elements (asthenia, anorexia, weight loss); research into antecedents (chronic pathologies, etc.), treatments, lifestyle, eating habits, sedentary lifestyle,~  * Complete clinical examination: particularly of the musculoskeletal system, morphological data (weight and height, calf circumference), analysis of risk of falls,~  * Current medical treatments~  * Autonomy for basic activities (ADL), instrumental activities of daily living (IADL), visual disorders, hearing impairment, etc.~  * Assessment of comorbidities (Charlson score)~  * Screening for sarcopenia (using the SARC-F questionnaire),~  * An inventory of falls and their traumatic consequences,~  * Assessment of frailty status using FRIED criteria,~2. Nutritional assessment :~   * nutritional status will also be asses"
215065071|NCT06659484|OTHER|Multicomponent exercise program|"After inclusion in the protocol, participants with mobility disability risk factors are assigned to specialized and experienced kinesiologists at the end of the medical consultation.~Patients will be invited to take part in group-based exercise sessions, in small groups of no more than 10 patients, under the supervision of a kinesiologist. There will be 20 sessions over 10 weeks, at a rate of 2 sessions per week, each lasting one hour. The Multicomponent exercise program included progressive resistance and balance training."
214922679|NCT01665157|DIETARY_SUPPLEMENT|Enimaclin®|"Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.~The duration of study is one day before colonoscopy."
214922680|NCT01665157|OTHER|Self-controlled diet|Self-controlled low residue diet.
214922681|NCT01665157|DRUG|2L PEG-ELS|Normal volume of PEG-ELS
214922682|NCT01665157|DRUG|low volume 1.5L PEG-ELS|Low volume PEG-ELS
214922683|NCT02425878|DRUG|Ulipristal Acetate|
214922684|NCT02425878|DRUG|Placebo|
214922685|NCT00347139|DRUG|GW642444 (25, 100 & 400 mcg/day)|25, 100 and 400mcg/dose
214922686|NCT00347139|DRUG|Salmeterol 50mcg|Salmeterol 50mcg
214922687|NCT01289639|DRUG|fenofibrate|micronized fenofibrate 200 mg 1 po qd
214922688|NCT01289639|DRUG|pioglitazone|pioglitazone 30 mg po qd
214922689|NCT01289639|DRUG|placebo|placebo 1 capsule po qd
214922690|NCT06099522|BEHAVIORAL|Internet-based cognitive behavioral therapy (iCBT)|The treatment is a newly developed iCBT 8 module program, with interventions targeting gambling-related loss of control, through 4 clinical processes: Gambling triggers, Gambling-related anticipation, the Gambling zone and Chasing behaviors. The treatment will be delivered with therapist support.
214922691|NCT02780713|DRUG|AZD9496 (Reference)|AZD9496 (Reference)
214922692|NCT02780713|DRUG|AZD9496 Variant A|AZD9496 Variant A.
214922693|NCT02780713|DRUG|AZD9496 Variant B|AZD9496 Variant B
214922694|NCT02780713|DRUG|AZD9496 Variant C|AZD9496 Variant C
214922695|NCT02780713|DRUG|AZD9496 Variant D|AZD9496 Variant D
214922696|NCT01910584|PROCEDURE|Novasure endometrial ablation|Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
214922697|NCT01267461|OTHER|Tissue sample from tumor|Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.
214922698|NCT00905593|DRUG|Nilotinib|
214922699|NCT05704348|PROCEDURE|Sleeve gastrectomy with gastropexy|Gastropexy in this project means suturing the gastric remnant to the gastrocolic ligament.
214922700|NCT05704348|PROCEDURE|Sleeve gastrectomy without gastropexy|Sleeve gastrectomy without suturing the gastric remnant to the gastrocolic ligament.
214922701|NCT04726072|BEHAVIORAL|Kundalini Yoga|Participants met once a week for two hours for 12 weeks total. The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises, and meditation. Participants were also asked to do at-home practice for half an hour daily.
214922702|NCT04726072|BEHAVIORAL|Psychoeducation|Participants met once a week for two hours for 10 weeks total. The psychoeducation group acted as our control group and consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily.
214922703|NCT04094987|DEVICE|inter-fascial pressure|The pressure between the fascia and the pressure line added to the catheter tip will be measured.
214922704|NCT01793961|OTHER|electroretinogram|
214922705|NCT01793961|OTHER|contrast sensitivity tests|
214922706|NCT06683261|BIOLOGICAL|Omalizumab|biological prescribed as add-on treatment as part of the standard of care
214922707|NCT06683261|BIOLOGICAL|Dupilumab|biological prescribed as add-on treatment as part of the standard of care
214922708|NCT06683261|BIOLOGICAL|Mepolizumab 100 mg|biological prescribed as add-on treatment as part of the standard of care
214922709|NCT02111577|BIOLOGICAL|DCVAC/PCa|DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
214922710|NCT02111577|BIOLOGICAL|Placebo|Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
214922711|NCT05783297|BEHAVIORAL|Treatment Text (TXTXT)|This study will test a tailored, personalized SMS text message reminder intervention to improve adherence to ART among non-adherent youth and young adults with HIV. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the 6-month intervention period. Participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.
214922712|NCT05783297|BEHAVIORAL|Standard of Care|Standard of care ART adherence support includes adherence counseling during visits scheduled at least twice annually and appointment reminders.
214922713|NCT04979780|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using US Optum De-Identified EHR data.
214922714|NCT04979780|DRUG|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)
214922715|NCT04979780|DRUG|Direct Oral Anticoagulants (DOAC)|Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).
214922716|NCT04136704|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
214922717|NCT02880280|DRUG|Human Menopausal Gonadotropin|Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
215065072|NCT06659484|OTHER|Follow-up at T3 + 6 months and T3 + 12 months|"Follow-up at T3 + 6 months :~\- After the T3 visit, patients will either be redirected to independent practice (booklet) or to relay structures. At T3 + 6 months (6 months after the 3-month visit), the kinesiologists will call each patient to assess their compliance with the program, any difficulties encountered, any falls (and their severity and consequences), fear of falling, their level of ADL/IADL autonomy, level of PA practice (RAPA), presence of frailty appreciation (FRIED), whether or not they have entered an institution.~Follow-up at T3 + 12 months :~At T3+12 months (12 months after the 3-month visit), patients will be seen again by the kinesiologists to make a final assessment of their physical and functional conditions, with measurements (Handgrip, SPPB, TUG, gait parameters, leg strength) and questionnaires (SarQol and FES-I).~Patients will only be seen again by the kinesilogists, as this is mainly a check-up and final advice visit, to continue the exercises performed since."
215065073|NCT03206918|DRUG|Zanubrutinib|Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
215065074|NCT06662318|DRUG|Fentanyl Citrate|Fentanyl was given as a bolus of 1 µg/kg injected followed by a fentanyl infusion of 0.4 µg/kg/h. Fentanyl infusion was continued as Postoperative analgesia for 24 hours in a dose of 0.3 µg/kg/h.
215065075|NCT06662318|DRUG|Dexmedetomidine|Dexmedetomidine was given as a loading dose of 0.6 µg/kg, which was diluted to a total volume of 10 cc of normal saline and injected before induction of anesthesia over 10 minutes. Then, a DXM infusion prepared to provide 0.2-0.7 µg/kg/h was started Intraoperative; Postoperative DXM infusion was provided in a dose of 0.15 µg/kg/h for 24-h.
215065076|NCT06662318|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride was provided as 2 mg/kg slowly IV before induction of anesthesia and as an IV infusion at a rate of 3 mg/kg/h. Postoprative lidocaine infusion at a dose of 1.5 mg/kg/h was administered for 24 Postoprative hours.
215065077|NCT06658561|PROCEDURE|cold snare polypectomy|Place the special cold snare in the normal mucosa 1-2mm away from the polyp edge. Tighten the snare at a constant speed and gently lift it up and then excision.
215065078|NCT06658561|PROCEDURE|hot snare polypectomy|According to evaluation of the polyps, directly place the snare on the edge of the polyp including a clear margin of normal tissue (1-2 mm) or after submucosal injection. Tighten the snare at a constant speed and gently lift it up.Use the electrocoagulation and electroscission mode, power on for several seconds until the polyp is cut off.
215065079|NCT03823287|DRUG|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
215065080|NCT03823287|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
215065081|NCT03823287|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
215065082|NCT05202262|DRUG|BFF MDI 320/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
215065083|NCT05202262|DRUG|BFF MDI 160/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
214922718|NCT02880280|DRUG|Human Chorionic Gonadotropin|Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
214922719|NCT06093165|RADIATION|Re-irradiation|20Gy on 10 fractions
214922720|NCT03832517|DRUG|Single intravenous doses of RC-01|Intravenous single escalating doses of RC-01
214922721|NCT03832517|DRUG|Single intravenous doses of placebo|Intravenous single doses of placebo to match RC-01
214922722|NCT03832517|DRUG|Multiple intravenous doses of RC-01|Multiple ascending doses of RC-01 given intravenously two or three times daily for 10 days
214922723|NCT03832517|DRUG|Multiple intravenous doses of placebo|Multiple doses of placebo to match RC-01 given intravenously two or three times daily for 10 days
214922724|NCT05838365|DEVICE|Zirconia implant|(Test group; within 7 days of implant placement) versus delayed (Control group; 8 weeks after implant placement)
215065084|NCT05202262|DRUG|BD MDI 320 μg|Budesonide MDI (BD MDI), 320 μg
215065085|NCT05202262|DRUG|Open-label Symbicort TBH 320/9 μg|Open-label Symbicort Turbuhaler 320/9 μg
215065086|NCT05909176|BEHAVIORAL|GYN Residency Training|The combined care model will be implemented and during months 5-14.
215065087|NCT05909176|BEHAVIORAL|Social Media Campaign|The social media campaign will be implemented along with the combined care model in months 15-18.
215065088|NCT06992713|DRUG|H1710 for Injection|Injection.
215065089|NCT04926636|BEHAVIORAL|Health and Wellness Coaching|An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
215065090|NCT05396846|BEHAVIORAL|Eating Plan 1|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
215065091|NCT05396846|BEHAVIORAL|Eating Plan 2|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
215065092|NCT05396846|BEHAVIORAL|Eating Plan 3|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
215065093|NCT07011173|DEVICE|Exotendon assistance|Assistive devices with distinct assistance dynamics
215065094|NCT07011173|DEVICE|End-effector assistance|Finger will be moved by the actuators connected to the fingertip
215065095|NCT02747459|BEHAVIORAL|Sensory Supported Swimming|A swimming and water safety program for children with autism spectrum disorders. Individualized instruction utilizing evidence-based teaching methods and sensory modifications.
214922725|NCT02042950|DRUG|Carfilzomib|Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m\^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
214922726|NCT02935179|DIETARY_SUPPLEMENT|White sweet potato diet|The diet were supplied 516 kcal daily
215065096|NCT07028528|DIETARY_SUPPLEMENT|Levagen+|Participants will take 1 capsule twice daily with water after food. Each capsule will contain: A175mg containing 150 mg of palmitoylethanolamide (PEA). Total daily dose of 350mg Levagen+ containing 300 mg PEA
214922727|NCT00305708|BIOLOGICAL|anti-thymocyte globulin|
214922728|NCT00305708|DRUG|busulfan|
214922729|NCT00305708|DRUG|fludarabine phosphate|
214922730|NCT00305708|PROCEDURE|allogeneic bone marrow transplantation|
215065097|NCT07028528|OTHER|Placebo|Participants will take 1 capsule twice daily with water after food. Each capsule will contain microcrystalline cellulose \[MCC\]
215065098|NCT07028957|PROCEDURE|Group A; Low volume local anesthetic in Ultrasound guided combined Supraclavicular and Interscalene block for Upper limb surgery|Group A; will receive ultrasound guided combined Supraclavicular Block (SCB) with 7-10 ml (3.5-5 ml bupivacaine 0.5% plus 3.5-5 ml lidocaine 2%) and Interscalene Block (ISB) with 7-10 ml (3.5-5 ml bupivacaine 0.5% plus 3.5-5 ml lidocaine 2%).
214922731|NCT00305708|PROCEDURE|peripheral blood stem cell transplantation|
215065099|NCT07028957|PROCEDURE|Group B; High volume local anesthetics (30-40ml) ultrasound guided combined Supraclavicular Block (SCB) and Interscalene Block (ISB)|Group B; High volume local anesthetics in ultrasound guided combined Supraclavicular Block (SCB) with 15-20 ml (7.5-10ml bupivacaine 0.5% plus 7.5-10 ml lidocaine 2%) and Interscalene Block (ISB) with 15-20 ml (7.5-10 ml bupivacaine 0.5% plus 7.5-10 ml lidocaine 2%).
215065100|NCT06880055|DIAGNOSTIC_TEST|Shield Blood Test for colo-rectal cancer Screening|Shield Blood Test for colo-rectal cancer Screening
214922732|NCT00305708|PROCEDURE|umbilical cord blood transplantation|
214922733|NCT00305708|RADIATION|radiation therapy|
214922734|NCT04523038|DIAGNOSTIC_TEST|S-Albumin|Preoperative serum albumin levels
214922735|NCT05982236|OTHER|Questionnaire|Questionnaire on WEPI software (secure data), with link sent by e-mail to patients included in the study, including PCOSQOL, HADS, FACT G7 et ASEX scores.
215065101|NCT07033507|DIAGNOSTIC_TEST|MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions|Compare MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions
215065102|NCT07033000|DIETARY_SUPPLEMENT|Placebo|Placebo
215065103|NCT07033000|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing blend of Digestive Enzymes, Dandelion, Ginger \& Fennel Extracts
215065104|NCT07034300|DRUG|Lidocaine (drug)|40 ml of 0.5% lidocaine
215065105|NCT07034300|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 μg/kg)
215065106|NCT07033442|DRUG|Sevoflurane (Volatile Anesthetic)|Inhalational anesthetic used for maintenance of anesthesia. Administered at 2-3% concentration in a 40% oxygen-air mixture to maintain BIS values between 40-60.
215065107|NCT07033442|DRUG|Propofol 1%|Intravenous hypnotic agent used for induction (2-3 mg/kg) and maintenance (50-150 μg/kg/min) of anesthesia. Titrated to maintain BIS values between 40-60.
214672523|NCT02980835|DRUG|Dexamethasone|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
214485701|NCT04554121|BEHAVIORAL|Brain Basics|"Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday.~life."
214485702|NCT04554121|BEHAVIORAL|Brain Training|Computer-based exercises targeting impairments in cognitive domains (processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday life.
214485703|NCT04688333|OTHER|Internet-Based Intervention - Complete iConquerFear program|Online adaptation of a highly effective face-to-face treatment for fear of recurrence.
214485704|NCT04688333|OTHER|Quality-of-Life Assessment|Ancillary studies
214485705|NCT04688333|OTHER|Questionnaire Administration|Complete questionnaires
214485706|NCT04242589|RADIATION|Radiotherapy|External beam radiation therapy is a type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays from outside the body into tumor
214672524|NCT01605305|DRUG|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
214672525|NCT02175667|PROCEDURE|Global Postural Reeducation|Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
214672526|NCT01638689|DRUG|Escitalopram|20 mg p.o.
214922736|NCT04914884|DIAGNOSTIC_TEST|intraocular fluid detection|This study mainly verified the use of molecular biology technology to detect the changes of VCAM, ICAM-1 and other cytokines, bacteria, viruses, fungi, Toxoplasma gondii IgG in patients' intraocular fluid, including aqueous humor and vitreous humor, so as to timely judge the etiology and progress of endophthalmitis, and provide reference for diagnosis and treatment.
214922737|NCT03169075|BEHAVIORAL|Supervised physical exercise programs|"A weekly supervised physical activity session of 60 min at the patient's home is planned for 3 months.~These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalized and adapted to each patient's profile.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE"
214922738|NCT03169075|BEHAVIORAL|Adapted physical activity|"Program based on the recommendations for performing a physical activity. A booklet containing physical activity recommendations will be given to the patients after randomization.~The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ"
214922739|NCT06676475|DRUG|MgSO4|2ml MgSo4 (Magnesium sulfate sterile ampoule 10 ml, 100 mg/ml = 0.41 mMol/ml. Egyptian Int. Pharmaceutical Industries Co., Egypt).
214672527|NCT05892185|DEVICE|GELA|GELA glaucoma implant
214922740|NCT06676475|DRUG|BOTOX-A|2ml of BTX
214922741|NCT06676475|DRUG|Saline (NaCl 0,9 %) (placebo)|2 ml of saline
215065108|NCT07033442|DRUG|Remifentanil 2 MG|Short-acting opioid used for induction and maintenance of anesthesia at a dose of 1 μg/kg IV (induction) and 0.05-0.25 μg/kg/min (maintenance).
215065109|NCT07033442|DRUG|Rocuronium 50 mg/5 ml|Neuromuscular blocker administered IV at 0.6-1.2 mg/kg for induction and 0.15 mg/kg for maintenance of muscle relaxation during surgery.
215065110|NCT07033442|DRUG|Lidocaine %2 ampoule|Administered intravenously at 1-1.5 mg/kg before anesthesia induction to reduce injection pain and facilitate induction.
215065111|NCT07033442|DRUG|Thiopental 500 mg vial for injection|Intravenous anesthetic agent used for induction of anesthesia at 4-6 mg/kg.
215065112|NCT07033442|DRUG|Neostigmine 0,5 mg/ml ampoule|Administered IV at 0.04 mg/kg for reversal of neuromuscular blockade at the end of the procedure.
215065113|NCT07033442|DRUG|Atropine Sulphate 0.5mg/ml ampoule|Administered intravenously (0.4 mg per 1 mg neostigmine) to counteract muscarinic effects during neuromuscular blockade reversal; also 0.5 mg IV in cases of intraoperative bradycardia (HR \< 45 bpm).
215065114|NCT07033442|DRUG|Ephedrine Hydrochloride 0,05 mg/ml ampoule|Used intravenously at 0.1 mg/kg to manage intraoperative hypotension unresponsive to fluid and anesthetic dose adjustment.
215065115|NCT07033442|PROCEDURE|CO₂ Pneumoperitoneum|Creation of pneumoperitoneum with CO₂ insufflation for robotic prostatectomy; monitoring and recording of intra-abdominal pressures.
215065116|NCT07033442|DEVICE|Bispectral index (BIS) Monitoring|Monitoring of depth of anesthesia using bispectral index values; frontal placement preoperatively and throughout surgery. BIS maintained between 40-60.
215065117|NCT07033442|PROCEDURE|intraocular pressure measurement|Measurement of intraocular pressure (IOP) in both eyes at multiple intraoperative and postoperative time points (T0-T9).
214323107|NCT01178892|BEHAVIORAL|Usual Activity|"Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership."
215065118|NCT07033442|PROCEDURE|intraarterial cannulation and pressure measurement|Invasive arterial blood pressure measurement and blood gas measurements via an 18G catheter inserted into the radial artery
215065119|NCT07033442|PROCEDURE|Mechanical Ventilation|Ventilation initiated after intubation with volume-controlled settings (TV 6-8 ml/kg, RR 12, FiO₂ 50%), adjusted to maintain ETCO₂ between 30-36 mmHg.
215065120|NCT07033442|PROCEDURE|Peripheral Intravenous Cannulation|All participants received peripheral intravenous cannulation using 18-20 G IV cannulas placed on the dorsum of the hand before anesthesia induction.
214485707|NCT04242589|PROCEDURE|Vertebropladty|Vertebroplasty is a procedure for stabilizing compression fractures in the spine. Bone cement is injected into vertebrae that have cracked or broken. The cement hardens, stabilizing the fractures and supporting your spine.
214922742|NCT04427475|DRUG|pabolizumab|100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.
214922743|NCT04427475|DRUG|nafulizumab|nafulizumab
214922744|NCT06666556|COMBINATION_PRODUCT|Bowel preparation before colonoscopy|In this multicenter single-blind randomized clinical trial study we will provide each patient that meets our inclusion criteria a randomized folio to include them in one of both arms in our protocol, meaning one of the groups and the bowel preparation assigned to perform the colonoscopy, they will be explained the benefits and minimum risks of participating and they will also be asked to sign an informed consent form so we can continue with the colonoscopy and collect all the data we need for our protocol and the analysis of the variables.
214922745|NCT06666556|COMBINATION_PRODUCT|Bowel preparation before colonoscopy|In this multicenter single-blind randomized clinical trial study we will provide each patient that meets our inclusion criteria a randomized folio to include them in one of both arms in our protocol, meaning one of the groups and the bowel preparation assigned to perform the colonoscopy, they will be explained the benefits and minimum risks of participating and they will also be asked to sign an informed consent form so we can continue with the colonoscopy and collect all the data we need for our protocol and the analysis of the variables.
214922746|NCT02429778|BEHAVIORAL|Diaphragmatic Breathing|Deep or diaphragmatic breathing is taught prior to relaxation.
214922747|NCT02429778|BEHAVIORAL|Progressive Muscle Relaxation|Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
215065121|NCT07033442|DRUG|Crystalloid solutions|Participants received calculated maintenance fluids with crystalloids through intravenous infusion prior to and during surgery.
215065122|NCT07033442|PROCEDURE|Endotracheal Intubation|After induction of anesthesia and neuromuscular blockade, endotracheal intubation was performed using standard technique in all participants.
215065123|NCT07033442|PROCEDURE|American Society of Anesthesiologists (ASA) Standard Monitors|Routine ASA monitoring, including noninvasive blood pressure, ECG (D2 derivation), End-tidal carbon dioxide (ETCO₂) and Peripheral Oxygen Saturation (SpO₂), was performed in all patients, starting from the preoperative period and continuing throughout the surgery.
214672528|NCT05892185|DEVICE|XEN|XEN gel stent implant
215065124|NCT07033442|PROCEDURE|Ventilatory Pressure and Compliance Monitoring|Throughout the procedure, the following lung mechanics were continuously measured: PEEP, peak airway pressure (PEAK), mean airway pressure (Pmean), plateau pressure (Pplato), and dynamic compliance.
215065125|NCT05506982|DRUG|Psilocybin|Given PO
215065126|NCT05506982|BEHAVIORAL|Psychotherapy|supportive care
215065127|NCT05506982|OTHER|Quality-of-Life Assessment|Ancillary studies
215065128|NCT05506982|OTHER|Questionnaire Administration|Ancillary studies
215065129|NCT07033923|DIAGNOSTIC_TEST|Brain magnetic resonance imaging (MRI) with structural (anatomical) and functional sequences (optional)|Brain MRI with structural (anatomical) and functional sequences (without contrast injection) will be collected. The cognitive tests will be carried out during the recording of the functional MRI (optional) in order to highlight the neural correlates of mood variations.
215065130|NCT07033923|BEHAVIORAL|Computerized cognitive tests|"Cognitive tests can be administered during the recording of a functional MRI, in order to highlight the neural correlates of mood variations.~Cognitive data from a computerized experimental psychology experiment: this test involves different tests on a computer or tablet, including a test evaluating the minimal variations in the subject's mood and motivational state during the task, as well as its decision-making abilities."
215065131|NCT07033923|DEVICE|Daily longitudinal monitoring by mobile MOODELING application|Daily longitudinal monitoring by mobile MOODELING application (mood, energy, events) with self-monitoring tools (calendar, mood curve) at home. Follow-up duration on the application: 12 months
214323108|NCT02662387|DEVICE|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
214323109|NCT02662387|OTHER|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
214323110|NCT04924777|OTHER|Brisk Walk|1-Brisk walk for 30 minutes 2-5 days a week 3-3months
214323111|NCT04924777|OTHER|Strength training|1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
214922748|NCT02216656|DRUG|Placebo|Oral administration
214323112|NCT04924777|OTHER|Aerobic Exercises|1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
214922749|NCT02216656|DRUG|KHK7580 low dose|Oral administration
214922750|NCT02216656|DRUG|KHK7580 middle dose|Oral administration
214323113|NCT05651464|DRUG|Vancomycine|Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
215065132|NCT07033546|BEHAVIORAL|Toy bracelets|The intervention involves the use of colorful, child-friendly toy bracelets worn by children during procedures requiring physical restraint in the pediatric intensive care unit. These bracelets are designed to offer a sense of familiarity, distraction, and emotional comfort during potentially distressing experiences. Unlike standard care, which involves restraint without any therapeutic distraction tools, the toy bracelets serve as a non-pharmacological, low-cost, and easily applicable intervention aimed at reducing emotional distress. The intervention is distinguished by its simplicity, immediate usability, and focus on integrating play-based elements into clinical care to address the psychological needs of hospitalized children.
214922751|NCT02216656|DRUG|KHK7580 high dose|Oral administration
215065133|NCT07033390|OTHER|survey|validity and reliability study of MOS
214323114|NCT04995016|DRUG|Pembrolizumab|PD-1 inhibitor，Pembrolizumab 200mg IV, every 3 weeks.
214323115|NCT04995016|DRUG|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
214323116|NCT01561066|PROCEDURE|Autologous platelet-rich fibrin glue (PRFG)|"1. Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.~2. PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings."
214323117|NCT01561066|DRUG|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
214323118|NCT01171716|OTHER|Meal Patterning|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
214922752|NCT02216656|DRUG|KRN1493|Oral administration
214922753|NCT04792801|RADIATION|PET TDM FDG-Choline|Performing an FDG TDM PET and a Choline TDM PET at two different times
214922754|NCT05906563|DRUG|Melatonin gel|local application of Melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
215065134|NCT07032779|OTHER|simulation|the students in the intervention group will have the Tag Team Patient Safety Simulation application. The students in the simulation group will be divided into 2 groups and each group will have the Tag Team Patient Safety Simulation application with the same scenario. The students in the labeling group will be included in the scenario as the scenario progresses. It will start with 4 students at the beginning, but with labeling, 7-8 students in each group will take the role of the actors, and the other students will take the role of the audience.
215065135|NCT06879041|DRUG|AZD2287|AZD2287 is administered through intravenous injection.
215065136|NCT06879041|DRUG|AZD2275|AZD2275 is administered through intravenous infusion.
214922755|NCT05906563|DRUG|Metformin and melatonin gel|local application of Metformin and melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
214922756|NCT05906563|DRUG|placebo gel|Local application of empty nanoparticles gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack.
214922757|NCT05906563|PROCEDURE|scaling and root planning|full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.
214323119|NCT04889625|DEVICE|senofilcon A C3|Test Lens
215065137|NCT06879041|DRUG|AZD2284|AZD2284 is administered through intravenous injection.
215065138|NCT07034833|BEHAVIORAL|Ventriloquist Puppet Interaction|children allocated to the Ventriloquist Puppet group were introduced to a Ventriloquist Puppet inside the clinic and were allowed to play, talk, and interact with the puppet for 5-10 minutes.
215065139|NCT06718998|DRUG|NNC0519-0130|Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.
215065140|NCT06086392|DRUG|Placebo|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the supraclavicular brachial plexus block
215065141|NCT06086392|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the supraclavicular brachial plexus block
215065142|NCT06086392|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0,2% ropivacaine with 0.05mg/kg Dexamethasone for the supraclavicular brachial plexus block
214922758|NCT00714012|OTHER|observational|presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
214922759|NCT06125938|PROCEDURE|tent pole technique|The screw tent-pole method is an effective technique to achieve initial reconstruction of alveolar bone deficiencies
214922760|NCT06125938|PROCEDURE|Autogenous bone block technique|Bone block graft has been the gold standard for restoring deficient regions.
214922761|NCT06667518|DEVICE|Neuromuscular Activity Assessment|"K-Pull dynamometer is an assessment tool used to quantify muscle strength. It uses traction through a non-elastic strap to facilitate isometric contractions.~K-Myo (non-invasive EMG sensor) is an assessment tool used to detect muscle activation and tracking patient's improvement."
214922762|NCT00784303|DRUG|Lenvatinib (DTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily, or 10 mg lenvatinib orally twice daily (20 mg total). Out of 58 participants in the DTC cohort, 56 participants received 24 mg lenvatinib once daily and 2 participants received 10 mg lenvatinib twice daily (total 20 mg daily), given continuously in 28-day treatment cycles.
214922763|NCT00784303|DRUG|Lenvatinib (MTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily given continuously in 28-day treatment cycles.
214922764|NCT06668519|OTHER|Magnetoencephalography|Magnetoencephalography
214922765|NCT00819559|RADIATION|PCRT|Preoperative chemoradiotherapy
214922766|NCT05256459|OTHER|Long term follow-up|No extra intervention.
214922767|NCT01468259|DRUG|Droxidopa|The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
214922768|NCT01202942|OTHER|Quest|Participants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.
214922769|NCT04501640|DRUG|mirabegron|Oral adminstration
214922770|NCT03749967|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
214922771|NCT04053712|DRUG|Glucagon|GlucaGen(R), Novo Nordisk, DK
214922772|NCT04053712|DEVICE|Closed-loop system|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
215065143|NCT05767047|DRUG|Apremilast|Oral tablets or liquid suspension
215065144|NCT07053046|OTHER|Standard engagement approach|"Large group meetings led by PRECIDENTD PIs; composed of \~20 sites (with \~25 site investigators and \~40 study staff). PRECIDENTD PIs will share updates and facilitate discussion around any problems.~Problem identification and steps toward solution occur sequentially. A problem is identified in the data (e.g., slow recruitment), then brought to the Stakeholder Advisory Council (SAC) for advisement, then back to site investigators and study staff to implement recommended changes, the PIs look at data to see if changes improved the problem. PIs and the Stakeholder Engagement Core broker information and relationships with SAC partners."
215065145|NCT07053046|OTHER|Agile methods engagement approach|"Small group meetings led by a coordinator trained in agile methods; composed of \~4 sites each (representing 4-6 investigators and 6-10 study staff), plus 2-3 Stakeholder Advisory Council (SAC) patient partners. Meetings will focus on problem-solving around specific topics and apply agile tools and principles.~Sites in each small group will review process data together and each site will identify a specific topic (recruitment, retention, medication adherence) to focus on improving over the next month. Research partners at sites and patient partners will contribute to discussion and reflection on barriers, challenges, successes, and facilitators. Steps toward solutions occur on a rapid timeframe, iteratively using data as a guidepost."
215065146|NCT07058922|DIAGNOSTIC_TEST|evaluation of systemic microvascular reactivity|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging.
215065147|NCT07058922|DIAGNOSTIC_TEST|ABPM|Ambulatory blood pressure measuring: systolic, diastolic and mean arterial pressures
215065148|NCT07058922|DIETARY_SUPPLEMENT|beetroot supplement|A powdered beetroot extract supplement containing 400 mg of nitrate per dose will be used in the supplement group, administered orally at a daily amount of 10 g.
215065149|NCT06774131|DRUG|UGN-104|UGN-104 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-104 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the UUT.
215065150|NCT07066397|BIOLOGICAL|ARM011|ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process
215065151|NCT07066397|DRUG|Fludarabine|Administered prior to infusion of ARM011
215065152|NCT07066397|DRUG|Cyclophosphamide|Administered prior to infusion of ARM011
215065153|NCT06875388|OTHER|Task specific Training|Group A will receive a basic protocol of 40 minutes involving 10 minutes of warm up 10 10 mins of task-specific training 10 mins of leg strength exercises and 10 mins of cool-down exercises.
214323120|NCT04889625|DEVICE|Dailies Total 1® Multifocal Contact Lenses|Control Lens
214323121|NCT03663595|OTHER|Model 1|Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
214323122|NCT03663595|OTHER|Model 2|Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
215065154|NCT06875388|OTHER|Specific Yoga Poses|For group B, a series of yoga poses will be applied. Each training session consists of a 10-minute warm-up, 20 minutes of yoga exercises, and a 10-minute cool-down.
215065155|NCT06875388|OTHER|Tasl specific Training with perturbation|GGroup C will be 40 minutes involving 10 minutes of warm-up 10 minutes of task-specific training involving perturbation 10 mins of leg strength exercises involving perturbation and 10 mins of cool-down exercises.
215065156|NCT06875388|OTHER|Specific yoga poses with perturbation|Group D training session consists of a 10-minute warm-up, 20 minutes of yoga exercises with perturbation, and a 10-minute cool-down
215065157|NCT07071116|OTHER|Communication skills training|See Detailed Description
215065158|NCT07071116|OTHER|Communication skills training-Facilitator|See Detailed Description
215065159|NCT04750486|DEVICE|Sequential compression devices|Two lower limb intermittent compression devices to be placed on the mid-calf of each leg.
215065160|NCT00964483|BEHAVIORAL|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
215065161|NCT00964483|BEHAVIORAL|Delayed Intervention|"The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure."
214323123|NCT04671810|BIOLOGICAL|Elizaria®|Elizaria® will be prescribed by the Physician according to the actual SMPC.
214323124|NCT03000582|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
214323125|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
215065162|NCT02453750|DRUG|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls \>10%, the previous step will be repeated.
215065163|NCT02453750|DRUG|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
215065164|NCT04531956|OTHER|Diagnostic decision aid s-decided|The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
215065165|NCT03641807|OTHER|Acupuncture|Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
215065166|NCT03641807|OTHER|Sham acupuncture|Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
215065167|NCT03320967|DIAGNOSTIC_TEST|Copeptin in plasma|Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
215065168|NCT01627626|DRUG|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute."
215065169|NCT01627626|DRUG|saline|0.9% saline solution
214323126|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
214323127|NCT03000582|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
214323128|NCT03746522|DRUG|Setmelanotide|SC injection of setmelanotide
214323129|NCT03746522|DRUG|Placebo|SC injection of placebo
214672529|NCT04833075|OTHER|blood sampling|A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
215065170|NCT01900522|DRUG|ITI-214 Dose A|ITI-214 Dose A Oral Solution
215065171|NCT01900522|DRUG|ITI-214 Dose B|ITI-214 Oral Solution Dose B
215065172|NCT01900522|DRUG|ITI-214 Dose C|ITI-214 Dose C Oral Solution
215065173|NCT01900522|DRUG|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
215065174|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
215065175|NCT01900522|DRUG|ITI-214 Dose E|ITI-214 Dose E Oral Solution
215065176|NCT01900522|DRUG|ITI-214 Dose F|ITI-214 Dose F Oral Solution
215065177|NCT01900522|DRUG|ITI-214 Dose G|ITI-214 Dose G Oral Solution
215065178|NCT01900522|DRUG|ITI-214 Dose H|ITI-214 Dose H Oral Solution
215065179|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
215065180|NCT00691457|DEVICE|Opti-Free contact lens solution|Solution
215065181|NCT00691457|DEVICE|ReNu Multiplus contact lens solution|Solution
215065182|NCT00691457|DEVICE|Clear Care contact lens solution|Solution
214485708|NCT06649435|PROCEDURE|PPG measurement|"PPG signal will be measured on CE certified medical devices. Two measurements will be performed - standing and in the recumbent position using reflectance and transmitance method on finger and in ear canal. The each measurement will be 120s long.~Detailed analysis of PPG signal and pathophysiological phenomena associated with HF - peripheral volume changes detectable in PPG signal - will help to understand better and clarify the pathophysiological mechanisms of peripheral volume changes in a failing heart."
214485709|NCT06474754|DIAGNOSTIC_TEST|High-sensitivity troponin, serum|A serum derived measure of myocardial injury. Threshold value of 14ng/L.
214922773|NCT05961072|DEVICE|Vibrotactile sensory feedback device|"The company Saphenus Medical Technology GmbH will provide all of the devices for this study. The non-invasive vibrotactile sensory feedback device consists of 4 vibration -motors, which are placed in a cuff or pant on the patient's residual limb (RL). Furthermore, the system consists of a foot sole with integrated sensors and transmitters. The patient will put the sole of their foot into the shoe of the amputated side.~There are 4 sensors matching the vibration motors - 3 under the forefoot and 1 on the heel - in the foot sole. Depending on whether the patient loads their forefoot or their heel while walking, the assigned vibration motor vibrates on the skin of their RL. The patient will learn which vibration motor is assigned to their forefoot and which to their heel. This gives the patient sensory feedback without having to check with their eyes which part of the prosthetic foot is currently touching the ground."
214323130|NCT04917055|DRUG|ropivacaine 0.25% with epinephrine and 6mg dexamethasone|Regional Nerve block behind the knee for posterior knee pain following total knee arthroplasty using ultrasound guidance, to be done distally between femoral chondyles
214323131|NCT04917055|DRUG|Saline|Injection of Saline behind knee using ultrasound guidance
214672530|NCT01675921|OTHER|Facebook group|Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
214323132|NCT05077254|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
214922774|NCT04765150|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
214922775|NCT04765150|OTHER|Electronic Health Record Review|Medical charts are reviewed
214922776|NCT05670795|DRUG|Recombinant Follicle Stimulating Hormone|clinical pregnancy rates
214922777|NCT05670795|DRUG|Recombinant Follicle Stimulating Hormone and Clomiphene Citrate|clinical pregnancy rates
214323133|NCT05077254|BIOLOGICAL|Moderna COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
214323134|NCT05077254|DRUG|SOC IS Regimen|Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.
214323135|NCT05077254|DRUG|SOC IS Reduction|Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
214323136|NCT05121519|OTHER|Consume coffee|Drink coffee regularly (recommend at least 1 cup of caffeinated coffee or one shot of espresso per day)
214323137|NCT05121519|OTHER|Avoid coffee|Abstain from coffee and other caffeinated products
214672531|NCT03714386|DEVICE|A synthetic high-flux dialyzer will be used for OL-HDF.|A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
214922778|NCT03870308|DIAGNOSTIC_TEST|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
215065183|NCT04952428|BEHAVIORAL|"Re-examination visit (today visit)"|"Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA\_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted."
214323138|NCT04644094|OTHER|Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration|"A. Electrocardiographic (ECG) leads will be place in the patient for electrocardiogram (ECG) recordings.~B. Echocardiography (ECHO) will be performed by an expert member of the Neonatal Echocardiography team C. Heart Rate Variability (HRV): ECG recordings D. Growth trajectory: body weight, length, head circumference, length/weight ratio at 1-, 2-weeks prior treatment, 1-, 2-, 3-, 4-,6-,8-weeks after treatment, at 36-week PMA."
214323139|NCT04413123|DRUG|Cabozantinib|Cabozantinib predetermined protocol dosage po daily
215065184|NCT01170273|DIETARY_SUPPLEMENT|vitamin D|cholecalciferol
215065185|NCT01170273|DIETARY_SUPPLEMENT|placebo|placebo tablet
214323140|NCT04413123|DRUG|Nivolumab|Nivolumab predetermined protocol dosage via IV every 3 weeks
215065186|NCT05820139|PROCEDURE|Control Group|Patients will be randomized to a 200mL (control group)
214323141|NCT04413123|DRUG|Ipilimumab|Ipilimumab predetermined protocol dosage via IV every 3 weeks
214323142|NCT03241706|DRUG|Low Fructose|IV fructose (1.3 mg/kg/min)
215065187|NCT05820139|PROCEDURE|Test Group|Patients will be randomized to a cut-off of 150mL (test group)
214922779|NCT06667050|DRUG|Chemotherapy plus sintilimab and bevacizumab|"Laparoscopic exploration should be performed to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum.~3 cycles of neoadjuvant therapy will be administered: capecitabine: 100 mg/m2, Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; sintilimab: 200 mg, iv drip, d1, bevacizumab biosimilar (IBI305) 10mg~/Kg, iv drip, d1, q3w. Radical D2 gastric cancer resection will be performed within 6-8 weeks after the last administration of chemotherapy plus sintilimab and bevacizumab biosimilar (IBI305).~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with CAPOX regimen for up to 3 cycles."
214922780|NCT05817747|OTHER|Dialogue support tool|The dialogue support tool will be used as a support for the participant and surgeon to decide on which treatment arm is optimal for the participant.
214922781|NCT03116555|DRUG|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
215065188|NCT01673854|DRUG|Ipilimumab|
215065189|NCT01673854|BIOLOGICAL|Vemurafenib|
215065190|NCT00334737|DRUG|Darbepoetin Alfa Injection|darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
215065191|NCT00334737|DRUG|erythropoietin alfa injection|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
215065192|NCT00334737|DRUG|sham injection|sham injection other names: not applicable
215065193|NCT00583752|BIOLOGICAL|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
215065194|NCT05107063|DRUG|Pravastatin|Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
215065195|NCT00285155|DRUG|Bupropion|
215065196|NCT04222894|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
214323143|NCT03241706|DRUG|Saline|Saline given as a comparison to fructose.
214323144|NCT03241706|DRUG|Somatostatin|IV infusion of somatostatin (60 ng/kg/min)
214323145|NCT03241706|DRUG|Insulin|IV infusion of insulin between 20-60 mU/m2/min.
215065197|NCT04222894|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 12-week study period.
215065198|NCT05958953|PROCEDURE|Induction of Labor IoL|Center-specific IOL protocols, based on international guidelines, will be used.
215065199|NCT02316353|BIOLOGICAL|C1-esterase inhibitor|
215065200|NCT04911647|DEVICE|ERCP using plastic stent|Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
215065201|NCT04911647|DEVICE|ERCP using metal stent|Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
215065202|NCT03529617|OTHER|Sample collection|Plasma, urine, BAL and ascitic fluid sample collection.
215065203|NCT07081464|OTHER|MRI, EEG, Pupillometry|Comparison of P300 wave amplitude, pupillometric responses, functional and structural brain connectivity, socio-adaptive function, cardiac autonomic balance between two phenotypic severity groups of young patients with Ondine Syndrome.
215065204|NCT07081802|DRUG|Da Jian Zhong Tang (Zanthoxylum, Ginger, Ginseng, Maltose)|"Da Jian Zhong Tang (Zanthoxylum, Ginger, Ginseng, Maltose)was administered orally twice daily from preoperative day 3 to postoperative day 3. The decoction aims to warm the middle jiao and promote gastrointestinal recovery, with dose adjustments based on syndrome differentiation."
215065205|NCT07081802|PROCEDURE|Transcutaneous Electrical Acupoint Stimulation (TEAS)|TEAS was delivered at acupoints ST36/ST37 (10Hz continuous wave, 30min/session) once daily from intraoperative day to postoperative day 4. On surgery day, stimulation started 30min preoperatively for 1 hour. Intensity was adjusted to elicit deqi sensation.
215065206|NCT07081802|OTHER|ERAS|"Standardized ERAS protocol included: (1) Preoperative carbohydrate loading; (2) Intraoperative goal-directed fluid therapy; (3) Minimally invasive surgery; (4) Multimodal opioid-sparing analgesia; (5) Early oral feeding (semi-liquid diet at 6h post-op); (6) Early ambulation (first mobilization at 8h post-op). Implemented by a multidisciplinary team."
215065207|NCT07081802|OTHER|Multimodal Prehabilitation Program|(1) Exercise: Daily aerobic/resistance training (30min, 5×/week); (2) Nutrition: High-protein diet (1.5g/kg/day) + oral supplements if needed; (3) Psychological Support: Cognitive-behavioral therapy sessions (2×/week). Tailored to individual patient risk profiles.
215065208|NCT07079592|DIAGNOSTIC_TEST|AI-ECG Guidance|Participants undergo screening using the AI-ECG system. Those identified as high-risk for pulmonary hypertension receive echocardiography to confirm the diagnosis and guide subsequent management.
215065209|NCT07079969|DEVICE|Photobiomodulation therapy (PBM) device|FDA-cleared near-infrared PBM device delivering therapeutic light to the affected knee. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks (2-3 times per week).
214672532|NCT03714386|DEVICE|A medium cut-off dialyzer will be used for HDx.|A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
214672533|NCT04389606|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
214672534|NCT04389606|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
214922782|NCT03116555|DRUG|Irinotecan|Irinotecan was used as second line treatment with AGC
214922783|NCT05183308|DRUG|Clodronic Acid|Osteoporotic fracture treated with surgical and medical therapy
214922784|NCT01623635|DRUG|Ropivacaine|"ADMINISTRATION OF STUDY DRUG All surgical port sites will be injected with 2 ml/each study drug prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~* each subdiaphragmatic area 3.5 ml + 3.5ml~* surgical dissection site 3 ml~* diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining medication with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining drug (no repeat port site injections)."
215065210|NCT07079969|DEVICE|Sham PBM device|Identical in appearance to the active PBM device but emits no therapeutic light. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks.
215065211|NCT07079969|DRUG|Diclofenac Sodium 1 % Topical Cream|Topical nonsteroidal anti-inflammatory drug applied at a dose of 4 grams to the affected knee, once per session, immediately before PBM/sham PBM. Used in six sessions over 2-3 weeks.
215065212|NCT07079969|DRUG|Placebo topical cream|Inert cream matching the appearance of diclofenac sodium 1% gel. Applied at 4 grams to the affected knee, once per session, immediately before PBM/sham PBM. Used in six sessions over 2-3 weeks
215065213|NCT07081568|DEVICE|transcutaneous auriculai vagus nerve stimulation|During bi-ear synchronous vagus nerve stimulation, the patient was positioned in a supine position. Two stimulating electrodes were placed bilaterally in the concha cymba and concha cavum of the ears. The patient received treatment for 30 minutes per session, once daily, 5 days per week, for a total of 4 weeks. Following each treatment session, the device was disinfected with 75% alcohol.
215065214|NCT07081529|DEVICE|Direct Restoration with Microhybrid Composite|Direct Class I restorations were placed in molar teeth using a microhybrid universal composite (Aelite All-Purpose Body, Bisco) and an adhesive system according to the manufacturer's instructions.
215065215|NCT07081529|DEVICE|Indirect Restoration with Reinforced Microfill Composite|Indirect Class I restorations were fabricated using a reinforced microfill composite system (Tescera Indirect Composite System Body, Bisco) in the laboratory and cemented into molar teeth using resin cement.
214672535|NCT01465737|OTHER|Histologic types|evaluate survival among different histologic types
214672536|NCT03959540|DRUG|Opicapone|Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.
214672537|NCT03959540|DRUG|Levodopa (L-DOPA) + Standard care|Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
215065216|NCT07080294|OTHER|extended platelet rich fibrin injection in pocket|Whole blood (10 mL) will be centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet- poor plasma (PPP) will be collected in a syringe. then PPP will be heated in a heat block device at 75°C for 10 minutes and thereafter cooled to room temperature for approximately 2 minutes. An injectable albumin gel will then be prepared. Then the liquid platelet-rich layer (liquid-PRF) including the buffy coat layer with accumulated platelets and leukocytes, will be collected in a separate syringe. The albumin gel and native liquid PRF will then be thoroughly mixed by utilizing a female-female luer lock connector. Now injectable e-PRF in final form is ready to be used.
215065217|NCT07080294|OTHER|albumin injection in pocket|Whole blood (10 mL) will be centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet- poor plasma (PPP) will be collected in a syringe. then PPP will be heated in a heat block device at 75°C for 10 minutes and thereafter cooled to room temperature for approximately 2 minutes. An injectable albumin gel will then be prepared.
215065218|NCT07080294|OTHER|scaling and root planing|removes plaque and calculus above and below the gumline using manual or ultrasonic instruments.
215065219|NCT07081828|DEVICE|Surgery|Patients who undergo surgery utilising the Senhance Surgical System.
215065220|NCT06890988|OTHER|Care Navigator|"The Care Navigator will be added to the dental team as an added resource to:~1. Champion the use of the multicomponent HIV intervention in the dental clinic among clinic administrators, residents, dental hygienists, dental assistants, and other dental team staff.~2. Provide technical assistance~3. Provide logistical assistance ; and~4. Support dental team in educating patients about HIV prevention and treatment options"
214485710|NCT06474754|DIAGNOSTIC_TEST|Submaximal Cardiopulmonary Exercise Testing|FDA-approved device uses breath by breath sampling during calibration and exercise challenge. Analysis is performed using a differential pressure pneumotach method for volume calibration and measurement, an infrared sensor for CO2 and a paramagnetic sensor for O2 measurements. Automated calibration using a calibration gas mixture (15.6% O2/5% CO2) is performed at regular intervals. The Shape II calculations used to differentiate causes of exertional dyspnea are Artificial Intelligence (AI) based algorithms and measurements have been previously validated to conventional cardiopulmonary exercise testing methods. Brief smCPET is comprised of a 2-minute calibration phase, 3 minutes of graded exercise using a stair-step and a 1 minute recovery phase for a total of 6 minutes. An instant report is then generated.
214485711|NCT06474754|DIAGNOSTIC_TEST|Duke Activity Status Index|A validated measure of preoperative functional capacity which will be utilized to cross-validate smCPET peak VO2. Low DASI score has been found to estimate peak oxygen uptake (VO2), predict MINS, myocardial infarction, and inducible myocardial ischemia on myocardial perfusion scintigraphy.
214485712|NCT03678350|DEVICE|Light Dosimetry for Intranoperative Therapy|Undergo IO-PDT
214485713|NCT03678350|PROCEDURE|Photodynamic Therapy|Undergo IO-PDT
214485714|NCT03678350|DRUG|Porfimer Sodium|Given IV
215065221|NCT06890988|OTHER|Multicomponent HIV Service Package|"Multicomponent HIV Service Package consisting of:~1. Clinical Decision Support (CDS) within electronic medical record (EMR) system to help providers identify patients who would benefit from HIV screening or re-engagement in HIV care.~2. Point-of-care HIV testing in the dental clinic.~3. Patient and provider-facing educational materials to support providers in discussing HIV prevention options (for patients who test HIV negative) and treatment (for patients who test HIV positive or are out of HIV care) options."
214922785|NCT01623635|DRUG|placebo (normal saline)|"ADMINSTRATION OF PLACEBO All surgical port sites will be injected with 2 ml/each placebo prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the placebo will be delivered as an atomized spray in the following volumes:~* each subdiaphragmatic area 3.5 ml + 3.5ml~* surgical dissection site 3 ml~* diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining placebo with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining placebo (no repeat port site injections)."
214485715|NCT04033822|PROCEDURE|cholecystectomy|If patients are randomized to the intervention arm of the study; said patient will undergo corrective cholecystectomy surgery to correct cholecystitis as soon as possible with a goal of surgery within 6 hours of diagnosis.
214485716|NCT05696704|OTHER|Behavioral: Mindfulness Based Cognitive Therapy|Individual tele-therapy 12 to 16 weeks
214485717|NCT05696704|OTHER|Behavioral: Behavior Activation|Individual therapy 12 to 16 weeks
214672538|NCT05506904|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. The clinical outcome case report form will be completed at the time of hospital discharge.
214922786|NCT02960035|DRUG|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
214922787|NCT02960035|DRUG|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
214922788|NCT02960035|DRUG|placebo|
214922789|NCT04661241|OTHER|Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches|The proposed sequence (\<15 minutes) will be added as a supplementary sequence only for the preoperative imaging for subjects who agree to participate: a 3D multi-echo GRE sequence will be performed during a preoperative MR imaging, using the following parameters: field of view = 220x170x75 mm3, matrix = 176x136x60, 1.25-mm isotropic resolution, flip angle = 22 degrees, TR = 92 ms, 20 TEs = 1.90 - 45.98 ms with echo spacing of 2.32 ms, bandwidth = 840 Hz/pixel.
214922790|NCT04661241|OTHER|Routine clinical MRI protocol|MRI will be performed using 3T scanner (Skyra, Siemens, Erlangen, Germany). All patients will undergo preoperative MRI of the brain including routine clinical MRI protocol (T1-/T2-weighted and diffusion imaging) under general anesthesia to reduce movement artifacts.
214922791|NCT04259658|COMBINATION_PRODUCT|Calcium electroporation|Patients with cutaneous metastases will be treated with calcium electroporation.
214922792|NCT06350435|DEVICE|Prefabricated foot orthoses (PFO) with metatarsal pads|A pair of prefabricated foot orthoses, each with a metatarsal pad to be affixed underneath
214922793|NCT06350435|DEVICE|Prefabricated foot orthoses (PFO) without metatarsal pads|A pair of prefabricated foot orthoses only
214922794|NCT02229279|DEVICE|Teleconsulting|
214922795|NCT00527033|DRUG|YM178|Oral
214922796|NCT00527033|DRUG|Placebo|Oral
214922797|NCT01404754|DRUG|Lactose (inactive placebo)|Placebo in an equivalent weight to midomafetamine HCl will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
214922798|NCT01404754|DRUG|midomafetamine HCl|120 mg midomafetamine HCl will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 40 mg may be administered 1.5 to 2.5 hours later.
214922799|NCT01981954|DRUG|Solifenacin succinate|Oral suspension
214922800|NCT06572579|PROCEDURE|Ultrasound-guided pharmacopuncture treatment|Pharmacopuncture treatment using ultrasound-guidance
214922801|NCT00971607|DRUG|Oxygen + Sevoflurane|Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
214922802|NCT00971607|DRUG|Oxygen (placebo)|Control will receive oxygen only.
214922803|NCT03655470|BEHAVIORAL|Safety Planning|Safety planning is an individual coping intervention to reduce suicidal risk in adolescents
214922804|NCT03655470|BEHAVIORAL|Standard care|Standard care entails sending an adolescent for an emergency evaluation for suicidal risk in an Emergency Department
214922805|NCT06304285|OTHER|Acupuncture treatment|Acupuncture was performed according to the corresponding acupoint of the patient
214922806|NCT06304285|OTHER|Sham acupuncture treatment|The needle only touches the patient's skin and does not penetrate the skin
214922807|NCT06624007|OTHER|pediatric Nursing Excellence (PNE) model|The intervention group will apply pediatric Nursing Excellence (PNE) model included 28 Likert-type questions to assess nurses' general excellence level regarding the care of children undergoing orthopedic surgeries grouped under five main categories including engagement, values, principles, care delivery and continuous improvement.
214485718|NCT04899479|DRUG|SGLT2 inhibitor|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
215065222|NCT07079527|DEVICE|Manual Positive End Expiratory Pressure (PEEP) Therapy|Participants in this group receive Manual Positive End Expiratory Pressure (PEEP) therapy. The intervention is delivered using a tight-fitting mask that applies positive pressure at the end of expiration, helping to keep the alveoli open, enhance oxygenation, and prevent airway collapse. The therapy is administered according to a structured protocol over a 4-week period, aiming to reduce breathlessness, improve lung function, and support ventilation. Along with PEEP, participants also receive baseline Active Cycle of Breathing Techniques (ACBTs) for airway clearance and breathing control.
214485719|NCT04899479|OTHER|Control|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
215065223|NCT07079527|DEVICE|Non-Invasive CPAP Therapy|Participants in this group receive Non-Invasive Continuous Positive Airway Pressure (CPAP) therapy. CPAP provides a constant level of positive pressure throughout the entire breathing cycle using a non-invasive ventilator and a full-face or nasal mask. This therapy improves gas exchange, reduces the work of breathing, and eases symptoms such as dyspnea. Like Group A, CPAP therapy is delivered following a standardized protocol for 4 weeks, and participants also perform baseline ACBTs to support respiratory function.
215065224|NCT07079852|DRUG|Placebo|This is an inactive control condition.
215065225|NCT07079852|DRUG|Psilocybin 15mg|This is a moderate psychoactive dose.
214485720|NCT06054295|OTHER|Biospecimen collection|Collection of both blood and saliva samples from participants at the time of study enrollment
214485721|NCT06054295|OTHER|Questionnaire Administration|The brief questionnaire will assess health history, demographics, environmental exposures, family history of cancer, and birth characteristics.
214922808|NCT05974488|DEVICE|McMurray Enhanced Airway|The MEA is non-sterile. It can be used in inpatient or outpatient surgery, in hospital or clinic settings, or in an emergency setting. The MEA has five parts: an optional 15 mm connector, flange (color-coded for size), elongated cushioned bite block, flexible cannula, and distal tip, and a channel to allow for passage of air and a suction catheter. The MEA is designed to open and maintain a patient's upper airway. Oxygen will be delivered through the breathing circuit with the following parameters: 40% oxygen at 6 liters/min flow throughout the procedure time. The MEA will be placed in the participant's oropharyngeal airway one time during an in-person visit.
215065226|NCT07080541|OTHER|Physical literacy and life satisfaction|Participants in the technology experimental group will engage in physical activity in nature while being exposed to information pills on physical literacy and the importance of physical activity in health to improve quality of life and life satisfaction via social media
214485725|NCT02591433|OTHER|Tobacco Cessation Counseling|Undergo JeffQuit group therapy
214485726|NCT02591433|OTHER|Support Group Therapy|Undergo JeffQuit group therapy
214485727|NCT02591433|OTHER|Quality-of-Life Assessment|Ancillary studies
215065227|NCT07080541|OTHER|Analogic information|Participants in the analogic experimental group will engage in physical activity in nature while being exposed to information pills on physical literacy and the importance of physical activity in health to improve quality of life and life satisfaction via paper sheets.
215065228|NCT02815657|DRUG|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
215065229|NCT02815657|DRUG|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
215065230|NCT02065843|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
215065231|NCT02065843|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
215065232|NCT02065843|DRUG|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
215065233|NCT02065843|DRUG|midazolam|15 mg/single dose/1 hour before dental surgery
215065234|NCT05377489|DRUG|RTX-GRT7039|RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
215065235|NCT01766804|DIETARY_SUPPLEMENT|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
215065236|NCT01766804|DIETARY_SUPPLEMENT|placebo|
215065237|NCT06895603|DEVICE|Philips Advanced Monitoring Cuff (AMC)|The Philips AMC is a Class II (USA) and Class IIb (EU) medical device that is a non-invasive, semirigid disposable upper arm cuff with an integrated pneumatic actuator enabling hydraulic coupling of tissue pressure waveforms from the upper arm tissue.
215065239|NCT06914245|DIAGNOSTIC_TEST|Electronic bowel diary|This bowel diary will be available on the smartphone in the form of an application.
215065240|NCT06914245|DIAGNOSTIC_TEST|Faecal Incontinence Quality of Life questionnaire (FIQL)|This questionnaire will be available online.
215065241|NCT06914245|DIAGNOSTIC_TEST|EuroQoL 5 dimensions, 5 levels (EQ-5D-5L)|This questionnaire will be available online.
215065242|NCT00006003|DRUG|semaxanib|Given IV
214485728|NCT05486793|BEHAVIORAL|Written Exposure Therapy (WET)|5 individual sessions that cover psychoeducation about PTSD, the rationale for exposure treatment, and directing patients to write in session for 30 minutes about their traumatic experience using scripted instructions. Each session includes unique writing instructions. Earlier sessions focus on describing the details of a traumatic stressor linked to their symptoms, with particular attention to felt emotions and thoughts. Later writing sessions focus on writing about the meaning of the traumatic event and how the event has changed their life and how they relate to other people. After writing, therapists spend \~10 minutes processing the patient's experience with the writing. WET does not include between session assignments.
214485729|NCT05486793|BEHAVIORAL|Emotion Focused Supportive Therapy (EFST)|5 individual sessions where patients choose what problems to discuss in each session. Therapists validate and clarify patients' emotions and engage in problem solving during sessions.
214485730|NCT04876339|DEVICE|"Gait rehabilitation with sonification"|The sonification system is composed by 2 inertial sensors, a computer and a pair of bluetooth headphones connected with the computer. The sensors will be placed one per leg at the ankle and connected with Matlab software. An home-made ad-hoc software associates patient's movements with music patterns. The patient's natural rhythm is detected and used at the beginning of the intervention. The first part of each exercise is supported by a pre-recorded chord progression with a click on the background. In the second part (sonification approach) the software notices and records the contact of the heel with the ground. Each contact activates musical stimuli listened to via headphones. The steps succession will build a regular and predictable musical progression in relation to the correct sequence of steps. The exercises planned in this intervention are the same as those planned in the gait standard rehabilitation (see below).
214922809|NCT05974488|DEVICE|Nasal Cannula|Participants in this group will use the nasal cannula to deliver oxygen as per standard of care one time during the in-person visit.
214922810|NCT02272907|OTHER|Injection of saline solution into specimen to test bursting pressure.|A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
214922811|NCT06682715|DIETARY_SUPPLEMENT|whey protein|10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.
215065243|NCT00006003|OTHER|laboratory biomarker analysis|Correlative studies
215065244|NCT01800331|BEHAVIORAL|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
215065245|NCT05269225|OTHER|Organic diet|Organically produced foods.
215065246|NCT05269225|OTHER|Conventional diet|Conventionally produced foods.
215065247|NCT05616585|OTHER|Pharmacokinetic (PK)- Controlled Feeding Diet|Pharmacokinetic- single-day isocaloric meals of beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, and oats with blood and urine samples taken at Time Zero and every hour (blood) or two hours (urine) after eating, over 10 hours; and at 24 hr.
215065248|NCT05616585|OTHER|Dose Response (DR)- Controlled Feeding Diet|Dose Response-3 level, six days controlled feeding study with assignment to either beef/whole wheat bread, chicken/potato, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for 6 days.
215065249|NCT06951464|DRUG|BL-B01D1|BL-B01D1 (2.2 or 2.5mg/kg) to be administered on Day 1 and Day 8 of every 3-week cycle for 2 cycles.
215065250|NCT06951464|DRUG|Almonertinib|Almonertinib 100mg QD
215065251|NCT06853990|DEVICE|twiist insulin delivery system|twiist system includes a novel insulin pump, a CGM sensor and the DEKA Loop algorithm
214323146|NCT03241706|DRUG|Glucagon|IV glucagon (0.65 ng/kg/min).
215065252|NCT04085653|DRUG|alpelisib|"Alpelisib will be provided as 50 mg, 125mg and 200 mg film coated tablets as individual patient supply, and will be dosed on a flat scale of mg/day not to be adjusted to body weight or surface area.~In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.~In Pediatric patients, alpelisib will be administered at a maximum starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed."
214672539|NCT00244218|DRUG|tetrahydrobiopterin (BH4)|Either placebo or tetrahydrobiopterin (BH4) , 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
215065253|NCT05981508|BEHAVIORAL|Together, Eating and Activity, Matter Plus (TEAM+) Online|TEAM+ is a 3-month, family enhanced behavioral weight loss (BWL) intervention designed for Black adults consisting of an online family dyadic skills training and in-person core behavioral weight loss sessions.
214323147|NCT03241706|DRUG|Dextrose solution|IV dextrose to clamp the plasma glucose at the desired level.
214323148|NCT03241706|DRUG|High Fructose|IV-fructose (6.5 mg/kg/min)
214323149|NCT02439775|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
214323150|NCT02439775|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
214922812|NCT06682715|DIETARY_SUPPLEMENT|maltodextrin|10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.
214922813|NCT06682715|BEHAVIORAL|nutrition education|Nutrition for sports knowledge questionnaire will be used to assess the pre-nutrition education and post-nutrition education knowledge of athletes. Nutrition education will be given using evidence based nutrition education hand-outs and one-on-one counselling for each athlete in which they will be guided about sources of high biological value protein sources to meet daily protein requirement. Dietary intake will be monitored using 3 day food record method during 2-6 weeks of supplementation. Food logs will be filled out by participants during each weeks to monitor their protein intake. Three food logs (2 weekdays \[Mon-Thurs/Tue-Fri\] and 1 weekend day \[Sat/Sun\]) will be submitted by each subject every week.
214922814|NCT03865615|DRUG|Oxytocin|intranasal oxytocin 40IU/mL
214922815|NCT03865615|DRUG|Placebo|Placebo
214922816|NCT01403688|PROCEDURE|RPFNA|"1. Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).~2. Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment~3. Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding"
214323151|NCT05007782|DRUG|Denikitug|Administered Intravenously
214323152|NCT05007782|DRUG|Zimberelimab|Administered Intravenously
214323153|NCT03639337|DIETARY_SUPPLEMENT|Multi-strain probiotic|30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
215065254|NCT05981508|BEHAVIORAL|Together, Eating and Activity, Matter Plus (TEAM+) In-Person|TEAM+ is a 3-month, family enhanced behavioral weight loss (BWL) intervention designed for Black adults consisting of in-person family dyadic skills training and core behavioral weight loss sessions.
214323154|NCT05945316|BEHAVIORAL|Accessing Confidence levels of Nursing students|Three mock CODE BLUE training events for Spring, Summer, and Fall Nursing Residents and Nursing Fellows are scheduled for 2022 followed by an actively participated CODE BLUE event. The PI plan to collect data from all new residents meeting the inclusion/exclusion criteria with voluntary participation to complete.
214323155|NCT04002414|BEHAVIORAL|Sufficient physical activity|Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
214672540|NCT04296292|OTHER|In-depth interviews|In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
214672541|NCT01601015|OTHER|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
214922817|NCT06200311|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation using pulsed field ablation (PFA), cryoballoon or radiofrequency ablation (RFA)
214922818|NCT06200311|DRUG|Pharmacological rhythm management|1st line: rate control, 2nd line: pharmacological rhythm management. 3rd line: AF ablation
215065255|NCT02954406|DRUG|TAK-659|TAK-659 immediate release tablet
215065256|NCT02954406|DRUG|Bendamustine|Bendamustine intravenous infusion
215065257|NCT02954406|DRUG|Rituximab|Rituximab intravenous infusion
215065258|NCT02954406|DRUG|Gemcitabine|Gemcitabine intravenous infusion
215065259|NCT02954406|DRUG|Lenalidomide|Lenalidomide capsule
215065260|NCT02954406|DRUG|Ibrutinib|Ibrutinib capsule
214922819|NCT06685471|DIAGNOSTIC_TEST|Screeing test|Simulation-Based Training Program Effect on Pediatric Nurses' Knowledge and Performance Regarding Heel-Prick during Newborn Blood Screening Test
215065261|NCT01373684|DRUG|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
215065262|NCT01373684|DRUG|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
214922820|NCT04723628|BEHAVIORAL|Intervention group (telephone counseling)|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
214922821|NCT00887783|DRUG|Navelbine|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
214922822|NCT00887783|RADIATION|66 Gy/33F|irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
215065263|NCT02965963|DRUG|Dopamine|
215065264|NCT02965963|DRUG|Metoclopramide|
215065265|NCT02965963|DRUG|Placebos|
215065266|NCT02965963|OTHER|Rest|
215065267|NCT02965963|OTHER|Exercise - 60%|60% of VO2max
215065268|NCT02965963|OTHER|Exercise - 85%|85% of VO2max
214672542|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
214922823|NCT00887783|RADIATION|60 Gy/30F|irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
214922824|NCT05420298|OTHER|cervical mobilization|All participants will receive only single session of cervical mobilization
214922825|NCT05420298|OTHER|cervical manipulation|All participants will receive only single session of cervical manipulation
214922826|NCT04335409|DIAGNOSTIC_TEST|Questionnaire|The patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
214922827|NCT04335409|OTHER|Mobile Application|In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with pneumonitis.
214922828|NCT05517109|OTHER|Hemodynamic goal including lower goal of systolic blood pressure|Different hemodynamic goals in different study arms
214922829|NCT04793529|DRUG|Cholecalciferol|Cholecalciferol injection
214922830|NCT04349462|DIAGNOSTIC_TEST|VideoFlurosocopy Swallow Study|VFSS is a radiological examination that can identify the presence, nature and severity of any abnormalities in oropharyngeal, laryngeal and upper esophageal swallow physiology. The VFSS will be administered via a standardized protocol by a registered speech-language pathologist (SLP). During the VFSS, the patient is seated upright and swallows a variety of consistencies (eg. liquids, semisolids and solids) and volumes of barium-coated foods. A dynamic fluoroscopic image will be digitally captured and recorded.
215065269|NCT05396014|BEHAVIORAL|Enhanced Self-Care (ESC)|The Enhanced Self-Care intervention will be comprised of educational modules on evidence-based cognitive-behavioral self-management skills for pain. These modules will be provided digitally for self-administration over a period of 12 weeks. There will be no therapist associated with the delivery of these educational materials; however, after the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment. Additionally, the walking program module will utilize Fitbit step tracking to allow participants to monitor their walking progress.
215065270|NCT05396014|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a form of cognitive behavioral therapy that is well established for the treatment of chronic pain. The goal of ACT is to build psychological flexibility thereby interrupting pain avoidance behavior patterns. Participants randomized to ACT will take part in 12 sessions over the course of 12 weeks. Sessions will be delivered as a combination of 4 remote face-to-face visits with a therapist and 8 therapist-supported online sessions (self-directed online modules supported by provider coaching). Online sessions will focus on helping participants accept pain, connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. During face-to-face sessions with the therapist, participants will be encouraged to share their experience of skills practice and mastery, provide examples of skill use at home, and describe what barriers they encountered.
215065271|NCT05396014|BEHAVIORAL|Evidence-Based Exercise and Manual Therapy (EBEM)|Licensed physical therapists (PTs) or Doctors of Chiropractic (DCs) will rely on evidence-based guidance to direct decision-making on the particular type of manual and exercise therapy that may be best suited to an individual study participant. Special attention will be paid to the clinician's choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions. A total of 10 sessions will be provided over an 8-week treatment period. Two sessions per week are provided in the first two weeks followed by weekly sessions over the next 6 weeks. Treatment sessions will last approximately 60 minutes each.
215065272|NCT05396014|DRUG|Duloxetine|Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for use in Chronic Low-Back Pain, and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low back pain. Study participants will be treated with duloxetine for 12 weeks during the active treatment phase. At the time of randomization, the approved drug pharmacy at each study site will dispense between 185 and 192 duloxetine 30 mg capsules and provide to participants. This will ensure enough capsules to maintain up to a 60 mg dosage through the 12-week intervention phase and to taper the dose in the 13th week if needed.
215065273|NCT06501638|DRUG|Memantine Hydrochloride 10 MG|Take Memantine Hydrochloride for intervention First week, 5mg(half the tablet), p.o.，bid. Second to Sixth week, 10mg(one tablet), p.o., bid
215065274|NCT06501638|DRUG|Placebo|Take placebo for intervention First week, half the tablet, p.o., bid. Second to Sixth week, one tablet, p.o., bid
215065275|NCT06349460|BEHAVIORAL|FoodSteps behavioral intervention|Behavioral intervention that targets binge eating and weight-related behaviors. Each week, users are recommended or assigned one of five targets, set a relevant goal, and track their progress. If a target is recommended, the user can choose to select that target or a different target.
214323156|NCT04002414|BEHAVIORAL|Insufficient physical activity|Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
214323157|NCT01506973|DRUG|Hydroxychloroquine (HCQ)|no other names
215065276|NCT06534541|BEHAVIORAL|Attentional bias to food cues|Measurement of the amount of attention given to food cues
214323158|NCT01506973|DRUG|Gemcitabine|no other names
214323159|NCT01506973|DRUG|Abraxane|no other names
214323160|NCT00981032|BEHAVIORAL|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
214323161|NCT00981032|BEHAVIORAL|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
214323162|NCT03601754|DIAGNOSTIC_TEST|Treadmill/Bicycle exercise testing|"Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W"
214323163|NCT03237767|OTHER|MIE|"The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold."
214323164|NCT03237767|OTHER|HIIE|"The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery."
214323165|NCT03047135|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
214323166|NCT05790876|PROCEDURE|SSO2 therapy|SSO2 therapy consists of overoxygenating the patient's blood and delivering it to the origin of the LAD for 60 min. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
214323167|NCT01968642|BEHAVIORAL|Educational Intervention|
214323168|NCT05325593|DRUG|romiplostim plus dexamethasone|Patients will be reviewed weekly for 8 weeks (56 days). After Week 8, patients will be reviewed every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
214323169|NCT05325593|DRUG|Dexamethasone|Patients will be reviewed weekly until the completion of dexamethasone cycles and for a minimum of 8 weeks (56 days). After that, every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
214323170|NCT05634525|DRUG|MRTX849|Given By PO
214323171|NCT00223106|DEVICE|Vaginal Sling|
214323172|NCT04374877|DRUG|CHS-388|CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
214323173|NCT04374877|DRUG|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
214323174|NCT04374877|DRUG|Toripalimab|Toripalimab by IV infusion
215065277|NCT03179982|BEHAVIORAL|Safe South Africa|"Core components of the Safe South Africa intervention include the following:~* Theory driven, best-evidence intervention approaches to adolescent HIV prevention~* Linkages between HIV and IPV~* Victim Empathy~* Healthy Norms Regarding Masculinity~* Bystander Intervention Skills"
215065278|NCT04230811|DIAGNOSTIC_TEST|Corneal impression membrane (Millicell Cell Culture Insert, 12mm, hydrophilic PTFE 0.4µm (PICM01250))|Application of corneal membrane to the cornea for 3-5 seconds, after anaesthesia
215065279|NCT05963204|COMBINATION_PRODUCT|Sculptra and Alastin Restorative Skin Complex|Biostimulator and cosmetics
215065280|NCT05963204|COMBINATION_PRODUCT|Sculptra and CeraVe Daily Moisturizing Lotion|Biostimulator and cosmetics
215065281|NCT05609877|DRUG|Isotonic saline|Isotonic saline will be administered intravenously instead of pre-procedure analgesia.
214922831|NCT04349462|DIAGNOSTIC_TEST|Water Sip Test|The steps of the water sip test include; 1. The patient will be given 5 ml of water, and if tolerated 20 ml followed by 50 ml of water (thin fluid) and the patient is assessed for cough/chocking during or after swallowing, wet or weak cough after swallowing. 2. The patient is asked to produce sustained vowel /a/ before and after swallowing of water and voice change after swallowing will be observed and recorded.
214922832|NCT05283343|DEVICE|SP-1P|A subject undergoes corneal thickness measurement with pachymeter.
215065282|NCT05609877|PROCEDURE|Less Invasive Surfactant Administration (LISA)|All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure
215065283|NCT05609877|DRUG|Fentanyl|Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia
215065284|NCT05609877|BEHAVIORAL|Non-pharmacological standard operating procedure|All infants will receive the same non-pharmacological standard operating procedure.
215065285|NCT05098574|DRUG|Yaz|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
215065286|NCT05098574|DRUG|Placebo|Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
215065287|NCT05815550|DRUG|PPI|Use of PPI defined as PPI mentioned in the safety report
215065288|NCT06781931|DEVICE|DG1 Spectacle Lens|DG1 spectacle lens, daily wear for 36 months
215065289|NCT06781931|DEVICE|Single Vision Spectacle Lens|Single vision spectacle lens, daily wear for 36 months
214922833|NCT00489086|DRUG|tazarotene|Tazarotene is a member of the acetylenic class of retinoids.
214922834|NCT02222350|DRUG|10mg DS-8500a tablet|
214922835|NCT02222350|DRUG|75mg DS-8500a tablet|
214922836|NCT02222350|DRUG|placebo|
214922837|NCT03063086|DRUG|QVM149 150/50/80 μg o.d.|A
214922838|NCT03063086|DRUG|QVM149 150/50/160 μg o.d.|B
214922839|NCT03063086|DRUG|salmeterol/fluticasone FDC 50/500 μg b.i.d.|C
214922840|NCT02070016|DEVICE|Transcranial Magnetic Stimulation|
214922841|NCT04590586|DRUG|Standard of care|Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
215065290|NCT04991870|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given CB-NK-TGF-betaR2-/NR3C1- intratumorally
215065291|NCT04991870|PROCEDURE|Resection|Undergo surgical resection
215065292|NCT03300141|OTHER|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
215065293|NCT03300141|OTHER|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
215065294|NCT03300141|OTHER|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
215065295|NCT01527305|DRUG|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
215065296|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, intraoperative stage|Trocar layout is recorded by photo or diagram. The video of conventional or robot-assisted laparoscopy and intraoperative laparoscopic ultrasound images (where applicable) are recorded by the surgeon and anonymized. Depth measurements of internal structures (tumors, cysts, vascular network, anatomical landmarks) are taken using identifiable points on the surface of the liver for tumour resection.
214922842|NCT04590586|DRUG|Apremilast|Apremilast administered orally as a tablet.
214922843|NCT04590586|DRUG|Apremilast placebo|Matching apremilast placebo administered orally as a tablet.
214922844|NCT04590586|DRUG|Lanadelumab|Lanadelumab administered as an intravenous (IV) infusion.
214922845|NCT04590586|DRUG|Lanadelumab placebo|Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
214922846|NCT04590586|DRUG|Zilucoplan|Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
214922847|NCT04590586|DRUG|Zilucoplan placebo|Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
215065297|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, postoperative stage|The registration of imaging data in conventional or robot-assisted laparoscopy is performed by the scientific team using the developed registration algorithm. The data obtained from the clinical intervention will help improve the registration algorithm.
215065298|NCT06044909|OTHER|Preoperative data collection|Patient code (anonymised) + inclusion number, repeated on each page. Anonymised CT or MRI scan and date of scan. Type of cancer, planned surgery and approach (robotic or laparoscopic). Patient's age. Patient's surgical history. Toxic habits: tobacco, alcohol. Healthy liver, liver disease, cirrhosis. Anticoagulant and antiaggregant treatment.
215065299|NCT06044909|OTHER|Intraoperative data collection|Endoscope calibration. Intraoperative surgical and ultrasound images. Measurements for tumor's size and tumor's distances from liver surface and vascular vascular structures.
214672543|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
214672544|NCT01601015|OTHER|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
214672545|NCT00379483|DRUG|Deferasirox|
214672546|NCT00795626|BEHAVIORAL|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
214922848|NCT03470155|PROCEDURE|mitral valve repair|operative reconstruction
214922849|NCT05130710|PROCEDURE|staging laparoscopy|All patients of both groups underwent staging laparoscopy by the same two attending onco-surgeon, using the same technique and the same laparoscopic device. Under general anesthesia and in supine position SL was performed. A 10 mm optic laparoscopic port was inserted via the midline incision below the umbilicus using Hasson technique. All four quadrants of the abdomen as well as pelvis were inspected during laparoscopy and biopsy was taken from any suspicious lesion through insertion of 5mm port. All specimens underwent cytological evaluation by two independent pathologists. The presence of any malignant cells, regardless of the number, confirmed the positive cytology. In the event of discordant reports between two pathologists, specimens were sent for the third review by a pathologist who was blinded to the previous results. Laparoscopic evaluation was considered positive as if adjacent organ involvement, omental involvement or peritoneal seeding were seen.
214922850|NCT04931823|DRUG|CPO-100|Docetaxel albumin-bound
214922851|NCT05879523|DRUG|HRS-1893|subcutaneous, single dose, multiple doses
214922852|NCT05879523|DRUG|Placebo|subcutaneous, single dose, multiple doses
214922853|NCT04028895|DIAGNOSTIC_TEST|Dosage of IRAP during OGTT|Visit 1: oral glucose tolerance test. visit 2: hyperinsulinemic euglycemic clamp
214922854|NCT03512717|DEVICE|Potenfill|Maximum: 22ml
214922855|NCT03512717|DEVICE|Powerfill|Maximum: 22ml
214922856|NCT04512534|DRUG|PD-1 antibody+ HDAC inhibitor|"Patients receive anti-PD-1 antibody Sintilimab+ HDAC inhibitor Chidamide three weeks for a cycle, detailed as follows:~* Anti-PD-1 antibody (Sintilimab): Fixed dose of 200 mg every 3 weeks, intravenous drip (without pretreatment), infusion time: 30 minutes (no less than 20 mins, no more than 60 mins), the maximum treatment period is 2 years (up to 35 doses), complete remission（CR）patients confirmed by imaging assessment can be considered off anti-PD-1 treatment after 12 treatment cycles.~* Chidamide: Chidamide is administered orally at a dose of 30mg (initial dose). It is recommended to be administered within 0.5h after a meal with a fixed time. Chidamide will be given until disease progression or intolerant toxicity. The maximum treatment is 2 years. If chidamide therapy requires to be continued over 2 years due to clinical benefit, the prescription/decision should be made after discussion with the principal investigator."
214922857|NCT06539624|GENETIC|EXG110 injection|EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.
214922858|NCT04450524|BEHAVIORAL|Hypnosis|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
214922859|NCT04450524|BEHAVIORAL|Food inhibition training|Training the associations between foods and motor inhibition using a GO-NO-GO computer task.
214922860|NCT04450524|BEHAVIORAL|Control|A simple GO-NO-GO task
214922861|NCT05847738|BEHAVIORAL|Pain assessment|Pain was assesd postoperatively in both groups at time intervals
214922862|NCT05628038|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w
214922863|NCT05628038|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
214922864|NCT05628038|DRUG|5FU|400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
214922865|NCT05628038|DRUG|folinic acid|400 mg/m2 q2w
214922866|NCT05628038|DRUG|Oxaliplatin|130 mg/m² q3w or 85 mg/m² q2w
214922867|NCT05628038|DRUG|Irinotecan|180 mg/m² q2w and 200 mg/m² q3w
214922868|NCT05628038|DRUG|Raltitrexed|2 mg/m² q2w and 3 mg/m² q3w
214922869|NCT05628038|DRUG|Cetuximab|400 mg/m² q2w
214922870|NCT05628038|DRUG|Bevacizumab|5 mg/kg q2w or 7.5mg/kg q3w
214922871|NCT05628038|RADIATION|Radiation|"25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence tumor.~35-60Gy/5-8Fx irradiation for distance metastasis tumor."
215065300|NCT06044909|OTHER|Postoperative data collection|Definitive anatomical pathology with the measurement of resection margins.
215065301|NCT06298214|BEHAVIORAL|Her Health Program|Addition of a community health worker navigator to assist subject in navigating their health in the first year postpartum.
215065302|NCT03797625|DRUG|Irinotecan|60mg/m2，D1，8
214922872|NCT06251635|DRUG|Olanzapine 2.5Mg Oral Tablet|"Olanzapine capsules (2.5mg) will be administered during one research visit for each menstrual cycle phase. The dosing schedule is as follows:~1. Day 0- 5mg~2. Day 1- 10mg"
214922873|NCT06251635|DRUG|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule during one research visit of each menstrual cycle phase.
214922874|NCT06251635|DRUG|Insulin Lispro 100 UNT/ML|At each visit, participants will be given an intranasal insulin challenge (160 IU) to assess brain insulin signalling via MRI based assay.
215065303|NCT03797625|DRUG|DDP|60mg/m2，D1
215065304|NCT03797625|DRUG|Endostar|15mg/d，d1-d7 civ
215065305|NCT02128906|DRUG|Cisplatin|Cisplatin 40 mg/m2 weekly x 7
214323175|NCT04087122|DEVICE|Esophageal warming device (Attune Medical, Chicago, IL|Prospective, single center pilot stud
214323176|NCT03628911|DEVICE|Tetanizing Burst Therapy|Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock
214323177|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 500 mg/day for 4 weeks.
214323178|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1000 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 10000 mg/day for 4 weeks.
214922875|NCT06251635|DRUG|Saline|At each visit, participants will be given an intranasal saline placebo (1.6 mL) in order to establish baseline brain insulin signalling via MRI based assay.
214922876|NCT04844034|DIETARY_SUPPLEMENT|High-EPA multinutrient supplement.|"Three capsules with the largest meal of the day providing:~* 1,125 mg EPA~* 441 mg DHA~* 330 mg Magnesium~* 7.5 mg a-tocopherol"
214922877|NCT04844034|OTHER|Placebo|"Three capsules with the largest meal of the day providing:~* 3,060 mg sunflower seed oil~* 60 mg lecithin~* 300 mg glyceryl monostearate~* 465 mg EPA/DHA (18%/12% respectively for blinding)"
214922878|NCT03341442|PROCEDURE|No hip precautions|No hip precautions practiced after THA surgery
214922879|NCT02218736|DRUG|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
214922880|NCT02218736|DRUG|placebo|oral dosing of 10 mg placebo daily for 8 weeks
214323179|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 1500 mg/day for 4 weeks.
214323180|NCT06404203|OTHER|Plasebo|Volunteers will receive a soft vegan gelatin capsule containing lactose in a dose of 1500 mg/day for 4 weeks.
214323181|NCT02659020|DRUG|Olaratumab|Administered IV
214323182|NCT02659020|DRUG|Gemcitabine|Administered IV
214323183|NCT02659020|DRUG|Docetaxel|Administered IV
214922881|NCT00761670|DRUG|amisulpride and risperidone|amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
214922882|NCT03778918|OTHER|inflammatory bowel disease|blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP
214922883|NCT03778918|OTHER|IBS or Normal Control|blood based biomarker compared normal control with IBD
214922884|NCT03374696|BEHAVIORAL|SAFETY|
214922885|NCT03374696|BEHAVIORAL|Standard education|
214922886|NCT06260111|DEVICE|Photobiomodulation|"Photobiomodulation will be used in sessions of approximately 5 to 10 minutes each. An InGaIP diode laser will be used with the following parameters: wavelength of 660 nm, output power of 40 mW, and an energy density of 4 J/cm2 measured at the end of the fiber optic with 0.04 cm2 of section area. The laser will be applied at 10 points in each oral region, with an exposure time of 4 s per point, using 0.16 J of energy per point.~The protocol was based on previous studies."
214922887|NCT06260111|OTHER|Usual care|Usual care for oral mucositis includes education, cryotherapy, and mouth hygiene.
215065306|NCT02128906|RADIATION|IMRT|IMRT: once daily, M-F, 7 weeks (70 Gy)
215065307|NCT02128906|DRUG|Docetaxel|Docetaxel 15 mg/m2 weekly x 7
215065308|NCT02128906|DRUG|Cetuximab|Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
215065309|NCT02112188|BEHAVIORAL|In-depth Patient Interviews|
215065310|NCT02112188|BEHAVIORAL|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
215065311|NCT02112188|BEHAVIORAL|Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)|The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.
215065312|NCT04953806|BEHAVIORAL|Step-CBT|Participants will complete Step-CBT, an integrative 8-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
215065313|NCT05011006|DIAGNOSTIC_TEST|NT3 blood draw|blood draw
215065314|NCT04148482|OTHER|Dietary intervention|To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.
215065315|NCT05318534|DRUG|GL-0719|Administration route: intravenous infusion and subcutaneous injection
214323184|NCT02659020|DRUG|Placebo|Administered IV
215065316|NCT05318534|DRUG|Placebo|Administration route: intravenous infusion and subcutaneous injection
215065317|NCT06375421|BEHAVIORAL|MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval|Participants complete their initial learning session, and the subsequent retrieval sessions are spaced out over the course of the week (two short retrieval sessions each day) using MEMI. Then, they complete a 15-minute test for their memory of all of the trained items at the end of the week.
215065318|NCT06375421|BEHAVIORAL|Blocked Retrieval|Participants will complete their initial learning session on the target words, then immediately receive all of the exposures to each of the items in a single block. They do not complete any more retrieval sessions until one week later, when they complete a 15-minute test for their memory of all of the trained items.
215065319|NCT04161092|PROCEDURE|Liver transplantation Ltx|Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.
214672547|NCT02770287|DEVICE|Venus Freeze Diamond Polar|The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system that combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
214323185|NCT03950518|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules, 12mg/d
214323186|NCT03950518|DRUG|Arginine hydrochloride|AHC,12mg/d AH,40g/d
214323187|NCT03950518|DRUG|levamisole|AHC,12mg/d AH,40mg/d LM,150mg/d
214922888|NCT02370628|PROCEDURE|Percutaneous vertebroplasty|"The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.~In our trial, vertebroplasty shall be performed in two steps:~* Step 1: facet block~* Step 2: cement infusion~Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention."
214922889|NCT02370628|PROCEDURE|Facet block|"A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty."
214922890|NCT04026828|GENETIC|Periodontitis Group|Periodontitis group consists of both chronic and aggressive periodontitis patients
214922891|NCT04767997|DIETARY_SUPPLEMENT|Probiotic formulation|Participants will be asked to take one capsule daily, containing 3 billion CFU of the probiotics.
214922892|NCT04767997|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take a placebo capsule daily.
215065320|NCT04161092|OTHER|Best alternative care|All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
215065321|NCT05926544|BEHAVIORAL|Standard implementation webinar and online training|"The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, booster eligibility, mechanisms of action, and outcomes.~The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients."
215065322|NCT05926544|BEHAVIORAL|Virtual facilitation|This intervention involves a 30-minute virtual facilitation site visit and 8 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
215065323|NCT05006937|PROCEDURE|Dusting|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
214323188|NCT03164967|BIOLOGICAL|Bivigam|
214323189|NCT06406530|PROCEDURE|PRF|Patients blood is standardized centrifuged and split in to a red-phase (erythrocytes) and white-phase (PRF). The gained PRF is processed to a clot-fort and is inserted into the alveolus.
214323190|NCT06406530|PROCEDURE|Natural Healing|After the tooth extraction, natural healing is aimed by allowing a blood clot formation without any further intervention.
214922893|NCT05407870|DRUG|Etomidate Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
214922894|NCT05407870|DRUG|Propofol Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
214485731|NCT04876339|OTHER|Standard gait rehabilitation (without sonification)|"The training will be carried out without any musical support. Exercises I Phase~1. Load shift in anteroposterior standing in tandem position, left foot forward (3 minutes exercise with a short break in the middle)~2. Load shift in anteroposterior standing in tandem position, right foot forward (3 minutes exercise with a short break in the middle)~3. Left foot swing (3 minutes exercise with a short break in the middle)~4. Right foot swing (3 minutes exercise with a short break in the middle)~5. March in place (3 minutes exercise with a short break in the middle) Exercises II phase (15 minutes): the patient will perform 14 minutes of walking with a 1 minute of break in the middle (7 minutes of walking, 1 minute rest, 7 minutes of walking). In the second part of walking the patient will be asked to slightly increase the pace of the step up to the maximum possible speed."
214485732|NCT04791943|DRUG|Melatonin 10 MG|3 melatonin 10mg capsules will be given to the treatment arm
214485733|NCT04791943|DRUG|Lactose pill|3 lactose pills will be provided to the control arm
214672548|NCT02162875|DRUG|Praziquantel|Six different treatment strategies with praziquantel
214922895|NCT03138031|PROCEDURE|Percutaneous ethanol alcohol injection|"Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of 8 limits the procedure. Post-procedure analgesia may be required."
214922896|NCT05481125|DEVICE|Clareon IOL|Alcon Clareon Aspheric Hydrophobic Acrylic IOL for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
214922897|NCT05481125|DEVICE|Clareon Toric IOL|Clareon Toric Aspheric Hydrophobic Acrylic Toric IOL for the visual correction of aphakia with pre-existing corneal astigmatism in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
214485734|NCT06103201|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
214485735|NCT06463951|OTHER|Psychotherapy - Gestalt psychotherapy|Gestalt psychotherapy is an aesthetic-phenomenological approach that aims to improve self-awareness and integration by promoting emotional and relational well-being through what is happening in the present moment in the relationship with the therapist. The patient's current experiences are explored to better understand problems and behaviors and by promoting relational self-regulation
214922898|NCT05481125|DEVICE|Eyhance IOL|TECNIS Eyhance IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
214922899|NCT05481125|DEVICE|Eyhance Toric IOL|TECNIS Eyhance Toric II IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire reduction in residual refractive cylinder. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
214922900|NCT05481125|PROCEDURE|Phacoemulsification surgery|Cataract removal by routine small incision phacoemulsification surgery
214922901|NCT06683963|DEVICE|Rebee|Tablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge
215065324|NCT05006937|PROCEDURE|Basket extraction|Basket extraction is when a small wire basket is used to remove stone fragments.
215065325|NCT05722197|BEHAVIORAL|Crisis Response Planning and Lethal Means Safety Counseling|Crisis Response Planning is an efficacious, one-session intervention that increases positive affect, decreases negative affect and psychiatric hospitalizations, and reduces suicide attempts by 76% among Servicemembers
215065326|NCT00686985|DRUG|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
215065327|NCT01477710|PROCEDURE|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
215065328|NCT01477710|PROCEDURE|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
215065329|NCT01477710|PROCEDURE|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
215065330|NCT06069362|OTHER|Manual physiotherapy and neurodynamic exercises|"* Cervical passive mobilisation techniques and techniques of the anatomical structures surrounding the nerve. These techniques aim to open the nerve root foramen. They are gentle traction techniques and contralateral lateral glide mobilisation techniques. Interface techniques for scalenes will also be included.~* Home exercises for cervical mobility and neurodynamic sliders of the upper extremity: Patients will be taught progressive upper extremity neurodynamic sliders, starting with gentle movement and progressing to exercises involving more movement based on the patient's irritability."
215065331|NCT00516893|BIOLOGICAL|BG00002-E (natalizumab high titer)|
215065332|NCT00284557|BEHAVIORAL|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
215065333|NCT03563742|DRUG|Rilpivirine 25 mg|Participants will receive rilpivirine 25 mg tablet orally once daily.
215065334|NCT03563742|DRUG|Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)|Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
215065335|NCT03451981|PROCEDURE|mechanical instrumentation|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments (titanium curettes) and the implant surface will be cleaned
214922902|NCT03879525|OTHER|EMR-based-interventional method|Questionnaire delivery method. Participants will complete standard care anxiety and depression screening and quality of life assessment directly into the patient entered section of the EMR, administered on arrival in the clinic.
214922903|NCT03879525|OTHER|Telephone-based-standard method|Questionnaires delivered via phone. Participants will complete standard care anxiety and depression screening and quality of life assessment via phone. Standard delivery method.
214922904|NCT02244463|DRUG|MLN0128|
214922905|NCT05017896|DIAGNOSTIC_TEST|Normal CT Renal Perfusion imaging indexes|A CT imaging which indicates the status of renal perfusion is normal.
215065336|NCT03451981|PROCEDURE|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments (titanium curettes) and the implant surface will be cleaned. Furthermore, Er:YAG laser treatment will be provided on the implant surface.
214922906|NCT05017896|DIAGNOSTIC_TEST|Low CT Renal Perfusion imaging indexes|A CT imaging which indicates the status of renal perfusion is low.
214922907|NCT06439381|DRUG|300mg/600mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
214922908|NCT03055481|OTHER|High irradiance level of phototherapy|High irradiance level of phototherapy: the target irradiance level is 30-35uW per square centimeter per nanometer of wavelength.
214922909|NCT03055481|OTHER|Low irradiance level of phototherapy|Low irradiance level of phototherapy: the target irradiance level is 12-15uW per square centimeter per nanometer of wavelength
214922910|NCT01769508|DRUG|5-Fluorouracil|5-FU, 225 mg/m2 IVCI, during XRT.
214922911|NCT01769508|DRUG|Oxaliplatin|Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
214922912|NCT01769508|DRUG|Lapatinib|Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
214922913|NCT01769508|RADIATION|Radiation Therapy|Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
215065337|NCT03451981|PROCEDURE|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments (titanium curettes) and the implant surface will be cleaned. Furthermore, an Air-Powder treatment will be provided on the implant surface.
214323191|NCT04126512|OTHER|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
214323192|NCT05996120|PROCEDURE|Hypothermic Cardiopulmonary Bypass|Mild hypothermia (between 32 - 35 °C) during cardiopulmonary bypass
214323193|NCT05996120|PROCEDURE|Normothermic Cardiopulmonary Bypass|Normothermia (active maintenance of temperature between 36.5 °C to 37.5°C; no active cooling below 36.5 °C) during cardiopulmonary bypass
214323194|NCT05950568|PROCEDURE|Quadratus lumborum block typen II|A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer
214323195|NCT05950568|PROCEDURE|Quadratus lumborum block III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
214323196|NCT05950568|PROCEDURE|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
214323197|NCT04059848|COMBINATION_PRODUCT|tDCS(Intelect Mobile Stimulation and Combination, DJO, France)|
214323198|NCT04059848|COMBINATION_PRODUCT|NMES(Enraf Nonius, Endomed-182, Netherlands)|
214323199|NCT06218043|BEHAVIORAL|Restrict subjects' intake of iodine-containing foods|Replace subjects' iodized salt with non-iodized salt.
214323200|NCT01794104|DRUG|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
214323201|NCT02583581|DEVICE|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
214323202|NCT02583581|DEVICE|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
214323203|NCT00482755|DRUG|sunitinib malate|
214323204|NCT00482755|OTHER|immunohistochemistry staining method|
214323205|NCT00482755|OTHER|laboratory biomarker analysis|
214323206|NCT00482755|OTHER|pharmacological study|
214323207|NCT00482755|PROCEDURE|needle biopsy|
214323208|NCT00482755|PROCEDURE|neoadjuvant therapy|
214323209|NCT02703571|DRUG|ribociclib|Combination treatment with LEE and TMT
214323210|NCT02703571|DRUG|Trametinib|Combination treatment with LEE and TMT
214323211|NCT06423235|DRUG|regular dose of JiRui® Prunella oral liquid|Take 10ml twice a day
214323212|NCT06423235|DRUG|2x regular dose of JiRui® Prunella oral liquid|Take 20ml twice a day
214323213|NCT06423235|DRUG|regular dose of placebo|Take 10ml twice a day
214323214|NCT06423235|DRUG|2x regular dose of placebo|Take 20ml twice a day
214323215|NCT01067404|BIOLOGICAL|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
214323216|NCT01585766|DRUG|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
214323217|NCT01585766|DRUG|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
214922914|NCT06685458|OTHER|Preoperative Clinical and Imaging Feature Evaluation for Predictive Modeling|This study involves preoperative evaluation of clinical and imaging features for constructing a predictive model to differentiate benign and malignant solid pulmonary nodules. Surgical resection is performed to obtain pathological confirmation as the reference standard.
215065338|NCT06472141|OTHER|Cervical stabilization exercises|Cervical Stabilization Exercises will be performed 3 days a week for 8 weeks.
214672549|NCT02666911|PROCEDURE|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
215065339|NCT06472141|OTHER|Standard treatment (Education + home exercises)|Individuals will be informed about TMJ disorders, parafunctional activities (chewing gum, nail/pen biting, etc.) and recommendations. In addition, Rocabado exercises will be given as a home program.
214672550|NCT02666911|PROCEDURE|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
214672551|NCT01677611|DRUG|Trans-resveratrol extract from Polygonum Cuspidatum|Starting dose of 500 mg daily of either resveratrol to be administered on Day 1 and increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
214672552|NCT01677611|DRUG|Placebo|
214672553|NCT04988126|OTHER|Interventions|Observational study, not applicable
214672554|NCT06283095|PROCEDURE|expansion palatoplasty|surgical procedure
214922915|NCT03804424|DRUG|64Cu-LLP2A|-64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
214922916|NCT03804424|DEVICE|PET/MR|-All PET imaging will be performed as PET/MR or PET/CT
214922917|NCT03804424|PROCEDURE|Blood samples for serum stability|-3 venous samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (2 mL each) will be obtained at the following time points: Cohort 1: prior to injection, at completion of dynamic scanning in those who undergo dynamic imaging and at completion of one of the body imaging time points. In those who do not undergo dynamic imaging, prior to injection, and after completing body imaging at 2 of the 3 time points. Cohort 2: subjects will have samples drawn prior to injection, at completion of dynamic scanning, and at completion of body imaging.
214922918|NCT03804424|PROCEDURE|Blood samples for metabolite analysis|-Typically, 2 blood samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (preferably 1 within the first 5 min and 1 at the completion of the first hour of imaging) will be obtained.
214922919|NCT03804424|PROCEDURE|Urine sample|-Cohort 1 only
214922920|NCT03804424|PROCEDURE|Tumor biopsy|-Cohort 2 only and only if there hasn't been a recent biopsy of disease
214672555|NCT02231216|PROCEDURE|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
214922921|NCT03804424|PROCEDURE|Electrocardiogram|-A standard 12-lead ECG will be obtained on all subjects at baseline (within 30 mins prior to injection of 64Cu-LLP2A), and at least 60 minutes post injection or prior to study discharge
215065340|NCT06087991|BEHAVIORAL|Implementation of the BINDeR-Tx service model|ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.
214672556|NCT02231216|PROCEDURE|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
214672557|NCT02231216|PROCEDURE|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
214672558|NCT03635190|DEVICE|Orbital Circumferential Atherectomy|Remove atherosclerotic plaque and modify vessel wall compliance within peripheral arterial vessels. The therapy is intended for patients who are acceptable candidates for percutaneous transluminal atherectomy.
214672559|NCT00970203|BIOLOGICAL|androgen ablation (AA)|Lupron 22.5 mg or Zoladex 10.8 mg
214672560|NCT00970203|BIOLOGICAL|DC1 vaccine|3-5 x 10e6 cells total
214922922|NCT03804424|DEVICE|PET/CT|-All PET imaging will be performed as PET/MR or PET/CT
214922923|NCT02940418|BIOLOGICAL|Adipose mesenchymal cells with bone marrow mononuclear cells|Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.
214922924|NCT01298869|BIOLOGICAL|HPV-6/11/16/18 vaccine|HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
215065344|NCT06519773|PROCEDURE|Modified periosteal inhibition|"After local anathesia, a traumatic extraction of the hopeless tooth will be made trying as much as possible to preserve the labial plate of bone and overlying soft tissue.~* Once the tooth is extracted, the socket is gently debrided and irrigated using sterile saline solution. Then the dental implant is placed in the best prosthetic driven position, following the guidelines for immediate implants using prefabricated computer guided surgical template.~* After accurate implant placement, a full-thickness flap will be elevated at mesial and distal papilla making a buccal envelope. A soft bone lamina will be trimmed and hydrated in sterile saline solution for 30 s to soften it; it should be 1-2 mm larger and deeper than the vestibular bone. Then the jumping gap between the dental implant and the buccal plate of bone will be filled using either collagen sponge or xenograft."
215065345|NCT05887492|DRUG|TNG260|CoREST inhibitor, administered orally
215065346|NCT05887492|DRUG|Pembrolizumab|Pembrolizumab, an anti-PD-1 antibody, administered intravenously
215065347|NCT05765604|BIOLOGICAL|Recombinant COVID-19 variant vaccine(Sf9 cell)|IM
215065348|NCT05765604|BIOLOGICAL|Recombinant COVID-19 vaccine(CHO cell)|IM
215065349|NCT05532722|DRUG|ABC008|Given subcutaneous injection
215065350|NCT05935878|DEVICE|Cementless Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth. The cementless femoral component also has a smaller second peg, located anteriorly to the larger central peg that is also present of the cemented femoral component.
215065351|NCT05935878|DEVICE|Cemented Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. All cemented components will be secured using the same cement.
215065352|NCT06523010|OTHER|Talocrural Joint Manipulation|This technique, aiming to increase ankle dorsiflexion and mechanoreceptor activation, is based on the application of high velocity low amplitude traction to the joint.
215065353|NCT06523010|OTHER|Placebo Talocrural Joint Manipulation|This intervention is a classic method used to evaluate the effect of talocrural joint manipulation.
215065354|NCT04812028|DRUG|Magnesium sulfate|Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
214922925|NCT06068881|DRUG|Tazverik (Tazemetostat)|Oral Tablet
214922926|NCT00595738|OTHER|Standard of care therapy for severe decompensated heart failure|Standard of care therapy for severe decompensated heart failure
214922927|NCT03615144|DRUG|Melphalan|Melphalan 70 mg/m2/day x 2
214922928|NCT03615144|DRUG|Thiotepa|Thiotepa 7.5 mg/kg/day x 2
214922929|NCT03615144|DRUG|Clofarabine|Clofarabine 20-30 mg/m2/day x 5
215065355|NCT02975167|OTHER|Outpatient Cervical Ripening|The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
214922930|NCT03615144|DRUG|Fludarabine|Fludarabine 30 mg/m2/day x 5
215065356|NCT02975167|OTHER|Inpatient Cervical Ripening|Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
215065357|NCT02975167|PROCEDURE|Foley catheter placement|Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
214922931|NCT03615144|DRUG|Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)|antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
214922932|NCT03615144|PROCEDURE|CliniMACS reagents|Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
215065358|NCT02975167|BEHAVIORAL|Pre-Foley Questionnaire|Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
215065359|NCT02975167|BEHAVIORAL|Post-Foley Questionnaire|Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
215065360|NCT02975167|PROCEDURE|Fetal Non-Stress Test|Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
215065361|NCT03350126|DRUG|Ipilimumab 200 MG in 40 ML Injection|"Induction therapy (12 weeks):~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W"
215065362|NCT03350126|DRUG|Nivolumab 10 MG/ML|"Induction therapy (12 weeks) :~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W~Maintenance therapy (40 weeks):~Nivolumab monotherapy IV over 60 minutes Q2W until iRECIST progression or if no PD for one year."
215065363|NCT01443364|BIOLOGICAL|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
215065364|NCT00559845|DRUG|5-fluorouracil|600 milligrams per meter squared (mg/m\^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
214323218|NCT01585766|DRUG|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
214323219|NCT01585766|DRUG|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
215065365|NCT00559845|DRUG|Epidoxorubicin|90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
215065366|NCT00559845|DRUG|Cyclophosphamide|600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
214922933|NCT06665750|BEHAVIORAL|Exercise|A progressive upper extremity neuromuscular exercise program was performed face to face with the researcher physiotherapist for the study group. The exercise program was applied for approximately 20 minutes, 2 days a week for 6 weeks, on the same days of the week, before the participants' tennis training. The exercise content and number of repetitions in the training program changed every 2 weeks with increasing difficulty.
215065367|NCT00559845|DRUG|Paclitaxel|Paclitaxel was administered at 80 mg/m\^2 i.v. over 1 hour weekly for 12 weeks.
215065368|NCT00559845|BIOLOGICAL|Bevacizumab|Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
215065369|NCT04904276|DRUG|Fostamatinib|Fostamatinib disodium
215065370|NCT06513546|DRUG|PLL001 or placebo daily subcutaneous injections|PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)
215065371|NCT00335283|DRUG|Lansoprazole Tablet|40 mg bid x 16 weeks
215065372|NCT00335283|PROCEDURE|PH and impedence testing|24 hour ph monitoring
215065373|NCT00335283|PROCEDURE|manometry|done prior to pH probe to measure length of esophagus
215065374|NCT00335283|DRUG|lansoprazole|40mg bid
215065375|NCT00335283|DRUG|placebo|one tablet bid
215065376|NCT03536481|DRUG|ensartinib capsules (test product)|Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
215065377|NCT03536481|DRUG|ensartinib capsules (reference product)|Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
215065378|NCT03203577|PROCEDURE|Initiation of mechanical ventilation|In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
215065379|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
215065380|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
215065381|NCT02290782|RADIATION|Intraoperative radiotherapy (IORT)|"The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.~To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm."
215065382|NCT01406938|DRUG|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
215065383|NCT01406938|DRUG|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
214323220|NCT01585766|DRUG|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
214323221|NCT01585766|DRUG|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
214323222|NCT04347304|DIETARY_SUPPLEMENT|Dark chocolate (20 grams) per day providing 508 mg of polyphenols|subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
214323223|NCT04347304|DIETARY_SUPPLEMENT|white chocolate (20 grams) with no polyphenols|subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
214323224|NCT01072695|DRUG|GS-9256|75 mg BID x 28 days
214323225|NCT01072695|DRUG|GS-9190|40 mg BID x 28 days
214323226|NCT01072695|DRUG|Ribavirin|1000-1200 mg/day given BID
214323227|NCT01072695|DRUG|Peginterferon alfa-2a|180 ug q week
214922934|NCT04791319|DRUG|Placebo|Placebo will be administered subcutaneously.
214922935|NCT04791319|DRUG|Bermekimab|Bermekimab will be administered subcutaneously.
214922936|NCT04791319|DRUG|Dupilumab|Dupilumab will be administered subcutaneously.
215065384|NCT00000805|DRUG|Ganciclovir|
215065385|NCT03230890|DEVICE|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
214672561|NCT06673225|OTHER|Analysis of results|Analysis of previous imaging and/or laboratory tests, vital signs, body composition, pulmonary function, peripheral muscle strength, calf circumference, nutritional risk, quality of life, frailty level, and anxiety and depression. Screening for respiratory diseases, including chronic obstructive pulmonary disease (COPD), lung cancer, tuberculosis, and other lung lesions, is based on spirometry and thoracic radiological images after the health professional's examination. After the multiprofessional procedures, patients will be evaluated by a physician to start specific treatment and/or perform complementary exams if necessary. Every year, they will be re-evaluated to record acute exacerbations of chronic respiratory diseases and assess disease progression through spirometry and thoracic radiological images.
214672562|NCT00147108|DEVICE|ExAblate 2000|
214672563|NCT00842517|BEHAVIORAL|Contingency Management|
214672564|NCT00056212|BEHAVIORAL|Yoga|
214672565|NCT00056212|BEHAVIORAL|Exercise|
214672566|NCT00631722|DRUG|Quatiapine Fumarate|600-750mg/day
214672567|NCT00631722|DRUG|Haloperidol|12-20mg/day
214672568|NCT03692910|DRUG|SAGE-217|SAGE-217 capsule
214672569|NCT03692910|DRUG|Placebo|SAGE-217 matching placebo capsule
214922937|NCT06668337|DRUG|Normal Saline (Placebo)|Participants in the control group receive a continuous intravenous infusion of normal saline, which serves as an inert placebo with no pharmacological effect. This intervention mimics the administration of the active treatments, allowing for direct comparison with the ephedrine groups to assess the effectiveness of the drug in preventing maternal hypotension during spinal anesthesia.
215065386|NCT03778749|DIAGNOSTIC_TEST|TOF measurements|The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
214323228|NCT02827058|DEVICE|G25 pencil point needle|
214323229|NCT02827058|DEVICE|G27 pencil point needle|
214323230|NCT02273648|DEVICE|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
214323231|NCT04569500|OTHER|PETAL program|patients and their close relations will benefit from the therapeutic education program PETAL in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.
214323232|NCT03065556|DRUG|188-0551 Solution|Topical solution containing active drug
214323233|NCT03065556|DRUG|Vehicle Solution|Topical solution containing no active drug
214323234|NCT00203749|BEHAVIORAL|Community-Based HIV VCT|"COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.~EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.~POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission."
214323235|NCT00203749|BEHAVIORAL|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
214323236|NCT03187405|DRUG|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
214323237|NCT01120210|DRUG|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
214323238|NCT01120210|DRUG|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
214323239|NCT01120210|DRUG|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
214323240|NCT01120210|DRUG|Placebo|1-hour infusion of matching placebo on Day 1
214485736|NCT06251050|DRUG|lithium-containing mouthwash|The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.30 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
214485737|NCT06251050|DRUG|Plcacebo mouthwash|Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
214922938|NCT06668337|DRUG|Ephedrine|The interventions in this study include a control group receiving normal saline, which serves as an inert placebo to assess the effectiveness of the active treatments. Participants in Group B receive an ephedrine infusion at 1.25 mg/min, while those in Group C receive a higher dosage of 1.5 mg/min. This design allows for direct comparison of the two dosages of ephedrine against the control, enabling evaluation of their effectiveness in preventing maternal hypotension following spinal anesthesia during cesarean sections.
214922939|NCT06668337|DRUG|Ephedrine|The interventions in this study include a control group receiving normal saline, which serves as an inert placebo to assess the effectiveness of the active treatments. Participants in Group B receive an ephedrine infusion at 1.25 mg/min, while those in Group C receive a higher dosage of 1.5 mg/min. This design allows for direct comparison of the two dosages of ephedrine against the control, enabling evaluation of their effectiveness in preventing maternal hypotension following spinal anesthesia during cesarean sections.
214323241|NCT01120210|DRUG|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
214323242|NCT05703061|BEHAVIORAL|10-hour Time in Bed|Participants will be asked to increase their time in bed to 10-hours per night for 7 consecutive days.
215065387|NCT02156206|BEHAVIORAL|123 women emergency phone line in Medellin, Colombia|"123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday."
215065388|NCT04182477|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Neuro-cognitive test evaluating general mental status and performance
215065389|NCT05733234|DEVICE|Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia|Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface
215065390|NCT05733234|DRUG|Mechanical Treatment|Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
215065391|NCT00878254|BIOLOGICAL|G-CSF|Granulocyte-colony stimulating factor (G-CSF) 480 mcg subcutaneously starting on Day 13 of Cycles 1 and 3; and Day 7 of Cycles 2 and 4.
215065392|NCT00878254|DRUG|Rituximab|Rituximab 375 mg/m\^2 intravenously (IV) on Day 1 for 4 Cycles during induction therapy. Participants achieving complete remission will then receive Rituximab maintenance therapy every 6 months for up to three years.
215065393|NCT00878254|DRUG|Cyclophosphamide|Cyclophosphamide 800 mg/m\^2 IV on Day 1 and 200 mg/m\^2 IV on Days 2 through 5 of Cycles 1 and 3.
215065394|NCT00878254|DRUG|Cytarabine|Cytarabine (AraC) 2 grams/m\^2 IV on Days 1 and 2 of Cycles 2 and 4.
215065395|NCT00878254|DRUG|Doxorubicin|Doxorubicin 45 mg/m\^2 IV bolus on Day 1 of Cycles 1 and 3.
215065396|NCT00878254|DRUG|Etoposide|Etoposide (VP16) 60 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4.
215065397|NCT00878254|DRUG|Ifosfamide|Ifosfamide 1.5 grams/m\^2 IV on Days 1 through 5 of Cycles 2 and 4.
215065398|NCT00878254|DRUG|Leucovorin|Leucovorin 100 mg/m\^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m\^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is \< 0.1 µmol/L during Cycles 1 and 3.
214922940|NCT02358109|BEHAVIORAL|exercise|The exercise intervention will be performed in groups of 20 participants which will train 3 days/week (60 min per session) for a 16-week period. Sessions will be designed and carefully supervised by exercise monitors, including a 15 minute warm-up period followed by 35 minute focused on aerobic exercises, developed progressively at intensity sufficient to achieve 50% (at the beginning of the intervention) and 80% (the last month of the intervention) of predicted maximum heart rate (209-0.73 × age) and resistance strength training.Monday sessions will involve resistance strength exercises. Wednesday sessions will include balance oriented activities and dancing aerobic exercises. Fridays will include aerobic, resistance strength and coordination using a circuit of different exercises.Sessions finish with a 10 minute cool-down period of stretching and relaxation exercises.
215065399|NCT00878254|DRUG|Mesna|Mesna 360 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4.
215065400|NCT00878254|DRUG|Methotrexate|Methotrexate (MTX) 1,200 mg/m\^2 in 250 mL with Dextrose 5% in water (D5W) IV over 1 hour, followed by Methotrexate 3,000 mg/m\^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3.
215065401|NCT00878254|DRUG|Vincristine|Vincristine 1.5 mg/m\^2 IV push (maximum of 2 mg) on Days 1 and 8 of Cycles 1 and 3.
215065402|NCT04819087|BEHAVIORAL|Questionnaires and Rehabilitation Programs|Questionnaires and Rehabilitation Programs
214323243|NCT04784767|BIOLOGICAL|25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN\_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
214323244|NCT04784767|DRUG|Sodium chloride, USP, for injection (0.9% NaCl)|Normal saline will be provided in a sterile, single-use 10 mL vial
215065403|NCT06837077|DRUG|SHR-1209 single-site subcutaneous injection|SHR-1209 single-site subcutaneous injection.
214323245|NCT04784767|BIOLOGICAL|50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN\_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
214323246|NCT02043015|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
214922941|NCT04548115|BEHAVIORAL|ARTISAN Condition|Youth and senior participants will be randomly paired and engage in the 5-weekly, 3-hour ARTISAN intervention as dyads (totaling 15 hours of intervention). In the first four weeks of the ARTISAN, dyads will engage in themed museum tours facilitated by a docent (45min), guided storytelling (45 min) and professionally-led art-making (45 min). The remaining time (45 min) is allocated for session breaks, session introduction/closing, and buffer time for movement around the gallery. The final week involves an exhibition where participants share their artworks with the public and reflect on their experiences and artworks. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
214922942|NCT04548115|BEHAVIORAL|Intergenerational Participatory Arts Condition|Youths and senior participants in this condition will be randomly paired and engage in a 5-weekly 45-minute group-based art activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). A professional artist or art therapist will facilitate art-making sessions with the participants in a community space, utilizing the same mediums that were used in ARTISAN. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
214922943|NCT04548115|BEHAVIORAL|Intergenerational Art-space Condition|Youths and senior participants in this condition will engage in a 5-weekly 45-minute group-based curated museum tour that follow the ARTISAN themes with 15 minutes of preparation/break time, and conducted by a trained docent at the National Museum Singapore (totaling 5 hours of intervention).The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
214922944|NCT04548115|BEHAVIORAL|Intergenerational Storytelling Condition|Youths and senior participants in this condition will be paired to engage in a 5-weekly 45 minute group-based storytelling activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). Storytelling sessions will be conducted by a trained facilitator, and conversation starters from ARTISAN intervention will be used. The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
214922945|NCT04548115|BEHAVIORAL|Control Condition|Participants in this condition will engage in a 5-weekly 45 minute group-based physical activity session conducted in the community with 15 minutes of preparation/break time (totaling 5 hours of intervention). Physical activity was selected over basic psychosocial care to test the effects of inter-generational contact independent of arts and heritage-based engagements.
214922946|NCT04049383|BIOLOGICAL|CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level -1: 5 x 10\^5 CAR-20/19-T cells/kg"
214922947|NCT04049383|BIOLOGICAL|CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 0: 1 x10\^6 CAR-20/19-T cells/kg (starting dose level)"
215065404|NCT06837077|DRUG|SHR-1209 multiple-site subcutaneous injections|SHR-1209 multiple-site subcutaneous injections.
215065405|NCT03879928|DRUG|Single ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
215065406|NCT03879928|DRUG|Multiple ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
215065407|NCT03879928|DRUG|Food effects of FM101|The study drug (FM101) will be administered orally under fasted condition and fed condition.
215065408|NCT05120895|DRUG|Mevalotin|Oral tablets (starting dose 5 mg)
215065409|NCT03086408|DEVICE|THRIVE|active nasal oxygen delivery system
215065410|NCT03086408|DEVICE|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
215065411|NCT03872778|DRUG|[177Lu]-NeoB|\[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion
215065412|NCT03872778|DRUG|[68Ga]-NeoB|\[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation
215065413|NCT03872778|DRUG|LCZ696|dose strength 49/51 mg, film-coated tablets for oral use
215065414|NCT00140296|BEHAVIORAL|Contraceptive counseling|
215065415|NCT02944708|DRUG|Conventional chemotherapy|
215065416|NCT02944708|DRUG|Maintenance chemotherapy 1|
215065417|NCT02944708|DRUG|Maintenance chemotherapy 2|
215065418|NCT01939522|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|
215065419|NCT05442723|PROCEDURE|On-Pump CABG|coronary artery grafting by using cardiopulmonary bypass machine
215065420|NCT05442723|PROCEDURE|Off-Pump CABG|coronary artery grafting by beating heart technique
215065421|NCT03367403|DRUG|Donanemab|Administered IV
215065422|NCT03367403|DRUG|Placebo|Administered IV
215065423|NCT03367403|DRUG|LY3202626|Administered orally
215065424|NCT00213941|DEVICE|Echocardiography|
215065425|NCT02934841|DRUG|Conbercept|
215065426|NCT02934841|DRUG|sham|
215065427|NCT00194077|DRUG|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
215065428|NCT00194077|DRUG|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
215065429|NCT03704844|OTHER|non applicable|non applicable
215065430|NCT04967287|DEVICE|MyopiaX|MyopiaX treatment twice a day
215065431|NCT04967287|DEVICE|Myopia control spectacles|To be used all as prescribed
215065432|NCT00985608|DRUG|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
215065433|NCT00985608|DRUG|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
215065434|NCT04928885|BEHAVIORAL|Wits Workout Program|12 week, one hour per week multi-modal, interactive training.
215065435|NCT04928885|OTHER|Control Group that receives intervention after the study|The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
215065436|NCT04607174|OTHER|Pathologic group|"Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb."
215065437|NCT06225518|BEHAVIORAL|Individualized physical activity management system|Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
215065438|NCT03470194|OTHER|Interpretation Modality: In Person|Use of In-Person interpretation support for LEP participant during clinical appointment
215065439|NCT03470194|OTHER|Interpretation Modality: Telephonic|Use of telephonic interpretation support for LEP participant during clinical appointment
215065440|NCT04305769|DRUG|Alanyl-glutamine|The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
214485738|NCT06251050|DRUG|lithium-containing mouthwash|Effective lithium salt concentrations screened in the Phase I trial is used as active interventions in this group of interventions. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
214922948|NCT04049383|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 1: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)"
214922949|NCT04049383|BIOLOGICAL|CAR-20/19-T cells|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~The dose expansion dose level is still to be determined and this section will be updated."
214922950|NCT04455477|DRUG|Nesiritide|The attending physicans decide whether to use Nesiritide for congestive heart failure patients. Only patients who will use Nesiritide are enrolled.
214922951|NCT02587598|DRUG|INCB053914|"Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth."
214922952|NCT02587598|DRUG|I-DAC (Intermediate dose cytarabine)|Cytarabine dose will be 1 g/m\^2. Cytarabine will be administered as an intravenous (IV) infusion.
214922953|NCT02587598|DRUG|Azacitidine|Azacitidine dose will be 75 mg/m\^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).
214922954|NCT02587598|DRUG|Ruxolitinib|Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.
214922955|NCT05326828|DEVICE|CONFIRM Rx implantable cardiac rhythm monitor (Abbott)|Implantation of CONFIRM Rx ICM
214922956|NCT05326828|DIAGNOSTIC_TEST|Systematic etiologic work-up for underlying causes of MINOCA|Intracoronary optical coherence tomography, cardiac magnetic resonance imaging, transesophageal echocardiography, vasospasm testing, thrombophilia screening, Holter ECG (only non-ICM group)
214922957|NCT00006471|DRUG|Fenretinide|1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
214485739|NCT06620952|PROCEDURE|O-ring technique|"O-ring technique. consists on a different arrangement of fibrin-glue on a polymethilmetacrylate cranioplasty, with the aim to create a gasket to prevent CSF leakage"
214485740|NCT06573424|COMBINATION_PRODUCT|Tislelizumab+anlotinib|Patients who have been treated with anlotinib + tislelizumabline
214485741|NCT06573424|DRUG|anlotinib|Patients who have been treated with anlotinib monotherapy
214922958|NCT05437861|BEHAVIORAL|Brief Intervention|A short conversation with the participant regarding their use of opioids will be conducted. During the conversation the participants potential drug dependency will be uncovered. Further the pros and cons of weaning of the medication will be explained and a new treatment plan will be proposed.
215065441|NCT04310436|BEHAVIORAL|Modifying saccades by looking down to naval.|Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
215065442|NCT04310436|BEHAVIORAL|Modifying saccades by looking in air.|Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
215065443|NCT03286543|DEVICE|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
215065444|NCT06264999|DEVICE|Journey II CR|Implantation of Journey II CR Crucite Retaining Knee
215065445|NCT06264999|DEVICE|Journey II XR|Implantation of Journey II XR Bi Cruciate Retaining Knee
214672570|NCT06252610|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~* 6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~* The catheter will be flushed with 0.9% saline solution;~* The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
214922959|NCT04912440|DEVICE|MSE-ERCP|No interventional study, MSE-ERCP performed within routine treatment, (approved indication of device)
214922960|NCT02764957|DIETARY_SUPPLEMENT|green coffee extract|
214922961|NCT02764957|DIETARY_SUPPLEMENT|placebo|
215065446|NCT06177262|BEHAVIORAL|cognitive behavioral therapy|Cognitive behavioral therapy for eating disorders.
215065447|NCT06289426|OTHER|Yoga|The yoga program will consist of body awareness, meditation, poses, breathing practices, relaxation, and positive affirmations in Sanskrit and English.
215065448|NCT00575107|OTHER|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
215065449|NCT00575107|OTHER|Exercise|Standard training of leg extension
215065450|NCT00758069|DRUG|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
215065451|NCT00758069|DRUG|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
215065452|NCT00758069|DRUG|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
215065453|NCT05778864|DRUG|LY3473329|Administered orally.
214922962|NCT03244631|PROCEDURE|Lumbar Plexus BLock|Peripheral nerve block
214922963|NCT03244631|PROCEDURE|Pericapsular injection|Injection around the area undergoing surgery
214922964|NCT04144582|DRUG|Sintilimab Combined With Docetaxel Monotherapy|Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
214922965|NCT04709692|DRUG|(+)-SJ000557733 (SJ733)|Anti-Malarial
214922966|NCT00623740|DRUG|hydrocortisone|Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
215065454|NCT04027283|DIETARY_SUPPLEMENT|Erythritol|50g erythritol dissolved in 300mL tap water
215065455|NCT04027283|DIETARY_SUPPLEMENT|Erythritol + lactisole|50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
215065456|NCT04027283|DIETARY_SUPPLEMENT|D-allulose|25g D-allulose dissolved in 300mL tap water
215065457|NCT04027283|DIETARY_SUPPLEMENT|D-allulose + lactisole|25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
214922967|NCT00623740|DRUG|placebo|intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
215065458|NCT04027283|DIETARY_SUPPLEMENT|Tap water|300mL tap water
214922968|NCT03253289|DRUG|Meclizine Oral Tablet|All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 28 (up to 35) days.
214922969|NCT00004465|DRUG|SYNSORB Pk|
214922970|NCT00004465|DRUG|Placebo|
215065459|NCT04027283|DIETARY_SUPPLEMENT|Tap water + lactisole|300mL tap water + lactisole (450ppm)
214323247|NCT02043015|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
214323248|NCT02043015|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
214323249|NCT02043015|DRUG|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
214485742|NCT05078879|DRUG|Empagliflozin|This is an open-label pilot study to evaluate the efficacy, safety, and tolerability of empagliflozin as a treatment for severe congenital neutropenia (SCN) in patients with glucose-6-phosphatase 3 (G6PC3) deficiency. Participants will be on a 12-month daily regimen of empagliflozin at a starting dose of 10 mg (phase A), which may be increased after 2 months to 25 mg (phase B). Evaluate the safety and efficacy of the biomarker response (the change in absolute neutrophil count \[ANC\] after one year of empagliflozin treatment relative to baseline ANC prior to drug treatment) in patients with G6PC3 deficiency.
214485743|NCT04430309|BEHAVIORAL|Baduanjin exercise program|The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
215065460|NCT00976287|PROCEDURE|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
215065461|NCT00976287|PROCEDURE|Conserved Therapy|Conserved Therapy
215065462|NCT00588237|DRUG|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
215065463|NCT04333979|OTHER|Drainage|Using drain after operation
215065464|NCT03712176|BEHAVIORAL|Lifestyle alteration|Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
215065465|NCT03309254|OTHER|High Glycemic Index|High Glycemic Index Food
215065466|NCT03309254|OTHER|Low Glycemic Index|Low Glycemic Index Food
215065467|NCT02160665|DRUG|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)
215065468|NCT02160665|DRUG|Vehicle|Vehicle of Test product (G \& W Laboratories, Inc.)
215065469|NCT02160665|DRUG|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
215065470|NCT04317521|DEVICE|Use of EKO Core and EKO Duo electronic stethoscopes|Listen to heart murmurs
215065471|NCT06134115|DIETARY_SUPPLEMENT|Lipocet® (food supplement)|1 sachet, 10 ml corresponding to 1500 mg of Cetylated fatty acids
215065472|NCT06134115|DIETARY_SUPPLEMENT|Lipocet Placebo|Lipocet Placebo matching to Lipocet
215065473|NCT02626429|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
215065474|NCT04494542|PROCEDURE|Sustained Low Efficiency Dialysis (SLED)|sustained low efficiency dialysis (SLED)
215065475|NCT04494542|PROCEDURE|Continuous Renal Replacement Therapy|Continuous Renal Replacement Therapy
215065476|NCT02428998|DIETARY_SUPPLEMENT|Korean Red Ginseng|
215065477|NCT02428998|DIETARY_SUPPLEMENT|Placebo|
215065478|NCT01469143|DRUG|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
215065479|NCT01469143|DRUG|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
215065480|NCT01228136|DRUG|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
215065481|NCT01228136|OTHER|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
215065482|NCT01241188|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
215065483|NCT01241188|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
215065484|NCT02342691|DRUG|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
215065485|NCT02342691|DRUG|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
215065486|NCT02931513|OTHER|Blood samples|
215065487|NCT02931513|DEVICE|Fibroscan|
215065488|NCT02931513|OTHER|Questionnaires|
215065489|NCT02931513|BIOLOGICAL|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
215065490|NCT05872542|DRUG|Silver Diamine Fluoride (SDF)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
214323250|NCT02043015|OTHER|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
214485744|NCT04430309|BEHAVIORAL|Brisk walking program|The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
214922971|NCT03636204|BIOLOGICAL|AL001|Active dose of AL001
214922972|NCT03636204|OTHER|Placebo|Saline solution administered as a single infusion as palcebo.
214922973|NCT03880968|DRUG|tapering or discontinuation of etanercept|Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).
214922974|NCT03407157|DIETARY_SUPPLEMENT|Probiotic supplementation|Participants will take two capsules daily of Urex Plus VCap-5 (each containing 2.5 billion CFUs of L. rhamnosus and L. reuteri) and one lozenge of Blis K12 (1 billion CFUs of streptococcus Salivarius)
214922975|NCT03407157|OTHER|Placebo|Participants will be asked to take 2 placebo capsules and 1 placebo lozenge daily from 25 weeks pregnancy
214922976|NCT06654830|PROCEDURE|RATT|Robotic-assisted thoracoscopic thymectomy (RATT) will be performed using Da Vinci Robotic Surgical Systems.
214922977|NCT06654830|PROCEDURE|VATT|Video-assisted thoracoscopic thymectomy (VATT) was performed using traditional thoracoscopic systems.
214922978|NCT06685666|OTHER|traditional warm-up method specific to handball|The traditional warm-up program specific to handball consists of 6 basic sections: static stretching, aerobic work, dynamic mobility exercises, passes and crosses, shooting on goal and shooting according to position, and lasts 17 minutes in total.
215065491|NCT05872542|OTHER|Glass Ionomer Restoration (GI)|Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.
215065492|NCT05872542|OTHER|Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
214323251|NCT02043015|BEHAVIORAL|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
214323252|NCT02043015|BEHAVIORAL|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
215065493|NCT04908865|DRUG|Belimumab|Belimumab will be administered.
215065494|NCT04908865|DRUG|Standard therapy|Standard therapy will be continued.
214323253|NCT05699070|DRUG|DWC202211 100mg|"DWC202211 for 5 days~Aspirin 100mg"
214323254|NCT05699070|DRUG|DWC202212 5mg|"DWC202212 for 3 days~Rabeprazole 5mg"
214323255|NCT05699070|DRUG|DWC202211 100mg + DWC202212 5mg|"DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg"
215065495|NCT03764566|BEHAVIORAL|Questionnaires|The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
215065496|NCT01380197|DRUG|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
215065497|NCT01380197|DRUG|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
215065498|NCT01003236|DRUG|placebo|140 mg placebo tablets, 3 times per day for 3 months
215065499|NCT01003236|DRUG|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
215065500|NCT03926741|DRUG|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
215065501|NCT00949923|DIETARY_SUPPLEMENT|tea capsule|3 tea capsules daily for 3 weeks
215065502|NCT03915574|DEVICE|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
215065503|NCT03915574|DEVICE|Standard Epidural|Control group - standard epidural (no dural puncture)
215065504|NCT05722938|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
215065505|NCT05722938|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
214323256|NCT04787939|BEHAVIORAL|Early Feeding|Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
215065506|NCT06643377|DRUG|Enlicitide|Oral tablet
215065507|NCT03663504|OTHER|No Preparation|No preparation before surgery
215065508|NCT03663504|DRUG|Neomycin and Flagyl|Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
215065509|NCT05340712|DIETARY_SUPPLEMENT|new infant formula|New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.
215065510|NCT05340712|DIETARY_SUPPLEMENT|Standard formula|Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
215065511|NCT01357538|DRUG|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
215065512|NCT01357538|DRUG|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
214485745|NCT05281744|BEHAVIORAL|Dementia Care Consultation program|The Dementia Care Consultation program uses a telephone-based intervention to provide an in-depth, personalized service for individuals living with ADRD and their care partners. It consists of comprehensive needs assessments, creation and implementation of personalized care plans, monitoring and revising care plans, disease education and support coaching, referrals to community-based organizations for service and support, and access to assistance.
214323257|NCT04512911|PROCEDURE|Endocardial ablation|Endocardial ablation of VT
215065513|NCT03249909|DEVICE|Exufiber Ag+|gelling fibre dressing with silver
214323258|NCT04512911|PROCEDURE|Endocardial- Epicardial ablation|Epicardial ablation of VT in addition to endocardial ablation
214323259|NCT04512911|DRUG|Antiarrhythmic medications|Addition of anti arrhythmic medication or dose increase
214323260|NCT06205849|DRUG|IRE + intratumoral mitazalimab (CD40 antibody) injection|Surgical IRE will be performed using the NanoKnife System with intraoperative ultrasound guidance via laparotomy under general anesthesia. Mitazalimab (CD40 antibody) will be administered 5 minutes after completion of IRE by slow injection into the center of the ablated zone using a small needle. Core needle biopsies of the tumor will be obtained immediately prior to IRE for identification of candidate tumor antigens. Peripheral blood will be obtained immediately prior to and 12 weeks after the study intervention for analysis of systemic immune effects.
214323261|NCT06205849|DEVICE|NanoKnife|Non-thermal tumor ablation using short pulses of high voltage electrical current delivered using 19-gauge needles placed via laparotomy using ultrasound guidance
215065514|NCT03249909|DEVICE|Exufiber|gelling fibre without silver
214323262|NCT06165354|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 20 mL-bottle.
214485746|NCT06099548|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
215065515|NCT03249909|DEVICE|Aquacel Ag Extra|gelling fibre with silver
215065516|NCT00606034|DRUG|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
215065517|NCT03542656|DRUG|amyloid PET|Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
215065518|NCT03116802|DRUG|Stamaril (live attenuated yellow fever vaccine)|They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
215065519|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
215065520|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
215065521|NCT00946608|DRUG|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
215065522|NCT02227082|RADIATION|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
215065523|NCT02227082|DRUG|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
215065524|NCT02078180|DRUG|generic bupropion|We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
214922979|NCT06685666|OTHER|elastic band exercises added to the traditional warm-up|The experimental group will be given elastic band exercises for 6 weeks after the static and dynamic exercises in the traditional warm-up and then continue with the warm-up with the ball. The exercise program was planned progressively. The exercises will be done in the first 3 weeks, 2 sets of 10 repetitions with a light resistance band. Then the exercises will be done in 3 sets of 10 repetitions with a medium resistance band. There are 8 band exercises in total.This exercise; Flexion and Extension Exercise in Diagonal Pattern, Internal and external rotation with the arm next to the body and the elbow in 90 degrees flexion, Internal and external rotation with the arm in 90 degrees abduction and the elbow in 90 degrees flexion, Scaption Exercise, Rowing, Biceps and Triceps (elbow flexion and extansion exercise), Wrist Flexors and Extensors (wrist flexion and extansion exercise).
214485747|NCT01248624|BEHAVIORAL|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
214485748|NCT03984318|PROCEDURE|Blood sample|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
214485749|NCT05492201|DRUG|LY3873862|Administered orally.
214485750|NCT05492201|DRUG|Placebo|Administered orally.
214485751|NCT05641207|DEVICE|RheOx™ with the RheOx™ Catheter treated in the trial|"Eligible patients be assigned two sessions of RheOx bronchial rheoplasty procedures~* Treatment 1 is for the treatment of right lung~* Treatment 2 is scheduled one month apart for left lung"
214922980|NCT05526846|BEHAVIORAL|Plant-based diet education|"Participants will receive weekly emails with information about plant-based diets and a goal/task for each week.~There will be a 'core curriculum' that will be sent to all participants, as well as additional information according to the participant's stage of change and food choice preferences.~All information will be available on a website that will be created for this study. The website will feature curated information about plant-based diets, that is tailored to patients who had recent colorectal operations and may have a colostomy or an ileostomy."
215065525|NCT00820859|BEHAVIORAL|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
214485752|NCT06265506|BEHAVIORAL|Contingency Management|Contingency Management (CM) is an intervention that uses positive reinforcement (e.g. gift cards) to reinforce a desired behavior (e.g. negative alcohol biomarker tests) on a frequent (e.g. weekly), escalating (e.g. $5/week) schedule (e.g. 26 weeks) in order to increase the occurrence of that behavior (e.g. long term alcohol abstinence or reduction in drinking).
214485753|NCT06265506|BEHAVIORAL|Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT)|CBT4CBT is an evidence-based online intervention that teaches CBT principles and skills to help people with alcohol use disorder reduce their drinking. CBT4CBT teaches CBT principles through video, graphics, audio instruction, and interactive exercises. Modules include video-based examples to emphasize learning of behavioral, cognitive, and affective strategies, with an emphasis on learning from examples of individuals using skills in a range of situations. Skills taught include functional analysis, coping with craving and emotions, problem solving, decision making, challenging thoughts, and assertive alcohol refusal. Interactive exercises and homework are used to encourage skills learning and practice.
215065526|NCT00820859|BEHAVIORAL|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
215065527|NCT06291012|DRUG|Quick response: Amoxicillin for 3 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Immediate stop of antibiotherapy (after 9 complete doses)~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
215065528|NCT06291012|DRUG|Delayed response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 5 days"
215065529|NCT06291012|DRUG|Quick response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Continuation of antibiotherapy for up to 5 days~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
214323263|NCT06165354|COMBINATION_PRODUCT|LiveSpo X-secret|"In Vietnam, LiveSpo X-SECRET is manufactured as two product lines: (1) Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam and ISO 13485:2016 (Certificate No YT117-19) and (2) comestic (Product declaration No.14981/22/CBMP-HA) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam (Certificate No 118/CNĐĐKSXMP. Both product lines have the same probiotic composition.~The cosmetic type was used for the clinical trial conducted at Hanoi OGH. The Class-A medical device type was used for the clinical trial conducted at Bac Ninh CDC."
214323264|NCT02134301|DRUG|Oritavancin|
214323265|NCT04729348|DRUG|Pembrolizumab|Oral, daily, dosage per protocol
214323266|NCT04729348|DRUG|Lenvatinib|Oral, daily, dosage per protocol
214922981|NCT03386396|DIETARY_SUPPLEMENT|High protein/low carbohydrate|A high protein/low carbohydrate shake will be given to the child.
214323267|NCT04989608|OTHER|Neuroimaging|realization of a neuroimaging 1 and 3 years after the transient ischemic accident
214323268|NCT06514521|OTHER|Lutetium vipivotide tetraxetan|This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement.
214323269|NCT05407324|DRUG|Dazucorilant 300 mg|300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.
214323270|NCT05407324|DRUG|Dazucorilant 150 mg|Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.
214323271|NCT05407324|OTHER|Placebo|Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.
214323272|NCT06491342|DIETARY_SUPPLEMENT|Probiotic|Probiotic-Lactobacillus Zeae and Lactobacillus reuteri
214323273|NCT06491342|DIETARY_SUPPLEMENT|Placebo|placebo
214323274|NCT05349591|BIOLOGICAL|cePolytreg|The treatment group will receive cePolyTregs 2 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
214323275|NCT02312102|DRUG|Lenalidomide|Chemotherapy
214922982|NCT03386396|DIETARY_SUPPLEMENT|High carbohydrate/low protein|A high carbohydrate/low protein shake will be given to the child
214922983|NCT00280358|DRUG|Fluticasone Propionate|
214922984|NCT00280358|DRUG|Formoterol Fumarate|
214922985|NCT03976687|DRUG|EYP001a|Oral tablets
214922986|NCT03989206|DRUG|Nemolizumab|Nemolizumab
214922987|NCT05522205|OTHER|Regulated cannabis access in pharmacies|The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
214922988|NCT06594133|DRUG|Antibiotic Treatment|"For lung transplant recipients with Nocardia infection, the treatment regimen could include:~Sulfamethoxazole/Trimethoprim (Bactrim): 800 mg/160 mg orally or intravenously twice daily for at least 6 months.~Imipenem: 500 mg intravenously every 6 hours for severe cases. Monitoring: Regular monitoring of blood levels of the drug to avoid toxicity and adjust doses accordingly."
215065530|NCT06291012|DRUG|Delayed response: Amoxicillin for 7 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 7 days"
214922989|NCT01451970|OTHER|High Fat Diet|Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
214922990|NCT02499653|BEHAVIORAL|Psychological Intervention|
214922991|NCT02499653|BEHAVIORAL|Videos|
214922992|NCT05038722|OTHER|Platelet transfusion|Transfusion of platelet concentrates according to routine practice.
214922993|NCT06968065|PROCEDURE|Ultrasound-guided serratus anterior plane block and serratus-intercostal interfascial plane block with bupivacaine|Participants will receive an ultrasound-guided serratus anterior plane (SAP) block using 30 mL of 0.25% bupivacaine combined with a serratus-intercostal interfascial plane (SIP) block using 10 mL of 0.25% bupivacaine. Both blocks will be administered after surgery but before emergence from anesthesia. This combination targets multiple interfascial planes to enhance postoperative analgesia in patients undergoing minimally invasive cardiac surgery (MICS).
214922994|NCT06968065|PROCEDURE|Local wound infiltration with bupivacaine|Participants will receive local wound infiltration with 40 mL of 0.25% bupivacaine applied to the surgical and drain sites following surgery. This approach represents a standard method for managing postoperative pain in MICS patients and serves as the active comparator.
214922995|NCT01211457|DRUG|sapacitabine and decitabine (Part 1 - completed)|decitabine will be administered in alternating cycles with sapacitabine
214922996|NCT01211457|DRUG|sapacitabine and venetoclax (Part 2 - recruiting)|sapacitabine will be administered concomitantly with venetoclax
214323276|NCT02312102|DRUG|Velcade|Chemotherapy
214922997|NCT01925066|DRUG|Vancomycin|
214922998|NCT03631914|PROCEDURE|Infraclavicular brachial plexus block|An infraclavicular brachial plexus block is performed using ultrasound guidance.
215065531|NCT04810013|PROCEDURE|non-invasive measurement of cerebral autoregulation|Non-invasive measurement of the cerebral autoregulation in the postoperative period in 80 neonates and infants with complex congenital heart disease undergoing cardiopulmonary bypass surgery. A continuous, moving Pearson's correlation coefficient will be calculated between the arterial pressure and near-infrared spectroscopy signals and displayed continuously during surgery using a laptop computer and the ICM+ software (Cambridge Enterprise).
215065532|NCT00994201|OTHER|DCE-MRI, DW-MRI and MRS|"Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.~Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS."
214323277|NCT06022510|DEVICE|Fetoscopy Sets for Anterior and Posterior Placentas|Patients who choose to undergo fetoscopic surgery for a complicated monochorionic-diamniotic pregnancy will be offered participation in this study. All patients will undergo selective laser photocoagulation with the use of the fetoscopes in this study.
214323278|NCT03205618|OTHER|Non-Interventional|Non-Interventional
214323279|NCT01436812|PROCEDURE|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
214323280|NCT01436812|PROCEDURE|positive end expiratory pressure|PEEP 0 cmH2O
215065533|NCT04222634|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
215065534|NCT06174454|OTHER|Respiratory Pediatric Physiotherapy|Prolonged slow expiration Tracheal pumping Controlled expiratory flow exercises Forced expiration technique
215065535|NCT06174454|OTHER|Control Group|Will be subject to muscle compressions of the upper limbs. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
214922999|NCT02069912|BEHAVIORAL|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
215065536|NCT06358664|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy will be performed
214923000|NCT06438523|PROCEDURE|PULPOTOMY OF MATURE PERMENANT TEETH|Removal of coronal pulp and expose the orifices to apply the materials with aim to preserve vitality of remaining pulp
214923001|NCT06967285|BEHAVIORAL|Prone ventilation|Cerebral Blood Flow Monitoring Before and After Prone Ventilation in Patients with ARDS.Cerebral blood flow,intracranial pressure,and systemic hemodynamic monitoring were performed at the following time points:before prone positioning(T0),1 hour after prone ventilation(T1),12 hours after prone ventilation(T2),1 hour after returning to the supine position(T3),and 7 days after returning to the supine position(T4).
214923002|NCT03115138|OTHER|Correlation between molecular anomalies of the primary tumor and circulating tumor DNA|The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
214923003|NCT05889364|DIAGNOSTIC_TEST|"AI-based x-ray analysis and triage (normal/tuberculosis suspected)"|All included x-rays will be analysed by the AI-based system. Then results will be compared with opinions of 2 experienced radiologists (they make peer-review of all included images independently of each other).
214923004|NCT01376921|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
215065537|NCT03197714|DRUG|OPB-111077|"Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily"
215065538|NCT02043106|OTHER|plantar vibration|
215065539|NCT02930382|OTHER|Baroreflex assessment|
215065540|NCT05720689|OTHER|using relaxing music|music diffusion during dental care under MEOPA
215065541|NCT05720689|OTHER|No relaxing music|dental care under MEOPA without music
215065542|NCT05366621|DRUG|Anti-osteoporosis medications|Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
215065543|NCT00060801|DRUG|BIIL 283 BS (Amelubent)|
214323281|NCT03784573|BEHAVIORAL|Dog + handler|Dog + handler
214323282|NCT03784573|BEHAVIORAL|No dog|No dog
214323283|NCT03156010|DEVICE|Neuro Kinetics IPAS|Testing with PAS device
214323284|NCT03156010|DEVICE|Oculogica EyeBox|Testing with Oculogica EyeBox device
214323285|NCT03156010|DEVICE|SyncThink EyeSync Device|Testing with SyncThink EyeSync device
214485754|NCT05763251|OTHER|therapy duration|the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy
214485755|NCT04696523|DRUG|Xenon|Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care
214485756|NCT04696523|DRUG|air/oxygen|Control group will be treated with air/oxygen
214485757|NCT06130826|PROCEDURE|Biopsy|Undergo tissue biopsy
214485758|NCT06130826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214485759|NCT06130826|PROCEDURE|Bone Scan|Undergo bone scan
214323286|NCT05164783|COMBINATION_PRODUCT|Sanacoach Parkinson (SCP)|A web-based monitoring tool for patients with PD, using questionnaires. It includes nine parts: 1) A 89-question, quarterly questionnaire about PD-symptoms. 2) Questionnaire responses are converted to scores on 16 PD-related domains. Both the current score and the score's change compared to the previous questionnaire are visible. 3) An interim evaluation is sent after 6 weeks with questions on any domains where a patient indicated problems. 4) A medication monitor can be initialized by the treating physician to evaluate the effect of a therapeutic change. 5) A consultation preparation module allows patients to indicate which topics they want to discuss during an outpatient visit. 6) Patients can ask for 'calling advise' if they are unsure whether to contact their physician. 7) Patients and healthcare providers can send each other text messages. 8) Interactive learning modules about PD. 9) Annual evaluation regarding patient satisfaction, self-management and healthcare consumption.
214323287|NCT01391975|PROCEDURE|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
215065544|NCT05800925|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current psychiatric symptoms. Vital signs, urine drug screens, and urine pregnancy tests may be collected.
215065545|NCT04573699|DEVICE|CNT-HF|A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.
215065546|NCT03960411|DRUG|Doxycycline 100Mg Capsule|Doxycycline capsule
215065547|NCT03960411|DRUG|Placebo oral capsule|Capsule manufactured to mimic doxycycline 100 mg capsule
214323288|NCT06325384|DEVICE|Lifelight|Contactless Vital Signs Measurement via RPPG
214323289|NCT06325384|DEVICE|Blood Pressure Cuff|Standard Blood Pressure Cuff Digital
214485760|NCT06130826|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214485761|NCT06130826|DRUG|Immunotherapy|Receive M5A-IL2 ICK SC
214485762|NCT06130826|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214485763|NCT06130826|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214485764|NCT06130826|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214485765|NCT06449482|DRUG|Selinexor|three dosage groups were set up, selinexor 60mg QW, 40mg BIW, or 60mg BIW
214485766|NCT06449482|DRUG|Venetoclax|cycle 1 100mg d1 200mg d2 400mg d3-28 cycle 2-4 400mg d1-d28
214485767|NCT06449482|DRUG|Azacitidine|75mg/m2 d1-d7 28d/cycle 4 cycles
214923005|NCT03156608|DEVICE|Novii ECG/EKG System|External fetal heart rate monitoring
214923006|NCT03156608|DEVICE|External fetal heart rate monitoring|External fetal heart rate monitoring
214923007|NCT03192670|DEVICE|Low-level light therapy device|Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
214923008|NCT02353442|OTHER|Posterior shoulder mobilizations|A second investigator performed 5min of posterior capsule shoulder mobilization for the experimental group, 3times/week during 4 weeks.
214923009|NCT02353442|OTHER|External rotators strengthening|Individuals performed 3x10 repetitions of external rotators strengthening in sidelying position 3times/week during 4 weeks.
214923010|NCT02353442|OTHER|Placebo ultrasound|A second investigator performed 5min of placebo ultrassound for the control group, 3times/week during 4 weeks.
214923011|NCT02353442|OTHER|Scapular squeezing|Individuals performed 3x10 repetitions scapular squeezing exercise 3times/week during 4 weeks.
214923012|NCT02353442|OTHER|Upper trapezius stretching|Individuals performed 3x30s of upper trapezius stretching, 3times/week during 4 weeks.
214923013|NCT02353442|OTHER|Posterior Capsule Stretching|Individuals performed 3x30s of posterior capsule stretching, 3times/week during 4 weeks.
214923014|NCT01194128|BEHAVIORAL|Psychoeducational Support|The intervention is comprised of three modules, each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
214923015|NCT01194128|BEHAVIORAL|Information only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition. Also provided will be a resource guide containing local contact information."
214923016|NCT06666959|DRUG|Anesthesia Agent|intravenous anesthetic and inhalation anesthetic
214923017|NCT02990585|OTHER|Back school|
214923018|NCT03895606|OTHER|Data collection|This study is an observational study collecting perioperative data. There is no intervention regarding this study.
214923019|NCT00993343|DRUG|Sirolimus/tacrolimus|Standard GVHD prophylaxis
214923020|NCT00993343|DRUG|cyclosporine/methotrexate|Standard GVHD prophylaxis
214923021|NCT02798289|DEVICE|Oculeve Intranasal Neurostimulator|Neurostimulation device
215065548|NCT05666934|DEVICE|Augmented Reality Storybook|The AR system was developed using a Vuforia Engine Package for Unity (PTC Inc, San Diego, CA), which enabled to create an application for children to view a storybook in their own homes. The children and caregivers could view eight scenarios (receiving a praise, broken toys, waiting in line at the playground, getting a vaccination, waiting for watching a video, hitting someone in an accident, grabbing a toy, understanding another person's feelings) and learn strategies for emotional events reflected in the tablet (Figure 1). This AR application supports a tablet size of 10.4 inches and is equipped with a Samsung Galaxy Tab A7.
215065549|NCT00182052|DRUG|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
214485768|NCT06965543|PROCEDURE|Immediate G-POEM|Gastric POEM (G-POEM) performed under general anesthesia. A submucosal tunnel will be created along the greater curvature of the stomach to access the pyloric muscle under endoscopic vision. The pylorus will be incised at two locations with a dual myotomy between the 5 and 8 o'clock positions on the clock face
214923022|NCT05885035|DRUG|Calcium Hydroxyapatite|Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
214923023|NCT02912260|DRUG|MGL-3196|
214923024|NCT02912260|DRUG|Placebo|
214923025|NCT02354755|DEVICE|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
214923026|NCT06278363|OTHER|Sexual Nursing care|"The Sexual Nursing Care approach is a specialized intervention for stroke patients and partners, addressing sexual health needs. It includes personalized counseling sessions with trained nurses, assessing dysfunctions and medical history. Active partner involvement fosters intimacy and understanding. Both receive sexual education covering anatomy, physiology, and post-stroke changes. Recommendations for activities like Kegel exercises are provided. Structured outpatient sessions occur, lasting 45 minutes, facilitated by a nurse. Pre- and post-treatment assessments are conducted to identify contraindications. Emerging issues during treatment are promptly communicated for management. Sexual Nursing Care aims to holistically address post-stroke sexual health and relational needs, improving awareness and communication.~Coaching and Counselling can be provided also via telemedicine."
214923027|NCT06278363|OTHER|Standard Nursing Care|Group 2 patients receive standard nursing care without structured interventions for sexual dysfunctions. Management relies on clinical case and routine care procedures. No specific sexual sphere interventions are provided. Any emerging issues needing diagnostic investigation are reported to the specialist. Both groups are assessed quantitatively for counseling effects on sexual and relational aspects and qualitatively for psychorelational changes and mood impact on couple's quality of life.
214923028|NCT02303223|DRUG|Propofol|
214923029|NCT00831714|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
214923030|NCT00831714|DRUG|Standard care treatment for VTE prophylaxis|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
214923031|NCT05568121|DRUG|L04RD1|1 tablet of L04RD1
214923032|NCT05568121|DRUG|L04TD1|1 tablet of L04TD1
214923033|NCT05568121|DRUG|L04TD1|1 tablet of L04TD1
214923034|NCT05568121|DRUG|L04RD1|1 tablet of L04RD1
214923035|NCT00679289|DRUG|HDI|20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression
214923036|NCT00679289|DRUG|KW2871|5 mg/m\^2 IV every 2 weeks until disease progression
214323290|NCT00974571|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
214323291|NCT00974571|DRUG|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
214323292|NCT00974571|DRUG|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
214323293|NCT01192971|DRUG|Apatinib|apatinib p.o. once daily for 4 weeks
214323294|NCT01990677|DRUG|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
214323295|NCT01990677|DRUG|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
214323296|NCT00273728|DRUG|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
214323297|NCT03879889|DRUG|Nicotine patch|Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
214323298|NCT02805530|OTHER|First line systemic treatment|Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
214923037|NCT00679289|DRUG|KW2871|10 mg/m\^2 IV every 2 weeks until disease progression
214923038|NCT00679289|DRUG|KW2871|20 mg/m\^2 IV every 2 weeks until disease progression
214923039|NCT00484562|DEVICE|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
215065550|NCT00182052|OTHER|Placebo|Given orally twice daily.
215065551|NCT03395691|PROCEDURE|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach
215065552|NCT03395691|PROCEDURE|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
215065553|NCT03704480|DRUG|Durvalumab|1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
214323299|NCT02805530|OTHER|Radical treatment|to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
214923040|NCT00484562|DEVICE|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
214923041|NCT00484562|DEVICE|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
214923042|NCT00484562|DEVICE|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
214923043|NCT05526807|DRUG|Ursodeoxycholic acid|Oral
214923044|NCT05882838|OTHER|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
214923045|NCT03808324|DIAGNOSTIC_TEST|Diagnostic investigations|Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.
214923046|NCT03279549|PROCEDURE|Routine dressing change|Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.
215065554|NCT03704480|DRUG|Tremelimumab|300mg by IV infusion on D1 at cycle 1 only
215065555|NCT06125236|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
215065556|NCT01202019|OTHER|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
215065557|NCT00712036|BEHAVIORAL|Interim|Methadone maintenance with emergency counseling only for up to 4 months
215065558|NCT00712036|BEHAVIORAL|Comprehensive|Methadone treatment with counseling as usual
215065559|NCT00712036|BEHAVIORAL|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
215065560|NCT02534025|PROCEDURE|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
215065561|NCT00070928|DRUG|valerian|
215065562|NCT04678037|BEHAVIORAL|PROs assessment using sickle cell disease mobile app (SCD-app)|A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
215065563|NCT05001984|DRUG|Alirocumab|Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.
215065564|NCT06299163|BIOLOGICAL|NM32-2668|Anti-ROR1/Anti-Cluster of Differentiation 3 (CD3)/Anti-Human Serum Albumin (HSA) Tri-Specific Antibody
215065565|NCT01547351|OTHER|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
214323300|NCT02805530|RADIATION|radiation therapy|Patients will receive dose and fraction regimen according to the metastatic site.
214323301|NCT02805530|OTHER|Chemoradiotherapy|Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
214323302|NCT01125111|PROCEDURE|surgery(robot versus laparoscopy)|
214323303|NCT03507556|PROCEDURE|Triple paste and induced bleeding|
215065566|NCT01667497|DRUG|Fampridine SR|
215065567|NCT01667497|DRUG|Placebo|
215065568|NCT06552546|DRUG|Icodextrin|Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.
215065569|NCT05725226|DEVICE|Double J Stent 6Fr x 26cms|Surgery will be performed by expert Urologist.
215065570|NCT05725226|DEVICE|Double J Stent 4Fr x26cms|Surgery will be performed by expert Urologist.
215065571|NCT02191878|DRUG|TKM-080301|TKM-080301 intravenous infusion
215065572|NCT02027311|DRUG|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
215065573|NCT02027311|DRUG|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
215065574|NCT02027311|DRUG|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders \> 80 years old were administered 25mg iv bolus.
214323304|NCT03507556|DRUG|Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol|triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
214323305|NCT02277496|BEHAVIORAL|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
214323306|NCT00966238|BIOLOGICAL|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
215065575|NCT06478316|PROCEDURE|Intracervical block|local injection of lidocain to the cervix
215065576|NCT01825512|DRUG|Deferiprone|Deferiprone 80 mg/mL oral solution
215065577|NCT01825512|DRUG|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
215065578|NCT06061263|OTHER|follow up|collecttion of clinicopathological data from a prespectively collected databse, including survival data.
214923047|NCT03279549|PROCEDURE|Limited debridement & Acellular dermal matrix dressing|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair."
215065579|NCT02466425|DRUG|SHP465|12.5mg and 25mg capsules (one capsule daily)
215065580|NCT02466425|DRUG|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
215065581|NCT04444986|DRUG|FAVIR 200 MG FT|FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
215065582|NCT04444986|DRUG|AVIGAN 200 mg FT|AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
215065583|NCT04698564|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
215065584|NCT06233110|DRUG|Fostamatinib|Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.
215065585|NCT06233110|DRUG|Ruxolitinib|Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.
214323307|NCT00127140|DRUG|vorinostat|
215065586|NCT00657137|DRUG|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
215065587|NCT00657137|DRUG|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
214672571|NCT06252610|DRUG|Contrast Media, Magnetic Resonance|"The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~* After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~* The catheter will be flushed before and after injection with 0.9% saline solution;~* About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~* The contrast will then be injected."
215065588|NCT01760499|DRUG|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
214672572|NCT06252610|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired When necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
214923048|NCT03279549|PROCEDURE|Limited debridement & Epidermal cell spraying|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site."
214923049|NCT03279549|PROCEDURE|Limited debridement & Basic fibroblast growth factor|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds."
214323308|NCT02927457|DRUG|GSK2646264 1%|A cream for topical application with a concentration of 1% GSK2646264.
215065589|NCT01760499|PROCEDURE|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
215065590|NCT02414945|DRUG|Cyclophosphamide|
215065591|NCT02414945|DRUG|Fludarabine|
215065592|NCT02414945|BIOLOGICAL|Autologous tumor infiltrating lymphocytes (TILs)|
215065593|NCT02414945|BIOLOGICAL|Interleukin-2|
215065594|NCT05068323|DIAGNOSTIC_TEST|Digital electroencephalography (EEG) for an hour (16 channels)|Digital electroencephalography (EEG) for an hour (16 channels)
215065595|NCT05657938|DEVICE|Wearable Device|The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.
215065596|NCT05657938|OTHER|Duchenne Video Assessment (DVA)|The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
215065597|NCT00435227|BIOLOGICAL|Motavizumab|A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
215065598|NCT00435227|OTHER|Placebo|A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
214672573|NCT02632058|OTHER|Cognitive Behavioral Therapy|
215065599|NCT03231917|PROCEDURE|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
215065600|NCT03231917|PROCEDURE|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
215065601|NCT00664339|BIOLOGICAL|Flu Vaccine|Single dose of Flu vaccine by year (1)
215065602|NCT00664339|OTHER|Conventional medical therapy for heart failure|According with the international guidelines
215065603|NCT05013346|OTHER|No intervention needed|No intervention required. Not a clinical trial
215065604|NCT06079281|DRUG|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
215065605|NCT06079281|DRUG|Placebo|Placebo will be administered via SC injection.
215065606|NCT00150215|DRUG|PF-00184562|
214672574|NCT05506332|DRUG|Venetoclax|Venetoclax and 6-mercaptopurine
214923050|NCT05775003|DIETARY_SUPPLEMENT|Exercise|8 week exercise training program - consisting of weight training and cardiovascular exercise
215065607|NCT00150215|DRUG|Olanzapine|
215065608|NCT06026072|OTHER|CLAD-V SCORE|the CLAD-V score is measured by the doctor during the emergency take care. After 7 days the patient will be call back to compare the prediction of CLAD-V score and the reality of surgical intervention or no.
215065609|NCT01721486|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
215065610|NCT01721486|DRUG|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
214323309|NCT02927457|DRUG|Placebo|Subjects will receive matching Placebo topically.
215065611|NCT04211792|DEVICE|Icare Tonometer|Icare tonometers are a new class of rebound tonometers for IOP measurements. The Icare series of tonometers are hand-held tonometers, which are easy to operate and generally do not require topical anaesthesia for IOP measurements.
215065612|NCT00582712|DRUG|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
214323310|NCT05393518|BEHAVIORAL|Anxiety-induced task|Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
214323311|NCT05393518|BEHAVIORAL|Neuropsychiatric assessment|Screening for depression and anxiety
214323312|NCT01494610|DRUG|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
214672575|NCT05506332|DRUG|6-mercaptopurine|Venetoclax and 6-mercaptopurine
215065613|NCT04492748|COMBINATION_PRODUCT|Collagen and platelet rich plasma (PRP)|Ultrasound guided injections
215065614|NCT04492748|COMBINATION_PRODUCT|Collagen|Ultrasound guided injections
215065615|NCT04492748|COMBINATION_PRODUCT|Platelet rich plasma (PRP)|Ultrasound guided injections
215065616|NCT05052463|OTHER|electrolyte imbalance analysis|ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
215065617|NCT02173483|PROCEDURE|Quadriceps graft|
215065618|NCT03245411|BEHAVIORAL|Intervention|All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
215065619|NCT01151384|DRUG|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
215065620|NCT00027144|BIOLOGICAL|Heat Shock Protein 70 HSP70|
214923051|NCT04733937|OTHER|a2 Platinum® stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
214923052|NCT04733937|OTHER|Conventional, A1 and A2 β-casein containing stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
214923053|NCT00224939|DRUG|Potassium Chloride|
215065621|NCT00733733|DRUG|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
215065622|NCT06129461|BEHAVIORAL|Single-session acceptance-based online workshop targeting food cravings as predictors of loss of control and binge eating in pregnancy|Participants in the intervention will learn acceptance-based strategies for reducing the adverse impact of food cravings on eating behaviors. Unlike control-based strategies, acceptance-based strategies do not attempt to change the content or frequency of thoughts; rather, they foster willingness to acknowledge and experience uncontrollable thoughts, urges, and emotions as what they are - nothing more, nothing less. Acceptance-based approaches have demonstrated efficacy in reducing the adverse impact of food cravings on eating behaviors in non-pregnant samples.
215065623|NCT05268692|DRUG|GS|drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (\< 1.25 m2, 60 mg/d; ≥ 1.25 to \< 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
215065624|NCT05268692|DRUG|GnP|"drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle."
214485769|NCT06965543|PROCEDURE|Delayed G-POEM|Participants will receive standard medical treatment, including prokinetic agents, antiemetics (ondansetron 8 mg twice daily), nutritional support, and dietary counseling. Laxative treatments will be prescribed as needed. After three months, participants will undergo G-POEM as described above
215065625|NCT02346227|DRUG|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
215065626|NCT02346227|DRUG|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
215065627|NCT06301776|DRUG|Ticagrelor|To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.
215065628|NCT03708315|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride
215065629|NCT03708315|DRUG|Placebos|Placebo
215065630|NCT00256464|BEHAVIORAL|Multi-component Yoga Intervention|
215065631|NCT05906680|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
215065632|NCT05746091|PROCEDURE|wrist arthroscopy|Arthroscopic Partial Trapeziectomy with Hematoma Distraction in Basal Thumb Arthritis
215065633|NCT05064501|DIAGNOSTIC_TEST|spirometry|Lung function test: pre and post bronchodilator spirometry
215065634|NCT05064501|OTHER|Asthma control test|Asthma control test
215065635|NCT05141175|DEVICE|Hypertension medication algorithm|The algorithm is configured to align medication choices based on the hemodynamic findings from the ICG readings. This decision support tool was created so as to organize these medications based on their mechanism of action and is consistent with the evidence-based treatment of hypertension.
215065636|NCT05141175|DEVICE|Impedance Cardiography|The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
215065637|NCT02688829|DEVICE|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
215065638|NCT04961346|DEVICE|Ultrapro® mesh|large-pore, lightweight polypropylene mesh
215065639|NCT04961346|DEVICE|Premilene® mesh|small-pore, heavyweight polypropylene mesh
215065640|NCT02758600|OTHER|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
215065641|NCT05174546|DIAGNOSTIC_TEST|T2 magnetic resonance|Samples for assessment by the T2MR will be collected once daily in occasion of any consecutive febrile episode during neutropenia when blood cultures are ordered as per standard of care. T2 magnetic resonance will be run according to manufacturer's instructions
215065642|NCT03356353|DRUG|Sildenafil Citrate|20 mg tablets
215065643|NCT00615693|DRUG|AEB071|
215065644|NCT06023121|DIAGNOSTIC_TEST|Measurement of levels of an exosome-based liquid biopsy signature|Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
214485770|NCT06834425|DRUG|Peritendinous NSAID injection|Peritendinous NSAID (parecoxib) injection
214485771|NCT06834425|DRUG|Control group (placebo)|Normal saline mixed with local anesthetics injection
215065645|NCT03496064|OTHER|Successful reperfusion|Defined as modified Thrombolysis in Cerebral Infarction 2b/3
215065646|NCT01901289|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
215065647|NCT02526953|DRUG|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
215065648|NCT02526953|DRUG|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
214485772|NCT02989662|DRUG|Mifepristone|Participants receive 6 doses.
214485773|NCT02989662|DRUG|Placebo - Cap|Participants receive 6 doses
214485774|NCT06280235|DRUG|BI 1569912|BI 1569912
214485775|NCT06280235|DRUG|Placebo|Placebo matching BI 1569912
214485776|NCT06014385|DRUG|Scopolamine|TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
215065649|NCT02526953|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
215065650|NCT02526953|DRUG|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
215065651|NCT02526953|DRUG|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
215065652|NCT02526953|RADIATION|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
214485777|NCT06014385|RADIATION|[11C]EMO ([11C]LSN3172176)|A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of \[11C\]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.
214485778|NCT06541522|DEVICE|EIT|Two PEEP titrations monitored by EIT will be performed, each with the electrode belt positioned at a different chest height (2nd intercostal space or 5th intercostal space). The order will be drawn at random.
214485779|NCT06752993|DEVICE|Expiratory Muscle Strength Training (EMST-150)|Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) used to exhale against a same-pressure load every exhalation for strengthening primarily the core muscles. The device pressure is adjusted according to PEmax and reliability/reproducibility has been demonstrated.
214485780|NCT06752993|DEVICE|Sham Training|Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) without physiological load. The sham device closely resembled the EMST device, with the only difference being that the pressure release valve was rendered nonfunctional by removing the spring. As a result, it exerted minimal to no physiological load on the targeted muscles.
214485781|NCT05010369|DIAGNOSTIC_TEST|spectroscopic measurement|measurement of the tissue with spectroscopy
214485782|NCT05010369|DIAGNOSTIC_TEST|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
214485783|NCT05010369|DIAGNOSTIC_TEST|histopathology and cytology|Histopathology and cytology will be performed on the samples
214485784|NCT04120805|DEVICE|Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon
214485785|NCT04120805|OTHER|No Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
214485786|NCT06690333|DEVICE|Pacemaker|Transvenous pacemaker with left bundle area pacing
214923054|NCT06388707|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2, burst length: 3 ms, duration: max. three consecutive 10-minute FUS exposures with two 5-minute intermission intervals.
214923055|NCT06967493|BEHAVIORAL|Amazonian Dance|"Dance intervention consists of 24 Amazonian Dance, 2 times/week, lasting 1 hour, over a period of 12 weeks. Classes will be taught by qualified dance professionals with experience teaching PwPD and will take place in a specific practice room (air-conditioned, spacious, and leveled), with adequate facilities, floors, chairs, bars, mirrors, and sound system.~Classes will be divided into 4 parts. The part 1 (10-15 min.) consists of welcoming students, warm-up exercises, and body awareness activities. In the Part 2 (10-15 min.) Weight transfer activities, static and dynamic balance, motor coordination, strengthening of lower and upper limbs will be carried out. The part 3 (25-30 min.) will be based on the Amazonian Lundum and Carimbó dances. In the part 4 (5-10 min.), the final part of the class, the calm down activity will be carried out, with breathing, stretching and relaxation activities."
214485787|NCT06690333|DEVICE|Pacemaker|Transcatheter pacemaker with MICRA AV
214485788|NCT05515978|DRUG|Metformin|Metformin is a medication used to treat type 2 diabetes, gestational diabetes, and prediabetes. In this study, patients on the Metformin arm will be started on 850 mg daily for 2 weeks, then escalated to a final dose of 850 mg twice daily, which is lower than the maximum recommended dose of 2550 mg total daily.
215065653|NCT05491096|OTHER|Proprioceptive Neuromuscular Training|Proprioceptive exercises will be divided into three components. The first component will be comprised of standing on Foam with eyes open and eyes closed and passing any object from one subject to the other for 10 minutes. The second component consists of activity that will be performed in groups of two. Throwing and catching a ball will be performed while standing on foam for additional10 minutes. The third component, throwing and catching a ball, will be performed on trampoline to further challenge the balance system. After each set of 10-minute exercise, the subjects will be given two-minute resting periods. In the end, 10 minutes will be given for cooling down in which deep breathing exercises and static back extensor stretching exercises will be performed to avoid fatigue and to bring the heart rate back to the normal resting level.
214923056|NCT06967493|BEHAVIORAL|Nordic Walking|The Nordic walking protocol consists of 3 moments: warm-up (10min), main part (40min) and final part (10min). At the beginning of the activity, a joint warm-up is performed and free walking, without poles, at a comfortable speed. Then, in the main part of the class, the participants performed an individual and daily training that is inserted in their general training cycle, elaborated from the specific and individual functional capacity, measured from the application of the 6-minute walk test. In the final part, return to calm and stretching.
214923057|NCT06969378|DEVICE|Pulsed field ablation using a pentaspline ablation catheter|After conclusion of AT ablation, transseptal or transbaffle puncture will be performed under fluoroscopic and intracardiac echocardiography guidance to access the left atrium (LA) or pulmonary venous atrium (PVA) if not already done so. PFA will be performed using a pentaspline catheter (Farawave, Boston Scientific) and a steerable sheath to achieve PVI of all veins draining to the LA/PVA with entrance and exit block confirmed at each vein. In patients where PFA is unable to achieve PVI, touch-up RFA will be performed. Programmed atrial stimulation will be performed to investigate for inducible atrial tachycardias. An implantable loop recorder will be placed at the conclusion of the procedure.
214923058|NCT06968780|PROCEDURE|Buccal Fat Pad|BFP has a long successful history in oral surgery for its use in closure of Oroantral communication and taking advantage of the fact that it contains progenitor stem cells showing similar phenotype with (ASC) adipose-derived stem cells characteristics, which can similarly differentiate into the chondrogenic, adipogenic, or osteogenic lineage. Making them an invaluable reservoir for tissue engineering.
214672576|NCT06119178|DEVICE|EX-PRESS P-50 filtration device|FDA-approved, stainless steel device with a 50-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
214672577|NCT06119178|DEVICE|EX-PRESS P-200 filtration device|FDA-approved, stainless steel device with a 200-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
214323313|NCT01494610|DRUG|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
214323314|NCT04505891|BEHAVIORAL|Education|Kidney health education will be delivered prior to discharge by trained nurse educators.
215065654|NCT05491096|OTHER|Conventional Physical Therapy|Conventional treatment protocolconsists of a structured exercise protocol Each training session consisted of three parts, the first part included the main movements (warming up 10 minutes plus 5 minutes stretching exercises), the second part consisted of specific movements (exercises with theraband and physioball, 20 minutes), and the third part composed of cool down exercises (10 minutes).(22)Experimental treatment protocolwill be proprioceptive training program. PTP will be based on earlier studies, and will be carried out for eight weeks, with two 60-minute sessions per week. It will start with 10 minutes of Warm-up activities when the subjects will be advised to do light manual stretches and to step up and down on foam to get their body warmed up to have improve muscular flexibility. This will be followed by 30 minutes of proprioceptive exercises targeting lower extremities.
215065655|NCT05970341|BEHAVIORAL|1. Welcome package|"At the end of the baseline data collection visit at the clinic, the Research Staff will hand the participant a welcome packet that includes:~* educational and motivational written materials (about such topics as CKD and healthy eating for early CKD stages)~* a collection of recipes featuring kidney-friendly vegetables"
215065656|NCT05970341|BEHAVIORAL|2. Welcome information (phone or text)|"Those allocated to the intervention arm will receive a welcome call from the Program Staff to provide further details and expectations about the program (such as delivery details and schedule).~Those allocated to the control arm will receive an SMS text that informs them of their arm allocation, what to expect and a phone number to call for questions."
214672578|NCT01322607|BEHAVIORAL|High-intensity Treadmill Exercise|High-intensity treadmill walking program
214672579|NCT01322607|BEHAVIORAL|Low-intensity Lifestyle Intervention|A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
214672580|NCT06014814|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation
214672581|NCT03207256|DRUG|TGR-1202|Oral Daily TGR-1202
214672582|NCT03207256|DRUG|TGR-1202 + Ublituximab|Oral Daily TGR-1202 + Ublituximab IV Administration
214672583|NCT00400491|DRUG|Cholecalciferol (vitamin D)|Cholecalciferol capsule 20.000 IU twice per week for 6 months
214323315|NCT04505891|BEHAVIORAL|Education and follow-up|In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
214672584|NCT00400491|DRUG|Placebo|Placebo capsule twice a week, identical to the cholecalciferol capsules
214672585|NCT03441191|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
214672586|NCT06386588|OTHER|Closed loop auditory stimulation during sleep|Short bursts of pink noise delivered at precise times during overnight sleep at home.
214672587|NCT05447130|PROCEDURE|phacoemulsification|phacoemulsification with corneal endothelial evaluation by specular microscopy
214672588|NCT03351322|DRUG|ENERGI-F701|ENERGI-F701 are applied for treatment of hair loss.
214672589|NCT03351322|DRUG|Regaine|Regaine are applied for treatment of hair loss.
214923059|NCT06968780|PROCEDURE|Palatal Rotation Scarf Graft|This technique uses tissue from the palatal area, which has a rich blood supply placed around the neck of the zygomatic implant aiming to protect the mucosal tissues buccal to the exteriorized implants from capillary compression and subsequent soft tissue recession. The palatal rotation scarf graft has been proven to provide a robust, resilient soft tissue flap with good potential for long-term stability and esthetic outcomes around implants.
214923060|NCT06648174|DEVICE|Continuous glucose monitor|"Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set); and 33 weeks of pregnancy to before delivery (second set) respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 7-14 days after starting to wear), the investigators will provide glucose monitor reports. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor reports was given approximately 7-14 days after starting to wear."
214923061|NCT06648174|BEHAVIORAL|Perinatal nursing care for gestational diabetes|Individual nursing care and consultation for women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum.
215065657|NCT05970341|BEHAVIORAL|3. Produce delivery + Recipes customized to produce|"* Content: Bags with kidney-friendly produce will include 2 vegetables sufficient for 2 meals for 4 people, 1 type of fruit, and 1 dried fruit. The total cost is estimated at USD 20, excluding delivery, for prices in June 2022.~* Delivery: Bags will be delivered to the participant's preferred location (e.g. home or work) and period of the day (e.g., morning, evening).~* Recipes: SMS texts will precede each delivery to share an URL to recipes customized to the items being delivered, and to inform of an upcoming produce bag, its content.~* Frequency:~  1. Weeks 1-2 (2 weeks): No bags delivered.~ 2. Weeks 3-10 (8 weeks): Delivered weekly, for a total of 8 bags.~ 3. Weeks 11-18 (8 weeks): Delivered every two weeks, for a total of 4 bags.~ 4. Weeks 19-26 (8 weeks): No bags delivered."
215065658|NCT05970341|BEHAVIORAL|4. E-gift cards to a grocery store of choice|"Five (5) e-gift cards to a major local grocery retailer chosen by the participant (from 3 options) at the following frequency:~1. Weeks 1-6: No e-gift card.~2. Week 7: One card of USD 30.00 value.~3. Week 11 \& 15: One card of USD 40.00, for a total of USD 80.00.~4. Week 19 \& 23: One card of USD 60.00, for a total of USD 120.00."
214323316|NCT04482569|DRUG|XNW4107|Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
214323317|NCT03395314|DRUG|Ketamine|1 single dose of IV ketamine
214323318|NCT03395314|DRUG|Midazolam|1 single dose of IV midazolam
214323319|NCT04628962|PROCEDURE|Collection and Raman analysis of saliva for the database|Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
214323320|NCT00157599|PROCEDURE|various diagnostic measures for DVT (e.g., CUS)|
214672590|NCT03774745|DRUG|Mifepristone 200 MG|All subjects receive mifepristone tablet on treatment day 1.
214923062|NCT06648174|OTHER|Blood glucose meters (BGM)|Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 7-14 days of glucose monitoring at 24-32 weeks of pregnancy, glucose monitor reports will be given to the participants. After the 7-14 days of glucose monitoring at 33 weeks to before delivery, another glucose monitor reports will be given to the participants.
214923063|NCT05956418|DRUG|Centhaquine|Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
214923064|NCT06967831|PROCEDURE|skin biopsy|Taking a punch skin biopsy of 3 mm diameter under local anesthesia and culturing skin fibroblasts from them.
214923065|NCT06967831|OTHER|generation of iPSCs|Using cultured skin fibroblasts of the patients, iPSCs will be generated according to standard procedures.
214923066|NCT06967831|DIAGNOSTIC_TEST|blood drawing|Drawing blood from a peripheral vein for DNA and RNA isolation. The degree of heteroplasmy (mutation load) for the mtDNA mutation will be determined in the blood DNA.
214923067|NCT06967831|DRUG|off-label compassionate drug use|In case the investigators identify a positive hit during drug repurposing with FDA and EMA approved substances, they will offer it as off-label compassionate use to patients for whom no standard treatment is available.
214923068|NCT06966856|DRUG|Cyanocobalamin 1000 Mcg Oral Tablet|Oral cyanocobalamin supplement administered as a 1000 mcg tablet taken once daily for 6 weeks. Used in patients with early-onset B12 deficiency during PPI therapy.
214347533|NCT02475096|BEHAVIORAL|Internet-delivered CBT|"The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.~Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire."
214672591|NCT03774745|DRUG|micronized Progesterone|Subjects randomized to progesterone receive treatment starting day 2.
214672592|NCT03774745|DRUG|Placebo oral capsule|Subjects randomized to placebo receive treatment starting day 2.
214923069|NCT06966856|DRUG|Cyanocobalamin 1000 Mcg Sublingual Tablet|Sublingual cyanocobalamin supplement administered as a 1000 mcg tablet placed under the tongue once daily for 6 weeks. Used in patients with early-onset B12 deficiency during PPI therapy.
215065659|NCT05970341|BEHAVIORAL|5. Personalized practical & emotional support through a dedicated health partner|"* Each participant is assigned a program staff (dedicated health partner) who call them briefly (15 min or so) over the phone for empathy-based support on the participant's health journey, and practical suggestions for shopping and food preparation.~* The Health Partner will share periodically via SMS text a curated list of evidence-based, trustworthy online educational resources.~* Health partners are not trained to answer medical or health-related questions and will not provide medical guidance or advice of any kind. For such questions, they will encourage participants to contact the clinic or physician.~* Frequency:~  1. Weeks 1-2 (2 weeks): No calls.~ 2. Weeks 3-7 (4 weeks): 2 calls a week, for a total of 8 calls.~ 3. Weeks 8-26 (18 weeks): 1 call every 2 weeks, for a total of 10. But during weeks 7, 11, and 19, participants will be given the choice to keep at 1x/week or decrease to 1x every 4 weeks."
215065660|NCT02972346|DRUG|ACTH|routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
214923070|NCT06966856|OTHER|Proton Pump Inhibitor therapy only|This group will continue their standard PPI therapy without receiving any vitamin B12 supplementation, serving as a control group for the comparison of B12 correction efficacy.
214923071|NCT03686943|OTHER|Family pharmacy|Observation of the family pharmacy in elderly group
215065661|NCT01813058|DRUG|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~1. placebo i.e. saline 0.9% (intravenous injection)~2. intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
215065662|NCT01813058|DRUG|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described."
215065663|NCT04493970|OTHER|High School Students Survey|To assess retention, effectiveness and factors impacting comprehension of cardiopulmonary resuscitation (CPR) training among high school students.
215065664|NCT01421238|BEHAVIORAL|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
215065665|NCT05906485|BEHAVIORAL|fNIRS Neurofeedback-VR Training|In the fNIRS Neurofeedback-VR Training, we have designed a classroom scenario modeled and children are expected to learn how to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
215065666|NCT05906485|BEHAVIORAL|Computerized Cognitive Training|In the Computerized Cognitive Training, children will complete a range of tasks covering attention control and working memory using a conventional training programme, namely Cogmed.
215065667|NCT05270148|OTHER|HIIT|12 weeks training High-Intensity Interval Training consists of 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes).Depending on the number of training session, the loadand the series will increase up to 40% more than the maximum load.
215065668|NCT05270148|OTHER|Fat Max|12 weeks training Fatmax consist in 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. MICTprogram will consist of sessions of approximately ˜45min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
215065669|NCT01545869|PROCEDURE|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
215065670|NCT02068677|OTHER|Sympathetic response|Sympathetic response will be defined as change in heart rate by \>10 bpm and change in BP \<10mmHg.
215065671|NCT02068677|OTHER|no sympathetic response|no Sympathetic response will be defined as change in heart rate by \<10 bpm and change in BP \<10mmHg.
215065672|NCT05689450|OTHER|Data collection: Amikacin concentration|Blood samples for the measurement of the concentration and calculation of the AUC of amikacin are collected 60 min (+/-30 min) and 8 h (+/-1 h) after the beginning of amikacin infusion. The blood collection after the start of the amikacin infusion will be repeated during every subsequent amikacin administration, but max. during 3 consecutive days.
215065673|NCT03719963|DEVICE|Cochlear implant|Cochlear implant for hearing process by surgical intervention
215065674|NCT02777203|DEVICE|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag. This study is a pilot study with one arm (all patients will use the new EcoSac400 ECO-T bag.
215065675|NCT01964495|DRUG|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
215065676|NCT01964495|DRUG|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
215065677|NCT01964495|DRUG|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
215065678|NCT02929199|OTHER|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
215065679|NCT02929199|OTHER|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
215065680|NCT03075280|PROCEDURE|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
214923072|NCT00056238|DRUG|NC-758 (Anti amyloidotic [Aß] agent)|
214923073|NCT00002172|BIOLOGICAL|HIV-1 Immunogen|
214923074|NCT01985932|DEVICE|MRI|
215065681|NCT02498054|BEHAVIORAL|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
215065682|NCT03760198|DRUG|Meditoxin|50U of MEDITOXIN is injected intradermally to each axilla
215065683|NCT03760198|OTHER|Placebo|normal saline is injected intradermally to each axilla
215065684|NCT00080834|DRUG|DJ-927|
215065685|NCT00423982|DRUG|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
215065686|NCT00423982|DRUG|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
215065687|NCT06349265|DRUG|Carpal Tunnel Hydrodissection with %5 dextrose in water injection|Under the inplane ulnar approach, 3ml injectate was injected to hydrodissect the median nerve from the flexor retinaculum, and the residual 2ml injectate was then injected to hydrodissect the inferior median nerve away from the flexor tendons.
215065688|NCT05739006|DRUG|BCD-201|up to 8 treatment cycles
215065689|NCT05739006|DRUG|Keytruda|up to 8 treatment cycles
215065690|NCT00182078|DRUG|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
215065691|NCT00182078|DRUG|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
215065692|NCT01098188|DRUG|LFB-R603|intravenous administration, dose-escalation study
215065693|NCT00395486|DRUG|Rosuvastatin|10mg
215065694|NCT00395486|DRUG|Atorvastatin|10mg
215065695|NCT05612893|OTHER|pathogen|"The patients were divided into groups according to the pathogen(bacteria or virus).~The influenza upper respiratory tract infection cohort will be grouped mainly according to age."
215065696|NCT01145001|BEHAVIORAL|Cognitive Behavioural Therapy|Weekly CBT for all subjects
215065697|NCT01145001|BEHAVIORAL|Contingency Management|incentives given for abstinence based on urine analysis
215065698|NCT01145001|DRUG|Nicotine Transdermal Patch|14mg ir 21mg doses based on weight and #cigs/day
215065699|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
215065700|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
215065701|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
215065702|NCT05347680|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
215065703|NCT05347680|DEVICE|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
215065704|NCT01668446|DRUG|Sildenafil|sildenafil tablets(50 mg) daily
215065705|NCT01668446|DRUG|estradiol valerat|
215065706|NCT04075890|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
215065707|NCT01538355|OTHER|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
215065708|NCT01538355|OTHER|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
215065709|NCT01538355|OTHER|Control diet|Patients stay on their regular diet.
215065710|NCT04839068|DEVICE|covid 19 on pregnancy outcomes|covid 19 on pregnancy outcomes and sex ratio at birth
215065711|NCT05242068|DEVICE|Veinlite|Use of vein imaging device for visualization of veins during peripheral IV placement
215065712|NCT05242068|OTHER|Standard care|Patients received standard intravenous catheterization.
215065713|NCT03601065|OTHER|Videos of polyps, resection of polyps|Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
215065714|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
215065715|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
215065716|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
215065717|NCT01205932|DRUG|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
215065718|NCT05891080|DRUG|Toripalimab|Specified dose on specified days.
215065719|NCT05891080|DRUG|JS004|Specified dose on specified days.
215065720|NCT05891080|DRUG|Pemetrexed|Specified dose on specified days.
215065721|NCT05891080|DRUG|Nab-paclitaxel|Specified dose on specified days.
215065722|NCT05891080|DRUG|Carboplatin|Specified dose on specified days.
215065723|NCT05891080|PROCEDURE|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
215065724|NCT03122808|DIAGNOSTIC_TEST|Uterine Activity Analysis|Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
215065725|NCT03122808|DIAGNOSTIC_TEST|Partogram Analysis|Analysis of slope of partogram
215065726|NCT02258568|BEHAVIORAL|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
215065727|NCT00019968|DRUG|melphalan|
215065728|NCT00019968|DRUG|tumor necrosis factor|
215065729|NCT03138460|OTHER|standard medications crossed over to cannabis|
214347534|NCT04522401|DIAGNOSTIC_TEST|"consultation: Bien vieillir"|Patients will benefit from a multidisciplinary assessment including a geriatric assessment standardized by a geriatrician, an evaluation by a dietician, an evaluation by an occupational therapist. They will then be exposed to a personalized plan of care in the form of a recommendation.Then, patients will be followed at home to evaluate the implementation of their personalized care plan at 3 months of their assessment day, then at 6 and 9 months.
214347535|NCT05006781|DRUG|DAOIB|The DAOIB dose in each group will be fixed during the 24 weeks duration
214347536|NCT03796624|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted"
214923075|NCT03240068|DRUG|Angiotensin 1-7|This is a biologically active hormone of the renin-angiotensin system. It may play a beneficial role in regulation of blood pressure by dilating blood vessels and reducing inflammation.
214923076|NCT03240068|DRUG|Saline|Normal saline will be used as the placebo comparator.
215065730|NCT04736290|OTHER|NLR|Calculation of NLR
215065731|NCT04736290|OTHER|PLR|Calculation of PLR
215065732|NCT04249492|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
215065733|NCT04249492|DEVICE|IOL implantation active comparator (Micropure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
214923077|NCT06051266|DEVICE|Dynamic navigation|Dynamic navigation eliminates the need for a laboratory fabrication process and allows for direct visualisation of the operative area during implant placement. Moreover, it can avoid interfering with water cooling. Navigation-assisted surgery makes it possible to modify the implant system, length, diameter or position in real time, both in the perioperative period and during surgery.
215065734|NCT05555641|DRUG|Nafamostat Mesylate|ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
215065735|NCT05555641|DRUG|Unfractionated Heparin|ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
214923078|NCT06051266|DEVICE|Static template|In most clinical situations, a static template can be used to assist in guiding the placement of implants precisely. The static guide has some limitations in that it requires additional fabrication time, has insufficient cooling in the surgical field and is not suitable for simultaneous grafting procedures.
214923079|NCT01528982|BEHAVIORAL|Mindfulness|Subjects receive mindfulness training
214923080|NCT01528982|BEHAVIORAL|Cognition|Subject receive cognitive training
215065736|NCT03176862|DIAGNOSTIC_TEST|cardiac magnetic resonance scan|An MRI scan of the heart
215065737|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test with stress echocardiogram|An exercise bicycle test with echocardiogram done during the exercise.
215065738|NCT03176862|DIAGNOSTIC_TEST|24-hour ECG holter monitor|3 stickers attached to a small monitor are worn for 24 hours.
215065739|NCT03176862|DIAGNOSTIC_TEST|12-lead ECG|Can be done immediately by the bedside.
215065740|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|An exercise bicycle test. No stress echocardiogram.
215065741|NCT03176862|BIOLOGICAL|Blood test|20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
215065742|NCT02963168|DRUG|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
215065743|NCT03302884|OTHER|biological sampling|Tumor and blood samples
215065744|NCT01139203|DRUG|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
215065745|NCT06176794|DRUG|Immediate release torsemide 20mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
215065746|NCT06176794|DRUG|Extended release torsemide 24mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
214672593|NCT03891069|DEVICE|AHA Exergame System|The AHA Exergame System consists of a mobile computing platform running a set of parameterizable exergames purposely designed for elderly fitness training. The platform is equipped with a 1000 lumens video projector capable of creating a 2.05m by 1.16m floor projection display and a Kinect V2 sensor to serve as game controller. The AHA exercise-based computer games have been designed for and tested with elderly people and were adapted for the functional limitations of PD patients. The system includes five different games that aim to train patients motor ability, cardiorespiratory and muscular strength.
214923081|NCT02304731|OTHER|Physical Exercise|Incremental running
214923082|NCT06023381|OTHER|Sliding sign|"All women had Transabdominal Ultra-sonography using SAMSUNG WS80 elite ultrasound machine during the preoperative examination, using the real-time Transabdominal pelvic features (the relative motion between the maternal abdominal and uterine wall).~The patient was asked to breathe deeply, accentuating her respiratory movements and the sonographer recorded a video clip in a mid-sagittal plane lateral to umbilicus focus on the infra-umbilical space, to determine whether the structure glided freely in relation to adjacent structures. To be considered as sliding, the structures had to glide easily, one against the other (positive sliding sign); no motion of the structure in question signaled a negative sliding sign."
214923083|NCT04684537|PROCEDURE|Extracorporeal shockwave therapy (ESWT)|The therapy will be performed with the focused piezoelectric shockwave (F10G4 Richard Wolf GmbH, Germany). The patient will be kept in the hip flexion, adduction and internal rotation position. After sonography-guided localization of the affected muscle and identification of the trigger point by the participant, ultrasound gel is applied to the skin and the applicator couple is placed with an impulse energy flux density of 0.456-0.882 mJ/mm2 for 3500 impulses.
215065747|NCT00143624|DRUG|Rosiglitazone maleate|See Detailed Description.
215065748|NCT00143624|DRUG|Placebo|See detailed description.
215065749|NCT04973202|OTHER|Stay for alcohol detoxification|Stay for alcohol detoxification : routine care.
215065750|NCT04731298|DRUG|Emapalumab|"Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first."
215065751|NCT03070860|RADIATION|PET scan 18-FDG and 18-NAF|"Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.~PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG)."
214672594|NCT00417365|DEVICE|WaterWorks Douching Device|
214672595|NCT03601338|DRUG|Bemiparin|second generation low molecular weight Heparin
214672596|NCT03601338|OTHER|multivitamins and routine antenatal follow up|multivitamins and routine antenatal follow up
214923084|NCT04684537|PROCEDURE|Ultrasound-guided piriformis steroid injection|all the participants will receive ultrasound-guided piriformis injection with 10 mg triamcinolone and 1 c.c. 1% lidocaine for one time.
214923085|NCT03138837|DIAGNOSTIC_TEST|Magnetic resonance imaging|Diffusion Weighted Magnetic resonance imaging
214923086|NCT05268783|PROCEDURE|EORTC QLQ-C30|Quality of life questionnaire that has to be completed every 6 months
214923087|NCT05268783|PROCEDURE|EORTC QLQ-GI.NET21|Quality of life questionnaire that has to be completed every 6 months
214923088|NCT05268783|PROCEDURE|Satisfaction survey|Questionnaire regarding satisfaction of care that has to be completed on Day 1.
214923089|NCT01355575|DRUG|Rifaximin|Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.
214923090|NCT01213732|OTHER|Isolated inferior limb perfusion|Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
215065752|NCT02177331|DRUG|Lacidipine|
215065753|NCT01591954|DEVICE|Video Augmentation|Assessment of value of video-based navigation system
215065754|NCT01323088|OTHER|Control|Standard care control (no exercise)
215065755|NCT01323088|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
215065756|NCT01323088|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
215065757|NCT06053151|BEHAVIORAL|exercise counselling|. The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy. The goal of the first phase was to start regular exercise, and the goal of the second phase was to continue regular exercise.
215065758|NCT01672281|OTHER|vibrox- vs. resistance training|Comparison between two exercise interventions
215065759|NCT00796731|DRUG|SAR3419|administered by intravenous infusion
214923091|NCT05051280|PROCEDURE|cone-beam computed tomography fusion image|Left Atrial Appendage Occlusion Under Cone-beam Computed Tomography Fusion Image Guidance
214923092|NCT05087316|DEVICE|biomimetic oral appliance therapy (BOAT)|BOAT appliance is designed to correct maxillo-mandibular underdevelopment in both children and adults (Singh and Lipka, 2009). However, adults will only use for this study. Typically, a BOAT appliance consists of 6 patented, anterior 3-D Axial Springs™, a midline actuator (such as omega loops or screws), posterior occlusal rests, and a round labial bow (Figure 1). Patients will be trained on activation of the screw
214923093|NCT05087316|DEVICE|Standard hospital treatment|Use of CPAP and similar methods
214923094|NCT00827216|DRUG|Placebo|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
215065760|NCT01420913|DRUG|Pregabalin|Pregabalin 300mg a day
214923095|NCT00827216|DRUG|Erythromycin|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
214923096|NCT02420080|DRUG|Brincidofovir|Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
214923097|NCT01521390|DRUG|GSK573719 62.5 mcg (one strip)|GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
215065761|NCT02548481|OTHER|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
215065762|NCT06506474|DIAGNOSTIC_TEST|Provision of any of six different low-value health services for treatment of bronchiolitis|This prospective observational will have six separate primary outcomes acting as exposures, (or interventions).The exposures are the the provision of any of the six low-value health services: 1) respiratory virus testing; 2) chest x-ray; 3) continuous pulse oximetry; 4) short-acting beta-agonists; 5) systemic corticosteroids; and 6) antibiotics.
215065763|NCT05101629|DRUG|Pembrolizumab|Pembrolizumab 200 mg, IV, over 30 minutes every 3 weeks
215065764|NCT05101629|DRUG|Lenvatinib Capsules|Lenvatinib 8 mg for BW \< 60 kg / 12 mg for BW ≥ 60 kg oral, once daily for 3 weeks
215065765|NCT06423456|DRUG|Lidocaine IV|Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
215065766|NCT06423456|DRUG|Saline|Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
215065767|NCT03554356|DEVICE|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation System
215065768|NCT00744380|DRUG|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
215065769|NCT00744380|DRUG|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
215065770|NCT01329653|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4X/week
215065771|NCT01329653|BEHAVIORAL|Wait list|wait list control condition
215065772|NCT04268121|DRUG|Neoadjuvant treatment|4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy
215065773|NCT04268121|DRUG|Adjuvant treatment|Surgery (before study entry) followed by 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide
214923098|NCT01521390|DRUG|GSK573719 62.5 mcg(two strips)|GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
214923099|NCT01521390|DRUG|GSK573719 125 mcg (one strip)|GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
214923100|NCT01521390|DRUG|GSK573719 125 mcg(two strips)|GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
214923101|NCT01521390|DRUG|Placebo|Placebo, no active ingredient
214923102|NCT02148757|PROCEDURE|Doppler Ultrasound|
214923103|NCT04221256|DRUG|Administration of SSRI escitalopram|Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation
214923104|NCT04221256|BEHAVIORAL|Paired Associative stimulation|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
214923105|NCT04221256|DRUG|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
214923106|NCT02659280|OTHER|Adjunct Therapy|"Store and Forward Tele-heath"
214923107|NCT02659280|OTHER|Standard of Care|Standard of Care Outpatient Physical Therapy
214923108|NCT02524743|DRUG|acetaminophen|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated acetaminophen (50mg and 25 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
214923109|NCT02524743|DRUG|Lidocaine|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated lidocaine (20 mg and 40 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
215065774|NCT01207076|BIOLOGICAL|90Y-AHN-12|"The intervention consists of two parts.~1. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~   * Dose escalation of nonradiolabeled AHN-12:~   Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~2. Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~   * the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy."
215065775|NCT00153140|DRUG|polyethyleneglycol3350|
215065776|NCT00253773|DRUG|acetominophen, sulfer amino acids; cysteine and methionine|
214672597|NCT04079556|BEHAVIORAL|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
214672598|NCT01981122|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
215065777|NCT02443116|BIOLOGICAL|NGM282|
215065778|NCT02443116|OTHER|Placebo|
215065779|NCT05144893|BEHAVIORAL|Virtual Mindfullness-Based Intervention|Virtual administration of the social support components of an adapted 4-week Mindfulness Based Cognitive Therapy for Postpartum Depression (MBCT-PD) intervention. Each session includes a review of assigned online mindfulness practice and barriers to practice, other homework if also assigned, psychoeducation, and mindfulness practices relevant to the session's theme.
215065780|NCT00330408|BEHAVIORAL|GP training|
215065781|NCT01932372|DRUG|Tofacitinib (Xeljanz)|5 mg Tablet BID
215065782|NCT01932372|DRUG|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
215065783|NCT03393936|BIOLOGICAL|CCT301-38|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
215065784|NCT03393936|BIOLOGICAL|CCT301-59|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
215065785|NCT06145581|BEHAVIORAL|Supportive Care (home-based physical activity)|Receive health coaching
215065786|NCT06145581|OTHER|Exercise Intervention|Participate in home-based physical activity
215065787|NCT06145581|OTHER|telephone interview|Participate in a telephone interview
215065788|NCT06145581|OTHER|Remote Monitoring|Undergo remote monitoring
215065789|NCT06145581|PROCEDURE|Patient Monitoring|Monitor physical activity
215065790|NCT06145581|OTHER|Questionnaire Administration|Ancillary studies
215065791|NCT06145581|OTHER|Electronic Health Record Review|Ancillary studies
214923110|NCT02524743|OTHER|Placebo|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated 5 ml iv normal saline before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
215065792|NCT04637776|OTHER|Hospitalization|Hospitalization for any reason
215065793|NCT04168008|BEHAVIORAL|WISH Adherence|The educational sessions will consist of an adherence-centered curriculum.
214347537|NCT03796624|DEVICE|PODEYE|"Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3."
214923111|NCT03050853|BEHAVIORAL|E-cigarette|The e-cigarette arm will be provided with 8 weeks of free e-cigarettes based on self-report of regular tobacco use. Participants assigned in this arm will be asked to switch combustible tobacco with e-cigarettes. The appeal of e-cigarettes and health impacts will be measured, but we are not targeting quitting combustible tobacco or reducing craving.
215065794|NCT04168008|BEHAVIORAL|WISH Parenting|The educational sessions will focus on parenting and baby care.
215065795|NCT04069468|DEVICE|TheraSphere|Participants will receive treatment with TheraSphere in accordance with Instructions for Use
215065796|NCT05070351|DRUG|PPI deprescribing|Patients currently on a proton pump inhibitor (PPI) undergoing transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized to receive instructions to stop taking their PPI.
215065797|NCT05046067|PROCEDURE|Computed Tomography|Undergo CT
215065798|NCT05046067|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery per standard of care
215065799|NCT01917929|DEVICE|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
215065800|NCT04106219|DRUG|LY3295668 Erbumine|Administered orally.
215065801|NCT04106219|DRUG|Topotecan|Administered IV.
215065802|NCT04106219|DRUG|Cyclophosphamide|Administered IV.
215065803|NCT06249061|DIETARY_SUPPLEMENT|oral sodium bicarbonate|Those in the oral sodium bicarbonate intervention group will be encouraged to sip a solution of 1 imperial teaspoon (\~5g) of sodium bicarbonate dissolved into 250ml of water throughout labour with other drinks. If the first solution is fully consumed, a second solution will be prepared and offered. Thus, each participant can receive a maximum dose of 2 imperial teaspoons (\~10g) of sodium bicarbonate.
215065804|NCT06387290|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative therapeutic approach.
215065805|NCT06387290|BEHAVIORAL|Patient-Centered Chronic Pain Management Visits|Participant will meet with their primary care provider for patient-centered care and shared decision making while discussing their chronic pain management strategy (e.g., opioid analgesics).
215065806|NCT03266744|DIAGNOSTIC_TEST|Computerised Tomography|
215065807|NCT03266744|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|
215065808|NCT03266744|DIAGNOSTIC_TEST|Bone scan|
215065809|NCT06368739|BEHAVIORAL|Nurture program|"1. Nurture Monthly Packages: Sent every four weeks until the member reaches the end of pregnancy (delivery or other reasons, e.g., miscarriage), with a maximum of eight packages. Each package includes:~   * A US$40 gift card (2 x $20 each) to a grocery store.~  * A healthy eating information sheet selected from Brighter Bites project (https://brighterbites.org/).~  * A set of three recipes.~  * Nutrition-related Frequently Asked Questions (included in four out of the eight packages).~2. Two 30-Minute Nutritional Consultations over the phone: Designed by a Registered Dietitian Nutritionist (RDN) who trained a bilingual nutrition specialist to deliver the consultations. Topics revolved around healthy eating during pregnancy, such as food choices, portion sizes, budget-friendly shopping, food safety, and food preparation. No nutrition therapy advice to manage diseases was provided."
215065810|NCT06368739|OTHER|Regular benefits|Includes regular healthcare services offered as part of the health plan coverage with Medicaid/CHIP.
215065811|NCT06305806|DRUG|Ivabradine|Participants will receive ivabradine for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months).
215065812|NCT06305806|DRUG|Ivabradine Placebo|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months)."
214347538|NCT05517317|COMBINATION_PRODUCT|Autologous BMMC transplantation|One administration of autologous bone marrow mononuclear cells via the hepatic artery
215065813|NCT06305806|BEHAVIORAL|Coordinated Care|Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
215065814|NCT06305806|BEHAVIORAL|Usual Care|Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
215065815|NCT02655757|DRUG|Sitagliptin|5 mg, 1 tablet per day for 12 months
215065816|NCT02655757|DRUG|Placebo|Placebo,1 tablet per day for 12 months
215065817|NCT00651014|DRUG|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
215065818|NCT00651014|DRUG|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
215065819|NCT03114111|DRUG|aminolevulinic acid (ALA)|
215065820|NCT03114111|DRUG|Placebo|
215065821|NCT03742479|DEVICE|Restylane® Silk|Injectable Hyaluronic Acid (HA)
215065822|NCT00810771|BEHAVIORAL|Standard Information|A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
215065823|NCT00810771|BEHAVIORAL|Preference-tailored Information|A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
214347539|NCT03845608|COMBINATION_PRODUCT|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation
214347540|NCT05880992|BEHAVIORAL|Exercise|Aerobic and Strength exercises (equipment free, simple, modifiable)
215065824|NCT02738541|DRUG|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
215065825|NCT02738541|DRUG|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
215065826|NCT03890900|OTHER|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
215065827|NCT06245486|DIETARY_SUPPLEMENT|Crispact®|Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247
215065828|NCT06245486|DIETARY_SUPPLEMENT|Placebo|Placebo
215065829|NCT00302354|DRUG|OROS methylphenidate HCl|
215065830|NCT00302354|DRUG|SODAS methylphenidate HCl|
215065831|NCT01185951|DRUG|Polidocanol|Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
215065832|NCT01185951|DEVICE|Focused extracorporeal shock wave therapy|Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks
215065833|NCT01185951|DRUG|Topical NO|Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
215065834|NCT01185951|BEHAVIORAL|Painful eccentric training in Achilles tendinopathy|Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks
215065835|NCT01185951|BEHAVIORAL|Painful eccentric training for patella tendinopathy on 25° decline board|Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks
215065836|NCT01185951|BEHAVIORAL|Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar|Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
215065837|NCT00332085|DRUG|Chromium Picolinate|
215065838|NCT02951403|PROCEDURE|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
215065839|NCT02951403|OTHER|Conservative treatment|Physiotherapy protocol is introduced to patients.
215065840|NCT00648388|DRUG|Cilostazol Tablets 100 mg|100mg, single dose fasting
215065841|NCT00648388|DRUG|Pletal® Tablets 100 mg|100 single dose fasting
215065842|NCT03828097|DIETARY_SUPPLEMENT|Experimental supplement|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
215065843|NCT03828097|DIETARY_SUPPLEMENT|Placebo|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
215065844|NCT00741897|DRUG|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
215065845|NCT02748044|DEVICE|CC-Cruiser|An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
215065846|NCT00066599|DRUG|voriconazole|
215065847|NCT03440151|PROCEDURE|contralateral submental flap for tongue cancer defect|"Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted."
214323321|NCT04593901|BEHAVIORAL|Video and App Review|"Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment."
214323322|NCT01983657|DRUG|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
214323323|NCT01983657|PROCEDURE|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
214347541|NCT05880992|DIETARY_SUPPLEMENT|Nutrition|Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)
214347542|NCT05880992|BEHAVIORAL|Mindfulness|Deep (box) breathing completing in the morning, evening and as needed.
214923112|NCT05748847|PROCEDURE|Intrastromal corneal ring segment implantation (Pocket)|"Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted pocket creation.~The device creates an intrastromal corneal pocket of 8-mm diameter and a depth of nearly 80% of the corneal thickness at the thinnest location with a superior tunnel incision at 90° of 5-mm width."
214347543|NCT03455426|DRUG|letrozole|Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.
214347544|NCT01754662|DIETARY_SUPPLEMENT|Soy protein|2 bars daily for 8 weeks.
214923113|NCT05748847|PROCEDURE|Intrastromal corneal ring segment implantation (Tunnel)|"Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted tunnel creation.~The device creates an intrastromal tunnel with a depth of nearly 80% of the corneal thickness at the site of implantation. The tunnel inner and outer diameters are at 5 and 6 mm from the corneal center, respectively with the incision located at the steepest keratometry axis."
214923114|NCT01707108|DEVICE|Dental Implant (MIS Technologies)|MIS Technologies Ltd. C1 Dental implants
214923115|NCT01088672|PROCEDURE|Mechanical Thrombectomy|The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
214923116|NCT02830113|PROCEDURE|non-surgical periodontal treatment|One session of complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution
214923117|NCT00526357|DRUG|omega-3 fatty acid|Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
214923118|NCT03036865|DRUG|BOS161721|Single dose administered IV or SC
214923119|NCT03036865|DRUG|Placebo|Single dose administered IV or SC
214923120|NCT04523103|BEHAVIORAL|Artificial Assisted Activation|Artificial assisted activation represents an effective technique to rescue the fertilization failure.
214923121|NCT05898984|DRUG|Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI|"CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[200 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg.~Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg.~Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve)."
214923122|NCT05898984|DRUG|Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI|with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg
214923123|NCT05898984|DRUG|Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)|pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
214923124|NCT05712629|OTHER|Bread and vla dadiah|Consumption bread and vla dadiah to pregnant women 1 Pieces a day during 12 weeks.
214923125|NCT05712629|OTHER|Bread and vla without dadiah|Consumption bread and vla without dadiah to pregnant women 1 Pieces a day during 12 weeks.
214923126|NCT00020644|DRUG|gemcitabine hydrochloride|
214923127|NCT05831644|DRUG|C21|C21 is an angiotensin II type 2 receptor agonist (ATRAG)
214923128|NCT02378428|DRUG|MIBG|
214347545|NCT01754662|DIETARY_SUPPLEMENT|Isoflavones|2 bars daily for 8 weeks.
214347546|NCT01754662|DIETARY_SUPPLEMENT|Cocoa|2 bars daily for 8 weeks.
214347547|NCT01754662|DIETARY_SUPPLEMENT|Placebo|
214347548|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
214347549|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to \<10.5 g/dL had occurred.
214347550|NCT04475913|OTHER|DIG Axial|patients received 4 axial implants and digital impression
214485789|NCT05515978|BEHAVIORAL|Lifestyle Modification|"Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.~Here are some examples of the educational material from the American Diabetes Association website, and topics will be rotated on quarterly basis:~Healthy eating: https://www.diabetes.org/nutrition/healthy-food-choices-made-easy Prediabetes: https://www.diabetes.org/diabetes-risk/prediabetes Fitness: https://www.diabetes.org/fitness/get-and-stay-fit Weight loss: https://www.diabetes.org/fitness/weight-loss"
214923129|NCT01094301|DEVICE|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
214923130|NCT03625648|DRUG|Pentoxifylline|The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
214923131|NCT03625648|DRUG|Placebo|placebo
214923132|NCT00131950|OTHER|physiologic testing|
214923133|NCT00131950|OTHER|study of socioeconomic and demographic variables|
214923134|NCT00131950|PROCEDURE|breast imaging study|
214923135|NCT00131950|PROCEDURE|study of high risk factors|
214923136|NCT02165280|BEHAVIORAL|Guided IMagery (GIM)|It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
214923137|NCT06455293|DRUG|Psilocybin|"Single dose of psilocybin ranging from low (microdose) to high delivered orally with psychological support and monitoring"
214923138|NCT01209585|OTHER|Blood samples|Subjects will have visits on Days 1, 30 and 120.
214923139|NCT01209585|OTHER|Synovial fluid aspiration|Subjects will have visits on Days 1, 30, and 120.
214923140|NCT01209585|OTHER|Synovial tissue sample|Subjects will have visits on Days 1, 30, and 120.
214923141|NCT06575491|DEVICE|Ultrasound-guided supraclavicular approach|Patients submitted to Supraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
214923142|NCT06575491|DEVICE|Ultrasound-guided infraclavicular approach|Patients submitted to Infraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
214923143|NCT00582608|DRUG|131I-8H9|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m\^2 dose \[intended specific activity of \~20 mCi/mg protein\]
214923144|NCT00582608|DRUG|8H9|administration of 50mg/1.73m\^2 of unlabeled 8H9.
214923145|NCT03714074|DEVICE|PEEK implant abutment|Implants will be restored with abutments made from polyetheretherketone (PEEK) abutments and a PEEK superstructure
215065848|NCT03440151|PROCEDURE|primary closure for tongue cancer defect|Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
215065849|NCT02315248|RADIATION|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
215065850|NCT03367923|OTHER|Communication Intervention|Receive email/text
215065851|NCT03367923|OTHER|Counseling|Undergo exercise counseling
214323324|NCT03298750|PROCEDURE|Resection of ovarian tissue and mechanical stimulation|"he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~1. One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~2. A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory."
214323325|NCT03758911|OTHER|Semi-structured Interview|
214323326|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 1
214323327|NCT00957437|DRUG|AZD1305|ER formulation 1, bid for 5 days
214323328|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 2
215065852|NCT03367923|OTHER|Fitbit tracker|Wear Fitbit tracker
214323329|NCT03074903|DEVICE|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
214323330|NCT00685152|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
215065853|NCT03367923|OTHER|Quality-of-Life Assessment|Ancillary studies
215065854|NCT03367923|OTHER|Questionnaire Administration|Ancillary studies
215065855|NCT03367923|BEHAVIORAL|Telephone-Based Intervention|Receive phone call
215065856|NCT02336685|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
215065857|NCT02336685|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
215065858|NCT02336685|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
215065859|NCT02336685|DRUG|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
215065860|NCT02224287|PROCEDURE|Technologist control of fluoroscopy|Technologist control of fluoroscopy
214323331|NCT05692141|DEVICE|ultrasound|For each lesion, ultrasound Elastography would be performed using a Linear probe ;
214323332|NCT00915798|BEHAVIORAL|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
215065861|NCT02224287|PROCEDURE|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
215065862|NCT06539754|BEHAVIORAL|Music|Participants will have bone conducting headphones available to listen to the music of their choice from premade Spotify playlists.
215065863|NCT02551380|DRUG|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
215065864|NCT02551380|OTHER|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
214323333|NCT00915798|BEHAVIORAL|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
214323334|NCT02130765|DEVICE|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
214323335|NCT03326427|BEHAVIORAL|Skill Training Group of the Dialectical Behavior Therapy|A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
214323336|NCT03326427|OTHER|Treatment as Usual|Conventional protocol using only medication (including drug adherence).
214323337|NCT01441427|DRUG|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
214323338|NCT01441427|DRUG|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
214323339|NCT01441427|DRUG|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
214323340|NCT01441427|DRUG|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
214323341|NCT01441427|DRUG|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
214347551|NCT04475913|OTHER|DIG Tilted|received two anterior axial implants and two distal tilted implants, and digital impression
214347552|NCT04475913|OTHER|CIG Axial|patients received 4 axial implants and conventional impression
215065865|NCT00706108|BEHAVIORAL|Observational study|Observational (descriptive) study of technical and non-technical performance
215065866|NCT02933424|DIETARY_SUPPLEMENT|Protein Powder|
214485790|NCT05989763|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
214923146|NCT03714074|DEVICE|Zirconia abutment|Imolants will be restored with zirconia abutments and a PEEK superstructure
215065867|NCT00750841|DRUG|cediranib|45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
215065868|NCT06452394|DRUG|Doxycyclin|Belongs to the class of tetracyclines. It has bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria. Its mechanism of action lies in the binding to the 30S ribosomal subunit
215065869|NCT00736749|PROCEDURE|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
215065870|NCT00736749|OTHER|Questionnaire Administration|"Complete patient response form, Health Status Update Form (called the Keep in Touch form), and Quality of Life Questionnaire (PROMIS)"
215065871|NCT05549232|DEVICE|Hypoxic Red Blood Cells|Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced
215065872|NCT06384131|DRUG|ABI-4334|10 mg or 50 mg tablets for oral administration
215065873|NCT06384131|DRUG|Placebo|10 mg or 50 mg tablets for oral administration
215065874|NCT04724369|DRUG|18F-MFBG|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
215065875|NCT04555577|DRUG|Peposertib|Given PO
215065876|NCT04555577|RADIATION|Radiation Therapy|Undergo radiation therapy
215065877|NCT04555577|PROCEDURE|Resection|Undergo surgical resection
215065878|NCT04555577|DRUG|Temozolomide|Given PO
215065879|NCT02778542|BEHAVIORAL|Electronic Pill Bottle|Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
215065880|NCT02778542|BEHAVIORAL|Bidirectional Text Messaging|Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
214323342|NCT05650372|OTHER|High intensity resistive exercise|Participants of this group will be applied manual lymphatic drainage and compression bandaging every day of the week, and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition, 2 days of the week. Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises.Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull-down, bicep curl, triceps extension, lateral raise, and wrist curl.
214323343|NCT05650372|OTHER|Low intensity resistive exercise|"participants in this group will be applied manual lymphatic drainage and compression bandaging every day of the week and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition 2 days of the week.~Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises. Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull- down, bicep curl, triceps extension, lateral raise, and wrist curl."
214485791|NCT05989763|DEVICE|Sham-TEA|Sham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
214485792|NCT04011839|DRUG|Levobupivacaïne|Use of Levobupivacaïne instead ropivacaïne
215065881|NCT04296188|PROCEDURE|serratus anterior plane block|ultrasound guided serratus anterior plane block will be done with % 0.25 bupivacaine.
215065882|NCT04296188|PROCEDURE|erector spina plane block|ultrasound guided erector spina plane block will be done with % 0.25 bupivacaine.
215065883|NCT03192293|DRUG|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
214923147|NCT02078440|DRUG|Bromocriptine mesylate|Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
214923148|NCT06736444|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
215065884|NCT05738967|BEHAVIORAL|Transdiagnostic cognitive behavioral therapy (CBT)|Adolescent-caregiver dyads will will participate in CBT focused on exposure therapy and behavioral activation. It will also include flexible incorporation of emotion-focused coping and adaptations for autism.
215065885|NCT05738967|BEHAVIORAL|Treatment as usual|Adolescent-caregiver dyads will participate in coordinated referrals to the community. They may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
215065886|NCT05275478|DRUG|TNG908|TNG908, a selective PRMT5 inhibitor, will be administered orally
215065887|NCT03168737|PROCEDURE|Computed Tomography|Undergo PET-CT scan
215065888|NCT03168737|RADIATION|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
215065889|NCT03168737|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
215065890|NCT06160687|PROCEDURE|PSV mode during NIV|NIV will be delivered using PSV mode of ventilation
214323344|NCT04574947|DRUG|Intravenous lidocaine|Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
214323345|NCT04574947|DRUG|Intravenous placebo|During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
214923149|NCT06736444|BEHAVIORAL|Brief Alcohol Screening and Intervention for College Students (BASICS)|Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
214923150|NCT06736444|BEHAVIORAL|Attention Control|Attention Control is comprised of 4 weekly 20-minute check-ins with a study therapists regarding the daily monitoring and mood/functioning. Referrals for additional services will be provided as needed.
214323346|NCT04574947|PROCEDURE|Intra-cuff lidocaine|The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
214923151|NCT06744582|OTHER|VO2 max|The aim of this study is to generate data on the estimation of natural variation in VO2 max changes before and after surgery using seismocardiography.
214923152|NCT03745976|PROCEDURE|questionnaire and Xray for all patients|questionnaire and Xray for all patients
214923153|NCT05872269|DRUG|Saroglitazar|4 Mg Oral Tablet
214923154|NCT05914662|DRUG|Zanubrutinib, Bendamustine and Rituximab|Zanubrutinib, 160mg orally, twice a day; Bendamustine 70 mg/m2 on days 1 and 2 of each cycle; Rituximab (375 mg/m2 intravenously on day 0 of each cycle. ZBR was administered every 4 weeks for a total of 6 cycles, followed by maintenance therapy with zanubrutinib monotherapy for another 6 months.
214923155|NCT03010800|DEVICE|With Yoni.Fit|Abbreviated Pad Test with Yoni.Fit first, then without Yoni.Fit.
214923156|NCT03010800|DEVICE|Without Yoni.Fit|Abbreviated Pad Test without Yoni.Fit, then with Yoni.Fit.
214923157|NCT05107609|BEHAVIORAL|Acute Self-Compassion Intervention|Participants will be guided through a 30-minute behavioural self-compassion intervention that seeks to mitigate their psychobiological responses to the subsequent weight stigma induction. The intervention is intended to induce a flexible self-compassionate mindset that will facilitate more adaptive psychological responding to stress and activate affiliative/self-soothing physiological systems that can dampen psychobiological stress reactivity. This acute self-compassion intervention will employ a multimodal, experiential approach that is regularly utilized in self-compassion training, drawing from approaches developed in Compassion-Focused Therapy and Mindful Self-Compassion.
214923158|NCT05619354|OTHER|Survey study|Participants will be asked to complete and evaluate the Dutch version of the Headache Disability Index. Validity (face validity, content validity, convergent validity with the RAND-36 and HIT-6) will be determined. Second, internal consistency and test-retest reliability will be evaluated.
214923159|NCT02698527|DRUG|Non-Buffered Lidocaine|Active comparator
214323347|NCT04574947|PROCEDURE|Intra-cuff placebo|The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
214323348|NCT03490084|OTHER|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
214923160|NCT02698527|DRUG|Buffered Lidocaine|Experimental, additIon of Sodium Bicarbonate to Lidocaine
215065891|NCT06160687|PROCEDURE|ASV intellisync|ASV intellisync mode will be used to deliver NIV
215065892|NCT04017819|DRUG|18F-C-SNAT4|Radiotracer- Dose 10 mCi
215065893|NCT04017819|DEVICE|Positron emission tomography (PET)/Computed tomography (CT) Scan|Positron emission tomography (PET)/Computed tomography (CT) Scan
215065894|NCT04394416|DRUG|Imatinib|Therapeutic
215065895|NCT04394416|DRUG|Placebo oral tablet|Placebo
215065896|NCT04575545|DIAGNOSTIC_TEST|Serology test for COVID-19|ELISA test
215065897|NCT06093880|DEVICE|monofocal intraocular lens|monofocal aspheric hydrophilic-hydrophobic intraocular lens
215065898|NCT04793204|DRUG|fezolinetant|oral
215065899|NCT05035225|OTHER|Survey|Multiple Pharmacy Use Survey
215065900|NCT06338748|DEVICE|Continuous glucose monitor (CGM) Dexcom G7 used in blinded mode|Dexcom G7 used in blinded mode
214323349|NCT03490084|OTHER|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
214323350|NCT02193594|RADIATION|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
214323351|NCT02193594|PROCEDURE|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
214323352|NCT02193594|DRUG|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
214323353|NCT03357406|PROCEDURE|ultrasound implant site preparation|piezoelectric bone surgery will be used to create implant bone ostectomy
214323354|NCT03357406|PROCEDURE|conventional implant site preparation|twist drills will be used to create implant bone ostectomy
214323355|NCT03009097|BIOLOGICAL|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
214323356|NCT03009097|DRUG|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
214323357|NCT00397995|PROCEDURE|above- or under elbow cast|
214323358|NCT00808938|DEVICE|MST|Magnetic Seizure Therapy
214323359|NCT04514991|DEVICE|Foundation|Collagen-based, bone filling augmentation material used to stimulate bone formation in extraction sockets or bone defects in the alveolar ridge.
214347553|NCT04475913|OTHER|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
214347554|NCT05051566|DRUG|LY3502970|Administered orally.
214347555|NCT05051566|DRUG|Esomeprazole|Administered orally.
214923161|NCT03763929|DRUG|Trans-Sodium Crocetinate|In the study drug kit containing the experimental drug (TSC), TSC will be reconstituted with the Sterile Water for Injection (USP) supplied in the same kit. There will be an unblinded paramedic who will reconstitute and inject the TSC on the ambulance.
214923162|NCT03763929|OTHER|Placebo|The study drug kit containing placebo (sterile saline for Injection) will be prepared and injected by the unblinded paramedic on the ambulance.
214923163|NCT04397497|DRUG|Mavrilimumab|human monoclonal antibody targeting GM-CSF receptor-alpha
214923164|NCT04397497|DRUG|Placebo|matching volume of diluent
214923165|NCT00568230|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
214923166|NCT02425124|BEHAVIORAL|PC101+Mental Health|Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
214923167|NCT03145454|DEVICE|electroencephalography helmet|electroencephalography helmet with twelve electrodes will be performed during surgical gesture to determine the pain of child.
214923168|NCT03145454|DEVICE|dermal electrode|dermal electrode on the back of the hand will be performed during surgical gesture to determine the pain of child.
214923169|NCT03145454|DEVICE|blood pressure sensors|blood pressure sensors on the finger will be performed during surgical gesture to determine the pain of child.
214923170|NCT03145454|DEVICE|Pupillometry glasses|Pupillometry glasses will be performed during surgical gesture to determine the pain of child.
214923171|NCT03145454|DEVICE|Holter|Three electrodes electrocardiography on the chest will be performed during surgical gesture to determine the heart rate variability.
214923172|NCT02569151|DEVICE|HBP & CBP measurement using systo 130 mmHg|
214923174|NCT01732640|DRUG|Afatinib|Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
214923175|NCT01732640|DRUG|Paclitaxel|Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
214923176|NCT01732640|DRUG|Carboplatin|Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
214923177|NCT01732640|DRUG|Cisplatin|Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
214923178|NCT01732640|RADIATION|Intensity Modulated Radiation Therapy|Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
214923179|NCT01832792|OTHER|Face-to-face self-help|Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.
214923180|NCT01832792|OTHER|E-mail self-help|Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.
214923181|NCT01832792|OTHER|Waiting List|Waiting list condition - participants assigned to a waiting list (no intervention) condition
214923182|NCT02240940|DEVICE|Parachute Implant|CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
214923183|NCT01037179|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
215065901|NCT05788432|DEVICE|Sequent Please Neo|Patients in whom treatment with (Sequent Please Neo) has been attempted
215065902|NCT03829969|BIOLOGICAL|Toripalimab|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy
215065903|NCT06224140|PROCEDURE|Heparin Anticoagulation|Conventional dialysis with heparin as anticoagulant treatment
215065904|NCT06224140|PROCEDURE|Regional Anticoagulation Procedure (RAP)|Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.
215065905|NCT04777435|DIAGNOSTIC_TEST|Therapeutic orientation test for TMA|Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.
214485793|NCT04457843|OTHER|usual medical care|Prospective monitoring of clinical Outcomes and digital collected outcomes via the mobile COPD staus test app.
214923184|NCT06129916|DRUG|long-acting depot buprenorphine (LADB)|The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.
215065906|NCT06545929|DRUG|Sunobinop|1 tablet taken orally at bedtime
215065907|NCT06545929|DRUG|Placebo to match sunobinop|1 tablet taken orally at bedtime
215065908|NCT00394758|PROCEDURE|CO2 laser surgery|
214323360|NCT06313372|DIAGNOSTIC_TEST|Respiratory oscillometry|This a Delphi study where we are obtaining expert opinion and input on the use of respiratory oscillometry (a diagnostic respiratory test) in the assessment and management of patients with asthma or chronic obstructive pulmonary disease. The participants are respiratory specialists/pulmonologists. They are sharing their insights into the clinical use of respiratory oscillometry via a series of online surveys. The Delphi process is used in an attempt to achieve consensus as to how respiratory oscillometry is used in clinical practice. As such there is no intervention being used on the study participants, but they are sharing insights on how the respiratory test is used in their clinical practice in order to obtain consensus on this use.
214323361|NCT00325806|DRUG|Ramipril|
214323362|NCT00791791|PROCEDURE|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
214323363|NCT05117463|OTHER|Optic Flow Stimulation|The optic flow will be displayed at different speeds. The subject will need to look at the center of the optic flow.
214323364|NCT05117463|OTHER|Auditory Reaction Time|Two different pitches of tones will be played. The participants will need to press a button on the right or left hand based on the pitch of the tone.
215065909|NCT00394758|PROCEDURE|ultrasonic surgical aspiration|
215065910|NCT04426149|DIETARY_SUPPLEMENT|trehalose|patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
215065911|NCT04130724|DIAGNOSTIC_TEST|Blood ketone testing|Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.
215065912|NCT04130724|DIAGNOSTIC_TEST|Breath ketone testing|Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
215065913|NCT03415451|DEVICE|Fiberscope-Guided Nasogastric tube insertion|Fiberscope-Guided Nasogastric tube insertion
215065914|NCT02865954|DEVICE|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
215065915|NCT02059499|DRUG|imiquimod|Given intra-anally
215065916|NCT02059499|DRUG|fluorouracil|Given intra-anally
215065917|NCT02059499|OTHER|questionnaire administration|Ancillary studies
215065918|NCT02059499|OTHER|laboratory biomarker analysis|Correlative studies
215065919|NCT06440200|BEHAVIORAL|group gamed-based activity|Participants in interventional group will play the active-type software with Switch game console which develops by Nintendo company. Team building, cooperation, cohesion, sense of belonging and sense of achieving will be emphasized.
215065920|NCT06653764|OTHER|Chest physiotherapy and aerobic exercise training|Chest Physiotherapy including Percussion, vibration and shaking; along with it aerobic exercises such as walking up and down stairs, bedside ambulation, step walking
215065921|NCT03645278|DRUG|SHR0532|Ascending dose oral adminstration
215065922|NCT03645278|DRUG|Placebo|Ascending dose oral administration
215065923|NCT06512779|OTHER|Control Group|sleep hygiene education
215065924|NCT06512779|PROCEDURE|Surgical Intervention|Surgical Intervention includes uvulopalatopharyngoplasty (UPPP) and transoral robotic surgery (TORS). UPPP involves the removal of the uvula and tonsils, while TORS consists of the removal of the uvula, tonsils, and adipose tissue at the base of the tongue.
215065925|NCT06512779|OTHER|Oropharyngeal Training (face-to-face)|Participants will attend face-to-face oropharyngeal training sessions with a therapist in the lab, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
215065926|NCT06512779|OTHER|Oropharyngeal Training (telerehabilitation)|Participants will attend online oropharyngeal training (telerehabilitation) sessions with a therapist, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
215065927|NCT06512779|DEVICE|Continuous Positive Airway Pressure|Participants will use Continuous Positive Airway Pressure (CPAP) throughout the intervention period.
215065928|NCT05016310|DIETARY_SUPPLEMENT|High Dose Vitamin D|High dose vitamin D: Subjects will receive 50,000 IU vitamin D2 weekly x 16 weeks followed by 4,000 IU of vitamin D3 daily with a goal 25(OH)D level of ≥45 but ≤80 ng/mL.
215065929|NCT05016310|DIETARY_SUPPLEMENT|Standard of Care Vitamin D|Standard of Care Vitamin D: Vitamin D will be supplemented to 25(OH)D levels, with a goal 25(OH)D level of \>30 ng/mL according to Endocrine Society Practice Guidelines.
215065930|NCT02134561|BEHAVIORAL|psychological interview|
215065931|NCT02134561|RADIATION|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
214323365|NCT06538623|DRUG|Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin|Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);
214323366|NCT06538623|DRUG|Tegodor|Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
214323367|NCT06279312|DIETARY_SUPPLEMENT|Placebo drink|consume 1 drink per day for 4 weeks
214323368|NCT06279312|DIETARY_SUPPLEMENT|Adaptogen Elixir drink|consume 1 drink per day for 4 weeks
214323369|NCT00283933|DRUG|migalastat HCl|
214323370|NCT03337100|BEHAVIORAL|Co-Dispensing|"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."
214323371|NCT02985242|DRUG|Empagliflozin|Empagliflozin film-coated tablet
215065932|NCT02134561|OTHER|cognitive tests|
215065933|NCT02134561|OTHER|neurological tests|
215065934|NCT00703846|DRUG|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
215065935|NCT03685903|DEVICE|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
215065936|NCT03877614|OTHER|ASCVD risk score|ASCVD score\< 10% will be in the control or low-risk group
214323372|NCT02985242|DRUG|Glimepiride|Glimepiride tablet
214323373|NCT02985242|DRUG|Empagliflozin placebo|Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
214323374|NCT02985242|DRUG|Glimepiride placebo|Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
215065937|NCT02620033|BEHAVIORAL|Yoga therapy|
215065938|NCT03873298|DRUG|Inhaled nitric oxide|Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
215065939|NCT01788397|BEHAVIORAL|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
215065940|NCT04437550|OTHER|Exercise|high intensity exercise = 15 x 60 s sprints at 85% velocity of VO2max (vVO2max) with 60 s walking at 20% vVO2max or moderate intensity exercise = walking at 60% vVO2max
215065941|NCT02511795|DRUG|AZD1775|"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
215065942|NCT02511795|DRUG|Olaparib|"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
215065943|NCT04392674|DEVICE|the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
215065944|NCT03303053|DRUG|Cholestyramine Powder 4g|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
214323375|NCT03802448|COMBINATION_PRODUCT|Study group|"Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
215065945|NCT03303053|DRUG|Prednisolone|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
214323376|NCT03802448|DEVICE|Control group|A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
214323377|NCT01408186|DRUG|Rabeprazole|Rabeprazole 20 mg daily
214323378|NCT01408186|DRUG|Famotidine|Famotidine 40mg daily
215065946|NCT03303053|DRUG|Standard treatment|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
215065947|NCT00292201|DRUG|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
214323379|NCT05867147|DRUG|Vanzacaftor|Tablets for oral administration.
214323380|NCT05867147|DRUG|Vanzacaftor Placebo|Placebo for oral administration.
215065948|NCT06991348|DRUG|Tegoprazan|Tegoprazan 50 mg daily for 28 days
215065949|NCT06991348|DRUG|Pantoprazole|Pantoprazole 40 mg daily for 28 days
215065950|NCT03512808|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
215065951|NCT03512808|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
214323381|NCT05867147|DRUG|Moxifloxacin|Tablets for oral administration.
214323382|NCT05867147|DRUG|Moxifloxacin Placebo|Tablets for oral administration.
214323383|NCT00861211|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
214923185|NCT02275455|BEHAVIORAL|real life situations|Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
214923186|NCT01289860|DIETARY_SUPPLEMENT|Flavonoids|475g of anthocyanidins in 300ml of blueberry drink.
214923187|NCT01289860|DIETARY_SUPPLEMENT|Control|29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
214923188|NCT00889876|DRUG|Metformin group|2000 mg/day for one year
214923189|NCT00889876|BEHAVIORAL|Exercise|3 times/week with a personal coach for one year. Endurance training.
214923190|NCT00712543|DRUG|lactulose (Kristalose®)|Crystals to be dissolved in water and taken as prescribed.
215065952|NCT06992843|OTHER|Goal-directed care bundle for neuroprotection|"Reducing lactate (Lac) to \<2 mmol/L within 24 hours.Maintaining systolic arterial pressure at 120-140 mmHg.~Elevating the head-of-bed to 30 degrees. Maintaining body temperature ≤37.7°C. Maintaining PaO₂ at 70-100 mmHg. Maintaining PaCO₂ at 35-45 mmHg. Maintaining blood glucose at 7.8-10.0 mmol/L. Maintaining serum sodium level at 140-150 mmol/L. If any management parameter falls outside the target range, immediate correction is required within 24 hours of enrollment and must be sustained for 72 hours. Given the dynamic nature of some targets (e.g., mean arterial pressure, body temperature), a degree of flexibility is permitted in achieving these goals. Patients are considered to have successfully implemented the neuroprotection bundle if the achievement rate of individual targets is ≥80% and all targets are met. The medications(antipyretics, vasopressor agents) is acceptable to achieve these targets."
214323384|NCT00861211|DRUG|Placebo|Placebo comparator
214323385|NCT03026621|DIETARY_SUPPLEMENT|Lignite Extract|"The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo."
214323386|NCT03026621|OTHER|Herbal tea|This is an herbal tea that will look like the control
214323387|NCT02244580|DEVICE|MammaTyper™|MammaTyper™ kit is a molecular in vitro diagnostic test for the quantitative detection of the ribonuclease acid (RNA) expression status of the genes for estrogen receptor (ESR1), progesterone receptor (PGR), human epidermal growth factor receptor 2 (HER2) and proliferation antigen KI 67.
214923191|NCT00712543|DRUG|liquid lactulose|Liquid to be taken as prescribed.
214923192|NCT03973879|BIOLOGICAL|PVSRIPO|Oncolytic polio/rhinovirus recombinant
214923193|NCT03973879|DRUG|Atezolizumab|Antibody
215065953|NCT06992843|OTHER|Usual Care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
214485794|NCT00328783|DEVICE|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
214323388|NCT03978975|BEHAVIORAL|Food intake|"For all those session, subjects will take a standardized breakfast (570kcal) three hours before experimental session.~Control session (CON): subject will stand sited without any activity during 40 min.~Subjects will be submitted to three aquatic cycling exercise session:~* session 27°C :aquatic cycling at 27°C without water jet during 40 min~* session 27°C+ water jets : aquatic cycling at 27 °C with water jets during 40 min~* session 18°C : aquatic cycling at 187°C without water jet during 40 min Every exercise session will be set at 70% of theorical maximal heart rate During each session, oxygen consumption and carbon dioxide production will be analysed with gas analysis system. Appetite and hunger sensation will be measured with a specific scale at different time point of each day of experimental session. Thirty minutes after the end of each experimental session subjects will have a buffet meal for lunch time."
214485795|NCT00328783|RADIATION|Radiation Therapy|
214323389|NCT01736696|DRUG|tofacitinib|5 mg BID For 13 days and once on Day 14
214323390|NCT01736696|DRUG|tofacitinib|10 mg BID for 13 days and once on Day 14\*
214323391|NCT01736696|DRUG|tofacitinib|20 mg BID for 13 days and once on Day 14
214323392|NCT01736696|DRUG|tofacitinib|30 mg BID for 13 days and once on Day 14
214323393|NCT01736696|DRUG|tofacitinib|60 mg tablet once a day (QD) for 14 days
214323394|NCT01736696|DRUG|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
215065954|NCT04601038|DRUG|CORT108297|120mg of a selective glucocorticoid receptor antagonist, taken as 2 tablets daily for 2 weeks
215065955|NCT04601038|DRUG|Placebo|Placebo taken as 2 tablets daily for 2 weeks
215065956|NCT07002996|BEHAVIORAL|SMIP|Participants will undergo a 3-month-long regimen of 60 minutes spatial memory training sessions held twice a week, consisting of a series of computerized virtual reality tasks.
215065957|NCT07002996|OTHER|No intervention|Control participants will not receive spatial memory intervention training. They will watch documentaries and then complete multiple choice quizzes on its content to ensure they are paying attention. The placebo condition will match the experimental condition in terms of duration and visit frequency.
214323395|NCT01701661|PROCEDURE|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
214323396|NCT01701661|OTHER|conservative treatment|Compression stockings class II
214323397|NCT01974193|DRUG|Floseal|application of floseal on intervention arm
214323398|NCT02114879|BEHAVIORAL|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
214323399|NCT02114879|BEHAVIORAL|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
214323400|NCT03189030|BIOLOGICAL|pLADD|via IV infusion
214323401|NCT02420028|DEVICE|Insertion of OptiVein IV catheter|Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
214323402|NCT02420028|DEVICE|Insertion of Vasofix Certo IV catheter|Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
214323403|NCT05881473|DIAGNOSTIC_TEST|pain assessment after clavicular fracture repair|This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
214323404|NCT06244862|DRUG|Ruxolitinib|Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
214323405|NCT01455012|DRUG|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
214323406|NCT01455012|DRUG|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
214323407|NCT06520709|OTHER|No intervention|No intervention
214323408|NCT02550847|DEVICE|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
214323409|NCT04110483|PROCEDURE|Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.
214347556|NCT04443738|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for recieved treatment will be conducted over the phone for patients.
215065958|NCT07019571|DEVICE|Wireless Multichannel Transcranial Current Stimulator (tDCS)|tDCS will be delivered for 13 minutes (active) or only at the beginning and end of the 13 minute period (sham) using Neuroelectrics Instrument Controller software and a battery-driven Starstim 8-channel transcranial direct current stimulator with 1cm2 ceramic electrodes and SIGNAGEL conductive saline gel.
215065959|NCT07019571|BEHAVIORAL|Cue exposure|Participants will undergo three, twenty-second trials of exposure to individualized cues at the top of the established urge hierarchy, previously determined to precede picking or biting behaviors before and after tDCS.
215065960|NCT07019571|BEHAVIORAL|Boredom induction|Participants will be left in the testing room without access to a cellphone or reading materials for 2 different 6 minute periods.
215065961|NCT06072833|BEHAVIORAL|Patient Financial Education / Navigation|The investigator anticipates that this will include a baseline financial assessment and educational content, likely using a virtual platform. Participants will be connected with a PAF case manager. There will be monthly follow-ups to the participant for 6-months to address any financial concerns through additional counseling/navigation.
215065962|NCT07030010|OTHER|Breakfast meal challenge with tonic drink|High-carbohydrate containing breakfast meal with the addition of the tonic drink
215065963|NCT07030010|OTHER|Breakfast meal challenge with placebo drink|High-carbohydrate containing breakfast meal with the addition of the placebo drink
215065964|NCT07035015|OTHER|VR UGRA|The simulator applied principles of cognitive task analysis, which is a method aimed at describing the knowledge, cognitive process, and goal structures experts rely upon while performing a complex procedure
215065965|NCT07035015|OTHER|Mannequin-based simulation|The hybrid simulator will consist of a 3G mannequin and a gel-based part-task trainer.
214923194|NCT00199238|DRUG|Rupatadine Fumarate|
214923195|NCT06238687|BIOLOGICAL|STRO-002|STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.
214923196|NCT00235885|DRUG|adalimumab|
214923197|NCT06128928|BEHAVIORAL|REDES|Training on motivational interviewing (MI) led by community health workers on how to use MI to address vaccine hesitancy using a guiding approach, open-ended questions, affirmations, reflections, and summaries.
214923198|NCT06128928|BEHAVIORAL|Control|Brief CHW-led training about the safety and efficacy of the COVID-19 vaccine. Participants will have the opportunity to ask clarifying questions from the CHWs during the training.
214923199|NCT06558383|OTHER|augmented posterior oblique sling activation|activation of posterior oblique sling for 18 sessions, three sessions per week for six weeks
214923200|NCT06558383|OTHER|selected physical therapy program|selected physical therapy program for 18 sessions, three sessions per week for six weeks in form hot packs, soft tissue techniques, mobilization and manipulation of lumbar spine, and neurodynamics and stabilization exercises
214923201|NCT02702388|DRUG|Lenvatinib|Lenvatinib capsule.
214923202|NCT02702388|DRUG|Lenvatinib matching placebo|Lenvatinib matching placebo capsule.
214923203|NCT04790461|OTHER|Pre-post test|Adult Caregiver Quality of Life Questionnaire (AC-QoL) Perceived Stress Scale (PSS) The Stress Coping Styles Questionnaire (SCSQ)
214923204|NCT04790461|BEHAVIORAL|face-to-face training + PMR exercise|4 weeks Roy adaptation-based face-to-face training + PMR exercises to be taught, 4 weeks exercise counseling
214923205|NCT04790461|BEHAVIORAL|mobile health education + PMR exercise|To provide awareness and exercise with 8 weeks Roy adaptation model-based training and mobile application access with PMR exercise content
214923206|NCT04790461|BEHAVIORAL|face-to-face and mobile health education + PMR exercise|4 weeks face-to-face training based on Roy adaptation model + teaching PMR exercises and 4 weeks based training on Roy adaptation model and mobile application access with PMR exercise content
214923207|NCT01134445|DEVICE|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
214923208|NCT01496378|BEHAVIORAL|Problem-Solving Skills Training|Parents will receive 8, 1-hour sessions of individual problem-solving therapy over 8 weeks. Caregivers will complete the first training session and at least 3 subsequent sessions in person. Remaining sessions will be completed via telephone. In session 1, parents will be introduced to the PSST program and a rationale and explanation for problem solving strategies will be provided. During sessions 2-8, parents will identify a problem that they wish to work on. The therapist will use the primary cognitive-behavioral strategies of modeling, behavioral rehearsal, performance feedback, and generalization of skills in the process of teaching problem solving skills to parents. Parents will complete homework assignments to practice using the problem-solving skills in real-life situations
214923209|NCT02729051|DRUG|FF/UMEC/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains UMEC and VI blended with lactose and magnesium stearate. It is available as dry white powder, 62.5 mcg per blister UMEC, 25 mcg per blister VI. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
214923210|NCT02729051|DRUG|FF/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains VI blended with lactose and magnesium stearate. It is available as dry white powder, 25 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
215065966|NCT07034326|OTHER|Electroacupuncture combined with immunotherapy|Connect the electroacupuncture therapy instrument, select the density wave 2 Hz/100 Hz, the current intensity should be tolerated by the patient, leave the needle for 20 min.Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.The period is 1 year, and maintenance treatment can be carried out in accordance with the drug instructions and guidelines.
215065967|NCT07034326|DRUG|Zilongjin tablet combined with immunotherapy|Take Zilongjin tablets orally, 4 tablets each time, 3 times a day.Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.The period is 1 year, and maintenance treatment can be carried out in accordance with the drug instructions and guidelines.
215065968|NCT07034326|DRUG|Immunotherapy|Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.The period is 1 year, and maintenance treatment can be carried out in accordance with the drug instructions and guidelines.
215065969|NCT07033780|DEVICE|Spaced iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left dorsolateral prefrontal cortex (DLPFC) to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity. TMS-EEG will be performed to measure changes in brain plasticity throughout the trial. An EEG cap will be placed on the participant's head, and the electrodes on the cap will be filled with saline gel using a dull syringe.~During the intervention, the study team will conduct a baseline TMS-EEG measurement consisting of single TMS pulses. Participants will then complete iTBS-s (experimental study intervention), which will be delivered to the left DLPFC. Following iTBS-s, post-iTBS TMS-EEG measurements will be obtained consisting of 3 TMS trains delivered to the left DLPFC (Post-0, Post-20, and Post-60 minutes)."
214672599|NCT01981122|DRUG|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
214672600|NCT03499041|DRUG|LY3314814|Administered orally
214923211|NCT02729051|DRUG|UMEC|This intervention is available in one strip. The strip contains UMEC blended with lactose and magnesium stearate. The formulation is available as dry white powder, 62.5 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
214672601|NCT05183958|RADIATION|Radiotherapy group|Stereotactic body radiotherapy (SBRT, 8Gy/time, 3 -5 times, if other segmentation schemes are used, recommend BED10 \>60Gy) or conventional fractional radiotherapy (parts that are not suitable for SBRT, the total dose is more than 30Gy); the primary lesion should be treated with conventional fractional radiotherapy with a dose of 4000cGy or more;
214672602|NCT05183958|DRUG|Camrelizumab|4 cycles for combined therapy. Camrelizumab maintenance.
214923212|NCT02729051|DRUG|Placebo|This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
214923213|NCT02729051|DRUG|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.
214923214|NCT04496193|PROCEDURE|Quadratus Lumborum block|Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
214923215|NCT02128373|PROCEDURE|Usual care|Health care provided by physician, physician's nurse, and social worker
214923216|NCT02128373|OTHER|computer-assisted intervention|Caregiver will virtually attend visit using the CLOSER intervention
214672603|NCT05183958|DRUG|Chemotherapy|4 cycles for combined therapy.
214672604|NCT06535399|DRUG|BMS-986369|Specified dose on specified days
214672605|NCT05358691|DRUG|AN0025|To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants
214923217|NCT02128373|OTHER|Distress Thermometer|Average score of a one item scale (range 0-10) where higher scores indicate more distress
214923218|NCT02128373|OTHER|Profile of Mood States (POMS-B)|average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort
214323410|NCT04110483|PROCEDURE|Transurethral resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
214323411|NCT02178384|PROCEDURE|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
214323412|NCT02178384|DEVICE|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
214323413|NCT02178384|PROCEDURE|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
214323414|NCT02643654|DRUG|MABp1|This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
214323415|NCT02643654|DRUG|Placebo|The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
214323416|NCT02294877|DRUG|Vimizim® (elosulfase alfa)|Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
214323417|NCT06967584|OTHER|Kinesio Taping|"The Kinesio tape will be applied anteriorly and posteriorly along the subcostal region to facilitate the respiratory muscles. Anteriorly, an I-shaped Kinesio tape will be applied with the base anchored on the xiphoid process, stretched to 50-75% tension, applied only to the linea alba. The ends of the tape will be applied without tension toward the subcostal curvature. Posteriorly, a second I-shaped Kinesio tape will be applied. The base of the tape will be anchored on the spinous process of the 12th thoracic vertebra with 50-75% tension, and the tails will be applied without tension toward the ribs"
214323418|NCT06967584|OTHER|Sham Kinesio Taping|The Kinesio tape will be applied anteriorly and posteriorly along the subcostal region but without tension
214923219|NCT02128373|OTHER|Quality of Life: Functional Assessment in Cancer Therapy - (FACT)|Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality
214923220|NCT02128373|OTHER|Tension-Anxiety Subscale|six item scale which asks to qualitatively describe which areas in you life are causing stress
214923221|NCT04674280|PROCEDURE|aHSCT|Autologous haematopoietic stem cell transplantation
214923222|NCT05127876|DRUG|Ondansetron 4 MG|Ondansetron 4mg was given over 1 min, 5 min before spinal anesthesia
214923223|NCT05127876|DRUG|Ondansetron 8mg|Ondansetron 8mg was given over 1 min, 5 min before spinal anesthesia
214923224|NCT05127876|DRUG|EPHEDrine 10 Mg/mL-NaCl 0.9% Intravenous Solution|Ephedrine 10mg was given over 1 min, 5 min before spinal anesthesia
214923225|NCT05127876|OTHER|10 mL normal saline|10 mL normal salinwe 0.9% was given over 1 min, 5 min before spinal anesthesia
214923226|NCT06529614|OTHER|In-situ detection for Micro-RNA|a new in-situ detection methods for Micro-RNA
214923227|NCT00802984|DEVICE|Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System|
214923228|NCT03687684|DRUG|TAK-831|TAK-831 Tablets.
214923229|NCT03687684|DRUG|Placebo|TAK-831 Matching Placebo Tablets.
214923230|NCT05018923|DRUG|Rabeprazole|20mg bid
214923231|NCT05018923|DRUG|Bismuth potassium citrate|0.6g bid
214923232|NCT05018923|DRUG|Metronidazole|0.4g qid
214923233|NCT05018923|DRUG|Doxycycline|0.1g bid
214923234|NCT05018923|DRUG|Tetracycline|0.5g qid
214923235|NCT05620498|DRUG|tislelizumab+lenvatinib+GMOX|tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2
214923236|NCT05620498|DRUG|tislelizumab+GEMOX|tislelizumab+GEMOX
214923237|NCT05034198|BEHAVIORAL|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
214923238|NCT05034198|BEHAVIORAL|Cognitive behavioral therapy (CBT) for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
214923239|NCT05034198|BEHAVIORAL|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
214923240|NCT03682861|BEHAVIORAL|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
214923241|NCT03682861|BEHAVIORAL|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
215065970|NCT07033780|DEVICE|Compressed iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left dorsolateral prefrontal cortex (DLPFC) to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity. TMS-EEG will be performed to measure changes in brain plasticity throughout the trial. An EEG cap will be placed on the participant's head, and the electrodes on the cap will be filled with saline gel using a dull syringe.~During the intervention, the study team will conduct a baseline TMS-EEG measurement consisting of single TMS pulses. Participants will then complete iTBS-c (active comparator), which will be delivered to the left DLPFC. Following iTBS-c, post-iTBS TMS-EEG measurements will be obtained consisting of 3 TMS trains delivered to the left DLPFC (Post-0, Post-20, and Post-60 minutes)."
215065971|NCT07034209|DRUG|Plonmarlimab|Subjects receive Plonmarlimab 6 mg/kg or 10 mg/kg, administered intravenously, once weekly for 8 weeks.
214923242|NCT00823147|BEHAVIORAL|Pain Catastrophizing Induction|Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
215065972|NCT07034794|DIETARY_SUPPLEMENT|Lysoveta|The Lysoveta capsules contain 500 mg of lysophosphatidylcholine-rich oil extract of Antarctic krill.
215065973|NCT07034794|OTHER|Placebo|The placebo capsules contain medium-chain triglyceride (MCT) oil, maize oil, olive oil, and palm kernel oil.
214923243|NCT00577980|DRUG|Testosterone|Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
214923244|NCT01497912|DRUG|Atorvastatin|Atorvastatin 80mg once daily for 8 weeks
214923245|NCT01497912|DRUG|Placebo|Placebo tablet once daily for 8 weeks
214923246|NCT02737943|DRUG|Moist Exposed Burn Ointment (MEBO)|is a registered USA patented formulation since 1995. MEBO is pure herbal, natural in origin, containing beta-sitosterol phellodendron amurense, scutellaria baicalensis, coptis chinensis, pheretima aspergillum, Beeswax and sesame oil. 15, 19 The pharmacological effects are attributable to: beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensis, Beeswax and sesame oil.
214323419|NCT03634553|OTHER|Training with e-health product|The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
214323420|NCT03634553|OTHER|Usual care|usual care, i.e. participates in regular training regime at the physiotherapy department
214323421|NCT04817228|DRUG|EscharEx (EX-02 formulation)|EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
214323422|NCT03409432|DRUG|Brentuximab Vedotin|Given IV
214323423|NCT03409432|OTHER|Laboratory Biomarker Analysis|Correlative studies
214323424|NCT03409432|DRUG|Lenalidomide|Given PO
214323425|NCT03326011|DEVICE|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
214323426|NCT05328830|OTHER|Instrument assisted soft tissue mobilization|Myofascial release technique will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity with the Graston technique®. The application will be at 450 angles for each muscle, 2 minutes, for a total of 6 minutes. The IASTM application will include sweep-fan-sweep strokes and cycle through each muscle for the specified time.
214323427|NCT05328830|OTHER|Foam Roller|Will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity using rigid Foam Roller. A total of 6 minutes will be applied to a person, 2 minutes for each muscle. Pressure intensity; According to the Visual Analog Scale, which is the point where pain will not be felt but moderate to severe discomfort will be felt, it will be done at a severity of 7/10.
214323428|NCT05721274|BEHAVIORAL|Community mobilization and Conditional community incentives|Non-cash, incentives would be given to clusters which improve the polio vaccine coverage and reduce the refusals and these incentives would be decided with consensus by community and costs would be shared
214323429|NCT04721249|DIETARY_SUPPLEMENT|D-serine|Patients will receive four 500mg capsules of D-serine each day over a course of six weeks (two after breakfast and two after dinner).
214323430|NCT04721249|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive four placebo capsules each day (two after breakfast and two after dinner). The placebo capsules will contain Mannotol / Mannitol-Silica (99.5/0.5, respectively) and will be indistinguishable from D-serine by matching colour, shape, size and packaging.
214923247|NCT02737943|DRUG|Zagazig|Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
214923248|NCT00164528|BEHAVIORAL|Positive Behavior Support|
214923249|NCT05515211|DIAGNOSTIC_TEST|Foot length|Foot length will be measured from the midpoint of the heel to the longest toe.
215065974|NCT07039955|BEHAVIORAL|Daily Chlorhexidine Bathing|Daily bathing using no-rinse, 4% chlorhexidine gluconate (CHG)-impregnated washcloths will be implemented in ICUs assigned to the intervention group. The purpose is to reduce CPE colonization and infection by maintaining effective residual CHG skin concentrations. Bathing will be performed by trained nursing staff following standardized protocols.
215065975|NCT07039955|BEHAVIORAL|Antimicrobial and PPI Stewardship Program|A targeted stewardship program will be implemented to reduce unnecessary carbapenem use and inappropriate proton pump inhibitor (PPI) prescriptions. The program includes audit and feedback, education of ICU physicians, and monthly monitoring of antimicrobial and PPI usage. Stewardship activities will be uniformly applied across both intervention and control ICUs.
215065976|NCT07039955|BEHAVIORAL|Standard Bathing|Patients in ICUs assigned to the control group will receive standard daily bathing without the use of chlorhexidine. No CHG-containing products will be applied. This represents usual care in the participating hospitals.
214923250|NCT03533361|DRUG|Lenvatinib|Oral capsules: 4 milligrams (mg) and 10 mg
214923251|NCT00449137|DRUG|Arsenic trioxide|ATO will be administered at dose levels determined by the dose escalation scheme (section 4.2). Intra-venous (IV) infusion of ATO (mg/kg body weight) over 1-4 hours will be administered for 5 consecutive days (day 1 to day 5) during the first week, twice a week on weeks 2 and 3 (days 8, 11, 15, and 18), and only one day (day 22) of week 4. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
214923252|NCT00449137|DRUG|Fluorouracil|Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
214672606|NCT05011552|BEHAVIORAL|Self-Compassion, Health, and Empowerment (SHE)|The SHE intervention includes 8 weekly sessions and 24-hour access to the intervener for any additional support needed. The first and last sessions will be delivered over the phone with the woman based on a brochure. The brochure describes the four major components: a) IPV information, b) Danger Assessment, c) Safety Planning, and d) Resources. It will be discussed with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Session 2-7 focus on providing mental health self-care resources, which are deep breathing, progressive muscle relaxation, visualization, general introduction and overview of self-compassion, mindfulness, and loving-kindness.
214672607|NCT05011552|BEHAVIORAL|The Control Condition|Women randomized to the control group will be provided with the same brochure and mental health care resources.
214923253|NCT00449137|DRUG|Leucovorin calcium|On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
214923254|NCT00449137|OTHER|Plasma levels of elemental arsenic|Pre-Treatment and and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22
214923255|NCT00449137|GENETIC|Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis|Peripheral blood samples (PAXgene Blood RNA tube, Qiagen, USA) will be obtained up to 2 weeks prior to start of treatment (same day as the first FNA) and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22. Along with FNA an additional blood sample will be obtained on day 23 of every odd treatment cycle.
214923256|NCT00449137|PROCEDURE|Tumor Biopsy (Fine-Needle Aspiration)|Pre-Treatment, Day 23 of Cycles 1, 3, 5, 7
214923257|NCT01045577|DRUG|Masitinib|6 mg/kg/day
214923258|NCT01045577|DRUG|Masitinib|3 mg/kg/day
215065977|NCT07033845|DEVICE|Phenylephrine|Topical Phenylephrine
214672608|NCT02293343|OTHER|blood profile|
214672609|NCT01419990|DRUG|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
214672610|NCT01419990|DRUG|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
215065978|NCT07042386|BEHAVIORAL|CROWN Intervention|"CROWN Intervention includes:~1. Private BP screenings in salon Heart Health Stations by trained Heart Health Stylists~2. Free Omron home BP monitor paired with a mobile app for twice-daily telemonitoring~3. In-depth coaching sessions + monthly check-ins with a community health worker~4. Bi-weekly medication review and adherence support by a clinical pharmacist~5. Digital social-needs screening (AHC HRSN) with referral to community resources"
215065979|NCT07042386|BEHAVIORAL|Enhanced Usual Care|"Enhanced Usual Care include:~1. Private BP screenings in salon Heart Health Stations by Heart Health Stylists~2. Printed cardiovascular health brochures~3. Free home blood pressure monitor (no app integration)~4. Standard referrals to social and health services"
214323431|NCT04166838|BIOLOGICAL|CD19 UCARTcells|This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 \^ 6 cells/kg,3 × 10 \^ 6 cells/kg,5 × 10 \^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
214323432|NCT02385175|OTHER|Different objective clinical tests of Eustachian tube function|
214923259|NCT01045577|DRUG|Placebo|Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
214923260|NCT05903105|OTHER|Questionnaires|Patients fill in a questionnaire
214923261|NCT06302153|PROCEDURE|Progressive Loading Exercises|At start of study, a formal educational session, lasting about 30 minutes will be given by the physiotherapist dealing with the treatment/interventions. Whole treatment plan will be given for six weeks. Pre and post intervention measurements will be taken.
214923262|NCT04088695|OTHER|Video through a web page|Participants will see a video about blood donation.
214923263|NCT04088695|OTHER|Informative text|Participants will see a brief text about blood donation.
215065981|NCT07048860|OTHER|ICOPE intense intervention|The ICOPE-intense intervention (45 hours centre-based (in-group and in-person) multidomain intervention, everyday home-based lifestyle improvement, and weekly individual phone/video call for support)
215065982|NCT07048860|DIETARY_SUPPLEMENT|Ketone Ester (KE) supplementation|12.5g once a day of KE for week 1, and 25g once a day of KE supplementation week 2 to week 8.
215065983|NCT07048860|DIETARY_SUPPLEMENT|Placebo|2.5 g of nonketogenic canola oil
214323433|NCT02385175|OTHER|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
214323434|NCT00613509|BIOLOGICAL|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
215065984|NCT07048860|DIETARY_SUPPLEMENT|Vitamin D3|2 sprays (i.e. 2000 iu) per day in the morning for 60 days
215065985|NCT07048860|DIETARY_SUPPLEMENT|OMega 3|1000 mg: 1 table per day in the morning during 60 days
215065986|NCT07048860|DIETARY_SUPPLEMENT|vitamin B9|5 mg cp: 1 tablet morning and 1 tablet evening for 60 days
215065987|NCT07048860|DIETARY_SUPPLEMENT|Vitamin B12|250 microgram: 1 tablet per day in the morning for 30 days, then 1 tablet every 10 days for 30 days
215065988|NCT07048860|DIETARY_SUPPLEMENT|Leucin-rich whey|In case of Sarcopenia or low protein intake (\<1.2 g/kg/day), Oral Nutritional Supplementation enriched in essential amino acid (leucin)
214672611|NCT01419990|DRUG|Placebo|Placebo oral capsules, qd, 10 days
214672612|NCT03905772|OTHER|Voluntary exercise|The participants will perform 36 maximal voluntary contractions, 3 times per week for 8 weeks.
214672613|NCT03905772|OTHER|Wide pulse responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in responder group in acute fase.
214923264|NCT05728827|OTHER|Blood flow restriction training + Anti-gravity treadmill|Blood flow restriction training is administered via straps applied to the proximal limb with the possibility to adjust the applied occlusion pressure in order to prevent venous return leaving the arterial flow partially free. The consequent blood pooling causes a reduction in tissue saturation with oxidative stress and an increased growth factors secretion. The intervention will be applied while walking/running on the anti-gravity treadmill.
214923265|NCT05728827|OTHER|Anti-gravity treadmill|The intervention will be applied walking/running on the anti-gravity treadmill.
214923266|NCT06651827|DIAGNOSTIC_TEST|Dentin sensitivity was measured using the Yeaple Probe and air stimulation tests before and after treatment|Dentin sensitivity was measured using the Yeaple Probe and air stimulation tests before and after treatment. The effectiveness of the treatment was assessed at baseline, 30 minutes, 1 week, and 1 month post-treatment using the Visual Analog Scale (VAS) and Yeaple Probe scores.
214923267|NCT02147158|DRUG|Ulipristal acetate (UPA)|Ulipristal acetate (UPA) tablet.
215065989|NCT07048860|OTHER|ICOPE Step 1|usual ICOPE Step 1
215065990|NCT06743425|OTHER|RAMP Reports|Participants will receive text-based requests for reports with embedded links to select radio button questionnaires directly on their mobile device. Questions include current inattention/hyperactivity symptoms, school performance, and any engagement in behavioral therapy. Inattention/hyperactivity symptom questions and scoring is taken directly from the publicly available Vanderbilt Rating Scales, which is a commonly used, guideline-recommended tool for both diagnosis and management of ADHD for use by parents and teachers.
214923268|NCT02147158|DRUG|Placebo|Matching placebo tablet.
215065991|NCT06743425|OTHER|Digital Education Handouts|The digital education handouts will be sent via email to the control group and will serve as an attention control. They will consist of information regarding a general pediatric health topic and will be emailed at intervals matching the RAMP requests in the intervention group.
215065992|NCT06899152|DIAGNOSTIC_TEST|HepQuant DuO|HepQuant DuO is a quantitative liver function test. It assesses cholate uptake, a liver specific function. Cholate is a naturally occurring substance that is cleared by the liver. Cholate uptake reflects the health of liver cells.
215065993|NCT06899152|OTHER|Multiparametric MRI Scans|Standard of care
215065994|NCT07071012|DRUG|Bupivacaine|Used for regional anesthesia during nephrectomy procedure (e.g., paravertebral or external oblique intercostal block)
215065995|NCT07071012|DRUG|morphine|Used for postoperative pain control via PCA device
215065996|NCT07071012|DRUG|paracetamol|Used as part of postoperative multimodal analgesia
215065997|NCT07071012|DRUG|Diclofenac|Administered for postoperative pain management
215065998|NCT07079423|DRUG|Teclistamab (Tec)|Teclistamab will be administered via a subcutaneous injection
215065999|NCT07080372|DIAGNOSTIC_TEST|assesment|This study aims to assess the role of early arterial phase in detecting and differentiating hepatocellular carcinoma from dysplastic nodules in chronic liver disease patients.
215066000|NCT07081763|DRUG|Baricitinib 2 MG|Administered orally at 2 mg QD from W0 to W10.
214672614|NCT03905772|OTHER|Wide pulse non responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in non responder group in acute fase.
215066001|NCT07081763|DRUG|Sirolimus 2 MG|Administered orally at 2 mg QD from W0 to W10.
215066002|NCT07081763|OTHER|Placebo of baricitinib 2 MG|Administered orally at 2 mg QD from W0 to W10.
215066003|NCT07081763|OTHER|Placebo of sirolimus 2 MG|Administered orally at 2 mg QD from W0 to W10.
215066004|NCT07079358|BEHAVIORAL|Veterans Cardiac Rehabilitation Referral Program|"1. A CDS tool that identifies Veterans hospitalized with CR-eligible conditions and prompts physicians to refer them to CR.~2. Educational materials that explain to Veterans the benefits and importance of participating in CR.~3. Defined responsibilities for a facility-based CR referral coordinator who will support development and oversight of the referral process."
214323435|NCT00613509|BIOLOGICAL|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
214323436|NCT01215227|DRUG|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
214323437|NCT01215227|DRUG|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
214323438|NCT01215227|DRUG|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
214323439|NCT01215227|DRUG|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
214323440|NCT03419728|BEHAVIORAL|Healthy Families, Healthy Futures|Home visiting program for pregnant and parenting teens
215066005|NCT07081035|DRUG|Warfarin (low-intensity anticoagulation)|"Low-intensity INR group (Experimental):~Participants will receive anticoagulation therapy with warfarin, aiming for a reduced INR range of 1.5-2.0, which is lower than the current standard recommendation. Warfarin dosing will be regularly adjusted based on INR monitoring throughout the 6-month study period."
215066006|NCT07081035|DRUG|Warfarin (standard anticoagulation)|"Standard INR group (Active Comparator):~Participants will receive anticoagulation therapy with warfarin, maintaining an INR within the standard therapeutic range of 2.0-3.0. Warfarin dosing adjustments will be made regularly according to standard clinical practice and INR monitoring throughout the 6-month study period."
215066007|NCT07080489|DEVICE|Active high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/F4|Participants receive anodal HD-tDCS targeting the left or right DLPFC (F3/F4).
215066008|NCT07080489|DEVICE|Sham high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/F4|Participants receive sham HD-tDCS targeting the left or right DLPFC (F3/F4). The device mimics the sensation of stimulation without delivering active current.
215066009|NCT07080489|DEVICE|Active high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/ kathodal F4|Participants receive anodal HD-tDCS targeting the left DLPFC (F3) and cathodal stimulation targeting the right DLPFC (F4).
214323441|NCT00001731|DRUG|Cyclosporin A|
215066010|NCT07080489|DEVICE|Sham high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/ kathodal F4|Participants receive sham HD-tDCS targeting the left DLPFC (F3) and right DLPFC (F4). The device mimics the sensation of stimulation without delivering active current.
215066011|NCT07080190|DRUG|Early N-Acetylcysteine|Patients received N-acetyl cysteine early (at admission) in the course of treatment of acute hair dye poisoning.
214323442|NCT04581642|DEVICE|PMD200|The NOL technology is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
214323443|NCT05164237|OTHER|nerve flossing technique|subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
215066012|NCT07080190|DRUG|Late N-Acetylcysteine|Patients received the standard treatment of N-acetyl cysteine after starting organ affection in the course of treatment of acute hair dye poisoning.
215066013|NCT07081698|OTHER|Infant walnut intake|The intervention group will receive walnuts at 10 g/day, and the control group will be advised to avoid walnuts/tree nuts during the intervention. The purpose of this research is to learn more about how walnuts as a first food in infants impact immunity and the development of bacteria living in your baby's gut.
215066014|NCT07079644|BIOLOGICAL|Nivolumab + Relatlimab|As per product label
215066015|NCT07079644|BIOLOGICAL|Nivolumab + Ipilimumab|As per product label
215066016|NCT07079644|BIOLOGICAL|Immunotherapy monotherapy|As per product label
215066017|NCT07079644|DRUG|BRAF/MEK inhibitors|As per product label
215066018|NCT07079540|DRUG|X842|X842 capsules
215066019|NCT07079540|DRUG|X842 Placebo|X842 placebo-matching capsules
215066020|NCT07079540|DRUG|Lansoprazole|Lansoprazole capsules
215066021|NCT07079540|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
214323444|NCT05164237|OTHER|multimodal electrotherapy|subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
214323445|NCT05164237|OTHER|exercises|subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
214323446|NCT02906774|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
214323447|NCT02253810|DRUG|Tranexamic Acid|Medication administered intra-operatively to promote blood clotting.
214485796|NCT04678752|OTHER|Weight management care path|"* Documentation and data capture built in the Electronic Health Record~* Clinical data support that suggests weight loss approach(es)~* Tracking of weight loss progress and weight loss maintenance during patient visits to guide the patient-clinician conversation~* Diagnosis and billing in EHR automatically adds the diagnosis of overweight or obesity and links the most common weight-related co-morbidities to ensure adequate provider reimbursement~* Evidence-based online training on weight management for clinicians~* Practice quality improvement and training for use of PATHWEIGH for weight-prioritized visits through practice coaches/facilitators~* Consultation support by practice facilitators with implementing PATHWEIGH and by obesity providers for clinicians with creating patient treatment plans"
214485797|NCT04678752|OTHER|Control|"Within primary care the option to select Obesity brief HPI, this is a brief historical intake of a patient's weight - when either they or their clinician decides to have a weight-prioritized visit. It is intended to initiate a discussion regarding potential strategies for weight loss (often eat less, exercise more). The provider has the discretion to augment or add support as they see fit."
214485798|NCT01054092|DRUG|ipragliflozin|oral
214485799|NCT00357682|DRUG|Esomeprazole|20mg per day
214923269|NCT06664996|RADIATION|stereotactic body radiation therapy (SBRT)|SBRT will be administered on days 1, 3, and 5 at a dose of 8 Gy per fraction, totaling 3 fractions.
214323448|NCT02253810|DRUG|Placebo|Saline solution
214323449|NCT06165796|DEVICE|routine cataract surgery and intraocular lens implantation|routine cataract surgery and intraocular lens implantation
214485800|NCT00357682|DRUG|Esomeprazole|80mg per day
214485801|NCT00357682|DRUG|Aspirin|300mg per day
214923270|NCT06664996|DRUG|Sintilimab (approved)|patients will receive a first dose of sintilimab at 200 mg on day 1, followed by a second dose of 200 mg on day 22 (week 4, ±3 days).
214923271|NCT06601946|OTHER|BLS Paper Based Cognitive App|BLS Paper Based Cognitive App
214323450|NCT04925063|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
214323451|NCT01877629|DRUG|ACT-129968 500 mg tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
214323452|NCT01877629|DRUG|ACT-129968 250 mg capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
214923272|NCT06601946|OTHER|First Aid App|First Aid App
214923273|NCT06601946|OTHER|Corpatch App|Corpatch App
214923274|NCT03033602|BEHAVIORAL|written exposure therapy|five sessions of writing about traumatic experience.
214923275|NCT03033602|BEHAVIORAL|CPT, cognitive only|12 sessions of cognitive therapy related to traumatic experience.
214923276|NCT01441765|DRUG|CT-011|CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks
214923277|NCT01441765|BIOLOGICAL|DC/RCC fusion vaccine|Vaccination once per cycle on Day 8 of treatment cycles 2-4
214923278|NCT00680485|DRUG|GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)|
215066022|NCT06363474|PROCEDURE|Decompressive Craniectomy|Patients allocated to this arm will undergo decompressive craniectomy, which involves the surgical removal of a section of the skull (bone flap). This procedure is performed to alleviate intracranial pressure (ICP) by providing additional space for the swollen brain to expand. The surgery will be performed by a single surgical team under general anesthesia. After the procedure, patients will be closely monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
215066023|NCT06363474|PROCEDURE|Cisternostomy|Patients allocated to this arm will undergo cisternostomy, a microsurgical technique used in neurosurgery. Cisternostomy involves the creation of an additional space for cerebrospinal fluid (CSF) circulation to alleviate brain edema and lower intracranial pressure (ICP). The surgery will be performed by the same surgical team under general anesthesia. Following the procedure, patients will be monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
215066024|NCT07081230|COMBINATION_PRODUCT|SRP with hyaluronic acid|patients will receive hyaluronic acid mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement
215066025|NCT07081230|COMBINATION_PRODUCT|SRP + Injectable Platelet-Rich Fibrin|patients will receive Albumin gel mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement
215066026|NCT07081048|OTHER|Buzzy®.Group|The ice pack, which has been removed from the deep freezer in advance, should be left at room temperature for 10 minutes, and the hole in the ice pack should be placed on the hook behind the Buzzy® will be placed on the lateral side of the left heel and activated for 30 seconds. After 30 seconds, Buzzy® will be pulled up 1 centimetre (cm), and the heel will be punctured with a sterile lancet to collect blood on the Guthrie card. After the heel blood collection procedure, Buzzy® will be pulled back to the punctured heel area and left for another 30 seconds.
215066027|NCT07081048|OTHER|ShotBlocker Group|"ShotBlocker will be placed on the designated area for collecting the baby's heel blood. After ensuring that the protrusions of the ShotBlocker are in contact, pressure will be applied for 20 seconds.~The heel will be punctured with a sterile lancet in the area designed for applying the ShotBlocker, and the ShotBlocker will be removed from the area. The blood collected will be collected on Guthrie paper."
215066028|NCT07081776|DEVICE|OptiNIV|"Patients assigned to the OptiNIV group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with an optimized mask (OptiNIV) and in the second session they will receive NIV with a traditional oronasal mask (Visairo). The study will follow a crossover design, meaning each patient will undergo both sessions, In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours."
215066029|NCT07081776|DEVICE|Visairo|"Patients assigned to the Visairo group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with a traditional oronasal mask (Visairo) and in the second session they will receive NIV with an optimized mask (OptiNIV). The study will follow a crossover design, meaning each patient will undergo both sessions. In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours."
214923279|NCT02112383|BEHAVIORAL|Cognitive behavior group therapy|For participants in the group intervention condition, the modules from a self-help treatment for procrastination will be delivered at four consecutive three-hour sessions at the Student Health Centre at Karolinska Institutet, with approximately two modules given at each session. The sessions will be spaced two weeks apart, during which participants are instructed to complete assignments related to the modules that were in focus of the previous session, e.g., goal-setting, time management, and behavioral experiments, which they are advised to present and discuss with the other participants.
214923280|NCT02112383|BEHAVIORAL|Internet-based cognitive behavior therapy|For participants in the Internet-based condition, the modules from a self-help treatment for procrastination will be distributed weekly during the treatment period, with one module given each week, i.e., ten weeks. In comparison to the group condition, participants will not receive a therapist contact or attend any sessions. In addition, the participants are expected to complete both the reading material and the assignments that are included in each module.
214323453|NCT06383663|PROCEDURE|Supraclavicular lymph node dissection combined with radiotherapy|Breast cancer patients in the expreimental cohort with only ipsilateral supraclavicular lymph node metastasis were first treated with supraclavicular lymph node dissection and received standard radiotherapy after surgery.
214323454|NCT06383663|RADIATION|radiotherapy|Patients in the control group received only standard radiation therapy.
214323455|NCT04022135|DIETARY_SUPPLEMENT|Folic acid|Participants will supplement with 0.6mg/day for 16 weeks.
214323456|NCT04022135|DIETARY_SUPPLEMENT|(6S)-5-methyltetrahydrofolic acid|Participants will supplement with 0.625mg/day for 16 weeks.
215066030|NCT07080827|BEHAVIORAL|TTM-Based Online Psychoeducation Program|A 5-week structured psychoeducation program based on the Transtheoretical Model (TTM), delivered via WhatsApp. Educational content was tailored to the participant's stage of change and included videos, texts, and interactive materials to promote treatment adherence in individuals with psychosis.
215066031|NCT07080827|BEHAVIORAL|Standard Face-to-Face Psychoeducation Program|A 3-week conventional psychoeducation program delivered face-to-face at the Community Mental Health Center. The program focused on general treatment adherence without utilizing the Transtheoretical Model and included verbal education, printed materials, and discussions.
215066032|NCT07080827|OTHER|TTM-Based Online Psychoeducation Program|The intervention was provided after a 3-month delay following initial observation. Participants received the same 5-week online psychoeducation program as the main intervention group
214672615|NCT03905772|OTHER|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
214672616|NCT02187640|BEHAVIORAL|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
214672617|NCT02187640|BEHAVIORAL|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
214923281|NCT06483620|DIAGNOSTIC_TEST|Neuropathy - and Foot Ulcer - Specific Quality of Life instrument (Neuro Qol)|The NeuroQoL questionnaire is a valid, reliable, and self-reported questionnaire. It has 35-items with six domains namely, painful symptoms and paresthesia (items 1-7), reduction or loss of ability to feel (items 8-10), unsteadiness while walking/standing/diffuse sensory-motor symptoms (items 11-13), limitation in daily living (items 14 - 16), interpersonal problems (items 17-20), emotional distress (items 21- 27) and end with an overall assessment of quality of life or satisfaction with experiences in the above six domains \[1 item in each domains, i.e. additional 6 items (items 28-33)\]. The two final items (items 34-35) assess overall impact of neuropathy on QoL \[5\]. The scoring of the questionnaire is according to a five-point Likert scale, all the time, most of the time, some of the time, occasionally, never. Each domain has a maximum score 5 and minimum 1, where 5 means that the QoL is affected all the time because of the foot problem while 1 means never it affects their QoL
214323457|NCT03794037|DRUG|dydrgesterone 10 mg( tab)/12hs/14 days|Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
214323458|NCT03794037|COMBINATION_PRODUCT|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days|montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&
215066033|NCT07079891|OTHER|MINS|MINS
214323459|NCT05207020|DEVICE|Glycemia estimated by exhaled air analyzer|Measurement of volatile compounds in the air exhaled by the volunteer on 3 different MIBs (3 breaths in total) at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
214323460|NCT05207020|BEHAVIORAL|Questionnaire|The questionnaire focuses on the methods and feelings of the blood glucose self-monitoring that he is currently carrying out, a first feedback on user experience on the operation of the prototype and the collection of his expectations for a future commercial device
214923282|NCT04610567|DRUG|Methotrexate-LDE phase 1|"3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE"
214923283|NCT04610567|DRUG|Methotrexate-LDE phase 2|44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
214923284|NCT04610567|DRUG|Placebo-LDE phase 2|44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
214923285|NCT03131973|DRUG|BMS-986195|Specified dose on specified days
214923286|NCT03131973|DRUG|Methotrexate|Specified dose on specified days
214923287|NCT03131973|DRUG|Leucovorin|Specified dose on specified days
215066034|NCT07081919|PROCEDURE|femtosecond laser-assisted arcuate keratotomy (FSAK) combined with standard cataract surgery|"1. 5-year follow-up assessing stability of astigmatism correction. Most FSAK studies track ≤2 years. This addresses critical evidence gaps in durability~2. Combines topographic data with patient-reported visual function (VF-14/QoV questionnaires at all visits. Links anatomical changes to real-world visual experiences"
215066035|NCT07080736|BEHAVIORAL|E-learning|"The training consists of an e-learning module created on the RISE - Articulate platform, and is based on previously developed e-learning modules (SP-reflex) and physical training aimed at other target groups, but was adapted to the specific context of detention.~This specific training will consist of sensitising information, theoretical knowledge, as well as some concrete tools and tips for suicide prevention within detention. Relevant examples and cases will be discussed. The following topics, among others, will be discussed:~* How common is suicide?~* What myths exist about suicide?~* Why do people contemplate suicide?~* What is the process from suicidal thoughts to suicide?~* How do I recognise signs of suicidal thoughts?~* What can I do if I notice signs?~* What if someone attempts suicide or a suicide occurs?~* How do I take care of myself?"
215066036|NCT07081113|OTHER|Cyriax Mobilization|Deep transverse friction massage applied to the wrist and forearm muscles, 3 sessions/week for 4 weeks, along with TENS and hot packs.
214323461|NCT05207020|BIOLOGICAL|Veinous glycemia|Measurement of the veinous glycemia at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
214323462|NCT05207020|BIOLOGICAL|Capillary glycemia|7-step capillary glycemia measurement: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
214923288|NCT03131973|DRUG|Caffeine|Specified dose on specified days
214923289|NCT03131973|DRUG|Montelukast|Specified dose on specified days
214923290|NCT03131973|DRUG|Flurbiprofen|Specified dose on specified days
214323463|NCT05207020|BIOLOGICAL|constitution biological collection|Sampling for storage of serum at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
214923291|NCT03131973|DRUG|Omeprazole|Specified dose on specified days
214923292|NCT03131973|DRUG|Midazolam|Specified dose on specified days
214923293|NCT03131973|DRUG|Digoxin|Specified dose on specified days
214923294|NCT03131973|DRUG|Pravastatin|Specified dose on specified days
214923295|NCT04445714|DRUG|dapagliflozin and saxagliptin|Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
214923296|NCT03582982|BEHAVIORAL|Eccentric overload exercise|12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.
214923297|NCT02805660|DRUG|Mocetinostat - 50 mg|Participants received mocetinostat three times weekly as an oral capsule.
214323464|NCT05207020|BIOLOGICAL|Blood sample|Single blood sample before mealtimes for HbA1C molecular analysis
214323465|NCT05207020|OTHER|Test meal|taking a test meal before the various blood sugar measurements
214672618|NCT00552799|DRUG|Penicillin VK|Biconcave tablet 250mg oral, b.d.
214923298|NCT02805660|DRUG|Mocetinostat - 70 mg|Participants received mocetinostat three times weekly as an oral capsule.
214923299|NCT02805660|DRUG|Mocetinostat - 90 mg|Participants received mocetinostat three times weekly as an oral capsule.
214923300|NCT02805660|DRUG|Mocetinostat - Recommended Phase 2 Dose (70 mg)|Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).
214923301|NCT02805660|DRUG|Durvalumab - 1500 mg|Participants received durvalumab as an intravenous infusion every 4 weeks.
214923302|NCT05607680|DRUG|Placebo|Placebo administered subcutaneously (SC) once a week.
214923303|NCT05607680|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
214923304|NCT05891223|OTHER|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
214923305|NCT05891223|OTHER|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214923306|NCT05891223|OTHER|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application."
214923307|NCT05891223|OTHER|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214672619|NCT00552799|OTHER|placebo|biconcave tablet matching active comparator as much as possible in size and shape
214672620|NCT03060577|DRUG|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
214672621|NCT03060577|DRUG|Evolocumab|Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
214672622|NCT05483543|DRUG|Pamiparib|Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
214672623|NCT00005963|DRUG|carboplatin|
214923308|NCT05891223|OTHER|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. Courtesy meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
214923309|NCT05891223|OTHER|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214923310|NCT05891223|OTHER|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
214923311|NCT05891223|OTHER|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
214923312|NCT01684943|OTHER|Multiplex pharmacokinetic profiling|
214923313|NCT01684943|OTHER|Continuous insulin monitoring|
214672624|NCT00005963|DRUG|docetaxel|
214323466|NCT06431893|DRUG|Pegtibatinase|Full Target Dose of pegtibatinase BIW
214923314|NCT02320773|DRUG|Betmiga®|Oral
214923315|NCT04223635|DRUG|Pexidartinib|Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
214923316|NCT02048098|DRUG|Vaginal misoprostol|400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
215066037|NCT07081113|OTHER|Muscle Energy Technique (MET)|Isometric contractions performed against therapist resistance to improve range of motion and reduce pain, 3 sessions/week for 4 weeks.
215066038|NCT07079436|DRUG|0.25% ropivacaine|During breast quadrantectomy, intercostal nerve block is performed at the 2nd to 6th intercostal spaces along the posterior axillary line using an in-plane technique. 4ml of 0.25% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space. Under ultrasound guidance, the needle tip is ensured to reach the space between the internal intercostal muscle (intercostal endomysium) and the innermost intercostal muscle below the rib margin. After aspiration shows no blood, the drug is injected, and anechoic fluid can be seen diffusing below the internal intercostal muscle, with the local parietal pleura gradually descending as the injected fluid volume increases.
215066039|NCT07079436|DRUG|0.375% Ropivacaine|During breast quadrantectomy, intercostal nerve block is performed at the 2nd to 6th intercostal spaces along the posterior axillary line using an in-plane technique. 4ml of 0.375% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space. Under ultrasound guidance, the needle tip is ensured to reach the space between the internal intercostal muscle (intercostal endomysium) and the innermost intercostal muscle below the rib margin. After aspiration shows no blood, the drug is injected, and anechoic fluid can be seen diffusing below the internal intercostal muscle, with the local parietal pleura gradually descending as the injected fluid volume increases.
215066040|NCT07079436|DRUG|0.5% Ropivacaine|During breast quadrantectomy, intercostal nerve block is performed at the 2nd to 6th intercostal spaces along the posterior axillary line using an in-plane technique. 4ml of 0.5% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space. Under ultrasound guidance, the needle tip is ensured to reach the space between the internal intercostal muscle (intercostal endomysium) and the innermost intercostal muscle below the rib margin. After aspiration shows no blood, the drug is injected, and anechoic fluid can be seen diffusing below the internal intercostal muscle, with the local parietal pleura gradually descending as the injected fluid volume increases.
214323467|NCT05132764|PROCEDURE|Microosteoperforations|2 inter radicular bone microosteoperforations using temporary anchorage device tip.
214323468|NCT04106310|DEVICE|High-flux dialyzer|a dialyzer meeting the definition of high-flux
214323469|NCT04106310|DEVICE|Theranova dialyzer|a middle cut-off dialyzer
214323470|NCT01955057|BEHAVIORAL|Research interviews|
214923317|NCT02048098|DRUG|Buccal misoprostol|400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
214923318|NCT03799692|DRUG|Chemotherapy|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15.~Drug: Carboplatin AUC=2 iv, d1, 8, 15."
214923319|NCT01762202|DRUG|Cyclophosphamide|
214923320|NCT01762202|DRUG|Fludarabine|
214923321|NCT01762202|DRUG|Ofatumumab|
214923322|NCT02737254|DRUG|Oxytocin|40 IU/ML nasal spray. One administration: children \<40kg administer 12IU, children \>40kg administer 24IU.
214923323|NCT02737254|DRUG|Placebo|NaCl 0,9 % nasal spray.
214923324|NCT02737254|OTHER|Secure CBM training|Children are trained to interpret ambiguous maternal behavior in a secure way.
214923325|NCT02737254|OTHER|Neutral CBM training|Children receive a training unrelated to the interpretation of maternal behavior.
214923326|NCT06822699|DEVICE|Leg elevation|leg will be raised 30 degrees after spinal anesthesia using standardized pillow
214923327|NCT05731947|DRUG|Revumenib|Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
214923328|NCT05731947|DRUG|Chemotherapy|Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
214323471|NCT01955057|BEHAVIORAL|Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)|
214323472|NCT01955057|BEHAVIORAL|Projective methods (Thematic apperception Test, Rorschach)|
214323473|NCT01955057|BEHAVIORAL|Carbon monoxide test|
214323474|NCT04854915|BEHAVIORAL|LOOP + mHealth technology assisted exercise counselling|Participants will complete a 3 month exercise and physical activity intervention supported by mHealth technology
214323475|NCT04854915|BEHAVIORAL|LOOP Only|Participants will complete the LOOP @ Alder Hey programme
214323476|NCT03272451|PROCEDURE|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
214323477|NCT03272451|PROCEDURE|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
214923329|NCT03459885|DEVICE|Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device)|Paired associative stimulation (PAS) administered several times per week for 8 weeks to lower limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
214923330|NCT06372379|OTHER|no intervention|no intervention
214923331|NCT06373718|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
215066041|NCT07079696|DRUG|ATRA|"Treatment Phase (Duration: 18 months) Intervention: ATRA oral administration using a stepwise titration protocol (detailed below). Patients may discontinue treatment if intolerable adverse events occur; post-withdrawal symptom exacerbation is monitored.~\*Titration Protocol\*~Treatment Cycle (C): 3 weeks per cycle. Dose escalation follows:~Cycle Dosage Duration C1.1 15 mg/m²/day 2 weeks on / 1 week off C1.2 20 mg/m²/day 2 weeks on / 1 week off C1.3 25 mg/m²/day 2 weeks on / 1 week off Blinded Assessments: primary endpoints: ADOS-2 SA score, CARS, SRS, ATEC, Gesell, and Sensory Motor (SM) scales.~Biomarker/Diagnostic tests: blood tests (CBC, liver/kidney function, vitamin panels, ATRA levels, hepatitis markers), neuroimaging (cranial fMRI), neurophysiology (EEG, audiometry), skeletal imaging (limb long-bone radiographs, growth monitoring), and biobanking: 1 blood tube for proteomics (baseline, 6/12/18 months). Repeat all assessments at 6, 12, and 18 months after ATRA treatment."
215066042|NCT00258908|BIOLOGICAL|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
215066043|NCT07081685|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|robot-guided high-frequency rTMS treatment (10hz - 5 sessions) of the primary motor cortex
215066044|NCT07081685|DEVICE|sham repetitive Magnetic Transcranial Stimulation (rTMS)|sham robot-guided high-frequency rTMS treatment (10hz - 5 sessions) of the primary motor cortex
214485802|NCT05567003|PROCEDURE|Percutaneous transhepatic cholangioscopic (PTCS) laser incision|Infrared percutaneous transhepatic cholangioscopic guided holmium laser incision for treatment of benign biliary strictures.
215066047|NCT07080359|DRUG|Isavuconazole treatment|Administer isavuconazole as follows: Loading dose: 200 mg every 8 hours (q8h) for three times, Maintenance dose: 200 mg once daily (qd)
215066048|NCT07080437|DRUG|Immunotherapy Therapy|"Patients will receive concurrent chemoradiotherapy (CCRT) combined with immunotherapy. The treatment includes:~Radiotherapy: Individualized radiotherapy targeting the tumor. Concurrent Chemotherapy: Platinum-based doublet chemotherapy (e.g., cisplatin + fluorouracil or S-1) administered during radiotherapy.~Immunotherapy: PD-1 inhibitor (e.g., tislelizumab) used to enhance the immune response against cancer cells.~The treatment will be tailored to each patient's condition, with regular follow-up assessments every 3 months for up to 2 years to monitor efficacy and safety."
214323478|NCT05435378|DRUG|Vitamin B3 100 MG Oral Tablet|After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
214923332|NCT05261477|BEHAVIORAL|Bilingual Brain Injury Education and outpatient Navigation for Hispanic families|1st BIEN was informed by Hispanic parents and clinical providers working with them. It considers their specific needs including lack of familiarity with shared decision models and of knowledge about patient rights and eligibility for community and school services. Based on principles of Social Cognitive Theory, 1st BIEN provides TBI education, teaches problem-solving skills to promote self-efficacy and advocacy; and provides outpatient navigation that allows for observational and experiential learning while supporting access to services in a timely manner. Central to the development of our intervention is the recognition of heterogeneity in individuals' level of readiness to adopt a health behavior according to their level of self-efficacy, expectations, and environment. The 1stBIEN intervention flexibly reduces barriers to access care, and simultaneously improves parental knowledge, health literacy, and self-efficacy to optimize outcomes.
214923333|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
214923334|NCT04537936|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
214923335|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
214923336|NCT04537936|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
214923337|NCT06437028|OTHER|Dual-layer perinatal tissue allograft|The dual-layer perinatal tissue allograft is an amnion - amnion allograft
214923338|NCT06437028|OTHER|Three-layer fenestrated perinatal tissue allograft|The three-layer fenestrated perinatal tissue allograft is an amnion - chorion - amnion allograft
214923339|NCT06437028|OTHER|Standard of care|Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.
215066049|NCT07081217|DIAGNOSTIC_TEST|Intravenous Radiocaine|Intravenous injection of Radiocaine
215066050|NCT07081334|BIOLOGICAL|PV-001|9-valent vaccine containing antigens for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
215066051|NCT07081334|BIOLOGICAL|PEV-001|PEV-001 is a formulation of the PV-001 vaccine that excludes the HPV antigens and contains only aluminum phosphate.
215066052|NCT07079917|PROCEDURE|subperiosteal tunneling for horizontal alveolar ridge augmentation|subperiosteal dissection through horizontal incision only
215066053|NCT07079917|PROCEDURE|conventional alveolar ridge augmentation|horizontal alveolar ridge augmentation through trapezoidal flap
214323479|NCT05435378|DRUG|vitamin B9|After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
214323480|NCT05435378|DRUG|Placebo|After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
214323481|NCT05435378|PROCEDURE|full mouth non surgical periodontal treatment|full mouth scaling and debridement will be done by the primary investigator using ultrasonic scaler and periodontal curettes. After the non surgical treatment patients will be given oral hygiene instructions where they will be instructed to brush twice daily and shown how to brush using the horizontal scraping technique they will also be instructed to use the dental floss and shown how to use it.
214323482|NCT02856542|DRUG|calcipotriol/betamethasone dipropionate gel in Applicator|Topical treatment of scalp using applicator device. The study as such is non-interventional as the intervention has been decided prior to and independently from the inclusion of the patient in the cohort to be observed.
214323483|NCT04566796|DRUG|Sugammadex|give 2 mg/ kg as muscle reversal drug in premature infants
215066054|NCT07079943|OTHER|Self-questionnaire : satisfaction and quality of life|Patient satisfaction and quality of life outcomes assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. )
215066055|NCT07079943|OTHER|Self-reported questionnaire : educational or professional|Patient educational or professional outcomes, assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. )
215066056|NCT07081724|BEHAVIORAL|Online Parent Training in Early Behavioral Intervention (OPT-In-Early)|"the Online Parent Training in Early Behavioral Intervention (OPT-In-Early; Dai et al., 2018, 2021,2022) is a self-directed online resource for caregivers of children with autism or high likelihood of autism. The OPT-In-Early program includes 14 modules (6 mandatory, 8 optional) comprising text and video demonstrations to teach caregivers effective methods for improving their children's language, social, and adaptive skills (e.g., using utensils, toilet training), and reducing their children's disruptive behavior. Parents are taught how to facilitate joint attention, imitation, pretend play, language, sharing, emotional engagement, social play, and self-help skills such as feeding and dressing in their child using behavioral principles (e.g. prompting, shaping and fading) during play and naturalistic daily routines. The optional modules cover such topics as picky eating and toilet training."
214323484|NCT04566796|DRUG|Neostigmine|give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
215066057|NCT07079956|DEVICE|TUBE Flow Diverter|TUBE Device
215066058|NCT07079488|DIAGNOSTIC_TEST|Motor proficiency scales|AIMS, PDMS-2, HINE
215066059|NCT07080385|DRUG|Encaleret|Oral tablets, age-appropriate pediatric formulation (currently under development).
214323485|NCT06418386|PROCEDURE|manual saline IA|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution, All carious tissue will be removed by hight speed handpiece, distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min ,The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium),using manual k file starting with #15 and irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
214485803|NCT06965790|DRUG|contrast media (Imeron 350, active ingredient Iomeprol) volume according to sex-specific blood volume|Calculation of the standardized contrast agent (Imeron 350, active ingredient Iomeprol) quantity (0.35 g iodine/kg) and calculation of the specific blood volume using the established Nadler formula for male and female. Adjustment of the contrast agent according to the ratio of the blood volumes. The amount of saved contrast agent is replaced 1:1 by NaCl.
214923340|NCT06156254|BEHAVIORAL|Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)|Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
214923341|NCT06046534|OTHER|None (Observational study)|Not applicable since this is observational study.
214923342|NCT06240585|OTHER|presence of gastroparesis as an early sign for sepsis (bacteremia)- measurement of gastric residual volume|presence of gastroparesis as an early sign for sepsis (bacteremia)-measurement of gastric residual volume
215066060|NCT02142400|DRUG|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
214323486|NCT06418386|PROCEDURE|manual neem IB|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by high speed hand piece~  , distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with neem leaf extract 100%~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
214485804|NCT06964984|OTHER|Music intervention|The patient will be asked to choose their favorite music. The playlist will include ten songs from each music group (pop, Turkish classical music, local folk songs and religious music), a total of 50 songs. The options will be shown to the patient via the phone (Apple/ MU783TU/A) and the music they want will be added to the playlist. The selected music will be listened to for 15 minutes before the surgery.
214923343|NCT03774524|DRUG|Misoprostol|400 μg of sublingual misoprostol
214923344|NCT03774524|DRUG|TA|1 gm of tranexamic acid in 100 ml saline iv
214923345|NCT03774524|DRUG|placebo to misoprostol|placebo tablets to misoprostol subligual
214923346|NCT03774524|DRUG|placebo to TA|110 ml saline iv
215066061|NCT02142400|DRUG|placebo|matching placebo capsules to DS-1093 capsules
215066062|NCT01034982|DRUG|AZD9668|20 mg
215066063|NCT01034982|DRUG|AZD9668|60 mg
215066064|NCT02374060|DRUG|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
214485805|NCT06964984|OTHER|stres ball|Stress balls will be given to the patient in both palms, they will be asked to count from one to five and squeeze twice. The patient will be shown and made to use the stress balls for 15 minutes before the surgery. When the 15 minutes are up, the patient will be informed by the nurse and the patient will be asked to release the balls.
214485806|NCT06964984|OTHER|Virtual Reality Glasses|The patient will be shown a video of a nature walk by the nurse providing nursing care to the patient. The patients will be shown a video with virtual reality glasses for 15 minutes before the surgery.
214485807|NCT06966830|DRUG|Lacosamide (LCM)|Intravenous lacosamide is given for the treatment of seizure termination in patients with status epilepticus
214672625|NCT05483972|BEHAVIORAL|Whole Prediabetes Diet Intervention|Participants will be instructed by RDN on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled adults in the study, the goal is to maintain complete diet adherence during the two-week intervention. The focus for children/adolescents will be on encouragement and exposure of the diet by the index parent and any additional household parent/guardian/caregiver. Participants will receive groceries that are tailored specifically to the prescribed diet menus/recipes for each week. Foods will be distributed using either a grocery delivery service or via participant pick-up. Each household will receive enough groceries to feed a household of four-persons for each week of the intervention.
214672626|NCT04111367|DRUG|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.
214923347|NCT03866083|DRUG|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
214923348|NCT03866083|DRUG|Standard Medical Treatment|Standard Medical Treatment
214923349|NCT01328145|DRUG|Acetylsalicylic acid|500 mg /day
214923350|NCT01190410|DRUG|certolizumab pegol|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg
214672627|NCT04111367|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
214923351|NCT01190410|DRUG|certolizumab pegol|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to \< 40 kg
214923352|NCT06620731|DRUG|FCN-437c capsule|Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.
214923353|NCT01399047|DRUG|Mycophenolate mofetil|The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
214923354|NCT01399047|DRUG|Liquid Placebo|The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
214923355|NCT01582633|BIOLOGICAL|2012 trivalent influenza vaccine|"2012 trivalent influenza vaccine:~* influenza A/California/7/2009 (H1N1)~* influenza A/Perth/16/2009 (H3N2)~* influenza B/Brisbane/60/2008 Single dose."
214323487|NCT06418386|PROCEDURE|manual sodium hypochlorite IC|"* adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by hight speed hand piece~* distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
214323488|NCT06418386|PROCEDURE|rotary saline IIA|"* shaping and cleaning done with using AF baby fanta files open file:#17 taper 08,then #20 taper 04 ,yellow then #25 taper 04 red , then #30 taper 04 blue . the files activated with torque 2 and speed 350 . Irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then restored with glass inomar and stainless steel crown"
214323489|NCT06418386|PROCEDURE|rotary neem IIB|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by high speed hand piece ,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS METION BEFORE ,and irrigation with 100%neem extract~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
214672628|NCT02884466|BEHAVIORAL|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
214923356|NCT06667388|DIAGNOSTIC_TEST|Group A|each participant of this groups will receive 4 weeks of FWT and 4 weeks of BWT (the training order of A group will FWT and BWT), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.
214923357|NCT06667388|COMBINATION_PRODUCT|Grojup B|each participant of B group will receive 4 weeks of BWT and 4 weeks of FWT (the training order of group B will be BWT and FWT, opposite to group A), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.
214923358|NCT05640726|DRUG|PD-1|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
214923359|NCT05640726|RADIATION|SCRT|Radiotherapy dose: 5×5 Gy
214923360|NCT05640726|DRUG|Bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks
214923361|NCT05640726|DRUG|Oxaliplatin|Participants will receive Oxaliplatin，85mg/m2，day1
214923362|NCT05640726|DRUG|Calcium folinate|Participants will receive calcium folinate ，400mg/m2，day1
214923363|NCT05640726|DRUG|5-fluorouracil|Participants will receive 5-fluorouracil ，400mg/m2，day1
214923364|NCT04827966|OTHER|Clinpro® 5% sodium fluoride plus tri calcium phosphate varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride
214923365|NCT04827966|OTHER|Tooth Mousse® - Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP)s|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization.
214923366|NCT04827966|OTHER|MI Paste® -Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF)|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes.
214923367|NCT04827966|OTHER|Zap® 1.23% APF gel - Acidulated phosphate fluoride|1.23% APF (Acidulated phosphate fluoride) gel is routinely used professional based fluoride for patients with high caries risk.
214923368|NCT04827966|OTHER|Listerine fluoride mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts
214923369|NCT04831697|BEHAVIORAL|Multi-Caregiving Intervention|The multi-caregiving intervention consists of individual-based, social support, and health educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15 minutes); and Structured Diabetes Education and Skills Training (15 minutes). The last 5 minutes will be used to debrief and review goals.
214672629|NCT01471873|PROCEDURE|Corneal Collagen Cross-linking (CXL)|"The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well."
214672630|NCT01717612|DRUG|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
214672631|NCT01717612|DRUG|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
214923370|NCT04831697|BEHAVIORAL|Diabetes Enhanced Usual Care Intervention|This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
214923371|NCT00995046|DRUG|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
214923372|NCT00995046|DRUG|FVIII|"1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done."
214923374|NCT06420557|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 1 session of neuro-reinforcement.
214923375|NCT06420557|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 3 sessions of neuro-reinforcement.
214672632|NCT02435173|DRUG|CDZ173|CDZ173 10 and 70 mg capsules for oral administration.
214672633|NCT02435173|OTHER|Placebo|Placebo capsules for oral administration
214672634|NCT01477632|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
214672635|NCT01477632|DRUG|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
214672636|NCT01477632|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
215066065|NCT02374060|DRUG|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
215066066|NCT02374060|DRUG|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
215066067|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 1|Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -
215066068|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 2|Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)
215066069|NCT03388216|BIOLOGICAL|Drug: INM004- Repeated dose|Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).
215066070|NCT03388216|OTHER|Placebo|A placebo infusion will be administered at the same infusion rate as the Drug arm
215066071|NCT07080853|OTHER|Exercise with Overdressing|Run for 30 minutes followed by walk for 60 minutes in a temperate (gym-like environment) wearing overdressing ensemble.
215066072|NCT07080853|OTHER|Control Exercise|Run for 30 minutes followed by walk for 60 minutes in a temperate (gym-like environment) wearing control clothing ensemble.
215066073|NCT07080333|BIOLOGICAL|biopsy|After verifying the patient's identity, obtaining their informed consent and confirming that there are no immediate contraindications to performing biopsies (haemorrhagic and infectious), the patient will be prepared for RTUV, which will be performed by cystoscopy under anaesthesia in the operating theatre.
215066074|NCT00830375|DRUG|Memantine|10-30mg, by mouth, daily
215066075|NCT01700959|DRUG|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
215066076|NCT01700959|DRUG|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
215066077|NCT04169984|OTHER|Myofunctional Therapy|Isometric, isokinetic and isotonic exercises for the upper airway muscles.
215066078|NCT04169984|OTHER|Placebo|Exercises that do not alter the function or morphology of the upper airway.
215066079|NCT02701959|DIETARY_SUPPLEMENT|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~530 mg nitrate derived).
215066080|NCT02701959|DIETARY_SUPPLEMENT|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~3 mg nitrate derived).
214923376|NCT06420557|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 5 sessions of neuro-reinforcement.
214923377|NCT02046005|BEHAVIORAL|PRE-RA|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information.
215066081|NCT03146559|DEVICE|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
215066082|NCT03146559|DEVICE|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
214923378|NCT02046005|BEHAVIORAL|PRE-RA Plus|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information. In addition, participants in this arm receive education from a health educator.
214923379|NCT02046005|BEHAVIORAL|General Rheumatoid Arthritis Education|Participants will receive general information about signs and symptoms of rheumatoid arthritis.
214923380|NCT05895890|GENETIC|Sequential sampling (stool, saliva, serum) .|Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.
214923381|NCT03671109|DRUG|Dihydroartemisinin-piperaquine (DHA-PPQ)|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-DHA-PPQ under supervision
214923382|NCT03671109|DRUG|Placebo Oral Tablet|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-Placebo under supervision
214923383|NCT04699201|PROCEDURE|Hincisional hernia prevention by onlay prosthesis trocar closure|Hincisional hernia prevention by onlay prosthesis trocar closure
215066083|NCT05051293|OTHER|serum concentration of estrogen (E1 and E2) and testosterone ratio measurement|To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
214923384|NCT04699201|PROCEDURE|laparoscopic cholecystectomy|Laparoscopic cholecystectomy with or without common bile duct exploration
215066084|NCT02242214|DRUG|Misoprostol|
215066085|NCT01696019|OTHER|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
215066086|NCT01696019|OTHER|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
214323490|NCT06418386|PROCEDURE|rotary sodoium hypochlorite IIC|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by hight speed hand piece,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS MENTION BEFORE , and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
214485808|NCT03228719|BEHAVIORAL|Standardize PT after TKR with a Physical Activity Intervention|Standardized PT and a physical activity intervention. Participants will be provided a FitbitTM Zip within one week after enrolling in the study. Participants will self-track their steps/day using their FitbitTM Zip. Participants ≤ 3 weeks' post-operative TKR are expected to maintain and not increase steps/day. Beyond 3 weeks after surgery, step goals will be initiated and evaluated on a weekly basis. Progression of weekly steps/day goal will be a joint decision between the participant and physical therapist. As a guide, a 10-20% increase in steps/day until at least 6,000 steps/day is achieved. Each week the physical therapist will review the participant's steps/day goal and if at least 4 of the 7 previous days per week were at or above the prior week's steps/day goal, then next week's steps/day goal will increase. The physical therapist will discuss current steps/day with the participant using the Fitbit TM Zip and set a personalized steps/day goal each week during PT.
215066087|NCT01696019|OTHER|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
215066088|NCT01696019|OTHER|Contact and testing only|
214485809|NCT03228719|OTHER|Standardized PT after TKR|Participants in the control group will receive standardized PT provided by a licensed physical therapist at UDPT using the University of Delaware's Rehabilitation Guidelines for Unilateral Total Knee Replacement. Standardized PT also includes a printed home exercise program with an exercise log that is updated weekly by a physical therapist. PT appointment times range from 45-60 minutes with appointment occurring 1-3 times a week for 6-8 weeks.
214485810|NCT06536049|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214485811|NCT06536049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214485812|NCT06536049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214923385|NCT04699201|DIAGNOSTIC_TEST|Abdominal ultrasound|Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
214923386|NCT05604222|DRUG|Mirabegron 50 MG|Medication to treat overactive bladder
214923387|NCT05604222|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|A behavioral intervention for insomnia
214923388|NCT05271318|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
214485813|NCT06536049|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
214485814|NCT06536049|BIOLOGICAL|Epcoritamab|Given SC
214485815|NCT06536049|DRUG|Ibrutinib|Given PO
214485816|NCT06536049|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214672637|NCT00471471|BIOLOGICAL|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
214923389|NCT05271318|BIOLOGICAL|pembrolizumab|pembrolizumab, a monoclonal antibody binding PD-1
214923390|NCT05271318|DRUG|pegylated liposomal doxorubicin|Pegylated Liposomal Doxorubicin is a chemotherapy and a pegylated liposomal form of the anthracycline topoisomerase inhibitor, doxorubicin.
215066089|NCT04261725|GENETIC|EGFR mutation|Searching the EGFR mutation in pulmonary biopsy
215066090|NCT00960791|DEVICE|AZD1656|Oral single dose
215066091|NCT07081789|BEHAVIORAL|Music Listening|Participants will listen to a 24 min 54 sec music track for 4 days (starting 3 days before menstruation).
215066092|NCT07081789|BEHAVIORAL|Puzzle Activity|Participants will do puzzles for the same duration and timing.
215066093|NCT07081620|OTHER|Physical examination of chest skin|soft touch and thermal (cold and warm) examination
215066094|NCT07079774|DEVICE|Transverse Bone Transport System|"This is a prospective, international, multicentre, observational post-market clinical follow-up (PMCF) study. Adult subjects will be treated according to the manufacturer's Instructions for Use, with follow-up extending to 12 months post-device removal. Participating sites include centres in the US, Europe, the UK, and South Africa.~Subjects will be followed using a phased framework:~T0: Index Surgery (baseline data, operative details, ulcer status) T1: End of Distraction (device parameters, adverse events, ulcer status) T2: End of Compression (similar to T1) T3: Device Removal (confirmation of union, ulcer status)~Post-removal visits:~F3: 3 months F6: 6 months F12: 12 months"
215066095|NCT07079787|DEVICE|TeleRehab DSS Pilot Test|Participants will perform an individualised multisensory balance rehabilitation program via augmented reality, while wearing motion sensors. The program will consist of multisensory balance exercises, cognitive games, and exergames. All participants will perform 2 sessions per week, carried in at each clinical site, over the course of 3-week.s
215066096|NCT07079657|PROCEDURE|Thulium laser + growth factor serum + LED|3 sessions at intervals of 6 weeks
215066097|NCT07079657|PROCEDURE|Thulium laser + growth factor serum|3 sessions at intervals of 6 weeks
215066098|NCT07079657|PROCEDURE|Thulium laser|3 sessions at intervals of 6 weeks
215066099|NCT00483366|DRUG|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid"
215066100|NCT00483366|DRUG|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~1. 550 mg/m2~2. 550 mg/m2~3. 675 mg/m2~4. 675 mg/m2~5. 825 mg/m2~6. 825 mg/m2~7. 1000 mg/m2"
214323491|NCT06481202|BIOLOGICAL|Complarate®|The test drug Complarate® was administered as an intravenous infusion at a single dose of 8 mg/kg.
214323492|NCT06481202|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a single dose of 8 mg/kg.
214323493|NCT01686646|DRUG|paracetamol + caffeine|paracetamol with caffeine
215066101|NCT00483366|DRUG|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~1. 400 mg/d~2. 400 mg/d~3. 400 mg/d~4. 400 mg/d~5. 400 mg/d~6. 400 mg/d~7. 400 mg/d"
215066102|NCT00483366|GENETIC|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
214323494|NCT01686646|DRUG|paracetamol|paracetamol
214672638|NCT00471471|BIOLOGICAL|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
215066103|NCT00483366|GENETIC|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
215066104|NCT00483366|GENETIC|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
215066105|NCT03753685|DRUG|X-396(Ensartinib) Capsule|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
215066106|NCT04153175|COMBINATION_PRODUCT|ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.
215066107|NCT04153175|COMBINATION_PRODUCT|Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
214923391|NCT04373512|DRUG|Culturelle 10 Billion CFU Capsule (2 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
215066108|NCT00230061|BIOLOGICAL|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
215066109|NCT04489147|DRUG|Metformin|metformin 850 mg orally twice daily along the cycle of ICSI
215066110|NCT03112512|DEVICE|optimal PEEP guided by EIT|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
214923392|NCT04373512|DRUG|Culturelle 10 Billion CFU Capsule (4 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
215066111|NCT03112512|DEVICE|optimal PEEP guided by G5 ventilator|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
215066112|NCT03090646|OTHER|Financial Incentive|Up to three gift cards to a major online retailer.
215066113|NCT03911323|OTHER|diabetic retinopathy|Patients with diabetes enrolled will undergo nonmydriatic fundus imaging and seven-field stereoscopic photography. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the AI algorithm will be compared to the diagnosis of seven-field stereoscopic photography by ophthalmologist. Sensitivity and specificity will be calculated to evaluate the performance of AI algorithm.
214323495|NCT02319538|PROCEDURE|Total thyroidectomy performed|Surgery combined with standard thyroxine treatment
214323496|NCT02839616|PROCEDURE|orthotopic liver transplantation|
214323497|NCT02012595|OTHER|[11C]donepezil PET|Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil
215066114|NCT06239480|DRUG|QTORIN 3.9% Rapamycin Anhydrous Gel|QTORIN 3.9% Rapamycin Anhydrous Gel
215066115|NCT03057041|DRUG|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
214323498|NCT05952622|DEVICE|Continuous passive motion therapy|Patients will be supplied with a continuous passive motion device which will allow additional individual treatment of the affected shoulder for 6 weeks.
214323499|NCT01401933|DRUG|Linifanib|QD on Days 1 and 13
214323500|NCT01401933|DRUG|Rifampin|QD on Days 5-16
214323501|NCT02776228|DRUG|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
214323502|NCT02776228|DRUG|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
214323503|NCT01464515|DEVICE|H-Coil Deep TMS|this group will receive high frequency treatment of deep TMS with 10Hz
215066116|NCT03057041|DRUG|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
215066117|NCT03604588|DIAGNOSTIC_TEST|HPV OncoTect™|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
215066118|NCT06347016|DRUG|Plozasiran Injection|ARO-APOC3 Injection
214923393|NCT01483274|BIOLOGICAL|Vaccine|Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
214923394|NCT05877690|DRUG|Bupivacaine 0.5% Injectable Solution|Patient will be received the drug intrathecal
214323504|NCT01464515|DEVICE|SHAM Coil TMS|this group will receive SHAM treatment of deep TMS
214923395|NCT05877690|DRUG|Prilocaine Hydrochloride 2% Injection|Patient will be received the drug intrathecal
214923396|NCT05822141|DIETARY_SUPPLEMENT|Fish Oil|For 12 weeks subjects will ingest 6 capsules per day of fish oil (7.8 g/day total omega--3 fatty acids: 3.75 g/day EPA and 1.5 g/day DHA)
214923397|NCT05822141|DIETARY_SUPPLEMENT|Placebo|For 12 weeks subjects will ingest 6 capsules per day of olive oil (each capsule contains 990 mg of olive oil)
214923398|NCT05011266|DRUG|Buprenorphine/naloxone|5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily
215066119|NCT06347016|DRUG|Placebo|sterile normal saline (0.9% NaCl)
215066120|NCT05925413|DRUG|Cadonilimab+TACE|Cadonilimab: 15mg/kg Q3W Day1 Select the best TACE treatment strategy. Traditional TACE (cTACE) or DEB-TACE can be selected. TACE treatment can be continued as needed based on disease control. The combination of cadonilimab is given 3 to 7 days after the first TACE treatment, and the subsequent administration of cardonilizumab is given once every 3 weeks, if the time overlaps with TACE treatment, it is generally administered 3 to 7 days after TACE treatment. Treatment was discontinued until intolerable toxicity, death, withdrawal of informed consent, initiation of a new antitumor therapy, or other reason specified in the protocol, whichever occurs first. Patients in this study received cadonilimab for up to 24 months.
215066121|NCT06292754|PROCEDURE|magnesium pin in additional to the suture anchor|magnesium pin in additional to the suture anchor used routinely in clinical practice
215066122|NCT06292754|PROCEDURE|routine suture anchor|routine suture anchor for the treatment-as-usual
215066123|NCT05077995|DEVICE|Polar M200|Participants will have to wear the activity monitors (AP and Polar M200) for at least 7 days. Minutes spent in each activity type will be summed to a total day score. Participants will be instructed to do their regular daily life activities without limitation, but to note their main activity categories in an activity diary, with a main focus on cycling and participation in structured exercise.
215066124|NCT03304054|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
215066125|NCT03304054|DRUG|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
215066126|NCT05246839|BEHAVIORAL|Brief Video|Videos about colorectal cancer screening.
215066127|NCT05246839|BEHAVIORAL|Brief Video Plus|Videos about colorectal cancer screening and modalities.
215066128|NCT03556228|DRUG|VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)|Taken orally once daily
215066129|NCT04937400|OTHER|Daily screening for delirium|Each child will be screened twice daily for delirium throughout the transplant hospitalization
215066130|NCT06643481|BIOLOGICAL|VHB937|VHB937 solution for infusion
214323505|NCT04657497|DRUG|FOY-305|Specified Dosage and Duration of Treatment
214323506|NCT04657497|DRUG|Placebo|Specified Dosage and Duration of Treatment
215066131|NCT06643481|OTHER|Placebo|Solution for infusion
215066132|NCT04261400|BEHAVIORAL|MAMAACT|Improved communication regarding warning signs of pregnancy complications
215066133|NCT03162510|DRUG|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
215066134|NCT03162510|DRUG|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
214323507|NCT02549508|DEVICE|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on
215066135|NCT03162510|DRUG|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
215066136|NCT03162510|DRUG|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
214323508|NCT02549508|DEVICE|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off
214323509|NCT00213148|DRUG|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
215066137|NCT06597266|DEVICE|Smart template - designed prosthetic check socket|Evidence-generated trial prosthetic sockets are designed automatically by performing machine learning analysis of past socket designs that were produced by expert clinicians, the participant's residual limb size and shape descriptors and patient descriptors
215066138|NCT06597266|DEVICE|Clinician-designed prosthetic check socket|Active comparator prosthetic sockets are designed by expert prosthetists, bespoke to the participant, in a computer aided design environment (CAD)
215066139|NCT02831738|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose 12 g
215066140|NCT02831738|DIETARY_SUPPLEMENT|Control Treatment|no polydextrose
214323510|NCT00213148|DRUG|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
214323511|NCT00213148|DRUG|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
214323512|NCT00213148|DRUG|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
214323513|NCT00213148|DRUG|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
214323514|NCT01220271|DRUG|LY2157299|Administered orally
214672639|NCT00471471|BIOLOGICAL|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
214672640|NCT02162745|DRUG|Isotonic solution (NaCl 0.9%)|
215066141|NCT03392389|BIOLOGICAL|mRNA-1653|Escalating dose levels
215066142|NCT03392389|OTHER|Placebo|Saline
215066143|NCT00137137|PROCEDURE|Placement of the mini-screw|
215066144|NCT05402176|OTHER|Whole Lung Lavage|Whole Lung Lavage (WLL) is performed as standard of care. Outcome following WLL is observed.
214672641|NCT02162745|DRUG|Hypertonic solution (NaCl 3%)|
214672642|NCT04467541|BIOLOGICAL|Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell)|Inactivated Enterovirus Type 71 (EV71) Vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
215066145|NCT00782171|DEVICE|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
215066146|NCT00005636|DRUG|cisplatin|
215066147|NCT00005636|DRUG|pemetrexed disodium|
215066148|NCT04618042|DRUG|FX06|FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
214672643|NCT02399878|DRUG|Inspiratory oxygen|
215066149|NCT04618042|DRUG|Placebo of FX06|Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
215066150|NCT00002955|DRUG|fluorouracil|
215066151|NCT00002955|DRUG|leucovorin calcium|
215066152|NCT00002955|DRUG|trimetrexate glucuronate|
215066153|NCT06762613|COMBINATION_PRODUCT|Generative AI Based Puncture Surgery Navigation System|Participants will receive percutaneous lung puncture under the guidance of GPS.
215066154|NCT06762613|DEVICE|Cone beam CT|Participants will receive percutaneous lung puncture under the guidance of cone beam CT.
215066155|NCT05440669|BEHAVIORAL|white noise|white noise will reduce pain and stress in nasal cpap application
215066156|NCT02310854|PROCEDURE|ACL Repair|augmented suture of acute ACL rupture (\<3 weeks after injury)
215066157|NCT02310854|PROCEDURE|ACL reconstruction|reconstruction hamstring autograft
215066158|NCT06007677|DRUG|STAR-0215|STAR-0215 will be administered as a subcutaneous injection.
215066159|NCT04664972|DRUG|Docetaxel +doxorubicin+ cyclophosphamide|The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
215066160|NCT04664972|DRUG|Docetaxel +Cisplatin|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
215066161|NCT06735872|PROCEDURE|Non invasive ventilation (NIV)|"This group will receive a unique 10-minute session of non invasive ventilation with standard parameters directly on the CT table. The treatment will be delivered via a naso-buccal mask.~Prior to treatment, each participant will have a planned standard care chest CT.~During the session, a senior intensivist watching for participant's comfort and safety."
215066162|NCT06735872|PROCEDURE|High flow oxygen therapy (HFO)|"This group will receive a unique 10-minute session of high flow oxygen directly on the CT table. The treatment will be delivered via a nasal cannula.~Prior to treatment, each participant will have a planned standard care chest CT.~During the session, a senior intensivist watching for participant's comfort and safety."
215066163|NCT04829825|DIAGNOSTIC_TEST|18F-GP1 PET/MR|Patients will receive 1-3 18F-GP1 PET/MR
215066164|NCT04874220|DEVICE|Deep Brain Stimulation|Deep brain stimulation will be used
215066165|NCT02383888|DRUG|BI 425809|
215066166|NCT02383888|DRUG|BI 425809|
215066167|NCT02383888|DRUG|Placebo|
215066168|NCT02383888|DRUG|BI 425809|
215066169|NCT05381428|DRUG|Indomethacin suppository|Control Group: Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
214323515|NCT01220271|DRUG|Radiation|Administered as approved
214672644|NCT04448249|BEHAVIORAL|APN intervention|"APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary,~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
214323516|NCT01220271|DRUG|Temozolomide|Administered orally
214672645|NCT02392208|DRUG|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
214923399|NCT05011266|DRUG|Placebo|placebo sub-lingual tablet daily
214923400|NCT06520982|DRUG|Norepinephrine|Infused intra-arterially in a dose-response fashion
214923401|NCT06520982|DRUG|Isoproterenol|Infused intra-arterially in a dose-response fashion
214923402|NCT06520982|DRUG|Acetylcholine|Infused intra-arterially in a dose-response fashion
214923403|NCT06520982|DRUG|Nitroprusside|Infused intra-arterially in a dose-response fashion
214323517|NCT04296981|OTHER|video-based patient information|explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
214323518|NCT00556842|DEVICE|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
214323519|NCT00556842|DEVICE|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
214323520|NCT06362148|DIAGNOSTIC_TEST|Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay|Blood sampling for circulating tumor DNA analysis at baseline, cycle 2 day 1, cycle 3 day 1, mid-treatment, end of induction/end of treatment, 100 day follow-up, 6 month, 12 month, 18 month and 24 month follow-up. Blood sampling will also be done in case of relapsing/refractory disease at any point prior to the abovementioned time points.
214323521|NCT06362148|DIAGNOSTIC_TEST|18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)|FDG-PET/CT performed at baseline, mid-treatment, end of induction/end of treatment and 6 month, 12 month, 18 month and 24 month follow-up.
214323522|NCT05994716|OTHER|Telemonitoring|"A) Monthly completion data on the web platform: 1) SCCAI for Ulcerative colitis and Harvey-Bradshaw index for Crohn disease. 2) IBD disk questionnaire to evaluate disease dynamics. 3) General blood test.~B) Possibility of online consultation with a gastroenterologist upon request via chat or phone call.~C) Access to educational information about IBD, necessary lifestyle changes, dietary recommendations;~D) monthly phone call will be made to each patient from the intervention group to answer any questions or concerns they may have and to interview them according to the checklist."
214323523|NCT02435251|DEVICE|dual energy X-ray absorptiometry|
214323524|NCT03400033|DRUG|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
214323525|NCT03400033|DRUG|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
214323526|NCT03400033|DRUG|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
214323527|NCT03400033|DRUG|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
214323528|NCT02296814|DRUG|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
214323529|NCT02296814|DRUG|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
214323530|NCT01449578|DRUG|Dexpramipexole|Oral Tablet at varying doses
214923404|NCT06520982|DRUG|Estrogen|Infused intra-arterially
214923405|NCT04188015|BIOLOGICAL|2.5mg ANX007|A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
214923406|NCT04188015|BIOLOGICAL|5.0mg ANX007|A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
214923407|NCT04188015|OTHER|Sham Procedure|The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.
214923408|NCT04645901|DRUG|Drug: SYHA1805 tablets|Oral tablets of SYHA1805 with several doses
214923409|NCT04645901|DRUG|Placebo|Oral tablets of placebo with matching several doses
214923410|NCT00032136|DRUG|exemestane|
214923411|NCT00032136|DRUG|tamoxifen citrate|
214923412|NCT00032136|PROCEDURE|adjuvant therapy|
214923413|NCT05136339|BEHAVIORAL|Community-based mentoring and education sessions|Community-based mentoring and education sessions, group activities, and application of a community toolkit for healthy weight loss delivered by trained Health Promoters from Hispanic and Somali communities to their social networks.
214923414|NCT01092819|OTHER|Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies|The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. Patients with current standard of care other than IV rtPA or IA therapies will be studied.
215066170|NCT05381428|COMBINATION_PRODUCT|Indomethacin suppository and high-flow lactated ringer infusion combination|Interventional group: Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
214672646|NCT02392208|PROCEDURE|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
214923415|NCT00251303|DRUG|Riluzole|Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
214923416|NCT00251303|DRUG|Placebo|Capsules matched active drug in appearance.
214923417|NCT04532619|BEHAVIORAL|Fathering Through Change|Fathering Through Change is an adaptation of Parent Management Training Oregon. This pilot provides a limited version of Fathering Through Change via text messaged and emailed weekly video content and includes individual coaching calls.
215066171|NCT04545723|DEVICE|FibriCheck|FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
215066172|NCT04628169|OTHER|no intervention applied|no intervention applied
215066173|NCT02189720|DRUG|Amifampridine Phosphate|"Dosage form: tablets containing the equivalent of 10 mg amifampridine per tablet.~Amifampridine Phosphate given based on Investigator assessment of optimal neuromuscular benefit. In adult patients \> 16 years of age, Doses ranged from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day and in pediatric patients age \< 16 years the maximum daily dose was 60 mg/day. No single dose to exceed 20 mg."
215066174|NCT03793426|BIOLOGICAL|Fibryga|Human plasma-derived fibrinogen concentrate
215066175|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
215066176|NCT04500171|BEHAVIORAL|CDC Colorectal cancer screening for life brochure: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
215066177|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
215066178|NCT04500171|BEHAVIORAL|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
214923418|NCT02511067|DRUG|Tocilizumab|Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
214323531|NCT01449578|DRUG|Dexpramipexole Placebo|Oral tablet at varying doses
214323532|NCT03941730|PROCEDURE|Biopsy|Undergo tissue biopsy
214323533|NCT03941730|PROCEDURE|Computed Tomography|Undergo CT
214672647|NCT04864977|DRUG|Basal Insulin|Participants administered basal insulin
214323534|NCT03941730|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214323535|NCT03941730|PROCEDURE|Positron Emission Tomography|Undergo PET
214323536|NCT03941730|BIOLOGICAL|Therapeutic Estradiol|Given PO
214323537|NCT04275596|DRUG|2QR complex|Application of topical gel containing 2QR complex on the anal wound until complete wound healing
214672648|NCT05588492|DRUG|Rifamycin-containing regimen|Rifamycin-containing regimen
214923419|NCT02511067|DRUG|Ranibizumab|Intravitreal injection of Ranibizumab (0.3mg)
214923420|NCT05280457|DRUG|nivolumab-GX-188E-GX-I7|"* Nivolumab 3 mg/kg IV administered every 2 weeks~* GX-188E 2 mg IM at Weeks 1, 2, 4, 7, 10, 13, and 19~* GX-I7 1200 μg/kg or the recommended dose of the introductory safety cohort is administered at weeks 2, 10, and 18"
214672649|NCT05588492|DRUG|Rifamycin-free regimen|Rifamycin-free regimen
214323538|NCT04275596|DRUG|Placebo|Application of topical placebo on the anal wound until complete wound healing
215066179|NCT04500171|BEHAVIORAL|Colocare Instruction Video: Modified SAM + CAM -Superior rating|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
215066180|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
215066181|NCT04500171|BEHAVIORAL|CDC Colorectal cancer screening for life brochure: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
214672650|NCT00092547|BIOLOGICAL|V501|0.5 mL intramuscular injection of V501
214672651|NCT00092547|BIOLOGICAL|Comparator: Placebo|0.5 mL intramuscular injection of placebo
214672652|NCT05640232|DRUG|CDE100 association|Experimental drug.
214672653|NCT05640232|DRUG|Buscopan® Composto association|Active comparator.
214672654|NCT00199511|DRUG|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
214672655|NCT06472895|DRUG|AK112 monotherapy|A novel PD-1/VEGF bispecific antibody; RP2D intravenously (IV)，Q3W
214672656|NCT03139955|DEVICE|Bodytrak|Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
214672657|NCT03375658|OTHER|PDWS Intervension|Patients admitted to the emergency department in the intervention period will have their vital values presented on the PDWS in addition to existing patient monitoring systems
214672658|NCT04328623|PROCEDURE|Hypnosis|"conversational hypnosis technique call the magic glove"
214672659|NCT04328623|PROCEDURE|Infiltration|Ultrasound-guided hand infiltration
214672660|NCT00653796|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
214672661|NCT00653796|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
214672662|NCT03544060|DRUG|Volanesorsen|Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
214923421|NCT05062707|PROCEDURE|Blood sampling|Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).
214323539|NCT03367377|DRUG|LY3209590|Administered SC
214323540|NCT03367377|DRUG|Insulin Glargine|Administered SC
214323541|NCT02635191|DRUG|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
214323542|NCT02635191|DRUG|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
214323543|NCT03254238|OTHER|Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior|development and identification of systems and tools able to detect earlier misuse phenomenon
214323544|NCT00368589|DRUG|atorvastatin|
214323545|NCT03903666|OTHER|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
214923422|NCT06623747|BEHAVIORAL|Diet|15 kcal per kg fat-free mass
214923423|NCT06623747|BEHAVIORAL|Diet|45 kcal per kg fat-free mass
214923424|NCT03490838|DRUG|177Lu-PSMA-R2|radio-ligand therapy
214923425|NCT05906550|DIAGNOSTIC_TEST|Vascular access monitoring|Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.
214923426|NCT05906550|DIAGNOSTIC_TEST|Vascular access blood flow measurement|Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume \<500mL/min.
214923427|NCT05097534|OTHER|iDSMES|Intensive Diabetes Self-Management Education and Support combined with Addressing Social Determinants of Health
214923428|NCT05097534|OTHER|Standard of Care|Standard of Care for patients with type 2 diabetes
215066182|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
215066183|NCT04500171|BEHAVIORAL|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
214323546|NCT02340533|PROCEDURE|hysteroscopic endo-myometrial biopsy|
215066184|NCT06955416|DRUG|Reamberin|Infusion of study drug REAMBERIN®, solution for infusion 1.5%, in a volume of 750-1500 ml per day (in accordance with the optimal dose established in stage 1), for 2 days or until resolution of DKA, whatever occurs earlier.
215066185|NCT06955416|DRUG|Placebo|Infusion of 0,9% normal saline in a volume of 750-1500 ml per day (in accordance with the optimal dose established in stage 1), for 2 days or until resolution of DKA, whatever occurs earlier.
215066186|NCT02551094|DRUG|colchicine|0.5 mg tablet taken once a day
214323547|NCT02340533|DEVICE|ultrasound|two dimensional trans-vaginal ultrasonography
214323548|NCT00755066|DRUG|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
214323549|NCT00755066|DRUG|Placebo|Placebo intranasal spray
214323550|NCT02112825|BEHAVIORAL|Exercise|Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
214323551|NCT03320681|DEVICE|Electrical Stimulation|Percutaneous electrical nerve stimulation
214323552|NCT03320681|OTHER|Dry Needling Stimulation|Percutaneous nerve stimulation
215066187|NCT02551094|DRUG|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
215066188|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
215066189|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
215066190|NCT02582814|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
214323553|NCT04130295|OTHER|Wearable intensive nerve stimulator|The wearable device consists of 2 leads that provide biphasic, with alternating lead phase, asymmetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
214323554|NCT06267612|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
214323555|NCT01437228|DRUG|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
214323556|NCT01437228|DRUG|placebo|NO İNTERVENTİON
214323557|NCT04165668|OTHER|Exposure: First on scene|To be first on scene for resuscitation at the suspected out-of hospital cardiac arrest, before EMS and first responders (fire and police services)
214323558|NCT01266213|DRUG|Fulvestrant plus Goserelin|Fulvestrant s.c. plus Goserelin s.c.
215066191|NCT02582814|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
215066192|NCT03530995|DRUG|Belumosudil|Development candidate
214323559|NCT01266213|DRUG|Anastrozole plus Goserelin|Anastrozole 1 mg p.o. plus Goserelin s.c.
214323560|NCT01266213|DRUG|Goserelin|Goserelin s.c.
214323561|NCT01458327|DRUG|Midomafetamine|125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later
214323562|NCT01458327|BEHAVIORAL|Therapy|Non-directive therapy
214323563|NCT06420154|BIOLOGICAL|anti-CD19-CAR-T cells|"The subjects received infusions of anti-CD19 CAR-T cells following completion of lymphodepleting preconditioning chemotherapy.~Dosage：1×10\^5 cells/Kg; 3×10\^5 cells/Kg; 1×10\^6 cells/Kg~frequency：single infusion"
214323564|NCT04999046|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.
214323565|NCT04035304|OTHER|Mindfulness Coach|"Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises."
214323566|NCT02045771|BEHAVIORAL|Behavioral Activation|"Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010)."
214323567|NCT02045771|BEHAVIORAL|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
214923429|NCT06204315|RADIATION|Stereotactic Radiosurgery|Given by RTx
214923430|NCT05242458|DRUG|Ustekinumab|No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.
214923431|NCT02087826|OTHER|Mixed Meal Tolerance Test|The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.
215066193|NCT03530995|DRUG|Itraconazole|Perpetrator drug
215066194|NCT03530995|DRUG|Rabeprazole|Perpetrator drug
215066195|NCT03530995|DRUG|Rifampicin|Perpetrator drug
215066196|NCT03530995|DRUG|Omeprazole|Perpetrator drug
215066197|NCT04158726|BEHAVIORAL|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
215066198|NCT02058511|DRUG|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
215066199|NCT02058511|PROCEDURE|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
214485817|NCT05258357|DEVICE|Ultrasound-assisted bone marrow biopsy|"After the usual landmark technique is performed and the potential site has been marked, the ultrasound machine fine tunes the drill site location. The probe is placed over the marked site in the transverse orientation. In this view, the location where the sacrum articulates near the ilium is visualized. The physician then searches for the location of the PSIS at its most superficial location, then the PSIS is centered. The probe is then rocked back and forth to determine the optimal drill angle.The skin is marked at the probe indicators on both long sides. In the sagittal orientation the PSIS is visualized and centered. The skin is then marked at the probe indicators on both long sides. The marker is then used to connect the marks, creating an X that marks the desired skin entry point"
214923432|NCT02087826|DRUG|Metformin|Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.
214923433|NCT06189859|PROCEDURE|endoscopic submucosal dissection using SPRAY COAG mode|After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Spray coag mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
214923434|NCT06189859|PROCEDURE|endoscopic submucosal dissection using Precisect mode|After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Precisect mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
214923435|NCT00504725|DRUG|Ketamine|Interventional
214923436|NCT00504725|DRUG|0.9% saline|placebo
215066200|NCT03784131|DRUG|P-TEV|Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
215066201|NCT04204694|OTHER|3-time blood sampling for septic shock patients|15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
215066202|NCT04204694|OTHER|Only one blood sampling for controls patients|15 mL blood are sampled from a blood donation
215066203|NCT05678816|DEVICE|BREATHER|respiratory muscle trainer used to strength inspiratory an expiratory muscles through breathing in and out against aresistence which is determined individually according to each patient.
215066204|NCT05678816|OTHER|physiotherapy prgramme for rehabilitation of stroke patients|"physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training."
215066205|NCT01000012|DEVICE|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
215066206|NCT01000012|DEVICE|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
214485818|NCT05258357|PROCEDURE|Landmark palpation bone marrow biopsy|The lateral, superior iliac crest is palpated and an attempt is made to follow the course of the posterior iliac crest until the posterior superior iliac spine (PSIS) is palpated. Additionally, the gluteal cleft is visualized indicating the patient midline. The area over the sacrum at midline is then palpated, proceeding laterally until the PSIS can be felt. The skin is marked with a marker at the estimated PSIS and point of entry.
214672663|NCT04988516|DEVICE|Virtual reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
214672664|NCT04988516|OTHER|Standard protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. The research nurse will be able to complete any information should they find it incomplete or substandard.
214923437|NCT05311839|OTHER|Exercise|Hot packs, active range of motion exercises, pendular exercises, wall climb exercises, mobilization exercises, and shoulder capsular stretching
214672665|NCT01127425|PROCEDURE|laparoscopic colonic resection|Conventional surgery compared to laparoscopic sigmoid resection
214672666|NCT01127425|PROCEDURE|laparoscopic sigmoid resection|sigmoid resection by laparoscopic surgery
214923438|NCT05311839|OTHER|Thera band|graded Thera band exercises for shoulder flexion, abduction, internal, and external rotation
214923439|NCT05789888|GENETIC|MT-ATP6 mtDNA gene variability in obesity and normal body weight patients.|As part of the research, the MT-ATP6 gene was tested in order to influence the modulation of the amount of fat contained.
214672667|NCT06017063|OTHER|Psychological intervention|The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
214672668|NCT01539837|DRUG|Deferiprone 20mg|20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
214672669|NCT01539837|DRUG|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
214672670|NCT01539837|DRUG|Deferiprone 30mg|30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
214923440|NCT05789888|GENETIC|SCD gene variability in obesity and normal body weight patients.|As part of the research, the SCD gene was tested in order to influence the modulation of the amount of fat contained.
214923441|NCT05789888|OTHER|Finding TOFI and FOTI phenotypes in participants with obesity and normal weight.|As part of the research, we measured the amount of VAT and SAT and calculate VAT/SAT ratio as a marker to determine the phenotype of fat tissue.
214923442|NCT03060174|OTHER|monitoring and non-medical prophylaxis of delirium|
214485819|NCT05259306|DEVICE|Insightec Exablate Neuro MR-guided focused ultrasound transducer|This study will be utilizing the Insightec Exablate Neuro MR-guided focused ultrasound transducer to deliver low-intensity ultrasonic energy precisely and safely to the target region of the brain. MRgFUS has been FDA approved at high-intensity to treat essential tremor and Parkinson's disease associated tremor. Device premarket approval number (PMA) is P150038, and FDA approval notice was July 11, 2016. This study will be using this device not to make any lesions in the brain (as it is currently FDA approved), but instead to use the precision and non-invasive nature of the device to target the MD thalamus region of the brain at intensities currently approved by the FDA for transcranial ultrasound.
214672671|NCT01771679|BIOLOGICAL|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
214672672|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Acacia Gum-MMST Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Acacia Gum 336.1 mg/capsule; Monomethylsilanetriol 34.9 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
214672673|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Malto-OSA Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Maltodextrin 311.4 mg/capsule; Silicic acid 35.6 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
214672674|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Collagen Booster|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 99.9646 g/100 ml; Silicic acid 23.65 mg/100 ml; Monomethylsilanetriol 11.75 mg/100 ml. Silicon content per dose: 10.4 mg.
214672675|NCT05116982|DIETARY_SUPPLEMENT|Placebo|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 100 ml.
214672676|NCT02292134|DEVICE|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
214672677|NCT04647136|DIAGNOSTIC_TEST|Fertility Health Screening|Basic fertility health screening comprising an anti-Mullerian hormone (AMH) test and semen analysis, a doctor's consultation to explain the results, and standardised reproductive counselling by a trained nurse comprising a discussion of reproductive plans (including addressing barriers the couple face), education on age-related fertility decline and limitations of artificial reproductive technologies, advice on the optimal reproductive timing and when to seek further help. An educational brochure will be handed to the couple during the counselling session.
214672678|NCT04647136|BEHAVIORAL|Fertility Awareness Tools|Online intervention consisting of 1) video targeting fertility education and specific attitudes, social norms and perceived control for having children, 2) a fertility awareness tool (FERTISTAT) and 3) an educational brochure on fertility. This intervention can be self-administered and is therefore easily scalable.
214923443|NCT04019613|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed at baseline (resting), prior to exercise with passive leg elevation, after 1.5 minutes of 20 Watts exercise, during each subsequent stage, at peak workload and at 1 minute recovery. Pulmonary thermodilution will be performed at rest, peak stress and at 1 minute recovery.
214923444|NCT02064504|DRUG|GSK961081|Dry white to off white powder
214923445|NCT02064504|DRUG|Fluticasone furoate|Dry white powder
214923446|NCT02926586|DRUG|Fludarabine|Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
214923447|NCT02926586|DRUG|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
215066207|NCT05486325|DEVICE|Endolumik Gastric Calibration Tube (EGCT)|"Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric sleeve~* To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric pouch~* To calibrate closure of the gastrojejunal anastomosis~* To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia."
215066208|NCT04327427|OTHER|Aspirin|Outcome Analysis of Aspirin in liver transplantation
214672679|NCT02389413|DRUG|PQ912 oral|
214672680|NCT02389413|OTHER|Placebo|
214672681|NCT05477771|PROCEDURE|Arthroscopic rotator cuff repair|The rotator cuff tears were repaired under arthroscopy. A subacromial decompression was performed in all patients. Then the long head of the biceps with severe lesions were treated by tenotomy while the others were reserved according to the surgeon's judgment during the surgery.
214672682|NCT04789785|DIAGNOSTIC_TEST|ultrasound|observation with usg
215066209|NCT03517839|OTHER|Inspiratory muscle trainig|Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
215066210|NCT05869058|DIAGNOSTIC_TEST|a deep convolutional neural network|a deep convolutional neural network developed for detection and assessing the perfusion of parathyroid gland during endoscopic thyroidectomy
214485820|NCT05862545|DRUG|BGF (budesonide/glycopyrrolate/formoterol fumarate)|BGF is a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.
214485821|NCT03565913|DRUG|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
214485822|NCT03565913|OTHER|CaAcS|CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
214485823|NCT02863107|PROCEDURE|Biospecimen Collection|Undergo collection of blood or saliva samples
214485824|NCT02863107|OTHER|Medical Chart Review|Review of medical charts
215066211|NCT02483923|DRUG|Ultrasound guided serratus anterior block with ropivacaine|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
215066212|NCT02483923|DRUG|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
215066213|NCT01379248|DEVICE|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
215066214|NCT00728208|DRUG|GSK372475|1.5mg for 28 days
215066215|NCT04981639|PROCEDURE|IVPCA|Intravenous patient controlled analgesia will be performed.
214485825|NCT02863107|OTHER|Quality-of-Life Assessment|Ancillary studies
214923448|NCT06502795|OTHER|Protected Range Quadriceps Strengthening group|"Warm-up: Start with 5 minutes of stationary biking. Then, proceed with two sets of 30-second dynamic stretches targeting the quadriceps, hamstrings, calf muscles, and adductors, followed by static stretching for the abductors.~Strengthening: Complete 3 sets of 8-12 repetitions for each exercise, aiming for a perceived effort level on the Borg scale between 60% and 80%. Increase the load by 2%-10% when the patient can perform 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~For the Leg Extension Machine, maintain a range of motion between 90 to 45 degrees. During Squats and Bulgarian Squats, aim for a range of motion between 0 to 45 degrees."
215066216|NCT04981639|PROCEDURE|TAP|Transversus abdominis plane block will be performed.
215066217|NCT04981639|PROCEDURE|IMS|Intramuscular electrical stimulation will be performed.
215066218|NCT05864430|OTHER|Face-to-face Training Group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
215066219|NCT05864430|OTHER|DataMatrix supported Face-to-face training group|Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.
215066220|NCT05864430|OTHER|Online training group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
215066221|NCT00168636|DRUG|Vitamin A|
215066222|NCT01772524|BIOLOGICAL|ALD403|
215066223|NCT01772524|DRUG|Placebo|
215066224|NCT05348356|DRUG|Nirogacestat|nirogacestat oral tablet
215066225|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
215066226|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
215066227|NCT01538979|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
215066228|NCT03833986|OTHER|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
215066229|NCT03010774|BEHAVIORAL|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
214323568|NCT04405609|DEVICE|ArmAssist|"The usability study protocol include 3 ArmAssist systems (2 designed for the left hand and one for the right hand) that could not be used in parallel because the aim of the study was to bring the systems to the home environment during part of the evaluation.~The usability study is carried out in two phases:~1. First phase: 5 weeks.~2. Second phase: 3 weeks. Each phase included a week of training at the Hospital or IMIBIC facilities with a physiotherapist, and then 2 weeks at the patient's home, being the first one with the physiotherapist supervision and the second one by their own with the possibility of physiotherapist remote support."
215066230|NCT03010774|BEHAVIORAL|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
215066231|NCT00408382|DRUG|atorvastatin, Lipitor|
215066232|NCT00789594|BEHAVIORAL|laboratory monitoring alerts|laboratory monitoring alerts
214923449|NCT06502795|OTHER|Patient-Guided Range Quadriceps Strengthening group|"Warm-up: 5 minutes of stationary biking. Next, perform two sets of 30-second stretches for the quadriceps, hamstrings, calf muscles, adductors and abductors hip.~Strengthening: Patients will complete 3 sets of 8 to 12 repetitions for each exercise, aiming for a perceived effort level of 60% to 80% on the Borg scale. Load will be increased by 2% to 10% when patients can complete 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~Quadriceps strengthening will be performed at the patient's maximum range guided by symptoms, with pain intensity capped at 5 points on the NPRS. The patient-guided range will be adjusted based on pain intensity, comfort, and patient response, using a shared decision-making approach. The goal is to maintain exercises at the maximum possible range of motion.~For the Leg Extension Machine, Squats, and Bulgarian Squats, the range of motion will be guided by the patient's pain tolerance."
214923450|NCT00137007|DRUG|Azithromycin|
214923451|NCT00137007|DRUG|Ampicillin/sulbactam|
215066233|NCT00789594|BEHAVIORAL|Result management module|Result management module
215066234|NCT03673085|DRUG|CN128|CN128
215066235|NCT03673085|OTHER|placebo|The tablets without CN128
214485826|NCT02863107|OTHER|Questionnaire Administration|Complete questionnaires
214485827|NCT05524844|OTHER|Sample Collection|Saliva, gastric aspirate, and esophageal brushings and biopsies.
214485828|NCT05524844|OTHER|Endoscopy results|Results from standard of care endoscopy (scheduled separate of study)
214485829|NCT05524844|OTHER|Dietary questionnaire|Diet History Questionnaire (II)
214485830|NCT05769634|BEHAVIORAL|Stereoelectroencephalography|Computer-based tasks designed to evoke changes in interoceptive attention, arousal and anticipation will be completed. The first asks patients to attend to their heartbeat to manipulate interoceptive attention. The second asks patients to judge affective pictures to manipulate states of arousals. The third engages patients in a probabilistic reward-learning task, or gambling task, and anticipate the outcomes of risky decision-making. A final task guides patients to slow their breathing to 6 breaths per minute.
214485831|NCT04811027|DRUG|eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
214485832|NCT04811027|DRUG|pembrolizumab (KEYTRUDA®)|anti-PD-1 antibody
214485833|NCT04715139|DEVICE|Products listed in Group/Cohort Description|Depending on approved indication per product
214485834|NCT04408755|DRUG|AVP-786|oral capsules
214485835|NCT04408755|DRUG|Placebo|oral capsules
214485836|NCT06649747|DRUG|AFA-281|A small molecule, orally available
214485837|NCT05677230|PROCEDURE|Balloon occluded/plug assisted retrograde transvenous obliteration.|Balloon occluded/plug assisted retrograde transvenous obliteration will be done one time only.
215066236|NCT05720858|OTHER|Aerobic exercise|Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
215066237|NCT05658848|OTHER|Collaborative infertility counseling|Collaborative infertility counseling for coping stratigies and marital satisfaction
214923452|NCT00272207|DRUG|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
214485838|NCT05677230|PROCEDURE|Endoscopic Variceal Obturation|Endoscopic Variceal Glue Therapy will be done till obturation every 3 weekly.
214485839|NCT04728230|DRUG|Carboplatin|Given IV
214485840|NCT04728230|BIOLOGICAL|Durvalumab|Given IV
214923453|NCT02534077|DIETARY_SUPPLEMENT|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
214923454|NCT02534077|DRUG|Omegaven|Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
214923455|NCT02534077|DRUG|Omegaven|If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
214923456|NCT06090903|PROCEDURE|Biospecimen Collection|patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.
214923457|NCT06090903|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
214923458|NCT06090903|OTHER|Medical Chart Review|Review Medical Chart
214923459|NCT02177903|DEVICE|Bair Paws Patient Adjustable Warming System|Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.
214923460|NCT00769067|DRUG|Erlotinib|Continuous oral dosing at 150 mg daily.
214923461|NCT00769067|DRUG|PF-00299804|Continuous oral dosing at 45mg daily
214923462|NCT06292598|OTHER|Blood sample|Sample taken to test plasma permeability markers
214923463|NCT06292598|OTHER|Stool sample|Sample taken to test microbial diversity and composition
214923464|NCT06292598|OTHER|CSF sample|Sample taken to test orexin level
214923465|NCT06584422|BEHAVIORAL|Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression|Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
214923466|NCT06584422|OTHER|Telephone friendly visits|Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
214485841|NCT04728230|DRUG|Etoposide|Given IV
214923467|NCT03073577|DRUG|Antiaging Glycopeptide|Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
214923468|NCT04810494|DRUG|2% Lidocaine HCl topical solution|0.5mL of 2% Lidocaine will be administered intranasally in each nostril with a mucosal atomization device.
214485842|NCT04728230|DRUG|Olaparib|Given PO
214485843|NCT04728230|RADIATION|Radiation Therapy|Undergo consolidative thoracic radiation therapy
214485844|NCT04821765|DRUG|PD-1 antibody|200mg, d1, q3W
214485845|NCT04821765|RADIATION|Chemoradiation|50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week
214485846|NCT04821765|DRUG|Albumin-Bound Paclitaxel|150mg/m2, d1, q3W
214485847|NCT04821765|DRUG|Cisplatin|75mg/m2, d1, q3W
214923469|NCT04810494|DRUG|0.9% Sodium chloride|0.5mL of 0.9% Sodium chloride (normal saline) will be administered intranasally in each nostril with a mucosal atomization device.
214923470|NCT05319873|DRUG|Carboplatin|Given IV
215066238|NCT04689490|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Only diagnostic tests
215066239|NCT00995397|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
214485848|NCT04002505|OTHER|Concussion and Brain Bleed App (CBB)|Tablet based decision aid that encourages shared decision making with the goal of educating patients to reduce unnecessary CT scans
214323569|NCT03993938|DEVICE|PVI measurement|Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure. After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes. Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment. Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
214323570|NCT03164798|PROCEDURE|Conventional inpatient rehabilitation|comprehensive inpatient rehabilitation for 2 weeks
214323571|NCT04466475|BIOLOGICAL|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
214485849|NCT06500910|OTHER|Physical Exercise|10 weeks of child-friendly physical exercise program
214485850|NCT06439693|DRUG|Nab-Paclitaxel|Anti-microtubule agent, via intravenous (into the vein) infusion per institutional guidelines.
214485851|NCT06439693|DRUG|Paclitaxel|Anti-microtubule agent, via intravenous infusion per institutional guidelines.
214485852|NCT06439693|DRUG|Docetaxel|Anti-microtubule agent, via intravenous infusion per institutional guidelines.
214485853|NCT06439693|DRUG|Phesgo|Pertuzumab plus trastuzumab plus hyaluronidase-zzxf, 10 or 15mL single-dose vial, via subcutaneous (under the skin) injection per protocol.
214923471|NCT05319873|DRUG|Docetaxel|Given IV
214923472|NCT05319873|DRUG|Fulvestrant|Given SC
214923473|NCT05319873|BIOLOGICAL|Pertuzumab|Given IV
215066240|NCT00995397|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
215066241|NCT04458441|OTHER|warm group/cold group|sequential randomization
214323572|NCT04466475|DRUG|Melphalan|Given via infusion
214323573|NCT04466475|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
215066242|NCT00801723|DRUG|Budesonide MMX 6 mg Tablet|Budesonide MMX 6 mg Tablet once daily.
215066243|NCT00801723|DRUG|Placebo Tablet|Placebo Tablet once daily.
215066244|NCT03401658|DEVICE|Sensor light detector|The intervention is based on a sensor technology that gathers data and transmit it to another location for processing. The monitoring utilises an LED light source, an integral detector set which has variance from device to device and chromatic based algorithms for extraction of information from the detectors. The integration of these components into a system provides robustness and stability for operation. The availability of smartphones which possess high quality cameras and constant internet connectivity provides an ideal platform for multimedia clinical data collection and real-time patient-provider communication.
214485854|NCT06439693|DRUG|T-DM1|HER2-targeted antibody-drug conjugate, 16 or 100 mg single-use vials, via intravenous infusion per institutional guidelines.
215066245|NCT01986231|DRUG|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
214485855|NCT06439693|DRUG|Pertuzumab|Recombinant humanized monoclonal antibody, 20mL single-use vial, via intravenous infusion per institutional guidelines.
214485856|NCT06439693|DRUG|Trastuzumab Deruxtecan|HER2-directed antibody drug conjugate, 100mg vial, via intravenous infusion per institutional guidelines.
214923474|NCT05319873|OTHER|Quality-of-Life Assessment|Ancillary Studies
214923475|NCT05319873|DRUG|Ribociclib|Given PO
214923476|NCT05319873|BIOLOGICAL|Trastuzumab|Given IV
214923477|NCT05319873|DRUG|Tucatinib|Given PO
214923478|NCT03806855|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary
214923479|NCT01527656|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
215066246|NCT02569372|BIOLOGICAL|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
215066247|NCT05558592|DIETARY_SUPPLEMENT|Dietary supplementation with fresh oranges|"the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis."
215066248|NCT05558592|DIETARY_SUPPLEMENT|Balanced Diet without oranges|the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
215066249|NCT06376669|RADIATION|Proton Stereotactic Body Radiation therapy (SBRT)|Radiation therapy will consist of 3-5 treatments over 1.5 - 2 weeks
215066250|NCT01558115|DRUG|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
215066251|NCT01558115|OTHER|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
215066252|NCT01696994|OTHER|Laboratory Biomarker Analysis|Correlative studies
215066253|NCT01696994|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
215066254|NCT01696994|PROCEDURE|Ultrasound Imaging|Undergo TVU
215066255|NCT02733822|DRUG|Naloxone|
214923480|NCT02490046|DIETARY_SUPPLEMENT|D Mannose|Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
214923481|NCT03316014|OTHER|Adverse drug reaction|description of the adverse drug reactions (ADR) and the drugs involved in pediatrics
215066256|NCT03870451|DEVICE|VascuTherm5 vascular compression device|VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
215066257|NCT05438719|DEVICE|MOTUS Total Joint Replacement|The MOTUS Total Joint Replacement is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level from L1/L2 to L5/S1 for skeletally mature patients due to symptomatic lumbar degeneration with or without foraminal or recess spinal stenosis confirmed by radiographic imaging (CT, MRI, X-rays), with no more than a Grade 1 spondylolisthesis at the involved level.
215066258|NCT04588220|OTHER|Obstetric ultrasound and fetal-maternal assessment|melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
215066259|NCT01589146|DRUG|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
214923482|NCT05197608|OTHER|System Navigator|Participants will be connected to a System Navigator, who is a trained staff embedded within their primary health clinic to support and help navigate biological, psychological and social needs in proactively identified vulnerable patients.
215066260|NCT00368680|DEVICE|Early Bubble CPAP|
215066261|NCT04682223|BEHAVIORAL|Semantically-focused therapy tasks|1\) Semantic feature analysis (SFA; Boyle \& Coelho, 1995; Boyle, 2004). For each pictured stimulus the participant is prompted to name the picture. Then, s/he is encouraged to produce semantically related words that represent features similar to the target word. 2) Semantic barrier task. This approach includes features of the Promoting Aphasics' Communication Effectiveness (PACE; Davis \& Wilcox,1985). The goal of the task is for one participant (e.g., person with aphasia) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. 3) Verb network strengthening therapy (VNeST; Edmonds et al., 2009; 2014) targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the participant to generate verb-noun associates with the purpose of strengthening the connections between the verb and its thematic roles.
214923483|NCT05197608|OTHER|Tailored list of resources|Control group will be provided a tailored list of resources
214923484|NCT03625466|DRUG|LUM/IVA|FDC tablets or granules for oral administration.
215066262|NCT04682223|BEHAVIORAL|Phonologically-focused therapy tasks|1\) Phonological components analysis task (PCA; Leonard et al., 2008). The participant first attempts to name a given picture and then to identify the phonological features of the target words. 2) Phonological production task focuses on the identification of phonological features of targeted, imageable nouns and verbs. It requires the participant to sort picture stimuli based on the number of syllables and then to identify a hierarchy of phonological features. Once each targeted feature is identified for the pair of words, the participant is required to blend the syllables/sounds together. 3) Phonological judgment task relies on computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features (e.g. # of syllables, initial phonemes, final phonemes, rhyming).
215066263|NCT04644276|DEVICE|Mask with Mask Adhesive/Arm 1|Patients will be randomized to Arm1 if they receive the mask adhesive and mask on the first study night then the mask without the mask adhesive on the second study night.
215066264|NCT04644276|DEVICE|Mask without Mask Adhesive / Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then the mask adhesive with the mask on the second study night.
215066265|NCT06163950|OTHER|Fatigability assessment|An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
215066266|NCT05464771|PROCEDURE|Surgery for hip and knee replacement|Elective inpatient surgery for hip and knee replacement
215066267|NCT04408391|OTHER|Brain MRI scan|Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner
215066268|NCT01413243|DRUG|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
215066269|NCT04727450|BEHAVIORAL|Cognitive training|Involves participants engaging in selected games which require thinking skills to be played in a group of 2-4 people.
215066270|NCT04727450|BEHAVIORAL|physical training|"Involves learning of preselected routines of line dancing taught by a line dance instructor."
214485857|NCT06439693|DRUG|Trastuzumab Subcutaneous Subcutaneous|Humanized IgG1 kappa monoclonal antibody, 6mL vial, via subcutaneous injection per institutional guidelines.
214923485|NCT03625466|DRUG|LUM/IVA|FDC granules for oral administration.
214923486|NCT03625466|DRUG|Placebo|Placebo matched to LUM/IVA for oral administration.
215066271|NCT04727450|BEHAVIORAL|Combination of cognitive and physical training (CCPT)-BIGMAP|BIGMAP is a program engaging participants in specially designed cognitive/memory games together with physical training (Fu \& Chow, 2019).
214923487|NCT02708537|BIOLOGICAL|PRGF in candidates for sperm donors|PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.
214923488|NCT06217237|DIAGNOSTIC_TEST|AD FDT DBL GROUP|All participants will undergo an MRI session. The MRI protocol will include the clinical diagnostic protocol defined within the Network and research sequences as specified above (T1 3D, DTI, FLAIR 3D, QSM).
214923489|NCT02469688|DRUG|ASP4070|intramuscular or intradermal
214923490|NCT02469688|DRUG|Placebo|intramuscular or intradermal
214923491|NCT06462352|DEVICE|Navicam SB capsule|Exploration of the small bowel by Navicam SB endoscopic capsule.
214923492|NCT06462352|DEVICE|Pillcam SB3|Exploration of the small bowel by Pillcam SB3 endoscopic capsule.
215066272|NCT03067519|OTHER|Fast track surgery|early feeding and mobilization after surgery
215066273|NCT03067519|OTHER|Conventional management|Management per the primary surgeon
215066274|NCT00705250|DRUG|bendamustine hcl|Patients will receive bendamustine 120mg/m\^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is \> 1000/ul and the platelet count is \> 75,000/ul.
214923493|NCT05225844|DRUG|Camrelizumab|Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle
214923494|NCT05225844|DRUG|Apatinib Mesylate|Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle
214923495|NCT00809471|DRUG|placebo|30 minutes orally prior to initiation of sexual activity
214923496|NCT00809471|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
214923497|NCT00809471|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
214923498|NCT02967328|OTHER|RP% Measurement by FCM as a Diagnostic Test for ITP|
214923499|NCT02180139|DEVICE|transcranial direct current stimulation|tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.
214923500|NCT05231772|DRUG|Saccharomyces Boulardii Probiotic Supplement|Probiotic yeast
215066275|NCT03637257|DEVICE|modified Guedel airway|Monitoring of breathing
215066276|NCT01576146|DRUG|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
215066277|NCT01610219|BEHAVIORAL|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
215066278|NCT01610219|OTHER|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
215066279|NCT00127452|DIETARY_SUPPLEMENT|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
215066280|NCT00351793|DEVICE|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
215066281|NCT05635396|DEVICE|Wearable, non invasive sensor for seizure detection|The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
215066282|NCT03090516|DRUG|Ginkgo biloba dispersible tablets|Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
215066283|NCT03090516|DRUG|Donepezil|Arm A：Aricept 5mg/day
215066284|NCT03090516|DRUG|Ginkgo biloba dispersible tablets and Donepezil|Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
215066285|NCT05354609|OTHER|MR-enterography|All patients will undergo a simplified MR-enterography, which includes four sequences, without bowel cleansing or injection. On the same day, the standard MR-enterography will be performed as in clinical practice, after ingestion of the usual oral preparation.
215066286|NCT02926027|DRUG|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
215066287|NCT02926027|DRUG|placebo|placebo
215066288|NCT02377752|BIOLOGICAL|Olaratumab|Administered IV
215066289|NCT02377752|DRUG|Doxorubicin|Administered IV
215066290|NCT03625947|OTHER|Argon Plasma Coagulation|Patients will be treated with Argon Plasma Coagulation. Argon plasma coagulation (APC) is a form of non contact electrocoagulation. APC utilizes electrically conductive argon plasma as a medium to deliver high-frequency current via a flexible probe. The argon plasma flow transfers electricity between the probe and the target tissue. Tracheobronchial access is obtained by passing the probe through the working channel of the bronchoscope. On arrival to the tissue, the application of energy causes uniform zones of desiccation, coagulation and devitalization in the areas receiving treatment, thus inducing hemostasis.
215066291|NCT01289288|BEHAVIORAL|Mailed printed materials and in-office training|"1. Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~2. Two sessions of in-office training with two standardized patients"
215066292|NCT01951586|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
215066293|NCT01951586|DRUG|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
215066294|NCT01951586|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
215066295|NCT01951586|DRUG|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
215066296|NCT01951586|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
214485858|NCT06439693|DRUG|Tucatinib|Tyrosine Kinase HER2 Inhibitor, 50 or 150mg tablet taken orally per institutional guidelines.
214485859|NCT06439693|DRUG|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150 mg single-dose vial, via intravenous infusion per institutional guidelines.
214485860|NCT05699525|BEHAVIORAL|Personalized MAYA Mobile App|All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
214485861|NCT05699525|BEHAVIORAL|General MAYA Mobile App|New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.
214485862|NCT01937039|PROCEDURE|Sample collection|Blood, tissue, urine, and other samples may be collected
214923501|NCT05231772|DRUG|Placebo|Placebo
214923502|NCT01172223|DRUG|Myocet (Non-pegylated liposomal doxorubicin (NPLD))|60 mg/m\^2 i.v. day 1 q3 weeks
214923503|NCT01172223|DRUG|Paclitaxel|175 mg/m\^2 i.v. day 1 q3 weeks
214923504|NCT01172223|DRUG|Lapatinib (GW572016, Tykerb)|750-1500 mg/d orally daily until the day of the definitive surgery
214923505|NCT00665860|DIETARY_SUPPLEMENT|Placebo|Three pills per day for two years
214923506|NCT00665860|DIETARY_SUPPLEMENT|Soy isoflavones|Three pills that delivered 80 mg of aglycone isoflavones per day for two years
214923507|NCT00665860|DIETARY_SUPPLEMENT|Soy isoflavones|Three pills that delivered 120 mg aglycone isoflavones per day for two years
214923508|NCT01713010|OTHER|Predictive indexes of weaning from mechanical ventilation|
215066297|NCT01558492|DRUG|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
215066298|NCT01558492|DRUG|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
214323574|NCT04116645|OTHER|genital and rectal swab|6\. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
214923509|NCT06056960|OTHER|Tailored Physical Activity|"The intervention will comprise 16 sessions (2 sessions/week). 30 minutes of walking training wearing a heart rate (HR) monitor to keep exercise intensity below 70% of maximal HR.~Right after, 30 minutes of balance exercises will be performed. An experienced physical therapist will tailor exercises. Subjects will be taught how to perform the exercises by themselves. A booklet will be provided to provide guidelines. A physical therapist will call subjects, every training day to check for any problem."
215066299|NCT05895331|DIAGNOSTIC_TEST|Thiol/Disulphide Homeostasis|An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
214323575|NCT05053672|DEVICE|ReOxy|"ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session.~The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min.~During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control)."
214323576|NCT05053672|DEVICE|Sham ReOxy|Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions. Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve. The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.
214323577|NCT00371943|PROCEDURE|band ligation|
214323578|NCT03470337|DRUG|Phlogenzym|Bromelain / Trypsin / Rutoside
214323579|NCT03470337|OTHER|Placebo|
215066300|NCT03454399|PROCEDURE|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
214323580|NCT04696705|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
214323581|NCT02469610|OTHER|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
214323582|NCT04784286|OTHER|Telemedicine 30-day post-op visit|Consented subjects randomized to the telemedicine visit arm will do their 30-day post-op visit via secure telemedicine video application through the Center of Connected Care. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
214485863|NCT02295072|BEHAVIORAL|A 5-months physical exercise-based program|"The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus exercise homework in the weekends, and will focus on high-intensity aerobic exercise mainly."
214485864|NCT06294691|PROCEDURE|Time of stem cell infusion|Randomization of patients according to the time of stem cell infusion
214485865|NCT05778617|DRUG|Ambroxol Hydrochloride (420mg)|Oral tablet
214485866|NCT05778617|DRUG|Placebo|Oral tablet
214672683|NCT01376739|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
214323583|NCT04784286|OTHER|In-Person 30-day post-op visit|Consented subjects randomized to the in-person visit arm will physically come to a clinical visit with the bariatric surgery midlevel providers. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
214672684|NCT01868087|DIETARY_SUPPLEMENT|Boost Plus®|
214323584|NCT03301324|DEVICE|Intubation Assist Dashboard|The ZOLL X Series Intubation Assist Dashboard feature guides the operator through a three-step auscultation process to verify the proper placement of an endotracheal tube.
214323585|NCT00584038|BEHAVIORAL|educational instruction and phone follow-up|Educational instruction and phone follow-up.
214672685|NCT01868087|DIETARY_SUPPLEMENT|Impact Advanced Recovery®|
214672686|NCT04952012|DRUG|LT4|LT4 is used to improve the thyroid function of pregnant women.
214672687|NCT00100555|DRUG|zoledronic acid|
214672688|NCT02502630|DEVICE|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
214672689|NCT04611464|DRUG|Misoprostol|Misoprostol is a PGE1 analog
214672690|NCT02760602|DRUG|Solanezumab|Administered IV
214672691|NCT02760602|DRUG|Placebo|Administered IV
214672692|NCT01972425|OTHER|Biomarker-based diagnostic|The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
214323586|NCT00584038|BEHAVIORAL|educational instruction in clinic|Educational instruction in clinic.
214672693|NCT00708877|PROCEDURE|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
214672694|NCT02137551|OTHER|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
214672695|NCT06449105|BEHAVIORAL|1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
214672696|NCT06449105|BEHAVIORAL|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214923510|NCT01783028|BEHAVIORAL|Community Health Worker support|For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
214923511|NCT04713254|DRUG|Lu AG06466|10, 20, 30 mg/day oral capsules on Day 5-18
214923512|NCT04713254|OTHER|Midazolam|4 mg syrup, oral single dose on Day 1 and Day 15
214923513|NCT04713254|OTHER|Metoprolol|100 mg tablets, oral single dose on Day 1 and Day 15
214923514|NCT04713254|OTHER|Bupropion|100 mg tablets, oral single dose on Day 3 and Day 17
214323587|NCT01637350|PROCEDURE|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
214923515|NCT05667116|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
214923516|NCT02990936|OTHER|Tumor delineation|Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns
214923517|NCT02497040|DRUG|Levobupivacaine|local injection
214323588|NCT02419118|DRUG|Daratumumab|Treatment of myeloma patients with Daratumumab
214323589|NCT02419118|DRUG|Lenalidomide|Treatment of myeloma patients
214923518|NCT02497040|DRUG|Bupivacaine|local injection
214923519|NCT02497040|DRUG|placebo|local injection
214323590|NCT02419118|DRUG|Dexamethasone|Treatment of myeloma patients
214323591|NCT01243346|DRUG|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
214323592|NCT03880851|RADIATION|Plan adaptation of Radiation Treatment in case of anatomical changes|Image guided radiotherapy is given to 60Gy in 20 fractions. Intervention: Radiation treatment plan adaption in case of volume changes of target volume or not meeting OAR constraints due to volume changes.
214323593|NCT04044417|PROCEDURE|currettage|open flap debridement
214323594|NCT04044417|DRUG|curcumin simvastatin paste|Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
214323595|NCT04044417|DRUG|EDTA root conditioning|EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
214323596|NCT01926795|PROCEDURE|Short leg cast|
214323597|NCT01926795|PROCEDURE|No Immobilization|
214672697|NCT06449105|BEHAVIORAL|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
214672698|NCT06449105|BEHAVIORAL|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214923520|NCT05076032|DRUG|OXO-001|OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
214923521|NCT05076032|DRUG|Placebo|Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
214923522|NCT03551769|DRUG|tricaprilin|Tricaprilin formulated as AC-SD-01
214923523|NCT03551769|OTHER|standard meal|standard meal
215066301|NCT05379218|DEVICE|Remote Ischemic Conditioning|"Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected."
215066302|NCT04023370|DEVICE|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
215066303|NCT05409053|PROCEDURE|open reduction|the displaced fractures will be treated with open reduction so as to achieve the near anatomical alignment
215066304|NCT05409053|PROCEDURE|Closed reduction|the non displaced fractures will be treated with closed reduction and percutaneous pinning
214923524|NCT03551769|OTHER|high-fat meal|high-fat meal
214323598|NCT06975176|BEHAVIORAL|Stigma reduction intervention|"Care providers will complete the Stigma Reduction Intervention curriculum. The intervention is a multi-day stigma reduction training program for providers.~Content design is greatly informed by materials developed in our pilot R34 study, and which may be modified prior to the intervention if the team gains new insights from the baseline round of unannounced visits and each of the two CABs. Briefly, the intervention consists of both didactic and experiential learning components. Didactic sessions include instruction on syphilis epidemiology, clinical management, and public health significance. Experiential sessions include discussion sessions that are facilitated by pre-recorded videos, followed by role play with trained SPs."
215066305|NCT05409053|OTHER|Conservative management|the non displaced fractures will be treated with closed reduction and castor slab
215066306|NCT03723330|DIETARY_SUPPLEMENT|plant sterols|Consumption a healthy eating pattern diet with a plant sterols-enriched food product
214923525|NCT03551769|OTHER|overnight fast|fasting for at least 9 hours
214923526|NCT00801203|DRUG|IRCT|Up to two administrations of the IRCT during a single cough testing session
214923527|NCT00956592|DEVICE|CMAC video laryngoscope|Intubation utilizing the assistance of video enhancement
215066307|NCT03723330|OTHER|healthy diet|Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
215066308|NCT00499512|BEHAVIORAL|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
215066309|NCT04399863|BEHAVIORAL|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
215066310|NCT04590430|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
215066311|NCT04590430|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
215066312|NCT02903225|BEHAVIORAL|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
214923528|NCT00956592|DEVICE|Macintosh laryngoscope|Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
215066313|NCT01557257|DRUG|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
215066314|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
215066315|NCT01557257|DRUG|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
215066316|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
215066317|NCT01557257|DRUG|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
215066318|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
215066319|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system with bone cement.
215066320|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system without bone cement.
215066321|NCT05433441|PROCEDURE|ESPark Intervention|The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
214323599|NCT05278429|DEVICE|Myosuit robotic device|The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.
214323600|NCT04219865|DRUG|Group 1: Compound Edaravone/Placebo Injection|Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min
214923529|NCT00574470|DRUG|daclizumab, infliximab|Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
214923530|NCT00287872|DRUG|bortezomib|
214923531|NCT00287872|DRUG|thalidomide|
214923532|NCT01355016|DRUG|MDT-637|Inhaled doses of MDT-637 over a 24 hour period
214923533|NCT05103280|OTHER|Assistive tennis shoes|Assistive shoes include carbon-fiber and spring loaded shoes.
214923534|NCT00751049|DRUG|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
215066322|NCT06836245|OTHER|Measure the patient's body temperature intraoperatively using instruments|"1. Core Body Temperature Measurement:~   Nasopharyngeal Temperature Probe: Insert the probe into the patient's nasal cavity to measure the temperature of the nasopharynx.~   Esophageal Probe: Insert the probe through the esophagus to measure the temperature of the lower esophagus.~   Bladder Temperature Probe: Insert the probe into the bladder to measure the temperature of the urine.~   Tympanic Temperature Probe: Place the probe in the ear canal to measure the temperature near the tympanic membrane.~2. Peripheral Body Temperature Measurement:~Axillary: Place the thermometer under the armpit, suitable for routine temperature monitoring, but may not be as accurate as core temperature measurement.~Oral: Place the thermometer under the tongue, suitable for conscious and cooperative patients.~Rectal: Insert the thermometer into the rectum to provide an accurate temperature measurement, but may not be suitable for all patients, especially those with rectal diseases or immunosuppressed conditions."
214485867|NCT04282304|BEHAVIORAL|Preoperative usual care|"Usual care during the preoperative preparation for bariatric surgery consists of:~* Endocrinologist work-up and follow-up, with at least 2 consultations;~* Dietary advice, provided during the endocrine consultation or dietician consultation~* Psychological counselling with the patient's usual psychiatrist (at least 2 consultations~* Physical activity and nutrition are encouraged, but entrusted to the patient's freedom of choice. Weight loss, or at least, weight stabilization, is recommended before the surgery, without initiating a specific behavioural procedure."
214672699|NCT06449105|BEHAVIORAL|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
214672700|NCT06449105|BEHAVIORAL|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
214672701|NCT06449105|BEHAVIORAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
214672702|NCT06449105|BEHAVIORAL|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
214672703|NCT03159754|PROCEDURE|Early Appendectomy|Removal of the appendix within 24 hours of admission
214672704|NCT03159754|PROCEDURE|Interval Appendectomy|Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.
214672705|NCT03159754|DRUG|Antibiotics|Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
214923535|NCT00751049|DRUG|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
214923536|NCT01554865|DIETARY_SUPPLEMENT|Optifast|1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
214923537|NCT01554865|BEHAVIORAL|Conventional diet counseling|
214923538|NCT00757458|DRUG|EDTA without re-filling|Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
214923539|NCT00757458|OTHER|Propofol syringe re-filling with propofol containing EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
214923540|NCT00757458|OTHER|Target controlled infusion of propofol without EDTA|Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
215066323|NCT04136093|OTHER|the MED|The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
214672706|NCT00784069|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
215066324|NCT04136093|OTHER|the DASH|The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
215066325|NCT04136093|OTHER|Control diet|"The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal."
215066326|NCT04995419|DRUG|Enfortumab vedotin|Intravenous Infusion
215066327|NCT06849765|BEHAVIORAL|Rehabilitation|The rehabilitation program will utilize the MORA app to create individualized interventions based on each patient's physical capabilities.
215066328|NCT01822899|DRUG|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
215066329|NCT01822899|DRUG|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
214672707|NCT05441046|DRUG|Genakumab|genakumab plus tislelizumab 200 mg
214923541|NCT00757458|OTHER|Re-filling of syringe with propofol without EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
215066330|NCT01822899|DRUG|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
215066331|NCT01822899|DRUG|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
215066332|NCT05332392|DEVICE|INVSENSOR00040|Noninvasive wearable health monitoring device
215066333|NCT02628405|DRUG|Carboplatin|Given IV
214672708|NCT06128941|OTHER|Repeated sprint|"* Duration of the study: 8 weeks of participation.~* Each repeated sprint training protocol: 2 training sessions per week for 4 weeks.~* Collection sessions: 3 collection sessions will be carried out: before the start of the training protocol - T0; at the end of the protocol, in week 4 - T1; and late, 4 weeks after the end of the protocol, in week 8 - T2.~* Training sessions: will be carried out on an ergometer and will consist of 3 sets of 5 sprints of 10s all-out with 20s of rest between sprints, and 5 minutes of rest between sets."
214672709|NCT02893254|DRUG|IBI303|12 cycles. IBI303: 40 mg, iH
214672710|NCT02893254|DRUG|Adalimumab|12 cycles. Adalimumab: 40mg, iH
214923542|NCT06968481|DRUG|Oxytocin|Sublingual oxytocin 1000 IU, 3000 IU or 6000 IU
214923543|NCT06968481|DRUG|Oxytocin|Intramuscular oxytocin 10 IU
215066334|NCT02628405|DRUG|Etoposide|Given IV
215066335|NCT02628405|DRUG|Ifosfamide|Given IV
215066336|NCT02628405|OTHER|Laboratory Biomarker Analysis|Correlative studies
215066337|NCT02628405|DRUG|Lenalidomide|Given PO
215066338|NCT02628405|BIOLOGICAL|Rituximab|Given IV
215066339|NCT02782234|BEHAVIORAL|Contract management|
215066340|NCT06196658|DRUG|anti-EX02 CAR T cells|"Conditioning chemotherapy:~• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion~Investigational Product:~• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator~• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg"
215066341|NCT02840318|OTHER|Compassion Intervention|See arm description
215066342|NCT02382731|BEHAVIORAL|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
214672711|NCT06005506|DIETARY_SUPPLEMENT|Prebiotic fiber|Moradyn active prebiotic fiber product
214672712|NCT06005506|DIETARY_SUPPLEMENT|Dietary fiber|Fibregum non-active fiber product
214672713|NCT06005506|DIETARY_SUPPLEMENT|Probiotic|Defense Plus probiotic complex
214923544|NCT06210035|BEHAVIORAL|Belly-focus meditation|Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
214923545|NCT06210035|BEHAVIORAL|Belly-focus meditation with slow breathing|Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
215066343|NCT02382731|BEHAVIORAL|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
215066344|NCT00570791|DEVICE|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
215066345|NCT00971581|DRUG|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
215066346|NCT02752633|DRUG|Allopurinol|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
214923546|NCT06968819|OTHER|Non-immersive virtual reality|Non-immersive virtual reality-based robot-assisted intervention includes balance and coordination training, muscle strengthening exercises as well as cognitive stimulation activities on an interactive treadmill, stabilometric platform and robot-assisted upper limb rehabilitation device. In addition, the experimental group takes part in group sessions featuring active and isometric exercises or motor coordination training.
214923547|NCT06968819|OTHER|Standard physical therapy|Participants receive standard physical therapy, which includes individual sessions focused on muscle strengthening, balance training, stretching, suspension therapy, and treadmill exercises. In addition, they take part in group sessions featuring active, isometric exercises or motor coordination training.
214923548|NCT02028767|DRUG|Empagliflozin 2.5 mg|Empagliflozin 2.5 mg tablet
215066347|NCT02752633|DRUG|Febuxostat|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
215066348|NCT03957668|DRUG|PEG 3350|PEG 3350 17 g once daily for 14 days
215066349|NCT03957668|DRUG|Lactulose|Lactulose 10 g once daily for 14 days
215066350|NCT02846389|OTHER|Moderate Exercise|Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
215066351|NCT03781895|DRUG|Cholecalciferol|"• Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)"
215066352|NCT01295840|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
215066353|NCT00002134|DRUG|Ganciclovir|
215066354|NCT05030610|BEHAVIORAL|BeatIt-ASD|BeatIt-ASD, designed to be implemented with autistic individuals, is an adaptation of BeatIt. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
215066355|NCT00006144|DRUG|Lopinavir/Ritonavir|
214672714|NCT04751279|OTHER|Blood sample|Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml
214672715|NCT02727114|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
214923549|NCT02028767|DRUG|Empagliflozin 10 mg|Empagliflozin 10 mg tablet
214923550|NCT02028767|DRUG|Metformin 500 mg|Metformin 500 mg tablet
214923551|NCT02028767|DRUG|Empagliflozin/Metformin FDC|12.5 mg Empagliflozin / 500 mg Metformin
214923552|NCT05804422|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
214923553|NCT05804422|DIETARY_SUPPLEMENT|Placebo|Placebo
215066356|NCT00006144|DRUG|Emtricitabine|
215066357|NCT00006144|DRUG|Stavudine|
214672716|NCT06326151|BEHAVIORAL|Interdisciplinary Psychoeducational Programme|This intervention is based on the principle of complementing and integrating both disciplines in order to meet the psychological needs of family carers and to train them in knowledge and strategies aimed at the correct performance of activities of daily living in order to promote the maximum autonomy and functionality of dependent people with cognitive impairment, and that this favours discharge, self-care, improvement of the affective state and quality of life of family carers.
214923554|NCT00162188|DRUG|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
214923555|NCT02454465|OTHER|Acceptance and Commitment Therapy group|Six week, Acceptance and Commitment Therapy group for those with adjustment difficulties following an acquired/traumatic brain injury or other neurological condition.
214923556|NCT02566382|PROCEDURE|arthroscopy arthrodesis of the shoulder|The shoulder surgery will be realized under arthroscopy only
214923557|NCT03322761|COMBINATION_PRODUCT|Systematic exercise training|Combination of standard medical treatment and systematic early exercise training in persons with MS.
214323601|NCT04219865|DRUG|Group 2: Compound Edaravone/Placebo Injection|Compound Edaravone 60mg-1200mg (containing edaravone 60 mg and 2-aminoethanesulfonic acid 1200 mg) / placebo single intravenous infusion for 30min
214323602|NCT04219865|DRUG|Group 3: Compound Edaravone/Placebo Injection|Compound Edaravone 90mg-1800mg (containing edaravone 90 mg and 2-aminoethanesulfonic acid 1800 mg) / placebo single intravenous infusion for 30min
214323603|NCT04219865|DRUG|Group 4: Compound Edaravone/Placebo Injection|Compound Edaravone 120mg-2400mg (containing edaravone 120 mg and 2-aminoethanesulfonic acid 2400 mg) / placebo single intravenous infusion for 30min
214323604|NCT04219865|DRUG|Group 5: Compound Edaravone/Placebo Injection|Maximum tolerated dose of drug / placebo for a single intravenous infusion for 30 minutes three times a day at an interval of 8 h until the last dose on the morning of Day 3, after which the sequential test drug 30 mg-600 mg / placebo will be administered daily from Day 3 night Intravenous infusion, 30 minutes at 12-hour intervals until morning on Day 7
214323605|NCT05982535|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
214323606|NCT02922270|OTHER|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
214323607|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 cell culture infectious dose 50% (CCID50)/dose and 10\^5.8 CCID50/dose, respectively.
214323608|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10\^6 CCID50/dose and 10\^5.8 CCID50/dose, respectively.
214323609|NCT02434770|BIOLOGICAL|BioFarma Bivalent Oral Poliomyelitis Vaccine|Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 and 10\^5.8 infective units per dose, respectively.
214323610|NCT06806176|BEHAVIORAL|Cognitive analytic therapy guided self-help (CAT-GSH)|Six session CAT-GSH treatment
214923558|NCT03322761|BEHAVIORAL|Educational program|Informations regarding health benefits of physical activity and exercise.
214923559|NCT03072589|DRUG|Regadenoson infusion|Dose escalation of Regadenoson when given as an infusion
214923560|NCT05707468|DRUG|ADT combined with abiraterone|The patients will receive long-term ADT combined with abiraterone.
214923561|NCT05707468|RADIATION|neoadjuvant hormone and RT|The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
214923562|NCT06379646|OTHER|YTS109|Subjects will receive YTS109 Cell Injection(3E6STAR+T cell/kg) once in this study.
214923563|NCT05147402|DRUG|midomafetamine|100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl).
214923564|NCT06965153|DRUG|Dual NRT|Dual nicotine replacement therapy
214485868|NCT04282304|BEHAVIORAL|Preoperative intensive behavioral lifestyle intervention|"The intensive behavioral lifestyle intervention program takes place over 4 weeks of 5 days. It includes:~* Rehabilitation to physical exercise every morning~* Therapeutic cooking sessions; during these sessions, the patients prepare the day's meals under the supervision of a nutritionist~* Psychological counselling~* One swimming session per week~* One relaxation session~* Regular physical activity (aerobics, work-up)~* Individual entertainment with the physiotherapist physician and discussion groups~* Weight, BMI and waist circumference control at the end of each week."
214485869|NCT02570347|DRUG|Co-amoxiclav|Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
214485870|NCT02570347|BIOLOGICAL|Tetanus toxoid|Injection Tetanus toxoid 0.5 ml intramuscularly Stat
215066358|NCT04661371|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
215066359|NCT04425967|RADIATION|pre-operative radiotherapy|pre-operative radiotherapy
214485871|NCT06776471|OTHER|Resin-based flowable filling material|Preventive restoration
214485872|NCT06776393|OTHER|ultrasound|"Dynamic translaryngeal Ultrasound Motion mode ultrasound of the laryngeal region during phonation Acoustic recordings VHI questionnaires "
214485873|NCT05923255|PROCEDURE|LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）|Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.
214672717|NCT06326151|BEHAVIORAL|Health Education Programme|Upon discharge from the hospital, at the end of the baseline assessment, caregivers will receive instructions and recommendations for maintaining an active and healthy lifestyle. This will be done by encouraging self-care and good practices in caring for their dependent family member, as part of a health education programme. The benefits of an active lifestyle and general guidelines are emphasized.
214323611|NCT06806176|BEHAVIORAL|Cognitive behavioural therapy guided self-help (CBT-GSH)|Six session CBT-GSH treatment
214323612|NCT01574352|BEHAVIORAL|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
214323613|NCT01574352|BEHAVIORAL|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
214323614|NCT00245765|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: solution for injection in pre-filled syringe~* Route of Administration: subcutaneous use"
214323615|NCT00245765|OTHER|Placebo|Matching Placebo to Certolizumab Pegol
214323616|NCT01483196|PROCEDURE|ultrasound imaging|Undergo TCD
214323617|NCT01483196|OTHER|questionnaire administration|Complete neurocognitive questionnaires
214323618|NCT01483196|PROCEDURE|assessment of therapy complications|Undergo TCD
214485874|NCT05923255|PROCEDURE|TRH（Traditional Laparoscopic Right Hemicolectomy）|Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.
214323619|NCT01483196|PROCEDURE|quality-of-life assessment|Ancillary studies
214923565|NCT06965153|BEHAVIORAL|PeerTTS|Peer recovery coach delivered tobacco cessation coaching
214923566|NCT06967025|PROCEDURE|Ischemic Postconditioning|Ischemic Postconditioning will consist of 4 cycles of 2-minute cycles of balloon inflation (occlusion) followed by 2 minutes of deflation (reperfusion), and will be initiated immediately upon successful recanalization (eTICI 2b-3) using low pressure balloon in situ of the location of thrombus.
214923567|NCT06967025|PROCEDURE|Endovascular Thrombectomy|Thrombectomy alone.
214323620|NCT01483196|PROCEDURE|magnetic resonance imaging|Undergo MRI
214323621|NCT00660348|DRUG|morphine sulfate|This is morphine given in the traditional methods.
214323622|NCT00660348|DEVICE|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
214323623|NCT04060407|DRUG|CD24Fc|CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
214323624|NCT04060407|DRUG|Ipilimumab|Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.
214923568|NCT05629221|OTHER|TreC Diabete App|Participants can download the App from Google Play or Apple Store and activate the App as soon as the clinician provides them a unique activation code, created through an online medical dashboard. The dashboard allows the interaction between healthcare staff and the participant through the use of a chat or a video-chat. Participants are asked to register some information in the App at set times (e.g. blood pressure). Reminders are periodically sent to remember the participants to perform some tasks. Clinicians will periodically check the information entered by the participant (min frequency 45 days).
214923569|NCT01597414|DRUG|Pertuzumab + trastuzumab|"Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks."
214923570|NCT01597414|DRUG|Pertuzumab + trastuzumab + metronomic chemotherapy|Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
214923571|NCT03131414|OTHER|Diet|Dietary intake
214923572|NCT03131414|OTHER|Gastrointestinal microbiome|Genomic sequencing of stool for gut bacteria
214923573|NCT01942486|DEVICE|Investigational Coating|
214923574|NCT06474988|OTHER|Skin tests|Acquisition of Skindex questionnaire 29 and execution of instrumental skin tests
214923575|NCT05845762|DRUG|Obinutuzumab Injection|1000mg intravenous injection
214923576|NCT03098238|BIOLOGICAL|Biological sample|Biological sampling of two citrate tubes (18 ml) during a normal blood
214923577|NCT02671084|DRUG|sevoflurane|compare effect of sevoflurane when administered before PCI
214923578|NCT06663202|PROCEDURE|Fiber retention osseous resective surgery|"At the buccal and lingual sides, paramarginal or intrasulcular incisions will be made based on probing pocket depth values and the width of keratinised tissues.~Thinned palatal flap technique will be performed on the palatal side. Bone remodelling will be carefully made using manual or rotary instruments in order to reshape positive attached fibres/bony architecture utilising the FibReORS technique, great attention will be made to distinguish between inflammatory granulation tissue and connective tissue fibres attached to root cementum by means of periodontal probe. Flaps will be positioned at the level of the alveolar crest without tension."
214923579|NCT06663202|PROCEDURE|Papilla preservation flap|Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used. Suturing will be performed with external vertical mattress sutures to achieve primary intention closure.
214323625|NCT04060407|DRUG|Nivolumab|Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
214323626|NCT01703793|DRUG|Test Product 49778|
214323627|NCT01703793|DRUG|Test Product 10156|
214323628|NCT01703793|DRUG|Vehicle (placebo)|
214672718|NCT00480194|DRUG|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
215066360|NCT03389412|DRUG|Desmopressin|The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
215066361|NCT03389412|DEVICE|Conditional alarm|Eight weeks of treatment.
214323629|NCT03717038|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
214323630|NCT03717038|DRUG|TAS-102|TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
214323631|NCT03346122|DRUG|JNJ-64991524 Dose Level 1|Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
215066362|NCT04457791|BEHAVIORAL|Personalized dietary advice|Via an self-developed website and algorithm, participants will receive digital personalized dietary advice to increase dietary fiber intake, aiming to reduce constipation complaints. The advice is personalized on phenotype (habitual diet, gender)
215066363|NCT02332993|DIETARY_SUPPLEMENT|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
215066364|NCT05265234|DRUG|Dupilumab|IL-4 antagonist to improve moderate-severe atopic dermatitis
215066365|NCT05265234|DEVICE|Optical Coherence Tomography|OCT is a noninvasive imaging device that can be used to monitor inflammatory skin disorders.
215066366|NCT05265234|DEVICE|Reflectance confocal microscopy|RCM is a noninvasive imaging device, with resolution approaching that of histology, which can monitor structural changes in the epidermis and superficial dermis, monitor inflammatory cells, and can overcome the limitations of a traditional biopsy.
215066367|NCT03981757|DEVICE|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
215066368|NCT03668496|DRUG|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
215066369|NCT03668496|DRUG|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
215066370|NCT00853242|DRUG|Placebo|
215066371|NCT00853242|DRUG|Genz-644470|
215066372|NCT00853242|DRUG|Sevelamer carbonate|
215066373|NCT05114707|DRUG|camrelizumab|Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.
215066374|NCT01444625|OTHER|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
215066375|NCT01444625|OTHER|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
215066376|NCT04078958|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
215066377|NCT04078958|DIETARY_SUPPLEMENT|Whey|Whey with high protein content
215066378|NCT03179930|DRUG|Entinostat|All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15
215066379|NCT03179930|DRUG|Pembrolizumab|pembrolizumab 200 mg IV on D1
215066380|NCT06322745|PROCEDURE|Suture renorrhaphy only for hemostasis of the tumor bed in laparoscopic partial nephrectomy|Suture renorrhaphy will be used in 2 layers; medullary and cortical, with Vicry 2/0 or 3/0 and secured with V-lock. Early unclamping will be done after hemostasis of the medullary layer. Renorrhaphy of the cortical layer will be continued after that.
215066381|NCT06322745|PROCEDURE|Thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy|A 2-μm continuous thulium laser with 365 μm laser fiber at 30-40 W will be used for coagulation of the tumor bed. Large vessels that may not be completely sealed with thulium beam will be closed by V-lock to achieve safe and stable hemostasis. Early unclamping will be done after hemostasis of the tumor bed. Suture renorrhaphy will be used in 1 layer to approximate the renal parenchyma.
215066382|NCT03590626|DRUG|Dulaglutide|0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks
214323632|NCT03346122|DRUG|JNJ-64991524 Dose Level 2|Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
214323633|NCT03346122|DRUG|JNJ-64991524 Dose Level 3|Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
214323634|NCT03346122|DRUG|JNJ-64991524 Dose Level 4|Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
214323635|NCT03346122|DRUG|JNJ-64991524 Dose Level 5|Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
215066383|NCT02214888|DRUG|BIRB 796 BS, low dose|
215066384|NCT02214888|DRUG|BIRB 796 BS, high dose|
215066385|NCT02214888|DRUG|Placebo|
215066386|NCT01651065|BEHAVIORAL|Microclinic Diabetes Education Program|"The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.~The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors."
215066387|NCT01651065|BEHAVIORAL|Control|
215066388|NCT05523167|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
214923580|NCT06663202|PROCEDURE|Widman flap procedure|"Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures."
215066389|NCT05523167|OTHER|PBO|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
215066390|NCT00000886|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
214923581|NCT05832502|DRUG|GBS6|The investigational products are GBS6 and placebo (saline control). The GBS6 dose will be GBS6 20mcg without AlPO4 (equivalent to 240 mcg/mL) 0.5mL dose or 20 mcg CPS/serotype).
215066391|NCT06455566|DEVICE|Leadless pacemaker implantation through right internal jugular vein|Leadless pacemaker implantation through right internal jugular vein
215066392|NCT05422495|BEHAVIORAL|training with Cycléo device (COTTOS ®),|8 weeks of training
215066393|NCT05422495|OTHER|non intervention|non intervention
215066394|NCT00431522|DRUG|Valproic acid, sodium salt|
215066395|NCT04077671|BIOLOGICAL|CHF6467 active|CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
215066396|NCT01265563|DRUG|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
215066397|NCT01265563|DRUG|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
215066398|NCT01265563|DRUG|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
214323636|NCT03346122|DRUG|JNJ-64991524 Dose Level 6|Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
214323637|NCT03346122|DRUG|Placebo|Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
214323638|NCT03346122|DRUG|JNJ-64991524 Dose Level 7|Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
214323639|NCT03346122|DRUG|JNJ-64991524 Dose Level 8|Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
214323640|NCT03346122|DRUG|JNJ-64991524 Dose Level 9|Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
214323641|NCT04272190|OTHER|clinical routine treatments|The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
214323642|NCT00425399|PROCEDURE|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
214323643|NCT02581774|OTHER|normal delivery tracking|normal delivery tracking
214323644|NCT01617603|OTHER|Cocoa Polyphenols|20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
215066399|NCT01265563|DRUG|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
215066400|NCT01265563|DRUG|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
215066401|NCT06393270|DIAGNOSTIC_TEST|Modified US Public Health Service (USPHS) criteria|Dental caries classification system
215066402|NCT04998318|DEVICE|Pocket Colposcope|Both arms will receive treatment in order to prevent cervical cancer. However, the intervention using the pocket colposcope device will be used on half the enrolled subjects.
214323645|NCT01242657|BEHAVIORAL|Physical Activity Module|"Participants were provided pedometers in order to track specific Step Goals, which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a Challenge Log."
214672719|NCT02395679|BIOLOGICAL|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
214923582|NCT05832502|DRUG|Placebo|Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle
215066403|NCT04998318|PROCEDURE|Standard of Care Colposcopy|VIA and VILI as previously described,
215066404|NCT05402163|DEVICE|Adaptive DBS|aDBS vs cDBS
214323646|NCT01242657|BEHAVIORAL|Not On Tobacco (N-O-T) Program|Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
215066405|NCT05402163|DEVICE|Continuous DBS|aDBS vs cDBS
214323647|NCT00873548|DEVICE|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:~1. Positioning of the patient~2. Definition of the CCD-angle~3. Fracture reduction~4. Determination of the nail diameter~5. Incision~6. Insertion of the device"
214323648|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
214323649|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
214323650|NCT03318614|DIETARY_SUPPLEMENT|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
214323651|NCT03318614|OTHER|Control group|No probiotic intervention was given to the control group for three months.
214323652|NCT06137950|DRUG|gel Interferon arm|0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.
214323653|NCT06137950|DRUG|gel Interferon and interferon suppository arm|"0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.~3MIU suppository will be given to patients and will be trained how to use. Each patient in the arm will use the suppository twice a day for 10 days with vaginal therapy."
214323654|NCT03316872|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
214323655|NCT03316872|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT involves delivery of high doses of radiation therapy in smaller fractions
214923583|NCT02727790|DEVICE|Stimulator|
214923584|NCT03173690|OTHER|Medication reconciliation at the ICU|Medication reconciliation performed according to Integrated Medicines Management model
214923585|NCT03173690|OTHER|Medication Reconciliation at the Ward|Medication reconciliation performed according to Integrated Medicines Management model
214923586|NCT04270409|DRUG|Isatuximab SAR650984|Pharmaceutical for: Solution for infusion Route of administration: Intravenous
214923587|NCT04270409|DRUG|Lenalidomide|Pharmaceutical form: Capsules Route of administration: Oral
214923588|NCT04270409|DRUG|Dexamethasone|Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous
214923589|NCT04270409|DRUG|Montelukast or equivalent|Auxiliary Medicinal Product (AxMP)/pre-medication; ATC code: R03DC03; Pharmaceutical form: tablet; Route of administration: Oral;
214923590|NCT04270409|DRUG|Acetaminophen|AxMP/pre-medication ATC code: N02BE01 Pharmaceutical form: tablet/ampule/capsule; Route of administration: Intravenous (IV) or per os (PO)
214923591|NCT04270409|DRUG|Diphenhydramine or equivalent|AxMP/pre-medication ATC code: R06AA02 Pharmaceutical form: ampule; Route of administration: Intravenous
214923592|NCT04270409|DRUG|Methylprednisolone or equivalent|AxMP/pre-medication; ATC code: H02AB04; Pharmaceutical form: vial; Route of administration: Intravenous
214923593|NCT00595985|DRUG|sorafenib|sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
214923594|NCT00226785|DRUG|Dexmedetomidine|
214923595|NCT06666985|DRUG|ITM + Usual Care|The participants allocated to this group will receive ITM (Intrathecal Morphine) in addition to usual care with opioid-based PCA(Patient-Controlled Analgesia). ITM consists of an intrathecal injection of 300 micrograms (0.3mg) of preservative-free morphine.Usual care involves postoperative analgesia with opioid-based PCA without postoperative continuous infusion of opioids. No other drugs other than opioids are allowed in the PCA.
214923596|NCT06666985|DRUG|Sham ITM + Usual Care|The sham ITM mimics the ITM procedure, but the dura is not breached.
214923597|NCT03521115|BEHAVIORAL|Smart Choices 4 Teens|This is a web-based prevention program designed to convey information about alcohol and relationships and the types of choices that they are making regarding these topics. General communications was another core element of the program that provided parents and teens with some key elements of talking to each other.
214923598|NCT05193344|DEVICE|A digital care solution for patients with Heart Failure|A digital solution that provides remote symptom monitoring and support of lifestyle-changes by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
214923599|NCT05193344|OTHER|Standard of Care for patients with Heart Failure|The best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF.
214923600|NCT06043960|OTHER|Humac Norm İsokinetic Machine|Tecno Body Prokin Isokinetic Balance System CSMI (CYBEX) Humac Norm Isokinetic Testing and Exercise System Romberg Test Mini Mental Test (MMSE) Fugl-Meyer Assessment of the lower limb
214923601|NCT01471340|DRUG|Mometasone Furoate/Formoterol MDI 100/5 mcg|two inhalations BID
214923602|NCT01471340|DRUG|Mometasone Furoate/Formoterol MDI 200/5 mcg|two inhalations BID
214672720|NCT06481358|DIAGNOSTIC_TEST|Artificial intelligence|AI extract intestinal region and reconstruct into 3D image.
214672721|NCT04641546|PROCEDURE|Therapeutic Exercise|Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
214672722|NCT04641546|PROCEDURE|Occupation-Based Intervention|Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
214923603|NCT01471340|DRUG|Mometasone Furoate MDI 100 mcg|two inhalations BID
214923604|NCT01471340|DRUG|Mometasone Furoate MDI 200 mcg|two inhalations BID
214323656|NCT01966926|BEHAVIORAL|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
214323657|NCT07010094|DEVICE|BM shockwave devices|Use the BM shockwave devices for pre-treatment of coronary calcification lesions.
214323658|NCT06873139|BEHAVIORAL|text messages|There will be two arms for the texting intervention: high and low. Both arms will receive text messages, but the frequency of the messages will vary by arm. Text intervention messaging will be sent through an automated text messaging service programmed by the CM Research Informatics team, which has been approved by the institution.
214323659|NCT07019285|BEHAVIORAL|High intensity interval walking training|High intensity intermittent walking training for a period of 8 weeks. The intensity of the training is 90 to 110% of 6MWTdistance. The frequency of the training is three times a week
214323660|NCT07019285|BEHAVIORAL|Moderate-intensity interval walking training|Moderate intensity intermittent walking training for a period of 8 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is three times a week
214323661|NCT07018531|PROCEDURE|VST augmentation with TPT|"For TPT group, vertical soft tissue augmentation will be performed simultaneously with implant placement using a 2 mm healing abutment. Than, to ensure tension-free primary closure, mucoperiosteal flaps will be mobilized through vertical releasing incisions. Wound closure will be achieved using horizontal mattress sutures, followed by simple interrupted sutures for optimal tissue adaptation. The healing abutment will act as a mechanical support to maintain space and prevent soft tissue collapse. This tented space is expected to allow blood to accumulate, clot, and gradually reorganize into connective tissue, thereby promoting an increase in vertical soft tissue thickness around the implant.~After 2 months , the initial 2-mm healing abutment will be removed, and a 4 mm healing abutment will be placed by mading a small semilunar incision without touching the bone."
214323662|NCT07018531|PROCEDURE|TPT-PRF|In the PRF group, the same surgical protocol as the TPT group will be followed. However, prior to wound closure, the tented space surrounding the healing abutment will be filled with PRF membranes.
214323663|NCT07018531|PROCEDURE|TPT-PBM|The PBM group will follow the same surgical protocol as the TPT group. In addition, this group will receive photobiomodulation therapy using red-light irradiation at a wavelength of 630 nm, applied to the occlusal site immediately after surgery and repeated after 7 days.
214323664|NCT07018531|PROCEDURE|Group control: implant placement without TPT|The negative control group will consist of patients randomly selected from the recruited population, in accordance with the study's inclusion criteria. Participants in this group will not receive any intervention aimed at VST augmentation during implant placement. This will allow for a clear assessment of the effect of the TPT on VST gain and its impact on MBL. In accordance with ethical guidelines, patients in the control group will undergo VST augmentation at a second stage, prior to the initiation of the prosthetic phase.
214323665|NCT07019402|BEHAVIORAL|Internet-based Mindfulness-Based Stress Reduction (iMBSR)|The iMBSR program is an adaptation of Jon Kabat-Zinn's Mindfulness-Based Stress Reduction (MBSR) to be delivered in an online and asynchronous manner. MBSR was developed by Kabat-Zinn in the 1970s as a method to help individuals manage stress and pain through mindfulness meditation. Mindfulness practice has been linked to numerous benefits such as boosting cognitive control and emotion regulation. MBSR includes practices such as orienting attention to the present moment, often through an object like the breath, nonjudgmental awareness of thoughts and emotions, mindful listening, mindful eating, and body scan meditation.
214323666|NCT07019402|BEHAVIORAL|Internet-based Lifestyle Education (iLifeEd)|iLifeEd is an online and asynchronous lifestyle education program. Participants will be presented with information and activities about healthy aging topics, including physical activity, sedentary behavior, sleep, stress, nutrition and hydration, social support, and cognitively stimulating activities. Stretching and toning exercises will also be included.
214323667|NCT06316063|DEVICE|Apnoeic oxygenation with high-flow nasal oxygen|The subjects in the intervention group will be oxygenated with HFNO during the surgical procedure.
214923605|NCT01471340|DRUG|Albuterol 90 mcg /salbutamol 100 mcg HFA MDI|use as needed for asthma symptoms
214923606|NCT01471340|DRUG|Prednisone/prednisolone|Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator
214923607|NCT06093048|PROCEDURE|Endoscopic retrograde cholangiopancreatography|saftey and outcome in patients older than 65 years old
214923608|NCT03662191|DRUG|Tafamidis|bioavailability study
214923609|NCT04570865|DRUG|Dapagliflozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
214923610|NCT04570865|DEVICE|CardioMEMS|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
214923611|NCT03903094|OTHER|Non-Interventional|Overview of anticholinergic burden, rather than to evaluate specific drugs
214923612|NCT01319474|OTHER|Whole-leg compression ultrasound|Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
214923613|NCT00059891|PROCEDURE|conventional surgery|
214923614|NCT00059891|PROCEDURE|management of therapy complications|
214923615|NCT03377504|BEHAVIORAL|mirror therapy|Mirror therapy will include wrist flexion/extension, ulnar/radial deviation, hand finger flexion/extension and abduction/adduction, thumb abduction/adduction/opposition, and forearm supination/pronation movements as well as various object grasping activities according to the status of the patient's hand functions.
215066406|NCT03102047|DRUG|durvalumab|Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
215066407|NCT06302426|DRUG|INI-4001|INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.
215066408|NCT06302426|COMBINATION_PRODUCT|Nivolumab|During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.
215066409|NCT06302426|COMBINATION_PRODUCT|Pembrolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
215066410|NCT06302426|COMBINATION_PRODUCT|Cemiplimab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
214672723|NCT05024838|OTHER|Machine learning methods|This is an observational study of the retrospective collection of patient data. Anesthesia-related factors such as anesthesiologist's expertise, injection site, patient position, the dosage of local anesthetics, needle size, the direction of needle bevel, and basic demographic information of the patients were used for data analysis. Patients less than 18 years old were excluded from this study. Twenty percent of the dataset was used as a testing dataset, and the remaining were used for model training. The investigators will utilize four machine learning algorithms as XGBoost (Extreme Gradient Boosting), AdaBoost (Adaptive Boosting), Random Forest (RF), and support vector machine (SVM). Model performances were evaluated visually with a confusion matrix.
214672724|NCT00105729|BEHAVIORAL|Intensive referral to 12-step self-help groups|
214672725|NCT02039271|OTHER|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
215066411|NCT06302426|COMBINATION_PRODUCT|Avelumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
215066412|NCT06302426|COMBINATION_PRODUCT|Atezolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
215066413|NCT06302426|COMBINATION_PRODUCT|Durvalumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
215066414|NCT05883540|DRUG|Lysergic Acid Diethylamide Tartrate|25 μg p.o.
215066415|NCT05883540|DRUG|Lysergic Acid Diethylamide Tartrate|100 or 200 μg p.o.
215066416|NCT06127836|PROCEDURE|ICG guided sentinel lymph node biopsy|The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only. Once the surgeon has identified the SLN in this way, he or she will be unblinded to the results of the lymphoscintigraphy and will use the results of preoperative imaging and an intraoperative gamma counter to confirm the SLNs.
215066417|NCT02141399|DRUG|ALKS 5461|Sublingual tablet, taken daily
214323668|NCT06316063|OTHER|Mechanical ventilation|Study subjects in the comparator group will be tracheally intubated and mechanically ventilated
214323669|NCT07024147|BIOLOGICAL|JWCAR239|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells targeting CD19/CD20
215066418|NCT01632475|BIOLOGICAL|Pneumostem®|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg, High Dose Group (6 patients): 2 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
215066419|NCT06640517|DRUG|Netakimab|netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks
215066420|NCT06640517|DRUG|Placebo|placebo will be administered subcutaneously at a scheme masking netakimab treatment
215066421|NCT06640517|DRUG|Adalimumab|adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks
214923616|NCT03377504|BEHAVIORAL|Routine physical therapy and exercise program|Routine physical therapy and exercise program including contrast baths, hot pack, TENS, desensitization, exercises and occupational therapy will be applied to all patients
214923617|NCT00526669|DRUG|Lapatinib and Capecitabine|oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine
215066422|NCT01296711|BIOLOGICAL|CDP6038 (olokizumab)|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
214923618|NCT03481101|DEVICE|PET/CT|3 extra scans with FDG-PET/CT and 4 blood samples
214923619|NCT01782625|OTHER|NO exercise at depth|Subjects will NOT exercise while at depth
214923620|NCT01782625|OTHER|exercise at depth|Subjects will exercise while at depth
214923621|NCT00544323|DEVICE|oral implant|
214923622|NCT01470625|OTHER|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
214923623|NCT02300038|DRUG|Lidocaine (Xylocaine)|perineuromally administration of 1 ml lidocaine
214485875|NCT06315166|DEVICE|triLift/Legend Pro+ Fractional RF System|The triLift/Legend Pro+ Fractional investigational device is intended for the treatment of acne vulgaris when using Fractional RF energy.
214923624|NCT02300038|DIETARY_SUPPLEMENT|NaCl|perineuromally administration of NaCL
215066423|NCT05947175|BIOLOGICAL|Vertebral bone marrow (vBMA) clot|The clotted vBMA will be obtained from vertebral bone marrow aspirate.The vBMA clot contain mesenchymal stem cells (MSCs), growth factors, platelet and osteogenic and anti-inflammatory mediators.
214485876|NCT02726386|DRUG|ND0612|ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
214485877|NCT00308997|DEVICE|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
214923625|NCT04259424|DEVICE|Aerobic Exercise + Duck Duck Punch|"Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. On each session the target intensity of aerobic exercise will be 70% heart rate reserve.~Following a 10-minute rest break subjects will perform 200 repetitions on an upper extremity rehabilitation game called Duck Duck Punch (DDP). Duck Duck Punch is an interactive game with an old school carnival theme. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. A therapist will oversee the subject's safety and progress during DDP. DDP will be dosed based on the number of repetitions performed. A repetition is recorded when the player moves his/her arm so that the avatar leaves a start position. The goal dose for subjects will be 200 repetitions per DDP session."
214923626|NCT05162625|DRUG|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|Topical moxifloxacin 0,5% 01 drop every 3 hours
215066424|NCT05947175|OTHER|Bone allograft chips|Bone allograft chips will be obtained from Musculoskeletal Tissue Bank at IRCCS Istituto Ortopedico Rizzoli.
215066425|NCT02765113|PROCEDURE|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
215066426|NCT02765113|PROCEDURE|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
215066427|NCT02881931|BEHAVIORAL|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
214485878|NCT00308997|DEVICE|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
214485879|NCT04008186|DRUG|Omaveloxolone|50 mg capsules
214485880|NCT04008186|DRUG|Midazolam oral solution|2 mg/mL oral solution
214485881|NCT04008186|DRUG|Repaglinide 1 MG|1 mg tablet
214485882|NCT04008186|DRUG|MetFORMIN 500 Mg Oral Tablet|500 mg tablet
214485883|NCT04008186|DRUG|Rosuvastatin|10 mg tablet
215066428|NCT05549297|DRUG|Tebentafusp|Soluble gp100-specific T cell receptor with anti-CD3 scFV
215066429|NCT05549297|DRUG|Tebentafusp with Pembrolizumab|Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab
215066430|NCT05549297|DRUG|Investigators Choice|Investigators choice of therapy
214485884|NCT04008186|DRUG|Digoxin tablet|0.25 mg tablet
214485885|NCT04008186|DRUG|Gemfibrozil Tablets|600 mg tablet
214485886|NCT04008186|DRUG|Itraconazole capsule|100 mg capsule
214485887|NCT04008186|DRUG|Verapamil Pill|120 mg tablet
215066431|NCT04293926|OTHER|Exercise|Resistance exercise program for 8 weeks, 3 times a week, with a 60 min session duration.
214923627|NCT05162625|DRUG|Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV]|Intravenous ciprofloxacin 400mg every 12 hours and cefazolin 1000mg every 6 hours
215066432|NCT04122911|DRUG|Temozolomide|pharmacological
215066433|NCT00439543|DRUG|Iloprost inhalation|
215066434|NCT03273452|DRUG|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
214923628|NCT01461317|DRUG|Etrolizumab|Participants will receive etrolizumab at a dose of 100 mg.
214923629|NCT05975034|DIETARY_SUPPLEMENT|Probiotic|Probiotic taken daily for 12 weeks.
215066435|NCT00770497|DRUG|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
215066436|NCT00770497|DRUG|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
215066437|NCT00770497|DRUG|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
215066438|NCT01872195|OTHER|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
215066439|NCT04826107|DRUG|DP303c treatment|DP303c injection, every 3 weeks.
215066440|NCT04826107|DRUG|DP303c treatment（second-line of HER2-positive）|DP303c injection, every 3 weeks.
215066441|NCT04826107|DRUG|DP303c treatment （third-line of HER2-positive）|DP303c injection, every 3 weeks.
215066442|NCT04826107|DRUG|DP303c treatment（≥second-line of HER2 low expressing）|DP303c injection, every 3 weeks.
215066443|NCT04826107|DRUG|DP303c + PD-1/PD-L1 treatment|DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
215066444|NCT06010758|DRUG|Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
215066445|NCT06010758|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
215066446|NCT06010758|DRUG|Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
215066447|NCT06010758|OTHER|Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
215066448|NCT05243524|OTHER|Maveropepimut-S|SC injection on days 7, 28, then q8w
215066449|NCT05243524|DRUG|Cyclophosphamide 50mg|PO BID, one week on, one week off
215066450|NCT05131867|DRUG|nimodipine|(60 mg/4 hours) orally or via nasogastric tube
214323670|NCT07024147|DRUG|Fludarabine|Administered according to package insert
215066451|NCT05131867|DRUG|Oral Nimodipine and milrinone|Oral Nimodipine then after the diagnosis of vasospasm is confirmed, start milrinone bolus
215066452|NCT04283214|OTHER|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
215066453|NCT03091517|BEHAVIORAL|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
215066454|NCT03571009|DEVICE|utilization of PAAS|utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device
215066455|NCT00946764|DRUG|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
214923630|NCT05975034|DIETARY_SUPPLEMENT|Placebo|Placebo taken daily for 12 weeks.
214923631|NCT00151190|BEHAVIORAL|Education for diabetes self-management|
214923632|NCT05083936|DRUG|[18F]FET|Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
214323671|NCT07024147|DRUG|Cyclophosphamide|Administered according to package insert
214923633|NCT01176149|BEHAVIORAL|SMBG plus intensive education|
214923634|NCT00641290|DEVICE|Vigileo FloTrac Sensor|Comparing the Vigileo FloTrac against the conventional Pulmonary Artery Catheter using the thermodilution method for measurements of cardiac output.
215066456|NCT00946764|DRUG|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
215066457|NCT01907308|DRUG|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
215066458|NCT01907308|DRUG|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
214923635|NCT04128306|BEHAVIORAL|Behavioral task|In the task, participants will see an object approaching toward them. During its movement, the object disappears, and the participants have to press a button to indicate when they estimate the object to contact with them. The motion parameters of the ball will be varied. The pre and post-surgery phases will test the participants in a long duration version of the task, approximately 30 minutes. The per surgery phase will be made of a 5 minutes version of the task, and the participants will receive a direct cortical stimulation for 4 seconds, at an intensity of 1 to 10 milliampere (mA), in the premotor ventral area, or posterior parietal cortex or somesthetic associative areas.
214923636|NCT04128306|PROCEDURE|Awake surgery|"The patient is first anesthetized for opening the scalp and skull, then awake. During this waking phase, the surgeon passes a few quick and simple tests to the patient, visual (for example, line bisection), language (for example, repeating a list of words) etc. While doing this task, the neurosurgeon disrupts the functioning of certain brain regions by direct electrical stimulation of the cortex in order to identify the regions whose dysfunction will have an impact on the current task.~During the operation, the areas involved in the construction of the peri-personal space will be stimulated by direct electrical stimulation, for a duration of 4 seconds at an intensity of 1 to 10 mA. These areas are:~* Ventral premotor cortex (with the exception of the primary motor cortex controlling the dominant hand, so as not to interfere with the motor response of the patient)~* Posterior parietal cortex~* Associative somesthetic areas"
214923637|NCT04128306|OTHER|Neurological assessment|The Mini Mental State Evaluation, which generally assesses the cognitive state of an individual through his 6 subtests testing both working memory, episodic and semantic praxies as well as spatio-temporal orientation capacity.
214923638|NCT04128306|OTHER|Neurological assessment|The Wechsler Adult Intelligence Scale was selected for two of its subtests: The Subtest Codes checking the processing of information, visuo-constructive abilities but also attention. The subtest Cubes evaluates the capacities of visuospatial and constructive organizations as well as the referencing of the space in relation to the subject.
214923639|NCT04128306|OTHER|Neurological assessment|The State-Trait Anxiety Inventory, consisting of two self-administered questionnaires: Questionnaire A, measuring the state of anxiety of the person on the present moment and B measuring anxiety as a character trait of the person
214923640|NCT04128306|OTHER|Neurological assessment|The Verbal Fluences test, in its oral version. Categorial and lexical fluences make it possible to quickly realize a possible lack of the word of the person as well as disturbances of working memory or the capacity of inhibition.
214923641|NCT04128306|OTHER|Neurological assessment|The board of the Corsi cubes that evaluates the non-verbal visual-spatial working memory of the participants with a reminder location that tests the visuo-spatial notebook and a reminder to who tests the central administrator of the working memory.
214923642|NCT04128306|OTHER|Neurological assessment|The neurocognitive naming test was chosen to verify correct access to both semantic memory and lexicon, as well as to test the early visual process of image processing necessary for our task.
214923643|NCT04128306|OTHER|Neurological assessment|Benton lines are commonly used to determine possible deficits in the localization of isolated objects or judgment of line direction.
214923644|NCT04128306|OTHER|Neurological assessment|The patient will finally pass a depression assessment test, answering Beck's questionnaire.
214923645|NCT03499899|DRUG|LAG525|LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first
214923646|NCT03499899|DRUG|PDR001|Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525
214923647|NCT03499899|DRUG|Carboplatin|Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed
214923648|NCT04647799|DEVICE|smartphone|Samsung A 71
214923649|NCT02033967|PROCEDURE|vasodilator induced hypovolemia|
214923650|NCT00905892|DIETARY_SUPPLEMENT|Hyperlipidic overfeeding|100g per day of cheese + 40g per day of almonds + 20g per day of butter
214923651|NCT00247650|DRUG|Zoledronic Acid; Letrozole|
214923652|NCT06682377|PROCEDURE|Radiofrequency ablation alone|No touch RFA with dual switching monopolar + bipolar mode
214923653|NCT00055653|BIOLOGICAL|anti-thymocyte globulin|
214923654|NCT00055653|BIOLOGICAL|filgrastim|
214923655|NCT00055653|DRUG|busulfan|
214923656|NCT00055653|DRUG|cyclophosphamide|
215066459|NCT05445778|DRUG|Mirvetuximab soravtansine plus Bevacizumab|Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks
214923657|NCT00055653|DRUG|cyclosporine|
214923658|NCT00055653|DRUG|fludarabine phosphate|
214923659|NCT00055653|DRUG|melphalan|
214923660|NCT00055653|DRUG|methylprednisolone|
214923661|NCT00055653|PROCEDURE|umbilical cord blood transplantation|
214923662|NCT00055653|RADIATION|radiation therapy|
214923663|NCT05194891|DIAGNOSTIC_TEST|Specular Microscopy|Phacoemulsification
214923664|NCT03154463|PROCEDURE|TAP Blocks|TAP blocks were performed using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
214923665|NCT03154463|PROCEDURE|continuous epidural infusion|Continuous epidural infusion was given with epidural regimen of 0.25% bupivacaine without any adjuvant
214923666|NCT05187286|DRUG|Apixaban|Administered as directed by treating physician
214923667|NCT05121714|DRUG|Caffeine|This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)
215066460|NCT05445778|DRUG|Bevacizumab|Participants will receive Bevacizumab 15mg/kg every 3 weeks
215066461|NCT04113707|BEHAVIORAL|Motor lab activity|fitness, gross motor, fine motor, and motor coordination activities
215066462|NCT04233307|DIAGNOSTIC_TEST|Telethermographic images|Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
215066463|NCT01126268|DRUG|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
215066464|NCT04071262|DRUG|Abemaciclib|Administered orally
214923668|NCT05121714|DRUG|ABX464|This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).
214923669|NCT05121714|DRUG|Fluvoxamine|his is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).
215066465|NCT04071262|DRUG|Abiraterone Acetate|Administered orally
215066466|NCT04071262|DRUG|Prednisolone|Administered orally
215066467|NCT05949255|DIETARY_SUPPLEMENT|Probiotic|10 subject will receive a probiotic daily for 12 weeks.
215066468|NCT05949255|DIETARY_SUPPLEMENT|Placebo|10 subjects will receive a placebo daily for 12 weeks.
215066469|NCT03639636|OTHER|non surgical and surgical periodontal therapy|scaling and root planing periodontal flap surgery
215066470|NCT02379026|DIETARY_SUPPLEMENT|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
215066471|NCT02379026|BEHAVIORAL|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
215066472|NCT02379026|DIETARY_SUPPLEMENT|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
215066473|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
215066474|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
215066475|NCT04026009|DRUG|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
214923670|NCT01983943|DIETARY_SUPPLEMENT|Hydroxytyrosol, the active ingredient in olive oil.|A 40mg capsule will be taken once daily for 6 months.
214923671|NCT01983943|DIETARY_SUPPLEMENT|Placebo|A 40mg placebo will be taken once per day for 6 months.
214923672|NCT01983943|BEHAVIORAL|Nutrition counseling|Nutrition counseling on eating a healthy diet will be offered once at baseline.
215066476|NCT02664649|DRUG|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~\- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily"
215066477|NCT02664649|DRUG|Standard of care|VKA or Antiplatelet therapy
215066478|NCT03289663|DRUG|synergistic combination of insecticides|third generation insecticide -treated bednets
215066479|NCT03289663|DRUG|Pyrethroids|Conventional insecticide
214485888|NCT04955431|BEHAVIORAL|Sleep Restriction|Participants will be allowed \~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
214485889|NCT04955431|BEHAVIORAL|Normal Sleep|Participants will be allowed \~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
214485890|NCT04490356|BEHAVIORAL|Legacy Intervention|The Legacy intervention is a nutrition and exercise protocol delivered using video conference technology. The Legacy protocol incorporates behavioral strategies along with nutrition and exercise to maintain and extend functional benefits of obesity treatment.
214485891|NCT03918252|DRUG|Nivolumab Injection|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
214485892|NCT03918252|DRUG|Ipilimumab Injection|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
214485893|NCT06191133|DRUG|Fenofibrate|Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.
214485894|NCT06191133|PROCEDURE|Cervical Conization|Cold knife conization or loop electrosurgical excision to remove cells and tissue in the cervix
215066480|NCT02169024|BEHAVIORAL|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
215066481|NCT02169024|OTHER|Standard individual prenatal care|Standard of care- individual prenatal care
215066482|NCT01413906|DRUG|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
215066483|NCT05440591|DRUG|Dapagliflozin|Dapagliflozin 10mg tablets
215066484|NCT05440591|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin 500 mg tablets twice daily
215066485|NCT05440591|DRUG|Dapagliflozin / metFORMIN Pill|Combination pill
215066486|NCT01562522|OTHER|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
215066487|NCT05723965|OTHER|As training material for deep learning model.|Using labeled images as training materials for artificial intelligence to develop object detecting model.
215066488|NCT05723965|OTHER|As materials for external validation for the buildup model.|Using the external validation set to evaluate prediction rate and survival outcome.
215066489|NCT02543177|PROCEDURE|coronary angiography|
214923673|NCT01983943|DEVICE|Endopat|An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
214923674|NCT01893281|DRUG|Topical Testosterone Solution|Administered topically to axillae.
214923675|NCT06432075|BIOLOGICAL|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
214323672|NCT07024004|BEHAVIORAL|Exergame-Based Exercise + Conventional Physical Therapy|"Participants in this group will engage in a combined intervention consisting of:~Multicomponent physical exercise (aerobic, strength, balance, and flexibility), delivered twice per week for 12 weeks.~Exergames training using the Nintendo Switch console and Ring Fit Adventure game. Sessions include warm-up, gameplay involving full-body movements (e.g., squats, running, balance tasks), and cooldown.~Sessions are adapted to individual physical capacities and supervised by a trained kinesiologist.~The intensity is monitored using the Borg Scale, following ACSM guidelines."
214485895|NCT06191133|PROCEDURE|Hysterectomy|In a hysterectomy, the uterus, cervix, both ovaries, both fallopian tubes, and nearby tissue are removed.
214485896|NCT06191133|RADIATION|Chemoradiation|Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in the bloodstream. Radiotherapy uses high energy waves similar to x-rays to kill cancer cells.
214485897|NCT05855954|COMBINATION_PRODUCT|controlled low central venous pressure technique (CLCVP)|20min after the end of cardiopulmonary bypass, on the basis of ensuring that the mean arterial pressure (MAP) ≥ 60mmHg, we maintain the patient's central venous pressure below 10 mmHg by adjusting the posture and pumping nitroglycerin.
214485898|NCT03299426|BIOLOGICAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
214485899|NCT03299426|BIOLOGICAL|Meningococcal A Conjugate Vaccine (MCV-A)|Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
214923676|NCT00829140|DRUG|Placebo|
214923677|NCT00829140|DRUG|Lorcaserin 10mg BID|
214923678|NCT04114201|PROCEDURE|PSI|Implantation of a Total Knee Arthroplasty patient-specific instrumentation using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
214923679|NCT04114201|PROCEDURE|Conventional|Implantation of a Total Knee Arthroplasty with conventional using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
214923680|NCT06682819|DIAGNOSTIC_TEST|Optical coherent tomography|We compare the metabolomics profile of healthy patients based on the OCT appearance of the optic disc and RNFL
214923681|NCT04623034|DRUG|Ademetionine|
214923682|NCT05448417|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
214923683|NCT05448417|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
214923684|NCT02374710|PROCEDURE|ACL Reconstruction: Anterior Tunnel|ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
215066490|NCT02543177|PROCEDURE|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
215066491|NCT02543177|PROCEDURE|prior kidney irrigation|
215066492|NCT04887610|PROCEDURE|Ischemic preconditioning|Four 5-minute cycles of 200 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
215066493|NCT04887610|PROCEDURE|Ischemic preconditioning control|Four 5-minute cycles of 20 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
215066494|NCT04887610|DIETARY_SUPPLEMENT|Low fat meal|Meal containing 1006 calories, 1 g fat, 0.2 g saturated fat, 0 g trans fat, 20 mg cholesterol, 191 g carbohydrates, 60 g protein, 1560 mg sodium
215066495|NCT04887610|DIETARY_SUPPLEMENT|High fat meal|Meal containing 1030 calories, 62 g fat, 23 g saturated fat, 0.5 g trans fat, 445 mg cholesterol, 76 g carbohydrates, 41 g protein, 2080 mg sodium.
215066496|NCT02079831|BEHAVIORAL|Energy Restriction|"Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity."
214323673|NCT07024004|BEHAVIORAL|Conventional Physical Therapy|"Participants in this group will receive a standard multicomponent physical exercise program consisting of:~Exercises for aerobic capacity, strength, balance, and flexibility.~Delivered in-person twice per week for 12 weeks at senior care centers.~Sessions include warm-up (5-10 min), main activity (30-40 min), and cooldown (5-10 min).~Intensity is controlled using the Borg Scale and monitored by a supervising kinesiologist."
214323674|NCT07024667|DEVICE|Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA)|Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA)
214323675|NCT07024771|DEVICE|Automated Pupillometer|An automated pupillometer will be used to measure pupil size and calculate NPi in newborns with HIE
215066497|NCT02079831|BEHAVIORAL|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
214672726|NCT02747043|BIOLOGICAL|ABP 798|ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
214923685|NCT02374710|PROCEDURE|ACL Reconstruction: Posterior Tunnel|ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
214923686|NCT05851313|COMBINATION_PRODUCT|Vitamin-D|The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
214923687|NCT05996341|DEVICE|blood flow restriction|12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg
214923688|NCT03933618|DRUG|Anastrozole 1mg|
214923689|NCT03933618|DRUG|Clomiphene Citrate 25mg|
214923690|NCT03933618|DRUG|Placebo - Cap|
214923691|NCT05283902|BIOLOGICAL|ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine|In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.
214923692|NCT06667258|DEVICE|Ear ECG/PPG sensors|Medical graded electrodes placed in the mastoid, in-ear foam-based earpiece (like commercial earplugs) with cloth electrodes, off-the-shelf pulse oximeter placed behind the ear
214923693|NCT01744379|DRUG|Lesinurad|
214923694|NCT01744379|DRUG|Placebo|
214923695|NCT04016779|DRUG|Placebo|Placebo will be administered once daily
214923696|NCT04016779|DRUG|SPN-812|SPN-812 will be administered once daily and compared to Placebo
214923697|NCT00910208|DEVICE|Patient-controlled analgesia|Intravenous morphine delivered via Curlin painsmart PCA device
214923698|NCT00910208|DRUG|morphine|Intravenous morphine
214923699|NCT01511874|DRUG|ELIGARD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
214923700|NCT02295020|DRUG|Standard treatment only|Standard treatment such as NSAIDs and injections
214923701|NCT02295020|DEVICE|Standard treatment plus Bioskin Ten-7 knee brace|Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.
214923702|NCT03770962|BEHAVIORAL|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will assist her."
214923703|NCT05799612|DRUG|Paclitaxel|Given by IV (vein)
214923704|NCT05799612|BIOLOGICAL|mRNA plus Lysate-loaded Dendritic Cell Vaccine|Given by IV (vein)
214923705|NCT05799612|DRUG|PEGYLATED-INTERFERON ALPHA-2A|Given by IV (vein)
214923706|NCT05799612|DRUG|Filgrastim|Given by IV (vein)
214923707|NCT02740868|DRUG|Xenon-129 and Perfluoropropane (19F)|Xenon gas and perfluoropropane to be inhaled by research participants
214923708|NCT02740868|DEVICE|Magnetic Resonance Imaging|Lung imaging will be performed for participants using MRI for all 3 arms
214923709|NCT02740868|DEVICE|Lung Clearance Index|Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms
214923710|NCT03046316|OTHER|local consolidative treatment|local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy
214923711|NCT02721810|BEHAVIORAL|Consideration of 3-month functional prognosis|
214923712|NCT03776110|DRUG|GRT9906 PR tablet|40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)
214923713|NCT03776110|DRUG|Placebo|Placebo tablet matching 40 mg GRT9906 PR tablet
214923714|NCT05279235|DRUG|JT001|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
214923715|NCT05279235|DRUG|JT001 placebo|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
214923716|NCT05279235|DRUG|Favipiravir|Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
214923717|NCT05279235|DRUG|Favipiravir placebo|Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
214923718|NCT00000260|DRUG|Nitrous oxide|
214923719|NCT04062162|BEHAVIORAL|Walking football training|Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.
214323676|NCT07024264|OTHER|Total energy requirement calculated by predictive equation|Critically ill patients are highly susceptible to malnutrition, making accurate caloric estimation essential to prevent both underfeeding and overfeeding during the acute phase in the ICU. Although predictive equations (PE) are widely used to estimate energy requirement, indirect calorimetry (IC) remains the gold standard. This study aimed to compare energy requirements estimated by PE and IC across different BMI categories.
214323677|NCT07024459|DEVICE|Monitoring|Participants will be monitored with secondary monitor collecting data from parameters under evaluation
214485900|NCT03733626|COMBINATION_PRODUCT|ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system|ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion.
214923720|NCT00974467|BEHAVIORAL|After The Injury website|Parents participate in a web-based prevention intervention, which provides education and tips specific to coping with a child's injury.
214923721|NCT00974467|OTHER|Control|Usual hospital care provided.
214923722|NCT02726906|BEHAVIORAL|Moderate-aerobic walking|
214923723|NCT02726906|RADIATION|Positron Emission Tomography (PET) scan|Radioligand that binds to proteins using a PET/CT scanner.
214923724|NCT02726906|BEHAVIORAL|Healthy living education|
214923725|NCT02726906|DEVICE|Physical activity monitor|Wrist device that will track daily physical activity
214923726|NCT05495152|DRUG|Sintilimab|Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.
214923727|NCT00355147|BEHAVIORAL|Physician stroke guideline adherence|Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors
214923728|NCT00355147|BEHAVIORAL|Stroke Self Management|Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
214923729|NCT00355147|OTHER|Attention Control Group|Received Phone Calls from Staff to Control for Attention
214923730|NCT04310605|BEHAVIORAL|CBT 1|CBT for tinnitus (Step 1) comprised: individual audiometric assessment, and counselling about hearing and tinnitus (1hr) with an audiologist; a one-off educational group session (a max 10 participants and partners) (2hrs); an assessment session with a psychologists (1 hr).
214923731|NCT04310605|BEHAVIORAL|CBT 2|Step 2 group sessions were 2 hrs long over a 12-week period. Two therapists (a psychologist and physiotherapist) were present at any one time for Step 2 sessions. Step 2 included: psycho-education; exposure therapy; mindfulness exercises; cognitive restructuring; attention redirecting techniques; stress reduction; and, relaxation techniques. Evening sessions were also provided for participants to attend with family or partners.
214923732|NCT04079192|DEVICE|Biolimus A9 Drug Coated Balloon|A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
214923733|NCT04079192|DEVICE|SeQuent Please Paclitaxel Drug Coated Balloon|A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
214923734|NCT02348346|OTHER|MVX (titanium dioxide)|The investigators have designed a prospective pre-post evaluation time-based pilot study addressing the microbial colonization of surfaces in four rooms of the ICU before and after coating with titanium dioxide (MVX). During a pre-intervention period cultures will be taken every 7 days from 10 prespecified and marked sites per room for a total duration of 4 weeks (sink, wall, floor, bed rail, door handle, ceiling, keyboard patient room, nurse call button, bedside table and monitor arm). After coating of the rooms with MVX another 4 weeks observation period will be used to gather samples in the post-intervention period.
214923735|NCT01183208|DRUG|Intervention A|A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
214923736|NCT01183208|DRUG|Intervention B|A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
214923737|NCT01183208|DRUG|Intervention C|A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
214923738|NCT01183208|DRUG|Intervention D|A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
214923739|NCT01183208|DRUG|Intervention E|A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
214923740|NCT06966661|BEHAVIORAL|Peer Support Intervention|In addition to all components of Standard Health Education, participants join biweekly, small-group meetings (6-8 peers) facilitated by trained upper-year student mentors who guide goal-setting, experience sharing, and mutual accountability. A moderated online chat forum provides daily encouragement, peer-to-peer Q\&A, and group reminders, distinguishing this arm by its structured social support network.
215066498|NCT02079831|BEHAVIORAL|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
215066499|NCT05452031|BEHAVIORAL|Care2Sleep|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
215066500|NCT05452031|BEHAVIORAL|Sleep Education|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
215066501|NCT01113008|PROCEDURE|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
215066502|NCT01113008|PROCEDURE|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
215066503|NCT01278121|DIETARY_SUPPLEMENT|Diet A|3 days, 6 meals a day
215066504|NCT01278121|DIETARY_SUPPLEMENT|Diet B|10 days, 6 meals a day
215066505|NCT04654624|DRUG|SDF|Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.
215066506|NCT04654624|DRUG|ART|Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
214485901|NCT03733626|COMBINATION_PRODUCT|Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system|Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion.
214485902|NCT05071105|RADIATION|Stereotactic Body Radiation Therapy|In every group, the dose is prescribed at the edge of the PTV. To be approved, 95% of the PTV will be conformally covered by the prescription isodose surface and 99% of PTV will receive a minimum of 90% of the prescription dose.
214672727|NCT02747043|BIOLOGICAL|Rituximab|Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
214672728|NCT02046564|DRUG|ASC-01|
214923741|NCT06966661|BEHAVIORAL|Peer Support and eHealth Intervention|This arm integrates the full Peer Support Intervention with a custom mobile/web application that delivers weekly, interactive modules on nutrition, exercise, and mental health; offers in-app self-monitoring tools for weight, dietary intake, and mood; and hosts monthly live Q\&A webinars with clinical nutritionists and mental health professionals. The combination of real-time peer interaction and scalable digital content differentiates it as a multifaceted, blended-delivery intervention.
214923742|NCT02828124|BIOLOGICAL|BMS-986183|specified dose on specified days
214672729|NCT02046564|DRUG|Placebo|
214672730|NCT00149331|BEHAVIORAL|Structured education program|
214923743|NCT02828124|BIOLOGICAL|Nivolumab|specified dose on specified days
214923744|NCT02717416|DEVICE|Endo-Clot|After epinephine injection therapy, Endo-Clot is applied immediately onto the bleeding lesion. A total of 2 g of AMP® particle powder will be sprayed onto the bleeding lesion by a catheter inserted through a working channel of the endoscope under continuous air flow.
214923745|NCT02717416|DEVICE|hemoclip or electrical coagulation|After epinephrine injection therapy, hemoclip (HX-610-135, Olympus, Japan) will be applied onto the bleeding lesions. The number of hemoclip will be decided by endoscopist. Electrical coagulation will be applied onto the bleeding lesions.
214923746|NCT03798301|BIOLOGICAL|CMV-specific T-cells|Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMVspecific CD4+ and CD8+ T-cells
214323678|NCT06876441|BEHAVIORAL|HDTC training program|Participants will receive usual care plus HDTC training program, including four parts: (1)30-minute educational seminar via Tencent: provide disease knowledge, propose strategies to replace sedentary behavior, and introduce Tai Chi. (2)1-hour online nurse-lead dyadic coaching session: introduce dyadic Tai Chi, clarify the roles and responsibilities, and establish a shared goal among dyads. (3)1-hour preliminary Tai Chi training session: face-to-face, introduce online Tai Chi learning, demonstrations on using heart rate monitor, and suggestions for safe home environment. (4)12-week Tai Chi training: Dyads learn Tai Chi following Tai Chi master online. Each session will last 30 minutes in week 2, increase to 40 minutes in week 3, and reach 50 minutes in week 4. The dyads' mastery of Tai Chi will then be assessed either onsite or online. Subsequently, they will practice Tai Chi with the master once a week and follow instructional videos twice a week, with each session lasting 50 minutes.
214323679|NCT06876441|OTHER|Usual Care Group|HF-caregiver dyads in the control group will receive the usual care, including a 30-min online comprehensive education and nurse-led support through telephone consultations in the aspects of symptom management, medication, dietary and exercise suggestions, psychosocial support, and regular monthly follow-up every month.
215066507|NCT02086487|DRUG|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript \> 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at \> 12 months; i.e (BCR-ABL1 0.1 -1%)"
215066508|NCT06451692|OTHER|Clinical pharmacist|The clinical pharmacist calls the patients' GP 90 days after discharge for follow-up
214323680|NCT06718413|DRUG|hyaluronidase plus saline|Injection of study drug with saline
214323681|NCT06718413|DRUG|saline|injection of normal saline and no study drug
214923747|NCT06968832|BEHAVIORAL|Massed Prolonged Exposure Therapy (M-PE)|Massed Prolonged Exposure (M-PE) is a trauma-focused, evidence-based behavioral intervention for posttraumatic stress disorder (PTSD). It is delivered over a compressed timeline (e.g., 10 sessions over 2-4 weeks) as opposed to weekly sessions over 3-4 months. This format has been shown to accelerate PTSD symptom reduction and reduce treatment dropout. In this study, M-PE will be delivered concurrently with an Intensive Outpatient Program (IOP) for substance use disorder (SUD) at Gateway Community Services. Sessions will be led by trained clinicians using a standardized PE protocol, with treatment including imaginal exposure, in vivo exposure, and processing.
214923748|NCT06968832|BEHAVIORAL|Standard outpatient SUD care|"Patients randomized to usual care will receive standard intensive outpatient SUD treatment.~* Resilience group (weekly)~* Peer support~* Individual therapy from a variety of modalities"
214923749|NCT06968273|BEHAVIORAL|Combined respiratory physiotherapy and cardiovascular-strength training program|20-session supervised hospital-based program including respiratory physiotherapy, aerobic training (guided by Borg scale and HR monitoring), and strength training using progressive loads (based on 1RM). Duration: 4 weeks (5 sessions/week).
214923750|NCT00620360|DIETARY_SUPPLEMENT|fructose|acute administration of 4 times 0.3g fructose/kg lean body mass
214923751|NCT00620360|DIETARY_SUPPLEMENT|Fructose|acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
214923752|NCT02079467|PROCEDURE|Unrestricted rehabilitation|Standard care range of motion restrictions will not be used
215066509|NCT01904474|OTHER|Next.Step - e-therapeutic intervention program|
215066510|NCT01904474|OTHER|Standard treatment protocol|
214923753|NCT02079467|PROCEDURE|Standard rehabilitation|Standard care range of motion restrictions will remain in place
214923754|NCT00759460|DRUG|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
214923755|NCT00759460|DRUG|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
214923756|NCT05280366|DEVICE|Streamline Surgical System|Completion of the Streamline Surgical System procedure
214923757|NCT05280366|DEVICE|iStent Inject W|Implantation of competitor device
215066511|NCT06556745|DRUG|BKR-017|BKR-017 is an oral tablet formulation designed to target delivery of sodium butyrate to the colon via colon-targeting technology.
215066512|NCT00057733|PROCEDURE|psychosocial assessment and care|
215066513|NCT00057733|PROCEDURE|quality-of-life assessment|
214323682|NCT04074317|DRUG|PRAM9|SC injection
215066514|NCT01581034|DRUG|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
214323683|NCT04074317|DRUG|Regular Insulin + Pramlintide|Separate SC injections
214323684|NCT04074317|DRUG|Regular Insulin|SC injection
214485903|NCT05283330|DRUG|²¹²Pb-DOTAM-GRPR1|²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
214485904|NCT03031249|DRUG|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
214485905|NCT03031249|DRUG|all-trans retinoic acid|ATRA at a dose of 30mg/㎡/d on day 1-14.
214485906|NCT03031249|DRUG|Arsenic Trioxide|ATO at a dose of 10mg/d on day 1-14
215066515|NCT01581034|DRUG|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
215066516|NCT02665351|DRUG|Peramivir|The two regimens of Peramivir were compared
214485907|NCT05804461|BEHAVIORAL|Motivational Interviewing|Upon refinement from Formative Research (Aim 1), a three-session, individual-level intervention to increase Pre-Exposure Prophylaxis (PrEP) uptake among men who have sex with men (MSM) in Puerto Rico will be implemented. The facilitator will use Motivational Interviewing techniques to guide the sessions. The intervention's design and content will be the same for each study group; the only difference will be the modality of implementation; one group of participants will receive a face-to-face intervention, while another group will receive an online intervention.A total of 170 participants will be randomized in a 1:1 ratio into each of the two intervention modalities (n=85 face-to-face and n=85 online) while a control group will be recruited following a 3:1 ratio of intervention vs. control. In addition to baseline assessment, participants will be asked to complete a post test at the end of the third session (60 days) and a follow-up post-test at the 150-day mark, separately.
214923758|NCT06618391|DRUG|Envafolimab|Envolimab :150 mg/time, intratumoral injection, at least 5 sites; Recombinant human endostatin： Q3W for 4-6 cycles，Maintenance therapy 210 mg ,CIV 72 hours ,administered as continuous intravenous pump, administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
214923759|NCT06618391|DRUG|Recombinant human endostatin|Recombinant human endostatin: 15mg/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
214923760|NCT06618391|DRUG|recombinant human adenovirus type 5|Recombinant Human Adenovirus Type 5: 1.0ml/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
214923761|NCT00964990|DRUG|JNJ-42160443|Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
214923762|NCT00964990|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
214923763|NCT01590121|OTHER|Aeroplane flight in the past- no active intervention for study|Aeroplane flight(s) previously taken by study participants
214923764|NCT01590121|OTHER|Questionnaire|Flight by aeroplane (previous)
214923765|NCT01488422|BEHAVIORAL|Stress Reduction|We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.
215066517|NCT02907983|DRUG|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
215066518|NCT02907983|DRUG|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
215066519|NCT06423495|DEVICE|low-intensity laser treatment|The experimental group will be subjected to a total of up to 24 sessions (2x a week for up to 12 weeks) of irradiation with red and infrared laser pulsed radiation, with 820mm wavelength, 60w power and 6 energy cages, applied in both nostrils and in 10 points under the tongue.
215066520|NCT03900130|DIETARY_SUPPLEMENT|Preload|"In the 2 x 2 factorial design we vary two factors:~1. caloric load of the preload such that it is either high calorie or low.~2. protein to carbohydrate ratio of the preload such that it is either high or low"
215066521|NCT02542033|OTHER|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
214923766|NCT01092039|DIETARY_SUPPLEMENT|lactoferrin, L-Glutamine and beta-glucans|Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
214923767|NCT01092039|DIETARY_SUPPLEMENT|Placebo Comparator|Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.
214485908|NCT06828822|OTHER|Neurodevelopmental assessment|This assessment will be conducted using the ASQ-3 test. (ASQ-3 stands for Ages and Stages Questionnaires, Third Edition, which is a common screening tool for evaluating developmental progress in young children.)
214485909|NCT06828822|OTHER|Meeting with the parents|This meeting will evaluate the parents' acceptance of the lesion and their quality of life using the MARKS test (Measure of Acceptance of Skin Marks). The results will provide insights into how the parents perceive the lesion and how it impacts their daily lives.
214485910|NCT06828822|OTHER|Patient quality of life assessment|Collection of patient quality of life data
214485911|NCT06977815|BEHAVIORAL|VR-Enhanced Cognitive Rehabilitation|A program consisting of 45-minute computer-based cognitive rehabilitation exercises, enhanced with 15-20 minutes of immersive virtual reality (VR) content per session. The VR component targets memory, attention, and executive function. Sessions are delivered twice per week over 12 weeks.
214485912|NCT06977815|BEHAVIORAL|Standard Cognitive Rehabilitation|A program consisting of 45-minute computer-based cognitive rehabilitation exercises targeting memory, attention, and executive function. Sessions are delivered twice per week over 12 weeks. No VR content is included.
214672731|NCT01674543|OTHER|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
214923768|NCT06967116|PROCEDURE|Procedure Steps|The data of the study were collected with the 'Patient Identification Form' and 'Meatal Pressure Injury Daily Monitoring Form'.
214923769|NCT06499610|DRUG|Irinotecan Hydrochloride Liposome Injection|At the dose of 70mg / m2, for patients homozygous for UGT1A1 \* 28, the first dose of irinotecan was adjusted to 50mg / m2,70mg / m2 if the patient tolerated during the first cycle and 70 mg / m 2 in the subsequent cycle; add 500 mL of 5% glucose injection or 0.9% sodium chloride injection for intravenous infusion within 90 minutes. On the first day of each treatment cycle.
214923770|NCT06967428|COMBINATION_PRODUCT|Combined metabolic modulator|This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to support energy metabolism.
214923771|NCT06967428|DIETARY_SUPPLEMENT|Rice Protein Powder with Vitamin C|Rice Protein Powder (39g) with Vitamin C (1g) daily
214923772|NCT00225225|DRUG|Rosiglitazone|
214923773|NCT00225225|BEHAVIORAL|dietary recommendation for weight maintenance|
214923774|NCT03909750|PROCEDURE|Lipoaspiration|Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells
214923775|NCT03909750|PROCEDURE|AD-cSVF|Isolation of AD-cSVF
214923776|NCT03909750|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
214923777|NCT03093649|OTHER|adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|The intervention was administrated through APP
215066522|NCT02542033|OTHER|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
215066523|NCT04052789|OTHER|BioHPP PEEK copings veneered with composite resin|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
214485913|NCT06737471|OTHER|Intensive rehabilitation treatment|"A 3-hour daily rehabilitation treatment will be delivered to each patient 5 days a week for 5 weeks (45 hours) in the care units of the Hospital.~Rehabilitation will address the following macro goals: gross motor, manipulative, visual and visual-cognitive."
214485914|NCT06737471|OTHER|Extensive rehabilitation treatment|"A 3-hour weekly rehabilitation treatment will be delivered to each patient for 15 weeks (45 hours) in an outpatient setting.~Rehabilitation will address the following macro goals: gross motor, manipulative, visual and visual-cognitive."
214923778|NCT03093649|OTHER|do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|patients receive normal care and visit
215066524|NCT01734954|PROCEDURE|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
215066525|NCT01734954|PROCEDURE|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
215066526|NCT01734954|DRUG|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
215066527|NCT01734954|DEVICE|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
215066528|NCT01734954|DEVICE|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
215066529|NCT01734954|DRUG|supplemental oxygen|supplemental oxygen during the block and/or during surgery
215066530|NCT01734954|DRUG|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
214323685|NCT06757413|OTHER|Enhanced Virtual reality|"This study evaluates a 4-week multidisciplinary intervention for patients with chronic non-specific low back pain, combining physiotherapy and psychological approaches. Both components leverage virtual reality (VR) technology to address physical and psychological aspects of pain management, operating in parallel to maximize patient outcomes. The physiotherapy intervention consists of a therapeutic exercise program based on the principles of the Back School. Over 8 sessions (2 per week), patients perform VR-guided exercises where visual-proprioceptive information is manipulated.~The psychological positive body image-based intervention consists of 4 sessions approaching 5 different clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. 2 sessions (Body Awareness and Pain Acceptancce) will include virtual reality environments to enhance the clinical outcomes."
214323686|NCT06757413|OTHER|Active Comparator: Treatment as usual|Participants will receive the usual treatment applied at the hospital
214323687|NCT02601287|BIOLOGICAL|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
214923779|NCT01307137|BEHAVIORAL|Peer-led intervention|"An expert patient in the peer-led intervention will provide effective support for patients and families to accelerate adoption of CER for diabetes prevention and management in the elderly. This will lead to better self-efficacy and clinical outcomes.~Those veterans enrolled in the MOVE! and HARC programs that have showed success in management of weight and Diabetes will be offered to become peer-leaders.~* Weight management success is defined as a loss of at least 5% of the weight since enrollment~* Diabetes management will be defined as adequate control of HbA1c and/ or blood pressure and lipids.~The potentials peer-leaders will have a pre-assessment test to evaluate diabetes prevention and management knowledge and motivation and support skills."
214923780|NCT01307137|BEHAVIORAL|Telehealth Intervention|Participants in the TAP group will receive mobile phones that will be programmed to monitor specific clinical parameters and promote adoption of CER on prevention and management of diabetes, with protocols developed in part based on the input from the focus groups. These devices display messages, tips, reminders and questions regarding healthy lifestyle and clinical parameters of diabetes, which will be developed using best practice guidelines. Participants will be asked to respond to the questions daily if they can. Also they are asked to provide their daily weight, blood pressure, and glucose levels (the later only for patients with diabetes).
214923781|NCT03613909|DEVICE|CP950 OTE Sound processor|CP950 is Off The Ear (OTE) Cochlear Implant Sound Processor
215066531|NCT01734954|DRUG|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
215066532|NCT01734954|PROCEDURE|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
215066533|NCT05157113|DRUG|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
215066534|NCT05157113|DRUG|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
215066540|NCT05010200|BIOLOGICAL|PGV-001|personalized genomic peptide vaccine
215066541|NCT05010200|BIOLOGICAL|Poly-ICLC|immune modulator
215066542|NCT05010200|BIOLOGICAL|CDX-301|soluble recombinant human protein to work on stem cell
215066543|NCT00930917|DEVICE|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
214323688|NCT07068308|BEHAVIORAL|web-based FRAIL-SM program|The 8-week web-based FRAIL-SM includes family involvement, self-regulation, autonomy support, information sharing and linkage.
214485915|NCT06644690|BEHAVIORAL|CO-OP with Creative Dance|The CO-OP with Creative Dance intervention integrates the Cognitive Orientation to daily Occupational Performance (CO-OP) approach with structured creative dance sessions. The CO-OP approach focuses on improving cognitive and functional performance through goal-setting, problem-solving, and the use of metacognitive strategies. Creative dance sessions involve simple, rhythmic movements aimed at enhancing motor coordination, memory, and attention. This intervention is administered three times per week for 60 minutes over 8 weeks. The sessions alternate between CO-OP activities and creative dance exercises.
214485916|NCT06644690|BEHAVIORAL|CO-OP Only|The CO-OP Only intervention involves the Cognitive Orientation to daily Occupational Performance (CO-OP) approach, which is designed to improve cognitive and functional performance through structured goal-setting, problem-solving, and metacognitive strategies. Participants engage in activities focused on improving their ability to perform daily tasks by using cognitive tools to develop and execute solutions. The intervention is administered three times per week for 60 minutes over an 8-week period. No additional physical or dance activities are included in this arm.
214923782|NCT06586788|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on a caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
215066544|NCT00930917|DEVICE|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
215066545|NCT00930917|OTHER|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
215066546|NCT02415049|OTHER|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
215066547|NCT02415049|OTHER|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
215066548|NCT04652206|DRUG|SCO-101|Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
215066549|NCT04652206|DRUG|Gemcitabine|Used according to marketing authorisation
215066550|NCT04652206|DRUG|Nab paclitaxel|Used according to marketing authorisation
214323689|NCT06853249|OTHER|liquid meal|An isocaloric amount (500 kcal) of a commercially available liquid meal with a matched macronutrient composition is consumed. After 5 hours, lunch is eaten ad libitum.
214323690|NCT06853249|OTHER|semi-solid meal|An isocaloric amount (500 kcal) of a commercially available semi-solid oatmeal with a matched macronutrient composition is consumed. After 5 hours, lunch is eaten ad libitum.
215066551|NCT00842153|DRUG|Clobetasol propionate foam|Topical Clobetasol propionate foam
214323691|NCT06853249|OTHER|caloric drink + semi-solid meal|A predefined amount of a caloric drink (= liquid meal) together with an ad libitum amount of a semi-solid meal is consumed. After 5 hours, lunch is eaten ad libitum.
214323692|NCT06853249|OTHER|non-caloric drink + semi-solid meal|A predefined amount of a non-caloric drink (= water, sucralose, flavor) together with an ad libitum amount of a semi-solid meal is consumed. After 5 hours, lunch is eaten ad libitum.
214323693|NCT06775964|BIOLOGICAL|adMSC|IV-infusion of autologous, adipose-derived, Mesenchymal Stem Cells (adMSCs), of approximately 2x10(8) adMSCs in 250mL saline.
214323694|NCT06782295|DEVICE|Constrained Condylar bearing|Patients in this intervention will receive a CCK bearing component
214323695|NCT06782295|DEVICE|posterior stabilized bearing|Patients in this intervention will receive a PS bearing component
214323696|NCT07075354|PROCEDURE|Hydraulic Condensation Root Canal Obturation with BioRoot RCS|Root canal obturation using the hydraulic condensation technique combined with BioRoot RCS, a bioceramic calcium silicate-based sealer. Treatment includes standardized irrigation with sonic activation and drying using a single calibrated paper point without alcohol. The sealer sets hydraulically in the presence of moisture, promotes hard tissue formation, and provides a durable, bioactive seal supporting periapical healing.
214323697|NCT06362590|DRUG|ladiratuzumab vedotin|
214323698|NCT06908265|DRUG|Toothpaste including mustard extract|"Intervention: Herbal toothpaste containing 0.5% white mustard (Sinapis alba) extract. To assess its effect on plaque index (PI), approximal plaque index (API), gingival index (GI), bleeding on probing (BoP), and bacterial loads of Streptococcus mutans and Lactobacillus spp.~Dosage and Usage: Participants brush their teeth twice daily for 4 weeks with the assigned toothpaste."
214323699|NCT06908265|DRUG|Placebo|"lacebo toothpaste, formulated identically to the experimental toothpaste but without white mustard extract. Serves as a control to compare the antibacterial and clinical effects of the herbal toothpaste.~Dosage and Usage: Participants brush their teeth twice daily for 4 weeks with the placebo toothpaste."
214323700|NCT06923644|OTHER|Optimal Metabotype-specific diet|Following screening, baseline measurements, and determination of Metabotype, participants will be randomly assigned, using minimisation, to either the Precision Nutrition (PN) group or the Control (CN) group. The PN group will receive a diet hypothesised to be optimal for their specific Metabotype. All participants will adhere to their assigned diets for 12 months. Each Metabotype-specific diet will align with the Dutch Healthy Dietary Guidelines, while varying in macronutrient composition and quality.
214323701|NCT06923644|OTHER|Sub-optimal diet|Participants randomised to the Control Group (CN), will be randomly assigned one of the two diets optimised for a different Metabotype of the same sex. The assigned CN Group diet will always have a macronutrient content and quality that is different than their hypothesised optimal diet. All diets will align with the Dutch Healthy Dietary Guidelines.
214672732|NCT01674543|OTHER|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
214672733|NCT01674543|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
214672734|NCT03711071|OTHER|"Workshop ICE training"|The workshop includes training in communication skills in relation to evidence based medicine.
214672735|NCT04992832|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group.
214672736|NCT04992832|OTHER|human serum albumin|Saline solution containing 1 percent human serum albumin will be infused to the control group.
214672737|NCT02288975|DEVICE|CytoSorb 300ml device (3804606CE01)|
214923783|NCT06586788|DIAGNOSTIC_TEST|Integrated PCP Diagnosis and Eye-tracking Biomarker|A Classification and Regression Tree (CART) Analysis, based on recursive partitioning, was used to determine which combination of variables (EE Hub PCP diagnosis, diagnostic certainty, composite biomarker, and biomarker frequency \[sum of all individual biomarkers (0-6) that exceeded the 95% specificity threshold for each child\]) best predicted reference standard autism diagnosis.
214923784|NCT03514485|BEHAVIORAL|Yes We Can Children's Asthma Program|The Yes We Can Children's Asthma Program intervention is a medical-social model based on a chronic care approach, including risk stratification, clinical care management, social care coordination by a community health worker, and primary care physician asthma champions. This intervention includes asthma education, trigger reduction visits and care coordination. There will be five clinic visits and four home visits over 12 months implemented by the primary care CHW who is integrated into the primary care practice.
214923785|NCT03514485|BEHAVIORAL|School-Based Asthma Therapy|School-Based Asthma Therapy includes enhanced care coordination for prescribed daily controller medication. The school nurse will coordinate with teachers and the school CHW to schedule daily controller asthma medication administration. The school CHW will assist in obtaining a current asthma care plan and medication administration form from the primary care provider.
214923786|NCT03514485|BEHAVIORAL|Open Airways for School Plus|"Open Airways for Schools Plus was designed to improve the asthma self-management skills in children and enhance control of asthma in the school. The school intervention includes:~1. Open Airways for Schools curriculum for all students with asthma. Classes will be conducted by the school CHW once each semester.~2. Environmental classroom assessments conducted by school CHWs for students enrolled in the study. These teachers will receive classroom supplies to create a more asthma-friendly classroom environment.~3. Asthma education for school staff/personnel at the start of each school year.~4. School facility walk-through assessments to detect potential environmental asthma triggers will be conducted by the School District of Philadelphia."
214923787|NCT01041846|DRUG|No intervention|This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
214923788|NCT03200730|BEHAVIORAL|Family Dignity Intervention group|A brief psychotherapeutic intervention offered to a family dyad (i.e., patient and one identified family caregiver) using narrative approach with life review elements. The purpose is to facilitate an open dialogue between the family dyad that strengthens family connectedness and emotional connection.
214923789|NCT01614782|DRUG|MK-5823|"MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo."
215066552|NCT00842153|DRUG|Vehicle foam|Vehicle foam does not include the active drug.
215066553|NCT02843035|DRUG|venglustat (GZ402671)|"Pharmaceutical form: capsule or tablet~Route of administration: oral"
215066554|NCT02843035|DRUG|imiglucerase|"Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous"
215066555|NCT00002540|OTHER|Laboratory Biomarker Analysis|Correlative studies
214672738|NCT05648838|DEVICE|Pivot Balloon Catheter|mornitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
215066556|NCT00002540|PROCEDURE|Medical Examination Assessment|Undergo DRE
215066557|NCT00002540|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
215066558|NCT05903898|DEVICE|AI software StrokeSens (Circle NVI)|Computed tomography (CT) and computed tomography angiography (CTA) imaging studies acquired upon admission will be assessed by the AI software StrokeSENS (Circle NVI). StrokeSENS is CE marked and available for clinical diagnostic purposes in the EU and UK.The software will be a decision support tool in addition to standard radiological services available in all primary stroke centers in Northern Norway where image interpretation is done by a radiologist or resident in radiology. The software can automatically evaluate the presence of ischemic changes in the vascular territory of the middle cerebral artery according to the Alberta Stroke Program Early CT Score (ASPECTS) and occlusions in the intracranial segment of the internal carotid artery and the proximal segments of the middle cerebral artery (MCA). Output to radiologists will be automated ASPECT scoring, automated search for LVO or MeVO.
215066559|NCT05241691|DEVICE|Guided Growth Plate System Plus|The implant is thought as one of the surgical options to perform epiphysiodesis and hemiepiphysiodesis minimally invasive, that is without recourse to a corrective osteotomy.
215066560|NCT04254562|BEHAVIORAL|Weekly Meetings with a Supported Employment/Supported Education Specialist|Participants will receive intervention for 12 months which includes weekly meetings with a Supported Employment/Supported Education Specialist (HYPE Specialist). During the weekly meetings, the HYPE Specialist will review each participant's education and employment goals, and deliver individualized support relevant to those goals which include use of structured HYPE tools and worksheets as needed.
215066561|NCT04254562|BEHAVIORAL|Focused Skill and Strategy Training (FSST)|Participants receive a 12 week Focused Skill and Strategy Training (FSST), a structured cognitive remediation intervention.
214923790|NCT01614782|OTHER|Placebo|Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
214923791|NCT00791661|DRUG|MK-1006|MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
214923792|NCT00791661|DRUG|Placebo|Matching placebo to MK-1006 in a single oral dose
214923793|NCT05332990|DIAGNOSTIC_TEST|HFO analysis|We use an automated data-independent prospective definition of clinically relevant HFO that has been validated in data from two independent epilepsy centers.
214923794|NCT06617819|DEVICE|CR prosthesis|For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.
214923795|NCT06617819|DEVICE|PS prosthesis|For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.
214923796|NCT03265821|PROCEDURE|Healing after treatment|
214923797|NCT02688062|BIOLOGICAL|NeuroRegen Scaffold with BMMCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
214923798|NCT02688062|PROCEDURE|Surgical intradural decompression and adhesiolysis|Patients with chronic SCI (ASIA grade A) will receive intradural decompression and adhesiolysis surgery and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
214923799|NCT06621615|BIOLOGICAL|CVL006 Injection|CVL006 injection, intravenous infusion, administered every 2 weeks. Every 28 days is a cycle. Until the subject cannot tolerate the disease progression or toxicity, or the researcher determines that the medication must be terminated or the sponsor terminates the study. SMC can adjust the dosing frequency based on safety, tolerability, and PK results data. If researchers consider that subjects enrolled in the lower dose group can benefit from the study intervention, they can allow them to continue treatment at a higher dose that has been proven safe based on the researcher's judgment.
214923800|NCT05403814|OTHER|observational screening procedure (no intervention)|observational screening procedure (no intervention)
214923801|NCT03740555|DRUG|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg
214923802|NCT03740555|DRUG|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose, matching placebo
214923803|NCT03740555|DRUG|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, anticipated doses: 300mg to 1200mg
214923804|NCT03740555|DRUG|Placebo multiple ascending doses|Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo
214923805|NCT04497870|DRUG|Peppermint oil|Administration of peppermint oil at one of two daily doses.
214923806|NCT04125914|BEHAVIORAL|Behavioral Dietary Intervention|Record food intake
214923807|NCT04125914|OTHER|E-mail|Receive e-mails
214923808|NCT04125914|BEHAVIORAL|Exercise Intervention|Undergo exercise
214923809|NCT04125914|OTHER|Health Promotion and Education|Receive text messages
214923810|NCT04125914|OTHER|Internet-Based Intervention|Join Facebook page
214923811|NCT04125914|OTHER|Questionnaire Administration|Ancillary studies
214923812|NCT04125914|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching
214923813|NCT05336188|DEVICE|Smartphone|Adjunctive Smartphone app for improving MAT outcomes
214923814|NCT04398238|COMBINATION_PRODUCT|evaluation by transfusion medicine specialist|screening for anemia causes and treatment: iron/folate/vitamin B12 supplementation, Erythropoietin administration if indicated
214323702|NCT06923865|BEHAVIORAL|training group|"Participants in training group are invited to take part in two structured training sessions per week, each lasting 90 minutes:~One session takes place in a larger group setting, where participants engage in physical activities and games together.~The second session is held in a small group format with 1-2 peers-either friends the participant already knows or peers they meet during the larger group session.~Each training session is supervised by a qualified instructor and includes:~Fun, game-based activities~Short workouts aimed at improving fitness~A focus on social interaction, enjoyment, and participation~The sessions are designed to be supportive, engaging, and motivating, with the goal of increasing physical activity in a positive group environment."
214323703|NCT06924671|BEHAVIORAL|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
214923815|NCT03445741|OTHER|Supervised treadmill group (%70 VO2 max) (group 1)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 70% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 3 days in a week and 20 minutes per day walking program was applied.
215066562|NCT04254562|BEHAVIORAL|Enhanced Services as Usual|One hour meetings every semester to review individual academic needs and review list of available on campus resources to best meet the student's needs.
215066563|NCT01345929|DRUG|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
215066564|NCT01345929|DRUG|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
214323704|NCT06923579|PROCEDURE|Titanium Mesh Cage|"the Harms cage was adapted for long bone reconstruction due to its structural stability and biocompatibility. The cage provides immediate mechanical support while allowing for bone ingrowth, addressing the limitations of traditional methods.~Advantages of the titanium mesh cage include its ability to maintain bone length, provide immediate stability, and allow for earlier weight-bearing. The porous structure facilitates vascularization and bone integration, potentially leading to improved healing outcomes"
215066565|NCT03396497|DRUG|LYC-55716|Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
215066566|NCT03396497|DRUG|Pembrolizumab|Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
215066567|NCT02151903|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
215066568|NCT02412189|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
215066569|NCT02412189|DRUG|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
215066570|NCT06626529|BEHAVIORAL|Guided mindfulness meditation|Watching a video of a guided mindfulness meditation include paying attention to the breath, promoting natural breathing without force; body scan, directing awareness from the head down to the toes, allowing tension to release in each area. The intervention emphasizes observing sensations without judgment, fostering a state of relaxed awareness.
215066571|NCT06626529|BEHAVIORAL|Scenery video|Watching a ten-minute video of calming music and images
215066572|NCT00004573|DRUG|ganciclovir|
215066573|NCT00505973|DRUG|SCA-136|
215066574|NCT02018536|DRUG|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
215066575|NCT02018536|DRUG|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
215066576|NCT02018536|DRUG|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
215066577|NCT02018536|DRUG|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
215066578|NCT02018536|DRUG|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
215066579|NCT02018536|DRUG|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
215066580|NCT02018536|DRUG|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
215066581|NCT05335304|OTHER|intervention group 1|Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.
215066582|NCT05335304|OTHER|intervention group 2|Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.
215066583|NCT05335304|OTHER|intervention group 3|Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants
215066584|NCT05335304|OTHER|intervention group 4|Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.
215066585|NCT05335304|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
215066586|NCT03772795|OTHER|Orthodontic Alignment|"Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
215066587|NCT03772795|OTHER|Orthodontic Alignment|Group 2: Teeth alignment using clear aligners.
215066588|NCT04405999|DRUG|Bromhexine Hydrochloride|Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
215066589|NCT03978741|DEVICE|Yōni.Fit Test Device|The Yōni.Fit Test Device is a silicone pessary.
215066590|NCT03978741|DEVICE|Yōni.Fit Comparator Device|The Yōni.Fit Comparator Device is a silicone pessary with a different configuration.
215066591|NCT01500252|DEVICE|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
215066592|NCT01500252|DEVICE|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
215066593|NCT04833686|BEHAVIORAL|Mozart|Music composed by Mozart, a musical piece 24 minutes long.
215066594|NCT04833686|BEHAVIORAL|Instrumental music|Instrumental music , a musical piece 24 minutes long
215066595|NCT04833686|BEHAVIORAL|Silence|Silence, a piece 24 minutes long.
215066596|NCT06073912|PROCEDURE|Open sinus lifting|Sinus lateral window to graft the floor of the sinus using sinus red diamond stone
215066597|NCT06073912|PROCEDURE|Collecting blood sample|Blood sample is collected to harvest PRP and PRF
214323705|NCT06923930|DEVICE|External Cueing Device|A portable product that provides movement pattern constraints to ensure improved exercise form, and provides a target zone for exercise effort
214323706|NCT06923930|OTHER|Exercise|"Shoulder stabilization exercise protocol contains 8 exercises (I, Y, T, i, w, alternating arm I/i, n, and supine serratus punch) completed for 8 repetitions each for 3 weeks, and in weeks 4-6 completed at 2 sets of 8 repetitions each."
215066598|NCT06073912|PROCEDURE|Bone graft harvesting|Bone graft harvesting from the chin area
215066599|NCT06073912|PROCEDURE|Autogenous corticocancellous block graft|Simultaneous implant placement with sinus lifting and grafting using autogenous corticocancellous block, stabilized inside the sinus using clamp or screws that will be removed before closure
215066600|NCT06073912|PROCEDURE|Mineralized plasmatic matrix graft|Simultaneous implant placement with sinus lifting and grafting using mineralized plasmatic matrix that is formed using PRP of the patient mixed with particulate autogenous graft from the chin area
214672739|NCT03174743|PROCEDURE|Convential Ventilation 1|High tidal volume, moderate inspired oygen fraction (FiO2).
214672740|NCT03174743|PROCEDURE|Convential Ventilation 2|High tidal volume, high inspired oygen fraction (FiO2).
215066601|NCT06073912|DEVICE|Centrifuge|Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups
214672741|NCT03174743|PROCEDURE|Protective Ventilation 1|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
214923816|NCT03445741|OTHER|Supervised treadmill group (%50 VO2 max) (group 2)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 50% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
214923817|NCT03445741|DEVICE|ECE PEDO pedometer group (%50 VO2 max) (group 3)|Target heart rate (HR) corresponding to values of 50 % VO2max were determined by the submaximal treadmill test. The number of steps taken in a minute corresponding to target HR was determined by a criterion pedometer and group 3 was instructed walking in this step range recorded to ECE PEDO giving audible feedback. During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
214923818|NCT00492648|PROCEDURE|Blood sampling for assay of persistence of immunogenicity|Two blood samples: 30 and 42 months after first vaccination
214923819|NCT01721096|DEVICE|XIENCE PRIME - Long Length (LL)|Long Length
214923820|NCT01721096|DEVICE|XIENCE PRIME - Core Size|Core Size
214923821|NCT01864551|DRUG|Lamotrigine|
214923822|NCT01864551|DRUG|Olanzapine|
215066602|NCT06073912|DEVICE|ACM bur|Auto Chip Maker will be used to collect the autogenous particulate bone graft for the sticky bone graft
215066603|NCT00152828|DRUG|Celecoxib|
215066604|NCT05171400|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
215066605|NCT05171400|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
215066606|NCT05171400|DEVICE|Palatal Wound treated with Insulin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
215066607|NCT04747054|DRUG|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
215066608|NCT04747054|RADIATION|Loco-regional radiotherapy|"Depending on the choice of radiotherapy timing:~* Before 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time between one week after the first administration of pembrolizumab and the first day of the 3rd cycle.~* After 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time after 3rd cycle (C3D1) and up to a maximum of 4 weeks after the 6th cycle of pembrolizumab.~Dose/fraction of radiotherapy: 54 Gy/18 fractions (recommended schedule) or 70Gy/33-35 fractions or other curative dose/fraction schedules with shorter duration and biologically equivalent dose of at least 60Gy at the discretion of local investigators, in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary. Other cycles of pembrolizumab will be administered during and after radiotherapy."
215066609|NCT04747054|DRUG|Chemotherapy|"If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles"
214672742|NCT03174743|PROCEDURE|Protective Ventilation 2|Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
214672743|NCT01566123|RADIATION|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
214672744|NCT01566123|RADIATION|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
214672745|NCT00192335|BIOLOGICAL|CAIV-T|
214672746|NCT00192335|BIOLOGICAL|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
214672747|NCT00192335|BIOLOGICAL|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
214672748|NCT02353078|DRUG|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
214672749|NCT02353078|PROCEDURE|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
214323707|NCT04943016|DRUG|CD19 Chimeric Antigen Receptor (CAR) T Cells|This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies. The overall goal of this study is to validate the safety profile of administration CD19 CAR T cells and describe the toxicities in children and adults with relapsed/ refractory B cell malignancies. Each patient implements leukapheresis 2 weeks after enrollment and infuse CD19 CAR-T cell around 2 weeks after leukapheresis, and administrated chemotherapy lymphodepletion regimen 1 week before infusion. Furthermore, the treated subject would be following up around 2 years.
214323708|NCT03640663|OTHER|Midwife led continuity model of care|Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
214323709|NCT04519632|OTHER|Qualitative study|Qualitative interviews
214323710|NCT06005025|OTHER|Reminder message|"Experimental group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received."
214323711|NCT03852329|DEVICE|Lateral skull base navigation|"Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards"
214323712|NCT03142295|PROCEDURE|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
214323713|NCT00936026|DRUG|Neramexane|Drug-Drug Interaction Study
214323714|NCT05586399|BEHAVIORAL|Maximal strength training in COPD|Participate in a rehabilitation program for 4 weeks, with exercise 5 times a week. Supervised maximal strength training in a leg press machine for a total of 20 exercise sessions. Patients will participate in rehabilitation in one of two rehabilitations centers in Trondheim, Norway.
214323715|NCT03063359|DRUG|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
214323716|NCT03063359|DRUG|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
214672750|NCT02353078|DEVICE|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
214923823|NCT03408301|PROCEDURE|Tourniquet deflation|Tourniquet deflation
214923824|NCT01547442|DEVICE|Artisan Aphakia Intraocular Lens|Implantation of an intraocular lens
214923825|NCT00542906|OTHER|localization|localization of the several types of somatosensory stimuli
214923826|NCT02748135|DRUG|TB-403 20mg/kg|bi-weekly intravenous doses of TB-403 20mg/kg
214923827|NCT02748135|DRUG|TB-403 50mg/kg|bi-weekly intravenous doses of TB-403 50mg/kg
214923828|NCT02748135|DRUG|TB-403 100mg/kg|bi-weekly intravenous doses of TB-403 100mg/kg
214323717|NCT06080620|PROCEDURE|Modified radical mastectomy for breast cancer|Modified radical mastectomy for breast cancer
214923829|NCT02748135|DRUG|TB-403 175mg/kg|bi-weekly intravenous doses of TB-403 175mg/kg
214923830|NCT01921790|BIOLOGICAL|Avastin|Avastin 7.5mg/Kg, intravenous drip D1
215066610|NCT05319600|BEHAVIORAL|Diabetes behavior change skills training|Behavior-change skills training will be provided through eight web-delivered content and activity sessions across the 12-week program. Sessions 1 through 4 will occur weekly and sessions 5 through 8 biweekly. Each session takes approximately 15-20 minutes for the adolescent to complete both content learning and related activities. These learning sessions focus on skills like problem solving and goal setting.
215066611|NCT05319600|BEHAVIORAL|Physical activity promotion program|The physical activity incentives program includes 12 weeks of personalized goals and incentives for increasing physically active minutes along with weekday text-based support. Active minutes, defined as minutes with moderate to vigorous physical activity, will be tracked via a Garmin fitness activity tracker.
215066612|NCT02497365|DRUG|Besifloxacin|
214923831|NCT01921790|DRUG|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
214923832|NCT01921790|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 intravenous drip D1
214923833|NCT01921790|DRUG|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
214923834|NCT01921790|DRUG|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
214923835|NCT04164043|BEHAVIORAL|Wellness Recovery Program|12-week community-based recreation therapy
215066613|NCT02497365|DRUG|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
215066614|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.
214923836|NCT06056687|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha Lipoic Acid 600 MG Oral Tablet once daily
214923837|NCT06056687|OTHER|Placebo Tablet|Placebo Tablet once daily
214923838|NCT02165189|DRUG|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.
214923839|NCT02165189|DRUG|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
214923840|NCT02165189|DRUG|Ribavirin|Participants will be administered ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram (\[kg\]) or 3 x 200 mg tablets (for participants weighing more than 75 kg) orally once daily up to 12 weeks.
214923841|NCT02165189|DRUG|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 24 weeks.
214923842|NCT02165189|DRUG|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 24 weeks.
215066615|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months.
214323718|NCT06080620|PROCEDURE|neoadjuvant therapy|"neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）"
214323719|NCT06080620|PROCEDURE|Systematic treatment|"chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）"
214323720|NCT04913493|PROCEDURE|Cytocam-IDF|Patients receive an extra medical imaging test perioperatively with the Cytocam-IDF
214323721|NCT00445614|BEHAVIORAL|Effects of trout on CVD risk markers and plasma proteome|
214923843|NCT06623617|BEHAVIORAL|Three-dimensional breathing training|Engage in app-based three-dimensional breathing training and learn to use a biofeedback pressure device at home for proper and effective training. They will also be guided to log their daily training, manually inputting data such as duration and frequency. A virtual assistant will provide real-time feedback based on this data, including encouragement and adjustments to training intensity.
214323722|NCT00653224|DRUG|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
214323723|NCT00653224|DRUG|placebo|0 mg daily (matching oral tablet) for 14 days
214923844|NCT06623617|BEHAVIORAL|control group：Health education|Provide participants with health education, which is conducted one-on-one by researchers during the recruitment of mothers. The content includes the etiology and risk factors of PPSUI (Pelvic Organ Prolapse during Straining), the benefits and precautions of pelvic floor muscle exercises and breathing techniques, as well as the implementation methods.
214923845|NCT00595517|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
214923846|NCT06296550|OTHER|Dulce Digital Text Messaging Intervention|"Text-based education support program:~* Participants will receive text messages about diabetes and how to take care of diabetes and health. Participants will receive 2-3 messages every day for first 3 months, and then will slowly decrease over the last 3-months.~* Participants will also receive text messages that will ask them to test their blood sugar and text back blood sugar reading."
214323724|NCT05041803|DRUG|CTP-543|Twice daily dosing
214323725|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 2-week intervals
214323726|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 4-week intervals
214323727|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 three times at 2-week intervals
214323728|NCT03736421|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
214323729|NCT03736421|PROCEDURE|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
214323730|NCT03736421|DIAGNOSTIC_TEST|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
214323731|NCT06029322|PROCEDURE|Socket seal after alveolar ridge preservation|Socket seal is performed after ARP. Using a collagen matrix or membrane the socket is sealed, at the control (membrane) site a small pouch is made at the buccal and lingual aspect. Monofilament sutures are used to secure the respective material in place.
214923847|NCT06296550|OTHER|CGM Device|Participants will be provided continuous glucose monitors (Dexcom G7) to actively monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months). In addition, participants will attend an information session (group or individual; in-person or virtual) that will provide instructions on using continuous glucose monitors.
214923848|NCT04563910|OTHER|young mania rating scale|questionnaires to the patients and their family after their written consent
214923849|NCT00305084|DRUG|NGR-hTNF|0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks
214923850|NCT00305084|DRUG|Doxorubicin|75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
214923851|NCT06285851|DIETARY_SUPPLEMENT|FeSC|Supplement
214923852|NCT04468308|OTHER|Questionnaire|Patients complete the National Eye Institute Visual Function Questionnaire 25 pre-operative, 1 month and 3 month postoperatively.
214923853|NCT06419842|OTHER|hypnosis|the patient benefits from a dedicated nurse consultation. During this consultation, the nurse will explain the highlights of the hospitalization, the procedure and anticipate the hypnosis technique to be used. The technique chosen during the consultation will be applied during the test. The nurse is positioned at the head of the patient and with physical contact.
214923854|NCT06419842|OTHER|comfort|the patient benefits from a nurse consultation. Non-medicinal techniques are not offered. During the infusion test, the nurse will be positioned at the patient's head allowing proximity but without oral or physical intervention.
215066616|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)|Performed booster immunization at 18 months of age.
215066617|NCT05584163|DEVICE|Extracorporeal shock waves|3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
215066618|NCT00566410|DRUG|Dichloroacetate|Continuous daily oral dosage (bid).
214323732|NCT01394575|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
214323733|NCT03427918|BEHAVIORAL|Mindfulness-Based Sex Therapy|Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
214323734|NCT03194763|DIAGNOSTIC_TEST|coronary angiography|computed tomography acquisitions performed on a revolution CT
214323735|NCT01942941|DEVICE|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
214323736|NCT04482179|DEVICE|Active TMS|Active TMS will be delivered at 100% motor threshold
214323737|NCT04482179|BEHAVIORAL|CILT|60-90 minutes of CILT will be administered during each treatment session
214323738|NCT04482179|DEVICE|Sham TMS|Sham TMS will be administered
214323739|NCT04709237|DEVICE|omafilcon A control lens|Participants were randomized to wear omafilcon A control soft contact lens for 10 days.
214323740|NCT04709237|DEVICE|omafilcon A test lens 1|Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.
214672751|NCT01419249|OTHER|Blood sampling|Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
214672752|NCT01295905|DEVICE|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
214323741|NCT04709237|DEVICE|omafilcon A test lens 2|Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.
214672753|NCT01295905|DEVICE|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
214672754|NCT05404854|OTHER|Physical Activity|wearing an accelerometer for 7 days before and after the rehabilitation program
214672755|NCT05404854|OTHER|sedentarity|wearing an accelerometer for 7 days before and after the rehabilitation program
214923855|NCT06530251|DRUG|AK112|Following a predefined dose and date.
214923856|NCT06530251|DRUG|Cadonilimab|Following a predefined dose and date.
214923857|NCT06530251|DRUG|AK127|Following a predefined dose and date.
214923858|NCT06530251|DRUG|AK130|Following a predefined dose and date.
214323742|NCT04048460|DEVICE|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
214323743|NCT03977324|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
214323744|NCT03977324|PROCEDURE|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
214323745|NCT06445374|DRUG|Inhaled Epinephrine|"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."
214323746|NCT05576025|OTHER|Lifestyle intervention (cold exposure)|Participants will undergo two cold exposures with different shivering intensities. Mild shivering is defined as energy expenditure increased by 1.5-fold compared to the resting metabolic rate. Moderate shivering is 2.5-fold increase in metabolic rate.
214323747|NCT06062056|OTHER|EHR alert|An EHR alert will be fired if a behavioral health patient is missing a COVID-19 or influenza vaccine.
214323748|NCT06062056|BEHAVIORAL|Motivational Interviewing|In response to the alert and using support tools in the EHR, the behavioral health clinician will integrate motivational interviewing into the counseling session to discuss vaccine hesitancy (if it is deemed appropriate based on patient needs and clinical judgment).
214323749|NCT06062056|BEHAVIORAL|Warm hand off to nurse|For patients interested in vaccination following motivational interviewing, the behavioral health clinician will do a warm hand off to a nurse for vaccination
214323750|NCT05684770|OTHER|4G tablet|Participants will receive for the whole period of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.
214323751|NCT05426174|BIOLOGICAL|mRNA NA vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214323752|NCT05426174|BIOLOGICAL|High Dose Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214323753|NCT06375798|PROCEDURE|radiotherapy|If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area.If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. Clinical standard treatment plan (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.
214323754|NCT02489318|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
214923859|NCT06530251|DRUG|Sintilimab Injection|Following the local label direction.
214923860|NCT06530251|DRUG|Bevacizumab biosimilar|Following the local label direction.
214923861|NCT06499454|DIAGNOSTIC_TEST|Ruby ROSE evaluation|Creation and digitization of ROSE slides produced using Ruby's instrument from bronchoscopic biopsy samples
214923862|NCT00680602|BEHAVIORAL|Group Cognitive Behavior Therapy|Structured protocol described by Cordioli et al., 2003
214923863|NCT00680602|DRUG|SSRI (fluoxetine, sertraline, paroxetine, citalopram)|Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
214923864|NCT01962077|PROCEDURE|MedCem MTA pulpotomies in primary teeth.|
214923865|NCT04736277|OTHER|Preoperative HbA1c|Documentation of the preopetative HbA1c in patients undergoing noncardiac surgery under general anesthesia
214923866|NCT04242290|DIAGNOSTIC_TEST|Lateral radiography|The lordosis angles were measured on the lateral cervical graphs of all patients.
214923867|NCT04105218|BEHAVIORAL|Exercise|Participants will perform 4 study visits over 1-3 months. The 1st study visit is a screening visit, during which eligibility will be determined. During the 2nd visit, resting metabolic rate (RMR) and body composition will be measured. Participants will also perform a submaximal exercise test. Prior to each condition, habitual sleep/wake patterns will then be measured for 1 week. Participants will then perform each of the 2 study conditions (evening exercise and control) in randomized order with at least a 1-week washout period between conditions. Females will be studied during the luteal phase to control for potential confounding effects of hormonal variations across the menstrual cycle.
214923868|NCT06424171|DIAGNOSTIC_TEST|Cardiac and brain magnetic resonance imaging.|Cardiac magnetic resonance imaging with analysis using 4D flow. Brain magnetic resonance imaging to detect strokes, including microvascular strokes.
214923869|NCT03570411|DIAGNOSTIC_TEST|T-SPOT®.CMV Test|The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
214923870|NCT00970541|DIETARY_SUPPLEMENT|Cinnamon Supplementation|1, 3, or 6g of cinnamon per day for 40 days
214923871|NCT00970541|DIETARY_SUPPLEMENT|Placebo (wheat flour)|1, 3, or 6g of placebo per day for 40 days
214923872|NCT06487000|DRUG|EC-18|oral administration, QD
214923873|NCT06487000|DRUG|Placebo EC-18|oral administration, QD
214923874|NCT05320705|DRUG|Intra Operative Dexmedetomidine|Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
214923875|NCT03670446|OTHER|Pharmacists' intervention|"1. Medication education: When the patient is enrolled in the intervention group, pharmacists issue an education manual to give a medical education which contains the reasons for using NOACs, the characteristics of the drug, the precautions, and how to monitor the efficacy. Pharmacists re-educate through telephone or clinic during follow-up.~2. Establish a medical record and remind their follow-up by message, phone every 2 weeks.~3. Follow-up in the 4th week and 8th week : Pharmacists recommend patients for drug therapy optimization after conducting a full pharmacotherapy review of each patient's medication regimen and remind them to test urinary occult blood every 1-3 months, detect hemoglobin and liver/kidney function every 3-6 months."
214923876|NCT03770039|DRUG|Oral PF-06700841 containing 14C microtracer|Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
214923877|NCT03770039|DRUG|Oral unlabeled PF-06700841|60 mg unlabeled PF-06700841 oral dose in 2nd period
214923878|NCT03770039|DRUG|IV 14C-labeled PF-06700841|30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
215066619|NCT01604525|BEHAVIORAL|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
214323755|NCT02489318|DRUG|Placebo|Participants will receive Placebo orally once daily in each 28 day treatment cycles.
214323756|NCT02489318|DRUG|Androgen Deprivation Therapy (ADT)|All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
214323757|NCT03773900|DIETARY_SUPPLEMENT|Kiotransine (chitin-glucan from aspergillus niger)|The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.
214323758|NCT03773900|DIETARY_SUPPLEMENT|Placebo|The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
214323759|NCT06184516|PROCEDURE|Reproductive organ sparing radical cystectomy|"Participants on this arm will undergo a reproductive organ sparing radical cystectomy if they are classified as favorable based on the decision tool."
214323760|NCT06184516|PROCEDURE|Radical cystectomy|"Participants on this arm will undergo a radical cystectomy if they are classified as unfavorable based on the decision tool."
214323761|NCT05723770|DRUG|instillation of NOV03|This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.
214323762|NCT04817254|DRUG|TMZ|150 mg/m2 on days 1-5 of cycles 1-6
214323763|NCT04817254|DRUG|ipilimumab 3mg/kg|3 mg/kg q 4 weeks for cycles 1-4
214323764|NCT04817254|DRUG|Nivolumab|1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16
214323765|NCT04817254|DRUG|ipilimumab 1mg/kg|1 mg/kg q 4 weeks for cycles 1-4
214323766|NCT05556876|DIETARY_SUPPLEMENT|Protein omega-3|An oral supplement with a high content of protein and with essential fatty acids
214923879|NCT06414395|DRUG|Precedex (Dexmedetomidine) 200 MCG in 2 ML Injection|The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study
214923880|NCT06414395|OTHER|C group: Patients received saline infusion over 10 minutes|the group will receive normal saline infusion over 10 minutes.
214923881|NCT00297180|DRUG|GW869682|
214923882|NCT04102748|PROCEDURE|I-incision, M-flap and conventional implant exposure techniques|Implant uncovering in the second stage using 3 different exposure techniques
214923883|NCT06681948|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
215066620|NCT01604525|BEHAVIORAL|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
215066621|NCT01604525|OTHER|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
214923884|NCT06681948|DIETARY_SUPPLEMENT|placebo|placebo
214923885|NCT05667363|COMBINATION_PRODUCT|Digital Intervention|Digital therapeutics are consist of a smartphone app and an intelligent medication recorder. The intelligent medication recorder can automatically record medication using data and reminds patients through the app. Patients can also record their symptom on the app for doctors to monitor.
214923886|NCT00650325|DRUG|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fasting
214923887|NCT00650325|DRUG|Zoloft® Tablets 100 mg|100mg, single dose fasting
215066622|NCT00323960|DRUG|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
215066623|NCT00323960|DRUG|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
215066624|NCT00323960|DRUG|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
215066625|NCT03768089|DRUG|Placebo (matched to VX-121 suspension)|Placebo matched to VX-121 suspension for oral administration.
215066626|NCT03768089|DRUG|VX-121 (Suspension)|Suspension for oral administration.
215066627|NCT03768089|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
215066628|NCT03768089|DRUG|IVA|Tablet for oral administration.
215066629|NCT03768089|DRUG|Placebo (matched to TEZ/IVA)|Placebo matched to TEZ/IVA for oral administration.
215066630|NCT03768089|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
214323767|NCT06273488|OTHER|Auriculotherapy|Treatment of pain, drug addictions, or other ailments by stimulating the various points on the external ear (EAR AURICLES). It is based on the ancient Chinese practices of EAR ACUPUNCTURE, but sometimes magnets and other modes of stimulation are used.
214323768|NCT01171898|DRUG|ARN-509 (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.
214323769|NCT01171898|DRUG|ARN-509 (Phase 2)|ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
214323770|NCT01659112|OTHER|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
215066631|NCT03768089|DRUG|VX-121 (Tablet)|Tablet for oral administration.
215066632|NCT03768089|DRUG|Placebo (matched to VX-121 tablet)|Placebo matched to VX-121 tablet for oral administration.
215066633|NCT05327842|DEVICE|New training simulator|Participants receive training with new simulator
215066634|NCT05327842|DEVICE|Traditional simulator|Participants receive traditional training
215066635|NCT05072860|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
215066636|NCT05072860|OTHER|: normal saline|temporary uterine packing with gauze of the dimensions soaked with placebo to 2 gm tranexamic diluted in 60ml saline acid
215066637|NCT01780337|DRUG|Oxytocin|Intranasal dose of 20 IU oxytocin
215066638|NCT01780337|OTHER|Saline|Intranasal dose of saline
214923888|NCT05561322|OTHER|Consultation involving pain evaluation, questionnaires and the Lasègue Manoeuver|Raising the lower limb with the knee in extension reproduces sciatica pain if there is an impression of discal pain with its origin at the roots of the sciatica nerve L5 and S1. This test is evaluated by the degree of elevation of the lower limb relative to the examination table. During the Lasègue manoeuvre the sciatica pain is improved during dorsal flexion of the foot.The doctor notes whether the Lasègue manoeuvre done on the healthy side exacerbates the pain on the opposite side. It is said that contralateral Lasègue sign is positive.
214923889|NCT05561322|OTHER|Magnetic Resonance Imaging of the lumbar spine|Sagittal proton density-weighted Dixon sequence on the lumbar spine and axial T2-weighted spin echo sequence on the lumbar discs.
215066639|NCT05558137|DRUG|Mivacurium|0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
215066640|NCT02427139|DEVICE|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
215066641|NCT06361394|OTHER|mindfulness course|"The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course."
215066642|NCT03319459|DRUG|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
215066643|NCT03319459|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
214323771|NCT01659112|OTHER|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
214323772|NCT02150564|DEVICE|Sonowand|Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure
214672756|NCT05404854|OTHER|Measurement of explicit motivation|Explicit motivation will be assessed using self-report questionnaires. Explicit attitudes using a 7-point bipolar response scale, participants will be asked to indicate for each of the 4 pairs of positive and negative adjectives used how much they associate them with regular PA and sedentary behaviors, respectively. Perceived behavioral control using a 7-point bipolar response scale, patients will be asked to indicate how well they felt they were able to engage in regular PA, and limit their sedentary behaviors, respectively, based on two items. Intentions using a 7-point bipolar response scale, patients will be asked to indicate how much they intend to adopt regular physical activity, and limit their sedentary behaviors, respectively, according to two items. Fears and beliefs related to physical activity and work will be measured by the FABQ in its French version
214672757|NCT05404854|OTHER|Measurement of implicit attitudes|Implicit attitudes will be assessed by administering an Implicit Association Test on physical and sedentary activities. Sitting in front of a computer, participants will see a series of words appear in the middle of the screen referring to 4 conceptual categories - located at the top of the screen. Two represent the targeted behaviours (here, physical activity versus sedentary lifestyle) while the remaining two represent attributes (here, positive versus negative adjectives). The adjectives used will be the same as those used to measure explicit attitudes. The instructions given to the participant are to classify the words as quickly as possible, according to the semantic category to which they belong
214672758|NCT03204227|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
214672759|NCT03204227|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
214672760|NCT06215339|BEHAVIORAL|diet therapy training|diet education
214672761|NCT00640783|BEHAVIORAL|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
214672762|NCT00640783|BEHAVIORAL|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, \<30%).
214672763|NCT00722605|PROCEDURE|cone-beam CT|"You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.~* During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.~* For all scans, an external monitor will be used to record your breathing.~* If needed, you will be repositioned by adjusting the radiation machine's treatment couch position."
214923890|NCT06049186|BEHAVIORAL|CRD|During the initial 8 weeks of the trial, polycystic ovary syndrome (PCOS) patients are instructed to follow a diet of 1200 to 1500 kcal per day supervised by dietitians. The CRD includes a combination of 40 to 55% of calories from carbohydrates, 15 to 20% from protein, and 20 to 30% from fat; this regimen represented approximately 75% of the participants' daily caloric intake at baseline. All the participants receive dietary counseling daily during the trial.
214323773|NCT02150564|PROCEDURE|Navigation|Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
214323774|NCT06845891|DEVICE|CONNECTED SMART CAP|The intervention in this study consists of attaching a smart cap to the insulin pen of individuals with type 1 diabetes who use flash glucose monitoring and experience a time above range (TAR \>180 mg/dL) for more than 25% of the time. This metric has been associated with diabetes-related complications, and the objective of this study is to determine whether this simple device could help reduce this underexplored parameter.
214323775|NCT02426281|DRUG|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
214323776|NCT02426281|DRUG|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
214323777|NCT04076969|BEHAVIORAL|Integrated educational session|The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
214672764|NCT05624255|OTHER|Ophthalmologic consultation|Complete ophthalmologic examination including angio-OCT
214672765|NCT06178510|DEVICE|INTELLiVENT-ASV.|INTELLiVENT-ASV® is a closed-loop ventilation mode that automatically adjusts respiratory rate and tidal volume according to the oxygen and ventilatory patient needs
214672766|NCT00676481|BEHAVIORAL|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
214672767|NCT06298773|OTHER|Spatial analysis of paraffin samples from solid tumors|The intervention involves the collection of tumour samples included in paraffin present in the pathological anatomy archive or requested to external archives for samples older than 2003 and the subsequent multiparametric spatial analysis of the main populations of the microenvironment tumor.
214672768|NCT05805371|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
215066644|NCT03319459|DRUG|Trastuzumab|HER2/neu receptor inhibitor
214672769|NCT05805371|PROCEDURE|Biopsy|Undergo tumor biopsy
214923891|NCT06049186|DRUG|Metformin|After randomization, patients entering the metformin group will be given 1500 mg daily (bid/tid) metformin and regular diets as control. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.
214923892|NCT00926848|BEHAVIORAL|Partners Together in Health (PaTH) Intervention|Patients and partners in the PaTH experimental group participated in 18-36 exercise and 18 educational sessions in a structured cardiac rehabilitation program. Patients in the Usual care group also participated in 18-36 exercise and 18 educational sessions; partners, however, only participated in the educational sessions.
214923893|NCT02650258|BEHAVIORAL|treadmill walking|all participants walking at increasing speeds on a treadmill
214923894|NCT00714857|DRUG|Dexmedetomidine|The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
214923895|NCT01694290|OTHER|Chemical Cold Pack|
214923896|NCT01167881|DRUG|BI 10773|Medium dose once daily
215066645|NCT05595265|DIAGNOSTIC_TEST|immunohistochemical|Immunohistochemical Evaluation: Corresponding sections of 4µm thickness from each Formalin-fixed paraffin blocks will be immunohistochemically stained by anti- PD-L1 antibody according to the recommended protocol.
215066646|NCT04815512|DIAGNOSTIC_TEST|Liver function tests.|serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.
215066647|NCT04815512|DIAGNOSTIC_TEST|kidney function tests|creatinine , urea and serum uric acid will be analysed in the serum.
214672770|NCT05805371|PROCEDURE|Biospecimen Collection|Undergo blood, stool, and urine sample collection
214672771|NCT05805371|PROCEDURE|Bone Scan|Undergo bone scan
214672772|NCT05805371|PROCEDURE|Computed Tomography|Undergo CT scan
214672773|NCT05805371|RADIATION|External Beam Radiation Therapy|Undergo radiation
214672774|NCT05805371|PROCEDURE|Leukapheresis|Undergo leukapheresis
214672775|NCT05805371|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion
214672776|NCT05595473|DRUG|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV
214923897|NCT01167881|DRUG|Glimepiride|1-4 mg once daily
214923898|NCT01167881|DRUG|Placebo|Placebo matching BI 10773
214923899|NCT01167881|DRUG|Placebo|Placebo matching Glimepiride
214923900|NCT05481385|BEHAVIORAL|Reference preparation-Reference preparation-Test Preparation|Under fed conditions, subjects randomly divided into RRT group were given one tablet of reference preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of test preparation after cleaning period.
214923901|NCT05481385|BEHAVIORAL|Reference preparation-Test Preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
214923902|NCT05481385|BEHAVIORAL|Test Preparation-Reference preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
215066648|NCT00961740|BEHAVIORAL|Cognitive Behavioural Therapy|See summary
215066649|NCT00961740|OTHER|Waitlist condition|See Summary
215066650|NCT02120300|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
215066651|NCT02120300|DRUG|SOF|400 mg tablet administered orally once daily
215066652|NCT02120300|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
215066653|NCT05770089|OTHER|Adapted Physical Activity (APA)|A 8-weeks program of APA (2x1hour per week) via videoconferencing composed of resistance training and yoga.
215066654|NCT04583215|DEVICE|Paired Associative Stimulation (PAS)|On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
214485917|NCT06852560|BEHAVIORAL|Gratitude, exercise, and mindfulness program|"Participants will be enrolled in an 8-week GEM (Gratitude, Exercise, and Mindfulness) program conducted entirely in person at Blossoming Butterfly in Gainesville, Florida. Participants will attend weekly group sessions combining gratitude journaling, mindfulness-based stress reduction/emotional freedom technique, and physical activity goal-setting. Participants will also be provided with a toolkit to support at-home practices, including gratitude journaling, physical activity tracking, and mindfulness meditation.~Blood, saliva and urine will be collected from each participant at baseline and post-intervention to measure the following allostatic load biomarkers: fasting glucose or hemoglobin A1c; lipid panel (total cholesterol, LDL, HDL); C-reactive protein; dehydroepiandrosterone sulfate; cortisol; glomerular filtration rate; and albumin-to-creatinine ratio."
214485918|NCT05570149|DRUG|Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution|migraine prophylaxis
215066655|NCT00265837|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
215066656|NCT00265837|PROCEDURE|allogeneic bone marrow transplantation|
215066657|NCT00265837|PROCEDURE|in vitro-treated bone marrow transplantation|
215066658|NCT04788485|DRUG|Diosmectite|use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
214672777|NCT05595473|DRUG|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV
215066659|NCT04601259|COMBINATION_PRODUCT|Orkla Corn Plaster with salicylic acid|Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
215066660|NCT04601259|DEVICE|Orkla Corn Protector|Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
215066661|NCT01258556|DIETARY_SUPPLEMENT|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10\*9 cfu/ml daily for 30 days.
215066662|NCT01258556|DIETARY_SUPPLEMENT|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
215066663|NCT04811755|BEHAVIORAL|Surgical timing from ED admission to surgery|the impact of delay of time between patient admission to ED and surgery for source control on 90-d mortality and postoperative outcomes in patients with gastrointestinal perforation with or without septic shock
215066664|NCT05171374|DRUG|Dabrafenib|Observational stusy. No intervention is planned
215066665|NCT05171374|DRUG|Trametinib|Observational stusy. No intervention is planned
215066666|NCT04528550|BIOLOGICAL|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.
215066667|NCT04528550|DRUG|Placebo|Included patients will receive the same amount of saline through lumbar injection.
215066668|NCT04277481|OTHER|10 minute cold pack|10 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
215066669|NCT04277481|OTHER|12 minute cold pack|12 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
215066670|NCT04277481|OTHER|15 minute cold pack|15, min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
214323778|NCT04347395|PROCEDURE|Respiratory Bundle & Prevention|The respiratory care bundle intervention comprised of: bed tilt, swallow screen, mouth wash and vaccinations. The bed tilt was a 30-degree whole bed-up positioning both day and night throughout the hospital stay and is shown in Figure 1. Swallow screen was undertaken within 48 hours of admission. Chlorhexidine mouth wash was prescribed initially four times daily. The protocol was amended to twice daily chlorhexidine mouth wash in August 2017 due to poor compliance with four times daily administration. Mouthwash administration was monitored in the intervention group only and deemed non-compliant if missed more than 3 times during the admission. Pneumococcal and influenza vaccination was offered at discharge or within 2-4 weeks post discharge, at no charge to the patient. Post discharge advice was to use pillows in bed to minimize the time the patient laid flat and to avoid lying down for an hour after meals.
214323779|NCT04262466|DRUG|Brenetafusp|Brenetafusp IV infusions
215066671|NCT04277481|OTHER|20 minute cold pack|20 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
215066672|NCT03981107|OTHER|Chest Compression Only CPR (CO-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions only~The instructions from the dispatcher in interventional arm include:~* An ambulance is dispatched and is on it´s way to you~* Do CPR with chest compressions only~* Push hard on the chest with a pace of 100/minute without interruptions for rescue breathing."
215066673|NCT03981107|OTHER|Standard CPR (S-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions and rescue breaths in a ration of 30:2~The Instructions from the dispatcher in the control arm include:~* An ambulance is dispatched and is on it´s way to you~* Do CPR with chest compressions and rescue breathing~* Push hard on the chest 30 times and give 2 rescue breaths. The pace of the compressions should be 100/minute."
215066674|NCT02283905|DRUG|amphotericin-B|continuously infused
214323780|NCT04262466|DRUG|Brenetafusp and pembrolizumab|Brenetafusp and pembrolizumab IV infusions
215066675|NCT02283905|DRUG|voriconazole|intravenously or orally administered
215066676|NCT05094063|OTHER|patient education by mobile application|Training will be given to the patients in the experimental group.
215066677|NCT06479291|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
215066678|NCT06479291|DRUG|Eltrombopag|Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
215066679|NCT02053922|DRUG|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
215066680|NCT02053922|DRUG|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . \[Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada\] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
215066681|NCT02053922|DRUG|Misoprostol|Misoprostol (200 mcg Tablet) \[Misotac, Sigma Pharmaceutical Industries, SAE, Egypt\] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
215066682|NCT03709069|DIETARY_SUPPLEMENT|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
215066683|NCT04887168|BEHAVIORAL|Survive & Thrive|Psychoeducational Intervention: Survive \& Thrive (Ferguson, 2008; Mahoney et al, 2018). A total of 10 manualised sessions of approximately 1.5 hour duration are offered. Individual sessions run using an educational format and in an informal setting, with a strong emphasis on avoiding individual disclosures. Groups will be delivered utilising a multi-disciplinary work force consisting of mental health staff in a ratio of 2 per group. Groups will consist of a maximum of 8-10 participants
215066684|NCT05803161|DRUG|Congrong Runtong oral liquid|"Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola"
215066685|NCT05803161|DRUG|Placental Congrong Runtong oral liquid|Placental Congrong Runtong oral liquid
215066686|NCT02018523|DRUG|Lenalidomide|lenalidomide 10mg/day orally until disease progression
215066687|NCT01308255|DRUG|Infliximab|"Prior to week 26~* Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~* Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~* Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity"
215066688|NCT01308255|DRUG|Methylprednisolone|Steroid
214323781|NCT04262466|DRUG|Brenetafusp and chemotherapy|Brenetafusp and chemotherapy IV infusions
214323782|NCT04262466|DRUG|Brenetafusp and monoclonal antibodies and chemotherapy|Brenetafusp and a monoclonal antibody therapy and chemotherapy
214323783|NCT04262466|DRUG|Brenetafusp and tebentafusp|Brenetafusp and tebentafusp IV infusions
214323784|NCT04262466|DRUG|Brenetafusp and bevacizumab|Brenetafusp and bevacizumab IV infusions
214323785|NCT04262466|DRUG|Brenetafusp and kinase inhibitors|Brenetafusp and oral kinase inhibitors
214323786|NCT00419562|DRUG|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
214323787|NCT00419562|DRUG|Placebo|Placebo capsule designed to match active drug
214323788|NCT04447716|DRUG|Venetoclax|Given PO
215066689|NCT01308255|DRUG|Methotrexate|All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
215066690|NCT01308255|DIETARY_SUPPLEMENT|Folic acid|All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
215066691|NCT03528876|DRUG|FOLFOX and FOLFIRI|a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
214323789|NCT04447716|DRUG|Lenalidomide|Given PO
214323790|NCT04447716|BIOLOGICAL|Rituximab|Given IV
215066692|NCT03614741|DRUG|Tinzaparin continuous infusion|4500 IU continuous infusion of Tinzaparin
214672778|NCT05595473|DRUG|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV
214323791|NCT04447716|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
214323792|NCT01621399|DRUG|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
214323793|NCT01621399|DRUG|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
214323794|NCT03854916|OTHER|Caminemos Juntas App|A tailored mobile app that encourages Latinas and Hispanic women to walk together using location-based services.
214923903|NCT06618690|OTHER|Exercise program|"A supervised training plan will be carried out for 12 weeks with a frequency of 3 sessions per week with a duration of 60 minutes, an ideal estimate according to the meta-analysis of Montaño-Rojas et al. The first two weeks the group exercises will be performed to familiarize the participants with the exercises and then each participant will perform them at home with a review every two weeks to assess the increase of the load.~The exercises and loads included in this treatment plan have been designed and modified based on previous clinical trials. The training plan will work upper limbs, lower limbs and trunk. All sessions begin with a general warm-up, which will be previously instructed to the participants, in which the heart rate will be increased (see Multimedia Appendix 1). After a two-minute break, the specific block of each session will begin (see Table 1 and Multimedia Appendix 1). All exercises will be performed with dumbbells, elastic bands and a ball."
214923904|NCT03606304|BEHAVIORAL|Problem-solving therapy|See previous
214923905|NCT04751955|DRUG|Olinvacimab added to Capecitabine|Olinvacimab: IV weekly administration In phase lb, 12mg/kg and 16mg/kg weekly IV will be tested. In phase ll, the RP2D in phase lb will be used. Capecitabine: fixed dose as an oral administration, 1250mg/m2 BID on day 1 to 14 followed by 7 days off
214323795|NCT03854916|OTHER|World Walking App|A mobile app that encourages users to walk.
214323796|NCT06424054|OTHER|eChemoCoach|the eChemoCoach is an electronic questionnaire which is accessible for patients via the secured electronic health portal (EHP) of the EHR, which is CE-certified. By utilizing the eChemoCoach, patients (for this project we focus on breast cancer patients) have the ability to complete a questionnaire on a daily basis, when experiencing side effects. The eChemoCoach has the potential to evaluate the severity of adverse effects based on the CTCAE criteria and triage them, mimicking the decision-making process of a HCP through computer adaptive testing (CAT). Upon completing the questionnaire, the eChemoCoach translates the responses for each specific side effect into corresponding CTCAE grades. The tool then promptly offers patients personalized advice, tailored to their individual condition.
214323797|NCT05194020|OTHER|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
215066693|NCT03614741|DRUG|Tinzaparin bolus|4500 IU bolus of Tinzaparin
215066694|NCT05302973|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
214323798|NCT01276314|DRUG|anti- TNF-a|25mg BIW, SC
214323799|NCT01276314|DRUG|Prednisolone|1-1.5 mg / kg / day
214323800|NCT01332734|DRUG|Magnesium Sulfate|2 gram in 1 hour
214323801|NCT01446562|BIOLOGICAL|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
214323802|NCT04261270|DRUG|ASC09F+Oseltamivir|ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
215066695|NCT05302973|OTHER|Aerobic exercise|30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
215066696|NCT00361231|DRUG|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
215066697|NCT00361231|DRUG|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
215066698|NCT00361231|DRUG|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
215066699|NCT03158740|BEHAVIORAL|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
215066700|NCT03158740|BEHAVIORAL|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
215066701|NCT01582516|BIOLOGICAL|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
215066702|NCT02387333|PROCEDURE|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin."
215066703|NCT02387333|PROCEDURE|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
214485919|NCT06655688|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
214485920|NCT06651580|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, urine or stool samples
215066704|NCT01208961|DRUG|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
215066705|NCT01208961|DRUG|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
214485921|NCT06651580|OTHER|Quality-of-Life Assessment|Complete QoL assessment
215066706|NCT02185560|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
215066707|NCT04616326|DRUG|Galcanezumab|Administered SQ
215066708|NCT04616326|DRUG|Placebo|Administered SQ
215066709|NCT06967337|BEHAVIORAL|Microsteps|Microsteps (behavioral nudges) are a series of short, written messages that were developed by the Thrive Global Wellbeing and Behavior Change Platform, based in the US. The Microsteps messages deliver step-wise, small health behavioral nudges that align with research on behavior change strategies. The behavioral nudges focus on health behaviors that could be useful adjunct interventions for GLP-1RA users, (improved food choices, exercise, sleep and stress management).
214485922|NCT06651580|OTHER|Questionnaire Administration|Complete questionnaire
215066710|NCT06967337|BEHAVIORAL|Storytelling video|The storytelling video is a short, 2D animated, wordless storytelling video, of 2:21 minutes duration. The humorous, animated story features a minion-like character who, with the help of their dog, learns to adopt better health behaviors after experiencing an episode of burnout. The video mirrors the written Microsteps messages, conveying them through comical demonstration, rather than through instructional language. The animated characters are free of cultural identifiers, with the intention of increasing the accessibility of the video by overcoming barriers associated with culture, education, language and literacy. The video is intended to underscore and complement the written Microsteps messages, enhance their durability and boost hope and happiness in viewers.
215066711|NCT06967337|BEHAVIORAL|Instructional Video|The Instructional Video is a short 2:27min video demonstrating the microsteps and presenting additional information about the rationale for adopting them. The video features an educator who explains these points in a didactic format, and a second educator who demonstrates performing a microstep (stretching at a desk).
215066712|NCT05817422|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
214323803|NCT04261270|DRUG|Ritonavir+Oseltamivir|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
214323804|NCT04261270|DRUG|Oseltamivir|75mg ,once a day
214923906|NCT01435460|DRUG|Loteprednol etabonate 0.2%|1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.
214923907|NCT01435460|DRUG|Olopatadine 0.1%|1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.
214923908|NCT01139957|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
214923909|NCT01139957|OTHER|Quality-of-Life Assessment|Ancillary studies
214923910|NCT01139957|OTHER|Questionnaire Administration|Ancillary studies
214923911|NCT01139957|PROCEDURE|Study of High Risk Factors|Ancillary studies
214923912|NCT01706939|RADIATION|Reduced Dose Radiation|Reduced Dose Radiation (5600 cGy) dose radiotherapy
214923913|NCT01706939|RADIATION|Standard Dose Radiation|Standard Dose Radiation (7000 cGy) dose radiotherapy
214923914|NCT01706939|DRUG|Carboplatin|Day 1, every 7 days ( + 2 days)
214923915|NCT00853645|DEVICE|Subcutaneous Implantable Defibrillator (S-ICD) System|
214923916|NCT05346081|DEVICE|Electrical impedance tomography|Electrical impedance tomography (EIT) is a potential alternative non-invasive diagnostic screening measure to spirometry.
214923917|NCT04047836|OTHER|Low Nicotine E-Liquid|Participants will vape e-liquid with nicotine concentration of 3 mg/ml.
214923918|NCT04047836|OTHER|Medium or High Nicotine E-Liquid|Participants will vape either e-liquid with nicotine concentration of 18 mg/ml or a JUUL device with JUUL pod of 59 mg/ml nicotine e-liquid.
214923919|NCT03300349|OTHER|Fulfillment of a preventive programme|Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
214923920|NCT03300349|OTHER|No fulfillment of a preventive programme|No fulfillment of the preventive programme: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
215066713|NCT05817422|OTHER|Placebo|0.9% NaCl solution for injection.
214923921|NCT05910138|DIAGNOSTIC_TEST|Serum Interlukin-15|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
214323805|NCT04709965|DIAGNOSTIC_TEST|Face2Gene|This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.
214323806|NCT01959646|DIETARY_SUPPLEMENT|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
214485923|NCT05088356|DRUG|Purified regulatory T-cells (Treg) plus CD34+ HSPC|"Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells (CD34+ HSPC), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10\^6 cells/ kg to 3x10\^6 cells/kg"
214485924|NCT05088356|DRUG|Fludarabine|Fludarabine (160 mg/m2)
214485925|NCT05088356|DRUG|Melphalan|Melphalan (50 mg/m2)
214485926|NCT05088356|DEVICE|CliniMACS CD34 Reagent System|The CliniMACS® CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations is manufactured by Miltenyi Biotec
214485927|NCT05088356|DRUG|Tacrolimus|4-6ng/mL
214323807|NCT01959646|OTHER|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
215066714|NCT00983333|DEVICE|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
215066715|NCT01258790|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
215066716|NCT01258790|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
215066717|NCT01943058|DRUG|megestrol acetate|Given PO
214672779|NCT05595473|DRUG|RZ-001 Dose 4|RZ-001 Dose 4 and VGCV
214923922|NCT05910138|DIAGNOSTIC_TEST|Serum Interlukin-21|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
214923923|NCT02404636|OTHER|Interview|Brief structured interview
214923924|NCT01826578|PROCEDURE|using only one port for laparoscopic surgery|using only one port for laparoscopic surgery
214923925|NCT00098137|DRUG|Olmesartan|
214923926|NCT02131285|OTHER|Sensory training|
214923927|NCT02868190|DEVICE|Two trabecular micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
214923928|NCT02329379|DRUG|Levothyroxine|
214923929|NCT01014364|DRUG|hydrocortisone|50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
214923930|NCT01014364|DRUG|isotonic saline|intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
214923931|NCT03621306|DEVICE|DXA and pQCT precision testing|The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
214923932|NCT01130259|DRUG|iniparib|5.6 mg/kg as a 60 (±10) minutes IV infusion. Administered on Days 1, 4, 8, and 11 of each 21 day cycle.
214923933|NCT02674958|DRUG|Aspirin|Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
214923934|NCT05893251|OTHER|Manual therapy|"Within the manual therapy protocol carried out in the experimental group, we performed a series of passive maneuvers. The patient remains in supine position on a treatment table throughout the treatment, while the therapist sits at the head of the patient on a stool. The sequence of application is as follows:~Suboccipital inhibition technique Cervical spinal mobilization Posterior fascia stretching"
214923935|NCT05893251|OTHER|Postural exercises|The treatment plan includes active postural exercises for the cervical spine.
214923936|NCT03163498|OTHER|No intervantion. It´s a Cross-Sectional Study|No intervential
214923937|NCT04644705|DRUG|Niclosamide|Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat
215066718|NCT01943058|DEVICE|levonorgestrel-releasing intrauterine system|Given IUD
214323808|NCT01959646|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
215066719|NCT01943058|OTHER|laboratory biomarker analysis|Correlative studies
215066720|NCT01943058|OTHER|questionnaire administration|Ancillary studies
214923938|NCT04644705|DRUG|Placebo|placebo to the interventional drug
214923939|NCT01981941|DRUG|Gabapentin enacarbil|Oral
214323809|NCT03613207|OTHER|Dermal pharmacokinetic measurement|"* Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~* Each test site receives 2 dOFM probes~* Dosing:~  * 2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~ * 2 test sites: untreated test site~* ISF sampling: 24 hours post-dose~* Blood sampling: 7 samples post-dose"
214323810|NCT03613207|DRUG|Lidocaine and prilocaine cream|lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
214323811|NCT03613207|DRUG|Oraqix® gel|Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
214923940|NCT04839523|DEVICE|Exufiber|A sterile nonwoven wound dressing made from highly absorbent PVA fibers.
214923941|NCT04839523|DEVICE|Exufiber Ag+|A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.
215066721|NCT02241733|BEHAVIORAL|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
215066722|NCT02241733|BEHAVIORAL|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
215066723|NCT01908491|DEVICE|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
215066724|NCT01908491|DEVICE|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15\~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
214323812|NCT03613207|DEVICE|dOFM-System|Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
215066725|NCT06094244|DRUG|Atorvastatin|Doses of atorvastatin of up to 20 mg/d.
215066726|NCT06094244|DRUG|Rosuvastatin|Doses of rosuvastatin of up to 10 mg/d.
215066727|NCT06094244|OTHER|No drugs|No drugs
214923942|NCT04880707|DRUG|Twin block local anesthetic nerve block using standard dental anesthetic|2% lidocaine with 1:100,000 epinephrine is the standard dental local anesthetic in universal use. This drug will be administered as the Twin block local anesthetic nerve block targeting the branches of the mandibular nerve supplying the temporalis and masseter muscles.
214923943|NCT04880707|OTHER|Twin block with placebo|Instead of the standard dental anesthetic, sterile normal saline will be delivered using the Twin block injection
215066728|NCT06137430|DRUG|Sodium-glucose cotransporter 2 inhibitor|Sodium glucose cotransporter 2 inhibitiors
215066729|NCT01605604|BEHAVIORAL|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
214323813|NCT03613207|PROCEDURE|Blood sampling|8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
214323814|NCT04776395|DRUG|Dexamethasone|Given PO
214485928|NCT05088356|DRUG|Cyclophosphamide|40mg/kg
214485929|NCT05088356|DRUG|Plerixafor|Dose 0.24 mg/kg, manufactured by Genzyme
214485930|NCT05088356|DRUG|Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent|Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL
214485931|NCT05088356|DRUG|Thiotepa|Thiotepa 10 mg/kg
214485932|NCT05088356|DRUG|Mycophenolate Mofetil (MMF)|MMF 1000 mg BID
214323815|NCT04776395|DRUG|Iberdomide Hydrochloride|Given PO
214323816|NCT04776395|OTHER|Quality-of-Life Assessment|Ancillary studies
215066730|NCT02285023|OTHER|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
215066731|NCT06078371|OTHER|Opioid-free pain treatment|Pain treatment includes any medications up to the medical team's discretion aside from opioids.
215066732|NCT06971978|OTHER|Online decision support platform to support evidence-based heat health risk assessment and extreme heat event preparedness planning|The intervention group will receive facilitated engagement with Chart. Chart is an online decision support platform designed to support evidence-based risk assessment and planning for extreme heat risk mitigation. Chart has a risk assessment platform that provides estimates of heat-health risks at a census tract level under various hazard conditions. It also has a decision support platform that links drivers of risk in a given location with information about potential risk reduction activities and includes information useful to policymakers regarding intervention efficacy, timing, and cost. Facilitated engagement includes an initial introduction to the platform, real-time questions and answers, and focused discussion regarding priority interventions and planning and implementation needs. This engagement comprises about five hours of time that can be provided over the course of a couple weeks or several months, depending on the needs of the health department.
214323817|NCT05057416|BEHAVIORAL|Exercise Adherence|Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.
214323818|NCT04717128|OTHER|Breastfeeding Skills Workshop|Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
214323819|NCT02267629|DRUG|Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13)
214323820|NCT05883982|PROCEDURE|I-PRF injection|Intra-articular I-PRF injection to temporomandibular joint cavity
214323821|NCT05836610|DRUG|Hydrocortisone|intravenous bolus hydrocortisone therapy during hypothermia treatment
214323822|NCT04237077|OTHER|telephone coaching program|telephone coaching program : 7 phone calls by nurse
214485933|NCT05088356|DRUG|Ruxolitinib|Ruxolitinib 5 mg BID
214923944|NCT06667778|DEVICE|Osseodesification densah burs|"Drill no. VT1525 (2mm) of densah burs will be used first in counter clockwise (in the osteotomy site).~Then drill no. VT2535 (3mm) of densah burs will be used in counter clockwise to put 3.5mm implant diameter."
214323823|NCT04237077|OTHER|no telephone coaching program|no telephone coaching program : 7 phone calls by nurse
214923945|NCT06667778|DEVICE|Microdent|"No. 1 Microdent expander will be placed and screwed slowely (to avoid heat generation) into the osteotomy site till reaching the full desired length.~N0. 2 microdent expander will be placed and screwed into the osteotomy site as the same step.~Then no. 3 Microdent expander will be inserted for placing 3.5mm implant diameter"
214923946|NCT06299878|DIAGNOSTIC_TEST|Gut microbiota analysis|Patients with resectable stage IIIB-D melanoma will have a lymph node core biopsy to confirm metastatic lesions, following standard procedures. Additionally, a portion of the tumor tissue will be preserved for biomarker analysis. Participants will then be instructed to submit fecal samples and complete a dietary questionnaire before receiving three doses of PD1 monotherapy, in accordance with the center\&#39;s routine practice, typically spanning 6-10 weeks. Between weeks 10 and 12, a radiological assessment of the response will be conducted. Following this, participants will undergo regional lymphadenectomy, and the pathological response will be evaluated. After surgery, patients will be placed on adjuvant therapy for 12 months as per routine practice of the center . Subsequently, they will be monitored for five years, adhering to the institution\&#39;s standard follow-up protocol.
214923947|NCT02674308|DRUG|Vedolizumab|
214323824|NCT02037711|DRUG|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
214323825|NCT02037711|DRUG|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
214323826|NCT01919424|DRUG|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma"
214923948|NCT02674308|OTHER|Other Biologic Agents|Other biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab
214923949|NCT00800774|PROCEDURE|LASIK|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (\>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
214923950|NCT03847753|OTHER|Organic Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
214923951|NCT03847753|OTHER|Substance Use Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
214923952|NCT03847753|OTHER|Schizophrenia Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
214923953|NCT03847753|OTHER|Mood disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
214323827|NCT01919424|DEVICE|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
214323828|NCT01919424|DEVICE|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada"
214323829|NCT00428545|DRUG|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
214323830|NCT00428545|DRUG|Bortezomib|Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days
214323831|NCT03435549|BEHAVIORAL|Remote monitoring|Patients given an activity tracker to wear for 6 weeks after LEJR replacement surgery. For 2 weeks after surgery, they will also receive a daily text messages asking what their pain is on a scale of 0 to 10. They will be asked to reply to the text with their pain score. They will also be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days.
214323832|NCT03435549|BEHAVIORAL|Remote monitoring plus goal setting and social support|Patients given activity tracker to wear for 6 weeks after LEJR surgery. For 2 weeks after surgery, they will receive a daily text messages asking what their pain is on a scale of 0 to 10 and asked to reply by text. They will be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days. Patients will be asked to identify a a friend or family member to act as support partner. The study will share progress updates with support partner and contact this individual if patient stops wearing the activity tracker for over 3 days. This partner will also be able to provide supportive messages to help encourage them to reach their activity goals.
214323833|NCT00701129|BIOLOGICAL|Alglucosidase Alfa|Administered as IV infusion.
214323834|NCT00701129|DRUG|Methotrexate|Administered subcutaneously.
214323835|NCT00701129|DRUG|Rituximab|Administered as IV infusion.
214323836|NCT04187365|OTHER|Duration of Indwelling Catheter|Foley catheter
214323837|NCT01280188|DRUG|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
214323838|NCT01280188|DRUG|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
214323839|NCT01872572|DRUG|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
214323840|NCT01872572|DRUG|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
214323841|NCT01872572|DRUG|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
214323842|NCT01872572|DRUG|Subcutaneous RB006 2.0 mg|"* Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
214323843|NCT01872572|DRUG|Placebo|Placebo
214323844|NCT01204866|BIOLOGICAL|Valortim and selected Components|"* Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.~* Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.~* Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1~* Histamine (1 mg/mL), positive control~* Saline (0.9%), negative control"
215066733|NCT06971978|OTHER|Heat and health risk assessment and preparedness information|Study participants in the control group will be provided with a package of information supportive of heat-health vulnerability and risk assessment and planning for risk reduction activities through built environment hazard mitigation and public health programming. This package will include an annotated list of online resources, including those available on Heat.gov and the CDC website, and a selected set of review papers on heat-health vulnerability, heat-health risk assessment, heat hazard mitigation through built environment strategies, and heat action planning and preparedness.
215066734|NCT05927519|DEVICE|airtraq video laryngoscope|airtraq video laryngoscope will be used for intubations
215066735|NCT06055309|DRUG|Cannabis (up to three doses)|a dose of cannabis will be baked into brownies
215066736|NCT01866111|DRUG|YKP3089|
214323845|NCT01204866|DRUG|Valortim and Selected Components|"• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~* Only one subject will be skin tested in a single day.~* The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively"
214323846|NCT05035069|DRUG|Ciprofol|Ciprofol infusion, starting with 0.8 \~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 \~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
214485934|NCT06589674|DIAGNOSTIC_TEST|Pulse variability index measurement|Peripheral perfusion index (PI) is an easy-to-implement and low-cost monitoring procedure obtained by interpreting non-invasive data obtained from pulse oximetry via plethysmography. It is a tool that allows interpretation of fluid status through changes in pulse oximetry waves caused by respiration. High perfusion indices are interpreted as low arterial tone. Changes in perfusion index are interpreted as indicators of vascular tone or fluid deficit problems in patients. The ratio of the highest and lowest PI values gives the Pleth Variability Index (PVI) (3,4). Hypotension can be predicted during anesthesia induction with PVI
214923954|NCT03847753|OTHER|Neurotic disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
214923955|NCT03847753|OTHER|Eating Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
214923956|NCT03847753|OTHER|Personality Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
214923957|NCT03847753|OTHER|Intellectual Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
215066737|NCT01866111|DRUG|Placebo|
215066738|NCT05079347|DIAGNOSTIC_TEST|HIV rapid test|Using a rapid test to assess a patient's HIV status
215066739|NCT05278000|OTHER|Presence of scarcity mindset|"This observational study will examine whether~1. Individuals exhibiting a scarcity mindset have lower adherence to asthma controller medication~2. Individuals with higher rates of future discounting have lower adherence to controller medication~3. Individuals with unmet social needs are more likely to experience scarcity and have higher rates of future discounting, and whether these relationships mediate adherence to asthma controller medication"
215066740|NCT05360160|DRUG|SNDX-5613|Given by PO
215066741|NCT05360160|DRUG|Venetoclax|Given by PO
215066742|NCT05360160|DRUG|ASTX727|Given by PO
215066743|NCT06573437|DEVICE|Vascular Stent - Vesto Endoprosthesis|Vascular Stent Implant - Vesto Endoprosthesis
215066744|NCT06414460|DRUG|ISM3412|ISM3412 will be administered orally once daily.
215066745|NCT05692518|DEVICE|MAGNET System, DI Bio-fragmentable|Anastomoses achieved by magnetic compression.
215066746|NCT03865589|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound shear wave elastography
215066747|NCT06081179|DRUG|Psilocybin|Single dose of psilocybin (15mg), orally in form of capsules
215066748|NCT06081179|DRUG|3,4 Methylenedioxymethamphetamine|Single dose of MDMA (100mg), orally in form of capsules
215066749|NCT06081179|DRUG|Methylphenidate|Single dose of methylphenidate (60mg), orally in form of capsules
215066750|NCT04075591|DEVICE|iDesign Refractive Studio with STAR S4 IR® Excimer laser System|Surgeons will perform wavefront-guided monovision LASIK for the treatment of myopic subjects with presbyopia based upon measurements obtained with an iDesign Refractive Studio.
215066751|NCT04017650|BIOLOGICAL|Cetuximab|Given IV
214672780|NCT03121742|BEHAVIORAL|Ecological Momentary Intervention|Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
214923958|NCT03847753|OTHER|Developmental Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
214923959|NCT03847753|OTHER|Behavioral Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
215066752|NCT04017650|DRUG|Encorafenib|Given PO
215066753|NCT04017650|BIOLOGICAL|Nivolumab|Given IV
215066754|NCT04255849|BIOLOGICAL|9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|Gardasil-9 HPV vaccine
215066755|NCT04255849|OTHER|Saline Placebo|Saline Placebo
214323847|NCT05035069|DRUG|Propofol|Propofol infusion, starting with 4 \~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 \~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
214323848|NCT06364124|DRUG|evolocumab|Preoperative subcutaneous injection of Evolocumab (420mg)，Atorvastatin 40mg per day
214323849|NCT06364124|PROCEDURE|standard post-treatment for STEMI|standard post-treatment for STEMI
214323850|NCT04276350|PROCEDURE|Acupuncture|Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
214323851|NCT04276350|PROCEDURE|Best Medical Therapy|Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
214323852|NCT00222495|DRUG|quetiapine|
214323853|NCT00222495|DRUG|olanzapine|
214323854|NCT00222495|DRUG|risperidone|
214323855|NCT04138927|DRUG|Fostamatinib disodium|Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
214323856|NCT01363778|DRUG|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
214323857|NCT05814120|BEHAVIORAL|BLS training program|BLS training program was in accordance with the 2020 AHA cardiopulmonary resuscitation (CPR) guidelines. The BLS training program adopts 4D teaching techniques, namely description (Describe), demonstration (Demo), implementation (Do), feedback (Debriefing).
214323858|NCT01800292|DRUG|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
214323859|NCT02093637|OTHER|Placebo acupuncture|Placebo Comparator
214323860|NCT02093637|OTHER|Battlefield Acupuncture|Experimental
214323861|NCT04708197|DEVICE|rTMS (repetitive transcranial magnetic stimulation )|applying high frequency TMS over the damaged hemisphere in chronic post stroke aphasic patients
214323862|NCT04948138|DIETARY_SUPPLEMENT|Glutamine oral supplementation|Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
214323863|NCT04027218|DEVICE|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
214323864|NCT04027218|DEVICE|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
214323865|NCT04027218|DEVICE|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
214323866|NCT05305599|DRUG|ZED1227|ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
214323867|NCT05305599|DRUG|Placebo|Placebo
214323868|NCT04577326|DRUG|cyclophosphamide|A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m\^2 will be administered 2-7 days before the infusion.
215066756|NCT03450343|DRUG|Oral azacitidine|Azacitidine can be taken with or without food at the same time every day.
215066757|NCT03450343|DRUG|R-ICE|R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
215066758|NCT05083884|OTHER|No Intervention|This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
215066759|NCT04576455|DRUG|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day cycle.
215066760|NCT04576455|DRUG|Fulvestrant or an Aromatase Inhibitor (Physician Choice)|Physician choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.
215066761|NCT04576455|DRUG|LHRH Agonist|Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
215066762|NCT05372978|BEHAVIORAL|Cash transfer|Participants will receive a one-time unconditional cash transfer of $8,500.
215066763|NCT02191657|DRUG|Deferiprone|Oral iron chelator
215066764|NCT01179269|DRUG|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
215066765|NCT02224443|DRUG|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
215066766|NCT02224443|DRUG|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
215066767|NCT02224443|DRUG|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
215066768|NCT02224443|DRUG|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
214323869|NCT04577326|BIOLOGICAL|CAR T cells|A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. Cohorts of 3 patients will be treated at each dose level, up to a maximum of 3 x 10\^7 T cells/kg or until the MTD has been reached.
215066769|NCT02224443|DRUG|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
215066770|NCT03144128|DIETARY_SUPPLEMENT|Vitamin D|5,000IU vitamin D given daily for 12 weeks
215066771|NCT03144128|DIETARY_SUPPLEMENT|Placebo|Placebo capsules given daily for 12 weeks
215066772|NCT01373255|PROCEDURE|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
215066773|NCT02689414|PROCEDURE|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
214323870|NCT05130411|DIETARY_SUPPLEMENT|DLM - Test product|The group will receive 60 gummies each (to take two gummies per day) across a four-week period. Each participant shall take two gummies per day
214323871|NCT03004534|DRUG|darolutamide|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
214323872|NCT00006475|DRUG|imatinib mesylate|
214323873|NCT00343317|DRUG|Intrapartum Cefoxitin (2g) vs. placebo|
215066774|NCT02689414|PROCEDURE|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
215066775|NCT03989349|DRUG|Placebo|Placebo
215066776|NCT03989349|DRUG|Nemolizumab|Nemolizumab
215066777|NCT01266252|DRUG|Dexmedetomidine|"Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
215066778|NCT01127672|BIOLOGICAL|platelet rich plasma|"30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
214923960|NCT05454761|BEHAVIORAL|Group-based Lifestyle Medicine Program|Participants will receive four core modules that focus on lifestyle modifications. Core Module 1 will be Diets and Nutrition. This module aims to provide simple and evidence-based information regarding nutrition for improving and maintaining mental health. Core Module 2 will be Physical Activity. Participants will practice various types of gentle and adaptable exercises during the session and learn simple ways to incorporate exercise into their daily lives. Core Module 3 will be Sleep Management. This module will include basic facts about sleep, with a focus on psychoeducation on insomnia and how the relationship between circadian and social rhythms relate to sleep and mental health. Core Module 4 will be Stress Management. This module will include psychoeducation about stress, worry management, the cultivation of positive psychology, and relaxation techniques such as diaphragmatic breathing and progressive muscle relaxation.
215066779|NCT01127672|DRUG|corticosteroid injection|"Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
215066780|NCT04469387|PROCEDURE|Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis|In terms of limited decompression at the adjacent segment, partial laminotomy, flavectomy, and bilateral medial facetectomies up to the pedicle will be performed. Complete laminectomy and destroy of posterior ligament complex will be avoided.
214672781|NCT03121742|BEHAVIORAL|Treatment as Usual|Standard care as part of inpatient hospitalization.
215066781|NCT04469387|PROCEDURE|Responsible segments fused|In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
215066782|NCT03252041|DEVICE|MRI|Magnetic Resonance imaging modalities and sequences in pelvic congestion syndrome
215066783|NCT03312790|DEVICE|Tasks|Augmented reality device Real condition
215066784|NCT01352221|DRUG|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
215066785|NCT01352221|DRUG|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
215066786|NCT03869567|DEVICE|cone beam CT|Just after thrombectomy, a cone beam CT will be done, while patient is on angiography table, in order to determine if hemorrhage image is due to contrast accumulation or blood-brain barrier disruption.
215066787|NCT02016716|DRUG|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
215066788|NCT02016716|DRUG|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
215066789|NCT02016716|DRUG|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
215066790|NCT02016716|DRUG|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
215066791|NCT05118165|DIETARY_SUPPLEMENT|Dietary supplement with protein|Will be included protein supplements in the preoperative diet.
215066792|NCT02248649|BEHAVIORAL|Structured physical activity|Walking instruction and encouragement
215066793|NCT02248649|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
214323874|NCT04871919|DRUG|Filgotinib|Tablets are administered in accordance with the product label
214672782|NCT01958606|OTHER|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
214672783|NCT01958606|OTHER|Traditional Aerobic Training|Moderate intensity continuous aerobic exercise on a treadmill
214672784|NCT04367701|DIAGNOSTIC_TEST|Hemolysis|Authors measured free plasma hemoglobin concentration in gram
214672785|NCT01940094|DRUG|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
214672786|NCT01940094|DRUG|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
214923961|NCT02275260|DEVICE|Cerebral Diffusion-Weighted Magnetic Resonance Imaging|Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)
215066794|NCT00248911|BEHAVIORAL|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
215066795|NCT01912443|DRUG|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
215066796|NCT05851534|BEHAVIORAL|Preoperative optimisation program|Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
215066797|NCT01505036|OTHER|SMARTCARE service|U-Healthcare service
215066798|NCT01749657|DEVICE|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
215066799|NCT05803863|DRUG|Myatro|myopia control with 0.01% atropine drops
215066800|NCT05803863|DRUG|Myatro XL|myopia control with 0.05% atropine drops
215066801|NCT01439971|BIOLOGICAL|PF-05280602|0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
215066802|NCT01439971|BIOLOGICAL|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
215066803|NCT01439971|BIOLOGICAL|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
215066804|NCT01439971|BIOLOGICAL|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
215066805|NCT01439971|BIOLOGICAL|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
215066806|NCT02533986|DIETARY_SUPPLEMENT|Berry peel drink|
215066807|NCT02533986|DIETARY_SUPPLEMENT|Control drink|
215066808|NCT01037725|DRUG|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
215066809|NCT01037725|DRUG|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
215066810|NCT00722722|DRUG|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
215066811|NCT02674919|OTHER|Nordic Hamstring|
214672787|NCT01496573|OTHER|laboratory biomarker analysis|Correlative studies
214923962|NCT02275260|DEVICE|Transesophageal Echocardiography|Patients undergo a Transesophageal Echocardiography prior to the ablation itself
214923963|NCT02275260|OTHER|Paperbased neurocognitive testing|To assess the impact of PVI on the patient's neurocognitive status
215066812|NCT02674919|OTHER|Control|
214672788|NCT01842893|DRUG|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
214923964|NCT03925233|DRUG|Trastuzumab|Trastuzumab Injection
214923965|NCT03925233|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride Injection
214923966|NCT03925233|DRUG|Epirubicin hydrochloride|Epirubicin hydrochloride injection
214923967|NCT03925233|DRUG|Fluorouracil|Fluorouracil injection
214923968|NCT03925233|DRUG|Paclitaxel|Paclitaxel injection
214923969|NCT03925233|DRUG|Gemcitabine|Gemcitabine injection
214923970|NCT03925233|DRUG|Cisplatin|Cisplatin injection
214923971|NCT03925233|DRUG|Recombinant Human Endostatin|Recombinant Human Endostatin Injection
214923972|NCT03925233|DRUG|Pirarubicin hydrochloride|Pirarubicin hydrochloride injection
214923973|NCT03925233|DRUG|Pyrrolidine|Pyrrolidine tablets
214923974|NCT03925233|DRUG|Ixabepilone|Ixapilone Injection
214923975|NCT03925233|DRUG|Tamoxifen citrate|Tamoxifen citrate tablets
214923976|NCT03925233|DRUG|Vinorelbine tartrate|Vinorelbine tartrate injection
214923977|NCT03925233|DRUG|Carboplatin|Carboplatin injection
214923978|NCT03925233|DRUG|Methotrexate|Methotrexate injection
215066813|NCT06166342|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
214323875|NCT06460727|OTHER|task oriented exercise training on dynamic surface|Following exercises will be performed in this group: Make the child bounce on swiss ball, reaching the toy with both hand kept over the head on platform swing, high sitting on swiss ball throwing ball with both hands, reaching the toy with one hand shifting the wait towards reaching side.
214323876|NCT06460727|OTHER|task oriented exercise training on static surface|The children in this group will receive following TOET: Sit to stand from various cjair heights , standing and reaching indifferent directions for an object, Stepping forwards, backwards, and sideways onto blocks of various heights, walking forward , backward and sideways, Walking up and down stairs
214923979|NCT03925233|DRUG|Eribulin mesylate|Eribulin mesylate injection
214923980|NCT03925233|DRUG|Toremifene citrate|Toremifene citrate tablets
214923981|NCT03925233|DRUG|Anastrozole|Anastrozole tablets
214923982|NCT03925233|DRUG|Letrozole|Letrozole tablets
215066814|NCT06166342|DIETARY_SUPPLEMENT|TCI153 probiotic sachet|Consume 1 sachet daily
215066815|NCT02628600|DRUG|LAI 590 mg|LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes
214323877|NCT05818371|DIAGNOSTIC_TEST|Sonographic determination of the optic nerve sheath diameter|Ultrasound-based determination of the optic nerve sheath diameter
214672789|NCT00510588|OTHER|training|regular physical exercise training for 6 months
214672790|NCT00510588|OTHER|training + metformin|regular physical exercise training in combination with metformin for 6 months
214672791|NCT00510588|OTHER|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
214672792|NCT01651130|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
214923983|NCT03925233|DRUG|Exemestane|Exemestane tablets
214923984|NCT03925233|DRUG|Fulvestrant|Fulvestrant injection
214923985|NCT03925233|DRUG|Olaparib|Olapani pill
214923986|NCT03925233|DRUG|Bevacizumab|Bevacizumab injection
214923987|NCT03925233|DRUG|Apatinib mesylate|Apatinib mesylate tablets
214923988|NCT03925233|DRUG|Pattozumab|Pattozumab injection
214923989|NCT03925233|DRUG|Capecitabine|Capecitabine tablets
214923990|NCT03925233|DRUG|Ear particles|Ear particles
214923991|NCT03925233|DRUG|Aidi Injection|Aidi Injection
214923992|NCT03925233|DRUG|Cyclophosphamide|Cyclophosphamide injection
214923993|NCT04678232|BEHAVIORAL|Positive Processes and Transition to Health (PATH)|See arm/group description for details regarding this intervention
214923994|NCT06659094|OTHER|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"Using a WeChat mini-program, we offer personalized OCD SC-ICBT remote services. Training is customized based on individual assessments, focusing on psychological education and homework to simulate CBT therapy. If a patient's YBOCS score drop from baseline isn't 25% after four therapist sessions (one week of theory, two sessions/week), they get three more weeks of online guidance.~The program includes four structured lessons over six weeks:~Lesson 1: Psychological Health Education on OCD and related disorders. Lesson 2: ERP theory, exposure item lists, and related info. Lesson 3: Daily ERP practice for about an hour, followed by two weeks of therapist guidance.~Lesson 4: Retrospection and relapse prevention."
215066816|NCT02628600|DRUG|Multi-drug regimen|Multidrug antimycobacterial regimen from study INS-212
215066817|NCT06525610|OTHER|Periprosthetic Fracture Knee Repaired CT Scans|We will be assessing the use of weight-bearing CT, specifically its imaging, with RSA-like software, for analyzing fracture healing over time for a periprosthetic distal knee fracture.
215066818|NCT06797856|DIAGNOSTIC_TEST|Refractive Error|"* Refractive error centrally (on-axis) and peripherally in both nasal and temporal visual fields~* Ocular wavefront measured centrally (on-axis) and peripherally in both nasal and temporal visual fields"
215066819|NCT01783197|DRUG|Paclitaxel|
215066820|NCT01783197|DRUG|Carboplatin|
215066821|NCT01783197|DRUG|Selumetinib|
215066822|NCT01783197|DRUG|Pemetrexed|
215066823|NCT01783197|DRUG|Cisplatin|
215066824|NCT05500573|PROCEDURE|Sperm Sorting|Selection of gender specific spermatozoa using a multilayer density gradient solution
215066825|NCT06660706|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
215066826|NCT02406573|DEVICE|Crest® Sensi-Stop™ Strips|
214923995|NCT06659094|OTHER|Cognitive Behavioral Group Therapy (CBGT)|The CBGT group will receive cognitive-behavioral group therapy for 6 weeks, twice a week, each session lasting 2 hours, at the Shanghai Mental Health Center. The CBGT program follows a structured process for treating OCD. During the prep phase, therapists assess patients for 50 minutes, collect data, and set CBGT groundwork. In Session 1, families join to understand CBGT, with goals reinforced and OCD education provided. Session 2 reviews homework and develops ERP strategies. Session 3 initiates ERP practice. Sessions 4-11 continue homework review and group ERP practice. The final session involves families in a review, discussing challenges, celebrating achievements, and focusing on relapse prevention.
215066827|NCT01892150|OTHER|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
214923996|NCT06659094|DRUG|conventional medical treatment (TAU)|Drug therapy, managed by a deputy chief psychiatrist unaware of patient groupings, utilizes China Food and Drug Administration (CFDA)-approved SSRIs for OCD. These include fluoxetine, paroxetine, sertraline, fluvoxamine, and others, with tricyclic drugs like clomipramine and SNRIs such as venlafaxine. The maximum dosage adheres to the instructions. Benzodiazepines may assist with sleep, but usage is capped at two weeks; no other psychotropics are co-administered. Common side effects comprise dry mouth, constipation, nausea, indigestion, dizziness, fatigue, and sweating. The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
214923997|NCT00004494|DRUG|vasoactive intestinal peptide|
214923998|NCT05529875|DRUG|Propofol|intravenous propofol using target-controlled infusion (TCI) devices.
214923999|NCT05529875|DRUG|sevoflurane|inhalator sevoflurane using sevoflurane vaporizer sevoflurane vaporizer.
214924000|NCT03831360|BEHAVIORAL|Yoga|Hatha yoga for depressed adolescents
214924001|NCT03831360|BEHAVIORAL|Group CBT|Group cognitive behavioral therapy for depressed adolescents
214924002|NCT06622798|OTHER|Non-interventional|Non-interventional
214924003|NCT05504798|OTHER|Selected physical therapy program|Selected physical therapy program one hour three times weekly for six successive weeks including stretching, strengthening, balance, and gait training.
214924004|NCT05504798|PROCEDURE|Interrupted serial casting|Interrupted casting for 5 days a week for six successive weeks using a dual cast which consists of a standard short leg cast and a circular cast from below the knee to above the knee.
214924005|NCT05504798|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation in form of faradic current with frequency of 50 Hz, and intensity of maximum tolerable intensity to produce a visible contraction but as tolerated by the child for ankle dorsiflexors and knee extensors muscles through cast windows over the motor points of these muscles for 30 min 3 times weekly for six successive weeks
214924006|NCT03388645|BIOLOGICAL|10^6.3 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10\^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
214924007|NCT03388645|BIOLOGICAL|10^7 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10\^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
214924008|NCT00162045|DRUG|Technetium Tc99m Sestamibi|Rest and/or stress SPECT imaging study
214924009|NCT04366297|DEVICE|Intravenous access|obtaining intravascular access using a standard intravenous cannula
214924010|NCT04366297|DEVICE|Intraosseous access|obtaining intravascular access using a ready intravenous NIO needle set
214924011|NCT00001353|DRUG|Genetically Marked Syngeneic T Lymphocytes|
214924012|NCT06015295|DIAGNOSTIC_TEST|18F-Fluciclovine (Axumin)|Given by Injection
214924013|NCT06015295|DIAGNOSTIC_TEST|Pet Scan|Scans
215066828|NCT04150237|OTHER|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
215066829|NCT06659237|DIAGNOSTIC_TEST|16s rRNA or shotgun metagenomics|16s rRNA or shotgun metagenomics on oral and fecal samples
215066830|NCT01221623|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
214323878|NCT02424240|OTHER|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 \& IGFBP-3 combination
214924014|NCT02396277|PROCEDURE|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
214924015|NCT06968000|DEVICE|EOX Anion-Enriched Hospital Room|Participants are assigned to hospital rooms equipped with an operational EOX device, which actively regenerates air and releases bioavailable anions through cold atmospheric plasma. Exposure lasts for 96 hours postoperatively. The intervention aims to enhance postoperative recovery by modulating oxidative stress, improving mitochondrial function, and promoting sleep quality.
214924016|NCT06567405|PROCEDURE|mechanical periodontal treatment|Patients will undergo subgingival scaling employing a Piezoelectric ultrasonic scaler to eliminate local factors.
215066831|NCT01221623|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
215066832|NCT06613711|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
215066833|NCT06991270|DEVICE|OMNI 3.0 Surgical System|Canaloplasty and trabeculotomy.
215066834|NCT05906134|PROCEDURE|Local intercostal nerve block|Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
214323879|NCT00934206|BEHAVIORAL|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
215066835|NCT05906134|PROCEDURE|Cryo-analgesia and intercostal nerve block|The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
215066836|NCT05906134|PROCEDURE|Serratus plane catheter blocks and intercostal nerve blocks|A total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine will be administered. A total of 20 cc of the weight-based calculation will be reserved for the serratus plane catheter. The remaining local anesthetic will be divided into two-thirds for the chest and one-third for the abdomen. Patients with serratus plane catheters will have an ongoing infusion of 0.2% ropivacaine at 8 ml per hour. The serratus plane catheters will also receive a bolus of 20 ml of 0.25% bupivacaine with epinephrine on POD #1, 2, 3, 4, and 5 by the pain service.
215066837|NCT05906134|PROCEDURE|Thoracic epidural catheter|"The pain service and thoracic surgery attending physician will assess if the patient's pain is not well-controlled using the pain modality they are randomized to. If additional pain control is needed, this will likely consist of a thoracic epidural catheter.~Any additional pain control will be added as an adjunct to the study arm and will be noted in the data set."
215066838|NCT06872489|BIOLOGICAL|SL-28.|Allogeneic, non-HLA matched, Leucocyte-Tells-based therapy
214672793|NCT03707977|DRUG|ART|ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.
214672794|NCT03707977|BIOLOGICAL|VRC01LS|Administered by intravenous (IV) infusion
214672795|NCT03707977|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
215066839|NCT07017673|DRUG|Ivonescimab|Drug: Ivonescimab Dose: 20 mg/kg Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
215066840|NCT07017673|DRUG|Carboplatin|Drug: Carboplatin Dose: AUC6 Route: IV infusion Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
215066841|NCT07017673|DRUG|Docetaxel|Drug: Docetaxel Dose: 75 mg/m\^2 Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
215066842|NCT05812924|BIOLOGICAL|Platelet-rich plasma (PRP)|0.1-0.2 mL injections of platelet-rich plasma (PRP) will be injected to the vulvovaginal area. The injections will be placed every 5mm and at an angle of 60° into the mucosa and lamina propria of the posterior wall of the vagina.
214924017|NCT06567405|DEVICE|Derma pen with topical ascorbic Acid|local anesthesia of 2% lignocaine will be administered by infiltration technique in the anterior maxillary region. Microneedling of the mucosa will be performed using dermapen needles, employing an intermittent back-and-forth motion in the anterior maxillary and mandibular region for 30-40 seconds, reaching a depth of 1.5 mm. This will involve the creation of microholes in the gingival tissue using derma pen to enhance the concentration and penetration of the ascorbic Acid through the gingival tissues.
214672796|NCT05032443|OTHER|Awareness survey|The 33-item questionnaire will sent to pediatric endoscopy nurses in our country. Questionnaires will be delivered to nurses through hospital visits or electronic media.
214924018|NCT05988983|OTHER|Availability of OTC contraceptive pill|Over the counter contraceptive pill
214924019|NCT04167033|DRUG|Hormone replacement therapy:effect on ventricular repolarization|Hormone replacement therapy and QTc measurement
214924020|NCT04167033|DIAGNOSTIC_TEST|ECG|QTc measurement
214924021|NCT04215211|DIAGNOSTIC_TEST|Survival prediction for glioma patients|Survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
214924022|NCT03000998|BEHAVIORAL|Web App Intervention Group|All baseline and follow-up data collection will be conducted via online surveys and a customized web portal and include parent self-reports and clinic records of vaccination of boys
214924023|NCT03000998|BEHAVIORAL|Usual Customary Care Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on HPV vaccination from the Centers for Disease Control and Prevention (CDC) in Portable Document Format (PDF) format.
214924024|NCT00482677|DRUG|temozolomide|Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
214924025|NCT00482677|GENETIC|DNA methylation analysis|A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
214924026|NCT00482677|PROCEDURE|quality-of-life assessment|prior to randomization until end of study
214924027|NCT00482677|RADIATION|Radiation|Short course radiotherapy
214672797|NCT03512223|DRUG|Dexamethasone|Intravenous and Perineural Dexamethasone for Brachial Plexus Block
214672798|NCT05458232|DRUG|Tadalafil 5mg|Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.
214323880|NCT06133543|PROCEDURE|Robot-assisted ICG-guided sentinel lymph node biopsy|The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
215066843|NCT06689007|OTHER|Implementation Intervention|The intervention employs four established implementation strategies according to the Expert Recommendations for Implementing Change: conduct educational meetings, provide ongoing consultation, provide technical assistance, and change physical structure and equipment. The first component is a six-week online course led by the PI that combines weekly pre-recorded lectures, hands-on activities, group mentoring sessions and a reflective assignment. The second component of the intervention is ensuring access to the equipment needed for FES. The third component of the intervention is access to the FES Toolkit.
214924028|NCT01894100|DEVICE|Shoe lift correction for leg length inequality|Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
214924029|NCT05236738|DRUG|Atazanavir|Specified dose on specified days
214924030|NCT05236738|DRUG|Cobicistat|Specified dose on specified days
214924031|NCT05236738|DRUG|Atazanavir/Cobicistat Mini-tablet|Specified dose on specified days
214924032|NCT03554395|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
214924033|NCT03554395|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
214924034|NCT02992977|BIOLOGICAL|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
214924035|NCT00000743|DRUG|Alvircept sudotox|
214924036|NCT00000743|DRUG|Zidovudine|
214924037|NCT06044350|DRUG|BAT4406F Injection|Intravenous infusion; Dosage:500mg/time
214924038|NCT06044350|DRUG|BAT4406F Placebos|Intravenous infusion; Dosage:500mg/time
214924039|NCT06291038|DIETARY_SUPPLEMENT|• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks|treatment with glutamine at a dose of 5g 3 times a day for 8 weeks
214924040|NCT06291038|DIETARY_SUPPLEMENT|• Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.|treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
214924041|NCT03857386|PROCEDURE|PECS group|Pecs block performed using ultrasound guidance
214924042|NCT03857386|PROCEDURE|Control group|Local infiltration anesthesia performed during the operation
214924043|NCT04192071|OTHER|virtual technology - high interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer and dietary intake. Interactive nutrition risk feedback will be customized based on user input.
214924044|NCT04192071|OTHER|virtual technology - low interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer. Minimally interactive risk feedback will be delivered.
214924045|NCT04192071|OTHER|non-colorectal cancer related module|Participants engage with web-based content not related to colorectal cancer or nutrition.
214924046|NCT06612762|DIETARY_SUPPLEMENT|The daily ingestion of capsules containing naringenin|Following surgical intervention, patients will be administered two capsules (equivalent to 500 mg) daily for a period of 14 days. Subsequently, patients will ingest the maintenance dose of 250 mg per day until the 90th day post-surgery.
214924047|NCT06612762|DIETARY_SUPPLEMENT|Placebo|The daily ingestion of capsules containing placebo
214924048|NCT06459414|OTHER|: Oropharyngeal Administration Of Colostrum|Preterm less than 34 weeks gestation will receive Oropharyngeal Colostrum for 3 days ( the first group) and for 10 days( the second group)
214924049|NCT01098760|DRUG|Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment|Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
214924050|NCT05313568|OTHER|static stretching|The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
215066844|NCT07026695|DEVICE|transcutaenous vagal nerve stimulation|Low level Stimulation of the Auricular Branch of the Vagal Nerve at the tragus
215066845|NCT07026695|DEVICE|Sham transcutaenous vagal nerve stimulation|Sham treatment
215066846|NCT07029503|DRUG|Eplerenone|"Participants will receive eplerenone 25 mg once daily or every other day, based on baseline potassium levels, eGFR, systolic blood pressure, and concomitant use of weak or moderate CYP3A4 inhibitors.~The study will implement a safety protocol with predefined procedures for managing significant hyperkalemia, worsening renal function, and hypotension. These will include temporary or permanent dose reduction or discontinuation of eplerenone, and, if necessary, administration of the potassium binder sodium zirconium cyclosilicate (SZC, Lokelma®)."
214924051|NCT05313568|OTHER|self massage|In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.
214924052|NCT05313568|OTHER|Manual Stimulation|"In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each)."
214924053|NCT02357160|BEHAVIORAL|Artwork|Prints by local artists that are hung on the walls of patient rooms.
214924054|NCT04097262|OTHER|Own-Price Elasticity|The price of fruit will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
214924055|NCT04097262|OTHER|Cross-Price Elasticity|The price of fruit will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
214924056|NCT06206577|PROCEDURE|Horizontal ridge augmentation by symphyseal bone block placed and fixed buccally as onlay graft|autogenous bone block harvested from chin area using piezosurgery and fixed buccally in deficient area with fixation screws
214924057|NCT06206577|PROCEDURE|Horizontal ridge augmentation by symphyseal bone block interpositioned in space created between buccal and lingual cortex as inlay graft|autogenous bone block harvested from chin area using piezosurgery and fixed in bone split created at deficient area with fixation screws
215066847|NCT07034729|BEHAVIORAL|training to develop emotional intelligence skills|2 hours in a week, 6 week training
215066848|NCT07034105|DIAGNOSTIC_TEST|Gait Analysis|"* Overground Walking: Stroke patients walk in a natural environment, collecting data on their gait parameters such as stride length, cadence, and gait speed.~* Treadmill: Patients walk on a treadmill at their comfortable pace, allowing for more control over their walking speed while measuring the same gait parameters as in overground walking.~* Body-Weight Supported Treadmill: Patients walk on a treadmill with a body-weight support system that reduces the load on the legs, enabling patients with more severe impairment to perform walking tasks safely while recording gait parameters."
214323881|NCT00479908|DRUG|Sildenafil citrate|
215066849|NCT07033208|DEVICE|Feasibility to obtain thermal variance measurements using a wireless thermal capsule|A total of 10 healthy volunteers will be enrolled in this study all consented participants will receive the same intervention.
215066850|NCT07035938|OTHER|observational study|observational study
214924058|NCT05700175|DIAGNOSTIC_TEST|Transcriptomic, epigenetic and proteomic analysis|"Next-generation sequencing will be used to identify differences in expression of circulating transcripts (protein-coding and not) in patients affected by Marfan Syndrome (MFS), subdivided based on the presence or absence of thoracic aortic aneurysms (TAA) and indication of TAA-surgery (TAA\_MFS\_signature).~The obtained TAA\_MFS\_signature will be correlated to fundamental biological parameters by analysing:~Blood-levels of cytokines and chemokines relevant for inflammation. Transcriptomic and epigenetic (Cytosine methylation) changes in aortic aneurysms tissue by Next-generation sequencing.~Progression of biomarkers in surgical-patients before and at 6 and 12 months after surgery."
214924059|NCT04218656|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to Aspirin 100mg once a day (standard care).
214924060|NCT05021874|OTHER|Four different physiotherapy treatment|Four different physiotherapy treatment will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 10th day of therapy, it will be measured ROM.
215066851|NCT07036419|DRUG|Remimazolam Tosilate for injection|Remimazolam Tosilate for injection.
215066852|NCT07036419|DRUG|Propofol Injection|Propofol injection.
214323882|NCT00479908|DRUG|Glyceryl trinitrate|
214323883|NCT03009240|DRUG|Decitabine|Given IV
214323884|NCT03009240|OTHER|Laboratory Biomarker Analysis|Correlative studies
214323885|NCT03009240|DRUG|Pevonedistat|Given IV
214323886|NCT03009240|OTHER|Pharmacological Study|Correlative studies
214323887|NCT04606693|OTHER|Treatment of SAHS|Patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
214323888|NCT04226716|BEHAVIORAL|Assessment of postural control, body perception, psychosocial factors and inflammation|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception, psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events) and inflammatory mediators
214323889|NCT05114291|OTHER|Explorations are planned as part of the one-day hospitalization|"* Clinical parameters : Interrogation, physical examination, morphological data measurements (weight, height, waist circumference, hip circumference) and impedencemetry (body composition).~* Biological samples : Blood and urine exam, fasting urine sample (urinary osmolarity)~* Standardized blood pressure measurement :~  * After 5 to 10 minutes of rest, with automated measurements at 1 minute intervals : un-attended, then attended~* Hemodynamic parameters :~  * Sphygmocor® : measure of the central blood pressure and pulse wave velocity~ * MESI® tool : measure of the Systolic Pressure Index (PSI or IPS)~ * pOpmetre® : Calculation of the speed of the pulse wave by the pOpmetre® device~* Others : if indicated (echocardiography, ABPM)"
214323890|NCT06158802|OTHER|Questionnaire|"Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient."
214323891|NCT05196412|DEVICE|PulseOn Arrhythmia Monitor device|Wearing of the wrist device for a period of two weeks
215066853|NCT07034690|OTHER|Educational Material|Health Education Intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit)
214924061|NCT02235077|DRUG|Spironolactone|"Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
214924062|NCT02235077|DRUG|Placebo|"Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
214323892|NCT03604055|PROCEDURE|Endobronchial hamartomas treatment|General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
214924063|NCT01399463|DEVICE|Angioplasty performed via Paclitaxel Eluting Balloon catheter|
214924064|NCT01399463|DEVICE|Angioplasty via DES|Angioplasty performed via commonly used Drug Eluting Stents
214323893|NCT06145308|DRUG|Cohort 1 (HER2-positive, RC48-ADC)|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323894|NCT06145308|DRUG|Cohort 2 (NTRK-fusion or NTRK-mutant)|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323895|NCT06145308|DRUG|Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323896|NCT06145308|DRUG|TROP2 ADC|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323897|NCT06145308|DRUG|TKI|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323898|NCT06145308|DRUG|Albumin-paclitaxel + platinum|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323899|NCT06145308|DRUG|Albumin-paclitaxel + carboplatin + apatinib + camrelizumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
215066854|NCT07034690|OTHER|Standard of care|Standard of care
215066855|NCT07033702|DEVICE|Airway-Exchange Broncholaryngoscope (AEBLScope)|Airway Exchange Broncholaryngoscope (AEBLScope) - A modified disposable flexible bronchoscope designed to allow visualization during airway tube exchange procedures.
215066856|NCT07033754|DIETARY_SUPPLEMENT|Propionibacterium freudenreichii P.UF1|one capsule once a day with/beforebreakfast for 120 days
214323900|NCT06145308|DRUG|albumin-bound paclitaxel+trastuzumab+pyrotinib|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214485935|NCT06589674|OTHER|Diastolic shock index|The Diastolic Shock Index (DSI) is a hemodynamic parameter calculated by dividing the heart rate (HR) by the diastolic blood pressure (DBP). It reflects the balance between cardiac output and systemic vascular resistance, particularly in critically ill patients. A higher DSI can indicate impaired vascular resistance and may be useful for predicting the need for vasopressor support, especially in conditions like septic shock. However, its application in predicting hypotension during anesthesia induction is still under investigation.
215066857|NCT07033754|DIETARY_SUPPLEMENT|Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia|one capsule once a day with/beforebreakfast for 120 days
215066858|NCT07032948|DEVICE|FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter、EasyStars™ High Density Mapping Catheter、Columbus™ 3D EP Navigation System|All patients were treated withFireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter、EasyStars™ High Density Mapping Catheter and Columbus™ 3D EP Navigation System for rapid arrhythmia.
215066859|NCT07034508|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
214924065|NCT01232686|OTHER|Online disease surveillance data access|In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
215066860|NCT07034508|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
215066861|NCT07034508|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm
215066862|NCT07034508|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
214924066|NCT04737252|BEHAVIORAL|Sage (formerly known as COMPASS)|Sage is a remote 12 session intervention for couples wherein one individual has Borderline Personality Disorder (BPD) and engages in self-injury thoughts and behaviours. The intervention consists of elements of Cognitive Behavioural Conjoint Therapy (CBCT) and has been adapted for this population. Couples will meet remotely with a clinician (registered psychologists and/or graduate level clinicians) for 8-12 sessions via Zoom Healthcare. The primary outcomes are self-injury thoughts and behaviours (as measured by the Suicide Attempt and Self-Injury Interview-modified, and the Beck Scale for Suicidal Ideation and ecological momentary assessment) and borderline personality disorder symptoms (as measured by the Borderline Symptom List-23).
215066863|NCT07034508|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
215066864|NCT07033234|DRUG|HS-20118|HS-20118
214924067|NCT06044636|OTHER|Digi-physical breastfeeding support|"* Breastfeeding support after birth is provided via chat~* Extended home visits by a pediatric nurse after discharge from the maternity ward~* Extra support from a lactation counselor when needed after discharge until one year after childbirth"
215066865|NCT07034170|BEHAVIORAL|Enhanced Rehabilitation Program|Participants in the intervention group receive an enhanced rehabilitation program, including muscular electrical stimulation, guided active rehabilitation sessions, and structured physical engagement during periods of consciousness. The intervention is designed to promote functional improvement in post-cardiac arrest patients.
215066866|NCT06883409|PROCEDURE|Interval Cytoreduction Surgery|"The procedure started with the cytoreduction of highest complexity (determined at the time of initial inspection), after which, if necessary, the patient underwent a complete hysterectomy, bilateral salpingo-oophorectomy, omentectomy, or partial peritonectomy and excision of any peritoneal implants present. The magnitude of the surgical procedures will be classified as:~1. Standard surgery: minimal hysterectomy, adnexectomy y omentectomy~2. Radical Surgery: included resection of the ovaries, of the rectouterine excavation (pouch of Douglas) and or the peritoneum between the bladder and uterus, hysterectomy, rectosigmoid colectomy, and complete omentectomy~3. Supra-radical Surgery: included other procedures such as splenectomy, diaphragm resection, or other intestinal resection."
215066867|NCT07032974|DEVICE|Franseen|Franseen needle
215066868|NCT07032974|DEVICE|Forward-bevel|Forward-bevel needle
215066869|NCT07032974|DEVICE|Fork-tip|Fork-tip needle
215066870|NCT07043270|DRUG|Nab-paclitaxel + Gemcitabine|Administered ion days 1, 8 and 15 of cycles 1 and 3 (28-day cycles).
215066871|NCT07043270|DRUG|modified FOLFIRINOX (mFOLFIRINOX)|Administered ion days 1 and 15 of cycles 2 and 4 (28-day cycles).
214672799|NCT00861042|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
215066872|NCT06883903|OTHER|day-night cycle application|In this group, colostrum delivered to the unit within the first 5 days of life was administered by the nurse every three hours for 14 days. In order to create a day/night cycle, a white incubator cover was used routinely in the unit during the day (between 08.00-20.00 hours) and a dark colored incubator cover was used at night (between 20.00-08.00 hours).
215066873|NCT06883903|OTHER|routine practice|"In this group, colostrum delivered to the unit within the first 5 days of life was administered every three hours for 14 days by the nurse.~is the group whose covers are used."
214323901|NCT06145308|DRUG|HER2,trastuzumab deruxtecan± pertuzumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323902|NCT06145308|DRUG|AR,darolutamide + goserelin+pertuzumab/trastuzumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
215066874|NCT07045649|DIAGNOSTIC_TEST|1-minute sit-to-stand test|The 1-minute sit-to-stand test will be assessed upon discharge from the Cardiac Intensive Care Unit. It may be assessed up to 48 hours after discharge from the unit. It will be performed on a standardized 46.0 cm chair without armrests, placed against the wall. Participants will be seated in the chair, without support, with their knees and hips at 90° flexion, with their feet parallel to the floor and their arms crossed over their chest. Participants will be instructed to stand up and sit down as quickly as possible without using their arms for 1 minute and will be instructed to stop whenever they wish. However, they must return as quickly as possible, since the goal is to complete as many repetitions as possible in 1 minute. Vital signs and dyspnea and leg fatigue will be assessed using the Modified Borg Scale before and after the test. A repetition will be identified as standing up completely straight and returning to the sitting position.
215066875|NCT07050654|DEVICE|Dual-task cycling|"Pairs of participants are formed, who will be the SocialBike players; these pairs consist of users from the same center. The two players are in the same room where two replicas of the SocialBike system are installed.~The participants can each view, on their own screen, the virtual scenario, either a park or a city environment. Movement within these VR environments is synchronized with the patient's actual pedaling speed, measured in revolutions per minute (RPM) from the cycle ergometer. Movement occurs along a predefined path. The participant's heart rate will always be monitored.~The therapist chooses the optimal ergometer workload, the type of exercise, and social/single-player mode. Each session (either single- or multi-player mode) lasts 10 minutes. The available exercise are: Find the intruder (go/no-go task); Prepare your Meal (spatial attention); Watch the road (working memory)."
215066876|NCT07068191|COMBINATION_PRODUCT|"Dietary supplement Gepaktiv"|"Dietary supplement Gepaktiv 60 minutes before meals 2 capsules × 3 times/day"
215066877|NCT07068191|DRUG|UDCA (Ursodeoxycholic acid)|UDCA 10-15 mg/kg/day
215066878|NCT07068191|DRUG|Ademetionine|Ademetionine 800-1600 mg/day.
215066879|NCT07080242|DRUG|BL-M14D1|BL-M14D1 will be administered on D1 every 3 weeks.
215066880|NCT07079670|BIOLOGICAL|NVX-CoV2705|Intramuscular (deltoid) injection at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant.
215066881|NCT07079475|DRUG|DZD6008|DZD6008 will be administered orally at 40/60 mg QD or selected dose.
215066882|NCT07079475|DRUG|Sunvozertinib|Sunvozertinib will be administered orally at 100 mg QD or selected dose.
215066883|NCT07079475|DRUG|Osimertinib|Osimertinib will be administered orally at 80 mg QD
215066884|NCT07081542|DEVICE|IotaSoft Robotic Insertion System|The IotaSoft robotic insertion device is an FDA-approved tool designed to provide precise and controlled insertion of the cochlear implant electrode array to minimize trauma during implantation.
215066885|NCT07081542|PROCEDURE|Manual Cochlear Implant Insertion|Standard surgical technique for manually inserting the cochlear implant electrode array. This method reflects the current standard of care without the assistance of robotic tools.
214323903|NCT06145308|DRUG|AR,darolutamide +goserelin +docetaxel|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323904|NCT06145308|DRUG|ivonescimab + investigator-choice platinum doublet+|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214485936|NCT06984380|OTHER|Telerehabilitation|Patients will receive a personalised home tele-rehabilitation exercise program consisting of 3 sessions per week for a duration of 12 weeks. BTS TELEREHAB is a platform that allows the delivery of remote rehabilitation services. The patient is given the system to take home, where they will connect the small Brain PC, that is the computer unit of the BTS TELEREHAB solution, to their television. During motor rehabilitation sessions, the patient wears a special inertial sensor, the G-Sensor device, that measures movements in real-time, allowing the clinician to remotely monitor the correct execution of the exercises. In addition to the proposed therapeutic exercises, functional assessment tests are also included for patient follow-up. The presence of the inertial sensor supports the clinician in verifying the correct execution of the motor task and in the precise quantification of joint mobility.
214485937|NCT06984380|OTHER|Usual care|Participants will receive a booklet containing information and activities on well- being. They will be invited to do whatever they wish with the information booklet and the proposed exercises.
215066886|NCT07081061|OTHER|BetterHelp|Use program as needed for 16 weeks
214485938|NCT06665568|DRUG|Intranasal ketamine hydrochloride|Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)
215066887|NCT07079553|DEVICE|Transcutaneous Electrical Diaphragmatic Stimulation (TEDS)|TEDS was applied using surface electrodes placed over the diaphragm region. The stimulation protocol was set at 50 Hz frequency, 300 μs pulse width, with 6 seconds of stimulation followed by 5 seconds of rest, daily for 12 weeks. It was combined with ACBT sessions.
215066888|NCT07079553|BEHAVIORAL|Active Cycle of Breathing Techniques (ACBT)|ACBT sessions included breathing control, thoracic expansion exercises, and forced expiration techniques (huffing). Sessions were performed daily for 12 weeks to aid in secretion clearance and improve lung function.
214924068|NCT05658263|DIETARY_SUPPLEMENT|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
214323905|NCT06145308|DRUG|iparomlimab + tuvonralimab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323906|NCT06145308|DRUG|cadonilimab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
215066889|NCT07081399|COMBINATION_PRODUCT|ETT cuff pressure monitoring, ETT suctioning, cough augmentation technique, swallowing exercises,: Nebulized budesonide 1mg and IV methylprednisolone 40 mg we|cough augmentation, larson maneuver, swallowing rehabilitation
215066890|NCT07080970|OTHER|observation of incidence of early vascular events|observation of difference incidence of early vascular events in the two cohorts
214485939|NCT05446662|OTHER|music therapy|Patients participating in the study will be informed about the application of music therapy in the preoperative period. The patients who will take part in the music group are given 30 minutes the day before the surgery, and 30 minutes a day on the 1st and 2nd days after the surgery. Music that is selected by the researcher and grouped as relaxing music, classical music, sufi music and Turkish folk music will be played. The patients will be listened to the music with headphones that cover the whole ear, and the music will be adjusted to make them feel comfortable.
214924069|NCT05658263|DIETARY_SUPPLEMENT|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
215066891|NCT07080099|OTHER|BIMANUAL INTENSIVE THERAPY WITH PASSIVE SENSORY TRAINING|"Bimanual intensive therapy Bimanual coordination training ,Functional training of the hands ,Trask oriented training, Bilateral arm training,~Passive sensory training:~Electrical stimulation."
215066892|NCT07080099|OTHER|BIMANUAL INTENSIVE THERAPY WITH ACTIVE SENSORY TRAINING|"Bimanual intensive therapy:~* Bimanual coordination training ,Functional training of the hands~* Trask oriented training, bilateral arm reaching~Active sensory training:~sensory re education techniques ,touching different objects, massage, identifying different temperatures, and sensory locating."
214924070|NCT05886140|DRUG|Carrilizumab with albumin-binding paclitaxel|All enrolled patients received carrilizumab combined with albumin-binding paclitaxel.
214924071|NCT00004642|DRUG|SDZ MSL-109|
214924072|NCT04674917|OTHER|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy|"Group A which includes the acute group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 ) Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
214924073|NCT04674917|OTHER|Decompression + Hot pack , TENS , Mobilization , Exercise Therapy|"Group B which includes the chronic group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
215066893|NCT07081906|DRUG|Oral Oxybutynin|The oral form of oxybutinin was preferred for patients who had no difficulty swallowing and whose families preferred a conventional administration route. Medication was given under parental supervision to ensure adherence. Patients were monitored monthly for potential anticholinergic side effects. The patch form of oxybutinin was chosen for patients who experienced difficulties with oral intake or had previous intolerance to oral anticholinergics. Application sites were rotated to reduce the risk of local skin reactions. Families received instructions on proper patch application technique.
215066894|NCT07081906|DRUG|transdermal oxybutinin|The oral form of oxybutinin was preferred for patients who had no difficulty swallowing and whose families preferred a conventional administration route. Medication was given under parental supervision to ensure adherence. Patients were monitored monthly for potential anticholinergic side effects. The patch form of oxybutinin was chosen for patients who experienced difficulties with oral intake or had previous intolerance to oral anticholinergics. Application sites were rotated to reduce the risk of local skin reactions. Families received instructions on proper patch application technique.
215066895|NCT07080424|PROCEDURE|Fistulectomy with Marsupialization|Patients with fistula in ano treated with Fistulectomy with Marsupialization and were compared for wound healing with other group
215066896|NCT07080424|PROCEDURE|Fistulectomy|Patients with fistula in ano treated with Fistulectomy and were compared for wound healing with other group
215066897|NCT07080645|OTHER|Pain Relieving|aim to relieve tooth pain with HMI Biosilicate
215066898|NCT07080645|OTHER|topical application|the operator will apply a solution to all the free surfaces of the selected teeth using a microapplicator. The solution will either be 10% Biosilicate® solution, fluoride varnish (Duraphat®), or distilled water . All products will be removed from their original containers and placed in identical 10ml plastic bottles, white and standardized. The different products will be applied equally for 15 seconds according to the application protocol.
215066899|NCT07080918|PROCEDURE|Irrigation|Irrigation procedures were performed with needles of different designs, each 30 G, for three different groups
215066900|NCT07079618|DRUG|SGC001|In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug SGC001 should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.
215066901|NCT07079618|DRUG|Placebo|In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug placebo should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.
215066902|NCT07080606|BEHAVIORAL|Brief exposure therapy and exercise|Treatment provided in this study includes an open label brief imaginal exposure therapy for Post Traumatic Stress Disorder (PTSD) and moderate intensity aerobic exercise (i.e., 70-75% max heart rate). Participants all receive 30 minutes of psychotherapy and 25 minutes of exercise.
215066903|NCT07081841|OTHER|Observation|This is an observational study in which safety laboratories and non-invasive routine clinical assessments are conducted to gauge long term safety and efficacy.
215066904|NCT07081295|OTHER|Injection of hypertonic saline|Injection 10 mL of 10% NaCl through central venous catheter
215066905|NCT02227069|DRUG|M518101|
215066906|NCT02227069|DRUG|M518101 Vehicle|
215066907|NCT02227069|OTHER|sodium lauryl sulfate|
215066908|NCT02227069|OTHER|saline|
215066909|NCT03831295|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IT or IV
215066910|NCT03831295|DRUG|TLR9 Agonist SD-101|Given IT
215066911|NCT07079579|DRUG|Enarodustat 2mg|initial phase：2mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
215066912|NCT07079579|DRUG|Enarodustat 3mg|initial phase：3mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
215066913|NCT07079579|DRUG|Enarodustat 4mg|initial phase：4mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
215066914|NCT00911196|OTHER|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
215066915|NCT05571644|DRUG|mFOLFOXIRI + Cadonilimab|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
215066916|NCT05571644|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycels before surgery
215066917|NCT05571644|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
215066918|NCT05571644|DRUG|mFOLFOXIRI+AK104+fruquintinib|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles, and fruquintinib (3mg Qd, D1-21, Q4W for 3 months) before surgery
215066919|NCT06456008|OTHER|Standard of care|Standard of care
215066920|NCT03515733|DRUG|PF-04995274|PF-04995274 tablets
215066921|NCT03515733|DRUG|Placebo Oral Tablet|Placebo tablet, identical appearance to experimental tablet
215066922|NCT06907888|DEVICE|Rhythm Express Wearable System|The Rhythm Express Wearable System consists of the FDA-cleared RX-1 mini Cardiac Monitor, an FDA-cleared pulse oximeter, and a cellular gateway to relay data from the pulse oximeter to the cloud-based RS-1 Server. The RS-1 Sleep Algorithm is a cloud-based software as a medical device (SWMD) that receives inputs from the two FDA-cleared wearable devices. The Algorithm, together with the two wearable devices, comprises the Rhythm Express Wearable System.
214924074|NCT04674917|OTHER|Hot pack , TENS, Mobilization, Exercise therapy|"Group C which is our control group to compare it with the groups A and B to study the effects of decompression on lumbar radiculopathy The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine It is kept in mind that in this group we will not apply the decompression along with the above treatments."
214924075|NCT06727565|DRUG|Domvanalimab|Administered intravenously
214323907|NCT06145308|DRUG|CDK4/6 inhibitor+AI or fulvestrant|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323908|NCT06145308|DRUG|alpelisib+fulvestrant|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323909|NCT06145308|DRUG|PARP inhibitor|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323910|NCT06145308|DRUG|enfortumab vedotin|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214485940|NCT05446662|OTHER|aromatherapy|Patients participating in the study will be informed about the application of aromatherapy in the preoperative period. During this period, patients undergo elbow test (1 drop of lavender oil will be dripped onto the inside of the patient's elbow, after 20 minutes, it will be evaluated whether an allergic reaction has developed). Lavender oil as aromatic oil will be administered to the patients in the aromatherapy group in the form of inhalation. Lavender oil inhalation (1 drop of 0.1 cc) It will be applied by inhalation with gauze on which 3-4 drops of lavender oil are poured. 30 minutes before surgery. Aromatherapy will be applied four times with an interval of 30 seconds on the 1st and 2nd days before and after the surgery.
214924076|NCT06727565|DRUG|Zimberelimab|Administered intravenously
214924077|NCT06727565|DRUG|Paclitaxel|Administered intravenously
214924078|NCT06727565|DRUG|Carboplatin|Administered intravenously
214924079|NCT04013672|DRUG|Pembrolizumab|200 mg IV every 3 weeks
214924080|NCT04013672|DRUG|SurVaxM|500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
214924081|NCT04013672|DRUG|Sargramostim|100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
214924082|NCT04013672|DRUG|Montanide ISA 51|1 ml per dose dosed every two weeks for 4 doses and then every 3 months
214924083|NCT06735911|OTHER|Spa therapy|Thermal treatments among the following: Filiform shower, simple bath, aerated bath, general shower, compresses, nebulization inhalation, multiple local mud applications, and drinking cure.
214323911|NCT06145308|DRUG|HER2, pyrotinib + pertuzumab/trastuzumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
214323912|NCT03963518|DRUG|nivolumab monotherapy|nivolumab monotherapy
214323913|NCT03963518|DRUG|nivolumab plus ipilimumab|nivolumab plus ipilimumab
215066923|NCT06838351|BEHAVIORAL|Guided Drawing Intervention|The guided drawing activity is a 20 minute session which integrates mindfulness and drawing elements. Participants were given a pencil and blank paper to use while they watched a pre-recorded video guiding them through a mindfulness and drawing activity. In the pre-recorded video, participants are instructed to draw elements of nature from exemplar photographs (e.g., leaves, twigs). The activity incorporates drawing with aspects of mindfulness meditation (i.e., being non-judgmental of thoughts and behaviors, focusing on breathing, and embodiment).
215066924|NCT06838351|BEHAVIORAL|Free Drawing Control|Participants are instructed to draw freely for about 20 minutes.
214323914|NCT05908097|DEVICE|Virtual Reality Avatar Intervention|In the Virtual Reality Avatar Intervention experience, participants will see an avatar resembling themselves in a park setting.
214323915|NCT05908097|DEVICE|Virtual Reality Empty Park|The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
214323916|NCT00976898|RADIATION|Proton Beam Irradiation|Given once a day, 5 days a week, for 3 weeks
214323917|NCT05107128|DRUG|SAGE-718|Oral capsules.
214323918|NCT05107128|DRUG|Placebo|SAGE-718-matching oral capsules.
214323919|NCT06447116|DEVICE|CGuard Prime™ Carotid Stent System|CGuard Prime™ Carotid Stent System
214323920|NCT01452308|BIOLOGICAL|Simtuzumab|
214323921|NCT01679275|OTHER|measuring cerebral oxygenation|
214323922|NCT01470469|DRUG|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
214672800|NCT04116034|DEVICE|alfapump DSR system|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
214924084|NCT02894944|BIOLOGICAL|Theragene®,Ad5-yCD/mutTKSR39rep-ADP|Theragene®,Ad5-yCD/mutTKSR39rep-ADP is Adenovirus-mediated Double Suicide Gene Therapy
214323923|NCT01470469|DRUG|Placebo|Once-daily oral dosing in the evening for 12 weeks.
214924085|NCT00586820|DRUG|BQ-123|BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
214924086|NCT00586820|DRUG|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
214924087|NCT01157104|DRUG|IDX320|IDX320 400 mg in tablets (8x50 mg) administered orally once daily
214924088|NCT01157104|DRUG|IDX184|IDX184 100 mg in capsules (2x50 mg) administered orally once daily
214924089|NCT01157104|DRUG|IDX184 placebo|IDX184 matching placebo in capsules administered orally once daily
214924090|NCT01157104|DRUG|IDX320 placebo|IDX320 matching placebo in tablets administered orally once daily
214924091|NCT01976429|OTHER|flight/diving simulation|measurement of ET function during simulated flight/diving in pressure chamber
214924092|NCT01976429|OTHER|ET function testing at ambient pressure|ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence
214924093|NCT01976429|OTHER|nasal video-endoscopy|examination of nose, nasopharynx,and Eustachian tube orifice
214924094|NCT00385047|BIOLOGICAL|Group A FMP2.1/AS01B|
215066925|NCT06838351|BEHAVIORAL|Basic Control|Participants are instructed to complete simple paper and pencil activities (e.g., mazes, connect the dots) for about 20 minutes.
214323924|NCT05916586|DRUG|Prednisone|Prednisone 40 mg orally once a day for 7 days
214323925|NCT03922568|OTHER|Density Gradient Centrifugation|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
214323926|NCT03922568|DEVICE|Physiological ICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
214323927|NCT03922568|DEVICE|Magnetic Activated Cell Sorting|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
214323928|NCT00607945|DRUG|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
214323929|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
214924095|NCT00385047|BIOLOGICAL|Group B FMP2.1/AS02A|
214924096|NCT03773029|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone (as 2 capsules)
214924097|NCT03773029|OTHER|placebo|2 capsules of placebo
214924098|NCT01283451|BEHAVIORAL|Muscle contraction|Participants will perform a 30-60 second exercise designed to cause a temporary decrease in muscle oxygenation of a specific muscle group.
214323930|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
214323931|NCT05339932|OTHER|Manual Wheelchair Skills Training|The intervention involves manual wheelchair skills training.
215066926|NCT06924918|OTHER|Scalp Acupuncture Treatment|"Acupoint Selection:~Baihui (GV20), Sishencong (EX-HN1), Frontal Midline Line (MS1), Vertex Midline Line (MS5), Lateral Line 1 of Vertex (MS7), Shenting (GV24), Yintang (EX-HN3), Shuaigu (GB8)~Acupuncture Manipulation:~Needles with a diameter of 0.18-0.35 mm and length of 13-25 mm are selected. After routine disinfection of the acupoint skin, the practitioner holds the micro-needle and quickly inserts it into the subcutaneous tissue at an insertion angle of 15°-30°, primarily using superficial horizontal insertion. The insertion depth is maintained at 15-20 mm, adjusted according to the child's head circumference, body size, and body mass. Needles are retained for 30 minutes.~Course of treatment:~2 times a week for 12 weeks"
214323932|NCT04355884|DIAGNOSTIC_TEST|Standard 12-lead ECG, NT-proBNP, echocardiography|Cardiac assessment
214323933|NCT03924492|DRUG|ZULRESSO (brexanolone) injection|ZULRESSO
214323934|NCT05206695|BEHAVIORAL|Multi-condition Pathway Intervention|See Experimental/Arm 1 description
214323935|NCT04140149|BEHAVIORAL|Living with Hope|12-week, CBT-based, psychoeducational skills class
215066927|NCT06924918|OTHER|Tuina Treatment Group|"Prescription:~Spleen Meridian (Pi Jing), Small Heavenly Heart (Xiao Tianxin), Five Finger Joints (Wu Zhi Jie), Internal Bagua (Nei Bagua), Hand Yin-Yang (Shou Yin Yang), Upper Three Passes (Shang San Guan), Gushing Spring (Yongquan, KI-1), Leg Three Miles (Zusanli, ST-36) Manipulation Techniques~Pushing/Kneading the Spleen Meridian (Tonifying Pi Jing):~Tapping Small Heavenly Heart (Xiao Tianxin):~Kneading the Five Finger Joints (Wu Zhi Jie):~Moving the Internal Bagua (Nei Bagua):~Separating Yin and Yang (Separating Shou Yin Yang):~Pushing Up the Upper Three Passes (Pushing San Guan):~Kneading Gushing Spring (Yongquan, KI-1):~Kneading Leg Three Miles (Zusanli, ST-36):~2 times a week for 12 weeks"
215066928|NCT04183465|OTHER|Health Education|Current gold standard in older patients admitted to hospital for MI. The group will receive a 20-minute session with one of the study physicians. Both the patient and relatives will attend these sessions. The study physician will stress the major issues related to a heart-healthy lifestyle and will explain the importance of PA as a powerful and independent factor to improve cardiovascular health and minimize cardiovascular risk. A detailed brochure explaining the benefits of physical activity will be provided to all patients
214924099|NCT00684320|BEHAVIORAL|Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
214924100|NCT00684320|BEHAVIORAL|Placebo Condition|The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
214924101|NCT03620305|OTHER|Description of treatment of septic pseudarthrosis|description of chirurgical 2 steps management of septic pseudarthrosis
214924102|NCT03616574|DRUG|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).
214323936|NCT03739775|PROCEDURE|Blood sampling|Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.
214672801|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
214672802|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
214672803|NCT01629667|OTHER|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
214672804|NCT01011205|DRUG|Advagraf|Capsule
214323941|NCT06631287|DRUG|Baricitinib|4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.
214323942|NCT06631287|OTHER|Placebo|Matched placebo capsule, PO once daily for 24 weeks.
214323943|NCT04706013|DRUG|Pyridoxal Phosphate|Oral tablets 50 mg
214323944|NCT06106373|DEVICE|iotaSOFT Insertion System|robotic assistive technology for cochlear implant electrode insertion
214323945|NCT06442462|DRUG|SPG302|small synthetic molecule
214323946|NCT06442462|DRUG|Placebo|Placebo
214323947|NCT05013554|DRUG|SAR443216 IV|Pharmaceutical form: Powder for solution; Route of administration: IV infusion
214323948|NCT05013554|DRUG|SAR443216 SC|Pharmaceutical form: Powder for solution; Route of administration: SC injection
214323949|NCT04988295|DRUG|Lazertinib|Lazertinib will be administered orally.
214323950|NCT04988295|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion.
214323951|NCT04988295|DRUG|Pemetrexed|Pemetrexed will be administered as an IV infusion.
214323952|NCT04988295|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion.
214485941|NCT05446662|OTHER|Progressive Relaxation Exercises|Patients participating in the study will be informed about relaxation exercises in the preoperative period. Progressive relaxation training will be applied to the patients for 30 minutes once a day, on the day before the operation and on the 1st and 2nd days after the operation.
214672805|NCT01011205|DRUG|Mycophenolate Mofetil|Solution for infusion
214672806|NCT01011205|DRUG|Basiliximab|IV infusion
214672807|NCT01011205|DRUG|Corticosteroids|IV bolus
214924103|NCT03616574|DRUG|LONSURF|LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.
214323953|NCT05400603|COMBINATION_PRODUCT|Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate|"The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10\^7 and then 3 x 10\^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10\^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels."
214323954|NCT05535361|DEVICE|Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome|The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 chromic sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
214323955|NCT04446260|DRUG|SHR-A1811|be administered via intravenous (IV) infusion
214323956|NCT06322771|BEHAVIORAL|Questionnaire|Questionnaire about acceptance
214323957|NCT06322771|BEHAVIORAL|Questionnaire|Questionnaire about refusal
214485942|NCT05446662|OTHER|Hand massage|Patients participating in the study will be informed about the application of massage therapy in the preoperative period. 10-15 minutes once in the preoperative period. And in the postoperative period, the 1st and 2nd days are 10-15 minutes. application will be carried out. Lavender oil (Lavandula Angustifolia) will be used in hand massage, sweet almond oil (Prunus Amygladus Sativa) will be used as essential oil.
214672808|NCT05085002|DRUG|Lerociclib + Letrozole or Fulvestrant|All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
214924104|NCT00226460|DRUG|Fetal porcine cells, Neurocell-PD|
214924105|NCT02607774|DRUG|Midazolam|midazolam administered to all patients Days -7, 1 and 35.
214924106|NCT02607774|DRUG|AIN457|secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
214672809|NCT01047787|OTHER|Polysomnography|examination for sleep disorders
214672810|NCT01409317|DEVICE|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
214672811|NCT01409317|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
214924107|NCT03813082|BEHAVIORAL|Prolonged wakefulness|40 hours of prolonged wakefulness
214924108|NCT00101166|BIOLOGICAL|Bystander-Based Autologous Tumor Cell Vaccine|The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
214924109|NCT03674320|DRUG|Testosterone Enanthate|Testosterone Enanthate (25 mg women, 100mg men) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
214924110|NCT03674320|DRUG|Placebo|Placebo Injection (saline) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
214924111|NCT03260829|DRUG|vitamin C|25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved
214924112|NCT01868022|DRUG|GSK3052230|A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
214924113|NCT01868022|DRUG|paclitaxel|paclitaxel will be from commercial stock.
214924114|NCT01868022|DRUG|carboplatin|carboplatin will be from commercial stock.
214924115|NCT01868022|DRUG|docetaxel|docetaxel will be from commercial stock.
214924116|NCT01868022|DRUG|pemetrexed|pemetrexed will be from commercial stock
214924117|NCT01868022|DRUG|cisplatin|cisplatin will be from commercial stock
214924118|NCT00686829|DRUG|Vicriviroc maleate|VCV 30 mg tablet once daily by mouth.
214323958|NCT06050564|OTHER|Treatment recommendations will be based on video documented PBS-Score|Therapeutic recommendations from orthopedic surgeons, will be summarized and described
214924119|NCT04161404|DRUG|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 1000mg capsules|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
214924120|NCT04161404|DRUG|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 2000mg|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
214323959|NCT06263608|DEVICE|(Cardio)Respiratory polygraphy (NOX T3s)|This home-based device enables the detection of obstructive sleep apnea by calculating the apnea hypopnea index (AHI).
214323960|NCT06263608|DIAGNOSTIC_TEST|Polysomnography|Polysomnography allows both sleep and respiration monitoring during an overnight stay in a dedicated sleep clinic.
214323961|NCT06263608|DEVICE|Devices to deliver Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP) or Adaptive support ventilation (ASV)|Devices can be used to deliver CPAP, BiPAP, or ASV treatment to open up the airways, making breathing during sleep possible.
214323962|NCT06263608|DEVICE|Fitbit smartwatch|The smartwatch enables the semi-continuous monitoring of the heart rhythm via the installed FibriCheck algorithm.
214323963|NCT04649151|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214323964|NCT04649151|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214323965|NCT04649151|BIOLOGICAL|mRNA-1273.222|Sterile solution for injection
214323966|NCT06567886|DEVICE|Light Therapy|"Participants will self-administer the daily light therapy within a few minutes of their assigned wake up time for one hour.~Researchers will provide a light log to note light on/off times, any interruptions to light therapy, and primary activity during light therapy."
214323967|NCT06567886|BEHAVIORAL|Sleep Stabilization|All participants will be asked to follow a fixed sleep schedule.
214323968|NCT02631811|OTHER|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
214924121|NCT04161404|DRUG|Metformin (Glucophage) 1000mg|Metformin is an oral glucose-lowering drug of the biguanides class. Drug: Period 1 Subjects
214924122|NCT03314532|PROCEDURE|TILA-TACE|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
214323969|NCT03752619|DEVICE|Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
214323970|NCT03752619|DEVICE|Non Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
214323971|NCT03752619|OTHER|Physical Therapy|All participants receive eight 1.0 hr. sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment. Each participant also performs home exercises. The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb. During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
214323972|NCT06146166|DIETARY_SUPPLEMENT|Oral herbal supplement|Oral supplement containing an oral blend taken once daily
214323973|NCT06146166|DIETARY_SUPPLEMENT|Oral placebo supplement|Oral placebo supplement taken once daily
214323974|NCT05430893|OTHER|Botulinum Toxin A|100 UI IM in the adductor longus
214323975|NCT03567213|DEVICE|Surgical implantation of CortiCom system|Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
214323976|NCT06764095|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
214323977|NCT06764095|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214924123|NCT01991509|BIOLOGICAL|LBR-101 IV|LBR-101 Administered Intravenously
214924124|NCT01991509|BIOLOGICAL|LBR-101 SC|LBR-101 Administered Subcutaneously
214323978|NCT06764095|PROCEDURE|Cystectomy|Undergo cytoreductive cystectomy
214323979|NCT06764095|DRUG|Enfortumab Vedotin|Given IV
214323980|NCT06764095|PROCEDURE|Local Therapy|Undergo MDT
214323981|NCT06764095|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214323982|NCT06764095|BIOLOGICAL|Pembrolizumab|Given IV
214924125|NCT02792543|DEVICE|Entéromate™|Chyme reinfusion (the experimental treatment) consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
214924126|NCT02792543|DRUG|parenteral nutrition|Parenteral nutrition (the gold standard treatment) consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
214924127|NCT03955913|OTHER|Archival Tumor Tissue Sample|Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue.
214924128|NCT04679311|BIOLOGICAL|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with fresh frozen plasma that has been preselected for ACE activity content of ≥ 50 U/L
214924129|NCT04679311|OTHER|Normal Saline|Subjects will be treated with normal saline 500 cc
215066929|NCT04183465|OTHER|Multi-domain lifestyle intervention|The intervention includes diet counselling, smoke cessation program, aggressive CV risk control and PA intervention. The PA intervention consisted of supervised sessions combined with an individualized home-based PA program. Centre-based sessions will be supervised by a sports physician and a nurse, and will take approximately 30 to 40 minutes, including a moderate standardized treadmill-walk, and strength and balance exercises. Based on the practice sessions, patients will receive a walking program to perform at home, unsupervised. The PA programs will be individualized, and consistent with current international recommendations. A selection of calisthenic exercises will be prescribed. Participants will be encouraged to perform the exercises three times per week (approximately 20 minutes). Adjustment of the type and intensity of the home-based PA regimen will be made at each visit. The PA program will be extensively described to the patient and family members.
214323983|NCT06764095|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214323984|NCT06764095|OTHER|Questionnaire Administration|Ancillary studies
215066930|NCT06948006|DRUG|AZD4144|Participants will receive AZD4144 orally.
215066931|NCT06948006|DRUG|Omeprazole|Participants will receive omeprazole orally.
214323985|NCT06764095|PROCEDURE|Ureterectomy|Undergo ureterectomy
214323986|NCT06232421|DRUG|Foscelantan|"Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus"
215066932|NCT06305793|DRUG|IVIG (intravenous immunoglobulin)|Participants will receive IVIG for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).
215066933|NCT06305793|DRUG|IVIG Placebo|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo.~Participants will receive placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months)."
214323987|NCT06232421|DRUG|Povidon-iodine|Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus
214323988|NCT06783283|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation (tACS) is a non-invasive electrical stimulation that will be used to stimulate the dorsolateral prefrontal cortex (dlPFC) and temporal cortices and in turn enhance Theta-Gamma Coupling (TGC) and working memory in Mild Cognitive Impairment (MCI). Each participant will receive daily stimulation for 10 days. To deliver the tACS, multiple electrodes embedded in a cap placed on the participant's head. Sham-tACS will follow the same procedure.
214323989|NCT06783283|DEVICE|Sham tACS|During sham-tACS, the device will ramp up to the desired intensity over 60 seconds, and then will immediately ramp down, and the stimulation will be shut off, until the end of the session. At the end of the session, the device will again ramp up for 60 seconds and then ramp down. Sham-tACS will also target dlPFC and temporal cortices (similar to active). Each participant will receive daily sham-tACS for 10 days. To deliver the sham-tACS, multiple electrodes will be embedded in a cap placed on the participant's head.
214924130|NCT02693028|DRUG|Probiotic lozenges|The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
214924131|NCT02693028|DRUG|Placebo lozenges|The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
214924132|NCT02693028|DRUG|Probiotic capsules|The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
214924133|NCT02693028|DRUG|Placebo capsules|The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
214924134|NCT02693028|DRUG|Probiotic chewing gum|The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
214323990|NCT05876182|DRUG|Oral Vancomycin|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
214323991|NCT05876182|OTHER|Placebo|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
214323992|NCT06700798|DRUG|Orelabrutinib|150mg po
214323993|NCT06700798|DRUG|rituximab|375mg/m\^2, intravenous
214323994|NCT06700798|DRUG|Cyclophosphamide|750mg/m\^2
214323995|NCT06700798|DRUG|Vincristine|1.4mg/m\^2
214323996|NCT06700798|DRUG|Prednisone tablet|60mg/m\^2
215066934|NCT06305793|BEHAVIORAL|Coordinated Care|Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
214323997|NCT06050746|OTHER|Systematic screening|Included children will be followed prospectively during five years through clinical visits and medical records, where need for additional treatment (casting, braces and/or surgery) is the primary endpoint.
214323998|NCT05847153|BEHAVIORAL|MASC|"The intervention arm will be comprised of:~1. Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~2. At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
214323999|NCT06188702|DRUG|S095035|S095035 will be taken orally once daily in 28-day cycles.
214924135|NCT06401473|BEHAVIORAL|Ipsilateral Scratch Task|Patients scratch the skin within the relevant cervical dermatome, ipsilateral to the injection site
214924136|NCT06401473|BEHAVIORAL|Motor Distraction Task|Patients scratch the skin of the shoulder/neck contralateral to the injection site
214924137|NCT00322270|DRUG|Alfimeprase|single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD
214924138|NCT05807698|BEHAVIORAL|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
214924139|NCT02429661|BEHAVIORAL|Peer support groups|
214324000|NCT06188702|DRUG|TNG462|TNG462 will be taken orally once daily in 28-day cycles.
214324001|NCT06287203|BEHAVIORAL|Addiction Risk Feedback Program|This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program). The information in part 2 of the program will vary between arms.
214324002|NCT03770156|BEHAVIORAL|Questionnaires|Overall Impression of the current state and evolution since the attacks
214324003|NCT03362502|GENETIC|PF-06939926|"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
214324004|NCT06283446|BEHAVIORAL|High-Intensity Cue|Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
214924140|NCT02985645|PROCEDURE|maxillary sinus augmentation with CGF|Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system
214924141|NCT02985645|DEVICE|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply the CGF to the maxillary sinus.
214924142|NCT04450277|PROCEDURE|Emergency surgery|Emergency surgery vs conservative management
214924143|NCT01217476|DRUG|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
215066935|NCT06305793|BEHAVIORAL|Usual Care|Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with IVIG administration.
214324005|NCT06283446|BEHAVIORAL|Low-Intensity Cue|Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
214324006|NCT05999578|OTHER|Hypnosis|Hypnosis support before, during and at the end of cardiac MRI exam
214324007|NCT04833348|OTHER|Motor function measurement using inertial sensors|"Measurement of motor skills at M0: start of the administration of the innovative therapy and then 1 month, 3 months, 6 months, 1 year and then 2 years later:~* Free motor skills in the supine position~* Motricity in the supine position stimulated by a play frame~* Measurement of the proximal and distal activity of the upper limbs in motor skills stimulated by the play gantry~* Measurement of activity in a supported sitting position Longitudinal study, the subject is his own control"
214324008|NCT06095102|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
214324009|NCT06095102|DRUG|Placebo|Placebo will be administered orally.
214324010|NCT04519528|OTHER|DENVER scale (under 2 years old) or Pediatric Cerebral Performance Category (PCPC) score (over 2 years old)|"The DENVER II is a measure of developmental problems in young children. It was designed to assess child performance on various age-appropriate tasks and compares a given child's performance to the performance of other children the same age. The instrument consists of 125 tasks, which broadly reflect the following areas: personal-social, fine motor-adaptive, language, and gross motor.~The target population corresponds to infants and pre-school age children.~The POPC and PCPC are global scales based on observer impressions. Scores include 1 for good, 2 for mild disability, 3 for moderate disability, 4 for severe disability, and 5 for vegetative state or coma (6 indicates death)."
214324011|NCT04519528|OTHER|Pediatric Quality of Life Inventory™ (PedsQL)|"The PedsQL questionnaire is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model integrates seamlessly both generic core scales and disease-specific modules into one measurement system. Twenty-three items divided into different functional areas are evaluated: physical (8 items), emotional (5 items), social (5 items) and school (5 items over 4 years old; 3 items before 4 y.o).~Child self-report and parent proxy report formats of the questionnaire allows self-assessment of child over 5 years old and parents' evaluations. Items can be reverse and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0) with higher scores indicating better quality of life."
214324012|NCT05441332|OTHER|EOS Radiation|One EOS exam of lower extremities
214924144|NCT03636971|DRUG|hyaluronic acid with mannitol|single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)
214324013|NCT05441332|BEHAVIORAL|Semi-structured interview|Semi-structured interview to identify factors influencing patient adherence behavior for a sub-group of 15 patients. By phone, between 1 to 3 months after inclusion.
214924145|NCT03636971|DRUG|hyaluronic acid with sorbitol|single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
214324014|NCT05176561|BEHAVIORAL|Auditory-Cognitive Training|"Treatment Participants will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Participants with spend 1 hour auditory training use Angel Sound and one hour of auditory cognitive training using auditory portions of Posit Science. A clinical paradigm including reviewing results, providing strategies and positive feedback and strategies in the 1 hour virtual meeting of clinician and participant. Practice for next week is assigned.~Control group intervention follows the same time and procedure but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search)."
214324015|NCT05176561|BEHAVIORAL|Non-auditory Cognitive Training|Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Control group intervention follows the same time and clinical paradigm, but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search).
214324016|NCT06553794|OTHER|Gastroscopy with duodenal mucosal tissue biopsies|"Subjects will undergo a standardized heavy water dosing protocol for 2 days (1 loading day, 1 maintenance day) and consume a standardized diet for 2 days. On the experimental test day, a gastroscopy with collection of duodenal mucosa tissue samples will be performed."
214324017|NCT00433654|DEVICE|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
214324018|NCT00433654|OTHER|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
215066936|NCT04058808|OTHER|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
214324019|NCT05582018|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
214324020|NCT03194165|BIOLOGICAL|Dolutegravir|Dosage
214324021|NCT03194165|BIOLOGICAL|Raltegravir|Dosage
214324022|NCT03194165|BIOLOGICAL|Rilpivirine|Dosage
214324023|NCT03194165|BIOLOGICAL|Nevirapine|Dosage
214324024|NCT03194165|BIOLOGICAL|Atazanavir|Dosage
214324025|NCT03194165|BIOLOGICAL|Darunavir|Dosage
214324026|NCT03194165|BIOLOGICAL|Ritonavir|Dosage
214324027|NCT04158297|PROCEDURE|ESWL vs SOPIL|To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.
214324028|NCT05904093|DRUG|Fostamatinib|Fostamatinib will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, orally, twice a day for 28 days (total 42 days).
214324029|NCT06028932|DRUG|Sacituzumab govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
214324030|NCT03100227|OTHER|PET [18F] FDG|Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
214324031|NCT03100227|OTHER|Anatomical MRI|All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
214924146|NCT03636971|DRUG|Placebos|single shot injection of saline, same volume
214924147|NCT06406907|OTHER|High Frequency Blood Flow Restriction Training Group|"Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
214924148|NCT06406907|OTHER|Low Frequency Blood Flow Restriction Training Group|"Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
215066937|NCT04058808|OTHER|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
215066938|NCT04058808|OTHER|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
215066939|NCT04058808|OTHER|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
214324032|NCT04984551|OTHER|Extension of Community Health (ECHO) Telementoring Clinic|Participate in ECHO clinics presenting cases for guidance and feedback
214324033|NCT04984551|OTHER|In-Country Workshops|In-Country Workshops Participate in hands-on training and workshops
214324034|NCT04984551|OTHER|Professional Oncology Educations Programs|Receive 5 core online lectures
214324035|NCT04984551|OTHER|Medical Chart Review|Medical charts are reviewed for data collection
214324036|NCT04984551|OTHER|Questionnaire Administration|Complete questionnaire(s)
214324037|NCT06484855|DRUG|IBI355|IBI355 IV. Q4W
214324038|NCT06484855|DRUG|IBI355 placebo|IBI355 placebo IV. Q4W
214324039|NCT01428193|DRUG|Flutamide|Subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day.
214324040|NCT01428193|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
214924149|NCT06406907|OTHER|High Frequency Blood Flow Restriction Training Instability Group|"Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
214324041|NCT01428193|DRUG|estrace|0.5-1 mg once a day for seven days
214324042|NCT06428019|DRUG|Venetoclax|Oral: Tablet
214324043|NCT06428019|DRUG|Acalabrutinib|Oral: Tablet
214324044|NCT06428019|DRUG|Obinutuzumab|Intravenous Infusion
214324045|NCT04590885|BEHAVIORAL|Couple Communication Skills Training|Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.
214324046|NCT04590885|BEHAVIORAL|Healthy Lifestyle Information|Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.
214324047|NCT05157100|DRUG|Ingrezza Pill|Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
214324048|NCT04589403|DRUG|OPT101|15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40
214324049|NCT02315768|DRUG|GA101|
214324050|NCT02315768|DRUG|Ibrutinib|
214324051|NCT02135575|BEHAVIORAL|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
214672812|NCT02517879|OTHER|Community point distribution|Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
214324052|NCT03700359|DRUG|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
214324053|NCT03700359|DRUG|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
214324054|NCT03700359|DRUG|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
214324055|NCT06086301|OTHER|PICTURE-THIS|Discharge plans include scheduling post-discharge appointments, community support referrals, transportation arrangements, and addressing identified gaps. Transition care includes 8 check-ins over 3 months post-discharge, focusing on assessing, troubleshooting, and celebrating transition successes, using phone or video. Telehealth-assisted 'warm hand-offs' will connect interventionists with home health and primary care teams during initial visits. '1st touch daytime troubleshooting' offers extra support between check-ins. Problem-solving rehabilitation will be continued from hospital to home, with 7-10 sessions over 3 months, including a home safety survey. A Post-ICU Caregiver Toolkit provides workbooks, training videos, and resources. Lastly, referrals for patient and caregiver social/mental health support are provided.
214324056|NCT06086301|OTHER|Enhanced Usual Care|Enhanced Usual Care (EUC) control group will receive: (1) Patient and Family Re-sources published by the SCCM for PICS prior to hospital discharge; (2) ongoing assessments on the same schedule as the PICTURE-THIS intervention; (3) referral for urgent or emergent issues identified during assessments. The investigators will not provide the URL for the Post-ICU Caregiving Toolkit but the investigators will not restrict its access either. This control design balances 3 goals: 1) masking participants to group allocation; 2) responding ethically to harm/distress; 3) maintaining group separation to optimize efficacy testing of PICTURE-THIS.
214324057|NCT06086301|BEHAVIORAL|Run-In Phase|All participants receive a Run-In Phase during the acute critical illness hospitalization. It consists of 3 inpatient study visits: (1) health and social screening; (2) planning for rehabilitation; (3) discharge education and training.
214324058|NCT05197270|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
214324059|NCT05197270|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator Other Name: Eylea
214324060|NCT03716934|DEVICE|Arctic Front Advance® balloon catheter|Cryoablation of bidirectional block of all pulmonary veins
214324061|NCT03716934|DRUG|Antiarrhythmic drug|The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.
214672813|NCT02517879|OTHER|Community health worker hang-up visit|CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
214672814|NCT01089855|DRUG|Carbamazepine|
215066940|NCT04058808|OTHER|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
214324062|NCT03716934|DEVICE|Confirm RX heart monitor® (Abbott)|Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function
214324063|NCT04135703|BEHAVIORAL|Risk Prevention Services + Housing|opioid and related prevention services in addition to 6 months of rental assistance
214324064|NCT04135703|BEHAVIORAL|Risk Prevention Services Only|opioid and related prevention services for 6 months
214324065|NCT01550575|DEVICE|Non Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc.
215066941|NCT04058808|OTHER|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
215066942|NCT00161577|DRUG|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
214324066|NCT01550575|DEVICE|Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc
215066943|NCT00161577|OTHER|Placebo|Placebo Comparator
215066944|NCT00994734|DRUG|Mifepristone|home administration of mifepristone
215066945|NCT06489704|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
214324067|NCT06517290|OTHER|Non applicable|Non applicable
214672815|NCT05631951|PROCEDURE|bone transport through induced membrane|Debridement done followed by external fixator and cement application to be followed by removal of cement (after 6 weeks) and start bone transport
214924150|NCT06406907|OTHER|Low Frequency Blood Flow Restriction Training Instability Group|"Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
215066946|NCT05409859|OTHER|Manual therapies|Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
215066947|NCT02658747|OTHER|No intervention|No intervention administered in this study
215066948|NCT05386719|OTHER|Prescreening|Eligible patients (history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins, reads and speaks English) complete survey for demographics, smoking status \& questions about cardiovascular disease.
214672816|NCT05631951|PROCEDURE|bone transport|Debridement done then external fixator was applied then bone transport started.
215066949|NCT05386719|OTHER|Screening and Enrollment|Consent
215066950|NCT05386719|BEHAVIORAL|Baseline|Behavioral Battery and Patient Reported Outcome Quality of Life questionnaires (EORTC QLQ-C30 and QLQ-BR23) Labs (Hba1c + lipid panel if not done within 12 months or if abnormal within 1 year) Abstract vitals from chart review
215066951|NCT05386719|BEHAVIORAL|Interpret BMI|Refer to Healthful Eating, Activity and Weight Program (HEAWP) if BMI ≥25 and not already on lifestyle intervention
215066952|NCT05386719|OTHER|Interpret HbA1c|"HbA1c results categorized as follows:~HbA1c \<5.7%; HbA1c 5.7-6.4%; HbA1c 6.5%+; or Known diabetic on medication"
215066953|NCT05386719|OTHER|Interpret lipid panel and assess other risk factors|"Based on above categories:~HbA1c \<5.7%: Any of these cardiovascular disease risk factors: current/former tobacco use, total cholesterol \>200, family history of Coronary Artery Disease/Heart Attack in first degree family \<55 year old male or \<65 year old female, systolic blood pressure \>130 HbA1c 5.7-6.4%: Refer to Primary Care Provider and consider Healthful Eating, Activity and Weight Program (HEAWP) HbA1c 6.5%+: Refer to Endocrinology if HbA1c ≥8% Known diabetic on medication: Refer to Endocrinology if HbA1c ≥7%"
214324068|NCT05806216|DEVICE|EarliPoint Diagnosis|Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder
214324069|NCT05806216|BEHAVIORAL|Clinically Certain Expert Clinician Diagnosis (CC-ECD)|Diagnosis by an expert clinician using gold standard developmental assessment tools.
214324070|NCT06494384|BEHAVIORAL|Problem Solving Treatment as usual (PST as usual)|PST is a skills-based intervention that teaches clients a 7-step approach in which they 1) select a specific problem and define it in concrete terms,2) select a goal that is feasible to reach before next session, 3) brainstorm various ways to accomplish the goal, 4) evaluate pros and cons of each solution, including the likelihood they can actually implement it, 5) select the best solution, 6) create a plan to implement the solution, and 7) evaluate the plan afterward to ascertain the effectiveness of the solution. Practitioners teach and illustrate the PST process to clients at each session and encourage clients to implement action plans developed using the PST process. Clients are also encouraged to practice the PST process with additional problems between sessions, in order to gain mastery over the PST skills, enhance behavioral activation and as a result improve their belief in their ability to solve problems on their own (self efficacy).
214324071|NCT06494384|BEHAVIORAL|Problem Solving Treatment Aid (PST-Aid)|PST-Aid is an internet-based tool to support the delivery of PST. PST-Aid incorporates decision support for the practitioner as well as client and provides PST treatment support functions (i.e., scaffolding), including patient problem lists and session worksheets. PST-Aid was designed to be used during remote sessions, such that practitioners and clients can interact throughout the session while collaboratively viewing and editing worksheets on their own browsers.This system was developed into a prototype that was piloted and found to be acceptable and with adequate usability.
214672817|NCT00628810|BIOLOGICAL|bevacizumab|
214672818|NCT00628810|DRUG|fluorouracil|
214672819|NCT00628810|DRUG|irinotecan hydrochloride|
214672820|NCT00628810|DRUG|leucovorin calcium|
214924151|NCT06406907|OTHER|Control Group|"The subjects of this group will perform squat exercise 6 days a week but without BFR. Pneumatic cuff will be wrapped around the thigh of the subjects but it would not be inflated.~Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
215066954|NCT05386719|BEHAVIORAL|Assess 10 year risk of cardiovascular event|If risk factors are present - refer to Cardiovascular Disease Prevention Program
214924152|NCT02953847|DRUG|Rimactane|150 mg capsules, Sandoz MCC registration # A/20.2.3/784
214324072|NCT04811274|BIOLOGICAL|Blood collection|2 to 5 ml
214324073|NCT04811274|BIOLOGICAL|Bronchoalveolar lavage fluid collection|5 to 25 ml
214324074|NCT03757182|OTHER|Wearable activity monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR)
215066955|NCT05386719|BEHAVIORAL|Recommendations|Provide individual patient handout based on all above interventions
215066956|NCT05386719|BEHAVIORAL|Follow-Up|6 and 12 month labs (if prior abnormal) and Patient Reported Outcome questionnaires
215066957|NCT05873192|DRUG|ADT|Given by PO
215066958|NCT05873192|DRUG|Enzalutamide|Given by PO
215066959|NCT05873192|DRUG|Talazoparib|Given by PO
215066960|NCT05873192|DRUG|Degarelix|Given PO or given INJ
215066961|NCT05873192|DRUG|Luprolide|Given PO or given INJ
214324075|NCT00132418|DRUG|Enbrel|Enbrel
214324076|NCT00132418|DRUG|Placebo|Placebo
214324077|NCT03653936|DEVICE|HITT device|Rebion has developed a noninvasive, handheld device that uses retinal polarization scanning (RPS) to rapidly assess eye fixation and retinal integrity in adults and children. RPS can automatically detect the fixation of the human eye with proprietary technology that uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. RPS requires no calibration or imaging, and eye movement recordings are not required. The HITT device is a repurposed Pediatric Vision Scanner (PVS), Rebion's first commercial product which has passed all applicable safety and performance standards.
214324078|NCT06301854|DRUG|TPN171H|10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.
214324079|NCT03364088|PROCEDURE|Spinal anesthesia with tourniquet|Operation is done under spinal anesthesia and surgical tourniquet is used.
214324080|NCT03364088|PROCEDURE|Spinal anesthesia without tourniquet|Operation is done under spinal anesthesia and without the use of surgical tourniquet.
214324081|NCT03364088|PROCEDURE|General anesthesia with tourniquet|Operation is done under general anesthesia and surgical tourniquet is used.
214924153|NCT02953847|DRUG|Rifafour e-275|Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
214924154|NCT02953847|DRUG|Rimactazid 150/75|Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
215066962|NCT06338280|OTHER|Sonara|Sonara virtual dosing window and engagement platform
215066963|NCT00875485|PROCEDURE|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
215066964|NCT00875485|BIOLOGICAL|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
215066965|NCT01837446|DRUG|2% morphine solution|
215066966|NCT01837446|DRUG|Magnesium aluminum hydroxide|
215066967|NCT01837446|DRUG|2% viscous lidocaine|
215066968|NCT01837446|DRUG|Diphenhydramine|
215066969|NCT00798629|BIOLOGICAL|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
215066970|NCT01611116|DRUG|sodium chloride solution 0.9%|intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
215066971|NCT01611116|DRUG|temsirolimus|intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
215066972|NCT01271010|DRUG|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
214324082|NCT03364088|PROCEDURE|General anesthesia without tourniquet|Operation is done under general anesthesia and without the use of surgical tourniquet.
214324083|NCT03364088|DRUG|Oxycodone by patient-controlled analgesia (PCA)|PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
214324084|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
214324085|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
214324086|NCT03962803|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
215066973|NCT01271010|DRUG|Fludarabine|Participants received fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle.
215066974|NCT01271010|DRUG|Rituximab|Participants received 375 mg/m\^2 IV on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle.
215066975|NCT02637414|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
215066976|NCT00025298|DRUG|amifostine trihydrate|
215066977|NCT00025298|DRUG|carboplatin|
215066978|NCT00025298|DRUG|cisplatin|
215066979|NCT00025298|DRUG|paclitaxel|
215066980|NCT00025298|RADIATION|radiation therapy|
215066981|NCT02285582|OTHER|Registry study|No intervention.
214924155|NCT03764397|BEHAVIORAL|Prehabilitation for behavioural change|The 4-week prehabilitation educational programme will consist of a meeting for one session (approximately 1 - 1.5 hours) per week. This behavioural change programme will involve a mixture of interactive and didactic sessions, facilitated by a physiotherapist, psychologists, and other health professionals. The purpose of the initial prehabilitation programme is to gain participant 'buy-in' to the programme, to assist participants engage with exercise, to help participants overcome barriers to exercise and improve self-efficacy for exercise. The prehabilitation phase will also enable participants to understand why and how to perform gentle self-paced exercise. After the prehabilitation programme, participants will be advised to engage in a 6-week gentle self-paced walking programme; i.e., a simple pedometer-driven walking programme with weekly telephone support.
214924156|NCT03324347|PROCEDURE|Therapydog|Presence of a therapydog during a clinical examination in a dental clinic
214924157|NCT01577953|DRUG|SB010|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.~Dose levels:~Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL)."
214924158|NCT01577953|DRUG|Placebo|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board."
214924159|NCT00541411|DRUG|Vincristine, Actinomycin-D, Ifosfamide|Chemotherapy
214924160|NCT06416891|DRUG|bupivacaine 0.25%|SCPB using 10 ml of bupivacaine 0.25%
214924161|NCT06416891|DRUG|dexamethasone 2 mg in bupivacaine 0.25%|SCPB using dexamethasone 2 mg in 10 ml of bupivacaine 0.25%
214924162|NCT06240273|DIETARY_SUPPLEMENT|Corn silk powder|Corn silk (CS) is abundant in phenolic compounds, especially flavonoids. It also contains proteins, vitamins, carbohydrates, calcium, potassium, magnesium, sodium salts, volatile oils, sterols like sitosterol and stigmasterol, alkaloids, and saponins. Numerous studies have explored the pharmacological activities associated with CS.
214924163|NCT03759015|BEHAVIORAL|Health education|All subjects are tasked to create an original 10-minute theater about physical activity and diet/nutrition.
214924164|NCT06479967|OTHER|The VR glasses group|"The Virtual Reality glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine The VR glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine After the SPT, the VR glasses group took a 1-minute break from watching videos and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the VR glasses group continued watching cartoon"
214924165|NCT06479967|OTHER|the music group|The music group listened to classical piano \&#34;The Best of Chopin.\&#34; After the music group took a 1-minute break from listening to music, and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the music group continued to listen to the music. During the SPT evaluation, the music group took a 1-minute break from listening to music at 5, 10, and 15 minutes, and the child evaluated the level of itching from 1 to 10.
215066982|NCT01631747|BEHAVIORAL|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer
215066983|NCT01631747|BEHAVIORAL|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
214324087|NCT05892510|DRUG|Intra-arterial tenecteplase injection at the completion of thrombectomy|Intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion, or in direct contact with the residual thrombus
214324088|NCT05892510|DRUG|Placebo|intra-arterial bolus of 0.9% Sodium Chloride solution
214324089|NCT06219915|DRUG|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
214324090|NCT06219915|DRUG|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
214324091|NCT06219915|DRUG|Placebo 1|Participants will take one 25mg placebo tablet 3 times a day for 10 days.
214324092|NCT06219915|DRUG|Placebo 2|Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
214324093|NCT05320029|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
214324094|NCT05320029|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
214324095|NCT02694419|DEVICE|Doppler evaluation|Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
214324096|NCT05581121|OTHER|Standard treatment: Control arm|Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations.
214324097|NCT05581121|PROCEDURE|Experimental arm|Pre-therapeutic para-aortic lymphadenectomy (by minimally invasive approach) followed by tailored chemo-radiotherapy and brachytherapy. Both traditional laparoscopy or robotically assisted laparoscopy approaches are accepted in the study.
214924166|NCT03738813|DEVICE|Gloreha Aria|Device offers specific programs that help patients to move arm, wrist and fingers
214924167|NCT03738813|OTHER|Usual care|Conventional occupational therapy
214324098|NCT06105528|DRUG|PMN310|60-minute intravenous infusion
214924168|NCT03953495|BEHAVIORAL|Better Together|The Better Together Intervention consists of a 7 self-paced online relationship education modules. Following an introductory and overview module couples will complete each of the following together on their web-connected device (computer, ipad, phone). Each module includes didactic material, demonstration vignettes, and guided discussions or skills building exercises. Module 1 focuses on identifying individual and relationship strengths; Module 2 focuses on destructive communication patterns, Module 3 focuses on positive communication skills; Module 4 teaches a problem-solving technique; Module 5 focuses on stress and coping; Module 6 focuses on relationship expectations and commitment, and Module 7 provides a summary of the program. Each module takes approximately 30 minutes to an hour to complete. Metrics will be assessed at baseline, post-intervention, and at a 3 month follow up.
214924169|NCT01612689|DEVICE|Accelerometer Device|A sensor platform that enables physiological monitoring in routine, home or office environments.
214924170|NCT02355184|DRUG|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
214924171|NCT02527252|OTHER|Craniosacral therapy|
214924172|NCT02527252|OTHER|Classic Massage|
214924173|NCT01436877|DEVICE|Insertion of Temporary Implantable Nitinol Device (TIND)|Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
214924174|NCT02480374|BIOLOGICAL|IMNN-001|
214324099|NCT06105528|DRUG|Placebo|60-minute intravenous infusion
214324100|NCT04114435|OTHER|Echocardiography|Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures
214324101|NCT00351234|DRUG|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
214324102|NCT05431062|DRUG|Bupivacain|%0.25
214324103|NCT05783505|OTHER|Multicomponent intervention program|Non-pharmacological interventions combined with goal directed sedation using dexmedetomidine if needed
214324104|NCT05373511|OTHER|"3D/4D spine and posture analysis DIERS FORMETRIC 4D ,The Biodex Balance System SD-"|"3D/4D spine and posture analysis DIERS FORMETRIC 4D for postural analysis assessment~,The Biodex Balance System SD- for balance assessment"
214324105|NCT03523377|OTHER|prolonged overnight fasting|Three phone calls using motivational interviewing, support via SMS text.
214324106|NCT03523377|OTHER|usual care|Eat a heart-healthy diet and exercise for at least 30 minutes five days a week
214324107|NCT04458714|PROCEDURE|Aortoiliac angioplasty|In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
214324108|NCT01246791|DRUG|NPC-01|NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
214324109|NCT06255028|BIOLOGICAL|CNTY-101|CNTY-101 cells for intravenous (IV) infusion
214324110|NCT06255028|BIOLOGICAL|IL-2|IL-2 subcutaneous (SC) injection
214324111|NCT06255028|DRUG|Lymphodepleting Chemotherapy|LDC as prespecified in the protocol.
214324112|NCT05843084|PROCEDURE|7T MRI network analysis for deep brain stimulation in Parkinson's disease|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in PD patients.
214324113|NCT04332653|DRUG|NT-I7|Administered by intramuscular (IM) injection
214324114|NCT04332653|DRUG|pembrolizumab (KEYTRUDA®)|Administered by intravenous (IV) injection
214324115|NCT05503173|BEHAVIORAL|MCBMAP|MCBMAP integrates motivational interviewing (MI) and cognitive-behavioral skill training interventions for unhealthy drinking with cognitive-behavioral and self- management approaches for chronic pain. The intervention is delivered through internet-based videoconferencing and supplemented with web-based content to support the intervention. The initial treatment session provides a rationale for addressing alcohol and pain together in the context of HIV management, and initiates MI related to alcohol use. Participants receive 6 additional treatment sessions over the subsequent weeks.
214324116|NCT05503173|OTHER|Brief Advice and Information|Through videoconferencing an interventionist will provide participants psychoeducation about the effects of alcohol and pain on HIV symptoms, advice/recommendations to reduce alcohol use, and a list of local treatment resources for alcohol and chronic pain.
214324117|NCT04049760|DRUG|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
214324118|NCT06441201|DIAGNOSTIC_TEST|Pulse flowmeter|Measures peripheral pulse volumes by an electrode applied non-invasively to the lower extremity (left or right) at the beginning of the endoscopic evaluation for the duration of the procedure, and up to 2 hours after the completion of the procedure.
214324119|NCT05541783|PROCEDURE|laparoscopy-assisted distal gastrectomy Group|LADG
214324120|NCT05541783|PROCEDURE|Totally laparoscopic distal gastrectomy|TLDG
214324121|NCT06120855|DRUG|Regulated cannabis from authorized pharmacies|"The intervention group is allowed to purchase regulated cannabis in authorized pharmacies. The intervention includes various offers: Participants can choose between cannabis sorts and delivery methods, and they are encouraged to shift from smoking cannabis to vaping cannabis-containing e-liquids, vaporizing cannabis blossoms or using oral cannabis. Vaping / vaporizing electronic devices are also recommended. At the same time, pharmacists offer opportunistic smoking cessation and problematic cannabis, alcohol use and further drug use counseling that conforms to motivational interviewing principles.~Study participants can choose between different cannabis-containing products such as dried cannabis flowers, cannabis concentrates (colloquially called hashish or hash), e-liquids and oral cannabis. Besides the cannabis products, participants can buy vaping or vaporizing electronic devices at the pharmacy (they are not considered as study products)."
214324122|NCT06120855|DRUG|Cannabis from the illicit market|The control group receives no intervention and is expected to continue purchasing cannabis from the illicit market.
214672821|NCT06511154|OTHER|Cognitive Rehabilitation|"Cognitive rehabilitation is a treatment method used to regain or improve cognitive abilities.For the cognitive rehabilitation program, the Daily Exercise Package of the Norosoft Program, which mainly includes exercises to improve attention, information processing speed, verbal and visual memory functions, will be applied.~Core-based Upper Extremity Exercises~Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises"
214324123|NCT05929495|DRUG|Metformin|"The investigator will identify potential participants and confirm the diagnosis of GBM. Subjects will be screened within 6 weeks before starting treatment.~Treatment will involve:~* Administration of the standard or partial Stupp protocol (Radiotherapy + Temozolomide) in combination with Metformin for 6 weeks,~* Treatment with only Metformin for 4 weeks;~* Resumption of adjuvant TMZ + Metformin treatment continuously until the end of the enrollment period."
214324124|NCT02457598|DRUG|Tirabrutinib|Capsules or tablets administered orally
214324125|NCT02457598|DRUG|Idelalisib|Tablets administered orally twice daily
214324126|NCT02457598|DRUG|Entospletinib|Tablets administered orally
214324127|NCT02457598|DRUG|Obinutuzumab|Administered intravenously
214324128|NCT03794115|PROCEDURE|Treatment for ovarian cancer|The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.
214672822|NCT06511154|OTHER|Core-based Upper Extremity Exercises|Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
214672823|NCT05668156|OTHER|Consensus Decision Making|Consensus-based decision-making process, where experts are asked to comment definitions of terms used for fasting interventions
214324129|NCT06272344|OTHER|Teleconsultation|Teleconsultation at 6 months
214324130|NCT01403974|DRUG|BI 836845|Intravenous infusion once every week
214324131|NCT06411678|DRUG|68GA-DOTA-dPNE|Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection
214924175|NCT00379444|BEHAVIORAL|Standard intervention (counseling + self-help written materials)|counseling
214324132|NCT04486378|DRUG|RO7198457 intravenous (IV)|RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
214324133|NCT04486378|OTHER|Observational group (no intervention)|watchful waiting
214924176|NCT00379444|BEHAVIORAL|Enhanced Intervention (same as standard treatment plus 10-15 min of counseling and a culturally tailored video)|counseling
214924177|NCT02511392|PROCEDURE|rTMS-1Hz|
214924178|NCT02511392|PROCEDURE|rTMS-10 Hz|
214924179|NCT02511392|PROCEDURE|Sham rTMS|
214924180|NCT04588870|DEVICE|Pre operative computer based cochlear implant surgical simulation|Prior to surgery, the surgeon will perform virtual cochlear implant surgery on patient specific imaging data within a computer simulation program. The surgeon will be able to iterate the procedure on the simulator until achieving the best electrode array location is achieved with respect to scalar location and modiolar distance. A written and graphical surgical plan will then be developed that the surgeon can use in the actual surgery.
214924181|NCT04443062|DRUG|177Lu-PSMA-617|PSMA radioligand therapy
214924182|NCT00268177|DRUG|Salmeterol/fluticasone propionate 50/500mcg Diskus|
214324134|NCT05147272|DRUG|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 in combination with gemcitabine
214324135|NCT01589757|OTHER|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
214485943|NCT06858527|OTHER|TAU+integrated group CBT|"TAU+integrated group CBT : participants receive a group psychotherapeutic intervention of Integrated CBT lasting eight weekly two-hour sessions, in parallel with their usual individual care. The sessions are led by a psychologist trained and certified in the practice of CBT and a psychiatrist specialized in addiction medicine. The psychotherapeutic intervention follows a fixed structure and is inspired by the CBT manual for the management of ADHD associated with SUDs published by Matthys et al. (2018). This intervention includes modules on planning and organization, time and distraction management, emotional regulation, work on impulsive behaviors and social skills, cognitive work, as well as substance use management and relapse prevention.~The sessions will be punctuated by regular breaks to ensure participants' comfort and the integration of the skills worked on during the sessions.~TAU : participants receive their usual care, in exception of group psychotherapeutic interventions."
214485944|NCT06988228|BIOLOGICAL|15% Dextrose Injection|15% dextrose solution will be administered by injection in three sessions at two-week intervals. It will be applied in combination with conventional exercise therapy.
214924183|NCT01659593|OTHER|procog|3 to 5 people group program
214924184|NCT01659593|OTHER|Placebo|
214485945|NCT06988228|OTHER|izotonic saline injection|Participants will receive isotonic saline solution injections in three sessions at two-week intervals, as a placebo comparator to the 15% dextrose injections. All participants will also receive conventional exercise therapy.
214924185|NCT03491046|DEVICE|PET scan|low dose fluorodeoxyglucose (FDG) PET research scan with CEST sequence
214924186|NCT03491046|DEVICE|MRI scan|standard of care MRI
214324136|NCT01589757|OTHER|Low GI diet|"Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate."
214485946|NCT06990386|BEHAVIORAL|self-management program|Self-management booklet based on the self-management framework consisting of 4 categories: a) self-monitoring, which consisted of self-observation and self-recording of DU and RP; b) performing special tasks to manage the disease, including keeping warm, maintaining moisture, and taking traumatic wound precautions; c) information seeking; and d) self-adjustment based on disease activity and treatment.
214485947|NCT06990386|BEHAVIORAL|Video guide and usual education|Video guide was the hand and joint exercise video guide that included a 3.27-minute educational video on 6 basic daily hand exercises including: a) stretching wrist flexion and extension, b) range of motion (ROM) ulnar and radial deviation, c) ROM finger abduction and adduction, d) finger pincer, e) finger flexion and extension, and f) finger grab.
214924187|NCT01672710|DRUG|plain crystalline niacin, exercise, sauna|A four to six week regimen consisting of daily, supervised, mild-moderate exercise as tolerated for 20 minutes, supervised, intermittent Finnish saunas (at about 140'F) sauna time with breaks and showers, gradually increased as tolerated to approximately 4 hours, dietary supplements including immediate release niacin in gradually increasing doses from 100 mg to a maximum of 5000 mg per day, salt and water, other vitamins, minerals and oils per Hubbard protocol.
214924188|NCT02122887|BEHAVIORAL|Peace-Building Intervention Process|"The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders."
214924189|NCT05175664|OTHER|Long-term study|No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
214924190|NCT05175664|OTHER|Short-term study|No intervention. Investigations: blood samples and pupillometry.
214924191|NCT05175664|OTHER|Cross-sectional study|No intervention. Investigations: cognitive tests, pupillometry and actigraphy.
214924192|NCT00806663|DRUG|sunitinib added to FOLFIRI|sunitinib 37 mg once daily (4 weeks on/2 weeks off)
214924193|NCT05122247|OTHER|Machine learning algorithm|machine learning directed identification of chemotherapy patients at high-risk for emergency department acute care and/or hospitalization
214924194|NCT04383938|DRUG|APR-246 (eprenetapopt) + Pembrolizumab|APR-246 D1-4 + Pembrolizumab D3
214324137|NCT06272097|BEHAVIORAL|Intervention program based on TIME-CDST tool led by wound specialist nurses|Based on the TIME CDST tool led by wound specialist nurses, which includes the following five areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment; E. Evaluate and reassess the treatment and wound management outcomes; Give patients health education on wound care management.
214324138|NCT06272097|BEHAVIORAL|A routine wound care program|A routine wound care program of wound cleaning and dressing changes
214485948|NCT06990386|BEHAVIORAL|Telephone notification, video guide and usual education|Telephone notifications consisted of weekly calls for further continuity and engagement with hand exercises. Each call lasted about 10 minutes, providing problem-solving support, knowledge reinforcement, and motivation to encourage adherence to the program.
214924195|NCT05457036|DEVICE|Spry Belt|The Spry Belt is a device worn around the hips which delivers gentle energy to the lower back. The level of energy is controlled by an internal microprocessor (computer) so that it is safe and comfortable. The energy is at a level that may or may not be perceptible to the user. The device is powered by an internal lithium-ion battery which must be recharged periodically. The device is designed to be used with its companion Spry app (via Bluetooth Low Energy (BLE)) so that anonymous usage statistics may be monitored. The expected shelf life of the device is longer than 2 years and the expected use life is at least 12-18 months.
214924196|NCT05457036|DEVICE|Sham Spry Belt|The Sham Spry Belt is a device worn around the hips which does not deliver gentle energy to the lower back. The device instead provides a clicking noise similar to a motor. The device is powered by an internal lithium-ion battery which must be recharged periodically. The device is designed to be used with its companion Spry app (via BLE) so that anonymous usage statistics may be monitored. The expected shelf life of the device is longer than 2 years and the expected use life is at least 12-18 months.
214924197|NCT06683651|DRUG|STN1013800 ophthalmic solution|Investigational Product: 0.1% STN1013800 ophthalmic solution
214924198|NCT06683651|DRUG|STN1013800 ophthalmic solution Liquid Base, without STN1013800|Placebo control: STN1013800 ophthalmic solution Liquid Base, without STN1013800
214924199|NCT06428721|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
215066984|NCT03024333|OTHER||Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
215066985|NCT02908685|DRUG|Placebo|Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
214324139|NCT03518320|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
214324140|NCT03518320|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
215066986|NCT02908685|DRUG|Risdiplam|Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
214324141|NCT05971849|DRUG|kisspeptin 112-121|IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin
214324142|NCT05750667|BEHAVIORAL|Cascade screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
214324143|NCT05086731|OTHER|Best Practice|Receive standard of care
214924200|NCT06959329|OTHER|Active and passive physical therapy without intensified sensory stimulation|"Intervention: Passive and active therapy without high sensory stimulation Duration: 4 weeks Frequency: 3 sessions per week Session duration: 60 minutes~Intervention structure:~Passive therapy (30 minutes):~• Stroking and rubbing techniques from classic massage applied in the area of arm forearm and hand with low force and frequency upper limb massage - 15 minutes per limb~Active therapy (30 minutes): upper limb muscle strengthening exercises (without globalized vibration); difficulty level individually adjusted to meet participants' current potential, so that in the last sets/reps little manual assistance from the therapist is needed:~* Supine pull-ups - 3 sets of 8 reps, \~45 seconds rest between sets~* Standing pull-ups - 3 sets of 8 reps, \~45 seconds rest between sets~* Standing push-ups - 3 sets of 8 reps, \~45 seconds rest between sets~* Standing elbow extensions - 3 sets of 8 reps, \~45 seconds rest between sets"
214324144|NCT05086731|OTHER|Informational Intervention|Receive reminders
214324145|NCT05086731|OTHER|Medical Device Usage and Evaluation|Receive a SMRxT smart pill bottle
214324146|NCT05086731|OTHER|Quality-of-Life Assessment|Ancillary studies
214485949|NCT06988943|DEVICE|Low-dose CT screening|Low-dose CT screening is conducted at primary healthcare institutions, and patients with detected lung nodules are referred to hospitals for further examination
214485950|NCT06988943|DEVICE|AI full-lung model interpretation system|Using artificial intelligence technology to assist in the interpretation of CT images
214324147|NCT05086731|OTHER|Survey Administration|Ancillary studies
214324148|NCT05475184|DRUG|JPI-547|"Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal."
214924201|NCT06959329|OTHER|Active and passive physical therapy with intensified sensory stimulation|"Intervention: Passive and active therapy incorporating high sensory stimulation Duration: 4 weeks Frequency: 3 sessions per week Session duration: 60 minutes~Intervention structure:~Passive therapy (30 minutes): stimulation of joint receptors, muscle spindles, and tactile pathways:~* High-frequency soft tissue mobilisations~* Localised high-amplitude vibration (30-50 Hz; Galileo Mano 30, Novotec Medical GmbH)~* Deep pressure techniques - Wilbarger brushing protocol followed by joint compressions Active therapy (30 minutes): upper limb and shoulder girdle muscle strengthening exercises with globalized vibration using Redcord Stimula (30-50 Hz; Redcord AS, Norway); difficulty level individually adjusted to meet participants' current potential. Excercises the same as in the control group."
214924202|NCT06005285|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model focuses on teaching inside children's play and care activities, carried out within a joint activity structure. Adults follow children's leads into activities, embed teaching objectives inside the play, use the play as the reward, and build targeted skills following developmental science and ABA principles.
214924203|NCT06005285|BEHAVIORAL|Early Intensive Behavioral Intervention (EIBI)|Treatment as usual provided by community-based autism agencies
214924204|NCT04342767|DEVICE|EZ Debride®|EZ Debride ® is intended for the mechanical debridement of topical wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post Mohs' surgery, post-laser surgery, podiatric, wound dehiscence) trauma wounds (abrasions, lacerations, second-degree burns and skin tears), draining wounds and tunnelled /undermined wounds.
214924205|NCT06431555|DEVICE|MRI|Non-contrast, free-breathing MRI scan
214924206|NCT00836888|BIOLOGICAL|ONO-4538|1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
214924207|NCT06049966|DRUG|Atezolizumab|TECENTRIQ C/S.SOL.IN 1200MG/VIAL (20ML) 1 VIAL x 20ML
214924208|NCT06049966|DRUG|Carboplatin|SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML
214924209|NCT06049966|DRUG|Etoposide|ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML
214924210|NCT03864731|DEVICE|Bone conduction device (ADHEAR)|adhesive bone conduction device
214924211|NCT03652636|DRUG|Sulfur Hexafluoride Microspheres|2.5 mL intravenous injection given at the time of ultrasound, with second 2.5 mL intravenous injection given during ultrasound as needed to improve visualization
214924212|NCT00177840|PROCEDURE|acupuncture|
214924213|NCT05550909|DRUG|Artesunate-amodiaquine combination|Tablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines
214324149|NCT05153382|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly meetings and individual therapy conducted in 60 minute biweekly sessions. Family participation in skills training is highly encouraged. Skills training proceeds as follows: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants by cell phone for in-vivo skills coaching between sessions.
214324150|NCT06367361|DRUG|Oxfendazole|Human studies have shown that doses up to 60 mg/kg (approximately 3.6 g for a 60-kg human, which is considered the average weight of an adult in developing countries) are safe and that repeated doses of 15 mg/kg (approximately 900 mg for a 60-kg human) daily for 5 days are safe. A single dose of OXF results in significant plasma drug concentrations that reach a Cmax plateau after doses of 15 mg/kg.75 The dose to be studied in this trial is 20 mg/kg (1200 mg maximum dose), a dose only slightly higher than that achieving a Cmax plateau. This dose was conservatively selected to account for interindividual variation in plasma levels and deemed well tolerated and safe based on laboratory and ECG evaluations.
214924214|NCT05550909|DRUG|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
214924215|NCT05550909|DRUG|Artemether-lumefantrine|Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines
214924216|NCT05550909|DRUG|Amodiaquine|Tablets containing 153 mg of amodiaquine will be administered according to weight, aiming for a dosage of approximately 10 mg (7.7-15.3mg)/kg/day, given once or twice daily (together with artemether-lumefantrine) for three days.
214924217|NCT00481052|DRUG|Nilotinib|
214924218|NCT00613691|DRUG|SPI-1620|SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
214924219|NCT05418582|DRUG|DZD9008 and intraconazole|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
214924220|NCT05418582|DRUG|DZD9008 and carbamazepine|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
214924221|NCT01694069|DRUG|Piperacillin-tazobactam combination product|400 mg/kg/day as either intermittent or continuous infusion
214924222|NCT01702480|DRUG|GSK2981710|Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
214924223|NCT01702480|DRUG|Placebo|Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
215066987|NCT06517251|OTHER|Arm-hand BOOST|"Aha BOOST consists of 20 one-hour BOOST sessions (spread over 4 weeks, 5 days a week) and one hour of individual technology-supported therapy per week (divided in two times 30 minutes), with the aim to provide intensive, goal-oriented upper limb therapy. The sessions will be executed with a maximum of two participants, under supervision of a trained therapist.~The group sessions are focused on four key aspects: neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. The different exercises are tailored to the individual patient, based upon ongoing assessment, discussion within the group of therapists, and individual treatment goals of the patient. Additionally, patients exercise two times 30 minutes per week with the AMADEO® (Tyromotion, Austria), an upper limb robotic device, focusing on finger and hand rehabilitation."
214924224|NCT03088163|DEVICE|Diffusion weighted magnetic resonance imaging|The enrolled colorectal liver metastases patients will receive DWI-MRI screening to evaluate the liver metastases before the chemotherapy, after the first cycle of chemotherapy and in the regular efficacy evaluation time, respectively.
214924225|NCT05482373|DIETARY_SUPPLEMENT|Oleuropein from olive tree|The capsules intake will last for a total of 4 months.
214924226|NCT05482373|DIETARY_SUPPLEMENT|Placebo|The capsules intake will last for a total of 4 months.
214924227|NCT06068829|DRUG|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inebilizumab was given after IVMP.
214924228|NCT06068829|DRUG|Rituximab(RTX)|RTX: 500mg IV on Day 1 and Day15. The first dose of RTX was given after IVMP.
214924229|NCT02951221|DRUG|BIIB074 Treatment A|Lower dose RCF fasted
214924230|NCT02951221|DRUG|BIIB074 Treatment B|Lower dose DCF fasted
214924231|NCT02951221|DRUG|BIIB074 Treatment C|Higher dose DCF fasted
214924232|NCT02951221|DRUG|BIIB074 Treatment D|Higher dose DCF fed
214672824|NCT04990570|OTHER|Telemedicine in the form Virtual clinic via video consultation|"Pediatric patients, with age ranging from 1 month-14 years, with surgical problems, encountered during the era of Covid-19 pandemic.~Some of them seen at the OPD clinic, while the majority failed to attend because of Covid-19 associated lock-down and Curfew, thus, rendering their approach to the service.~Telemedicine, in the form of Virtual clinic, was utilized to address the distressing problem of difficult approach of patients to the pedia surgery OPD because of Covid-19 pandemic restrictive regulatory precautions, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship \& encounter."
214924233|NCT01767506|OTHER|Surveillance and treatment with azithromycin of newcomer and traveler families|The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
214924234|NCT01767506|OTHER|Usual care|Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
214324151|NCT06367361|DRUG|Triclabendazole|The standard of care for the treatment of fascioliasis according to the same guidelines is two 10 mg/kg doses of TCBZ 24 hours apart administered with a fat containing meal. The subjects in one of the arms of the study will receive this treatment as the standard of care. Subjects from any of the arms that fail to achieve parasitological cure will receive rescue treatment off the study with two doses of TCBZ as recommended by the Peruvian guidelines.
214324152|NCT00260754|BEHAVIORAL|Community-Popular Opinion Leader Model|
214324153|NCT00260754|BEHAVIORAL|Diffusion of Innovations|
214324154|NCT05251246|BEHAVIORAL|recovery management program|The recovery management program consists in training the nurses and physicians during a 15-day training course to optimize their recovery abilities : sleep management according to the schedules by anticipation and recovery, and stress management through cardio-feedback techniques (cardiac coherence) also called controlled breathing techniques and mental imagery.
214324155|NCT01526889|DRUG|LFG316|LFG316 administered intravitreally (IVT)
214324156|NCT01526889|DRUG|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
214324157|NCT05928910|DEVICE|SmileyScope VR|The SmileyScope Virtual Reality Headset is a VR headset to reduce pain and anxiety undergoing medical procedures. The device comes pre-loaded with a static virtual reality scenario. Participants will use the device in person when coming to clinic during an in-person, one time PNE procedure.
214324158|NCT05928910|OTHER|Standard of Care Treatment|Participants in this group will receive standard of care treatment during an in-person, one time PNE procedure.
214324159|NCT03438890|DEVICE|Warm saline|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
214485951|NCT06988943|DEVICE|Digital Health Platform|"Community health centers and streets in Guangzhou use a program called Fei Anxin to manage residents' information in a unified way"
215066988|NCT06517251|OTHER|Lower limb BOOST|L-BOOST consists of 20 one-hour sessions and a personalized two times 30 minutes self-exercise program per week and focused on strengthening exercises for the lower limbs and general reconditioning. During the group sessions, circuit-class training is performed according to a standardized written protocol: 20 minutes of cycling on a sitting bike, 20 minutes of strengthening exercises for muscles around hip and knee (e.g. sit-to-stand training), 10 minutes of knee exercises using quadriceps bench in free swing mode and 10 minutes of leg press exercises. Again, a gradual increase in levels of difficulty is provided. Additionally, each patient receives a self-exercise program (balance; strengthening of foot, knee, and hip muscles; walking exercises), which is executed two times 30 minutes per week under minimal supervision of a therapist. None of the exercises involve the use of the upper limb.
214324160|NCT03438890|DEVICE|anti-fog agent|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
214924235|NCT00076752|DRUG|fludarabine phosphate|Conditioning and transplant regimen: 30 mg/m\^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)
214924236|NCT00076752|DRUG|cyclophosphamide|Priming regimen: 2000 mg/m\^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m\^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
214924237|NCT00076752|BIOLOGICAL|Rituxan (rituximab)|Priming regimen: 375 mg/m\^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m\^2 intravenous infusion, day -7.
214924238|NCT00076752|BIOLOGICAL|filgrastim|Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC \>500 microliters.
214924239|NCT00076752|DRUG|methylprednisolone|Priming regimen:1000 mg intravenous over 30 minutes, day 1.
214324161|NCT03438890|DEVICE|chlorhexidine|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
214924240|NCT00076752|OTHER|immunologic technique|Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.
214924241|NCT00076752|OTHER|laboratory biomarker analysis|Standard human immunology research laboratory ex vivo studies.
214924242|NCT00076752|PROCEDURE|autologous hematopoietic stem cell transplantation|Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.
214324162|NCT02171481|DRUG|Dabigatran etexilate polymorph II|
214924243|NCT00076752|DRUG|Diphenhydramine|Conditioning and transplant regimen 25-50 mg orally or intravenously.
214924244|NCT00076752|DRUG|Mesna|Priming regimen: 600 mg/m\^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m\^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
215066989|NCT01359241|PROCEDURE|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
214324163|NCT02171481|DRUG|Dabigatran etexilate polymorph I|
214324164|NCT05550051|PROCEDURE|Awake nasal fiberoptic intubation|Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
214672825|NCT02865369|DRUG|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
215066990|NCT01359241|DRUG|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
215066991|NCT06397651|BEHAVIORAL|Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application|"Participants will get access to Complement Theory's 24-week Live 1:1 Coaching program, focusing on Exercise and Meditation and supplemented with evidence-based information on Diet, Sleep, and other lifestyle practices, adjunct to the core treatment.~* Each week, up to five sessions of 45 minutes each will be offered, with a recommendation for participants to engage in a minimum of three sessions to ensure adequate program exposure and benefits.~* Each session will consist of 30 Minutes of Physical Exercise and 7 minutes of meditation. Each session will be a combination session focused on Aerobic and Strength, with flexibility and balance exercises included as supplements."
214324165|NCT04852744|OTHER|Brain MRI|"Anatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min).~The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner \& Friston, 2000\]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups."
214324166|NCT06300554|DEVICE|Healthy Minds Program App|freely available well-being app
214324167|NCT02321696|DEVICE|Acupuncture|
214324168|NCT02321696|OTHER|Physiotherapy and eccentric exercise|
214324169|NCT02321696|OTHER|Watchful waiting and eccentric exercise|
214924245|NCT06545773|PROCEDURE|Root Canal Treatment with ProTaper Next Nickel-Titanium File (PTN)|ProTaper Next (Dentsply Sirona) is a rotational system made of a nickel-titanium alloy called M-Wire. It has a rectangular cross-sectional design; thus, only two sides touch the root canal. Five files are available: X1 17/. 04, X2 25/.06, X3 30/. 07, X4 40/.06, and X5 50/.06. This file aggressively removes the coronal dentine of root canals due to its large taper. PTN nickel-titanium systemis used in root canal treatments to debride and shape the root canals.
214324170|NCT02321696|OTHER|eccentric exercise|
214324171|NCT00041431|DRUG|Hormone Replacement Therapy|
214324172|NCT06423898|DRUG|Ampicillin plus ceftriaxone in continuous infusion|Continuous intravenous antibiotic infusion during 42 days for Infective Endocarditis
214924246|NCT06545773|PROCEDURE|Root Canal Treatment withTruNatomy Nickel-Titanium File (TN)|TruNatomy (Dentsply Sirona) is a heat-treated nickel-titanium system that consists of an orifice modifier, glide path, and shaping files. The TruNatomy Small, Prime, and Medium files have sizes of 20/.04, 26/.04, and 35/.04, respectively. It has a rectangular cross-section and a regressive taper. Its slim design allows for a conservative preparation of root canals and the preservation of the coronal dentine. TN nickel-titanium system is used in root canal treatments to debride and shape the root canals.
214924247|NCT00905281|OTHER|Action Group|"On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.~Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary."
214924248|NCT00905281|OTHER|Standard care|No specific intervention
214924249|NCT05554536|PROCEDURE|PEEP titration trial|PEEP trial, starting from clinical PEEP 16 cmH2O and ending at PEEP 6 cmH2O. The PEEP trial will be stopped for haemodynamic instability (defined as arterial pressure \< 80 mmHg and /or heart rate \> 150 bpm) or desaturation (defined as SpO2 \< 92%).
214324173|NCT06423898|DRUG|Ampicillin plus ceftriaxone in intermittent infusion of 14 days, after which the treatment may be changed|"Ampicillin plus ceftriaxone as an intermittent infusion for a minimum of 14 days. After, if the patient is discharged from the hospital, the following treatments, until the 42-day treatment period is completed:~1. Intravenous treatment according to the following regimens:~   Ampicillin plus ceftriaxone as an intermittent infusion, teicoplanin, daptomycin, dalbavancin or linezolid.~2. Oral treatment according to the following regimens: amoxicillin plus moxifloxacin, amoxicillin plus linezolid, amoxicillin plus rifampin, linezolid plus moxifloxacin or linezolid plus rifampin."
214324174|NCT00524446|DIETARY_SUPPLEMENT|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
214324175|NCT00524446|DIETARY_SUPPLEMENT|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
214324176|NCT00524446|DIETARY_SUPPLEMENT|Maize-soy flour|Counseling + Vitamin A as for ST\_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
215066992|NCT06397651|BEHAVIORAL|Digital application with expert guidelines on lifestyle modification|24 weeks access to Digital application with expert guidelines on lifestyle modification focusing on exercise, meditation, as well as information on diet, sleep and other lifestyle practices.
214324177|NCT06028711|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
214324178|NCT06028711|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
214324179|NCT01589302|DRUG|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214672826|NCT03399890|DIAGNOSTIC_TEST|Neurological physical exam|Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
214672827|NCT03386708|PROCEDURE|intrauterine injection|intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times
214924250|NCT03863171|DIAGNOSTIC_TEST|Arterial spin labeling (ASL) magnetic resonance imaging|Arterial spin labeling (ASL) magnetic resonance imaging test
214924251|NCT03863171|DIAGNOSTIC_TEST|Fundus fluorescein angiography|Fundus fluorescein angiography test
214924252|NCT01671072|BIOLOGICAL|TissueGene-C|TissueGene-C at 1.8 x 10\^7 cells
214924253|NCT01671072|DRUG|Normal Saline|Sodium chloride 0.9%, 3.5ml
215066993|NCT03160274|GENETIC|Genetic screening|Germline and/or tumor samples will be screened for mutations
215066994|NCT04272866|OTHER|Clinpro sealant|Resin based sealant
215066995|NCT04272866|OTHER|Embrace wetbond sealant|Moisture tolerant hydrophilic resin based sealant
215066996|NCT04272866|OTHER|Triage sealant|Glass ionomer sealant
215066997|NCT03866538|DRUG|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
214324180|NCT01589302|OTHER|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
214324181|NCT01589302|OTHER|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
214672828|NCT03386708|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2 \* 10\^7 cells (2ml)
214672829|NCT00161317|BEHAVIORAL|Living with Hope Program|
214924254|NCT02603068|DRUG|Oral treprostinil|Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
214924255|NCT03728426|DRUG|Letermovir|"Patients will receive intravenous or oral letermovir at a dose of 480mg/day.~Patients weighing 40 or more kilograms will receive a second, loading, dose 12 hours after the first dose of letermovir treatment.~For patients receiving concomitant cyclosporine treatment, the letermovir dose will be 240mg/day."
214924256|NCT06685341|DRUG|YZJ-1139|YZJ-1139
214924257|NCT06685341|DRUG|Placebo|Oral tablet
215066998|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
214324182|NCT01567969|BEHAVIORAL|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
214324183|NCT01567969|BEHAVIORAL|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
214924258|NCT06685341|DRUG|Zolpidem|Oral tablet
214924259|NCT04616638|BEHAVIORAL|Resistance Training for Empowerment (RT-POWER)|The EG intervention was designed using the Social Cognitive Theory and its four sources of self-efficacy to promote a participant's (a) involvement in exercise planning, (b) muscular strength, and (c) independent functional performance. It consisted of three phases, which were adapted from the Self-Determined Learning Model of Instruction (Wehmeyer et al., 2000). This model draws from theory and research on self-management and self-control (Bandura, 1986; Martin et al., 1988). Participants were taught by their coaches how to (a) set a goal to meet fitness needs (Phase 1), (b) make a plan to meet goals (Phase 2), and (c) adjust actions to complete the plan (Phase 3).
215066999|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
215067000|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
214324184|NCT03929965|DRUG|Anlotinib|Anlotinib
214324185|NCT01274624|BIOLOGICAL|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
214324186|NCT01274624|DRUG|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
214324187|NCT01274624|DRUG|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
214324188|NCT01274624|DRUG|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
214324189|NCT01274624|DRUG|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
214324190|NCT01438320|DIETARY_SUPPLEMENT|Quercetin|Bioflavonoid
214324191|NCT03789201|DEVICE|TMS EEG|attempt to use TMS EEG to measure connectivity between cortical areas
214324192|NCT03789201|DEVICE|TMS fMRI|compare measurements to established functional connectivity measures; e.g., EEG coherence and fMRI
214672830|NCT01542372|DRUG|Medication augmentation|
214672831|NCT01542372|BEHAVIORAL|CBT|
214924260|NCT04616638|BEHAVIORAL|A traditional RT intervention|The control intervention also consisted of a three-phase instructional process. Consistent with traditional RT interventions (ACSM, 2009), the coaches rather than the participants, were the primary agents for goal-setting, exercise planning, goal attainment monitoring, and readjusting of the exercise plan. Neither the visual activity schedules nor the system of least-to-most prompts was used in this intervention.
214924261|NCT02064270|DEVICE|Single-Use Negative Pressure Wound Therapy|Application of PICO Single-Use Negative Pressure Wound Therapy
214924262|NCT02064270|DEVICE|Standard postsurgical dressings|Use of Standard postsurgical dressings
214672832|NCT05755789|DRUG|Loading bolus of cefoxitin|Cefoxitin \[2g\] before incision
214672833|NCT05755789|DRUG|Intermittent cefoxitin|Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure
214672834|NCT05755789|DRUG|Continuous infusion of placebo|Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
215067001|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
215067002|NCT02370537|DRUG|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
215067003|NCT02370537|DRUG|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
215067004|NCT02612701|OTHER|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
215067005|NCT02612701|OTHER|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
215067006|NCT02612701|OTHER|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
215067007|NCT02612701|OTHER|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
215067008|NCT03591614|BIOLOGICAL|DKK1|The investigational agent is a DKK1 peptide-loaded autologous dendritic cell vaccine dispensed at a dose of 5-10x106 in 0.5 mL Plasma-Lyte A + 5% HSA.
215067009|NCT03452033|DRUG|H-1337 Placebo|H-1337 Placebo Vehicle
215067010|NCT03452033|DRUG|H-1337 [1]|H-1337 Ophthalmic Solution Concentration 1
215067011|NCT03452033|DRUG|H-1337 [2]|H-1337 Ophthalmic Solution Concentration 2
215067012|NCT03452033|DRUG|H-1337 [3]|H-1337 Ophthalmic Solution Concentration 3
215067013|NCT05012007|OTHER|Reminder Phone|Standard reminder via phone (audiocare)
215067014|NCT05012007|OTHER|Reminder Text|reminder via text (VEText)
215067015|NCT04511871|BIOLOGICAL|CCT303-406|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.
215067016|NCT02784119|PROCEDURE|temporary porto-caval shunt|temporary porto-caval shunt
215067017|NCT06789042|DRUG|0.9%NaCl|20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl
215067018|NCT06789042|DRUG|Dexamethasone 4mg|20ml 0.2% Ropivacaine + 4mg Dexamethasone
215067019|NCT00087776|DRUG|Taxoprexin|Administered by intravenous infusion over 2 hour infusion on Day 1 followed by a 20-day observation period for a total of 21 days (three weeks) per course
215067020|NCT00087776|DRUG|Dacarbazine|Administered by intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (three weeks) per course
215067021|NCT04469920|DRUG|Saroglitazar Magnesium 2 mg|1 tablet, single dose at Day 1
215067022|NCT04469920|DRUG|Saroglitazar Magnesium 4 mg|1 tablet, single dose at Day 1
215067023|NCT05714618|DIAGNOSTIC_TEST|Gadolinium-enhanced cardiac MRI|Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.
214672835|NCT05755789|DRUG|Continuous infusion of cefoxitin|Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure
214924263|NCT06264557|DEVICE|SB-100|"Cognitive training will be conducted once a day, and it will take 15 to 30 minutes.~It consists of cognitive training and educational videos."
214924264|NCT06264557|OTHER|Educational book|Book of education on daily rules for preventing dementia
214924265|NCT04490044|OTHER|Under & Over rehabilitation tool|Under \& Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.
215067024|NCT05714618|DIAGNOSTIC_TEST|B Natriuretic Peptide|Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.
215067025|NCT05714618|DIAGNOSTIC_TEST|Systemic inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.
215067026|NCT05539950|OTHER|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation helps patients maximize functional potential due to progressive deconditioning or acute decompensation following an acute medical event. This intervention is medically supervised and individualized according to their results of the cardiopulmonary Exercise Testing (CPET).
215067027|NCT05539950|OTHER|Health education|Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.
215067028|NCT03045406|DRUG|Apixaban|Tablets
215067029|NCT03045406|DRUG|Dalteparin|Injections
214672836|NCT05755789|DRUG|Intermittent placebo|Additional bolus of placebo every 2 hours until the end of surgical closure
215067030|NCT06252961|DRUG|Levamisole 3 days|Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
215067031|NCT06252961|DRUG|Levamisole 5 days|Levamisole for 5 days (2,5 mg/kg)
215067032|NCT06252961|DRUG|Placebo|Placebo for 5 days
215067033|NCT03100539|OTHER|Therapist treated massage|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
215067034|NCT03100539|OTHER|Care ally assisted massage|CA-M consisted of in-person training for veteran/care-ally dyads to learn a standardized 30-minue massage routine, instructional DVD, and printed treatment manual. Participants were to complete three care ally-assisted massage sessions weekly for 12-weeks.
215067035|NCT05897242|BEHAVIORAL|Smartphone app|Use ACT on Vaping smartphone app
215067036|NCT05897242|OTHER|Text Message|Receive text messages
215067037|NCT05897242|OTHER|Survey Administration|Ancillary studies
215067038|NCT04309890|OTHER|Arabic version of the Overactive Bladder Symptom Score Questionnaire|All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
215067039|NCT00809835|DRUG|Galantamine|Daily 8 mg galantamine capsule
214672837|NCT04516902|DRUG|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
214672838|NCT04516902|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
214672839|NCT04516902|OTHER|LSD Placebo|Pure alcohol instead of an alcoholic solution containing LSD
214672840|NCT04516902|OTHER|MDMA Placebo|Mannitol capsules instead of capsules containing MDMA
214672841|NCT03574207|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
214672842|NCT06244186|DIETARY_SUPPLEMENT|Probiotics|Probiotics contains a probiotic known as Lactobacillus delbrueckii subsp. Bulgaricus, a key bacterium utilized in the production of yogurt, cheeses, and various naturally fermented products. Studies suggest that the metabolites of Lactobacillus bulgaricus can enhance immunity and digestion, reduce the risk of infection, and lower blood cholesterol levels. The composition of probiotics has been developed by TCI CO., Ltd.
214672843|NCT06244186|DIETARY_SUPPLEMENT|Placebo|Placebo is provided by TCI CO., Ltd.
215067040|NCT00809835|BEHAVIORAL|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
215067041|NCT03245554|DRUG|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
215067042|NCT04463342|COMBINATION_PRODUCT|Non Coated Glass Ionomer|KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.
214672844|NCT01984814|BIOLOGICAL|Stem cell|Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
215067043|NCT04463342|COMBINATION_PRODUCT|Conventional Glass Ionomer with Coat|Conventional Glass Ionomer with Coat
214672845|NCT04850950|DRUG|Tenofovir Alafenamide fumarate 25mg Oral Tablet|Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.
214924266|NCT03909061|BEHAVIORAL|Wheelchair Maintenance Training|Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.
214924267|NCT02048826|DEVICE|FINGER I|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I
215067044|NCT05400473|OTHER|Therapeutic exercise|This group will consist of 30 participants. A program consisting of specific therapeutic exercises for the cervical region will be applied.
215067045|NCT05400473|OTHER|Photobiomodulation|Photobiomodulation will be applied on the cervical region. To perform the photobiomodulation protocol, a low power infrared laser therapy unit will be used.
215067046|NCT00066703|DRUG|exemestane|
215067047|NCT00066703|DRUG|tamoxifen|
215067048|NCT00066703|DRUG|triptorelin|
214324193|NCT02703636|DRUG|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
214324194|NCT01068938|DEVICE|three different perimeters: HFA, Octopus, MATRIX|visual fields
214324195|NCT01505127|DRUG|TAK-438|
214324196|NCT01505127|DRUG|Lansoprazole|
214324197|NCT01505127|DRUG|Amoxicillin|
214924268|NCT02048826|DEVICE|FINGER II|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
214924269|NCT04436562|DRUG|[14C]-Poziotinib|Single oral administration of 8 mg (as the hydrocholoride salt) of \[14C\]-poziotinib
214924270|NCT04470544|DRUG|Camostat Mesilate|Given PO
214924271|NCT04470544|OTHER|Standard of Care|At Investigator discretion
214324198|NCT01505127|DRUG|Clarithromycin|
214324199|NCT04270916|DIAGNOSTIC_TEST|High frequency pure tone audiometry|Hearing test carried out routinely, non invasive
214324200|NCT04464681|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
214672846|NCT05659615|OTHER|Study will not have intervention|Study will not have intervention
214924272|NCT02027597|OTHER|Attack of the S. Mutans|A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.
214924273|NCT02027597|OTHER|Follow-up|This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.
215067049|NCT06473831|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
215067050|NCT06346483|PROCEDURE|Dusting without Moses 2.0 Modulation|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
215067051|NCT06346483|PROCEDURE|Dusting with Moses 2.0 Modulation|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
215067052|NCT06346483|OTHER|Moses 2.0 Modulation|Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology used for lithotripsy and BPH treatments
215067053|NCT04314193|DRUG|Methotrexate|Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
215067054|NCT04314193|DRUG|Prednisone|Oral prednisone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
215067055|NCT01696968|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
215067056|NCT01696968|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
215067057|NCT05357339|OTHER|20% Albumin|100ml boluses 20% Albumin
215067058|NCT05357339|OTHER|Crystalloid|100ml bolus of crystalloid
215067059|NCT05838625|DEVICE|Digital Therapeutic|A prescription digital therapeutic in the form of a smartphone app.
215067060|NCT05100017|DRUG|Methocarbamol|Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.
215067061|NCT05100017|DRUG|Oxybutynin|Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.
215067062|NCT05767398|DRUG|Zanubrutinib|Administered as a tablet or capsule
215067063|NCT06500013|BEHAVIORAL|Self-designed messages|Messages designed by participants
215067064|NCT06500013|BEHAVIORAL|Standardized messages|Messages designed by researchers based on behavioral change theories
215067065|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy|CPT as described in the treatment manual
215067066|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
215067067|NCT05659719|OTHER|Recifercept|Patients received recifercept intervention in the phase 2 clinical trial
215067068|NCT03679546|DRUG|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
215067069|NCT03679546|DRUG|Vedolizumab Injection|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
215067070|NCT05591768|PROCEDURE|Monopolar radiofrequency|In monopolar group : . Inferomedial, superomedial, and superolateral GN branches of the patients were identified with ultrasonography, and a 22 Gauge, 10 cm radiofrequency (RF) cannula with a 10 mm active tip was advanced to the targeted nerves under fluoroscopy guidance. The location of the RF cannula was visualized by anteriorposterior and lateral images. Sensory stimulation was applied at 50 Hz to determine the nerve position. Since the sensory stimulation threshold must be \< 0.6 V, nerve position was tested with the absence of fasciculation in the relevant area of the lower extremity upon 2.0 V stimulation at 2 Hz.
215067071|NCT05591768|PROCEDURE|Bipolar radiofrequency|a similar technique will be used to insert the canula, except that, instead of one cannula two cannulae (approximately 10 mm apart) apart) will be inserted and no manipulation of cannulae was done to stimulate the target nerve as done in MRFA Target areas were similar to monopolar technique Each nerve will be ablated for 90 s in both the groups. All procedures were done by one pain physician who had more then 10 years' experience of radiofrequency procedures.
215067072|NCT05126030|DEVICE|Topaz TTVR System|Transcatheter tricuspid heart valve replacement
215067073|NCT04270149|BIOLOGICAL|ESR1 peptide vaccine|ESR1 peptides plus Montanide and GM-CSF
215067074|NCT02756962|DRUG|Cytarabine|
215067075|NCT02756962|PROCEDURE|Allogeneic stem cell transplant|
215067076|NCT02756962|PROCEDURE|Bone marrow aspiration|"* Baseline~* Approximately 30 days after cytotoxic induction therapy~* End of treatment"
215067077|NCT02756962|PROCEDURE|Punch skin biopsy|"* The first will be obtained with the initial blood and bone marrow collections, whenever possible.~* The second will be obtained at the time of re-biopsy to confirm remission."
215067078|NCT02756962|DEVICE|ClinSeq|Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab
215067079|NCT04829643|DIAGNOSTIC_TEST|PET/MRI|A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited
215067080|NCT06342310|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
215067081|NCT01628029|OTHER|Counseling|Undergo CBT
215067082|NCT01628029|DRUG|Methylphenidate Hydrochloride|Given PO
215067083|NCT01628029|PROCEDURE|Phototherapy|Undergo light therapy
215067084|NCT01628029|OTHER|Placebo Administration|Given PO
215067085|NCT01628029|OTHER|Quality-of-Life Assessment|Ancillary studies
215067086|NCT01628029|PROCEDURE|Sham Intervention|Undergo sham light therapy
215067087|NCT01628029|DRUG|Therapeutic Melatonin|Given PO
215067088|NCT03981445|BEHAVIORAL|ARTAS Adapted Patient Navigation|Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
215067089|NCT03981445|BEHAVIORAL|Adherence Counseling|Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
215067090|NCT06282471|BEHAVIORAL|Expressive Writing and Problem-Solving Therapy (EW+PST)|Participants will undergo a 6-week self-guided EW+PST. Participants will be provided with 6 printed journals (one for each week of the study) and instructed to write at least 2 entries per week.
215067091|NCT02417662|RADIATION|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
215067092|NCT02417662|OTHER|Non-investigational SACT|There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
215067093|NCT05624931|BEHAVIORAL|Brief CBT-Based Intervention|"Aims 1 (n=30) and 2 (n=18) will inform the Aim 3 intervention. We anticipate that the intervention will be comprised of four treatment sessions. These sessions will likely target two pathways to PrEP adherence and persistence: (1) decreased withdrawal and avoidance and (2) behavioral skill building to increase self-care/health behaviors. To decrease withdrawal and avoidance, we will likely include CBT-based exercises that improve distress tolerance and coping. To help participants build new behavioral skills, we will likely incorporate behavioral activation and problem-solving. Behavioral activation is a CBT strategy that promotes scheduling activities that align with an individual's values, which will also break maladaptive patterns of withdrawal and avoidance. Problem-solving is an empirically-supported treatment for depression; training patients to problem-solve adaptively will help them approach PrEP use by navigating barriers."
215067094|NCT05624931|OTHER|Enhanced Treatment as Usual|This is the control intervention. Participants will receive antenatal care as usual, which is monthly visits to the MOU, information about using PrEP during pregnancy (information sheet or pamphlet), and a psychological services referral.
214485952|NCT06996847|BEHAVIORAL|psychoeducational programme to promote a critical attitude towards the symbolic consumption of yoghurt in primary school children|The promotion of critical consumption in children is to be developed in primary school classrooms. Students will spend a total of 7 hours: (2 sessions of 1 hour per week) for 3 consecutive weeks, plus a feedback session (1 hour per week); and there will be another session with parents (1 hour per week). The psychologist tutor will receive a set of six activities related to discriminating between symbolic and critical yoghurt consumption in children, understanding the persuasive intent of yoghurt advertising, awareness of social pressure and critical attitude. Psychological tutors will be trained and provided with support materials and equipment
214485953|NCT05727163|DRUG|Dexamethasone|25mg via HAI (Pre-chemotherapy)
214485954|NCT05727163|DRUG|Anisodamine|10 mg via HAI (Pre-chemotherapy)
214924274|NCT02027597|OTHER|SnowWorld|SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
214485955|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 via HAI over 3 hours
214485956|NCT05727163|DRUG|Leucovorin|200 mg/m2 via HAI
214485957|NCT05727163|DRUG|Fluorouracil|400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
214924275|NCT05991336|GENETIC|Gene therapy|Autologous edited hematopoietic stem cell transplantation
214924276|NCT00113854|DRUG|Mannitol|
214924277|NCT06682351|DRUG|Metformin|16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.
214924278|NCT06682351|DRUG|GLP-1A|16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.
214924279|NCT06682351|DIETARY_SUPPLEMENT|MED|16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.
214924280|NCT02931084|OTHER|Rehabilitation|In line with current treatment guidelines, patients will undergo rehabilitation for at least the first three months, before a decision regarding ACL reconstruction is taken
214924281|NCT02931084|PROCEDURE|ACL reconstruction|Approximately half of the patients will have ACL-reconstruction after an initial time of rehabilitation
215067095|NCT01673906|DRUG|Diagnostic work up|Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
215067096|NCT03423030|DRUG|PBTZ169 Formulation|PBTZ169 Formulation supplied as powder for oral solution
214924282|NCT06621095|DRUG|anlotinib + benmelstobart + nab-paclitaxel + gemcitabine|"1. Before 8 cycles, anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
214924283|NCT06621095|DRUG|nab-paclitaxel + gemcitabine|"1. Before 8 cycles, nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
214924284|NCT03436693|DRUG|Canagliflozin|Canagliflozin 100mg orally once daily
215067097|NCT03423030|DRUG|Placebo|matching placebo supplied as powder for oral solution
214324201|NCT04464681|DRUG|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
214324202|NCT00804336|DRUG|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
214324203|NCT00804336|DRUG|RAD001|Given orally once a day
214324204|NCT00393939|DRUG|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
214324205|NCT00393939|DRUG|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
214324206|NCT05611086|DRUG|N-Acetylcysteine|Subjects in treatment group will be given capsules containing 600 mg of NAC
214324207|NCT05611086|DRUG|Placebo|subjects in the control group will be given capsules containing placebo (lactose)
214324208|NCT00748956|DRUG|Low dose NPY|50nmol, administered intranasally
214324209|NCT00748956|DRUG|High dose NPY|100nmol administered intranasally
214324210|NCT00748956|DRUG|Placebo|placebo comparator (0nmol)) administered intranasally
214324211|NCT02561130|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
214324212|NCT02561130|DRUG|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
214324213|NCT02561130|DRUG|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
214324214|NCT02561130|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
214324215|NCT00225836|DEVICE|OVA (TENS apparatus)|
214324216|NCT06020066|DRUG|EGFR-TK Inhibitor|Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
214324217|NCT06020066|RADIATION|Stereotactic radiotherapy|Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
214324218|NCT00020670|BIOLOGICAL|CD 40|
214324219|NCT01575327|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
214324220|NCT01575327|DEVICE|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
214324221|NCT01105507|DRUG|canakinumab (company code: ACZ885D)|
214324222|NCT05374265|OTHER|Cardiovascular Magnetic Resonance Scan|Patients will receive a baseline CMR scan to detect viability within 7 days of index admission
214324223|NCT05529212|PROCEDURE|ischemic reperfusion injury|ischemic reperfusion injury is a pathological process in which the ischemic myocardium is restored to normal perfusion, but the tissue damage is progressively aggravated when the coronary artery supply is completely blocked after cardiopulmonary bypass surgery and then recanalised at a certain time.
215067098|NCT03423030|DRUG|PBTZ169 NCP|PBTZ169 NCP supplied as powder for oral solution
215067099|NCT05354466|DRUG|Sugammadex injection|sugammadex as reversal agent
215067100|NCT05354466|DRUG|Neostigmine|neostigmine as a reversal agent
215067101|NCT01681186|DRUG|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
215067102|NCT01681186|DRUG|LY2940680 Tablet (Test)|Administered orally as a tablet
215067103|NCT01681186|DRUG|Lansoprazole|Administered orally as a capsule
215067104|NCT01681186|DRUG|Placebo Capsule(s)|Administered orally as a capsule(s)
214485958|NCT05727163|DRUG|Irinotecan|150 mg/m2 intravenously
215067105|NCT05818540|DEVICE|Eclipse novel CPAP mask|Participants will wear the mask for 6 hours a night for 60 days.
215067106|NCT05818540|DEVICE|ResMed P-10 mask|Participants will wear the mask for 6 hours a night for 60 days.
215067107|NCT05160415|DRUG|Sevasemten|Daily oral dose of 10 mg daily until Visit 8 (Day 57), followed by 15 mg daily until Visit 13 (Month 6), followed by 20 mg until Visit 21 (Month 15), followed by 10 mg daily to Visit 27 (Month 24).
215067108|NCT00148993|BIOLOGICAL|Tumor Cell Vaccine|
215067109|NCT03106441|DEVICE|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
215067110|NCT03106441|DEVICE|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
215067111|NCT05483712|DEVICE|Brass Mesh Bolus|During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
215067112|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
215067113|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
215067114|NCT04193111|DIAGNOSTIC_TEST|TMD pain screener|The danish TMD pain screener is given to all participants
215067115|NCT03916536|PROCEDURE|Holmium Laser|Holmium laser enucleation of large sized prostate
215067116|NCT03916536|PROCEDURE|Thulium Laser|Thulium laser enucleation of large sized prostate
215067117|NCT03916536|PROCEDURE|Bipolar diathermy|Bipolar enucleation of large sized prostate
215067118|NCT03978052|DIETARY_SUPPLEMENT|EGCG|"FontUp capsules (100 mg of EGCG each)~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
214324224|NCT00356551|BEHAVIORAL|Family Spirit curriculum|
214324225|NCT04334460|DRUG|BLD-2660|BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.
214324226|NCT00000403|DRUG|Doxycycline|
214324227|NCT02133729|OTHER|Blood sampling and OGTT|
214324228|NCT05716035|DRUG|Tocilizumab Injection|Participants will receive IV tocilizumab
214324229|NCT00210314|DRUG|high dose methotrexate|
214324230|NCT00210314|DRUG|high dose cytarabine|
214324231|NCT00210314|RADIATION|radiotherapy|
214324232|NCT00547703|DRUG|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
214324233|NCT00547703|DRUG|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
214324234|NCT04062916|OTHER|BSGE pelvic pain questionnaire and VAS scores|Patients were evaluated using the BSGE pelvic pain questionnaire in terms of pre-operative and post-operative pain assessment in order to determine the effects of endometriosis surgery on the quality of life. The patients were asked to indicate their levels of dyspareunia, dysmenorrhea, and chronic pelvic pain on a VAS on the pelvic pain questionnaire.
214924285|NCT03436693|DRUG|Placebo|Placebo orally once daily
214924286|NCT06618820|DRUG|Tranexamic acid|One dose consists of three 650 milligram (mg) capsules, to be taken orally.
215067119|NCT03978052|DIETARY_SUPPLEMENT|Placebo EGCG|"Placebo FontUp (same appearance as active).~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
214324235|NCT01606085|BEHAVIORAL|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
214924287|NCT06618820|DRUG|Placebo|One dose consists of three microcrystalline cellulose capsules.
214924288|NCT00002251|DRUG|Ganciclovir|
215067120|NCT03978052|OTHER|Healthy lifestyle recommendations|Personalized advice on diet, physical activity, cognitive training, and social stimulation activities.
215067121|NCT03978052|OTHER|Multimodal lifestyle intervention|"* Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions."
215067122|NCT06331286|DRUG|dulaglutide injection|0.75mg Subcutaneous injection once a week for 24 weeks
215067123|NCT04848220|DRUG|Temanogrel|Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
215067124|NCT04848220|DRUG|Placebo|Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
215067125|NCT02923830|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
215067126|NCT02923830|DRUG|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
215067127|NCT02882789|DRUG|LCB01-0371|Cohort1 \& 3: Placebo-controlled, Single ascending dose administration
214924289|NCT04798729|DEVICE|Digital Occlusal Recording with T-Scan|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the T-Scan (T-Scan III, version 9.1, Tekscan Inc., South Boston, USA).
215067128|NCT02882789|DRUG|LCB01-0371 400mg|Cohort 2: Crossover designed administration
215067129|NCT06350136|BEHAVIORAL|With Tele-Nursing|no With Tele-Nursing
215067130|NCT04748757|DRUG|recombinant human annexin A5|recombinant human annexin A5, manufactured as SY-005
215067131|NCT04748757|DRUG|Placebo|Normal saline 50 ml
215067132|NCT05340387|OTHER|Balance Resistance Aerobic Cognitive exercises (BRACE)|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. Week 1-3 : Balance: Romberg, tandom standing, single leg stance Resistance: chair rise Aerobic exercises: 6mint walk Cognitive: count reverse from 50 Week 4-6: Balance: Sit to stand, functional reach, Tug Test Resistance: stair climbing Aerobic Exercises: Marching in space Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Perturbation, throwing a ball, kicking a ball Resistance: Floor transfer, squatting Aerobic Exercises: Cycling Cognitive: Count even number from 1-50, calculation, addition, subtraction, multiplication division Week 10-12: Balance: Combination of All Resistance: Combination of All Aerobic Exercises: 6 minutes' walk test, marching steps, cycling Cognitive: Combination of all
215067133|NCT05340387|OTHER|Otago's Protocol|"Study will be conducted after the approval of Ethical review board. The Otago's exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. WEEK 1-3: Warm up: March, head movement, neck movement, back extension, trunk movement, ankle movements Strength: Front knee strengthening, Back knee strengthening, Side hip strengthening, Calf raises, Toe raises (10 repetitions each) Balance: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel toe stand), Tandem walk (heel toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backwards, Sit to stand, Stair walking. (10 repetitions each) Flexibility: calf stretch, back of thigh stretch Hold for 10 to 15 seconds and repeat on other leg.~Walk: 5 or 10 minutes' walk~This protocol will be followed for 12 weeks with increased repetitions after every 3 week."
215067134|NCT04206254|BIOLOGICAL|gp96|heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
215067135|NCT05755256|DIETARY_SUPPLEMENT|Probiotic|After randomization, participants will consume the probiotic for 12 weeks.
215067136|NCT05755256|DIETARY_SUPPLEMENT|Placebo|After randomization, participants will consume the placebo for 12 weeks.
215067137|NCT03379857|OTHER|Drug urinal test|Non Applicable
214924290|NCT04798729|DEVICE|Digital Occlusal Recording with Cerec Omnicam|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the CEREC Omnicam™ (version 4.2, Sirona Dental Systems, New York, USA).
214324236|NCT01606085|BEHAVIORAL|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
214485959|NCT05727163|DRUG|Bevacizumab|5 mg/kg intravenously
214485960|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 intravenously over 3 hours
215067138|NCT05825430|PROCEDURE|Direct pecs block|"Patients will receive direct PECS block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
215067139|NCT05825430|PROCEDURE|Ultrasound guided pecs block|"Patients will receive ultrasound guided pecs block after induction and before skin incision.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
215067140|NCT05825430|DRUG|general anaesthetic technique only|All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
215067141|NCT03183258|OTHER|Sentinel skin flap|Donor-derived vascularised composite allograft (sentinel skin flap)
215067142|NCT01751906|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
214485961|NCT05727163|DRUG|Leucovorin|200 mg/m2 intravenously
214485962|NCT05727163|DRUG|Fluorouracil|400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
215067143|NCT01751906|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
215067144|NCT02352272|OTHER|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
214324237|NCT01583010|DEVICE|ANV(R)|"Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group"
214324238|NCT04458064|OTHER|LMA i gel|insertion of LMA for maintaining airway during anesthesia
214324239|NCT00358462|DRUG|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
214324240|NCT00358462|DRUG|Doxycycline|one 100mg capsule administered twice daily for seven days
214324241|NCT05498636|COMBINATION_PRODUCT|Selinexor combined with Prednisone, Etoposide, and Lenalidomide|Selinexor combined with Prednisone, Etoposide, and Lenalidomide
214324242|NCT03995953|BEHAVIORAL|SHIELD intervention (Support for HIV Integrated Education, Linkages to care, and Destigmatization)|The SHIELD intervention includes a three-session, six-module program for AGYW that increases knowledge, skills, and self-efficacy to engage along the HIV prevention and care continuum, and a two-session, four-module program for caregivers to increase social support. In addition, the SHIELD intervention includes youth clubs to foster peer support.
214324243|NCT03995953|OTHER|Integrated wellness care (IWC) clinics|IWC clinics will be created within health facilities where AGYWs can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and HPV vaccination in a youth-friendly environment.
215067145|NCT04771923|DRUG|Tranexamic acid|Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.
215067146|NCT04771923|DRUG|Adrenaline|Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.
215067147|NCT04985409|BEHAVIORAL|Feedback|The system uses Sonifi health (TV content and visualizations) and Fitabase (3rd party server to process Fitbit data and export to Sonifi). The system utilizes the patient's TVs to engage the patient and multidisciplinary team in monitoring ambulation status.
214324244|NCT03279939|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
215067148|NCT05771636|BEHAVIORAL|Mental Imagery|"Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done."
215067149|NCT05771636|BEHAVIORAL|Control condition (activity planification)|The participant identifies 4 activities that he plans to do in the course of the next 2 weeks.
215067150|NCT03484156|DEVICE|Installation of 3PEGASE Sensor|Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss
215067151|NCT01097265|DRUG|capecitabine|
214324245|NCT03279939|DEVICE|Color Fundus Photography|Non-contact white light photography.
215067152|NCT01097265|DRUG|oxaliplatin|
215067153|NCT01097265|OTHER|active surveillance|
215067154|NCT01097265|OTHER|laboratory biomarker analysis|
215067155|NCT01097265|PROCEDURE|adjuvant therapy|
215067156|NCT01097265|PROCEDURE|lymph node mapping|
214924291|NCT04905472|DEVICE|Vestibular prosthesis/implant|The intervention is a vestibular prosthesis which our collaborators at the University of Geneva are implanting into the inner ear in deaf patients without vestibular function who are receiving a cochlear implant. The vestibular implant (VI) has three rate sensors and senses angular head velocity in three dimensions and provides this information to the brain by stimulation the afferent nerves innervating the three semicircular canals. Our goal is to use the VI to better understand how the brain processes this prosthetic information and uses it to generate meaningful behavioral responses including eye movements, postural control, and perception.
214324246|NCT03279939|DEVICE|Fluorescein Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.
215067157|NCT01097265|PROCEDURE|sentinel lymph node biopsy|
215067158|NCT01110330|DRUG|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
215067159|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
215067160|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
215067161|NCT00529230|BEHAVIORAL|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
215067162|NCT00529230|OTHER|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
215067163|NCT04925076|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
215067164|NCT04925076|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
215067165|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|10 ml extrafascial interscalene brachial plexus block
215067166|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|20 ml extrafascial interscalene brachial plexus block
215067167|NCT02557100|DRUG|Abatacept|
215067168|NCT02557100|DRUG|Adalimumab|
215067169|NCT02557100|DRUG|Methotrexate|
215067170|NCT00529347|DEVICE|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
215067171|NCT03289910|DRUG|Carboplatin|Given IV
215067172|NCT03289910|DRUG|Topotecan|Given IV
215067173|NCT03289910|DRUG|Topotecan Hydrochloride|Given IV
215067174|NCT03289910|DRUG|Veliparib|Given PO
215067175|NCT00510718|DRUG|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
215067176|NCT00938821|PROCEDURE|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
215067177|NCT03038607|DRUG|Aspirin|This group were subjected to aspirin 75 mg once daily for 6 weeks.
215067178|NCT03195348|OTHER|HBF Bed Rest|7 days of bed rest on hyper-buoyancy floatation (HBF)
215067179|NCT04749758|BIOLOGICAL|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
215067180|NCT03041675|DEVICE|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
214324247|NCT03279939|DEVICE|Indocyaine Green Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
214324248|NCT02422433|DEVICE|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
214324249|NCT02961426|DRUG|sofosbuvir + ravidasvir|combination of sofosbuvir + ravidasvir
215067181|NCT03041675|DEVICE|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
215067182|NCT00442442|DEVICE|mosquito coils|mosquito coil / night mosquito coil \& LLIN / night
214672847|NCT05240937|BEHAVIORAL|mindfulness-based self-compassion will be applied|A mindfulness-based self-compassion program will be applied to this group of patients who have had breast cancer and have fully completed their treatment.
214672848|NCT04740749|DEVICE|Compress Compliant Pre-Stress System|Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System
215067183|NCT00442442|DEVICE|LLIN|Sleep under LLIN every night
214324250|NCT04252105|DIETARY_SUPPLEMENT|Antioxidant|Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
214324251|NCT03183791|BEHAVIORAL|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
214324252|NCT03183791|BEHAVIORAL|Monitored Usual Care (MUC)|"The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app."
215067184|NCT02584231|DRUG|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: \>6 months and \< 2years: 60µg; ≥2 years and \<4 years: 120µg PO and ≥4 years and \<8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
215067185|NCT05191888|DRUG|Vonoprazan and Amoxicillin|14-day vonoprazan high-dose two-in-one therapy
215067186|NCT05191888|DRUG|Vonoprazan, Amoxicillin and Clarithromycin|14-day vonoprazan triple therapy
215067187|NCT05191888|DRUG|Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole|14th Rabeprazole reverse mixed therapy
215067188|NCT00616811|DRUG|vildagliptin|
215067189|NCT00616811|DRUG|Sitagliptin|
215067190|NCT05645978|DEVICE|Pacemaker insertion|Patients who underwent pacemaker insertion between January 2015 and December 2020
215067191|NCT06457776|PROCEDURE|Dental management|The oral conditions of the included patients will be evaluated at baseline. When indicated, dental extractions will be performed before the beginning of Antiresorptive Therapy. Patients will then receive a six-months intervals follow-up, during which primary and secondary prevention of dental diseases will be performed.
215067192|NCT01460875|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
214672849|NCT05982977|OTHER|Acupuncture|The patient was placed in a supine position, selected Lianquan, Fengchi, and acupoints.
215067193|NCT01460875|OTHER|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
214324253|NCT00384813|BEHAVIORAL|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
214324254|NCT00384813|BEHAVIORAL|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
214324255|NCT03743948|GENETIC|Non invasive prenatal diagnosis|15 pregnant women and their spouses Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
214324256|NCT03522376|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% and 50% of maximal inspiratory pressure. The orders of the two loaded test conditions will be conducted in random order with at least 24 hours separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
214324257|NCT01764607|DRUG|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
214324258|NCT00961324|DRUG|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
214324259|NCT00961324|DRUG|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
214324260|NCT02459691|BEHAVIORAL|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
214324261|NCT02459691|OTHER|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
214324262|NCT03440879|DRUG|Zoladex|Patients currently treated with Zoladex
214324263|NCT00167934|DRUG|Valproate|Depakote ER 500 mg to 3000 mg taken every night
214324264|NCT00167934|DRUG|Placebo|Placebo given at same frequency as Valproate
214324265|NCT04707534|DRUG|Dexamethasone|Dexamethasone
214324266|NCT00464724|PROCEDURE|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
214324267|NCT04951622|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
214324268|NCT04951622|DRUG|Placebo|Matching placebo will be administered as an IV infusion.
214324269|NCT04951622|DRUG|Nipocalimab SC-LIV|Nipocalimab will be administered subcutaneously.
214324270|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
214324271|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
214324272|NCT04531943|DRUG|Estrogen|Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.
214324273|NCT04531943|DRUG|Estrogen plus Progesterone|Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
214324274|NCT05051254|OTHER|Esogastric pressure measurement|"Measurement of work of breathing and respiratory muscles strength using an esogastric catheter.~One measurement or before and after (6 months and 1 year) the initiation of a pharmacological treatment in order to assess the effect of the treatment on respiratory muscle function."
214324275|NCT05675371|BEHAVIORAL|Assessment by Expert Clinician During Behavioral Intervention (ABA or similar)|Assessment (e.g., responder vs. non-responder status) utilizing gold-standard clinical reference assessments performed by expert clinicians as the subject undergoes Applied Behavioral Analysis (ABA) or similar intervention for autism spectrum disorder and related developmental delays
214324276|NCT05675371|DEVICE|Assessment by the EarliPoint Assessment For Autism Spectrum Disorder|Assessment by The EarliPoint™ Evaluation for Autism Spectrum Disorder (ASD), a medical device which employs Dynamic Quantification of Social-Visual Engagement (DQSVE) to aid clinicians in the diagnosis, assessment, and treatment monitoring of ASD related developmental delays, is a diagnostic tool which measures an individual's visual preferential attention to social information in the environment relative to normative age-specific benchmarks.
214324277|NCT05718258|DRUG|Venglustat (GZ402671)|"Pharmaceutical form: tablet~Route of administration: oral"
214324278|NCT06640556|BEHAVIORAL|watching animation show|The intervention group will watch the animation titled 'A Green Future with the Hand of a Midwife' on days 7, 21, and 30 to mothers who have just given birth, and the scale will be evaluated on three separate days in total.
214672850|NCT05982977|BEHAVIORAL|Conventional rehabilitation|swallowing training included breathing training, masticatory muscle training, oral movement training and feeding training.
214672851|NCT02673112|BEHAVIORAL|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
214672852|NCT02673112|BEHAVIORAL|Light stretching (LS)|Brief daily stretching routine.
214324279|NCT06322602|PROCEDURE|Intracranial Catheter Placement|Undergo Ommaya reservoir placement
214324280|NCT06322602|PROCEDURE|Lumbar Puncture|Undergo LP
214324281|NCT06322602|PROCEDURE|Biopsy|Undergo biopsy
214324282|NCT06322602|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
214485963|NCT06997289|DRUG|Group that is receiving treatment.|"Incorporate the following regimen into your daily routine for optimal health benefits:~Chinese Medicine: Take a combination of Modified Xiaoyao Powder (2g), Tianwang Buxin Dan (1.5g), Wendan Decoction (0.5g), Night Jiaoteng (0.5g), and Fushen (0.5g) twice a day for a duration of 1 month. This regimen comes from Keda GMP Pharmaceutical Factory.~Auricular Point Stimulation: Apply small 0.2cm ear magnetic beads on the Shenmen, heart, and brainstem points on both sides of the ear.~Consistency is key to achieving positive results, so make sure to follow this routine diligently.~Two treatment methods are carried out simultaneously"
214672853|NCT02280005|DEVICE|WAK Treatment|Hemodialysis with WAK device.
215067194|NCT04898790|BEHAVIORAL|CHAMPS-II adapted to adults 60+ years in HCT setting|CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.
215067195|NCT04915170|DEVICE|Inspiratory muscle training|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O)
215067196|NCT06335537|DRUG|Potassium citrate|Urocit-K 30 mEQ orally taken in the morning and evening.
215067197|NCT06335537|DRUG|Sodium bicarbonate|Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in the morning and ½ Teaspoon (29.5 mEq) in the evening.
215067198|NCT05878327|OTHER|Thrombophilia screening|No intervention. Blood is drawn for analysis.
215067199|NCT00611442|DRUG|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
215067200|NCT00611442|DRUG|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
215067201|NCT02582073|BIOLOGICAL|Placebo (0.5ml)|
215067202|NCT02582073|BIOLOGICAL|Placebo (1.0ml)|
215067203|NCT02582073|BIOLOGICAL|Grass MATA MPL (0.5ml) 5100SU|
215067204|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 10200SU|
215067205|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 18200SU|
215067206|NCT02582073|BIOLOGICAL|Grass MATA (0.5ml) 5100SU|
215067207|NCT01314170|DEVICE|Susanna Implant|device
215067208|NCT01511614|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).
215067209|NCT01511614|DEVICE|sham|Sham Comparator
215067210|NCT01511614|DRUG|Nicotine patch|Dose-match Nicotine for non-deprived scan
214324283|NCT06322602|PROCEDURE|Computed Tomography|Undergo CT
214324284|NCT06322602|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214324285|NCT04108208|DRUG|Apalutamide|Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.
214324286|NCT04108208|DRUG|Placebo|Matching placebo will be administered orally.
214324287|NCT04108208|DRUG|Androgen-deprivation Therapy (ADT)|Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
214485964|NCT06997757|BEHAVIORAL|Mobile health|Instructions for brushing twice daily and using interdental cleaning aids via regular mobile phone messages will be sent atleast twice a week.
214485965|NCT06997757|PROCEDURE|Phase I Therapy|Instructions for brushing twice daily and using interdental cleaning aids during appointment only.
215067211|NCT01511614|DRUG|Placebo patch|Nicotine deprived
215067212|NCT01511614|DRUG|Varenicline Pill|Treatment
214324288|NCT03463889|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
214324289|NCT03463889|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI in combination with PET
214324290|NCT03463889|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET in combination with MRI
214324291|NCT01753089|BIOLOGICAL|WDVAX|
215067213|NCT01511614|DRUG|Placebo pill|Active comparator to varenicline
214324292|NCT06731816|OTHER|Neck and stabilization exercise group|Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. In addition to neck stretching, range of motion, and isometric exercises applied in the neck exercise group, they will also apply spinal and cervical region stabilization exercises.
214324293|NCT06731816|OTHER|Neck exercise group|Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. They will perform neck stretching, range of motion and isometric exercises.
214485966|NCT06997367|BIOLOGICAL|MTBVAC|MTBVAC (BBV169) vaccine is a freeze-dried powder containing live attenuated Mycobacterium tuberculosis (M. tb), which is presented as a lyophilized product in a 10- dose vial. After reconstitution with 1.0 mL sterile water for injection, one dose (0.1mL) of vaccine contains 5 x10\^5 CFU live attenuated M. tb. One dose (0.1mL) of the MTBVAC (BBV169) vaccine is to be administered in the right deltoid region via the intradermal route.
214485967|NCT06997367|BIOLOGICAL|BCG Sii|Comparator vaccine: BCG Vaccine (TUBERVAC- Moscow strain), manufactured by Serum Institute of India, is a freeze-dried powder containing an attenuated strain of Bacillus Calmette-Guerin Mycobacterium bovis as a lyophilized product in a 10-dose vial. After reconstitution with 1.0 mL diluent (Sodium chloride) for injection, one dose (0.1mL) of BCG vaccine will be administered in the right deltoid region via the intradermal route.
214672854|NCT02521246|DRUG|Candesartan + Chlorthalidone|
214924292|NCT04905472|DEVICE|Vestibular Implant Stimulation|VI subjects will be studied before the implant is activated (pre) and then after it is turned on (acute On); this will take about 2 hrs. Then they will have 8 hours of motion-modulated VI stimulation while they actively explore the hospital environment, after studies will be repeated (chronic On). Each set of outcome experiments will be performed twice, once with and once without low-levels of stochastic noise added to the VI stimulation provided for the 8-hour period. The noise amplitude is tailored to each patient to maximize stochastic resonance so extraction \& integration of spatial signal provided by the VI will always be the first experiment, but the order of the subsequent outcome sessions (active/passive head rotations, tilt/translation motion discrimination and VOR behavioral changes \& postural control) will be randomized. VI subjects will participate in 4 full-day sessions, each separated by at least a month.
214924293|NCT00966004|DRUG|YM178|oral
214924294|NCT00966004|DRUG|Placebo|oral
214924295|NCT00966004|DRUG|tolterodine|oral
214324294|NCT05831592|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound assessment (sensitivity, specificity) in undernutrition in patients
214324295|NCT05520034|BEHAVIORAL|Health Education|The participants received a 45mins, face-to-face group health education after enrollment and during the 6th month by a RA nurse. Participants received the same health education over the phone call if the patient and family caregiver could not come for any reason. They also received a digital BP machine, a salt-measurement spoon, a medication box, and a recording notebook for monitoring. The intervention group receives health education above and reminder telephone calls provided by research assistant nurses every month (1st month to 3rd month: twice a month, and 4th month to 12th month: once a month)
214324296|NCT05397665|DRUG|AT-007|AT-007, aldose reductase inhibitor
214672855|NCT02521246|DRUG|Candesartan + Chlorthalidone|
214924296|NCT02173522|DEVICE|Prostate artery embolization (PAE)|Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
214324297|NCT05397665|DRUG|Placebo|Liquid oral suspension
214924297|NCT00522639|OTHER|18F-deoxyglucose (FDG)|contrast medium
214924298|NCT06181734|DRUG|Ivosidenib|inhibitor of mutant IDH1
214924299|NCT02610335|OTHER|Control group (C)|"* kyphosis reeducation on Huber platform during 2 weeks,~* patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~* flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~* exercises on cycle ergometer or walking on treadmill : to continue at home."
214324298|NCT04961892|PROCEDURE|surgical treatment|Anatomical contraction and termination reconstruction of the lateral ligament
214324299|NCT04961892|PROCEDURE|conservative treatment|Rehabilitation intervention training
214324300|NCT02948842|DRUG|Clostridium Histolyticum Collagenase|0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
214485968|NCT06997562|OTHER|Greater occipital nerve blockade|Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.
214485969|NCT06997562|OTHER|Sphenopalatine ganglion blockade|Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.
214485970|NCT06996262|OTHER|observational study|The questionnaire consisted of structured questions covering sociodemographic information, health status, dietary habits, and physical activity levels.
214485971|NCT06996262|OTHER|observational study|Anthropometric measurements was taken.
214485972|NCT06996262|OTHER|observational study|Biochemical analyses were measured was measured using routine methods.
214924300|NCT02610335|OTHER|Test group|"* spinal mobility reeducation on Huber platform during 2 weeks,~* patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~* flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~* exercises on cycle ergometer or walking on treadmill : to continue at home."
215067214|NCT01511614|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing for smoking cessation preparation
214324301|NCT02948842|OTHER|Saline|0.08ml of injectable normal saline
214324302|NCT00409292|DRUG|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
214324303|NCT04865432|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 4 weeks of UVB exposure intervention
215067215|NCT04975126|OTHER|CatInfo tool|Presentation about cataract surgery
215067216|NCT01035437|DRUG|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
215067217|NCT05867420|BIOLOGICAL|ASKG915|ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
215067218|NCT02150057|DEVICE|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
215067219|NCT00489424|DRUG|Placebo|
215067220|NCT00489424|DRUG|Acetaminophen|
215067221|NCT00489424|DRUG|Fluvastatin|
214324304|NCT05124873|DEVICE|Moisture Management Liner|A prototype liner designed to reduce heat that builds up on the limb.
214324305|NCT04528758|DRUG|Rhodamine 6G|Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
214324306|NCT04649034|DIAGNOSTIC_TEST|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
214324307|NCT04649034|DIAGNOSTIC_TEST|Cardiac magnetic resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
214324308|NCT04649034|DIAGNOSTIC_TEST|Brain magnetic resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
214324309|NCT04649034|DIAGNOSTIC_TEST|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
214324310|NCT04649034|DIAGNOSTIC_TEST|Holter monitoring|At inclusion all patients will carry a Holter device for 24 hours to ensure absence of atrial fibrillation
214324311|NCT06052618|DRUG|Pacritinib|Pacritinib is administered orally as 200 mg twice daily for a total of 6, 28-day cycles
214324312|NCT04181827|DRUG|Cilta-cel|Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).
214324313|NCT04181827|DRUG|Pomalidomide|Pomalidomide 4 mg will be administered orally.
214324314|NCT04181827|DRUG|Bortezomib|Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).
214324315|NCT04181827|DRUG|Dexamethasone|Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.
214324316|NCT04181827|DRUG|Daratumumab|Daratumumab 1800 mg will be administered SC.
214324317|NCT04911166|COMBINATION_PRODUCT|Atezolizumab and Interleukin-12 Gene Therapy|To determine the safety and tolerability of the atezolizumab and ADV/IL-12 gene therapy combination in patients with metastatic NSCLC who have disease progression after a prior line of either single agent immunotherapy or a regimen of chemoimmunotherapy.
214324318|NCT03037788|DRUG|WO3979|Application of cream to each axilla
214324319|NCT03037788|DRUG|WO3970|Application of cream to each axilla
214324320|NCT03037788|DRUG|WO3992|Application of cream to each axilla
214324321|NCT03037788|DRUG|Placebo (WO3988)|Application of cream to each axilla
214324322|NCT01256710|DEVICE|Trifecta™ aortic bioprosthesis|Surgical aortic valve replacement with the Trifecta™ valve.
214672856|NCT02521246|DRUG|Losartan+hydrochlorothiazide|
214924301|NCT00060203|DRUG|brostallicin|"Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity."
214924302|NCT01609699|DEVICE|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
214924303|NCT01609699|DEVICE|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
214924304|NCT06665503|DIETARY_SUPPLEMENT|Zinc Supplement, probiotic|received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children; the probiotics group received oral probiotics; 1 probiotic sachet
214924305|NCT04370756|DIETARY_SUPPLEMENT|Beetroot Juice|Participants randomly assigned to the EX + BR group will consume 140 mL beetroot juice containing approximately 12 mmol of nitrate 3 hours prior to the supervised exercise training component.
214924306|NCT04370756|OTHER|Exercise Training|Participants will perform 8 weeks of supervised exercise training at a frequency of 3x per week.
214924307|NCT01985607|DIETARY_SUPPLEMENT|new extensively hydrolysed formula|
214924308|NCT01985607|DIETARY_SUPPLEMENT|Extensively hydrolysed formula|
214924309|NCT04176315|OTHER|Conventional Home-based Rehabilitation Plan|Usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients. Participants receive inpatient care and rehabilitation for 2 weeks. At discharge, they receive a 5-exercise home-based rehabilitation plan. For the sake of homogeneity of all participants, they receive from 2 to 4 of training prior to discharge. At home, participants shall perform the exercises in the rehabilitation plan daily.
214924310|NCT04176315|DEVICE|ReHub Home-based Rehabilitation Plan|"Combination of the usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients with ReHub, a telerehabilitation platform that serves as a guide to perform the TKA rehabilitation exercises.~Participants receive inpatient care and rehabilitation at San Camillo for 2 weeks. At discharge, a 5-exercise home-based rehabilitation plan is carried out by a site physiotherapist by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor. Participants receive from 2 to 4 sessions of ReHub prior to discharge.~At home, participants shall perform the exercises in the rehabilitation plan with ReHub daily. The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. Participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
215067222|NCT02616497|DRUG|Aspirin|COX-1 inhibitor
215067223|NCT02616497|DRUG|Triflusal|COX-1 inhibitor
215067224|NCT06179628|DRUG|Low bolus concentration and volume|Compare Low and Standard concentrations and volumes of bupivacaine boluses for continuous adductor block
215067225|NCT02545660|OTHER|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
214324323|NCT03664609|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.
214324324|NCT06419335|DRUG|CoQ10|The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).
214324325|NCT04973605|DRUG|Sonrotoclax|Administered orally daily
214324326|NCT04973605|DRUG|Dexamethasone|Once weekly either orally or intravenously
214485973|NCT06996262|OTHER|observational study|Blood pressure were measured was measured using routine methods.
214324327|NCT04973605|DRUG|Carfilzomib|Administered intravenously weekly
214324328|NCT04973605|DRUG|Daratumumab|Administered subcutaneously weekly
214324329|NCT04973605|DRUG|Pomalidomide|Administered orally daily
214324330|NCT00003585|BIOLOGICAL|aldesleukin|
214485974|NCT06996067|BEHAVIORAL|Essential Coaching Postpartum|Essential Coaching Postpartum consists of one-way, standardized text messages sent to parents from birth to 6-weeks postpartum to provide evidence-based information on newborn care and mental health. Messages are sent twice a day for the first three weeks (10am and 5pm) and then once a day for the following three weeks (10am), starting the second day after birth.
214485975|NCT06996860|DEVICE|foam roller|fascial therapy for performance effect
214485976|NCT06996860|DEVICE|theragun|fascial therapy for performance effect
214485977|NCT06996860|OTHER|general warm up|fascial therapy for performance effect
214485978|NCT06996639|BEHAVIORAL|Non-Fasting|No pre-procedural fasting required; participants may eat and drink as usual.
214324331|NCT00003585|BIOLOGICAL|recombinant interferon alfa|
214924311|NCT00654875|DRUG|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
214924312|NCT00654875|DRUG|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
214924313|NCT04967885|BEHAVIORAL|Ecological Momentary Implementation Intentions Intervention (EMI-II)|To reduce smoking, this text messaging intervention will use a self-regulatory strategy, Implementation Intentions (II) to deliver appropriate alternative responses to cigarette smoking. Participants will create personalized II messages before starting the two-week intervention period. Then during the intervention period, after receiving Ecological Momentary Assessments (EMAs), participants will be micro-randomized to receive the EMI-II. During the EMA + EMI-II period, participants will complete five daily EMAs. After approximately 40% of these EMAs, participants will also receive the personalized EMI-II by text messaging.
214485979|NCT06996639|BEHAVIORAL|Fasting|"Standard pre-procedural fasting (≥6 hours for solids, ≥2 hours for clear liquids) or NPO at Midnight."
215067226|NCT02545660|OTHER|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
215067227|NCT00394251|DRUG|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
214324332|NCT00003585|DRUG|fluorouracil|
214485980|NCT06997172|PROCEDURE|TCTR (thread carpal tunnel release)|Percutaneous sonography guided release of carpal tunnel release
214485981|NCT06997172|PROCEDURE|Standard-of-care|Open or endoscopic carpal tunnel release based on patients' and physicians' preferences
214672857|NCT00609609|PROCEDURE|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
214924314|NCT01011465|DRUG|intranasal oxytocin|The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
215067228|NCT00394251|DRUG|ABI-007|260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
214324333|NCT00003585|DRUG|isotretinoin|
215067229|NCT00394251|DRUG|Taxol|175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
215067230|NCT00394251|DRUG|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
214324334|NCT00003585|PROCEDURE|surgical procedure|
214324335|NCT05188170|DRUG|Niclosamide|Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
214324336|NCT06390033|DEVICE|Prosthetic foot|Experimental prosthetic foot.
214324337|NCT02681302|DRUG|Ipilimumab|1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
214324338|NCT02681302|DRUG|Nivolumab|3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
214324339|NCT02942017|DRUG|Placebo|Intravenous infusion of matching placebo for SAGE-547.
214485982|NCT06997796|DRUG|Tranexamic Acid|Tranexamic acid powder intranasally
214485983|NCT06997458|DIAGNOSTIC_TEST|xF Tempus assay|"The blood will be collected and sent to Tempus Labs using the standard sample collection kit containing all the necessary elements to guarantee shipment to Tempus Labs. Two Streck tubes with 8.5mL of blood per tube will be sent to Tempus Labs.~The ctDNA isolation and automatic library preparation will be performed using TEMPUS technology (Finkel et al 2021).~The NGS analyses will be developed using the xF Tempus assay. This assay involves a panel with hybrid gene capture that detects actionable oncologic targets in four variant classes: single-nucleotide variants (SNVs), insertions/deletions (indels), copy number variants (CNVs), and gene rearrangements. The NGS sequencing is performed using NovaSeq 6000Dx Sequencing System (Illumina, Inc) equipment, according to Tempus protocols. (Finkel et al 2021)."
214324340|NCT02942017|DRUG|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547
214485984|NCT06996834|DEVICE|Non-Invasive ventilation (NIV)|Participants in this arm will receive noninvasive ventilation using bilevel positive airway pressure (BiPAP) delivered via a full-face mask to support ventilation in patients with acute hypoxemic respiratory failure due to CAP.
214485985|NCT06996834|DEVICE|High Velocity Nasal Insufflation|Participants in this arm will receive high-velocity nasal insufflation therapy, a type of high-flow nasal cannula (HFNC) therapy that delivers heated and humidified oxygen at high flow rates to support patients with acute hypoxemic respiratory failure resulting from community-acquired pneumonia (CAP).
214672858|NCT00609609|DRUG|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
214324341|NCT06513286|BIOLOGICAL|TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)|Administration of the described combinations via the intramuscular route
214324342|NCT06513286|BIOLOGICAL|TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac)|Administration of the described combinations via the intramuscular route
214324343|NCT05033028|OTHER|Smartphone app|SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.
215067231|NCT00394251|DRUG|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
215067232|NCT02304913|OTHER|Hypoglossal acupuncture|
215067233|NCT02304913|OTHER|Sham acupuncture|
215067234|NCT02304913|BEHAVIORAL|Dietary recommendations|
215067235|NCT05791565|DRUG|Salbutamol HFA-152a|Salbutamol HFA-152a will be administered.
215067236|NCT05791565|DRUG|Salbutamol HFA-134a|Salbutamol HFA-134a will be administered.
214324344|NCT02892981|OTHER|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
214324345|NCT06145009|BEHAVIORAL|Time restricted eating|Limit food intake to 10 hours per day as described in the experimental arm section.
214324346|NCT00457197|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
214924315|NCT01011465|DRUG|Placebo|Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
214924316|NCT01011465|BEHAVIORAL|Social support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
214324347|NCT00457197|DRUG|Quetiapine|Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
214324348|NCT00193882|DRUG|Cisplatin|80mg/m2 IV day 1
214324349|NCT00193882|RADIATION|Radiotherapy|35 Gy in 15 fractions
214324350|NCT00193882|DRUG|5-Fluorouracil|800mg/m2/day IV days 1 - 4
214324351|NCT00123188|PROCEDURE|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
214485986|NCT06996535|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
214485987|NCT06996535|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
214924317|NCT01011465|BEHAVIORAL|No Social Support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
214924318|NCT03927521|PROCEDURE|Focal HIFU using PET-MRI/68Ga-PSMA imaging guidance|Focal HIFU treatment will be conducted with the Focal One® device using the PET-MRI/68Ga-PSMA imaging. The treatment area will be defined using PET-MRI/68Ga-PSMA imaging data and 3D biopsies.
215067237|NCT05389423|DRUG|Vincristine|0.4 mg/m2/day administered by CIVI on days 1 to 4
215067238|NCT05389423|DRUG|Prednisone|60 mg/m2/day administered orally on days 1 to 5
215067239|NCT05389423|DRUG|Doxorubicin|10 mg/m2/day administered by CIVI on days 1 to 4
215067240|NCT05389423|DRUG|Etoposide|50 mg/m2/day administered by CIVI on days 1 to 4
215067241|NCT05389423|DRUG|Pomalidomide|An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
215067242|NCT05389423|DRUG|Cyclophosphamide|750 mg/m2 administered IV on day 5
215067243|NCT05389423|DRUG|Rituximab|375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
215067244|NCT06581614|DIAGNOSTIC_TEST|masticatory function test|During the test, participants will be given a piece of chewing gum to assess their masticatory function when the second molar implant-supported fixed denture is in place.
215067245|NCT04612348|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound to measure gastric contents.
215067246|NCT06195046|DEVICE|Baroreflex Activation Therapy (BAT)|activation of BAROSTIM NEO system that affects autonomic modulation with BAT therapy.
215067254|NCT02850224|BEHAVIORAL|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
215067255|NCT02388165|BIOLOGICAL|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
215067256|NCT02388165|OTHER|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
215067257|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
214485988|NCT06996535|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
214485989|NCT06996652|DRUG|Adalimumab|40 mg self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years
214485990|NCT06996652|DRUG|Placebo|40 mg matching placebo self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years
215067258|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
215067259|NCT00880269|DRUG|Panobinostat/LBH589|
215067260|NCT01996488|DRUG|Olanzapine Orally Disintegrating Tablets 5mg|
215067261|NCT01720004|OTHER|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
215067262|NCT04723472|DRUG|Cefuroxime containing bismuth quadruple treatment|"Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days."
215067263|NCT04723472|DRUG|Classic bismuth quadruple treatment|"Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days."
215067264|NCT04233398|DEVICE|Device: Echopulse (HIFU ablation)|High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
215067265|NCT03403530|DRUG|IgM rich Immunoglobin|the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
214485991|NCT06997315|OTHER|Time of exercise|The intervention is 1 hour of exercise at 50% between lactate threshold 1 and 2 either in the morning or the evening at the start of the 24 hour sampling period.
214485992|NCT06997315|OTHER|No exercise|The participants will rest for the full 24 hour sampling period.
215067266|NCT04015427|DEVICE|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
215067267|NCT06174012|DRUG|Sodium Fluoride|Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
215067268|NCT03462927|DRUG|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
214485993|NCT06996028|OTHER|Strengthening domain, Balance domain, Coordination domain, Gait domain|The experimental group will engage in a structured exercise program targeting strength, balance, gait, and coordination. Strength exercises include sit-to-stand, step-ups, vertical jumping, and stair climbing. Balance training involves tandem walking, one-leg standing, and balancing on unstable surfaces. Gait exercises include bridging, clamshells, and heel rises, while coordination activities involve ball kicking, hopping through squares, and galloping/skipping. The program runs for 2 hours per day, 5 days a week, over 6 weeks, with sessions optionally split into shorter segments.
214672859|NCT02441803|DRUG|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
214672860|NCT02441803|DRUG|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
214672861|NCT02441803|DRUG|Clofarabine|"Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3."
214672862|NCT02441803|RADIATION|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
214672863|NCT02441803|DRUG|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
214672864|NCT02441803|BIOLOGICAL|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or \>3.0 X 108 marrow mononuclear cells/kg if bone marrow.
215067269|NCT03462927|DRUG|CAL/BDP combination|Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
215067270|NCT01289275|DRUG|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
215067271|NCT01289275|BEHAVIORAL|Telephone Counseling|Up to 5 proactive counseling sessions from California Smokers' Helpline.
215067272|NCT01289275|BEHAVIORAL|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
215067273|NCT02364427|DEVICE|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
215067274|NCT00640380|OTHER|Nerve stimulation|CPVB with NS
215067275|NCT00640380|OTHER|Loss of resistance to air|CPVB with LOR
215067276|NCT05761639|OTHER|conventional rehabilitation|The program will be attended in person in the clinic's cardiac rehabilitation program and consists of physical exercise supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation, for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up. , muscle strengthening of lower and upper limbs, continuous aerobic training and return to calm.
215067277|NCT05761639|BEHAVIORAL|Education|1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition
215067278|NCT05761639|OTHER|telerehabilitation|"The program will be assisted by virtual technology and consists of physical exercise at home (for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up, muscle strengthening of lower and upper limbs, continuous aerobic training and cool down ) supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation through the Google Meet platform"
215067279|NCT05761639|BEHAVIORAL|follow-up|Telephone calls will be made 3 times a week as a follow-up method to obtain information from each person about their heart rate and perception of effort in relation to the activities carried out where they are encouraged to exercise at home on days without intervention.
215067280|NCT04624919|OTHER|Hot/Dry|Work is completed in a hot/dry environment.
215067281|NCT04624919|OTHER|Warm/Humid|Work is completed in a warm/humid environment
214924319|NCT03937921|DRUG|Gadavist 15Ml Solution for Injection|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
215067282|NCT06537128|BEHAVIORAL|LUNA-Adolescent|Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) includes parent-led, internet-based cognitive behavioral therapy (CBT) for anxiety among autistic youth.
215067283|NCT06537128|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes 12 weekly sessions of transdiagnostic cognitive behavioral therapy (CBT) for anxiety in autistic youth.
215067284|NCT05289817|DEVICE|Transcutaneous Vagus Nerve Stimulation (t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: cymba conchae at right ear (vagus branch nerve area); a clip electrode will be applied with its cathode on anterior cymba conchae, the anode placed behind.~Amplitude: from 2 times the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
215067285|NCT05289817|DEVICE|Transcutaneous Sympathetic Ganglion Electrical Stimulation (t-SES)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 5 Hz Number of channels: two Location and electrodes: cervicothoracic area (stellate ganglion region); first channel: new 5 cm x 5 cm self-adhesive electrodes will be applied at 1-1.5 cm both sides of the vertebral spinous processes, approximately from C7 to T4, upper cathode on the left side of C7 and lower cathode on the right side.~Amplitude: 2 mA above the muscle contraction threshold (individualized) at a comfortable, non-painful amplitude and to a maximum of 25 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of muscle contraction On-Off times: no trains, continuously delivered Duration: 20 minutes"
214924320|NCT00800592|DRUG|sildenafil|10 mg sildenafil bolus
214924321|NCT00068367|DRUG|erlotinib hydrochloride|150 mg per day, daily until disease progression
214672865|NCT02441803|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
214672866|NCT02441803|DRUG|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
214672867|NCT02441803|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
214672868|NCT02441803|DRUG|Decitabine|20 mg/m2 by vein on Days 1 - 5.
214672869|NCT02441803|DRUG|Cytarabine|1 g/m2 by vein on Days 6 - 10.
214672870|NCT02441803|DRUG|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
214924322|NCT04024540|DIETARY_SUPPLEMENT|isocaloric dietary restriction|Very low caloric diet
214924323|NCT04024540|PROCEDURE|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
214924324|NCT06682026|OTHER|listening to music or chatting|"Written consent will be obtained from the patients just before they enter the procedure, and Personal Information Forms and the State Anxiety Inventory (STAI) will be applied to all participants.~Women in the experimental group will be asked to listen to a lively music of their own choosing during the mammography, or for those who do not want music, their attention will be drawn in a different direction by chatting.~At the end of the procedure, the Visual Acuity Scale (VAS) pain scale and the State Anxiety Inventory (STAI) will be applied to both groups."
214924325|NCT04019340|OTHER|Education|Usual care as described for the CG will also be provided to the IG. Wound size measurement, wound care, and questionnaires will be provided by the institute's nurses. Usual care will be enhanced by a pluridisciplinary educational program
214924326|NCT03010150|PROCEDURE|Biospecimen Collection|Provide blood samples
214924327|NCT03010150|OTHER|Questionnaire Administration|Ancillary studies
215067286|NCT05289817|DEVICE|Sham Transcutaneous vagus nerve stimulation (Sham t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: scapha at right ear (non vagus innervated region); a clip electrode will be applied with its cathode on anterior scapha, the anode placed behind.~Amplitude: from 2 times above the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
215067287|NCT04496206|OTHER|No intervention|No intervention, it is retrospective study.
215067288|NCT06308341|OTHER|Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy|Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min
215067289|NCT06308341|OTHER|Virtual Reality + Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes The first eight weeks focus on simple activities to enhance balance and motor function, such as tennis, boxing, bowling, kicking, soccer, table tilt, penguin slide, tilt city, single-leg extension, and torso twist. Exercise difficulty is adjusted based on performance, gradually progressing from easier to more challenging activities."
214324352|NCT01054638|DRUG|HAART Treatment|"Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs."
214324353|NCT06198907|DRUG|Golidocitinib|Daily dosing of golidocitinib
214324354|NCT06198907|DRUG|Sintilimab|Sintilimab, 200mg, intravenous, every 3 weeks.
214324355|NCT06198907|DRUG|platinum doublet chemotherapy|Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
214324356|NCT03080103|PROCEDURE|Laparoscopic or Open appendectomy|Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision
214324357|NCT03080103|DRUG|Antibiotic-first therapy|Patients treated with antibiotics as first-line approach
214324358|NCT02974985|DEVICE|injection of Restylane Lyft and Restylane L|Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
214324359|NCT05756322|DRUG|LBS-007|Open Label.
214324360|NCT03629015|BIOLOGICAL|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
214324361|NCT05059600|DRUG|ZULRESSO®|Intravenous infusion of ZULRESSO®.
214324362|NCT05954325|PROCEDURE|Immunoadsorption vs. sham immunoadsorption|5 treatments within 14 days
214324363|NCT05390801|OTHER|Survey|Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.
214324364|NCT02152995|PROCEDURE|Computed Tomography|Undergo iodine I-124 PET/CT
214324365|NCT02152995|OTHER|Iodine I 124|Undergo iodine I-124 PET/CT
214324366|NCT02152995|RADIATION|Iodine I-131|Given PO
214324367|NCT02152995|OTHER|Laboratory Biomarker Analysis|Correlative studies
214324368|NCT02152995|OTHER|Pharmacodynamic Study|Correlative studies
214324369|NCT02152995|PROCEDURE|Positron Emission Tomography|Undergo iodine I-124 PET/CT
214324370|NCT02152995|DRUG|Trametinib|Given PO
214324371|NCT05189457|DRUG|Luteinizing Hormone Releasing Hormone|During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
214324372|NCT05189457|DRUG|New Hormonal Agent|During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
214324373|NCT05189457|DRUG|Docetaxel|"During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel."
214924328|NCT04698538|BEHAVIORAL|JASPER|JASPER is a naturalistic, developmental, behavioral intervention (NDBI) that focuses on developing social communication and language skills in the context of a play based intervention.
214924329|NCT02584595|DEVICE|ICD/CRT-D with NIPS or EP Study|ICD/CRT-D implanted patients are tested for inducible MMVT during electrophysiology (EP) Study or Non-Invasive Programmed Stimulation (NIPS) Study
215067290|NCT06308341|OTHER|Motor Imagery +Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes The motor imagery program me will be performed in three steps; STEP I: The patients will watch the videos recorded by the examiner. STEP II: The patients will be asked to close their eyes, focus, and imagine how they are doing the task they had previously observed ten times.~Step III: The patient will be asked to attempt the activity with his affected limbs according to the verbal command of the examiner Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min."
214672871|NCT01853124|DRUG|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
215067291|NCT02412891|DEVICE|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
215067292|NCT02412891|DEVICE|Sham UroShield device|
215067293|NCT02819258|OTHER|Endodontic treatment|
215067294|NCT01667224|DIETARY_SUPPLEMENT|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
215067295|NCT01667224|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Actiponin.
215067296|NCT01222091|DRUG|Propranolol|Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
215067297|NCT01222091|DRUG|Placebo to Match Propranolol|
215067298|NCT01222091|DRUG|Remifentanil|Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
215067299|NCT04378998|OTHER|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
215067300|NCT04385472|RADIATION|3T MRI|The main method used will be 3 Tesla MRI, which is a high resolution imaging technique. The participants will be asked to undergo musculoskeletal MRI scanning (pelvis and lumbar spine).MRI is a non-invasive procedure which excludes the risk of radiation (in comparison to other imaging modalities: X-ray, CT
214324374|NCT05189457|DRUG|Tislelizumab|During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
214324375|NCT04804462|DEVICE|Virtual Reality Meditation|After donning the VR headset, participants will be able to use a handheld controller to choose from several virtual outdoor settings, three types of meditation, and three session lengths. After choosing their desired option, participants will experience virtual reality meditation in the desired virtual location, of the desired meditation type, and for the allotted duration chosen.
214324376|NCT00872846|DEVICE|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
214324377|NCT00145054|BEHAVIORAL|MoodHelper Internet program for Depression Self-Help|
214324378|NCT00106782|PROCEDURE|Transcranial Electrical Polarization (TEP)|
214324379|NCT03384121|DRUG|Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension|Starting Dose (V2): 5 mg/kg/day (max 600mg/day) orally for 2 months followed by a 2 month washout period V4: After washout period, only Non-responders will escalate dose to 10 mg/kg/day (max 600mg/day) orally for 2 months
214324380|NCT02155023|DRUG|Insulin dosing|
214324381|NCT02155023|DEVICE|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
214324382|NCT01625247|PROCEDURE|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
214324383|NCT01248299|DRUG|FU-CDDP|"every 21 days:~* Fluoro-uracil \[800 mg/m2, day 1 to day 5\]~* CisPlatin \[75 mg/m2, day 1 or day 2\]"
215067301|NCT00395187|PROCEDURE|Photodynamic Therapy|
215067302|NCT03322176|OTHER|Genetic testing|LYNCH genetic testing
215067303|NCT03593122|DEVICE|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
215067304|NCT00374946|DEVICE|THA|
215067305|NCT06567210|BEHAVIORAL|CBCTi|The program is composed of weekly online modules that include written information and interactive components such as schematics, images, videos, and questions. The content of the modules follows traditional and validated cognitive-behavioural therapy for insomnia protocols including sleep education, behavioural strategies (e.g., stimulus control, bedtime retraining, sleep hygiene), cognitive restructuration approaches (e.g., thought reappraisal, imagery, mindfulness), and relaxation practices (progressive muscle relaxation and autogenic training). In addition, further content aims to stabilize and amplify circadian rhythmicity through light exposure in the morning, daytime moderate physical activity, and evening time warm baths. Participants complete daily sleep diaries throughout the intervention.
215067306|NCT06567210|BEHAVIORAL|General sleep information|General sleep health information and access to daily sleep diaries during 8 weeks
215067307|NCT00125463|DRUG|Candesartan cilexetil|
215067308|NCT01601106|DRUG|liposomal prednisolone|Two weekly dosages with 150 mg.
215067309|NCT01601106|DRUG|Placebo|
215067310|NCT00072930|BIOLOGICAL|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
215067311|NCT00072930|BIOLOGICAL|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
215067312|NCT02189044|OTHER|Pilates Exercise|"The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall."
215067313|NCT05607511|OTHER|Probiotics baby immunity formula (SIM03)|Daily oral intake of a probiotics sachet
215067314|NCT00246181|PROCEDURE|radiation therapy|Patients will receive 3 fractions
214924330|NCT03597750|DEVICE|Repose®|"* Repose® Mattress~* Repose® Cushion~* Repose® Wedge or Foot Protectors"
214924331|NCT06668701|DEVICE|"ich bin alles"|"The web-based information platform ich bin alles (www-ich-bin-alles.de) on depression and mental health in childhood and adolescence was developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy of the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. It is aimed at children and adolescents with depression, healthy children and adolescents and parents. The project focuses on education, prevention, support and destigmatisation through the transfer of evidence-based knowledge."
214924332|NCT04610112|DEVICE|cochlear implantation|patients receive a cochlear implantation within clinical routine
215067315|NCT02774200|DRUG|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
215067316|NCT04266301|DRUG|Sabatolimab|A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
215067317|NCT04266301|DRUG|Azacitidine|A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
215067318|NCT04266301|DRUG|Placebo|A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
215067319|NCT05001152|DRUG|Ozanimod|Taste assessment
215067320|NCT00316225|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles
215067321|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 6 months in addition to standard of care
215067322|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 3 months in addition to standard of care
215067323|NCT03660202|DEVICE|Firesorb|Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
215067324|NCT04624386|OTHER|Thiol disulfide level|Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
215067325|NCT06567028|DIAGNOSTIC_TEST|OSPM-Enhanced AI Model|Analyze tumor images using the model developed in our study
214924333|NCT04115917|DEVICE|Schocket scleral depressor|Scleral Depression on eye with Schocket scleral depressor
215067326|NCT04410562|DRUG|Hydroxychloroquine|Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
215067327|NCT04410562|DRUG|Placebo|Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
215067328|NCT00289068|PROCEDURE|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
215067329|NCT00289068|PROCEDURE|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
215067330|NCT00289068|PROCEDURE|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
215067331|NCT04036474|OTHER|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
215067332|NCT04547335|DRUG|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
215067333|NCT02976636|BEHAVIORAL|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
215067334|NCT02976636|BEHAVIORAL|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
214924334|NCT04115917|DEVICE|Cotton tipped applicator|Scleral Depression on eye with cotton tipped applicator
214924335|NCT00723008|DEVICE|Alpha Stim 100 (Cranial Electrotherapy Stimulation)|cranial electrical stimulation 100 microamps
214924336|NCT02484781|OTHER|Gait analysis on a trendmill|"Gait analysis on a trendmill GRAIL to analyse spatio-temporal kinetics and kinematics when flat walking and inclining"
214924337|NCT04409808|DEVICE|IRIS|prototype IRIS vitrectomy device.
214924338|NCT02879617|DRUG|durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
214324384|NCT01248299|DRUG|LV5FU2-CDDP|"every 14 days:~* Elvorin \[200 mg/m2, 2h IV, day 1 and day 2\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, 22h continous infusion, day 1 and day 2\]~* CisPlatin \[50 mg/m2, day 2\]"
214324385|NCT01248299|DRUG|FOLFOX|"every 14 days:~* Oxaliplatin \[85 mg/m2 by 2h infusion, day 1\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, by 22h continous infusion, day 1 and day 2\]~* Elvorin \[500 mg/m2, day 1 and day 2\]"
214324386|NCT01248299|DRUG|TPF|"every 21 days:~* Docetaxel \[30 mg/m2, day 1 and day 8\]~* CisPlatin \[60 mg/m2, day 1\]~* Fluoro-uracil \[200 mg/m2/day by continous infusion\]~Or every 21 days:~* Docetaxel \[50 mg/m2, day 1\]~* CisPlatine \[70 mg/m2, day 1\]~* Fluoro-uracile \[700 mg/m2 /day, day 1 to day 5\]"
214324387|NCT01248299|OTHER|Best Supportive Care|See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
214324388|NCT03546751|DEVICE|Continuous Positive Airway Pressure|This device delivers air pressure non invasively through a mask to stent open the upper airway to prevent obstruction during sleep. This is an FDA approved device that has been used for several decades to treat OSA.
214324389|NCT03546751|OTHER|Diet And Exercise|This will consist of weekly telephone and monthly face to face visits to monitor and suggest measures to improve diet and regular exercise as conducted by a registered dietician.
214324390|NCT06561217|OTHER|Chart review|Chart review
214324391|NCT04488120|DEVICE|transcatheter closure of secundum atrial septal defects in patients|transcatheter closure of secundum atrial septal defects in patients
214324392|NCT04294134|BEHAVIORAL|MIO-CPP|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) Studies have revealed that CPP caregivers' outcomes include decreased depression, PTSD and other symptoms, increased empathy towards children and an increase in the quality of parent-child interactions. CPP focuses on working with families offering weekly sessions for nine-12 months."
214324393|NCT04294134|BEHAVIORAL|MIO-CPP-CRS|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) CPP focuses on working with families offering weekly sessions for nine-12 months.~Certified Recovery Specialists (CRS) provide peer support services are an evidence-based…model of care which consists of a qualified peer support provider who assists individuals with their recovery from mental illness and substance use disorders."
214324394|NCT06447844|DEVICE|OsteoGen Plug|OsteoGen® Plug is contoured to fill the three roots of the socket. Plug is delivered dry into a thoroughly debrided and actively bleeding socket. The OsteoGen® Plug is condensed firmly into the socket.
214324395|NCT06447844|DEVICE|BioGide|BioGide is a resorbable collagen membrane
214324396|NCT05548023|DEVICE|The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent|The Angiolite stent is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design and a high overexpansion capacity that might overcomes some of these challenges in LMCA PCI. The ANGIOLITE randomized trial confirmed the non-inferiority of the Angiolite stent against the conventional DES
214924339|NCT05534386|BEHAVIORAL|Cancer survivorship care intervention|A one-off face-to-face assessment and personal advice by members of a multidisciplinary team
214924340|NCT05534386|BEHAVIORAL|Step-up targeted personalized intervention|To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.
214924341|NCT05534386|BEHAVIORAL|First stage control intervention|A set of skill-based pamphlets will be given.
214924342|NCT05534386|BEHAVIORAL|Second stage control intervention|Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet
214924343|NCT01928602|BEHAVIORAL|TherAppy Language App|Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, \& adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
214924344|NCT01928602|BEHAVIORAL|Mind-Games|A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
214924345|NCT06123221|PROCEDURE|Osseodensification with Versah system|Access to the bone crest will be performed through a slightly palatinized crestal incision, and a full-thickness mucoperiosteal flap will be elevated. Implant site preparation will be performed according to the bone densification drilling sequence established by the Densah® technique protocol
214924346|NCT06123221|PROCEDURE|Lateral window|A full-thickness mucoperiosteal flap will be elevated. The lateral window will be made with a spherical diamond drill (number 8) at 20,000 rpm. The mesiodistal and apicocoronal dimensions of the lateral access window to the sinus will be measured in all the participants using a caliper. Sinus membrane elevation will be performed with manual instruments.
214924347|NCT02089308|DRUG|Test treatment : V0116 transdermal patch|
214924348|NCT02089308|DRUG|Reference treatment : Nicotine transdermal patch|
215067335|NCT02710981|DRUG|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
215067336|NCT02710981|DRUG|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
214324397|NCT01059370|PROCEDURE|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
214324398|NCT04048642|BEHAVIORAL|DASH|7 days of a DASH diet
214324399|NCT04048642|BEHAVIORAL|Whole-Food, Plant-Based|7 days of a WFPB diet
214924349|NCT06665451|OTHER|Non coated dental implants|Patients with fresh extraction sockets in the anterior maxilla will be treated by non coated immediate implant .
214924350|NCT06665451|OTHER|Erythropoietin gel coated implants|Patients with fresh extraction sockets in the anterior maxilla will be treated by immediate implant coated by erythropoietin gel.
214924351|NCT04678154|DRUG|Standard of care|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
214672872|NCT01853124|DRUG|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
215067337|NCT05980273|BEHAVIORAL|Educational sessions|session for oral health education
215067338|NCT01576419|DRUG|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
215067339|NCT01576419|DRUG|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
215067340|NCT01280058|DRUG|Carboplatin|Given IV
215067341|NCT01280058|OTHER|Laboratory Biomarker Analysis|Correlative studies
215067342|NCT01280058|DRUG|Paclitaxel|Given IV
215067343|NCT01280058|BIOLOGICAL|Wild-type Reovirus|Given IV
215067344|NCT01942668|DRUG|Estradiol|
215067345|NCT01942668|DRUG|Progesterone|
215067346|NCT01942668|DRUG|Placebo|
215067347|NCT02839187|RADIATION|Neuroimaging|AV45-positron emission tomography
215067348|NCT04321473|PROCEDURE|PCI on left main|PCI on left main coronary stenosis
215067349|NCT06959862|DEVICE|Transcatheter Aortic Valve Implantation/Replacement|The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU
214324400|NCT04552587|BEHAVIORAL|Heart APP|The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
214324401|NCT02440386|BEHAVIORAL|Conditional economic incentive|"Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:~1. Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and~2. send a text message to the study team to let us know they have started ART;~3. Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation."
214485994|NCT06996028|OTHER|Lower extremity strengthening, Cardiorespiratory endurance|Group B will follow the PEDALS program, involving stationary cycling three times a week for 30 minutes per session. Each session includes lower-limb strengthening with gradual resistance progression and cardiorespiratory endurance training aimed at increasing cycling duration to 15-30 minutes. Proper bike setup and participant support are ensured, and each session ends with a cool-down period of pedaling without resistance until heart rate returns near baseline.
215067350|NCT05464914|DRUG|CEO Pack|is a eugenol-free, surgical dressing and periodontal pack that has no burning sensation, no unpleasant taste or odor, and offers proven protection to surgical sites. This product promotes cleanliness and healing. Plastic and cohesive, ropes of any length or thickness can be formed. The smooth texture allows this product to adapt closely to the teeth and tissue in order to protect the wound. It sets with resilient, non-brittle hardness.
215067351|NCT06004895|DEVICE|Actual IPL|Five light pulses along lower lid region of one eye of the participant ranging from 59 to 69 Joules (J) over an area of 2.5cm by 4.5cm for each pulse
214324402|NCT06146530|DEVICE|Treatment|The intervention consists of 7 sessions of CBT for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will be applicable to them. The intervention is based on an evidence-based treatment protocol; hence the sessions will flow from one to the other and the user will complete the sessions in a progressive direction. However, they can repeat a session before going on to the next session. Once all sessions have been completed, the user can go back over any of the sessions. There are anxiety management exercises, which the user can go to whenever they wish. There are also a therapy reflection journal and self-care resources including further anxiety management techniques, resources, and podcasts that the user will have access to whenever they want.
214324403|NCT00480779|BEHAVIORAL|GLB Group|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
214324404|NCT00480779|BEHAVIORAL|GLB DVD|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
214924352|NCT04678154|DRUG|Vancomycin and Tobramycin|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
214324405|NCT02660320|DEVICE|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
214324406|NCT02660320|DEVICE|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
214324407|NCT03072134|BIOLOGICAL|Neural stem cells loaded with an oncolytic adenovirus|The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
214324408|NCT03678155|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
214924353|NCT05334342|DIETARY_SUPPLEMENT|Low-GI Diet|Participants will be given a low glycemic index diet
214924354|NCT05334342|DIETARY_SUPPLEMENT|High-GI Diet|Participants will be given a high glycemic index diet
214924355|NCT01014988|DRUG|zanamivir aqueous solution|Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
214924356|NCT00882778|DRUG|eptacog alfa (activated)|Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
214924357|NCT06682611|DRUG|SYHA1813|In accordance with the protocol
214924358|NCT06682611|DRUG|SG001|In accordance with the protocol
214924359|NCT06682611|DRUG|HB1801|In accordance with the protocol
214924360|NCT06682611|DRUG|Carboplatin|In accordance with the protocol
214924361|NCT06682611|DRUG|Cisplatin|In accordance with the protocol
214924362|NCT06682611|DRUG|Paclitaxel|In accordance with the protocol
214924363|NCT06682611|DRUG|Etoposide|In accordance with the protocol
214924364|NCT06682611|DRUG|Everolimus|In accordance with the protocol
214924365|NCT06682611|DRUG|Regorafenib|In accordance with the protocol
214924366|NCT02880878|PROCEDURE|Early Surgical Hematoma Evacuation|Early Minimally Invasive Parafascicular Surgery (MIPS)
214924367|NCT00986128|DRUG|topiramate|100 mg tablet twice daily for 3 weeks
214924368|NCT00986128|DRUG|topiramate|One 100 mg and one 200 mg tablet twice daily for 3 weeks
214924369|NCT05631093|DRUG|ART|Standard of care ART, per approved product list, taken orally
214924370|NCT05631093|DRUG|DOR/ISL|Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
214924371|NCT03604393|BEHAVIORAL|Practice facilitation|For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
214924372|NCT03850730|DRUG|Pazopanib|Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study
214924373|NCT01683266|DRUG|HOE901-U300 (Insulin glargine new formulation)|
214924374|NCT01683266|DRUG|Lantus (Insulin glargine)|
214924375|NCT01235026|DIETARY_SUPPLEMENT|Synbiotic|"5g of the prebiotic Oligofructose + 1 g of the probiotic Bifidobacterium animalis subsp. lactis Bb12 (4x10\^10 CFU/g), twice a day, for 6 weeks."
214924376|NCT01235026|DIETARY_SUPPLEMENT|Placebo|6g of maltodextrin, twice a day for 6 weeks.
214924377|NCT00096616|DRUG|Combivent® CFC MDI|
214924378|NCT00096616|DRUG|Albuterol HFA MDI|
214924379|NCT03766165|BEHAVIORAL|Intervention|Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
214924380|NCT03766165|BEHAVIORAL|Control|Participants will receive job announcements only.
214924381|NCT06220981|OTHER|Endovascular treatment|
214924382|NCT05594836|BEHAVIORAL|Infant Calming Training|Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy during Infant Calming Training
214924383|NCT06532812|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
214924384|NCT06532812|DRUG|Cyclophosphamid|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
214924385|NCT06532812|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
215067352|NCT06004895|DEVICE|Sham IPL|Simulated five light pulses along lower lid region of the other eye of the same participant
215067353|NCT06004895|DEVICE|LLLT|Mask with LEDs transferring a total of about 32 J/cm\^2 of energy to facial and eyelids region with their eyes closed
215067354|NCT06554886|DEVICE|Cryoneurolysis|Cryoneurolysis
214485995|NCT06997471|BIOLOGICAL|Investigational cellular therapy consisting on a HSCT using a graft enriched in CD34+, depleted of naïve T-lymphocytes and supplemented with memory lymphocytes|"Infusion Schedule~1. Primary Infusion: the enriched graft, containing the CD34+ progenitors and depleted naïve T cells, will be infused after the patient has undergone conditioning therapy.~2. In the case of haploidentical donors, an additional NK cell infusion will be administered whenever possible around day 7 post-transplant from a non-mobilized apheresis collection, aiming to enhance graft tolerance and prevente HHV6 disease.~3. Post-Transplant Memory T cell Infusions: beginning on days 15 and 30, and then administered monthly up to a maximum of one year or until the supply is depleted, memory T cells will be infused.~Conditioning Regimen~Prior to HSCT, all patients will undergo a low-intensity conditioning regimen designed to allow engraftment of the donor cells while minimizing toxicity:~1. Total Lymphoid Irradiation (TLI): 8 Gy of total lymphoid irradiation will be administered.~2. Fludarabine: a total dose of 120 mg/m², spread over 4 days (-6 to -3 before transplant), will serv"
215067355|NCT03946774|DIETARY_SUPPLEMENT|Dietary protein shake|"It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate."
215067356|NCT05849675|DRUG|Pitolisant 17.8 MG [Wakix]|Single dose pitoliosant (36mg)
215067357|NCT05849675|DRUG|Placebo|Single dose placebo
215067358|NCT01346943|DEVICE|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
214485996|NCT06995911|DEVICE|Virtual Far-sight Reading Device|The Virtual Far-sight Reading Device utilizes a birdbath optical configuration and freeform surface technology to extend the working distance from 30 cm to over 6 meters, thereby simulating distance viewing conditions and maintaining ciliary muscle relaxation. Study participants were required to engage in reading and writing tasks using the device for a cumulative daily duration of at least 1 hour.
214485997|NCT06997575|DRUG|Magnesium Sulphate infusion|Infusion of 20% MgSO4 solution
214924386|NCT06532812|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
214924387|NCT06532812|DRUG|Pembrolizumab|Intravenous (IV) infusion
214924388|NCT00011258|DRUG|Paraoxonase|
214924389|NCT00886743|DRUG|oprelvekin|injection, 50 mg/kg, once daily
214924390|NCT00756236|DRUG|Metoprolol|60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
214924391|NCT00756236|DRUG|Esmolol|60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
214924392|NCT00756236|DRUG|P-Group|0.9%NaCl dispensed in 60ml \& 5ml syringes
214924393|NCT00000818|DRUG|Zidovudine|
214924394|NCT05217641|BIOLOGICAL|BG505 MD39.3 mRNA|Administered by IM injection
214924395|NCT05217641|BIOLOGICAL|BG505 MD39.3 gp151 mRNA|Administered by IM injection
214924396|NCT05217641|BIOLOGICAL|BG505 MD39.3 gp151 CD4KO mRNA|Administered by IM injection
214924397|NCT04001218|DRUG|Injection of hypertonic saline|Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
214924398|NCT04001218|DRUG|Injection of Isotonic saline|Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
214924399|NCT00626821|DEVICE|SenSura|Real life assessment of SenSura
214924400|NCT01800643|OTHER|Analyze the pharmacokinetics of busulfan for transplantation|"Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target."
214924401|NCT06287632|DEVICE|Recruitment/ITP-CPAP (Intervention A)|Participant will receive a recruitment maneuver followed by CPAP set to the level of end-expiratory esophageal pressure (measured during atmospheric pressure breathing). The intervention will last for 20 minutes.
214924402|NCT06287632|DEVICE|Standard CPAP (Intervention B)|Participant will receive their home CPAP (if on CPAP at home) or CPAP at 8-10 cmH20 (if not on CPAP at home or no known diagnosis of OSA). The intervention will last for 20 minutes.
214924403|NCT06287632|DEVICE|Atmospheric Pressure|Participant will breathe at atmosphere pressure (no CPAP) with supplemental oxygen as needed per clinical guidance.
214924404|NCT02632409|BIOLOGICAL|Nivolumab|
214924405|NCT02632409|OTHER|Placebo|
214924406|NCT06261983|PROCEDURE|Sentinel node biopsy guided by magnetic probe|Sentinel nodes exeresis guided by magnetic probe after injection submucosally and peritumorally of super-para-magnetic contrast. Standard neck dissection (levels I-II) were carry out after sentinel node biopsy
214924407|NCT06094283|DRUG|YCT-529|Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
215067359|NCT04457206|BEHAVIORAL|SCI Group and one-on-one services through student led occupational therapy clinic|The Collaborative Community Clinic (CCC) students collaborate with Dr. Walker to conduct the spinal cord injury/disease (SCI/D) Health and Participation Program, which consists of a combination of groups and one-on-one OT sessions serving persons with spinal cord injury and disease who are un- or under-insured. The program includes a pre-assessment session, four groups, optional individual sessions and a post-survey. Group topics include bowel/bladder management, community mobility, advocacy, transportation, promoting intimacy, adaptive parenting and finding resources. Students are involved in recruiting participants, co-leading group sessions, treatment planning and implementation for individual sessions, and development of topic-specific materials.
215067360|NCT06468605|BIOLOGICAL|JCXH-211|JCXH-211 is a lipid nanoparticle (LNP) encapsulated srRNA, encoding the human IL-12 protein.
215067361|NCT05107635|DEVICE|AtriCure Commercially Available Devices|Epicardial and endocardial hybrid ablation procedure used to treat the IST or POTS using AtriCure commercially available devices.
215067362|NCT02465788|DEVICE|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
215067363|NCT04646746|DIETARY_SUPPLEMENT|100% wheat|100 g of bread backed with 100% wheat
215067364|NCT04646746|DIETARY_SUPPLEMENT|50% nude barley and 50% wheat|100 g of bread backed with 50% nude barley and 50% wheat
215067365|NCT04646746|DIETARY_SUPPLEMENT|75% nude barley and 25% wheat|100 g of bread backed with 75% of nude barley and 25% wheat
215067366|NCT04646746|DIETARY_SUPPLEMENT|50% gene-modified high-amylose barley and 50% wheat|100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
215067367|NCT03159676|RADIATION|Proton beam|Proton beam
215067368|NCT01918605|DEVICE|Diluted spacer|
215067369|NCT01918605|DEVICE|Non-diluted spacer|
215067373|NCT02964884|DRUG|Lovastatin|Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
215067374|NCT02964884|BEHAVIORAL|reading tutoring intervention|After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)
215067375|NCT02964884|DRUG|Placebo Oral Tablet|Those in the placebo group will receive a tablet daily
215067376|NCT02964884|BEHAVIORAL|"Other Academic sham tutoring"|No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
215067377|NCT01332591|PROCEDURE|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
214485998|NCT06997575|DRUG|Magnesium sulphate intramuscular|Intramuscular injections will be instituted in gluteal region.
215067378|NCT05503095|GENETIC|Genetic analysis for PCSK9 polymorphisms|Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
215067379|NCT05594225|BEHAVIORAL|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
215067380|NCT01781793|OTHER|Room air|Humidified room air (21% oxygen) will be inspired
215067381|NCT01781793|OTHER|Hyperoxia|60% oxygen will be inspired
215067382|NCT04522882|DEVICE|Actimetry|Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.
215067383|NCT04522882|OTHER|Questionnaires|Patients will complete food and medication intake questionnaires for 7 days.
215067384|NCT04522882|OTHER|Glucose level and insulin administration|Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
215067385|NCT01574820|DRUG|placebo tablet|placebo tablet for 6 months
215067386|NCT01574820|DRUG|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
215067387|NCT05392673|OTHER|KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)|Artificial liver scavenges inflammatory factors.
215067388|NCT04882878|OTHER|Placebo|Placebo will be administered intravenously.
215067389|NCT04882878|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
215067390|NCT04882878|DRUG|Standard-of-care treatment|Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
215067391|NCT01780246|DRUG|nusinersen|Administered by intrathecal (IT) injection
215067392|NCT05875207|BEHAVIORAL|Mindfulness based practice|Physical therapists who are randomized to this arm will receive mindfulness training. This training will teach physical therapists to use the following with their patients: 1) use mindfulness to strengthen self-regulation of habitual and compulsive opioid use, and to mitigate pain by reinterpreting these experiences as innocuous sensory information, 2) use reappraisal to reframe stressors and maladaptive thoughts to decrease negative emotions and engender meaning in life, 3) use savoring of pleasant events and pleasurable sensations to enhance positive emotions and reward and, 4) to integrate mindfulness, reappraisal and savoring with evidence-based physical therapy.
215067393|NCT05875207|BEHAVIORAL|Control/Standard Physical Therapy|Physical therapists randomized to this arm will receive no additional training and will provide standard care to patients with chronic musculoskeletal pain and long-term opioid treatment. Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about their pain and opioid use before and after treatment. We plan on enrolling 2 patients for each physical therapist.
214672873|NCT02267577|DEVICE|Sphygmo: Automatic Blood Pressure Monitor|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals.
214672874|NCT02267577|DEVICE|GE Dinamap ProCare Automatic Blood Pressure Monitor|This commercially available gold standard blood pressure monitor will be used as a control to assess the accuracy of the Sphygmo device.
214672875|NCT00129714|OTHER|cervical collar|
214672876|NCT00129714|OTHER|physiotherapy|
215067394|NCT02434653|OTHER|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
215067395|NCT02434653|OTHER|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
215067396|NCT02363972|DEVICE|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
215067397|NCT02314156|DRUG|Telapristone Acetate|Given transdermally
215067398|NCT02314156|OTHER|Placebo|Given PO
215067399|NCT02314156|DRUG|Telapristone Acetate|Given PO
214485999|NCT06879483|PROCEDURE|Thoraco-laparoscopic partial esophagogastrectomy|"1. Laparoscopic Phase:~   * The stomach is mobilized, and a part of it is resected to include the lower esophageal segment.~  * Left gastric nodes, the splenic and common hepatic nodes are dissected.~  * A gastric tube is created using endoscopic staplers for esophageal reconstruction and fixed to the proximal gastrectomy specimen using sutures~2. Thoracoscopic Phase:~   * The patient is positioned in prone position~  * Three small incisions are made in the thorax~  * Further esophageal mobilization through a right thoracoscopy is performed in left lateral decubitus. Periesophageal nodes are retrieved en bloc. Left and right paratracheal and subcarinal lymph nodes are resected separately. The esophagus is transected at the tumor's proximal margin.~3. Reconstruction:~   * An anastomosis (esophagogastric connection) is performed to restore continuity, typically using a circular stapler or hand-sewn technique."
214486000|NCT06865209|DEVICE|Monolithic Zirconia Posterior Single Screw Retained Implant Crowns|Posterior single edentulous sites will be rehabilitated with monolithic zirconia single posterior implant crowns following two different full digital workflows
214486001|NCT06864728|BEHAVIORAL|Video Diabetes Education|Participants will receive a link to a short video explaining their findings. They can use the link as often as they'd like. They will get the results for the CGM and the laboratory findings. They will be linked to their 2 week diet diary
214486002|NCT06864728|BEHAVIORAL|In person or virtual diabetes education|Participants will meet with a nurse to discuss their CGM results and their lab results and get appropriate education.
215067400|NCT02314156|OTHER|Placebo|Given transdermally
215067401|NCT02314156|OTHER|Laboratory Biomarker Analysis|Correlative studies
215067402|NCT02314156|OTHER|Questionnaire Administration|Ancillary studies
215067403|NCT06351774|BEHAVIORAL|Physical therapy|Physical therapy for the treatment of chronic low back pain, as directed by a licensed Physical Therapist. The Healthy Minds Innovations (HMI) program is an app-based learning platform developed through the University of Wisconsin-Madison Center for Healthy Minds. The HMI app includes foundational meditation practices and short podcast-style lessons based on the science of wellbeing to cultivate mindfulness, positive relationships, and insight into the nature of the self.
215067404|NCT04342949|BEHAVIORAL|quality of life|To observe the difference of quality of life
215067405|NCT02317601|DRUG|methylprednisolone sodium succinate|Single dose Intravenous
215067406|NCT02317601|DRUG|placebo saline|
215067407|NCT03002324|BEHAVIORAL|Baseline Survey|The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
215067408|NCT03002324|BEHAVIORAL|Current CDC Message|Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
215067409|NCT03002324|BEHAVIORAL|Cervical Cancer Message|Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
215067410|NCT03002324|BEHAVIORAL|Control Message|Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
215067411|NCT03002324|BEHAVIORAL|Post-Intervention Survey|The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
215067412|NCT06510179|OTHER|Toothbrushing|Patients brush their teeth using the technique instructed to them using the toothbrush provided.
215067413|NCT02131090|DEVICE|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
215067414|NCT02131090|DEVICE|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
214672877|NCT02511080|DEVICE|Spot-On|use of active hot measures
214672878|NCT02561377|BEHAVIORAL|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
214924408|NCT06094283|DRUG|YCT-529 Placebo|YCT-529 Placebo
214924409|NCT00604097|BEHAVIORAL|Attachment-Based Family Therapy|12-16 week family-based therapy
214924410|NCT00604097|BEHAVIORAL|Enhanced Usual Care|Rapid referral to community outpatient care with weekly monitoring of symptoms by study team
214924411|NCT00210197|PROCEDURE|Blood collection (pre and postoperative): plasma coagulation parameters|
214924412|NCT02644863|DRUG|Paclitaxel|Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles
214924413|NCT02644863|BIOLOGICAL|DC-CIK|Antigen-sensitized DC-CIK 8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
214924414|NCT02644863|DRUG|Cisplatin|Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
214924415|NCT03609931|PROCEDURE|Mitral Valve Model|Creation of a mitral valve patient specific model to see if it mimics the patients valve
214924416|NCT05269173|DRUG|Flos gossypii flavonoids tablet|The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
214924417|NCT04040231|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.
214924418|NCT04040231|DRUG|Nivolumab|Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.
214924419|NCT04040231|BIOLOGICAL|Sargramostim|All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle
214924420|NCT00200174|DRUG|Raloxifene followed by combination therapy|Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
214924421|NCT00200174|DRUG|Exemestane followed by combination therapy|Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
214924422|NCT03118362|DRUG|Plasmalyte|"Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
214924423|NCT03118362|DRUG|Ringer lactate|"Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
214924424|NCT02102620|DRUG|Intra-articular injection with corticosteroid|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
215067415|NCT02131090|DEVICE|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
215067416|NCT06479512|DEVICE|ultrasonography to measure the index of the caval aorta and non-invasive pulse oximetry for perfusion index|Inferior vena cava and aortic diameter measurements will be made by ultrasonography and perfusion index determination using non-invasive pulse oximetry
215067417|NCT04057209|RADIATION|Single Vocal Cord Irradiation (SVCI)|The following planning aim will be pursued: full coverage of the PTV with at least 95% of the prescribed dose and a maximum (0.03 cc) PTV dose of \<107%: 16 x 3.63 = 58.08 Gy in 5 fractions per week using 5 to 9 static IMRT or VMAT.
215067418|NCT04057209|PROCEDURE|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|"The TLM has to be performed using a CO2 laser, coupled to an operative microscope, at 4-8W in ultrapulse mode. The type of cordectomy performed must be mentioned using the following classification according the classification of the European Laryngological Society.~The type of resection chosen should provide complete removal of the primary lesion with negative margins.~Surgery will generally be performed within 3 weeks after randomization and not more than 6 weeks after panendoscopy.~The extent of the cordectomy must include a complete anterior, posterior, inferior and supero-lateral mucosal and deep soft tissue margin."
215067419|NCT02088879|BEHAVIORAL|chest compression with kneeling position|
215067420|NCT02088879|BEHAVIORAL|chest compression with standing position|
215067421|NCT01334216|OTHER|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
215067422|NCT01334216|OTHER|CHICA Placebo|This was CHICA without the study module.
215067423|NCT05962242|RADIATION|Radiation Therapy|External Beam Radiation to Head and Neck
215067424|NCT01491789|DEVICE|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
214486003|NCT06860685|DIETARY_SUPPLEMENT|gum chewing|Participants allocated to chewing gum will be instructed to chew commercially available sugar-free gum (Extra \& Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily from the first postoperative morning until oral dietary intake. They were instructed to chew the piece of gum for at least 10 minutes.
214486004|NCT06860945|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
214486005|NCT06617364|PROCEDURE|gastrointestinal transit time measurement using MSOT and ICG contrast agent|The subject arrives at the clinic in the morning, fasting according to the preparation instructions from the Childrens Hospital Erlangen for the H2 breath test. Before taking the liquid containing lactose and ICG, the first measurement is performed using MSOT, followed by the H2 breath test. After the liquid to be detected is fully consumed, the second H2 breath test measurement, which only takes a few minutes, is conducted. According to the official guidelines of the Childrens Hospital Erlangen, the hydrogen concentration in the breath is measured at 30-minute intervals. During the 30-minute breaks, further MSOT measurements are carried out, also at 30-minute intervals. Each of these only takes about 10 minutes, they do not interfere with the H2 breath test measurement routine. After the ninth and final H2 breath test measurement a final MSOT examination is conducted. Afterwards participants are offered an optional MRI examination, which can be used to measure intestinal motility.
214486006|NCT06997159|DRUG|LXE408|LXE408 film-coated tablets.
214486007|NCT06997159|DRUG|Miltefosine 50 MG Oral Capsule [Impavido]|Each capsule contains 50 mg miltefosine in an opaque, red, hard gelatin capsule. Capsules are supplied in packs of 56 capsules sealed in 8 aluminum blister stripes, each containing 7 capsules.
215067425|NCT02982434|DRUG|Pharmaceutical composition containing botulinum toxin|
214486008|NCT06997159|DRUG|Placebo to LXE408|Film-coated tablets.
214486009|NCT06997146|BIOLOGICAL|Blood and Urine Sampling|Collection of 10 mL of blood (separated into aliquots for RNA-seq and metabolomic analysis) and 5 mL of urine from participants at various timepoints during sleep and wakefulness. These samples will be used to analyze biomarkers and dysregulated biological pathways related to CCHS.
214486010|NCT06997146|DEVICE|Polysomnography|Participants will undergo polysomnography to assess sleep patterns and respiratory function during sleep. This will help evaluate any sleep-related breathing abnormalities in patients with CCHS and compare them with healthy controls.
214486011|NCT06997146|OTHER|lung function tests|spirometry, ventilatory response to CO2
214672879|NCT02561377|BEHAVIORAL|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
214672880|NCT01467739|DEVICE|Ambu ® aScope®|
214672881|NCT01467739|DEVICE|a conventional reusable fiberscope|
214672882|NCT01857986|DEVICE|AnapnoGuard 100 control unit|
214672883|NCT05056480|OTHER|Surveys|Parent/caregivers participants will complete multiple repeating surveys to gather family-reported perspectives on the impact of the PCCI care management program. Clinical staff participants will complete multiple repeating surveys that gather clinician perspectives on the impact of the PCCI care management program. Parent/caregiver and clinical staff participants will also be invited to participated in one-on-one semi-structured interviews with the study team.
214924425|NCT02102620|DRUG|Intra-articular injection with lidocaine|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
214924426|NCT01337492|DRUG|Nexavar|400 mg of Sorafenib
214924427|NCT00049166|DRUG|erlotinib hydrochloride|Given orally
214924428|NCT00049166|DRUG|cisplatin|Given IV
214924429|NCT00049166|RADIATION|intensity-modulated radiation therapy|Undergo intensity modulated radiation therapy
214924430|NCT00049166|OTHER|laboratory biomarker analysis|Correlative studies
214924431|NCT06284057|PROCEDURE|Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte|Patient with CAD and coexisting bifurcation lesion requiring two-stent approach treated with Culotte Technique or Double Kiss (DK) Culotte due to operator distraction.
214924432|NCT01397396|PROCEDURE|Inspiratory Muscle Training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of \>50% Pi,max
214924433|NCT06294366|DEVICE|Bipolar Bowa device|Bipolar Bowa device used in prostatic resection and enucleation
214924434|NCT00537316|BIOLOGICAL|Infliximab (IFX)|IFX intravenous (IV) infusion dosed at 5mg/kg of body weight
214924435|NCT00537316|DRUG|Azathioprine (AZA)|AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
214924436|NCT00537316|DRUG|Placebo to Azathioprine|Placebo to AZA tablet orally every day
214924437|NCT00537316|DRUG|Placebo infusion|Placebo to IFX intravenous (IV) infusion
214924438|NCT01867710|DRUG|Abiraterone Acetate|Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
214924439|NCT01867710|DRUG|Prednisone 5 mg twice daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
214924440|NCT01867710|DRUG|Prednisone 5 mg once daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
215067426|NCT02982434|DRUG|0.9% normal saline|
215067427|NCT02982434|PROCEDURE|Coronary artery bypass grafting|
215067428|NCT00597623|OTHER|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
215067429|NCT00597623|OTHER|Placebo|syringes under cutaneous vol = 8 ml
215067430|NCT03497975|DRUG|Nalbuphine ER Tablets|Active Nalbuphine ER Tablets
215067431|NCT03497975|DRUG|Placebo Tablets|Placebo matching NAL ER with no active substance
215067432|NCT05495243|DRUG|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
215067433|NCT05495243|DRUG|Placebo|Isotonic saline (0.9%)
215067434|NCT01208883|OTHER|repetitive per-treatment [18F]FDG-PET for treatment adaptation|repetitive per-treatment \[18F\]FDG-PET for treatment adaptation
215067435|NCT06314373|DRUG|HSK39775 Monotherapy|HSK39775 will be administered orally once daily
215067436|NCT04961528|DRUG|Tranexamic Acid 500 MG|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days"
215067437|NCT04961528|DRUG|Terlipressin|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days"
215067438|NCT04961528|DRUG|Placebo|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days."
214486012|NCT03907982|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
214486013|NCT03907982|PROCEDURE|Pulmonary vein isolation|The cryoballoon (CE marked) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential freeze around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
214486014|NCT03907982|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at the end of the procedure clinic by the electrophysiologist performing the procedure. The device will provide a continuous recording of the heart rhythm and rate, and will be able to down load duration of AF episodes via a home monitoring system to establish the primary endpoint of the study.
214486015|NCT06997484|DRUG|HL-400|Part 1:Experimental: Single oral dose of HL-400, Single ascending doses, sequential assignment group design; Part 2: Experimental: Multiple oral doses of HL-400, Multiple ascending doses, QD for 14 days, sequential assignment group design; Part 3: Experimental: Multiple oral doses of HL-400, QD for 5 days.
214486016|NCT06997484|DRUG|Placebo|Part 1: Placebo comparator: Single oral dose of placebo, single doses, matching placebo; Part 2: Placebo comparator: Multiple oral doses of placebo, multiple ascending doses, QD for 14 days, matching placebo.
214486017|NCT05590663|OTHER|Physiotherapy|routine referral-based physiotherapy treatment for patients with knee osteoarthritis
214486018|NCT07002671|PROCEDURE|Appendectomy|Appendectomy (Laparoscopic or conventional open surgery)
214486019|NCT07002671|DIAGNOSTIC_TEST|blood sampling|Blood samples, in the preoperative period, routinely collected from the patients of acute appendicitis cases
214486020|NCT06865092|BIOLOGICAL|injectable platelet-rich fibrin|Blood samples were collected in two 10 ml plastic tubes without anticoagulant. The tubes were centrifuged for 3 min at 2500 rpm in a centrifuge device and i-prf was obtained.
214486021|NCT06865092|BIOLOGICAL|titanium-prepared platelet-rich fibrin|The blood was drawn into a 20 ml syringe and immediately divided into two sterile grade IV titanium tubes containing 10 ml of blood. The tubes were placed opposite each other and centrifuged at 2700 rpm for 12 minutes at room temperature and t-prf was obtained.
214924441|NCT01867710|DRUG|Prednisone 2.5 mg twice daily|type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
214924442|NCT01867710|DRUG|Dexamethasone 0.5 mg once daily|type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
214924443|NCT06160895|DRUG|TQ-A3334 tablets|TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
214924444|NCT06160895|DRUG|TQ-A3334 placebo tablets|TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
214924445|NCT05712213|PROCEDURE|Intraperitoneal onlay mesh reinforcement with defect closure before placement of mesh (pIPOM)|The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. The laparoscopic closure of the hernia defect was performed with non-reabsorbable detached stitches of prolene 1/0 suture at a distance of 1.5 cm from stich to stich using a Reverdin' needle. The final fixation of the mesh took place with a non-resorbable tacks.
215067439|NCT06157632|PROCEDURE|Thyriodectomy|Thyroidectomy
215067440|NCT04218214|OTHER|LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)|Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
215067441|NCT00397761|DRUG|capecitabine|
215067442|NCT00397761|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
215067443|NCT00397761|PROCEDURE|neoadjuvant therapy|
215067444|NCT01723293|BEHAVIORAL|Exercise group|"The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training."
215067445|NCT06267937|PROCEDURE|Access to surgery|access to surgery after hip fracture
215067446|NCT06267937|OTHER|type of intitution|public or private health care facility
215067447|NCT05200611|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Participants with positive fecal immunochemical test results were further examined by colonoscopy.
215067448|NCT00733161|OTHER|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
215067449|NCT00733161|OTHER|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
215067450|NCT03558269|BIOLOGICAL|Autlogous UCB infusion|Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
215067451|NCT02672059|OTHER|Observation|No intervention
215067452|NCT02253563|BEHAVIORAL|Resistance Training|
215067453|NCT02253563|BEHAVIORAL|Balance Training|
214324409|NCT06966063|PROCEDURE|4-7-8 breathing along with standard management.|"For 4-7-8 breathing, Patient is asked sit in comfortable position. Patient is asked place the tip of your tongue up against the back of your front teeth. Keep it there through the entire breathing process. Instruct the patient to breathe in silently through your nose to the count of four (4sec) and Hold your breath to the count of seven (7sec). Exhale through your mouth to the count of eight (8sec), making an audible whoosh sound. That completes one full breath. Repeat the cycle another three time, and gradually in increase the cycle four time.~Total 4 weeks protocol. Two sessions per week will be supervised by physiotherapist and 5 days at home. Week 01 and 02 Frequenc: 01 session/day Intensity: Start with comfortable duration. Time: 10 minutes Week 03 and 04 Frequecy: 02 sessions/day Intensity: 4 sec inhale, 7 sec hold and 8 sec exhale Time: 15 minutes"
214486022|NCT06865092|DRUG|Hyaluronic Acid (HA)|0.8% hyaluronic acid (HA) gel (Gengigel) was applied to the wound sites.
215067454|NCT04339933|DIAGNOSTIC_TEST|FGFR test|Detection of FGFR gene mutations in the tumor tissue and urine of patients
215067455|NCT04956276|DRUG|ALXN1830|Administered as an SC infusion.
215067456|NCT04956276|DRUG|Placebo|Administered as an SC infusion.
215067457|NCT01611688|DRUG|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
215067458|NCT01611688|DRUG|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
215067459|NCT01611688|DRUG|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
215067460|NCT01097317|DRUG|carboplatin|
215067461|NCT01097317|DRUG|vinorelbine tartrate|
215067462|NCT01097317|OTHER|neuromuscular electrical stimulation|
215067463|NCT01097317|OTHER|physiologic testing|
214486023|NCT06865092|OTHER|control group|Nothing has applied.
214486024|NCT05954091|DRUG|OH2 Injection|OH2 injection will be given intratumorally, and Q2W.
215067464|NCT01097317|PROCEDURE|fatigue assessment and management|
215067465|NCT01097317|PROCEDURE|quality-of-life assessment|
215067466|NCT00964041|DRUG|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
215067467|NCT00964041|DRUG|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
215067468|NCT01257230|DRUG|tiotropium Respimat low dose|IMP
215067469|NCT01257230|DRUG|placebo Respimat|placebo representing comparator
215067470|NCT01257230|DRUG|tiotropium Respimat high dose|IMP
215067471|NCT06187766|DIAGNOSTIC_TEST|Social Media Addiction|Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
215067472|NCT00378625|DRUG|Artesunate|
215067473|NCT02209545|DRUG|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
215067474|NCT02209545|DRUG|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
215067475|NCT01205061|DEVICE|Emervel Deep Lidocaine|20 mg/mL + 0.3% lidocaine
215067476|NCT01205061|DEVICE|Juvederm Ultra Plus|24mg/mL
215067477|NCT03401021|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
215067478|NCT00491855|DRUG|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
215067479|NCT00491855|DRUG|Oxaliplatin|Starting dose level 25 mg/m\^2 given intraperitoneally on day 2.
215067480|NCT00491855|DRUG|Paclitaxel|Starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.
215067481|NCT00369174|DRUG|rosiglitazone maleate|Given orally
214924446|NCT05712213|PROCEDURE|Standard intraperitoneal onlay mesh repair (sIPOM)|The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. In sIPOM, the defect was not closed. The final fixation of the mesh took place with a non-resorbable tacks.
215067482|NCT00369174|OTHER|laboratory biomarker analysis|Correlative studies
214924447|NCT01062113|DRUG|Celecoxib|"Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS"
215067483|NCT00765037|DEVICE|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
215067484|NCT01598883|DRUG|Heparin|150 U/kg
215067485|NCT01598883|DRUG|ATryn|1000 IU
215067486|NCT01320553|DRUG|SPARC1102 I|SPARC1102 I will be administered in both eyes
215067487|NCT01320553|DRUG|SPARC1102 II|SPARC1102 II will be administered in both eyes
215067488|NCT01320553|DRUG|SPARC1102 III|SPARC1102 III will be administered in both eyes
215067489|NCT01320553|DRUG|Vehicle|Vehicle will be administered in both eyes
215067490|NCT05507021|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
214486025|NCT06867653|OTHER|Retraining|Each retraining session begins with a 15-minute comprehensive review, followed by hands-on practice
214486026|NCT06875713|BEHAVIORAL|Parenting for Lifelong Health Program (DAYEM)|This intervention consists of the Parenting for Lifelong Health (PLH) program, delivered through eight in-person sessions, supplemented by a digital parenting program (ParentApp). The intervention aims to enhance positive parenting behaviors and reduce child maltreatment.
215067491|NCT05507021|DIETARY_SUPPLEMENT|Placebo|Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
215067492|NCT01693341|OTHER|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
214486027|NCT06875713|BEHAVIORAL|Adult nutrition|The control group will receive education on adult nutrition over the same period.
214486028|NCT06870032|OTHER|standard medical care|standard medical care
214924448|NCT01062113|DRUG|Celecoxib|Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
215067493|NCT01258465|BEHAVIORAL|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
215067494|NCT01258465|BEHAVIORAL|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
215067495|NCT01686425|PROCEDURE|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
215067496|NCT02309983|OTHER|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
215067497|NCT02309983|OTHER|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
215067498|NCT01293630|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
215067499|NCT01293630|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
215067500|NCT01293630|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
215067501|NCT03293849|OTHER|Patient Navigation|The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
215067502|NCT03894631|PROCEDURE|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
215067503|NCT03894631|PROCEDURE|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
215067504|NCT01988662|PROCEDURE|Neovascular Age-related Macular Degeneration|Blood measurement
215067505|NCT01997957|DRUG|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
215067506|NCT05280002|BIOLOGICAL|Adipose Tissue derived Total-Stromal-Cells (TOST)|Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
214486029|NCT06870032|OTHER|structured pulmonary rehabilitation|"structured pulmonary rehabilitation program including:~* Physical Therapy: Breathing exercises, airway clearance techniques, inspiratory muscle training.~* Pediatrics \& Chest Medicine: Medical supervision, optimization of pharmacological treatment.~* Physiology: Monitoring pulmonary function and physiological responses to exercise.~* Public Health: Evaluating program feasibility and its impact on healthcare utilization."
215067507|NCT03503591|DEVICE|Hummingbird Tympanostomy Tube System|Insertion of a ventilation tube under sedation and local anesthetic
215067508|NCT05611645|RADIATION|Hypofractionated Stereotactic Radiotherapy|Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
215067509|NCT05611645|DRUG|Bevacizumab|Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
215067510|NCT01880294|DRUG|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
215067511|NCT01891799|OTHER|Option B+|"* Using one low toxicity triple ARV regimen \[(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)\] for all women, rather than adapting regimens by CD4+~* Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~* Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women"
215067512|NCT03070171|DRUG|dabigatran etexilate|single dose
215067513|NCT02182661|DRUG|Ba253BINEB|
215067514|NCT03374683|BEHAVIORAL|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
215067515|NCT03374683|BEHAVIORAL|RR In-Person Workshop|Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
215067516|NCT03374683|BEHAVIORAL|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
215067517|NCT00703521|BIOLOGICAL|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
215067518|NCT03517514|OTHER|Physical Therapy service|routine physical therapy care
214672884|NCT00003530|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214672885|NCT03424551|DEVICE|vibrator|Local or whole body vibration was applied at six different frequencies
214672886|NCT00537823|DRUG|Cetuximab|
214672887|NCT00537823|DRUG|Bevacizumab|
214672888|NCT00537823|DRUG|Leucovorin|
214924449|NCT01062113|DRUG|Placebo|Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
214924450|NCT06598202|DRUG|exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop|Exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop (administered once daily, twice a week, for a total of two weeks, based on the recommended dose during the dose-escalation phase).
214924451|NCT06598202|DRUG|a placebo of exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop|Exosomes placebo
214924452|NCT02675621|OTHER|Phenolic Beverage|
214672889|NCT00537823|DRUG|Oxaliplatin|
214672890|NCT00537823|DRUG|Fluorouracil|
214672891|NCT00702312|BEHAVIORAL|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
214924453|NCT03999827|OTHER|Low Glycaemic Index Diet|Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
215067519|NCT02592720|DRUG|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
215067520|NCT02592720|DEVICE|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
215067521|NCT02592720|DEVICE|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
215067522|NCT03094091|OTHER|News items with spin|Interpretation of news items with spin
215067523|NCT03094091|OTHER|News items without spin|Interpretation of news items without spin
215067524|NCT01260090|DEVICE|Vagus nerve stimulation;|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
215067525|NCT01260090|DEVICE|No stimulation|Vagus nerve stimulation
215067526|NCT06265792|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
215067527|NCT06265792|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
215067528|NCT01788839|BEHAVIORAL|surveys|A survey including the Female Sexual Function Index (FSFI), the Modified Female Sexual Function Index (FSFI-M), the Modified Female Sexual Function Index Follow-Up (FSFI-M Follow-Up) the Sexual Activity Questionnaire (SAQ), the Female Sexual Distress Scale (FSDS-R), the Menopausal Symptom Check List (MSCL), Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF), Abbreviated Dyadic Adjustment Scale for Relationships (ADAS), Reproductive Health Survey-baseline (RHS-B). Reproductive Health Survey-followup and (RHS-F1)Reproductive Health Survey-followup (RHS-F2) will be conducted at the following intervals: baseline/before chemotherapy +/- 1 month, 3 months after baseline +/- 1 month, 6 months after baseline +/- 1 month, 1 year after baseline +/- 1 month, and at intervals during survivorship that include yearly for 5 years +/- 2 months.
215067529|NCT01788839|OTHER|Blood draw|Those patients receiving chemotherapy who consent to the optional blood draw will provide blood at baseline (before start of chemotherapy), 12 months after baseline (+/-1 month) and 24 months after baseline (+/-2 months). All patients in the subset of the premenopausal cohort receiving tamoxifen only will have required blood draws at baseline (before they begin taking tamoxifen), at 6 months post-baseline/start of tamoxifen (+/- 2 weeks), 12 months post-start of tamoxifen (+/-1 month) and 24 months post-start of tamoxifen (+/-2 months). We will ask these participants for blood draws on day 1, 2, 3 or 4 of their menses at baseline and 6 months post-baseline/start of tamoxifen and during months 1 through 5 post-baseline/start of tamoxifen.
214324410|NCT06966063|PROCEDURE|Control Group|"Patients will recieve medication as prescribed by pulmonologist through stepwise approach according to symptoms and severity.~Total 4 weeks protocol. Before and after 4 weeks pre and post interventional values will be taken.~Week 01 and 02 Patients will receive medications prescribed by pulmonologist. Week 03 and 04 Patients will receive medications prescribed by pulmonologist."
214324411|NCT04907032|DRUG|Mirabegron 50 MG|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
214324412|NCT04907032|DEVICE|Posterior Tibial Nerve Stimulation (PTNS)|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
214324413|NCT04182581|BIOLOGICAL|BCMA/CD19 Dual-Target CAR-T|BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.
214324414|NCT00876304|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
214324415|NCT00876304|DRUG|Placebo|Placebo capsules every 12 hours for 10 days
215067530|NCT01788839|DEVICE|Transvaginal ultrasounds|Transvaginal ultrasounds are used to determine the number of antral follicles in each ovary. They will be performed to evaluate both the number and size of antral follicles of premenopausal women on Tamoxifen as antral follicle count is a good predictor of ovarian reserve and response. All patients in the subset of the premenopausal cohort receiving tamoxifen only will also have required transvaginal ultrasounds at baseline (before they begin taking tamoxifen) and at 6 months post-start of tamoxifen (+/- 2 weeks).
214324416|NCT04677556|OTHER|Esogastric pressures measurement|"Catheter placement : at least 2 hours after and within 24 hours following the initial ventilation support establishment (CPAP or NiPPV according to usual practice and clinical conditions). 2 periods of measurements : with the initial and with the 2nd ventilation support using a cross-over for each patient. For each period, the first serie of measurements will be carried out without modifying the settings of the support ( clinical setting), and the second one using esogastric pressures by adjusting the settings of the ventilation support in order to obtain an optimal normalization or reduction of the amplitude of the Pes and Pdi deltas (physiological setting). 5 minutes of spontaneous breathing with/without oxygen between period 1 and 2 (depending on the patient's conditions). All measurements will be performed for 5 minutes after a 15 minutes quiet breathing. After measurements, the optimal respiratory support will be continued."
214486030|NCT06627426|OTHER|VR-based patient informed consent|"The intervention group will be the on receiving VR-based patient informed consent. One surgeon from the study team will be guiding the patient through their VR model first with demonstration of the technology and the model, afterwards the patient will be enabled to use the VR system by themselves. During the whole process the patient will be able to ask questions. Depending on the planned surgery, the surgical approach as well important anatomical structures will be explained."
214486031|NCT06875349|OTHER|foot reflexology|Foot reflexology is a complementary therapy that involves applying pressure to specific points on the feet, which are believed to correspond to different organs and systems in the body. This technique aims to promote healing by improving blood circulation, reducing stress, and supporting overall well-being. Reflexology is often used to help with issues such as constipation, stress, sleep disorders, and pain management.
214324417|NCT02895958|DRUG|Zepatier|Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
214324418|NCT06144736|PROCEDURE|Robot-assisted retroperitoneal lymph node dissection|"Robot-assisted, if possibe ipsilateral nerve-sparing, retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field (template)"
214324419|NCT06144736|DRUG|Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin|The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
214324420|NCT04692337|PROCEDURE|Intra-operative Ommaya Reservoir placement|An Ommaya reservoir is a small device implanted under the scalp that enables percutaneous access to cerebrospinal fluid.
214324421|NCT04954742|DRUG|Riociguat|Treatment will be initiated and individually adjusted according to systolic blood pressure and tolerability. During the titration phase, each patient will be asked to measure their peripheral systolic blood pressure and the heart rate at home three times per day and document the values in the patient diary. The results will be examined by the investigator during each visit/phone call-visit. Provided that the systolic blood pressure is ≥ 95 mmHg measured at trough before intake of each dose and the patient has no signs or symptoms of hypotension, the dose of study medication will be titrated by +0.5 mg tid every 2 weeks until maximal tolerated dosage (maximal permitted dose: of 2.5 mg tid). After the titration period, blood pressure should be measured upon signs or symptoms of hypotension. Maintenance dose: The established individual dose should be maintained unless signs and symptoms of hypotension occur.
214324422|NCT06017089|DEVICE|AI-based Advisor system|Tandem t:slim X2 with Control-IQ and t:connect mobile application and Dexcom G6 or G7 system, connected to UVA cloud-based Physician Dashboard with insulin pump parameters driven by an AI-based Advisor system.
214324423|NCT06477029|DEVICE|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
214324424|NCT06477029|DEVICE|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
214324425|NCT01565135|BEHAVIORAL|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~* Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~* Practice-based reminder/recall~* Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
214324426|NCT01254799|DRUG|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
214486032|NCT06875349|OTHER|abdominal massage|Abdominal massage is a therapeutic technique that involves applying gentle pressure and circular motions to the abdominal area to stimulate digestion, improve bowel movements, and relieve discomfort. It is commonly used to help with issues such as constipation, bloating, and digestive disorders by promoting intestinal motility and blood circulation. This technique can be performed manually or with the help of tools and is often incorporated into holistic and nursing care practices.
214486033|NCT06874608|DIETARY_SUPPLEMENT|complete, polymeric formula, fiber, lactose and gluten free|The dietary intervention attempts to induce remission in the first 4-week treatment without any change in the pharmaceutical therapy. In case of worsening or not reaching the outcomes, the patient will be defined as a failure and start rescue therapy with the standard of care.
214672892|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
214324427|NCT01254799|DRUG|Placebo|Placebo capsules twice daily for 5 days
214324428|NCT02153866|BIOLOGICAL|rotavirus vaccine|3ml/dose, oral
214324429|NCT02153866|BIOLOGICAL|measles-rubella vaccine|0.5ml per dose, subcutaneous injection
214486034|NCT06694766|PROCEDURE|Blood sample collection|A blood sample collection of 18.5 mL will be required for the immunogenicity component.
214924454|NCT02261948|DRUG|Levosimendan|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
214924455|NCT02261948|DRUG|Placebo|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
214924456|NCT01382472|DRUG|Rosuvastatin|40 mg per operative in PPCI, the 40 daily during hospital stay
214924457|NCT01382472|DRUG|Simvastatin|No statin acutely. Simvastatin 20 mg from day 2.
214924458|NCT01913535|DRUG|CERC-501|"Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
214924459|NCT01913535|DRUG|Placebo|"For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
214924460|NCT04723498|DIAGNOSTIC_TEST|screening questionnaire|Fill in screening questionnaire
214924461|NCT03149133|OTHER|Heavy hypertrophy training|Training with 75-80 % of 1-RM
214924462|NCT03149133|OTHER|Light hypertrophy training|Training with 35-50 % of 1-RM
214924463|NCT03408509|BEHAVIORAL|Computerized cognitive training|Posit Science Inc. will supply the software for the computerized cognitive training through the platform BrainHQ, which is available on line. The training program consists of a set of computerized exercises designed to improve the speed and accuracy of sensory information processing while engaging neuromodulatory systems involved in attention and reward. The rationale is that, in order to understand and remember information, the brain must first generate precise and reliable neurological responses that represent the sensory stimuli. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations. The goal is to increase the effectiveness with which these stimuli engage and drive plastic changes in brain systems. Engagement is monitored by electronic data upload following each training session.
214924464|NCT00166309|DRUG|FEIBA and NovoSeven|
214924465|NCT04121156|DEVICE|HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
214924466|NCT04121156|DEVICE|sham (placebo) HD-tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 5 consecutive twice daily sessions
214924467|NCT06684756|PROCEDURE|Retrograde intrarenal surgery|Flexible optic devices and lasers fragment kidney stones during this operation. In this surgery, an ureteral access sheath is recommended to be used.
214924468|NCT06664385|OTHER|concurrent physical exercise|It consists of a periodization which consists of three moments adapted to the patient's needs distributed in 6 weeks and increasing the intensity gradually.
214924469|NCT03406585|DRUG|ProTrans: Allogeneic transplantation with WJMSCs|The drug is a cell suspension with allogeneic mesenchymal stromal cells derived from umbilical cord tissue.
214924470|NCT03406585|DRUG|Placebos|Placebo treatment
214924471|NCT06166407|OTHER|no intervention|no intervention
214486035|NCT06687408|PROCEDURE|RATS Group|The participants with centrally located lung cancer in this group were performed sleeve lobectomy in robotic-assisted thoracic surgery (RATS) approach, which has been already applied to these patients in minimally invasive surgical techniques as part of their regular medical care recently.
214924472|NCT01864109|DRUG|Cyclophosphamide|
214924473|NCT01864109|DEVICE|Doxorubicin|
214924474|NCT01864109|DRUG|Vincristine|
214924475|NCT01864109|DRUG|Ifosfamide|
214924476|NCT01864109|DRUG|Etoposide|
214924477|NCT01864109|PROCEDURE|Surgery|
214924478|NCT01864109|RADIATION|Radiation Therapy*|If local control includes RT, RT should be given concurrently with chemotherapy cycles
214924479|NCT01864109|DRUG|Temozolomide|
214924480|NCT01864109|DRUG|Irinotecan|
214924481|NCT01864109|DRUG|Mesna|Mesna 2,100 mg/m2 (or 70 mg/kg if \< 10 yrs of age) administered intravenously in concordance with institutional pediatric administration guidelines.
214924482|NCT01864109|DRUG|Dexrazoxane|Dexrazoxane 375 mg/m2 intravenously over approximately 15-30 minutes and as clinically indicated. To be administered immediately prior to doxorubicin.
214324430|NCT02153866|BIOLOGICAL|measles-mumps-rubella vaccine|0.5ml per dose, subcutaneous injection
214324431|NCT05599178|OTHER|Ultrasound examination in early labor|Combined trans-abdominal and trans-perineal ultrasound examination
214324432|NCT04623333|DRUG|TQB2450|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
214324433|NCT01941446|DRUG|Eravacyline, Moxifloxacin, and placebo|
214324434|NCT03242681|PROCEDURE|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
214324435|NCT00712296|DRUG|ASHMI 4|4 capsules orally twice a day
214486036|NCT06687408|PROCEDURE|VATS group|The participants with centrally located lung cancer in this group were performed sleeve lobectomy in video-assisted thoracic surgery (VATS) approach.
214324436|NCT00712296|DRUG|ASHMI 12|12 capsules orally twice a day
214324437|NCT00712296|DRUG|Placebo|Placebo 6 capsules twice a day
214672893|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
214324438|NCT05605665|DRUG|low-dose interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.
215067531|NCT03737448|DRUG|Trimetazidine|Subjects with receive up to 60 mg daily
215067532|NCT01471028|BIOLOGICAL|ELAD treatment|ELAD treatment consists of treatment with an extracorporeal liver assist system.
214324439|NCT05605665|DRUG|rapamycin|Rapamycin 0.5ml was taken orally once per day
214324440|NCT03904706|OTHER|Audits only|Formalized audit teams with monthly meetings at each facility.
214324441|NCT03904706|OTHER|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
214324442|NCT02696356|BIOLOGICAL|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
215067533|NCT01471028|OTHER|Standard of care (Control)|Control receives standard medical treatment.
215067534|NCT02161094|BEHAVIORAL|Give incentives to physicians based on their patient's HbA1c improvement|
215067535|NCT02161094|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|
214324443|NCT05411796|DEVICE|Tampax menstrual cup|regular flow size
214672894|NCT00401583|DRUG|GW786034 (pazopanib)|Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
214672895|NCT00401583|DRUG|Probe drugs|probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).
215067536|NCT04821375|DRUG|bazedoxifene plus conjugated estrogens|6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
215067537|NCT01812213|DRUG|[18F]NAV4694|
215067538|NCT05947461|DRUG|100mg diclofenac|All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
214672896|NCT03163030|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
214672897|NCT02281058|DRUG|Abatacept|self-injected subcutaneous biologic medication
214672898|NCT06070129|PROCEDURE|surgical pulmonary embolectomy|open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus
215067539|NCT05947461|DRUG|100mg indomethacin|All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
214324444|NCT05411796|DEVICE|Other menstrual cup|size 1
214324445|NCT02084628|DRUG|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.
214324446|NCT06265402|PROCEDURE|Tab block versus retrolaminar block in abdominal plastic surgery|i inject 20ml bupivacine either 4mg dead in each side
214324447|NCT00494572|DRUG|Montelukast|10 mg rapid dissolving granule in sterile water orally once
214324448|NCT00494572|OTHER|sterile water|sterile water
215067540|NCT00610857|DRUG|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
214324449|NCT00204256|DRUG|Iron sucrose|
214324450|NCT04212468|OTHER|no intervention|no intervention
214924483|NCT01864109|DRUG|G-CSF|G-CSF-to be administered after the completion of appropriate chemotherapy cycles as per institutional guidelines.
214672899|NCT00542698|BEHAVIORAL|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
214924484|NCT02976753|DRUG|efmoroctocog alfa|extended half-life factor VIII product
214924485|NCT02976753|DRUG|Factor VIII|conventional factor VIII product
214924486|NCT03269721|BEHAVIORAL|Neuropsychological Assessment|Assessments include: Paper and pencil computerized measures of Memory, Language, Visuospatial Function, Executive Functioning-Processing Speed, and Attention
214672900|NCT03065530|DRUG|Normal Saline|Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
214672901|NCT03065530|DRUG|Dexmedetomidine 0.03ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
214924487|NCT03269721|PROCEDURE|Spirometry|Pre and post bronchodilator spirometry will be administered according to the American Thoracic Society (ATS) guidelines.
214324451|NCT04001569|DRUG|AZD8186 in combination with paclitaxel|"Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~* AZD8186 ( )mg po bid, 5 days on, 2 days off~* Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks"
214324452|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb.
214672902|NCT03065530|DRUG|Dexmedetomidine 0.05ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
215067541|NCT06477965|PROCEDURE|Artery Embolization|Embolic Solution are intended for use in occluding blood vessels for therapeutic or operative purposes. The embolic solution is used during an outpatient procedure, the physician will insert a small catheter onto the artery supplying the lining of the target joint or target localized pain. Tiny particles are then injected through the catheter into these arteries, reducing blood flow to the target area. This reduces the amount of inflammation associated with osteoarthritis, tendonitis, tenosynovitis or an injury, a process that can help decrease symptoms or eliminate the associated localized pain to this area. With understanding that it does not treat the underlying cartilage destruction or underlying condition causing pain but would like to determine the efficacy and validity of this treatment.
214324453|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass with fundus resection|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb. Fundus resection is further applied in this arm.
215067542|NCT04826094|BIOLOGICAL|Env-C Plasmid DNA|2 mg per dose. Administered by intramuscular injection.
214324454|NCT00170079|BEHAVIORAL|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
214324455|NCT03929835|DRUG|Cannabis oil|T1/C20 CBD
214324456|NCT03929835|DRUG|Placebo|Olive oil with chlorophyl
214324457|NCT05459870|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR T cells at 10\^6 cells/kg body weight via IV
214324458|NCT05495412|OTHER|Rebound therapy|Exercise therapy delivered twice weekly for 6 weeks, during Phase B of an ABA single case study design.
214324459|NCT01321801|DRUG|Pregabalin|Preoperative administration of pregabalin 600mg
214324460|NCT01321801|DRUG|placebo|Preoperative administration of a matching placebo
214672903|NCT03065530|DRUG|Dexmedetomidine 0.08ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
214672904|NCT05041543|DRUG|NTX-101|Eye drops, topical administration
214324461|NCT05122897|DEVICE|Rings made of PA (test)|Rings made of PA (test) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Test rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
214324462|NCT05122897|DEVICE|Rings made of TAN (control)|Rings made of TAN (control) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Control rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
214324463|NCT05687019|COMBINATION_PRODUCT|Intravesical instillations of Ialuril® Prefill|5 injections of Ialuril® Prefill on D0 or D1, D7, D14, D21 and D28 after Holmium laser surgery for prostate adenoma
214324464|NCT04388839|DRUG|Vincristine|IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg
214324465|NCT04388839|DRUG|Cyclophosphamide|IV over 60 minutes with dosing ranging from 220mg to 1200mg
214324466|NCT04388839|DRUG|Vinorelbine|IV push over 6-10 minutes with dosing ranging from 4mg-25mg
214324467|NCT04388839|DRUG|Actinomycin D|Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg
214324468|NCT04388839|DRUG|Cyclophosphamide Pill|Based on Body Surface Area (BSA) round to nearest 25mg
214324469|NCT04209946|PROCEDURE|Less Invasive Surfactant Administration LISA|Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.
214324470|NCT04209946|PROCEDURE|Continuous Positive Airway Pressure CPAP|Infant will remain on CPAP Therapy during spontaneous respirations
214324471|NCT04635241|DRUG|Unfractionated heparin|Inhaled nebulised 6 hourly
214324472|NCT06391879|GENETIC|Single cell sequencing, whole genome and metabolomic sequencing|The blood specimen of subjects in this cohort would be collected to conduct single cell sequencing, whole genome and metabolomic sequencing.
215067543|NCT04826094|BIOLOGICAL|HIV Env gp145 C.6980 protein|100 µg per dose. Administered by intramuscular injection.
215067544|NCT04826094|DRUG|Rehydragel®|Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
215067545|NCT04826094|BIOLOGICAL|ALF43|Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.
215067546|NCT04826094|BIOLOGICAL|dmLT|Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.
215067547|NCT04826094|DRUG|Placebo (IM)|0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
215067548|NCT04826094|DRUG|Placebo (TCl)|Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
215067549|NCT05604560|DRUG|Tislelizumab|Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
215067550|NCT05604560|DRUG|SX-682|Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
214324473|NCT03726177|DRUG|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
215067551|NCT04753970|DRUG|Cilostazol|Cilostazol 100mg BID
215067552|NCT06342024|OTHER|Pistachio group|Participants will be giving 1.5 ounces of pistachios to consume during the 6-month trial.
215067553|NCT06471491|OTHER|Driving pressure-guided positive end-expiratory pressure|Driving pressure-guided positive end-expiratory pressure during the surgical procedure
215067554|NCT06189963|BIOLOGICAL|SNK01|SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
215067555|NCT06189963|OTHER|Placebo|Sodium Lactate Hartmann's Solution
215067556|NCT05312697|BIOLOGICAL|Setrusumab|A fully human anti-sclerostin monoclonal antibody (mAb)
214324474|NCT03726177|DRUG|aspirin 81 mg|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
214324475|NCT03726177|DRUG|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
214324476|NCT05958212|BEHAVIORAL|Gait training program|"Gait training program at PolyU is a supervised rehabilitation program performed on the dual-belt treadmill. It consists of forward walking at increased speed over the affected leg and retro walking (backward walking) at individual's own pace (5 minutes/set for three sets, with rest periods in each session). This program also consists of a standardized set of warm-up and cool-down exercises at each training session.~Participants will also receive conventional physiotherapy treatment in the outpatient physiotherapy clinic."
214324477|NCT05958212|BEHAVIORAL|Conventional training only|Conventional physiotherapy treatment in the outpatient physiotherapy clinic.
214324478|NCT02741115|DRUG|Udenafil|Active drug
214324479|NCT02741115|DRUG|Placebo|Matching Placebo
214324480|NCT04912921|DIETARY_SUPPLEMENT|palmitoylethanolamide|4 tablets taken daily (2 in the am and 2 in the pm)
214324481|NCT04912921|DIETARY_SUPPLEMENT|Placebo|4 tablets taken daily (2 in am and 2 in pm)
215067557|NCT06482671|DRUG|Rikkunshi-to|Kampo medicine (Herbal). ikkunshito is composed of the following eight herbal medicines: extracts of Atractylodes lancea Rhizome, Ginseng, Pinellia tuber, Poria sclerotium, Jujube, Citrus unshiu Peel, Glycyrrhiza, and Ginger. Among these, the extracts of the Atractylodes lancea Rhizome, Ginseng, Poria sclerotium, Pinellia tuber, Citrus unshiu Peel, and Glycyrrhiza
215067558|NCT06482671|OTHER|Placebo|inactive drug, The matching placebo contains Corn Starch (vehicle), Lactose Hydrate (vehicle), Dextrin (vehicle), Magnesium Stearate (lubricant), FD\&C Blue No.1 Aluminum Lake (coloring agent), FD\&C Yellow No.5 Aluminum Lake (coloring agent), and Red Ferric Oxide (coloring agent).
215067559|NCT04869007|DEVICE|hysterosonography|Isthmocele mesured by hysterosonography before ART procedure
215067560|NCT05902910|DEVICE|LUNA-EMG Robot|During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.
214324482|NCT04912921|DIETARY_SUPPLEMENT|Curcumin|500 mg HydroCurc® twice a day
214324483|NCT04912921|DIETARY_SUPPLEMENT|Control (microcrystalline cellulose)|2 tablets taken daily
215067561|NCT05529264|OTHER|Memory Tasks|Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.
215067562|NCT05529264|OTHER|Attention/arousal tasks|Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.
215067563|NCT05529264|OTHER|Language tasks|Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.
215067564|NCT05529264|OTHER|Visuospatial tasks|Participants will be asked to copy 3 dimensional designs or make judgements of angle size.
214324484|NCT04106479|DEVICE|NIRS evaluation|NIRS will be used for measurement of cerebral and renal saturation.
214486037|NCT05386173|PROCEDURE|Fetal aortic balloon dilatation|Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.
215067565|NCT05529264|OTHER|Auditory Tasks|Participants will be presented with short, approximately 8-minute clips of music from various genres ( i.e. classical, country, rock, etc.) with an attention task (modified sustained attention to response task) nested within each trial. Participants will receive approximately 8 music stimuli and 1 control stimulus (pink noise) twice over the course of two testing sessions ( 90 mins each). Additionally, participants will be asked to answer questions about their hearing, music preferences/training, and certain demographic information (age, handedness, and language proficiency).
215067566|NCT05529264|PROCEDURE|Brain Stimulation|A brain stimulator will be used to understand new functions of the brain. Participants will be presented with pictures on a computer screen and may be asked to tell researchers what is seen or remembered by participants. As pictures are viewed by the participants, the brain stimulator may be activated, which would not be something that would be felt by an individual participant.
215067567|NCT05529264|OTHER|Social Emotional Task|Participants will be asked to view presented pictures and videos of people engaged in social interaction. Additionally, participants will be presented with the standardized tasks that are designed to help the researchers with understanding the nature of emotions. Some of these images may be emotionally disturbing. If participants are not comfortable viewing such images, they will be asked to refrain from participation in this study.
215067568|NCT05529264|OTHER|Recording of facial expressions|Some participants may be asked permission to record the video of their facial expressions during performance of a research task. Generally, this will include only research tasks investigating brain representation of social/emotional information. Automated analysis of facial expression may be used in certain experiments to provide information on experience of emotional states such as happiness and sadness related to the images being presented.
215067569|NCT05529264|OTHER|Judgement/Impulsivity Task|Certain study participants may be enrolled into research tasks designed to activate regions important for judgment and impulse control. These tasks will present participants with choices of varying monetary rewards and ask them to make judgements to measure one's tendency to prefer immediate over delayed rewards.
215067570|NCT06424743|OTHER|exercise|exercise programs with different volumes
215067571|NCT04445519|DRUG|NCX 470 0.065% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
215067572|NCT04445519|DRUG|Latanoprost 0.005% (initial phase of trial)|Latanoprost Ophthalmic Solution, 0.005%
215067573|NCT04445519|DRUG|NCX 470 0.1% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.1%
214324485|NCT06476587|OTHER|Assessment of postural stability and active motion perception|"This assessment, designed to evaluate the impact of the vestibular deficit on everyday tasks, will include questionnaires and standardised clinical tests.~The questionnaires are the Fall Efficacy Scale; the Dizziness Handicap Inventory; the Oscillopsia Severity Questionnaire; the Hospital Anxiety and Depression Scale; the Hamilton Anxiety Scale; the Global Physical Activity Questionnaire; the Motion Sickness Susceptibility Questionnaire part B; and the Cambridge Depersonalization Scale.~In addition, three standardised clinical tests will be carried out: Five Times Sit to Stand Test; Tandem walking test; and Fukuda step test (50 steps).~Five specific clinical tests will also be carried out: Sit-to-stand-with-walk-and-turn; Perception of active body rotation; Perception of walking distance; Triangle Completion Task; and Gait assessment."
214324486|NCT06476587|OTHER|Cognitive tests|Four cognitive tests from the French Focus Group on Executive Functions Assessment (GREFEX) battery will be carried out: the Stroop test; the Trail Making Test; the Baddeley's dual task; and a test of Corsi's Blocks.
214324487|NCT06476587|OTHER|Eccentric axis rotation|This test, also known as the unilateral centrifugation test, provides a quantitative assessment of unilateral utricular otolith function, whereas the tests currently used (vestibular evoked myogenic potential, VEMP) only provide a qualitative assessment.
214324488|NCT06476587|OTHER|Osteodensitometry|To assess the participants' bone mineral density, the reference technique of densitometry using two-photon absorptiometry will be used.
214324489|NCT06476587|OTHER|Posturography|Participants' ability to maintain their balance will be assessed using measurements taken on the Synapsys platform. To standardise their position, they will have to stand on the platform with their feet apart, arms at their sides and look straight ahead. Volunteers will be asked to sit down between each trial. The surface area and length of the centre of pressure will be measured under open-eye balance conditions with and without image reading/exploration and dynamics. During this test, 9 balance assessment situations lasting approximately 1 minute each will be performed.
214486038|NCT06873477|DIAGNOSTIC_TEST|Gross Motor Function Classification System|Clinical assessment of the outcome of patients with traumatic and hypoxic-ischemic brain injury at least 2 years post-event.
214486039|NCT06873737|OTHER|Blood samples for inflammatory markers|Blood sampling in the first, second, trimester of pregnancy
214486040|NCT05931393|DRUG|Cabozantinib 80 MG|cabozantinib 80mg daily
214672905|NCT05041543|DRUG|Placebo|Placebo as eye drops
215067574|NCT04445519|DRUG|NCX 470 0.1% (remainder of trial)|NCX 470 Ophthalmic Solution, 0.1%
215067575|NCT04445519|DRUG|Latanoprost 0.005% (remainder of trial)|Latanoprost Ophthalmic Solution, 0.005%
215067576|NCT05785286|OTHER|BPH 3-item questionnaire|BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).
215067577|NCT02456753|DEVICE|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
215067578|NCT02325570|DEVICE|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
215067579|NCT02325570|PROCEDURE|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
215067580|NCT05727007|DIAGNOSTIC_TEST|MRI in colon cancer|The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
215067581|NCT05727007|DIAGNOSTIC_TEST|CT in colon cancer|The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
215067582|NCT04772352|DRUG|febuxostat treatment|According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
215067583|NCT04772352|BEHAVIORAL|lifestyle intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
214672906|NCT02629705|DIETARY_SUPPLEMENT|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
214672907|NCT02629705|DIETARY_SUPPLEMENT|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
214672908|NCT06128837|DRUG|Irinotecan hydrochloride liposome Injection|Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk
214672909|NCT06128837|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3w
214672910|NCT02718677|DRUG|Refacto AF|Observational - Non-Interventional Study
214672911|NCT00852930|PROCEDURE|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
214924488|NCT03269721|PROCEDURE|Arterial Blood Gas|Radial artery blood sample will be collected to measure gas exchange hemoglobin; arterial oxygen and carbon dioxide will be examined as potential covariates.
214924489|NCT03269721|PROCEDURE|Diffusion Capacity of the Lung for Carbon Monoxide|For measurement of gas exchange in the lung. DLCO adjusted for hemoglobin will be the primary variable of interest and will be examined as a potential covariate.
214924490|NCT03269721|DIAGNOSTIC_TEST|6 Minute Walk Test|Distance walked in 6 minutes will be the primary outcome.
214924491|NCT03269721|PROCEDURE|Systemic Vascular Measures|Carotid artery ultrasound, pulse wave velocity, brachial artery endothelium-dependent flow mediated dilation and endothelium-independent dilation will be measured.
214924492|NCT03269721|BIOLOGICAL|Blood Biomarkers|High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.
214924493|NCT03269721|BEHAVIORAL|Symptom Questionnaire Measures|M.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire
214924494|NCT03269721|PROCEDURE|Brain MRI|Primary neuroimaging outcomes of interest are white matter structural integrity
214924495|NCT06666595|PROCEDURE|Titanium dental implant (Conical SPI, Vitronix, Italy), Medical device that interfaces with the jawbone to support a dental prosthesis.|Placement of titanium dental implant to retain and support Kennedy class 1 removable partial denture (RPD).The implant fuses with the bone through a process called osseointegration.
214924496|NCT02410434|OTHER|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
214924497|NCT05887258|DRUG|Opioid free anesthesia|It administers a combination of drugs to replace the opioid derivatives. Among them, we will use lidocaine, ketamine, dexmetomidine, and magnesium sulfate in continuous infusion adjusted to the patient's weight during surgery.
214924498|NCT05887258|DRUG|Opioid based Anesthesia|administer anesthesia based on opioids such as fentanyl and/or morphine to guarantee analgesia during the surgical intervention.
214924499|NCT05426486|DRUG|ARX788|HER2 antibody-drug conjugate
214924500|NCT05426486|DRUG|Pyrotinib maleate|EGFR/HER2 dual inhibitor
214924501|NCT05426486|DRUG|Trastuzumab|anti-Her2 monoclonal antibody
214924502|NCT05426486|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
214924503|NCT05426486|DRUG|Docetaxel|Cytotoxic chemotherapy
214924504|NCT05426486|DRUG|Carboplatin|Cytotoxic chemotherapy
214924505|NCT06398496|BEHAVIORAL|Aerobic Exercise|Aerobic exercise intervention will involve multiple exercise sessions completed (unsupervised) by participants. Exercise programs will be given to participants, matched to their current level of fitness as determined via a maximal cardiorespiratory fitness test, and will be adjusted via progressive overload every 1-2 weeks by an exercise and sports science professional.
214924506|NCT03341143|DRUG|Fecal Microbiota Transplant with Pembrolizumab|"FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by doing a colonoscopy. The FMT consists of introducing normal bacterial flora contained in stool collected from a donor into your small intestine. In this case, the donor is patient with advanced melanoma who has been treated with a PD-1 inhibitor (nivolumab or pembrolizumab) and has been rendered disease-free as a result. The FMT will be performed on Cycle 1 Day 1.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT, and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
214924507|NCT06233916|DRUG|[14C] D-1553|\[14C\] D-1553 (approximately 400 mg/80 μCi)
214924508|NCT01951612|BEHAVIORAL|Executive Function Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
214924509|NCT01951612|BEHAVIORAL|Psychoeducational Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
214924510|NCT04257123|DEVICE|Gelesis100|Participants will administer Gelesis100 before lunch and dinner meals.
214924511|NCT04257123|OTHER|Placebo|Participants will administer a placebo before lunch and dinner meals.
214924512|NCT00685724|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.
214924513|NCT00685724|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
214924514|NCT04116658|BIOLOGICAL|Multiple dose of EO2401|Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase
214924515|NCT03383835|DIETARY_SUPPLEMENT|Omega-3 Supplementation|"DHA 600 milligrams (mg) per day for 6 months~EPA 300mg per day for 6 months"
214924516|NCT05779033|BEHAVIORAL|scapular stabilization exercises|scapular stabilization exercises 3 times per week for 4 weeks.
215067584|NCT02340858|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
215067585|NCT04550520|DIAGNOSTIC_TEST|Glucagon|Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
214324490|NCT06476587|OTHER|Vestibulo-sympathetic regulation test|"Participants will be seated on a rotating chair in the dark. Using a virtual reality headset, three visual stimuli will be presented: (A) no visual stimulus (darkness), (B) visual stimulus corresponding to a displacement of the participant along a cylindrical trajectory, (C) visual stimulus corresponding to a displacement of the participant along a conical trajectory. These 3 types of visual stimuli will be presented alone or during an Off-Vertical Axis Rotation (OVAR) with the chair axis inclined at an angle of 10° to the vertical and a rotation speed of 60°/s.~During each sequence, blood pressure, heart rate and end-tidal carbon dioxide (CO2) will be continuously recorded using standard medical equipment."
215067586|NCT04550520|DIAGNOSTIC_TEST|Placebo|As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
214324491|NCT06476587|OTHER|Sleep quality assessment|"Participants will have to complete five standardised clinical questionnaires: Pittsburgh Sleep Quality Index; Spiegel questionnaire assessing sleep quality; Morningness-Eveningness questionnaire; Insomnia Severity Scale; and Epworth Sleepiness Scale.~Moreover, the activity/rest rhythm will be measured continuously by actimetry over a period of 11 days.~The volunteer will also have to wear a Somno-Art® bracelet all night long during the eleven days of monitoring to collect the volunteer's actimetry and heart rate in order to specify which sleep stage the volunteer is in and thus monitor changes in sleep stages over the course of the night.~Finally, participants will have to complete a sleep diary."
215067587|NCT04521946|DRUG|Etoposide|Given IV
215067588|NCT04521946|DRUG|Fludarabine Phosphate|Given IV
215067589|NCT04521946|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
215067590|NCT04521946|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
214324492|NCT06476587|OTHER|Representation of space and time assessment|"* Classic geometric illusions (inverted T, Mueller-Lyer, Ponzo, Poggendorff, Zoellner, Hering) which generate systematic distortions will be used.~* Time perception task: Participants will wear a virtual reality headset in which instructions will appear for 6 consecutive tasks each repeated 10 times with different durations.~* Perception of rotation amplitude and duration: Participants will be seated on a rotating chair, in complete darkness with noise-cancelling headphones. Participant will have to estimate the duration and the amplitude of rotations of the chair.~* Perceptual time constant: Participants will be seated on a rotating chair, in complete darkness, with a mask over their eyes and noise-cancelling headphones. After each chair rotation, participants will have to turn a crank every time the chair stops and reproduce their sensation of rotation in terms of direction (left or right) and intensity."
214324493|NCT06476587|OTHER|Influence of vestibular information on the bodily self-consciousness|"Participants will wear a virtual reality headset which allows them to be immersed in a virtual room similar in appearance to the one they are in. They will sit on a stool and hold a joystick in their hand. An avatar seen from behind, also sitting on a stool, will be presented in the centre of the virtual room approximately 2 m from them. The experimenter will touch several areas of the participant's back, over his clothes, with the end of the joystick. This movement will be reproduced by the virtual joystick in contact with the avatar's back, in two conditions: the synchronous condition, and the asynchronous condition.~After 2 min of stimulation, participants will perform a mental imagery task: a ball in the background of the virtual scene will roll towards them. After 3'', a black screen will appear and participants will have to imagine that the ball keeps moving towards them at the same speed. They will have to press the trigger when they think the ball has reached their level."
214324494|NCT06476587|OTHER|3 Tesla MRI|"The imaging evaluation will include an acquisition of anatomical images of the brain in its entirety and centred on the hippocampus.; and T2\*-weighted images sensitive to the blood-oxygen-level-dependent (BOLD) effect to assess functional brain activation during cognitive tasks and functional brain connectivity during rest.~For the functional activation sequences, three activation tasks will be performed, each lasting approximately 5 minutes: a mental rotation task, a time estimation task, and a prediction task.~These acquisitions will be combined with a collection of cardiorespiratory variables: respiratory movements and plethysmography. These signals will be used in the pre-processing of the functional MRI to remove physiological noise from the BOLD signal."
215067591|NCT04521946|DRUG|Melphalan|Given IV
214324495|NCT03723655|DRUG|mavacamten|mavacamten capsules
215067592|NCT04521946|DRUG|Mycophenolate Mofetil|Given PO or IV
215067593|NCT04521946|DRUG|Tacrolimus|Given IV
215067594|NCT04521946|DRUG|Thiotepa|Given IV
215067595|NCT00832598|RADIATION|[18F]FACBC PET and [18F]FLT PET imaging|\[18F\]FACBC PET and \[18F\]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
215067596|NCT04823728|GENETIC|Autoimmune encephalitis and paraneoplastic neurological syndromes|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
214324496|NCT03233594|OTHER|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
215067597|NCT05647837|DIAGNOSTIC_TEST|lumper puncture|lumper puncture
214324497|NCT03233594|OTHER|Healthy Control Group|Participants will not receive any interventions.
214324498|NCT06642818|OTHER|protocolized interview and prevention messages|This care consists of a consultation carried out by an environmental health expert (midwife, environmental health engineer) from the PREVENIR platforms. This consultation is carried out through a protocolized interview already developed which allows the identification of exposure to risk factors on reproduction. During the interview, prevention messages targeted at the exposures identified during the interview are delivered.
214324499|NCT06855160|BIOLOGICAL|Candidate varicella vaccine|Investigational varicella vaccine administered intramuscularly.
214324500|NCT06855160|BIOLOGICAL|Marketed varicella vaccine|Marketed varicella vaccine administered subcutaneously.
214324501|NCT06855160|BIOLOGICAL|MMR vaccine|MMR vaccine administered subcutaneously or intramuscularly.
215067598|NCT04757480|PROCEDURE|Thoracolumbar Interfascial Plane Block (TLIP)|(20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
215067599|NCT04757480|PROCEDURE|Bilateral Erector Spinae plane Block (ESB)|Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
215067600|NCT00586716|DRUG|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
215067601|NCT03544489|BEHAVIORAL|E-ICD Intervention|Home walking 3 days/week x 12 weeks
215067602|NCT00908323|BIOLOGICAL|JS7 DNA vaccine|
215067603|NCT00908323|BIOLOGICAL|MVA/HIV62 vaccine|
215067604|NCT02600416|OTHER|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
215067605|NCT04641728|DRUG|Pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
214324502|NCT06855160|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
214324503|NCT06855160|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
215067606|NCT04641728|DRUG|Olaparib|olaparib 300 mg twice daily (BID)
215067607|NCT02274480|DEVICE|cardiac MRI with DWI|
215067608|NCT06403982|OTHER|Continuation of oxytocin after ELA|"The use of oxytocin will be continued after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor.~Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery."
214324504|NCT06855160|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214324505|NCT06855160|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries Vaxneuvancewill only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
214324506|NCT04761185|DRUG|Raltitrexed|The RTX-HIPEC protocol used a modified Fibonacci dose escalation method with 7 dose levels (3, 4, 5, 6, 7, 8, 9 mg/m2)
214324507|NCT02598180|DEVICE|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
215067609|NCT06403982|OTHER|Discontinuation of oxytocin after ELA|The oxytocin pump will be changed to 0.9% sodium chloride solution pump after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor. If no progress is detected due to the secondary weakening of uterus contractile function, the oxytocin will be reintroduced. Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery.
215067610|NCT05659017|GENETIC|Genetic analysis|The DNA will then be analyzed with a custom panel designed ad hoc to study the candidate gene by Next Generation Sequencing according to the protocols of the supplier of the kit.
214324508|NCT03553875|DRUG|Memantine Hydrochloride|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
215067611|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat|A preparation of autologous microfat (5mL) will be injected intra-articularly.
215067612|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
215067613|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat and platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
215067614|NCT00711230|BIOLOGICAL|DermaVir|
214324509|NCT03553875|DRUG|Placebo|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
214672912|NCT00852930|PROCEDURE|laser alone|The intervention is therapist administered laser
215067615|NCT00711230|BIOLOGICAL|Placebo|glucose/dextrose
215067616|NCT01601756|DEVICE|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
215067617|NCT01601756|DEVICE|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
215067618|NCT02110654|DRUG|Montelukast|
215067619|NCT02110654|DRUG|mometasone furoate nasal spray|
215067620|NCT03466281|BEHAVIORAL|Structured patient group education|Patient education in a group setting
214324510|NCT06981234|DRUG|Acetazolamide|Acetazolamide is a potent carbonic anhydrase inhibitor that acts on the renal proximal tubule. Through this mechanism, it inhibits proximal tubule sodium reabsorption.
215067621|NCT03466281|BEHAVIORAL|Education via Internet|Patient education via the internet
215067622|NCT06319469|DRUG|silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
215067623|NCT06319469|DRUG|silodosin 8 mg capsule|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
215067624|NCT02241655|DEVICE|a pragmatic EEG-guided anesthetic protocol|
215067625|NCT05750056|DRUG|lidocaine|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
215067626|NCT05750056|DRUG|0.9% saline|Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
215067627|NCT05750056|DRUG|Propofol|An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
214324511|NCT06981234|DRUG|Placebo|Standard pharmaceutical filler will be capsulated and packaged identically to the acetazolamide.
214324512|NCT06807411|OTHER|Conventional exercise|Participants in the conventional exercise group will receive a total of 24 sessions of conventional therapy over 8 weeks (3 days per week, 30-minute sessions).
214324513|NCT06807411|OTHER|Video game based exercise|The video-based game exercise group will undergo the same conventional therapy, with an additional video game-based exercise program using the Becure Extremity ROM device under physiotherapist supervision. The program will include KinectPong, KinectBalloon, ArmRotate, and Uball games. Balance, joint position sense, ROM, functionality, and quality of life parameters will be assessed before and after treatment.
214924517|NCT05779033|DEVICE|ultrasound|Ultrasound 3 times per week for 4 weeks.continuous US operated at a frequency of 1 MHz and at an intensity of 1.5 W/cm2 for 5 minutes
214924518|NCT05779033|OTHER|Kinesio Tape|"Kinesiotape 3 times per week for 4 weeks. We will apply taping to two muscles (deltoideus and supraspinatus). A Y' tape was placed over the deltoid muscle using the muscle stimulation (KT strip arms were located by stretching slightly by 15%-25%) and mechanical correction techniques (KT strip arms were located with maximal stretching). Another Y tape was placed over the supraspinatus muscle using the muscle inhibition technique (the starting point of the tape was attached to the sub acromial-greater tubercle with submaximal (75%) stretching and without stretching on strip arms)."
215067628|NCT05750056|DRUG|Sufentanil|Sufentail 0.1 ug/kg was administered for sedation induction.
215067629|NCT01375816|DRUG|FOLFIRI 1-Bevacizumab|
215067630|NCT01375816|DRUG|fluorouracil|
215067631|NCT01375816|DRUG|irinotecan hydrochloride|
215067632|NCT01375816|DRUG|leucovorin calcium|
215067633|NCT01375816|DRUG|liposome-encapsulated irinotecan hydrochloride PEP02|
214324514|NCT04961034|PROCEDURE|kasai portoenterostomy|surgical creation of stoma between porta hepatis and jejunal loop
214324515|NCT03621137|OTHER|No study-specific intervention|Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
214324516|NCT05433389|BEHAVIORAL|Breath Counting|Patients will listen to a 5-minute, audio-recorded breath counting practice.
214324517|NCT05433389|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
214324518|NCT05433389|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
214324519|NCT05433389|BEHAVIORAL|Mindfulness of Pain|Patients will listen to a 5-minute, audio-recorded mindfulness of pain practice.
215067634|NCT01375816|DRUG|Bevacizumab|
215067635|NCT06308601|OTHER|Laughter yoga|Laughter is an innate, most natural, sincere and universal response to humorous stimuli. Philosophically, it is explained by relief theory, conflict theory and superiority theory (Öztürk \& Tezel, 2021). The emergence of laughter yoga was made by Dr., an Indian medical doctor, in 1995. It was created by combining breathing exercises and unconditional laughter with the work of Madan Kataria and his wife Madhuri Kataria. In laughter yoga, the individual can laugh in a simulated way with the interaction of group members, without a funny situation, joke or joke. The body cannot distinguish between real and unreal laughter, and fake laughter begins to turn into real laughter (Kataria, 2011).
215067636|NCT03030352|BEHAVIORAL|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
215067637|NCT00399217|DEVICE|Subcutaneous Implantable Defibrillator (S-ICD) system|
215067638|NCT00399217|DEVICE|ICD|
214324520|NCT05433389|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
214324521|NCT06864013|DRUG|Experimental|The experimental group will receive neoadjuvant short-course radiotherapy (dose 25Gy/5f), followed by CAPEOX+Iparomlimab and Tuvonralimab (capecitabine 1000mg/m2 bid po d1-d14, q3w; oxaliplatin 130mg/m2 iv d1, q3w; Iparomlimab and Tuvonralimab 5mg/kg iv d1, q3w) for 4 cycles. Patients who undergo surgery will receive CAPEOX combined with Iparomlimab and Tuvonralimab for 4 cycles, followed by sequential treatment with Iparomlimab and Tuvonralimab for up to 1 year.
214324522|NCT06864013|DRUG|Control|The control group will receive neoadjuvant short-course radiotherapy,followed by CAPEOX (capecitabine 1000mg/m2 bid po d1-d14, q3w; oxaliplatin 130mg/m2 iv d1, q3w) for 4 cycles. Patients who undergo sugery will receive CAPEOX for 4 cycles.
215067639|NCT06310941|DEVICE|Mechanical insufflation-exsufflation|Combined use of mechanical insufflation-exsufflation with nebulized hypertonic saline in intubated patients with nosocomial respiratory tract infection
214672913|NCT00852930|PROCEDURE|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
214924519|NCT00217893|BEHAVIORAL|Counseling|One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.
214924520|NCT00217893|BEHAVIORAL|Urine Cotinine Feedback|Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.
214924521|NCT00217893|BEHAVIORAL|Contingent Incentives|Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).
215067640|NCT06310941|OTHER|Standard of Care|systemic antibiotic therapy and catheter suctioning of secretions as recommended by guidelines
214324523|NCT02863835|OTHER|EIT|All participants will have continuous monitoring of EIT whilst self venting
214324524|NCT02863835|OTHER|Salbutamol nebulisation and with CPAP|All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
215067641|NCT06310941|OTHER|Hypertonic saline with hyaluronic acid|Commercially available combination of 7% hypertonic saline with 0.1% hyaluronic acid given as nebulization during the MI-E session
215067642|NCT03511014|DEVICE|Microcurrent|Micrucurrent will be apply
214924522|NCT00217893|BEHAVIORAL|Usual education program|Participants will receive the usual education about ETS.
214924523|NCT00899171|GENETIC|DNA analysis|
214924524|NCT00899171|GENETIC|DNA methylation analysis|
214924525|NCT00899171|GENETIC|RNA analysis|
214924526|NCT00899171|GENETIC|gene expression analysis|
215067643|NCT00177294|DRUG|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
215067644|NCT00177294|BEHAVIORAL|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
215067645|NCT00177294|BEHAVIORAL|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
215067646|NCT04607434|DRUG|Ocotillol Type Ginsenoside Derivatives|Peripheral blood PMN of patients with ARDS were taken. The neutrophils isolated from peripheral blood of ARDS patients were incubated with different doses of OCT glycine derivatives (20,50,100 UM) for 20 h
215067647|NCT03309033|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214924527|NCT00899171|GENETIC|reverse transcriptase-polymerase chain reaction|
214924528|NCT00899171|OTHER|laboratory biomarker analysis|
215067648|NCT03309033|OTHER|Questionnaire Administration|Complete questionnaire
215067649|NCT04827147|DEVICE|Multi-Periscopic Prism (MPP) glasses|Spectacles with multi-periscopic prisms mounted as oblique peripheral prism segments
214324525|NCT03331692|OTHER|monitoring of the proper level of general anesthesia|The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
214324526|NCT06670625|BEHAVIORAL|IDAC+|Diet and physical activity counselling at baseline, 6, 12 and 24 months visit.
214486041|NCT05424718|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk young men that have sex with men (YMSM).
214672914|NCT01979744|PROCEDURE|IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
215067650|NCT04827147|DEVICE|Fresnel Peripheral Prism (FPP) glasses|Spectacles with conventional permanent Fresnel prisms mounted as oblique peripheral prism segments
215067651|NCT04154605|DEVICE|ClariFix cryotherapy|Bilateral freeze ablation of nasal tissue using the ClariFix device.
215067652|NCT04154605|DEVICE|Sham ClariFix cryotherapy|Bilateral sham ablation procedure using the ClariFix device.
215067653|NCT01830283|BIOLOGICAL|varicella vaccine|The providers would get varicella vaccine
215067654|NCT03972462|DRUG|NPC-12G Gel 0.2%|Period 1
215067655|NCT03972462|DRUG|Rapamune® 2 mg tablet|Period 2
215067656|NCT03400865|DRUG|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
215067657|NCT04380194|DIAGNOSTIC_TEST|nano-composite screening|Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
215067658|NCT04569864|PROCEDURE|Hypothermic circulatory arrest with unilateral selective anterograde cerebral perfusion|Hypothermic circulatory arrest provides protection to cerebral and visceral organs.
214324527|NCT07003620|DRUG|Neoadjuvant immunochemotherapy|All patients will receive three cycles of paclitaxel and carboplatin chemotherapy combined with PD-1/PD-L1 inhibitor therapy, followed by open radical hysterectomy and pelvic lymphadenectomy. Postoperative adjuvant therapy (chemotherapy, chemoradiation, or maintenance immunotherapy) will be determined based on pathological assessment. Tumor tissue samples will be collected during treatment for single-cell sequencing analysis.
215067659|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
215067660|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
215067661|NCT06387927|OTHER|home exercise program|Patients in group B were taught the core stability exercise in the first visit they received Arabic printed booklet for exercise description repetitions with diagrams in addition to Arabic illustration videos, they received a weekly telephone call to ensure their compliance to the exercise \& motivation.
215067662|NCT06387927|OTHER|the core stability exercise|supervised conventional core stability exercise
215067663|NCT04486430|DRUG|Neu2000KWL|1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
215067664|NCT04486430|DRUG|Neu2000KWL|1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
215067665|NCT04486430|DRUG|Neu2000KWL|1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
215067666|NCT04486430|DRUG|Placebos|1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
215067667|NCT05352412|BEHAVIORAL|Shared Decision Making Aid - Patients|Patients will be randomized to the shared decision making aid intervention.
215067668|NCT05352412|BEHAVIORAL|Shared Decision Making Aid - Providers|Providers of patients randomized o the shared decision making aid intervention.
215067669|NCT06730867|BEHAVIORAL|EMDR Therapy Protocol|The intervention involves an eight-week program that details a specific EMDR protocol and questionnaire for people living with HIV. The EMDR sessions occur once a week for eight weeks under the supervision of the investigator.
215067670|NCT06359028|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2
215067671|NCT06359028|DRUG|Crest cavity protection toothpaste|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
215067672|NCT06235632|BEHAVIORAL|Policy and Training Intervention|The intervention is a combination of a policy training and access to an in-depth training program to teach marijuana vendors the skills needed to refuse intoxicated customers
215067673|NCT06235632|BEHAVIORAL|Usual and Customary Policy and Training (UC-PT) (Control) Condition|The active control training that is already provided to marijuana vendors by the Oregon Liquor and Cannabis Commission
215067674|NCT06384313|DIETARY_SUPPLEMENT|butyrate/hexanoate-enriched triglycerides|The oils are consumed two times a day for 24 weeks (six months).
215067675|NCT00002552|BIOLOGICAL|filgrastim|
215067676|NCT00002552|BIOLOGICAL|sargramostim|
215067677|NCT00002552|DRUG|carmustine|
215067678|NCT00002552|DRUG|cyclophosphamide|
215067679|NCT00002552|DRUG|cytarabine|
215067680|NCT00002552|DRUG|etoposide|
215067681|NCT00002552|DRUG|leucovorin calcium|
215067682|NCT00002552|DRUG|methotrexate|
215067683|NCT00002552|DRUG|perfosfamide|
215067684|NCT00002552|DRUG|therapeutic hydrocortisone|
215067685|NCT00002552|PROCEDURE|allogeneic bone marrow transplantation|
215067686|NCT00002552|PROCEDURE|autologous bone marrow transplantation|
215067687|NCT00002552|PROCEDURE|in vitro-treated bone marrow transplantation|
214672915|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
215067688|NCT00002552|PROCEDURE|peripheral blood stem cell transplantation|
215067689|NCT00002552|PROCEDURE|syngeneic bone marrow transplantation|
215067690|NCT00002552|RADIATION|radiation therapy|
215067691|NCT05976646|DRUG|Placebo|Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
215067692|NCT05976646|DRUG|Auvelity|Orally-administered combination of 45 mg dextromethorphan with 105 mg Bupropion (trade name Auvelity). Auvelity will initially be administered orally once daily for three days. After 3 days on once daily AUVELITY, the participants will begin taking AUVELITY twice daily for 4 additional days as recommended in the FDA-approved prescribing information.
215067693|NCT04787549|DEVICE|Virtual reality exergames|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
215067694|NCT03236909|DEVICE|MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System|Subjects will be implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System with +FLEX28 or +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO (single-unit) external audio processors.
215067695|NCT06660940|DRUG|Keluoxin Capsules|Treatment period (52 weeks):Keluoxin Capsules, 4 capsules/time, swallow with warm water after meals, 3 times/day
215067696|NCT06660940|DRUG|Keluoxin Capsule Simulants|Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day
215067697|NCT06660940|DRUG|Irbesartan|"1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD"
215067698|NCT06661005|DRUG|Nitrous oxide|The Nitrous oxide group will receive instructions to arrive at clinic 30 minutes before her procedure in order to sign consent forms. She will not be given instructions to remain NPO and will not be required to have someone bring her to and from the appointment. No IV will be placed. Anesthesia induction will be done by an anesthesiologist with a nitrous oxygen mixture at a 70:30 ratio
215067699|NCT06661005|DRUG|IV Sedation|Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol. A pulse oximeter will be placed and oxygen will be administered through a nasal cannula and the patient will be instructed to breath.
215067700|NCT04580836|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215067701|NCT04580836|OTHER|Questionnaire Administration|Ancillary studies
215067702|NCT04580836|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215067703|NCT06611163|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter
215067704|NCT06611163|DRUG|Placebo|Placebo SC injection at Day 1 and Week 4
215067705|NCT07003893|OTHER|Diaphragmatic Proprioceptive Neuromuscular Facilitation + Aerobic exercises|Control group will perform aerobic exercises only Experimental group will perform diaphragmatic proprioceptive neuromuscular facilitation in addition to aerobic exercises
215067706|NCT06877299|DRUG|Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)|Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)
215067707|NCT07034560|DRUG|Tranexamic Acid (TXA)|500 mg oral tranexamic acid (Transamin®), taken once daily at bedtime for 12 weeks.
215067708|NCT07034560|DRUG|melatonin (Circadin)|2 mg oral melatonin (Circadin®), taken once daily at bedtime for 12 weeks.
215067709|NCT07034560|DRUG|Placebo|Placebo capsule identical in appearance, taken once daily at bedtime for 12 weeks.
215067710|NCT07034937|OTHER|Combination of aerobic training (treadmill walking) and resistance training|Combination of aerobic training (treadmill walking) and resistance training using resistance bands for deltoid, biceps, triceps, and quadriceps muscles. Conducted twice weekly for 6 weeks (12 sessions). Tools include treadmill and theraband loop bands.
214924529|NCT03655093|OTHER|Validation of AMSQ questionnaire|"Participation in the study will be proposed to any patient meeting the inclusion criteria and consulting a neurologist from the SEP reference center of the University Hospital of Rennes.~The neurologist will explain the purpose of the study to the patient, give him the information form.~Without opposition from the patient, the neurologist will give him the self-questionnaire. The patient will fill it during the consultation. In case of disability to the upper limbs making it impossible to fill the questionnaire by the patient, it will be filled by the neurologist or the patient's companion, according to the answers given by the patient.~While the patient completes the questionnaire, a record of clinical information will be filled in by the neurologist.~No additional act will be performed except the questionnaire, which result will not change the patient's management."
214924530|NCT01914471|BEHAVIORAL|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
214924531|NCT05529615|PROCEDURE|detection of ctDNA|the ctDNA will be detected during the treatment and served as the andomization basis
214924532|NCT01316211|DEVICE|Implantation of coflex™ after surgical decompression|The device will be implanted after surgical decompression in patients with spinal stenosis.
214924533|NCT01316211|PROCEDURE|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant
215067711|NCT07034235|PROCEDURE|Dentin Wet|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on wet dentin in the etch-and-rinse application strategy.
215067712|NCT07034235|PROCEDURE|Dentin Overwet|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on overwet dentin in the etch-and-rinse application strategy.
215067713|NCT07034235|DEVICE|Ambar Universal APS Plus; FGM|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive
215067714|NCT07034235|DEVICE|Prime&Bond Active; Dentsply Sirona|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive
215067715|NCT07033910|DEVICE|sepsis adsorption column|after the initiation of fluid and antibiotic therapy according to the Surviving Sepsis Campaign 2021 Guidelines, an additional routine sepsis adsorption column (Biosky® MG350) was used within 48-72 hours.
215067716|NCT07034846|OTHER|High-intensity intermittent IMT and Otago Exercises Group|Patients in the experimental group will perform 7 sets of high-intensity intermittent inspiratory muscle training (IMT) for eight weeks, one day a week face-to-face with the researcher and two days at home, for a total of three days, each set consisting of 2 minutes of loading and 1 minute of rest for a total of 21 minutes. The Otago exercise program will be conducted for eight weeks, two days a week home-based and one day face-to-face with the researcher. The Otago exercise program will be complemented with walking exercise every day of the week. The Otago exercise program is designed to be progressive. The protocol was created to increase the difficulty of training at four different levels and every 2 weeks. The Otago exercise program will be applied to both the experimental group and the control group in the same protocol.
215067717|NCT07034846|OTHER|Sham IMT and Otago Exercises Group|Patients in the control group will perform 7 sets of sham inspiratory muscle training (IMT), consisting of 2 minutes of loading and 1 minute of rest in each set for a total of 21 minutes, one day a week face-to-face with the researcher and two days at home, for eight weeks. The Otago exercise program will be conducted for eight weeks, two days a week home-based and one day face-to-face with the researcher. The Otago exercise program will be complemented with walking exercise every day of the week. The Otago exercise program is designed to be progressive. The protocol was created to increase the difficulty of training at four different levels and every 2 weeks. The Otago exercise program will be applied to both the experimental group and the control group in the same protocol.
215067718|NCT07034287|OTHER|Telehealth physical therapy and pharmacy consultation|Telehealth physical therapy and pharmacy consultation at baseline emergency department visit.
215067719|NCT07033143|DRUG|Adebrelimab+SOX|"Adebrelimab: 1200mg, intravenous drip, day 1, 21 days as one cycle, treatment duration is 1 year.~SOX: Eight cycles after the operation, intravenous infusion of oxaliplatin at 130 mg/m2. On the first day, oral administration of S-1 at 40-60 mg twice a day. From the first to the 14th day, 21 days constitute one cycle.~Enhanced CT examinations of the chest, abdomen and pelvis were conducted every 9-12 weeks in the first year of treatment. Then have a check-up every 24 weeks."
215067720|NCT07052669|RADIATION|Hypofractionated Radiation Therapy|All patients will receive split-course hypofractionated radiotherapy. First course of radiotherapy: Total dose of 4000 cGy in 10 daily fractions (400 cGy per fraction) or 3000 cGy in 6 daily fractions (500 cGy per fraction). Three weeks after the completion of the first course of hypofractionated radiotherapy, tumor response and toxicity will be evaluated. For patients who achieve a partial response and without grade 2 or higher respiratory toxicity, a second course of radiotherapy will be planned for the residue disease at a total dose of 2000 \~2400 cGy in 5\~6 fractions (400 cGy per fraction). The interval between the two courses of radiotherapy will be 28 days.
215067721|NCT07052669|RADIATION|Conventionally Fractionated Radiation Therapy|Patients in this group will receive a total dose of 6000- 6400 cGy in 30- 32 fractions, with 200 cGy per fraction.
215067722|NCT07052669|DRUG|Concurrent Chemotherapy|Paclitaxel plus platinum-based chemotherapy.
215067723|NCT07052669|DRUG|concurrent chemotherapy|Paclitaxel plus platinum-based chemotherapy or pemetrexed plus platinum-based chemotherapy.
215067724|NCT07052669|DRUG|Consolidative immunotherapy|Following the completion of chemoradiotherapy, PD-1/PD-L1 immune checkpoint inhibitor consolidation therapy will be administered for up to 12 months.
215067725|NCT07066306|DRUG|Ketamine|In the ketamine group, 0.2 mg/kg of ketamine will be administered locally. This application will be performed twice: once during the Le Fort I osteotomy and once during the sagittal split osteotomy. After calculating the total dose, it will be equally divided and administered locally to both the maxilla and the mandible.
215067726|NCT07066306|DRUG|Articaine Hydrochloride + Epinephrine|A total of 4 ampoules of articaine hydrochloride will be used. Two ampoules will be administered prior to the incision during the Le Fort I osteotomy, and the remaining two ampoules will be used prior to the incision during the sagittal split osteotomy.
215067729|NCT06817707|OTHER|Evaluation of urinary dysfunction in patients with CANVAS|Urinary dysfunction will be evaluated with neurologic exam, interrogation, urinary dairy report, self-questionnaires, biologic analysis, Sudoscan and urological exams
214324528|NCT06924034|OTHER|Phase I and Phase II Cardiac Rehabilitation Program|The program consisted of two stages: an inpatient phase lasting until discharge, followed by an outpatient-supervised Phase II lasting eight weeks. In the intervention group, the participants in the inpatient phase received active-participatory lower extremity movements and progressive walking training (i.e., progressive walking in the room-corridor-hospital) to prepare them for discharge. The inpatient phase I was conducted with supervision following the American Heart Association recommendations. Participants in the intervention group were then administered phase II of the supervised CR program. Phase II CR was performed 3 non-consecutive days a week for 8 weeks as an aerobic exercise program.
214924534|NCT04024111|BEHAVIORAL|KONTAKT(c)|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes facilitated by two health professionals with experience of running groups for autistic children
215067730|NCT06222827|DRUG|Satralizumab Prefilled Syringe|Satralizumab is supplied as prefilled syringe with 1 millimeter of solution for subcutaneous injection corresponding to 120mg of satralizumab. During the first period (double blind period), satralizumab will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
215067731|NCT06222827|DRUG|Placebo Comparator|Placebo prefilled syringe is identical in composition to satralizumab, but does not contain the satralizumab active agent. It is identical in appearance and packaging to satralizumab. During the first period (double blind period), placebo will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
214924535|NCT04024111|OTHER|Art group|Art program, a manualized Art group delivered in a social format, has been designed for children on the Autism Spectrum delivered by health professionals with experience of running social groups for Autistic children. The Art program's participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes.
214924536|NCT05017311|DRUG|Escitalopram|All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).
214924537|NCT05017311|DRUG|Brexpiprazole|Depending on the initial randomization process, patients will either receive blinded brexpiprazole (0.5-2 mg/d) for the entire study duration (12 weeks) or for the last 4 weeks of the study if they received the placebo during the first 8 weeks of the study and were non-responders.
214924538|NCT01082211|RADIATION|3D-Conformal External Beam|Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
214924539|NCT06684145|OTHER|Kinesiotape application|Kinesiotape application will be performed by a certified researcher using 5cm x 5cm kinesiotape material. The standing patient, prepared in terms of clothing and skin, will be asked to lean forward. While adhering the tape to the right paravertebral region, the lower end of the tape will be adhered 7 cm below the sacroiliac joint at the level of the paravertebral muscles. The patient, still leaning forward, will be then asked to make a slight rotation to the left; in this position, the tape will be adhered upwards on the paravertebral muscles without any tension. For the left paravertebral region, the procedure will be reversed as compared to the right, ensuring that the tape was not stretched at all.
214924540|NCT06684145|OTHER|Exercise|Patients will be given a 30-day home exercise program. This consists of passive lumbar flexion (single and double leg stretching), hamstring stretching, pelvic tilt, half sit-up, bridge, straight leg raises, and hip and back extensor strengthening exercises.
214924541|NCT00653770|BIOLOGICAL|FP85A|Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10\^7 pfu)
214924542|NCT00653770|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10\^7 pfu)
214924543|NCT01065870|DRUG|Neoadjuvant gemcitabine, capecitabine, and docetaxel|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment."
214924544|NCT01065870|DRUG|Gemcitabine, capecitabine, docetaxel followed by radiotherapy|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.~Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.~Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm."
215067732|NCT06927947|OTHER|Communication Intervention|Use relative invitation tool
215067733|NCT06927947|OTHER|Health Promotion and Education|Receive access to the VGN
215067734|NCT06927947|OTHER|Informational Intervention|Receive access to a Genetic Testing Family Letter
215067735|NCT06927947|OTHER|Survey Administration|Ancillary studies
215067736|NCT00661726|DRUG|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
215067737|NCT01248572|DEVICE|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
215067738|NCT07081867|PROCEDURE|Supra-inguinal Fascia Iliaca Block (SIFIB)|Ultrasound-guided injection of 40 mL of 0.25% bupivacaine between the iliacus muscle and fascia iliaca via a supra-inguinal approach, performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
215067739|NCT07081867|PROCEDURE|Sacral Erector Spinae Plane Block (SESPB)|Ultrasound-guided injection of 40 mL of 0.25% bupivacaine into the fascial plane deep to the erector spinae muscle at the sacral level (S2), performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
215067740|NCT04362800|OTHER|MRI|MRI at baseline and J90
214924545|NCT06682195|DRUG|Neoadjuvant chemotherapy combined with Toripalimab|"1, Neoadjuvant Chemotherapy Phase Combined with Toripalimab~1. First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab. Administered intravenously: 100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2. Second Phase of Neoadjuvant Chemotherapy: Albumin-bound Paclitaxel + Toripalimab. Administered intravenously: 260 mg/m² Albumin-bound Paclitaxel + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2, Receive Breast Cancer Radical Surgery After 4 Cycles of Neoadjuvant Chemotherapy 3, Postoperative Adjuvant Therapy~1. If pathology indicates pCR: Continue immunotherapy, administering 240 mg Toripalimab intravenously every 3 weeks for a total of 1 year.~2. If pathology indicates non-PCR: Continue postoperative adjuvant chemotherapy combined with Toripalimab.~4, Perform Gene Testing on Biopsy Tissue Before Treatment, and Collect Blood Samples for ctDNA Testing Before and After Treatment."
215067741|NCT04362800|OTHER|Electro-Encephalography-High Density|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
215067742|NCT04362800|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
215067743|NCT04362800|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
215067744|NCT00322413|DRUG|Epoetin|
214924546|NCT06665412|DRUG|Radotinib Hydrochloride|200mg BID, every day up to 12months
214924547|NCT03834766|DRUG|AMPH ER Tab 5, 10, 15 and 20 mg|Amphetamine
214924548|NCT03834766|DRUG|AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg|Placebo
214924549|NCT03702010|DEVICE|spinal cord stimulation conventional|If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.
214924550|NCT03702010|DEVICE|spinal cord stimulation experimental|If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.
214924551|NCT05713396|DRUG|Quinapril|Per os
214924552|NCT05713396|DRUG|Losartan|Per os
214924553|NCT05713396|DRUG|Quinapril + Losartan|Per os
214924554|NCT00059696|PROCEDURE|Constraint-Induced Movement Therapy|
214924555|NCT06355258|DRUG|Troxerutin|Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
214924556|NCT06355258|DRUG|Placebo|Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
214924557|NCT06355258|DRUG|placebo + low molecular weight heparin|2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
214924558|NCT06355258|DRUG|troxerutin + low molecular weight heparin|2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
214924559|NCT00003416|BIOLOGICAL|filgrastim|
214924560|NCT00003416|BIOLOGICAL|recombinant interferon alfa|
214924561|NCT00003416|DRUG|dexamethasone|
214924562|NCT00003416|DRUG|melphalan|
214924563|NCT00003416|PROCEDURE|peripheral blood stem cell transplantation|
215067745|NCT07079293|OTHER|Preparation of Extended PRF|Whole blood (10 mL) will be centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet- poor plasma (PPP) will be collected in a syringe. then PPP will be heated in a heat block device at 75°C for 10 minutes and thereafter cooled to room temperature for approximately 2 minutes. An injectable albumin gel will then be prepared. Then the liquid platelet-rich layer (liquid-PRF) including the buffy coat layer with accumulated platelets and leukocytes, will be collected in a separate syringe. The albumin gel and native liquid PRF will then be thoroughly mixed by utilizing a female-female luer lock connector. Now injectable e-PRF in final form is ready to be used .
215067746|NCT07079293|PROCEDURE|Harvesting of Free Gingival Graft and preparation of CTG|The region distal from the canines, commencing at least 2 mm from the gingival margin with a width of 5-8 mm and a desirable length to cover the entire recipient site is an ideal site for harvesting a FGG from the hard palate for root coverage. Harvesting of FGG is performed as follows: The graft is prepared by outlining with two parallel longitudinal incisions that are interconnected with vertical incisions. Graft deliberation is initiated along the paramarginal incision in a split-thickness fashion with a goal of removing an FGG of 1.5-2-mm thickness without touching the periosteum. The harvested free gingival graft will be de-epithelialized to obtain an DFGG. The donor site wound will be covered by gel foam which will be sutured in place and then healing will occur by secondary intention .
215067747|NCT07079293|PROCEDURE|VISTA technique|Following Zadeh's (2011) protocol, under local anesthesia, a vestibular access incision is made depending on the treatment site (midline frenum for maxillary anterior, frenal area between canine and lateral incisor for maxillary posterior, and similar for mandibular regions). The incision passes through the periosteum to create a subperiosteal tunnel exposing the facial bone and root dehiscence. In the test group, the extended platelet-rich fibrin (e-PRF) membrane is inserted into the tunnel and secured to the flap with horizontal sutures; in the control group, a de-epithelialized free gingival graft (DFGG) is used similarly. Each tooth's facial enamel is briefly acid-etched, washed, and dried to attach vicryl sutures fixed with flowable composite resin to prevent apical relapse during healing. Finally, the access incision is closed and sutured with vicryl sutures
215067748|NCT07079605|OTHER|Standard treatment for sepsis of any focus|This group of patients will be treated for the sepsis of any focus as per standard.
214924564|NCT03753919|DRUG|Durvalumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
214924565|NCT03753919|DRUG|Tremelimumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
214924566|NCT01782417|BEHAVIORAL|patient and provider intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
214924567|NCT00002641|BIOLOGICAL|filgrastim|
214924568|NCT00002641|DRUG|doxorubicin hydrochloride|
214924569|NCT00002641|DRUG|ifosfamide|
214924570|NCT00002641|DRUG|isolated perfusion|
214924571|NCT00002641|PROCEDURE|adjuvant therapy|
214924572|NCT00002641|PROCEDURE|conventional surgery|
214924573|NCT00002641|RADIATION|radiation therapy|
214924574|NCT03878836|OTHER|Routine assessments|Routine assessments, no specific intervention
214924575|NCT02691819|DEVICE|single stent and embedded balloon angioplasty|
214924576|NCT03999736|DEVICE|transcranial direct current stimulation using a Soterix mini-CT device|TDCS is used to non-invasively stimulate the brain through the application of electrical currents to a small region of the scalp using a battery-powered stimulator (Soterix Medical 2018) with rubber electrodes and conductive material (saline-soaked sponges). Both electrodes are attached to the scalp with a band. The stimulation points will be located using the 10-20 system of electroencephalogram (EEG) electrode location (localization carried out using a bespoke head strap). The electrode size of the stimulator used in this study is large (25 cm2) and the current strength used is low (2 mA) resulting in very low current density (0.08 mA/cm2). This protocol applies no more than 30 minutes of stimulation in a single session, which is typical for experimental studies (Brunoni et al. 2015; Loo et al. 2017). TDCS is an investigational device and has proceeded with a non-significant risk designation in many past trials and not required an investigational device exemption from the FDA.
214924577|NCT05127213|PROCEDURE|Intragastric balloon system|Intragastric balloon system (PA450) developed and produced by Changzhou Zhishan Medical Technology Co., Ltd. It is a swallowable capsule intragastric balloon.The degradable material on the intragastric balloon can be degraded naturally, and the balloon is naturally discharged from the body through the gastrointestinal tract
214924578|NCT05127213|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy is the use of laparoscopy to cut out the greater curvature of the stomach, mainly for weight loss.
214924579|NCT02866149|BIOLOGICAL|Blood sampling|Up to 5 blood samplings can be performed at different time points
215067749|NCT07079605|OTHER|Treatment for the sepsis with standard management of cardiac failure|This group of patients will be treated for the sepsis and management of cardiac failure with additional supportive care cocktails based on the specific indication.
214924580|NCT02866149|PROCEDURE|Tumor sampling|One tumor sampling can be performed, if applicable
214924581|NCT02866149|OTHER|Stool sampling|Up to 5 blood samplings can be performed at different time points
214924582|NCT02775149|OTHER|Collection of saliva samples|Collection of saliva samples
215067750|NCT07081451|OTHER|Guided ımagery supported psychoeducation|Guided Imagery Technique is an effective, economical and therapeutic technique that can be easily used in nursing practices. Guided Imagery Technique is a set of stories that individuals create by visualising the symbols given by the practitioner after relaxation exercises. Within the scope of this technique, which is a window to the inner world of the person, the creation of his/her own unique story through symbols is encouraged
214924583|NCT02775149|OTHER|Visual detection of BEWE-index|Visual detection of BEWE-index
214924584|NCT00510913|DRUG|tacrolimus|
214924585|NCT01080118|DEVICE|Airtraq|Subjects were taught with the Airtraq video laryngoscope
214924586|NCT01080118|OTHER|Control group, taught with a standard Macintosh laryngoscope|Subjects were taught how to use the Mackintosh blade first
214924587|NCT01185184|DRUG|CP-690,550|Single doses separated by a minimum of 72 hour washout between treatments
214924588|NCT06683690|PROCEDURE|Measurement of TGF- β1 in leprosy patients|Study TGF- β1gene polymorphism in leprosy patients, and Correlate their results with different types of leprosy before and after treatment.
214924589|NCT02667964|OTHER|spiroergometry|Spiroergometry on a bicycle ergometer
214924590|NCT05875779|BEHAVIORAL|Peer-led vaccine education intervention|"The intervention will be delivered face-to-face by a trained peer-educator and will consist of one session of 10-20 minutes.~Peer vaccine educators will receive written vaccine materials for distribution. These materials will present content that accurately represents the risks and benefits of vaccination.~Responsibilities of the vaccine educators will be to: provide motivational interviewing with patients, provide vaccine counseling, address questions and concerns regarding available vaccines, brief clinical provider on hesitant patients and areas of their vaccine-related concerns, and provide follow-up with participants at day 30, day 60 and day 90 for additional engagement."
214324529|NCT06920147|DRUG|Ertapenem|Participants will receive a single dose of IV ertapenem (1g) in the operating room prior to incision or as soon as possible given the patient's hemodynamic status
215067751|NCT07080697|PROCEDURE|Splenectomy|Open Debridement combined with distal pancreatectomy and total splenectomy
215067752|NCT07080697|PROCEDURE|Control|Open Debridement alone
214924591|NCT01624779|DRUG|autologous adipose tissue derived mesenchymal stem cells|autologous adipose tissue derived mesenchymal stem cells 9x107cells / 3mL Day 1 and Month 1\&2
214924592|NCT02196688|DRUG|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
214924593|NCT02196688|DRUG|placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
214924594|NCT01604980|DIETARY_SUPPLEMENT|Protein intake.|protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
214924595|NCT00312260|DRUG|Gabapentin|Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.
214924596|NCT00312260|DRUG|Amitriptyline|Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.
215067753|NCT07081477|DRUG|Intravenous Anesthetic Induction with Ciprofol for Painless Colonoscopy in Elderly Patients|Cirpropofol is a 2,6-disubstituted phenol derivative that introduces a cyclopropyl group based on the chemical structure of propofol, increasing its affinity with GABA receptors and stereoeffect, thus its effect is 4-5 times that of propofol. Studies have found that the incidence of hypotension, injection pain, and respiratory depression during cirpropofol anesthesia is lower than that of propofol.
215067754|NCT07081477|DRUG|Propofol Intravenous Anesthesia Induction for Painless Colonoscopy in Elderly Patients|Propofol has favorable pharmacokinetic properties with minimal residue. Currently, it is widely used for endoscopic procedure sedation, but there are still many limitations, such as a narrow therapeutic window, injection pain, hypotension, and respiratory depression.
215067755|NCT04786821|BEHAVIORAL|Standard Exercise Training|Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.
215067756|NCT04786821|DEVICE|Phoenix Exoskeleton suit|Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
214924597|NCT03444948|DEVICE|EUS-RFA using Habib Tm as a probe|3 EUS-RFA interventions at 1-month interval
214924598|NCT03444948|PROCEDURE|EUS|Standard intervention
214924599|NCT03990194|DRUG|Leuprolide Acetate|Administration of Leptoprol implant every 3 months
214924600|NCT03922217|BEHAVIORAL|Mindful My Way|Mindful My Way (MMW) is a mobile application created for iOS, designed to delivered a form of mindfulness-based therapy to depressed older adults
214924601|NCT03024203|BEHAVIORAL|Cognitive Remediation - Executive Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as memory, and problem solving ability.
214924602|NCT03024203|BEHAVIORAL|Cognitive Remediation - Perceptual Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as attention, and processing speed.
214924603|NCT02658955|PROCEDURE|Short stitch|Surgeons will receive instructions to change the technique of abdominal wall closure
214924604|NCT01137110|OTHER|Brief LEV|Levetiracetam 1000mg BID x 3 days for prophylaxis
214924605|NCT01137110|OTHER|Extended LEV|Levetiracetam 1000mg BID for length of hospital stay for prophylaxis
214924606|NCT05971238|OTHER|Indoor vs. outdoor scenes|Light conditions in indoor (artificial light) and outdoor (daylight) settings
214324530|NCT06920147|DRUG|Cefazolin and Metronidazole.|Participants will receive a single dose of a combination of IV cefazolin (re-dosed during the case every 4 hours and/or after every 1,500 mL of blood loss) and IV metronidazole (single dose 500 mg) in the operating room prior to incision or as soon as possible given the patient's hemodynamic status
214324531|NCT06117397|OTHER|Text Messaging Intervention|A text messaging intervention that includes enhanced content such as tailoring, video links and a chat function
214324532|NCT07018765|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of eight weekly sessions, each lasting 60-90 minutes. The first session will be delivered face-to-face in the hospital, and the remaining sessions will be conducted online via Zoom. The program content includes mindful breathing, body scanning, stress management, emotional regulation, and interpersonal mindfulness exercises.
214924607|NCT06215989|DRUG|Colchicine Pill|Colchicine 0.5mg once daily will be given on the basis of standard treatment of ACS recommended by guidelines
215067757|NCT02873455|OTHER|Short video clip including the circumstance of operation theater, and surgeon's interview|
215067758|NCT00006459|DRUG|gemcitabine hydrochloride|
215067759|NCT00006459|DRUG|paclitaxel|
214924608|NCT06215989|DRUG|Placebo|Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines
214924609|NCT03394898|OTHER|body mass index, eating behaviour|The patients' weights and heights will be measured and the body mass index will be calculated from the measured values.Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
214924610|NCT06662461|PROCEDURE|ultrasound guided Greater occipital nerve block|"Patients will be positioned in a prone position with their neck slightly flexed.~The trapezius , semispinalis, obliqus capitis muscles will be revealed on short-axis view.~A 25- or 21 gauge is used, with puncture point 1-1.5 cm away from the ultrasound probe.~Under the guidance of the ultrasound, GOB will performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine."
214924611|NCT06662461|PROCEDURE|Ultrasound guided Stellate ganglion block|"Patients are positioned in a lateral position with their necks slightly hyperextended. Assisted by ultrasound imaging equipment the C7 level is confirmed. The thyroid gland, carotid artery, compressible internal jugular vein, vertebral artery, brachial plexus and the oval-shaped structure of the longus collis muscle are revealed on this short-axis view.~A 25- or 21 gauge is used and the puncture point is 1-1.5 cm away from the ultrasound probe The tip of the needle reach the surface of the longus collis muscle and the 5 o'clock position of the carotid artery. Under the guidance of the ultrasound, SGB is performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine."
214924612|NCT05160246|OTHER|kinesiology tape|The tape will be fixed without any tension 10 cm below the origin of the rectus femoris muscle. Then 35-50% tension will be applied to the band and descended to the patella. After this point, the Y-shaped band will be terminated to wrap the patella medially and laterally without any tension.
214924613|NCT05160246|OTHER|Placebo tape|The tape will attach to the rectus femoris without any tension.
214924614|NCT01946958|BEHAVIORAL|Training in PC Triple P|PC Triple P is a brief parenting intervention combining specific advice from provider with parent rehearsal and self-evaluation.
214924615|NCT01946958|OTHER|Care As Usual|Pediatric residents not exposed to PC Triple P provide their standard care to parents struggling with parenting issues or child behavior concerns.
215067760|NCT04219449|DIAGNOSTIC_TEST|PT|measuring PT drawn on citrated blood sample
215067761|NCT04219449|DIAGNOSTIC_TEST|Protein C|measuring protein C drawn on citrated blood sample
215067762|NCT04219449|DIAGNOSTIC_TEST|Platelet aggregation by ADP and arachidonic acid|measuring platelet aggregation drawn on citrated blood sample
215067763|NCT06789328|DRUG|perineural Dexamethasone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg perineural Dexamethasone
215067764|NCT06789328|DRUG|intravenous Dexamethsone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg intravenous Dexamethasone
215067765|NCT00531440|DRUG|Everolimus (RAD001)|
215067766|NCT07080411|RADIATION|short course radiotherapy using MR-linac|Patients in the MRgART group will receive standard total neoadjuvant therapy (TNT) and surgical treatment, including short-course radiotherapy and chemotherapy, with the addition of immunotherapy at the investigator's discretion based on individual patient characteristics.
215067767|NCT07080788|BEHAVIORAL|Smoking Cessation|Investigators will provide financial incentives for biochemically verified abstinence at 4 weeks following treatment. This incentive is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.
215067768|NCT01321255|DRUG|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
215067769|NCT01321255|DRUG|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
214324533|NCT07018752|DRUG|roginolisib|Roginolisib daily intake
215067770|NCT07079878|OTHER|Group with Bed Head Height 30°|30 minutes before feeding, the bed head height of the preterm newborn is adjusted to 30° and vital signs are monitored. After 30 minutes, the newborn is fed and vital signs are monitored during feeding. The vital signs are monitored again 30 minutes after feeding. While evaluating nutritional tolerance, abdominal distension, abdominal circumference measurement and vomiting are monitored. Growth parameters of the newborn are recorded on the growth monitoring form for 7 days.
215067771|NCT07079878|OTHER|Group with Bed Head Height 45°|The bed head height of the preterm newborn is adjusted to 45° 30 minutes before feeding and vital signs are monitored. After 30 minutes, the newborn is fed and vital signs are monitored during feeding. The vital signs are monitored again 30 minutes after feeding. While evaluating nutritional tolerance, abdominal distension, abdominal circumference measurement and vomiting are monitored. Growth parameters of the newborn are recorded on the growth monitoring form for 7 days.
215067772|NCT07076992|PROCEDURE|Circumcision by Plastibell|Patients will undergo circumcision by Plastibell (PB).
215067773|NCT07076992|PROCEDURE|Circumcision by Gomco|Patients will undergo circumcision by the Gomco (GM).
214924616|NCT04779528|PROCEDURE|Fiberoptic intubation in supine position.|"Patients will be placed in supine position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
214924617|NCT04779528|PROCEDURE|Fiberoptic intubation in lateral position.|"Patients will be placed in lateral position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
214924618|NCT03229928|DEVICE|MOCHA|"* MOCHA phone-based application~* Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~* Wrist based sensor (applicable only to sensor wearing participants)."
214924619|NCT04782453|BEHAVIORAL|ToQuit, a technology delivered tobacco cessation intervention|"The intervention messages will consist of specific content areas derived from the formative research of the study. Some of the components of the intervention include~* Psychoeducation about consequences of tobacco use and benefits of quitting;~* goal setting;~* managing goals and self-monitoring of behavior;~* avoidance strategies;~* self-awareness and reflection messages;~* social and pharmacological support, and help-seeking;~* identifying and managing cravings;~* relapse prevention strategies."
214924620|NCT04782453|BEHAVIORAL|Tobacco quitting helplines|Participants from the control group will be sent the details of other functional tobacco helplines in India.
214924621|NCT02793674|DEVICE|Fisher & Paykel high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
214924622|NCT02793674|DEVICE|Vapotherm high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
214924623|NCT06662474|OTHER|1. cognitive stimulation|sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks
214924624|NCT06662474|OTHER|2. psychoeducation and cognitive stimulation|sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks and also hold open group meetings for psychoeducation (1 meeting every 2 weeks, 6 meetings in total)
214924625|NCT06662474|OTHER|3. no intervention|maintaines their lifestyle up until their inclusion in the study without following additional measures
214924626|NCT03998644|OTHER||
214924627|NCT04286789|DRUG|Low dose ORTD-1|Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
214924628|NCT04286789|DRUG|Low dose vehicle control|Once weekly subcutaneous injection of vehicle at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
215067774|NCT07080112|BEHAVIORAL|Peer education|The study was designed as a randomized controlled trial. The population consisted of third-year nursing students (84 students) enrolled in the spring semester of the 2024-2025 academic year. The entire population was included in the study. For randomization, the class list of 84 students was used based on their order, and randomization was performed via the website https://www.random.org/ to form the experimental and control groups.
215067775|NCT07081854|OTHER|Land-Based Plyometric Training|"Participants will perform traditional plyometric exercises on land aimed at improving lower-body power and neuromuscular performance.~Exercises:~1. Box Jumps: Jumping onto a box of progressively higher levels to build explosive strength.~2. Depth Jumps: Stepping off a box and immediately jumping vertically upon landing.~3. Jump Squats: Explosive vertical jumps starting from a squat position.~4. Lateral Bounding: Jumping side-to-side to enhance lateral agility.~5. Broad Jumps: Maximal horizontal jumps for distance.~6. Tuck Jumps: Jumping while bringing knees to the chest in mid-air."
215067776|NCT07081854|OTHER|Aquatic Plyometric Training|"Participants will perform plyometric exercises in a shallow pool, with the water depth fixed at the xiphoid process level (chest height). Greater peak mechanical power was observed for jumps performed in the water and was influenced by immersion depth.~Exercises:~1. Box Jumps: Jumping onto a box of progressively higher levels to build explosive strength.~2. Depth Jumps: Stepping off a box and immediately jumping vertically upon landing.~3. Jump Squats: Explosive vertical jumps starting from a squat position.~4. Lateral Bounding: Jumping side-to-side to enhance lateral agility.~5. Broad Jumps: Maximal horizontal jumps for distance.~6. Tuck Jumps: Jumping while bringing knees to the chest in mid-air.~Key Points:~* Encouraged to perform movements explosively while applying maximal effort.~* Proper execution is emphasized to maintain biomechanical integrity even in the water environment.~* Water temperature: 25-28 °"
215067777|NCT07081854|OTHER|General conditioning exercises|"Participants will follow a general conditioning routine that does not include plyometric exercises.~Exercises:~1. Bodyweight squats.~2. Lunges.~3. Core stability exercises (e.g., planks, bridges).~4. General cardio activities such as light jogging or cycling."
215067778|NCT07080047|OTHER|Mackenzie exercise for lateral shift|Participants in the McKenzie group will perform standing side glide exercises, where they stand perpendicular to a wall (painful side away), press their hips toward the wall, and hold for 2-3 seconds, repeated 30 times
214924629|NCT04286789|DRUG|High dose ORTD-1|Two subcutaneous injections of ORTD-1 at two injection sites once weekly; 0.90 mL of ORTD-1 per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
214924630|NCT04286789|DRUG|High dose vehicle control|Two subcutaneous injections of vehicle at two injection sites once weekly; 0.90 mL of vehicle per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
214924631|NCT05177536|DRUG|Iberdomide|Iberdomide is a novel potent cereblon E3 ligase modulator
214924632|NCT03492814|PROCEDURE|partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
214924633|NCT03492814|PROCEDURE|total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
214924634|NCT01858116|DRUG|[68Ga]ABY-025|Intravenous injection followed by PET imaging
214924635|NCT05536024|DIAGNOSTIC_TEST|Prediction of glioma grading and molecular subtype|Prediction of WHO grading(II/III/IV), IDH gene mutation status, ATRX deletion status, 1p/19q deletion status, CDKN2A/B homozygous deletion status, TERT gene mutation status, epidermal growth factor receptor (EGFR) mutation status, chromosome 7gain and chromosome 10 less status, H3F3A G34 (H3.3 G34) mutation status, H3 K27M mutation status
214924636|NCT03551717|OTHER|Optical Coherence Tomography angiography|At the inclusion visit for all patients and at M3 only for 50 patients.
214924637|NCT03551717|OTHER|Fundus|At the inclusion visit for all patients and at M3 only for 50 patients.
214924638|NCT03551717|OTHER|cardiac ultrasound scan|Only for 50 patients, 3 months after the initial cardiovascular event
214924639|NCT01144039|DRUG|LG-group|
214924640|NCT01144039|DRUG|HG-group|
214924641|NCT01144039|DRUG|Placebo-group|
214924642|NCT04287725|DEVICE|exercise + photobiomodulation therapy|Treatment sessions will be provided twice a week for 6 weeks (totaling 12 sessions) with participants receiving either placebo or active PBMT + exercise protocol.
214924643|NCT02980419|BEHAVIORAL|presentation of visual and vestibular stimuli|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
214924644|NCT00543517|DRUG|MK0767|
214924645|NCT06620536|DEVICE|Electrical stimulation|Electrical stimulation of peripheral nerves for the recovery of hand function in tetraplegic patients of fundamental importance in improving quality of life.
214924646|NCT06084819|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"1. Azacytidine (75mg/m2/day, days 1 to 7).~2. Cytarabine (75-100mg/m2 q12h, days 1 to 5).~3. Aclacinomycin(20mg/day, days 1,3,5).~4. Chidamide(30mg/day , days 1,4,8,11).~5. Venetoclax (100mg on day 1,200mg on day 2,400mg on days 3-14).~6. Granulocyte colony stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
215067779|NCT07080047|OTHER|Traditional physical therapy|Participants in the traditional therapy group will receive posteroanterior lumbar mobilizations (30 repetitions × 3), 10-minute hot pack application, myofascial release of paraspinal muscles, and core stability exercises (plank and bridging).
214324534|NCT07018752|DRUG|golcadomide|Golcadomide daily intake
214324535|NCT07018752|DRUG|azacitidine|oral 5-azacitidine daily intake
214324536|NCT07019766|OTHER|A combined retrospective and prospective observational follow-up|The NICHE-LGLL will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
214324537|NCT07019038|OTHER|A combined retrospective and prospective observational follow-up|The NICHE-AIHA will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
214324538|NCT07075367|OTHER|Proximal/distal protocol|The experimental group will receive a proximal/distal exercise program (trunk, hip, knee and ankle) consisting of four stages: warm-up, strengthening, sensorimotor training and relaxation.
214324539|NCT07075367|OTHER|Distal protocol|The control group will receive a distal exercise program available in the literature and previously tested. This will contain warm-up exercises, intrinsic foot muscle strengthening, extrinsic foot-ankle muscle strengthening, and functional exercises.
215067780|NCT04165382|OTHER|Interventions in the guideline to infants receiving NIV|"Interventions in the guideline involve six components as~1. choice of right nasal interfaces and bonnet~2. use of skin protective dressing~3. alternate the nasal interfaces every 6 hours;~4. positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~5. supportive care with more new interventions~6. regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV"
215067781|NCT04165382|OTHER|Usual care to infants receiving NIV|Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
215067782|NCT00002412|DRUG|Emivirine|
215067783|NCT00002412|DRUG|Hydroxyurea|
214924647|NCT06084819|DRUG|Best-Available Therapy(BAT) Regimen|"1. FLAG regimen:Fludarabine(30mg/m2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~2. CLAG regimen:Cladribine(5mg/2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~3. MAE regimen:Mitox(10mg/m2,days 1 to 5)+VP-16(100mg/m2,days 1 to 5)+Cytarabine (100-150mg/m2,days 1 to 7)~4. DCAG regimen:Decitabine(20mg/m2,days 1 to 5)+Aclacinomycin(20mg/day on days 1,3,5)+Cytarabine (100mg q12h,days 1 to 5)+Granulocyte colony-stimulating factor(300 ug/day,day 0 until agranulocytosi recovery)~5. HAA regimen:HHT(2mg/m2,days 1 to 7)+Aclacinomycin(20mg/day,days 1 to 7) and Cytarabine (100-200 mg/m2, days 1 to 5);~6. HAD regimen:HHT(2mg/m2,days 1 to 7)+Daunorubicin(45mg/m2/day,days 1 to 3)+Cytarabine (100-200 mg/m2,days 1 to 5)."
214924648|NCT00611949|OTHER|Geranium oil|2 applications of topical oil per week for 2 weeks
214924649|NCT04721119|PROCEDURE|Local Infiltration Anesthetic|For the local infiltration anesthetic, patients will receive 20 cc of 0.5% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision.
214924650|NCT04721119|PROCEDURE|Local Infiltration Anesthetic + Adductor Canal Block|For the local infiltration anesthetic, patients will receive 20 cc of 0.25% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision. For the adductor canal block, patients will receive 20 cc of 0.25% ropivicaine, through injection performed by the anesthesiologist. The injection is done under the sartorius muscle, in mid-thigh, using ultrasound guidance.
215067784|NCT00002412|DRUG|Stavudine|
215067785|NCT00002412|DRUG|Didanosine|
215067786|NCT07081282|BEHAVIORAL|Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)|Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)
215067787|NCT07081282|BEHAVIORAL|Centre-Based Exercise Health Session|Participants will receive one time centre-based exercise health programme each week.
215067788|NCT07074990|DRUG|conventional sepsis therapy alone|fluid resuscitation a minimum of 30 mL/kg of intravenous (IV) crystalloid fluid administered during the initial 3 hours of resuscitation, along with empiric antibiotic therapy aimed at the suspected pathogens and infection sites, ideally starting within the first hour.
215067789|NCT07074990|DRUG|colchicine 500 mcg oral twice daily plus conventional sepsis therapy.|colchicine 500 mcg oral twice daily plus conventional sepsis therapy for 5 days.
215067790|NCT07081373|DRUG|A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.|At surgical closure, a single dose of undiluted liposomal bupivacaine (266 mg/20 mL) is administered without concurrent analgesics. The total 20 mL volume is divided into six equal aliquots (≈3.3 mL each) and infiltrated circumferentially around the incision using a 25-gauge or larger-bore needle. Injections target tissue layers above and below the fascia and within the subcutaneous plane, with frequent aspiration during administration to mitigate intravascular injection risk. Seventy-two hours postoperatively, a repeat dose of undiluted liposomal bupivacaine (266 mg/20 mL) is administered. Prior to infiltration, topical lidocaine cream is applied to the per-incisional skin for ≥20 minutes. The full 20 mL volume is then injected uniformly around the incision via circumferential needle advancement into pericicatricial tissues.
214924651|NCT04725318|OTHER|One-lung ventilation|One-lung ventilation as part of routine clinical care for patients undergoing thoracic surgery under general anesthesia
214924652|NCT01146379|OTHER|Intensive task-specific upper extremity rehabilitation|The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
214924653|NCT06967103|DRUG|QL1706|bispecific antibody targeting PD-1 and CLTA-4
214924654|NCT06967103|DRUG|Nab-PE|Nab-paclitaxel+Epirubicin
214924655|NCT06969118|PROCEDURE|Minimalism Transcatheter LAAC Group|Patients will undergo transcatheter LAAC under local anesthesia, guided by DSA and TTE, using the WATCHMAN FLX system. The release criteria (PASS: Position, Anchor, Size, Seal) will be confirmed through DSA and TTE.
214924656|NCT06969118|PROCEDURE|Standard Transcatheter LAAC Group|Patients will undergo LAAC under general anesthesia, guided by TEE, using the WATCHMAN FLX system, following the steps outlined in the product manual.
214924657|NCT06560229|OTHER|Grocery gift card|Monthly $100 grocery gift cards for 12 months
214924658|NCT00222365|DRUG|Arnica montana, 5 CH|
214924659|NCT00222365|DRUG|Bryonia alba, 5 CH|
214924660|NCT00222365|DRUG|Hypericum perforatum, 5 CH|
214924661|NCT00222365|DRUG|Ruta graveolens, 3 DH|
214924662|NCT03637140|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
214924663|NCT03637140|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
215067791|NCT07079566|BEHAVIORAL|Primal Reflex Release Technique (PRRT)he Primal Reflex Release Technique (PRRT) is a hands-on, non-invasive therapeutic approach designed to deactivate overactive protective reflexes believed to contr|The Primal Reflex Release Technique (PRRT) is a non-invasive, manual therapy that targets specific neurogenic reflex points to reduce muscle tension, pain, and dysfunction. It works by modulating the autonomic nervous system to interrupt hyperactive primal reflexes such as withdrawal and startle reflexes, which are often involved in chronic musculoskeletal pain conditions like plantar fasciitis. In this study, PRRT was applied to participants in the experimental group over a 3-week period, consisting of multiple sessions per week. Each session included a series of gentle manual techniques such as the sternocleidomastoid (SCM) release, startle reflex inhibition, and positional reflex modulation. These techniques aim to reset the body's reflex-driven pain responses and promote functional mobility. PRRT was performed by trained physiotherapists following a standardized protocol to ensure consistency throughout the study.
215067792|NCT07079566|BEHAVIORAL|Conventional Physiotherapy Treatment This reflects the standard care or routine treatment used as a comparison in your randomized controlled trial on plantar fasciitis. Let me know if your control gr|"The control group in this randomized controlled trial received standard conventional physiotherapy treatment for plantar fasciitis. This treatment protocol consisted of traditional evidence-based physiotherapy interventions commonly used in clinical practice. Participants received supervised sessions including static and dynamic stretching exercises targeting the plantar fascia, Achilles tendon, and calf muscles. In addition, the intervention included modalities such as cryotherapy (application of ice packs), ultrasound therapy for soft tissue healing, and patient education on activity modification, proper footwear, and home exercise programs.~The conventional treatment was administered for 3 sessions per week over a period of 3 weeks. Each session lasted approximately 30 to 40 minutes. The objective of this intervention was to reduce inflammation, relieve pain, and improve foot function through mechanical and thermal means, without involving neuromuscular reflex reprogramming. This a"
215067793|NCT07074015|DEVICE|Use of IntelliWell to identify and localize sperm for ICSI|The experimental arm will have surgically extracted testicular sperm processed with IntelliWell. If identified and confirmed by embryology, cryopreservation of sperm will occur. On day of ICSI, thaw of testicular sperm will occur and be processed by IntelliWell for identification and localization for use in ICSI.
215067794|NCT07079384|OTHER|The patient will be instructed about wearing the prosthesis. First, seat the prosthesis in a posterior undercut, then rotate the prosthesis slightly superiorly in the defect area and engage the anteri|"* The obturator will then be printed using Denture Base Resin and teeth.~* The printed obturator will be tried in, two magnets, one anteriorly and another posteriorly will be picked up then inserted into the patient mouth.~* The patient will be again instructed regarding the care of the prosthesis and hygiene maintenance as formerly. The patient will also be instructed to wear the obturator plate first, and once this is comfortably seated, the denture part will be inserted. During removal, the patient will be instructed to first remove the denture part gently to disengage the magnetic attraction after the obturator part as formerly instructed. The patient will be recalle"
215067795|NCT07080073|OTHER|Maitland Mobilization Group|"Participants in this group will receive Maitland Grade III central posterior-anterior spinal mobilizations targeting the lumbar spine. The intervention will be administered by a licensed physiotherapist with the patient in a prone position, applying oscillatory mobilization for 3 sets of 40 seconds with 1-minute rest intervals.~Canal enlargement exercises (bilateral knee-to-chest, LION stretch, cat-camel exercise) The total treatment will be administered four sessions per week for three weeks (12 sessions total)."
214924664|NCT06038344|BEHAVIORAL|Gluten-free food guide teaching|Teaching the gluten-free food guide will be done over Zoom within 1-2 weeks of the dietitian's standard of care teaching (group Zoom session). This teaching will take 30-45 minutes and will be conducted by a trained researcher. The investigators will use the gluten-free food guide as teaching materials with a focus on the GF plate model, the rationale for the GF plate model, nutritional consideration of gluten-free diet and content related to the additional 24 teaching materials (e.g. folate, fibre, eating out, school lunches etc.) contained within the guide. Individualized dietary suggestions based on participants' food records will also be provided.
214924665|NCT02878265|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A supplements
214924666|NCT02878265|DIETARY_SUPPLEMENT|Vitamin A and ZInc|Combination of vitamin A and zinc supplements
214924667|NCT02878265|DIETARY_SUPPLEMENT|Vitamin A , Zinc and Multivitamin|Combination of vitamin A, zinc and multivitamins
214924668|NCT02394340|DRUG|Omeprazole 40 mg|Oral capsule to be taken as per the instructions regarding proper dosing technique.
214924669|NCT02394340|DRUG|Luliconazole Cream 1%|Topical cream to be applied as per the instructions regarding proper study drug application technique.
215067796|NCT07080073|OTHER|Mulligan Mobilization Group|"Participants in this group will receive Mulligan spinal mobilizations with lower limb movement (SNAGs). The therapist will apply sustained passive glides to the lumbar spinous process while the patient actively elevates the leg in a pain-free range. Mobilizations will be performed in 3 sets of 7-10 repetitions.~Canal enlargement exercises (bilateral knee-to-chest, LION stretch, cat-camel exercise) The total treatment will be administered four sessions per week for three weeks (12 sessions total)."
215067797|NCT07079514|DRUG|Placebo|normal saline in 100ml piggy bag
215067798|NCT07079514|DRUG|Magnesium|Magnesium Sulphate will be given as doses of 20-50mg/kg in 2 -3 minutes. In order to standardize the dose in every patient we will be using 3g
215067799|NCT07079462|COMBINATION_PRODUCT|Radiotherapy followed by chemotherapy|"Radiotherapy: Low-dose radiotherapy to the abdominal cavity region, 5-10 Gy/5 fractions. For visible local lesions, large fraction radiotherapy is administered, 15-30 Gy/5 fractions, once daily.~Immunotherapy: One week after the completion of radiotherapy, cadonilimab, 6 mg/kg, is administered every two weeks."
214324540|NCT06916039|OTHER|immediate verbal memory after high GI breakfast|Difference in immediate verbal memory after high GI breakfast at 150-180 minutes (i.e., in the late postprandial phase)
214324541|NCT06916039|OTHER|immediate verbal memory after low glycemic index breakfast|Difference in immediate verbal memory after low GI breakfast at 150-180 minutes (i.e., in the late postprandial phase)
215067800|NCT07079462|DRUG|Chemotherapy (control)|Standard second-line treatment regimen: (XELOX/FOLFOX or XELIRI/FOLFIRI + bevacizumab/ cetuximab)
214324542|NCT06545955|DRUG|Nadofaragene Firadenovec|vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
214324543|NCT06545955|DRUG|Gemcitabine|Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.
214324544|NCT06545955|DRUG|Docetaxel|Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.
214324545|NCT06545955|DRUG|Pembrolizumab|Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.
214924670|NCT00239746|DRUG|Ibuprofen|200mg taken orally daily for 6-12 weeks
214924671|NCT00239746|DRUG|Placebo|200mg matched placebo taken orally daily for 6-12 weeks
214924672|NCT06665230|DRUG|MK-6552|Oral administration
215067801|NCT07080684|DRUG|Ticagrelor 60 mg|"Patients in this arm will receive dual antiplatelet therapy (DAPT) consisting of low-dose ticagrelor (60 mg twice daily) plus aspirin (75-100 mg once daily) for 1 month, followed by ticagrelor 60 mg monotherapy for 5 additional months (total 6 months of therapy).~This strategy aims to reduce ischemic events while minimizing bleeding risk by leveraging the potent antiplatelet effect of ticagrelor at a lower maintenance dose."
215067802|NCT07080684|DRUG|clopidogrel 75 mg|"Patients in the control group will receive standard DAPT consisting of clopidogrel 75 mg once daily plus aspirin 75-100 mg once daily for 6 months.~This represents the current standard of care in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents."
214324546|NCT03548584|DRUG|Brexpiprazole|Oral tablets
214324547|NCT03548584|OTHER|Placebo|Oral tablets
214324548|NCT04268342|OTHER|Resistance guided treatment for gonorrhoea infection|For cases of gonorrhoea infection treated at the return visit, a nucleic acid assay will be used to determine individual eligibility for ciprofloxacin treatment
214324549|NCT03481959|DRUG|Methylphenidate|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
214924673|NCT06665230|DRUG|Modafinil|Oral administration
214924674|NCT04169048|BEHAVIORAL|Group training for mothers with Borderline Personality Disorder|The group programme is designed to teach mothers with BPD parenting skills and to reduce dysfunctional parenting attitudes and strategies. The components are: childrens basics needs, mindfulness, stress and stress reduction, dealing with conflicts, dealing with emotions, dysfunctional attitudes, physical contact, parenting rules, self care.
214924675|NCT02470065|DRUG|Afatinib|once daily afatinib at a dose of 40 mg for 8 weeks
214924676|NCT02470065|PROCEDURE|Immediate surgery|anatomical resection and systematic lymph node dissection
214924677|NCT05942014|BEHAVIORAL|dental anxiety|Evaluate dental anxiety in children and its relation with screen time exposure
214924678|NCT00001016|DRUG|Trimetrexate glucuronate|
214924679|NCT00001016|DRUG|Leucovorin calcium|
214924680|NCT06969326|DRUG|Use of topical estradiol|The investigators will conduct a double blinded randomized control pilot trial. Participants will be randomized in 1:1 fashion to either receive no treatment or receive 2g of estradiol cream, placed after clearing the vaginal vault of any blood and discharge, at the conclusion of the surgery.
214924681|NCT06969326|OTHER|No intervention|This arm will not receive estradiol or other cream
214924682|NCT05192590|OTHER|Educational Materials and Chronic Disease Management Test (CDMT)|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the CDMT technology. These materials are comprised of a PowerPoint presentation.~Intervention 1 participants only will receive the CDMT test results whether they select it or not, and Intervention 2 participants will receive the CDMT test results only if they select it during the second round of case simulations."
214924683|NCT06966973|OTHER|Polysomnograpy|All successive patients who underwent polysomnography
214924684|NCT06966999|PROCEDURE|Botulinum Toxin Type A Injection [Botox]|for patients \>12 years presenting with large-angle esotropia (\>50 PD), primary surgical intervention was recommended as the preferred approach to minimize failure and recurrence risk. Conversely, for patients ≤12 years, BTXA injection was maintained as the first-line treatment regardless of the deviation angle.
214924685|NCT01010295|DRUG|doxycycline (tetracycline)|doxycycline 100 mg twice daily for 3 weeks
214924686|NCT03589638|DEVICE|Direct laryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
214924687|NCT03589638|DEVICE|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
214924688|NCT03589638|DEVICE|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
214924689|NCT04457102|DEVICE|MANIV|mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac
214924690|NCT04457102|OTHER|Spontaneous DIBH|performed on Varian® Halcyon LINAC and Infinity Elekta® linac
214924691|NCT03957603|DIETARY_SUPPLEMENT|Enteral Nutrition Suspension (TFP-DM)|Individualized dietary and lifestyle intervention combined with the recommendation of Enteral Nutrition Suspension (TPF-DM, Diason 0.75 kcal/ml)
214924692|NCT03957603|BEHAVIORAL|Medical Nutrition Therpay|Individualized dietary and lifestyle intervention
214924693|NCT03257852|DRUG|ASP5094|intravenously administration
214924694|NCT03257852|DRUG|Placebo|intravenously administration
214924695|NCT03257852|OTHER|Methotrexate therapy|MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
215067803|NCT07079722|BEHAVIORAL|Exercise|This project is a randomized controlled trial (RCT) with three distinct groups: a control group (CG), an online intervention group (OIG), and an in-person intervention group (IIG). The OIG will receive online educational sessions and structured home-based exercises, while the IIG will participate in in-person educational sessions and supervised physical exercise. The control group will not participate in educational sessions or structured physical exercise.
215067804|NCT03088930|DRUG|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
215067805|NCT07080749|OTHER|Vagal nerve stimulation through deep exhalation exercise|Deep Exhalation Treatment: Participants will receive a set of standard balloons to use for deep exhalation. They will sit in a comfortable position, take a deep breath in and blow their breath continuously out into the balloon. They repeat the deep exhalation process for a total of 4 consecutive breaths. They perform this breathing exercise once every hour during waking hours each day.
215067806|NCT07080749|OTHER|Vagal nerve stimulation through ear electrical stimulation|Ear Electrical Stimulation Treatment: Participants will receive a small electrical stimulator and electrode set to be applied to their left ear. The investigators will train the participants to use the device safely and effectively. Once they are comfortable with the procedure, they will perform the procedure at home for 20 minutes twice daily.
215067807|NCT07080749|OTHER|No intervention (observational study)|The no intervention group will not receive treatment immediately after their baseline assessments, they will be scheduled for another visit after two weeks, then a new set of baseline measurements will be recorded as the post intervention data.
214924696|NCT00256854|DRUG|Ropinirole IR 1 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance.
214924697|NCT00256854|DRUG|Ropinirole IR 2 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.
215067808|NCT07079709|BEHAVIORAL|Workfocused CBT|In WCBT, the central idea is that CBT techniques can be applied in a work context with the aim of achieving both usual treatment goals related to symptoms and RTW. To ensure positive effects at both symptomatic and functional levels, a work perspective must be fully integrated into the intervention to optimize the treatment effect which demands collaboration with the sick leave prescribing doctor and the patient's employer. The protocol is based on principles of increasing return-to-work self-efficacy (RTW-SE). Work-specific components, such as work anamnesis, adjusting the difficulty of work tasks, and developing a return-to-work plan that includes recommendations for workplace accommodations, are integrated into all treatment sessions.
215067809|NCT07079709|OTHER|Standard Care (in control arm)|Standard Care is defined as care by the sick leave prescribing physician and the rehab coordinator. Other interventions such as psychological treatment, physiotherapy etc. may also be included in this arm.
214324550|NCT03481959|OTHER|Matching Placebo|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
214924698|NCT00256854|DRUG|Ropinirole IR 1 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg.
214924699|NCT00256854|DRUG|Ropinirole IR 2 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
214924700|NCT00256854|DRUG|Ropinirole CR 2 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance.
214924701|NCT00256854|DRUG|Ropinirole CR 3 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.
214924702|NCT00256854|DRUG|Ropinirole CR 2 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
214924703|NCT00256854|DRUG|Ropinirole CR 3 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg.
214924704|NCT06307756|OTHER|Music group|"Mothers will be informed about the application before the procedure. Mothers who agree to participate in the study will be asked to listen to music that relaxes them for 20 minutes a day for 4 days. The mothers' state anxiety levels and milk quantities will be evaluated before starting the application and every day during the application. Mothers' anxiety levels will be evaluated with the State Anxiety Inventory. Mothers' anxiety levels and milk quantities will be evaluated every day at 11.45 when they come to the NICU to express milk."
214924705|NCT05667831|OTHER|Alginate silver silver ion dressing|Alginate silver silver ion dressing is a soft, comfortable wound dressing with a high mannuronic acid content. Gels on contact with wound exudate or blood, creating a moist wound environment for optimal wound healing. Silver ions protect the dressing from a range of microorganisms.
214924706|NCT05503602|OTHER|Classical Physiotherapy|Only classical physiotherapy application, 5 sessions per week for 4 weeks.
214924707|NCT05503602|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization application 2 sessions per week together with 3 sessions of classical physiotherapy per week for 4 weeks. IASTM application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
215067810|NCT00420082|DRUG|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
214324551|NCT05750641|OTHER|removing milk and dairy products from diets without medical treatment|A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
215067811|NCT00420082|DRUG|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
215067812|NCT00420082|DRUG|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
215067813|NCT00420082|DRUG|Placebo|Encapsulated Placebo tablets Q.D.
215067814|NCT03648177|BEHAVIORAL|IPGT|Behavioral Intervention for Patients with Chronic Pain
215067815|NCT03648177|BEHAVIORAL|Treatment as Usual|Standard Care
215067816|NCT06473077|PROCEDURE|ETT beyond C7 level|Endotracheal cuff is placed deeper beyond C7 level, but above carina
214324552|NCT05750641|OTHER|According to current standard algorithms and guidelines, appropriate treatment for FD types.|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
214324553|NCT01786408|DEVICE|TAP20-C|
215067817|NCT05285761|BEHAVIORAL|Provision of extended information on the conduct of complementary feeding|"Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child."
215067818|NCT05285761|BEHAVIORAL|Provision of current official information on complementary feeding|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
215067819|NCT01787396|DRUG|Gemigliptin 50mg|
215067820|NCT01787396|DRUG|Placebo(Metformin)|
215067821|NCT01787396|DRUG|Metformin|
215067822|NCT01787396|DRUG|Placebo(Gemigliptin)|
214924708|NCT05503602|OTHER|Foam Roller Technique Application|2 sessions of foam roller technique per week along with 3 sessions of classical physiotherapy per week for 4 weeks. Foam roller application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
214924709|NCT02004886|DRUG|MK-0893|10 mg and 100 mg tablets
214924710|NCT02004886|DRUG|Metformin|500 mg metformin tablets
214924711|NCT02004886|DRUG|Placebo|Placebo tablets matching MK-0893
214924712|NCT02004886|DRUG|Placebo|Placebo tablets matching metformin
214924713|NCT05801939|DRUG|Cevostamab|Cevostamab will be given as an IV infusion once every 3 weeks, starting roughly 10 weeks (day 70 +/- 4 days) post-CAR T cell infusion, with subjects planned to receive 8 cycles initially. Subjects receive a single step-up dose of 3.6 mg of cevostamab on cycle 1, day 1 (C1D1), followed by the recommended target dose (160 mg, 132mg, or 90 mg based on results of safety run-in data and safety review) on C1D8. Myeloma responses are assessed every cycle, and a repeat bone marrow aspirate and biopsy (BMbx) is performed at the start of cycle 8. If participants are not in an MRD-negative CR at this timepoint (or if the BM bx is inevaluable/indeterminate for CR or MRD testing), they continue with another 8 cycles (C9-16) of cevostamab. If they are in MRD-negative CR at start of C8, they stop therapy after receiving this cycle and are observed.
215067823|NCT07080723|OTHER|Algorithm guided treatment (AGT)|"AGTs consist of strategies (which treatments to use), tactics (how to implement each treatment) and treatment steps (in what order to implement the different treatments). Furthermore, AGTs also define critical decision points during the treatment at which the effects of a certain treatment are assessed and based on this assessment recommend specific treatment revisions according to preset if-then rules. This is most often done by implementing measurement-based care."
214924714|NCT03775863|PROCEDURE|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma
215067824|NCT07080723|OTHER|Treatment as usual (TAU)|TAU includes the standard clinical care for patients with TRD as determined by a senior consultant.
214324554|NCT01786408|DEVICE|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
214324555|NCT00004917|BIOLOGICAL|epoetin alfa|
214924715|NCT01813214|DRUG|Vemurafenib|
214924716|NCT01813214|DRUG|Cobimetinib|
214924717|NCT06648538|DEVICE|Phonix Care|Phonix Care consists of a 5-month digital therapeutic program that encourages the user to engage in non-digital activities through pre-defined screen rules and off-screen challenges validated by smartphone sensors.
215067825|NCT06906549|DRUG|Rituximab 200mg/6months|perfusion of Rituximab 200mg
215067826|NCT06906549|DRUG|Rituximab 1g/6months|perfusion of Rituximab 1g
214324556|NCT00004917|DRUG|cisplatin|
214324557|NCT00004917|RADIATION|radiation therapy|
215067827|NCT06827886|BIOLOGICAL|GCAR1|GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
215067828|NCT04147377|BEHAVIORAL|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
215067829|NCT06950177|BIOLOGICAL|CoV-RBD-scNP-001 and 3M-052-AF|All subjects will receive the investigational vaccine CoV-RBD-scNP-001 adjuvanted with 3M-052-AF.
215067830|NCT05878951|DRUG|OnabotulinumtoxinA|Intra-detrusor OnabotulinumtoxinA is commonly known as botox
215067831|NCT06283459|BIOLOGICAL|IMNN-101|IMNN-101 is a DNA vaccine encoding SARS-CoV-2 Omicron XBB.1.5 spike antigen. The drug product is a suspension of the DNA plasmid formulated with the facilitating agent, bis-(aza-18-crown-6)-poloxamer (Crown poloxamer, CP), and adjuvant AlPO4.
215067832|NCT04488159|DRUG|Capecitabine|Tablet
215067833|NCT04488159|DRUG|Oxaliplatin|Infusion
215067834|NCT04488159|DRUG|Fluorouracil|Infusion
215067835|NCT04488159|DRUG|Leucovorin|Infusion
214324558|NCT05281367|PROCEDURE|Breast milk odor group|The researcher applied the breast milk that dripped on the pad for 3 minutes before the heel stick for 36 premature newborns in the breast milk odor group. About three cc breast milk dripped onto a sterile pad and placed at a distance of 10 cm from the nose of the newborn. It continued until 3 minutes after the invasive procedure. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
215067836|NCT04488159|DEVICE|Immunoscore® assay|Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin
215067837|NCT04488159|OTHER|Physical exercise|Increasing stair walking exercise twice a week over 12 weeks total.
215067838|NCT04884490|DRUG|Co-trimoxazole|Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
215067839|NCT04884490|DRUG|Placebo|Placebo thrice (8 hourly) daily for 7 days orally.
215067840|NCT03970174|OTHER|Care Connector care transition module|Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
215067841|NCT02463747|DRUG|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
215067842|NCT02463747|DRUG|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
215067843|NCT02463747|DRUG|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
215067844|NCT02463747|DRUG|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
215067845|NCT02109432|BEHAVIORAL|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
215067846|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
215067847|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
215067848|NCT06543498|DIAGNOSTIC_TEST|Lactulose/Mannitol Ratio Test|To test for gut permeability, Urine collected over 8hrs after ingestion of lactulose/mannitol drink.
215067849|NCT06543498|DIAGNOSTIC_TEST|Serum biomarkers of intestinal permeability|Phlebotomy and subsequent lab tests to analyse concentration of LPS, LPB, sCD14, Zonulin and Occludin.
215067850|NCT06543498|OTHER|Rome IV questionnaire|Diagnositic questionnaire for IBS-D
215067851|NCT06543498|OTHER|Irritable bowel severity scoring system|Questionnaire to determine severity of abdominal and bowel symptoms
215067852|NCT06543498|OTHER|Bowel Habit diary|Assess bowel habit at baseline and changes in bowel habit over the study
215067853|NCT06543498|OTHER|3 day dietary record|Used to verify compliance to exclusion criteria #5.
215067854|NCT06543498|DIETARY_SUPPLEMENT|NCT and NFT|N-transcaffeoyltyramine and N-transferuloyltyramine supplement taken once per day.
215067855|NCT06543498|OTHER|Placebo|Placebo supplement taken once per day.
215067856|NCT02511834|DEVICE|VEST External Support|
215067857|NCT02511834|PROCEDURE|Coronary Artery Bypass Surgery|
215067858|NCT04983485|OTHER|Observational|Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
215067859|NCT02518087|DEVICE|oXiris®|"oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[oXiris® (Baxter Gambro)\].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
214672916|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
215067860|NCT01121627|OTHER|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
215067861|NCT05820152|DRUG|NFS-02 Injection|The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
214924718|NCT00733239|DRUG|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
215067862|NCT05467839|DEVICE|derma pen|Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
215067863|NCT06224998|BEHAVIORAL|Exercise|Exercise is the most appropriate treatment for low and moderate AIS cases due to its low cost and low risk of complications. Exercises prevent the development of many problems by controlling the severity of curvature and preventing the progression of curvature. It is thought that scoliosis exercises can delay or even prevent surgery and reduce the duration or degree of brace, especially in patients with low-to-moderate curvature during growth. One of these exercise approaches, the Schroth technique, is primarily based on isometric muscle contraction exercises that aim to rotate, lengthen and stabilize the spine. The core component of the Schroth method is autocorrection, defined as the patient's ability to reduce spinal deformity through active postural realignment of the spine in three dimensions.
215067864|NCT02920528|DRUG|Ketamine|sub-dissociative ketamine
214924719|NCT03369834|DEVICE|Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
215067865|NCT02920528|DRUG|Placebo|Normal Saline
215067866|NCT00680979|BEHAVIORAL|Interpersonal Psychotherapy|
215067867|NCT00680979|BEHAVIORAL|Health Education|
215067868|NCT05793255|BEHAVIORAL|Social Phone Calls|Following the collection of baseline data, the study participant will be randomly assigned to a student volunteer to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6weeks. Each phone call is expected to last around 1 hour with flexibility to be shorter or longer. The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer. If the stroke survivor and student volunteer wish to speak more than the designated one call a week, that will be allowed if both parties agree. The same student volunteer will conduct all six sessions
215067869|NCT02483793|DRUG|Tamsulosin|
215067870|NCT02483793|DRUG|Oxybutynin|
215067871|NCT02481648|OTHER|Exercise|
215067872|NCT03883347|DRUG|Dexmedetomidine|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery
215067873|NCT03883347|DRUG|Remifentanil|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
215067874|NCT02196883|PROCEDURE|Transforaminal Epidural Steroid Injection|
214672917|NCT01979744|PROCEDURE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
215067875|NCT05290246|BEHAVIORAL|Time restricted eating|Limiting daily eating time to an 8 hour window
215067876|NCT05290246|BEHAVIORAL|Caloric reduction|Cut caloric intake by 15%
215067877|NCT03165240|DRUG|BI 690517|Film-coated tablet
215067878|NCT03165240|DRUG|Eplerenone|Film-coated tablet
214924720|NCT03369834|DEVICE|Infrared Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
214924721|NCT03369834|DEVICE|Infrared and Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared and Red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
214924722|NCT03369834|DEVICE|Sham|LED device off.
214924723|NCT04150484|OTHER|Mediterranean diet, physical exercise and mindfulness workshops|a group of dietary intervention, physical exercise and mindfulness and another control group, and a longitudinal follow-up was carried out for 6 months from the beginning of the intervention.
214924724|NCT01876784|DRUG|Vandetanib (SAR390530)|"Pharmaceutical form: tablet~Route of administration: oral"
214486042|NCT06696521|BEHAVIORAL|Intervention A- Telephone|For intervention A: Once a patient is randomized to telephone (Intervention A), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.
214486043|NCT06696521|BEHAVIORAL|Intervention B- Televideo|For intervention B: Once a patient is randomized to televideo (Intervention B), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.
214486044|NCT05198765|BEHAVIORAL|BMI-CDS|The BMI-CDS is a sophisticated point of care shared decision support tool for patients with type 2 diabetes and high BMI. The intervention is built on existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and updated CDS all subsequent primary care office, video, and phone encounters.
214486045|NCT04552119|DEVICE|HEALICOIL Knotless PEEK|HEALICOIL Knotless PEEK Self-Tapping HEALICOIL Knotless Non-Self Tapping
214486046|NCT04552119|DEVICE|HEALICOIL Knotless REGENESORB|HEALICOIL Knotless REGENESORB Self -Tapping HEALICOIL Knotless REGENSORB Non-Self Tapping
215067879|NCT03165240|DRUG|Placebo|Film-coated tablet
215067880|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
215067881|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
215067882|NCT05240157|DRUG|Corticosteroid Derivatives|observational
214486047|NCT06501924|DIETARY_SUPPLEMENT|DA-005|Oral Botanical Supplement HIF-1a inhibitor
214924725|NCT01876784|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214924726|NCT05453279|COMBINATION_PRODUCT|Delcetravir dry powder inhaler|Placebo dry powder inhaler
215067883|NCT01716039|DRUG|MTX 12.5|"once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
215067884|NCT01716039|DRUG|MTX 25|"once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
215067885|NCT01716039|DRUG|Adalimumab|Subjects will receive 18 weekly doses of adalimumab
215067886|NCT03155087|DRUG|Metformin|
215067887|NCT01879462|DRUG|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
215067888|NCT01879462|DRUG|Placebo|Visually matching GSK2878175
215067889|NCT03398642|BEHAVIORAL|French Lifestyle Redesign|Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
214672918|NCT03827148|OTHER|Pharmaceutical Care|Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
214924727|NCT03944759|PROCEDURE|serratus anterior plan block|serratus anterior plan block
215067890|NCT02348879|DRUG|AMG 403|AMG 403 is for treatment of subjects with chronic pain
215067891|NCT02348879|DRUG|Placebo|contains no active drug
214924728|NCT03425578|DIETARY_SUPPLEMENT|MSG|150 mg/kg body mass monosodium glutamate (MSG).
214924729|NCT03425578|DIETARY_SUPPLEMENT|CHO|75g CHO (i.e. dextrose)
214924730|NCT03425578|DIETARY_SUPPLEMENT|Placebo A|A non-caloric placebo composed of table salt (NaCl) and sucralose (Splenda).
214924731|NCT03425578|DIETARY_SUPPLEMENT|Placebo B|A non-caloric placebo composed of flavoured water.
214924732|NCT05501015|OTHER|Ice chips|Consuming small amounts of ice chips with supervision
214924733|NCT00783315|BEHAVIORAL|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
214924734|NCT00783315|BEHAVIORAL|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
214924735|NCT00783315|BEHAVIORAL|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
214924736|NCT03605862|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
215067892|NCT02479685|PROCEDURE|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
215067893|NCT02058316|DEVICE|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
215067894|NCT01015495|DRUG|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
214672919|NCT01505062|DRUG|SAR421869|"Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
214924737|NCT03605862|DRUG|Placebo|Placebo administered orally twice daily for five days
214924738|NCT03250767|DEVICE|Integra Titan Modular Shoulder System 2.5|Primary Shoulder Joint Replacement
214924739|NCT01194531|DEVICE|24 Chromosome Aneuploidy Screening with Parental Support|Preimplantation Genetic Screening (PGS)
214924740|NCT00818467|OTHER|Tanning spray|using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
214924741|NCT00818467|OTHER|UVB|receiving 40mJ UV-B phototherapy three times a week for four weeks
214924742|NCT03322774|BEHAVIORAL|digital Cognitive Behavioral Therapy for Insomnia|"Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment."
214924743|NCT03322774|BEHAVIORAL|face-to-face Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.
215067895|NCT01586598|BEHAVIORAL|sensory retraining protocol|"1. within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day~2. one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day~3. three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day"
215067896|NCT01179750|DEVICE|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
215067897|NCT00182715|BIOLOGICAL|cetuximab|
215067898|NCT00182715|DRUG|capecitabine|
215067899|NCT00182715|DRUG|fluorouracil|
215067900|NCT00182715|DRUG|leucovorin calcium|
215067901|NCT00182715|DRUG|oxaliplatin|
215067902|NCT01196468|OTHER|HIV test (serological or salivary)|"An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition"
215067903|NCT01196468|OTHER|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
215067904|NCT06509997|DRUG|MRG003 combined with Dalpicicilip|MRG003, intravenous infusion, D1, once every 3 weeks; Dalpicicilip, taking orally, D1-21, once every 4 weeks, maintain use until progression or emergence of intolerable toxicity.
215067905|NCT06076252|PROCEDURE|Modified Blumgart Anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
215067906|NCT06076252|PROCEDURE|conventional Blumgart anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
215067907|NCT03055325|OTHER|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
215067908|NCT01707433|OTHER|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
215067909|NCT04554966|DRUG|ABBV-382|Intravenous (IV) infusion
215067910|NCT04554966|DRUG|ABBV-382|Subcutaneous (SC) injection
215067911|NCT04554966|DRUG|Placebo for ABBV-382|Intravenous (IV) infusion
215067912|NCT04998994|DIETARY_SUPPLEMENT|wheat sprouts supplement|Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy
215067913|NCT01033006|PROCEDURE|Active Comparator: Arm 1: catheter injection|
215067914|NCT01033006|PROCEDURE|Active Comparator: Arm 2: transarterial injection|
215067915|NCT01033006|PROCEDURE|Active Comparator: Arm 3: catheter and transarterial injection|
215067916|NCT03055728|DIAGNOSTIC_TEST|Rapid strep antigen detection test|Pharyngeal swab for rapid antigen detection of streptococcus
214324559|NCT05281367|PROCEDURE|Facilitated tucking group|The Facilitated tucking position was given to 36 premature newborns in the Facilitated tucking group, from 3 minutes before to 3 minutes after the heel stick procedure. Premature newborns were kept in the facilitated tucking position by the investigator using the incubator windows without opening the incubator cover to prevent heat loss of the newborn. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
214324560|NCT05281367|PROCEDURE|Non-nutritive sucking group|36 premature newborns who were in the non-nutritive sucking group were given a silicone pacifier suitable for the week of the baby's mouth from 3 minutes before to 3 minutes after the heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
214324561|NCT05281367|PROCEDURE|Control group|"The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study.~Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP)."
214324562|NCT05766891|BEHAVIORAL|Group 1|Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery
214324563|NCT05766891|BEHAVIORAL|Group 2|Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room
214324564|NCT05766891|BEHAVIORAL|Group 3|Participants will receive standard general anesthesia and medications during surgery to control your pain.
214486048|NCT06501924|DRUG|Topical minoxidil 5%|Topical minoxidil 5%
214486049|NCT06501924|DRUG|DA-002|Topical Alpha 1 Agonist (GRAS)
215067917|NCT03055728|DIAGNOSTIC_TEST|throat culture|Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
215067918|NCT04827342|OTHER|data collection in the Ada DDSS prototype|Entry of patients' data (medical history, symptoms and findings) in the Ada DDSS prototype. The tool then automatically creates a list of possible diagnostic suggestions based on the information, which are compared with the diagnoses of the attending physician.
215067919|NCT01054131|BEHAVIORAL|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
214324565|NCT02283216|DEVICE|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
214324566|NCT02283216|DEVICE|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
214324567|NCT02283216|DEVICE|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
214324568|NCT03250728|BIOLOGICAL|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~* the endothelial permeability~* the protein C system"
214324569|NCT01101841|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
214324570|NCT01101841|DRUG|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
214324571|NCT03154619|DRUG|0.1% TR 987|TR 987 0.1%
214324572|NCT03154619|DRUG|Placebo gel|Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
214324573|NCT05780242|BEHAVIORAL|Self-questionnaire Eating Attitudes|self-diagnostic and quantitative questionnaire of 40 questions evaluating the behavior, severity and evolution of anorexia nervosa
214324574|NCT05780242|BEHAVIORAL|Situational Anxiety and Trait Anxiety|"assess anxiety as a personality trait (feelings of apprehension, tension, nervousness and worry that the subject usually feels), and anxiety as a ' emotional state linked to a particular situation"
215067920|NCT00426595|DRUG|Administration of omeprazole suspension|
215067921|NCT00426595|DRUG|omeprazole administered as a multi-unit-pellet system|
215067922|NCT05137288|DRUG|Ondansetron , atropine and bupivacaine|"Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) ."
215067923|NCT03036683|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
215067924|NCT03036683|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
214324575|NCT05780242|BEHAVIORAL|Beck Depression Inventory (BDI) scale|a diagnostic self-questionnaire allowing a quantitative estimation of the intensity of depressive symptoms in adults and adolescents
214324576|NCT05780242|BEHAVIORAL|• Post-traumatic Check List Scale|questionnaire includes 20 items, each question is to be rated between 1 and 5 depending on the intensity and frequency of symptoms during the previous month.
214324577|NCT02616250|DRUG|Brimonidine 0.33% gel (Br)|
214324578|NCT02616250|OTHER|CD07805/47 (Br) placebo gel|
214324579|NCT02616250|DRUG|Ivermectin 1% cream (IVM)|
214324580|NCT02616250|OTHER|CD5024 (IVM) placebo cream|
214324581|NCT00585065|DEVICE|CRT device implant|The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
214324582|NCT03950284|DEVICE|immediate loading with all on four technique in FFF|All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
214324583|NCT03040258|OTHER|Health-E-PALS-Pilot|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
214324584|NCT02520024|BEHAVIORAL|self-directed care|
214324585|NCT02800044|DEVICE|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
214324586|NCT04453852|BIOLOGICAL|COVID19 vaccine|COVID19 recombinant spike protein with Advax-SM adjuvant
214324587|NCT04453852|BIOLOGICAL|Saline|Saline control
214486050|NCT06501924|DIETARY_SUPPLEMENT|Placebo Oral Tablet|Placebo Oral Tablet
215067925|NCT02350166|PROCEDURE|laparoscopic surgery|laparoscopic-assisted small-incision surgery
215067926|NCT00097227|BIOLOGICAL|Cetuximab|"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."
215067927|NCT00097227|DRUG|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
215067928|NCT00097227|DRUG|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
215067929|NCT02503358|OTHER|Laboratory Biomarker Analysis|Correlative studies
215067930|NCT02503358|DRUG|Paclitaxel|Given IV
215067931|NCT02503358|OTHER|Pharmacological Study|Correlative studies
214324588|NCT04484246|OTHER|Prevalence of sarcopenia in older patient with prostate cancer|All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.
214924744|NCT03322774|BEHAVIORAL|Sleep Hygiene Education Control|Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
215067932|NCT02503358|DRUG|Selumetinib|Given PO
214324589|NCT05337059|OTHER|PEEP and Tidal Volume Titration|PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures
214324590|NCT01701466|OTHER|Aveeno cream|Twice a day
214324591|NCT01701466|OTHER|Flamazine cream|Twice a day, when there is dry desquamation
214324592|NCT01701466|OTHER|NeoVIDERM cream|Three times a day
214924745|NCT03891862|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
214924746|NCT03891862|DRUG|Placebo oral capsule|non-active dosage form
214924747|NCT05239494|DEVICE|DT1 Sphere Contact Lenses|Devices: Dailies Total 1 Sphere Contact Lenses
214924748|NCT01531530|BIOLOGICAL|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|The vaccine is mixed with salt water and given by mouth.
214924749|NCT01531530|OTHER|Placebo|Corn starch and baking soda are mixed with salt water and given by mouth.
214924750|NCT06647992|BEHAVIORAL|Nurse Navigation Program|"It is planned to provide Cervical Cancer Education and Counseling to women in the experimental group about cervical cancer. Training and counseling is planned to be implemented face to face. An information booklet will be given to the experimental group. After 30 and 60 days after the training and counseling given to the experimental and control groups, it was planned to provide online (WhatApp) training and counseling to the patients in the experimental group:~Participants will be given a contact number that they can reach during the day when they want to receive counseling about HPV-DNA or Pap smear. Interviews will be scheduled between 08.00-20.00.~Individuals who are not screened will receive a reminder message by phone on the 45th and 75th day. Transtheoretical Model In the study, interventions will be planned for the experimental group according to the stages of the transtheoretical model.~The researcher will conduct motivational interviews with the individuals."
214924751|NCT02370589|BIOLOGICAL|Base Dose EBOV GP Vaccine|
214924752|NCT02370589|BIOLOGICAL|2x Base Dose EBOV GP Vaccine|
214924753|NCT02370589|BIOLOGICAL|4x Base Dose EBOV GP Vaccine|
214924754|NCT02370589|BIOLOGICAL|8x Base Dose EBOV GP Vaccine|
214924755|NCT02370589|BIOLOGICAL|Placebo|
214924756|NCT02370589|BIOLOGICAL|Matrix-M Adjuvant|
214924757|NCT01053962|DRUG|SP-304 0.3 mg|SP-304 0.3 mg
214924758|NCT01053962|DRUG|SP-304 1.0 mg|SP-304 1.0 mg
214924759|NCT01053962|DRUG|SP-304 3.0 mg|SP-304 3.0 mg
214924760|NCT01053962|DRUG|SP-304 9.0 mg|SP-304 9.0 mg
214924761|NCT01053962|DRUG|Placebo|Placebo
214924762|NCT05763394|OTHER|Polarized workout program|Polarized workout lasting approximately 40 minutes (two sessions/day, 5 days a week), characterized by a 5-minute warm-up performed at 50% of the peak V'O2, followed by 3 sets of 2 minutes at 95% of peak V'O2, interspersed with 1 minute of recovery at 40% of peak V'O2, followed by 30 minutes of moderate activity at 60% of V'O2 peak. Total of 24 sessions in 12 days.
214924763|NCT05763394|OTHER|High intensity workout program|High intensity workout (HIIT) (two sessions/day, 5 days a week), characterized by a 10-minute warm-up performed at 50% of peak V'O2 , followed by 6 series of 40 s of high-intensity walking corresponding to 95% of peak V'O2, interspersed with 5 minutes of walking at 40% of peak V'O2, ending with 5' of cool-down at 50% of the peak V'O2. Total of 24 sessions in 12 days.
214924764|NCT03928262|BIOLOGICAL|Benralizumab|Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.
214924765|NCT01298726|OTHER|PHARMACEUTICAL CARE|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
214924766|NCT01298726|OTHER|HEALTH USUAL CARE|Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
214924767|NCT03373994|DIAGNOSTIC_TEST|18F-FDG PET/CT initial-time imaging|18F-FDG intravenous bolus injection after a fasting perid of more than 6 hours, simultaneously,PET/CT imaging using one bed lasting 5 minutes was underwent.
214924768|NCT03373994|DIAGNOSTIC_TEST|18F-FDG PET/CT balanced-time imaging|18F-FDG intravenous injection after a fasting perid of more than 6 hours. After 60 minutes, PET/CT imaging using 6-7 bed positions each lasting 2 minutes was underwent.
214924769|NCT00493662|DRUG|Polyethylene Glycol 400 0.4%|
214924770|NCT00493662|DRUG|Propylene Glycol 0.3%|
214924771|NCT00493662|DRUG|0.15% sodium Hyaluronate|
214924772|NCT00493662|DRUG|sodium chloride|
214924773|NCT00493662|DRUG|sodium phosphate monobasic|
214924774|NCT05210465|OTHER|speckle tracking mode of the stress ECHO test with dobutamine|speckle tracking mode of the stress ECHO test with dobutamine
214924775|NCT04303026|DRUG|Zoledronic Acid|5mg IV infusion
215067933|NCT05920681|PROCEDURE|Transanal irrigation|The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - d it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
215067934|NCT05920681|COMBINATION_PRODUCT|Best supportive care|Diet modification, Loperamidum if needed, diapers, etc.
215067935|NCT02118181|DIETARY_SUPPLEMENT|HMB|
215067936|NCT05175222|RADIATION|Laser therapy|Patients receive laser therapy in 7 points in oral cavity every day from the first day of conditioning chemotherapy till the second day post HSCT. Each point is irradiated for 1 minute.
214486051|NCT06501924|OTHER|Placebo Topical Solution|Placebo Topical Solution
215067937|NCT03420495|BEHAVIORAL|Decision-Making Tasks|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
215067938|NCT03081819|DRUG|SH003|Herbal medicine for cancer treatment
214486052|NCT06700187|OTHER|Interrupting sitting with walking breaks|Participants will engage in 27 minutes walking in different frequencies, including short breaks (walk 1 minute every 10 minutes), moderate breaks (walk 3 minutes every 30 minutes), and long breaks (walk 27 minutes in one time during the intervention).
214486053|NCT00638898|DRUG|busulfan|Given IV
214486054|NCT00638898|DRUG|melphalan|Given IV
215067939|NCT01851265|DRUG|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
215067940|NCT01851265|OTHER|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
215067941|NCT01851265|OTHER|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
215067942|NCT01851265|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
215067943|NCT04089241|OTHER|Contrast 3D Ultrasound|an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
214924776|NCT04303026|DRUG|Saline 0.9%|Placebo Group. Saline 0.9% 100 ml infusion
214924777|NCT02772874|OTHER|No intervention|No intervention
214924778|NCT01785225|DEVICE|A product type of the modified commercial drape Tegaderm (R)|We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
214924779|NCT01839617|DIETARY_SUPPLEMENT|Early parenteral nutrition|
215067944|NCT05099055|DRUG|Dexmedetomidine 0.004 MG/ML [Precedex]|Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
215067945|NCT05099055|DRUG|Opioids|Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
215067946|NCT03713398|BEHAVIORAL|T4C-SMI|T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
214324593|NCT05117827|DEVICE|Power Wheelchair Standing Device|A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
214924780|NCT01839617|DIETARY_SUPPLEMENT|Late parenteral nutrition|
215067947|NCT04348565|OTHER|Diabetes Care Programme|20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
215067948|NCT00774839|BEHAVIORAL|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
214324594|NCT01088516|DRUG|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
214324595|NCT04898218|OTHER|Exercise|The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
214324596|NCT03944122|DEVICE|ultrasound|therapeutical ultrasound were applied to the patients
214324597|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 1|5.0 e5/ kg CD19-BCMA CAR-T positive T cells
214324598|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|1.5 e6/ kg CD19-BCMA CAR-T positive T cells
214324599|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|5 e6/ kg CD19-BCMA CAR-T positive T cells
214324600|NCT04485559|DRUG|Everolimus|Given PO
214924781|NCT03269617|DIETARY_SUPPLEMENT|Bacteriophage mixture|Four bacteriophage strains: LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae.
214924782|NCT03269617|OTHER|Placebo Control|Placebo control capsule consisting of rice maltodextrin
214924783|NCT02012842|OTHER|Non surgical periodontal treatment|Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
214924784|NCT01329809|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
214924785|NCT03360409|PROCEDURE|ACD|Undertake anterior cervical discectomy without fusion
214924786|NCT03360409|PROCEDURE|ACDF|anterior cervical discectomy with fusion
214924787|NCT03360409|PROCEDURE|ACDA|anterior cervical discectomy with arthroplasty
214924788|NCT05785585|DIETARY_SUPPLEMENT|Methylcobalamin|Treatment with Methylcobalamin during 12 weeks
214924789|NCT05785585|DIETARY_SUPPLEMENT|Cyanocobalamin group|Treatment with Cyanocobalamin during 12 weeks
214924790|NCT05785585|DIETARY_SUPPLEMENT|Control group|Treatment with microcrystalline cellulose during 12 weeks
214924791|NCT03580109|OTHER|Immediate spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
214924792|NCT03580109|OTHER|Late spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
215067949|NCT01941979|DRUG|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
215067950|NCT00925106|DRUG|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
215067951|NCT00925106|DRUG|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
215067952|NCT00925106|DRUG|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
215067953|NCT00925106|DRUG|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
215067954|NCT00623233|DRUG|Gemcitabine|Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
215067955|NCT00623233|DRUG|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
215067956|NCT01748812|DRUG|Osteomalacia|
215067957|NCT05566691|OTHER|Positive thinking|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
214924793|NCT02966678|PROCEDURE|Color Vision Test|Farnsworth Panel D15/Hue test plus Ishihara charts
214924794|NCT01690728|BEHAVIORAL|Physical Activity|The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
214924795|NCT04871061|PROCEDURE|PENG Block|Pericapsular Nerve Group Block
214486055|NCT00638898|DRUG|topotecan hydrochloride|Given IV
214924796|NCT04871061|DRUG|Conventional opioid analgesia (Fentanyl)|standardised intravenous opioid
214924797|NCT06407661|OTHER|"Disaster Nursing course/education"|"In this study, the Disaster Nursing course, which was integrated into the nursing curriculum, was an elective course, and it was carried out as a theoretical course for two hours a week. The topics in the content of this course regarding prevention, preparedness, response and recovery stages were designed in line with Jennings Disaster Nursing Management Model. The purpose of its development was to educate students on disaster management and disaster nursing. The course content included identification of risks and resources for disasters at the primary protection level, nurse's caregiver (triage and holistic care) and case manager role at the secondary protection level, reassessment of individuals' care needs at the tertiary level, and review of education and the current disaster plan at the protection level."
214924798|NCT02648893|OTHER|Multiple biofortified food crops (MBFC-Exp)|Meals from three biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.
214924799|NCT02648893|OTHER|Commercially available non-fortified food crops (MBFC-C)|This arm will consume meals based on three commercially available (non-biofortified) food crops three times per day, six days per week, for 9 months.
215067958|NCT05566691|OTHER|Positive thinking + Mood induction|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
215067959|NCT05566691|OTHER|Thought reevaluation|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.
215067960|NCT05566691|OTHER|Thought reevaluation + Mood induction|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
215067961|NCT05852652|DEVICE|cryolipolysis and aerobic exercise|"the patients in this arm adjusted low calorie diet . According to the Recommended Dietary Intake (RDI), the low-calorie diet plan with three carefully calculated meals had a balanced macronutrient quantity of carbohydrate and protein, was low in fat, and was abundant in fruits, vegetables, and dietary fibres.~they got two cryolipolysis sessions,one session in the month ,they got two sessions in two months,then took our outcome measures with walking 60 minutes in the park"
214924800|NCT03699462|DRUG|Plasma solution-A injection|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
214924801|NCT03699462|DRUG|5% Albumin|The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
214924802|NCT03931473|OTHER|Bed nets|Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
215067962|NCT00345566|PROCEDURE|Nutrition composition|
214486056|NCT00638898|OTHER|laboratory biomarker analysis|Correlative studies
214486057|NCT00638898|BIOLOGICAL|filgrastim|Given IV or subcutaneously
214486058|NCT00638898|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transplantation
214486059|NCT00638898|OTHER|pharmacological study|Correlative studies
214486060|NCT00638898|PROCEDURE|autologous bone marrow transplantation|Undergo transplantation
214924803|NCT03212092|DIETARY_SUPPLEMENT|Multivitamin, mineral & n-3 FA|The 2 multi vitamin capsules with the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
215067963|NCT01811485|DRUG|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
215067964|NCT01811485|DRUG|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
215067965|NCT01811485|DRUG|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
215067966|NCT01545934|BEHAVIORAL|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
214924804|NCT03212092|DIETARY_SUPPLEMENT|Placebo|The placebo of the multi vitamin capsules and the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
215067967|NCT03654404|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
215067968|NCT02767726|DEVICE|non-invasive multimodal imaging|
215067969|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
215067970|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
215067971|NCT02581046|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
215067972|NCT02003638|DRUG|Niacin|Niacin titrated to 6000 mg daily
215067973|NCT02003638|DRUG|Placebo|Placebo provided in the same pill quantity as niacin arm
215067974|NCT03299205|BEHAVIORAL|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
215067975|NCT03215758|DRUG|QAW039|QAW039 once daily
214324601|NCT04485559|DRUG|Trametinib|Given PO
215067976|NCT03215758|DRUG|Placebo|Placebo once daily
214924805|NCT00937040|DRUG|OROS MPH|Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
214924806|NCT00937040|DRUG|Placebo|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
214324602|NCT06784167|OTHER|Non-Interventional Study|Non-interventional study
214324603|NCT05181033|DRUG|Lenvatinib + Letrozole|"Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity.~Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities.~Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled.~Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing.~For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake.~There is no dose modifications for letrozole."
214924807|NCT00937040|DRUG|OROS MPH Tablets|Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
214924808|NCT00937040|DRUG|Placebo Tablets|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
215067977|NCT02991794|DEVICE|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
215067978|NCT02182206|DRUG|BIBF 1120|
215067979|NCT04240041|DIAGNOSTIC_TEST|Transcerebellar diamater|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.
215067980|NCT04240041|DIAGNOSTIC_TEST|Placental thickness|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
215067981|NCT04224636|COMBINATION_PRODUCT|Atezolizumab Injection, Bevacizumab Injection|Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE
215067982|NCT04115748|DRUG|Filgotinib|Tablets administered orally once daily with or without food
215067983|NCT04115748|DRUG|Adalimumab|Injection administered subcutaneously once every 2 weeks
214324604|NCT05181033|DRUG|Fulvestrant|Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
215067984|NCT04115748|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food
215067985|NCT04115748|DRUG|Placebo to match adalimumab|Injection administered subcutaneously once every 2 weeks
215067986|NCT00808613|DEVICE|Optetrak PS|Optetrak Posterior Stabilized total knee replacement
215067987|NCT00808613|DEVICE|Optetrak Hi-Flex|Optetrak Hi-Flex total knee replacement
215067988|NCT03418311|DEVICE|Cervical Pessary-Group|Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
215067989|NCT00713349|DRUG|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
214924809|NCT01747889|DEVICE|electronic chest drainage system|"Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.~On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients"
214924810|NCT02657057|DEVICE|PTNS|The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
214924811|NCT02657057|DEVICE|TENS SNS|Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
214924812|NCT03431025|DEVICE|Wearable sensors and biofeedback|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
214924813|NCT05104216|BIOLOGICAL|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
214924814|NCT03898479|DRUG|CTP-543|Twice daily dosing
215067990|NCT00713349|OTHER|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
215067991|NCT03478475|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|
215067992|NCT03478475|OTHER|Placebo|Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
215067993|NCT04245670|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
215067994|NCT02363361|DRUG|Imatinib|Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day
215067995|NCT02319161|DRUG|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
215067996|NCT05295901|DEVICE|mKOAH application|mobile app installed group
214324605|NCT03940508|BEHAVIORAL|Making Connections Intervention|The MCI is a one to two session intervention that addresses barriers to mental health treatment and helps adolescents build skills to get the most out of their treatment experience. It is designed to be delivered by a trained clinician in conjunction with an evidence-based treatment.
214324606|NCT03940508|BEHAVIORAL|IPT-A|IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
214924815|NCT01858779|BEHAVIORAL|Measurement of peripheral pulse|All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.
214324607|NCT03633396|BIOLOGICAL|Imsidolimab|Administered by subcutaneous injection once a month
214924816|NCT01858779|DEVICE|72h holter ECG|All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
214924817|NCT03078179|DIETARY_SUPPLEMENT|Commercial Dairy Cow Milk|After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) for 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
215067997|NCT00881998|PROCEDURE|Minimally Invasive Total Hip Arthroplasty|
215067998|NCT00881998|PROCEDURE|Conventional Total Hip Arthroplasty|
214486061|NCT06875570|OTHER|Pliometric Training|The full intervention program will cover 12 weeks in the season. Prior to training, players will be instructed to warm-up for ten minutes with general running exercises and dynamic stretching. The plyometric training intervention will consist of 5 exercises performed in the following order: Leap forward and backward on the line, leap sideways on the line, double leg knee to chest, split squat jump, and squat jump (Bavli, 2012). A volleyball coach will monitor the whole training.
214924818|NCT03078179|DIETARY_SUPPLEMENT|Commercial Cow Milk with Probiotic|The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics. They will drink the milk with probiotic for 3 months. Clinical and microbiological testing of saliva will be performed. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
214924819|NCT05550987|OTHER|Rehabilitation program with the use of mechanical vibration using the Vibramoov device and conventional physiotherapy|The Vibramoov device (Techno Concept, France) will be used in the rehabilitation program. Before starting the training session, each subject will undergo a diagnosis in order to qualify for the use of Functional Proprioceptive Vibration. Before starting the therapy, pads are placed on the patient's body to fix the vibrating modules in the places to be treated (lower limbs, left upper limb or right upper limb). Then the vibrating modules are attached to the supports. The therapy carried out with the use of the Vibramoov device consists in the targeted and individualized stimulation of the nervous system, as in the course of natural movements of the upper or lower limbs with the use of visual biofeedback. Therapy with the use of the Vibramoov device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
215067999|NCT05659407|DRUG|Belimumab in SLE patients / Rituximab in RA patients|Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
214924820|NCT05550987|OTHER|Rehabilitation program with gait training using the Ekso GT exoskeleton and conventional physiotherapy|The Ekso GT ™ exoskeleton (Ekso Bionics, Inc. Richmond, CA, USA) used in the rehabilitation program has been approved by the Food and Drug Administration (FDA). Before starting the training session, each subject will undergo a thorough diagnosis to individually adjust the bionic skeleton. After entering the patient's data into the device's software, the physiotherapist selects the optimal training parameters. As the patient progresses during the training unit, the therapist will update the exoskeleton settings on an ongoing basis, so that the training is best suited to the current capabilities of the subject. Therapy with the use of the exoskeleton device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
215068000|NCT03764631|DRUG|Empagliflozin|Drug
215068001|NCT03764631|DRUG|Dipeptidyl-peptidase 4 (DPP-4) inhibitors|Dipeptidyl-peptidase 4 - Drug
215068002|NCT02969291|BEHAVIORAL|Reduced Sedentary Time Intervention (RSTI)|Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
215068003|NCT02958891|OTHER|Data collection|Collection epidemiological dental measures
215068004|NCT01200407|DRUG|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
215068005|NCT03299881|DEVICE|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
215068006|NCT03299881|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
215068007|NCT00006253|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
214324608|NCT03633396|DRUG|Placebo|Administered by subcutaneous injection once a month
214324609|NCT01012817|OTHER|Laboratory Biomarker Analysis|Correlative studies
214324610|NCT01012817|OTHER|Pharmacogenomic Study|Correlative studies
214324611|NCT01012817|OTHER|Pharmacological Study|Correlative studies
214324612|NCT01012817|DRUG|Topotecan Hydrochloride|Given IV
214324613|NCT01012817|DRUG|Veliparib|Given PO
214924821|NCT05550987|OTHER|Rehabilitation program with the use of gait training with the use of a RoboGait stationary robot and conventional physiotherapy.|The RoboGait stationary robot (Bama technologist, Turkey) will be used in the rehabilitation program. Before starting the training session, each subject will undergo detailed diagnostics in order to individually adjust the orthoses. The next step will be to put on a vest and inguinal straps on a wheelchair or standing, and then lift it up with the device, then attach it to the Robogait orthoses. After entering the patient's data into the software of the device, the physiotherapist selects the optimal training parameters. During the session, biofeedback is also displayed informing the patient and the therapist about the patient's activity level in the transfer phase and the support during walking for both lower limbs. Therapy with the use of the RoboGait device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
214924822|NCT05550987|OTHER|Rehabilitation program with the use of gait training with the use of the ZEBRIS treadmill and conventional physiotherapy|The Zebris FDM-T treadmill will be used in the rehabilitation program for gait analysis. Before each session, patients will be equipped with a harness for safety reasons. The need for a handrail will be assessed prior to each session and patients will be encouraged to support their hands as little as possible. Before starting the training session, each subject will undergo a thorough diagnosis in order to individually adjust the training parameters. Therapy with the use of the Zebris FDM-T treadmill will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
214924823|NCT05550987|OTHER|Rehabilitation program with the use of upper limb function training with the use of the PABLO device and conventional physiotherapy|The Pablo (Tyromotion) device will be used in the rehabilitation program. Before the start of the training session, each subject will undergo detailed diagnostics assessing the range of mobility in the shoulder, radiocarpal (frontal and sagittal plane), elbow (sagittal plane), and explosive strength of the cylindrical, pinch and lateral and three-point grip. The Force Control Index will also be designated. The next stage will be training on the Pablo device using visual and auditory biofeedback. The physiotherapist selects the optimal training parameters (type of pad, type of game, level of the game). Each training session will be stored in the software and recorded in the patient's medical records. Therapy with the use of the Pablo device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
214924824|NCT05550987|OTHER|Control Group|In control Group the rehabilitation program will be carried out for a period of 4 weeks. In each of the studied groups, the rehabilitation program will include conventional physiotherapy sessions performed 5 times a week, consisting of 50 minutes a day of individual physiotherapy and 50 minutes a day of standing upright.
214924825|NCT01125670|DRUG|YM150|oral
214924826|NCT00004638|PROCEDURE|pathogenesis study|
214924827|NCT02573558|DRUG|Dexmedetomidine|
214924828|NCT02573558|DRUG|Propofol|
214924829|NCT06452836|OTHER|Green color exposure|Patients will wear green colored glasses before and during the surgery.
215068008|NCT00006253|BEHAVIORAL|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
215068009|NCT01549886|DRUG|Y-90-Zevalin|Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
214924830|NCT06452836|OTHER|Red color exposure|Patients will wear red colored glasses before and during the surgery.
215068010|NCT01549886|DRUG|Moxtezafin Gadolinium|"Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m\^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily"
215068011|NCT01549886|DRUG|Rituximab|Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion
215068012|NCT01505673|DRUG|Liraglutide|Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
215068013|NCT01505673|DRUG|Saline|Placebo injection of 1.8mg saline once daily for 6-months
214924831|NCT06452836|OTHER|Blue color exposure|Patients will wear blue colored glasses before and during the surgery.
214924832|NCT06452836|OTHER|control|Patients will wear translucent glasses before and during the surgery.
214924833|NCT06390514|OTHER|vibrating floor|activities with vibrating floor
214924834|NCT06390514|OTHER|No vibrating floor|activities without vibrating floor
215068014|NCT01390831|DEVICE|THERMOCOOL® Catheter|Catheter-based renal denervation
215068015|NCT05985993|DEVICE|low-intensity transcranial ultrasound stimulation (TUS)|The rTUS was administered using an immersion-type focused ultrasound transducer (V391-SU, Olympus NDT, Waltham, USA). Low-intensity transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
215068016|NCT04301479|DRUG|hydrocortisone sodium succinate|Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
214324614|NCT03015077|DIETARY_SUPPLEMENT|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
214924835|NCT03033927|DIAGNOSTIC_TEST|CTC isolocation and analysis|Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
214924836|NCT06679049|PROCEDURE|micromotion intramedullary nail cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal tibial interlocking screw
214924837|NCT06679049|PROCEDURE|standard intramedullary nail cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal interlocking screw
214924838|NCT06578013|OTHER|acupressure ice massage|"* It will be used for participants in group (A), 2 cm diameter circular ice pieces will be placed inside plastic bags and covered with a thin gauze to prevent moisture transmission and direct ice contact with the skin to apply ice massage.~* Ice massage will carried out rotationally each 1 minute (30 seconds clockwise and 30 seconds counterclockwise) on L14 point for 10 minutes and on SP6 point for another 10 minutes."
214924839|NCT06578013|OTHER|pelvic rocking exercises|"* Pelvic rocking exercise will be used for all participants in both groups (A \& B).~* Each participant will be encouraged to lie down on her back on matrix with a pillow under head then bend her knees and keep her foot flat on the floor and place one hand under curve of her back and the other hand on the top of. her abdomen then tighten buttocks and abdominal muscles simultaneously. After that each participant will be encouraged to inhale and hold (1-2-3-4) then exhale and hold 4-3-2-1 then relax muscles and feel her back flat on the underneath hand. Finally, each participant will be encouraged to repeat the last two steps about 10 times each session.~* The exercise will be repeated for 15times/ session, 3 times /week, for 3 successive menstrual cycles."
214924840|NCT02454816|DEVICE|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
214924841|NCT02454816|DEVICE|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
214924842|NCT04037475|DEVICE|photodynamic therapy herpes labialis|Patients will receive Photodynamic Therapy (PDT), irradiations will be performed with the Laser Duo® red laser diode (MMOptics, São Carlos, SP, Brazil) with a wavelength of 660 nm, with a power of 100 mW, the energy density of 300 J / cm², with energy of 3 J in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each isolated lesion that presents with fixed energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. All treatment proposed in group 1 (simulation of PDT + delivery of aciclovir cream) in each patient will be concluded in a single session. Treatment for group 2 (PDT + placebo cream) will also be completed in a single session. All possible adverse effects will be noted and qualified during the treatment protocol and maintenance period (3/3 months) using the questionnaire developed for this protocol.
214924843|NCT03053791|PROCEDURE|Deep brain stimulation in mesencephalic locomotor region|Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait
214924844|NCT03053791|DEVICE|Implantation of a Deep brain stimulation system|Implantation of a Medtronic Percept PC Impulse Generator for chronic Stimulation of the selected target.
215068017|NCT04301479|DRUG|Saline|Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
215068018|NCT04225052|DRUG|YHP1903|YHP1903 Tab. 1mg
215068019|NCT04225052|DRUG|Champix|Comparator Champix Tab. 1mg
215068020|NCT04613557|BIOLOGICAL|CYAD-211|Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
215068021|NCT04613557|DRUG|Endoxan|Preconditioning chemotherapy
215068022|NCT04613557|DRUG|Fludara|Preconditioning chemotherapy
215068023|NCT02599207|BIOLOGICAL|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
215068024|NCT03859440|DEVICE|DSiHy Silicone hydrogel soft contact lens|•Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.
215068025|NCT03859440|DEVICE|CE-marked Silicone hydrogel soft contact lens|"・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay"
214324615|NCT03015077|DIETARY_SUPPLEMENT|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
214324616|NCT03015077|RADIATION|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
214324617|NCT04612179|DEVICE|The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system|"Investigational device: SUPRAFLEX CRUZ™ Sirolimus eluting Coronary Stent System The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system consists of a balloon ex-pandable Sirolimus eluting stent, premounted on a stent delivery system. The active pharmaceutical ingredient in the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent is Sirolimus (also known as Rapamycin).~The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system is indicated for improving coronary luminal diameter in patients with symptomatic Ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions in native coronary arter-ies with a reference vessel diameter of 2.00 mm to 4.50 mm."
214324618|NCT06096324|BEHAVIORAL|Job announcements plus HIV prevention text messages, educational sessions, economic resources, and mentoring.|Participants will receive job announcements plus HIV prevention text messages, educational sessions, economic resources, and mentoring.
214924845|NCT03943069|PROCEDURE|Thoracoscopic bullectomy alone|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.
214924846|NCT03943069|PROCEDURE|Thoracoscopic bullectomy with pleurodesis|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.in addition to mechanical pleurodesis.
214924847|NCT05577013|OTHER|kinesiotaping|It will be applied by kinesiotape certified physiotherapist on tendons in the direction of extensor muscle to facilitate range of motion by stretching 50%. At first it will be applied on extensor pollicis longus and extensor pollicis brevis muscles of hand, extensor digitorum and extensor indicis of last 4 fingers of hand. Triceps brachii in arm and Supraspinatus and Infraspinatus muscles to stabilize the gelnohumeral joint
214924848|NCT05577013|OTHER|motor relearning program|Stacking up blocks Stacking up polystyrene cups Folding piece of cloth Using cutlery Pouring water into glass Closing/opening lid of bottles turning the pages of books or newspaper writing on paper Squeezing of ball Coloring in different shapes
214924849|NCT01204684|BIOLOGICAL|autologous tumor lysate-pulsed DC vaccination|
214924850|NCT01204684|BIOLOGICAL|Tumor lysate-pulsed DC vaccination+0.2% resiquimod|
214924851|NCT01204684|BIOLOGICAL|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC|
214924852|NCT00449358|PROCEDURE|apply methyl-ALA cream|
214924853|NCT02294396|DRUG|Mirabegron tablet|orally administered at a dose of 1 tablet once daily after breakfast
214924854|NCT02294396|DRUG|Solifenacin tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
214924855|NCT02294396|DRUG|Propiverine tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
214924856|NCT02294396|DRUG|Imidafenacin tablet|orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
214924857|NCT02294396|DRUG|Tolterodine capsule|orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
214924858|NCT03179020|OTHER|Checklist use|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
214924859|NCT03179020|OTHER|Usual care|Management of the potential donor according usual care.
214924860|NCT03835624|DIAGNOSTIC_TEST|interleukin 33|serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
214924861|NCT03243669|DIAGNOSTIC_TEST|High-definition|High-definition colonoscopy
214924862|NCT03243669|DIAGNOSTIC_TEST|Virtual chromoendoscopy|Virtual chromoendoscopy
215068026|NCT01152255|DRUG|MK6186|Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose \<= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose \<= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)
215068027|NCT01152255|DRUG|Comparator: Placebo|Placebo tablets taken orally for seven day
215068028|NCT01628679|BEHAVIORAL|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
214924863|NCT03243669|DIAGNOSTIC_TEST|Standard|Standard colonoscopy
215068029|NCT05049707|DRUG|IV magnesium sulfate|15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
214924864|NCT03125538|OTHER|Motor Imagery|"Together with physical rehabilitation performed with physiotherapists, participants from the experimental group will mentally rehearse 3 different locomotor exercises that they already physically performed beforehand.~Exercise 1: 10m Walk~Exercise 2: Timed Up and Go test (rise up from a chair, walk 3 meters, turn around, come back to the chair, turn around and sit down)~Exercise 3: Stairs climbing test (climb up 4 stairs, turn around, climb down the for stairs)~Two min of MIP will be scheduled 5 times/day, during rest periods, so that patients complete 10min of MIP per day."
215068030|NCT05049707|OTHER|Placebo|500 cc normal saline delivered in equivalent rates as the treatment group
215068031|NCT00733837|OTHER|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
215068032|NCT00473668|BIOLOGICAL|Zilbrix-Hib|Intramuscular injection, 1 dose
215068033|NCT00473668|BIOLOGICAL|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
215068034|NCT04220242|OTHER|Video recordings with analysis thereafter applied|Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis
215068035|NCT04220242|OTHER|Examination of microsections of tissue excised for the purposes of cancer resection|Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution
215068036|NCT04220242|OTHER|Cancer organoid development and testing|Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer
215068037|NCT01588340|PROCEDURE|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
215068038|NCT01588340|PROCEDURE|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
215068039|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os until proven disease progression
215068040|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
214924865|NCT03125538|OTHER|Control Task|"Together with physical rehabilitation performed with physiotherapists, participants from the control group will spend equivalent time focusing on a cognitive task without impact on motor rehabilitation ((word scramble game).~Two min of this cognitive task will be scheduled 5 times/day, during rest periods, so that patients complete 10min of control task per day."
214924866|NCT04559438|OTHER|Rotary Neoniti GPS file|Glide path creation will be achieved using Neoniti GPS file (15/.03). The file will be introduced passively inside the canal, in continuous rotation at a constant speed between 300 and 500 rpm and torque of 1.5 N.
214924867|NCT04559438|OTHER|Manual stainless steel K-files|Glide path preparation will be done by hand instrumentation using K-files #10 and 15.
215068041|NCT01131429|DRUG|Cisplatin|cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
215068042|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
215068043|NCT01131429|DRUG|Cisplatin|Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
214324619|NCT06096324|BEHAVIORAL|Job announcements|Participants will receive job announcements only.
214924868|NCT02154503|DEVICE|topical 5% Minoxidil (Microneedling)|
215068044|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os as second-line treatment
215068045|NCT05699252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention will be used to help participants learn about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
215068046|NCT05699252|BEHAVIORAL|Hypnotic Cognitive Therapy (HYP-CT)|The HYP-CT intervention will be used to help participants learn about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
215068047|NCT05699252|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will be used to help participants learn about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
215068048|NCT03153644|BEHAVIORAL|Interview|1 hour semi-structured
215068049|NCT03153644|BEHAVIORAL|Observation|Field Observation
215068050|NCT00724269|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
215068051|NCT00724269|DEVICE|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
215068052|NCT01991080|BEHAVIORAL|biofeedback|Patients will go through biofeedback sessions
215068053|NCT01991080|DRUG|Wheatgerm juice|Patient will drink wheatgerm juice
214324620|NCT02307578|DRUG|Perampanel|Perampanel will be available in 2-milligrams (mg), 4-mg and 8-mg tablets and as 0.5 milligram per milliliter (mg/mL) oral suspension. Participants will start this EAP with the dose that they were receiving at the end of their participation in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401. Doses of perampanel can be adjusted based on clinical judgment.
214324621|NCT05683171|DRUG|Rituximab|Given by IV (vein)
214924869|NCT06685406|DIAGNOSTIC_TEST|Thorathic fluid content measurement by cardiometry|Thorathic fluid content measurement by using cardiometry
214924870|NCT02120833|DEVICE|EpiCeram® Skin Barrier Emulsion|Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
215068054|NCT05281328|DRUG|CAM2029|SC injection using a pre-filled pen
215068055|NCT05281328|DRUG|Placebo|SC injection using a pre-filled pen
215068056|NCT03195660|DEVICE|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
215068057|NCT00961246|BEHAVIORAL|general health information|participants received general health information
215068058|NCT00961246|BEHAVIORAL|individually-tailored intervention|participants received individually-tailored intervention
215068059|NCT03713294|DRUG|Dexamethasone|Given IV and PO
215068060|NCT03713294|BIOLOGICAL|Elotuzumab|Given IV
215068061|NCT03713294|DRUG|Pomalidomide|Given PO
215068062|NCT05260073|DRUG|Tirbanibulin|Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.
215068063|NCT03458910|BEHAVIORAL|HRV training|Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
214924871|NCT02120833|DRUG|Colloidal Oatmeal Cream|Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
214924872|NCT01386398|DRUG|bortezomib|
214924873|NCT01386398|DRUG|vorinostat|
214924874|NCT01386398|OTHER|laboratory biomarker analysis|
214924875|NCT04764981|OTHER|Essence oils|Consists in olfactory training using essence oils
214924876|NCT03831464|DRUG|Metformin Hydrochloride|"The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment ."
214924877|NCT03831464|DRUG|Placebo Oral Tablet|The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
214924878|NCT05026437|OTHER|Cardiac surgery score and APACHE II scoring|Cardiac surgery score and APACHE II will calculated on the first postoperative day.
214924879|NCT05845021|COMBINATION_PRODUCT|Surgeon-Initiated Bone Health Referral Pathway|Described in arm description
214924880|NCT03282721|PROCEDURE|precise location of commissure|
214924881|NCT01366703|DEVICE|implantable loop recorder Medtronic reveal XT Full view|Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
214924882|NCT06685315|OTHER|Participants fill out the questionnaire|Participants fill out the questionnaire
214924883|NCT01363245|BEHAVIORAL|Telephone Counseling|Telephone counseling: 7 calls over 6 weeks
214924884|NCT01363245|BEHAVIORAL|Fax-to-quit|referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
214924885|NCT03468413|DRUG|CP1050 or Placebo|Randomised, double-blinded, placebo-controlled
214924886|NCT03502070|DRUG|Placebo|One dose (4 capsules) of placebo
214924887|NCT03502070|DEVICE|Tobi Podhaler|The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use
214924888|NCT05890989|DIAGNOSTIC_TEST|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT OF THE PARTICIPANTS WAS MADE.
214924889|NCT05346315|OTHER|RDN Medical Nutrition Therapy|The RDNs will provide bi-monthly nutrition care, counseling, and dietary recommendations for a 6-month intervention, delivered either in-person or via telehealth, to the grocery store patrons during the study intervention. The RDN will provided care to the participant based upon the participant's unique dietary and nutritional needs. The RDN will provide nutrition recommendations and create meal plans via NutriStyle for the participants to follow. The meal plans will be uploaded into the grocery store's E-commerce shopping platform, which the participant can utilize to purchase foods that are needed to follow the RDNs nutrition recommendations for an individual person.
214924890|NCT03466203|BIOLOGICAL|LLF580|LLF580 300mg
214924891|NCT03466203|DRUG|Placebo|Placebo to LLF580
214924892|NCT06597448|BEHAVIORAL|Cognitive Behavioral Therapy for Postpartum Depression (PPD)|Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). The intervention consists of 9- 2hr sessions, the first half involves teaching and practice of CBT skills (cognitive restructuring, thinking errors, problem solving etc) followed by one hour of unstructured discussion around topics relevant to participants with Postpartum Depression (PPD) (sleep, supports, transitions, etc). Each group will be delivered by one randomly selected PHN and one randomly selected peer using our intervention manual.
214924893|NCT04937933|DRUG|Coolant spray (Cryos ®Spray, Phyto Performance, Italy)|The coolant spray treatment method is a cryotherapy non-pharmacological treatment choice.
214924894|NCT04937933|DRUG|Saline solution|saline solution
214924895|NCT03417089|PROCEDURE|Falciform ligament suspension|routine of falciform ligament suspension during Mini gastric bypass
214924896|NCT03417089|PROCEDURE|no suspension|working without of falciform ligament suspension during Mini gastric bypass
214924897|NCT04028869|DRUG|Glycyrrhizic acid preparation|To analyze the clinical effect of glycyrrhizic acid preparation for autoimmune liver disease for 144 weeks and the safety during treatment
214924898|NCT02594904|DRUG|Yinzhihuang Oral Liquid|All the four groups will be given same treatment as being described in arm description.
214924899|NCT05927740|DIAGNOSTIC_TEST|Optic coherence tomography|Every participant was subjected to a comprehensive ophthalmologic examination which included measuring auto-refraction (average of three values, Topcon Autorefractometer model KM 8900, Japan), uncorrected visual acuity with cycloplegic refraction (with 0.5% cyclopentolate HCl), and IOP in millimeters of mercury (mmHg, Goldmann applanation tonometer). Moreover, slit-lamp biomicroscopy (HaagStreit, Bern, Switzerland) was performed, concentrating on potential corneal scarring and/or lenticular opacities.
214924900|NCT03189667|DEVICE|Vessel preparation with angioplasty|"Vessel preparation with Pre dilatation:~* All lesions to be predilated with high pressure balloons until waist is obliterated.~* At least two minutes dilatation.~* Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~* Multiple lesions:~  * To be treated with single balloon if possible.~ * To be treated with multiple inflation if cannot be covered with single balloon."
214924901|NCT03189667|DEVICE|Plain balloon angioplasty|"Plain balloon angioplasty~* Vessel treatment with additional Plain balloon angioplasty:~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to predilation balloon."
215068064|NCT04800575|DEVICE|semi-permeable film|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
215068065|NCT04800575|DEVICE|sterile gauze and tape|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
215068066|NCT06381063|DRUG|pain management|o Pain management in both arms Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day, patient control analgesia with morphine or oxycontin
214324622|NCT05683171|DRUG|Lenalidomide|Given by PO
215068067|NCT06381063|DRUG|ketoprofen|Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration
215068068|NCT06381063|DRUG|PLacebo|Placebo twice a day, during 48 h after surgery, intravenous administration
214672920|NCT04459910|PROCEDURE|Arthroscopic Brostrom combined with Arthroscopic Deltoid Repair|After anesthesia and surgical site preparation, traditional arthroscopic portals were performed. A 4.5mm set was used to clean the joint and assess possible associated injuries. Anterolateral and anteromedial impacts were resected when needed. Lateral and medial instability were confirmed arthroscopically, and ligament repairs prepared, starting by the lateral compartment. A traditional Arthroscopic Brostrom was performed, using one anchor and suture passers. Sutures are passed but not tightened. Medial anchor insertion is executed at the medial malleolus, in the quadrant described by Vega et al. Sutures were passed respecting the safe zone illustrated by Acevedo at al. The ankle was positioned in neutral (no posterior drawer) and the lateral sutures tightened with arthroscopic knots. Finally, the medial repair is finalized by tightening the deltoid sutures with the ankle at the same position. Portals were closed and a dressing applied.
214672921|NCT03803215|DRUG|Theophylline|Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
214672922|NCT01686204|OTHER|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
214672923|NCT01686204|OTHER|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
214672924|NCT05763940|DIETARY_SUPPLEMENT|OmegaBoost|"An ultra-pure omega-3 fish oil supplement with no fishy aftertaste and no fish burps.~10x more omega-3 from fish oil than the leading omega-3 gummies. Gel bites have better absorption than ordinary, hard-to-swallow fish oil pills."
214672925|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (soft gel)|A commercially-available omega-3 soft gel formula
214672926|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (gummy)|A commercially-available omega-3 formula in gummy form
215068069|NCT05023980|DRUG|Pirtobrutinib|Oral
214672927|NCT01512368|OTHER|Supervised Exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
214924902|NCT03189667|DEVICE|Drug coated balloon angioplasty|"Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to the predilation balloon.~* New drug coated balloon will be required for each lesion."
214924903|NCT04525014|DRUG|RRx-001|RRx-001 will be administered every 3 weeks via intravenous infusion at three dose levels: 0.5 mg/m2 (Max 1 mg), 1 mg/m2 (Max 2 mg), and 2 mg/m2 (Max 4 mg).
214924904|NCT04525014|DRUG|Temozolomide|100 mg/m2 (children ≥0.5 m2) or 3 mg/kg (children \<0.5 m2) daily for 5 days beginning on day 1 of each cycle
214924905|NCT04525014|DRUG|Irinotecan|90 mg/m2 taken orally daily for 5 days administered 1 hour after temozolomide
214924906|NCT05277636|DRUG|3,4-methylenedioxymethamphetamine|A dose of 125 mg racemic MDMA will be administered.
214924907|NCT05277636|DRUG|S-3,4-methylenedioxymethamphetamine|A dose of 125 mg enantiomeric S-MDMA will be administered.
215068070|NCT05023980|DRUG|Bendamustine|IV
215068071|NCT05023980|DRUG|Rituximab|IV
215068072|NCT04484649|BEHAVIORAL|Sleeping Healthy/Living Healthy|Sleeping Healthy/Living Healthy will be a school based health center (SBHC)-based intervention integrating mind-body integrative health (MBIH) and sleep hygiene strategies to improve sleep quality in urban adolescents. The Sleeping Healthy/Living Healthy intervention content and format will be determined in a Development Phase 1. The investigator anticipates the intervention will consist of two group and two one-on-one sessions. The intervention will be grounded in social-cognitive theory and use motivational interviewing to support MBIH and sleep hygiene strategies. Sessions will be delivered once per week by SBHC providers and health educators.
215068073|NCT04484649|BEHAVIORAL|Attention Control|"The Attention Control Intervention condition will meet the requirements for a comparison treatment for testing behavioral interventions - equivalent in contact time, credible and interesting, and exert limited treatment effects.~In the same number of sessions and format as the Sleeping Healthy/Living Healthy intervention (anticipated to be two group and two one-on-one sessions delivered once per week by SBHC providers and health educators), the study will teach participants about sleep and other health topics relevant to adolescents (e.g., nutrition, injury prevention) devoid of the MBIH elements in our integrated intervention."
215068074|NCT03548311|DRUG|methylcobalamin|Patients receive methylcobalamin 50mg intramuscular injection twice a week.
215068075|NCT03548311|DRUG|saline solution|Patients receive saline solution intramuscular injection twice a week.
215068076|NCT03356834|DRUG|Tenofovir alafenamide(TAF)|25 mg tablet administered orally once daily
215068077|NCT03356834|DRUG|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily
215068078|NCT04054479|DRUG|Penehyclidine|Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
214672928|NCT01277224|BEHAVIORAL|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
214672929|NCT02625142|OTHER|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
214672930|NCT00066781|DRUG|gemcitabine hydrochloride|Given IV
214672931|NCT00066781|DRUG|irinotecan hydrochloride|Given IV
214672932|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation during a month
214672933|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation + electrostimulation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation added electrostimulation during a month
215068079|NCT04054479|DRUG|normal saline|Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
214924908|NCT05277636|DRUG|R-3,4-methylenedioxymethamphetamine (125 mg)|A dose of 125 mg enantiomeric R-MDMA will be administered.
214924909|NCT05277636|DRUG|R-3,4-methylenedioxymethamphetamine (250 mg)|A dose of 250 mg enantiomeric R-MDMA will be administered.
214924910|NCT05277636|OTHER|Placebo|Placebo (Mannitol)
215068080|NCT00346658|DRUG|magnesium|
215068081|NCT01764269|OTHER|text message surveillance for fever|
215068082|NCT02250794|DRUG|metformin and sitagliptin|metformin 750 mg PO twice daily
215068083|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin glargine given once daily
215068084|NCT02250794|DRUG|metformin and sitagliptin|sitagliptin 100 mg PO once daily
215068085|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
215068086|NCT04706312|OTHER|stem cells|hAMSCs injection via venous in the dorsum of hand
215068087|NCT01450696|DRUG|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
215068088|NCT01450696|DRUG|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
215068089|NCT01450696|DRUG|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
215068090|NCT01709617|DIETARY_SUPPLEMENT|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
215068091|NCT02690688|DEVICE|determination of dynamic preload variables|
214924911|NCT03361969|DRUG|Estetrol|estetrol formulated in tablets
215068092|NCT00699387|DRUG|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
214924912|NCT03361969|DRUG|Placebo Oral Tablet|placebo tablets
215068093|NCT05742646|BEHAVIORAL|MATADORS|Youth will have access to the MATADORS app to include basic information and expanded educational features. They will be asked to log into the app daily for one month and they will be asked to report within the app how they are feeling each day and their medications taken.
215068094|NCT05742646|BEHAVIORAL|MATADORS Control|Youth will have access to the MATADORS app basic information. They will be asked to log into the app daily for one month and they will be asked to report within the app their medications taken.
215068095|NCT05570110|DRUG|Enoxolone|one capsule of active or placebo in the evening
214324623|NCT05683171|DRUG|Valemetostat|Given by PO
214324624|NCT05797792|DRUG|Intraarterial alteplase|See arm/group descriptions.
214324625|NCT03621631|BEHAVIORAL|Optimized Tai Chi intervention|Optimized Tai Chi intervention
214324626|NCT03621631|BEHAVIORAL|Traditional Tai Chi intervention|Traditional Tai Chi intervention
214324627|NCT06056063|DEVICE|Halcyon 4.0|This Halcyon 4.0 is a new imaging hardware recently developed by Varian and approved by the FDA.
214324628|NCT06465329|DRUG|Cemiplimab|Intravenous (IV) infusion administration
214324629|NCT06465329|DRUG|Platinum-based chemotherapy|IV infusion
214924913|NCT06666686|DEVICE|Active noise control headphone|This is the group where active noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
215068096|NCT06185907|OTHER|Surgery|We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.
215068097|NCT00693537|BEHAVIORAL|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
215068098|NCT06467955|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
215068099|NCT03770325|DRUG|Berberine|Purified berberine (500 mg orally twice a day) in tablets for 12 weeks
215068100|NCT03770325|DRUG|Placebo|Placebo tablets, prepared with the same appearance, for 12 weeks
215068101|NCT02814240|OTHER|NMR|
215068102|NCT02814240|BIOLOGICAL|Blood samples|
215068103|NCT02814240|OTHER|fibroscan|
215068104|NCT02406924|PROCEDURE|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
215068105|NCT02406924|RADIATION|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
215068106|NCT02406924|OTHER|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
215068107|NCT02406924|OTHER|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
214324630|NCT06465329|DRUG|REGN7075|IV infusion
214324631|NCT06352177|OTHER|Noom Weight Application|This commercially available program (Noom Weight) promotes clinically significant body weight loss and behavior change in multiple populations. The program is delivered through a smartphone application and includes self-monitoring and feedback features for diet, physical activity, and body weight, as well as digital access to a 1:1 behavior change coach, a support group facilitated by a health coach, and a curriculum delivered via daily articles focused on nutrition, physical activity, and sustainable behavioral change.
214924914|NCT06666686|DEVICE|Passive noise control headphone|This is the group where passive noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
214924915|NCT02622412|OTHER|Multi-professional breathlessness service (MBS)|Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
215068108|NCT06084182|OTHER|Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment|6-minute walk test and 5-time sit-to-stand test (STS-5) were used for functional capacity assessment. For cognitive reserve assessment, the Cognitive Reserve Index questionnaire was used. Reaction time, cognitive function and visiospatial perception were evaluated with the mobile application. In addition, the Fatigue Severity Scale; Beck Depression Questionnaire and Nottingham Health Profile were used.
214672934|NCT05537363|OTHER|Health education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.
214672935|NCT05537363|OTHER|Multicomponent training|Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
214672936|NCT05537363|OTHER|Agility training|The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
214924916|NCT02622412|OTHER|Delayed MBS Intervention|Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
214924917|NCT06330246|DIETARY_SUPPLEMENT|Low oxalate fixed diets pre-colonization|4 days of fixed eucaloric diet with low oxalate (\< 60 mg/day), normal calcium (600-1000 mg/day)
214924918|NCT06330246|DIETARY_SUPPLEMENT|Moderately high oxalate fixed diets pre-colonization|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium (600-1000 mg/day)
214924919|NCT06330246|DIETARY_SUPPLEMENT|Colonization with Oxalobacter formigenes|Ingestion of live Oxalobacter formigenes
215068109|NCT02182063|DRUG|BIBF 1120 low dose|
215068110|NCT02182063|DRUG|BIBF 1120 high dose|
215068111|NCT05062694|OTHER|Survey|It will be created a questionnaire to investigate, among Italian physiotherapists, their clinical approach to the patient with Central Sensitisation
215068112|NCT02249091|DRUG|Selinexor|Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).
215068113|NCT02249091|DRUG|Idarubicin|Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
215068114|NCT02249091|DRUG|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m\^2, iv,
215068115|NCT00582543|OTHER|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
214324632|NCT04026503|OTHER|Live Long Walk Strong rehabilitation program|Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
214924920|NCT06330246|DIETARY_SUPPLEMENT|Low oxalate fixed diets post-colonization|4 days of fixed eucaloric diet with low oxalate (\< 60 mg/day), normal calcium (600-1000 mg/day)
214924921|NCT06330246|DIETARY_SUPPLEMENT|Moderately high oxalate fixed diets post-colonization|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium (600-1000 mg/day)
214924922|NCT04715542|DRUG|Stibium metallicum praeparatum 6x|Stibium metallicum praeparatum 6x will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
214924923|NCT04715542|DRUG|Placebo|Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
214924924|NCT02602132|PROCEDURE|Clamping|To clamp before the removal of short-term indwelling urethral catheters
215068116|NCT03825146|BIOLOGICAL|Autologous Multi-lineage Potential Cells (AMPC)|"Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10\^8 (0.5 to 5.0 x 10\^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0."
215068117|NCT03483779|DRUG|Ginkgo biloba pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
215068118|NCT03483779|DRUG|placebo pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
215068119|NCT00433966|DRUG|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
214924925|NCT03939780|DIAGNOSTIC_TEST|[F18]RO-948|Single radiotracer IV injection with subsequent emission scan
215068120|NCT00433966|DRUG|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
215068121|NCT00433966|DEVICE|Bare metal stent|Uncoated bare metal stent
215068122|NCT00433966|DEVICE|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
215068123|NCT02180919|DEVICE|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
215068124|NCT02570152|PROCEDURE|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
215068125|NCT02957747|BEHAVIORAL|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
215068126|NCT03976024|OTHER|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
215068127|NCT03976024|OTHER|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
214924926|NCT03939780|DIAGNOSTIC_TEST|[F18]MK-6240|Single radiotracer IV injection with subsequent emission scan
214924927|NCT03939780|DIAGNOSTIC_TEST|[F18]AV1451|Single radiotracer IV injection with subsequent emission scan
215068128|NCT05850130|OTHER|Acupuncture intervention|"6 weeks of acupuncture once a week. The acupuncture intervention will consist of weekly session administered over a period of 6 weeks (± 4 days). A two-way verum acupuncture treatment protocol will employ 8 selected acupoints.~After week 7, patients included in Arm A may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist."
214324633|NCT04262167|BIOLOGICAL|Lung Spheroid Stem Cells 100 million|LSCs grown from autologous trans-bronchial biopsy specimens
214924928|NCT02805179|RADIATION|High Dose Radiation|Radiation will be delivered once daily for a total of 30 fractions, five days per week.
214924929|NCT02805179|DRUG|Temozolomide|Patients will receive concurrent temozolomide (75 mg/m\^2 daily for 6 weeks). Adjuvant temozolomide will be given at 150-200 mg/m\^2, D1-5 every 28 days for a minimum of six cycles and will be started approximately four weeks following completion of radiotherapy.
214924930|NCT02749994|DRUG|Rosuvastatin|
214924931|NCT02749994|DRUG|Ezetimibe|
214924932|NCT00520611|BEHAVIORAL|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
214924933|NCT00520611|BEHAVIORAL|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
214924934|NCT02836379|OTHER|No intervention|No intervention
214924935|NCT03912649|DEVICE|RemovAid|The RemovAid device is used for removal
214924936|NCT03788408|BEHAVIORAL|Intensive Psychotherapy and case management for refugee trauma|CVT's approach emphasized active interdisciplinary coordination and a relational focus anchored in cultural humilityX to address survivors' priorities, empower survivors as the primary architects of their healing, and work alongside each survivor to co-construct meaning and behavioral change.
214924937|NCT02380261|OTHER|Systane® Lid Wipes|Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
214924938|NCT06071143|BIOLOGICAL|KDSTEM Inj.|"1. Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10\^8 cells/10mL/2 syringes)~2. High dose: The following study drugs are pre-mixed with 70mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10\^8 cells/30mL/6 syringes)"
214924939|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 1|Liposomal Mitoxantrone Hydrochloride 16 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
214924940|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 2|Liposomal Mitoxantrone Hydrochloride 18 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
214924941|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 3|Liposomal Mitoxantrone Hydrochloride 20 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
214924942|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 4|Liposomal Mitoxantrone Hydrochloride 22 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
214924943|NCT00426296|DRUG|atazanavir (Reyataz)|
214924944|NCT00426296|DRUG|ritonavir (Norvir)|
214924945|NCT06685393|PROCEDURE|Platelet rich plasma (PRP)|At the 1st visit, each quadrant is scaled and root planned using an ultrasonic scaler and manual instruments until tactile sensation detects smooth crown and root surfaces these procedures were repeated on both sides starting from 1st visit of treatment,2nd,4th, and 6th-week intervals local anesthetic was utilized in some instances where it was the necessary and subgingival application of (PRP) at test side only at baseline,3ed, 6th week.
214924946|NCT06685393|PROCEDURE|INJECTABLE PLATELET RICH FIBRIN(I-PRF)|At the 1st visit, each quadrant is scaled and root planned using an ultrasonic scaler and manual instruments until tactile sensation detects smooth crown and root surfaces these procedures were repeated on both sides starting from 1st visit of treatment,2nd,4th, and 6th-week intervals local anesthetic was utilized in some instances where it was the necessary and subgingival application of (I-PRF) at test side only at baseline,3ed, 6th week.
214924947|NCT02258373|DEVICE|CGM+BGM|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm + Abbot Precision Xtra Blood Glucose-Ketone Meter
214924948|NCT02258373|DEVICE|CGM Only|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm
214924949|NCT06446115|DEVICE|Virtual Reality|Virtual Reality Headset applied to the participants during chemotherapy session. Participants select their preferred virtual reality experience (i.e., nature videos, meditations, interactive applications, etc). Virtual reality (VR) by definition, is a simulated experience consisting of an experiential environment created by hardware and software technology capable of provoking sensations of real experiences. It can be further divided into 1) immersive; 2) semi-immersive; and 3) non-immersive. Immersive VR employs head-mounted display (HMD) system technology to separate users from their surroundings and engage in real-time with a three-dimensional environment generated by a computer.
214924950|NCT06446115|OTHER|Preferred activity|Participants will engage in a preferred activity such as reading, watching television, coloring, etc. during chemotherapy.
215068129|NCT05850130|OTHER|No acupuncture|The patient in the Arm B will not receive acupuncture treatment for a period of 6 weeks after randomization (weeks 1-6) and during the following weeks 8-13 (acupuncture intervention) if its NRS score is \<4/10 at week 7. If the patient' NRS score is ≥ 4/10 at week 7, the patient in control Arm B will receive the same acupuncture intervention that the patient in the Arm A (6 weeks).
215068130|NCT00480558|BIOLOGICAL|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7
215068131|NCT00632827|DRUG|Gemcitabine|Chemotherapy medication used to treat a number of types of cancer
215068132|NCT00632827|DRUG|Navelbine|Navelbine is an chemotherapy medication used to treat a number of types of cancer
215068133|NCT00632827|DRUG|Doxorubicin Hydrochloride Liposome Injection|Doxorubicin Hydrochloride Liposome Injection is an anti-cancer chemotherapy drug
215068134|NCT00632827|DRUG|Granulocyte-colony stimulating factor (G-CSF)|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
215068135|NCT00632827|DRUG|Pegfilgrastim|Colony-stimulating factor 3 (CSF 3) and, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. May be used instead of G-CSF
215068136|NCT00632827|DRUG|Cyclophosphamide|Cancer medication that interferes with the growth and spread of cancer cells in the body
215068137|NCT00632827|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat cancer. Vincristine works by stopping the cancer cells from separating into 2 new cells to stops the growth of the cancer
215068138|NCT00632827|DRUG|Leucovorin|Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.
215068139|NCT00632827|DRUG|Methotrexate|Methotrexate is a chemotherapy medication used to treat cancer
215068140|NCT00632827|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer
215068141|NCT00632827|DRUG|Cytarabine|Medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma
215068142|NCT00632827|DRUG|Etoposide|Etoposide is a is a chemotherapy medication used to treat cancer
215068143|NCT00632827|DRUG|Carmustine|Carmustine is a chemotherapy medication used to treat cancer
215068144|NCT00632827|DRUG|Denileukin diftitox|Denileukin diftitox is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells
215068145|NCT06266468|BEHAVIORAL|Nutricity|Nutricity is a bilingual (English/Spanish) mobile website supplemented by an automated text-messaging system.
215068146|NCT06019663|BEHAVIORAL|The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP|"YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change."
214924951|NCT06446115|OTHER|Questionnaires|Participants will be administered multiple pre and post intervention questionnaires including NCCN Distress thermometer, GAD-7 and CCVA.
215068147|NCT00416065|DEVICE|PET/CT imaging|
215068148|NCT03771131|BEHAVIORAL|Multi-domain cognitive training|Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
215068149|NCT06362330|OTHER|magnetic resonance imaging|Patients of bladder cancer underwent multiparameter magnetic resonance imaging before surgery
215068150|NCT03840304|OTHER|Yoga@work|Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
215068151|NCT04630860|DRUG|LY03003|Rotigotine,extended-release microspheres
215068152|NCT05834933|BEHAVIORAL|Individualized breast cancer risk assessment|Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.
215068153|NCT05834933|BEHAVIORAL|Individualized breast cancer risk counselling|Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The
215068154|NCT05193201|DRUG|recombinant human thrombopoietin injection|recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
215068155|NCT02419222|BEHAVIORAL|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
215068156|NCT01177553|PROCEDURE|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
214924952|NCT01046903|DRUG|Fragmin® (Dalteparin Sodium)|Administered per prescribing physician
214324634|NCT04262167|BIOLOGICAL|Lung Spheroid Stem Cells 200 million|LSCs grown from autologous trans-bronchial biopsy specimens
214924953|NCT01328977|BEHAVIORAL|education|teaching
215068157|NCT01177553|DEVICE|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
215068158|NCT03560752|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given via injection
215068159|NCT01922947|BEHAVIORAL|Motivational Interviewing w/Social Network Counseling|This is the active arm of the study.
215068160|NCT01922947|BEHAVIORAL|Active Control Condition|20-minute health counseling
215068161|NCT02119195|PROCEDURE|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
214924954|NCT06212700|BEHAVIORAL|Preoperative Exercise|Aerobic (HIIT) Endurance Respiratory Muscle Strength Education
214924955|NCT06212700|BEHAVIORAL|Postoperative Exercise|Aerobic Muscle Strength Walking Program Education
214924956|NCT06212700|DIETARY_SUPPLEMENT|Preoperative Nutrition|Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
214924957|NCT06212700|DIETARY_SUPPLEMENT|Postoperative Nutrition|Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
214924958|NCT06212700|BEHAVIORAL|Preoperative Psychology|CBT skills Skills training Emotional validation Behavioural activation Psycho-education
215068162|NCT05721352|BEHAVIORAL|Virtual Reality Nature scene plus heart rate variability biofeedback phone application|phone app for slow- paced breath training with biofeedback in a virtual reality nature scene
215068163|NCT06602674|OTHER|Observe the medical images|Observe the medical images via work station or local image analysing software
214672937|NCT05006612|PROCEDURE|Serratus Anterior Plane Block|"SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle."
214924959|NCT06212700|BEHAVIORAL|Postoperative Psychology|CBT skills Skills training Emotional validation Behavioural activation Psycho-education
214924960|NCT06212700|OTHER|Preoperative Nursing|Comorbidities Managing pain Wound care Complications Surgical education ERAS
214924961|NCT06212700|OTHER|Postoperative Nursing|Managing pain Cardiovascular stability Wound care Bowel function/Stoma Complications Education
214924962|NCT06212700|OTHER|Preoperative Peer Support Group|"Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education"
214924963|NCT06212700|OTHER|Postoperative Peer Support Group|"Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education"
214924964|NCT06212700|OTHER|Usual Care|Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
214924965|NCT05051553|DRUG|Fedratinib|Specified dose on specified days
214924966|NCT05236777|DRUG|Natalizumab|Administered as specified in the treatment arm.
214924967|NCT04002245|PROCEDURE|antiseptic application|The application of the antiseptic on the healthy and visibly clean skin of the bend of the elbow will be carried out for all participant
214924968|NCT01548911|DRUG|gemtuzumab ozogamicin|Given IV
214924969|NCT01548911|OTHER|laboratory biomarker analysis|Correlative studies
214924970|NCT03884517|DRUG|BAT8003|Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
214924971|NCT06683287|DEVICE|red light and distant image screen|red light plus distant image screen, children use these two devices at the same time
214924972|NCT06683287|DEVICE|red light|children use red light for 3 minutes each time, twice a day
215068164|NCT06602674|OTHER|Feature extraction|Extracting image feature via radiomics or deep learning methods
215068165|NCT01384552|OTHER|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
215068166|NCT01384552|OTHER|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
215068167|NCT00080080|DRUG|talabostat (PT-100) tablets|
214924973|NCT06683287|DEVICE|distant image screen|Children in this group were asked to use this device for ≥1 hour/day
214324635|NCT05970575|DRUG|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (6 months)
214924974|NCT06684340|PROCEDURE|Exposure to major abdominal surgery|This study is a retrospective cohort study. The 'exposure' situation is based on historical records and observation, and no active intervention has been conducted on the study subjects to change their exposure status.
214924975|NCT05804019|BEHAVIORAL|Nutritional and physical interventions|The intervention is developed with a focus on nutritional needs and physical activities. The Plan-Do-Study-Act (PDSA) model is used to redefine issues and relevant actions together with residents, relatives, care staff, and nursing home management. The intervention will be developed based on new knowledge from sub-study 1, previous studies, practical experiences, the participant's experiences and wishes as well as the staff's experiences and wishes. Together they will form an implementation catalog, from here, the intervention nursing homes can select a relevant number of components, which will be tested and implemented in practice. The implementation duration is 6 months and the PDSA model is repeated at two-month intervals to strengthen and qualify the intervention. The PDSA model is known to the city's staff in advance and is additionally used in connection to continuing education. The Usual Care Group will continue the usual care.
214924976|NCT00555919|DRUG|Lonaprisan (ZK 230211, BAY86-5044)|25 mg daily oral treatment
214924977|NCT00555919|DRUG|Lonaprisan (ZK 230211, BAY86-5044)|100 mg daily oral treatment
214924978|NCT05207657|DRUG|Lentiviral vector transduced CD34+ cells|Gene therapy for p47 AR-CGD will be performed by introduction a normal copy of the NCF-1 gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient
214924979|NCT04872894|OTHER|Observational study. No intervention is performed|Descriptive study in participants with clinical and biochemical suspicion of FHH. Comparison between genotype-negative and genotype-positive participants with clinical and biochemical suspicion of FHH.
214924980|NCT05754762|DRUG|Remifentanil|Advanced intravenous injection of remifentanil before the etomidate injection
215068168|NCT00080080|DRUG|Docetaxel|
215068169|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
214324636|NCT04373902|PROCEDURE|Physiological-based cord clamping|See 'Arm'
214324637|NCT04342832|PROCEDURE|Cryoballoon ablation|If a patient is randomized to early invasive treatment, the ablation is performed within 3 months by an experienced cardiac electrophysiologist using CE-certified equipment. Via the femoral vein a guiding catheter is advanced through the inferior vena cava to the right atrium and into the left atrium via transseptal puncture. Then, the cryoballoon is advanced, inflated, and placed against one of the four PVs. PV occlusion is assessed by selective contrast injection. When adequate PV antral seal is confirmed, ablation of the tissue in contact with the balloon is performed using pressurized liquid nitrous oxide. The cold inflated balloon thus creates circular lesions around the PV. The balloon and tissue interface are then allowed to reach normal temperatures. Depending on local practice, the freeze-thaw cycle may be repeated twice. Electrical isolation is assessed and when it is confirmed, the next PV is treated in the same way. The procedure ends when all PV's are isolated.
215068170|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
215068171|NCT05618041|BIOLOGICAL|CAR-T Autologous T cell injection|Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis
215068172|NCT05754151|BEHAVIORAL|MAYA Mobile Application|The mobile cognitive behavioral therapy (CBT) application, MAYA, teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, exposure and psychoeducation (i.e. information about anxiety and depression). The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Although the MAYA application is new, its content and structure are similar to how CBT- a well-established and widely used psychosocial intervention - is commonly delivered in the more traditional setting of a psychotherapist's office.
215068173|NCT06030466|OTHER|With virtual standardized patients|The virtual standardized patient is a software system that presents on a computer screen like a video conference, allowing medical students to interact with it for medical consultation. The virtual character modeling adopts 3D model, the expression of the character is delicate, and the voice feedback is clear. After the students' questions are asked by voice recognition and key words are extracted, appropriate responses are given.
214924981|NCT00392938|DRUG|antiandrogen therapy|
214924982|NCT00392938|DRUG|docetaxel|
214924983|NCT00392938|DIAGNOSTIC_TEST|C-11 acetate PET scan|
214924984|NCT00392938|DIAGNOSTIC_TEST|F-18 FDG PET scan|
214924985|NCT00392938|DIAGNOSTIC_TEST|Tc-99m bone scan|
214924986|NCT00392938|DIAGNOSTIC_TEST|CT scan of the chest, abdomen and pelvis|
214924987|NCT05283980|DRUG|0.25% Bupivacaine|The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
214924988|NCT06669949|OTHER|no intervention|No interventions are involved in this observational study.
214924989|NCT06610981|DEVICE|Laser acupuncture|Laser acupuncture will be used in this study with energy of 4 J per point for 80 s, with a total dosage of 24 J in each session, 2 times /week for 4 weeks
214924990|NCT06610981|OTHER|traditional physical therapy|exercise program consisted of stretching for hamstring, gastrocnemius and iliotibial band, and strengthening exercises, which include isometric quadriceps exercises, straight leg raising, lateral straight leg raise, isometric hip adduction and squat to 30° knee flexion, 2 times /week for 4 weeks
214924991|NCT06610981|DEVICE|Sham laser acupuncture|Participants will receive laser acupuncture while the device is turned off.
214924992|NCT02855372|PROCEDURE|Lung transplantation|
214924993|NCT06030232|DEVICE|Therasphere|Transarterial radioembolization
214924994|NCT06628037|BIOLOGICAL|SN514-066b|Enzyme debrider
214924995|NCT00544401|OTHER|Hypnopuncture (Hypnosis+Acupuncture)|hypnosis and acupuncture
214924996|NCT01073813|DRUG|Minocycline|100mg twice daily
215068174|NCT06030466|OTHER|With physical standardized patients|The physical standardized patient is a real person who has received professional training courses in the department of medical education of National Taiwan University Hospital, and can help medical students practice consultations.
215068175|NCT05980871|DRUG|Doxycycline|doxycycline (100 mg orally twice daily for 7 days)
215068176|NCT05980871|DRUG|Ceftriaxone|Ceftriaxone (1g intramuscularly once)
215068177|NCT05980871|DRUG|benzathine penicillin G|benzathine penicillin G (2.4 MU intramuscularly once)
215068178|NCT06440980|DRUG|Orforglipron|Administered orally
214324638|NCT02870907|OTHER|Observation|no post operative chemotherapy
214324639|NCT02870907|DRUG|Etoposide|100 mg/m²/d, IV (in the vein) from D1 to D5.
214324640|NCT02870907|DRUG|Vincristine|1, 5 mg/m²/d, IV at D1.
214324641|NCT02870907|RADIATION|Orbital irradiation|45 Grays (Standard or external beam radiotherapy).
214924997|NCT05476250|DEVICE|INVSENSOR00057|Noninvasive wearable health monitoring device
214924998|NCT06316193|OTHER|Diary|The diary is the tool through which the experiences and experiences of the parents of infants admitted to Neonatal Pathology and included in the study and the health care personnel who decide to participate will be collected and analyzed. This tool is given to the parents of infants included in the study in the first few days of the infant's stay (by the third day after admission), subject to the parents' written consent, accompanied by a brief letter of introduction to the diary itself, written by the nurses on the ward. This tool has been part of current clinical practice since January 2023.
214924999|NCT06721559|BEHAVIORAL|Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression|Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
215068179|NCT05085340|DRUG|Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)|IPTi will be administered as full therapeutic courses of SP alongside routine EPI immunisations at defined intervals corresponding to vaccination schedules - usually at 10 weeks, 14 weeks, and 9 months of age - to infants living in project districts. Additional doses of IPTi will be administered at 6, 12, and 15 or 18 months of age, coinciding with vitamin A administration and measles booster immunisation. The number of doses of IPTi a child will receive will depend of the EPI schedule in the country, with a maximum of six doses in the first two years of life.
215068180|NCT04314531|DRUG|TILD|one 1 mL injection of study medication
215068181|NCT04314531|DRUG|matching placebo injections|one 1 mL injection of placebo
215068182|NCT04450771|BEHAVIORAL|Family-based Treatment for ARFID|This treatment includes 14 1-hour sessions that will be conducted approximately weekly over a 4 month period. It is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior.
214925000|NCT06721559|OTHER|Telephone friendly visits|Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
214925001|NCT04858061|BEHAVIORAL|Virtual Reality Cue Exposure Therapy|Exposure to alcohol-related cues within virtual environments
214925002|NCT04858061|BEHAVIORAL|Treatment-as-usual|Pharmacotherapy and psychotherapy
214925003|NCT00755599|PROCEDURE|no-stirrup vaginal examination|Vaginal speculum examination done with feet on table extender.
214925004|NCT00755599|PROCEDURE|Vaginal speculum examination done with stirrups.|Speculum examination done with feet in stirrups.
214925005|NCT06343467|DEVICE|Generic Volar Locking Plate|Application of a generic volar locking plate is done in the generic implant arm compared to the other commonly used implants by surgeons in the conventional implant arm.
214925006|NCT06343467|DEVICE|Conventional Volar Locking Plate|Application of a conventional, brand name volar locking plate is done in the conventional implant arm compared to the generic implant arm.
214925007|NCT02214329|DEVICE|Sensor-based exercise training|Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.
215068183|NCT04450771|BEHAVIORAL|Manualized Non-Specific Usual Care for ARFID|This treatment is a manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model. It consists of sessions with the child alone and 5 parent-only meetings, all of which are 1-hour over a 4 month period.
215068184|NCT06580249|DEVICE|Repetitive transcranial magnetic stimulation|The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。
214925008|NCT02214329|OTHER|In-home balance training|The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
214925009|NCT02523976|DRUG|Dasatinib|Second-generation tyrosine kinase inhibitor
214925010|NCT02523976|DRUG|prednisone|
215068185|NCT05467410|BEHAVIORAL|COG-AM|Participants who are randomized to the COG-AM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during morning hours (between 09:00-12:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
215068186|NCT05467410|BEHAVIORAL|COG-PM|Participants who are randomized to the COG-PM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during late afternoon/early evening hours (between 15:00-18:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
215068187|NCT05120570|DRUG|VIC- 1911|25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.
215068188|NCT04741789|DRUG|Capmatinib|Tablet for oral use, dose Up to 400mg, twice daily
215068189|NCT05817058|DRUG|AFM28|AFM28 dose escalation
215068190|NCT05170724|DRUG|Remibrutinib|Remibrutinib should be taken in accordance with the recommendations in the treatment plan.
215068191|NCT06096116|DRUG|Human plasma derived antithrombin|A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma
214925011|NCT02523976|DRUG|cyclophosphamide|
214925012|NCT02523976|DRUG|daunorubicin|
214925013|NCT02523976|DRUG|vincristine|
214925014|NCT02523976|DRUG|cytarabine|
214925015|NCT02523976|DRUG|mercaptopurine|
214925016|NCT02523976|DRUG|methotrexate|
214925017|NCT02523976|DRUG|dexamethasone|
214925018|NCT02523976|DRUG|mitoxantrone|
215068192|NCT06096116|DRUG|Placebo|Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ
214925019|NCT02523976|DRUG|etoposide|
214925020|NCT02523976|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214925021|NCT02523976|PROCEDURE|autologous hematopoietic stem cell transplantation|
214925022|NCT00688662|PROCEDURE|ERCP with sphincterotomy|cutting the biliary sphincter muscle (sphincterotomy)
214925023|NCT00688662|PROCEDURE|ERCP without sphincterotomy|ERCP with sphincter manometry, but no sphincterotomy
214925024|NCT01668173|DRUG|AUY922|AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
214925025|NCT01883726|DEVICE|Grayson's presurgical nasoalveolar molding|Grayson NAM
215068193|NCT03910751|DEVICE|Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis|Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis
214925026|NCT01883726|DEVICE|Figueroa's presurgical nasoalveolar molding|Figueroa NAM
214925027|NCT06809777|DRUG|Topical 25% podophyllin|25% podophyllin applied topically once weekly for 4 weeks
214925028|NCT06809777|PROCEDURE|Cryotherapy|cryotherapy of 10 sec freeze cycle applied twice weekly for 4 weeks
214925029|NCT04671498|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
215068194|NCT03931382|BEHAVIORAL|Virtual Reality Simulator|The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.
215068195|NCT03931382|BEHAVIORAL|Mock MRI Simulator|The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.
215068196|NCT03931382|BEHAVIORAL|Standard Preparation Manual|The standard MRI preparation manual provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
215068197|NCT04975659|BEHAVIORAL|Placebo and Nocebo effect|Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
215068198|NCT04303013|BEHAVIORAL|Meditation|Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
214324642|NCT02870907|DRUG|Carboplatin|160 mg/m²/d, IV from D1 to D5.
214324643|NCT02870907|DRUG|Vincristine|1,5 mg/m²/d, IV at D22 and D26
214925030|NCT04671498|PROCEDURE|Droplet-BC Test|Undergo Droplet-BC Test
214925031|NCT04671498|OTHER|Electronic Health Record Review|Medical records are reviewed
214324644|NCT02870907|DRUG|Cyclophosphamide|300 mg/m²/d, IV from D22 to D26.
214324645|NCT02870907|DRUG|Carboplatin|560 mg/m²/d, IV at D1.
214324646|NCT02870907|DRUG|Etoposide|100 mg/m²/d, IV from D1 to D5
214324647|NCT02870907|DRUG|Carboplatin|160 mg/m²/d,IV from D1 to D5
214324648|NCT02870907|DRUG|Thiotepa|15 mg, intrathecal Thiotepa injection at D1.
214324649|NCT02870907|DRUG|Vincristine|1,5 mg/m²/d), IV at D22
214324650|NCT02870907|DRUG|Cyclophosphamide|1000 mg/m²/d, IV from D22 à D24.
214925032|NCT00077298|BIOLOGICAL|cetuximab|Given IV
214925033|NCT00077298|BIOLOGICAL|bevacizumab|Given IV
214925034|NCT00077298|DRUG|irinotecan hydrochloride|Given IV
214925035|NCT00077298|OTHER|laboratory biomarker analysis|Correlative studies
214925036|NCT01628198|DEVICE|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter|"Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions.~There are 2 devices that can be used---this is optional, based on physician preference:~Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California~or~Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California"
214925037|NCT03059745|PROCEDURE|Cholecystectomy|Single Port and Multi-Port approaches trans-laparoscopic approaches with or without the use of the daVinci Surgical Robotic System.
214925038|NCT04836962|DRUG|normal saline|2cc of normal saline is administered to patient instead of dexamethasone.
214925039|NCT04836962|DRUG|dexamethasone|dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
214925040|NCT03732482|DRUG|Temozolomide capsules|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
214925041|NCT03732482|DEVICE|radiotherapy|Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost
214925042|NCT04412343|BEHAVIORAL|Virtual Group Intervention|Participants will receive weekly exercise courses delivered virtually to a group of older adults. This intervention will last for 12 weeks. Participants in addition to participating in exercise will have designated time after each exercise class to socially connect. Participants in this condition will also receive a t-shirt.
214925043|NCT04412343|BEHAVIORAL|Personal Exercise Intervention|Participants will receive weekly exercise courses delivered virtually. These classes will be pre-recorded so the individual can complete sessions at any time that is convenient for them.
214925044|NCT00536159|OTHER|Medicaid Maternal and Infant Support Services|Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
215068199|NCT04303013|OTHER|Standard of Care|Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
215068200|NCT05457907|DEVICE|Ultrasound device|Low energy ultrasound therapy will be administered to the spleen
215068201|NCT05623475|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
215068202|NCT05623475|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
215068203|NCT05623475|BEHAVIORAL|E-learning|Delirium care video
215068204|NCT00542490|RADIATION|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
214324651|NCT02870907|PROCEDURE|Cytapheresis|Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamid.
215068205|NCT02606123|DRUG|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
214925045|NCT00536159|OTHER|Nurse-CHW team|A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
214925046|NCT05331755|DRUG|Dupilumab|start medication in cohort
214925047|NCT05747573|DRUG|GB1211|Hard tablet or capsules for oral use
214925048|NCT03918902|BEHAVIORAL|Qestinnaires|Questionnaires
214925049|NCT02898428|DEVICE|Continuous glucose monitoring (CGM)|
214925050|NCT05550454|DEVICE|Automatic Mechanical Ventilation|"Ventilation settings:~Mode: (S)Continuous Mandatory Ventilation Rate: 10 b/min. Tidal Volume: 500 ml (male), 450 ml (female) I:E=1:1 Positive end expiratory pressure (PEEP): 5 cmH2O Flow trigger: off Oxygen: 100% Alarms: Pressure 70 cmH20, Tidal volume 100 \~ 1,000 ml"
214925051|NCT05550454|DEVICE|Manual Ventilation|Ambu-bagging (It is recommended in the guidelines as a ventilation method.) Methods: 10 times per minutes by medical personnel
214925052|NCT02586038|DRUG|MLN9708|
215068206|NCT05213637|BIOLOGICAL|Expanded Activated Lymphocytes (EAL)|12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.
215068207|NCT05213637|PROCEDURE|transarterial chemoembolization (TACE)|After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
215068208|NCT05271253|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.
214925053|NCT02586038|DRUG|Dexamethasone|
214925054|NCT02586038|DRUG|Cyclophosphamide|
214925055|NCT02586038|DRUG|Thalidomide|
215068209|NCT05271253|DRUG|bupivacaine|0.25% bupivacaine is injected in the caudal epidural space
215068210|NCT05271253|DRUG|normal Saline|injection of normal Saline
215068211|NCT05376059|BEHAVIORAL|How Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.
215068212|NCT05376059|BEHAVIORAL|How and Why Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.
215068213|NCT05376059|BEHAVIORAL|Incentive|Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
215068214|NCT03589989|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
215068215|NCT03589989|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
215068216|NCT04231682|DRUG|Denosumab Injection|Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
215068217|NCT04231682|DRUG|Placebos|Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
215068218|NCT04379687|OTHER|Virtual reality|Use of virtual reality glasses for balance work
214925056|NCT04649840|DIAGNOSTIC_TEST|Humoral and cellular immunity|Humoral (IgG) and cellular (antigen-specific cells) immunity
214925057|NCT04199169|BIOLOGICAL|HeV-sG-V|A Hendra virus soluble glycoprotein vaccine formulated in phosphate buffer and adjuvanted with aluminum hydroxide. Placebo is normal saline.
214925058|NCT04199169|BIOLOGICAL|Normal Saline Placebo|0.9% Saline
215068219|NCT04379687|OTHER|Control group|Balance treatment with according to Bayouk physiotherapy
214925059|NCT03660774|OTHER|No treatment given|The participants will undergo a brief physical examination focused on neurologic function (muscle function, sensation, coordination, walking). Parents will be asked by the study team or the psychologist about their children and will complete several commonly used standard surveys about brain development, thinking, behavior, and decision making. The participants will also engage with the psychologist to evaluate development or thinking (IQ), and depending on their age they may be asked to complete one or more commonly used standard surveys about behavior and decision making.
214925060|NCT04321174|DRUG|Lopinavir/ritonavir|The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.
214925061|NCT04435990|BIOLOGICAL|10,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL
214925062|NCT04435990|BIOLOGICAL|30,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL
215068220|NCT03316118|DRUG|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
215068221|NCT03316118|DRUG|saline|Group 2 will receive genicular nerve block using normal saline
215068222|NCT00100074|DRUG|Lobeline|
214925063|NCT04435990|BIOLOGICAL|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
214925064|NCT01809301|DRUG|Niaspan|
214925065|NCT01809301|DRUG|TRIA-662|
214925066|NCT06068673|DRUG|Clindamycin 600 mg|Clindamycin 900 - 1200 mg TWICE per day during 2 weeks period.
214925067|NCT06068673|DRUG|standard regimen|standard regimen
214925068|NCT04404517|DRUG|Adalimumab|Monoclonal antibody used in IBD treatment
214925069|NCT02772770|OTHER|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
214324652|NCT02870907|DRUG|Carboplatin|AUC : 7/d, IV from D-8 to D-6.
214324653|NCT02870907|DRUG|Etoposide|250 mg/m²/d, IV from D -5 to D-3.
214324654|NCT02870907|DRUG|Thiotepa|300 mg/m²/d, IV from D-5 to D-3.
214324655|NCT02870907|PROCEDURE|Peripheral bood stem cell transplantation|at D0
214925070|NCT02772770|PROCEDURE|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
215068223|NCT00472654|BEHAVIORAL|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
215068224|NCT00472654|DIETARY_SUPPLEMENT|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
215068225|NCT00472654|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 weeks
215068226|NCT06237127|DIETARY_SUPPLEMENT|Goji berry|Participants will be instructed to consume 14 grams of goji berries 5 days a week for 6 months
215068227|NCT06237127|DIETARY_SUPPLEMENT|Fiber|Participants will be instructed to consume the fiber supplements 5 days a week for 6 months
215068228|NCT01152593|DRUG|Mupirocin|Intranasal cream given to patient after confirmation of colonization
215068229|NCT03115827|DRUG|Droxidopa|Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
215068230|NCT03115827|DRUG|Carbidopa|Carbidopa 200mg twice a day
215068231|NCT06493786|OTHER|Collection of body odor samples|"Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion."
215068232|NCT02965794|OTHER|Care pathways for colorectal cancer|development of a care pathway for this patient group
215068233|NCT06121076|OTHER|SDM-EBP training|A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.
215068234|NCT01312493|DRUG|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
215068235|NCT01312493|RADIATION|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
215068236|NCT01049204|DRUG|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
215068237|NCT01049204|DRUG|placebo|Placebo twice daily for 24 weeks
215068238|NCT01731340|DIETARY_SUPPLEMENT|Calcium Citrate|750mg
215068239|NCT01731340|OTHER|Low Dietary Calcium|450 mg
215068240|NCT01731340|OTHER|High Dietary Calcium|1200 mg
215068241|NCT00203866|DRUG|G250 peptide|
215068242|NCT00203866|DRUG|IL-2|
215068243|NCT00778375|DRUG|Clofarabine|20 mg/m\^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
215068244|NCT00778375|DRUG|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
215068245|NCT00778375|DRUG|Decitabine|20 mg/m\^2 as a 1- to 2-hour infusion daily for 5 days.
215068246|NCT02030925|DRUG|IW-3718|
215068247|NCT02030925|DRUG|Matching Placebo|
215068248|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
215068249|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
215068250|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
215068251|NCT02989818|OTHER|Endoscopic Submucosal Dissection|This intervention is part of the subjects standard of care and is a method to remove the Gastrointestinal lesion.
214925071|NCT02772770|PROCEDURE|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
214925072|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
214925073|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
215068252|NCT03668470|DRUG|Dulaglutide|Dulaglutide 1.5mg : One injection per week during 24 weeks
215068253|NCT03668470|DRUG|Placebo|Placebo: one injection per week during 24 weeks
215068254|NCT03772028|DRUG|cisplatin|HIPEC with cisplatin after cytoreductive surgery
215068255|NCT00613002|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
215068256|NCT00613002|DRUG|placebo gel|once daily transdermal placebo gel
215068257|NCT03773536|DRUG|Artesunate-amodiaquine given with single low dose primaquine|Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
215068258|NCT04105348|DIAGNOSTIC_TEST|HbA1c|patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
215068259|NCT04588857|DRUG|Dexamethasone|The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.
215068260|NCT04588857|DRUG|Saline|The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
215068261|NCT05760131|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
215068262|NCT01151059|BIOLOGICAL|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
215068263|NCT06187194|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Tonsil Reduction for The Treatment of Chronic Symptomatic Tonsillar Hypertrophy
215068264|NCT04189965|OTHER|Validation of virtual environment and auditive stimulation with virtual reality glasses (Pilot phase)|The goal of this phase is the development of the experimental protocol in virtual reality. Virtual environment will be checked and auditive stimulation will be graduated.
215068265|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Principal Experimental phase)|This phase is the principal step of the study: during moving in virtual environment, electrical stimulation on one hand and auditive stimulation will be applied. EEG, ECG and skin conductance will be measured during conditioning phase and extinction phase (day 1, 30 minutes each phase). Behavioral measures will be done throughout the 3 sessions (day 1, day 2 and day 30)
215068266|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Secondary Experimental phase)|This phase is the same of the Principal Experimental phase except for the EEG that will not be performed.
215068267|NCT00144989|DRUG|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
215068268|NCT00144989|DRUG|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
214925074|NCT05786469|DRUG|Veltassa Oral Powder Product|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
214925075|NCT05786469|OTHER|Placebo|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
214925076|NCT06253715|DRUG|Isoniazid|Once daily weight-based dose
214925077|NCT06253715|DRUG|Rifampin|Once daily weight-based dose
214925078|NCT06253715|DRUG|Pyrazinamide|Once daily weight-based dose
214925079|NCT06253715|DRUG|Ethambutol|Once daily weight-based dose
214925080|NCT06253715|DRUG|Rifapentine|Once daily weight-based dose
214925081|NCT06253715|DRUG|Moxifloxacin|Once daily weight-based dose
214925082|NCT04959240|DRUG|Velmanase Alfa|
214925083|NCT06160492|DRUG|5-aminolevulinic acid|Patients were randomly assigned to 5-aminolevulinic acid (20 mg/kg bodyweight）Those randomly allocated to 5-aminolevulinic acid were scheduled to receive freshly prepared solutions of 5-aminolevulinic acid orally 3 h (range 2-4) before induction of anaesthesia. Solutions were prepared by dissolving the contents of a vial (1·5 g) in 50 mL of drinking water.
214925084|NCT04999163|DEVICE|Aortix System|Aortix is indicated as a partial circulatory support device to increase renal perfusion and reduce the incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery who are at heightened risk of developing AKI.
214925085|NCT06958120|PROCEDURE|superficial parasternal intercostal Plane block|A high-frequency linear transducer was used to guide the insertion of a needle 2 cm lateral to the sternum. After identifying key anatomical structures, the needle was advanced in-plane into the pectointercostal fascial plane between the pectoralis major and internal intercostal muscle. Correct placement was confirmed with a saline injection, and then a local anesthetic (0.4 ml/kg of a 1:1 mix of bupivacaine 0.25% and lidocaine 1%) was injected bilaterally at the second and fourth ribs.
214925086|NCT06958120|PROCEDURE|Erecto spinea plane block|Using ultrasound, a needle is inserted near the T5 vertebra into the plane beneath the erector spinae muscle. After confirming correct positioning with saline, a local anesthetic mixture is injected in the fascial plane.
214925087|NCT03016130|OTHER|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
214925088|NCT04437225|DIETARY_SUPPLEMENT|Low oxalate controlled Diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
214925089|NCT04437225|OTHER|Primed, continuous intravenous infusion of 13C2-Glycolate|Participants will receive a continuous intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, over the course of several hours until steady-state is achieved, using an IV catheter.
214925090|NCT04437225|OTHER|Bolus intravenous infusion of 13C2-Glycolate|Participants will receive a bolus intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, using an IV catheter.
214925091|NCT04437225|OTHER|Oral bolus administration of 13C2-Glycolate|Participants will orally ingest a single dose of carbon-13 glycolate, a naturally occurring form of glycolate.
214925092|NCT04913155|RADIATION|Low-dose CT screening|Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
214925093|NCT00001810|DRUG|Voriconazole|
214925094|NCT00887523|BEHAVIORAL|radiation in prone position|radiation in prone position
214925095|NCT00887523|BEHAVIORAL|radiation in supine position|radiation in supine position
214925096|NCT04803422|DRUG|Antibiotic|The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.
214925097|NCT00355225|PROCEDURE|ITN distribution channel|
214925098|NCT04606823|PROCEDURE|Minimally invasive surgery|The subjects will be implanted with a bone anchored hearing system using a minimally invasive surgery.
214925099|NCT04606823|OTHER|Glasgow Benefit Inventory (GBI)|A quality of life-questionnaire is to be completed by the subjects at one occasion.
214925100|NCT04606823|OTHER|Additional follow-up visits after surgery|There are 1-3 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
214925101|NCT06622993|OTHER|Psychotherapy|The experimental group will receive the SKILLS program, i.e. 10 group psychotherapy sessions.
214925102|NCT06554522|DRUG|Surfactant|Surfactant is instilled into the lungs through a thin catheter passed into the trachea during laryngoscopy while on continuous positive airway pressure (CPAP)
214925103|NCT01729338|DRUG|Velcade|Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \[10,12,14, etc.\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
214925104|NCT01729338|DRUG|Cyclophosphamide|Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
214925105|NCT01729338|DRUG|Revlimid|"Lenalidomide (odd cycles \[9,11,13, etc.\]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.~Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately."
214925106|NCT03933579|DIAGNOSTIC_TEST|Deep phenotyping|Each participating hospitals will be collecting whole blood from each patient, through which DNA, RNA, serum, plasma, and peripheral blood mononuclear cells will be extracted from the buffy coat layer for further multi-omics analysis.
214925107|NCT02041143|DIETARY_SUPPLEMENT|Milk protein|Study product will provide 25 g of protein to subjects.
214925108|NCT02041143|DIETARY_SUPPLEMENT|Placebo|Product with no protein
214925109|NCT06206551|OTHER|Spiritual Needs Questionnaire|This questionnaire captures the spiritual needs of patients and is used in its short version (screener).This questionnaire is used as part of standard treatment for all palliative care inpatients.
214925110|NCT00593710|DRUG|Losartan|Losartan (25mg OD)
214925111|NCT00593710|DRUG|Atenolol|Atenolol (25-50mg OD)
214925112|NCT04842617|DRUG|SHR6390|SHR6390 combined with endocrine therapy
214925113|NCT04842617|DRUG|placebo|placebo combined with endocrine therapy
214925114|NCT04611867|OTHER|Supportive application with integrated weekly PRO|Patients will fill in a web-based application PRO-CTCAE with integrated preparation questionnaire every week. If their weekly reported symptoms exceed a predefined threshold of severity, this results in a notification on the staff application interface and a nurse will contact a patient for verification of symptoms. Nurse will review patient recent treatment and PRO reports and advise patient according to the local practice for symptom management and reinforce reporting. Nurse will consult with or refers to (if possible) treating physician if patient will require medical intervention and/or physician assistance.
215068269|NCT00612417|DRUG|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
215068270|NCT03951493|COMBINATION_PRODUCT|Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.~The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.~The injections will be carried out either at the patient's home by the nurses or in the investigator centre."
214925115|NCT06222060|OTHER|Questionnaire about Shaken Baby Syndrome|Knowledge assessment questionnaire completed in the maternity ward by both parents
214925116|NCT02260869|PROCEDURE|Genicular nerve radiofrequency ablation|Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
214925117|NCT02260869|DEVICE|Pain Management Radiofrequency Kit|The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
214925118|NCT04081090|BEHAVIORAL|Brain HQ Cognitive Modules|Online personalized cognitive therapy modules to address and improve neuroplasticity.
214925119|NCT02572596|DRUG|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
214925120|NCT02572596|DRUG|CTX|CTX 2.5/m2 for 2 days.
215068271|NCT03951493|RADIATION|Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy."
214925121|NCT02572596|DRUG|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
214925122|NCT06482723|DEVICE|mGlobal L+AS|The investigated dermal filler mGlobal L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
214925123|NCT06074809|DRUG|Modified Guizhi Fuling granules|Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.
214925124|NCT06074809|OTHER|Placebo|Placebo will be orally administered to patients in the placebo group twice a day throughout the treatment period, which lasts for 8 weeks.
214925125|NCT06085144|DRUG|Galcanezumab|Receiving either 120mg or 300mg injections.
214925126|NCT00725790|DRUG|Vardenafil|"10 mg vardenafil on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period."
214925127|NCT00725790|DRUG|Placebo|"10 mg placebo on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period."
214925128|NCT05716256|DRUG|Ulinastatin|The CIS-ULI group received ulinastatin 5000U/kg followed by cisatracurium 0.1 mg/kg The CIS-NS (control) group received normal saline 0.1ml/kg followed by cisatracurium 0.1 mg/kg. The ROC-ULI group received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg The ROC-NS (control) group received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg
214925129|NCT05716256|PROCEDURE|TOF monitoring|The acceleromyograph TOF-Watch® SX (Organon, Ireland) is used for TOF monitoring. When the Narcotrend™ index is below 50 and level of anesthesia assessed as deep enough, TOF stimulation is started at 50 mA amplitudes and the setup is checked for any problem concerning the electrodes impedance and local hand temperature. After 1 minute, TOF stimulation is stopped and a tetanic stimulation (each electrical stimulus of 200μs duration and 50 mA amplitude) is delivered at a frequency of 50Hz for 5 seconds. After this procedure the alignment of sensors are checked to see if they are intact and readjust to their initial position if necessary. A no stimulation pause is observed during 3 minutes.
215068272|NCT03819556|OTHER|Milk protein in fresh milk|Milk protein in increasing doses.
215068273|NCT02943330|OTHER|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
215068274|NCT05467332|DEVICE|HIGH FLOW NASAL OXYGEN|"BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES."
215068275|NCT01671293|BEHAVIORAL|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer \& waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
215068276|NCT01671293|OTHER|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
215068277|NCT06400576|OTHER|Headphone and Smartphone Intervention|Asessment of participants' static balance and pressure distrubiton, posturographic balance and dynamic balance whilst using headphones and messaging.
215068278|NCT04590404|BEHAVIORAL|Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.|Automated calls to assess smoking status, medication use, and additional support for quit attempt.
215068279|NCT04590404|DRUG|Nicotine Replacement Therapy|FDA-approved forms of nicotine replacement therapy for smoking cessation.
215068280|NCT04590404|DRUG|Varenicline|FDA-approved smoking cessation medication.
214925130|NCT04234295|PROCEDURE|Fat Tissue Biopsy|If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
214925131|NCT06350695|DEVICE|low grade compression stockings (10-15 mmHg)|Patient will wear low grade compression stockings (10-15 mmHg) at least 8 hours a day 5 days a week
214925132|NCT06350695|DEVICE|high grade compression stockings (20-30 mmHg)|Patient will wear low grade compression stockings (20-30 mmHg) at least 8 hours a day 5 days a week
214925133|NCT04288921|DIAGNOSTIC_TEST|Swab|Swab samples for diagnostic test
214925134|NCT00378508|DRUG|mAb hOKT3gamma1(Ala-Ala), Teplizumab|This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
214925135|NCT00378508|DRUG|Placebo Arm|
214925136|NCT01167738|DRUG|capecitabine|1250 mg/mq days 1-28 every 4 weeks
214925137|NCT01167738|DRUG|cisplatin|30 mg/mq on days 1 and 15 every 4 weeks
214925138|NCT01167738|DRUG|epirubicin|30 mg/mq on days 1 and 15 every 4 weeks
214925139|NCT01167738|DRUG|gemcitabine|800 mg/mq on days 1 and 15 every 4 weeks
214925140|NCT01167738|DRUG|metformin|2 g days 1-28 every 4 weeks
214925141|NCT02568020|DRUG|keto-amino acids|Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
214925142|NCT00006485|DRUG|alvocidib|
214925143|NCT00006485|DRUG|irinotecan hydrochloride|
215068281|NCT04590404|OTHER|Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)|Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy. NMR is a blood test to measure how fast the body breaks down nicotine.
214925144|NCT04289207|DRUG|Romiplostim and danazol|Treatment with romiplostim and danazol
214925145|NCT03105635|OTHER|Mixed method feasibility study|"Participating practices will receive the following:~1. Training on community resources : An orientation regarding the availability of the local community health and social resources, and the existing navigation services that can support individuals identify the appropriate resource.~2. Facilitation to enhance referrals: help support practices to make the desired adaptations to enhance referrals~3. Promotional material to engagement patients: Practices will provide an area in the waiting room where promotional material on the benefit and availability of community resources will be displayed.~4. Navigator: The services of a Navigator"
214925146|NCT04827628|DIETARY_SUPPLEMENT|Oryza Sativa Extract|The product is a suspension of 5.6 gram/100 mL given once daily, contains 71.9%, purple in color, range pH 3-5. Stored in the darker bottle. The frequency of administration is once-daily after the meal.
214925147|NCT04827628|DIETARY_SUPPLEMENT|Control|citric acid 0.1g/oz and 1% sorbitol mixture, given once daily after meal
214925148|NCT05197647|OTHER|Patients with symptomatic COVID-19 disease not requiring hospitalization.|Patients with symptomatic COVID-19 disease not requiring hospitalization.
214925149|NCT04563871|DRUG|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
215068282|NCT02445014|DEVICE|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
214925150|NCT04960683|DEVICE|Lokomat training|"Control group will receive the routine conventional physiotherapy treatment and the treatment for this group consists of the following:~Conventional therapy protocol:~* 5 sessions of 45 minutes a week, each session includes:~* 5 minutes of stretching exercise~* 20 minutes of strengthening exercise~* 10 minutes of balance exercise~* 10 minutes of gait training~Experimental group will receive 45 min of Lokomat in addition to the conventional approach (as explained above). Since Lokomat appointments can be only 8 per day, it is planned to have two groups of 8 participants for 4 weeks each. The Lokomat training include the following:~* 5 sessions of 45 minutes of conventional therapy (same as above) per week~* 5 sessions of 45 minutes on Lokomat per week"
214925151|NCT02014233|DIETARY_SUPPLEMENT|Omega-3|
214925152|NCT02014233|DIETARY_SUPPLEMENT|Olive oil|
214925153|NCT03258840|DIETARY_SUPPLEMENT|EPA Supplement|EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.
214925154|NCT03258840|DIETARY_SUPPLEMENT|EPA Placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.
214925155|NCT01283334|DRUG|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
214925156|NCT01283334|DRUG|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
214925157|NCT01283334|DRUG|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
214925158|NCT00559624|DRUG|Acadesine|For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
214925159|NCT04265638|BEHAVIORAL|Exercise|One on one exercise with a cancer exercise specialist 1 hour 3 times a week for 12 weeks.
214925160|NCT03467217|DRUG|Losartan potassium|Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype
214925161|NCT03467217|DRUG|Placebo losartan capsule|Matching placebo losartan oral capsule
214925162|NCT02393924|OTHER|No intervention|
214925163|NCT03540004|DEVICE|MolecuLight i:X Imaging Device|The i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
214925164|NCT01556568|DRUG|MEK162|
214925165|NCT01665820|DEVICE|Auscultate with electronic or mechanical stethoscope (3M Littmann)|
214925166|NCT06620601|DIAGNOSTIC_TEST|Portable Polysomnography|Research assistants set up the portable polysomnography (Prodigy) for the overnight sleep study.
214925167|NCT06620601|DEVICE|Treatment|Based on the decision aid, patient preference, and CADTH recommendations, the sleep physicians will recommend the participant to use Auto-CPAP or MAD for six months.
214925168|NCT06620601|OTHER|Questionnaires|Participants will complete eleven questionnaires: Stop-Bang, Insomnia severity index, Epworth sleepiness score (ESS), quality of life (FOSQ-10), Beck Depression Inventory (BDI), Chalder Fatigue Scale (CFQ), primary care post-traumatic stress disorder (PTSD) scale (PC-PTSD-5), Asthma control questionnaire (ACQ), OHIP-14, and Participant demographics. The RA will help the participants complete the questionnaires (\~one and a half hours in total).
214925169|NCT04530266|DIAGNOSTIC_TEST|Six minute walk test|Assessment of walking related performance fatigability using six minute walk test
214925170|NCT04833725|DEVICE|wearable devices|All patients use wearable devices and IoT technology for information collection and data management. Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
214925171|NCT01770366|DEVICE|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
214925172|NCT01770366|DEVICE|Usual Care|
215068283|NCT05851079|DIAGNOSTIC_TEST|TCT test|These tests were performed on cervical exfoliated cells.
215068284|NCT05851079|DIAGNOSTIC_TEST|Vaginoscopy|To obtain the results of the patient's pathology report.
215068285|NCT05851079|DIAGNOSTIC_TEST|High throughput HPV typing and integration detection methods|This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
214324656|NCT06128265|BEHAVIORAL|Sleep Extension|Extending time in bed by 2 hours (going to bed earlier and/or waking up later)
214324657|NCT06128265|BEHAVIORAL|Sleep Regularity|Consistent bedtimes (within 30min)
214324658|NCT06401486|DEVICE|Videolaryngoscope|For patients assigned to the videolaryngoscope Group, the operator will use a video laryngoscope on the first laryngoscopy attempt.
214324659|NCT06401486|DEVICE|Macintosh laryngoscope|For patients assigned to the laryngoscope Group, the operator will use a Macintosh laryngoscope on the first laryngoscopy attempt.
215068286|NCT05851079|DIAGNOSTIC_TEST|Cobas HPV test|To obtain HPV typing results.
215068287|NCT00718575|PROCEDURE|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
215068288|NCT01002235|BIOLOGICAL|VM202|Intramuscular injections in the calf on Day 0 and Day 14.
214324660|NCT02143414|PROCEDURE|Biopsy Procedure|Undergo a biopsy
215068289|NCT02374788|BEHAVIORAL|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
215068290|NCT02374788|BEHAVIORAL|Group meetings|Participants receive 12 group meetings over two years' time.
215068291|NCT02374788|BEHAVIORAL|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
215068292|NCT05288790|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement
214925173|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
215068293|NCT05288790|DIETARY_SUPPLEMENT|Placebo|Placebo sachet
214925174|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
214925175|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
215068294|NCT04972396|DRUG|Pemvidutide|Injected subcutaneously (SC)
215068295|NCT04972396|DRUG|Metformin|Taken by mouth (PO)
214324661|NCT02143414|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
214324662|NCT02143414|BIOLOGICAL|Blinatumomab|Given IV
214324663|NCT02143414|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
214324664|NCT02143414|PROCEDURE|Computed Tomography|Undergo a CT scan
214324665|NCT02143414|DRUG|Dasatinib|Given PO
214324666|NCT02143414|PROCEDURE|Echocardiography Test|Undergo ECHO
214324667|NCT02143414|PROCEDURE|Lumbar Puncture|Undergo a lumbar puncture
214324668|NCT02143414|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214324669|NCT02143414|DRUG|Mercaptopurine|Given PO
214324670|NCT02143414|DRUG|Methotrexate|Given PO
214925176|NCT00006024|DRUG|lomustine|
214925177|NCT00006024|DRUG|temozolomide|
214925178|NCT03281187|DRUG|Nasotestt 5 mg|The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
214925179|NCT03281187|DRUG|Androgel 50 mg|The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.
214925180|NCT03281187|OTHER|Nasotestt Placebo|The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
214925181|NCT03281187|OTHER|Androgel Placebo|The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
215068296|NCT04972396|DRUG|Atorvastatin|Taken by mouth (PO)
215068297|NCT04972396|DRUG|Warfarin|Taken by mouth (PO)
215068298|NCT04972396|DRUG|Digoxin|Taken by mouth (PO)
215068299|NCT04972396|DRUG|Ethinylestradiol and Levonorgestrel|Taken by mouth (PO)
215068300|NCT00113633|BEHAVIORAL|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
215068301|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy + Hiatal hernia repair|To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.
215068302|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy alone|Current mainstay and standard surgical treatment for morbidly obese patients.
215068303|NCT03935672|PROCEDURE|PET-CT scans|"Patients will have three scans during the trial.~* The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV\_P. bGTV\_P will then be used as an adjunct to help us delineate the GTV\_P.~* The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV\_iP).~* The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment."
215068304|NCT03935672|PROCEDURE|Outlining the biological GTVs (bGTV_P and bGTV_iP)|The biological GTVs (bGTV\_P and bGTV\_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.
214324671|NCT02143414|DRUG|Methotrexate Sodium|Given PO
214324672|NCT02143414|DRUG|Prednisone|Given PO
214324673|NCT02143414|DRUG|Vincristine|Given IV
214925182|NCT02796859|DRUG|Siltuximab|Investigational agent
214925183|NCT02796859|DRUG|normal saline|Placebo
214925184|NCT04635826|DRUG|Adderall 10Mg Tablet|Participants will be administered Adderall
214925185|NCT04635826|DRUG|Placebo|Participants will be administered placebo
214925186|NCT00964938|DEVICE|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
214925187|NCT00367731|DRUG|Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)|
214925188|NCT05233748|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
215068305|NCT03935672|PROCEDURE|Blood samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
215068306|NCT03935672|PROCEDURE|Salivary samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
214925189|NCT04027725|BEHAVIORAL|Neurofeedback|Neurofeedback experiment will consist of 20 sessions of neurofeedback training, twice or three times a week during seven weeks. Each session will last for 40 minutes. The experimental group will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-trianing (T1) and 1 month follow-up (T2). Electroencephalography will be recorded by a technician in EEG for each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T1 and T2.
214925190|NCT06513143|OTHER|CT images into virtual 3D model demonstration|The investigators have finished is personalized 3D model translation from CT images into virtual 3D model demonstrated in VR glasses using Synapse.
214925191|NCT02787824|DRUG|Iron Sucrose Supplement|
214925192|NCT04669873|RADIATION|Active Comparator: Standard|Radiation: Whole Breast Irradiation + Boost Whole breast, either 40Gy, in 15 fractions, in 3 weeks
214925193|NCT04669873|RADIATION|Experimental 1: Hypofractionated radiotherapy|Radiation: Hypofractionated irradiation Whole Breast Irradiation 26Gy in 5 fractions in one week
214925194|NCT04669873|RADIATION|Experimental 2: Accelerated Partial Breast Irradiation|Radiation: Accelerated partial breast irradiation Tumor bed 26Gy in 5 fractions, in 5 days.
214925195|NCT05143229|DRUG|Alpelisib|PI3K inhibitor
214925196|NCT05143229|DRUG|Sacituzumab govitecan|Trop-2-directed antibody and topoisomerase inhibitor drug conjugate
214925197|NCT04480671|PROCEDURE|Level III support procedure|A level III support procedure is aimed at repairing the distal support of the vagina with either a posterior colporrhaphy and/or a perineorrhaphy.
214925198|NCT04480671|PROCEDURE|Minimally Invasive Sacrocolpopexy|All study participants are planning with their surgeon a minimally invasive sacrocolpopexy (robotic or laparoscopic) to repair pelvic organ prolapse.
215068307|NCT01581021|DEVICE|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
215068308|NCT01581021|DEVICE|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
215068309|NCT00419211|BEHAVIORAL|Exercise|Tailored exercise program
215068310|NCT00675441|DRUG|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
215068311|NCT00392587|DRUG|GW856553|
215068312|NCT02471534|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
215068313|NCT04377321|DRUG|Colchicine Tablets|colchicine tabletes for 6 months
214324674|NCT02143414|DRUG|Vincristine Sulfate|Given IV
214324675|NCT02143414|PROCEDURE|X-Ray Imaging|Undergo an x-ray
214324676|NCT01356511|DRUG|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
214324677|NCT01356511|DRUG|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
214324678|NCT06342713|DRUG|BGB-45035|Administered orally
214324679|NCT06342713|DRUG|Placebo|Administered orally
214925199|NCT04480671|OTHER|Transperineal ultrasound of the Pelvic Floor|Subjects from either arm will be invited to participate in this exploratory arm of the study. If they choose to participate, they will have a preoperative ultrasound performed and an ultrasound performed at the time of their 6 month visit.
214925200|NCT01105078|PROCEDURE|Flow rate|Different flow rate during cardiopulmonary bypass
214925201|NCT06010693|DRUG|Daridorexant|Participants will receive one Daridorexant 50mg tablet, orally, once daily for about 28 consecutive night on each night approximately 30mintues before participants intends to try to sleep.
214925202|NCT06010693|DRUG|Placebo|Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.
215068314|NCT03085134|OTHER|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
215068315|NCT03085134|OTHER|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
215068316|NCT05848466|DRUG|BAT8010 for Injection|Intravenous
215068317|NCT03116035|OTHER|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
215068318|NCT03116035|OTHER|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
215068319|NCT03851328|OTHER|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
215068320|NCT01006655|DRUG|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
215068321|NCT01006655|DRUG|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
215068322|NCT01198704|OTHER|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
215068323|NCT04432649|BIOLOGICAL|4SCAR-276|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
214672938|NCT05814029|OTHER|Mobilization with movement for Ankle|The participant will assume a lunge position on a rigid serving table with the relevant extremity in a weight-bearing stance and the foot in a neutral position. An inelastic belt will be placed around the clinician's waist, flush with the lower edge of the medial malleolus, around the distal tibia and fibula. The clinician will stabilize the talus and forefoot with the web spacing of the hands and pressure dimensions on the talus and forefoot, and maintain posterior to anterior sliding of the tibia over the talus using the arch. The clinician will continue to apply pressure while the person is reporting discomfort and/or while the lunge moves, which will continue until the end of the range of motion. Mobilization will be performed as a 3 set of 10 repetitions.
214925203|NCT00811811|BEHAVIORAL|Behavioral neurocardiac training|6 training sessions scheduled over 8 weeks
214925204|NCT00811811|BEHAVIORAL|Autogenic relaxation training|6 training sessions scheduled over 8 weeks
214925205|NCT05262309|DRUG|Pamrevlumab|"Pamrevlumab dosing, 30 mg/kg IV, will be administered at day 1, day 7 and day 14.~Based on Investigator's decision, treatment may be continued every 3 weeks after day 14, up to 11 weeks."
214925206|NCT06086145|OTHER|No intervention|No intervention
215068324|NCT00256360|DRUG|dose dense with neulasta|
215068325|NCT00599534|DRUG|Montelukast|4 mg oral tablets
215068326|NCT00599534|DRUG|Placebo|5mg tablets
215068327|NCT01266109|BEHAVIORAL|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
215068328|NCT01266109|OTHER|Usual Services (US)|Typical community-based substance abuse treatment services
215068329|NCT05049564|PROCEDURE|keyhole microneurosurgery|microsurgical clipping via keyhole approach
214925207|NCT06685653|BIOLOGICAL|Adebrelimab+RGL-270|"Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines"
214925208|NCT06685653|BIOLOGICAL|Adebrelimab+RGL-270/single RGL-270|"Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines"
214925209|NCT05013151|DIETARY_SUPPLEMENT|Dates|Consumption of 6 dates a days until 41 weeks of gestation
214925210|NCT05013151|DIETARY_SUPPLEMENT|Castor oil|One time consumption of 60 CC Castor oil
215068330|NCT05049564|PROCEDURE|conventional microneurosurgery|microsurgical clipping via conventional craniotomy
214925211|NCT06619314|DRUG|MK-1084|Oral Tablet
214925212|NCT06619314|DRUG|PPI|Oral Capsule
214925213|NCT04113655|BIOLOGICAL|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
215068331|NCT05049564|PROCEDURE|endovascular coiling|endovascular coiling via femoral approach
215068332|NCT00154700|DRUG|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
215068333|NCT01232504|DRUG|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
215068334|NCT01232504|DRUG|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
215068335|NCT01232504|DRUG|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
215068336|NCT00054327|DRUG|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
215068337|NCT00054327|DRUG|cyclophosphamide|Given IV
215068338|NCT00054327|DRUG|cytarabine|Given IV
214925214|NCT04113655|BIOLOGICAL|Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
214925215|NCT04113655|BIOLOGICAL|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202"
215068339|NCT00054327|RADIATION|radiation therapy|Patients undergo total body irradiation
215068340|NCT00054327|DRUG|Etoposide|infusion
215068341|NCT00054327|PROCEDURE|Stem Cell Transfusion|
215068342|NCT05948527|DEVICE|high flow nasal canula|administration of high flow nasal canula at initial flow 35 liters per minute and Fio2 (fraction of inspired oxygen of 50%) with titration to reach oxygen saturation of 88-92%.
215068343|NCT02021383|BEHAVIORAL|Bi-weekly in person meetings with a Registered Dietician|"Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings."
215068344|NCT02021383|BEHAVIORAL|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
215068345|NCT00135538|DEVICE|Noninvasive positive pressure ventilation|
215068346|NCT04044053|DRUG|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
215068347|NCT04044053|DRUG|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
214672939|NCT02648230|DEVICE|St. Jude Medical Pressure Wire|FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
214925216|NCT06683872|PROCEDURE|surgical myectomy|Our procedure was performed via a right infra-axillary incision (4-5 cm), enter the thoracic cavity through the third intercostal space lateral to the pectoralis major muscle. Generally, neither rib resection nor division of the pectoralis major muscle were required. The intervention utilized femoral-femoral cardiopulmonary bypass (CPB). The aorta was clamped using a Glauber clamp (CardioVision MICAortic Clamp, Cardiomedical GmbH). Myocardial protection was achieved with antegrade Del Nido cardioplegia. After inducing of cardiac asystole, a transverse incision was made in the aorta and the aorta incision was suspended to enhance visualization. A mesh retractor (FEHLING INSTRUMENTS, Karlstein, Germany) was placed in the aortic sinus to protect the aortic leaflets. The extent of the septal myectomy, determined based on preoperative TEE, started 5 mm below the midpoint of the right coronary cusp. It extended counterclockwise towards the anterior commissure of the mitral valve a
214925217|NCT02989246|OTHER|Ventilator protocol|Open loop ventilator management by a computer based protocol
214925218|NCT02989246|DEVICE|Esophageal Catheter|Esophageal manometry measurements of patient effort of breathing will be used to guide the protocol recommendations
214925219|NCT06666712|DRUG|Topotecan|Topotecan (TPT) is a chemotherapeutic agent that is a topoisomerase inhibitor. This intervention is uniquely distinguished through its administration using an externalized catheter and external microinfusion pump (Convection-Enhanced Delivery)
214925220|NCT02610543|DRUG|UCB5857|Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
214925221|NCT02610543|DRUG|Placebo|Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
214925222|NCT03429933|DRUG|BMS-986278|Specified dose on specified days
214925223|NCT03429933|OTHER|Placebo|Specified dose on specified days
214925224|NCT01477996|PROCEDURE|27-gauge|27-gauge needle for IVT
214925225|NCT01477996|PROCEDURE|30-gauge|30-gauge needle for IVT
214925226|NCT00287196|RADIATION|Radiotherapy|48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
214925227|NCT04126902|OTHER|interleukin-6, presepsin and pentraxin-3|measurements and compare
214925228|NCT00692471|DEVICE|Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter|Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
214925229|NCT04166344|BEHAVIORAL|Happyair Ecosystem|"Happyair Ecosystem is a Smart Community for the integral care of patients with chronic or rare respiratory diseases such as Asthma, COPD or Alfa-1.~Our community provides online \& offline training and resources in digital health and social care to patients, family, caregivers, healthcare professionals and researchers.~Using our platform, all of our members will be able to connect in order to improve the health and well-being of patients, learn to manage self-care, ensure an active lifestyle, and contribute to the development of current and future research projects."
214925230|NCT06684509|DRUG|Atrovastain|atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months
214925231|NCT02649244|BEHAVIORAL|The Family Caregiver Training Program|The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
214925232|NCT03233529|DRUG|Crisaborole ointment 2% BID|Crisaborole ointment 2% BID for 15 days (double blind); additional 28 days (open label)
214925233|NCT03233529|DRUG|Placebo ointment (vehicle)|Placebo ointment (vehicle) BID for 15 days (double blind)
214925234|NCT05194761|DRUG|Normal saline|Using normal saline nebulization in neonates postextubation
214925235|NCT01177293|DRUG|Amlodipine - reference|Amlodipine capsule, 10 mg, single dose, with water
214925236|NCT01177293|DRUG|Amlodipine ODT - test|Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
215068348|NCT04044053|DRUG|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
215068349|NCT04044053|DRUG|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
215068350|NCT01803100|OTHER|No intervention|There is no intervention in this trial
215068351|NCT05962684|OTHER|ERAS|Implementation of ERAS protocol in elective craniotomy patients
215068352|NCT01634880|DRUG|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
214672940|NCT02648230|DEVICE|ACIST Navvus Microcatheter|FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
214672941|NCT00188994|DRUG|Insulin Cardioplegia|
214672942|NCT05509244|DRUG|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
214672943|NCT05509244|DRUG|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
214672944|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
214672945|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
214672946|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet|Brazilian cardioprotective diet prescription
214925237|NCT01003483|DRUG|orlistat|Tablet,120mg,three times a day,three months
214925238|NCT03858361|DEVICE|Atrial Flutter Ablation|Catheter-based electrophysiological (EP) intervention.
214925239|NCT00052130|BIOLOGICAL|CancerVax vaccine (CANVAXIN)|
214925240|NCT00633815|OTHER|Supine positioning|Subjects underwent exercise testing on a stationary bicycle in the supine position
214925241|NCT00633815|OTHER|Upright positioning|Subjects underwent exercise testing on a stationary bicycle in the upright position
214925242|NCT03614468|OTHER|Formula A|Formula A is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
214925243|NCT03614468|OTHER|Formula B|Formula B is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
214925244|NCT01883050|DEVICE|Self Monitoring Software Application|Computer Software application to track health progress after interventional surgery
214925245|NCT03917316|OTHER|Language and neuropsychological tests|Tests related to language, narrative and specific and general cognitive function
214925246|NCT00981669|BIOLOGICAL|rotavirus vaccine|3 doses with 6 weeks interval
214925247|NCT00981669|BIOLOGICAL|placebo|3 doses with 6 weeks interval
214925248|NCT01491204|DRUG|Paclitaxel+HM30181|oral, 3times for 4weeks
214925249|NCT00800657|PROCEDURE|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
214925250|NCT00800657|PROCEDURE|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
214925251|NCT01038401|PROCEDURE|GI endoscopy and GALT biopsies|This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
215068353|NCT03160248|DRUG|Apremilast|This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
215068354|NCT03160248|DRUG|Placebo Oral Tablet|This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
215068355|NCT00140049|DRUG|Xalacom|
215068356|NCT00140049|DRUG|Cosopt|
215068357|NCT01268592|PROCEDURE|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
215068358|NCT00386217|BEHAVIORAL|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
215068359|NCT00700882|DRUG|dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
214925252|NCT01038401|BIOLOGICAL|A sample of venous blood will also be collected|These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
214925253|NCT01623401|DRUG|TR-701 FA|TR-701 FA 200 mg once daily
214925254|NCT05902091|BEHAVIORAL|Neurophysiology-based intervention|
214925255|NCT00648622|DRUG|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
214925256|NCT00648622|DRUG|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
214925257|NCT03719248|DEVICE|thoracic epidural|high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG
214925258|NCT04194762|OTHER|Non pharmacological therapy|treadmill training and cycling training in equal intensity exercise.
214925259|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction)|This intervention involves performing a One Anastomosis Gastric Bypass surgery with the bypassed length of the small intestine set at 150 centimeters from the duodenojejunal junction. This shorter limb length is designed to achieve weight loss while potentially reducing the risk of nutritional deficiencies. The procedure is performed laparoscopically, with the stomach divided to create a gastric tube attached to a loop of the small intestine. Postoperative outcomes will include assessments of weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers such as albumin, calcium, and iron.
215068360|NCT04166578|DRUG|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
215068361|NCT04166578|PROCEDURE|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
215068362|NCT04166578|PROCEDURE|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
215068363|NCT04166578|BEHAVIORAL|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
215068364|NCT04166578|BEHAVIORAL|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
214672947|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet plus 30g/day of mixed nuts|Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
215068365|NCT04166578|DIAGNOSTIC_TEST|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
214672948|NCT01823653|DEVICE|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
215068366|NCT04166578|DIAGNOSTIC_TEST|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
215068367|NCT00683930|DRUG|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
215068368|NCT00683930|DRUG|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
215068369|NCT00683930|DRUG|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
215068370|NCT02591537|DEVICE|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
214925260|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction)|This intervention involves performing a One Anastomosis Gastric Bypass surgery with a bypassed length of 170 centimeters from the duodenojejunal junction, offering an intermediate limb length. This distance is intended to balance weight loss effectiveness with moderate risks of nutritional deficiencies. The laparoscopic procedure involves creating a gastric tube attached to a segment of the small intestine, bypassing the proximal portion. Outcomes monitored postoperatively include weight loss, percentage of total and excess weight loss, and nutritional parameters such as albumin, calcium, and iron levels.
214925261|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)|This intervention consists of performing a One Anastomosis Gastric Bypass with the bypass length set at 200 centimeters from the duodenojejunal junction. This longer bypass length is designed to maximize weight loss outcomes but may carry a higher risk of nutritional deficiencies. The procedure is done laparoscopically, where the stomach is divided, creating a tube that is joined to the small intestine at the specified length. Postoperative assessments will focus on weight loss effectiveness, total and excess weight loss percentages, and the risk of nutritional deficiencies by measuring markers such as albumin, calcium, and iron.
214925262|NCT02339324|DRUG|Pembrolizumab and high dose interferon alfa-2b (HDI)|Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
214925263|NCT02590575|DEVICE|Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform|"1. With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows~2. Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value"
214925264|NCT03305861|PROCEDURE|ThuLEP|Thulium laser enucleation of prostate
214925265|NCT03305861|PROCEDURE|Green LEP|Greenlight laser enucleation of prostate
214925266|NCT02807571|PROCEDURE|Wide Awake Local Anesthesia No Tourniquet|Wide Awake Local Anesthesia No Tourniquet for office based hand surgery.
214925267|NCT02297178|PROCEDURE|Cystoscopy only|Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
214925268|NCT02297178|PROCEDURE|Cystoscopy and Urethral dilatation|Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
214925269|NCT01905553|DRUG|SSP-004184SS|Disodium salt
214925270|NCT05118776|DRUG|ASC40 tablets|ASC40 tablets administered orally once daily
214925271|NCT05118776|DRUG|Placebo tablets|Placebo administered orally once daily.
214925272|NCT05118776|DRUG|Bevacizumab|Bevacizumab once every 2 weeks, intravenous drip.
214925273|NCT01233960|DRUG|adult human mesenchymal stem cells|PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
214925274|NCT02240927|DRUG|Low Molecular Weight Heparine : Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
215068371|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
214925275|NCT02240927|DRUG|Enoxaparine and 2.5 mg Warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4)
214925276|NCT02240927|DRUG|Enoxaparine and 4mg Warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
215068372|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
215068373|NCT00913887|DRUG|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
215068374|NCT04933045|DEVICE|Arthrex InternalBrace|Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
215068375|NCT02733770|PROCEDURE|Laparoscopic sleeve gastrectomy|Doppler ultrasound.
215068376|NCT02733770|PROCEDURE|Laparoscopic mini gastric bypass|Doppler ultrasound.
215068377|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose L|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
214324680|NCT05757817|PROCEDURE|Oropharyngeal or oral cavity reconstruction|"Oropharyngeal or oral cavity reconstruction will be performed using a free super thin external pudendal artery flap (STEPA flap).~Post-operative follow-up and adjuvant treatment: Post-operative follow-up of patients will be performed according to the standards of the participating centers."
215068378|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose A|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
215068379|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose B|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
215068380|NCT06134648|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
215068381|NCT01454505|DRUG|AL-53817 nasal spray solution|Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
215068382|NCT01454505|OTHER|Vehicle nasal spray|Inactive ingredients used as placebo comparator during Stage A and Stage B.
215068383|NCT03580278|BIOLOGICAL|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
214324681|NCT05893654|DRUG|Melphalan Injection|7.5mg of melphalan injected via intra-arterial catheterization of the ophthalmic artery.
215068384|NCT03714217|BEHAVIORAL|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
214925277|NCT02240927|DRUG|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
214925278|NCT03879980|DRUG|Bilateral QL block|Bilateral lateral Quadratus Lumborum block using 20 ml of 0.25% bupivacaine each injection as preemptive analgesia.
214925279|NCT03879980|DRUG|Non-QL block|Only received fentanyl IV during surgery.
215068385|NCT04626687|DEVICE|test DCB|use paclitaxel coated coronary balloon catheters to treat SVD
215068386|NCT04626687|DEVICE|RESTORE DCB|use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD
215068387|NCT00559429|DRUG|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
215068388|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
214324682|NCT05893654|RADIATION|Plaque brachytherapy|Brachytherapy will be performed using a 24-mm notched plaque with Ruthenium-106 seeds.
214324683|NCT03968744|DRUG|Safinamide|Safinamide taken per Os for 12 weeks
214324684|NCT05427500|DRUG|5 mL of 0.5% preservative-free bupivacaine|IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.
214324685|NCT05518279|DRUG|Tranexamic Acid Pill|Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.
214925280|NCT05632198|OTHER|Survey|Valid and reliable questionnaires covering perceived uncertainty, self-care behaviors and quality of life will be administered.
214925281|NCT03459898|DEVICE|AlignRT system (VisionRT Ltd., London, UK)|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
214925282|NCT04181047|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|Psychotherapy.
214925283|NCT04181047|OTHER|Usual care|Access to usual care, including psychiatrist, medications, mental health therapist, general community mental health programs. TAU will NOT include electroconvulsive therapy or another trauma specific psychotherapy.
214925284|NCT02538289|BEHAVIORAL|Teaching talks|Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.
214925285|NCT02644629|DRUG|Placebo|Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
215068389|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
215068390|NCT00559429|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
215068391|NCT03572959|DRUG|0.1 % topical triamcinolone acetonide|0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.
215068392|NCT03572959|DEVICE|SIROIaser|"Oral Lichen Planus lesions were irradiated with a 970-nm diode laser with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly (once every third day) for two months until the resolution of signs for a maximum of ten sessions."
215068393|NCT04154293|DRUG|Isotretinoin|Topical Isotretinoin ointment
215068394|NCT04154293|OTHER|Vehicle|Topical Vehicle Ointment
215068395|NCT00879151|BEHAVIORAL|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
215068396|NCT00879151|BEHAVIORAL|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
215068397|NCT00879151|BEHAVIORAL|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
214672949|NCT02717546|DEVICE|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
214672950|NCT05937711|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG|"PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes~Duloxetine 30 mg p.o 1X1 (daily)"
214672951|NCT05937711|DRUG|Duloxetine 30 MG|Duloxetine 30 mg p.o 1X1 (daily)
214672952|NCT05901181|BEHAVIORAL|Laughter Yoga|"Laughter yoga is a childlike practice where group members make eye contact with each other.~It is a breath yoga practiced by imitating games and fake laughing. Brain the effects of real laughter on the body, as it cannot distinguish between fake and real laughter.~showing positive effects. It consists of sessions lasting at least 20 minutes and an average of 45 minutes."
214672953|NCT02120586|OTHER|Inspiratory Muscle Training (IMT).|"Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10."
215068398|NCT05686746|DRUG|Baricitinib 4 MG|4 mg oral daily
215068399|NCT05686746|DRUG|Baricitinib 2 MG|2 mg oral daily
215068400|NCT05686746|DRUG|MMF|1000 mg oral daily
215068401|NCT05894980|DEVICE|active tDCS stimulating left DLPFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
215068402|NCT05894980|DEVICE|active tDCS stimulating right OFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
215068403|NCT05894980|DEVICE|sham tDCS|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
215068404|NCT06251466|DEVICE|iHealth Gluco-Smart application|iHealth Gluco-Smart is an application where blood glucose measurements can be registered. This application can be coupled to a platform in the hospital, called Dharma, that enables the researchers to evaluate these blood glucose levels.
215068405|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as Monotherapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
215068406|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as a Boost|The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
215068407|NCT02952508|DRUG|Iopofosine I 131 single dose|Radiopharmaceutical
215068408|NCT02952508|DRUG|Iopofosine I 131 multiple dose|Radiopharmaceutical
215068409|NCT02952508|DRUG|Iopofosine I 131 fractionated dose|Radiopharmaceutical
214925286|NCT02644629|DRUG|Ketamine (1st phase)|Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
214672954|NCT02120586|OTHER|Peripheral muscle training|"The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10."
214925287|NCT02644629|DRUG|Ketamine (2st phase)|Patients failing to achieve response (\<50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.
214925288|NCT02586519|DEVICE|SurroSense Rx System|"The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur."
214672955|NCT05207436|DRUG|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.
214925289|NCT04453072|OTHER|Interview|Participate in interviews
214925290|NCT04453072|OTHER|Media Intervention|Receive iPhone with W8Loss2Go app
214925291|NCT04453072|OTHER|Questionnaire Administration|Complete questionnaires
214925292|NCT04453072|OTHER|Scale Device|Receive body scale and food scale
214925293|NCT04453072|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
214925294|NCT04453072|OTHER|Text Message|Receive text message
215068410|NCT02152371|DRUG|Dulaglutide|Administered SQ
215068411|NCT02152371|DRUG|Placebo|Administered SQ
215068412|NCT02152371|DRUG|Insulin Glargine|Administered SQ
215068413|NCT02152371|DRUG|Metformin|Administered orally
215068414|NCT03814382|DEVICE|Acupuncture needle|Acupuncture needle
215068415|NCT05704023|BEHAVIORAL|Reminder to exercise|Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
215068416|NCT06241924|PROCEDURE|High Resolution Electroencephalogram (EEG-HR)|Local field potentials (LFP) recording using EEG-HR
215068417|NCT06241924|PROCEDURE|Stereo-electro-encephalography (SEEG)|Local field potentials (LFP) recording using sEEG
215068418|NCT06007339|DEVICE|PerQseal ELITE|"The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer."
215068419|NCT04677595|DRUG|Capmatinib|400 mg of capmatinib tablets, administered orally twice daily
215068420|NCT04188067|DEVICE|ACTIVE rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
215068421|NCT04188067|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
215068422|NCT04382586|DRUG|Zanubrutinib|320 mg (4 x 80 mg) capsules administered orally once daily
215068423|NCT04382586|DRUG|Supportive Care|Supportive care treatment was selected and administered as deemed appropriate by the study investigator
215068424|NCT04382586|DRUG|Placebo|Placebo to match zanubrutinib
215068425|NCT04442633|DRUG|Glutamine Cap/Tab|Glutamine Capsules: One capsule three times daily on an empty stomach for one month
215068426|NCT04442633|DRUG|Miconazole Oral gel|Miconazole oral gel: applied three to four times daily for three weeks
215068427|NCT04442633|DRUG|Kenacort in orabase|Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
215068428|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
215068429|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
215068430|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
215068431|NCT02425956|DEVICE|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
215068432|NCT05975619|DEVICE|HyperSight imaging|Subjects are scheduled for 1 to 5 HyperSight imaging sessions, which will occur on the same days as their standard clinical visits during planning and treatment delivery. A total of 5 to 10 HyperSight CBCT images will be acquired over all imaging sessions.
214925295|NCT04885179|OTHER|no intervention|No interventions are involved in this observational study.
214925296|NCT01083888|DRUG|roxadustat|oral
214925297|NCT00655707|BIOLOGICAL|Autologous Expanded CD34+ Haemopoietic cells|"Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.~Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells"
214925298|NCT06622356|OTHER|MRI with Eovist|The study was retrospective and did not design an intervention
215068433|NCT05961111|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
214672956|NCT05207436|BEHAVIORAL|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
214672957|NCT03756012|DEVICE|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
214925299|NCT03138252|DRUG|Oxytocin|
214925300|NCT03854370|OTHER|Baby shampoo|baby shampoo will be used to prepare the surgical site prior to incision
214925301|NCT03854370|OTHER|Betadine|Betadine (Povidone- iodine) will be used to prepare the surgical site prior to incision
215068434|NCT04207593|DRUG|Oxygen|Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2\>90% or pO2 \>60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
215068435|NCT06971614|BIOLOGICAL|T3011|T3011 will be administered at a dose of 1x10\^10 PFU intravesically.
215068436|NCT06149520|DRUG|BAY3018250|Dose 1 or dose 2 of BAY3018250
214672958|NCT01731691|BIOLOGICAL|α1 Proteinase Inhibitor|Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
214672959|NCT01731691|DRUG|Placebos|Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.
214925302|NCT03854370|OTHER|Peridex|Peridex (Chlorhexidine) will be used to prepare the surgical site prior to incision
214925303|NCT03854370|OTHER|TechniCare|TechniCare (chloroxynel) will be used to prepare the surgical site prior to incision
214925304|NCT03152331|BEHAVIORAL|Receptive Awareness Training|Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
215068437|NCT06149520|DRUG|Placebo to BAY3018250|Matching placebo to BAY3018250
215068438|NCT04829682|BEHAVIORAL|ACT for Life|ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.
215068439|NCT04829682|BEHAVIORAL|Present Centered Therapy|PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
214324686|NCT05518279|DRUG|Placebo Oral Tablet|Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
214324687|NCT03366077|DIETARY_SUPPLEMENT|Probiotic|Probiotic
214324688|NCT01666340|OTHER|Exercise intervention|Group asked to perform exercise at a given moderate intensity for a set time
214324689|NCT01666340|OTHER|Exercise intervention|High intensity exercise
214324690|NCT06043297|DRUG|Apixaban 5MG|Each film-coated tablet contains 5 mg apixaban
214925305|NCT04071548|OTHER|HIIT Exercise|"HIIT exercise bike protocol~* 3 minute warm up~* Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age~* 10x60 second Recovery period~* 5 minute cool-down"
214925306|NCT00452673|DRUG|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
215068440|NCT05596734|BIOLOGICAL|bivalent BNT162b2 (original/Omi BA.4/BA.5)|Intramuscular injection
215068441|NCT05596734|BIOLOGICAL|qIRV (22/23)|Intramuscular injection
215068442|NCT05596734|BIOLOGICAL|QIV|Intramuscular injection
215068443|NCT05596734|BIOLOGICAL|bIRV|Intramuscular injection
215068444|NCT05596734|BIOLOGICAL|tIRV|Intramuscular injection
215068445|NCT06651268|DRUG|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
214925307|NCT00452673|DRUG|Capecitabine|Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.
214925308|NCT06221592|DEVICE|defocus spectacle lenses|To evaluate the differences in controlling the progression of myopia in adolescents and the safety and comfort of wearing different types of defocus incorporated multiple segments spectacle lenses, to explore the feasibility of effective defocus micro lens design, and apply personalized defocus frame lenses for myopia prevention and control.
214925309|NCT02656290|DEVICE|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position; a trileaflet bioprosthesis comprised of bovine pericardium
214925310|NCT04259203|BEHAVIORAL|Erickson hypnosis|Erickson hypnosis sessions performed by an experienced hypnotherapist, according to a pre-established protocol : 5 sessions (1 per week). Between each session : exercise of auto-hypnosis by the patient himself, at home
214925311|NCT05195918|COMBINATION_PRODUCT|EGCG 300 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
214925312|NCT05195918|COMBINATION_PRODUCT|EGCG 300 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
215068446|NCT04113018|DRUG|Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab|Experimental
215068447|NCT04763252|OTHER|Spectrum Therapeutics cannabis products|"For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products."
215068448|NCT05047913|DRUG|18F-FTX|Given By IV
215068449|NCT05877937|OTHER|Supportive care (Watching a comedy movie)|A 10.1 inch Android tablet (2 pieces) and disposable earplugs for each patient were used in the study. A comic film archive was created in line with the recommendation and consultancy of department of state conservatory and performing arts. In this regard, the officials of the Conservatory stated that they had no standardized comedy films specific to society and emphasized that the standardization of art limits art activities. Therefore, there should be no limitations for art. In the film archive cre-ated according to their suggestions, there were a total of five comedy movies, including three Turkish comedies, one foreign romantic comedy, and one foreign Turkish-dubbed family comedy. The original/licensed versions of the movies in this archive were ob-tained and uploaded to the tablet. The movies lasted 90-120 minutes (as long as the av-erage duration of IV treatment). The patients selected the movie that they would watch during the treatment.
215068450|NCT04475419|PROCEDURE|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)|covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
215068451|NCT02526810|DRUG|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
214925313|NCT05195918|COMBINATION_PRODUCT|Placebo 2 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
214925314|NCT05195918|COMBINATION_PRODUCT|EGCG 600 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
214925315|NCT05195918|COMBINATION_PRODUCT|EGCG 600 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
214324691|NCT06043297|DRUG|Eliquis 5 mg|Each film-coated tablet contains 5 mg apixaban
214324692|NCT02885363|OTHER|Clinical examination|
214925316|NCT05195918|COMBINATION_PRODUCT|Placebo 4 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
214925317|NCT04638881|DRUG|Magnesium sulfate|Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.
214324693|NCT02885363|OTHER|Blood sample|
214324694|NCT02885363|PROCEDURE|Echocardiography|
214324695|NCT01163383|DRUG|131 I-Metaiodobenzylguanidine (131 I-MIBG)|131 I-MIBG 1-18mCi/kg given intravenously on day 1. Subjects may receive multiple courses every 4-8 weeks depending on the dose given.
214324696|NCT01163383|DRUG|131 I-MIBG|131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
214324697|NCT06361888|DRUG|Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine|"Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Camrelizumab: 200mg, IV drip, Q3W, D1~3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
214925318|NCT04638881|DRUG|Normal Saline|Placebo. Bolus and infusion administered similarly under general anesthesia.
214925319|NCT00563810|DRUG|MYO-029|
214925320|NCT05504486|DRUG|Brexpiprazole|Oral tablet; take once daily; target daily dose of 2 mg
214925321|NCT01672749|DEVICE|Growth guiding construct using TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)
214925322|NCT01672749|DEVICE|Spine based dual growing rod or rib based VEPTR|spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
214925323|NCT04537117|OTHER|Questionaire|Questionnaire addressing pediatric dentists behaviors and practices during the COVID-19 pandemic
214925324|NCT00100113|DRUG|GBR 12909|
214925325|NCT06494332|OTHER|Exercise and stretching programe|It consists in: a serie of mobility exercises, which were used as warp-up; the mobility of the elbow, forearm, wrist and fingers of both upper limbs was worked on; and, exercises were performed to strengthen the muscles of both forearms.
215068452|NCT02526810|DRUG|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
214925326|NCT03076788|OTHER|electrocardiogram and echocardiography|"We retrieved all electrocardiograms and echocardiography made during the clinical examination of each athlete and each sedentary control.~* Standard 12 lead ECG~* Trans-thoracic echocardiography examination of cardiac function, morphology and intracardiac flow."
214925327|NCT01608087|DRUG|BI 695502|BI 695502 single i.v. infusion
214925328|NCT01608087|DRUG|bevacizumab|bevacizumab single i.v. infusion
214925329|NCT01608087|DRUG|bevacizumab|bevacizumab single i.v. infusion
215068453|NCT02370316|BEHAVIORAL|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
215068454|NCT02370316|BEHAVIORAL|Clinical Structured Treatment|structured case management and symptom-targeted medication
214925330|NCT02877394|DEVICE|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
214925331|NCT02877394|DEVICE|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
214324698|NCT06361888|DRUG|Nab-paclitaxel Plus Gemcitabine|"Drug: Nab-paclitaxel Plus Gemcitabine~1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
215068455|NCT00257582|DRUG|Cetirizine Dry Syrup|
215068456|NCT04734483|DIAGNOSTIC_TEST|spirometry|spirometry
215068457|NCT04734483|RADIATION|MRI and CT|MRI and CT
215068458|NCT04734483|OTHER|Laryngoscopy|laryngoscopy
215068459|NCT04734483|OTHER|electromyography|electromyography
215068460|NCT01447498|OTHER|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~1. screening and risk assessment~2. control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: \< 60: 0; 60-69: 1; 70-79: 2; \>=80: 3 \_\_\_ Dyspepsia: 1 \_\_\_ Uncomplicated ulcer: 2 \_\_\_ Complicated ulcer 3 \_\_\_ NSAID 2 \_\_\_ Steroids 2 \_\_\_ SSRI 2 \_\_\_ Anticoagulant Tx 2 \_\_\_"
215068461|NCT00079391|DEVICE|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
214925332|NCT02760212|DEVICE|Radial Shockwave Therapy|5 treatments in total scheduled weekly; RSWT to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot within each of the 3 most painful regions as described by the participant.
214324699|NCT06361888|DRUG|Surufatinib with Nab-paclitaxel, and Gemcitabine|"Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
214925333|NCT02760212|OTHER|Placebo Comparator: Group 2 - Placebo Group|5 treatments in total scheduled weekly; placebo to the painful areas will be undertaken with 2000 shocks to the most painful spot within each of the 3 most painful regions as described by the participant.
214925334|NCT02410421|PROCEDURE|Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning|
214925335|NCT04984863|DEVICE|Magnetically controlled capsule endoscopy|Magnetically controlled capsule endoscopy (MCE) is a non-invasive detection method independently developed in China that covers the whole digestive tract (except colon) mucosa.
215068462|NCT06341296|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.
215068463|NCT06341296|DRUG|5-FU|5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
215068464|NCT06341296|DRUG|LV|400mg/m\^2, d1, 14 days per cycle, 8 cycles.
215068465|NCT06341296|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle, 8 cycles.
215068466|NCT02274935|OTHER|Exercise|Balance and gait exercise twice a week for an hour
215068467|NCT01773005|DRUG|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
215068468|NCT01773005|DRUG|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
214925336|NCT03586674|DRUG|Lipanthyl|Tablet
214925337|NCT03586674|DRUG|Ursogal|suspension
214925338|NCT04958681|OTHER|exercise|The participants were subsequently asked whether the pandemic had altered their physical activity status and rate the severity of reduction in mobility level compared to the period before the Covid-19 with the following options: none, 0; mild, 1; moderate, 2; severe, 3. Then, the participants were also asked whether they perform a physical exercise in a home setting. We recorded regular outdoor physical activity and home-based exercises (only after the pandemic) as a dichotomous variable (yes or no). The number of physical activity days per week was also obtained.
214324700|NCT05592912|DRUG|HydroLenz Injection|The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day
214925339|NCT06620887|OTHER|Evaluate the impact of HEMAGO program on maternal morbidity and mortality in sickle cell disease patients during their pregnancies.|"HEMAGO pregnancy monitoring is a joint consultation program between the sickle cell disease hematologist and an obstetrician. This program was implemented in April 2016 at the Croix-Rousse maternity Hospital. This program offers close, complete and personalized pregnancy monitoring for each patient with major sickle cell syndrome.~These are follow-up consultations once a month until 24 weeks then every 15 days until delivery. At each consultation, doctors evaluate a general and obstetric clinical examination. The team establishes a precise schedule adapted to each patient for pregnancy monitoring : monthly blood tests, monthly ultrasounds with maternal and fetal Doppler, adaptation of basic treatment, transfusion exchange program according to eligibility criteria, and organization of childbirth."
214925340|NCT02883075|OTHER|Supine position|Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration
214925341|NCT02883075|OTHER|Right lateral position|Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration
214925342|NCT02883075|OTHER|Left lateral position|Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
214925343|NCT00348595|DRUG|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
214925344|NCT05213013|OTHER|inhaler treatment with the toy-type nebulizer and training on on the use of a nebulizer/mask|"The children (experimental group), will receive training and inhaler treatment with the toy-type nebulizer. The training topics is as follows:~* For effective nebulization, it should be ensured that the parts of the mask are assembled completely and correctly.~* The child should be in an upright sitting position during nebulization.~* During the procedure, normal breathing should be given into the mask.~* As the medicine is finished, a sizzling sound is heard from the device.~* After the nebula is over, the face should be washed and the mouth should be rinsed to remove the drug residues accumulated on the face and mouth."
214925345|NCT04682652|DEVICE|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
214925346|NCT05475587|OTHER|Routine care|Both two groups received the same routine care.
214925347|NCT05499260|DRUG|CB03-154|CB03-154 tablet once daily.
214925348|NCT05499260|DRUG|Placebo|Placebo tablet once daily.
214925349|NCT05427760|DRUG|Oxygen|After changing the diaper, free flow oxygen will be provided to the diaper area for 1 hour with an oxygen cannula placed inside the diaper (oxygen flow is %21 Fio2, 5 L/min)
214925350|NCT04457375|DIAGNOSTIC_TEST|TDC|measurements
214925351|NCT00665587|PROCEDURE|Cox-MAZE III|Maze procedure according to standards of the department
214925352|NCT01323153|DRUG|dalcetrapib|Oral doses of 600 mg once daily for 20 weeks
214925353|NCT01323153|DRUG|placebo|Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
214925354|NCT00459004|DRUG|rimonabant (SR141716)|
214925355|NCT04875988|PROCEDURE|Butterfly iQ+ Ultrasound|ultrasound will be used in the intervention group for IV access
214925356|NCT04875988|PROCEDURE|Traditional|ultrasound will not be used in the traditional IV placement group
214324701|NCT05592912|OTHER|No HydroLenz Injection|No HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day.
214925357|NCT00245076|BEHAVIORAL|smoking cessation intervention|
214925358|NCT00245076|OTHER|internet-based intervention|
214925359|NCT04898283|BIOLOGICAL|10,000 MG01 +10,000 T521|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
214925360|NCT04898283|BIOLOGICAL|30,000 MG01 +10,000 T521|Purified allergen extract polymerized with glutaraldehyde, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections.
214324702|NCT04644224|OTHER|Educational Activity|Attend health coaching session
214324703|NCT04644224|OTHER|Educational Intervention|Attend resource navigation session
214925361|NCT04898283|OTHER|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients
214925362|NCT04587791|DRUG|400mg Cannabidiol|Participants will receive 400mg
214925363|NCT04587791|DRUG|800mg Cannabidiol|Participants will receive 800mg
214925364|NCT04587791|DRUG|1200mg Cannabidiol|Participants will receive 1200mg
214925365|NCT04587791|DRUG|Saline|Participants will receive saline
214925366|NCT06968572|DRUG|HSK41959|Oral administration, QD
214925367|NCT06968455|OTHER|parabens|endocrine disruptors
214925368|NCT06968546|DRUG|Intranasal Sufentanil|After randomization, the children will receive intranasal Sufentanil .
214925369|NCT06968546|DRUG|Intranasal Ketamine (IN)|After randomization, chidren will receive intranasal Ketamine
215068469|NCT01931488|OTHER|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
214925370|NCT06966635|DRUG|Sodium Bicarbonate Oral Capsule|On the basis of the standard uric acid-lowering treatment plan, sodium bicarbonate should be taken three times a day, 1.0g each time
214925371|NCT06966635|DRUG|Potassium Citrate Tablets|On the basis of the standard uric acid-lowering treatment plan, potassium citrate was taken three times a day, 2.16g each time
214925372|NCT06966635|DRUG|uric-acid-lowering drug|The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable. The treatment plan for lowering uric acid remained unchanged for 4 weeks after enrollment in the clinical study until the endpoint.
214925373|NCT06967909|BEHAVIORAL|Tai Chi training|Participants will receive 24 weeks of Tai Chi training. For the first 12 weeks, they will receive 3 instructor-led Tai Chi training sessions per week, and practice 2 Tai Chi sessions by themselves. In the next 12 weeks, they will receive 1 instructor-led Tai Chi session and self-practice 2 Tai Chi sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified instructors. Each 1-hour training session consists of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors are required to attend a training session that ensure all of them to deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training session will be delivered in group. The group size is 25-30 persons.
214925374|NCT06967909|PROCEDURE|Acupuncture|Participants in the acupuncture group will receive 30 acupuncture treatment sessions, each last for 1 hour. Acupuncture will be performed every 2 days within one week, followed by a 3-day break, i.e., twice a week for the first 12 weeks; then it will be performed once every two weeks for the next 12 weeks. In total 30 sessions during 24 weeks treatment period. All acupuncture sessions will be administered by registered Traditional Chinese Medicine practitioners in Hong Kong with at least three years of clinical experience.
214925375|NCT06968039|DEVICE|Neuroelectrics StarStim 32|Using the advanced Neuroelectrics StarStim 32 device from Spain, individualized imaging modeling systems are employed to precisely target the frontal and parietal cortex. Personalized EEG-guided electrical stimulation protocols are selected. The stimulation parameters are as follows: a current intensity of 2 mA, a duration of 21 minutes per session for one time with EEG monitoring conducted before and after electrical stimulation.
214925376|NCT06968039|DEVICE|Neuroelectrics StarStim 32|Sham stimulation is performed using the same device and procedures as the neuromodulation group. The stimulator automatically shuts off after 30 seconds, while maintaining the device's connection. This design creates an initial sensation similar to actual stimulation while preserving the double-blind nature of the study.
214925377|NCT06968767|OTHER|bioflx crown|"(Group A: Preformed Biofix Crown - Assigned Intervention)~Crown Selection \& Tooth Preparation:~Measure the mesiodistal width using calipers to select an appropriately sized crown. If a mesial or distal wall is missing, use the contralateral tooth for size selection. Choose the crown that closely matches the measured mesiodistal width. Select the smallest crown that preserves proximal contacts using a trial-and-error approach. If crimping is necessary, use Howe's pliers.~Perform 1-1.5 mm occlusal reduction using a tapered diamond bur.~Reduce proximal areas by approximately 0.5 mm to clear the contact area.~Crown Placement \& Cementation:~Ensure a snug fit of the selected crown. Apply a thin layer of glass ionomer cement inside the crown. Seat the crown firmly using finger pressure. Have the child bite down gently to ensure proper seating.~Final Adjustments \& Cleanup:~Remove excess cement with floss or an explorer. Verify the crown's fit, occlusion, and stability."
214925378|NCT06968767|OTHER|zirconia crown|"Group B: Preformed Zirconia Crown - Assigned Intervention)~Crown Selection:~Measure the mesiodistal width using calipers to select the appropriate crown. If a mesial or distal wall is missing, use the contralateral tooth for size selection. Choose the one that closely matches the mesiodistal width. Select the smallest crown that preserves proximal contacts.~Tooth Preparation:~Reduce the occlusal surface by 1.5-2 mm using a tapered diamond bur.~Reduce interproximal areas by 1-1.5 mm, ensuring a feather-edge finish.~Perform a 1-2 mm subgingival preparation in passively placed fissure bur.~Crown Placement \& Passive Fit Check:~Place the selected crown on the prepared tooth.~Cementation of the Crown:~Apply a thin layer of glass ionomer cement inside the crown. Seat the crown with passive finger pressure. Have the child bite down gently to ensure seating."
215068470|NCT01931488|DEVICE|SPECT imaging|
215068471|NCT02264379|RADIATION|normal fractionated irradiation|25\*2 Gy (once a day, 5 days a week)
215068472|NCT02264379|RADIATION|hypo fractionated irradiation|3\*10 Gy (once a day, 2-3 days a week)
215068473|NCT02832557|OTHER|Salivary collection|Collection of saliva via swab for miRNA processing
215068474|NCT02832557|OTHER|Vineland Adaptive Behavior Scale-III Assessment|
214925379|NCT06966908|OTHER|Facilitate the referral of in-hospital chronic hepatitis B patients and provide treatment and follow-up in the infectious disease department.|After visiting the hospital, high-risk HBV patients are prescribed HBsAg testing by their primary physician. If HBsAg positivity is detected in patients from non-infectious disease departments, their lab reports will include a reminder to visit the Hepatitis B Health Clinic. Some primary physicians may also request an infectious disease consultation or recommend patient referral. Additionally, within two weeks, the Hepatitis B Specialist Assistant will contact the patients by phone to provide referral recommendations. Once referred to the Hepatitis B Health Clinic, physicians will conduct health education, complete liver function and virological assessments, and develop individualized treatment and follow-up plans.
214925380|NCT03991299|DRUG|Botox 200 UNT Injection|Botox will be injected into duodenums of subjects by endoscopy.
214925381|NCT04304235|DEVICE|Pediatric Rapid Sepsis Trigger (PRST) tool|The digital platform consists of a mobile application integrating a pulse oximetry sensor attached to this device, with embedded smart algorithms that predict a critically ill state, or level of risk (below) in a child presenting at the hospital. The platform also includes an interactive dashboard located in strategic locations (e.g., laboratory, consultation rooms), which connects to the mobile application through a secure local network and displays the triage data to provide real-time monitoring for the physicians who manage the patients.
214925382|NCT04304235|OTHER|Emergency Triage and Treatment (ETAT) guidelines|These are the triage guidelines currently applied in the study hospital sites. This will be the comparator group.
215068475|NCT02832557|OTHER|Medical history questionaire|
215068476|NCT02832557|OTHER|Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|
215068477|NCT02832557|OTHER|Mullen Scales of Early Learning|
215068478|NCT02504398|OTHER|Fast injection speed by immunizer|
215068479|NCT02504398|OTHER|Slow injection speed by immunizer|
215068480|NCT02066831|BEHAVIORAL|Telemedical coaching|
215068481|NCT02066831|OTHER|Telemedicine|
215068482|NCT03216343|DRUG|Chiauranib|CS2164
215068483|NCT02620878|DEVICE|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
215068484|NCT02620878|OTHER|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
215068485|NCT02664311|DEVICE|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
215068486|NCT02664311|DEVICE|Conventional ventilation|Conventional ventilator - control arm
215068487|NCT02791516|DRUG|Romosozumab|Administered by subcutaneous injection once a month (QM)
215068488|NCT02791516|DRUG|Placebo|Administered by subcutaneous injections once a month
215068489|NCT01016119|DRUG|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
214324704|NCT04644224|OTHER|Informational Intervention|Receive handbook
214324705|NCT04644224|OTHER|Questionnaire Administration|Ancillary studies
215068490|NCT01016119|DRUG|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
215068491|NCT05805696|BEHAVIORAL|Impostor tasks|Tasks to do every week
215068492|NCT03759886|DRUG|Paromomycin Sulfate Powder|The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
215068493|NCT03475706|DRUG|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
214324706|NCT04644224|PROCEDURE|Support Group Therapy|Attend support group
214324707|NCT04581460|OTHER|Questionnaire|Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
215068494|NCT03475706|DRUG|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
215068495|NCT03475706|DRUG|Matching Placebo|twice daily for 12 weeks.
215068496|NCT05137197|DEVICE|Predictix Genetics Antidepressant|Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.
215068497|NCT01905228|DRUG|CBL0137|"All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops"
215068498|NCT00663884|DRUG|Mitiglinide|mitiglinide 10mg three times a day before a meal
215068499|NCT00663884|DRUG|Voglibose|voglibose 0.2mg three times a day before a meal
215068500|NCT06061705|PROCEDURE|Tumor Biopsy|"Following the start of immunotherapy, an ENT surgeon will perform a cervico-facial tumor biopsy between D30 and D180. This will only be carried out if the tumour tissue is externalized and therefore accessible, and if the biopsy can be performed under local anaesthetic without any constraints for the patient (pain, risk of bleeding).~It consists of a superficial sampling of the externalized tumour lesion under local anaesthetic (xylocaine spray 5%, or xylocaine injectable 1%).~Biopsy of cervico-facial lesions under local anaesthetic is a commonly performed procedure. The main risk of this procedure is bleeding, which is very rare.~The biopsy will not be performed if the surgeon considers that the risk of bleeding is too great. Given the externalized nature of the lesion, biopsy does not entail any risk of tumour dissemination (possible for deep biopsies).~* Four 10-mL blood samples from two heparinized tubes~* Four 5-mL unstimulated saliva samples: non-invasive examination."
215068501|NCT06814886|BEHAVIORAL|wearable devices to initiate behavioral intervention|12 week wearable devices to initiate behavioral intervention including line APP recruited participants and give some behavior change advises, also give a APP-based motivational interviewing 15 minutes per week.
215068502|NCT06814886|BEHAVIORAL|12 week wearable devices monitor|12 week wearable devices monitor physical activity and sleep quality only
215068503|NCT06657092|PROCEDURE|Erector Spinae Plane Block|Single-shot ultrasound (US)-guided ESP block with 20 ml 0.25% bupivacaine ( Marcaine ) at the T4 vertebral level will be performed.
215068504|NCT06657092|PROCEDURE|Standart therapy|Postoperative 0.5 mg/kg morphine and 1 gr paracetamol will be admistered intravenously in the operation theatre and intravenous patient controlled analgesia (PCA) will be performed in the plastic surgery ward postoperatively
214925383|NCT06315309|DRUG|ATG Combined with Tacrolimus and Mini Methotrexate|On Day -7, subjects will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). Subjects will receive a steroid injection 3 hours before every ATG infusion. On day -6, subjects will receive a small dose of ATG as an IV infusion. ATG will be repeated on days -5,-4 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -6 to -2 as daily IV infusions. Busulfan, a routine transplant chemotherapy will be given on days -5 to -2 as IV infusion. Subjects with lymphoblastic leukemia will receive an alternative regimen of cyclophosphamide, a routine chemotherapy on days -6 and -5, followed by total body radiation on days -3 to -1. Tacrolimus (standard immune suppression agent) starts on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate a standard immune suppression medication which is given IV on day +1,+3,+6, and +11 post-transplant. Blood draws on days -4,-1,+3,+7,+14 to measure ATG levels.
214925384|NCT01351792|DRUG|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
214324708|NCT06219551|OTHER|Mobile messages via What's App|The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.
215068505|NCT06855654|BEHAVIORAL|Promoting Resilience in Women with Breast Cancer (PRISM)|PRISM is a brief, skills-based intervention targeting 4 core resilience resources (stress management, goal setting, cognitive reframing, and meaning-making) followed by an optional family session. This adapted version of the PRISM intervention will be delivered1:1 by trained coaches who speak English or Spanish via HIPAA-compliant video conference.A single coach conducts the program with a single patient. Each session is 30-60 minutes, for a total of 2- 4 hours. Sessions are delivered every 1-2 weeks per patient's preference. To facilitate on-demand skills-practice between sessions, all participants have access to the PRISM app, available for iOS/Android, and thus available to the \>90% of U.S. adults who own a smartphone. Participants will be assisted to download the PRISM app to their device at the time of registration; however, coaches can also provide assistance with app access during intervention sessions.
215068506|NCT06661967|DRUG|Lidocaine spray|Comparison of the success rate of endotracheal intubations between lidocaine spray and placebo
215068507|NCT06662240|DEVICE|The effect of vibration anesthesia on pain, ecchymosis and comfort level in subcutaneous heparin injection|The patient in the experimental group received one vibrating injection and one non-vibrating injection into the abdomen. The patient in the control group received 2 standard subcutaneous injections in the abdomen without vibration.
215068508|NCT06659003|OTHER|Pilot Implementation of Network Canvas into HBH Partner Services|Our team deployed our network data capture software - Network Canvas - into Partner Services at HBH to examine feasibility and acceptability and to provide initial evidence of efficacy (examining impacts on data quality, number of partners notified, and timeliness). Further, our team worked closely with HBH on developing implementation strategies, a Network Canvas interview protocol, evaluation measures, and training materials for their staff. Finally, we provided the HBH team technical support, and regular coaching, supervision, and evaluation.
215068509|NCT06659302|BEHAVIORAL|I-inTERACT North Step 1|Initial questionnaires completed followed by initial meeting with therapist for baseline evaluation.
215068510|NCT06659302|BEHAVIORAL|I-inTERACT North step 2|Two online modules completed by family plus two online zoom coaching sessions with therapist.
215068511|NCT06659302|BEHAVIORAL|I-inTERACT North|Full program will consist of an additional 5 sessions with online modules and virtual coaching sessions with therapist.
214925385|NCT01351792|DRUG|Symbicort® Turbohaler® 200/6 μg/actuation|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
214925386|NCT01916681|DEVICE|Cervical Foley & Misoprostol|A cervical foley combined with misoprostol will be used to induce the patient.
214925387|NCT01916681|DRUG|Misoprostol Alone|Misoprostol will be used alone to induce the patient
214925388|NCT01916681|DEVICE|Cervical Foley Alone|A cervical foley alone will be used to induce the patient
214925389|NCT01916681|DEVICE|Cervical Foley & Pitocin|A cervical foley combined with pitocin will be used to induce the patient
214324709|NCT05478174|DRUG|HSK3486|HSK3486 for induction of general anesthesia
214324710|NCT05478174|DRUG|Propofol|Propofol for induction of general anesthesia.
214324711|NCT06771128|DRUG|Ginkgo Biloba oral tablet|patients receive Ginkgo Biloba oral tablet 120 mg once daily
215068512|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Floragyn® probiotic tablets (Lapi, Indonesia)|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~One tablet Floragyn contains Lactobacillus rhamnosus and lactobacillus reuteri, bacteria that are normal flora (good bacteria) of the vagina."
214925390|NCT04080024|DRUG|SN132D|Novel manganese-based macromolecular MRI contrast agent
214925391|NCT05668585|DRUG|CFT1946|Specified oral dose on specified day
214925392|NCT05668585|DRUG|Trametinib|Specified oral dose on specified day
214925393|NCT05668585|DRUG|Cetuximab|Specified intravenous dose on specified day
214925394|NCT04122703|DEVICE|percutaneous tibial nerve stimulation (PTNS)|The PTNS treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
214925395|NCT04122703|DEVICE|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
214925396|NCT00163761|DRUG|gemcitabine, vinorelbine, ifosfamide, filgastrim|Drug
214925397|NCT00163761|DRUG|gemcitabine, vinorelbine, filgastrim|Drug
214925398|NCT03815877|DIETARY_SUPPLEMENT|Nescafe Gold ® coffee|"Nescafe Gold ® coffee (5gm per 100cc water containing 170 mg of caffeine) will be used for all the women in the intervention group.~\- patients will drink 100cc coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
214925399|NCT03815877|DIETARY_SUPPLEMENT|Nescafe Gold DECAF® coffee|"Nescafe Gold DECAF coffee (5 gm per 100cc water containing 5-10 mg of caffeine) will be used for all the women in the control group.~the control group will drink 100cc decaffeinated coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
214925400|NCT01132248|DRUG|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
214925401|NCT01132248|DRUG|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
214925402|NCT00005807|DRUG|BMS-247550|anticancer agent for the treatment of patients with malignant tumors.
215068513|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Cal95|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~Cal 95 is a supplement containing multivitamins and minerals including: Calcium, Zinc, Boron and Magnesium. This tablet is used to help meet calcium needs and maintain bone health in menopausal women."
215068514|NCT06659380|DIETARY_SUPPLEMENT|Floragyn® probiotic tablets (Lapi, Indonesia)|Given to the control group to ensure the ability of probiotics to maintain a healthy vaginal ecosystem and not the opposite.
214324712|NCT06771128|DRUG|Desmopressin Acetate 0.2 mg Tablets|patient receives desmopressin 0.2 mg oral tablet once daily
214324713|NCT06771128|DRUG|Placebo|patients receive Placebo oral tablet once daily
214925403|NCT04429555|DRUG|Ibudilast|50 mg (5 x 10 mg capsules) twice daily for 7 days
214925404|NCT04429555|DRUG|Placebo|0 mg (5 matching capsules) twice daily for 7 days
214925405|NCT00231114|DEVICE|Alair System|Treatment of airways with the Alair System
214925406|NCT00231114|DEVICE|Alair System|Sham treatment of airways with the Alair System
214925407|NCT06335693|OTHER|Radiotherapy|The patients after radical prostatectomy with high-risk pathological factors will receive adjuvant hypofractionated radiation therapy in 15 fractions.
214925408|NCT01949844|DRUG|regadenoson|Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
214925409|NCT01949844|DRUG|Optimark®|For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
214925410|NCT01949844|DEVICE|Myocardial perfusion MRI|
214925411|NCT04792593|BIOLOGICAL|Senl-h19 CAR-T|Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
214925412|NCT03748810|DRUG|Empagliflozin|Empagliflozin 25 mg once daily add on the background OADs for 3 years
214925413|NCT03748810|DRUG|Dapagliflozin|Dapagliflozin 25 mg once daily add on the background OADs for 3 years
214925414|NCT00419848|DRUG|Doxycycline|Cap 100mg- 100mg/daily
214925415|NCT00419848|DRUG|Azithromycin|Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
214925416|NCT03721692|DEVICE|RIC|The patients will use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
214925417|NCT03592667|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
214925418|NCT03592667|DRUG|Placebo - Cap|One per day before breakfast during 12 weeks.
214925419|NCT05340933|OTHER|Voice registration|Voice registration
215068515|NCT06332768|DEVICE|Respiratory support|High-flow nasal oxygenation
215068516|NCT03838601|DRUG|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
215068517|NCT06051019|OTHER|Aerobic training|Aerobic training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Sessions will be performed with the assistance or supervision of a physical therapist and will consist of the following steps: 1) warm up with a stationary bike (no load, 10 min, 60 cycles/min); 2) upper and lower limb stretching (10 min); 3) 10 min rest in a sitting position; 4) first exercise bout: stationary bike, 15 min, 60 cycles/min (the load will be modulated so that the participant's heart rate is between 60 and 70% of the estimated maximum heart rate, and the patient perceives moderate fatigue on the Borg Rating of Perceived Exertion; 5) upper and lower limb stretching (10 min); 6) 10 min rest in a sitting position; 7) second exercise bout (same parameters as the first exercise bout); 8) upper and lower limb stretching (10 min).
214925420|NCT06683027|BEHAVIORAL|Nonattachment for Post Traumatic Stress|"This study seeks to cultivate nonattachment specifically for the alleviation of symptoms of post-traumatic stress. This is an 8-week online intervention where, following a Qualrics-hosted pre-screen, users are directed to www.npts.online to use as they wish. Users are then solicited to re-take quantitative assessments, and a subset of 10 (target number) will be recruited for a qualitative interview regarding their experience of the intervention.~A final prompt for assessment re-takes will follow at 3 months post-intervention to determine longitudinal efficacy."
214925421|NCT04379531|DIAGNOSTIC_TEST|Low-dose Chest CT|Patients referred by the primary care physician with suspected pneumonia.
214925422|NCT05296668|DEVICE|Cuffed ETT (Microcuff®, Halyard Health Inc., Atlanta, GA, USA)|(group C) to receive a cuffed ETT for airway management.
214925423|NCT05296668|DEVICE|Uncuffed ETT group|(group U) to receive an uncuffed ETT for airway management.
214925424|NCT00712881|DRUG|Liposomal doxorubicin hydrochloride|Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
214925425|NCT00712881|DRUG|Cyclophosphamide|Cyclophosphamide will be administered per dose and schedule specified in the arm description.
214925426|NCT00712881|DRUG|Trastuzumab|Trastuzumab will be administered per dose and schedule specified in the arm description.
215068518|NCT06051019|OTHER|Balance training|Balance training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Treatments will be performed with a physical therapist and will consist of the following exercises: 1) standing with feet together, 2) standing with closed eyes, 3) standing on unstable surfaces, 4) standing while performing upper limbs movements; 5) standing while performing head rotations; 6) walking on a treadmill at alternating speeds; 7) leg press and chest press exercises for training trunk balance during ballistic movements of the upper and lower limbs. These constituents of balance training can be combined in the same task according to the participant's ability.
215068519|NCT04410848|OTHER|To determine the diagnostic of Choledocholithiasis with symbolic regression model|To determine the diagnostic of Choledocholithiasis with symbolic regression model
215068520|NCT06850363|DEVICE|ExaStim Stimulation System|Transcutaneous Spinal Cord Stimulation
215068521|NCT06610461|DEVICE|HFNO-Treatment|The investigated intervention is the application of HFNO throughout a high-risk upper GI-endoscopy. Concentration of oxygen is 100%. Prior to induction, flow rate is set to 20 l/min and increased to 30 l/min if tolerated by the patient. After induction of anesthesia, flow rate is increased to 60 l/min and maintained throughout the anesthesia.
215068522|NCT04102124|DRUG|SHR3680|Tablet. Specifications of 80mg
215068523|NCT04102124|DRUG|SHR3162|Tablet. Specifications of 10mg、40mg、50mg and 100mg
215068524|NCT04102124|DRUG|SHR3680(Placebo)|Tablet. Specifications of 80mg
215068525|NCT04102124|DRUG|SHR3162(Placebo)|Tablet. Specifications of 10mg、40mg、50mg and 100mg
215068526|NCT06614101|OTHER|Exhaled air analysis|The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.
215068527|NCT06669507|BEHAVIORAL|Chronotherapy|"1. The effect of light exposure follows a phase-response curve where circadian phase advancement is strongest in the biological morning, whereas light in the biological evening/night may lead to a phase delay. Light therapy is provided by 30 min light exposure using 10 000 lux light boxes.~2. Melatonin 3 milligram is prescribed in tablet forms (not depot), usually 12 hours before the planned rise time.~3. Additionally, blue-light-blocking glasses are used to block light exposure at night, which has been found to advance circadian rhythms. Patients are advised to wear their blue-blocking glasses 12 hours before rise time.~Which chronotherapeutic interventions that are used, is considered individually by the clinicians in the Sleep Clinic, but often all three treatment components are used at the same time. Duration of chronotherapy given in the Sleep Clinic vary from 4 to 8 consultations over 1 to 4 months depending on the patients' needs and progress during treatment."
214672960|NCT03865342|BEHAVIORAL|Noom Coach DPP|Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
214925427|NCT00712881|DRUG|Free doxorubicin hydrochloride|Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
214925428|NCT00712881|DRUG|Docetaxel|Docetaxel will be administered per dose and schedule specified in the arm description.
214672961|NCT05429684|DRUG|Trastuzumab|Trastuzumab (6mg/Kg, iv.drip, d1, q3w)
214672962|NCT05429684|DRUG|Pertuzumab|Patuzumab (420mg iv.drip, d1,q3w)
214672963|NCT05429684|DRUG|Nab paclitaxel|nab-paclitaxel (200mg iv.drip, d1,d8, q3w)
215068528|NCT06669507|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|All participants will receive treatment as usual. CBT-I has several components and consists of the following interventions including psychoeducation about sleep: sleep hygiene, sleep restriction therapy, stimulus control, and challenging beliefs and perceptions of sleep. Special emphasis is placed on providing a rationale for behavior change as a primary means of improving sleep as well as addressing dysfunctional beliefs the patients may hold about sleep. During treatment, tapering sleep medication is not necessary. However, if the patients are motivated to do so, this is discussed and a plan for tapering is provided. Treatment duration is typically between 4 to 8 consultations over 1 to 4 months depending on the patients' needs and progress during treatment.
214925429|NCT00823069|DEVICE|Perlane and Perlane-L|This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
214925430|NCT04483817|DEVICE|Transcutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
214925431|NCT04483817|DEVICE|Percutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
214925432|NCT06666023|DEVICE|Device|Use of the device in groups to test its ability to diagnose infections.
214925433|NCT03572816|DEVICE|Settner shoe|custom-made heel-unloading orthosis ('Settner shoe') in aftercare of calcaneus fractures (used according to manufacturer), certified 'CE' product with more than 10 years experience
214925434|NCT01594190|BEHAVIORAL|physical activity 15 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
214925435|NCT01594190|BEHAVIORAL|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
214925436|NCT00589134|DIETARY_SUPPLEMENT|Gatorade Endurance Formula|carbohydrate electrolyte beverage
215068529|NCT06669442|BEHAVIORAL|Guided Imagery|Guided imagery is a mindfulness based therapeutic technique that involves utilizing positive imagery allowing one to cultivate awareness of their mental state and shift their attention from ruminative thought patterns to the present moment. Evidence-based research shows that benefits of Guided imagery include relaxation, stress reduction, anxiety reduction, immune system enhancement, and overall well-being.
215068530|NCT06995339|DRUG|Febuxostat Tablets|Febuxostat is a selective xanthine oxidase inhibitor (XOI) that targets uric acid generation. It has been used as a SUA lowering agent in patients not responding to allopurinol
215068531|NCT06995339|DRUG|Metformin|Metformin is an oral antihyperglycemic drug widely used in type 2 diabetes (T2DM) treatment. Most of its effects are exerted via an indirect induction of the phosphorylated activation of AMP-activated protein kinase (AMPK)
215068532|NCT06152172|DRUG|KYV-101|The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
215068533|NCT06152172|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
215068534|NCT06152172|DRUG|Fludarabine|Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)
215068535|NCT05041907|DRUG|Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7
215068536|NCT05041907|DRUG|Nitazoxanide|Nitazoxanide 1.5g BD 7/7
215068537|NCT05041907|DRUG|Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7
215068538|NCT05041907|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7
215068539|NCT05041907|OTHER|No treatment|No treatment (except antipyretics- paracetamol)
215068540|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
214324714|NCT03440970|DRUG|Lysine Chloride|Patients will receive the study drug thrice daily for 5 days.
214672964|NCT05429684|DRUG|Pyrotinib|Pyroltinib (400mg po qd)
214925437|NCT00589134|OTHER|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
214925438|NCT00006251|RADIATION|total-body irradiation|Undergo TBI
214925439|NCT00006251|DRUG|fludarabine phosphate|Given IV
214925440|NCT00006251|DRUG|cyclosporine|Given PO
214925441|NCT00006251|DRUG|mycophenolate mofetil|Given PO
214925442|NCT00006251|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
214925443|NCT00006251|BIOLOGICAL|donor lymphocytes|Undergo DLI
214925444|NCT00006251|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
215068541|NCT05041907|DRUG|Fluoxetine|Fluoxetine 40mg OD for 7/7
215068542|NCT05041907|DRUG|Molnupiravir|Molnupiravir 800mg BD for 5/7
215068543|NCT05041907|DRUG|Sotrovimab|Sotrovimab 500mg given once on D0
215068544|NCT05041907|DRUG|Ensitrelvir|Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7
215068545|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
215068546|NCT05041907|DRUG|Favipiravir|Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7
214324715|NCT03440970|OTHER|Placebo|Patients will receive the placebo thrice daily for 5 days.
214925445|NCT00006251|OTHER|laboratory biomarker analysis|Correlative studies
214925446|NCT01873456|OTHER|multifactorial nutritional intervention|
214925447|NCT03990571|DRUG|Avelumab|Given IV
214925448|NCT03990571|DRUG|Axitinib|Given PO
214925449|NCT03474016|DIAGNOSTIC_TEST|Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction|Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction
214925450|NCT00399412|DEVICE|subcutaneous ICD|
214925451|NCT01369108|DEVICE|Flowable composite|Restoration of small Class V and I cavities in molar and premolar teeth
214925452|NCT01369108|DEVICE|Conventional composite restorative|Restoration of small Class V and I cavities in molar and premolar teeth
214925453|NCT00260312|BIOLOGICAL|Inactivated Polio Vaccine given at an accelerated schedule|
214925454|NCT00370318|BIOLOGICAL|10 valent pneumococcal conjugate vaccine|
214925455|NCT00370318|BIOLOGICAL|Infanrix Hexa|
215068547|NCT05041907|DRUG|Ivermectin|Ivermectin 600micrograms/kg/day for 7/7.
215068548|NCT05041907|DRUG|Remdesivir|Remdesivir 200mg D0 and 100mg for a further 4/7.
215068549|NCT05041907|DRUG|Atilotrelvir/ritonavir|Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7
214925456|NCT00370318|BIOLOGICAL|Rotarix|
214925457|NCT00370318|DRUG|Paracetamol|
214925458|NCT06437821|DIAGNOSTIC_TEST|Petrissage|The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
214925459|NCT06437821|OTHER|Graston Technique|The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
214925460|NCT04143594|DRUG|Oral Lenacapavir|Tablets administered without regard to food
214925461|NCT04143594|DRUG|F/TAF|Tablets administered without regard to food
214925462|NCT04143594|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
214925463|NCT04143594|DRUG|TAF|Tablets administered without regard to food
214925464|NCT04143594|DRUG|BIC|Tablets administered without regard to food
214925465|NCT04143594|DRUG|B/F/TAF|Tablets administered without regard to food
214925466|NCT03247465|OTHER|Image Fusion|Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
214925467|NCT04711174|BEHAVIORAL|LMA removal|the timing when conducting LMA removal
214925468|NCT00940966|DIETARY_SUPPLEMENT|standard ADA diet|standard ADA diet
214925469|NCT00940966|DIETARY_SUPPLEMENT|energy restricted very-low carbohydrate diet|energy restricted very-low carbohydrate diet
214925470|NCT00940966|DIETARY_SUPPLEMENT|low glycemic diet|restricted ketogenic diet
214925471|NCT00746824|DRUG|TM30339 and/or placebo|The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
215068550|NCT05041907|DRUG|Metformin|Metformin 500mg TDS 5/7
215068551|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7
214925472|NCT01608243|BIOLOGICAL|SLIT tablets of house dust mite allergen extracts|10 dosing days
214925473|NCT01608243|BIOLOGICAL|Matching placebo|10 dosing days
215068552|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7
215068553|NCT05041907|DRUG|Nirmatrelvir|Nirmatrelvir 300mg BD for 5/7
215068554|NCT06604858|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered every three weeks intravenously on day 1 of each cycle.
215068555|NCT06604858|DRUG|Carboplatin|Carboplatin: area under the curve (AUC) 1.5, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
215068556|NCT06604858|DRUG|Paclitaxel|Paclitaxel: 80 mg/m2, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
215068557|NCT07000136|DRUG|AZD0780|Participants will receive daily oral dose of AZD0780
215068558|NCT07000136|DRUG|Placebo|Participants will receive daily oral dose of placebo
215068559|NCT07001618|DRUG|MaaT033 capsule|MaaT033 capsule will be taken orally once a day for a week before every Cemiplimab cycle for the first 6 months of treatment.
215068560|NCT07001618|DRUG|Cemiplimab|CB will be administered 350 mg IV over 30 minutes every 21 days up to 2 years
215068561|NCT07001618|DRUG|Cisplatin|75mg/m2 at day 1 (d1) every 21 days (q21)
214672965|NCT05429684|DRUG|Capecitabine|Capecitabine (1250mg/m2, po, bid, d1-d14, q3w).
214672966|NCT05429684|DRUG|T-DM1|T-DM1(3.6mg/Kg, iv.drip, d1, q3w)
214925474|NCT04178707|DEVICE|OnZurf Probe, Senzime AB, Uppsala, Sweden|Probe is inserted into the fistula and measurements are made of the inner environment.
215068562|NCT07001618|DRUG|Carboplatine|Area Under the Curve (AUC) 5-6 at d1 q21
215068563|NCT07001618|DRUG|Pemetrexed (Alimta)|500mg/m2 at day 1 (d1) q21
215068564|NCT07001618|DRUG|Bevacizumab|10mg/kg at d1 and day 15 (d15) every 28 days (q28)
215068565|NCT07001618|DRUG|Paclitaxel|175mg/m2 at d1 q21 or 80 mg/m2 at d1, day 8 (d8), day 15 q28
215068566|NCT07001618|DRUG|gemcitabine|1250 or 1000 mg/m2 d1, d8 q21
215068567|NCT07001618|DRUG|Docetaxel|75 mg/m2 d1 q21 or 33mg/mq d1, d8 q21 q21
215068568|NCT07001618|DRUG|Vinorelbine i.v. 25 mg/m²|25-30 mg/m2 d1, d8 q21
214925475|NCT00285116|PROCEDURE|Clinical examination and radiological evaluation|
215068569|NCT07001618|DRUG|Vinorelbine oral|30 mg/50 mg per os 3 days per week (metronomic)
215068570|NCT06808451|DEVICE|DNA PCR|Gene analysis with PCR will be conducted from the urine samples of the patients with acute UTI symptoms.
215068571|NCT06808451|DIAGNOSTIC_TEST|Urine Culture|Urine samples of the patients with acute UTI symptoms will be sent to the UH lab for routine urine culture.
214925476|NCT00638443|DRUG|Pregabalin|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
215068572|NCT06681818|OTHER|carbon monoxide measurement via smokerlyzer|participants in this study will provide breath samples for carbon monoxide measurements pre and post liver resection
215068573|NCT07001215|DEVICE|In the intervention group, patients will be treated with auto-adjusting APAP, providing variable pressures throughout the sleep hours.|AutoCPAP will be prescribed to patients undergoing bariatric surgery.
215068574|NCT07001215|DEVICE|CPAP|In the control group, patients will be treated with CPAP.
215068575|NCT06625385|DEVICE|3M™ V.A.C.® Peel and Place Dressing|Application of 3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy
215068576|NCT07013916|DIETARY_SUPPLEMENT|fructose|Fructose powder
215068577|NCT07013916|DIETARY_SUPPLEMENT|glucose|Glucose powder
215068578|NCT07021040|DIAGNOSTIC_TEST|olfactory testing|"Patients will undergo smell testing, using the Smell Identification Test (Sensonics), a validated widely-used 40-item scratch-and-sniff style psychophysical test to determine olfactory function."
215068579|NCT07021040|OTHER|Odor stimulation|"subset of patients will be asked to sniff a specific odor for about an hour, using commercially available odor pens (Sniffin' Sticks or Sensonics). These odor pens are widely used for olfactory training therapy, a treatment designed to help people with some forms of smell loss; they are also used in psychophysical olfactory testing."
214925477|NCT00638443|DRUG|Diphenhydramine|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
214925478|NCT04867993|DRUG|Amikacin|15 mg/kg/36h
214925479|NCT02199353|OTHER|Stimulation of Activities Daily Living|"Experimental group: SADL programme which is a new treatment approach created by the authors of this study for the training of ADL through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
214925480|NCT02199353|OTHER|Conventional ADLOccupational Therapy|"Control group treatment: conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
214925481|NCT02410798|DEVICE|TransLoc electrode|Patients will have 2 electrodes placed in either side of the diaphragm (total 4 electrodes) during their primary surgery.
214925482|NCT06504953|OTHER|Questionnaire|Questionnaires on contraception and sports activities
215068580|NCT07021040|PROCEDURE|Olfactory biopsy|Biopsy involves a simple cytology brush technique of the lining of the nose in a region called the olfactory cleft, using a nasal endoscope, and can be done in clinic or in the operating room at the time of a nasal surgery. Topical oxymetazoline and tetracaine spray is applied to the nasal cavity, a rigid nasal endoscopy (0-degree 4 mm endoscope, Karl Storz) is performed to visualize the olfactory cleft, and a small nasal cytology brush biopsy (Hobbs Medical)is performed by swabbing and rotating brush gently in the olfactory cleft. Cytology sample is placed into a buffer (Hibernate-E, Thermo Fisher)on ice for transport to the research lab.
214672967|NCT05429684|DRUG|Everolimus|Everolimus (4mg, po, qd)
214672968|NCT05429684|DRUG|CDK4/6 inhibitor|Palbociclib (125mg, po, qd)
214672969|NCT05429684|DRUG|AI|Letrozole (2.5mg, qd).
214672970|NCT05429684|DRUG|Anti-PD-1 monoclonal antibody|Cindilimab (200mg, iv.drip, d1, q3w)
214672971|NCT00065975|PROCEDURE|massage therapy|
214672972|NCT00065975|PROCEDURE|chiropractic|
214672973|NCT00065975|PROCEDURE|acupuncture|
214925483|NCT06504953|OTHER|Beighton test|A popular screening technique for hypermobility. It consists of a nine-point scale requiring the performance of five maneuvers, four passive bilateral and one active unilateral.
215068581|NCT07023471|DEVICE|Group A (Trainee --> expert)|The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy (white-light mode) without AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy (white-light mode) without AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.
214925484|NCT06504953|OTHER|Lachman Test|"To perform this test, place your patient in a supine position and bring your patient's test leg to 30 degrees of flexion. Fix the femur with the other hand. Put the tibia in slight external rotation, then try to translate it forwards.~This test is positive if you feel a soft or limp end or if the anterior part."
214925485|NCT05122910|BEHAVIORAL|Stress Management and Resilience Training - Moral Resilience (SMART-MR) program|All participants will attend an initial 2.5 hour workshop and a 1-hour follow-up workshop. The workshop will include general resilience strategies with a focus on the moral/ethical dimensions of clinical practice to offer participants specific skills to address ethical challenges. In addition to the workshops, there will be follow-up supplemental resources.
214925486|NCT03415789|DIAGNOSTIC_TEST|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
215068582|NCT07023471|DEVICE|Group B (Trainee +AI --> expert)|"The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy with AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy (white-light mode) without AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.~Artificial intelligent (AI) assisted colonoscopy; ENdoscopy as AI-powered Device (ENAD) ENAD system (ENdoscopy as AI-powered Device, AINEX Corporation, Seoul, South Korea) is the system using CADe system (Computer-aided detection) which developed from 66,397 images and 8,756 polyps via deep learning-based object detection algorithm (YOLOv4) . It was validated by 15,753 images of polyp from 80 colonoscopy videos and 90,144 images of non-polyps from 50 colonoscopy videos. This system decreases false positive rate from 3.2% to 0.6% and increases sensitivity from 86.4% to 87.1%."
215068583|NCT07023471|DEVICE|Group C (Trainee --> expert + AI)|"The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy (white-light mode) without AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy with AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.~Artificial intelligent (AI) assisted colonoscopy; ENdoscopy as AI-powered Device (ENAD) ENAD system (ENdoscopy as AI-powered Device, AINEX Corporation, Seoul, South Korea) is the system using CADe system (Computer-aided detection) which developed from 66,397 images and 8,756 polyps via deep learning-based object detection algorithm (YOLOv4) . It was validated by 15,753 images of polyp from 80 colonoscopy videos and 90,144 images of non-polyps from 50 colonoscopy videos. This system decreases false positive rate from 3.2% to 0.6% and increases sensitivity from 86.4% to 87.1%."
214925487|NCT03415789|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
215068584|NCT07023471|DEVICE|Group D (Trainee + AI --> expert + AI)|"The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy with AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy with AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.~Artificial intelligent (AI) assisted colonoscopy; ENdoscopy as AI-powered Device (ENAD) ENAD system (ENdoscopy as AI-powered Device, AINEX Corporation, Seoul, South Korea) is the system using CADe system (Computer-aided detection) which developed from 66,397 images and 8,756 polyps via deep learning-based object detection algorithm (YOLOv4) . It was validated by 15,753 images of polyp from 80 colonoscopy videos and 90,144 images of non-polyps from 50 colonoscopy videos. This system decreases false positive rate from 3.2% to 0.6% and increases sensitivity from 86.4% to 87.1%."
215068585|NCT00604318|DRUG|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
214672974|NCT01285921|OTHER|vestibular test before and after hippocampal surgery|"* Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)~* HIT (testing semicircular canal function at high frequency).Results: Gain in %~* VEMp (testing saccular function). Results: Amplitude in μV and latency in ms~* ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s~* Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S"
214925488|NCT03415789|DIAGNOSTIC_TEST|Brain Magnetic Resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
214925489|NCT03415789|DIAGNOSTIC_TEST|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
214925490|NCT00834639|DRUG|divalproex sodium|delayed-release 500 mg tablet
214925491|NCT00834639|DRUG|Depakote®|delayed-release 500 mg tablet
215068586|NCT03479541|BEHAVIORAL|Timing of Rehabilitation|Participants in the Earlier Physical Therapy group will start physical therapy within a week of enrollment and baseline testing. Participants allocated to the Later Physical Therapy group will wait 6 weeks after enrollment and baseline testing before starting physical therapy, and re-test on study outcomes before starting physical therapy. Both groups will see a physical therapist in person twice per week for 2 weeks and once per week for 4 weeks for a total of 8 sessions over 6 weeks. Each session will last 60 minutes and consist of cardiovascular, cervical spine, and vestibular therapy exercises (static and dynamic balance). Participants will perform daily home exercises for 30 minutes with similar subcategories from the in-person sessions. Both the in-person physical therapy and home exercises will be individualized and progressive at the discretion of the physical therapist depending on the performance of the participant.
215068587|NCT03479541|BEHAVIORAL|Biofeedback|Wearable sensors measure movement during the home exercise program for later feedback.
214925492|NCT03852368|OTHER|Exercise|The effects of exercise with different intensity on the executive functions of adolescents
214925493|NCT02289508|DEVICE|Ultrasonic cardiac output monitor|An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.
214925494|NCT02289508|DEVICE|Echocardiography|2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.
214925495|NCT01909323|OTHER|maltitol 85% / FOS15%|
214925496|NCT01909323|OTHER|maltitol alone|
214925497|NCT01909323|OTHER|maltitol 68% / FOS 32%|
214925498|NCT01909323|OTHER|maltitol 50% / FOS 50%|
215068588|NCT06875609|DIAGNOSTIC_TEST|Blood and Tissue Collection|Blood samples, and tissue samples will be collected from the participants, and used to determine whether circulating tumor DNA (ctDNA) testing can help monitor treatment in patients with CSCC, and to determine how ctDNA levels change in patients.
215068589|NCT07033650|OTHER|Bulk-fill composite (X-tra Fil)|Bulk fill resin composite
214672975|NCT03429907|BEHAVIORAL|Mind-Body Exercises|Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
214672976|NCT03429907|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
214672977|NCT04982913|DRUG|HEC116094|Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
214925499|NCT01909323|OTHER|FOS alone|
214925500|NCT01909323|OTHER|Placebo|
214925501|NCT00171938|DRUG|imatinib mesylate|
214925502|NCT06390774|DRUG|SSGJ-705|anti-PD-1 and anti-HER2 bispecific antibody
214925503|NCT06643364|OTHER|Vision Training Program|Vision Training Programme: A training programme including exercises such as saccadic movements of the eye, spiral movements, converging-diverging exercises, peripheral walking was applied.
214925504|NCT06643364|OTHER|Routine Training Program|All athletes continued their routine training programmes planned by the national team coaches for karate sport during the training period.
214925505|NCT04603482|BEHAVIORAL|Resourcefulness training|Resourcefulness training is a cognitive behavioral intervention that consists of teaching and reinforcing personal (self-help) and social (help-seeking) strategies to overcome adversity.
214925506|NCT04603482|BEHAVIORAL|Biofeedback|Biofeedback training combines teaching slow, deep, paced breathing with real-time tracking to increase an individual's heart rate variability and ultimately improve self-regulation.
214925507|NCT04603482|BEHAVIORAL|Attention Control|Participants randomly assigned to this intervention will receive suggested Diversional Activities, presented in an audiovisual format.
214925508|NCT05232604|OTHER|Aerobic exercise|30-45 minutes of aerobic exercise in a cycle ergometer will be applied in three different intensities (low, moderate and high) along 12 weeks of treatment.
214925509|NCT05232604|OTHER|Neck motor control exercise|An specific neck motor control exercise targeted to the neck flexor and extensor muscles supervised by a physical therapist will be applied during 12 weeks of treatment.
215068590|NCT07033650|OTHER|flowable Bulk-fill composite (X-tra Base)|flowable resin composite
215068591|NCT07033650|DEVICE|compothixo oscillating packing|oscillating packing device
214925510|NCT03500913|DRUG|Growth Hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
214925511|NCT05229952|DIETARY_SUPPLEMENT|Low-oxalate controlled diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
214925512|NCT05229952|OTHER|Primed, continuous intravenous infusion of 13C2-oxalate|Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
214925513|NCT05955326|DRUG|Sovateltide|Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
214925514|NCT05955326|OTHER|Normal Saline|Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.
214925515|NCT01054196|DRUG|lenalidomide|daily dose dependent on dose-escalation schedule
214925516|NCT01054196|DRUG|melphalan|100 mg/m2 given Days -2 and -1
214925517|NCT03888404|OTHER|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
214925518|NCT03888404|OTHER|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
215068592|NCT07034040|BEHAVIORAL|SmaRTWork|The SmaRTWork app provides weekly individually tailored self-management plans by matching the participant's health information and sick leave status with targeted educational messages, physical activity advice, and exercise recommendations. In addition, participants with specific problems regarding i) work accommodations, ii) workplace conflicts, iii) large responsibilities as caregivers, iv) financial problems, or v) who do not think they will return to the old workplace are offered to be set in contact with a caseworker at the social insurance office. The intervention is given in addition to usual care.
215068593|NCT07032753|DEVICE|eOPRA|Electronic Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system for transhumeral amputees.
214925519|NCT03888404|OTHER|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
214925520|NCT03888404|OTHER|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
214925521|NCT03665545|DRUG|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
214925522|NCT03665545|DRUG|IMA950/Poly-ICLC and pembrolizumab|IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
214925523|NCT00179673|DRUG|Lenalidomide|
214925524|NCT02426905|DRUG|trientine dihydrochloride|A retrospective review of patients' medical records
214925525|NCT00282113|DIETARY_SUPPLEMENT|ProBioPlus|ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.
214925526|NCT00282113|DIETARY_SUPPLEMENT|Culturelle|Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.
214925527|NCT00282113|OTHER|Placebo|A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
214925528|NCT05902299|DRUG|Antibiotic|Evaluate the choice of antibiotic therapy prescribed for P. aeruginosa ou S. aureus infection
214925529|NCT02949843|DRUG|Chemotherapy|Receive other treatment
214925530|NCT02949843|BIOLOGICAL|Immunotherapy|Receive other treatment
214925531|NCT02949843|OTHER|Laboratory Biomarker Analysis|Correlative studies
214925532|NCT02949843|BIOLOGICAL|Nivolumab|Given IV
214925533|NCT02949843|BIOLOGICAL|Pembrolizumab|Given IV
214925534|NCT02949843|DRUG|Targeted Molecular Therapy|Receive drug targeting secondary mutation
214925535|NCT02949843|DRUG|Tyrosine Kinase Inhibitor|Given PO
214925536|NCT00421018|DRUG|Single corticosteroid inhalers and Singulair|Treatment steps according to preset algorithm
214925537|NCT06346821|DEVICE|Optune® (Tumor Treating Fields)|TTFields at 200 kHz to the brain using the Optune® System
214925538|NCT05069402|DIETARY_SUPPLEMENT|Immunonutrition|diet with immunonutrients
215068594|NCT07032753|DEVICE|OPRA|Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations
215068595|NCT07032753|DEVICE|eOPRA with sensory feedback|Electronic Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations with sensory feedback.
214925539|NCT05069402|DIETARY_SUPPLEMENT|High-protein|Oral nutrition with high-protein content
214925540|NCT05069402|DIETARY_SUPPLEMENT|Standard ONS|Oral nutrition with standard ingredients
214925541|NCT05882305|BIOLOGICAL|Autologous monocyte-derived DCs pulsed withEBV-associated antigen|Patients will receive approximately （2.5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
214925542|NCT05932589|OTHER|EEG and Auditory and Visual Evoked Potentials (AEP and VEP)|Through up to eight standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.
214925543|NCT05932589|OTHER|Clinical assessment|Established clinical measures for RTT will be collected for RTT participants
215068596|NCT07032753|DEVICE|eOPRA without sensory feedback|Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations without sensory feedback.
215068597|NCT06713798|DRUG|Atezolizumab 1200 mg IV|atezolizumab (intravenous 1200mg Q3W)
214925544|NCT01927003|PROCEDURE|Dorsal digito-metacarpal flap|The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
215068598|NCT06713798|DRUG|Tiragolumab 600 mg IV|Tiragolumab (intravenous 600mg Q3W)
214672978|NCT01116245|BIOLOGICAL|ADXS11-001 (Lm-LLO-E7)|ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
214925545|NCT04974281|COMBINATION_PRODUCT|PD-1 and Lenvatinib Plus TACE|PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE )： Patients were recommended to receive TACE once every 6 weeks. Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.
214925546|NCT06668532|DEVICE|Digital toolkit|Access to the Flourish app and instruction to use at least twice a week for 6 weeks.
214925547|NCT06668532|OTHER|National mental health resources|Access to national mental health resources from Mental Health America, which can be found here: https://mhanational.org/ten-tools. Participants will receive one resource each week for 6 weeks and each time, will be asked to reflect on how the information can be applied to their own lives.
214925548|NCT00417716|DRUG|Intravitreal Bevacizumab|
214925549|NCT05370586|OTHER|Pericapsular nerve Group Block|Patients of study group will receive PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone
214925550|NCT05370586|OTHER|Infrainguinal Fascia Iliaca Block|Patients of control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone
214925551|NCT00474201|DRUG|Lopinavir/Ritonavir|lopinavir 400 mg + ritonavir 100 mg twice daily for 2 weeks
214925552|NCT00474201|DRUG|Gemfibrozil|Control arm (no intervention used in this arm)
214672979|NCT01116245|DRUG|Placebo Control|3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
214925553|NCT05265923|DRUG|CM310|IL-4Rα monoclonal antibody
214925554|NCT05265923|OTHER|Placebo|Placebo
214925555|NCT03503643|DEVICE|Hemigland Cryoablation|Hemigland cryoablation for the treatment of prostate cancer
214925556|NCT02180295|BIOLOGICAL|V212 Lot 1|Inactivated Varicella Zoster Virus vaccine
215068599|NCT07032740|DIAGNOSTIC_TEST|Bruce test|In the Bruce test, a breath pattern was obtained by means of an OEP (once with a respirator and once without a respirator).
215068600|NCT06729502|OTHER|Questionnaire - Pictorial Fit-Frail Scale|All patients over 60 years old, or their caregivers, will be asked to fill the PFFS questionnaire
215068601|NCT06749236|DRUG|test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension|Participants will receive a single dose of the test formulation(T) (one bag of 200 mg deuteriumremidvir hydrobromide for suspension).
215068602|NCT06749236|DRUG|reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension|Participants will receive a single dose of the reference formulation(R) ( two bags of 100 mg deuteriumremidvir hydrobromide for suspension).
214672980|NCT04354753|OTHER|No Intervention|No intervention
214672981|NCT06544408|DEVICE|Cool B70 AP Coil - Active (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
214672982|NCT06544408|DEVICE|Cool B70 AP Coil- Sham (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
214925557|NCT02180295|BIOLOGICAL|V212 Lot 2|Inactivated Varicella Zoster Virus vaccine
214925558|NCT02180295|BIOLOGICAL|V212 Lot 3|Inactivated Varicella Zoster Virus vaccine
214925559|NCT02253316|BIOLOGICAL|Ixazomib|
214925560|NCT02253316|DRUG|Lenalidomide|
214925561|NCT02253316|DRUG|Dexamethasone|
214925562|NCT06239571|BEHAVIORAL|Resilient Families (R-FAM)|Dyadic, resiliency intervention that aims to reduce depression, anxiety, and posttraumatic stress among parents of babies in the NICU
214925563|NCT02521051|DRUG|Alectinib|
214925564|NCT02521051|DRUG|Bevacizumab|
214925565|NCT02784613|DRUG|Ospemifene|FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
214925566|NCT01082263|DRUG|Lurasidone HCl|Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
214925567|NCT03086928|OTHER|lava ultimate|resin nano ceramic material
214925568|NCT03086928|OTHER|E.max cad|Lithium disilicate glass ceramic
214925569|NCT02983188|DRUG|Berberine|Berberine tablets, 0.3g every time, two times daily
214925570|NCT02983188|DRUG|Placebos|Placebo tablets, 0.3g every time, two times daily
214925571|NCT02983188|DRUG|Antipsychotic Agents|Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
214925572|NCT01303406|DRUG|Idebenone|All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).
214925573|NCT01303406|DRUG|Placebo|
214925574|NCT02107859|DRUG|Ataluren|Ataluren will be administered per dose and schedule specified in the arm.
214925575|NCT00039351|DRUG|cyclophosphamide|
214925576|NCT00039351|DRUG|prednisone|
214925577|NCT00039351|DRUG|vincristine sulfate|
214925578|NCT00039351|RADIATION|radiation therapy|
214925579|NCT03953053|DEVICE|Femtosecond Laser Assissted Cataract Surgery|During routine Catarct Surgery the Femtolaser cuts a ACCC (Anterior Continous Curvilinear Capsulotomy) into the lensbag and fragmentise the cataract affilited lens body
214925580|NCT03297918|BEHAVIORAL|Respiratory muscle training|The intervention is two-parted and includes weekly singing lessons in a choir, held by a professional instructor, with additional instructions for daily breathing exercise at home.
214925581|NCT03557216|DIAGNOSTIC_TEST|Colonoscopy|Anal introduction of a long, flexible, tubular instrument about 1/2-inch in diameter that transmits an image of the lining of the colon so the doctor can examine it for any abnormalities
214925582|NCT03557216|DIAGNOSTIC_TEST|Fecal immunochemical and occult blood test|A test for fecal occult blood looks for blood in your feces. It can be a sign of a problem in the digestive system, such as a polyp or cancer in the colon.
214925583|NCT03557216|DIAGNOSTIC_TEST|Fecal calprotectin test|Calprotectin is a protein released by neutrophils. When there is inflammation in the colon, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. This test measures the level of calprotectin in stool as a way to detect inflammation and lesions in the colon.
215068603|NCT06767098|OTHER|theraputic exercises for neck muscles and smartphone holder|strech and strength exercises for neck muscles. and using smartphone holder daily.
214925584|NCT04190511|DIETARY_SUPPLEMENT|Prebiotic-containing dairy|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition. On this basis, intervention was carried out using prebiotic-containing dairy products (200g/day).
214925585|NCT04190511|DIETARY_SUPPLEMENT|Dietary intervention|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.
214925586|NCT00135512|DRUG|bupropion hydrochloride|Study drug
214925587|NCT06621745|BEHAVIORAL|Gratitude Intervention App|The GIA app, an iOS application designed for this study, is based on effective gratitude interventions and tailored for youth. Access required a unique login. It features five exercises: a journal, photo book, imagine exercise, speech exercise, and meditation. The journal encourages daily entries. The photo book involves uploading photos of things users are grateful for, promoting mindfulness. The imagine exercise reflects on gratitude, while the speech exercise records users' gratitude. The meditation exercise enhances well-being. During the three-week study, daily notifications prompted exercise completion. The app, green and white with a flower-heart icon, offers email support for technical issues.
214925588|NCT04439214|BIOLOGICAL|Nivolumab|Given IV
214925589|NCT03500783|DRUG|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting.
215068604|NCT06767098|OTHER|theraputic exercises for neck muscles|strech and strength exercises for neck muscles.
215068605|NCT00050830|DRUG|CI 1033|
214925590|NCT03500783|OTHER|Standard CPB|Standard protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit
215068606|NCT03486301|DRUG|BDB001 (EIK1001)|BDB001 (EIK1001) is an immunotherapy agent.
215068607|NCT03486301|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
215068608|NCT06889090|DRUG|: two syringes of lidocaine 10 mg/mL will be prepared. A 10-mL syringe (induction syringe) will be given during the induction of anesthesia and A 50 mL syringe (infusion syringe) will be used as conti|: two syringes of lidocaine 10 mg/mL will be prepared. A 10-mL syringe (induction syringe) will be given during the induction of anesthesia and A 50 mL syringe (infusion syringe) will be used as continuous infusion.
215068609|NCT06889090|DRUG|A 10-mL syringe of 10 mcg/mL fentanyl (induction syringe) and a 50-mL syringe of saline (infusion syringe) will be prepared as placebo.|A 10-mL syringe of 10 mcg/mL fentanyl (induction syringe) and a 50-mL syringe of saline (infusion syringe) will be prepared as placebo.
215068610|NCT05027347|DIAGNOSTIC_TEST|plasma circulating tumor DNA|A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
215068611|NCT01101958|DEVICE|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
215068612|NCT01101958|DEVICE|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
214925591|NCT05645640|COMBINATION_PRODUCT|Village doctor-led tailored health management|"Investigators will sketch features of cardiovascular risk factor combinations for the high-risk subjects and accordingly set tailored promotion targets for them. Subjects will receive individualized consultation about their cardiovascular risk profile and tailored health management led by village doctors. They will receive tailored health text messages pushed by village doctors 3 times a week, including contents in physical activity, healthy diet, smoking abstinence, responsible alcohol drinking, sleep, and medication adherence. They will be provided with a smart band, and supposed to daily wear the smart band to collect health data. The progress of tailored promotion targets will be evaluated every 3 months, and feedback will be given in the form of virtual rewards and punishments: completed (a virtual golden egg) and failed (a virtual bomb). According to the number of virtual golden eggs, participants could redeem project gift in real life."
215068613|NCT02645565|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
214925592|NCT05486533|OTHER|Acupressure|The experimental group will start with LI4 points and continue P6 and LI11 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
214925593|NCT05665075|DRUG|QN-023a|NK cell therapy
214925594|NCT05665075|DRUG|Cyclophosphamid|Lympho-conditioning Agent
214925595|NCT05665075|DRUG|Fludarabine|Lympho-conditioning Agent
214925596|NCT05665075|DRUG|Cytarabine|Lympho-conditioning Agent
214925597|NCT05665075|DRUG|VP-16|Lympho-conditioning Agent
214925598|NCT06332274|DRUG|Tislelizumab|"Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.~Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
214925599|NCT06332274|OTHER|Blood sampling|Blood sampling for analyses of MRD (Molecular Residual Disease)
215068614|NCT02645565|DRUG|Azathioprine|azathioprine will be given at 2 mg/kg.
214925600|NCT06332274|DRUG|Placebo|"Pharmaceutical form : Solvent IV bags used for dilution of tislelizumab (for example: CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable) Dose Regimen: every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
214925601|NCT01964144|DRUG|Dovitinib|Dovitinib 500mg (5 capsules x 100 mg/day) for 5 consecutive days and 2 days rest
214925602|NCT05119322|DIAGNOSTIC_TEST|GlutenDetect home urine test|GFD compliance self-asessment using a home rapid test for GIP detection in urine.
214925603|NCT04172259|DRUG|Doxorubicin liposome|PLD
214925604|NCT04172259|DRUG|Cyclophosphamide|CTX
214925605|NCT04172259|DRUG|Trastuzumab|H
214925606|NCT04172259|DRUG|Docetaxel|DOC
214925607|NCT04172259|DRUG|Epirubicin|EPI
214925608|NCT04172259|DRUG|Pertuzumab|P
214925609|NCT04172259|DRUG|Paclitaxel|paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week
215068615|NCT02645565|DRUG|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
215068616|NCT04061616|BEHAVIORAL|PASIPD-Fr|Fill-out the PASIPD-Fr self questionaire twice (2 completions at a 2-week interval)
215068617|NCT07081659|DRUG|sildosin 4mg|ondemand sildosin 4mg
215068618|NCT07081659|DRUG|dapoxetine 60mg|ondemand dapoxetine 60mg
214925610|NCT04172259|DRUG|Paclitaxel-albumin|albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
214925611|NCT06784895|BEHAVIORAL|Women only Cardiac Rehab program|"This is a 12-week program and will include 36 sessions 3 times a week. This group will also have Women-Only Education sessions. Participants will also have a 24-week follow-up visit from the time of entry.~This group orientation prior to starting CR will allow additional time for enhanced story telling among patients, provide a more detailed description of what to expect in CR, and allow additional time to address participant concerns or worries prior to starting CR. Women-specific education content will be provided monthly in addition to the standard weekly mini-teaches. This education content will be developed and delivered by experience health care professionals that are experts in women's health."
214925612|NCT06784895|BEHAVIORAL|Standard of Care (mixed-sex) rehab program|This is a 12-week program and will include up to 36 sessions 3 times a week. Participants will also have a 24-week follow-up visit from the time of entry. Exercise classes are medically supervised, and each program is individualized based upon medical history, cardiac risk factors, goals, and initial fitness level. Educational programs are arranged in a continuing series, with sessions taught by experts in nutrition therapy, stress reduction therapy, and exercise.
214925613|NCT05280444|DRUG|Idarubicin Hydrochloride for Injection|The initial dose of idarubicin is 10 mg and the maximum tolerated dose is 20 mg. Idarubicin is first dissolved in water for injection to make a solvent of 2mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents.
215068619|NCT03915990|DIAGNOSTIC_TEST|umbilical and middle cerebral artery Doppler|Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
215068620|NCT05595070|PROCEDURE|Haematopoietic stem cell transplantation|Haematopoietic stem cell transplantation (HSCT) is widely used in the treatment of malignant and non-malignant conditions to reconstitute the immune system secondary to cytotoxic conditioning regimens. These regimens, consisting of chemotherapy with or without total body irradiation, cause severe immunosuppression prior to, during and after HSCT. Immune reconstitution takes place by infusion of stem cells either harvested from the patient (autologous HSCT) or from a donor (allogeneic HSCT).
215068621|NCT00107900|DRUG|DU-176b|
215068622|NCT02085044|DIETARY_SUPPLEMENT|Ready-to-Used Supplement Food administration|
214925614|NCT04152837|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
214925615|NCT00602459|DRUG|Cyclophosphamide|Given IV
214925616|NCT00602459|DRUG|Fludarabine Phosphate|Given IV or PO
214925617|NCT00602459|OTHER|Laboratory Biomarker Analysis|Correlative studies
214925618|NCT00602459|DRUG|Lenalidomide|Given PO
214925619|NCT00602459|BIOLOGICAL|Rituximab|Given IV
214925620|NCT00005777|PROCEDURE|Minimal mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target (\>52 mm Hg)
214925621|NCT00005777|PROCEDURE|Routine mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target \<48 mm Hg)
214925622|NCT00005777|DRUG|Dexamethasone|Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
214925623|NCT00005777|DRUG|Placebo|The infants in the placebo groups received equal volumes of saline.
214925624|NCT06346444|OTHER|Diagnostic test and behavioral|Questionnaires (CGI, RSBQ) and Outcome measurements (Neuroscope, EEG, Brain MRI, Bone densitometry, X-ray of thoracic and lumbosacral spine Blood biomarkers-RNA, proteins, other metabolites-)
214925625|NCT00445497|DRUG|amoxicillin-clavulanate potassium|
214925626|NCT00445497|DRUG|ciprofloxacin|
215068623|NCT03840044|OTHER|Cold air exercise test|Subjects will perform a submaximal 90 minutes exercise test in a controlled cold air environment (-5°C, 60% relative humidity) in a climate chamber with evaluation pre§/during\*/post§ of heart rate (HR)§\* and blood pressure (BP)§\*, spirometry§\*, PNIF§, FeNO§, electrocardiogram (ECG)§\*, body \& exhaled air temperature§\*, capsaicin cough threshold test§, histamine bronchial challenge test§, and sampling of nasal fluid§, induced sputum§, and venous blood§.
215068624|NCT03533959|DRUG|Alirocumab|the administration of Alirocumab at least 75mg every 2 weeks
214672983|NCT06544408|DEVICE|Cool D-B80 AP Coil - Active (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
214925627|NCT00445497|PROCEDURE|psychosocial assessment and care|
214925628|NCT00445497|PROCEDURE|quality-of-life assessment|
214925629|NCT01295827|BIOLOGICAL|Pembrolizumab|IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.
214925630|NCT01174706|BEHAVIORAL|Information prescriptions|One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.
214925631|NCT01240577|DRUG|IPdR|
214925632|NCT02300662|DEVICE|Cycle Ergometer|Passive movement of the cycle ergometer will execute alternate flexions and extensions of the patients' knee and hips bilaterally for 20 minutes consecutively.
214925633|NCT02300662|OTHER|Conventional physiotherapy|Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
214925634|NCT06235021|OTHER|Saffron|"Saffron powder (purchased from Moayeri Copmany2 in Oman, prepared from the stigma of Crocus sativus L.).~Total of 10 mg of saffron powder will be added to 100 ml of distilled water. Then, it will be incubated on a shaker for 24 h. The material will be passed through several layers of muslin cloth. The extracts will then be poured into a round bottom balloon and placed in the freezer at a temperature of -80°C. After freezing, the extracts were placed in a freeze-dryer.~In vacuum, the solvent will be removed and saffron powder will be obtained. After preparing the initial concentration, serial dilution with ratios of one-half and one-third will be performed in sterile vials and one-half of the final concentration will be discarded.~After the preparation of extract, the 0.2% saffron mouthwash will be prepared by mixing the following ingredients: 1. propylene glycol (5 g) 2. saffron extract (0.2 g) 3. polysorbate 80 (1.8 g) 4. sodium benzoate (0.2 g) 5. water (91 g)."
214925635|NCT06235021|OTHER|chlorhexidine mouthwash|commercial product of 0.2% chlorhexidine mouthwash.
214925636|NCT00746564|DEVICE|SJM Confirm|All patients in this study will receive the SJM Confirm device.
215068625|NCT00086528|DRUG|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
214925637|NCT03318497|DRUG|3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT|Given IV The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
214925638|NCT03318497|PROCEDURE|Computed Tomography|Undergo PET/CT
214925639|NCT03318497|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214925640|NCT03318497|OTHER|Laboratory Biomarker Analysis|Correlative studies
214925641|NCT00264745|BEHAVIORAL|TASK intervention|The Telephone Assessment and Skill-building Kit (TASK) is an individualized 8-week intervention program geared toward reducing depression and improving general health in stroke caregivers.
214925642|NCT00264745|BEHAVIORAL|Attention Control|Minimal intervention beyond initial hospital visit.
214925643|NCT06578598|DEVICE|Igelplus|Intubation with Igelplus laryngeal mask
214925644|NCT00907491|DEVICE|pulmonary sounds analyzer|Cough counting device based on the WIM Technology
215068626|NCT06093308|DRUG|Deuremidevir Hydrobromide Tablets|Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
215068627|NCT00540241|DRUG|Pemetrexed|in-label use
215068628|NCT04105192|DIETARY_SUPPLEMENT|dietary supplement consumption|Consumption of the product under study for 84 days, plecebo or experimental product
215068629|NCT02644096|OTHER|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
215068630|NCT03671421|PROCEDURE|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
214925645|NCT02921880|OTHER|Cardiac Rehabilitation|
214925646|NCT02842580|DRUG|5 FLUOROURACYL|"Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days."
214925647|NCT02842580|DRUG|acide folinique|200 mg/m² if Elvorine
214925648|NCT02842580|DRUG|irinotecan|"Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
214925649|NCT02842580|DRUG|Oxaliplatin|"Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
214925650|NCT02842580|DRUG|capécitabine|For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
214925651|NCT02842580|DRUG|bevacizumab|Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
214925652|NCT03226769|DEVICE|TrueTear™|Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.
214925653|NCT03226769|DEVICE|Thermalon Dry Eye Compress|Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.
214925654|NCT00669565|DRUG|Bavituximab|Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
214925655|NCT01827267|DRUG|neratinib|
214925656|NCT01827267|DRUG|temsirolimus|
214925657|NCT04896398|DEVICE|ESWT|In the study group, a total of 5 sessions of focused ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the affected wrist within 2 weeks.
214925658|NCT00406263|PROCEDURE|Scheimpflug crystalline lens photographs|scheimpflug photographs
214925659|NCT01408316|DRUG|PX-866|Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
215068631|NCT07075510|DRUG|Daratumumab Injection|Daratumumab Administration in the Anterior Upper Thigh versus the Abdomen
215068632|NCT01198210|DRUG|saline|local peritonsillar infiltration of 2 ml saline,
215068633|NCT01198210|DRUG|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
215068634|NCT01198210|DRUG|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
215068635|NCT01198210|DRUG|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
215068636|NCT07080138|DRUG|All kinds of INSTI medications|All kinds of INSTI medications, such as Bictegravir/Emtricitabine/Tenofovir alafenamide Fumarate, Dolutegravir/Emtricitabine/Tenofovir alafenamide Fumarate for PLWH
215068637|NCT07080138|DRUG|All kinds of conventional medications|All kinds of conventional medications, such as Abacavir, Efavirenz for PLWH
215068638|NCT02461290|RADIATION|Chemotherapy|
215068639|NCT02461290|DRUG|Rituximab|
215068640|NCT01518686|DEVICE|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
215068641|NCT03076060|BEHAVIORAL|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD."
215068642|NCT03076060|BEHAVIORAL|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD."
215068643|NCT03990623|RADIATION|Computed Tomography Perfusion Imaging|Undergo perfusion CT
215068644|NCT03990623|PROCEDURE|Liver Biopsy|Undergo liver biopsy
215068645|NCT07080398|DIAGNOSTIC_TEST|serum bilirubin level measurement|Total serum bilirubin levels and concurrent transcutaneous bilirubin measurements will be done and the results will be evaluated comperatively.
214925660|NCT02400554|BEHAVIORAL|Yappalli|"Month 1-3: Up to 8 group sessions on Choctaw history, traditions, cultural systems, \& women's roles. Up to 3 individual Motivational Interviewing (MI) sessions to identify community leadership \& personal change goals on the main outcome.~Month 2: Overnight Culture Camp to strengthen group cohesion \& synthesize goals.~Month 3: Walk for a week on the Choctaw Trail of Tears, upon completion make a commitment to conduct a community-wide event based on personal \& leadership goals \& experience on the Trail.~Months 3-12: Up to 6 group meetings to plan community leadership events related to ATOD \& obesity prevention. Includes: digital storytelling training to create a story related to ATOD \& obesity prevention \& an individual MI booster session to revise their personal \& community leadership goals.~Month 12: Share digital stories \& community event experiences \& undergo a ceremony to transition to health leaders within their communities."
214925661|NCT00537576|BIOLOGICAL|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10\^8 CFU), administered vaginally once a day for 5 consecutive days
214925662|NCT00537576|BIOLOGICAL|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
214925663|NCT00537576|BIOLOGICAL|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
214925664|NCT00537576|OTHER|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
214925665|NCT00537576|OTHER|Medium dose Placebo|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
214925666|NCT00537576|OTHER|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
214925667|NCT03222089|DRUG|Irinotecan|Irinotecan 165 mg/m² 1-hour IV day 1
214925668|NCT03222089|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² 2-hours IV day 1
214925669|NCT03222089|DRUG|Levoleucovorin|Levoleucovorin 200 mg/m² 2-hours IV day 1
215068646|NCT07081490|OTHER|Virtual Escape Room Game|Virtual escape rooms are digital versions of physical escape rooms that can be accessed remotely. Virtual escape rooms are adaptations of physical escape rooms that use online interactive environments where participants aim to solve puzzles within a set timeframe.
215068647|NCT07080164|OTHER|mini implant retained overdenture|mini implant retained overdenture
215068648|NCT07081581|DRUG|Bupivacain|In Group B( control group), bupivacaine was given as additional medication in the serratus block application.
215068649|NCT07081581|DRUG|Bupivacaine and Magnesium sulfate|In Group M, bupivacaine and magnesium were given as additional medication in the serratus block application.
215068650|NCT07081581|DRUG|Bupivacaine and Dexmedetomidine ile Blokaj|In Group D, bupivacaine and dexmedetomidine were given as additional medication in the serratus block application.
215068651|NCT07080346|DRUG|Upadacitinib 15 MG|All the BS patients discontinued other biologic agents and received oral upadacitinib treatment at a dose of 15mg per day with background glucocorticoids and immunosuppressants for 48 weeks. All the patients will be followed up prospectively for 48 weeks.
215068652|NCT07079319|OTHER|MET + Biofeedback Strengthening + Kinesiotaping|Participants in this group will receive the same treatment protocol as Arm 1 (MET and biofeedback strengthening), with the addition of Kinesiotaping (KT) applied across the shoulder girdle. KT will be applied with 50-70% stretch from the anterior acromion to the opposite scapula, 3 times per week for 4 weeks. The tape will be worn for 14-16 hours per application. Standard physiotherapy (heat, ultrasound, neck isometrics, and stretching) will also be administered as part of the protocol.
214925670|NCT03222089|DRUG|5-FU|5-FU 2800 mg/m² 46-hours flat continuous infusion IV
214925671|NCT03222089|DRUG|GM-CSF|GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.
214925672|NCT03222089|DRUG|IL-2|Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
214925673|NCT01516008|DRUG|Tapentadol IR 50 mg|Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
214925674|NCT01516008|DRUG|Tapentadol IR 75 mg|Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
215068653|NCT07079319|OTHER|MET + Biofeedback Strengthening|Participants in this group will receive Muscle Energy Technique (MET) for the upper trapezius, levator scapulae, pectoralis major, and pectoralis minor using post-isometric relaxation technique. Additionally, they will perform biofeedback-based cranio-cervical flexion exercises using a pressure biofeedback unit (PBU). The intervention will be administered 3 times per week for 4 weeks, with a total of 12 sessions. Standard physiotherapy (heat application, ultrasound, neck isometrics, and stretching exercises) will also be provided.
215068654|NCT07080281|DEVICE|Oculus Meta Quest 2 All In-One model virtual reality glasses|"During the caesarean section, Meta Quest 2 All In-One model virtual reality glasses from Oculus were used for 15 minutes. In this virtual environment, the licensed product video Breathe- Relax and Meditate was watched via the Meta Horizon application."
215068655|NCT07081737|OTHER|Interdisciplinary treatment (IDT) + Clinical Decision Support System (CDSS)|Interdisciplinary treatment (IDT) combined with Clinical Decision Support System (CDSS)
215068656|NCT07081737|OTHER|Interdisciplinary treatment (IDT)|Interdisciplinary treatment (IDT)
215068657|NCT07079410|DRUG|Sintilimab+Cetuximab|Neoadjuvant treatment: the participants will receive Sintilimab 200 mg (each 3-week/cycle) and Cetuximab (400 mg/m2 first time and followed 250 mg/m2, day 1, day 8, day 15) for 2 cycles. Adjuvant treatment: the participants will receive Sintilimab 200 mg (each 3-week cycle, a total of 17 cycle) for a total of one year.
215068658|NCT07080814|DEVICE|Tecnobody ProKin Balance Training|Balance training using Tecnobody ProKin dynamometric platform, administered 5 sessions per week for 3 weeks in addition to standard rehabilitation.
215068659|NCT07080814|BEHAVIORAL|Standard rehabilitation|The standard rehabilitation protocol includes cold pack application to the knee region, transcutaneous electrical nerve stimulation (TENS), quadriceps muscle stimulation, knee stretching, active-assisted and active range of motion (ROM) exercises, strengthening exercises for the knee extensors and hip abductors/extensors, gait training, and balance exercises. Each patient will undergo a total of 15 physical therapy sessions.
214486062|NCT06875570|OTHER|Jump Rope Training|The entire intervention program will last for 12 weeks during the season. Before training, players will be instructed to warm up with general running exercises and dynamic stretching for ten minutes. The jump rope intervention will consist of 5 exercises performed in the following order: basic jump step, double leg double jump, double leg jump left and right, double leg jump forward and backward, and scissor steps (Trecroci et al., 2015). Each exercise will be performed by all participants using a jump rope with the same characteristics in terms of weight (e.g. 230g), length (e.g. shoulder size) and material (e.g. PVC, Polyvinyl Chloride). A metronome speed of 120 beats per minute will be used to ensure equal exercise intensity in both exercise programs Furthermore, a volleyball coach will monitor the entire workout.
214925675|NCT01516008|DRUG|Placebo|Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
214925676|NCT06129435|BEHAVIORAL|Visuospatial Task (VST)|Participants randomized to the VST condition will play a visuospatial game (i.e., Tetris). Participants will be given two minutes to practice Tetris and then will be instructed to play for 15 minutes without stopping.
214486063|NCT06875570|OTHER|Small Sided Games|More complex, skill-based conditioning exercises for volleyball are small-sided games (2v2, 3v3) and competition drills (6v6). Although the duration of each rally in these drills is not controlled by the coach, the total duration of the drill will be recorded to aid in-session and inter-session planning. Total repetitions will be easily measured by adding up the total points played in the rally and then multiplying by the number of rallies per point. The coach will create an emotionally intense environment by applying a scoring system (e.g. team winning 2 out of 3 rallies gets 1 big point, 5 seconds rest) and encouraging the players (Trajkovic et al., 2012).
214925677|NCT06129435|BEHAVIORAL|Word Association Task (WAT)|Participants randomized to the WAT condition will play a word association game. Research staff members will read from a list of 300 words, not associated with trauma, to the participant. The participant will verbally respond to each word out loud with the first word that comes to their mind. This word association task will continue for 15 minutes or until all 300 words are read, whichever occurs first.
214925678|NCT04326946|DEVICE|Alfapump|alfapump implementation
214925679|NCT05704998|OTHER|Physiotherapy|Posture exercises, myofascial release techniques, sternocleidomastoideus and upper trapezius kinesio taping, trigger point ischemic compression, suboccipital release technique, cervical traction, deep neck flexors endurance exercises, massage
215068660|NCT07081412|DEVICE|Efficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a test device at 12 week and 12 month|"T-PTNS treatment will be performed at home with an external generator and two surface electrodes SmartUric medical device. Each T-PTNS session will consist of test and treatment sections. The treatment will be planned and carried out by researchers.~The treatment dose is 1 day/week, 30 minutes/session, totaling 12 sessions. Treatment Pulse Frequency: 20 Hz, Treatment Pulse Width: 200us (microsecond)."
215068661|NCT07081412|DEVICE|Efficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a placebo device at 12 week|These are devices that have the same physical appearance, interface and feedback features, but are prepared in a way that they will not provide electrical stimulation during the treatment session. They are delivered to the Contract Research Organization (CRO) by the project manager and are randomized through the CRO and given to the researchers with a code. The duration and frequency of treatment will be the same as the treatment group.
215068662|NCT07080710|PROCEDURE|Immediate implant placement|Immediate implant placement with socket grafting and soft tissue augmentation. In cases with a buccal dehiscence \>3mm only this technique is applied. In cases with a buccal dehiscence between 4-6mm a collagen membrane is applied prior to socket grafting. In cases with a buccal dehiscence \> 6 mm, a collagen membrane is also applied and a mixture of C-DBBM and autogenous bone chips (1:1 ratio) is used as grafting material.
215068663|NCT06437288|PROCEDURE|photodynamic therapy|Receive an intravenous infusion of hematoporphyrin injection
215068664|NCT00526656|DRUG|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
215068665|NCT06895330|OTHER|Virtual Reality Group|A brief orientation regarding the use of the virtual reality headset will be provided to the children. One minute prior to the vaccination procedure, the selected video-either a roller coaster or Formula 1 experience, based on the child's preference-will be initiated through the virtual reality headset. Throughout the procedure, the children will continue to watch the video using the virtual reality headset.
215068666|NCT06895330|OTHER|Helfer Skin Tap Group|"The Helfer Skin Tap technique is applied to reduce pain and muscle tension during intramuscular injection by stimulating large nerve fibers through rhythmic tapping. After determining the injection site and preparing the skin with alcohol, the area is tapped for approximately 5 seconds using the dominant hand. The syringe is then held in the dominant hand while a V shape is formed with the non-dominant hand to tap the skin firmly three times. On the count of three, the needle is inserted at a 90° angle. After aspiration, the medication is injected slowly while gentle tapping continues to maintain muscle relaxation. The procedure concludes with simultaneous needle withdrawal and a final V-shaped tap to minimize discomfort."
214925680|NCT04159454|DEVICE|PITA|Patients will have PITA turned on to patients' existing Medtronic devices, such that patients will be RV-paced from midnight to 6 AM each night at a rate \~10 beats per minute (BPM) above patients' baseline heart rates during this time period as determined by Holter monitors.
215068667|NCT06896656|BEHAVIORAL|Marigold Mobile Peer Support Intervention|"The MPS App is a secure platform that allows text-based peer support for individuals in recovery from OUD. Participants assigned to this condition will be enrolled on a rolling basis into a peer support group on the app. All participants will receive onboarding assistance and will have access to the app for 6 months.~The app will include live moderation from a certified Peer Recovery Support Specialist and trained research assistants. Moderators will begin discussions with prompts and regulate the flow of conversation with standardized text language. Moderators will be able to respond in real-time to malicious messages or other flags that could impact participant safety. Built in natural language processing algorithms will also detect language requiring intervention and automatically alter the moderators and on-call clinicians."
215068668|NCT06896656|BEHAVIORAL|Resources|A list of online peer support and mental health resources, drawn from SAMSHA and equivalent websites, will be provided to all participants, as an enhanced adjunct to their standard recovery plans.
214925681|NCT01421160|DRUG|sodium citrate and citric acid|sodium citrate and citric acid equivalent to 1 mEq/ml bicarbonate (usual dose 10-30 mls/day diluted with water)
214925682|NCT06389045|OTHER|Procedural Sedation|Profopol Sedation in Endoscopic Ultrasonography
215068669|NCT05915416|BEHAVIORAL|Child Abuse and Neglect Prevention Program|The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
215068670|NCT03689491|BEHAVIORAL|rTMS|The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.
215068671|NCT03689491|BEHAVIORAL|visual feedback training|Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.
215068672|NCT03689491|BEHAVIORAL|traditional rehabilitation|30 min traditional rehabilitation. The traditional rehabilitation programs included balance training, postural training, muscle strengthening, ambulation training and etc..
215068673|NCT07080060|OTHER|Niel-Asher Technique|"Participants in this group will receive the Niel-Asher Technique, a manual therapy approach focusing on trigger point release and myofascial decompression of the shoulder girdle. Treatment will involve structured pressure techniques applied to specific muscular trigger points including the infraspinatus, supraspinatus, subscapularis, and levator scapulae. The intervention will be delivered in side-lying and sitting positions.~Conventional physiotherapy, includes a 10-minute hot pack, 15-minute TENS, Codman exercises, finger ladder exercises (2-3 sets, 3-5 repetitions), and capsular stretching (20-30 sec hold, 2-4 repetitions). Sessions will be conducted 3 times per week for 4 weeks."
214486064|NCT06873061|OTHER|telenursing|This study aims to examine the impact of telemedicine training on nursing students. The training content is designed specifically for nursing students and includes various techniques such as simulations.
214925683|NCT04488198|OTHER|Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with acupuncture needles.
214925684|NCT04488198|OTHER|Placebo-Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with placebo-needles.
214925685|NCT03129945|DRUG|Nifedipine|Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.
214925686|NCT03129945|DRUG|Indomethacin|Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.
214925687|NCT05397392|OTHER|guideline recommended routine treatment|
215068674|NCT07080060|OTHER|Spencer Technique|"Participants in this group will receive the Spencer Technique, an osteopathic manual therapy consisting of eight mobilization steps: extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction with external rotation, internal rotation, and traction stretch. Each movement will be performed with patient participation using muscle energy techniques.~Conventional physiotherapy, includes a 10-minute hot pack, 15-minute TENS, Codman exercises, finger ladder exercises (2-3 sets, 3-5 repetitions), and capsular stretching (20-30 sec hold, 2-4 repetitions). Sessions will be conducted 3 times per week for 4 weeks."
214925688|NCT03082157|BEHAVIORAL|Mighty Men Intervention|African American men assigned to this condition will receive: tailored goals/ messages, self-monitoring, small group meetings and educational and community-based information and resources.
214925689|NCT03183089|DRUG|Rohto Dry-Aid®|
214925690|NCT03183089|DRUG|Systane® Ultra|
214925691|NCT02953444|OTHER|Thirty-Second Mindfulness Practice|
214925692|NCT02953444|OTHER|Three-Minute Mindfulness Practice|
214925693|NCT06398067|BEHAVIORAL|Vietnamese Self-Help Plus (vSH+)|vSH+ is a stress management program delivered through four 75-minute sessions. It includes the five core SH+ skills. Healthcare workers (nurses and social workers) function as lead facilitators (called 'HW Facilitators') and cancer survivors as co-facilitators (called 'Peer Facilitators').
215068675|NCT05921695|DRUG|Normal Saline infusion and Ringer lactate infusion|The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
215068676|NCT05756166|PROCEDURE|Biopsy|Undergo tumor biopsy
215068677|NCT05756166|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215068678|NCT05756166|DRUG|Celecoxib|Given PO
214925694|NCT06398067|OTHER|'Doing What Matters in Times of Stress' (DWM) Guide|An illustrated guide developed by WHO to equip people with practical skills to help cope with stress which has been translated to Vietnamese and reviewed and revised by the investigators.
214925695|NCT05736640|DRUG|Denosumab|
214925696|NCT05736640|DRUG|Placebo|
215068679|NCT05756166|PROCEDURE|Computed Tomography|Undergo CT scan
215068680|NCT05756166|BIOLOGICAL|Interferon Alpha-2|Given IV
214925697|NCT05566704|DEVICE|Modulus ALIF System|The Modulus ALIF System is designed to address lumbar pathologies utilizing interbody placement through an anterior or anterolateral surgical approach. The Modulus ALIF System is an interfixated interbody system available in various shapes and sizes to suit the individual pathology and anatomical conditions of the patient.
214925698|NCT03424772|DIAGNOSTIC_TEST|Whole genome sequencing|WGS will be performed for the trio
214925699|NCT02660281|RADIATION|Total Body Irradiation 1200 cGy|1200 cGy TBI in 8 fractions
214925700|NCT02660281|DRUG|Fludarabine|Fludarabine
215068681|NCT05756166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215068682|NCT05756166|BIOLOGICAL|Pembrolizumab|Given IV
214925701|NCT02660281|DRUG|Pre-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given prior to the stem cell infusion
214925702|NCT02660281|DRUG|Pre-Stem Cell Infusion Mesna|Mesna given prior to the stem cell infusion
214925703|NCT02660281|DRUG|Busulfan|Busulfan
214925704|NCT02660281|DRUG|Melphalan|Melphalan
214925705|NCT02660281|PROCEDURE|Stem Cell Infusion|Stem cell infusion
214925706|NCT02660281|DRUG|Post-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given after the stem cell infusion
214925707|NCT02660281|DRUG|Post-Stem Cell Infusion Mesna|Mesna given after the Stem Cell Infusion
215068683|NCT05756166|DRUG|Rintatolimod|Given IV
215068684|NCT04294498|DRUG|Durvalumab|Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
215068685|NCT05879354|OTHER|Active Cycle of Breathing Techniques|Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
215068686|NCT04368091|DEVICE|Xtreme Touch - Neo sirolimus coated PTA balloon catheter|The Xtreme Touch (Magic Touch PTA) - Neo Sirolimus PTA Balloon Catheter is the world's first sirolimus coated PTA balloon. The purpose of the X-TOSI all-comers registry is to collect short and long-term clinical performance data on the Xtreme Touch (Magic Touch PTA) -Neo sirolimus PTA balloon catheter in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in real world daily clinical practice.
215068687|NCT01090934|DEVICE|High Resolution EEG|High Resolution EEG
215068688|NCT01090934|DEVICE|Stereo-electroencephalography|SEEG
215068689|NCT02631174|DRUG|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
215068690|NCT03884192|DRUG|Consolidation Sintilimab|Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
215068691|NCT03224403|DRUG|Test acetaminophen|single dose of 2 Test acetaminophen 500 mg tablets
215068692|NCT03224403|DRUG|Commercial acetaminophen|single dose of 2 acetaminophen 500 mg caplets
215068693|NCT03224403|DRUG|Commercial ibuprofen|Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
215068694|NCT03224403|DRUG|Placebo|2 placebo caplets
215068695|NCT00569309|BIOLOGICAL|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
215068696|NCT00569309|OTHER|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
215068697|NCT00569309|OTHER|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
215068698|NCT05346146|DRUG|Sintilimab; Gemcitabine; Albumin-paclitaxel|Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
215068699|NCT04720716|DRUG|IBI310|IBI310 IV d1, Q6W
215068700|NCT04720716|DRUG|Sintilimab|sintilimab IV d1, Q3W
215068701|NCT04720716|DRUG|Sorafenib|Sorafenib 400mg po
215068702|NCT05014139|DRUG|Enfortumab vedotin|Given into the bladder (intravesically)
215068703|NCT03840772|DRUG|Eribulin|Treatment with eribulin
215068704|NCT01456195|DRUG|Placebo|Fasiglifam placebo-matching tablets
214925708|NCT02660281|DRUG|Thiotepa|Thiotepa
214925709|NCT00813813|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
214925710|NCT05353855|OTHER|No intervention|No intervention
214925711|NCT00986921|DRUG|mifepristone 200 mg|mifepristone would be given the day before the procedure
214925712|NCT00986921|DEVICE|osmotic dilator insertion|osmotic dilators (3-6) would be inserted as usual the day before the procedure
214925713|NCT06234748|RADIATION|Radiation|"Patients will undergo 2 phases of RT replanning:~1. Based on 2-week DCE-MRI low BV tumor subvolume, patients will have a PTVboost1 that will start to receive 2.5Gy/day with fraction 16. PTVboost1=(persistent lowBVsubvolume\_2 wks+ MTV3\_2 weeks)+ 3mm margin.~2. Based on 4-week FDG-PET MTV3, patients with have a PTVboost2 cone down that will receive 2.5Gy/day starting with fraction 23. PTVboost2=(LBV\_2 wks + MTV3\_4wks)+ 3mm margin~3. Thus, the tumor subvolumes that are included in the boost from fx16-35 will receive 86 Gy EQD2 (80Gy physical dose) and the FDG-avid subvolumes which start boost at 2 weeks but are not persistently avid at 4 wks will receive 76Gy EQD2 (74Gy physical dose)."
215068705|NCT01456195|DRUG|Fasiglifam|Fasiglifam tablets
215068706|NCT02547038|DRUG|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
215068707|NCT02547038|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
215068708|NCT01368692|PROCEDURE|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
215068709|NCT01368692|PROCEDURE|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
215068710|NCT01340625|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
214925714|NCT06234748|DRUG|Platinum based chemotherapy|Standard of care therapy, weekly, with either Cisplatin or Carboplatin
215068711|NCT01340625|DRUG|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
214925715|NCT01528826|DRUG|vinorelbine plus oxaliplatin|Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
214925716|NCT02017795|OTHER|electronic asthma action plan (eAAP)|An electronic asthma action plan (eAAP) will be provided to intervention group
214925717|NCT02017795|OTHER|written asthma action plan (WAAP)|A written asthma action plan will be given to control group arm
214925718|NCT00419484|DRUG|pioglitazone|
214925719|NCT01167114|DRUG|STA-9090|Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
215068712|NCT04460339|OTHER|Swimming participants in the 25-km|The 25-km race was the French national Open Championship event and participants were the swimmers registered for the race who volunteered to participate in this study
215068713|NCT04847258|OTHER|Standard rehabilitation|Patients follow standard municipal rehabilitation
215068714|NCT06402279|DEVICE|Efferon CT therapy|Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross- linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886. Hemoperfusion procedures were performed using the Efferon CT device no later than 6 hours after the start of invasive ventilation. Hemosorption was performed twice within 12 hours, with an interval of 24 hours between hemoperfusion.
215068715|NCT06116253|DEVICE|Magnetic Resonance Imaging (MRI) Scan|Participants will undergo a 1-hour research MRI scan.
215068716|NCT06116253|DRUG|Tc-99m Pentetate|Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
215068717|NCT05255549|PROCEDURE|ESWT + Stretching|"3 weeks intervention:~* 3 sessions of ESWT, once a week~* 6 sessions of passive stretching, twice a week"
215068718|NCT05255549|PROCEDURE|ESWT and SHAM + Stretching|"3 weeks intervention:~* 1 sessions of ESWT + 2 sessions of Sham, once a week~* 6 sessions of passive stretching, twice a week"
215068719|NCT06447337|DIAGNOSTIC_TEST|Continous body temperature monitoring|The investigational product will be placed on the participants' body in axilar joint and connected to the mobile phone. The values of the current temperature will apear on the monitor and it will be recorded in the database with date and time for each record. In parallel, study staff will occasionally measure the temperature using standard hospital thermometer.
215068720|NCT04506164|OTHER|Multicomponent Implementation Strategy|The eScreening MCIS was developed over the past seven years and consists of: 1) eScreening software provision, 2) training, 3) RPIW, and 4) ongoing blended facilitation. The investigators developed our MCIS to address specific eScreening implementation barriers found in the investigators' prior research.
215068721|NCT04506164|OTHER|eScreening|eScreening is a clinical patient self report system that allows Veterans to complete clinical reminders and other self report screens using a secure connection from any internet connected device.
215068722|NCT04047875|DRUG|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting
215068723|NCT04047875|DRUG|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
215068724|NCT01633632|BEHAVIORAL|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
214925720|NCT03371017|DRUG|Atezolizumab|"Atezolizumab will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
215068725|NCT01633632|BEHAVIORAL|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
215068726|NCT01688245|BEHAVIORAL|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
215068727|NCT01688245|BEHAVIORAL|SMS Assessments|Weekly post-weekend drinking outcome assessments
214925721|NCT03371017|DRUG|Placebo|"Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
215068728|NCT03566771|BEHAVIORAL|Usual care|The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment
215068729|NCT03566771|BEHAVIORAL|CLOSS|Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
215068730|NCT05980130|BEHAVIORAL|Rumination-Focused Cognitive Behavior Therapy|The RFCBT exclusively addresses one possible mechanism underlying depression, rumination. In general, a participant and their therapist will identify when the participant ruminates in an unhelpful manner, what triggers the rumination, what function the rumination fulfills for the participant, and how the participant already does to stop ruminating. Building on this knowledge both together will change the environment to reduce the likelihood of the participant to ruminate, use consciously strategies to stop rumination when it occurs, and replace rumination by more helpful strategies. In the proposed single subject study, the participant and the therapist will meet in person or using a UofL approved video platform up to 18 times for 50-minutes.
215068731|NCT03150966|DRUG|Nanocurcumin|Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
215068732|NCT03150966|DRUG|Placebo|Patients will take placebo in the form of capsules daily during 6 months study period
215068733|NCT05896098|OTHER|Ultrasound|Measurement of the airway by ultrasound in obese patients.
215068734|NCT01224340|BEHAVIORAL|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
215068735|NCT01224340|BEHAVIORAL|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
215068736|NCT01224340|OTHER|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
215068737|NCT00274235|DRUG|sulfadoxine-pyrimethamine / mefloquine|
215068738|NCT01537159|DEVICE|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
215068739|NCT05081167|DRUG|REL-1017|REL-1017 tablet
215068740|NCT05081167|DRUG|Placebo|Placebo tablet
215068741|NCT03341364|BEHAVIORAL|ACT-based group therapy|6 group therapy sessions over 6 weeks (one session à 2 hours weekly), plus one follow-up session 6 weeks after last session. The sessions are lead by a psychologist and a social worker. Each session containing discussions, experimental exercises and home-work assignment.
214925722|NCT03371017|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
214925723|NCT03371017|DRUG|Capecitabine|Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
214925724|NCT03371017|DRUG|Carboplatin|Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
214925725|NCT01220388|DIETARY_SUPPLEMENT|L-lysine|L-lysine, 4,95 G at day : 0,55 G 3 times a day, orally, during meals
214925726|NCT01220388|DIETARY_SUPPLEMENT|placebo|placebo, 3 times a day, orally, during meals
215068742|NCT03341364|BEHAVIORAL|ACT individual treatment|3-12 individual therapy sessions over 3-16 weeks, plus one follow-up session 6 weeks after last session, lead by a clinical psychologist. Each session containing discussion, experimental exercises and home-work assignment.
215068743|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
215068744|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
215068745|NCT05108272|PROCEDURE|Microneedling|Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm
215068746|NCT05108272|PROCEDURE|Percutaneous Collagen Induction|It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
215068747|NCT01842035|DRUG|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
215068748|NCT03441997|OTHER|Mind-body exercise|Exercise program.
215068749|NCT03441997|OTHER|Light mobility exercises|Modified mind-body program.
215068750|NCT00734604|DRUG|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
215068751|NCT00734604|DRUG|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
215068752|NCT00734604|DRUG|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
214925727|NCT01720654|BEHAVIORAL|EPT|Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
215068753|NCT02482597|DEVICE|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
215068754|NCT06552975|OTHER|Infection|Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
215068755|NCT01678573|DRUG|Treatment A: abiraterone acetate|250 mg/day tablet administered orally on Day 1 of each treatment period.
215068756|NCT01678573|DRUG|Treatment B: abiraterone acetate|500 mg/day tablets administered orally on Day 1 of each treatment period.
215068757|NCT01678573|DRUG|Treatment C: abiraterone acetate|1000 mg/day tablets administered orally on Day 1 of each treatment period.
215068758|NCT04310982|DEVICE|The G-Walk sensor system (G-Walk)|The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
215068759|NCT03490591|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
215068760|NCT00426816|DRUG|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
214925728|NCT02932527|BEHAVIORAL|Questionnaire about cannabis consumption|Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.
214925729|NCT02932527|PROCEDURE|blood intake|blood intake is done for infertile male exposed and infertile male not exposed.
214925730|NCT02932527|PROCEDURE|Semen samples collection|Semen samples are collected for infertile male exposed and infertile male not exposed.
214925731|NCT00003427|DRUG|irinotecan hydrochloride|
214925732|NCT00003427|DRUG|oxaliplatin|
214925733|NCT00250627|DRUG|Saredutant succinate (SR48968C)|
214925734|NCT00833482|DRUG|Voriconazole|Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
214925735|NCT00833482|DRUG|Atazanavir|Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
215068761|NCT00426816|DRUG|Placebo|Placebo to match SB-649868
215068762|NCT01428037|DRUG|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
215068763|NCT01428037|DRUG|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
215068764|NCT05974618|DIAGNOSTIC_TEST|Ultrasound|"A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age."
215068765|NCT00053976|BIOLOGICAL|Daclizumab|
215068766|NCT00053976|DRUG|methylprednisolone|
215068767|NCT00053976|DRUG|Placebo|
215068768|NCT02589665|DRUG|Mirikizumab|
215068769|NCT02589665|DRUG|Placebo|
215068770|NCT00978380|DRUG|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
215068771|NCT05148442|DRUG|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody
215068772|NCT00327015|DRUG|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
215068773|NCT00327015|DRUG|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
215068774|NCT00327015|DRUG|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
215068775|NCT00327015|DRUG|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
215068776|NCT00327015|DRUG|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
215068777|NCT05955820|DEVICE|Suspension system|Participants will be tested by four exercises designed for impingement syndrome using the suspension system
215068778|NCT05955820|DEVICE|Dumbbells|Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
215068779|NCT05611567|PROCEDURE|POSE2.0 procedure|The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
215068780|NCT05611567|BEHAVIORAL|Life style and behavioral intervention|The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
215068781|NCT03114579|DEVICE|Intraoperative heart rate measurement (reference method)|Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
215068782|NCT03114579|DEVICE|NEXFIN HD|
215068783|NCT02797665|DRUG|corticosteroids|prednisone 0.6mg/kg/d
214672984|NCT06544408|DEVICE|Cool D-B80 AP Coil - Sham (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
214672985|NCT06544408|DEVICE|Cool B70 Treatment Coil - Active Only|The treatment will be the same as the left dl-PFC accel-TMS dl-PFC except that the Cool B70 Treatment coil only has an active treatment coil.
214925736|NCT00833482|DRUG|Ritonavir|"Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.~Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal."
215068784|NCT02797665|PROCEDURE|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
215068785|NCT04433689|DEVICE|Non-Contact measurement of corneal properties|Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
215068786|NCT04960059|OTHER|No intervention|This is an observational study
215068787|NCT02330666|BEHAVIORAL|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
215068788|NCT01618045|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
215068789|NCT02818023|DRUG|Pembrolizumab|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
215068790|NCT02818023|DRUG|Vemurafenib|"Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
215068791|NCT02818023|DRUG|Cobimetinib|Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
214672986|NCT05096169|DRUG|Clomiphene Citrate 25mg|clomiphene citrate at a dose of 25mg daily
214672987|NCT05096169|DRUG|Clomiphene Citrate 50mg|clomiphene citrate at a dose of 50mg every other day
214672988|NCT02498821|DEVICE|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
214925737|NCT03960489|DRUG|Roxadustat|Participants will receive single dose of 100 mg azo dye free tablet or mini tablet suspension or solid mini tablet or dye containing tablet.
214925738|NCT01710189|DRUG|TicoVac|Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
214925739|NCT06683430|DIETARY_SUPPLEMENT|High Potassium, Low Sodium Diet|Daily intake of 3500 mg K and 1500 mg Na for 14 days.
214925740|NCT06683430|DIETARY_SUPPLEMENT|Standard Diet|Daily intake of 1700 mg K and 2000 mg Na for 14 days.
214925741|NCT01128998|DRUG|Sorafenib|"1. Name: Sorafenib~2. Dosage form: 200 mg / Tablet~3. Dosing schedule: 200 mg bid, po, everyday, since Day 8 of Cycle 1"
214925742|NCT01128998|DRUG|S-1|"1. Name:S-1~2. Dosage form: 20 mg or 25 mg / Capsule~3. Dosing schedule: 20-40 mg/m2 bid,po, 14 days on \& 7 days off"
214925743|NCT05866744|OTHER|Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow an early 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 08:00-18:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
215068792|NCT03269916|OTHER|Anti Mueller hormone|used to assess ovarian reserve parameters
215068793|NCT03269916|OTHER|Estrogen|used to assess ovarian reserve parameters
215068794|NCT03269916|OTHER|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
215068795|NCT03269916|OTHER|Antral alveolar cell count|used to assess ovarian reserve parameters
215068796|NCT00284284|DEVICE|Use of a rehabilitation brace|
215068797|NCT00697866|BIOLOGICAL|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
215068798|NCT00697866|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
214324716|NCT05492773|DEVICE|Micro-osteoperforations Technique|Micro-Osteoperforations Technique (MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
214672989|NCT02498821|DEVICE|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
214925744|NCT05866744|OTHER|Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow a late 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 12:00-22:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
214925745|NCT05866744|OTHER|Hypocaloric Mediterranean Diet Without Time Restriction In Feeding|18 patients with NAFLD will be asked to follow an individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) without time restriction in feeding (eating throughout the day) for 12 weeks
214925746|NCT05711056|BEHAVIORAL|Sociobehavioral Intervention|"Utilizes two primary evidence-based strategies:~* Delivering OUD consultation via telemedicine, which has been demonstrated to be a safe and effective means for initiating MOUD with buprenorphine; and,~* Incorporating psychosocial support in the form of PRC, whose involvement in patient care is associated with increased treatment retention and MOUD initiation."
214925747|NCT05956132|OTHER|retrospective study|data collection from clinical history and medical records
215068799|NCT03528239|OTHER|Refugee patients|To investigate characteristics of outpatient visits of refugee patients
215068800|NCT04812769|DEVICE|eCARE-ID|The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel
215068801|NCT04812769|OTHER|Standard of Care|Standard of care will be delivered to the control home.
215068802|NCT00388388|DRUG|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
215068803|NCT03761888|DIAGNOSTIC_TEST|optic nerve sheath measurement and transcranial doppler|evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
215068804|NCT03924063|DEVICE|Hemiverse|Implantation of the hemiverse shoulderprothesis
215068805|NCT01519791|BIOLOGICAL|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
215068806|NCT01519791|OTHER|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
215068807|NCT01519791|BIOLOGICAL|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
214324717|NCT05492773|DEVICE|Active comparater|Active Comparator: Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
214324718|NCT06271655|DEVICE|SPOTFIRE R Panel|The intervention involves the use of a rapid point-of-care multiplex PCR test (Spotfire) to identify etiology of patients with ARI. Specimen samples will be collected by research staff at the time of ED presentation. Upon collection, the sample will be promptly prepared for testing on the SPOTFIRE R Panel device. The device will be in the ED to facilitate testing and accelerate delivery of diagnostic results to clinicians. The time when the provider receives the results will be recorded to evaluate the incorporation of results in clinical decision making.
214324719|NCT06109870|BEHAVIORAL|PRECEDE-PROCEED|delivered self-sampling (CHWSS) to increase screening participation.
215068808|NCT00837265|BIOLOGICAL|Balugrastim|Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
215068809|NCT00837265|DRUG|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
215068810|NCT00837265|DRUG|Chemotherapy Regimen|The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
215068811|NCT05665660|BEHAVIORAL|CARE|CARE is a culturally tailored mammography education module.
215068812|NCT05665660|BEHAVIORAL|CARE + COACH|CARE + COACH is a culturally tailored mammography education module + access to an Apache paraprofessional women's health coach who functions as a patient navigator
215068813|NCT04727632|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT
215068814|NCT03337802|BEHAVIORAL|mediterranean diet|The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
215068815|NCT00320554|BEHAVIORAL|Durometer analysis|
214672990|NCT02498821|PROCEDURE|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
214925748|NCT06665087|DRUG|Ultrafractionated RT and CGA Guided systemic treatment.|in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed, with/without targeted therapy, and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, with/without targeted therapy, and BSC.
214925749|NCT06665087|RADIATION|Ultrafractionated Radiotherapy|1Fx every 3 or 4weeks
214925750|NCT06665087|DRUG|PD-1 antibody|Sintilimab
214925751|NCT06665087|DRUG|Chemotherapy (Fluorouracil)|5-Fluorouracil or capecitabine
214925752|NCT06665087|DRUG|Chemotherapy (Raltitrexed)|Raltitrexed
214925753|NCT06665087|DRUG|Chemotherapy (Oxaliplatin)|Oxaliplatin
214925754|NCT06665087|DRUG|Chemotherapy (CPT-11)|Irinotecan
214925755|NCT06665087|DRUG|Targeted Therapy (anti-VEGF)|anti-VEGF antibody
214925756|NCT06665087|DRUG|Targeted Therapy (anti-EGFR)|anti-EGFR antibody
214925757|NCT00004647|DRUG|mexiletine|
214925758|NCT04153149|DRUG|Vutrisiran|Vutrisiran will be administered by SC injection.
215068816|NCT03533816|DRUG|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
214925759|NCT04153149|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile normal saline (0.9% NaCl) will be administered by SC injection.
214925760|NCT02876991|PROCEDURE|Sodium fluoride PET|"Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results."
214925761|NCT02779764|DRUG|roxadustat|Oral
214925762|NCT01392027|PROCEDURE|Blood Draw|Blood draw for research specimens only
214925763|NCT02778074|BEHAVIORAL|Internet cognitive behavioural therapy|A nine-week tailored I-CBT program for patients with CVD. The CBT program consists of the components of psychoeducation, relaxation, problem-solving and behavioural activation.
214925764|NCT02778074|BEHAVIORAL|Moderated Discussion Forum|Participants will be allocated to an internet moderated discussion forum during 9 weeks. Patients will discuss issues related to cardiovascular disease. A new topic will be discussed every week. After 9 weeks, those in the moderated discussion forum will be offered to perform the I-CBT program.
215068817|NCT03533816|DRUG|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
215068818|NCT00077714|DRUG|Paliperidone ER|
215068819|NCT05962619|PROCEDURE|arthrocentesis alone|The procedure is done under general anesthesia. The patient is seated inclined at a 45 degree angle with the head turned to contralateral side. The points of needle insertion on the skin, are as follow: a line is drawn from the middle of the tragus to the outer canthus of the eye. The posterior entrance point is located along the canthotragal line, 10 mm from the middle of the tragus line and 2 mm below, the anterior entrance point is placed 10 mm further forward along the line and 10 mm below it . A needle connected to a 10 ml syringe with the Ringer's lactate solution is then inserted into the superior compartment (posterior point), and solution is injected . Another needle is then inserted into the area of articular eminence to enable the free flow of solution through the superior compartment. During the lavage, the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions
214925765|NCT03699280|OTHER|Virtual Reality|Oculus Go VR device
214324720|NCT06208410|DRUG|JS105|JS105 is administered once daily, orally
214324721|NCT06208410|DRUG|Fulvestrant injection|Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle
214324722|NCT06208410|DRUG|Dalpiciclib Isetionate Tablets|Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle
214324723|NCT06208410|DRUG|Toripalimab Injection|Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle
214324724|NCT06208410|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle
215068820|NCT05962619|PROCEDURE|arthrocentesis with hyaluronic acid injection|in this group Once arthrocentesis is completed, an ampule of sodium HA (Hyalgan 1 ml) is connected to the needle in situ And 0.5 ml injected into the superior joint space. Pressure dressing is placed in site of injection. so We use arthrocentesis hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction
214672991|NCT06970548|DRUG|Levobupivacaine|To evaluate efficacy of addition of dexamethasone to levopubivacaine in tranversusabdominis plane block (TAP) in postoperative pain management, postoperative analgesic consumption, and patient comfort after laparoscopic bariatric surgery.
214672992|NCT06969820|PROCEDURE|Low-dose Radiation Therapy (LDRT) using MRI-based imaging techniques|LDRT using MRI-based imaging techniques by developing an MRI imaging protocol, deep learning-based image enhancement and resolution increase.
214925766|NCT04229329|COMBINATION_PRODUCT|Intensive Finger Individuation Therapy|Interactive robot-mediated treatment aimed at increased individuation done repeatedly for at least1 hour per day for 2 weeks (5 training days a week).
214925767|NCT04229329|COMBINATION_PRODUCT|Intensive non-directed finger movement therapy|Interactive robot-mediated treatment not aimed specifically at increased individuation done repeatedly for at least 1 hour per day for 2 weeks (5 training days per week)
214925768|NCT04454684|DRUG|Midomafetamine|Initial dose of 80 or 120 mg midomafetamine HCl administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg midomafetamine HCl 1.5 to 2.5 hours later, unless contraindicated.
214925769|NCT04454684|BEHAVIORAL|Non-directive therapy|Non-directive therapy will be conducted during Experimental Sessions.
214925770|NCT04454684|BEHAVIORAL|Therapy|Therapy will be conducted during Preparatory Sessions and Integrative Sessions.
214925771|NCT06684808|OTHER|Fitness|The Fitness group engaged in active breaks aimed at improving cardiovascular efficiency. These breaks were designed to provide moderate to vigorous physical activity, incorporating both strength and aerobic exercises such as squats, jumping jacks, lunges, and running in place. Children were instructed to imitate the teacher's movements.
214925772|NCT06684808|OTHER|Creative|The Creative group participated in active breaks that combined cognitive-creative and physical demands, incorporating activities like improvisations, dramatizations of events or short stories, simulation, and imitation games. These activities aimed to stimulate the creative process and enhance emotional expression within environmental constraints. Constraints, set by the teacher-such as specific rules, partner positioning, or speed of execution-limited movement options, encouraging students to explore new solutions to complete each task.
214925773|NCT06684808|OTHER|Combined|The Combined group took active breaks by combining the Fitness protocol in the first break and the Creative protocol in the second.
214925774|NCT06684808|OTHER|Control|Regular physical activity at school during the weeks.
214925775|NCT03319342|BEHAVIORAL|Behavioral Intervention|Perform acts of kindness to others
214925776|NCT03319342|BEHAVIORAL|Behavioral Intervention|Perform acts of kindness to self
214925777|NCT03319342|BEHAVIORAL|Behavioral Intervention|Perform self-kindness meditation
214925778|NCT03319342|BEHAVIORAL|Behavioral Intervention|Keep track of daily activities
214925779|NCT03319342|OTHER|Questionnaire Administration|Ancillary studies
214925780|NCT06209970|DRUG|HA35|All the freshly made HA35 or B-HA samples were diluted to a final concentration of 5 mg/ml. The filter membrane with 220nm pore size was used to filter freshly made HA35 or B-HA injection in order to test its human tissue permeability as \<220nm nino-particle.
215068821|NCT02855866|PROCEDURE|thyroidectomy|
214925781|NCT04173975|DEVICE|With knee exoskeleton|BELK is a wearable system that assists when and where the patient needs it intelligently through proper control of the system and optimized gait assistance techniques. Assisted-as-needed control allows to create a force field along a desired trajectory, proportionally applying torque only when patient deviates from the pre-programmed correct pattern. This force field control, by assisting only the segments that the patient need, produces a natural gait pattern, improving the rehabilitation process.
215068822|NCT02855866|OTHER|cryotherapy|
215068823|NCT02855866|DRUG|cortisone aerosol|
215068824|NCT02855866|DRUG|Dexamethasone acetate|
215068825|NCT02855866|DRUG|paracetamol|
215068826|NCT00656149|PROCEDURE|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
215068827|NCT00656149|PROCEDURE|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
215068828|NCT01080924|DEVICE|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
214324725|NCT06208410|DRUG|Fluzoparib Capsules|Fluzoparib Capsules is administered once daily, orally
214324726|NCT06208410|DRUG|Pyrotinib Maleate Tablets|Pyrotinib Maleate Tablets is administered once daily, orally
214324727|NCT06208410|DRUG|Capecitabine Tablets|Capecitabine Tablets is administered once daily, orally
214324728|NCT04661124|DEVICE|SPECTRALIS|ophthalmic imaging device with head and chinrest
214324729|NCT04661124|DEVICE|SPECTRALIS with Flex Module|ophthalmic imaging device on mobile instrumentation stand
214324730|NCT05709002|BEHAVIORAL|MASP+|mHealth (mobile app) for smoking cessation
214324731|NCT05709002|BEHAVIORAL|Control|A mobile app designed to assist the general population with smoking cessation.
214925782|NCT03270852|DEVICE|Enhanced reality|"This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.~The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro."
214925783|NCT03270852|OTHER|No Enhanced reality|Identical rehabilitation without enhanced reality
214925784|NCT00481598|PROCEDURE|magnet resonance spectroscopy|magnet resonance spectroscopy
214925785|NCT06684197|DRUG|Dexmedetomidine|Intravenous dexmedetomidine will be given as a bolus (0.5 μg.kg-1) over 10 minutes. A perfusion of 0.5 mcg.kg-1.h-1 of dexmedetomidine will be programmed and maintained up until the pneumoperitoneum is deflated or up until a total dose of 2.5μg.kg-1 has been administered.
214925786|NCT06684197|DRUG|Placebo|Saline will be used instead of dexmedetomidine
215068829|NCT01490008|DRUG|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
214672993|NCT06970119|DRUG|INR102 injection|INR102 injection is a lutetium-177 (\[177Lu\])-labeled radiopharmaceutical agent targeting prostate-specific membrane antigen (PSMA). It is clinically indicated for the treatment of patients with PSMA-positive prostate cancer.
214925787|NCT04538547|RADIATION|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
214925788|NCT04538547|RADIATION|Non Accelerated Radiotherapy|Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday
214925789|NCT06079177|DEVICE|Ultrasound|LUS using B-lines Caval-Aorta index using ultrasound
214925790|NCT06137131|BEHAVIORAL|Straw phonation in air|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in air
214925791|NCT06137131|BEHAVIORAL|straw phonation in water|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in 2 cm or 5 cm water
214925792|NCT06137131|BEHAVIORAL|/u/ phonation|/u/ phonation without a straw, control condition
214925793|NCT02715362|DRUG|TAI-GPC3-CART cells|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
214672994|NCT06971536|DIETARY_SUPPLEMENT|Standard Green Tea|A maximum single dose of 300 mg green tea (hard gel capsules)
214672995|NCT06971536|DIETARY_SUPPLEMENT|Phytosome Green Tea|A maximum single dose of 250 mg green tea (hard gel capsules)
214672996|NCT06971536|DIETARY_SUPPLEMENT|LipoMicel Green Tea|A maximum single dose of 300 mg green tea (soft gel capsules)
214672997|NCT06971913|DRUG|Interleukin-2 (IL-2)|Low-dose IL-2 at 1MIU will be administered subcutaneously every other day from baseline to CMV negativity.
214672998|NCT06971913|DRUG|Ganciclovir (GCV)|Ganciclovir injection will be administrated intravenously at a dose of 5mg/kg per day.
214672999|NCT06969599|DIAGNOSTIC_TEST|No intervention measures|No intervention measures
214673000|NCT06971549|OTHER|Accelerated iTBS|Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) will be delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold.
214673001|NCT06971406|DRUG|Combination therapy prospective cohort|high-dose firmonertinib (240 mg, daily), bevacizumab (15 mg/kg, every 3 weeks), and pemetrexed (50 mg, intrathecal chemotherapy C1d1d5, then every 3 weeks)
214673002|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version does not provide any normative feedback information."
214673003|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version provides personalized normative feedback with descriptive norms information about local HIV testing rates."
214925794|NCT05861492|OTHER|Fatigue Differential Diagnosis Aid|The Fatigue Differential Diagnosis Aid is a systematic questionnaire covering the symptoms and signs of fatigue and the collateral clinical data trying to facilitate the diagnostic process in the care of patient with symptoms of fatigue.
214925795|NCT03892382|DEVICE|rTMS|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.
214925796|NCT00621868|DRUG|ipragliflozin|Oral
214925797|NCT00621868|DRUG|Placebo|Oral
215068830|NCT01490008|OTHER|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
215068831|NCT05118464|OTHER|Dual-task training|Dual-task training includes simultaneous execution of motor and cognitive tasks. The motor tasks in this study will be walking, going up and downstairs, turning, throwing, and holding a ball. Cognitive tasks will be an n-back test, verbal fluency, remembering sequences of numbers, and performing simple summing.
215068832|NCT01289353|DRUG|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
215068833|NCT01289353|RADIATION|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
214324732|NCT06529705|DEVICE|EkiYou V2|Use of a mobile application that help users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.
214673004|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version provides personalized normative feedback with injunctive norms information about local HIV stigma rates."
214673005|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version provides personalized normative feedback with descriptive and injunctive norms information about both local HIV testing rates and local HIV stigma rates."
214925798|NCT02231138|DRUG|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
214925799|NCT05402969|PROCEDURE|Transimedance Matrix measurements|TIM measurements are based on cochlear implant back-telemetry function. Each electrode contact is stimulated in monopolar mode. Transimpedance is represented by the ratio between the voltage measured at each recording electrode and the current injected at the stimulation contact. The result of the measurements is a matrix of 21x21 transimpedances. Stimulation current cannot be perceived by a patient thus making TIM measurements a non-invasive and painless procedure. The test duration is only 2-3 minutes
215068834|NCT01242891|DEVICE|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
215068835|NCT06323941|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Isometric exercises (20 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
215068836|NCT06323941|BEHAVIORAL|Therapeutic exercises|Isometric exercises (20 minutes) to which will be added a placebo motor imagery intervention (imagining a blue sky).
215068837|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention|The BAI contained components of effective interventions developed for young adult drinkers both in health care and educational settings and was specifically tailored to the unique needs and risk factors of Airmen. The 1-hour group intervention was administered using the principles of motivational interviewing (MI) in an interactive Socratic style to generate feedback and discussion. Open-ended questions, reflections, as well as the decisional balance scale were used to increase Airmen's motivation to remain alcohol free.
215068838|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention Booster|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
215068839|NCT01398319|BEHAVIORAL|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
215068840|NCT00538967|DRUG|doxycycline|2 weeks once daily
215068841|NCT04049253|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
215068842|NCT03199326|OTHER|Collaborative Care|CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
214324733|NCT00679341|DRUG|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
214925800|NCT05402969|PROCEDURE|Depth sounding and spectroscopy|Depth sounding and spectroscopy are based on the matrixes obtained after TIM imaging. Deep sounding measures the capacitances throughout the electrode array whereas spectroscopy determines the phase of every transimpedance value. These tests take 10 to 15 minutes together. The stimulation intensity used by depth sounding technique can be perceived by a patient. If it is considered as unpleasant, the test will be stopped.
214925801|NCT05402969|PROCEDURE|Cone Beam Computer Tomography|CBCT is a routine postoperative assessment after CI, non-invasive and painless for patients.
214925802|NCT00487006|OTHER|Serum Lab testing|Serum Lab testing
214673006|NCT03738956|DRUG|Tofacitinib|"The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment."
214925803|NCT01062542|PROCEDURE|Blood Draw and Ultrasound|Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
214925804|NCT03764878|DIAGNOSTIC_TEST|functional MRI|Participants will undergo a functional MRI using multiple imaging modalities.
214925805|NCT05742009|DEVICE|iCare ST500|Measurement of Intraocular Pressure (IOP)
214925806|NCT05742009|DEVICE|GAT|Measurement of Intraocular Pressure (IOP)
214925807|NCT05742009|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP)
214925808|NCT02587507|OTHER|Orange juice|Individuals will consume the HFHC meal with 500mL of orange juice.
214925809|NCT02587507|OTHER|Water|Individuals will consume the HFHC meal with 500mL of water.
214925810|NCT02587507|OTHER|Water with glucose|Individuals will consume the HFHC meal with 500mL of water with glucose.
214925811|NCT03489707|BEHAVIORAL|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
214925812|NCT03489707|BEHAVIORAL|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
214925813|NCT01817582|DRUG|Lotemax|Lotemax gel will be administered as per the dose and schedule specified in the arms.
214673007|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
214925814|NCT01817582|DRUG|Restasis|Restasis emulsion will be administered as per the dose and schedule specified in the arms.
214925815|NCT01817582|DRUG|Soothe® Lubricant Eye Drops|
214925816|NCT06094660|PROCEDURE|Diagnostic genicular nerve block|Diagnostic block will be done with 1,5ml of Lidocaine 2% at the 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.
214925817|NCT06094660|PROCEDURE|Genicular nerve block with Radiofrequency Ablation (RFA)|"Genicular nerve block with RFA will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Radiofrequency ablation (RFA) is performed by creating two RFA lesions at the 3 treatment sites (6 lesions in total) after local anesthesia with 1,5ml lidocaine 2%. The lesions are made by heating the 5mm active tip of the needle to 80°C for 90 seconds."
214925818|NCT06094660|PROCEDURE|Genicular nerve block with Phenol 6%|"Genicular nerve block with Phenol 6% will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Chemical ablation with phenol is done by injection of 1 ,5ml of phenol 6 % at the 3 target sites after infiltration with contrast dye to rule out intravascular injection. Because infiltration with phenol is painless, prior infiltration of the target site with al local anaesthetic is not necessary."
214925819|NCT01092091|BIOLOGICAL|Pegylated Recombinant Human Arginase I|Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
214925820|NCT06576440|DRUG|Ghrelin|Participants in this arm will receive a subcutaneous injection of acyl-ghrelin as the active condition.
214925821|NCT06576440|DRUG|Saline|Participants in this arm will receive a subcutaneous injection of saline as placebo control condition.
214925822|NCT02358096|DRUG|ASP8232|oral capsule
214673008|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
214925823|NCT02358096|DRUG|Placebo|oral capsule
214925824|NCT06057662|OTHER|personalized comprehensive diabetes support|personalized comprehensive diabetes support
214925825|NCT05432154|DEVICE|Film forming silicone gel (7-0940)|"Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances."
214925826|NCT04233047|DRUG|Fostemsavir|Fostemsavir 600 mg extended release tablets, administered 600 mg twice daily, will be supplied for compassionate use for the identified individual patient.
214925827|NCT01489215|BEHAVIORAL|"presence"|"constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the checking method if the child is actively protesting or crying."
214925828|NCT01489215|BEHAVIORAL|"checking"|putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
214925829|NCT04744233|OTHER|Orange juice|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed were: freshly squeezed (FS), commercially available low pasteurized juice (LP) and juices treated by high-pressure processing (HPP) and by pulsed electric fields (PEF). All participants consumed the LP and the HPP orange juices. Six subjects consumed PEF-orange juice and other six consumed the FS-orange juice.
214925830|NCT04630691|PROCEDURE|Implantation|Patients received narrow diameter implants in posterior mandible or maxilla
214925831|NCT06769256|DRUG|rhTNK-tPA, 4-8 mg|Intracoronary influsion of rhTNK-tPA (4 mg). After 10 minutes of administration, 4 mg may be given again if the thrombus burden is not significantly reduced.
214925832|NCT06769256|DRUG|Tirofiban|Intracoronary influsion of Tirofiban (10 µg/kg) , and then administered intravenously at 0.075-0.15 µg/kg.min for 36 h or longer
214925833|NCT04690192|BIOLOGICAL|CNCT19|2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion
214925834|NCT04690192|DRUG|Gemcitabine Injection|600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,
214925835|NCT04690192|DRUG|busulfan|105mg/m2, day -7 until -5,
214925836|NCT04690192|DRUG|Melphalan Injection|60mg/m2, day -3, -2
214925837|NCT04237103|DRUG|Methotrexate|oral capsules taken once a week
214925838|NCT04237103|DRUG|Placebos|Administered identically to the experimental group
214925839|NCT00170625|DRUG|Hycamtin|Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
214925840|NCT05305885|DRUG|Pemetrexed|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.
214925841|NCT05305885|RADIATION|Radiotherapy|Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
214925842|NCT00685204|DRUG|Milataxel|Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
214925843|NCT04514445|OTHER|Observational|
214925844|NCT04604392|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
215068843|NCT04686851|OTHER|Comprehensive Geriatric Assessment and follow-up|"All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.~Follow-up on initial treatment plan is scheduled to one month after baseline CGA."
215068844|NCT01952548|DRUG|K-312|
214925845|NCT01600456|BEHAVIORAL|Prolonged exposure (PE)|PE will include 10 weekly sessions of individual cognitive behavioral therapy.
214925846|NCT01600456|OTHER|PE plus Sertraline|PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
214925847|NCT01733290|DRUG|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
214925848|NCT01733290|DRUG|Normal saline instillation|Normal saline instillation
214925849|NCT02842710|DEVICE|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
214673009|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
214925850|NCT00792792|DEVICE|Modulated Imaging|Modulated Imaging Spectroscopy
214925851|NCT03963232|DRUG|Galcanezumab|Administered SC
214925852|NCT03963232|DRUG|Placebo|Administered SC
214925853|NCT03617770|BEHAVIORAL|Sleep Opt-In|8-week intervention that includes a wearable sleep tracker, didactic content, smartphone application and counseling
214925854|NCT03617770|BEHAVIORAL|Healthy Living|8-week intervention that includes weekly telephone counseling on healthy living.
214925855|NCT04921826|OTHER|online survey|online survey
214925856|NCT03563352|OTHER|Interview|Attend an interview
214925857|NCT03563352|OTHER|Survey Administration|Ancillary studies
214925858|NCT03475862|DRUG|PTI-821 capsule Manipulated|PTI-821 (oxycodone) 40 mg extended release capsule
214925859|NCT03475862|DRUG|PTI-821 Non-manipulated|PTI-821 (oxycodone) 40 mg capsule extended release capsule
214925860|NCT03475862|DRUG|OxyContin|Crushed OxyContin (oxycodone) extended-release 40 mg tablet
214925861|NCT03475862|OTHER|Placebo|Matching placebos for PTI-821 and oxycodone IR
214925862|NCT03475862|DRUG|Oxycodone|Crushed oxycodone 40 mg immediate release tablet
214925863|NCT00356135|DRUG|prasugrel 10 mg|10 mg tablet taken orally
214925864|NCT00356135|DRUG|clopidogrel|75 mg tablet taken orally
214925865|NCT00356135|DRUG|prasugrel placebo|oral, as blinding mechanism.
214925866|NCT00356135|DRUG|prasugrel 60 mg|60 mg (six 10-mg tablets) taken orally
214925867|NCT00356135|DRUG|clopidogrel placebo|oral, as blinding mechanism
214925868|NCT05510570|GENETIC|The research does not require interventions|We use Whole-exome sequence (WES) to analyze if there is any gene mutations for DLD(developmental language disorder) children.
215068845|NCT01952548|DRUG|Placebo|
215068846|NCT02965183|OTHER|Temperature measurements|
215068847|NCT02226562|DRUG|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
215068848|NCT02226562|DRUG|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
215068849|NCT03902457|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.
215068850|NCT04147897|DEVICE|FOCUS|FOCUS is a self management mHealth application for people with serious mental illness.
215068851|NCT06283940|OTHER|Physiotherapist-led exercise based cardiac rehabilitation (PT-X)|Individually prescribed centralcirculatory aerobic exercise and muscular endurance training twice a week for 60 minutes each session over 12 weeks in a hospital-based setting, and two sessions of home-based exercise recorded in an exercise diary.
214673010|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
215068852|NCT03257202|DRUG|Clindamycin 1% Gel|topical clindamycin
215068853|NCT03257202|DRUG|Benzoyl peroxide 5% gel|topical benzoyl peroxide
215068854|NCT03257202|DRUG|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
214925869|NCT05806632|OTHER|Prognostic model|Risk assessment and risk stratification
214673011|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
214925870|NCT04965311|BIOLOGICAL|Botulinum Toxin Type A|Given via endoscopic injection into intraduodenal sphincter of Oddi segment
214925871|NCT03512210|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.
215068855|NCT04187508|DRUG|AZD8154 nebulizer suspension, 20 mg/mL|Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
215068856|NCT04187508|DRUG|Placebo|Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
215068857|NCT00562497|DRUG|Prochymal®|Prochymal® intravenous infusion.
215068858|NCT00562497|OTHER|Placebo|Placebo-matching Prochymal® intravenous infusion.
215068859|NCT00562497|OTHER|Corticosteroid|Administration will be intravenously as prescribed by the caregiver.
215068860|NCT04424628|RADIATION|Low dose radiotherapy A|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
215068861|NCT04424628|RADIATION|Low dose radiotherapy B|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
214673012|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
214925872|NCT03512210|OTHER|Minimal Monitoring (MINMON) Strategy|"MINMON Strategy:~1. No pre-treatment HCV genotyping~2. Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry~3. No scheduled on-treatment laboratory monitoring or clinic visits~4. Remote contact with participants at week 4 and week 22"
215068862|NCT06484257|BEHAVIORAL|Myopia|Participants in this arm would receive progressive addition lenses specifically designed to correct myopia. These lenses would typically have a prescription for correcting nearsightedness (myopia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
215068863|NCT06484257|OTHER|Hypermetropia|Participants in this arm would receive progressive addition lenses specifically designed to correct hypermetropia. These lenses would typically have a prescription for correcting farsightedness (hypermetropia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
215068864|NCT05196230|DEVICE|Control Condition (Social Story)|The control condition is a social story, which is treatment as usual for preparing clients for their initial visit at Holland Bloorview's dental clinic. The control condition will be delivered through the study tablet. The investigators will ask parents to read it to their child once a day for the week leading up to their appointment. If the child is reading on their own, the investigators will request that parents be in the room with participants while they are. The social story takes approximately five minutes to read.
215068865|NCT05196230|DEVICE|Experimental Condition (360° Video)|The 360° video is from the point of view of a seated dental client and the participant will be able to explore the scene around them (navigating through the tablet's touch screen). The simulation will include scenes/features that may be anxiety-provoking for some participants. These will include loud noises commonly encountered in the dentist's office (e.g. tooth brushing, dental drills), as well as social stimuli (e.g. the dental clinician), and new environments (e.g., the dental visit room). The investigators will ensure that participants understand that they can stop at any time (e.g., if they are feeling anxious or overwhelmed), and the investigators will ask parents to explore the 360° video with their child for the week leading up to their appointment.
215068866|NCT01474772|DRUG|Pregabalin|150-300 mg/day given in 3 divided doses as capsules
215068867|NCT01474772|OTHER|placebo|matching placebo capsules given in 3 divided doses
215068868|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 12
215068869|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 6
215068870|NCT01637636|DRUG|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
215068871|NCT01637636|DRUG|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
215068872|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 40 minutes later.
215068873|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment and fumigation|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 60 minutes later (when fumigation was finished)
215068874|NCT00649766|BEHAVIORAL|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
215068875|NCT00649766|BEHAVIORAL|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
214324734|NCT00679341|DRUG|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
214324735|NCT00679341|DRUG|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m\^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
214925873|NCT01253005|BEHAVIORAL|Nutritional intervention|This study will investigate the effects of particle size of different triglyceride emulsions as well as the dynamics of intragastric structure formation and breakdown of the emulsions on GI function, the kinetics of the endocrine and the satiation response in healthy volunteers.
214925874|NCT03138759|DRUG|Pexidartinib|Orally, on Day 2
214925875|NCT03138759|DRUG|Probenecid|Orally, on Day 2
214925876|NCT04143854|DRUG|MBA-P01(Botulinum toxin A)|Intramuscular injection; Dose varies by group
215068876|NCT01112774|DEVICE|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
215068877|NCT06511596|OTHER|BR-AC|BR-AC is an amnion layer, intermediate layer, and chorion layer placental membrane processed together with no separation of the layers. BR-AC is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.
215068878|NCT06511596|OTHER|Standard Care|"Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
214324736|NCT05825469|BEHAVIORAL|Nutrition Algorithm|A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
214324737|NCT04613297|OTHER|Baseline and during hospitalization blood samples|"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~* at day 3~* day 5 and~* In case of aggravation~* At the discharge from hospital"
214324738|NCT04613297|OTHER|Baseline blood sample|Blood sample will be performed at the inclusion visit only
214324739|NCT06520566|BEHAVIORAL|Holistic care partner perinatal nurse navigation|The nurse navigators assess patient medical, social, and structural needs at enrollment, 20-, 28-, and 36-weeks gestation; and at 1-week, and 3, 6, and 9 months postpartum. They provide coordination, support, and referrals, and enhanced communication with or escalate concerns to the primary physician as indicated. The nurse navigator tailors additional visits to the individual needs of the patients (for example, managing comorbidities, social isolation, breastfeeding support). Participants also have access to a Black woman-led support group during pregnancy and the first postpartum year, and access to Black woman-led childbirth and lactation classes.
214925877|NCT04143854|DRUG|Placebo|Intramuscular injection; normal saline
214324740|NCT05782686|PROCEDURE|Margin shaving|In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.
214324741|NCT04015219|DEVICE|Self retained cryopreserved amniotic membrane|PROKERA SLIM
214324742|NCT04015219|OTHER|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
214324743|NCT01433263|DRUG|BYM338 active drug|
215068879|NCT00223808|OTHER|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
215068880|NCT00223808|OTHER|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
214324744|NCT01433263|DRUG|Placebo|
214324745|NCT03827486|OTHER|Standard of care (exercise)|Exercise program according to the standard of care
214324746|NCT03827486|OTHER|Domicilary exercise program|Domicilary exercise program according to protocol (evidence based medicine)
214324747|NCT06394570|DRUG|Enfortumab vedotin|Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles
214324748|NCT05351255|DEVICE|Transcranial Magnetic Stimulation (TMS)|Aim 2 of the study includes an intervention where participants receive a repetitive TMS protocol called theta burst stimulation (TBS) to study its effect on motor learning behavior.
214324749|NCT01400594|DRUG|HTU-520 Patch|Terbinafine hydrochloride patch
214324750|NCT01400594|OTHER|Placebo Patch|Treatment with Placebo Patch
214324751|NCT01795924|DRUG|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
214324752|NCT03595111|PROCEDURE|myocardial biopsy|Myocardial cell edema either focal or diffuse was detected in histopathological examination
214324753|NCT05341544|DEVICE|Parasym device|The study will utilize the Parasym device (Parasym Health, London, United Kingdom) paired with compatible electrodes to administer the transcutaneous LLTS.
214324754|NCT05341544|DEVICE|Sham device|Sham device
214925878|NCT02497443|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
214925879|NCT02551770|PROCEDURE|Scaling and root planing|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw.
214324755|NCT05081323|BEHAVIORAL|Self-applied treatment for phobias|The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
214925880|NCT02551770|PROCEDURE|Scaling and root planing without Emdogain|Using minimally invasive surgical procedure (scaling and root planing) without Emdogain application to treat one contra-lateral quadrant in subject's jaw.
214925881|NCT02551770|DEVICE|Emdogain application|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw
214324756|NCT03107988|DRUG|Lorlatinib|Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
214324757|NCT03107988|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
214324758|NCT03107988|DRUG|Topotecan|Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle
214324759|NCT03107988|DRUG|Filgrastim/pegfilgrastim|"Filgrastim is to be given with each course beginning 24-48 hours following completion of cyclophosphamide and topotecan and continued through post-nadir count recovery with an ANC \> 2000/mm\^3 at 5mcg/kg/day. Filgrastim must be discontinued at least 24 hours prior to the start of the next course of therapy.~Pegfilgrastim (100mcg/kg; 6mg maximum dose) may be substituted and is given one time at 24-48 hours from completion of cyclophosphamide and topotecan."
214324760|NCT02191488|DRUG|5-aminolevulinic acid|
214925882|NCT01927549|PROCEDURE|Immediate multivessel PCI|
214925883|NCT01927549|PROCEDURE|Culprit Lesion only PCI|
214925884|NCT05669131|OTHER|Motor imagery training|Participants imagine themselves through their own eyes performing submaximal elbow flexion contractions.
214925885|NCT05172440|DRUG|tislelizumab combined with axitinib|Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
214925886|NCT06937060|BIOLOGICAL|semaglutide|Semaglutide is act as an adjunct to a reduced calorie diet and increase physical activity for chronic weight management in adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
214925887|NCT04638764|OTHER|Aerobic interval training combined with high intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 70 %- 80 % of one repetition maximum (1-RM)).
214925888|NCT04638764|OTHER|Aerobic interval training combined with low intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 30 %- 40 % 1-RM).
214925889|NCT04638764|OTHER|Aerobic interval training|Patients enrolled in arm of the study will perform 12 weeks of aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing).
214925890|NCT04725955|OTHER|Enriched wheat bread|Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).
214925891|NCT01547260|DRUG|Gemzar|Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
214925892|NCT01547260|DRUG|Revlimid|Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
214925893|NCT04328129|PROCEDURE|Human biological samples|"* Blood sample~* Nasopharyngeal swab."
214925894|NCT01590069|BIOLOGICAL|Aerosolized Aldesleukin|Breathe aerosolized aldesleukin
214925895|NCT01590069|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214925896|NCT06947460|DRUG|CD19-BCMA CAR-T cells infusion|Approximately 3-5 days prior to CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
214925897|NCT03285867|PROCEDURE|TACE|transcatheter arterial chemoembolization
214925898|NCT03642964|DRUG|CTC-501|pramipexole IR, given with ondansetron
214925899|NCT06946914|DRUG|Misoprostol|administration of 100mg of misoprostol to evaluate the efficacy of Misoprostol before elective cesarean section in pregnant women with gestational age less than 38 weeks for preventing the occurrence of neonatal respiratory morbidity.
214925900|NCT02169141|OTHER|Pharmacokinetics|multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
215068881|NCT00223808|OTHER|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
215068882|NCT00000467|BEHAVIORAL|diet|
215068883|NCT00000467|BEHAVIORAL|exercise|
215068884|NCT00000467|BEHAVIORAL|smoking cessation|
215068885|NCT05365061|OTHER|periosteal electrical dry needling with no maintenance treatments|periosteal electrical dry needling
215068886|NCT05365061|OTHER|periosteal electrical dry needling with maintenance treatments every other month|periosteal electrical dry needling with maintenance treatments every other month
214925901|NCT00880854|DRUG|BCG and CP-675,206|"Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15"
214925902|NCT03721263|BIOLOGICAL|ASLAN004|Single Dose
214925903|NCT04089904|DRUG|Pembrolizumab Injection|Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery
214925904|NCT02531477|DRUG|propofol|intracarotid propofol as an anesthetic agent
214925905|NCT04320693|DRUG|IMMU-132|IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles
214925906|NCT06434805|OTHER|sex workers and sexual minorities education workshop|The participants will receive a one-day workshop (four sessions). The generic content aims at enhancing the understanding of sexual orientation, gender identities, social stigma, sex work and sexual orientation and human rights (session 1), the lived experience of SWSM (session 2), the content specifically related to the medical and healthcare field, including be familiar with the professional and ethical obligations (session 3), the skills that can be adopted when providing services to SWSM (session 4).
214925907|NCT03287362|BEHAVIORAL|schema therapy|The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept
214925908|NCT03287362|BEHAVIORAL|cognitive behavioral therapy|The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment
214925909|NCT03287362|BEHAVIORAL|individualized supportive therapy|The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
214925910|NCT00321698|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
214925911|NCT00321698|DRUG|Docetaxel+IMRT|"Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
215068887|NCT05365061|OTHER|periosteal electrical dry needling with monthly maintenance treatments|periosteal electrical dry needling with monthly maintenance treatments
214324761|NCT06840782|RADIATION|Radical local treatment|"RLT of all metastatic sites. The possible RLT options will be SBRT, interventional radiology and/or minimally invasive surgery. Depending on the metastatic site, access and patient condition, the best RLT should be initially discussed in a case-to-case basis at the local multidisciplinary board (MTB).~The primary tumour and initially invaded lymph nodes should be treated during the maintenance phase. Curative-intent approach modalities (e.g. hypofractionated intensity-modulated thoracic radiation therapy or surgery) should be discussed at the local MTB."
214925912|NCT05270395|BEHAVIORAL|mPal|"mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider.~The provider-level component includes provider education on palliative care. The system-level component includes electronic health record modifications to facilitate palliative care discussions and referrals."
214925913|NCT05258279|DRUG|Pembrolizumab|IV infusion Q3W
214925914|NCT05258279|DRUG|Lenvatinib|Oral capsule once daily
214925915|NCT05258279|DRUG|Carboplatin|IV infusion Q3W
214925916|NCT05258279|DRUG|Pemetrexed|IV infusion Q3W
215068888|NCT06252870|DRUG|Methotrexate|15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
215068889|NCT06252870|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
215068890|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
215068891|NCT06252870|DRUG|Cycophosphamide|Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)
215068892|NCT06252870|DRUG|Anti-Thymoglobulin|Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
215068893|NCT06252870|RADIATION|total body irradiation|2 grays on Day-1 before graft (=Day0)
215068894|NCT06252870|OTHER|hematopoietic stem cells|High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
214925917|NCT05844020|BEHAVIORAL|Educational materials|Trauma-informed intimate partner violence screening, brief interventions, and referrals to treatment by providers
214925918|NCT04691986|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside is a form of vitamin B3 and is naturally occurring in humans.
214925919|NCT04691986|OTHER|Placebo|Placebo pills contain micro cellulose powder.
214925920|NCT03725761|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan is a novel Antibody Drug Conjugate (ADC) based on a humanized anti-Trop-2 antibody (hRS7) conjugated to SN-38 payload.
214925921|NCT00124202|BEHAVIORAL|a fatty meal|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
214925922|NCT03638284|DEVICE|Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation that does not require general anaesthesia or surgical implantation of a device. It uses two AA size batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
214925923|NCT05218356|DRUG|Covidir injections|administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
214925924|NCT05218356|DIAGNOSTIC_TEST|Quantitative PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
214925925|NCT05218356|DIAGNOSTIC_TEST|IgM and IgG dosage|lood collection for dosage of Anti SARS-CoV-2 antibodies.
214925926|NCT05218356|DIAGNOSTIC_TEST|Screening Blood tests|omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.
214925927|NCT05218356|DIAGNOSTIC_TEST|Electrocardiogram|valuation by the principal investigator or assistant physician with a complete physical examination
214925928|NCT05218356|OTHER|NEWS-2 score|assessment of the participant by the NEWS-2 score.
214925929|NCT05218356|OTHER|WHO score|assessment of the participant by the score of the World Health Organization.
214925930|NCT05218356|OTHER|Physical examination|evaluation by the principal investigator or assistant physician
214925931|NCT05218356|OTHER|COVID-19-Related Symptoms assessment|will be completed by the study staff member based on patient status and answers.
214925932|NCT04283682|BEHAVIORAL|Early skin-to-skin combined with breast-feeding|Premature infants in the intervention group have access to skin-to-skin once a day for 1 hour at least once no ventilation support needed. During the skin-to-skin period,the breastfeeding is encouraged for about 5-10 minutes. The whole intervention stop until the baby achieve the full oral feeding.
214925933|NCT06181292|BIOLOGICAL|PHH-1V81|booster of PHH-1V81
215068895|NCT06252870|OTHER|Graft nuclear cells|Graft nuclear cells CD3+ cells if needed after transplantation
214925934|NCT06181292|BIOLOGICAL|Comirnaty Omicron XBB1.5|booster of Comirnaty Omicron XBB1.5
214925935|NCT00002104|DRUG|Thalidomide|
214925936|NCT01192529|DIETARY_SUPPLEMENT|Supressi. T-Diet plus Range|"Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.~Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months."
214925937|NCT01192529|DIETARY_SUPPLEMENT|High Protein. T-Diet plus Range|T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
214925938|NCT02794701|OTHER|People with silicosis|
214925939|NCT04083469|BEHAVIORAL|Peer-Led Peer-Elected Intervention|The intervention will be given to students by a peer opinion leader that the students in the audience elected. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
214925940|NCT04083469|BEHAVIORAL|Adult-Led Intervention|The intervention will be given to students by an adult. The intervention is a version of CATCH My Breath curriculum that has been modified to match the Peer-Led Intervention curriculum but is able to be administered by an adult.
214925941|NCT04083469|BEHAVIORAL|Peer-Led Non-Elected Intervention|The intervention will be given to students by a peer opinion leader that was elected by other students. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
214925942|NCT06618716|BIOLOGICAL|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|Intravenous administration of endotoxin (0.8 ng/kg body weight)
214925943|NCT06618716|OTHER|Placcebo|Placebo injection of 0.9% NaCl
214925944|NCT02668809|OTHER|oral health assessment|A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
214925945|NCT02668809|OTHER|Questionnaires|Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
215068896|NCT06252870|OTHER|Donor Lymphocytes Injection|DLI with CD3+ if relapse after transplantation or in prevention of relapse
215068897|NCT06252870|DRUG|Clofarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
215068898|NCT06252870|DRUG|Thiotepa|Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)
215068899|NCT06252870|DRUG|Busulfan|Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)
215068900|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
215068901|NCT06434363|DRUG|Tafasitamab|Given by vein (IV)
215068902|NCT06434363|DRUG|Fludarabine phosphate|Given by vein (IV)
214324762|NCT06840782|DRUG|SoC-based immunotherapy (+/- chemotherapy)|"Current French SoC will be used. Main SoC-based immunotherapy includes:~* Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab). Pemetrexed-platinum combinations may be used in non- squamous carcinoma, while paclitaxel-platinum combination is favoured in squamous carcinoma.~* Anti PD-1 monotherapy if PD-L1 ≥ 50% is a possible alternative (pembrolizumab or atezolizumab or cemiplimab).~Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT.~Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...)."
214324763|NCT06221696|DIETARY_SUPPLEMENT|Active Fiber Supplement Group|Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
214324764|NCT06221696|OTHER|Placebo Group|Three daily packets of placebo powder, taken 30 minutes before each main meal.
214324765|NCT01359592|BIOLOGICAL|rituximab|
214324766|NCT01359592|DRUG|cyclophosphamide|
214324767|NCT01359592|DRUG|doxorubicin hydrochloride|
214324768|NCT01359592|DRUG|prednisone|
214324769|NCT01359592|DRUG|vincristine sulfate|
214925946|NCT02668809|OTHER|Clinical Exam|Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
214925947|NCT02668809|OTHER|Microbiological sampling|Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
214925948|NCT02668809|OTHER|Monitoring Adherence|Adherence to the protocol will be evaluated through unannounced observations at the NF by study personnel twice per month. Adherence is determined by direct observation of the DCW administering the intervention.
215068903|NCT06434363|DRUG|Cyclophosphamide|Given by vein (IV)
215068904|NCT06434363|DRUG|Tafasitamab and NK cells|Given by vein (IV)
215068905|NCT04265651|DRUG|Infigratinib 0.016 mg/kg|"Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
215068906|NCT04265651|DRUG|Infigratinib 0.032 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
214324770|NCT01359592|OTHER|R-CHOP regimen|
214324771|NCT01359592|OTHER|laboratory biomarker analysis|
214925949|NCT02668809|OTHER|Varnish application|"1% chlorhexidine varnish application group will receive the educational program described above. In addition, residents who need supervision or are unable to perform oral hygiene procedures will receive 1% chlorhexidine varnish application monthly by the dental hygienist. No additional time commitment will be necessary.The direct care workers will NOT receive any varnish."
215068907|NCT04265651|DRUG|Infigratinib 0.064 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
214324772|NCT01359592|RADIATION|fludeoxyglucose F 18|
214324773|NCT01359592|RADIATION|selective external radiation therapy|
215068908|NCT04265651|DRUG|Infigratinib 0.128 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
214324774|NCT01359592|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214324775|NCT01422499|DRUG|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
214324776|NCT00326612|DRUG|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
214324777|NCT00326612|DRUG|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
214324778|NCT00772096|DRUG|n-3 fatty acids|
214324779|NCT04263818|PROCEDURE|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for|"Carrying out the endoscopic procedure planned for the patient with the dedicated colonoscope which has magnetic coils over the entire length of the insertion tube. These magnetic coils generate a pulsed magnetic field at low frequency. These pulses are transmitted to an external receiver, refreshed at 15 images per second, then relayed to the processor to generate a 3D representation of the colonoscope next to it of the endoscopic image. There is no additional risk to the patient compared to current practice.~Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for."
214324780|NCT02281721|DEVICE|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
214324781|NCT04186910|BEHAVIORAL|Control group|The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.
214324782|NCT04186910|BEHAVIORAL|Feedback group|The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.
214324783|NCT00548808|DRUG|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
214925950|NCT02668809|OTHER|Consent|Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
214925951|NCT02668809|OTHER|Educational Program|Cognitively capable residents will receive instruction on how to perform their own oral hygiene accordingly to their own needs; and 2) Direct care workers will receive instruction on how to perform oral hygiene for dependent residents or supervise the oral hygiene routines of independent patients. For both 1) and 2) above, dental hygienists will provide a short, standardized presentation and hands-on demonstration.
214324784|NCT00548808|DRUG|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
214925952|NCT02140528|BIOLOGICAL|Mesenchymal stem cell injection|Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .
214925953|NCT02140528|BIOLOGICAL|Placebo|
214486065|NCT03501836|DEVICE|Rapid Rhythm Handheld 8-lead ECG Device|"We want to explore whether using 6 electrodes on the chest (as in the Rapid Rhythm Handheld 8-lead ECG device) can give the same diagnostic result to the standard 10 electrode (12-lead) ECG, which uses 6 chest electrodes plus 4 electrodes on the arms and legs.~To do this we need to compare measurements taken with the 6 electrode (8 lead) study device to those taken with the gold-standard 10 electrode (12 lead) method.~We want to find out whether the new equipment can detect the same heart rhythms as the standard method, so that ECG measurements might be made more quickly and easily in the future."
214324785|NCT00548808|DRUG|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
214324786|NCT03307148|DRUG|ATRA|Administered orally on D1-15 of each 28 day cycle.
214925954|NCT05785013|DIETARY_SUPPLEMENT|Zinc|Zinc Supplementation
214925955|NCT01470651|DRUG|Armodafinil|50mg - 250mg pills, taken each morning, for 14 weeks
214925956|NCT01470651|DRUG|Sugar Pill|Inactive pill, matched to look like active medication
214925957|NCT01936181|DRUG|Remicade (infliximab)|
215068909|NCT04265651|DRUG|Infigratinib 0.25 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
214324787|NCT03307148|DRUG|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
214324788|NCT03307148|DRUG|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
214324789|NCT02607488|DRUG|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
214486066|NCT03965234|DRUG|Cisplatin|Given via infusion
214486067|NCT03965234|PROCEDURE|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
214324790|NCT02607488|DRUG|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
214486068|NCT03965234|PROCEDURE|Metastasectomy|Undergo metastasectomy
214925958|NCT01936181|DRUG|SB2 (proposed biosimilar to infliximab)|
214925959|NCT00970632|DRUG|Tadalafil 5 mg|Tadalafil 5 mg po QD for 12 weeks
214925960|NCT00970632|DRUG|Placebo tablet|Placebo tablet po QD for 12 weeks
214925961|NCT00970632|DRUG|Tamsulosin|Tamsulosin 0.4 mg po QD for 12 weeks
214925962|NCT00970632|DRUG|Placebo capsule|Placebo capsule po QD for 12 weeks
214925963|NCT05545631|OTHER|no intervention|no intervention in this study
214925964|NCT05700916|DRUG|Milk Polar Lipid-Rich Dairy Powder|Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
214925965|NCT05700916|DIETARY_SUPPLEMENT|Dairy Powder|Effects of dairy control powder
214925966|NCT04962724|DRUG|Radiolabelled Xevinapant 200 mg (Oral Solution)|\[14C\]-Xevinapant 200 mg administered as an oral solution on Day 1 of Part 1, containing approximately 100 microcurie (μCi) \[3.7 megabecquerel (MBq)\] in fasted conditions.
214925967|NCT04962724|DRUG|Radiolabelled Xevinapant 100 μg (IV Solution)|100 μg \[14C\]-xevinapant single dose administered as an IV bolus on Day 1, containing approximately 0.2 μCi \[7.4 kilobecquerel (kBq)\].
215068910|NCT04643873|OTHER|physical activity counseiling +pilates exercise group|It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
215068911|NCT04643873|BEHAVIORAL|physical activity counseiling group|During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
215068912|NCT03586895|BEHAVIORAL|e-Connect|e-Connect
214324791|NCT02607488|DRUG|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
214324792|NCT02607488|DRUG|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
214324793|NCT04186442|DRUG|Botulinum toxin type A injection|Experimental
214486069|NCT07029945|DRUG|BRX011|Subjects will ingest BRX011 orally, as capsules.
214925968|NCT04962724|DRUG|Xevinapant 200 mg (Oral Solution)|Xevinapant 200 mg administered as an oral solution on Day 1 of Part 2 in fasted conditions
214925969|NCT05958316|BEHAVIORAL|Computerized Symptom Capture Tool (C-SCAT) Intervention|"The C-SCAT includes the 32 symptoms from the Memorial Symptom Assessment Scale (MSAS). Users select symptoms they have experienced over the past week, rate each symptom's severity and distress, and name a perceived cause. They then identify temporal and causal relationships between symptoms using lines and arrows, designate groups, i.e., clusters of symptoms, and give a name to each cluster. They are asked the reason for a symptom's designation as a priority symptom and what they do to alleviate that symptom. Next, they are asked to designate a priority cluster and finally, to confirm whether the image accurately reflects their symptom experience. Then, at the clinic visit, the AYA shares the visual image with the HCP, and more importantly, their priority symptoms, which can facilitate the symptom discussion. The C-SCAT intervention group will complete the C-SCAT prior to each of three encounters with their health care providers (HCPs)."
214925970|NCT05958316|BEHAVIORAL|Usual Care Control|Usual care is defined as the usual approach to assessing symptoms during the HCP encounter. To provide attentional control to the usual care control group and prevent disproportionate attrition from that group, study staff will contact participants three times during the intervention period (approximately 3 months) when they are in for a scheduled clinic visit and communicate the following: 1) express appreciation for ongoing study participation; 2) ask how everything is going with their treatment; 3) ask if anything has changed with their treatment plan since the last study visit; and 4) confirm continued participation in the study.
214925971|NCT02817516|DRUG|TAK-828|TAK-828 solution.
214925972|NCT02817516|DRUG|Placebo|TAK-828 placebo-matching solution.
214925973|NCT02620241|OTHER|sitting position|
214925974|NCT03777813|DRUG|Durvalumab|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions
214925975|NCT03777813|COMBINATION_PRODUCT|IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)
214925976|NCT06621433|OTHER|T-PRF with CAF|Blood sample will be obtained from the patient, conveyed into a titanium tube and immediately centrifuged at 2700 rpm for 12 mins at room temperature using fixed angle centrifuge (PRF Process, Tangkula800-1, China). The fibrin clot will be collected and placed in the PRF compression device (PRF GRF box) and condensed to produce a uniform T-PRF membrane which will be inserted over the recession area and covered by the coronally advanced flap.
214925977|NCT06621433|OTHER|SECTG with CAF|Sub epithelial connective tissue graft will be obtained from the donor site (hard palate), placed into recipient site and secured by sutures, then covered by a coronally advanced flap.
214324794|NCT04186442|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
214324795|NCT05351203|PROCEDURE|caudal block|". Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
214486070|NCT07029945|DRUG|Placebo|Subjects will ingest Placebo orally, as capsules.
215068913|NCT04909606|OTHER|nurse-led prevention program|"Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)~The nurse-led prevention program will include:~1. A video explaining corticosteroids related adverse events and adequate preventive measures~2. An individual interview with the trained nurse~3. A consultation with a dietetician~4. An individual sheet summarizing appropriate non-pharmacological preventive measures for the participant~5. An individual sheet summarizing appropriate pharmacological preventive measures for the referent physician~6. Phone calls at week-12, week-24 and week-36 to ensure the appropriate implementation of preventive measures"
215068914|NCT04909606|OTHER|Current care|Subjects randomized to the standard of care group will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
215068915|NCT06002477|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
214486071|NCT06694935|DRUG|QX1206|QX1206 will be administered orally before bedtime
215068916|NCT06002477|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
215068917|NCT05547503|DRUG|AFA-281|Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)
215068918|NCT00100568|DRUG|Efavirenz|600 mg tablet taken orally daily
214486072|NCT06694337|DIETARY_SUPPLEMENT|300 mg Palmitoylethanolamide (PEA) Phytosome®|Oral supplement intake
214486073|NCT06694337|DIETARY_SUPPLEMENT|450 mg Palmitoylethanolamide (PEA) Phytosome®|Oral supplement intake
214486074|NCT06694337|OTHER|Control group|Placebo
214486075|NCT06689488|DEVICE|Ablation|Bronchoscopy and microwave ablation prior to surgical resection.
214324796|NCT05351203|PROCEDURE|Erector spinae block|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
214324797|NCT06178874|DRUG|Insulin Glargine|hyperglycemic control
214324798|NCT06178874|DRUG|Insulin Degludec|hyperglycemic control
214324799|NCT06178874|DRUG|Insulin regular|hyperglycemic control
214925980|NCT03911986|DEVICE|R Test 4 External Loop Recorder|The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.
214925981|NCT00832442|DRUG|Beta blocker|as determined by individual study
214925982|NCT00832442|OTHER|Placebo|in addition to usual care
214925983|NCT01567566|OTHER|exercise rehabilitation program|6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
214925984|NCT00748189|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
215068919|NCT00100568|DRUG|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
215068920|NCT02594930|PROCEDURE|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
215068921|NCT05592327|PROCEDURE|Citric acid abutment|The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
215068922|NCT00020098|PROCEDURE|evaluation of cancer risk factors|
215068923|NCT01157572|DRUG|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
215068924|NCT01157572|DRUG|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
215068925|NCT06115473|DRUG|epinephrine|patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
215068926|NCT06115473|DRUG|isotonic fluid|patients will receive IV bolus isotonic fluid 500 ml
214324800|NCT03218722|DRUG|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
214324801|NCT03218722|DRUG|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
214324802|NCT00749775|DRUG|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
214324803|NCT01233375|DRUG|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
214925985|NCT00748189|DRUG|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
214324804|NCT01280773|DEVICE|NAVA|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
214925986|NCT04982692|DRUG|intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
214925987|NCT04982692|DRUG|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
214925988|NCT04766489|PROCEDURE|Complete Decongtestive Therapy|Patients will be given complete decongestive therapy, which includes decongestive exercises, manual lymphatic drainage, compression therapy(either through short stretch bandaging and/or pneumatic device) and exercise, for 5 days a week and for a mean of 20 sessions. Each session will be of 1 hour duration for compressive therapies(Short stretch bandages will be left on for 23 hours a day), 30 minutes of manual lymphatic drainage, and decongestive exercises 3 times a day for 15 minutes each time.
214925989|NCT02784626|DRUG|Dexmedetomidine|Intraoperative sedation using dexmedetomidine
214925990|NCT02784626|DRUG|Propofol|Intraoperative sedation using propofol
214925991|NCT01287091|DRUG|GDC-0980|Oral tablet dose
214925992|NCT01287091|DRUG|GDC-0980|Oral capsule dose
214925993|NCT01287091|DRUG|GDC-0980|Oral tablet dose in fed state
214925994|NCT01287091|DRUG|GDC-0980|Oral repeating dose in fasting state
214925995|NCT01287091|DRUG|GDC-0980|Oral repeating dose in fed state
215068927|NCT04424823|PROCEDURE|LED photobiomodulation|Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
215068928|NCT01935323|OTHER|High Intensity Interval Training|
214925996|NCT01287091|DRUG|GDC-0980|Oral tablet in a fasting state
214925997|NCT01287091|DRUG|rabeprazole|Oral repeating dose
215068929|NCT01935323|OTHER|Moderate Intensity Training|
215068930|NCT05306834|PROCEDURE|Retinal Imaging|Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
215068931|NCT05306834|GENETIC|Blood sample|Analyses of molecular biomarkers including
215068932|NCT05306834|PROCEDURE|Evaluation of cardiovascular risks|Measurement of blood pressure and arterial stiffness
215068933|NCT05306834|PROCEDURE|Brain imaging (MRI)|3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
215068934|NCT05306834|OTHER|Cognitive Tests|Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
215068935|NCT05306834|OTHER|Geriatric Depression Scale (GDS)|15 items
215068936|NCT05306834|OTHER|Instrumental Activities of Daily Living (IADL)|Instrumental Activities of Daily Living (IADL)
214324805|NCT03499652|DIAGNOSTIC_TEST|neonatal bacterial meningitis risk score|In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
214486076|NCT06874400|OTHER|Dairy|The dairy products that participants will be required to consume include: 1) Trial 1: 2% cow's milk; 2) Trial 2: dairy yogurt; 3) Trial 3: 2% cottage cheese; 4) Trial 4: 2% cow's milk; and 5) Trial 5: isolated whey protein beverage. Participants will only be enrolled in 1 of the 5 trials; as such, they will only consume the 1 dairy product in that trial.
214486077|NCT06874400|OTHER|Plant-based alternative|The plant-based products that participants will be required to consume include: 1) Trial 1: soy beverage; 2) Trial 2: plant-based yogurt; 3) Trial 3: tofu; 4) Trial 4: 2% simulated milk; and 5) Trial 5: isolated soy protein beverage. Participants will only be enrolled in 1 of the 5 trials; as such, they will only consume the 1 plant-based alternative product in that trial.
214486078|NCT06289153|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
214486079|NCT06289153|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.
214925998|NCT04105946|DRUG|Dexmedetomidine|dexmedetomidine administration intraoperatively in combination with other drugs used in OFA
214925999|NCT04105946|DRUG|Remifentanil|remifentanil administration intraoperatively in combination with other drugs used in TIVA
214926000|NCT00058968|DRUG|Duloxetine hydrochloride|
214926001|NCT00058968|DRUG|placebo|
214926002|NCT06344533|DRUG|JMKX003142 Injection|JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
214926003|NCT06344533|DRUG|Placebo|Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
214926004|NCT00616980|BIOLOGICAL|CD34-positive cells|
214926005|NCT00616980|BIOLOGICAL|CD34-positive cells|
214926006|NCT00616980|BIOLOGICAL|Saline and 5% autologous plasma|
214926007|NCT01335880|BEHAVIORAL|Coupons for use within the next week|Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.
214926008|NCT01335880|BEHAVIORAL|Coupons for use within the next 3 months|Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.
215068937|NCT05306834|DIAGNOSTIC_TEST|Unipodal standing test|Unipodal standing test
215068938|NCT05306834|OTHER|Walking speed measurement|over 5 meters
215068939|NCT02731820|DIETARY_SUPPLEMENT|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
215068940|NCT02731820|DIETARY_SUPPLEMENT|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
214324806|NCT03676452|BEHAVIORAL|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
214324807|NCT05782595|OTHER|Aquatic therapy|"• Each session was divided into three phases:~1. Aquatic environment adaptation phase~2. stretching phase~3. a phase of static and dynamic exercises for balance"
214324808|NCT04488705|DRUG|ETD002 - single dose|Single ascending doses of ETD002
214324809|NCT04488705|DRUG|Placebo - single dose|Single doses of placebo
214324810|NCT04488705|DRUG|ETD002 - 7 day repeat dose|Twice daily doses of ETD002 for 7 days
214324811|NCT04488705|DRUG|Placebo - 7 day repeat dose|Twice daily doses of Placebo for 7 days
214324812|NCT04488705|DRUG|ETD002 - 14 day repeat dose|Twice daily doses of ETD002 for 14 days
214324813|NCT04488705|DRUG|Placebo - 14 day repeat dose|Twice daily doses of Placebo for 14 days
214324814|NCT04488705|DRUG|Salbutamol|Twice daily doses of salbutamol for 3 days (Days 5, 6 \& 7)
214324815|NCT05728112|OTHER|Hydrogen Inhalation|The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.
214926009|NCT02168374|OTHER|Indirect pulp treatment|Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
214926010|NCT02742116|GENETIC|DNA screening before Pregnancy|"Saliva/swab shall be collected from couple for Hereditary Disease DNA screening test. Blood sample shall be taken by venipuncture of women for Fragile X carrier screening A pre-test questionnaire will be conducted to assess subject's knowledge, views and preferences in receiving expanded carrier screening, choice of having concurrent or sequential screening, factors affecting their choices, anxiety level, and their willingness to pay for the test.~A post-test self-administered questionnaire shall be filled in by the patient on receiving the test results.~Couples who receive a screen positive result shall be subsequently referred to Queen Mary Hospital for joint counselling by clinical geneticist and gynaecologist. This consultation shall be audiotaped or videotaped."
214926011|NCT01424514|DRUG|SB-705498|12mg intra nasal
214926012|NCT01424514|DRUG|Placebo|Placebo intra nasal
214926013|NCT06624241|PROCEDURE|Lipo-Curcumin gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo- Curcumin gel. The pocket will be sealed with cyanoacrylate.
215068941|NCT02731820|DIETARY_SUPPLEMENT|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
215068942|NCT02731820|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
215068943|NCT04624867|DRUG|HP-1050 Patch|Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
215068944|NCT06245109|DRUG|Duloxetine|60 mg, oral
215068945|NCT06245109|DRUG|Celecoxib|200 mg, oral
214324816|NCT05728112|OTHER|Ordinary Air Inhalation|The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
214324817|NCT06408116|RADIATION|photon|radiation with 4-5 cm safte margin
214324818|NCT06408116|PROCEDURE|surgical therapy|surgery based on PET-CT/MRI staging
214324819|NCT06408116|DRUG|Chemotherapy|neoadjuvant chemotherapy
214324820|NCT00417183|DRUG|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
214324821|NCT00417183|DRUG|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
214324822|NCT01400841|DEVICE|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
214324823|NCT01588782|DRUG|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
214324824|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
214324825|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
214324826|NCT02836171|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
214324827|NCT02836171|DRUG|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
214324828|NCT06036069|OTHER|Conventional physical therapy|"* Standing with feet together while the therapist was sitting behind and manually locking the child knees.~* Step standing with the therapist behind the child.~* High step standing and trying to keep balanced. The child stood on exercise mattress.~* Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~* Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
215068946|NCT06245109|DRUG|Placebo|Matching placebo, oral
215068947|NCT00630006|GENETIC|TNF-alpha and IL-10|
215068948|NCT03783000|DRUG|BI 425809|Treatment T
214324829|NCT00770120|DRUG|everolimus|
214324830|NCT03078998|DEVICE|Leap Motion Based Exercises|Game based exercise
214324831|NCT04088461|DRUG|Linagliptin / Metformin Oral Tablet|Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
214324832|NCT04088461|DRUG|Metformin|Metformin 850 mg twice daily plus lifestyle modifications program
214324833|NCT06193135|DRUG|Corifolitropin Alfa|Patients will receive a single dose of Colifolitropin alfa, then will receive daily dose of Folitropin Beta since triggering criteria are met.
214324834|NCT06193135|DRUG|Folitropin Beta|Patient will receive daily dose of Folitropin Beta since triggering criteria are met.
214324835|NCT05907135|DIETARY_SUPPLEMENT|Beet|Beet-based powder with other ingredients
214324836|NCT05907135|DIETARY_SUPPLEMENT|Placebo|Placebo powder.
214324837|NCT03527212|DRUG|SJP-0035 0.001%|Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
214324838|NCT03527212|DRUG|Placebo|Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
214324839|NCT06161792|DRUG|0.8 mg RCN3028|Oral
214926014|NCT06624241|PROCEDURE|Lipo gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo gel. The pocket will be sealed with cyanoacrylate.
214926015|NCT06624241|PROCEDURE|Discharged Gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of discharged gel. The pocket will be sealed with cyanoacrylate.
214926016|NCT06624241|PROCEDURE|SRP alone|The pocket defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
214926017|NCT02638675|BEHAVIORAL|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
214324840|NCT06161792|DRUG|Placebo|Oral
214324841|NCT01383902|OTHER|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
214324842|NCT02886585|DRUG|Pembrolizumab|
214324843|NCT02886585|RADIATION|MRI|
214324844|NCT02886585|RADIATION|PET/CT|
214324845|NCT02886585|PROCEDURE|Stereotactic Radiosurgery|
214324846|NCT03626116|PROCEDURE|silicone metacarpophalangeal arthroplasty (SMPA)|Replacement of the metacarpophalangeal (MCP) joint using a silicone arthroplasty
214324847|NCT00480636|DRUG|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
214324848|NCT02583256|BIOLOGICAL|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
214324849|NCT02583256|BIOLOGICAL|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
214324850|NCT05552040|BEHAVIORAL|START NOW Group|START NOW psychotherapy is a CBT, DBT and skills-based intervention
214324851|NCT01043796|OTHER|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
214324852|NCT01043796|OTHER|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
214324853|NCT04537806|DRUG|Brexanolone|Administered as IV infusion.
214324854|NCT04537806|DRUG|Placebo|Administered as IV infusion.
214324855|NCT04226079|DIAGNOSTIC_TEST|Collection of exhaled breath|Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
214324856|NCT03362840|BEHAVIORAL|Early Start Denver Model|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system
214324857|NCT03362840|BEHAVIORAL|Eclectic preschool intervention|"The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria."
214324858|NCT02720913|DEVICE|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
214324859|NCT02720913|PROCEDURE|Standard Suture Tying|Standard Suture Tying
214324860|NCT01283048|DRUG|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
214926018|NCT02638675|DEVICE|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
214926019|NCT02638675|BEHAVIORAL|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
215068949|NCT03783000|DRUG|BI 425809 mixed with [C-14]-BI 425809|Treatment R
215068950|NCT00967694|DRUG|Nitrous oxide|Nitrous oxide sedation by inhalation
215068951|NCT06153849|DIAGNOSTIC_TEST|urine sample collection|Urine samples from patients receiving BCG instillation was collected for LC-WGS to evaluate CIN and urinary microbiome.
214324861|NCT06421142|PROCEDURE|imaging examinations:FAPI PET/MRI, FDG PET/MRI, MRI|"FAPI PET/MRI and FDG PET/MRI examination Data acquisition was performed using a GE Healthcare SIGNA PET/MR instrument. Enrolled patients were injected intravenously with 68Ga-FAPI or 18F-FDG tracer and underwent simultaneous PET and MRI scanning approximately 30-60 minutes after intravenous administration of the tracer at a dose of 1.85-3.7 MBq/kg.~MRI examination MRI examination was performed using a Skyra 3.0T MRI scanner from Siemens, Germany, with a 16-channel phased-array surface coil, and the scanning range was from the superior margin of the iliac wing to the inferior margin of the pubic symphysis."
214324862|NCT05459129|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
214324863|NCT05459129|DRUG|Tiragolumab|Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
214926020|NCT04178642|DRUG|percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment|Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
214324864|NCT05459129|DRUG|Carboplatin|Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
214926021|NCT04178642|PROCEDURE|Percutaneous destruction of the tumor|Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
215068952|NCT04075747|DRUG|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
215068953|NCT04075747|DRUG|Venetoclax|Will be administered over specified duration during induction and consolidation courses
215068954|NCT04075747|DRUG|Midostaurin|Will be administered over specified duration during induction and consolidation courses
215068955|NCT04075747|DRUG|Enasidenib|Will be administered over specified duration during induction and consolidation courses
214324865|NCT05459129|DRUG|Paclitaxel|Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.
214324866|NCT03816358|BIOLOGICAL|Anetumab Ravtansine|Given IV
215068956|NCT05275387|OTHER|observational study, no intervention|observational study, no intervention
215068957|NCT02321319|DRUG|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
215068958|NCT00152477|DRUG|Carboplatin|"10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles."
215068959|NCT00152477|DRUG|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
215068960|NCT00152477|DRUG|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
215068961|NCT00152477|DRUG|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
215068962|NCT01835288|DRUG|arsenic trioxide|Given IV
214324867|NCT03816358|PROCEDURE|Biopsy Procedure|Undergo biopsy
214324868|NCT03816358|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214324869|NCT03816358|DRUG|Gemcitabine Hydrochloride|Given IV
214324870|NCT03816358|BIOLOGICAL|Ipilimumab|Given IV
214324871|NCT03816358|BIOLOGICAL|Nivolumab|Given IV
214324872|NCT04182100|DRUG|P1101|P1101 (ropeginterferon alfa-2b) will be administered subcutaneously every 2 weeks at the starting dose of 100 μg every two weeks (or 50 μg in patients under another cytoreductive therapy). The dose should be gradually increased by 50 μg every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is achieved (hematocrit \<45%, platelets \<400 x 10\^9/L and leukocytes \<10 x 10\^9/L). The maximum recommended single dose is 500 μg injected every two weeks. The dose will be maintained at the highest level which can be tolerated and delivers best possible disease response.
214324873|NCT04182100|DRUG|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
214926022|NCT02670733|PROCEDURE|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
214926023|NCT00373009|BEHAVIORAL|Traditional Army training|As usual training for Soldiers
214926024|NCT00373009|BEHAVIORAL|Core stabilization exercise only|Core stabilization exercise
214926025|NCT00373009|BEHAVIORAL|Psychosocial education class only|Psychosocial education class
215068963|NCT01835288|OTHER|laboratory biomarker analysis|Correlative studies
215068964|NCT03877315|DEVICE|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
215068965|NCT03877315|DEVICE|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
215068966|NCT05116319|DIAGNOSTIC_TEST|point-of-care HbA1c|The Afinion2™ (Abbott, Oslo, Norway), will be used for the current study as it is recently validated. According to American Diabetes Association (ADA), pre-diabetes (pre-DM) is diagnosed if HbA1c is 5.7-6.4% and diabetes (DM) is diagnosed if HbA1c is ≥6.5%
214324874|NCT04182100|PROCEDURE|Phlebotomy|Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
214324875|NCT06285981|DEVICE|Chimaera Long Nail|The CHIMAERATM, is an internal fixation system intended intended for insertion into the medullary canal of a femur in individuals suffering from stable and unstable pertrochanteric, intertrochanteric and subtrochanteric fractures of the femur alone or when these fractures occur in combination with shaft fractures extending distally to a point approximately 10cm proximal to the intercondylar notch.
214673013|NCT05774470|DEVICE|Owlet OSS 3.0|The Owlet OSS 3.0 is a non-invasive monitoring device. The Sock secures the Sensor to the baby's foot. The Sensor measures the baby's SpO2, heart rate, and movement, and transmits the baby's readings to the Base Station. The Base Station records and monitors the baby's readings and can indicate prompts as needed based on the data sent from the Sensor.
214926026|NCT00373009|BEHAVIORAL|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
214926027|NCT02653170|OTHER|SCM|"One intervention (SCM) is provided. Stroke Case Managers (SCMs) will conduct 2 home visits; the first within 72-96 hours and the other after 30-days of returning home. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted if needed. Home visit activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services."
214926028|NCT02653170|OTHER|SCM and VSSP|"SCM: Stroke Case Managers (SCMs) will conduct home visits at 72-96 hours and after 30-days. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted as needed. Activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services.~VSSP: Access and training on the Virtual Stroke Support Portal, an online information and support website which includes:~1. Contact list of care team members.~2. Access to hospital patient portal.~3. Stroke education materials, resources, and guidelines.~4. Access to Michigan 2-1-1 services.~5. Medication information and adherence tools.~6. Patient and Caregiver support networks."
214926029|NCT02147522|BEHAVIORAL|Self-care management|AHH behavioral intervention is provided by promotoras
214926030|NCT04002999|DEVICE|3D printed ceramic bracket and tray|The 3D ceramic bracket being investigated is the only available customized ceramic bracket. This will be a first for the orthodontic speciality. This will also be the first and only customized bracket system that includes customization of the bracket base. This helps in the control of first order orthodontic movements and allows brackets to be bonded on any labial surface of the tooth while maintaining an ideal prescription. As 3D printing is not limited by the mold-ejection in CIM, \[24\] the bracket system being tested here has the potential to achieve a more accurate slot dimension.
214926031|NCT04002999|DEVICE|Stock ceramic bracket + 3D printed tray|Traditionally, indirect bonding, starts with creating a mold of all the teeth as an exact replica of the mouth of the patient. From there, in the lab, the orthodontist positions each bracket precisely where it should go on each tooth and then creates a custom tray that allows transfer of the brackets from the lab model to the patient's teeth. By taking the time to place the brackets in a proper position on the lab model, orthodontists eliminate the inaccurate process of placing orthodontic brackets directly on the teeth. It theoretically also takes less chairside time and is more comfortable for the patient. It is however more technique sensitive. In this study, indirect bonding setup will be done virtually using commonly-available orthodontic software. The trays/jigs will then be 3-D printed
215068967|NCT02687971|DRUG|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
215068968|NCT00960011|DEVICE|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
215068969|NCT00960011|DEVICE|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
215068970|NCT05957393|OTHER|Quantity of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
215068971|NCT05957393|OTHER|Quality of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
215068972|NCT05957393|OTHER|Control|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
214926032|NCT04002999|DEVICE|Stock bracket, no tray|Direct bonding is the traditional way of placing orthodontic brackets, in which orthodontists clinically eyeball the tooth and place the bracket where they deem most appropriate
214486080|NCT02739711|DRUG|Glycoprotein IIb/IIIa inhibitors|Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
214926033|NCT06648577|PROCEDURE|Ultrasound imaging|The participants are scanned with an ultrasound scanner
214926034|NCT06623851|OTHER|Intraoral scanner|"* The digital impressions will be made with the intraoral scanner following the procedure reported by the manufacturer.~* The intraoral scanning process is divided into the lower jaw scan, upper jaw scan, and bite scan stages"
214926035|NCT06623851|OTHER|Alginate impression|Conventional impressions of both arches will be made according to the manufacturer's instructions, using steel impression trays and alginate
214926036|NCT05901350|DRUG|Levodopa|Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
214926037|NCT04775498|BEHAVIORAL|Face-to-face psychoeducation group|All of the investigation centers participating in this study have a psychoeducation programme on bipolar disorders labeled and monitored by their Regional Health Agency. For this, he must respect the decree of January 14, 2015 relating to the specifications of therapeutic education programs for the patient. Patients will be receive by an investigator, for inclusion and baseline evaluation and at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
214926038|NCT04775498|BEHAVIORAL|SIMPLe mobile application|The experimental intervention consists of 12 months use SIMPLe smartphone application who has been developed by the Barcelona Institute of neuroscience. The purpose of this application is to deliver individualized psychoeducation messages to the patient's clinical condition. The psychoeducational messages correspond to the contents of the different modules and sessions carried out in face-to-face psychoeducation groups (Colomm \& Vieta ; 2015). Patients will be receive by an investigator for inclusion and baseline evaluation, at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
214926039|NCT01619540|OTHER|Valsalva maneuver|
214486081|NCT07030049|DEVICE|Postero-stabilized total knee replacement for knee osteoarthritis|Total knee arthroplasty in which the osteoarthritic knee is replaced with a postero-stabilized total knee replacement. The postero-stabilized TKA consists of a femoral component with a build-in cam mechanism and a tibial component with a post-mechanism.
214673014|NCT04165395|DEVICE|Five-layer foam dressing|Five-layer foam dressing applied on the sacrum within 48 hours of spinal surgery
214926040|NCT01433068|DEVICE|NBTXR3|One intratumor implantation by injection
215068973|NCT02255448|DEVICE|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
215068974|NCT01969396|DEVICE|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
215068975|NCT01969396|DEVICE|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
215068976|NCT00614445|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
215068977|NCT00614445|DRUG|Placebo|2 to 4 tablets daily titrated according to the protocol
214673015|NCT04165395|DEVICE|Heelmedix boot|Heelmedix boot will be installed alternately from one foot to the other.
215068978|NCT01467037|OTHER|No intervention done|Not applicable because no intervention was done.
215068979|NCT01194089|DRUG|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
215068980|NCT01194089|DRUG|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
215068981|NCT05247970|DRUG|S-309309|Capsule administered orally
215068982|NCT05247970|DRUG|Midazolam|Syrup administered orally
215068983|NCT05247970|DRUG|Placebo|Matching capsule to S-309309 administered orally
214926041|NCT04305925|DEVICE|Focal Laser Ablation|Orion system to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy. MRI guidance will be achieved by MRI/ultrasound fusion, overlaying stored MRI images upon real-time ultrasound images. Interstitial laser treatments would be achieved by inserting the fiber into the cancerous regions guided by the Artemis image-fusion device. Applications of laser energy up to 15 watts of power will be used to treat the target region.
214926042|NCT06965556|OTHER|Medical Humanities-based Patient Education Strategy|Medical Humanities-based Patient Education with Comic-based Medical Education Materials for Breast Cancer Patients during Perioperative Hospitalization Stage
214926043|NCT06052202|BEHAVIORAL|CRC mHealth|Participants receive text messages that contain information about colorectal cancer and screening. Some text messages include links to videos that are intended to reduce barriers to colorectal cancer screening. Other text messages include links to brief web-based assessments. Responses to assessment questions are used to make sure each man receives only the information relevant to his needs. The main educational content is completed in the first 6 weeks. Additional educational and motivation text messages continue for up to 4 more months if a participant reports not having completed colorectal cancer screening.
214926044|NCT06052202|BEHAVIORAL|Control|Participants receive text messages that include links to videos and/or brochures developed by the Centers for Disease Control. This information is designed to educate the public about colorectal cancer and motivate screening. Text messages are sent every 2-3 days for 6 weeks.
214926045|NCT06967467|BEHAVIORAL|Semi-structured interview|Interviews designed to obtain information about patient reasons for enrolling or declining participation in the RENEW Intervention
214926046|NCT06967467|BEHAVIORAL|Survey|Survey which will incorporate a series of closed-ended questions eliciting attitudes about the feasibility and acceptability of the intervention, allergy delabeling and future BL antibiotic use
214926047|NCT06967467|BEHAVIORAL|Ethnographic observation|Observations designed to identify communication and contextual barriers to the implementation of RENEW
214926048|NCT06967467|BEHAVIORAL|Survey|Survey instruments will measure knowledge,attitudes, and practices surrounding allergy delabeling and antibiotic stewardship in patients with HM and perceptions of the feasibility and acceptability of the RENEW intervention
214926049|NCT06967467|BEHAVIORAL|Semi-structured interview|Interviews designed to obtain information from clinicians about their perception of the implementation of the RENEW intervention
214926050|NCT06966609|PROCEDURE|Control Group|Conventional Physical Therapy ( 12 weeks intervention) 24 randomly allocated participants will get the conventional physical therapy that includes the stretching exercises (PNF technique) for 6 weeks; targeting all the affected lower limb muscles, strengthening exercises of all the weak lower limb muscles for 12 weeks along with gait training on parallel bars. Duration of session is 45 min.
214926051|NCT06966609|PROCEDURE|Experimental Group|Conventional Physical Therapy and Cuevas Medek Exercises ( 12 weeks intervention) 24 randomly allocated participants will get the conventional physical therapy that includes the stretching exercises (PNF technique) for 6 weeks; targeting all the affected lower limb muscles, strengthening exercises of all the weak lower limb muscles for 12 weeks along with gait training on parallel bars.Along with conventional physical therapy, experimental group participants will get Cuevas Medek Exercises that includes antigravity exercises, specefic types of stretchings and balancing exercises. Types of exercises that will be performed on the patient out of 100 exercises,will depend on the patient's need that is affecting his or her gross motor proficiency.Total duration of session is 90 min.
214926052|NCT06969157|PROCEDURE|Surgery|Minor or major surgeries were performed depending upon the primary diagnosis. Major surgery was defined as one done under general anesthesia while minor was one done under local anesthesia.
214926053|NCT03652220|BEHAVIORAL|Meditation Based Lifestyle Modification|8 weekly modules, each 3.5 hours of Life ethics, Yoga exercises and Mantra Meditation
215068984|NCT06428942|OTHER|low-potassium vegetables|low-potassium vegetables 3 to 5 serving according to their daily suggested requirement
214324876|NCT06066151|DIETARY_SUPPLEMENT|Minayo Yeast Drink Product|Participants need to drink one piece of the products each day, for 4 consecutive weeks.
214324877|NCT05286034|BEHAVIORAL|Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms|"Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels."
214926054|NCT03652220|OTHER|Minimal treatment|Drug continuation under medical supervision
214926055|NCT03652220|OTHER|Multimodal specific treatment:|Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR
214926056|NCT02055989|RADIATION|Dose-escalated radiotherapy level 1|
214926057|NCT02055989|RADIATION|Sequential dose-escalated radiotherapy level 2|
215068985|NCT06635785|DRUG|AI-081|AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF.
215068986|NCT00969644|DRUG|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
215068987|NCT00969644|DRUG|Pegvisomant|s.c. injections once daily (10-15 mg/day)
215068988|NCT03026114|OTHER|No intervention is planned in our study.|No intervention is planned in our study.
215068989|NCT04446624|OTHER|Music therapy intervention|Group psychotherapy with music intervention
215068990|NCT02018848|BEHAVIORAL|Attention Training Program|
215068991|NCT02182024|DRUG|Dabigatran etexilate high dose|
214324878|NCT03328273|DRUG|Ceralasertib|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
214324879|NCT03328273|DRUG|Acalabrutinib|An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
215068992|NCT02182024|DRUG|Dabigatran etexilate low dose|
214926058|NCT04298814|OTHER|severe covid-19 pneumonia with ET|severe covid-19 pneumonia undergoing endotracheal intubation
214324880|NCT04083976|DRUG|Erdafitinib|Participants will receive erdafitinib oral tablets.
214324881|NCT06332404|DEVICE|Hypoglossal nerve stimulation Inspire system (Inspire Medical Systems Inc., USA)|Hypoglossal nerve stimulation therapy
214324882|NCT05359211|DRUG|Cyclophosphamide|Given IV
214324883|NCT05359211|DRUG|Fludarabine|Given IV
214324884|NCT05359211|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
214324885|NCT05359211|DRUG|Polymer-conjugated IL-15 Receptor Agonist NKTR-255|Given IV
214324886|NCT05359211|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214324887|NCT05359211|PROCEDURE|Echocardiography|Undergo ECHO
214324888|NCT05359211|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214926059|NCT06333067|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
214926060|NCT01905202|DRUG|Secretrol|
214324889|NCT05359211|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214926061|NCT04512196|DRUG|Superoxidized Water|Super-oxidized solution contains hypochlorous acid (HOCl) which exhibits bactericidal activity. These reactive species create an imbalanced osmotic gradient which damages the cell membrane integrity of single celled organisms, and subsequently denaturing its lipid and protein content. Multicellular organisms including host tissue are not susceptible to such changes in osmolarity hence spared from damage.
214324890|NCT05359211|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214324891|NCT05359211|PROCEDURE|Lumbar Puncture|Undergo LP
214324892|NCT05359211|PROCEDURE|Computed Tomography|Undergo PET/CT
214324893|NCT05359211|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214324894|NCT05359211|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214324895|NCT05359211|PROCEDURE|Biopsy|Undergo tissue biopsy
214324896|NCT05027139|DRUG|Zanidatamab|Administered intravenously (IV)
214324897|NCT05027139|DRUG|Evorpacept|Administered IV
214324898|NCT05448846|PROCEDURE|Enhanced Recovery After Surgery|ERAS protocol includes preoperative counselling, optimization of nutrition, standardized analgesic and anesthetic regimens and early mobilization.
214926062|NCT04512196|DRUG|Normal Saline|Normal saline contains 0.9% sodium chloride.
214926063|NCT02821338|DRUG|Lamotrigine Extended Release|Lamotrigine Extended Release (generic) and Lamictal XR (brand).
214926064|NCT06968260|OTHER|Education Type|Machine Guidance group will receive education from a software, while the Instructor Guidance Group will receive education from a human instructor.
214324899|NCT05448846|BEHAVIORAL|Home-based multicomponent exercise program (EXE)|"Home-based multicomponent exercise program:~A) Strength and balance (20 to 40 minutes, 2 days/week):~* Chair sit to stand exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 in the Rated of Perceived Exertion, 0-10 scale (RPE).~* Seated curl to press exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 RPE.~* Monopodal balance \| 1 to 3 sets with progressive time targets up to 60-second for each leg.~B) Gait (at least 30 minutes at an intensity that allows for comfortable conversation, 2 days/week on separate days from strength and balance exercise)~C) Inspiratory Muscle Training: 30 inspirations at 40% of maximal inspiratory pressure through a Power Breathe device, 2 times per day)"
214324900|NCT05149950|BEHAVIORAL|Active internet treatment|The patient gets access to the internet treatment via a secure login to 1177 The care guide e-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
214324901|NCT06504719|DRUG|Antibody-Drug Conjugates|Patients with advanced breast cancer treated with ADCs
214324902|NCT04861506|PROCEDURE|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as pharmacomechanical thrombectomy (PMT) and mechanical thrombectomy device (MTD) and/or pharmacomechanical thrombectomy (PMT）and/or percutaneous aspiration thrombectom (PAT) and/or CDT(catheter-directed thrombolysis) and/or percutaneous aspiration thrombectom (PAT) thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
214324903|NCT05552313|PROCEDURE|kinesio tape|kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.
214324904|NCT05552313|PROCEDURE|standard therapy|Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature
214926065|NCT02476812|BEHAVIORAL|Positive Piggy Bank|Already noted.
214926066|NCT06582784|BEHAVIORAL|Behavioral Activation Therapy App|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
214324905|NCT05544344|BEHAVIORAL|Healthy ReStart|In addition to receiving mental health services as usual, subjects receive services from health coaches over a four-month period to assist them in creating a Restart plan and attaining related life goals.
214324906|NCT05544344|OTHER|Services as Usual|Subjects receive mental health services as usual.
214324907|NCT05049785|OTHER|Counseling|Attend nutrition counseling sessions
214324908|NCT05049785|BEHAVIORAL|Exercise Intervention|Complete PA sessions
214926067|NCT06582784|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at week 12.
214926068|NCT02014493|PROCEDURE|High Flow Nasal Cannulae (HFNC)|HFNC 6 l/pr.min
214926069|NCT02014493|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|CPAP 6 l/pr.min
214926070|NCT00495209|OTHER|Qigong|EQT daily for 5 consecutive days prior to surgery.
214926071|NCT05537779|DEVICE|CT examination|Administration of contrast medium using the power injector
214926072|NCT00792974|BEHAVIORAL|A brief psycho-educational intervention|"A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.~This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment."
214926073|NCT06522087|DEVICE|40Hz stimulation|Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
214926074|NCT04189939|OTHER|clinical assessments|"Behavioral tasks will be executed via a computer interface. Below, we provide an estimated timeline for each visit and subsequently provide detail for the relevant stages.~Each participant's visit will last approximately 4-5 hours. Each visit will consist of the following tasks (in this order):"
214926075|NCT06608563|PROCEDURE|Fissure sealant without adhesive system (NO BOND)|"1. Cotton roll isolation~2. Etching of the enamel surface: 17% phosphoric 15 seconds over the surface to be sealed (Phosphoric etchant gel - Vococid, VOCO)~3. Washing/drying: a 3-1 syringe will be used to rinse all etch material from the toothsurface.~4. Sealant application: a light-curing nano-hybrid fissure sealant material (Grandio Seal; VOCO) will be applied using the applicator tip.~5. Lightcuring: The material will be lightcured for 20 seconds."
214926076|NCT06608563|PROCEDURE|Fissure sealant with adhesive system (BOND)|"1. Cotton roll isolation~2. Etching of the enamel surface: 17% phosphoric 15 seconds over the surface to be sealed (Phosphoric etchant gel - Vococid, VOCO)~3. Washing/drying: a 3-1 syringe will be used to rinse all etch material from the toothsurface.~4. Adhesive system application: the adhesive system (Futurabond, VOCO) single dose capsule will be applied over the surface to be sealed for 5 seconds using a microbrush. The adhesive system will be air thin dried and lightcured for 10s before sealant placement.~5. Sealant application: a light-curing nano-hybrid fissure sealant material (Grandio Seal; VOCO) will be applied using the applicator tip.~6. Lightcuring: The material will be lightcured for 20 seconds."
214926077|NCT01881334|BIOLOGICAL|CliniMACS CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.
214324909|NCT05049785|OTHER|Informational Intervention|Receive nutrition handouts
214926078|NCT00860535|OTHER|Comparator: Biomarker evaluation|"Patients on standard of care treatment will have blood drawn to evaluate biomarker changes in response to treatment with BCR-ABL inhibitors over a \~3.5 month period.~Part I will enroll patients who are beginning treatment with imatinib (recommended dose 400 mg every day \[qd\]), dasatinib (recommended dose 70 mg twice a day \[bid\]), or nilotinib (recommended dose 400 mg bid).~Part II will enroll patients who are changing from imatinib therapy to either dasatinib or nilotinib. A decision to initiate Part II will be made based on analysis of the results of Part I."
214926079|NCT02176863|BIOLOGICAL|Flebogamma 5% DIF|Human plasma-derived immunoglobulin
214324910|NCT05049785|DIETARY_SUPPLEMENT|Nutritional Intervention|Attend tasting sessions
214324911|NCT05049785|OTHER|Questionnaire Administration|Ancillary studies
214324912|NCT05358821|DRUG|SAGE-718|SAGE-718 oral softgel lipid capsules
214324913|NCT05358821|DRUG|Placebo|SAGE-718-matching oral capsules
214324914|NCT06836180|DEVICE|Near infrared light therapy|Once a day, once 30 minutes of near-infrared light treatment, 6 times a week for 96 weeks
214324915|NCT00118807|DRUG|Amodiaquine plus artesunate (AQ/AS)|
214324916|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)|
214324917|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)|
214324918|NCT05922332|DIETARY_SUPPLEMENT|Rich medium chain fatty acid milk powder group|In intervention group,there are 32 infants.They will be fed with rich medium chain fatty acid milk powder, formula with MCT content of 39%, total energy of 68kcal/100ml, and feeding frequency at a 3-hour interval
214324919|NCT05922332|DIETARY_SUPPLEMENT|Regular milk powder group|In control group,there are 32 infants.They will be fed regular milk powder,formula with MCT content of less than 30%, total energy of 67kcal/100ml, and feeding frequency at a 3 hours interval
214324920|NCT06618287|DRUG|BMS-986507|Specified dose on specified days
214324921|NCT06618287|DRUG|Osimertinib|Specified dose on specified days
214324922|NCT06618287|DRUG|Pembrolizumab|Specified dose on specified days
214324923|NCT06618287|DRUG|Nivolumab|Specified dose on specified days
214324924|NCT05516628|PROCEDURE|Surgical Resection|Resection of Primary Hepatocellular Cancer Tumour.
214324925|NCT05516628|DRUG|Adjuvant Atezolizumab-Bevacizumab Therapy|Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for two years following resection of hepatocellular carcinoma tumour.
214324926|NCT02504372|BIOLOGICAL|Pembrolizumab|IV infusion
214324927|NCT02504372|OTHER|Placebo|IV infusion
214324928|NCT06588686|DRUG|Buloxibutid|Buloxibutid
214324929|NCT06588686|DRUG|Placebo|Placebo
214324930|NCT05620940|DRUG|Vivitrol Injectable Product|Naltrexone Long-Acting Injection
214324931|NCT05620940|DRUG|IVL3004|Naltrexone Long-Acting Injection
214324932|NCT05620940|DRUG|IVL4002|Naltrexone Long-Acting Injection
214324933|NCT03901963|DRUG|Daratumumab|Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
214324934|NCT03901963|DRUG|Lenalidomide|Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
214324935|NCT06829017|OTHER|Postoperative Hypothermia Management Care Bundle|"The postoperative hypothermia care bundle consists of three main parameters, Diagnose hypothermia, Maintain/maintain normothermia and Monitor body temperature at regular intervals, and eight sub-parameters of these parameters. For this purpose, this study evaluates the pilot implementation and effectiveness of the postoperative hypothermia management care bundle developed within the scope of the research."
214324936|NCT01683279|BIOLOGICAL|Autologous CD19 CAR+ EGFTt + T cells|Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
214324937|NCT06559995|DIETARY_SUPPLEMENT|"ketone supplement D-beta-hydroxybutryric acid and R-1,3 butanediol 12g of ketones,"|ketone supplement
214324938|NCT06559995|DIAGNOSTIC_TEST|magnetic resonance imaging session|1.5 hour magnetic resonance imaging session
214324939|NCT06559995|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage, visually matched, three times a day before meals, by mouth for 4 days plus 1 dose on day 5 for magnetic resonance imaging session visit.
214926080|NCT02176863|DRUG|Placebo|Normal saline solution
214926081|NCT00484835|PROCEDURE|Performing abdominal hysterectomy using gyrus electrocoagulation forceps|
214926082|NCT02989376|PROCEDURE|After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.|When the ratio of the end diastolic velocity in the common carotid arteries is greater than 1.4 or the diastolic flow in the internal carotid artery is not detected by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment. If vessel occlusion is not detected by carotid duplex ultrasound, additional vascular imaging including MR angiography or CT angiography is considered.
214324940|NCT02102256|DEVICE|Auditory Brainstem Implant|
214324941|NCT03032796|BEHAVIORAL|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
214486082|NCT07030049|DEVICE|Cruciate-retaining total knee replacement for knee osteoarthritis|Total knee arthroplasty in which the osteoarthritic knee is replaced with a cruciate-retaining total knee replacement. The cruciate-retaining TKA consists of a femoral component and a tibial component that leaves the posterior cruciate ligament intact.
214486083|NCT06868368|OTHER|Biospecimen Collection|Undergo blood sample collection
214486084|NCT06868368|OTHER|Survey Administration|Complete Surveys
214486085|NCT06868368|BEHAVIORAL|Vaping Topography|Use e-cigarette connected to a topography device
214486086|NCT06868368|OTHER|Participant's Own Preferred E-cigarette|Participant vapes their own preferred e-cigarette for 30 minutes
214486087|NCT06868368|OTHER|Nicotine E-cigarette|Participant vapes a commercially available nicotine e-cigarette for 30 minutes
214673016|NCT03446170|BEHAVIORAL|Graphic cigarette warning labels, plain packaging|This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
214673017|NCT06970587|PROCEDURE|percutaneous cystolithotripsy|to compare percutaneous cystolithotripsy with transurethral cystolithotripsy as minimally invasive surgical treatments for urinary bladder stones in pre-school age boys, and to assess the safety and the possible complications of both procedures
214673018|NCT06969911|PROCEDURE|Laminate veneer CAD/CAM|Minimally invasive therapeutic intervention with CAD/CAM veneers
214926083|NCT03024762|PROCEDURE|targeted Provider-Initiated-Testing and Counseling (tPITC)|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
214926084|NCT02609620|DEVICE|Peristaltic Feeding Tube|
214926085|NCT02609620|DEVICE|ConvaTec Levin Duodenal Tube|
214926086|NCT01194999|DEVICE|Pubovaginal sling procedure|The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
214926087|NCT02135185|OTHER|custom work endurance|Experimental: Rehabilitation effort
214486088|NCT06868368|OTHER|6-methyl-nicotine (metatine) e-cigarette|Participant vapes a commercially available metatine e-cigarette for 30 minutes
214486089|NCT04149210|DRUG|Fluorometholone 0.1% Oph Susp|fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
214486090|NCT04149210|DRUG|Artificial Tears|Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
214486091|NCT05220553|DEVICE|PROLIMB Prosthesis|Participants will be given the PROLIMB prosthesis to test in the lab and to use in their daily lives
214673019|NCT06969911|PROCEDURE|Laminate Veneer Convetional|Minimally invasive therapeutic intervention with CAD/CAM veneers
214324942|NCT03032796|BEHAVIORAL|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
215068993|NCT04793724|DEVICE|Simeox|"A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~* clearance of the upper airways before the physiotherapy session~* correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~* slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~* step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~* comfortable, relaxed sitting position with straightened spine~* controlled cough, which will be encouraged only when it is productive"
214324943|NCT03032796|BEHAVIORAL|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
214673020|NCT06971679|BEHAVIORAL|Flipped Method|In the first week of the clinical practice, the E-learning module prepared by the researchers within the scope of the flipped education method was shared with the intervention group students and all students were shown in a conference room. After the training, PBL modules (different cases related to patient safety for each group) were shared with the students divided into groups of 3-5 students within the scope of PBL and they were given one week to prepare. In the other weeks of the clinical practice, face-to-face case discussions were held with the groups. These case discussions lasted an average of 40 minutes.
214673021|NCT06970808|DEVICE|Sampling from the resection margins|"After polypectomy, the base will be irrigated and assessed by the endoscopist, who may also use virtual or vital chromoendoscopy, if needed.~Any residual adenomatous tissue will be removed using the same technique. To confirm the completeness of each polypectomy, two biopsies will be taken from the resection margins for polyps ≤ 5 mm, and three biopsies for polyps 6-9 mm, using standard biopsy forces."
214673022|NCT06969560|DEVICE|Remote Physiologic Monitoring (RPM)|The intervention consists of a remote physiologic monitoring (RPM) program which makes use of a wearable Skiin chest band and ECG device, a blood pressure monitor, a pulse oximeter, and a weight scale; the RPM program will occur for 12 weeks Participants will wear the Skiin device continuously for the first 48-hours and then for a 12-hour span each day following that. Participants will measure their blood pressure, oxygen saturation, and weight once a day for the full 12 weeks.
214926088|NCT02135185|BEHAVIORAL|dietary management adapted to the nutritional status|dietary management adapted to the nutritional status
214926089|NCT05262907|DEVICE|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
215068994|NCT04793724|DEVICE|PARI O PEP|"ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~* horizontal;~* low;~* transition of the device from the low position to the horizontal position;~* upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum."
214324944|NCT03032796|BEHAVIORAL|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
214324945|NCT05429203|DEVICE|Duodenoscope with single-use distal cover|Newer duodenoscope with a single-use distal cover
215068995|NCT05487651|GENETIC|KUR-502|KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.
215068996|NCT03252249|OTHER|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
215068997|NCT03252249|OTHER|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
214926090|NCT05262907|DEVICE|Ventripoint Echocardiogram|Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.
214926091|NCT04437875|BIOLOGICAL|Gam-COVID-Vac Lyo|adenoviral-based vaccine against SARS-CoV-2
214926092|NCT06200415|DRUG|Glucosamine Sulfate|Glucosamine sulphate (GLcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of the chitosan with significant anti-inflammatory action.
214926093|NCT06200415|DRUG|Ginger Oil|Ginger (Zingiber officinale Roscoe) has been found to have biological activities such as antioxidant, anti-inflammatory, antimicrobial, and anticancer activities.
214926094|NCT00325481|DRUG|FluMist|
215068998|NCT02660450|OTHER|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
214324946|NCT05429203|DEVICE|Conventional duodenoscope|Conventional duodenoscope with standard methods of reprocessing
214324947|NCT04731610|OTHER|Radiotherapy|postoperative radiotherapy after complete resection of thymoma
214324948|NCT04731610|OTHER|Surveillance after resection|Surveillance after tumour resection
214324949|NCT04009330|DIAGNOSTIC_TEST|POC Assay|"Interventions:~Blood Baseline - up to 40ml Day 3 - up to 40ml~Urine Baseline - 10ml Day 3 - 10ml~Study population:~Adults (18 plus) in ICU units diagnosed with ARDS."
214926095|NCT01514058|PROCEDURE|EUS-FNA first, followed by CRCP with bilinary stenting|EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)
214324950|NCT03944499|DRUG|FS-1502|"Dose-Escalation Phase (Phase 1a)： FS-1502 dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle in the V1.2 and V2.0 regimens; IV, once per 21 days, 21 days as a cycle in the V3.0 regimens..~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg. If 1.3mg/kg is still tolerated safely and in line with linear kinetic characteristics, and combined with the results of PK, PD, safety and effectiveness, a comprehensive assessment is made to determine whether to continue the dose escalating. The subsequent dose increase ratio is 33% (the dose increase ratio can be adjusted according to the previous data results) until MTD or RP2D.~Dose-expansion Phase (Phase 1b) : RP2D determined in phase 1a, IV."
214486092|NCT07031726|BEHAVIORAL|Worksite Nutrition and Wellness Program|A structured behavioral intervention combining personalized physical activity and structured physical activity (Zumba classes), personalized nutrition counseling, and mobile app-based self-monitoring.
214486093|NCT07031726|BEHAVIORAL|Standard education|General educational materials on healthy eating and physical activity based on the Ministry of Health guidelines. No tailored or active intervention provided.
214926096|NCT01514058|PROCEDURE|ERCP with stent placement, followed by EUS-FNA|ERCP with stent placement, followed by EUS-FNA
214926097|NCT04290208|DRUG|Acetaminophen|IV Acetaminophen
214926098|NCT04290208|DRUG|Acetaminophen|Acetaminophen liquid syrup
214926099|NCT04290208|DRUG|Placebos|Flavored, non-medicated (placebo) liquid syrup
214926100|NCT04290208|DRUG|Placebos|IV salt solution (non-medicated)
214926101|NCT00186979|DRUG|Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.|See Detailed Description section for details of treatment interventions.
214926102|NCT01703247|PROCEDURE|Pulmonary vein isolation|
214926103|NCT01703247|PROCEDURE|Ganglionated plexi ablation|
214926104|NCT01703247|PROCEDURE|Linear Lesion Ablation|
214926105|NCT00230854|DRUG|EMZ702|
214926106|NCT03268200|OTHER|segmental reexamination|segmental reexamination during colonoscopy
214926107|NCT00826254|DRUG|Vitamin K|180 micrograms vitamin K daily
215068999|NCT02660450|OTHER|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
214486094|NCT06879834|DEVICE|taking fundus photos using non-mydriatic fundus camera|using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
214926108|NCT00826254|DRUG|Vitamin K|"2 capsules daily 180 micrograms vitamin K daily or placebo~1 year"
214926109|NCT04102254|PROCEDURE|ANT recording and stimulation|In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
214926110|NCT06648200|DRUG|JS004|Specified dose on specified days.
214926111|NCT06648200|DRUG|Toripalimab|Specified dose on specified days.
214926112|NCT06648200|DRUG|Etoposide|Specified dose on specified days.
215069000|NCT02660450|OTHER|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
215069001|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, TID
214926113|NCT06648200|DRUG|Platinum|Specified dose on specified days.
214926114|NCT04719052|OTHER|Diet and behavioural intervention|Intervention will receive a specific diet designed following the characteristics of Mediterranean Diet
214926115|NCT04719052|OTHER|Diet and behavioural intervention|Control group will receive a specific diet designed following the characteristics of Low fat Diet.
214926116|NCT02844842|BIOLOGICAL|Allergovac Poliplus|
214926117|NCT02666378|OTHER|Cardiac Magnetic Resonance Imaging (CMR)|Subjects will be recruited for observational cardiac magnetic resonance imaging.
214926118|NCT02666378|OTHER|Echocardiogram (ECHO)|Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.
214926119|NCT01404156|DRUG|(Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1\) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2\) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)"
215069002|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, BID
215069003|NCT01626118|DRUG|Indomethacin|capsules, 20 mg, TID
215069004|NCT01626118|DRUG|Placebo|capsules
215069005|NCT06506032|DRUG|Intravenous Vancomycin administration|Vancomycin was administered to the patients at the discretion of the physician
215069006|NCT06506032|OTHER|Standard postoperative therapy|The patients received standard postoperative therapy
215069007|NCT00086801|DRUG|doxorubicin hydrochloride|given IV
215069008|NCT00086801|DRUG|gemcitabine hydrochloride|given IV
215069009|NCT00086801|DRUG|vinblastine|given IV
215069010|NCT00086801|PROCEDURE|fludeoxyglucose F 18 positron-emission tomography (PET) scan|
215069011|NCT00086801|PROCEDURE|CT scan|
215069012|NCT01961284|DEVICE|Zygomatic implant placement|
215069013|NCT01961284|DEVICE|conventional implants and augmentation of maxilla|
214926120|NCT01404156|OTHER|Carboplatin paclitaxel plus concurrent radiotherapy|"5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:~* paclitaxel: 50 mg / m2 IV over 1 hour~* carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion~Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~1\. Dose specifications:~1. Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.~2. Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment ."
214926121|NCT06289478|DRUG|Topical tranexamic acid administration|Tranexamic acid will be topically administered in intervention groups
214926122|NCT06668688|DEVICE|"ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de)"|"The web-based information platform for educational professionals ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de) on depression and mental health in childhood and adolescence was developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. The website is intended to provide low-threshold information about depression and mental health in the school context."
214926123|NCT05835011|DRUG|Decitabine/Cedazuridine|Oral FDC tablets administration
214926124|NCT05835011|DRUG|Magrolimab|IV administration
215069014|NCT00888329|DRUG|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
214926125|NCT04756193|DIAGNOSTIC_TEST|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry
214926126|NCT03208478|PROCEDURE|Adductor Canal perineural catheter placement|Patients will receive an Adductor Canal Block intervention for pain control following ACL reconstructive surgeries.
215069015|NCT00888329|DRUG|Placebo|Placebo
215069016|NCT04355897|BIOLOGICAL|Convalescent COVID 19 Plasma|Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma
214324951|NCT00462696|DRUG|Neoadjuvant chemotherapy|"Neoadjuvant tehrapy as per standard practice :~Patients will be treated with six cycles of neoadjuvant chemotherapy combining epirubicin (75 mg/m² on day 1) and docetaxel (75 mg/m² on day 1), administered every 21 days (Delcambre, 2005; Wenzel, 1999). This treatment regimen is in line with the latest international recommendations (Kaufmann, 2003). The addition of a leukocyte growth factor in cases of grade IV leukopenia and/or treatment postponements due to grade 3-4 toxicity will be authorized with a maximum delay of 2 weeks per cycle. Dose reductions will be authorized in 25% increments for grade 3-4 toxicity~. Systematic surgical excision of the residual lesion (or the initial tumor site) will be performed between 22 and 35 days after the last chemotherapy treatment, in the form of a lumpectomy or mastectomy, depending on the residual tumor. Lymph node dissection will be systematically associated."
214324952|NCT05074186|DEVICE|neurological thrombectomy device is an investigational device.|Revascularization device is an investigational device.
214324953|NCT05026060|DIAGNOSTIC_TEST|Imaging|4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
214324954|NCT06471920|BEHAVIORAL|Standardized Education|Patients randomized to the standardized education group will receive registered access to a study website with access to evidence-based education for patients with chronic LBP. Each participant will have unique login credentials to allow for tracking of individual patient use. The website will include important education on the etiology of chronic LBP and evidence-based suggestions for self-management of symptoms. Education will focus on the importance of maintaining healthy levels of physical activity and avoiding bedrest.
214324955|NCT06471920|BEHAVIORAL|Telerehabilitation|Based on prior SBTS risk stratification, participants in the risk-informed telerehabilitation group will receive subsequent care using an evidence-based treatment protocol designed for video visits to be informed by a participant's baseline risk score with elements ranging from standard physical therapy telehealth visits (low-to-medium risk) to PIPT telehealth visits (high-risk).
214324956|NCT06095947|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.
214324957|NCT06050395|BEHAVIORAL|Quality fo Life Questionnaire (FHSI)|Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14). The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much. A lower total score indicates better quality of life.
214926127|NCT03208478|PROCEDURE|Femoral Nerve perineural catheter placement|Patients will have a Femoral perineural catheter placed for pain control following ACL reconstructive surgery.
214926128|NCT03208478|DEVICE|Nimbus pump (Infutronix)|This is a FDA approved infusion device that is used in standard of care to store pain medication and to provide patients with continuous pain control medication at a set rate. This pump will be used for both the Adductor Canal and Femoral Nerve block participants.
214926129|NCT05839197|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
215069017|NCT01203436|PROCEDURE|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
215069018|NCT01203436|PROCEDURE|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
215069019|NCT03626272|OTHER|educational intervention|The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
214324958|NCT06050395|BEHAVIORAL|Vioscreen Food Frequency Questionnaire (FFQ)|Participants will receive a web-based link and information to complete VioScreen, a web-based food frequency questionnaire, which allows participants to choose the average frequency of consumption of food items over a given time frame (1 month, 3 month, 1 year, etc.) on a Likert scale with choices ranging by individual questions. Total energy and nutrient intake is estimated by summing intakes from each food based on the selected portion size, reported frequency of consumption, and nutrient content of each food item. Anti-inflammatory and pro-inflammatory dietary patterns are calculated using the energy-adjusted dietary inflammatory index (DII) score to represent the inflammatory potential of an individual's overall diet, using data from FFQ responses. Higher DII scores represent more pro-inflammatory diets while lower (i.e., more negative) DII scores represent more anti-inflammatory diet.
214926130|NCT05839197|DRUG|Camrelizumab plus Apatinib|"Apatinib(250 mg; p.o.; qd.); camrelizumab (200 mg; iv drip; q3w) If the liver function was grade Child-Pugh A, Camrelizumab was given intravenously once every 3 weeks (D1) on the same day, 200mg/, once every 3 weeks (D1).~Apatinib capsule was given orally to 250mg within half an hour after breakfast on the second day (D2) after the first HAIC. The drug was given continuously once a day and stopped on the same day of each HAIC."
214926131|NCT03834974|BEHAVIORAL|Sun Safety Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about sun safety and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should include a sun safety message (e.g., promoting sunscreen use and protective clothing/hats or discouraging risk behaviors like tanning and burning). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
214926132|NCT03834974|BEHAVIORAL|Digital Health Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about using technology to get healthy and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should mention some way that technology (e.g., mobile apps, wearables) can be used to promote a healthy habit (e.g., diet, exercise). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
214926133|NCT06180369|OTHER|GC Fuji Triage ® GC America Inc., Alsip, Illinois )|Fissur Sealent application
214926134|NCT06180369|OTHER|BeutiSealant (Shofu, Kyoto, Japonya)|Fissur Sealent application
214926135|NCT00187681|DRUG|Metformin|2 doses of Metformin Day 1 1000mg, Day 2 850 mg
214926136|NCT04675918|PROCEDURE|Cardiac arrest|Definition of characteristics of cardiac arrest and resuscitation as well as post-resuscitational care and follow up.
214926137|NCT00312832|DRUG|switching; dose reduction|
214926138|NCT01055275|DEVICE|Implantation with a Cook Iliac Branch Graft|Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
214926139|NCT04720911|BEHAVIORAL|In-person TASCS|In-person clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
214324959|NCT06050395|BEHAVIORAL|Educational Handouts|Participants will receive educational handouts on diet.
214324960|NCT06050395|BEHAVIORAL|NutritionCoaching|Participants will receive bi-weekly nutrition coaching on anti-inflammatory dietary patterns and foods.
214324961|NCT06050395|BEHAVIORAL|Follow-Up Survey|Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators. This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree. A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
214324962|NCT06050395|BEHAVIORAL|Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire|The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much. A higher score indicates better appetite and quality of life.
214926140|NCT04720911|BEHAVIORAL|Telehealth TASCS|Telehealth clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
214926141|NCT04720911|BEHAVIORAL|Self-administered TASCS|Self-administration of the intervention, including the Safety Planning Intervention, facilitated by the TASCS ED Patient App.
214926142|NCT04720911|BEHAVIORAL|Follow-up care|Counseling calls and access to the Post-ED Patient and Family App for three months after the index presentation. These resources allow the patient and family to review their safety plan, life plan, and outpatient care plan
214926143|NCT02737085|BIOLOGICAL|Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells|Patients receive autologous-derived CD19-targeted CAR-T cells following CD20-targeted CAR-T cells after receiving lymphodepleting chemotherapy.
214926144|NCT05406115|DRUG|AMG 786|Oral tablet
214926145|NCT05406115|OTHER|Placebo|Oral tablet
214926146|NCT03927261|DRUG|PRGN-3006 T Cells|Participants will receive up to 2 intravenous (IV) administrations of PRGN-3006 T Cells with or without lymphodepletion and will be monitored for safety, efficacy, and correlative endpoints for up to 12 months following infusion.
214926147|NCT00491309|BEHAVIORAL|exercise training|exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
214926148|NCT05620732|BIOLOGICAL|Claudin18.2 CAR-T cells|patients treated with Claudin18.2 CAR-T cells
214926149|NCT04444193|DRUG|Durvalumab|Anti-PD-L1 Monoclonal Antibody
214926150|NCT04444193|DRUG|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
214926151|NCT00090220|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1
214324963|NCT06050395|BEHAVIORAL|Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire|Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits. The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never. A higher score indicates higher cognitive function.
214926152|NCT00090220|BIOLOGICAL|Comparator: Placebo|Placebo intramuscular injection in three 0.5 mL doses over 6 months.
214926153|NCT02482948|DEVICE|Active Leptospermum Honey (Medihoney)|STudy agent to be applied to the wound daily.
214926154|NCT02482948|DRUG|Collagenase|Study agent to be applied daily to the wound.
214926155|NCT00941863|DRUG|Sorafenib 100 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
214926156|NCT00941863|DRUG|Sorafenib 200 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
214926157|NCT00941863|DRUG|Sorafenib 400 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
214926158|NCT00941863|DRUG|Sorafenib 400 mg (200-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
214926159|NCT00941863|DRUG|Sorafenib 400 mg (Expansion)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
214926160|NCT01167673|DIETARY_SUPPLEMENT|coltect|green tea 250 mg, selenium 100 micro gram, curcumin 500 mg
214926161|NCT01167673|DIETARY_SUPPLEMENT|Placebo|placebo
214926162|NCT02698657|DRUG|ASP5094|Intravenous (IV)
214926163|NCT02698657|DRUG|Placebo|Intravenous (IV)
214926164|NCT01859117|BIOLOGICAL|3 x 10^6 cells|3 x 10\^6 cells administered on Study Days 1 and 8
215069020|NCT02789423|PROCEDURE|Direct Pulp Capping using Dycal and Biodentine|The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
215069021|NCT02621541|DEVICE|PET/CT|
214324964|NCT04575025|DRUG|Tabrecta tablets|There was no treatment allocation. Patients administered Tabrecta by prescription that had started before inclusion of the patient into the study were enrolled.
214324965|NCT05480956|BEHAVIORAL|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
214324966|NCT05480956|BEHAVIORAL|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
214926165|NCT01859117|BIOLOGICAL|10 x 10^6 cells|10 x 10\^6 cells administered on Study Days 1 and 8
214926166|NCT01859117|BIOLOGICAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
214926167|NCT01859117|BIOLOGICAL|100 x 10^6 cells|100 x 10\^6 cells administered on Study Days 1 and 8
214926168|NCT04080557|OTHER|Surgery|All patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
214926169|NCT00823043|DRUG|timolol hemihydrate|timolol hemihydrate 0.5% solution
214926170|NCT00823043|DRUG|timolol maleate|timolol maleate in sorbate
214926171|NCT04080843|DRUG|Anlotinib Hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
214926172|NCT04080843|DRUG|Capecitabine|Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.
214926173|NCT04080843|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2,D1
214926174|NCT04091412|DRUG|Butylphthalide Soft Capsules|The first class national new drug for the Treatment of Mild to Moderate Acute Ischemic Stroke; Long-term application can improve collateral circulation.
214926175|NCT00890708|DRUG|Voriconazole (therapeutic drug monitoring)|dosage adjustment according to trough level of voriconazole in plasma
214926176|NCT04579835|OTHER|External Cephalic Version|External Cephalic Version Twin A
215069022|NCT02613494|DRUG|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
215069023|NCT02613494|DRUG|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
215069024|NCT02613494|OTHER|Placebo|Placebo twice daily, increasing to placebo three times daily
214926177|NCT05113979|DEVICE|AccuraSee IOPCL with +3.0D add|The IOPCL (intraocular pseudophakic contact lens) consists of a 4.5mm diameter optic. All subjects will receive a +3.0 power regardless of diopter power based on IOL Master. This IOPCL will be coupled to a Bausch and Lomb Model LI61SE or LI61AO intraocular lens to correct residual refractive errors after cataract surgery.
214926178|NCT06685367|DEVICE|Acura AKI|When the AI algorithm (Acura AKI) identifies a high-risk AKI patient, nephrologists and ICU pharmacists will receive an alert message. Upon receiving the alert, they will review the patient's electronic health record and make treatment suggestions based on AKI bundle care protocols. They will also coordinate with the patient's primary care team to ensure that the recommendations are implemented
215069025|NCT01618435|BIOLOGICAL|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
215069026|NCT04715854|DEVICE|Mask|addition of the mask above the nasal cannulas
215069027|NCT05017389|DIAGNOSTIC_TEST|Griffiths development scales|Griffiths development scales Chinese Edition (gds-c) was used to evaluate the development levels of children up to 6 years and WISC for children more than 6 years.
215069028|NCT05210699|OTHER|Product A|Usual Brand (UB) filtered, menthol combustible cigarette
215069029|NCT05210699|OTHER|Product B|Flavor variant P1211216 of a 1.5% nicotine ENDS product
215069030|NCT05210699|OTHER|Product C|Flavor variant P1211217 of a 2.4% nicotine ENDS product
215069031|NCT05210699|OTHER|Product D|Flavor variant P1211222 of a 5.0% nicotine ENDS product
215069032|NCT05210699|OTHER|Product E|Flavor variant P1213616 of a 1.5% nicotine ENDS product
214324967|NCT05480956|BEHAVIORAL|SIRI Checklist + Enhanced Peer Recovery Coach|A standardized checklist of clinical items to review by the attending hospitalist with participants. Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
214324968|NCT06345742|OTHER|No parental participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Diaper care will be performed by the primary nurse.~4. Premature Infant Comfort Scale will be evaluated during and after the diaper care application."
214324969|NCT06345742|OTHER|Mother participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Mothers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Mothers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the mothers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application."
214324970|NCT06345742|OTHER|Father participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Fathers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Fathers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the fathers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application."
214324971|NCT05432336|DIAGNOSTIC_TEST|NGS for endohtalmitis / Multiplex PCR for keratitis|"For endophtalmitis : optimizing culture and NGS will be realized~For keratitis: Multiplex PCR will be added on ocular samples"
214324972|NCT05874544|DRUG|Vonoprazan|Proton pump inhibitor
214324973|NCT05874544|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214324974|NCT05874544|DRUG|Tetracycline|Antibiotics for H. pylori eradication
214926179|NCT05094635|DIAGNOSTIC_TEST|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: \< 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
214926180|NCT03453879|OTHER|no intervention|No intervention - only observation of teams delivering acute obstetric care
214926181|NCT06277323|BEHAVIORAL|Monthly report card intervention|The investigators will increase the frequency (monthly instead of quarterly) and enhance the content of the performance feedback emails sent to cardiologists (i.e., behaviorally-informed).
214926182|NCT06277323|BEHAVIORAL|Storyboard intervention|The visibility of the care gap banner in the electronic health record (EHR) upon patient encounter will be enhanced.
214926183|NCT01472016|DRUG|ABT-700|ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
214926184|NCT01472016|DRUG|docetaxel|Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
214926185|NCT01472016|DRUG|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
214926186|NCT01472016|DRUG|cetuximab|Cetuximab will be administered by intravenous infusion weekly.
214926187|NCT01472016|DRUG|erlotinib|Erlotinib will be taken orally daily.
214926188|NCT01472016|DRUG|ABT-700|ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
214926189|NCT04270071|DRUG|Yangxin Shengmai|Yangxin Shengmai Granules
214926190|NCT04270071|DRUG|Yangxin Shengmai placebo|Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.
214926191|NCT04270071|DRUG|nitroglycerin tablets|Be used when angina attack
214926192|NCT06682507|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
214926193|NCT03032328|DIETARY_SUPPLEMENT|vitamin D supplement|Patients will be given a dose of vitamin D for at least 2 months
214926194|NCT05484440|OTHER|Psychological|
214926195|NCT01513265|OTHER|Pharmaceutical care plan, mostly based on the RASP|Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
214926196|NCT05032495|OTHER|Surveys|Surveys to evaluate prior experience, opinions and intervention acceptability.
214926197|NCT05032495|OTHER|Focus group|To answer any questions and discuss topics covered in the standard presentation.
214926198|NCT01671995|PROCEDURE|Nurse monitored heart failure program|Standard program for a heart failure clinic with information, education, drug titration
214926199|NCT01671995|PROCEDURE|Standard primary health care|Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
215069033|NCT05210699|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
215069034|NCT00939029|DRUG|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
215069035|NCT00939029|DRUG|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
214324975|NCT05874544|DRUG|Metronidazole|Antibiotics for H. pylori eradication
214324976|NCT05874544|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
214324977|NCT05874544|DRUG|Rifabutin|Antibiotics for H. pylori eradication
214324978|NCT06564532|BEHAVIORAL|Evaluatively conditioning participant to like partner|The intervention is a computerized learning task that leads the participant to associate the partner with positive stimuli
214324979|NCT06564532|BEHAVIORAL|Evaluatively conditioning partner to like participant|The intervention is a computerized learning task that leads the partner to associate the participant with positive stimuli
214324980|NCT06561685|DRUG|LY4050784|Oral
214324981|NCT06561685|DRUG|Pembrolizumab|Administered IV.
214324982|NCT06561685|DRUG|Cisplatin|Administered IV.
214926200|NCT00565643|DEVICE|modified sodium hyaluronic acid and carboxymethylcellulose|Adhesion barrier applied at the time of initial cesarean delivery
214926201|NCT00565643|DEVICE|Placebo|Routine abdominal closure without placement of adhesion barrier
214926202|NCT05080114|PROCEDURE|Modified Bakay technique (MT)|The conventional standard technique for laparoscopic hysterectomy was followed until the colpotomy. The remaining steps were as follows: A 0-Monocryl™ violet (poliglecaprone-25) or a 0-PDS-II (polydioxanone) suture with a 36-mm needle (Ethicon Inc., NJ, USA) was placed first on the right USL, proximal to the ischial spine and 1-3 cm away from its uterine insertion, then helically proceeded by 1 to 3 bite(s) (depending on the length of the ligament) for suspension/plication. The suture continued circumferentially in counter clockwise direction on the line between the cervicovaginal junction and the bladder in a full-thickness purse string fashion, at least 1 cm away to the bladder. This suture symmetrically ended in the left USL, with forming nearly an Ohm sign (Ω). Colpotomy was performed circumferentially using laparoscopic cold scissors and/or knife, maintaining a safe distance from the suture line. Following removal of the uterus, both ends of the prior suture line were knotted.
214926203|NCT05080114|PROCEDURE|Standard technique (ST)|"The conventional standard total laparoscopic hysterectomy technique was used in this control group.~All operations were performed under general anaesthesia with nasogastric intubation and a bladder catheter in place. Cefazolin 2 g was administered to all patients for prophylaxis 30 min prior to surgery. Operations were performed with a 10-mm laparoscope (Karl Storz, Germany) through the trocar placed usually in the umbilicus. Two lateral 5-mm trocars and one midline 10-mm trocar were used. The placement of trocars varied according to the uterine size. Haemostasis was usually performed using bipolar forceps (Karl Storz Robi, Germany), whereas dissection was performed using the LigaSure™ (Covidien, Medtronic, USA). Maryland jaw laparoscopic sealer/divider, bipolar forceps and scissors. Colpotomy was performed with electrocautery devices and sutured intracorporeally."
214926204|NCT02960165|BEHAVIORAL|Virtual interface group|First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).
214324983|NCT06561685|DRUG|Carboplatin|Administered IV.
214324984|NCT06561685|DRUG|Pemetrexed|Administered IV.
214324985|NCT06561685|DRUG|Paclitaxel|Administered IV.
214324986|NCT06561685|DRUG|Nab paclitaxel|Administered IV.
214926205|NCT02960165|BEHAVIORAL|Real interface group|First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
214926206|NCT03374501|DIETARY_SUPPLEMENT|Sugardown™|Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)
214926207|NCT03374501|DIETARY_SUPPLEMENT|Soft drink|Test food #1: 495.0 g Sprite™ soft drink consumed with 250 mL water (repeated twice)
214926208|NCT06249347|PROCEDURE|PROMISED|CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Roof linear ablation: linear ablation in the left atria roof; Anterior septal linear ablation: linear ablation in the anterior septal linear which coursed from the middle of the right superior and inferior pulmonary veins or the middle of the right superior pulmonary vein to the mitral valve annulus; Mitral isthmus linear ablation: linear ablation in the mitral isthmus; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.
214926209|NCT06249347|PROCEDURE|CPVI and LAAC|CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.
214926210|NCT06249347|DEVICE|Radiofrequency ablation catheter|Device： Radiofrequency ablation catheter
214926211|NCT06249347|DEVICE|left atrial appendage occlusion device|Device： left atrial appendage occlusion device
214324987|NCT03413423|BEHAVIORAL|BAT-CS|All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
214324988|NCT03413423|BEHAVIORAL|Smoking Cessation and Health & Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
214324989|NCT05379166|DRUG|Azacitidine|Given IV
214324990|NCT05379166|OTHER|Quality-of-Life Assessment|Ancillary studies
214324991|NCT05379166|OTHER|Questionnaire Administration|Ancillary studies
214324992|NCT05379166|DRUG|Venetoclax|Given PO
214324993|NCT06505031|DRUG|TAK-861|Oral tablet.
214324994|NCT06505031|DRUG|Placebo|TAK-861-matching placebo tablet.
214324995|NCT01351961|BIOLOGICAL|blood sampling|take a sample of blood, 46 ml
214324996|NCT01351961|PROCEDURE|brain MRI and TEP cerebral|magnetic resonance imaging
214324997|NCT01351961|OTHER|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
214324998|NCT01351961|OTHER|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
214324999|NCT01351961|PROCEDURE|Vascular explorations|Pulse wave velocity, VWF, IMT
214926212|NCT02880774|OTHER|mandibular nonspecific mobilization|The mobilization will be held with the individual in supine position, by a trained and experienced therapist, where using disposable gloves, will position the first finger on the last molar, performing intermittently mobilization during 1 minute, will be held five repetitions. Going on a break during the repetition, in that the individual will carry out 15 times language exercises on the palate. With regard to mobilizing joint side, this will be previously set by means of the RDC/TMD and may be unilateral or bilateral basis, depending on the diagnosis. The therapist will remain in orthostatic in opposite side the mobilization to prevent any pressure on the jaw. The treatment will last for 4 weeks, 3 times a week, for a total of 12 sessions.
214926213|NCT02880774|OTHER|Ultrasound detuned,|Will be held the identical positioning to group A with the individual supine on the stretcher, used ultrasound equipment detuned on the region of the face with the presence of TMD. The procedures of this group will have a duration of 4 weeks, 3 times a week, for a total of 12 sessions.
214926214|NCT06246123|OTHER|Non-interventional|No intervention will be administered.
214926215|NCT01524939|DRUG|immunoglobulin G|Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
214926216|NCT06069349|OTHER|Early Rehabilitation|Early Rehabilitation for patients after cardiac surgery
214926217|NCT06069349|OTHER|usual treatment|Patients are not allowed to exercise Early Rehabilitation
214926218|NCT03452384|OTHER|Acupuncture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
214926219|NCT04980820|OTHER|No mask|The participant is asked to wear no mask for 10 minutes.
214926220|NCT04980820|DEVICE|Filtering face mask 2 (FFP2)|The participant is asked to wear a FFP2 mask for 1 hour during work.
214926221|NCT04980820|DEVICE|Filtering face mask 3 (FFP3)|The participant is asked to wear a FFP3 mask for 1 hour during work.
214926222|NCT03557931|DRUG|ASP4345|oral administration
214926223|NCT03557931|DRUG|placebo|oral administration
214926224|NCT03557931|DRUG|risperidone|oral or depot administration
214926225|NCT03557931|DRUG|quetiapine|oral administration
214926226|NCT03557931|DRUG|olanzapine|Oral or depot administration
214926227|NCT03557931|DRUG|ziprasidone|Oral or depot administration
214926228|NCT03557931|DRUG|aripiprazole|Oral or depot administration
214926229|NCT03557931|DRUG|brexpiprazole|Oral administration
214926230|NCT03557931|DRUG|paliperidone|Oral or depot administration
214926231|NCT03557931|DRUG|lurasidone|Oral administration
214325000|NCT01351961|BIOLOGICAL|Urine sample|
214325001|NCT06075147|DRUG|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.
214926232|NCT04259931|DIAGNOSTIC_TEST|microbiome analysis|gut microbiome composition of C. difficile infected patients with relapsing (basal, at the end of first treatment, at the begin of the relapses and at four and twelve weeks after definitive treatment) and non-relapsing ( basal and four and twelve week after treatment) , will be analyzed.
214926233|NCT05353244|DEVICE|PrTMS|Each participant will receive a personalized rTMS treatment based on their individual alpha frequency.
214926234|NCT05353244|DEVICE|Sham|Using a sham coil that looks and sounds like an actual TMS coil, each participant will receive sham rTMS treatments.
214926235|NCT06967870|OTHER|Osteopathic intervention|"Researcher will use osteopathic techniques on cranial area includes light touch.~Home based exercises will be show on cases and demand to do exercise regularly"
214926236|NCT06967870|OTHER|Home based exercise education|Home based exercises will be show on cases and demand to do exercise regularly.
214926237|NCT00737204|DRUG|Armodafinil|Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
214926238|NCT00737204|DRUG|Placebo|Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
214926239|NCT06457412|OTHER|Intervention group for the treatment of childhood obesity|Intervention for children aged 6 to 12 years with childhood obesity (with a BMI greater than the 99th percentile), fostering motivation and encouraging changes toward healthy lifestyle habits to achieve greater adherence and to improve health. The program comprises 9 educational sessions designed by specialized professionals (code of Spanish register: 2007144741729) to be conducted in a health center. The sessions will be held every 15 days, with a duration of 90 minutes for a group of 10 children and another group of 10 family members and/or caregivers. Professionals from different disciplines (paediatricians, psychologists, nurses and nutritionists), will meet with groups of pediatric patients and in another group with their family members or primary caregivers.
214926240|NCT04975750|BEHAVIORAL|Problem solving intervention|The intervention focuses on the individual employee and his/her work situation and work-private life balance. The following steps are implemented: inventory and prioritization of problems; brainstorming options and solutions; formulation of an action plan; evaluation, and follow-up. The intervention is carried out in about 3 planned meetings (30 - 45 min) between the manager and the employee. However, given the lack of research regarding the intervention delivered to this specific population and which dose that should be considered as beneficial as well as the complexities of the identified problems, the number of meetings is not specified
214325002|NCT01351896|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214325003|NCT01351896|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214325004|NCT01351896|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214325005|NCT01351896|PROCEDURE|Computed Tomography|Undergo CT
214325006|NCT01351896|DRUG|Lenalidomide|Given PO
214325007|NCT01351896|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
214926241|NCT04975750|BEHAVIORAL|Care as usual|The managers and the employee have meetings regarding the employee and his/her work situation and work-private life balance. However, the managers are not educated in and do not use the problem solving intervention. They are instead instructed to use their usual procedures.
214926242|NCT03476408|OTHER|Correlation / Observational|correlation between Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia
214325008|NCT05752955|OTHER|SMARThealth Pregnancy|"At each visit, the CHW will:~* Update history and contact details~* Check haemoglobin with a point of care device.~* Check BP~* Check iron folic acid (IFA) supply and compliance~* Brief screen for mental health problems~An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:~* Generate an automated list of all patients in the community who require review, with the dates of testing and referral, and with two-way communication back to the CHW.~* Suggest management based on current Indian guidelines for the diagnosis and management of anaemia, hypertension and diabetes in pregnant and non-pregnant adults."
214926243|NCT06666881|OTHER|HIIT only|After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times a week and total 24-36 times.
214926244|NCT06666881|OTHER|HIIT & Record of physical activities at home.|After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times in a week and total 24-36 times. And do the recording of physical activities at home.
214926245|NCT06968715|DIETARY_SUPPLEMENT|Experimental 1: low-breath hydrogen|Hydrogen-rich water (1.0 L/day)
214926246|NCT06968715|DIETARY_SUPPLEMENT|Experimental 2: high-breath hydrogen|Hydrogen-rich water (1.0 L/day)
214926247|NCT06968715|DIETARY_SUPPLEMENT|Experimental 3: low-breath hydrogen|Placebo water (1.0 L/day)
214926248|NCT06968715|DIETARY_SUPPLEMENT|Experimental 4: high-breath hydrogen|Placebo water (1.0 L/day)
214926249|NCT05888389|PROCEDURE|Cranial Nerve Block Anesthesia Combined With Sedative Anesthesia|Patients in the nerve block anesthesia combined with sedative anesthesia group will first receive cranial nerve blocks under standard monitoring. At the same time, intravenous dexmedetomidine infusion is started for sedation at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5-1ug/kg/h until the Richmond Agitation-Sedation Scale (RASS) of -3.
214926250|NCT05888389|PROCEDURE|General Anesthesia|Patients will be induced with propofol or etomidate, sufentanil , rocuronium or cisatracurium .
214926251|NCT02829723|DRUG|BLZ945|"BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days."
214926252|NCT02829723|DRUG|PDR001|PDR001 400 mg administered via intravenous (i.v.) infusion every 4 weeks (Q4W)
214926253|NCT04662866|DRUG|Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg|Comparison of 4 different antihyperglycemic drugs
214926254|NCT01871181|PROCEDURE|Ilioinguinal block|0.25% bupivacaine will be administered on a mg/kg basis
214926255|NCT01871181|PROCEDURE|Local infiltration|Surgeon will infiltrate incision area with local anesthetic before closure.
214926256|NCT02989649|DRUG|Alogliptin|Alogliptin tablets
214926257|NCT02989649|DRUG|Alogliptin FDC With Pioglitazone|Alogliptin FDC with pioglitazone tablets
214926258|NCT02989649|DRUG|Alogliptin FDC With Metformin|Alogliptin FDC with metformin tablets
214926259|NCT06052423|DRUG|HS-20093|HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
214926260|NCT00330343|DRUG|naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
214926261|NCT00003779|BIOLOGICAL|Connaught|Compare two strains of BCG
214926262|NCT00003779|BIOLOGICAL|Tice|Compare two strains of BCG
214926263|NCT01677884|DRUG|Bevacizumab|Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
214926264|NCT01677884|DRUG|Capecitabine|Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
214926265|NCT01677884|DRUG|Irinotecan|Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)
214926266|NCT03840759|OTHER|inpatient geriatric consultation team|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant after a complete CGA.
214926267|NCT02251145|DRUG|Tipranavir low dose|
214926268|NCT02251145|DRUG|Tipranavir high dose|
214926269|NCT02251145|DRUG|Ritonavir low dose|
214926270|NCT02251145|DRUG|Ritonavir high dose|
214926271|NCT02251145|DRUG|Tenofovir disoproxil fumarate|
214926272|NCT00281632|DRUG|GW786034|800 mg GW786034 administered orally on a daily basis.
214926273|NCT04510506|DEVICE|Artificial Pancreas (AP)|The AP system used in this trial is the Tandem t:slim insulin pump with Control-IQ Technology. This system is FDA approved for use starting at age 14 years.
214926274|NCT05728606|PROCEDURE|Robot-assisted D2 distal gastrectomy|Robot-assisted D2 distal gastrectomy after 3-Cycle SOX neoadjuvant chemotherapy
214926275|NCT06320015|BEHAVIORAL|Substance Misuse Assistance Response Team (SMART)|The study intervention is engagement with a Substance Misuse Assistance Response Team (SMART) community health worker-peer recovery specialist (PCHW). SMART PCHWs engage ED patients with substance use disorders and facilitates ED services provision and linkages to outpatient care. Services provided include supporting ED initiation of buprenorphine, harm reduction services, social services (transportation, housing assistance, etc.), and engagement in peer recovery, behavioral health services, and addiction treatment services. Services are provided at the time of the ED visit. A subgroup of patients is provided short term case management and outpatient services navigation depending on PCHW caseload availability and individual needs.
214926276|NCT06320015|OTHER|Usual Care Group|Patient not seen by a SMART community health worker in the emergency department. Care and treatment referral at discretion of emergency department treating team.
214926277|NCT04861285|DEVICE|RACESTYPTINE Solution with cord|The dentist inserts a non-medicated gingival retraction cord into the sulcus and then impregnates the cord in situ with a few drops of RACESTYPTINE Solution. The impregnated cord is left in place a few minutes and then removed. The gingival sulcus is washed and gently air-dried before taking impression.
214926278|NCT04861285|DEVICE|RACEGEL with cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth, and then inserts a non-medicated gingival retraction cord into the sulcus. The impregnated cord is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
214926279|NCT04861285|DEVICE|RACEGEL without cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth. The gel is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
214926280|NCT03432793|DRUG|TD-9855|oral tablet, QD
214926281|NCT03432793|DRUG|Fluvoxamine|oral tablet, QD
214926282|NCT03432793|DRUG|Itraconazole|oral tablet solution, QD
214926283|NCT03432793|DRUG|Caffeine|oral solution, single dose
214926284|NCT04679012|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.
214926285|NCT04679012|DRUG|Rituximab|Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
214926286|NCT04679012|DRUG|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
214926287|NCT04679012|DRUG|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
214926288|NCT04679012|DRUG|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
214926289|NCT04679012|DRUG|Hydroxydaunomycin|Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
214926290|NCT02587585|BEHAVIORAL|Feedback against tailored target|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. In the active group, the watch will summate activity movement in two hour epochs and the target for the day for that epoch is the activity in the same epoch 24 hours earlier, plus 5%. During an epoch the patient is shown progress towards the target at at the end of an epoch, they will see their final process towards target for that epoch.
214926291|NCT02587585|BEHAVIORAL|No feedback|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. However the watch face will simply show which epoch a person is in. The watch will collect the activity in exactly the same way over the day.
214926292|NCT00447031|DRUG|intravitreal bevacizumab and triamcinolone acetonide|
214926293|NCT01173731|DRUG|AFQ056|
214926294|NCT04216693|DRUG|Digoxin tablet|The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.
214926295|NCT04216693|OTHER|Placebo|The control group will receive the digoxin-like placebo treatment.
214926296|NCT03614078|DRUG|PRCL-02|Oral tablets
214926297|NCT03614078|DRUG|Placebo|Oral tablets
214926298|NCT04052386|BEHAVIORAL|BASICCS|Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. The personalized feedback intervention included tailored feedback on drinking quantity and frequency of alcohol, BAC, alcohol-related consequences, normative perceptions of peer drinking, alcohol outcome expectancies, family history of risk, and financial costs of alcohol. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
214926299|NCT03796416|DRUG|Misoprostol|used at a rate of 25 mcg Q4hours for cervical ripening.
214926300|NCT02091596|DRUG|PluroGel N|Study Drug
214926301|NCT02091596|DRUG|PluroGel|PluroGel Vehicle Placebo Comparator
214926302|NCT02894125|OTHER|SPA Therapy|
214926303|NCT05150808|OTHER|IRS insecticide: Vectron T500|public health insecticide
214926304|NCT04335981|DEVICE|FT-CC and Swallow Exercises|Once daily treatment with FT Plus with investigational connectivity software and standard of care swallow exercises.
214926305|NCT04335981|OTHER|Swallow Exercises|Standard of care swallow exercises.
214926306|NCT04090138|DIETARY_SUPPLEMENT|Setria performance blend|Oral capsules
214926307|NCT04090138|DIETARY_SUPPLEMENT|Placebo|Oral capsules
214926308|NCT04282317|OTHER|MRI scan|MRI scan
214926309|NCT00295035|DRUG|CELECOXIB|
214926310|NCT00295035|DRUG|CURCUMIN|
214926311|NCT06078358|OTHER|Resistance exercise training|Traditional linear periodization resistance training.
214926312|NCT04530058|DRUG|Metformin|Metformin 500 mg twice a day, administered orally or via gastric tube.
214926313|NCT04530058|DRUG|Placebos|Placebo twice a day, administered orally or via gastric tube.
215069036|NCT01496326|DRUG|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
215069037|NCT01496326|DRUG|placebo|2 grams of placebo cream for 14 days
215069038|NCT02250079|DEVICE|polyethylene plastic bag|Inborn neonates with both a gestational age \>29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
215069039|NCT02250079|DEVICE|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
215069040|NCT01058915|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
215069041|NCT01058915|DRUG|Rosuvastatin 40mg|Rosuvastatin 40mg/day
215069042|NCT03220464|RADIATION|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
214325009|NCT06577987|DRUG|CID-078 Monotherapy|Cyclin A/B-RxL inhibitor, twice-a-day in repeating 21-day treatment cycles until disease progression or discontinuation criteria.
214926314|NCT05929196|DIAGNOSTIC_TEST|In vitro full blood diagnostic test.|Participant will donate approximately 5 ml blood sample. Later in a laboratory the sample will be processed in the microwave metamaterial sensor for non invasive blood glucose monitoring and standard biochemical analyzer. Specific dielectric properties and scattering parameters will be measured for blood glucose level determination.
214926315|NCT04748458|DEVICE|Conical tapered stem|Implantation of conical tapered stem
214926316|NCT02691936|DEVICE|CO2 fractionated vaginal laser|Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
214926317|NCT02691936|DRUG|Estrogens, Conjugated (USP)|Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
214926318|NCT04894149|OTHER|Physiotherapy|Supervised physiotherapy one hour twice weekly and 20 minutes three times weekly during 14- 17 weeks before surgery during neoadjuvant chemotherapy or chemoradiotherapy and during eight weeks after surgery (sometimes during adjuvant chemotherapy)
214325010|NCT05132582|DRUG|Tucatinib|300mg given by mouth (orally) twice daily
214926319|NCT02698202|DEVICE|Digital Breast Tomosynthesis|twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
214926320|NCT06624306|PROCEDURE|Prone PNL|Prone PNL
214926321|NCT06624306|PROCEDURE|Prone-flexed PNL|Prone-flexed PNL
214926322|NCT03228524|DRUG|D-Aspartate|Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
214926323|NCT03228524|BEHAVIORAL|Therapeutic exercise|Standard physiotherapy
214926324|NCT03228524|DRUG|Placebo Oral Tablet|Placebo
214926325|NCT01773161|PROCEDURE|Cerebral palsy, post hip surgery|All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
214926326|NCT00306358|DRUG|Vitamin B12 (Cyanocobalamin)|
214926327|NCT02078895|DRUG|Botox|Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
214926328|NCT01050010|OTHER|MRI|dedicated extremity MRI
214926329|NCT00000238|DRUG|Buprenorphine|
214926330|NCT02140216|BIOLOGICAL|No blood transfusion|No blood transfusion
214926331|NCT02140216|BIOLOGICAL|Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
214926332|NCT02140216|BIOLOGICAL|Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
214926333|NCT04010903|DIAGNOSTIC_TEST|assessment of biomarkers of insulin resistance|blood and urine sample collection for assays of BCAAs
214926334|NCT05901233|DEVICE|Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS)|tDCS is a type of non-invasive brain stimulation. 1.5 milliamp (mA) of current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. The stimulation will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
215069043|NCT03220464|RADIATION|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
214325011|NCT05132582|DRUG|Trastuzumab|6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
214325012|NCT05132582|DRUG|Pertuzumab|420mg given by IV every 21 days
214325013|NCT05132582|DRUG|Combination product: Trastuzumab + Pertuzumab|600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
214325014|NCT05132582|DRUG|Placebo|Given orally twice daily
214325015|NCT04961047|BEHAVIORAL|Digital neurotherapy (DNT) Treatment|The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program
214325016|NCT04961047|BEHAVIORAL|Wait list control group|Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
214325017|NCT06184750|PROCEDURE|Biopsy Procedure|Undergo biopsy
214325018|NCT06184750|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214926335|NCT05901233|DEVICE|Remotely supervised sham tDCS (RS-sham-tDCS)|tDCS is a type of non-invasive brain stimulation. During sham stimulation 1.5 milliamp (mA) of current will be delivered for a brief period and then turned off. Current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. Sham will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
214926336|NCT05901233|BEHAVIORAL|Lexical Retrieval Training (LRT)|Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 3 times per week.
215069044|NCT03220464|DIAGNOSTIC_TEST|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
215069045|NCT06003777|DRUG|PF-06954522|PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.
215069046|NCT06003777|DRUG|Placebo|Placebo will be administered as oral suspensions as escalating single doses to be determined.
215069047|NCT03621176|OTHER|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
214325019|NCT06184750|PROCEDURE|Mammography|Undergo mammography
214926337|NCT05901233|BEHAVIORAL|Video Implemented Script Training in Aphasia (VISTA)|Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 3 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
214926338|NCT06201975|OTHER|Thyme honey|Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters
214926339|NCT03706885|DRUG|Sustiva Pill|One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
214926340|NCT03492671|DRUG|Gemcitabine 1000 mg|Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
214926341|NCT03492671|DRUG|nab-paclitaxel|Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
214926342|NCT03492671|RADIATION|Stereotactic Body Radiation Therapy|Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
214926343|NCT06041308|OTHER|valve|bioprothetic valve versus mechanical valve
214926344|NCT04866628|DIETARY_SUPPLEMENT|Helichrysum italicum infusion|Comparison of metabolic syndrome components before and after four weeks of daily consumption of Helichrysum italicum infusion.
214325020|NCT06184750|OTHER|Questionnaire Administration|Ancillary studies
214325021|NCT06184750|DRUG|Tamoxifen|Given PO
214325022|NCT05944250|DEVICE|Spincare matrix|The Spincare device, developed by Nanomedic, is the first portable tool that delivers a non-invasive, non-therapeutic electrospun, nanofibrous matrix dressing to wounds to promote healing.
214325023|NCT02365597|DRUG|Erdafitinib|8 mg orally once daily for 28 days on a 28 day cycle.
214325024|NCT02365597|DRUG|Midazolam|Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.
214325025|NCT02365597|DRUG|Metformin|Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.
214325026|NCT03409471|DEVICE|Flocked Swab|At the colposcopy clinic, vaginal self-sample will be collected with the Flocked Swab (Noble Bioscience, Inc., Korea).
214325027|NCT03409471|DEVICE|Cervical Brush|Physician collected cervical sample will be collected also at the colposcopy center with the Cervical Brush (Noble Bioscience, Inc., Korea).
214325028|NCT03409471|DIAGNOSTIC_TEST|HPV assay|The hrHPV assay used, will be the Roche Cobas® 4800 HPV test, Anyplex™ II HPV HR detection kit and Realtime HPV HR-S Detection kit.
214325029|NCT06371222|DRUG|Ivabradine|5 mg for 3 months
214325030|NCT06371222|DRUG|Beta blocker|controlled group
214325031|NCT03444714|DRUG|RiMO-301|"Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks"
214325032|NCT05658562|DRUG|MT-2111|i.v. infusion
214325033|NCT06803056|DIAGNOSTIC_TEST|Clinical exam|An experienced physical therapist with expertise in dry needling will confirm study eligibility and complete a standard clinical exam for myofascial pain. Gold standard for diagnosing myofascial pain as defined by Travell and Simons will be used. The criteria for muscle trigger point (TrP) include: 1) a taut band of skeletal muscle that is tender to palpation, 2) sustained compression of the taut band reproduces or exacerbates the participant's symptoms. Healthy tissue is defined as no palpable taut band.
214325034|NCT06803056|DIAGNOSTIC_TEST|Ultrasound imaging|Shear wave elastography and b-mode ultrasound imaging techniques will capture the biomechanical and structural profile of foot and ankle muscle on the involved side.
214325035|NCT06803056|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|T1rho and IDEAL sequences will be used to capture the biochemical and structural profile of foot and ankle muscles on the involved side
214325036|NCT03852797|DRUG|Oxytocin|Oxytocin solution, 20nM concentration
214325037|NCT03852797|DRUG|Ketamine|Ketamine in solution, 10-4M to 10-7M
214926345|NCT04866628|DIETARY_SUPPLEMENT|Helichrysum arenarium|Comparison of metabolic syndrome components before and after four weeks of daily consumption of Helichrysum arenarium infusion.
214926346|NCT06617221|BIOLOGICAL|Composite graft plug|after tooth extraction the socket was grafted with a composite graft plug
214926347|NCT06617221|BIOLOGICAL|Allograft|after tooth extraction the socket was grafted with allograft
214325038|NCT03852797|DRUG|Propofol|Propofol in solution, 10-4M to 10-7M
214325039|NCT03852797|DRUG|Etomidate|Etomidate in solution, 10-4M to 10-7M
214325040|NCT06803680|DRUG|BGB-B455|Planned doses administered on specified days per protocol.
214325041|NCT06803680|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
214325042|NCT05132127|DRUG|sutimlimab|Pharmaceutical form: solution for injection Route of administration: intravenous (IV)
214926348|NCT01729000|OTHER|Gloves|All staff must wear gloves for subjects that are in the experimental group.
214926349|NCT06614998|DRUG|Patients diagnosed with HLH-94 should be treated as soon as possible|For some highly suspicious patients, after diagnosis, according to the patient's etiology, the treatment plan should be determined as soon as possible, such as lymphoma-related patients treated with hormones combined with etoposide, which can greatly improve the prognosis of patients
214926350|NCT04804267|DRUG|Linaclotide|Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
214926351|NCT04804267|DRUG|LINZESS®|Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
214926352|NCT04804267|DRUG|Placebo|Drug: Placebo orally once daily
214325043|NCT04917146|OTHER|Self-administered questionnaires for relatives (caregivers=CG)|"Sociodemographic and medical information for the patient and the CG. SF36 questionnaire for the quality of life (physical, mental) of family CGs This assessment will be supplemented by specific questions relating to: physical health, emotional state, personal and leisure activities of the caregiver.~The CG's knowledge and representations of the disease : questions adapted from the Brief-IPQ disease representation questionnaire.~Questions will also focus on the caregiver's reactions to the patient's illness.~We have constructed a questionnaire to assess the main areas of aid in the context of SSc: emotional, domestic help, administrative, medical, for trave (16 items and an open question).~The CG Reaction Assessment-CRA questionnaire to assess the positive and negative dimensions of helping (24 items). It assesses five dimensions: self-esteem, financial impact, impact on health, impact on time and lack of family support.~The reason for the assistance provided."
214926353|NCT04007068|DIAGNOSTIC_TEST|FDG PET/CT|FDG PET/CT baseline, month 1, month 4, month 10, than every 6 months
214926354|NCT05051267|OTHER|Non-Pharmacological Methods|All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.
214926355|NCT06591884|DRUG|Tacrolimus modified-release|0.08% tacrolimus nanoencapsulated aqueous solution spray
214926356|NCT06591884|DRUG|tacrolimus ointment 0.1%|0.1% free tacrolimus commercial ointment
214926357|NCT06519643|BEHAVIORAL|career planning application|"Arm 1 \[Experimental group\]: The experimental group will be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. They will receive the full career planning mobile application intervention along with two online career mentoring sessions.~Arm 2 \[Control group\]: The control group will also be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. However, the control group will only receive a sham treatment. They will only access a few interfaces of the app."
214926358|NCT05337540|DEVICE|EVI-01|Single intra-articular injection of high molecular weight hyaluronic acid
214926359|NCT05337540|DEVICE|Active comparator Synvisc-One|Single intra-articular injection of active comparator Synvisc-One
214926360|NCT01136889|OTHER|PFMT|Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.
214325044|NCT05927792|DEVICE|repeated transcranial magnetic stimulation (continuous theta-burst stimulation)|Participants in intervention group will receive cTBS over the left M1for 5 consecutive days. The detailed parameters as follows: 80% of resting motor threshold (RMT), 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with no intertrain interval (i.e. triplet standard cTBS, 1800 pulses, 120s). Stimulation sessions were delivered hourly, 10 sessions were applied per day (18,000 pulses/day).
214325045|NCT05927792|DEVICE|sham repeated transcranial magnetic stimulation|The sham group will be stimulated with a pseudo-stimulation coil, which emitted sounds with the same intensity, rhythm and vibratory sensation as the real stimulation, and the intervention target, duration and frequency are the same as the real intervention group.
214926361|NCT05512806|DRUG|AZD5462|Participants will receive AZD5462 orally.
214926362|NCT01609439|DRUG|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
214926363|NCT01609439|DRUG|Placebo|Placebo
214926364|NCT06191393|DIAGNOSTIC_TEST|Aptitude Medical Systems Metrix COVID/Flu Test|The Metrix COVID/Flu Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2, Influenza A, and Influenza B via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result, detection of the Flu A gene target will produce a positive Flu A result, and detection of the Flu B gene target will produce a positive Flu B result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
214926365|NCT03617263|DRUG|Saroglitazar Magnesium 4 mg Tablet|Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
214926366|NCT03617263|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
214926367|NCT04276857|DEVICE|Irreversible electroporation (NanoKnife® )|IRE is a unique treatment modality as it ablates tumor cells without using heat or radiation and hence does not cause injury to nearby blood vessels, ducts, and bowel. This makes it particularly appealing for the treatment of locally advanced unresectable pancreatic cancers. This local treatment for cancer involves delivering brief pulses of high voltage electrical current across the tumor (either percutaneously or open surgery), which results in the formation of tiny holes (nanopores) in the cell membranes.
214926368|NCT03411174|RADIATION|hypofractionated partial breast irradiation|deliver 40Gy/15Fx to tumor bed areas
214926369|NCT03750669|DRUG|AG regimen|Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2
214926370|NCT03750669|DRUG|mFolfirinox|Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
214926371|NCT05986838|DEVICE|aser puncture|laser puncture (3 sessions per week)
215069048|NCT01263431|PROCEDURE|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
214325046|NCT02433314|DRUG|SAGE-547|
214926372|NCT05986838|DEVICE|ultraviolet radiatio|ultraviolet radiation (3 sessions per week)
214926373|NCT05986838|DRUG|Metformin|for 3 months
215069049|NCT01263431|PROCEDURE|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
215069050|NCT01106651|DRUG|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
215069051|NCT01106651|DRUG|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
214926374|NCT06968871|PROCEDURE|Modified Pap test|For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds.
214325047|NCT06771635|OTHER|concurrent|"The concurrent training program is divided into three types of training: endurance, cardiovascular and neuromotor.~Resistance training sessions were performed in a circuit format with \>30 rest periods between exercises. The volume of work ranged from 8 to 12 repetitions at 60% of the estimated 1 maximum repetition (RM).~The cardiovascular work time per session ranged from 25-50 min depending on the intensity of the exercise and the intensity was regulated according to the maximum heart rate (FHR) estimated for each subject between 60-75%~The neuromotor training intensity of the sessions was low. The participants wore a heart rate monitor and were instructed not to exceed 60% of their HRF"
214325048|NCT06771635|OTHER|Control|Non training intervention
214926375|NCT06967571|PROCEDURE|Jejunal Pouch reconstruction.|The JP will be fashioned with a standard length of 12 cm using two 60 mm staple lines, the esophago-pouch anastomosis will be performed with a circular mechanical 25 mm stapling device, and finally the staple entrance on the pouch will be closed with two layers of running sutures in Vicryl 3/0
214926376|NCT02697526|OTHER|Terumo|
214926377|NCT02697526|OTHER|Tensoplast|
214926378|NCT03775902|DRUG|Placebo|placebo tablet
214926379|NCT03775902|DRUG|Nicorandil|20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)
214926380|NCT01691495|DRUG|Fondaparinux|Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
214926381|NCT04348864|DIAGNOSTIC_TEST|COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|An immunodiagnostic rapid (5-20 minute) test detects circulating antibodies in the blood, serum or plasma of individuals who have been infected with the novel coronavirus SARS-COV-2 as detected by rapid antigen test or LAMP/PCR-based molecular test taken from nasopharyngeal swab samples in the recent past.
214926382|NCT04348864|OTHER|Telemedicine|Imaging of the test using the software application COVIDscanDX and upload to server by the subject and phone, video or messaging consult with a clinician for interpretation and instructions establishes the telemedicine (i.e. virtual point-of-care).
214926383|NCT03382834|DRUG|Tamoxifen|20 mg orally
214926384|NCT03382834|DRUG|Vorinostat|400 mg orally
214325049|NCT06484075|DRUG|Placebo|The placebo will be a tablet, but only containing inert inactive ingredients.
214325050|NCT06484075|DRUG|Suvorexant|Drug approved for improving sleep
214325051|NCT05619692|DRUG|SAGE-718|Softgel lipid capsules.
214325052|NCT05619692|DRUG|SAGE-718-matching Placebo|Softgel lipid capsules.
214325053|NCT05626049|OTHER|Primary Spine Provider Model|Patients with LBP seeking care at intervention clinics will be offered an appointment with a DC or PT at the initial point of contact.
214926385|NCT03382834|DRUG|Antiretroviral drugs|Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
214926386|NCT03220295|DRUG|Single Dose of VU319|Single dose of VU319
214926387|NCT03220295|DRUG|Single Dose Placebo|Single dose of placebo
214325054|NCT05626049|OTHER|Usual Care|Patients in this arm will receive usual care (no change to medical care).Usual care is defined as any care designated by a primary care physician (PCP).
214325055|NCT05277896|DRUG|Ketamine|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation
214325056|NCT05277896|DRUG|Etomidate|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation
214926388|NCT03220295|OTHER|Fed State|drug is given 30 minutes after a high fat breakfast
214325058|NCT04863703|DRUG|Bulevirtide|Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.
214325059|NCT05386043|DRUG|FET F-18|PET scan with FET prior to biopsy
214325060|NCT05386043|DRUG|O-15 Radioisotope|PET scan with O-15 Water prior to biopsy
214325061|NCT05386043|PROCEDURE|CT scan|CT scan prior to biopsy
214926389|NCT03220295|OTHER|Fasted State|drug is given after an overnight fast
214926390|NCT03220295|DRUG|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
214926391|NCT03220295|DRUG|Placebo Dose Escalation|dose levels of the cohorts will be increased step wise
214926392|NCT02387957|DRUG|Fovista®|
214926393|NCT02387957|DRUG|bevacizumab|
214926394|NCT02387957|DRUG|ranibizumab|
214926395|NCT02387957|DRUG|aflibercept|
214926396|NCT02685358|BEHAVIORAL|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.
214926397|NCT02685358|BEHAVIORAL|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
214926398|NCT04150796|PROCEDURE|Ventral Hernia Repair|Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.
214926399|NCT05510115|DRUG|Empagliflozin|Empagliflozin: The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-\[4-chloro-3-\[\[4-\[\[(3S)-tetrahydro-3furanyl\]oxy\]phenyl\]methyl\]phenyl\]-, (1S). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Empagliflozin power will be added in white and bovine origin gelatin capsules. Each capsule of empagliflozin will contain 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
214926400|NCT05510115|DRUG|Placebo|Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
214926401|NCT00065936|DRUG|Naltrexone hydrochloride|
214926402|NCT00065936|PROCEDURE|Transcutaneous sensory nerve stimulation|
214926403|NCT03994133|OTHER|Measurement of the hydration state by bio-impedance spectroscopy|"* The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~* The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.~* The measurement will be done in pre-dialytic"
214926404|NCT06363110|DRUG|Vericiguat (Verquvo, BAY1021189)|Follow clinical practice/administration
214926405|NCT01490879|DRUG|Nexagon® Low Dose|Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
214926406|NCT01490879|DRUG|Nexagon® Medium Dose|Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
214325062|NCT05386043|PROCEDURE|MRI with gadolinium-based contrast|MRI prior to biopsy
214325063|NCT05386043|PROCEDURE|Biopsy Collection|Biopsy collection during standard of care neurosurgery for glioma diagnosis/excision
214325064|NCT06322719|DEVICE|Hyperangulated blade videolaryngoscope|For patients assigned to the Hyperangulated videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
214325065|NCT06322719|DEVICE|Macintosh blade videolaryngoscope|For patients assigned to the Macintosh videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
214325066|NCT03988699|DEVICE|Tinnitus Implant System|Device will deliver stimulation below hearing thresholds continuously or intermittently.
214325067|NCT05998109|DEVICE|PheCheck™|"Quantitative, single-use, rapid test Intended for home-based self-testing and monitoring of PKU.~1 fingerstick specimen collected at each study visit"
214325068|NCT05998109|DIAGNOSTIC_TEST|HPLC Amino Acid Analyzer|1 venous specimen collected at each study visit
214325069|NCT05998109|DIAGNOSTIC_TEST|Dried Blood Spot Cards|capillary blood specimen collected at each study visit
214325070|NCT05472623|DRUG|Adagrasib|Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.
214325071|NCT05472623|COMBINATION_PRODUCT|Adagrasib/Nivolumab|Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.
214325072|NCT04592003|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection
214325073|NCT05297903|DRUG|XmAb20717|10mg/kg IV
214325074|NCT06022939|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Given IV
214325075|NCT06022939|PROCEDURE|Biopsy|Undergo fat pad biopsy
214325076|NCT06022939|PROCEDURE|Biospecimen Collection|Undergo blood and urine specimen collection
214325077|NCT06022939|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214325078|NCT06022939|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214325079|NCT06022939|DRUG|Bortezomib|Given SC
214926407|NCT01490879|DRUG|Nexagon® High Dose|Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
214926408|NCT01490879|DRUG|Nexagon® vehicle|Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
214926409|NCT02034981|DRUG|Crizotinib|"Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.~-250 mg twice daily for adults ≥ 18 years of age~* 280 mg/m² twice daily for children and adolescents aged from 1 to 17 (except ALCL).~* 165 mg/m² twice daily for ALCL patients aged from 1 to 17."
214926410|NCT04722510|DEVICE|repeated transcranial magnetic stimulation|Transcranial magnetic stimulation is a non-invasive brain modulation technique that has proven to be a useful study and treatment tool in neuropsychiatric disorders. This technique allows to increase (with high frequency protocol, \> 1 Hz) or decrease (with low frecuency protocols, 1 hz or less) neuronal excitability in a focused cortical area.
214926411|NCT06253390|BEHAVIORAL|Metacognitive training|Metacognitive training therapy
214926412|NCT06253390|BEHAVIORAL|control|management technique as usual
214926413|NCT05794984|OTHER|Focus group discussions and survey questionnaire|Questions regarding internet and social media usage, as well as telemedicine concept and knowledge. Assessment of the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare. Perceptions for high-quality healthcare access, confidentiality, privacy, and security, will also be explored.
214926414|NCT05245149|DIAGNOSTIC_TEST|Cardiac CTA on a photon-counting detector CT (PCD-CT)|Cardiac CTA will be performed on a dual-source photon-counting CT
214926415|NCT05245149|DIAGNOSTIC_TEST|Cardiac CTA on a regular CT with Energy-Integrating Detector (EID-CT)|Cardiac CTA was performed on a dual-source CT with regular energy-integrating detector (EID-CT)
214926416|NCT00764036|DRUG|artesunate|add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
214926417|NCT03546036|DEVICE|Weighted metal chain blanket|Use of a weighted metal chain blanket of 8 kg
214926418|NCT03546036|DEVICE|Control plastic chain blanket|A blanket with light plastic chains
214926419|NCT03328871|DEVICE|Fractional CO2 Laser|Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.
214926420|NCT03328871|PROCEDURE|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
214926421|NCT03328871|PROCEDURE|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
214926422|NCT04293029|DRUG|SHR0302|SHR0302
214926423|NCT04804670|DEVICE|Power device A|Oral hygiene regimen completed daily
214926424|NCT04804670|DEVICE|Power device B|Oral hygiene regimen completed daily
214926425|NCT04804670|DEVICE|Routine Oral Hygiene|Oral hygiene regimen completed daily
214926426|NCT05808868|OTHER|Screening|"The detailed management is not different from that usually practiced in our department.~Each patient benefits from an ENT consultation where an interrogation is carried out concerning the sleep disorders, the answer to the usual questionnaires screening for sleep disorders, a detailed ENT clinical examination including a nasofibroscopy. Each patient then benefits from a sleep recording by ventilatory polygraph."
214926427|NCT05819086|BEHAVIORAL|Rate Emotional Response|Participants will view their assigned video package, and will be asked to rate their emotional response to the message
214926428|NCT05819086|BEHAVIORAL|Rate Impact of Message|Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.
214926429|NCT02851589|BIOLOGICAL|PCAR-019 (anti-CD19 CAR-T cells)|
214325080|NCT06022939|PROCEDURE|Computed Tomography|Undergo CT scan
214325081|NCT06022939|DRUG|Cyclophosphamide|Given PO or IV
214325082|NCT06022939|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
214325083|NCT06022939|DRUG|Dexamethasone|Given PO or IV
214926430|NCT00355563|DEVICE|PAS-Port Automated Proximal Anastomosis System|
214926431|NCT05410405|PROCEDURE|implant site preparation|piezoelectric bone surgery osseodensification drills
214926432|NCT02570412|DRUG|aldoxorubicin|aldoxorubicin administered at 350 mg/m2
214926433|NCT05063357|DRUG|131I-Omburtamab|Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).
214325084|NCT06022939|PROCEDURE|Echocardiography|Undergo echocardiography
214325085|NCT06022939|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214926434|NCT05063357|DEVICE|Convention Enhanced Delivery|The planned intervention includes surgical placement of a small caliber cannula into the tumor located in the pons using standard stereotactic techniques followed by CED of 131Iomburtamb.
214926435|NCT05421702|PROCEDURE|laparoscopic conventional colectomy|Laparoscopic colectomy with only lymph node dissection up to level 2 lymph nodes D2.
214325086|NCT06022939|DRUG|Melphalan|Given IV
214325087|NCT06022939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
214325088|NCT06022939|PROCEDURE|Stem Cell Isolation|Undergo stem cell collection
214325089|NCT06022939|OTHER|Survey Administration|Ancillary study
214325090|NCT06505590|DEVICE|Educational content|Patients will have access to educational content on the mobile app Resilience © in the format of articles, videos or podcasts on treatment related symptoms and on validated supportive care interventions. This version is currently public available in France and Belgium at www.resilience.care and is considered the control group (education only).
214926436|NCT05421702|PROCEDURE|laparoscopic complete mesocolic excision|Laparoscopic colectomy with lymphovascular dissection from level 3 lymph nodes or more D3.
214926437|NCT01415713|DRUG|S-1,Leucovorin,Oxaliplatin,Gemcitabine|Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
214926438|NCT01665625|PROCEDURE|regional interventional chemotherapy group|The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
214926439|NCT03568370|OTHER|olive oil|Evaluate the effectiveness of olive oil and human milk in the prevention of nipple cracking, nipple pain and maternal satisfaction in lactating women during the first 3 days of treatment and the 7th and 10th day after delivery.
215069052|NCT01106651|DRUG|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.
215069053|NCT01106651|DRUG|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
214325091|NCT06505590|DEVICE|Educational material plus self-management program - self-administered version|Patients will have access to the same mobile app (Resilience ©) with its educational content will be powered with a self-guided fatigue self-management program based on a cognitive behavioral therapy approach.
214325092|NCT06505590|DEVICE|Educational material plus self-management program - guided version with mental health professional|Patients will have access to the same mobile app (Resilience ©) with its educational content and the self-management program of arm 2 and weekly calls with a certified mental health professional certified in cognitive behavioural therapy for guided coaching across the self-management program.
214325093|NCT06425562|OTHER|Full lung function|This includes spirometry, body plethysmography and single breath gas transfer test. These are all non-invasive physiological measurements / lung function tests. Measures flow volumes, lung volumes and gas transfer respectively.
214325094|NCT06425562|OTHER|Multiple breath nitrogen washout|Non-invasive physiological measurement / lung function test. 100% oxygen is inhaled and the nitrogen concentration in the lungs is measured. This test gives information on the ventilation distribution in the lungs.
214325095|NCT06425562|OTHER|Impulse oscillometry|Non-invasive physiological measurement / lung function test. This technique superimposes sound waves on tidal breathing. The patient can breathe normally trough the device, no forced respiratory maneuvers are required. It gives information on the reactance and resistance of the lung.
214926440|NCT00977314|DEVICE|The Sonitus Bone Conduction Hearing System|Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
214926441|NCT00977314|DEVICE|SoundBite|
214325097|NCT01351870|RADIATION|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
214926442|NCT00977314|DEVICE|SoundBite Hearing System|
214926443|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|phase 3 tablets
214926444|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|registration tablets
214926445|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment C)|registration tablets
215069054|NCT00602004|DRUG|losartan|losartan 50 mg a day
214926446|NCT00153543|BIOLOGICAL|PCV7 + PPV23, 2 months|
214926447|NCT00153543|BIOLOGICAL|PCV7 + PPV23, 6 months|
214926448|NCT01658124|DRUG|Tranexamic Acid|
214926449|NCT01658124|DRUG|Placebo|
214325098|NCT01351870|RADIATION|Hyperfractionated Radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
214325099|NCT06388720|DRUG|Mitomycin-C|Intravesical instillation of Mitomycin-c 40 mg in 20 ml as the first agent in sequential treatment.
214325100|NCT06388720|DRUG|gemcitabine|Intravesical instillation of Gemcitabine 2000 mg in 50 ml following Mitomycin-c administration.
214325101|NCT04836429|DRUG|Porfimer Sodium|Given IV
214325102|NCT04836429|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo VATS
214325103|NCT04836429|DRUG|Photodynamic Therapy|Undergo photodynamic therapy
214325104|NCT04836429|DEVICE|Intraoperative PDT|Subjects will receive one course of light therapy at the time of surgery
214926450|NCT01752881|BIOLOGICAL|Influenza vaccine (split virion, inactivated)|"AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013~Dosage: 0.5mL/per syringe~Administration route: Intramuscular Injection, once"
214325105|NCT01946204|DRUG|Apalutamide|240 mg tablets administered by mouth on a continuous once daily dosing regimen
214325106|NCT01946204|DRUG|Placebo|Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
214325107|NCT03466411|DRUG|Guselkumab Dose 1|Guselkumab will be administered by IV infusion.
214325108|NCT03466411|DRUG|Guselkumab Dose 2|Guselkumab will be administered by SC injection.
214325109|NCT03466411|DRUG|Guselkumab Dose 3|Guselkumab will be administered by IV infusion.
214325110|NCT03466411|DRUG|Guselkumab Dose 4|Guselkumab will be administered by IV infusion.
214325111|NCT03466411|DRUG|Guselkumab Dose 5|Guselkumab will be by SC injection.
214325112|NCT03466411|DRUG|Guselkumab|Guselkumab will be administered by IV infusion and SC injection.
214325113|NCT03466411|DRUG|Ustekinumab|Ustekinumab will be administered by IV infusion and SC injection.
214325114|NCT03466411|DRUG|Placebo|Placebo will be administered as IV infusion.
214325115|NCT04932590|OTHER|End-expiratory occlusion test|The test consists in interrupting the ventilator at end-expiration for 15 seconds and assessing the resulting changes in cardiac output. Delays necessary to allow sufficient pulmonary transit time to allow good pulmonary venous return and therefore an increase in cardiac preload.
214673023|NCT06969716|OTHER|Detailed geriatric assessment|The demographic characteristics of the patients, comorbid diseases, history and number of falls in the last 6 months will be questioned, and the thyroid stimulating hormone, calciferol, cobalamin, glycosylated hemoglobin, folic acid and glomerular filtration rate levels routinely requested from each patient in the last 3 months will be recorded. During the outpatient clinic application, the patients will undergo neurocognitive assessment, mood assessment, daily living activities assessment, balance and walking assessment, nutritional assessment and frailty assessment. The patients' handgrip strength from their dominant hand will be assessed with a hand dynamometer. The walking speed of the patients will be measured as the number of seconds it takes to walk 4 meters and recorded in seconds. All patients will be questioned about the presence of body pain with the numerical pain scale score and all patients will be evaluated for the presence of fibromyalgia syndrome.
214926451|NCT01752881|BIOLOGICAL|AdimFlu-S|
214926452|NCT01343277|DRUG|Trabectedin|Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
214926453|NCT01343277|DRUG|Dacarbazine|Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
214926454|NCT02344251|DEVICE|MEMS Cap|MEMS Track Cap records when the medication bottle is opened and closed
214926455|NCT02344251|DEVICE|ID-Cap|ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
214926456|NCT03264924|BEHAVIORAL|IPAIR|Motivational interview training
214926457|NCT04982354|DRUG|CPX-351|For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.
214325116|NCT03778931|DRUG|Elacestrant|400 mg/day once daily oral dosing
214325117|NCT03778931|DRUG|Standard of Care|"* Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle~* Anastrozole 1 mg/day on a continuous dosing schedule~* Letrozole: 2.5 mg/day on a continuous dosing schedule~* Exemestane: 25 mg/day on a continuous dosing schedule"
214325118|NCT06444646|OTHER|Adipose tissue biopsy|From each patient, two biopsies will be taken during surgery; one from the subcutaneous and one from the visceral adipose tissue.
214325119|NCT06444646|OTHER|Blood sampling|From each patient, two venous blood samples (citrate, LiHe and EDTA plasma) will be taken before surgery.
214325120|NCT06444646|OTHER|Questionnaire|Before bariatric surgery, every patient will fill out questions about general health (physical activity, sedentary behavior, sleeping pattern, ...), physical condition before surgery (nausea, food intake, ...), etc.
214325121|NCT06444646|OTHER|Patient phenotyping|Length and weight will be measured to calculate body mass index (BMI). Waist and hip circumference will be assessed, as well as blood pressure (both systolic and diastolic) and heart rate at rest. Body composition will be determined using a bioelectrical impedance analysis (BIA) in the hospital. Medication use and comorbidities (that are allowed within the in-/exclusion criteria) will also be derived from the patient's medical files with patient's permission.
214325122|NCT05265611|BEHAVIORAL|low intensity psychosocial intervention - Problem Management Plus (PM+)|Syrian refugee young adults will be trained to implement Problem Management Plus (PM+). PM+ is a low-intensity mental health intervention, developed by WHO, and delivered by non-specialized CMHW. It is a transdiagnostic treatment approach that includes four evidence-based problem solving and behavioral treatment techniques: managing stress, managing problems, get going/get doing, and social support. These strategies are implemented over five weekly sessions, of 90 minutes each.
214926458|NCT04982354|DRUG|Midostaurin|The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.
214486095|NCT06876818|OTHER|Evaluation of transcriptomic and cardio-metabolic profiles|The parameters and variables collected in 2006-2007 (T0) will be re-evaluated at the follow-up visit (T1), including demographic, anthropometric, lifestyle data (smoking habit, physical activity, sleep quality) blood pressure, standard biochemical analysis and inflammatory profile. To assess the evolution of glucose tolerance and vascular damage, metabolic (OGTT) and cardiovascular (carotid ecodoppler) profile analyses will be repeated. For gene expression analyses, in addition to messenger RNA from PBMCs (as at T0), RNA from PBMC-derived monocytes will also be extracted and sequenced at T1.
214673024|NCT06969508|OTHER|core stabilitation exercises|The core stabilization exercise program aimed to strengthen deep spinal muscles: transversus abdominis (abdominal bracing), multifidus (segmental stability), and pelvic floor muscles (pelvic support). Participants received videotaped instructions for performing these exercises at home regularly for 6 months, with a gradual increase in difficulty.
214673025|NCT06339424|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
214673026|NCT06339424|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
214673027|NCT06339424|RADIATION|Photon radiotherapy|"* 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
214673028|NCT04978753|DRUG|Anlotinib|"1. Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week;~2. Almonertinib: 110mg, orally once a day;"
214673029|NCT04219137|GENETIC|Molecular Profiling|This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.
214673030|NCT05395416|DRUG|HEC74647PA+HEC110114|administered orally once daily for 12 weeks
214926459|NCT04982354|DRUG|Busulfan|0.8 mg/kg/dose every six hours x 12 doses administered intravenously
214926460|NCT04982354|DRUG|Melphalan|70 mg/m2/day x 2 doses administered intravenously
214926461|NCT04982354|DRUG|Fludarabine|25 mg/m2/day x 5 doses administered intravenously
214926462|NCT04982354|BIOLOGICAL|CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor|Allogeneic stem cell transplant infused intravenously
214325123|NCT05265611|BEHAVIORAL|Tutoring|Young adults will be trained to tutor students in elementary school.
214325124|NCT05454501|OTHER|Exercise Training|For eight weeks, they will receive real-time online exercise training for 30 minutes, three days a week, with a peer group of 5-6 people. Before starting the exercise, physical activity will be monitored for seven days.
214325125|NCT05454501|OTHER|Patient Education|After the first face-to-face evaluation session, these patients and their families will receive a 1-hour patient education program specific to the disease and exercise. Information brochures containing physical activity and exercise recommendations will be given. They will be followed up with weekly phone calls throughout the study period. At the end of 8 weeks, the second evaluation interview will be held. Afterward, the patients in the control group will be able to participate in the online exercise training program if they request it.
214325126|NCT06120491|DRUG|Saruparib|Oral
214325127|NCT06120491|DRUG|Placebo|Oral
214325128|NCT06120491|DRUG|Abiraterone Acetate|Oral
214325129|NCT06120491|DRUG|Darolutamide|Oral
214325130|NCT06120491|DRUG|Enzalutamide|Oral
214486096|NCT06879587|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants could take BC99 daily and record any adverse reactions. Participants filled out questionnaires and collected stool and serum samples, which were used to detect and analyze the improvement of participants' constipation function.
214325131|NCT06033144|DIAGNOSTIC_TEST|Diagnosis of Tapia's Syndrome|"The diagnostic includes :~* Lingual clinical examination~* Nasofibroscopy~* Ultrasonography"
214325132|NCT05256069|DRUG|Propranolol Pill|Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).
214325133|NCT05256069|DRUG|Placebo|Participants will receive a placebo in pill form.
214325134|NCT06506461|DRUG|Plerixafor|Given Subcutaneous (under the skin)
214325135|NCT06506461|DRUG|Busulfan|Given Intravenous (IV)
214325136|NCT06506461|BIOLOGICAL|Gene-modified CD34+ cells|Given Intravenous (IV)
214486097|NCT06879587|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants could take maltodextrin daily and record any adverse reactions. Participants filled out questionnaires and collected stool and serum samples, which were used to detect and analyze the improvement of participants' constipation function.
214673031|NCT05395416|DRUG|Placebo|administered orally once daily for 12 weeks
214926463|NCT02078453|PROCEDURE|Dental treatment|Dental treatment of all dental needs present in the children related or not to the dental caries.
214926464|NCT04435977|DRUG|Cabozantinib 60 MG|"• The assigned dose for study treatment is 60 mg qd. Two dose reductions will be permitted (Table 2):~* 60 mg qd to 40 mg qd (level 1)~* 40 mg qd to 20 mg qd (level 2)"
214926465|NCT00798343|BIOLOGICAL|Seasonal vaccine|Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
214926466|NCT00798343|BIOLOGICAL|H5 vaccine|MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
214926467|NCT04588051|DRUG|Cabozantinib|60mg daily
214325137|NCT06506461|DRUG|Motixafortide|Given Subcutaneous (under the skin)
214325138|NCT02115282|PROCEDURE|Biospecimen Collection|Undergo collection of blood and archived tissue samples
214325139|NCT02115282|PROCEDURE|Computed Tomography|Undergo CT
214325140|NCT02115282|DRUG|Entinostat|Given PO
214325141|NCT02115282|DRUG|Exemestane|Given PO
214926468|NCT02901119|DIETARY_SUPPLEMENT|Whey protein|Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.
214325142|NCT02115282|DRUG|Goserelin|Given PO
214926469|NCT06060990|OTHER|trace elements|trace elements as biomarkers for response to systemic therapy in metastatic BTCs
214926470|NCT04310709|DRUG|Regorafenib/Nivolumab|Combination of regorafenib and nivolumab
214926471|NCT04563533|BIOLOGICAL|Low-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 12.5μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 1 μg, sodium dihydrogen phosphate: 47 μg, disodium hydrogen phosphate: 87 μg."
214926472|NCT04563533|BIOLOGICAL|High-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 25μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg."
214926473|NCT04563533|BIOLOGICAL|Placebo (containing aluminum)|Active ingredients: none Other ingredients: aluminum hydroxide adjuvant: 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
214926474|NCT04563533|BIOLOGICAL|Placebo (without aluminum)|Active ingredients: none Other ingredients: L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
214926475|NCT06969352|DRUG|Vorasidenib|"Treatment group: recommended dosage in adults and paediatric patients 12 years of age and older:~* For patients weighing at least 40 kg: 40 mg, orally, once daily.~* For patients weighing less than 40 kg: 20 mg, orally, once daily."
214926476|NCT01926613|BEHAVIORAL|Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and supported employment services.
214926477|NCT01926613|BEHAVIORAL|Supported Employment|Supported Employment is an evidence based vocational rehabilitation program
214926478|NCT02308423|RADIATION|XR of shoulder|Radiologic examination: Axial view, Axillary view and Anterior posterior view- to evaluate the level of osteoarthritis by Kellgren Lawrence score and Samilson score.
214926479|NCT06513013|PROCEDURE|transversus abdominis plane (TAP) block in cesarean section|.an intravenous (IV) access will be secured . Standard ASA monitoring will be instituted which include(SpO2), ECG and (NIBP) . At the end of surgery , a bilateral USG-guided TAP block will be carried out under strict aseptic precautions, and 20 mL of study solution was injected into each side. After draping the abdominal region between the 12th rib and anterior superior iliac crest with the umbilicus in the center, the external oblique muscle, internal oblique muscle, transversus abdominis muscle , and their fascia will be located beneath the skin and subcutaneous tissue using a linear high-frequency probe 6-13 Megahertz of the SonoSite Micromax machine. A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered.
214926480|NCT06513013|DRUG|Magnesium sulfate|25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 250 mg of MgSO4) to keep the total volume the same in both group
215069055|NCT05875636|OTHER|Esophagogastroduodenoscopy|All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.
215069056|NCT04599023|DEVICE|MSPT|The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
215069057|NCT00190021|DRUG|donepezil|
215069058|NCT00151684|DRUG|Diazoxide|
215069059|NCT01127464|DRUG|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
215069060|NCT01127464|DRUG|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
214325143|NCT02115282|DRUG|Goserelin Acetate|Given SC
214325144|NCT02115282|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214325145|NCT02115282|OTHER|Placebo Administration|Given PO
214325146|NCT02115282|OTHER|Quality-of-Life Assessment|Ancillary studies
214325147|NCT05149755|DEVICE|Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)|Patients will have a Transcatheter Aortic Valve Replacement (TAVR) with either an Evolut PRO+ TAVR, or Evolut FX TAVR, heart valve, and given clinical site-determined guideline-directed management and therapy (GDMT).
214325148|NCT06468111|BEHAVIORAL|Animal Assisted Therapy|Blood and dental extraction will be performed according to the usual protocol of the health center in both groups; with the additional assistance of the therapy dog in experimental group.
214325149|NCT02610855|PROCEDURE|Spinal Fusion Surgery|Participants with severe scoliosis curves requiring spinal fusion surgery.
214325150|NCT02610855|OTHER|Bracing|Participants with scoliosis curves that require brace treatment for at least the next year. Braces include monitors to record hours of brace wear, as is current standard of care.
214325151|NCT02610855|DEVICE|Tri-axial Accelerometers|Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
214325152|NCT02610855|OTHER|Shear Wave Elastography (SWUE)|SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
214325153|NCT06457373|PROCEDURE|Demineralized Dentin Allograft|20 sockets are randomly allocated to receive the Demineralized Dentin Allograft (split-mouth study)
214325154|NCT06457373|PROCEDURE|Demineralized Dentin Autograft|20 sockets are randomly allocated to receive the Demineralized Dentin Autograft (split-mouth study)
214926481|NCT06513013|DRUG|Neostigmine|"25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 500 mcg neostigmine.~A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered. Following the affirmation of a hypoechoic region on the USG image, the study solutions will be injected as per group allocation. Postoperatively,both groups of patients received an injection of paracetamol 1gm intravenously every 8th hourly as a part of multimodal analgesia and the patients will be evaluated for pain, nausea or vomiting in the post anaesthesia care unit at time 0 (time of completion of TAP block), 2, 4, 6,12 and 24 h by an investigator blinded to the group assignment. Whenever the NRS \>4, Nalbuphine 0.1 mg/kg IV will be administered as a rescue analgesic."
214926482|NCT02838914|PROCEDURE|radiofrequency ablation (RFCA)|Patients undergo radiofrequency ablation (RFCA)
214926483|NCT05545514|DRUG|One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,|To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
214926484|NCT03127735|DRUG|BAY1436032|"BAY1436032 administered continuously as a single agent dosed twice a day orally on Days 1 to 28 of a 28-day cycle.~Patients may continue treatment with BAY1436032 until disease progression, development of other unacceptable toxicity or Investigator discretion."
214926485|NCT02482714|BEHAVIORAL|Physical activity.|Have subject do moderate physical activity.
214926486|NCT06419543|DRUG|Remimazolam|Observe the incidence of paradoxical reactions after the first induction.
214926487|NCT01101945|DRUG|dutogliptin|400 mg QD
214325155|NCT04515459|OTHER|Surgical prehabilitation program.|"This programme will include the practice of general physical activity and the implementation of nutritional and psychological support.~Each patient will have 8 Oncorehabilitation Transdisciplinary Evaluations (OTE):~* 2 OTE will be performed before the surgery,~* 6 OTE will be performed after the surgery.~During the program (at each OTE), patients will also be asked to complete the QLQ-C30 questionnaire."
214486098|NCT06875856|OTHER|Kendall exercises|"1. Positioning supine with the chin tucked in and lifting the head for 2 to 8 sec to strengthen deep cervical flexors.~2. Maintaining a sitting posture, with hands on the occipital region, and flexed spine while moving head downwards to stretch cervical extensors, maintaining an upright posture.~3. Keep the resistance band circling with strong support and stretching it with the upper limbs of both sides so that there is full retraction of the scapula to strengthen retractors of the shoulder.~4. Stretching the pectoralis major and minor while keeping the patient's hands-on the occipital region and standing behind the patient and pulling both elbows backward to target the bilateral pectoralis muscles"
214673032|NCT04491279|PROCEDURE|Home 'General' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the general exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
214926488|NCT00288600|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin
214926489|NCT00288600|DRUG|Normal saline solution|Normal saline solution 10 ml/Kg
214926490|NCT05727566|OTHER|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
214926491|NCT01654120|DRUG|Liraglutide|SC, 1.8mg,QD, six months to one year
214926492|NCT01654120|DRUG|Insulin|SC, will be titrated during the study, 4 times a day, 1 year
215069061|NCT01127464|DRUG|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
215069062|NCT03397394|DRUG|Rucaparib|Rucaparib will be administered daily.
215069063|NCT05382468|OTHER|Intradialytic exercise|Intradialytic exercise comprised of a set warm up, aerobic, active,passive \& cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month \& supervised by principle investigator.
215069064|NCT00543933|DRUG|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
215069065|NCT03730233|PROCEDURE|Hiatal hernia repair by tension-free mesh closure|
215069066|NCT03730233|PROCEDURE|Hiatal hernia repair by simple suturing|
215069067|NCT00703274|BEHAVIORAL|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
215069068|NCT00613327|DRUG|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
215069069|NCT00386750|DRUG|Artemether-lumefantrine|
215069070|NCT04679506|DRUG|Cladribine|CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL
215069071|NCT02745678|DRUG|Thermosensitive gel rectal formulation|
215069072|NCT04351399|OTHER|questionnaire assesment|The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine
214325156|NCT03887481|DEVICE|"High-definition active tDCS (HD-tDCS) + Repeat After Me (RAM) Treatment"|"Device: Active HD-tDCS \& Repeat After Me (RAM) Treatment~Stimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L\_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
214325157|NCT03887481|DEVICE|"Sham + Repeat After Me (RAM) Treatment"|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
214926493|NCT05938660|OTHER|acupressure at Sanyinjiao point|When pressing Sanyinjiao point, the subject should be in a comfortable sitting position. Press the acupoints with the thumb until the subject feels soreness, then press and knead in a circle according to the strength acceptable to the subject. Press and knead once a second, and rest for 1 second every 5 seconds are one cycle, the speed is 10 cycles/minute, and it lasts for five minutes.
214926494|NCT06612242|PROCEDURE|early tracheostomy (less than 7 days from intubation)|Early tracheostomy (less than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome
214926495|NCT06612242|PROCEDURE|Late tracheostomy (more than 7 days from intubation)|Late tracheostomy (more than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome
214926496|NCT04365504|DIAGNOSTIC_TEST|Dual energy X ray absorbtiometry|The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.
214926497|NCT03600194|DEVICE|PowerSleep Stim|The PowerSleep Stim device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. Soft audio tones (below 65dB) will be administered via the speakers system during deep sleep as determined by the functionality of the device. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
215069073|NCT00565162|DRUG|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
214325158|NCT04583761|BEHAVIORAL|questionnaire|Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
214325159|NCT04184674|OTHER|Pneumotachograph|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
214325160|NCT04184674|OTHER|Esophageal catheter|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
214325161|NCT04184674|OTHER|Transthoracic and / or transesophageal cardiac ultrasound|"The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
214325162|NCT04184674|OTHER|Electrical impedance tomography (EIT) for pediatric patients|For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
214325163|NCT06541457|DRUG|HRS-7249 injection|6 subjects for HRS-7249 injection
214325164|NCT06541457|DRUG|Placebo|2 subjects for placebo
214325165|NCT06540066|DRUG|BGB-B3227|Administered intravenously.
214325166|NCT06540066|DRUG|Tislelizumab|Administered intravenously.
214325167|NCT06540066|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
214325168|NCT05518045|DRUG|LM-108|Administered intravenously
214325169|NCT05518045|DRUG|Toripalimab|Administered intravenously
214325170|NCT06237309|DRUG|REGN5381|Single dose intravenous (IV) infusion
214325171|NCT06237309|DRUG|Placebo|Single dose IV infusion
214325172|NCT06015880|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214325173|NCT06015880|PROCEDURE|Computed Tomography|Undergo PET/CT
214325174|NCT06015880|DRUG|Lenalidomide|Given PO
214325175|NCT06015880|BIOLOGICAL|Mosunetuzumab|Given IV
214325176|NCT06015880|DRUG|Polatuzumab Vedotin|Given IV
214325177|NCT06015880|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214486099|NCT06875856|OTHER|Cailliet exercises|The intervention of group B will include baseline treatment, followed by maneuvers, including: Neck Cailliet exercise using isometric contractions against the prisoner to the maximum that ends with relaxation and continued with stretching. Each posture was maintained for 30 s and 3 sets of 10 repetitions were performed with 3 sessions per week on alternate days for 4 weeks.
214673033|NCT04491279|PROCEDURE|Home 'Neuropilates' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the neuropilates exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
214926498|NCT03600194|DEVICE|Northwestern Stim|The Northwestern Stim Device will function similarly to the PowerSleep device, but stimulation will be provided using a standard PC (computer) setup at the bedside using standard PSG electrodes. EEG will be monitored and slow wave sleep (SWS) identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves and to control acoustic stimulation in a phase-locked manner (targeting the up phase of the slow wave). Acoustic stimulation will be provided by headphones with an audible soft volume that do not result in arousals.
214926499|NCT03600194|DEVICE|PowerSleep Sham|The PowerSleep Sham device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. There are no audio tones played in the Sham condition. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
214926500|NCT03600194|DEVICE|NorthWestern Sham|The Northwestern Sham device is set up will function similarly to the PowerSleep prototype. EEG will be monitored and SWS identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves. Participant will wear headphones but no audio tones played in the Sham condition.
214325178|NCT06113419|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed using the standard American 4-port technique, insufflation will be achieved using CO2 to 15mmHg of pressure. Calot's triangle will be dissected until the critical view of safety is reached, being careful to dissect above the R4U line. After reaching the critical view of safety, two proximal and one distal clip will be placed on both the cystic conduct and artery separately, cutting the clips and then dissecting the gallbladder in a cystfundic direction. When the critical view of safety is not reached, the surgeon may perform a fundus-first cholecystectomy, subtotal cholecystectomy, conversion to open procedure, intraoperative cholangiography or cholecystostomy to their own discretion. It will also be the surgeon's criteria to employ or not a drain system in the surgical site. The decision for theses interventions will be taken intraoperatively and will be according to findings during the procedure.
214673034|NCT04491279|PROCEDURE|Supervised Neuropilates Group Class|Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (a chartered physiotherapist who is also a pilates instructor).
214673035|NCT04491279|PROCEDURE|Supervised General Exercises Group Class|Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility
214673036|NCT02845869|DEVICE|THOR Laser LX2 System|Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
214673037|NCT02845869|DEVICE|Sham Therapy|The therapeutic light will be turned off but the system will produce similar noises and mild heat.
214673038|NCT03013595|BEHAVIORAL|TRAM feedback|
214673039|NCT01363843|DRUG|FOLFOX6|FOLFOX6
214673040|NCT01363843|RADIATION|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
214926501|NCT06618079|DRUG|HUC2-565-A, HUC2-565-A and HUC2-565-B|Cohort A received HUC2-565-A for 5 days, followed by HUC2-565-A and HUC2-565-B for 9 days.
214926502|NCT06618079|DRUG|HUC2-565-B, HUC2-565-A and HUC2-565-B|Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.
214926503|NCT02913404|PROCEDURE|ACL Reconstruction|standard surgical procedure
214926504|NCT02913404|PROCEDURE|ACL Recon. extra-articular-tenodesis|standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
214926505|NCT01585662|PROCEDURE|EUS-guided pancreatic pseudocyst drainage|EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.
214926506|NCT06254001|DRUG|Bupropion|Bupropion will be added at doses of 150 mg to 300 mg per day in addition to nicotine replacement therapy, counseling and cognitive behavioral therapy
214926507|NCT06254001|DRUG|Nicotine replacement therapy (Nicotine patches)|Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy
214926508|NCT01582178|PROCEDURE|Warm Water Immersion Colonoscopy|Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
214926509|NCT01582178|PROCEDURE|Cool Water Immersion Colonoscopy|Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
214325179|NCT05012813|OTHER|Aromatherapy with Essential Oils|Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
214926510|NCT04110561|DEVICE|Use of the Atalante exoskeleton|A session basically includes a stand up, walks over a distance of 10 meters, exercises, U-turns and a sitting
214926511|NCT00045370|BIOLOGICAL|recombinant interferon alfa|
214926512|NCT00045370|DRUG|temsirolimus|
215069074|NCT03203824|DIETARY_SUPPLEMENT|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
215069075|NCT03203824|OTHER|non dark chocolate|No dark chocolate will be given to this group during the procedures.
215069076|NCT02286804|DEVICE|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
214325180|NCT05984277|DRUG|Volrustomig|Volrustomig
214325181|NCT05984277|DRUG|Pembrolizumab|Pembrolizumab
214325182|NCT05984277|DRUG|Carboplatin|Carboplatin
214325183|NCT05984277|DRUG|Paclitaxel|Paclitaxel
214325184|NCT05984277|DRUG|Pemetrexed|Pemetrexed
214325185|NCT05388669|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
214325186|NCT05388669|DRUG|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Amivantamab injection will be administered subcutaneously by manual injection.
214325187|NCT05388669|DRUG|Amivantamab Intravenous|Amivantamab will be administered by IV infusion.
214325188|NCT06267625|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, cough strength, functional mobility and hand grip strength.They will be asked to answer the Standardized Mini Mental Test, Modified Medical Research Council Scale, Physical Activity Scale for the Elderly, Berg Balance Scale. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
214325189|NCT05705258|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
214325190|NCT06329102|PROCEDURE|Surgical access|Complications by Clavien Dindo Number of lymph nodes. Disease free and Overall survival
214325191|NCT06082102|DRUG|Orelabrutinib|Orelabrutinib Tablets
214325192|NCT06082102|DRUG|Rituximab|Rituximab Injection
214325193|NCT06082102|DRUG|Lenalidomide|Lenalidomide Capsules
214325194|NCT06082102|DRUG|Rituximab|Rituximab Injection
214325195|NCT03431350|DRUG|Niraparib 200 mg|Participants will receive niraparib 200 mg orally.
214325196|NCT03431350|DRUG|Cetrelimab 240 mg|Participants will receive cetrelimab 240 mg IV every 2 weeks.
214325197|NCT03431350|DRUG|Cetrelimab 480 mg|Participants will receive cetrelimab 480 mg IV every 4 weeks.
214325198|NCT03431350|DRUG|Abiraterone acetate 1000 mg|Participants will receive AA 1000 mg orally.
214325199|NCT03431350|DRUG|Prednisone 5 mg|Participants will receive prednisone 5 mg orally.
214325200|NCT04989946|DRUG|Degarelix|standard Gonadotropin-releasing hormone (GnRH) antagonist
214673041|NCT01363843|PROCEDURE|Surgery|
215069077|NCT00118248|DRUG|tanespimycin|Given IV
215069078|NCT02574884|PROCEDURE|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
215069079|NCT01255176|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
215069080|NCT02704975|DEVICE|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
214325201|NCT04989946|BIOLOGICAL|pTVG-AR|DNA vaccine encoding androgen receptor ligand-binding domain
214325202|NCT04989946|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
214325203|NCT04989946|DRUG|Cemiplimab|Cemiplimab is a human PD-1 blocking antibody approved for the treatment of patients with non-small cell lung cancer, cutaneous squamous cell carcinoma, and locally advanced basal cell carcinoma.
214325204|NCT04989946|DRUG|Fianlimab|Lymphocyte activation gene-3 (LAG-3) is a protein that is upregulated on activated CD4+ and CD8+ T cells following T-cell receptor engagement. Binding of LAG-3 to MHC II on professional antigen-presenting cells suppresses the proliferation, activation, and cytokine secretion of T cells. Fianlimab is a human IgG4 antibody to lymphocyte activation gene-3 (LAG-3) that blocks LAG-3/MHC II-mediated T-cell inhibition.
214325205|NCT04989946|DRUG|FLT PET/CT|Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43
214325206|NCT02147808|DRUG|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
214325207|NCT02147808|DRUG|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup \[2mg/mL\]).
214325208|NCT00243516|DEVICE|PREtest Consult|
214325209|NCT04568252|DEVICE|Wristband with millimeter wave emission.|Wristband treatment with millimeter wave emission twice a day for 3 months.
214325210|NCT04568252|DEVICE|Placebo of wristband with millimeter wave emission.|Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
214325211|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
214325212|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
214325213|NCT04774510|OTHER|Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography|Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
214325214|NCT05390203|DIAGNOSTIC_TEST|Penile duplex study, Hormonal Assay (Total Testosterone, Prolactin and E2)|we will do penile duplex and hormonal profile preoperatively and 6 months postoperatively.
214325215|NCT00279565|DRUG|buprenorphine|
214325216|NCT00279565|DRUG|methadone|
214325217|NCT00279565|DRUG|pegylated interferon alfa-2b plus ribavirin|
214673042|NCT02708212|PROCEDURE|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
214325218|NCT05183685|PROCEDURE|telecare consultation|Participants will use zoom to communicate with the doctors in clinic.
214325219|NCT05183685|PROCEDURE|Usual face to face consultation|Participants will have face-to-face communication with the doctors in clinic.
214325220|NCT05950581|DEVICE|Modified Twin-Block Appliance with Clear Plates.|Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily
214325221|NCT05950581|DEVICE|Traditional Twin-Block appliance|Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
214325222|NCT05864274|DEVICE|Cognitive training application|Patients will participate with a cognitive training application and undergo neurocognitive testing during and after chemotherapy.
214325223|NCT04325828|DRUG|Apalutamide|Apalutamide 240 mg (4\*60-mg tablets) will be administered orally once daily with or without food.
214325224|NCT04325828|DRUG|GnRH Agonist|A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.
214325225|NCT06731218|BIOLOGICAL|RGB-5088|Transplantation under the anterior rectus sheath
214325226|NCT05754684|BIOLOGICAL|Natural killer cell|Natural killer cells isolated from HLA-haploidentical relative donor
214325227|NCT05754684|DRUG|Dinutuximab beta|Dinutuximab beta iv for 5 days
214325228|NCT05754684|DRUG|Interleukin-2|Interleukin-2 sc alternate day for 6 doses
214325229|NCT05754684|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|Granulocyte-macrophage colony-stimulating factor sc daily till ANC \>2,000/mm3
214325230|NCT05754684|DRUG|Spironolactone|Spironolactone po three time daily
214325231|NCT05754684|DRUG|Naxitamab|Naxitamab iv for 4 days (as alternative for dinutuximab)
214325232|NCT04127578|BIOLOGICAL|LY3884961|Participants will receive a single dose of LY3884961, administered intra-cisterna magna
214325233|NCT04127578|DRUG|Methylprednisolone|6 IV pulses administered as concomitant medication over 3 months
214325234|NCT04127578|DRUG|Sirolimus|Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
214325235|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, 10 Hz condition|10 Hz (2,000 pulses) at left DLPFC
214325236|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, Sham condition|sham
214325237|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, iTBS condition|50 Hz, iTBS (600 pulses) at left DLPFC
214325238|NCT02026115|BEHAVIORAL|PAINReportIt|PAINReportIt is a software program developed with an electronic McGill Pain Questionnaire (MPQ) and now includes questions about analgesics used by patients and a shortened version of the pain Barriers Questionnaire (BQ). It is designed as an interactive, touch screen way to assess pain. It can be self-administered and requires little or no patient computer experience and little or no provider time. The patient can read instructions on-screen and practice all types of selection responses found the program. Directions from the paper tools were modified to address the touch screen method of recording responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both individuals authorized the modifications, format, and computerized use of the tools.
214325239|NCT02026115|BEHAVIORAL|PAINConsultN|PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
214325240|NCT02026115|BEHAVIORAL|PAINUCope|We tested the PAINUCope piece of the intervention in 3 completed studies. PAINUCope is a multimedia, computer generated tool that gives tailored information to overcome patients' misconceptions about pain and help them engage in activities that help reduce their pain. PAINUCope focuses on 2 crucial aspects of pain management: 1) reporting cancer pain and 2) safe and effective use of pain medicines. The educational materials are written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt guide the specific information shared via PAINUCope.
214926513|NCT04092946|DEVICE|Digital intervention|"Individuals included will be offered a program based on three pillars: education, cognitive-behavioural therapy (CBT) and therapeutic exercise.~The therapeutic exercise component will be delivered in the form of exercise sessions to be performed independently by the individual at home using SWORD Phoenix. These programs will have a duration of between 8 and 12 weeks, according to the condition, following pre-defined protocols. These protocols can be adapted to the needs, performance and progress of each individual by their assigned physical therapist. Individuals will be asked to perform at least 3 exercise sessions per week, in different days, but will not be excluded in case of lower adherence.~In addition to the exercises, the individuals will also have access to educational articles written by the clinical team, as well as to a CBT program delivered through a combination of written articles and pre-recorded audio sessions."
214926514|NCT06362993|OTHER|Bundling|Education on and screening for diabetes and hypertension offered together with education and screening for breast cancer.
215069081|NCT02704975|DEVICE|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
215069082|NCT04445207|BIOLOGICAL|Convalescent Plasma|One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.
215069083|NCT03540589|DEVICE|Buzzy specific vibration device|It is a device that produces vibration
215069084|NCT03540589|BEHAVIORAL|Distraction|The distraction will be obtained through tablet with videos
215069085|NCT03652363|DRUG|glial cell line-derived neurotrophic factor|Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
214325241|NCT02219815|BEHAVIORAL|Prehab Intervention|Pre-operative, structured exercise intervention.
214325242|NCT05160337|DIAGNOSTIC_TEST|Biomarker based IVD tests|Biomarker based IVD tests
214325243|NCT04602624|DRUG|SAGE-718|SAGE-718 oral tablets.
214486100|NCT06878196|DRUG|cadonilimab combined with cisplatin-based chemotherapy ± bevacizumab|Patients with persistent, recurrent, or advanced metastatic cervical cancer who have not received systemic treatment are treated with cadonilimab combined with cisplatin-based chemotherapy ± bevacizumab (treatment dosage: cadonilimab 10 mg/kg, paclitaxel 175 mg/m\^2, cisplatin 50 mg/m\^2, cisplatin AUC 4-5, bevacizumab 7.5-15 mg/kg), once every 3 weeks, for a total of 6 cycles (if the patient continues to benefit, chemotherapy is allowed beyond 6 cycles), followed by maintenance treatment with cadonilab ± bevacizumab.
214486101|NCT06877728|OTHER|Neck isometric exercises: 3 times weekly for 6 consecutive weeks (18 sessions)|Neck isometric exercises: 3 times weekly for 6 consecutive weeks (18 sessions) Duration: 10 to 15 repetitions with 3 sets, and 6 sec hold in flexion, extension and side flexion on both right and left.
214486102|NCT07032714|DRUG|Talquetamab|Talquetamab is injected under the skin (subcutaneously injected) by trained medical staff. During first cycle of talquetamab, the dose of talquetamab will increase until the goal dose (treatment dose) is reached (pre-determined dose escalation).
214486103|NCT07032714|DRUG|Mezigdomide|Administered orally once per day (days 1-21 of applicable 28-day cycles; Days 1-7 of the 7-day Cohort B pre-phase cycle).
215069086|NCT02607475|DEVICE|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
215069087|NCT02607475|DEVICE|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
214325244|NCT04754282|OTHER|Position of labouring women for epidural analgesia catheter placement : Traditional Sitting Position (TSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
214325245|NCT04754282|OTHER|Position of labouring women for epidural analgesia catheter placement : Cross-legged Sitting Position (CSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
214325246|NCT04084769|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: IM
214325247|NCT04084769|BIOLOGICAL|Meningococcal Group B vaccine (Trumenba®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
214325248|NCT04084769|BIOLOGICAL|Meningococcal group B vaccine (Bexsero®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
214325249|NCT03492177|DRUG|selexipag (Uptravi)|Film-coated tablets for oral administration
214325250|NCT03527420|OTHER|Exercise training|Twelve weeks of aerobic exercise training
214325251|NCT03546686|DRUG|Pembrolizumab|Pembro will be administered 1-20 days before the cryoablation date per SOC and q3 weeks after surgery for 9 cycles per SOC.
214325252|NCT03546686|PROCEDURE|Core Biopsy/Cryoablation|US-guided core biopsy and cryoablation 7-10 days prior to surgery.
214325253|NCT03546686|PROCEDURE|Breast Surgery|Standard-of-care definitive surgery.
214325254|NCT03546686|DRUG|Ipilimumab|ipilimumab 1mg/Kg IV is administered 1-5 days prior to cryoablation.
214926515|NCT06362993|OTHER|MEGH|Education on breast cancer and discussion sessions to male partners to change men's gender attitudes and behaviors.
214926516|NCT00137475|PROCEDURE|Intensity-Modulated Radiation Therapy|
214926517|NCT04793490|PROCEDURE|Sphenopalatine ganglion block|Patients will receive the SPGB via the transnasal approache by a cotton tipped applicator soaked in lignocaine 2% with 4 mg dexamethasone
214926518|NCT04793490|DRUG|paracetamol|patients will receive paracetamol 1 g thrice daily intravenously
214926519|NCT04266587|BIOLOGICAL|Blood sampling|blood sampling is done on healthy volunteers
215069088|NCT04252313|OTHER|Music|Studies have been conducted to assess the effects of sound and noise on neonatal stress. Recently, music is being used in neonatal units to improve physiological and behavioral outcomes (Harling et al, 2009). Of the few studies done on the effectiveness of music during circumcision is a randomized double-blinded controlled trial conducted by Joyce et al (2001): it found that some physiologic outcomes were significantly lower among the music group in comparison to the EMLA group. They concluded that there is preliminary evidence to support the efficacy of EMLA and music in pain management of newborn circumcision; however, more rigorous studies are warranted for conclusive results.
214325255|NCT03546686|DRUG|Nivolumab|nivolumab 240mg IV flat dose is administered 1-5 days prior to cryoablation and 240mg IV every 2 weeks ± 3 days starting 3 (+/-1) weeks after surgery.
214325256|NCT03543189|DRUG|Nivolumab|Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
214325257|NCT03543189|RADIATION|Brachytherapy|High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.
214325258|NCT03543189|RADIATION|External Beam Radiation Therapy|External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.
214325259|NCT03543189|DRUG|Androgen Deprivation Therapy|Standard of care.
214325260|NCT06425458|BEHAVIORAL|Co-Designed Strengths-Based Leadership Program|Please see arm description.
214673043|NCT05738616|COMBINATION_PRODUCT|Lenvatinib combined with TACE and Camrelizumab|Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).
214673044|NCT02467114|DEVICE|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
214926520|NCT02611271|OTHER|Monitoring of antibiotic drug removal|No study specific intervention will be performed
215069089|NCT05394597|OTHER|Repellent lotion|lotion of the repellent active ingredient IR3535
215069090|NCT05394597|OTHER|Repellent Wipe|wipe of the repellent active ingredient IR3535
215069091|NCT05040503|BIOLOGICAL|Blood sampling at inclusion|"Sampling of 2 tubes of 3 ml:~* patient: H0: 0-6h post-admission~* healthy volunteer: at inclusion"
215069092|NCT05040503|BIOLOGICAL|Blood sampling at 24 hours|Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)
214673045|NCT02467114|DEVICE|Sham coil stimulation|Stimulation with a sham coil as a comparison
214926521|NCT02526420|DRUG|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
214926522|NCT00657488|DRUG|Thalidomide|Thalidomide 100mg/day or 400 mg/day at bed time during one year
214325261|NCT05483790|BEHAVIORAL|the multimodal intervention|"The in-person training course included 25 minutescognitive training activities were conducted for , followed by a 15-minute healthy lifestyle education. After a 10-minute break, physical exercise training was administered for 15 minutes. Finally, 15 minutes wrap-up session.~The cognitive training encompassed memory-related training and attention-related training. The physical exercise included finger exercises, elastic band exercises, Tai Chi/ Baduanjin with guidance. The healthy lifestyle education included guidance on nutrition, sleep, stress management, and mood adjustment by teaching problem-solving skills. Additionally, the intervention provided information and support to facilitate lifestyle changes and included discussions and practical exercises, such as tools for assessing dietary behavior."
214325262|NCT06310707|DEVICE|ePatch ® Extended Wear Holter (EWH)|"Diagnostic Test: Extended ECG investigation~• An ambulatory ECG recordings with a duration of 7 days using Philips ePatch (https://www.myheartmonitor.com/device/epatch/) will be applied"
214325263|NCT04624659|DRUG|Etavopivat Tablets Low dose|200 mg once daily
214325264|NCT04624659|DRUG|Etavopivat Tablets High dose|400 mg once daily
214325265|NCT04624659|DRUG|Placebo Tablets|Placebo once daily
214926523|NCT03846154|BEHAVIORAL|Comprehensive family intervention including individual sessions of FORNET|"1. A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~2. Access to schools and school material~3. Family visits~4. Their parents received training regarding agriculture and microcredit projects, and financial assistance~5. FORNET if affected by trauma-related symptoms, and/or acting aggressive~6. If needed medical assistance /.) If needed, legal assistance"
214926524|NCT00327028|DRUG|Diphenine|
214926525|NCT00771017|BIOLOGICAL|GVAX prostate cancer vaccine|Given intradermally
214926526|NCT00771017|DRUG|bicalutamide|Given orally
214926527|NCT00771017|DRUG|goserelin|Given intramuscularly
214926528|NCT00771017|DRUG|leuprolide acetate|Given intramuscularly
214926529|NCT04984369|DRUG|HLX208|HLX208 450mg bid po OR 600mg bid po OR 900mg bid po
214926530|NCT04984369|DRUG|Cetuximab Injection [Erbitux]|Cetuximab 500 mg/m2 IV Q2W
214926531|NCT03852628|DRUG|2mg Buprenex and 380mg Vivitrol|Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX
214926532|NCT03852628|DRUG|Placebo (SL pill qd, IM injection q4weeks)|Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
214926533|NCT03601312|BEHAVIORAL|Exposure and Response Prevention|Exposure and response prevention is an evidence-based behavioral treatment that primarily focuses on exposures, in which the child faces OCD-related fears in a methodical manner and acquires more adaptive coping strategies.
214325266|NCT04624659|DRUG|Etavopivat Tablets|Selected dose once daily
214673046|NCT02467114|OTHER|Control without stimulation|
215069093|NCT05040503|OTHER|Data collection|clinical and biological medical data for patients and general health data for healthy volunteers
214325267|NCT05526989|DRUG|Dostarlimab|300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.
214325268|NCT05526989|DRUG|Niraparib|200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.
214325269|NCT06821945|DRUG|BR5402A|Subjects take the investigational products once a day
214325270|NCT06821945|DRUG|BR5402A-1|Subjects take the investigational products once a day
214325271|NCT06821945|DRUG|BR5402B|Subjects take the investigational products once a day
214325272|NCT06821945|DRUG|BR5402B-1|Subjects take the investigational products once a day
214325273|NCT06821945|DRUG|BR5402C|Subjects take the investigational products once a day
214325274|NCT06821945|DRUG|BR5402C-1|Subjects take the investigational products once a day
214325275|NCT06821945|DRUG|BR5402D|Subjects take the investigational products once a day
214926534|NCT03601312|BEHAVIORAL|OC-Go|OC-Go is a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices. Individuals receiving this intervention will receive exposure and response prevention with OC-Go.
214926535|NCT05405361|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
214926536|NCT05405361|OTHER|Placebo|Intravenous administration of placebo
214926537|NCT01803217|OTHER|pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function|
214926538|NCT04590911|BEHAVIORAL|Cognitive Enrichment Program (CEP)|Multimodal cognitive rehabilitation program for individuals having sustained a traumatic brain injury during older adulthood
214926539|NCT03150511|DRUG|Tesamorelin 2 Milligrams (MG)|Daily self-administered study drug
214926540|NCT06651112|DRUG|Antipsychotic drugs|Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton
215069094|NCT06164652|DEVICE|walking with Ceriter Stride One|Subjects walk on the GAITRite with the CSO insole in their shoes.
215069095|NCT03482648|DRUG|BBT-401-1S, Single dose|Single dose of BBT-401-1S, 7 dose levels, oral capsule
215069096|NCT03482648|DRUG|BBT-401-1S, Multiple doses|Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
215069097|NCT03482648|DRUG|Placebo|Placebo matched to BBT-401-1S, oral capsule
214325276|NCT06821945|DRUG|BR5402D-1|Subjects take the investigational products once a day
214325277|NCT01330758|DRUG|AZD8931|40 mg AZD8931 wet granulation tablet formulation
214325278|NCT01330758|DRUG|AZD8931|40 mg AZD8931 roller compacted tablet formulation
214325279|NCT04694196|DEVICE|Dentulous subjects|Determine the occlusal plane using CN in anterior border of ramus
215069098|NCT02921217|DIETARY_SUPPLEMENT|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
215069099|NCT02921217|DIETARY_SUPPLEMENT|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
215069100|NCT02921217|DIETARY_SUPPLEMENT|Control|Placebo: 300 mg maltodextrin.
214325280|NCT05480566|OTHER|Functional strength training|Functional strength training will include lower limb (e.g. rising from chair, heel rises) and upper limb (e.g. push-ups from the chair and against the wall) exercises for 15 min/day. Target levels of dyspnoea and/or perceived exertion will be 4 to 6 in the modified Borg scale.
214325281|NCT05480566|DEVICE|NMES|For neuromuscular electrical stimulation, electrodes will be placed longitudinally on the vastus intermedius and vastus medialis and a symmetric biphasic pulse waveform, with a pulse duration of 400ms, a frequency of 50Hz, in cycles of 8s of contraction and 20s of rest, will be used for 30min/day. The highest intensity tolerated by the patient will be used and intensity will be increased every time the patient feels comfortable with increasing the intensity. The device Compex Pro Rehab (CE-0473) will be used.
214325282|NCT05480566|DRUG|Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine)|Patients will be treated with daily medication prescribed by the physician, which can include oxygen, medrol, duovent, azitromycine or other medications that physicians consider that are needed.
214325283|NCT05480566|OTHER|Routine physiotherapy|Daily sessions of approximately 15 minutes consisting of airway clearance techniques and breathing exercises upon indication, mobilization, and low-intensity daily walking/cycling exercise (5 to 10 minutes) according to patients' tolerance.
214325284|NCT06282315|DRUG|Pre-screening Phase|"The entire school population will be invited to participate in the study. The purpose of this phase is to confirm participant eligibility for enrolment in the study based on the inclusion and exclusion criteria. Given the context in which the clinical trial is being conducted, in many instances, group meetings with the parents/guardians of potential participants in the community or at school might be necessary as part of the informed consent process. This consent process may be performed up to three months before the start of the screening visit activities.~Participants and parents/guardians of subjects will be asked to confirm in writing their agreement to participate in the trial before any study-specific procedure is conducted. In addition, written assent will be sought for participants over 12 years of age."
214325285|NCT06282315|DRUG|Screenig Phase|"The purpose of the screening visit is to confirm subject eligibility for enrolment in the study based on the inclusion/exclusion criteria. Screening visits in a particular school can be performed between 14 and 7 days before the intervention (Day 0).~To continue with the screening activities, participants must have signed written consent from their parent or legal guardian, and in the case of participants aged 12 years or older, they must also have a signed assent form before any specific study procedure is performed.If the consent/assent process has not been finalized during the pre-screening phase, this can be completed during the screening visit, but always before any trial procedure.~All participants who consent to participate in the trial will be given a Participant Screening Number, which will be assigned sequentially as the informed and assent forms are signed."
215069101|NCT05860257|BEHAVIORAL|PeerLearning.net|PeerLearning.net provides an easy-to-use, scalable, and widely accessible means to support teachers in effectively designing and delivering high-fidelity Cooperative Learning (CL) lessons and, in turn, it has the potential to amplify the positive effects of CL found in previous research. Using PeerLearning.net, teachers design their lesson by selecting from among a set of typical CL lesson templates (e.g., jigsaw, peer tutoring, group projects) which they can customize and populate with their own curriculum and materials. These design templates represent the optimal, high-fidelity design that is required in order for CL to be successful. During lesson delivery, PeerLearning.net manages membership in learning groups, distributes instructional materials, directs student activities according to a pre-specified timetable, supports teacher observations of student behavior, and delivers post-lesson group activities and reviews.
214325286|NCT06282315|DRUG|Randomization|Only when the screening process is finalized in a particular school, and the list of eligible participants is closed, with at least 100 eligible participants, will the school be a candidate for randomization. Once the screening process is finalized, the investigator or designee will notify the ISGlobal Trial Statistician, who will provide the School Randomization ID allocated based on the randomization lists created before the trial starts. School Randomization ID will be assigned sequentially per site, following the order of school randomization. Additionally, the ISGlobal Trial Statistician will provide the site with the list of eligible participants per school randomly selected to participate in the Effectiveness Cohort.
214325287|NCT06282315|DRUG|Baseline Effectiveness Cohort|"Before the administration of the study drug at school, participants selected for the Effectiveness Cohort will perform an additional study visit during which they will provide the study team with a stool sample for STH analysis. A dried blood spot (DBS) sample will also be taken to test for S. stercoralis.~Sampling of the baseline effectiveness cohort will be conducted within 7 days before the start of the school study intervention. In addition to the delivery of the stool/blood sample, participants from the effectiveness cohort will be evaluated for scabies by designated study personnel following the IACs simplified criteria."
214325288|NCT06282315|DRUG|Day 0 Trial Intervention|"Within seven days after the first sample for the baseline effectiveness cohort is collected, the school's mass administration of the allocated drug will take place. All participants included in the list of eligible subjects from a particular randomized school will receive a single dose of the medication administered to their school (FDC or ALB). Before the administration, participants will be asked about any medical condition that has arisen since the last study visit, in which case information will be documented as a concomitant disease.~In case a participant vomits within one hour after the study drug intake (during the study physician observation period), the participant will continue participating in the trial and may still participate in the effectiveness cohort. If they are chosen for the day 21 or month 11 effectiveness cohort, an additional sensitivity analysis will be performed without including these participants, considered as Intervention Fail."
214486104|NCT07032714|DRUG|Dexamethasone|Administered orally once per day, at the schedule outlined in the Arm Descriptions.
214486105|NCT06696326|DIAGNOSTIC_TEST|standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals 68Ga-MY6349 and 68Ga-PSMA-11, and undergoes PET/CT imaging within the specified time.
214486106|NCT06876519|PROCEDURE|Translateral Maxillary Sinus Floor Elevation|Translateral maxillary sinus floor elevation with simultaneous implantation in the maxillary molar region.
214486107|NCT06876519|PROCEDURE|Hydraulic Transcrestal Maxillary Sinus Floor Elevation|Hydraulic transcrestal maxillary sinus floor elevation with simultaneous implantation in the maxillary molar region.
214486108|NCT06882226|OTHER|Maslach burnout inventory|Assessing the emotional burden on nursing staff
214926541|NCT03156179|DIAGNOSTIC_TEST|calcium isotope analysis|A dual stable calcium isotope method will be used to determine fractional calcium absorption. Two stable calcium isotopes will be administered to participants in order to determine fractional calcium absorption. 7 mg of 44Ca will be administered orally in 60 mL of liquid at the start of the study. 2 mg of 42Ca will then be administered intravenously. 24 hour urine collection will begin immediately following oral tracer administration for the assessment of urinary calcium excretion. The enrichment of 44Ca and 42Ca in urine will be determined by magnetic sector thermal ionization mass spectrometry. The isotopic ratios of 44Ca and 42Ca to 48Ca (another naturally occurring calcium isotope present in the human body) will be calculated (42Ca/48Ca and 44Ca/48Ca). The relative fraction of the oral to intravenously administered isotope in the 24 hour urine sample \[(42Ca/48Ca) / (44Ca/48Ca)\] is the fractional calcium absorption.
214325289|NCT06282315|DRUG|Active Surveillance (study visit Day 1, Day 2 and Day 7)|Active safety surveillance will be performed at school during the trial intervention on day 0 until day 7 post-intervention. The assessment will include recording of all AEs and SAEs presented by study participants from the intake of the study drugs, and for two additional days (Day 1 and Day 2 study visits). During active surveillance, participants will be visited by a study physician at school during the study intervention, on day one and day two, and they will be questioned about any potential AE or change in a pre-existing condition. In addition, a final safety visit will be conducted to all participants at Day 7 to collect data on any potential AE occurred between day 2 and the end of the surveillance period and to perform a follow up of any AE ongoing after Day 2 visit.
214325290|NCT06282315|DRUG|Passive Surveillance|Passive surveillance will be carried out by monitoring AEs in health facilities near the schools involved in the study for six days after the intervention until Day 7 (end of the safety surveillance period). Although AE will be actively monitored during the scheduled study visits, this passive surveillance will allow for the identification of AEs and potential SAEs that might occur and remained underreported in case the participant does not attend school during the active safety surveillance period. In addition, a diary cards will be given to participants to write any AE they may have from Day 2 to Day 6 post intervention.
214325291|NCT06282315|DRUG|Post-Treatment Effectiveness Evaluation|"Post-treatment effectiveness evaluation will be performed by measuring the prevalence of STH at two time points: 21 days after the intervention (± 7 days) and 11 months after intervention (± 28 days). Additionally, the reduction in S. stercoralis seroprevalence will be evaluated 11 months after the intervention.~These participants will be tested for STH by Kato-Katz at the two post-treatment time points (day 21 and month 11) and for S. stercoralis by NIE ELISA at 11 months. The diagnostic test will be the same as in the intervention of Baseline Effectiveness Cohort.~As part of the genetic monitoring pilot study and the microbiome analysis, the same samples will be collected as described in the intervection of Baseline Effectiveness Cohort."
214325292|NCT04674969|DEVICE|Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.|Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
214325293|NCT06808204|OTHER|Questionnaire|Quality of life questionnaire : Peds QL 4.0 (Pediatric Quality of Life )
214325294|NCT06808204|OTHER|questionnaire|Physical activity level : Ricci and Gagnon questionnaire
214325295|NCT06808204|OTHER|questionnaire|Anxiety questionnaire : State and Trait Inventory
214325296|NCT06808204|OTHER|questionnaire|Depression questionnaire : Child Depression Inventory
214325297|NCT06808204|OTHER|questionnaire|Child Depression Inventory
214325298|NCT06808204|OTHER|questionnaire|Quality of life of parents before and after transcatheter ablation
214325299|NCT07130058|DIETARY_SUPPLEMENT|GI Product Form - Control|Participants will use their GI Health Product Form - Control as directed for a period of 6 weeks
214325300|NCT07130058|DIETARY_SUPPLEMENT|GI Health Product Form - Active|Participants will use their GI Health Product Form - Active as directed for a period of 6 weeks
214325301|NCT04850378|DRUG|Dalteparin|Drug: Dalteparin 200 units/kg once a day for 4-7 days.
214325302|NCT04850378|DRUG|Apixaban|Drug: Apixaban 5 mg twice a day for 4-7 days.
214325303|NCT06343363|BEHAVIORAL|Early discharge protocol|Patients admitted for transcatheter edge-to-edge repair to either mitral or tricuspid valve and then discharged within 36 hours
214325304|NCT03069378|DRUG|Talimogene Laherparepvec (T-VEC)|Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
214325305|NCT03069378|DRUG|Pembrolizumab|Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
214325306|NCT03945981|DRUG|Dolutegravir + Lamivudine FDC|Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
214325307|NCT06979180|DIETARY_SUPPLEMENT|Papillex®|Participants will be instructed to take two capsules twice daily with food, with the first dose taken with the first meal of the day and the second dose taken with the last meal of the day.
214325308|NCT06979180|OTHER|Placebo|Participants will be instructed to take two capsules twice daily with food, with the first dose taken with the first meal of the day and the second dose taken with the last meal of the day.
214325309|NCT06977451|DRUG|nL-CHCHD-001|Personalized Antisense Oligonucleotide
214325310|NCT06980636|DRUG|Shengmai Liquid|The Shengmaiyin treatment group will be given the traditional Chinese medicine Shengmaiyin oral liquid (produced by Jilin Aodong Yanbian Pharmaceutical Co., Ltd., with the approval number Z41021384. Ingredients: Codonopsis pilosula, Ophiopogon japonicus, Schisandra chinensis, excipients: sucrose, sodium benzoate, ethylparaben, specification 10m1/bottle), taken orally at a dose of 10ml per time, three times a day
214926542|NCT06920303|DEVICE|transcranial colour coded duplex|transcranial colour coded duplex is good non invasive tool in detect velocity and obstructions of intracranial arteries
214926543|NCT00001460|BEHAVIORAL|inpatient evaluation and management|
214926544|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.
214926545|NCT04948463|DRUG|Cefepime Injection|Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.
214926546|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly
214325311|NCT06980636|OTHER|Placebo|A simulated Shengmaiyin oral liquid (provided by Jilin Aodong Yanbian Pharmaceutical Co., Ltd., with main ingredients water, brown sugar, flavoring agents, etc., specification 10m/bottle), 10ml per time, three times a day. The treatment course for Shengmaiyin or placebo will be 8 weeks (56 days), with follow-up continuing until 30 days after the end of the treatment course.
214325312|NCT03665038|DRUG|Brexanolone|Administered as IV infusion.
214325313|NCT06842836|OTHER|Study intervention|From the date of study authorization, the principal investigator, together with his specially identified collaborators, will proceed to identify patients who meet the inclusion criteria. Then, during the first follow-up visit, the principal investigator, or one of his co-investigators, will deliver the informed consent to the parent(s) of the minor subject candidate for enrollment in the study, explaining all the characteristics and evaluations stipulated in the protocol and answering any questions. After the informed consent is signed, patients will be enrolled and the data required to conduct the study will be collected, and a fecal sample will be requested specifically for the conduct of the study. At the same time, completion of the KIDMED (Mediterranean Diet Quality Index in children and adolescents) questionnaire will be requested.
214325314|NCT05849467|DRUG|89 Zr-Df-crefmirlimab|"an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours)."
214325315|NCT05764564|DIAGNOSTIC_TEST|Positive or negative pressure|Positive or negative pressure is applied via a closed chamber.
214325316|NCT06592274|BIOLOGICAL|HB0017|300mg Q12W
214325317|NCT06592274|BIOLOGICAL|HB0017|300mg Q8W
214926547|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly
214926548|NCT04948463|DRUG|Amikacin Injection|Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.
214926549|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly
214926550|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.
214926551|NCT04948463|DRUG|Cefepime Injection|If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
214926552|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
214926553|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution
214926554|NCT04948463|DRUG|Amikacin Injection|At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution
214325318|NCT06592274|BIOLOGICAL|HB0017|150mg Q4W
214325319|NCT06268873|DRUG|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
214325320|NCT06268873|DRUG|Dapagliflozin in combination with placebo|"dapagliflozin tablet~placebo tablet"
214325321|NCT04477603|DEVICE|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
214325322|NCT06095115|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
214325323|NCT06095115|DRUG|Placebo|Placebo will be administered orally
214325324|NCT06808828|BEHAVIORAL|Health and coping skills|An occupational therapist and occupational therapy graduate capstone student will lead in-person sessions. Subjects will participate in an occupational therapy program that meets 2x/week x 4 weeks for eight sessions. Topics will include sleep hygiene, physical activity, healthy cooking, self-management, coping skills, self-esteem, mindfulness, and goal setting. Subjects will receive education as well as actively engage in activities related to the topic. Subjects will be provided with a personal journal to complete homework involving reflections on the topics discussed in the sessions.
214325325|NCT04331158|OTHER|Dry cupping therapy|Dry cupping therapy application on the patient's skin
214325326|NCT06806267|DEVICE|Virtual reality exposure therapy|Exposure therapy applied through virtual reality goggles, controlled by a clinician
214325327|NCT06806267|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation applied to the vmpfc, 2mA
214325328|NCT06806267|BEHAVIORAL|Imaginal exposure therapy|Imaginal exposure therapy
214325329|NCT06581263|DEVICE|Meta Quest 3|Meta Quest 3 is a virtual reality headset device
214926555|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
214926556|NCT01989325|DRUG|Carfilzomib, proteasome inhibitor; intravenous|multiple dose, single schedule
214926557|NCT01989325|DRUG|Filanesib, KSP(Eg5) inhibitor; intravenous|multiple dose, single schedule
215069102|NCT06531213|OTHER|experimental|"Experimental Group: Baseline rehabilitation, Visual Perception Interventions. Home base activities, Baseline Rehabilitation (Strengthing exercise, achieving missing milestones).~Visual Perception Interventions~• Puzzle:Give step-by-step • printable activities • Sudoku. SET, Search Word, Spot it, what is missing, Tic Tac Toe, I Spy"
214926558|NCT01989325|DRUG|Dexamethasone, steroid; oral or intravenous|as indicated, per the carfilzomib prescribing information
214926559|NCT01989325|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
214926560|NCT02964208|DEVICE|AMPLATZER™ LAA Occluder|The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
215069103|NCT06531213|OTHER|controlled|Controlled: Baseline rehabilitation. Home-based activities, Baseline Rehabilitation (strengthening exercise, achieving missing milestones).3. Activities Play Dough ( Manipulation) Draw on sketch Cup stacking.
215069104|NCT00911976|DEVICE|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
215069105|NCT02540187|OTHER|blood specimen|
215069106|NCT02765815|DRUG|Liposomal bupivacaine, 266mg|
214486109|NCT06882382|OTHER|conventional physiotherapy|normal joint movements, chest physiotherapy, and mobilization for 40 min
214486110|NCT06882382|OTHER|Virtual reality|normal joint movements, chest physiotherapy, and mobilization for 40 min and 20 min virtual reality
214926561|NCT06680687|BEHAVIORAL|Educational Program (video, information booklet, Survivorship Card)|"Caregivers will be invited to attend an educational group session. Each session will be organized weekly to monthly. A maximum of ten caregivers can be present at a session.~First a video will be displayed in which healthcare providers explain medical aspects of survivorship. Caregivers of survivors and young adult survivors discuss experiences after completing cancer treatment in the video.~Secondly, the present healthcare provider will hand over an information booklet 'Life after childhood cancer' to the caregivers. The booklet covers similar topics as presented in the video.~Lastly, a Survivorship Card will be shared with the caregivers. The card contains a record of the patient's cancer and treatment history and the expected follow-up appointment schedule. The survivor and family take one card home and a duplicate copy of the card remains in the medical file."
214926562|NCT06680687|BEHAVIORAL|Follow-Up Program (form and healthcare provider training)|"Healthcare providers will attend a training session of approximately 90 minutes, in which investigators will discuss the same topics as covered in the educational group session supported by PowerPoint slides.~A Follow-Up Form will be introduced to be used by healthcare providers in the outpatient follow-up clinic. The form will include questions referring to symptoms specific for certain late effects. Specific questions will be included per subcategory: hematological malignancies, solid tumors or central nervous system (CNS) tumors."
214926563|NCT04996316|OTHER|Electronic Health Record Review|Health record reviewed
214926564|NCT04996316|OTHER|Interview|Participate in interview
214926565|NCT04996316|OTHER|Media Intervention|Use MammoScreen
214926566|NCT04996316|OTHER|Survey Administration|Complete survey
214926567|NCT04996316|OTHER|Training and Education|Undergo training
214926568|NCT02526979|DRUG|mirabegron|oral
214926569|NCT06686680|DEVICE|extracorporeal shockwave therapy (ESWT)|Participants will receive ESWT administered by research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-top focus.Radial pressure waves will be applied using the Extracorporeal Pressure Activation Treatment (EPAT) device. For the anterior knee, patella tendon, vastus lateralis, and vastus medialis, treatment will aim for 1500 strikes at induction dose of 1.5 bars and titrating up by 0.5 bars to 3 bars and this will be performed to participant tolerance to pain, as pain is experienced due to clinical focusing technique which is standard of care in delivering effective treatment. For the calf muscles, the patient will be positioned prone and a similar protocol of starting at 1.5 and titrating up as tolerated to 3 bars. Focused shockwave therapy will be applied for 1000 shocks to four anatomical locations for a total of 4000 shocks. Each site will receive 1000 shocks: medial and lateral tibial plateau and medial and lateral femoral condyle.
214926570|NCT06686680|DEVICE|Sham Comparator|All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits separated by seven days +/- 7 day. Sham ESWT will administered by trained research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.
214926571|NCT06879717|DRUG|roginolisib|tablet, 40mg tablet strength
214926572|NCT06879717|DRUG|Dostarlimab|500 mg administered as IV infusion
214926573|NCT06879717|DRUG|Docetaxel|75 mg/m2 administered over 1 hour as IV infusion
214926574|NCT06882577|OTHER|observational only- no intervention|observational only- no intervention
214926575|NCT05193071|DRUG|Aspirin 100mg; Clopidogrel 300mg|Aspirin 100mg plus Clopidogrel 300mg will be orally administrated after randomization
214926576|NCT00671528|DRUG|Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)|Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
214926577|NCT00671528|DRUG|Cream (betamethasone diproprionate and gentamicin)|Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
215069107|NCT02765815|DRUG|Bupivacaine 0.5 % with Epinephrine|
215069108|NCT02765815|DRUG|Ketorolac 30mg|
215069109|NCT02765815|DRUG|Morphine 10mg|
214325330|NCT06807190|DRUG|Insulin Icodec|Participants will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician.
214325331|NCT03841149|OTHER|Ultrasound Imaging|3D volume calculation using on-line and off-line softwares
214325332|NCT05663515|DRUG|Exenatide|All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.
214325333|NCT05663515|DRUG|Non-GLP-1 RA based glucose lowering drugs|Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
214325334|NCT04466891|DRUG|ZW25 (Zanidatamab)|Administered intravenously
214486111|NCT06877780|DEVICE|RMR with SME|The RMR will be used in conjunction with slow maxillary expansion
214486112|NCT06877780|DEVICE|BAIMT with RME|The bone-anchored intermaxillary traction will be used with rapid maxillary expansion
214673047|NCT06971952|BEHAVIORAL|Conditional Cash Transfer Incentive for Household Contact Screening|Households with index people with TB (PWTB) will be consecutively recruited and offered a conditional cash transfer once all HHCs complete the facility-based tuberculosis (TB) screening procedures. The participants will be notified of the cash transfer during the consenting process for this phase. They will be informed that if all household contacts complete the recommended TB screening, the cash transfer will be given to the head of household during the home visit at 2 months.
215069110|NCT02765815|DRUG|Bupivacaine 0.25% with Epinephrine|
214926578|NCT00671528|DRUG|Cream (betamethasone diproprionate)|Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
214926579|NCT05039814|OTHER|postoperative acute kidney injury|patients suffered postoperative acute kidney injury
214926580|NCT05039814|OTHER|none postoperative acute kidney injury|patients did not suffered postoperative acute kidney injury
214926581|NCT06667570|PROCEDURE|SALFOAM 3%|"* Drug: Polidocanol 3%~* Device: Lidstop®"
214926582|NCT06667570|PROCEDURE|Control Group|"* Drug: Polidocanol 3%~* Device: Standard compression with dental roll and elastic stockings"
214926583|NCT00352222|DEVICE|stent implantation|
214926584|NCT06720584|BEHAVIORAL|Health coach-led, online support program for people living with lupus|"The health coach-led online support and education program for people living with lupus. It includes 8 group sessions and 2 individual sessions with the health coach to set individual goals. Each program group will include up to 10 participants.~Program Session Structure (\~60-75 minutes): educational component presented using a slide set, discussion questions interspersed, mindfulness activities, goal check-ins.~Associated Materials: Notebook, expert videos available."
214926585|NCT06729554|OTHER|Education & Care in RARE|Education \& Care in RARE (https://www.youtube.com/watch?v=R3fr-q-6JIw) is a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases. It promotes knowledge and competence on rare diseases in children in order to reduce the psychosocial rare disease burden and to improve individual self-competence in managing the rare disease and to improve their quality of life. Education \& Care in RARE can be used for all pediatric rare diseases. This has the great advantage that users only need to be trained in the use of one program.
214926586|NCT06730594|DIETARY_SUPPLEMENT|VL-BK-02 (25 billion CFU/Capsule)|One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
214926587|NCT06730594|DIETARY_SUPPLEMENT|Placebo (Microcrystalline Cellulose - 375 mg/capsule)|One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
214926590|NCT06729450|DEVICE|DispersinB Acne Cleanser|DispersinB Acne Cleanser, strength: 80 ug/g, topical gel
214926591|NCT06664775|BIOLOGICAL|TachoSil|Adjunct to hemostasis
214926592|NCT06664775|BIOLOGICAL|Surgicel Original|Adjunct to hemostasis
214926593|NCT06296927|OTHER|Emotional Freedom Technique|The researcher will apply the Emotional Freedom Technique to women in the intervention group who apply for mammography screening for 30-40 minutes before the screening.
214926594|NCT02166736|DEVICE|iFR|Treatment guided by Instantaneous wave-free ratio (iFR®)
214926595|NCT02166736|DEVICE|FFR|Intervention guided by Fractional Flow Reserve
214926596|NCT02913274|DEVICE|Paclitaxel (Taxol) eluting angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation by a DEB of the same size for 2 minutes.
214926597|NCT02913274|DEVICE|high-pressure angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.
214926598|NCT02913274|DEVICE|low-pressure balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Thenn dilatation by a shame balloon i.e conventional low pression balloon of the same size for 2 minutes.
214926599|NCT06627309|DRUG|Dara IV|The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
214926600|NCT06627309|DRUG|Bortezomib (drug)|Bortezomib is administered subcutaneously. The dosage range from 0.7 to 1.3 mg/m2 on days 1, 8, 15, and 22 of each cycle, for a maximum of 6 cycles
214926601|NCT06627309|DRUG|Dexamethasone|Dexamethasone is administered intravenously at a dose of 40 mg weekly for each cycle, for a maximum of 6 cycles. For patients over 70 years of age or with severe edema, heart failure, or uncontrolled diabetes mellitus, dexamethasone can be administered at a dose of 10-20 mg per week.
215069111|NCT03992716|DRUG|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
215069112|NCT03992716|DRUG|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
215069113|NCT04867720|DRUG|Everolimus|\- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.
214673048|NCT06971198|DRUG|HSK39004|0.75\~4mg
214673049|NCT06971198|DRUG|Placebo|0.75\~4mg
214325335|NCT06984861|DIAGNOSTIC_TEST|18F-FMISO PET/CT Scan|The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. Subjects will undergo 18F-FMISO scan (only 1 injection) occurs at 8-10 treatment days\* into chemoradiation. Each patient will have a baseline staging FDG PET scan which is used to localize the tumor at the primary site and all suspicious cervical neck nodes (\> 1 cm in short axis diameter with focal abnormal increased FDG avidity). These lesions are then assessed on the respective 18F-FMISO PET/CT.
214325336|NCT06984861|COMBINATION_PRODUCT|Chemoradiation|Patients will start with induction chemotherapy of carboplatin, paclitaxel and cetuximab for 6 weeks and when downstaged to T1-2 and \< N3, the patient is eligible to receive concurrent chemoradiation per protocol.A total radiation therapy of 30Gy will be delivered to the oropharynx and neck at 2Gy per fraction per day over 15 days for patients who exhibited no evidence of hypoxia on the intra-treatment 18F-FMISO PET/CT. Concurrent chemotherapy (2 cycles) will be given. After completion of chemotherapy and radiation therapy, a 4 month (+/- 4 weeks)
214325337|NCT06984861|OTHER|Questionnaires|EQ-5D-5L, MDADI-HN, COST-FACIT
214325338|NCT06978621|BIOLOGICAL|Inactivated hepatitis A vaccine (I-HAV)|"A formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain)~Dose and administration: 0.5 mL intramuscular injection for participants age \<=18 years, and 1.0 mL intramuscular injection for participants age 19 years and above."
214325339|NCT06599697|BIOLOGICAL|Intravenously administered pooled human immunoglobulin (IVIG)|IVIG 2g/kg every 4 weeks for 12 weeks (3 doses)
214325340|NCT02620098|OTHER|Size Matters Handwriting Program|The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
214325341|NCT00004078|DRUG|irinotecan hydrochloride|Given IV
215069114|NCT00695916|PROCEDURE|Breast MRI|
215069115|NCT01877486|PROCEDURE|Ablation|Pulmonary vein isolation following dofetilide
215069116|NCT00869791|DRUG|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
215069117|NCT00869791|DRUG|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
215069118|NCT00119769|DRUG|Placebo|Placebo, 0.7 mg/day injected subcutaneously
214325342|NCT00445328|DRUG|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
214325343|NCT00445328|DRUG|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
214325344|NCT01356433|DRUG|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
214325345|NCT01356433|DRUG|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
214486113|NCT06878352|OTHER|Educational intervention BUNDLE, prepared in accordance with the recommendations of the Global Initiative for Asthma- GINA (2024)).|"The educational intervention bundle was designed in accordance with the recommendations of GINA (2024), and will cover topics on the etiopathogenesis and pathophysiology of asthma, inhaler treatment, precipitating factors for crises, self-management skills, environmental control, as well as the importance of drawing up a written therapeutic plan and regular medical follow-up.~The educational intervention will be offered as a group activity and will be conducted in a single meeting, lasting approximately sixty minutes. Users will attend a standardized dialogical lecture using audiovisual resources, where they will have the opportunity to discuss and answer any questions related to the topics covered. At the end of the intervention, participants will receive a booklet containing all the points covered in the intervention, as well as a diary to record the amount of medication used, visits to the emergency room and asthma-related hospitalizations."
214486114|NCT06684327|DRUG|Albumin-paclitaxel Injection|Participant will receive albumin-paclitaxel 260mg/m2 d1, isocyclophosphamide 1500mg/m2 d2-5, and cisplatin 25mg/m2 d2-5 every 21 days until disease progression, intolerable toxicity, or full 6 cycles of treatment, whichever occurs first.
214486115|NCT06694714|DRUG|0.5 ml lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
214486116|NCT06694714|DRUG|1.0 ml lidocaine + epinephrine 1:100,000|1.0 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
214486117|NCT06718621|DRUG|BL-M08D1|Administration by intravenous infusion for a cycle of 3 weeks.
214486118|NCT07038941|DRUG|CG2001|combination of minoxidil and finasteride
214486119|NCT07038941|DRUG|Placebo foam|Placebo foam
215069119|NCT00119769|DRUG|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
215069120|NCT00290771|DRUG|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
215069121|NCT00290771|DRUG|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
215069122|NCT00005901|DRUG|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
215069123|NCT05223569|DEVICE|Home OCT monitoring model|A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester
215069124|NCT05223569|DEVICE|Hospital-based monitoring with a staff-administrated OCT|Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
215069125|NCT05764005|BEHAVIORAL|web-based tool (MAP- Management of Active surveillance in Prostate Cancer)|A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
215069126|NCT05764005|BEHAVIORAL|MUSIC website|Standard of care educational materials {add more detail}
215069127|NCT00939289|DEVICE|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
214325346|NCT04246970|OTHER|Prehabilitation|Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device \[2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)\]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.
214325347|NCT04246970|OTHER|Prehabilitation and posttransplant training program|Prehabilitation will be followed by a posttransplant training program. In this, the patient will perform supervised exercise (IIa interval aerobic exercise and resistance training) 2 days / week, and a physical exercise program at home until completing a total of 5 sessions / week in the aerobic modality. In the unsupervised phase (IIb), the patient will continue with the learned physical exercise program, but without supervision, 5 sessions / week (including a minimum of 2 non-consecutive sessions to perform resistance training).
214325348|NCT04669457|DRUG|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
214325349|NCT04669457|DRUG|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
214325350|NCT04975347|DRUG|Naloxone|One bolus and one infusion of naloxone
214325351|NCT06984536|DRUG|Reduced ATG plus mini PTCy|The conditioning protocol comprises cytarabine (Ara-C) (4 g/m2/day, days -9), busulfan (Bu) (3.2 mg/kg/day, days -8 to -6), cyclophosphamide (Cy) (1.8 g/m2/kg, days -5 and -4), simustine (250 mg/m2, day -3) and r-ATG (total 7.5mg/kg ,from days -5 to -2). Mini PTCy 14.5mg/kg/day will be given on day +3 and +4.
214325352|NCT05403710|DRUG|Botulinum toxin|Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
214325353|NCT02710682|PROCEDURE|Mini-open surgery|"This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.~1. Skin disinfection; Local anesthesia (lidocaine 1%).~2. Skin incision, slightly anterior to lateral epicondyle.~3. Exposure of the plane between the tendon and fascia.~4. Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.~5. Excision of diseased tissue of the ECRB tendon.~6. ECRL tendon is sutured back to the fascia. The skin is closed.~7. Patient is monitored for 30 minutes after procedure."
214325354|NCT02710682|DEVICE|Ultrasound-guided Tendon fenestration|"This treatment will be administered by a fellowship-trained MSK radiologist.~1. Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.~2. Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.~3. Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.~4. Patient monitored for 30 minutes, before being discharged."
214325355|NCT06033638|OTHER|Score assessment|PBS Score
214325356|NCT05114005|BEHAVIORAL|Rhythmic Auditory Stimulation|Rhythmically-entrained sensorimotor activity.
214325357|NCT05114005|BEHAVIORAL|Evidence-Based Exercise|This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hour training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
214325358|NCT06664333|OTHER|Semi-structured interviews|"The study consists of conducting two semi-structured interviews, with an estimated duration of 15 to 30 minutes, with siblings of children hospitalized in pediatric intensive care at Necker-Enfants Malades Hospital and Robert Debré Hospital.~The first interview will take place during the stay in intensive care, the second 1 month after discharge from pediatric intensive care."
214325359|NCT01852448|GENETIC|Blood or Saliva Sample Collection|A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.
214926602|NCT06627309|DRUG|Cyclophosphamide (CTX)|Some patients may receive cyclophosphamide orally or intravenously at a dosage of 300 mg/m2 weekly.
215069128|NCT04129268|OTHER|Cycle ergometry exercise at 60% VO2max|Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
214325360|NCT05514405|DRUG|Remimazolam (Byfavo)|Remimazolam is continuously infused based on bispectral index (within 40-60).
214325361|NCT05514405|DRUG|Propofol|Propofol is continuously infused based on bispectral index (within 40-60).
214486120|NCT07037823|OTHER|Modified Yishen Daluo Yin formula|The specific application of the modified Yishen Daluo Yin formula, including the starting point, dosage, and duration of treatment, should be determined based on medical advice, the patient's condition, and their individual preferences.
214486121|NCT07038330|DRUG|Sucrosomial Iron|Sideral Forte, Italian market formulation of Sucrosomila Iron 30mg per cp
214486122|NCT06717867|DIETARY_SUPPLEMENT|Palmitoylethanolamide (PEA)|Levagen™ capsule containing 300mg Palmitoylethanolamide (PEA). 600mg PEA per day.
214486123|NCT06717867|OTHER|Placebo|Placebo capsules contain 300 mg microcrystalline cellulose (MCC), 600mg per day.
214926603|NCT06627309|DRUG|Dara SC|The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
214926604|NCT03530605|DEVICE|Optune TTF device|portable device which produces electrical fields
214926605|NCT06405828|BEHAVIORAL|ACCESS Supportive Care|"ACCESS Supportive Care includes:~1. Coaching sessions: 6 one-hour weekly Community Navigator led supportive and early palliative care health coaching sessions. Sessions will be hybrid (in-person or virtual) per participant preference.~2. Monthly check-in: Monthly check-ins (\~5-10 minutes) about their supportive care and social determinants of health needs over 16 weeks.~3. Scheduling of outpatient supportive oncology appointment if interested.~4. Community linkage: Warm hand offs and connection to community resources to enhance access to support groups, educational workshops, and healthy lifestyle services."
214325362|NCT05074290|DRUG|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
214325363|NCT05074290|DRUG|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
214325364|NCT06600620|DEVICE|Monitoring patients heart rythms with a wireless patch device|The investigators will collect data in patients at high risk of atrial fibrillation (AF) without a known history of AF to determine clinical predicators of AF. This data will be used to generate virtual digital twins to to predict clinical and subclinical episodes of AF
214325365|NCT02284503|DRUG|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
214325366|NCT06601309|DRUG|Serplulimab|Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.
214325367|NCT06601309|DRUG|Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)|Paclitaxel (175 mg/m²) and Cisplatin (75 mg/m²) administered intravenously on day 1 of each 21-day cycle for 2 cycles as part of neoadjuvant chemotherapy.
214325368|NCT06601309|DRUG|Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)|Paclitaxel (50 mg/m²) and Cisplatin (25 mg/m²) administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle as part of concurrent chemoradiotherapy.
214325369|NCT06601309|RADIATION|Radiotherapy|Radiotherapy at a dose of 40 Gy, delivered in 20 fractions over 4 weeks.
214926606|NCT06405828|BEHAVIORAL|Phone sessions|6 weekly phone sessions, approximately 10 minutes in length each, to review breast cancer and supportive and palliative care resources in NYC and online. The 6 weekly phone sessions will include the topics discussed in the intervention arm but will be informational in nature. The phone sessions will be followed by monthly check-ins (\~5 minutes) to review and answer questions about the resources for the duration of 16 weeks.
214325370|NCT05742451|OTHER|kids yoga|"The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.~Kids yoga training included: 5-minute warm-up consisting of jogging, jumping, stretching, relaxation exercises; 20 minutes of asanas (positions) consisting of standing, sitting, prone, supine postures and pranayamas (breathing exercises) consisting of vigorous inspiration and expiration, slow and rhythmic alternating nostril breathing; 10-minute yogic games about balance, reaction time and agility; meditation with focus for 5 minutes with resuscitation techniques."
214325371|NCT00316199|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
214325372|NCT00316199|DRUG|paclitaxel|175 mg/m2, intravenous (IV), every 21 days until disease progression
214325373|NCT03203902|OTHER|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
214325374|NCT02801318|PROCEDURE|Polysomnography|
214926607|NCT06826807|OTHER|Regular monitoring with transient elastography|MASLD patients were received their liver fat and fibrosis status regularly using transient elastography
214926608|NCT06737432|OTHER|RKP Monitoring Software|Use of RKP alerting and monitoring software.
214926609|NCT06756984|PROCEDURE|Partial Cyst Wall Resection with Nerve Root Sleeve Plasty|Surgical technique involving partial removal of the cyst wall to decompress the nerve root, followed by plasty of the nerve root sleeve to restore nerve function and prevent recurrence.
214325375|NCT00333684|DEVICE|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
214926610|NCT06756984|PROCEDURE|Partial Cyst Wall Resection with Nerve Root Sleeve Reinforcement and Reconstruction:|Advanced surgical technique combining partial cyst wall removal with additional reinforcement and reconstruction of the nerve root sleeve to provide enhanced support and reduce the risk of cyst recurrence.
214486124|NCT06719180|DRUG|Bupivacain|Injection into the vaginal cuff will occur before vaginal cuff closure with stratafix suture. There will be four points of injection 1cm from the edges of the vaginal cuff with a sterilized needle to a depth of 3-4cm. 5cc of bupivacaine with epinephrine or 5cc of normal saline will be injected into each area
214486125|NCT06719180|OTHER|Saline (NaCl 0,9 %) (placebo)|A saline placebo
214486126|NCT06874348|DIAGNOSTIC_TEST|structural and functional MRI|structural and functional MRI
214926611|NCT06756984|PROCEDURE|Autologous Fat/Muscle with Fibrin Glue Microscopic Cyst Filling|Minimally invasive surgical technique where autologous fat or muscle tissue is used to fill the cyst cavity, and fibrin glue is applied to seal the defect, aiming to obliterate the cyst and prevent cerebrospinal fluid leakage.
214926612|NCT04180852|OTHER|Functional tests without clinical consequence for the patients therapy|Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
214926613|NCT05390242|DIAGNOSTIC_TEST|Radiographic study|Candidates undergo a radiographic study (Orthopantomography and Implant periapical radiography)
214926614|NCT04986410|DIAGNOSTIC_TEST|CCTA, CT-MPI, CT-FFR, SPECT-MPI|Subjects undergo CCTA, CT-MPI, CT-FFR or SPECT-MPI
214926615|NCT06258720|DRUG|Lu AF82422|Lu AF82422 solution for intravenous infusion
214926616|NCT00796952|BEHAVIORAL|focused attention sessions|"Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period."
215069129|NCT04818502|DEVICE|Tendyne™ Mitral Valve System|Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.
215069130|NCT02661737|DEVICE|YVOIRE volume s|
214325376|NCT00590954|DRUG|Perifosine|"Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4."
215069131|NCT03316716|PROCEDURE|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
215069132|NCT00171457|DRUG|Tegaserod|
215069133|NCT03441867|BEHAVIORAL|Cognitive Behavioral Therapy for Seizures|CBT-informed psychotherapy for patients with PNES and PTE
215069134|NCT03441867|OTHER|Standard Medical Care|Observational - standard medical care
215069135|NCT00348699|DRUG|AFP464|Given IV
215069136|NCT00348699|OTHER|pharmacological study|Correlative studies
214926617|NCT00796952|BEHAVIORAL|Valchuff|"Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment."
214926618|NCT00796952|BEHAVIORAL|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
215069137|NCT00348699|OTHER|laboratory biomarker analysis|Correlative studies
215069138|NCT04974346|RADIATION|Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation|The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm.
215069139|NCT04974346|RADIATION|Pelvic definitive concurrent chemoradiation|Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
215069140|NCT00491270|DEVICE|VS Sense|An applicator to diagnose pH increase above 5.2
215069141|NCT00797264|DRUG|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
214325377|NCT06858306|DEVICE|Sphere-9™ Catheter and Affera™ Ablation System|De novo pulmonary vein isolation procedure using commercially available Sphere-9™ Catheter and Affera™ Ablation System
214325378|NCT05733351|DRUG|Abiraterone|Given PO
214325379|NCT05733351|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
214325380|NCT05733351|PROCEDURE|Bone Scan|Undergo bone scan
215069142|NCT00797264|DRUG|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
214325381|NCT05733351|PROCEDURE|Computed Tomography|Undergo CT
214325382|NCT05733351|DRUG|Docetaxel|Given IV
214325383|NCT05733351|DRUG|Enzalutamide|Given PO
214325384|NCT05733351|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET
214325385|NCT05733351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214325386|NCT05733351|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
214325387|NCT05733351|DRUG|Vudalimab|Given IV
214325388|NCT06858111|BIOLOGICAL|Fertilo|Fertilo is an engineered line of ovarian support cells that aid egg maturation.
214325389|NCT06858111|DEVICE|Medicult IVM|MediCult IVM is a system of culture media designed for the in vitro maturation of immature oocytes.
214325390|NCT06663761|BEHAVIORAL|Stimuli|"Stimuli (the order of stimuli 1-4 will be electronically randomized), with a break time between stimuli of 5-10 minutes:~1. Non-invasive blood pressure measurement~2. Heat~3. Mechanical stimulation~4. Visual stimulation~5. Cold pressor test~6. Spicy taste"
214325391|NCT06670443|DEVICE|experimental group|Electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
214325392|NCT06670443|DEVICE|control group|Placebo electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
214325393|NCT02313025|OTHER|speech sound intervention|"An intervention that stimulates speech sound perception and production in four-year-olds.~Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks"
214325394|NCT02313025|OTHER|World-project|An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
214486127|NCT06874127|DRUG|Nucleos(t)ide Analogs (NA)|all patients received NAs
215069143|NCT00797264|DRUG|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
215069144|NCT02225847|OTHER|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
215069145|NCT02225847|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
215069146|NCT02225847|BEHAVIORAL|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
215069147|NCT04606706|OTHER|Mobile health nutrition education intervention|Nutrition education will be given through mobile phone
214325395|NCT04222179|DEVICE|ultrathın esophagogastroduodenoscope|Place the naso-enteric tube together with the ultrathin esophagogastroduodenoscope from the same nasal cavity
214325396|NCT03869138|BEHAVIORAL|Virtual-reality based dance training|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
214325397|NCT06669403|DRUG|OPT101|OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
214325398|NCT06669403|OTHER|Placebo|0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.
214926619|NCT06532864|BEHAVIORAL|Practice Mawangdui Guiding Technique|Nursing staff with experience in teaching Mawangdui Daoyin Exercise conducted the operation instruction on different floors. A feasibility assessment of the older adults was carried out by the nursing staff at the end of the teaching, and only after passing this assessment could the experimental part begin. The treatment group participated in five Mawangdui Daoyin Exercise sessions per week, each lasting approximately 45 minutes, and the exercises continued for 12 weeks.
214325399|NCT06669897|OTHER|Questionnaire|Chronic cough questionnaire
214325400|NCT06994897|DRUG|PF-07985631|Experimental Pfizer compound which will be SC or IV
214325401|NCT06994897|DRUG|Placebo|Placebo which will be SC or IV
214325402|NCT04853667|OTHER|Interview|Semi-structured interview, lasting a maximum of one hour
214325403|NCT05903131|BEHAVIORAL|Telemedicine behavioral weight intervention|Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (12 months total). Each telephone session will be 30 minutes long.
214325404|NCT05903131|DRUG|Progestin|Released via the levonorgestrel-releasing IUD.
214325405|NCT05903131|BEHAVIORAL|Enhanced usual care|1-3 page handouts
214325406|NCT05903131|DRUG|Levonorgestrel-releasing IUD.|Standard of care
214325407|NCT05972044|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
214325408|NCT05972044|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
214325409|NCT05972044|DRUG|Placebo|Placebo tablets, taken once daily
214325410|NCT01811121|DRUG|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
214325411|NCT01811121|DRUG|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
214486128|NCT06875245|DRUG|Faricimab Injection|Intravitreal Injection
214486129|NCT06299514|DEVICE|Pace and Ablate|Conduction System Pacing (CSP) followed by AtrioVentricular Node Ablation (AVNA)
214325412|NCT06856590|DIETARY_SUPPLEMENT|Zinc Supplementation|Participants assigned to zinc-containing arms will receive oral zinc gluconate supplementation (78 mg twice daily) for 8 weeks. This intervention aims to evaluate the effect of zinc in preventing and reducing the severity of regorafenib-induced hand-foot skin reaction (HFSR).
214926620|NCT03364400|DRUG|VT1021|Peptide
214926621|NCT00556933|DRUG|rabbit anti-thymocyte globulin - single dose|A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
214926622|NCT00556933|DRUG|mycophenolate mofetil|Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.
215069148|NCT03548025|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-FR2000 Device
215069149|NCT06126718|DRUG|BR201|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
214325413|NCT06856590|DRUG|Clobetasol Propionate 0.05% Cream|Participants assigned to clobetasol-containing arms will receive topical clobetasol propionate 0.05% cream, applied twice daily to the palms and soles for 8 weeks. This intervention aims to assess the efficacy of clobetasol in preventing regorafenib-induced HFSR.
214325414|NCT05124782|OTHER|Rheumatoid Arthritis Impact of Disease questionnaire|Rheumatoid Arthritis Impact of Disease questionnaire
214325415|NCT02626065|BIOLOGICAL|blood sampling|Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
214325416|NCT02626065|DRUG|Nivolumab|injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
214486130|NCT06299514|DRUG|Medication|Optimization of heart failure therapies includes maximum tolerated doses of beta-blockers, aldosterone antagonists, ACE inhibitors, ARB, diuretics, ARNis
214486131|NCT05975736|BEHAVIORAL|Search only for masses|Participants search the simulated mammogram for simulated masses.
215069150|NCT06126718|DRUG|Cosentyx（Secukinumab ）|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
215069151|NCT03403361|DEVICE|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
215069152|NCT03403361|DEVICE|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
215069153|NCT04726150|OTHER|ILR implantation|If LGE is present on CMR, ILR implantation will be proposed
214325417|NCT00864773|PROCEDURE|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
214325418|NCT06997445|OTHER|Interventional group: Jacobson's progressive muscle relaxation technique with aerobic exercise|Jacobaon's progressive muscle relaxation technique for 15 minutes Total duration: 45 minutes
214325419|NCT06997445|OTHER|Aerobic Exercise|"Participants in this group will only be provided aerobic exercise for 4 weeks supervised by physiotherapist.~Aerobic Exercise include the following:~* Warm up exercises for 5 minutes.~* Brisk walking on treadmill for 25 minutes which include warm up period for 10 minutes then 14 minutes brisk walk and cool down period included 1 minute walk.~* Stepper for 5 minutes.~* Static cycling for 5 minutes.~* Cool down for 5 minutes.~Week 03 and Week 04:~Frequency: 5 days per week Intensity: 60-80% Target heart rate Time: 45 minutes~Week 01 and Week 02:~Frequency: 5 days per week Intensity: 50-60 % Target heart rate Time: 45 minutes"
214325420|NCT06339736|OTHER|Questionnaires administered to all study participants|Ten treatment sessions were performed, which initially involved muscular stretching and relaxation exercises and then strengthening and endurance exercises to achieve stabilization. An oral splint was applied to he upper dental arch.
214325421|NCT06434649|PROCEDURE|Extrafascial robotic assisted radical prostatectomy via posterior approach|Extrafascial robotic assisted radical prostatectomy via posterior approach will be applied in the intermediate or high risk patients.
214325422|NCT06434649|PROCEDURE|Extrafascial robotic assisted radical prostatectomy via anterior approach|Extrafascial robotic assisted radical prostatectomy via anterior approach will be applied in the intermediate or high risk patients.
214926623|NCT00556933|DRUG|rabbit anti-thymocyte globulin - 4 doses|6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.
214926624|NCT00556933|DRUG|sirolimus|Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection
214926625|NCT00556933|DRUG|tacrolimus|Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.
214926626|NCT01466504|PROCEDURE|skin punch biopsy|Skin biopsy prior to sorafenib or regorafenib treatment and when rash appears or 12 weeks into treatment.
214926627|NCT05314127|DRUG|Tazarotene 0.1% Gel,Top|once daily topical application at night with a cotton tipped applicator on every lesion
214926628|NCT05314127|DRUG|Imiquimod|Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.
214926629|NCT05314127|DRUG|Fluorouracil Cream|5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
214926630|NCT05314127|DRUG|Petrolatum|applied once daily at night
214926631|NCT04057482|DRUG|D|treatment of BV with dequalinium chloride vaginal tablets
214325423|NCT07003997|DRUG|Baricitinib|This small molecule, orally bioavailable agent is an immunosuppressant (a medicine that reduces the activity of the immune system). It works by blocking the action of enzymes known as Janus kinases (JAK). These enzymes play an important role in the processes of inflammation. Patients will receive a dose of 2 mg oral daily.
214325424|NCT07003997|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.
214926632|NCT01375972|DRUG|S-1 plus cisplatin|S-1 40 mg/m2 D1-D14 Cisplatin 60 mg/m2 D1 every 3 weeks
214325425|NCT06672523|DRUG|BMS-986504|Specified dose on specified days
214325426|NCT06672523|DRUG|[14C]-BMS-986504|Specified dose on specified days
214325427|NCT06541795|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV-absorbing, with or without blue light filtering, foldable IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients from whom a cataractous lens has been removed. The IOL mitigates the effects of presbyopia by providing an extended depth of focus. The toric models in addition reduce residual refractive astigmatism in patients with pre-existing corneal astigmatism.
214325428|NCT06588634|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
214325429|NCT06588634|PROCEDURE|Standard of Care|Standard of care treatment for pulmonary embolism
214325430|NCT07005141|DEVICE|Endovascular Iliac Branch Stent-Graft Implantation|Implantation of a self-expanding dual-lumen iliac branch stent-graft designed to treat iliac artery aneurysms while preserving perfusion to the internal iliac artery. The device enables connection to bridging stent-grafts directed to both the internal and external iliac arteries. It is compatible with previously implanted or concurrently implanted bifurcated aortic stent-grafts with branch diameters between 14 and 16 mm. The stent-graft is delivered endovascularly using a low-profile catheter-based system under fluoroscopic guidance. Once in position, the device is deployed via a controlled pull-back release mechanism. Radiopaque markers assist in precise alignment and facilitate the placement of bridging components.
214325431|NCT06868277|BIOLOGICAL|Rilvegostomig|Administered intravenously (IV) on Day 1 of each 21-day cycle
214486132|NCT05975736|BEHAVIORAL|Search only for calcifications|Participants search the simulated mammogram for simulated calcifications.
214486133|NCT05975736|BEHAVIORAL|Search for both together|Search the simulated mammogram for both simulated masses and simulated calcifications at the same time.
214926633|NCT01375972|DRUG|Gemcitabine plus Cisplatin|Gemcitabine 1000 mg/m2 IV D1, D8 Cisplatin 60 mg/m2 IV D1 Every 3 weeks
214926634|NCT00944086|OTHER|Recruitment Manoeuvre|Recruitment Manoeuvre
214926635|NCT01743560|DRUG|RAD001|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
214926636|NCT01743560|DRUG|Exemestane|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
215069154|NCT01824810|PROCEDURE|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
214325432|NCT06868277|BIOLOGICAL|Pembrolizumab|Administered intravenously (IV) on Day 1 of each 21-day cycle
214325433|NCT06864403|DRUG|Mirikizumab - Intravenous (IV)|300 mg mirikizumab at Weeks 0, 4, and 8
214325434|NCT06864403|DRUG|Mirikizumab - Subcutaneous (SC)|Pre-filled syringes administered at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
214325435|NCT03377712|DEVICE|optoelectronic plethysmography|Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations
214325436|NCT03377712|DEVICE|diaphragmatic ultrasound|Evaluates the diaphragmatic mobility through images, simple and non-invasive use
214325437|NCT03377712|DEVICE|Postural evaluation|Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive
214325438|NCT03377712|DEVICE|Pain evaluation|by means of questionnaires
214926637|NCT03296644|DEVICE|Class II correction using PowerScope2|
214926638|NCT03296644|DEVICE|Class II correction using Forsus|
214325439|NCT03377712|DEVICE|Evaluation of the function|through questionnaires
214325440|NCT03377712|DEVICE|Functional capacity assessment|Evaluated through the six-minute walk test, where the patient walks along a 30-meter corridor, simple, fast and safe assessment
214325441|NCT03377712|DEVICE|Quality of life assessment|through questionnaire
214926639|NCT05972408|PROCEDURE|percutaneous nephrlolithotomy|Endoscopic removal of renal stones
214926640|NCT05972408|GENETIC|VDR gene, CASR gene|checking possible mutations of VDR and CASR genes
214926641|NCT05581784|OTHER|Pain neuroscience education|"PNE sessions will be led by an experienced physical therapist certified in PNE in 35-minute face-to-face group sessions. Here elements of the neurophysiology of pain are addressed, as well as the different psychosocial dimensions that influence it. The distribution of themes will be carried out as follows:~Week One: Coping with Pain. Week 2: Pain and Cognition Week 3: Your security system Week 4: Altered Alarm System (extra sensitive). Week 5: The defense system is in distress. Week 6: Fatigue, anxiety, and stress Week 7: Current Models of Treatment Week 8: Achievements and goals Week 9: Pain emphasis and differentiation This group remains with pharmacological treatment and the usual guidelines given by the doctor."
214926642|NCT05581784|OTHER|Conventional management or Usual care|This group will only have pharmacological treatment and the usual guidelines given by the doctor. Without educational intervention.
214325442|NCT07009132|DEVICE|Dual cholate clearance assay|Study participants are administered labeled oral and intravenous cholate, and then two blood samples are taken over 60-minutes. Serum cholate levels are measured by blood draws.
214325443|NCT07009132|RADIATION|MRI|Unsedated non contrast cardiac magnetic resonance imaging (MRI)
214325444|NCT07133178|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine
214325445|NCT07133178|BIOLOGICAL|Control|Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization
214325446|NCT07008118|DRUG|INCA035784|INCA035784 will be administered at protocol defined dose.
214325447|NCT05871008|OTHER|Assessment tool IA3-CP with SDoH|Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.
214926643|NCT06218537|DIAGNOSTIC_TEST|Test group|Contains protease from KREON capsules, activated by adding sodium bicarbonate.
214926644|NCT06218537|DIAGNOSTIC_TEST|Control group|Contains only sodium bicarbonate.
214926645|NCT00004237|DRUG|cyclophosphamide|
214926646|NCT00004237|DRUG|doxorubicin hydrochloride|
214926647|NCT00004237|DRUG|epirubicin hydrochloride|
214926648|NCT00004237|DRUG|mitoxantrone hydrochloride|
214325448|NCT05871008|OTHER|Assessment tool IA3-CP without SDoH|Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.
214325449|NCT06619457|OTHER|Mitopure (Urolithin A) Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
214926649|NCT00004237|DRUG|vinorelbine tartrate|
214325450|NCT06619457|OTHER|Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
214325451|NCT06504251|DIAGNOSTIC_TEST|Delirium Diagnostic Tool-Provisional ( DDT-Pro )|The Delirium Diagnostic Tool-Provisional (DDT-Pro) is another tool created to assist in the diagnosis of delirium. It does not require specialist expertise. It can assess the main symptoms of acute confusion, including cognitive ability (Cognition), higher-level thinking skills (Higher level thinking), and the sleep-wake cycle (Sleep-wake cycle).
214325452|NCT06120283|DRUG|BGB-43395|Planned doses administered orally.
214325453|NCT06120283|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
214325454|NCT06120283|DRUG|Letrozole|Standard dose administered orally as a tablet.
214325455|NCT06120283|DRUG|Elacestrant|Standard dose administered orally as a tablet.
214325456|NCT07010705|DEVICE|ActiGraph LEAP|The ActiGraph LEAP has received 510(k) clearance from the US FDA and offers extensive sensor collections, providing continuous digital measures of activity, sleep, mobility, and additional vital signs, including heart rate and variability, oxygen saturation, and skin temperature, in a single fit-for-purpose device.
214325457|NCT07010705|DEVICE|Axivity AX6|The Axivity AX6 is a data logger capable of recording raw data from a suite of integrated sensors. It features a state of the art 6-Axis movement sensor measuring linear acceleration and angular velocity at high precision. All sensor locations and Orientations are identical to the AX3 for maximum compatibility. All data is stored in its raw, unaltered format on the embedded flash memory.
214325458|NCT06625593|DRUG|BG-C137|Administered intravenously
214926650|NCT00004237|PROCEDURE|conventional surgery|
214926651|NCT00004237|RADIATION|radiation therapy|
214325459|NCT05875246|BEHAVIORAL|Micro-interventions|Group 1: No intervention Group 2: Brief stress reduction messages Group 3: App based stress reduction audio activity
214325460|NCT07015190|DRUG|Darovasertib|Dosed orally, twice daily (28-day/ cycle
214325461|NCT07015190|PROCEDURE|Primary Local Therapy|Plaque Brachytherapy or Enucleation
214325462|NCT02285504|DRUG|SAGE-547|Intravenous injection
214325463|NCT06686771|RADIATION|SBRT|Please refer to the current NCCN NSCLC guidelines for possible treatment options
214325464|NCT06686771|OTHER|Second-line standard of care therapy|Please refer to the current NCCN NSCLC guidelines for possible treatment options.
214486134|NCT05975736|BEHAVIORAL|Search for one after the other|Search the simulated mammogram for first for simulated masses and then for simulated calcifications sequentially (or vice versa).
214673050|NCT06971328|OTHER|ACT-based psychoeducation|It is thought that ACT-based psychoeducation will be an effective psychiatric nursing practice in reducing the care burden of individuals caring for schizophrenia patients and increasing their post-traumatic development and psychological resilience. However, no study has been found in the literature evaluating the effects of these three parameters. In general, the number of ACT-based psychoeducation studies applied to schizophrenia caregivers is quite low. Three thesis studies were found in our country, and no study examining the effect of ACT-based psychoeducation on the post-traumatic development levels of schizophrenia caregivers was found in the domestic and foreign literature. Based on this gap in the literature, the planned study is aimed to be presented to the literature as an intervention that can be used in holistic psychiatric nursing care and to reveal its effects in the specified parameters.
214926652|NCT03321851|DEVICE|V-sensor device user|Participants use device to detect the 5 vital signs (Blood Pressure, Pulse, Respiration, SpO2, Temperature).
214926653|NCT04222998|OTHER|Home-based growth charts|The growth chart contains simple information of nutritious food, health, and sanitation information at the top and height chart is located at the bottom where caregivers can measure their child's linear growth. Growth charts will be installed in intervention group homes just after the baseline survey.
214926654|NCT04222998|OTHER|Home visits for baseline surveys|Households will be visited for baseline surveys.
214926655|NCT04222998|OTHER|Home visits for end line surveys|Households will be revisited after 1 year of grace-period for baseline end line surveys.
214926656|NCT04222998|OTHER|Measurement of child's height-for-age and weight-for-age|The child's height-for-age and weight-for-age will be measured for participating dyads at the time of the baseline and end line surveys.
214926657|NCT04901247|BEHAVIORAL|media refreshment|20µL of culture medium is aspirated using Eppendorf PCR tips, and freshly, overnight equilibrated 20µL global total LP will be added to the same well
214926658|NCT04901247|BEHAVIORAL|embryo grading|embryo grading should be done prior to media refreshment
214926659|NCT06529445|DRUG|High Dose VC004 Capsules|VC004 Capsules qd per period, for two periods
214926660|NCT06529445|DRUG|Median Dose VC004 Capsules|VC004 Capsules qd per period, for two periods
214926661|NCT06529445|DRUG|Low Dose VC004 Capsules|VC004 Capsules qd per period, for two periods
214926662|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension (dry powder) in fasted conditions.
214325465|NCT04656600|DRUG|Cerezyme® / Imiglucerase|Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous
214325466|NCT01592968|OTHER|Cognitive Assessment|Ancillary studies
214926663|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 20 mg oral suspension (dry powder) in fed conditions.
214325467|NCT01592968|OTHER|Quality-of-Life Assessment|Ancillary studies
214325468|NCT01592968|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214325469|NCT01592968|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
214325470|NCT07020117|DRUG|[225Ac]Ac-AKY-1189 (therapeutic)|\[225Ac\]Ac-AKY-1189 Injection
214325471|NCT07020117|DRUG|[64Cu]Cu-AKY-1189 (imaging)|\[64Cu\]Cu-AKY-1189 Injection
214325472|NCT07018895|DRUG|Sham treatment|ambient air (FiO2 = 21%) will be delivered for 3 days 1 time a day for 45 minutes
214325473|NCT07018895|DRUG|FiO2 reduced by 20% alternating with 34% FiO2|FiO2 reduced by 20% alternating with 34% FiO2
214673051|NCT06971237|DRUG|Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization|"Atezolizumab ± Bevacizumab: Peri-immunotherapy with , with or without bevacizumab, given before and after SIRT.~\- Yttrium-90 Radioembolization: Selective Internal Radiation Therapy (SIRT) via intra-arterial injection of Yttrium-90 microspheres for liver tumor control"
214325474|NCT07019818|DRUG|Esmolol Hcl 10Mg/Ml Inj|Esmolol is an injectable cardioselective beta-blocker, preferentially inhibiting beta-1 adrenergic receptors, while avoiding an increase in peripheral vascular resistance.
214673052|NCT06971237|DRUG|Atezolizumab ± Bevacizumab|Standard systemic immunotherapy administered without SIRT, using atezolizumab with or without bevacizumab.
214673053|NCT06969976|PROCEDURE|curl exericse|we use the curl exercise for control group to investigate the immediate effect of it on muscle strength in normal adults
214673054|NCT06969976|PROCEDURE|dry cupping and curl exercise|use dynamometer to measure biceps muscle strength in normal adults during the application of dry cupping with curl exercise
214926664|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension in fasted conditions.
214926665|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg tablet in fasted conditions.
214926666|NCT03556501|DIAGNOSTIC_TEST|Endoscopy|Purpose of this study is to create a prospective registry of patients with pancreatic collections and their imaging studies
214926667|NCT01432301|DRUG|uridine triacetate|uridine triacetate granules, 10gms, q6H x 20 doses
214926668|NCT01130441|BEHAVIORAL|psychotherapy|short problem-solving skills therapy intervention
214926669|NCT03200314|OTHER|Measurment of blood recirculation|Ultrasound based measurments of blood recirculating through the vvECMO circuit.
214926670|NCT06576141|OTHER|Kaleidoscope|The participation of patients in this group in the study will take approximately 15-20 minutes.
214926671|NCT06576141|OTHER|Virtual Reality|The participation of patients in this group in the study will take approximately 15-20 minutes.
214926672|NCT06576141|OTHER|control|The participation of patients in this group in the study will take approximately 5-10 minutes.
214926673|NCT02882217|DRUG|XC8 (histamine glutarimide)|
214926674|NCT02882217|DRUG|Placebo|
214325475|NCT07019818|DRUG|Sufentanil 5 mcg|Sufentanil is a synthetic opioid with the pharmacological properties of a µ-receptor agonist.
214325476|NCT07018323|DRUG|IMVT-1402|Dose 1 for 26 weeks
214325477|NCT07018323|DRUG|IMVT-1402|Dose 2 for 26 weeks
214325478|NCT07018323|DRUG|Placebo|For 26 weeks
214325479|NCT04918303|DEVICE|SKNA recording|"The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.~It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6"
214325480|NCT06097845|DIAGNOSTIC_TEST|Transcranial Ultrasound|Patients who underwent reconstructive sonolucent cranioplasty will receive standard of care postoperative imaging (i.e. CT, MRI) in addition to ultrasound imaging. Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices (GE Venue Go, Fujifilm Sonosite X-Porte, GE Volusion E10 and Clarius HD3 etc.) currently used in routine clinical practice.
214325481|NCT04154111|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; double blinded
214325482|NCT04154111|DEVICE|Sham TBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
214325483|NCT04154111|DEVICE|Real TBS to the dlPFC|This will be delivered with the Magventure Magpro system (double blinded).
214325484|NCT04154111|DEVICE|Sham TBS to the dlPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
214325485|NCT06698497|BEHAVIORAL|Communication Campaign|A social media vaccine communications campaign is deployed once increasing amounts of SARS-CoV-2 RNA are identified in the New York State wastewater surveillance network. The social media campaigns on Facebook, Instagram, and NextDoor social media platforms will run for 11 weeks. The campaign disseminates information about the wastewater surveillance network and vaccination (not COVID-19 specific) to residents in intervention counties. These social media platforms not only allow for quick and cost-effective exposure, but also allow for participation and interaction with participants. The campaign ads include a call-to-action link to the New York State wastewater surveillance network webpage which has information and links regarding vaccines for respiratory transmitted pathogens (COVID-19, influenza, and RSV) and how to schedule an appointment.
214325486|NCT06879457|BEHAVIORAL|PCC-based mHealth-assisted self-care support intervention|Participants receive six bi-weekly WhatsApp video call sessions with a NCM over three months, using a person-centred care (PCC) approach.
214325487|NCT06879457|BEHAVIORAL|Provider-led mHealth-assisted self-care support intervention|Participants receive six bi-weekly WhatsApp video call sessions with a NCM over three months, based on the conventional provider-led model.
214325492|NCT06695845|DRUG|Zanidatamab|Administered by intravenous (IV) infusion
214926675|NCT04535869|DRUG|Sofosbuvir 400 MG plus Daclatasvir 200mg|This group which receive sofosbuvir and daclatasvir for 14 days plus standard therapy
214926676|NCT05533008|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg as a bolus injection
214926677|NCT05533008|OTHER|Placebo|IV Placebo as a bolus injection
214926678|NCT04808063|PROCEDURE|Prophylactic mesh implantation|Use of an algorithm for prophylactic mesh implantation in high risk patients after emergency midline laparotomy.
214926679|NCT03860402|OTHER|Temperature|temperature of drug
214926680|NCT02119455|DEVICE|Vibration Device|Subjects receiving the OrthoAccel Aura device will be instructed to use the device for 20 minutes/day per the manufacturer's instructions during the study period.
214926681|NCT02695550|DRUG|CT-707|
214926682|NCT02439814|DRUG|Pregnenolone|Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
214926683|NCT02439814|OTHER|Placebo|Inactive comparator
214926684|NCT03418233|DRUG|CardioCell|"Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
214926685|NCT03418233|DRUG|Placebos|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
214926686|NCT01745536|PROCEDURE|Oocytes are vitrified/stored using a closed device|Vitrification will be carried out using a modification of the current device (Cryotop®), thus providing air tight sealing. Closed systems are devices that are hermetically sealed before vitrification and remain sealed during storage.
214926687|NCT01745536|PROCEDURE|Oocytes are vitrified/stored using an open device|The vitrification process takes place through direct contact with liquid nitrogen. The system has an external straw to protect the samples during storage, but the device is not hermetically sealed.
214926688|NCT00134706|DRUG|Docetaxel|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
214325493|NCT07034976|DEVICE|Active Radiofrequency (Capenergy C500 UpGradeC200)|"Non-ablative radiofrequency is applied using a Capenergy C500 device at a target tissue temperature of ≤ 45 °C, once a week for 6 consecutive weeks. Treatment is delivered through two channels simultaneously: a capacitive plate placed on the suprapubic area and an intracavitary vaginal probe. Each session lasts 20 minutes and is followed by 20 minutes of pelvic-floor muscle training guided by biofeedback. Participants will also follow a progressive home exercise programme and record adherence and events.~In addition, all participants will receive education on pelvic-floor anatomy and function, underlying mechanisms of pain after breast cancer, bladder and bowel retraining, respiratory pattern re-education, and-if interested-information on sexual health."
214325494|NCT07034976|DEVICE|Sham Radiofrequency (Capenergy C500 UpGrade C200 - Placebo Mode)|"Participants will receive one session per week for 6 weeks of sham (placebo) radiofrequency using the Capenergy C500 in Placebo Mode (no temperature increase), designed to simulate active treatment. The screen will display a simulated delivered energy value; temperature and energy readings will be hidden; LED indicators will activate sequentially; and a suprapubic capacitive plate and intracavitary probe will be used with the same protocol as in the intervention group. This will be followed by 20 minutes of pelvic-floor muscle training guided by biofeedback, identical to the intervention group. Participants will also follow a progressive home exercise programme and record adherence and events. All participants will receive education on pelvic-floor function, pain mechanisms after breast cancer, bladder/bowel retraining, breathing pattern correction, and-if interested-sexual health."
214325495|NCT07030894|DRUG|"Nefecon®,Ambrisentan"|"Subjects who meet the screening criteria will be treated with Budesonide in combination with Ambrisentan.~Budesonide (Nefecon®), 16mg/d for 36 weeks, taken orally. Ambrisentan , 5mg/d for 36 weeks, taken orally."
214926689|NCT00134706|DRUG|Carboplatin|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
214926690|NCT06572306|DEVICE|FreeStyle Libre 2 Continuous Glucose Monitor|Subjects included in the intervention group (continuous glucose monitoring) will be recruited from the USF Health Department of Family Medicine. Each subject will be enrolled for 12 weeks.
214325496|NCT06876779|BEHAVIORAL|VR intervention|The intervention comprises six sessions of 60 minutes each. There are six VR scenarios such as a café, MTR, school scene, and classroom. The difficulty levels of these scenarios are determined by several factors: (1) the density and proximity of individuals present, as observed in a café or MTR setting, (2) the presence of familiar individuals, such as acquaintances or classmates who may be encountered and greeted in a school environment, and (3) the level of interaction required, such as engaging in a group discussion within a classroom. Participants have the flexibility to choose a different scenario for each session or repeat a previously selected one.
214325497|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
214325498|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
214325499|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
214325500|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
214325501|NCT06749964|BEHAVIORAL|Internet-delivered, therapist-assisted, pain-focused CBT based on the psychological flexibility model for chronic pain|8-session intervention, twice weekly for the first 3 weeks and once weekly for the final 2 weeks (45-60 min each session) aimed at promoting psychological flexibility. Treatment involves a mixture of video and audiotaped presentations and homework activities for the participant.
214325502|NCT00323154|DRUG|Nalbuphine|
214926691|NCT03191461|DIAGNOSTIC_TEST|Adenosine stress test MRI|Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane
214926692|NCT02640677|BIOLOGICAL|4CMenB|This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
214926693|NCT01167933|DRUG|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
214926694|NCT02246179|DEVICE|AFXL|Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density
214926695|NCT02246179|DRUG|AHES|Topical application at test region 1 and 3 under occlusion for 10 minutes
214926696|NCT02246179|DRUG|EMLA cream|Topical application at test region 2 and 4 under occlusion for 10 minutes
214926697|NCT04813575|OTHER|Cryo lung biopsies|Bronchoscopic lung biopsy utilizing the cryo technique
214926698|NCT04589936|PROCEDURE|Prone positioning|Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.
214926699|NCT00077142|DRUG|TAC-101|Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.
214926700|NCT04152070|OTHER|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
214325503|NCT06900985|BEHAVIORAL|8-sessions CBT + App|It will consist of 8 one-hour sessions applied in group format once a week and participants will be followed at 3, 6, and 12 months. The sessions will be conducted by clinical psychology/general health psychology professionals and will be carried out using video calls. The smoking cessation treatment follows a cognitive-behavioral approach with components for anhedonia reduction, increased physical activity and positive social support, being a modified, multidisciplinary, and extended version of the original smoking cessation program (Becoña, 2007; Becoña et al., 2017). The treatment will be complemented with an App with active therapeutic components that participants will use during treatment and the one-year follow-up period.
214673055|NCT06971601|DIAGNOSTIC_TEST|Provocative test|The clinical evaluation specific to Infrapatellar fat pad is based on a series of five standardized clinical tests, extensively described in the specialized literature: provoked palpation of the fat pad, provoked passive extension, Hoffa's test, gliding test, and provoked passive flexion. These tests are performed in a randomized order to limit sequence bias. A test is considered positive if it reproduces the patient's typical anterior knee pain with an intensity greater than 2/10 on the numerical pain scale. Although widely used, these tests have not yet undergone rigorous methodological validation, which this study specifically aims to address.
214673056|NCT03897491|DRUG|5-aminolevulinic acid|5-aminolevulinic acid powder for oral solution
214926701|NCT03565159|BIOLOGICAL|Prevenar 13|Pneumococcal polysaccharide conjugate vaccine
214926702|NCT03565159|OTHER|Sodium Chloride 0.9%|Placebo
214926703|NCT06111859|DIAGNOSTIC_TEST|Ultrasound based Elastography and fat quantification|Correlation of ultrasound-based elastography and fat quantification on liver biopsy
214926704|NCT06461299|DRUG|Seysara Oral Product|"Subjects with a clinical diagnosis of POD will be given sarecycline for four weeks. Dosing of sarecycline will be weight based, either 60mg, 100mg, or 150mg PO qday. Each subject will have at least three visits, including a screening/baseline visit, a two-week follow-up, and a four-week follow-up. The initial diagnosis will be made by a board-certified dermatologist or a dermatology-certified nurse practitioner. The Perioral Dermatitis Severity Index, PODSI, (Appendix I) will be used to grade the severity of periorificial dermatitis throughout the three visits. This published scoring method ranges from 0 to 9. To be included in the study, patients must need to have a PODSI score of moderate (PODSI = 3.0-5.5) or severe (PODSI = 6.0-9.0) at baseline. The primary endpoint is the percentage of patients that receive a PODSI score ranging from 0 (none) to 2.5 (mild) at week four. The secondary endpoint is the patient reported an adverse event at week four."
214926705|NCT05580627|OTHER|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment group.
214926706|NCT05580627|OTHER|Live Modality (control)|For this evaluation, the live modality is considered the control group.
214926707|NCT02203227|DIETARY_SUPPLEMENT|Placebo|
214926708|NCT02203227|DIETARY_SUPPLEMENT|BioTurmin (Curcuma longa rhizomes extract)|
214673057|NCT06971965|DRUG|Levothyroxin|During the five-year study intervention period, thyroid hormone (oral administration) supplementary doses are determined according to a dose-adjustment protocol established for the group's target TSH range.
214926709|NCT02203227|DIETARY_SUPPLEMENT|BioTurmin-WD (Water dispersible curcuminoids)|
214926710|NCT02203227|DIETARY_SUPPLEMENT|MaQxan|
214926711|NCT05322889|DRUG|Telmisartan tablets|12 weeks treatment
214926712|NCT04993638|DEVICE|hip arthroplasty|Hip prosthesis surgery
214926713|NCT01741766|OTHER|Stretching Training|The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
214926714|NCT06533956|OTHER|10-week gait training program combined with simultaneous blood flow restriction (BFR).|The children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.
214926715|NCT05401500|BIOLOGICAL|blood sample|blood sampling
214926716|NCT04553471|RADIATION|Stereotactic body radiotherapy|Treatment will take approximately 2 weeks.
214926717|NCT04553471|PROCEDURE|Research blood draw|-Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up
214926718|NCT05154019|BEHAVIORAL|Managing Minds at Work Online Training|"The intervention will be an online, interactive training course which will include evidence-based material, guidance, and practical exercises. The training will cover the following topics, presented as a series of independent, stand-alone modules:~Module one: Looking after your own mental health Module two: Designing and managing work to promote mental well-being Module three: Management Competencies that Prevent Work-related Stress Module four: Developing a Psychologically Safe Workplace Module five: Having conversations about mental health at work Each module will be designed to take between 20 and 30 minutes to complete. Participants will be permitted by their employer to complete the training within their work time. The training is self-led, so each participant can progress through each module at their own pace and at a time that suits them."
214926719|NCT06363773|RADIATION|Stereotactic Radiotherapy|"Patients will perform stereotactic radiotherapy with 3 sessions (8 Gy) during 20 minutes each and with 72 hours in-between.~Patients enrolled in the study would not have received this stereotactic radiotherapy outside the study, that is why this procedure is additional (compared to Standard of care) and considered as burdensome (as this is radiation). Before performing the stereotactic radiotherapy, patients will do a radiotherapy CT scanner (no injected) in order to prepare precisely the radiotherapy (treatment plan)."
215069155|NCT01824810|PROCEDURE|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
214325504|NCT06900985|BEHAVIORAL|4-sessions CBT+App|It will consist of 4 one-hour sessions applied in group format every two-weeks (8 weeks total duration) and participants will be followed at 3, 6, and 12 months. The sessions will be conducted by clinical psychology/general health psychology professionals and will be carried out using video calls. The 4 sessions will have the following content: 1) explanation of treatment rationale and components available in the App; 2) participants' progress monitoring, reinforcement of achieved goals, and analysis of difficulties; 3) cessation planning support; and 4) relapse prevention support. The treatment sessions will be protocolized in a treatment manual. The treatment will be complemented with the same App that the other conditions
214325505|NCT06900985|BEHAVIORAL|Smoking cessation App|It will consist in the same App than the other two conditions. No therapeutic contact will be avaliable.
214325506|NCT06540144|DRUG|rozanolixizumab|rozanolixizumab solution for injection
214325507|NCT07075094|PROCEDURE|Bladder stimulation|This stimulation consists of two stages. In the first maneuver, the bladder is stimulated by gentle tapping of the suprapubic area for 30 seconds. In the second maneuver, the paravertebral area is massaged in a circular motion for 30 seconds. The two stimulation maneuvers are repeated sequentially for 5 minutes.
214325508|NCT07075094|PROCEDURE|Subrapubic cutaneous stimulation|Circular rubbing movements will be made on the baby's suprapubic area with gauze soaked in cold salt water until micturition begins.
214926720|NCT05917834|BIOLOGICAL|Nipple sparing mastecomy with different incision placements|Nipple sparing mastectomy was performed using Radial/Peri-areolar incision or imframammary incision
214926721|NCT05277051|DRUG|GSK4381562|GSK4381562 will be administered.
214325509|NCT07125261|DRUG|BHV-700|75 mg daily for the 4-week treatment period (dose which may be adjusted based on tolerability)
214325510|NCT06665100|DRUG|PUL-042|Pam2 : ODN (PUL-042) PUL-042 Inhalation Solution
214325511|NCT06665100|DRUG|Placebo|Sterile Saline for Inhalation
214325512|NCT03290456|DRUG|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
214325513|NCT03290456|DRUG|Placebo 5mg/day extended of 12 additionnal months.|1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 13
214325514|NCT06901570|DRUG|Kuangxiong Aerosol|Patients in the intervention group will receive Kuangxiong Aerosol for eight weeks, in addition to guideline-recommended medications. The aerosol will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.
214325515|NCT06901570|DRUG|Placebo Drug|Patients in the control group will receive a placebo version of Kuangxiong Aerosol for eight weeks, alongside guideline-recommended medications. The placebo will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.
214325516|NCT07087210|OTHER|Positron Emission Tomography (PET)|18F-TPP+ PET/CT imaging
214486135|NCT06883994|OTHER|Fermented vegetable intervention|"Participants will be provided with reduced-sodium fermented vegetables developed by Dr. Ilenys Pérez-Díaz at the USDA-ARS Food Science and Market Quality and Handling Research Unit. The fermented, refrigerated vegetables have been shown to have Lactiplantibacillus spp. content \>10\^7 CFU/mL at 21 days shelf-life.~Products are prepared in a Good Manufacturing Practices Facility at North Carolina State University, Department of Food, Bioprocessing, and Nutrition Sciences.~The fermented vegetables will be shipped in coolers on cold packs with temperature indicators to the WHNRC. Participants will be asked to consume two pre-packaged 50g servings of fermented vegetables a day, for a total daily serving of 100g, not to heat the fermented vegetables prior to consumption, to log their consumption and to rate the acceptability of the fermented vegetables. They will be advised to avoid other fermented foods and to otherwise maintain their habitual diet."
214926722|NCT05277051|DRUG|Dostarlimab|Dostarlimab will be administered.
214926723|NCT05277051|DRUG|Belrestotug|Belrestotug will be administered.
214926724|NCT05277051|DRUG|Nelistotug|Nelistotug will be administered.
214926725|NCT05277051|DRUG|GSK5764227|GSK5764227 will be administered.
214926726|NCT04399135|DIAGNOSTIC_TEST|Orthopantomogram X-ray view|taking an X-ray to determine bone loss level and attachment loss level for periodontitis classification
214325517|NCT07086014|BEHAVIORAL|Cognitive Reappraisal|an emotion-regulation strategy while being asked to complete cognitive tasks.
214926727|NCT04399135|DIAGNOSTIC_TEST|Endo-Ice|Included teeth will be dried with 4x4 gauze then tested with a cold test using Endo-Ice.
214926728|NCT04399135|DIAGNOSTIC_TEST|Electric Pulp Tester (EPT)|Included teeth will be dried with 4x4 gauze then tested with an Electric test using electric pulp tester (EPT).
214926729|NCT02449382|PROCEDURE|continuous venovenous hemofiltration|If the serum sodium concentration \>150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment
214926730|NCT02449382|DRUG|Control group|If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
214325518|NCT06805318|BEHAVIORAL|Vocational Rehabilitation intervention for pwMS|"The VR intervention will cover three areas of intervention:~* Rehabilitation Area: this intervention has the goal of managing the work performance from a rehabilitative point of view.~* Reasonable accommodation area: this intervention has the goal of assessing the needs of reasonable accommodations, such has workspace modification, change in organization of the activities, management of work time, etc.., and propose it to the employer.~* Educational and Formative Area: this area is responsible for the implementation of educational intervention for the employees and the employers about multiple sclerosis and its impact on work performance, the rights and obligations of the employer and employee about disability management on the workplace."
214325519|NCT06888609|OTHER|Back Extensor Strengthening Exercises|"1. Superman Exercise Sets/Reps: 2 sets × 10-12 reps, hold 5-10 sec~2. Prone Arm and Leg Raise Sets/Reps: 2 sets × 10-12 reps, hold 5-10 sec~3. Seated Row (Resistance Band) Sets/Reps: 2 sets × 12-15 reps, hold 3-5 sec~4. Wall Angels Sets/Reps: 2 sets × 10-12 reps, 3-5 sec per cycle"
214325520|NCT06888609|OTHER|Core Stability Exercises|"1. Side Plank Sets/Reps: 3 sets, hold 10-60 sec per side~2. Dead Bug Exercise Sets/Reps: 3 sets × 6-15 reps per side~3. Bridging Exercise Sets/Reps: 3 sets × 10-20 reps, hold 2-5 sec~4. Bird-Dog Exercise Sets/Reps: 3 sets × 8-15 reps per side, hold 2-5 sec"
214325521|NCT07174167|DRUG|Genicular nerve block with prilocaine|ultrasound guided genicular nerve block (GNB) injecting 6 mL of 2% prilocaine to the genicular nerves
214325522|NCT07174167|DRUG|genicular nerve block with prilocaine and triamcinolone|ultrasound guided genicular nerve block (GNB) injecting 5 mL of 2% prilocaine in combination with 1 mL/40 mg of triamcinolone to the genicular nerves
214325523|NCT07174167|DRUG|Sham injection|placebo injection using 6 mL of 0.9% saline to knee region other than genicular nerves
214325524|NCT07174141|OTHER|Ophthalmological examination|at inclusion, at 3 months and 6 months; OCT-A retina
214325525|NCT07174141|BIOLOGICAL|Blood sample|Collection of a 2 mL blood sample at inclusion
214325526|NCT07174128|OTHER|Fluid Therapy|Patients would receive the second round of fluid loading if the Plethysmographic Variability Index (PVI) was 14%.
214325527|NCT07174128|OTHER|Fluid Therapy|Patients would receive the second round of fluid loading if the Plethysmographic Variability Index (PVI) was 20%.
214325528|NCT07172503|DRUG|68Ga-NOTA-GPA33 nanobody|To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed colorectal cancer, gastric cancer, pancreatic cancer and other malignant tumors with high GPA33 expression and healthy volunteers, using specific positron imaging agents target GPA33(in the case of \[68Ga\]Ga-NOTA-GPA33 nanobody) , to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
214325529|NCT07164742|BEHAVIORAL|8 week (short arm) Intervention - pulmonary rehabilitation|8 weeks (short arm) of a pulmonary rehabilitation (PR) program, administered during TB treatment, comprising of exercise training, counselling and education, and airway clearance techniques.
214325530|NCT07164742|BEHAVIORAL|24 week (long arm) Intervention - pulmonary rehabilitation|24 weeks (extended arm) of a pulmonary rehabilitation (PR) program, administered during TB treatment, comprising of exercise training, counselling and education, and airway clearance techniques.
214325531|NCT07173231|DEVICE|Immersive Virtual Reality Distraction (IVR)|The first experimental group will receive the INSPIRE® IVR intervention in addition to usual care. Developed by Paperplane Therapeutics®, INSPIRE® is specifically designed to help manage pain and anxiety in clinical settings. This intervention integrates immersive virtual environments with sensor-guided deep breathing techniques to engage the parasympathetic nervous system and promote relaxation. Within a calming forest environment, participants are guided to synchronize their breathing with the movement of a feather, encouraging breath control and relaxation. The immersive experience is enhanced through personalized therapeutic content and calming visual and auditory stimuli, helping to reduce anxiety while minimizing the risk of cybersickness. This program has been endorsed by a multidisciplinary team of healthcare professionals.
214926731|NCT03448731|DRUG|Doxycycline 50Mg Tablet|Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
214926732|NCT04155229|OTHER|Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)|"For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg."
214325532|NCT07173231|DEVICE|Hypno-Virtual Reality Distraction (HVR)|The second experimental group will receive the HVR intervention in addition to usual care. This intervention, developed by HypnoVR, consists of a VR visual scenario combined with hypnotic verbal guidance specifically designed to reduce pain and anxiety during medical procedures. It is delivered through a validated and clinically approved HVR headset. The intervention includes reassuring and calming verbal suggestions aimed at helping participants regulate their emotions and manage anxiety throughout the procedure. Participants will be able to choose from 11 different visual scenarios, select their preferred language, and choose between a male or female voice for the hypnotic guidance. 6 different musical soundtracks will also be available to personalize the experience more.
214325533|NCT07173231|OTHER|Usual Care Group|The usual care group will only receive the standard preparation, which includes pre-treatment with Tylenol (1000mg) , Naproxen (500mg) and Ativan (1 mg) administered one hour prior to the procedure.
214926733|NCT01259804|DIETARY_SUPPLEMENT|Peanut oral immunotherapy|Daily doses of peanut flour
214926734|NCT03048292|OTHER|Acute Endovascular Stroke Treatment|
214926735|NCT02573415|PROCEDURE|Uterus Transplant|transplant of a deceased donor uterus.
214926736|NCT00535717|PROCEDURE|uttarbasti (per urethral administration of medicated oil )|
214926737|NCT01886209|DRUG|Prednisone|
214325534|NCT07173348|OTHER|Hypnosis|Participants will undergo three 15-minute individual hypnosis intervention, conducted by a trained hypnotherapist, with a two-week interval between each session. A guide for the session has been developed by two experimented hypnotherapists specifically for this intervention and will be used for all sessions. A total of 3 hypnosis session will be realized.
214325535|NCT07173751|DRUG|Pumitamig|Solution for intravenous (IV) infusion
214325536|NCT07173751|DRUG|Nab-paclitaxel/Paclitaxel|IV infusion
214325537|NCT07173751|DRUG|Gemcitabine|IV infusion
214325538|NCT07173751|DRUG|Carboplatin|IV infusion
214325539|NCT07173751|DRUG|Eribulin|IV infusion
214325540|NCT07173751|DRUG|Matching placebo|IV infusion
214325541|NCT07171814|DRUG|Honghua Xiaoyao tablets|The non-exposed group (patients who did not receive Honghua Xiaoyao Tablets or other targeted drug treatments) only received routine clinical observation, and no drug intervention was applied after obtaining informed consent. If patients need to withdraw from the study due to their condition during the study period, on the premise that the patients have given full informed consent, doctors shall recommend other treatment regimens in accordance with clinical standards (when necessary, first-line drugs such as selective serotonin reuptake inhibitors (SSRIs) may be selected for intervention).
214325542|NCT07172113|DEVICE|CBT + VR|This CBT intervention is conducted in VR using Embodied AI technology. A virtual therapist will present in a virtual therapy room. Participants can freely talk to and interactive with the virtual therapist.
214325543|NCT07172633|OTHER|scenario-based simulation teaching with virtual technology|5-week scenario-based simulation teaching with a virtual coach acting as an older adult with dementia in addition to regular dementia care lectures
214325544|NCT07172633|OTHER|traditional dementia case discussions|5-week traditional dementia case discussions in addition to regular dementia care lectures
214325545|NCT07172438|OTHER|P2611222|Menthol flavor
214325546|NCT07172438|OTHER|P2615022|Non-tobacco non-menthol flavor
214325547|NCT07172438|OTHER|P2615122|Non-tobacco non-menthol flavor
214325548|NCT07172438|OTHER|P2613422|Tobacco flavor
214325549|NCT07172841|DEVICE|"Intervention group Virtual OFF"|"Patients randomized to shunt setting Virtual Off at the three month follow-up visit. After 5-7 days, the setting will be restored to the previous setting."
214325550|NCT07172841|DEVICE|Control group (no change in shunt setting)|Patients randomized to continue their shunt setting unchanged
214325551|NCT07174206|DEVICE|Smartwatch - all data|Single-lead ECG, blood pressure (BP), oxygen saturation (SpO2), and continuous heart rate (HR).
214325552|NCT07174206|DEVICE|Portable holter system|continuous ECG monitoring for 14 days for comparison with the data from the smartwatch
214325553|NCT07174206|PROCEDURE|Telemonitoring|Remote consultations triggered by critical alerts based on predefined thresholds.
214926738|NCT01886209|DRUG|VX-509|
214926739|NCT01886209|DRUG|Methylprednisolone|
214325554|NCT07174206|OTHER|AI Model Development|Data analysis using artificial intelligence for prioritization of patients based on health data collected from wearables.
214926740|NCT02754271|OTHER|Fit for Dialysis|A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
214926741|NCT00940823|DEVICE|Ahmed FP7 Valve|Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
214926742|NCT00940823|DEVICE|Baerveldt-350 Tube|Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
214926743|NCT02236845|DEVICE|Lacrima Medical Device and sham comparator|
214926744|NCT06028685|DEVICE|Acupoint stimulation|The experimental group will receive low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3). The stimulation will be administered three times per week for a duration of six weeks.
214325555|NCT07174206|DEVICE|Smartwatch - ECG and HR|Single-lead ECG and continuous heart rate (HR)
214325556|NCT07172854|OTHER|Pelvic Floor Muscle Training|Supervised PFMT with biofeedback, 3 times per week for 12 weeks, plus home exercises.
214325557|NCT07172854|OTHER|Aerobic Exercise|Treadmill walking, moderate intensity (Borg 4-6), 60 minutes/session, 3 times per week for 12 weeks.
214325558|NCT07172854|OTHER|Relaxation Training|Guided breathing, imagery, and meditation, once weekly for 12 weeks, in addition to home practice.
214325559|NCT07172854|OTHER|Patient Education|Standardized education on urinary incontinence, pelvic anatomy, lifestyle modification, and stress management.
214325560|NCT07173842|OTHER|Biobanking and Phenotypic Data Collection|This intervention involves the systematic collection of blood samples (EDTA tubes for DNA extraction) and detailed phenotypic/clinical data using the NeuroCybe Data Collector software. All biospecimens are processed and stored at the RTSGD-NeuroPsyBiT Biobank under ISO-compliant procedures. Data are entered into a secure on-premises server infrastructure (GDPR/KVKK compliant) for long-term use in genomic and epigenomic studies. No therapeutic intervention is applied; all activities are non-invasive and focused on sample and data acquisition.
214325561|NCT07173933|GENETIC|GC310|GC310 is an adeno-associated virus 5 (AAV5) vector delivering a functional copy of the truncated human ATP7B gene
214325562|NCT07173075|DIAGNOSTIC_TEST|impedancemetry|impedancemetry by the InBody S10 device, during a visit, after stabilization of the patient's blood volume, within a limit of 7 days after inclusion
214926745|NCT06028685|DEVICE|Acupoint stimulation(placebo)|The control group will receive sham low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3), without emitting laser beams.The stimulation will be administered three times per week for a duration of six weeks.
214325563|NCT05391633|BEHAVIORAL|Recorded Maternal Voice|60-minute looped recording of maternal voice, played once daily for 14 total days.
214325564|NCT05391633|BEHAVIORAL|Placebo Recording|60-minute blank recording played once daily for 14 total days.
214325565|NCT06085313|BEHAVIORAL|CAI|Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality
214325566|NCT06085313|BEHAVIORAL|CAPA|Web App-based information and coaching/support program for cancer pain management
214325567|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
214325568|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
214325569|NCT03890367|BIOLOGICAL|Meningococcal group C polysaccharide Conjugate vaccine adsorbed|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214325570|NCT01501812|BEHAVIORAL|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
214325571|NCT03826329|OTHER|observational study|this is an observational study, there is no intervention in this study
214926746|NCT02194712|OTHER|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
214926747|NCT01869205|DEVICE|Endobronchial valve|One-way endobronchial valves are placed in segmental bronchi of the most hyperinflated and least perfused lobe of the emphysematous lungs on computed tomography (CT). Before the procedure, we confirm that the target lobe has no collateral ventilation with other lobes using Chartis® System (Pulmonx, Inc. Redwood City, CA, USA).
214325572|NCT04176770|PROCEDURE|ESP Block|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
214325573|NCT04176770|PROCEDURE|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
214325574|NCT02533921|OTHER|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
214325575|NCT02533921|OTHER|Standard of Care|Usual care defined as including both a PCP and neurologist
214325576|NCT06342440|DIAGNOSTIC_TEST|DENEB|A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.
214325577|NCT03447327|PROCEDURE|single burr hole|patients with CSDH operated by single burr hole craniostomy under local anaesthesia
214325578|NCT01707004|DRUG|decitabine|Given IV
214325579|NCT01707004|DRUG|fludarabine phosphate|Given IV
214325580|NCT01707004|DRUG|busulfan|Given IV
214325581|NCT01707004|DRUG|cyclophosphamide|Given IV
214325582|NCT01707004|DRUG|tacrolimus|Given PO or IV
214325583|NCT01707004|DRUG|mycophenolate mofetil|Given PO
214325584|NCT01707004|BIOLOGICAL|filgrastim|Given SC
214325585|NCT01707004|RADIATION|total-body irradiation|Undergo total-body irradiation
214325586|NCT01707004|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
214325587|NCT01707004|OTHER|laboratory biomarker analysis|Correlative studies
214325588|NCT02042976|BEHAVIORAL|Mindfulness-based cognitive therapy|
214325589|NCT02042976|BEHAVIORAL|Pulmonary rehabilitation|
214325590|NCT03488576|PROCEDURE|Complete Macular Peeling|A complete peeling of the internal limiting membrane was performed
214926748|NCT03211780|DEVICE|General Electric LOGIQ E9 ultrasound system|Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
214325591|NCT03488576|PROCEDURE|Macular Peeling with Foveal Sparing|A partial peeling of the internal limiting membrane was performed, sparing the fovea.
214325592|NCT04865822|BEHAVIORAL|Single session pain education class|Pain education classes will be provided in person group or virtual settings
214325593|NCT03132597|BEHAVIORAL|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
214325594|NCT02188368|DRUG|POM|
214325595|NCT02188368|DRUG|Steroids|
214325596|NCT02188368|DRUG|PLD|
214325597|NCT02188368|DRUG|CFZ|
214325598|NCT02188368|DRUG|BTZ|
214325599|NCT02188368|DRUG|CLA|
214325600|NCT02188368|DRUG|CY|
214325601|NCT06028867|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
214325602|NCT04657159|OTHER|Pain rehabilitation program|Effect on health related quality of life och health-care consumption after rehabilitation
214325603|NCT00072345|DRUG|lomustine|
214325604|NCT00072345|DRUG|temozolomide|
214325605|NCT00072345|DRUG|thalidomide|
214325606|NCT00948805|DRUG|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
214325607|NCT00948805|DRUG|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
214325608|NCT06392555|DEVICE|Device-Aided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, aided by the device
214325609|NCT06392555|OTHER|Device-Unaided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, unaided by the device
214325610|NCT02864641|BEHAVIORAL|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
214325611|NCT05924464|OTHER|Group Preconception Care|Groups of 6-10 patients to initiate biweekly virtual group care sessions on a rolling basis, with completion of enrollment and the virtual curriculum within a year.
214325612|NCT04368429|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)|Pharmaceutical form: Liquid solution Route of administration: IM
214325613|NCT04368429|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration: IM
214325614|NCT04702633|OTHER|Results obtained by biopsy and MRI results.|Results obtained by biopsy and MRI results.
214325615|NCT04702633|OTHER|Clinical data|Clinical data
214325616|NCT04071457|DRUG|Lenalidomide|Commercially available intervention
214325617|NCT04071457|DRUG|Daratumumab/rHuPH20|SWOG-Held IND
214325618|NCT05301270|DIAGNOSTIC_TEST|EMG Evaluation|Muscle activations in the lower extremity and trunk muscles during compensatory postural responses will be evaluated. The Delsys Trigno IM (Delsys Inc. Natick, Massachusetts, USA) wireless surface electromyography (EMG) system will be used to evaluate muscle activation. In the lower extremity; Muscle activations of tibialis anterior, gastrocnemius, quadriceps and hamstring muscle groups and erector spinae in the trunk will be evaluated. While the muscle groups above the stump on the amputated side of the individuals in the amputation group will be evaluated, all muscle groups specified on the healthy side will be evaluated. In the control group, all muscle groups on the dominant side, but on the non-dominant side, all other muscles except the tibialis anterior and gastrocnemius muscles will be evaluated in order to be compatible with the amputation group.
214325619|NCT01167712|BIOLOGICAL|Bevacizumab|Given IV
214325620|NCT01167712|DRUG|Carboplatin|Given IV
214325621|NCT01167712|PROCEDURE|Computed Tomography|Correlative studies
214926749|NCT06665360|OTHER|The high speed bur was used to mill the cancellous cortical bone of the lamina|The high speed bur was used to mill the cancellous cortical bone of the lamina
214926750|NCT03641326|DRUG|Sunitinib|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.
214325622|NCT01167712|DRUG|Paclitaxel|Given IV
214325623|NCT01167712|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214325624|NCT04798274|DEVICE|Continuous Theta Burst Stimulation|Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
214325625|NCT03756558|DEVICE|Cross-Seal System|Use of the Cross-Seal system to close the femoral arteriotomy
214325626|NCT05132075|DRUG|JDQ443|JDQ443 tablets, orally administered
214325627|NCT05132075|DRUG|docetaxel|docetaxel concentrated solution for infusion, intravenously administered
214486136|NCT06717243|DRUG|Carboplatin/Cisplatin -Etoposide - Atezolizumab|"This intervention represents the standard-of-care first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC). The regimen includes:~Carboplatin or Cisplatin: Platinum-based chemotherapeutic agents that cause DNA cross-linking, leading to tumor cell death.~Etoposide: A topoisomerase II inhibitor that prevents DNA replication and tumor growth.~Atezolizumab: A PD-L1 immune checkpoint inhibitor that enhances the immune system's ability to detect and destroy cancer cells.~This combination therapy is administered as part of routine clinical practice. The study does not investigate the efficacy or safety of these drugs but rather focuses on analyzing molecular changes in tumors, such as genomic and epigenetic alterations, to understand mechanisms of treatment resistance. Biospecimens are collected from patients during treatment and progression for detailed analysis."
214486137|NCT06718686|DRUG|Rifaximin SSD 40 mg IR tablet|Drug therapy vs placebo
214926751|NCT03641326|DEVICE|wGT3x-BT|Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
214926752|NCT00323791|DRUG|gemcitabine hydrochloride|
214325628|NCT04861402|DEVICE|The ICP monitoring will be performed in a non-invasive method developed by Brain4Care|"The ICP monitoring will be performed in a non-invasive way through the cranial deformation method developed by Brain4Care Inc.~The selected patients will be monitored until 1h/day for 7 sequential days or even discharge. The clinical outcomes such as ventilatory status will be noted (if the subject is under oxygen supplementation, using non-invasive mechanical ventilation or intubated), the ventilatory parameters during the monitorization will be analyzed in the intubated group (or those from a non-intubated group who was intubated during the seven days of hospitalization) including IFO2, CV, PEEP, driving pressure, and pressure plate as well as ventilatory asynchronies. Some changes in ventilatory parameters during monitorization will be noted. These procedures will be applied to all groups, excepted to the healthy group. This last group will be monitored only once for 30 minutes at the Federal University of São Carlos (UFSCar)."
214325629|NCT05978700|DEVICE|Video-game|The video-game has three games: (1) Game One - Lip Exercise; (2) Game Two - Tongue Exercises; (3) Game Three - Lower Jaw Exercise. The whole training will take about once a day for 30 min per session, 5 times a week for 4 weeks.
214325630|NCT05978700|BEHAVIORAL|Conventional therapy|The control group used the conventional swallowing function training. The lip exercise consisted of the following specific movements: opening mouth, closing mouth, drumming cheeks, left drumming cheeks, and right drumming cheeks; the tongue exercise consisted of the following specific movements: extending the tongue, tongue up, tongue down, tongue left, and tongue right. Each specific movement in the steps lasts 2-3s, repeat 15 times and continue with the next movement. The lower jaw movement contains the following specific movements: keep the head as low as possible, and squeeze the rubber ball placed on the neck for 2-3 seconds, repeat 15 times.
214926753|NCT00323791|DRUG|imatinib mesylate|
214926754|NCT00323791|GENETIC|gene expression analysis|
214926755|NCT00323791|GENETIC|protein expression analysis|
214926756|NCT00323791|OTHER|immunohistochemistry staining method|
214926757|NCT00323791|OTHER|laboratory biomarker analysis|
214325631|NCT04253171|DEVICE|Lithoplasty|"The lithoplasty balloon should be utilized as early as possible. If it is necessary for passage of the lithoplasty balloon, the lesion may first be predilated with an undersized conventional balloon, non-compliant or semi-compliant. If passage of the lithoplasty balloon is still not possible, it is recommended to perform rotational atherectomy with a small burr size.~The lithoplasty balloon is sized 1:1 to reference diameter. Lithoplasty is performed with the balloon dilated at 4 atmospheres, and 10 shocks are delivered, after which the balloon is expanded to 6 atmospheres for 30 seconds, and then deflated. Up to 8 series of balloon expansion/deflation can be delivered in this manner if necessary, and several balloons may be used for long lesions."
214926758|NCT06675526|BEHAVIORAL|Detour|"Detour is a mobile game designed to assist youth with smoking cessation. First, Detour targets stimuli devaluation using a gamified go/no-go training. Second, the researchers aimed to reduce delay discounting in two ways; 1) players can replace neutral images in the go/no-go training with positive images from their own lives related to their future self; 2) players can set and monitor personal goals via the game, to promote future-self priming. Third, participants join a social shell comprising Instagram and TikTok content to provide psychoeducation about quitting smoking and to interact with fellow players who quit simultaneously. Finally, the timing and content of in-game messaging is personalized to each participant based on information provided in an ecological momentary assessment component and a stop plan filled out during the week before the quit attempt."
214926759|NCT06675526|BEHAVIORAL|Self-help brochure|The brochure provides guidelines to independently design a stop-plan including questions about seeking support from others, strategies to fight cravings, and setting rewards for milestones after quitting. Participants will be encouraged to complete this stop-plan in week 0 of the intervention, so the week before quit day. Additionally, the brochure includes psychoeducational information that is valuable when planning to quit smoking.
214926760|NCT01268930|PROCEDURE|Bipolar electrocautery for ovarian hemostasis|after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.
214926761|NCT01268930|PROCEDURE|hemostatic matrix (FloSeal)|after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.
214926762|NCT00001344|DRUG|dextromethorphan|
214926763|NCT05484856|BIOLOGICAL|Autologous adipose tissue derived stromal cells|autologous adipose tissue derived stromal cells is recovered as pellet after non enzymatic processing with sonication using ultrasound . This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ , the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC,2-- 20%), plus a wide number of CD34+ hematopoietic cells (40%)
214926764|NCT06458582|DEVICE|High-Flow Nasal Cannula|The intervention involves administering High-Flow Nasal Cannula therapy to very preterm infants immediately after birth.
214926765|NCT04673474|DRUG|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
214926766|NCT04673474|DRUG|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
214926767|NCT04393480|OTHER|Robotic therapy|ReoGo™ - Motorika robotic therapy - upper extremity robotic rehabilitation system
214926768|NCT04393480|OTHER|Conventional therapy|Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment
214926769|NCT02843776|OTHER|Questionnaires completion|
214325632|NCT04253171|DEVICE|Conventional|Lesion preparation is performed starting with conventional balloons, non-compliant or semi-compliant. Unless fully satisfactory dilatation is achieved with conventional balloons, it is recommended to also use modified balloons (scoring balloons, cutting balloons). If balloons cannot be passed or if dilatation is inadequate, the lesion may first be predilated with an undersized conventional, non-compliant, or semi-compliant balloon. If necessary, rotational atherectomy with a small burr size can be used to facilitate adequate balloon preparation.
214325634|NCT06095063|DEVICE|Active Brainsway H7-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
214325635|NCT06095063|DEVICE|Sham Brainsway H7-Coil Deep TMS System|In addition to the active H-coil, a sham coil is included in the system. The active and sham coils are connected to a control switch, which alternates between real and sham operation modes. The sham treatment will be administered daily for 4 consecutive weeks.
214325636|NCT06095063|OTHER|Cognitive Training|Cognitive training will be conducted using the BrainHQ software program.
214325637|NCT05787587|DRUG|IDE-161|Oral Medication
214325638|NCT05787587|DRUG|Pembrolizumab|Intravenous Infusion
214325639|NCT05668923|BEHAVIORAL|Speech sound stimulation|Behavioral-, electrophysiological-, and magnetic resonance imaging-based speech sound testing
214486138|NCT06718686|DRUG|Placebo|Placebo drug
214325640|NCT06126757|DEVICE|PelviSense-assisted pelvic floor muscle training|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays the electrical activity of the PFMs on the user's mobile device. The re-usable sensor can be attached to the user's perineal region, and when positioned correctly, the width of the sensor is oriented along the medial-lateral axis, and the length is oriented along the anterior-posterior axis of the perineal region. The sensor detects PFM activity as the voltage between the two surface electrodes and transmits this activity to the data acquisition unit, which processes the signal and conveys it to a smartphone via a Wi-Fi connection. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts.
214926770|NCT04287231|DEVICE|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
214325641|NCT06126757|OTHER|Active Comparator|Pelvic Floor Muscle Training Exercise will be performed without the assistance of the PelviSense Device.
214325642|NCT04180215|DRUG|HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
214325643|NCT04180215|DRUG|HB-202 intravenous administration alternating with HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
214325644|NCT04180215|DRUG|HB-201 intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
214325645|NCT04180215|DRUG|HB-202 / HB-201 alternating intravenous administration + pembrolizumab.|Dose Expansion
214325646|NCT04180215|DRUG|HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
214926771|NCT04801680|DEVICE|Mpact 3D metal cup|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. They'll receive the Mpact 3D metal cup device
214926772|NCT05284591|BIOLOGICAL|Daratumumab|intravenous or subcutaneous
214926773|NCT02036840|DRUG|Antibiotic|
214926774|NCT02482480|OTHER|Exercise|Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education
214926775|NCT02482480|OTHER|Control|Dietary and general recommendations
214325647|NCT04180215|DRUG|HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)|Dose escalation; 10 patients
214325648|NCT06381921|BEHAVIORAL|IBS-PPSM intervention|IBS-PPSM intervention includes 10 video modules focused on IBS knowledge and self-management skills plus one-on-one consultation with a nurse for personalized advice about self-monitoring, diet, sleep, and goal setting.
214325649|NCT00394030|DRUG|GSK716155 subcutaneous injections|GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
214325650|NCT03615950|DIAGNOSTIC_TEST|Bone Mineral Density (DEXA) scan|Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
214325651|NCT03615950|DIAGNOSTIC_TEST|Vitamin D Measurement|Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
214325652|NCT03615950|DIAGNOSTIC_TEST|Height measurement|Height will be measured at baseline and 12 months.
214325653|NCT03615950|OTHER|Assessment of medication compliance|Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
214325654|NCT00326911|BIOLOGICAL|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
214325655|NCT00326911|BIOLOGICAL|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
214325656|NCT00326911|DRUG|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
214325657|NCT00326911|BIOLOGICAL|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
214325658|NCT01429766|OTHER|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed~1. st visit Within one day of the date of simulation~2. nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
214325659|NCT04605575|DRUG|Pyrotinib 320mg + Vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
214325660|NCT04605575|DRUG|Pyrotinib 400mg + Vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
214325661|NCT04605575|DRUG|Pyrotinib plus Vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
214325662|NCT01530126|BIOLOGICAL|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
214926776|NCT04463420|DRUG|PHR160 Spray|One puff spray per hour containing 300 mg of the drug will be given to patients. This treatment lasts up to 10 days.
214325663|NCT01530126|BIOLOGICAL|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
214926777|NCT04463420|DRUG|Placebo|participants will receive a placebo spray every hour. This process will continue for 10 days.
214926778|NCT04463420|DRUG|Standard treatment|: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days
214926779|NCT05152758|DEVICE|PARx|Prescription Physical Activity Programming Application
214926780|NCT05139212|PROCEDURE|Optimum time for intravenous cannulation in children premedicated with dexmedetomidine|The optimum time for intravenous cannulation after the induction of anesthesia with sevoflurane, oxygen, and nitrous oxide in children with intranasal dexmedetomidine premedication will be searched in children undergoing elective surgery.
214325664|NCT01530126|BIOLOGICAL|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
214325665|NCT02530294|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
214325666|NCT02530294|OTHER|Vehicle|Vehicle (placebo) topical wipes
214325667|NCT01948375|DEVICE|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
214325668|NCT01948375|DEVICE|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
214325669|NCT02440880|DRUG|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
214325670|NCT02440880|DRUG|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
214325671|NCT02440880|DRUG|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
214325672|NCT02440880|DRUG|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
214325673|NCT02440880|OTHER|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
214325674|NCT05941039|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.
214325675|NCT05941039|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
214325676|NCT02111486|OTHER|breakfast|
214926781|NCT05342077|BEHAVIORAL|Virtual Reality-Reward Training (VR-RT)|Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
214325677|NCT03019627|DRUG|NGF|Eye Drop 20 μg/mL
214325678|NCT03019627|OTHER|Vehicle|Vehicle Eye Drop
214325679|NCT02904811|OTHER|Testing for Ct infection immediately|Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
214325680|NCT02904811|OTHER|Testing for Ct infection at the end of the study|Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
214325681|NCT01433224|GENETIC|DNA methylation analysis|
214926782|NCT05342077|BEHAVIORAL|Virtual Reality-Memory Training (VR-MT)|Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral autobiographical memories.
214325682|NCT01433224|GENETIC|RNA analysis|
214926783|NCT04302454|RADIATION|Radiotherapy|Radiotherapy
214926784|NCT04302454|DRUG|Leuprorelin|Hormonal therapy
214926785|NCT06265649|OTHER|NOM|Non-operative management (NOM) for ALCD consists of lab test monitoring, fluid therapy, antibiotic therapy, abscess drainage if \>4cm, restoring a regular diet
214926786|NCT06621368|OTHER|Exercise|the RT program will consist of eight exercises for different body segments, namely: vertical bench press, horizontal leg press, low row, leg extension, scott curl, leg curl, triceps pulley and seated calf raise. Every 12 weeks of training, the program will be restructured with changes in the order in which the exercises are performed, the number of sets, the number of repetitions or the training system in an attempt to avoid a supposed adaptive plateau. The protocols in each stage will follow the recommendations for prescribing RT for the elderly, aiming at improving strength and hypertrophy, namely: a combination of single-joint and multi-joint exercises (free weights and machines), slow or moderate execution speed (ratio 1:2 for concentric and eccentric muscle actions, respectively), one to three sets of multiple repetitions, 8-12 RM or 10-15 RM, with recovery intervals between sets of one to two minutes, and a training frequency of two to three weekly sessions, on alternate days.
214926787|NCT06621368|OTHER|Control-no treatment|Participants will maintain their daily activities.
214926788|NCT06622564|DRUG|Before CPB Tranexamic Acid|Tranexamic acid 1 to 10 g (10 to 100 mL) administered intravenously as per standard care at the induction of anesthesia as a bolus and/or continuous infusion (i.e., before CPB).
214926789|NCT06622564|DRUG|After CPB Tranexamic Acid|Tranexamic acid 5 g (50 mL) administered after heparin reversal (i.e., after CPB).
214926790|NCT06622564|DRUG|Before CPB Placebo|Placebo (10 to 100 mL saline) administered intravenously at the induction of anesthesia as a bolus and/or continuous infusion.
214926791|NCT06622564|DRUG|After CPB Placebo|Placebo (50 mL saline) administered after heparin reversal.
214926792|NCT04948541|COMBINATION_PRODUCT|osa treatment|different treatments can be included
214926793|NCT04948541|OTHER|no treatment|no treatment was undergone
214926794|NCT03196661|BIOLOGICAL|Influenza A (H7N9) virus vaccine|To prevent the infection of H7N9 virus.
214926795|NCT04194320|PROCEDURE|Ultrasound (US) guided supraclavicular brachial plexus block|Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block
214926796|NCT01862263|DRUG|Vildagliptin|Orally active and highly selective inhibitor of DPP-4
214926797|NCT01862263|DRUG|Insulin|Long- acting human insulin analog indicated to improve glycemic control
214926798|NCT01862263|DRUG|Placebo|Matching placebo of vildagliptin
214926799|NCT04622514|OTHER|Village doctor-led telemedicine integrated care|1\. Reorienting the model of care: using of telemedicine platform and online consulting clinic; 2. Coordinating services: contract service by village doctor and on-line AF specialist; 3. Empowering and engaging people: provide village doctor ABC pathway training course; regular visit and drug delivery by village doctor (community support); patients and their family members education.
214926800|NCT04622514|OTHER|Enhanced usual care|1\. Usual care; 2. Intensified education to patients, their family members, and their village doctors.
214926801|NCT06174298|DRUG|Granulocyte Colony-Stimulating Factor (Filgrastim)|"Intervention Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
214926802|NCT06174298|OTHER|Standard Embryo Transfer Media|"Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
214325683|NCT01433224|GENETIC|mutation analysis|
214325684|NCT01433224|GENETIC|nucleic acid sequencing|
214325685|NCT01433224|GENETIC|polymerase chain reaction|
214325686|NCT01433224|GENETIC|polymorphism analysis|
214325687|NCT01433224|OTHER|laboratory biomarker analysis|
214325688|NCT01433224|OTHER|medical chart review|
214325689|NCT03364049|DRUG|MK-7162|oral tablets
214325690|NCT03364049|BIOLOGICAL|Pembrolizumab|IV infusion
214325691|NCT00807781|BIOLOGICAL|Mammaglobin-A DNA vaccine|
214325692|NCT02953821|DRUG|Acthar Gel|1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
214325693|NCT02953821|DRUG|Placebo Gel|1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
214325694|NCT00484302|BEHAVIORAL|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
214325695|NCT00484302|BEHAVIORAL|Non-manualized standard treatment|Treatment by case-manager
214325696|NCT04884152|PROCEDURE|Home Exercise Group|Educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
214325697|NCT04884152|PROCEDURE|Telerehabilitation Group|Telerehabilitation program combined with educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
214325698|NCT00251394|DRUG|Rituxan|Given intravenously once weekly for four weeks.
215069156|NCT01824810|PROCEDURE|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
214325699|NCT00251394|DRUG|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
214325700|NCT02103478|DRUG|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
215069157|NCT01824810|PROCEDURE|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
214325701|NCT02103478|DRUG|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
214926803|NCT02618837|PROCEDURE|Downstream strategy|"At diagnosis:~Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel~Pre-procedure:~Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.~In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor~At the time of PCI, the loading doses required (according to randomization):~* Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months~* Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel\* daily for at least 12 months~  * If subject is \>75 years old or \<60 kg, daily dose of prasugrel should be 5mg"
215069158|NCT06009237|DRUG|ABBV-903|Tablet; oral
215069159|NCT06009237|DRUG|Placebo for ABBV-903|Tablet; oral
215069160|NCT03955224|DEVICE|Basic Oral Care + active LLLT|"* Compliance with the Basic Oral Care Associated with~* Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
215069161|NCT03955224|OTHER|Basic oral Care + inactive LLLT|"* Compliance with the Basic Oral Care Associated with~* Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
215069162|NCT03955224|OTHER|Basic Oral Care|Compliance with the Basic Oral Care only
215069163|NCT05548712|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
214325702|NCT02103478|DRUG|ASTX727 Fixed-Dose Combination|Fixed-dose investigational product
214325703|NCT03219333|DRUG|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
214325704|NCT01947530|PROCEDURE|Navigational Bronchoscopy|
214325705|NCT01947530|PROCEDURE|Standard Bronchoscopy|
214325706|NCT05075876|DRUG|SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)|Single application for 6 days
214325707|NCT05075876|DRUG|SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)|Single application for 6 days
214325708|NCT04488276|OTHER|In-depth interviews|In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
214325709|NCT04930029|OTHER|Ten year evaluation|Clinical, biological and endoscopic evaluation
214325710|NCT04934306|OTHER|Nasometry|Repetition of several stimuli (syllables, sentences ) in the microphones of the Nasometer
215069164|NCT05548712|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
215069165|NCT05409560|OTHER|Swimming participants in the 6-hour cold water swim|The 6-hour cold water swim was the qualifying swim for the English Channel swim during the Channel Swim Camp Dinard 2021 and participants were the swimmers registered for the 6-hour cold water swim who volunteered to participate in this study
215069166|NCT01292356|DRUG|cetuximab|
215069167|NCT03641716|BEHAVIORAL|Mealtime PREP Intervention|Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
215069168|NCT04176874|PROCEDURE|Robotic-assisted diastasis of the rectus abdominis muscles repair|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
215069169|NCT02365610|DRUG|GWP42006|
215069170|NCT02365610|DRUG|Placebo Control|
215069171|NCT03069248|DRUG|Rituximab|
215069172|NCT03069248|DRUG|Alpha Interferon|
214325711|NCT06246643|DRUG|Regorafenib (Stivarga, BAY73-4506)|Participants will be treated with the regorafenib dose taken during the last cycle of the feeder study. Adult participants will receive either 60, 80, 90, 120, or 160 mg orally (p.o.) once daily (qd) for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off). Pediatric participants will receive 82 mg/m\^2 p.o. qd for 14 days, in a 14 days on/7 days off schedule (21-day cycle).
214325712|NCT06637371|DRUG|AMG 691|Subcutaneous (SC) injection
214325713|NCT06637371|DRUG|Placebo|SC injection
214325714|NCT05141058|BIOLOGICAL|Coronavirus-specific T cell (CST)|Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after hematopoietic stem cell transplantation (HSCT).
214325715|NCT05921994|OTHER|secukinumab|Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.
215069173|NCT02974959|DEVICE|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
215069174|NCT02974959|DEVICE|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
215069175|NCT00311740|DRUG|Valsartan|
214325716|NCT06189092|DRUG|Bleomycin|Using electroporation to infuse bleomycin in the lesion
214325717|NCT05980676|BEHAVIORAL|Personalized Two-Week Email-Based Program|Both intervention groups will complete an activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. The Coached group will be able to reply to the emails to give feedback, ask questions, and receive additional support.
214325718|NCT06232629|DEVICE|TUS Active|Bilateral GPis will be sonicated using NeuroFUS device for either two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and with 30 W/cm2 Isppa
214325719|NCT06232629|DEVICE|TUS Sham|"Passive sham: Bilateral GPis will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 0 W/cm2 Isppa~Active sham: Bilateral occipital cortices will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 30 W/cm2 Isppa"
214325720|NCT02487589|OTHER|Telephone support, telemonitoring and tele-exercise|"The care model will provide 24/24 h assistance for six months and include:~Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .~Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.~Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist."
214325721|NCT04528446|RADIATION|Dual-energy X-ray absorptiometry|DXA whole body, hip, spine, and radius at baseline, and 12-month visit.
214325722|NCT04528446|RADIATION|High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)|HR-pQCT of the radius and tibia at baseline, and 12-month visit.
214926804|NCT02618837|PROCEDURE|Upstream strategy|"At the time of diagnosis:~Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.~Pre-procedure:~All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.~All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF)."
214926805|NCT02068781|DIETARY_SUPPLEMENT|Low-sodium diet|50 mmol NaCl per 24h
214926806|NCT02068781|DIETARY_SUPPLEMENT|High-sodium diet|250 mmol NaCl per 24h
214926807|NCT05128630|DRUG|Durvalumab|Patients will receive 1500 mg durvalumab via IV infusion q3w concomitant with chemotherapy (Cisplatin/carboplatin plus etoposide) for up to a maximum of 3 cycles, then via IV infusion at the same interval during sequential radiotherapy and then every 4 weeks for up to a maximum of 12 months or until confirmed disease progression, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
215069176|NCT00311740|DRUG|Hydrochlorothiazide|
215069177|NCT00272155|BEHAVIORAL|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
214325723|NCT04528446|OTHER|Blood draw and Urine collection|The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
214325724|NCT04528446|OTHER|Questionnaires|Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
214325725|NCT04011878|PROCEDURE|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
214325726|NCT02755272|DRUG|Pembrolizumab|IV Infusion of 200 mg given on day one of each 21 day treatment cycle.
214325727|NCT02755272|DRUG|Carboplatin|IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.
214325728|NCT02755272|DRUG|Gemcitabine|IV infusion of 800 mg/m\^2 given on days one and eight of each 21 day treatment cycle.
214325729|NCT06322121|OTHER|MRI|Assessment of vascular reactivity and CAA/SVD MRI markers
214325730|NCT04163289|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
214926808|NCT02809105|DRUG|linaclotide|Oral administration once daily
214926809|NCT02809105|DRUG|Placebo|Oral administration once daily
214325731|NCT03912753|BEHAVIORAL|Comunică|Comunică is based on the Information-Motivation-Behavioral Skills (IMB) model of health behavior change, which postulates that individuals must possess the requisite information for enacting sexual health, motivation to change their HIV risk and alcohol use, and behavioral skills necessary for reducing their risk. Therefore, Comunică includes MI to provide accurate information about HIV transmission, alcohol abuse, and local GBM-affirmative health resources and build motivation to improve behavioral skills (via CBST). CBST is a therapeutic approach used in the treatment of various behavioral problems, such as alcohol abuse and depression and more recently HIV risk. CBST can help modify cognitions driving unhealthy behaviors, promote awareness of contextual triggers and unhealthy behavioral patterns, and teach coping skills to improve health. Comunică also draws upon minority stress theory recognizing that stigmatizing societal contexts compromise health behavior.
214325732|NCT03912753|OTHER|Education Attention Control|The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.
214325733|NCT04530552|DRUG|Apalutamide|Given PO
214325734|NCT04530552|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214325735|NCT04530552|OTHER|Quality-of-Life Assessment|Ancillary studies
214325736|NCT06297122|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file (electronic health record). The identification of eligible cases will be conducted through an examination of the hospital's electronic microbiology database. Subsequently, the complete hospital record(s) of each patient will be used to extract a pre-defined set of variables required for data analysis.
214325737|NCT05431699|DIAGNOSTIC_TEST|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
214325738|NCT05431699|DIAGNOSTIC_TEST|careHPV test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
214325739|NCT05431699|PROCEDURE|Colposcopy and biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
214325740|NCT05431699|PROCEDURE|Gas-based cryotherapy|"Cryotherapy is performed to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, a metal probe is inserted into the vagina and the tip is pressed against the cervix. Compressed carbon dioxide or nitrous oxide gas at a temperature of approximately -50ºC/-58ºF freezes the tip and creates an ice ball on the cervix. The ice ball ablates or destroys the abnormal cells."
214325741|NCT05431699|PROCEDURE|Thermal ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
214325742|NCT03916146|BEHAVIORAL|Parent Training Intervention|Adapted version of the Family Check-Up/Everyday Parenting intervention
214926810|NCT05177926|DRUG|antiviral prophylaxis with Tenofovir Alafenamide Fumarate|All participants will receive antiviral prophylaxis with Tenofovir Alafenamide Fumarate for preventing of Mother-to-child transmission of HBV
214325743|NCT05624112|DRUG|Dupilumab|Dupilumab solution in a pre-filled syringe for Subcutaneous injection
214325744|NCT03748641|DRUG|Niraparib|Participants will receive niraparib 200 mg capsules or tablets once daily.
214325745|NCT03748641|DRUG|Abiraterone Acetate|Participants will receive AA 1000 mg tablets once daily.
214325746|NCT03748641|DRUG|Prednisone|Participants will receive prednisone 10 mg tablets daily.
214325747|NCT03748641|DRUG|Placebo|Participants will receive matching placebo once daily.
214926811|NCT06209398|BIOLOGICAL|Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell )|Used for EV71 virus susceptible individuals aged 6 months to 5 years. Each bottle (bottle) contains 0.5ml of neutralizing antibody with a potency of no less than 3.0EU for the inactivated 71 type intestinal disease vaccine. Intramuscular injection into the deltoid muscle of the upper arm. The immunization program consists of 2 doses with 1-month interval.
214926812|NCT06209398|BIOLOGICAL|Recombinant Hepatitis B Vaccine|Each vaccine bottle (tube) is 0.5ml, containing 10ug of HBsAg and inject into the upper deltoid muscle. The immunization program consists of three doses, administered at 0, 1, and 6 months respectively. Newborns are given the first dose within 24 hours after birth, with one dose of vaccine administered each time.
214926813|NCT06209398|BIOLOGICAL|Group A meningococcal polysaccharide vaccine|This product is made by lyophilizing the purified polysaccharide antigen obtained from Group A meningococcus liquid culture. The vaccination targets children aged 6 months to 15 years old, and the initial immunization age starts from 6 months old. Infants and young children aged 6 to 12 months old are vaccinated with 2 doses of 30 micrograms, with an interval of 3 months. Subcutaneously inject 0.5ml into the lateral deltoid muscle of the upper arm at a dose of 30 μg of polysaccharide antigen (0.5ml).
214325748|NCT03748641|DRUG|New Formulation of Niraparib and Abiraterone Acetate (AA)|Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
214325749|NCT05552716|OTHER|School safety tactics and policies|A list of school safety tactics and policies (such as metal detectors, armed security guards, active shooter drills) that were in place at the school at the time of shooting.
214325750|NCT03456336|OTHER|Active Treatment|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.
214325751|NCT03456336|OTHER|Expectant Management|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
214325752|NCT06034496|DEVICE|Active CES|Active CES group will receive a minimum of 250µA and up to 500µA depending on thresholding, once daily for 20 days (over the course of 4\~6 weeks), 20 minutes per day.
214325753|NCT06034496|DEVICE|Sham CES|Sham CES group will be identical to Active CES group with the exception of the device not administering any electrical current
214325754|NCT06124976|DRUG|ST-02|ST-02 drug instillation into the upper urinary tract (renal pelvis)
214325755|NCT04397263|DRUG|Guselkumab|Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
214325756|NCT02377089|DEVICE|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
214486139|NCT06719076|BEHAVIORAL|Diabetes Healthcare Program (DHCP)|"Training for Type-II Diabetics~The program includes 6 structured training sessions, each session will delivered biweekly and lasting for 1 hour and 20 minutes , covering topics such as:~Week 1: Diabetes Education and Goal Setting Week 3: Nutrition and Meal Planning Week 5: Physical Activity and Exercise Week 7: Medication Management Week 9: Stress Management and Emotional Well-being Week 11: Review and Future Plans Time, Venue, and Interactive Activities Sessions will be held at the Federal General Hospital Basement, on Fridays, from 10:00 am to 11:20 am. Each session includes interactive elements, such as group discussions, practical exercises, and hands-on activities, to ensure participants are fully engaged and equipped to manage their T2DM diabetes."
214926814|NCT03622398|PROCEDURE|Total knee arthroplasty with HXLPE liner|Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.
214926815|NCT03622398|PROCEDURE|Total knee arthroplasty with conventional polyethylene liner|Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
214325757|NCT02377089|DEVICE|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
214325758|NCT03277261|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
214325759|NCT03277261|DRUG|Teriflunomide|Film-coated tablets administered orally.
214325760|NCT03277261|DRUG|Oral Placebo|Administered orally.
214325761|NCT03277261|DRUG|IV Placebo|Administered as an IV infusion.
214325762|NCT02597010|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
214926816|NCT01684098|DRUG|Tc 99m EC20|
214325763|NCT02597010|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
215069178|NCT00272155|BEHAVIORAL|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
214325764|NCT06168526|BEHAVIORAL|Acute physical activity|Regarding the first aim, participants will go through five different conditions using a within-participants cross-over design in a randomized order: control group (quietly sitting), light intensity (40% VO2max), moderate intensity (63% VO2max), or vigorous intensity (100% VO2max) exercise. All conditions will last 16 minutes and 15 seconds. The exercise conditions will be organized following an interval protocol, which includes 22 bouts of 30 seconds running at the established intensity with 15 seconds of passive rest between bouts. In addition, to achieve the second aim, the active break will be designed taking into account the intensity of physical activity that proves to have the greatest benefits on cognition and well-being.
214325765|NCT03111654|DIAGNOSTIC_TEST|Compare the risk of a vascular event|"Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events."
214325766|NCT00499603|DRUG|Paclitaxel|80 mg/m\^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
214325767|NCT00499603|DRUG|5-Fluorouracil|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
214325768|NCT00499603|DRUG|Epirubicin|100 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
214325769|NCT00499603|DRUG|Cyclophosphamide|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
214325770|NCT00499603|DRUG|RAD001|30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.
214325771|NCT02142530|DRUG|Carfilzomib|
214486140|NCT07038174|OTHER|Fertility preservation decision aid intervention group|Visited the website containing the web-based decision aid regarding fertility preservation at least once before cancer treatment initiation to independently use the tool in a private setting
214325772|NCT02142530|DRUG|Belinostat|
214926817|NCT06666777|BEHAVIORAL|Intervention focused on intersubjective prelinguistic and socio-communicative skills|"The intervention consists of 8 45-minute, weekly sessions over two months. These sessions may take place in various settings, such as free play, snack time, or structured activities. The speech therapist will use these settings to help parents observe intersubjective and social-communicative behaviors, providing guidance and strategies to support them.~The following topics will be addressed: Attention; Multisensory Stimulation and Integration: Sensitivity and Responsiveness; Communicative Codes and Preference/Discrimination; Gestures; Intentionality and Communicative Styles.~These topics are not structured into rigid levels for each session. Instead, several topics may be addressed within the same session and revisited across multiple sessions. This flexibility allows the speech therapist to adapt the intervention based on observations, interactions with the child, and discussions with the parent."
215069179|NCT05998070|OTHER|Training group|Hip strengthening exercises will be performed 3 times a week for 6 weeks in the training group. 3 exercises consisting of 2 sets and 10 repetitions will be performed every week. A rest interval will be given between sets.
215069180|NCT06105775|DIETARY_SUPPLEMENT|Inorganic Nitrate Capsule|Starting from the 16th week of gestation and continuing for 22 weeks (154 days) or until delivery, whichever comes first, participants will consume a daily capsule containing 400 mg of inorganic nitrate. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
214325773|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
214325774|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
214325775|NCT00143611|DRUG|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
214325776|NCT01888289|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
214325777|NCT00006279|DRUG|Nevirapine|
214325778|NCT05244629|DEVICE|BMS vs. CS|Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
214325779|NCT05063396|PROCEDURE|opioid free anesthesia|Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
214325780|NCT05063396|PROCEDURE|Opioid-sparing anesthesia|patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
214325781|NCT00000781|DRUG|Nevirapine|
214325782|NCT00000781|DRUG|Zidovudine|
214325783|NCT00000781|DRUG|Zalcitabine|
214325784|NCT00000781|DRUG|Didanosine|
214325785|NCT05179421|DRUG|Low dose oxytocin|10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
214325786|NCT05179421|DRUG|High dose oxytocin|10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
214486141|NCT07038720|DRUG|UA026|UA026 will be administered as tablet
214325787|NCT00005758|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214325788|NCT00005758|BIOLOGICAL|HIV-1 Immunogen|
214325789|NCT00792610|BIOLOGICAL|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
214486142|NCT07038720|DRUG|Placebo|Matching placebo will be administered as tablet
214486143|NCT07039760|DRUG|Asciminib|Commercially available stock
214325790|NCT01771133|BEHAVIORAL|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
214325791|NCT06372249|DRUG|Inulin|Soluble tapioca starch from Ingredion.
214325792|NCT06175221|BIOLOGICAL|Tumor lysate, particle only (TLPO) vaccine|A novel technology in which a patient's tumor lysate (TL) is loaded into microparticles for DC phagocytosis and antigen processing allows for vaccine efficacy, while minimizing tissue demands by only requiring approximately 250-500ug of tumor. Immature DCs avidly phagocytose small particles in the range of 1-5 microns. Tumor tissue collected from the patient undergoes a process of freeze-thaw cycling to create a TL suspension. The microparticles, yeast-cell wall particles (YCWP), are created from Saccharomyces cerevisiae by NaOH/HCl digestion of all non-cell wall components and washed, producing β-glycan shells. The TL is then loaded into these YCWP.
214325793|NCT03058133|OTHER|fMRI study|Functional brain activations of face-voice processing during a gender task
214325794|NCT04893954|DIAGNOSTIC_TEST|Full Spine Radiography|Full Spine Radiography
214325795|NCT04893954|DIAGNOSTIC_TEST|Lumbar spine MRI|Lumbar spine MRI
214325796|NCT03473743|DRUG|Erdafitinib|Participants will receive erdafitinib orally.
214325797|NCT03473743|DRUG|Cetrelimab|Participants will receive cetrelimab by intravenous infusion.
214325798|NCT03473743|DRUG|Cisplatin|Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.
214325799|NCT03473743|DRUG|Carboplatin|Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
214325800|NCT04677491|DRUG|Ospemifene 60 mg|Ospemifene vs placebo
214325801|NCT04677491|BEHAVIORAL|fMRI experiments|Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.
214926818|NCT06666777|BEHAVIORAL|Standard speech therapy intervention|The standard speech therapy intervention, as typically conducted in rehabilitation centers, consists of 8 weekly sessions, each lasting 45 minutes, over a two-month period (same as the experimental intervention). During these sessions, the therapist may provide various stimulations aimed at enhancing the child's vocalization, verbal comprehension, and speech production. While the therapist may offer guidance to parents on how to continue these stimulations in daily routines, they will not be directly involved in the sessions unless strictly necessary.
214926819|NCT01351480|BIOLOGICAL|abatacept|Abatacept administered SC weekly at 125 mg dose
214926820|NCT00199797|DRUG|Oxaliplatin|Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.
214325802|NCT04521166|DEVICE|Hearing aid|Settings in a wearable hearing aid will be adjusted within a clinically-relevant range for two features. The features include wide dynamic range compression and microphone directionality.
214325803|NCT06431061|DEVICE|Lens A (omafilcon B)|15 minutes of daily wear.
214325804|NCT06431061|DEVICE|Lens B (comfilcon A)|15 minutes of daily wear.
214325805|NCT02614547|DRUG|SAGE-547|Administered as intravenous infusion.
214325806|NCT02614547|DRUG|Placebo|Administered as intravenous infusion.
214486144|NCT07039760|DRUG|Sildenafil|Commercially available stock
214926821|NCT00199797|DRUG|5-Fluorouracil|The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.
214926822|NCT00199797|DRUG|Leucovorin|Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
215069181|NCT06105775|DIETARY_SUPPLEMENT|Placebo Capsule|From the 16th week of gestation and lasting 22 weeks (154 days) or until delivery, participants will consume a daily capsule containing sodium chloride with the nitrate replaced by plant-based flour, design to mimic the appearance of the active capsule. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
214486145|NCT07039760|PROCEDURE|Surgical resection or biopsy|Standard of care
214926823|NCT00199797|DRUG|huA33|huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.
214926824|NCT05789784|OTHER|mymobility Physical Therapy|Physical therapy protocol administered at home through the mymobility application.
214926825|NCT05789784|OTHER|Standard Office-based Physical Therapy|Physical Therapy protocol administered through exercise handouts and formal office-based therapy directed by physical therapist.
214926826|NCT03429751|DRUG|30 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
214926827|NCT03429751|DRUG|10 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
215069182|NCT00004112|BIOLOGICAL|rituximab|
215069183|NCT00004112|DRUG|CHOP regimen|Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.
215069184|NCT00004112|DRUG|cyclophosphamide|
214325807|NCT06418256|OTHER|Spleen, blood and plasma collection|Adult patients for whom a splenic intervention (spleno-pancreectomy, or a total or partial splenectomy) is planned as part of their care. One or more tubes of venous blood collected for the care will be recovered following the pre- or intra-operative assessment. Immediately following surgery, after careful examination by the pathologist in charge, the whole spleen or spleen fragments will be collected for further analysis. Whenever possible a catheter will be introduced in the splenic artery, the spleen will be flushed/rinsed with 0.1 - 2 L of cold perfusion medium then transferred to the laboratory for ex-vivo perfusion. Before and at the end of the ex-vivo perfusion, splenic blood and spleen fragments will be collected and processed for further analyses.
214325808|NCT02052739|DRUG|SAGE-547|Solution for injection for IV infusion
214325809|NCT06348719|PROCEDURE|Robot-assisted laparoscopy|The experimental procedure corresponds to robot-assisted laparoscopy.
214325810|NCT06348719|PROCEDURE|conventional laparoscopy|"The control procedure corresponds to conventional laparoscopy."
214325811|NCT06348719|OTHER|Prospective cohort study|A prospective cohort of patients will be set up to support the randomized controlled trial. Patients will be offered participation in this cohort if the center is unable to participate in the randomized trial (i.e., does not have a robot, or does not have a laparoscopic column with fluorescence), if the patient refuses randomization in the randomized controlled trial, if the surgeon refuses to randomize the patient, or if the surgeon does not meet the learning curve criteria required for robotic surgery. These patients will be followed in exactly the same way as patients included in the randomized controlled trial, once their consent has been obtained.
214673058|NCT06964867|OTHER|Multimedia Health Education|Multimedia health education was designed as an intervention. This intervention was administered by a single vitreoretinal specialist with over a decade of clinical experience. This standardized protocol comprised a 30-minute didactic session utilizing power point presentations (PPT), systematically covering: 1) Etiopathogenesis: Molecular mechanisms of vitreous syneresis and collagen aggregation; 2) Symptomatology: Characteristic visual phenomena and differential diagnosis; 3) Therapeutic modalities: Evidence hierarchy from observation to vitrectomy (including Nd:YAG laser efficacy controversies); 4) Follow-up necessity: Red flag symptoms warranting urgent re-evaluation (sudden floaters with photopsia)
214673059|NCT06970132|DRUG|SY-5933|KRAS p.G12C inhibitor
214926828|NCT01103453|BEHAVIORAL|Virtual Action Planning Supermarket (VAP-S) Software|"The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.~We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention."
214926829|NCT02121015|BEHAVIORAL|Share|
214926830|NCT02121015|BEHAVIORAL|Self-Directed|
214926831|NCT06649422|DRUG|Blinatumomab|The 14-day blinatumomab combined with reduced-dose chemotherapy is used for the induction treatment of newly diagnosed Ph-chromosome negative acute B-lymphoblastic leukemia.
214673060|NCT06970132|DRUG|CT-707|Focal Adhesion Kinase (FAK) inhibitor
214673061|NCT05341466|OTHER|Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
214926832|NCT06619925|BEHAVIORAL|after-school extended sports service|Impact of voluntary participation in different types (e.g. outdoor physical activities, indoor physical activities, ball games, calisthenics, etc.), intensity and duration of after-school extended physical education services on children\&#39;s myopia and other physical and psychological well-being
214926833|NCT06619925|BEHAVIORAL|non-after school extended sports service|Students in the same grade as the exposure group but participating in after-school non-physical education extended services (e.g., homework help, static activities such as calligraphy, chess, etc.) served as a control group, aiming to maximise the control of the influence of potential factors other than physical activity on the results of the study.
214926834|NCT02338297|PROCEDURE|TACE|Transarterial chemoembolisation (TACE)
214926835|NCT02338297|DRUG|EGM|Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
214926836|NCT02338297|DRUG|PVA|Occlude arterioportal shunts(APS) with PVA
214926837|NCT01843114|DEVICE|FDOCT|Measurement of retinal blood velocities
214926838|NCT01843114|OTHER|Dynamic Vessel Analyzer|Measurement of retinal vessel diameters
215069185|NCT00004112|DRUG|doxorubicin hydrochloride|
215069186|NCT00004112|DRUG|prednisone|
215069187|NCT00004112|DRUG|vincristine sulfate|
215069188|NCT02487654|PROCEDURE|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
215069189|NCT02487654|PROCEDURE|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
215069190|NCT06458764|OTHER|Questionnaire|none, it's a incidence-prevalence study
215069191|NCT04038632|OTHER|Decentralization of Childhood TB Diagnosis|The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
215069192|NCT05262530|BIOLOGICAL|BNT142|Intravenous bolus/infusion
215069193|NCT03803358|OTHER|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
215069194|NCT03803358|OTHER|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
214325812|NCT06348719|OTHER|Retrospective cohort study|Retrospective data collection from the medical records of all patients who underwent hysterectomy for low- or intermediate-risk endometrial cancer during the inclusion period at a participating center and who were not included in the randomized controlled trial or prospective cohort; up to a limit of 1000 inclusions. For this retrospective cohort, only data concerning initial age, BMI, histological type of cancer and surgical approach used will be collected.
214325813|NCT06348719|OTHER|information and consent|information and consent
214325814|NCT06348719|OTHER|randomization|Randomization
214325815|NCT06348719|OTHER|Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence|Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
214325816|NCT06348719|OTHER|Surgical data collection|Surgical data collection at Day 0
214325817|NCT06348719|OTHER|Biological data collection|Biological data collection at Day 1
214325818|NCT06348719|OTHER|Collection of histological data from the surgical specimen|Collection of histological data from the surgical specimen et Day 42
214325819|NCT06348719|OTHER|Phone calls|Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3
214926839|NCT02556619|BEHAVIORAL|Early Palliative Care/Symptom Control|"1. Establish palliative care goals~   1. Determination of Medical Power of Attorney~  2. Discuss/plan code status/advance directives~  3. Document palliative care goals~2. Symptom Assessment and Control~   1. Pain-treatment with opioid and non-opioid medications~  2. Itching-H2 blockers, steroids~  3. Nutrition-appetite stimulated with Megace, review low sodium diet~  4. Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed~  5. Nausea- treated with anti-emetics~  6. Jaundice and Body Image- counselling regarding symptoms~3. End-of-Life Care~   1. Discuss religious preferences~  2. Assess for distress- ensure interaction with Cancer Resource Center~  3. Hospice- charity Hospice options for select patients."
214926840|NCT06618495|DRUG|Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 4 weeks.
214926841|NCT03356119|DEVICE|RemovAid device|The contraceptive implants of the subjects in this arm are removed by the new IMD.
215069195|NCT05598944|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
214325820|NCT06348719|OTHER|Pain assessment|Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3
214325821|NCT06348719|OTHER|Collect of data on non-reimbursed transport|Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
214325822|NCT06348719|OTHER|Collect of everyday help|Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
214325823|NCT06348719|OTHER|Collection of the business resumption date|Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
214325824|NCT06348719|OTHER|SF36 questionnaire|SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6
214325825|NCT06348719|OTHER|Questionnaire EQ5D-5L|Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
214325826|NCT06348719|OTHER|FIGO Stadium|FIGO Stadium at inclusion and Day 42
214325827|NCT06348719|OTHER|Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)|Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
214325828|NCT06348719|OTHER|Collection of adjuvant treatments|Collection of adjuvant treatments at month 6
214325829|NCT06348719|OTHER|Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one|Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
214325830|NCT06348719|OTHER|Collection of data|Collection of data on age, baseline, BMI, histological type of cancer and surgical approach used
214325831|NCT05598047|BEHAVIORAL|Executive Functioning Training|Those in the Executive Functioning Training Group will engage in exercises requiring one to set shift; that is, to maintain at least two sets of rules and decide which is appropriate to determine the response. In using these training exercises in the TOPS study, the effects size was quite large (d=-0.89). Dosage of 20 hours of training is considered an upper range on how much training is needed to produce an optimal therapeutic effect.
214325832|NCT05201469|DRUG|VIB4920|Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
214325833|NCT05201469|DRUG|Placebo for VIB4920|Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
214325834|NCT05402397|DRUG|Losartan Potassium|Patients will receive losartan potassium for 30 days.
214325835|NCT05909085|DEVICE|Traditional ultrasound|Labor epidural will be performed after marking patient skin using traditional ultrasound guidance
214325836|NCT05909085|DEVICE|Automated ultrasound|Labor epidural will be performed after marking patient skin using an automated ultrasound device
214325837|NCT06580197|OTHER|Auricular Acupoint Therapy|Ear point diagnosis and treatment is one of acupuncture and moxibustion methods, which originates from the theory of acupuncture and moxibustion meridians and is the product of the combination of modern Chinese medicine and western medicine, including two parts: auricular acupoint diagnosis and auriculotherapy. Ear point diagnosis refers to the determination of auricle positive reaction points through vision, touch, pressure and other methods to diagnose diseases in some parts of the body on the basis of ear point theory. Ear point treatment refers to the use of certain therapeutic devices on ear points to achieve the purpose of prevention and treatment of diseases by stimulating ear points, which are often carried out simultaneously in clinical practice.
214926842|NCT00771251|DRUG|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
214926843|NCT00771251|DRUG|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
214926844|NCT01892111|OTHER|Structured exercise program.|
214926845|NCT02925715|PROCEDURE|ultrasound guided central venous cannulation|ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
214926846|NCT05773651|OTHER|Data collection|The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature
214926847|NCT05970588|BEHAVIORAL|Standing Promotion Intervention|Participants will be provided with a standing desk converter to set on top of their existing desk for 4 weeks.
214926848|NCT01004224|DRUG|BGJ398|
214926849|NCT04432090|DRUG|Placebo|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
214926850|NCT04432090|DRUG|Study Medication (MBX-2982)|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
214926851|NCT04432090|OTHER|No medication for this group|This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
214926852|NCT04250350|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
214926853|NCT02358785|DEVICE|ECHELON FLEX™ Powered Plus Stapler|ECHELON FLEX™ Powered Plus Stapler using ENDOPATH ECHELON™ Reloads with Gripping Surface Technology (GST). The combination of stapler plus reload is referred to as the ECHELON FLEX™ GST System.
214926854|NCT06356974|DRUG|Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)|Subjects agreeing to participate in the study and matching the inclusion/exclusion criteria will receive acoziborole 960 or 640 mg in a single intake at study day 1. Following treatment, participants will attend follow-up visits at home or at the study centre at 3 days and 3-months post treatment.
214926855|NCT05901194|DRUG|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight \< or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
214926856|NCT03737708|DRUG|tacrolimus|Administered orally
214926857|NCT03737708|DRUG|methotrexate|Administered orally
214926858|NCT03737708|BIOLOGICAL|adalimumab|Administered as subcutaneous injection
214926859|NCT03737708|BIOLOGICAL|tocilizumab|Administered by intravenous injection
214325838|NCT00989820|DRUG|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
214325839|NCT05267054|DRUG|Ociperlimab|administered intravenously
214325840|NCT05267054|DRUG|Tislelizumab|Administered intravenously once every 3 weeks
214325841|NCT05267054|DRUG|Rituximab|Administered intravenously once every 3 weeks
214325842|NCT06031844|DRUG|DFV890|oral film-coated tablets
214325843|NCT06031844|DRUG|Placebo|oral film-coated tablets
214325844|NCT02276430|OTHER|Vena punction|Once 90 ml
214325845|NCT05841758|DRUG|Hydroxychloroquine|Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)
214325846|NCT05841758|DRUG|Placebo|Placebo during a 12 months double blind placebo-controlled period
214325847|NCT06521476|DRUG|Acetazolamide|Oral acetazolamide 250 mg daily for 7 days
214325848|NCT06521476|DRUG|Placebo|Oral placebo daily for 7 days
214325849|NCT05744427|DRUG|JSKN003|JSKN003 should be administered intravenously on the first day of each 3-week cycle.
214325850|NCT01552226|DEVICE|Continuous Preperitoneal Analgesia|Preperitoneal catheter placed at the completion of surgery in the standard fashion.
214325851|NCT01552226|DEVICE|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion.
214325852|NCT04697628|DRUG|tisotumab vedotin|2.0 mg/kg every 3 weeks (Q3W)
214325853|NCT04697628|DRUG|topotecan|1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days
214325854|NCT04697628|DRUG|vinorelbine|30 mg/m2 IV on Days 1 and 8, every 21 days
214325855|NCT04697628|DRUG|gemcitabine|1000 mg/m2 IV on Days 1 and 8, every 21 days
214325856|NCT04697628|DRUG|irinotecan|100 or 125 mg/m2 IV weekly for 28 days, every 42 days
214325857|NCT04697628|DRUG|pemetrexed|500 mg/m2 IV on Day 1, every 21 days
214673062|NCT05341466|OTHER|SHAM Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 21% O2 (SHAM AIH) alternating with 21% O2 at 1 min intervals
215069196|NCT05598944|BEHAVIORAL|Más Presente, the UGRComp program|"Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life."
215069197|NCT05598944|OTHER|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
215069198|NCT00568763|BIOLOGICAL|sargramostim|
214325858|NCT03604692|DRUG|axatilimab|axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
214926860|NCT03737708|BIOLOGICAL|abatacept|Administered by intravenous injection
214926861|NCT04502147|PROCEDURE|Laparoscopic Splenectomy|Laparoscopic splenectomy by ligating the splenic artery
214926862|NCT00546676|DRUG|Telithromycin|
215069199|NCT00568763|OTHER|immunoenzyme technique|
215069200|NCT00568763|OTHER|immunohistochemistry staining method|
215069201|NCT00568763|OTHER|immunologic technique|
215069202|NCT00568763|OTHER|laboratory biomarker analysis|
214926863|NCT05555615|DRUG|Pimavanserin|Pimavanserin given once daily, as capsule of 10, 20, or 34 mg dose strength, respectively, according to the patient's age
214926864|NCT06405347|BEHAVIORAL|Inpatient Whole Health Bundle|Hospitalized patients on the intervention units will be offered participation in the Inpatient Whole Health Bundle, which is comprised of a variety of offerings aimed at improving the wellbeing of the patient. They can choose to use any or none of the bundle elements.
214926865|NCT04707703|DRUG|Isavuconazonium Injection [Cresemba]|Intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous isavuconazonium sulfate 372 mg once daily for up to 28 days
215069203|NCT00568763|PROCEDURE|biopsy|
215069204|NCT00568763|PROCEDURE|cryosurgery|
215069205|NCT00568763|PROCEDURE|radiofrequency ablation|
215069206|NCT02247011|OTHER|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
215069207|NCT02247011|RADIATION|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
215069208|NCT02247011|RADIATION|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
214325859|NCT06133426|DEVICE|"Connected scale Body Comp Pro from Withings"|Use once a day from inclusion to week 7.
214325860|NCT04943874|DEVICE|Technology Based Intervention Group 1|In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
214926866|NCT04707703|DRUG|Placebo|Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days
214926867|NCT04606485|OTHER|Acupressure|Acupressure is accepted as a non-invasive application that can easily be applied by trained nurses, which increases the quality of the medical care administered and contributes to physical and psychological recovery.
214926868|NCT03070769|PROCEDURE|Venous blood collection for biomarkers measurements|Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
214926869|NCT05924815|DRUG|Aficamten|Oral Tablet
214926870|NCT05924815|DRUG|Aficamten-matching Placebo|Oral Tablet
214325861|NCT04943874|DEVICE|Technology Based Intervention Group 2|Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
214325862|NCT05994378|DRUG|SHR7280；Ganirelix Acetate Injection simulant|SHR7280 200mg Q12h and Ganirelix Acetate Injection simulant 0.5mL qd;
214325863|NCT05994378|DRUG|SHR7280 simulant； Ganirelix Acetate Injection|SHR7280 simulant 200mg Q12h and Ganirelix Acetate Injection 0.5mL:0.25mg qd;
214325864|NCT03917134|DRUG|cephalosporin + Metronidazole Vaginal|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
214673063|NCT05420012|DRUG|Vericiguat|A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
214926871|NCT05924815|DRUG|Moxifloxacin|Oral Tablet
214926872|NCT03190668|DRUG|Bolus dose of Cefazolin|Mode of Cefazolin administration will be a intermittent bolus
214926873|NCT03190668|DRUG|Continuous Cefazolin drip|Mode of Cefazolin administration will be a continuous drip
214926874|NCT03190668|DEVICE|Paraspinal muscle microdialysis catheters|Two dialysis probes will be inserted into a paraspinal muscle
214926875|NCT03190668|DEVICE|Subcutaneous microdialysis catheters|Two dialysis probes will be inserted into a paraspinal subcutaneous region
214926876|NCT04569422|DRUG|Benoxyl|reduce pain
214926877|NCT02836236|DRUG|TAF|TAF 25 mg tablet administered orally once daily
215069209|NCT02247011|OTHER|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
215069210|NCT02904629|BEHAVIORAL|Respecting the Circle of Life (RCL)|"Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT)."
215069211|NCT02904629|OTHER|Control Program|Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
214325865|NCT03917134|DRUG|cephalosporin + Placebos|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
214325866|NCT06374433|PROCEDURE|Occipital tACS at IAF-2Hz|tACS applied to occipital areas at 2 Hz below the individual alpha frequency (IAF)
214325867|NCT06374433|PROCEDURE|Occipital tACS at IAF+2Hz|tACS applied to occipital areas at 2 Hz above the individual alpha frequency (IAF)
214325868|NCT06374433|PROCEDURE|Frontal tACS at 4-7 Hz|tACS applied to frontal areas at 4-7 Hz
214325869|NCT06374433|PROCEDURE|Occipital tRNS|tRNS applied to occipital brain regions
214325870|NCT06374433|PROCEDURE|Frontal tRNS|tRNS applied to frontal brain regions
214325871|NCT06374433|PROCEDURE|Sham/placebo tACS|tACS is activated only for 30 seconds and then turned off, thus resulting ineffective
214325872|NCT06374433|PROCEDURE|Sham/placebo tRNS|tRNS is activated only for 30 seconds and then turned off, thus resulting ineffective
214325873|NCT00270972|DEVICE|Bilayered Cellular Matrix (OrCel)|
214325874|NCT00006184|DRUG|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
214325875|NCT00006184|DRUG|Bortezomib|Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
214325876|NCT00006184|DRUG|Cyclophosphamide|Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)
214325877|NCT00006184|DRUG|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
214325878|NCT00006184|DRUG|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
214325879|NCT00006184|DRUG|Etoposide|Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3
214325880|NCT00006184|DRUG|Fludarabine phosphate|Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )
214325881|NCT00006184|DRUG|Prednisone|60 mg/m\^2 day 1-4
214325882|NCT00006184|DRUG|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3
214325883|NCT00006184|DRUG|Methotrexate|Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
214926878|NCT02836236|DRUG|TDF|TDF 300 mg tablet administered orally once daily
214926879|NCT02836236|DRUG|TAF Placebo|TAF placebo tablet administered orally once daily
214926880|NCT02836236|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
214926881|NCT02589236|DRUG|Cavosonstat|GSNOR inhibitor
214926882|NCT02589236|DRUG|Placebo|Control sample with only capsule excipients and fillers
214926883|NCT05601622|PROCEDURE|Fluid loading|Intravenous administration of 10ml/kg of crystalloids over 10 minutes
214926884|NCT05601622|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiographic measurement of stroke volume index
214926885|NCT05601622|DIAGNOSTIC_TEST|PVI, RPVI|Continuous measurement of pleth variability index and Rainbow pleth variability index
214926886|NCT05601622|PROCEDURE|Tidal volume change|Changing tidal volume for mechanical ventilation as 6, 8, 10 ml/kg
214926887|NCT04546529|DEVICE|Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing real TsMS with coil
214926888|NCT04546529|DEVICE|Sham Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing placebo TsMS with coil
214926889|NCT02222363|DRUG|VLX600|Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
214926890|NCT05068778|BEHAVIORAL|Artificial Intelligence Application|AI application through smart phone
214926891|NCT03760367|OTHER|Blue covarine toothpaste|2 min toothbrushing with 1 g of Pepsodent White Now Gold
214926892|NCT03760367|OTHER|Control toothpaste|2 min toothbrushing with 1 g of Colgate Advanced Whitening
214926893|NCT06492265|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
214926894|NCT06492265|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
214926895|NCT05299944|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in opioid consumption, opioid craving, pain, peripheral markers of inflammation, and anxiety, as well as changes in sleep, AEA, and cognition.
214926896|NCT05299944|DRUG|Placebo|Placebo arm
214926897|NCT05678244|DRUG|Acetaminophen|IV acetaminophen will be added to standard of care opioid based pain regimes.
215069212|NCT04958993|DRUG|Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy|radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
214325884|NCT00006184|BIOLOGICAL|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m\^2 subcutaneously every day, days 1-4
214325885|NCT00006184|BIOLOGICAL|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) \> 1000/ul x 2 days
214325886|NCT04341181|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
214926898|NCT05678244|DRUG|Placebo|In control group placebo will be added to standard of care opioid based pain regimes.
214926899|NCT00811317|DEVICE|Closed-loop|Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target
214926900|NCT03136341|DRUG|Abobotulinum toxin A|Dosing will be determined at each study visit based upon muscles involved
214926901|NCT03136341|OTHER|Placebo|Dosing will be determined at each study visit based upon muscles involved
214926902|NCT01803503|DRUG|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks
214926903|NCT01803503|DRUG|Sunitinib|7 days of sunitinib 12.5mg orally daily during each cycle
214926904|NCT04809857|OTHER|Exercise|
214926905|NCT06035081|DRUG|Prednisolone|see arm description
214926906|NCT06035081|OTHER|Placebo|Placebo similar to prednisolone
214926907|NCT00811785|DRUG|Copper Histidine|Daily subcutaneous injections for three years
214926908|NCT03928756|BEHAVIORAL|Push Notifications with Tailored Intervention Content|Participants will receive a push notification with a therapeutic message (e.g., about stress, mood, substance use motives, tools to reduce risky substance use) tailored to their recent daily or weekly survey responses. Messages include visual (memes, images, videos) and written content.
214926909|NCT03928756|BEHAVIORAL|Push Notifications with Engaging, Non-therapeutic Content|Participants will receive a push notification with an engaging, non-therapeutic message (e.g., fun facts).
214926910|NCT03928756|BEHAVIORAL|No Push Notifications|Participants will not receive a push notification.
214926911|NCT03806699|BIOLOGICAL|Placebo|Sterile normal saline
214926912|NCT03806699|BIOLOGICAL|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
214926913|NCT00115245|DRUG|Telbivudine (LdT)|
214325887|NCT04341181|DRUG|Atezolizumab|Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile.
214926914|NCT00115245|DRUG|Adefovir Dipivoxil|
214926915|NCT05830981|OTHER|Educational intervention|3 months of educational intervention (Lectures, information bulletin, handbook and hardcopy presentation slides) among professionals and patients.
214926916|NCT06341543|DIAGNOSTIC_TEST|Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).|The QF-CMV will be performed in all participants.
214926917|NCT06341543|OTHER|Communication of the result of the QF-CMV to the clinician in charge|"The result of the CMV-QF will be communicated to the clinician in charge only for the patients randomised in the group communication of the QF-CMV result to the clinician in charge."
214926918|NCT03653351|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 mA (current density = 0.57 A/m2) and will be applied for approximately 30 minutes per day during meditative practices of the MBSR protocol.
214325888|NCT04341181|DRUG|Avelumab|Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile.
214325889|NCT04341181|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
214325890|NCT04341181|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile.
214325891|NCT04341181|DRUG|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile.
214325892|NCT04341181|DRUG|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile.
214325893|NCT04341181|DRUG|Trastuzumab emtansine|Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile.
214325894|NCT04341181|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile.
214325895|NCT04341181|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile.
214486146|NCT07039162|DRUG|Tislelizumab|"1. ICRT phase -Tislelizumab and CRT regimen Tislelizumab 200 mg IV, C1D1 and C4D1~2. Consolidation phase: Tislelizumab-Paclitaxel-Cisplatin regimen Tislelizumab 200 mg IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of 2 cycles. )~3. Adjuvant phase-Tislelizumab Tislelizumab 200 mg IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of one year or 17 cycles.)"
214926919|NCT03653351|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 milliampere (mA) (current density = 0.57 A/m2), however, the device is pre-programmed to turn off after 1 minute of active stimulation (and then turn back on briefly at the end of the 30 minutes).
215069213|NCT04683276|PROCEDURE|pars plana vitrectomy with ILM inverted flap|Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
215069214|NCT06205381|DRUG|AV078|Oral solution containing active ingredient, AV078
215069215|NCT06205381|DRUG|Placebo|Oral solution with no active ingredients
214325896|NCT05608785|DRUG|IBI315|IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
214325897|NCT05608785|DRUG|Oxaliplatin|Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
214325898|NCT05608785|DRUG|Capecitabine|Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
214325899|NCT05608785|DRUG|TST001|TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
214325900|NCT05608785|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214325901|NCT05608785|DRUG|Anrotinib|Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
214926920|NCT03150654|DEVICE|Laser pan-retinal photocoagulation|Green laser photocoagulator
214926921|NCT05697237|DRUG|Carrelizumab|Carrelizumab 200mg/3 weeks
214926922|NCT05697237|DRUG|Solfantinib|Solfantinib 300mg/d
214926923|NCT05034861|DEVICE|cCTG|Self-applied home computerized CTG device used twice weekly instead of standard Doppler assessment once weekly.
215069216|NCT06205381|DRUG|Itraconazole|Once daily oral dose of 200 mg itraconazole administered for 9 days
215069217|NCT06205381|DRUG|Midazolam|2.5 mg midazolam administered orally on day 1 and day 18
214486147|NCT07039162|DRUG|Paclitaxel|"1. ICRT phase -Tislelizumab and CRT regimen Paclitaxel 50 mg/m2 IV, D1, weekly (\* 4-6 cycles judged by investigators.)~2. Consolidation phase: Tislelizumab-Paclitaxel-Cisplatin regimen Paclitaxel 135 mg/m2 IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of 2 cycles.)"
214926924|NCT05034861|DIAGNOSTIC_TEST|Doppler|Standard Doppler assessment provided once weekly in case of late FGR with positive end diastolic flow in the umbilical artery.
214926925|NCT02287285|DRUG|Exendin9|Dosed at 600 pmol/kg/min for 210 minutes.
214926926|NCT01106677|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
214926927|NCT01106677|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
214926928|NCT01106677|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
214926929|NCT01106677|DRUG|Metformin immediate release|The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
214926930|NCT00950040|BEHAVIORAL|Brief alcohol intervention|The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
214926931|NCT00950040|BEHAVIORAL|General health education|The intervention will consist of information about several general health behaviors.
214926932|NCT02567734|PROCEDURE|CT-guided percutaneous irreversible electroporation|Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
214926933|NCT03681990|DRUG|3M CHG/IPA Prep|Apply topically to intact skin
214926934|NCT06392139|BEHAVIORAL|Specific Therapy Program for Personality Disorders|The program was founded in 1999; since then, it has provided a wide range of different treatment interventions (outpatient, inpatient and day care). The interventions are psychoanalytically oriented and specifically for patients with Borderline Personality Disorder. Most of them are in the form of group psychoanalytic psychotherapy. The program consists of two steps: 1) an initial reception outpatient clinic where patients are followed after the referral to the Program, for a period of 6-8 months. This first step consists of monthly psychodynamically oriented sessions, monthly psychiatric appointments and application of psychological assessment instruments. The intervention focuses on crisis management and construction of the treatment plan for every patient. 2) The second step consists of long-term psychodynamic psychotherapy interventions, in combination with psychiatric treatment when it is is needed.
214926935|NCT06392139|OTHER|Treatment As Usual (TAU) Group|"The TAU group receives the common practice treatment in the two Specific Outpatient Clinics for BPD patients:~The Outpatient Clinic for Borderline Personality Disorder Patients of the 2nd Psychiatric Clinic at the Medical School of National and Kapodistrian University of Athens called Attikon General University Hospital and The Outpatient Clinic for Borderline Personality Disorder Patients of the Psychiatric Clinic of Sismanogleion General Hospital.~Treatment As Usual (TAU) The TAU includes the psychiatric management, consultation and pharmacotherapy if needed in the two Specific Outpatient Clinics for BPD patients. TAU provides one thirty minutes session per month. In case of crisis management patients contact their psychiatrist during the working hours, or after that they leave a message on the telephone answering machine and if needed make a visit in the Emergency Department of the Hospital on Duty."
214926936|NCT02478034|OTHER|Fludrocortisone|effects of fludrocortisone on cognition compared to placebo
215069218|NCT06205381|DRUG|Fexofenadine|120 mg fexofenadine administered orally on day 1 and day 18
215069219|NCT03867266|PROCEDURE|Ablation with radiofrequency|Ablation point by point on the cavo tricuspid isthmus guided by an index lesion
214486148|NCT07039162|DRUG|Cisplatin|"1. ICRT phase -Tislelizumab and CRT regimen Cisplatin 25 mg/m2 IV, D1, weekly ( 4-6 cycles judged by investigators.)~2. Consolidation phase: Tislelizumab-Paclitaxel-Cisplatin regimen Cisplatin 75 mg/m2 IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of 2 cycles. )"
214926937|NCT05454969|BEHAVIORAL|One-4-ALL Initiative|We can successfully implement a patient app that will be used by families to 1) increase throughput for all patients, including minoritized, low-income, and low health literacy patients, and 2) reduce administrative burdens on providers.
215069220|NCT01781650|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
215069221|NCT01781650|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
215069222|NCT01781650|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
215069223|NCT00656058|DRUG|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
215069224|NCT00139542|OTHER|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
214926938|NCT05454969|BEHAVIORAL|Control|Patients will receive standard of care.
215069225|NCT00139542|OTHER|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
215069226|NCT02216968|BEHAVIORAL|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
215069227|NCT05489354|OTHER|mHealth psychoeducational intervention|The mPEI program will be delivered through a mobile application (app). The app has five components which include: Breast cancer education, coping skills training, discussion forum, nurse-led consultation, and psychological support. Breast cancer education and coping skills training will be conducted by the principal investigator for 30 minutes per week for six weeks and will be delivered via text, audio and video on the mobile app. Group discussion will be moderated by the principal investigator in a text format for 30 minutes per week. Nurse-led consultation and psychological support will be provided by the oncology nurse on the research team through a 15-20-minute call in the first week, third week and fifth week.
215069228|NCT03303170|DEVICE|Sebacia Microparticles|Topical microparticle suspension
215069229|NCT03303170|DEVICE|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
215069230|NCT00876850|DRUG|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
215069231|NCT00876850|DRUG|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
215069232|NCT05484505|DRUG|Nicotine patch, Nicotine gums|"Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~* 14 mg: Next 4 weeks~* 7 mg: Last 4 weeks"
215069233|NCT05484505|BEHAVIORAL|Brief Advice (5 A's & 5 R's)|Brief Advice (5 A's \& 5 R's) at Day 0, 1 month, 3,6,9 \& 12 months
214926939|NCT04248140|OTHER|radio frequency electromagnetic field|Exposure system delivers emissions comparable to those from WiFi access point close to the bed or sham (nor exposure)
214926940|NCT03937908|DRUG|2g Centella asiatica water extract product|2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
214926941|NCT03937908|DRUG|4g Centella asiatica water extract product|4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
215069234|NCT05484505|DRUG|Nicotine Patch: Preloading for 4 weeks|Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
215069235|NCT03750760|DRUG|Alirocumab|PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
215069236|NCT03750760|DRUG|Atorvastatin 80mg|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
215069237|NCT03750760|DRUG|Ezetimibe 10mg|Cholesterol absorption inhibitor
215069238|NCT00499291|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
215069239|NCT00499291|PROCEDURE|gene expression analysis|
215069240|NCT00499291|PROCEDURE|laboratory biomarker analysis|
215069241|NCT00499291|PROCEDURE|pharmacological study|
215069242|NCT00499291|PROCEDURE|polymerase chain reaction|
215069243|NCT03718884|DRUG|Drug Cocktail|Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
215069244|NCT03718884|DRUG|Mirikizumab|Administered SC
215069245|NCT02687555|BEHAVIORAL|Cognitive Bias Modification of Appraisals (CBM-App)|
215069246|NCT02687555|BEHAVIORAL|Peripheral Vision Task (control condition)|
215069247|NCT00382421|DRUG|bisoprolol|
214486149|NCT07039162|RADIATION|Radiation Therapy|1\. ICRT phase -Tislelizumab and CRT regimen Radiotherapy treatment: IMRT 41-50.4Gy, a dose of 1.8 to 2Gy per day, 5 days per week for 5 weeks during the RT phase.
214486150|NCT07039825|OTHER|Computed tomography angiography|The results of computed tomography angiography on abdominal aortic aneurysm are collected.
214926942|NCT05919472|DIETARY_SUPPLEMENT|Oral iron supplementation (pre-treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 1-56
214926943|NCT05919472|BIOLOGICAL|COVID-19 vaccine|Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
214926944|NCT05919472|BIOLOGICAL|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
214926945|NCT05919472|DIETARY_SUPPLEMENT|Oral iron supplementation (simultaneous treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 28-56
214926946|NCT05919472|BIOLOGICAL|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
214926947|NCT03337945|DRUG|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
215069248|NCT00382421|DRUG|amlodipine|
215069249|NCT00382421|DRUG|molsidomine|
215069250|NCT00382421|DRUG|acetylsalicylic acid|
215069251|NCT00061815|BIOLOGICAL|cetuximab|400 mg/m2 IV
215069252|NCT00061815|DRUG|oxaliplatin|85 mg/m2 IV
215069253|NCT00061815|DRUG|leucovorin|200 mg/m2 IV
215069254|NCT00061815|DRUG|5-fluorouracil|400 mg/m2 IV
215069255|NCT00061815|DRUG|5-fluorouracil|600 mg/m2 IV
215069256|NCT00061815|BIOLOGICAL|cetuximab|250 mg/m2 IV
215069257|NCT01794663|DRUG|OPN-305|Intravenous infusion for 1 hour at start of transplant procedure
215069258|NCT01794663|DRUG|Placebo|Intravenous infusion for 1 hour at start of transplant procedure
215069259|NCT03393819|DRUG|DuraPrep|DuraPrep surgical solution
215069260|NCT03393819|DRUG|ChloraPrep|ChloraPrep surgical solution
215069261|NCT05359003|BEHAVIORAL|12-week physical activity program|Program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps). Includes weekly meetings with a trained health coach.
215069262|NCT04700540|DEVICE|Smartwatch Reminder (SR) system|The Smartwatch Reminder (SR) system will automatically transmit pictures and relevant information, such as name or relationship, to a smartwatch worn by the PWMC when family or friends visit.
214325902|NCT05225961|DRUG|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
214926948|NCT03326349|OTHER|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) is a telerehabilitation platform. GNPT consists of a set of computerized cognitive exercises covering different cognitive functions and subfunctions. Every task has been specifically based on cognitive paradigms to address specific cognitive subfunction. The rehabilitation process starts by assigning a patient to a therapist responsible for the treatment. The therapist has then to perform the initial neuropsychological assessment, consisting of a set of validated tests used to attention, memory and executive functions prior to the treatment. The results of these tests will be stored in GNPT system. Then, the cognitive profile is calculated using these results, and taking into account the patient's age and study level. Using this profile, the program assigns a set of computerized tasks to a certain day, configuring the input parameters of each task in order to personalize treatments.
214926949|NCT03326349|OTHER|Ictus.online|"An online domain which provides a daily session of one hour of duration. Each session consists of four ten-minute videos. After each video, the participant must complete a three-question quiz about the contents of the video (for example, What animal appears in in the video?). The difficulty level is minimal, and does not vary depending on the execution of the participant."
214926950|NCT05524818|DIAGNOSTIC_TEST|the Computerized Adaptive Testing System of the Functional Assessment of Stroke (CAT-FAS)|The CAT-FAS comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper Limb, 11 items from the Fugl-Meyer Assessment-Lower Limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. The CAT-FAS assesses all these functions simultaneously. Results are automatically reported as Rasch scores. A higher score indicates greater physical functions. In the previous study, results indicated that the CAT-FAS had sufficient efficiency (\< 10 items on average), reliability (Rasch reliability ≥ 0.88), concurrent validity (Pearson r ≥ 0.91), and responsiveness (SRM ≥ 0.65) in persons with stroke.
214926951|NCT02416128|DRUG|Euphrasia|1 drop in the treated eye QID X 10 days
214926952|NCT02416128|DRUG|Prednisolone acetate|1 drop in the treated eye QID X 10 days
214926953|NCT03482297|DEVICE|automated abdominal binder|The binder automatically inflates every time the participant stands up to apply a compression level of about 40 mmHg. Participants will wear the device throughout the active/sham study day.
214926954|NCT03482297|DEVICE|Sham binder|The binder automatically inflates every time the participant stands up to apply a compression level of about 5 mmHg. Participants will wear the device throughout the active/sham study day.
214926955|NCT03482297|DRUG|Placebo|Oral placebo will be given three times a day on the baseline day (placebo)
214926956|NCT03482297|DRUG|Midodrine|A midodrine pill 10mg will be given three times a day on the standard of care study day
214926957|NCT04967547|OTHER|Self-care PD ability assessment form|Subjects will be evaluated using the self-care PD feasibility assessment tool within 7 days after randomization. The evaluation results will be provided to the patient on the same day
214926958|NCT04967547|OTHER|Education|Education on renal replacement therapy and dialysis
214926959|NCT05753267|DRUG|Mesalamine|Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC
214926960|NCT05753267|DRUG|Fenofibrate 160mg|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.
214926961|NCT01969786|OTHER|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
214926962|NCT06485440|DRUG|Dysport 300 UNT Injection|300 UNITS of BTA (Dysport) injected to lateral abdominal muscles prior to abdominal wall reconstruction (4 weeks before surgery)
214926963|NCT06648057|DRUG|lenvatinib plus pembrolizumab|"* The collection of peripheral blood samples will follow the schedule below (20 cc per collection, up to 5 times):~* Before systemic therapy, at 3 weeks after starting systemic therapy (Cycle 1), at 6 weeks (Cycle 2)~* (If possible) at the time of confirmed partial response (1 time), and at the time of disease progression (1 time).~* Additional tumor tissue samples will be collected only if possible, according to the following schedule:~If the patient undergoes surgery or additional biopsy related to treatment (collected from preserved specimens)."
215069263|NCT05085093|BIOLOGICAL|HPV vaccine|Patients choose to be vaccinated or not to be vaccinated with HPV vaccine according to their own wishes
215069264|NCT05337124|DRUG|LUPKYNIS|LUPKYNIS treatment per the approved US Prescribing Information
215069265|NCT06853301|OTHER|Blood culture sampling|Patients with blood culture sampling as standard of care. Two to four additional blood culture bottles sampled that will be spiked with known bacterial species to determine their electrochemical profiles
215069266|NCT03515551|DRUG|IMCnyeso|Weekly IV infusions of IMCnyeso
215069267|NCT04021108|DRUG|Nivolumab 240 MG|Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
214926964|NCT03940274|BEHAVIORAL|walking training|Participants will receive three sessions a week of BWSTT with assistive training device for 8 weeks; a total of 24 sessions. The duration of each training session will an hour. During walk-training, the participant will wear a harness which is attached to an overhead motorized lift to provide body-weight support and to prevent the risk of falling.
214926965|NCT01764789|OTHER|questionnaire administration|Ancillary studies
214926966|NCT01764789|PROCEDURE|quality-of-life assessment|Patients will participate in a quality life assessment.
214926967|NCT01764789|PROCEDURE|psychosocial assessment and care|Participate in multi-component biobehavioral intervention
214926968|NCT01764789|BEHAVIORAL|behavioral intervention|Participate in multi-component biobehavioral intervention
214926969|NCT01764789|OTHER|cognitive intervention|A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
214926970|NCT01764789|OTHER|educational intervention|Participate in multi-component biobehavioral intervention
215069268|NCT05364684|DRUG|LUM-201|LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.
215069269|NCT02543073|BIOLOGICAL|MSCs|MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 weeks as one cycle treatment.
215069270|NCT02543073|DRUG|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
215069271|NCT02543073|DRUG|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
215069272|NCT02209558|BEHAVIORAL|Visual Sternal Precautions|"Visual depiction of SPs in addition to standard of care written precautions"
215069273|NCT02342847|OTHER|N/A (non-interventional study)|
215069274|NCT05131334|DEVICE|auriStim, for auricular vagal stimulation|For auricular vagal stimulation we used auriStim (AU0115, Multisana GmbH, Vienna, Austria). Using a green light-emitting diode (LEDs) flashlight, blood vessels in the cymba conchae of the left ear side were detected. Minimal invasive needles (penetrating 1-2mm) were placed close to the vessel-bifurcation to provide efficient stimulation of the auricular branch of the vagus nerve. The built-in microchip controls monophasic volt pulses of 1 ms, with alternating polarity, a frequency of 1 Hz and an amplitude of 4V. Stimulation lasted for 72h in total with alternating on/off periods of three hours. Thereafter, the device was removed, and patients continued their therapy consisting of anti-withdrawal medication.
215069275|NCT05109429|BEHAVIORAL|Neutral Cue-induced Craving|For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
215069276|NCT05109429|BEHAVIORAL|Visual Opioid Cue-induced Craving|For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
214347557|NCT06352710|OTHER|OP-Tracker App|"There will be no study-specific therapeutic intervention. The OP-Tracker App will be downloaded and installed on the patient's smartphone. Preoperative assessment: baseline factors such as age, gender, medical conditions, type of disease and of surgery, EQ-5D-5L. Before and after surgery surgery, SWI (Quality of life) will be assessed daily using pop-ups; the patient will input the value (0-10) using a slide-bar. After completion of the surgery, the app will automatically modify the number of SWI assessments over time according to the occurrence of AEs. At any point in time, the patient will be able to register an AE in the smartphone app. The patient can select the AE via a drop-down menu in the app, and can additionally input free text in case of an AE of type other. Using a further drop-down menu, the patient will classify the AE according to the CDG and TDN grade. QoL assessments (EQ-5D-5L questionnaire) will pop up before, and at 3 and 12 months after surgery."
214926971|NCT01607229|OTHER|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
214926972|NCT04384861|BEHAVIORAL|Mayo Clinic SMART program (Stress Management and Resilience Training)|The SMART program included a workshop and ongoing eLearning Support. The learning objectives of the workshop are: (1) learn the neuroscience and behavioural aspects of human experience, particularly with respect to stress, resiliency, performance and wellness and (2) learn practical approaches to enhance engagement and emotional intelligence and thereby decrease stress and anxiety, increase resilience, enhance performance, and improve relationships. The goal of the eLearning support is to support and reinforce the messages and techniques delivered in the 2-hour workshop.
214926973|NCT03205761|DRUG|Olaparib|Olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
214926974|NCT04760041|DRUG|Midazolam nebulized|midazolam nebulized
214926975|NCT04760041|DRUG|Midazolam oral solution|midazolam given oral
214926976|NCT04420585|DRUG|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
214926977|NCT01513109|BIOLOGICAL|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|i.m. administration
215069277|NCT05109429|BEHAVIORAL|Visual and Tactile Opioid Cue-induced Craving|For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
214325903|NCT05225961|DRUG|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
214325904|NCT05186467|DRUG|intraperitoneal Magnesium sulfate|Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
214347558|NCT02771951|BEHAVIORAL|"Lights of Change"|
214926978|NCT06430502|BIOLOGICAL|Tumor Treatment Vaccine; PD-1/L1 inhibitors|Before and after the patient's treatment period using PD-1 inhibitors，patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml each time, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml each time.The interval between injections can be shortened or extended depending on the patient's condition and response.
214926979|NCT04181515|DRUG|Placebo oral tablet|placebo stressor
214926980|NCT04181515|DRUG|Yohimbine + Hydrocortisone|Yohimbine 54mg + Hydrocortisone 20mg
214926981|NCT04181515|DEVICE|sham rTMS|sham rTMS (inactive coil)
214926982|NCT04181515|DEVICE|active rTMS|active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)
214926983|NCT00065637|DRUG|Teriparatide|Synthetic human parathyroid hormone
214926984|NCT00065637|DRUG|Placebo teriparatide|Placebo injections
214926985|NCT00641576|DEVICE|ACE CONNECT Endosseous dental implant|"Subjects in this study receive ACE CONNECT Internal-Connection dental implants to: 1)replace a missing tooth in an edentulous area of the maxilla or mandible restored with a single-unit crown (may include up to two non-adjacent areas as study sites) or, 2)subjects with an edentulous mandible will receive two implants placed in the lower canine position and restored with an implant-retained removable over-denture.~Subjects will return for four follow-up evaluations scheduled at 6, 12, 18 and 24 months after delivery of the permanent restoration."
214926986|NCT05164640|OTHER|not required|This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms
214926987|NCT00972816|BIOLOGICAL|MF59-eH1N1|MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
214926988|NCT02756780|OTHER|Tenovus Cancer Choir|Choir sessions will take place at both of the Royal Marsden Hospital sites on a weekly basis. Sessions typically consist of learning popular songs with messages of support. Songs are learnt without sheet music, using specially created backing tracks. These are also made available to participants at home so they can continue singing away from the sessions. No singing experience is required and the main aim of the sessions is enjoyment and meeting other people. Sessions will take place in the early evening so that participants have the option of staying to socialise afterwards.
214926989|NCT04277650|OTHER|Machine learning algorithm|machine learning directed identification of radiotherapy or chemoradiotherapy patients at high-risk for emergency department acute care and/or hospitalization
214926990|NCT05839652|DRUG|Midodrine Hydrochloride|Determine best drug and dose to increase and stabilize SBP during orthostatic tilt
214926991|NCT06107270|DEVICE|pressure biofeedback|uninﬂated pressure sensor will be kept below the neck suboccipital
214926992|NCT06107270|DEVICE|therapeutic ultra sound|continuous US waves of 1 MHz frequency and 1-1.5 W/cm2 power
214926993|NCT06107270|DEVICE|infra red radiation|(R 125, 250watt, Philips)
214926994|NCT06107270|OTHER|post isometric relaxation|sustained contraction followed by relaxation
214926995|NCT01374932|DEVICE|CPAP|Continuous positive airways pressure (CPAP)
214926996|NCT02615015|OTHER|Blood draw|
214926997|NCT03916367|RADIATION|CT-guided Radioactive I-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
214926998|NCT04114357|DRUG|Acetylated and Butyrylated High Amylose Maize Starch|Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner for 4 weeks
214325905|NCT05186467|DRUG|intravenous magnesium sulfate|Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
214325906|NCT05690295|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
214325907|NCT00087633|DRUG|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
214325908|NCT00087633|DRUG|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
214325909|NCT00581282|RADIATION|PET scan|positron emission tomography PET scan
214926999|NCT02163226|RADIATION|Hypofractionated Radiation Treatment|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row.
214927000|NCT02163226|RADIATION|One Radiation Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV).
214927001|NCT02163226|BEHAVIORAL|Questionnaire|Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
214927002|NCT02533557|DEVICE|stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.~1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time."
214927003|NCT02533557|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
214927004|NCT06232057|OTHER|Virtual Reality|Women in the intervention group will be given a pre-test (STAI) before cesarean. Then, they will be shown a relaxing video (video with nature views accompanied by nature sounds) through virtual reality glasses for a maximum of 20 minutes. After a cesarean, women's anxiety levels (STAI) will be evaluated within the first 4 hours postoperatively. Pain levels (VAS) will be assessed postoperatively at the 2nd, 4th, and 6th hours.
214927005|NCT05435625|PROCEDURE|FCO2|Fractional Carbon dioxide laser
214927006|NCT05435625|PROCEDURE|FRF|Fractional Microneedling Radiofrequency
214927007|NCT02358525|BEHAVIORAL|multi-modality rehabilitation program for heart failure|rehabilitation consists of supervised exercise training, both endurance and strength, as well as gymnastics, diet and psychosocial education around living with heart failure
214927008|NCT02958358|OTHER|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.
214927009|NCT00878566|OTHER|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
214325910|NCT00581282|OTHER|fMRI|functional magnetic resonance imaging fMRI
214927010|NCT00878566|OTHER|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
214325911|NCT04035772|OTHER|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
214927011|NCT00801281|DRUG|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
214927012|NCT00801281|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
214927013|NCT00801281|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
214927014|NCT00801281|DRUG|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
214927015|NCT00801281|DRUG|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
214927016|NCT00801281|DRUG|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
214927017|NCT04958148|DIETARY_SUPPLEMENT|Salt pills|Subjects will supplement salt pills with meals.
214927018|NCT04958148|DIETARY_SUPPLEMENT|Placebo pills|Subjects will supplement placebo pills with meals.
214927019|NCT05491525|DRUG|Vibegron|Participants will be administered Vibegron orally, once daily (QD)
214927020|NCT00477750|DRUG|lenalidomide|"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression"
214927021|NCT00477750|DRUG|melphalan|"Phase I - dose escalating: 5mg/m\^2 dose level -1, 5 mg/m\^2 dose level 0, 8 mg/m\^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m\^2 orally days 1-4 every 28 days until progression"
214927022|NCT00477750|DRUG|prednisone|60mg/m\^2, orally days 1-4 every 28 days until progression
214927023|NCT01585324|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly
215069278|NCT02289911|OTHER|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
215069279|NCT03316287|DEVICE|Hearing aid|Smart hearing aid to allow collection of real time hearing aid usage data
214927024|NCT01585324|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
215069280|NCT03316287|DEVICE|Mobile phone|Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
215069281|NCT03316287|DEVICE|Sensor|Wearable biosensor for the collection of physiological data
215069282|NCT02255058|OTHER|No intervention|The study is a Prospective observational cohort study
214927025|NCT02790359|OTHER|Air|Group of patients who would receive air insufflation
214927026|NCT02790359|OTHER|Carbon dioxide|Group of patients who would receive carbon dioxide insufflation
214927027|NCT05277142|OTHER|oral motor training|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
214927028|NCT05277142|DEVICE|Neuromuscular Electrical Stimulation|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks
214927029|NCT03558152|DRUG|UTTR1147A|UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
214927030|NCT03558152|DRUG|UTTR1147A Placebo|The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
214927031|NCT03558152|DRUG|Vedolizumab|Vedolizumab will be administered IV, as specified in the prescribing information.
214927032|NCT03558152|DRUG|Vedolizumab Placebo|The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.
214927033|NCT00522535|PROCEDURE|Open surgical repair|Open surgical repair of abdominal aortic aneurysm
214927034|NCT00522535|DEVICE|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
215069283|NCT05818956|DRUG|TAK-227|TAK-227 capsules.
215069284|NCT00044837|DRUG|Medroxyprogesterone acetate|
215069285|NCT00044837|DRUG|Estradiol|
214325912|NCT04579913|OTHER|Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound|Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
214927035|NCT05142150|OTHER|Questionaire|"Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.~Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying."
214927036|NCT05780970|OTHER|No intervention|Non-treated children and caregivers complete assessments only. The primary (treated) parent / adolescent dyad participate in family based weight management treatment through the main trial. In the main trial, families are randomized to either TEENS+Parents as Coaches (parent skills training) or TEENS+Parent Weight Loss (parent behavioral weight loss).
214927037|NCT03147079|BEHAVIORAL|Lifestyle intervention|
214927038|NCT05713669|BEHAVIORAL|Encounter visit with Patients|Participants in this encounter group will be asked to complete a pre and post-intervention survey, participate in a meeting with a former ICU patient at a post-ICU clinic, and undergo an in-person interview within fourteen days following the encounter.
214927039|NCT05713669|BEHAVIORAL|Non-encounter surveys|Surveys will be completed pre and post patient follow-up.
214927040|NCT04738097|DRUG|Ticagrelor 90mg|ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.Treatment will be continue with ASA 80 until 3 months.
214927041|NCT04738097|DRUG|Clopidogrel 75 mg|ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.Treatment will be continue with ASA 80 until 3 months.
215069286|NCT05238207|DRUG|BBI-001|Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
215069287|NCT05238207|DIETARY_SUPPLEMENT|Original Fibre Metamucil|Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
215069288|NCT03641768|DEVICE|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
215069289|NCT03641768|DEVICE|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
215069290|NCT03641768|DEVICE|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
214325913|NCT06042088|OTHER|Regular Size Glove and Bigger One|Different sizes of surgical gloves will be worn by participants
214325914|NCT03697200|OTHER|APA|Light touch using vaccaria seeds on specific points of the ear
214325915|NCT03697200|OTHER|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
214325916|NCT03697200|OTHER|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
214927042|NCT03018496|DIETARY_SUPPLEMENT|Beta-Hydroxy-Beta-Methylbutyrate|
214927043|NCT03018496|OTHER|Placebo|
214927044|NCT03490461|DRUG|Statin|Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
214927045|NCT06621901|OTHER|High Protein Diet|Individuals will be placed on a high protein diet for 10 days.
214927046|NCT06621901|OTHER|Normal Protein Diet|Individuals will be placed on a normal protein diet for 10 days.
214927047|NCT03693612|DRUG|feladilimab|feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.
214325917|NCT01110915|DEVICE|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
214325918|NCT01110915|DEVICE|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
214325919|NCT06439758|DRUG|Metformin|Metformin 1000 mg/day for 6 months
214325920|NCT06439758|BEHAVIORAL|Lifestyle|Dietary lifestyle modifications
214927048|NCT03693612|DRUG|Tremelimumab|Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .
214927049|NCT03693612|DRUG|Docetaxel|Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m\^2).
214927050|NCT03693612|DRUG|Paclitaxel|Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m\^2.
214927051|NCT03693612|DRUG|Cetuximab|Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m\^2 followed by 250 mg/m\^2 once weekly.
214927052|NCT01037517|DRUG|Plerixafor|Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
214927053|NCT01037517|OTHER|Observation: Nonintervention|Nonintervention group, no drug will be given, observation only
214927054|NCT05156372|OTHER|High Intensity Interval Training|Participants will perform high-intensity aerobic and resistance exercise
214927055|NCT00166543|DRUG|TAS-108|
214927056|NCT03513809|DEVICE|Thoracic electrical impedance tomography|Non invasive, radiation-free, bedside monitoring tool for distribution of pulmonary ventilation.
214927057|NCT03784209|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|When suspected lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
214325921|NCT00159523|DIETARY_SUPPLEMENT|Probiotic|
214927058|NCT05678868|PROCEDURE|MitraClip procedure|MitraClip is surgical procedure to repair the mitral valve in your heart. During the procedure, the doctor will access the mitral valve using a thin tube (called a catheter) that is guided through a vein in your leg to reach your heart. A small implanted clip is attached to the mitral valve to reduce the leaking across the valve and to reduce symptoms and stress on the heart.
214325922|NCT00159523|BIOLOGICAL|placebo|
214325923|NCT02705950|DRUG|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
214325924|NCT02705950|OTHER|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
214325925|NCT03985813|BEHAVIORAL|Screening Wizard|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
214325926|NCT05486949|DRUG|AZD4205 and carbamazepine|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
214325927|NCT05486949|DRUG|AZD4205 and itraconazole|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
214325928|NCT00764075|DEVICE|Beutel TM|application of BeutelTM
214325929|NCT00764075|OTHER|standard|standard procedure will be applied but no Beutel TM software
214325930|NCT00764075|DEVICE|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
214325931|NCT02425631|DEVICE|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
214325932|NCT05481619|DRUG|Vedolizumab|"Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit."
214325933|NCT01851005|DRUG|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
214325934|NCT01851005|DRUG|Sevoflurane|Control Vol% to maintain BIS 40\~45
214325935|NCT01851005|DRUG|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.
214325936|NCT01851005|DRUG|Normal saline|Use as placebo
214927059|NCT05900869|OTHER|FSFI|Female Sexual Function Index questionnaire
214927060|NCT05900869|OTHER|BES|Body Esteem Scale questionnaire
214325937|NCT01851005|DRUG|Rocuronium|0.8 mg/kg for induction
214325938|NCT06463535|DRUG|Omega 3|SRP + OMEGA 3
214927061|NCT05830136|DRUG|sodium bicarbonate Ringer's solution|Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.
214927062|NCT03430479|DRUG|Cohort A|Radiation + Nivolumab + hormone therapy
214927063|NCT03659175|OTHER|SIBO|SIBO: Small intestinal bacterial overgrowth, refers to a bacterial overgrowth due to organic or functional stasis in small intestine, leading to the change in number or types of bacteria in small intestine.
214927064|NCT02461706|DRUG|cannabidiol|All subjects will have a dosing titration starting with 25 mg/kg/day and will be titrated weekly as tolerated based on clinical response. All subjects will be clinically evaluated at baseline, once a month for three months and every three months thereafter. In order to ensure safe use at higher doses, patients receiving more than 600 mg of daily CBD will be evaluated at least monthly until they achieve steady state at the final fixed maintenance dose.
214927065|NCT02461706|OTHER|Blood Test|All subjects will have the following clinical laboratory tests including changes in bone marrow (CBC), liver (AST, ALT), and kidney function (creatinine, electrolytes, BUN) will be assessed at baseline, each month during months 1 to 3, and every 3 months thereafter.
214927066|NCT03448575|OTHER|Control - Provider Medication Alert Only|Simple text medication alert referencing Choosing Wisely guidelines.
214927067|NCT03448575|OTHER|Intervention - Alert + CAP Review AND Enhanced BH Access|Interactive medication alert referencing SUAY Clinical Guidelines and offering options to keep/remove orders for the antipsychotic, virtual CAP consult, BH navigation for the patient, and access to bridging therapy for the patient.
214927068|NCT03247153|DIAGNOSTIC_TEST|Echocardiography|Imaging of the heart using ultrasound
214927069|NCT00177853|DRUG|celecoxib|Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
214927070|NCT00177853|DRUG|irinotecan|Preoperative chemoradiation will consist of escalating doses of irinotecan (30 50 mg/m2 IV) once weekly for a total of 4 doses.
214927071|NCT00177853|PROCEDURE|concurrent radiotherapy|50.4 cGy of standard external beam radiation. The radiation will be given in 28 treatments of 1.8 cGy per treatment over 5.5 weeks. This will be given in an outpatient setting.
214927072|NCT03109353|DRUG|ECP with 5-aminolevulinic acid|extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles
214927073|NCT05318092|DEVICE|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|The AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has five main components, a flexible cannula (F1885), sheath, tapered obturator, aspirator handle, and waste bag.
214927074|NCT02661269|DEVICE|Videomicroscopy of the sublingual microcirculation|Measuring total vessel density with the Cytocam-IDF camera.
214927075|NCT02661269|DEVICE|Bio-impedance measurements.|measuring resistance and reactance with the BIVA method.
214927076|NCT02872974|OTHER|GDM|Exposure to GDM during fetal life
214927077|NCT02383368|DRUG|ASP4132|oral
214325939|NCT06463535|PROCEDURE|SRP alone|Scaling and root planning
214325940|NCT02161718|DRUG|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
214325941|NCT02161718|DRUG|Placebo + olanzapine|Oral tablet, taken once daily
214325942|NCT06960096|OTHER|DBS combined with fMRI|Participants will undergo fMRI scanning while their DBS device is either turned OFF or ON. BOLD (blood oxygen level dependent) changes in response to DBS will be evaluated across PD participants. These scans and DBS procedure will be used for research purposes only and are not for treatment or diagnostic purposes.
214927078|NCT04815265|DRUG|Remimazolam|Remimazolam is used for sedation
214927079|NCT04815265|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation
214927080|NCT04376944|OTHER|Survey|questionnaire on their symptoms and their exposures
214927081|NCT00601172|DRUG|Casopitant|Experimental NK-1 receptor antagonist
214927082|NCT00601172|DRUG|Dexamethasone|Standard antiemetics
214927083|NCT00601172|DRUG|Placebo|Placebo to match IV casopitant
214325944|NCT06644040|DRUG|TeriQ Patch|"Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart.~Route of administration- Dermal patch"
214325945|NCT06644040|DRUG|Teribone Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
214325946|NCT06644040|DRUG|Forteo Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
214927084|NCT00601172|DRUG|Ondansetron|Standard antiemetics
214927085|NCT01914146|OTHER|Insulin|Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
214927086|NCT01914146|OTHER|No Insulin|Study session will occur prior to initiation of insulin therapy.
214927087|NCT03303573|DRUG|recombinant human erythropoietin|Subcutaneous rhEPO injection
214927088|NCT02422966|DRUG|Paracetamol|
214927089|NCT02422966|DRUG|Ibuprofen|
214325947|NCT04564755|DRUG|abrocitinib|Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
214325948|NCT05033964|COMBINATION_PRODUCT|Percutaneous Coronary Intervention with drug eluting stents|Coronary drug eluting stent implantation
214927090|NCT06665139|DIAGNOSTIC_TEST|muscle thickness|Pain intensity will be measured with visual analog scale, sonographic severity grade of shoulder impingement syndrome, muscle thickness of serratus anterior muscle, upper trapezius and middle trapezius with USG in patients diagnosed with impingement and meeting the criteria and healthy volunteers.
214927091|NCT02219581|DRUG|Dexamethasone 10 mg|Two doses of dexamethasone 10 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
214927092|NCT02219581|DRUG|Dexamethasone 20 mg|Two doses of dexamethasone 20 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
214927093|NCT02219581|DRUG|Standard multimodal pain management regimen|"The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~* Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~* Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~* Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~* Tylenol: 1000mg po q 8hr (scheduled)~* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~* IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~* Morphine patient-controlled analgesia (PCA): only for failure of the above~* Morphine Sulfate (MS) Contin: Use as backup prn pain"
214927094|NCT02219581|DRUG|Placebo|Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
214927095|NCT06666166|DRUG|SHR-A1811 & Apartinib|SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.
214927096|NCT00048802|DRUG|Lithium|
214927097|NCT00048802|DRUG|Olanzapine|
215069291|NCT03641768|DEVICE|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
215069292|NCT06232746|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
215069293|NCT05617508|OTHER|Placebo|Placebo capsules administered twice daily for a total of 12 weeks.
215069294|NCT05617508|DIETARY_SUPPLEMENT|Nicotinamide Riboside supplementation 1000mg daily in total|Nicotinamide Riboside supplementation 1000mg daily in total
215069295|NCT05617508|DIETARY_SUPPLEMENT|Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)|Nicotinamide Riboside supplementation up to 3000mg daily in total
214325949|NCT03495882|DRUG|AGEN1884 + AGEN2034|AGEN1884 + AGEN2034 according to protocol design
214325950|NCT02151526|DRUG|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
214927098|NCT00048802|DRUG|Divalproex|
214927099|NCT00048802|DRUG|Risperidone|
214927100|NCT00048802|DRUG|Quetiapine|
214927101|NCT00048802|DRUG|Ziprasidone|
215069296|NCT04084366|DRUG|OBI-999|For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
215069297|NCT04084366|DRUG|OBI-999|For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
215069298|NCT02265536|DRUG|LY3022855|Administered IV
215069299|NCT06481878|DIAGNOSTIC_TEST|faecal analysis|Collection of medical data and stool sampling
215069300|NCT05913713|BEHAVIORAL|12-week Intervention Period|Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
215069301|NCT05913713|BEHAVIORAL|12-week Observation Period|After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
215069302|NCT02905539|DRUG|Iron Isomaltoside 1000|
215069303|NCT02905539|DRUG|Ferric Carboxymaltose|
215069304|NCT05031299|BEHAVIORAL|Standard care|Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
215069305|NCT05031299|BEHAVIORAL|Health-promotion application for self-management|Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
214325951|NCT05929482|BEHAVIORAL|Infección de Amor (Infectious Love)|"Infectious Love is a filmed dramatized story (telenovela/soap opera) culturally tailored for US Latinas and delivered online.~IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
214325952|NCT04601688|DRUG|Bevacizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
214325953|NCT04601688|DRUG|Bevacizumab Ophthalmic|Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
214325954|NCT03858387|DRUG|Meropenem|"This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration."
214347559|NCT02771951|BEHAVIORAL|Usual Care|
214347560|NCT03139487|DRUG|Rivaroxaban|15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
214927102|NCT00048802|DRUG|Aripriprazole|
214927103|NCT03030989|DRUG|Chlorhexidine Gluconate 2% Wipe|
214927104|NCT03030989|DRUG|Placebo Wipe|
214927105|NCT06559865|BEHAVIORAL|Breathing exercises|as per group description
214927106|NCT04796623|DRUG|TQB3616 capsules|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
214927107|NCT04796623|DRUG|Fulvestrant injection|Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
214927108|NCT02872610|BEHAVIORAL|Self-help Online|"The internet-based self-help program consist of 6 modules that each take a week to complete. Every module consists of a theoretical section, a compulsory exercise, and several optional exercises: Participants are encouraged to spend a minimum of 30 minutes every day with the self-help program. On the website, the participants in the intervention condition may also access an Acute Help page where information on help options are listed and a My Profile page where changes to login and contact details may be made, also, the informed consent form is found here. Participants may furthermore access a message system where they can write questions to the trial manager."
214927109|NCT04183153|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.
214927110|NCT04677751|DEVICE|Acupuncture intervention|Participants will undergo 12 weeks of acupuncture therapy. There will be one 40 minute-1 hour. session per week.
214927111|NCT05117281|DRUG|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 1 ml/kg
214927112|NCT05117281|DRUG|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 0.25 mg/kg
215069306|NCT05031299|DEVICE|Wearables and devices|Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
215069307|NCT02048137|DEVICE|Transcranial direct current stimulation|
215069308|NCT03935867|BEHAVIORAL|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
214325955|NCT03858387|DRUG|Imipenem|"This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration."
215069309|NCT00093899|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
214325956|NCT06160076|DEVICE|Radiofrequency|Patient with atrial fibrillation ablated per catheter using radiofrequency energy
214325957|NCT06160076|DEVICE|Pulsed electric field|Patient with atrial fibrillation ablated per catheter using pulsed electric field
214325958|NCT00799968|DRUG|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
214325959|NCT00799968|DRUG|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
214325960|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (NH formulation)|Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
214927113|NCT03638999|DRUG|Ketorolac Trometamol 30Mg/1mL Injection|Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.
214927114|NCT03638999|DRUG|Normal saline|Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
214927115|NCT04653337|COMBINATION_PRODUCT|Robot-assisted accelerated iTBS-1800 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-1800 (10 sessions of iTBS1800 with 50 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine).
214927116|NCT04653337|COMBINATION_PRODUCT|Robot-assisted accelerated iTBS-600 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-600 (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
214927117|NCT04653337|COMBINATION_PRODUCT|Sham accelerated iTBS combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of sham accelerated iTBS (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
214927118|NCT00123617|PROCEDURE|Phase III group-based cardiac rehabilitation|Phase III group-based cardiac rehabilitation
215069310|NCT00883818|DRUG|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
215069311|NCT05822570|DIAGNOSTIC_TEST|Assessment of Oxygen Dissociation Curve (ODC)|ODC will be assessed at 5 timepoints: T0 after installation of arterial catheter, T1 before clamping of the liver, T2 5-10 min before reperfusion of the liver graft, T3 45 min after reperfusion, T4 1 h after T3 or at end of surgery
215069312|NCT02789436|DRUG|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
215069313|NCT02789436|OTHER|Placebo lozenges|Twice daily, for 28 days
215069314|NCT06078592|DRUG|BRIDIN-plus Eye drops|BRIDIN-plus Eye drops
215069315|NCT06078592|DRUG|Combigan Eye drops|Combigan Eye drops
214325961|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (SH formulation)|Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
214325962|NCT02957890|BIOLOGICAL|Placebo|Round 2 (May): 0.5mL normal saline
214325963|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m\^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
214325964|NCT03281369|DRUG|Leucovorin|Leucovorin: 100 mg/m\^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
214325965|NCT03281369|DRUG|Oxaliplatin|Oxaliplatin: 100 mg/m\^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
214325966|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
214927119|NCT05269875|OTHER|ACP|The intervention covers a formal ACP discussion, including provision of a holistic approach (physical, psychological, spiritual, social) and includes symptom control and discussion on illness limitations and prognosis, goal assessment and goal adjustment, financial issue, (un)desirable treatments for current and future care, hopes and wishes, and possibility of involvement of a palliative care team.
214927120|NCT03917472|DRUG|Brolucizumab|Intravitreal injection
214927121|NCT03917472|DRUG|Aflibercept|Intravitreal injection
214927122|NCT05681468|OTHER|Keto-SAT|"Nutrition counselling focused on Keto diet (saturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
214927123|NCT05681468|OTHER|Keto-CAN|"Nutrition counselling focused on Keto diet (unsaturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
214927124|NCT05681468|OTHER|LFD|"Nutrition counselling focused on low-fat diet.~30% total energy (TE) as fat, 50% TE as carbohydrates (primarily whole grains) and 17-20% TE protein (mainly lean sources)."
215069316|NCT06579404|DEVICE|CamAPS HX|"The automated closed loop system (CamAPS HX) will consist of:~YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm"
214927125|NCT02706886|DRUG|Lumasiran|Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
214927126|NCT02706886|DRUG|Placebo|Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
214927127|NCT00090701|DRUG|AG2037|
214927128|NCT03075345|BEHAVIORAL|Acceptance and commitment therapy|Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.
214927129|NCT03075345|BEHAVIORAL|Treatment as usual (dietetic intervention)|Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
215069317|NCT06579404|OTHER|Standard insulin therapy with glucose sensor|Participants usual insulin therapy with Freestyle Libre 3 glucose sensor
215069318|NCT06574087|DIAGNOSTIC_TEST|hrHPV test and cytology|Perfomance of hrHPV test and cytology
215069319|NCT06651151|DRUG|LTX-315 + pembrolizumab|LTX-315 as intratumoral injection once weekly for a maximum of 5 dosing days, in combination with pembrolizumab as intravenous infusion, 200 mg every 3 weeks for a maximum of 18 doses
215069320|NCT03268954|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
215069321|NCT03268954|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
214325967|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
214325968|NCT03281369|BIOLOGICAL|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
214325969|NCT03281369|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
214325970|NCT03281369|BIOLOGICAL|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
215069322|NCT00129584|PROCEDURE|Emphasys Endobronchial Valve and procedure|
215069323|NCT03909906|DRUG|Euphytose®|(50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
215069324|NCT03909906|DRUG|Placebo Oral Tablet|Placebo comparator
214325971|NCT03281369|DRUG|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
214325972|NCT03281369|DRUG|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
214325973|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
214325974|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
214325975|NCT03281369|DRUG|Cisplatin|Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
214325976|NCT03281369|DRUG|Tiragolumab|Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
214325977|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
214325978|NCT05233462|OTHER|standardized dose|intrathecal anesthesia with 10 mg of bupivacaine
214325979|NCT05233462|OTHER|adjusted dose|intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
214325980|NCT01545921|OTHER|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
214325981|NCT01650363|OTHER|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
214325982|NCT01650363|DRUG|Homeopathic placebo medication|2-3 mm small spheric suger pils
214347561|NCT03139487|DRUG|Dalteparin|200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks
214347562|NCT03139487|DRUG|apixaban|10 mg q12 hours for 7days followed by 5mg q12 hours for 21 weeks
214347563|NCT02261363|OTHER|Ecig group 1|E-cigarettes were 3% nicotine and of tobacco or menthol flavor, depending on participants' usual flavor preference.
215069325|NCT03802630|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
215069326|NCT03802630|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
214325983|NCT05812053|PROCEDURE|pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline was performed by sterile #330 high speed bur using water spray. Caries was removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber removed by low speed round bur. Haemostasis was obtained by applying pressure with moist cotton pellet with saline. Then the test materials was applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material then the tooth will be restored with a preformed stainless steel crown
214325984|NCT05812053|RADIATION|cone beam computed tomography (CBCT) assessment|a post-operative CBCT image will be taken immediately after completing the procedure with fixed exposure parameters (120 Kv, 5mA, and 0.125mm voxel size) using the smallest field of view (8D, 8Hcm) also, after 12 months follow-up periods.
214325985|NCT05096611|BEHAVIORAL|Attachment and Biobehavioral Catch up|ABC is delivered by a trained parent coach. The parent coach provides information about parenting and child development. The focus is on providing support for parents of young children and improving the parent-child relationship.
214325986|NCT05096611|BEHAVIORAL|Attachment and Biobehavioral Catch up Plus Depression Treatment|ABC+D offers the same 10-sessions of parenting support that is provided by ABC and additionally provides weekly short videos that help mothers develop skills for coping with stress and regulating mood.
214325987|NCT00207142|DRUG|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
214325988|NCT00207142|DRUG|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
214325989|NCT06390020|OTHER|MBSR|The MBSR training spans eight weeks and follows a standardized protocol. It consists of eight weekly sessions, each lasting 2.5 hours, a single 6-hour silent day, and daily home exercises. Additionally, the program incorporates personalized psychoeducation on high sensory processing sensitivity, covering its characteristics, scientific foundations, its relation with stress-related symptoms, and why mindfulness might be helpful.
214325990|NCT01026051|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
214927130|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Healthcare workers will receive standard PPE and a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at the beginning of their shift, in the middle, and at the end of their shift.
214325991|NCT03748940|DRUG|LY3074828|Administered SC
214325992|NCT03748940|DRUG|Placebo|Administered SC
214325993|NCT03748940|DRUG|LY900021|Administered SC
214325994|NCT05550012|OTHER|low-dose CT|those patients undergo low-dose liver CT in portal vein and delayed phase.
214325995|NCT01857063|DRUG|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
214325996|NCT01857063|DRUG|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
214927131|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Patients will receive standard of care treatment and a pre- and post-study nasal spray COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle shortly after admission or preoperatively.
214927132|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Community members will receive a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at home.
214927133|NCT06667349|DRUG|Ticagrelor|Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI
214927134|NCT06395506|DIETARY_SUPPLEMENT|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
214927135|NCT04434469|DRUG|RO7297089|RO7297089 will be given via intravenous (IV) infusion
214927136|NCT01669174|DRUG|Placebo|
214927137|NCT01669174|DRUG|BYM338|BYM338
214927138|NCT01261572|DRUG|degarelix|periodic injection
214347564|NCT01517802|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
214347565|NCT01517802|DRUG|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
214927139|NCT05622058|DRUG|ALRN-6924|ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).
214927140|NCT05622058|DRUG|TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)|TAC will be administered as an IV infusion on Day 1 of every 3-week treatment cycle
214927141|NCT03788434|DRUG|VE303|VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under Good Manufacturing Practices (GMP) conditions.
214927142|NCT03788434|DRUG|Placebo|Placebo capsules contained microcrystalline cellulose and were visually identical to VE303 capsules. Placebo capsules did not contain any VE303 Drug Product.
214927143|NCT04353167|OTHER|observational evaluation|Patients will be evaluated only observationally without intervention
214927144|NCT03146689|DRUG|Topical NSAID|Applied four times daily
214927145|NCT03146689|DRUG|Topical Capsaicin|Applied four times daily
214927146|NCT01953601|DRUG|Verubecestat 12 mg (Parts 1 and 2)|Verubecestat 12 mg oral tablet, given once daily.
214927147|NCT01953601|DRUG|Verubecestat 40 mg (Parts 1 and 2)|Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.
214927148|NCT01953601|OTHER|Placebo (Part 1)|Placebo matching verubecestat, given once daily as an oral tablet.
214927149|NCT03554863|DEVICE|Nasal High Flow Oxygen|Nasal High Flow Oxygen using Optiflow device of Fisher and Paykel
214927150|NCT03554863|DEVICE|Facial Mask|Preoxygenation with facial mask
214927151|NCT04582929|DRUG|Neuronox ® Injection|Neuronox ® 50 or 100 unit intramuscular injection
214927152|NCT06667492|DEVICE|Traction Dynamometry|K-Pull dynamometer (Model MP.09.02.FN, Kinvent, Montpellier, France) is an assessment tool used to quantify muscle strength. It uses traction through a non-elastic strap to facilitate isometric contractions. This instrument will be used to evaluate isometric activity (maximum and average torque values) of the hip and knee flexors and extensors at specific joint angles.
214927153|NCT03473639|DRUG|Entinostat|In metastatic breast cancer patients, entinostat will be taken orally starting at 3 mg per week and will increase to 5 mg per week in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
214927154|NCT03473639|DRUG|Capecitabine|In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
214927155|NCT02991729|OTHER|iPad-based decision aid|This is a novel decision aid developed by genetic counselors and Maternal Fetal Medicine physicians. It is used via an iPad and is interactive. It is available in English and Spanish has been piloted by 20 English and Spanish speaking women. It takes approximately 15 minutes to complete.
214927156|NCT02991729|OTHER|Genetic counseling appointment|All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
214927157|NCT02230696|DRUG|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
214927158|NCT02230696|DRUG|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
214325997|NCT04698356|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed in order to train each individual at their own level and to make the task challenging. A short-term memory component was also added to the original training paradigm, to enhance the cognitive skills of our participants. To provide maximal speech-in-noise benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate this in young, normal-hearing adults (18-30 years) by studying our outcome measure (speech reception threshold) for the different sentence-scenarios and test-retest sessions.
214325998|NCT00531843|DRUG|fondaparinux sodium|fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
214325999|NCT00531843|DEVICE|sequential compression devices|Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
214927159|NCT02230696|DRUG|Placebo nasal spray|Placebo nasal spray
214927160|NCT02837939|DRUG|Human derived Transfer factor|"One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~* 3 x TF in first week: day 1,3,5~* 2 x TF in week 2: day 8 , 11~* 1 xTF in week 3 and 4 : day 15, 22~* 1 x TF once a month up to 6 month"
214927161|NCT02837939|DRUG|Aqua pro injectione 4ml ampules for subcutaneous injection|"12 doses in total:~* 3 doses in first week: day 1,3,5~* 2 doses in week 2: day 8 , 11~* 1 dose in week 3 and 4 : day 15, 22~* 1 dose once a month up to 6 month"
214927162|NCT06430372|DRUG|Bev-ICG|Probe targeting VEGF-A that is topically administrated during the endoscopy
214927163|NCT06430372|DEVICE|NIR-II fluorescence endoscopy platform|An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy
214927164|NCT03274141|OTHER|Non-Interventional|Non-Interventional
214927165|NCT01154296|BEHAVIORAL|RESPECT-2 Counseling|Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
215069327|NCT03802630|OTHER|Sham injection|"Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator."
215069328|NCT02565758|DRUG|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
215069329|NCT03016624|DEVICE|OCT guided PCI|oct guided
215069330|NCT03016624|DEVICE|Angiography guided PCI|angio guided
214326000|NCT00375843|DRUG|Escitalopram|Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
214326001|NCT00375843|DRUG|Sertraline|Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
214326002|NCT00136292|DRUG|daptomycin|
214326003|NCT05427435|DEVICE|Marshall ethanolisation|Destruction of Marshall bundles by ethanol 96% infusion (3 separate injections of 3.3ml)
214927166|NCT03005275|OTHER|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later). Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU. Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
214927167|NCT03005275|OTHER|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred"
214927168|NCT05537441|BEHAVIORAL|Text messaging|Patients will receive up to 3 text messages reminding them about the importance of influenza vaccination during the 2022-2023 flu season.
215069331|NCT06678139|OTHER|physiotherapy|Bilateral gastrosoleus stretching, iliopsoas and hamstring stretching (if a shortness is detected), foot intrinsic and extrinsic muscle strengthening, lower extremity muscle strengthening and parkour walking training will be performed. Therapeutic exercises will be performed once a week for 12 weeks under the supervision of a physiotherapist. Parents will be asked to follow a 12-week home exercise program at home during the five days. The home exercise program will include the exercises performed in the pediatric physiotherapy and research laboratory. Parents will be instructed to perform each exercise twice a day at home. Children will be given a weekly exercise diary to increase adherence to the exercise program.
214486151|NCT07030751|BEHAVIORAL|Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.|"The study seeks to quantify the impact of a complex intervention based on 3 modules :~1. Stress management~2. Sleep improvement and fatigue reduction,~3. Sedentary behaviors reduction and physical activity promotion.~Students from the interventional group will follow these 3 different health-related modules in a specific order (stress, sleep, physical activity). Each module will be composed of 3 sessions. Each session includes individual interviews covering initial assessment and personalized goal setting."
215069332|NCT05005013|OTHER|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
215069333|NCT05005013|OTHER|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
215069334|NCT05005013|OTHER|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
215069335|NCT06073457|DEVICE|MagGJ System|Anastomoses achieved by magnetic compression.
215069336|NCT06651853|DRUG|Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab|"Large fraction radiotherapy is administered at 5Gy/day for 3 days, with one to two courses carried out on a single target lesion as determined by the investigator. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is administered at 400µg per day for 3 days starting on the first day after the end of radiotherapy. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Glofitamab is administered starting on the 7th day after the end of radiotherapy.~For cycles 2-6, each cycle is 21 days. GM-CSF is administered at 400µg per day for 3 days starting on the first day of each cycle. Glofitamab is administered at 30mg on the 4th day of each cycle. Lenalidomide is administered at 25mg per day for 14 days starting on the first day. Treatment consists of 6 cycles or until disease progression, death, intolerable toxicity, withdrawal of informed consent."
214326004|NCT05221853|DIAGNOSTIC_TEST|cardiovascular magnetic resonance|CMR scan at 3 Tesla
214326005|NCT06205927|RADIATION|Standard carbon ion beam radiotherapy|The standard treatment arm will receive carbon ion beam radiotherapy of 77Gy (RBE equivalent) per 22 fractions for gross tumor volume.
214326006|NCT06205927|RADIATION|Carbon ion beam radiotherapy simultaneously dose boost|The hypoxic lesions dose boost arm will receive 77Gy (RBE equivalent) per 22 fractions for gross tumor volume and a simultaneously dose boost of 83.6Gy (RBE equivalent) per 22 fractions for hypoxic lesions detected by 18F-Misonidazole PET/CT.
214927169|NCT03697759|OTHER|Usual care + selfBACK|"The selfBACK intervention is a digital Decision Support System (DSS) for self-management of LBP provided to the participant via a smartphone app (selfBACK app). In addition, the participant is provided with a step-detecting wristband (Xiaomi Mi Band 2) that interacts with the selfBACK app.~The DSS provides individually tailored self-management plans including content from three categories; 1) information/education, 2) physical activity monitoring through wearing the step-detecting wristband, and 3) strength and flexibility exercises. The weekly plans are individually tailored to the specific patient, using the data available from the patient, and each week the patients report back their progress on physical activity (step count) and exercise (volume completed). These data are matched with the patients follow-up data to create a self-management plan that is up to date and adaptable to variation in health-status of the individual patient."
214927170|NCT01264237|DRUG|Etoricoxib|90mg Tablet QD at 10:00a.m.
214927171|NCT01264237|DRUG|Placebo|One tablet QD at 10:00a.m.
214927172|NCT03425409|DEVICE|Integra Pulse Portable- Continuous flow|4 liters per minute oxygen flow
214927173|NCT03425409|DEVICE|Integra Pulse Portable- Pneumatic pulsed flow|Oxygen flow determined by test device
214927174|NCT05528107|PROCEDURE|Lap IPOM plus|Participants will undergo Lap IPOM plus repair according to the assigned treatment arm.
215069337|NCT06977113|OTHER|High Fibre Fermented Food Diet|Participants will be provided with and asked to consume specific foods high in various types of fibre to promote a variety of substrates for gut bacteria including inulin, galactooligosaccharides (GOS), and β-glucan. Participants will also be asked to consume 2 fermented items, yogurt and kefir. Study foods will be commercially available including a high-fibre bar made from chicory-derived inulin (1 bar of 35 g/d), oat-containing cakes (4 oatcakes of 35 g/d) or oat porridge (1 sachet of 38.5 g/d), shredded wheat cereal biscuits (2 biscuits of 45 g/d), hummus (½ pot of 100 g/d), and/or baked beans (½ can of 100 g/d) or lentil soup (1 can of 400 g/d), and low fat yogurt (1/3 pot of 150 g/d) and kefir (½ bottle of 250 ml/d). The total amount of fibre study foods will provide is approximately 25 g/day which will be consumed in addition to the habitual diet. The total amount of fibre will be expected to reach the 30 g/day recommendation and will range between 25 - 40 g/day.
215069338|NCT06977113|OTHER|Control Habitual Diet|Participants will follow their habitual diet and will not consume any of the study foods (i.e., high-fibre fermented foods). The population average fibre intake for women in Scotland is 16 g/day (The Scottish Health Survey 2021).
215069339|NCT06099223|DEVICE|Acupuncture needles|"The acupuncture intervention includes a combination of auricular and body acupuncture. The auricular points used are Shen men, Zero point, Tranquilizer point, and Master cerebral.~The body points used are the wrist PC6."
215069340|NCT02988947|OTHER|PNE+HyP|This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
214326007|NCT05539235|DRUG|different degrees of adjustment of the injection interval|"Treatment was an intravitreal injection of 0.5 mg conbercept using modified T\&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks."
214326008|NCT05052229|DRUG|Nitric Oxide|Nitric oxide gas for inhalation
214326009|NCT05052229|DRUG|Medical air|Medical grade air for inhalation (placebo)
214326010|NCT06049420|BEHAVIORAL|Lifestyle counseling and coaching|Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.
214326011|NCT03623958|DEVICE|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
214326012|NCT03623958|PROCEDURE|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
214326013|NCT03536039|DRUG|NGR-hTNF|dose of 0.8 mcg/sqm
215069341|NCT01652053|DEVICE|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
215069342|NCT05037695|DRUG|empagliflozin 25 MG|empagliflozin 25mg - daily
215069343|NCT04931797|BEHAVIORAL|video decision aid|advance care planning video decision aid
214326014|NCT03536039|OTHER|RITUXIMAB|dose of 375 mg/mq
214326015|NCT03536039|DRUG|Doxorubicin|dose of 50 mg/mq
214326016|NCT03536039|DRUG|Cyclophosphamide|dose of 750 mg/mq
215069344|NCT04931797|BEHAVIORAL|control arm ACP information sheet|control arm ACP information sheet
214326017|NCT03536039|DRUG|Vincristine|dose of 1.4 mg/mq (max 2 mg)
214326018|NCT03536039|DRUG|Prednisone|75 mg
214326019|NCT04115358|PROCEDURE|Hyaluronic acid: Gengigel teething|Applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
214326020|NCT04115358|PROCEDURE|Formocresol Buckley formula: Formacresol|Applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
214927175|NCT05528107|PROCEDURE|eTEP|Participants will undergo eTEP repair according to the assigned treatment arm.
214927176|NCT02464475|OTHER|osteopathic manipulative treatment|
214927177|NCT02464475|OTHER|sham osteopathic treatment|
214927178|NCT05441111|BEHAVIORAL|Common Elements Toolbox|"COMET consists of the following modules: cognitive restructuring (labeled flexible thinking), behavioral activation (labeled positive activities), gratitude, and self-compassion. Participants complete these COMET modules by themselves. The format is reading psychoeducational along with completing specific activities"
214927179|NCT05441111|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
214927180|NCT05441111|BEHAVIORAL|Guided self-help|"Participants in the guided self-help condition are assigned an eCoach who provides emotional support as well as who promote adherence to the intervention"
214927181|NCT06191328|DRUG|Chiglitazar sodium|In patients with type 2 diabetes mellitus (T2DM), on the basis of one or two oral hypoglycemic agents combination with Chiglitazar sodium.
214927182|NCT04164251|OTHER|Screening mammography|The purpose of the study was to evaluate the feasibility of securing inpatient breast cancer screening mammograms for non-adherent hospitalized women prior to hospital discharge.
214927183|NCT06621147|PROCEDURE|Surgery|Surgery
214927184|NCT06328400|DRUG|Deuremidevir Hydrobromide for Suspension|Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
214927185|NCT06328400|DRUG|Deuremidevir Hydrobromide for Suspension Placebo|Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
214927186|NCT02819180|BIOLOGICAL|Butantan Influenza Trivalent, Fragmented and Inactivated vaccine|
214927187|NCT02849860|DRUG|IDP-121 Lotion|Lotion
214927188|NCT05800197|DRUG|Tamoxifen 20mg|Selective estrogen receptor modulator
214927189|NCT05800197|DRUG|Anastrozole 1mg|Aromatase Inhibitor
214927190|NCT05800197|DRUG|Letrozole 2.5mg|Aromatase Inhibitor
214927191|NCT05800197|DRUG|Goserelin|Gonadotropin Releasing Hormone (GnRH) agonist
214927192|NCT05800197|DRUG|Triptorelin|Gonadotropin Releasing Hormone (GnRH) agonist
214927193|NCT00270153|DRUG|enalapril|5mg enalapril daily for 6 months
214927194|NCT00270153|DRUG|Placebo|5mg enalapril-matching placebo daily for 6 months
214927195|NCT03397329|DRUG|AG-348 Sequence A|"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)"
215069345|NCT04055272|BEHAVIORAL|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
215069346|NCT04338607|PROCEDURE|Subtalar (Talocalcaneal) arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
214326021|NCT04115358|PROCEDURE|Ferric sulfate: ViscoStat|Applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
214326022|NCT04979585|DRUG|Camrelizumab|200mg ,IV,d1,Q3W.
214326023|NCT04979585|DRUG|Anlotinib|8mg,oral, d1-14,Q3W.
214326024|NCT04979585|DRUG|nab-Paclitaxel|260mg/m2,IV,d1,Q3W.
214326025|NCT01205165|DRUG|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
214326026|NCT01149798|DRUG|Abraxane and Cisplatin combination|"Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1."
214326027|NCT02121340|BEHAVIORAL|Behavioral Activation|
214347566|NCT04195464|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
214927196|NCT03397329|DRUG|AG-348 Sequence B|"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)"
214927197|NCT04310397|DRUG|Dabrafenib|Given PO
214927198|NCT04310397|BIOLOGICAL|Spartalizumab|Given IV
214927199|NCT04310397|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214927200|NCT04310397|DRUG|Trametinib|Given PO
214927201|NCT05241405|DIETARY_SUPPLEMENT|QISENG|2 capsules/day for 8 weeks.
214927202|NCT05241405|DIETARY_SUPPLEMENT|PLACEBO|2 capsules/day for 8 weeks.
214927203|NCT01641497|RADIATION|3D conformational radiation|25 \* 1.8 Gy in 5 weeks (=45 Gy)
214927204|NCT01641497|RADIATION|IMRT|25 \* 1.8 Gy in 5 weeks (=45 Gy)
214927205|NCT04518098|OTHER|Strength and balance exercise|The exercise program consists of muscle strengthening and balance training exercises that progress in difficulty. After completion of the baseline assessment and randomization, IG participants will receive orientation and learn the exercise routines (in the Cancer Rehabilitation Clinic within the Faculty of Rehabilitation Medicine at the University of Alberta). The duration of training is 3 months (40-50 minutes per scheduled session, three times a week) at home, with a minimum of one live group session supervised by the CEP, a minimum of one independent home session supported by the Active Living module of the HEAL-ME application; (the third session can be a live session or independent session at the participant's discretion).
214927206|NCT06263998|DRUG|NCP112|NCP112 topical ophthalmic solution
214927207|NCT06263998|DRUG|NCP112 Placebo|Placebo comparator
215069347|NCT04338607|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
215069348|NCT02031991|BIOLOGICAL|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
215069349|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
215069350|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
214326028|NCT05676892|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured"
214927208|NCT05225298|BEHAVIORAL|Offering SARS-CoV-2 test|A pragmatic cluster (facility-level) randomized clinical trial, comparing test-based screening performed at a static (every two weeks) frequency versus a dynamic frequency (ranging from once a week to once every four weeks) anchored to county COVID-19 case rates
214927209|NCT00985998|DRUG|Nimotuzumab and chemotherapy|"The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4\~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4\~6cycles).~the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12\~18 weeks)."
214927210|NCT05012904|BEHAVIORAL|parent involvement application|A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
214927211|NCT05234879|OTHER|Frame Running|Frame Running (FR) provides an opportunity for people with walking and balance problems to walk or run safely without the risk of falling. The frame consists of three wheels and has a saddle and handlebars like a trike without pedals.
214927212|NCT01383629|BEHAVIORAL|Counselling|Preoperative counselling
214927213|NCT04231929|DEVICE|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of BioPearl™ microspheres used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved."
214927214|NCT01450826|DRUG|aprepitant|On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).
214927215|NCT01450826|DRUG|ondansetron|On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.
214927216|NCT03224416|OTHER|Alcohol Administration|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
214927217|NCT03224416|OTHER|Placebo Alcohol Administration|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
214927218|NCT03224416|OTHER|No Alcohol Administration|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
214927219|NCT05038501|OTHER|To study comorbidities in patients undergoing Oncosurgeries|In the Preoperative Anaesthesia checkup we will study prevalence of comorbidities as Coronary artery Disease, Hypertension, Diabetes Mellitus , Hypothyroidism and prior Corona Virus Infection in patients undergoing Oncosurgeries
215069351|NCT05974384|DEVICE|No Music|No listening to music while intervention is carried out
214326029|NCT04352140|DEVICE|Tetragraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
214326030|NCT04352140|DEVICE|ToFscan|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
214927220|NCT01037595|DRUG|turmeric|turmeric 500 md tid orally for 8 weeks
214927221|NCT01037595|DRUG|placebo|placebo 3 time orally for 8 weeks
214927222|NCT01037595|DRUG|turmeric|500 mg tid orally for 8 weeks
214927223|NCT02877095|DRUG|Furosemide|subcutaneous furosemide delivered via subcutaneous pump
214927224|NCT02327338|DEVICE|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
214927225|NCT02327338|DRUG|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
214927226|NCT02223650|DEVICE|Overminus treatment|2.50D overminus spectacles
215069352|NCT05974384|DEVICE|Music|Listening to music while intervention is carried out
215069353|NCT03435120|OTHER|No intervention|No intervention
214326031|NCT05719428|OTHER|DRUID AI Program|Patients will begin single agent therapy within 4 weeks of enrolment and continue until disease progression, maximum safe cumulative dose reached (where applicable, per standard institution practice) or unacceptable toxicity as per physician's discretion.
214347567|NCT04195464|OTHER|Sham dry needling|Sham Dry needling use a non-penetrating acupuncture needle
214927227|NCT02223650|DEVICE|Non-overminus treatment|spectacles without overminus or no spectacles
214927228|NCT02753387|DRUG|Chlorhexidine|4 mouthwashes during 30 seconds with Eludril Perio 10 ml and 1 application after intubation with Eludril Perio
214927229|NCT02753387|DEVICE|NaCl 0.9 %|4 mouthwashes during 30 seconds with NaCl 0.9 % 10 ml and 1 application after intubation with NaCl 0.9 %
215069354|NCT05031117|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Technique at L4-5 interspace using Tuhoy needle (18G) then epidural catheter (20G) inserted, then 15ml 0.5% Bupivacane and 50ug fentanyl given.
214927230|NCT05167370|DRUG|Amifostine|Amifostine (Ethyol) 1125 mg/m2 will be given intravenously daily over 5 minutes starting 30 minutes prior to chemotherapy (melphalan or thiotepa) on days -5, -4, -3, -2, and on day -1 twenty four hours after prior dose of amifostine.
214927231|NCT01084200|DRUG|Propofol for maintenance|Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
214927232|NCT01084200|DRUG|Sevoflurane|Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
214927233|NCT01084200|DRUG|Sevoflurane+Propofol|Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
214927234|NCT06616675|DRUG|Darifenacin|Anticholinergic drug therapy for OAB treatment - Darifenacin, 15mg/day
214927235|NCT06616675|DEVICE|Neuromodulation - Sacral nerve stimulation|Neurodyn Portable TENS FES neuromuscular stimulation device in an outpatient clinic. Two self-adhesive electrodes (5x9cm) were used, positioned one in each gluteal region, below the iliac spine to apply low-frequency biphasic current with 10 Hz. Pulse duration of 0.5 milliseconds was applied for 40 minutes with continuous stimulation, 3 times a week, for 20 sessions.
214927236|NCT03812770|DRUG|Sorafenib|Oral Sorafenib, 400mg, Bid
214927237|NCT03812770|DRUG|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214927238|NCT03812770|DRUG|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
214927239|NCT00318500|DRUG|ERB-041|
214927240|NCT06623175|DEVICE|Acupuncture needles|See arm description
214927241|NCT00570544|DRUG|tiotropium|18ug capsule daily for 30 days
214927242|NCT05514587|BEHAVIORAL|Meaning of Life Questionnaire (MLQ)|Completion of questionnaires at crisis centre entry and 3 months later.
214927243|NCT01785511|RADIATION|UVA Radiation|UVA radiation exposure for 20 minutes
214927244|NCT03914261|DRUG|Risankizumab|Tablet
214927245|NCT06428552|DEVICE|Mobile Application|Daily rehabilitation program of 40 minutes duration using a mobile application to be completed 6 days per week for 12 weeks
214927246|NCT05923242|BEHAVIORAL|Computerized Intervention Authoring Software (CIAS)|CIAS is a web based intervention. The CIAS tool walks the participant through a Motivational Interviewing process whereby they think through the reasons for and against completing screening. CIAS makes use of an automated avatar (Emmi) who is programed to ask them questions and lead them through several topic areas related to screening. The CIAS pathways include options for participants to request a link of resources after they complete each session and for patients to request a list of the cancer treatments listed in their study records in order to confirm their understanding of their cancer history.
214927247|NCT06257342|PROCEDURE|6 minutes walk|A 6 minutes walk test
214927248|NCT02935504|BEHAVIORAL|PRogram In Support of Moms (PRISM)|"PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:~Toolkit Care coordination Psychiatric consultation Implementation support~1. Engage clinic leaders and staff~2. Identify leadership group and prepare for change~3. Assess readiness to implement PRISM~4. Identify steps to achieve goals~5. Implement PRISM components into the clinic~6. Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention"
214927249|NCT02935504|BEHAVIORAL|MCPAP for Moms|MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals
214927250|NCT05444725|OTHER|Stage of Decision Making|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
214927251|NCT05444725|OTHER|Choice framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
214927252|NCT05444725|OTHER|Opportunity Framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
215069355|NCT05031117|PROCEDURE|25G Dural Puncture Epidural Technique|25G pencil point spinal needle will be inserted at L4-5 interspace through the tuhoy needle
215069356|NCT02604368|DRUG|SC411|Soft gelatin capsule
215069357|NCT02604368|DRUG|Placebo|Soft gelatin capsule
215069358|NCT04930276|OTHER|Diet intervention|Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.
215069359|NCT03958864|DRUG|CC-90001|CC-90001
215069360|NCT02488135|DEVICE|Floseal Hemostatic Matrix|Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
215069361|NCT02488135|PROCEDURE|Traditional Nasal Packing|Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
215069362|NCT06170463|DRUG|Metformin Hydrochloride|Met Group Received metformin hydrochloride 500 mg tab 3 times Daily
215069363|NCT06170463|DRUG|MI/DCI combination in 40:1 ratio|MI-group received MI/DCI combination in 40:1 ratio twice daily
215069364|NCT06170463|DRUG|Combination of Metformin hydrochloride and MI/DCI|MM Group Received both Met and MI Groups Treatment
214326032|NCT04748146|OTHER|Brain stimulation|Theta-burst stimulation will be applied to selected regions of distributed networks to test whether distal stimulation can modulate hippocampus-mediated episodic recollection.
214927253|NCT05313022|BIOLOGICAL|ZR-202-CoV|Adjuvanted Recombinant SARS-CoV-2 S-protein Subunit Vaccine
214326033|NCT04988685|DEVICE|Sirolimus Eluting Balloon|PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
214326034|NCT03306264|DRUG|ASTX727|ASTX727 oral tablet
214927254|NCT05313022|OTHER|Placebo|Normal saline solution
214326035|NCT03306264|DRUG|Dacogen|Decitabine 20 mg/m\^2 one-hour IV infusion
214927255|NCT00545246|DRUG|aflibercept (AVE0005)|intravenous infusion
214927256|NCT00545246|DRUG|docetaxel|intravenous infusion
214927257|NCT00415116|DRUG|carboplatin|
215069365|NCT03139994|OTHER|Diagnostic|OBSERVATIONAL, DIAGNOSTIC PROCEDURES. Young adults with no signs or symptoms of TMD will be assessed. The chewing function, condylar path angles and lateral guidance angles will be recorded. Maximum comfortable and unassisted jaw opening, hemispheric dominance and hemimandibular retrognathia will be considered as secondary pre-specified outcomes. Three-Four years later, both TMJs of each participant presenting signs and/or symptoms will be evaluated according to DC/TMD. Same recordings as baseline will be carried out.
214326036|NCT06569069|OTHER|US guided PE|"The multifidus muscle near the posterior dorsal root (at L4-L5 or L5-S1) was targeted using a transverse ultrasound view, inserting the needle at an 80º short axis or a 45º long axis, based on vessel presence. For the tibial nerve in the popliteal region, the needle was inserted at an 80º angle after a transverse cut of the nerve.~Physio invasiva® needles (0.30 x 40-60 mm) were used in the lumbar region, and 0.30 x 30 mm needles in the popliteal region. Both areas received galvanic current (1.5 mA for three seconds and three impacts). Treatment included three US-guided PE sessions over a 1:7:14 schedule, though two participants skipped the third due to pain resolution."
214326037|NCT06569069|OTHER|Sham Acupuncture|"Participants in the control group were also treated in a prone position. Sham acupuncture treatment was applied at the superficial level of the posterior face of the thigh on the affected side, using five Agupunt® needles of 0.16 x 25 mm, inserted superficially in the lateral aspect of the lumbar area (L3-L4), lateral gluteal region, greater trochanter, lateral part of the distal third of the thigh, head of the fibula and lateral aspect of the leg in its middle third. The needles were left superficially subcutaneously for 15 minutes, performing this approach in three different sessions, again following a periodicity of 1:7:14 days."
214326038|NCT02886052|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|
214326039|NCT02886052|OTHER|Active control|
214326040|NCT04126291|BEHAVIORAL|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
214927258|NCT00415116|DRUG|docetaxel|
214927259|NCT00415116|DRUG|lenalidomide|
214927260|NCT03966924|DEVICE|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
214927261|NCT02807012|OTHER|Nursing educational intervention|"The nursing educational intervention by home visits will consist in three home visits by nurses until 14, 21 and 30 days after discharge to the intervention group. The nurses will give verbal information to family caregiver related to the care of elderly with stroke based on protocol with orientation related: information about stroke; emotional support; how to access health services; nutrition; airway; hygiene; positioning and transferring; prevent falls; dress/undress; medications; physiological eliminations; skin care. Furthermore, nurses will give some printed materials that contain orientations related to the care.~The control group could have ou not the usual care guidelines provide by health services that have access."
214927262|NCT00869284|DRUG|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
214927263|NCT00869284|PROCEDURE|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|"The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.~The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8."
215069366|NCT06176430|DRUG|Ferrous Sulfate Oral Product|ferrous sulphate oral in the form of syrup
215069367|NCT01027494|DRUG|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
215069368|NCT02143453|OTHER|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
215069369|NCT02143453|OTHER|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
215069370|NCT00828802|DRUG|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
215069371|NCT01802580|BEHAVIORAL|Internet Survey|
215069372|NCT01802580|DRUG|fluocinonide 0.05% ointment|
215069373|NCT05420311|OTHER|MedDiet Arm|A balanced hypocaloric diet in macronutrients (MedDiet)
215069374|NCT05420311|OTHER|KetoDiet Arm|A very low carbohydrate diet (KetoDiet).
215069375|NCT05420311|OTHER|IF Arm|An intermittent fasting (IF) approach
215069376|NCT04018820|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
215069377|NCT04164095|PROCEDURE|lappg|Preservation of pylorus and vagus nerve by laparoscopy
214326041|NCT03612622|OTHER|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
214326042|NCT04685304|GENETIC|Pharmacogenetic Testing|Genetic results will be reported for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4, CYP3A5, SLCO1B1, TPMT, and VKORC1.
214326043|NCT04685304|OTHER|Pharmacist Consultation Note|Recommendations will be based on phenotypes translated from genetic data in accordance with CPIC guidelines. Drug interactions will be incorporated into phenotype assignments when appropriate.
214326044|NCT04685304|OTHER|Delayed pharmacogenetic testing|Pharmacogenetic testing and a pharmacist consultation note will be provided to participants provided to the standard care arm once 3 months have passed since their baseline visit.
214927264|NCT04887090|DEVICE|Acupuncture and Drug Compound Technology|Before operation: The points of the meridian: Hegu, Neiguan, Chize, Zusanli, both sides are taken. TEAS (transcutaneous electrical acupoints stimulation) was performed every day for three days before the operation, using the Han's acupoint nerve stimulator to adjust the density and density waveforms at a frequency of 2/100 Hz (Hz). Current intensity is 10mA, and all acupuncture points are continuously stimulated for 30 minutes. During the operation: take the acupoints Hegu, Neiguan, Houxi, and Zhigou on both sides and give TEAS 30 minutes before induction of anesthesia. The stimulation intensity and frequency are the same as those before the operation until the end of the operation. Postoperative: Take the acupoints Chize, Waiguan, Taichong, and Yanglingquan, and take both sides. TEAS will be performed every 12 hours from the first day after surgery. Each treatment is 30 minutes until 48 hours after surgery. The intensity and frequency are the same as before surgery.
214927265|NCT04887090|OTHER|Routine perioperative management|Comprehensive evaluation of cardiopulmonary function, preparation of respiratory tract, active treatment of coexisting diseases before operation, correction of water and electrolyte disorders and hypoproteinemia before operation. To prevent cross-infection during the operation, the intraoperative blood volume should be supplemented within the tolerance of cardiac function, the tissue perfusion should be sufficient, and the infusion should be uniform. Strengthen respiratory care after operation, prevent cardiovascular complications, pay attention to the speed and amount of blood transfusion, encourage early activities, promote lung expansion and prevent thrombophlebitis.
214326045|NCT06969196|OTHER|Written Communicatoin|ICU clinicians will be asked to edit AI-generated written summaries for content and clarity before they are delivered to families
214326046|NCT01716728|OTHER|enzyme analysis|
214326047|NCT00945022|DEVICE|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
214326048|NCT03351764|DEVICE|Sham TMS|Subjects receive sham TMS via coil designed to produce the clicking sound of active TMS without delivering the magnetic field to the brain.
215069378|NCT00121758|BIOLOGICAL|LIPO-5|
215069379|NCT02279433|DRUG|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
215069380|NCT00211757|DRUG|Divalproex sodium|Study drug.
215069381|NCT00211757|DRUG|Placebo|Placebo comparator.
215069382|NCT06657794|DEVICE|Implantation of Physician-Modified Terumo Aortic TREO abdominal stent graft system|A Physician Modified Endograft is a commercially available, off-the-shelf endograft that has been altered at the time of the procedure by creating fenestrations in the seal zone of the graft to preserve blood flow into vital branch vessels. These fenestrations are marked with medical grade gold markers to facilitate fluoroscopic visualization during the procedure. In order to prevent branch vessel occlusion, these branch vessels are typically stented with covered balloon expandable stents using standardized techniques.
215069383|NCT07019389|OTHER|Turkish Version of the Scale of Food Allergy Anxiety (SOFAA)|Participants will complete the Turkish-translated versions of the Scale of Food Allergy Anxiety (SOFAA). Children will complete the SOFAA-C; their parents will complete the SOFAA-P. The study aims to evaluate the reliability and validity of the translated scales through internal consistency, factor analysis, and test-retest reliability methods.
214326049|NCT03351764|DEVICE|TMS|non-invasive transcranial magnetic stimulation is used to temporarily modulation ongoing cortical activity
214326050|NCT03791658|OTHER|The 12-question TAI|The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).
214326051|NCT03791658|OTHER|Information from patients file|Depending on which arm or group specific information will be gathered from the patients file after informed consent.
214326052|NCT03791658|OTHER|The Asthma Control Test (ACT)|An international validated questionnaire on the symptoms an asthmatic experiences and the disease control in the patient. Only for the Asthmatics arm of the study
214326053|NCT03791658|OTHER|The COPD Assessment Test (CAT)|An international validated questionnaire on the symptoms a COPD-patient experiences and the disease control in the patient. Only for the COPD arm of the study
214347568|NCT06219759|OTHER|Observational study|Observational study.
214347569|NCT02590354|OTHER|ART interruption|
214347570|NCT00885404|DRUG|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
214347571|NCT06496529|BEHAVIORAL|DoF intervention|Training of specific uniarticular and single plane movement of the upper limb through an exoskeleton and videogames that will be supervised by a physiotherapist.
214347572|NCT06496529|BEHAVIORAL|Task intervention|Training of multiarticular upper limb movements (vertical, horizontal and diagonal) through videogames and also training of functional task (raise and lower your hand on the table, cleaning a table, put cream on the non-paretic arm, hold a bottle, put a piece of bread or something similar in your mouth, wash your face, brush your hair, store items in a basket, brush teeth, wrote and serve water in glass). This activities will be supervised by a physiotherapist.
214347573|NCT00760929|DRUG|Placebo|iv 9mg/kg weekly
214347574|NCT00760929|DRUG|Placebo|iv 16mg/kg every 3 weeks
214347575|NCT00760929|DRUG|RG1507|iv 9mg/kg weekly
214347576|NCT00760929|DRUG|RG1507|iv 16mg/kg every 3 weeks
214347577|NCT00760929|DRUG|erlotinib [Tarceva]|150mg oral daily
214347578|NCT04957966|BEHAVIORAL|self-selected relaxing music|20 minutes music listening
214347579|NCT02099838|DRUG|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
214326054|NCT04725461|DEVICE|Low cost lower limb prosthetic socket|"A pre-made 3D printed cylinder used as an outer shell is selected for each subject based on their measurements. The space between the residual limb and the outer shell will be filled with an expanding polyurethane foam (Foam IT 8, Smooth On Inc.) that conforms to the residual limb and bonds with the outer shell to form a strong and lightweight socket. The foam forms a smooth surface against the protective sheath; the socket is fully formed once the foam has hardened to the 3D printed cylinder.~A prefabricated supracondylar suspension cuff made of Dacron or nylon, or a commercially available suspension sleeve may be will be applied to the prosthetic socket to aid in suspension. Commercially available components, including the International Committee of the Red Cross (ICRC) transtibial polypropylene component system will be attached to the bottom of the socket to allow the patient to ambulate in the prosthesis."
214326055|NCT04209361|OTHER|Questionnaire|Data will be obtained through a printed questionnaire for assessment of knowledge, attitude and practice of dentists at military hospitals regarding child abuse and neglect. The collected data will be saved and tabulated on a computer and finally will be statistically analyzed.
214927266|NCT02180984|DEVICE|TMS|Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
214927267|NCT06440330|DEVICE|continuous glucose monitoring|continuous glucose monitoring will be used during the first 14 days post-transplantation
214927268|NCT01070095|OTHER|Electronic Asthma Action Plan System|The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
214927269|NCT02153671|BIOLOGICAL|A(H5N1) inactivated influenza vaccine (IIV)|Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.
214927270|NCT02153671|BIOLOGICAL|A(H5N2) live attenuated influenza vaccine (LAIV)|Two doses of A(H5N2) live attenuated influenza vaccine (LAIV) administered 28 days apart, approximately 1.5 years prior to receiving A(H5N1) IIV
214927271|NCT01740271|DRUG|Epirubicin|
214927272|NCT02428049|RADIATION|Stereotactic or conventional radiotherapy and chemotherapy in curative intent|
214927273|NCT05481528|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
214927274|NCT05481528|DRUG|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant
214927275|NCT05481528|DRUG|Placebo|Single oral dose of placebo
214927276|NCT06667193|OTHER|Cold Water Immersion (CWI) - Cold Tub Immersion (CI)|Once thermoneutral procedures are complete, participants in the CI group will be seated in the cold tub and submerged into the water (10º C). The sternal notch of each participant will be used as the anatomical marker to mark submersion point. Participants will sit with both arms outstretched underwater with their backs not touching the sides of the tub. Participants with a shorter stature will be provided an underwater cushion to meet the submersion requirements. The 4-minute timer will begin once confirmation of the participants submersion level and posture is determined. Once completed, the participant will be instructed to slowly exit the tub and allowed to dry and change as necessary.
214927277|NCT06667193|OTHER|Cold Water Immersion (CWI) - Cold Shower (CS)|Once thermoneutral procedures are complete, participants in the CS group will be instructed to enter the research shower area in Gunter 1610. Within the shower area, the walls of the shower will be numbered from 1 to 4, with 1 defined as facing the faucet, 2 defined as 90° to the right of side 1, 3 defined as 180° from the faucet, and 4 defined as 270° to the right or 90° C to the left from side 1. Participants will be instructed to turn 90° to the right cycling through sides 1 to 4 and then back to 1 every 15 seconds prompted by the researcher. This will allow the participant to complete three full rotations in the shower during the 4-minute intervention time. The shower faucet is modified and oriented in a way where it only produces cold water (10º C) when turned on. Once completed, the participant will be instructed to slowly exit the shower and is allowed to dry and change as necessary.
214326056|NCT05896839|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214326057|NCT05896839|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214326058|NCT05896839|PROCEDURE|Computed Tomography|Undergo CT scan
214326059|NCT05896839|BIOLOGICAL|Ipilimumab|Given IV
214927278|NCT02796352|DRUG|High dose bolus interleukin-2 (HD IL2)|"Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).~The planned treatment consists of 3 courses (6 cycles) of HD IL-2."
214927279|NCT00489775|DRUG|Duloxetine|
214326060|NCT05896839|PROCEDURE|Kidney Biopsy|Undergo kidney biopsy
214326061|NCT05896839|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214927280|NCT00489775|DRUG|Paroxetine|
215069385|NCT07020923|DRUG|Atacicept|Drug: Atacicept
215069386|NCT07024953|OTHER|Chronic Kidney Disease Structured Agenda-Setting Tool|Chronic Kidney Disease (CKD) Topics is a novel clinical visit agenda-setting intervention developed through participatory research methods for people with CKD living in rural areas. CKD Topics includes structured discussion topic areas.
215069387|NCT07023328|BEHAVIORAL|A structured ball exercise program|Pre-frail older adults will undergo a structured ball exercise program
215069388|NCT04066504|DRUG|sonidegib|Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
215069389|NCT07027059|BEHAVIORAL|median nerve mobilization|An exercise to increase median nerve mobility by flexing and extending fingers, wrist, elbow, shoulder, and neck
215069390|NCT07027059|BEHAVIORAL|routine exercises for lateral epicondylisits|eccentric strengthening exercises
214326062|NCT05896839|BIOLOGICAL|Nivolumab|Given IV
214326063|NCT05896839|DRUG|Prednisone|Given PO
214326064|NCT05896839|DRUG|Sirolimus|Given PO
214927281|NCT03992170|DRUG|Daratumumab|Daratumumab is a human monoclonal antibody (mAb) IgG1 that binds to the highly expressed CD38 protein on the surface of multiple myeloma cells and, at various levels, also in other types of cells and tissues. The CD38 protein has multiple functions, such as receptor-mediated adhesion, signal transduction activity and enzymatic activity.
214927282|NCT05887570|BEHAVIORAL|Educational intervention|intervention through extra education, modules, instruction on models
214927283|NCT05887570|OTHER|Control - Regular Instruction|participants receive usual training
214927284|NCT04481230|DRUG|99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)
214927285|NCT04481230|DRUG|99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)
214927286|NCT04481230|DRUG|99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
214927287|NCT02070731|DEVICE|TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
214927288|NCT06347055|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Continuous theta burst rTMS
214927289|NCT01828541|BEHAVIORAL|Hypnosis|Patients in this group will receive standard care plus 4 sessions of hypnosis.
214927290|NCT01828541|OTHER|Standard of Care|
214927291|NCT06649136|DRUG|Methotrexate|comparison between oral and subcutaneous methotrexate dosis of 25mg
214927292|NCT04062032|DRUG|Aspirin 81 mg|ASA 81mg taken daily
215069391|NCT04691622|BIOLOGICAL|Norovirus -specific T-cell (NST) therapy|"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."
215069392|NCT07029022|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|This intervention consisted of three 90-minute in-person workshops delivered monthly over a three-month period. Content included psychoeducation, guided stretching, and focused-attention meditation. Participants were also encouraged to practice mindfulness at home for 10 minutes daily and to follow lifestyle guidance on diet and physical activity.
214326065|NCT00458484|RADIATION|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions."
214326066|NCT00458484|PROCEDURE|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
214326067|NCT00458484|PROCEDURE|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
214326068|NCT05091424|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab
214927293|NCT04062032|DRUG|Aspirin 325mg|ASA 325mg taken daily
214927294|NCT04826887|OTHER|SOLTIVE Thulium Laser|Use of SOLTIVE Thulium laser for HoLEP
214927295|NCT04826887|OTHER|Standard of Care (Holmium Laser)|Use of Holmium laser for HoLEP
214927296|NCT02429388|DRUG|Spironolactone|Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
214326069|NCT05091424|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.
214927297|NCT05603195|DRUG|REGN7508 (IV)|Administered sequential, ascending single intravenous (IV) dose
214927298|NCT05603195|DRUG|REGN7508 (SC)|Administered sequential, ascending single subcutaneous (SC) dose
214927299|NCT05603195|DRUG|Matching Placebo (IV)|Administered sequential, ascending single intravenous (IV) dose
214927300|NCT05603195|DRUG|Matching Placebo (SC)|Administered sequential, ascending single subcutaneous (SC) dose
214326070|NCT05091424|DRUG|Venetoclax|Participants will receive daily oral venetoclax
214326071|NCT06534333|OTHER|Ultrasonography|musculoskeletal ultrasonography
214326072|NCT05083481|DRUG|ASP1570|Oral tablet
214326073|NCT05083481|DRUG|pembrolizumab|Intravenous Infusion
214326074|NCT05083481|DRUG|Trifluridine + Tipiracil|Oral Administration
214326075|NCT05083481|DRUG|Bevacizumab|Intravenous Infusion
214326076|NCT05083481|DRUG|Docetaxel|Intravenous Infusion
214326077|NCT04538664|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
214927301|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single intravenous (IV) dose (lowest dose)
214927302|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (next highest dose)
214927303|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (next highest dose)
214927304|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (next highest dose)
214927305|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (highest dose)
215069393|NCT07028346|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is a first-line, non-medication treatment for insomnia that helps individuals identify and change the thoughts and behaviors that contribute to their sleep problems.
214326078|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.
214326079|NCT04538664|DRUG|Carboplatin|Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
214326080|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
214326081|NCT04971850|OTHER|Sleep study|"Procedures added by research during PSG :~* SDB screening questionnaires~* Electromyography (EMG) of accessory and abdominal muscles~* Cerebral oxygenation~* Mandibular movements~* Sleep headband (pre-teens and teens) or other connected device~* Automatic PSG analyzes~* Psychological and neuropsychological assessment The recordings of the study will be repeated at one year if the patient needs a treatment (surgery or noninvasive ventilation) following the results of the PSG."
214326082|NCT05339087|DRUG|Riociguat Oral Tablet|Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study
214326083|NCT05339087|OTHER|Placebo|Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
214326084|NCT04802174|DRUG|Lurbinectedin|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
214326085|NCT04802174|DRUG|Berzosertib|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
214927306|NCT01322594|OTHER|Placebo|Placebo single IV dose
214927307|NCT03831412|BEHAVIORAL|CBT-I|Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
214927308|NCT03831412|BEHAVIORAL|ERRT|Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
214927309|NCT04070690|PROCEDURE|Concentration of dialysate bicarbonate|Adjust the dialysate bicarbonate concentration
214927310|NCT04184362|DEVICE|Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
214927311|NCT06622772|DEVICE|Valsalva assist device|A valsalva assist device designed to provide the recommended resistance to exhalation at a pressure of 40 mmHg.
214927312|NCT06622772|OTHER|standard Valsalva manoeuvre|The Valsalva manoeuvre is carried out without any device.
214326086|NCT03334006|DRUG|Pentaglobin®/Standard of Care|Standard-of-Care treatment + Pentaglobin®
214347580|NCT02099838|DRUG|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
214347581|NCT02301143|DRUG|nab-Paclitaxel|
214927313|NCT04676958|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2
214347582|NCT02301143|DRUG|Gemcitabine|
214347583|NCT02301143|DRUG|Chemoradiation|
214927314|NCT04676958|DIETARY_SUPPLEMENT|Micro-crystalline cellulose|Micro-crystalline cellulose
214927315|NCT05838339|BEHAVIORAL|Healthy Sleep Intervention|The existing intervention consists of the following components: Posters, Instagram, kick-off event, flyer for parents, parents-teacher conference, class discussions, app, classes on sleep (and relaxation), blue lights installations, alarm clocks and t-shirts, T-days without phone in the bedroom (Tuesdays and Thursdays), class competition.
214927316|NCT05796284|BEHAVIORAL|Breast pressure relief intervention at the end of pregnancy|When teaching pregnant women, the researchers will use tablet computers and models to explain the operation of breast combing and acupressure one-on-one, and use the model to demonstrate. Emphasis on breast grooming during pregnancy, twice a day, once in the morning and evening, 5 minutes on one breast each time, 10 minutes on both sides; strengthen breast grooming and acupressure after delivery. The first breast combing, 5 minutes on one breast each time, and 10 minutes on both sides 4 to 6 times a day. After combing, according to expert advice, massage the 6 acupoints around the breast for 5-10 seconds, and then use hand expressing or breastfeeding to discharge the milk .
214927317|NCT05796284|OTHER|Routine care|Cases in the routine care group received routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery.
214927318|NCT06620718|PROCEDURE|coronectomy|The inferior alveolar nerve and buccal nerve were blocked with maxicaine anaesthetic solution (articaine hydrochloride 40 mg, epinephrine hydrochloride 0.006 mg). Incisions were applied uniformly across all patients, and a triangular flap technique was employed. After elevating the flap and exposing the bone, the bone overlying the crown of the tooth was removed using a bone round bur to fully visualize the tooth\&#39;s crown. Once the crown was fully exposed, the crown preparation was initiated at the enamel-dentin junction using a fissure bur. The crown preparation was completed without leaving any sharp edges, and the crown was extracted. Then, the exposed pulp was washed with sterile serum without any further intervention. The surgical area was sutured using 5/0 silk. Analgesic (25 mg of dexketoprofen trometamol twice a day) and antibiotic (125 mg clavulanic acid, 875 mg amoxicilin twice a day) drugs were described.
214927319|NCT03761758|DEVICE|Spectacle lenses|Spectacle lenses with clear central apertures
214927320|NCT06648018|BEHAVIORAL|Nutritional information|Written nutritional information about food with high content of iron.
214927321|NCT06648018|DIETARY_SUPPLEMENT|Iron-succinate|100 mg of Iron-succinate per day.
215069394|NCT07028346|BEHAVIORAL|Sleep Education|Sleep Education group comprises psychoeducation sessions on sleep hygiene.
215069395|NCT05534594|DRUG|18F-PSMA-1007|As explained under 'Arms'.
215069396|NCT07034482|DRUG|Intralesional Triamcinolone 5 mg/ml|Solution containing 5 mg TAC was injected intralesionally, every week for 6 weeks or until the scar flattened, whichever occurred earlier. Not more than 2 ml of the solution was injected per session, using 27G needle pre-mounted on an insulin syringe.
215069397|NCT07034482|DRUG|Intralesional 5-fluorouracil|Solution containing 45 mg 5-FU was injected intralesionally, every week for 6 weeks or until the scar flattened, whichever occurred earlier. Not more than 2 ml of the solution was injected per session, using 27G needle pre-mounted on an insulin syringe.
215069398|NCT07034391|DRUG|denosumab combined anti-PD-1 inhibitor with chemotherapy|120mg of denosumab，d1 in a 28-days cycle；200mg of anti-PD-1 inhibitor, d1 in a 21-days cycle；500mg/m2 of pemetrexed, d1 in a 21-days cycle; AUC4-5 of carboplatin, d1 in a 21-days cycle, for 4-6 cycle
215069399|NCT07033260|OTHER|Non-invasive Monitoring|All participants will undergo non-invasive ultrasonographic measurement of carotid corrected flow time (FTc) and peak flow velocity variability (PFVV) before and during hemodialysis sessions. No treatment or experimental intervention will be applied.
214326087|NCT06585137|OTHER|Web-Based Mind-Body Awareness Program|The program has been developed in line with peer-reviewed literature and expert opinions. It will incorporate a nursing approach based on the Meleis transition theory, education, mind-body awareness practices, and messages specific to women's health. Participants will be involved in an awareness program consisting of 3 sessions over an average of 2 weeks. Participants will be asked to complete their first final test one day after the egg retrieval (OPU) procedure, i.e., an average of 8-12 days after ovulation induction. There will be no intervention between the embryo transfer and the pregnancy test day. During this time period, interactive sessions between the researcher and participants will be conducted, and nursing care will be provided according to Meleis. The implementation phase of the study will be completed with 39 participants after the second final test following the pregnancy test.
214927322|NCT06623513|DRUG|Parecoxib Sodium|Parecoxib Sodium 40 mg administered intravenously 30 minutes before the ERCP procedure.
214927323|NCT06623513|DRUG|Indomethacin suppository|Indomethacin suppository 100 mg administered rectally 30 minutes before the ERCP procedure.
214927324|NCT01099501|DIETARY_SUPPLEMENT|Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.|Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding
215069400|NCT07032792|DRUG|FEIBA|Subjects randomized to FEIBA will receive up to 2 vials of 500U of FEIBA through a preexisting central line at a rate that does not exceed 2 units per kg of body weight per minute for the study intervention.
215069401|NCT07032792|DRUG|FFP|Subjects randomized to FFP will receive up to 2 units of FFP intravenously through a preexisting central line.
215069402|NCT07033767|DRUG|genistein|Participants will receive genistein treatment (10-15 mg/kg/day with a maximum dose of 1500mg/day) for 3 months. From the 3-month- to 6-month follow-up, participants will receive a dose of 20-25 mg/kg/day (with a maximum dose of 1500mg/day). According to participant preference, Genistein will be provided as a capsule (250mg per capsule). For participants that are unable to swallow the capsule the capsule may be opened and the powder from the capsule can be mixed with a beverage or food. Interim clinical evaluations will occur at 3 and 6 months to assess, tolerability, adherence and efficacy.. Post-treatment assessment after a 3-month washout will occur at 9 months to determine delayed adverse effects and persistence of beneficial effects after genistein discontinuation.
215069403|NCT07034599|DEVICE|Negative pressure ventilation|All participants are ventilated with negative pressure ventilation first
215069404|NCT07034599|DEVICE|positive pressure ventilation|All participants are ventilated using positive pressure ventilation after negative pressure ventilation
215069405|NCT07033377|OTHER|Self-administered paper-based questionnaires|Participants will complete the Persian version of the CBQ-NSCLBP and other self-report measures as part of a psychometric validation study. No clinical or therapeutic intervention is involved.
215069406|NCT07034651|PROCEDURE|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
215069407|NCT07034157|PROCEDURE|Percutaneous Coronary Intervention|Coronary stenting performed as part of routine care for patients with coronary artery stenosis.
215069408|NCT07034157|PROCEDURE|Cerebrovascular Intervention (CAS ）|Patients with intervention-indicated head and neck artery stenosis will receive carotid artery stenting based on clinical evaluation.
215069409|NCT07034157|OTHER|No Intervention / Observation|Clinical observation or standard follow-up in patients without significant disease
215069410|NCT07033325|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT) for Trypanosoma cruzi infection.|Rapid diagnostic tests (RDTs) for the detection of Trypanosoma cruzi infection are performed in university facilities, outside of a clinical care setting, using a point-of-care approach. The study population includes adult male and female participants from the university community. This intervention differs from most existing strategies that target exclusively women of reproductive age and/or newborns to control vertical transmission; instead, it focuses on broader population-based screening and linkage to care for chronic infections.
215069411|NCT07032987|OTHER|Not an intervention study|This is not an intervention study
214347584|NCT02301143|DRUG|Capecitabine|
214347585|NCT02301143|PROCEDURE|Surgery|Surgical intervention
214927325|NCT01099501|DIETARY_SUPPLEMENT|oxepa|A dose determined by a patient's energy expenditure and tolerance of enteral feeding.
214927326|NCT01099501|DIETARY_SUPPLEMENT|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
214927327|NCT06317142|DRUG|Acipimox 250 mg Oral Capsule|A subset of prediabetes individuals (first 10 IFG and 10 IGT subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast,one with lunch and one with snack) and 1x 250mg in the morning of day 4.
214927328|NCT03309657|DRUG|Ceftolozane/tazobactam|This is an observational pharmacokinetic study whereby patients received a single dose of ceftolozane/tazobactam and plasma and cerebrospinal fluid samples were subsequently collected and analyzed to described the pharmacokinetics.
214927329|NCT00496275|DRUG|Zactima (ZD6474)|
214927330|NCT00496275|DRUG|Vinorelbine plus cisplatin|
214927331|NCT00496275|DRUG|Gemcitabine plus cisplatin|
214326088|NCT01952522|BEHAVIORAL|Weighted brace|People will have to wear all the day additional weights (between 2 and 4 kilograms) at the nonparetic ankle during 3 months
214326089|NCT01952522|BEHAVIORAL|Non weighted brace|People will be given a brace with no weight they will have to wear all the day during three months.
214927332|NCT03811327|BEHAVIORAL|Zero-time Exercise|A 2-hour group ZTEx training once per week for 2 consecutive weeks (totally 4 hours)
214927333|NCT00664859|DRUG|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
214326090|NCT05452447|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
214326091|NCT05452447|DEVICE|Placebo|Passive emanator with formulated inert ingredients
214326092|NCT04944017|DRUG|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
214326093|NCT04944017|OTHER|Placebo - Saline Infusion|Participants will receive 6 infusions of saline administered over 40 minutes while on continuous cardiac monitoring and oximetry
214927334|NCT01950559|OTHER|Oral food challenge|Oral food challenge to determine allergy to soy
214927335|NCT01943851|DRUG|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
214927336|NCT00900757|DRUG|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
214927337|NCT00039494|DRUG|erlotinib hydrochloride|Given orally
214927338|NCT00039494|RADIATION|3-dimensional conformal radiation therapy|
214927339|NCT00039494|DRUG|temozolomide|Given orally
215069412|NCT07033715|OTHER|Exercise|"The exercise sessions will have a frequency of 3 times a week and a duration of 60 minutes per session. Exercise intensity will be gradually increased throughout the program and will be monitored every session using Borg's Rated Perceived Exertion scale, aiming at levels of 12-13 (fairly light to somewhat hard). The program will be mainly composed of cardiorespiratory exercises and resistance exercises. It will also comprise flexibility exercises to improve joint range of motion and neuromotor exercises involving motor skills (balance, agility, coordination, gait...), proprioceptive training and multifaceted activities (tai ji, yoga...)."
215069413|NCT07034872|OTHER|Control Group|Participants in the control group will receive two face-to-face physiotherapy sessions and one asynchronous video-based exercise training session per week for eight weeks. Following the baseline assessments, a conventional exercise program will be individually planned by the physiotherapist for each child. Each 60-minute session will include strengthening exercises for upper and lower extremity muscles, active and passive stretching exercises for spastic muscles, static and dynamic balance training in standing, and gait exercises.
214326094|NCT04278144|DRUG|BDC-1001|Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
214326095|NCT04278144|DRUG|Nivolumab|Programmed death receptor-1 (PD 1)-blocking antibody
214326096|NCT04116164|DRUG|111In-DOTA-h11B6|4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
214326097|NCT01018199|OTHER|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
214927340|NCT05969366|PROCEDURE|Total hip arthroplasty|
214326098|NCT01018199|OTHER|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
214326099|NCT01763775|DEVICE|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
214326100|NCT01763775|DEVICE|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
214326101|NCT06971224|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|2000 mg NR daily.
214326102|NCT06971224|OTHER|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
214326103|NCT03549247|BEHAVIORAL|quality of life in healthy,gingivitis,periodontitis groups|a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
214326104|NCT01946399|DRUG|Ozurdex implant|Intravitreal injection of Dexamethasone implant
214326105|NCT01341886|DRUG|Metformin|in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
214326106|NCT04738916|DEVICE|Whole-body vibration training|Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
214326107|NCT03179176|OTHER|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
214326108|NCT02325011|DRUG|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
214347586|NCT04064034|OTHER|Lateral Flow Assay (LFA)|Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
214927341|NCT03320850|DRUG|OnabotulinumtoxinA and Hydrogel admixture|BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
214927342|NCT03320850|DRUG|Placebo and Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation
214326109|NCT02325011|DRUG|Sativex® and fluconazole concomitantly (Treatment B)|"Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose."
214927343|NCT00546117|DRUG|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing \>30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
214927344|NCT00546117|DRUG|placebo|Placebo Solutab in 15 and 30 mg dosages.
214326110|NCT04519619|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
214326111|NCT06193681|OTHER|Pedi@ctivity Exercise Mobile Application Exercise Program|The first group of the study received a mobile application (Pedi@ctivity) based exercise program. With the Pedi@ctivity exercise mobile application, the selected exercises and exercise program will be offered personalized to each adolescent for 12 weeks. After 12 weeks, the effectiveness of the Pedi@ctivity mobile application-based exercise program on the evaluation parameters will be investigated.
214326112|NCT06193681|OTHER|Supervised Exercise Group|In the physiotherapist-supervised personalized exercise program, the exercises selected through the Pedi@ctivity exercise mobile application will be applied to adolescents under the supervision of a physiotherapist (2 sessions face-to-face, 1 session online/synchronous).
214326113|NCT04029363|DEVICE|HighLife Transcatheter Mitral Valve Replacement|Transcatheter Mitral Valve Replacement
214326114|NCT04136912|DRUG|Definity|Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information. When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
214326115|NCT04136912|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8).~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
214326116|NCT04797273|BEHAVIORAL|Internet-based cognitive behavior therapy|12 week Internet-based cognitive behavior therapy, delivered via an online treatment platform. The treatment includes components such as exercises in conducting recuperating activities, methods to improve sleep, exposure, and behavioral activation. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
214326117|NCT04797273|BEHAVIORAL|Internet-based structured treatment-as-usual|This is a 12-week treatment, delivered via an online treatment platform. The treatment components in this treatment are designed to be similar to what is typically provided in primary care to these patients and includes information about stress and how different factors such as eating habits, physical exercise, and alcohol can contribute to stress problems. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
214326118|NCT05828589|DRUG|BGB-21447|BGB-21447 will be administered orally
214326119|NCT06331793|DEVICE|Active AlgoCare|Device that emits Pulsed Electromagnetic Fields
214326120|NCT06331793|DEVICE|Non-active AlgoCare|Device that doesn't emit Pulsed Electromagnetic Fields
214326121|NCT06972732|DRUG|Metformin|The dosage and dose frequency are maintained as they were before the screening.
214326122|NCT06972732|DRUG|Dapagliflozin/Pioglitazone|Dapagliflozin 10mg/Pioglitazone 30mg QD
214326123|NCT06972732|DRUG|Dapagliflozin/Sitagliptin|Dapagliflozin 10mg/Sitagliptin 100mg QD
214347587|NCT04518124|DRUG|Propranolol|Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
214347588|NCT03740490|COMBINATION_PRODUCT|Smart-T + NRT|Smart-Treatment App and Nicotine Replacement Therapy
214927345|NCT06642155|BEHAVIORAL|RESPONSIBLEPLAY© MTM-Based Intervention|Participants in this group will receive a theory-based intervention using the Multi-theory Model (MTM) of health behavior change. The intervention includes participatory dialogue, behavioral confidence-building, and strategies to modify the physical and social environments. It also incorporates emotional transformation and practice for change. Sessions will be delivered in-person over three weeks, focusing on promoting responsible gambling behaviors.
214927346|NCT06642155|BEHAVIORAL|Knowledge-Based Intervention|Participants in this group will receive a knowledge-based intervention that provides information on gambling risks and responsible gambling strategies. The intervention consists of lectures and reading materials delivered in-person over three weeks. It focuses on raising awareness of gambling risks but does not include the behavioral change strategies used in the MTM-based intervention.
214927347|NCT00079586|DRUG|Heparin|Unfractionated Heparin per institutional practice
214927348|NCT00079586|DRUG|Bivalirudin|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
214927349|NCT06207149|BEHAVIORAL|ASISTIR|This will be a 24 hour advocacy program focused on adult disability services.
214927350|NCT01439022|BEHAVIORAL|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
214347589|NCT03740490|COMBINATION_PRODUCT|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
214927351|NCT01439022|BEHAVIORAL|Hand Writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
214326124|NCT05819034|OTHER|Scoliosis-Specific Exercise Program|"Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour."
214927352|NCT06130891|OTHER|Cognitive sensory motor relearning|"Cognitive Exercises:~* Orientation: Checking awareness of date, time, and weather.~* Attention: Tasks like connecting dots or spotting differences.~* Shape Sorting: Sorting objects by size, color, etc.~* Calculation Training: Counting money, beads, basic arithmetic.~* Memory: Recalling objects on a tray, numbers backward, word associations.~Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
214927353|NCT06130891|OTHER|Sensory motor relearning|"Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
214927354|NCT06130891|OTHER|Motor Relearning|"Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
214927355|NCT04409535|OTHER|WHOQOL-BREF survey|Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency
214927356|NCT05588869|OTHER|observation of the adverse outcomes of Cyclosporine in steroid dependent and frequent relapsing nephrotic syndrome in children|The interventions that will be done include collection of the following data : age at disease onset, disease duration, type of steroid response, age at the start of CsA treatment, dose and duration of CsA treatment, mean values of the maintenance doses of CsA and their trough blood levels and observation of the side effects. serum creatinine at regular intervals before and after CsA treatment and renal biopsy for those who are on CsA for more than 2-3 years would be done.
214927357|NCT05039567|BEHAVIORAL|optimal heart team protocol|Heart teams in the experimental group will be established and trained based on the optimal heart team implementation protocol. The protocol included instructions on specialist selection, specialist training, team composition, team training and formal implementation precess.
214927358|NCT01968356|DRUG|3M CHG/IPA Prep Colorless|Apply topically.
214927359|NCT01968356|DRUG|3M CHG/IPA Prep Tint|Apply topically.
214927360|NCT01968356|DRUG|ChloraPrep|Apply topically.
214927361|NCT01968356|DRUG|Saline|Apply topically.
214927362|NCT03133091|DRUG|PIEB: Patient Intermittent Epidural Boluses|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
214326125|NCT05819034|OTHER|Soft orthoses with external strapping.|Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
214326126|NCT06108817|OTHER|Information material|The intervention consists of the distribution of a poster for the waiting room and flyers to be given to patients aiming to inform both patients and GPs with respect to the correct indications for treatment of dyspepsia. After signing up, practices assigned to the intervention group received a package containing 60 flyers and one waiting room poster to use during consultations. The flyer and poster provide a short description of the correct indications for treatment of dyspepsia. Additionally, both the flyers and posters contained a QR-code linking to a decision aid explaining the correct indications and causes of dyspepsia.
214927363|NCT03133091|DRUG|PCEA: Patient Controlled Epidural Analgesia|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
214927364|NCT01859052|OTHER|Low carbohydrate diet|Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.
214927365|NCT01859052|OTHER|Low calorie low fat diet|The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet
214927366|NCT01859052|OTHER|AHA diet recommendations|given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
214927367|NCT04377425|DIAGNOSTIC_TEST|COVID-19 swap test PCR|COVID-19 swap test PCR performed according to hospital standard operating procedures
214927368|NCT04240717|BEHAVIORAL|Patient Decision Aid|The Patient Decision Aid is an interactive, web-based tool that provides information on advanced melanoma and its treatment options with a strong focus on immunotherapies (i.e. response to therapy, risk of side effects).
214927369|NCT00155272|DRUG|Thalidomide|
214927370|NCT05021016|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
215069414|NCT07034872|OTHER|Intervention Group|Following baseline assessments, a personalized 60-minute exercise program will be developed by the physiotherapist for each child in the intervention group, consisting of two face-to-face sessions and one asynchronous video-based session per week for eight weeks. Each session will include 30 minutes of multidimensional trunk-focused exercises-such as static and dynamic trunk control (e.g., reaching, rotational movements), scapular and pelvic mobilizations, isolated muscle training, proprioceptive activities, and core strengthening-followed by 30 minutes of conventional therapy, including upper and lower extremity strengthening, stretching for spastic muscles, balance training in standing, and gait exercises.
214326127|NCT06108817|OTHER|No Intervention|These practices do not receive information material
214326128|NCT02448875|DEVICE|CyPass Micro-Stent|Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
214326129|NCT02448875|DEVICE|Viscoelastic|Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
214326130|NCT06533189|DEVICE|Enhanced Diffusion Software|Application of specific sequences with the use of Enhanced Diffusion Software during Patient MRI
214326131|NCT01313429|DRUG|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
214326132|NCT01313429|BIOLOGICAL|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
214326133|NCT01313429|DRUG|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
214927371|NCT04400864|OTHER|Dietary intervention|dietary counseling based on the principals pf the dietary intervention group.
214927372|NCT02234830|DEVICE|Exoseal closure device|Closure device for femoral artery access closure
214927373|NCT02234830|DEVICE|Angioseal closure device|Closure device for femoral artery access closure
214326134|NCT05093426|OTHER|Stage 2 Digital sleep diary app|Participants in Stage 2 will be asked to download a digital sleep diary app and complete a sleep log every day for 21 days.
214927374|NCT00093418|DRUG|tipifarnib|Given orally
214927375|NCT05906212|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification and autotransplantation of anterior lens capsule|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification with autotransplantation of anterior lens capsule.
214927376|NCT05906212|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification alone.
214326135|NCT04936958|OTHER|patients having had an osteomyelitis since 2017|description of osteomyelitis and their management
214927377|NCT00657033|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
214927378|NCT00657033|DRUG|Placebo|Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
214927379|NCT06084949|DEVICE|Nordic walking or inspiratory muscle training|Nordic walking is a form of low-impact aerobic exercise that incorporates the use of walking poles. And inspiratory muscle training is a type of exercise that provides resistance during the inhalation phase.
214927380|NCT05329363|DIAGNOSTIC_TEST|PEPITS Programme|"The programme has three main phases:~Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and stepping stone phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery."
214927381|NCT05329363|OTHER|Usual care|Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.
214927382|NCT04685772|DRUG|Methylprednisolone|"The Methylprednisolone dose pack (Medrol Dose Pack) is pre-packaged with dosing instructions. This dose pack is tapered over 7 days and administration will be the following for all patients:~Day 1 (total 24 milligrams (mg)) - 8mg before breakfast, 4mg after lunch and dinner, and 8mg at bedtime Day 2 (total 20mg) - 4mg before breakfast, after lunch and dinner, and 8mg at bedtime Day 3 (total 16mg) - 4mg before breakfast, lunch, dinner, and at bedtime Day 4 (total 12mg) - 4mg before breakfast, after lunch, and at bedtime Day 5 (total 8mg) - 4mg before breakfast and at bedtime Day 6 (total 4mg) - 4mg before breakfast Day 7 (total 0mg) - Completed"
214927383|NCT04030390|BEHAVIORAL|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
214927384|NCT04030390|BEHAVIORAL|Control|time-matched task (sitting on the bike without pedalling)
214927385|NCT05109884|DIAGNOSTIC_TEST|PSMA PET Scan|\[68Ga\]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan
214927386|NCT05109884|DIAGNOSTIC_TEST|FDHT PET Scan|\[18F\]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan
214927387|NCT01808079|OTHER|Laboratory Biomarker Analysis|Correlative studies
214927388|NCT05616507|DIETARY_SUPPLEMENT|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
214927389|NCT01372488|PROCEDURE|Suture self removal|Suture self removal
214927390|NCT01372488|PROCEDURE|Suture removal by family doctor or clinic|As above
214326136|NCT04949438|DRUG|AZD4831|Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
214326137|NCT02256046|DEVICE|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
214927391|NCT03380078|BEHAVIORAL|Teams Leadership Institute (TLI)|TLI is training for leaders in how to improve implementation of evidence-based interventions in community settings. TLI includes 5 key components : 1. Assessment: The Implementation Leadership Scale (ILS) and Implementation Climate Scale (ICS) will be completed by first-level leaders participating in the intervention, his/her subordinates (i.e. providers) and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training in implementation leadership Leaders will develop a plan for using specific implementation support strategies. 3. Coaching: Weekly, brief (15-30 min) coaching calls keep leaders on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up : At month 4, leaders attend a 2-hour booster session . 5. Graduation: TLI programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
214326138|NCT03889119|RADIATION|Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.|SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer.
214326139|NCT04753840|OTHER|Antihypertensive drugs|One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic
214927392|NCT03380078|BEHAVIORAL|Motivational Enhancement (TIPS for Training)|The TIPS module applies MI principles and strategies to address attitudinal barriers and improve engagement in training. I AIM HI and CPRT trainers (in the TIPS Conditions ) will incorporate MI during training and ongoing consultation/coaching with providers to increase provider engagement and problem solving throughout training: 1. Providers will receive a call designed to provide information about training and the intervention. 2. During the workshop, trainers will assess concerns about participating and will use reflective problem solving to address barriers . Trainers will work with the provider to develop a plan through the use of Planning Worksheets . 3. During each consultation , planning worksheets will be updated collaboratively with the provider. 4. Providers will receive a weekly motivational text to encourage on-going participation.
215069415|NCT07034625|OTHER|Low Level Laser Therapy|940 nm wavelength diode laser was applied to the wound area on the surgery day, 3rd, 5th and 7th days postoperatively. The power of the laser was set to 3W, power density 1.07 W/cm2, probe spot size 2.8 cm2, application mode continuous wave, application distance 1mm and application type stable.
215069416|NCT07034625|OTHER|Gengigel Spray|Patients were given a high molecular weight hyaluronic acid spray and instructions for use were explained. Accordingly, the patients applied the spray to the wound area twice a day for the first 7 days.
215069417|NCT07035132|DIETARY_SUPPLEMENT|Oral supplementation with nutritional oligomeric formula|Patients will be supplemented with the specific oligomeric formula (1 or 2 bottles/day, as per investigator's decision) during, at least, the 12 weeks of the study follow-up.
214326140|NCT04753840|OTHER|remote ischemic preconditioning（RIPC）|40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.
214326141|NCT04753840|BEHAVIORAL|lifestyle intervention|Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
214326142|NCT06466850|BIOLOGICAL|Exosome|intra-articular injection is suggested for two times: day 1and day 90
214326143|NCT04436640|DRUG|Bimekizumab|Subjects will receive bimekizumab at prespecified time-points.
214326144|NCT05091619|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|Intramuscular injection
214326145|NCT05091619|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed|Intramuscular injection
214326146|NCT05091619|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|Intramuscular injection
214326147|NCT04791748|DIAGNOSTIC_TEST|Vestibular tests|Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
214326148|NCT04791748|OTHER|Virtual reality|Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
214326149|NCT04832477|BEHAVIORAL|Stigma counseling for PrEP use|This counseling consists of a single-session (45 minute) delivered by trained peer counselors. The primary aims and relevant content areas for counseling are: (1) Assessing and discussing factors known to be drivers of emotional barriers to accessing health care. This counseling aim has two main sub-components: (a) participants will be asked about their prior experiences with accessing health care and their concerns regarding future access, and (b) the counseling will focus on creating personal agency around needing to prioritize one's health. (2) Evaluating concerns around discussing PrEP with health care providers. The counseling combines motivational interviewing with medical decisional balance, which focuses on points to consider when evaluating PrEP. (3) Promoting resiliency beliefs and positive adaptation. For this objective the counselor works with the participant to establish PrEP use goals and problem-solving strategies.
214927393|NCT03380078|BEHAVIORAL|Classroom Pivotal Response Teaching (CPRT)|CPRT is a naturalistic behavioral intervention adapted from pivotal response training (PRT) for use during classroom activities to target social, communication, behavior, and learning skills. CPRT is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. CPRT has an established training plan and the training curriculum that follows the manual. Training and coaching including standard EBI training is conducted by MA or postdoctoral level researchers with extensive training and experience with CPRT.
214927394|NCT03380078|BEHAVIORAL|An Individualized Mental Health Intervention for ASD (AIM HI)|A package of well-established, evidence-based behavioral strategies designed to reduce challenging behaviors in children served in MH service settings. AIM HI is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. AIM HI is a package of evidence-based parent-mediated and child focused strategies, designed to reduce behavior problems in children with ASD ages 5 to 13 served in MH programs. AIM HI has an established training plan and the training curriculum follows the manual. Training and coaching is conducted by MA or postdoctoral level researchers with extensive training and experience with AIM HI.
214927395|NCT03380078|BEHAVIORAL|Team-Enhanced Teams Leadership Institute (TLI)|TLI-2 enhances TLI training by (a) including additional team members important to EBI implementation (e.g., supervisors, support staff) and (b) including the team in the development of an implementation plan using a team charter process. TLI-2 includes 5 components : 1. Assessment: The Implementation Climate Scale (ICS) will be completed by team members, providers, and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training for the implementation team in implementation climate and development of an implementation plan. 3. Coaching: Bi-monthly, brief (15-30 min) coaching calls keep the team on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up: At month 4, team members attend a 2-hour booster session . 5. Graduation: TLI-2 programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
214486152|NCT03142009|OTHER|Intergenerational culturally adapted curriculum|"Each session starts with a collective dinner with families eating together. Then practice their Indian and clan names. The sessions are led by facilitators in their own language or bilingually. The facilitators then divide the families into children and adult groups to address the theme of the session, and they then return together at the end of the session to share their learnings. The sessions always end with the children and adults writing in their journals which are individual pages that they then put in their curriculum binders. Families are then given their home practice, which is a task that the families do together during the intervening week. The facilitators collect the curriculum binders after each session to bring back to the families the next week."
215069418|NCT07032805|PROCEDURE|personalized outpatient rehabilitation treatment after TKA|personalized outpatients rehabilitation treatment after TKA, including posturographic assessment, psychomotivational framing, and telemedicine-based rehabilitation interventions
215069419|NCT07032805|PROCEDURE|standard outpatient rehabilitation treatment after TKA|standard outpatient rehabilitation treatment after TKA
214326151|NCT03390504|DRUG|Erdafitinib|Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
214326152|NCT03390504|DRUG|Vinflunine|Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.
214326153|NCT03390504|DRUG|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.
214326154|NCT03390504|DRUG|Pembrolizumab|Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
214326155|NCT03390504|DEVICE|Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)|FGFRi CTA will be used to determine molecular eligibility.
214326156|NCT03301220|DRUG|Daratumumab SC: daratumumab + rHuPH20|Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 \[2000 U/mL\]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
214326157|NCT03652064|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.
214326158|NCT03652064|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.
214326159|NCT03652064|DRUG|Lenalidomide|Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.
214927396|NCT03631615|DRUG|Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)|"Patients will be given the perioperative treatment as below once recruited:~1. induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~2. within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~3. consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery."
214927397|NCT04884360|DRUG|Olaparib|Olaparib tablets 300 mg oral twice daily
214927398|NCT04884360|OTHER|Matching placebo|Matching placebo tablets taken orally at a dose of 300 mg twice daily
214927399|NCT04561557|BIOLOGICAL|CT103A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CAR+ T cells/kg will be infused on day 0.
214326160|NCT03652064|DRUG|Dexamethasone|Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
214326161|NCT06368492|DRUG|Psilocybin|Each participant will receive 2 different doses of psilocybin (5mg and 10mg) and a matching placebo on three separate occasions.
214326162|NCT06368492|BEHAVIORAL|Hypnosis script|All participants will receive a brief hypnotic induction aimed at producing analgesia before the second administration of CPT
214326163|NCT04816734|OTHER|Self-report questionnaires|"Evaluation system of initial therapeutic education program about pediatric home parenteral nutrition.~The assessment takes place after the parents have participated in the therapeutic education program and before their child returns home."
214326164|NCT03508219|DEVICE|BiOSS LIM C|"The BiOSS LIM C (Bifurcation Optimization Stent System, Balton, Warsaw, Poland). The BiOSS LIM C is a dedicated bifurcation stent covered with a mixture of a biodegradable polymer and the antiproliferative substance sirolimus. BiOSS LIM C will be used for treatment of the Left-Main bifurcation, according to its instructions for use.~The Alex-Plus cobaltchromium sirolimus eluting stent (Balton, Warsaw, Poland) will be used for treatment of distal left-main side branches according to its instructions for use (i.e. proximal segments of the left anterior descending and left circumflex arteries as well as the ramus intermedius if the latter vessel is part of a trifurcation).~All other lesions (other than left-main bifurcations) will be treated with XIENCE family everolimus-eluting coronary stent systems."
214326165|NCT03878199|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
214326166|NCT03878199|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214927400|NCT04561557|DRUG|Cyclophosphamide and fludarabine|"Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 300 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide."
214927401|NCT03871946|DIAGNOSTIC_TEST|oral glucose tolerance test (OGTT)|Implementation of OGTT: The patient was seated in a quiet room after 10-12 h of overnight fasting, and blood samples were drawn. Thereafter, 75 g glucose solution dissolved in 300 mL of water was administeredwithin 5 min. Two hours after this,another blood sample was drawn. During the test, the patient wasn't allowed to rest and eat, but not smoke.
214927402|NCT00879346|DRUG|AZD8931|160mg oral single dose (4 x 40mg tablets)
214927403|NCT00697125|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
214927404|NCT00697125|BIOLOGICAL|HBV-MPL vaccine (208129)|
214326167|NCT03878199|DRUG|Ruxolitinib|Given PO
214347590|NCT04654689|DIETARY_SUPPLEMENT|Liposomed polyphenols resveratrol and curcumin|Combination of resveratrol (75mg) and curcumin (200mg) liposomed
214347591|NCT04654689|OTHER|Placebo for liposomed resveratrol and curcumin|Water with sucrose replacing the liposomed polyphenols
214347592|NCT04654689|DIETARY_SUPPLEMENT|Isocaloric Diet|40% carbohydrates, 40% lipids and 20% proteins
214347593|NCT04654689|DRUG|G04CB02|G04CB02, in a single daily dose for 4 months
214326168|NCT05711927|DEVICE|SNOO Smart Sleeper|"Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The preemie mode will be enabled, which caps motion at level 2 out of 5."
214326169|NCT05711927|DEVICE|Traditional bassinet|Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.
214326170|NCT06974877|DRUG|124I AT-01|124I-AT-01 is an amyloid-reactive synthetic 45-L amino acid polypeptide radiolabeled with iodine-124, with a theoretical molecular weight of 4763.6 Da (based on amino acid sequence). The polypeptide, AT-01, is not pharmacologically active. 124I-AT-01 binds many forms of human and murine amyloid and is intended to be a PET imaging agent for the detection of amyloid deposits.
214326171|NCT06635876|BEHAVIORAL|Coaching Sessions|"The coach will use motivational interviewing techniques to:~1. To assist and guide the caregiver to establish a standby caregiver relationship~2. To assist and guide the caregiver as to how to use the EPT"
214673064|NCT05420012|DRUG|Placebo|A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
214673065|NCT05542342|DRUG|Tislelizumab|200 mg IV once every 3 weeks
214326172|NCT04563884|OTHER|Questionnaires|"Children 12 months to 5 years old will receive PEACH alone, children 5 years old to 11 years old will receive PEACH and SSQ-P, and children and adolescents over 11 years old will receive SSQ-P and SSQ-C (even between 11 and 13 years old, the PEACH also).~Questionnaires will be completed twice, 15 days apart."
214326173|NCT03026998|PROCEDURE|MRI|MRI will be performed each year during 10 years.
214673066|NCT05542342|DRUG|Sitravatinib Malate|100 mg orally once daily
214673067|NCT02450357|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
214673068|NCT02450357|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
214673069|NCT03489291|GENETIC|AAV5-hFIXco-Padua (AMT-061)|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
214927405|NCT00697125|BIOLOGICAL|Hepatitis B vaccine, experimental formulation|Intramuscular injection, 3 doses
214927406|NCT03014895|DRUG|Placebo|Intravenous infusion
214927407|NCT03014895|DRUG|E3112|Intravenous infusion
214927408|NCT00643825|DRUG|Temozolomide|Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
214927409|NCT00643825|DRUG|Temozolomide|Observation till Progression then rechallenging with TMZ
214927410|NCT05147922|BEHAVIORAL|Booster Training with the Neonatal Resuscitation Quality Improvement Cart|The cart will give providers audio-visual feedback and walk them through how to perform effective positive pressure ventilation with correct head positioning, appropriate Peak Inspiratory Pressure and Peak End Expiratory Pressure, no mask leak and ventilation rate of 40 per minute. Participants will be able to spend up to 30 minutes with the cart before undergoing their 1 minute assessment, which will be without feedback.
214927411|NCT02149758|DRUG|Etoricoxib|
214927412|NCT06683443|BEHAVIORAL|Robotic Joy for All™ pet|Patients will be provided with the robotic pet within 48 hours of admission and have access to the pets throughout their hospitalization to provide comfort and engagement.
214927413|NCT06665490|OTHER|CLn Body Wash|All enrolled patients will self-administer at home the commercially available study product (CLn Body Wash) containing 0.006% NaOCl body wash in a sealed, child-safe pump dispenser to use daily for 8 weeks by wetting the body thoroughly with showering, lathering the study product on the body with special attention to affected areas, leaving on the skin for 2 minutes, and rinsing off with warm water.
214326174|NCT06809595|OTHER|Placebo|A substance that is designed to have no therapeutic value
214326175|NCT06809595|DRUG|MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
214326176|NCT03130322|OTHER|Imagery and Sleep questionnaires|Participants complete a motor imagery questionnaire to assess their ability to form vivid mental images, as well as sleep questionnaires to control the quality of their sleep
214326177|NCT03130322|OTHER|MEG recordings (pre-test)|"Participants of the Day group perform two motor tasks (a finger sequential motor task and an adaptation motor task using a trackball) in the MEG, during a pre-test (Day 1 - 9h).~Task 1: Participants perform an 8-digit motor sequential task where each finger (except the thumb) is used twice. Performance is assessed by using a 4-keys keyboard. Participants are required to keep their fingers on the keys to minimize amplitude are instructed to tap the sequence as few errors as possible Task 2: Participants perform a motor adaptation task requiring scrolling a trackball to superimpose a geometric shape on another one, strictly similar but presented from another angle, as fast as possible."
214326178|NCT03130322|OTHER|Practice session|Participants of the Day group perform a block of motor imagery practice of the two motor tasks.
214326179|NCT03130322|OTHER|MEG recordings (Post-test)|Participants perform the two motor tasks in the MEG (post-test, strictly similar to the pre-test)
214326180|NCT03130322|OTHER|MRI|The registration of the brain anatomy of each participant will be done by MRI 3D / T the week before the first experimental session.
214326181|NCT06038838|DEVICE|Tioga TMVR System|A bioprosthetic mitral valve, as part of the Tioga TMVR System, is implanted percutaneously in a patient with MR via transfemoral-transseptal access.
214326182|NCT06683729|DEVICE|Trans-septal (TS) Mitral Valve Replacement (TSMVR) Valve system|Trans-catheter, trans-septal mitral valve replacement.
214326183|NCT06998407|DRUG|AVZO-021|AVZO-021 is an oral selective CDK2 inhibitor
214326184|NCT06998407|DRUG|Fulvestrant|Antineoplastic agent, estrogen receptor antagonist
214326185|NCT06998407|DRUG|Letrozole|Antineoplastic agent, aromatase inhibitor
214673070|NCT03195790|BEHAVIORAL|Family-based pediatric obesity treatment|Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
214927414|NCT06074796|BEHAVIORAL|No intervention.|"No intervention. This is a retrospective study. Data will have been collected in routine consultations as part of the transition process for transgender patients.~Description of the collected informations : gender of destination, BMI, siblings, children, moral, previous hormone therapy, when the project was born, change of marital status desired or carried out, ALD status, psychiatric assessment, desire for future care for the transition course. Desire to preserve erectile function, parenthood desire, couple projections, type of couple, cryopreservation desired, done or not, desire of pregnancy, ultrasound count of antral follicles, initial hormone assays and tests : BMD, pelvic ultrasound? Data relating to stimulation and ovarian puncture and sperm collection."
214927415|NCT04988906|DEVICE|Zoll Accuvent Ventilation Monitor|Provides real-time ventilation quality monitoring (rate and volume)
214927416|NCT00119691|DRUG|Nesiritide|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
214927417|NCT03821714|DRUG|Glucocorticoid combination therapy|Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C, and vitamin B1.
214326186|NCT06998407|DRUG|AVZO-023|AVZO-023 is an oral selective CDK4 inhibitor
214326187|NCT06592820|DEVICE|Endoscopic Ultrasound Shear Wave Elastography (EUS) and Attenuation Imaging|EUS combines ultrasound technology with endoscopy to gain an internal vantage point to obtain higher resolution ultrasound images. Shear Wave is a software option on the ultrasound system EUS that provides an advanced measure and dynamic display of tissue stiffness which is being evaluated for use in assessing liver fibrosis. Attenuation Imaging (ATI) is a novel application that provides the capability to quantify and color-code the changes in attenuation coefficient of the liver that may arise with changes in liver composition (e.g., increased fat levels).
214326188|NCT06592820|DEVICE|FibroScan|A small ultrasound probe to measure the velocity of a sound wave passing through the liver. This is converted into kilopascals (kPa), which is used to assess liver fibrosis.
214326189|NCT06592820|DEVICE|Liver biopsy|"A biopsy of liver tissue could be obtained under endoscopic ultrasound guidance, interventional radiology (percutaneously), or surgically.~Endoscopic Ultrasound-guided liver biopsy provides high resolution images of left lobe of the liver and a good portion of the right lobe of the liver. This, coupled with Doppler capability, allows the physician to direct the biopsy needle safely into the liver for sampling under real time image guidance."
214326190|NCT06619561|DRUG|Vimseltinib|Administered orally
214326191|NCT07009665|OTHER|Personalized SV-guided resuscitation|Participants will receive an IV fluid bolus directly after inclusion. Next, measurement of the cardiac output change in response to the fluid bolus by the Starling SV will be used to determine fluid responsiveness. Vital parameters and fluid responsiveness will be used to guide hemodynamic resuscitation, consisting of IV fluids and/or vasopressors, during the first 3 hours.
214927418|NCT03821714|DRUG|Glucocorticoid|The glucocorticoid group was defined as the use of hydrocortisone alone.
214927419|NCT05950737|PROCEDURE|Sentinel node biopsy|All patients have undergone completion neck dissection following SNB in the process of standardization.
214927420|NCT00078975|DRUG|gemcitabine hydrochloride|
214927421|NCT00078975|DRUG|triapine|
214927422|NCT02274870|DRUG|Liposome Bupivacaine|Administered via local tissue infiltration around the knee joint
214927423|NCT02274870|DRUG|Bupivacaine HCl|Administered via CFNB
214927424|NCT04180137|PROCEDURE|Endovenous laser ablation of great saphenous vein (GSV) and microphlebectomy of varicose veins|"Surgical treatment is performed as endovenous laser ablation of GSV and microphlebectomy of varicose branches according to a standard protocol:~The intervention includes treatment of the pathological upright reflux and varicose veins. Ultrasound-guided GSV puncture at the upper third of the leg under local anesthesia. The light guide is inserted into the vein lumen and pushed through to the saphenofemoral junction. Under ultrasound guidance the light guide is positioned at v. epigastrica superficialis junction. Under ultrasound guidance tumescent anesthesia is produced around the GSV from puncture site up to the saphenofemoral junction. Laser coagulation (with radial light guide), linear energy density - 75 J/cm, automatic traction of the light guide at the speed 0.7 mm/sec. Varicose veins are resected through skin punctures using Varady hook 1-2 mm."
214326192|NCT07009665|OTHER|Standard Care Resuscitation|In the control group, IV fluid and vasopressor administration will be determined at the discretion of the physician and in accordance with currently available guidelines (e.g. Sepsis Surviving Campaign).
214326193|NCT02782949|DRUG|Curcumin|Given PO
214927425|NCT04180137|DRUG|Pharmacotherapy|After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.
214927426|NCT06089109|BEHAVIORAL|The Big 3|Our research team has developed an online, interactive learning management system (LMS) training. This training seeks to provide helping professionals with information and resources to identify, intervene, and prevent maternal injuries from interpersonal violence, substance use/disorder (IPV and SU/D). This training will provide healthcare professionals with the knowledge, skills, and efficacy to intervene and build capacity for prevention of maternal injuries and death due to violence.
214927427|NCT06089109|BEHAVIORAL|Implementation and Effectiveness of VIP Corps Training|Implement and evaluate the effectiveness of VIP Corps training aimed at students enrolled in helping professions in their last program year. intervention efficacy to change in students' knowledge, attitudes, and practices of intimate partner violence (IPV) screening, detection, and referrals; participant practices will be the primary, longer-term outcome; while changes in knowledge and attitudes will be short-term outcomes. Secondary outcomes will include changes in detecting symptoms of a) SU/D and b) depression and/or anxiety and providing appropriate resources.
214927428|NCT04199078|DEVICE|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a singledose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
214927429|NCT01310088|BEHAVIORAL|Lifestyle intervention|Treatment protocol. The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
214927430|NCT01975571|DEVICE|Cochlear® Nucleus™ Hybrid L24|The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.
214927431|NCT01975571|DEVICE|Cochlear® Nucleus™ Hybrid S12|The Nucleus Hybrid S12 cochlear implant incorporates an electrode array designed to stimulate the high-frequency, basal region of the cochlea while maintaining useful acoustic hearing in the low-frequency, apical region. This has been accomplished by employing a short, thin, straight intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The electrode array incorporates a collar to prevent over-insertion, or further migration, into the cochlea beyond the point where the basal turn curves into the ascending segment. Thus, the electrode array is placed within the straight segment of the basal turn of the scala tympani via a cochleostomy.
214927432|NCT03119753|DEVICE|Rapid Prototyping method of fabrication of complete denture|For Rapid Prototyping Method of fabrication of complete denture : the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
214673071|NCT06513195|PROCEDURE|endoscopic ultrasound-guided portal pressure measurement|The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
214326194|NCT02782949|OTHER|Laboratory Biomarker Analysis|Correlative studies
214326195|NCT02782949|OTHER|Placebo Administration|Given PO
214326196|NCT02782949|OTHER|Quality-of-Life Assessment|Ancillary studies
214326197|NCT07021144|BEHAVIORAL|"VA|PREVENTION web application (digital intervention)"|"VA\|PREVENTION web app, a digital intervention incorporating behaviour change techniques delivered by a Virtual Human Coach (VHC), educational content and progress tracking via a dashboard."
214347594|NCT04654689|OTHER|Placebo microcrystalline methylcellulose|Placebo replacing G04CB02
214673072|NCT05621512|OTHER|Preventive sessions|Preventive sessions between the pregnant employee, her manager and a midwife.
214673073|NCT05717322|BEHAVIORAL|TENS|apply TENS after orthognathic surgery
214927433|NCT03119753|DEVICE|Conventional method of fabrication of complete denture|For Conventional Method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
214927434|NCT05449587|OTHER|MRI and PRO|MRI as a standard of care for the analysis of silent rupture. BREAST-Q Postoperative Augmentation module scales to record patients for satisfaction: Satisfaction with breasts; Satisfaction with outcome; Psychosocial well-being; Physical well-being
214927435|NCT04486053|OTHER|Screening|The patients who agreed to participate to the study were assessed with a survey which included age, gender, height, weight and hand dominancy questions. Sensory, motor and functional assessments of the bilateral hand were performed.
214927436|NCT06683716|OTHER|Training in presence of the instructor|The instructor gives the trainee instructions for the examination while he/she is present in the examination room.
214927437|NCT06683716|OTHER|Telemedically training by an instructor|The trainer gives instructions to the trainee through a telemedical connection to the examiner using SmartGlasses
214927438|NCT04290910|BEHAVIORAL|Weight Loss Program|There are three components of the intervention, this includes: psychology, nutrition, and physical activity. For the psychological portion, a therapist will assess the participant at baseline to determine if there are barriers associated with making lifestyle changes. For nutrition, the dietitian will assess the participant and create a meal plan based on their nutritional needs and guide the participant to reaching their nutritional goals. The psychological and nutrition portion may be interchangeable depending on the participants needs. For physical activity, the personal trainer will assess the participant and create an exercise plan that consists of resistance training and weight bearing exercises suitable for the participant while also guiding the participant to reach their exercise goals.
214927439|NCT05578716|DIETARY_SUPPLEMENT|Partially hydrolysed formula|Partially hydrolysed formula
214927440|NCT01609543|DRUG|erlotinib [Tarceva]|150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
214927441|NCT00507819|DRUG|Sildenafil|One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
214927442|NCT00507819|DRUG|Placebo|One placebo capsule will be taken by mouth three times-a-day.
214927443|NCT00111319|DRUG|bortezomib|
214927444|NCT03807219|DIETARY_SUPPLEMENT|Magnox Comfort|Magnox Comfort (Magnesium (226 mg in equivalent), Vitamin E - 45 mg, Vitamin B6 - 2 mg.).
214927445|NCT03807219|OTHER|Placebo|placebo
214326198|NCT07021144|BEHAVIORAL|Type 2 Diabetes Guidebook|T2D prevention guidebook, an educational material that include standard guidelines on healthy eating and the importance of regular physical activity and reduction of sedentary behaviour.
214326199|NCT07019116|OTHER|Standard gatekeeping|Human evaluators (mostly physicians) review referrals and determine, based on established protocols, whether they should be authorized.
214326200|NCT07019116|OTHER|AI algorithm|An AI algorithm was developed to perform the first evaluation (triaging) of the referrals inserted in the electronic referral system from the Rio Grande do Sul Health Department.
214673074|NCT05717322|BEHAVIORAL|sham TENS|apply non active TENS after orthognathic surgery
214673075|NCT06969950|OTHER|App-Delivered Mindfulness Training (MT).|The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based for two weeks
214673076|NCT06969950|OTHER|Online Virtual Training|A sub-group of 25 participants, either from the both intervention or control group, the will receive a virtual online training delivered via zoom calls. It is a group session program which includes 4 mindfulness-based sessions of about 60 minutes of brief didactic and experience-based for four weeks.
214673077|NCT00153166|DRUG|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
214673078|NCT00153166|DRUG|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
214927446|NCT00004235|DRUG|docetaxel|
214927447|NCT00004235|DRUG|irinotecan hydrochloride|
214927448|NCT06683833|DRUG|Egyptian MTA|"* Complete caries removal from the cavity.~* The liquid of Egyptian MTA (Toothmate) will be mixed with powder according to the manufacturers' instructions.~* The capping materials will be placed with the passive application on the deepest part of the cavity. Only light pressure will be applied on the MTA mixture using a wet cotton pellet to ensure adaptation of the material onto the dentin.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
214326201|NCT07019116|OTHER|Subsequent interactions between primary care and regulation system|After the first evaluation of a referral, several subsequent rounds of interaction between gatekeepers and primary care physicians can be conducted to further detail patient needs and urgency.
214927449|NCT06683833|DRUG|Biodentine|"* Complete caries removal from the cavity.~* Gently tapping a capsule of Biodentine (Septodont) on a hard surface to loosen the powder, then opening the capsule, Detaching a single-dose container of liquid and gently tapping on the sealed cap to force all the liquid down the container, Twisting cap to open, Then Pouring 5 drops from the single-dose container into the capsule, Then Closing the capsule and Placing it on a mixing device for 30 seconds, Then Collecting Biodentine with the instrument supplied in the box.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
215069420|NCT07033884|BEHAVIORAL|Peer Engagement and Exploration of Responsibility and Safety|PEERS involves a one-on-one session with a firearm-owning Veteran peer interventionist. The appointment will last between 15 minutes and one hour, and the modality (i.e., in-person or virtual) will be based on Veteran participant preference. Principal components of the PEERS session will include: 1) engaging - initiating conversation in a non-confrontational manner; 2) focusing - quickly concentrating the discussion on the topic of firearms and means safety; 3) evoking - reflecting the participants' reasons both for and against engaging in means safety, leveraging the participants' own rationale for change as a tool for increasing behavior change; and 4) planning - once a plan is agreed upon, this information is put into writing. Participants will also be provided the same psychoeducational materials provided to the participants in the active control condition.
214326202|NCT07021209|BIOLOGICAL|GT719 Injection|GT719 Injection
214326203|NCT06878677|OTHER|Data-driven exercise|"The result from the Statistical Parametric Mapping 1D (SPM1D) analysis will be used to identify the magnitude of deviation from normal gait patterns in reference to healthy subjects for each lower limb joint. Thereby, the targeted action and joint position can be identified. Training will focus on the specific movement where the steepest gradients are observed.~The targeted exercises will be selected based on the five largest deviations observed during the swing or stance phase. Open-chain exercises will be applied to address deviations in the swing phase, while closed-chain exercises will be applied to address deviation in the stance phase. Each exercise will be performed for approximately 80-100 repetitions, with a total duration of 10 minutes per exercise, including rest periods."
215069421|NCT07033884|OTHER|Active Control|"Veterans will receive no treatment and will not interact with peers. A no treatment control condition was selected due to the preventative nature of PEERS, as well as the early stage of evaluation for this intervention. However, given the varied recruitment outlets and subsequent lack of standardized usual care, as well as ethical concerns with not providing important resources to firearm owning Veterans, two informational handouts will be added to this control condition. Specifically, Veterans in this condition will be provided with an informational handout developed by the National Sports Shooting Foundation, which includes a variety of secure firearm storage options, as well as a handout listing national mental health and suicide prevention resources."
215069422|NCT07034521|DEVICE|HIWIN MRG-P110|HIWIN MRG-P110 is a robotics for lower limbs rehabilitation
215069423|NCT07034716|PROCEDURE|CORONARY BYPASS SURGERY USING CARDIOPULMONARY BYPASS|The study will be conducted on cardiac surgical patients who will undergo isolated elective CABG with nonpulsatile flow during cardiopulmonary bypass
214326204|NCT06878677|BEHAVIORAL|Standardized exercises|The participants will perform dose match standardised exericse program.
214326205|NCT06728293|OTHER|Liver Link|Support Program
214326206|NCT06889246|DIETARY_SUPPLEMENT|Anvitra Gastric Suspension|Anvitra Gastric Suspension is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in patients. The intervention involves administering 1 packet (15 ml) per dose three times daily, taken orally 30 minutes after meals, for a duration of 14 days. The supplement is intended to alleviate symptoms of GERD (heartburn, regurgitation, and dyspepsia). Anvitra Gastric Suspension has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in GERD treament.
215069424|NCT07034716|PROCEDURE|cardiac surgical patients who will undergo isolated elective cardiopulmonary bypass|The study will be conducted on cardiac surgical patients who will undergo isolated elective CABG with pulsatile flow during cardiopulmonary bypass
215069425|NCT07034196|OTHER|Primary Care Treatment in lieu of Rheumatologist|RA patients will be randomized to receive their RA care via their established PCP who completed a structured training course in RA and who has monthly case review/consultation sessions with the rheumatology team in this study
214326207|NCT07042997|PROCEDURE|Evaluation of Anatomical Accuracy in Targeting Forearm Extensor Muscles with Blind Dry Needling in Patients with Lateral Epicondylitis Using Ultrasound Guidance|"Using a high-resolution linear probe (5-12 MHz) , the muscle in which the needle tip is located is monitored in real time in the transverse and longitudinal planes. Whether the needle is in the targeted muscle is recorded as correct or incorrect."
214326208|NCT06888895|OTHER|Passive-active stretching (PAS)|Passive-active stretching (PAS) combines conventional passive stretching with active exercises designed to activate muscles that promote hamstring elongation. On the other hand, passive stretching (PS) is a commonly administered intervention to improve hamstring flexibility.
214326209|NCT06888895|OTHER|Passive hamstring stretching|Participants will receive one minute of passive hamstring stretching applied three times for each lower limb, with a 30-second rest time between stretches.
214326210|NCT06889857|BIOLOGICAL|The study drug is SHED-CM manufactured by U-Factor|This study will involve informed consent, a 12-week observation period, a 12-week study drug administration period, and a 4-week follow-up period.
214326211|NCT05026554|GENETIC|Tape stripping|Optional genetic analysis for chronic hand eczema
214326212|NCT05677360|BEHAVIORAL|HPV MISTICS -Provider Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.
214326213|NCT05677360|BEHAVIORAL|HPV MISTICS - Parent Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.
214486153|NCT06887725|OTHER|Exercise|The Cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) is an innovative exercise approach developed based on the biopsychosocial model. The parameters that form the basis of BETY are function-oriented core stabilization exercises, information management in pain, information management in mood, and information management in sexuality. BETY was shaped by the feedback of individuals with rheumatism who participated in regular exercise sessions for years and was introduced to the literature as a treatment method aiming to create changes in the cognitive structures of patients through exercise.
214486154|NCT06886425|OTHER|genetic study|"Blood sampling :~Cure 1 before starting treatment Cure 3 before starting treatment Cure 6 after completion of treatment"
214927450|NCT06683833|DRUG|Calcium Hydroxide (Ca(OH)2)|"* Complete caries removal from the cavity.~* According to the manufacturers' instructions, Dispensing equal volumes of base and catalyst pastes on the parchment paper pad provided. Using a Dycal (Dentsply) Liner applicator, stirring immediately to mix thoroughly until a uniform color is achieved, complete mixing occurs within 10 seconds, using the ball-pointed Dycal Liner applicator or similar instrument, the mix will be placed directly on the cavity.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
214927451|NCT03452488|DRUG|BIO101|Oral capsules
214927452|NCT03452488|DRUG|Placebo|Oral capsules
214927453|NCT06684067|BEHAVIORAL|Patient navigation|Participants will receive online educational material, hospital site navigation guidance and direct contact with the patient navigator, in addition to standard instructions on the colonoscopy procedure.
214927454|NCT06122012|DRUG|HSK16149 20mg BID|HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；
214927455|NCT05830734|OTHER|injection of freshly collected adipose cells|"A small incision is made bilaterally in the lumbar region. 2-300 ml of Ringer's acetate with 1 mg of added adrenaline is introduced with an infusion cannula fan-shaped into the subcutaneous adipose tissue on each side of the region.~Adipose tissue is harvested for a total of approx. 80 ml. 20 ml Bupivacaine 5 mg/ml is distributed on each side of the lower back. The incisions are then closed with Steri-Strips and a compressive dressing is applied to reduce the risk of hematoma.~The harvested adipose tissue then centrifuged in bulks of four at 1000 rpm. minute for 3 minutes. The liquid fraction is discarded. Using a three-way tap system, the adipose tissue is microfragmented between two 10 ml syringes by moving the contents back and forth at least 20 times. The adipose tissue is then distributed in 2 ml syringes for injection. A total of between 25 and 55 ml of usable adipose tissue will be harvested."
214927456|NCT05830734|PROCEDURE|Bascoms Cleft lift procedure|The procedure is carried out according to standardized principles previously decribed by Drs. John and Tom Bascom
215069426|NCT07034079|DEVICE|complete dentures|"Participants were randomly allocated into two intervention sequences using a computer-generated randomization list. The two sequences were:~* Group A: Received maxillary complete denture with palatal rugae first, followed by a smooth polished palatal surface denture after a 2-month adaptation period.~* Group B: Received a smooth polished palatal surface denture first, followed by a rugae-enhanced denture after a 2-month adaptation period."
215069427|NCT07032519|BEHAVIORAL|Mindfulness Intervention|Participants will use the smartphone app daily for pain tracking and weekly to engage with mindfulness content and complete additional assessments.
214927457|NCT02780141|DRUG|roxadustat|Oral
215069428|NCT07034443|DEVICE|High Intensity Focused Electromagnetic Stimulation|Patients will sit on the device, the high intensity for 28 minutes, twice a week for three weeks
214326214|NCT05677360|BEHAVIORAL|HPV MISTICS- HPV Vaccine Champion Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses
214927458|NCT01254318|OTHER|Standard Care|Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
215069429|NCT06895915|PROCEDURE|dynamic navigation surgery|immediate implant placement assisted by dynamic navigation
215069430|NCT06895915|PROCEDURE|robotic surgery|immediate implant placement assisted by robotic surgery
215069431|NCT06749847|OTHER|Women receive invitation letter with HPV self-sampling kit|Direct mailing of HPV self-sampling kit. Women receive HPV self-sampling kit with instructions. SMS reminder at 3 months if no participation. Assistance provided for triage cytology if HPV positive.
214326215|NCT06787222|DRUG|tretinoin 0.025% + Z. officinale patch|Material used for patch formulation were 3,15 grams of polyvinyl alcohol, 4,2 grams of polyvinyl pyrrolidone, 12,6 ml distilled water, and 1,05 grams of Z. officinale extract.
214326216|NCT06787222|DRUG|tretinoin 0.025% cream|no Z. officinale patch applied after tretinoin 0.025% application
214326217|NCT06747156|DRUG|ABO2203 Injection|Name of Active Ingredient: mRNA encoding CD19/CD3 T cell engager
214326218|NCT06811116|PROCEDURE|Biospecimen Collection|Undergo blood collection
215069432|NCT06749847|OTHER|Women receive invitation letter with choice of ordering a free self-sampling kit or visit healthcare provider|Option between self-sampling and healthcare provider: women can choose testing method. If self-sampling chosen, kit sent to home. SMS reminder at 3 months if no participation.
215069433|NCT03044119|BIOLOGICAL|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
215069434|NCT03044119|BIOLOGICAL|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
215069435|NCT07081607|DRUG|golidocitinib with azacytidine and chidamide|"In Phase I, a 3+3 dose-escalation design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of golidocitinib: 150 mg every other day (QOD) and 150 mg once daily (QD).~In Phase II, we aim to evaluate the efficacy and safety of golidocitinib RP2D po in combination with chidamide 20mg biw po and azacytidine 100mg d1-7, SC in patients with peripheral T-cell lymphoma"
215069436|NCT07080983|PROCEDURE|Crosslinking|Corneal Cross-Linking (CXL) is a minimally invasive procedure used to strengthen the cornea by increasing the chemical bonds between collagen fibers. It is primarily used to treat keratoconus and corneal ectasia, conditions where the cornea becomes progressively thinner and weaker.
215069437|NCT07079371|PROCEDURE|Micellar Water Application (No Rinse)|Participants apply micellar water to the forehead once daily and leave it on the skin without rinsing for 21 days.
215069438|NCT07079371|PROCEDURE|Micellar Water Application (With Rinse)|Participants apply micellar water to the forehead once daily and rinse it off after application for 21 days.
214927459|NCT05833113|DEVICE|Placebo-Transcutaneous Electrical Nerve Stimulation (TENS)|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~The control group will also receive the TENS-pants electrodes, connected to TENS treatment. In the placebo-TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. However, the TENS treatment to the control group will be set so that no electricity will reach the patient.~A multimodal analgesia regimen will be applied postoperatively"
214927460|NCT05833113|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~In the TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. TENS device will be applied 4 times a day with treatment periods of 30 minutes.~A multimodal analgesia regimen will be applied postoperatively"
214927461|NCT05311436|BEHAVIORAL|Experimental - Intensive nutrition counselling for pregnant, adolescent and under2 children|"Pregnant women: Intensive dietary counseling using diet chart for locally available food, and to attend antenatal care services from local ANC providers, daily Iron, folic acid, and calcium supplementation.~Adolescent girls: Group sessions in the nutrition centers with the adolescent girls will be conducted twice monthly for 6 months. Iron and folic acid (200 mg ferrous fumarate and 400 μg folic acid); once weekly for 3 months; zinc 10 mg daily for 1 month.~Children \<2 years: Behavioral counseling sessions through monthly home visits on Infant and Young Child feeding, Growth monitoring and promotion, and water sanitation and hygiene, and food safety.~Intensive WASH counselling: Intensive WASH counseling will be provided to separate group of child participants twice a month for 6 months.~Severely stunted children: 1 egg supplementation for 3 months and 1 sachet of multiple micronutrient powder (1 RDA of vitamin A and C, iron-folic acid, and zinc) daily for 2 months."
215069439|NCT07080593|BEHAVIORAL|Novel Physical Activity Program|A structured phase and a self-directed phase, involving both in center and out-of-center exercise. Our novel intervention provides patient's the autonomy to choose the types of physical activity and exercise that they are willing and able to participate in. In brief, it involves working one-on-one with patients to develop an activity prescription that aligns with the participants' goals and motivations to increase physical activity levels.
215069440|NCT07080593|BEHAVIORAL|Standard of Care Physical Activity Program|"Those in the control group will undergo a variety of exercises including intradialytic cycling and resistance (strength training)"
215069441|NCT02497144|OTHER|NMES Group|Neuromuscular electrical stimulation
215069442|NCT02497144|OTHER|Control Group|Breathing exercises
215069443|NCT04091581|DRUG|Systane Complete|Systane Complete will be instilled and rate of evaporation assessed before and after.
215069444|NCT01519687|DRUG|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
215069445|NCT03296748|PROCEDURE|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
215069446|NCT03296748|PROCEDURE|anterior colporraphy|
215069447|NCT04473274|DRUG|Pioglitazone|Receive pioglitazone 15mg - 30mg daily
215069448|NCT01269229|DRUG|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous
215069449|NCT01269229|RADIATION|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
215069450|NCT04742803|DEVICE|Straberi Epistamp Microneedling Treatment|"The patient's entire face will be treated with the Straberi Epistamp needling device.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
214326219|NCT06811116|DRUG|Cabozantinib S-malate|Given PO
214326220|NCT06811116|PROCEDURE|Imaging Procedure|Undergo imaging scans
215069451|NCT04041544|DRUG|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
215069452|NCT04041544|DRUG|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
215069453|NCT02889289|OTHER|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
215069454|NCT04544930|BEHAVIORAL|therapist-guided|Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
215069455|NCT04732702|OTHER|no intervention|There will be no intervention.
214326221|NCT06811116|DRUG|Sapanisertib|Given orally (PO)
214326222|NCT07069751|DIETARY_SUPPLEMENT|diet rich in fiber|Enrolled and eligible patients will be encouraged to consume a balanced diet rich in fiber for the entire duration of the trial (i.e., 12 weeks). Patients will also be encouraged to prolong plant-based diets beyond week 12. Free outpatient medical visit will be performed at enrollment and at week 12, and nutritional counseling will be given at the time of enrollment, one month later and on demand. Dietary measurements will be conducted along the entire duration of the nutritional regimen by questionnaires. In particular, the patient will write for each day of the trial the number associated to the chosen diet plan or food.
214326223|NCT06848868|PROCEDURE|Ambulatory flexible ureterorenoscopy|Ambulatory flexible ureterorenoscopy (experimental)
214927462|NCT06622902|OTHER|change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours|change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours
214927463|NCT06622902|OTHER|change flow from 2 to 6 LPM. Follow TcCO2 for 3h|change flow from 2 to 6 LPM. Follow TcCO2 for 3h
214927464|NCT00952796|DRUG|moxifloxacin|moxifloxacin 400mg once daily (IV form, 60minutes)
215069456|NCT06062667|OTHER|accompany the birth|Fathers will accompany their husbands during the birth process
214927465|NCT00952796|DRUG|ampicillin/sulbactam|ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
214927466|NCT03805984|DRUG|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
215069457|NCT05446766|BEHAVIORAL|Self-guided Exposure-based Digital Intervention for Health Anxiety|"An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days."
215069458|NCT01244789|DRUG|carboplatin and paclitaxel|6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
215069459|NCT01244789|OTHER|observation|active observation
214326224|NCT06903650|PROCEDURE|bilateral salpingectomy, ovarian arter doppler ultrasonography|The effect of salpingectomy operation on ovarian reserve
214673079|NCT00153166|DRUG|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
214927467|NCT03805984|DRUG|Placebo|Placebo will be administered ID on Day 0 and Week 4.
214927468|NCT03805984|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
214927469|NCT04079413|DRUG|GP40071|GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
214927470|NCT04079413|DRUG|NovoRapid® Penfill®|NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
214927471|NCT00581321|DIETARY_SUPPLEMENT|water|water 500 ml x 1
214927472|NCT02877810|OTHER|Telemedicine|Telemedicine is a live, interactive, audiovisual teleconferencing system.
214927473|NCT02877810|OTHER|Telephone|Consultations will be given over telephone.
214927474|NCT06051838|PROCEDURE|surgery|if the patients is TD positive, we recommond careful surgery and pathological examination.
214927475|NCT02058784|DRUG|pracinostat|
214927476|NCT02119689|OTHER|Diabetic Patients|measuring CD34 cell function in relation to diabetic retinopathy status
214927477|NCT02119689|OTHER|Healthy Controls|measuring CD34 cell function
214927478|NCT04590508|DRUG|Xanthohumol|The xanthohumol supplement will be administered in a capsule and taken orally.
214927479|NCT04590508|OTHER|Placebo|The placebo will be administered in a capsule and taken orally.
214927480|NCT01532843|DRUG|PegIFN alfa-2b|Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
214927481|NCT06487221|DRUG|Avutometinib|3.2mg orally
214927482|NCT06487221|DRUG|Defactinib|200 mg orally
214927483|NCT00804102|DEVICE|Transcorneal Electrical Stimulation|Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.
214927484|NCT00804102|DEVICE|DTL-electrode attached without energy|DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.
214927485|NCT04264390|BEHAVIORAL|Movement-to-music|Movement-to-music is a physical activity program that was developed onsite at a state-of-the-art adapted fitness facility. The program includes movements that are coupled with music to enhance muscular strength, cardiorespiratory capacity, flexibility, and balance. For this study, the program will be packaged into playlists of exercise videos that will be given to participants. Participants will be instructed to complete the prescribed videos 3 times per week. Participants will also be asked to attend 4 behavioral coaching calls with a telecoach. The goals of the behavioral coaching calls will be to address issues with the technology components of the program and promote physical activity participation within the community and adherence to the movement-to-music videos.
214927486|NCT01595464|BEHAVIORAL|Mind-Body Skills Groups|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
214927487|NCT04447352|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
214927488|NCT04447352|DRUG|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
214927489|NCT04447352|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
214927490|NCT04447352|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
214927491|NCT04447352|DRUG|Cisplatin|intraoperative: 75mg/m² intraabdominal solution over 1 hour and 30 minutes
214927492|NCT01542437|DRUG|BIBW 2992|"All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug."
214927493|NCT05622318|DRUG|Cyclophosphamide|25 mg/kg by IV on Days +3 and +4.
214927494|NCT05622318|DRUG|Tacrolimus|Target level 5-10 ng/mL (If the subject experiences nausea and vomiting that prevents the oral intake of tacrolimus anytime during treatment, tacrolimus is to be given by IV at the appropriate dose that was used to obtain the therapeutic level \[IV:PO ratio = 1:4\]). Administered Days +5 through +90. Taper after Day +90 and discontinue on Day +180.
214927495|NCT05622318|DRUG|Mycophenolate Mofetil|15 mg/kg tablet thrice daily Days +5 through +35 every eight hours.
214927496|NCT05622318|DRUG|Ruxolitinib|5 mg tablet twice daily after engraftment through Day +365. Taper after Day +365.
214927497|NCT05827042|DRUG|Intravenous thrombolysis|Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.
214927498|NCT05827042|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy
214927499|NCT03996356|OTHER|No study intervention - observational study|This is an observational study where the comparative groups will be determined by the genetic variants (SNPs) of subjects and not an intervention, per se.
215069460|NCT06206720|DRUG|Deuremidevir Hydrobromide for Suspension|"15 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg TID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension 3 times every day, total 15 times."
214927500|NCT05657197|BEHAVIORAL|Exercise intervention|A 12-week exercise program consisting of three times per week 1-hour sessions, including 30-minutes aerobic- and 30-minutes progressive resistance training. The intensity of training will be adjusted to each individual, based on a cardiopulmonary exercise test. Training sessions will be performed in groups of 10 participants under supervision of a sports physical therapist.
214326225|NCT06903442|BEHAVIORAL|Co-designed cardiovascular brief intervention|Patients will be randomised to a brief intervention where they will be informed of their high-sensitivity cardiac troponin value and cardiovascular risk.
214326226|NCT06928506|DEVICE|Hi-OxSR device|The Hi-OxSR device consists of the Hi-Ox mask connected to a portable oxygen concentrator, with added tubing serving as a reservoir for rebreathed exhaled breath.
214326227|NCT06928506|DEVICE|Hi-Ox device|The Hi-Ox mask is connected to a portable oxygen concentrator.
214673080|NCT00153166|DRUG|placebo/placebo|placebo orally three times daily
214927501|NCT05657197|OTHER|Usual care|Usual care, including general advice concerning chronic fatigue.
214927502|NCT03562611|DRUG|Nalbuphine|Nalbuphine administration during surgery
214927503|NCT03562611|DRUG|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
215069461|NCT06206720|DRUG|Placebo|"15 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg TID group: 5 subjects will receive placebo 3 times every day, total 15 times."
214326228|NCT07084844|DEVICE|WaveLigh Plus LASIK|Wavelight plus LASIK is an advanced laser eye surgery technology designed to enhance visual outcomes through personalized treatment plans. This system integrates comprehensive diagnostics, including biometry, tomography, and wavefront measurements, to create a tailored ablation profile for each patient.
214326229|NCT07085429|BIOLOGICAL|Blood and tissue sampling|"Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~During the blood samples taken for diagnosis and / or treatment when possible. Additional samples for research purposes will be carried out, these blood samples will be collected:~* before any therapeutic intervention (T1) for a total volume of 36mL,~* prior to surgery (T-Surg) for a total volume of 24mL,~* at each progression (T2a, b, c…) for a total volume of 24mL,~* at the end of follow-up (T3) for a total volume of 24mL."
214927504|NCT03562611|DRUG|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
214927505|NCT01945970|OTHER|Black tea extract|Black tea extract
214927506|NCT01945970|OTHER|Positive control|Positive control
214927507|NCT01945970|OTHER|Placebo|Placebo
214673081|NCT02333045|DRUG|Truvada qd|Truvada 1 tablet PO daily for 7 days
214927508|NCT04850261|DRUG|hCG Injection|Ovulation will be induced by subcutaneous hCG injection
214326230|NCT07085286|DEVICE|Continous IAP measurement|Continuous IAP measurement via existing Foley bladder catheter - allowing continuous APP, MPP and RPP calculation
214326231|NCT06923046|OTHER|Standard of Care|Multidisciplinary team based care every 3 months.
214486155|NCT06886425|OTHER|Pharmacokinetic study|"Cure 1: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase.~Cure 3: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase.~Cure 6: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase."
214486156|NCT06886425|OTHER|Study of phenotypic activity of cytidine deaminase|"Blood sampling :~Cure 1 before starting treatment Cure 3 before starting treatment Cure 6 after completion of treatment"
214673082|NCT02333045|DRUG|Maraviroc 300 qd|Maraviroc 300 mg PO daily for 7 days
214927509|NCT04850261|DRUG|Nafarelin nasal spray|Ovulation will be induced by nasal application of Nafarelin
214486157|NCT06885840|DRUG|MCLA-129|MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
214486158|NCT06885112|DEVICE|FoLix treatment for improving the scalp hair appearance|The study patients will receive 4 FoLix treatment in 4 weeks intervals. the scalp hair improvement will be evaluated by 3 blinded assessors who shall review before and after images, as well as hair count data
214486159|NCT06882395|DEVICE|Group 1: FLX aligners for 10 days|FLX aligners worn for 10 days
214486160|NCT06882395|DEVICE|Group 3: FLX aligners for 7 days, followed by new FLX aligners for 3 days.|Group 3: FLX aligners worn for 7 days, followed by new FLX aligners for 3 days.
214927510|NCT03830684|DRUG|Baicalein Tablets 400mg|4 Baicalein Tablets and 2 placebo per time, three times a day
214927511|NCT03830684|DRUG|Baicalein Tablets 600mg|6 Baicalein Tablets per time, three times a day
214927512|NCT03830684|DRUG|blank control 0mg|6 placebo per time, three times a day
214927513|NCT00782184|DRUG|ezetimibe/simvastatin 10/40|ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
214927514|NCT00782184|DRUG|atorvastatin 40 mg|atorvastatin 40 mg tablet once daily for 6 weeks
214927515|NCT00782184|DRUG|atorvastatin 20 mg|All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
214927516|NCT01760967|DRUG|Dexmedetomidine|intervention to administer dexmedetomidine or not
214927517|NCT01388244|OTHER|Screening|Screening by risk factor assessment (FRAX) followed by DXA
214927518|NCT01388244|OTHER|Control|Observation by use of register data
214927519|NCT01891565|BEHAVIORAL|Feedback|
214927520|NCT02406079|PROCEDURE|tracheotomy|Tracheotomy is one of most performed surgical procedures to assure airway by making a hole in front of the trachea in ICU.
214927521|NCT03340220|DRUG|XPF-008|Capsule filled with XEN1101
214927522|NCT03340220|DRUG|Microcrystalline Cellulose|Placebo capsule
214927523|NCT03340220|DRUG|XPF-010|Capsule filled with XEN1101
214927524|NCT03340220|DRUG|Itraconazole 400mg|Oral
214927525|NCT05499221|DEVICE|Carriere motion appliance|The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.
214326232|NCT06923046|BEHAVIORAL|Shared Medical Appointments|Participants will attend 4 quarterly appointments. In additionto time with their clinician, they will also have groupactivities that address relevant topics.
214927526|NCT02385838|BEHAVIORAL|5-CNL|The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
214927527|NCT02385838|BEHAVIORAL|MTL|The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
214927528|NCT02385838|BEHAVIORAL|GDA|The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
214927529|NCT02385838|BEHAVIORAL|Tick|The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
214927530|NCT06683625|DIAGNOSTIC_TEST|6K Max Effort Erg Test|"6K Max Effort Erg Test, involves participants completing a 6000-meter rowing distance on an ergometer as quickly as possible. This test is designed to measure peak endurance and performance under controlled conditions and will serve as a primary assessment of each athlete's physical output and adaptive capacity."
214326233|NCT07078812|BEHAVIORAL|Mirror Therapy|Mirror Therapy involves placing a mirror in the patient's midsagittal plane to reflect movements of the unaffected upper limb, creating a visual illusion of movement in the paretic limb. Patients perform bilateral symmetrical movements while focusing on the mirror reflection, helping to stimulate motor cortex activation and promote neuroplasticity. Sessions last 30 minutes, 5 days per week, for 6 weeks. This intervention is delivered in addition to standard stroke rehabilitation.
214326234|NCT07078812|BEHAVIORAL|Action Observation Therapy|Action Observation Therapy consists of observing video demonstrations of functional upper limb movements, followed by the patient imitating the observed actions. Each session includes 15 minutes of watching goal-directed tasks and 15 minutes of active execution. This therapy aims to activate the mirror neuron system and enhance motor recovery. The protocol is administered 5 days per week for 6 weeks and is combined with routine stroke rehabilitation practices.
214326235|NCT07085598|DIETARY_SUPPLEMENT|Vitamin D|15 male epileptic patients with hypovitaminosis D will be enrolled. They will be supplemented with Vitamin D orally 50,000 IU/week for 8 weeks
214326236|NCT07086755|DRUG|Vadadustat 900mg|Participants will receive 900mg vadadustat (as oral tablets) for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
214326237|NCT07086755|DRUG|Vadadustat 1200mg|Participants will receive 1200mg vadadustat (as oral tablets) for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
214927531|NCT01551264|DEVICE|Foot Abduction Brace (FAB)|After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
214927532|NCT01992653|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
214927533|NCT01992653|DRUG|Doxorubicin|Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
214927534|NCT01992653|DRUG|Obinutuzumab|Obinutuzumab will be administered at 1000 milligrams (mg) IV on Cycle 1 Days 1, 8, and 15 and on Day 1 of Cycles 3-8.
214927535|NCT01992653|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at escalating doses (at a starting dose of 1 mg/kg) IV every 3 weeks, for 6 or 8 cycles.
214927536|NCT01992653|DRUG|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
214927537|NCT01992653|DRUG|Prednisone|Prednisone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
214927538|NCT01992653|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
214927539|NCT05016141|BEHAVIORAL|digital fall prevention program|The participants will receive a digital fall prevention program consisting of fall risk reduction education (modified Matter of Balance), Otago Exercise Program, Personalized S.M.A.R.T Goals, and will use the app to keep track of their health and health events, including falls.
214326238|NCT07086755|DRUG|Placebo|Participants will matching placebo (as oral tablets) for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
214326239|NCT07085884|BEHAVIORAL|The Static-Dynamic Balance Training Combined with Reminiscence Therapy|The intervention group received a 12-week SDBT-RT program, conducted twice weekly: 40-minute reminiscence therapy plus 50-minute balance training in odd weeks, and 50-minute balance training alone in even week.
214927540|NCT05764538|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
214927541|NCT00356356|DRUG|Etanercept|Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
214927542|NCT05849883|DRUG|Omeprazole 20 mg Capsules|Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production
214326240|NCT07085481|DRUG|room temperature Bupivacaine|bupivacaine will be on a sterile shelf in the operating room at 23°C. The empty syringes and needles will be also on the same shelf before their use.
214326241|NCT07085481|DRUG|warm Bupivacaine|bupivacaine will be warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature for at least 2 hours before initiating the block.
214347595|NCT02972580|GENETIC|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
214326242|NCT07086950|DEVICE|Body Brain Trainer software|Patients will engage in cognitive and physical exercises with the training software Body Brain Training (BBT) for 4 consecutive weeks. Participants will be asked to complete 3 sessions per week for a length of \~1h per session.
214326243|NCT07086950|DEVICE|RehaCom software|Patients will engage in exercises with the cognitive training software RehaCom (Hasomed®), which is a proxy to the standard of care, for 4 consecutive weeks. Participants will be asked to complete 3 sessions per week for a length of \~1h per session.
214927543|NCT05326347|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.
214927544|NCT02001844|DEVICE|Trial Foot Orthoses (FOs)|"Trial Group:~The children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
214927545|NCT02001844|DEVICE|placebo foot orthoses (FOs)|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
214927546|NCT06663540|OTHER|Exercise & Abacus|"Features two main interventions: physical exercise sessions and abacus training activities.~Physical Exercise Sessions aim to enhance fitness and cognitive function through activities like aerobic exercises and team sports. Research indicates that regular physical activity can improve memory, attention, and problem-solving skills essential for academic success.~Abacus Training Activities focus on developing mathematical skills and cognitive abilities. Children learn to manipulate the abacus for calculations, which enhances numerical understanding and memory retention, positively impacting academic performance.~The program's innovative dual approach suggests that integrating physical and cognitive training can lead to greater improvements in academic performance and emotional resilience than either intervention alone."
214927547|NCT02572076|DEVICE|Motus Cleansing System|
214927548|NCT02591901|DRUG|Uro vaxom|Prevention of recurrent symptomatic lower urinary tract infections
214927549|NCT02591901|OTHER|Placebo comparator|Placebo comparator
214326249|NCT07087301|OTHER|subtherapeutic concentration risk group|The second model (for subtherapeutic concentration risk prediction) defined low concentration as trough \<10 mg/L and target as 10-20 mg/L to analyze predictors of target concentration attainment.
214326250|NCT07087301|DRUG|subtherapeutic concentration risk group|The second model (for subtherapeutic concentration risk prediction) defined low concentration as trough \<10 mg/L and target as 10-20 mg/L to analyze predictors of target concentration attainment.
214326251|NCT07085143|DRUG|Compound Ciwujia Granules|Take Compound Ciwujia Granules or placebo twice daily for 8 weeks; Continue concomitant SSRI medication therapy throughout the treatment period;
214326252|NCT07085143|DRUG|placebo|"1. Take placebo twice daily for 8 weeks;~2. Continue concomitant SSRI medication therapy throughout the treatment period;"
214326253|NCT06773936|DRUG|Induction Phase|Asciminib, Dasatinib, Prednisone, and Methotrexate
214326254|NCT06773936|DRUG|Re-Induction Phase|Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone
214326255|NCT06773936|DRUG|Post-Remission|Blinatumomab, Dasatinib, Methotrexate and Dexamethasone
214326256|NCT06773936|DRUG|Maintenance|Asciminib, Dasatinib, Prednisone, and Methotrexate
214326257|NCT05637775|OTHER|EEG-based BCI system for (hands) Motor Imagery training|For the purposes of this study we adapted an available BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback and a screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. This software allows the therapists to create an artificial reproduction of patient's hands/forearms by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hands/forearms. Training consists of the MI tasks of both hands, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
214326258|NCT05637775|OTHER|Control - MI intervention|Training consists of MI tasks of both hands, grasping or finger extension in separate runs. MI training will be delivered with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
214927550|NCT01068067|OTHER|drug (tacrolimus and SchE) and genetics|Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.
214347596|NCT05626361|OTHER|Dysphagia training|Training using PowerPoint and simulation. Training includes anatomy physiology, screening and management sections. Simulation will be used for practice. Reading material will also be provided
214326259|NCT07085195|GENETIC|gene therapy|Six participants are planned to be divided into three dose groups in the dose escalation principle. The dose escalation principle is as follows: After the first sentinel subject receives 1×10¹² vg virus vectors, the research team will evaluate the safety, tolerability, and efficacy of the current drug dose after 4 weeks. If this sentinel does not experience dose-limiting toxicity, another sentinel subject will receive a 2×10¹² vg dose; if this sentinel develops dose-limiting toxicity (DLT), this dose will be defined as an intolerable dose, and the Data Review Committee will determine whether to select a lower dose for exploration or terminate dose escalation based on the existing data. If this sentinel subject doesn't experience dose-limiting toxicity, another participant will receive a 4×10¹² vg dose as a new sentinel subject. If this sentinel subject doesn't experience DLT, all of the next three subjects will receive a 4×10¹² vg dose.
214326260|NCT07085195|DRUG|clozapine|Clozapine ramp-up will be performed four weeks after neurosurgery, when the participants have recovered, and the participants will be treated orally with clozapine. Clozapine is 25mg per tablet, and the oral dose is 1/32, 1/16, and 1/8 tablet twice a day, in the morning and at noon, respectively, with each dose repeated for 3 days for a total of 9 days. If no DLT develops during this time, the participants will continue to take 1/8 pill orally twice a day as a maintenance dose, and they will be monitored for 12 months.
214326261|NCT07086924|DRUG|Methotrexate|Assessing the response of psoriasis and psoriatic arthritis to Methotrexate. and also Assessing the pharmacogenetic association between TRAF3IP2 ( rs13190932 ) gene Polymorphism in psoriatic and psoriatic arthritis patients taking Methotrexate.
214326262|NCT07085936|BEHAVIORAL|Video-based orientation program|The intervention group will receive a structured video-based orientation program developed for first-degree relatives of psychiatric inpatients. The program consists of four sessions (each 45-60 minutes) delivered over one week by psychiatric nurses. Topics include an introduction to the psychiatric unit, understanding stigma, basic information on mental illnesses, and strategies for coping with stigma. Educational videos support learning and discussion. Unlike the control group, this intervention emphasizes stigma awareness and emotional support. Pre- and post-tests are used to assess perceived stress and stigma.
214927551|NCT01068067|DRUG|tacrolimus|After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
214927552|NCT04287946|DEVICE|Ablation|Ablation of a single-side of the greater splanchnic nerve
214927553|NCT01280032|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
214927554|NCT06682676|DEVICE|Nasal ventilation function test and cold and dry air nasal provocation test|The visual analogue scale (VAS) of nasal symptoms, rhinoconjunctivitis quality of life questionnaire (RQLQ), total nasal symptom score (TNSS), total nasal volume (TNV), minimum cross-sectional area (MCA), peak inspiratory flow (PNIF), and total nasal resistance (TNR) at 75Pa were recorded before and after nasal ventilation function test and CDA nasal provocation test.
214927555|NCT06188455|DRUG|Fluzoparib Capsules|Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily
214927556|NCT06188455|DRUG|Apatinib Mesylate Tablets|Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)
214927557|NCT03687398|DIAGNOSTIC_TEST|genetic testing with nanoclonal technique|endometrial sampling
214927558|NCT02255305|BIOLOGICAL|FMT|Patients in the FMT group will receive \~50 grams of fecal material suspended in bacteriostatic normal saline and glycerol.
214927559|NCT02255305|DRUG|Antimicrobials|Patients randomized to the control group will receive antimicrobials targeting C. difficile.
214927560|NCT02330367|DRUG|AC0010|"Phase 1: AC0010 will be administered in escalating dosages in a period of 28-day cycles.~Phase 2: AC0010 will be administered twice-daily at RP2D."
214927561|NCT00172601|PROCEDURE|mobilization|
215069462|NCT06242847|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|Participants ingest 75 g of glucose in 10 fl oz aqueous solution (fruit flavored) after an overnight fast. Blood is drawn at baseline (t = 0 min) and at 120 min after ingestion. This test is non-experimental.
214927562|NCT06137573|DRUG|[14C]TNP-2198|600mg suspension containing 150μCi of \[14C\] TNP-2198
214927563|NCT06598592|OTHER|Video-Emergency|Video Emergency Call using a webbased platform
214927564|NCT06598592|OTHER|Audio-Emergency Call|Audio Emergency Call
214927565|NCT01640379|BEHAVIORAL|Technology Enhanced Community Health Nursing|"* Text-messaging (twice daily medication reminders w/ positive adherence messages, positive sexual health messages throughout the 30 day treatment period)~* Enhanced community health nursing visit on day 3-5, includes evidence-based STI/HIV prevention component (Sister to Sister Teen)"
214927566|NCT05263856|DEVICE|laser acupuncture|The parameter setting of 810nm wavelength laser acupuncture device in 1) ear were irradiated with a 4mm probe, adjusted to Nogier A frequency for acute treatment, and the pulsed mode was irradiated with an emission frequency of 200mW for 10seconds, each acupoint provided 1 joule of energy with total of 12joules,and 2) myofascial trigger point were irradiated with a 10mm probe, adjusted to Nogier C frequency for muscle treatment, and the pulsed mode was irradiated with an emission frequency of 500mW for 20 seconds, each acupoint provided 5 joule of energy with total of 50 joules, providing a total of 62 joules of one intervention session.
214927567|NCT02114450|BEHAVIORAL|Robot-assisted training with the H2 lower limb powered exoskeleton|The H2 is a powered, robotic lower limb exoskeleton with actuated hips, knees and ankles. A custom control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
214927568|NCT02114450|BEHAVIORAL|Supervised motor practice|Supervised motor practice involves lower limb rehabilitation, primarily walking and other applicable lower limb exercises performed by participants under the guidance and supervision of a research physical therapist.
214927569|NCT03395184|DRUG|PF-06651600 Placebo|12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks
214927570|NCT03395184|DRUG|PF-06651600|200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
215069463|NCT06242847|PROCEDURE|Skin punch biopsy|Punch biopsies are taken from lesional (psoriatic) and non-lesional skin after an overnight fast and at 120 min after ingestion of glucose during OGTT. This procedure is non-experimental.
215069464|NCT05229263|DIAGNOSTIC_TEST|Non- contrast Enhanced Multiparametric Renal Magnetic Resonance|MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
214326263|NCT07085520|DRUG|Microneedle with 0.24mg Denosumab|This intervention uses microneedle patches loaded with 0.24mg of denosumab. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It aims to evaluate the skin safety and tolerability of the microneedle patch at this specific dose. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
214927571|NCT03395184|DRUG|Placebo PF-06700841|12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks
214927572|NCT03395184|DRUG|PF-06700841|60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
214927573|NCT03207464|DRUG|[C-11]Methylreboxetine|8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a \[C-11\]MRB PET scan and a MRI scan.
214927574|NCT05404256|OTHER|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface
214927575|NCT05404256|OTHER|Radical gastrectomy +D2 lymphadenectomy|Radical gastrectomy +D2 lymphadenectomy
214927576|NCT01868698|OTHER|high-voltage electrical stimulation|
215069465|NCT06025734|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS) treatment|Spina Bifida pediatric patients with neurogenic bladder will be in Transcutaneous Tibial Nerve Stimulation (TTNS) treatment. Patient will complete 6 weeks of 30 minute treatment sessions (these can be done at home after the first teaching session)
215069466|NCT05978102|DRUG|STI-7349|Administered by intravenous infusion (IV)
215069467|NCT05978102|DRUG|Pembrolizumab|Administered by intravenous infusion (IV)
215069468|NCT05978102|DRUG|Standard treatment（SoC）|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.
214326264|NCT07085520|DRUG|Saline Microneedle Patch|This intervention involves the use of a microneedle patch loaded with saline. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It serves as a control to assess the skin safety of the microneedle patch without the active drug. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
214326265|NCT07085520|DRUG|Microneedle with 1.2mg Denosumab|This intervention uses microneedle patches loaded with 1.2mg of denosumab. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It aims to evaluate the skin safety and tolerability of the microneedle patch at this specific dose. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
214326266|NCT07085520|DRUG|Microneedle with 6mg Denosumab|This intervention uses microneedle patches loaded with 6mg of denosumab. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It aims to evaluate the skin safety and tolerability of the microneedle patch at this specific dose. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
214326267|NCT07086365|DEVICE|Immersive virtual reality|Virtual reality with hand tracking and immersive environment
214326268|NCT07086365|DEVICE|Immersive Virtual Reality|Immersive virtual reality is a digital therapeutic approach to enhance neuroplasticity using virtual environment and hand tracking for functional motion in upper extremity
214326269|NCT06619379|OTHER|Retention time of speculum|"According to the randomization, the speculum can be extracted :~1. just after the transfer catheter is withdrawn~2. 60 seconds after the transfer catheter is withdrawn~3. 420 second (7 minutes) after the catheter is withdrawn"
214326270|NCT06906614|BEHAVIORAL|Simulation-Based Communication Training|"In our study, the intervention is more of an experimental situation - a scenario.~High-fidelity scenarios include patients played by real actors displaying anxiety, aggression, silence, and emotional distress in various clinical situations such as delivering serious news or frustration for waiting for physicians. The average time of each simulation is 12 minutes."
214326271|NCT06902779|OTHER|Support of the hospital pharmacist for the medication management at hospital discharge|1\) The hospital pharmacist calls the community pharmacy the day before discharge to order unusual or specific medications 2) The day of discharge, the hospital pharmacist performs a medication reconciliation in collaboration with the hospital physician 3) Once completed, the discharge prescription is sent to the community pharmacy before the patient is discharged. 4) The hospital pharmacist calls the community pharmacy to provide additional information about the patient and the prescription and to answer any questions. Additional information will help the community pharmacist to understand the prescription : administrative data, clinical data, medication-related information, patient follow-up and patient concerns.
214326272|NCT07092150|OTHER|School meals|Daily mid-day meals sourced locally and supplemented by school gardens.
214927577|NCT01868698|OTHER|Kinesiotherapy|
214927578|NCT01868698|OTHER|shortwave diathermy|
214927579|NCT06925464|DRUG|CD7 CAR-T cells infusion|Approximately 3-5 days prior to CD7 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
214673083|NCT01863862|RADIATION|Radiochemotherapy or radiotherapy|"50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision."
214673084|NCT04387474|DEVICE|Brain-computer interface|brain-computer interface rehabilitation training.
214326273|NCT07092150|OTHER|School gardens|A school vegetable garden to grow green leafy vegetables on school grounds.
214326274|NCT07092150|DIETARY_SUPPLEMENT|IFA and Deworming|Weekly iron and folic acid supplements and annual deworming.
214673085|NCT04387474|OTHER|Traditional rehabilitation|traditional rehabilitation training.
214673086|NCT04710940|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
214673087|NCT04710940|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
214673088|NCT00000681|DRUG|Bleomycin sulfate|
214673089|NCT00000681|DRUG|Vincristine sulfate|
214673090|NCT00000681|DRUG|Doxorubicin hydrochloride|
214326275|NCT07092150|BEHAVIORAL|Nutrition education|Nutrition education, led by trained teachers, that will cover health, agriculture, and WASH topics.
214326276|NCT07092150|BEHAVIORAL|Women's workshops|Community workshops that will engage mothers or female guardians in gardening, nutrition, and entrepreneurship, offering support and training for small businesses and homestead gardens.
214673091|NCT00000681|DRUG|Zidovudine|
214673092|NCT00000681|DRUG|Sargramostim|
214673093|NCT02226510|DRUG|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
214486161|NCT06882395|DEVICE|Group 2: FLX aligners worn for 7 days, followed by FLX35 aligners for 3 days.|Group 2: FLX aligners for 7 days, followed by FLX35 aligners for 3 days.
214486162|NCT06881732|BIOLOGICAL|NF54/iGP3|Mosquito-generated sporozoites of the genetically modified, inducible gametocyte-producing parasite line NF54/iGP3, created via CRISPR/Cas9 genetic engineering of the parental wildtype strain Plasmodium falciparum (Pf) NF54 to contain a trimethoprim (TMP)-inducible copy of the Pf gdv1 gene in the dispensable Pf cg6 locus.
214486163|NCT06882213|OTHER|transcranial direct current stimulation|transcranial direct current stimulation
214486164|NCT06882213|OTHER|core stability exercise.|core stability exercise.
214486165|NCT06886035|DRUG|liposomal curcumin|The study group began a regimen of 100 mg oral liposomal curcumin (administered as 50 mg twice daily) one day prior to the procedure. Following surgery, oral liposomal curcumin (50 mg twice daily) was restarted 8 hours postoperatively and maintained for an additional two days. ( A total dose 300 mg)
214673094|NCT02226510|DRUG|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
214673095|NCT01057303|GENETIC|RNA analysis|
214673096|NCT01057303|GENETIC|gene expression analysis|
214673097|NCT01057303|GENETIC|reverse transcriptase-polymerase chain reaction|
214673098|NCT01057303|OTHER|laboratory biomarker analysis|
214673099|NCT01145391|OTHER|Active Outreach to Patients and Providers|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
214673100|NCT04606511|DIAGNOSTIC_TEST|Circumference tape measurements|centimeter and volume criterias
214673101|NCT04606511|DIAGNOSTIC_TEST|Indocyanine green lymphangiography|Presence of dermal backflow
214673102|NCT04606511|DIAGNOSTIC_TEST|bioimpedance spectroscopy|7.5 and 10 L-DEX criterias
214673103|NCT04606511|DIAGNOSTIC_TEST|Symptom score|using lymph-icf, DASH and SF-36 questionnaires
214927580|NCT06904807|DRUG|LIFE-001|Single dose of LIFE-001 between 10mg and 300mg administered subcutaneously
214927581|NCT06904807|DRUG|Placebo|Single dose of placebo comparator administered subcutaneously
214927582|NCT06904807|DRUG|LIFE-001|Four doses of LIFE-001 between 50mg and 300mg administered subcutaneously seven days apart
214927583|NCT06904807|DRUG|Placebo|Four doses of placebo comparator administered subcutaneously seven days apart
214927584|NCT06841419|PROCEDURE|surgical reconstruction of a soft tissue defects by a pedicled flap|harvesting of a fasciocutaneous flap from the anterolateral aspect of thigh based on a perforators from the descending branch of lateral femoral circumflex artery to reconstruct a neighboring soft tissue defect.
214927585|NCT05608291|DRUG|Fianlimab|Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
214927586|NCT05608291|DRUG|Cemiplimab|Cemiplimab will be administered by IV infusion Q 3 weeks
214927587|NCT05608291|DRUG|Pembrolizumab|Pembrolizumab will be administered by IV infusion Q 3 weeks
214927588|NCT05608291|DRUG|Placebo|Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
214927589|NCT05738551|OTHER|stress ball|Applicable to group 1
214927590|NCT05738551|OTHER|chewing gum|Applicable to group 2
214927591|NCT03677323|DEVICE|Virtual reality|"The patient will have the choice between different environments and the use of this device will remain under the control of the medical team.~The patient will wear the virtual reality device at the time of the completion of the ankle block and will remove it once the nerve puncture is complete."
214927592|NCT03677323|DRUG|Droleptan|Venous administration of 1.25 mg of Droleptan
214673104|NCT02975154|DEVICE|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
214927593|NCT03677323|DRUG|Propofol|Venous administration of 20 mg of Propofol
214673105|NCT05258058|BEHAVIORAL|Memory and Adaptation Training-Geriatrics|MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.
214927594|NCT03677323|DRUG|Sufentanyl|Venous administration of 5 μg of Sufentanyl.
214927595|NCT03692975|OTHER|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
214927596|NCT03692975|OTHER|Neuropsychological evaluation|cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
214927597|NCT03692975|OTHER|Psychological evaluation|included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
214927598|NCT03692975|DEVICE|MRI Evaluation|Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
214927599|NCT02416648|BEHAVIORAL|Clinician Client Centered (CCC) Counseling|"Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action."
214927600|NCT01397786|DRUG|OPC-34712|"Phase A: 1-2 mgs/day by mouth, max of 4 wks.~Phase B: 1-4 mgs/day by mouth, up to 52 weeks"
214927601|NCT05735990|DEVICE|Intraocular lens|Aspheric hydrophilic acrylic IOL for implantation into the capsular bag
214927602|NCT03926390|DIETARY_SUPPLEMENT|Bovine colostrum|bovine colostrum for first 2 weeks
214927603|NCT00784550|DRUG|Tiotropium Bromide|Long-acting muscarinic antagonist
215069469|NCT05978102|DRUG|approved PD-1/PD-L1 inhibitors (e.g., Tislelizumab, etc.)|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines or the corresponding drug Labeling.
214927604|NCT00784550|DRUG|Fluticasone Propionate/Salmeterol|Inhaled corticosteroid plus long-acting bronchodilator
214927605|NCT03711149|OTHER|Activity monitor feedback loop|The intervention arm will test if the feedback system (i.e., activity monitor, real-time feedback, and art tours) increases daily step count, decreases length of stay, and improves patient and provider communication, patient awareness of step count goals, and patient confidence in accomplishment of daily goals.
215069470|NCT05728281|OTHER|Recommended time after hysterectomy|Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.
215069471|NCT03255577|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
215069472|NCT01766349|BEHAVIORAL|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
215069473|NCT03165123|DRUG|Oral Azithromycin tablet|Oral azithromycin tablet will be given one hour before induction of anaesthesia.
214326277|NCT07090018|BEHAVIORAL|Empowered Relief|The participants will attend a pain relief skills intervention (Empowered Relief). The two-hour session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
215069474|NCT03165123|DRUG|Intravenous dexamethasone|5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
215069475|NCT05889442|DRUG|Levcromakalim|Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
215069476|NCT05889442|OTHER|Placebo|Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
215069477|NCT03724981|DRUG|Dulaglutide Pen|Injected on a practice pad.
215069478|NCT03724981|DRUG|Semaglutide Pen|Injected on a practice pad.
214326278|NCT05416489|DEVICE|C-MAC videolayngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscopy.
214326279|NCT05416489|DEVICE|Laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a laryngoscopy
214326280|NCT07093489|BIOLOGICAL|LC16m8|LC16m8 vaccine will be offered to all individuals aged \>1 year and meet the inclusion criteria within the catchment population. This will be done in line with the DRC government's LC16m8 vaccine roll out plan.
214326281|NCT06909045|OTHER|Adaptive DBS|The Medtronic Percept device will be activated with the aDBS functionality. Participant will receive adaptive DBS.
214326282|NCT06909045|OTHER|Continue DBS|The Medtronic Percept device will be equipped with aDBS functionality (to maintain the blinding of the allocation), but this functionality will remain inactive. Participant will receive continue DBS.
214326283|NCT06903754|DRUG|With ISGLT2|Patients for whom we will prescribe ISGLT2
215069479|NCT03727022|DRUG|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
215069480|NCT03727022|DRUG|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
214347597|NCT05626361|OTHER|Reading material|Reading material provided to nurses covering knowledge related to nursing evaluation and caring for dysphagia patients
214927606|NCT00772824|DIETARY_SUPPLEMENT|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
214927607|NCT00772824|DIETARY_SUPPLEMENT|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
214927608|NCT04796883|DEVICE|Hanita Glaucoma shunt Ver.3.2|The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.
214927609|NCT02425761|PROCEDURE|Ventriculoperitoneal shunt insertion surgery|The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
214927610|NCT05705115|DRUG|Ringer acetate|Ringer acetate 5 ml/kg.
214927611|NCT05705115|OTHER|Lower body negative pressure|Lower body negative pressure, 40 mmHg. Experimental hypovolemia.
214927612|NCT04900844|DEVICE|CGuard Carotid Stent implantation|Implantation of CGuard carotid stent in the eligible patients
214927613|NCT04822636|BEHAVIORAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
214927614|NCT05987553|OTHER|e-learning program|All participants participate in this intervention: an e-learning program about the recognition of actinic keratosis. The program exists of 30 cases. Each case exists of a question and thorough explanation including references to various sources.
214927615|NCT02221700|PROCEDURE|Massage Therapy|Undergo massage therapy
214927616|NCT02221700|OTHER|Quality-of-Life Assessment|Ancillary studies
214927617|NCT02221700|OTHER|Questionnaire Administration|Ancillary studies
214927618|NCT05839847|DEVICE|Low-intensity focused ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can reduce reactions to sensory stimuli.
214927619|NCT05839847|DEVICE|Low-intensity focused ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
214927620|NCT05608369|DRUG|Cisplatin|Cisplatin100 mg/m2 every 3 weeks or 40 mg/m2 weekly
214927621|NCT05608369|RADIATION|Radiation therapy|Radiation therapy (70 Gy) for total of 7 weeks
214927622|NCT05608369|DRUG|Vorinostat|Pre-treatment; 300 mg every other day and ends with the dose closest to the last fraction of radiation (total of 8 weeks)
214927623|NCT03582800|DRUG|STS|"M0-M6 (run-in phase): medical care and follow-up as usual~M6-M12 (STS phase):~* Patients with iPPSD2 will be treated with subcutaneous infusion using a portable pump.~* Patients with dermatomyositis or systemic sclerosis will be treated with repeated injections every two weeks.~Patients will receive a maximal total number of 11 STS injections. M12: final visit (V5): clinical evaluation, photograph and CT scan of the treated lesion, pain and quality of life evaluation."
214486166|NCT06725693|DIAGNOSTIC_TEST|18F/68Ga-Exendin 4|Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.
214486167|NCT06727409|DRUG|Finerenone|Finerenone 10mg or 20 mg as tolerated on top of maximal tolerated RASi and stable SGLT2i therapy
214486168|NCT07038109|OTHER|Progressive relaxation exercise|The intervention was based on Jacobson's Progressive Muscle Relaxation (PMR) technique. Participants in the experimental group practiced PMR three times per week for four weeks. Each session lasted approximately 45 minutes and was conducted in a quiet environment. In the first session, the researcher provided face-to-face instruction. Subsequent sessions were guided by standardized audio recordings, and the participants were followed through scheduled online video calls. The intervention aimed to reduce depression, anxiety, and stress symptoms and to promote biopsychosocial well-being in nursing students.
214486169|NCT06729723|DEVICE|SAT-001|SAT-001 Treatment Group Participants in this group will use the SAT-001 device for 30 minutes. Before and after using the device, choroidal thickness will be measured using Optical Coherence Tomography (OCT) to assess changes in choroidal thickness.
214927624|NCT03665675|BIOLOGICAL|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given intravenously
214927625|NCT03665675|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given intravenously
214927626|NCT04270864|DRUG|Ipilimumab|20mg (4mL) IT
214927627|NCT04270864|DRUG|Nivolumab|360mg IV then 480mg IV
214927628|NCT04270864|DRUG|Tilsotolimod|8 mg (2mL) IT
214927629|NCT01098656|DRUG|lenalidomide|"The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.~Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)"
214927630|NCT05094765|BIOLOGICAL|FMT|Fecal Microbiota Transplantation
214927631|NCT00688701|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214927632|NCT00688701|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214927633|NCT00688701|DEVICE|Pen auto-injector|
214927634|NCT02195622|DEVICE|Lumenis VersaCut Morcellator|
214927635|NCT02195622|DEVICE|Wolf Piranha Morcellator|
214927636|NCT00743730|OTHER|Pain and standard side effect management for PNCA with basal method.|"Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
214326284|NCT07096102|BEHAVIORAL|ENRICH Group|Participants will undertake a six-week programme to enhance their health information literacy. The specific details are as follows: (1) Capacity Building on Health Information Management via Health Education Based on the Health Empowerment Theory:①Strengthening skills related to Health Information Literacy; ②Training on Medication Management Skills;③ Practice of Self-Monitoring Skills;④Education on Diet and Exercise Management Knowledge. (2) Health Behavior Motivation Management Based on the Health Empowerment Theory:① Personalized Goal Setting;②Behavioral Incentives and Feedback;③Construction of Peer Support Networks;④Demonstration Effect of Role Models. (3) Health Management Support System Based on the Health Empowerment Theory:①Online Dynamic Monitoring;②Family-Community Collaborative Support;③Digital Monitoring Platform;④Continuous Supply of Resources.
214927637|NCT00743730|OTHER|Pain and standard side effect management with PNCA without basal|"Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
214927638|NCT00743730|OTHER|Pain and standard side effect management with IV on an as needed basis method.|"Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol."
214927639|NCT00095641|DRUG|capecitabine|
214927640|NCT00095641|PROCEDURE|adjuvant therapy|
214927641|NCT00095641|PROCEDURE|chemotherapy|
214927642|NCT04183738|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
214927643|NCT04183738|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
214927644|NCT04183738|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
214927645|NCT04183738|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
214927646|NCT04596709|DIETARY_SUPPLEMENT|Vitalose|dissolved in water
214927647|NCT04596709|DIETARY_SUPPLEMENT|isomaltulose|dissolved in water
214927648|NCT04596709|DIETARY_SUPPLEMENT|sucrose|dissolved in water
214927649|NCT04596709|DIETARY_SUPPLEMENT|glucose|dissolved in water
214927650|NCT03410407|OTHER|Observation of CNS involvement|AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
215069481|NCT04796103|PROCEDURE|Dextrose Prolotherapy|In the patients in the prolotherapy injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of 5% dextrose, 1 ml each, will be applied periarticularly. In addition, home exercise program will be given to this group.
214927651|NCT06032052|DRUG|Single drug chemotherapy plus immunotherapy|The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on
214927652|NCT06640985|DEVICE|EDX110 wound dressing system|EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement
214927653|NCT00283855|BEHAVIORAL|Online Self-Management|Online Self-Management
214927654|NCT00102648|DRUG|Lonafarnib|Given PO
214927655|NCT00102648|DRUG|Temozolomide|Given PO
214927656|NCT06623825|DEVICE|teleconsultation by Augmented Reality smart glasses|The device operated on Android 9.0 and it connected to 5G connection with a bandwidth speed 30-mbps delivering a very low latency. The device supported real time screen sharing and therefore the data were collected from smart glasses including visual and audio with real-time two-way communications. Physicians at the hospital can access the information and video via a mobile app, enabling continuous monitoring of patients. The features facilitate healthcare providers at SRRSH and medical personnel in the HAG2022 polyclinic to discuss the patient's condition, exchange, and deliberate on the pre-hospital medical examinations of the patient.
214927657|NCT06623825|DEVICE|teleconsultation by two-way radio connection.|adhering to the standard conventional triage process without the AR tool, only using a two-way radio connection.
214927658|NCT04649736|OTHER|Respiratory and psychological rehabilitation|"Respiratory rehabilitation consists of 12 sessions of respiratory and physical exercises that patients perform at home with the help of a physiotherapist. Sessions have 1 hour of duration and are performing twice a week. Exercises include (1) Training of the respiratory muscles through pursed-lip breaths. (2) Effective cough exercises. (3) Diaphragmatic contractions in a supine position with a lightweight placed on the anterior abdominal wall. (4) Stretching exercise of extremities and the back.~The psychological support consists of 1 session to make the psychological history of the participant, and 6 sessions of emotion-centered problem-solving therapy, with cognitive-behavioral components and psychological management of emergencies and crises. These sessions have a 1-hour duration and are telephone-provided once a week by psychologists following the guidelines of the Inter-Agency Standing Committee on Mental Health and Psychosocial Support in Humanitarian and Disaster Emergencies."
215069482|NCT04796103|PROCEDURE|Serum Physiological Group (placebo control group)|In the patients in serum physiological injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of saline will be applied periarticularly. In addition, home exercise program will be given to this group.
214927659|NCT01393509|DRUG|PU-H71|PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
214927660|NCT05018767|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214927661|NCT05279729|OTHER|Mobile health application|Intervention will be with two different mobile health (mHealth) applications, Weight Watchers and Healthi app (formerly iTrackBites)
214927662|NCT04097795|OTHER|Prehabilitation|According to our definition, prehabilitation consists of exercise therapy during at least 2 weeks. This is combined with optimalisation of the patients' nutritional status at least 2 weeks before surgery.
214927663|NCT05887271|DRUG|Low calorie meal replacement plan|Meal replacement diet containing \~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
214927664|NCT05887271|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
214927665|NCT05887271|DIAGNOSTIC_TEST|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function
214927666|NCT05887271|DIAGNOSTIC_TEST|Blood test|Collection of blood samples from each participant to characterise the participant's health status and fibroinflammatory markers.
214927667|NCT05887271|DIAGNOSTIC_TEST|Electrocardiogram|An ECG will be obtained to assess for baseline rhythm.
214927668|NCT05887271|DIAGNOSTIC_TEST|Accelerometery|Accelerometer (GeneActiv) measured daily activity levels continuously for 7 consecutive days.
214927669|NCT05887271|DIAGNOSTIC_TEST|6 minute walk test (6MWT)|Supervised 6MWT will be performed with symptom assessment using dyspnoea scale (Borg's).
214927670|NCT05887271|DIAGNOSTIC_TEST|Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)|Skeletal muscle strength will be measured using a cybex dynamometer.
214927671|NCT05887271|OTHER|Assessment of quality of life and heart failure symptoms|Quality of life and HF symptoms will be assessed using the Minnesota Living with Heart Failure (MLWHF) questionnaire, which is used as a standardised measure of self-reported health status, and HF symptoms and is considered to have a good discriminatory power and validity
214927672|NCT05887271|OTHER|Assessment of sarcopenia|Participants will be assessed for presence of sarcopenia using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire. It is a robust tool for diagnosis of sarcopenia and prediction poor physical function, with excellent specificity in multimorbid individuals.
214927673|NCT05887271|OTHER|Assessment of frailty|Frailty will be assessed using the Edmonton Frail Scale (EFS). The EFS is a multidimensional frailty assessment which assesses multiple domains of frailty including functional independence, social support, cognition, medication use, and mood.
214927674|NCT05887271|OTHER|Qualitative interview|Participants in the MRP and control groups will be invited to attend a focused semi-structured, 1-2-1 interview aimed to elicit barriers and enablers to the MRP and describe their perspective on the relationship between healthy eating and health interview during the 12-week visit. Participants who complete or drop out will be eligible. Inclusion of participants in the control arm will allow us to compare the experiences of MRP versus health coaching and detect any specific issues people face when trying to introduce lifestyle changes themselves.
215069483|NCT00434603|BEHAVIORAL|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
215069484|NCT04736368|OTHER|EDIP Diet Suggestions|CD participants will receive EDIP diet suggestions after random allocation.
214486170|NCT06729723|DEVICE|modified SAT-001|"mSAT-001 Treatment Group Participants in this group will use the modified SAT-001 (mSAT-001) device for 15 minutes. Similar to the SAT-001 group, choroidal thickness will be measured using Optical Coherence Tomography (OCT) before and after device usage.~This protocol will help evaluate the effect of the SAT-001 and modified device on choroidal thickness, with measurements taken before and after each usage."
214486171|NCT06883812|DEVICE|CGM|The CGM sensor is worn on the back of the arm and glucose levels are recorded continuously but levels are not shown on the participant's phone app in phase A.
215069485|NCT04736368|OTHER|diet guidance|Control group will be given diet guidance according to routine experience under the participant's request.
215069486|NCT01360372|DRUG|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
215069487|NCT01360372|DRUG|Saline injection|Saline 0.4 to 0.8 ml injection
215069488|NCT02108717|DEVICE|Remote CT reading using the iPhone|
214326285|NCT07096102|BEHAVIORAL|Routine Care Group|①Distribute 3-5 push publics on screening health information and health disinformation in the first week；②Distribute 3-5 push publics on medicine knowledge in the second week；③Distribute 3-5 push publics on self-monitoring knowledge in the third week；④Distribute 3-5 publics on exercise knowledge in week 4；⑤Distribute 3-5 push publics on dietary knowledge in week 5 and week 6.
214927675|NCT05887271|DIAGNOSTIC_TEST|Skeletal muscle magnetic resonance spectroscopy|Assessment of skeletal muscle volume (quadriceps and calf muscle) using MRI, and 31P-magnetic resonance spectroscopy (31P-MRS) of the skeletal muscle using fysiometer and during isometric exercise at rest and after 5 minutes of exercise to assess changes in muscle energetics at rest and on exercise.
215069489|NCT02108717|DEVICE|CT reading using LCD monitor|
215069490|NCT00130143|DRUG|Ethyol (Amifostine)|
215069491|NCT01255007|OTHER|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
214326286|NCT06909877|DRUG|HH2853 Tablets|25mg, 100mg and 200 mg BID oral administration
214326287|NCT07096232|DIAGNOSTIC_TEST|Multi-Agent AI Diagnostic Workflow (AEYE)|This intervention consists of an orchestrated diagnostic workflow utilizing multiple specialized artificial intelligence (AI) agents to analyze patient data and ophthalmic imaging for the diagnosis of refractive errors and keratoconus. The workflow, named Automated Evaluation for Your Eye (AEYE), integrates various AI modules designed for data extraction, image interpretation, and decision support. Each patient's clinical information, corneal topography, tomography, and other relevant imaging are processed sequentially through these AI agents, with results synthesized into a diagnostic recommendation. The system operates independently of clinician input, and outputs are blinded prior to comparison with consultant ophthalmologist assessments. The intervention is intended to assess diagnostic accuracy, efficiency, and concordance with expert clinical decision-making.
214326288|NCT07095829|OTHER|No intervention|Evaluation of natural history of the disease
214326292|NCT05054686|OTHER|Stretching and Aerobic Exercise at Clinic|In this group of knee osteoarthritis patients will be applied both stretching and 30 minutes bicycle exercises in the same session, strengthening exercises and 30 minutes walking will be given in seperate days as home program.
214326293|NCT05054686|OTHER|Strenghthening and Aerobic Exercise|In this group of knee osteoarthritis patients will be applied both strengthening and 30 minutes bicycle exercises in the same session, 2 days strecthing exercises and 30 minutes walking will be given in seperate days as home program.
214326294|NCT05054686|OTHER|Strengthening, Stretching and Aerobic Exercises at clinic|In this group of knee osteoarthritis patients will be applied all stretching, strengthening and 30 minutes bicycle exercises in the same session, only 30 minutes walking will be given as home program.
214326295|NCT05645432|DRUG|Brexanolone|Brexanolone IV infusion
215069492|NCT03062553|BEHAVIORAL|Metacognitive Training (MCT)|MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
215069493|NCT03062553|BEHAVIORAL|Sham/MCT|"The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions."
214326296|NCT04708470|DRUG|Bintrafusp Alfa|"Subjects will receive bintrafusp alfa via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. Bintrafusp alfa will be administered as a flat dose of 300 mg independent of body weight. Bintrafusp alfa is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
214326297|NCT04708470|DRUG|PDS01ADC|PDS01ADC will be administered at as dose of 4, 8, 12, or 16.8 micrograms/kg by SC injection every 2 or 4 weeks. The dose of PDS01ADC will be calculated based on the weight of the subject determined within 72 hours prior to the day of drug administration. The dose of PDS01ADC used for the previous administration can be repeated if the change in the subject's weight is 10% or less than the weight used for the last dose calculation.
214326298|NCT04708470|DRUG|Entinostat|The entinostat used in this study is a self-administered investigational agent and will be given orally at a designated dose once a week or as directed. Number of entinostat tablets will be calculated based on the dose for the participant.
214326299|NCT06361095|BEHAVIORAL|Traditional Attention Bias Modification|Each ABM trial begins with a central fixation cross for 1500ms, followed by a pair of POFA or IAPS stimuli (see Figure 3). POFA pairs will be presented for 3000ms, while IAPS pairs will be presented for 4500ms (due to the increased image complexity of IAPS images relative to POFA images). Longer stimulus duration times were selected based on evidence that attention biases for sad stimuli are prolonged in depression. Following offset of the images, either a single or double asterisk probe appears in the location of one of the images and will remain until a participant response or 10,000ms. In active ABM, the probe had an 80% probability of appearing in the location of the neutral stimulus. Investigators selected 80% rather than 100% to allow for computing attention bias during training and to facilitate task engagement. At the end of each ABM session, participants are provided feedback regarding their task performance relative to their last five sessions in a visual format.
214486172|NCT06883812|DEVICE|CGM|The CGM sensor is worn on the back of the arm and glucose levels are recorded continuously with levels shown on the participant's phone app in phase B.
214927676|NCT05533957|OTHER|Application of different dosages of oxygen therapy|To evaluate the response (vasodilation, neuromuscular fatigue and muscle oxygenation) of the administration of different dosages of oxygen therapy (ie. FiO2) in patients with COPD associated with CRF and LTOT
214927677|NCT03122743|PROCEDURE|Biospecimen Collection|Undergo collection of serum samples
214927678|NCT03122743|OTHER|Laboratory Biomarker Analysis|Correlative studies
214927679|NCT03122743|OTHER|Questionnaire Administration|Ancillary studies
214927680|NCT03875092|BIOLOGICAL|Pembrolizumab|IV infusion
214927681|NCT03875092|DRUG|Paclitaxel|IV infusion
214927682|NCT03875092|DRUG|Carboplatin|IV infusion Carboplatin dose should not exceed 900 mg.
214927683|NCT03875092|DRUG|Saline placebo for pembrolizumab|IV infusion
214927684|NCT02444364|DRUG|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
214927685|NCT01048060|PROCEDURE|Bone marrow specimen banking|
214927686|NCT06618508|PROCEDURE|Manual debridement|Traditional technique which consists of scraping off the irregular epithelium to allow a new layer to form.
214927687|NCT06618508|PROCEDURE|Phototherapeutic keratectomy|New technique which has been increasingly used and which consists of a 193nm excimer laser that breaks molecular bonds between cells on the epithelial surface.
214927688|NCT01047826|PROCEDURE|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
214927689|NCT01047826|PROCEDURE|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
214927690|NCT00784238|DRUG|Paliperidone|Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
214927691|NCT01335217|PROCEDURE|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
214927692|NCT03126162|PROCEDURE|InstilIing normal saline into bladder|Backfilling the bladder with 200 mL of normal saline immediately postoperatively, prior to foley catheter removal, after same-day total laparoscopic hysterectomy can potentially increase time to first spontaneous void and time to discharge.
214927693|NCT03126162|PROCEDURE|Removal of foley catheter|Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
214927694|NCT06682585|OTHER|Individualised dietary intervention|"* Energy Intake: Caloric needs will be calculated based on the patient's age, weight, and activity level, taking into account the potential impact of corticosteroid therapy on energy expenditure.~* Protein Intake: Protein requirements will be met through a balanced diet, aiming to optimize muscle protein synthesis.~* Calcium and Vitamin D Intake: Adequate intake of these nutrients will be emphasized to support bone health and prevent osteoporosis.~* Fluid Intake: Fluid intake will be monitored to prevent dehydration and constipation.~* Carbohydrate Intake: A low-glycemic index diet will be recommended to manage blood glucose levels and insulin resistance, especially in patients on corticosteroid therapy.~* Sodium Intake: Sodium intake will be restricted to minimize fluid retention and hypertension."
214927695|NCT00136136|PROCEDURE|Registration of the bispectral index and spectral edge frequency|Registration of the bispectral index and spectral edge frequency
214927696|NCT00476268|DRUG|beclomethasone/formoterol (100/6µg) pMDI|Two puffs b.i.d
214927697|NCT00476268|DRUG|Beclometasone dipropionate 250 µg/unit dose pMDI|2 inhalations bid
214326300|NCT06361095|BEHAVIORAL|Gamified Attention Bias Modification|Each trial consists of the fixation stage, facial cue stage, and response stage. At the fixation stage, an image appears (a colorful medallion) for 500 ms. The fixation appears randomly within a fixed rectangular field on the user's smartphone screen, and is always at the midpoint between the two face cues that will appear in the next stage. Next, after the cue disappears, two animated faces appear on the screen, one happy and one sad, with a 1000ms duration. Immediately after they disappear, a target probe (a trail) appears in the location of the happy face cue. The path remains (up to 3 seconds) until participants respond by tracing it starting from the point at which the face cue disappeared. They are instructed to quickly but accurately trace the path with their finger and receive visual and haptic feedback during tracing to indicate they are tracing accurately, followed by the path disappearing.
214326301|NCT06361095|BEHAVIORAL|Sham Attention Bias Modification|Sham attention bias modification designed to match the active ABM condition in all respects except for the shifting attention away from negative stimuli in active attention bias modification.
214927698|NCT00476268|DRUG|Formoterol powder 12 µg/unit dose|2 inhalations bid
214927699|NCT01214369|PROCEDURE|Type of Supplementary Injection|Patients will be selected from a group who were not anesthetized following 3.6 ml block injection. Half of the randomly selected patients will receive X-tip intraosseous injection and half will receive PDL injection as a supplementary for completing the anesthesia in selected hot mandibular molar teeth.
214927700|NCT04158674|DRUG|Levosimendan|Levosimendan 2.5mg/ml, solution to be diluted for infusion Dilution in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
214927701|NCT04158674|DRUG|Cernevit|mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
214927702|NCT05437874|DRUG|Natural Water|"355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
214927703|NCT02241083|DRUG|Dopamine|
214927704|NCT02241083|DRUG|Norepinephrine|
214927705|NCT02241083|OTHER|no medication|
214927706|NCT05330364|DRUG|Chidamide|Chidamide 30mg/d p.o. begin at day 1, twice per week, during a 28-days cycle.
214927707|NCT05330364|DRUG|Cladribine|Cladribine 5mg/m2/d i.v. d1-5, once per day, during a 28-days cycle.
214927708|NCT00102375|DRUG|Topotecan|
214326302|NCT07107061|OTHER|Pilates exercises plus aerobic exercise|Pilates exercises are characterized as muscle strengthening and stretching, while aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
214927709|NCT02083055|DRUG|Dexmedetomidine|controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
214927710|NCT02083055|DRUG|Nitroglycerin|controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
214927711|NCT03862794|BEHAVIORAL|new social norm feedback letter with bar chart|letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
214927712|NCT03862794|BEHAVIORAL|standard social norm feedback letter|social norm feedback letter used as standard practice, without specific information about the prescribing percentile
214927713|NCT01115920|DRUG|MTP-131 (Bendavia™)|Single 4 hour intravenous infusion
214927714|NCT05595564|DEVICE|Photobiomodulation therapy|A previous application of photobiomodulation therapy was offered or not, for possible performance enhancement.
214927715|NCT01793480|DRUG|Methadone|
214927716|NCT01249924|DEVICE|auto-titrated CPAP|Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
215069494|NCT03062553|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
215069495|NCT05512065|DEVICE|Ultrasound|Ultrasound scan of the right and left uterine arteries and umbilical artery.
214326303|NCT07107061|OTHER|Pilates exercises|Pilates exercises are characterized as muscle strengthening and stretching.
214326304|NCT07107061|OTHER|Aerobic exercise|Aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
214326305|NCT05835921|DEVICE|Virtual Reality|Both groups will receive a Virtual Reality Park experience, which is an empty park with no avatars. Only the experimental group will have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
214326306|NCT07106814|DRUG|Metabolically Armed TIL cells|Each subject receive metabolically armed TIL cells by intravenous infusion.
214326307|NCT07134881|BEHAVIORAL|Careverse|Careverse is a digital psychoeducational website designed to assist caregivers and patients to clarify their values, end-of-life preferences, enable surrogates to further their understanding of the patient's wishes, and prepare surrogates for the role and responsibilities of a medical decision maker. The intervention consists of values elicitation tools, educational materials, and testimonies. The participants will receive guides on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and clinicians.
214326308|NCT07134881|OTHER|Usual Care|Caregivers in the comparator arm will receive a digital version of standard advanced care planning education material prepared by Agency of Integrated Care. The ACP Workbook is created by AIC to help individuals explore their values, care preferences, and end-of-life goals in a structured, reflective way.
214326309|NCT07134725|BIOLOGICAL|SpiN-Tec MCTI UFMG|Chimeric recombinant protein (SpiN) adjuvanted with CTVad1
214326310|NCT07134725|OTHER|Active Comparator: Covishield® vaccine|active comparator using vaccine approved by ANVISA (Brazilian Health Regulatory Agency)
214326311|NCT07134725|OTHER|Active Comparator: Comirnaty® vaccine|active comparator using vaccine approved by ANVISA (Brazilian Health Regulatory Agency)
214326312|NCT07140380|DRUG|IVW-1001 Ophthalmic Eyelid Wipe|Dry eye treatment
214326313|NCT06943521|DRUG|MT-4561|i.v.
214326314|NCT07148986|DIETARY_SUPPLEMENT|Clarity Active Product 1|Participants will use their Clarity Active Product 1 as directed for a period of 6 weeks.
214326315|NCT07148986|DIETARY_SUPPLEMENT|Clarity Product Placebo Control|Participants will use their Clarity Product Placebo Control as directed for a period of 6 weeks.
214927717|NCT01249924|DEVICE|Control|Patients in this group will receive routine care, undergo sleep study on the third postoperative night and be monitored by a pulse oximeter for oxygen saturation level for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
214927718|NCT06317714|OTHER|questionnaires|"o Quality of life questionnaires EORTC QLQC-30 and EQ-5D-5L~° questionnaires NCI- PRO-CTCAE"
214927719|NCT02759055|OTHER|Clinical Decision Support|an EHR-linked, Web-based clinical decision support (CDS) system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke
214927720|NCT00723255|BIOLOGICAL|bevacizumab|Given IV
214927721|NCT00723255|DRUG|temsirolimus|Given IV
214927722|NCT00614523|DRUG|Placebo|Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
214927723|NCT00614523|BIOLOGICAL|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
215069496|NCT03804021|GENETIC|No Intervention|Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)
215069497|NCT04439539|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
215069498|NCT04439539|DRUG|PegIFN-alpha-2a|PegIFN-alpha-2a injection will be administered subcutaneously.
215069499|NCT04439539|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
215069500|NCT04439539|DRUG|Tenofovir alafenamide|Tenofovir alafenamide film-coated tablet will be administered orally.
215069501|NCT04439539|DRUG|JNJ-56136379|JNJ-56136379 will be administered orally.
215069504|NCT05392790|OTHER|Progressive resisted exercise training|Progressive resisted exercises will be started with the 8 maximum repetition test (8 RM) performed at progressive intensities. The subject will perform the 8 RM test at the beginning and the end of each cycle over the two-month training period. Each training session lasts sixty minutes and will be performed three times per week on alternate days.
214326316|NCT07153081|DEVICE|Actigraphy watch intervention|Participants in this group only will be given an Actigraphy watch to track their physical activity levels.
214326317|NCT07163117|OTHER|lumbar stabilization exercises|The participants required to be in a prone position with pillow under abdomen, first raise one leg then the other leg, raise one arm then the other arm, after that raise two legs together, then raise two arms together, raise right arm with left leg then left arm with right leg, then raise both arms and both legs together, every position hold for 20 seconds. Then they required to be in a half kneeling on standing for right leg hold for 20 second and repeat for other leg, do it again but their knees doesn't touch the ground. Finally they required to lie on their backs, and bend their knees at around a 90 degree angle. Place their hands to their sides and their feet flat on the floor at about shoulder width and asked to raise their hips off the floor, hold 20 second.
214326318|NCT07163117|OTHER|endurance training|"1. Back extensor endurance training exercise:~   The participants lay prone over the end of a treatment table with the anterior superior iliac spine supported on the bench edge. Their ankles were fixed by the researcher. They maintained the horizontal position for as long as possible, beginning timing when the horizontal unsupported position was achieved and ending when they dropped below the horizontal plane. The duration of holding was measured in seconds.~2. Back flexor endurance training exercise:~The participants asked to sit on the table with your arms crossed against their chest and their back against the wedge. Fix them to the table with a belt across the feet. They asked to remove the wedge from their back using the timing device to record how much time is accumulated until the original position can no longer be maintained."
214326319|NCT07163117|OTHER|Home based program|General and similar exercises for back muscles introduced for this group. They instructed to do knee to chest stretch, lower back rotational stretch, bridge exercise. The required measure data were obtained from the selected cases in this group before and after the end of rehabilitation program.
214326320|NCT07168863|DEVICE|EUS-guided FNB|EUS-guided FNB from the lesions in the pancreatobiliary tract
214326321|NCT07163429|DRUG|Flurbiprofen 8.75 MG|Topical administration of flurbiprofen 8.75 mg spray applied directly to the tracheal and bronchial cuffs of the double-lumen endobronchial tube before intubation. A total of three sprays will be applied: one spray to the bronchial cuff and two sprays to the tracheal cuff, immediately before intubation.
214326322|NCT07163429|DRUG|Saline spray|Topical administration of placebo spray (0.9% normal saline) applied in the same manner as the active intervention, with one spray to the bronchial cuff and two sprays to the tracheal cuff of the double-lumen tube before intubation.
214326323|NCT07172802|DRUG|GI-108|Dose level will be escalated from 0.1mg/kg to 0.6 mg/kg and Recommended phase 2 dose (or RP2D) of GI-108 will be administered via IV infusion Q3W upto 2 years (approximately 35 years)
214326324|NCT07173582|DIAGNOSTIC_TEST|Serum samples will be collected at the time of registry enrollment, MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays.|"All patients will be subjected to:~A- Complete medical history:~including demographic data (age, sex, disease duration, morning stiffness, joint involvement, smoking, habits of medical importance), articular and extra articular manifestations. Detailed respiratory manifestations.~B- Clinical examination:~* General and local rheumatologic examination.~* Local chest examination (inspection, palpation, percussion, auscultation).~* Assessment of RA disease activity using DAS 28 ESR.~C- Laboratory investigations:~CBC, C-reactive protein, erythrocyte sedimentation rate, antibody status.~D- Radiology and PFT:~PFTs and HRCT chest patterns will be done for patients.~E- MMP measurement:~MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays.~F. The capillaroscopy procedure"
214673106|NCT03715543|PROCEDURE|Surgical Resection of the Greater Splanchnic Nerve|"Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated."
214927724|NCT04594226|PROCEDURE|EA combined with medication|"Primary acupoints include Ashi points, Jiaji acupoints and Xi-cleft points. Jiaji points on the ipsilateral side will be selected according to the corresponding ganglia involved by HZ. Xi-cleft points will be selected based on the distribution regions of PHN. For pain sites that mainly distributed in the gallbladder meridian, GB36 will be selected. For pain sites that mainly distributed in the stomach meridian, ST34 will be selected. For pain sites that mainly distributed in the gallbladder meridian, BL63 will be selected. For pain sites that mainly distributed in the large intestine meridian, LI7 will be selected. Supplementary acupoints will be chosen based on TCM syndrome differentiation.~Operation: Two paired of acupoints are connected to the EA apparatus. EA parameter is selected as 2/100Hz wave. EA intensity is selected according to the patients' endurance. Needles will be retained and EA will last for 30 mins for each session."
214927725|NCT04594226|DRUG|Medication|The dosage of gabapentin starts from 100mg Tid. 100mg-300mg can be increased every 3-7 days and taken in three doses, but the total amount is not more than 1800mg/day. The dosage of gabapentin will be adjusted according to the patient's condition until his pain is effectively controlled. After maintaining the medication for two weeks, the dosage can be gradually reduced and 100mg can be reduced every 3-7 days.
215069505|NCT05392790|DRUG|Calcium and Vit D|Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
214326325|NCT07173088|OTHER|Ankle Muscle Power (AMP) program|The AMP program targets various aspects of muscle power development through a program that takes the participant through 3 different stages of training over the course of their rehabilitation. This portion of the program is in addition to receiving standard rehabilitation exercises as well.
214326326|NCT07173088|BEHAVIORAL|Standard of Care|Standard rehabilitation program
214326327|NCT07173699|PROCEDURE|root canal treatment|Standardized root canal treatment performed on asymptomatic mandibular molars. Procedures include local anesthesia, rubber dam isolation, access cavity preparation, cleaning and shaping with rotary instruments, irrigation with NaOCl and EDTA, and obturation using a standardized protocol. Saliva samples are collected prior to treatment for melatonin analysis. Postoperative pain and sleep quality are assessed using validated questionnaires.
214927726|NCT06623812|OTHER|Behavioral: Post- meal satiety and subsequent ad-libitum meal energy intake|Investigate differences in post meal satiety and subsequent post meal energy intake after consuming fixed portion meals with different protein source and/ or different protein quality
214927727|NCT00776113|DRUG|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol fasting
214927728|NCT00575718|BEHAVIORAL|Hospital Counseling + Nicotine Replacement Therapy. questionaires|"brief face-to-face or telephone tobacco cessation counseling provided by a tobacco cessation specialist prior to admission and during hospitalization (15-20 minutes per encounter)provision of multi-media self-help materials (e.g., Smoking Cessation Guide for Cancer Patients and Their Families) tailored to address cancer-specific issues such as the benefits and barriers of quitting for cancer patients; 3) tobacco cessation pharmacotherapy, unless medically contraindicated (for this study we will standardize the pharmacotherapy as transdermal nicotine patch), and; 4) two brief telephone counseling (15 minutes) sessions completed as seen clinically appropriate by the tobacco cessation specialists. The content of these counseling sessions is based on the patient's smoking status."
214927729|NCT00575718|BEHAVIORAL|Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires|Same components of HC+NRT as well as the PS/SRS enhancement.The research team will provide education about scheduled reduced smoking either in person or over the phone. Purpose of the training session, will be audio taped, to prepare participants for daily PDA use over the dur of the scheduled-reduced smoking intervention. Training will demonstrate use of PDA and simulate common technical and procedural issues that might arise during the intervention (e.g., forgetting to record a cigarette or wake time; repeating a day's schedule if needed, prior to the quit date). The simulation will reflect anticipated problems and those identified by users of the PDA. A study helpline number and instructional manual will be provided. A member of the research staff will contact the study participants, once the reduced smoking schedule has begun, to check that the patient understands the schedule and that the PDA is working properly. Estimate patient training with the PDA will require 30 minutes.
214927730|NCT03635905|DRUG|Gabapentin|Gabapentin (Neurontin®) is FDA-approved for the treatment of post-herpetic neuralgia and seizure disorder. Off-label uses include chronic refractory cough, neuropathy, hot flashes, restless leg syndrome, social anxiety disorder, and post-operative pain
214927731|NCT03635905|DRUG|Placebo|Methylcellulose placebo capsule
214927732|NCT02000336|DRUG|Prednisolone|To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
214927733|NCT02000336|DRUG|Placebo|
214927734|NCT05565001|DRUG|Levcromakalim|Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.
214927735|NCT06342219|BEHAVIORAL|Neurofeedback Mindfulness|The participants will use a portable EEG headband (MUSE) which is a noninvasive tool for collecting EEG data. They will receive real-time EEG data given an audio feedback while doing their daily mindfulness practice.
214927736|NCT06342219|BEHAVIORAL|Attention Task|The participants in this arm will use the portable EEG while listening to an audiobook. They will receive a summary of their brain activities after task completion on each day.
214927737|NCT03310801|PROCEDURE|ACP or Watchman|Left atrial appnedage occlusion using ACP or Watchman
214927738|NCT02130804|DRUG|Salsalate (4 g/day)|Given orally twice daily
214927739|NCT02130804|DRUG|Placebo (4 g/day)|Given orally twice daily
214927740|NCT04220749|RADIATION|Radiation|Standard of Care: Radiation +/- Chemotherapy
214927741|NCT04220749|PROCEDURE|Trans-Oral Surgery (TOS) + Neck Dissection|Trans-Oral Surgery (TOS) + Neck Dissection (plus radiation, if required)
214927742|NCT00109681|DRUG|Iloprost Inhalation Solution (Ventavis)|
214927743|NCT01865201|DRUG|Edaravone|Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
214927744|NCT01865201|OTHER|Common fundamental management|common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
214927745|NCT02339350|DRUG|high dose methotrexate|HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
214326328|NCT07172087|OTHER|Baduanjin for patients with enterostomy|Modified Baduanjin exercise: a standardized, low-to-moderate intensity qigong regimen consisting of eight sequential movements combined with diaphragmatic breathing. The program excludes any additional resistance or aerobic training and is compared with routine walking exercise only.
214326329|NCT07173452|OTHER|vaginal examination|pelvic dimensions measured via vaginal examination.
214326330|NCT07173452|OTHER|physical body measurements|Anthrometric measurements of the participants were made
214326331|NCT07173452|DIAGNOSTIC_TEST|transvaginal ultrasonographic|intrapartum pelvic evaluations were performed by transvaginal ultrasonography
214326332|NCT07172893|BIOLOGICAL|DermaBind TL|Full-Thickness Dehydrated Placental Allograft
214326333|NCT07172971|DRUG|SGLT-2 inhibitor|SGLT-2 inhibitor will be given once daily by mouth
214927746|NCT02339350|DRUG|Intrathecal triple chemotherapy|Intrathecal triple chemotherapy for SEG group instead of radiotherapy
214927747|NCT05743101|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
214927748|NCT05743101|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
214326334|NCT07172971|DRUG|SGLT2 inhibitor|SGLT-2 inhibitor will be given once daily by mouth
214486173|NCT06883825|OTHER|Myofunctional Therapy|Participants will only receive myofunctional rehabilitation therapy. This treatment includes massage and exercises to improve the function of the jaw muscles.
214486174|NCT06883825|OTHER|Myofunctional Therapy + Respiratory Exercises|Participants will receive breathing exercises as well as myofunctional therapy. This treatment includes exercises to improve jaw function and support the respiratory system.
214486175|NCT06883825|OTHER|Myofunctional Therapy + Thoracic Region Exercises|Participants will receive myofunctional therapy as well as exercises for the thoracic region. This treatment includes exercises to improve jaw function and increase the flexibility of the chest area.
214326335|NCT07173881|DIETARY_SUPPLEMENT|Fortified powder milk|Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.
214326336|NCT07173647|DEVICE|Electrical Muscle Stimulation (EMS)|Electrical Muscle Stimulation (EMS) will be applied to the quadriceps muscles of children with cerebral palsy during stationary cycling sessions as part of the Pediatric Endurance and Limb Strengthening (PEDAL) program. EMS will be delivered using clinically approved portable stimulators at parameters appropriate for muscle strengthening and endurance training (frequency 35-50 Hz, pulse width 200-400 μs, duty cycle on/off as tolerated). EMS will be administered simultaneously with cycling to enhance muscle activation and improve motor outcome
214326337|NCT07173647|BEHAVIORAL|Pediatric Endurance and Limb Strengthening (PEDAL) Program|The PEDAL program is a structured exercise intervention designed for children with cerebral palsy. It includes 60-minute sessions of stationary cycling, warm-up, endurance and limb strengthening exercises, and cool-down stretching. Sessions are conducted three times per week for four weeks under therapist supervision. This program is used in both arms of the trial, with or without adjunct Electrical Muscle Stimulation (EMS).
214927749|NCT06459349|OTHER|exteroceptive and proprioceptive sensory stimulation training|Patients in this group will receive intervention exteroceptive and proprioceptive sensory stimulation for 50 minutes per session, 03 times a week, for 06 weeks
214927750|NCT06459349|OTHER|sensorimotor therapy group|Patients will receive sensorimotor therapy for 50 minutes per session, 03 times a week, for 06 weeks
214927751|NCT00063791|DRUG|Bortezomib|
214927752|NCT05742139|OTHER|Non intervention|Non intervention
215069506|NCT05392790|OTHER|Aerobic exercises|Aerobic exercises will be applied at 70 - 80% of their maximum heart rate. Trained health professionals supervised the exercise program. Each exercise session will begin with a 5-10-minute warm-up, will be followed by 20 -30 minutes of aerobic activity, and will be concluded with a 5-10-minute cool-down period.
215069507|NCT00970723|BEHAVIORAL|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
215069508|NCT00970723|BEHAVIORAL|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
215069509|NCT00970723|BEHAVIORAL|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
215069510|NCT00073411|DRUG|duloxetine|
215069511|NCT00073411|DRUG|escitalopram|
215069512|NCT00073411|DRUG|placebo|
215069513|NCT03581149|DRUG|Sodium Picosulfate/Magnesium Citrate Laxative|● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
215069514|NCT03581149|DRUG|2L polyethylene glycol/ascorbic acid|"* First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet."
215069515|NCT05427136|DIAGNOSTIC_TEST|Lung function measurements|"All lung function tests are non-invasive and last about 60 minutes per child:~* Multiple Breath Washout: The nitrogen multiple-breath-washout test (N2MBW) measures ventilation inhomogeneity of the lung that occurs when smaller airways are damaged.~* Spirometry/Bodyplethysmography/DLCO: Spirometry measures dynamic air flows to quantify airway obstruction of large airways and pulmonary restriction. Plethysmography assesses static lung volumes. Diffusing capacity of the lung for carbon monoxide (DLCO) evaluates diffusion deficits."
215069516|NCT05427136|DIAGNOSTIC_TEST|Breath Analysis|Patients will exhale into a secondary electrospray-ionization-mass spectrometry (SESI-MS) breath analysis platform. SESI-MS allows real-time breath-printing by detection of both volatile and non-volatile trace components.
215069517|NCT05427136|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Functional MRI scan assessing regional fractional lung ventilation and relative perfusion, followed by a morphological MRI scan. This technique allows simultaneous assessment of all affected lung components, the airways, alveoli and pulmonary vasculature.
215069518|NCT05427136|OTHER|Standardized interview to assess respiratory symptoms|Short questions on current airway symptoms, recent colds, exercise-related respiratory symptoms, and passive smoking exposure will be assessed. The interview takes about 10 minutes.
215069519|NCT05427136|OTHER|Data collection for assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and HSCT|Assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and hematopoietic stem cell transplantation (HSCT). Data on cumulative doses of pulmotoxic chemotherapy (carmustine, lomustine, busulfan, bleomycin, methotrexate and cyclophosphamide, fludarabine, ifosfamide, melphalan and thiotepa) and radiation therapy at the region of the chest from patient's hospital charts will be collected. Information on chest wall and lung surgery will be retrieved from the surgical reports. Information about conditioning regimens including cumulative chemotherapy doses and total body irradiation of patients undergoing HSCT will be collected. Further information on the health state of the patient and interventions (e.g. development of pneumonia, antibiotic treatment) will be collected from the hospital charts.
215069520|NCT05427136|OTHER|Collection of genetic samples|Germline DNA is collected (e.g. through saliva or buccal cell sampling) for later analysis on genetic risk factors for pulmonary complications.
214326338|NCT07165704|OTHER|Visual arts|The arts intervention will consist of two parts: (a) implementation of one-hour session of Visual Arts (e.g., painting, drawing, printing techniques exercises). The activities will be guided through a theme (Emotions), by a professional artist, to obtain a final individual artistic product. Peer contact, shared learning, and a feeling of community are all made possible by the group-based approach. This facilitator will offer assistance, motivation, and technical training as they lead participants through the creative process. Using narrative-building and dialogue-based methods, the artist will encourage children to share their stories, experiences, and perspectives, through art. (b) Children's final artistic products will be displayed in Community Galleries in their neighbourhood in an opening ceremony.
214326339|NCT07172490|OTHER|APA-FIT interdisciplinary program|"Intervention: APA-FIT~The APA-FIT program is an interdisciplinary intervention targeting three core domains in adults with chronic conditions at moderate or high risk for physical activity (PA): physical exercise, nutritional habits, and positive mental health. Over nine months, participants receive:~* Individualized PA Prescription~  * Bimonthly follow-up visits with a certified PA prescriber (physician, nurse, or physiotherapist)~ * Weekly supervised exercise sessions led by a coach~ * Automated PA logging and goal tracking via the APA-FIT app~* Nutritional Counseling~  * Initial and final dietary assessments with a registered nutritionist~ * Bimonthly follow-up and three hands-on Mediterranean-diet workshops~* Psychosocial Support for Positive Mental Health~  * Four bimonthly group sessions facilitated by the primary-care emotional-well-being lead~ * In-app materials, peer support features, and one-on-one check-ins"
214326340|NCT07172282|DRUG|Nelitolimod|Nelitolimod drug product is a clear to slightly opalescent, colorless to pale yellow solution free of visible particles and is supplied by TriSalus to the study sites in single-use vials. One vial is to be used per patient, and each vial should be discarded immediately after use.
214326341|NCT07172191|BIOLOGICAL|Fecal Microbial Transplantation|The technical implementation of FMT procedure is consistent with the methodological letter issued by the National Public Health Center of Hungary. FMT is performed via nasogastric tube with suspended fresh stool graft obtained from a pre-selected stool donor. Following FMT, the patient is observed for 24 hours at our center. The process is supervised and performed by the lead researcher.
214326342|NCT07172217|DRUG|RC48|Disitamab Vedotin (RC48) : 2.5 mg/kg, administered once every 3 weeks (Q3w), via intravenous infusion on Day 1 of each treatment cycle
214326343|NCT07172217|DRUG|QL1706|Drug: QL1706 Iparomlimab and Tuvonralimab (QL1706) : 5 mg/kg in total, administered once every 3 weeks (Q3w), via intravenous infusion on Day 1 of each treatment cycle
214326344|NCT07173465|DEVICE|Virtual Reality (VR)|Participants will engage in the VR gaming intervention three times a week for 12 weeks. Each session will last approximately 45 minutes, providing ample gameplay, instruction, and debriefing time.
214326345|NCT07173465|OTHER|Physical Activity (PA group)|The intervention includes a 5-minute warm-up, 10 minutes of strengthening exercises (lunges and squats), 20 minutes of balance and cardiovascular endurance activities (HIIT exercises), 20 minutes of aerobic exercises (stationary bike and dancing), and a 5-minute cool-down with breathing control. Participants also continue with personalized occupational therapy to enhance their functional abilities.
214326346|NCT07173465|OTHER|occupational therapy|the group will undergo their normal occupational therapy activities that include drawing, coloring, mathematical problems as well as solving mazes
214326347|NCT07172399|PROCEDURE|blood sampling|blood samples will be taken to discover if there is hyperlipedemia,hyperthrodism or acute kidney injury
214326348|NCT07172399|OTHER|• BP will be measured using a calibrated, automated oscillometric device suitable for pediatric use.|All the study participants will be examined for assessment of the height and weight using calibrated equipment, Body Mass Index ,blood pressure will be measured.
214927753|NCT05115422|BEHAVIORAL|'Coping with Brain Fog' program|The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.
214326349|NCT07172360|DRUG|VC005 tablets|VC005 groups repeat administration for 48 weeks
214326350|NCT07172360|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 48 weeks
214326351|NCT07173387|DRUG|NALIRIFOX (liposomal irinotecan-based chemotherapy).|NALIRIFOX is a chemotherapy regimen that includes liposomal irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and leucovorin, administered intravenously in 10-12 cycles every two weeks.
214326352|NCT07173387|RADIATION|Stereotactic Body Radiation Therapy (SBRT).|Stereotactic Body Radiation Therapy (SBRT) is a form of high-precision radiation therapy that delivers focused radiation beams to the tumor while minimizing damage to surrounding healthy tissue. In this study, SBRT will be applied in two different timing schedules after NALIRIFOX chemotherapy: early after 1 cycle (Cohort 1) or late after 6-8 cycles (Cohort 2). The total radiation dose will be 25-50 Gy, delivered in 5 fractions.
214326353|NCT07173829|OTHER|samples|A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.
214326354|NCT07172321|DRUG|PF-08049820 MR1|Administered orally
214326355|NCT07172321|DRUG|PF-08049820 MR2|Administered orally
214326356|NCT07172321|DRUG|PF-08049820 IR|Administered orally
214326357|NCT07171996|OTHER|Dual-Simulation TPS + Biomechanical Planning|Combines TG-43-based TPS with a patient-specific FE biomechanical model to optimize needle paths and seed placement considering OAR limits, fracture risk, needle stability, and seed migration risk.
214326358|NCT07171996|OTHER|Conventional TPS Planning|Conventional TPS-driven plan per institutional practice; no biomechanical modeling.
214326359|NCT07174011|DRUG|Roflumilast|Phosphodiesterase-4 (PDE4) inhibitor assigned to arm A
214326360|NCT07174011|DRUG|intralesional steroid|intralesional injection of corticosteroid
214927754|NCT03743103|DRUG|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
214927755|NCT03743103|DRUG|Nitroprusside, Sodium|0.5 ug/kg/min every 3 minutes until reaching the pressure target
214927756|NCT04450784|OTHER|collection of the clinical and biological characteristics of secondary AMLs in children|to record scientific and medical information on cases of secondary Acute Myeloid Leukemias that have occurred in France since 2013
214927757|NCT05454384|OTHER|Medical Record Examination|The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.
214927758|NCT03692325|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
214927759|NCT04274504|DIAGNOSTIC_TEST|Osteopontin|Serum osteopontin (OPN) was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.
214927760|NCT03961386|BEHAVIORAL|FallsTalk-C|The FT-C experimental intervention involves two face-to-face visits including Initial and Follow-up Interviews, CG training, daily interaction with the PwD using a computer with FT-C software, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
214927761|NCT03961386|BEHAVIORAL|FallsTalk|The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
214927762|NCT03087422|BEHAVIORAL|Text message intervention|The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
214927763|NCT04456868|BEHAVIORAL|Electroencephalogram|Electroencephalogram will be done for P300 wave assessment
214927764|NCT04456868|BEHAVIORAL|walking test|8-Meter walking test will be done for gait parameter assessment
214927765|NCT04456868|BEHAVIORAL|Quality of life questionnaire|Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
214927766|NCT04456868|PROCEDURE|Position emission tomography|Position emission tomography will be done for
214927767|NCT01306318|DRUG|eperisone hydrochloride plus diclofenac sodium capsule|Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
214927768|NCT01306318|DRUG|eperisone hydrochloride tablet and diclofenac sodium tablet|Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
214927769|NCT00922467|DRUG|NaCl 9/00|Same volume as in the esmolol group
214326361|NCT07173621|OTHER|Amnioeffect|Amnioeffect is a placental-based allograft made of lyophilized human amnion/intermediate/chorion membrane (LHACM)
214326362|NCT07173283|OTHER|MenTOras: Peer Mentorship Program for Newly Graduated Occupational Therapists|The MenTOras intervention is a structured peer mentorship program designed for newly graduated occupational therapists in Aragón, Spain. The program pairs early-career occupational therapists (mentees, graduated within the past two years) with experienced colleagues (mentors, with at least five years of practice). Over approximately three months, each mentor-mentee pair participates in at least six structured sessions (online or in person). Sessions follow three phases-initiation, development, and closure-focusing on professional identity, reflective practice, emotional support, and skill integration. Mentors receive orientation and guidance to ensure program consistency. COPTOA also offers topic-specific training to address emerging professional needs. The intervention aims to foster professional integration, enhance self-confidence, and promote well-being among new occupational therapists, while strengthening professional cohesion and retention.
214326363|NCT07171905|DRUG|investigating the role of CAIX as target in VHL disease and in VHL-/- tumors.|Participants VHL disease and in VHL-/- tumors, will receive a single dose of the diagnostic radiopharmaceutical \[89Zr\]Zr-DFO-Girentuximab and subsequently undergo imaging with a hybrid PET/CT scanner.
214927770|NCT00922467|DRUG|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
214927771|NCT01928342|DRUG|Coenzyme A|Coenzyme A 400mg per day
214927772|NCT01928342|DRUG|Placebo|Capsule without coenzyme A.
214927773|NCT01202370|DRUG|7-t-butyldimethylsilyl-10-hydroxycamptothecin|IV Over 1 hour Days 1, 4, 8, 12 \& 15 of a 21 day cycle (7.5 mg/m\^2).
214927774|NCT01413789|DRUG|Dermatix|1 application of Dermatix
214927775|NCT01413789|DRUG|Kelocote|1 application of Kelocote
214927776|NCT01413789|DRUG|BAP scar gel|1 application of BAP scar gel
214927777|NCT01413789|DRUG|Alhydran|1 application of Alhydran
214927778|NCT01413789|DRUG|Bap Scar Care T|1 application of BAP Scar Care T
214927779|NCT01413789|DRUG|Bap Scar Care S|1 Application of Bap Scar Care S
214927780|NCT01413789|DRUG|Mepiform|1 application of Mepiform
214927781|NCT01413789|DRUG|Scar Ban Elastic|1 application of Scar Ban Elastic
214927782|NCT00562289|DRUG|aspirin|during the follow up
214927783|NCT00562289|DRUG|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
214927784|NCT00562289|DEVICE|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
215069521|NCT04654169|PROCEDURE|Ultrasound-guided IAI|Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.
215069522|NCT04654169|PROCEDURE|Ultrasound-guided SSNB|Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
215069523|NCT02833090|PROCEDURE|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
215069524|NCT01234740|DRUG|bafetinib|Given orally
215069525|NCT01234740|PROCEDURE|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
215069526|NCT01234740|OTHER|pharmacological study|Correlative studies
215069527|NCT01234740|OTHER|liquid chromatography|Correlative studies
215069528|NCT01234740|OTHER|mass spectrometry|Correlative studies
215069529|NCT01234740|OTHER|laboratory biomarker analysis|Correlative studies
215069530|NCT01234740|GENETIC|protein expression analysis|Correlative studies
214326364|NCT07173127|DRUG|Ryeqo treatment|Ryeqo treatment will be administered and hemostasis markers will be measured at T0 and T1
214326365|NCT07173530|DEVICE|Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).|A mask with Light Emitting Diodes wavelength 633nm will be placed over closed eyes for 15 minutes.
214326366|NCT07173192|BEHAVIORAL|Individual empowerment program|"Data collection tools will be applied to individuals in the experimental and control groups as a pre-test.~Individual empowerment training sessions will be applied to individuals in the experimental group totaling (6 sessions) as part of the individual empowerment program. No intervention will be performed on individuals in the control group; they will receive standard discharge education. Data collection tools will be applied to individuals in both groups for post-tests immediately after the experimental group completes all individual empowerment program sessions."
214326367|NCT07172061|OTHER|PSV + sigh (Clinical PEEP and Clinical PEEP + 3 cmH₂O)|Each patient undergoes two sequential 15-minute steps: 1) pressure support ventilation at the clinical PEEP and 2) the same settings with PEEP increased by 3 cmH₂O. A ventilator-delivered sigh is programmed as one sustained inflation at 30 cmH₂O for 3 seconds every minute. All other ventilator parameters (trigger sensitivity, pressure support level, mandatory breath timing) remain unchanged. At the end of each step, inspiratory and expiratory holds are performed to collect respiratory mechanics and arterial blood gases; compliance during the sigh is calculated once flow is zero and airway pressure is stable.
214326368|NCT07172022|DRUG|Crovalimab|Crovalimab will be administered at a dose of 680 mg (for participants with BW ≥ 40 kilograms \[kg\] to \< 100 kg) or 1020 mg (for participants with BW ≥ 100 kg), as a SC injection, at Weeks 1, 2, and 3 and Q4W from Week 5 onwards.
214326369|NCT07172022|DRUG|Placebo|Placebo matching crovalimab will be administered as per the schedule specified in the respective arm.
214326370|NCT07172022|DRUG|VKA|Dose administration of VKA will be in accordance with the local prescribing information for the respective product. The VKA regimen will be titrated to a therapeutic target INR based on investigator discretion and local standard of care (SOC).
214326371|NCT07173673|OTHER|Usual Care (General Practice)|Participants receive routine care based on current clinical guidelines. Symptom-driven evaluation is performed by physicians, including at least one diagnostic test within 6 months such as a standard 12-lead ECG, Holter monitoring, or patch ECG. The choice and frequency of monitoring are determined by physician discretion, reflecting real-world practice patterns.
214673107|NCT03312010|DEVICE|Spinal Cord Stimulator HF|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
215069531|NCT01234740|GENETIC|western blotting|Correlative studies
215069532|NCT01234740|OTHER|immunohistochemistry staining method|Correlative studies
215069533|NCT01234740|PROCEDURE|therapeutic conventional surgery|debulking craniotomy
215069534|NCT01292980|DEVICE|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
214673108|NCT03312010|DEVICE|Spinal Cord Stimulator Sham|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
214673109|NCT05610969|OTHER|Music|patients in this group will receive self-selected music after the golden moment has been completed between the patient, provider, and nursing staff
214673110|NCT05610969|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
215069535|NCT03161912|DRUG|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion.
214673111|NCT03689738|OTHER|Potato (Resistant Starch)|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
214673112|NCT03689738|OTHER|CHO-matched (Low-fiber, RS-free)|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
215069536|NCT03257111|OTHER|activity monitors|activity monitors are worn on the wrist, much like a watch. Data from the activity monitors will be downloaded once a week and at discharge. Normal hospital and therapy activities will not be altered.
214326372|NCT07173673|DEVICE|AI-ECG Guided Care (SmartECG-AFrisk)|Participants undergo SmartECG-AFrisk analysis of baseline 12-lead ECGs recorded in sinus rhythm. The algorithm calculates an atrial fibrillation risk score, classifying participants as high-risk (score ≥50) or low-risk (\<50). Monitoring strategies are adapted accordingly: high-risk participants undergo targeted and potentially repeated ECG monitoring using 12-lead ECG, Holter, or patch ECG, while low-risk participants follow standard guideline-based care.
214326373|NCT07173478|DRUG|OPA-15406|1% foam, topical, twice daily, for 4 weeks
214326374|NCT07173478|DRUG|Vehicle|vehicle, topical, twice daily, for 4 weeks
214326375|NCT07173959|DEVICE|GDM digital Therapy mini-program|The main functions of digital therapy products include personalized recipe recommendations, exercise and diet records and personalized analysis, blood sugar and weight monitoring, and the generation of weekly and monthly electronic comprehensive reports. The content of the electronic comprehensive reports includes the weight gain, blood sugar status, examination indicators, mood, and the proportion of diet and exercise of pregnant women in line with the system's recommendations during this period of time.
214326376|NCT07173959|DEVICE|Pregnancy record and education mini-program|This mini-program looks the same as digital therapy products but only has the functions of education and record-keeping
214326377|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out the questionnaire Mediterranean diet questionnaire (MEDAS)"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the patients' dietary choices and how beneficial they are for their health, according to the Mediterranean diet model.
214326378|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out the Mini Nutritional Asessment questionnaire"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the nutritional status of the patients, their level of nutrition and appetite for food, and the potential risk of malnutrition.
214326379|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out Nottingham Health Profile Scale questionnaire"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the subjective discomfort of the individual with health problems as well as the extent to which these problems affect their normal activities.
214326380|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out the Cardiovascular Diet Questionnaire-2"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the dietary choices of patients with cardiovascular diseases, such as the patients in this study.
214326381|NCT07172906|OTHER|Measurement of patient somatometric characteristics|Measurement of body weight, Body Mass Index, Fat and Water Percentage, Chest, Waist and Hip Circumference of patients using a tape measure and electronic scale-lipometer. Also, measurement of bloodless blood pressure and fasting glucose.
214326382|NCT07172906|BEHAVIORAL|Nutritional education and discussion with group B patients|Nutritional education using an information leaflet, e-mails and telephone calls to patients in group B only. Discussion regarding their dietary choices before surgery, identification of wrong habits and efforts to improve them afterwards. It will concern all the basic categories of healthy eating (preference for fruits, vegetables, proteins, healthy carbohydrates, reduction of saturated fat, salt and sugar and information about nutritional labels and how to choose foods according to them). The goal is for patients who will receive this education to improve their measurements in repeat meetings with the researcher, compared to those who will not be informed.
214326383|NCT07172295|PROCEDURE|Accelerated NaviFUS-ctbFUS stimulation|"Three consecutive sessions of NaviFUS-ctbTUS stimulation were performed, with a 5-minute interval between each session.~The acoustic pressure was set such that the estimated intracranial pressure at 30% skull transmission was approximately 0.5 MPa.~The stimulation target was the center of the Vop, with a total of 7 stimulation points."
214326384|NCT07172997|PROCEDURE|Bariatric Surgery|A surgical procedure used to manage obesity and obesity-related conditions.
214326385|NCT07172269|DRUG|Sitagliptin + Metformin|Oral tablets, 50/1000 mg, taken twice daily after meals for 12 weeks
214326386|NCT07172269|DIETARY_SUPPLEMENT|mangosteen supplement|Capsules, 500 mg, taken twice daily after meals for 12 weeks
214326387|NCT07172269|BEHAVIORAL|Lifestyle Management|Diabetes education, diet counseling, and exercise guidance provided throughout the 12-week study period.
214326388|NCT07173296|OTHER|Opalescence XTra Boost 40% HP|In-office tooth bleaching material
214326389|NCT07173296|OTHER|Pola Office Plus 37.5% HP|In-office tooth bleaching material
214326390|NCT07174375|DRUG|PCSK9 inhibitor|PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitors are a class of monoclonal antibody drugs that lower low-density lipoprotein cholesterol (LDL-C) by inhibiting the PCSK9 protein, which increases the liver's ability to remove LDL-C from the blood. This intervention involves the use of established PCSK9 inhibitor agents.
214486176|NCT06883422|DIETARY_SUPPLEMENT|Preoperative oral immunonutrition formula|Intervention arm will daily receive, for 7 days, a preoperative oral formula with immunonutrients: 500 kcal of energy, 41 g of protein, 60 g of carbohydrates, 11 g of lipids, 5.7 g of glutamine, 7 g of arginine, 3.6 g of leucine, 2.7 g of isoleucine, 3.7 g of valine, and 0.35 g of omega 3
214486177|NCT06883422|DIETARY_SUPPLEMENT|Preoperative oral Isocaloric and isoproteic polymeric formula|Control arm will daily receive, for 7 days, an isocaloric and isoproteic preoperative oral formula: 500 kcal of energy, 41 g of protein, 60 g of carbohydrates, and 11 g of lipids
214326391|NCT07171944|BEHAVIORAL|Structured orientation program|Artificial intelligence technology will be incorporated into the orientation training program developed for patients in the intensive care unit who are assigned to the intervention group. The program will be administered twice daily over a three-day period. In this group, delirium-free days will be tracked, changes in anxiety and depression levels will be evaluated, and the length of intensive care unit stay among patients who remain free of delirium through this intervention will be examined.
215069537|NCT03596047|DEVICE|Radial wave therapy|6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
214673113|NCT03037905|DEVICE|SignatureSuite OR Integration System by STERIS Corporation|SignatureSuite OR Integration System by STERIS Corporation is a device that controls audio and visual components of the operating room environment in order to provide a more relaxing and calming operating room environment for patients prior to surgery and on emergence from anesthesia after surgery.
214673114|NCT00101088|DRUG|imatinib mesylate|Given orally
215069538|NCT03596047|DEVICE|Placebo therapy|"There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation."
215069539|NCT04244981|DRUG|Prothrombin Complex Concentrate, Human|A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
215069540|NCT04244981|DRUG|Fresh Frozen Plasma|When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
215069541|NCT03727646|DIETARY_SUPPLEMENT|Nicotinamide riboside|nicotinamide riboside supplied as 250mg capsules
214326392|NCT07171944|BEHAVIORAL|Human Nurse|Researchers will administer a structured orientation training program lasting approximately 10 minutes face-to-face to participants in the control group. This training program will be administered twice daily for 3 days. Following the training program, delirium-free days, anxiety and depression scores, and length of stay in the intensive care unit will be evaluated.
214326393|NCT07172477|DEVICE|Pivot Extend|"The investigational Pivot Extend device will be inserted through a small incision in the femoral vein and guided to the heart using a catheter. The Pivot Extend device is designed to sit in the space where the valve isn't closing, helping the flaps of the valve to close tightly and reducing the amount of blood leaking back through the valve."
214326394|NCT07172750|OTHER|Education on Urinary Catheter Care|"Urinary catheter care training based on the Roper, Logan, and Tierney Lifestyle Model was developed based on daily living activities.~A training booklet was created based on 11 daily living activities (providing and maintaining a safe environment, communication, breathing, nutrition, etc.).~To increase the effectiveness of the training, a booklet based on this model will be prepared and used as a guide in the training program."
214326395|NCT07172568|PROCEDURE|Blood Flow Restriction|In the intervention group, 50% of limb occlussion pressure are applied to the extremity during exercises.
215069542|NCT00195052|DIAGNOSTIC_TEST|Intrinsic signal imaging of human cortex|Light is shined on the brain at 540 nm and 610 nm and images are acquired at 10 frames per second.
214326396|NCT07172568|PROCEDURE|sham-Blood Flow Restriction|In the control group, 20 mmHg are applied to the extremity during exercises.
214326397|NCT07173712|DRUG|CSII followed by iGlarLixi|Short term intensive insulin therapy followed by Insulin Glargine and Lixisenatide Injection(iGlarLixi) for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.
214326398|NCT07173712|DRUG|CSII followed by IDegAsp|Short term intensive insulin therapy followed by Insulin Degludec and Insulin Aspart Injection(IDegAsp) for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.
215069543|NCT05280158|DRUG|mRNA-1273 (Moderna COVID-19 vaccine)|Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
215069544|NCT05187884|DRUG|Darovasertib|Oral Darovasertib 300 mg tablets twice daily
215069545|NCT04770545|DRUG|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
215069546|NCT06458920|BEHAVIORAL|Social regulation|Participants will regulate emotion with the help of a friend
215069547|NCT06458920|BEHAVIORAL|Cognitive regulation|Participants will regulate emotion on their own
215069548|NCT00332384|DRUG|brimonidine/timolol fixed combination|
214326399|NCT07173712|DRUG|CSII followed by iGlar+MET|Short term intensive insulin therapy followed by Insulin Glargine Injection(iGlar） plus metformin 0.5g tid for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.
214326400|NCT07173335|BEHAVIORAL|In-person physiotherapist led integrated healthy lifestyle and pain care|"Participants allocated to in-person intervention will be offered:~A) Up to four in-person physiotherapist consultations (up to one hour in duration) over 12 weeks (weeks 1, 3, 6, and 12);~B) Tailored pain education and healthy lifestyle education and resource bundles, including video content, web resources and interactive tools sent to participants via email or text;~C) Referral to telephone-based population wide health behaviour change support services, the NSW Get Healthy Coaching and information service and the Quitline for smokers, by the week 12 consultation (up to 6 telehealth consultations).~Total = up to 10 consultations over 6 months."
214326401|NCT07173335|BEHAVIORAL|Virtual multidisciplinary integrated healthy lifestyle and pain care|"Participants allocated to the virtual multidisciplinary intervention will receive:~A) 10 consultations over 6 months with a multidisciplinary team, including a minimum 4 with a physiotherapist (week 1, 3, 6, 12) and remainder with a dietitian and/or psychologist, tailored to participants needs. Virtual care consultations may be individual or joint multidisciplinary sessions conducted on standard virtual care platforms used by NSW Health. Consultation will be up to one hour in duration, or use an equivalent total duration with a higher frequency schedule. Where appropriate, participants may be referred to alcohol or smoking cessation support, including individualised virtual or telephone-based counselling with access to nicotine replacement therapy;~B) Tailored pain education and healthy lifestyle education and resource bundles, including video content, web resources and interactive tools sent to participants via email or text."
214326402|NCT07173816|BEHAVIORAL|EMPOWER|EMPOWER, a group-based 6 sessions telehealth behavioral intervention, will comprise sexual health goals and values elicitation, sexual health plan development, and motivational enhancement skills will be used to promote effective HIV prevention decision-making within the relationship context, incorporating the sexual values of each participant. This will allow each participant to develop a personalized, tailored sexual health plan that includes PrEP deliberation to enhance PrEP decision-making, uptake and persistence within a culturally congruent and empowering program that aims to reduce stigma around HIV and barriers to access.
214326403|NCT07173166|OTHER|Physical activity|"Patients assigned to intervention group A will follow a supervised programme of physical activity and exercise at home and during hospitalisation. All patients will follow the same exercise programme, which will be adapted to a basic, intermediate and advanced level to suit the patients' physical condition. The loads, intensity and number of sets will be adapted to each level.~Aerobic exercise will consist of walking and/or cycling at an intensity of between two and five on the Borg perceived exertion (RPE) scale. Resistance exercise will consist of one session focusing on the trunk and upper limbs, and another on the lower limbs. Both sessions will include seven exercises, performed at an intensity of between three and four on the Borg RPE scale."
214326404|NCT07173166|OTHER|Physical activity and nutrition|The intervention integrates a structured physical activity programme with individualized nutritional recommendations based on the Mediterranean diet. Macronutrient distribution was 50-55% carbohydrates, 30-35% fats, and 10-15% proteins. The protocol emphasized the intake of vegetables (≥2 servings/day, 200 g each), fruits (1-2 servings/day, 150 g each), legumes (≥3 servings/week, 150 g cooked), whole grains (1-2 servings/meal, 40-60 g), and low-fat dairy products (1-2 servings/day; 200 ml milk or 125 g yoghurt). Lean meats were prescribed at 3-4 servings/week (100-125 g each), fish and seafood at 4 servings/week (150 g each), nuts at 3-7 servings/week (30 g each), and olive oil as the principal fat source (≤4 tbsp/day). Micronutrients and bioactive compounds from these foods, including antioxidants, polyphenols, and essential fatty acids, were recognized as pivotal for modulating protective mechanisms and mitigating toxicological effects.
214326405|NCT07172724|BIOLOGICAL|Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory|lyophilized antigen for reconstitution with the adjuvant CTVad (a squalene-based nanoemulsion), at the time of use.
214326406|NCT07172724|OTHER|Placebo|adjuvant CTVad (a squalene-based nanoemulsion)
214326407|NCT07172945|OTHER|Blood, fecal, saliva|Blood, fecal and saliva samples
214326408|NCT07172945|OTHER|intestinal content samples and biopsies|intestinal content samples and biopsies obtained per upper or lower gastrointestinal tract endoscopy
214326409|NCT07172334|OTHER|Questionnaires|Patients will complete questionnaires on professional exposures with the help of a trained professional (estimated time: 30 minutes), followed by self-questionnaires on indoor and outdoor pollution, medications, drugs and socio-economic variables (estimated time: 30 minutes).
214326410|NCT07172334|OTHER|Samples|Two strands of hair (or beard or axillary hair) will be taken, along with a urine and blood sample.
214326411|NCT07172256|DRUG|CUE-101|CUE-101 will be administered by IV infusion with a commercially available syringe pump or IV infusion pump over 60 minutes on Day 1 and Day 21 after all procedures and assessments are completed. It will be administered at a dosage level of 4 mg/kg x 2
214326412|NCT07172256|DRUG|Pembrolizumab|Pembrolizumab will be administered on Day 1 and Day 21 after all procedures and assessments are completed according to the Study Calendar. Pembrolizumab will be administered as a dose of 200 mg using a 30-minute (- 5 min/+10 min) IV infusion.
214673115|NCT00101088|DRUG|temsirolimus|Given IV
214673116|NCT00101088|OTHER|laboratory biomarker analysis|Correlative studies
214673117|NCT01333189|OTHER|Weight-bearing biofeedback exercise|"Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.~Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games."
215069549|NCT02290691|BIOLOGICAL|Influenza Vaccine|Influenza Vaccine
215069550|NCT04324541|DIAGNOSTIC_TEST|PET scan of the brain with Flortaucipir|PET scan of the brain with non FDA approved Radio tracer.
215069551|NCT01983384|OTHER|Processed EEG-guided anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
215069552|NCT03019328|OTHER|Peanut in diet|
214927785|NCT06622629|OTHER|Nature based Therapy (NbT): Planned therapeutic techniques performed in natural settings and based on nature-human active participation and connection|"The intervention consists of a 5-week (35-day) conscious immersion treatment in a natural coastal urban environment, involving approximately three sessions per week of semi-structured walking and mindfulness exercises lasting 60 minutes. Following this, there will be a follow-up period that will end 5 weeks after the intervention has concluded (day 70). Participants will document and evaluate the therapy sessions at the location where the mindfulness exercises take place, using the mobile phone application App, a digital tool for assessing the environment and health. The aim is to integrate nature-based physical activity and relaxation sessions into daily life.~The intervention will be standardized as much as possible to allow comparison of the results with those from the other study centers in Salzburg (Vienna) and Padua (Italy)."
214326413|NCT07171931|PROCEDURE|IPACK block|After the general anesthesia induction, IPACK block will be performed with 0.25% bupivacaine (20 mL) using ultrasound in addition to adductor canal block.
214326414|NCT07171931|PROCEDURE|Genicular nerve block with bupivacaine|After the general anesthesia induction, genicular block will be performed with 0.25% bupivacaine (20 mL) using ultrasound in addition to adductor canal block.
214326415|NCT07173153|BIOLOGICAL|AAV9.SLC6A1 Gene Therapy|This is an open-label, single injection study of an AAV9 vector carrying the SLCA1 coding sequence delivered one time through an intrathecal injection.
214326416|NCT07173036|OTHER|metabolic and auxological outcomes|Evaluation over a three-year period following the initiation of treatment with daily recombinant human growth hormone (rhGH)
214326417|NCT07173036|OTHER|metabolic and auxological outcomes|Evaluation over a three-year period following the initiation of treatment with weekly long-acting growth hormone (LAGH).
214326418|NCT07172659|DRUG|Dovramilast|Dovramilast
214326419|NCT07172659|DRUG|Prednisolone|Standard of care
214326420|NCT07172659|DRUG|Thalidomide|Standard of care (US only)
214326421|NCT07173101|DEVICE|Semiconductor embedded headband|"Week 1-3: Participants will be provided with either an active semi-conductor headbands OR a sham headband, absent of semi-conducting fabric. Participants will be instructed to wear them \>18 hours per day and report their daily device usage.~Week 4-5: Washout. Participants will not wear any headbands that were provided.~Week 6-8: Participants who wore sham headbands in intervention A will be provided with active semi-conductor embedded headbands and instructed to wear them \>18 hours per day, and vice versa."
214326422|NCT07173101|DEVICE|Sham Headband|"Week 1-3: Participants will be provided with either an active semi-conductor headbands OR a sham headband, absent of semi-conducting fabric. Participants will be instructed to wear them \>18 hours per day and report their daily device usage.~Week 4-5: Washout. Participants will not wear any headbands that were provided.~Week 6-8: Participants who wore sham headbands in intervention A will be provided with active semi-conductor embedded headbands and instructed to wear them \>18 hours per day, and vice versa."
214326423|NCT07174154|BEHAVIORAL|Interview|Recorded interviews
214326424|NCT07172425|DIETARY_SUPPLEMENT|Inorganic potassium nitrate-fortified biscuits supplementation|Four millimoles of inorganic potassium nitrate, within the acceptable daily intake (ADI), were added to commonly consumed oat-based products (biscuits). During the trial, participants will receive nitrate-fortified biscuits as a single-day acute supplementation.
214326425|NCT07172425|DIETARY_SUPPLEMENT|Inorganic potassium nitrate-fortified cereal bar supplementation|Four millimoles of inorganic potassium nitrate, within the acceptable daily intake (ADI), were added to commonly consumed oat-based products (cereal bar). During the trial, participants will receive nitrate-fortified cereal bar as a single-day acute supplementation.
214326426|NCT07172425|DIETARY_SUPPLEMENT|Inorganic potassium nitrate-fortified porridge supplementation|Four millimoles of inorganic potassium nitrate, within the acceptable daily intake (ADI), were added to commonly consumed oat-based products (instant porridge). During the trial, participants will receive nitrate-fortified porridge as a single-day acute supplementation.
214326427|NCT07172867|DRUG|HT-6184|2mg QD
214326428|NCT07172867|DRUG|HT-6184 Matching Placebo|2mg QD
214326429|NCT07172867|DRUG|Semaglutide 1 mg|Semaglutide 1 mg, every week
214673118|NCT01333189|OTHER|Standard of care exercise|Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
214326430|NCT07174063|DRUG|JSB462|300 mg or 100 mg once a day (QD) with food
214326431|NCT07173894|PROCEDURE|Shoulder Field Block by Orthopedic Surgeon|"For Shoulder Field Block intervention:~This intervention involves a regional anesthesia technique targeting the sensory nerves of the shoulder surgical field: the suprascapular, axillary, and lateral pectoral nerves. The block is performed intraoperatively by the orthopedic surgeon using anatomical landmarks after induction of general anesthesia. A mixture of lidocaine with epinephrine, bupivacaine, and saline is injected into the shoulder area to provide local anesthesia and prolonged postoperative analgesia. This technique aims to spare the phrenic nerve, potentially reducing respiratory complications associated with traditional blocks."
214326432|NCT07173894|PROCEDURE|Interscalene brachial plexus block and superficial cervical plexus block|This intervention involves a standard interscalene brachial plexus block performed preoperatively by an anesthesiologist under ultrasound guidance. It anesthetizes the upper roots (C5-C7) of the brachial plexus to provide effective analgesia for shoulder surgery. While effective, it carries risks such as hemi-diaphragmatic paralysis, Horner's syndrome, and motor weakness of the ipsilateral arm due to spread to adjacent nerves.
214326433|NCT07172100|DRUG|Carica Papaya Leaf Extract Group|Carica papaya leaf extract syrup will be administered orally at a dose of 10 mL three times daily (TID) for a total of 3 days. Each 10 mL dose contains 1000 mg of papaya leaf extract. This intervention will be given in addition to standard supportive therapy for dengue fever
214326434|NCT07172100|OTHER|standard treatment|patients in this group will receive only the standard treatment for dengue fever
214326435|NCT07173426|DEVICE|Bioimpedance analysis|"Bioimpedance analysis involves electrodes attached to the patient's limbs which measures the resistance in the body to an imperceptible high-frequency, low-amplitude alternating electrical current. BIA measurements will include total body water (TBW), intracellular water (ICW), extracellular water (ECW), and the derived parameter dry weight. Results are available at the bedside within 2 minutes."
214927786|NCT06622629|OTHER|Nature based Therapy (NbT)|"The intervention consists of a 5-week (35-day) conscious immersion treatment in a natural coastal urban environment, involving approximately three sessions per week of semi-structured walking and mindfulness exercises lasting 60 minutes. Following this, there will be a follow-up period that will end 5 weeks after the intervention has concluded (day 70). Participants will document and evaluate the therapy sessions at the location where the mindfulness exercises take place, using the mobile phone application MyCap app, a digital tool for assessing the environment and health. The aim is to integrate nature-based physical activity and relaxation sessions into daily life.~The intervention will be standardized as much as possible to allow comparison of the results with those from the other study centers in Salzburg (Vienna) and Padua (Italy)."
214927787|NCT04888429|DRUG|Camrelizumab|Patients received camrelizumab 200 mg every 3 weeks
214326436|NCT07172984|PROCEDURE|Anesthesia|"Receives local anesthesia with 5 cc of lidocaine before the infiltration procedure.The patient will receive breathing instructions as part of SHAM treatment, which will not allow them to achieve cardiac coherence."
214326437|NCT07172984|PROCEDURE|breathing group|The procedure will use 5 cc of saline solution instead of the usual anesthesia. Explanations for performing 5-minute breathing cycles that facilitate the achievement of cardiac coherence, with visual feedback.
214326438|NCT07173556|DRUG|QLC1401|CDK4/6 inhibitors: Palbociclib, Abemaciclib, Ribociclib
214927788|NCT04888429|DRUG|Famitinib|Patients received Famitinib 20 mg once per day
214486178|NCT06886919|BIOLOGICAL|Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells|"About 6 subjects will be included in the study, and a 3+3 dose escalation method will be used. The dosage will be gradually increased in two dose groups: 1 × 10 \^ 8 CAR-T cells/dose and 2 × 10 \^ 8 CAR-T cells/dose. Three subjects are enrolled in each dose group first, and within the same dose group, the cell transfusion interval between the first two subjects should not be less than 14 days. If no dose limiting toxicity (DLT) is observed in a certain dose group, the dose will be increased to the next dose; If one case of DLT occurs, this dose group needs to be divided into three additional subjects (a total of six subjects). If no new DLT occurs, the dosage will be increased to the next dose; If more than 1/6 of the 6 subjects develop DLT, the dose escalation will be terminated, and the Safety Review Committee (SRC) will discuss whether to reduce the dose and continue the monotherapy study."
214486179|NCT06888219|OTHER|Acupuncture and Auricolotherapy|"Based on the patient's condition and the physiology of traditional Chinese medicine, sterile disposable acupuncture needles will be placed on selected points:~Auricular:~* Esophagus point~* Shen Men point~* Palate area/ Throat point~* II and III Trigeminal branches~Somatic:~* 17 Triple heater (if bruxisme)~* 22 Conception Vessel~* 23 Conception Vessel~* 3 Small Intestine~* Yin Tang (if apathy)~* 3 Large Intestine (if xerostomy)~* 36 and 44 Stomach"
214673119|NCT06178640|DRUG|Simvastatin 40 mg film-coated tablet|Simvastatin 40 mg film-coated tablet
214673120|NCT06178640|DRUG|Zocor 40 mg film-coated tablet|Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)
214673121|NCT01363505|DEVICE|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
214326439|NCT07173556|DRUG|QLC1401|mTOR inhibitors: Everolimus
214326440|NCT07174089|OTHER|RadEye SPRD-ER device: spectrometric radiation detector capable of detecting gamma radiation.|Acquisition of data during the infusion of PET radiotracers and the administration of α and β emitting radiopharmaceuticals for therapy.
214673122|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated barbed suture|Use of Triclosan-coated Polydioxanone barbed suture
214673123|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated monofilament suture|Use of Triclosan-coated Polydioxanone monofilament suture
214673124|NCT03763279|DEVICE|Monofilament suture|Use of Polydioxanone monofilament suture
214927789|NCT04001894|DRUG|Ticagrelor 90mg|Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).
214927790|NCT04001894|DRUG|Clopidogrel 75mg|Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).
214927791|NCT05856994|DRUG|Tacrolimus ointment|For the active comparator group, the wound(s) will be cleaned and bacitracin ointment will be applied to the wound. External dressings on all treated wounds will be placed based on the current standard of care. For the control group, the wound(s) will be cleaned and a hydrocolloid Dressing will be affixed to the burn and treated area. For the treatment group, the wound(s) will be cleaned and tacrolimus (0.03%) ointment will be applied over the burn. Hydrocolloid Dressing will be affixed to the burn and treated area. External dressings on all treated wounds will be placed based on the current standard of care.
214326441|NCT07174349|DRUG|Uroselective alpha-1-adrenergic receptor antagonist|Subjects will receive Tamsulosin (0.4 mg daily) beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)
214326442|NCT07174349|OTHER|Placebo|Subjects will receive placebo beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)
214326443|NCT07170332|DEVICE|ZIPPER™ Stent-Graft Trial for Aortic Arch Dissection|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
214326444|NCT07171983|DRUG|BMS-986454|Specified dose on specified days
214326445|NCT07171983|OTHER|Placebo|Specified dose on specified days
214673125|NCT03477916|BIOLOGICAL|FMT|fecal microbial transplantation (FMT)
214927792|NCT06621134|OTHER|AI Chatbot|Participants will be required to provide consent for randomization when they first access our system. Users can ask questions covered by the question bank, as well as specific questions not covered by the bank, through an AI chatbox. The aim is to understand the significant difference between using AI chatbots and telephone hotlines to assist parents, as well as the effectiveness of AI chatbots compared to telephone hotlines.
214927793|NCT06621134|OTHER|Telephone hotline|Participants will be asked to consent to randomization on their first access to our system. Users ask questions covered by the question bank and specific questions not covered by the question through a telephone hotline.
214927794|NCT05031650|PROCEDURE|openCPAP|Randomized to : Individualized high level CPAP between 8-10 cmH2O pressure
214927795|NCT05031650|PROCEDURE|standardCPAP|Randomized to : Standard level CPAP between 6-8 cmH2O pressure
214927796|NCT01506765|DRUG|N-Acetyl-Cysteine (NAC)|Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
214927797|NCT04694950|PROCEDURE|Usual care|Intravenous morphine according to clinician´s discretion.
214927798|NCT06597565|DRUG|Gemcitabine|Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368.
214927799|NCT06597565|DRUG|ACR-368|ACR-368 is an experimental drug.
214927800|NCT02071862|DRUG|CB-839|CB-839 monotherapy
214927801|NCT02071862|DRUG|Pac-CB|CB-839 in combination with standard dose paclitaxel
214927802|NCT02071862|DRUG|CBE|CB-839 in combination with standard dose everolimus
214927803|NCT02071862|DRUG|CB-Erl|CB-839 in combination with standard dose erlotnib
214927804|NCT02071862|DRUG|CBD|CB-839 in combination with standard dose docetaxel
214927805|NCT02071862|DRUG|CB-Cabo|CB-839 in combination with standard dose cabozantinib
214927806|NCT02461524|DEVICE|Endurant Evo AAA Stent Graft System|
214927807|NCT02461524|PROCEDURE|Endovascular aneurysm repair (EVAR)|
214927808|NCT01470781|BEHAVIORAL|BrainWorks|"13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as directors for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training."
214927809|NCT01470781|BEHAVIORAL|Computer Control|"Sessions will involve generic computer games administered via the game interface Sporcle. Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session."
214927810|NCT00878150|BEHAVIORAL|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
214927811|NCT00878150|BEHAVIORAL|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
215069553|NCT01534585|DRUG|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.~Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
214326446|NCT07173907|PROCEDURE|CuRV CXL|A two-part transepithelial isotonic riboflavin system (ParaCel™ Part 1 and Part 2) was used. Part 1 was applied with a surgical spear and repeated drops, followed by Part 2 instillation for 6 minutes. After rinsing with balanced salt solution, UVA irradiation was performed using the Mosaic® device with Boost Goggles™ delivering supplemental oxygen. Pulsed UVA (365 nm, 30 mW/cm²) was applied in a personalized, three-zone pattern (15 J/cm² to the cone apex, 10 J/cm² to an intermediate annulus, and 7.2 J/cm² to the periphery), guided by Pentacam tomography. A bandage contact lens was placed at the end of the procedure.
214326447|NCT07173907|PROCEDURE|Accelerated CXL Procedure (aCXL)|The subjects underwent the aCXL procedure was performed under topical anesthesia after tailored epithelial removal, leaving a small island over the thinnest corneal area. Riboflavin-dextran solution was applied for 30 minutes, followed by UVA irradiation (9 mW/cm², total 5.4 J/cm²) using the KXL device. The cornea was rinsed with Ringer's solution during treatment, and a bandage contact lens was placed afterward.
214326448|NCT07172139|COMBINATION_PRODUCT|Active rTMS + Pinaverium Bromide|A figure-of-eight coil is used to apply active low-frequency (1 Hz) rTMS to the corresponding representation area of the prefrontal cortex (mPFC). The treatment is administered for 20 minutes daily for a total of 2 weeks.
214927812|NCT00478010|OTHER|counseling intervention|
214927813|NCT00478010|OTHER|study of socioeconomic and demographic variables|
214927814|NCT00478010|PROCEDURE|psychosocial assessment and care|
214927815|NCT00478010|PROCEDURE|quality-of-life assessment|
214927816|NCT01171781|DRUG|cisplatin (3 weekly)|radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
214927817|NCT01171781|DRUG|cisplatin (weekly)|radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
214326449|NCT07172139|COMBINATION_PRODUCT|Active rTMS + Bifidobacterium|Bifidobacterium animalis subsp. lactis BB-12, provided in capsule form. Each capsule contains a minimum of 5 billion colony-forming units (CFU). Administered orally at a dosage of one capsule twice per day, with meals, for a duration of 2 weeks. The product will be stored refrigerated as per manufacturer's instructions.
214326450|NCT07172139|COMBINATION_PRODUCT|Sham Comparator: Sham rTMS + Pinaverium Bromide|Pinaverium Bromide 50 mg film-coated tablets. Administered orally at a dosage of 50 mg (one tablet) three times daily, 30 minutes before meals, for a duration of 2 weeks.
214326451|NCT07172139|COMBINATION_PRODUCT|Placebo Comparator: Sham rTMS + Bifidobacterium|Description: Sham stimulation is delivered using a placebo coil that mimics the sound and sensation of active rTMS but does not deliver the full magnetic field. Parameters identical to active arm.
214326452|NCT07171827|DRUG|Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine|Patients received Brentuximab Vedotin (BV)+ Doxorubicin, Vinblastine, and Dacarbazine (AVD) drug regimen by intravenous infusion on Days 1 and 15 of each 28-day cycle.
214326453|NCT07171827|DRUG|Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine|Patients received Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) drug regimen by intravenous infusion on Days 1 and 15 of each 28-day cycle.
214326454|NCT07172126|DRUG|TQB3201 tablets|TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to AR and the other end to a ligand of E3 ligase (CRBN) via a linker. This product is effective against anti-androgen drugs (such as abiraterone, enzalutamide, etc.) resistance mutations, including AR amplification, point mutations (L702H, H875Y, T878A mutations, etc.), and can target the degradation of wild-type AR and AR ligand-binding domain mutants, especially L702H mutations, which is a new generation of AR-PROTAC.
214326455|NCT07172347|DRUG|VC005 tablets|VC005 groups repeat administration for 52 weeks
214326456|NCT07172347|DRUG|VC005 Tablets Placebo|VC005 Placebo groups repeat administration for 52 weeks
214927818|NCT00765895|DRUG|Nortriptyline Hydrochloride|Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
214927819|NCT00765895|DRUG|Placebo (for nortriptyline)|Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
214326457|NCT07172607|DIETARY_SUPPLEMENT|Avance eZZe drink|25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
214326458|NCT07172607|DIETARY_SUPPLEMENT|Avance eZZe drink (without liposomal)|25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
214326459|NCT07172607|DIETARY_SUPPLEMENT|Placebo drink|25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
214326460|NCT07174323|DIETARY_SUPPLEMENT|Peptide derived from collagen protein|Peptide derived from collagen protein
214326461|NCT07174323|DIETARY_SUPPLEMENT|Whey protein isolate|Whey protein isolate
214326462|NCT07174076|DRUG|cordyceps sinesis capsule|cordyceps sinesis capsule 4 capsules tid po for 12 months
214326463|NCT07174076|DRUG|cordyceps sinesis capsule placebo|cordyceps sinesis capsule placebo 4 capsules tid po for 12 months
214326464|NCT07174284|OTHER|No Intervention: Observational Cohort|No intervention was applied to the patients within the scope of this study.
214326465|NCT07174037|OTHER|Low spasticity group|low sapsticity (grade 1-2) unilateral ischemic stroke will be participate in this group
214326466|NCT07174037|OTHER|High spasticity group|high sapsticity (grade 3-4) unilateral ischemic stroke will be participate in this group
214326467|NCT07173439|DEVICE|Model Name: EMT-SR01;red|The investigational device incorporated both a driving simulation and an N-Back cognitive training function. These features were designed to engage and improve key cognitive abilities such as attention, working memory, and executive function, which are often impaired in individuals with ADHD. The combined use of driving tasks and N-Back exercises aimed to provide a comprehensive and interactive therapeutic intervention to reduce core ADHD symptoms.
214326468|NCT07173439|DEVICE|Model Name: EMT-SR01;red (Placebo)|The placebo device incorporated only the driving simulation function and excluded the N-Back cognitive training component. The driving simulation was designed as a sham intervention to mimic the user experience without providing the active therapeutic elements targeting cognitive functions. This setup enabled a controlled comparison with the active digital therapeutic device.
214326469|NCT03865836|BIOLOGICAL|ATB200|
214326470|NCT03865836|DRUG|AT2221|
214326471|NCT04186416|OTHER|Mostcare® device|The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
214326472|NCT04186416|OTHER|Transthoracic cardiac ultrasound|Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
214326473|NCT04527068|DRUG|Bevacizumab|7.5 mg/kg intravenously every 3week
214673126|NCT03477916|BIOLOGICAL|Placebo FMT|Placebo fecal microbial transplantation (FMT)
214326474|NCT04527068|DRUG|Tripleitriumab|240mg intravenously every 3week
214326475|NCT05597527|DRUG|Fluzopari and apatinib|Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
214326476|NCT04414384|OTHER|Abdominal Binder|Abdominal Binder placement
214326477|NCT04414384|OTHER|Step Counter|step counter to track steps
214326478|NCT01122199|DRUG|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
214326479|NCT00881309|DRUG|Tripterygium|TW 90mg/d
214673127|NCT03477916|DIETARY_SUPPLEMENT|Prebiotic Fiber|combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
214673128|NCT03477916|DIETARY_SUPPLEMENT|Cellulose|Cellulose
214927820|NCT02810470|DIETARY_SUPPLEMENT|Fortimel Compact Protein|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
214326480|NCT06504030|DRUG|modified-DEP|"For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed."
214927821|NCT02810470|DIETARY_SUPPLEMENT|Fortimel Cream|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
214927822|NCT06243952|DEVICE|ARC-BSI Lumbar system|Implantation of a 64 channel - ECoG array over the sensory motor cortex of the lower limbs, combined with an implantation of 16 channel spinal cord stimulation system over the lumbar region. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
214927823|NCT05885295|DIAGNOSTIC_TEST|MRI brain, Blood tests, cognitive assessments|observational study examining cognition post stroke using behavioural tests, MRI brain and blood tests
214927824|NCT03360006|DRUG|ABBV-744|Tablet, oral
214927825|NCT06010238|DEVICE|Short term variation|Short term variation in computer software analysis
214326481|NCT04516161|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
214326482|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
214326483|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
214326484|NCT00513422|DIETARY_SUPPLEMENT|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
214326485|NCT00513422|DIETARY_SUPPLEMENT|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
214326486|NCT03370341|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks to assess IA
214326487|NCT03370341|DEVICE|sham tDCS|sham tDCS with behavioral tasks to assess IA
214326488|NCT00960700|DEVICE|Visual Acuity|Assessment of visual acuity
214326489|NCT00960700|DEVICE|Contrast sensitivity|Assessment of contrast sensitivity
214326490|NCT00960700|DEVICE|Reading Speed|Assessment of reading speed
214326491|NCT00960700|PROCEDURE|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
214326492|NCT01072487|PROCEDURE|Capnography|Monitoring of the capnography curve for early detection of apnea
214927826|NCT06010238|DEVICE|Visual interpretation|Visual interpretation of cardiotocography
214326493|NCT06108856|DEVICE|Hemodialysis machine|machine by which people undergo dialysis on it.
214927827|NCT05817487|BEHAVIORAL|high-intensity interval training (HIIT)|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The training sessions in the HIIT group involved five high-intensity intervals of 4 minutes each (running or walking on a treadmill) at 85% VO2max interspersed with 3 minutes of low-intensity walking.
214927828|NCT05817487|BEHAVIORAL|crossover point(COP) exercise training|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The COP exercise training sessions involved 45 minutes of continuous exercise at the COP on a treadmill.
214927829|NCT04055376|DEVICE|GENUS device (Active Settings)|"Participants in the experimental group will use the GENUS device configured to active settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
214927830|NCT04055376|DEVICE|GENUS device (Sham Settings)|"Participants in the control group will use the GENUS device configured to sham settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
214927831|NCT03272659|DRUG|Cysview|250 mL enema containing 1.6 mmol of hexaminolevulinate
214927832|NCT03706859|PROCEDURE|Pneumatic tourniquet inflation pressure|Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
214326494|NCT04661176|DIAGNOSTIC_TEST|miR Sentinel™ PCC4 Assay|This study is a prospective clinical utility study. Urine samples will be collected from participants for the miR Sentinel™ PCC4 Assay, which interrogates the expression profile of 442 small non-coding RNAs to classify disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk prostate cancer.
214486180|NCT06888219|OTHER|Conventional logopedic rehabilitation|"Patients assigned to the control arm will undergo a total of 3 hours of speech and physiotherapy rehabilitation per day from Monday to Friday, and 1 hour on Saturday.~Regarding speech therapy treatment, both restorative and compensatory interventions will be applied, based on the patient's clinical condition.~Compensatory approaches include postural techniques (such as adopting a flexed head posture) and swallowing techniques (e.g., supraglottic swallowing, forced swallowing, the Mendelsohn maneuver), as well as modifying the consistency of liquids and food.~Restorative methods involve swallowing exercises aimed at enhancing muscular strength, resistance training, and motor training of the oral structures involved in swallowing."
214486181|NCT06723808|OTHER|Leisure-Time Physical Activity and Occupational Physical Activity|This study does not involve a specific intervention but explores the relationship between leisure-time physical activity (LTPA) and occupational physical activity (OPA) in university staff, with a focus on work ability, musculoskeletal disorders, and quality of life.
214326495|NCT02307552|DEVICE|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
214326496|NCT04852094|OTHER|Qualitative focus group|A qualitative focus group is performed with staff members and parents of hospitalised newborns in a NICU during Family-centered rounds management. The transcribed interviews are analyzed with qualitative content analysis in order to illuminate the experience, feelings and thoughts arisen among the staff members and the parents.
214486182|NCT06889636|OTHER|Pharmaceutical care in solving drug-related problems in subjects using psychotropic medicines based on standardized protocol..|Pharmacists' interventions were based on Medication Review and Medication Therapy Management evaluations of a subjects' pharmacotherapy to optimize medicine use, improve treatment outcomes and quality of life. The intervention involved the identification of drug-related problems and addressing these issues through pharmacist interventions. The intervention was based on information gathered from the subjects and a list of medicines in use.
214486183|NCT06889636|OTHER|Common pharmacists' practice in Croatia.|Group B participants received pharmaceutical care based on common pharmacists' practice in Croatia during the dispensing of psychotropic drugs.
214927833|NCT06485349|DIETARY_SUPPLEMENT|Olive Leaf Extract (OLE)|Daily dose of 750mg OLE consumed with water after breakfast without any modification of their dietary patterns for 90 days.
214927834|NCT06485349|OTHER|Placebo|100mg microcrystalline cellulose
214927835|NCT02085616|BEHAVIORAL|Proactive service|In the proactive service the callers to the quitline are offered a number of callbacks.
214927836|NCT02085616|BEHAVIORAL|Reactive service|In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
214326497|NCT00953797|DEVICE|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
214326498|NCT05295173|DRUG|Injection of recombinant human tissue plasminogen kinase derivatives|18mg/10ml/stick, provided by Angde Biotech
214326499|NCT05295173|DRUG|Recombinant human tissue plasminogen activator|20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
214326500|NCT02912286|DEVICE|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
214927837|NCT01940315|BIOLOGICAL|rBV A/B|0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
214927838|NCT01940315|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
214927839|NCT01389570|PROCEDURE|Acupressure wrist band|Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
214927840|NCT04766957|DEVICE|Idracare|Treatment will last 3 months (12 weeks). The treatment will be applied 2 times a week, preferably at night before going to bed.
214927841|NCT00672386|DRUG|JNJ16269110|5 mg twice daily for 12 weeks
215069554|NCT01534585|RADIATION|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
214927842|NCT00672386|DRUG|JNJ16269110|10 mg twice daily for 12 weeks
214927843|NCT00672386|DRUG|JNJ16269110|15 mg twice daily for 12 weeks
214326501|NCT02912286|DEVICE|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
214326502|NCT02912286|DEVICE|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
214326503|NCT06193538|DRUG|Recombinant NV-A01 adenovirus injection|Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
214486184|NCT06888752|BIOLOGICAL|Cell injection|LCAR-M61SQ cells intravenous infusion; Prior to infusion of the LCAR-M61SQ cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
214927844|NCT00672386|DRUG|Placebo|twice daily for 12 weeks
214927845|NCT00672386|DRUG|Metformin|Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
214927846|NCT00672386|OTHER|Dietary Counseling|Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
214927847|NCT00868491|DRUG|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
214927848|NCT00868491|RADIATION|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
214927849|NCT00868491|DRUG|cetuximab, cisplatin|"* cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~* cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)"
214927850|NCT03358589|DIAGNOSTIC_TEST|FDG-PET/CT|Scans
214927851|NCT00492596|DEVICE|AttenueX IntraVesical System|Insertion of the Solace AttenueX Intravesical System on Day 0
214927852|NCT00492596|PROCEDURE|Sham Procedure|Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
214927853|NCT03343717|OTHER|Rehabilitation|physical therapy exercise
214927854|NCT03343717|OTHER|Chest physical therapy|chest physical therapy exercise
214927855|NCT02128425|DRUG|FOLFOXIRI|"irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~\*reduced in UGT1A1 7/7 patients"
214927856|NCT02128425|DRUG|FOLFOX|oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
214927857|NCT04458025|OTHER|Standard rehabilitation program|Standard rehabilitation will start 4 weeks after surgery according to the standard of cre
214927858|NCT04458025|OTHER|Early rehabilitation program|Early rehabilitation program will start 2 weeks
214927859|NCT05961410|DRUG|Eltrombopag olamine|Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.
214326504|NCT00864500|DRUG|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
214326505|NCT00864500|DRUG|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
214326506|NCT00123981|PROCEDURE|Off-Pump Coronary Artery Bypass Grafting|
214326507|NCT03969355|OTHER|Mortality|Patients who died during PICU stay
214326508|NCT05252026|BEHAVIORAL|PROCARE-I (UP-A for indicated purposes)|This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
214326509|NCT05252026|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
214326510|NCT04928222|COMBINATION_PRODUCT|Doxorubicin-containing MNA|A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent
214326511|NCT04928222|DRUG|Placebo-containing MNA|A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
214927860|NCT02062710|DRUG|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
214927861|NCT02062710|DRUG|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
214486185|NCT06888037|DRUG|Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX）|"CAPOX/SOX (each cycle is 21 days): Oxaliplatin 130mg/m2, ivgtt, D1; Capecitabine 1000 mg/m2, po, bid, D1-14 or S-1: 40-60mg according to BSA, bid, D1-14.~FOLFOX (each cycle is 14 days): Oxaliplatin 85mg/m2, ivgtt, D1, Q2W; 5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours; Leucovorin: 400mg/m2, iv, D1.~PD-1 monoclonal antibody:~Nivolumab 360mg/3 weeks or 240mg /2 weeks, iv, D1; If weight ≥60 kg, Sintilimab 200mg/3 weeks; if weight \< 60 kg, Sintilimab 3mg/kg/3 weeks, iv, D1; Tislelizumab 200mg/3 weeks, iv, D1; Pembrolizumab 200mg/3 weeks, iv, D1;"
214927862|NCT02062710|DRUG|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
214927863|NCT02062710|DRUG|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
214326512|NCT06054672|DEVICE|Subthreshold Electrical stimulation|We will use a electrotherapy device to deliver subthreshold Electrical stimulation
214927864|NCT02062710|DRUG|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
214326513|NCT01728155|DRUG|chemotherapy|
214326514|NCT04140669|DEVICE|Automated Myocardial Performance Index (MPI)|Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
214326515|NCT04466514|DRUG|ASTX029|Form: tablet; Route of Administration: oral
214927865|NCT02062710|DRUG|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
214927866|NCT04481191|BIOLOGICAL|RotaTeq (V260)|Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution
214326516|NCT01014494|DEVICE|Adaprev|Class III Medical Device
214326517|NCT05108493|OTHER|Dry needling|Three sessions dry needling of lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).
214326518|NCT05108493|OTHER|Home exercise program|All participants will start the home exercise program during the study period consisting of range of motion exercises for wrist flexion, extension, ulnar and radial deviation, elbow flexion and extensor; forearm supinator, and pronator muscles; stretching exercises. Eccentric strengthening of the wrist flexor extensors, ulnar and radial deviation, forearm pronation, supination, and strengthening exercise training will be given to the elbow extensors and flexors. Progressive strengthening exercises will be added to the program. The exercise program will be terminated with stretching exercises. The exercises will be performed for 10 repetitions 2 times a day, stay in each position for 10 seconds, and rest for 30 seconds between periods. Both groups will be advised to continue the exercise program for 12 weeks.
214927867|NCT04481191|BIOLOGICAL|IPV|0.5 mL dose IPV (Sabin strain based), administered via IM injection
214927868|NCT05754580|RADIATION|High Dose Brachytherapy|This technique involves transient insertion of a stronger (i.e. more active) source (Ir-192) into the prostate, with dose delivery over the course of several minutes followed by immediate removal.
214326519|NCT02320019|DRUG|Placebo|Placebo matching YH14618
214326520|NCT02320019|DRUG|YH14618|
214326521|NCT05206968|RADIATION|pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph
214326522|NCT03388073|OTHER|Berry extract I|Seabuckthorn berry proanthocyanidin extract 250 mg single dose
214326523|NCT03388073|OTHER|Berry Extract II|Seabuckthorn berry proanthocyanidin extract 500 mg single dose
214326524|NCT03388073|OTHER|Berry extract blend|Seabuckthorn berry blend with other berry-based antioxidants
214326525|NCT03388073|OTHER|Placebo|Placebo
214927869|NCT05754580|RADIATION|Stereostatic Body Radiation Therapy|ultra-hypofractionation radiation therapy.
214927870|NCT01950104|OTHER|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development.
214927871|NCT01950104|OTHER|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development
214927872|NCT04955665|PROCEDURE|bone block procedure|a 20 × 15 × 3 mm3 bone block was cut from the lateral malleolus, rotated backwards 45°, and sutured back to the periosteum of the lateral malleolus using non-absorbable sutures.
214927873|NCT04955665|PROCEDURE|Reattachment of the superior peroneal retinaculum|two suture anchors (Mini Quickanchor,DePuy Mitek) were inserted into the postero-lateral ridge of the lateral malleolus without damaging the cartilaginous ridge, after which the SPR was reattached to the lateral malleolus with the anchored suture. The inner layer of the false pouch was incised, and the outer layer (periosteum) was sutured with the SPR in a pants-over-vest style.
214927874|NCT00297531|DEVICE|PerioWave|
214326526|NCT01683591|PROCEDURE|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
214326527|NCT00178958|DEVICE|Holter Monitor|
214326528|NCT01260610|DRUG|Tenofovir|300 mg of Tenofovir daily
214326529|NCT01260610|DRUG|Telbivudine|600 mg of Telbivudine daily
214326530|NCT01260610|DRUG|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
214326531|NCT01557660|DRUG|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
214326532|NCT05133648|PROCEDURE|Hip Fracture Surgery|Hip fracture surgery
214326533|NCT05133648|OTHER|COVID-19 infection|COVID-19 infection
214927875|NCT00297531|PROCEDURE|Scaling and Root Planing|
214927876|NCT01702194|DRUG|TD-1211 IV [C14]|
214927877|NCT01702194|DRUG|TD-1211 PO [C14]|
215069555|NCT01534585|DRUG|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
215069556|NCT01534585|OTHER|Quality of life|The EORTC QLQ-C30 and H\&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
215069557|NCT01534585|GENETIC|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
215069558|NCT04319341|OTHER|To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS|ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
214326534|NCT03108339|OTHER|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
214326535|NCT05484401|DRUG|Ibuprofen 200Mg Oral Cap|2 x 200mg Liquid Capsules once in 12 hours
214326536|NCT05484401|DRUG|Ibuprofen 200Mg Oral Tablet|2 x 200mg Tablets once in 12 hours
214326537|NCT05484401|OTHER|Placebo Liquid Capsule|2 x Liquid Capsules once in 12 hours
214326538|NCT05484401|OTHER|Placebo Tablets|2 x Tablets once in 12 hours
214326539|NCT05057676|BEHAVIORAL|Immediate Autoimmune Intervention Mastery Course (AIM)|Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
214326540|NCT05057676|BEHAVIORAL|Immediate Question and Answer sessions. (AIM Q and A sessions)|Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
214326541|NCT05057676|BEHAVIORAL|Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
214326542|NCT05057676|BEHAVIORAL|Delayed AIM Question and Answer sessions|Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
214927878|NCT04376086|PROCEDURE|Epidural anesthesia|Segmental epidural analgesia
214927879|NCT04376086|PROCEDURE|general anesthesia|general anesthesia
214927880|NCT03091881|DRUG|Granisetron 0.1 MG/ML|Granisetron 0.1 MG/ML Will be given 10 min before spinal block
214927881|NCT03091881|DRUG|Placebos|Placebos will be given 10 min before spinal block
214927882|NCT01670734|DRUG|alirocumab SAR236553 (REGN727)|"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous"
215069559|NCT02745782|OTHER|Observational Study|Observational Study
215069560|NCT04963244|OTHER||
215069561|NCT00641238|DEVICE|Radiofrequency ablation|Radiofrequency ablation
215069562|NCT06532526|OTHER|Predicta® Bioactive Desensitizer (PBD, PARKELL, EDGEWOOD, NY, USA)|A bioactive desensitizer gel that applied on teeth to reduce tooth sensitivity associated with dental bleaching.
215069563|NCT06532526|OTHER|Gel with 1.23% sodium fluoride (EAZIGEL, VERICOM CO., LTD. SOUTH KOREA)|Fluoride gel that applied on the teeth to reduce tooth sensitivity
215069564|NCT06532526|OTHER|Placebo gel without any active ingredients.|Water-based glycerin gel is used as the Placebo gel without active ingredients
215069565|NCT05034497|DRUG|186RNL|"All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.~Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir."
215069566|NCT05289141|DEVICE|Use of high flow nasal oxygen therapy|Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).
215069567|NCT05289141|DEVICE|Use of other non-invasive ventilation or high concentration oxygen masks|Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
214927883|NCT03048123|PROCEDURE|Hepatic arterial infusion|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially
214927884|NCT03048123|PROCEDURE|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
214927885|NCT03048123|DRUG|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
214927886|NCT03048123|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
214927887|NCT02487771|DRUG|DHA|600 mg DHA capsule
214326543|NCT04306224|BIOLOGICAL|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
214326544|NCT03945500|DEVICE|Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter|"Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet, an FDA approved Bluetooth spirometer, an FDA approved pulse oximeter. HIPAA compliant data will be sent to an Investigational IT dashboard maintained at the Central Monitoring Institute Server.~Volunteers will train in-center or remotely \& perform baseline testing with the SHS method along with a baseline laboratory-based spirometry test (if practicable).~Pre-Surveillance Phase: Daily home spirometry method testing for 4 to 10 weeks to enable normal range calibration.~Surveillance Phase: At least weekly home spirometry method testing for 2-10 months of participation. Volunteers will maintain a test log during study team directed SHS software pathway functionality testing."
214326545|NCT04916249|DRUG|Tibetree Pain Relieving Plaster|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
214326546|NCT04916249|OTHER|Placebo|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
214326547|NCT05390502|BEHAVIORAL|manual monitoring and general education on use|Patients will receive a standard blood pressure monitor and education on how to use it. Data will be reported as part of usual care.
214326548|NCT05390502|BEHAVIORAL|integrated monitoring and local wrap-around hypertension program|Patients will receive a standard blood pressure monitor and a local wrap-around hypertension program. Data will be sent directly to their participating health system.
214326549|NCT00634647|DRUG|Satraplatin|80 mg/m\^2 days 1-5 of every 35 day cycle
214326550|NCT00634647|DRUG|prednisone|5 mg twice daily every 35 days
214326551|NCT05757570|DRUG|povetacicept|Administered by subcutaneous injection every 4 weeks
214326552|NCT05714527|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
214326553|NCT05714527|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
214673129|NCT05296057|DEVICE|Participants Receiving VR-Exposure Therapy Treatment|In the baseline interview with an exposure therapy specialist and a member of the research team, participants will be presented with approximately three sets of possible exposure scenarios, each associated with approximately three different scenes that increase in severity level. Through discussion with the exposure therapy specialist, the participant will choose the exposure scenario (out of the three options) that most closely resembles their own epilepsy- or seizure-related fears. As the treatment, the participant will be exposed to the scenes that are associated with their chosen exposure set in a hierarchical manner using an immersive head-mounted display. The participant will work through the three levels of the chosen exposure scenario for approximately two weeks, ideally on each level for four days.
214927888|NCT02487771|DRUG|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
214927889|NCT00996411|DRUG|Salvinorin A|This is an initial dose ranging study
214927890|NCT02043951|DEVICE|Lutonix Drug Coated Balloon Catheter|
214927891|NCT02002533|BEHAVIORAL|Brief Behavioral Therapy|Undergo BBT intervention
214927892|NCT02002533|BEHAVIORAL|Telephone-Based Intervention|Undergo BBT intervention
214326554|NCT05101187|DRUG|Olorofim|Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
214326555|NCT05101187|DRUG|AmBisome®|Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
214673130|NCT03762980|OTHER|Bilateral training (BAT)|Each group received bilateral training) for upper extremities for 3 days per week for 01 hour/day for up to 6 weeks. Tasks included functional tasks such as stacking cones and cups, positioning the cup upright, throw a ball into basket, carrying a wooden block and buttoning and unbuttoning of shirt with counting. Each task was performed for 10 minutes and had a rest break of 1 minute.
214927893|NCT02002533|OTHER|Educational Intervention|Undergo HEAL
214927894|NCT02002533|BEHAVIORAL|Telephone-Based Intervention|Undergo HEAL
214927895|NCT00451295|DRUG|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
214326556|NCT04293887|DRUG|Recombinant human interferon α1β|Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
214326557|NCT04261712|DRUG|Paltusotine|Paltusotine, once daily by mouth
214326558|NCT05035745|DRUG|Talazoparib|Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)
214927896|NCT00451295|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
214326559|NCT05035745|DRUG|Selinexor|Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)
214326560|NCT03587935|OTHER|3D-Colonoscopy Progression Score|The score is based on a movement analysis of the colonoscope from anus until max insertion(cecum). It is scaled from 0-1000. A score of zero equals an incomplete procedure and a score of 1 is a very poor score but the cecum was reached. Increasing score represents better technical performance with a maximum score of 1000.
214673131|NCT03303430|DIAGNOSTIC_TEST|MRI|Diffusion weighted imaging 24 hours after revascularisation
214927897|NCT00241124|DRUG|valsartan|
214927898|NCT00241124|DRUG|lisinopril|
214927899|NCT02351908|DRUG|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
214927900|NCT02351908|DRUG|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
214927901|NCT02351908|DRUG|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
214927902|NCT04319081|DRUG|PCSK9 inhibitor|Patients are included after PCSK9 inhibitors prescription , at the first dispensation
214927903|NCT03710070|DEVICE|Amplatzer vascular plug 4|See above
214927904|NCT03710070|OTHER|Sham Control|Angiography of the IMA without occlusion
214326561|NCT03587935|OTHER|3D-Colonoscopy Retraction Score|The score is based on a movement analysis of the colonoscope from cecum to the anus. It is scaled from 0-1000. A score of zero equals a very poor score, Increasing score represents better technical performance with a maximum score of 1000.
214673132|NCT04775043|DIAGNOSTIC_TEST|HFRDIS questionnaire completion|HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
214673133|NCT03560895|DEVICE|cuffed endotracheal tube|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube
214927905|NCT02362776|OTHER|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
214927906|NCT05984264|DRUG|lidocaine 2.5% and prilocaine 2.5% cream in pain management before pleurocentesis.|Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) will be applied at least 30 min before the pleurocentesis on the skin overlying the chosen aspiration site using ultrasound under occlusive dressing over a 5 × 5 cm area. The time interval between topical Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) application and pleural aspiration will be 30 min, and 45 min.
214927907|NCT02312453|PROCEDURE|Posterior approach|We adopted the technique as described by Hebbard et al.
214927908|NCT06017817|DEVICE|Lumoral Treatment|Anti-infective photodynamic therapy for plaque-induced oral conditions
214673134|NCT03560895|DEVICE|Uncuffed endotracheal tube|Patients will be anesthetized using uncuffed endotracheal tube
214927909|NCT06017817|PROCEDURE|Standard oral hygiene instructions|Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use
214927910|NCT06017817|PROCEDURE|Scaling and root planing (SRP|non-surgical anti-infective treatment by scaling and root planing
214927911|NCT06017817|PROCEDURE|surgical anti-infective peri-implantitis treatment|surgical anti-infective peri-implantitis treatment
214927912|NCT04574934|OTHER|aquatic therapy|Aquatic therapy refers to water-based treatments or exercises of therapeutic intent, in particular for relaxation, fitness, and physical rehabilitation. Treatments and exercises are performed while floating, partially submerged, or fully submerged in water. Many aquatic therapy procedures require constant attendance by a trained therapist and are performed in a specialized temperature-controlled pool. Rehabilitation commonly focuses on improving the physical function associated with illness, injury, or disability
214927913|NCT00101036|DRUG|lapatinib ditosylate|Given PO
214927914|NCT00101036|OTHER|laboratory biomarker analysis|Correlative studies
214927915|NCT04761549|PROCEDURE|Adolescent Idiopathic Scoliosis|Adolescent Idiopathic Scoliosis
214927916|NCT02823392|OTHER|DBMV|the occurrence of at least two following events which were requiring application of CPAP with opening airway maneuvers, requiring oropharyngeal airway, requiring two-person bag mask ventilation, unable to perform bag mask ventilation or presence of desaturation (SpO2 \< 95%).
214326562|NCT04270825|BEHAVIORAL|Group CBT with IPT|Group treatment designed to target relationships with both possessions and people.
214326563|NCT06297356|DEVICE|Stress ball|Stress balls are soft sponges with a diameter of 2-4 cm. The lightest starting level was preferred for the patients. Patients were allowed to take the stress ball in any hand they wanted. They were asked to squeeze and loosen the ball in their palm at 2-3 second intervals.
214326564|NCT02610868|DRUG|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
214326565|NCT05002946|DRUG|SP-104|single oral dose
214326566|NCT05002946|DRUG|Naltrexone Hydrochloride 50Mg Oral Tablet|single oral dose
214326567|NCT02560636|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
214326568|NCT02560636|RADIATION|Radiotherapy|Radiotherapy
214673135|NCT04891601|PROCEDURE|polypropelene mesh|compare use mesh alone or combined mesh and darn repair
214326569|NCT06254417|PROCEDURE|Diaphragmatic ultrasound|Diaphragmatic ultrasound will be performed to all patients with respiratory disease to evaluate diaphragmatic thickening and estimate thickening fraction and to evaluate diaphragmatic excursion. Measurements will be obtained at bedside with a portable ultrasound machine equipped with a linear probe (Logic P6 Pro, GE Healthcare). Diaphragmatic thickness measures will be performed on right Intercostal approach through the zone of apposition. Diaphragmatic excursion will be performed using curved-array probe (Logic P6 Pro, GE Healthcare) is positioned below right costal arch at the mid-clavicular line. The ultrasound study will be done and /or supervised by ultrasound expert
214326570|NCT00753207|DRUG|epirubicin hydrochloride|
214326571|NCT00753207|DRUG|lapatinib ditosylate|
214326572|NCT00753207|OTHER|biomarker analysis|
214326573|NCT00753207|OTHER|immunohistochemistry staining method|
214326574|NCT00753207|OTHER|liquid chromatography|
214326575|NCT00753207|OTHER|mass spectrometry|
214326576|NCT01700179|DRUG|ACH-0143102|
214326577|NCT01700179|DRUG|Ribavirin|
214326578|NCT00184899|DRUG|Intravenous infusion of Intralipid/heparin|
214326579|NCT00184899|DRUG|Intravenous infusion of Glycerol/heparin|
214326580|NCT01004367|OTHER|Experimental|Environmental- and individual based components carried out in the school.
214673136|NCT01928030|BIOLOGICAL|recombinant human hyaluronidase|Given SC
214673137|NCT05054946|PROCEDURE|Laparoscopic cystectomy|All surgeries will be performed under general anesthesia by laparoscopically.
214927917|NCT03675295|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
214927918|NCT03675295|DRUG|Saline|injection of 10 cc saline injection nearby median nerve as hydro-dissection
214927919|NCT06667895|OTHER|respiratory gated taVNS|Electrical stimulation will be delivered in bursts during expiration
214927920|NCT06667895|OTHER|random burst stimulation|Electrical stimulation will be delivered in bursts at random timepoints during the breathing cycle
214927921|NCT06667895|OTHER|continuous stimulation|Electrical stimulation will be delivered continuously for 30sec followed by a 30sec break.
214927922|NCT06667895|OTHER|Sham stimulation|Electrical stimulation will be identical to the taVNS, but the electrodes will be placed at a different position on the ear
214927923|NCT01539395|OTHER|MSDx Complex-1 Biomarker Test|A biomarker test for the level of MSDx Complex-1
214927924|NCT00722566|DRUG|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
214927925|NCT00722566|DRUG|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
214927926|NCT04621526|DRUG|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
214927927|NCT04621526|DRUG|dexmedetomidine- propofol|patients will receive combination from 0.5 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
214927928|NCT06619145|DRUG|Low dose Oliceridine|Low dose Oliceridine
214927929|NCT06619145|DRUG|High dose Oliceridine|High dose Oliceridine
215069568|NCT04660851|BEHAVIORAL|Coached|10-weeks of diet coaching weekly by telephone to improve dietary protein intake
214326581|NCT06399328|DIAGNOSTIC_TEST|Surface Enhanced Raman Spectroscopy|Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.
214326582|NCT00667342|BIOLOGICAL|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
214326583|NCT00667342|DRUG|Cisplatin|Given IV.
214326584|NCT00667342|DRUG|Doxorubicin|Given IV.
214326585|NCT00667342|DRUG|Methotrexate|Given IV.
214326586|NCT00667342|DRUG|Ifosfamide|Given IV.
214326587|NCT00667342|DRUG|etoposide|Given IV.
214326588|NCT00667342|PROCEDURE|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
214326589|NCT00667342|RADIATION|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
214326590|NCT03828305|OTHER|Training and creation of the Network-CPR|Training and creation of the Network-CPR that will cover the city. This network will be created with certain population groups that are routinely in contact with susceptible persons of OHCA (police, firemen, teaching staff, health personnel, merchants, pharmacists, university students, etc.), in addition, relatives of people with heart disease will be included. In the case of elderly people who are alone, they will include their neighbors or caregivers. In the city, there are 2,105 people with heart disease susceptible to OHCA. The research team and the health personnel of the participating primary care centers (PCC) will offer training courses on basic CPR maneuvers and use of the AED, following the protocol of the Center Català de Ressucitació (CCR). The training is aimed at training 430 people (20% of the relatives of people with heart disease) and will be made by trainers accredited by the CCR. There will be a total of 30 sessions with groups of approximately 15 people.
214326591|NCT03828305|OTHER|Control Group|No intervention
214326592|NCT02206113|BEHAVIORAL|Standing workstation|
214673138|NCT01064089|DRUG|HSP990|
214326593|NCT05122949|DEVICE|3D Printed Ankle-Foot Orthosis|3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material
214326594|NCT05122949|DEVICE|Thermoformed Ankle-Foot Orthosis|Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
214326595|NCT05740722|DIETARY_SUPPLEMENT|Nicotinamid riboside|500 mg x 2 po
214326596|NCT05740722|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
214326597|NCT04142541|DEVICE|Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)|The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
214326598|NCT06382857|DIETARY_SUPPLEMENT|MDF|MDF will be provided to children on a weekly basis for children with SAM and bi-weekly basis for children with MAM at the health center until programmatic recovery but not thereafter.
214326599|NCT06382857|DIETARY_SUPPLEMENT|RUTF|RUTF will be provided to all children on a weekly basis at the health center until programmatic recovery but not thereafter
214326600|NCT06382857|DIETARY_SUPPLEMENT|RUSF|RUSF will be provided on a biweekly basis at the health center until programmatic recovery but not thereafter
214326601|NCT02247310|DRUG|Interferon beta-1b (Betaferon®, BAY 86-5046)|Patients will be treated with Betaferon
214326602|NCT02247310|DEVICE|BETACONNECT|Auto-injector device to support the injection of Betaferon
214326603|NCT06572826|OTHER|Cardiac Rehabilitation intervention|The cardiac rehabilitation program for post-CS patients includes respiratory physiotherapy, muscle strengthening and endurance training such as walking, treadmill exercises, and cycling, all tailored to the patient's capabilities. Cardiovascular training involves interval and continuous aerobic exercises to improve heart function. The program emphasizes secondary prevention strategies, including lifestyle changes and medication management. Neuromotor rehabilitation addresses sarcopenia and polyneuropathies through targeted exercises like balance training, gait retraining, and the use of advanced technologies like functional electrical stimulation (FES), robotic devices, and virtual/augmented reality. Cognitive-behavioral therapy (CBT) helps manage the psychological effects of severe cardiovascular events. The program also includes speech and occupational therapy, planning for home reintegration, and telerehabilitation to ensure long-term recovery.
214326604|NCT00403091|BEHAVIORAL|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
214326605|NCT00403091|BEHAVIORAL|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
214927930|NCT06649188|DEVICE|Magnesium Sulphate Iontophoresis|"Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED) The phoresors II auto model PM850 IOMED allows the user to deliver a specific dose from 0 to 80 mA/min, control the current from 0 to 4 mA and automatically calculates required time for the selected dose. Current ramp-up and down, shut-off, error messages and safety checks are also performed automatically. The builtin option for manual current shut-off is an added safety feature (Teslim et al., 2013).~* Electrodes: Active-Anode (Drug Delivery).~* Drug Used: MgSO4 Aqueous Solution.~* Drug Ion Polarity: Positive Polarity."
214927931|NCT06649188|OTHER|traditional physical therapy program|Deep friction massage, stretching and pressure therapy.
215069569|NCT06094361|PROCEDURE|Iontophoresis Intervention|Iontophoresis was applied with a Chattanooga Physio (DJO Global, Herentals, Belgium) brand device. The galvanic current mode was selected for the intervention. Intervention area was cleaned to prevent irritation and active electrode pad (cathode-5 cm2) was immersed in 75 mg diclofenac sodium solution. The current intensity of the application for 10 minutes was 0.1-0.2 mA/cm2.
214326606|NCT00963664|DRUG|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
214326607|NCT00963664|DRUG|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
214326608|NCT04777344|BEHAVIORAL|Tobacco Treatment Specialist (TTS) intervention|A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
214326609|NCT06459518|OTHER|Bowen Therapy along with conventional therapy|"Bowen Technique Group Assignment: Participants will be assigned to undergo targeted Bowen Technique therapy sessions.~Session Details: The therapy sessions will include:~* Gentle, rolling-type maneuvers~* Specific placements of fingers and thumbs~* Focus on muscles, tendons, and ligaments associated with neck pain Therapeutic Pauses: There will be intentional pauses between sets of moves to allow the body time to respond to the therapeutic stimulation.~Conventional Therapy: Hot pack, TENS, Passive Stretching 2 times a week for 4 weeks"
214927932|NCT04533243|DRUG|2.5ug/h transdermal fentanyl|2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
215069570|NCT06094361|PROCEDURE|Phonophoresis|Phonophoresis was performed with a Chattanooga brand ultrasound device (Chattanooga, Intelect Legend Ultrasound, TN, USA). 75 mg gel containing 1% diclofenac sodium was applied to the shoulder area. The ultrasound was conducted continuously for 6 minutes with frequency of 1 MHz and an intensity of 1.5 watts/cm2.
215069571|NCT06094361|PROCEDURE|Conventional Therapy|All groups received a treatment program consisting of hot pack, Transcutaneous Electrical Nerve Stimulation and Shoulder girdle exercises for 30 minutes.
214927933|NCT04533243|DRUG|Oral immediate-released morphine|5mg immediate-released morphine every 4 hours, double dose before sleep.
214927934|NCT03863704|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
214927935|NCT03469180|OTHER|Treadmill training|Treadmill training Each season will be supervised and last 45 minutes. Treadmill speed will be adjusted to the child's maximal heart rate (MHR) (between 65 to 75 percent of the MHR).
214927936|NCT03469180|OTHER|Whole body vibration training|Whole body vibration training whole body vibration frequence will be 50 Hertz and childrens will be standing position on vibration platform .
214927937|NCT05136144|DRUG|SM-020|Topical Akt Inhibitor SM-020 Gel
215069572|NCT06212115|DIAGNOSTIC_TEST|mNGS|metagenomics next generation sequencing
215069573|NCT05222893|DIAGNOSTIC_TEST|Respiratory monitoring|Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation
214326610|NCT06459518|OTHER|Muscle Energy Technique with Conventional Therapy|"MET Session Structure: Participants will engage in Muscle Energy Technique (MET) sessions that focus on:~* Isometric muscle contractions, where muscles are contracted without changing length.~* Therapist-guided, controlled contractions against specific resistance.~* Relaxation Periods: Each contraction session will be followed by a period of relaxation to allow muscles to recover and respond to the therapy.~conventional therapy: Hot pack, TENS, Passive Stretching 2times a week for 4 weeks."
214927938|NCT01570569|DRUG|Omeprazole|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
214927939|NCT01570569|DRUG|Losartan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
214927940|NCT01570569|DRUG|Dextromethorphan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
214927941|NCT01570569|DRUG|Cocktail|"Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days."
214927942|NCT01570569|DRUG|Midazolam|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
214927943|NCT01570569|DRUG|Caffeine|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
214927944|NCT04875026|DRUG|5-fluorouracil 4% (Tolak)|Application of Tolak once daily in the evening for 4 weeks
214927945|NCT04875026|DEVICE|Dexeryl|Application of Dexeryl once daily in the morning for 8 weeks
214927946|NCT04076423|DRUG|Dual Therapy|DTG + 3TC
214927947|NCT04076423|DRUG|Triple therapy|BIC / FTC / TAF
214927948|NCT00854919|DRUG|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
214927949|NCT00854919|BEHAVIORAL|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
214927950|NCT03291470|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1
214927951|NCT03291470|BIOLOGICAL|Placebo Control|2 mL normal saline intraarticular injection
214927952|NCT03504306|OTHER|Ventriject validation|comparing measurements from echocardiography, echoseismography to measurements of maximal oxygen uptake
214927953|NCT00340106|BEHAVIORAL|Counseling|
214927954|NCT05967923|RADIATION|Shock wave therapy|Patients in this group will receive shock wave therapy once a week for four weeks in addition to routine physical therapy program.
214326611|NCT05952037|DRUG|Sonrotoclax|Administered orally as a tablet.
214326612|NCT05952037|DRUG|Zanubrutinib|Administered orally as a capsule.
214326613|NCT04977323|OTHER|TICK-B group|These interventions will use as distraction techniques.
214326614|NCT00714246|DRUG|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
214326615|NCT00714246|DRUG|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
214326616|NCT00714246|DRUG|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
214326617|NCT00262548|DRUG|Rosuvastatin; improvement of lipid profile|
214326618|NCT03524027|PROCEDURE|Posterior Vertebral Column Resection (PVCR)|Posterior Vertebral Column Resection (PVCR) Surgical Technique for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity
214326619|NCT01585142|OTHER|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
214326620|NCT04358497|DEVICE|Medtronic® Concerto® detachable coil system|coil embolization of the reflux pathways
214326621|NCT04358497|PROCEDURE|sclerosis|Pelvic varices sclerosis with polidocanol foam
214326622|NCT04358497|DRUG|Diosmin / Hesperidin|Best chronic medial treatment
214326623|NCT04358497|DRUG|Ibuprofen 400 mg|NSAID treatment
214927955|NCT05967923|RADIATION|Low level lazer therapy|Patients in this group will receive low level lazer therapy three times a week week for four weeks in addition to routine physical therapy program.
214927956|NCT05967923|OTHER|Routine physical therapy program|Patients in this group will receive only routine physical therapy program three times a week for four weeks.
214927957|NCT04885400|BEHAVIORAL|iJobs|During the program, the participants will learn and exercise successful job search strategies. The web-based adaptation of the Jobs program will allow self-administration. After each session, they will receive written feedback from trainers on the platform.
214927958|NCT06730737|OTHER|Video preventive education|Interactive video that teaches the subject about the overall importance of prevention, smoking cessation, proper diet, exercise, and sleep.
214673139|NCT03557372|RADIATION|Mathematical Model-Adapted Radiation Fractionation Schedule|"* Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks~* Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes.~* Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment."
214927959|NCT04984278|DRUG|Nabiximols|oromucosal spray
214927960|NCT04984278|DRUG|Placebo|oromucosal spray
214927961|NCT05806996|DRUG|Magnesium|Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour
214927962|NCT05806996|DRUG|Placebo|Equivalent volume of normal saline
214927963|NCT06517043|BEHAVIORAL|Balance Training|Complex balance task involving static and dynamic weight shifting and coordinated stepping
214927964|NCT06517043|DEVICE|Spinal Active tsDCS|Active tsDCS over lumbar regions
214927965|NCT06517043|DEVICE|Spinal Sham tsDCS|Sham tsDCS over lumbar regions
214326624|NCT04296812|BEHAVIORAL|Self-Love Model|"The model is a visual illustration shaped as a triangle.~* The bottom left line is title Zero Self-Love, moving upward are characteristics identified from zero self-love along the line.~* The bottom right side is titled Self-Love moving upward are characteristics identified from having self-love.~* At the top of the triangle is a circle with the letter R within for relationship.~* Two small lines project horizontally, from the circle, left and right.~* At the end of the Left line is a circle with the word break-up in the middle, surrounded by terms: drugs, alcohol, self-harming, suicide, and sex as the consequence of zero self-love.~* At the end of right line is a circle with the word break-up in the middle surrounded by terms: support system, coping skills, spirituality reflection as the consequences of having self-love.~The strategies being discussed:~* Exploring self-esteem strategies.~* Importance of self-worth in relationships.~* Importance of self-awareness."
214326625|NCT01901380|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|
214326626|NCT03808896|PROCEDURE|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
214326627|NCT03808896|DEVICE|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
214927966|NCT03225755|DRUG|Growth hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
215069574|NCT05222893|DIAGNOSTIC_TEST|Capnography|Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute
215069575|NCT05222893|DIAGNOSTIC_TEST|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
215069576|NCT05222893|DEVICE|Esophageal pressure|Measurement the pressure in the lower third of esophagus during inspiration and expiration
215069577|NCT00620178|DRUG|Candesartan Cilexetil|oral once daily dose
215069578|NCT00620178|DRUG|Losartan|once daily oral dose
214326628|NCT03410979|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single ascending doses
214326629|NCT03410979|DRUG|Placebo single dose|Placebo, oral suspension.
215069579|NCT06013358|GENETIC|AlloSeq cfDNA|An in vitro diagnostic medical device is employed for predicting damage to and rejection of transplanted organs (kidney, heart, liver, lung) by measuring the ratio of Donor-Derived Cell-Free DNA (dd-cfDNA) to total Cell-Free DNA (cfDNA) extracted from the plasma of patients who have undergone solid organ transplantation. This measurement is carried out using next-generation sequencing methods.
215069580|NCT04120753|DRUG|OLOMAX 20/5/5mg|Tablets, Oral, QD
215069581|NCT04120753|DRUG|OLOMAX 20/5/10mg|Tablets, Oral, QD
214326630|NCT03410979|DRUG|GLPG2737 multiple dose|GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
214326631|NCT03410979|DRUG|GLPG2737 multiple dose|Placebo, oral suspension, daily for 14 days
214326632|NCT03534856|BEHAVIORAL|Mindfulness meditation|Short guided mindfulness meditations were provided on an MP3 player.
214673140|NCT05778318|DRUG|The group of patients who received Lianhua Qingwen orally|Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
214673141|NCT05778318|OTHER|The group of patients who did not receive Lianhua Qingwen orally|The group of patients who did not receive Lianhua Qingwen orally.
214927967|NCT03750513|RADIATION|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Given LET optimized IMPT
214927968|NCT03750513|OTHER|Quality-of-Life Assessment|Ancillary studies
215069582|NCT04120753|DRUG|Olmesartan 20 mg/Amlodipine 5 mg|Tablets, Oral, QD
215069583|NCT01858545|DEVICE|MatriStem|MatriStem MicroMatrix and MatriStem Wound Matrix
215069584|NCT01858545|DEVICE|Cellular Dermal Replacement Tissue|Cellular Dermal Replacement Tissue
215069585|NCT05594017|DRUG|Scopolamine (0.4mg)|Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
215069586|NCT05594017|DRUG|Placebo|Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
215069587|NCT01578642|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
215069588|NCT04352764|DIAGNOSTIC_TEST|CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test|The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19
215069589|NCT01832129|DRUG|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
214927969|NCT03750513|OTHER|Questionnaire Administration|Ancillary studies
214927970|NCT04185428|BEHAVIORAL|Integrative Therapy|still meditation, meditative movement, relaxation techniques, and massage therapy
214927971|NCT05195684|OTHER|imaginal probe|trauma and nightmare imaginal probe/challenge for which psychophysiological and CNS responses are recorded
214927972|NCT03697512|DRUG|Ibrutinib|capsules for oral intake in a dosage of 560 mg (four capsules) daily
215069590|NCT01832129|DRUG|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
215069591|NCT03692377|DEVICE|Virtual Reality|Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
215069592|NCT05016661|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
215069593|NCT05203757|PROCEDURE|ArthroCT scan|Conventional CT arthrogram as routine care
214927973|NCT03697512|DRUG|Rituximab|Concentrate solution for infusion - intravenous use; Solution for injection - subcutaneous use.
214927974|NCT03683927|COMBINATION_PRODUCT|Bacillus clausii|The probiotic (Bacillus clausii) will be administered 4 times a week to the infant
214927975|NCT03683927|OTHER|Sterile water|The placebo group will receive sterile water 4 times a week
214927976|NCT00546065|DRUG|esomeprazole treatment|concomitant esomeprazole treatment
214927977|NCT01749709|BEHAVIORAL|Music listening|
214927978|NCT01749709|BEHAVIORAL|Audiobook listening|
214927979|NCT06967077|OTHER|Virtual reality head set.|Tennis game exercise using virtual reality head set
214927980|NCT06968858|DIAGNOSTIC_TEST|NIMBLE test|Non-invasive assessment of ISR with the NIMBLE System (Microwave Interferometry)
214927981|NCT05579197|DEVICE|Lower-limb robotic intervention|"The intervention proposed in this study involves the use of an exosuit for lower limbs, the Myosuit. The selection of the tasks has been done in order to replicate typical activities of daily living in a structured environment, i.e. a rehabilitation hospital.~Specifically, the tasks involve walking, sit to stand, balance and stair climbing.~During the phases of assessment (session 2 and session 10), other devices are be used. Specifically:~* The Optogait system; for a markerless gait analysis;~* The Gyko sensor; an inertial sensor that will be used at the beginning of the training for the synchronisation of the signals recorded by the Myosuit and the signal recorded by the Optogait.~Finally, during all the sessions, the Polar heart rate sensor is used to constantly monitor the cardiac frequency of the patients."
214927982|NCT03813901|OTHER|Samalochana Counselling|Counselling program was individual, based on advaita vedanta and traditional philosophical grounds to answer individual fears, concerns,conflicts and difficulties in order to cope and recover.
214927983|NCT03813901|OTHER|Wait list control|Wait list had no intervention offered during the study period. Afterwards, they were offered the counselling for the same duration.
214927984|NCT06665893|DEVICE|Digi-physical treatment tool|A support tool named Evira will be used to provide behavioral treatment. Through daily weightings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored.
214927985|NCT01482065|DEVICE|CPAP (ResMed S9 autoset CPAP)|A ResMed S9 autoset CPAP device will be utilized throughout the study. Throughout the study intervention period, subjects (for AHI\> 15) will be instructed to utilize their CPAP and adherence will be monitored using an automatic meter that is built into the CPAP device.
214927986|NCT05590416|DRUG|Adalimumab|Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
214927987|NCT02907528|BIOLOGICAL|Bone|Furcation defect regenerated with bone graft material
214927988|NCT02907528|BIOLOGICAL|EMD|Furcation defect regenerated with EMD
214927989|NCT02202993|DRUG|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
214927990|NCT04321369|DIAGNOSTIC_TEST|Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals|This is an operational project. Patients will collect a sample from the tongue, nasal cavity and MT and then clinicians will collect a NP sample from the nostril corresponding to each participant's dominant hand.
214927991|NCT04541108|BIOLOGICAL|Rilvegostomig|Intratumoral microdose injection by the CIVO device.
214927992|NCT04541108|BIOLOGICAL|Volrustomig|Intratumoral microdose injection by the CIVO device.
214927993|NCT04541108|BIOLOGICAL|Sabestomig|Intratumoral microdose injection by the CIVO device.
215069594|NCT05203757|PROCEDURE|CBCT|Cone Beam CT scan.
215069595|NCT02842515|OTHER|teeth avulsion|
215069596|NCT00885586|DEVICE|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
214927994|NCT04541108|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
214927995|NCT04884113|DEVICE|Motorized Spiral enteroscopy|Small-bowel enteroscopy for diagnosis and intervention
214673142|NCT01720771|DIETARY_SUPPLEMENT|probiotic tablet|Intake of one probiotic lozenge tablet per day
214673143|NCT01720771|DIETARY_SUPPLEMENT|sugar pill|one tablet daily
214927996|NCT02942381|DRUG|Hydroxychloroquine Sulfate|200mg Bid (eGFR\>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
214927997|NCT02942381|DRUG|Placebo|
214927998|NCT04711928|BEHAVIORAL|Physical activity and sedentary behaviour|Athletes with a high physical activity and a low or high sedentary time
214927999|NCT02158468|DEVICE|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
214928000|NCT02158468|DEVICE|Postconditioning|After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
214928001|NCT05320783|OTHER|music|Classical music pre-selected was started to the patients with individual comfortable volume.
214928002|NCT05320783|OTHER|control|music player was not started.
214928003|NCT04447001|BEHAVIORAL|Tai-chi prime (TCP)|TCP is a 6-week twice-weekly simplified tai chi class of 1.5 hr per session with two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
214928004|NCT01337713|OTHER|Swedish Massage|Swedish massage, 45 minutes, 2 x per week for 6 weeks
214928005|NCT01337713|OTHER|Light Touch|Light touch, 45 minutes, 2 x week for 6 weeks
215069597|NCT00885586|DRUG|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
215069598|NCT00885586|PROCEDURE|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
215069599|NCT01707654|DEVICE|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
214326633|NCT04690127|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
214928006|NCT02657213|DEVICE|Minimed 640G with smartguard activated|Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation
214928007|NCT02657213|DEVICE|Minimed 640G with smartguard off|Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
214928008|NCT00277303|DRUG|XL999|XL999 will be administered at 2.4 mg/kg as a 4-hour intravenous (IV) infusion. Subjects will receive XL999 infusions weekly for 8 weeks of treatment unless drug-related toxicity requires dosing delay. In the absence of progressive disease and unacceptable toxicity, subjects may receive XL999 treatment weekly for up to a year on this study. After 8 weeks, at the discretion of the investigator, one dose of four may be omitted for a subject's convenience.
214928009|NCT01405417|PROCEDURE|Endoscopic Peroral Myotomy|Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
214928010|NCT06147947|DIAGNOSTIC_TEST|Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Hepatic venous pressure gradient (HVPG) will be conducted by experienced interventionists. There should be a maximum interval of no more than 1 week between the HVPG and ultrasound examination, and patients should fast for at least 2 hours before undergoing HVPG."
214928011|NCT02401490|DRUG|Human albumin|1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
214928012|NCT02401490|DRUG|Placebo|
214928013|NCT00000861|DRUG|Indinavir sulfate|
214928014|NCT02860975|OTHER|Inhaled Nitrogen|"To create the correct gas mixture, nitrogen tanks or membrane technology nitrogen generators will be utilized.~Humidified, high flow, hypoxic gas by nasal cannula will allow the participant to walk short distances, eat, execute basic personal needs (e.g., use of toilette, washing, bathing etc.), or take breaks from wearing the mask."
214928015|NCT03933644|DEVICE|Gastric Tube|SGA is inserted with a gastric tube as guide for insertion
215069600|NCT04155918|DRUG|Group 1: AR882 Alone and in Combination with Febuxostat (FBX)|AR882 + Febuxostat, AR882 alone, Febuxostat alone
215069601|NCT04155918|DRUG|Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)|AR882 + Allopurinol, AR882 alone, Allopurinol alone
214928016|NCT03933644|DEVICE|No gastric Tube|SGA is inserted without a gastric tube as guide for insertion
214928017|NCT02848365|DEVICE|Endotracheal intubation|Endotracheal intubation will be done with any of these equipments
214928018|NCT04558606|DEVICE|Sonic Toothbrush|Sonic Toothbrush (Philips Sonicare Flexcare Platinum Toothbrush®)
214928019|NCT04558606|DEVICE|Manual Toothbrush|Manual brushing (Technique Pro - GUM® Sunstar Italiana SRL)
214928020|NCT00425061|BIOLOGICAL|IMA-638|SC Injection, 12 weeks
214928021|NCT00425061|BIOLOGICAL|IMA-638|SC Injection, 12 weeks
214928022|NCT00425061|OTHER|placebo|placebo
215069602|NCT05587296|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
215069603|NCT05587296|DRUG|Placebo|Matching placebo orally once daily
215069604|NCT00923975|DEVICE|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
215069605|NCT01328535|DRUG|temozolomide|Given PO
215069606|NCT01328535|OTHER|flow cytometry|Correlative studies
215069607|NCT01328535|OTHER|staining method|Correlative studies
215069608|NCT01328535|PROCEDURE|biopsy|Optional correlative studies
215069609|NCT01328535|OTHER|laboratory biomarker analysis|Correlative studies
215069610|NCT02974127|RADIATION|Radiotherapy|Multisession radiosurgery
214326634|NCT05220397|BIOLOGICAL|Janssen Ad26.CoV2.S Vaccine|Single dose vaccine of 0.5 mL administered via intramuscular injection, typically in the deltoid muscle
214928023|NCT03358771|OTHER|COPD discharge care bundle|As a part of RHSCN quality improvement initiative, the elements of the COPD discharge bundle were integrated into a standardized COPD admission order set and are being implemented province-wide. The discharging physician/team will complete the COPD bundle (with reminders facilitated by clinical decision support tools) prior to patient discharge. A copy of the bundle is retained in the patient's medical record, and another copy is sent to the patient's primary care provider detailing the components of the bundle that were completed prior to discharge, and those still needing to be addressed. The patient will also receive a patient-focused discharge checklist detailing discharge bundle items
214928024|NCT03358771|OTHER|COPD discharge care bundle & coordinator|The coordinator will be health professional associated with a Primary Care Network, ED or AHS with access to patient information. Patients will be informed that care coordinator may contact them for follow up after discharge. At 48-72 hours after hospital/ED discharge and then at intervals to be determined, the care coordinator will contact the patient by phone. The care coordinator will identify specific needs or problems that patient may have encountered after discharge, which could potentially affect the successful transition from acute to community care setting. Specifically, the care coordinator will seek information on any follow up with family doctor visit, pulmonary rehabilitation and smoking cessation referrals
214928025|NCT02161484|PROCEDURE|Continuous Lumbar Plexus Block|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
214928026|NCT02161484|PROCEDURE|Parasacral Nerve Block|A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.
214928027|NCT02161484|DRUG|Ropivacine 0.2%|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.
214928028|NCT02161484|DRUG|Bupivacaine 0.0625%|In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
214928029|NCT02793401|DEVICE|Hıgh İntensity Laser (HILT)|HILT was performed using a BTL-6000 High Intensity Laser, 12 W(watt), 1064 nm device was a hot laser with Nd: YAG LASER source. In HILT group, the investigators applied the device on the shoulder area in two phases: phase I - analgesia, and phase II - biostimulation.
214928030|NCT02793401|DEVICE|Ultrasound|BTL 4710 US device was applied at 3 MHz frequency, and 1.5watt/cm2 intensity over 25 cm2 surface area. Headpiece area of the device was 5 cm2, and the application was performed as the head of device was positioned at 90º (perpendicular) at full contact for 5 minutes by using gel, and performing continuous circular motions.
214326635|NCT05220397|OTHER|Reduction in Immunosuppression Medication|Reduction in immunosuppression medication dosage
214928031|NCT02793401|DEVICE|Hotpack|All patients had the same physical therapy (PT) protocol including hot pack (HP) for 20 min/session,
214928032|NCT02793401|DEVICE|Transcutaneous electrical nerve stimulation|All patients had the same physical therapy (PT) protocol includingTENS (Fizyotens 4000, Fizyomed Medical Devices Ltd,Turkey) (50-100 Hz) for 20 min/session,
214928033|NCT02793401|OTHER|Therapeutic exercises|All patients had the same physical therapy (PT) protocol including therapeutic exercises for shoulder muscles
214928034|NCT02793401|OTHER|Balneotherapy|All patients had the same physical therapy (PT) protocol including balneotherapy in 38-40 °C thermomineralized water for 20 minutes.
214928035|NCT06136182|PROCEDURE|Pericardial Closure Using Gentrix Following Cardiac Surgery|To determine feasibility and effectiveness of Gentrix for cardiac use, and if this product is patient population specific.
214928036|NCT02259192|DEVICE|MED-EL Maestro Cochlear Implant|cochlear implant
214326636|NCT05220397|OTHER|Maintenance in Immunosuppression Medication|Maintain current immunosuppression medication dosage
214928037|NCT01054274|DEVICE|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
214928038|NCT01054274|DEVICE|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
214928039|NCT02103192|OTHER|Anti-Oxidant Drink|
214928040|NCT03822663|DIETARY_SUPPLEMENT|Caffeine supplementation|The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 70 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced.
214928041|NCT03822663|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 70 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced.
214928042|NCT04164173|DEVICE|EzPAP|Patient will receive 10 min EzPAP 4 times daily
214928043|NCT04164173|DEVICE|Metaneb|Patient will receive 10 min Metaneb 4 times daily
214928044|NCT04164173|DEVICE|Intermittent Positive Pressure Breathing (IPPB)|Patient will receive 10 min IPPB 4 times daily
215069611|NCT01005316|DRUG|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
215069612|NCT01005316|DRUG|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
214326637|NCT05091528|DRUG|SBT6050|Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles
214326638|NCT05091528|DRUG|trastuzumab deruxtecan|5.4 mg/kg by intravenous (IV) infusion in 21-day cycles
215069613|NCT01005316|DRUG|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
214326639|NCT05091528|DRUG|tucatinib|300 mg by mouth (PO) twice daily (BID)
214326640|NCT05091528|DRUG|trastuzumab|8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles
214326641|NCT05091528|DRUG|capecitabine|1000 mg/m2 PO BID for 14 days of each 21-day cycle
214326642|NCT05091528|DRUG|trastuzumab deruxtecan|6.4 mg/kg by IV infusion in 21-day cycles
214326643|NCT04958109|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Administration of a 75 gm oral glucose tolerance test
214326644|NCT04958109|DRUG|Kisspeptin|Intravenous administration of kisspeptin 112-121 x 16 hours
214326645|NCT04958109|DRUG|Placebo|Intravenous administration of Placebo 16 hours
214326646|NCT00021268|DRUG|tocladesine|
214326647|NCT03640676|DEVICE|FlowOx|FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
214326648|NCT00835497|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
214326649|NCT00835497|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
214326650|NCT01573624|DRUG|FF/GSK573719|100/15.6
214326651|NCT01573624|DRUG|FF/GSK573719|100/31.25
214326652|NCT01573624|DRUG|FF/GSK573719|100/62.5
214673144|NCT04397133|OTHER|inspiratory muscle training|inspiratory muscle training will be done with Philips Respironics Threshold IMT device starting with resistance of % 50 of MIP value
214928045|NCT05926973|OTHER|Enhanced cardiac arrest bundle|"* Delivering shocks with the LUCAS mechanical CPR device running~* After 5 shocks have been delivered placing new pads in the Anterior Posterior (AP) position~* Delivering shocks using the TVAA Tempus Pro defibrillator rather than the Ambulance Service defibrillator."
214928046|NCT03730467|BEHAVIORAL|Phone call to the patient|Phone call to the patient
214928047|NCT02137850|DRUG|turoctocog alfa pegol|For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
214673145|NCT04397133|OTHER|sham intervention|in these group the patients will get sham intervention with Philips Respironics Threshold IMT device
214326653|NCT01573624|DRUG|FF/GSK573719|100/125
214326654|NCT01573624|DRUG|FF/GSK573719|100/250
214326655|NCT01573624|DRUG|FF|100
214928048|NCT05231746|BIOLOGICAL|hSTC810|hSTC810 will be administered as an intravenous infusion (IV)
214928049|NCT05764616|PROCEDURE|PARASTERNAL BLOCK|After induction of general anesthesia, an ultrasound-guided Parasternal Block will be performed with 20 mL of ropivacaine 0.5 % per side.
214928050|NCT05764616|PROCEDURE|LOCAL INFILTRATION OF DRAINAGE EXIT SITES|At the end of surgery, a local infiltration of drainage exit sites will be performed with 10 mL of ropivacaine 0.25% per side
214928051|NCT05764616|PROCEDURE|RECTUS SHEATH BLOCK|At the end of surgery, a rectus sheath block will be performed with 10 mL of ropivacaine 0.25% per side.
214928052|NCT02651155|DRUG|Lubiprostone|Lubiprostone capsules
214928053|NCT02651155|DRUG|Placebo|Lubiprostone placebo-matching capsules
214928054|NCT01402843|DRUG|pitavastatin, valsartan, placebo|pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
214928055|NCT04533412|BEHAVIORAL|Self-management barrier support|For the intervention, community health workers will assess barriers to good self-management behaviors that lie within 4 domains: 1) social context, 2) physical health and functioning, 3) cognitive factors, and 4) psychological factors. They will work with participants for 6 months to help them work through their barriers to self-management of COPD. Participants can also participate in home-based pulmonary rehabilitation and can receive emergency pack/action pack medication for COPD exacerbations.
214326656|NCT01573624|DRUG|FF/VI|100/25
214326657|NCT05493267|DRUG|Vγ2Vδ2 T lymphocyte-based immunotherapy|Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
214326658|NCT05493267|DRUG|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
214326659|NCT05382208|DRUG|Doxycycline|Doxycycline 100 mg orally twice a day.
214326660|NCT05382208|DRUG|Placebo|Matching placebo orally twice a day.
214326661|NCT05435885|OTHER|Pulmonary Tele-Rehabilitation|12 supervised training sessions via a specific mobile messenger during four weeks. (3 sessions/week)
214326662|NCT05435885|OTHER|Control (Education)|Usual care with only one educational session.
214326663|NCT05012605|OTHER|Observation|Observe physical function and sleep disorder symptoms following stroke
214326664|NCT06099197|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
214673146|NCT03972371|DEVICE|The ProVee Urethral Expander System|The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
214673147|NCT04713319|DRUG|Panavital|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
214673148|NCT04713319|OTHER|Placebo|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
214673149|NCT05418946|DRUG|Dapagliflozin 10mg|Treatment of T2D and cardio-renal prevention
214673150|NCT01252329|PROCEDURE|elective lymph node dissection|This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.
214673151|NCT03666767|OTHER|Comparisons will be made between LMICs and HICs|Countries will be defined as low, middle or high-income using the World Bank classification.
214673152|NCT03540017|DRUG|Cisplatin|Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
214326665|NCT06099197|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
214928056|NCT04533412|BEHAVIORAL|Basic COPD Education|"The attention control will consist of 4 visits by a COPD educator to the home to review the COPD education booklet. During the first visit, this COPD educator will review the COPD 1-2-3 booklet in its entirety with the patient. During visits 2 and 3, the COPD educator will make a visit to check in with the patient, ask how they are doing with their respiratory symptoms, and review any sections of the COPD 1-2-3 booklet the patient chooses. The COPD educator will recommend visits every 2 months but the patient and COPD educator may choose to modify the interval as needed. If the patient appears to be experiencing worsening respiratory symptoms during any visit, the COPD educator will notify the patient's physician."
214928057|NCT02655510|DRUG|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
214928058|NCT06684912|OTHER|High-intensity interval exercise|The number of bouts of exercise-recovery for each participant was tailored to achieve the desired EE. For example, a participant with a peak oxygen uptake (V̇O2) peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.
214928059|NCT06684912|OTHER|Moderate continuous exercise|Energy expenditure of exercise conditions (HIIE and MICE) were matched for energy expenditure. A participant with a V̇O2 peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.
214928060|NCT02582450|OTHER|Patients with haemophilia|Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
214928061|NCT05182814|DIETARY_SUPPLEMENT|Placebo drink|Blank
214928062|NCT05182814|DIETARY_SUPPLEMENT|Collagen Juice Drink|Testing product
214928063|NCT05087810|BEHAVIORAL|Psychological stress induction|Subjects will undergo acute psychological stress induction by performing mental arithmetic tasks.
214673153|NCT00735423|DEVICE|No intervention|IDE used for outcome measurement not intervention
215069614|NCT01005316|PROCEDURE|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
214326666|NCT00003694|DRUG|omacetaxine mepesuccinate|Given IV
214326667|NCT00003694|DRUG|cytarabine|Given IV
214326668|NCT00003694|OTHER|laboratory biomarker analysis|Correlative studies
214326669|NCT01485458|PROCEDURE|Early surgery|Surgery within 24 hours after admission
214326670|NCT01485458|PROCEDURE|Delayed surgery|Surgery more than 2 weeks after injury
214326671|NCT02577965|PROCEDURE|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
214326672|NCT02577965|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
214326673|NCT04029467|DRUG|Dexmedetomidine|addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
214928064|NCT05087810|OTHER|Accelerated oral hydration|Participants will drink 2L of fluid in a short period of time to force diuresis and urine production.
214928065|NCT03300635|OTHER|Mental distress and relaxation test|
214928066|NCT03300635|OTHER|Glucose tolerance test|
214928067|NCT03300635|OTHER|Exercise test|
214928068|NCT03386643|DRUG|Bifidobacterium animalis subsp. lactis HN019|The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
214326674|NCT00259558|DRUG|retarded release phosphatidylcholine|
214673154|NCT00196885|DRUG|N-acetylcysteine|
214673155|NCT03667131|DRUG|Enalapril Maleate|Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.
214673156|NCT03667131|DRUG|Placebo|Placebo 5 mg tablet, every 12 hrs for 90 days.
214673157|NCT02042131|BEHAVIORAL|Treatment As Usual (TAU)|
214673158|NCT02042131|BEHAVIORAL|Standard Crisis Response Plan (S-CRP)|
214673159|NCT02042131|BEHAVIORAL|Enhanced Crisis Response Plan (E-CRP)|
214673160|NCT03167697|DIETARY_SUPPLEMENT|Synergy|Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
214673161|NCT03167697|OTHER|Routine|Patients will continue their usual dietary and/or protein substitute regimen (28 days).
214673162|NCT05045053|DRUG|Xiidra 5% Ophthalmic Solution|lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
214928069|NCT03386643|DRUG|Clobetasol propionate 0.05%|The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
214928070|NCT02355821|DRUG|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
214928071|NCT02355821|DRUG|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
214928072|NCT00968981|DRUG|GDC-0449|Daily oral repeating dose
214928073|NCT00968981|DRUG|GDC-0449|Three times weekly oral repeating dose
214928074|NCT00968981|DRUG|GDC-0449|Once weekly oral repeating dose
215069615|NCT01005316|PROCEDURE|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
215069616|NCT01005316|DRUG|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
215069617|NCT01005316|DRUG|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
214326675|NCT02102139|DRUG|DXM + Propofol|"After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP \> ±20% from baseline), the target concentration was increased by 0.5 ng mL-1."
214928075|NCT05875025|OTHER|Placebo formulated with HFA-152a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
214928076|NCT05875025|OTHER|Placebo formulated with HFA-134a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
215069618|NCT05859412|OTHER|Neurodynamic exercises|The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
215069619|NCT05859412|DRUG|Steroid injection (Depomedrone 40mg)|Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
214326676|NCT02102139|DRUG|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
215069620|NCT05859412|OTHER|Advice|Group receiving advice but no additional treatment
214326677|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
214326678|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
214326679|NCT01894789|DRUG|Ticagrelor|Blinded administration of ticagrelor for 10 days
214326680|NCT01894789|DRUG|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
214326681|NCT02353247|DRUG|Norethindrone acetate|
214326682|NCT04102371|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
214928077|NCT03669055|OTHER|Magnetic Resonance Imaging|Realization of a MRI before and after the endovascular treatment of the aortic dissection. Use of the 4D phase-contrast sequence during the MRI.
214928078|NCT05286255|BIOLOGICAL|Allogeneic Mesenchymal Stromal Cells|Intravenous MSCs 1.2-1.5 x 10\^6 cells/kg on Days 1 and 3 after study enrollment
214928079|NCT05131464|DRUG|CM310|CM310, 300 mg/2 mL, SC, every 2 weeks
214928080|NCT01489254|DRUG|Glatiramer Acetate (GTR)|Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
215069621|NCT01490736|DRUG|Lemuteporfin|lemuteporfin topical solution, 1%
215069622|NCT06052254|DRUG|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
214928081|NCT01489254|DRUG|Glatiramer Acetate (Copaxone®)|Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
214928082|NCT01489254|DRUG|Placebo|Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
214326683|NCT04102371|DRUG|Normal Saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
214928083|NCT04073433|DRUG|Midomafetamine HCl|120 mg midomafetamine HCl
214928084|NCT04073433|BEHAVIORAL|Therapy|Non-directive therapy conducted during MDMA-assisted therapy session
214928085|NCT03199807|BIOLOGICAL|NRT|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory. NRTs 0.5\~1 x 10\^10, will be i.v.Q3 weeks for total 4-6 doses.
214928086|NCT03199807|RADIATION|Radiotherapy|Radiotherapy of the major mass by dose of 5Gy/F \* 10F
215069623|NCT06052254|DRUG|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
215069624|NCT06052254|DRUG|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
214326684|NCT04102371|DRUG|Plasma-lyte|PL is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).
214326685|NCT02166489|BIOLOGICAL|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
214326686|NCT01591473|DRUG|Poly I:Poly C12U 50 ug|Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
214326687|NCT01591473|DRUG|Poly I:Poly C12U 200 ug|Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
214326688|NCT01591473|DRUG|Poly I:Poly C12U 500 ug|Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
214326689|NCT01591473|DRUG|Poly I:Poly C12U 1250 ug|Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
214326690|NCT01591473|DRUG|Placebo|Placebo; 3 doses; nasal administration every 28 days
214326691|NCT01591473|DRUG|FluMist|FluMist 0.2 ml; 3 doses; nasal administration every 28 days
214326692|NCT01133184|BIOLOGICAL|Sci B vac|Sci B vac
214326693|NCT06974110|DRUG|MOMA-341|MOMA-341 administered orally
214326694|NCT06974110|DRUG|Irinotecan|Irinotecan administered by IV infusion
214326695|NCT06974110|DRUG|Immunotherapy|Immunotherapy administered by IV infusion
214326696|NCT02445027|DEVICE|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
214326697|NCT03127891|BEHAVIORAL|pranayama yoga|providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.
214326698|NCT03127891|OTHER|control group|no intervention should be given to patients allocated to this group
214326699|NCT05735561|DIAGNOSTIC_TEST|X-Ray|Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.
214326700|NCT03037528|BEHAVIORAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.
214326701|NCT03037528|BEHAVIORAL|positive affect informational materials|Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
214326702|NCT03037528|BEHAVIORAL|mindfulness informational materials|Participants will be taught about mindfulness and mindful eating techniques.
214326703|NCT03037528|BEHAVIORAL|dietary tracking|Participants will be asked to track their diet consistently.
214326704|NCT05222113|DRUG|Remdesivir|The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.
214326705|NCT00607282|DRUG|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
214326706|NCT03958240|OTHER|Blood samples, tumor biopsy specimens and ascites samples will be collected.|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice) for a maximum follow-up period of 5 years from baseline:~* at Baseline.~* at every surgical procedure or tumor biopsy.~* every 6 months (± 2 months) (only blood sample).~* at the time of the progression or recurrence, additional samples will be collected, and optionally at the time of the following progressions or recurrences (if applicable).~For patients undergoing a RT treatment, blood samples will be collected before the RT (i.e. at the time of planning CT-scan), at the last session of RT (± 2 days) and 3 months after the end of the RT (± 2 weeks)."
214928087|NCT02968693|DEVICE|antibiotic-loaded calcium sulfate|To obtain a paste suitable for pellets, the following steps should be used: 1. Empty 10 cc Stimulan® calcium sulfate powder (Stimulan; Biocomposites Ltd; United Kingdom) into a sterile mixing bowl. 2. The calcium sulfate powder was mixed with 2,000 mg of vancomycin powder. 3. Add approximately 5 ml mixing solution into the above mixture. Mix thoroughly until a smooth paste is formed (approximately 30 seconds). 4. The resultant paste is uniformly smooth into the mould provided to form pellets with diameters of 4.8 mm and height of 3.3 mm. 5. Allow paste to cure undisturbed for at least 15 minutes after mixing. Flex mould to release pellets.
215069625|NCT02431910|OTHER|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
215069626|NCT02431910|OTHER|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
214326707|NCT00253578|DRUG|sorafenib tosylate|Given PO
214326708|NCT00253578|OTHER|laboratory biomarker analysis|Correlative studies
214326709|NCT01188603|DRUG|flibanserin 100 mg dose every evening|all subjects receive flibanserin
214326710|NCT02257736|DRUG|Apalutamide|Participants will receive 240 mg (4\*60 mg tablets) of apalutamide once daily orally.
215069627|NCT03201926|DIETARY_SUPPLEMENT|mealworms|10g , 3 times a day , po, 2 months
215069628|NCT03201926|DIETARY_SUPPLEMENT|grain powder|grain powder, 10g ,3times one day,2months
215069629|NCT05021302|PROCEDURE|NOVAMAG NT-60|The Electromagnetic stimulation consists of 15 sessions with 20 minutes duration and three times a week. The total length of therapy is five weeks.
215069630|NCT05021302|BEHAVIORAL|Kegel Exercises|Self-supporting pelvic floor muscle strengthening exercises performed at home by contracting and relaxing quickly (2 seconds of contraction and 4 seconds of rest), followed by a slow contraction (contraction for 5 seconds, and rest for 10 seconds with five times each) five sets per day. The average length of exercise for each session is 2 minutes, with total exercise per day is 50 times. Thus, the total length of exercise is 10 minutes. It was done every day for eight weeks.
215069631|NCT04605497|DIAGNOSTIC_TEST|Continuous glucose monitoring (CGM)|Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission \& discharge + additional 10 days during postpartum period
215069632|NCT04605497|DIAGNOSTIC_TEST|Self-Capillary Blood Glucose Monitoring (SCBG)|Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
215069633|NCT05771441|OTHER|neck stabilization exercise (nse)|neck stabilization exercise (nse)- exercise
215069634|NCT05771441|OTHER|NSE + HOT PACK THERAPY|NSE + HOT PACK THERAPY- exercise plus heat therapy
215069635|NCT05771441|OTHER|NSE + infrared therapy|NSE + infrared therapy- exercise plus heat therapy
215069636|NCT05771441|OTHER|NSE + ultrasound therapy|NSE + ultrasound therapy exercise plus heat therapy
215069637|NCT04775862|DRUG|investigator choice re-challenge with anti EGFR Rx|Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
215069638|NCT03554057|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography|All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
215069639|NCT04417218|DIETARY_SUPPLEMENT|Lysine|Lysine is an essential amino acid which is acquired from dietary sources.
215069640|NCT04417218|DIETARY_SUPPLEMENT|Controlled Diet|Individuals will be instructed to consume specific foods, to adhere to a controlled lysine diet.
215069641|NCT00051012|DRUG|ONTAK|
215069642|NCT00625196|DRUG|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
214326711|NCT02257736|DRUG|Abiraterone acetate|Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.
214326712|NCT02257736|DRUG|Prednisone|Participants will receive 5 mg tablet of prednisone twice daily orally.
215069643|NCT00625196|DRUG|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
215069644|NCT00625196|DRUG|Vilanterol|Vilanterol will be available as dry powder inhaler.
215069645|NCT00625196|DRUG|Placebo|Placebo will be supplied as dry powder inhaler.
215069646|NCT06232603|OTHER|Education of medication management|Video and handout materials will be provided
215069647|NCT02925078|DEVICE|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with \<2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
215069648|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged \> 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
215069649|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~1. Fit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~2. Unfit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~3. Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
214326713|NCT02257736|DRUG|Placebo|Participants will receive matching placebo to apalutamide once daily orally.
214326714|NCT03655678|BIOLOGICAL|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan
214326715|NCT01664013|DRUG|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
214326716|NCT04909086|PROCEDURE|Standard physical Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle stretching, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
214326717|NCT04909086|PROCEDURE|Closed Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of seated leg press and partial squat exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
214326718|NCT04909086|PROCEDURE|Open Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of Quadriceps seated strengthening and Hamstring curl-up exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
214326719|NCT00308711|DRUG|Misoprostol vaginal insert 100 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
214326720|NCT00308711|DRUG|Misoprostol vaginal insert 50 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
214928088|NCT02968693|DEVICE|antibiotic-loaded polymethyl methacrylate|One sachet of 40g PALACOSR®+G power containing 33.6g PMMA and with the addition of 0.5g gentamicin sulphate (Heraeus Medical Gesellschaft mit beschränkter Haftung,Germany) was mixed with 4,000 mg of vancomycin powder in a sterile bowl. The liquid provided was poured into the resultant mixture above. Then, the mixture was stirred carefully for 30 sec. If the dough-like mass no longer sticked to the rubber gloves, it can be progressed. If the required consistency was obtained, the cement can be applied to the bony defect until it hardened completely.
214928089|NCT02968693|DRUG|Vancomycin|Vancomycin powder was added into the combination therapy group and PMMA groups
214928090|NCT05778435|DEVICE|wireless fetal monitoring system|The wireless fetal monitoring system shortens the period of labor by enabling the woman to be more mobile during the intrapartum period.
214928091|NCT05508035|DRUG|Sacubitril / Valsartan|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
214928092|NCT05508035|DRUG|Ramipril|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
215069650|NCT03720041|DRUG|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
215069651|NCT03720041|DRUG|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
214326721|NCT00308711|DRUG|Dinoprostone vaginal insert (Cervidil)|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
214326722|NCT02167256|DRUG|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
214326723|NCT02167256|DRUG|AZD0530 125mg daily|Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
214928093|NCT03016481|BEHAVIORAL|Active Comparator: the Community Health Worker -Personalized Support for Progress|Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.
214928094|NCT03016481|BEHAVIORAL|Care as Usual- Social Worker|Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
214928095|NCT03705650|DIAGNOSTIC_TEST|Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance, feedback and interpretation assistance to users during image acquisition. For this study, CMAs will use EchoGPS to perform point-of-care echocardiogram examinations.
215069652|NCT00199472|PROCEDURE|Dynamic Contrast Enhanced CT & Diuretic Renogram|
214326724|NCT02167256|DRUG|Placebo|50% of patients will receive placebo treatment for the duration of the study.
214326725|NCT02163928|OTHER|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
214326726|NCT03389711|COMBINATION_PRODUCT|DMARD´s and multidisciplinary treatment|"At study enrollment, medical history, disease-specific autoantibodies, ACR 1987 classification criteria for RA were applied. Medical evaluations were standardized and included at least 66 swollen and 68 tender joint counts, acute reactant-phase determinations , patient and physician reported outcomes, comorbidity established by record review, and treatment assessments (name, dose and schedule of all drug they were taking) along with an evaluation of persistence, at six-month intervals.~Patients were evaluated by a single rheumatologist every two months during the first two years of follow-up, and every two, four or six months thereafter.~Also the following scores: Michigan Hand Outcome Questionnaire (MHQ), Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH),Mayor Depressive Episodes (MDE) was defined using the Mini International Neuropsychiatric Interview and the severity of depressive symptoms was assessed with the Beck Depression Inventory (BDI-II)."
214326727|NCT04203550|PROCEDURE|Intraoperative irrigation|Operation with irrigation
214326728|NCT04203550|PROCEDURE|No irrigation|Operation without irrigation
214326729|NCT04295603|OTHER|Toucher Massage (TM) on the feet|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.
214673163|NCT01787591|OTHER|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
214673164|NCT01787591|OTHER|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
214928096|NCT04432714|DRUG|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
214928097|NCT04432714|DRUG|Rituximab|Rituximab 375 mg/m2，IV, d0
214928098|NCT04432714|DRUG|Etoposide|Etoposide 50 mg/m2/day CI24h d1-d4
214928099|NCT04432714|DRUG|Doxorubicin|Doxorubicin 10 mg/m2/day CI24h d1-d4
214928100|NCT04432714|DRUG|Vincristine|Vincristine 0.4mg/m2/day CI24h d1-d4
214928101|NCT04432714|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2/day IV d5
214928102|NCT04432714|DRUG|Prednisone|Prednisone 60 mg/m2/bid oral or IV d1-d5
214928103|NCT04157114|DRUG|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
215069653|NCT00234871|DRUG|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
215069654|NCT00234871|DRUG|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
214673165|NCT01787591|OTHER|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
214673166|NCT01787591|OTHER|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
214673167|NCT02513381|OTHER|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
214673168|NCT02513381|OTHER|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
214673169|NCT01581190|DIETARY_SUPPLEMENT|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
214673170|NCT01565486|DEVICE|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
215069655|NCT00873041|DRUG|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
215069656|NCT00873041|DRUG|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
214928104|NCT04157114|DRUG|Placebo|Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
214928105|NCT04157114|BEHAVIORAL|Standardized behavioral counseling|Subjects receive manually-guided counseling 1 time per week for a 6 week duration
215069657|NCT04271748|OTHER|Time Restricted Feeding|The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
214326730|NCT04295603|OTHER|Homedics HM MP RELEX 90 device|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator."
214326731|NCT04590495|DRUG|300 mg Cannabidiol (CBD) oil|Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
214326732|NCT04590495|DRUG|Placebo|Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
214326733|NCT00414388|DRUG|Sorafenib|400mg twice daily
214326734|NCT00180375|DEVICE|Prizm, Vitality, Renewal|Follow-up during 2 years
214326735|NCT04615559|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
214326736|NCT04719416|BEHAVIORAL|Guided Meditation|Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
214326737|NCT00947492|BIOLOGICAL|Venous blood sample|Venous blood sample twice a year during 3 years
214326738|NCT04940845|DRUG|HS-20090-2|Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
214326739|NCT04940845|DRUG|Prolia|Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
214326740|NCT03591575|DRUG|Deferiprone oral solution|Liquid formulation of deferiprone, with a concentration of 80 mg/mL
214673171|NCT01565486|DEVICE|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
214673172|NCT05739708|OTHER|Questionnaires|The time to complete the different questionnaires is estimated to be 60 minutes.
214326741|NCT03591575|DRUG|Placebo|Liquid solution that matches deferiprone oral solution in appearance and taste
214326742|NCT01723228|DRUG|Rasagiline|
214326743|NCT01723228|DRUG|Placebo|
214326744|NCT03464864|DRUG|Treprostinil Inhalation Powder|Single ascending dose
214326745|NCT05263661|PROCEDURE|LIFT|Ligation of fistula tract between external and internal sphincter
214326746|NCT05263661|PROCEDURE|FLAP|Creation of a partial wall rectal flap to close internal opening of fistula tract
214326747|NCT04643106|PROCEDURE|Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)
214326748|NCT04643106|PROCEDURE|suturing with barbed sutures during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding
214673173|NCT00011895|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
214673174|NCT00011895|DRUG|Efavirenz|
214326749|NCT00220025|DEVICE|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
214673175|NCT02725177|DRUG|Repository Corticotropin Injection|"Treatment with ACTHAR Gel for 24 weeks~* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
214673176|NCT02725177|DRUG|Repository Corticotropin Injection -Treatment Extension|24 open label extension permitted in subjects who respond to treatment
214928106|NCT01232881|PROCEDURE|Tumor Sample|Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
214928107|NCT01232881|PROCEDURE|Serum Sample|Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
214928108|NCT01345981|DRUG|Lidocaine|dosage 20 mg and 40 mg
214928109|NCT02175134|OTHER|Blood and Ascites ELISPOT|
215069658|NCT05587231|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The experimental group will have the Dextenza Insert implanted immediately after surgery
215069659|NCT05587231|DRUG|Topical Fluorometholone|Steroid drops will be administered by the subject according to the standard of care taper
215069660|NCT00685269|DRUG|Eszopiclone|Eszopiclone 3 mg QD
215069661|NCT00685269|DRUG|Placebo|Placebo tablet
215069662|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
215069663|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
214326750|NCT05681429|DRUG|Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib|To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
214928110|NCT01628796|OTHER|contrast material injection|using ultrasound to locate ac joint and injecting contrast material to ensure that the dye is actually in the joint
214928111|NCT02050919|DRUG|Epirubicin Hydrochloride|Given IV
214928112|NCT02050919|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214928113|NCT02050919|DRUG|Ifosfamide|Given IV
214928114|NCT02050919|OTHER|Laboratory Biomarker Analysis|Correlative studies
214928115|NCT02050919|DRUG|Sorafenib Tosylate|Given PO
214928116|NCT02050919|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214928117|NCT03701841|DRUG|PEG-rhG-CSF|All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles
215069664|NCT03582865|DRUG|Tamoxifen 20 mg|Tamoxifen 20 mg is a selective estrogen receptor modulator
215069665|NCT05825534|OTHER|EIT monitoring|EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
214326751|NCT00218543|DRUG|Atomoxetine|At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
214326752|NCT01864291|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
214326753|NCT03196752|PROCEDURE|laryngeal handshake|palpate for the cricothyroid membrane using the laryngeal handshake technique
214326754|NCT03196752|OTHER|simple palpation|conventional
214326755|NCT02170246|DRUG|Telmisartan|
214326756|NCT05037565|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
214326757|NCT06343077|DRUG|Poly-ICLC intramuscular (IM) injection|1.5 mg IM (week 1), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
214326758|NCT06343077|DRUG|Poly-ICLC, Intertumoral (IT) injection|1 mg IT once (week 2)
214928118|NCT01435096|DRUG|BN80927|Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
214928119|NCT06062602|DRUG|TAK-676|Intratumoral microdose injection by the CIVO device.
214928120|NCT06062602|DRUG|Carboplatin|Intratumoral microdose injection by the CIVO device.
214928121|NCT06062602|DRUG|5-FU|Intratumoral microdose injection by the CIVO device.
214928122|NCT06062602|DRUG|Paclitaxel|Intratumoral microdose injection by the CIVO device.
214928123|NCT06062602|COMBINATION_PRODUCT|TAK-676 + Carboplatin|Intratumoral microdose injection by the CIVO device.
214326759|NCT01451424|DRUG|Proellex|vaginal suppository, daily, for 12 weeks
214326760|NCT01895738|BEHAVIORAL|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
214326761|NCT04376034|BIOLOGICAL|Convalescent Plasma 1 Unit|"Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma."
214928124|NCT06062602|COMBINATION_PRODUCT|Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
214928125|NCT06062602|COMBINATION_PRODUCT|Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
214928126|NCT06062602|COMBINATION_PRODUCT|TAK-676 + Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
214928127|NCT06062602|COMBINATION_PRODUCT|TAK-676 + Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
214928128|NCT01878084|OTHER|bioactive glass (sol-gel)|Extraction sockets will be augmented using bioactive glass (sol-gel)
214928129|NCT01878084|OTHER|empty extraction socket|Extraction socket will be left empty
214928130|NCT03024684|DRUG|Atorvastatin|Atorvastatin 10mg daily
214928131|NCT03024684|DRUG|Placebo Oral Tablet|Placebo one tablet daily
214928132|NCT06092827|BEHAVIORAL|Non weight-bearing physical activity program|12-week duration, 2 supervised trainings/week, 1 unsupervised home-based training/week Aerobic, resistance and flexibility exercises
214928133|NCT06631521|DRUG|Darolutamide|600 mg (two 300 mg tablets) taken orally twice daily.
214928134|NCT06631521|DRUG|Relugolix|A loading dose of 360 mg on the first day, followed by 120 mg taken orally once daily.
214928135|NCT06631521|PROCEDURE|Radical Prostatectomy|Performed at least 48 hours and within 2 weeks after the completion of neoadjuvant therapy.
214928136|NCT00749684|BIOLOGICAL|Interferon α-2b|20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
214928137|NCT00921102|DRUG|Bupivacaine|12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
215069666|NCT02526563|PROCEDURE|ropivicaine|Blood draws to measure serum ropivicaine
215069667|NCT02352454|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
215069668|NCT00144469|DRUG|peginterferon alfa-2a|
215069669|NCT00144469|DRUG|rivavirin|
215069670|NCT06232850|OTHER|Position sense and manual dexterity evaluate|Position sense and manual dexterity evaluate
214928138|NCT00921102|DRUG|Morphine|200 µg of a 200 µg/ml solution, intrathecally
214928139|NCT00921102|DRUG|Isotonic saline solution|"0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine"
214326762|NCT04376034|BIOLOGICAL|Convalescent Plasma 2 Units|"Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma."
214326763|NCT04376034|OTHER|Standard of Care|Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
214326764|NCT00689481|DRUG|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
214326765|NCT00689481|DRUG|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
214326766|NCT02986204|PROCEDURE|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~* questions about your medical/contraception history~* Review medical record~* physical examination~* urine sample for pregnancy test~Visit 2a - Radiology~* Have an ultrasound of your arm~* The radiologist will mark your arm at the location of the implant.~Visit 2b~* ultrasound of your arm to locate the implant. This is done by feeling the area.~* Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~* Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~* Provide a urine sample for pregnancy test~* Have the implant removal site examined"
214326767|NCT02986204|PROCEDURE|continuation of ING implant|"the researcher(s) will ask you to:~* To answer questions about your medical and contraception history~* Review your medical record~* Have a physical examination by the researcher~* Provide a urine sample for pregnancy test~* Have an ultrasound of your arm"
214326768|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
214928140|NCT00921102|DRUG|Atropine|"100 µg of a 1 mg/ml preservative-free solution~* intrathecally in group Intrathecal Atropine~* intravenously in group IV Atropine"
214928141|NCT05970549|DEVICE|IRRAflow® Active Fluid Exchange System|"All patients in the prospective arm of the study who met the study criteria and consent will be enrolled in the IRRAflow with Active Fluid Exchange arm.~Insertion of the IRRaflow catheter will be performed by neurosurgical attendings and residents who are privileged to place external ventricular drains and who have be instructed on how to appropriately connect the inserted IRRAflow catheter to the system. The on-site IRRAflow instructor will be present and available at all time to assist with any issues or questions should they arise."
215069671|NCT00737854|PROCEDURE|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
215069672|NCT00406874|DRUG|omega 3 fats|1,000 mg daily
215069673|NCT00406874|DRUG|folic acid|800 micrograms daily
215069674|NCT02559934|DRUG|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
215069675|NCT02375737|BEHAVIORAL|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
215069676|NCT05210517|DRUG|Empagliflozin 25 MG|25 once daily one week treatment
215069677|NCT05210517|DRUG|Benzbromaron|100 mg once daily 1 one week treatment
215069678|NCT05210517|DRUG|Empagliflozin 25 MG + benzbromarone 100 mg|combined treatment once daily for one week
215069679|NCT00346606|DRUG|Denosin® and Xyzal®|
215069680|NCT02425228|DEVICE|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
215069681|NCT05556135|DIAGNOSTIC_TEST|level of serun adiponectin|estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
215069682|NCT05849935|DIAGNOSTIC_TEST|abioSCOPE|The abioSCOPE device with the PSP assay is intended to be indicated for ICU admitted patients at risk of developing sepsis. Results of abioSCOPE PSP assay may aid to identify sepsis in critically ill patients, together with all other clinical assessment and laboratory findings.
214326769|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
214326770|NCT01879696|DEVICE|ECSPRESS catheter with active vacuum|
214326771|NCT01778166|DRUG|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
214326772|NCT01778166|DRUG|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
214326773|NCT00473915|DRUG|fluticasone furoate|corticosteroid nasal spray
214326774|NCT01000246|BIOLOGICAL|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
214326775|NCT04335344|OTHER|Observation of suPAR plasma and salivary levels|Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
214326776|NCT00827892|DRUG|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
214928142|NCT05970549|DEVICE|Traditional extraventricular drain|The retrospective analysis will be performed on the last 60 traditional external ventricular drains.
215069683|NCT00592163|DRUG|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
215069684|NCT01734395|DRUG|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
214326777|NCT00827892|DRUG|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
214326778|NCT06428500|DRUG|QTX3046|QTX3046 will be administered at protocol defined dose.
214326779|NCT06428500|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
214326780|NCT06079164|DRUG|KITE-197|A single infusion of CAR-transduced autologous T cells administered intravenously
214326781|NCT06079164|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
214326782|NCT06079164|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
214928143|NCT05970549|PROCEDURE|Non-contrast head CTs|Non-contrast head CTs will be performed at least every 48 hours to document effectiveness. This frequency is standard, if not more frequent as necessary, for patients with external ventricular drainage and intraventricular hemorrhage. Scans are routinely obtained at this frequency to evaluate, for example: evacuation of hemorrhage, admission pathology, post-placement of catheters, any change in neurological exam, or after elevations in intracranial pressure. With these common CT scans we will be able to assess the efficacy of the IRRAflow catheter on the specified parameters. These scans are routinely performed due to this pathology and as such are covered as a necessity of the hospitalization by the insurance companies. MRI may be used in place of a CT scan if medically indicated as determined by the neurosurgical attending or neurocritical care attending according to standard of care for treatment of the neurological pathology.
214928144|NCT03376308|DIAGNOSTIC_TEST|Pain Score|"Four poin scala 0=No Pain~1. mild~2. intermediate~3. severe"
215069685|NCT02839447|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
215069686|NCT05349409|DRUG|SHR-A1811|SHR-A1811 for Injection: Given IV.
215069687|NCT05349409|DRUG|Fluzoparib Capsule|Fluzoparib Capsule: Given PO.
215069688|NCT02464995|DEVICE|Bronchial thermoplasty with the Alair System|
214326783|NCT05660265|DRUG|GSK4172239D|Different strength of GSK4172239D will be administered in different cohorts.
214326784|NCT05660265|OTHER|Placebo|Matching placebo will be administered.
214326785|NCT06974565|DRUG|AZD2389|AZD2389 will be administered orally.
214326786|NCT06974565|DRUG|Quinidine|Quinidine will be administered orally.
214326787|NCT06505954|OTHER|Survey study|Survey study among medical students about lower urinary tract symptoms
214486186|NCT06888037|DRUG|Maintenance treatment (after 3 months): fruquintinib+PD-1|"After 3 months (12 weeks) of initial treatment with oxaliplatin-based chemotherapy combined with PD-1 monoclonal antibody, those with complete response (CR), partial response (PR) or stable disease (SD) assessed by imaging evaluation continued to receive maintenance treatment with furoquininib and PD-1 monoclonal antibody.~Fruquintinib 3 mg/d, qd po, D1-21, Q4W; PD-1 monoclonal antibody is repeated as initial treatment until the disease progresses or unacceptable toxicity."
214486187|NCT06739031|DEVICE|PEF Treatment|PEF Energy ablation of lung tumors
214928145|NCT03376308|DIAGNOSTIC_TEST|Withdrawal movement score|"Withdrawal movements~1. no movement response~2. movement limited to the wrist~3. movement limited to the elbow/shoulder,~4. generalized movement response."
214326788|NCT06282926|DIAGNOSTIC_TEST|Echocardiography assessment|"Group 1 will have healthy adult volunteers recruited at the workplace following specific criteria to participate in the study. A research cardiac ultrasound protocol to assess the RV will be performed at two different visits, with a maximum interval of two weeks between them.~Group 2 will have ACHD patients with known moderate or severe pulmonary regurgitation after ToF repair, following specific criteria to participate in the study. This group of patients will be studied in two separate visits. The patients will be recruited during the first visit when attending to an existing hospital appointment for ACHD CMR. A research cardiac ultrasound protocol to assess the RV will be performed on the same day, either before or after the CMR. For all patients who will have a second follow-up visit at the ACHD outpatient clinic within a maximum interval of one year, the same research protocol will be performed, in addition to the usual cardiac ultrasound."
214326789|NCT02696551|OTHER|Medical education|
214326790|NCT00095758|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
214326791|NCT00095758|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
214326792|NCT04063033|DRUG|IV iron - Sodium Ferric Gluconate Complex|IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
214326793|NCT02254278|DRUG|Cisplatin|40 mg/m2 IV (intravenously) weekly for 6 weeks
215069689|NCT04379245|OTHER|Data research, database analysis|"Extraction of virological data at the virology laboratory (date, SARS-COV2 PCR result, identification number, sex, date of birth) (Excel file)~* Extraction of demographic and viro-immunological data from patients infected with HIV and on PrEP followed at the Hospices Civils de Lyon, France, over the period concerned (Access extraction)~* Data crossing (Excel / Access) and statistical analysis~* Calculation of the positivity rate per calendar period (= number of diagnosed cases / number of patients tested) and the attack rate per calendar period (number of diagnosed cases / number of people exposed (= active file of patients followed reduced by the number already known to be positive))."
214326794|NCT02254278|RADIATION|IMRT 6 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
214326795|NCT02254278|RADIATION|IMRT 5 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
214326796|NCT06325540|PROCEDURE|indirect pulp capping with theracal pt|indirect pulp capping using the theracal pt material
214326797|NCT06325540|PROCEDURE|indirect pulp capping with therabase|indirect pulp capping using the therabase material
214326798|NCT06325540|PROCEDURE|indirect pulp capping with biodentine|indirect pulp capping using the biodentine material
214326799|NCT06861439|DRUG|Tirzepatide|Tirzepatide will be initiated at a dose of 2.5 mg weekly and increased as tolerated to 5 mg weekly at four weeks for the remainder of the 9-month intervention period. Participants who are unable to tolerate the 5 mg dose will be decreased to the 2.5 mg dose.
214326800|NCT07001644|DEVICE|microneedling|microneedling with topical application of PRP on one side of abdomen and microneedling only on the other side.
214326801|NCT07001644|DEVICE|Carboxytherapy|carboxytherapy with intradermal injection of PRP on one side of abdomen and carboxytherapy only on the other side.
214326802|NCT07007234|BEHAVIORAL|Physical activity intervention|The INTERVENTION group will participate in a 4-month goal-setting intervention aimed to replace mentally passive sedentary behaviors with mentally active sedentary behaviors, light physical activity, or moderate-to-vigorous activity.
214326803|NCT07007234|BEHAVIORAL|Standard of care|The CONTROL group also will participate of 4 face-to-face individual sessions during the experimental period, lasting \~15-30 minutes, however they will receive general instructions related to WHO guidelines for physical activity
214326804|NCT04413929|DRUG|Ergoferon|Oral administration
214326805|NCT04850612|OTHER|Survey|Delphi Survey on core outcomes, CSDH definition and data elements
214326806|NCT07010432|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
214928146|NCT03376308|DIAGNOSTIC_TEST|hemodynamic response|Hemodynamic data were recorded in the patients taken in the operation room. (T0). Hemodynamic values (T1) measured 1 minute after administration of intravenous propofol were recorded. Hemodynamic values (T2) measured 1 minute after administration of intravenous rocuronium were recorded. Hemodynamic values (T3) measured 1 minute after administration of endotracheal intubation were recorded.
214928147|NCT02647970|BEHAVIORAL|PUFA-Cys/Met diet|Provision of food and supplements that are rich in polyunsaturated fatty acids (PUFA, n-3 and n-6) and low in the amino acids cysteine (Cys) and methionine (Met).
214928148|NCT02647970|BEHAVIORAL|SFA+Cys/Met diet|Provision of food and supplements that are rich in saturated fatty acids (SFA) and the amino acids cysteine (Cys) and methionine (Met).
214928149|NCT02039518|DRUG|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
214928150|NCT02039518|OTHER|observation group|observation group
214928151|NCT02103959|DRUG|CMX-2043|Slow bolus IV administration of CMX-2043
214326807|NCT07010432|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
214326808|NCT07010432|DRUG|Placebo cagrilintide|Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
214326809|NCT07010432|DRUG|Placebo semaglutide|Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
214326810|NCT06691269|DEVICE|Photobiomodulation|Photomodulation (PBM) is a promising non-tissue penetrating (i.e. minimally invasive) approach for achieving tooth and soft tissue anesthesia/analgesia in dental patients. A patent pending near-infrared laser technology that aims to provide dental analgesia will be used for PBM. This intra-oral PBM device comes with a tip comprising of a series of photonic emitters with specific wavelengths that can go through the tooth structure and bone, blocking the nerve conduction like local anesthetics. Research has shown that one burst of light application (for about 20 second) can provide up to 15-20 minutes of pain relief. Based on existing research PBM does not present a serious risk to health, safety, or welfare of a subject.
214326811|NCT06691269|DRUG|Topical Benzocaine|Topical Benzocaine at injection site to reduce discomfort of local infiltration
214326812|NCT06691269|DRUG|Local Anesthesia|Local infiltration using local anesthetics with epinephrine
214928152|NCT02103959|DRUG|Placebo comparator|Slow bolus IV administration of PBS
214326813|NCT07015242|DRUG|Rituximab|Specified dose on specified days
214326814|NCT07015242|DRUG|Methotrexate|Specified dose on specified days
214326815|NCT07015242|DRUG|Procarbazine|Specified dose on specified days
214326816|NCT07015242|DRUG|Temozolomide|Specified dose on specified days
214326817|NCT07015242|BIOLOGICAL|Liso-cel|Specified dose on specified days
214326818|NCT07015242|DRUG|Fludarabine|Specified dose on specified days
214326819|NCT07015242|DRUG|Cyclophosphamide|Specified dose on specified days
214326820|NCT07015242|DRUG|Calcium folinate|Specified dose on specified days
214326821|NCT07019792|OTHER|Protaper ultimate|Using Protaper Ultimate file system for canal preperation
214326822|NCT07019792|OTHER|Truanatomy file system|Using Truanatomy file system for canal preperation
214326823|NCT07019792|OTHER|Hyflex EDM|Using Hyflex file system for canal preperation
214326824|NCT07019792|OTHER|Xp shaper rise|Using XPshaper rise system for canal preperation
214326825|NCT07024329|OTHER|Remote Symptom Monitoring and Management|A study nurse will digitally monitor symptom complexity and provide symptom management between clinic visits. This will increase the frequency of collection and use of electronic PROs to provide responsive symptom management. Electronic PROs are collected digitally, and a complexity algorithm is used to flag patients with high symptom complexity. This will allow the study nurse to proactively manage symptoms in a timelier way.
214928153|NCT04725942|DRUG|Oral Posaconazole tablets|Posaconazole tablets (300 mg Q12h D1) taken orally on the day of transplantation, and followed by 300mg Qd, until 90 days after transplantation.
214928154|NCT01620775|OTHER|MRIs|Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.
214928155|NCT01620775|OTHER|Pain testing|There will be a 1-1.5 hour session including pain tolerance testing.
214928156|NCT04000542|OTHER|Pharmacist Intervention|The pharmacist will record a 30 second rhythm strip from patients using the KardiaMobile device and calculate the QTc interval using the Bazett calculation formula. The pharmacist will discuss the result with the patient and if necessary, will contact the prescriber to effect a medication change. If the QTc interval is greater than the 99th percentile, (470 ms for males, 480 ms for females) the pharmacist must contact the prescriber. The pharmacist will record any prescription changes which resulted from the intervention and the prescriber response. The pharmacist will email the rhythm strip (with study participation number) to a secure email at the Northeast Iowa Family Practice Center (NEIFPC). Rhythm strips will be archived for future potential research evaluation in a secure, electronic file.
214928157|NCT04888442|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214928158|NCT02643849|DEVICE|The Spanner Temporary Prostatic Stent|
214928159|NCT00372606|BEHAVIORAL|Online MiDieta Diet and Weight Management Program for Hispanics|
214326826|NCT07024329|OTHER|Clinic Team Huddle|Support will be provided to clinic teams to implement a team huddle (team planning session) one week prior to clinics, to assess how additional electronic PROs data for patients participating in RESPONd impacts their ability to identify stable patients with low symptom complexity who could receive virtual care or Registered Nurse (RN) led clinic care.
214326827|NCT07024225|PROCEDURE|Endoscope|Lower endoscopy
214326828|NCT07018986|OTHER|MIND Diet|a combination of the Mediterranean and DASH diets emphasizing consumption of high-nutrient, plant-based foods such as green leafy vegetables, nuts, berries, fish, and olive oil while limiting intake of foods high in saturated fat, pre-processed snacks, sugar, red and processed meat.
214326829|NCT07018986|OTHER|Usual Diet|Check-in sessions for the usual diet arm will focus on general health (e.g., healthy hair, skin, eyesight). None of the topics will include dietary information for the usual diet arm.
214326830|NCT07023601|OTHER|Sentinel Lymph Node Biopsy in first local recurrent vulvar carcinoma|All patients will undergo a local tumor radical excision and unilateral (if medial border \> 1 cm from midline) or bilateral (medial border \< or equal to 1 cm from midline) Sentinel Lymph Node procedure, followed by bilateral Inguinophemoral lymphadenectomy. .
214928160|NCT02993952|DEVICE|Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
214928161|NCT02993952|DEVICE|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
214326831|NCT07024992|BEHAVIORAL|ESCAPE app + NRT|ESCAPE is a mobile intervention that targets anxiety sensitivity among Black adults who smoke cigarettes and have HIV. This intervention is framed within the cultural context of interoceptive stress among Black adults who smoke, which is supported by theory, empirical evidence, and characteristics of this group. The intervention employs a variety of features to educate users on how to deal with stress, anxiety, and nicotine withdrawal symptoms. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos. ESCAPE also utilizes Ecological Momentary Assessments (EMAs) to gather information and provide personalized messages to users in real time. All participants will receive free nicotine replacement therapy (NRT).
214326832|NCT07024992|BEHAVIORAL|quiSTART app + NRT|quitSTART is a smartphone-based National Cancer Institute (NCI) intervention for standard mobile smoking cessation treatment. The intervention contains features that allow its' users to better understand their smoking patterns, and build skills needed to become and stay smoke free. The app allows users to track cravings and delivers motivational messages to users for each craving they track. All participants will receive free nicotine replacement therapy (NRT).
214326833|NCT07024992|BEHAVIORAL|Control (CTRL)|The CTRL group will complete the same baseline survey, follow-up surveys, and ecological momentary assessments as the ESCAPE app + NRT and the quitSTART app + NRT group. All participants will receive free nicotine replacement therapy (NRT). They will not receive additional intervention content.
214326834|NCT07023744|DRUG|Placebo|Placebo arm: participants will receive Placebo MPL-012 oil only through the trial participation. MPL-012 is produced by MediPharm Labs, each mL contains 0mg CBD and 0mg THC.
214326835|NCT07023744|DRUG|CBD Isolate|CBD Isolate: MPL-015 is a CBD isolate, produced by MediPharm Labs, each mL contains 100mg CBD and 0mg THC.
214326836|NCT07023744|DRUG|CBD CHE|CBD-CHE arm: MPL -016 is a CBD-enriched cannabis herbal extract, produced by MediPharm Labs, each mL contains 100mg of CBD and 3mg of THC.
214928162|NCT01645878|BEHAVIORAL|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
214928163|NCT01645878|BEHAVIORAL|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
214928164|NCT01645878|BEHAVIORAL|routin breast feeding education|
214928165|NCT06293989|DRUG|Diazepam 5mg|For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam 5 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
214673177|NCT01513018|OTHER|high tidal volumes|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
214928166|NCT06293989|DRUG|Diazepam 10 mg|For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam10 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
214928167|NCT06293989|DRUG|Placebo|For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups:Placebo . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
214928168|NCT02556294|BEHAVIORAL|Self-acceptance based intervention|The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
214928169|NCT02556294|BEHAVIORAL|HIV/STI counseling and testing|The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
214928170|NCT01913431|DRUG|Baracle Tab.®|
214928171|NCT01913431|DRUG|Baraclude Tab.®|
214928172|NCT02892422|DRUG|Lu AF35700|"Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.~From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)~Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study"
214928173|NCT02544425|DRUG|Etoposide|Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
214928174|NCT02544425|DRUG|Ifosfamide|It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
214928175|NCT02544425|DRUG|Dexamethasone|It will be administered 40mg/day PO or IV D1-3
214928176|NCT02544425|DRUG|L-asparaginase|It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
214928177|NCT02544425|DRUG|Busulfan|"Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6"
214928178|NCT02544425|DRUG|Melphalan|"Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2"
215069690|NCT01032291|DRUG|cetuximab|Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
214928179|NCT05521334|DEVICE|micropulse transscleral cyclophotocoagulation|glaucomatous patients with uncontrolled intraocular pressure (despite maximal tolerated anti-glaucoma medical treatment) were selected for micro-pulse trans-scleral cyclophotocoagulation using an MP3 handpiece with Iridex Cyclo G6 Laser settings (2000mW of 810 nm infrared diode laser set on micro-pulse delivery mode with 31.3 % duty cycle). The laser will be delivered over three quadrants for 90 seconds for each quadrant (total 270 sec) in Zigzag mode sparing the fourth quadrant for either further intervention or a previous surgery performed. Follow up examination (for at least 6 months) will include assessment of IOP in terms of percentage of IOP reduction and sustainability of results, BCVA, and the number of medications post-operatively.
214928180|NCT04016922|OTHER|Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C|"Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\\U ratio.~\* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~* As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US."
214928181|NCT03676296|DRUG|Puerarin|Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
214928182|NCT03676296|DRUG|Placebo|Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
214928183|NCT01064258|DEVICE|CPAP|CPAP at 4 cm H2O
214928184|NCT01064258|DEVICE|autoCPAP|autoCPAP working between 4 and 15 cm H2O
214928185|NCT04058535|BIOLOGICAL|Eylea|Aflibercept
214928186|NCT04058535|BIOLOGICAL|ALT-L9|Aflibercept biosimilar
214928187|NCT05081700|DRUG|All patients in the study will be treated with ocrelizumab|300 mg of OCR IV infusion will be given on Day 0 followed by a second dose of 300 mg OCR 14 days later ± 2 days, and then 600 mg of OCR as a single infusion will be given every 24 weeks thereafter per standard medical care.
214928188|NCT05890352|PROCEDURE|Biospecimen Collection|Undergo optional collection of blood
214928189|NCT05890352|PROCEDURE|Computed Tomography|Undergo PET/CT and CT
214928190|NCT05890352|DRUG|Lenalidomide|Given PO
215069691|NCT01032291|DRUG|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
215069692|NCT04609358|OTHER|intervention group|When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
215069693|NCT03699059|OTHER|ExeRTiOn|REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
215069694|NCT06372171|DIETARY_SUPPLEMENT|Satge 1|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 1-10 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 11-20
214326837|NCT07024277|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
214326838|NCT07025356|DRUG|Implantation of a trigeminal Vagus cervical nerve stimulator system|The NS 100 is a medical device used for the treatment of diabetic neuropathy pain. Routine observational monitoring will be performed
214928191|NCT05890352|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214928192|NCT05890352|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214326839|NCT07025356|DEVICE|Implantation of a neurostimulator system for trigeminal vagal cervical nerve stimulation|The medium term outcomes of neurostimulation will be assessed on diabetic neuropathy pain, glucose and drug usage
214928193|NCT05890352|OTHER|Quality-of-Life Assessment|Ancillary studies
214928194|NCT05890352|OTHER|Questionnaire Administration|Ancillary studies
215069695|NCT06372171|DIETARY_SUPPLEMENT|Stage 2|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 11-20 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 1-10
215069696|NCT03600636|PROCEDURE|Diffusion tensor imaging MRI|"1. axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~2. Fluid-attenuated inversion recovery~3. three-dimensional axial image weighted in T1~4. axial echo-planar image sequence~5. three-dimensional pulse sequence axial flight time"
215069697|NCT05027126|DRUG|Dexketoprofen 25 MG|Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral
215069698|NCT05027126|DRUG|Fixed dose Dexketoprofen-Vitamin B Complex|Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
215069699|NCT05155761|DEVICE|FeetMe® Monitor|"Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days."
215069700|NCT00320905|BEHAVIORAL|Observational|No intervention
215069701|NCT01522521|DRUG|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
215069702|NCT01522521|DRUG|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
214326840|NCT07024628|OTHER|Heat adaptation digital messaging|Digital messages to equip and prepare patients for extreme heat events. The first message will to encourage patients to prepare by creating a heat safety plan, and to form Check-in Companion groups among friends, neighbours, and relatives as well as to connect patients with existing key infrastructure that can be vital during heat events (ex: cooling stations and public facilities with air conditioning). When a heat-advisory is announced, additional messages will be sent to alert patients in the Treated group to activate their heat safety plans.
214928195|NCT05890352|BIOLOGICAL|Tafasitamab|Given IV
214928196|NCT05890352|DRUG|Tazemetostat|Given PO
214928197|NCT05890352|DRUG|Zanubrutinib|Given PO
214928198|NCT03200756|BEHAVIORAL|Sedentary Group|The sedentary group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
214928199|NCT03200756|BEHAVIORAL|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
214928200|NCT00032188|BIOLOGICAL|aldesleukin|Given subcutaneously
214928201|NCT00032188|DRUG|bryostatin 1|Given IV
214928202|NCT00032188|OTHER|laboratory biomarker analysis|Correlative studies
214928203|NCT01023256|DRUG|MOR103|MOR103 0.3 mg/kg or placebo iv x 4 doses
214928204|NCT01023256|DRUG|MOR103|MOR103 1.0 mg/kg or placebo iv x 4 doses
215069703|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])
215069704|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
215069705|NCT00313313|DRUG|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
215069706|NCT00313313|DRUG|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
215069707|NCT00313313|DRUG|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
214326841|NCT07024628|OTHER|Non-heat-related digital messaging|Digital health promotion messages not related to heatwaves
214326842|NCT05277194|BEHAVIORAL|KeepCalm app|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism.
214326843|NCT04745689|DRUG|Durvalumab|"IV infusions through induction phase.~IV infusions through maintenance phase until PD or other discontinuation criteria."
214326844|NCT04745689|DRUG|AZD2811|IV infusions through maintenance phase until PD or other discontinuation criteria.
214326845|NCT04745689|DRUG|Carboplatin|IV infusions through induction phase if chosen by Investigator.
214326846|NCT04745689|DRUG|Cisplatin|IV infusions through induction phase if chosen by Investigator.
214928205|NCT01023256|DRUG|MOR103|MOR103 1.5 mg/kg or placebo iv x 4 doses
214326847|NCT04745689|DRUG|Etoposide|IV infusions through induction phase.
214326848|NCT07023900|OTHER|Manual traction|The pacemaker or ICD lead extraction with manually.
214326849|NCT07025200|DRUG|Dupilumab|Clinical assessment, lung function, CT-scans and Bronchoscopy prior to and 22 weeks after initiation of Dupilumab.
214326850|NCT07023770|BEHAVIORAL|specific lateropulsion rehabilitation program (exoskeleton + specific physiotherapy orientation rehabilitation)|"5 times a week during 30 minutes sessions = 15 Physiotherapy sessions, focused on the active vertical body orientation in the frontal plane and comprising exoskeleton-assisted balance and gait exercises.~\+ 5 times a week during 30 minutes sessions = 15 conventional physiotherapy without exercises dedicated to lateropulsion or verticality representation alleviation The intervention description is more extensive in the study description section"
214326851|NCT07023770|BEHAVIORAL|Conventional physiotherapy without without exercises dedicated to lateropulsion or verticality representation alleviation|10 times a week, during 30-minutes
214928206|NCT03155178|DRUG|3M CHG/IPA Prep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
214928207|NCT03155178|DRUG|ChloraPrep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
215069708|NCT00313313|DRUG|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
214326852|NCT07025057|BEHAVIORAL|Provider training|The study will address patient-provider interactions through actionable, experiential provider trainings focused on communication provider, cultural relevance, and awareness of and referrals to community care services including Community Health Workers (CHW) and home visiting, for both clinical and community settings. Trainings are rooted in both history and in current research about how to address maternal mortality disparities, and will include self-learning, didactics, reflection, discussion, and identifying ways to tailor trainees settings to better hear, respect, and meet the needs of perinatal Black and Hispanic women.
214326853|NCT07023549|PROCEDURE|ABC|Suction sampling should be conducted in the sequence of dry-suction, slow-pull and wet-suction.
214326854|NCT07023549|PROCEDURE|ACB|Suction sampling should be conducted in the sequence of dry-suction, wet-suction and slow-pull.
214326855|NCT07023549|PROCEDURE|BAC|Suction sampling should be conducted in the sequence of slow-pull, dry-suction and wet-suction.
214326856|NCT07023549|PROCEDURE|BCA|Suction sampling should be conducted in the sequence of slow-pull, wet-suction and dry-suction.
214326857|NCT07023549|PROCEDURE|CAB|Suction sampling should be conducted in the sequence of wet-suction, dry-suction and slow-pull.
214326858|NCT07023549|PROCEDURE|CBA|Suction sampling should be conducted in the sequence of wet-suction, slow-pull and dry-suction.
214326859|NCT07023835|DRUG|50 mg Usnoflast|50 mg Usnoflast (50 mg Usnoflast capsules and matching placebo of 25 mg capsule)
214928208|NCT03065088|BEHAVIORAL|aLIFE|The aLiFE programme is taught by an instructor during six home visits and 3 phone calls during the 6-month intervention period. The programme will be personalised by use of an initial balance and strength assessment (aLiFE assessment tool). The participants assigns activities to his or her daily activities, and during subsequent home visits, the number of activities and task demands are upgraded. Participants will be taught how to select opportunities themselves to embed activities into their individual daily routine, and how to progress over time.
214928209|NCT03065088|BEHAVIORAL|eLIFE|The eLIFE includes a personalised ICT-administered training schedule using the activities developed in aLiFE, delivered in the form of video clips, pictures and text/verbal instructions on a smartphone and smartwatch application. Personalisation of activity content will be decided based on a phenotype tool and initial difficulty level is decided through the aLiFE assessment tool. In addition, a virtual instructor teaches the participants how to carry out the eLiFE programme. The user receives motivational messages and feedback, and there will be a possibility for social interaction between the participants. The instructors teach the eLiFE participants the programme during 4 home visits and 3 phone calls during the 6 month intervention period.
215069709|NCT00797745|BIOLOGICAL|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
215069710|NCT00797745|DRUG|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
215069711|NCT00797745|DRUG|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
214326860|NCT07023835|DRUG|75 mg Usnoflast|75 mg Usnoflast (25 mg + 50 mg Usnoflast capsules)
214326861|NCT07023835|DRUG|Placebo|Matching placebo of 25 mg and 50 mg
214326862|NCT06633302|OTHER|Simulated multi-day heatwave exposure|Older adults exposed to a multi-day simulated heat wave exposure
214326863|NCT03738410|BEHAVIORAL|Mobile Health Messaging application|Mobile messaging sent to participants over a 12-month period.
214326864|NCT03738410|OTHER|Standard of Care Treatment|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat HIV/AIDS. SOC associated procedures and policies may vary across clinical settings.
214486188|NCT06740175|DEVICE|Multispectral optoacoustic tomography|If patients are willing to participate in this study, they are imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo) at the department of nuclear medicine and molecular imaging. The imaging procedure takes 15 minutes at most.
214486189|NCT06738108|DRUG|ECOS|The EkoSonic Endovascular System, developed by EKOS Corporation, is a specialized CDT system that combines ultrasound technology with thrombolytic infusion to treat PE
214486190|NCT06738108|DRUG|Control group|Alteplase IV infusion
215069712|NCT00797745|DRUG|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
214326865|NCT07024810|OTHER|remote ischemic preconditioning|Participants randomized to the PIR intervention group will receive a hand-held blood pressure device (Welch Allyn DuraShock™ DS45, NY, USA) to self-administer PIR. The cuff will be placed around the upper arm and inflated to 220 mmHg for 5 minutes, followed by 5 minutes of deflation, and this cycle will be repeated another three times. This process will be performed 5 days a week for 3 months. The arm on which participants will apply the PIR is the left arm. Participants will be supervised during their first PIR session and every 15 days to ensure that it is performed correctly and, they will be free to perform the PIR at any time during the day and will record it in a diary to monitor compliance. Participants will be instructed to follow their normal routine and refrain from engaging in any new physical activity or changing their eating habits.
214928210|NCT03065088|BEHAVIORAL|control|The control group follows the World Health Organization's recommendations of physical activity. The control participants will receive one home visit and be given a written letter with the activity recommendations.
214928211|NCT04018456|OTHER|Biodentine|Biodentine is calcium silicate based cement which is bioactive and inductive material. Biodentine will be applied as coronal plug material.
214928212|NCT04018456|OTHER|White MTA|MTA is calcium silicate based cement which is bioactive and inductive material. MTA is used in most cases of regenerative endodontics and it will be applied as coronal plug material.
214928213|NCT03241628|DEVICE|Dressing Glove|Viscose dressing glove
214928214|NCT03089697|BIOLOGICAL|N-Rephasin® SAL200|A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
214928215|NCT03089697|OTHER|Placebo|A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
214928216|NCT01077609|DRUG|Intermittent, sub-chronic and chronic Flixonase use|Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
214928217|NCT01077609|DRUG|Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase|Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
214928218|NCT02768116|PROCEDURE|Sirolimus Drug-eluting Stent via Active Transfer of Plaque|
214928219|NCT02768116|PROCEDURE|Sirolimus Drug-eluting Stent implantation via Provisional T Stenting|
214928220|NCT03207542|DRUG|Daratumumab|16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
214928221|NCT04346901|DRUG|Thiamazol|All new hyperthyroid with melasma patients were recruited and their mMASI were calculated All subjects were given thiamazole by Internist based on their clinical hyperthyroidism After 3 months of taking hyperthyroid drugs (thiamazole), mMASI were recalculated and compared
214928222|NCT03785912|BEHAVIORAL|Internet-based self-help|Eight cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of adjustment problems after having an accident.
214928223|NCT01406145|DRUG|ASP0777|oral tablet
215069713|NCT04801238|PROCEDURE|LCBDE + LC|"Experimental group: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC) is performed under full anaesthesia. Once the dissection has exposed the cystic a clip or ligature is placed peripherally on the cystic duct. Through an incision in the duct central to the clip or ligature a cholangiogram catheter is introduced into the cystic duct and the cholangiogram is completed.~After identification of the bile duct stones and anatomy, a cholangioscope is introduced through the duct incision into common bile duct. The stones are identified visually and removed by Dormia basket. If the stones are very large, they may be partitioned mechanically or by electrohydraulic lithotripsy. In the presence of CBDS wedged in the papilla these stones will be removed and a secondary cholangiogram will be performed. Subsequently, the cholangioscope is taken out. Then the cystic duct is divided and the gallbladder is dissected out from the liver by hook cautery and removed."
214928224|NCT01406145|DRUG|Placebo|oral tablet
214326866|NCT07024537|DRUG|FOLFOXIRI-HAIP+Fuquinitinib|All patients received oral fruquintinib at an initial dose of 4 mg once daily from day 1 to day 21 of each 28-day cycle, and FOLFOXIRI-HAIP chemotherapy with Oxaliplatin 85 mg/m² and Leucovorin 400 mg/m² infused via arterial pump over 2 hours on day 1, Irinotecan 150 mg/m² infused via arterial pump over 90 minutes on day 1,and 5-Fluorouracil 2400 mg/m² infused via arterial pump over 46 hours, repeated biweekly until disease progression, patient's refusal, unacceptable toxic effects, or withdrawal of consent.
214673178|NCT01513018|OTHER|low tidal volume|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
214928225|NCT03613649|DRUG|AZD0914|Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
214928226|NCT03613649|DRUG|Moxifloxacin|Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.
214928227|NCT03613649|OTHER|Placebo|Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
214928228|NCT01259349|PROCEDURE|one percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
215069714|NCT04801238|PROCEDURE|ERC + LC|Control intervention: (First step) Endoscopic retrograde cholangiography (ERC) is routinely performed in sedation but or in full anaesthesia. ERC is performed with the patient in the supine position. The endoscope is passed down to the second part of the duodenum where the papilla is identified. Cannulation of the papilla and the common bile duct is performed with a papillotome and a guidewire. A cholangiography will confirm the presence, location and size of the CBDS and aims in further choice of extraction method. Stones can be extracted by papillotomy and by either balloon or by a basket. Additional balloon dilation of the papilla, or lithotripsy may be required. If stone extraction is incomplete or if the conditions are unclear a temporary common bile duct stent is placed which has to be removed with additional ERC after 1-2 months (Second step) laparoscopic cholecystectomy is performed after 2-14 days
215069715|NCT03923621|PROCEDURE|EPSiT|Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.
215069716|NCT03923621|PROCEDURE|Excision|Surgery to remove all affected tissue, followed by wound closure.
214326867|NCT07023874|PROCEDURE|Bupivacaine group|Participants will receive bilateral ultrasound-guided pecto-intercostal fascial plane block
215069717|NCT02652208|BEHAVIORAL|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
215069718|NCT02652208|BEHAVIORAL|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
215069719|NCT06439433|DRUG|Aminolaevulinic acid (500-mg bottle)|once a week for 6 weeks
215069720|NCT06439433|DRUG|Aminolaevulinic acid (750-mg bottle)|once a week for 6 weeks
214326868|NCT07023874|PROCEDURE|bupivacaine + dexmedetomidine group|Participants will receive bilateral ultrasound-guided pecto intercostal fascial plane block using 30 mL of 0.25% bupivacaine with one µg/kg dexmedetomidine in each side
215069721|NCT06439433|DRUG|Placebo|once a week for 6 weeks
215069722|NCT05354895|DEVICE|Transcranial infrared laser stimulation|non-invasive, non-pharmacologic photobiomodulation device
215069723|NCT04186988|DRUG|Fluorine F 18 Ara-G|Given IV
215069724|NCT04969601|BIOLOGICAL|vaccine COMIRNATY® (BNT162b2)|two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
215069725|NCT02601235|DRUG|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
215069726|NCT02601235|DRUG|Afrin|2 pumps in each nostril every 12 hours.
215069727|NCT03294174|DRUG|Ropivacaine injection|Ropivacaine administered to provide nerve block
214673179|NCT02108730|PROCEDURE|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
214673180|NCT03901183|OTHER|Plant-based Diet|Patients are guided to change their nutrition to a plant-based diet.
215069728|NCT03991403|DRUG|Atezolizumab(Tecentriq)|Atezolizumab(1200 mg IV);Over 60 (± 15) min (for the first infusion); 30 (± 10) min for subsequent infusions if tolerated Frequency: Day 1 of every 21 days Induction: Four or Six Cycles Maintenance : until PD
215069729|NCT03991403|DRUG|Pemetrexed|"Induction Period (Four or Six Cycles)~(1) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w~Maintenance Period (Until PD) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w"
215069730|NCT03991403|DRUG|Bevacizumab|Bevacizumab(15 mg/kg IV);Over 90 (±15) min (for the first infusion); shortening to 60 (± 10) then 30 (± 10) min for subsequent infusions if tolerated
215069731|NCT03991403|DRUG|Carboplatin|Carboplatin(AUC 5 or 5.5 IV a); Over approximately 15-30 min
215069732|NCT03991403|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 IV); Over 3 hours
215069733|NCT03991403|DRUG|Carboplatin or cisplatin|Carboplatin(AUC 5.5 IV);Over approximately 30-60 minutes on Day 1 q3W or Cisplatin(75 mg/m²) ; Over 1-2 hours on Day 1 q3w
215069734|NCT03490422|PROCEDURE|Pulpotomy|Pulpotomy in mature carious permanent teeth
214326869|NCT07025499|BEHAVIORAL|Group ICT Intervention|Participants will be given access to a tablet. With this technology, participants will be invited to set personal goals related to using this technology to foster social connection and community participation. Participants will attend a group led by two occupational therapy students and an occupational therapist focused on digital literacy and how to use technology to meet their goals. In the group, participants will learn how to use their device and how to safely access various online resources and tools to support their recovery. Participants will keep their provided devices upon conclusion of the group sessions. Participants will complete quantitative outcome measures at the start and end of the group intervention. Participants will be invited to attend a semi-structured interview one month after the completion of the group about their experiences with the program.
214326870|NCT07024485|DEVICE|AR animations and 5As model based on smoking cessation counseling Knowledge-Attitude-Practice (KAP)|The intervention group received a tutorial that incorporated Augmented Reality (AR) animations alongside conventional teaching materials. In addition to watching four real-life smoker scenario videos and reading corresponding case texts, students used their smartphones to interact with AR animations that visualized the physiological effects of smoking (e.g., lung cancer, vascular disease, aging). These animations were used during group discussions and role-play sessions, helping students to assess smokers' knowledge, illustrate health risks, and tailor counseling plans using the 5As model. The AR experience was designed to enhance learning engagement, emotional connection, and self-efficacy in delivering smoking cessation counseling.
214326871|NCT07024485|DEVICE|5As model based on smoking cessation counseling Knowledge-Attitude-Practice (KAP)|The control group, received a conventional tutorial without the use of AR technology. They watched the same four smoker scenario videos and read the same case texts, then engaged in small group discussions and role-play activities to develop quit plans using the 5As counseling model. However, unlike the intervention group, their learning process relied solely on textual and video materials, without the immersive or interactive elements provided by AR. This approach represents standard smoking cessation training methods commonly used in nursing education.
214326872|NCT07024511|OTHER|Auricular acupuncture|Auricular acupuncture
214928229|NCT01259349|PROCEDURE|40 percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
214326873|NCT07024511|OTHER|Acupuncture|Acupuncture
214326874|NCT06714513|BIOLOGICAL|QTP101|QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
214326875|NCT06714513|BIOLOGICAL|Placebo|Sterile 0.9% normal saline
214326876|NCT06885034|BIOLOGICAL|GSK5764227|GSK5764227 will be administered
214326877|NCT06711965|PROCEDURE|Standard of care reconstruction|Participants will receive standard of care reconstruction
214928230|NCT00299897|DRUG|SP01A|
214928231|NCT06447597|DRUG|B007|B007 high dose and low dose： Subcutaneous injection was administered on days 1 and 15
214928232|NCT06447597|DRUG|Placebo|B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
214928233|NCT05335395|BEHAVIORAL|SUNRISE radio campaign|"The SUNRISE radio campaign will be promoting responsive caregiving and providing opportunities for early learning to support child development during the first 3 years of life.~The SUNRISE campaign will follow DMI's established intervention approach with:~1. 60-second radio spots, tailored to increase awareness, knowledge, motivation, skills and opportunity regarding the target behaviours, will include scripted dramas and modelling of responsive parent-child interactions. Each spot will be broadcast 10 times a day for a week; the content of the spots will be changed on a weekly basis. This weekly cycle will continue for three years.~2. Long format 60-minute programmes broadcast 2-3 times a week, incorporating longer dramas, real life testimonials and practical 'how to' advice, with space for listeners to call in, express opinions and uncertainties and ask questions."
214326878|NCT06711965|PROCEDURE|Surgery, Breast Mold|Participants will undergo surgery. The surgeon may utilize the custom breast mold in shaping the autologous tissue flap for particiapnts.
214326879|NCT06886230|DRUG|Placebo (Normal Saline)|Patients in this group will receive an intravenous (IV) injection of normal saline before surgery. This serves as a control group to compare the efficacy of active treatment groups in preventing postoperative nausea and vomiting.
214326880|NCT06886230|DRUG|Ondansetron (Zofran)|Patients in this group will receive a single intravenous (IV) dose of Ondansetron 4 mg before surgery. Ondansetron is a selective 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting associated with anesthesia and surgery.
214326881|NCT06886230|DRUG|Dexamethasone|Patients in this group will receive a single intravenous (IV) dose of Dexamethasone 8 mg before surgery. Dexamethasone is a corticosteroid with anti-inflammatory properties that has been shown to reduce the incidence of PONV by modulating inflammatory pathways and neuroreceptor activity.
214326882|NCT06881472|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|GIP
214326883|NCT06881472|DRUG|alanine|Alanine
214326884|NCT06881472|DRUG|Saline (NaCl 0,9 %) (placebo)|Placebo
214326885|NCT06719219|BIOLOGICAL|LTB-SA7|LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.
214928234|NCT06684392|OTHER|Inspiratory muscle training|Subjects will train only inspiratory muscle strength if they do not achieve VP or definitive disconnection of MV, and, when they already achieve these VP or definitive disconnection, the new EMI regimen that combines strength and resistance training will begin to be applied. Inspiratory muscle training guideline (EMI). On the day that, according to the EMI guideline, the Pimax evaluation corresponds, the training time will be replaced by the evaluation to avoid overloading the subjects with ventilatory work, training them only once a day.
214928235|NCT03937440|DRUG|Deep neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for post-tetanic count (PTC) in deep neuromuscular group.
214928236|NCT03937440|DRUG|Moderate neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for train-of-four (TOF) in moderate neuromuscular group.
214928237|NCT03132064|PROCEDURE|total knee arthroplasty|surgical repair for end stage of knee osteoarthritis.
214928238|NCT01334671|DRUG|Atorvastatin|Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
214928239|NCT00093587|BIOLOGICAL|anti-thymocyte globulin|
214928240|NCT00093587|DRUG|busulfan|
214928241|NCT00093587|DRUG|cyclophosphamide|
214928242|NCT00093587|DRUG|cyclosporine|
214928243|NCT00093587|PROCEDURE|allogeneic bone marrow transplantation|
215069735|NCT03392831|OTHER|Peripherally inserted central catheter (PICC)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
215069736|NCT03392831|OTHER|Central venous catheter|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
214326886|NCT06719219|BIOLOGICAL|Placebo|Sodium Phosphate with Sodium Chloride
214326887|NCT07042672|DRUG|GLP-1|Subcutaneous GLP-1 receptor agonist prescribed for weight management according to routine clinical practice. Acceptable agents include liraglutide (up-titrated to ≤ 3.0 mg daily), semaglutide (≤ 2.4 mg weekly), or tirzepatide (≤ 15 mg weekly). Dose escalation and maintenance follow approved product labels and treating-physician judgment. Planned treatment duration: 12 months or longer.
214326888|NCT07042672|BEHAVIORAL|CBTe Group Therapy|Ten weekly 2-hour group sessions based on Cognitive Behavioral Therapy-Enhanced (CBT-E) plus individualized lifestyle consultations every 4 months over a 12-month period. Content targets eating patterns, weight-management behaviors, and emotion-regulation skills. Delivered by trained multidisciplinary staff at the Obesity Centre.
214326889|NCT06885177|DEVICE|Experimental|Participants will receive treatment with Abbott's Coronary IVL System followed by stenting.
214928244|NCT00093587|PROCEDURE|peripheral blood stem cell transplantation|
214928245|NCT00093587|RADIATION|radiation therapy|
214928246|NCT00675428|DRUG|BG00002 (natalizumab)|
214928247|NCT02064842|DRUG|TMC647055|TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
214928248|NCT02064842|DRUG|TMC435|TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
214928249|NCT02064842|DRUG|Placebo|Placebo capsule once daily taken orally on Day 1 in Part 1
214928250|NCT02064842|DRUG|Ritonavir (RTV)|RTV 30 mg (ie, 0.38 mL oral solution of RTV \[80 mg/mL strength\]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
214928251|NCT04144348|BIOLOGICAL|mRNA-1653|Sterile liquid for injection
214928252|NCT04144348|BIOLOGICAL|Placebo|Sterile liquid for injection
214928253|NCT06205901|DEVICE|PET-CT, MRI|whole body MRI and PET-CT for cancer patients with distant metastasis
214928254|NCT00319592|BIOLOGICAL|ChimeriVax™-JE vaccine|0.5 mL, subcutaneously
214928255|NCT00319592|BIOLOGICAL|JE-VAX® vaccine|1.0 mL, subcutaneously
214928256|NCT00120562|PROCEDURE|Gastric Bypass Surgery|
214928257|NCT03244540|PROCEDURE|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
214928258|NCT03244540|PROCEDURE|QLB (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
215069737|NCT05740163|DIETARY_SUPPLEMENT|Egg product including egg white and yolk allergens|Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
215069738|NCT00904930|DEVICE|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
214928259|NCT03244540|DEVICE|Stimuplex Ultra 360 needle|ultrasound-guided needle will be used for QLB and TAP and regional blocks
214928260|NCT03244540|DRUG|Ropivacaine|0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)
214326890|NCT06310031|DEVICE|BrioVAD System|Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.
214326891|NCT06310031|DEVICE|HeartMate 3|Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.
214326892|NCT06724965|BEHAVIORAL|Trans STAIR|Skills Training in Affect and Interpersonal Regulation (STAIR) is a transdiagnostic evidenced-based mental health treatment for individuals who have experienced multiple traumas. STAIR is based in cognitive-behavioral principles and delivered in a flexible manner over 8 group sessions, with demonstrated efficacy for the treatment of PTSD and other mental health symptoms. This trial will adapt and pilot test the STAIR intervention to be culturally appropriate and acceptable for TGD persons, adding content related to TGD health and wellness, coping with minority stress, responding to stigma and microaggressions, social support, and community connectedness, self-compassion, celebrating trans joy, trans advocacy, sexual health and PrEP use.
214326893|NCT06724965|BEHAVIORAL|PrEP Well|"This pilot trial will leverage PrEP Well, a multi-level implementation strategy for providing PrEP in TGD-serving contexts by integrating peer-led PrEP navigation with programming that addresses other social and structural needs of the TGD community (e.g., housing, legal, employment, gender-affirmation, primary care)"
214326894|NCT07045168|OTHER|risk-scoring model|This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting ISS stage III, hypercalcemia, high LDH, and t(14;16).Patients with ISS stage III, elevated LDH, hypercalcemia, and t(14;16) were assigned scores of 1 point, 1 point, 2 points, and 3 points, respectively. According to the tertiles of their scores,the patients with +1q were classified into low- (0 point),intermediate- (1-3 points), and high-risk (4-7 points) groups.
214928261|NCT03244540|DRUG|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
214928262|NCT03244540|PROCEDURE|subarachnoid anesthesia|subarachnoid anesthesia for each patients participating in the study with pencil point needle
214928263|NCT03244540|PROCEDURE|PCA (patient controlled analgesia)|All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)
214928264|NCT03244540|DRUG|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
214928265|NCT03244540|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
214928266|NCT03244540|DRUG|Bupivacaine|Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)
214928267|NCT01707355|BEHAVIORAL|intervention - poster|
214326895|NCT06890026|DRUG|Faricimab Injection [Vabysmo]|The procedures were carried out according to the local standard protocol, which involved applying 2-3 drops of topical tetracaine anesthesia, using an eye speculum, disinfecting with 5% povidone-iodine, employing a 33G needle, marking the injection site 3.5 mm posterior to the limbus with calipers in either the superotemporal or inferotemporal quadrant, applying a sterile cotton tip for tamponade after needle removal, and omitting post-procedure antibiotics.
214326896|NCT06744465|DEVICE|NearWave monitoring|NearWave optical molecular monitoring
214673181|NCT06163781|DEVICE|Blood culture prediction tool|Machine learning based predicition tool
214673182|NCT04419415|DIETARY_SUPPLEMENT|Breakfast with high protein dairy|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.
214673183|NCT04419415|OTHER|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
214673184|NCT04419415|OTHER|Skipping breakfast|Participants will be asked to skip breakfast.
214928268|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
214928269|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
214928270|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
214928271|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
214928272|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
214928273|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
214928274|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
214928275|NCT01297439|PROCEDURE|suctioning of fetal nose and mouth during delivery|"Normal delivery without pushing maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes)."
214928276|NCT01297439|PROCEDURE|Pushing maneuver|"The pushing maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia."
214928277|NCT01512446|DRUG|Alendronate|70 mg per week
214928278|NCT01512446|DRUG|Placebo|1 pill per week
215069739|NCT00904930|DEVICE|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
215069740|NCT02934880|OTHER|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
215069741|NCT02934880|OTHER|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
215069742|NCT00758264|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
215069743|NCT00758264|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
215069744|NCT01274923|DEVICE|"MEDISPEC treatment probe"|shock wave treatment
215069745|NCT02354131|DRUG|Niraparib|Niraparib versus Bevacizumab-Niraparib combo
215069746|NCT02354131|DRUG|Bevacizumab|
214928279|NCT05938829|OTHER|Ultrasound following the SMFM guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery. This information will be captured in our ultrasound reporting software, Viewpoint.
214928280|NCT05938829|OTHER|Ultrasound following the ISUOG guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery, middle cerebral artery, and ductus venosus. This information will be captured in our ultrasound reporting software, Viewpoint.
214928281|NCT05655910|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition shake|Nutrition shake to support immune health and recovery from surgery.
214928282|NCT03808597|OTHER|Digital health promotion intervention|Digital health promition related to HIV, Tuberculosis and TSCT in a digital format.
214928283|NCT03627338|DIAGNOSTIC_TEST|questionaire, interview|questionaire, interview
214326897|NCT06737718|OTHER|Eye tracking|"The eye-tracking session will take place in the Pediatric Radiology department of Necker Hospital. The child will be seated in front of a computer screen. Films and images with social and/or non-social content will be shown to the children. The session will be unique, will last approximately 15 minutes and will not involve any constraints for the child.~Eye tracking allows to measure where and how a person looks. An infrared light is emitted towards the subject's eye. It is reflected there and a camera records the reflections generated, allowing a real-time calculation of the position of the gaze. The technique is harmless and non-invasive."
214326898|NCT06737718|OTHER|Data collection from patients' medical files|"Data collection from patients' medical files:~* Brain imaging data if this examination was carried out as part of the patient's care,~* Angelman syndrome genotypes."
214326899|NCT04459806|PROCEDURE|intracranial pressure monitoring|Invasive monitoring of intracranial pressure by using CereLink monitor.
214673185|NCT00793585|DRUG|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.
214928284|NCT05450003|DEVICE|Irrigation activation using xp endo finisher file , new sonic eddy tip and conventional needle syringe irrigation|irrigation activation using 3 different irrigation activation systems including xp endo finisher file , new sonic eddy system and conventional needle syringe irrigation
214928285|NCT06027918|PROCEDURE|Infraclavicular brachial plexus block|In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.
214928286|NCT01500187|DEVICE|Vanish Varnish|5% sodium fluoride varnish with tricalcium phosphate
214673186|NCT00793585|OTHER|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
214928287|NCT01500187|DEVICE|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
214928288|NCT05573477|DRUG|ATB-1011|Oral tablet
214928289|NCT05573477|DRUG|ATB-1012|Oral tablet
214928290|NCT05573477|DRUG|ATB-1013|Oral tablet
214928291|NCT05573477|DRUG|ATB-1011 placebo|Placebo matched to ATB-1011
214928292|NCT05573477|DRUG|ATB-1012 placebo|Placebo matched to ATB-1012
214928293|NCT05573477|DRUG|ATB-1013 placebo|Placebo matched to ATB-1013
214928294|NCT04756570|OTHER|Control|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
215069747|NCT03425006|DRUG|Itacitinib|a JAK 1 selective small molecule inhibitor
214928295|NCT04756570|OTHER|Robotic Group 1|Individuals in this group will receive one session of robotic rehabilitation in addition to conventional therapy each week
214928296|NCT04756570|OTHER|Robotic Group 2|Individuals in this group will receive two sessions of robotic rehabilitation in addition to conventional therapy each week
214928297|NCT05929729|DRUG|Ferric derisomaltose|Refer to arm/group descriptions
215069748|NCT03425006|BIOLOGICAL|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
214928298|NCT05929729|DRUG|NovaFerrum|Refer to arm/group descriptions
214928299|NCT04167631|RADIATION|Multi-parametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
214928300|NCT05761210|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection
214928301|NCT01609634|OTHER|Test Product|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
214928302|NCT01609634|OTHER|Control Product 1|Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
214928303|NCT01609634|OTHER|Control Product 2|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
215069749|NCT02007057|PROCEDURE|Suprascapular nerve block|
215069750|NCT02007057|PROCEDURE|Interscalene nerve block|
215069751|NCT04282096|OTHER|native and non native casein|selected participant will test the 3 treatments in a random order
215069752|NCT01076868|DRUG|Primaquine|Primaquine x 14 days
215069753|NCT02527226|BEHAVIORAL|Facial exercises|A series of self-administered facial movements and expressions.
215069754|NCT03319563|DRUG|Local anesthetic-epinephrine|"* Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~* Lidocaine 5 mg/Kg.~* Epinephrine 5 mcg/ml of the total volume.~* Add normal saline to a total volume of 100 ml/10 cm of the wound length."
214326900|NCT07052786|BEHAVIORAL|Infants will receive group care based on individualized developmental care according to the guide.|A guide to implementing group care based on individualized developmental care will be developed, and nurses working in the NICU will be trained in group care practices and how to use the guide.
214326901|NCT07052786|BEHAVIORAL|Standard care|Nurses working in the NICU will continue to provide standard care. After the study is completed, nurses in the control group will also receive the same training as the other group.
214326902|NCT06893380|DRUG|Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab.|Tislelizumab: IV 200mg on Day 1 of every 3-week cycle Nab-paclitaxel: IV 75mg/m2 on Days 1 and 8 of every 3-week cycle (up to 16 cycles) Gemcitabine: IV 800mg/m2 on Days 1 and 8 of every 3-week cycle Cisplatin: IV 25mg/m2 on Days 1 and 8 of every 3-week cycle (up to 8 cycles)
214928304|NCT00429936|DRUG|Fenretinide|Once daily 30 minutes after the evening meal for 24 months
214928305|NCT00186836|BIOLOGICAL|Engerix-B and Twinrix|
214928306|NCT06651801|BEHAVIORAL|Group Medical Visits|Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.
214928307|NCT01739218|DRUG|Carboplatin|Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).
214928308|NCT01739218|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
214928309|NCT01739218|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
214326903|NCT07053566|BEHAVIORAL|Rotator Cuff Strengthening Exercises|Progressive exercise program focused on rotator cuff muscles
214928310|NCT06602050|OTHER|HG and NIF|In mechanically ventilated patients, handgrip strength, the Negative Inspiratory Force (NIF) value obtained via the ventilator, and physical function through various tests will be assessed.
215069755|NCT03319563|DRUG|Saline|normal saline 100 ml/10 cm of the wound length
214326904|NCT07053566|BEHAVIORAL|Latissimus Dorsi Strengthening Exercises|Progressive exercise program targeting the latissimus dorsi muscle
214326905|NCT06787066|DRUG|Propranolol Hydrochloride|Examine how IV propranolol impacts sympathetic transduction
215069756|NCT01152047|DRUG|oxytocin|40mU/min as infusion of oxytocin
215069757|NCT02126553|OTHER|Laboratory Biomarker Analysis|Correlative studies
215069758|NCT02126553|DRUG|Lenalidomide|Given PO
214326906|NCT06787066|DRUG|Phentolamine Injection|Examine how IV phentolamine impacts sympathetic transduction
214326907|NCT06785402|DRUG|Ceftriaxone treatment|9 infusions spaced out approximately every 5 days
214326908|NCT06785402|DRUG|Placebo|D5W (placebo)
214326909|NCT07056140|PROCEDURE|Epidural Simulation Training|The group will have access to a epidural simulator and would have possibility to freely experiment and improve their skill on the phantom before their residency period in the obstetric unit
214326910|NCT07056140|PROCEDURE|Standard Clinical Training|Participants will receive a standard clinical training based on frontal lessons regarding indications , controindications to epidural analgesia and the technique will be explained also with the use of video material
214326911|NCT07057323|DEVICE|Coronary Sinus Reducer|Subjects will have the Coronary Sinus Reducer implanted in their coronary sinus during a right heart catheterization procedure.
214326912|NCT06836609|DRUG|ALN-CIDEB|Administered per the protocol
214326913|NCT06836609|DRUG|Placebo|Administered per the protocol
214326914|NCT06747091|PROCEDURE|Catheter Ablation|This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:
214928311|NCT00778284|DRUG|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
214928312|NCT00949819|OTHER|Active surveillance|Serial, long term data collection and active surveillance
215069759|NCT05878886|DIETARY_SUPPLEMENT|Emergency Food Product|Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.
215069760|NCT01218750|PROCEDURE|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
215069761|NCT04082390|DIETARY_SUPPLEMENT|RELEASE|Dietary supplement
215069762|NCT04082390|DIETARY_SUPPLEMENT|Placebo|Placebo
215069763|NCT04117581|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU (125 μg) vitamin D3 capsules daily over 12 weeks (84 days)
215069764|NCT04117581|OTHER|Placebo|Inert filler capsules daily over 12 weeks (84 days)
215069765|NCT02049827|OTHER|participation in the study|
215069766|NCT00072943|DRUG|anti-Interferon-gamma monoclonal antibody|
215069767|NCT04446507|DRUG|Saroglitazar magnesium|1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1
215069768|NCT05781334|OTHER|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
215069769|NCT02300558|DRUG|Eleclazine|Tablets administered orally
215069770|NCT02300558|DRUG|Eleclazine placebo|Tablets administered orally
215069771|NCT00000593|PROCEDURE|blood transfusion|
214326915|NCT07049068|DRUG|Oral Nicotinamide|"Participants from group 1 received 120 capsules of 500 mg nicotinamide and a tube of placebo cream at each visit. . All participants were instructed to take 1 capsule every 12 hours and to apply the cream to their entire face twice a day.~Participants were unaware of which group they were allocated to and participants in both groups received either capsules (active or placebo, which looked identical) or a tube of cream (active or placebo, which looked identical). In follow-up visits participants returned empty tubes to the responsible pharmacist.~At the initial assessment and at 6 months photographs of the participants' faces were taken."
214326916|NCT07049068|DRUG|topical nicotinamide|"Participants from group 2 received a tube of 5% nicotinamide cream and 120 placebo capsules. All participants were instructed to take 1 capsule every 12 hours and to apply the cream to their entire face twice a day.~Participants were unaware of which group they were allocated to and participants in both groups received either capsules (active or placebo, which looked identical) or a tube of cream (active or placebo, which looked identical). In follow-up visits participants returned empty tubes to the responsible pharmacist.~At the initial assessment and at 6 months photographs of the participants' faces were taken."
214326917|NCT06743204|OTHER|Self-Reported Risk Screening for PrEP and Diagnostic STI testing|The intervention arm will include: 1) Standard-of-care STI symptom screening: The investigators will ask participants if any STI symptoms 2) PrEP screening (if HIV- only): PrEP eligibility screening will be done using the standard-care Ministry Health self-reported risk screening (SRST) tool for PrEP 3) STI laboratory diagnostic testing: Regardless of HIV serostatus, vaginal swabs will be collected to test for chlamydia, gonorrhea, trichomonas, and human papilloma virus. Syphilis testing will be performed using blood samples participants provided in the Rakai Community Cohort Study. Participants who test positive for a curable sexually transmitted infection (chlamydia, gonorrhea, trichomonas, or syphilis) OR who screen eligible for PrEP using the Ministry of Health SRST AND are HIV- will be referred for same-day PrEP initiation. Participants who have symptoms indicative of STIs or who test positive for an STI will be provided with free treatment, as will the partner(s).
214928313|NCT06819228|DRUG|Panitumumab IRDye 800|Study participation would last approximately 60 days from screening to follow-up visits. Participants dose of Panitumumab would be based on weight and Panitumumab IRDye800 is dosed the same for all participants.
214928314|NCT02710253|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214326918|NCT06743204|OTHER|Self-reported risk screening for PrEP and syndromic management for STIs|This active comparator (control) arm will receive the following: 1) Standard-of-care STI symptom screening: Regardless of HIV serostatus, participants will be asked if any STI symptoms 2) Syphilis testing for pregnant participants: Regardless of HIV serostatus, syphilis testing will be performed using blood samples provided in the Rakai Community Cohort Study. 3) PrEP screening (if HIV- only): Participants will be screened for PrEP eligibility using the standard-care Ministry Health self-reported risk screening (SRST) tool for PrEP. Participants who screen eligible for PrEP using the Ministry of Health SRST OR pregnant participant's who test positive for syphilis AND are HIV- will be referred for same-day PrEP initiation. Participants who have symptoms indicative of STIs or who test positive for syphilis will be provided with free treatment, as will the partner(s).
214326919|NCT06895499|DRUG|HB0043|Low dose
214928315|NCT02710253|OTHER|Laboratory Biomarker Analysis|Correlative studies
214928316|NCT02710253|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214928317|NCT04529785|PROCEDURE|SVC only|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC alone
214928318|NCT04529785|PROCEDURE|SVC isolation with substrate modification and vein of Marshal ethanol infusion|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC, substrate modification and vein of Marshal ethanol infusion
214928319|NCT01483729|DRUG|danoprevir|Phase 3 Tablet Formulation 1, single oral dose
214326920|NCT06895499|DRUG|HB0043|Medium dose
214326921|NCT06895499|DRUG|HB0043|High dose
214326922|NCT06083519|BEHAVIORAL|White Noise|This is the control condition. Listening to white noise -- participants listen to white noise for 24 minutes
214326923|NCT06083519|BEHAVIORAL|Music and Auditory Beat Stimulation|Listening to music and auditory beat stimulation. The VIBE app (LUCID) incorporates theta-band (4 Hz) auditory beat stimulation and an auditory music recommendation system. Participants will listen to this music with theta auditory beat stimulation for 24 minutes.
214928320|NCT01483729|DRUG|danoprevir|Phase 3 Tablet Formulation 2, single oral dose
214928321|NCT01483729|DRUG|danoprevir|Reference Phase 2 Tablet Formulation, single oral dose
214928322|NCT01483729|DRUG|ritonavir|Test Formulation 1, single oral dose
214928323|NCT01483729|DRUG|ritonavir|Test Formulation 2, single oral dose
214928324|NCT01483729|DRUG|ritonavir|Reference Formulation, single oral dose
214928325|NCT02076503|PROCEDURE|PET-MR 18f-FACBC|
214928326|NCT02076503|PROCEDURE|histology (gold standard)|histopathological classification of co-located dissected lymph nodes
214928327|NCT04811092|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1
214928328|NCT04811092|OTHER|Placebo|Placebo
214928329|NCT06767306|RADIATION|Stereotactic Body Radiotherapy (extracranial) concurrent with immunotherapy|A minimum SBRT biologically effective dose (BED) of 48Gy10 to all sites of extracranial metastatic disease should be administered between cycle 1 and cycle 3 of standard of care immunotherapy.
214928330|NCT06767306|DRUG|Immunotherapy alone|All patients will receive standard of care 1st line immunotherapy as decided by the treating clinician and in accordance with the current listing on the Australian Register of Therapeutic Goods (ARTG) or applicable international regulatory agency.
214928331|NCT04074681|BEHAVIORAL|Gambling Internet-based Protocol|Gambling Internet-based protocol is a multimedia interactive and self-help program for problem and pathological gamblers, which will allow individuals to learn and practice adaptive ways to cope with this problem. The main therapeutic modules included in this program are: 1) Motivational for change; 2) Psychoeducation; 3) Stimulus control (e.g. self-prohibition and blocking of usual gambling websites with therapist confirmation) and responsible return of debts; 4) Cognitive restructuring; 5) Emotion regulation; 6) Planning of significant activities; 7) Coping skills and exposure with response prevention; 8) Relapse prevention.
214928332|NCT00058929|DRUG|treprostinil sodium|
214928333|NCT02646540|DRUG|Tolvaptan 30 mg + IV Diuretics|Participants will receive oral daily tolvaptan 30 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
214326924|NCT03091192|DRUG|Savolitinib|600 mg (400 mg if \<50 kg) by mouth (PO) with a meal once daily (QD), continuously
214326925|NCT03091192|DRUG|Sunitinib|50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
214928334|NCT02646540|DRUG|Metolazone 5 mg + IV Diuretics|Participants will receive oral daily metolazone 5 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
215069772|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
215069773|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
214326926|NCT07061275|BEHAVIORAL|Telehealth-Supervised Resistance Training|"The exercise protocol will incorporate a variety of exercise modalities adapted for home use in limited space environments. Elastic resistance bands will be used for lower-limb strength exercises such as leg presses, hip abduction, and ankle dorsiflexion, while sandbag-style leg weights will be employed for activities including knee extensions, seated marches, and standing squats. To target balance, low-cost tools such as foam pads, balance cushions, or step platforms will be used for tasks including static standing, single-leg stance, and step-up exercises designed to challenge postural control in a safe, progressive manner.~Sessions will be delivered through a secure live-streaming platform accessible on smartphones. The streaming platform supports background audio, allowing exercise sessions to be accompanied by music, which may help increase motivation and enjoyment for participating children. Each session will be led by trained instructors from the Hunan Normal University."
214326927|NCT07060573|BEHAVIORAL|Parental Oral Stimulation Protocol|This intervention consists of a structured oral stimulation protocol composed of 4 extraoral and 4 intraoral exercises designed to improve oral motor function in preterm neonates. Exercises include perioral massage, stimulation of sucking reflex, and non-nutritive sucking using a pacifier. The protocol is administered once daily for 14 consecutive days. In this study arm, the intervention is performed by parents, previously trained and supervised in the neonatal unit.
214326928|NCT07060573|BEHAVIORAL|Physiotherapist-led Oral Stimulation|This intervention consists of a structured oral stimulation protocol composed of 4 extraoral and 4 intraoral exercises designed to improve oral motor function in preterm neonates. Exercises include perioral massage, stimulation of sucking reflex, and non-nutritive sucking using a pacifier. The protocol is administered once daily for 14 consecutive days. In this study arm, the intervention is performed by a licensed physiotherapist.
214326929|NCT07059728|DEVICE|Oxygen therapy during sedation provided via high nasal cannulae (60L/min at 60% FiO2)|Intervention group: Oxygen therapy during sedation provided via high nasal cannulae (60L/min at 60% FiO2)
214326930|NCT07059728|DEVICE|Oxygen therapy during sedation delivered via nasal cannulae at 5L/min|Control group: Oxygen therapy during sedation delivered via nasal cannulae at 5L/min
214326931|NCT05262023|DRUG|DNL593|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
214326932|NCT05262023|DRUG|Placebo|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
214326933|NCT06143891|DRUG|Belumosudil|Pharmaceutical form:Tablet-Route of administration:oral
214326934|NCT06143891|DRUG|Placebo|Pharmaceutical form:Table-Route of administration:oral
214326935|NCT06143891|DRUG|Prednisone|Pharmaceutical form:Tablet-Route of administration:oral
214326936|NCT06143891|DRUG|Prednisolone|Pharmaceutical form:Tablet-Route of administration:oral
214326937|NCT06767514|BIOLOGICAL|Ivonescimab Injection|Subject will receive ivonescimab as an IV injection
214326938|NCT06767514|BIOLOGICAL|Pembrolizumab Injection|Subject will receive Pembrolizumab as an IV injection
214928335|NCT02646540|DRUG|2.5 times the Diuretics Dose|Participants will receive two and a half (2.5) times their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
214928336|NCT04272944|DRUG|10 mg/kg Q2W|10 mg/kg MSB2311 every two weeks
214928337|NCT04272944|DRUG|20 mg/kg Q3W|20 mg/kg MSB2311 every three weeks.
214928338|NCT05887440|BEHAVIORAL|isokinetic strength training of knee extensor and flexor muscles|"Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks.~Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)"
215069774|NCT05064410|BEHAVIORAL|Educational Intervention|The colorectal cancer (CRC) educational activities will include the use of NCI CRC resources and materials, including a PowerPoint presentation, and CRC educational models and displays. The CRC education will be delivered in Spanish and English, and will consist of pre and post knowledge assessments including screening and behavioral intention questions. The educational intervention will take approximately 45 minutes-1 hour.
215069775|NCT05474781|DRUG|Epclusa|HCV treatment
214928339|NCT03992027|BEHAVIORAL|CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis|CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
214326939|NCT06448481|PROCEDURE|Intra-dermal purse-string closure|Sutures are placed below the skin surface around a circular surgical wound, and the ends are cinched together like a coin purse.
214928340|NCT03992027|BEHAVIORAL|Waitlist Control|Participants receive usual care for 3 months followed by CF-CBT. CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
214928341|NCT02686463|PROCEDURE|Laparoscopy|Laparoscopy is an operation performed in the abdomen or pelvis through small incisions (usually 0.5-1.5 cm) with the aid of a camera. It can either be used to inspect and diagnose a condition or to perform surgery.
214928342|NCT02686463|PROCEDURE|Laparotomy|A laparotomy is a surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity. It is also known as a celiotomy.
214928343|NCT03998384|PROCEDURE|retrobulbar injection of autoserum|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.
214928344|NCT03998384|PROCEDURE|retrobulbar injection of placebo|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison
215069776|NCT01932320|DRUG|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
215069777|NCT01932320|DRUG|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
215069778|NCT01932320|DRUG|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
214326940|NCT06448481|PROCEDURE|Transcutaneous purse-string closure|Sutures are placed through the skin surface around a circular surgical wound, and cinched together like a coin purse.
214326941|NCT06885931|DEVICE|Pudendal neuromodulation|In this feasibility study, all subjects will receive the Amber UI system.
214326942|NCT07061977|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214326943|NCT07061977|RADIATION|Brachytherapy|Undergo brachytherapy
214326944|NCT07061977|DRUG|Carboplatin|Given IV
214326945|NCT07061977|PROCEDURE|Chest Radiography|Undergo chest x-ray
214326946|NCT07061977|DRUG|Cisplatin|Given IV
214326947|NCT07061977|PROCEDURE|Computed Tomography|Undergo CT scan
214326948|NCT07061977|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214326949|NCT07061977|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214326950|NCT07061977|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214326951|NCT07061977|BIOLOGICAL|Pembrolizumab|Given IV
214326952|NCT07061977|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214928345|NCT01829100|BEHAVIORAL|Group Behavioral Activation Therapy (GBAT)|GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
214673187|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
214326953|NCT06773845|DEVICE|TheraSphere|The multicompartment MIRD model (a.k.a. partition model) based on diagnostic CT/MRI and 99mTc-MAA SPECT-CT will be used to plan a targeted dose of 700 Gy (± 50%) to the tumor. Given the high tumor burden, a scheduled second radioembolization within 120 days from the initial treatment will be permitted at the discretion of the operators provided the cumulative lung dose remains below 50 Gy. A scheduled second radioembolization may be considered when the largest tumor diameter exceeds 8 cm, or the estimated lung dose reaches 30 Gy while the tumor absorbed dose remains below the target dose of 700 Gy. The radioactive microsphere delivery device used will be glass-based (TheraSphere; Boston Scientific, MA, USA), in which Y90 is an integral constituent of the biocompatible glass matrix. Dosimetry planning will be made by personalized dosimetry software (Simplicit90y; Boston Scientific).
214326954|NCT07064785|BEHAVIORAL|Video-based ART adherence counseling|"* Clinical visit which includes ART provision at 0, 12 and 24 weeks~* Two one-hour video-based sessions with associated activities at 0 and 12 weeks~* Enhanced/Intensive adherence counselling with video component between 24-35 weeks for those with high viral load"
214326955|NCT07064785|BEHAVIORAL|Standard of Care (SOC)|"* Clinical visit which includes ART provision at 0, 12 and 24 weeks~* Basic adherence counselling between 24-35 weeks for those with high viral load"
214326956|NCT07066722|DRUG|VH4524184|VH4524184 will be administered.
214326957|NCT07066722|DRUG|Itraconazole|Itraconazole will be administered.
214928346|NCT02270047|DIETARY_SUPPLEMENT|Orange nectar|Orange nectar
215069779|NCT01932320|DRUG|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
215069780|NCT01491386|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
214928347|NCT02270047|DIETARY_SUPPLEMENT|Orange Nectar with fibre|
214928348|NCT03550755|BIOLOGICAL|V3-Cervix|Oral tableted preparation containing hydrolyzed tumor antigens derived from peripheral blood and tumor tissue
214928349|NCT00002837|BIOLOGICAL|Filgrastim (G-CSF)|
215069781|NCT01491386|DEVICE|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
215069782|NCT00875238|BIOLOGICAL|trastuzumab|
215069783|NCT00875238|DRUG|doxorubicin hydrochloride|
215069784|NCT00875238|GENETIC|polymorphism analysis|
215069785|NCT00875238|OTHER|laboratory biomarker analysis|
214326958|NCT07066722|DRUG|Rifabutin|Rifabutin will be administered.
214326959|NCT07066722|DRUG|Phenytoin|Extended phenytoin sodium will be administered.
214326960|NCT07066722|DRUG|Metformin|Metformin will be administered.
214326961|NCT07064109|DRUG|Colchicine 0.5 MG Oral Tablet Once Daily|Colchicine 0.5 MG Oral Tablet Once Daily
214326962|NCT04953442|BEHAVIORAL|Fit 24|This 12-week goal-setting intervention will test the feasibility of using a Fitbit watch and motivational text messaging to improve physical activity and sleep in Hispanic youth (14-16 years of age) with obesity. Youth will be prompted to set weekly steps per day and hours of sleep per night goals. Text messages will be grounded in the Self-Determination Theory and will provide evidence-based strategies, support, and motivation to encourage youth to meet their goals.
214326963|NCT04562129|DRUG|Interleukin-2|High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)
214326964|NCT04562129|DRUG|Ipilimumab|Low dose Ipilimumab given at time of HD IL2 administration on day 1 of the first 2 cycles of each course.
214326965|NCT04562129|DRUG|Nivolumab|Nivolumab will be given at a dose of 480 mg IV week 7 of each course.
214673188|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
215069786|NCT00875238|OTHER|questionnaire administration|
215069787|NCT00875238|PROCEDURE|assessment of therapy complications|
215069788|NCT00875238|PROCEDURE|magnetic resonance imaging|
215069789|NCT04302701|OTHER|Dichoptic treatment using virtual reality|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
214928350|NCT00002837|DRUG|Cyclophosphamide|
214928351|NCT00002837|DRUG|Doxorubicin Hydrochloride|
214326966|NCT07071311|BEHAVIORAL|Growth Mindset Intervention|"This single-session growth mindset intervention consists of reading and reflective writing activities that present mental health as something that can be improved, rather than something fixed. The goal is to show that adopting a growth mindset of mental health can encourage more proactive mental health behaviors.~To begin, participants will read stories of three employees who share their personal experiences navigating mental health challenges in the workplace. Each story highlights the employee's struggles, how they came to see mental health as changeable, and the steps they took to care for their well-being (e.g., practicing self-care or seeking therapy). After reading, participants will complete a short reflective essay in response to three prompts. These prompts guide them to examine their own mindset about mental health, endorse a growth mindset towards mental health, and outline specific actions they can take to proactively support their own mental well-being."
214326967|NCT07071311|BEHAVIORAL|Digital Technology Condition|"This single-session control exercise aims to encourage the use of digital technology in the workplace. It positions participants as experts who provide guidance to others on how to use digital tools more effectively at work.~First, participants will read stories about employees' experiences navigating their workload with the help of workplace technology. Each story highlights the employee's initial struggles with learning new digital tools and how they eventually recognized the value of these technologies. This includes examples of how they viewed digital learning as manageable and took proactive steps-such as seeking help from colleagues or setting aside time to practice. Then, participants will complete a short reflective essay in response to three writing prompts. These prompts guide them to reflect on their own experiences with digital tools and offer practical advice to others on how to use new technologies effectively in the workplace."
214326968|NCT07068919|BEHAVIORAL|Seizure diary|collection of a seizure diary during 3 months
214326969|NCT07068919|BEHAVIORAL|Questionnaries|Daily self-assessment via the Epiday application during 3 months
214326970|NCT06767345|DRUG|statins, ezetimibe|Rosuvastatin 20mg once daily
214326971|NCT06767345|DRUG|Combination therapy|Rosuvastatin 10mg + Ezetimibe 10mg
214326972|NCT06894212|DRUG|SEP-363856|tablet
214326973|NCT06894212|OTHER|Placebo|tablet
214673189|NCT02438072|DRUG|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
214326974|NCT07067632|DRUG|Antihypertensive treatment|"Any intervention (pharmacological, device-based, lifestyle) intentionally directed at lowering BP~Control groups receiving placebo, standard of care, or no intervention"
214928352|NCT00002837|DRUG|Paclitaxel|
214928353|NCT00002837|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
215069790|NCT04302701|OTHER|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near.
215069791|NCT02471274|DRUG|sotagliflozin|single 400 mg dose
215069792|NCT01059682|DRUG|Dalcetrapib|Dalcetrapib 600 mg orally once daily
214326975|NCT06772025|OTHER|No investigational study intervention|No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood (not exceeding 200 mL) and urine samples and of available clinical data are the only activities performed in addition.
214326976|NCT06466837|BEHAVIORAL|Just-in-time intervention|The intervention group participants will receive just-in-time intervention from a developed app for healthy behavior reminder
214673190|NCT01936337|DRUG|DLX105 Hydrogel|topical administration on psoriatic plaque
214673191|NCT01936337|DRUG|Placebo|topical administration on psoriatic plaque
214928354|NCT04538833|DRUG|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin-bound paclitaxel(GM1 is a single infusion).
214928355|NCT04538833|OTHER|Placebo|The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel (placebo as a single infusion)
214928356|NCT03045432|OTHER|video-teaching|By watching a video specially designed by a rehabilitation team, the participants may learn how to position their affected arm properly (30 minutes per time, twice a day for five days in a week), how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly (15 minutes per time, twice a day for five days in a week), and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy.
215069793|NCT01059682|DRUG|Placebo|Placebo orally once daily
215069794|NCT06636318|DIAGNOSTIC_TEST|Blood Sample Collection|"To characterize the phenotype and function of immune cells in surgery residents before and after a 24-hour shift, and before and after a month of being on call. Along with to investigate the relationship between sleep deprivation, physical activity, and different immune responses."
214326977|NCT06466837|BEHAVIORAL|Active control|The control group participants will receive six nursing consultations during the 3-month program period.
214326978|NCT06832787|DEVICE|Negative Pressure Wound Therapy|NPWT applied over wound without any adjuncts
214326979|NCT06832787|DEVICE|Kerecis|Kerecis Omega3 Wound Dressing is derived from fish skin and is used as a dermal substitute.
214928357|NCT03045432|OTHER|oral-teaching|The nurses will teach patients how to position their affected arm properly, how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly, and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy on the admission date of hospitalization.
214928358|NCT03045432|OTHER|regular rehabilitation program|Regular occupational therapy program and regular physical therapy program in the rehabilitation department of the hospital.
214928359|NCT04350437|DRUG|induction of labor|Giving drugs to facilitate uterine contractions and fasten the process of delivery
214928360|NCT06522698|DEVICE|Smart Pill Bottle|Patients in the intervention group will have their opioid medication consumption monitored through a smart pill bottle that records medication usage and streamlines the data into an online platform accessible by the medical staff. This group will also fill out surveys delivered through the smart pill bottle's online platform.
214928361|NCT02026791|DEVICE|I-gel|"* The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, I-gel prepared in advance was inserted."
215069795|NCT06636318|DEVICE|Actigraph (GT9X-BT) Monitor|Participants will be asked to wear their monitor every day for a week. The monitor will collect their step count, sleep and heart rate automatically. Participants will return their monitor at visit 5 (day 30) of the study.
214326980|NCT06832787|DEVICE|Delayed primary closure with local flap|Delayed primary closure with local flap to close wound
214326981|NCT06901037|OTHER|A chatbot-based intervention|A smartphone-delivered AI-based chatbot program designed to provide personalized physical activity and dietary recommendations
214326982|NCT07064876|DRUG|Serplulimab|PD-1 inhibitor, 300 mg intravenous infusion, once every 3 weeks (Q3W) for up to 6 cycles, starting after cryoablation recovery and in the absence of major procedural complications.
214326983|NCT07064876|PROCEDURE|CT-guided Cryoablation|Percutaneous cryoablation performed under CT guidance to achieve local tumor ablation. Procedure done once (per-protocol) prior to systemic therapy.
214326984|NCT04078828|PROCEDURE|Pelvic floor Reconstruction|Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.
214326985|NCT06606847|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
214326986|NCT06606847|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
214326987|NCT06849544|DRUG|0.03mg/kg ZOPOCIANINE given day of surgery|A single dose of 0.03mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
214326988|NCT06849544|DRUG|0.06mg/kg ZOPOCIANINE given day of surgery|A single dose of 0.06mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
214326989|NCT06849544|DRUG|0.03mg/kg ZOPOCIANINE given day prior to surgery|A single dose of 0.03mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
214326990|NCT06849544|DRUG|0.06mg/kg ZOPOCIANINE given days prior to surgery|A single dose of 0.06mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
214326991|NCT06841341|DIAGNOSTIC_TEST|electromyography|electromyography of a set of muscles usually examined during diagnosis of ALS (typically tongue, bilateral deltoid, first dorsal interosseur, abductor pollicis brevis, paraspinals, vastus lateralis, anterior tibialis and additionally bilateral sternocleidomastoideus and rectus abdominis). In each muscle recording in relaxation and in maximal voluntary effort will be done. The presence of signs of acute (fibrillations, sharp waves) and chronic (fasciculations, reduction of the recording of the effort) denervation as well as presence of activity coupled with the rhythm of respiration will be assessed.
214326992|NCT06841341|DIAGNOSTIC_TEST|ultrasonography|Ultrasonographic measurements include cross-sectional area (CSA) and diameter of bilateral phrenicus, vagus and accessory nerves as well as diameter of diaphragm. The diameter of diaphragm will be measured during normal, quiet respiration as well as at the peak inspiration and expiration.
214326993|NCT06841341|DIAGNOSTIC_TEST|Arterial blood gas analysis|Assessment of partial oxygen (PaO2) and partial carbondioxide pressure (PaCO2) in arterial blood.
214326994|NCT06841341|DIAGNOSTIC_TEST|slow vital capacity|Slow vital capacity (SVC) will be measured as the full exhalation done after inspiration which will follow a period of quiet breathing. The test will be performed thrice and the final value will be the average value.
214326995|NCT01038778|BIOLOGICAL|Aldesleukin|Given IV
214326996|NCT01038778|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
214326997|NCT01038778|DRUG|Entinostat|Given PO
214326998|NCT01038778|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
214326999|NCT01038778|OTHER|Laboratory Biomarker Analysis|Correlative studies
214327000|NCT01038778|OTHER|Pharmacological Study|Correlative studies
214327001|NCT01038778|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
214327002|NCT06830200|PROCEDURE|Non-surgical periodontal treatment with chitosan brush|Non-surgical treatment of pre-implantitis with chitosan brush
214327003|NCT06830200|DEVICE|Non-surgical treatment of pre-implantitis with titanium curette|Description: Non-surgical treatment of pre-implantitis with titanium curette
214327004|NCT06896435|BEHAVIORAL|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
214327005|NCT06896435|BEHAVIORAL|Relaxing Video|Participants are asked to view weekly videos lasting 15 minutes each to engage in relaxation exercises.
214327006|NCT04487080|DRUG|Amivantamab|Participants will receive amivantamab intravenously.
214928362|NCT02026791|DEVICE|Supreme-LMA|"* The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, Supreme LMA prepared in advance was inserted."
214928363|NCT06574945|DRUG|intravenous injection of propofol only|Propofol was administered intravenously 2 mg/kg
214928364|NCT06574945|DRUG|intravenous injection of propofol +esketamine|intravenous injection of 0.5 mg/kg ESK followed by 1.5 mg/kg of propofol or intravenous injection of 0.25 mg/kg ESK followed by 1.5 mg/kg of propofol
215069796|NCT05669755|DRUG|Cagrilintide|Participants will receive cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
215069797|NCT05669755|DRUG|Semaglutide|Participants will receive semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
214327007|NCT04487080|DRUG|Osimertinib|Participants will receive osimertinib capsules orally.
214327008|NCT04487080|DRUG|Lazertinib|Participants will receive lazertinib tablets orally.
214327009|NCT04487080|DRUG|Placebo|Participants will receive matching placebo orally.
214327010|NCT03596645|DRUG|Golimumab|Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
214327011|NCT03596645|DRUG|Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
214327012|NCT04768101|DRUG|[11C]-PIB|\[11C\]-PIB is a PET radiotracer used to evaluate levels of Αβ burden.
214327013|NCT07075523|OTHER|Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers|Pathognomonic magnetic resonance imaging; neurocognitive assessments with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); quality of life assessment with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30; measurement of liquid biomarkers.
214327014|NCT07085780|OTHER|LEP|"1. Apply a thin, even layer of the Lep directly onto the clean and dry affected area.~2. Cover the application with a layer of clean cotton.~3. Allow the Lep to remain on the area for at least 2 days,~4. Avoiding exposure to direct heat or open flame during this period.~5. In this study, on Day 04, gently remove the Lep using warm water and soft cotton cloth and thoroughly cleanse the area with mild soap and water."
214327015|NCT07086833|OTHER|Low Cysteine Diet|A diet low in cysteine, about 1.4 g/1000 kcal.
214327016|NCT07086833|OTHER|High Cysteine Diet|A diet high in cysteine, about 3 g/1000 kcal.
214327017|NCT07085416|DEVICE|Sensor-enabled Athletic X Ankle Brace (sXAB)|The intervention is a sensor-enabled version of the TayCo Brace, Inc. Athletic X Ankle Brace (sXAB), which integrates commercially available inertial measurement units (IMUs) into the structure of the brace. The brace is worn on the ankle of the dominant limb during functional movement tasks to evaluate its ability to produce valid gait and balance metrics compared to laboratory-grade measurement systems.
214327018|NCT07084987|OTHER|neonatal massage|Standardized neonatal massage before phototherapy
214327019|NCT07084987|OTHER|Tub Bathing|Tub bath before phototherapy
214327020|NCT07084987|OTHER|sponge bath|Sponge (wipe) bath before phototherapy
214327021|NCT07085078|BEHAVIORAL|progressive relaxation exercises|Participants with menopausal symptoms received progressive relaxation exercise training, led by the responsible researcher who assigned them to the experimental group.
214327022|NCT07085871|OTHER|Fish Powder|This RCT aims to test the effectiveness of fish powder (produced from dried fish from Lake Malawi - Lake Malawi sardine) used to fortify school meals. The intervention meal will be the normal school meal, however substituing 3-5g of ingredients (such as soya flour, maize flour or groundnut flour) for 3-5g of fish powder.
214327023|NCT07085988|OTHER|Rapid glitter|Patients with nasopharyngeal carcinoma are given rapid gamin during concurrent chemoradiotherapy
214928365|NCT04205331|DEVICE|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
215069798|NCT05669755|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
215069799|NCT05925283|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
215069800|NCT05925283|DRUG|Esketamine|intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
215069801|NCT05925283|DRUG|midazolam and esketamine|oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
214928366|NCT03148860|DRUG|Methotrexate|subjects will receive once weekly 15 mg (3 capsules) MTX
214928367|NCT03148860|DRUG|Ustekinumab|subject will receive Ustekinumab open-label over a treatment period of 52 weeks
214928368|NCT03148860|OTHER|Placebo|subjects will receive once weekly 3 capsules PLC to MTX
214928369|NCT02298062|DRUG|Infliximab|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
214928370|NCT02298062|DRUG|IVIG|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
214928371|NCT01681680|DRUG|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
214928372|NCT02537431|BIOLOGICAL|burosumab|solution for subcutaneous injection
214928373|NCT06242392|GENETIC|homologous recombination deficiency|Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.
214928374|NCT06436950|DEVICE|transcutaneous electrical phrenic nerve stimulation (TEPNS)|TEPNS is conducted twice a day for consecutive 5 days. Electrodes are applied to bilateral neck skin which phrenic nerve runs underneath.
214928375|NCT01529788|DRUG|Right lateral orbital injection of Botox Cosmetic or Dysport|Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study
215069802|NCT00284505|DRUG|thalidomide|
215069803|NCT05527587|OTHER|Nature Connections Intervention|10 PLWD and their 10 caregivers will be examined for the effects of a park visit program on their behaviour and mood symptoms, cognition, and quality of life over the period of 8-weeks. If participants meet the study criteria, an initial education session on the health benefits of nature will be provided to the them. Participants will then be invited to participate in the park visit program which will have them visiting local parks or outdoors spaces with their caregivers. They will be encouraged to allocate approximately 120 minutes each week to outdoor park activities for 8 weeks. Participants will be provided with a visit passport to record a log of activities completed during the park visits. During the 8 weeks of intervention, participants will also participate in a weekly check-in meeting with other participants to discuss about their experiences with the park visits.
214327024|NCT07087028|DEVICE|SleeperOne™|Computerized intraosseous anesthesia was delivered using the SleeperOne™ (Dental HiTec, France) device with a 30 G × 9 mm Effitec needle at a 15° angle to the mucosa. A total of 2 mL 2% articaine with 1:100,000 epinephrine was administered per site.
214327025|NCT07087028|OTHER|Conventional Infiltration Anesthesia|The intervention for the Conventional Infiltration Anesthesia involves the manual administration of a local anesthetic using a standard dental syringe with a fine-gauge needle.
214327026|NCT07086937|DRUG|Nitazoxanide|Children were given nitazoxanide, PPI, and clarithromycin for 14 days.
214327027|NCT07086937|DRUG|Metronidazole|Children received MTZ, PPI, and clarithromycin for 14 days.
214327028|NCT07086937|DRUG|PPI|Children were given omeprazole for 14 days.
215069804|NCT03076216|DEVICE|OncoSil™|The implantation of OncoSil™ under EUS
214327029|NCT07086937|DRUG|Clarithromycin|Children were given clarithromycin for 14 days.
214327030|NCT07085559|DRUG|Metabolically Armed BCMA CAR-T cells.|Each subject receive metabolically armed BCMA CAR- T cells by intravenous infusion.
214327031|NCT07086209|DIETARY_SUPPLEMENT|Branched-Chain Amino Acid Supplement|Oral BCAA blend (leucine, isoleucine, valine), 10 g/day divided into two doses, pre- and post-training, for 6 weeks.
214327032|NCT07086209|BEHAVIORAL|Therapeutic Exercise Program|6-week structured program including isometric, eccentric, plyometric, and sprint-specific exercises.
214327033|NCT07087106|DRUG|[F-18]FDG|PET radiopharmaceutical
214327034|NCT06903468|PROCEDURE|Novel cavity marking technique|A novel cavity marking technique will be performed on all participants during their breast conservation surgery. For this technique, cavity marking will be in a clockwise fashion per breast starting with the superior margin of the tumor bed. The superior margin of the left breast will be marked with a single large clip, followed by a double clip for the lateral margin, a triple clip for the inferior margin, and a quadruple clip for the medial margin. The superior margin of the right breast will be marked with a single large clip, followed by a double clip for the medial margin, a triple clip for the inferior margin and a quadruple clip for the lateral margin. Margins with multiple clips will always have one large clip with the remaining clips standard medium size.
215069805|NCT01620515|DRUG|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
215069806|NCT01620515|DRUG|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
214928376|NCT01529788|DRUG|Left lateral orbital injection of Botox Cosmetic or Dysport|Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study
214928377|NCT02727777|DRUG|TAK228|Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.
214928378|NCT02727777|OTHER|Blood Sugar Testing|Participant given a glucometer to check pre-dose blood sugar levels at home every day.
214928379|NCT04881227|DEVICE|Chatbot on COVID-19 vaccine hesitancy|This intervention will provide to participants information on COVID-19 vaccine hesitancy consisting of the possibility of accessing a long series of questions and answers online about this vaccination.
214327035|NCT07085455|DIETARY_SUPPLEMENT|Early Supplemental Parenteral Nutrition (SPN)|SPN is initiated on ICU day 4 if enteral nutrition remains \<50% of the target caloric requirement. Nutrition support is guided by protocol
214327036|NCT07085455|DIETARY_SUPPLEMENT|Late Supplemental Parenteral Nutrition (SPN)|SPN is initiated on ICU day 8 if enteral nutrition remains \<50% of the target caloric requirement. Nutrition support is guided by the same protocol as in the early SPN group.
214327037|NCT06929845|PROCEDURE|organoids models|Enrolled patients will undergo liver biopsy with sampling of tumor tissue and adjacent nontumor liver parenchyma. Alternatively, patients who are candidates for surgical resection of HCC will be enrolled. The tumor tissue obtained will be used partly for histological confirmation of HCC and then included in kerosene, partly used for organoid construction, and the nontumor tissue will be used solely for organoids. Genomic and transcriptomic changes resulting from the integration of PDO of HCC with the gut microbiota and host immune cells derived from the patient will be evaluated. In addition, PDOs from HCC will be tested for the efficacy of systemic therapies (ICI and TKI) and understand possible modifying co-factors.
214327038|NCT07086391|DEVICE|Polymyxin B Sulfate 25mg Jet Nebulization / Vibrating Mesh Nebulization|"* Group A: 25mg polymyxin B sulfate dissolved in 5ml sterile water, administered via jet nebulizer under mechanical ventilation.~* Group B: 25mg polymyxin B sulfate dissolved in 5ml sterile water, administered via vibrating mesh nebulizer under mechanical ventilation."
214327039|NCT07085494|BEHAVIORAL|neurofeedback|\- Neurofeedback Training : Feedback is based on individualized alpha band power. Participants see a game-like display (for instance, a plane) that reflects their alpha activity. Excessive EMG (muscle tension) causes performance drops, encouraging relaxation.
214327040|NCT07085494|BEHAVIORAL|Cognitive Training|\- Cogmed Training : Participants complete adaptive tasks focusing on working memory. The difficulty adjusts in real time based on performance.
214327041|NCT07085494|BEHAVIORAL|Sham feedback|The sham neurofeedback protocol was identical to the verum neurofeedback protocol except that the animation (horizontal plane movement) was based on the EEG results of another participant. EMG-based feedback will still be provided for the sham condition
214327042|NCT07085741|DEVICE|MAGNET System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
214327043|NCT07086690|DRUG|Group (1): Patients will receive nebulized ketamine (2 mg/kg)|"Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of oxygen at 6 L/min for 10 to 15 minutes. Treatment will be stopped when the nebulizer begin to sputter. All solutions will be prepared in identical syringes with matching random codes by an independent investigator not involved in the observation or the administration of the anesthesia.~\- All patients will be admitted on the day of the surgery and will be instructed to fast 6 hours before surgery for older patients, as for breast fed patients, they will be instructed for 4 hours for breast feeding and for formula fed patients they will be instructed to fast for 6 hours as recommended by the American society of anesthesiologists. Preoperative assessment will be done before surgery by one of the members of the team who will make sure that the inclusion and exclusion criteria of the patients are considered, and baseline vital signs willbe rec"
214327044|NCT07086690|DRUG|Group (2): Patients will receive nebulized combination of dexmedetomidine and ketamine (1 μg/kg + 1 mg/kg)|"Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of oxygen at 6 L/min for 10 to 15 minutes. Treatment will be stopped when the nebulizer begin to sputter. All solutions will be prepared in identical syringes with matching random codes by an independent investigator not involved in the observation or the administration of the anesthesia.~\- All patients will be admitted on the day of the surgery and will be instructed to fast 6 hours before surgery for older patients, as for breast fed patients, they will be instructed for 4 hours for breast feeding and for formula fed patients they will be instructed to fast for 6 hours as recommended by the American society of anesthesiologists. Preoperative assessment will be done before surgery by one of the members of the team who will make sure that the inclusion and exclusion criteria of the patients are considered, and baseline vital signs will be re"
214327045|NCT07086690|DRUG|Patients will receive intramuscular ketamine (4 mg/kg, intramuscularly) 15 mins before starting the procedure.|"Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of oxygen at 6 L/min for 10 to 15 minutes. Treatment will be stopped when the nebulizer begin to sputter. All solutions will be prepared in identical syringes with matching random codes by an independent investigator not involved in the observation or the administration of the anesthesia.~\- All patients will be admitted on the day of the surgery and will be instructed to fast 6 hours before surgery for older patients, as for breast fed patients, they will be instructed for 4 hours for breast feeding and for formula fed patients they will be instructed to fast for 6 hours as recommended by the American society of anesthesiologists. Preoperative assessment will be done before surgery by one of the members of the team who will make sure that the inclusion and exclusion criteria of the patients are considered, and baseline vital signs will be re"
214327046|NCT06594159|DRUG|LY4065967|Administered orally
214327047|NCT06594159|DRUG|Placebo|Administered orally
214327048|NCT06594159|DRUG|Rosuvastatin|Administered orally
214928380|NCT04881227|OTHER|Control intervention|This control intervention will provide to participants a brief text decribing the way vaccines works.
214928381|NCT05152966|DEVICE|Ablation|Ablation using the FARAPULSE™ Cardiac Ablation System Plus
214928382|NCT01872065|DRUG|ARC-520|
214928383|NCT01872065|DRUG|Placebo|
214928384|NCT00107965|DRUG|PEP005|0.0025% PEP005 Topical Gel (Day 1,2 application)
214327049|NCT06302296|DEVICE|injectable form of PRF|A group of patients in which participants will be undergo to orthodontic treatment will be received a 0.9 ml injection of PRF after 1st premolar extraction.
214327050|NCT06302296|BEHAVIORAL|Placebo injection|A group of patients in which participants will be undergo to traditional orthodontic treatment will be received a Placebo injection after 1st premolar extraction.
214928385|NCT00107965|DRUG|PEP005|0.01% PEP005 Topical Gel (Day 1,2 application)
214928386|NCT00107965|DRUG|PEP005|0.05% PEP005 Topical Gel (Day 1,2 application)
214928387|NCT00107965|DRUG|PEP005|Vehicle Gel (Day 1,2 application)
214928388|NCT00107965|DRUG|PEP005|0.0025% PEP005 Topical Gel (Day 1,8 application)
214928389|NCT00107965|DRUG|PEP005|0.01% PEP005 Topical Gel (Day 1,8 application)
214928390|NCT00107965|DRUG|PEP005|0.05% PEP005 Topical Gel (Day 1,8 application)
214928391|NCT00107965|DRUG|PEP005|Vehicle Gel (Day 1,8 application)
214928392|NCT00919373|PROCEDURE|Substrate modification|Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
214928393|NCT00919373|PROCEDURE|VT ablation|Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
214327051|NCT06748274|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a sophisticated neuromodulation technique that involves the use of a magnetic coil placed against the scalp to generate brief magnetic pulses. These pulses induce electric currents in the cortical neurons, leading to depolarization or hyperpolarization depending on the parameters of the stimulation.
214928394|NCT00919373|PROCEDURE|ICD Implantation|Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
214928395|NCT00005944|DRUG|chemotherapy|
214928396|NCT00005944|DRUG|fluorouracil|
214928397|NCT00005944|DRUG|leucovorin calcium|
214928398|NCT00005944|DRUG|mitomycin C|
214928399|NCT00005944|PROCEDURE|conventional surgery|
214928400|NCT00005944|PROCEDURE|laparoscopic surgery|
214928401|NCT05052372|DRUG|Balversa|BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery
214327052|NCT06748274|DEVICE|High-definition transcranial direct current stimulation (HD-tDCS)|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation technique that involves applying a low-intensity electrical current to specific areas of the scalp. The electric current induces alterations in the membrane potentials of underlying neuronal networks. The application of tDCS with concentric ring electrodes is a more targeted form of tDCS, allowing for more precise modulation of cortical activity compared to traditional tDCS methods.
214327053|NCT06908655|OTHER|MRI|The procedure to be investigated will be to perform a diffusion tensor sequence during the MRI indicated as part of the treatment. The diffusion tensor sequence takes 10 minutes to acquire, for a total examination time of 30 minutes instead of 20 minutes, including set-up.
214327054|NCT07087093|OTHER|Ketone ester|KetoneAid Ke4 Pro Ketone Ester：20ml, tid po
214327055|NCT07085572|DRUG|Cemiplimab|350 mg IV Q3W
214327056|NCT06908759|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|In the first phase of the study all enrolled patients will perform exercise in the context of an in-hospital intesive rehabilitation after the acute event. At discharge they will be randomized in two groups: supervised exercise in the context of a cardiac rehabilitation facility or home-based exercise
214327057|NCT06912165|DRUG|WD-890 tablet|Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
214327058|NCT06912165|DRUG|WD-890 tablet|Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
214327059|NCT06912165|DRUG|WD-890 tablet|Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
214327060|NCT06912165|DRUG|Placebo|Participants will receive placebo QD from Week 0 through Week 16.
214327061|NCT06904547|OTHER|No intervention administered|No intervention administered
214327062|NCT06904547|OTHER|Non Interventional Study|Non Interventional Study
214327063|NCT06909890|BEHAVIORAL|Chios mastic beverage|Participants of this intervention arm will be provided with a sparkling beverage enriched with the natural mastic aqueous extract (0.2%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to maintain their usual lifestyle practices and medical treatment stable.
214327064|NCT06909890|BEHAVIORAL|Placebo beverage|Participants of this intervention arm will be provided with a placebo sparkling beverage (same organoleptic characteristics with experimental beverage but no active ingredients) and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to maintain their usual lifestyle practices and medical treatment stable.
214327065|NCT06185842|BEHAVIORAL|breathing exercise, walking exercise and vaccination counseling|"Participants will perform diaphragmatic breathing exercises and pursed lip breathing exercises two days a week for eight weeks.~Participants will be asked to walk for 20-30 minutes every day for eight weeks. Monitoring will be done weekly.~Participants will be counseled about infectious diseases, modes of transmission and the importance of vaccination, and will be advised to receive influenza and pneumococcal vaccines recommended for this age group.~The 5A model guide will be used regarding behavioral change towards physical activity and vaccination."
214928402|NCT03925038|BEHAVIORAL|Augmented Care: Electronic Media Dashboard|A participant-specific dashboard that highlights patterns of patient electronic communication usage relevant to understanding participants' mental health will be developed and used to augment treatment as usual.
214928403|NCT03925038|BEHAVIORAL|Treatment as Usual|Participants will receive psychotherapy as treatment as usual.
214928404|NCT02787421|DEVICE|Breathe-Rite Nasal Dilator Strip|During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
214928405|NCT00836381|DRUG|Tolterodine extended-release (ER) 4mg|Tolterodine extended-release (ER) 4mg once daily for 12 weeks
214928406|NCT00836381|DRUG|Placebo|Identical Placebo once daily
214928407|NCT01017523|BEHAVIORAL|Telephone support and behavior change|Diabetes self-management education provided over the telephone either for individual or couples
214928408|NCT01017523|OTHER|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
214928409|NCT05504538|PROCEDURE|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope
214928410|NCT05504538|DEVICE|Tight rope|Adjustable button device from Arthrex Naples USA
214928411|NCT00392743|PROCEDURE|pet/spect scan|
214928412|NCT06669884|OTHER|Cardiodynamicsgram (CDG)|Cardiodynamicsgram (CDG) technique
214928413|NCT06372587|OTHER|genetically encoded engineered proteins|using genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons promoting synaptic plasticity and/or preventing dendritic spines loss
214327066|NCT06181786|DRUG|NAV-240|Intravenous administration of NAV-240
214327067|NCT06181786|DRUG|Placebo|Intravenous administration of matching placebo for NAV-240
214327068|NCT05909761|DRUG|UPLIZNA|Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
214327069|NCT06928467|BEHAVIORAL|Building Better Caregivers workshop|The BBC workshop is a 6-week, online, peer-led small group workshop designed for family caregivers of persons living with dementia or other form of cognitive impairment. It is an evidence-based workshop of the Self-Management Resource Center originally developed at Stanford University for the Veterans Administration and is now licensed for online delivery by Canary Health. Content focuses on increasing participant self-management behaviors, dementia caregiving skills, and peer social support. The workshop uses a peer-facilitated small group format with frequent online interactions between approximately 27 participants on threaded discussion boards. Activities are guided by two trained peer co-facilitators (caregivers themselves). Each week focuses on 2-3 new topics and tools for participants to learn and use. In threaded discussion board conversations participants interact, help each other, and provide peer social support.
214327070|NCT06909448|DEVICE|abdominal belt|40 postpartum women will only wear abdominal belt for 14 weeks.
214928414|NCT06685354|DRUG|hepatic arterial infusion of recombinant human type 5 adenovirus|Participants will receive hepatic arterial infusion of recombinant human type 5 adenovirus (H101). The H101 treatment regimen consists of 3 cycles or until a specific treatment discontinuation event occurs as outlined in the protocol. The H101 administration method is as follows: if the sum of the largest diameters of lesions is ≤10 cm, the total dose is 1.0×10\^12 vp (2 vials); if the sum of the largest diameters is \&gt;10 cm, the total dose is 1.5×10\^12 vp (3 vials). Treatment cycles are every 3 weeks.
214928415|NCT03732352|OTHER|Fludeoxyglucose F-18|Given IV
214928416|NCT03732352|DRUG|Osimertinib|Given PO
214928417|NCT03732352|PROCEDURE|Positron Emission Tomography|Undergo fludeoxyglucose F-18 PET scan
214928418|NCT01794182|DRUG|Glyburide for Injection|Administered as specified in the treatment arm.
214928419|NCT01794182|DRUG|Placebo|Administered as specified in the treatment arm.
214928420|NCT01340027|DRUG|Mirabegron|oral
214928421|NCT01340027|DRUG|Solifenacin succinate|oral
214928422|NCT01340027|DRUG|Placebo|oral
214928423|NCT01758731|DRUG|Olaparib|Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.
214928424|NCT01758731|DRUG|Cetuximab|Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.
214928425|NCT01758731|RADIATION|Radiation Therapy|RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
214928426|NCT02211482|DRUG|dolutegravir, lamivudine|single arm
214928427|NCT04448457|DRUG|Sufentanil Sublingual Tablet|15 mcg with lockout interval of 20 min
214928428|NCT04448457|DRUG|Oxycodone oral tablet and oxycodone extended-release oral tablet|Oxycodone hydrochloride 5 mg and Oxycodone extended-release 10 mg
214928429|NCT02615431|OTHER|MitraClip Intervention|
214928430|NCT04280744|OTHER|Music therapy|Patient preferred song will be provided in a sedative manor (e.g., 60-80 beats per minute) using live music (singing with guitar accompaniment) by a board certified music therapist.
214928431|NCT02626130|PROCEDURE|Cryosurgery|Undergo cryoablation
214928432|NCT02626130|OTHER|Laboratory Biomarker Analysis|Correlative studies
214928433|NCT02626130|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214327071|NCT06909448|DEVICE|TECAR therapy|will wear the same abdominal belt for 6 weeks then participating in TECAR therapy 3 sessions /week for 8 weeks.
214327072|NCT06909383|DRUG|Nanocrystalline megestrol acetate|Nanocrystalline megestrol acetate
214327073|NCT06909331|DIETARY_SUPPLEMENT|Exogenous ketone salt|Exogenous ketone salt supplement will be taken once to determine acute circulating levels of beta-hydroxybuyrate and acetoacetate compared to a control supplement.
214327074|NCT06909331|DIETARY_SUPPLEMENT|Placebo drink solution|Participants consumed a placebo drink that was flavor, color and calorie matched to the experimental drink.
214673192|NCT00316901|PROCEDURE|computed tomography|
214673193|NCT00316901|PROCEDURE|positron emission tomography|
214928434|NCT02626130|BIOLOGICAL|Tremelimumab|Given IV
214928435|NCT01987739|DRUG|200 mg almorexant|
214928436|NCT01987739|DRUG|400 mg almorexant|
214673194|NCT00316901|RADIATION|fludeoxyglucose F 18|
214928437|NCT01987739|DRUG|1000 mg almorexant|
214928438|NCT01987739|DRUG|20 mg zolpidem|
214928439|NCT01987739|DRUG|40 mg zolpidem|
214928440|NCT01987739|DRUG|placebo|
214928441|NCT03718520|OTHER|no intervention, this is a purely observational study|No intervention
214928442|NCT04687072|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
214928443|NCT04687072|OTHER|Placebo PH20 SC|Subcutaneous injection with placebo PH20 SC
214928444|NCT00335569|DRUG|hCG-IBSA|
214928445|NCT04523272|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214928446|NCT04523272|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
214928447|NCT04523272|DRUG|Sunitinib|A multi-target receptor tyrosine kinase inhibitor.
214928448|NCT05076669|OTHER|stoma follow-up|delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites
214928449|NCT05076669|OTHER|standard of care|routine management of stoma
214928450|NCT04505072|BEHAVIORAL|PR-ESSENCE|Manual-based training of mutual problem-solving
214928451|NCT04505072|BEHAVIORAL|Treatment as usual|General support in daily structure and activities that is given to all youth staying at the treatment homes
214928452|NCT05274854|BEHAVIORAL|a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing|Pre consultation interventions consist of one of four intervention a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
214928453|NCT05274854|BEHAVIORAL|a) consultant-led outpatient clinic or b) a integrated care clinic|Consultation intervention consists of one of two interventions a) consultant-led outpatient clinic or b) a integrated care clinic
214928454|NCT02173678|DRUG|COMBIVENT® HFA-MDI|
214928455|NCT02173678|DRUG|COMBIVENT® CFC-MDI|
214327075|NCT05947279|BEHAVIORAL|Comparing motor adaptation reaching performance|By comparing motor adaptation reaching performance between these three groups, the investigators can examine how stimulation to each specific area of the brain modulates different aspects of motor adaptation
214327076|NCT03977259|OTHER|Individually targeted fortification|"Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the base milk has protein 1 g/dL and calories 67/dL."
214327077|NCT06754280|BEHAVIORAL|RESET-CKD|RESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues.
214327078|NCT06754280|OTHER|Attention Control|CKD-related education
214928456|NCT02173678|DRUG|Placebo HFA-MDI|
214928457|NCT06668727|DRUG|HepB mAb19|"The study has two parts:~Part A will involve administering a single ascending dose of HepB mAb19 or placebo using a randomized, double-blind method in Groups 1-3 at dose levels of 3, 10, and 30 mg/kg. Participants enrolled in Groups 1-3 will be randomized at a 3:1 ratio to receive HepB mAb19 or placebo. Part B will assess the maximum tolerated dose (MTD) in Group 4 in an openlabel fashion. Participants will receive HepB mAb19 at MTD."
214928458|NCT01990131|OTHER|Cognitive Anxiety Sensitivity Treatment|
214928459|NCT01990131|OTHER|Physical Health Education Training|
214928460|NCT02094976|DEVICE|Jackson surgical table|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Jackson table with two padded supports on each side. The supports were positioned under the lateral chest and at the iliac crest.
214928461|NCT02094976|DEVICE|Wilson frame|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Wilson frame. The supports were positioned vertically from shoulder to iliac crest.
214928462|NCT02094976|DEVICE|Chest roll|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a chest roll. The supports were positioned vertically from shoulder to iliac crest.
214928463|NCT06003374|DEVICE|Ultrasound|"At international protocol U/S examination is performed from an anterior approach, with the transducer in a sagittal plane parallel to the femoral neck. The patients are positioned supine with the hips in neutral position. Also a coronal view is performed from the lateral approach. Establish a new protocol in the MSK unit to perform hip US,~* adductor view: flexion, abduction and lateral rotation of the hip joint with viewing the hip via adductor muscle group.~* gluteal view: posterior approach of the hip joint via gluteal region with the patient lying on the contralateral examined hip.~Psoas and thigh views: US examination of psoas and quadriceps muscles to exclude the presence of absecess .~-finally US guided aspiration under complete a septic condition."
214928464|NCT06530680|BEHAVIORAL|Hippotherapy|Two 1-hour sessions of hippotherapy for eight weeks.
214928465|NCT00915876|DRUG|Paricalcitol|paricalcitol 1 mcg QD x 8 weeks
214928466|NCT00915876|DRUG|Placebo|Placebo for Paricalcitol 1 mcg QD x 8 weeks
214928467|NCT01662791|DRUG|Rifaximin|All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
214928468|NCT03902184|BIOLOGICAL|IPH4102|Patients will receive a flat dose of 750mg
214928469|NCT00037947|PROCEDURE|Hearing in Multiple Sclerosis|
214327079|NCT06908330|BEHAVIORAL|Social-emotional Skills for Thriving and Relating at School Program|The SSTRS Program is a developmentally-tailored, school-based preventive intervention focusing on children and their parents at the critical transition to kindergarten to prevent deficits in children's social-emotional skills-which are known transdiagnostic risk factors for a range of mental health problems. Children receive SSTRS programming during their regular school day for eight weeks at the beginning of the school year. Parents receive SSTRS programming via informational videos and virtual parenting groups during the same time period.
214327080|NCT04638894|PROCEDURE|Surgical treatment of patients with adult spinal deformity|Including all surgical interventions for patients with adult spinal deformity.
214327081|NCT06909396|DRUG|General anesthesia|Patients received general anesthesia
214327082|NCT06909396|DRUG|Intrathecal Anesthesia|Patients received intrathecal Anesthesia
214327083|NCT06909396|DRUG|Caudal block|Patients received caudal epidural anesthesia.
214327084|NCT06860230|DEVICE|Philips FAST SpO2 with Nellcor Pulse Oximetry Sensors|Noninvasive pulse oximeter
214327085|NCT05684510|DEVICE|clear aligners|clear aligners will be applied to the upper and lower arch, then a class II elastics 1\\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
214673195|NCT03373786|DRUG|RG012|RG012 in 0.3% sodium chloride
214928470|NCT01923298|DRUG|Estradiol|
214928471|NCT05303298|DEVICE|Anti-reflux oesophageal stent|Fully covered self-expanding metal stent with anti-reflux mechanism
214928472|NCT05303298|DEVICE|Conventional oesophageal stent|Fully covered self-expanding metal stent without an anti-reflux mechanism
214928473|NCT03008265|OTHER|Postoperative fascial dehiscence|
214928474|NCT06840587|BEHAVIORAL|Connect-Home ADRD|Connect-Home ADRD will introduce new structure and processes to support SNF staff delivery of transitional care for transitions to home, assisted living, or long-term care, and post-discharge transitional care by the Dementia Caregiving Specialist.
214928475|NCT00186966|DRUG|Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|See Detailed Description section for details of treatment interventions.
214928476|NCT00186966|DRUG|Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|See Detailed Description section for details of treatment interventions.
214928477|NCT00186966|PROCEDURE|Hematopoietic stem cell transplant|See Detailed Description section for details of treatment interventions.
214327086|NCT05684510|DEVICE|traditional treatment Fixed appliances with class II elastics.|Agroup of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
214327087|NCT05527184|DRUG|IMGN151|IMGN151 is an antibody-drug conjugate (ADC).
214327088|NCT06238921|RADIATION|Stereotactic Radiation|Stereotactic Radiation to intact brain metastases or post-operative cavity.
214327089|NCT06238921|DRUG|Zimberelimab|One week +/- 4 days following receipt of SRS, zimberelimab 360 mg IV will be administered. This will be followed by zimberelimab 360 mg IV every 3 weeks.
214327090|NCT06238921|DRUG|Sacituzumab govitecan|SG will be administered on days 1 and 8 (10 mg/kg) of 21 day treatment cycles. This will be one week +/- 4 days following receipt of SRS for the first dose.
214327091|NCT06598800|DRUG|Drug: BG-T187|Intravenous administration
214327092|NCT07107113|OTHER|Pilates Exercise|Pilates exercises are characterized as muscle strengthening and stretching.
214327093|NCT07107113|OTHER|Aerobic exercises|Aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
214327094|NCT07107113|OTHER|Pilates exercises plus aerobic exercise|Pilates exercises are characterized as muscle strengthening and stretching, while aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
214327095|NCT07111234|PROCEDURE|Carbon Monoxide Measurement|Ancillary studies
214327096|NCT07111234|DRUG|Nicotine Oral Pouch|Sample randomly-ordered ONPs
214327097|NCT07111234|OTHER|Questionnaire Administration|Ancillary studies
214327098|NCT07111234|DRUG|Smoke usual brand cigarette|Participant will smoke their usual brand of cigarette during 1 study visit for 5 minutes.
214327099|NCT07111065|DIETARY_SUPPLEMENT|FISH OIL 500MG OMEGA-3 SOFT GEL MINIS|Translucent, light yellow, oblong soft gelatin capsule containing a straw to amber light liquid.
214327100|NCT07111065|OTHER|Dietary Guidelines for Americans diet|The Dietary Guidelines provides science-based advice on what to eat and drink to promote health, help reduce risk of chronic disease, and meet nutrient needs.
214327101|NCT07109050|DEVICE|VR Headset|VR will be offered on either an individual or joint-experience basis, whereby the participant(s) wear a VR headset with 360 degree views, to explore various VR experiences of their choice for up to 3 sessions on a weekly basis. Goals for using VR will be ascertained by completing the goal based measure with the patient who is accessing specialist palliative care. This will define the purpose of the VR intervention in future sessions. The participant will be shown a list of VR experience options so they are aware of these prior to the next session. Pre-VR and post-VR questionnaires will be completed.
214327102|NCT07116291|OTHER|Karate|karate practice
214327103|NCT07117994|DIETARY_SUPPLEMENT|Radicle Revive Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214327104|NCT07117994|DIETARY_SUPPLEMENT|Radicle Revive Active Study Product 1|Participants will use their Radicle Revive Active Study Product 1 as directed for a period of 6 weeks.
214327105|NCT06922929|DRUG|INR101|INR101 PET/ CT
214327106|NCT06922942|DEVICE|MSCopilot Flower mobile application|MSCopilot Flower includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Anxiety
214327107|NCT07116694|DRUG|BXCL501 Sublingual Film|Single dose BXCL501 120 mcg
214327108|NCT06923826|DRUG|Sacituzumab govitecan|Day 1 and Day 8: Sacituzumab Govitecan will be administered at the dose of 10 mg/kg via intravenous infusion.
214327109|NCT04597125|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
214327110|NCT04597125|DRUG|NAH therapy|Participants will receive continuous NAH (either Abiraterone acetate plus prednisone/prednisolone \[AAP\] or enzalutamide) by mouth (per os) daily
214327111|NCT07086781|BEHAVIORAL|Virtual Family Navigation|Participants randomized to the Family Navigation condition will receive up to 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.
214928478|NCT00186966|RADIATION|Total body irradiation|See Detailed Description section for details of treatment interventions.
214327112|NCT07086781|BEHAVIORAL|Educational Materials|"The comparison condition (Educational Materials) consists of providing the participant's caregivers information about early intervention and community-based supports (i.e., infant-toddler programs, transition to school-based supports, family support groups, local organizations. Families in this condition will receive this information throughout 4 timepoints in the first 3 months after enrolling."
214327113|NCT07119307|PROCEDURE|Entire Papilla Preservation Technique|Entire Papilla Preservation Surgical Technique (EPPT) alone and combined with enamel matrix derivative (EMD) plus bone mineral derived xenograph (BMDX)
214327114|NCT07119307|PROCEDURE|Entire Papilla Preservation Surgical Technique (EPPT) alone|Entire Papilla Preservation Surgical Technique (EPPT) alone
214327115|NCT07119307|PROCEDURE|Entire Papilla Preservation Surgical Technique (EPPT) alone and combined with enamel matrix derivative (EMD)|Entire Papilla Preservation Surgical Technique (EPPT) alone and combined with enamel matrix derivative (EMD)
214327116|NCT07118124|DEVICE|Zio monitor|Evaluate analyzable time of the Zio monitor over the wear duration of up to 14 days in a pediatric population.
214327117|NCT07120100|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation will be administered Monday-Friday for two weeks (10 sessions total)
214928479|NCT00052052|DRUG|interferon-gamma 1b|200 mcg, SQ, 3x per week
214928480|NCT06058520|DRUG|Fecal Microbiota - lyophilized|Patients receive 2 capsules daily for one week followed by one capsule daily for 2 weeks. MTT capsules are derived from a single donor per patient.
214928481|NCT06058520|DRUG|Placebo drug|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product.
214928482|NCT03951974|BEHAVIORAL|Social Emotion Regulation Strategy Development|Participants will work one-on-one with an interventionist to develop goals (in the form of implementation intentions) to develop social emotion regulation strategies to combat frequent emotional challenges.
214327118|NCT03195478|DRUG|Nivolumab|Specified dose on specified days
214327119|NCT03195478|DRUG|Ipilimumab|Specified dose on specified days
214327120|NCT06919835|DRUG|Cilostazol 100 mg|Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.
214327121|NCT06915766|DRUG|Bezuclastinib|Drug: Bezuclastinib Tablets
214327122|NCT06923657|DIAGNOSTIC_TEST|PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy|The experimental group will undergo PSMA PET/MRI examination. For those with positive PSMA PET/MRI results, a PSMA PET/MRI-TRUS guided prostate targeted biopsy will be performed based on transrectal ultrasound (TRUS) guided transperineal saturation biopsy, targeting the positive lesions. For those with negative PSMA PET/MRI results, only TRUS guided transperineal saturation biopsy will be performed. Clinical and pathological data of the patients will be collected for statistical analysis.
214327123|NCT06923657|DIAGNOSTIC_TEST|TRUS guided transperineal saturation biopsy|The control group will receive TRUS guided transperineal saturation biopsy. Clinical and pathological data of the patients will be collected for statistical analysis.
214327124|NCT07131293|PROCEDURE|Lymphatic intervention|This intervention was made as part of their clinical treatment.
214928483|NCT03951974|BEHAVIORAL|Control|Participants will work one-on-one with an interventionist to report on their frequent emotional challenges, and report the emotion regulation strategies that they frequently use to combat them.
214928484|NCT04119076|OTHER|Classroom-based physical activity|
214928485|NCT04119076|OTHER|Control Group|
214928486|NCT03174873|PROCEDURE|laparoscopy|Laparoscopy will be done for unexplained infertile couples before starting IVF because not all pathologic lesions that discovered by laparoscope need IVF and so, protect patients from unneeded IVF program
214928487|NCT05769400|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
214928488|NCT01740752|BEHAVIORAL|UCAN+CBT|weekly manualized couple therapy plus weekly manualized individual CBT
214928489|NCT01740752|BEHAVIORAL|CBT|"weekly manualized higher dose of individual CBT"
214928490|NCT04829617|BEHAVIORAL|PP-MI Intervention|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and promoting adherence to physical activity, diet, and medications (through MI). Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to monitor health behavior adherence, resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in health behaviors.
215069807|NCT03888235|PROCEDURE|Immediate corrective exercises|The sacroiliac forward flexion test (SIFFT) finds the position of each innominate bone. Subjects learn 1 of 3 exercises. To correct anterior rotation, flex the thigh hard against the ilium, pushing it backwards. To correct posterior rotation, hyperextend the thigh to pull the ilium forward. 1.Genuflect, anterior foot and posterior knee on the floor hands on the floor on either side of the foot, sliding the knee backwards to hyperextend the thigh. 2. Supine, anterior foot on an assistant's sternum, posterior thigh hyperextended. Assistant leans forward, forcing the anterior thigh against the ilium and pushing down on the posterior thigh. 3. For anterior rotation alone: anterior foot on a chair seat, pulling up hard with both hands, leaning back, forcing the thigh against the ilium. Hold position for 2 minutes. Use as needed for pain control. They are reassessed one month later when they receive the pelvic support belt. Both treatments used together will be assessed one month after.
215069808|NCT03888235|DEVICE|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their sacroiliac joints. The belt is fitted tightly around the pelvis, over the sacrum and below the anterior superior iliac spines (ASISs) to prevent opening the joint. (The upper part of the innominate bones flares out so pushing them inwards will move the lower part outwards, away from the sacrum, opening the sacroiliac joints, increasing their instability). They will use this belt for activities which have in the past precipitated back pain. They will be reassessed one month later.~At that time they will be given the exercises to correct their sacroiliac malrotation and the concurrent use of both treatments will be assessed at their last visit one month later."
214673196|NCT06509516|OTHER|Modified Sleeper-Stretch|Self-administered stretch in which the individual remains side-lying on the upper limb to be stretched, keeping the scapula stabilized by his/her own weight, and rolls the trunk 20-30º posteriorly, maintaining a 90º flexion in the shoulder and elbow. Using the opposite hand over the forearm of the limb to be stretched, the individual passively brings the shoulder to maximum internal rotation.
214673197|NCT04711421|DEVICE|4 VIVOFIT-|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
215069809|NCT03888235|OTHER|Delayed treatment|Participants will continue the treatments they are currently using to relieve their low back pain for one month. At their one-month visit, they will be taught how to assess the direction of sacroiliac malrotation and how to do the corrective exercise. They will also be fitted for a pelvic stabilization belt.
214327131|NCT04348045|DRUG|Arm A - Olaparib|"300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued."
214327132|NCT04348045|DRUG|ARM B - durvalumab plus selumetinib|"Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily"
214327133|NCT04348045|DRUG|ARM C FOLFIRI|FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
214327134|NCT03950128|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|"This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well."
214327135|NCT03950128|BEHAVIORAL|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
214327136|NCT06936748|COMBINATION_PRODUCT|Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab|"Radiotherapy Phase: Spatially fractionated radiotherapy (SFRT, 10-20 Gy/1F) to the tumor, followed by hypofractionated/conventional fractionated radiotherapy (dose investigator-determined).~Immunotherapy Phase: Iparomlimab and Tuvonralimab (5 mg/kg) initiated within 1 week post-radiotherapy, infused IV over 20-60 minutes (Day 1, every 3 weeks) in 100 mL saline/5% glucose. Treatment continues until disease progression, intolerable toxicity, new antitumor therapy, consent withdrawal, or investigator decision, with a maximum duration of 1 year. Progression may allow continued therapy after patient-investigator discussion; re-progression mandates permanent discontinuation."
214928491|NCT04829617|BEHAVIORAL|MI-alone Intervention|The time- and attention-matched MI-alone intervention focuses on providing education about heart failure (HF) and promoting adherence to physical activity, diet, and medications. Each week, participants will independently complete an activity related to HF education or adherence to a health behavior, then complete a phone session with a study trainer. HF educational topics will include the causes and types of HF, risk factors for cardiovascular disease, methods for monitoring risk factors and symptoms, and the importance of adherence to physical activity, diet, and medications. For each health behavior, study trainers will assist participants to monitor adherence, identify realistic behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) that provide education and encourage engagement in health behaviors.
214928492|NCT06435325|BEHAVIORAL|Precision diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
214928493|NCT06435325|BEHAVIORAL|Control diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
215069810|NCT01575093|OTHER|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
215069811|NCT00666653|DRUG|pramipexole|
215069812|NCT05530863|BEHAVIORAL|Assisted Therapy|The participant will receive coaching calls and support
214327137|NCT06938724|OTHER|Omission of local therapies|"Omission of surgery (arm A) or radiotherapy (arm B) in those patients who have had the maximum response by neoadjuvant treatments. Maximum responders are those patients with no evidence of residual disease after neoadjuvant treatment at imaging -including mammography, US evaluation and contrast imaging procedures (MRI and/or CEM)-, confirmed by VABB on marked site of ascertained lesion.~This study is open to all patients with T1-2, N0-1, M0 HER2-positive or triple negative breast cancer, treated with neoadjuvant systemic treatment, irrespective of treatments delivered."
214327138|NCT06941844|OTHER|Placebo|A substance that is designed to have no therapeutic value
214327139|NCT06941844|DRUG|MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
214327140|NCT06933056|DRUG|Sotagliflozin (SOTA) followed by 3 drugs in a random order|400 mg/day SOTA Each drug will be given daily for 2 weeks.
214928494|NCT00071656|BEHAVIORAL|Psychosocial (behavioral) Intervention|
214327141|NCT06933056|DRUG|Aspirin followed by 3 drugs in a random order|81 mg/day Aspirin Each drug will be given daily for 2 weeks.
214327142|NCT06933056|DRUG|Clopidogrel followed by 3 drugs in a random order|75 mg/day clopidogrel Each drug will be given daily for 2 weeks.
214327143|NCT06933056|DRUG|Eliquis followed by 3 drugs in a random order|5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks.
214327144|NCT06944964|PROCEDURE|Single Implant Fixation (SIF)|This intervention involves using one implant for fracture fixation. The implant can be either a lateral locked plate or a retrograde intramedullary nail, based on the surgeon's preference.
214928495|NCT03902717|PROCEDURE|Minimally invasive cardiac surgery|Patients will undergo minimally invasive cardiac surgery
214928496|NCT03717051|DRUG|Nicotine replacement therapy (NRT) sampling|1-week free NRT samples (patch or gum)
215069813|NCT05530863|BEHAVIORAL|Sleep Hygiene|Standard Sleep Hygiene instructions.
215069814|NCT03314974|BIOLOGICAL|HSCT with TBI Regimen|Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
214928497|NCT03717051|BEHAVIORAL|Medication counseling|Medication counseling
214928498|NCT04378959|DRUG|Lidocaine patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
215069815|NCT03314974|BIOLOGICAL|HSCT with Non-TBI Regimen|Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
215069816|NCT06162494|BIOLOGICAL|Recombinant Zoster Vaccine|After giving consent, participants will be given first dose of vaccine. Participants will be brought back 60-90 days post-vaccine for follow up testing and second dose of vaccine
214327145|NCT06944964|PROCEDURE|Dual Implant Fixation (DIF)|This intervention involves using two implants for fracture fixation. The combination can be either dual plate fixation (DPF) or combination nail plate fixation (NPF) .
214928499|NCT04378959|DRUG|Placebo patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
214928500|NCT00928941|BEHAVIORAL|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
214928501|NCT00928941|BEHAVIORAL|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
214928502|NCT00029536|BIOLOGICAL|Progesterone Lozenges|200mg Progesterone Lozenges
214928503|NCT00029536|OTHER|Matched Placebo Lozenges|Matched Placebo Lozenges
214928504|NCT03509428|BEHAVIORAL|SRETP|SRETP will involve short periods of exercise at a high intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session. Exercise intensities during the interval exercise-training program are specific to each patient and derived from CPET. Moderate intensity exercise is below the anaerobic threshold (AT). Patients will exercise at 80% of oxygen uptake (VO2) obtained at the anaerobic threshold (80%AT) for moderate intensity exercise - 3 minutes. Severe exercise intensity is recognised as 50% of the difference between the VO2 AT and VO2 Peak (50%∆) - 2 minutes.
214928505|NCT03509428|BEHAVIORAL|Psychological support|Support sessions will be patient-centred, giving the patient an opportunity to raise any issues/concerns they are having, this may include (but will not be limited to) ways of coping with their reactions to cancer, family and relationship issues, exploring personal issues and dealing with practical issues. Patients will have access to other resources available at the cancer centres including but not restricted to further information about their condition and how to access financial support. These processes reflect the best practice currently being delivered by cancer support centre staff in the Wessex region. Any patient deemed at risk (i.e. from suicidal ideation or self harm) will be reported to their GP, followed up by a letter.
214928506|NCT03892577|DRUG|Precision oncology including targeted therapy and immunotherapy|Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.
214928507|NCT01168908|DRUG|Sildenafil|20mg tablet three times daily
214928508|NCT00418366|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days|
214928509|NCT00166257|DEVICE|Percutaneous closure of patent foramen ovale|Percutaneous implantation of an AMPLATZER® PFO Occluder
214928510|NCT00166257|DRUG|Medical antitrhombotic treatment|Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
214928511|NCT01765777|PROCEDURE|Osteopathic Manipulative Medicine|
214928512|NCT01765777|PROCEDURE|Phototherapy|
214928513|NCT05848492|DRUG|Fluconazole|Fluconazole will be given for prevention of invasive candidiasis in preterm and very low birthweight babies.
214928514|NCT05848492|DRUG|Saline|0.9% Saline 2cc intravenous will be given to preterm babies in placebo group.
215069817|NCT06135350|DRUG|Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day|"Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:~* 2400 mg/day (4 tablets twice a day) for the first 2 days and;~* 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
214327146|NCT06171789|DRUG|GEN1107|IV infusion of GEN1107
214327147|NCT07138339|DIETARY_SUPPLEMENT|Menstrual Wellness Product Placebo Control|Participants will use their Menstrual Wellness Product Placebo Control as directed for a period of 12 weeks
214327148|NCT07138339|DIETARY_SUPPLEMENT|Menstrual Wellness Product 1|Participants will use their Menstrual Wellness Product 1 as directed for a period of 12 weeks
214327149|NCT04397328|DRUG|Hydroxychloroquine|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
214327150|NCT04397328|DRUG|Placebo|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
214327151|NCT07145515|DEVICE|OCS Heart|Preservation of donor hearts with OCS Heart System and novel OCS Solution and OCS Functional Enhancer.
214327152|NCT07145515|OTHER|Static Cold Storage (SCS)|Preservation of donor hearts with static cold storage.
214928515|NCT05740189|DEVICE|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
214928516|NCT06665880|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for DRE.
214928517|NCT01826890|OTHER|NAVA Technology|Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
214928518|NCT05630521|BEHAVIORAL|Medication Adherence Problem Solving for Hypertension|The MASH program is a 12-week intervention containing two components: (1) four education modules on HTN causes, risks, treatment, and barriers to treatment; and (2) telehealth visits every 2 weeks with a registered nurse to deliver evidence-based managed problem solving strategies tailored on patients' responses to assessments of HTN beliefs, medication beliefs, and barriers impacting their medication adherence.
214928519|NCT01300338|DEVICE|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
214928520|NCT01300338|DEVICE|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
214928521|NCT02123615|DRUG|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
214928522|NCT02123615|DRUG|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs."
214327153|NCT07146802|BEHAVIORAL|Metacognitive Training (MCT) for psychosis|MCT for psychosis is based on the theoretical foundations of the cognitive-behavioral model of schizophrenia, but it employs a somewhat different therapeutic approach. The program is comprised of ten modules targeting common cognitive errors, problem-solving biases as well as emotional problems in schizophrenia. These errors and biases may, on their own or in combination, culminate in the establishment of false beliefs to the point of delusions. The aim of the sessions is to raise the participants' awareness of these distortions and to prompt them to critically reflect on, expand upon, and change their current repertoire of problem solving. In addition to the sessions, the program includes homework tasks to reinforce the skills learned between sessions.
214928523|NCT02123615|DRUG|Gadolinium For abdomen|Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
214928524|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
214928525|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
214928526|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
214327154|NCT07147036|PROCEDURE|Biodentine - Indirect Pulp Capping|"Caries removal under rubber dam isolation using round bur (#BR-45) and water spray~Tooth disinfection with 0.2% chlorhexidine~Mixing of Biodentine (Septodont, France) in an amalgamator (30 seconds at 4000 rpm)~Placement of Biodentine into the prepared cavity using an amalgam carrier and condensation~After 1 week: Placement of self-cure GIC (Fuji, Japan) as a base~Final restoration with light-cure composite resin~Follow-up at 2, 6, and 12 weeks"
214327155|NCT07147036|PROCEDURE|Calcium Hydroxide - Indirect Pulp Capping|"Caries removal under rubber dam isolation using round bur (#BR-45) and water spray~Tooth disinfection with 0.2% chlorhexidine~Cavity dried with cotton pellet~Placement of a 0.5 mm layer of Calcium Hydroxide (Dycal)~After 2-3 minutes (setting time): Placement of self-cure GIC (Fuji, Japan)~After 1 week: Final restoration with light-cure composite resin~Follow-up at 2, 6, and 12 weeks"
214928527|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
214928528|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
214928529|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
214928530|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
214928531|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
214928532|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
215069818|NCT06135350|OTHER|Placebo|"Placebo arm patients will receive placebo:~* 4 tablets twice a day for the first 2 days and;~* 3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
215069819|NCT05230667|OTHER|PRP injection (PRP group)|Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for one time. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance.
215069820|NCT05230667|OTHER|Corticosteroid injection (CS group)|Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa). The techniques of injection are the same as those used in the PRP injection.
215069821|NCT05230667|OTHER|Normal saline injection (NS group)|Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml). The techniques of injection are the same as those used in the PRP injection.
214928533|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
214928534|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
214928535|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
214928536|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
214928537|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
214928538|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
215069822|NCT05292092|DRUG|Essential pro|Patients in whom treatment with (Essential Pro) has been attempted
215069823|NCT00719498|DRUG|Epo-alpha|
215069824|NCT03159169|DEVICE|Spinal Cord Stimulation (SCS)|Implantation of SCS electrodes and stimulator according to clinical standards
215069825|NCT06491745|OTHER|ESWT+PT+corticosteroid injection, ESWT group|ESWT group. Patients in the ESWT group will receive ESWT, physical therapy, and both shoulder joint (glenohumeral joint, GHJ) and SASD bursa injection for 2 times in a 2-week interval. 3ml triamcinolone (1ml triamcinolone= 10mg) will be added to 3ml 1% xylocaine to make 6ml injectate. Among them, 4ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. After withdrawing the needle to subcutaneous layer, another 2ml injectate will be injected into the SASD bursa of the affected shoulder under US guidance.
215069826|NCT06491745|OTHER|Sham ESWT+PT+corticosteroid injection, SHAM group.|SHAM group. The participants will receive the same dosage and technique of corticosteroid posterior GHJ and SASD bursa injection for 2 times at 2 weekly interval as participants do in the ESWT group. For creating a single-blinded condition, they will also receive 4 ESWT treatments at weekly interval except that the energy flux density is set at 0.04 mJ/mm2. For sham ESWT, the machine still makes a noise with every shock wave delivered in order to enhance the sham design.
215069827|NCT05407012|OTHER|Application of the barrier enhancing preparation.|Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
215069828|NCT01054560|DEVICE|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
215069829|NCT01054560|DEVICE|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
215069830|NCT02522182|BEHAVIORAL|Nurse-led Intensive Secondary Prevention Programme|Information related to intervention description have been already included in arm/group description
215069831|NCT02522182|BEHAVIORAL|Usual Treatment|Information related to intervention description have been already included in arm/group description
214928539|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
214928540|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
214928541|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
214928542|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
214928543|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
214928544|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
214928545|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
214928546|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
214928547|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
214928548|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
214928549|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
214928550|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
214928551|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
214928552|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
214928553|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
215069832|NCT03066960|PROCEDURE|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
215069833|NCT03066960|PROCEDURE|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
215069834|NCT01532076|PROCEDURE|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
215069835|NCT01532076|PROCEDURE|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
215069836|NCT01947621|OTHER||
214928554|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
215069837|NCT01804933|DRUG|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
215069838|NCT01516580|DRUG|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
215069839|NCT01516580|DRUG|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
215069840|NCT02793349|DEVICE|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
215069841|NCT01421303|DRUG|Enbrel|Enbrel
214928555|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
214928556|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
214928557|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
214928558|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
214928559|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
214928560|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
214928561|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
214928562|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
214928563|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
214928564|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
214928565|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
214928566|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
214928567|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
214928568|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
214928569|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
214928570|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
214928571|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
214928572|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
214928573|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
214928574|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
214928575|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 12|Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
214928576|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 24|Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
214928577|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 36|Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
214928578|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 12|Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
214928579|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 24|Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
214928580|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 36|Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
214928581|NCT05759429|OTHER|BWRP|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education
214928582|NCT05759429|OTHER|BWRP + melatonin|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
214928583|NCT06523543|PROCEDURE|Inclusion (Visit 1 - Week 7-16)|Extraction of cervico-vaginal sampling
214928584|NCT06523543|DIAGNOSTIC_TEST|Second semester of pregnancy (Visit 2 - Week 20-24)|Ultrasound examination (determination of chromosomal sex)
214928585|NCT06523543|DIAGNOSTIC_TEST|Third semester of pregnancy (Visit 3- Week 34)|Ultrasound examination (determination of chromosomal sex) if this has not be done during the Visit 2 or if a new determination correcting the previous one is provided.
214928586|NCT06183307|DIETARY_SUPPLEMENT|Nattokinase|Participants will receive 1 capsule per day, providing the active nattokinase daily, at a dosage of 100mg, standardized at 2,000 Fibrinolytic Units for 2 months
214928587|NCT06183307|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive 1 capsule per day with 100mg containing corn starch for 2 months.
214928588|NCT05675904|PROCEDURE|Colon oncological resection|Scheduled colon cancer surgery
214928589|NCT04251793|OTHER|Observation|Soft tissue implant measurements and radiographs
214928590|NCT06011395|DEVICE|Smartwatch|Activity tracker (step count, calories burned), heart rate monitor
214928591|NCT06011395|DEVICE|Imperial Healthy Hearts app|Digital cardiac rehabilitation smartphone application. Represents smart watch data and source of educational materials for cardiac rehabilitiation programme.
215069842|NCT00142168|DRUG|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
215069843|NCT00142168|DRUG|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
214928592|NCT05204160|BIOLOGICAL|Pembrolizumab|Given IV
214928593|NCT01895270|DRUG|Isradipine|Isradipine extended release formulation
214928594|NCT01895270|DRUG|Placebo|Placebo will consist of microcrystalline cellulose.
214928595|NCT04236661|DEVICE|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
214928596|NCT06664905|OTHER|Resistance Exercise|10 Repetition Maximum (RM)
214928597|NCT06664905|OTHER|Placebo|No exercise
214928598|NCT01337466|RADIATION|[124I]FIAU|This is a single dose study of 2 mCi \[124I\]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
214928599|NCT05399862|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17648 probiotic|Lactobacillus reuteri DSM 17648 is a single-strain probiotic used as adjunct treatment in H.pylori infection
214327156|NCT07148011|DIETARY_SUPPLEMENT|Revive Product Form - Placebo Control|Participants will use their Revive Product Form - Placebo Control as directed for a period of 12 weeks.
214327157|NCT07148011|DIETARY_SUPPLEMENT|Revive Product Form - Active|Participants will use their Revive Product Form - Active as directed for a period of 12 weeks.
214673198|NCT00377299|DRUG|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
214928600|NCT05399862|OTHER|Placebo|Placebo capsule with no microbial cell preparation
214928601|NCT04609774|OTHER|Severe Acute Respiratory Syndrome CoronaVirus 2 detection|Severe Acute Respiratory Syndrome CoronaVirus 2 Detection by Real-Time Polymerase Chain Reaction and cell culture
214928602|NCT03123835|PROCEDURE|Endoscopic Intervention|After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
214928603|NCT01046058|DRUG|TMC435|150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
214928604|NCT00976820|BIOLOGICAL|GSK2340274A|Two intramuscular injections
214928605|NCT00976820|BIOLOGICAL|GSK2340273A|Two intramuscular injections
214928606|NCT06572748|OTHER|10-week programme|"1. 2-week health education (4 sessions, 60 minutes per session) Social workers and occupational therapists will explain the cognitive training elements of the program and introduce the DementiAbility Methods to the participants. Nutritionist, speech therapists, and Chinese medicine practitioner will share insights from their perspectives to enhance participants' understanding of cognitive impairments.~2. 8-week cooking class (5 sessions, 120 minutes per session) The culinary instructor will teach participants to cook homemade dishes while integrating procedural memory into recipes. Older adults and their caregivers will cook together based on the procedural recipe designed by caregivers, aiming to enhance communication between them and create joyful memories. The cooking class will begin with 20-30 minutes an interactive nutrition-based session. The session themes will focus on healthy diet and food safety. Participants will be able to ask questions and make comments."
215069844|NCT03287934|DEVICE|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
215069845|NCT03287934|DEVICE|digital light processing(dlp)|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
215069846|NCT02083848|OTHER|7T MRI|Ultra high field magnetic resonance imaging
215069847|NCT02429492|DEVICE|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
214673199|NCT00377299|DRUG|Placebo|Placebo matching active medication in all other physical aspects
214327160|NCT06947967|DRUG|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Cyclophosphamide 750 mg/m2 , intravenous infusion on day 1 of each 21-day cycle. Doxorubicin 70mg/m2 , intravenous infusion on day 1 of each 21-day cycle, total 6 cycles. Vincristine 1.4mg/m2(Max dose 2mg), intravenous injection on day 1 of each 21-day cycle , total 6 cycles. Prednisone 100 mg, oral, day 1-5 of each 21-day cycle,total 6 cycles.
214327161|NCT06947967|DRUG|Tucidinostat|oral, taking as prescribed by the protocol
214327162|NCT06947967|DRUG|Placebo|oral, taking as prescribed by the protocol
214928607|NCT02233296|DRUG|Lasmiditan|2 discrete doses separated by 6 days.
214327163|NCT04683679|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses
214327164|NCT04683679|DRUG|Olaparib|Olaparib will be administered twice daily continuously without breaks on a 21-day (3 week) cycle length, for a total of 2 cycles. Olaparib tablets will be administered bid (2 x 150 mg tablets twice daily; total 600 mg daily) on continuous days without interruption for 2 cycles. Each 3 week period constitutes one cycle.
214327165|NCT04683679|RADIATION|Radiation|The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.
214327166|NCT07124351|DRUG|CYTALUX™ (pafolacianine)|All subjects participating in the study are expected to receive CYTALUX™ (pafolacianine) injection and standard care surgery; 1 to 24 hours after CYTALUX™ (pafolacianine) injection infusion is completed, all tumors planned to be removed as part of standard care will undergo assessment with NIR light imaging both intraoperatively and on the back table following surgery.
214327167|NCT07138677|OTHER|transcranial magnetic stimulation|Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
214673200|NCT00804440|DRUG|Ibuprofen Tablets, 800 mg|
214673201|NCT00035815|DRUG|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
214673202|NCT00035815|DRUG|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
214928608|NCT06665334|DRUG|Huaier granule|Oral administration, 10g per dose (1 bag), 3 times a day, recommended for at least 6 months.
214928609|NCT06229288|DRUG|Amoxicillin|"Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily).~Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)"
214928610|NCT06229288|DRUG|Amoxicillin/clavulanate|"Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)"
214327168|NCT07152184|DRUG|Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup|"Biological A blood sample of up to 5 mL will be taken at visits V0, V5, and V14, for a maximum total volume of 15 mL for the study.~Behavioral Quality of life and disease assessment questionnaires will need to be completed by the patient and their caregiver."
214928611|NCT05377554|DRUG|Bevonescein|Bevonescein will be infused during the pre-operative period.
214928612|NCT05377554|OTHER|Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay|Intra-operative real time nerve visualization will be undertaken using WLR with FL Overlay.
214928613|NCT05377554|OTHER|Intra-operative Visualization using White Light Reflectance (WLR)|Intra-operative real time nerve visualization will be undertaken using WLR.
214928614|NCT06110754|BEHAVIORAL|I-STRONG for SCD|I-STRONG for SCD is a group-based, multi-component intervention that includes mind-body, cognitive-behavioral, and neuromuscular movement training. The intervention includes 16 sessions that occur over 8 weeks. Adolescents attend every session and parents attend 6 of the 16 sessions.
214928615|NCT03741751|DEVICE|rTMS|Participants will receive either active or sham bilateral rTMS over the dorsolateral prefrontal cortex (DLPFC) for 12.5 min per side.
214928616|NCT03741751|BEHAVIORAL|Computerized cognitive training|All participants will receive computerized cognitive training for 40 min after each rTMS session.
214928617|NCT01098500|DRUG|Tyrosine kinase inhibitors|Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
214928618|NCT05161975|DIETARY_SUPPLEMENT|Vitamin K2|Volunteers will be randomly assigned to vitamin K2 or placebo group and consume one tablet of the food supplement per day.
214928619|NCT04684459|BIOLOGICAL|Dual-targeting HER2 and PD-L1 CAR-T cells|HER2-positive solid tumor serosal cavity infusion
214928620|NCT01698242|BEHAVIORAL|Enhanced Training|"PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.~Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up)."
215069848|NCT03620578|DRUG|DA-EPOCH-R followed by Nivolumab|5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
215069849|NCT01986192|DRUG|rivaroxaban|
215069850|NCT01986192|DRUG|Warfarin|
215069851|NCT04487535|OTHER|Cytokine level|Serum cytokine level will be measured before surgery, 72nd after surgery and 6 weeks after surgery
215069852|NCT01980303|DRUG|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
215069853|NCT00712725|DRUG|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
215069854|NCT00712725|DRUG|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
215069855|NCT00712725|DRUG|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
215069856|NCT00712725|DRUG|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
214673203|NCT02519764|OTHER|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
215069857|NCT00712725|DRUG|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
215069858|NCT00712725|DRUG|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
215069859|NCT00712725|DRUG|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
214327169|NCT07156721|DEVICE|Phototherapy with White Reflective Drape|Phototherapy device (24 blue LED, 1 red LED, Ertunç Özcan) at 35 cm distance; a double-layer white reflective drape (125 × 105 cm) was placed around three sides and overhead, with a white sheet under the infant.
214327170|NCT07156721|DEVICE|Standard Phototherapy|Phototherapy device (24 blue LED, 1 red LED, Ertunç Özcan) at 35 cm distance; no reflective drape or additional reflective material used.
214327171|NCT05570409|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil 1g bid for 6 months
214327172|NCT05570409|DRUG|Prednisolone|initially 1mg/kg in a step-down regime for 6 months
214327173|NCT05570409|DRUG|Mycophenolate Mofetil Placebo|MMF matching Placebo
214673204|NCT02519764|OTHER|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
214673205|NCT06272253|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|Dose : 1 dose 0.5 ml containing 5 μg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
215069860|NCT00657293|BEHAVIORAL|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
214327174|NCT05570409|DRUG|Prednisolone Placebo|Prednisolone matching placebo
214928621|NCT01698242|BEHAVIORAL|Enhanced Education|"The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.~PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.~Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month."
214928622|NCT02157649|DRUG|IR Tablet under Fasted conditions|Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.
214327175|NCT07161115|RADIATION|Reduced-field short-course radiotherapy|A dose of 25 Gy in 5 fractions was delivered as short-course radiotherapy, with one fraction per day, completing treatment within one week. The target volume was delineated using both CT and MRI. Compared to conventional radiotherapy fields, the irradiated volume was significantly reduced to include only the primary tumor and any metastatic lymph nodes as identified on MRI and CT.
214928623|NCT02157649|DRUG|ER Tablet under Fed Conditions|Administration of two ER Tablet combination of Codeine Phosphate/Guaifenesin 30mg/600mg
214327176|NCT07161115|DRUG|Immunotherapy combined with chemotherapy|After completion of radiotherapy, chemotherapy with the XELOX regimen (oxaliplatin 130 mg/m² on day 1 plus capecitabine 1500 mg/m² on days 1-14, every 3 weeks) was initiated in combination with sintilimab immunotherapy (200 mg every 3 weeks) for 4 cycles.
214928624|NCT02157649|DRUG|ER Tablet under Fasted Conditions|Administration of two Codeine Phosphate/Guaifenesin 30mg/600mg ER Tablets under fasted conditions.
215069861|NCT00657293|BEHAVIORAL|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
215069862|NCT03466099|DRUG|KVD001 Injection|Intravitreal KVD001 Injection
215069863|NCT03466099|OTHER|Sham Procedure|Sham Procedure
214327177|NCT07161115|RADIATION|Standard short-course radiotherapy|"Patients in the standard short-course radiotherapy group will receive 25 Gy in 5 fractions, once daily. Target volumes will be delineated according to the 2023 Guidelines for Target Volume Delineation and Planning of Rectal Cancer (National Cancer Center/National Cancer Quality Control Center), including the primary tumor, mesorectal region, and internal iliac and obturator lymph node drainage areas."
214327178|NCT07161115|RADIATION|Standard long-course radiotherapy|Patients in the standard long-course radiotherapy group will receive 50 Gy in 25 fractions, once daily, five days per week, with concurrent oral capecitabine chemotherapy. Target volumes will be delineated according to the 2023 Guidelines for Target Volume Delineation and Planning of Rectal Cancer (National Cancer Center/National Cancer Quality Control Center), including the primary tumor, mesorectal region, and internal iliac and obturator lymph node drainage areas.
214327179|NCT07161115|DRUG|Chemotherapy|Two weeks after the completion of radiotherapy, patients will receive four cycles of CAPOX chemotherapy.
214327180|NCT07160712|DIETARY_SUPPLEMENT|Relief Product Placebo Control|Participants will use their Relief Product Control as directed for a period of 6 weeks.
215069864|NCT02543866|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
215069865|NCT02829736|PROCEDURE|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
215069866|NCT02829736|PROCEDURE|Standard post-operative chest tube|A regular chest tube is left in the pleura.
215069867|NCT02829736|PROCEDURE|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
215069868|NCT00048022|DRUG|Dual Integrin Antagonist|
215069869|NCT01142869|DRUG|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
215069870|NCT06045793|DRUG|TNX-1300 (Injection)|Patients will receive a single IV injection of TNX-1300.
215069871|NCT06045793|DRUG|Placebo (Injection)|Patients will receive a single IV injection of placebo with usual care (UC).
215069872|NCT06049225|BEHAVIORAL|High-Tech|Access to technological platform and weekly health coaching
215069873|NCT06049225|BEHAVIORAL|Low-Tech|Weekly email with educational content and weekly health coaching
215069874|NCT06049225|BEHAVIORAL|Attention Control|No technology access or health coaching
215069875|NCT05448573|DIAGNOSTIC_TEST|Fatigue Screening and assessment|(Newly) diagnosed cancer-patients from any cancer entity. No intervention.
215069876|NCT01766739|BIOLOGICAL|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
214327181|NCT07160712|DIETARY_SUPPLEMENT|Relief Active Product 1|Participants will use their Relief Active Product 1 as directed for a period of 6 weeks.
214327182|NCT07160712|DIETARY_SUPPLEMENT|Relief Active Product 2|Participants will use their Relief Active Product 2 as directed for a period of 6 weeks.
214327183|NCT07160712|DIETARY_SUPPLEMENT|Relief Active Product 3|Participants will use their Relief Active Product 3 as directed for a period of 6 weeks.
214327184|NCT07160101|OTHER|Eggshell derived nano hydroxyapatite|Eggshell derived nano hydroxyapatite has high solubility and allows faster integration \& replaces with osseous tissue
214928625|NCT01187771|PROCEDURE|Laparoscopic Gastric Banding|Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.
214928626|NCT01187771|PROCEDURE|Continuous Positive Airway Pressure|Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
214327185|NCT07160101|OTHER|Hydroxyapatite|Hydroxyapatite has similar chemical composition with crystalline structure of native bone
214327186|NCT07163546|BEHAVIORAL|Lifestyle intervention|"A lifestyle intervention is an occupational therapy intervention program that aims to help individuals change their lifestyle by encouraging greater engagement in meaningful activities. This program aims to help participants develop healthy routines and habits. It offers a perspective that combines various approaches such as patient education, occupational self-analysis, problem-solving, and building motivation to prevent and manage chronic health problems. Participants gain self-analysis and problem-solving skills while experiencing positive lifestyle changes and developing healthy routines.~The lifestyle intervention was planned as a total of 8 sessions, 2 sessions per week."
214327187|NCT07160036|DEVICE|RLRL(Model RS-200-2A, Eyerising; Suzhou Xuanjia Optoelectronic Technology Co., Ltd., Suzhou, China))|use RLRL twice a day
214327188|NCT07164001|OTHER|Twin-Specific Growth Chart Interpretation|Participants in this arm will have their fetal growth assessed using twin-specific growth charts. These charts account for twin gestation norms and may influence clinical decision-making regarding growth restriction and perinatal management. The intervention does not involve any direct physical procedure or device but rather a change in the interpretation framework of routinely collected ultrasound data.
214928627|NCT00965978|DRUG|ONO-5920 / YM529|oral
214928628|NCT04072393|PROCEDURE|Home-based cardiac rehabilitation|-Patients will be evaluated by the clinical team at The Heart Care Institute (HCI). They will receive a heart rate monitor, blood pressure monitor, and weight scale that they will take home with them. They will receive training on how to use the heart rate monitor and blood pressure monitor. They will receive training on how to record their exercises and weights in the teleHeart application by an exercise physiologist from HCI. Within 6 weeks of completion of standard of care radiation therapy or cytotoxic chemotherapy (whichever is last), they will be prescribed a course of home-based CR by a cardiologist at HCI and be instructed on the regimen by an exercise physiologist from HCI.
215069877|NCT02693080|DEVICE|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
214673206|NCT04908072|DEVICE|Orbis-FundamentalVR MSICS Simulator|Cataract surgery training device, using virtual reality software combined with existing gaming technology for simulated surgery
214673207|NCT02789696|OTHER|Diagnosis of acromegaly|Biological analysis of IGF-1
214673208|NCT04805931|BEHAVIORAL|Behavioral economics|Tailored behavioral economic text messaging vs. standard text messaging
214673209|NCT06725303|DEVICE|Excimer|Light energy
214673210|NCT00710645|DEVICE|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
214673211|NCT06739668|DEVICE|Pascal device|The study devices consist of a tabletop Console with user interface and a head-worn applicator (Headset) that is connected via coaxial cable. The Headset is positioned on the head per instructions, and then the study subject powers on the device by pressing the power button and initiates a 15-minute treatment by pressing the start button. LED lights on the console count down during the treatment to indicate time remaining and, once the treatment is complete, the device automatically powers off.
214673212|NCT06739668|DEVICE|Sham Device|The sham device will look identical to the active device and will have the same indicator lights and sounds, but will not emit magnetic field therapy.
214673213|NCT01470339|DRUG|duloxetine|duloxetine 60mg once a day for 5 weeks
215069878|NCT02693080|DRUG|Isovue-200|Contrast agent
215069879|NCT02693080|RADIATION|Computed Tomography Perfusion Imaging|
215069880|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo|Low Repeat Dose
215069881|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13)|High Repeat Dose/High Repeat Multiple Dose
215069882|NCT04681833|DRUG|Placebo|Liquid diluent/Lyophilised Powder
215069883|NCT05723536|PROCEDURE|Partial Left Atrial Isolation|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
215069884|NCT05723536|PROCEDURE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
215069885|NCT06355609|DRUG|sunvozertinib in combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle.
215069886|NCT03861416|DRUG|L-arginine 1.4% 500 ml|Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
214673214|NCT06916156|DRUG|ANT3310|ANT3310 will be administered in combination with Meropenem. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.
214928629|NCT06666478|OTHER|Exercise protocol at workspace|"The exercise protocol at Workspace begins in a sitting position with spinal mobility exercises that mobilize the hips, lumbar spine, thoracic spine, and cervical spine, accompanied by progressive activation of the peripheral joints in the upper limbs. This is followed by multiaxial functional exercises for the trunk and upper limbs, which combine various movements (e.g., lateral bending and twisting) that simulate the positions employees assume while working.~Subsequently, exercises are performed in an upright position, focusing on stretching and mobilizing the joints and nervous tissue to promote relaxation and release. Coordination, fluid movement, and controlled breathing are emphasized to help workers develop and maintain a stable core while on the job. These principles are essential for workers who are frequently exposed to stressors and physical exertion, as they seek to improve the quality of their movements-namely, smoothness, rhythm, and appropriate speed-while at work."
214928630|NCT02222311|OTHER|Blood Samples|
214928631|NCT06684795|DRUG|FG001 prior to surgery|Patients will receive a single intravenous injection of 36 mg FG001 administered the day before surgery.
215069887|NCT03861416|DRUG|L-arginine 1.4% 250 ml + placebo 250 ml|Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
215069888|NCT03861416|DRUG|Placebo solution|Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
215069889|NCT03149354|OTHER|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
215069890|NCT06278506|PROCEDURE|Ablation|Microwave ablation, Radiofrequency ablation, Cryo ablation
215069891|NCT06278506|PROCEDURE|Surgery|Partial or total nefrectomy
215069892|NCT02664168|DEVICE|Aquacel Ag Surgical Dressing|
215069893|NCT02664168|DEVICE|Single-Use Negative Pressure Wound Therapy (PICO)|
215069894|NCT02973295|DRUG|Silymarin|Capsules contains 100 mg of silymarin
215069895|NCT02973295|OTHER|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
215069896|NCT03754127|DEVICE|tDCS|Transcranial direct current stimulation
215069897|NCT03754127|DEVICE|sham tDCS|Sham transcranial direct current stimulation
215069898|NCT01764477|DRUG|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
215069899|NCT04891718|BIOLOGICAL|MVC-101|Intratumoural microdose injection by the CIVO device.
214673215|NCT06916156|DRUG|Meropenem|Meropenem will be administered in combination with ANT3310. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.
214673216|NCT06774417|OTHER|Digital nudge|Digital help seeking advancement strategies over text and online.
215069900|NCT04891718|BIOLOGICAL|Nivolumab|Intratumoural microdose injection by the CIVO device.
215069901|NCT04891718|COMBINATION_PRODUCT|MVC-101 + Nivolumab|Intratumoural microdose injection by the CIVO device.
215069902|NCT03013387|RADIATION|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
215069903|NCT03013387|PROCEDURE|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
214928632|NCT01949012|OTHER|Capnography|Capnography waveform and capnometry readings
214928633|NCT03722758|DEVICE|Spectrum TPH3|tooth restoration with two different restorative materials
215069904|NCT03013387|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
215069905|NCT06080893|DRUG|Ferric carboxymaltose|"FCM can be administered in a short IV infusion of 15-20 minutes, allowing doses of 2 g in a single session, and furthermore, FCM is excellently tolerated and safe for patients.~FCM will be administered intravenously at preop 24th hour according to weight and preop hgb level"
215069906|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
214673217|NCT06666673|DRUG|Tizanidine|Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.
215069907|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
214327189|NCT07164001|OTHER|Singleton-Based Growth Chart Interpretation|Participants in this arm will have their fetal growth assessed using singleton-based growth charts. These charts are commonly used in standard practice but may overestimate growth restriction in twin pregnancies. The intervention does not involve any direct physical procedure or device but alters the interpretation framework for standard prenatal ultrasound findings.
214928634|NCT03722758|DEVICE|Riva LC|tooth restoration with two different restorative materials
214928635|NCT01719913|OTHER|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
214928636|NCT01719913|OTHER|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
214928637|NCT03261674|BEHAVIORAL|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I)
214928638|NCT03261674|BEHAVIORAL|ABT-I|Arousal-Based Therapy for Insomnia (ABT-I)
214928639|NCT02901743|OTHER|Scaling and Root planing|All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
214928640|NCT00737295|PROCEDURE|CCK Injection and Ultrasound|"All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:~If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.~An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder."
214928641|NCT03159234|RADIATION|fetal lung volume|the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia
214327190|NCT07166094|DRUG|Rina-S|Intravenous (IV) infusion.
214327191|NCT07166094|DRUG|IC|"* Paclitaxel: IV infusion~* Doxorubicin: IV bolus injection/infusion"
214327192|NCT07166640|DRUG|Propofol|The initial dose is 1.5 mg/kg, adjusted in increments or decrements of 0.1 mg/kg according to the modified Dixon's up-and-down method. Additional rescue doses of 0.25-0.5 mg/kg is titrated if insertion is unsuccessful.
214327193|NCT07167810|PROCEDURE|bone cement|chest wall reconstruction using polymethyl methacrylate PMMA bone cement
214327194|NCT07167810|PROCEDURE|steel wires|chest wall reconstruction using no 05 stainless sternal steel wires
214327195|NCT07167199|PROCEDURE|Subcuticular monocryl suture|Under the skin suture placed by hand
214928642|NCT03159234|RADIATION|pulmonary artery resistance index|Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
215069908|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
215069909|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
214327196|NCT07167199|DEVICE|Subcuticular absorbable staple using Insorb device|Under the skin stapling device that delivers absorbable staples
214327197|NCT07164261|OTHER|progressive muscle relaxation training|Progressive muscle relaxation training will be performed twice a week, each session lasting 20-30 minutes, for a total of 12 sessions over 6 weeks.
214327198|NCT07170566|DEVICE|innovaMatrix AC|"nnovaMatrix® AC consists of ECM derived from porcine placental material. The device is supplied in a variety of sterile sheet configurations. It is packaged in double peel-open packages and is intended for single use only. The device is terminally sterilised using E-Beam sterilisation and is for licensed healthcare practitioner use only.~InnovaMatrix® AC is composed of collagen, elastin, laminin, fibronectin, hyaluronic acid and sulphated glycosaminoglycans. The wound dressing is provided in sheets that are approximately 40-100 microns thick in sizes ranging from 1 x 1cm to 5 x 5cm. They are provided as single-use, sterile wound coverings.~InnovaMatrix® AC received Food and Drug Administration (FDA) clearance under K193552 on October 21, 2020. InnovaMatrix® AC has an FDA classification of KGN, which designates it as a collagen wound dressing."
214327199|NCT07161830|DEVICE|Omeza® Complete Matrix|OCM Application, Surgical sharp debridement, offloading (TCC gold standard, fixed ankle-walker alternative), and proper moisture balance
214327200|NCT07161830|OTHER|Standard of Care|Surgical sharp debridement, offloading (TCC gold standard, fixed ankle-walker alternative), and proper moisture balance
214327201|NCT07164950|DEVICE|Medical-grade compression stocking|A knee-high compression stocking providing 20-30 mmHg pressure will be applied to the assigned foot during the ADC treatment period to prevent chemotherapy-induced peripheral neuropathy (CIPN). Stockings will be worn daily, except during bathing.
214327202|NCT07171099|DRUG|Rengalin|Solution for oral administration
214327203|NCT07171099|DRUG|Placebo|Solution for oral administration
214327204|NCT07163559|BEHAVIORAL|coping skills training|"CST aims to improve physical/mental health in chronic headache patients by reducing pain intensity, migraine attacks, and medication use. The program includes 8 sessions (2/week) covering:~Client-centered problem-solving \& migraine education (COPM-based), Activity pacing, stress management, and healthy habits, Energy conservation techniques, Social participation, Program evaluation. Session durations: Session 1 (45 min), Sessions 2-6 (60-75 min), Sessions 7-8 (60 min)."
214327205|NCT07163858|PROCEDURE|passive leg raising for hemodynamic management during open-heart coronary bypass grafting|Passive leg raising will be used in the experimental group in order to manage hemodynamics: legs will be raised to an angle of approx. 45°
214327206|NCT07163858|PROCEDURE|Use of Noradrenaline only in control group|Noradrenaline will be used for hemodynamic management. Passive leg raising will not be used in this group
214928643|NCT03159234|RADIATION|Fetal adrenal gland volume:|the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
214327207|NCT07168616|DIAGNOSTIC_TEST|Ga-68 PSMA11 PET/CT|delayed (120-minute) Ga-68 PSMA PET/CT and will be evaluated by using Istanbul PSMA PET/CT Criteria (IPPC)
214327208|NCT07168551|DIAGNOSTIC_TEST|*Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .|Lab methods
214327209|NCT07168551|RADIATION|*Imaging Studies:* 1- Ultrasound 2 - FibroScan|Imaging
214327210|NCT07168551|DEVICE|Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.|Instrument
214928644|NCT01883817|DRUG|DHA Omega-3|Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
214327211|NCT07167992|PROCEDURE|Pleurodesis|Talc slurry pleurodesis is a chemical technique for managing recurrent pleural effusions and pneumothoraces. The procedure involves instilling a suspension of talc (4-5 grams) in sterile saline (50-100 mL) into the pleural space via a chest tube. This induces an inflammatory reaction, leading to fibrosis and fusion of pleural surfaces. The technique demonstrates 70-90% success rates in malignant pleural effusions and pneumothoraces, with efficacy comparable to talc poudrage. While generally safe, potential complications include pain, fever, and rarely, pneumonitis or empyema. Use of large-particle, asbestos-free talc and standardized protocols has improved its safety profile.
214327212|NCT07167992|PROCEDURE|pleurodesis|Talc insufflation, is a pleurodesis technique involving direct insufflation of dry talc powder into the pleural cavity during thoracoscopy. It allows visual inspection of the pleural space and concurrent diagnostic procedures. Success rates range from 85% to 93% for malignant pleural effusions and pneumothoraces, with efficacy comparable or potentially superior to talc slurry in some studies. The procedure typically requires general anesthesia and is more invasive than talc slurry. Common side effects include chest pain, fever, and dyspnea. The risk of severe respiratory complications has decreased with large-particle, asbestos-free talc. While effective, the choice between insufflation and slurry depends on patient factors, institutional expertise, and resource availability.
214327213|NCT07152938|BEHAVIORAL|AVR Group (Chemotherapy + AVR)|the intervention group received AVR before they started treatment and during the session. The researcher administered the posttest questionnaire The questionnaire assessed immediately after finishing AVR. Participants informed not to discuss AVR with each other's, as the researcher explained to the participants the purpose of the study and their participation will not affect their care or treatment
214327214|NCT07141641|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV)|
214327215|NCT07167823|PROCEDURE|Decortication|removal of fibrinous infected material from pleural cavity and thick fibrous entrapping peel over the lung resulting in full expansion of lung.
214327216|NCT07167823|PROCEDURE|Decortication|removal of fibrinous infected material and thick fibrinous entrapping peel over the lung
214673218|NCT06666673|DRUG|Placebo|Administered as control
214928645|NCT01883817|DRUG|Placebo|corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
214673219|NCT06747624|DIETARY_SUPPLEMENT|Geranylgeraniol 300 mg|300 mg of trans-geranylgeraniol (GG)
214673220|NCT06747624|DIETARY_SUPPLEMENT|Placebo|300 mg medium chain triglycerides
214327217|NCT07168369|DIETARY_SUPPLEMENT|protein and energy-rich supplement|The nutritional supplements were provided in the form of ready-to-drink liquid solutions rich in protein and energy. Patients without diabetes received one 235 ml bottle per day of Ensure® Protéine Max (Abbott Nutrition, Montreal, Canada), which contained 350 kcal, 20 g of protein, 11 g of fat, 44 g of carbohydrates, 1.5 g of calcium-HMB and other essential micronutrients. Patients diagnosed with diabetes prior to LT received one 237 ml bottle per day of Boost® Diabetic (Nestlé, Montreal, Canada), which provided 190 kcal, 16 g of protein, 7 g of fat, 17 g of carbohydrates, and other essential micronutrients. Patients were instructed to consume the supplement in four equal doses of \~60 ml each, taken daily with breakfast, lunch, dinner, and as a bedtime snack, totaling one full bottle per day. The supplementation lasted for 12 weeks, beginning once solid oral feeding was initiated.
214327218|NCT07172516|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
214673221|NCT06911255|DRUG|Tremelimumab Plus Durvalumab (MEDI4736)|Study subjects will receive 1,500 mg of durvalumab intravenously every 4 weeks until PD is observed. However, treatment will be discontinued if unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria are met. Tremelimumab will be administered first, and durvalumab infusion will begin approximately 1 hour (up to 2 hours) after the completion of tremelimumab infusion. The standard infusion time for each drug is 1 hour, but if the infusion is temporarily interrupted, the total duration should not exceed 8 hours at room temperature.
214928646|NCT06411535|BEHAVIORAL|Full-mouth ultrasonic debridement plus Nutritional counseling|After diagnosis of gingivitis, patients will receive a nutritional counseling focused on ultra-processed foods entails educating individuals about the nutritional content and potential health implications of highly processed food products. They will undergo a session of full-mouth ultrasonic debridement and reinforcment of dietary counseling. Between consecutive time points, patients will receive motivational emails.
214928647|NCT06411535|OTHER|Full-mouth ultrasonic debridement|After diagnosis of gingivitis, patients will receive a session of full mouth ultrasonic debridement
214928648|NCT04013360|OTHER|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
214327219|NCT07172516|DRUG|Placebo|Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
214327220|NCT07173309|DEVICE|Augmented reality|Augmented reality markers show the surgical trainee the expert's gaze location during the kidney exploration phase of surgery.
214327221|NCT07171788|OTHER|low level laser therapy|patients will receive LLT. The LLLT system used in the study (ASA LASER M6) delivered 1.0 W in continuous wave at a wave length in the near infrared of 808 nm. The incident power density will be 670 mW/cm2.The probe head will held with light pressure in contact with the skin over the course of median nerve on the dysfunctional limb for 15 minutes. Protective goggles will be used to prevent direct eye contact of the laser beam. plus selected phyiscal therapy program
214327222|NCT07171788|OTHER|selected physical therapy program|patient will receive standard physical therapy program for wrist flexors spasticity post-stroke typically includes the following components: Passive stretching: Passive static or dynamic stretching of the wrist flexorss is the mainstay to reduce spasticity and Physical therapy exercises in form of specific techniques of proprioceptive facilitation, relaxation techniques, passive and self-passive motions, and proper limb positioning. plus sham low level laser therapy
214327223|NCT07173374|RADIATION|SCART Dose Escalation Arm|Patients will receive SCART with escalating dose cohorts (10 Gy, 13 Gy, 16 Gy, and 19 Gy per fraction within the SCART region) using a standard 3+3 design. All patients will also receive background SBRT (25 Gy in 5 fractions) to the gross tumor volume and margin.
214673222|NCT06911255|PROCEDURE|Transarterial chemoembolization (TACE)|TACE will be carried out 1 to 2 weeks (7 to 14 days) after the administration of tremelimumab + durvalumab, and thereafter, it will be performed as needed at the discretion of the investigator during the treatment period. If additional TACE is performed, there must be at least a 1-week interval between the additional TACE and the administration of durvalumab.
214928649|NCT04013360|OTHER|Expiratory Positive Airway Pressure|Patients will perform exhalation of air through a facial mask containing an extrinsic positive expiratory pressure valve with a defined load of 10 cmH2O for 5 min. During the application of the technique the patients will have a trunk inclined 30º and will be stimulated to breathe normally, without effort or deep and fast breaths.
214928650|NCT04158895|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
214928651|NCT05500638|BEHAVIORAL|Virtual Reality|At this stage, trainings were given for epileptic seizures. Parents were asked to wear SG glasses and they were trained on the correct approach to seizures over the Focal to bilateral tonic-clonic seizure scenario integrated into the SG glasses. The clinic and process of focal to bilateral tonic-clonic seizure and the training of what to do and not to do during the seizure were given again through SG glasses. Parents interfered with the patient scenario many times during their free work time and had the chance to interfere with the seizure again and again by restarting the seizure.
214928652|NCT04336319|BIOLOGICAL|Fecal Microbial Transplantation|"1. At baseline, the fecal fluid from 3 different donors, 150 ml, will be delivered via pouchoscopy after which the patient will roll in to the right lateral position and stay in that position for at least 15 minutes. Prior to the procedure, the patient will fast for 12 hours and preform two fleet enemas as preperation.~2. FMT at 7 days and 4 weeks will be delivered via ingestion of 15 capsules containing 650 µL of fecal fluid from 3 different donors (the same three donors as at baseline)."
214928653|NCT04126915|GENETIC|Whole Exome Sequencing|Whole Exome Sequencing of the patient's primary tumor, metastases
214928654|NCT05325489|DRUG|Nebulized Budesonide|use 0.5mg/2ml Pulmicort Respules BIS QD and oral montelukast sodium chewable tablets 4mg QD
214928655|NCT05325489|DRUG|Intranasal Budesonide Spray|nasal spray 100μg QD and oral montelukast sodium chewable tablets 4mg QD
214928656|NCT00576160|BEHAVIORAL|PST therapy|Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
214928657|NCT05449301|OTHER|Rhythmic Auditory Stimulation|The participants will receive RAS on regular treadmill for balance and gait improvement. one session per day, 3 session per week for consecutively 12 weeks.
214928658|NCT05449301|OTHER|Treadmill Training|participants will be trained conventionally (bipedal) on regular treadmill. one session per day, 3 session per week for consecutively 12 weeks.
214928659|NCT05449301|OTHER|Unilateral Step Training|Patients will be trained on regular treadmill for both paretic and non paretic lower extremity. Single session per day, 3 session per week for consecutively 12 weeks.
214928660|NCT02952092|DRUG|roxadustat|Oral
214928661|NCT02952092|DRUG|Darbepoetin alfa|Intravenous
214928662|NCT03285568|DRUG|Palbociclib|Observe patients receiving palbociclib for dose adjustment and lab monitoring
214928663|NCT03108768|DEVICE|Hearing Aid (Successor of Phonak Virto V)|The successor of Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
214928664|NCT03108768|DEVICE|Hearing Aid (Phonak Virto V)|Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
214928665|NCT04560972|DRUG|Atezolizumab|Given IV
214928666|NCT04560972|DRUG|Carboplatin|Given IV
214928667|NCT04560972|DRUG|Etoposide|Given IV
214928668|NCT04560972|DRUG|Protein Phosphatase 2A Inhibitor LB-100|Given IV
214928669|NCT05919225|PROCEDURE|Risk stratification before decision-making about patient hospitalization or discharge|Once AHF has been diagnosed at ED, and before decision-making about hospitalize/discharge home is taken, physicians will objectively measure the severity of decompensation, based on risk of 30-day death using MEESSI scale. As result, patient can be allocated to low, intermediate, high or very-high risk. For patients classified as low-risk, the propocol recommendation will be discharge patient to home. For patients classified as increased risk (i.e., intermediate, high or very-high risk categories), the protocol recommendation will be to hospitalize patient. Nonetheless, final decission will be left to emergency physician, and overruling (disposition against recommendation) will be allowed.
214928670|NCT00623935|DRUG|Fludarabine|Fludarabine (40 mg/m2/day x 4 days)
214928671|NCT00623935|DRUG|Busulfan|Busulfan (3.2 mg/m2/day x 2 days or x 4 days).
214928672|NCT00623935|RADIATION|Total Body Irradiation|Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.
214928673|NCT00623935|PROCEDURE|Stem Cell Transplant|Allogeneic stem cell transplant from related or unrelated donor
214928674|NCT03628339|DRUG|Midazolam|Participant received single oral dose of 7.5 mg midazolam tablet on Day 1 of treatment period 1 and Day 11 in treatment period 2.
214928675|NCT03628339|DRUG|Tepotinib|Participants received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 in treatment period 2.
214928676|NCT06665152|DEVICE|ProTaper File System|A rotary file system
214928677|NCT06665152|DEVICE|WaveOne File System|A reciprocating file system
214928678|NCT01571999|DRUG|Inhaled GSK573719|All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
214928679|NCT01571999|DRUG|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
214928680|NCT01665885|DEVICE|ZOLL Thermogard XP|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.
214928681|NCT01665885|DEVICE|BARD/Medivance Arctic Sun 5000|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.
214928682|NCT03986788|OTHER|Weightlessness|Volunteers will be studied during parabolic flight. Cerebral blood flow will be measured in different part of the brain during weightlessness ans compared to 1g and hypergravity measurements.
214928683|NCT01172496|DRUG|treprostinil diethanolamine|Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
215069910|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
215069911|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
214928684|NCT05036577|DRUG|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d or 200 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6-8 cycles during combination induction treatment.~Daily Orelabrutinb with dose in last cycle of induction will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
214928685|NCT05036577|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 21 days for 6-8 cycles during combination induction treatment.
214327224|NCT07173608|BEHAVIORAL|Inner Engineering Program|"The intervention is a comprehensive secular training called Inner Engineering (IE), offered by the international non-profit Isha Foundation. This program combines cognitive reappraisal and emotion regulation strategies, breath-based meditation and simple yoga practices. The training provides precise, step by step and easy to follow instructions on how to perform the practices. No previous experience of yoga and meditation is required. By fostering health, exuberance and awareness, one can engineer their inner climate the way they want it to lead a joyful, fulfilling life. Previous research shows improved wellbeing, mindfulness, joy, sleep, relationships, psychological capital, and work engagement, compassion, and parent-child relationships. Evidence suggest it may promote enhanced Heart Rate Variability and Sympathovagal balance."
214327225|NCT07173738|DRUG|BIA 5-1058|During treatment period 1, a single oral dose of BIA 5-1058 (400 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.
214327226|NCT07173738|DRUG|Furosemide|During treatment period 2, a single oral dose of furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.
214327227|NCT07173738|DRUG|BIA 5-1058 and Furosemide|During treatment period 3, a single oral dose of both investigational medicinal product (IMPs) BIA 5-1058 (400 mg) concomitantly with furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.
214673223|NCT06916468|DEVICE|VAD with Cotton Dampener|A standard pen-like Vibratory Anesthetic Device (VAD) with and without cotton will be applied across five anatomical sites (lateral nasal wall, sub-malar region of the cheek, ear helix, lateral neck, and dorsal side of the forearm) of participants. For each anatomical site, one side (either right or left) will receive vibration with cotton, and the opposite side will receive vibration without cotton in a randomized order.
214673224|NCT06916468|DEVICE|Vibratory Anesthetic Device (VAD)|A standard pen-like Vibratory Anesthetic Device (VAD) with and without cotton will be applied across five anatomical sites (lateral nasal wall, sub-malar region of the cheek, ear helix, lateral neck, and dorsal side of the forearm) of participants.
214673225|NCT06131944|BEHAVIORAL|Rested & Ready to Learn|The intervention arm targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
214673226|NCT06916364|DEVICE|Fiberoptic Assisted Endotracheal Rod Intubation|Fiberoptic-Assisted Endotracheal Rod for Endotracheal Intubation Through a Supraglottic Airway
214673227|NCT06943885|OTHER|5G Mobile Stroke Unit Management|5G MSU is a specialized stroke ambulance equipped with point of care lab, CT scanner, Telemedicine, allowing patients to receive intravenous thrombolysis.
214673228|NCT06943885|OTHER|Standard Management|A regular ambulance. The standard management by EMS includes Electrocardiographic（ECG）monitoring, blood glucose management, airway, respiration, and blood pressure control, complication management, intravenous access establishment and other emergency measures.
214673229|NCT06949813|BEHAVIORAL|BE-OR: Brief Intervention to the Operating Room|See intervention group section for details
214673230|NCT06949813|OTHER|Interaction: Facetime with Clinical Provider|See Interaction group section for details
214928686|NCT05036577|DRUG|Methotrexate (MTX)|high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.
214928687|NCT05036577|DRUG|Dexamethasone|Dexamethasone 10-15 mg, iv, d1-4, every 21 days for 6-8 cycles during combination induction treatment.
214928688|NCT03961061|BEHAVIORAL|Brenner mFIT (standard care)|Families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and PA specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, PA, and parenting. Specialized visits with the PA specialist or dietician are scheduled as pertinent issues arise. Motivational interviewing, modified by Brenner FIT for use with families, is the key to treatment; family counselors are trained in cognitive behavioral therapy, parenting support/mindfulness, and employ these approaches to assist families in developing healthy habits.
214673231|NCT06946537|OTHER|Exposures and measurements|Anthropometry, Body composition (BIA), Nutritional screening (GLIM, SNAQ, NIS, NRS-2002), Functional tests, Seisomocardiography, Muscle strength, Blood tests, Fecal swabs, Indirect calorimetry Orientation-Memory-Concentration (OMC), Sarcopenia, Frailty (Clinical Frailty Scale), Comobidity, Polypharmacy, Portrait photo.
214928689|NCT03961061|BEHAVIORAL|Brenner mFIT (standard care plus mobile health components)|"Brenner mFIT includes all components of the standard Brenner FIT program in addition to six mobile health components.~The six mHealth components that will be used in addition to standard Brenner Families in Training program include-~1. a mobile-enabled website,~2. diet and physical activity tracking apps and physical activity tracker~3. tailored self-monitoring feedback~4. caregiver podcasts~5. animated videos for adolescent patients~6. social support via social media."
214928690|NCT05342051|OTHER|balneotherapy|immersion in radon, calcium, natrium, bicarbonate content 42 ℃ thermal-mineral water 15 times in 3 weeks, plus usual care. The total mineral substance of the water is 1530 mg/l. The suggested daily time spent in water is 20 minutes altogether with breaks.
214673232|NCT06952439|DEVICE|Images and cines captured through the capture card (ICC)|A screen capture/recording of the entire exam performed by the ARDMS as per the Image Acquisition Protocol for the FDA Study will be obtained, and the images/cines required for the study that correspond to IUS shall be obtained. The independent research coordinator for the study will review the screen recording and identify the frame/cine for each diagnostic view (ICC) that corresponds to IUS based on the time stamps.
214673233|NCT06954766|DEVICE|CKD-981(1)|20 minutes per day, 5 days a week for 6 weeks.
214327228|NCT07174050|DEVICE|King Vision Channeled Video Laryngoscope|King Vision Videolaryngoscope (KVVL) is one of the new indirect laryngoscopes with disposable (either with channeled or non-channeled) blades .Both designs include an anti-fog lens coating . The channelled KVVL has a rigid blade with an integrated channel for introducing the endotracheal tube. The height and width of the standard non-channeled and channeled blades are 13 mm and 26 mm vs 18 mm and 29 mm, respectively. The KVVL has a unique design and high-quality image . It has a camera that enables a clear view of the glottis. It is a solid, portable, battery-operated device with an organic LED display for video laryngoscopy . It allows better glottis visualization and Cormack Lehane score than DL. Compared with Airtraq, the KVVL has wide field of view (160° vs 80° respectively) and potentially shortens the time to tracheal intubation .
214327229|NCT07174050|DEVICE|Macintosh Laryngoscopy|In clinical practice, direct laryngoscopy (DL) with either a curved (Macintosh) or straight (Miller) blade is a well-known and reliable technique in the hands of an experienced operator.
214327230|NCT07173023|PROCEDURE|Transnasal Puncture with Mitomycin C application|"* Performed under general anesthesia.~* Nasal cavities decongested with oxymetazoline.~* Atretic plate perforated using serial dilators under direct visualization.~* Additional removal of bony/membranous tissue including the posterior nasal septum as possible.~* Topical mitomycin C (0.5 mg/mL) applied to the edges of the newly created choana for 2 minutes using cotton pledget in a transparent tube , followed by irrigation with saline.~* syndromatic patients and patients requiring less time UGA will be included in this group"
214327231|NCT07173023|PROCEDURE|Endoscopic Crossover Flap Repair|"* Performed under general anesthesia using a 0° 4 mm endoscope.~* Elevation of mucosal crossover flaps to cover exposed bone following resection of the atretic plate where one flap is inferiorly based and the other is superiorly based.~* Precise removal of the posterior vomer and lateral bony plates as needed using cold steel instruments and possible nasal drill.~* Flaps will be repositioned to minimize exposed bone and promote mucosal healing preventing restenosis."
214327232|NCT07172776|BEHAVIORAL|oral cancer communication tool|The overall goal is to determine if the OPC communication tool has potential to enhance Black-men's and dentists' comfort discussing oral and pharyngeal cancers in clinical-like settings. This communication tool will ideally help dentists communicate with their patients about oral cancer risk and treatment. The oral cancer screenings will occur in person. Participants will complete a pre-survey either on paper or online, engage with a dentist or dental student, then complete a post-survey
214327233|NCT07174024|DEVICE|Narrow Band UVB Treatment|type of phototherapy
214928691|NCT05318248|DRUG|Clonidin|0,15mg Clonidin orally versus placebo pill
214928692|NCT05318248|DRUG|Placebo|placebo pill
214928693|NCT05189301|DIAGNOSTIC_TEST|first pass study|Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)
214327234|NCT07174024|DEVICE|blue light emitting diode|type of diode
214327235|NCT07172789|OTHER|head down position|the patient is positioned at a -20° Trendelenburg
214327236|NCT07173946|OTHER|Standard of Care Anti-tumor Therapy|This is an observational cohort study. There is no intervention assigned by the study protocol. Treatment strategies (including but not limited to chemotherapy, immunotherapy, radiotherapy, and local interventional therapy) are determined solely by the treating physician based on clinical practice guidelines and individual patient circumstances.Patients will receive real-world anti-tumor treatments as prescribed by their physicians. Common treatments for extensive-stage small cell lung cancer (ES-SCLC) may include platinum-etoposide chemotherapy, immune checkpoint inhibitors (such as anti-PD-L1/PD-1 antibodies), radiotherapy, and other therapies per standard clinical practice. The study will observe and record these treatments and their outcomes.
214486191|NCT05591794|OTHER|Aerobic and resistance exercises|Participants in the study group will be given an aerobic exercise program on the treadmill for 8 weeks, 2 days a week, 20 minutes at a rate of 60-80% of the target heart rate. Participants will work on the treadmill for 20 minutes at 60-70% of the target heart rate for the first four weeks, and at 70-80% of the target heart rate for the last four weeks. Resistance exercises will consist of exercises that will work large muscle groups with rubber bands. According to Borg, the resistance exercises to be applied will be three sets of 10 repetitions for each movement at an RPE of 11-12 during the first four weeks, and 3 sets of 15 repetitions at the same RPE for the last four weeks, 2 times a week for 20 minutes.
214928694|NCT05189301|DIAGNOSTIC_TEST|cardiopulmonary exercise testing|to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)
214928695|NCT02735512|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
214928696|NCT02735512|OTHER|Laboratory Biomarker Analysis|Samples undergo MDSC clinical assay
214928697|NCT06685523|PROCEDURE|Subgingival debridement|To be applied 1 times (0. days)
215069912|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
215069913|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
215069914|NCT05807854|PROCEDURE|Arthroscopy|The surgeon reattaches the torn tendon to the bone with anchors and sutures.
215069915|NCT05807854|DEVICE|Reverse Shoulder Arthroplasty|It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
214928698|NCT06685523|PROCEDURE|Er:YAG laser decontamination|To be applied 3 times
214928699|NCT06685523|PROCEDURE|Diyot laser decontamination|To be applied 3 times
214928700|NCT05069025|OTHER|music|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
214928701|NCT05069025|OTHER|no-music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
214928702|NCT02846116|OTHER|Prosthetic crown|
214928703|NCT04878484|BIOLOGICAL|TCRT-ESO-A2|TCRT-ESO-A2 is an autologous cell therapy comprised of a subject's T cells stimulated ex vivo and transduced with a lentiviral vector encoding an affinity enhanced TCR targeting tumor-associated antigen NY-ESO-1.
214928704|NCT01354743|DRUG|Dysport|"Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits."
214928705|NCT01354743|DEVICE|Perlane L|The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
215069916|NCT03709277|BEHAVIORAL|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
215069917|NCT06501092|DEVICE|Point Mini|Patient is fit with the Point Mini finger prosthetic system, which consists of 1-4 ratcheting mechanical digits and mounting brackets
215069918|NCT00708591|DRUG|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
214928706|NCT02117908|DEVICE|RESMED AUTOSET S9|Continuous positive pressure during surgery
214928707|NCT02845960|BEHAVIORAL|rapid recovery|rapid recovery
214928708|NCT04736446|DEVICE|I-gel® supraglottic device|Use of an i-gel® supraglottic device to deliver ventilations
215069919|NCT00708591|DRUG|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
215069920|NCT02110355|DRUG|AMG 232|Given as an oral tablet in escalating doses
215069921|NCT02110355|DRUG|Trametinib|Trametinib is an anti-cancer agent
215069922|NCT02110355|DRUG|Dabrafenib|Dabrafenib is an anti-cancer agent
215069923|NCT00251368|DRUG|9-Aminocamptothecin (9-AC)|
214486192|NCT05591794|DIETARY_SUPPLEMENT|Diet program|Initially, participants will be educated on healthy eating habits through one-on-one dietitian consultation. A personalized calorie-restricting diet will be given. According to this program, the daily energy intake of the individual will be reduced to provide 0.5-1.0 kg of body weight loss per week.
214486193|NCT05591794|OTHER|Regular walking program|Regular walking will be recommended as 30 minutes/5 days or 50 minutes/3 days per week.
214673234|NCT06954766|DEVICE|CKD-981(2)|20 minutes per day, 5 days a week for 6 weeks.
215069924|NCT01811589|DEVICE|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
215069925|NCT01811589|OTHER|Free-hand|Ventricular catheter placement without a guidance (free-hand)
215069926|NCT05781945|DIETARY_SUPPLEMENT|probiotics|supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2
215069927|NCT05781945|OTHER|standard therapy|standard therapy for sars-cov-2
214673235|NCT06954766|DEVICE|Sham device|20 minutes per day, 5 days a week for 6 weeks.
214673236|NCT06954766|DRUG|Reference Drug|QD for 6 weeks
214673237|NCT06954766|DRUG|Placebo Drug|QD for 6 weeks
214928709|NCT04736446|DEVICE|Face mask ventilation|Use of a face mask to deliver ventilations
214928710|NCT00644176|DRUG|azithromycin immediate release (Zithromax)|azithromycin IR 500 mg tablet by mouth for 1 dose
214928711|NCT00644176|OTHER|placebo|placebo
214928712|NCT00644176|DRUG|azithromycin SR|2.0 g by mouth in the form of liquid for 1 dose
214928713|NCT00644176|OTHER|placebo|placebo
214928714|NCT02263391|BEHAVIORAL|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
214928715|NCT02263391|BEHAVIORAL|Focus Group|Study participants will be invited to participate in a focus group discussion.
214928716|NCT04611191|OTHER|Team Sports|The intervention involves team sports in sports clubs in local municipalities
214928717|NCT04611191|OTHER|Control|The intervention involves a control condition with participants continuing their normal way of living
215069928|NCT03208660|DRUG|Fycompa|Oral suspension
215069929|NCT05684445|OTHER|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
215069930|NCT02024360|BEHAVIORAL|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
215069931|NCT00344318|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
215069932|NCT00344318|BIOLOGICAL|Prevenar|3 Intramuscular injections
215069933|NCT00344318|BIOLOGICAL|Tritanrix-HepB|3 Intramuscular injections
215069934|NCT00344318|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix before injection
215069935|NCT00344318|BIOLOGICAL|Polio Sabin.|3 oral doses.
215069936|NCT00344318|BIOLOGICAL|Poliorix.|3 intramuscular injections
214928718|NCT03718481|OTHER|ARCP Process|One Annual Review of Competence Progression (ARCP) cycle. In the U.K., doctors, across all specialities, undergo an Annual Review of Competence Progression (ARCP) to evaluate performance during each training year and determine progression to the next year of training. Similar processes exist in the Republic of Ireland. The process and requirements for ARCP in the UK are specified in the Gold Guide, the Reference Guide for Postgraduate Specialty Training \[1\]. It defines ARCP as a formal process that uses evidence collected by trainees to review and record performance, demonstrate competencies achieved and inform decisions regarding progression in training
214928719|NCT01188824|DRUG|Cilostazol|100 mg, bid p.o.
215069937|NCT03832322|PROCEDURE|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
215069938|NCT03832322|PROCEDURE|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
215069939|NCT01997606|OTHER|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
215069940|NCT01997606|OTHER|placebo|
215069941|NCT01899508|PROCEDURE|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
215069942|NCT01899508|DEVICE|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
215069943|NCT02117960|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
215069944|NCT02117960|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
215069945|NCT03734640|OTHER|Low-intensity monitoring strategy|Post-tpa patients will be monitored in a lower intensity with less vital status and neurological assessment
215069946|NCT03734640|OTHER|Guideline recommended standard monitoring|Post-tpa patients will be monitored in the usual care monitoring environment
215069947|NCT01923363|DRUG|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
215069948|NCT00411827|PROCEDURE|PRK with conjunctival impression cytology before and after surgery|
215069949|NCT00411827|PROCEDURE|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
215069950|NCT03402204|DRUG|Simvastatin 10 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
214486194|NCT06048263|BEHAVIORAL|interpersonal psychotherapy (IPT)|The ROSE intervention is a five-session intervention developed to build communication skills, improve social support, and improve stress management. It is easy to learn and does not require a healthcare professional or mental health specialist to deliver. For this study, the investigators plan to deliver to individuals during inpatient visits, in-person appointments or via telemedicine (phone or videoconference), as appropriate or per participant preference. The first four sessions are approximately 60 minutes in length.
214928720|NCT01188824|OTHER|placebo|1 tablet, bid
214928721|NCT02804139|OTHER|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization.
214928722|NCT02804139|OTHER|Standard Care|Standard Care after C-section with no additional physical therapy.
214928723|NCT03308591|DRUG|NACT|Platin based chemotherapy
214928724|NCT03308591|PROCEDURE|RT+PLND|radical hysterectomy+pelvic lymphadenectomy
215069951|NCT03402204|DRUG|Simvastatin 40 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
215069952|NCT06552949|PROCEDURE|Emergent laparoscopic cholecystectomy guided by ICG cholangiography (ELC-ICGC)|Emergent conventional laparoscopic cholecystectomy
215069953|NCT00932438|DEVICE|LC beads loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan
215069954|NCT00932438|DRUG|Oxaliplatin|Oxaliplatin 85 mg/sqm, IV infusion every two weeks
215069955|NCT00932438|DRUG|Leucovorin|Leucovorin 200 mg/sqm, IV infusion every two weeks
215069956|NCT00932438|DRUG|5-Fluorouracil|5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
215069957|NCT00932438|DRUG|Bevacizumab|Bevacizumab 5 mg/kg given at the discretion of the treating physician
215069958|NCT00488449|DRUG|GSK256073A tablets|
215069959|NCT05993312|OTHER|quality of life|To describe the relationship between distant sequelae of trauma assessed by the GOSE scale and quality of life
215069960|NCT00183781|BEHAVIORAL|FITT: Family Intervention - Telephone Tracking|
215069961|NCT05550870|DIETARY_SUPPLEMENT|Raw fenugreek seed powder|It will be given to group 1
215069962|NCT05550870|DIETARY_SUPPLEMENT|Roasted fenugreek seed powder|It will be given to group 2
214928725|NCT03308591|DRUG|Adjuvant chemotherapy|Platin based chemotherapy
214928726|NCT02056457|BEHAVIORAL|Responsible Fatherhood or Healthy Marriage Program|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
214928727|NCT02056457|BEHAVIORAL|Other services in the community|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
214928728|NCT00747474|DRUG|Lipotecan|Lipotecan IV day 1, 8, 15
214928729|NCT05461521|OTHER|Family members of patients admitted to the ICU|"At inclusion:~* Collection of demographic data, Anxiety-Depression Scale (HADS), Insomnia Severity Index (ISI), Resilience Insomnia Severity Index (ISI), Resilience Scale (CD RISC 10), Peritraumatic Dissociation Peritraumatic Dissociation Experience Scale (PDEQ) and MEDEC questionnaire.~* Venous blood sampling at 350 relatives~* Upon discharge of the patient (alive or deceased): Resuscitation questionnaire, HADS, ISI and PDEQ.~  3 months after discharge: Demographic questionnaire, Post Traumatic Stress Disorder questionnaire (PCL-5), THS Past Trauma Experience Questionnaire, HADS experiences, HADS, ISI, CD RISC 10, MEDEC and Who- assist questionnaire (Question 2) on the use of psychoactive substances.~  6 months after patient discharge: PCL-5, HADS, ISI, CD RISC 10, MEDEC, Who-assist (Question 2) and Prolonged Grief disorder (PG-13) questionnaire on bereavement if patient died in the ICU."
214928730|NCT05461521|OTHER|Health care professionals|All professionals in all categories and in all participating departments will be asked to complete questionnaires to assess the level of conflict, work stress and burn out in the units : Masclach Burnout Inventory (MBI), Job Content Questionnaire (JCQ), Ethical Decision-Making Climate Questionnaire (EDMCQ), Professional Quality Of Life scale (ProQOL), Connor-Davidson Resilience scale (CD-RISC 10), Cultural Awareness Scale (CAS).
215069963|NCT04633070|BEHAVIORAL|Gamification|Gamification (including, but not limited to a ranking system, badges and achievements, points, social media interaction, and leveling up) within mobile and web-based applications (also referred to as 'apps') for lifestyle modification (diet, physical activity, smoking cessation etc).
215069964|NCT06325241|OTHER|No intervention|There is no intervention. This is an observational study.
215069965|NCT04918290|DEVICE|Tegaderm Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
215069966|NCT04918290|DEVICE|Transpore Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
214327237|NCT07173270|OTHER|Oral health support|The intervention group will receive examination and treatment by a dental hygienist every 3 months starting 6 months after completion of RT/CRT up to 3 years. During visits to the dental hygienist, they will be asked about oral hygiene habits, fluoride use, dry mouth problems, and dietary habits (including intake of easily degradable carbohydrates). Oral dryness will be assessed using the Clinical Oral Dryness Scale. The stimulated salivary secretion and buffering capacity will be assessed, and the ability to open the mouth, cariological and periodontal status and registered plaque. Based on the results of the clinical examination, the patient will get individually tailored advice and recommendations on oral hygiene, fluoride use, dry mouth relief, and support in reducing the intake of food items and drinks with high sugar content. Professional oral care will be given, and fluoride applications when indicated.
214327238|NCT07172178|BIOLOGICAL|γδ T-PD-1 Ab cells|Patients will receive 6 cycles of ex-vivo expanded γδ T-PD-1 Ab cells treatments,at two-weeks' intervals.γδ T-PD-1 Ab cells are injected through the Ommaya device in a typical 3+3 dose-escalation design(Dose escalation, 1×10\^7, 3×10\^7, 1×10\^8).
215069967|NCT04300855|DRUG|Sunphenon|The study agent will be administered in divided doses with food, three capsules twice a day (405 mg) for 24 months
215069968|NCT04300855|DRUG|Placebo|Matching placebo
215069969|NCT01378702|DRUG|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
215069970|NCT02531425|BIOLOGICAL|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
215069971|NCT03504540|PROCEDURE|Blood test|Blood test for complement factors and genetic polymorphisms of AMD analysis
215069972|NCT03721484|DIAGNOSTIC_TEST|CINtec PLUS|CINtec PLUS testing will be used to triage HPV positive women to colposcopy
215069973|NCT05425394|BEHAVIORAL|Delay first bath|Newborns delay first bath to 8 hours after birth
215069974|NCT01129713|DRUG|Secretol|Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
215069975|NCT01129713|DRUG|Nexium|Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
215069976|NCT02138305|DEVICE|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
214928731|NCT05461521|OTHER|Patients|Inclusion (at D3 after admission to the ICU): collection of demographic data Discharge from the ICU: characteristics of the stay and outcome (alive/deceased)
214928732|NCT00694252|DRUG|Lapatinib|Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
214928733|NCT05170100|BEHAVIORAL|NUIG OAB App|An interactive software-delivered 8-week intervention accessed through the patients' mobile device. It provides best-practice behavioural therapy, and delivers evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
214928734|NCT03417232|PROCEDURE|CAF|The design of the flap consisted of two horizontal beveled incisions (3mm in length) and two slightly oblique beveled incisions. The resulting trapezoidal-shaped flap was elevated in the coronal-apical direction. The suture of the flap started with two interrupted periosteal sutures performed at the most apical extension of the vertical releasing incisions; afterwards, it proceeded coronally with other interrupted sutures, each of them directed, from the flap to the adjacent buccal soft tissue, in the apical-coronal direction. The last sling suture allowed for the stabilization of the surgical papillae over the inter-dental connective tissue bed and allowed for a precise adaptation of the flap margin over the underlying convexity of the crown.
214928735|NCT05511532|OTHER|Orthopaedic treatment|"Female and male patients aged between 6 and 12 years are included in the study. Initially, the values of dorsiflexion of the tibio-fibular-talar joint and dorsiflexion of the first metatarsophalangeal joint will be measured to rule out hallux rigidus and ankle equinus, respectively.~Those patients who do not present hallux rigidus or equinus ankle, will be included in the study and will have their computerized foot pressures taken."
214928736|NCT06648070|PROCEDURE|Neuromuscular reeducation technique|"5 repetitions of neuromuscular reeducation technique i.e. deep pressure along muscles origin to insertion with active movement of that muscle with 10 seconds rest of each repetitions.~Control group will receive 3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds."
214928737|NCT06648070|PROCEDURE|Post Facilitation Stretch|3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds.
214928738|NCT01558856|PROCEDURE|Unilateral electrode placement and testing|An electrode is placed near a sacral nerve with an anal motor response under general anesthesia. During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
214928739|NCT01558856|PROCEDURE|Bilateral electrode placement and testing|Two electrodes are placed, one near each sacral nerve under general anesthesia. During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters. This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
214928740|NCT03975556|BEHAVIORAL|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
214928741|NCT03975556|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate dietary recommendations
214928742|NCT06244056|PROCEDURE|Stellate Ganglion Block|A stellate ganglion block is performed by a medical professional in a sterile setting. Firstly Position of patient: Semi-lateral decubitus position, with the neck turned contralateral. Using Probe of ultrasound: Linear 6-13 MHz to guide the needle to the stellate ganglion , The skin at the injection site is cleaned with an antiseptic solution to reduce the risk of infection. A local anesthetic is injected into the skin and deeper tissues to numb the area. Needle:25G 1.5 inch or 22G 3.5 inch is inserted through the skin and deeper tissues until it reaches the stellate ganglion.Once the needle is in the correct position, 3-5 mL of local anesthetic (0.25-0.5% bupivacaine) The procedure typically takes about 15-20 minutes.
214928743|NCT04507256|COMBINATION_PRODUCT|AZD7442|Participants randomized to AZD7442 will be administered dose 1, each in Cohort 1a (IM) and Cohort 1b (IV). Participants in Cohort 2 and 3 will receive AZD7442 (IV) doses 2 and 3, respectively. Participants in Cohort 4 will receive AZD7442 (IV) dose 4.
214928744|NCT04507256|OTHER|Placebo|Participants randomised to placebo will receive the same volume of solution as participants on active treatment.
214928745|NCT00972556|DRUG|Gray Mineral Trioxide Aggregate (GMTA)|Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
215069977|NCT02138305|PROCEDURE|'SPY' NIRF During CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
215069978|NCT01267110|OTHER|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
215069979|NCT01267110|OTHER|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
215069980|NCT00484380|PROCEDURE|Coronary scanner|multislice spiral computed tomography coronary angiography
214327239|NCT07171918|DRUG|Antibiotics, Vasopressors|Both groups are scored on REMS and NEWS2, and then observed closely for the period of hospital stay with regard to ICU stay duration, ventilator days, vasopressor dependent days and total hospital duration
214928746|NCT00972556|DRUG|Diluted (20%) Formocresol (DFC)|After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
214928747|NCT04025411|DEVICE|Intensive Visual Simulation 3 (IVS3) device|"Visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).~The patient looks on a screen in front of him, mirroring the movements made by his healthy hand, while attempting to perform the same movement with his paretic hand."
214928748|NCT04025411|DEVICE|traditional Mirror Therapy (TM)|Simulation with the traditional Mirror Therapy (TM) will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).
214928749|NCT04025411|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) will be performed during the 1st, 6th, 11th, 16th and 20th session of their programme will be made in order to evaluate brain activity.
214928750|NCT01814293|DEVICE|Handheld humidifier|Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) \& control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
214928751|NCT04008771|DEVICE|SeeQ CdSe 655 ALT|SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
214928752|NCT00631410|DRUG|sunitinib + mFOLFOX6|37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
214928753|NCT00631410|DRUG|sunitinib + mFOLFOX6|50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
214928754|NCT02413385|BEHAVIORAL|HealtheSteps Program|6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
214928755|NCT00316615|BIOLOGICAL|influenza vaccine|
214928756|NCT01675570|DRUG|RX-10045|One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
214928757|NCT01675570|DRUG|Vehicle for RX-10045|One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
214928758|NCT04762485|BIOLOGICAL|Humanized CD7 CAR-T cells|Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (0.5-10)x10\^6 CD7 CAR-T cells/kg
214928759|NCT00504699|PROCEDURE|Ovarian stimulation in vitro fertilization cryopreservation|Letrozole 5 mg/day during ovarian stimulation
215069981|NCT03181217|OTHER|water 0|300 ml tap water at 0 ºC
215069982|NCT03181217|OTHER|water 22|300 ml tap water at 22 ºC
215069983|NCT03181217|OTHER|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
215069984|NCT03181217|OTHER|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
214327240|NCT07173595|DRUG|QLS2309|initial dose - MTD; QW; intravenous infusion
214327241|NCT07172828|BEHAVIORAL|Virtual Reality-Based Rehabilitation|Participants receive 20 minutes of motor control exercises combined with 20 minutes of Pilates-inspired virtual reality games (5 repetitions per set). Training will be delivered three times per week, 40 minutes per session, for 8 weeks (24 sessions in total).
214327242|NCT07172828|BEHAVIORAL|Conventional Motor Control Exercises|Participants perform 40 minutes of progressive spinal stabilization and motor control exercises (10 repetitions per set), three times per week for 8 weeks (24 sessions in total).
214673238|NCT00584064|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
214928760|NCT00890084|DRUG|Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)|Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
214928761|NCT02233101|DRUG|Oral Tranexamic Acid|patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement
214928762|NCT02233101|DRUG|Intravenous Tranexamic Acid|Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative
214928763|NCT04726644|PROCEDURE|hernia repair|different methods for hernia repair
214928764|NCT04306744|DEVICE|Vorso PROTECT System|The Vorso PROTECT System is designed to deliver targeted, imperceptible, non-invasive stimulation to the ear to treat the signs and symptoms (e.g., tender and swollen joints, pain, synovitis) of patients with rheumatoid arthritis.
214928765|NCT04306744|DEVICE|Vorso PROTECT System - Sham (OFF)|Identical device to experimental arm, but the device will not deliver stimulation
215069985|NCT00616018|DRUG|acetaminophen|4 g/day for 10 consecutive days
215069986|NCT03331601|DRUG|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
215069987|NCT01925118|BIOLOGICAL|Irradiated donor lymphocyte infusion|
215069988|NCT06290466|DRUG|Low dose group|300 mg,single dose.
215069989|NCT06290466|DRUG|High dose group|400 mg, single dose.
214673239|NCT05222386|OTHER|Parkinson Disease Standard Care|Under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. After one year of baseline data collection, eight practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. Per the stepped-wedge design an additional eight practices will be randomized 18 months into the data collection period, and the final eight will enter the intervention 24 months into the data collection period to allow for 12 months intervention recruitment for all practices.
214673240|NCT05222386|OTHER|Online Community-Supported Palliative Care|"Neurologist Teleconferences: Training and coaching in palliative care will be provided using the Extension for Community Healthcare Outcomes (ECHO) model augmented by a Community of Inquiry Framework to address a desire for greater peer connection, enhance self-efficacy, and to address potential weaknesses in the ECHO model for more complex interventions such as palliative care.~Additional support services provided to carepartners and patients will be through the Family Caregiver Alliance's CareNav platform, including tailored educational materials, support groups and social support."
214928766|NCT04633629|OTHER|Lung ultrasound|We will perform daily a lung ultrasound to evaluate pulmonary congestion by counting B-lines.
214928767|NCT03330262|DEVICE|BALCAP prosthesis|The noninvasive BALCAP prosthesis offers uses six degrees-of-freedom (6-DOF) sensing to detect postural imbalance and actuate low-amplitude vibrotactile cues directly to the head to provide the wearer with feedback concerning head tilt in the pitch and roll plane.
214928768|NCT06093646|BEHAVIORAL|Ebola+D intervention|Ebola+D intervention will include psycho-education, Problem Solving Therapy, antidepressant medication and referral to a supervising specialist mental health worker.
214928769|NCT00619567|BEHAVIORAL|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
214928770|NCT05098912|OTHER|Manual acupuncture|Manual acupuncture using filiform needle
214928771|NCT05098912|OTHER|Thread embedding acupuncture|Thread Embedding acupuncture using Polydioxanone thread
214928772|NCT02980341|DRUG|Patritumab Deruxtecan|U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
214928773|NCT01647516|DRUG|Ozanimod|Ozanimod capsules by mouth daily.
214928774|NCT01647516|DRUG|Placebo|
214928775|NCT05959096|DRUG|LY3437943|Administered SC
214928776|NCT05959096|DRUG|LY3437943|Administered IV
214928777|NCT01065376|PROCEDURE|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
214928778|NCT01065376|PROCEDURE|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
214928779|NCT04028427|BEHAVIORAL|Values-plus-goals intervention|The VGI is a four-week intervention, adapted from an existing online value-affirmation and goals intervention (Kingston \& Ellett, 2014) and an existing 'Living Well with Physical Health Conditions' programme handbook. Participants are first introduced to the concept of values as understood in Acceptance and Commitment Therapy. They are then asked to complete a card-sort task, which involves organising ten life domains according to their perceived level of importance. Participants will be asked to choose one values that is the most important and meaningful to them and to write for up to 10 minutes about it, thinking about why it is meaningful to them. Following this, participants will be given information on how to set value-based 'SMART' goals and asked to choose one to focus on over the next month. Participants will be sent a reminder e-mail every week over the 4 weeks, asking them to review their progress towards the SMART goal they set themselves.
214928780|NCT04028427|BEHAVIORAL|Mindfulness-based intervention|The MBI is a four-week intervention, where participants are introduced to the concept of mindfulness and acceptance as understood in ACT (Hayes et al., 1999). They will be asked to complete a 10-minute health-focused mindfulness meditation exercise by listening to a recording of a script focusing on cultivating mindful awareness of internal experiences, particularly in relation to diabetes, and practising making room for any difficult internal experiences. This will be followed by some prompts to promote reflections related to their diabetes following the exercise. They will be asked to practise this exercise 3-4 times a week over a four-week period. As a manipulation check, participants will be sent a reminder e-mail every week over the four weeks to record how many times they practised the exercise over the past week.
214928781|NCT01844180|DRUG|ONO-2952|
214928782|NCT01844180|DRUG|ONO-2952 Matching Placebo|
214327248|NCT07174245|DEVICE|continuous glucose monitor|All participants who wear CGM
214928783|NCT04424082|OTHER|Removal of dead space filter|Dead space filters will be removed and Vcap parameters (VCO2 ml/min, PaCO2 kPa, alveolar dead space in ml) recorded before and after removal
214327249|NCT07174193|DEVICE|Piezosurgery|Initially introduced in the field of implantology, piezosurgery has gained increasing popularity in orthognathic surgery in recent years (7-9). This technique utilizes ultrasonic vibrations ranging from 60-210 μm/s at frequencies between 24-29 kHz to cut bone, thereby minimizing trauma to surrounding soft tissue (10). Although numerous studies have been conducted, many clinical investigations have been limited by small sample sizes and insufficiently described methodologies (17, 18). Furthermore, the lack of standardized assessment tools hinders reliable comparisons of outcomes across studies (19). While surgeons increasingly recommend the use of piezosurqical instruments in orthognathic surgery, robust evidence from the literature remains insufficient to support the change in surgical technique.
214327250|NCT07174193|DEVICE|Conventional techniques|In the control group a Lindemann burr will be used to perform the horizontal and vertical osteotomies and the cut at the lower border of the mandible. A reciprocal saw will then be used to connect the horizontal and vertical osteotomies in the sagittal plane.
214928784|NCT03177031|DEVICE|Stay Safe Link (SSL)|CAPD system produced in Malaysia by Fresenius Medical Care
214928785|NCT03177031|DEVICE|Stay Safe (STS)|CAPD system produce in Germany by Fresenius Medical Care
214928786|NCT02630329|PROCEDURE|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
214928787|NCT02630329|PROCEDURE|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
214327251|NCT07172555|OTHER|Virtual Dietetic First-Appointment Webinar for Coeliac Disease|This intervention is a dietitian-led, pre-recorded on-demand webinar specifically designed for adults who have been newly diagnosed with coeliac disease. It acts as a patient's first formal dietetic appointment after diagnosis and provides comprehensive education about coeliac disease and the strict gluten-free diet required for its management. Unlike traditional approaches, which rely on face-to-face or telephone appointments with a dietitian-and which often involve significant waiting times-the webinar is available immediately online, allowing patients to access trusted, specialist information at their own pace and convenience, including the opportunity to re-watch as needed
214327252|NCT07172555|OTHER|Standard Dietetic Consultation (Face-to-Face or Telephone)|Participants in this group are allocated to receive the existing standard of care: an individual appointment with a specialist dietitian, delivered either in person (face-to-face) or by telephone. During the appointment, the dietitian provides a comprehensive overview of the gluten-free diet, strategies for avoiding cross-contamination, and advice on nutritional adequacy. As in the experimental arm, baseline assessment and validated questionnaires are administered pre- and post-intervention, with follow-up at 6 months to collect clinical, adherence, satisfaction, and quality of life data for direct comparison with the on-demand webinar intervention.
214327253|NCT07172451|DRUG|Balanced Gelatin Solution|Balanced gelatin solution (4% succinylated gelatin in a balanced crystalloid carrier). Administered as resuscitation fluid in patients with sepsis undergoing emergency abdominal surgery. Infusion follows a stroke volume-guided, goal-directed fluid therapy protocol. The total dose is limited to 30 mL/kg (ideal body weight) during the intraoperative period and the first 24 postoperative hours. If the maximum dose is reached, additional resuscitation is provided with balanced crystalloid solution.
214327254|NCT07172451|DRUG|Acetate Ringer's Solution|Acetate Ringer's solution, a balanced crystalloid, administered as the sole resuscitation fluid in patients with sepsis undergoing emergency abdominal surgery. Fluid therapy follows the same stroke volume-guided, goal-directed protocol as the experimental arm. There is no upper limit for the total volume of crystalloid infusion during the intraoperative and first 24 postoperative hours.
214327255|NCT07173140|DIAGNOSTIC_TEST|MRI|Participants undergo an additional MRI scan using novel MRI sequences
214327256|NCT07166523|DIETARY_SUPPLEMENT|Energy Product Placebo Control|Participants will use their Energy Product Placebo Control as directed for a period of 6 weeks
214327257|NCT07166523|DIETARY_SUPPLEMENT|Energy Active Product 1|Participants will use their Energy Active Product 1 as directed for a period of 6 weeks
214327258|NCT07172230|BEHAVIORAL|Immersive Virtual Reality|Immersive VR
214327259|NCT07172230|BEHAVIORAL|No distraction Control condition|No VR during word list study phase
214327260|NCT07173179|DRUG|Papillary epinephrine injection combined with rectal indomethacin|All patients in this group receive preprocedural 100mg indomethacin spp and post-procedure 4 ml of undiluted epinephrine injected around the duodenal papilla on four quadrants, over a period of 60 seconds using a sclerotherapy needle
214327261|NCT07173179|DRUG|Rectal indomethacin alone|All patients in this group receive preprocedural 100mg indomethacin spp
214327262|NCT07173725|DRUG|Octenidine dihydrochloride 0.1%|Final intracanal irrigant (aqueous solution); single administration during the final irrigation phase. Sonic activation performed in three 20-second cycles; solution refreshed with 2 mL between cycles (approximate total 6 mL per canal). Delivered through a side-vented needle positioned short of the working length.
214327263|NCT07173725|DRUG|Chlorhexidine 2%|Final intracanal irrigant (aqueous solution); single administration during the final irrigation phase. Sonic activation performed in three 20-second cycles; solution refreshed with 2 mL between cycles (approximate total 6 mL per canal). Delivered through a side-vented needle positioned short of the working length.
214327264|NCT07172815|DRUG|tadalafil|Once daily dose of Tadalafil will be commenced at 10 mg for 2 weeks, followed by an increase to 20 mg for another 2 weeks and finally increased to 40 mg.
214327265|NCT07172815|DRUG|Placebo|Matched Placebo will be taken once daily.
214327266|NCT07173244|DRUG|Adebrelimab|adebrelimab-based regimen
214327267|NCT07174310|DRUG|Prasinezumab|Participants will receive Prasinezumab as an IV Infusion as per the schedule mentioned in the protocol.
214327268|NCT07174310|DRUG|Placebo|Participants will receive Placebo as an IV Infusion per the schedule mentioned in the protocol
214327269|NCT07172620|PROCEDURE|Non-extracorporeal multiple coronary artery bypass graft (CABG) performed under direct visualization through a small incision in the left side of the chest.|Exposure group (MICS-Notouch group): Direct visualization non-extracorporeal coronary artery bypass grafting with a small left chest incision, including the use of LIMA (left internal mammary artery) + SVG (saphenous vein) multibranch bypass grafting.
214327270|NCT07172620|PROCEDURE|Multi-branch coronary artery bypass grafting with conventional median open heart and off-pump circulation|Control Group (OPCAB Group): Conventional median open multiple coronary artery bypass grafting with extracorporeal circulation.
214673241|NCT03590574|BIOLOGICAL|AUTO4|AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine), patients will be treated with doses from 25 to 900 x 10\^6 RQR8/aTRBC1 CAR T cells in Phase I. Following dose determination patients will be treated with the selected doses of RQR8/aTRBC1 CAR T cells (AUTO4) in Phase II.
214327271|NCT07173049|BEHAVIORAL|AAC Speech supplementation|The speech supplementation intervention involves learning to point to pictures, words, or letters on a communication board while simultaneously producing speech. Children will spend up to 30 minutes learning to use the strategy in one- on-one interaction with a speech therapist and demonstrate mastery by using the strategy successfully on a series of test stimuli.
214327272|NCT07172919|DRUG|Sotorasib|Sotorasib will be administered orally as a tablet.
214327273|NCT07172919|DRUG|Panitumumab|Panitumumab will be administered as an IV infusion.
214673242|NCT06477913|DEVICE|Rauha|A dual mental health treatment consisting of digitally-administered Cognitive Behavioral Therapy combined with National Board Health and Wellness Coach (NBHWC) trained Mental Health Coaches
215069990|NCT02483156|DRUG|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
214928788|NCT01354665|BIOLOGICAL|Interferon beta-1b (Betaferon, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
214928789|NCT02997644|BEHAVIORAL|Video Education|"The content of the education focuses on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage.~The consent, enrollment, and video education will take about 20-30 minutes for patients in this group, and occur at the end of their preoperative visit. The patient will watch the video on a portable Tablet computer."
214928790|NCT02997644|BEHAVIORAL|Usual Care Group|Patients that are randomized to usual care will only receive the regular instructions about opioid usage they typically receive from their surgeon.
214928791|NCT05987904|DEVICE|LynxPatch|Measurements with the LynxPatch device are conducted.
214928792|NCT02375594|OTHER|Exercise in park equipment|
215069991|NCT02483156|DRUG|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
215069992|NCT02483156|DRUG|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
214928793|NCT01323595|DRUG|Celecoxib|Celecoxib 200mg PO BID x 6 days
214928794|NCT01323595|DRUG|Sugar Pill|Sugar pill PO BID x 6 days
214928795|NCT03592537|DRUG|Fentanyl|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into three groups of 30 children
215069993|NCT03849053|OTHER|Mézières Therapy for Low back pain|Spinal muscular global stretching
215069994|NCT00632047|OTHER|active surveillance|
215069995|NCT00632047|OTHER|educational intervention|
215069996|NCT00632047|PROCEDURE|examination|
215069997|NCT00632047|PROCEDURE|long-term screening|
214673243|NCT04652635|PROCEDURE|Nail plate removal, nail bed repair|Injection of local anesthetic, removal of nail plate, inspection of nail bed, repair of nail bed with suture and/or adhesive
215069998|NCT06379035|DIAGNOSTIC_TEST|ELISA / PCR|"Multiplex PCR for confirmation of diagnosis of Blastocystis and Cryptosporidium infection.~Enzyme linked immunosorbent assay (Elisa) for detection of :~Different cytokines level in Colorectal cancer patients that may be involved in the tumor progression due to Blastocystis and Cryptosporidium infection."
215069999|NCT02609841|DEVICE|Cardiac rhythm remote monitoring system|Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
215070000|NCT02260778|BEHAVIORAL|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
215070001|NCT04103307|PROCEDURE|Dialysis cooling|Cooling the blood in the CRRT circuit during delivery
215070002|NCT00404755|DRUG|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
214673244|NCT05842681|DRUG|Azithromycin|A single daily oral dose of Azithromycin tablet 500 mg for five days
214673245|NCT05842681|DRUG|Methylprednisolone|methylprednisolone 500 mg single intra-venous daily dose for three days
214673246|NCT06166771|DEVICE|Alma system|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
214928796|NCT03592537|DRUG|Midazolam|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
214928797|NCT03592537|DRUG|Bupivacaine Hydrochloride|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
214928798|NCT06277635|DRUG|Silymarin|Silymarin is randomly assigned to the participants for 12 weeks during study.
214928799|NCT06277635|DRUG|Placebo|Placebo is randomly assigned to the participants for 12 weeks during study.
214928800|NCT00215696|GENETIC|BioBypass®|
214928801|NCT04567368|DIAGNOSTIC_TEST|Xpert MTB/XDR|Cepheid Xpert MTB/XDR assay for detection of resistance to INH, FQ and SLID
215070003|NCT00404755|DRUG|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
215070004|NCT00404755|DRUG|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
215070005|NCT02603601|BEHAVIORAL|Mind-body lifestyle intervention|
215070006|NCT02603601|BEHAVIORAL|Standard lifestyle intervention|
215070007|NCT00350870|DRUG|disulfiram|250mg per day of Disulfiram plus CBT
215070008|NCT00350870|DRUG|Placebo|Placebo plus CBT
215070009|NCT00350870|BEHAVIORAL|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
215070010|NCT00350870|DRUG|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
215070011|NCT01969383|OTHER|Heated pool training|
214327274|NCT07172685|COMBINATION_PRODUCT|Darolutamide , Docetaxel , ADT and Transrectal HIFU Focal Therapy|"Darolutamide , Docetaxel , ADT and Transrectal HIFU Focal Therapy Group:~Darolutamide (600 mg, orally, twice daily) GnRHa (Goserelin 10.8 mg sustained-release implant, subcutaneous injection, every 3 months) Docetaxel (75 mg/m², intravenous infusion, every 3 weeks, for 6 cycles) Dexamethasone (8 mg, orally, 12/3/1 hour before docetaxel infusion)\* Prednisone/Prednisolone (at the investigator's discretion)\* Transrectal High-Intensity Focused Ultrasound (HIFU) for prostate focal therapy (ablation extent determined based on MRI and biopsy findings; number of treatments ≤ 2)~\*Note: Dexamethasone and prednisone/prednisolone are adjunct medications and are not assigned as separate intervention arms; urinary catheter placement is a procedural detail and not listed as an intervention."
214327275|NCT07173972|RADIATION|Definitive radiotherapy|The prescribed dose is 56 Gray (Gy) in 16 fractions over 4 weeks (14 Gy per week) with a maximum dose-escalation to the tumor core of 80 Gy (5 Gy per fraction).
214327276|NCT07173777|DEVICE|Cardiac Waveform Generator|A pacing device that allows for programmable pulse waveforms to generate a predefined set of anodal biphasic waveforms. It possesses a battery-powered floating point gate array (FPGA) using software that allows flexibility in waveform configuration.
214327277|NCT07173504|OTHER|Intermittent enteral nutrition|Participants will receive intermittent enteral nutrition in four separate portions between 8:00 a.m. and 8:00 p.m. Each portion will be administered over a one-hour period.
214327278|NCT07173920|DEVICE|repetitive Transcranial Magnetic Stimulation|"Patients will receive rTMS treatment for a total of 14 days. Prior to treatment, patients will undergo an MRI scan; the images will be preprocessed to construct a structural network, and precise localization of the pre-SMA (preSupplementary Motor Area) region and the SCAN (Somatosensory-Cognitive-Action Network) will be performed based on coordinates.~Participants will receive two treatment sessions per day, with an interval of at least 1 hour between each session. Each treatment session consists of 3 cTBS (Continuous theta-Burst Stimulation) treatments, and the interval between each cTBS treatment is at least 15 minutes. Each cTBS treatment lasts 40 seconds, comprising 3 pulses at 50 Hz, repeated every 200 ms (equivalent to 5 Hz), totaling 600 pulses per cTBS treatment. Accordingly, patients receive a total of 3,600 pulses per day, and a cumulative total of 50,400 pulses are delivered throughout the entire treatment period."
214327279|NCT07172165|DIAGNOSTIC_TEST|Expert double-blind evaluation|Expert reading will be using TCDPlayer and will be blinded to clinical data, source information, and other assessments. They will manually annotate six predefined signal features: characteristic audible signal increase, characteristic wave-like of raw Doppler signals, Emboli-to-Background Ratio, Emboli-to-Mirror Ratio, signal duration, and average velocity of maximum intensity. Analysis will be completed within 90 days.
214327280|NCT07174102|DIAGNOSTIC_TEST|High resolution computed tomography|High resolution computed tomography perfomed in patients with rheumatoid arthritis and connective tissue diseases with or without interstitial lung disease, and idiopathic pulmonary fibrosis
214327281|NCT07172646|DRUG|SRSD216 injection|Administered SC.
214327282|NCT07172646|DRUG|Placebo|Administered SC.
214486195|NCT06048263|DRUG|Ketamine|During the first four post-cesarean days, the investigators will administer subcutaneous ketamine (0.5 mg/kg) and a repeated dose of 0.5 or 0.7 mg/kg \~24 hours later (the second dose will be increased to 0.7 mg/kg if no severe adverse effects are reported after the first dose and the patient is in agreement with the dose escalation).
214486196|NCT06492213|OTHER|No interventions|It is a observational study to investigate the efficacy and safety of PRP combined PRF on IONa compared to PRF alone.
214928802|NCT03134846|DRUG|Cetuximab-IRDye800CW|Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
214928803|NCT06623864|OTHER|meaningful activities|The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
214928804|NCT06623864|OTHER|other activities|The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
214928805|NCT00482404|BEHAVIORAL|Romantic kissing|
214928806|NCT01760486|BEHAVIORAL|Shape Up Rhode Island|
214928807|NCT01760486|BEHAVIORAL|Shape Up Rhode Island + Professional Coach + Incentives|
214928808|NCT01760486|BEHAVIORAL|Shape Up Rhode Island + Peer Coach + Incentives|
215070012|NCT05519436|OTHER|Assessment|"Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System."
214928809|NCT05245916|DRUG|IBI397|IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
214928810|NCT05245916|DRUG|IBI397+Sintilimab|IBI397 in combination with sintilimab： Subjects will receive IBI397 combination therapy with sintilimab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
214928811|NCT05245916|DRUG|IBI397+Rituximab|IBI397 in combination with rituximab： Subjects will receive IBI397 combination therapy with rituximab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
214928812|NCT05670041|BEHAVIORAL|Intensified follow-up|Early, intensified follow-up after discharge from TAVI-procedure.
215070013|NCT04418869|OTHER|Exercise bouts|Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
214327283|NCT07172204|DRUG|Alternately treated with VA/low CHA regimen|"1. Induction Phase (4 alternating cycles):~   Participants will receive 4 cycles of alternating therapy:~  * VA Cycle:~     * Venetoclax 400 mg PO daily on Days 1-28~    * Azacitidine 75 mg/m² SC/IV daily on Days 1-7~  * Low-dose CHA Cycle:~     * Cladribine 5 mg/m² IV daily on Days 1-3~    * Homoharringtonine 1 mg/m² IV daily on Days 1-5~    * Cytarabine 20 mg SC every 12 hours on Days 1-10 Alternating sequence: VA → CHA → VA → CHA → VA → CHA → VA → CHA The interval between the VA to low-CHA is 2 weeks, and the interval between the two alternations (one alternation is VA plus low-CHA）is 4 weeks.~2. Maintenance Phase (24 months):~Following induction, participants will receive:~* Venetoclax 400 mg PO daily on Days 1-28~* Azacitidine 75 mg/m² SC/IV daily on Days 1-7 Repeated every 28 days for 24 cycles. The interval between the two cycles is 2 weeks."
214327284|NCT07173062|DIETARY_SUPPLEMENT|Spirulina Arthrospira platensis (microalgae)|Spirulina Arthrospira platensis (4 x \~500mg), taken twice daily as 2 capsules in the morning + 2 capsules in the evening
214327285|NCT07173062|DIETARY_SUPPLEMENT|Gelidium corneum|Gelidium corneum (4 x \~500mg), taken twice daily as 2 capsules in the morning + 2 capsules in the evening
214327286|NCT07173062|OTHER|Placebo|Microcrystalline cellulose, silicon dioxide and dicalcium phosphate (4 x \~500mg), taken twice daily as 2 capsules in the morning + 2 capsules in the evening
214327287|NCT07173413|OTHER|Telephone post-surgery physiotherapy follow-up|Post-operative physiotherapy follow-up delivered via a structured telephone consultation. The session focuses on recovery after lumbar spine surgery, addressing pain management, mobility, exercise recommendations, and guidance on daily activities. The physiotherapist evaluates the patient's status verbally, answers questions, and provides tailored advice to support safe rehabilitation without requiring the patient to attend the hospital physically.
214327288|NCT07173413|OTHER|In person post-operative physiotherapy follow-up|Post-operative physiotherapy follow-up delivered as an in-person consultation at the hospital. The session includes assessment of recovery after lumbar spine surgery, hands-on evaluation if needed, and tailored advice on pain management, mobility, exercise progression, and daily activity. This format allows the physiotherapist to physically observe and, if relevant, demonstrate exercises to ensure correct performance and safe rehabilitation.
214327289|NCT07172737|OTHER|Respiratory Muscle Training|Respiratory Muscle Training with Telerehabilitation
214327290|NCT07172698|OTHER|multicomponent training with an emphasis on muscle power|Group 1 will perform an exercise protocol that includes warm-up, mobility, muscle strength, and flexibility. Group 2 will perform the same exercise protocol, with the caveat that, whenever feasible, exercises will be executed in the muscle power modality (at the highest possible speed). This latter training is characterized by a lower number of repetitions and a higher movement speed, guided by the therapists assisting. The progression of muscle power exercises will occur at 35%, 40%, 45%, 50%, 55%, and 60% of 1RM over the 12 weeks, distributed in 2 sets of 6 to 8 repetitions, with rest times of 60 to 120 seconds.
214327291|NCT07172698|OTHER|traditional multicomponent training|Group 1 will perform an exercise protocol that includes warm-up, mobility, muscle strength, and flexibility
214928813|NCT02588716|DRUG|Terlipressin|Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.
214928814|NCT02588716|DRUG|normal saline|Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
214928815|NCT00616616|PROCEDURE|single incision laparoscopic surgery|Surgery will be performed with ine laparoscopic incision
214928816|NCT05771896|DRUG|Darolutamide|"Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (\>56 days between cycles). Any participant requiring dose interruption \>28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly."
214928817|NCT05771896|DRUG|Radium-223|"Radium-223 should be given for 6 cycles, administered IV on Day 1 of each cycle or until radiological progression, withdrawal, death, termination, or study completion. The placebo will be administered in precisely the same fashion as the active drug.~Subsequent cycles 2-6 should be scheduled to occur every 28 ± 7 days following the previous cycle, but dosing may be delayed up to 28 days per cycle (maximum 56 days between cycles). Any participant requiring dose interruption \>28 consecutive days (\>56 days between cycles) may restart treatment with radium-223/placebo if clinical benefit is anticipated and after discussion with the Medical Monitor. Participants will continue with darolutamide irrespective of Radium-223 administration.~Upon radiological progression, further treatments are decided by the site investigator according to standard local practice."
214928818|NCT02247596|DRUG|Resveratrol|1g tds 2 weeks
214928819|NCT02247596|DRUG|Placebo|Sugar pill 1g tds for 2 weeks
214928820|NCT06149650|DEVICE|Shockwave Medical IVL System|Comprehensive system consisting of generator, a connector cable and a single-use sterile catheter with integrated balloon for intravascular lithotripsy of peripheral artery calcification.
214928821|NCT02331550|PROCEDURE|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
214928822|NCT02331550|PROCEDURE|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
214928823|NCT04671381|BEHAVIORAL|Hearing Evaluation|Behavioral thresholds for pure tones will be conducted along with speech perception measures.
214928824|NCT04671381|DEVICE|Over-the-Counter Hearing Aid (OTC HA) Fitting and Orientation|Study participants will be fitted with binaural OTC HAs in addition to receiving information on how to use and care for their devices.
214928825|NCT04671381|BEHAVIORAL|Four Weeks of Aural Rehabilitation|Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.
214327292|NCT07172048|DIAGNOSTIC_TEST|Foot pressure Distribution test|"This study is observational and does not involve any therapeutic or experimental intervention. Participants will be divided into two groups based on their scoliosis curve pattern:~Group 1: Adolescents with a major thoracic curve. Group 2: Adolescents with a major lumbar curve.~Each participant will undergo non-invasive assessments including:~Baropodometric foot pressure analysis during static standing to evaluate pressure distribution in both coronal and sagittal planes.~Radiographic evaluation to classify curve patterns using Cobb's angle, Central Sacral Vertical Line, and Plumb Line."
214928826|NCT04671381|DEVICE|Provision of Over-the-Counter Hearing Aids|Study participants will receive binaural OTC HAs. Participants will fit their OTC HAs based on manufacturer guidelines without the help of an audiologist.
214928827|NCT05447819|PROCEDURE|Reverse shoulder arthroplsaty|Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty
214928828|NCT03886519|PROCEDURE|BRAP (Bevel/rotate/advance procedure)|Trichiasis surgery using the BRAP procedure
214928829|NCT03886519|PROCEDURE|Trabut|Trichiasis surgery using the Trabut procedure
214928830|NCT03216590|DEVICE|Compressive draping using adhesive incise drape|In the intervention group the shoulder will be drape with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA).
214928831|NCT03193801|DEVICE|Edwards SAPIEN 3 transcatheter valve, Model 9600TFX|Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
214928832|NCT00387140|DRUG|MK2295|
214928833|NCT04964544|COMBINATION_PRODUCT|5 mg rosuvastatin calcium with a Web App (combination product)|The combination product will be a Drug (Rosuvastatin calcium 5 mg) and Software as a Medical Device (Web App that features a Technology-Assisted Self-Selection (TASS) tool). Rosuvastatin calcium 5 mg will be taken orally, 1 tablet daily to use for lowering cholesterol, a key risk factor that can lead to heart disease.
214673247|NCT04317482|BEHAVIORAL|Standard social stress task|Participants will be asked to respond in detail to three scenarios. This is a standard social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
214928834|NCT03993574|OTHER|Self- management program|"The program sessions are either adapted from the Stanford Patient Education Research Center's program called the Chronic Disease Self-Management Program (CDSMP) or from a vision self-management program.~Despite which self-management program, the format for each session will include, review of educational materials (using the CDSMP book/article), discussion via a case vignette (which is always stroke related), and participation in an activity based on that session's topic. These group sessions will be 1.5 hours each week for 6 weeks"
214928835|NCT03993574|OTHER|Standard care|"All stroke patients being discharged from the acute hospital receive the following care:~1. 1 follow-up call within 2 weeks by a nurse coordinator. The call involves checking if medications were able to be filled and how the person is feeling.~2. A stroke clinic appointment that is set to occur 90-days post discharge.~3. A list of their personal medications and generic educational materials. The educational materials are standard forms located in the Epic system. It is the nurses' responsibility to choose what forms to provide, however it is mandatory that stroke risk factor information is included.~4. Information on local support groups.~5. Referrals to start physical, occupational or speech therapy, if recommended by their physician."
214928836|NCT03875274|DRUG|Ropivacaine, Morphine|Morphine added to ropivacaine for fascia iliaca compartment block
214327293|NCT07172373|PROCEDURE|antegrade flexible ureteroscopy-assisted PCNL|antegrade flexible ureteroscopy-assisted PCNL
214327294|NCT07172373|PROCEDURE|single PCNL|single PCNL
214327295|NCT07174180|OTHER|Exercise-heat stress with no hijab|Participants perform exercise in the heat with no hijab
214327296|NCT07174180|OTHER|Exercise-heat stress with a hijab|Participants perform exercise in the heat with a hijab
214327297|NCT07173400|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|Active TaVNS delivered with the VagusStim® device (Vagus Medical Technologies, Istanbul, Türkiye). The bipolar electrode was placed on the left cymba concha. Stimulation was applied for 30 minutes per day, 5 days per week, for 4 weeks (20 sessions). Parameters included frequency 1-30 Hz, pulse width 50-250 μs, and current intensity individually adjusted (0.1-36 mA) to the participant's sensory threshold.
214327298|NCT07173400|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Sham stimulation delivered with the same VagusStim® device under identical conditions. The electrode was rotated and placed on the left earlobe, which lacks vagal innervation. Sessions lasted 30 minutes per day, 5 days per week, for 4 weeks (20 sessions). No effective vagus nerve stimulation was delivered, preserving participant blinding.
214327299|NCT06132360|DRUG|RN0191|This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
214327300|NCT03997318|BIOLOGICAL|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
214327301|NCT03997318|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
214327302|NCT05414409|DRUG|Metformin|Metformin is an oral medication that improves insulin sensitivity.
215070014|NCT03383913|BEHAVIORAL|Heart Rate Variability Biofeedback|Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
215070015|NCT06718036|OTHER|Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice|Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice
215070016|NCT03194568|DEVICE|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
215070017|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet A|Healthy, balanced diet following Eatwell Guide recommendations
215070018|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet B|Healthy, balanced diet following Eatwell Guide recommendations
214327303|NCT05648565|DEVICE|Radiofrequency ablation (RFA)|The NEUROMARK device is an in-office, disposable bipolar RFA device with a treatment tip consisting of micro electrodes which delivers RF energy while monitoring appropriate tissue contact to maximize delivery to posterior nasal nerve and its variable branching. After topical anesthesia consisting of oxymetazoline and 1% lido followed by 4% lidocaine, the device will be placed in the posterior inferior turbinate under endoscopic visualization. The device will be activated per manufacturer's instructions
214327304|NCT05346406|DEVICE|Midline Catheter|Bard Powerglide 8 cm midline catheter
214327305|NCT05346406|DEVICE|Peripherally Inserted Central Catheter|Bard 3fr, 4fr or 6fr; Cook 4fr; or Medcomp 1.9fr and 2.6fr
214327306|NCT06482944|BEHAVIORAL|Whole Foods for Families|"This diet intervention will encourage the consumption of a whole foods dietary patterns such as a wide variety of fruits, vegetables, proteins, seafood, dairy and whole grains. During the partial feeding period (weeks 3-8), families will be asked to continue the whole foods diet with support that includes: 1) 3 weekly dinners of the families' choosing (described above), 2) rotating menus (\~3 weeks' worth) that will allow for customization (e.g., protein, vegetable, grain swaps) to support cultural/dietary preferences, and 3) dietetic support to help with customization and diet maintenance. Participants will be instructed by the registered dietitian nutritionist (RDN) on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled families in the study, the goal is to maintain complete diet adherence during the twelve-week intervention."
214327307|NCT01659749|BEHAVIORAL|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
214327308|NCT01135810|BEHAVIORAL|Hypnosis|
214327309|NCT01135810|BEHAVIORAL|Meditation|
214327310|NCT01668095|OTHER|Laboratory Biomarker Analysis|Correlative studies
214327311|NCT01677195|DRUG|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
214327312|NCT01677195|DRUG|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
214327313|NCT06346977|DRUG|Pemetrexed|Intrathecal injection of pemetrexed
214327314|NCT05884437|PROCEDURE|Chiropractic adjustment|Participants will receive 6 weeks of chiropractic care. The frequency of care will be determined by the field clinician. Participants will have their spine assessed for the presence of vertebral subluxations per their clinician's normal and customary procedures. The adjustment technique(s) utilized by the field clinician will be at their discretion.
214327315|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 1 (CPMSM)|Test group 1 will receive investigational product 1 (CPMSM: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg).
214327316|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 2 (HC+)|Test group 2 (TG2) will receive investigational product 2 (HC+: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg).
214327317|NCT06174441|DIETARY_SUPPLEMENT|Placebo|Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients).
215070019|NCT05627570|BEHAVIORAL|Behavioural support intervention|Participants will work with a behavioural scientist to create a personal plan to eat a healthier diet and be more physically active. This support will last for 6 months, with ongoing monthly telephone/video calls with the research team.
214327318|NCT05250505|DEVICE|eShunt Implant|The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.
214327319|NCT05027945|PROCEDURE|Allogeneic HSCT|stem cell transplant on day 0
214327320|NCT05027945|DRUG|Busulfan test dose|0.8 mg/kg IV over 2 hours. May be skipped if real-time PKs are done during conditioning.
214327321|NCT05027945|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil (MMF): 15 mg/kg IV over 2 hours BID starting on day +5 until approximately day +35 (+/-2 days)
214327322|NCT05027945|DRUG|Tacrolimus|Starting on day +5, start at 0.02 mg/kg IV continuous infusion over 24 hours until day +180 and titrated to trough levels of 5-15 mg/ml.
214327323|NCT05027945|DRUG|Busulfan|AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 8/8 Matched Related or Unrelated Donor Busulfan dose will be on days -6, -5, and -4 For 7/8 Matched Related or Unrelated or Haploidentical Donor Busulfan dose will be on days -4 and -3
214327324|NCT05027945|RADIATION|Total Body Irradiation (TBI)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, 200cGy on day -1
215070020|NCT06450964|OTHER|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and the mitochondrial DNA mutation heterogeneity level was determined.|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and some granulosa cells, trophoderm cells, embryo culture fluid, embryo biopsy fluid, and embryo trophoblast cells were collected. Placenta and umbilical cord blood samples of some fetuses were collected after delivery, and the mitochondrial DNA mutation heterogeneity level was determined.
214327325|NCT05027945|DRUG|Fludarabine|40 mg/m2 IV over 30 mins daily For 8/8 Matched Related or Unrelated Donor Fludarabine dose will be on days -6, -5, -4, and -3 For 7/8 Matched Related or Unrelated or Haploidentical Donor Fludarabine dose will be on days -6, -5, -4, -3, and -2
215070021|NCT05248997|DRUG|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
214327326|NCT05027945|DRUG|Cyclophosphamide (CY)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, prior to transplant 14.5 mg/kg IV daily on days -6 and -5
214327327|NCT05027945|DRUG|Post-Transplant Cyclophosphamide (PTCY)|Post-Transplant Cyclophosphamide: 50 mg/kg IV daily over 2 hours on days +3 and +4, dosed according to ideal body weight
214327328|NCT00208429|DEVICE|Pinnacle Acetabular System|
214327329|NCT01706952|DRUG|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
214928837|NCT03875274|DRUG|Ropivacaine, Saline|Normal saline added to ropivacaine for fascia iliaca compartment block
214327330|NCT01706952|DRUG|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
214327331|NCT06477315|OTHER|survey|telephone surveys
214928838|NCT03316469|DRUG|Clomiphene Citrate|100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods
214928839|NCT03316469|DIAGNOSTIC_TEST|Follicular growth|Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.
214928840|NCT01098201|DRUG|Certolizumab|Subcutaneous administration on a monthly basis for six months
214928841|NCT00831974|DRUG|masitinib (AB1010)|3 mg/kg/day
214928842|NCT00831974|DRUG|masitinib (AB1010)|6 mg/kg/day
214928843|NCT02350686|DRUG|capecitabine|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
215070022|NCT05248997|DRUG|Matching placebo|One dose of matching placebo
215070023|NCT05447650|DEVICE|i-Lumen(TM) AMD|Transpalpebral microcrurrent stimulation
215070024|NCT05447650|DEVICE|i-Lumen(TM) AMD Sham|Transpalpebral sham stimulation
215070025|NCT04916353|DRUG|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain
215070026|NCT04916353|DRUG|Triamcinolone Acetonide.|Triamcinolone Acetonide 40mg/1ml injection
214327332|NCT04406896|DRUG|Selatogrel|A single subcutaneous injection of 16 mg.
214327333|NCT06335329|BEHAVIORAL|Discussion of point-of-care ultrasound lung findings|"The investigator will obtain point-of-care ultrasound images to assess the lung findings in 12 lung fields. These 12 lung fields will include the standard protocol of the upper and lower halves of the anterior, lateral, and posterior chest bilaterally. Subjects' ultrasound images will be scored using a modified lung ultrasound score (LUS). Each of the 12 lung fields will be scored from 0-5, with a total score of 0-60 (noted below). The participants will watch their ultrasound being performed, looking at their lungs in real time. Then, the ultrasound findings will be discussed with the participant.~Modified LUS 0: No B-lines present~1. 1 well-defined B-line~2. 2-3 well-defined B-lines~3. \>3 B-lines~4. Confluent B-lines~5. Lobar consolidation~   * C: Noted if subpleural consolidation present~  * E: Noted if pleural effusion present"
214327334|NCT05666310|DRUG|Denosumab|Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.
214327335|NCT05666310|DRUG|Zoledronic Acid|Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
214327336|NCT05666310|OTHER|Denosumab Placebo|Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.
214327337|NCT05666310|OTHER|Zoledronic Acid Placebo|Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.
215070027|NCT05465070|DEVICE|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
215070028|NCT05465070|DEVICE|Sham Control|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
215070029|NCT06292195|OTHER|Exposure|Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)
215070030|NCT06407128|BIOLOGICAL|Collection of biological samples|Collection of biological samples (blood sample + valve tissue sample + saliva, periodontal and feces sample)
215070031|NCT02291783|DRUG|HTL0009936|Single dose
215070032|NCT02291783|DRUG|HTL0009936 placebo|Placebo single dose
214327338|NCT06831019|DIAGNOSTIC_TEST|Oxidative stress markers|We will measure markers of oxidative stress in the follicular fluid, semen, and blood and correlate this with IVF and reproductive outcomes
214928844|NCT02350686|DRUG|oxaliplatin|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
214928845|NCT00874835|DEVICE|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
214928846|NCT01613222|DEVICE|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
214928847|NCT06419686|OTHER|Placebo (saline)|Intravenous saline during experimental days.
214928848|NCT06419686|DRUG|GIP|Intravenous GIP administration during experimental days.
214928849|NCT06419686|DRUG|Alanine|Intravenous alanine administration during experimental days.
214928850|NCT06419686|DRUG|GIP + alanine|Intravenous administration of GIP and alanine during experimental days.
214928851|NCT01550081|OTHER|Rate of perceived exertion|Exercise intensity controlled by Borg scale
214928852|NCT01550081|OTHER|Heart rate monitor|Exercise intensity controlled by heart rate monitors
214928853|NCT02205008|PROCEDURE|surgery|Total or subtotal gastrectomy with D2
214928854|NCT02205008|DRUG|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, \>1.5m2:60mg, bid)
214928855|NCT02205008|DRUG|Early postoperative intraperitoneal chemothgerapy|"operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq"
214928856|NCT05524896|DEVICE|ElucidVivo|Plaque morphology characterization for predicting non-invasive fractional flow reserve (FFR)
214928857|NCT06647719|OTHER|Educational Videos|Subjects in the experimental group will be provided with 3 links to videos to be watched after CTR surgery. These videos will be available through YouTube, Twitter, Facebook, Instagram, TikTok, or MyChart. Videos will be available to watch multiple times at the subjects choice.
215070033|NCT03982784|PROCEDURE|single-injection TQLB(transmuscular quadratus lumborum block)|Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
215070034|NCT03982784|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
214327339|NCT05141591|OTHER|Anxiety level assessment|To investigate the impact of psychological variables e.g. pre-surgical anxiety on postoperative opioid consumption and pain level, the investigators will perform the STOA, APAIS, PCS and the VAS-A anxiety questionnaires before surgery.
214327340|NCT04789239|DRUG|Sodium zirconium cyclosilicate|SZC is an approved drug in Sweden and subsidized for patients with chronic kidney disease in stages 3 to 5, with or without chronic heart failure, for whom treatment with Resonium is not suitable and for patients with chronic heart failure without con-comitant chronic kidney disease
214928858|NCT01348308|DRUG|Maraviroc (Celsentri)|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
214928859|NCT01348308|DRUG|Placebo|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
214928860|NCT05123664|OTHER|Capsule|1 cap daily at same time of the day with or without food for 4 weeks
214928861|NCT01328106|DRUG|GSK1120212|Repeating oral dose
214928862|NCT04109287|DEVICE|REVITIVE® device|The REVITIVE® device applies neuromuscular electrical stimulation to the soles of the feet, causing the muscles of the leg to contract and relax, thus improving blood circulation through the legs.
214928863|NCT03696108|DRUG|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID
214928864|NCT03696108|DRUG|Placebo|Placebo matched to gefapixant 15 mg or 45 mg administered orally BID
214928865|NCT02437500|BIOLOGICAL|SER-109|SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
214928866|NCT02209142|OTHER|blood prelevement|blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
214928867|NCT02209142|OTHER|psychometric data collection|
214928868|NCT04692480|BEHAVIORAL|Breastfeeding Video Education|"Video entitled Breastfeeding in the First Hour, It's in Your Hands"
214928869|NCT04692480|BEHAVIORAL|Breastfeeding PDF education|PDF of standard breastfeeding education handouts
214928870|NCT04513080|BEHAVIORAL|Video-chat psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
214327341|NCT04789239|OTHER|Placebo|Treatment with the same dose of placebo medicine as they would have received had they been treated with the interventional drug (SZC).
214327342|NCT02472756|DRUG|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
214928871|NCT04513080|BEHAVIORAL|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
214928872|NCT04513080|BEHAVIORAL|Message-based psychotherapy with monthly video chat (Premium Plan)|The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care will be based on CBT, PST or IPT.
214928873|NCT04513080|BEHAVIORAL|Message-based psychotherapy with weekly video chat (Ultimate Plan)|The Ultimate Plan allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT.
214928874|NCT02319174|DEVICE|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
215070035|NCT01396824|OTHER|No intervention|No intervention
215070036|NCT00517348|BIOLOGICAL|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
215070037|NCT00189800|DRUG|Solifenacin succinate|
215070038|NCT01453205|DRUG|MEDI-551 2 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
214327343|NCT02472756|DRUG|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
214327344|NCT01234129|DRUG|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
214327345|NCT01885442|DEVICE|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
214928875|NCT02196376|OTHER|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
214928876|NCT02196376|OTHER|Physical|"the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis"
214928877|NCT02196376|OTHER|blood draw|"blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn."
215070039|NCT01453205|DRUG|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
215070040|NCT01453205|DRUG|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
215070041|NCT01453205|DRUG|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
215070042|NCT01453205|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
215070043|NCT01453205|DRUG|MEDI-551 4 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
215070044|NCT01738607|DIETARY_SUPPLEMENT|Psyllium|
215070045|NCT01738607|DIETARY_SUPPLEMENT|Gum Arabic|Gum acacia dietary fiber
215070046|NCT01738607|DIETARY_SUPPLEMENT|carboxymethylcellulose|dietary fiber
215070047|NCT01738607|DIETARY_SUPPLEMENT|Placebo|
214327346|NCT04229134|BEHAVIORAL|Project CONNECT|Home based pain self-management intervention using peer reinforcement to promote engagement and skill uptake
214327347|NCT01532362|DRUG|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
214327348|NCT02453113|OTHER|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
214327349|NCT01316848|DRUG|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
214327350|NCT04895579|DRUG|Durvalumab|Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.
214928878|NCT02196376|BEHAVIORAL|Questionnaires|"The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31"
215070048|NCT00724685|DRUG|Naropeine (Ropivacaine)|
215070049|NCT00724685|DRUG|Placebo|saline
215070050|NCT05783063|DEVICE|Active iTBS|Mag-TD
215070051|NCT05783063|DEVICE|Sham iTBS|Mag-TD
215070052|NCT02835313|BEHAVIORAL|FAST alone|Subjects participate in fast walking training 3x/week for 12 weeks.
215070053|NCT02835313|BEHAVIORAL|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
215070054|NCT02835313|BEHAVIORAL|SAM alone|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
215070055|NCT05307640|BEHAVIORAL|CG-Well|CG-Well is a web \& phone based psychosocial intervention that teaches caregivers how to obtain information, education \& support
215070056|NCT05307640|BEHAVIORAL|Information Support & Referral (ISR)|Attention control group that receives phone calls and modules from the Brain Injury Association of America.
215070057|NCT05582707|DRUG|Pioglitazone 15mg|Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
215070058|NCT06232668|PROCEDURE|Chorionic biopsy and peripheral blood collection in cases group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.
215070059|NCT06232668|PROCEDURE|Chorionic biopsy and peripheral blood collection in control group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.
215070060|NCT05274971|OTHER|Active dietary management and aerobic exercise training.|Active dietary management and aerobic exercise training.
214327351|NCT04895579|DRUG|Copanlisib|Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.
214327352|NCT04295538|DRUG|Elezanumab|Solution for infusion; Intravenous (IV)
214327353|NCT04295538|DRUG|Placebo|Solution for infusion; Intravenous (IV)
214327354|NCT01706510|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
214327355|NCT01706510|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
214327356|NCT05679791|DEVICE|Dynamometer|to assses hand grip
214327357|NCT04605757|OTHER|Clinical, functional and radiological lung involvement evolution|Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
214928879|NCT05098665|COMBINATION_PRODUCT|Telemonitoring service|Patients in the active arm will receive a cellular network connected set of digital scales, and instructed to take their weight each morning at the same time. This device (BodyTrace) automatically uploads each daily weight reading to a central database. A clinical algorithm is applied to detect those at risk of acute and subacute decompensated heart failure. Patients are contacted within 24-48 hours of being flagged as at risk by a heart failure specialist. A clinical history is taken, and medication review undertaken, in line with a protocol. Diuretics are adjusted as per the protocolised changes, or for patients at ceiling of treatment, referral for local specialist review is made. A third protocol for follow-up is then followed to close the loop of intervention.
214928880|NCT04798989|DRUG|CY6463|CY6463 Oral Tablet
214928881|NCT04798989|DRUG|Placebo|Placebo Oral Tablet
214928882|NCT05748392|DEVICE|Wound and per-wound assessments While using Device|3D imaging and wound and per-wound skin characteristics will be conducted initially, at dressing changes and at end of treatment/study.
214928883|NCT00704444|DRUG|Ezetimibe|Ezetimibe, 10-mg tablets
214928884|NCT00704444|DRUG|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
214928885|NCT05219292|OTHER|Active music therapy|"Active music therapy is not a musical learning process. The restrictive character of classical respiratory rehabilitation will be alleviated by the playful aspect and the pleasure generated by the sessions, which will facilitate the commitment of the patients in their post-transplant respiratory rehabilitation.~The recorder was chosen among other wind instruments for several reasons:~* Its use is simple,~* It acts as an oscillating exhalation resistance device that generates a positive expiratory pressure (auto-PEP) produced by this wind instrument allows to obtain conditions similar to the treatment performed by a flutter (classical respiratory rehabilitation), a pressure on the expiratory flow with the obtaining of an oscillating effect during the trills, an increase of the respiratory capacities,~* The characteristics of the sound it produces (duration, intensity, timbre and frequency) will generate auditory feedback allowing patients to become aware of their breathing patterns."
214928886|NCT05219292|OTHER|Questionnaires|"We chose the HAD (Hospital Anxiety and Depression Scale) to assess anxiety and depression. This test is a reference test, often used in studies of transplant patients. The results obtained in previous studies allowed us to create our hypotheses.~To measure pain we chose the visual analogue scale (VAS). This reference test is often used in pain studies. It has the advantage of being simple to perform and easy to understand.~Quality of life will be assessed using the SF-12 (Short Form 12 Health Survey Questionary). We consider it to be simple and easy for patients to understand."
214928887|NCT00528060|DRUG|Atazanavir|2pills/day
214928888|NCT00528060|DRUG|Ritonavir|1 pill/day
214928889|NCT00528060|DRUG|Tenofovir/emtricitabine|1 pill/day
214327358|NCT06098820|OTHER|Vitamin D status|Four different groups will be compared with each other in terms of vitamin D effect.
214327359|NCT00110266|DRUG|Deferasirox|20 mg/kg/day over one year in patients with MDS
214327360|NCT02896400|BEHAVIORAL|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
214327361|NCT02896400|DRUG|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
214928890|NCT05120466|BEHAVIORAL|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
214928891|NCT05120466|BEHAVIORAL|Usual health education curriculum|The school's regular health education curriculum includes classroom lectures, hands on activities and group work.
214928892|NCT02861326|DEVICE|Gracey Curettes|
214928893|NCT00003134|DRUG|irinotecan hydrochloride|
214928894|NCT04033341|DRUG|LY3214996|Administered orally
214928895|NCT04033341|DRUG|[14C]-LY3214996|Administered orally
215070061|NCT05747209|OTHER|Observation of Exercise Program Adherence|Observation of a monitored group exercise regimen utilizing standard of care high-load resistance training and functional exercises with compound movements under close supervision and with the goal of improving functional mobility, body composition, and strength after cancer treatment to study adherence and attendance to the exercise program.
215070062|NCT05021133|BEHAVIORAL|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS using a video or telephone call
214327362|NCT02896400|OTHER|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
214327363|NCT02896400|OTHER|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
214327364|NCT02293785|DRUG|Oxycodone-Naloxone|
214327365|NCT03721198|COMBINATION_PRODUCT|Acidulated phosphorous flouride|Acidulated phosphorous flouride is used to prevent white spot lesions
214327366|NCT03721198|OTHER|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish is used to prevent white spot lesions
214327367|NCT01978405|DRUG|Alpha lipoic acid|
214327368|NCT06518356|DEVICE|Transcutaneous Auricular Neurostimulation (tAN)|The intervention the investigators are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets the auricular branch of the vagus nerve (ABVN) at the cymba conchae and mastoid process, and to a sham site (earlobe).
214928896|NCT05082558|OTHER|No intervention, as this was retrospective study.|No intervention performed. Participants were entolled retrospectively and medical records were accessed for data.
214928897|NCT05246059|OTHER|Olfactory Training|Sniffin' Sticks (Duft-Quartett, Burghart Messtechnik, GmbH, Germany)
214928898|NCT02611570|OTHER|LDCT|LDCT at enrollment, annually for two years and biennially for 6 years if no lung cancer is detected
214928899|NCT01619137|DRUG|water and soap|water and soap for 6-8 hours per day.
214928900|NCT01619137|DRUG|Povidone-iodine And normal salin treatment|use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
215070063|NCT03869385|DRUG|Albutein® 200 g/L or Plasbumin® 20|The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
215070064|NCT02602275|DRUG|Neurexan|0.6 mg / tablet
214327369|NCT03345602|DIAGNOSTIC_TEST|serum S100B protein assay measurement|serum S100B protein assay measurement within the 3 hours after head trauma
214327370|NCT04596878|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to Alhydrogel as an adjuvant.
214327371|NCT04596878|BIOLOGICAL|Placebo|Normal Saline 0.9%
214327372|NCT04705545|DEVICE|transpalatal arch group|transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.
214928901|NCT05290909|OTHER|The protocol of blended and problem-based learning|The protocol of blended and problem-based learnin: The online platforms used in this research are the school's iLMS platform, online digital learning, and online opinion exchange platform. It will use online resources (Google, open educational resources, YouTube copyrighted medical micro-movies, and audio-visual materials), and the theme will be elderly care or emerging Multimedia resources on infectious themes, as well as real-time interaction with kahoot or Slido electronic whiteboards, will be uploaded to the office3655The One website. Drive is provided by the school (the school account is used to store course resources) and the system of digital theoretical course concepts in advance. Broadcasting, video (such as: values and conflicts; ethics and morality; patient rights and responsibilities; nurses' rights and responsibilities; ethical theory; basic ethical principles; ethical dilemmas and ethical decision-making; etc.), pre-recorded and stored on the Internet Road platform iLMS.
214928902|NCT05290909|OTHER|The traditional problem-oriented teaching model|The traditional problem-oriented teaching model: There will be two PBL case introductions throughout the semester, with face-to-face teaching in physical classrooms.
214928903|NCT01008956|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
214928904|NCT04760509|OTHER|In this study, the short-term follow-up of patients with neural tube defects in the neonatal intensive care unit will be evaluated retrospectively.|there is no intervention. It is retrospective study.
214928905|NCT02184585|DRUG|Treatment sequence A|FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
214928906|NCT02184585|DRUG|Treatment sequence B|FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
215070065|NCT02602275|DRUG|Placebo|Neurexan-matched Placebo tablet
214327373|NCT04705545|DEVICE|Nance button|Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
214327374|NCT00809289|DRUG|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
214327375|NCT00809289|DRUG|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
214327376|NCT00809289|DRUG|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
214327377|NCT01010581|DRUG|SC12267 (4SC-101)|oral administration
215070066|NCT03574766|BEHAVIORAL|Meditation|Daily meditation
215070067|NCT03332199|OTHER|Psycho-educational intervention|The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
215070068|NCT03742310|DRUG|Vitamin D|Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
214327378|NCT01010581|DRUG|Placebo|oral administration
214327379|NCT01010581|DRUG|Methotrexate|oral administration
214327380|NCT01010581|DRUG|Folic Acid|oral administration
214327381|NCT05544461|BEHAVIORAL|eNutri personalised nutrition advice|eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
214327382|NCT01008111|DRUG|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
214327383|NCT01008111|DRUG|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
215070069|NCT00394043|PROCEDURE|Osteopathic Manipulative Treatment|A protocol of specific Osteopathic manipulative techniques was used.
215070070|NCT00394043|PROCEDURE|Placebo Sub-Therapeutic Ultrasound|Sub-therapeutic ultrasound was applied in a standardized method.
215070071|NCT04262882|BEHAVIORAL|Multilevel Family Planning Intervention|"The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community."
215070072|NCT04262882|BEHAVIORAL|Time and attention matched control|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda."
214327384|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
214327385|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
214327386|NCT02694081|PROCEDURE|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
214327387|NCT02694081|PROCEDURE|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
214327388|NCT05933434|BIOLOGICAL|Allogenic adipose derived mesenchymal stem cells (AD-MSC)|Laboratory isolated, cultivated and cryopreserved allogenic adipose derived mesenchymal stem cells (AD-MSC) from health donors undergoing cometic plastic surgery will be thawed on the injection day and formulated in 10 mL saline. The AD-MSCs will then be intraarticular injected using ultrasonic guidance.
214327389|NCT05933434|OTHER|Saline|10 mL saline will be intraarticular injected using ultrasonic guidance.
214327390|NCT00623883|PROCEDURE|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
214327391|NCT00623883|PROCEDURE|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
214327392|NCT01504334|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
214928907|NCT02184585|DRUG|Treatment sequence C|Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
214928908|NCT04217837|DEVICE|Transcranial Magnetic Stimulator|Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.
214928909|NCT00880061|DRUG|IL13-PE38QQR|
214928910|NCT00330109|PROCEDURE|MRS Imaging|Performed on a 3.0 Tesla Philips Intera MRI Unit (Best, Netherlands). Scout views and T2 transverse images are obtained to locate the tumor in conjunction with any previous diagnostic images.
215070073|NCT02566187|DRUG|Fimasartan/Atorvastatin Combination Tablet|
214327393|NCT01504334|DRUG|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
214327394|NCT03979365|DRUG|Envarsus XR|Twice daily tacrolimus vs. Envarsus XR
214327395|NCT03979365|DRUG|Tacrolimus twice daily|Twice daily tacrolimus vs. Envarsus XR
214928911|NCT00330109|PROCEDURE|PET Scanning|Using an Allegro scanner, the patient will be scanned for approximately 20-30 minutes. All emission scan data is processed by a multi-step procedure.
214928912|NCT00330109|PROCEDURE|Diffusion Tensor Imaging|Subjects will be scanned with a 3T Philips Intera MRI scanner for approximately 26 minutes for anatomical and DTI imaging. Total DTI acquisition time will be 6:06 minutes with 40 contiguous axial slices for full brain coverage.
214928913|NCT03855020|DIAGNOSTIC_TEST|Plasma EBV DNA|Parameters analyzed will include (1) the changing pattern of plasma EBV DNA concentrations during chemotherapy and radiotherapy (2) half-life values (t1/2) of plasma EBV DNA clearance rate
214928914|NCT02584127|BEHAVIORAL|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
214327396|NCT02473575|DIETARY_SUPPLEMENT|caffeine gum|Gum is consumed 30 minutes before commencement of run
214928915|NCT02584127|BEHAVIORAL|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
215070074|NCT02566187|DRUG|Fimasartan|
215070075|NCT02566187|DRUG|Atorvastatin|
215070076|NCT00014443|DRUG|thalidomide|
214327397|NCT02473575|DIETARY_SUPPLEMENT|placebo gum|Gum is consumed 30 minutes before commencement of run
214327398|NCT03236844|DRUG|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
214928916|NCT02833844|DRUG|Evolocumab|Dose of subcutaneous evolocumab QM
214928917|NCT02833844|DRUG|Placebo|Dose of matching placebo QM
214327399|NCT04377139|PROCEDURE|Prophylaxis|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
215070077|NCT00014443|DRUG|topotecan hydrochloride|
215070078|NCT01301066|DRUG|Pitavastatin|Pitavastatin 4 mg QD
215070079|NCT01301066|DRUG|Pravastatin|Pravastatin 40 mg QD
215070080|NCT00002389|DRUG|Abacavir sulfate|
215070081|NCT00002389|DRUG|Lamivudine|
215070082|NCT00002389|DRUG|Zidovudine|
214327400|NCT04377139|PROCEDURE|Preemptive|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
214327401|NCT05166122|DIAGNOSTIC_TEST|Artificial Intelligence|Introduction of digitized system with an AI tool to detect and intrepret the severity of diabetic retinopathy and presence of diabetic macular edema in screening for diabetes patients
214928918|NCT03632629|OTHER|interactive cognitive training|Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
214327402|NCT00646204|DRUG|Memantine|10 mg bid
214928919|NCT04042766|PROCEDURE|laser vaginal treatment|Er:YAG laser
215070083|NCT06036706|RADIATION|Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning|Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy…)
215070084|NCT06036706|RADIATION|Hypo-fractionated stereotactic brain irradiation|Patients receiving hypo-fractionated stereotactic brain irradiation
215070085|NCT06036706|RADIATION|Normo-fractionated proton therapy brain irradiation|Patients receiving normo-fractionated proton therapy brain irradiation
214327403|NCT00646204|DRUG|placebo|2 tabs bid
214327404|NCT01634204|OTHER|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
214327405|NCT01634204|OTHER|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
214327406|NCT01157481|DRUG|Conventional therapy plus nifedipine|Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
215070086|NCT06036706|OTHER|Cognitive assessment by a trained neuropsychologis|Participants without any meningioma, cancer history or neurological comorbidities will undergo cognitive assessment by a trained neuropsychologist, similarly as for patients
215070087|NCT01891617|OTHER|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
214327407|NCT01157481|DRUG|Conventional therapy|Conventional therapy
214327408|NCT03886064|OTHER|Multi-behavioral intervention|The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
214327409|NCT02402010|BEHAVIORAL|Adjunctive Yoga|
214327410|NCT02402010|BEHAVIORAL|Enhanced Treatment as Usual|
214327411|NCT02582840|DRUG|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
214327412|NCT02582840|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
214327413|NCT02582840|DRUG|Placebo tablet|Placebo tablet. Oral dose
214327414|NCT06114576|OTHER|Orange juice enriched with vitamin D3 and encapsulated probiotics|25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10\^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.
214327415|NCT06114576|OTHER|Conventional orange juice|25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.
214327416|NCT01934153|DRUG|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
214327417|NCT06166953|OTHER|digital technology-supported education|The education will include information about surgical process and care after surgery.
214327418|NCT00515333|DRUG|TRx0014|Hard capsule; 60 milligrams; t.i.d.
214486197|NCT06307002|OTHER|Playing a contraception education videogame|"The WMM game is divided into three parts- a reproductive anatomy quiz (Parts), an interactive tool for education about each individual birth control method (Methods), and a section in which players help avatar couples choose the most effective method for them."
214486198|NCT03696433|DIETARY_SUPPLEMENT|Low-salt diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
215070088|NCT02507466|BEHAVIORAL|exercise|Variable conditions of stepping practice
215070089|NCT05040165|DEVICE|Iceform liner and sleeve|Subjects will be asked to use the investigational device as their primary prosthesis for up to 6 months. TPE material durability evaluated through monthly online questionnaires.
215070090|NCT00868140|DRUG|pioglitazone|pioglitazone 45 mg
215070091|NCT00868140|DRUG|Placebo|placebo daily
215070092|NCT04047433|GENETIC|screening for single nucleotide polymorphism|samples from both arms will be tested for a set of single nucleotide polymorphism
215070093|NCT04047433|GENETIC|whole exome sequencing|samples from arm #1 (women with external anal sphincter) will be tested for identifying specific genetic mutation
215070094|NCT05453500|DRUG|Cyclophosphamide|Given IV
214327419|NCT00515333|DRUG|TRx0014|Hard capsule; 30 milligrams; t.i.d.
214327420|NCT00515333|DRUG|Placebo|Hard capsule; 0 milligrams; t.i.d.
214327421|NCT00515333|DRUG|TRx0014|Hard capsule, 100 milligrams, t.i.d.
214327422|NCT03152812|PROCEDURE|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
214327423|NCT05878938|DRUG|NNC0365-3769 (Mim8) PPX|Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.
214327424|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
214327425|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
214327426|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)|Minimal surgical margin \< 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
214327427|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)|Minimal surgical margin \< 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
214327428|NCT05676671|PROCEDURE|Applications of self-etching adhesives and dental restorations|
214327429|NCT00949780|DRUG|Chloral Hydrate|
214327430|NCT01015846|OTHER|Exercise|Redcord (sling exercise) and traditional exercise
214327431|NCT01015846|OTHER|Core stability exercise|Traditional core stability exercise
214327432|NCT01730495|DRUG|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
214327433|NCT01081808|BIOLOGICAL|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
214327434|NCT02213276|OTHER|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
214327435|NCT02213276|OTHER|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
214327436|NCT01792999|DEVICE|Contrast-enhanced KBCT|Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
214327437|NCT04440293|OTHER|BBAT|The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.
214327438|NCT04440293|OTHER|CT|The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.
214327439|NCT04512937|DEVICE|Computer-assisted navigation surgery|Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.
214928920|NCT06386068|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for chronic Whiplash-Associated Disorder (WAD). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants' lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
214928921|NCT05697029|DRUG|Tetrandrine|tetrandrine TID for 28 days
214928922|NCT00065104|DRUG|DHEA|
214928923|NCT01051544|DRUG|FVIII Concentrates|Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
214928924|NCT01051544|DRUG|FVIII/VWF concentrates|Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
215070095|NCT05453500|DRUG|Doxorubicin|Given IV
215070096|NCT05453500|DRUG|Etoposide|Given IV
214327440|NCT02306980|OTHER|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
214327441|NCT02492451|OTHER|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
214327442|NCT02492451|DRUG|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
214327443|NCT01075334|DIETARY_SUPPLEMENT|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
214327444|NCT01075334|DIETARY_SUPPLEMENT|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
214928925|NCT03608657|DRUG|Apremilast|Apremilast
215070097|NCT05453500|DRUG|Prednisone|Given PO
215070098|NCT05453500|BIOLOGICAL|Rituximab|Given IV
214928926|NCT02372929|PROCEDURE|Endoscopic Ultrasound|Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
214928927|NCT04811612|DIAGNOSTIC_TEST|Warmed heel stick|One heel will be warmed before sampling with the other heel will not be warmed
214928928|NCT06644469|DEVICE|Dynatronics VF5 Model vibration platform|The Dynatronics VF5 Model vibration platform is a specialized therapeutic device designed for rehabilitation and wellness applications. Utilizing advanced vibration technology, it provides whole-body vibration therapy that can enhance muscle strength, improve flexibility, and promote overall physical well-being. The platform features adjustable frequency and amplitude settings, allowing customization based on individual needs. Its user-friendly interface and robust, durable design make it suitable for both clinical and mobile therapy settings. Additionally, the compact and portable nature of the VF5 facilitates easy storage and transport, while safety features such as non-slip surfaces ensure user protection.
214928929|NCT06644469|DEVICE|Placebo Dynatronics VF5 Model vibration platform|Placebo intensity with vertical vibration of 0.2 mm
214928930|NCT03655912|DEVICE|Red/green glasses|The use of red/green glasses and electronic devices for two hours a day during 4 months.
214928931|NCT03655912|DEVICE|Electronic Tablet|The use of eye patch on the fellow eye and electronic tablet for 2 hours a day during 4 months.
214928932|NCT03655912|DEVICE|Eye patch|The use of eye patch on the fellow eye and near vision activities for 2 hours a day during 4 months.
214928933|NCT05565040|PROCEDURE|Circumcision in concealed penis|comparison of three surgical techniques (as described in the arms) in the management of concealed penis in pediatrics
214928934|NCT02952846|OTHER|Algorithm for tapering og analgosedation|Algorithm for tapering og analgosedation
215070099|NCT05453500|BIOLOGICAL|Tafasitamab|Given IV
215070100|NCT05453500|DRUG|Vincristine|Given IV
215070101|NCT05453500|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214327445|NCT05438082|DRUG|Antibiotic Prophylaxis|This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
214327446|NCT05438082|OTHER|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
214928935|NCT05209126|DIETARY_SUPPLEMENT|Beetroot juice|Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
214928936|NCT01128101|DRUG|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
214928937|NCT06498622|DRUG|Donafenib + Envafolimab|"Drug: Envafolimab Envafolimab 300mg IH D1 q3w Other Name: Immunotherapy, Anti-PD-L1 antibody~Drug: Donafenib Donafenib 100mg PO bid Other Name: tyrosine kinase inhibitor, TKI"
214928938|NCT02449317|OTHER|Bioimpedance guided|"bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~* extracellular water/total body water \< 0.36 : 4 ml/kg/hr~* extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~* extracellular water/total body water \> 0.4 : 1 ml/kg/hr"
214928939|NCT02449317|OTHER|standard hydration|standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
214928940|NCT01748617|OTHER|Controlled diet|1 week of controlled diet
214928941|NCT00196066|DEVICE|Peripheral Vessel Stenting|
214928942|NCT02619110|OTHER|backward walking treadmill training|subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.
215070102|NCT05453500|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215070103|NCT05453500|PROCEDURE|Computed Tomography|Undergo CT scan
215070104|NCT05453500|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
215070105|NCT05453500|PROCEDURE|Biospecimen Collection|Undergo blood sample and cerebrospinal fluid collection
215070106|NCT04746924|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
215070107|NCT04746924|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
215070108|NCT04746924|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
215070109|NCT04746924|DRUG|Placebo|Placebo infusions will consist of a sterile, normal saline solution.
215070110|NCT05239143|BIOLOGICAL|P-MUC1C-ALLO1 CAR-T cells|P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.
215070111|NCT05239143|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
215070112|NCT06974929|DRUG|HRS-6209 Capsules|Oral HRS-6209 capsules.
215070113|NCT06974929|DRUG|Letrozole Tablets|Oral Letrozole tablets.
215070114|NCT05819541|DRUG|Montelukast Oral Granules|Oral montelukast granules, USP powder, or crushed tablets at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.
215070115|NCT05819541|DRUG|Albuterol|Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
215070116|NCT05819541|DRUG|Corticosteroid|Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
215070117|NCT06069856|DIETARY_SUPPLEMENT|Iron Folic Acid Tablets with 60 mg of iron|IFA with 60 mg iron is an intervention group. IFA with 60 mg of iron will be taken orally once daily from the time of randomization
214327447|NCT03394872|PROCEDURE|Drainage of the pleural effusion|
214327448|NCT00298896|DRUG|SNS-595|
214327449|NCT02348242|DEVICE|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
214327450|NCT02348242|DEVICE|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
214327451|NCT02348242|DEVICE|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
214327452|NCT06273553|BIOLOGICAL|RG002 injection|In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
214928943|NCT02619110|OTHER|conventional physical therapy|subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
214928944|NCT02312596|DEVICE|PRP Concepts Fibrin Bio-Matrix|Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
214928945|NCT02312596|OTHER|Usual and Customary Practice|Usual and customary care for non-healing wounds
215070118|NCT06069856|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization.
215070119|NCT02187887|BEHAVIORAL|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
215070120|NCT06046859|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
215070121|NCT06046859|DRUG|Placebo|When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
215070122|NCT05666778|DEVICE|Menstrual Cup|Menstrual cups are inserted vaginally to collect menstrual flow, with some designed especially for use during intercourse, which will be used in this study. Medical devices registered with the U.S. FDA, a reusable silicon cup can last up to 10 years, is cost-effective, and has reduced environmental impact.
215070123|NCT03057002|DIAGNOSTIC_TEST|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized \[1-13C\]pyruvate flux during magnetic resonance spectroscopic imaging.
215070124|NCT03352466|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine.
214327453|NCT01221441|BIOLOGICAL|TissueGene-C|Single intraarticular injection at 3 x 10e7 cells
214327454|NCT01221441|DRUG|Normal Saline|Single intraarticular injection of normal saline as a placebo control
215070125|NCT03352466|BIOLOGICAL|BioThrax|Commercially available anthrax vaccine
215070126|NCT03352466|OTHER|Placebo|Normal saline
214327455|NCT02912481|PROCEDURE|posterior tibial artery|
214327456|NCT02912481|PROCEDURE|radial artery|
214327457|NCT02912481|PROCEDURE|dorsalis pedis artery|
214327458|NCT03022149|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
214327459|NCT03022149|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
214327460|NCT04837794|DEVICE|Digital Pain-Management Tool|Digital Pain-Management Tool
214327461|NCT02649972|DRUG|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
214327462|NCT06788964|DRUG|Loncastuximab Tesirine|Patients will receive Loncastuximab Tesirine intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
214928946|NCT06111196|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection|100mg/4ml;single dose;intravenous injection
214928947|NCT06111196|DRUG|Pembrolizumab injection|100mg/4ml;single dose;intravenous injection
214928948|NCT03805217|DEVICE|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software
214327463|NCT06788964|DRUG|Rituximab|Rituximab is administered intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
214928949|NCT05451550|PROCEDURE|Brachial plexus block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
214928950|NCT05451550|PROCEDURE|General anesthesia|General anesthesia were performed according to clinical routine: induction drugs: propofol, sufentanil, rocuronium, maintenance drugs: propofol, sevoflurane and remifentanil, Laryngeal mask ventilation.
214928951|NCT05451550|PROCEDURE|Suprascapular nerve block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
214928952|NCT06665295|BEHAVIORAL|THRIVE-CAR-T|The intervention will begin several weeks prior to CAR-T cell therapy and will continue up until 30 days post CAR-T cell therapy. THRIVE-CAR-T is an educational and interactive digital application on an iPad for patients as they navigate receiving CAR-T. THRIVE-CAR-T is self-administered and provides education about the CAR-T cell therapy process, with several features to promote coping skills training informed by various well-established supportive psychotherapy strategies (e.g., cognitive behavior therapy, mindfulness, positive psychology), engagement, and health behavior change including gamification strategies, videos of patients who received CAR-T, and optional content.
214928953|NCT03596281|DRUG|Pembrolizumab|200mg Q3W IV
214928954|NCT03596281|DRUG|Bevacizumab|400 or 300 mg Q3W IV
214928955|NCT03596281|DRUG|pegylated liposomal doxorubicin (PLD)|15 or 20 or 30 mg/m² Q3W IV
214928956|NCT06616714|OTHER|Observtional Study|Observtional Study
214928957|NCT04629781|DRUG|Docetaxel micellar|There will be three dose levels, 1-3, with each level consisting initially of a cohort containing 3 patients. One additional dose level, dose level -1, shall be allowed in the event that dose level 1 is considered too toxic
214327464|NCT01845155|BEHAVIORAL|Neuro-Music-Therapy according to the Heidelberg Model|"The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012"
214327465|NCT01845155|BEHAVIORAL|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
214928958|NCT06570343|DRUG|Fentanyl-Morphine|Intrathecal injection of bupivacaine, fentanyl and morphine
214928959|NCT06570343|DRUG|Morphine|Intrathecal injection of bupivacaine and morphine
214928960|NCT06653608|DRUG|Nano-reinforced calcium hydroxide medicament|Group A (Calcium hydroxide intracanal medicament reinforced with jasminum derived- titania nanoparticles)
214928961|NCT06653608|DRUG|Calcium hydroxide without nanoparicles|Group B ( Calcium hydroxide medicament without nanoparticles)
214928962|NCT01623843|PROCEDURE|Arthroscopic Lavage|Lavage: inflammation debris caused from continual friction in the hip is washed out.
214928963|NCT01623843|PROCEDURE|Arthroscopic Osteochondroplasty|"Osteochondroplasty: reshaping the hip ball and socket (osteoplasty or rim trimming)."
214928964|NCT01245543|DRUG|AC480IV|AC480IV will be administered as an infusion using a dose escalation design.
214327466|NCT03079258|OTHER|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
214327467|NCT06794047|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablets, please instruct the patient to swallow with water, 500mg twice daily, morning and evening.
214928965|NCT01245543|DRUG|Docetaxel|Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
214928966|NCT06499233|DRUG|Trimethoprim/Sulfamethoxazole|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).
214928967|NCT01899742|DRUG|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
214327468|NCT06794047|OTHER|Placebo|Tablets with the same material, flavor, and appearance as the intervention group.
214327469|NCT05644327|BEHAVIORAL|Cardiovascular training (CT)|12 weeks of CT
214327470|NCT05644327|BEHAVIORAL|Resistance training (RT)|12 weeks of RT
214928968|NCT01899742|DRUG|Tiotropium 18 mcg|Inhalation Powder
214928969|NCT05132712|DRUG|Losartan Potassium|ACE inhibitor
214928970|NCT05132712|DRUG|multi-vitamins|placebo drug
214928971|NCT05845905|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by the inflation of an automated cuff to the pressure rising by 20 mmHg from baseline systolic pressure. RIC will be conducted twice daily for 7 days.
214928972|NCT05845905|PROCEDURE|Sham remote ischemic conditioning|Sham-RIC is performed in the same way as the treatment group except that the blood pressure cuff is inflated to 60 mmHg, which produces mild pressure sensations but has no blocking impact on blood flow.
214928973|NCT05484349|DRUG|Tizanidine Hydrochloride|Tizanidine Hydrochloride 1 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
214928974|NCT05484349|DRUG|Tizanidine Hydrochloride|Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
214327471|NCT05644327|BEHAVIORAL|Multimodal training (MT)|12 weeks of MT
214327472|NCT00178438|DEVICE|Capsule Endoscopy|
214928975|NCT05484349|DRUG|Tizanidine Hydrochloride Placebo|Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks
214327473|NCT03830294|OTHER|different temperature-controlled breast prostheses|Two types of temperature-controlled breast prostheses were applied to patients in each group
214327474|NCT01395472|BEHAVIORAL|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
214327475|NCT01395472|BEHAVIORAL|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
214327476|NCT04163549|BEHAVIORAL|Safe at Home|Discussion-based intervention
214327477|NCT02665481|BEHAVIORAL|MBSR|
214928976|NCT01692249|OTHER|immediate spa therapy|, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
214928977|NCT02662764|DRUG|Zalviso™ 15 mcg|Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
214928978|NCT05398952|DIAGNOSTIC_TEST|Laboratory investigations|Laboratory investigations correlated with symptoms and imaging results
214928979|NCT05824052|OTHER|Ozone injection|Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.
214928980|NCT06411600|DRUG|Encorafenib|Encorafenib is administered orally at a daily dose of 300 mg, typically in the form of four 75 mg capsules taken together.
214928981|NCT06411600|DRUG|Cetuximab|Cetuximab is administered intravenously every two weeks at a dose of 500 mg/m².
214928982|NCT06411600|DRUG|Bevacizumab|Bevacizumab is administered intravenously every two weeks at a dose of 5 mg/kg.
214928983|NCT02852200|OTHER|SEGAm|
214327478|NCT02665481|BEHAVIORAL|Exercise|
214327479|NCT02665481|BEHAVIORAL|Health Education|
214327480|NCT02294201|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent product
214327481|NCT02294201|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
214327482|NCT02294201|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
214327483|NCT05397379|DRUG|HEC96719|Oral tablets
214928984|NCT04323306|DRUG|MMV688533|Investigational medicinal product
214928985|NCT00089778|DRUG|117-126:Fibroblast growth factor 5 (FGF-5)|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
214928986|NCT00089778|DRUG|Fibroblast growth factor 5 (FGF-5):172-176/217-220|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
214928987|NCT00089778|OTHER|IL-2|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
214928988|NCT01946893|BEHAVIORAL|Mindfulness Meditation|A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.
214327484|NCT05397379|DRUG|Placebo|Comparator
214327485|NCT03285646|DRUG|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
214327486|NCT03285646|DRUG|Placebo|Subcutaneous (SC) every 4 weeks (Q4W)
214327487|NCT04955938|DRUG|Ivosidenib|A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).
214327488|NCT04955938|DRUG|Enasidenib|A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.
214327489|NCT04955938|DRUG|Fedratinib|This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
214327490|NCT03623828|DRUG|Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe|Product administered using an external continuous subcutaneous infusion pump.
214327491|NCT06366490|BIOLOGICAL|Innocell Autologous Cellular Immunotherapy|Innocell Autologous Cellular Immunotherapy
214327492|NCT01299233|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
214327493|NCT03275727|BEHAVIORAL|iACT-BC|A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
214327494|NCT02653196|PROCEDURE|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
214327495|NCT02653196|DRUG|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
214327496|NCT02653196|DRUG|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
214928989|NCT01946893|BEHAVIORAL|Education|The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
214928990|NCT06043778|BEHAVIORAL|Community care for People with Schizophrenia in India (COPSI)|This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).
214928991|NCT06043778|BEHAVIORAL|mindLAMP Mobile Application|Participants in COPSI plus mindLAMP arm will have access to COPSI and the mindLAMP mobile application. mindLAMP has already been co-developed and culturally adapted by patients, family members, and clinicians at both Indian sites. Materials (articles, videos, web links, audio files, etc.) will be available on-demand and can be accessed by patients at any time. Community Health Officers will also schedule content to specific participants to promote engagement.
214327497|NCT02653196|DRUG|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
214327498|NCT02653196|DRUG|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
214327499|NCT02653196|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
214327500|NCT02653196|DRUG|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
214327501|NCT02653196|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
214327502|NCT02653196|DRUG|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age \> 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
214327503|NCT02653196|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
214327504|NCT05448924|DIAGNOSTIC_TEST|Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone
214327505|NCT01922310|BEHAVIORAL|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
214327506|NCT04016324|DEVICE|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
214327507|NCT00309933|PROCEDURE|cognitive assessment|
214327508|NCT00309933|PROCEDURE|psychosocial assessment and care|
214327509|NCT00309933|PROCEDURE|quality-of-life assessment|
214928992|NCT00707278|RADIATION|Radiation Therapy|Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
214928993|NCT00707278|DRUG|Capecitabine|Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
214928994|NCT00707278|DRUG|Oxaliplatin|Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
214327510|NCT00503841|DRUG|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
214327511|NCT00503841|OTHER|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
214327512|NCT00503841|OTHER|laboratory biomarker analysis|Correlative studies
214327513|NCT00503841|PROCEDURE|biopsy|14 days prior to surgery
214327514|NCT00503841|PROCEDURE|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
214327515|NCT00503841|PROCEDURE|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
214928995|NCT02197286|DRUG|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
214928996|NCT02197286|DRUG|Placebo|Daily dose of a single gelatin placebo capsule.
214928997|NCT06523881|PROCEDURE|Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey)|Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey) is a medication used during anesthesia. It is administered by inhalation with an anesthesia device.
214928998|NCT06523881|PROCEDURE|Propofol (Propofol-PF® 1% (Polifarma Pharmaceuticals, Tekirdag, Turkey)|Propofol is a drug used during anesthesia. It is administered intravenously using an infusion pump during surgical procedures.
214928999|NCT00372710|DRUG|Zoledronic acid|
214327516|NCT01437514|RADIATION|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
214327517|NCT01344057|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
214486199|NCT03696433|DIETARY_SUPPLEMENT|High-salt diet|The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
214929000|NCT05307016|DIAGNOSTIC_TEST|Two dimensional ultrasonography power and color doppler|"transabdominal and transvaginal two-dimensional power Doppler ultrasound volumes of the placental bed were obtained according to a predefined protocol with the participant in a semi-recumbent position and a full bladder using a RAB4-8-D 3D/4D curved array abdominal transducer (4-8.5 MHz) on a Voluson E8. Predetermined machine settings were used. To allow for differences in attenuation of the power Doppler signal resulting from variation in placental site and maternal adiposity.~Intraoperative staging of degree of placental invasion will be done according to clinical grading system by Collins et al., 2015.~Specimens obtained from patients who underwent hysterectomy or resection of segment of anterior uterine wall in cases with anterior placenta previa will be immersed in formalin 10% concentration and will be sent for histopathological evaluation that will be done by the same pathologist."
214929001|NCT05787535|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
214327518|NCT05951816|DRUG|99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.|Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.
214327519|NCT05951816|DRUG|99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.|99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.
214929002|NCT05787535|BIOLOGICAL|HRYZ-T101 TCR-T Cell|On day 1, the TCR-T cells will be administered one time.
214929003|NCT06623708|DEVICE|SMARTCLOTH|The intervention consists of using SMARTCLOTH. This device makes it possible to monitor dietary intake throughout the day and record it in a database that, through a website, allows to track it. SMARTCLOTH is a digital tablecloth consisting of a scale, several buttons and a screen. The device allows weighing the food to be consumed and recording its nutritional value (macronutrients in grams, macronutrient servings and kilocalories). The latter is achieved because SMARTCLOTH allows the patient to select to which food group the food being weighed belongs, increasing the accuracy of the nutritional estimation.
214929004|NCT01783600|DEVICE|NanoCross .014 balloon catheter|
214929005|NCT04660500|OTHER|PD Drivers Using AV Technologies On-road|All drives will include events to assess the impact of in-vehicle information systems (IVIS) and advanced driver assistance systems (ADAS) on the driving performance (driving errors) of drivers with PD. For IVIS the investigators will include options to assess errors with lane maintenance (with and without the lane departure warning system) and signaling (with and without blind spot detection). For ADAS the investigators will include conditions to assess errors in speeding (with and without adaptive cruise control) and lane exceedances (with and without lane keeping assist).
214929006|NCT06452199|DIETARY_SUPPLEMENT|B. infantis|1000 newborn children are randomized 50/50 to receive either B. infanits or placebo in a dietary supplement, for daily oral administration in three weeks from 7 days of age.
214929007|NCT06452199|DIETARY_SUPPLEMENT|Placebo|Identical looking placebo (without any probiotics/B. infantis) for double-blinded daily oral administration in three weeks from 7 days of age.
214929008|NCT04123106|PROCEDURE|ESP block|ESP block bilaterally performed at the level of the surgical site prior to surgery.
214929009|NCT04123106|PROCEDURE|Wound infiltration|Wound infiltration performed at the surgical site at the end of surgery.
214929010|NCT03768011|COMBINATION_PRODUCT|transdermal cream and or patch|transdermal cream and/or transdermal patch(s) with or without oral medication
214929011|NCT02195310|DEVICE|Prevena™ Incision Management System|Prevena™ Incision Management System is used after sternotomy on the closed incision
214929012|NCT02195310|DEVICE|Conventional sterile wound dressings|Conventional sterile wound dressings are placed after sternotomy on the closed incision
214929013|NCT06313086|DRUG|DP303c|intravenous injection
214929014|NCT06313086|DRUG|trastuzumab emtansine|intravenous injection
214327520|NCT00306592|BIOLOGICAL|BG00002 (natalizumab)|
214327521|NCT01401491|DRUG|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
214327522|NCT01401491|DRUG|clozapine plus placebo|clozapine 300 mg/day plus placebo
214327523|NCT03245567|OTHER|PLM|Participants will take the PLM on the visual estimation of LVEF. They will also take a pretest, a post-test and a delayed test at 6 months.
214327524|NCT03245567|OTHER|Pre, post, delayed test|Participants will perform a pretest, a posttest and a delayed test at 6 months.
214327525|NCT05439226|OTHER|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
215070127|NCT05772455|DRUG|XZB-0004|Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with Penpulimab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
214327526|NCT05958992|OTHER|E-cigarette|Participants will self-administer experimenter-provided e-cigarettes
214327527|NCT05580913|BEHAVIORAL|Resistance training|12 weeks of resistance-training performed two times per week
214327528|NCT02348164|OTHER|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
214327529|NCT02348164|OTHER|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
214327530|NCT05669092|DRUG|Toripalimab|3mg/Kg iv d1q2w
214327531|NCT05669092|RADIATION|CRT|IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
214327532|NCT05669092|RADIATION|SCRT|25Gy/5fx
214327533|NCT05669092|DRUG|XELIRI|Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
214327534|NCT05669092|DRUG|FOLFRINOX|Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
214327535|NCT06271551|DRUG|Transdermal estrogen|Participants (n=155) receiving transdermal estradiol for 12 months.
214327536|NCT06271551|DRUG|Active Comparator: Androgen deprivation therapy|Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
214327537|NCT06271551|BEHAVIORAL|Resistance training|Participants (n=30 in each arm) performing supervised resistance training for six months.
214327538|NCT02182544|DRUG|WAL801CL dry syrup|
214327539|NCT02182544|DRUG|Ketotifen fumarate dry syrup|
214327540|NCT02182544|DRUG|Ketotifen fumarate dry syrup placebo|
214327541|NCT02182544|DRUG|WAL 801 CL dry syrup placebo|
214327542|NCT05682547|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
214327543|NCT05682547|DRUG|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
214327544|NCT06455774|DEVICE|Wearable Postural Feedback Device|The postural feedback wearable device we will use in the study is programmed to vibrate when hunched postures are detected (based on changes in the curvature and curvature of the spine), alerting users to changes in their body position.
214327545|NCT06455774|OTHER|Exercise|Trapezius, Sternocleidomastoid (SCM), Scalene, pectoral muscles will be targeted for stretching exercises and deep neck flexors, Trapezius, Levator Scapula, Rhomboids will be targeted for strengthening exercises. The intensity of the exercises will be increased according to the weeks. Stretching exercises will be performed as a single set at the pain limit, maintaining the position of the muscle groups in the longest tolerable position for 30 seconds. In strengthening exercises, participants will hold the position for 5-10 seconds at the end of the movement. Moderate resistance elastic bands and free weights will be used for resistance exercises. In the following weeks, progression will be made in all exercises according to the patient's condition.
214327546|NCT06289257|DIAGNOSTIC_TEST|Vitamin D level|Vitamin D level in blood
214327547|NCT06289257|OTHER|Vitamin D receptor|Vitamin D receptor in endometriosis tissue
214327548|NCT05114304|OTHER|Evaluation of co-morbid psychiatric disorders|"Added scales :~* Mini Internationnal Neuropsychiatric Interview~* Fagerström test~* DSM-5 Scale~Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics~Expired carbon monoxide for patients using nicotine substitutes"
214327549|NCT05023590|PROCEDURE|ablation of left atrium during mitral valve open chest intervention|open chest mitral valve surgery (reconstruction or replacement) with additional ablation of left atrium by cryo or radio frequency method
214327550|NCT03148548|GENETIC|thrombophilia screening|genetic Evaluation of Factor-V-Leiden, Factor-II\_G20210A Mutation;
214327551|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
214327552|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
214327553|NCT01690039|DRUG|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
214327554|NCT00124215|BIOLOGICAL|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
214327555|NCT02888028|PROCEDURE|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
214327556|NCT02888028|OTHER|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
214327557|NCT04173338|DRUG|Cabozantinib|start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
214327558|NCT04173338|DRUG|Pemetrexed|Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
214327559|NCT06236958|DEVICE|Transnasal jejunal tube|A naso-jejunal tube was placed in the operation, which is placed 15 cm below Traitz's ligament. A short-peptide enteral nutrient solution was heated by an enteral nutrient pump and infused into the patients within 24 hours after the operation. Before and at the end of the infusion, physiological saline was given to flush the tube, and at the end of the infusion, the catheter was closed to prevent liquid reflux and blockage of the tube. The catheter should be clamped shut at the end of the infusion. During the infusion period, the patient's gastrointestinal tolerance was dynamically evaluated. According to the results of a regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the amount of enteral nutrients; remove the nasojejunal tube when the patient has no abdominal distension after exhaustion and feeding; and change to feeding through the mouth.
214327560|NCT06236958|OTHER|Transvenous access|A uniform drip of nutritional solution was started 24 hours postoperatively. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, calculated at 30 \~ 35 kcal/(kg-d), glucose-fat ratio is 6:4, pancreatic glucose ratio for those without a history of diabetes mellitus is 1:6 \~ 8, and for diabetic patients depending on the level of glucose, pancreatic glucose ratio is 1:3 \~ 4, and then assisted with subcutaneous injections of insulin to control glucose, if necessary. Pay attention to the total amount of rehydration fluid, electrolytes, vitamins, and trace elements supplemented. Mix the nutrient solution evenly in the laminar flow clean table and infuse it through the route at 2500\~3000 ml/d; the infusion time is 8\~12 h/d. After exhaustion, start to eat through the mouth.
214327561|NCT02156427|DEVICE|VITICELL|graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid
214327562|NCT02156427|DEVICE|PLACEBO|hyaluronic acid alone
214929015|NCT02141568|OTHER|Medical and Psychological treatment|"Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist)."
214327563|NCT02488629|DRUG|SCB01A|This study is a single arm, open-label, Phase II trial
214929016|NCT02493010|DEVICE|Arousal-based biofeedback system|
214327564|NCT00471913|DEVICE|Femoral Nailing with Different Entry Points|See Detailed Description.
214327565|NCT00225706|DRUG|Caldolor|
214327566|NCT02160366|OTHER|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
214327567|NCT06153108|DEVICE|PAMSys pendant PAMSys wrist sensors|The PAMSysTM sensor consists of a 3-axis accelerometer, battery, and built-in memory for recording long-term data. Accelerometer data is recorded at a sampling frequency of 50 Hz
214327568|NCT02142452|BEHAVIORAL|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
214327569|NCT02142452|OTHER|Usual Prenatal Care|
214327570|NCT06014255|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
214327571|NCT06014255|OTHER|Standard of Care|Radical prostatectomy within 4-8 weeks of randomization.
214327572|NCT02940691|DRUG|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
214327573|NCT02718638|OTHER|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
214327574|NCT01045226|PROCEDURE|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
214327575|NCT01045226|OTHER|Quality-of-Life assessment|Quality of Life Assessment
214327576|NCT01045226|OTHER|Questionnaire Administration|Questionnaire Administration
214327577|NCT02866877|OTHER|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
214327578|NCT00001996|DRUG|Atovaquone|
214327579|NCT00001996|DRUG|Pentamidine isethionate|
214327580|NCT01440309|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
214327581|NCT01440309|DRUG|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
214486200|NCT06742983|OTHER|Isobutyl cyanoacrylate|Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution
214486201|NCT06742983|OTHER|Chlorhexidine (0.2%)|Chlorhexidine Digluconate 0.2%
214929017|NCT06668610|DEVICE|StarStim 32, Neuroelectrics, Spain - Real multifocal tDCS|Real multifocal tDCS will be delivered with an intensity of 2.0 mA over 8 electrodes positioned over the frontal and temporal areas in the left hemisphere according to the international 10/10 EEG system. The overall duration of stimulation will be set at 20 minutes.
214929018|NCT06668610|DEVICE|StarStim 32, Neuroelectrics, Spain - Sham multifocal tDCS|Sham multifocal tDCS will be delivered with an intensity of 2.0 mA over 8 electrodes positioned over the frontal and temporal areas in the left hemisphere according to the international 10/10 EEG system. The overall duration of stimulation will be set at 30 seconds.
214929019|NCT06668610|BEHAVIORAL|Cognitive treatment|During the two cycles, all participants will undergo traditional cognitive stimulation therapy, involving paper-and-pencil exercise and computerised activity on several cognitive domains including memory, attention, and executive functions (duration 30-40 minutes) .
214929020|NCT04086212|DRUG|Icodextrin, xylitol and carnitine solution for peritoneal dialysis|Patients will receive a long dwell exchange for three days.
214929021|NCT04086212|DRUG|EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution|Patients will receive a long dwell exchange for three days.
214929022|NCT04843124|DEVICE|Remote HA adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
215070128|NCT02333396|OTHER|PICU Supports|The PICU Supports intervention includes navigator activities and ancillary tools. The Navigator activities include: initial visits with the healthcare team members (HTMs) and parents; weekday visits with the parents and feedback to the HTMs as needed; coordination of weekly family meetings between the parents and HTMs; and support during transitions out of the unit. The ancillary tools include: a PICU handbook; a place for parents to keep track of events and their goals; a provider sheet to inform PICU HTMs about important parental issues, concerns or goals; a bedside communication log so parents know which non-PICU HTMs have visited; an end-of-life checklist; a bereavement packet for those whose child dies; and informational resources.
214486202|NCT06742983|OTHER|Normal Saline (0.9% NaCl)|Sodium chloride 0.9%
214929023|NCT04843124|OTHER|Traditional hearing aid|Traditional hearing aid
215070129|NCT02333396|OTHER|Educational Brochure|Parents will receive a short educational brochure with information about the pediatric intensive care unit.
215070130|NCT05481502|PROCEDURE|Tumor biopsy|3 biopsies will be collected: at baseline, at day+15 and optionally at relapse
215070131|NCT05481502|PROCEDURE|Blood sample|7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse
215070132|NCT05481502|PROCEDURE|Bone marrow sample|If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
215070133|NCT05493254|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
214929024|NCT02830958|DEVICE|Kinesiotaping|The Kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting. Latex-free and wearable for days at a time, Kinesio® Tex Tape is safe for populations ranging from pediatric to geriatric, and successfully treats a variety of orthopedic, neuromuscular, neurological and other medical conditions.
214929025|NCT02830958|OTHER|No intervention|No intervention. Uses of an ordinary tape
214929026|NCT02723903|DRUG|Deanxit|we use Deanxit for the patient with anxiety
214929027|NCT02723903|DRUG|Prozac|we use Prozac for the patient with depression
214929028|NCT02723903|PROCEDURE|coronary artery disease treatment|including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries
214929029|NCT02284659|DEVICE|Functional Electrical Stimulation (FES)|FES (50Hz / 500us)
214929030|NCT02284659|DEVICE|FES- Sham|
214929031|NCT04613661|OTHER|Australian Spasticity Assessment Scale|Australian Spasticity Assessment Scale is a clinical measure to assess the severity of spasticity
214929032|NCT05905666|BEHAVIORAL|health education and counseling|In the control stage, participants only received standard nursing care. In the experimental stage, intervention measures (health education and counseling) were implemented. The baseline data were the pretest data collected in the control stage. Four weeks later, a posttest was performed, namely the pretest of the experimental stage. Subsequently, 4 weeks of health education and counseling were introduced to smokers according to different stages. After 4 weeks of intervention, participants were asked to fill out the posttest questionnaire again to measure the stages of change for smoking cessation, smoking decisional balance, and self-efficacy of smoking cessation.
214929033|NCT06149065|DRUG|Testosterone|Masculinizing hormone therapy (testosterone) is used in female-to-male transgenders for medical reason.
214929034|NCT04651049|DRUG|propranolol|This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.
214929035|NCT04651049|DEVICE||
214929036|NCT06031935|BEHAVIORAL|Yoga|The patients will receive links to two yoga videos. They will do each of these videos at home for 4 weeks.
214929037|NCT02937142|BEHAVIORAL|cognitive behavior group therapy|1,5 hours weekly session during 12 weeks, 8 participants, 2 therapists.
214929038|NCT02937142|OTHER|Treatment as usual|Education on ADHD, and ADHD medication if indicated
214929039|NCT01154088|BIOLOGICAL|Mencevax ACWY|One dose, Subcutaneous injection
215070134|NCT05493254|BEHAVIORAL|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
215070135|NCT04113733|OTHER|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
214327582|NCT06131515|DEVICE|extra corporeal shock wave therapy device|"Patients were seated in a relaxed position with their forearm and finger placed on the table. The median nerve was identified at the pisiform level of the proximal carpal tunnel, with the palm facing upwards. rESWT was delivered with the Physio Shock Wave Therapy system .The rESWT probe was located and oriented perpendicularly on the median nerve, and treatment comprised graduated shots at a bar pressure of 4 and a pulse repetition frequency of 5Hz for each patient ( The treated area was parallel to the median nerve from the pisiform level to 2 cm proximal to the inlet of the carpal tunnel with equal diffusion of 800, 900, 1000, 1100 shots from first to fourth session respectively. The procedure was painless, and there was no need for additional anesthesia or analgesia.~In the control group, sham rESWT just made the same sound without energy emission"
214929040|NCT01154088|BIOLOGICAL|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
214929041|NCT01191775|DRUG|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
214929042|NCT01122407|DRUG|L-NMMA|L-NMMA 250 ug/Kg/min
214929043|NCT01122407|DRUG|Trimethaphan|Will infuse trimethaphan for until complete autonomic blockade is achieved.
214929044|NCT00534885|BIOLOGICAL|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
214929045|NCT00534885|BIOLOGICAL|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
214929046|NCT00534885|BIOLOGICAL|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
214929047|NCT00534885|BIOLOGICAL|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
214929048|NCT06617871|PROCEDURE|Mechanical Alignment (MA)|Primary TKA with the Medacta SpheriKA, utilizing either MA methodology.
214929049|NCT06617871|PROCEDURE|Kinematic Alignment (KA) Interventions:|Primary TKA with the Medacta SpheriKA, utilizing either KA methodology.
214327583|NCT03712475|DRUG|Pregabalin|pharmacokinetic study under fasting conditions
214327584|NCT00164450|DRUG|Rifapentine + isoniazid once weekly for 3 months|
214929050|NCT05129137|DRUG|nefopam hydrochloride 30mg X2|nefopam hydrochloride 30mg X2
214929051|NCT05129137|DRUG|paracetamol 500 mg X2|paracetamol 500 mg X2
214929052|NCT05129137|DRUG|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
214929053|NCT06617182|DRUG|Thalidomide|Patients in thalidomide group took thalidomide orally at a dose of 100mg once a day for 8 weeks.
215070136|NCT06407869|OTHER|Functional Progressive Strength Training|The Functional Progressive Resistance Exercise (FPRE) protocol is designed to improve functional strength through structured workouts. It begins with a 3-minute warmup involving stretching and range of motion exercises, followed by progressively intense sit-to-stand exercises over six weeks. Participants also perform half-kneeling, standing up, and side-step-up exercises, with 20 minutes of total activity and rest intervals. The session ends with a 2-minute cooldown. Weights are gradually increased up to 15 times the initial load, with a minimum of one-minute rest between sets. The regimen is tailored through trial and error to find the maximum load participants can effectively manage.
215070137|NCT06407869|OTHER|Control|conventional physical therapy techniques will be applied
215070138|NCT02202915|BEHAVIORAL|Behavioral Checklist|
215070139|NCT03441035|OTHER|General anesthesia and surgery (liver transplantation)|The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
215070140|NCT04414592|OTHER|human umbilical cord mesenchymal stem cells|Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
215070141|NCT01108731|DRUG|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
214327585|NCT02210585|OTHER|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
214929054|NCT06617182|DRUG|Glutamine|In the glutamine group, two capsules of glutamine were taken orally 3 times a day for 8 weeks.
214929055|NCT06617182|DRUG|Thalidomide+Glutamine|Patients in thalidomide combined with glutamine group took thalidomide orally at a dose of 100mg once a day and two capsules of glutamine were taken orally 3 times a day for 8 weeks.
215070142|NCT01108731|DRUG|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
215070143|NCT04210245|BIOLOGICAL|aldafermin|aldafermin
215070144|NCT04210245|OTHER|Placebo|Placebo for aldafermin
215070145|NCT01892722|DRUG|Interferon beta-1a|Administration once weekly via i.m. injections.
214327586|NCT00370526|PROCEDURE|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
214327587|NCT03912233|DRUG|VX-121|Tablets for oral administration.
214929056|NCT03367546|PROCEDURE|Blood and Marrow Transplant|Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
215070146|NCT01892722|DRUG|Fingolimod|"Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less."
214327588|NCT03912233|DRUG|TEZ|TEZ tablet for oral administration.
215070147|NCT01892722|DRUG|Placebo capsule|Matching placebo capsule required for double-dummy masking to blind formulations.
215070148|NCT01892722|DRUG|Placebo i.m. injection|Matching placebo i.m. injection required for double-dummy masking to blind formulations.
214327589|NCT03912233|DRUG|VX-561|Tablets for oral administration.
214327590|NCT03912233|DRUG|TEZ/IVA|Fixed-dose combination tablets for oral administration.
214327591|NCT03912233|DRUG|IVA|Tablets for oral administration.
214327592|NCT03912233|DRUG|Placebo|Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
214327593|NCT03996200|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
214327594|NCT03082794|DIETARY_SUPPLEMENT|NCD|Negative Calorie Diet
214327595|NCT03082794|DIETARY_SUPPLEMENT|LCD|Low Calorie Diet
214327596|NCT04135638|PROCEDURE|Cover Group|"Cover when the ILM flap is everted over the MH gap in a single layer"
214327597|NCT04135638|PROCEDURE|Fill Group|"Fill when the ILM is folded into multiple layers within the MH"
214327598|NCT01464320|DRUG|ABT-614|Active
214327599|NCT01464320|DRUG|Placebo Comparator|Placebo
214327600|NCT01646697|OTHER|cytology specimen collection procedure|Undergo cytopathologic sample collection
214929057|NCT01684982|DEVICE|everolimus eluting stent|experimental arm of a comparison between drug eluting stents
214929058|NCT01684982|DEVICE|sirolimus eluting stent|control arm of a comparison between drug eluting stents
214929059|NCT04429204|PROCEDURE|Biospecimen Collection|Undergo collection of tissue
214929060|NCT04429204|PROCEDURE|Cryosurgery|Undergo cryoablation
214929061|NCT02491372|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
214929062|NCT01104246|DRUG|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
215070149|NCT06977594|OTHER|Proactive immune tolerance induction|Proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles
215070150|NCT06977594|OTHER|Standard Treatment|Standard treatment throughout all chemotherapy cycles
215070151|NCT06977594|DRUG|Paclitaxel and carboplatin|A chemotherapy regimen for gynecologic cancers.
215070152|NCT06977594|DRUG|Standard premedication (20 mg)|Premedication includes 20 mg of dexamethasone.
215070153|NCT06977594|DRUG|Reduced premedication (10 mg)|Premedication includes 20 mg of dexamethasone.
215070154|NCT06977594|DRUG|Reduced premedication (5 mg)|Premedication includes 5 mg of dexamethasone.
215070155|NCT02457689|BIOLOGICAL|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
214929063|NCT06621550|OTHER|High Intensity Interval Training|Participants will receive a single session of HIIT, which last for 19 minutes in duration. During the HIIT session, participants will complete 2 minutes stretching warm-up exercise, followed by a video of exercises which will be projected on the screen to facilitate the participants to follow. The exercise in the video involves various combinations of aerobic and core resistance exercise such as squat jump, jump lunge, push up, burpee, mountain climber etc. The exercise involved bodyweight or minimal basic equipment only, the workout to rest ratio is 45 secs: 15 secs. Participants' heart rate will be kept surveillance and to maintain their respective heart rate attained 85% of aged predicted maximal heart rate during the workout period.
214929064|NCT04128722|DRUG|Sirolimus Oral Liquid Product 1mg/mL|0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation
214929065|NCT05093530|DRUG|Neumifil|Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
214929066|NCT05093530|DRUG|Placebo|Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
214929067|NCT03374930|PROCEDURE|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
214929068|NCT04042350|OTHER|Non-interventional|Exploring clinical risk factors associated with the risk for cardiovascular events and mortality, rather than to evaluate specific drugs.
214929069|NCT06648941|PROCEDURE|Muscle release|supraspinatus muscle release
214929070|NCT06141616|OTHER|Asthma Rehabilitation Program|The group will receive free physiotherapy treatment with aerobic exercises, 3x/week, 60 minutes a day, lasting 3 months, in addition to educational sessions in a playful way.
214929071|NCT05178641|DEVICE|Ninjamas Pyjama Pants|Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.
214929072|NCT05178641|OTHER|Participant's Overnight Current Standard of Care|Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.
214929073|NCT06623916|DEVICE|Endometrial Cancer Survivors|strain sonoelastograghy method has not been studied before in endometrial cancer as a prognostic factor. we compared well known pathologic prognostic factors with elastographic methods.
214929074|NCT05877417|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine supplementation for 8 weeks, 5g daily. A 5 day loading phase will be implemented with 20g daily for 5 days.
214929075|NCT05877417|DEVICE|Blood Flow Restriction|Blood Flow Restriction Cuffs applied during exercise
214929076|NCT05877417|OTHER|Exercise|Participants will exercise
214929077|NCT00811824|BEHAVIORAL|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
214929078|NCT05022524|DIETARY_SUPPLEMENT|Acetate (Apple Cider Vinegar)|Consumer-grade apple cider vinegar (ACV) capsules will have extra enteric coating applied for delivery further into the GI tract.
214327601|NCT00625599|OTHER|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
214327602|NCT06211816|OTHER|communication strategy|an intensive communication strategy on end-of-life practice was implemented, based on a framework developed by the International Delphi Conference.
214929079|NCT02317835|DEVICE|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet
214929080|NCT03367052|PROCEDURE|Two level Prodisc-C vivo|Two level of Prodisc-C vivo artificial disc replacement will be done in one group of patients.
214929081|NCT03367052|PROCEDURE|Hybrid|The hybrid method will be used in one group of patients.
214929082|NCT01869699|DRUG|Acetaminophen|acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
214929083|NCT01869699|DRUG|Placebo|Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
214929084|NCT06619548|OTHER|Auricular magnet with a magnetic strength of 1800 Gauss|Auricular magnets with a magnetic strength of 1800 Gauss are used as the experimental group.
214929085|NCT06619548|OTHER|Auricular magnet with no magnetic strength|Auricular magnets with no magnetic strength are used as placebo control.
214327603|NCT00654628|DRUG|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
214327604|NCT03392636|PROCEDURE|Herniotomy|In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
214327605|NCT02177266|DRUG|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
214327606|NCT02177266|DRUG|Placebo|The placebo will match the study drug.
214929086|NCT01475851|DRUG|GSK548470 300 mg tablet|Blue tablets containing 300 mg of tenofovir disoproxil fumarate
214929087|NCT04979195|OTHER|Patients with stable normal kidney function|Covid-19 patients with stable kidney function will represent group 1.
214929088|NCT04979195|OTHER|Patients with unstable kidney function|Covid-19 patients with unstable kidney function will represent group 2.
215070156|NCT02457689|OTHER|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
215070157|NCT01058681|DIETARY_SUPPLEMENT|effect of metabolic variations on LH pulsatility|"Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia."
215070158|NCT03981094|DRUG|BMS-986278|suspension
215070159|NCT03981094|DRUG|Pirfenidone|capsule
214327607|NCT06390475|DIAGNOSTIC_TEST|MR Direct Thrombus Imaging (MRDTI)|Both groups will get the same MRDTI, the study is a proof-of-concept study to investigate if MRDTI can reliable distinguish between acute and chronic splanchnic thrombosis.
214929089|NCT05400070|DRUG|Neoadjuvant therapy 1|Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.
214929090|NCT01867294|DRUG|Doxycycline|Given PO
214929091|NCT01867294|PROCEDURE|Management of Therapy Complications|Moisturizer given topically
214929092|NCT01867294|OTHER|Placebo|Given topically
214929093|NCT01867294|OTHER|Questionnaire Administration|Ancillary studies
214929094|NCT01867294|DRUG|Spironolactone|Given topically
214929095|NCT01867294|DRUG|Sunscreen|Given topically
214929096|NCT01867294|DRUG|Therapeutic Hydrocortisone|Given topically
214929097|NCT01576276|RADIATION|Integrated MR-PET scan|Integrated MR-PET scan using \[11C\]diprenorphine
214929098|NCT01576276|DRUG|Ketorolac|3 administrations of ketorolac over course of study
214327608|NCT01288534|RADIATION|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
214327609|NCT00494494|DRUG|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
214327610|NCT00494494|DRUG|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
214327611|NCT01367808|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
214929099|NCT05161520|PROCEDURE|phacoemulsification combined with IOL and CTR implantation|Device: CTR (276001G； OPHTEC BV, Netherlands) Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL is implanted.
214929100|NCT05161520|PROCEDURE|phacoemulsification combined with IOL implantation|Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag.
214929101|NCT01993589|DRUG|comparison of pain relievers during curattage|
214929102|NCT01993589|DRUG|comparison of pain relievers|
214929103|NCT01993589|DRUG|comparison of pain relievers during curattage|
214929104|NCT01993589|DRUG|comparison of pain relievers during curattage|
214929105|NCT01993589|DRUG|comparison of pain relievers during curattage|
214929106|NCT03149289|DRUG|Antiviral drugs|sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvir, ombitasvir
214929107|NCT06648083|OTHER|Food autonomy|Determine the age of acquisition of full oral feeding in extremely premature infants hospitalised in a neonatal unit where that applies a strategy of specific and individualized stimulation of orality.
214929108|NCT04255732|DEVICE|extent of retinal area viewing Optos, Daytona, Optos PLC, Dunfermline, UK|Comparison of the extent of retinal periphery view between two wide field imaging devices.
214929109|NCT04255732|DEVICE|extent of retinal area viewing Clarus, 500 Carl Zeiss, Meditec AG, Jena, Germany|Comparison of the extent of retinal periphery view between two wide field imaging devices.
214929110|NCT03521297|DRUG|Probiotic|UDCA combined probiotic
214929111|NCT03521297|DIETARY_SUPPLEMENT|Placebo|UDCA combined placebo
214929112|NCT06261060|DRUG|Sirolimus|Given by PO
214929113|NCT02873572|BEHAVIORAL|step 1: online assessment|Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
214929114|NCT02873572|BEHAVIORAL|step2: biomarkers of gamblers/gamers|"For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:~* psychiatric assesment and~* registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015)."
214929115|NCT02017912|BIOLOGICAL|Nurown MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
214929116|NCT02017912|BIOLOGICAL|Placebo|Excipient administration by combined intramuscular and intrathecal administration
214929117|NCT06622681|OTHER|No intervention|No intervention
214929118|NCT02231281|DRUG|cART(TDF/AZT+3TC+LPV/r)|Standard antiretroviral therapy for HIV infection
214929119|NCT02231281|PROCEDURE|CTL infusion|cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
214929120|NCT03228316|PROCEDURE|superior hypogastric plexus block|nerve plexus block
214929121|NCT03228316|RADIATION|pulsed radiofrequency|pulsed radiofrequency on sacral nerve roots 2,3 and 4
214929122|NCT02900417|DRUG|Sitagliptin|All the patients will receive sitagliptin 100mg daily
214929123|NCT05214586|PROCEDURE|Follow up of the clinical stage|Pain, Swelling, Infection, Patient satisfaction and recurrence of the disease will be measured
214929124|NCT02991716|OTHER|recorded patients|No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
214327612|NCT01367808|DRUG|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
214327613|NCT01367808|DRUG|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
214327614|NCT00546715|DRUG|Daclatasvir|Oral Solution, Oral, Single Dose
214327615|NCT00546715|DRUG|Placebo|Oral Solution, Oral, Single Dose
214327616|NCT02568488|DRUG|Metformin|850 mg orally twice daily for 6 months
214327617|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
214929125|NCT04127032|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
214929126|NCT02673268|PROCEDURE|Mastectomy|
214929127|NCT02673268|DEVICE|Da Vinci Robot Xi|
214327618|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
214929128|NCT02271399|DRUG|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
215070160|NCT04475562|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
215070161|NCT02107625|BEHAVIORAL|Diet A i.e. Low FODMAP diet|
215070162|NCT02107625|BEHAVIORAL|Diet B, i.e. Traditional IBS diet|
215070163|NCT04381624|OTHER|Exercise program|exercise program in 12 sessions, of approximately one hour, distributed in 3 sessions per week during a month
215070164|NCT05252013|OTHER|Experimental: Bean Hull Bread|The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
214929129|NCT02271399|DRUG|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
214929130|NCT01894659|OTHER|24% oral sucrose|
214327619|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol.
214327620|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
214327621|NCT04425499|OTHER|Learning running subcuticular sutures on the Gamified Educational Network|Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
214327622|NCT00723606|DRUG|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
214327623|NCT00723606|DRUG|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
214327624|NCT05263427|DEVICE|TOCONAUTE|"This study will be carried out during delivery. The will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph.~For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient."
214327625|NCT06320470|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
214327626|NCT00215826|DRUG|Alferon LDO|
214327627|NCT00226616|DRUG|Zinc|
214327628|NCT01830140|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
214327629|NCT01830140|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
214327630|NCT04403022|DEVICE|Robotic Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision
214327631|NCT06127134|PROCEDURE|peripheral angioplasty for tibial vessels|repair tibials blood vessels throughout two concepts using angioplasty ballooning
214929131|NCT01894659|OTHER|30% oral glucose|
214929132|NCT04722029|BIOLOGICAL|Adenovirus Specific T lymphocytes|ADV-VSTs is being proposed for the treatment of refractory ADV infection and/or disease in these populations using haploidentical donors for ease of donor selection, antiviral immunity, coupled with a high-throughput antigen stimulation/IFN-γ capture system (Miltenyi Biotec, CliniMACS Prodigy® System) for rapid and less costly isolation of ADV-VSTs.
214327632|NCT04293159|DIETARY_SUPPLEMENT|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
214327633|NCT06384729|DEVICE|EXOPULSE Mollii Ⓡ|The EXOPULSE Mollii method (EXONEURAL NETWORK AB, Danderyd, Sweden) is an innovative approach to non-invasive and self-administered electrical stimulation with multiple electrodes incorporated into a full-body suit. It consists of comfortable, breathable, and washable synthetic material pants and a jacket. It has been primarily designed to reduce disabling spasticity and improve motor function. The method refers to the concept of reciprocal inhibition induced by stimulating the antagonist of a spastic muscle, at low frequencies and intensities, which is considered to reduce spasticity.
214327634|NCT01502644|DRUG|Oxycodone|Daily dosage up to 120 mg
214327635|NCT01502644|DRUG|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
214327636|NCT01502644|DRUG|Placebo|Placebo-matching oxycodone, placebo-matching morphine
215070165|NCT05252013|OTHER|Experimental: Plain Bread|The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
215070166|NCT04746118|BEHAVIORAL|DIET CHANGE|Nutritional supervision will be carried out individually based on the Food Guide for the Brazilian Population, ensuring an accessible, hygienic and contextualized diet according to the subject's culture and physiology. The protocol includes an initial assessment to define the meal plan and individual reassessments every four weeks. In the first evaluation participants will receive an eating plan with a 20% reduction in the total calories consumed or even the equivalent of their daily energy needs with a distribution of macronutrients comprised of 65% carbohydrate, 15% protein and 20% fat. The intention is to promote a reduction in weekly consumption by about 2000 kilocalories (Kcal). The prescription and diet control plan will include and be conducted by a team coordinated by a clinical nutritionist.
215070167|NCT04746118|BEHAVIORAL|PHYSICAL ACTIVITY|The physical activity program will consist of daily walking sessions performed outdoors and on a flat surface suitable for hiking. Each session will last 70 minutes and will be performed between 55% -60% of the maximum oxygen consumption (VO2), six times a week, for 24 weeks, with alternate on-site supervision on odd days and remote monitoring on even days. On-site supervision will be carried out by a team coordinated by a Physical Education teacher and implemented at two times in the morning and another two in the afternoon with meeting points previously defined. At the end of each supervised walking session, 20 minutes of exercise will be performed using the equipment available at the Senior Citizens Academy set up in public squares in the region so that the total expenditure of calories spent weekly with physical activities reach about 2000 kilocalories.
215070168|NCT04746118|OTHER|INTEGRATIVE PRACTICES|The health integrative practices will includes Mind-Fullness, auriculotherapy and laying on of hands. A suitably qualified professional, using it use a practical manual so that the practice became uniform among the subjects, will apply the practice of Mind-Fullness in weekly 1-hour sessions to individuals. The practice of auriculotherapy will be applied to individuals by a professional qualified to perform the technique, which consists in the selection of auricular points according to the health problems presented and the therapeutic objectives that are to be achieved, followed by the insertion of the mustard seed at specific points in the ear over a six-month period. The laying on of hands will be carried out by properly trained individuals.
215070169|NCT00298623|DRUG|XP13512 (GSK1838262)|
215070170|NCT00298623|OTHER|placebo|
215070171|NCT00221000|DRUG|Methoxsalen|
215070172|NCT00221000|PROCEDURE|Extracorporeal Photopheresis|
215070173|NCT03686306|DRUG|Sildenafil|"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
215070174|NCT03686306|DRUG|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
215070175|NCT01555034|BEHAVIORAL|movement therapy|exercise, nutrition, movement therapy
214327637|NCT03618797|DRUG|HL-PIF cap.160/2mg + Placebo|Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
215070176|NCT01555034|OTHER|exercise plus nutrition|exercise, nutrition
215070177|NCT00189579|DRUG|Herceptin|
215070178|NCT03401944|DRUG|TPN|
215070179|NCT03401944|OTHER|Control|
214327638|NCT03618797|DRUG|Livalo tab. 2mg + Placebo|Pitavastatin ca 2mg
214327639|NCT03704181|DRUG|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
214327640|NCT03704181|DRUG|Placebo Oral Tablet|placebo twice day for one year
214327641|NCT00637195|BIOLOGICAL|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)|Intramuscular administration, 3 doses.
214327642|NCT00637195|BIOLOGICAL|Engerix™|Intramuscular administration, 4 doses.
214327643|NCT01092247|OTHER|Nutritional support with Standard diet|Nutritional support with Standard diet
214327644|NCT01092247|OTHER|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
215070180|NCT05475743|OTHER|Pain Informed Movement program|The patients included in the experimental group attended an 8-week Pain Informed Movement program in addition to standard medical care. The program was led by a physical therapist with experience in treating patients with chronic pain. This program consisted of 2 face-to-face sessions per week, and they were asked to complete two sessions at home weekly. The first face-to-face session was a group session with 3-6 participants, and the second face-to-face session was individual. Both sessions lasted approximately 1 h. In the group sessions, pain neuroscience education was conducted. In the individual sessions, an individualized functional exercise program was performed by each patient, as well as relaxation techniques. Patients were asked to perform the functional exercises and relaxation techniques at home. Participants were asked to record their compliance with the program and their progress.
215070181|NCT05475743|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
215070182|NCT00551343|DRUG|Exenatide|10ug Exenatide single s.c. injection
214327645|NCT02388997|DRUG|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
214327646|NCT02388997|BIOLOGICAL|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
214327647|NCT05844696|DEVICE|Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.|"〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation."
214327648|NCT02999958|BIOLOGICAL|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
214327649|NCT05474144|DIETARY_SUPPLEMENT|SmartProbio C|Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.
214327650|NCT05474144|DIETARY_SUPPLEMENT|Placebo|Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.
214327651|NCT03244228|DRUG|HTL0016878|Oral solution
214327652|NCT03244228|DRUG|Placebo - Concentrate|Matching placebo
214327653|NCT04631497|DIAGNOSTIC_TEST|test|"1. Beck's Test~2. Test STAI~3. Test PSS~4. the scale of the fascination with death~5. COPE"
214929133|NCT03845491|DEVICE|Mechanical Thrombectomy|Treatment of LVO with mechanical thrombectomy
214929134|NCT06679569|DRUG|rocuronium 0.2 mg/kg/hr continuous infusion|To maintain Train-of-four count 1 to 3 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.2 mg/kg/hr to achieve and sustain moderate neuromuscular blockade.
214929135|NCT06679569|DRUG|rocuronium 0.6 mg/kg/hr continuous infusion|To maintain Train-of-four count 0 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.6 mg/kg/hr to achieve and sustain deep neuromuscular blockade.
214929136|NCT03406559|OTHER|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion,
214929137|NCT01590043|OTHER|Salivary samples|Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
214929138|NCT04670952|OTHER|Low Pressure Laparoscopic Cholecystectomy|Low Pressure Laparoscopic Cholecystectomy (10mmHg) is set as the experimental group.
214929139|NCT04670952|OTHER|Standard Pressure Laparoscopic Cholecystectomy|Standard Pressure Laparoscopic Cholecystectomy (14mmHg) is set as the control group.
214929140|NCT02322658|DRUG|Eszopiclone Tablets 3 mg|
214929141|NCT01680159|DRUG|TA-650|
214929142|NCT06683313|COMBINATION_PRODUCT|combination femoral nerve and popliteal sciatica block|Combination of femoral nerve and popliteal sciatica block performed after knee surgery
214929143|NCT06683313|COMBINATION_PRODUCT|combination adductor canal and IPACK block|Combination of adductor canal and IPACK block performed after knee surgery
214929144|NCT03633305|DRUG|Hypnotics|Medication used 1 to 7 nights/week for 6 to 8 weeks.
214929145|NCT03633305|BEHAVIORAL|Online CBT|Internet self-help program for insomnia with 6 cores.
214929146|NCT03633305|BEHAVIORAL|Face-to-face CBT|Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
214929147|NCT02200536|OTHER|Infant oral health promotion package|Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
214929148|NCT02200536|OTHER|Infant oral health pamphlet|Infant oral health pamphlet
214929149|NCT04936802|DEVICE|Transcatheter tricuspid valve repair system (Trialign)|To assess the Trialign System to treat subjects with moderate to severe tricuspid regurgitation
214929150|NCT00380289|DRUG|Thiazide and beta blocker|
214929151|NCT06682767|DIETARY_SUPPLEMENT|FMD1 (LNT22-017-1)|FMD is a plant-based ketogenic diet that provides essential nutrients while maintaining hypo-caloric content. FMD is administered cyclically with 3-5 consecutive days of the diet followed by resumption of normal eating.
214929152|NCT00061867|DRUG|pegylated liposomal doxorubicin hydrochloride|
214929153|NCT00061867|PROCEDURE|hyperthermia treatment|
214929154|NCT03745690|PROCEDURE|Image-Guided Surgery|Undergo near-infrared image guided surgical resection
214929155|NCT03745690|DRUG|Indocyanine Green Drug|Given IV
214929156|NCT01148303|DRUG|Etoricoxib|Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
214929157|NCT01148303|DRUG|Etoricoxib|This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
214929158|NCT01148303|DRUG|Placebo|Placebo
214929159|NCT02388815|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
214929160|NCT05909878|DEVICE|Virtual Reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
214929161|NCT05909878|OTHER|Standard Protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. Specifically at the hospital (HSJ), standard care also includes access to a television mounted near the MRI playing videos.The research nurse will be able to complete any information should they find it incomplete or substandard.
214929162|NCT00310752|DEVICE|DermaStream(tm) application and Streaming of Saline|
214929163|NCT00005889|DRUG|alanine|
214929164|NCT00005889|DRUG|amino acids|
215070183|NCT01252186|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
215070184|NCT01252186|DRUG|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
214929165|NCT00005889|DRUG|glucagon|
214929166|NCT00005889|DRUG|glucose|
214929167|NCT00005889|DRUG|glutamine|
214929168|NCT00005889|DRUG|glycerol|
214929169|NCT00005889|DRUG|insulin|
214929170|NCT00005889|DRUG|leucine|
214929171|NCT00005889|DRUG|lipids|
214929172|NCT00005889|DRUG|urea|
214929173|NCT04225429|DRUG|Tazemetostat|800mg/dose taken orally twice every day.
214929174|NCT05747898|PROCEDURE|cannula- based subcision|Insertion of a needle into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
215070185|NCT01252186|DRUG|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
215070186|NCT04239066|PROCEDURE|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
215070187|NCT04239066|PROCEDURE|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
215070188|NCT02200003|BEHAVIORAL|attention bias modification for anxiety|
214929175|NCT05747898|PROCEDURE|common- needle based subcision|Insertion of a cannula into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
214929176|NCT03025139|OTHER|Educational Intervention|Attend survivorship education
214929177|NCT03025139|OTHER|Laboratory Biomarker Analysis|Correlative studies
214929178|NCT03025139|PROCEDURE|Meditation Therapy|Attend mindfulness meditation
214929179|NCT03025139|OTHER|Questionnaire Administration|Ancillary studies
214929180|NCT01497964|DRUG|cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
214929181|NCT04701229|GENETIC|somatic cytogenetic and genetic characterization|investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.
214929182|NCT03429244|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET-MRI|Patients will undergo injection of 68Ga-PSMA-11 at the time of pre-treatment MRI scan and followed until biopsy and/or surgical resection.
214929183|NCT01062243|BEHAVIORAL|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
214929184|NCT04724629|BIOLOGICAL|Ixekizumab|80 mg of IL-17 inhibitor
214929185|NCT04724629|BIOLOGICAL|Aldesleukin|1.5 million IU (low-dose) of IL-2
214929186|NCT04724629|DRUG|Colchicine|0.5 mg of indirect IL-6 inhibitor
214929187|NCT04724629|DRUG|Standard of care (SOC)|Active comparator (Corticoids and antiretrovirals)
215070189|NCT01621256|DRUG|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
215070190|NCT01621256|DRUG|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
214327654|NCT06351605|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
214929188|NCT02716831|BEHAVIORAL|Nutritional Counseling & Acceptance-based Therapy|
214929189|NCT02716831|BEHAVIORAL|Cognitive Behavioral Therapy for Eating Disorders|
214929190|NCT00055770|DRUG|erlotinib hydrochloride|Given orally
214929191|NCT00055770|DRUG|docetaxel|Given IV
214929192|NCT00055770|OTHER|laboratory biomarker analysis|Correlative studies
214929193|NCT00055770|OTHER|pharmacological study|Correlative studies
215070191|NCT06395675|DIAGNOSTIC_TEST|ID NOW™|"The ID NOW™ CT/NG is an in vitro qualitative molecular assay for the rapid differential.~detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in urine, and self-collected vaginal swabs (SVS) in symptomatic and asymptomatic individuals."
215070192|NCT03007329|DRUG|Exenatide|Exenatide will be combined with Dapagliflozin
214327655|NCT06251076|DRUG|Teclistamab|Teclistamab is an antibody therapy (bispecific T-cell engager \[BiTE\]) that binds to two target proteins on different cells; CD3 on healthy T cells and B cell maturation antigen (BCMA) on myeloma cells. This brings healthy T cells and the myeloma cells close together so the T cells can more effectively kill them. Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
214327656|NCT06251076|DRUG|Tocilizumab|Toclilzumab is an interleukin inhibitor approved for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and other indications.
214929194|NCT00774553|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
215070193|NCT03007329|DRUG|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
215070194|NCT03007329|DRUG|Dapagliflozin|Dapagliflozin, in both arms
215070195|NCT00562263|BEHAVIORAL|Lifestyle modification|Dietary modification and regular physical activity
215070196|NCT02896491|RADIATION|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
215070197|NCT06306729|DIAGNOSTIC_TEST|Computed Tomography, Magnetic Resonance Imaging|Computed Tomography, Magnetic Resonance Imaging
215070198|NCT02407340|DRUG|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
215070199|NCT02407340|DRUG|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
215070200|NCT01186926|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
215070201|NCT03614481|GENETIC|Sampling|Sampling
214327657|NCT01022034|PROCEDURE|sacral rectopexy with sutures or meshes|
214327658|NCT01022034|PROCEDURE|full rectal mobilization from the sacrum without sacral rectopexy|
214327659|NCT05158205|BEHAVIORAL|Yoga|12-week yoga intervention in which 60-minute classes are completed at Texas State University 3 times per week
214327660|NCT05158205|BEHAVIORAL|Slow, deep breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
214327661|NCT05158205|BEHAVIORAL|Control breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
214327662|NCT00322062|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
214327663|NCT00322062|DRUG|Sodium Phosphate Solution|1 x 45ml solution, BID
214929195|NCT00774553|DRUG|Placebo|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
214929196|NCT03403751|DRUG|Reltecimod 0.5 mg/kg|Single IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL) over approximately 10 minutes
215070202|NCT00500058|DRUG|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
215070203|NCT00500058|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered by IV infusion.
215070204|NCT05329480|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.
215070205|NCT05329480|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder, 4 separate 5g doses per day for 7 days.
215070206|NCT04470804|DRUG|Sirolimus|Sirolimus treats in experimental group
215070207|NCT04470804|DRUG|Cyclosporine A|Cyclosporine A uses for active comparator group.
215070208|NCT01120860|DEVICE|MRI|MRI - routine imaging sequences, designed for anatomical quantification
215070209|NCT06811103|OTHER|patient reported outcome|after enrollment, patient will have to answer to several patient reported outcome (PRO) to evaluate their pain, and well being. They will also answer to the MacCatT PRO to assess their understanding, reasoning, appreciation and choice expression
214327664|NCT05532176|OTHER|Posture standards|Dynamic and static Postural measurements according to four types of tests
214929197|NCT03403751|DRUG|Placebo|Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
214929198|NCT03404726|DRUG|BAY2402234|BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.
214929199|NCT00004422|DRUG|immune globulin|
214929200|NCT00750139|DRUG|NAFT-500|topical cream 1 application every day up to 4 weeks weeks
214929201|NCT00750139|DRUG|Placebo 2-weeks|placebo cream 1 application every day for up to 4 weeks
214929202|NCT00750139|DRUG|Naftin 1%|topical allylamine cream applied once a day for up to 4 weeks
214929203|NCT00750139|DRUG|Placebo 4-weeks|topical placebo cream applied once a day for up to 4 weeks
214327665|NCT06644170|BEHAVIORAL|Behavioral Intervention|Attend individual visits
214327666|NCT06644170|BEHAVIORAL|Group Therapy|Attend group visits
214327667|NCT06644170|DRUG|Psilocybin|Given PO
214327668|NCT06644170|OTHER|Questionnaire Administration|Ancillary studies
214327669|NCT03492333|OTHER|Gluten free diet|Gluten-free diet- Instructions provided by a dietitian
214929204|NCT02411058|BEHAVIORAL|Uninformed|Users will receive 20x their usual incentives for two weeks, but will either receive no emails informing them about the incentive program.
214327670|NCT03025828|DRUG|ACTHar|for 6 months
214327671|NCT01020019|DRUG|Dronabinol|Dronabinol: 20 mg/TID
214327672|NCT01020019|DRUG|Placebo|Placebo control
214327673|NCT01020019|DRUG|Lofexidine|Lofex: .6 mg/ TID
214327674|NCT03566628|OTHER|Warmed Isotonic Saline|Isotonic saline warmed to 39ºC.
214327675|NCT03566628|OTHER|Room-Temperature Isotonic Saline|Isotonic saline at room temperature
214327676|NCT01690767|DRUG|2% lidocaine gel|Children \< 7 kg and \> 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
214327677|NCT01690767|DRUG|Health Care Lubricating Jelly|Non-medicinal lubrication gel
214327678|NCT00649337|PROCEDURE|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|"AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed."
214327679|NCT02615951|OTHER|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
214327680|NCT02375672|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
214327681|NCT02375672|DRUG|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion"
214327682|NCT02459314|DIETARY_SUPPLEMENT|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
214327683|NCT02459314|DIETARY_SUPPLEMENT|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
214327684|NCT02149433|DRUG|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
214327685|NCT02149433|DRUG|Placebo|
214327686|NCT01559311|DEVICE|CRT-P OFF|CRT Pacemaker
214327687|NCT01559311|DEVICE|CRT-P ON|CRT Pacemaker
214327688|NCT01559311|DEVICE|DDDR|Dual-chamber, rate-modulated pacemaker
214929205|NCT02411058|BEHAVIORAL|Informed|Users will receive 20x their usual incentives for two weeks, and they will receive emails informing them about the incentives (one announcement before the incentives begin, and one email every two days reminding them about the overall incentive program). These emails will contain information about the incentives and the purpose of the incentives. The reminder emails sent every two days, however, will include more information about the overall program incentives to maximize the number of participants who learn about the incentive program at some point.
214929206|NCT00266643|DRUG|duloxetine hydrochloride|
214327689|NCT02500069|OTHER|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
214327690|NCT02500069|OTHER|Casein (in duodenum)|infusion of protein in duodenum
214327691|NCT02500069|OTHER|Casein (in jejunum)|infusion of protein in jejunum
214327692|NCT02500069|OTHER|Casein (in ileum)|infusion of protein in ileum
214327693|NCT04552366|BIOLOGICAL|Ad5-nCoV|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
214327694|NCT01486563|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
214327695|NCT01486563|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
214327696|NCT00000327|DRUG|Heroin Dependence|
214327697|NCT02903667|DEVICE|Bone grafting|
214327698|NCT01350427|DIETARY_SUPPLEMENT|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
214327699|NCT01350427|DIETARY_SUPPLEMENT|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
214327700|NCT01350427|DIETARY_SUPPLEMENT|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
214929207|NCT06622343|DRUG|Antivenom Serum|Intravenous administration of 6000 IU of antivenom serum was given to patients envenomed by pit vipers. This treatment was based on Chinese guidelines for the management of snakebites. Additionally, patients received supportive treatments, including antibiotics to prevent infection, antihistamines for allergic reactions, and magnesium sulfate for localized swelling and pain relief.
214327701|NCT03023488|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy is an endourological procedure performed for kidney stones. The flexible ureteroscope is a device used to reach the renal cavities through the natural urinary tract in a retrograde fashion. During the operation, irrigation fluid is used to expand the cavities to provide space for movement of the device and also to provide clear vision.
214327702|NCT03023488|DEVICE|Doppler Ultrasound examination|peak systolic velocities (PSV) and end diastolic velocities (EDV) of the arteries will be measured and then resistive index (RI) and pulsatility index (PI) will be calculated.
214327703|NCT03023488|DEVICE|laser lithotripsy|The laser fiber extending into the cavities through the working channel of the ureteroscope is used to fragment the stones. Laser energy is generated by the laser machine and transmitted to the stones via the laser fiber.
214929208|NCT06622343|PROCEDURE|Wound Debridement|Patients who did not develop necrotizing skin infections received wound management, including multiple punctures using a three-edged needle for toxin drainage, along with standard wound care and debridement as necessary to prevent infection and promote healing.
214929209|NCT00351741|DEVICE|Ventilation - High Frequency Percussive Ventilation|Ventilatory support delivering high frequency percussive ventilation using the Volumetric Diffusive Respirator
214929210|NCT00351741|DEVICE|Ventilation - ARDSnet|Respiratory support with a conventional mode of ventilation using a conventional ventilator (Draeger Evita XL)
214929212|NCT00658775|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
214929213|NCT00658775|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
214929214|NCT02368743|DRUG|mesalazine|
214327704|NCT02423941|PROCEDURE|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
214327705|NCT02423941|PROCEDURE|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
214327706|NCT03033797|DEVICE|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
214327707|NCT03033797|DEVICE|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
214929215|NCT00588211|BEHAVIORAL|Interviews|45-minute individual interviews after the conclusion of their dental appointment
214929216|NCT00588211|BEHAVIORAL|focus group|A focus group of the preliminary cancer-related risk perception item pool.
214327708|NCT02346240|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/ mL~* Route of Administration: Subcutaneous use"
214327709|NCT02346240|BIOLOGICAL|Etanercept|"* Active Substance: Etanercept~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 50 mg / mL~* Route of Administration: Subcutaneous use"
214327710|NCT02346240|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
214327711|NCT04065919|DRUG|Liposomal bupivacaine|20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
214327712|NCT04065919|DRUG|0.25% Bupivacaine with epinephrine|0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
214327713|NCT06236009|DRUG|TAK-004|TAK-004 subcutaneous injections.
214327714|NCT06236009|DRUG|Placebo|Matching- placebo subcutaneous injections.
214327715|NCT03244306|BIOLOGICAL|Patient-derived CD22-specific CAR T-cells also expressing an EGFRt|Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt
214327716|NCT03894059|OTHER|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
214929217|NCT00588211|BEHAVIORAL|Survey|Quantitative item analysis of the final item pool.
214929218|NCT00588211|BEHAVIORAL|Survey|A second confirmatory factor analysis.
214929219|NCT05108142|OTHER|Dietary intervention|fresh, hot pasta and re-heated pasta
214929220|NCT01118793|DRUG|Clopidogrel|150 mg dosage of Clopidogrel for 7 to 10 days.
214929221|NCT02589990|BEHAVIORAL|Strength training|see arm description
214929222|NCT01453478|DRUG|GSK1325756|CXCR2 antagonist
214929223|NCT06287164|OTHER|Data collection|Data collection on heart failure therapy and follow up
214929224|NCT00191347|DRUG|pemetrexed|
214929225|NCT00191347|DRUG|gemcitabine|
214929226|NCT00002059|DRUG|Inosine pranobex|
214929227|NCT05314842|DRUG|Formocresol|dressing agents in pulpotomized primary molas using formocresol in cariously exposed vital primary molars
214929228|NCT05314842|DRUG|Premixed bioceramic MTA|dressing agents in pulpotomized primary molas using premixed bioceramic MTA in cariously exposed vital primary molars
214929229|NCT06760572|DEVICE|Airway insertion|Tube will be inserted into the trachea to make airway data measurements.
214929230|NCT06411730|DRUG|BMS-986368|Specified dose on specified days
214929231|NCT01510795|DRUG|spironolactone|Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
214929232|NCT06257927|BEHAVIORAL|Tuko Pamoja|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
214929233|NCT01883180|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
214327717|NCT06538688|PROCEDURE|Orthodontic extrusion of the impacted mandibular third molar by using the maxillary miniscrew and cross arch elastic power chain as a temporary anchorage device before extraction|Orthodontic extrusion of the impacted mandibular third molar of high-risk for nerve injury using maxillary TAD.
214327718|NCT05572502|BEHAVIORAL|plant-based diet|For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
214929234|NCT06668129|BEHAVIORAL|Back care intervention program|"The back care intervention consists of:~1. Nine oral presentations. Include Programa Suma't programme developed by the Provincial Council of Majorca.~2. Multisubject Teaching Unit.~3. Information campaign widespread by the school (i.e. posters, triptychs, school website, social networks, etc.)~4. The Back Care Day at school."
214929235|NCT06682260|DRUG|Nitroglycerin (NTG)|Infusion of intravenous nitroglycerin beginning at 2 microgram/kg/min (2 ml/hour) and titrated with the aim of a MAP reduction of 20-30%. Infusion rate will not be increased after the first 30 minutes and is limited to 0.1 µg/kg/min to 5 µg/kg/min.
214929236|NCT03242876|OTHER|Control|Control will be 109 g white bread to be consumed together with 200 mL water
214929237|NCT03242876|OTHER|Test|Test will be 109 g white bread to be consumed together with 3.819 g citric acid and 119 mg malic acid dissolved in 200 mL water adjusted to pH 3.2.
214929238|NCT02807298|DRUG|4%articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine
214327719|NCT01889017|OTHER|patient questionnaire (tablet pc based)|
214327720|NCT02961699|DEVICE|Transpose ® RT System|adipose-derived stem cell therapy
214327721|NCT02961699|OTHER|debridement/dressing of wound|standard of care debridement and wound dressing
214327722|NCT00237588|DRUG|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
214327723|NCT03906318|DRUG|Iticitinib|
214327724|NCT03718611|DRUG|BR9001|BR9001 is a test drug as generic
214327725|NCT03718611|DRUG|BR900A|BR900A is a reference drug
214327726|NCT03833284|BEHAVIORAL|Participant Barriers to TVU Screening|Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
214327727|NCT03833284|BEHAVIORAL|Provider Barriers to TVU Screening|Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
214327728|NCT05216367|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions
214327729|NCT00554749|BEHAVIORAL|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
214327730|NCT03109275|OTHER|Single complete MRI intervention|MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
214327731|NCT03417141|DRUG|Mechlorethamine 0.016% Top Gel|Valchlor, a 0.016% gel formulation of mechlorethamine. Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
214327732|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine high dose|Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.
214327733|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine low dose|Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.
214327734|NCT06167395|DIETARY_SUPPLEMENT|Control product|Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
214929239|NCT02807298|DRUG|2% Lignocaine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
214929240|NCT02807298|DRUG|Epinephrine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
214929241|NCT05209776|BIOLOGICAL|Peripheral immunological assessment on venous blood|Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube
214929242|NCT05209776|BIOLOGICAL|Immunological assessment carried out on intracardiac material|Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube
214929243|NCT06249737|BEHAVIORAL|Training|Each participan will train the kinematic control of each degree of freedom, according to each arm, playing a videogame using an inertial sensor.
214929244|NCT04183582|BEHAVIORAL|Behavioural Activation|"Behavioural Activation is a treatment for depression, the current programme has been adapted to suit the needs of postnatal women Session 1: Getting Started Session 2: Identifying Triggers, Reactions and Avoidance Patterns (TRAPs) Session 3: Turning TRACs in to Triggers, Reactions and Alternative Coping (TRACs) Session 4: Support and Communication Session 5: Being a Good Enough Mum Session 6: Staying Well"
214929245|NCT06674655|BEHAVIORAL|Motor Imagery Plus Therapeutic Exercise|This group will perform three days of lumbo-pelvic motor control exercise intervention along with a motor imagery intervention program during active breaks between exercises.
214327735|NCT06968845|DRUG|LTI-03|Caveolin-1-Scaffolding-Protein-Derived Peptide
214327736|NCT06968845|DEVICE|Dry Powder Inhaler|Plastiape Monodose RS01 Model 7
214327737|NCT06968845|DRUG|Placebo|Lactose powder
214327738|NCT04249804|DRUG|Magnesium Sulfate 1000 MG|intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
214327739|NCT05774899|DRUG|CB-103|First-in-class pan-NOTCH inhibitor, capsule taken orally.
214327740|NCT05774899|DRUG|Abemaciclib|CDK4/6 inhibitor, tablet taken orally.
214327741|NCT05774899|DRUG|Lenvatinib|Per standard care, capsule taken orally.
214327742|NCT04099667|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
214327743|NCT04099667|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
214327744|NCT04099667|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
214327745|NCT04099667|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
214327746|NCT04099667|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
214327747|NCT01159964|BIOLOGICAL|Immunotherapeutic GSK2302032A, different formulations|Intramuscular administration
214327748|NCT02165111|DRUG|Onabotulinumtoxin A|
214327749|NCT02165111|DRUG|sterile saline solution|
214327750|NCT02806479|OTHER|Observational: Arrhythmogenic Substrate|
214327751|NCT05137795|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
214327752|NCT05137795|DRUG|Placebo|Normal Saline Inhalation
214929246|NCT06674655|BEHAVIORAL|Therapeutic Exercise|This group will perform a lumbo-pelvic motor control exercise program for three consecutive days.
214929247|NCT06674655|BEHAVIORAL|Minimal intervention|This group will carry out a therapeutic counseling and minimal education intervention during a one-day intervention.
215070210|NCT06655298|DEVICE|US guided block|"Group Q; (28 patients) Quadratus lumborum block group; patients will receive general anesthesia initially then bilateral QLB type III (anterior subcoastal approach) with a volume of 30 mL of bupivacaine 0.25% for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg) \[9\].~✓ Group E; (28 patients) Erector spinae plane block; patients will receive general anesthesia initially then bilateral ESPB with a volume of 30 mL of bupivacaine 0.25 % for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg"
215070211|NCT05707442|PROCEDURE|Stent Implantation|Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to \> 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
215070212|NCT05707442|DRUG|Acetazolamide-based medical therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
215070213|NCT05707442|BEHAVIORAL|Weight loss|The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
215070214|NCT04935190|DIAGNOSTIC_TEST|Vitalpercept|Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography
215070215|NCT06811675|DRUG|Dexamethasone and N-acetylcysteine (NAC)|Dexamethasone 10mg IV STAT +QD for 3 days+NAC IV 200mg/kg over 4 hours, then 100 mg/kg over 16 hours
215070216|NCT06811675|DRUG|Placebo|Placebo
214327753|NCT05137795|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
214327754|NCT05403554|DRUG|Biological NI-1801|Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
214327755|NCT05403554|DRUG|NI-1801 in combination with anti-PD1 (Pembrolizumab)|In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
214327756|NCT05403554|DRUG|NI-1801 in combination with paclitaxel|The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
214327757|NCT05403554|DRUG|Paclitaxel|The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
215070217|NCT02221635|PROCEDURE|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
215070218|NCT02221635|DRUG|Risperidone|Risperidone (2-4 mg) was took orally.
215070219|NCT06657391|DRUG|recombinant humanized anti-CD25 monoclonal antibody|The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
214327758|NCT00972803|DRUG|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
214327759|NCT00972803|DRUG|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
214327760|NCT00972803|DRUG|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
214327761|NCT03214003|RADIATION|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
214929248|NCT00138398|BIOLOGICAL|Commercial TriValent Split Influenza Virus|
215070220|NCT06656650|BEHAVIORAL|Commensality groups|Participants will attend at least 3 out of 6 commensality groups over the course of 6 months.
214327762|NCT03214003|RADIATION|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
214327763|NCT00153491|DRUG|artemether-lumefantrine|
214929249|NCT05832905|BEHAVIORAL|Mobile and Wearable-assisted Case Management|The MCM group received case management and Mobile-and wearable recording. The actual intervention for Panic disorder, including pharmacotherapy or psychological treatment is the same as in MCM and TAU group
214327764|NCT03594591|DRUG|Antidiabetic treatment by usual care|Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
214327765|NCT02569047|PROCEDURE|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
214327766|NCT02569047|PROCEDURE|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
214929250|NCT05033262|OTHER|Our Memory Care Wishes|Our Memory Care Wishes is a web-based advance care planning platform designed for persons living with dementia in nursing homes to discuss and document healthcare and daily life preferences with the help of shared decision-makers. Penn researchers meet via Zoom with PLWD and their SDMS and nursing home staff to facilitate website completion.
214929251|NCT03193112|DRUG|Agomelatine 25 MG Oral Tablet|We will treat our patients with Agomelatine tablet of 25 mg.
214929252|NCT03518619|BEHAVIORAL|PFIcope+EMI|The intervention will be comprised of (1) an initial orientation session where the intervention is introduced, receipt of personalized normative information, motives feedback, and the development of an individual's personalized relapse prevention coping skills messages to be utilized through the course of the intervention; (2) EMA for monitoring of affect, drinking intention, alcohol use, and coping skills use; (3) EMI-tailored text messages sent based on EMA responses: individualized, self-chosen relapse prevention coping skills messages when participants report negative affect and intent to drink.
214929253|NCT04016038|OTHER|a psycho-social investigation|The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.
214929254|NCT02731937|DEVICE|GE Healthcare Revolution CT Scanner (CT Scanner)|Raw CT Scan Data
214929255|NCT03449654|DRUG|Liraglutide|Liraglutid
214929256|NCT03449654|DRUG|Placebo (for liraglutide)|Placebo (for liraglutide)
214929257|NCT05970276|DEVICE|Deep Sleep (N3) Enhancement with TES|As participants sleep, their sleep EEG will be measured and automatically scored by the computer to determine stage of sleep. When slow wave sleep is detected, low-level current (.5-1 mA total) will be applied through pre-set electrodes.
214929258|NCT05144308|PROCEDURE|Images of the operated eye (s)|Through the operating microscope or a slit lamp, dilated pupil. Taken on the day of surgery (D0) and at 1 week, 1 month and 3 months post-op
214929259|NCT02117921|BEHAVIORAL|One-on-one interview and educational sessions. Reading material for educational series provided.|A one-on-one interview with the patient and the principal investigator and group educational sessions.
214929260|NCT04729179|DRUG|Cannabidiol|Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
214929261|NCT04729179|DRUG|Placebo|Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
214929262|NCT01960270|DEVICE|Device: INTERSTIM II|A second stimulator is implanted on controlateral site
214929263|NCT06665243|BEHAVIORAL|Technology-enhanced horticultural activities|The indoor technology-enhanced horticultural activities will be delivered to people with dementia and their family caregivers through a smart grower. The smart grower is a hydroponic indoor grower that creates a controllable environment with auto optimization for growing healthy plants, fresh vegetables, herbs, and fruits. A mobile app will be connected to the grower for controlling the growing environment (e.g., lighting, watering), tracking the progress of the plants, and guiding the older people with dementia and their family caregivers in conducting the horticultural activities. The program will consist of eight face-to-face (F-T-F) horticultural activity training sessions for groups of 6-8 participants. The indoor program contains various horticultural, cognitive, and multisensory stimulation activities, such as asking PWD and family caregivers to record the sense of touch and odor when caring for the plants and to observe the various changes in the plants using the smart grower.
214327767|NCT03706690|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/ deterioration or confirmed radiological progression.
214327768|NCT03706690|OTHER|Placebo|Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
214929264|NCT01919684|DRUG|LGD-6972|
214929265|NCT01919684|DRUG|Placebo (Captisol®)|
214929266|NCT00811902|DRUG|Nerispirdine|tablet, oral administration
214929267|NCT00811902|DRUG|placebo|tablet, oral administration
214929268|NCT02057484|DRUG|Tacrolimus|oral
214929269|NCT03901833|BEHAVIORAL|Telemedicine Support|Telemedicine intervention
214929270|NCT03901833|OTHER|Standard of Care|Standard of Care
214929271|NCT03368885|OTHER|Maternal dietary diversity|Counsel pregnant women for proper dietary intake and create awareness among family members and community to support her on maternal nutrition
214929272|NCT03368885|OTHER|Diet diversity in complementary feeding|Counsel mothers of children of 6-23 months on diet diversity in complementary feeding by demonstration during home-visits and seek support from father and family members
214327769|NCT04450966|BEHAVIORAL|Computer-facilitated Screening and Brief Intervention|cSBI includes: 1) computer self-administered screening that adolescents complete prior to seeing their clinician, immediately followed by 2) computer-delivered brief psychoeducation on the health risks of substance use to prime patients for the clinician encounter, and 3) a Clinician Report Form with screen results and prompts that clinicians use to provide motivational interviewing-based individualized counseling during the visit.
214929273|NCT03368885|OTHER|Exclusive Breast Feeding|Counselling on exclusive breast feeding among children under 6 months-Provide information to mothers of children of 3-6 months for exclusive breast feeding through home visits, and mothers meetings
214929274|NCT03368885|OTHER|Community mobilization|Engagement of local/religious leader, husbands to support diet diversity for pregnant women and doctors and fathers to support diet diversity for complementary feeding
214929275|NCT03368885|OTHER|Capacity Building|Capacity Building-Training of Community mobilization coordinator and mentoring for knowledge enhancement on nutrition for pregnant women and children below 2 years
214929276|NCT03368885|OTHER|Use of existing platforms VHSND|Convergence- Strengthen Village Health Sanitation and Nutrition Day for creating awareness on diet diversity for maternal nutrition and complementary feeding
214929277|NCT03368885|OTHER|Strategic use of data|Strategic use of data-Data analysis for concurrent monitoring,planning and decision making to improve the performance of CMCs
214929278|NCT00570427|BEHAVIORAL|Problem Solving Therapy (PST)|Counseling
214327770|NCT03679871|OTHER|Questionnaire validation|"Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)"
214929279|NCT00570427|BEHAVIORAL|Medication Management|If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
214929280|NCT03726294|DRUG|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
214929281|NCT02824601|DEVICE|Laser|1-visit-treatment (n=12): Chemomechanical preparation (CMP) - CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP
214929282|NCT02824601|DRUG|Calcium hydroxide|2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
214929283|NCT04182269|OTHER|Measurement of functional exercise capacity|The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.
214929284|NCT03828552|OTHER|Questionnaire|"Parents will be recruited in a Pediatric Resuscitation Department of the Mother and Child Hospital for 3 months. The doctor taking care of a child and his parents meeting the eligibility criteria will distribute, during the stay, a questionnaire accompanied by a pre-stamped envelope to the two parents not opposing the study.~A phone call and / or an email reminder by the intern in the month of the exit will invite each parent to return the questionnaire.~The completed questionnaire will be mailed back by the parents using the pre-stamped envelope."
214929285|NCT03096678|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Using a comprehensive MR study (Function, LGE, Tissue Characterization, Strain, T1/T2 mapping) to predict the outcome of LBBB with different cardiac function.
214929286|NCT04174183|DEVICE|Closed-incision Negative-pressure Therapy - Dry dressing|A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .
214929287|NCT03546426|DRUG|Pembrolizumab|200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years
214327771|NCT00747968|DRUG|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
214327772|NCT02098109|DRUG|XM02 Filgrastim|
214327773|NCT02098109|DRUG|Filgrastim|
214327774|NCT02098109|PROCEDURE|Apheresis|
214327775|NCT02098109|DRUG|Plerixafor|
214327776|NCT02098109|PROCEDURE|Stem Cell Transplant|
214327777|NCT00496847|DRUG|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
214327778|NCT00496847|DRUG|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
214929288|NCT03546426|BIOLOGICAL|Autologous dendritic cells|Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses
214929289|NCT03546426|DRUG|Interleukin-2|3 MU s.c. from day +2 to day +6 after each DC administration
214327779|NCT04021264|DRUG|Ropivacaine-Sufentanil|Local anesthetic injection
214327780|NCT04021264|DRUG|Dextrose 5|Sham injection
214327781|NCT04123496|DEVICE|rTMS|Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
214327782|NCT03728894|DRUG|Midazolam-hydroxyzine with 100% O2|Patients received Oral Sedatives with 100% O2 ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
214327783|NCT03728894|DRUG|Midazolam-hydroxyzine with 50% N2O/O2|Patients received Oral Sedatives with 50% nitrous ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
214929290|NCT04285424|BIOLOGICAL|Fecal Microbiota Transplantation|The fecal collection produced from a single healthy donor, unrelated to the patients
214929291|NCT03139006|DEVICE|Dual-layer spectral detector CT|A dual energy CT approach
214929292|NCT04413552|DRUG|INDV-2000|INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.
214929293|NCT04413552|DRUG|Placebo|Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
214929294|NCT06772987|DEVICE|Accelerated rTMS treatment|1 Day x 3 Sessions of 19-minutes rTMS treatment, with 60 minutes rest between sessions.
214929295|NCT05496959|DRUG|Lutetium Lu-177 PNT2002|Given IV
214929296|NCT05496959|OTHER|Quality-of-Life Assessment|Ancillary studies
214929297|NCT05496959|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214327784|NCT03072485|DRUG|Sirolimus|Topical sirolimus applied to the skin
214327785|NCT03072485|DRUG|Metformin|Topical metformin applied to the skin
214327786|NCT03072485|DRUG|Diclofenac|Topical diclofenac applied to the skin
214327787|NCT06232382|OTHER|Hypnosis audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Hypnosis audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session (5 minutes).~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires (5 minutes).~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
214929298|NCT01188876|DRUG|carboplatin|Given intravenously on Day 1 of each 28-day cycle
214929299|NCT01188876|DRUG|pralatrexate|Given intravenously on Day 1 and Day 15 of each 28-day cycle.
214929300|NCT01188876|DRUG|Folic Acid|Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
214929301|NCT01188876|DRUG|Vitamin B12 Injection|Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
214929302|NCT02070627|DRUG|Indocyanine Green (ICG)|60-30 minutes prior to cholecystectomy, 2.5 mg of indocyanine green (ICG) will be injected intravenously. An additional 2.5 mg of ICG may be injected intraoperatively if the fluorescence fades prior to imaging.
214929303|NCT02070627|DEVICE|Near Infrared Fluorescence Cholangiography (NIRF-C)|Near infrared fluorescence cholangiography will be performed intraoperatively in order to image anatomy.
214929304|NCT00941499|DRUG|HAI Oxaliplatin|140 mg/m\^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
214929305|NCT00941499|DRUG|5-FU|900-1750 mg/m\^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
214929306|NCT00941499|DRUG|Bevacizumab|10 mg/Kg by vein on Day 1 of 21 day cycle.
214929307|NCT00941499|DRUG|Cetuximab|Loading dose of 250-500mg/m\^2 and Maintenance dose of 125-250 mg/m\^2 by vein on Day 1 of 21 day cycle.
214929308|NCT00941499|DRUG|Leucovorin|200 mg/m\^2 by vein on Days 1 and 2 of each 21 day cycle.
215070221|NCT06662084|DIAGNOSTIC_TEST|phenotype|"Eligible patients will receive orally the cocktail probe drugs ( via a naso-gastric tube at D3 after tMCS implantation or after the beginning of the cardiogenic shock for the control group) and via an oral administration at 14 days after tMCS explantation (or cardiogenic shock termination for the control group defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency). The phenotyping probe drugs of the Geneva Cocktail will be given as: one capsule containing the remaining probe 'cocktail' drugs. According to clinical experience in our intensive care unit department, inflammation related to tMCS peaks at D3 after tMCS implantation.~Blood samples will be collected from the central venous line 2 hours after drug administration for CYP phenotyping and genotyping. Inflammatory markers blood levels (Il-6, TNF-α, Il-1β, IFN-γ) will be measured at tMCS implantation or shock initiation and at the same time than CYP phenotyping."
214929309|NCT00941499|DRUG|5-FU|300-400 mg/m\^2 bolus + 600-1000 mg/m\^2 infusion over 22 hours on Days 1-2 of each cycle.
214929310|NCT00941499|DRUG|Bevacizumab|7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
214929311|NCT01985087|RADIATION|Hypofractionated radiotherapy|Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.
214929312|NCT01985087|DRUG|Temozolomide|During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
214929313|NCT00206687|BIOLOGICAL|Spheramine (BAY86-5280)|Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
214929314|NCT00206687|PROCEDURE|Placebo|Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
214929315|NCT04754958|DEVICE|Immersion in virtual reality using Nordic Neurolab(™) Visual System|In addition to the standard MRI procedure, the VR intervention group will be looking at stereoscopic computer generated images through a pair of head-coil-mounted googles (Nordic Neurolab ™ Visual System). Two markers (color balls) will be fixed on their knees to capture their movement (camera tracking from the outside of the MRI room). The VR scenario will consist in showing a replication of the actual MRI examination room, as seen from the point of view of the participant lying on the MRI bed, but without the MRI tunnel. Participant can see themselves in the large room (a simplified gender-matched avatar), and an entertaining video can be displayed.
215070222|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the Left DLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI).
215070223|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the right VLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med)
215070224|NCT06658795|DEVICE|Sham stimulation group|The electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.
214486203|NCT06741384|OTHER|Diaphragmatic breathing exercises|Participants will be directed to position their hands on the rectus abdominis muscle located under the anterior chest wall while resting in a hook position. They will be instructed to inhale slowly and deeply via the nostrils, expanding their abdomen without raising their upper chest, and resting their shoulders. Following the cessation of respiration, the woman will slowly exhale by pursing her lips. A respiratory cycle will consist of a three-second inhalation, a three-second pause, and a six-second exhalation. The diaphragmatic training regimen will consist of doing 3-5 sets of 5-10 deep breaths, with 2-minute intervals of rest in between sets.
214673248|NCT04317482|BEHAVIORAL|Stressful experience in the ED|Participants will be asked to imagine and then describe both feelings and bodily sensations experienced at their most stressful ED visit, in order to help them more fully re-experience the situation. In this regard, the second condition is more similar to stress imagery employed by Sinha et al, which elevated cortisol to a greater degree than a social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
214673249|NCT03165981|BIOLOGICAL|PCV13|ACIP Recommended vaccine
214673250|NCT03165981|BIOLOGICAL|DTaP|ACIP Recommended vaccine
214929316|NCT05837104|DRUG|Magnesium vitamin B6|Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
214929317|NCT05837104|DRUG|Placebo|Placebo tablet, three times daily for four weeks.
215070227|NCT06661174|PROCEDURE|Bariatric surgery|Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function
215070228|NCT06661174|OTHER|Non-surgical therapy|Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.
215070229|NCT06660927|DEVICE|liac Bifurcation Stent Graft System|to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA)
215070230|NCT06658106|BEHAVIORAL|Thera-Band Elastic Band-Assisted Progressive Resistance Training|Thera-Band Elastic Band-Assisted Progressive Resistance Training: This intervention involves a structured exercise program using Thera-Band elastic bands for resistance training, conducted three times a week for 12 weeks. Each session lasts approximately 50 minutes and includes exercises targeting major muscle groups, such as upper arms, shoulders, chest, lumbar, and lower limbs. Participants will perform each exercise for 8-12 repetitions in 2-3 sets with 1-minute intervals, aiming for an intensity of 60%-80% of their maximum heart rate. The program is designed to improve strength, balance, and overall physical function, thereby reducing frailty in older adults with diabetes.
214673251|NCT03165981|BIOLOGICAL|IIV|ACIP Recommended vaccine
214673252|NCT05176847|BEHAVIORAL|Podcasts and tips of the day (within app)|Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.
214327788|NCT06232382|OTHER|Mindfulness meditation audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Mindfulness Meditation audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
214327789|NCT06232382|OTHER|Natural text audio (control audio)|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Control audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
214929318|NCT05237102|PROCEDURE|Cerebrospinal fluid shunt|"The procedure is designed to reduce the amount of cerebrospinal fluid in a patient's brain by draining it through a shunt tube:~①V-P shunt is suitable for most types of hydrocephalus; ②L-P shunt is suitable for traffic hydrocephalus and positive pressure hydrocephalus, and patients with lower cerebellar tonsil hernia are contraindications; ③ Common terms of ventriculoatrial (V-A) shunt are not suitable for V-P shunt (abdominal infection, serious respiratory and circulatory diseases are contraindications); ④ The third ventriculostomy is suitable for patients with non-traffic and partial traffic hydrocephalus （infants and patients with severe ventricular enlargement should be cautious, and patients with shunt tube cannot be placed due to ventricular conditions）; ⑤Other shunt methods include septum pellucidum fistula and Torshunt （ventriculo-occipital cistern shunt after tumor resection）"
214929319|NCT04905602|DRUG|SHR-1905/placebo|"Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose"
214929320|NCT06939335|DEVICE|Disposable PEEP Valve set at 5 cm H20.|Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 and a 22 mm disposable PEEP Valve set at 5 cm H20.
214929321|NCT06939335|DEVICE|Controle|Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 without a disposable PEEP Valve.
214929322|NCT02700373|DRUG|PDC-APB|
214327790|NCT04917276|DIAGNOSTIC_TEST|Circulating tumor cell|Detecting CTC in different time points of treatment (like PR, PD, pre and post-operation)
214327791|NCT03528434|DIETARY_SUPPLEMENT|Zinc|10mg dispersible zinc sulfate tablet
214327792|NCT03528434|OTHER|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
214327793|NCT05218759|DRUG|Anlotinib|anlotinib administration at a dose of 10 mg daily
214327794|NCT04321304|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
214327795|NCT04321304|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
214327796|NCT04321304|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
214327797|NCT00847275|OTHER|Exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
214673253|NCT05176847|BEHAVIORAL|mLIFE app (self-regulation features)|Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.
214673254|NCT05176847|BEHAVIORAL|mLIFE app (social support features)|"The gamified mLIFE app contains several components to help facilitate social gaming and support. This includes a newsfeed, to view the progress of other users, the ability to send others encouragement (likes/thumbs-up) for achieving goals, user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.~For the experimental group, the app also includes features that facilitate healthy competition among participants through receipt of points for provision of social support and tracking health behaviors."
214929323|NCT02700373|DRUG|Placebo|
214929324|NCT05542628|OTHER|No intervention included|No intervention included
214929325|NCT03625765|DEVICE|SmartGoggles|the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
214929326|NCT01741792|DRUG|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
214929327|NCT06394466|OTHER|Non Applicable|Non Applicable
214929328|NCT04349059|OTHER|Animal based diet|Food will be provided by Montefiore-Einstein Food Services
214929329|NCT04349059|OTHER|Plant based diet|Food will be provided by Montefiore-Einstein Food Services
214929330|NCT03268759|OTHER|fMRI|Observation of neural markers of reward processing
214929331|NCT00555126|DEVICE|Forced Air Warming|Warming after Randomization
214929332|NCT00555126|DEVICE|Warming with endovascular catheter + forced air warming|Warming after Randomization
214929333|NCT04499300|OTHER|Data collection from medical files|Data collection from medical files
214929334|NCT00112528|BIOLOGICAL|bevacizumab|
214929335|NCT00112528|DRUG|gemcitabine hydrochloride|
214929336|NCT00112528|DRUG|oxaliplatin|
214929337|NCT05863507|DIETARY_SUPPLEMENT|Grape powder supplementation|The participants will be willing to consume the grape powder dissolve in water daily for 6 weeks
214929338|NCT05863507|DIETARY_SUPPLEMENT|Placebo|The participants will be willing to consume the placebo powder, similar to the grape powder, dissolve in water daily for 6 weeks
214929339|NCT06193811|DRUG|Avenciguat (BI 685509) (intended commercial formulation (iCF))|Avenciguat (BI 685509) (intended commercial formulation (iCF))
214929340|NCT06193811|DRUG|Avenciguat (BI 685509) (trial formulation 2 (TF2))|Avenciguat (BI 685509) (trial formulation 2 (TF2))
214929341|NCT06193811|DRUG|esomeprazole|esomeprazole (Nexium mups)
214929342|NCT02222545|BIOLOGICAL|OMS721|
214929343|NCT06576960|DRUG|Nano silver fluoride varnish and tri calcium phosphate varnish|Fluoride varnishes
214929344|NCT00761280|DRUG|trabedersen|
214929345|NCT00761280|DRUG|temozolomide|
214929346|NCT00761280|DEVICE|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
214929347|NCT00761280|PROCEDURE|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
214929348|NCT00761280|DRUG|carmustine|
214929349|NCT00761280|DRUG|lomustine|
214929350|NCT02918474|OTHER|Decision Aid|Use decision making tool
214929351|NCT02918474|OTHER|Questionnaire Administration|Ancillary studies
214929352|NCT01938430|DRUG|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
214929353|NCT01938430|DRUG|RBV|RBV tablets administered orally in a divided daily dose
215070231|NCT06658106|BEHAVIORAL|Conventional Diabetes Management|Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.
214929354|NCT00462592|DRUG|budesonide|inhaled budesonide turbuhaler 200ug taken 1 puff morning \& 1 puff evening.
214929355|NCT00462592|DRUG|montelukast|montelukast 5 mg ( \< 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
214929356|NCT00462592|OTHER|placebo|placebo
214929357|NCT03875482|DRUG|Risankizumab|Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously
214929358|NCT03875482|DRUG|Placebo solution for risankizumab|Placebo solution in prefilled syringes, self-administered subcutaneously
214929359|NCT00949403|DRUG|Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate|injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism
214929360|NCT03511040|DEVICE|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
214929361|NCT06366516|DIAGNOSTIC_TEST|Methylation Test|"Participants who aged 25-65 years with high-risk HPV infection are recruited.To start with,cervical exfoliated cells are collected, coded (according to the actual enrollment sequence), and stored in the pathology department where methylation testing is performed.In addition,patients will underwent colposcopy and biopsy.~Patients are followed up by cytology, high-risk HPV and methylation tests at 6 and 12 months after enrollment.Cervical conization and hysterectomy will be taken if necessary according to histopathological results. The clinical endpoint is reached when CIN2+ is confirmed by histopathological result."
214929362|NCT03156842|DRUG|Fimasartan/Amlodipine, Rosuvastatin|"A fixed dose combination tablet of Fimasartan and Amlodipine and Rosuvastatin will be administrated once daily on treatment period."
214929363|NCT03156842|DRUG|Fimasartan/Amlodipine|"A fixed dose combination tablet of Fimasartan and Amlodipine will be administrated once daily on treatment period."
214929364|NCT03156842|DRUG|Fimasartan, Rosuvastatin|"Fimasartan and Rosuvastatin will be administrated once daily on treatment period."
214929365|NCT06665711|PROCEDURE|3% Hypertonic Saline|In this arm of the study, participants will receive nebulized 3% hypertonic saline as the primary treatment for bronchiolitis. The administration of hypertonic saline is aimed at reducing airway edema and improving mucociliary clearance in infants experiencing respiratory distress due to bronchiolitis.
214929366|NCT06665711|PROCEDURE|Intervention: Salbutamol (Ventolin)|In this arm of the study, participants will receive nebulized Salbutamol, a bronchodilator commonly used in the management of bronchospasm associated with respiratory conditions, including bronchiolitis. The objective is to evaluate the effectiveness of Salbutamol in comparison to 3% hypertonic saline in improving the clinical outcomes of infants with bronchiolitis.
214929367|NCT01813253|DRUG|Irinotecan|150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops
214929368|NCT01813253|DRUG|Nimotuzumab|400mg IV once weekly until progression or unacceptable toxicity develops
214929369|NCT01432912|BEHAVIORAL|Physician Educational Seminar|Participating Physicians will attend an hour long seminar on smoking cessation counselling.
214929370|NCT05120518|OTHER|Collection of post mortem tissue donation|Collection of post mortem tissue from pediatric participants with cancer and non-cancer tumor types from whom post mortem tissue donation and autopsy consent is obtained.
214929371|NCT06665282|DEVICE|Pulsed high intensity laser therapy|"The study employs a BTL-6000 high-intensity laser therapy (12 W) to apply high intensity laser therapy to deep tissues. high intensity laser therapy therapy uses powerful beams (\>500 mw) to penetrate deeper, delivering high multi-directional energy in a short time. Pulsed laser therapy, a form of high intensity laser therapy therapy, enhances cell metabolism without disrupting it.~High-intensity laser therapy is a safe treatment method consisting of three phases. The first phase involves fast scanning around the wrist, hand, and fingers, with fluencies set at 510, 610, and 710mJ/cm2. The second phase involves holding the handpiece vertically to 90° on 10 fixed points around the metacarpophalangeal and interphalangeal joints, each radiated for 15 seconds, and a total dose of 1500 J. The third phase is the same but at a slower rate, with a total energy of 300 J."
214327798|NCT00847275|OTHER|Geriatric follow-up|"250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
214673255|NCT05176847|BEHAVIORAL|standard mLIFE app (social support features)|"The standard mLIFE app has the ability to send others encouragement (likes/thumbs-up) for achieving goals and a user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members."
214673256|NCT04294264|DRUG|Oxaliplatin|Given IV
214673257|NCT04294264|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214929372|NCT06665282|DEVICE|sham pulsed high intensity laser therapy|Patients in the control group will receive sham high-intensity laser therapy, where all parameters will be set up without switching on the start button and high intensity laser therapy machine is switched on with a visible light beam only
214929373|NCT06665282|OTHER|Routine physical therapy program|All patients of the study and control groups will receive the same routine physical therapy program for 30minutes and three times per week for successive eight weeks in the form of hot therapy, stretching and strengthening exercises. Hot therapy, in the form of warm baths for 10minutes, is applied before stretching exercises on the wrist joint and fingers to relieve joint pain and increase the range of motion. Strengthening exercises are in the form of isometric exercise for hand muscles and fingers to maintain muscles strength and joints flexibility
214929374|NCT05045781|DRUG|Eptinezumab|single iv infusion
214929375|NCT04324346|DRUG|FEC75 (or EC90) x 6|Type of Chemotherapy
214929376|NCT04324346|DRUG|FEC100 + Taxotere (EC90 + Taxotere) 3+3|Type of Chemotherapy
214929377|NCT04324346|DRUG|Paclitaxel|Type of Chemotherapy
214929378|NCT05193617|DRUG|GP+Penpulimab+Anlotinib|GP combine with penpulimab and anlotinib neoadjuvant therapy+CCRT+penpulimab adjuvant therapy
214929379|NCT05193617|DRUG|GP+Penpulimab|GP combine with penpulimab neoadjuvant therapy+CCRT+penpulimab adjuvant therapy
214929380|NCT04193956|OTHER|Standard-of-care procedures|Patients receive standard of care anti-PD-1 treatment as monotherapy or in combination with other checkpoint inhibitors. Related assessments, as laboratory assessments, CT-thorax-abdomen and FDG-PET will be performed according to clinical routine procedures.
214929381|NCT04193956|OTHER|Study procedures|Patients will undergo tumor biopsies, venous blood sampling and feces sampling in combination with a food questionnaire before, during and at the end of standard of care anti-PD-1 treatment.
214929382|NCT02111785|DRUG|Dexamethasone|Treatment with a short course of oral dexamethasone
214929383|NCT02111785|PROCEDURE|Burr Hole Craniostomy|Treatment with surgical burr hole craniostomy and evacuation of SDH
214929384|NCT01844661|BIOLOGICAL|CELYVIR|
215070232|NCT06659133|OTHER|Music intervention|"The women participating in the study were divided into control and experimental groups.~The control group included women who underwent pipelle endometrial biopsy with routine care, and the experimental group included women who underwent pipelle endometrial biopsy accompanied by music. Pipelle endometrial biopsy was performed by the same physician working in the Department of Obstetrics and Gynecology at the hospital. Patients in both groups were interviewed 10 minutes before the endometrial biopsy procedure and the Personal Information Form and State and Trait Anxiety Scale were applied. The application of the GKO was explained to the patients before the pipelle endometrial biopsy procedure. Before the pipelle endometrial biopsy, all patients were routinely given local anesthesia with 8 cc of 2% lidocaine solution and waited for 5 minutes after the application of local anesthesia.~During the pipelle endometrial biopsy, the experimental group was given a music recital from an mp3 play"
215070233|NCT04613492|BIOLOGICAL|MEDI9253|Participants will receive either single or multiple dose of MEDI9253; sequentially or concurrent with Durvalumab
215070234|NCT04613492|BIOLOGICAL|Durvalumab|Participants will receive durvalumab treatment sequentially or concurrently with MEDI9253
215070235|NCT06654284|OTHER|quality of life questionnaires|"All patients will receive a combination of quality of life questionnaires aimed at predeifined time points (baseline, 3 months, 1 year, 3 year, 6 year, 9 year and 12 year) collecting a complete overview of different aspects of quality of life, including: - Florida patient acceptance score (FPAS) - Short Form Health Survey (SF-12) - Kansas City Cardiomyopathy Questionnaire (KCCQ-12) - Hospital Anxiety and Depression Scale (HADS) - Florida Shock Acceptance score (FSAS) - Steinke Sexual Concerns Inventory - the Good Death questionnaire"
215070236|NCT04254653|BEHAVIORAL|American Indian and Alaska Native What Can I Eat?|Participants will engage in 5 \~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
215070237|NCT00753103|BIOLOGICAL|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
215070238|NCT00753103|DRUG|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
215070239|NCT00753103|DRUG|Prednisolone|Daily oral 1mg/kg tapered over 12 months
215070240|NCT00753103|DRUG|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
215070241|NCT00753103|PROCEDURE|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine \> 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
214327799|NCT00443183|BEHAVIORAL|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
214327800|NCT00443183|BEHAVIORAL|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
214327801|NCT01652456|OTHER|Addiction support|one consultation with an addiction specialist
214327802|NCT06104189|DIAGNOSTIC_TEST|MRI|MRI based classification of breast cancer histological factors and subtypes
214929385|NCT04026893|PROCEDURE|Uterine Transplant from Deceased Donor|The recipient will be started on anti-rejection medications (as is routine for transplant recipients) prior to the OR. Standard of care anesthesia and line placement will take place. The recipient will be appropriately identified as an organ recipient and the donor organ identified per required transplant protocols already in place. The recipient team will then connect the vasculature and appropriate supporting structures for the uterus transplant. Once the organ has been re-perfused, the remainder of the operation will take place and the patient will be moved to the Intensive Care Unit and later to the transplant patient floor for standard monitoring.
214327803|NCT00019435|BIOLOGICAL|LMB-9 immunotoxin|
214929386|NCT03790228|DRUG|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
215070242|NCT00753103|DRUG|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
215070243|NCT00753103|DRUG|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
215070244|NCT03684603|BEHAVIORAL|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
214327804|NCT05954234|OTHER|Postural re-education|"Each session of the experimental approach will be composed of 40 minutes of postural exercise. Participants will be asked to maintain two different postures to stretch both the anterior and posterior muscle chains. The first posture will consist of lying on the back maintaining the extension of the legs to release the respiratory diaphragm and stretch the anterior muscle chain. For the second posture, participants wiil be asked to lie on their back with their legs flexed to stretch the posterior chai. For each posture, the physical therapist will use verbal commands and manual contact to maintain alignment and make the necessary postural corrections to optimize the stretching and discourage compensatory movements.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
214327805|NCT05954234|OTHER|Spinal mobilization|"This approach will consist of 40 minutes of thoracolumbar spine mobilization. Two different mobilizations will be carried out. In the first one the patient will be in sitting position with both legs out of the bed and a mobilization in antero-posterior direction will be provide by the physiotherapist; the second one will consist in rotational mobilisation provide with the patient in lateral decubitus position.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
214327806|NCT05954234|OTHER|Perineal Exercises|Perineal Exercises will be performed in both the allocated approach. The protocol will consist in 10 minutes of perineal contraction and relaxation and 10 minutes of stretch-reflex for a total of 20 minutes of perineal exercises.10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks.
214929387|NCT06247007|PROCEDURE|Electroacupuncture|LI-4, LI-11, GV-14, GV-20 acupuncture points were needled bilaterally.
215070245|NCT03684603|BEHAVIORAL|melody only during motor training|sequence of tones which are presented to the patient using earphones
215070246|NCT06659354|BEHAVIORAL|Pregnant Body Project (PBP)|The Body Project is typically delivered as four 1-hour weekly sessions consisting of written, verbal, and behavioral exercises. The sessions aim to induce cognitive dissonance by encouraging participants to challenge the thin-ideal, a theoretically and empirically supported component of ED prevention. This adapted version of the Body Project (the Pregnant Body Project; PBP) consists of 6 1-hour, weekly group sessions delivered via Zoom. Since the target population consists of individuals with histories of an ED or disordered eating behaviors, PBP also includes elements from a treatment intervention (i.e., the Body Project Treatment 8.0 manual). PBP was adapted iteratively with a needs assessment, expert stakeholder input, and participant feedback following a mock trial with individuals with lived experience (i.e., individuals with histories of an ED who have given birth). This condition will be peer-delivered by facilitators with lived experience.
215070247|NCT06659354|BEHAVIORAL|Pregnancy Health Education (PHE)|This time- dose- and attention- matched control condition accounts for the potential effects of time spent and support from group members and facilitators. Participants assigned to the PHE group will also be asked to attend 6, 1-hour, weekly group sessions via Zoom. During the sessions participants receive psychoeducation on body image and disordered eating during pregnancy but will not engage in any dissonance-inducing exercises. Participants will also receive lifestyle education specific to pregnancy (e.g., proper nutrition, sleep, physical activity), tied back to body image and disordered eating.
214327807|NCT04647058|PROCEDURE|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
214327808|NCT04647058|PROCEDURE|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
214327809|NCT00017758|DRUG|Pravastatin sodium|
214327810|NCT00017758|DRUG|Simvastatin|
214327811|NCT00017758|DRUG|Atorvastatin calcium|
214673258|NCT05454176|DEVICE|Libre 2|"The unblinded FreeStyle Libre 2 CGM will be placed every two weeks during months 0-12 for the CGM Cohort. Patients will be taught to insert the sensor themselves.~They will be given a 1 month supply at each monthly clinic visit and extra sensors in case a sensor falls out early. Patients will be given SMBG test strips to test capillary glucose for confirmation of any CGM glucose level \<=60mg/dl. They will keep track of the number of times this is necessary. Patients will return used sensors at each clinic visit. The study team will upload the data to a study website. Patients and care providers will have access to unblinded sensor data for clinical use."
214327812|NCT00017758|DRUG|Nelfinavir mesylate|
214327813|NCT00017758|DRUG|Efavirenz|
214327814|NCT00648219|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fed
214327815|NCT00648219|DRUG|Benicar® Tablets 40 mg|40mg, single dose fed
214327816|NCT02143843|DRUG|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
214327817|NCT05117944|OTHER|"drama-supported patient role experience"|The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
214327818|NCT03560713|DEVICE|Functional Electrical Stimulation (FES)|Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
214327819|NCT03560713|OTHER|Functional Electrical Stimulation (FES) sham|Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
214327820|NCT04768647|DEVICE|TNM|TNM is a small portable head set that can be used by the participants at home to stimulate the vestibular system
214327821|NCT03781518|PROCEDURE|ridge splitting in group and khoury shell technique in the other group|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
214327822|NCT00665184|BEHAVIORAL|Resistance Exercise via Negative Eccentric Work|High intensity resistance training delivered 2-3 times per week for 12 weeks
214327823|NCT00665184|BEHAVIORAL|Standard care exercise training|Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
215070248|NCT06659731|OTHER|Quantitative Sensory testing (QST)|The QST protocol (Rolke et al., 2006; Blankenburg et al., 2010), implies the administration of 7 short sensory test in order to measure up to 13 parameters, which can be grouped as follows: thermal detection thresholds for the perception of cold, warm and paradoxical heat sensations, thermal pain thresholds for cold and hot stimuli, mechanical detection thresholds for touch and vibration, mechanical pain thresholds and sensitivity for pinprick and blunt pressure, vibration detection threshold and pressure pain threshold.
215070249|NCT06659731|OTHER|EEG|EEG recording at rest and while receiving heat stimuli to study cortical processing of salient thermal stimuli. Up to 30 painful thermal stimuli, will be delivered to the patients' hand dorsum in order to register contact heat evoked potentials (CHEPs).
215070250|NCT06658769|OTHER|Theta Burst Stimulation|Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation (NIBS) technique that involves modulating brain excitability and activity, which can increase or decrease depending on the parameters used. Theta Burst Stimulation (TBS) mimics the brain's natural firing patterns more closely and may have greater effects on cognitive performance.
215070251|NCT06658769|OTHER|Theta Burst Stimulation Sham|Theta Burst Stimulation simulated with 90º coil orientation with lower part external to the scalp.
215070252|NCT06659081|PROCEDURE|socket shield technique|partial extraction therapy : sectioning the root and keeping part of it in contact with labial plate of bone
215070253|NCT06659081|PROCEDURE|subepithelial connective tissue graft|A connective tissue graft harvesting from maxillary tuberosity area
215070254|NCT06659081|PROCEDURE|implant placement|implant placement
215070255|NCT05691062|DEVICE|Titanium Fusion Device|Titanium fusion device will be utilized for one-level lumbar fusion.
215070256|NCT05691062|DEVICE|PEEK Fusion Device|PEEK fusion device will be utilized for one-level lumbar fusion.
215070257|NCT05434065|DRUG|Celecoxib 200mg|Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
215070258|NCT02408718|BEHAVIORAL|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
215070259|NCT00772915|DRUG|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
214327824|NCT03144882|DRUG|Curcumin Pill|Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin
214327825|NCT03144882|DRUG|Placebo|placebo
214327826|NCT02327923|DRUG|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
214327827|NCT02327923|DRUG|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
214327828|NCT02327923|DRUG|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
214327829|NCT02327923|DRUG|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
214327830|NCT02327923|DRUG|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
214673259|NCT05454176|DEVICE|Device for SMBG and Libre Pro|"A glucose meter and sufficient teststrips for fingerpoke glucose monitoring 3x/day will be provided for months 1-6. This is standard-of-care in Uganda. Glucose meters will be downloaded monthly in clinic as per usual clinical practice.~DeviceBlinded CGM device: Libre Pro (blinded data collection device, not an intervention) The blinded FreeStyle Libre Pro CGM will be inserted at each monthly clinic visit to provide control data, months 0-6 for the Control Group. They will return all used sensors at each clinic visit. The study team will upload the data to a study website. Neither patients nor the local research teams will have access to the blinded sensor data for clinical use until the end of months 0-6 so as not to influence standard diabetes management. They will instead rely on SMBG values as per usual routine.~After the first 6 months they will receive Libre 2 CGM systems as described above for the intervention group."
214929388|NCT03692793|OTHER|Pulmonary rehabilitation|Patients will perform continuous aerobic training (treadmill walking) during 30min (60% of the 6MWT mean speed) and progression according to dyspnea (4-6 of the modified Borg scale). Upper limbs resistance training will be performed using the modified diagonals from the proprioceptive neuromuscular facilitation method (2 sets of 2min). Lower limbs strength training will be performed for quadriceps and triceps sural (2 sets of 10 repetitions), with progression when the patients report that the exercise are ´easy´. All the muscle exercised and the breathing accessory muscles will be stretched for 30s. Eleven educational sessions will be delivered addressing topics related to COPD self-management.
214929389|NCT03755869|DRUG|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
214929390|NCT04519320|DIAGNOSTIC_TEST|Pulmonary function testing|"D0: date of first symptoms of SARS-COV-2~M3: D0 + 3 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan~* Pulmonary function testing (PFT)~* 6-minute walk test (6MWT)~* MOS SF-36 Questionnaire~* HADS scale~* Ventilatory polygraphy~M6: D0 + 6 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~M12: D0 + 12 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan (If anomaly found at M3)~* PFT~* Pulmonary Exercise Stress Test~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~Subsequent follow-up will be performed only in patients with an alteration defined by a DLCO \<LLN and / or an abnormality objectified at CT-Scan attributable to SARS-CoV-2.~M24, M36, M48 and M60: D0 + 24, 36, 48, 60 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale"
214673260|NCT04537390|DIAGNOSTIC_TEST|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
214673261|NCT06396156|PROCEDURE|Anterior enclavation|Anterior enclavation of iris-claw lens
214673262|NCT06396156|PROCEDURE|Posterior enclavation|Posterior enclavation of iris-claw lens
214673263|NCT01894516|DRUG|GLPG0634|GLPG0634 capsules.
214929391|NCT06281210|PROCEDURE|Omission of surgical treatment|Omission of surgery in patients with pCR after neoadjuvant chemotherapy and negative VABB biopsy
214929392|NCT01287949|BIOLOGICAL|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later
214929393|NCT00979875|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
214929394|NCT00979875|DRUG|Insulin lispro|
214929395|NCT00979875|DRUG|Insulin glulisine|
214929396|NCT00979875|DRUG|Insulin aspart|
214929397|NCT02606006|BEHAVIORAL|Canine Animal-Assisted Therapy|Canine Animal-Assisted Therapy is the inclusion of a certified therapy canine in the standard of care physical therapy session, such as for walking, fetching balls, standing/petting, etc.
214327831|NCT02327923|DRUG|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
214327832|NCT02327923|DRUG|Vecuronium|Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
214327833|NCT02327923|DRUG|Atropine|Inj Atropine 0.4 mg IV will be given for bradycardia (HR \< 50/min)
214327834|NCT02327923|DRUG|Ephedrine|
214327835|NCT02327923|DRUG|Morphine|
214327836|NCT02327923|DRUG|Ketorolac|
214327837|NCT02327923|DRUG|Ondansetron|
214327838|NCT02327923|DRUG|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
214327839|NCT02327923|DRUG|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
214327840|NCT02327923|DRUG|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
214327841|NCT02327923|DRUG|Glycopyrrolate|10 mcg/kg with neostigmine
214327842|NCT01148602|OTHER|LED stopwatch-clock timers|"We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation."
214327843|NCT01822132|DRUG|Extended release naltrexone|
214327844|NCT01822132|DRUG|Placebo|
214327845|NCT04389125|DIETARY_SUPPLEMENT|Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures|One packet once a day, after breakfast, for 12 week
214327846|NCT04389125|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 week
214673264|NCT01894516|DRUG|Placebo|Placebo capsules.
214929398|NCT02606006|BEHAVIORAL|Standard of Care Physical Therapy|This intervention is the standard of care physical therapy currently offered. No canine is present.
214929399|NCT00682370|DRUG|saline solution|intravenous infusion, single dose
214929400|NCT00682370|DRUG|heme arginate|"intravenous infusion, single dose~0.3 mg/kg heme arginate"
214929401|NCT00682370|DRUG|heme arginate|"intravenous infusion, single dose~1 mg/kg heme arginate"
214929402|NCT00682370|DRUG|heme arginate|"intravenous infusion, single dose~3 mg/kg heme arginate"
214929403|NCT03644485|DRUG|Tacrolimus immediate-release formulation|oral
214929404|NCT03644485|DRUG|Tacrolimus prolonged-release formulation|oral
214929405|NCT03644485|DRUG|Induction therapy|All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
214929406|NCT03644485|DRUG|Mycophenolic acid drugs|All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
214929407|NCT03644485|DRUG|Corticosteroids|All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
214929408|NCT03251261|DEVICE|illumigene CMV assay, illumipro-10|CMV assay for detection of CMV
215070260|NCT00772915|DRUG|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
215070261|NCT00256035|PROCEDURE|Measuring IL-4 levels|
215070262|NCT06607653|DEVICE|Olfactory training|Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.
215070263|NCT06608082|DIAGNOSTIC_TEST|indocyanine green injected intravenously|During the procedure, after performing the hysterectomy, indocyanine green will be injected intravenously into the patient. A fluorescence video of the vaginal cuff will be recorded. The fluorescence of the recorded images will be analyzed by fluorescence analysis software to obtain an objective value of fluorescence.
215070264|NCT04420598|DRUG|Trastuzumab deruxtecan|"After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.~In patients with hormone receptor (HR)-positive status (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) administration of endocrine therapy is not allowed.~In patients allocated in study cohort 5, administration of intrathecal therapy is not allowed"
215070265|NCT06598540|BEHAVIORAL|Kindness-focused|This mindset intervention frames food choices as an opportunity to practice self-kindness. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session delivered via the Stanford Zoom platform. The recording of the session will be available for 7 days on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 5. Examples of such activities include sharing their experiences about considering food choices as an act of self-kindness with other study participants or writing an encouraging letter to a study participant and physician colleague through the private and secure message board of a web-based educational platform.
214929409|NCT05243485|DIAGNOSTIC_TEST|PreHEART|"The PreHEART score is validated for use in the pre-hospital setting.The score can be calculated based on five different elements: history, ECG, age, gender, and a Point-of-Care (POC)-Troponin. A minimum of 0 points and a maximum of 2 points can be scored in each element, the total PreHEART can contain a maximum of 10 points. The score of the history is based on the symptoms of the patient in accordance with the symptoms of a myocardial infarction. Based on the suspicion of ischemia on the ECG. Age will be based on the date of birth. Compared to the female gender, the male gender has higher risk of developing myocardial infarction and will be scored higher. The biomarker Troponin will be collected via intravenous access and measured using a POC-analyzer I-Stat from Abbott industries. In total 17 µl of blood is required to fill a cardiac Troponin I (cTnI) cartridge. Analyzing the blood will take approximately 10 minutes."
214929410|NCT00000161|DRUG|Aspirin|
214929411|NCT00000161|DRUG|Beta-Carotene|
214929412|NCT00000161|DRUG|Vitamin C|
214929413|NCT00000161|DRUG|Vitamin E|
214673265|NCT00683241|BIOLOGICAL|DCVac-L|Subjects will receive three doses of intradermal vaccination with \~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
214673266|NCT05664048|BEHAVIORAL|Dry heat application|Self- dry heat application on the foot during menstrual period with pain.
214929414|NCT06503783|DRUG|BL-M17D1|Administration by intravenous infusion for a cycle of 3 weeks.
214929415|NCT02976779|DRUG|OWC MGC cream|Topical cream containing 3% CBD and 3% THC for Psoriasis treatment
214929416|NCT02976779|DRUG|OWC Control Cream|Topical Cream without active ingredients
214929417|NCT06620679|BIOLOGICAL|Lipopolysaccharide (LPS)|Lipopolysaccharide (LPS), single i.v. bolus, 0.4 ng/kg body weight
214929418|NCT06620679|OTHER|Placebo|Normal saline, single i.v. bolus, in equal volume to intervention
214929419|NCT02738879|DRUG|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
214929420|NCT02738879|DRUG|Placebo to sitagliptin|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
214929421|NCT02738879|DRUG|Metformin|At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
214929422|NCT02738879|DRUG|Metformin XR|At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
214929423|NCT02738879|DRUG|Insulin glargine|Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
214327847|NCT05682131|DRUG|Realgar Indigo naturalis formula|Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk
214929424|NCT01438294|OTHER|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
214929425|NCT01438294|OTHER|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
214929426|NCT03184194|DRUG|nivolumab-daratumumab|nivolumab-daratumumab will be given without low-dose cyclophosphamide until progression
214929427|NCT03184194|DRUG|nivolumab-daratumumab with low-dose cyclophosphamide|nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
214929428|NCT01302444|DRUG|Tadalafil|Tadalafil 40mg for 12 weeks
214929429|NCT01302444|DRUG|Placebo|Placebo for 12 weeks
214929430|NCT05587829|OTHER|• Diaphragmatic breathing technique|In supine position, the participant inhales through the mouth for 5 s to expand the abdomen to the maximal level, minimizing movement of the thorax, and performs a long exhalation to maintain a lower abdominal contraction and retroversion of the pelvis
214929431|NCT05587829|OTHER|basic breathing technique|Deep Breathing for 15 minutes
214929432|NCT01346189|BEHAVIORAL|Behavioral Economic Intervention|Various combinations of financial incentives to patients and providers.
214327848|NCT05682131|COMBINATION_PRODUCT|Conventional chemotherapy|conventional chemotherapy
214327849|NCT04601545|BEHAVIORAL|Pulmonary rehabilitation|"Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~* 5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~* 5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~* 5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~* relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation."
214327850|NCT04601545|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
214327851|NCT05873465|DRUG|Sedation with Midazolam, Fentanyl, and Propofol|Patients will have teeth extracted under sedation with Midazolam, Fentanyl, and Propofol
214327852|NCT05873465|PROCEDURE|Extraction of teeth|The necessary teeth will be extracted
214327853|NCT04745897|OTHER|eTB Catalogue of Recommendations (eTB)|eTB Catalogue of Recommendations (eTB)
214327854|NCT04745897|OTHER|World Health Organization Tuberculosis Website (WHO TB)|World Health Organization Tuberculosis Website (WHO TB)
214327855|NCT05281614|DRUG|Etanercept|Etanercept is a fully humanized monoclonal antibody that targets TNFα.
214327856|NCT05281614|DRUG|Vedolizumab|Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.
214327857|NCT03196466|BIOLOGICAL|Valproic acid|titration
214327858|NCT03196466|BIOLOGICAL|carbamazepine|titration
214327859|NCT03196466|BIOLOGICAL|phenobarbital|titration
214327860|NCT03196466|BIOLOGICAL|phenytoin|titration
214327861|NCT03196466|BIOLOGICAL|levetiracetam|titration
214929433|NCT06620029|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates. BMX-001 (7-28 mg) will be given by subcutaneous (s.c.) injection starting on Day 1, Day 8, Day 15, and Day 22 of each 28-day PTX treatment cycle.
214929434|NCT06620029|DRUG|Paclitaxel (Taxol)|Paclitaxel will be given via IV infusion at a dose = 80 mg/m2 on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle and will be sourced from standard commercial sources. Appropriate pretreatment prior to PTX will be given as per institutional standards. PTX management for any adverse event (AE) in any cycle, reasonably attributed to the chemotherapy agent that requires dose interruption should be managed per package insert, and/or institutional guidelines. Dose modification recommendations are provided in protocol to provide general consistency with dosing. Study Treatment dosing BMX-001 should continue even if the PTX is omitted. The subject may continue on PTX if the AE does not prohibit dosing per institutional practice. Grade 3 or higher infusion PTX reactions or recurrent infusion reactions may require permanent discontinuation of PTX. PTX may be continued in select patients using institutional desensitization protocol.
214327862|NCT03196466|BIOLOGICAL|lamotrigine|titration
214327863|NCT03196466|BIOLOGICAL|topiramate|titration
214327864|NCT03196466|BIOLOGICAL|oxcarbazepine|titration
214327865|NCT03196466|BIOLOGICAL|stiripentol|titration
214327866|NCT03196466|BIOLOGICAL|clobazam|titration
214929435|NCT05715489|PROCEDURE|Comparison of pre and postoperative POP-Q values of the patients|Pectopexy Without Using Mesh will be applied to the patients and POP-Q values will be compared pre and postoperatively
214929436|NCT05715489|PROCEDURE|Comparison of pre and postoperative PISQ-12 scores of the patients|Pectopexy Without Using Mesh will be applied to the patients and PISQ-12 scores will be compared pre and postoperatively
214929437|NCT04241744|DRUG|Vancomycin 125 MG po BID|prevention to develop CDI during hospitalization
215070266|NCT06598540|BEHAVIORAL|Health-focused|Brief education intervention framing food choices as a component of a healthy lifestyle. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session. The recording of the session will be available for 7 days on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 5. Examples of such activities include writing a brief statement about their perspective on the usefulness of healthy eating and sharing it with physician colleagues in their group through the private and secure message board of a web-based educational platform.
215070267|NCT01051531|DRUG|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
215070268|NCT04283994|BEHAVIORAL|Survey-based Patient/Clinician Jumpstart|"The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The Jumpstart takes two forms. One is EHR-based and provides information to the clinician about prior advance care planning documentation derived from the EHR. The other is bi-directional and patient-specific (Survey-based Patient/Clinician Jumpstart Guide). It provides the same information as the EHR-based Clinician Jumpstart Guide but also includes information about patients' self-reported preferences for communication and care as well as primary barriers and facilitators to this communication. The Jumpstart Guides include tips to improve this communication for clinicians, patients and families."
215070269|NCT04283994|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page EHR-based Clinician Jumpstart Guide provides information to the clinician about prior advance care planning documentation derived from the EHR. The EHR-based Clinician Jumpstart Guide includes tips to improve goals-of-care communication.
215070270|NCT06342492|OTHER|Coronary Sinus Lead Revision|Coronary Sinus Lead Revision
214327867|NCT03196466|BIOLOGICAL|brivaracétam|titration
214327868|NCT03196466|BIOLOGICAL|felbamate|titration
214327869|NCT03196466|BIOLOGICAL|lacosamide|titration
214327870|NCT03196466|BIOLOGICAL|rufinamide|titration
214327871|NCT03196466|BIOLOGICAL|gabapentine|titration
214327872|NCT03196466|BIOLOGICAL|pregabaline|titration
214327873|NCT03196466|BIOLOGICAL|sultiame|titration
214327874|NCT03196466|BIOLOGICAL|tiagabine|titration
214327875|NCT03196466|BIOLOGICAL|vigabatrine|titration
214327876|NCT03196466|BIOLOGICAL|mesuximide|titration
214929438|NCT00904865|PROCEDURE|SPA cholecystectomy|SPA cholecystectomy
214327877|NCT03196466|BIOLOGICAL|primidone|titration
214327878|NCT03196466|BIOLOGICAL|perampanel|titration
214327879|NCT03196466|BIOLOGICAL|ethosuximide|titration
214327880|NCT03196466|BIOLOGICAL|zonisamide|titration
214327881|NCT03196466|BIOLOGICAL|cannabidiol|titration
214327882|NCT03196466|OTHER|genetic polymorphisms|genetic polymorphisms
214327883|NCT00719004|PROCEDURE|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
214327884|NCT06362135|DEVICE|Virtual Home Visit|The virtual home visit will be made through the mobile application developed by the researchers. First, the patients who meet the sampling criteria will be included in the study after the caregivers of the patients apply to the Antalya Health Directorate Antalya Training and Research Hospital Home Health Unit. The virtual home visit is scheduled twice
214327885|NCT06362135|DEVICE|Control Group|"Face-to-face home visits will be carried out by the Antalya Education and Research Hospital home health team, as planned."
214929439|NCT00904865|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
214929440|NCT01607060|DRUG|Lactulone|Patients will receive lactulone to daily laxation
214929441|NCT03199482|DRUG|Dexamethasone Oral Tablet|single dose of tablet 0.5 mg dexamethasone given to patients before starting of root canal treatment by 30 minutes or placebo
214929442|NCT03199482|DRUG|Placebo|Placebo will be administrated 30 minutes before start of root canal treatment
214929443|NCT02360631|DRUG|Chantix|A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
214929444|NCT02360631|DRUG|Placebo|Health education counseling will be provided to all participants.
214929445|NCT00786331|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
214929446|NCT00786331|DRUG|Pemetrexed plus carboplatin|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
214929447|NCT05631691|BEHAVIORAL|Support for Students exposed to Trauma Program|Support for students exposed to trauma program (SSET) is a school-based intervention program for students who have been exposed to traumatic events and exhibit signs of post-traumatic stress disorder (PTSD). (Jaycox, Langley, \& Dean, 2009; Jaycox, Langley, Stein et al., 2009). SSET is specifically designed for school teachers, school counsellors, and other non-clinical staff. SSET program is a series of 10 structured lessons designed to reduce post-traumatic and depressive symptoms and improve functioning in school children exposed to traumatic events. it includes psycho-education, relaxation, cognitive restructuring, social problems solving and behavioral exposure.
214929448|NCT04188431|DRUG|Dexamethasone|Is usually commercialized as dexamethasone phosphate as solution for injection
214929449|NCT04188431|DRUG|Sodium chloride|prepared in the same intravenous volume to mimic experimental arm
214929450|NCT04704492|DRUG|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
214929451|NCT00020046|DRUG|docetaxel|
214929452|NCT00020046|DRUG|thalidomide|
214929453|NCT00205868|DEVICE|Precision Spinal Cord Stimulation System|Stimulation on throughout study
214929454|NCT01955772|DRUG|Enteral nutrition alanyl-glutamin, Dipeptiven|Enteral nutrition versus parenteral nutrition
214929455|NCT00857168|DRUG|Testosterone MD-Lotion|
214929456|NCT06664840|OTHER|MDR diet assessment|Participants will record their dietary intake on the MyRareDiet (MRD) app and nutrient content will be assessed to validate MRD compared to a traditional interviewer assessed 24 hour recall.
214929457|NCT06664840|OTHER|24 hour recall|A trained nutritionist will conduct a telephone multi-pass 24 hour diet recall on 3 randomized nonconsecutive days. The dietary intake will be analyzed using NDSR and metabolic pro and nutrient intake will be compared to the nutrient intake assessed with the MRD app.
214929458|NCT01341340|DEVICE|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
214929459|NCT02689869|DRUG|Ibrutinib|Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research \& Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
214327886|NCT00005669|DRUG|Metformin HCL|Medication studied for ability to alter body weight and body composition.
214929460|NCT02689869|DRUG|GA 101|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
214929461|NCT05024240|DIAGNOSTIC_TEST|Stabilometry|Probands will stand on stabilometric platform (double leg stance) and we will measure CoP parameters area and length. We also make this task harder by using foam and exclusion of visual control. Length of one test is 30s.
214929462|NCT05024240|DIAGNOSTIC_TEST|Stroop test|There are various names of colours written in non-matching font colour in this test. During this test probands are required to name the colour which is written in text not the colour of the font. We will measure reaction time and number of mistakes.
214929463|NCT05024240|DIAGNOSTIC_TEST|Backward counting test|In this counting test probands are given number from interval \<180-200\> and they are asked to subtract 7 during 30s interval of the testing. We will measure reaction time and number of mistakes.
214929464|NCT03166540|OTHER|cup of espresso coffee|Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
214929465|NCT03166540|OTHER|cocoa-based products containing coffee|Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
214929466|NCT03572725|PROCEDURE|Gas tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
214929467|NCT03572725|PROCEDURE|Air tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
214929468|NCT04117672|DIETARY_SUPPLEMENT|Salovum|Active egg yolk powder
214929469|NCT04117672|DIETARY_SUPPLEMENT|Placebo egg yolk powder|Normal egg yolk powder
214929470|NCT00416130|DRUG|Vorinostat|MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
214327887|NCT00005669|DRUG|Placebo|Control capsules for metformin
214327888|NCT03044132|OTHER|DermACELL AWM|Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology
214327889|NCT02519712|DRUG|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
214327890|NCT02519712|PROCEDURE|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
214327891|NCT04437966|BEHAVIORAL|Enhanced Chronic Disease Self-management program|CDSMP workshops will last for approximately 2.5 hours and occur weekly for six weeks. Sessions will focus on appropriate diet for persons with hypertension and to facilitate weight loss; managing medications, adherence to medical clinic appointments; physical activity and stress management. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management program. Participants will also be given pill boxes and will be prompted by social media messages to make and keep clinic appointments as well as maintain a healthy lifestyle.
214327892|NCT03029689|DRUG|Raltegravir|Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
214327893|NCT03029689|DRUG|Placebo|Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
214327894|NCT03029689|DRUG|Current ART|3-drug antiretroviral treatment including PI/r/c or NNRTI
214327895|NCT05675553|DEVICE|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, and explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants. The treatment framework is semi-structured through human-computer interaction. The forms of interaction include inquiries, statements, recommendations summaries, and knowledge assessments.
214327896|NCT05675553|OTHER|treatment as usual|Both groups will receive treatment as usual, including medication, exercise, and psychological education.
214327897|NCT03057028|DRUG|Anakinra|
214327898|NCT05206474|DEVICE|IRADYN|"One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2 ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
214327899|NCT00560690|DRUG|Metformin|500 mg oral three times a day for 6 months
214327900|NCT00560690|DRUG|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
214327901|NCT00560690|DRUG|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
214327902|NCT02915614|PROCEDURE|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
214327903|NCT06317311|BIOLOGICAL|Dostarlimab|Dostarlimab is administered via intravenous (IV) infusion at a dose of 500 milligram (mg) for first 6 cycles (each cycle is of 21 days) followed by 1,000 mg from cycle 7 (each cycle is of 42 days)
214327904|NCT06317311|DRUG|Carboplatin|Carboplatin is administered IV at a dose of Area under the concentration time curve (AUC) 5 milligram\*millilitre/ minute (mg•mL/min) for cycles 1 to 6 (each cycle is of 21 days)
214327905|NCT06317311|DRUG|Paclitaxel|Paclitaxel is administered IV at a dose of 175 milligram per meter square (mg/m2) for cycles 1 to 6 (each cycle is of 21 days)
214327906|NCT02850003|DRUG|IDP-120 Gel|Gel
214673267|NCT01591590|OTHER|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
214673268|NCT01591590|OTHER|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
214673269|NCT01591590|OTHER|Blood samples (plasma preparation and CTC)|
214929471|NCT01197625|BIOLOGICAL|Dendritic cell vaccine|Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin
214929472|NCT02228239|DRUG|Esketamine|Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
214929473|NCT02228239|DRUG|Mirtazapine|Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.
214929474|NCT02228239|DRUG|Placebo (Matched to Esketamine)|Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
214929475|NCT02228239|DRUG|Placebo (Matched to Mirtazapine)|Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
215070271|NCT03763656|DRUG|Oral Hydroxyurea (100 mg/mL) Solution|Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
215070272|NCT00487942|DRUG|armodafinil|50 mg/day armodafinil
214327907|NCT03489395|DRUG|Edoxaban|Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
214327908|NCT00367172|BEHAVIORAL|Directly Administered Antiretroviral Therapy|
214673270|NCT03270085|DRUG|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
214673271|NCT03270085|OTHER|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
214673272|NCT02525224|DIETARY_SUPPLEMENT|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
215070273|NCT00487942|DRUG|armodafinil|100 mg/day armodafinil
215070274|NCT00487942|DRUG|armodafinil|200 mg/day armodafinil
215070275|NCT00487942|DRUG|placebo|placebo
215070276|NCT06362876|BEHAVIORAL|Breastfeeding Counseling Based on Motivational Interviewing|Breastfeeding Counseling Based on Motivational Interviewing Program The breastfeeding counseling based on motivational interviewing program consists of 6 sessions and 4 hours. It includes information about breastfeeding, motivational preparation for the breastfeeding experience.
214327909|NCT02665208|OTHER|Treatment As Usual (TAU)|informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
214929476|NCT02064322|DEVICE|SImmetry Implant|"The SImmetry system is commercially available. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
215070277|NCT06362876|BEHAVIORAL|Standard Breastfeeding Consultancy|Standart Breastfeeding Consultancy The standard breastfeeding consultancy program consists of 6session and 4 hours. It contains only information and applications about breastfeeding
214327910|NCT02665208|DRUG|Nicotine Replacement Therapies|a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
214327911|NCT02665208|BEHAVIORAL|Text Message Intervention (TMI)|
214327912|NCT00000946|BIOLOGICAL|HIV p24/MF59 Vaccine|
214327913|NCT00000946|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
214327914|NCT00000946|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
214327915|NCT00000946|BIOLOGICAL|rgp120/HIV-1 SF-2|
214327916|NCT04107480|PROCEDURE|Endoscopic trans-sphenoidal adenoma resection|"Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice."
214327917|NCT04107480|DRUG|Dopamine Agonists|"The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care."
214327918|NCT00006916|BIOLOGICAL|bleomycin|
214327919|NCT00006916|DEVICE|Ommaya reservoir|
214327920|NCT00006916|RADIATION|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
214327921|NCT01922024|DEVICE|LRT55 Testing|Testing on the Unyvero LRT55
214327922|NCT04732637|DIAGNOSTIC_TEST|"Test At Home's Proprietary Lollipop Buccal Cavity Swab"|"Self-collected Test At Home's proprietary Lollipop Buccal Cavity Swab with VTM."
214327923|NCT05340153|DRUG|Artemether-Lumefantrine Drug Combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
214929477|NCT00330330|DRUG|ISIS 113715|
214929478|NCT06484348|BEHAVIORAL|Monitoring of eating behaviors|Overall eating behaviors will be assessed from pictures of consumed food and drinks taken by the participants with their smartphones. A complete assessment of eating habits will be carried out daily for 4 days. For each photo, the participants will indicate the reasons why they ate by completing analogical scales (hunger, craving, sleepiness, stress, negative emotion) and an open question (other reason). These data will be used to determine the reason and timing of food intake and the number of calories ingested for each food category. Eating behaviors specifically related to sugar intake will be monitored using the FREESTYLE PRO® sensor. This small device is used routinely for diabetes care and is placed on the back of the arm. The system is designed to measure glucose levels in the interstitial fluid every 15 minutes for up to 14 days. The recorded data can be downloaded by an investigator using the FREESTYLE LIBRE PRO® reader.
214929479|NCT06484348|BEHAVIORAL|Monitoring of sleep/wake rhythm|"The sleep-wake rhythm will be measured continuously during the 5 days, both subjectively (sleep diary) and objectively, using the GT9X LINK ACTIGRAPH."
215070278|NCT06996145|OTHER|dynamic 4D scanner|dynamic 4D scanner
215070279|NCT07004244|BIOLOGICAL|KRAS-mutated mRNA vaccine|"Cohort 1:From the initial dose, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose.~Cohort 2:KRAS-mutated mRNA vaccine+ Toripalimab + pemetrexed + carboplatin as neo-adjuvant treatment followed by surgery"
215070280|NCT07004244|BIOLOGICAL|TORIPALIMAB|intravenous injection
215070281|NCT07004244|DRUG|Pemetrexed+carboplatin|intravenous injection
215070282|NCT07003217|BEHAVIORAL|Virtual Reality-based practical education|VR-based practical education is an interactive learning method that utilizes virtual reality, where participants engage in a 3D environment for learning.
214327924|NCT05340153|DRUG|Dihydroartemisinin-Piperaquine drug combination|Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
214327925|NCT03325907|DEVICE|navigational template|The navigational template was created based on computed tomography data using three-dimensional technology.
214327926|NCT03545607|BIOLOGICAL|MultiStem|single intravenous infusion 18-36 hours after stroke
214327927|NCT03545607|BIOLOGICAL|Placebo|single intravenous infusion 18-36 hours after stroke
214327928|NCT01865825|RADIATION|Esophageal Barium Xray|"•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day."
214327929|NCT01703637|DRUG|Sitagliptin|"* before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
214327930|NCT01703637|DRUG|Vildagliptin|"* before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
214327931|NCT01703637|DRUG|Saxagliptin|"* before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~* before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
214327932|NCT05561972|DEVICE|injectable multifractional intercalated hyaluronic acid [Armonia®, Regenyal, Italy]|Armonia® 2 ml was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
214327933|NCT03759756|OTHER|AI presentation|AI presentation means the automatic diagnosis information of AI and AI presentation means it is visible in the group.
214327934|NCT03759756|OTHER|no AI presentation|AI presentation means the automatic diagnosis information of AI and no AI presentation means it is invisible in the group.
214327935|NCT01301222|DRUG|Inj. Octreotide|100 mcg subcutaneously for 5 days
214327936|NCT04561401|DEVICE|Repeated Transcranial Magnetic Stimulation (rTMS)|rTMS will be applied at 10 Hz. Each train will consist of 40 supra threshold (120% resting motor threshold) pulses over 4 seconds with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3,000 pulses), and occur at the same time of day on every weekday for a period of three weeks (15 days total). During TMS, only passive activities will be allowed (i.e., watching movies or TV, listening to music). Three weeks of treatment was selected based on existing rTMS evidence in youth with treatment resistant major depressive disorder.
214327937|NCT04561401|OTHER|Intensive Pain Rehabilitation Program (IPRP)|The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.
214327938|NCT00772551|DRUG|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
214327939|NCT00772551|DRUG|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
214327940|NCT02911675|DEVICE|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
214327941|NCT03703635|DEVICE|intracranial balloon angioplasty|A balloon (recommending the Neuro RX and Neuro LPS Intracranial Balloon Dilation Catheter \[Sinomed Inc., Tianjin, China\]) is navigated by the microwire to the lesion of the target artery.
214327942|NCT03703635|DRUG|aggressive medical management|Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.
214929480|NCT06484348|BEHAVIORAL|Measure of nocturnal sleep parameters|The quality and quantity of the participants' sleep will be recorded using the SOMFIT® device. This non-invasive portable device will allow the determination of sleep architecture as well as sleep EEG microstructure.
214929481|NCT06484348|BEHAVIORAL|Measure of sleepiness|Sleepiness will be assessed by the Karolinska Sleepiness Scale (KSS) at the initiation of food intake and 30 min and 2 hours afterwards, and by analysis of EEG activity recorded by the SOMFIT® over a time window surrounding food intake. Indeed, participants will also be asked to wear the device as much as possible during the day when they are at home in order to explore sleepiness markers during wakefulness.
215070283|NCT07003217|BEHAVIORAL|Video Watching-based practical education|Video Watching-based practical education is a passive learning method, where information is delivered solely through video viewing.
215070284|NCT05034627|PROCEDURE|Biopsy|Undergo biopsy
215070285|NCT05034627|DRUG|Calaspargase Pegol-mknl|Given IV
215070286|NCT05034627|DRUG|Cobimetinib|Given PO
214327943|NCT00816868|DRUG|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
214327944|NCT02485028|DRUG|Dapoxetine 30mg tablet|
214327945|NCT02485028|DRUG|Mirodenafil 50mg tablet|
214327946|NCT02322554|BIOLOGICAL|Cellular and tissue based products|Procedure: Application of device or biological to wounds
214327947|NCT02967367|DEVICE|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
214929482|NCT02554058|DEVICE|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
214327948|NCT02967367|DEVICE|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
214327949|NCT02967367|DEVICE|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
214327950|NCT01524770|BIOLOGICAL|Dulaglutide|Administered by subcutaneous (SC) injection
214327951|NCT05264324|PROCEDURE|Maximal Exercise Capacity|Maximal Exercise Capacity in incremental ramp exercise tests.
214929483|NCT01520558|BIOLOGICAL|CNDO-109-AANK Cells|Single dose, infusion
214929484|NCT04624958|DRUG|Zanubrutinib and Rituximab|Zanubrutinb 160mg PO BID d1-28; Rituximab 375mg/m2 iv.drip d1.
214929485|NCT04624958|DRUG|R-DHAOx|Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.
215070287|NCT06828029|BEHAVIORAL|Problem-Solving|The problem-solving training consists of five modules, blending theory and practice. Module 1 covers the basics of problem-solving, including key steps like identification, analysis, and evaluation, with group activities for hands-on practice. Module 2 focuses on creative techniques, such as brainstorming and mind mapping, to develop innovative solutions. Module 3 teaches decision-making and prioritization, using tools like SWOT analysis and decision trees, with applied exercises. Module 4 emphasizes teamwork and communication, highlighting conflict resolution and effective collaboration through team-based problem-solving activities. Module 5 integrates all techniques, applying them to real-life scenarios, particularly clinical cases, with group discussions and solution evaluations. The training incorporates interactive learning, simulations, and structured feedback, aiming to enhance problem-solving and leadership skills. Evaluation includes self-assessment and performance observation
215070288|NCT05544227|DRUG|SV-102|SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
215070291|NCT07014085|PROCEDURE|"Histomorphometric Evaluation of Bone Augmentation Using Xenografts Versus Autologous Bone Grafts in Dental Implant Patients: A Comparative Clinical Study"|Split mouth comparative clinical prospective study xenograft vs autologous graft
215070292|NCT06682728|DRUG|Sacituzumab Govitecan (SG)|Given IV
215070293|NCT06682728|DRUG|Nivolumab|Given IV
215070294|NCT07011082|OTHER|Stress preventative measures|These studies will address fundamental gaps in our current knowledge and establish a scientific framework to investigate the long-term effects of early childhood adversity, physical or emotional trauma, child maltreatment, or other adverse experiences in early childhood, as well as the preventive and protective effects of loving, nurturing, and consistent caregiving offered to young children during their early childhood
215070295|NCT06773130|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
215070296|NCT06773130|DRUG|Nimotuzumab|400mg，ivgtt，d1，qw
215070297|NCT06692348|DRUG|Orforglipron|Administered orally
215070298|NCT06875635|OTHER|Pre and Post op pelvic floor muscle training|pre op exercises: Breathing exercise ,Kegel exercise ,Abdominals exercise include pelvic tilt ,knee rolling with abdominal contraction post op exercise :breathing exercise, circulatory exercise i.e ankle pump and heel slides, and bed mobility along with pre op exercise
215070299|NCT06875635|OTHER|Only post op pelvic floor muscle training|post op exercise :breathing exercise, circulatory exercise i.e ankle pump and heel slides, and bed mobility along with pre op protocol
215070300|NCT06875635|OTHER|Routine medical care|Circulatory exercise Breathing exercise Administrating analgesic Nursing care
215070301|NCT07022405|DRUG|Pramipexole Immediate Release|The intervention involves taking pramipexole immediate release (IR) for 8 weeks followed by 2 weeks of down titration and follow up.
215070302|NCT07025746|DEVICE|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
214327952|NCT05545670|DRUG|Placebo|not containing drugs
214929486|NCT04624958|DRUG|Zanubrutinib Maintenance|Zanubrutinb 160mg PO BID.
214929487|NCT01730534|DRUG|Dapagliflozin 10 mg|Oral dose (od)
214929488|NCT01730534|DRUG|Placebo tablet|Oral dose (od)
214929489|NCT02089958|PROCEDURE|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
214929490|NCT05988463|DRUG|Artesunate Oral Product|Artesunate capsules administered orally twice daily beginning at 10 mg for 4 weeks, followed by 20 mg for 4 weeks, and then 30 mg for 4 weeks.
214929491|NCT01676896|BEHAVIORAL|Asthma in-school class|
214929492|NCT01676896|BEHAVIORAL|Asthma Day Camp|
214929493|NCT01676896|BEHAVIORAL|Health Promotion in-school class|
214327953|NCT05545670|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
214327954|NCT01607983|DRUG|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
214327955|NCT05508412|BEHAVIORAL|CancerPEP|CancerPEP
214327956|NCT02751983|BEHAVIORAL|ACT for Life|A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
214327957|NCT02751983|OTHER|Treatment as usual|All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
214327958|NCT00616850|PROCEDURE|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
214327959|NCT00616850|DRUG|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
214327960|NCT00616850|OTHER|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
214327961|NCT03023566|DRUG|Dotarem|Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
214327962|NCT02311751|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
214327963|NCT05441735|COMBINATION_PRODUCT|APP|APP as an instructional tool for visiting health education
214327964|NCT01955070|OTHER|Multimedia Presentation for Ketamine sedation|PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
214327965|NCT04004728|PROCEDURE|1064 Nd:YAG laser|1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
214327966|NCT06087965|DRUG|Fingolimod|0.5mg/day oral fingolimod over a course of 3 consecutive days
214327967|NCT02467725|OTHER|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
214327968|NCT04334499|OTHER|Sample collection from tissue discard|Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.
214327969|NCT01420081|DRUG|PF-05212384|154mg IV weekly
214327970|NCT01420081|DRUG|PF-05212384|154mg IV weekly
214327971|NCT01420081|DRUG|PF-05212384|154mg IV weekly
214327972|NCT04670991|RADIATION|EXATRAC imaging|Exatrac imaging performed before the standard CBCT imaging prior to each chemotherapy session
214929494|NCT04540341|OTHER|Mulligan mobilization|Mulligan mobilization technique will be apply.
214929495|NCT04540341|OTHER|Core stabilization|Core stabilization technique will be apply.
214929496|NCT04540341|OTHER|Conventional therapy|Conventional therapy exercise will be apply.
214929497|NCT05622682|OTHER|Observational only: Serology and flow cytometry for ALL cohort participants|Blood samples from ALL cohort participants will be tested to measure antibodies to vaccine-preventable diseases and immune recovery
214929498|NCT05622682|OTHER|Observational only: Infection rates|Number of infections during the study period will be obtained from both ALL cohort and healthy control participants and captured for comparison and evaluation of infection rates during the first year off-chemotherapy.
214929499|NCT02256982|DRUG|Gemcitabine|
214929500|NCT02256982|DRUG|Cisplatin|
214929501|NCT02256982|PROCEDURE|Surgery|Surgical Resection and Lymphadenectomy
214327973|NCT05098535|OTHER|Visual Aid|"The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual description stating the anticipated risk.~For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS."
214327974|NCT05098535|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
214327975|NCT02153775|BEHAVIORAL|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
214327976|NCT05404269|DEVICE|AGC mode|Automated Gas Control mode at Maquet FLOW-i anesthesia machine
214327977|NCT01997268|DRUG|Placebo|Corn Oil
214327978|NCT01997268|DRUG|SC401B 2 capsules|
214327979|NCT01997268|DRUG|SC401B 4 capsules|
214327980|NCT01997268|DRUG|SC401B 6 capsules|
214327981|NCT03467425|DRUG|FF/UMEC/VI|FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
214327982|NCT03467425|DRUG|Inhaled Corticosteroid|Inhaled Corticosteroid (ICS) as prescribed by the physician.
214327983|NCT03467425|DRUG|LAMA|LAMA as prescribed by the physician.
214327984|NCT03467425|DRUG|LABA|LABA as prescribed by the physician.
214327985|NCT03467425|DRUG|COPD rescue medications|Rescue medications for COPD will be prescribed and obtained according to usual practice.
214327986|NCT03676361|DRUG|Desmopressin|Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
214929502|NCT02256982|RADIATION|Radiation|Radiation Therapy
214673273|NCT00674934|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
214673274|NCT05378659|BEHAVIORAL|Montreal Cognitive Assessment|Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place
214673275|NCT05378659|BEHAVIORAL|Stroop Test|Evaluates Processing Speed and Executive Control
214673276|NCT05378659|DIAGNOSTIC_TEST|4AT Delirium|Screening tool to test for delirium post surgery
214673277|NCT05378659|BEHAVIORAL|Grooved Pegboard|Evaluation testing for dominant and non dominant sensory-motor speed
214673278|NCT05378659|BEHAVIORAL|NACC Cognitive Battery|A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.
214673279|NCT05378659|DIAGNOSTIC_TEST|ERP Testing|An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
214673280|NCT05378659|DIAGNOSTIC_TEST|Blood Plasma and Serum sampling|Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.
214673281|NCT05378659|DIAGNOSTIC_TEST|Cerebral Spinal Fluid Sample|At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
214673282|NCT05416606|PROCEDURE|transurethral bipolar enucleation and resection of the prostate|transurethral bipolar enucleation and resection of the prostate
214673283|NCT05416606|PROCEDURE|open surgical transvesical prostatectomy|open surgical transvesical prostatectomy
214673284|NCT04805372|OTHER|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
214673285|NCT04805372|OTHER|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
214673286|NCT01204112|DRUG|Tasocitinib (CP-690,550) plus Rifampin|Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
214673287|NCT01300286|DRUG|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
214673288|NCT02901717|DRUG|Mino-Lok|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
215070303|NCT07026539|DRUG|Finerenone (BAY 94-8862)|Patients with an eGFR of 25-60 ml/min/1.73m2 will receive an initial dose of 10 mg finerenone/placebo once daily and those with an eGFR of at least 60 ml/ in/1.73m2 will receive an initial dose of 20 mg finerenone/placebo once daily. From 4 weeks the target dose is 20 mg finerenone/placebo once daily. An increase in dose from 10 to 20 mg once daily will be encouraged after 4 weeks provided the plasma potassium level is 4.8 mmol/L or less and the eGFR stable. If eGFR is reduced with \>30 % compared to the previous measurement, we will not increase the dose of finerenone/placebo. Plasma potassium and eGFR will be measured 4 weeks after any initiation, re-start or increase in dose. A decrease in dose from 20 to 10 mg is allowed at any time after initiation of finerenone or placebo. Patients in the placebo group will undergo sham adjustment of the dose. Finerenone or placebo will be withheld if potassium concentrations exceed 5.5 mmol/L and restarted if potassium levels fall to 5.0 mmol/L
215070304|NCT07026539|DRUG|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
215070305|NCT07028372|OTHER|Short Form Health Survey (SF-36)|Heath-related quality-of-life is assessed using the SF-36 questionnaire, which is administered at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, in the form of a telephone interview.
215070306|NCT07028372|OTHER|Modified Rankin Score (mRS)|The degree of disability/dependence is evaluated using the mRS scale at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.
215070307|NCT07028372|OTHER|Activity of Daily Living (ADL) questionnaire|Level of independence is evaluated using the ADL questionnaire, which is administered at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, in the form of a telephone interview.
215070308|NCT07028372|OTHER|New York Heart Association (NYHA) Classification|The extent of heart failure is assessed using the NYHA functional classification at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.
215070309|NCT07028372|OTHER|St George's Respiratory Questionnaire (SGRQ)|Respiratory status is assessed using the SGRQ questionnaire at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.
215070310|NCT07034807|DRUG|the traditional Chinese medicine prescription ' Shenzhuo Decoction '|The traditional Chinese medicine prescription ' Shenzhuo Decoction ' is composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort. It is a traditional Chinese medicine prescription for the treatment of diabetic kidney disease, which was founded by Tong Xiaolin, an academician of the Chinese Academy of Sciences.
215070311|NCT07034807|COMBINATION_PRODUCT|basic treatment|Basic treatment includes six aspects : nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, and control of other risk factors, which are implemented in accordance with clinical standard treatment specifications.
215070312|NCT07035041|DRUG|D-2570|Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
215070313|NCT07035041|DRUG|Placebo|Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
215070314|NCT07033611|DIETARY_SUPPLEMENT|Creatine|Five grams of creatine were administered to each patient daily for eight weeks.
214929503|NCT01775982|OTHER|Psychiatric evaluation|"This evaluation is carried out in several stages:~* Assessment of cognitive functioning;~* Interview with a relative;~* Interview with caregivers;~* Evaluation of the presence of delirium according to DSM-IV criteria;~* Evaluation of the presence of anxiety, depressive syndrome, dementia or other DSM IV;~* Reports of adverse events.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
214929504|NCT01775982|OTHER|Geriatric evaluation|"This evaluation includes a brief interview with a caregiver, diverse scorings (CAM, Delirium Index, Mini Geriatric Depression Scale, Modified Early Warning Score, Clinical Global Impression sclae, Algo Plus), and adverse event reporting.~CAM scoring is carried out by a trained geriatrician and a trained nurse and/or a psychologist.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
214327987|NCT00411619|DRUG|Everolimus|Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
214327988|NCT02397356|DRUG|Ketamine first AB|Nebulised ketamine 1mg/kg
214327989|NCT02397356|DRUG|Placebo first BA|Nebulised saline 1-2ml
214327990|NCT00000102|DRUG|Nifedipine|
214327991|NCT02318693|DRUG|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
214327992|NCT02318693|DRUG|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
214327993|NCT00025883|DRUG|Metreleptin|Drug treatment
214327994|NCT00862784|BIOLOGICAL|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
214327995|NCT00862784|DRUG|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
214327996|NCT00862784|DRUG|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
214929505|NCT01735344|DRUG|Lisinopril Tablets 40 mg|40 mg tablet once a day
214929506|NCT01735344|DRUG|Lisinopril|40 mg tablet once a day
214929507|NCT04369131|DEVICE|Functional electrical stimulation|Randomized placement of FES pads in one of four locations during each session. Locations include: (a) none, (b) calves only, (c) quads and abdominals only, and (d) calves, quads, and abdominals.
214929508|NCT00639444|DIETARY_SUPPLEMENT|gluten-free, normocaloric diet from 6 to 12 months|Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
214929509|NCT03355157|DRUG|Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)|Drug intervention
215070315|NCT07033039|DEVICE|Photobiomodulation|The photobiomodulation device used in this study will be the ECCO Reability (Ecco Fibras, Campinas, SP, Brazil), which is approved for clinical use by the Brazilian Health Regulatory Agency (ANVISA) under registration number 80323310001. The equipment is also certified by INMETRO, ensuring adherence to nationally established safety and performance standards.
215070316|NCT07033039|OTHER|Simulation of Photobiomodulation|In the sham group, the photobiomodulation procedure will be simulated with the device turned off. To preserve blinding, the equipment will be positioned as in the active treatment and its operational sound will be reproduced during the simulation, ensuring that the intervention remains indistinguishable from the actual PBM application.
215070317|NCT07033039|PROCEDURE|Standard treatment protocol|Participants in the control group will receive the standard medical protocol. No medication will be given preoperatively. Intraoperatively, dexamethasone 4 mg and tranexamic acid 1 g will be administered IV. Postoperative hospital care will include hydrocortisone 200 mg IV, tranexamic acid 250 mg IV, dipyrone 1 g IV, and cefazolin 1 g IV every 8 hours, plus ketorolac 10 mg sublingual as needed. At home, patients will take cefuroxime axetil 500 mg orally every 12 hours for 10 days, prednisolone 40 mg orally in the morning for 3 days, and dipyrone 1 g orally as needed. They will also apply a fibrinolysin and chloramphenicol ointment twice daily for 30 days and perform nasal irrigation with 0.9% sodium chloride six times daily for 60 days.
214327997|NCT00862784|DRUG|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
215070318|NCT07034781|DRUG|Comparator 1|Dapagliflozin 10mg + Linagliptin 5mg
214327998|NCT00862784|DRUG|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
214327999|NCT06296303|OTHER|Pulsed electromagnetic therapy|Pulsed etromagnetic therapy (1000 gauss) on sciatic nerve in gluteal fold. ( 30 min )
214328000|NCT06296303|OTHER|Ultrasound phonophoresis|Phonophoresis using dexamethasone and topical diclofenac sodium gel on sciatic nerve in subgluteal fold and mid thigh
215070319|NCT07034781|DRUG|Comparator 2|Metformin 1000mg
214328001|NCT06296303|OTHER|Conventional physical therapy|"Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises"
214328002|NCT00085943|DRUG|LEXIVA (GW433908)|
214328003|NCT00085943|DRUG|Ritonavir|
214328004|NCT00085943|DRUG|KALETRA|
214328005|NCT00085943|DRUG|EPIVIR|
214328006|NCT00085943|DRUG|Ziagen|
214328007|NCT00085943|DRUG|Abacavir/Lamivudine|
214328008|NCT00085943|DRUG|Fosamprenavir|
214328009|NCT06561347|DRUG|Zanubrutinib|A potent, specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor
214328010|NCT06561347|DRUG|Bendamustine|Alkylating agent
214328011|NCT06561347|DRUG|Rituximab|Monoclonal antibody
214328012|NCT01698229|OTHER|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
214328013|NCT03660410|OTHER|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
214328014|NCT03660410|OTHER|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
214328015|NCT00578500|PROCEDURE|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
214328016|NCT03633435|PROCEDURE|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
214328017|NCT02282696|OTHER|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
214328018|NCT06347081|PROCEDURE|Nd- YAG laser at 532nm wavelength|Nd-YAG laser at 532nm wavelength every 2 weeks for 14 sessions. patients will also receive standard medical care, nursing, physiotherapy
214328019|NCT05880433|DEVICE|NIRS(INVOS 5100; Covidien Somanetics, Troy, MI|NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
214328020|NCT04042883|PROCEDURE|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
214328021|NCT00064246|BIOLOGICAL|rituximab|Given IV
214328022|NCT00064246|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
214328023|NCT00064246|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
215070320|NCT07034781|DRUG|Test Drug|Fixed-dose combination tablet (AJU-A53)
215070321|NCT06722989|BEHAVIORAL|mobile-guided exercise|"Exercises for pregnant women in the SG will fall into moderate physical activity. They will be previously assessed by a perinatologist with a license to guide exercise during pregnancy. Each exercise will last 30 minutes, including initial warm-up exercises and final stretching exercises.~The recommended moderate activity for pregnant women is at least 150 minutes per week, achieved on at least three days. For pregnant women aged 29 years or less, this means within the limits of a heart rate of 125 to 146 beats/min. For pregnant women aged 30 years or more, it is within the limits of a heart rate of between 121 and 141 beats per minute. According to the Borg scale of perceived exertion from six to 20, moderate exercise is rated between 13 and 14, corresponding to the specified heart rate thresholds. The pregnant woman will rate her exercise on the Borg perceived exertion scale from six to 20. The recommended number of steps per day will be at least 6,000."
215070322|NCT06722989|BEHAVIORAL|Unguided physical activity|In this group, pregnant women will be physically active at their discretion.
215070323|NCT06721689|DRUG|PEEL-224|PEEL-224 (PEG-\[SN22\]4) is a novel topoisomerase I inhibitor
215070324|NCT06721689|DRUG|Vincristine|Vincristine is an inhibitor of microtubular formation which is approved by the Food and Drug Administration (FDA) and is commercially available.
215070325|NCT06721689|DRUG|Temozolomide (TMZ)|Temozolomide is an alkylating agent which is approved by the FDA and is commercially available.
215070326|NCT06725927|BIOLOGICAL|Influenza vaccination|Influenza vaccination pre-discharge in patients hospitalized due to heart failure exacerbation
215070327|NCT06885385|BIOLOGICAL|JS207|JS207 will be administered every 3 weeks for a treatment cycle of 21 days
215070328|NCT06885385|BIOLOGICAL|JS015|JS015 will be administered every 3 weeks for a treatment cycle of 21 days
214328024|NCT00869648|PROCEDURE|Extension|After anaesthesia induction the head is placed in extension
214486204|NCT06741384|OTHER|Aerobic training|The women will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
214486205|NCT01242215|DEVICE|ipragliflozin|oral
215070329|NCT06885385|DRUG|Capecitabine|Capecitabine of 1000mg/m2 will be administered orally twice daily from day 1 to 14 every 21 day cycle
215070330|NCT06885385|DRUG|Oxaliplatin|Oxaliplatin of 130mg/m2 will be administered intravenously (IV) on day 1 every 21 day cycle
215070331|NCT06890676|OTHER|Comprehensive Oral Evaluation|A thorough check-up of teeth, gums, and surrounding tissues, including medical and dental history, to assess overall oral health and identify any infections.
214486206|NCT01242215|DRUG|Placebo|oral
214486207|NCT01242215|DRUG|Sulfonylurea|oral
214486208|NCT06891274|DEVICE|USN before SVN|The group that received ultrasonic rock salt aerosol inhalation therapy followed by small-volume nebulized inhalation therapy.
214328025|NCT00869648|PROCEDURE|Neutral head position|After anaesthesia induction the head is placed in neutral position
214328026|NCT00869648|PROCEDURE|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
214328027|NCT03736824|PROCEDURE|endoscopy|All endoscopy was performed by qualified gastroenterologists or endoscopic physicians in Renji hospital,Shanghai Jiaotong University School of Medicine.
214328028|NCT04174313|DIAGNOSTIC_TEST|CT scan|"Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions.~Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased.~Refractory hypoxemia was defined as PaO2/FiO2 \<100 despite the optimization of mechanical ventilation and prone positioning."
214328029|NCT00682019|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
214328030|NCT00682019|DRUG|Placebo|matching placebo
214328031|NCT00019474|BIOLOGICAL|filgrastim|
214328032|NCT00019474|BIOLOGICAL|recombinant interferon alfa|
214328033|NCT00019474|DRUG|fluorouracil|
214328034|NCT00019474|DRUG|hydroxyurea|
214328035|NCT00352612|DRUG|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
214328036|NCT00352612|DRUG|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
214328037|NCT00528528|DRUG|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
214328038|NCT00528528|DRUG|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
214328039|NCT00528528|DRUG|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
214328040|NCT00528528|DRUG|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
214328041|NCT00528528|DRUG|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
214328042|NCT05068440|DRUG|Zanubrutinib|administered orally as capsules
215070332|NCT06890676|OTHER|Intraoral Complete Radiographic Series|A series of x-rays of the whole mouth intended to display the, teeth, roots, periapical areas, bone, and areas without teeth.
215070333|NCT06890676|OTHER|• Teledentistry-synchronous and asynchronous|The delivery or coordination of care for a patient using synchronous; real-time or aysnchronous communication between care providers or between care providers and a patient.
215070334|NCT06890676|PROCEDURE|Periodontal Therapy|A therapeutic procedure designed to remove plaque and calculus (hardened plaque) causing gum infections that can lead to tooth loss and other medical complications.
215070335|NCT06890676|PROCEDURE|Periodontal Maintenance Procedure|A periodic evaluation and therapeutic support procedure for patients with a history of gum infections.
215070336|NCT06890676|PROCEDURE|Application of Caries Arresting Medicament|Topical application of decay arresting or inhibiting medicament.
215070337|NCT06890676|OTHER|Oral Hygiene Assistance|Dental procedures aimed at educating patients on, and assisting patients with ,proper oral hygiene practices removing food debris, germ-laden plaque, and soft tartar using cloth wipes, toothbrush, floss, and using oral hygiene aids.
215070338|NCT06890676|PROCEDURE|Referral for Treatment of Acute Oral Infection|Diagnosis and treatment of oral infection outside the scope of a dental hygienist or Expanded Function Dental Assistant.
214328043|NCT06518668|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK. NKX019 will be administered at a dose of 1 × 109 CAR NK cells (dose normalized for weight for subjects ≤ 50 kg) administered IV.
214328044|NCT06518668|DRUG|Cyclophosphamide LD|"Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)"
214328045|NCT04973488|OTHER|Therapeutic plasma exchange|The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
214328046|NCT06641687|OTHER|24% Sucrose|Participants will be given either sugar water (24% sucrose) randomly
214328047|NCT06641687|OTHER|Sterile water|Participants will be given sterile water randomly
214328048|NCT02687906|DRUG|Vabomere|Vabomere (meropenem-vaborbactam) for IV injection
214328049|NCT06152744|OTHER|Monitoring membrane lung function at different altitudes|The altitude in Beijing is 100m, while the altitude in Xining, Qinghai is 2600m. We will monitor the partial pressure of post-ML arterial oxygen in ECMO patients in these two locations and evaluate whether the normal values of membrane lung function are consistent in different altitudes.
214328050|NCT04175210|RADIATION|Radiation therapy - 3 weeks|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
214328051|NCT04175210|RADIATION|Radiation therapy - 2 weeks|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
214328052|NCT05355870|BEHAVIORAL|Cognitive Training Intervention|Participants in the intervention group will complete a series of cognitive training exercises adapted from the BrainHQ. Results from the intervention development activities will be used to finalize the dose, frequency, and duration of the training. Each session will include 2 training exercises that target different cognitive domains. As participants progress, the difficulty level will be automatically adapted based on participants' performance.
214328053|NCT05182385|DRUG|Blinatumomab|"All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type."
214328054|NCT05182385|DRUG|Venetoclax|"In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type."
214929510|NCT01120080|BEHAVIORAL|Practical Counseling|To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
214929511|NCT01120080|BEHAVIORAL|Alcohol Intervention Counseling|The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
214929512|NCT04053140|DEVICE|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
214929513|NCT04053140|DEVICE|Microneedle array and closed-loop control of penicillin delivery|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.
214929514|NCT04053140|DRUG|Penicillin G_1200mg|Benzylpenicillin IV 1200mg administered every 4 hours.
214929515|NCT04053140|DRUG|Penicillin G_2400mg|Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
214929516|NCT04053140|DRUG|Penicillin G_600mg/hr|Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
214328055|NCT05703178|BEHAVIORAL|Online Pain Coping Skills Training|The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.
214929517|NCT04814550|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire, AccuFFRangio computed by coronary angiographic images
214929518|NCT00672581|DRUG|ZD4054|10mg, Oral tablet, single dose
214929519|NCT04782895|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 45 day and 6 month.
214929520|NCT04782895|BIOLOGICAL|Gardasil®9|Three doses administered intramuscularly at 0, 45 day and 6 month.
214929521|NCT03545295|PROCEDURE|Quadratus Lumborum Block type 2|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle
214929522|NCT03545295|PROCEDURE|Quadratus Lumborum Block type 3|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle
214929523|NCT00031681|DRUG|7-hydroxystaurosporine|Given IV
214929524|NCT00031681|DRUG|irinotecan hydrochloride|Given IV
214929525|NCT00031681|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214929526|NCT06322095|DRUG|PD-1|Previous PD-1
214929527|NCT06322095|DRUG|MET inhibitor|Previous MET inhibitor
214929528|NCT06322095|DRUG|ALK inhibitor|Previous ALK inhibitor
214929529|NCT06322095|DRUG|BRAF Inhibito|Previous BRAF inhibitor
214929530|NCT06322095|DRUG|EGFR Monoclonal antibody|Previous EGFR Monoclonal antibody
214929531|NCT06322095|DRUG|GH21|Oral, 15mg BIW or 6mg QD
214929532|NCT06322095|DRUG|MEK Inhibitor|Previous MEK Inhibitor
214929533|NCT01072435|DEVICE|Patient-controlled sedation|Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
214929534|NCT01072435|DEVICE|Target-controlled infusion|Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
214929535|NCT03194750|OTHER|Share ultrasound measurement of IVC collapsibility to Nephrology Attending|Nephrology attending will be provided with the respiratory variability of IVC diameter as a percent, in addition to a predefined cutoff for responsiveness to volume resuscitation of \< 12%. The information will be provided before rounds and before the attending sets the fluid removal goals on dialysis for that day.
214929536|NCT03194750|OTHER|Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending|Respiratory variability of IVC diameter will be measured, but the measurement result will not be shared with the treating team.
215070339|NCT06845579|PROCEDURE|Renal sympathetic denervation|All procedures will be carried out by highly experienced interventional cardiologists, each having performed a minimum of 20 RDN prior to treating study patients. All interventions will be performed with the CE-marked Symplicity SpyralTM (Medtronic, Minneapolis, MN, USA) renal denervation system following current treatment standards. Procedures will be performed as stated in the IFU. The specific ablation points will be determined by the discretion of the interventionalist.
214328056|NCT05703178|OTHER|Education|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
214328057|NCT02019849|DEVICE|Plasmafit® Total Hip Arthroplasty|
214328058|NCT06412107|OTHER|True acupressure|Participants will receive a 7-week true self-acupressure practice and a 12-week follow-up.
214328059|NCT06412107|OTHER|Sham acupressure|Participants will receive a 7-week sham self-acupressure practice and a 12-week follow-up.
214328060|NCT06412107|OTHER|Usual care|Routine methods of treatment and care along with an updated education booklet.
214929537|NCT05174858|DEVICE|Hemostatic dressing ETIK COLLAGENE|The hemostatic dressing ETIK COLLAGENE is placed in the alveolus immediately after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the surgical site is sutured.
214328061|NCT04197713|DRUG|Adavosertib|Given PO
214328062|NCT04197713|DRUG|Olaparib|Given PO
214328063|NCT06328894|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214328064|NCT06328894|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214486209|NCT06891274|DEVICE|SVN before USN|The group that received small-volume nebulized inhalation therapy followed by ultrasonic rock salt aerosol inhalation therapy.
214929538|NCT05174858|OTHER|Comparator|The alveolus is left empty after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the dressing ETIK COLLAGENE is placed in the alveolus and the surgical site is sutured.
214929539|NCT04201158|DIAGNOSTIC_TEST|Exercise Capacity|Modified Shuttle Walk Test
214929540|NCT03275675|DRUG|Oral anticancer medications|All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
214929541|NCT00262470|DRUG|Acetazolamide|250 mg PO x 1
214486210|NCT06890858|DRUG|Fasudil Hydrochloride|Exploring whether the study of using Exploring whether the study of using Fasudil Hydrochloride for the treatment of gene specific ovarian cancer can be used to predict the sensitivity of immunotherapy for non-small cell lung cancer and other tumors for the treatment of gene specific ovarian cancer can be used to predict the sensitivity of immunotherapy for non-small cell lung cancer and other tumors
214929542|NCT00262470|DRUG|Atomoxetine|10-40 mg PO x 1 dose
214929543|NCT00262470|OTHER|NO Drug|No intervention - just monitoring
214929544|NCT00262470|DRUG|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
214929545|NCT00262470|DRUG|Entacapone|Entacapone 200-400 mg PO x 1 dose
214328065|NCT06328894|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214328066|NCT06485271|DRUG|Camrelizumab|200mg,iv,d1,Q2W/Q3W
214328067|NCT06485271|DRUG|apatinib|250mg,qd
214328068|NCT06485271|DRUG|chemotherapy|Standard treatment
214328069|NCT05177042|DRUG|ARV-110 in Combination with Abiraterone|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles
214328070|NCT02259413|BEHAVIORAL|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
214929546|NCT00262470|DRUG|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
214929547|NCT00262470|DRUG|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
214929548|NCT00262470|DRUG|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
214929549|NCT00262470|DRUG|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
214929550|NCT00262470|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
214328071|NCT05569954|BIOLOGICAL|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
214929551|NCT00262470|DIETARY_SUPPLEMENT|Melatonin|melatonin 3 mg PO x 1 dose
214929552|NCT00262470|DRUG|Midodrine|midodrine 2.5-10 mg PO x 1 dose
214929553|NCT00262470|DRUG|Modafinil|modafinil 100-200 mg PO x 1 dose
214929554|NCT00262470|DRUG|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
214929555|NCT00262470|RADIATION|Placebo|lactose tablet x 1 pill
214328072|NCT05569954|BIOLOGICAL|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
214328073|NCT01660412|DRUG|Standard of Care First|For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40.
214328074|NCT01660412|DRUG|ph Altered first|For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
214929556|NCT00262470|DRUG|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
214929557|NCT00262470|DRUG|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
214328075|NCT06639490|DEVICE|RUS GA|he RUS GA (Endoscopic Imaging Treatment Planning Software, E04010.01(2)) is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the actual intra-abdominal surgical environment, allowing for the visualization of vascular structures and intra-abdominal organs during the surgical planning process and the operation. RUS GA utilizes preoperative CT images of the patient to segment organs and blood vessels and reconstructs them into a 3D model. Although there is no direct intervention with the patient, the surgeon uses RUS GA as a surgical navigation tool to simulate the surgery before performing the actual procedure.
214328076|NCT06639490|PROCEDURE|standard treatment|Only standard treatment is performed.(Robot-assisted gastrectomy will be performed using without software RUS GA.)
214328077|NCT06663397|OTHER|Laughter Yoga|Laughter Yoga sessions lasting 45 minutes each week for a total of 4 sessions. These sessions will include 30 minutes of laughter and breathing exercises, followed by 15 minutes of laughter meditation and relaxation
214328078|NCT06663397|OTHER|Standard Childbirth Preparation Training|the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions
214328079|NCT02184221|DEVICE|High frequency stimulation|The parameter of DMS: alpha frequency
214328080|NCT02184221|DEVICE|Low frequency stimulation|The parameter of DMS: 0.5Hz
214929558|NCT00262470|DRUG|Sertraline|sertraline 25-50 mg PO x 1 dose
214929559|NCT00262470|PROCEDURE|IV Saline|1 liter IV over 2 hours
214929560|NCT00262470|OTHER|Drinking Water|16 fluid ounces
214929561|NCT00262470|DEVICE|Breathing Device|Breathing through a dead space tube
214929562|NCT00262470|DRUG|memantine|memantine 5-20 mg PO x 1 dose
214929563|NCT00262470|DEVICE|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
214929564|NCT06004856|DRUG|Orelabrutinib|Orelabrutinib once daily (QD)
214929565|NCT06004856|DRUG|Placebo|Placebo once daily (QD)
214929566|NCT00877409|DRUG|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
214929567|NCT00877409|DRUG|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
214929568|NCT01864876|BIOLOGICAL|GLA-AF|Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
214929569|NCT01864876|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
214929570|NCT01864876|BIOLOGICAL|EM060G (SE)|The same stable oil-in-water emulsion (SE), but without GLA.
214929571|NCT02704572|BIOLOGICAL|Zostavax|Zostavax will be administrated by subcutaneous injection.
215070340|NCT06880042|DRUG|Tacrolimus|Tacrolimus is calcineurin inhibitor that will act as immunomodulator
215070341|NCT06880042|DRUG|Calcipotriol|Calcipotriol is a vitamin D analogue that will act as immunomodulator
215070342|NCT06755632|DIAGNOSTIC_TEST|TROD (rapid diagnostic orientation test) and FibroScan®|"Fast-track appointment at the hepatology consultation at Avicenne Hospital (Bobigny) or the hepatology consultation at Jean Verdier Hospital (Bondy) for any patient :~* with Fibroscan® ≥ 9.6 KPa or~* positive hepatitis C serology or~* HBsAg positive"
214929572|NCT03369067|DEVICE|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
214929573|NCT03369067|DEVICE|Dexcom CGM G5|"The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes"
214929574|NCT03369067|DEVICE|Continuous Subcutaneous Insulin Infusion|Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
214929575|NCT04828265|BIOLOGICAL|Aldafermin|Single dose of aldafermin
214929576|NCT02377479|DRUG|Clomiphene|Taken for controlled ovarian hyperstimulation.
214929577|NCT02377479|DRUG|Letrozole|Taken for controlled ovarian hyperstimulation
214929578|NCT05013879|DEVICE|Kinesio(R)Tape for edema control|Kinesio(R)Tape is an elastic, cotton tape with an adhesive backing. When applied for edema management, strips of Kinesio(R)Tape are applied to the lower leg in a criss-cross fashion by a physical therapist who is a Certified Kinesiotape Practitioner.
214929579|NCT03963050|OTHER|Exercise Training|The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
214929580|NCT03963050|OTHER|Exercise Training + Cognitive Training|"ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.~CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts."
214929581|NCT03963050|OTHER|Control|NO changes in lifestyle
214929582|NCT05172869|PROCEDURE|Suprainguinal Performed FICB|Linear ultrasound probe places above inguinal ligament sagittally, close to the femoral crease and superior-lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
214328081|NCT03118128|DRUG|Metformin|Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
214328082|NCT05733949|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214328083|NCT05733949|PROCEDURE|Computed Tomography|Undergo CT
214328084|NCT05733949|RADIATION|Stereotactic Body Radiation Therapy|Undergo ST-SBRT
214673289|NCT02901717|DRUG|Antibiotic lock|Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
214673290|NCT01292395|OTHER|Dietary Protein Intake|Protein intakes within the current recommendation
214673291|NCT05351086|DRUG|PUR3100|PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
214929583|NCT05172869|PROCEDURE|Infrainguinal Performed FICB|Linear ultrasound probe places below inguinal ligament transversally, close to the femoral crease and lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
214328085|NCT06658847|OTHER|Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. The investigational night cream will be used daily in the evening/at night.
214328086|NCT06658847|OTHER|No Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. No night cream will be used.
214328087|NCT06824181|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214328088|NCT06824181|BIOLOGICAL|Prevnar 20 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214328089|NCT06824181|BIOLOGICAL|M-M-R II vaccine|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
214328090|NCT06824181|BIOLOGICAL|Rotarix|Pharmaceutical form:Solution-Route of administration:Oral
214929584|NCT03310658|DEVICE|Zip-Stitch Soft Tissue Closure System|The novel Zip-Stitch System employed a laparoscopic applicator, a series of bio-absorbable clips, and an application procedure to close the vaginal cuff during otherwise standard of care total laparoscopic hysterectomy.
214673292|NCT05351086|DRUG|Dihydroergotamine (D.H.E 45)|D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
214929585|NCT02155517|DRUG|Evaluation of propofol effect|"The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
214929586|NCT02155517|DRUG|Evaluation of propofol effect|STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
214929587|NCT06618560|DEVICE|Enamel Matrix Derivative application|After submarginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush), implant surfaces will be conditioned for 2 min with 24% ethylene-diaminetetraacetate EDTA (PrefGel®, Institut Straumann AG). Then, the sites will be completely rinsed with saline solution and thoroughly dried with air. Repeated irrigation and air-drying will be done in the area until complete bleeding control with sterile gauzes. Then EMD (Emdogain®, Institut Straumann AG) will be gently applied with a blunt-tipped sterile syringe until overflowing from the mucosal margin.
215070343|NCT06893549|DIETARY_SUPPLEMENT|Lactobacillus plantarum GKK1 Probiotic|Participants in the probiotic group will receive a daily oral supplementation of Lactobacillus plantarum GKK1 probiotic capsules for 28 days. Each capsule contains 50 billion CFU, with a total daily intake of 100 billion CFU. The probiotic strain Lactobacillus plantarum GKK1 has been selected for its potential benefits in reducing exercise-induced fatigue and enhancing physical performance. The supplementation period will be followed by an exhaustive exercise test to assess physiological and biochemical changes.
215070344|NCT06893549|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will receive a daily oral supplementation of placebo capsules for 28 days. The placebo capsules are identical in appearance, taste, and weight to the probiotic capsules but contain only microcrystalline α-cellulose, magnesium stearate, and silicon dioxide. The supplementation period will be followed by an exhaustive exercise test to assess physiological and biochemical changes.
215070345|NCT03950544|DRUG|Fosfomycin|Fosfomycin and meropenem
215070346|NCT03950544|DRUG|Tigecycline|Tigecycline and meropenem
215070347|NCT03950544|DRUG|Polymyxin B|Polymyxin B and meropenem
215070348|NCT07080931|DRUG|5% minoxidil foam|Participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
215070349|NCT07080931|DRUG|Placebo for 5% Minoxidil Foam|Participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
215070350|NCT07080879|DEVICE|Linear Anastomat|The product registration certificate numbers of linear anastomat is Su Wei registered 20202021581.
215070351|NCT07080879|DEVICE|Tubular Anastomat|The product registration certificate numbers of tubular anastomat is Su Wei registered 20182020305.
215070352|NCT06889779|DIETARY_SUPPLEMENT|MIX 1|Humiome® Post LB postbiotic 300 mg , Human Milk Oligosaccharides 2'-Ofucosyllactose 300 mg 1 capsule per day Orally
215070353|NCT06889779|DIETARY_SUPPLEMENT|MIX 2|Humiome® Post LB postbiotic 100 mg Human Milk Oligosaccharides 2'-O-fucosyllactose 500 mg 1 capsule per day Orally
215070354|NCT06889779|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose 1 capsule per day Orally
214328091|NCT06824181|BIOLOGICAL|RotaTeq|Pharmaceutical form:Solution-Route of administration:Oral
215070355|NCT07079267|DRUG|Olpasiran|
215070356|NCT03359707|OTHER|survey|no intervention just survey
215070357|NCT00002598|BIOLOGICAL|recombinant interferon alfa|
215070358|NCT00002598|BIOLOGICAL|sargramostim|
215070359|NCT00002598|DRUG|cyclophosphamide|
215070360|NCT00002598|DRUG|cytarabine|
215070361|NCT00002598|DRUG|etoposide|
215070362|NCT00002598|DRUG|methotrexate|
215070363|NCT00002598|DRUG|mitoxantrone hydrochloride|
215070364|NCT00002598|PROCEDURE|bone marrow ablation with stem cell support|
215070365|NCT00002598|RADIATION|radiation therapy|
215070366|NCT04374591|DRUG|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
215070367|NCT06385093|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
214328092|NCT06824181|BIOLOGICAL|Vaxelis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214328093|NCT06824181|BIOLOGICAL|Varivax|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
214328094|NCT06824181|BIOLOGICAL|Priorix|Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous
215070368|NCT06385093|DRUG|Alfacalcidol tablets|Oral Alfacalcidol 0.5μg daily
215070369|NCT06385093|DRUG|Calcium carbonate tablets|1.5g Calcium carbonate daily
215070370|NCT00197145|DRUG|GW873140|400 mg twice daily
214328095|NCT06824181|BIOLOGICAL|VAQTA|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
214328096|NCT06824181|BIOLOGICAL|Havrix|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
214328097|NCT04920448|DRUG|N-Acetyl cysteine|Administered as specified in the treatment arm
214929588|NCT06618560|DEVICE|Hyaluronic Acid (HA)|After submarginal instrumentation of the implant surface (i.e., titanium curettes plus oscillating chitosan brush), the cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) will be will be implemented to the peri-implant pockets.
214929589|NCT06618560|PROCEDURE|Control|Implants allocated to the control group will be treated with the same sub-marginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush). Implant surface will be irrigated with with sterile saline.
214929590|NCT04799548|DRUG|Transcatheter Arterial Chemoembolization|"Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid."
214328098|NCT05741658|DRUG|Dapagliflozin 10mg Tab|Participants will take one Dapagliflozin 10mg tablet once per day for 4 weeks.
214328099|NCT05354375|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.
214929591|NCT04799548|DRUG|Tislelizumab|PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
214328100|NCT06995300|PROCEDURE|minimally invasive decompression via the posterior approach|All patients will undergo minimally invasive isolated decompression via the posterior approach to the cervical spine.
214328101|NCT06084013|OTHER|Non-Interventional Study|Non-interventional study
214328102|NCT01686412|DEVICE|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
215070373|NCT04670458|OTHER|no intervention|no intervention
215070374|NCT05834088|OTHER|Myofascial release techniques|12 treatment sessions will be given in 12 weeks
215070375|NCT05834088|OTHER|Thiele massage|12 treatment sessions will be given in 12 weeks
214328103|NCT07000994|DRUG|Dobutamine|In patient assigned to dobutamine administration, dobutamine (concentration: 5 mg mL-1) will be administered with an infusion rate of 3 µg kg-1 min-1 (ideal body weight).
214328104|NCT07000994|OTHER|Routine care|In patients assigned to routine care, intraoperative hemodynamic management will be in accordance with routine care.
214328105|NCT05269628|DRUG|Cannabidiol (CBD)|"Epidiolex® dose will be 0.5 mL (50 mg) twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 1 mL (100 mg) twice daily for the remainder of the treatment interval (full dose). If the full dose (100 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (50 mg twice daily).~Participants who go back to the half-dose of Cannabidiol (50 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 100 mg Cannabidiol per day. Participants who are tolerating the full-dose of medication (Cannabidiol 100 mg twice daily) will not be allowed to combine these doses into one daily dose."
215070376|NCT04217135|DRUG|evidence-based medications vs. high-dose hydralazine + evidence-based medications|randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
215070377|NCT05751590|DEVICE|comined use of gliddescope and fiberoptic broncscopy|endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
215070378|NCT05751590|DEVICE|fiberoptic bronscopy|endotrachotreal intubation will be done by Fiberoptic broncscopy
214328106|NCT05269628|DRUG|Tetrahydrocannabinol (THC)|"Dronabinol dose will be 2.5 mg twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 5 mg twice daily for the remainder of the treatment interval (full dose). If the full dose (5 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (2.5 mg twice daily).~Participants who go back to the half-dose of Dronabinol (2.5 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 5 mg Dronabinol per day. Participants who are tolerating the full-dose of medication (Dronabinol 5 mg BID) will not be allowed to combine these doses into one daily dose."
214328107|NCT05269628|DRUG|Placebo CBD|Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
214328108|NCT05269628|DRUG|Placebo THC|Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
214328109|NCT04579679|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
214673293|NCT05351086|OTHER|Matching Placebo for PUR3100|Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).
214673294|NCT05351086|OTHER|Matching Placebo for D.H.E 45|The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
214673295|NCT00893503|PROCEDURE|colonoscopy|Patients will provide stool and urine samples and will be scheduled to undergo a colonoscopy. The colonoscopy will be done per standard of care - no study specific procedural requirements imposed.
214929592|NCT05053048|DEVICE|SL-PLUS-Stem for total hip arthroplasty|Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
214673296|NCT00077987|DRUG|SU011248|
214929593|NCT05591612|BEHAVIORAL|Salt replacement seasoning (50% salt and 50% MSG) mix|Individuals in this group were provided a seasoning that replaced 50 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 50/50 MSG Mix to be added to vegetables in diet.
214673297|NCT01772225|OTHER|Data collection|Medical record abstraction form and patient survey questionnaire.
214673298|NCT04716439|PROCEDURE|Spine Surgery|spine decompression and fixation
214929594|NCT05591612|BEHAVIORAL|Salt replacement seasoning (70% salt and 30% MSG) mix|Individuals in this group were provided a seasoning that replaced 30 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 70/30 MSG Mix to be added to vegetables in diet.
215070379|NCT00018330|BEHAVIORAL|Weight Loss|
214673299|NCT00417612|DRUG|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
214673300|NCT00417612|OTHER|Placebo|Placebo sugar pill
214673301|NCT03549273|DIETARY_SUPPLEMENT|Glizigen® + Ocoxin-Viusid®|"* Glizigen® spray, topical use, 2 times a day for 6 months with an interruption for 2 months at the end of the third month.~* Ocoxin®-Viusid® 60 ml daily (1 vial every 12 hours) by oral route for 8 months, preferably administered after breakfast and lunch, without interruption."
214673302|NCT01005472|DRUG|sunitinib malate|
214929595|NCT05591612|BEHAVIORAL|NaCl (sodium chloride/table salt)|Individuals in this group were asked to use normal seasoning of regular salt. This study assessed the vegetable intake using table salt to be added to vegetables in diet.
215070380|NCT03040011|DRUG|Dexamethasone|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
215070381|NCT03040011|DRUG|Bupivacaine|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
214673303|NCT01005472|DRUG|temozolomide|
214929596|NCT04913350|OTHER|Russian current|One of the preferred common neuromuscular electrical stimulation techniques for muscle strengthening is the Russian current (RC) It stimulates almost all muscle motor units to contract synchronously, resulting in a greater muscle hypertrophy.
214929597|NCT04913350|DEVICE|elbow support|tennis elbow brace is recommended to decrease pain and improve function by restricting the movement of the forearm or relieving loads on the origin of the muscles of the extensor
214929598|NCT01783639|PROCEDURE|Carotid Artery Stent|Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
215070382|NCT03040011|PROCEDURE|Bilateral Pudendal Nerve Block|Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
214673304|NCT02318394|BIOLOGICAL|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
214673305|NCT01841008|DRUG|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
214328110|NCT06678438|PROCEDURE|Ultrasound-guided brachial plexus block|The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block
214328111|NCT06678438|PROCEDURE|Haematoma Block|Participants will receive no peripheral nerve block and receive a haematoma block, with or without supplemental sedation and/or systemic analgesia for the closed reduction according to local guidelines and clinical practices
214673306|NCT01841008|DRUG|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
214929599|NCT05267925|DIETARY_SUPPLEMENT|CuraLin|"CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs.~The CuraLin formulation contains the following ingredients (per 2 capsules):~* Mormordica charantia (fruit) - 300mg~* Gymnema sylvestre (leaf) - 80mg~* Trigonella foenum-Graecum (seed) - 100mg~* Curcuma longa (rhizome) - 100mg~* Phyllanthus embilica officinalis (fruit) - 100mg~* Swertia chiraytia (leaf) - 80mg~* Syzgium Cumini (seed) - 100mg~* Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root) - 100mg~* Cinnamoum verum/zeylanicum - 40 mg~* Hydroxypropyl methylcellulose~* Rice Flour"
214929600|NCT00122122|BEHAVIORAL|Enhanced Pharmacy Care|
214929601|NCT02774122|DEVICE|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
214929602|NCT02774122|DEVICE|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
214929603|NCT03028857|DRUG|Choline|Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
214929604|NCT03028857|DRUG|Placebo|Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
214929605|NCT05555225|OTHER|Methylome|Epigenetic study : analysis of DNA methylation
214929606|NCT02952625|OTHER|Imaging|Single arm Imaging (PET/MR) study
214929607|NCT00549913|BIOLOGICAL|NeoFuse|immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
214929608|NCT00549913|PROCEDURE|posterolateral spinal fusion with instrumentation|autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
214929609|NCT00567385|DRUG|somatropin|
214328112|NCT04107636|PROCEDURE|Vacuum assisted biopsy|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (\<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location.
214328113|NCT04107636|PROCEDURE|conventional lumpectomy|After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
214673307|NCT02268565|DRUG|Aspirin|81mg aspirin daily at bedtime over a 2 week period
215070383|NCT03040011|PROCEDURE|Bilateral Levator Ani Muscle Injection|Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
214929610|NCT03748576|BEHAVIORAL|telemedicine: management through WeChat group chat|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care
215070384|NCT03040011|DRUG|Saline|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
215070385|NCT00822705|DRUG|Placebo tablet|Control arm
215070386|NCT00305032|PROCEDURE|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
214929611|NCT06451289|DIAGNOSTIC_TEST|Head computered tomography|Retrospective data collecting from medical records
214929612|NCT01305889|BEHAVIORAL|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
214929613|NCT01305889|DRUG|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
214929614|NCT02085668|DEVICE|Renal denervation (Symplicity™)|Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
214328114|NCT07019246|DRUG|EP mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
214673308|NCT02268565|DRUG|Placebo|pill that looks like aspirin without the effects of aspirin
214328115|NCT07019246|DRUG|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
214328116|NCT06630832|OTHER|Simulated work in the heat with no cooling during rest breaks|Young and older adults will not undergo cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
214328117|NCT06630832|OTHER|Simulated work in the heat with partial cooling during rest breaks|Young and older adults will not undergo partial cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
214328118|NCT06630832|OTHER|Simulated work in the heat with full cooling during rest breaks|Young and older adults will not undergo full cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
214328119|NCT06462131|BEHAVIORAL|Cultural Adapted Group cognitive Behaviroal therapy (CaGCBT)|In first session, introduction of the therapist/facilitator and group members will be made. Group rules will be discussed with members. Group members' introduction primarily focuses on participant/clients' expectations, addictive behaviors and its status, and goals. Moreover, it also emphasize on identification of any other significant issue that is contributing in burden of disease.
214929615|NCT00396552|DEVICE|refractory transcranial magnetic stimulation (rTMS)|Bilateral rTMS will be delivered according to the following protocol: high frequency left (HFL) stimulation will initially be applied at 20 Hz, in 25 trains of 1.5 second duration with a 30 second interval between trains and at 100% of the RMT for a total of 25 minutes of stimulation. Following this HFR stimulation will be applied at the same parameters. Therefore a total of 50 minutes of stimulation will be delivered.
214328120|NCT07023653|PROCEDURE|All-Inside Techniques|All-inside ACL reconstruction technique avoids creating full-length bone tunnels. Instead, it uses retrograde drilling to form bone sockets, and the graft is secured with adjustable-loop suspensory fixation on both the femur and tibia.
214328121|NCT07023653|PROCEDURE|Complete Tibial Tunnel techniques|Complete Tibial Tunnel Technique is a conventional technique for ACL reconstruction which involves the creation of full-length bone tunnels in the tibia for graft passage via an anterograde approach. Graft fixation is typically achieved using a bio-interference screw on the tibial side and a fixed-loop suspensory device on the femoral side
214328122|NCT07024030|DRUG|0.02mg/kg|Slowly infuse intravenously 24 hours before the scheduled surgery. The investigator shall conduct near-infrared fluorescence imaging during the operation to assist with the surgery. Tissues detected with fluorescence need to be marked, and resection shall be guided by fluorescence until there is no fluorescent tissue within the surgical field.
214929616|NCT00396552|DEVICE|Sham condition|Sham stimulation will be made at the site of active treatment but with only the side edge resting on the scalp. It will be administered as HFL and HFR for 50 minutes but with the coil angled 45-90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those with active stimulation but with minimal direct brain effects. Participants will be unable to see the stimulating coil and therefore will remain blind to the treatment condition.
214929617|NCT06431399|DRUG|JLP-2004 qd|Group I(Peroid I-JLP-2004 FAST, Peroid II-JLP-2004 FED), Group II(Period I-JLP-2004 FED, Period II-JLP-2004 FAST)
214328123|NCT07024030|DRUG|0.04mg/kg|Slowly infuse intravenously 24 hours before the scheduled surgery. The investigator shall conduct near-infrared fluorescence imaging during the operation to assist with the surgery. Tissues detected with fluorescence need to be marked, and resection shall be guided by fluorescence until there is no fluorescent tissue within the surgical field.
214929618|NCT00655733|DRUG|HMPL-004|HMPL-004 1200 mg/d
214929619|NCT00655733|DRUG|Placebo|Placebo 1200 mg/d
214929620|NCT03440307|BEHAVIORAL|Face-to-Face Meetings|Participants received health and fitness education, and a face-to-face 3-week intervention to reduce bisphenol exposure.
214929621|NCT03440307|BEHAVIORAL|Email Only|Participants received health and fitness education.
214929622|NCT04087629|DEVICE|StrataCTX® gel|Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
214929623|NCT00662662|BEHAVIORAL|Questionnaire|The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
214929624|NCT01011166|DRUG|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
214929625|NCT01011166|DRUG|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
214929626|NCT01011166|BIOLOGICAL|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
214929627|NCT01011166|DRUG|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
214929628|NCT05990348|OTHER|difficult weaning patients|intercostal thickening fraction values during PSV and NAVA modalities in patients with difficult weaning from MV admitted in ICU.
214929629|NCT01264666|DIETARY_SUPPLEMENT|Chinese tea flavor liquor|60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
214929630|NCT01264666|DIETARY_SUPPLEMENT|Chinese Meijiao liquor|
214929631|NCT01264666|DIETARY_SUPPLEMENT|Water control|
214929632|NCT05567432|PROCEDURE|thyroidectomy|use diathermy or ligasure for homeostatic during thyroidectomy
214328124|NCT07025772|BEHAVIORAL|ST+ABR|ST+ABR participants will complete seven weekly sessions of 15 minutes of computerized training (ABR), followed by a 45-minute session of standard smoking cessation treatment (CBT+NRT). Participants will be instructed to pull or push a joystick depending on the tilt, which will be positive-related or smoking-related images.
214673309|NCT01680224|BEHAVIORAL|Healthy Weight|
214673310|NCT01680224|BEHAVIORAL|Project Health|
214929633|NCT05481593|BEHAVIORAL|Scheduled Coaching + Gamified Rewards|Participants will receive scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
214328125|NCT07025772|BEHAVIORAL|ST+Sham|ST+Sham participants will complete seven weekly sessions of 15 minute computerized control sessions (AAT), followed by a 45-minute session of standard smoking cessation treatment (CBT+NRT). Participants will be instructed to pull or push a joystick depending on the tilt, which will be positive-related or smoking-related images.
214328126|NCT07025772|BEHAVIORAL|ST Only|ST Only will consist of 7 weekly 45-minute sessions of standard treatment (CBT+NRT) for smoking cessation.
214328127|NCT07025733|DEVICE|Semiconductor Embedded Sock|Semiconductor Embedded sock will be given to this intervention arm
214673311|NCT01680224|BEHAVIORAL|Placebo Control|Participants will view a video on overweight and obesity
214929634|NCT05481593|BEHAVIORAL|Scheduled Coaching Calls + Independent Rewards|Participants will receive scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
214929635|NCT05481593|BEHAVIORAL|No Scheduled Coaching Calls + Gamified Rewards|Participants will not have scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
214929636|NCT05481593|BEHAVIORAL|No Scheduled Coaching Calls + Independent rewards|Participants will not have scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
214328128|NCT07025733|DEVICE|Control Compression Sock|Control sock that is just compression sock
214673312|NCT01483040|DEVICE|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
214673313|NCT01646008|OTHER|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
215070387|NCT02279771|PROCEDURE|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
215070388|NCT02279771|PROCEDURE|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
215070389|NCT02279771|DEVICE|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
215070390|NCT02968160|DRUG|Telmisartan 40mg + Rosuvastatin 20mg|
215070391|NCT02968160|DRUG|Telmisartan 80mg + Rosuvastatin 20mg|
215070392|NCT02968160|DRUG|Telmisartan 40mg, 80 mg|
215070393|NCT02968160|DRUG|Rosuvastatin 20mg|
215070394|NCT01809145|OTHER|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
215070395|NCT02518958|DRUG|RRx-001|
215070396|NCT02518958|DRUG|Nivolumab|
215070397|NCT01174277|OTHER|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
214328129|NCT07024927|PROCEDURE|AF ablation|Catheter ablation will be performed under general anesthesia or local anesthesia. Pulmonary vein isolation (PVI) was performed in all patients. Beyond this mandatory step, the specific ablation strategy/protocol and ablation parameters/settings will be determined at the discretion of the operating physicians at each participating center.
214328130|NCT07024927|PROCEDURE|VT ablation|For patients with hemodynamically stable VT, comprehensive chamber mapping (including activation mapping, substrate mapping, and entrainment mapping) is recommended. This aims to elucidate the VT activation sequence and identify the critical isthmus. Precise ablation targeting the isthmus should be performed to terminate the VT. For patients with hemodynamically unstable VT, substrate mapping during sinus rhythm can be performed first. This includes identification of low-voltage zones and abnormal electrograms (e.g., late potentials, local abnormal ventricular activities - LAVAs). Targeted substrate modification ablation should then be conducted based on the mapping findings. For all patients, complete substrate mapping is recommended after VT termination.
214328131|NCT07024862|BIOLOGICAL|nivolumab + ipilimumab|First-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC)
214673314|NCT01646008|OTHER|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
215070398|NCT01301521|DRUG|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
215070399|NCT02987907|DRUG|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
215070400|NCT02987907|DRUG|Normal Saline|use normal saline 2ml I.A. during TACE
215070401|NCT06195969|BEHAVIORAL|automated instant message-guided hypertension management intervention group|Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al., we will develop a message content library and protocol for EMI delivery
215070402|NCT03511508|BEHAVIORAL|ChroPreg + standard care|"* Ongoing update of individual maternity care plan.~* Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~* Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~* Possibility for psychologist consultation.~* Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~* Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth."
215070403|NCT03372551|DEVICE|somofilcon A 1 day test lens|Contact lens
215070404|NCT03372551|DEVICE|somofilcon A 1 day control lens|Contact lens
214328132|NCT07025473|DIAGNOSTIC_TEST|Smartphone-enabled otoscopy|Belle AI for ear image assessment
214328133|NCT07024368|DEVICE|Reliability of the Sensory Organization Test on the SMART Balance Master across multiple administrations|"The Sensory Organization Test (SOT) on the SMART Balance Master® will be administered a total of five times. On the first day, participants will complete three SOT sessions, each separated by a 20-minute break. An additional SOT will be conducted on day 45, followed by a final SOT on day 50.~SOT test scores will be analyzed using Equilibrium Scores (ESs), which provide information on the integration of multiple sensory systems involved in balance through a linear measurement method. Additionally, scores will be evaluated using Multiscale Entropy (MSE), a non-linear model for assessing complexity in postural stability."
214328134|NCT07023913|OTHER|kinetic Control exercises|Kinetic Control exercises consist of 45-minute sessions, with 3 sessions per week for 8 weeks. The framework for testing and rehabilitation includes initial assessment, rehabilitation before failure, and retesting the same position. Biofeedback measures scapular retraction, and biofeedback pressure training assesses and improves scapular stabilizer control by monitoring pressure changes during specific movements.
214328135|NCT07023913|OTHER|traditional treatment|traditional therapy inform of stretching and strengthening exercise as shoulder roll, arm circle, wall climb, back climb and hand behind neck. Patients will receive 3 sessions per week for 8 weeks, the time of session is 45 - 60 min according to patient ability
214328136|NCT07023861|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15 mCi/kg.
214328137|NCT07023861|DRUG|89Zr-LNCab190|89Zr-LNCab190 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
214328138|NCT07023861|DRUG|89Zr-LNCab002|89Zr-LNCab002 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
214328139|NCT07023861|DRUG|89Zr-LNCab072|89Zr-LNCab072 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
214328140|NCT07024498|OTHER|care coordination implementation strategies|The intervention will be a bundle of implementation strategies developed during a prior study and informed by the multi-team systems framework. Core implementation strategies are expected to include a standardized ED substance use navigator note (with education and billing support), a mechanism for sharing PHI information across ED-clinic pairs that use different electronic health record systems, an improved ability for patients to directly contact EDs and clinics, ensuring ED and outpatient teams mutually understand each other roles, implementing procedures to increase capacity for same-day outpatient buprenorphine refills, and interactive problem solving with an external facilitation team. Strategies will be adapted to local contexts at each site.
214328141|NCT07024212|DRUG|DR10624 Injection|Drug: DR10624 injection
214328142|NCT07024212|DRUG|Placebo|Drug: Placebo
214929637|NCT06418477|DRUG|Dara-CyBorD|"Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.~Drug: Daratumumab: 16mg/kg IV dose OR 1800 mg subcutaneously Drug: Cyclophosphamide: 300 mg/m\^2 as an oral or IV dose Drug: Bortezomib: 1.3 mg/m\^2 as an subcutaneous (SC) injection. Drug: Dexamethasone: 20-40mg Patients will receive the above drugs (Dara-CyBorD) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 1 years.~Note: If patients achieve less than hematologic VGPR by cycle 3 or less than PR by cycle 2, treatment plan will be allowed to discontinued, according to treatment principle in systemic light chain amyloidosis."
214929638|NCT03410472|BEHAVIORAL|Web based diet application|This group will be asked to record their diets for 8 weeks after being told an approximate calorie goal. This group will receive weekly emails with tips on how to eat healthy
214328143|NCT07025603|BEHAVIORAL|The social ABCs|"The Social ABCs, a parent-mediated intervention for toddlers with suspected or confirmed Autism Spectrum Disorder (ASD), originally developed in Canada (Brian et al., 2016). It is based on principles of Pivotal Response Treatment (PRT, grounded in Applied Behavioural Analysis). The two main goals of the intervention: early functional verbal communication and positive affect sharing in the context of play and caregiving activities.~The current study follows the Group Social ABCs protocol, a 6-week parent-mediated intervention designed to support early social communication in young children with autism. The program is delivered at two research sites: Soroka and Hebrew University of Jerusalem. Each week, parents participate in: One group session via Zoom, led by a trained Social ABCs coach, with 3-5 parents per group. These sessions introduce strategies and provide peer support, and one to two individual face-to-face coach (See #17-745 for more information)."
214486211|NCT04096066|DRUG|Carfilzomib|"* 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~* 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~* 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards."
214486212|NCT04096066|DRUG|Lenalidomide|\- 25 mg orally on days 1-21 of each cycle.
214929639|NCT06647563|BIOLOGICAL|Toripalimab|Specified dose on specified days
214929640|NCT06647563|BIOLOGICAL|Cetuximab|Specified dose on specified days
214929641|NCT06647563|DRUG|Albumin-Bound Paclitaxel|Specified dose on specified days
214929642|NCT06647563|DRUG|Carboplatin|Specified dose on specified days
214929643|NCT06647563|DRUG|Cisplatin|Specified dose on specified days
214929644|NCT06647563|RADIATION|Radiotherapy 60 Gray/day|Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
214929645|NCT06647563|RADIATION|Radiotherapy 66 Gray/day|High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
214929646|NCT06647563|RADIATION|Radiotherapy 70 Gray/day|Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
214929647|NCT01028638|OTHER|89Zr-bevacizumab PET scan|"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43."
214929648|NCT02236806|DRUG|Bisoprolol|5 mg daily
214929649|NCT02236806|DRUG|Ramipril|5 mg daily
214929650|NCT02236806|DRUG|Placebo|1 capsule daily
214929651|NCT00101075|DRUG|Capecitabine|
214929652|NCT00101075|DRUG|Oxaliplatin|
214929653|NCT02658734|DRUG|Trastuzumab emtansine|3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
214328144|NCT07025447|BEHAVIORAL|Familia Bora|"Familia Bora is a couples-based group parenting program that takes place in a preferred location within the community among participants. Twelve couples will be enrolled in each village and form one parenting group. CHWs will be trained to deliver the intervention.~The program will involve 17 group sessions. Each session is expected to last 1.5 hours and will be delivered weekly for approximately 6 months. Each session will focus on various topics, including responsive caregiving, positive discipline, managing emotions and stress management, child nutrition, couples' communication, non-violent conflict resolution strategies in relationships, and gender equity. In addition to the weekly group parenting sessions, CHWs will provide home visits to couples on an approximately monthly basis to reinforce key messages related to early childhood development, responsive caregiving, mental health, positive discipline, and healthy couples' relationships."
214328145|NCT07085156|DRUG|Fludarabine; melphalan; busulfan|The conditioning regimen includes fludarabine, busulfan, and melphalan, with a transplant conditioning intensity of 3.0. The RIC is used in the allo-HCT in the MDS patients.
214328146|NCT07085715|DIAGNOSTIC_TEST|Online self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HIV)|"The TESTATE website (https://testate.org/) will be expanded to include the offer of free HBV/HCV/HIV self-sampling kit. Users will log in and complete a sociodemographic, behavioral and hepB vaccination survey, which will include the HCVMOSAIC questionnaire. Users identified at HCV risk will be sent a DBS collection kit by post to detect HCV RNA, HBsAg and HIV Ab. Participants will self-collect the DBS sample by finger prick at home and send them to the laboratory by post. The results will be delivered online. All participants who return samples will receive an acceptance survey by email.~All participants recruited into the study will be provided with online information about the study and given the opportunity to ask questions and clarify queries to the field coordinator by email or phone."
214328147|NCT07085832|OTHER|Education (ALS provider course) in Egypt|Participants complete an ALS course, including theoretical and practical components focused on scenario based simulations for CPR and chest compressions.
214929654|NCT02396017|DEVICE|Capsule endoscopy|Endoscopic device
214929655|NCT02396017|DRUG|Polyethylene Glycol|Bowel purgative
214929656|NCT05409313|BEHAVIORAL|EBP training|The EBP training program was modified by the 5A-steps EBP teaching model that which aimed to enhance nurses' EBP competencies and application. A 12-hours EBP training consisted of lectures, hand-on practice, group and individual consulting, group presentations and reflections, and disseminating findings to publish.
214929657|NCT05409313|BEHAVIORAL|SDM training|A 10-hour SDM training program included lecture 4 hours and workshops 6 hours, with focused on 3-talk model for SDM skills, 4-habit model for communication skill, and how to use Ottawa personal decision guide. Teaching strategies included lectures, clinical scenarios role play, and post-scenario debriefing. The major contents were SDM concepts and essential steps, SDM tools, strategies for the clinical implementation, the concept and purpose of choosing wisely campaign, and patient-centered communication skills.
214929658|NCT03647735|OTHER|patient-controlled sedation|Patient-controlled propofol boluses for patients undergoing elective orthopaedic surgery under central neuraxial block
214929659|NCT05839106|DRUG|PM1032 injection|Subjects will receive PM1032 by intravenous administration.
214929660|NCT00459706|DEVICE|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
214929661|NCT00459706|DEVICE|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
214929662|NCT00074997|OTHER|Placebo|Single intravenous infusion of placebo.
214929663|NCT00074997|GENETIC|OZ1|Single intravenous infusion of OZ1.
214929664|NCT00074997|GENETIC|CD34+ cells|Autologous CD34+ cells.
214929665|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
214929666|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
214929667|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
215070405|NCT00678535|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m\^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
215070406|NCT00678535|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
215070407|NCT00678535|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
215070408|NCT04178993|DRUG|Methamphetamine|In each arm, subjects will receive doses of methamphetamine.
215070409|NCT04178993|DRUG|Methylphenidate|In each arm, subjects will receive methylphenidate capsules.
215070410|NCT04178993|DRUG|Placebo oral capsule|In each arm, subjects will receive placebo capsules.
215070411|NCT04178993|DRUG|Duloxetine|Subjects will receive duloxetine capsules in the duloxetine arm.
214929668|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
214929669|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
214929670|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
214929671|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
214929672|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
214929673|NCT02447497|DRUG|3M CHG/IPA Surgical Skin Preparation - Abdominal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
214929674|NCT02447497|OTHER|Normal Saline - Abdominal Region|0.9% sodium chloride applied with foam applicator
214929675|NCT02447497|DRUG|3M CHG/IPA Surgical Skin Preparation - Inguinal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
214929676|NCT02447497|OTHER|Normal Saline - Inguinal Region|0.9% sodium chloride applied with foam applicator
214929677|NCT04642677|OTHER|healthcare provider's recommended communication with sympathy and printed paper|"Patients and caregivers were received healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock) during palliative sedation."
214929678|NCT05797415|PROCEDURE|Sentinel Lymph Node Biopsy|"* Injection of 99mTc-labeled nanocolloids~* Preoperative lymphoscintigraphy~* Intraoperative gamma probe search of the sentinel lymph node~* Sentinel lymph node biopsy~* Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~* If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy."
215070412|NCT02933840|DEVICE|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
215070413|NCT01134406|DEVICE|Hydros Joint Therapy|Single intra-articular injection.
215070414|NCT01134406|DEVICE|Hydros-TA Joint Therapy|Single intra-articular injection
215070415|NCT01134406|DEVICE|Synvisc-One|Single intra-articular injection.
215070416|NCT03285958|BEHAVIORAL|STEPS Intervention|Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
215070417|NCT06178289|DEVICE|3M Cavilon Advanced Skin Protectant|3M Cavilon Advanced Skin Protectant is applied to the study area of partial-thickness wounds (IAD category 2A, peri-wound MASD, peri-stomal MASD). Application of the study device should be according to the manufacturer's IFU. Comprehensive training for nurses will be provided to the study nurses.
215070418|NCT06178289|DEVICE|Standard hospital wound treatment protocol|Comparator: Standard hospital wound treatment protocol
215070419|NCT05988294|OTHER|Pilates exercises|One-hour Pilates exercise program was given by a certified trainer to patients three times per week for 12 weeks. The exercise program followed the basic principles of the Pilates method. Our protocol comprised the following components of Pilates-based exercises: strength and stabilization, flexibility and range of motion, proper body alignment, balance, coordination, and body awareness. Resistance bands and 26 cm Pilates balls were used as supportive equipment. The exercise sections consisted of 5 minutes breathing, 10 minutes warm-up, 35 minutes conditioning phase and 10 minutes cool-down.
215070420|NCT05988294|OTHER|Conventional physical therapy exercise program|Diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs for 45 minutes, 3 days/ week for 12 weeks.
215070421|NCT05519501|DEVICE|SyntrFuge System|Microsized Adipose Tissue
215070422|NCT05519501|PROCEDURE|Standard of Care|Offloading
215070423|NCT02578680|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
215070424|NCT02578680|DRUG|Cisplatin|IV infusion
215070425|NCT02578680|DRUG|Carboplatin|IV infusion
215070426|NCT02578680|DRUG|Pemetrexed|IV infusion
215070427|NCT02578680|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
214328148|NCT07084805|BEHAVIORAL|Diabetes Inspired Culinary Education (DICE) - Phase 1|The DICE intervention is a 10-lesson family-and community-based culinary nutrition and diabetes education program. Intervention Mapping, a protocol for developing theory- and evidence-based health promotion programs, was utilized to develop the DICE intervention. Rooted in the Social Cognitive Theory, the DICE intervention targets key personal, behavioral, and environmental constructs as mechanistic pathways for eliciting change in the consequential health outcomes of poor glycemic control in children and adolescents with type 1 diabetes.
214673315|NCT04789746|BEHAVIORAL|adapted Chicago Run running program|The intervention being piloted is a 6-8 week running program modified from a running curriculum designed for school-aged children. The children will use a RaceRunner device to facilitate their participation, but this device is not explicitly evaluated in this study. Depending on transportation, they may be given access to the device in their home or school between sessions after it has been fit for them. If given access, guardians will be instructed on care and usage.
214673316|NCT00989430|BEHAVIORAL|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
214673317|NCT00734422|BEHAVIORAL|Virtual Reality Exposure Therapy|Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
214673318|NCT05393583|PROCEDURE|Outpatient hysterectomy|Discharge on the day of the hysterectomy
214673319|NCT05393583|PROCEDURE|Inpatient hysterectomy|1 night hospital stay after hysterectomy
214673320|NCT02425267|OTHER|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
214673321|NCT03640091|PROCEDURE|Post-extractive inter-radicular implant bed preparation|Implant placement in mandibular molars
214673322|NCT02135601|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
214673323|NCT04547244|OTHER|echocardiographic optimization of CRTd|the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
214328149|NCT07084805|BEHAVIORAL|Diabetes Inspired Culinary Education (DICE) - Phase 2|The DICE intervention is a 10-lesson family-and community-based culinary nutrition and diabetes education program. Intervention Mapping, a protocol for developing theory- and evidence-based health promotion programs, was utilized to develop the DICE intervention. Rooted in the Social Cognitive Theory, the DICE intervention targets key personal, behavioral, and environmental constructs as mechanistic pathways for eliciting change in the consequential health outcomes of poor glycemic control in children and adolescents with type 1 diabetes.
214328150|NCT07085897|BEHAVIORAL|Web-based Single-session Intervention of Mindset on Intelligence, Failure, and Emotion (We-SMILE) for allied health practicum trainees|The intervention is structured into three video-and-exercise sessions. Part one focuses on students' mindsets in coping with practicum-related challenges and their attitudes towards setbacks, encouraging them to shift from a 'fear-of-failure' mindset to a 'failure-is-enhancing' mindset. Part two introduces the nature and concept of neuroplasticity to promote students' understanding of effective learning. Part three centers on providing guidance for students on strategies to cope with stress and emotional turbulence with growth mindset regarding emotion.
214328151|NCT07085065|DEVICE|VR session|"Standard care: Standard care. In both the external control group and the intervention group during Period 1, painful procedures will be performed ccording to usual clinical practice by trained healthcare professionals.~VR session: The device includes a VR headset connected to a smartphone, which displays immersive visual content, along with headphones that deliver audio content. Scenarios are culturally and demographically adapted to the study population. The duration of each VR session will correspond to the time required for each painful procedure."
214486213|NCT04096066|DRUG|Dexamethasone|"\- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients \>75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle."
214673324|NCT00017316|DRUG|semaxanib|
214673325|NCT00017316|DRUG|thalidomide|
214929679|NCT06645353|DEVICE|MSOT Multispectral Optoacoustic Tomography|MSOT Multispectral Optoacoustic Tomography, single-wavelength, HbT, Hb, HbO2, collagen and mSO2 (700-1.100 nm wavelength range, in 10 nm increments) in the tibialis anterior and flexor hallucis brevis, at multiple time-points before, during and after interventional LER Lower Extremity Revascularization .
214929680|NCT01653860|BEHAVIORAL|The Brøset anger management model|manualised structured cognitive treatment program 15 weeks (30 hours)
214929681|NCT01653860|BEHAVIORAL|Ordinary group treatment|group treatment 8 weeks (16 hours)
214929682|NCT02289781|DEVICE|posterior crowns|teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
214929683|NCT05292417|RADIATION|hypofractionation Radiotherapy|Patients will receive radiation to the target lesion at a dose of 5Gy, 5 fractions a week, or a dose of 8Gy, 3 fractions a week. The course last once or twice depending on the investigator.
214929684|NCT05292417|DRUG|sintilimab|200 mg per IV infusion every 21 days until disease progression or participant withdrawal from study or last for two years
214673326|NCT02286115|BEHAVIORAL|Life-Stress Interview|A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
214673327|NCT01444521|DRUG|irinotecan and cisplatin|"irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
214929685|NCT05292417|DRUG|GM-CSF|200µg given 7-14 days(until WBC≥40x109/L), every 21 days until disease progression or participant withdrawal from study or last for two years.
214929686|NCT05292417|DRUG|Fruquintinib|Fruquintinib will be given 5mg qd for 2 weeks on and 1 week off, Q3W.
214929687|NCT05015621|DRUG|Surufatinib plus Toripalimab|Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
214929688|NCT05015621|DRUG|5-fluorouracil, Calcium folinate and Irinotecan|Irinotecan 180 mg/m\^2, Calcium folinate 400 mg/m\^2, 5-FU total 2800 mg/m\^2 will be administrated once two weeks.
214929689|NCT03285503|DRUG|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
214929690|NCT00307632|DRUG|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
214929691|NCT05811052|OTHER|Suboccipital Release Technique|The suboccipital release technique was applied to the participants in the experimental group by an experienced practitioner who had received osteopathy training. The individual lay in the supine position, and the practitioner applied the relaxation technique by placing his hands on the patient's nape-atlantooccipital joint. The application was continued until the relaxation of the muscles under the hand of the practitioner.
214929692|NCT05811052|OTHER|Sham Suboccipital Release|The participants in the control group were given a sham application by touching the hands of the therapist on the nape of the neck and waiting for a while.
214929693|NCT04706806|DIETARY_SUPPLEMENT|apple cider vinegar|2 tablespoons diluted in water taken twice daily with meals
214929694|NCT04706806|DIETARY_SUPPLEMENT|vinegar pill|one pill taken daily
214929695|NCT01022294|DRUG|Nitrousoxide-oxygen and atmospheric air|Nitrousoxide-oxygen and atmospheric air
214929696|NCT01022294|DRUG|Atmospheric air; nitrousoxide-oxygen|Atmospheric air; nitrousoxide-oxygen
214929697|NCT05587868|BIOLOGICAL|COVID-19 Vaccine|Mandatory COVID-19 vaccination as part of the the Indonesian national government program.
214929698|NCT04553640|OTHER|Group A/Intervention Curriculum|Virtual patient cases and feedback
214929699|NCT04553640|OTHER|Group B/Control Curriculum|Online articles on dizziness and emergency department clinical experience
214929700|NCT01301781|DRUG|BLI801|BLI801 laxative - oral solution
214929701|NCT01301781|DRUG|Placebo|BLI801 placebo - oral solution
214328152|NCT07086066|OTHER|Diaphragm mobilization|This group underwent treatment three times a week, with each session lasting 40 to 60 minutes, over a period of six weeks. Diaphragm mobilization included techniques aimed at increasing muscle elasticity, improving postural balance, and reducing pain by stimulating the sympathetic and parasympathetic nervous systems. In each session, participants received 20 minutes of TENS and 10 minutes of cryotherapy. Following this, diaphragm mobilization was applied. During the application, participants were positioned comfortably in the supine position. The physiotherapist palpated the diaphragm, instructed the participant in diaphragmatic breathing, and asked them to take a deep diaphragmatic breath. During expiration, the diaphragm was mobilized in the posterior and inferior directions. This mobilization was performed 10 times per session. Following that, posterior glide and inferior glide techniques were performed.
214929702|NCT03105986|DRUG|JNJ-64041575|Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
214929703|NCT03105986|DRUG|Probenecid|One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
214929704|NCT04085224|DRUG|Somatropin|LG Somatropin
214929705|NCT02453217|BEHAVIORAL|Chinese CHIP|The CHIP physical health screening tool will be used by community psychiatric nurses in the treatment group to assess patients' physical health risk and identify problematic lifestyle behaviours. The findings from the assessment will be used to devise an individualized care plan with patients. This treatment plan may involve community psychiatric nurses collaborated with psychiatrists, drawing patients attention to indicators of physical health risk by using a traffic light system The community nurses will use motivational interviewing approaches to make patients be aware of their physical health risks and enhance their motivation to adopt healthier behaviours.
215070428|NCT02578680|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
214328153|NCT07086066|OTHER|conventional physical therapy|As with the experimental group, therapy will be delivered three times per week for six weeks, with each session lasting between 40 and 60 minutes. Each session will include 20 minutes of TENS and 10 minutes of cryotherapy, followed by posterior and inferior gliding techniques on the glenohumeral joint and capsular stretching. Functional exercises will also include wand exercises (two sets of 10 repetitions) and finger ladder exercises targeting shoulder flexion and abduction, but without the addition of diaphragm mobilization techniques.
214328154|NCT07086443|OTHER|Activate™ Matrix|Participants will receive weekly applications of Activate™ Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214328155|NCT07086443|OTHER|AmnioDefend™ FT Matrix|Participants will receive weekly applications of AmnioDefend™ FT Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214328156|NCT07086443|OTHER|Palisade™ DM Matrix|Participants will receive weekly applications of Palisade™ DM Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215070429|NCT02578680|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
215070430|NCT02578680|DRUG|Saline solution|IV infusion
215070431|NCT05760313|DRUG|Linaclotide|Capsule; oral
215070432|NCT05760313|DRUG|Placebo|Capsule; oral
215070433|NCT05103579|DEVICE|MindMics|Patients rhythms was recorded using MindMics device
214929706|NCT02453217|OTHER|Treatment as usual|The routine community mental health care provided by the community psychiatric nursing service and outpatient clinic.
214929707|NCT00732758|DIETARY_SUPPLEMENT|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
215070434|NCT04268329|OTHER|Educational website|A website is used to educate patients and family members about head and neck cancer.
214929708|NCT00732758|DIETARY_SUPPLEMENT|Placebo Tablet|Placebo Tablet once daily for 6 months
215070435|NCT03424967|BEHAVIORAL|ABM|Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
215070436|NCT00451009|DEVICE|Viacell's product Media Kits|
215070437|NCT02645877|PROCEDURE|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
215070438|NCT02879591|OTHER|Social Skills training with Avatar therapist|
215070439|NCT03116828|DRUG|Eslicarbazepine acetate|eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
214328157|NCT07086443|OTHER|Enclose™ TL Matrix|Participants will receive weekly applications of Enclose™ TL Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214328158|NCT07086443|OTHER|Sentry™ SL Matrix|Participants will receive weekly applications of Sentry™ SL Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214929709|NCT02918435|BEHAVIORAL|WE CARE|The WE CARE (Well-child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) survey consists of 12 questions used to identify six unmet material needs (education, employment, food security, housing, childcare, household utilities). It will be administered at health supervision visits during the WE CARE phase at each study site. The Family Resource Book will contain resource information sheets for each of these needs listing available community resources. A physician champion will conduct regular booster sessions every 4 months and train new providers should there be staff turnover.
214328159|NCT07086443|OTHER|Shelter™ DM Matrix + SOC|Participants will receive weekly applications of Shelter™ DM Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214328160|NCT07085364|BEHAVIORAL|Attentional focus|Every training session will include the following activities for both groups: a 5-minute warm-up; a 30-minute walking training; and a 5-minute cool-down. The walking training will be conducted within a level-ground walking field. Participants will be instructed to look at and step on specific markers/labels that will be attached along the walking paths.
214328161|NCT07085364|BEHAVIORAL|Control|Every training session will include the following activities for both groups: a 5-minute warm-up; a 30-minute walking training; and a 5-minute cool-down. The walking training will be conducted within a level-ground walking field. No markers/labels will be attached and no relevant instructions will be provided apart from the general instruction.
214328162|NCT07085221|COMBINATION_PRODUCT|hospital external management|"(I) Symptom management: After enrollment, health managers regularly promoted health education to enhance patients' awareness of the disease and adherence to post-discharge management. Simultaneously, patients were managed via a digital platform, with each patient being provided with a chip-implanted sphygmomanometer to monitor their blood pressure and pulse in real time. If patients develop symptoms, they can report them in real-time and generate alerts to health managers. Through internal clinical decision-making algorithms, the telemedicine team would conduct clinical evaluations and seek decision guidance from clinical cardiologists if necessary.~(II) Clinical evaluation: the system stratified patients by risk levels and determined the frequency and intensity of management accordingly, with blood pressure and heart rate monitored daily. The digital management system automatically transmitted abnormal data to a doctor's assistant, with early detection of life-threatening complication"
214328163|NCT07085858|DIETARY_SUPPLEMENT|yeast β-glucan|Participants in the intervention group will take yeast β-glucan capsules daily. Each capsule contains 250 mg of yeast β-glucan, along with an appropriate amount of maltodextrin and silicon dioxide. All participants in the intervention group will take two capsules once daily, swallowed with warm water after meals.
214328164|NCT07085858|DIETARY_SUPPLEMENT|placebo|Participants in the placebo group will take two placebo capsules once daily in the same manner. The placebo capsules are identical to the intervention capsules in form, taste, appearance, and packaging, but contain only maltodextrin and a small amount of silicon dioxide.
214486214|NCT06891391|OTHER|Dynamic Neuromuscular Stabilization exercises|DNS is a method used to enhance muscle stability. It is a manual and rehabilitative approach based on developmental kinesiology to optimize the movement system. These exercises optimize internal muscle forces on each spinal segment.
214929710|NCT03373058|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m\^2 and cisplatin 75 mg/m\^2, respectively, 43°C, 90min.
214929711|NCT03373058|PROCEDURE|cytoreductive surgery|Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.
214929712|NCT03373058|DRUG|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
214929713|NCT01385488|BEHAVIORAL|self-monitor arm volume|bioelectrical impedance
215070440|NCT03116828|DRUG|Eslicarbazepine Acetate|eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
214929714|NCT02553785|DEVICE|Revivent TC|
214929715|NCT02205905|DRUG|14C PER977|Open-label, single dose
214929716|NCT01844206|DRUG|Epidural Morphine|Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
214929717|NCT01844206|DRUG|Epidural Saline|Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
214929718|NCT05583292|OTHER|ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.
214929719|NCT05583292|OTHER|SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.
214929720|NCT05583292|OTHER|Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity
214929721|NCT05085106|DRUG|Felbinac trometamol eye drop|Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
214929722|NCT05085106|DRUG|Placebo eye drop|Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
214929723|NCT03408249|DIAGNOSTIC_TEST|IBDoc calprotectin test|Patients are asked to perform a single IBDoc calprotectin home test.
214328165|NCT07084896|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
214328166|NCT07084896|DRUG|Nirogacestat|Nirogacestat will be administered.
214328167|NCT07085208|PROCEDURE|Unsupervised Machine Learning for Clinical Phenotyping|This is a data-driven study that uses an unsupervised machine learning algorithm to perform clustering on patient multimodal features. These features include: preoperative demographics, comorbidities, and laboratory data; surgical information; and high-resolution intraoperative data, most notably continuous vital sign trajectories.
214328168|NCT07086508|BEHAVIORAL|e-CHECKUP TO GO (eCTG)|A brief, web-based program designed by San Diego State University to reduce high-risk drinking by providing personalized normative feedback regarding alcohol use, risk factors, and risks associated with drinking and accurate information about alcohol.
214328169|NCT07086508|BEHAVIORAL|e-Parent Intervention and eCTG (eCTG+)|The eCTG+ is a combination of the eCTG and the e-Parent Intervention, which is an electronic handbook developed by Rob Turrisi to guide parents in discussing drinking, behaviors, and consequences with their teens.
215070441|NCT01689025|DRUG|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
215070442|NCT01689025|DRUG|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
214328170|NCT04740034|DRUG|AMG 340|AMG 340 is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T-cells
214328171|NCT06929923|DEVICE|Pro-2-Cool Device|"The Pro-2-Cool Device is a non-invasive hypothermic therapy (cold therapy) device that provides localized cooling of the head and neck. Water and isopropyl alcohol cooled to 6°C by the chiller assembly circulate through the cooling garment to create conductive heat transfer from the scalp and carotid arteries, thus achieving cooling of the brain."
214328172|NCT06896825|BEHAVIORAL|Self-monitoring|All participants will receive a Garmin and use the associated app to monitor their weekly physical activity (in Intensity Minutes, the term used by Garmin for moderate to vigorous physical activity). Enrolled participants are insufficiently active (engaging in 60 minutes or less of moderate to vigorous physical activity per week) and will receive weekly text messages to incrementally increase physical activity over the course of the study. Goals will be 20% greater than the number of Intensity Minutes from the previous week, with the ultimate goal of reaching 150 Intensity Minutes or more per week, aligning with national activity guidelines.
214328173|NCT07085689|DEVICE|Sodium Fluoride Varnish (5%)|After isolating and drying the teeth to be treated using cotton rolls, 5% sodium fluoride (NaF) varnish (Proshield Varnish, President Dental, Munich, Germany) was applied to the tooth surfaces in two thin layers with the help of a disposable microbrush. The cotton rolls were then removed to allow the varnish to come into contact with saliva and harden. After the procedure, participants were advised to avoid consuming hard foods and brushing their teeth for 4 to 6 hours.
214328174|NCT07085689|DEVICE|Silver diamine fluoride- potassium iodide|After isolating and drying the teeth to be treated using cotton rolls, a gingival barrier (Top Dam, FGM Dental Group, Brazil) was applied around the cervical area of the crown to cover the surrounding gingiva and was light-cured. After applying petroleum jelly to the lips for isolation, the first step, 38% silver diamine fluoride (Riva Star, SDI, Bayswater, Australia), was applied to the entire tooth surface using a disposable microbrush. Immediately afterward, the second step, potassium iodide, was applied generously to the entire tooth surface using another disposable microbrush. The agent was applied until the creamy white appearance on the tooth disappeared. Excess material on the tooth surface was gently dabbed dry with a cotton pellet.
214929724|NCT03408249|OTHER|questionnaire|Patients evaluate the ease-of-use of the test, clearness of test results and comprehensiveness of the instructions for use through a specific questionnaire implementing Likert scales.
214929725|NCT04240457|COMBINATION_PRODUCT|Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.
214929726|NCT02179970|DRUG|Plerixafor|A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
214929727|NCT04676451|DEVICE|Femto-AK|Astigmatic Keratotomy / Arcuate Incisions for the correction of astigmatism
214929728|NCT06120569|DEVICE|Soleus ms exercise|Soleus muscle exercise before and after eating by half an hour
214929729|NCT00168272|DEVICE|Transcranial Magnetic Stimulation|
215070443|NCT03509363|BEHAVIORAL|Stroke physiotherapy home exercise video|a set of exercise video with QR code provided in home exercise pamphlets
215070444|NCT05013918|OTHER|Observational study|No intervention
214328175|NCT07085689|DEVICE|Aqueous Silver Fluoride|After isolating and drying the teeth to be treated using cotton rolls, a gingival barrier (Top Dam, FGM Dental Group, Brazil) was applied around the cervical area of the crown to cover the surrounding gingiva and was light-cured. After applying petroleum jelly to the lips for isolation, the first step, 38% aqueous silver fluoride (Riva Star Aqua, SDI, Bayswater, Australia), was applied to the entire tooth surface using a disposable microbrush. Immediately afterward, the second step, potassium iodide, was applied generously to the entire tooth surface using another disposable microbrush. The agent was applied until the creamy white appearance on the tooth disappeared. Excess material on the tooth surface was gently dabbed dry with a cotton pellet.
214328176|NCT07085689|DEVICE|Hydroxyethyl Methacrylate and Glutaraldehyde|After isolating and drying the teeth to be treated using cotton rolls, a gingival barrier (Top Dam, FGM Dental Group, Brazil) was applied around the cervical area of the crown to cover the surrounding gingiva and was light-cured. One to two drops of a desensitizing agent containing hydroxyethyl methacrylate and glutaraldehyde (Gluma, Heraeus Kulzer GmbH, Hanau, Germany) were applied to the tooth surface using a disposable microbrush in a rubbing motion. After waiting for 30-60 seconds, the tooth surface was completely dried until the liquid disappeared and the surface lost its shine, and then rinsed with water.
214328177|NCT07086729|OTHER|CT-Based Morphologic and Attenuation Scoring|Retrospective analysis of CT images to extract morphological and Hounsfield Unit (HU) parameters for development of a predictive scoring model (TSMAS). No clinical or therapeutic intervention was performed.
214328178|NCT07087262|DRUG|SNH-119014|study drug
214328179|NCT07087262|DRUG|Placebo|placebo
214673328|NCT01879605|DRUG|Docusate natrium and sorbitol|
214673329|NCT01879605|DRUG|Bisacodyl|
215070445|NCT01007929|DRUG|14C-AZD1236|Oral solution 1mg/mL
214929730|NCT03204929|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
214328180|NCT07085923|BEHAVIORAL|Lifestyle Intervention|The Lifestyle Program consists of monthly one-on-one dietary counselling sessions with a registered clinical dietitian, monthly group-based physical activity sessions led by an instructor, and support to follow a personalized exercise plan. The intervention focuses on cardioprotective dietary changes, weight reduction, and increasing physical activity at moderate-to-high intensity to meet recommended amount. Participants will receive dietary supplementation corresponding to a therapeutic dose of 1000 mg EPA+DHA per day from fish oil. During monthly visits with the dietitian, data will be collected to monitor progress and support adherence. The intervention is designed to be feasible within routine mental health care and tailored to the needs of adults with severe mental illness.
214929731|NCT01252563|DRUG|Amlodipine|Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
214328181|NCT07085663|OTHER|Exergame-assisted simultaneous motor-cognitive training|Exergame-assisted simultaneous motor-cognitive training
214929732|NCT02537002|DRUG|PF-05230907|A single intravenous dose of 3 μg/kg
214929733|NCT02537002|DRUG|PF-05230907|A single intravenous dose of 5 μg/kg
214929734|NCT02537002|DRUG|Placebo|A single intravenous dose of matched placebo
214929735|NCT06028802|DIAGNOSTIC_TEST|CT Clock Tool measurement|Ratio of CT attenuation measurements acquired from within the visible ischaemic lesion (or estimated location if not visible) ÷ CT attenuation measurements acquired from within the equivalent normal brain.
214929736|NCT01880086|DRUG|Clomiphene citrate|
214929737|NCT01880086|DRUG|Placebo|Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
214929738|NCT02497963|PROCEDURE|Foreskin Graft-Tubularized Incised Plate|TIP Urethroplasty with foreskin graft in primary hypospadias
214929739|NCT02497963|PROCEDURE|Tubularized Incised Plate|TIP Urethroplasty without foreskin graft in primary hypospadias
214929740|NCT01068886|PROCEDURE|External pancreatic stent|stent through pancreatic anastomosis
214929741|NCT02825758|DIETARY_SUPPLEMENT|ZestiVits|"The study product is a low-carbohydrate, orange flavour, vitamin, mineral and trace element (micronutrient) supplement for use in ketogenic and restricted therapeutic diets, for children aged from 11 years of age and adults.~The recommended dosage of the study product for each subject will be determined and prescribed by a dietitian. This will be based on individual requirements for micronutrient supplementation."
214929742|NCT02223936|OTHER|group exposed|Assessment by Brunet Lezine scale
214929743|NCT02223936|OTHER|Control|Not exposed group
214929744|NCT04293913|BEHAVIORAL|illustrated communication material|Illustrated communication material was introduced to the patients in the intervention group. In the process (intensive care) that patients received mechanical ventilation support after the operation, agitation and sedation levels were monitored by the intensive care nurse who was to communicate with the patient using the Richmond Agitation Sedation Scale (RASS). According to this scale, having minimum -2 and maximum +2 points was accepted as the starting criteria for communication (Sessler et al., 2002). Communication was established with the illustrated communication material.
214929745|NCT01246869|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
214929746|NCT01246869|DRUG|1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole|Brain scan with radiopharmaceutical imaging tracer that directly assesses tumor hypoxia
214929747|NCT01246869|DRUG|[15O]water|Brain scan with imaging tracer used for measuring tumor blood flow/perfusion
214328182|NCT07085624|DRUG|ceftazidime|ceftazidime loading dose and maintenance dose
214929748|NCT01246869|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Brain scan to assess tumor size and tumor blood flow/perfusion
214929749|NCT02458768|DRUG|IVF-M HP Inj.|
214929750|NCT02458768|DRUG|Menopur® Inj.|
215070446|NCT05422365|DRUG|Intravenous immunoglobulin (IVIG), 10% solution for infusion|The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
215070447|NCT05789823|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery achieve by thrombectomy. Ischemic post-conditioning consists of briefly repeated 4 cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
215070448|NCT05789823|PROCEDURE|Mechanical thrombectomy alone|Successful recanalization was achieved by mechanical thrombectomy without subsequent ischemic post-conditioning.
215070449|NCT06442358|DEVICE|Pulsenmore ES home ultrasound device|Pulsenmore ES device is a portable home used ultrasound device which allow the patient to perform an ultrasound scan from the comfort of their home under the supervision of a healthcare provider
215070450|NCT06002555|DRUG|Apraglutide|Peptide analogue of GLP-2
214328183|NCT07085624|BIOLOGICAL|plasma ceftazidime dosage|"plasma ceftazidime dosage kinetics will be performed according to an optimal D- sampling plan (4 measurements per subject: T0+5min, T0+3h, T0+6h, T0+24h, PFIM software).~T0 corresponds to the time to administer the ceftazidime loading dose."
214328184|NCT07084857|OTHER|correlational analysis between BMD and isokinetic lower extremity strength|correlational analysis between BMD and isokinetic lower extremity strength
214328185|NCT07086872|OTHER|Integrated Neuromuscular Inhibition Technique and mulligan therapy|patients will receive Integrated Neuromuscular Inhibition Technique in the form of intermittent ischemic compression, strain counter strain and muscle energy technique and mulligan therapy for limited cervical range of motion
215070451|NCT03900949|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
215070452|NCT03900949|DRUG|Cytarabine|Given IV
215070453|NCT03900949|DRUG|Daunorubicin Hydrochloride|Given IV
215070454|NCT03900949|DRUG|Gemtuzumab Ozogamicin|Given IV
215070455|NCT03900949|DRUG|Midostaurin|Given PO
214328186|NCT07086872|OTHER|Integrated Neuromuscular Inhibition Technique|patients will receive Integrated Neuromuscular Inhibition Technique in the form of intermittent ischemic compression, strain counter strain and muscle energy technique
214328187|NCT07086872|OTHER|mulligan therapy|patients will receive mulligan therapy for limited cervical range of motion
214328188|NCT07086872|OTHER|postural correction exercises|the patients will receive two strengthening exercises (deep cervical flexors and scapular retractors) and two stretching: cervical extensors (sub-occipital muscles) and pectoral muscles). The program was based on a program by Harman and Kendall
214328189|NCT04346615|DRUG|Zavegepant (BHV-3500)|10 mg intranasal (IN) for 14 days
214328190|NCT04346615|DRUG|Placebo|Placebo Q8h for 14 days
214929751|NCT06429345|DRUG|Coenzyme Q10 100 Milligrams Oral Capsule|Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.
215070456|NCT04610645|DEVICE|OCT|3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck
214328191|NCT02851108|DRUG|Methylene Blue|50 patients will receive methylene blue
214328192|NCT02851108|DRUG|Primaquine|50 patients will receive primaquine
214328193|NCT04524403|DRUG|Miricorlilant|Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing
214328194|NCT04524403|DRUG|Miricorlilant|Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing
214328195|NCT04524403|DRUG|Placebo|Placebo for once-daily oral dosing
214328196|NCT04795414|BIOLOGICAL|SARS-CoV-2 Vaccine(Vero Cell), Inactivated|The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)
214328197|NCT00002604|DRUG|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
214328198|NCT00002604|DRUG|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
214328199|NCT00002604|DRUG|chemosensitization/potentiation therapy|
214328200|NCT04124549|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 HD hours.
214328201|NCT04124549|OTHER|Intradialytic Combined Exercise|Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Patients were asked to perform aerobic exercise 20-min and resistance exercise 10-min in the first stage. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE. In the following stages, aerobic exercise was continued 15-min for the second stage, 10-min for the third and the forth stage, 15-min for the fifth stage and 20-min for the last stage. And the time for resistance exercise was adjusted for the total exercise time. The resistance of exercise also progressive increased in order to adapt the target RPE. It was accessible to patients of different ages, gender, cultures and ethnicities.
214328202|NCT06085417|DRUG|Bupivacaine + dexamethasone|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
214486215|NCT06891391|OTHER|Deep Cervical Muscle exercises|Deep cervical muscle exercises are isometric exercises that strengthen weak muscles without causing discomfort to pain-sensitive structures like ligaments, tendons, or neck joints. This involves contracting specific muscles without changing muscle length or impeding joint movement.
214486216|NCT06890819|BEHAVIORAL|Assigned Interventions|Behavioral: Structured Feedback, Clinical Decision-Making, Anxiety, Self-Confidence,
214929752|NCT06429345|DRUG|Placebo|placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.
215070457|NCT04610645|DEVICE|Dermatoscope|2x2 pictures taken with a dermatoscope
215070458|NCT04610645|GENETIC|3-Colour FISH|Blood sample is examined for breaks per metaphase to determine radiation sensibility of the individual
214929753|NCT04502225|OTHER|Tilt|Tilt of the whole bed so that the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
215070459|NCT05888467|OTHER|supervised infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
214929754|NCT04502225|OTHER|Elevated trunk|Elevation of the trunk through raising just the head of the bed until the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
214929755|NCT04502225|OTHER|Tilt - In home|Tilt of the whole bed so that the head is elevated by 8 inches overnight.
214929756|NCT04502225|OTHER|Elevated Trunk - In home|Elevation of the trunk through raising the head 8 inches on a wedge pillow overnight.
214929757|NCT02773212|DRUG|d-amphetamine|Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
214929758|NCT02773212|BEHAVIORAL|Contingency management|Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
214929759|NCT02773212|DRUG|Placebo (for d-amphetamine)|60 mg of riboflavin and cornstarch as needed.
214929760|NCT06093737|BEHAVIORAL|COPE: Communities Organizing for Power through Empathy|A three session brief group psychoeducational intervention. Session 1 is 4 hours, Session 2 and 3 are 1.5 hours. It is delivered in groups of 8-15 people with sessions spaced 1 month apart.
214929761|NCT04901351|PROCEDURE|Smear|In addition to the routine gynecological follow-up including a cervico-vaginal smear and an HPV test (HPV-HR genome detection), the doctor will propose prospectively to all consecutive patients who meet the inclusion criteria, during a follow-up consultation (post treatment of cervical dysplasia), to participate in the study, that is to have 2 other anal and ENT samples for an HPV test
214929762|NCT03843632|BIOLOGICAL|VARIVAX™|VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).
214929763|NCT06619873|DRUG|HRS-8080|"Medication regimen A~Drug:~600mg, Old process tablets，NPO~Medication regimen B~Drug:~600mg, New process tablets，NPO~Medication regimen C~Drug:~600mg, New process tablets，PC.，low-fat diet~Medication regimen D~Drug:~600mg, New process tablets，PC.，high-fat diet"
214929764|NCT00271011|DRUG|Mitomycin C|Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
214929765|NCT00271011|DRUG|Cetuximab|Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
214929766|NCT00271011|DRUG|Irinotecan.|Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1\*28 allele will receive irinotecan 110 mg/m2.
214929767|NCT05853549|DEVICE|optical surface monitoring system|An optical surface monitoring system (OSMS) could achieve continuous monitoring of patient position through a nonradiographic and noninvasive technology, which has been widely applied to many sites of radiation therapy, including breast, intracranial, head and neck, abdomen, and extremities
214929768|NCT01820572|DRUG|Belatacept|
214929769|NCT01820572|DRUG|Tacrolimus|
214929770|NCT01820572|DRUG|Cyclosporine|
214929771|NCT01279122|DEVICE|Nanoflex IOL|Patients who were implanted with the Nanoflex IOL
214673330|NCT04608097|BEHAVIORAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
214673331|NCT04608097|BEHAVIORAL|Attention Placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
214673332|NCT06369324|OTHER|Pain education|It consisted of holding information sessions on each of the days that the subjects were scheduled for treatment. These sessions will be supported by supplementary material in the form of brochures, posters and videos which briefly explain interesting knowledge about spondyloarthropathies.
214929772|NCT03876366|OTHER|online survey|Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP.
214929773|NCT03876366|OTHER|focus group meeting|Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine.
214929774|NCT00896181|DRUG|docetaxel|Given IV
214929775|NCT00896181|DRUG|cisplatin|Given IV
214929776|NCT00896181|DRUG|carboplatin|Given IV
214929777|NCT00896181|DRUG|fluorouracil|Given IV
214929778|NCT00896181|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
214929779|NCT00896181|RADIATION|intensity-modulated radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
214328203|NCT06085417|DRUG|Bupivacaine + magnesium sulphate|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
214328204|NCT06085417|DRUG|bupivacaine|bupivacaine
214328205|NCT00795691|BEHAVIORAL|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
214929780|NCT01629810|DEVICE|Whole body periodic acceleration (Exer-Rest)|Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.
214929781|NCT03319264|OTHER|Dynamometry exam|Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
215070460|NCT05888467|OTHER|supervised non-infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
215070461|NCT05888467|OTHER|Control group|Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
215070462|NCT05515588|DRUG|BI 690517 (C-14)|BI 690517 (C-14)
215070463|NCT05515588|DRUG|BI 690517|BI 690517
215070464|NCT06472128|BEHAVIORAL|DREAMLAND|Participants assigned to DREAMLAND will start using DREAMLAND during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
215070465|NCT06472128|BEHAVIORAL|VITAL WELLNESS|Participants assigned to VITAL WELLNESS will start using VITAL WELLNESS during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
214328206|NCT00795691|BEHAVIORAL|low-fat diet|low-fat diet in patients with type 2 diabetes
214328207|NCT02449356|DEVICE|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
214328208|NCT01636141|DRUG|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
214929782|NCT03319264|OTHER|Walking test|A 4 metres walking test will be performed to assess patient's walking speed
214929783|NCT03319264|RADIATION|DXA measurement|DXA measurement will be performed to assess patient's body composition
214328209|NCT01636141|DRUG|Placebo gel|
214929784|NCT03319264|OTHER|SARQOL questionnaire|Patient's quality of life will be assessed thanks to the SARQOL questionnaire
214929785|NCT03319264|BEHAVIORAL|Life habits Questionnaire|Life habits Questionnaire
214929786|NCT03134534|PROCEDURE|VATS lobectomy|a minimal invasive surgical types for NSCLC: VATS lobectomy
214929787|NCT03134534|PROCEDURE|RATS lobectomy|a minimal invasive surgical types for NSCLC: RATS lobectomy
214929788|NCT04675957|OTHER|cardiac rehabilitation|stationary or ambulatory cardiac rehabilitation
215070466|NCT00709176|BEHAVIORAL|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
215070467|NCT00709176|BEHAVIORAL|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
215070468|NCT05577377|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a structured attention training practice that you do with another person by following a predefined set of detailed instructions. One of the two people participating in the OM must have a clitoris. In this partnered practice, one person strokes the clitoris of another person with the tip of their left index finger for 15 minutes.
215070469|NCT01454128|BEHAVIORAL|exercise|36 session supervised exercise intervention
214328210|NCT04486287|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo Stereotactic Ablation Brachytherapy. Sintilimab shall be started no later than 4 weeks after Stereotactic Ablation Brachytherapy."
214328211|NCT02078739|BEHAVIORAL|Yoga Program at home using internet technology|
214328212|NCT00533949|BIOLOGICAL|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
214328213|NCT00533949|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
214929789|NCT01863316|DEVICE|I gel|
214929790|NCT01863316|DEVICE|LMA Supreme|
214328214|NCT00533949|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
214328215|NCT00533949|RADIATION|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
214328216|NCT00533949|RADIATION|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
214328217|NCT00727194|DRUG|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
214929791|NCT02105246|BEHAVIORAL|Referral to home-based cardiac rehab|Home-based cardiac rehab is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
214929792|NCT02105246|BEHAVIORAL|Referral to center-based cardiac rehab|Center-based cardiac rehab is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
215070470|NCT03907865|DRUG|Softacort|Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
215070471|NCT01762735|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
215070472|NCT01762735|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
215070473|NCT01073397|BEHAVIORAL|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
215070474|NCT00176488|DRUG|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
215070475|NCT00176488|DRUG|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
215070476|NCT05470179|DEVICE|Hybrid hyrax distalizer|class 2 Angle malocclusion
215070477|NCT05470179|DEVICE|Pendulum distalizer|class 2 Angle malocclusion
215070478|NCT05865340|BEHAVIORAL|oral health + MED diet|oral health + MED diet education
214328218|NCT00727194|DRUG|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
214328219|NCT01360034|DRUG|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
214328220|NCT01360034|DRUG|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
214328221|NCT05063734|DRUG|THR-687 dose level 1|3 intravitreal injections of THR-687 dose level 1, 1 month apart
214328222|NCT05063734|DRUG|THR-687 dose level 2|3 intravitreal injections of THR-687 dose level 2, 1 month apart
214328223|NCT05063734|DRUG|THR-687 selected dose level|3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
214328224|NCT05063734|DRUG|Aflibercept|3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
214929793|NCT05036668|BIOLOGICAL|Cryptosporidium parvum oocysts (ABO809)|ABO809 3x10\^6 CE/3mL concentrate for oral suspension, single dose at Day 1
214929794|NCT02683252|OTHER|T1 mapping and MR perfusion acquisition|One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
215070479|NCT05865340|BEHAVIORAL|oral health|oral health education
215070480|NCT05865340|BEHAVIORAL|MED diet|MED diet education
215070481|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 30 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
214328225|NCT01455883|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
214328226|NCT01455883|DRUG|glimepiride|oral glimepiride does-escalated,if tolerated, to 8 mg/day
214328227|NCT03853707|DRUG|Atezolizumab|Given IV
214328228|NCT03853707|DRUG|Capecitabine|Given PO
214328229|NCT03853707|DRUG|Carboplatin|Given IV
214328230|NCT03853707|DRUG|Ipatasertib|Given PO
215070482|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 60 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
215070483|NCT03156686|PROCEDURE|HOME-based hospitalization|patients in Home care treatment (HC) group will be treated at home
214328231|NCT03853707|DRUG|Paclitaxel|Given IV
214328232|NCT03853707|OTHER|Quality-of-Life Assessment|Ancillary studies
214929795|NCT05855590|DRUG|Tranexamic acid|10mg/kg intravenous single dose
214929796|NCT05855590|OTHER|0.9% isotonic saline solution|100 ml intravenous single dose
215070484|NCT03892668|DRUG|Tranexamic Acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
215070485|NCT03892668|DRUG|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
215070486|NCT03892668|DRUG|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
215070487|NCT04388319|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 12 weeks.
215070488|NCT04388319|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
214328233|NCT03853707|OTHER|Questionnaire Administration|Ancillary studies
214929797|NCT04025775|DEVICE|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~* Glooko/Diasend cloud upload system to monitor CGM/insulin data."
214929798|NCT04025775|OTHER|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
214929799|NCT04091100|PROCEDURE|Electroacupuncture|An electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes. All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
215070489|NCT04388319|OTHER|Halo G6 e-cigarette|G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
215070490|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
215070491|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
215070492|NCT02918396|DEVICE|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (\>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as \<0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
215070493|NCT02918396|DEVICE|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
215070494|NCT02918396|DEVICE|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
215070495|NCT00963716|DEVICE|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
215070496|NCT00963716|DEVICE|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
215070497|NCT00121524|DRUG|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
215070498|NCT00121524|DEVICE|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
214328234|NCT06454981|DEVICE|Hemodiafilter|"The enrolled patients were randomly divided into the experimental group and the control group, using the hemodiafilter (experimental device) produced by Shinva Medical Instrument Co.,Ltd."
214328235|NCT06454981|DEVICE|Fresenius Medical Care AG & Co.KGaA|The enrolled patients were randomly divided into the experimental group and the control group, using the FX 800HDF hollow fiber hemodialysis/filter (control device) produced by Fresenius Medical Care AG \& Co.KGaA (registered agent: Fresenius Medical Care (shanghai) Company Limted).
214328236|NCT03111992|DRUG|PDR001|Anti-PD1 antibody
214328237|NCT03111992|DRUG|CJM112|Anti-IL-17A antibody
214328238|NCT03111992|DRUG|LCL161|Oral small molecule SMAC-mimetic
214328239|NCT05943444|PROCEDURE|Parks technique|compare different operational styles of low rectal cancer
214328240|NCT05943444|PROCEDURE|Bacon technique|Bacon technique
214328241|NCT03384446|OTHER|Tooth-borne treatment|Titanium curettes
214328242|NCT03384446|OTHER|Implant-specific treatment|Implant brush
214328243|NCT02954913|PROCEDURE|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
214328244|NCT02984501|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by CTV with a safety margin of 1cm in all directions to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a 15-MV linear accelerator (Varian Medical System) with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied for all patients with periodical digital portal images to evaluate the precision of the set-up.
214328245|NCT02984501|DRUG|Chemotherapy|The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
214929800|NCT04091100|PROCEDURE|Myofascial Release|longitudinal stretching, friction massage and pinching technique, All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
214328246|NCT04585334|DRUG|Tricortin 1000|Tricortin 1000 \[2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)\] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
214328247|NCT04585334|DRUG|Itami|Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).
214328248|NCT04585334|DRUG|Placebo|Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
214929801|NCT05970770|DEVICE|Hypotension Prediction Index|in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA; internal memory 60 gigabyte, 10 gigabyte used for operating system) with ClearSight non-invasive hemodynamic monitoring and with the Hypotension Prediction Index software enabled. They will not receive preventive vasopressors but only norepinephrine boluses if Hypotension Prediction Index \>85
214929802|NCT05970770|DRUG|Norepinephrine|Patients in the HPI group will receive a norepinephrine bolus when HPI is below 85
214673333|NCT06369324|OTHER|Exercise supervised by external focus|This therapeutic exercise involves proprioceptive training with external feedback to enhance exercise execution and promote optimal postural control, particularly for individuals with back pain. The method, based on research by Abdollahipour et al. and Chiviacowsky et al., focuses on automatic control, reducing the cognitive load during exercises and improving movement retention. The Motion Guidance Clinician Kit will be utilized, consisting of a panel and laser guide for precise cervical movement. Exercises progress in difficulty over 12 sessions, targeting cervical and lumbopelvic stabilization, flexion-extension, rotations, and lateral flexions. Sessions start with seated exercises and progress to standing, with increasing distance between laser targets to expand cervical range of motion. Thoracic and lumbar exercises involve 10 repetitions each. The entire program lasts around 20 minutes and follows Tidier recommendations for intervention.
214929803|NCT03001349|PROCEDURE|Computed Tomography|Undergo PET/CT
214929804|NCT03001349|DRUG|Gallium Ga 68-Edotreotide|Given IV
214929805|NCT03001349|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214929806|NCT01539551|OTHER|check BNP and lactate|we will collect patients's blood samples on Day 0, Day1 and Day2
214929807|NCT05755607|PROCEDURE|laparoscopic pancreaticoduodenectomy|The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
214929808|NCT05755607|PROCEDURE|Robot Pancreaticoduodenectomy|The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
214929809|NCT05525988|PROCEDURE|Hemi-Hamate Transfer for Proximal Pole Scaphoid Reconstruction|"Surgical Technique:~The participants will be positioned in the supine decubitus on the surgical table with the operated upper limb put on a C-arm (Mobile fluoroscopy device) compatible surgical arm-board. After anesthesia, a pneumatic tourniquet will be placed with a cuff pressure raised to 250 mmHg, then the limb is draped in the regular sterile fashion. Through a dorsal approach to the wrist joint, the proximal pole of scaphoid bone will be assessed before resectioning for confirmation that it cannot be preserved. The hamate bone will be exposed through capsulotomy and the measurements of the resected scaphoid will be transferred. The harvested H-H autograft will be placed and fixed to the distal scaphoid segment. Wound closure is then performed in layers in the usual fashion, and the wound will be covered by a sterile gauze, then a short-arm thumb spica splint will be put on."
214929810|NCT02947256|PROCEDURE|standard laparoscopic cholecystectomy|which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
214929811|NCT02947256|PROCEDURE|RI approach|which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
214929812|NCT00387010|DRUG|Fentanyl Buccal Tablets|"Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.~Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.~Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily."
215070499|NCT00121524|DRUG|Atropine|Atropine 3 mg iv in initial systole
215070500|NCT00121524|DRUG|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
215070501|NCT02450383|DRUG|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
215070502|NCT02450383|PROCEDURE|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
215070503|NCT05069714|DRUG|MTX-hold|Temporary discontinuation of methotrexate for 1 or 2 weeks
214328249|NCT05514834|DEVICE|Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)|Injections with platelet-rich plasma and hyaluronic acid
214328250|NCT05514834|OTHER|PRP Only|platelet rich plasma without hyaluronic acid
214328251|NCT05514834|OTHER|Placebo|Neither PRP nor hyaluronic acid
215070504|NCT04449952|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
215070505|NCT04449952|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
214328252|NCT06536218|BEHAVIORAL|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the PSG patients are determined according to the randomization criteria, they receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to hold online individual interviews with patients who agree to participate in this study.
214328253|NCT04269161|DEVICE|Automatic control of inspired oxygen|A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
214673334|NCT06369324|OTHER|Therapy by means of electrical stimulation (electro-massage)|This technique combines manual therapy (massage) with interferential current. Following a supervised therapeutic exercise program, this intervention targets the spine for 15 minutes. Using a Sonopuls 692® device, a bipolar current mode with specific frequencies is applied. The physiotherapist moistens sponges with warm water and administers the current through them while performing manual soft tissue therapy on the neck, shoulders, scapulae, thoracic, lumbar, and sacral areas. The intensity is adjusted to provide a strong but comfortable tingling sensation, without muscle twitching. The therapy sequence includes superficial stroking, deep gliding movements, trapezius kneading, muscle stretching, and deep rubbing on the thoracic and lumbar areas. The electro-massage protocol lasts 14 minutes.
214929813|NCT06620978|PROCEDURE|Low pressure: Operative hysteroscopy without anesthesia with normal Saline medium in low pressure..|"Low pressure: Operative hysteroscopy without anesthesia with normal Saline medium in low pressure..~Operative hysteroscopy without anesthesia using normal Saline as medium with different pressure according to the arm allocated. The procedure is done for endometrial polyp removal, retained products of conception removal, intrauterine adhesyolisis and intrauterine device removal."
214929814|NCT06620978|PROCEDURE|High pressure: Operative hysteroscopy without anesthesia with normal Saline medium in High pressure.|High pressure: Operative hysteroscopy without anesthesia with normal Saline medium at high pressure.
214929815|NCT00520481|DRUG|IMC-A12 (Cixutumumab)|10 mg/kg i.v. infusion over 1 hour every 2 weeks or 20 mg/kg i.v. infusion over 1 hour every 3 weeks.
214929816|NCT04586634|DEVICE|Peristeen cone catheter|The active intervention is the Peristeen cone catheter device. The comparator in this investigation is current standard of care for patients with LARS which is conservative bowel management.
214929817|NCT00871442|OTHER|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
214929818|NCT00871442|OTHER|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
214929819|NCT00871442|DRUG|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
214328254|NCT00268528|BEHAVIORAL|Compliance Monitoring|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
214328255|NCT00268528|OTHER|Laboratory Biomarker Analysis|Correlative studies
214673335|NCT02606773|DRUG|Ascorbic Acid|Ascorbic acid in different ways and doses
214929820|NCT02856724|DRUG|PGE2|10 mg PGE2 vaginal ovul(Propess)
214929821|NCT06656702|DRUG|Psilocybin|Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.
214929822|NCT06036810|OTHER|Shared Medical Decision Tool|standard of care
214929823|NCT06036810|BEHAVIORAL|Engaging Patients in Decision Making|standard of care
215070506|NCT04449952|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
214673336|NCT04222621|OTHER|Pregnant women without intervention|Pregnant women with those exposures of interest determined in specific research based on the registry
214673337|NCT01330381|DRUG|prucalopride|"prucalopride~* subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~* subjects with weight \>50 kg: prucalopride 2 mg tablet once daily"
214673338|NCT01330381|DRUG|Placebo|Matching oral solution or oral tablets given once daily
214929824|NCT06036810|BEHAVIORAL|Literacy Spanish Language|standard of care
215070507|NCT04449952|OTHER|Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula|Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.
215070508|NCT04449952|DEVICE|Concept Curve Winter Series Toothbrush|Participants will brush teeth at least one minute with provided bristled toothbrush.
214328256|NCT00268528|DRUG|Mercaptopurine|Given PO
215070509|NCT04449952|DEVICE|Listerine Cool Mint Floss|Participants will use marketed fluoride-containing dentifrice, floss.
215070510|NCT03990415|BEHAVIORAL|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
215070511|NCT00243451|OTHER|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
214328257|NCT00268528|DRUG|Methotrexate|Given PO
214328258|NCT00268528|OTHER|Questionnaire Administration|Ancillary studies
214328259|NCT00268528|OTHER|Study of Socioeconomic and Demographic Variables|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
214929825|NCT04896346|OTHER|Punch biopsy|punch biopsies will be used for histologic analysis and biochemical assays
214929826|NCT04896346|OTHER|non-invasive photography, assessments, and measurements|photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity
214929827|NCT04255680|DIAGNOSTIC_TEST|Buccal Swabs and Blood Draws|Buccal Swabs - Frataxin \& specific RNA markers Blood Draws - Lipid panel, Uric Acid, Protein Marker Analysis and PAX Gene RNA Analysis
214929828|NCT05905653|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
214929829|NCT03048318|PROCEDURE|Arterial Flushing|
214929830|NCT03048318|PROCEDURE|Portal Flushing|
214929831|NCT03381079|PROCEDURE|Posterior scleral reinforcement|Posterior scleral reinforcement (pPSR) is a procedure applied with autologous or biological material or synthetic materials reinforcing pole of the sclera after eyeball, in order to prevent or alleviate myopic development.
214929832|NCT00789256|DRUG|Melphalan|Melphalan: 2mg orally, once daily
214929833|NCT00789256|DRUG|Bortezomib|Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11
215070512|NCT01192503|DRUG|rasagiline|1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
214328260|NCT00260923|DRUG|aliskiren|
214328261|NCT01509859|DEVICE|PFNA proximal femur nail device (Synthes)|"synthes PFNA proximal femur nail device"
214328262|NCT01509859|DEVICE|INTERTAN proximal femur nail device (Smith&Nephew)|"Smith\&Nephew INTERTAN proximal femur nail device"
214328263|NCT03095300|PROCEDURE|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
214328264|NCT04788732|DEVICE|ECG and EEG monitoring|the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
214328265|NCT00461903|DRUG|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
214328266|NCT05104398|DEVICE|Efferon CT|extracorporeal adsorbers containing mesoporous styrene-divinylbenzene copolymer to remove pro-inflammatory 6-60 kD molecules
214328267|NCT00623220|OTHER|N2O|EMONO
214328268|NCT00623220|OTHER|oxygen|oxygen
214328269|NCT04987359|BEHAVIORAL|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling.
214929834|NCT00789256|DRUG|Melphalan and bortezomib|
214929835|NCT04455191|PROCEDURE|Thawing Embryos in Advance|Thaw Embryos one day in Advance
214929836|NCT04455191|PROCEDURE|Thawing Embryos on the Day of Transfer|Thaw Embryos on the morning of transfer day.
214929837|NCT05798741|PROCEDURE|Hardware removal|The surgery of hardware removal after an ORIF of an ankle fracture
214929838|NCT00589758|DIAGNOSTIC_TEST|Echocardiography|2D and 3D echocardiography
215070513|NCT01192503|DRUG|placebo (sugar pill)|1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
215070514|NCT02419196|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
215070515|NCT03258281|DRUG|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
214328270|NCT01513317|DRUG|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
214328271|NCT01513317|DRUG|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
214328272|NCT01513317|DRUG|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
214328273|NCT00585949|PROCEDURE|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
214328274|NCT00585949|PROCEDURE|Angiography|Angiography is an imaging technique to see coronary blood vessels.
214328275|NCT03548610|OTHER|Nanofat-seeded biological scaffold on surgical defect|Nanofat-seeded biological scaffold in healing larger surgical defects (\>1.5cm) involving the lower limbs
214328276|NCT02721212|DEVICE|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
214328277|NCT02721212|OTHER|Conventional Rehabilitation|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
214328278|NCT05733676|DEVICE|Resin infiltration|Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.
214328279|NCT05733676|DEVICE|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride|Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe
214328280|NCT06957821|DRUG|Pegulicianine|Pegulicianine (LUMISIGHT) Inflammatory activity
214328281|NCT06957821|OTHER|Placebo|Control group for the study
214328282|NCT04108130|OTHER|Preoperative Education|Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
214328283|NCT04108130|PROCEDURE|Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization|PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
214328284|NCT04108130|OTHER|Individualization of Neuromuscular Blockade|Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
214673339|NCT01330381|DRUG|PEG 4000|
214929839|NCT00589758|OTHER|Biomarker evaluation|Blood and urine collected
214929840|NCT01148160|DRUG|voriconazole|intravenous, oral administration
215070516|NCT03258281|DRUG|Placebo|Patients will receive placebo administered subcutaneously
215070517|NCT03504982|DRUG|Vericiguat (BAY1021189)|A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat
215070518|NCT03504982|DRUG|Moxifloxacin|D: 400 mg moxifloxacin
215070519|NCT03504982|DRUG|Placebo|A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
215070520|NCT00731653|DRUG|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
215070521|NCT01357824|PROCEDURE|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
214328285|NCT04108130|PROCEDURE|Postoperative Incentive Spirometry|Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
214328286|NCT04108130|BEHAVIORAL|Postoperative Ambulation|Participants will be encouraged to adhere to prescription of early ambulation.
214929841|NCT06478433|DEVICE|Munatoril Aerosol Combo|"Munatoril® Aerosol Combo is a Medical Device that contains:~5 ml single-dose vials of sterile, 3% hypertonic, near-neutral pH bromine-iodine saline solution, based on Cervia integral sea salt, salso-bromo-iodine saline mother water from the Cervia Thermal Baths and hyaluronic acid with high molecular weight.~Lavonase® syringe with blue nebulizer valve (microsol), 10 ml, Medical Device for the administration of solutions in nebulized form within the nasal cavities and nasopharynx."
214929842|NCT06478433|DEVICE|Iperclenny|Hypertonic and Isotonic solution present on market in italy.
214929843|NCT06219824|DRUG|premixed Bio-ceramic MTA|pulpotomy treatment will be done and the premixed bioceramic MTA will be applied in the pulp chamber
214929844|NCT06219824|DRUG|Conventional MTA|pulpotomy treatment will be done and powder and liquid MTA will be mixed and applied in the pulp chamber
214929845|NCT06684236|OTHER|transcutaneous electrical stimulation|electrical stimulation is given through electrodes attached to the skin
214929846|NCT06684236|OTHER|electrodes attachment|electrodes are attached to the skin area of Neiguan acupoint, which is located on 3cm above the transverse crease of the wrist
214929847|NCT01190267|DRUG|asenapine|asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
214929848|NCT06500065|PROCEDURE|Computed Tomography|Undergo dPET/CT
214929849|NCT06500065|RADIATION|Gallium Ga 68-HA-DOTA-TATE|Given IV
214929850|NCT06500065|PROCEDURE|Positron Emission Tomography|Undergo dPET/CT
214929851|NCT02952131|PROCEDURE|Lipoaspiration|Closed Syringe Harvesting Autologous Subdermal Fat
214929852|NCT02952131|PROCEDURE|AD-cSVF|Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
214929853|NCT02952131|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
214929854|NCT03064100|OTHER|Observational Study|Exclusion from the study
214929855|NCT06181305|DRUG|estradiol valerate and letrozole|hormone replacement therapy by estradiol valerate plus letrozole incorporation .
214929856|NCT06181305|DRUG|letrozole 2,5 mg tablet|mild ovarian stimulation
215070522|NCT03470324|DEVICE|[standard STN]|standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
215070523|NCT03470324|DEVICE|[STN+SNr]|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
214328287|NCT01587326|DRUG|Escitalopram|escitalopram 10 mg/d to 20 mg/d
214929857|NCT06666101|DIETARY_SUPPLEMENT|Long chain polyunsaturated Omega-3|2 capsules of fatty acids in the morning and 2 capsules in the evening except the first day, 4 soft gels in a single administration in the morning, ± 2,6 g/d
215070524|NCT03470324|BEHAVIORAL|Swallowing therapy|Swallowing therapy with speech therapist
214328288|NCT03554083|DRUG|Atezolizumab|Given IV
214328289|NCT03554083|DRUG|Cobimetinib|Given PO
214328290|NCT03554083|BIOLOGICAL|Tiragolumab|Given IV
214328291|NCT03554083|DRUG|Vemurafenib|Given PO
214328292|NCT03457012|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
214328293|NCT05892458|BEHAVIORAL|Abdominal massage|To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
214328294|NCT01929668|DRUG|polyethylene glycol|
214328295|NCT01929668|DRUG|Ascorbic Acid|
214328296|NCT00362804|DRUG|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
214328297|NCT02692157|DRUG|Placebo|Placebo for Neurokinin 1,3 antagonist
214328298|NCT02692157|DRUG|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
214328299|NCT02692157|DRUG|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
214328300|NCT02692157|DRUG|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
214328301|NCT04031885|DRUG|Abemaciclib|Administered orally
214929858|NCT06666101|DIETARY_SUPPLEMENT|Placebo|Olive oil
214929859|NCT06667934|DRUG|Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night|Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
214929860|NCT06667934|DRUG|Methalazine suppository was given rectally once a day|Methalazine suppository was given rectally once a day
214929861|NCT05306314|DIETARY_SUPPLEMENT|TREATAPROST|oral administration before meals 30 minutes
215070525|NCT02947854|DRUG|Fimaporfin (Photosensitizer)|
215070526|NCT02947854|BIOLOGICAL|Hiltonol (Poly-ICLC)|
214328302|NCT04031885|DRUG|Fulvestrant|Administered IM
214328303|NCT04031885|DRUG|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label.
214328304|NCT02366481|DIETARY_SUPPLEMENT|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
214929862|NCT02963428|BEHAVIORAL|Enhanced Care|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
214328305|NCT02366481|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
214328306|NCT02366481|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
214328307|NCT02086435|PROCEDURE|Extracorporeal morcellation|"patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
214328308|NCT02086435|PROCEDURE|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
214328309|NCT05112497|OTHER|No intervention procedure|No intervention procedure
214486217|NCT06890910|OTHER|evidence based intervention|"sleep hygiene education. This education focused on four main aspects as follows:~* Personal habits: Women were educated on establishing a regular bedtime routine, engaging in regular exercise, maintaining a healthy diet, avoiding caffeine and nicotine before bedtime, consuming adequate calcium and magnesium, drinking warm milk before sleep, and avoiding gas-producing foods or excessive fluid intake before bed.~* Sleep environment: Women were advised to associate the bedroom only with sleep and intimacy, remove electronic devices, maintain a dark, quiet, and cool environment, ensure mattress and pillows were comfortable, and eliminate noise disturbances such as television.~* Stimulus control: Participants were instructed to use the bed only for sleeping, avoid staying in bed if unable to sleep, and engage in minimally stimulating activities instead of worrying about insomnia.~* Progressive muscle relaxation: Women in the study group received an educational session on the Jacobson's met"
214929863|NCT04848779|DRUG|Alglucosidase alfa GZ419829|"Pharmaceutical form: Lyophilized powder for solution~Route of administration: intravenous"
214929864|NCT05110846|DRUG|Placebo|Placebo
214929865|NCT05110846|DRUG|CT-868|CT-868
214929866|NCT02808728|DRUG|Pain Cocktail with Exparel|pain cocktail: bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel (bupivacaine liposome injectable suspension), 20cc of 1.3% Exparel, to total 100cc.
214929867|NCT02808728|DRUG|Pain Cocktail with Ropivacaine|pain cocktail: ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.
214929868|NCT01931956|DEVICE|MitraClip® implant|Percutaneous mitral valve repair using MitraClip implant
214929869|NCT00431028|DEVICE|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
214929870|NCT02847494|DRUG|metoclopramide|metoclopramide 10mg intravenous infusion over 15 minutes
214929871|NCT02847494|DRUG|Dexamethasone|dexamethasone 10mg intramuscular injection
214328310|NCT02866617|DEVICE|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
214328311|NCT01663272|DRUG|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
214328312|NCT01663272|DRUG|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
214328313|NCT04371276|OTHER|No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
214486218|NCT06737341|DRUG|Bupivacaine Liposomes(BL)|20ml of bupivacaine liposomes (266mg) + 10 ml of bupivacaine 0.75% hydrochloride + 20ml saline for ultrasound guided CMB.
214486219|NCT06737341|DRUG|Bupivacaine(B)|10 ml of 0.75% bupivacaine hydrochloride + 40ml normal saline for ultrasound-guided bilateral costal margin block
214486220|NCT06737900|OTHER|traditional physical therapy|"* Heating pad for 10 minutes~* Core stability exercises for 20 minutes with 10 seconds of rest intervals~* Patients were advised to stretch for 5 minutes then perform lumber stability exercises.~* These stability exercises included side bridges, supine extension bridge, straight leg raise in prone lying, alternate arm and leg raise from quadruped position and prone bridges.~Both groups took sessions thrice a week for a total of 4 weeks."
214929872|NCT02847494|DRUG|methylprednisolone acetate|methylprednislone acetate 160mg intramuscular injection
214929873|NCT02468154|DEVICE|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
214929874|NCT02468154|OTHER|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
214929875|NCT06898580|OTHER|sacral massage with tennis ball|When the cervical dilatation in labor is 5-6 cm, 7-8 cm and 9-10 cm, the woman will be asked to mark the intensity of the pain she feels on the VAS scale before starting the procedure. Then, the researcher explains sacral massage to the pregnant woman. While performing this application, the researcher will apply pressure to the sacral area with a tennis ball in a circular motion so that the patient can feel but not feel pain. The application will be applied to the pregnant woman for a total of 3 contractions. 30 minutes after each procedure, the woman will be asked to mark the intensity of the pain she feels on the VAS scale and mark the Birth Comfort Scale. The research will end when a total of 70 experimental groups and 70 control groups are reached.
215070527|NCT02947854|BIOLOGICAL|HPV E7 (Human Papilloma Virus E7) peptides|
215070528|NCT02947854|BIOLOGICAL|KLH (Keyhole Limpet Hemocyanin)|
215070529|NCT02710123|OTHER|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
215070530|NCT02710123|OTHER|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
214486221|NCT06737900|OTHER|jandas approach|"* Stretching exercise for erector spinae and back extensors muscles~* Stretching exercises for iliopsoas muscle and rectus femoris muscle~* Strengthening exercise for abdominal muscle and gluteal maximus muscle Stretching exercise was performed actively for 3 repetitions x 1 set and 4 days a week Strengthening exercise was performed for 10 second hold and 10 repetitions. All Exercises was performed 3 times per week for total of 4 weeks"
214486222|NCT06739213|DRUG|SYHA1813|The starting dose of SYHA1813 is 20mg QD
214486223|NCT06739213|DRUG|Investigator's Choice Treatment|Investigator's Choice Treatment
214929876|NCT03002948|OTHER|Orgasm|"clitoris volume, suprapubic angle, urethra-levator gap, suburethral triangle area measurement could made using 4 D transperineal ultrasonography. Clitoris fourchette distance, clitoris perineal body distance, clitoris urethra distance could made with special compasses.~Female Sexual Function Index orgasm domain score"
214929877|NCT01017133|RADIATION|fludeoxyglucose F 18|Given IV
214929878|NCT01017133|RADIATION|Fluorine F 18 EF5|Given IV
215070531|NCT04465032|OTHER|Gut microbiome transplantation|Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
215070532|NCT04051710|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
215070533|NCT04051710|DRUG|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
215070534|NCT04051710|DRUG|Placebo|Placebo Product
215070535|NCT04915118|OTHER|Decompensation event|NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
215070536|NCT01801176|OTHER|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
215070537|NCT01938508|DRUG|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
215070538|NCT01773343|PROCEDURE|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
215070539|NCT00664560|DRUG|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
215070540|NCT00664560|DRUG|celebrex|200 mg celecoxib qd
215070541|NCT00664560|DRUG|Placebo|sugar pill bid
215070542|NCT00664560|DRUG|Rescue Antacid|Antacid Tablets
215070543|NCT02834117|OTHER|natural cycle|Ovulation is not induced by drugs
214929879|NCT01017133|PROCEDURE|Positron emission tomography|Undergo scan
214929880|NCT02841280|DRUG|Chlorthalidone|This is a forced-titration study and the study drug will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
214929881|NCT02841280|DRUG|Placebo|This is a forced-titration study and placebo will be increased if goal BP is not achieved.
214929882|NCT00323570|DRUG|activated recombinant human factor VII|
214929883|NCT02027987|DRUG|valproate acid|valproate acid is a common drug which is applied for epilepsy prevention and treatment.
214929884|NCT01357070|DIETARY_SUPPLEMENT|Brocco-sprout homogenate|Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).
214929885|NCT01357070|DIETARY_SUPPLEMENT|Alfalfa sprout homogenate|Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.
215070544|NCT02834117|DRUG|moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
214486224|NCT06741358|OTHER|Glialia|Participants in the PPPD-Glialia group will receive the Glialia supplement, which contains 700 mg of Palmitoylethanolamide (umPEA) along with 70 mg of additional supportive ingredients. Each participant will be instructed to take two soluble sachets daily for a total duration of 60 days. This group aims to evaluate the effects of Glialia on PPPD, with outcomes assessed for neuroinflammation, mental clarity, quality of life, balance, and gait quality.
214673340|NCT00663858|DRUG|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
214673341|NCT00663858|DRUG|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
215070545|NCT00999635|DEVICE|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
214673342|NCT00663858|OTHER|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
214929886|NCT06452849|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
215070546|NCT00590174|DRUG|Aspirin|stopping clopidogrel at 1 year after DES implantation
215070547|NCT00590174|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
215070548|NCT03462017|DRUG|SAR247799|Pharmaceutical form:Capsule Route of administration: Oral
215070549|NCT03462017|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
215070550|NCT03462017|DRUG|Sildenafil|Pharmaceutical form:Encapsulated tablet Route of administration: Oral
215070551|NCT03462017|DRUG|Acetylcholine|Pharmaceutical form:Solution Route of administration: Transdermal
214929887|NCT06667830|OTHER|Physical exercise program|The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
214929888|NCT06667830|OTHER|Neural mobilization techniques|Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
215070552|NCT03350035|DRUG|IV Ganaxolone active|IV
215070553|NCT03350035|DRUG|IV Placebo, non-active|IV
215070554|NCT02973347|OTHER|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
214328314|NCT03652298|OTHER|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
214328315|NCT03652298|OTHER|support and attention (usual care)|support and attention (usual care)
214929889|NCT01738503|DRUG|RBP-6000|18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.
214929890|NCT01738503|DRUG|Subutex|Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.
214929891|NCT02375308|BEHAVIORAL|HDT|20 sessions, individual psychotherapy
214929892|NCT02375308|BEHAVIORAL|ACDT|20 sessions, individual psychotherapy
214929893|NCT03005327|DRUG|X4P-001|Mavorixafor will be provided as either 25 mg or 100 mg capsules.
215070555|NCT02973347|OTHER|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
214929894|NCT01377740|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214929895|NCT04683692|DEVICE|Magnetic Resonance Imaging (MRI)|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
214328316|NCT05717998|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214929896|NCT04683692|OTHER|Laboratory Testing|Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation
214929897|NCT03359668|DIAGNOSTIC_TEST|Use of IV contrast during head and neck CT|Use of IV contrast during head and neck CT
214929898|NCT06685627|OTHER|Open water wetsuited swimming.|All swimmers used their own well-fitting wetsuits (5 mm maximum thickness in accordance with World Triathlon guidelines7) and were free to supplement additional neoprene hats, gloves and booties as desired. A safety paramedic attended all swims. Swim distance was self-determined
214929899|NCT06666920|RADIATION|laser irradiation|Immediately after applying the bleaching agent, the gel on the left upper and lower hemiarches (teeth 21-25 and 31-35) was irradiated using an Er,Cr:YSGG laser (2780 nm). Specifically, an Er,Cr:YSGG solid-state laser device (Waterlase MD Turbo, BIOLASE, Irvine, CA, USA) equipped with a Z-type glass tip (MZ8) measuring 800 μm in diameter and 6 mm in length was used. This tip was attached to the laser system's gold handpiece. The laser parameters for the treatment included an average output power of 1.25 W, a pulse duration of 700 μs (S-mode), and a pulse repetition rate of 10 Hz, without water or air flow, according to a previous study. Each tooth received two 15-s irradiation intervals, one for each 20-min session (totaling 30 s), while maintaining the laser handpiece approximately 2.5 cm from the tooth surface, perpendicular to the enamel. The gel was irradiated using a scanning mode, with the handpiece moved slowly in both horizontal and vertical directions at a speed of 2 mm/s.
214929900|NCT05933174|OTHER|Prompt-sheet|Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
214929901|NCT05933174|OTHER|Usual education|Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
214929902|NCT03181269|OTHER|Intervention education|An education package that includes an enhanced emphasis on maternal-infant skin-to-skin contact and a detailed activity log for recording early post-partum care practices that includes specific skin-to-skin contact time and frequency goals.
214328317|NCT05717998|PROCEDURE|Computed Tomography|Undergo cardiac PET/CT
215070556|NCT02269176|DRUG|Low dose of telmisartan|
215070557|NCT02269176|DRUG|High dose of telmisartan|
215070558|NCT02269176|DRUG|Low dose of losartan|
215070559|NCT02269176|DRUG|High dose of losartan|
214328318|NCT05717998|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo CMR
214328319|NCT05717998|PROCEDURE|Positron Emission Tomography|Undergo cardiac PET/CT
214328320|NCT05524324|DEVICE|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|Patients randomized to the CRT ON / CRT OFF arm will undergo a first intervention to activate their device and then a second intervention for 3 months to inactivate their device.
214328321|NCT05524324|DEVICE|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|Patients randomized to the CRT OFF / CRT ON arm will undergo a first intervention to inactivate their device and then a second intervention for 3 months to activate their device.
214328322|NCT02610192|DEVICE|nSTRIDE Autologous Protein Solution (APS) Kit|Intra-articular injection of APS
214328323|NCT04147013|DRUG|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
214328324|NCT04147013|DRUG|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
215070560|NCT04779567|DRUG|Acetaminophen|Acetaminophen 1 gr iv 4 times a day
215070561|NCT04779567|DRUG|Placebo|100 ml saline 0.9% iv 4 times a day
215070562|NCT04187794|OTHER|Interview patient|to investigate an association between literacy level and medication adherence in patients with rheumatic diseases.
215070563|NCT01023555|OTHER|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
214328325|NCT04387253|DIAGNOSTIC_TEST|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Presence of SARS-COV-2 virus in samples taken from mother and father. Circulating anti-SARS-COV-2 antibodies in the mother.
214328326|NCT04889560|OTHER|Experimental group|Home-based version of a computerized cognitive training (CoRe)
214929903|NCT03181269|OTHER|Placebo Education|An education package that includes a basic emphasis on maternal-infant skin-to-skin contact, as well as other general post-partum care practices and a general early post-partum care practices log without specific skin-to-skin contact goals.
214929904|NCT04619329|DEVICE|GSMs-TACE|TACE using Lobaplatin (30-40mg/m2) and gelatin sponge microspheres (150-350μm, 350-560μm, 560-710μm or 710-1000μm)
214929905|NCT04619329|PROCEDURE|Surgical Resection|Surgical Resection of HCC
214929906|NCT06665529|OTHER|28-day mortality prediction by ICU staff and mortality scores|28-day mortality prediction by ICU staff (three senior physicians and ICU nurse) and mortality scores (APACHE 2, MPM 2 and MODS).
214929907|NCT02782065|OTHER|Not an interventional study|
214929908|NCT02130089|BEHAVIORAL|Intensive Tailored Education|
214929909|NCT06684548|PROCEDURE|Hip/shoulder width ratio|the effect of hip/shoulder-width ratio on sensory blockade level in patients undergoing intrathecal anesthesia for subumbilical herniorrhaphy
214929910|NCT01490073|DRUG|Insertion of nitroglycerin ointment|Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion
214929911|NCT01490073|DRUG|Insertion of placebo ointment|Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion
214929912|NCT03404947|DIETARY_SUPPLEMENT|Ethanol|For one exercise session, participants will be asked to ingest a quantity of ethanol (in the form of vodka) sufficient to maximally stimulate liver alcohol metabolism.
214929913|NCT02074098|DEVICE|Macintosh laryngoscope|Direct Laryngoscope
214929914|NCT02074098|DEVICE|Glidescope|Videolaryngoscope-1
214929915|NCT02074098|DEVICE|Airwayscope|Videolaryngoscope-2
214328327|NCT04889560|OTHER|Control group|Computerized cognitive training (CoRe)
214328328|NCT06843668|DRUG|EMA colistin dosing strategy|The EMA colistin group will receive I.V colistin based on creatinine clearance (mL/min) level , with fixed loading dose 9 MIU equivalent to 300 mg of colistin-based activity (CBA). The maintenance dose will be administered after 12 h following the loading dose over 1 h every 12h (twice daily).
214328329|NCT06843668|DRUG|US FDA colistin dosing strategy|The weight-based colistin group will receive I.V. colistin based on the lower (ideal body weight or actual body weight) with a loading dose of (4) X (patient weight in kg). Loading dose might exceed 300 mg.
214328330|NCT00486122|DRUG|Atomoxetine Hydrochloride|
214673343|NCT04685330|PROCEDURE|Ultrasound guided procedure|Single-arm, open-label device efficacy study to enroll 200 patients who have been ordered to have an ultrasound-guided procedure by the MGH Interventional Radiology department, including paracentesis, thoracentesis, biopsy, or ultrasound-guided drain placement. Patients will be restricted to adults who can consent.
214673344|NCT04685330|DEVICE|Portable ultrasound|The FDA approved Healcerion SONON portable ultrasound (linear and curved) will be used during clinically indicated standard ultrasound-guided procedures following clinical standard of care. A standard clinical ultrasound will subsequently be used for image guidance as the gold standard. Images will be compared and improved. The efficacy of the portable ultrasound will be monitored by the clinical user and any complications within 30 days will be determined by chart review.
214929916|NCT04880798|DIAGNOSTIC_TEST|124I PET/CT|The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, and the second 124I PET/CT was prepared with endogenous thyrotropin \>100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.
214929917|NCT04525768|DIAGNOSTIC_TEST|JAK2 mutation test|Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test
214929918|NCT00883467|PROCEDURE|preconditioning|3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
214929919|NCT00883467|PROCEDURE|no preconditioning|no preconditioning
214328331|NCT00486122|DRUG|Placebo|
214328332|NCT01594593|BEHAVIORAL|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
214673345|NCT03245476|OTHER|Physical therapy focus on manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
214673346|NCT03245476|OTHER|Physical therapy focus on education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
214929920|NCT05016401|DEVICE|KONTACT PERIO LEVEL (KPL)|The Kontact™ Perio Level is an implant with a transgingival neck that facilitates one-step surgery.
214328333|NCT05764213|BEHAVIORAL|Listening to Women & Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.
214328334|NCT00315276|DRUG|Modafinil|
214328335|NCT00972491|PROCEDURE|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
214328336|NCT00239057|DRUG|Enteric-Coated Mycophenolate Sodium|
214328337|NCT06287060|OTHER|strawberry extract.|strawberry has a whitening effect due to its content of ellagic and maleic acids. the presence of acidic components namely ascorbic acid may increase the surface energy by removing the surface debris, thereby allowing the citric and maleic acids to penetrate into tooth surface to remove the surface stains.
214929921|NCT06186427|DIAGNOSTIC_TEST|68Ga-DOTA-GPFAPI-04 PET/CT|The same group of patients underwent 68Ga-DOTA-GPFAPI-04 PET/CT and FDG PET/CT examinations respectively
214328339|NCT01638338|BEHAVIORAL|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
214929922|NCT02496091|DEVICE|ATLANTIS Abutment|
214929923|NCT01986127|DRUG|Adalimumab|single intralesional administration during endoscopy process
214929924|NCT01986127|DRUG|placebo|single intralesional administration during endoscopy
214929925|NCT04304482|DRUG|ANAVEX2-73 oral liquid|Liquid oral solution
214929926|NCT04304482|DRUG|Placebo oral liquid|Liquid oral solution
214929927|NCT06621160|OTHER|Observation|After the participants\&#39; physical and sociodemographic characteristics were recorded, they were asked to fill out the Constipation Severity Scale and 7- Day Stool Diary to determine their constipation levels. The individuals\&#39; anthropometric characteristics were assessed with triceps, subscapula, suprailiac and calf skinfold thickness, humerus and femur epicondyle diameter, biceps and calf circumference measurements, spinal postures were assessed with the Spinal Mouse, and physical activity levels were assessed with the International Physical Activity Questionnaire-Short Form UFAA-KF and pedometer.
214328340|NCT01638338|BEHAVIORAL|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
214328341|NCT04065724|OTHER|Physical training as resistance and aerobic training.|
214328342|NCT00279708|DRUG|Atorvastatin|Placebo vs. Atorvastatin
214929928|NCT05908123|BEHAVIORAL|The Blank Center CARE Model(TM) for Individuals who Stutter|The over-arching goal of the Blank Center CARE Model is to ensure individuals who stutter communicate effectively, advocate for themselves in a manner that maintains agency, and ensure their quality of life does not depend on producing, or attempting to control, stuttered speech.
214929929|NCT06061523|DRUG|Sotorasib|Oral Tablet
214929930|NCT06685614|DEVICE|orthodontic bracket bonding|compare the effectiveness of different bonding methods including traditional direct bonding, traditional indirect bonding, indirect bonding using 3D-printed transfer tray, and indirect bonding using vacuum-formed transfer tray made with 3D-printed models
214929931|NCT04275921|DIAGNOSTIC_TEST|MRI scan|MRI analysis using TWIST and HASTE
214929932|NCT04275921|DIAGNOSTIC_TEST|4D MRI|4D MRI alongside 4D CT in lung cancer
214929933|NCT06459050|OTHER|Dominant Limb Overcoming Isometric Conditioning Activity|Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by the dominant limb.
214929934|NCT06459050|OTHER|Non-dominant Limb Overcoming Isometric Conditioning Activity|Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by non-dominant limb.
214328343|NCT00279708|OTHER|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
214328344|NCT02251665|OTHER|No intervention|a single-center prospective observational study
214929935|NCT00922506|DRUG|doxazosin plus tolterodine SR|doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
214929936|NCT02272842|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 in a multivitamin paste.
214929937|NCT04540159|DIAGNOSTIC_TEST|Flow-cytometric analysis|Measuring the level of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 in the intraabdominal ascites
214929938|NCT04339647|BEHAVIORAL|The SIMS programme|The intervention targets 5-6-year-old preschool children and their parents. Apart from the usual care, 5-6-year-old children receive oral health lessons and supervised daily tooth brushing (1000ppm F) at school over a period of 6 months, as well as home tooth brushing supervision by parents for 6 months. Parents/guardians attend a meeting with a DT team at school to discuss on child's oral health status, receive OHE and free toothbrush and fluoride toothpaste (1000ppm F) for child home tooth brushing, and receive 10 oral health infographic messages from DT over a period of 5 months (with printed versions available).
215070564|NCT03729258|DRUG|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
215070565|NCT03729258|DRUG|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
214328345|NCT05041088|DIETARY_SUPPLEMENT|ProdromeNeuro Plasmalogen|The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
214328346|NCT03287856|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
214328347|NCT01592188|BEHAVIORAL|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
214328348|NCT01592188|BEHAVIORAL|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
214328349|NCT03354429|DRUG|Ticagrelor|Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
215070566|NCT06251661|OTHER|Cognitive multi-sensory Rehabilition|Kinetic awareness: Initially, only one joint will be moved at a time. Then the therapist will reposition the joint and ask the participants to report their perception of the joint position. Initially, the participants will distinguish between just two positions. If they reliably answer correctly, increase up to five points and integrate speed and dexterity in functional movements. Participants will be asked to relax and feel the movement during this training. Discrimination exercise: The therapist places a part of the participant's limb, the fingertip, on an external object (a block) and the participant will be asked to actively move his or her limb over the object and try to sense the shape of the object. If the participants differentiate between the two objects, then increase the number of objects (up to five). Functional training: The patient reaches toward many objects functionally (cup, ball, cane) from different angles, holds them, and relocates them again.
215070567|NCT06251661|OTHER|selected traditional physical therapy program.|The selected physical therapy program session will be occupational therapy training for the hand, strengthening exercises for the weak upper limb stretching exercises for short upper limb muscles, balance exercise, and gait training.
215070568|NCT04924894|OTHER|no intervention|no intervention
214328350|NCT03354429|DRUG|Placebo|Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
214486225|NCT06741358|OTHER|Placebo|Participants assigned to the PPPD-Placebo group will receive a placebo that is designed to be indistinguishable from the Glialia supplement in terms of appearance and packaging. They will also take two soluble sachets daily for 60 days. The purpose of this group is to serve as a control to evaluate the effects of the Glialia supplement by comparing the outcomes with those of the PPPD-Glialia group. The same assessments for neuroinflammation, mental clarity, quality of life, balance, and gait quality will be performed.
214673347|NCT00148629|DRUG|multivitamin, mebendazole|
214328351|NCT02694341|PROCEDURE|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
214328352|NCT02694341|DEVICE|Bakri Balloon|uterine compression balloon
214328353|NCT03194048|OTHER|Functional Chewing Training|"FuCT;~* Family training~* Providing optimal sitting posture for children to support oral sensorimotor functions~* Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~* Massage of the upper and lower gums through the front teeth to molar area~* Chewing training to stimulate lateral and rotational tongue movements~* Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
214328354|NCT03194048|OTHER|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;~* Family training~* passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
214328355|NCT06086184|BEHAVIORAL|ACT group therapy|"Participation in four sessions of the inpatient Compass Group and eight sessions of the inpatient Here-and-Now Group. This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan."
214328356|NCT01873989|DRUG|Testosterone replacement|
214328357|NCT01873989|OTHER|Waitlist control|
214328358|NCT00226603|BEHAVIORAL|Specific training programme (behavior)|
214328359|NCT01997086|PROCEDURE|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
214328360|NCT01997086|PROCEDURE|Microendoscopic discectomy (MED)|Microendoscopic discectomy
214328361|NCT00953329|DRUG|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
214328362|NCT00184340|DEVICE|eTherapy|secured e-mail system between patient and therapist
214328363|NCT00895219|OTHER|Breathing re-training|Breathing re-training
214328364|NCT00895219|OTHER|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
214328365|NCT01045291|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
214673348|NCT00619541|DRUG|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
214673349|NCT00619541|DRUG|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
214929939|NCT05590897|PROCEDURE|Teeth Brushing|All 52 participants were instructed through a lecture on how to perform toothbrushing with a fluoridated toothpaste (Colgate T®) and dental flossing three times per day after meals for 30 days. The Bass technique was taught, by which the bristles should be positioned at an approximate angle of 45º to the gingival pocket on both the free and proximal faces, with the performance of short, slightly circular vibrating movements.
214673350|NCT00097422|DRUG|OPT-80|
214929940|NCT05590897|PROCEDURE|Dental Flossing|All 52 participants were instructed to floss, 3 times a day after meals for 30 days.
214328366|NCT00075868|DRUG|octreotide acetate|
214673351|NCT00520689|DEVICE|Silicone Hydrogel Contact Lens|use of lens over 2 days
214929941|NCT05590897|PROCEDURE|Tongue Scraping|Tongue scraping was performed by the same operator for all participants. Posteroanterior movements were performed with the scraper on the dorsum of the tongue, followed by the cleaning of the scraper with gauze. The procedure was performed ten times on each participant to standardize mechanical removal.
215070569|NCT03593343|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
215070570|NCT06355596|OTHER|Virtual teaching|Virtual teaching of laparoscopic skills
215070571|NCT00134992|DRUG|Prednisolone acetate|
215070572|NCT04277858|DRUG|Docetaxel|Subjects will be treated with neoadjuvant docetaxel and cisplatin for 3 cycles. This is followed by transoral robotic surgery (TORS) and neck dissection as definitive treatment, reserving radiotherapy for salvage.
215070573|NCT04696367|PROCEDURE|Emergency laparotomy|Midline laparotomy for acute intra-abdominal pathology
214328367|NCT00075868|OTHER|Placebo|
214328368|NCT06316466|OTHER|Lp(a)|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
214673352|NCT05706467|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
214673353|NCT05706467|DEVICE|Non-invasive continuous positive airway pressure ventilation|Non-invasive positive airway pressure ventilation is carried out through non-invasive ventilator.
214673354|NCT00068952|DRUG|Edotecarin|
214673355|NCT00068952|DRUG|Temozolomide|
214673356|NCT00068952|DRUG|Carmustine (BCNU)|
214328369|NCT04341480|DRUG|Chemotherapy|Routine chemotherapy for individual tumor type.
214328370|NCT03515460|OTHER|sugar oral load|The individuals will receive a sugar oral load (high sugar meal)
214328371|NCT03515460|OTHER|fat oral load|The individuals will a receive fat oral load (high fat meal)
214929942|NCT05590897|RADIATION|Antimicrobial Photodynamic Therapy (aPDT)|"One session of aPDT was performed. The annatto photosensitizer was mixed at a concentration of 20% (Fórmula e Ação®, Brazil) in spray form, applied with a sufficient quantity to coat the middle third of the dorsum of the tongue (five sprays) and left for two minutes for incubation. The excess was removed with an aspirator. \|The surface of the tongue remained moist with the photosensitizer itself without the use of water. Six points were irradiated with a distance of 1 cm between points, considering the spread of the light and effectiveness of aPDT. The device was previously calibrated at a wavelength of 395-480 nm. Light was irradiated to ensure a beam area of 2 cm in diameter per point. Energy was 9.6 J and exposure time was 20 seconds per point."
214929943|NCT06069076|DIAGNOSTIC_TEST|cathepsin S and chromogranin A|Diagnostic value of serum Cathepsin S and Chromogranin A
214929944|NCT00569673|BIOLOGICAL|filgrastim|
214929945|NCT00569673|BIOLOGICAL|pegfilgrastim|
214929946|NCT00569673|DRUG|docetaxel|
214929947|NCT00569673|DRUG|trabectedin|
214929948|NCT00334529|DRUG|Oseltamivir|
214929949|NCT05002673|DEVICE|DENTAL LOCAL ANESTHESİA|doing local and topical anesthesia with two different device
214929950|NCT06131684|DEVICE|Intrauterine pressure catheter (IUPC) present|Amniotic fluid will be analyzed every 3 hours for the duration of labor for patients who require an IUPC through the standard of care.
214929951|NCT06131684|DEVICE|Intrauterine pressure catheter (IUPC) absent|Patients that do not require an IUPC through the standard of care will not have amniotic fluid analyzed.
214929952|NCT02050217|PROCEDURE|Neurally Adjusted Ventilatory Assist|
214929953|NCT06240702|OTHER|Telerehabilitation Group|Unlike the control group, the experimental group will be given a phase II telerehabilitation program and sleep hygiene training for 3 weeks after discharge. Within the scope of the Phase II telerehabilitation program, breathing exercises and calisthenic exercises will be performed at increasing intensity according to the patient's tolerance, 3 days a week for 3 weeks. In addition, walking training will be continued over increasing distances. In addition, it will be aimed to increase sleep quality by giving a sleep hygiene education brochure to the patients in the experimental group. During the sessions, the vital signs and clinical status of the patients will be monitored according to the severity level determined by the finger pulse oximeter device, digital blood pressure monitor, perceived difficulty level (Borg Scale) and maximum heart rate. In addition, patients will be kept in a diary to monitor their compliance with the treatment program.
215070574|NCT02715024|DRUG|Tamsulosin|Oral
215070575|NCT02715024|DRUG|Solifenacin|Oral
214929954|NCT04068012|OTHER|Ventilator protocol|open loop ventilator management by a computer based protocol
214929955|NCT01812317|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
215070576|NCT04251767|OTHER|washed microbiota transplantation|"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.~Dose and frequency: 5u, once."
214929956|NCT01812317|PROCEDURE|Badimon Chamber Study|Ex-vivo assessment of thrombus formation using the Badimon Chamber
214328372|NCT03515460|OTHER|sugar and fat oral load|The individuals will a receive sugar and fat oral load (high sugar and high fat meal)
215070577|NCT04251767|OTHER|placebo|"Placebo (edible suspension of the same color as the washed microbiota suspension，5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.~Dose and frequency: 5u, once."
215070578|NCT05940363|COMBINATION_PRODUCT|Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies|To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
215070579|NCT03155919|DIETARY_SUPPLEMENT|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
215070580|NCT03155919|DIETARY_SUPPLEMENT|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
215070581|NCT01679548|PROCEDURE|Single-port LAVH|LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
215070582|NCT01679548|PROCEDURE|Three-port LAVH|Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
215070583|NCT01242696|PROCEDURE|Coronary artery stenting|Coronary artery stenting with drug eluting stents
215070584|NCT02537587|OTHER|Control 1|67g of control bar
215070585|NCT02537587|OTHER|Control 2|86g of control bar
215070586|NCT02537587|OTHER|15/0|66g of experimental bar 15/0
215070587|NCT02537587|OTHER|15/0LS|84g of experimental bar 15/0LS
215070588|NCT02537587|OTHER|15/5|75g of experimental bar 15/5
215070589|NCT02537587|OTHER|10/5|72g of experimental bar 10/5
215070590|NCT02537587|OTHER|10/10|80g of experimental bar 10/10
215070591|NCT05186103|OTHER|observation|The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
215070592|NCT03695627|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
215070593|NCT03576066|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
214328373|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
214328374|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
214328375|NCT01465802|DRUG|Doxycycline|Doxycycline or Doxycycline placebo BID for 4 weeks
214673357|NCT00068952|DRUG|Lomustine (CCNU)|
214929957|NCT00589381|DRUG|fenretinide lipid matrix|
214929958|NCT02238912|DRUG|kandhaga rasayanam|KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
214929959|NCT01493284|DEVICE|Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a transfemoral delivery system
214929960|NCT02714088|OTHER|Novel high-intensity interval training|
214929961|NCT05792332|OTHER|Telemonitoring|Patients are followed up by a nurse specialist in parkinsonism who interacts with the treating neurologist and a multidisciplinary team
214929962|NCT05792332|OTHER|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
214929963|NCT00519428|DRUG|escitalopram|10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
214929964|NCT00519428|DRUG|bupropion extra long (XL)|150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
214929965|NCT00519428|DRUG|escitalopram + bupropion|same dosing schedule as for monotherapy
214929966|NCT02393807|DRUG|PF 06260414 solid dose formulation|Single dose of 30 mg PF-06260414 given under fed/fasted conditions
214929967|NCT02393807|DRUG|PF-06260414 nanosuspension|Single dose of 30 mg PF-06260414 given under fasted conditions
214929968|NCT02949193|DRUG|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg
214929969|NCT02949193|DRUG|Sitagliptin|sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
214929970|NCT00325156|BIOLOGICAL|GSK Biologicals' combined DTPa-IPV/Hib vaccine|4 intramuscular injections
214929971|NCT02648854|DRUG|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
214929972|NCT02648854|DRUG|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
214929973|NCT01598233|DEVICE|Silimed Intragastric balloon|Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
214929974|NCT06664697|DEVICE|Cochlear Implantation with Robotic-Assisted Insertion System|The purpose of the study is to collect additional safety data in retrospective and prospective subjects who receive a cochlear implant using the iotaSOFT Insertion System.
214929975|NCT05507476|DRUG|Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray|The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery.
214929976|NCT05507476|DRUG|Epinephrine topical 1:100,000 Nasal Packs|The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
214929977|NCT03626363|BEHAVIORAL|Stress Management|An eight week stress reduction course.
214929978|NCT02663102|OTHER|Data collection|Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.
214929979|NCT00533702|BIOLOGICAL|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
214929980|NCT00533702|DRUG|Dacarbazine|1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
214328376|NCT01465802|DRUG|Probiotic|VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
214328377|NCT01465802|DRUG|Alclometasone cream|Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
214328378|NCT05996250|OTHER|Immersive virtual reality task|participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks
214929981|NCT01443338|DRUG|Triptergium Wilfordii|Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
214929982|NCT01443338|DRUG|Acitretin|Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
214929983|NCT06668038|OTHER|Multidisciplinary and multicenter validation of re-irradiation with curative intent|"Validation in multidisciplinary and multicenter meeting of re-irradiation indication after review of technical data (images, structures and doses) of 1st irradiation and recent diagnosis images of the lesion to be irradiated, merged using MIM.~In case of re-irradiation validation, validation in multidisciplinary and multicenter meeting of cumulated doses after review of EQD2 doses summation using MIM."
214929984|NCT03507764|OTHER|Use of the treadmill workstation at work|"During the randomized study phase, provision of the treadmill workstation with the recommendation to use it for at least one hour (continuous or split) during each of the working shifts.~After six months, all subjects will use treadmill without restrictions or conditions."
214929985|NCT05685264|DRUG|Ponsegromab|Participants will receive one subcutaneous injection
214929986|NCT05685264|DRUG|Ponsegromab|Participants will receive four subcutaneous injections
214929987|NCT05494008|PROCEDURE|Korean herbal medicine treatment|Korean herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients with post-traffic accident syndromes.
214929988|NCT05494008|PROCEDURE|Non-Korean herbal medicine treatment|acupuncture, pharmacoacupuncture, cupping, chuna
214929989|NCT06045403|BEHAVIORAL|Issuing health risk warning for a heat or cold|Whenever a health risk warning for a heat or cold is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
214929990|NCT06045403|DEVICE|A digital heat or cold health risk early warning tool|A WeChat mini-program provides real-time updates on early warnings and health advisories.
214929991|NCT06045403|BEHAVIORAL|Perform daily self-monitoring of their BP and ECG|Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
214929992|NCT06045403|DEVICE|Self-monitoring blood pressure and ECG device|Devices for self-monitoring blood pressure and electrocardiography (ECG).
214328379|NCT01340976|DRUG|LY2787106|Administered IV.
214328380|NCT01340976|DIETARY_SUPPLEMENT|Iron Supplementation|Administered orally.
214328381|NCT02331446|BEHAVIORAL|Physical exercise intervention|
214328382|NCT05054296|BEHAVIORAL|Educational Intervention|Receive general education exercise packet
214328383|NCT05054296|BEHAVIORAL|Exercise Intervention|Participate in supervised and self-directed exercise sessions
214328384|NCT05054296|DEVICE|FitBit|Wear FitBit for activity tracking
214328385|NCT05054296|OTHER|Quality-of-Life Assessment|Ancillary studies
214673358|NCT02847611|DEVICE|Dynamometer LABIN|LABIN is a prototype of dynamometer containing a handle of metal strength, connected with a sensor of pressure registering(recording) the applied strength and transmitting the data in a computer showing an IT curve of the strength according to time.
214929993|NCT03069599|PROCEDURE|irreversible electroporation (IRE)|Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
214929994|NCT02522156|BEHAVIORAL|Looming Vulnerability Induction|guided imagery aimed at inducing smoking cessation attempts. See description of the looming vulnerability arm.
214929995|NCT02522156|BEHAVIORAL|Control|Neutral guided imagery scenarios making no reference to smoking.
214929996|NCT05971511|OTHER|Questionnaire|Questionnaire
214929997|NCT01182597|DRUG|Pantoprazole (Pantoloc)|Pantoprazole (Pantoloc) 3.3mg/hr for 72hrs
214328386|NCT05054296|OTHER|Questionnaire Administration|Ancillary studies
214929998|NCT01182597|DRUG|Lansoprazole (Takepron OD)|Lansoprazole (Takepron OD) 30mg q12h PO
214328387|NCT03090399|DEVICE|FloTrac|For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
214328388|NCT02717533|OTHER|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
214328389|NCT00125827|DRUG|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
214328390|NCT01963624|DEVICE|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
214328391|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays with reservoir.|During bleaching using trays with reservoir.
214328392|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays without reservoir.|During bleaching using trays without reservoir.
214328393|NCT04560803|DEVICE|CelluTomeTM Epidermal Harvesting System|Autologous epidermal grafts that will be placed at the treatment site
214328394|NCT02634294|DRUG|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1\~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
214328395|NCT02566759|DRUG|TAK-831 Oral Suspension|TAK-831 oral suspension.
214328396|NCT02566759|DRUG|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
214328397|NCT02566759|DRUG|TAK-831 Tablet|TAK-831 tablet.
214929999|NCT03224611|DEVICE|light wand|"The light wand is used as a stylet of the flexible LMA. When the investigator inserts the flexible LMA in light wand group, the correct position of the LMA is confirmed by the light."
214930000|NCT04500483|DIAGNOSTIC_TEST|indirect calorimetry|measurement of resting energy expenditure using indirect calorimetry
214930001|NCT05629611|DEVICE|Vi-Sealer|using Reusable device, Vi-Sealer
214930002|NCT05629611|DEVICE|Ligasure|using Ligasure
214930003|NCT05629611|DEVICE|Other AHD|Using other AHDs such as Thunderbeat, Harmonic scalpel, Caiman®, Enseal, etc. except Ligasure
215070594|NCT03576066|DRUG|SOC NUC|Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
215070595|NCT03576066|DRUG|Placebo Oral Tablet|Participants will receive placebo matching ABI-0731 tablets orally QD.
215070596|NCT01215617|BEHAVIORAL|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
215070597|NCT01215617|BEHAVIORAL|Control|Standard medical treatment
214328398|NCT00117091|DRUG|Anakinra (Kineret®)|
214328399|NCT01423513|OTHER|Fibular Taping|Tape with be applied with tension.
214328400|NCT01423513|OTHER|Sham Taping|Tape will be applied without tension
214328401|NCT04878705|DRUG|TWP-201|a single subcutaneous injection
214328402|NCT04878705|DRUG|placebo|a single subcutaneous injection
214328403|NCT05647824|DEVICE|Capillary Testing|Testing Contour Fit BGMS with capillary blood
214328404|NCT05647824|DEVICE|Alternative Site Testing (AST)|Testing Contour Fit BGMS using blood from alternative site
214328405|NCT05647824|DEVICE|Venous Testing|Testing Contour Fit BGMS with venous blood
214930004|NCT01893060|DRUG|Povidone-Iodine|Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
214930005|NCT01893060|DRUG|Chlorhexidine gluconate|Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
214930006|NCT01893060|DRUG|Pluronic Cream|Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
214328406|NCT00226941|DRUG|Cetuximab|Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
214328407|NCT00226941|DRUG|Oxaliplatin|Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
214930007|NCT01893060|OTHER|control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
214930008|NCT04410120|OTHER|Interview|Semi-structured 45 minute interviews regarding impact of asthma attacks
214930009|NCT04245540|DIETARY_SUPPLEMENT|Pau d' Arco|Encapsulated herbal Pau d' Arco.
214930010|NCT00286780|DRUG|AT-101|80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
214930011|NCT00517140|PROCEDURE|Repeat Caesaen section|
214930012|NCT00517140|PROCEDURE|vaginal delivery|
214930013|NCT01881204|DIETARY_SUPPLEMENT|Hesperidin and Calcilock|Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
214930014|NCT01881204|DIETARY_SUPPLEMENT|Hesperidin|Hesperidin (552mg) will be administered in the form of cookies (biscuit).
214930015|NCT01881204|DIETARY_SUPPLEMENT|Control|Cookies without Hesperidin or Calcilock added.
214930016|NCT05872867|BIOLOGICAL|WM-A1-3389|Anti-IGSF1 (Immunoglobulin superfamily member 1)
214930017|NCT05872867|BIOLOGICAL|Pembrolizumab|Anti-PD-1(Programmed cell death protein 1)
215070598|NCT00006164|DRUG|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks
214328408|NCT00226941|DRUG|Capecitabine|Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
214673359|NCT03188211|OTHER|E-learning educational program|A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.
214673360|NCT03188211|OTHER|Control|Any educational program will be delivered to clinicians assigned to control arm
214673361|NCT03216265|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
214930018|NCT05261724|DIAGNOSTIC_TEST|MRI|In this study patients with suspected primary and secondary brain tumors, confirmed by routine MRI evaluation (T1, T2, T2\*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation.
214930019|NCT06601569|DIAGNOSTIC_TEST|balance and range of motion|"* Spinal alignment and range of motion measure scale (SAROMM): is a measure of spinal alignment and range of motion using standard physical therapy techniques scored on a 5-point ordinal score of 0 (normal alignment and range with active correction) to4 (severe ﬁxed deformity) (Bartlett ey al., 2005)~* Modified Ashworth scale (MAS): is a measure of muscle motion and scoring the perceived resistance to movement on a scale of 1 (no increase in tone) to 5 (rigid in ﬂexion or extension) (Clopton et al., 2005).~* Early clinical assessment of balance (ECAB) scale: Is a 13-item test that estimates postural stability for children with CP across all levels of functional ability (Jeffries etal., 2016).~* Functional strength assessment scale: Therapists completed a functional strength assessment (FSA) to obtain an estimate of strength for major muscle groups including the neck and trunk ﬂexors and extensors, and hip extensors, knee extensors, and shoulder ﬂexors bilaterally."
214930020|NCT05296044|DRUG|JT-003|Subjects take the investigational products once a day for 24 weeks.
214930021|NCT05296044|DRUG|JT-003 Placebo|Subjects take the investigational products once a day for 24 weeks.
214930022|NCT03053063|DRUG|SEL|Tablets administered orally once daily
214328409|NCT00226941|RADIATION|Radiotherapy|"Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)"
214328410|NCT00226941|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
214328411|NCT01513291|DRUG|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
214328412|NCT01513291|DRUG|Placebo|Placebo, 2 tablets, orally, once daily
214328413|NCT03732638|DRUG|Rimegepant|Rimegepant 75 mg tablet EOD
214930023|NCT03053063|DRUG|Placebo to match SEL 6 mg|Tablets administered orally once daily
214930024|NCT03053063|DRUG|Placebo to match SEL 18 mg|Tablets administered orally once daily
214930025|NCT03743324|PROCEDURE|Immediate Breast reconstruction|Immediate Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
214930026|NCT03743324|PROCEDURE|Delayed Breast Reconstruction|Delayed Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
214930027|NCT03743324|RADIATION|Radiation|Radiation is performed to the surgical site and complies with the ASCO guidelines on post-mastectomy radiotherapy
215070599|NCT00006164|DRUG|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
215070600|NCT03521232|DRUG|Niclosamide|enema given twice daily for 6 weeks
215070601|NCT02642393|DRUG|Inosine|capsules containing 500 mg of inosine
215070602|NCT02642393|DRUG|Placebo|capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
215070603|NCT00633074|BIOLOGICAL|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
215070604|NCT00633074|BIOLOGICAL|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
215070605|NCT04147390|DRUG|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
215070606|NCT04147390|DRUG|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
214930028|NCT06903559|DRUG|Roxadustat|Intervention Description: Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Administered orally three times per week. Dosage will be initiated and adjusted according to prescribing guidelines for the treatment of anemia associated with chronic kidney disease in patients on dialysis, based on hemoglobin levels.
214930029|NCT06903559|DRUG|Conventional Anemia Management|Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron supplementation. Dosing and specific agents used are per standard clinical practice at the study site and adjusted based on hemoglobin levels and iron status according to prevailing guidelines.
215070607|NCT02204605|BEHAVIORAL|Video-based Consensus Opinion|
215070608|NCT02591667|PROCEDURE|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
215070609|NCT02591667|DRUG|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
214328414|NCT03732638|DRUG|Placebo|Placebo tablet to match rimegepant tablet EOD
214328415|NCT01358981|DRUG|LY2881835|Administered orally
214328416|NCT01358981|DRUG|Placebo|Administered orally
214328417|NCT01083381|DRUG|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
214328418|NCT01083381|DRUG|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
214328419|NCT01114841|DRUG|Tazarotene Foam|"Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
214328420|NCT01114841|DRUG|Vehicle Foam|"Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
214328421|NCT00967408|DRUG|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
214328422|NCT00967408|DRUG|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
214328423|NCT00967408|OTHER|Rehabilitative treatment|Rehabilitative treatment
214328424|NCT03728582|DEVICE|Active tDCS plus Speech-Language Therapy|1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
214328425|NCT03728582|DEVICE|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
215070610|NCT02591667|PROCEDURE|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
214328426|NCT01068327|DRUG|gemcitabine hydrochloride|Given IV
214328427|NCT01068327|DRUG|leucovorin calcium|Given IV
214328428|NCT01068327|DRUG|fluorouracil|Given IV
214328429|NCT01068327|DRUG|nelfinavir mesylate|Given PO
214930030|NCT02578121|DRUG|Ixazomib|4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
214930031|NCT02578121|DRUG|Pomalidomide|4.0 mg will be given on days 1-21 of a 28 day cycle
214328430|NCT01068327|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
214328431|NCT01068327|RADIATION|hypofractionated radiation therapy|Undergo radiotherapy
214328432|NCT01068327|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214328433|NCT01431768|DEVICE|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
214328434|NCT03830502|PROCEDURE|Surgical sterilization|Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
214328435|NCT02174094|DRUG|Clobazam|
214328436|NCT02174094|DRUG|Placebo|
214328437|NCT01034397|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
214328438|NCT01034397|DRUG|placebo|iv every 4 weeks for 24 weeks
214328439|NCT01034397|DRUG|non-biological DMARDs|stable dose at investigator's prescription
214930032|NCT02578121|DRUG|Dexamethasone|20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
214930033|NCT06487338|OTHER|Low-level laser therapy|Is a form of medicine that applies low-level (low-power) lasers that relieve pain.The effects appear to be limited to a specified set of wavelengths
214673362|NCT03216265|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
214328440|NCT04384536|PROCEDURE|Neural therapy application|Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
214328441|NCT01396616|DEVICE|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
214328442|NCT04745143|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of schizophrenia
214328443|NCT04745143|DRUG|Placebo Cap|Use of placebo as a comparator
214328444|NCT01018264|DRUG|solifenacin succinate (VESIcare)|up to 10mg every day orally
214328445|NCT01018264|DRUG|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
214328446|NCT03055234|DRUG|Oral Treprostinil|Extended-release oral tablet for TID administration
214328447|NCT03055234|DRUG|Placebo|Matching placebo for TID administration
214328448|NCT01785524|DRUG|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
214328449|NCT01785524|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
214328450|NCT06314698|DRUG|Narlumosbart|Administered by subcutaneous injection once every 4 weeks.
214328451|NCT06314698|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
214328452|NCT01936961|DRUG|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
214328453|NCT01936961|RADIATION|Hypofractionated Radiotherapy|
214930034|NCT06487338|OTHER|Shock wave Therapy|is a non-invasive treatment that stimulates the body's natural healing process. It can relieve pain and promote healing of injured tendons, ligaments, and other soft tissues
214930035|NCT04391738|OTHER|Patients admitted to Intensive Care Unit with SARS-CoV2|Patients admitted to Intensive Care Unit with SARS-CoV2
215070611|NCT03846726|PROCEDURE|standard TME surgery|radical resection for rectal cancer
214328454|NCT00402389|DRUG|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
214328455|NCT00402389|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
214328456|NCT00402389|DRUG|Placebo|Four capsules will be taken daily for 8 weeks.
214328457|NCT01339533|DEVICE|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
214328458|NCT05578560|PROCEDURE|Prehabituation|chemical labyrinthectomy with intratympanically installed gentamicin
214328459|NCT05578560|PROCEDURE|3D optokinetic stimulation in virtual reality space|3D optokinetic stimulation via virtual reality goggles with the software designed by Pro-Zeta comp.
214328460|NCT05578560|PROCEDURE|Vestibular training|vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.
214328461|NCT05664646|DEVICE|DS8R|transcutaneous stimulation of the spinal cord.
214673363|NCT03216265|OTHER|No treatment|No treatment.
214930036|NCT02600845|DEVICE|ACCU-CHEK|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.
214930037|NCT03477747|DEVICE|Microcurrent|Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially should calibrate the microcurrent devices. There is no physical sensation associated with microcurrent based treatments as the strength of the current is not high enough to stimulate sensory nerve fibres. The application of electric fields and currents similar to those generated within the body can substantially change the cell structure and the metabolic behaviour of cells. For example, the application of microcurrent increases the number of organelles responsible for cellular activities; it increases concentrations of adenosine triphosphate (ATP) and amino acid transport; promotes protein synthesis; fastens regrowth of atrophied soleus muscle and would also activate hormone-sensitive lipase which can increase lipolysis from the internal and external adipose tissue. The microcurrent treatment with training would maximize exercise and recovery outcomes in athletes.
214328462|NCT05664646|OTHER|Arm Ergometry|Study 1 will use the arm ergometry as a form of exercise.
214328463|NCT05664646|OTHER|Cool Environment|Study 2 will be completed in a cool environment setting.
214328464|NCT01421810|DRUG|Dexamethasone|1 mg PO
214328465|NCT01421810|DRUG|rhCG|25 mcg IV
214673364|NCT00358592|DEVICE|Mobius™ retractor|
214673365|NCT00358592|DEVICE|traditional metal retraction instruments|
214930038|NCT02341495|DRUG|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
215070612|NCT00365105|DIETARY_SUPPLEMENT|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
215070613|NCT00365105|DIETARY_SUPPLEMENT|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
215070614|NCT00365105|DRUG|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
214328466|NCT04603430|OTHER|Participation in a community wellness program|Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.
215070615|NCT00365105|DRUG|Sm-153|Single dose intravenously 1 mCi/kg body weight.
215070616|NCT00365105|RADIATION|Sr-89|Single dose intravenously 4 mCi.
214328467|NCT01264861|DRUG|Safinamide|"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."
214930039|NCT02341495|DRUG|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
214930040|NCT02341495|DRUG|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
214930041|NCT02208284|DRUG|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
215070617|NCT03075722|DEVICE|Saturn nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
215070618|NCT04299503|DRUG|Crisaborole Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
215070619|NCT04299503|DRUG|Placebo Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
215070620|NCT06422364|DEVICE|Weighted Wearable Blanket provided by Dreamland Baby Co.|All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete a nap polysomnogram.
215070621|NCT06422364|DEVICE|Weighted Wearable Blanket provided by Dreamland Baby Co.|All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete an overnight polysomnogram.
215070622|NCT05964530|PROCEDURE|Surgery|Surgery procedures include LAR+ anal preservation or APR
214328468|NCT00626977|DRUG|ropivacaine|15 ml of ropivacaine 0.125% peridural once
214328469|NCT00626977|DRUG|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
214328470|NCT05242614|BEHAVIORAL|The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)|The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.
214930042|NCT02208284|DRUG|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
214930043|NCT02208284|DRUG|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
214930044|NCT02208284|DRUG|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
214930045|NCT02208284|DRUG|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
215070623|NCT04093323|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given ID
215070624|NCT04093323|DRUG|Celecoxib|Given PO
215070625|NCT04093323|DRUG|PD-1 Ligand Inhibitor|Given IV
215070626|NCT04093323|DRUG|PD1 Inhibitor|Given IV
215070627|NCT04093323|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
214930046|NCT02208284|DRUG|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
214930047|NCT05941143|OTHER|mindfulness-based intervention|8 weekly group 2-hour sessions program adapted from mindfulness-based stress reduction and mindfulness-based cognitive therapy protocols. It was specifically tailored to older adults.
214930048|NCT04837508|DRUG|MRG002|Administrated intravenously
214930049|NCT04374162|PROCEDURE|PEEP|different PEEP set on the anesthetic machine
215070628|NCT04093323|DRUG|Rintatolimod|Given IV
215070629|NCT05082012|DEVICE|Treatment of Hallux Valgus|Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.
215070630|NCT06444555|DIETARY_SUPPLEMENT|BEP supplement|The BEP supplement used in Burkina Faso is a fortified medium-quantity lipid-based nutrient supplement called Plumpy'Doz. The product is a peanut and milk-based ready-to-use nutritional formulation produced by Nutriset. A peanut-based BEP formulation with a trademark Plumpy'Sup produced by Hilina Enriched Foods PLC will be used in Ethiopia.
215070631|NCT06444555|DIETARY_SUPPLEMENT|Multiple Micronutrient supplement|The MMN formulation is based on the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP). The formulation contains 15 minerals and vitamins and is administered as a tablet.
215070632|NCT06259006|DRUG|Dexamethasone Oral|Dexamethasone suspension (1mg/ml) 20mg/m2/day (maximum dose 24mg/day) given in three divided doses
215070633|NCT06259006|DRUG|Placebo|Matching capsules taken orally three times daily for three days
214328471|NCT05242614|BEHAVIORAL|Psychoeducation educational program|This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
214930050|NCT06489327|DRUG|melatonin (Circadin ®) 0.2 mg/kg|Patients will receive oral melatonin at a dose of 0.2 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
214930051|NCT06489327|DRUG|melatonin (Circadin ®) 0.4 mg/kg|Patients will receive oral melatonin at a dose of 0.4 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
214930052|NCT06489327|DRUG|placebo group|Patients will receive oral placebo as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
214930053|NCT03633162|OTHER||
214930054|NCT05897086|DRUG|Polyethylene Glycol 3350|Topical irrigation with approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water
215070634|NCT03853850|BEHAVIORAL|Mobile phone text messages|From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (\*\*\*) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
215070635|NCT06044233|DRUG|STI-1558|STI-1558 test preparation and reference preparation
215070636|NCT04506593|OTHER|no intervention|
215070637|NCT03090659|BIOLOGICAL|LCAR-B38M CAR-T cell injection|
214328472|NCT00672438|DRUG|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
214328473|NCT00672438|OTHER|Saline placebo infusion|Intravenous infusion of normal saline
214673366|NCT03645252|PROCEDURE|Vein interruption before any other surgical manipulation|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner."
214930055|NCT02529124|DIETARY_SUPPLEMENT|CONTROL|Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
214930056|NCT02529124|DIETARY_SUPPLEMENT|PROTEIN|The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
214930057|NCT02529124|BEHAVIORAL|PHYSICAL ACTIVITY|A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
214930058|NCT02409563|DRUG|Budesonide nasal spray (100 mcg bid)|
214930059|NCT02409563|DRUG|Budesonide nasal spray (50 mcg bid|
214930060|NCT02151734|DRUG|KALOMIN™ Tab.|
214930061|NCT02151734|DRUG|Umckamin syrup|
214930062|NCT03183713|BEHAVIORAL|Cognitive Behavioral Therapy|Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.
214930063|NCT03183713|BEHAVIORAL|Sham Therapy|Study nurse will conduct six sessions (30 minutes/ session) over a 4-8 week time period. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone. Sham sessions will entail how to prepare for surgery and expectations for recovery, and will go over content that the treatment and control groups will receive in handout form.
214930064|NCT04311749|GENETIC|Expanded panel cell free DNA testing (non-invasive prenatal testing)|Maternal blood sampling
214930065|NCT04311749|GENETIC|Placental biopsy|Post-delivery placental sampling
214930066|NCT04311749|GENETIC|Umbilical cord blood|Post-delivery umbilical cord blood sampling
214930067|NCT01080469|DRUG|Tacrolimus 1 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
214930068|NCT04416867|DEVICE|splint and home exercise|Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
215070638|NCT04880629|BEHAVIORAL|Baseline condition|In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
214930069|NCT04416867|DEVICE|RESWT|RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
214328474|NCT03915548|BEHAVIORAL|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
214328475|NCT03915548|BEHAVIORAL|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
214328476|NCT05871125|BEHAVIORAL|Reimbursement|Patients will be dosed in cohorts of 5, with a maximum available sample size of 30. The first cohort of 5 patients will be enrolled at the first reimbursement dose level of $1000 per month for 4 months ($4000 per patient in total). At the end of the 4-month period, reimbursement dose suitability will be determined as suitable by a cumulative negative financial toxicity screen and reimbursement dose deemed acceptable and appropriate in at least 4 patients. If the reimbursement dose is found suitable, we will de-escalate the reimbursement dose for the next cohort of 5 patients. If the reimbursement dose is found unsuitable, the next cohort of 5 patients will be enrolled at the same reimbursement amount ($1000 per month for 4 months).
214328477|NCT03217136|DRUG|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.
214328478|NCT03217136|DRUG|Metronidazole|Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if \> 2 kg are dosed 10 mg/kg every 8 hours.
214930070|NCT04416867|DEVICE|physical therapy|20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks
214930071|NCT02531776|DEVICE|Subcutaneous insertions of needles|"Various types of needles with different designs and mechanical properties.~Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson \& Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).~Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.~Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.~No drugs are injected. Only the needle insertion is evaluated."
214930072|NCT06668662|DEVICE|Endoactivator|Endoactivator is an irrigation technique which will help to reduce post-operative pain in patients following endodontic treatment.
214328479|NCT03217136|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.
214328480|NCT03217136|DRUG|Placebo for Metronidazole|Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
214328481|NCT01785745|OTHER|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
214328482|NCT01785745|OTHER|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
214328483|NCT04408820|DRUG|Roxadustat|Oral
214328484|NCT03839667|BEHAVIORAL|intensive diet intervention|the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
214328485|NCT03839667|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
214930073|NCT06668662|DEVICE|Conventional irrigation|Conventional irrigation is an irrigation technique which will help to reduce post-operative pain in patients following endodontic treatment.
214930074|NCT06022276|DRUG|Nimotuzumab|Nitozumab injection 400mg/cycle, every 21 days/cycle, until disease progression, intolerable toxicity or death, or subject decision to withdraw from the study.The molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Nitozumab+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
214930075|NCT03587883|OTHER|Cocoa flavanols I|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
214328486|NCT03839667|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
214930076|NCT03587883|OTHER|Control I|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
214930077|NCT03587883|OTHER|Cocoa flavanols II|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
214930078|NCT03587883|OTHER|Control II|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
215070639|NCT04880629|BEHAVIORAL|Sleep restriction condition|In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
215070640|NCT01038479|DIETARY_SUPPLEMENT|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
214328487|NCT03169140|DEVICE|TheraBand Kinesiology Tape|A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.
214930079|NCT05154500|OTHER|Iron biofortified potato|A non-blinded randomized cross-over design with multiple meal feedings will be used to quantify iron bioavailability from iron biofortified and non-biofortified potatoes. Women volunteers will consume biofortified ('A') and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p\<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p\>0.05). Based on this study design, every woman is her own control.
214930080|NCT05154500|OTHER|Zinc biofortified potato|A crossover study will be used to compare zinc bioavailability of biofortified and non-fortified potatoes. Nutritional pre-screening is not required as there are no major systemic influences on zinc absorption.Volunteers will be randomly assigned to consume first either the biofortified or the non-biofortified potato, and consume the second potato-type 30 days later. Zinc absorption from two meals of biofortified or non-fortified potato will be measured using the double stable isotope technique.
214328488|NCT03169140|DEVICE|Biofreeze|The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.
214930081|NCT02289547|DRUG|Capecitabine|maintenance capecitabine therapy after six cycles of XELOX
214328489|NCT03169140|BEHAVIORAL|Advice|An at-home pain management care sheet, outlining standard care advice will be followed for at home pain management for one week.
214328490|NCT04088786|DRUG|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
214930082|NCT03145961|DRUG|Pembrolizumab|200mg intravenous infusion
214328491|NCT03131063|OTHER|Antibiotic plasma dosage|Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
214328492|NCT01740596|DEVICE|C-Pulse® System Counterpulsation|The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
214930083|NCT06929624|DRUG|SHR-A1912 Injection|SHR-A1912 injection.
214930084|NCT06929624|DRUG|Rituximab Injection|Rituximab injection.
214930085|NCT06929624|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine hydrochloride for injection.
214930086|NCT06929624|DRUG|Oxaliplatin Injection|Oxaliplatin injection.
214930087|NCT00963027|DRUG|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
214930088|NCT00963027|DRUG|Esomeprazole|Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
214328493|NCT02559388|DRUG|Montelukast|
214930089|NCT06922747|OTHER|Group exercising|Weekly, supervised exercise sessions in groups
214930090|NCT06922747|OTHER|Somatic tracking|A psychological intervention aiming to learn the brain to reinterpret pain signals.
214328494|NCT02559388|DRUG|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
214328495|NCT00395239|DRUG|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
214930091|NCT06922747|OTHER|General activity recommendaitons|General recommendaitons for physical activity and healthy lifestyle
214930092|NCT00536627|BIOLOGICAL|DNA vaccine pCMVS2.S|Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
215070641|NCT01038479|BEHAVIORAL|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
214930093|NCT01904292|DRUG|Tocilizumab|Subcutaneous 162 mg dose QW or Q2W for 52 weeks
214930094|NCT06315881|PROCEDURE|Biospecimen Collection|Undergo blood sample and oral mucosa sample collection
214930095|NCT06315881|DRUG|Cigarette|Smoke usual brand cigarette
214930096|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN R/S ONP
214930097|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN \> 99% S ONP
214930098|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high R/S ONP
214930099|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high FBN \> 99% ONP
214930100|NCT06315881|DRUG|Smokeless Tobacco|Insert ST
214930101|NCT06315881|OTHER|Survey Administration|Ancillary studies
215070642|NCT01681069|DIETARY_SUPPLEMENT|IQP-VV-102|
214930102|NCT06315881|OTHER|Text Message-Based Navigation Intervention|Receive text with a link to daily diary surveys
214930103|NCT05711186|OTHER|Structured SDM|The conversation between the heart team member and the patient will be structured according the adapted three-talk model for patients with symptomatic aortic stenosis and using the American College of Cardiology's decision aid for patients deciding between TAVR and SAVR
214930104|NCT05711186|OTHER|Usual Care|Usual care will include baseline visits without a structured SDM approach. Usual care includes at least one decision making talk with a heart team member discussing information about the disease, treatment options as well as benefits and risks of each procedure.
214930105|NCT05946785|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
215070643|NCT01681069|OTHER|Placebo|
215070644|NCT01463696|DRUG|MK-8242|10 mg, 100 mg and 150 mg capsules
215070645|NCT06407349|OTHER|Communication Board|communication board based on a functional communication picture of basic needs of categories ( food, clothes, object, and actions)
215070646|NCT06407349|OTHER|Traditional Therapy|Traditional Therapy
214930106|NCT05946785|DRUG|insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
214930107|NCT04628390|DEVICE|Laser|The laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
214930108|NCT04628390|OTHER|Placebo|Simulation laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
214930109|NCT05250102|DEVICE|Pulse oximeter sensors|Pulse oximeter reading will be compared to CO-oximeter reading.
214930110|NCT03675165|BEHAVIORAL|Best Possible Self|A writing exercise developed in 2001 by Laura King. The frequency of engagement with the exercise is down to the user's discretion though we recommend to them to write things down once every week for the duration of the study.
214930111|NCT06815783|DEVICE|Ultrasound guidance|Use of ultrasound in group 2
214930112|NCT06815783|DEVICE|Fluoroscopy guided|Conventional techniques for implanting LBBAP lead
214930113|NCT04693832|DEVICE|5inD|Interactive Mobile Application which is includes five different game (mandala, puzzle, tetris, music, breath exercise)
214328496|NCT03670810|DRUG|Lasmiditan|Administered orally.
214328497|NCT03670810|DRUG|Placebo|Administered orally.
214328498|NCT03584672|OTHER|Static Balance Test|Balance control is assessed by the Static Balance Test.
214328499|NCT03584672|OTHER|Berg Balance Scale|Functional balance is assessed by the Berg Balance Scale.
214328500|NCT03584672|OTHER|Timed Up an Go Test|Functional mobility is assessed by the Timed Up and Go test.
214328501|NCT03584672|OTHER|Four Square Step Test|Dynamic balance is assessed by the Four Square Step Test.
214328502|NCT03584672|OTHER|Functional Reach Test|Limits of stability is assessed by the Functional Reach Test.
214930114|NCT04971200|DRUG|Tildrakizumab|2 100mg subcutaneous injections Q4W
214930115|NCT04940754|PROCEDURE|osteosynthesis|Closed reduction, internal fixation
215070647|NCT00763191|OTHER|examination of ocular movements|
215070648|NCT00763191|OTHER|MATTIS test|
215070649|NCT00763191|OTHER|UPDRS test|
215070650|NCT00763191|OTHER|CRST test|
215070651|NCT03831516|DIAGNOSTIC_TEST|Non Invasive Electroanatomical Mapping|All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
215070652|NCT06334159|PROCEDURE|Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).
215070653|NCT06334159|PROCEDURE|Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).
215070654|NCT05336929|OTHER|Roy adaptation model-based nursing education|
214328503|NCT03584672|OTHER|One-leg Stance Test|Postural steadiness is assessed by the One-leg Stance Test.
214328504|NCT04139928|DIETARY_SUPPLEMENT|Picometer-ionic form of magnesium chloride|Single-dose (300 mg) of the picometer-ionic form of magnesium chloride
214328505|NCT04139928|DIETARY_SUPPLEMENT|Magnesium citrate or magnesium oxide|Single-dose (300 mg) of magnesium citrate or magnesium oxide
214673367|NCT03645252|PROCEDURE|Arteries interruption before vein interruption|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above."
214930116|NCT06576388|DRUG|EXG001-307 injection|Research process includes filter (subjects signed informed consent for screening period before the pretreatment to the hormone, the longest 28 days), treatment period (the subjects accept including single hormone pretreatment, the study drug infusion) hospitalization and observation and follow-up treatment period (subjects to the participants to 18 months, lost to follow-up, active exit research subjects, or death). Subjects qualified in the screening period entered the treatment period and received EXG001-307, and entered the follow-up period after hospitalization. At the end of the study visit (subject at 18 months of age), eligible subjects will be asked to transfer to the long-term follow-up study.
214930117|NCT04021537|DEVICE|non-invasive nerve stimulation|Electrical stimulation will be provided via a TENS unit.
214930118|NCT05692531|BEHAVIORAL|A Story Within A Story|"The intervention is the screening via Zoom of A Story Within A Story, two dramatized scenarios. The first depicts a reinforcing feedback loop connecting internalized, anticipated and enacted HIV stigma and serosorting within the Black SGL/MSM community. Set during the COVID-19 pandemic, it depicts a Zoom call among three generations of Black SGL/MSM, a chosen family. In this scene, the oldest member of the family, not knowing that the youngest has just tested positive for HIV, describes how they would never partner with someone who was living with HIV because of what they saw at the beginning of the HIV epidemic. The middle-aged member attempts to mitigate the damage done by this, while the youngest member describes what kind of support he needs. The second scenario depicts a Telehealth visit between a young Black gay man and his sexual health provider; his older lover joins the call at one point and the focus is on sexual communication and PrEP use."
214930119|NCT01840150|PROCEDURE|breath test|Undergo NA-NOSE breath test
214930120|NCT01840150|OTHER|laboratory biomarker analysis|Correlative studies
214930121|NCT02100670|DRUG|1% diclofenac sodium plus 3% menthol|To be applied four times daily for 10 days.
214930122|NCT02100670|DRUG|1% diclofenac sodium plus 0.09% menthol|To be applied four times daily for 10 days.
214930123|NCT02100670|DRUG|3% menthol|To be applied four times daily for 10 days.
214930124|NCT02100670|DRUG|Placebo with 0.09% menthol gel|To be applied four times daily for 10 days.
215070655|NCT03883165|OTHER|high-intensity neck strengthening|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a higher number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions,as well as dumbbell shoulder shrugs."
215070656|NCT03883165|OTHER|Control group|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting only the chest, shoulders, back, upper and lower extremities, and core, without resistance exercises specifically targeting the neck."
215070657|NCT04478071|DRUG|vadadustat|Participants will receive vadadustat once daily for 14 days.
215070658|NCT04478071|DRUG|placebo|Participants will receive matching placebo once daily for 14 days.
215070659|NCT03716778|OTHER|Eccentric rehabilitation sessions|"ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode."
214328506|NCT04139928|DIETARY_SUPPLEMENT|Placebo|Placebo
214328507|NCT00475007|DEVICE|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
214328508|NCT02760134|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
214328509|NCT03192150|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
214328510|NCT03192150|OTHER|Vehicle|Vehicle twice daily for 16 days
214328511|NCT01187082|BEHAVIORAL|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
214328512|NCT01187082|BEHAVIORAL|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
214328513|NCT02579616|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
214328514|NCT00133081|DRUG|All registered antiepileptic drugs|
215070660|NCT01697423|DRUG|platelet-rich plasma|
214328515|NCT03866759|BEHAVIORAL|Determine the Incidence and Point Prevalence|Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.
214328516|NCT04073095|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
214328517|NCT04073095|OTHER|modified-thoracolumbar interfascial plane block (Group T)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
214328518|NCT03040297|DEVICE|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
214930125|NCT04115995|DIAGNOSTIC_TEST|Dynamic infrared thermography (DIRT) and indocyanine green fluorescence angiography (ICG-FA)|DIRT and ICG FA are used intraoperatively to evaluate perfusion of the perforators and the anastomosis. Both technique are compared in their ability to visualize perfusion.
214930126|NCT04693377|PROCEDURE|Cryosurgery|Undergo cryoablation
214930127|NCT04693377|OTHER|Quality-of-Life Assessment|Ancillary studies
214930128|NCT04693377|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
214930129|NCT06059261|DRUG|Envafolimab and recombinant human endostatin combined with chemoradiotherapy|Induction treatment phase: Envafolimab administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 3 cycles, cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles, gemcitabine was administered by intravenous infusion on days 1 and 8 of each cycle at 1 g/m2 every 3 weeks for 3 cycles, recombinant human endostatin was administered on day 1 every 3 weeks at 210 mg for 3 cycles. Concurrent treatment phase: Cisplatin was administered by intravenous infusion on day 1 of each cycle at 100mg/m2 every 3 weeks for 2 cycles. Adjuvant treatment Phase: Envafolimab was administered on day 1 every 3 weeks at 300 mg for 8 cycles as a subcutaneous injection. Intensity-modulated radiotherapy: 69.96Gy/33fractions/7 weeks,5 fractions/week, 1 fraction/day.
215070661|NCT01697423|DRUG|durolane|
215070662|NCT05033587|DRUG|Anlotinib|Anlotinib a multi-target receptor tyrosine kinase inhibitor.
214328519|NCT03040297|DEVICE|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
214328520|NCT03040297|DEVICE|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
214328521|NCT05355636|BEHAVIORAL|Fertility Management Counseling|counseling
214328522|NCT05600218|DRUG|No intervention - Observational study|Real life drug evaluation
214328523|NCT00482391|BIOLOGICAL|trastuzumab|
214328524|NCT00482391|DRUG|cyclophosphamide|
214328525|NCT00482391|DRUG|doxorubicin hydrochloride|
214328526|NCT00482391|DRUG|lapatinib ditosylate|
214328527|NCT00482391|DRUG|paclitaxel|
214328528|NCT00482391|OTHER|laboratory biomarker analysis|
214328529|NCT04155320|BEHAVIORAL|IMPART|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
215070663|NCT05033587|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
215070664|NCT05033587|RADIATION|Radiotherapy|The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
215070665|NCT00515606|DRUG|helium:oxygen|
214328530|NCT04155320|BEHAVIORAL|Standard Care|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
214328531|NCT02596529|DEVICE|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
214328532|NCT02596529|OTHER|NO Fixation|NO Fixation of the posterior malleolus.
214328533|NCT00333112|DRUG|solifenacin succinate|Oral
214328534|NCT00333112|DRUG|tamsulosin|oral
214328535|NCT00333112|DRUG|placebo|oral
214328536|NCT04819997|OTHER|Educational Intervention|Participate in videoconference session
214328537|NCT04927338|DIETARY_SUPPLEMENT|BacoMind® (Bacopa monnieri standardized extract)|BacoMind® (Bacopa monnieri standardized extract) 300 mg daily capsule.
215070666|NCT04149470|DRUG|Omeprazole 20mg BID|High dose PPI therapy (Omeprazole 20mg twice daily)
215070667|NCT00245050|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
215070668|NCT00245050|DRUG|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
215070669|NCT00245050|DRUG|doxorubicin HCL liposome|IV, 40mg/m2
214328538|NCT04927338|DRUG|Placebo|Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
214328544|NCT06314958|OTHER|CENSURE|A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
214328545|NCT05620823|DRUG|Povorcitinib|Oral; Tablet
214328546|NCT05620823|DRUG|Placebo|Oral; Tablet
214328547|NCT04151940|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214930130|NCT06253637|DRUG|Daratumumab plus chemotherapy according to the national treatment program|"Daratumumab is a human IgG1қ monoclonal antibody that binds with high affinity to a unique epitope on CD38, a transmembrane glycoprotein which is expressed in several hematological malignancies including multiple myeloma (MM) and ALL. Daratumumab induces lysis of CD38-expressing tumor cells by several mechanisms. Intravenous daratumumab has been approved first as a single agent and then in combinations in the MM setting and in AL amyloidosis.~The activity of daratumumab in ALL is being explored in the DELPHINUS trial, in which the drug was combined with chemotherapy in pediatric and young adult patients with relapsed/refractory T-cell ALL or lymphoblastic lymphoma (LL).~In the present trial, daratumumab will be administered to adult Very high risk T-lineage ALL weekly in induction and early consolidation (C1-C2), and the first day of each of the following intensive cycles up to C8."
214328548|NCT04151940|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214328549|NCT04151940|DRUG|Chemotherapy|Receive standard of care chemotherapy
214328550|NCT04151940|BIOLOGICAL|Immunotherapy|Receive standard of care immunotherapy
214328551|NCT04151940|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
214328552|NCT04151940|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214328553|NCT04151940|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215070670|NCT04713345|OTHER|Virtual Reality Observations|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
214328554|NCT05246605|OTHER|change in body position|changing from supine to prone position and the back to supine
214328555|NCT05460065|DRUG|single E4 28.3 mg|Administration of a single intravenous (i.v.) infusion of estetrol (E4) 28.3 mg (n=6)
214328556|NCT05460065|DRUG|single E4 94.4 mg|Administration of a single i.v. infusion of E4 94.4 mg (n=6)
215070671|NCT04713345|OTHER|Relaxation|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
215070672|NCT04370483|DRUG|Leflunomide|Gievn PO
215070673|NCT04370483|OTHER|Quality-of-Life Assessment|Ancillary studies
214328557|NCT05460065|DRUG|multiple E4 94.4 mg|Administration of an i.v. infusion of E4 94.4 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)
214328558|NCT05460065|DRUG|Placebo|"Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)"
214328559|NCT03758040|OTHER|Slips on Turns|A slip will be administered to participants at 3 different times in the gait cycle for each of 3 different patch curvatures and 2 different legs for a total of 18 slip episodes. Slips will be delivered while walking along a straight path (infinite radius), or curved paths with radii 2, or 1 meters.
214328560|NCT03758040|OTHER|Slips on Slopes|Slips will be administered to participants at 3 different times in the gait cycle over sloped ground surface of no slope, ±5.0 and ±10.0 degrees slopes in the direction of walking, and 5.0 and 10.0 degrees perpendicular to the direction of walking. On slopes perpendicular to the direction of walking, slips will be administered to the uphill or downhill foot. A total of 27 slip episodes will be administered. Sloped walking surfaces will be generated with the Computer Assisted Rehabilitation Environment (CAREN) system treadmill.
214328561|NCT05620836|DRUG|Povorcitinib|Oral, Tablet
214328562|NCT05620836|DRUG|Placebo|Oral, Tablet
214328563|NCT06373614|OTHER|foot massage|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
214328564|NCT06373614|OTHER|bed bath|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
214328565|NCT05619705|BEHAVIORAL|Healthy for Two-Health Coaching (H42)|The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.
214328566|NCT05619705|BEHAVIORAL|Maintain Healthy in Pregnancy and Postpartum(mHIPP)|A brief video on maternal warning signs that is available in English or Spanish.
214328567|NCT04648046|DRUG|Cyclophosphamide|Non-ablative conditioning with cyclophosphamide.
214328568|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, low dose|A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused.
214328569|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, high dose|A single dose of 1 x 10\^6 cells/kg LVgp120duoCAR-T cells will be infused.
214328570|NCT04648046|OTHER|Analytic Treatment Interruption|HIV antiretroviral therapy medications will be paused.
214930131|NCT06934174|BEHAVIORAL|WeSafe (myPlan Thailand: Friends and Family)|WeSafe, a Web-Based App (myPlan Thailand) is a culturally tailored web-based app designed to empower and support friends and family of IPV survivors. It gathers key data on survivors' demographics, relationship status, living situation, and children's ages to personalize the safety support plan. The app delivers comprehensive IPV information through text, videos, images, and illustrations, addressing culturally specific issues. It guides users in setting priorities through pairwise comparisons and includes a risk assessment tool adapted from Danger Assessment (DA)-Thailand. Based on the inputs, myPlan Thailand provides a tailored plan with supportive strategies, communication scripts, advocacy tips, self-care resources, and child safety strategies, enhancing overall safety and well-being.
214930132|NCT06934174|BEHAVIORAL|DV learning|Control group. The control condition will be the publicly-available Thai-language DV learning launched in 2019.49 This app screens users for Domestic violence (physical, psychological, and sexual violence), and provides information about 6 modules include 1. Understanding situation of domestic violence 2. Key principles of helping survivors 3. Guideline for helping survivors 4. Case management and working with multi professionals 5. Legal Proceedings and Justice System Processes for Domestic Violence and Intimate Partner Violence Cases 6. Selfcare for providers. This platform put the knowledge from understanding the basic situation through practical intervention for providers and other people who are interested in. It is optional to get the certificate if participants have 80% pass rate on quizzes.
214930133|NCT05374187|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. Participants deemed to be positive responders to blinded active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
214930134|NCT05374187|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. At conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open active eTNS treatment. Participants deemed to be positive responders to open active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
214930135|NCT03144271|DRUG|semaglutide|A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
214930136|NCT03144271|DRUG|Placebo|A single dose of placebo will be administered subcutaneously (s.c. under the skin)
214930137|NCT03467061|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|concentrated beetroot juice
214930138|NCT03467061|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|concentrated beetroot juice
214930139|NCT03467061|OTHER|Mouthwash|2 x 10 mL antibacterial mouthwash per day for 14 days
215070674|NCT01843673|PROCEDURE|computed tomography|Undergo FBCT
215070675|NCT01843673|PROCEDURE|cone-beam computed tomography|Undergo dual CBCT
215070676|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian kV OBI
214328571|NCT04747236|DRUG|Azacytidine|Azacytidine, 300 mg po daily on Days 1-14
214328572|NCT04747236|DRUG|Romidepsin|Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
214328573|NCT04747236|DRUG|Belinostat|Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
214328574|NCT04747236|DRUG|Pralatrexate|Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
214930140|NCT03014297|DRUG|everolimus|everolimus
215070677|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
215070678|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian MV OBI
215070679|NCT01843673|PROCEDURE|electronic portal imaging|Undergo EPID imaging
215070680|NCT01843673|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
214328575|NCT04747236|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
214328576|NCT06288867|PROCEDURE|Arthroscopic Labral Repair|Patients with Hip Labral tears will be treated with labral repair
214328577|NCT06288867|PROCEDURE|Arthroscopic Labral Debridement|Patients with Hip Labral tears will be treated with labral debridement
214328578|NCT04875520|OTHER|Screening testing strategy|The intervention we are evaluating is the use of weekly screening testing among students and staff.
214328579|NCT04875520|OTHER|No screening testing strategy|a group of schools will not receive screening testing.
214328580|NCT06528405|DRUG|dapagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
214328581|NCT06528405|OTHER|Other anti-diabetic drug or no anti-diabetic drug|"Other anti-diabetic drug or no anti-diabetic drug for 90 days during the acute kidney disease period.~Other anti-diabetic drug includes metformin, sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitor, insulin, α-glucosidase inhibitors, thiazolidinediones, and glucagon-like peptide-1 receptor agonist."
214328582|NCT06528405|DRUG|empagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
214328583|NCT06528405|DRUG|canagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
215070681|NCT02776462|DEVICE|EyeBox CNS|
215070682|NCT04848519|DRUG|Pembrolizumab|Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy
215070683|NCT04848519|DRUG|Propranolol Hydrochloride|Given PO for patients on the ICI plus propranolol arm
214328584|NCT04898010|DEVICE|Selective Cytopheretic Device|The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
214328585|NCT04938362|OTHER|FDG-PET|\[18F\]Deoxyglucose-positron emission tomography at 0-10 years after brain abscess
214328586|NCT04938362|OTHER|EEG|Electroencephalography (EEG) at 0-10 years after brain abscess
214328587|NCT06350513|OTHER|Animation movie, story book|"Animation movie: For this study, an animated film (Professor bumblebee animation) prepared for newly diagnosed children with type 1 diabetes will be shown in the experimental group. This is an approximately 10 minute film produced by Life for a children's center in New South Wales (DIABETES AUSTRALIA). The animated film will be translated into Turkish and sent to experts (specialists in the field of Children and Diabetes) for expert opinion. It will be shown to children after all permissions have been obtained following expert opinions. This animated movie is a guide to diabetes for children. Additionally, the storybook will be given as a gift for the children in the experimental group to read.~Story Book: It is an educational booklet version of the Professor Bumblebee animation translated into Turkish and illustrated. The aim here is to serve as an auxiliary tool for newly diagnosed T1D children to look at later and where they are confused."
214328588|NCT02791334|DRUG|LY3300054|Administered IV
214328589|NCT02791334|DRUG|Ramucirumab|Administered IV
214328590|NCT02791334|DRUG|Abemaciclib|Administered orally
214328591|NCT02791334|DRUG|Merestinib|Administered orally
214328592|NCT02791334|DRUG|LY3321367|Administered IV
214328593|NCT05263947|DRUG|Bevacizumab and Icotinib|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
214328594|NCT05936567|DRUG|Povorcitinib|oral; tablet
214328595|NCT05936567|DRUG|Placebo|oral; tablet
214328596|NCT05889286|DRUG|[F-18]MHF|Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) \[F-18\]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of \[F-18\]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
214328597|NCT04793698|OTHER|Compassion meditation|10 week meditation course taught in 90-minute groups
214328598|NCT04793698|BEHAVIORAL|Applied relaxation|10 week applied relaxation course taught in 90-minute groups
214328599|NCT06556680|DEVICE|Optical coherence tomography|In the OCT-guided biopsy arm, n=100 study subjects will be enrolled. The investigators will conduct biopsies and imaging using our newly developed OCT catheters and real-time image processing and display algorithms.
214328600|NCT04198116|DRUG|Varenicline|Varenicline 2mg/day
214328601|NCT04198116|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
214930141|NCT03014297|DRUG|fosbretabulin|fosbretabulin
214930142|NCT01514838|DRUG|ASP1941|oral
214930143|NCT01514838|DRUG|acarbose|oral
215070684|NCT04848519|DRUG|Nivolumab|Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection
215070685|NCT04848519|DRUG|Avelumab|Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy
215070686|NCT00222235|DRUG|d-cycloserine|
214328602|NCT06013618|DRUG|Naxitamab monotherapy|Naxitamab is administered on days 1, 3, and 5
215070687|NCT00222235|DRUG|glycine|
214328603|NCT06013618|DRUG|GM-CSF|Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.
214328604|NCT06013618|DRUG|Irinotecan|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
214328605|NCT06013618|DRUG|Temozolomide|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
214328606|NCT06013618|DRUG|Naxitamab in combination therapy|Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.
214328607|NCT06013618|DRUG|GM-CSF with combination regimen|GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.
214328608|NCT06013618|DRUG|Sintilimab|Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.
214328609|NCT05371054|DEVICE|Vysis LSI MYC Break Apart Rearrangement Probe Kit|MYC rearrangement fluorescence in situ hybridization (FISH) testing is performed using the Vysis LSI MYC Break Apart Rearrangement Probe (Abbott Molecular, Inc.) in the Chromosome Pathology Section, Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI). This kit is not Food and Drug Administration (FDA) approved. It is being used as a treatment determining in-vitro diagnostic device in this study.
214328610|NCT05371054|DRUG|Venetoclax|"Dose Escalation: Administered orally, days 1-10, per specified dose level; every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity.~Dose Expansion: Administered orally, days 1-10, at the recommended phase 2 dose (RP2D); every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity"
214328611|NCT05371054|DRUG|VIP152|"Dose Escalation: Administered intravenously, days 2 and 9, per specified dose level; every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity.~Dose Expansion: Administered intravenously, days 2 and 9, at the recommended phase 2 dose (RP2D); every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity."
214930144|NCT01514838|DRUG|Placebo|oral, used only during placebo run-in period
214930145|NCT04875728|DRUG|Cefazolin|Given IV
214930146|NCT04875728|PROCEDURE|Resection|Undergo standard of care surgical resection
214930147|NCT06507839|DRUG|THRV-1268|THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
214930148|NCT06507839|OTHER|Placebo|Matching placebo
214930149|NCT06943937|DRUG|YTS109 cell injection|Subjects will receive YTS109 Cell Injection(1E6 STAR+T cell/kg or 2E6 STAR+T cell/kg) once in this study.
215070688|NCT00222235|DRUG|placebo|
214328612|NCT05371054|DRUG|Prednisone|Administered orally, days 1-10, at a dose of 100 mg; every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity
214328613|NCT05371054|DIAGNOSTIC_TEST|PET|Screening, pre-cycle 7, pre-cycle 13, and at end-of-treatment (post-cycle 24).
214328614|NCT05371054|DIAGNOSTIC_TEST|EKG|Screening
214328615|NCT05371054|DIAGNOSTIC_TEST|ECHO|Screening
214328616|NCT05371054|DIAGNOSTIC_TEST|CT neck chest, abdomen, and pelvis|Screening, pre-cycle 2, pre-cycle 3, pre-cycle 5, pre-cycle 7, pre-cycle 9, pre-cycle 11, pre-cycle 13, pre-cycle 15, pre-cycle 17, pre-cycle 19, pre-cycle 21, pre-cycle 23, and at end-of-treatment (post cycle 24).
214328617|NCT05371054|DIAGNOSTIC_TEST|MRI|As indicated. Screening, pre-cycle 2, pre-cycle 3, pre-cycle 5, pre-cycle 7, pre-cycle 9, pre-cycle 11, pre-cycle 13, pre-cycle 15, pre-cycle 17, pre-cycle 19, pre-cycle 21, pre-cycle 23, and at end-of-treatment (post cycle 24).
214328618|NCT05371054|PROCEDURE|Bone marrow aspiration/Biopsy|Baseline, post-cycle 6, post-cycle 12, and at end-of-treatment (post-cycle 24).
214930150|NCT01442311|OTHER|enhanced DOT (both pegylated interferon alfa-2a and ribavirin)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
214930151|NCT01442311|OTHER|standard DOT (PEG-DOT control arm)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
214328619|NCT04355000|PROCEDURE|Hall technique|SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
214328620|NCT04355000|PROCEDURE|RMGIC restoration|Complete removal of caries and filling will be done with RMGIC material
214328621|NCT04016870|DEVICE|Reconditioned Pacemaker|Devices from the three manufacturers below will be used.
214328622|NCT04016870|DEVICE|New Pacemaker|Devices from the four manufacturers below will be used.
214328623|NCT01895751|PROCEDURE|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
214328624|NCT04771208|BEHAVIORAL|"I kua na'u Let Me Carry Out Your Last Wishes"|A combination of Native Hawaiian advance care planning video decision support tool and personalized video declarations shared with providers and family members.
214930152|NCT00251082|DRUG|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
214930153|NCT00251082|DRUG|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
214930154|NCT00251082|DRUG|Placebo|Placebo
214930155|NCT03277469|DEVICE|MRI|Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
214328625|NCT05773287|BEHAVIORAL|Targeted Health Coaching Group|Participants in the THC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will partake in 6 virtual or in-person health coaching sessions lasting approximately 30-60 minutes in duration. These sessions will take place approximately every other week during the 3-month intervention period.
214328626|NCT05773287|BEHAVIORAL|Standard Care Group|Participants in the SC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will be provided with a single virtual or in-person education session, lasting approximately 30 minutes, at the beginning of the 3-month intervention period.
214930156|NCT03277469|RADIATION|Brachytherapy|Radiation therapy that is delivered by inserting radioactive sources directly into a tumor
214930157|NCT03277469|DEVICE|MRI Tracker|The MR tracking device consists of a series of radiofrequency (RF) microcoils that are embedded into brachytherapy catheter stylet. The RF microcoils allows for accurate spatial localization of an individual brachytherapy catheter.
214930158|NCT05711485|OTHER|Whole blood transfusion|Whole blood is sourced from the Zambia National Blood Transfusion Service.
214328627|NCT01801787|DEVICE|tDCS|active vs. sham tDCS left hemisphere
214328628|NCT01350128|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 7 days
214328629|NCT01350128|DRUG|Ipratropium Bromide HFA Inhalation Aerosol|Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
214328630|NCT01350128|OTHER|Placebo MDI|Matching placebo to PT001 MDI administered as two puffs BID for 7 days
214328631|NCT03592329|BEHAVIORAL|Stress Reduction Training A|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
214328632|NCT03592329|DEVICE|active tVNS|non-painful electrical stimulation of the auricle
214328633|NCT03592329|BEHAVIORAL|Stress Reduction Training B|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
214930159|NCT04852679|DRUG|Lanreotide autogel|Administered as deep subcutaneous (SC) injections
214930160|NCT03466606|BEHAVIORAL|pre-habilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
214930161|NCT04604444|BEHAVIORAL|Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech|Intensive Comprehensive Aphasia (ICAP) and Apraxia of Speech Program
214930162|NCT01294696|DRUG|Standard of care for treatment of osteoarthritis (OA) of knee(s)|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
214328634|NCT03592329|DEVICE|sham tVNS|sham stimulation
214328635|NCT02762669|DRUG|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
214328636|NCT05053503|DEVICE|Sparrow Ascent Therapy System|Transcutaneous auricular neurostimulation (tAN)
214328637|NCT05053503|DRUG|Lofexidine|Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
214328638|NCT05053503|DRUG|Extended-release injectable naltrexone|Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
214328639|NCT02909556|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
214328640|NCT05098353|DRUG|Quetiapine|25-75 mg per day for 6 weeks
214930163|NCT02686866|DEVICE|bioelectrical impedance analysis (Bodystat, Quadscan 4000)|
214328641|NCT04593030|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
214930164|NCT02686866|DEVICE|dual-energy X-ray absorptiometry (Hologic, Delphi QDR)|
214930165|NCT02686866|DEVICE|hand grip strength|
214930166|NCT03340233|DIAGNOSTIC_TEST|MRI (cardiac) off-label use gadolinium contrast (IND exempt)|Clinical MRI
215070689|NCT00425698|DRUG|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
214328642|NCT04593030|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure
214328643|NCT00215046|DRUG|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
214328644|NCT00215046|DRUG|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
214328645|NCT04522024|PROCEDURE|Epicardial focal cryoablation|Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area
214328646|NCT04522024|PROCEDURE|Mei Mini Maze procedure|Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
214930167|NCT03340233|DIAGNOSTIC_TEST|MRI (cardiac)|MRI without contrast
214930168|NCT05782270|DRUG|Warfarin|dual antiplatelet therapy combined with warfarin
214930169|NCT05782270|DRUG|DAPT|Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)
214930170|NCT05782270|OTHER|CE+CABG|Coronary endarterectomy combined with coronary artery bypass grafting
215070690|NCT00425698|DRUG|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
215070691|NCT00351767|DRUG|placebo|Topically applied
215070692|NCT00351767|DRUG|telbermin|Topically applied
215070693|NCT02340247|OTHER|Water|
215070694|NCT02340247|DRUG|Ursodeoxycholic Acid|
215070695|NCT02340247|DRUG|Chenodeoxycholic Acid|
214328647|NCT06007014|DRUG|Chiglitazar sodium|tablets 48mg/ day administered for 18 weeks
215070696|NCT02704702|DRUG|Fimasartan|
215070697|NCT02704702|DRUG|Rosuvastatin|
215070698|NCT02704702|DRUG|Fimasartan + Rosuvastatin|
215070699|NCT04806776|OTHER|24hrs dressings change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
215070700|NCT04806776|OTHER|7days dressings change|The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
215070701|NCT03392363|DEVICE|Recordings of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.
215070702|NCT04452058|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
215070703|NCT01835977|DEVICE|Irreversible Electroporation (Nanoknife)|
214328648|NCT06007014|DRUG|Chiglitazar placebo|tablets 48mg/ day administered for 18 weeks
214328649|NCT03892720|OTHER|Quality-of-Life Assessment|Ancillary studies
214328650|NCT03892720|OTHER|Questionnaire Administration|Ancillary studies
214328651|NCT03892720|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214328652|NCT03523117|DRUG|Ferric carboxymaltose|Intravenous iron
214328653|NCT03523117|DRUG|Ferrous Sulfate|oral iron therapy
214328654|NCT02786485|BIOLOGICAL|rivogenlecleucel|T cells transduced with iCasp safety switch
214328655|NCT02786485|DRUG|Rimiducid|administered to treat GVHD
214328656|NCT06214208|OTHER|Transcutaneous Spinal Stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic pulses. A single cathode electrode will be placed over the skin of the back spine at the T11/T12 spinous interspace. Two reference electrodes will be placed over the stomach. Stimulation intensity will be set to 0.8x reflex threshold, as determined by posterior root muscle reflex testing before the intervention. Treatments will be a minimum of 72 hours apart.
214328657|NCT02983071|DRUG|G1T38|
214328658|NCT02983071|DRUG|Fulvestrant|
214328659|NCT05385939|OTHER|Observational|This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.
214328660|NCT00015275|BEHAVIORAL|Cocaine-Related Disorders|
214930171|NCT06037161|PROCEDURE|Mandibular Incisor root coverage procedure|Mucogingival procedure to cover mandibular incisor tooth with receded gums
214930172|NCT06666660|DIETARY_SUPPLEMENT|Multivitamin/Mineral supplements|Each participant will be given 180 MVM tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally daily, in the morning before food. Participants will be asked to return the remainder of dispensed MVM tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm.
215070704|NCT04533971|OTHER|Whole body cryotherapy|The WBC procedure consisted of 2-3 min walk in the cryogenic chamber at -110℃. Immediately before the WBC procedures, the patients were provided with a special treatment suit, they were instructed as to how to protect the parts of the body that are particularly vulnerable to frostbite, on the proper way of moving and breathing during the treatment. Excluding Saturdays and Sundays, the WBC treatments were performed daily for the next four weeks. Each time after the WBC the subjects participated in 15-minute kinesitherapy exercises conducted in groups of 5-6 people. The exercises were of general improvement nature and took into account the mobility of the subjects.
215070705|NCT03275246|DEVICE|X-PSI Knee System|Patients are operated with X-PSI Knee System guides
215070706|NCT05806541|BEHAVIORAL|laughter therapy|Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
215070707|NCT02292082|DRUG|Bupivacaine|
215070708|NCT02292082|DRUG|Morphine|
214328661|NCT02092090|BEHAVIORAL|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
214328662|NCT03909009|DEVICE|rTMS + Neuronavigation|Repetitive Transcranial Magnetic Stimulation (Neuro-MS/D) + Neural Navigator
214328663|NCT05548192|DEVICE|SmartPICC-1 System|The SmartPICC system is indicated for use as an alternative method to chest x-ray or fluoroscopy confirmation of PICC tip placement in adult patients when proper ECG detection is available. The SmartPICC system provides a supplemental intravascular ionic dilution feature that provides qualitative blood flow information to the user to aid catheter navigation during PICC placement.
214930173|NCT06666660|OTHER|Placebo|Each participant will be given 180 placebo tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally, daily, in the morning before food. Participants will be asked to return the remainder of dispensed placebo tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm. The placebo pills and bottles will be identical in appearance as MVM to ensure effective blinding.
214930174|NCT05523479|BEHAVIORAL|Traditional online education|A 30-60 minute, online, interactive, educational video that is customized to each provider type and offered with provider-specific continuing education credits
214930175|NCT05523479|BEHAVIORAL|Interprofessional education|Interprofessional education (IPE) consists of both classroom-based IPE and just-in-time IPE. In classroom-based IPE, a trained physician educator with content expertise who works in the ICU leads a 60-to-90-minute, in-person, IPE workshop consisting of a 30-minute didactic session and a 30-to-60-minute small group session, during which participants work together to apply the content to authentic cases. The workshops, which are designed according to modern principles of adult learning and IPE, present the rationale and evidence supporting the preventive, post-extubation therapies. They are specifically designed to foster authenticity, reinforce role identity, and relate the content to life experience. In just-in-time IPE, trained local champions meet with the interprofessional ICU team each morning to identify eligible patients and, as needed, briefly review the evidence supporting proper use of the assigned preventive, post-extubation strategy.
215070709|NCT02292082|DRUG|Methylprednisolone|
215070710|NCT02292082|DRUG|Cefazolin|
215070711|NCT02292082|DRUG|Normal saline|
215070712|NCT02292082|DRUG|Midazolam|
215070713|NCT02292082|DRUG|Propofol|
215070714|NCT02292082|DRUG|Dexamethasone|
214328664|NCT05161065|DEVICE|Cardiologs|Apple Watch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
215070715|NCT02292082|DEVICE|8 MHz. Chiba needle, 22 G / 4 inches|
215070716|NCT02429219|DRUG|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
215070717|NCT02429219|PROCEDURE|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
215070718|NCT02429219|PROCEDURE|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
215070719|NCT03139643|OTHER|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
215070720|NCT03139643|OTHER|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
215070721|NCT03139643|OTHER|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
215070722|NCT04150146|DRUG|Rebamipide SR 150mg after high-fat meal|Test Drug
214328665|NCT04474652|OTHER|Single Blood Draw from each participant|Health Professionals will seek informed consent and take a single blood collection from the participant. This will take place during the patient's visit to the breast one stop clinic as part of their routine urgent breast referral pathway.
214328666|NCT01015352|DRUG|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
214328667|NCT01015352|DRUG|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections~NeoRecormon®"
215070723|NCT04150146|DRUG|Rebamipide SR 150mg under fasting condition|Reference Drug
214328668|NCT05500365|PROCEDURE|Catheter ablation therapy|Pace mapping procedure performed during catheter ablation therapy
214328669|NCT01448018|DRUG|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
214328670|NCT01448018|PROCEDURE|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
214328671|NCT00658281|PROCEDURE|CBCT Scan|Cone Beam Computed Tomography (CBCT) scan performed once a week.
214328672|NCT00658281|PROCEDURE|OBI KV Imaging|On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
214328673|NCT04060329|BEHAVIORAL|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
214328674|NCT04920851|DEVICE|cytokine hemadsorption|to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
214328675|NCT03898661|DRUG|Collagenase histiolyticum|local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
214328676|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected.
214328677|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected
214328678|NCT02851537|OTHER|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
214328679|NCT01495481|DRUG|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
214328680|NCT01495481|DRUG|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
214328681|NCT04734444|DEVICE|SonoClear ACF|The SonoClear ACF is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
214328682|NCT04700696|BEHAVIORAL|Peer Recovery Support|Weekly visits with peer who has lived experience related to child welfare and addiction
214328683|NCT04700696|BEHAVIORAL|Family Treatment Drug Court with Medications for Opioid Use Disorders (MOUD)|Incentivized to participate in Family Treatment Drug Court with option for Medications for Opioid Use Disorders (MOUD)
214328684|NCT04700696|BEHAVIORAL|Relational Skill Building based on the Nurturing Parenting Program (NPP)|Home-based parenting support
214328685|NCT04698161|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
214328686|NCT04698161|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
214328687|NCT04698161|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
214328688|NCT02611492|DRUG|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
214328689|NCT02611492|DRUG|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
214328690|NCT02611492|DRUG|Aracytine (Ara C)|Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
214328691|NCT02611492|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
214328692|NCT02611492|DRUG|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
214328693|NCT02611492|DRUG|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
214328694|NCT02611492|DRUG|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
214930176|NCT05523479|BEHAVIORAL|Clinical protocol|"An adequately explicit protocol provides specific rules for use of the preventive, post-extubation therapy based on patient data. A ready-to-customize version of the protocol with instructions to work with key local stakeholders to revise the protocol, accounting for local needs and resources, is provided. After local customization, a local champion then disseminates the protocol based on local practices."
214930177|NCT05523479|OTHER|Risk-stratified preventive post-extubation noninvasive ventilation (NIV) or high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation NIV for high-risk patients and preventive post-extubation HFNC for low-risk patients
214930178|NCT05523479|OTHER|Preventive post-extubation high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation HFNC for all eligible patients (without risk stratification)
214930179|NCT06483048|BIOLOGICAL|Autologous MUC1-activated T-cells|Given IV
214930180|NCT06483048|DRUG|Bendamustine|Given IV
214930181|NCT06483048|PROCEDURE|Biospecimen Collection|Undergo blood and possible ascites sample collection
214930182|NCT06483048|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214930183|NCT06483048|DRUG|Cyclophosphamide|Given IV
215070724|NCT05406219|DRUG|BAY2395840|Immediate release (IR) tablet, oral administration
214328695|NCT02611492|DRUG|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
214930184|NCT06483048|PROCEDURE|Echocardiography|Undergo ECHO
214930185|NCT06483048|PROCEDURE|Leukapheresis|Undergo leukapheresis
214930186|NCT06483048|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215070725|NCT00579618|OTHER|Saliva or Blood samples|Extracting sample of saliva or blood only once.
214930187|NCT06483048|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214930188|NCT06483048|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214930189|NCT00264069|DRUG|antipsychotic|as prescribed
214930190|NCT00264069|DRUG|antidepressants|as prescribed
214930191|NCT03945370|DIETARY_SUPPLEMENT|β-hydroxybuturate esters|Oral dietary supplement product containing β-hydroxybuturate esters
214930192|NCT03945370|DIETARY_SUPPLEMENT|Placebo drink|Oral placebo drink
215070726|NCT00003191|DRUG|fenretinide|
215070727|NCT02546258|DEVICE|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
214328696|NCT02611492|DRUG|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
214328697|NCT04894045|OTHER|Personalized management|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
214328698|NCT04152122|DIAGNOSTIC_TEST|The dynamic stereopsis test|The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
214328699|NCT00450710|PROCEDURE|ileal interposition with a sleeve gastrectomy|
214328700|NCT04996992|PROCEDURE|MR-guided focused ultrasound|MR-guided focused ultrasound pallidothalamic tractotomy is a minimally invasive and effective procedure for thetreatment of Parkinson's disease(PD) patients.
214930193|NCT03527810|PROCEDURE|Sleeve Gastrectomy Without Interrogation of Hiatus|Weight-loss procedure to reduce the stomach.
215070728|NCT02193737|PROCEDURE|Early oral fluid recovery.|
215070729|NCT02193737|PROCEDURE|Delayed oral fluid recovery.|
215070730|NCT01273116|OTHER|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~* will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~* a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~* will be discussed at least once in a multidisciplinary meeting;~* a structured medication review will be carried out by a geriatrician;~* is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~* may receive a consult of a geriatrician, if judged necessary;~* will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
215070731|NCT04227795|DEVICE|Artificial intelligence-Assisted real time colonoscopy|The colonoscopy was performed under artificial intelligence assistance
215070732|NCT05156840|BEHAVIORAL|Telehealth follow-up|A telehealth follow-up visit will be conducted via the Epic electronic medical record with a pediatric hospitalist following hospital discharge.
215070733|NCT06111040|OTHER|Measurement|The only interventions are at the measurement level and consist of two behavioral protocols designed to assess children's eating behavior, where food stimuli are provided and children's behavioral responses are recorded.
215070734|NCT06297317|DIAGNOSTIC_TEST|Ultrasound measurement of triceps surae muscle-tendon architecture|The resting plantar-flexors MTU architecture assessment was performed using a conventional B-mode and extended-field-of-view (EFOV) ultrasound imaging. Achille tendon cross-sectionnal area, Medial gastrocnemius thickness, pennation angle, fascicle length and muscle length were collected on the dominant lower limb.
214328701|NCT00461539|OTHER|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
214328702|NCT00461539|BEHAVIORAL|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
214328703|NCT04902859|DRUG|Clonidine Oral Liquid Product|Clonidine prepared from pharmacy with 20 mcg/ml concentration.
214930194|NCT03527810|PROCEDURE|Sleeve Gastrectomy With Interrogation of Hiatus|Weight-loss procedure to reduce the stomach with hiatal repair.
214930195|NCT01953874|DEVICE|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
214328704|NCT04902859|DRUG|Sterile water|Sterile water used as placebo
214930196|NCT01953874|DRUG|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
214930197|NCT03339726|DRUG|New Formulation Phenylephrine HCl|2 doses of one tablet 12 hours apart
214930198|NCT03339726|DRUG|Marketed Phenylephrine HCl|4 doses of one capsule 4 hours apart
214930199|NCT03339726|DRUG|Placebo|4 doses of placebo capsule and tablet taken 4 hours apart
214930200|NCT01275755|DRUG|Placebo|
215070735|NCT05052814|OTHER|root canal medicament-calcium hydroxide|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
214328705|NCT01410149|OTHER|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
214930201|NCT01275755|DRUG|ADL5945 0.25 mg|
214930202|NCT02010281|DEVICE|rTMS of prefrontal or motor cortex|description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
214328706|NCT01410149|OTHER|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
214328707|NCT01410149|OTHER|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
214328708|NCT03770468|PROCEDURE|Blood drawl|
214328709|NCT00274599|DRUG|Telmisartan|
214328710|NCT00274599|DRUG|Ramipril|
214328711|NCT01584947|DRUG|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
214328712|NCT01584947|DRUG|Placebo|Placebo lozenge taken three times a day for two weeks
215070736|NCT05052814|OTHER|root canal medicament-chlorhexidine gel|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
214328713|NCT03932942|DIAGNOSTIC_TEST|QIAstat at pediatric emergency room|Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
214328714|NCT02676544|DEVICE|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
214328715|NCT02644967|DRUG|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
214328716|NCT02644967|DRUG|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
214930203|NCT05288595|DEVICE|CliniMACS Plus Instrument|Miltenyi Biotec's CliniMACS Plus Instrument is to be used to TCRαβ CD19 deplete products utilized in this protocol. The CliniMACS Plus is an automated cell separation platform which is functionally closed, maintaining a sterile system for cell depletion and enrichment utilizing a magnetic separation column. Reagents and supplies are to be used for research only but are manufactured and tested under a quality system certified to ISO 13485. Should CD34 selection be required to augment stem cell dose, Miltenyi Biotec's CliniMACS® Plus CD34 Reagent System is FDA approved as a Humanitarian Use Device (HUD). The approved indication was the treatment of patients with acute myeloid leukemia (AML) undergoing myeloablative transplant from matched related allogeneic donors. The CliniMACS® Plus reagent system was approved to obtain an enriched CD34+ cell population for hematopoietic reconstitution without the need for GVHD prophylaxis.
215070737|NCT05052814|OTHER|root canal medicament-calcuim hyroxide &chlorhexidine ge|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
215070738|NCT03905265|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
215070739|NCT02493803|BEHAVIORAL|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
215070740|NCT04092894|DRUG|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
215070741|NCT04092894|DRUG|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
215070742|NCT01683747|DRUG|Tranexamic Acid|
214328717|NCT02442817|DRUG|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
215070743|NCT01683747|DRUG|Control Intervention (Carrier fluid only)|
215070744|NCT03726918|PROCEDURE|Surgery for implantation of a prosthesis|Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
215070745|NCT04689906|OTHER|surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis
215070746|NCT02516098|DRUG|hyoscine butylbromide|
215070747|NCT01057576|DIETARY_SUPPLEMENT|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
215070748|NCT01057576|OTHER|Placebo|capsule, daily dosage
214328718|NCT02867605|DIETARY_SUPPLEMENT|Hyaluronan|
214328719|NCT03551470|PROCEDURE|Robotic one-stage colorectal and liver resection|
214328720|NCT00116389|DRUG|talabostat mesylate tablets|
214328721|NCT00116389|DRUG|gemcitabine|
215070749|NCT05462444|OTHER|Skin prick test|Skin prick test with a standard pallete of inhalational and nutritional allergens
215070750|NCT02522585|OTHER|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
215070751|NCT04571424|DRUG|BIIB133 (Dapirolizumab pegol)|Administered as specified in the treatment arm
214328722|NCT02538926|DRUG|Asparaginase|Given IM or IV
214328723|NCT02538926|DRUG|Cyclophosphamide|Given IV
214328724|NCT02538926|DRUG|Doxorubicin Hydrochloride|Given IV
214328725|NCT02538926|DRUG|Etoposide|Given IV
214328726|NCT02538926|DRUG|Imatinib Mesylate|Given PO
215070752|NCT04571424|DRUG|Placebo|Administered as specified in the treatment arm
215070753|NCT03418649|DRUG|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
214328727|NCT02538926|OTHER|Laboratory Biomarker Analysis|Correlative studies
214328728|NCT02538926|DRUG|Prednisone|Given PO
214328729|NCT02538926|BIOLOGICAL|Rituximab|Given IV
214328730|NCT02538926|DRUG|Vincristine Sulfate|Given IV
214930204|NCT00006398|DRUG|Timolol Maleate|
214930205|NCT00006398|DRUG|Placebo|
214930206|NCT01885702|BIOLOGICAL|DC vaccination|DC vaccination
214930207|NCT05592015|DRUG|Ruxolitinib|Given PO
214930208|NCT05892939|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
214930209|NCT05892939|DRUG|intranasal Placebo|Administration of intranasal Placebo
214930210|NCT04624490|DRUG|Hyperpolarized Xe129|During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
214930211|NCT00979589|DRUG|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
214930212|NCT00979589|DRUG|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
214930213|NCT04792840|DRUG|Femara Pill|study effect on bone
214930214|NCT03754634|DRUG|Eltrombopag and Diacerein|The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
214930215|NCT03871738|OTHER|Proprioceptive training|"The intervention to the experimental group will consist of the application of the protocol of proprioception exercises. Before the exercises of the protocol, a warm-up will be carried out that will last 3 minutes and consists of exercises of joint mobility and jumping rope.~The protocol consists in carrying out two exercises per session, of 10 minutes each. A minute of rest will be implemented between the warm-up and the completion of the protocol, in addition to one minute between the two proprioception exercises in each session. The exercises will vary from week to week, and all the protocol exercises should be done barefoot. The exercise protocol proposed in this study consists of a total of 7 exercises: of unipodal and bipodal support, with unstable surfaces and postural changes."
214930216|NCT03048695|BEHAVIORAL|GMT|Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
214930217|NCT04136977|DEVICE|Eustachian tube dilation|Unilateral or bilateral balloon dilation of the Eustachian tube using the FDA-cleared XprESS ENT Dilation System
214930218|NCT00196339|DRUG|Cyproterone acetate 5|Cyproterone acetate 5 mg
214930219|NCT00196339|DRUG|Placebo|Matching placebo
214930220|NCT00196339|DRUG|Cyproterone acetate 15|Cyproterone acetate 15 mg
214930221|NCT00196339|DRUG|Cyproterone acetate 25|Cyproterone acetate 25 mg
214930222|NCT01318590|DRUG|EUS procedure with drug injection|EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
215070754|NCT03418649|DRUG|Placebo Oral Tablet|PO once daily for 10 days
214328731|NCT01263574|DRUG|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
214328732|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received 10HZ rTMS protocol consisted of 5 sessions over 5 consecutive workdays
214328733|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received pcTBS protocol consisted of 5 sessions over 5 consecutive workdays
214328734|NCT05168319|DEVICE|Sham stimulation|Participants received Sham rTMS stimulations consisted of 5 sessions over 5 consecutive workdays
214328735|NCT06207279|DIAGNOSTIC_TEST|rating|rating scales, test ANT
214328736|NCT03323099|BEHAVIORAL|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
214328737|NCT03323099|BEHAVIORAL|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
214328738|NCT05142683|OTHER|Treatment As Usual|Various typical interventions for adolescents with depression.
214328739|NCT05142683|OTHER|CARIBOU-2|Integrated Care Pathway intervention for adolescents with depression.
214328740|NCT02082717|DRUG|potassium chloride replacement|
214930223|NCT01318590|OTHER|EUS procedure|EUS procedure without any drug injection
214930224|NCT06252051|DRUG|Trivalent Influenza Vaccine|We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.
214930225|NCT02210247|DRUG|EXPAREL|
214930226|NCT01621451|DRUG|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
215070755|NCT01424891|DRUG|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
215070756|NCT01424891|DRUG|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
215070757|NCT01424891|DRUG|Placebo|treatment with placebo over 8 weeks
214328741|NCT02082717|DRUG|Experimental - 4% Sodium Bicarbonate|
214328742|NCT04404959|OTHER|fascia iliaca compartment block with ropivacaine|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of ropivacaine 0.25%)
214328743|NCT04404959|OTHER|fascia iliaca compartment block with placebo|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of normal saline)
214328744|NCT04879303|BEHAVIORAL|Robot-assisted social skill intervention|Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
214328745|NCT04879303|BEHAVIORAL|Human-only instruction programme on social skill training|The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
214930227|NCT01621451|DRUG|aspirin and/or clopidogrel|"Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.~In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer."
214930228|NCT05791630|OTHER|the labour care guide (LCG)|The labour care guide is a tool to be used for assessing labour progression and monitoring care in labour
214328746|NCT03526523|BEHAVIORAL|Mindfulness-based stress reduction|8 weekly 2.5-hour group sessions of mindfulness based stress reduction, led by a certified MBSR instructor
214328747|NCT01177501|DRUG|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
214328748|NCT05418556|DRUG|aspirin|DAPT strategy
214328749|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
214328750|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
214328751|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
214328752|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
214673368|NCT02448823|OTHER|Mass media and Stylish Events|"1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~2. Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses."
214673369|NCT02448823|OTHER|Mass Media|1\. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
214930229|NCT02161237|DRUG|Advagraf®|oral
214930230|NCT05113888|DRUG|Qizhi weitong granules(High）|take orally before meals, 1 bag each time, 3 times a day.
214930231|NCT05113888|DRUG|Qizhi weitong granules(Low）|take orally before meals, 1 bag each time, 3 times a day.
214328753|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
214328754|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
214328755|NCT04953923|DRUG|Cedazuridine|Tablet for oral administration
214328756|NCT04953923|DRUG|Placebo|Capsule for oral administration
214328757|NCT04953923|DRUG|Moxifloxacin|Tablet for oral administration
214673370|NCT01277289|DRUG|Dexamethasone|500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
214673371|NCT00546858|OTHER|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
214673372|NCT03679481|DRUG|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
214673373|NCT03679481|DRUG|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
214673374|NCT02772497|DRUG|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
214673375|NCT05366907|OTHER|No intervention is done|It is a descriptive cross-sectional study so no groups like case/controls are present. All the cases are included in the study.
214673376|NCT05615701|DIAGNOSTIC_TEST|EOSedge imaging|Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery
214673377|NCT03804346|DIAGNOSTIC_TEST|Acceleromyography|At the End of Surgery, shortly before Extubation, the TOF-Ratio is measured by an independent investigator using Acceleromyography.
214673378|NCT00130299|BEHAVIORAL|low glycemic load diet|
214328758|NCT03844373|DIETARY_SUPPLEMENT|STOCKHOLM|STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
214328759|NCT04143451|BIOLOGICAL|Vaxigrip tetra|quadrivalent influenza vaccine
214328760|NCT04143451|BIOLOGICAL|Fluzone high-dose|high-dose trivalent influenza vaccine
214328761|NCT04143451|DRUG|Aldara 5% Topical Cream|imiquimod cream
214328762|NCT04143451|DRUG|Aqueous cream BP|inactive aqueous cream
214673379|NCT00130299|BEHAVIORAL|low fat diet|
214930232|NCT05113888|DRUG|Placebo|take orally before meals, 1 bag each time, 3 times a day.
214930233|NCT01865669|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
214930234|NCT04238143|PROCEDURE|Tissue Stromal Vascular Fraction (tSVF) Arm 1|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
214328763|NCT01424488|DRUG|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
214328764|NCT01424488|DRUG|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
214328765|NCT03867513|OTHER|Multimodal imaging|All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.
214328766|NCT01739530|BIOLOGICAL|Repaircell|allogenic differentiated adipocyte
214673380|NCT06044753|DEVICE|Virtual Reality Headset|"Non immersive VR experience basically means providing a near reality environment for viewers, however, viewers won't be able to make any changes to it as they can only watch.~This Non-immersive Virtual reality experience will be applied unto the child by using a headset that incorporates a computerized dimensional environment which will be simulated to make the child feel near reality .The VR headset consist of a cover for handphone slot, screen display, two lenses with adjustable eye pieces to focus, foam padding and adjustable elastic head mount strap."
215070758|NCT00974441|DRUG|Divalproex Sodium|500 mg Extended Release Tablet
215070759|NCT00974441|DRUG|Depakote®|500 mg Extended Release Tablet
215070760|NCT05099354|DIAGNOSTIC_TEST|autonomic nervous system testing|"* Autonomic tests, including heart rate variability (HRV) and baroreceptor sensitivity (BRS), are performed with a 10min ECG with non-invasive or invasive blood pressor measuring during rest. During the time at the stroke unit, this data will be calculated using the existing continuous monitoring.~* Valsalva maneuver during continuous ECG and blood pressure monitoring. The patient will be instructed to exhale against a mouthpiece with a defined resistance for 15 seconds.~* Assessment of the cerebrovascular reserve capacity will be done with continuous transcranial duplex sonography (TCD) and breath holding index (BHI). The patient will be instructed to hold his breath for 30 seconds, 4 times in a row with intervals of 4 minutes. This test will be performed only in responsive and compliant patients."
215070761|NCT06077955|PROCEDURE|Mini-gastric bypass with stapled anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler."
214673381|NCT05794997|DRUG|Propranolol or Carvedilol|Propranolol or Carvedilol claim is used as the exposure group.
215070762|NCT06077955|PROCEDURE|Mini-gastric bypass with hand-sewn anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture."
215070763|NCT01973387|DRUG|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
215070764|NCT01973387|DRUG|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
215070765|NCT00149136|DRUG|imatinib|
215070766|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
215070767|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
215070768|NCT05786937|OTHER|Commercial ringer´s lactate solution|Placebo
215070769|NCT01520701|DEVICE|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
215070770|NCT01520701|DRUG|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
215070771|NCT06230549|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist
215070772|NCT05829447|DEVICE|G-EYE 760 R endoscope|The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
214328767|NCT00323128|PROCEDURE|Calculation of inuline clearance|Calculation of inuline clearance.
214328768|NCT00323128|PROCEDURE|Measuring serum creatinine|Measuring serum creatinine.
214328769|NCT05700552|BEHAVIORAL|skin to skin contact|For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
214328770|NCT05755828|BIOLOGICAL|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d\*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was \> 2\*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
214673382|NCT05794997|DRUG|Atenolol, Bisoprolol or Sotalol|Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
214673383|NCT00235729|DRUG|Lofexidine|Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
215070773|NCT04215939|BEHAVIORAL|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
215070774|NCT04215939|BEHAVIORAL|Thermoneutral environment participants with spinal cord injury|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
215070775|NCT04215939|BEHAVIORAL|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
215070776|NCT04215939|BEHAVIORAL|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
215070777|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy male participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
215070778|NCT04215939|BEHAVIORAL|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
215070779|NCT04215939|BEHAVIORAL|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
215070780|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy female participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
215070781|NCT04215939|BEHAVIORAL|Warm environment healthy female participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
214328771|NCT03066765|DEVICE|Linguaflex Tongue Retractor|Tongue implant
214328772|NCT00448422|DRUG|prulifloxacin|Tablet
214328773|NCT02171598|DRUG|Clopidogrel|
214930235|NCT04238143|BIOLOGICAL|PRP Concentrate Arm 1|Preparation of PRP Concentrate via sterile Terumo-Harvest System
214930236|NCT04238143|PROCEDURE|Tissue Stromal Vascular Fraction (tSVF) Arm 2|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
214930237|NCT04238143|BIOLOGICAL|PRP Concentrate Arm 2|Preparation of PRP Concentrate via sterile Terumo-Harvest System
214930238|NCT04238143|PROCEDURE|Cellular Stromal Vascular Fraction (cSVF) Arm 2|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
214930239|NCT04238143|PROCEDURE|Cellular Stromal Vascular Fraction (cSVF) Arm 3|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
214930240|NCT04238143|DRUG|Sterile Normal Saline (IV Solution)|Suspension of cSVF in 500 cc Sterile Normal Saline (IV Solution)
214930241|NCT03452046|OTHER|IVC diametres|
214930242|NCT05431023|DRUG|Lactoferrin|Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection
214930243|NCT05431023|DRUG|Pneumonia treatment|Antibiotics for pneumonia
215070782|NCT00139295|DEVICE|Hylastan|
215070783|NCT06014606|DRUG|placebo|oral formulation
215070784|NCT06014606|DRUG|haloperidol 2mg|oral formulation
215070785|NCT06014606|DRUG|propranolol 40mg|oral formulation
215070786|NCT01676753|DRUG|Dinaciclib|Given IV
215070787|NCT01676753|DRUG|Pembrolizumab|Given IV
214673384|NCT00235729|DRUG|Placebo|Placebo is an exact match of lofexidine, less the active ingredient.
214930244|NCT05264792|OTHER|Enhanced Implementation Support|"This support package will include:~1. one-on-one remote (phone/web-based) technical assistance sessions (every two weeks) between the facility team and the study team Implementation Support Coaches. These sessions will involve a discussion on successes and challenges in integrating depression screening with routine care and developing strategies to improve screening, using the PDSA (Plan Do Study Act) cycle model.~2. remote peer learning community (peers include ANMs and Nurses who administer screening) through a cross-facility WhatsApp group moderated by the study team Coaching Support Team.~3. virtual peer learning network conferences (quarterly) moderated by the Coaching Support Team focused on lessons learned in improving depression screening.~The 9-month intervention duration is informed by the Institute of Healthcare Improvement's Breakthrough Series guidelines."
214930245|NCT05264792|OTHER|Routine Implementation Support|This support package will include weekly meetings between District and facility teams, to review and discuss mental health performance indicators, such as depression screening rate, refusal rate for PHQ-2 screening, proportion of referrals of screened positive patients from auxiliary nurse midwife (ANM) to Medical Officer, and rates of diagnosis and initiation of treatment of depression. These indicators will be collated and reviewed by the district team as part of existing non-communicable disease (NCD) care indicators. Monthly performance data will be then emailed by the district team to the facilities, in addition to further data submission reminders. Note that these weekly interactions between the district and facility teams does not include the additional PDSA cycle-based coaching support.
215070788|NCT01296633|BEHAVIORAL|Medtable|Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
215070789|NCT04277663|DRUG|IBI310+IBI308|In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
215070790|NCT04277663|DRUG|IBI308|In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
215070791|NCT04277663|DRUG|High-dose recombinant interferon a-2B|In this group, subjects will be given 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
215070792|NCT04124562|OTHER|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
215070793|NCT06279364|DRUG|SKB264|IV Infusion
215070794|NCT06279364|DRUG|Paclitaxel|IV Infusion.
215070795|NCT06279364|DRUG|Nab-paclitaxel|IV infusion.
215070796|NCT06279364|DRUG|Capecitabine|Tablet. Oral route of administration.
215070797|NCT06279364|DRUG|Eribulin|IV infusion.
215070798|NCT06279364|DRUG|Carboplatin|IV infusion.
215070799|NCT00022360|DRUG|taurolidine|
215070800|NCT00167609|DRUG|dehydroepiandrosterone 100 and 400 mg|
215070801|NCT03027856|DEVICE|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
214328774|NCT02171598|DRUG|Dabigatran high dose|
214328775|NCT02171598|DRUG|Dabigatran low dose|
214930246|NCT03133273|OTHER|Oncogramme®|Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.
214930247|NCT02416531|DRUG|Clobetasol propionate|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
214930248|NCT02416531|RADIATION|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
214930249|NCT02416531|RADIATION|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
214930250|NCT03350061|DEVICE|SENSY|The sensory feedback will be delivered by SENSY with or without the leg prosthesis. Benefits connected to the stimulation of sensory nerves will be assessed.
214930251|NCT03541954|OTHER|Sensory testing of lower urinary tract.|Non invasive lower urinary tract sensitivity testing: provoked diuresis with sonographic estimates of sensory thresholds.
214930252|NCT03541954|OTHER|Sensory testing of lower rectal tract|Lower digestive tract sensitivity testing: rectal electronic barostat with ascending pressure (phasic distension).
214930253|NCT03541954|OTHER|Sensory testing of vulva muscles|Vulvar sensitivity testing: pressure pain threshold evaluated using vulvagesiometer.
214930254|NCT03541954|OTHER|Sensory testing of pelvic muscles|Myofascial sensitivity testing: piriformis, levator ani and obturator internus muscles pressure pain threshold evaluated using intra-vaginal algometer.
214930255|NCT01088880|DRUG|Canakinumab|
214930256|NCT00636194|DEVICE|Bausch & Lomb Multipurpose Solution|daily care of contact lenses
215070802|NCT02084706|PROCEDURE|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
215070803|NCT02084706|DRUG|2% Lidocaine|
215070804|NCT02084706|DRUG|Triamcinolone (20 g)|
214328776|NCT01313572|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
214328777|NCT01313572|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
214328778|NCT06317805|DRUG|Generic treprostinil sodium + Standard of Care (Double Oral)|Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.
214328779|NCT06317805|DRUG|Standard of Care - Double Oral|All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
214328780|NCT04510935|PROCEDURE|general anesthesia|the patient will receive general anesthesia during surgery in this group.
214328781|NCT04510935|PROCEDURE|local anesthesia|the patient will receive local anesthesia during surgery in this group.
214930257|NCT00636194|DEVICE|Alcon OptiFree Replenish Multipurpose Solution|daily care for contact lenses
214930258|NCT03470012|DEVICE|Multi-Purpose Gentle Tape|The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.
214930259|NCT02449135|PROCEDURE|interventional therapy|Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.
214930260|NCT05144789|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
214930261|NCT05144789|DEVICE|Active TBS-DMPFC|"Participants in the active stimulation group will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
214930262|NCT05144789|DEVICE|Sham TBS-DLPFC or DMPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214930263|NCT05482464|DIETARY_SUPPLEMENT|Casein glycomacropeptide (CGMP)|Casein glycomacropeptide (CGMP) supplementation for 3 weeks
215070805|NCT02084706|PROCEDURE|J-tip lidocaine administration|
215070806|NCT02084706|PROCEDURE|Triamcinolone (20 g) Injection over the A1 pulley.|
215070807|NCT03831191|DRUG|LY3375880|Administered SC
215070808|NCT03831191|DRUG|Placebo|Administered SC
215070809|NCT03796390|BIOLOGICAL|CD123 CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
215070810|NCT00883012|BIOLOGICAL|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus\*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms\*\*, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms\*\*, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms\*\* Two doses, one month apart"
214930264|NCT03808350|PROCEDURE|Families Invited to Be Present at Procedures|Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree
214930265|NCT03808350|OTHER|Placebo/Control|Family members will not be invited to remain in the ICU room
214930266|NCT04412200|DEVICE|Hyperbaric oxygen chamber (HBOC)|HBOC group will receive 100% oxygen at 2 ATA for 90 min with 5 min air breaks every 20 min at each session. Intensive management period includes 60 daily sessions, 5 days per week within 12 weeks,
214930267|NCT01537874|BEHAVIORAL|Motivational Interview|30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques
214930268|NCT01537874|BEHAVIORAL|Usual best practices|Standard care delivered using informational materials
214930269|NCT04599725|DRUG|medical abortion|medical abortion
214930270|NCT05462223|COMBINATION_PRODUCT|Alucent Vessel Restoration System for AVF|"Alucent Vessel Restoration System for AVF (VRS-AVF) consists of the following components:~1. VRS 10-8-10 Dimer Coated Balloon Catheter for AVF~2. VRS Light Fiber~3. VRS Light Source"
214930271|NCT04187625|BIOLOGICAL|endothelial progenitor cell|Kidney-derived endothelial progenitor cells will be delivered percutaneously to the kidney blood supply.
214930272|NCT06033430|OTHER|True dry needling|Prior to the procedure, participants will be given a detailed explanation of the dry needling technique. Afterward, the specific area will be thoroughly cleaned using an alcohol pad. In the true dry needling group, along with routine physiotherapy, a sterile filiform acupuncture needle, measuring 2 cm in length and designed for single-use, will be inserted at a 15-degree angle relative to the skin's surface, directly into the scar tissue. Once inserted, the needle will be gently rotated to aid in separating tissue adhesions along the path of the scar. Routine physiotherapy includes the application of kinesiology taping, in addition to a 20-minute session of infrared therapy positioned 30 cm away from the scar tissue. A total of six treatment sessions will be administered to the patients, with three sessions per week scheduled over a two-week period.
214930273|NCT06033430|OTHER|Sham dry needling|The sham group participants will be positioned in a similar manner to those in the experimental group, with a minor exception. Instead of inserting the 2-cm single-use sterile filiform acupuncture needle into the scar tissue, it will be superficially inserted at a point further away from the scar tissue and removed after 20 minutes. Moreover, routine physiotherapy administered to the participants in the sham group will be identical to that of the experimental group, ensuring consistency between the two groups.
214930274|NCT06682936|PROCEDURE|ambulatory chest drain and talc pleurodesis|a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis
214930275|NCT02056366|DRUG|α-lipoic acid|α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks
214930276|NCT03715972|DRUG|Hydroxyurea|info included in arm group
214930277|NCT03715972|DRUG|Acetazolamide|Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.
214930278|NCT01745224|DEVICE|Revlite Q switched Nd:YAG|Revlite Q switched Nd:YAG 1064nm
215070811|NCT00883012|BIOLOGICAL|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
214328782|NCT02847793|BEHAVIORAL|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
214930279|NCT01745224|DEVICE|Trivantage Q switched Nd: YAG|Trivantage Q switched Nd: YAG 1064nm
214930280|NCT01826136|DEVICE|Acapella device|
214930281|NCT04015921|OTHER|No intervention|There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.
214930282|NCT05876624|OTHER|Blood Pressure measurement|Blood Pressure measurement
214930283|NCT06490380|DRUG|PARPi|Poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi)
214930284|NCT00441376|DRUG|ThermoDox|15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
214930285|NCT00246272|DRUG|risperidone|
214930286|NCT02621489|DRUG|Bydureon|2 mg Once Weekly
214930287|NCT02621489|DRUG|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
215070812|NCT05223023|OTHER|questionnaire|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
215070813|NCT02580123|BEHAVIORAL|Intervention taught by trained educators|
215070814|NCT02570724|DRUG|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
215070815|NCT02570724|BIOLOGICAL|blood patch|
214930288|NCT02621489|DRUG|Metformin|Metformin 1g BID
214930289|NCT00278122|BIOLOGICAL|sargramostim|
214930290|NCT00278122|DRUG|paclitaxel|
214930291|NCT05046379|OTHER|Lipidomics|Lipidomics is the large-scale study of lipids (fats and fat-like molecules) within biological systems. It involves identifying and quantifying the wide variety of lipids in cells, tissues, or organisms to understand their roles in metabolism, signaling, and disease. Lipidomics is a subfield of metabolomics and uses advanced analytical techniques, like mass spectrometry, to profile lipid molecules. It helps in studying how lipids contribute to cellular functions, disease development, and responses to therapies.
215070816|NCT05501210|DEVICE|WBV|Whole body vibration (WBV) therapy
215070817|NCT05501210|DEVICE|PEMF|Pulsed electromagnetic fields (PEMF)
215070818|NCT01562314|DRUG|GWP42003|1 to 5 50 mg capsules taken BID
215070819|NCT01562314|DRUG|Placebo|1 to 5 matching capsules taken BID
215070820|NCT00120081|BIOLOGICAL|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
215070821|NCT00120081|BIOLOGICAL|Saline placebo|Inactive saline placebo control
215070822|NCT03655054|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
215070823|NCT05523609|DRUG|Letrozole 2.5mg|20 patients will receive Letrozole only for 12 weeks
215070824|NCT05523609|DRUG|Letrozole + vitamin D3 and calcium|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
214328783|NCT02847793|BEHAVIORAL|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
214328784|NCT05304260|OTHER|clinical and radiographic examination|Prevalence of dental anomalies in deciduous dentition and risk factors associated with non-syndromic oral clefts patients: A cross-sectional study.
214328785|NCT02815228|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-034)
214328786|NCT01120431|OTHER|Oral rehydration fluid|Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
214328787|NCT01120431|DRUG|Isotonic hydration fluid and recombinant human hyaluronidase|Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
214328788|NCT00273572|OTHER|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
214328789|NCT00273572|OTHER|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
214328790|NCT06109584|DEVICE|Insertion of central venous catheter|Central venous catheter verified by ultrasound and then verified by radiography.
214328791|NCT03254134|DRUG|Warfarin|patients treated with warfarin
215070825|NCT05605275|DIAGNOSTIC_TEST|PCT levels|All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.
215070826|NCT05605275|DIAGNOSTIC_TEST|CRP levels|All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.
215070827|NCT05605275|DIAGNOSTIC_TEST|White blood cell count|All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.
215070828|NCT05605275|DIAGNOSTIC_TEST|Platelet count|All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.
215070829|NCT02808052|DRUG|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
215070830|NCT03118856|DIAGNOSTIC_TEST|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
215070831|NCT05305222|DRUG|Risankizumab|Intravenous (IV) Infusion
214328792|NCT03254134|DRUG|Dabigatran|patients treated with Dabigatran
214328793|NCT06471036|OTHER|Care Champion Intervention|The care champion will communicate with the patient according to an algorithm and will emphasize adherence to appropriate lipid lowering therapy, LDL-C retesting, and outpatient follow-up. The care champion will also facilitate communication of any challenges or issues with the patient's outpatient care team. Of note, the care champion will NOT be responsible for prescriptions or drug management.
214328794|NCT05983497|OTHER|Self-Care Skill Educational Intervention|An evidence-based interactive self-care skill educational intervention that supports the clinical nurses to reduce compassion fatigue and increase the compassion satisfaction. The intervention will be delivered as 1-day activity-based educational training. The educational activity consists of the following content: the concept of compassionate fatigue, burnout awareness and recognition, eight dimensions of well-being, and followed by a demonstration of 7 guided self-care skill activities \*on practicing sleep hygiene, self-talk, gratitude practice, Journaling, breathing exercise, heartfulness relaxation, and heartfulness meditation. After the activity participants will develop their own self-care plan for practicing the self-care skills. At the end of the session, they will receive the instructional leaflet to practice the 7 self care skills that they gained from the educational activity.
214328795|NCT00501202|DRUG|placebo|twice daily for 4 weeks
214328796|NCT00501202|DRUG|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
214328797|NCT02976896|DRUG|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
214328798|NCT00806546|DRUG|NP101|NP101 study patch four hour application
214328799|NCT01398111|DRUG|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
214328800|NCT01398111|DRUG|Glycopyrrolate|glycopyrrolate pMDI
214328801|NCT01398111|DRUG|Formoterol|formoterol pMDI
214328802|NCT01398111|DRUG|Placebo|placebo pMDI
214328803|NCT03234738|DRUG|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
214328804|NCT03234738|DRUG|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
214328805|NCT01505192|DEVICE|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
214328806|NCT01891851|DRUG|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
214328807|NCT01891851|DRUG|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
214328808|NCT05973747|DRUG|Calcium Gluconate|Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
214328809|NCT05973747|DRUG|Calcium chloride|0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
214328810|NCT01247090|DRUG|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU \* 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
215070832|NCT05305222|DRUG|Placebo|Intravenous (IV) Infusion
215070833|NCT03182946|DIAGNOSTIC_TEST|Platelet mapping Thromboelastography|These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
215070834|NCT01190761|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
215070835|NCT01190761|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
214930292|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)|single application
214930293|NCT00650117|DRUG|Duragesic 25 mcg/h + Scotch Duct Tape (3M)|single application
214930294|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
214930295|NCT00650117|DRUG|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
214930296|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)|single application
214930297|NCT00650117|DRUG|Duragesic 25 mcg/h + Microfoam Tape (3M)|single application
214930298|NCT04833270|OTHER|KM non-pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
214930299|NCT04833270|OTHER|Pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
214930300|NCT01246349|BEHAVIORAL|Motivational Interviewing (Treatment Group)|Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.
214930301|NCT01246349|BEHAVIORAL|Social Skills Training (Control Group)|Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
214930302|NCT02000700|DRUG|Canagliflozin 100 mg|One 100-mg tablet of canagliflozin orally administered daily for 14 days.
214930303|NCT02000700|DRUG|Canagliflozin 50 mg|One 50-mg tablet of canagliflozin orally administered daily for 14 days.
214328811|NCT01247090|DRUG|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU \* 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
214328812|NCT01247090|DRUG|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
214930304|NCT02000700|DRUG|Canagliflozin 300 mg|One 300-mg tablet of canagliflozin orally administered daily for 14 days.
214930305|NCT02000700|DRUG|Placebo|One matching placebo tablet orally administered at baseline phase.
214930306|NCT04025437|PROCEDURE|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
214930307|NCT04025437|RADIATION|Neoadjuvant radiotherapy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
214930308|NCT00024037|PROCEDURE|management of therapy complications|
214930309|NCT01772745|PROCEDURE|SILS cholecystectomy|Single incision laparoscopic cholecystectomy will be performed
214930310|NCT01772745|PROCEDURE|TPCL cholecystectomy|Three port laparoscopic cholecystectomy will br performed
214930311|NCT01579045|DEVICE|senofilcon A|bilateral daily use soft contact lens
214930312|NCT01579045|DEVICE|etafilcon A|bilateral daily use soft contact lens
214930313|NCT01579045|DEVICE|nelfilcon A|bilateral daily use soft contact lens
214930314|NCT01579045|DEVICE|Filcon II 3|bilateral daily use soft contact lens
214328813|NCT00637039|DRUG|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
214930315|NCT01579045|DEVICE|Filcon II 3|bilateral daily use soft contact lenses
214930316|NCT01566942|DRUG|Oxaliplatin|In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
214930317|NCT01566942|DRUG|Irinotecan|In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
214930318|NCT05637047|PROCEDURE|pulsed radiofrequency|ultrasound-guided intramuscular and interfascial pulsed radiofrequency ablation
214930319|NCT05637047|PROCEDURE|Dry needling|ultrasound-guided intramuscular and interfascial dry needling
214930320|NCT04673747|PROCEDURE|Total Hip Arthroplasty|Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants
214930321|NCT04673747|PROCEDURE|Manual correction of the sacroiliac joint|Manual correction of the iliosacral displacement of the sacroiliac joint in total hip arthroplasty is performed in the operating room after anesthesia just before total hip arthroplasty. It is carried out according to the methodology developed by us.
214930322|NCT05613998|OTHER|GPR Group|"6-week treatment using the GPR method. 1 weekly session (45 min) with frog on the ground and sitting postures + daily home self-postures (10 min)"
214930323|NCT05613998|OTHER|Aerobic Exercice Group|6-week nonspecific aerobic exercise treatment. Participants will take a daily walk (20 min)
214930324|NCT01472653|DRUG|cisplatin|cisplatin 30 mg/m2/week I.V. during radiotherapy
214930325|NCT01472653|RADIATION|radiotherapy|3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks
214930326|NCT01472653|DRUG|cetuximab|cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
214930327|NCT03552224|PROCEDURE|Recording of auditory nerve activity|near field recording of auditory nerve activity with contact electrode
214930328|NCT00438243|DRUG|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
214930329|NCT00438243|DRUG|Refresh Plus|1 drop in the affected eye twice daily
214328814|NCT01226719|DRUG|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
214930330|NCT03500458|BEHAVIORAL|Sleep Extension|Participants will be asked to increase time in bed at least 1 hour more than baseline
214930331|NCT04934189|BEHAVIORAL|Empowerment Self Defense Training|We have contracted with Prepare, Inc., the New York City chapter of IMPACT International to deliver the tailored ESD violence prevention intervention. IMPACT is an international ESD violence prevention organization with chapters across the United States. Prepare, Inc. will provide facilitators who have completed IMPACT's nationally standardized ESD violence prevention program requirements that include receipt of over 100 hours of training. IMPACT training is open to trans and cisgender women. The extensive training of IMPACT facilitators promotes intervention efficacy, while the risk of potential bias conferred by their experience with a pre-existing curriculum is mitigated by our community-engaged approach (i.e.,TW community members, service providers, and scientists \[PI and Co-I\] collectively shape the content of the final tailored ESD intervention, and TW co-facilitators will be present in every training session).
214930332|NCT05551546|BEHAVIORAL|Functional Medicine Health Coaching for Elimination Diet for Elimination Diet|"All participants will receive 5 coaching sessions to support them through the elimination diet.~First session: The foundation session is where the coach and participant begin to develop rapport and outline the participant's goals. This occurs before the start of the Elimination Diet for motivation, expectations, education, and preparation.~Second session: This can occur during week 1 of the elimination diet to support working through the implementation.~Third session: This session is recommended to occur during week 3 of the diet to prepare for the reintroduction of foods.~Fourth session: A session is recommended while the participant is reintroducing foods as this is typically the most difficult part of the diet as participants may be experiencing symptoms to reactive foods.~Fifth session: A wrap up session is recommended after all of the food re-introductions to support the participant with maintenance, goals to move forward, and reflection."
214930333|NCT05551546|BEHAVIORAL|Self-guided Elimination Diet|"The Elimination Diet course materials include self-guided materials designed to guide participants through all phases of a comprehensive elimination diet, including preparation, elimination, and reintroduction phases.~All participants in this wait-list control group will be presented via email with the opportunity to receive the five sessions of coaching (described above) at the conclusion of the study."
214930334|NCT03962790|DEVICE|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with a new manufacturing technology
214930335|NCT03962790|DEVICE|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with the current manufacturing technology
214930336|NCT00745238|OTHER|withdrawal of non-invasive ventilation|Four weeks withdrawal of non-invasive ventilation
214930337|NCT05530200|RADIATION|Hypofractionated radiotherapy|24Gy/8Gy/3f
214930338|NCT05530200|DRUG|PD-L1 inhibitor|q3w
214930339|NCT05530200|DRUG|GM-CSF|200μg, D1-D7
214930340|NCT05530200|DRUG|IL-2|at a dose of 2 million IU, D8-D14
214930341|NCT01532336|DRUG|NVC-422 Solution, 0.3%|NVC-422 Ophthalmic Solution dropped onto the eye
214930342|NCT01532336|DRUG|NVC-422 Vehicle Solution|NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
214930343|NCT04326296|DRUG|PD-L1 Monoclonal Antibody Combined With Lenalidomide|PD-L1 monoclonal antibody was administered by intravenous drip every 3 weeks.Lenalidomide was administered orally, 25mg once a day on days 1-21 of each repeat cycle of 28 days.
214930344|NCT03911661|OTHER|Fearon warfarin dosing algorithm|Blood test drawn by patient using a point of care INR monitor
214930345|NCT03911661|OTHER|Usual care|Historical management of warfarin by patient's usual care providers
214930346|NCT05911828|DRUG|ZY19489 + Ferroquine (FQ)|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
214930347|NCT05911828|DRUG|Placebo|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
214930348|NCT02781753|BIOLOGICAL|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0
214328815|NCT01226719|DRUG|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
214328816|NCT01226719|DRUG|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
214328817|NCT01226719|DRUG|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
214328818|NCT01226719|DRUG|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
214328819|NCT02895399|OTHER|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
214328820|NCT06484777|DRUG|SHR-9539 for injection|SHR-9539 for dose escalation/dose extension
214328821|NCT05395962|DRUG|Carboplatin|treatment with bleomycin and carboplatin in association with electroporation
214328822|NCT05395962|DRUG|Bleomycin|treatment with bleomycin in association with electroporation
214328823|NCT02362165|DRUG|Cyclophosphamide|500mg/d,once-weekly,per oral.
214930349|NCT02781753|BIOLOGICAL|Peginterferon 180 μg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
214930350|NCT02726438|DRUG|Debio 1450|Debio 1450, 40 mg, powder for oral solution, for reconstitution in 5% dextrose in water.
214930351|NCT00880581|DRUG|PF-3512676|18 mg injection
214930352|NCT00880581|RADIATION|Local radiotherapy|2 gray (2 Gy) on each of Days 1 and 2
214930353|NCT06006494|OTHER|aerobic|"We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week."
214930354|NCT06006494|OTHER|resistant|Resistance exercises are the whole of the exercises in which effort is made against the weight and the weight is lifted. Exercises with therabands, dumbbells or body weight will be given. The exercises will be done 2 days a week for an average of 30-40 minutes.
214328824|NCT02362165|DRUG|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
214328825|NCT02362165|DRUG|Dexamethasone|40mg/d,once-weekly,per oral
214328826|NCT02362165|DRUG|Doxorubicin|9mg/㎡,d1-4
214328827|NCT02611622|BEHAVIORAL|LUMA ENT™|
214328828|NCT02611622|OTHER|Survey|Demographic and Patient Satisfaction Survey
214930355|NCT06006494|OTHER|yoga|Yoga is basically breathing exercises, warm-up exercises, relaxation, It is a session consisting of movements and relaxation exercises.movements are performed by standing in a fixed posture for 15 seconds to 2 minutes in a certain posture, they are postures for both strengthening, stretching and balance. Yoga practice will be done 2 days a week for an average of 40 minutes.
214930356|NCT00564837|PROCEDURE|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
214930357|NCT00564837|PROCEDURE|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
214930358|NCT00735137|DEVICE|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
214930359|NCT03780465|DRUG|Oral idronoxil suspension|Idronoxil powder up to 150 ml ORA-BLEND® flavoured syrup
214930360|NCT03780465|DRUG|NOX66 (A)|Idronoxil formulated in suppository base A
214930361|NCT03780465|DRUG|NOX66 (B)|Idronoxil formulated in suppository base B
214930362|NCT06483243|DRUG|Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG|At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.
214930363|NCT02558621|DEVICE|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
214930364|NCT04512599|OTHER|Prebiotic Bar|The prebiotic bar is a proprietary formula created by the study co-investigators, who will not be involved in participant recruitment, selection or outcome measures.The prebiotic bars will be shipped and stored at room temperature prior to consumption.
214930365|NCT06333574|OTHER|Family weight self-measurement and remote follow-up management based on wechat.|On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
214930366|NCT06333574|OTHER|Routine care|The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
214930367|NCT02170896|DRUG|BIBR 1048 MS Capsule A|
214930368|NCT02170896|DRUG|BIBR 1048 MS Capsule B|
214930369|NCT02170896|DRUG|BIBR 1048 MS Capsule C|
215070836|NCT02512874|OTHER|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
215070837|NCT02512874|DEVICE|Dynamometer|Grip Test
214328829|NCT00196781|BEHAVIORAL|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
214930370|NCT02170896|DRUG|BIBR 1048 MS Capsule D|
215070838|NCT02512874|RADIATION|DEXA|Body Composition Testing
215070839|NCT02512874|OTHER|Gait Speed Test|15 foot walk test
215070840|NCT02512874|DEVICE|Activity Monitor|Measures energy expenditure and activity
214328830|NCT00196781|BEHAVIORAL|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
214930371|NCT02170896|DRUG|BIBR 1048 MS tartaric acid solution|
214930372|NCT02170896|DRUG|Pantoprazole|
214930373|NCT04763655|DIAGNOSTIC_TEST|clinical and neuropsychological testing|Patients are monitored with Brief Psychiatric Rating Scale (BPRS) weekly and structural and functional MRI and MATRICS battery before and at the end of the course of the study
214930374|NCT00508287|DRUG|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
214930375|NCT00508287|DRUG|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
214930376|NCT00508287|DRUG|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
214328831|NCT02367599|DRUG|Vitamin D Supplement|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
214328832|NCT01302821|BIOLOGICAL|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
214930377|NCT03357575|BIOLOGICAL|Mesenchymal Stem Cells from adipose|inject mesenchymal Stem Cells from adipose
214930378|NCT03357575|BIOLOGICAL|Hyaluronic Acid|inject hyaluronic acid
214930379|NCT02312869|OTHER|No intervention|not applicable, observational study
214930380|NCT01286168|DEVICE|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
215070841|NCT02512874|OTHER|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
215070842|NCT03397745|DEVICE|BIS|All patients applied BIS on both side (Left and Right)
215070843|NCT01404559|DEVICE|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
215070844|NCT01404559|DEVICE|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
215070845|NCT01404559|DEVICE|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
215070846|NCT02330653|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
215070847|NCT02330653|BIOLOGICAL|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
214328833|NCT01302821|DRUG|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
214328834|NCT01302821|RADIATION|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
214328835|NCT03385239|DRUG|ISIS 678354|ISIS 678354 solution for SC injection.
214328836|NCT03385239|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl).
214328837|NCT00423969|DRUG|Galantamine|
214328838|NCT00423969|DRUG|Escitalopram|
214328839|NCT01357993|DRUG|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
214328840|NCT04952220|DEVICE|ultrasound|Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
214328841|NCT01574703|DRUG|placebo|All dosing to have taken place per study A3051123
214328842|NCT01574703|DRUG|varenicline tartrate|All dosing to have taken place per study A3051123
214328843|NCT01574703|DRUG|bupropion hydrochloride|All dosing to have taken place per study A3051123
214328844|NCT01574703|DRUG|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
214328845|NCT04906642|DEVICE|Next Science|Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.
214328846|NCT04906642|OTHER|Standard of Care|Normal Saline will be used in place of Next Science for irrigation
214328847|NCT05339607|OTHER|Thermal ablation of resection margins by STSC and biliary orifice by cystotome.|Patients who are eligible will undergo thermal ablation of the resection margins.
214328848|NCT00758511|PROCEDURE|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
214328849|NCT00758511|PROCEDURE|facilitated tucking|facilitated tucking before, during and after heel stick
214328850|NCT00758511|PROCEDURE|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
214930381|NCT01286168|DEVICE|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
214930382|NCT01286168|PROCEDURE|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
214930383|NCT01286168|DEVICE|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
215070848|NCT05053815|OTHER|Pharmacogenomic Testing|Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.
215070849|NCT02256384|DEVICE|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
215070850|NCT02854488|DRUG|Yervoy|
215070851|NCT02970006|DEVICE|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
215070852|NCT05173688|DRUG|Propofol|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
215070853|NCT05828875|OTHER|questionnaire investigation|Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
215070854|NCT05562674|BEHAVIORAL|Support group|"This is a group-based, peer specialist and clinician co-facilitated psychosocial intervention for Veterans with SMI, called Veteran Voices and Visions (VVV). VVV is an adaptation of a community-based support group model called the Hearing Voices (HV) approach. The approach facilitates group cohesion around and normalization of the common psychotic symptoms of SMI: hallucinations, delusions, and social isolation."
215070855|NCT01906385|DRUG|Rhenium Liposome Treatment|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
214328851|NCT05558293|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
214328852|NCT03365284|DEVICE|Smart Kneebrace with a smart phone app|Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
214328853|NCT03365284|OTHER|regular rehabilitation procedure|regular rehabilitation procedure, especially muscle strengthening exercises
214328854|NCT04216082|DRUG|Anlotinib|Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
214328855|NCT04401891|BEHAVIORAL|Formal pre-operative education|One group of patients will receive formal pre-operative education prior to surgery from an occupational or physical therapists while the other group of patients will only receive routine education in the MD office.
214328856|NCT00122720|DRUG|Darbepoetin Alfa|
214328857|NCT01639027|DRUG|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
214328858|NCT01639027|DRUG|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
214328859|NCT04712604|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|MSOS Program is a weekly one-hour Zoom session that focuses on psychoeducation on sleep health for both patients and their sleep partners.
214930384|NCT06617910|RADIATION|SBRT by Cyberknife|The patients with sinonasal maliganacy receive curative surgery then receive adjuvant RT by the method of SBRT by Cyberknife.
214930385|NCT02870816|PROCEDURE|Tissue Engineered Skin Substitute|Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
214930386|NCT02870816|DEVICE|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
214930387|NCT02870816|PROCEDURE|Amnionic Membrane Graft|Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
214930388|NCT02542241|DRUG|Sodium Chloride [3%]|Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
214930389|NCT02542241|DRUG|Sodium Chloride [0.9%]|Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
214930390|NCT02548000|OTHER|Resistance training|The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
214930391|NCT02548000|OTHER|Stretching control|The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
214930392|NCT01768975|DRUG|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
214930393|NCT01768975|OTHER|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
214930394|NCT01763723|DEVICE|IPL-home use device|A light based home use device for hair removal
214930395|NCT05269212|OTHER|Usual Care trajectory|Usual care after Spinal Cord Stimulation implantation
214930396|NCT05269212|OTHER|A biopsychosocial rehabilitation program|A personalized biopsychosocial rehabilitation program specifically targeting return to work.
214930397|NCT04598451|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
214930398|NCT04598451|OTHER|Placebo|Subcutaneous injection of placebo
214930399|NCT04598451|DRUG|prednisone|Oral prednisone tablets
214930400|NCT04630249|BEHAVIORAL|Listening to Women and Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to telemedicine mental health and substance use disorder treatment services.
214930401|NCT05165199|DRUG|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
214930402|NCT03764228|BIOLOGICAL|hAECs|Human amniotic epithelial cells（hAECs）
214328860|NCT04007172|PROCEDURE|neural therapy|Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
214930403|NCT01443091|OTHER|application of mother's own colostrum|application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
214930404|NCT01443091|OTHER|application of sterile water|application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
214930405|NCT00492882|DRUG|usual administration of exogenous recombinant FSH|
214930406|NCT02893553|DRUG|Midodrine Hydrochloride|study 1 will be single blind. study 2 will be blinded randomized-control trial.
214930407|NCT02893553|DRUG|Pyridostigmine Bromide|study 1 will be single blind. study 2 will be blinded randomized-control trial.
214930408|NCT02893553|DRUG|Mirabegron|study 1 will be single blind. study 2 will be blinded randomized-control trial.
214930409|NCT02893553|OTHER|Placebo|placebo will only be used for study arm 2, the randomized blinded phase.
214930410|NCT03578016|OTHER|Circle of Security-Parenting|COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.
214328861|NCT04007172|DEVICE|Physical Therapy|Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
214328862|NCT02456324|DEVICE|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
214328863|NCT02456324|DEVICE|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
214328864|NCT02915744|DRUG|NKTR-102|
214328865|NCT02915744|DRUG|Eribulin|
214328866|NCT02915744|DRUG|Ixabepilone|
214328867|NCT02915744|DRUG|Vinorelbine|
214328868|NCT02915744|DRUG|Gemcitabine|
214328869|NCT02915744|DRUG|Paclitaxel|
214328870|NCT02915744|DRUG|Docetaxel|
214328871|NCT02915744|DRUG|Nab-paclitaxel|
214328872|NCT02423265|DRUG|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
214930411|NCT03578016|OTHER|Treatment as Usual|TAU consists of clinical assessment and treatment.
214930412|NCT04317924|DEVICE|Polyglycolic acid felt|Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.
215070856|NCT05441605|OTHER|Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections|Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
215070857|NCT05282108|DRUG|Carcemia|Generic Imatinib
214930413|NCT04317924|OTHER|Standard of care|Standard of care after air leak post lung resection
214930414|NCT01899716|OTHER|Exercise|
214930415|NCT02889250|DEVICE|Medtronic Activa SC DBS, Lead Model 3387|Deep Brain Stimulation
214930416|NCT01311518|DRUG|Drug: Placebo|Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks
214930417|NCT01311518|DRUG|Drug: Injectable Thymosin beta 4|Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
214930418|NCT03338543|DEVICE|PENS|percutaneous electrical nerve stimulation
214930419|NCT03338543|DEVICE|TENS|transcutaneous electrical nerve stimulation
214930420|NCT01976468|OTHER|SCC metastasis|occurrence of SCC metastasis
214930421|NCT05383092|OTHER|Adapted Physical Activity Strong|Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.
214930422|NCT00061373|DRUG|Aspirin|A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.
214930423|NCT00061373|DRUG|tinzaparin sodium|A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.
214930424|NCT00061373|DRUG|eptifibatide|Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.
214930425|NCT01264848|PROCEDURE|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins
214930426|NCT01264848|PROCEDURE|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
214328873|NCT02423265|DRUG|Placebo|Matching placebo: up-titration after 1 week
214328874|NCT02064738|BEHAVIORAL|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
214328875|NCT00813358|DEVICE|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
214930427|NCT01310556|OTHER|ogtt for patients with coronary artery disease|75 g OGTT
214930428|NCT03651687|OTHER||
215070858|NCT05282108|DRUG|Glivec|Imatinib
215070859|NCT06401746|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
215070860|NCT06806241|DRUG|Tranexamic acid|in the study group, a combination of two ampules of Tranexamic acid solution mixed with saline will be used. Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.
215070861|NCT06806241|DRUG|saline irrigation|In control group, saline will be used for irrigation.Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.
215070862|NCT06409871|OTHER|Physiotherapy treatment.|-Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.
215070863|NCT06409871|OTHER|Physiotherapy treatment and modification of the biorhythm.|"* Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.~* Modification of the biorhythm will consist of eliminating methylxanthine-rich foods and/or beverages from their diet, as well as no exposure to electronic devices two hours before bedtime."
215070864|NCT03887988|PROCEDURE|"Primary early reconstruction"|Primary surgical reconstruction of the fracture within 3 weeks after injury
214930429|NCT01237249|DRUG|Melphalan|
214930430|NCT01237249|DRUG|Prednisone|
214930431|NCT01237249|DRUG|Velcade|
215070865|NCT03887988|OTHER|Nonsurgical|Nonsurgical treatment of fracture
215070866|NCT03887988|PROCEDURE|"Primary delayed reconstruction"|Primary surgical reconstruction of the fracture more than 3 weeks after injury
215070867|NCT03887988|PROCEDURE|Secondary reconstruction|Second surgical reconstruction of the fracture after a primary reconstruction.
214328876|NCT01282216|BIOLOGICAL|Havrix|1440 ELISA units, or 1 mL, IM
214328877|NCT01282216|BIOLOGICAL|PCV13|0.5 mL IM
214930432|NCT01237249|DRUG|Revlimid|
214930433|NCT01237249|DRUG|Dexamethasone|
214930434|NCT01029171|BEHAVIORAL|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
214930435|NCT01029171|BEHAVIORAL|control; usual care|Usual care as prescribed by geriatrician.
214930436|NCT04889196|DRUG|Silver diamine fluoride|Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)
214930437|NCT04889196|DEVICE|hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
214930438|NCT00369200|DRUG|AFP464|Given IV
214930439|NCT00369200|OTHER|laboratory biomarker analysis|Correlative study
214930440|NCT00369200|OTHER|pharmacological study|Correlative study
214930441|NCT04682262|PROCEDURE|Cervical dilatation|Patients undergo to cervical dilatation prior to the hysteroscopy under general anaesthesia with using Hegar dilator (no.10)
214328878|NCT03490370|DEVICE|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4|In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
214328879|NCT03261583|OTHER|Thoracis Surgery - Common care|Observational study. It is only a matter of collecting clinical data.
214328880|NCT03766763|DRUG|Venetoclax|"Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.~* For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).~* For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment)."
214930442|NCT05192408|BEHAVIORAL|Multi-component intervention|"Individual intervention will comprise:~1. Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~2. Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~3. Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone."
214930443|NCT05192408|OTHER|Usual Care|Patient Education Materials
214930444|NCT03121924|PROCEDURE|timing for oocyte denudation and Intracytoplasmatic Sperm injection|"Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.~The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed."
214930445|NCT05382195|OTHER|hospital anxiety and depression scale|questionare on patients with multiple sclerosis
214930446|NCT06619223|DIAGNOSTIC_TEST|Duplex Ultrasound|The primary intervention in this study is the use of ankle Doppler waveform assessment for post-revascularisation surveillance in patients with Peripheral Arterial Disease (PAD). This technique utilises continuous-wave Doppler (CWD) and pulsed-wave Doppler (PWD) to assess the blood flow in the key ankle arteries, including the dorsalis pedis artery (DPA) and posterior tibial artery (PTA).
214930447|NCT00421824|DRUG|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
214930448|NCT00421824|DRUG|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
214930449|NCT01825083|DRUG|Ketamine|Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
214930450|NCT01825083|DRUG|Placebo|0.9 % normal saline group receives same volume as the ketamine dose
214930451|NCT04685668|BEHAVIORAL|The PartoMa guidelines and training|"All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics in five study sites during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.~The intervention includes the following two components:~1. Implementation of a pocket booklet with simple and locally achievable clinical guidance for safe and respectful care at birth developed by the research team and birth attendants at the five hospital study sites;~2. Quarterly, the birth attendants will be offered training in the use of the booklet in 3-hour case-based seminars."
214930452|NCT05500482|BIOLOGICAL|Typhoid conjugate Vaccine|TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
214328881|NCT03851016|BEHAVIORAL|Life Story Book|Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.
214328882|NCT03851016|BEHAVIORAL|Usual Care|Three weeks of Usual Care with no visits from research team
214328883|NCT03080961|DEVICE|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
214930453|NCT04594941|DRUG|Flurpiridaz (18F) Injection|All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein at rest.
214328884|NCT03878134|DEVICE|PHOTON COUNTING CT Scanner|Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.
214328885|NCT01619670|DEVICE|Apligraf|non adhesive layer
214930454|NCT04399603|OTHER|no intervention-mechanistic study|no intervention-mechanistic study
214930455|NCT06467994|OTHER|Cashew oral immunotherapy|Cashew Flour (boiled/ roasted) that is prepared under food manufacturing regulations
214930456|NCT06467994|OTHER|Placebo oral immunotherapy|Placebo oral immunotherapy consists of corn flour with food colouring that has similar appearance, taste and smell to the active product
214930457|NCT02679989|BEHAVIORAL|Intermittent Energy Restriction|Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
214930458|NCT02679989|BEHAVIORAL|Continuous Energy Restriction|Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
214930459|NCT05497232|PROCEDURE|simultaneous pancreas-kidney transplantation|"Renal transplants were performed to the right external iliac artery and vein, and the ureter was anastomosed to the recipient ureter by using end-to-end anastomoses techniques. All the renal allografts were placed into retroperitoneum.~Enteric drainage of exocrine secretions was performed on all pancreas transplants, systemic venous outflow (postcava), and arterial reconstruction with y graft (iliac artery). Lastly in all cases of renal transplant, the artery was anastomosed in all cases. The pancreas was placed intra-abdominally in all cases."
214930460|NCT00571571|BEHAVIORAL|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
214930461|NCT00571571|BEHAVIORAL|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
214930462|NCT00179205|DRUG|Nepro nutritional supplement|oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
214930463|NCT00179205|DRUG|placebo|oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
214930464|NCT05646966|OTHER|one time testing|
214930465|NCT03535194|DRUG|Mirikizumab|Administered SC
214328886|NCT00586469|BIOLOGICAL|Fluviral|One dose, Intramuscular injection
214328887|NCT05361681|OTHER|Electromagnetic Field Exposure|All participants were exposed to the electromagnetic field of 4-5 different high power charging systems, charging 4-5 different, commercially available full electric cars
214930466|NCT03535194|DRUG|Placebo|Administered SC
214328888|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
214328889|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
214328890|NCT03090256|DEVICE|AcrySof® IQ PanOptix™ IOL|Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
214930467|NCT03535194|DRUG|Secukinumab|Administered SC
214930468|NCT02091960|DRUG|Enzalutamide|Capsules for oral administration
214328891|NCT03429491|DIETARY_SUPPLEMENT|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
214930469|NCT02091960|DRUG|Trastuzumab|Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
214930470|NCT00382590|DRUG|5-Azacytidine|75 mg/m\^2 daily for 7 days (days 1-7) via subcutaneous injection.
214930471|NCT00382590|DRUG|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
214930472|NCT00382590|DRUG|Valproic Acid (VPA)|50 mg/m\^2 orally daily days 1-7.
214930473|NCT02794792|DRUG|Ipragliflozin L-proline|Oral
214930474|NCT02794792|DRUG|Metformin|Oral
214930475|NCT02794792|DRUG|Placebo|Oral
214930476|NCT01654718|DRUG|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
214930477|NCT01654718|DRUG|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
214930478|NCT03460405|BIOLOGICAL|Vi-DT Vaccine|1 dose of Vi-DT Vaccine
214930479|NCT03460405|BIOLOGICAL|Vi Polysaccharide Vaccine|1 dose of Vi Polysaccharide Vaccine
214930480|NCT03460405|BIOLOGICAL|IPV Vaccine|1 dose of IPV Vaccine
214930481|NCT06666842|BEHAVIORAL|Noom Weight|Participants assigned to Noom Weight will be provided access to the app-based program for 16 weeks. This program offers access to self-monitoring features, psychoeducational articles, one-on-one coaching from health experts, and group support. The app includes a robust database of foods, allowing users to track their energy intake. Self-monitoring via the app enables users to review and monitor behavior and weight change patterns. Daily articles review principles of behavior change, nutrition, exercise, etc.
214930482|NCT06666842|BEHAVIORAL|Educational Control|Participants assigned to the educational control will receive 16 brief (5-10 minute read) weekly newsletters outlining information on developing and maintaining a healthy diet and lifestyle adapted from the 2015-2020 Department of Health and Human Services (HHS) and Department of Agriculture (USDA) Dietary Guidelines for Americans. Newsletters include detailed information on topics such as nutrition fundamentals (e.g., calorie limits; healthy eating), food groups and dietary guidelines (e.g., importance of vegetables, fruits, and grains), and tips for habit change (e.g., reducing added sugar and saturated fats). Each week includes prompts for individuals to try new strategies (e.g., make a conscious decision about everything you eat; try to eat at your calorie budget).
214930483|NCT01579084|DRUG|AGN-199201 Formulation A|AGN-199201 Formulation A applied to the face as per protocol twice daily.
214930484|NCT01579084|DRUG|AGN-199201 Formulation B|AGN-199201 Formulation B applied to the face as per protocol twice daily.
214930485|NCT01579084|DRUG|AGN-199201 Formulation C|AGN-199201 Formulation C applied to the face as per protocol twice daily.
214930486|NCT01579084|DRUG|AGN-199201 Vehicle|AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
214930487|NCT05691335|PROCEDURE|Standard CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 30 minutes.
214930488|NCT05691335|PROCEDURE|Accelerated CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
214930489|NCT05691335|PROCEDURE|Transepithelial CXL|Epithelium-on CXL performed by instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
214930490|NCT02424630|DEVICE|Ultrasound-guided ISB|ISB was performed by one anesthesiologist under ultrasound-guidance. The superior, middle, and inferior trunks of the brachial plexus were identified approximately 2 cm above the clavicle. A 50 mm 22-gauge needle was introduced percutaneously using an out-of-plane technique. The needle was placed beside each trunk in succession, and 2.5 mL ropivacaine was injected into each site. The total volume of ropivacaine used for ISB was 7.5 mL.
214930491|NCT02424630|DEVICE|Arthroscopy-guided SSNB|At the end of the surgery, SSNB was performed under arthroscopic guidance by one shoulder arthroscopist. The suprascapular ligament was found using the lateral portal for visualization. The supraclavicular ligament was visualized at the end of the conoid ligament when the arthroscope was advanced following the coracoclavicular ligament. A 23-gauge spinal needle was introduced in a posteroanterior direction at a 20° angle percutaneously and 7 cm medial to the lateral margin of the acromion. Then, the needle was placed at the upper margin of the suprascapular ligament and advanced slightly under arthroscopy-guidance. After suctioning the saline from the portal, the injection material was administered according to the random assignment.
215070868|NCT05824923|PROCEDURE|Pulmonary arterial denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 ℃ for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.~For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician."
214328892|NCT03429491|DIETARY_SUPPLEMENT|Leucine-enriched protein|Leucine-enriched whey protein
214930492|NCT02424630|DRUG|Placebo|All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
214930493|NCT02424630|DRUG|Ropivacaine|All the regional blocks in this study were performed using 10mL ropivacaine.
214328893|NCT03429491|DIETARY_SUPPLEMENT|LC n-3 PUFA|LC n-3 PUFA
214930494|NCT03992989|DEVICE|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
214328894|NCT02295748|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
214673385|NCT05397613|BEHAVIORAL|STAIR|Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials. STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
214673386|NCT05734781|OTHER|Not Application as this is a qualitative study|Not Application as this is a qualitative study
214328895|NCT04625738|BIOLOGICAL|Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10\^6 MSC/kg day 3: 0.5. 10\^6 MSC/kg day 5: 0.5 . 10\^6 MSC/kg"
214328896|NCT04625738|BIOLOGICAL|Placebo|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
214328897|NCT00844792|DIETARY_SUPPLEMENT|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
214328898|NCT00844792|DRUG|Placebo|Twice a day with meals.
214328899|NCT05639270|DEVICE|use of an auricular electrode|Use of the auricular electrode throughout the duration of the study (30minutes/day) combined with assessment of pain, tolerance, vagal tone.
214328900|NCT02908529|DRUG|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
214328901|NCT02908529|DRUG|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
214328902|NCT03651791|COMBINATION_PRODUCT|USPIO labeled MSC injection|USPIO labeled MSC injection
214930495|NCT03992989|DEVICE|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
214930496|NCT02703272|DRUG|Ibrutinib|Participants will receive Ibrutinib (dose 240 mg/m\^2 /329 mg/m\^2 per day) during part 1 and part 2.
214930497|NCT02703272|DRUG|Rituximab|Participants will receive a cumulative dose of rituximab 750 mg/m\^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.
214930498|NCT02703272|DRUG|Ifosfamide|Participants will receive a cumulative dose of Ifosfamide 9 g/m\^2 and 10 g/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
214930499|NCT02703272|DRUG|Carboplatin|Participants will receive a cumulative dose of carboplatin 635 mg/m\^2 and 800 mg/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
215070869|NCT05824923|DRUG|Guideline-directed medical therapy (GDMT) for heart failure|"GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion."
215070870|NCT03200834|PROCEDURE|Right Hemicolectomy with D2 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
215070871|NCT03200834|PROCEDURE|Right Hemicolectomy with D3 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
214328903|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
214328904|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
215070872|NCT04824911|DRUG|Clopidogrel|300mg loading and 75mg/day from day 2
215070873|NCT04824911|DRUG|Aspirin|Aspirin(100-300mg/day)
215070874|NCT04824911|DRUG|Atorvastatin|Atorvastatin 40-80mg/day
215070875|NCT04824911|DRUG|Rosuvastatin|Rosuvastatin 20 mg/day.
215070876|NCT02357472|DIETARY_SUPPLEMENT|dehydroepiandrosterone|high dose group treatment represent for 50mg t.i.d. Patients in these group will take one capsule each time and three times a day for three months before entering into IVF cycles.
214328905|NCT03787316|DEVICE|Study group|4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
214328906|NCT06290856|DIAGNOSTIC_TEST|Multiplex PCR-test for circulating tumor DNA|All recruited patients will be tested for
214328907|NCT04204018|OTHER|Experimental Arm|"* First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~* Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case."
214328908|NCT00218348|DRUG|Dextro-Amphetamine Sulfate|
214328909|NCT00569686|DRUG|lovaza|lovaza 4 gm po daily
214328910|NCT00569686|DRUG|placebo|placebo
214673387|NCT03807973|DRUG|[Zr-89]Oxine-labeled leukocytes PET/MRI|All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
214673388|NCT03993353|DRUG|Pembrolizumab|200 mg intravenously every 3 weeks
214673389|NCT03993353|DRUG|Tadalafil|10 mg by mouth daily
214673390|NCT04925544|DRUG|VK-2019|VK-2019 binds to EBNA1 and inhibits EBNA1 DNA binding activity. VK-2019 API is synthesized by Anthem BioSciences Pvt. Ltd and formulated into capsules by Emerson Resources Inc,
214930500|NCT02703272|DRUG|Etoposide|Participants will receive a cumulative dose of etoposide 300 mg/m\^2 in part 1 and part 2 as a part of RICE regimen per cycle.
214930501|NCT02703272|DRUG|Vincristine|Participants will receive a cumulative dose of vincristine 1.6 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
214930502|NCT02703272|DRUG|Idarubicin|Participants will receive a cumulative dose of idarubicin 20 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
214930503|NCT02703272|DRUG|Dexamethasone|Participants will receive a cumulative dose of dexamethasone 100 mg/m\^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
215070877|NCT04704505|RADIATION|radium-223|Radium-223 is an alpha-particle-emitting bone-targeted therapy. All patients will receive Treatment with Radium-223 at a dose of 55 kBq per kilogram of body weight IV every 28 days, for 6 cycles,
214328911|NCT05980780|BEHAVIORAL|video game group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a video game. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The game will be played at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
214328912|NCT05980780|BEHAVIORAL|Education booklet group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a training booklet. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The booklet will be read at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
214328913|NCT04919967|BEHAVIORAL|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
214930504|NCT04923581|BEHAVIORAL|Oral Health Behavioral Interventions|The study will use a factorial design to evaluate the efficacy of three distinct intervention components: Motivational interviewing, storytelling videos and oral health promotion messages, in enhancing mothers' brushing of their preschool children's teeth using fluoridated toothpaste.
214930505|NCT00384748|BEHAVIORAL|TR intervention|The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.
214930506|NCT00384748|BEHAVIORAL|In-home messaging device.|The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
214930507|NCT00384748|BEHAVIORAL|Usual care|Routine VA care.
214930508|NCT01226498|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.
214930509|NCT03375671|DRUG|Ketalar|single administration of 5 mg/kg, IM
214930510|NCT03375671|DRUG|Midazolam injection|single administration of 5 mg, IM
214930511|NCT03375671|DRUG|Haloperidol|single administration of 5 mg, IM
214930512|NCT05756803|DEVICE|Low-intensity acoustic shockwave therapy|The study is being done to find out if low-intensity shockwave therapy can improve penile blood flow and restore sexual function in men with impaired erectile function.
214930513|NCT02637895|DRUG|Placebo|Placebo pill matching Vortioxetine.
214930514|NCT02637895|DRUG|Vortioxetine|Immediate Release 10 mg. Vortioxetine Pill
215070878|NCT04704505|DRUG|Bipolar Androgen Therapy (BAT)|All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
215070880|NCT05636046|PROCEDURE|transseptal catheterization|puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.
215070881|NCT03049358|OTHER|Physiologic Testing|Undergo UPSIT smell test
214930515|NCT05415605|DEVICE|Lung Strain|The main objective of this study is to describe the physiological values of lung strain in healthy volunteers as well as its variations induced by non-invasive positive pressure ventilation and their correlation with tidal volume.
214930516|NCT03104062|DIAGNOSTIC_TEST|Microbubble Contrasted Echocardiography|Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography
214930517|NCT03104062|DIAGNOSTIC_TEST|Platelet Aggregability|Obtained using Multiplate Analyzer
214930518|NCT03104062|DIAGNOSTIC_TEST|Laboratory|it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.
214930519|NCT03727126|PROCEDURE|Robotic esophagectomy|Removal of the esophagus and its draining lymph nodes using robotic surgical instruments
214930520|NCT03727126|PROCEDURE|Thoracolaparoscopic esophagectomy|Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques
214930521|NCT00757965|GENETIC|polymorphism analysis|
214930522|NCT00757965|OTHER|laboratory biomarker analysis|
214930523|NCT00757965|OTHER|questionnaire administration|
215070882|NCT03049358|OTHER|Quality-of-Life Assessment|Ancillary studies
215070883|NCT03049358|PROCEDURE|Sham Intervention|Undergo sham training
214328914|NCT04919967|BEHAVIORAL|e-learning toolkit|A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
214328915|NCT02056171|DRUG|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
214930524|NCT05222152|DRUG|Chronocort|Hydrocortisone modified-release hard gelatin capsules for oral administration - 5mg and 10mg
214930525|NCT05222152|DRUG|Plenadren|Hydrocortisone modified-release tablets for oral administration - 5mg and 20mg
214930526|NCT00991471|BEHAVIORAL|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
215070884|NCT03049358|PROCEDURE|Therapeutic Procedure|Undergo olfactory training
215070885|NCT03049358|OTHER|rose essential oil|patient smells rose oil in vial
215070886|NCT03049358|OTHER|lemon essential oil|patient smells lemon oil in vial
215070887|NCT03049358|OTHER|clove essential oil|patient smells clove oil in vial
215070888|NCT03049358|OTHER|eucalyptus essential oil|patient smells eucalyptus oil in vial
215070889|NCT03049358|OTHER|canola oil placebo|patient smells canola oil in vial
215070890|NCT04556955|DEVICE|Graston technique|Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.
215070891|NCT04556955|OTHER|post isometric relaxation|Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier
215070892|NCT00884962|DEVICE|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
215070893|NCT03745872|BEHAVIORAL|Knowledge Assessment|Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
215070894|NCT04823455|PROCEDURE|fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion|Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
214328916|NCT02056171|OTHER|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
214328917|NCT05355844|DRUG|Benzoyl peroxide|Benzoyl peroxide application in the incision area before surgery
214328918|NCT03337724|DRUG|Ipatasertib|Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
214328919|NCT03337724|DRUG|Paclitaxel|Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
214328920|NCT03337724|DRUG|Placebo|Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
214328921|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|Arthroscopic reconstruction of damaged Medial Meniscus using Fast-Fix (Smith \& Nephew) implant.
214328922|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|Arthroscopic reconstruction of damaged Medial Meniscus using Fiber-Stitch (Arthrex) implant
214328923|NCT00192452|DRUG|MEDI-507|
214328924|NCT01831375|BEHAVIORAL|Speak Up|Intervention group\_treatment group
214328925|NCT01831375|BEHAVIORAL|Get connected|Participants will learn to be connected with social resources in the community.
214328926|NCT02544893|DRUG|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
214328927|NCT02544893|DRUG|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
214328928|NCT02544893|DRUG|serum physiologic|21 ml serum physiologic is applied paravertebral space
214328929|NCT06575374|DRUG|Letermovir|Given by mouth or intravenously
214930527|NCT00991471|BEHAVIORAL|No MDRNSTAT|Standard management of nurse-only triage for assignment of CTAS
214930528|NCT02005692|DEVICE|DynaSense sensor|
214930529|NCT01847781|BIOLOGICAL|Prevenar13|
214930530|NCT06141122|OTHER|A recipe booklet|A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
214930531|NCT04333407|DRUG|Aspirin 75mg|• If patient not on aspirin, add aspirin 75mg once daily unless contraindicated.
214930532|NCT04333407|DRUG|Clopidogrel 75mg|• If patient not on clopidogrel or equivalent, add clopidogrel 75mg once daily unless contraindicated
215070895|NCT06382103|DIAGNOSTIC_TEST|ctDNA monitoring|The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.
215070896|NCT06382103|DIAGNOSTIC_TEST|Plasma proteomic analysis|plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis
215070897|NCT02258750|DIETARY_SUPPLEMENT|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
214930533|NCT04333407|DRUG|Rivaroxaban 2.5 MG|"* If patient not on an anticoagulation, add rivaroxaban 2.5mg bd unless contraindicated~* If patient on DOAC then change to rivaroxaban 2.5mg unless contraindicated"
214930534|NCT04333407|DRUG|Atorvastatin 40mg|• If patient not on a statin, add atorvastatin 40mg once daily unless contraindicated
214930535|NCT04333407|DRUG|Omeprazole 20mg|• If patient not on a proton pump inhibitor, add omeprazole 20mg once daily.
214930536|NCT01892709|DRUG|Hydromorphone|
214930537|NCT06011356|DEVICE|Smartwatch|Activity tracker (step count, calories burned), measures heart rate, heart variability and other physiological variables.
214930538|NCT06166537|OTHER|Graduated compression stockings|Graduated compression stockings are standard care (control)
214930539|NCT06166537|OTHER|No Graduated compression stockings|No Graduated compression stockings is the intervention
214930540|NCT02091375|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
214930541|NCT02091375|DRUG|Placebo control|Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
214930542|NCT06582407|OTHER|Mathematical Prediction of unforseen patient reorientation|The goal of this project is to develop models to predict in the preoperative period which patients will require hospital admission after ambulatory surgery or unforeseen hospital discharge after surgery
214930543|NCT03603470|OTHER|EOS imagery|Whole body EOS imaging in seated and standing position
214930544|NCT03184337|BEHAVIORAL|CDC's PreventT2 Program|The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.
214930545|NCT03184337|BEHAVIORAL|CDC's PreventT2 Program with Added Sleep Content|The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
215070898|NCT02258750|OTHER|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
215070899|NCT00244933|DIETARY_SUPPLEMENT|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
214328930|NCT05951244|DEVICE|Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)|Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.
214328931|NCT00079352|DRUG|alvocidib|Given IV
214328932|NCT00079352|DRUG|gemcitabine hydrochloride|Given IV
214328933|NCT00079352|DRUG|irinotecan hydrochloride|Given IV
214930546|NCT02682823|DEVICE|AI-1000 G2|Tocilizumab will be administered using the AI-1000 G2.
215070900|NCT00244933|DRUG|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 \& 8 every 21 days
215070901|NCT00244933|PROCEDURE|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
215070902|NCT02677207|DRUG|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
215070903|NCT02677207|DRUG|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
214930547|NCT02682823|DRUG|Tocilizumab|Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
214930548|NCT05021458|OTHER|Gong's mobilization|Ten patients will be treated with Gong's mobilization.
214930549|NCT05021458|OTHER|SNAG|: Ten patients will be treated with SNAGs
214930550|NCT00731718|DEVICE|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
214930551|NCT06622213|OTHER|mucoadhesive film with Acmella oleracea extract|Apply 1 patch on ulcer 3 times per day (after meals)
214930552|NCT06622213|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Apply ¼ inch on ulcer 3 times per day (after meals)
215070904|NCT05451706|BEHAVIORAL|Mental help-seeking self-persuasion|Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
215070905|NCT02584543|BIOLOGICAL|HEV vaccine|
215070906|NCT02584543|BIOLOGICAL|HBV vaccine|
215070907|NCT01404403|DEVICE|Rapid System|
214328936|NCT06151717|OTHER|Non-Interventional Study|Non-interventional study
214328937|NCT05356884|BEHAVIORAL|Diabetes Intervention|A 12-session group-based intervention that will target diabetes knowledge and leadership and communication skills through facilitated discussion and experiential learning.
214328938|NCT05356884|BEHAVIORAL|Leadership & Life Skills|A 12-session group based intervention that will teach leadership and life skills (planning strategies, leadership values, emotional awareness, effective reasoning skills)
214328939|NCT06019988|OTHER|Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening|All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)
214328940|NCT03551210|DRUG|Nemonoxacin|Solution for infusion, 500 mg (250 ml)
214328941|NCT03551210|DRUG|Nemonoxacin|Capsules, 250 mg
214328942|NCT03551210|DRUG|Tavanic|Solution for infusion, 500 mg (100 ml)
214328943|NCT03551210|DRUG|Tavanic|Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
214930553|NCT06622213|OTHER|mucoadhesive film without Acmella oleracea extract|Apply 1 patch on ulcer 3 times per day (after meals)
214930554|NCT06237413|DRUG|ZG2001 Tosilate Tablets|ZG2001 will be administered orally once or twice daily in a continuous regimen
214930555|NCT06622473|DEVICE|hand dexterity assessement|Each participant will perform the VET, with their most affected hand, followed by the VET with the less affected hand.
214328944|NCT03551210|DRUG|Placebo (250 ml)|0.9% NaCl (250 ml), solution for infusion
214930556|NCT02666196|DRUG|DAA-I|
214930557|NCT02666196|DRUG|Placebo|
214930558|NCT03066245|BIOLOGICAL|MSC-PLGA|Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
215070908|NCT03551405|RADIATION|CBCT scan|CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
214328945|NCT03551210|DRUG|Placebo (100 ml)|0.9% NaCl (100 ml), solution for infusion
214328946|NCT03421288|DRUG|Atezolizumab|Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)
215070909|NCT03170115|DRUG|Aspirin|chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
215070910|NCT03170115|DRUG|Placebo Oral Tablet|chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
215070911|NCT03163693|DRUG|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
215070912|NCT03163693|OTHER|normal saline|receive equal volume of normal saline
215070913|NCT00349921|DRUG|clonidine|Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
215070914|NCT00349921|DRUG|adenosine|Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
215070915|NCT00349921|DRUG|placebo|inactive substance
215070916|NCT00349921|DRUG|placebo|inactive substance
215070917|NCT02072135|DRUG|Exparel|
215070918|NCT05923827|DEVICE|Omnipod 5 System|The Omnipod 5 system is a tubeless patch pump that receives glucose values and trend data from the glucose sensor every 5 minutes, automatically calculates insulin dose, and sends delivery commands to the Pod for the delivery of insulin.
214328947|NCT03421288|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
214328948|NCT03421288|DRUG|Calciumfolinat|Day 1 q2w: 200 mg/m² IV over 1 hour
214328949|NCT03421288|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
214328950|NCT03421288|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
214328951|NCT06671015|DEVICE|Airvo 3|Provides effective therapy for acute hypoxemic respiratory failure and post-extubation respiratory support for 24 hours post-extubation.
214328952|NCT05445128|BIOLOGICAL|MGTA-145|MGTA-145 will be administered as an IV infusion
214328953|NCT05445128|DRUG|Plerixafor|240 µg/kg administered subcutaneously
214328954|NCT07007429|OTHER|Ipsilesional Side Stimulated Occlusal Imbalance|In this group, a 1 cm thick cotton roll will be placed on the ipsilesional occlusal surfaces of the patients, and they will be instructed to hold it in place without clenching.
214328955|NCT07007429|OTHER|Contralesional Side Stimulated Occlusal Imbalance|In this group, a 1 cm thick cotton roll will be placed on the contralesional occlusal surfaces of the patients, and they will be instructed to hold it in place without clenching.
214930559|NCT04550975|OTHER|Advanced Cognitive Stimulation Therapy|An adapted version of Cognitive Stimulation Therapy for people with moderate to severe dementia.
214930560|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
214328956|NCT07007429|OTHER|Bilateral Cotton Roll with Jaw Clenching|In this group, a 1 cm thick cotton roll will be placed on both occlusal surfaces, and the patients will then be instructed to clench their teeth.
214328957|NCT07025694|DEVICE|A eHealth application on a computer tablet contected to a secure severer with an interface on a computer to deliver exercise interventions.|Feasibility, acceptability and usability testing of delivering home-based exercise MICT and HIIT via a Vidoe-call at fixed time-points. Tuesday, Thursday, Saturday during the 3 week-period of supervision via zoom.
214930561|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
214930562|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
214930563|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
214930564|NCT06017752|BEHAVIORAL|STAC Teacher Module|"The STAC Teacher Module is a 30-minute presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies teachers can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
214930565|NCT04130542|BIOLOGICAL|LVGN6051|IV infusion once every 3 weeks (Q3W).
214930566|NCT04130542|BIOLOGICAL|KEYTRUDA® (pembrolizumab)|IV infusion once every 3 weeks (Q3W).
215070919|NCT06826690|PROCEDURE|Group 1: ultrasound guided wrist block with bupivacane alone|Ultrasound guided wrist block with 15 ml volume of bupivacane.25%
215070920|NCT06826690|PROCEDURE|Group 2 : ultrasound guided wrist block with bupivacane and dexamethasone|Group 2 : patients receive ultrasound guided wrist block with bupivacane.25% and 8 mg dexamethasone.. 15 ml volume totally
215070921|NCT06826690|PROCEDURE|Group 3: ultrasound guided wrist block with bupivacane and dexametmiodine|Group 3 will receive ultrasound guided wrist block with bupivacane.25% and 50 mcg dexametmiodine... 15 ml volume totally
215070922|NCT06826690|PROCEDURE|Group 4: patients will receive ultrasound guided wrist block with bupivacane and dexamethasone and dexametmiodine|Group 4 patients will receive ultrasound guided wrist block with bupivacan.25%e and 8 mg dexamethasone and 50 mcg dexametmiodine
215070923|NCT06572891|OTHER|Maxillary obturator|conventional acrylic obturator
214328958|NCT07025694|DEVICE|A eHealth application on a computer tablet contected to a secure severer with an interface on a computer to deliver exercise interventions|Feasibility, acceptability and usability testing of delivering home-based exercise MICT and HIIT via a pre-recorded videos at convenient time-point with at least one day in between during the periods of video-supervision
214328959|NCT07025694|OTHER|Moderate Intensity Continues Training|The MICT exercise training on a spinning-bike will consist of moderate intensity-longer (60%Wpeak) duration exercise carried out 3 times per week. Tuesday, Thursday, Saturday during the 3 week-period of supervision via zoom, and at time-point with at least one day in between during the periods of video-supervision. Exercise will consist of continuous biking at an individualized workload based on pre-exercise testing, for a total time of 30 minutes.
214328960|NCT07025694|OTHER|High intensity interval training|The HIIT exercise training on a spinning-bike will begin by using a protocol consisting of bouts of high-intensity (95%Wpeak) exercise lasting for 60 seconds. These bouts will be interspersed by 4 minutes of low intensity exercising (40%Wpeak). There will be 5 bouts per session. Exercise will consist of continuous biking at individualized workloads based on pre-exercise testing. The exercise will be carried out 3 times per week. Tuesday, Thursday, Saturday during the 3 week-period of supervision via zoom, and at time-point with at least one day in between during the periods of video-supervision.
214328961|NCT07025759|DEVICE|Peripheral magnetic stimulation (90% of RMT + 1 Hz)|Low-frequency stimulation (1 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
214328962|NCT07025759|DEVICE|Peripheral magnetic stimulation (90% of RMT + 10 Hz)|High-frequency stimulation (10 Hz) at 90% of resting motor threshold intensity, totaling 2400 pulses.
214328963|NCT07025759|DEVICE|Peripheral magnetic stimulation (90% of RMT + 25 Hz)|High-frequency stimulation (25 Hz) at 90% of resting muscle threshold intensity, with 2400 pulses.
214328964|NCT07025759|DEVICE|Peripheral magnetic stimulation (100% of RMT + 1 Hz)|Low-frequency (1 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
214328965|NCT07025759|DEVICE|Peripheral magnetic stimulation (100% of RMT + 10 Hz)|High-frequency (10 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
214328966|NCT07025759|DEVICE|Peripheral magnetic stimulation (100% of RMT + 25 Hz)|High-frequency (25 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
214328967|NCT07025759|DEVICE|Peripheral magnetic stimulation (110% of RMT + 1Hz)|Low-frequency (1 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
214328968|NCT07025759|DEVICE|Peripheral magnetic stimulation (110% of RMT + 10Hz)|High-frequency (10 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
214930567|NCT04410016|OTHER|Staff Wellbeing Centres|2 Centres (rooms) accessible to staff for rest and relaxation, work breaks, supports advice and signposting. They are manned by support workers called Wellbeing Buddies.
214930568|NCT05705882|OTHER|Malnutrition|For the diagnosis of malnutrition, the investigators adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
214930569|NCT05855174|DIETARY_SUPPLEMENT|Whey protein|Weight protein provided in a shake with carbohydrate and water
214930570|NCT06434220|DIAGNOSTIC_TEST|Baseline model|Model prediction of patient disposition including feature importance scores driving prediction.
214930571|NCT06434220|DIAGNOSTIC_TEST|Fairness-aware model|Model prediction of patient disposition including feature importance scores driving prediction. This model has been tuned to minimize subgroup calibration errors.
214930572|NCT03231540|DIETARY_SUPPLEMENT|Whey protein supplement|Whey protein supplement to target protein intake of 1.5 g/kg/day
214930573|NCT06339411|DRUG|Cerebrolysin|Cerebrolysin post-mechanical thrombectomy, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery.
214930574|NCT05010512|DEVICE|Delefilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
215070924|NCT06572891|OTHER|Implant supported obturator|"Implants inserted as planned The necks of the implants were bent up to 15 degrees to be parallel.~* The maxillary obturator was adjusted on the poured mode, modified and access holes will be made above the abutment to be finally relined in the patient mouth at the correct vertical dimension of occlusion to allow for immediate loading protocol.~* Impressions were made"
215070925|NCT04850196|DEVICE|TEAS|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
214930575|NCT05010512|DEVICE|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
214930576|NCT02191722|BEHAVIORAL|reading comics booklet|
214930577|NCT06621342|BIOLOGICAL|PRP Experimental|All participants will have 5 2ml tubes of blood collected at 72 +/- 5 hr prior to embryo transfer and again at 48 +/- 5 hour prior to embryo transfer. This blood will be processed to create PRP for the uterine infusion per protocol.
214930578|NCT03308136|PROCEDURE|1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.|1\) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
214930579|NCT03308136|PROCEDURE|1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.|2\) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3\~4ml of local anesthetics to the muscle layer along the expected needle pathway.
214930580|NCT03308136|DRUG|1% Lidocaine|1% Lidocaine
215070926|NCT04850196|OTHER|control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
214328969|NCT07025759|DEVICE|Peripheral magnetic stimulation (110% of RMT + 25Hz)|High-frequency (25 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
214328970|NCT07025239|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of QL1706 lasts for up to 2 years.
214328971|NCT07025239|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 7.5mg/kg on Day 1 of each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of Bevacizumab lasts for up to 2 years.
214328972|NCT07025239|DRUG|Oxaliplatin|Oxaliplatin will be administered by IV infusion at 130 mg/m2 on Day 1 of each 21-day cycle up to 8 treatment cycles.
214328973|NCT07025239|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 twice daily for 2 consecutive weeks, followed by one-week rest in each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of Capecitabine lasts for up to 2 years.
214328974|NCT07025239|DRUG|Placebo|Placebo will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of Placebo lasts for up to 2 years.
214328975|NCT07024069|OTHER|Tongue ultrasound via submental approach|"Descriptive and anthropometric data will be recorded for each participant, including age, sex, weight (kg), height (m), neck circumferences (cm). Body mass index (expressed in kg/m2) will be calculated.~Submental ultrasound (US) images of the tongue will be performed on a patient lying supine, using a 5-15 MHz convex transducer. The parameters will be identical for all subjects and set at a depth of 9 cm, a focus of 4 cm and a gain of 45%. Each measurement will be taken thrice by a trained operator; the mean and standard deviation being used for analysis."
214328976|NCT07025512|DRUG|177Lu-PSMA-617|Given by IV
214328977|NCT07032298|DRUG|SSGJ-612|Intravenous injection
214328978|NCT02239536|PROCEDURE|hot snare polypectomy|hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
214328979|NCT02239536|PROCEDURE|hot snare polypectomy after saline injection|hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
214930581|NCT00902343|PROCEDURE|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
214930582|NCT00902343|PROCEDURE|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
214930583|NCT05668143|BEHAVIORAL|Virtual reality|The Patient Information Form and the State Anxiety Scale will be administered to the patients just before the surgery. The researcher will measure the patient's respiratory, blood pressure, pulse and oxygen saturation values on the monitor just before the start of the operation and every 15 minutes after the operation, and the vital signs will be recorded in the follow-up form. Virtual reality glasses will be put on the patient immediately after anesthesia is given to the patient by the anesthesiologist. Glasses will be worn during the total knee replacement surgery. Total knee replacement surgery takes an average of 60 minutes. During the surgery, patients will be shown nature and landscape images with virtual reality glasses. Virtual reality glasses will be removed immediately after the operation and the State Anxiety Scale and vital signs follow-up form will be applied before the patient is sent to the service from the operating room.
215070927|NCT05521854|BEHAVIORAL|DynamiCare app (app-based contingency management)|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
215070928|NCT05521854|BEHAVIORAL|Sham control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
215070929|NCT06150365|BIOLOGICAL|KSX01-TCRT cell therapy|Patient autologous T cell therapy
214328980|NCT05944120|COMBINATION_PRODUCT|Aromatherapy patches|This study anticipates that Staff-reported stress levels will decrease when nurses use strategies from the Crisis Intervention Cart while at work.
214328981|NCT06766305|DRUG|QL1706 combined with SOX|QL1706 + SOX (3 cycles) before surgery → radical surgery (D2) → QL1706 + SOX (5 cycles) after surgery → QL1706 monotherapy maintenance （up to 1 year before and after surgery); Phase 1 (initial dose cohort) ： QL1706 5mg/kg ；Phase 1 (dose escalation cohort)：QL1706 7.5mg/kg ；Phase 2：QL1706 RP2D
215070930|NCT04683549|DIAGNOSTIC_TEST|HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy|"Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~1. FDG PET Scan before treatment and 3 months after treatment~2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy."
215070931|NCT00777985|DRUG|bosentan|62.5 mg b.i.d for 4 weeks
215070932|NCT00777985|DEVICE|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
215070933|NCT00920387|DRUG|200 mcg LSD|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
215070934|NCT00920387|DRUG|20 mcg LSD|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
215070935|NCT00920387|BEHAVIORAL|Therapy|Therapy provided by male and female co-therapists
214930584|NCT01071486|DRUG|Hematological Stem Cell Transplantation|Oral or Intravenous Busulfan as part of the preparative protocol for transplantation
214930585|NCT00866086|OTHER|questionnaire administration|
214930586|NCT00866086|PROCEDURE|computed tomography|
214930587|NCT00866086|RADIATION|radiation therapy treatment planning/simulation|
214930588|NCT03359486|BEHAVIORAL|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
214930589|NCT03359486|BEHAVIORAL|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
214930590|NCT00136435|DRUG|prednisone|Induction Phase: Given orally on days 1-28
214930591|NCT00136435|DRUG|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
214930592|NCT00136435|DRUG|vincristine|"Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.~CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle"
215070936|NCT04105920|DEVICE|Hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
215070939|NCT05849207|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
215070940|NCT03880370|BEHAVIORAL|Questionnaires / scales|EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)
214328982|NCT07074197|OTHER|OOKIE doll|The infants who met the selection criteria were wrapped with OOCIE upon admission and remained in contact with OOCIE for approximately 24 hours without affecting their routine care and position. After 24 hours, when the mother came for the first visit, the mother and baby introductory information form, Neonatal Intensive Care Unit Parent Stress Scale, Inadequate Milk Perception Scale, Mother-Infant Attachment Scale and NICU Parental Beliefs Scale pretest were administered. During the visit, the mother received the OOKIE wrapped around her baby in the incubator and stayed with the mother for 3 days and the mother could smell her baby's odor whenever she wanted.
214328983|NCT07082374|OTHER|Dual subsartorial block|Patients will receive dual subsartorial block (DSB).
214328984|NCT07082374|OTHER|Adductor canal block|Patients will receive an adductor canal block (ACB).
214328985|NCT07082374|OTHER|Femoral nerve block|Patients will receive a femoral nerve block (FNB).
214328986|NCT07085962|DRUG|Calculus bovis sativus|Calculus bovis sativus 200mg qd
214328987|NCT07085962|DRUG|Placebo|Placebo 200mg qd
214328988|NCT07086612|DIAGNOSTIC_TEST|over nigtht ventilatory polysomnograph test|Every patient will have an overnight polysomnography test.
214328989|NCT07086144|DIAGNOSTIC_TEST|Determination of viral genome, bacterial serology, and markers of inflammation in pediatrics diagnosed with myocarditis|N=15 patients from 2025, in which management and treatment of arrhythmias and or myocardial dysfunction were driven by the panel
214328990|NCT07085676|BIOLOGICAL|HBI0101 CART|HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART may be provided fresh or cryopreserved.
214930593|NCT00136435|DRUG|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
214930594|NCT00136435|DRUG|asparaginase|Induction: Given into the muscle on day 5
214930595|NCT00136435|DRUG|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
214930596|NCT00136435|RADIATION|cranial radiation|Given in 10 daily treatments during CNS therapy phase
214930597|NCT00136435|DRUG|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
215070941|NCT03880370|DIAGNOSTIC_TEST|Ultrasound imaging|Rectus abdominis dominant side \& non-dominant side external oblique dominant side \& non-dominant side internal oblique dominant side \& non-dominant side transversus abdominis dominant side \& non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side \& non-dominant side
215070942|NCT03880370|DIAGNOSTIC_TEST|FLEXIBILITY|weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test
215070943|NCT03880370|DIAGNOSTIC_TEST|FUNCTIONAL TESTS|Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen
215070944|NCT03267979|OTHER|Video-pupillometer|Video-pupillometer will be performed. In this study data will be collected and analyzed.
215070945|NCT03267979|OTHER|Electrocardiogram|Electrocardiogram will be performed. In this study data will be collected and analyzed.
215070946|NCT04645316|DRUG|Sevoflurane|In the sevoflurane group (n = 25), after the induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, the Sevoflurane concentration will be adjusted between 1-2%, the BIS value will be 40-60, and it will be inhaled with an air / O2 mixture to be FiO2: 0.4.
214930598|NCT00136435|DRUG|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
214930599|NCT00136435|DRUG|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
214930600|NCT00136435|DRUG|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
214930601|NCT00136435|DRUG|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
214328991|NCT07084909|DRUG|piflufolastat F 18|18F-DCFPyL is a fluorine-18 radiolabeled low molecular weight positron emission tomography (PET) tracer that binds to the extracellular domain of prostate-specific membrane antigen (PSMA) with high affinity.
214328992|NCT07085013|BEHAVIORAL|Individually Trained Oral Prophylaxis (iTOP)|The iTOP intervention consists of a single, structured, 45-minute, small-group oral hygiene training session conducted by certified dental professional. The session includes personalized instruction on proper toothbrushing techniques (e.g., Bass technique), use of interdental brushes and floss, and patient motivation. At the 3-month follow-up, participants also received a short reinforcement session. Standardized oral hygiene kits (toothbrush, interdental brushes) were provided at each time point.
214328993|NCT07085949|OTHER|5 cmH2O PEEP|5 cmH2O PEEP will be administered during mechanical ventilation
214328994|NCT07085949|OTHER|10 cmH2O PEEP|10 cmH2O PEEP will be administered during mechanical ventilation
214328995|NCT07085806|DRUG|Pentoxifylline (also known as oxpentifylline)|Intravenous injection Pentoxifylline 1 mg/kg/hr dissolved in Plasma Lyte/0.9% Normal saline from12 hours before the surgery to 72 hours after the Surgery
214930602|NCT06621303|BIOLOGICAL|Diabetic foot ulcer treatment|The trial is designed to last up to 26 weeks, including a screening period of 1 week, a treatment period of 1 week, and an observation period of 24 weeks. According to the inclusion criteria, 10 diabetic patients with ulcers will be clinically screened, and after signing the informed consent form, they will be assigned a number. Post-injection of OPM cells, wound assessments are conducted weekly, with physical examinations and vital signs (pulse, blood pressure) recorded at weeks 4, 8, 12, 16, 20, and 24. Clinical laboratory tests (routine blood tests, tumor markers, etc.) are performed at week 12. Vascular CTA and immune cell count in wound lavage fluid are conducted at week 24 post-cellular intervention, followed by a final examination at week 24.
214930603|NCT03937401|DRUG|Oxytocin|Oxytocin infusion during MRI-HIFU treatment
214328996|NCT07085806|OTHER|Plasmalyte|Plasmalyte
215070947|NCT04645316|DRUG|Desflurane|In the desflurane group (n = 25), after induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, Desflurane concentration will be adjusted between 6-8%, BIS value will be 40-60 and it will be inhaled with a mixture of air / O2 mixture to be FiO2: 0.4.
215070948|NCT04645316|DRUG|Propofol|In the propofol-remifentanyl group (n = 25), rocuronium 0.6 mg / kg will be administered for intubation after 2 mg / kg propofol and 1 µg / kg remifentanil. Maintenance of anesthesia will be adjusted to be between 10 mg / kg / h for the first 10 minutes, 8 mg / kg / h for the following 10 minutes, and then by 6 mg / kg / h propofol infusion, with the BIS value between 40-60. Patients in this group will be inhaled with a mixture of air / O2 to be FiO2: 0.4. Inhalation anesthetics will not be used in this group.
215070949|NCT00157196|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide \[L-BLP25\]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
214328997|NCT07080216|BIOLOGICAL|ZG005|ZG005 20mg/kg, intravenous infusion(IV), once every 3 weeks (Q3W)
214328998|NCT07080216|DRUG|Gecacitinib|Part 1: Cohort A：Gecacitinib is administered continuously until the end of treatment; Cohort B：Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21；Part 2：Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.
214328999|NCT07080216|BIOLOGICAL|Bevacizumab|Bevacizumab 7.5 mg/kg，intravenous infusion(IV), once every 3 weeks (Q3W)
214329000|NCT07086274|DEVICE|Individualized location-based Repetitive Transcranial Magnetic Stimulation|Enhancing targeting accuracy through personalized target localization to improve the analgesic response rate of rTMS.
214329001|NCT07086274|DEVICE|Traditional location-based Repetitive Transcranial Magnetic Stimulation|Recent studies have shown that the dorsolateral prefrontal cortex (DLPFC) plays an inhibitory role in the human pain pathway. High-frequency repetitive transcranial magnetic stimulation (rTMS) applied to the left DLPFC has been found to improve chronic migraine.
214329002|NCT07086287|DRUG|rhBNP and standard basic treatment|After administering a bolus of rhBNP at 1.5-2 μg/kg intravenously, a maintenance dose of 0.0075-0.01 μg/kg/min is continuously infused intravenously for 72 hours, with the dosage adjusted based on blood pressure and heart rate; the control group receives standard basic treatment.
214329003|NCT07087236|BEHAVIORAL|Maximum Cognitive Load|Participants will perform a working memory task (through N-back 1-to-3) to evaluate the upper limit of cognitive demand.
214930604|NCT02512081|OTHER|No intervention applied|No intervention applied
215070950|NCT00157196|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
215070951|NCT00157196|OTHER|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
215070952|NCT02353702|PROCEDURE|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
215070953|NCT02353702|DRUG|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
215070954|NCT02353702|DEVICE|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
214930605|NCT04446195|BEHAVIORAL|Individualized Intervention|In this study, patients with the risk factors of insufficient intestinal preparation were treated with individualized intervention (mainly from the following aspects: chronic constipation, intestinal preparation not strictly in accordance with the requirements, body mass index \> 25 kg / m2, age \> 70 years old, with other diseases such as diabetes, Parkinson's disease, history of stroke or spinal cord injury, etc., application of tricyclic antidepressants or anesthetics).
214930606|NCT04987099|DIETARY_SUPPLEMENT|550 mg/day Choline|Choline chloride (550 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
214930607|NCT04987099|DIETARY_SUPPLEMENT|25 mg/day Choline|Choline chloride (25 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
214930608|NCT02847143|DRUG|nasal oxytocin or placebo|nasal administration of oxytocin or palcebo 45 min befor fMRI session
214930609|NCT02847143|DEVICE|fMRI|FMRI during emotional image visualization
214930610|NCT02847143|BEHAVIORAL|Attachement scale interview (ASI)|this scale is used to determine the attachement style of each participant
214930611|NCT02847143|BEHAVIORAL|psychometric scales|self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)
214930612|NCT00858299|DRUG|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
214930613|NCT04873453|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
214930614|NCT04873453|DRUG|Placebo|Placebo arm
214930615|NCT06618768|DIETARY_SUPPLEMENT|Consumption of an aronia-mixture to prevent Urinary Tract Infections in female patients|The present pilot study will assess the feasibility of methods and procedures to be used in a larger study and contribute to establish power calculations required to conduct a randomised clinical trial which will examine whether consumption of 1 dL aronia-mixture/day for six months will reduce prevalence of symptomativ UTi episodes among adult women with a recent history of uncomplicated, recurrent UTIs.
214930616|NCT03242187|PROCEDURE|Trans-anal total mesorectal excision(TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
214930617|NCT03242187|PROCEDURE|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
215070955|NCT02353702|DRUG|Infusion of placebo during 48 hours|
214329004|NCT07087236|BEHAVIORAL|Mental active/pasive activities|"Participants will engage in 7 activities, presented in a randomly assigned order across two separate days, to assess their impact on cognitive load:~1. playing a videogame (Tetris ®)~2. listening a podcast (including a final question)~3. watching a documentary (including a final question)~4. reading a document extract (including a final question)~5. watch a reality show extract (including a final question)~6. listening music, they like it~7. scrolling their Tik-Tok/Instagram"
214329005|NCT07087236|BEHAVIORAL|Baseline Cognitive Load|Participants will sit quietly for 5 minutes to establish baseline spontaneous neurophysiological parameters.
214329006|NCT07086001|BEHAVIORAL|stress management and coping|Online intervention focusing on stress and coping in university students. All resources were grouped in five main categories: Managing Stress, Enhancing Performance, Adulting, Socialising, and Well-being. The resource was hosted on a website and presented information in several multimedia formats (i.e., text, audio, video, interactive infographic) to account for diversity of preferences. All students in the intervention groups were provided with unlimited access to the intervention. Furthermore, all students were asked to complete screener questions on their stress and coping but only students in the directed group were directed to one of three unique pages on the website based on their responses on the screening questionnaire demonstrating low, moderate, or high need for support around stress and coping.
214930618|NCT02122770|DRUG|MLN4924|MLN4924 intravenous solution.
214930619|NCT02122770|DRUG|Fluconazole|Fluconazole tablets.
214930620|NCT02122770|DRUG|Itraconazole|Itraconazole oral solution.
214930621|NCT02122770|DRUG|Docetaxel|Docetaxel intravenous solution.
214930622|NCT02122770|DRUG|Carboplatin|Carboplatin intravenous solution.
214930623|NCT02122770|DRUG|Paclitaxel|Paclitaxel intravenous solution.
214930624|NCT06312111|BEHAVIORAL|recommendation to increase physical activity|education on the benefits of physical activity in PAH from the first visit and doctor's recommendation to increase physical activity above 5,000 steps a day in inactive patients and above 5,000 steps per person in active patients
214930625|NCT03179293|DRUG|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
214930626|NCT03179293|DRUG|Normal saline|Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
214930627|NCT03089671|OTHER|Vitamin B (riboflavin, vitamin B2)|Vitamin B is a natural health product approved as a colouring agent.
215070956|NCT02353702|DRUG|NaCl|
215070957|NCT00116675|DRUG|Resiquimod|
215070958|NCT02524275|DRUG|Capecitabine|Given PO
215070959|NCT02524275|DRUG|Docetaxel|Given IV
215070960|NCT02524275|OTHER|Quality-of-Life Assessment|Ancillary studies
215070961|NCT02524275|OTHER|Questionnaire Administration|Ancillary studies
215070962|NCT04017572|PROCEDURE|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
215070963|NCT03628482|PROCEDURE|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
215070964|NCT03628482|PROCEDURE|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
215070965|NCT00467194|DRUG|Rapamycin|
215070966|NCT00467194|DRUG|Bevacizumab|
215070967|NCT04418492|BEHAVIORAL|Skills for Adaptive Functioning through Executive training (SAFE; tentative title)|An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
214329007|NCT07086495|OTHER|Aromatherapy|Participants inhaled lavender essential oil (3 drops in 100 ml water) via diffuser during a 15-minute post-exercise recovery period following the Bruce treadmill protocol.
214930628|NCT03089671|OTHER|5% Dextrose in Water (D5W)|5% Dextrose in Water is an irrigation/instillation fluid, commonly used in intravenous lines.
214930629|NCT06443398|OTHER|There is no intervention in the study|There is no intervention in the study
214930630|NCT06619262|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS stands for transcutaneous electrical nerve stimulation. Transcutaneous means across the skin. TENS machines pass a small electrical current across your skin to stimulate the nerves.
214930631|NCT06619262|DEVICE|Neuromuscular and Muscular Electrical Stimulation|Neuromuscular and Muscular Electrical Stimulation (NMES) is a modality that sends electrical impulses to nerves which causes the muscles to contract mimicking the action potential coming from the central nervous system.
214930632|NCT06619262|OTHER|Exercise program|Specific exercise program for patients with lower extremity hemiparesis after stroke
214930633|NCT00036491|DRUG|Rituximab|Subjects received four weekly infusions of rituximab at a dose of 375 mg/m\^2
214930634|NCT01734538|DIETARY_SUPPLEMENT|Omega-3 Complete|
214930635|NCT01734538|DIETARY_SUPPLEMENT|Placebo capsule|
214930636|NCT06298695|BEHAVIORAL|Individual Schema Therapy|"Schema therapy focuses on adapting maladaptive schemas (i.e., core representations of oneself, others or the world) and dysfunctional personality traits, while also incorporating exposure therapy. It consists of a maximum of 40 sessions within one year."
214930637|NCT06298695|OTHER|TAU|Treatment As Usual according to the Dutch Multidisciplinary Guidelines Anxiety Disorders and the Dutch Quality Standard for Anxiety Disorders. TAU often consists of a continuation of Cognitive Behavioral Therapy (CBT) and (different) medications, sometimes in a more treatment-intensive format. There are no restrictions to TAU, except that it may not be schema therapy. The actual content of TAU will be tracked.
214930638|NCT02012738|BEHAVIORAL|FORNET|"8 individual sessions:~* 1 lifeline~* 6 exposure sessions~* 1 outlook"
214930639|NCT02012738|BEHAVIORAL|CBT|"7 individual sessions, according to the Integrated cognitive behavior change program manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice."
214930640|NCT02012738|OTHER|Waiting List Control Group (camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
214930641|NCT02012738|OTHER|Waiting List Control Group (no camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
214930642|NCT00132938|DRUG|telithromycin|
214930643|NCT04342741|DEVICE|Foley catheter cervical ripening|Participants were assessed when labour was established or the following morning.
215070968|NCT06039436|DRUG|Anti-Thymocyte Globulin (Rabbit)|Indications for trial stopping: subjects occur pregnancy events, severe organ function impairments, or emergency events related or unrelated to treatment; or subjects are unwilling to continue participating in the clinical trial.
215070969|NCT00778258|BIOLOGICAL|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
214329008|NCT07086495|OTHER|Placebo Diffuser (No Essential Oil)|Participants were exposed to plain water vapor (100 ml of water without essential oil) via diffuser for 15 minutes during post-exercise recovery.
214329009|NCT07084831|DRUG|Xanomeline/trospium|Participants will receive xanomeline/trospium during the trial
214329010|NCT07086040|BEHAVIORAL|RAS incorporated in upper-limb movement training|RAS will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session for a total of 21 sessions.
214329011|NCT07086040|BEHAVIORAL|Upper-limb movement training|Upper-limb movement training will last for 40 minutes per session for a total of 21 sessions.
214930644|NCT04902313|BEHAVIORAL|Awareness and insight Modules (AiM)|12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
214930645|NCT00688935|BIOLOGICAL|Melatonin|0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
214930646|NCT00236158|DEVICE|AAIR/DDDR pacemaker|Pacemaker with single lead or dual lead
214930647|NCT01944618|DRUG|Forxiga|FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor \[DPP 4 inhibitor\] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
214930648|NCT04247464|PROCEDURE|Fasting|Food intake restriction
214930649|NCT01684579|BEHAVIORAL|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
215070970|NCT00778258|BIOLOGICAL|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
215070971|NCT02034682|DRUG|Volulyte 6%|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
215070972|NCT02034682|DRUG|Geloplasma|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
214329012|NCT07086859|PROCEDURE|TEST 1|Autogenous whole tooth graft with metformin
214329013|NCT07086859|PROCEDURE|Control|Autogenous whole tooth graft
214930650|NCT01684579|BEHAVIORAL|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
214930651|NCT01684579|BEHAVIORAL|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
214930652|NCT02965196|DRUG|IV Dexamethasone Therapy|
214930653|NCT02965196|OTHER|IV Normal Saline (NaCl 0.9%)|
214930654|NCT03108599|OTHER|Enhanced Cab|The enhanced cab intervention includes the introduction of an active suspension seat and a therapeutic mattress system. After a baseline phase, the intervention arm will receive the enhanced cab intervention alone, and then the enhanced cab plus a behavioral sleep program.
214930655|NCT03108599|BEHAVIORAL|Fit4Sleep|The behavioral sleep program includes a friendly dyad-based physical activity competition; self-monitoring and logging of physical activity, sleep hygiene behaviors, and sleep; and individual coaching. The behavioral sleep program includes an optional body weight management component. The intervention arm will receive the behavioral sleep program in combination with the enhanced cab intervention.
214930656|NCT04586218|BEHAVIORAL|Computer guided vasopressor infusion|automated titration of vasopressor infusion to maintain a mean arterial pressure \> 65mmHg
214930657|NCT04586218|BEHAVIORAL|Manual control of vasopressor infusion|manual adjustments of noradrenaline infusion
214930658|NCT04113408|OTHER|FABIR sequence|The FABIR sequence with a duration of 8 minutes is added to the imaging protocol.
214930659|NCT01577849|DRUG|Vitamin D3|administration of Vitamin D3 24,000 IU
214930660|NCT01577849|DRUG|DP-R206|administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
214930661|NCT00189306|DRUG|Imiquimod 5% cream|Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
214930662|NCT06078449|DEVICE|Therapeutic Ultrasonic|Ultrasound is a therapeutic modality that has been used by physical therapists to achieve therapeutic benefits. It is alternating compression and rarefaction of sound waves with a frequency of \>20,000 cycles/second. Therapeutic ultrasound frequency will be used by 0.7 to 3.3 MHz. Maximum energy absorption in soft tissue will be 2 to 5 cm. Intensity decreases as the waves penetrate deeper. It is applied using a round headed wand or probe that is put in direct contact with the patient's skin. Ultrasound gel must be used on all surfaces of the head as a conducting medium in order to assist in the transmission of the ultrasonic waves \& to reduce friction.
214930663|NCT06078449|DRUG|Hyaluronan intra-articular injection|The type of Hyaluronan injection that will be used in this study consists of High Molecular Weight Hyaluronic acid (High MW HA 3000 kDa), will be given by the orthopedic surgeon.
214930664|NCT02658006|PROCEDURE|Cardiac surgery|All cardiac surgery procedures
214930665|NCT00001111|DRUG|Nevirapine|
214930666|NCT00001111|DRUG|Zidovudine|
214930667|NCT05073328|OTHER|COVID-19 required hospitalisation|Patients who contracted a COVID19 required hospitalisation
214930668|NCT04036305|DRUG|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
214930669|NCT04036305|DRUG|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
214930670|NCT04036305|DRUG|Bupivacaine Injection 0.5%|All participants will be injected subcutaneously with a single 0.5ml dose
214930671|NCT02638571|OTHER|enhanced education on pulse use in complementary foods|Enhanced Nutrition education with sessions and counseling by health extension workers
214930672|NCT04448132|BIOLOGICAL|IPV-Al|adjuvanted reduced dose inactivated polio vaccine
214930673|NCT06617728|PROCEDURE|Intervention 1: Regional Analgesia|Regional analgesia techniques like epidural or peripheral nerve blocks.
214930674|NCT06617728|DRUG|Intervention 2: Intravenous (IV) Analgesia|IV medications used for pain control, including opioids and non-opioid analgesics.
214930675|NCT05390528|DRUG|HLX301|HLX301 will be administered as a single intravenous (IV) infusion on Day1 in each 14-day cycle.
214930676|NCT05642260|OTHER|fall prevention programe|Patients in the experimental group will receive a comprehensive fall prevention program (guided by the post-TKR protocol followed at Al-Razi Orthopedic Hospital) into the conventional physiotherapy treatment
214930677|NCT04982068|BIOLOGICAL|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
215070973|NCT00193791|OTHER|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
215070974|NCT00123279|DRUG|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
215070975|NCT05699993|DRUG|Itraconazole|Itraconazole was administered orally
215070976|NCT05699993|DRUG|IBI351|IBI351 was administered orally
215070977|NCT05699993|DRUG|Dextromethorphan|Dextromethorphan was administered orally
214930678|NCT04982068|BIOLOGICAL|202-CoV low antigen dose|low dose 202-CoV with CpG / alum adjuvant
214930679|NCT04982068|BIOLOGICAL|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
214930680|NCT04982068|OTHER|Placebo|Normal saline solution
214930681|NCT02434172|OTHER|Pre-emptive screening and treatment for cryptococcal disease|Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
214930682|NCT01735968|DRUG|ST571 + BYL719|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
214329014|NCT07085130|BEHAVIORAL|Exercises and cold application|Hand and foot exercises combined with cold application interventions are non-pharmacological methods used to reduce pain, kinesiophobia, and fragility levels in patients with diabetic peripheral neuropathy.
214930683|NCT06265701|BEHAVIORAL|Derailment-Focused Reflective Journaling|Experimental group aimed at decreasing anxiety symptoms
214930684|NCT06265701|OTHER|Everyday Tasks Reflective Journaling|Control group
214930685|NCT02160522|DEVICE|Cuffed ETT|Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
214930686|NCT04933916|DRUG|EMB-001|Combination product metyrapone and oxazepam
214930687|NCT06646510|OTHER|traditional exercises|strengthening exercise for the shoulder muscles( shoulder extensors, shoulder retractors from prone position and shoulder external rotation exercise for 3 sets 10 repetition , weight bearing exercise on the hand from quadruped position and sitting position and strengthening exercise on the intrinsic muscles of the hand
214930688|NCT06646510|OTHER|sensory electrical stimulation|The stimulated muscles included the flexor carpi radialis (FCR), extensor carpi radialis (ECR), and flexor carpi ulnaris (FCU). Rectangular surface electrodes (Ag/AgCl; 50mm \_ 50mm size) were attached on the motor point of each muscle, i.e., at four fingerbreadths from biceps tendon of FCR, at two fingerbreadths distal from lateral epicondyle for the ECR, at two fingerbreadths volar to ulna at the junction of the upper and middle thirds of the forearm for FCU.14 Portable stimulators will use with the following stimulation settings: constant current (0.2 mA step), 100 Hz stimulation frequency, biphasic pulse, and 300 \_s pulsewidth.
214930689|NCT03640481|DRUG|Belumosudil (KD025)|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
214329015|NCT07085130|OTHER|Exercises and virtual reality|Performing hand and foot exercises in a cold, snowy virtual environment using virtual reality goggles may be a non-pharmacological intervention to alleviate burning-type hand and foot pain in patients with diabetic neuropathy.
214930690|NCT02835950|DEVICE|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
214930691|NCT06511323|DIAGNOSTIC_TEST|dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases|at baseline prior to stereotactic radiation, at 10 weeks after treatment, and at first concern for progression at treated lesion or 12 months post-treatment, whichever comes earlier.
214930692|NCT05248113|DEVICE|Electrical stimulation of cochlear nerve|Intraoperative electrical stimulation of the cochlear nerve in patients undergoing surgery for resection of vestibular schwannoma. Activation of the auditory system monitored with scalp recording of auditory brainstem response.
214930693|NCT03990935|OTHER|ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
214930694|NCT06311435|DIAGNOSTIC_TEST|RNA Biomarker Blood Test|Blood will be collected into a PaxGene Blood tube for processing by sponsor
214930695|NCT00311519|DRUG|Hylenex|
214930696|NCT05470621|BEHAVIORAL|PlayOn! playground curriculum|A staff and student training to implement a playground curriculum in after-school and recess settings
214930697|NCT06579937|DRUG|Esketamine hydrochloride|During anesthesia induction, a 0.2 mg/kg esketamine bolus was administered intravenously.
214930698|NCT06579937|DRUG|normal saline|During anesthesia induction, a bolus of equal 0.9% saline was administered intravenously.
214930699|NCT02004899|DRUG|Fentanyl|After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
214930700|NCT01250132|OTHER|Biological and behavioral explorations|"Blood dosages:~* biochemistry~* pituitary gland~* somatotropic axis~* corticotropic axis~* gonadotropic axis~* thyrotropic axis~* antidiuretic axis~Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)"
214930701|NCT01329718|OTHER|Blood Sample|Blood sample collection
214930702|NCT03081806|DRUG|X0002|Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
214486226|NCT06741358|OTHER|Control|Individuals in the Control Group will receive the same Glialia supplement as the PPPD-Glialia group, containing 700 mg of Palmitoylethanolamide (umPEA) and 70 mg of supportive ingredients. They will also take two soluble sachets daily for 60 days. The primary goal for this group is to assess how the Glialia supplement affects neuroinflammation and related outcomes in individuals who have recovered from COVID-19 but do not have PPPD. This comparison will help clarify the potential effects of Glialia in the context of both PPPD and recovery from COVID-19.
214930703|NCT00311636|DRUG|cyclophosphamide|
214930704|NCT00311636|DRUG|docetaxel|
214930705|NCT00311636|DRUG|doxorubicin hydrochloride|
214930706|NCT00311636|DRUG|epirubicin hydrochloride|
214930707|NCT00311636|DRUG|fluorouracil|
214930708|NCT00311636|DRUG|methotrexate|
214930709|NCT00311636|DRUG|paclitaxel|
214930710|NCT00311636|DRUG|triptorelin|
214930711|NCT00311636|PROCEDURE|adjuvant therapy|
214930712|NCT00535847|DRUG|Telaprevir|Tablet
214930713|NCT00535847|DRUG|Ribavirin|Tablet
214930714|NCT00535847|DRUG|Pegylated interferon alfa 2a|Solution for Injection
214930715|NCT03944369|OTHER|KB109|KB109 is a novel glycan
214930716|NCT03944369|OTHER|No intervention|No intervention
214930717|NCT00727844|DRUG|Immediate Start Linezolid|
214930718|NCT00727844|DRUG|Delayed Start Linezolid|
214930719|NCT05454540|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|"daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS"
214329016|NCT07085377|PROCEDURE|DIADEME strategy|"This strategy consists of implementing the standardized DIADEME protocol. It, in line with best practice recommendations, enables nurses to adjust methadone dosage on the basis of a clinical assessment scheme incorporating opioid withdrawal and overdosing and includes:~* initial medical consultation with the hospital practitioner for an addictology and psychiatry assessment, OUD assessment, and initial prescription of methadone for 3 months~* ECG prior to any methadone prescription, hepatitis B, C, HIV testing may be offered, and an emergency NALOXONE kit will be given to the patient or prescribed~* follow-up consultations with an nurse at least every 7 days, and more frequently if necessary.Dosages can be adjusted by the nurse on the basis of the standardized DIADEME protocol~* medical consultation are only in the event of major withdrawal symptoms or overdosing or in the event of any incident not covered by the protocol and warranting rapid medical advice or at the patient's request"
214329017|NCT07085377|PROCEDURE|Controle strategy|The control strategy corresponds to standard practice guidelines for patients suffering from drug addiction, with the care pathway provided by the hospital practitioner, assisted by the nursing team.
214486227|NCT06737523|DRUG|CVA|Chiglitazar Sodium in combination with Venetoclax and Azacitidine
214930720|NCT04569968|OTHER|Expiratory muscle training|For training group first maximum expiratory pressure measurement will be assessed with portable expiratory measurement device. Measurement will be taken while the patient in a sitting position. Three measurement values with 5% variation will be taken an average of these values recorded as a maximum expiratory pressure of the patient. After the maximum expiratory pressure of the patient is measured 50% percent of the related value will be set on the expiratory muscle trainer. Then patient will be informed about how to use the trainer. Trainer will be used daily for four weeks with 50 repetitions. At the end of every week pressures will be measured again for re-calibration of the trainer.
215070978|NCT05470842|DEVICE|Continuous glucose monitoring (Dexcom G6)|"All participants will be issued with the Dexcom G6 device. The trial team will buy the readers or smartphones and sensors and provide the participants with all the necessary equipment. Participants will be shown how to wear the Dexcom G6 device, which they will be asked to wear for up to 10 days (=the lifespan of one sensor).~There will be no change in the standard care of the participants' diabetes management, during the study period."
215070979|NCT06282406|OTHER|Transcutaneous Electrical Stimulation|Electrical pulse trains applied to the skin overlying putative sites of auricular vagal innervation.
215070980|NCT06282406|OTHER|Sham|Electrodes placed on the skin overlying putative sites of auricular vagal innervation but no current administered.
215070981|NCT06655532|BEHAVIORAL|Exercise Program|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training twice weekly.
214930721|NCT06619340|DRUG|Exparel|20 milliliter (mL) EXPAREL with 20mL bupivacaine hydrochloride (HCL) 0.5% will be expanded. An 18-gauge bevel needle will be introduced through the capsular pocket at 1 to 2cm proximal to the adductor tubercle at the proximal border of the posteromedial femoral condyle. The needle will be angled proximally and posteriorly, and then advanced to contact the posteromedial capsule. A 20mL bolus of the study drug admixture will be administered. The remaining 20mL of the study drug admixture will be administered to the anterior and lateral knee structures with approximately 1 to 1.5mL administered with each stick to the intended area.
214930722|NCT01905501|DRUG|Balanced anesthesia|Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
214930723|NCT01905501|DRUG|Total intravenous anesthesia|Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
214930724|NCT04944810|PROCEDURE|Magnetic Gastric Bypass|Perform a gastric bypass with the magnetic grasper to do the liver retraction, upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb and perform the section of the limb and finish the gastric bypass
214930725|NCT04944810|PROCEDURE|Magnetic Sleeve Gastrectomy|Perform a sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach
214930726|NCT04944810|PROCEDURE|Revisional Bariatric Surgery|Perform liver retraction and also steps of the surgery like upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb, upper retraction of the stomach
214930727|NCT04944810|PROCEDURE|Nissen/Sleeve Gastrectomy with Magnetic Assistance|Perform a nissen-sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach, retraction of the stomach to close the hiatal defect and perform a nissen funduplication before do the sleeve gastrectomy
215070982|NCT06655532|BEHAVIORAL|Usual Care|Patients allocated to this arm will receive standard medical treatment plus explicit recommendations for 12-week home-based moderate-intensity aerobic and strength training. They will also receive a weekly phone call and an in-person monthly visit to monitor exercise training performance.
215070983|NCT05076409|DRUG|BI 425809|Period 1 and period 2
215070984|NCT05076409|DRUG|fluconazole|Period 2
215070985|NCT06267872|BIOLOGICAL|CD4BS CH505M5 Pr-NP1|A ferritin NP expressing 8 copies of an HIV-1 Env protein trimer. To be administered intramuscularly (IM).
215070986|NCT06267872|BIOLOGICAL|CH505TF chTrimer|A stabilized chimeric SOSIP Env trimer protein with the N-terminal sequence of CH505 TF gp120 Env transplanted into the BG505 SOSIP sequence. To be administered IM.
215070987|NCT06267872|BIOLOGICAL|3M-052-AF (labeled as AP 60-702)|An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.
215070988|NCT06267872|BIOLOGICAL|Aluminum Hydroxide Suspension (Alum)|Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.
215070989|NCT06267872|BIOLOGICAL|ACU-026-001-1 (labeled as empty LNP)|An AF consisting of 4 lipid components.
215070990|NCT06980272|DRUG|SSGJ-707|Subjects receive SSGJ-707 intravenously.
215070991|NCT06980272|DRUG|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
215070992|NCT01926041|DRUG|Varenicline for tobacco smoking cessation|The 16-week varenicline course conforms to real-practice government regulations in Taiwan.
214329018|NCT07085377|PROCEDURE|Individual semi directive interview|"Individual semi-directive interviews with a sample of patients from the DIADEME group (2 to 3 volunteer patients per CSAPA for a total of 20 to 30 interviews) will be conducted by a research psychologist and carried out at one month after the end of follow-up (3 months).~Themes covered will include: commitment to care, patient/professional relationship, understanding of follow-up and treatment, experience of care and services at the addictology center, satisfaction with services received, level of response to expectations).~Individual semi-directive interviews with a sample of healthcare professionals focus group will be also conducted by a research psychologist and carried out after the last patient has been included in the center. The aim will be to understand the effects of the intervention and identify its impact on professionals and the organization of the centers."
214329019|NCT07086534|DEVICE|GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System|"The GeminiOne TEER System consists of a TEER clip implant, transcatheter delivery system and a guide sheath.~The clip is made of cobalt-chromium-nickel alloy with a nickel-titanium alloy gripper, covered with a braided mesh of polyethylene terephthalate (PET) materials."
214329020|NCT07085234|DRUG|Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen|"Induction therapy: Albumin-bound paclitaxel 260 mg/m² + cisplatin 75 mg/m² (divided on days 1 - 3) + S1 calculated according to body surface area, taken twice daily (days 1 - 14) + Iparomlimab/Tuvorlimab(QL-1706) 5 mg/kg (day 1). One cycle lasts for 21 days, and the treatment continues for three consecutive cycles.~Concurrent chemotherapy: Cisplatin 80 mg/m², divided on days 1 - 3. One cycle lasts for 21 days, and the treatment continues for two consecutive cycles.~Radiotherapy regimen: Whole-course IMRT."
214329021|NCT06864624|DRUG|Sunvozertinib|Neoadjuvant stage: 300mg for 12 weeks Adjuvant stage: 300mg for first 4 weeks, then 150mg for up to 2 years
214329022|NCT06597487|PROCEDURE|Full pulpotomy|"The patients will receive full pulpotomy as follows:~-Under rubber dam isolation, the operator will perform caries removal, complete the access cavity preparation, achieve hemostasis from all canals, and apply the bioceramic material. The operator will seal the cavity with glass ionomer restoration."
214329023|NCT06597487|PROCEDURE|Conventional root canal treatment|The patients will receive conventional root canal treatment, which is the gold standard treatment protocol in cases with irreversible pulpitis.
214930728|NCT04944810|PROCEDURE|Mangetic General Surgery|Use the magnetic grasper to do the gallbladder retraction in cholecystectomies and upper retraction of the stomach to close the defect on hiatal hernia cases.
214930729|NCT04747067|DEVICE|BIOPURE 260HF dialyzer|Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)
214930730|NCT05212324|PROCEDURE|widening of first web space|widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
214930731|NCT01489124|DRUG|Imipenem|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
214930732|NCT01489124|DRUG|Imipenem|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
214930733|NCT01489124|DRUG|Imipenem|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
214329024|NCT07085312|PROCEDURE|Exosome-Enriched IVF Culture|IVF culture media supplemented with 10 µg per well of GMP-certified exosomes (Exosmart or equivalent). Retrieved MI oocytes are cultured in this media for up to 4 hours to assess progression to MII.
214673391|NCT02484261|DRUG|Bortezomib|1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
214930734|NCT00373958|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
214930735|NCT00373958|BIOLOGICAL|7vPnc pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
214930736|NCT00591058|DRUG|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
214930737|NCT05540041|OTHER|Bubble breathing play therapy group|The efficacy of bubble breathing play therapy in the preoperative anxiety children and their parent.
214930738|NCT05540041|OTHER|Tell-show-do play therapy group|The efficacy of tell-show-do play therapy in the preoperative anxiety children and their parent.
214930739|NCT05540041|OTHER|No intervention|Routine nursing care
215070993|NCT01926041|BEHAVIORAL|Individualized counseling about both smoking cessation and weight control techniques|The FIT2 program also offers behavior coaching in diet and physical activity to restrict post-cessation weight gain, which is not covered in conventional smoking cessation services.
214673392|NCT02484261|DRUG|Pravastatin|10 mg for age \< 8 years, 20 mg for age 8-\<13 years, 40 mg for ages \>14 years
214673393|NCT02988986|DRUG|TAK-228|MTORC1/2 inhibitor
214673394|NCT02988986|DRUG|Tamoxifen|Non-steroidal anti-estrogen
214930740|NCT03375879|DEVICE|Bandage contact lens|Bandage contact lens
214930741|NCT06622551|DIETARY_SUPPLEMENT|Iron-folic acid supplement|The major thing distinguishing this clinical study from another clinical trial is that we differentiate intervention based on nutritional status as we want to observe whether different nutritional status, especially overweight/obese will diminish the effect of IFA supplementation.
214930742|NCT05007041|BIOLOGICAL|FLUAD® Quadrivalent|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
215070994|NCT05547399|DRUG|Zanubrutinib|Administered orally as a tablet or capsule
214930743|NCT05007041|BIOLOGICAL|Fluzone® High-Dose Quadrivalent|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
214930744|NCT05007041|BIOLOGICAL|SHINGRIX®|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
214930745|NCT02743390|BIOLOGICAL|Infliximab|Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
215070995|NCT06604546|DRUG|hyaluronidase|150 IU group D1:150 IU hyaluronidase+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:150 IU hyaluronidase+250 ml Lactated Ringe's (LR)(Subject's left or right arm)； D3:150 IU hyaluronidase+500 ml Normal Saline (NS)(subject's left or right leg)； D4:150 IU hyaluronidase+1000 ml Lactated Ringer's (LR)(Subject's back)； 385 IU group D1:385 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:1500 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm).
215070996|NCT06604546|DRUG|Placebo|150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg)； 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
214930746|NCT02743390|OTHER|Saline|Saline for 2 hours (250mL)
214930747|NCT04887636|OTHER||
214930748|NCT05899075|OTHER|xylitol wipes|group A will receive xylitol wipes and group B will receive placebo wipes
214930749|NCT05899075|OTHER|placebo wipes|group A will receive xylitol wipes and group B will receive placebo wipes
214930750|NCT01552915|DRUG|Lisdexamfetamine dimesylate|Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
214930751|NCT01552915|DRUG|Methylphenidate Hydrochloride|Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
214930752|NCT01552915|DRUG|Placebo|Daily oral dosing in the AM for 8 weeks
214329025|NCT07086157|DIETARY_SUPPLEMENT|Probiotic|"A probiotic supplement in capsule form containing 4 strains of microorganisms, with a total of 10 × 10⁹ CFU (colony-forming units) per capsule. The strain composition per capsule was:~Lactobacillus acidophilus L1 - 2.9 × 10⁹ CFU, Bifidobacterium longum LBL-01 - 2.9 × 10⁹ CFU, Lactobacillus rhamnosus - 2.9 × 10⁹ CFU, Saccharomyces boulardii - 1.3 × 10⁹ CFU. Each participant in this arm took one capsule per day in the morning on a full stomach, for a duration of 4 weeks. No other dietary interventions were applied to this group. This probiotic supplement was chosen because the strains in its content are among the most frequently researched and known strains in terms of intestinal health. Additionally, it does not contain FOS or inulin due to FODMAP restriction.~."
214329026|NCT07086157|OTHER|Low-FODMAP Diet|A structured low-FODMAP diet intervention designed to restrict intake of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. The diet was individualized and monitored by a registered dietitian over a 4-week period to ensure adherence and nutritional adequacy.
214930753|NCT06315478|DRUG|Omeprazole 20 MG Oral Tablet|standard triple therapy for 14 days Bid for each drug
214930754|NCT06315478|DRUG|Amoxicillin 500Mg Tab|Quadruple regimen for 14 days Bid for each drug
214930755|NCT06315478|DRUG|Clarithromycin 500Mg Tab|Hybrid regimen, PPI and Amoxicillin for first 7 days then adding clarithromycin and metronidazole for the second 7 days
214930756|NCT03896711|BEHAVIORAL|MEMORI Corps program|Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.
214930757|NCT03896711|OTHER|Augmented Waitlist Control|"Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm."
215070997|NCT05810571|PROCEDURE|preoperative remifentanil consumption|continuous remifentanil infusion will applied for peroperative analgesia
214329027|NCT07086313|DRUG|EB-1020 (Centanafadine) low dose|low dose, capsule, oral, once daily, for 6 weeks
214329028|NCT07086313|DRUG|EB-1020 (Centanafadine) high dose|high dose, capsule, oral, once daily, for 6 weeks
214329029|NCT07086313|DRUG|Placebo|Placebo, capsule, oral, once daily, for 6 weeks
214329030|NCT07086417|PROCEDURE|Robot-Assisted Arthroscopic ACL Reconstruction|This intervention involves the use of a customized robotic surgical system to assist in arthroscopic anterior cruciate ligament (ACL) reconstruction. The system integrates preoperative planning with CT/MRI fusion imaging, intraoperative surgical guidance for femoral and tibial tunnel creation, and real-time biomechanical evaluation. The robot provides enhanced precision in tunnel positioning and graft placement compared to conventional techniques.
214930758|NCT03873415|DRUG|BMS-986165|Oral administration
214930759|NCT05720026|DRUG|SYSA1901|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
214930760|NCT05720026|DRUG|Pertuzumab|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
214930761|NCT05720026|DRUG|Trastuzumab|loading dose of 8 mg/kg IV, followed by 6 mg/kg IV, q3w/cycle, total 4cycle
214930762|NCT05720026|DRUG|Docetaxel|75 mg/m\^2 IV, q3w/cycle, total 4cycle
214930763|NCT01983072|DIETARY_SUPPLEMENT|Infant formula|
214930764|NCT01983072|OTHER|Breastfeeding|Breastfeeding
214930765|NCT00005072|BIOLOGICAL|Leuvectin|1000 ug of Leuvectin injected intratumorally
214930766|NCT01902758|DRUG|ambrisentan and theophylline|
214930767|NCT01902758|DRUG|placebo|placebo for comparison group
214930768|NCT02850016|DRUG|3BNC117|Intravenous Infusion of 3BNC117
214930769|NCT02850016|DRUG|Romidepsin|Intravenous Infusion of Romidepsin
214930770|NCT02987517|OTHER|Increased running cadence gait retraining|Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence
214930771|NCT02987517|OTHER|Forefoot Strike gait retraining|Runners use a forefoot strike running gait instead of a rear foot strike running gait.
214329031|NCT07086417|PROCEDURE|Conventional Arthroscopic ACL Reconstruction|This intervention uses standard arthroscopic techniques for ACL reconstruction without robotic assistance. Tunnel positions are determined manually using surgical landmarks and guides. Graft placement, tensioning, and isometry assessment are performed by the surgeon using conventional methods.
214329032|NCT06907381|BEHAVIORAL|Blood flow-restricted resistance exercise|Participants will engage in baseline measurement of blood pressure, strength of target muscle contractions, and level of support needed for functional task performance. They will then begin BFRE treatment supplemented by electrical stimulation, if needed, two times weekly. Each exercise session will include performance of four sets of 20 repetitions of target muscle contraction on each side of the body followed by functional task performance.
214329033|NCT06908070|DRUG|Consolidation durvalumab|Patients with initially unresectable stage III NSCLC will undergo surgery after chemoradiotherapy completion when the tumor is deemed resectable by the thoracic oncology tumor board and will then receive durvalumab
214329034|NCT07086469|DRUG|Neoadjuvant immunochemotherapy|Albumin-bound paclitaxel 260 mg/m² on day 1, cisplatin 25 mg/m² on days 1-3, and toripalimab 240 mg on day 1 of each 3-week cycle (q3w), for a total of 2 cycles.
214329035|NCT07086469|DRUG|Surufatinib Administration|Surufatinib 200 mg orally once daily (po, qd) on days 1-14, administered concurrently with immunochemotherapy. During radiotherapy, surufatinib will be administered at the start of each radiotherapy phase.
214329036|NCT07086469|DRUG|Concurrent Chemotherapy|Toripalimab 240 mg on day 1 of each 3-week cycle (q3w), starting one day prior to the initiation of radiotherapy. Weekly administration of albumin-bound paclitaxel 50 mg/m² and cisplatin 25 mg/m² on day 1 during the radiotherapy course.
214329037|NCT07086469|RADIATION|Radiotherapy|All patients will undergo thoracic intensity-modulated radiotherapy (IMRT), delivered once daily, 5 days per week, at a total prescribed dose of 50 Gy.
214329038|NCT05092165|DRUG|Methylene Blue|1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
214329039|NCT05092165|OTHER|Control|Usual care during renal replacement therapy
214329040|NCT06909188|OTHER|No intervention|No Intervention
214329041|NCT06917482|DRUG|BW-40202 injection|BW-40202 is a conjugate drug, dosage form is solution for injection and route of administration is subcutaneous injection
214329042|NCT06917482|OTHER|Sodium Chloride|Placebo (sodium chloride injection) will be administered as Subcutaneous injection
214930772|NCT02987517|OTHER|Strengthening exercises|foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
214930773|NCT05919914|OTHER|Exercise with Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric) with BFR. BFR involves the reduction of blood flow to working skeletal muscle by applying a flexible cuff to the most proximal portions of a person's arms or legs that results in decreased arterial flow to the exercising muscle and occluded venous return back to the central circulation.
214930774|NCT05919914|OTHER|Exercise without Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric)
214930775|NCT02946814|DRUG|essential oils|
214930776|NCT02946814|DRUG|essential oils without mouthwash|
215070998|NCT05810571|PROCEDURE|postopeartive controlled anlagesia with morphine|postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
214329043|NCT06912100|DIETARY_SUPPLEMENT|Placebo|Participants consume capsules containing only an inactive placebo (maltodextrin and magnesium stearate).
215070999|NCT06652386|OTHER|Telemedicine Group|"* Nursing-led lactation support via secure video conferencing platforms (e.g., Zoom for Healthcare).~* Scheduled sessions at postpartum days 1, 3, 7, and 14.~* Additional support available upon request."
215071000|NCT02601638|OTHER|Demographics and Health History Questionnaire|
215071001|NCT02601638|OTHER|Pre-Class Laryngectomy Survey|
215071002|NCT02601638|BEHAVIORAL|Counseling session with speech pathologist|
215071003|NCT02601638|BEHAVIORAL|Total Laryngectomy Preoperative Education Class|
215071004|NCT02601638|OTHER|Day of Hospital Discharge Laryngectomy Survey|
215071005|NCT02601638|OTHER|Day of Discharge Practicum|
214329044|NCT06912100|DIETARY_SUPPLEMENT|Probiotic|Participants consume capsules containing L. acidophilus (TW01) at 4×10\^10 CFU/capsule (three capsules daily, totaling 1.2×10\^11 CFU/day) plus a commercial fiber source (Fibersol-2).
214930777|NCT02946814|DRUG|sterile water|
214930778|NCT05959408|PROCEDURE|Collection of throat swab|Introduction of a cotton swab for self-collection
214930779|NCT05959408|PROCEDURE|Collection of anal swab|Introduction of a cotton swab for self-collection
214930780|NCT05959408|PROCEDURE|Collection of first void urine|first void urine collected on urine pot
214930781|NCT00525941|DRUG|NBI-34060|10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.
215071006|NCT02601638|OTHER|Laryngectomy Education Study Exit Survey|
215071007|NCT06660524|DRUG|Sevelamer|Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
215071008|NCT06660524|DRUG|Calcium carbonate|Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
215071009|NCT06659809|BEHAVIORAL|Tele-care video-feedback intervention (TVFI)|The TVFI 6 weekly sessions are organized in two subsequent phases: 4 sharing the focus sessions and 2 integration sessions. Sharing the focus sessions are dedicated to the discussion between the psychologist and the mother of specific themes related to parenting and parent-infant interaction: physical stimulation, responsiveness, teaching, and parenting experience. The goal of the sharing the focus sessions is to develop insights about the infants' behavioral signals, the best ways to provide stimulations and get in touch, strategies to promote emotion regulation, and to sustain cognitive and behavioral achievements. In the subsequent two integration sessions, the mother plays with the infant while the psychologist provides guidance based on topics previously discussed during the first four sessions. The goal is to promote a pragmatical translation of the insights developed during the sharing the focus sessions into the interactive exchanges between the mother and the infant.
214329045|NCT05505188|OTHER|Questionnaire|"Self-questionnaires are completed by the patient at the time of this consultation:~* Neuropathic pain: NPSI in screening~* Anxiety/depression: HADS in screening~* Quality of life: EORTC (QLQC30 and H\&N43)~* Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification.~Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain.~Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression.~Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report"
214329046|NCT06920134|DEVICE|ARC-IM Investigational System|Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
214930782|NCT02457832|BEHAVIORAL|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
214930783|NCT02457832|BEHAVIORAL|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
214930784|NCT02211690|DRUG|dolutegravir 50 mg (one tablet daily)|
214930785|NCT02211690|DRUG|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
214930786|NCT00423189|DRUG|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
214930787|NCT00423189|DRUG|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
214930788|NCT02546791|DRUG|Dasatinib|
214930789|NCT06621992|OTHER|Skills to Enhance Positivity|
214930790|NCT06621992|OTHER|Treatment as Usual|Participants received treatment as usual
214930791|NCT03826810|RADIATION|aPDT|For the aPDT the PapacarieMblue (Fórmula e Ação) was used. It was left for 5 minutes in the cavity. The carious tissue was removed and the application of the PapacarieMblue was repeated. The tissue was then irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ. These parameters were also applied in the vestibular root of the teeth, to try and prevent sensitivity.
214930792|NCT03826810|PROCEDURE|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
214930793|NCT01040936|DRUG|Atorvastatin|patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
214930794|NCT01040936|DRUG|Atorvastatin|patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
214930795|NCT00691899|DRUG|odanacatib|odanacatib; 5mg oral, once daily for Approximately 36 months.
214930796|NCT00691899|DRUG|placebo (unspecified)|placebo; oral, once daily for Approximately 36 months
214930797|NCT06621225|DEVICE|Artificial Intelligence|Medtronic GI Genius is an advanced AI-powered platform designed to assist gastroenterologists during colonoscopies. Utilizing deep learning algorithms, it analyzes real-time endoscopic images to detect and highlight polyps and other abnormalities, enhancing the detection rate and accuracy. The system provides visual cues to guide physicians in identifying potentially problematic areas that might be missed by the human eye alone. This technology aims to improve diagnostic precision, reduce missed detections, and ultimately enhance patient outcomes by facilitating earlier and more accurate interventions. GI Genius integrates seamlessly with existing endoscopy equipment, offering a valuable tool in the fight against colorectal cancer.
214930798|NCT06621225|DEVICE|Mucosal Exposure Device|The Olympus Endocuff is an innovative device designed to enhance the effectiveness of colonoscopy procedures. It is a soft, flexible cuff that attaches to the end of the colonoscope and features multiple protruding \&#34;fingers\&#34; that help to improve mucosal exposure. By providing better visibility and maneuverability, the Endocuff helps gastroenterologists navigate and inspect the colon more thoroughly. It aids in the detection of polyps and other abnormalities by flattening folds and improving the overall view of the colon lining. This enhanced visualization contributes to more accurate diagnoses and can potentially reduce the miss rate of significant lesions, ultimately leading to better patient outcomes.
215071010|NCT06658054|DRUG|Adjuvant analgesia|Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.
215071011|NCT06658054|DRUG|Control (Standard treatment)|Patient will receive standard ESPB with bupivacaine and normal saline
215071012|NCT06607224|DEVICE|Experimental (Decision making guided by CGM)|Patients use FSL2 and a smartphone. Libreview app will be used to assess interstitial glucose, alarms, and trend arrows, and LibreLinkUp app for research team. Concurrently, CG will be performed using the FreeStyle Optium Neo glucometer from Abbott. The nursing staff will be trained to manage and respond to alarms and trend arrows according to established protocols. The basal insulin adjustment protocol establishes with fasting and premeal targets between 140-180 mg/dL. For prandial insulin, corrective guidelines set according to each patient sensitivity factor, with additional adjustments for the intervention group based on trend arrows. The hypoglycemia alarm sets below 85 mg/dL. If activated, nursing staff will confirm the value via CG. If values are below 70 mg/dL, follow hypoglycemia protocol and if below 100 mg/dL with a descending trend arrow, 15 grams of slow-acting carbs. The hyperglycemia alarm will be set above 300 mg/dL and nurse inform investigators to make decisions.
215071013|NCT02373956|DEVICE|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
215071014|NCT02373956|PROCEDURE|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
214930799|NCT01930344|DEVICE|3D Laparoscopic visual system|Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
214329047|NCT05744375|DRUG|Trastuzumab deruxtecan|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
214930800|NCT01930344|DEVICE|2D Laparoscopic visual system|Standard 2D HD Laparoscopic Visual System
214930801|NCT04690725|DRUG|TQB3525|TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
214329048|NCT06924632|DRUG|Minoxidil|2.5 mg Sublingual Minoxidil Tablet
214329049|NCT06924632|DRUG|Placebo|Placebo
214930802|NCT03541330|OTHER|semi-directive interview|semi-structured interview conducted by a clinical psychologist
214930803|NCT01200732|DRUG|Tadalafil, placebo|20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
214930804|NCT05737017|DEVICE|ClearCoajet|The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure.
214930805|NCT03400709|DRUG|N Acetylcysteine|Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.
214930806|NCT03400709|DRUG|Placebo Oral Tablet|Placebo treatment
214930807|NCT03366766|BIOLOGICAL|Nivolumab|Given IV
214930808|NCT03366766|DRUG|Cisplatin|Given IV
215071015|NCT06658223|OTHER|Exercise with virtual reality|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
214930809|NCT03366766|DRUG|Pemetrexed Disodium|Given IV
214930810|NCT03366766|DRUG|Gemcitabine Hydrochloride|Given IV
214329050|NCT04424992|OTHER|Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.|Describe the natural history and clinical evolution of hospitalized patients over time affected by SARS-COV-2 infection, understand the pathogenesis of the disease and improve the aids and therapeutic procedures.
214930811|NCT04088279|DIAGNOSTIC_TEST|MRI|Oxygen enhanced and fourier decomposition MRI
215071016|NCT06658392|OTHER|cognitive tasks|no intervention in a medical sense, only observing changes of BOLD signal during different experimental conditions in cognitive tasks (arithmetic, attention, inhibition)
215071017|NCT06987604|DEVICE|High-dose continuous renal replacement therapy|Continuous renal replacement therapy administered at an effluent dose of 45-55 mL/kg/h using standard equipment and protocols for critically ill patients with ALF or ACLF and hyperammonemia.
215071018|NCT06987604|DEVICE|Conventional-dose continuous renal replacement therapy|Continuous renal replacement therapy administered at an effluent dose of 25-35 mL/kg/h using standard equipment and protocols for critically ill patients with ALF or ACLF and hyperammonemia.
214329051|NCT06932770|DIETARY_SUPPLEMENT|Food Supplement active|The food supplement active (2 soft gels) will be consumed once per day with a large glass of water.
214329052|NCT06932770|DIETARY_SUPPLEMENT|Food supplement placebo|The food supplement placebo (2 soft gels) will be consumed once per day with a large glass of water.
214329053|NCT06932770|OTHER|Skin care product active|The cosmetic skin care product active will be applied twice daily to half of the face and to one volar forearm.
214329054|NCT06932770|OTHER|Skin care product placebo|The cosmetic skin care product placebo will be applied twice daily to half of the face and to one volar forearm.
214930812|NCT03421145|DEVICE|3M™ Oral Rinse|The Investigational Rinse contains a sugar-based surfactant using a proprietary formula. The intended use of the product is to help prevent and reduce plaque accumulation on the teeth and related gum-tissue inflammation (gingivitis).
214930813|NCT03421145|OTHER|Vehicle Control Oral Rinse|The Placebo Comparator oral rinse is similar to the Experimental Oral Rinse only it does not contain the active ingredient.
214930814|NCT03421145|DEVICE|PerioShield™ Oral Health Rinse|PerioShield™ Oral Health Rinse (0.2% delmopinol hydrochloride) is marketed in the US and was purchased for use in this study.
214930815|NCT03421145|OTHER|Water|Purified bottled water containing no active ingredients.
214930816|NCT00552981|PROCEDURE|inhalation of warm air in a Finnish sauna|three times on three following days, each 2-3 minutes
214930817|NCT00552981|PROCEDURE|inhalation of ambient air in a Finnish sauna|three times on three following days, each 2-3 minutes
214930818|NCT03973918|DRUG|Encorafenib|450mg QD 28 day cycle
214930819|NCT03973918|DRUG|Binimetinib|45mg BID 28 day cycle
214930820|NCT03973918|BIOLOGICAL|Research Bloods|Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
214930821|NCT03973918|BIOLOGICAL|Tumor Tissue|at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides
214930822|NCT03826628|DRUG|rapamycin|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
214930823|NCT03826628|DRUG|placebo|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
214930824|NCT02357095|PROCEDURE|monitoring|uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
214930825|NCT05335447|DRUG|GLPG3667 capsule|On Day 1, participants will receive a single oral dose of GLPG3667
214329055|NCT06077097|GENETIC|Biological samples|This project also includes an auxiliary exploratory biological study of subcellular mechanisms, using high-throughput sequencing (Next Generation Sequencing, NGS) to identify gene expression variations in order to determine the resilience/vulnerability of the variables studied with respect to the DC experience (cytogenetics and transcriptome).
214329056|NCT05633966|DRUG|Kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)
214329057|NCT06937996|DEVICE|NanoKnife|The NanoKnife, System has been commercially available since 2009, and is FDA-approved to treat soft tissue tumors. The NanoKnife System has received FDA clearance for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.
214329058|NCT06938802|BEHAVIORAL|Sleep coaching|Participants will receive an 8-week sleep coaching program delivered by smartphone/tablet app
214329059|NCT06938802|BEHAVIORAL|Sleep education|Participants will receive electronic access to educational information about sleep for 8 weeks
214329060|NCT06937749|DRUG|Placebo|Placebo administered subcutaneously (SC) once a week.
214930826|NCT05335447|DRUG|[14C]-GLPG3667 solution for infusion|On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion
214329061|NCT06937749|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
214329062|NCT06940817|BEHAVIORAL|CHEF-ED + Food Delivery|CHEF-ED is a 7-week, digital, video-based parental intervention that teaches healthy cooking practices and an optimal way to involve children in home cooking. Each week features a video, infographics, and recipe content. The content is designed to be integrated into the home food environment without major changes to shopping habits. However, some basic culinary ingredients that are featured may not already be part of participating family pantry stocks. To support participants in effectively learning the healthy cooking strategies, participating families are provided a one-time home food delivery of non-perishable basic culinary ingredients and kitchen utensils, such as cooking oil, spices, whole wheat pasta, low sodium soy sauce, bowls.
214329063|NCT06940817|BEHAVIORAL|Food Delivery Only|The Food Delivery Only intervention involves participants receiving a one-time home food delivery of non-perishable basic culinary ingredients and kitchen utensils, such as cooking oil, spices, whole wheat pasta, low sodium soy sauce, bowls.
214329064|NCT06942455|BEHAVIORAL|SIESTA|Active condition
214930827|NCT05335447|DRUG|[14C]-GLPG3667 capsule|On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667
214930828|NCT03538977|PROCEDURE|Hydrotherapy|A re-sterilizable stainless steel bucket with an upper diameter of 30 cm, a depth of 32 cm, with water at a temperature between 37 and 38º Celsius will be used. The amount of water used will be sufficient to keep the baby submerged up to shoulder height. The baby will be immersed in the heated water of the bucket and will be suspended by occipital support performed by the physiotherapist, who alternates lateral-lateral and anteroposterior movements with only static suspension. The therapy will last from eight to ten minutes and will be discontinued if there is agitation, cyanosis, worsening respiratory distress or major evacuation. If the baby is using any type of ventilatory support or oxygen therapy, the same will be maintained during the procedure of hydrotherapy.
214930829|NCT03538977|PROCEDURE|Conventional Physiotherapy|Conventional physiotherapy consists of manipulations of Thoracoabdominal Rebalancing, a registered technique which uses simultaneous passive stretching of inspiratory muscles and stimulation of the diaphragm. The manipulation used to improve the dynamic diaphragm included the thoracic-abdominal and lower abdominal support maneuvers. Back repositioning was used to minimize posteriorization of the ribs and costal kyphosis due to thoracic distortion.
214930830|NCT02951533|DRUG|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.
214930831|NCT02951533|DRUG|Fumaric Acid Esters|Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.
214930832|NCT05306782|DEVICE|transcranial Electrical Stimulation|transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).
214930833|NCT05306782|BEHAVIORAL|Speech Therapy|Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes
215071019|NCT06611969|PROCEDURE|Exercise|The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility, plus specific training of the inspiratory muscles, 3 times a week, at a load between 50 and 80% of the maximum inspiratory pressure of each participant, after re-education of their diaphragmatic ventilation.
215071020|NCT06611969|PROCEDURE|Exercise|The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility.
215071021|NCT06608134|BIOLOGICAL|Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection|Direct injection of biologic into the knee joint.
215071022|NCT06857214|DRUG|GNC-038|Administration by intravenous infusion. Once a week (IV, QW), twice in total.
215071023|NCT06857214|DRUG|Placebo|The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.
215071024|NCT06606522|DIAGNOSTIC_TEST|Clinical model|Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
215071025|NCT06606522|DIAGNOSTIC_TEST|Urinary biomarkers|Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
215071026|NCT06861010|OTHER|Placebo|Placebo tablets will have the same look and appearance of ondansetron.
215071027|NCT06861010|DRUG|Ondansetron|ondansetron is commonly used as anti-emetics to prevent and treat chemotherapy-induced vomiting and nausea
215071028|NCT06865768|DRUG|Flotufolastat F-18 Gallium|Given IV
215071029|NCT06865768|PROCEDURE|Magnetic Resonance Imaging|Undergo TRUS-MR fusion biopsy
214329065|NCT06942455|BEHAVIORAL|Sleep education and health education control|Attention Control
214673395|NCT03925844|OTHER|Classification according to the cardiovascular risk|All patients are cognitively assessed at the beginning of the study and their cardiovascular risk is calculated. After 5 years of follow-up, patients are re-evaluated cognitively and their cardiovascular risk is recalculated.
215071030|NCT06865768|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
215071031|NCT06865768|PROCEDURE|Positron Emission Tomography|Undergo PET
214329066|NCT05559320|DEVICE|Ride-on-toy navigation training|The training program will involve a set of activities where children will be encouraged to drive a joystick-operated ride-on-toy to navigate through their physical environment. The training will involve will involve progressively challenging multi-directional navigational games such as shape mazes, treasure hunts, relay races, and obstacle courses that will require children to use their affected arm skillfully to navigate through the courses.
214329067|NCT05559320|BEHAVIORAL|Upper extremity functional training|In addition to the navigation practice, along the multi-directional courses, children will complete tasks at multiple stations that will involve both gross and fine motor activities. The goal of the training will be to use their arm for functional goal-directed tasks and games that will involve elements of reaching, grasping, in-hand manipulation, and release. We will use props such as balls, bean bags, cups, cones, and small toys to practice skills such as catching, throwing, picking up, pushing, pulling, opening, closing, etc.
214329068|NCT05568550|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
214930834|NCT03376451|OTHER|Assessment of endometrium and blood biomarkers for endometriosis diagnosis|Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
214930835|NCT03101826|BEHAVIORAL|Listening Project Protocol|The filtered music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
214930836|NCT03338803|DRUG|Linagliptin|drug
214930837|NCT03887507|OTHER|Vojta Therapy|Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling reflex, and 1st phase and 2nd phase Rolling reflex.
214930838|NCT03887507|OTHER|Standard Program|The program consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept.
214930839|NCT06117501|DEVICE|Axoguard HA+ Nerve Protector™|Axoguard HA+ Nerve Protector™ is a surgical implant that provides non-constricting protection for non-transected peripheral nerve injuries where there is no gap. Axoguard HA+ Nerve Protector™ is designed to be an interface between the nerve and the surrounding tissue.
214930840|NCT06330792|OTHER|bio-mechanical awareness|Biomechanical awareness advices for physiotherapists during session: consist of group of awareness advices and McKenzie extension part method exercises to help physiotherapist working in correct position and consume his energy.
214930841|NCT06330792|OTHER|core stability exercises|Core stabilization exercise Program: The procedure for core stabilization exercises to improve core muscles in lumbar area
214930842|NCT05870956|DRUG|Nintedanib|Nintedanib
214930843|NCT02006797|OTHER|reconciliation|medication reconciliation at discharge and communication of this intervention to patient's community pharmacist
214930844|NCT06166745|DEVICE|Sensi-IP toothpaste|Brushing daily with the Sensi-IP toothpaste for 14 days for dentinal hypersensitivity.
214329069|NCT05568550|DRUG|Olaparib|200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
214329070|NCT05568550|DRUG|Androgen Deprivation Therapy|Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
214329071|NCT05568550|RADIATION|Radiation Therapy|Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
214329072|NCT06952426|OTHER|No intervention|Participants and their caregivers will report home reported outcomes (HRO) data on symptom burden to understand symptom variability and health-related quality of life (HRQoL).
214329073|NCT06952426|OTHER|Other treatment|Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL.
214329074|NCT06952426|OTHER|Iptacopan|Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking iptacopan.
214329075|NCT06952426|OTHER|Atrasentan|Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking atrasentan.
214930845|NCT06166745|DEVICE|Sodium Fluoride Toothpaste|Brushing daily with the Sodium Fluoride toothpaste for 14 days for dentinal hypersensitivity.
214930846|NCT03724877|DRUG|Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)|(LABA-LAMA-ICS)
214930847|NCT03724877|DRUG|Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)|(LABA-LAMA)
215071032|NCT06865768|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo TRUS-MR fusion biopsy
214930848|NCT01446237|OTHER|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
214930849|NCT04737798|OTHER|oil pulling with coconut oil|using oil pulling therapy with coconut oil
214930850|NCT04737798|OTHER|oil pulling with sesame oil|using oil pulling therapy with sesame oil
215071033|NCT07009418|DIAGNOSTIC_TEST|Coronary CT Angiography (CCTA)|In the surveillance by CCTA group, patients will be evaluated by CCTA at 1 year from index hospitalization. CCTA will be done according to current acquisition guidelines. Downstream management according to the results from CCTA will be performed under recommendations from current guidelines.
214329076|NCT06949735|DIETARY_SUPPLEMENT|Digestive Enzyme Blend|Oral
214329077|NCT06949735|DIETARY_SUPPLEMENT|Placebo|Oral
214329078|NCT06409494|BIOLOGICAL|EuHZV|Drug(injection)
214329079|NCT06409494|BIOLOGICAL|Shingrix|Drug(injection)
214930851|NCT06666153|BIOLOGICAL|EBV immunological agent|"27 participants with will be enrolled in the study and divided into three groups, including EBV-LPD (Adults group), EBV-LPD (Children group) and PTLD (Adults group） each with 9 people.The participants will be divided into three different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^5, the medium dose is 2.0×10\^6 and the high dose is 5.0×10\^6 for children and low dose is 5.0×10\^6, the medium dose is 2.0×10\^7 and the high dose is 5.0×10\^7 for adults. Only one dose will be administered to each participant with EBV immunological agent combined with Toripalimab 240mg."
214930852|NCT00611845|DRUG|Aprotinin (Trasylol, BAYA0128)|Trasylol at either 1,000,000 KIU or 2,000,000 KIU
214930853|NCT04535531|DRUG|SB206 10.3% berdazimer|Topically once daily
214930854|NCT04535531|DRUG|vehicle gel|Topically once daily
214930855|NCT04724343|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
214930856|NCT04724343|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
214930857|NCT04724343|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
214930858|NCT04724343|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
214930859|NCT04203992|BEHAVIORAL|Videogame|"True Champion is an educational, values-based game that aims to empower young athletes to make informed decisions to avoid doping.~Participants engaging in the videogame sessions will encounter a series of thought-provoking situations and knowledge tests. Players will help their assigned character navigate through these curriculum-rich scenarios in order to reach their performance goals in a healthy and ethical way."
214930860|NCT04203992|BEHAVIORAL|Control|Participants will be given an anti-doping booklet prepared by UNESCO. This booklet is considered standard educational material, i.e. what might be presented to young athletes as part of their regular sports curriculum.
214930861|NCT00591617|OTHER|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
214930862|NCT06339164|OTHER|skills and learning quality in breech delivery|evaluation of different skill retention and learning quality after different learning methods
214930863|NCT00630721|OTHER|IFNbeta-1b|no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
214930864|NCT00742508|DRUG|SK&F-105517-D 10 mg capsule|1 capsule once a day
214930865|NCT00742508|DRUG|Carvedilol-immediate release (IR) 2.5 mg tablet|1 or 2 tablet(s) twice a day
215071034|NCT06504329|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT) + Subepithelial Connective Tissue Graft (SCTG)|The modified coronally advanced tunnel (MCAT) technique is performed to prepare a recipient site. A subepithelial connective tissue graft (SCTG), harvested from the palate, is inserted into the tunnel using guiding sutures and stabilized. The flap is advanced coronally to completely cover the graft and achieve primary closure.
215071035|NCT06504329|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT) + Enamel Matrix Derivative (EMD)|This intervention involves the application of enamel matrix derivative (EMD; Emdogain, 0.15 ml gel form) in conjunction with the modified coronally advanced tunnel (MCAT) technique. Following tunnel preparation, EMD is applied to the exposed root surface to enhance periodontal tissue regeneration.
214329080|NCT04317989|OTHER|Practice Facilitation|"1. Implementing evidence-based protocols and the use of clinical algorithms (for screening, counseling, referral, and MAT) to engage the entire clinical team in a high standard delivery of care.~2. Promoting a strong use of decision support tools and templates to support the practice workflow.~3. Optimizing the use of the electronic health record (EHR) to pull clinical data on a monthly basis to guide the change process.~4. Developing patient registries (e.g., for those identified to have AUD) to identify needed care~5. Proactive, team-based care with assigned roles and responsibilities to prepare the clinical team to develop needed care and engage patients throughout the entire visit process.~6. Enhancing the understanding of available counseling and referral resources to ensure that practices are confident that they have appropriate evidence-based intervention options."
214329081|NCT02373124|DRUG|infusion of NMDA antagonist|52 minute infusion
214329082|NCT04809129|DEVICE|Weighted vest|Patients will wear a weighted vest following bariatric surgery with weight increased incrementally to maintain baseline weight. This vest will be worn for a minimum of 8 hours a day for three months postoperatively.
214930866|NCT00742508|DRUG|SK&F-105517-D 20 mg capsule|1 capsule once a day
214930867|NCT00742508|DRUG|SK&F-105517-D 40 mg capsule|1 or 2 capsule(s) once a day
214930868|NCT00742508|DRUG|Carvedilol-IR 10 mg tablet|1 tablet twice a day
214930869|NCT01952119|OTHER|Secure message reminder|Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
215071036|NCT07011654|DRUG|Sacituzumab govitecan|Given by IV
215071037|NCT07011654|DRUG|Naxitamab|Given by IV
215071038|NCT07012772|DEVICE|The COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
215071039|NCT07012954|DRUG|Cetuximab (Erbitux, C225)|cetuximab 500 mg/m² repeated every two weeks.
215071040|NCT07012954|DRUG|trifluridine/tipiracil|Trifluridine/tipiracil 35 mg/m² (orally for 5 days, followed by 9 days off)
215071041|NCT07012954|DRUG|Bevacizumab ( Avastin)|bevacizumab 5 mg/kg
214930870|NCT02269410|DIETARY_SUPPLEMENT|GBP-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
214930871|NCT02269410|DIETARY_SUPPLEMENT|GBP-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
214930872|NCT02269410|DIETARY_SUPPLEMENT|VSG-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
214930873|NCT02269410|DIETARY_SUPPLEMENT|VSG-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
214930874|NCT03942068|DRUG|albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor
214930875|NCT03942068|DRUG|Apatinib|a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)
214930876|NCT03481374|DIAGNOSTIC_TEST|autonomic function testing|"autonomic function testing, ergospirometry, three questionnaires~Other Names:~* The autonomic function tests consist of five tests:~  * The Valsalva maneuver~ * The isometric handgrip test~ * The deep breathing test~ * The cold pressor test~ * A short head-up tilt test~* A maximal ergospirometry~* Three questionnaires:~  * EQ-5D-3L: quality of life~ * IPAQ: capacity to do physical activities"
214930877|NCT04017832|DRUG|Oral semaglutide|Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
214930878|NCT04017832|DRUG|Sitagliptin|Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
214930879|NCT04017832|DRUG|Placebo (oral semaglutide)|Placebo tablet to be taken first thing in the morning
214930880|NCT04017832|DRUG|Placebo (sitagliptin)|Placebo tablet to be taken 30 minutes after oral semaglutide
214930881|NCT03633149|BEHAVIORAL|Computer tablet-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered on a computer-tablet.
214930882|NCT03633149|BEHAVIORAL|Person-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered by a counselor.
214930883|NCT03633149|BEHAVIORAL|Brief Advice|Brief advice delivered by a research associate about healthy behaviors for women including use of contraception and alcohol, tobacco, and marijuana use
214930884|NCT06620783|BEHAVIORAL|exercise|Those in the exercise program group will access and undertake the exercise program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
214930885|NCT06620783|BEHAVIORAL|yoga|The yoga program group will access and perform the yoga program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
214930886|NCT06620783|BEHAVIORAL|active self-care|The self-care group will access materials helpful for stress management via a web or mobile platform and engage in self-study three times a week, for a total of 12 sessions over 4 weeks.
214930887|NCT04829032|PROCEDURE|Hartmann's procedure|Hartmann's procedure
214930888|NCT06038461|DRUG|Surufatinib Combined With Temozolomide and S-1|"Phase I:~Surufatinib: 250mg, QD, PO, Q3W; Temozolomide: 200-300mg, d10-d14, QD, PO, Q3W; S-1: 40-60mg, d1-d14, BID, PO, Q3W.~Phase II:~Surufatinib, Temozolomide and S-1：RP2D"
214930889|NCT04441957|DEVICE|Endovenous Mechano- Chemical Ablation|The Flebogrif™ catheter (Balton® Sp. z o.o., Warsaw, Poland) represents endoluminal Non Thermal Non Tumescent devices designed to cause occlusion (fibrosis) of the target vein through the combined mechanical and chemical damage to its endothelial lining with retractable cutters and foamed sclerosant.
214930890|NCT06665854|BEHAVIORAL|Rhythmic Song Group|The rhythmic song group will first click on the start button on the mobile application. When starting the application to stimulate the baby, a bell will ring, and the baby movements will be coded as present/absent via the mobile application; then they will sing a rhythmic song and recode the baby movements as present/absent via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
214930891|NCT06665854|BEHAVIORAL|Rhythmic Instrument Group|The Rhythmic Instrument Group will first click on the start button on the mobile application. Then, they will ring a bell to start the application to warn the baby, and they will code the baby's movements as present/absent via the mobile application; then they will play a rhythmic instrument and code the baby's movements as present/absent via the mobile application again. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
215071042|NCT07014891|DEVICE|Intelligent Visual Feedback Motor Control Training|Patients receive motor control training using the intelligent training system (Monitored Rehab Systems B.V., 2031 CW Haarlem, The Netherlands). The Monitored Rehab Systems-Functional Squat is selected for lower - limb motor control training. The patient assumes a supine position, with both feet fixed at the correct position on the pushing - training board. The relative position of the patient can be displayed on the computer screen. The system represents the degree of joint flexion and extension and the duration of muscle contraction through the height, length, and size of images, while the speed of moving images reflects the speed of joint movement during exercise. Patients complete various simulated actions through interactive video games. During the training, the load of exercise training can be adjusted according to the patient's functional status and tolerance. The training is conducted once a day, 20 minutes per session, five times a week, for a total of four weeks.
214329083|NCT05505630|DRUG|Ketamine|A single dose of IV ketamine will be administered.
214329084|NCT05505630|DRUG|Midazolam|A single dose of IV midazolam will be administered
214329085|NCT05505630|DRUG|Dexmedetomidine|A single dose of IV dexmedetomidine will be administered
214930892|NCT06665854|BEHAVIORAL|Control Group|"Control Group will first code Start via the mobile application. Then, a bell will ring to warn the baby, they will code the baby's movements as present/absent via the mobile application again and will only rest. When the application is over, all pregnant women will code Finish via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week."
214930893|NCT06668766|DEVICE|10-cm Single Lumen Mildine|Arm Description: The BD Powerglide Pro Midline catheter is currently approved for use by the FDA and by Albany Medical Center. This 18-gauge or 20-guage MC is distinct in that it is a standard 10-cm, does not require premeasurement or trimming of the catheter prior to placement, and features an accelerated Seldinger technique, meaning that it has a built-in deployable internal wire system. Additionally, because it is only 10-cm, it does not require a confirmatory chest x-ray prior to use. The provider will use standard aseptic technique for placing the MC (e.g., chlorhexidine prep, sterile probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number from the randomization packet to allow for vessel depth and size measurement.
214329086|NCT05505630|DRUG|Saline|A single dose of IV saline will be administered
214329087|NCT04473040|DRUG|alpelisib|Alpelisib is provided as 50 mg and 200 mg film coated tablets as individual patient supply, packaged in bottles. Alpelisib will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. Alpelisib will be administered at a starting dose of 300 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.
214329088|NCT06146387|DIETARY_SUPPLEMENT|Investigational Formula|Participants in this arm will receive stage 1 and stage 2 investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
214329089|NCT06146387|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
214329090|NCT06146387|DIETARY_SUPPLEMENT|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
214930894|NCT06668766|DEVICE|4.78 cm Long Peripheral Intravenous Catheter|The BD Insyte Autoguard 4.78 cm 18- or 20-gauge needle with self-retraction is currently approved for use by the FDA and by Albany Medical center. The long PIV will be placed using standard aseptic technique (e.g., chlorhexidine prep, sterile gloves, sterile ultrasound probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number in the comments section of the QPATH worksheet to allow for vessel depth and size measurement. Operators will be instructed to use standard techniques in US-guided vascular access.
214930895|NCT06684600|DRUG|Dalpiciclib + Pyrotinib|Dalpiciclib Isethionate tablets, 125mg, oral administration on days 1 to 21, followed by a 7-day drug holiday, every 4 weeks; Pyrotinib Maleate tablets, 320mg, oral administration once daily on days 1 to 28, every 4 weeks; Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, or the investigator determines that the subject should discontinue study treatment.
214930896|NCT05709951|OTHER|Functional Exercises|The patients were requested to perform these functional exercises for 4 days per week three times for 20 min (8 weeks).
214930897|NCT05709951|OTHER|Core Stability Exercises|The patients were requested to perform 4 core strengthening exercises for 4 days per week three times for 20 min (8 weeks)
214930898|NCT05019846|DRUG|Triptorelin Embonate|single administration before SRT starting
214930899|NCT05019846|DRUG|Bicalutamide 50 mg|1 dose each day, 7 days before LHRH until 10 days after LHRH administration
214930900|NCT03195725|OTHER|Review of notes|No intervention will occur
214930901|NCT02046395|DRUG|amlodipine, hydralazine, terazosin or hydrochlorothiazide|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
214930902|NCT02408289|DIETARY_SUPPLEMENT|Lo-Flav|low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage.
214930903|NCT02408289|DIETARY_SUPPLEMENT|Hi-Flav|High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
214930904|NCT02408289|DIETARY_SUPPLEMENT|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage
214930905|NCT02408289|DIETARY_SUPPLEMENT|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
214930906|NCT03283293|RADIATION|Target Volume Delineation after NACT|The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) were delineated in accordance with the head and neck magnetic resonance imaging (MRI) and endoscopy, which obtained two weeks after the last cycle of NACT. The first clinical target volume (CTV1) was defined as the GTVnx plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the high-risk sites of microscopic extension, the whole nasopharynx, and the location and extent of the primary tumor before NACT. The second clinical target volume (CTV2) was defined as the CTV1 plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the low-risk sites of microscopic extension, the level of the lymph node located before NACT, and the elective neck area. The prescribed dose to GTVnx, GTVnd, CTV1 and CTV2 were 68Gy/30f, 62-66Gy/30f, 60Gy/30f and 54Gy/30f, respectively.
214930907|NCT04257032|DRUG|Rosuvastatin|Tablet
214930908|NCT04257032|DRUG|Rosuvastatin + BI 1323495|Tablets
214930909|NCT04257032|DRUG|Dabigatran etexilate|Capsule
214329091|NCT00368940|BEHAVIORAL|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
214329092|NCT00368940|BEHAVIORAL|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
214329093|NCT03992326|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
214329094|NCT03992326|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
214329095|NCT03992326|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
214329096|NCT03992326|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
214930910|NCT04257032|DRUG|Dabigatran etexilate + BI 1323495|Capsule and tablets
214930911|NCT03560726|BEHAVIORAL|Cognitive Behavioral Stress Management|Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
214930912|NCT04406584|PROCEDURE|Injection into olfactory cleft|Already stated above.
214930913|NCT00868725|OTHER|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
214930914|NCT01901653|DRUG|Rovalpituzumab tesirine (SC16LD6.5)|
214930915|NCT05029128|BEHAVIORAL|Endurance exercise intervention|All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.
214930916|NCT02091986|DRUG|Symbicort pMDI|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
214930917|NCT02091986|DRUG|Symbicort pMDI|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
214930918|NCT02091986|OTHER|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
214930919|NCT00751504|DRUG|Quetiapine|Dosage form: tablets Dosage: between 300 mg/die and 600 mg/die Frequency: once daily Duration: 6 weeks
214930920|NCT01558440|DIETARY_SUPPLEMENT|Infant Formula|A diet that is being fed to the young infants.
214329097|NCT03992326|OTHER|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
214329098|NCT03269279|DRUG|Mifepristone|Medication used in conjunction with misoprostol for abortion
214930921|NCT01558440|DIETARY_SUPPLEMENT|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
214930922|NCT01558440|DIETARY_SUPPLEMENT|Diluted F-100|300 ml of water is added to 1000 ml of f-100
214930923|NCT03792100|DRUG|SmofKabiven emulsion for infusion|Total Parenteral Nutrition
214930924|NCT03792100|DRUG|"Hospital compounded All in one emulsion"|Total Parenteral Nutrition
214329099|NCT03269279|DRUG|Misoprostol|Medication used in conjunction with mifepristone for abortion
214930925|NCT04616573|DEVICE|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
214930926|NCT04616573|DEVICE|iStent inject|Trabecular meshwork implantation
214930927|NCT00957268|DRUG|Alogliptin|Alogliptin tablets
214930928|NCT03887026|DRUG|Norketotifen|Norketotifen oral capsule
214930929|NCT03887026|DRUG|Placebo|Placebo oral capsule
214930930|NCT00794040|DRUG|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
214930931|NCT00794040|DRUG|Add-on placebo following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
214930932|NCT02348801|BEHAVIORAL|Weight loss and Exercise|"Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~Exercise sessions of \~90 min duration 15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and, after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months."
214930933|NCT02348801|BEHAVIORAL|Healthy lifestyle|Diabetes support and education
214930934|NCT06078267|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
214930935|NCT04778943|OTHER|Surgery(OLIF and MIS-TLIF)|oblique lateral interbody fusion (OLIF); minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
214930936|NCT04482998|OTHER|No intervention - retrospective study|No intervention - retrospective study
214930937|NCT05236374|OTHER|Beef protein|Animal protein source
214930938|NCT02396420|DEVICE|Embosphere Microspheres|
214930939|NCT01273623|DEVICE|Jetstream Atherectomy System|to perform atherectomy on calcified lesions
214930940|NCT04064411|COMBINATION_PRODUCT|abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
214930941|NCT04064411|COMBINATION_PRODUCT|abaloparatide solid microstructured transdermal system|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto a sMTS array for transdermal administration of abaloparatide.
214930942|NCT05045027|PROCEDURE|Biospecimen Collection|Undergo collection of tissue samples
214930943|NCT05045027|PROCEDURE|Diagnostic Imaging|Undergo multinuclear metabolic imaging
214930944|NCT05045027|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214930945|NCT00296946|DRUG|ipratropium bromide (drug)|
214930946|NCT02433821|OTHER|Pilates|
214329100|NCT02694991|OTHER|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
214329101|NCT03290508|DIAGNOSTIC_TEST|Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
214930947|NCT05698979|DRUG|BOTOX INJECTION|"The patient will be treated with a single session with botulinum toxin A injections at the hospital, and the judgmental criteria will be assessed at 1, 3 and 6 months post injections.~The injections will be made in 4 injection points at the palmar or distal plantar fold, at the level of the neurovascular beams, 2h after topical anesthesia by lidocaine cream under occlusion, associated or not with nitrous oxide inhaled at the time of the injections (BOTOX® 100 U).~In the event of multiple lesions, a single limb is injected based on clinical severity (ulcer, gangrene) and ischemia parameters (lowest TCPO2)."
214930948|NCT06301607|DEVICE|Intermittent Oro-esophageal Tube Feeding|The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214930949|NCT06301607|DEVICE|Nasogastric Tube|The group is given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
215071043|NCT07014891|DEVICE|Bobath Ball Training|Bobath Ball Training Specific operations include: ① In the supine position, the heel controls the ball to move back and forth; ② In the supine position, both feet step on the ball to perform stepping movements, etc. The training is conducted 1 session daily, 20 minutes per session, 5 days per week, for a total of 4 weeks.
215071044|NCT07016386|PROCEDURE|Group A: will receive an ultrasound-guided interscalene block (ISB)|Group A: will receive an ultrasound-guided interscalene block (ISB) using a 15ml mixture of lidocaine (7.5ml 2%) and bupivacaine (7.5ml 0.5%).
215071045|NCT07016386|PROCEDURE|Group B:will receive an ultrasound-guided infraspinatus-teres minor (ITM) interfacial plane block|Group B:will receive an ultrasound-guided infraspinatus-teres minor (ITM) interfacial plane block using a 15ml mixture of lidocaine (7.5ml 2%) and bupivacaine (7.5ml 0.5%).
215071046|NCT03111550|DEVICE|Investigational Intraocular Lens Device #1: TECNIS Model ZHR00|Intraocular lens replaces the natural lens removed during cataract surgery.
215071047|NCT03111550|DEVICE|Investigational Intraocular Lens Device #2: TECNIS Model ZQR00|Intraocular lens replaces the natural lens removed during cataract surgery.
215071048|NCT03111550|DEVICE|TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00|Intraocular lens replaces the natural lens removed during cataract surgery.
214329102|NCT05226104|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated twice over the affected areas, once each month for a total of two months.
214329103|NCT00678600|OTHER|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
214329104|NCT00678600|OTHER|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
214329105|NCT01312545|DEVICE|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
214329106|NCT01312545|DEVICE|Medpor|commercial porous polyethylene
214329107|NCT03058731|DEVICE|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
214329108|NCT03058731|DEVICE|Control|Paraesophageal hernia repair with other biologic mesh
215071049|NCT07013656|OTHER|L-tryptophan|L-tryptophan, an aromatic amino acid and one of the building blocks of protein, is a part of our daily diet. The load of L-tryptophan (0.1 kcal/minute) is based on our previous study, in which L-tryptophan represented a submaximal load.
214329109|NCT02564198|DRUG|Ramucirumab|Administered IV
214930950|NCT06301607|BEHAVIORAL|comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214930951|NCT05452499|OTHER|Pain neuroscience education and therapeutic exercise|Participants will receive a 9-week physiotherapy program. Consisting of 3 sessions of pain neuroscience education and 24 sessions of therapeutic exercise (16 face-to-face sessions and 8 at home).
214930952|NCT02779699|DRUG|AL2846|AL2846 p.o. qd
214930953|NCT01290978|DRUG|ChloraPrep|The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
214930954|NCT01290978|DRUG|DuraPrep|The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
214930955|NCT06662487|BEHAVIORAL|Resistance Training|Participants in the experimental group will perform free weight resistance training sessions focused on push, pull, and leg movement patterns. The program will last for 10 weeks, progressively increasing in load and intensity. The intervention will be designed to improve the participants' physical strength and observe how these changes affect their cognitive performance.
214930956|NCT03215511|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
214930957|NCT02342197|DRUG|Decapeptyl|half the dose of Gn agonist
214930958|NCT01746420|DRUG|rhPDGF-BB Injection|Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
214930959|NCT01746420|DRUG|Placebo|sodium acetate buffer (0 mg rhPDGF-BB)
214930960|NCT03088046|DRUG|Micronized Progesterone|"Anovulatory women with Polycystic ovary syndrome and clinical hyperandrogenism attended in our Hospital will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study.~Blood samples will be collected at baseline (Sample #1) and between the 3rd and the 5th day of withdrawal after 7 days of 100mg vaginal MP every 12 hours of administration(Sample#2)."
214329110|NCT03777124|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous every 2 weeks
214329111|NCT03777124|DRUG|Apatinib|Subjects receive Apatinib orally every day
214329112|NCT03777124|DRUG|Pemetrexed|Subjects receive Pemetrexed intravenous every 3 weeks
214329113|NCT03777124|DRUG|Carboplatin|subjects receive carboplatin intravenous every 3 weeks
214329114|NCT00225355|DRUG|Rosiglitazone|
214329115|NCT06532201|OTHER|Su jok seed therapy|Su Jok will be applied to the reflection points on the hand based on the painful area of the individual. The painful areas will be determined with the applicator and black pepper seeds will be placed on these areas. Circular massage will be applied to the areas where the seeds are located for 30 minutes.
214329116|NCT00824863|DRUG|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
214329117|NCT04385602|DRUG|Intratracheal dexmedetomidine|Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
214329118|NCT04385602|DRUG|Saline Solution|Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
214329119|NCT01440322|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
214329120|NCT01440322|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
214329121|NCT04835402|DRUG|Pembrolizumab|400mg every 6 weeks
214329122|NCT04835402|DEVICE|Irreversible electroporation|Percutaneous ablation of one liver metastasis
214930961|NCT05173168|DIETARY_SUPPLEMENT|Probiotic Dietary Supplement|Probiotic dietary supplement containing 3 probiotic strains and 3 herbal extracts
214930962|NCT00489905|DRUG|Zolderonic acid (Zometa)|
214930963|NCT01945853|DEVICE|7 Tesla MRI|
214930964|NCT06287827|PROCEDURE|Simplified protocol|"MUAC-based dosing:~* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets Ready to use Therapeutic Food (RUTF)/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day)."
214930965|NCT06287827|PROCEDURE|Standard protocol|"Weight-based dosing~* SAM: Mid-upper-arm circumference (MUAC) \<115mm or Weight-Height/length Z Score \<-3 or mild or moderate bipedal oedema: 150-185 kcal/kg/day is offered using RUTF until the patient passes to MAM and then the dose is reduced to 100 -130 kcal/kg/day using RUTF until recovery.~* MAM: MUAC 115-\<125mm or Weight-Height/length Z Score \<-2: 100-130 kcal/kg/day is offered using RUTF until recovery."
214930966|NCT03845582|DRUG|ALK-001 oral capsule|Daily administration for 24 months
214930967|NCT03845582|DRUG|Placebo oral capsule|Daily administration for 24 months
214329123|NCT02246504|DEVICE|HIFU treatment|
214329124|NCT04991740|DRUG|JNJ-78306358|JNJ-78306358 will be administered.
214329125|NCT04659070|DRUG|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
214329126|NCT04659070|DRUG|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
214329127|NCT04659070|DRUG|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
214329128|NCT00348205|DEVICE|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
215071050|NCT07013656|OTHER|Combination of L-tryptophan + Ca-500|Calcium, an essential mineral and a key component of dairy products, is a regular part of our daily diet. In this condition, both L-tryptophan and calcium will be administered as 'active'. Recent studies have shown that calcium in a dose of 500 mg enhances the effects of L-tryptophan to stimulate gut functions and reduce energy intake. This dose of calcium will be considered 'lower dose'.
215071051|NCT07013656|OTHER|Combination of L-tryptophan + Ca-1000|In this condition, both L-tryptophan and calcium will be administered. In our study calcium in a dose of 1000 mg enhances the effects of L-tryptophan to stimulate gut functions and reduce energy intake. This dose of calcium will be considered 'higher dose'.
215071052|NCT07013656|OTHER|Control|An isotonic solution containing 2.5 g of NaCl, dissolved in 225 mL of distilled water.
215071053|NCT04291105|BIOLOGICAL|VV1|VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit
215071054|NCT04291105|BIOLOGICAL|Cemiplimab|Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
215071055|NCT06076551|DIAGNOSTIC_TEST|Adenosine stress echocardiography|Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood ﬂow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel ﬂow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary ﬂow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.
215071056|NCT07029217|RADIATION|Radiation (Standard)|24 Gy in 12 fractions
214930968|NCT00352092|DRUG|calcineurin inhibitor|
214930969|NCT00352092|DRUG|sirolimus|
214930970|NCT00352092|DRUG|mycophenolate mofetil|
214930971|NCT04084834|OTHER|Exercise|Participants will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital, receiving information about the osteoarthritis disease, symptoms and the importance of exercise and physical activity. Participants will then be given a weekly web-based exercise program (12 weeks) consisting of three aerobic exercise sessions per week. The exercise program consists of five levels, and the participants will each week be guided to the most appropriate level based on their measured physical fitness level and the weekly exercise diary. The participants will at initial assessment at Diakonhjemmet Hospital be instructed to use Borgs scale to adjust exercise level. Based on the weekly exercise diary the participants will also get motivational messages by email.
214930972|NCT00199706|DRUG|7.2% NaCl in 6% hydroxyethyl starch solution|
214930973|NCT01970475|BIOLOGICAL|ABP 501|Solution for subcutaneous injection in pre-filled syringe
214930974|NCT01970475|BIOLOGICAL|Adalimumab|Solution for subcutaneous injection in pre-filled syringe
214930975|NCT03548142|BEHAVIORAL|provision of relevant information|caregivers are provided with brochure that informs about end-of-life issues for persons with advanced dementia
214930976|NCT04010929|PROCEDURE|Partial pulpotomy with laser+MTA|After removing caries, laser+MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
214930977|NCT04010929|PROCEDURE|Partial pulpotomy with MTA|After removing caries, MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
214930978|NCT00355576|DRUG|Celecoxib|Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
214930979|NCT00355576|DRUG|Creatine|10 g BID for either study arm
214930980|NCT00355576|DRUG|Minocycline|Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
215071057|NCT07029217|RADIATION|Radiation (Very low dose)|4 Gy in 1-2 consecutive daily fractions
215071058|NCT07033182|DRUG|Levornidazole Disodium Phosphate for Injection|Single dose, IV
215071059|NCT07033104|OTHER|us guided Transversalis fascia plane block|addition of calcitonin to pubivacaine
215071060|NCT07032441|DEVICE|PSG|"Polysomnography (PSG) is a comprehensive test used to assess sleep disorders and monitor sleep quality. PSG is typically conducted in specialized sleep laboratories and can simultaneously record various physiological parameters to help doctors diagnose different types of sleep disorders, such as obstructive sleep apnea, insomnia, and periodic limb movement disorder.~The monitored components of PSG usually include:~Electroencephalogram (EEG): Records the electrical activity of the brain to determine different sleep stages.~Electrooculogram (EOG): Records eye movements to identify rapid eye movement (REM) sleep stages.~Electromyogram (EMG): Records muscle activity, typically monitoring the muscles of the jaw or legs.~Electrocardiogram (ECG): Monitors the electrical activity of the heart. Respiratory flow monitoring: Records the flow and frequency of breathing. Oxygen saturation monitoring: Monitors blood oxygen levels using a pulse oximeter."
215071061|NCT07034378|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of pulmonary veins
215071062|NCT07034378|PROCEDURE|Extended cryoballoon ablation|Cryoablation of pulmonary veins + posterior wall isolation
215071063|NCT07034378|PROCEDURE|Standard cryoballoon ablation|Standard cryoablation of pulmonary veins
214930981|NCT01000220|DRUG|Omeprazole|
214930982|NCT01000220|DRUG|Placebo|
214930983|NCT04195620|OTHER|High self-disclosure|"The high self-disclosure condition involves individuals asking and answering a series of questions that are more personal in nature and involve sharing or receiving information that is likely to be emotionally laden and information that is not readily shared in typical conversations. An example of a question from this condition includes If you were to die today without the chance to speak with anyone, what would you most regret not having said to someone? Why haven't you said it yet?"
214930984|NCT04195620|OTHER|Low self-disclosure|"The low self-disclosure condition involves individuals asking and answering a series of questions that are not personal in nature and involve sharing or receiving information that is shared in very casual conversations. An example of a question from this condition includes What did you do to celebrate Halloween last year?"
214930985|NCT05675527|BIOLOGICAL|Low-dose PRP|Injection
214930986|NCT05675527|BIOLOGICAL|High-dose PRP|Injection
214930987|NCT05675527|OTHER|Saline|Injection
214930988|NCT02224027|DEVICE|proceal laryngeal mask airway|In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.
214930989|NCT02224027|DEVICE|tracheal tube|In tracheal tube group, tracheal tube is intubated by novices.
214930990|NCT02224027|DEVICE|i-gel|In i-gel group, i-gel is inserted by novices.
214930991|NCT05663645|BEHAVIORAL|Health insurance educational guide|The educational guide includes 4 content areas: 1) Definition of key insurance terms; 2) premiums, deductibles across the five 2023 health plans; 3) Summary of how premiums and deductibles can affect out of pocket costs; 4) Guide to finding in-network IVF providers and facilities.
214930992|NCT03861299|PROCEDURE|Awake craniotomy|Awake craniotomy
214930993|NCT03861299|PROCEDURE|Craniotomy under general anesthesia|Craniotomy under general anesthesia
214930994|NCT04398485|DRUG|ION251|ION251 administered by IV infusion
214930995|NCT06468800|DEVICE|TRACMOTION|Patients already scheduled for ESD will undergo an ESD procedure with the aid of the Tracmotion device
214930996|NCT06796036|OTHER|Combat Medic Decision-Making with and without artificial intelligence assistance|Participants will complete 10 simulated Tactical Combat Casualty Care (TCCC) scenarios, with 5 scenarios conducted using AI assistance (GPT-4) and 5 without AI. In AI-assisted scenarios, participants will use GPT-4 to query and optimize ventilator settings based on patient data, while non-AI scenarios rely solely on their clinical judgment.
214930997|NCT03008863|OTHER|Education|
214930998|NCT06914999|PROCEDURE|Computed Tomography|Undergo PET/CT
214930999|NCT06914999|OTHER|Fludeoxyglucose F-18|Given F-18 FDG
214931000|NCT06914999|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
214931001|NCT06914999|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214931002|NCT06914999|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214931003|NCT06914999|DRUG|Sodium Fluoride F-18|Given IV
214931004|NCT06667635|DIAGNOSTIC_TEST|Artificial intelligence|Artificial intelligence (AI) tools developed through the training of large amounts of image data can assist with the analysis and interpretation of neuroimaging data of cerebral small vascular disease（CSVD）.
214931005|NCT04096638|DRUG|SB 11285|SB 11285 2mg lyophilized powder for IV infusion
214931006|NCT04096638|DRUG|Atezolizumab|1680 mg every 4 weeks
214931007|NCT01993953|OTHER|BodyPump|Participants will be offered BP sessions at fitness centers in Oslo/Akershus. They will exercise three times a week. The instructors at all centers have a BP license from Les Mills, and the same program will be conducted at all centers at all times. The project manager has been in contact with Les Mills Scandinavia and has been given permission to use the training concept for research.
214931008|NCT01993953|OTHER|Personal training|Participants in this group will be offered training with a PT at the Norwegian School of Sports Sciences. They will exercise with their PT three times per week. The training program for this group will be based on the exercises in the BP class, but repetitions will vary between 3-15, and series between 2-4.
214931009|NCT01993953|OTHER|Resistance training with instructor|Participants in this group will be invited to train on their own, three times a week, at the Norwegian School of Sports Science. Prior to the intervention period they will receive a training manual, instructions of the exercises and advice about progression during the intervention period. They will also have a follow-up with the same instructor after six weeks. The training program for this group will be the same as for group B. The PT's from group B will also serve as training instructors.
214931010|NCT06433622|DIAGNOSTIC_TEST|Repeat Thromboelastography with Platelet Mapping|Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.
214931011|NCT04183413|OTHER|DSD|This intervention consist of three Differentiated Service Delivery Models in which stable clients can be enrolled. The fast-track model gives preferential treatment to enrolled clients. Clients arrive at clinics, usually early in the morning, and can see the nurse as well as collect their medication without queuing. This model mainly targets the working population. The facility-based treatment clubs consist of bimonthly meetings where clients meet in groups of approximately 20 members. They receive health counselling, risk factor screening and medication prescription. This model mainly targets clients living close to the facility. The community advisory groups consist of groups of up to six clients. Groups are equipped with a point of care blood pressure and blood glucose measurement devices. They take turns in collecting the medication for the entire group and meet on a monthly basis. This model targets clients in hard-to-reach areas.
214931012|NCT04183413|OTHER|CDP|Community Distribution Points are set up on a monthly basis in communities linked to the clinic. Healthcare staff sets up a temporary point of contact where clients can obtain screening for diabetes and hypertension, health counselling, referral to primary or tertiary facilities, and medication.
214931013|NCT00795080|PROCEDURE|Dynamic cervical MRI scans|Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
214931014|NCT06453928|DEVICE|Hybrid Closed Loop Insulin Pump System|Patients will be started on an automated insulin delivery system.
214931015|NCT06797297|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
214931016|NCT06797297|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal anti-PD1 antibody
215071064|NCT07035002|BIOLOGICAL|transfusion of 5×10^8 PD-1 knockout TILs per kg body weight|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
215071065|NCT07035002|BIOLOGICAL|transfusion of 1×10^9 PD-1 edited TILs per kg body weight|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
214329129|NCT03394391|BEHAVIORAL|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
214329130|NCT03394391|BEHAVIORAL|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
214329131|NCT03509129|BEHAVIORAL|TECH (Technology)|"Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR"
214329132|NCT03509129|BEHAVIORAL|TECH+COMP (Technology + Competition)|"Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR"
214329133|NCT03587610|BIOLOGICAL|Remedial vaccination|"* if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
214329134|NCT05044234|DRUG|Cedirogant|Capsule, Oral
214329135|NCT05044234|DRUG|Placebo|Capsule, Oral
214329136|NCT02081495|DRUG|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
214329137|NCT02081495|DRUG|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
214329138|NCT04173130|DEVICE|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
214329139|NCT03766503|OTHER|Daily|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
214329140|NCT02896127|DRUG|Secukinumab|"Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment."
214329141|NCT02896127|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
214329142|NCT03909776|DRUG|Cisplatin|Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
214329143|NCT02753712|DRUG|Fluticasone/Formoterol BAI|
214931017|NCT05044936|DRUG|Cannabidiol Oil|"The dose that will be used for each administration of CBD will be 0.5mg/kg of body mass. As there are no recommendations for CBD from the FDA or through previous research in humans, and especially for CBD cream, the dosage is based on the United Kingdom's governing body recommending maximal amounts of CBD ingestion being 1 mg/kg per day. Further, the practical amount that companies recommend is anywhere from a pea size to a handful, which can range from high and low amounts. Using 0.5mg/kg of body mass allows for a moderate use of the lotion, as well as leaving extra quantities throughout the day should people want to use CBD outside of their post-workout recovery strategies outside of a laboratory setting. To convert the amount of CBD to the amount of lotion, we will divide the amount of CBD (0.5 mg/kg) by 4.85 (the amount of mg of CBD per gram of lotion). This will calculate the amount (in grams) of lotion each participant will receive."
214931018|NCT05044936|OTHER|Resistance Exercise|Participants will complete eccentric-based leg press (4-s lowering phase and 1-s upward phase) for 10 sets of 8 repetitions at 70% 1RM in order to induce muscle damage using a leg press machine. Three minutes of rest will be permitted between sets. Following the 10th leg press, participants will complete 4 sets of 20 consecutive plyometric lunges using only their body weight. Two minutes of rest will be permitted between sets. The muscle damaging protocol will be done upon completion of the 4th set of plyometric lunges.
214931019|NCT01073228|DRUG|EVP-6124|
214931020|NCT01073228|DRUG|Placebo|
214931021|NCT00854425|DRUG|L-asparaginase|L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
214931022|NCT05489991|BIOLOGICAL|TmPSMA-02|Intravenous administration of genetically modified autologous T-cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) with a lentiviral vector to express anti-PSMA scFv, CD2 co-stimulatory domain and dually armored with a dominant negative TGFβ receptor and PD1.CD28 switch, will be infused intravenously on Day 0 as a single flat dose following standard lymphodepleting (LD) regimen.
214931023|NCT00828724|DRUG|Lorcaserin 10mg|
214931024|NCT05592561|OTHER|mental stress task|The stress protocol used for this experiment utilized a cognitive challenge and a previously studied virtual reality active shooter drill (VR-ASD). The cognitive challenge included a modified version of the Stroop challenge (2 min) and mental arithmetic calculations (2 min) presented to the subject via e-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh, PA, USA). Immediately upon completion of the cognitive challenge, the subjects completed the VR-ASD scenario (\~2 min) followed by the same cognitive challenge with different questions (another 4 min). The total duration was \~10 min.
214931025|NCT01275651|OTHER|laboratory biomarker analysis|Correlative studies
214931026|NCT03191136|DRUG|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
214931027|NCT03191136|DRUG|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition
214931028|NCT01210196|PROCEDURE|MRI|Cardiac MRI after 12 and 24 months.
214931029|NCT00908791|DRUG|Conjugated Linoleic Acid (CLA)|Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
214931030|NCT03716843|OTHER|Pressure monitoring system|"The pressure measurement undergarment will be given to all consenting AIS patients who have received their own thoraco-lumbo-sacral orthosis (TLSO) rigid brace. Each patient will wear the undergarment first and the TLSO brace on top. FBG sensors embedded in the undergarment will measure each pressure signal at approximately 2 minutes. The average force reading will be calculated.~Then, the experiment will be repeated once, but the anisotropic textile brace will replace the TLSO brace. The pressure measurement system will be used to obtain an accurate and adequate comparison of the forces applied to the patients. The effectiveness of the anisotropic textile brace will be evaluated through X-ray radiography, and its correction effect with be compared with that of the TLSO brace."
214931031|NCT06441032|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
215071066|NCT07035002|BIOLOGICAL|transfusion of 2×10^9 PD-1 edited TILs per kg body weight|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
214329144|NCT02753712|DRUG|Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)|
214329145|NCT03093805|DIETARY_SUPPLEMENT|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
214329146|NCT05236309|DRUG|Jing-Guan-Fang(JGF) : Chinese herbal decoction|Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
214329147|NCT02443376|DEVICE|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
214931032|NCT03192995|DRUG|lorcaserin|lorcaserin 20 mg tablet
214931033|NCT03192995|DRUG|Placebo Oral Tablet|placebo 20 mg. tablet
214931034|NCT03192995|BEHAVIORAL|Substance use counseling|Manual-driven psychosocial substance use counseling program using cognitive behavioral therapy and motivational interviewing techniques and incorporating the Stages of Change Model.
214329148|NCT02443376|DEVICE|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
214329149|NCT01251133|BIOLOGICAL|LBVH0101 (Hib vaccine)|0.5mL
214329150|NCT01251133|BIOLOGICAL|Hiberix™ Vaccine|0.5mL
214931035|NCT03192995|BEHAVIORAL|ACASI|Audio-computer assisted self-interviews (ACASI) is a self-administered standardized questionnaire on substance and alcohol use, substance use treatment, sexual risk behavior, partnership sexual risk, and
214931036|NCT03192995|DIAGNOSTIC_TEST|Cocaine metabolites|Rapid qualitative urine test Medtox Verdict II (Medtox Diagnostics, Burlington, NC) and tamper-evident sweat patches (PharmChek®, PharmChem, Inc., Fort Worth, Tx)
214931037|NCT03192995|BEHAVIORAL|Ecological Momentary Assessment (EMA)|EMA are questions sent to the participant 4-5 times a day to determine real-time behavior and participant experiences.
214931038|NCT03192995|BEHAVIORAL|Balloon Analogue Risk Task (BART)|BART is a computerized measure of risk taking behavior. The BART models real-world risk behavior through the conceptual frame of balancing the potential for reward versus loss. This is a test for impulsivity.
214931039|NCT03192995|BEHAVIORAL|Qualitative Exit Interview|The qualitative exit interview assessed acceptability measures and included questions on attitudes about trial participation, level of satisfaction with trial procedures, and trial medication.
214931040|NCT03506568|DEVICE|Devers Drop Device (D3) app|A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.
215071067|NCT07035002|BIOLOGICAL|transfusion of maximum dose without side effects among group A, B and C|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
215071068|NCT07034118|RADIATION|Proton radiotherapy|Patients enrolled would receive proton radiotherapy with chemoimmunotherapy.
215071069|NCT07034118|DRUG|Immune Checkpoint Inhibitors|Patients enrolled would receive proton radiotherapy and chemoimmunotherapy
214329151|NCT04985253|OTHER|prediction of overall survival using Web based PREDICTV2.0 portal|"Predict is an online prognostication and treatment benefit tool developed in the UK, using cancer registration and survival data recorded by the Eastern Cancer Registration and Information Centre (ECRIC) for 5694 women diagnosed in East Anglia from 1999-2003.~The model was validated in a second cohort of 5468 women from the West Midlands Cancer Intelligence Unit and is available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions. Wong et al, tested the predictive accuracy of PREDICT V1.0 in the southeast Asian population. There were 67% Chinese patients while 13% were Indians. They showed concordance in observed and predicted OS in most subgroups except for women whore less than 40 years of age."
214329152|NCT02548013|OTHER|outpatient management|patients if stable will be discharged to continue treatment at home
214931041|NCT04476342|DEVICE|minimal invasive cardiopulmonary bypass (MICPB) system|The experimental group was MICPB group, with built-in micro-thrombotic oxygenator and MP formula (15mL 15%KCl+10ml compound potassium, calcium and magnesium +25ml normal saline)
214931042|NCT04175782|PROCEDURE|Enhanced recovery after surgery (ERAS) protocol|"Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
214931043|NCT01596153|DIETARY_SUPPLEMENT|Go Live|Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic
214931044|NCT02900495|DEVICE|transcutaneous electric nerve stimulation|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
214931045|NCT03615716|BEHAVIORAL|Multi-level Violence Prevention Intervention - Boys|Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.
214931046|NCT03615716|BEHAVIORAL|Multi-level Violence Prevention Intervention - Caregivers|This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
214931047|NCT00083941|BIOLOGICAL|TroVax|1ml intramuscular injection
214931048|NCT00083941|BIOLOGICAL|Interleukin-2|Intravenous IL-2
214931049|NCT03043157|DRUG|rocuronium|intravenous rocuronium infusion
214931050|NCT01373112|PROCEDURE|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
214329153|NCT02548013|OTHER|Inpatient management|patients will continue there treatment in hospital till delivery
214329154|NCT04206111|PROCEDURE|Preoxygenation|preoxygenation with high flow nasal cannula at 40l/min for 5min
214329155|NCT06382623|PROCEDURE|The percutaneous A1 pulley release|Ultrasound-guided percutaneous pulley release is a procedure aimed at loosening the pulley using various cutting instruments or hypodermic needles under ultrasound guidance.
214329156|NCT06382623|OTHER|The peritendinous Betamethasone group|USG-guided injection of corticosteroid between the A1 pulley and the flexor tendon sheath.
214329157|NCT03595371|DRUG|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
214329158|NCT00739336|BEHAVIORAL|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
214329159|NCT00384137|DRUG|Tacrolimus|Immunosuppression
214329160|NCT00211471|DRUG|anecortave acetate|
214329161|NCT02652533|DEVICE|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
214329162|NCT05649163|DRUG|Disitamab Vedotin|Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
214329163|NCT04453384|DRUG|XAV-19|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
214931051|NCT01373112|PROCEDURE|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
214931052|NCT05809258|PROCEDURE|Supraclavicular block|brachial plexus nerve block by supraclavicular route
214931053|NCT05809258|PROCEDURE|Axillary block|brachial plexus nerve block by axillary route
214931054|NCT06514755|PROCEDURE|GNA followed by GAE|Participants in the experimental arm will undergo genicular nerve ablation (GNA), a minimally invasive procedure targeting the genicular nerves to interrupt pain transmission. One month after undergoing GNA, participants will receive geniculate artery embolization (GAE), which targets the geniculate arteries to reduce inflammation and pain.
214931055|NCT06514755|PROCEDURE|GAE alone|Participants in the active comparator arm will receive geniculate artery embolization (GAE) alone, a minimally invasive procedure targeting the geniculate arteries to reduce inflammation and pain, without prior genicular nerve ablation (GNA).
214931056|NCT03097055|PROCEDURE|Traditional Acupuncture|"widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient"
214931057|NCT03097055|PROCEDURE|Minimal Acupuncture|non-traditional acupoints in scalp and limbs, with minimal manipulation
214931058|NCT02579343|DEVICE|Auricular Acupuncture|Auricular acupuncture is a form of acupuncture which utilizes the surface of the external ear to identify points of inflammation in the body. It does this, in this case, by utilizing the Pointer Excel II probe which can pick up a change in electrical conductivity on the surface of the ear, which reflects an internal point of inflammation or stress. Once the point of inflammation is identified, the Pointer Excel II is equipped with a sensor that it will not only illuminate by way of a small light on the front of the probe will also identify the point of inflammation by way of an auditory signal. Once the point of inflammation is identified auricular acupuncture will treat that point with a micro-current of electricity for several seconds.
214931059|NCT02579343|DRUG|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
214931060|NCT01671150|DRUG|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
214931061|NCT00035295|DRUG|MK0869, aprepitant|
214931062|NCT00035295|DRUG|Comparator: placebo|
214931063|NCT00381238|DRUG|rosiglitazone|Extended Release Tablets
214931064|NCT03364517|OTHER|Predictor score of the imminence of a childbirth (SPIA)|The SPIA score is based on the analysis of 6 types of criteria: panic during the call, the possibility of having a telephone contact with the parturient, the urge to push and if so for how long, the rhythm of the CU, some aggravating factors (history of fast delivery or at home, maternal age between 26 and 35 years, lack of follow-up of pregnancy) and 2 minor factors (nulliparity and the taking of a tocolytic treatment). Each criteria is between 0 to 8, except for the 2 minor criteria for which 7 and 3 points are removed if they are present. This gives a score between -10 and +33, which is weighted according to the admission time estimated at the hospital (30 minutes, 1h and 2h).
214931065|NCT03410212|DRUG|Ketorolac Tromethamine|The 30mg/mL vial of Ketorolac will be injected as second inferior alveolar nerve block and the success of anesthesia will be evaluated using visual analog scale.
214931066|NCT03410212|BEHAVIORAL|Sham injection|In the control group, the sham injection will be provided at the same place of the first inferior alveolar nerve block but any injection would be done.
214931067|NCT00002701|DRUG|busulfan|
214329164|NCT04453384|DRUG|Placebo|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
214931068|NCT00002701|DRUG|cyclophosphamide|
214931069|NCT00002701|DRUG|cytarabine|
214931070|NCT00002701|DRUG|etoposide|
214931071|NCT00002701|DRUG|idarubicin|
215071070|NCT07034573|OTHER|context adapted air filtration system for operating theatre|"This observational pilot study combines a retrospective design (technical data) and a prospective design (microbial data) to evaluate a new air filtration system adapted to the context. For this research, the technical data of the system concerning air velocity, temperature, etc. will be used retrospectively. Microbial sampling in the operating theatre will be carried out prospectively.~No patient contact will take place."
214329165|NCT05666401|PROCEDURE|follicle diameter and duration of procedure|to investigate if smaller follicles thrive embryos as the bigger follicles
214931072|NCT00002701|DRUG|mercaptopurine|
214931073|NCT00002701|DRUG|methotrexate|
214329166|NCT02880566|PROCEDURE|Scalp block|Full scalp block
214329167|NCT05172505|DEVICE|prefrontal tDCS|2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
214329168|NCT01639170|RADIATION|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
214329169|NCT01434823|OTHER|Nocturnal coverage|"The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage."
214329170|NCT02483234|DRUG|secukinumab|
214329171|NCT00622427|DRUG|Ramelteon|8 mg tablets every night for 2 weeks
214329172|NCT00622427|DRUG|Placebo|placebo tablets for every night for 2 weeks
214329173|NCT03302858|DEVICE|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
214931074|NCT00002701|DRUG|mitoxantrone hydrochloride|
214931075|NCT00002701|DRUG|thioguanine|
214931076|NCT00002701|DRUG|tretinoin|
214931077|NCT00002701|PROCEDURE|allogeneic bone marrow transplantation|
214931078|NCT00002701|PROCEDURE|autologous bone marrow transplantation|
214931079|NCT00002701|RADIATION|radiation therapy|
214931080|NCT02806544|DRUG|Tamoxifen|Tamoxifen 20mg by mouth daily
215071071|NCT07035080|OTHER|interferential therapy|Thirty hemophilic males (type A and B) children with unilateral hemarthrosis, age ranged from 8 to 12 years participated in this study. They were selected from the outpatient clinic. Faculty of physical therapy, kafrelsheik university. The patients were divided randomly into two groups of equal number , control and study groups, 15 patients each . the control group (7 left and 8 right hemarthrosis) received traditional treatment program for one hour per session includeing (ultrasound stretching and strengthening exercise ) , while the study group (6 left and 9 right hemarthrosis) received interferential therapy in addition to the same treatment program given to the control groups.
214329174|NCT04410926|OTHER|Corrective exercises|The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes
214329175|NCT04410926|OTHER|Neuromuscular electrical stimulation|The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles for 30 minutes. The surface electrodes were placed over the abductor halluces. The control group received placebo NMES with no current stimulation.
214673396|NCT06017232|OTHER|Hybrid telerehabilitation program|"The telerehabilitation program lasts 12 week (3 per week). The program includes aerobic, strength, coordination, balance, flexibility, and breathing exercises, in addition to educational components focused on disease management.~This hybrid program incorporates both supervised and unsupervised sessions. A progressive approach from synchronous (supervised) to asynchronous (unsupervised) sessions is adopted.~Each session is structured into 4 components: Warm-up; Muscle strengthening, coordination, and balance; Flexibility; and Breathing exercises.~Participants are asked to maintain a log of their aerobic activity, recording details such as the type of activity, duration, and intensity. The aim is to align with the recommended aerobic physical activity guidelines (150 min/week). Weekly assessments are conducted to provide personalized guidance based on individual progress.~Also, participants engage in weekly educational videos that cover a diverse range of PD-related topics."
214673397|NCT02778048|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter
214931081|NCT02968667|BEHAVIORAL|Empowerment|6 weeks of empowerment program and supported face to face discussion
214931082|NCT05027048|DRUG|Calcium chloride|See arm description above
214931083|NCT05027048|DRUG|Saline placebo|see arm description above
214931084|NCT01758107|OTHER|Withdraw cyclosporine|
214931085|NCT02068170|DRUG|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
214931086|NCT00344591|BEHAVIORAL|Structured Ecosystems Therapy (SET)|
214931087|NCT00344591|BEHAVIORAL|Individually tailored intervention|
214931088|NCT00560287|DEVICE|Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
214329176|NCT02967952|DEVICE|supraglottic airway (SGA) V.S. endotracheal intubation (ETI)|already being described above
214931089|NCT00560287|DEVICE|Non invasive ventilation|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
214931090|NCT02086448|DEVICE|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
214931091|NCT02086448|DEVICE|sham-CPAP|
214931092|NCT02086448|OTHER|Sleep hygiene|Information about sleep apnea and healthy sleep. Information about local sleep resources
214931093|NCT04973059|DEVICE|SmartDrive Summer|The SmartDrive is a power assist accessory for a manual wheelchair
214931094|NCT04973059|DEVICE|SmartDrive Winter|The SmartDrive is a power assist accessory for a manual wheelchair
214329177|NCT01403207|OTHER|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
214931095|NCT06162845|BEHAVIORAL|A smartphone based application free to download from the google play and iphone store to provide auditory and visual cues and counting for number of perscribed pelvic floor muscle contractions|Use of a smartphone-based home exercise application for pelvic floor muscle exercises with visual and auditory feedback for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
214931096|NCT06162845|BEHAVIORAL|Paper-based home exercise program for pelvic floor muscle exercise|Written instructions on a piece of paper for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
214931097|NCT00843037|DRUG|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
214931098|NCT03879057|DRUG|Surufatinib/humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
214931099|NCT04112160|DRUG|Ketorolac|IM injection of either normal saline or Ketorolac
214931100|NCT04112160|DRUG|normal saline|normal saline
214931101|NCT01895348|DRUG|Propofol|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
214931102|NCT01895348|DRUG|propofol-remifentanil|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
214931103|NCT01895348|DRUG|Dexmedetomidine-remifentanil|Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
214931104|NCT03055468|BEHAVIORAL|Peer support|Peer support and antidepressant medications
214931105|NCT02982616|DIETARY_SUPPLEMENT|Dodecanoic acid|The middle chain saturated fatty acid that can be widely found in daily food.
214931106|NCT02982616|BEHAVIORAL|Positive emotion|Positive emotion induced by facial expressions and classic music.
215071072|NCT07035080|OTHER|tradional physical therapy|Thirty hemophilic males (type A and B) children with unilateral hemarthrosis, age ranged from 8 to 12 years participated in this study. They were selected from the outpatient clinic. Faculty of physical therapy, kafrelsheik university. The patients were divided randomly into two groups of equal number , control and study groups, 15 patients each . the control group (7 left and 8 right hemarthrosis) received traditional treatment program for one hour per session includeing (ultrasound stretching and strengthening exercise ) , while the study group (6 left and 9 right hemarthrosis) received interferential therapy in addition to the same treatment program given to the control groups.
214329178|NCT02477020|DRUG|TAK-063 20 mg|TAK-063 tablet.
214329179|NCT02477020|DRUG|Placebo|TAK-063 matching-placebo tablet.
214329180|NCT01927250|BEHAVIORAL|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
214329181|NCT00894075|BIOLOGICAL|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
214329182|NCT00004144|DRUG|bryostatin 1|
214329183|NCT00004144|DRUG|gemcitabine hydrochloride|
214931107|NCT02982616|DIETARY_SUPPLEMENT|saline|saline
214931108|NCT02982616|BEHAVIORAL|neutral emotion|Neutral emotion induced by facial expressions and classic music.
215071073|NCT07032662|DRUG|IMVT-1402|Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2)
215071074|NCT07032662|DRUG|Placebo|Matching placebo SC QW for 24 weeks (Period 1)
214329184|NCT06352944|DIAGNOSTIC_TEST|procalcitonin|level of procalcitonin in bronchoalveolar lavage
214329185|NCT01873482|BEHAVIORAL|Movement to rhythm|Movement to rhythm
214329186|NCT00519649|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
214329187|NCT00130962|DRUG|ALGRX 4975|
214329188|NCT05523531|OTHER|Self-administered questionnaires|"* Neuropathic Eye Pain Questionnaire~* 5-item Dry Eye Evaluation Questionnaire (DEQ-5)~* Visual Impact Assessment Questionnaire~* Concise Ophthalmic Pain Questionnaire~* Questionnaire to evaluate the effectiveness and tolerance of treatments~* Chronic pain questionnaire"
214329189|NCT05523531|PROCEDURE|Bilateral ophthalmologic examination|"* Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~* Lipiview® test~* Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~* In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy"
214329190|NCT00062426|BIOLOGICAL|bevacizumab|
214673398|NCT02778048|OTHER|US (ultra sound)|Assessment of the sphincter
214931109|NCT04977362|OTHER|Enhanced Recovery After Surgery|Enhanced recovery after surgery is a multimodal, transdisciplinary care approach for patients undergoing surgical procedures. It is implemented in various surgical specialties, among others in cardiac surgery. The care approach aims at promotion of recovery of the patients throughout their perioperative process, reduction of complications, and early return to normal activities.
214329191|NCT00062426|DRUG|capecitabine|
214329192|NCT00062426|DRUG|fluorouracil|
214329193|NCT00062426|DRUG|leucovorin calcium|
214329194|NCT00062426|DRUG|oxaliplatin|
214329195|NCT04355416|DRUG|curcumin Oral gel|application of curcumin oral gel after scaling and root planing
214329196|NCT04355416|PROCEDURE|subgingival scaling and root planing|subgingival scaling and root planing without application of curcumin gel
214329197|NCT01108549|DIETARY_SUPPLEMENT|Ribose|Ribose 5 grams PO TID was taken daily
214329198|NCT02258282|DRUG|Etanercept|
214329199|NCT02258282|DRUG|Control|
214931110|NCT04977362|OTHER|Treatment as Usual|treatment as usual according to standard care in heart valve surgery
214931111|NCT06621056|OTHER|not applicable for observational research|This is an observational research and has no intervention
214931112|NCT00642109|PROCEDURE|midurethral sling procedure|quality of life, voiding dysfunction
214931113|NCT01883947|PROCEDURE|Touch massage|Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
214931114|NCT01883947|OTHER|non-TENS|Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
214931115|NCT06372418|OTHER|Breastfeeding peer support intervention|In addition to support as currently recommended by the World Health Organization (WHO) and National IMAM guidelines, care givers will receive a homebased individualized face to face support provided by breastfeeding peer supporters and phone call support upto 7 weeks post hospital discharge.
214931116|NCT06372418|OTHER|Standard Care|Caregivers will receive post-discharge support as currently recommended by the World Health Organization (WHO) and national IMAM guidelines.
214931117|NCT03153267|DRUG|Doxycycline 100 MG Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
214931118|NCT03153267|DRUG|Doxycycline 100 MG Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
214931119|NCT03153267|DRUG|Controls without a history of lyme disease.|No intervention.
214329200|NCT04879745|OTHER|MyVoice:Rheum|Participants will be given access to MyVoice:Rheum, a web-based decision aid (DA).
214329201|NCT04879745|OTHER|Pamphlet|Participants in this arm will be given a copy of an existing patient pamphlet
214329202|NCT03777189|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
214329203|NCT00120042|DRUG|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
214329204|NCT00120042|DRUG|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
214329205|NCT06448234|OTHER|Standart supplementation therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles
214673399|NCT02778048|OTHER|FLIP (functional lumen imaging probe)|Assessment of the sphincter
214673400|NCT02778048|OTHER|HRAM (high resolution anal manometry)|Assessment of the sphincter
214673401|NCT02355912|DEVICE|Powered knee and ankle prosthesis|A powered knee and ankle prosthesis developed by Vanderbilt University.
214673402|NCT02844205|OTHER|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
214931120|NCT00923663|DRUG|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
214931121|NCT00509379|DRUG|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
214931122|NCT00509379|DRUG|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
214931123|NCT01871402|DRUG|000-0551 Lotion|
214931124|NCT01871402|DRUG|Vehicle Lotion|
214931125|NCT04012281|DEVICE|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
214931126|NCT00600990|DRUG|GW597599|
214931127|NCT03790449|BEHAVIORAL|PreLiFe-programme|The intervention group will receive a mobile preconception lifestyle programme (the PreLiFe-programme) in addition to standard care for 12 months or until an ongoing pregnancy is confirmed by ultrasound. The PreLiFe-programme includes a mobile application (PreLiFe-app) with the same treatment information as the attention control group in combination with a lifestyle programme. This new lifestyle programme includes tailored advice and skills training on diet and physical activity and mindfulness exercises. Additionally couples will be offered interaction with a health care provider through text messages and telephone interaction following the concept of blended care.
214931128|NCT03790449|BEHAVIORAL|Attention Control Programme|The standard care serving as control for this intervention is fertility treatment i.e. IVF with or without ICSI according to local protocols for infertility patients. This implies no guidance on lifestyle. However, to have attention control the control group will receive an attention control programme. The attention control programme includes a mobile application (app) with treatment information including medication instructions, reminders of injection of human Chorionic Gonadotropin (hCG) and time of fertility treatment appointments for 12 months or until an ongoing pregnancy is confirmed by ultrasound.
215071075|NCT04415749|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine
215071076|NCT04415749|OTHER|Placebo|Normal saline
215071077|NCT07035028|DIAGNOSTIC_TEST|Digital fetal scalp stimulation dFSS|Digital fetal scalp stimulation will be performed for a period of 30 seconds, prior to obtaining the fetal blood sample. Digital fetal scalp stimulation will be performed by vaginal touch with a gauze pad and rubbing the fetal scalp with pressure for 30 to 60 seconds.
215071078|NCT07034222|DRUG|Administer Leqemi 10 mg/kg, every two weeks.|Receive 10 mg/kg of Leqembi once every two weeks. Dissolve Leqembi in normal saline and administer it intravenously over 60 minutes. The infusion system must use a 0.2-μM terminal line filter for administration.
214329206|NCT06448234|OTHER|AI-guided supplementation therapy group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
214931129|NCT02716493|BEHAVIORAL|Telerehabilitation program|"The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.~Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.~In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions"
214931130|NCT00997217|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min upper limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis or cardiopulmonary bypass)
214931131|NCT00154804|DRUG|Paclitaxel, Cisplatin,Surgery, CCRT|
214931132|NCT04568954|DIAGNOSTIC_TEST|Truenat TB platform/TB assays|"Truenat TB platform/TB assays, a molecular diagnostic test developed by Molbio diagnostics, for the diagnosis of Mycobacterium tuberculosis complex (MTBC) and Truenat MTB-RIF Dx for detection of RIF resistance was endorsed in 2020 by the WHO for TB diagnosis.~The system has been designed to be operated as a point-of-care- diagnostic solution in peripheral laboratories with minimal infrastructure.~It takes about 25 minutes to do the DNA extraction and another 35 minutes to diagnose TB.~It is portable and battery operated, have no need for a computer or laptop, and operate from 2-40 C ambient temperature. The system uses room temperature stable reagents with long shelf life."
214931133|NCT00687843|DRUG|Tegafur-gimeracil-oteracil potassium (TS-1)|80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
215071079|NCT07033819|DRUG|Neoadjuvant therapy with fluazoparib in combination with apatinib|"Neoadjuvant Treatment Period Furazopanib: 150 mg, twice daily, orally, either before or after meals. It is recommended to take it within 0.5 hours after breakfast and dinner. Continuous administration for 3 weeks constitutes one cycle, for a total of three cycles.~Apatinib: 250 mg, once daily, orally, recommended to be taken within 0.5 hours after breakfast. Continuous administration for 3 weeks constitutes one cycle, for a total of three cycles."
215071080|NCT07033819|PROCEDURE|Preoperative Period|Discontinue Furazopanib 7 days before surgery. Discontinue Apatinib 14 days before surgery. The specific timing will be assessed by the investigator based on postoperative wound healing.
214931134|NCT00687843|DRUG|Krestin (PSK)|3 g, PO from day 1 to day 336
214931135|NCT06086210|OTHER|Low-level laser therapy|Low-level laser therapy was applied to each area for 1 minute, with a wavelength of 808 nm and a dose of 2j/cm2 for a total of 5 minutes,10j/cm2 in continuous mode. A total of 15 sessions were applied 5 days a week for 3 weeks.
214931136|NCT06086210|OTHER|Sham|Sham therapy was applied to each area for 1 minute, with a wavelength of 0 nm and a dose of 0j/cm2 for a total of 5 minutes, 0j/cm2. A total of 15 sessions were applied 5 days a week for 3 weeks.
214931137|NCT06793943|DRUG|Zasocitinib|Zasocitinib tablets specified doses on specified days.
214931138|NCT06793943|DRUG|COC|COC tablets (containing LNG and EE) specified doses on specified days.
214931139|NCT06793943|DRUG|Metformin|Metformin tablets specified doses on specified days.
214931140|NCT06793943|DRUG|Digoxin|Digoxin tablets specified doses on specified days.
214931141|NCT06793943|DRUG|Esomeprazole|Esomeprazole capsules specified doses on specified days.
214931142|NCT04947228|DEVICE|trackPAD|TrackPAD is a smartphone app to provide PAD-specific support for SET
215071081|NCT07033819|DRUG|Chemotherapy|Postoperative Adjuvant Chemotherapy Period (≥4 cycles) Paclitaxel: 150-175 mg/m², intravenous infusion, every 3 weeks (Q3W). Carboplatin: AUC 4-5, intravenous infusion, every 3 weeks (Q3W).
214673403|NCT04893330|DIETARY_SUPPLEMENT|pepticate syneo|follow up of pepticate syneo for one month
214673404|NCT01819688|PROCEDURE|laparoscopic liver resection|
214329207|NCT02472665|DRUG|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
214329208|NCT02628275|BEHAVIORAL|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
214329209|NCT02628275|BEHAVIORAL|Light physical activity|40-55% maximum heart rate for 150min/week
214931143|NCT00030667|DRUG|imatinib mesylate|Given orally
214931144|NCT00030667|OTHER|laboratory biomarker analysis|Correlative studies
214931145|NCT00030667|OTHER|pharmacological study|Correlative studies
214931146|NCT03892174|OTHER|Treatment protocol with adsorption|Adsorption while patients are in the OR on the extracorporeal circuit
214931147|NCT06012448|DRUG|Dupilumab|"Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.~In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks."
214931148|NCT06821347|DRUG|NanO2TM|Intravenous NanO2 0.17ml/kg (three doses given over 4.5 hours)
214931149|NCT06821347|OTHER|Sodium Chloride 0.9% Intravenous|Placebo
214931150|NCT01689246|DRUG|TRx0237 150 mg/day|TRx0237 75 mg tablets will be administered twice daily.
214931151|NCT01689246|DRUG|TRx0237 250 mg/day|TRx0237 125 mg tablets will be administered twice daily.
214931152|NCT01689246|DRUG|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
214931153|NCT02197832|PROCEDURE|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
214931154|NCT02197832|PROCEDURE|control procedure|Using pipelle catheter without entering the uterine cavity.
214931155|NCT02197832|DEVICE|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
214931156|NCT06008197|DRUG|Finerenone|Oral finerenone
214931157|NCT06008197|DRUG|Placebo|Matching oral placebo
214931158|NCT00503958|GENETIC|DNA methylation analysis|
214931159|NCT00503958|GENETIC|DNA stability analysis|
214931160|NCT00503958|GENETIC|gene expression analysis|
214931161|NCT00503958|OTHER|epidemiologic study|
214931162|NCT00503958|OTHER|study of socioeconomic and demographic variables|
214931163|NCT00503958|PROCEDURE|biopsy|
214931164|NCT00503958|PROCEDURE|evaluation of cancer risk factors|
214931165|NCT00503958|PROCEDURE|study of high risk factors|
214931166|NCT00217776|BEHAVIORAL|Open Airways Educational Intervention|
214931167|NCT00217776|BEHAVIORAL|Peer Asthma Action Educational Intervention|
214931168|NCT03495674|BEHAVIORAL|Exercise Intervention|Complete cycling classes
214931169|NCT03495674|OTHER|Informational Intervention|Receive information about exercise guidelines
214931170|NCT03495674|DEVICE|Monitoring Device|Wear Fitbit
214931171|NCT03495674|OTHER|Questionnaire Administration|Complete questionnaire
214931172|NCT05033730|DEVICE|Flow Controlled Ventilation|Mechanically ventilated using Flow Controlled Ventilation (FCV)
214931173|NCT06358846|BEHAVIORAL|Self-care behavior to promote foot care through educational guidance among individual with diabetes|Apart from physician consultation, individuals will received structured training of how to care their foot to avoid ulcer and inflammation.
215071082|NCT07033819|DRUG|Maintenance treatment|"Maintenance Treatment Period Furazopanib: 150 mg, twice daily, orally. Continuous administration for 3 weeks constitutes one cycle.~Apatinib: 250 mg, once daily, orally. Continuous administration for 3 weeks constitutes one cycle.~Treatment will continue until disease progression, intolerable toxicity, or other reasons as specified in the protocol."
214931174|NCT06620575|PROCEDURE|Atrial fibrillation ablation|Persistent atrial fibrillation ablation
214931175|NCT05528198|DRUG|Montelukast sodium oral thin films without water (A)|Single-dose montelukast sodium oral thin film 5mg under fasted condition without water
214931176|NCT05528198|DRUG|Montelukast sodium oral thin films with water (B)|Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL
214931177|NCT05528198|DRUG|Montelukast sodium chewable tablets with water (C)|Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL
214931178|NCT03946683|RADIATION|Cyberknife for Early Stage Breast Cancer|Utilization of Cyberknife Robotic Radiosurgery as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer
214931179|NCT00369070|BIOLOGICAL|Bevacizumab|15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks
214931180|NCT00369070|DRUG|AMG 706|subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days
214931181|NCT00369070|DRUG|Paclitaxel|All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.
214931182|NCT00369070|DRUG|Carboplatin|All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
214931183|NCT02530411|DRUG|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
215071083|NCT07034742|DRUG|Intraperitoneal chemotherapy PLUS systemic chemotherapy|Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)
215071084|NCT07034859|DRUG|Cabergoline 0.5 MG|Cabergoline (Dostinex ®) 0.5 mg/tablet. Cabergoline will be given orally 1mg/week (Day1-14), 2mg/week (Day15-end of the study).
214329210|NCT02099721|DEVICE|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
214329211|NCT04453124|BIOLOGICAL|Topical antiseptic treatment|Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.
214931184|NCT02530411|DRUG|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
214931185|NCT05409001|DIAGNOSTIC_TEST|tomography pan scan|This is a retrospective chart review
214931186|NCT04514640|BEHAVIORAL|The Calm app|"All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention."
214931187|NCT02395640|DRUG|Epirubicin|50mg/m2 ivgtt d1
215071085|NCT07033741|BEHAVIORAL|EMDR|The EMDR process follows an eight-phase protocol that includes (1) history taking: gathering patient's background information and planning treatment, (2) preparation: preparing the patient for processing target, (3) assessment: accessing target of the traumatic memories, (4) desensitization: processing target memories using dual task , (5) installation: strengthening the alternative positive cognition, (6) body scan: noting any physical sensations related to the target memory, (7) closure: ensuring patient's stability at the end of the session, and (8) revaluation: assessing effectiveness of the session and future planning.
215071086|NCT07033299|BIOLOGICAL|CAR-T Therapy|CT1192 cells infusion
215071087|NCT06829849|DIAGNOSTIC_TEST|Landing error assessment during a SHD task using the SHD-LESS scale|Participants will perform a 2D-camera-recorded SHD task, with the SHD-LESS scored by two sports medicine physicians. Additional tests include isokinetic muscle testing, as well as functional and psychological status assessments, following standard clinical practice.
215071088|NCT07033273|OTHER|Non-invasive Monitoring|All participants will undergo non-invasive measurement of Inferior Vena Cava Collapsibility Index (IVCCI) using ultrasound and routine blood pressure monitoring before and during hemodialysis sessions. No treatment or experimental intervention will be applied.
214329212|NCT05925894|DRUG|Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma|60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
214329213|NCT00054613|DRUG|Methoxsalen|
214329214|NCT00054613|PROCEDURE|Extracorporeal Photopheresis|
214329215|NCT00830193|DRUG|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
214329216|NCT00830193|DRUG|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
214329217|NCT04285190|DRUG|T89|The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.
214329218|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
214329219|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
214329220|NCT01175694|RADIATION|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
214329221|NCT04688840|PROCEDURE|hip arthropalsty|follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
214329222|NCT02077517|PROCEDURE|Roux en Y Gastric Bypass|
214329223|NCT01751464|BEHAVIORAL|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
214673405|NCT00973830|OTHER|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
214673406|NCT00670917|OTHER|questionnaire administration|
214931188|NCT02395640|DRUG|Oxaliplatin|
214931189|NCT02395640|DRUG|Capecitabine|1000mg/m2 po d1-14
214931190|NCT06416410|DRUG|JAB-21822|JAB-21822 administered orally as a tablet
214931191|NCT06416410|DRUG|Tislelizumab|Tislelizumab administered as an intravenous (IV) infusion
214931192|NCT06416410|DRUG|JAB-3312|JAB-3312 administered orally as a tablet or capsule
214329224|NCT05040711|BEHAVIORAL|Mindfulness Coach|"This study will use Mindfulness Coach, an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. The app provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness. To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
214329225|NCT05040711|BEHAVIORAL|Active Comparator|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
214329226|NCT06020404|PROCEDURE|supine position|At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate \< 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.
214673407|NCT00670917|PROCEDURE|acupressure therapy|
214673408|NCT00670917|PROCEDURE|biopsy|
214673409|NCT00670917|PROCEDURE|bone marrow aspiration|
214931193|NCT06416410|DRUG|Pemetrexed|Pemetrexed administered as an intravenous (IV) infusion
214931194|NCT06416410|DRUG|Carboplatin|Carboplatin administered as an intravenous (IV) infusion
214931195|NCT06090409|OTHER|Implementing free/subsidized agricultural produce to encourage a plant-based diet.|Providing educational material on the benefits of a plant-based diet, simple recipes, food swaps and free/subsidized produce.
214931196|NCT05356533|BEHAVIORAL|Drinking to Cope CBT skills|Young adults who drink to cope with negative affect will receive 8 web-based modules with cognitive behavioral skills
214931197|NCT01654653|DRUG|Hypertonic sodium lactate|Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
214931198|NCT01654653|DRUG|6% Hydroxy Ethyl Starch|Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
215071089|NCT07033637|OTHER|Dietary Supplement|A daily oral capsule containing 1 x 10⁹ CFU of Lactiplantibacillus plantarum CECT 7481 (32.5 mg), microcrystalline cellulose (304.1 mg), and magnesium stearate (3.4 mg). Administered once daily before the main meal for 6 weeks. Used to evaluate its effects on gut microbiota and physical health in older adults.
215071090|NCT07033637|OTHER|Placebo|A daily oral capsule identical in appearance to the probiotic capsule, containing maltodextrin instead of Lactiplantibacillus plantarum. Administered once daily before the main meal for 6 weeks. Used to control for placebo effects in the assessment of probiotic efficacy.
215071091|NCT07033637|BEHAVIORAL|Structured Physical Activity Program|A 12-week supervised physical activity program conducted at municipal sports centers. Participants engage in moderate-intensity exercise at least 2 times per week. Designed to assess the impact of physical activity on gut microbiota, physical condition, and quality of life in older adults.
215071092|NCT07032545|OTHER|Broccoli microgreen (BMG)|All participants will consume one serving size (one cup, \~57 gram) of raw BMG daily for 2-week period of time.
215071093|NCT07032883|OTHER|Benson relaxation technique|"It will be performed every day, twice daily (in the morning and evening), for 4weeks, the Benson relaxation technique instruction included these steps.~1. Sit in a comfortable position.~2. Close their eyes.~3. Relax all their muscles beginning from the soles of the feet, moving forward up, and relax all parts of their body.~(4 ) Breath through their nose, pay attention to the sound of their breathing, and say the word ''one'' quietly to themselves when the breath is out.~(5) Continue for 20 min. the patients were instructed to check the time by opening their eyes. However, using an alarm was prohibited. The training sessions were held during the patients hospitalization period after one week from surgery, the technique continued during the hospitalization and after discharge from the hospital."
214673410|NCT00670917|PROCEDURE|pain therapy|
214673411|NCT01094340|DRUG|Thalidomide|fixed dose over 8 clinic visits
214931199|NCT05212688|OTHER|Acupuncture|Weekly treatment of 15 minutes for 6 weeks using Seirin 36 g 30 mm needles applied to two upper midline sternal points, thoracic paravertebral points, 5 pairs, 2 bilateral Trapezius trigger points, LI4, TE5, ST36, GB34, SP6, LR3 bilaterally, GV20 \& GV24 midline.
214931200|NCT05212688|OTHER|Active Control|Weekly contact once per week for 6 weeks for a semi-structured telephone consultation.
214931201|NCT03595813|PROCEDURE|Blood sample collection|Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression
214931202|NCT03595813|PROCEDURE|Biopsy collection|Optional biopsy collection at baseline and progression
214931203|NCT02898324|OTHER|KiVa program|KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
214931204|NCT05768750|OTHER|Rehabilitation|X
214931205|NCT03785613|DRUG|Test Product T1: Buprenorphine patch (9 mg)|Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters.
214329227|NCT06020404|PROCEDURE|prone position|"After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position."
214329228|NCT05834140|OTHER|Traditional Physical Therapy|"TENS (transcutaneous electrical nerve stimulation) on continuous mode at 80-120 Hz for 15-20 min and Heating pads for 10-15 min~Total 4 sessions will be given in 2 days"
214329229|NCT05834140|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) along with TENS and Heating pads.~* MET of the scaleni~* MET of Sternocleidomastoid~* MET of Levator Scapulae~* MET of Upper fibers of Trapezius~Total 4 sessions will be given in 2 days"
214673412|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
214673413|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
214931206|NCT03785613|DRUG|Test Product T2: Buprenorphine patch (3.8 mg)|Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters.
214931207|NCT03785613|DRUG|Reference Product R: Transtec patch (20 mg)|Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.
214931208|NCT03785613|DRUG|Matching placebo patch to T1|Placebo patch to T1.
215071094|NCT07032883|OTHER|Routine physiotherapy program|The participants will receive routine physical therapy program (gentle stretching, manual therapy, mobility and strengthening exercises and posture training) for 40 minutes , for 4 weeks.
214931209|NCT03785613|DRUG|Matching placebo patch to T2|Placebo patch to T2.
214931210|NCT03785613|DRUG|Matching placebo patch to R|Placebo patch to R.
215071095|NCT07032883|DRUG|Medications|"the participants will receive the following medications:~1. Antibiotic: Ancef 1 g intravenous (IV) ( cefazolin) intravenous post-surgery every 8 hours for 24 hours. If allergic to ampicillin /cephalosporins clindamycin IV 600\_900 mg every 8 hours for 24 hours. Then continue oral with keflex 1g tablets (cephalexin) twice daily for 7 days.~2. Anti-inflammatory:~   Adolor ( ketorolac) 15\_30 mg IV every 6 hours up to 5 days post-operation ( not exceed 120 mg/day) then followed by oral celecoxib 200 mg once or twice daily till pain subsides.~3. paracetamol 500\_1000 mg I.V every 6 hours for 5 days (Not exceed 4000 mg / day) Then followed by oral paracetamol tablets till pain subsides.~4. Zurcal 40 mg IV (pantoprazol) then followed by oral zurcal tablets."
214931211|NCT05896527|DRUG|DC-806|DC-806 was supplied as tablets to be administered orally.
215071096|NCT07034898|DRUG|Dexmedetomidine|Participants in this arm will receive dexmedetomidine at a dose of 0.5 mcg/kg, diluted with normal saline to a total volume of 50 mL. The solution will be administered intravenously via a syringe pump at an infusion rate of 300 mL/hour, completing over 10 minutes immediately prior to extubation.
215071097|NCT07034898|DRUG|Labetalol|Participants in this arm will receive labetalol at a dose of 0.5 mg/kg, diluted with normal saline to a total volume of 50 mL. The solution will be administered intravenously via a syringe pump at an infusion rate of 300 mL/hour, completing over 10 minutes immediately prior to extubation.
215071098|NCT07034547|PROCEDURE|Botulinum toxin infiltration|Botulinum toxin is a medication that is injected directly into the muscles selected by a physiatrist, based on a clinical evaluation. The doses are determined according to the clinical condition of the spasticity, the patient's age, and weight. The procedure is performed under deep sedation and uses ultrasound and electrostimulation to ensure greater safety and precision.
215071099|NCT07034417|OTHER|Exercise|Cognitive Exercise Therapy Approach
215071100|NCT07034417|OTHER|Home exercise|Home exercise
214931212|NCT05896527|OTHER|Placebo|Matching placebo was supplied as tablets to be administered orally.
214329230|NCT06563323|DRUG|Guselkumab|Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.
214329231|NCT01126541|DRUG|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
214329232|NCT05972434|OTHER|Sunscreen A|Participants will apply sunscreen A topically.
214931213|NCT01254838|BIOLOGICAL|HLA-A02 restricted HIG2|
214931214|NCT03195023|DRUG|Lisinopril|
214931215|NCT03195023|DRUG|Amlodipine|Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
214931216|NCT06621797|DIETARY_SUPPLEMENT|Intervention 1: Dietary Supplement - Caffeine Supplement|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) taken orally 45 minutes before performance testing. No additional interventions will be administered.
214931217|NCT06621797|DIETARY_SUPPLEMENT|Intervention 2: Dietary Supplement - Caffeine + L-Theanine Supplement|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) along with L-theanine in a 1:2 ratio taken orally 45 minutes before performance testing.
214931218|NCT06621797|BEHAVIORAL|Intervention 3: Dietary Supplement - Caffeine Supplement + Diaphragmatic Breathing Exercises|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) 45 minutes before performance testing, followed by a 10-minute session of diaphragmatic breathing exercises.
214931219|NCT01279070|BEHAVIORAL|Repyflec cognitive remediation training|Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
214931220|NCT05497479|DRUG|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic (per randomization), before and after instillation of 0.003% AR-15512
214931221|NCT05497479|DRUG|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic, before and after instillation of Vehicle
214931222|NCT05497479|DRUG|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of 0.003% AR-15512
214931223|NCT05497479|DRUG|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of Vehicle
214931224|NCT03926364|OTHER|Patients with referred pain|The project does not affect treatment or does not offer any intervention.
214931225|NCT06622369|OTHER|Virtual Reality-Game group|Children in the play group will be allowed to choose a game that is compatible with virtual reality. Children in this group will be allowed to play the game they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use
214931226|NCT06622369|OTHER|Virtual Reality-Cartoon-video group|Children in the cartoon-video group will be allowed to choose a cartoon they want compatible with virtual reality. Children in this group will be allowed to watch the cartoon they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use in terms of infection risk.
214931227|NCT06412185|BIOLOGICAL|CM383|CM383 Injection
214931228|NCT06412185|OTHER|Placebo|Placebo
214931229|NCT05115188|DIETARY_SUPPLEMENT|Dex4/ dextrose|Participants will be asked to ingest 21 Dex4® tablets and no more than 300ml of water within 5 minutes. Blood draws will be performed at fasting (before ingesting the dextrose monohydrate tablets), as well as 1 hour after (+/- 15 minutes) and 2 hours (+/- 15 minutes) after ingesting the dextrose monohydrate tablets.
214931230|NCT05115188|DIETARY_SUPPLEMENT|Glucose beverage|For the 2 hour oral glucose tolerance test (OGTT), women fast for 8 hours and then consume 75g of glucose beverage, and serum glucose levels are taken at fasting, 1 and 2 hours after drinking the glucose beverage. The 75g OGTT is the gold standard and is performed for GDM diagnosis.
214931231|NCT03789578|DRUG|NNC0148-0287sema|Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
214931232|NCT03789578|DRUG|Semaglutide|Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
214931233|NCT03789578|DRUG|NNC0148-0287|Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
214329233|NCT05972434|OTHER|Sunscreen B|Participants will apply sunscreen B topically.
214329234|NCT04502771|DRUG|Antifungal treatment|Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit
214329235|NCT05494125|OTHER|Ropivacaine|Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
214329236|NCT05494125|OTHER|Placebo|Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
214329237|NCT03865121|DRUG|Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
214673414|NCT03849469|BIOLOGICAL|XmAb®22841|Monoclonal bispecific antibody
214673415|NCT03849469|BIOLOGICAL|Pembrolizumab (Keytruda®)|FDA-approved humanized monoclonal antibody
214931234|NCT06002529|OTHER|HFR|patient received HFR treatment
214931235|NCT06683040|DRUG|Oxacom|Lyophilisate for solution for intravenous administration, 6.3 mg
214931236|NCT06683040|DRUG|Placebo|0.9% sodium chloride
214931237|NCT00800605|BIOLOGICAL|Vero cell-derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
214931238|NCT00800605|BIOLOGICAL|Placebo: Phosphate-buffered saline|Single intramuscular injection
214329238|NCT01570075|PROCEDURE|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
214329239|NCT01570075|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
214329240|NCT06100068|BEHAVIORAL|Mental Exercises and Temporal Alteration|Mental exercises during L-DIBH to distort the awareness of passage of time
214329241|NCT06198192|OTHER|Pilates Exercises|Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Pilate group will receive the intervention program three times/week for total 10 weeks
214329242|NCT06198192|OTHER|Conventional Therapy and Balance Exercises|this group receive conventional therapy along with balance exercises. Standing with feet together while the therapist sitting behind and manually locking the child knees, and then slowly tilt him to each side, forward and backward. Step standing with therapist behind the child guiding him to shift his weight forward then backward alternately. High step standing and try to keep balanced. Standing with manual locking of the knees then tries actively to stoop and recover. Equilibrium, righting and protective reactions training. Open environment gait training will be conducted with the different obstacles. Session includes three times/week for total 10 weeks
214329243|NCT06573827|DIAGNOSTIC_TEST|Blood and urine sample evaluation|Blood and urine sample evaluation will be performed in healthy female volunteers.
214329244|NCT04844229|PROCEDURE|Bilateral transnasal sphenopalatine ganglion block.|SPG block will be performed with the patient in supine position using cotton-tipped plastic hollow applicator inserted in the nose with the swab soaked in 1.5 ml 10%lignocaine. The applicator will be inserted parallel to the floor of the nose until resistance encountered. The swab will be rested in the pterygopalatine fossa superior to the middle turbinate and removed after 10 min. This procedure will be repeated in the other nostril too.
214329245|NCT04844229|PROCEDURE|Bilateral ultrasound guided greater occipital nerve block.|GONB will be performed with the patients lying in prone position using high frequency (6-13 MHz) probe of Siemens Acuson X300 machine placed in transverse orientation lateral to external occipital protuberance parallel to the superior nuchal line to detect occipital artery where the nerve is located medial to it 1.5inch; then 20 gauge needle will be inserted out of plane to avoid vascular injury. 4 ml of treatment solution containing 2.5 mg/ml bupivacaine and 1 mg/ml dexamethasone (prepared by adding 2 ml bupivacaine 0.5% + 1 ml dexamethasone + 1 ml saline) will be injected on each side.
214329246|NCT04612491|BEHAVIORAL|Pre-operative Consultation|Pre-operative consultation will be given before Mohs surgery
214673416|NCT03701165|DEVICE|DryMouth Shield|The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
214673417|NCT00380484|DRUG|Budesonide|200µg daily
214673418|NCT00380484|DRUG|Montelukast|5 mg daily
214673419|NCT00224107|DRUG|Silodosin|8 mg daily for 12 weeks
214673420|NCT00224107|OTHER|Placebo|1 capsule daily for 12 weeks
214931239|NCT01279174|OTHER|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
214931240|NCT00005601|BIOLOGICAL|rituximab|
214931241|NCT00005601|DRUG|cisplatin|
214931242|NCT00005601|DRUG|cytarabine|
214931243|NCT00005601|DRUG|dexamethasone|
214931244|NCT00005601|DRUG|sargramostim|
214931245|NCT00005836|DRUG|oxaliplatin|
214931246|NCT06388616|DRUG|Balcinrenone|50 mg, Immediate release capsule to be taken orally.
214931247|NCT03781583|DEVICE|SmartHMD version 1|First version of the SmartHMD device, which used custom software running on commercially available ODG R7 smart glasses and accompanying earbuds.
214931248|NCT03781583|DEVICE|SmartHMD version 2|Second version of the SmartHMD device, which uses RGB-D smart glasses, custom software running on a laptop, and bone-conducting earphones.
214931249|NCT03781583|DEVICE|SmartHMD version 3|Third iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and custom software.
214931250|NCT03781583|DEVICE|SmartHMD version 4|Fourth iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and a specific version of custom software.
214329247|NCT03127124|DRUG|NANT-008|Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)
214329248|NCT03127124|DRUG|Fluorouracil Injectable Product|5-fluoro-2,4 (1H,3H)-pyrimidinedione.
214329249|NCT03127124|DRUG|Avastin Injectable Product|Recombinant humanized monoclonal IgG1 antibody
214329250|NCT03127124|DRUG|Leucovorin Calcium Injection|Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).
214931251|NCT01925235|PROCEDURE|remote ischemic preconditioning|
214329251|NCT03127124|DRUG|Eloxatin Injectable Product|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.
214329252|NCT03271437|BEHAVIORAL|PC-based Flash|Progressive counting with Flash technique
214673421|NCT05431582|DRUG|ZN-c3|Given by PO 1 time a day with a glass (about 8 ounces) of water
214931252|NCT03724903|PROCEDURE|Ductal lavage|The patients received ductal lavage and breast massage every other day for two weeks. We used lidocaine (1%) for local anesthesia around the nipple. We used a lacrimal probe to identify 4-5 openings in the lactiferous ducts on the nipple and inserted the infusion cannula (21-23G). A total of 25ml of irrigation solution (5 ml of 2% lidocaine, 40 mg of triamcinolone acetonide, 20 ml of 0.9% saline and 1.0 g of ceftriaxone) was pumped into the ducts over 20-25 minutes. The patient returned to the clinic the next day for breast massage, and the cycle was repeated for two weeks.
214931253|NCT03724903|DRUG|Corticosteroid therapy|Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
214931254|NCT05535075|DEVICE|Vancomycin model-informed precision dosing|A dosing calculator is used for a posteriori calculation of vancomycin dose using a target AUC/MIC between 400-600 mg\*h/L
214931255|NCT05535075|DRUG|Vancomycin|Vancomycin treatment
214931256|NCT05139303|DEVICE|Orthoapnea NOA®|The efficacy of the appliance for the management of OSA will be stablished based on two criteria. Criterion I: \> 50% reduction of AHI/RDI. Criterion II: AHI/RDI \< 5 events/hour or \<15 events/hour with a significative reduction of OSA associates symptoms as defined before. Therapeutic failure will be established when at 100% of advancement of the device, there is less than 50% of reduction of the AHI/RDI with a residual AHI/RDI \>5 events/hour with OSA associates symptoms.
214931257|NCT03884699|PROCEDURE|Accuracy of planned transverse Maxillary distance using Mimics software after fixation using Patient specific implant|"Virtual planning: based on clinical evaluation and 3D cephalometric analysis. Virtual osteotomies mimicking segmental Lefort I and a bilateral sagittal split osteotomy.~Designing the virtual cutting guide. Virtual movement into the desired positions of the segmented maxilla and mandible, based on: clinical evaluation, 3D cephalometric analysis and the desired occlusion.~Once the optimal position of the maxilla is achieved, a patient specific implant will be virtually designed to fix the segmented maxilla in its new position.~Fabrication of the cutting guide using additive manufacturing technique from polymer material.~Fabrication of PSI from titanium alloy using additive manufacturing technique."
214931258|NCT01248052|DRUG|LY2979165|administered orally
214931259|NCT01248052|DRUG|Placebo|administered orally
214931260|NCT05862337|DRUG|Anlotinib hydrochloride capsules, Penpulimab injection|"Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor.~Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1)."
214329253|NCT03271437|BEHAVIORAL|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
214931261|NCT05862337|DRUG|Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo|placebo control, no active substance.
214931262|NCT05474170|OTHER|AHA resuscitation sequence|Starting the cardiopulmonary resuscitation by following the AHA guideline, meaning starting with 15 chest compressions, followed by 2 ventilations
214673422|NCT05431582|DRUG|Bevacizumab|Given by vein over about 30-60 minutes on Day 1 of each cycle
214931263|NCT05474170|OTHER|ERC resuscitation sequence|Starting the cardiopulmonary resuscitation by following the ERC guideline, meaning starting with 5 initial ventilations, then alternating 15 chest compressions with 2 ventilations
214931264|NCT00943956|DRUG|bicalutamide|
214931265|NCT00943956|DRUG|everolimus|
214329254|NCT02483247|DRUG|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
214329255|NCT02483247|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
214329256|NCT02483247|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).
214329257|NCT02483247|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
214329258|NCT02483247|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
214329259|NCT02483247|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
214329260|NCT02483247|DRUG|Sunitinib|Sunitinib 37.5 mg is administered once daily.
214329261|NCT01946308|OTHER|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
214673423|NCT05431582|DRUG|Pembrolizumab|Given by vein over 30-60 minutes on Day 1 of each cycle.
214673424|NCT06382493|DRUG|Tegoprazan-containing sequential H. pylori eradication therapy|tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy
214931266|NCT00943956|DRUG|leuprolide acetate|
214931267|NCT00943956|RADIATION|external beam radiation therapy|
214329262|NCT01953484|OTHER|Change in extracorporeal carbon dioxide removal|
214329263|NCT00476424|DRUG|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
214486228|NCT06738238|OTHER|ELDOA|"In this, each position will be maintained for 1 minute Level: C0/C1/C2 The patient is side lying with bottom arm folded under the head and maintain the neck in a horizontal position with the spine. the bottom leg is bent to stabilize the torso in a vertical position.~Level: C4/C5 Patient lying in supine position and raise both hand arm towards the roof of the room with extended wrist. Bilateral knee to chest with planter flexion at ankle joint.~Level: C5/C6 Same position as for c4/c5 with the arms will be elevated 120 degree Level C6/C7 Supine position with one arm abducted 90 degree and wrist joint at extension and the other hand abducted 30degrees with wrist joint at extension and one leg knee to chest and one leg raise with knee extension and planter flexion at ankle joint.~Level: T4/T5 Quadruped position with one arm abducted 90degrees with wrist at extension Level: T6/T7. Conventional TX is Hot Pack, Tens for 10min. Patient is assessed through baseline, week 1, week 2 and week 4."
214931268|NCT04399109|DEVICE|TCC-COVID mHealth solution|Patients place their index finger in the pulse oximeter to measure their oxygen saturation and pulse rate twice a day, which will take approximately 5 minutes each time. Patients then enter the results into the TCC-COVID app twice daily, and complete a symptom questionnaire via the TCC-COVID app once daily, which will take approximately 5 minutes. The symptom questionnaire was designed specifically for this study. The measurements and information are directly connected to a clinician interface (KIOLA database) which provides the data of all patients in aggregate and an easy to use responsive format with customisable alerts. The alerts identify if the oxygen saturation levels are low or the pulse rate is out of range. The alerts also identify if a measurement has not been completed in a timely manner and the central monitoring service will contact the patient to check on their safety or if they are experiencing any technical issues. The overall duration of participation will be 14 days.
214931269|NCT06436898|DEVICE|Combined overground gait exoskeleton and FES applied to lower limb|Gait rehabilitation for persons with stroke, with an overground exoskeleton combined with an electromyographically controlled FES applied to lower limb muscles during gait.
214329264|NCT01162629|DEVICE|Osteon bone graft|Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
214329265|NCT01903278|DRUG|PEG-IFN-SA /RBV|
214329266|NCT01903278|DRUG|Pegasys /RBV|
214329267|NCT02476565|DEVICE|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
214673425|NCT06382493|DRUG|Esomeprazole-containing sequential H. pylori eradication therapy|Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)
214329268|NCT02476565|DEVICE|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
214329269|NCT00124150|DRUG|Intravenous magnesium sulfate infusion|80mg per day
214329270|NCT01263873|DEVICE|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
214329271|NCT01263873|DEVICE|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
214329272|NCT00004026|DRUG|CT-2584|
214329273|NCT00004026|DRUG|chemotherapy|
214329274|NCT01503489|DRUG|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
214329275|NCT05734560|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
214329276|NCT05734560|DRUG|2141-V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
214329277|NCT03398993|DRUG|Clomiphene Citrate|50 mg twice daily from3rd day of cycle till 7th day of cycle
214329278|NCT03398993|DRUG|Human chorionic gonadotropin|75 IU dail;y from 6th day of cycle till 8th of cycle once daily
214329279|NCT03398993|DEVICE|Endometrial scratch|"The procedure was carried out in preovulatory day (known when dominant follicle reached 18\_20 mm in diameter), usually, done around day 14-day of the cycle.~In the theatre, Patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- A cuscoe's speculum was inserted into the vagina in order to visualize the cervix.~Cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus.~The procedure took approximately 15minutes to complete"
214486229|NCT06738238|OTHER|CORRECTIVE EXERCISES|All position will be held for 10 seconds. Initial phase Duration of this phase is 2 weeks. Exercise 1: lying supine on a foam roll with different abduction angles Exercise 2: side lying with external rotation Exercise 3: side lying with forward flexion Exercise 4: standing diagonal flexion Exercise 5: military press Improvement phase. Duration of this phase is 1 week we only add thera- band and dumbbells to the previously mentioned exercises Exercise 1: side lying external rotation with dumbbell Exercise 2: side lying forward flexion with dumbbell Exercise 3: standing diagonal flexion with thera-band Exercise 4: standing external rotation with thera band. Exercise 5: abduction in sitting on training ball. Exercise 6: lying prone on foam ball with different abduction angles Maintenance phase. Duration of this phase is 1 week. Conventional treatment Hot Pack, Tens for 10 minutes Patient is assessed through baseline, week 1, week 2 and week 4.
214486230|NCT06735495|DRUG|CD19&CD22 bispecific CAR-T cells|Each patient will receive CD19\&CD22 bispecific CAR-T cells by intravenous infusion on day 0
214486231|NCT06736314|DEVICE|a removable titanium clip|The removable titanium clip is a new type of titanium clip that offers advantages such as easy operation and convenient disassembly.
214329280|NCT04203719|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
214329281|NCT04203719|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
214329282|NCT04690608|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
214329283|NCT01905982|PROCEDURE|reflectory breathing therapy|duration:2x60 minutes
214329284|NCT01905982|PROCEDURE|conventional breathing therapy|duration:4x30 minutes
214329285|NCT03705039|OTHER|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
214329286|NCT03705039|OTHER|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
214329287|NCT00046345|DRUG|Atazanavir (BMS-232632)|
214329288|NCT00228592|DRUG|HepeX-B|
214329289|NCT00228592|DRUG|Hepatitis B Immune Globulin (HBIg)|
214329290|NCT05471362|DEVICE|Postpartum IUD|Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
214329291|NCT04428866|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed during visit 1 in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
214329292|NCT04428866|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days to assess activity, concurrent with CGM sensor wear.
214329293|NCT04428866|DIAGNOSTIC_TEST|Mixed meal tolerance test|After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
214329294|NCT04428866|DIAGNOSTIC_TEST|Glucagon Sensitivity Testing|After baseline blood sampling, glucagon will be administered by injection, and blood samples will be collected for analysis of glucose and hormone responses. This will allow us to assess whether sensitivity to glucagon is altered in PBH.
214329295|NCT04428866|DIAGNOSTIC_TEST|Hypoglycemic Hyperinsulinemic Clamp|This test will assess hormonal responses to hypoglycemia. Participants will arrive after an overnight fast. After baseline blood sampling, an infusion of insulin and glucose will be started, and infusions will be adjusted to allow glucose levels to drop very gradually. Blood samples will be collected for measurement of hormonal responses to lowering of glucose. This test will allow us to determine whether secretion of hormones which counteract hypoglycemia (counterregulatory hormones) is reduced in patients with PBH as compared with other groups.
214329296|NCT04428866|DIAGNOSTIC_TEST|analysis of fecal microbiome|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
214329297|NCT06010394|OTHER|conventional physiotherapy|ultrasound electrotherapy cold applications
214329298|NCT06010394|OTHER|exercises for the knee area|range of motion exercises strengthening exercises exercises to reduce edema
214329299|NCT06010394|OTHER|payment oriented massage|10 / 15-minute massage treatments to reduce payment
214329300|NCT02275897|PROCEDURE|Slow Speed of spinal injection|Speed of injection over 60 seconds
214329301|NCT02275897|PROCEDURE|Fast Speed of spinal injection|Speed of injection over 15 seconds
214931270|NCT06436898|DEVICE|Overground gait exoskeleton|Gait rehabilitation for persons with stroke, with an overground exoskeleton.
214329302|NCT01971827|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
214329303|NCT05437757|DEVICE|Surgical implantation of the PCL Breast scaffold with autologous fat grafting|Single shot of prophylactic perioperative antibiotics is given to the patient. A suitable incision is made to provide access followed by mobilisation of the breast gland.If present, the silicone implant is removed and capsulectomy performed. The implant pocket shall be rinsed with saline or antiseptic and a surgical drain shall be placed in the pocket at the discretion of the PI. The PCL Breast scaffold shall be inserted into the pocket and fixed using 2 to 4 sutures. The incision is closed. Liposuction is performed from another area of the body and lipofilling is performed within the breast scaffold. Sterile bandaging is applied and a daily wound revision is performed whilst an inpatient. A prophylactic antibiotic shall be administered to the patient.The patients shall be hospitalized overnight for clinical observation.
214329304|NCT01172691|PROCEDURE|Inhaled Nitric Oxide (iNO)|iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
214329305|NCT02537964|OTHER|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
214329306|NCT02601040|BIOLOGICAL|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old
214329307|NCT02601040|BIOLOGICAL|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \\320EU/Vial in children aged 3-16 years \\640EU/Vial in adults aged 17 up to 65 years old\\boost at month 6\\two-dose
214329308|NCT02601040|BIOLOGICAL|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
214329309|NCT01420302|PROCEDURE|Nurse directed|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
214329310|NCT01420302|PROCEDURE|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
214486232|NCT06736197|PROCEDURE|Group TVB|Patients who could not reach ETO2 value 90 with tidal volume breathing for 3 min were included in Group TVB tidal volume breathing was continued for 2 min.
214486233|NCT06736197|PROCEDURE|Group PSV|Preoxygenation was continued by providing 6cmH2O pressure support to the patients included in this group.
214486234|NCT06736197|PROCEDURE|Group PSV+PEEP|At the 4th minute, preoxygenation was continued by adding 4 cmH2O positive end-expiratory pressure to the same 6 cmH2O pressure support for 1 min in patients whose end-tidal O2 value still reached 90% and who were included in this group.
214931271|NCT03723161|DEVICE|Bone Achored Hearing surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected data will be used to assess the implant stability development of the Ponto BHX implant during up tp 24 months after implantation in a pediatric population undergoing bone anchored hearing surgery.
214931272|NCT03187847|DEVICE|Actigraph GT3X|"The primary outcomes are measured by the Actigraph GT3X (step counts) and FSMC (fatigue scale for motor and cognitive functions questionnaire) at three different points in time (Actigraph is worn for three weeks in total).~The secondary outcomes are emotional status, measured by the hospital anxiety and depression scale (HADS) and quality of life, measured by the Hamburg Quality of Life Questionnaire in MS (HAQUAMS)."
214931273|NCT04954794|DRUG|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214329311|NCT04910867|BEHAVIORAL|Components of Genetic Counseling|"The APOL1 testing program is designed to help living donor candidates to reduce their decisional conflict and enhance their informed consent regarding living donation. This intervention component entails: (1) an artificial intelligence-based conversational agent chatbot providing foundational information about the relationship between APOL1 and kidney disease and living donor outcomes, and APOL1 testing. The chatbot helps to relieve the workload on clinicians and scale up information giving. (2) The transplant nephrologist counseling component includes discussion about the APOL1 test results and shared decision making about donation, in a culturally competent manner, so as to enhance donor candidates' informed consent for living donation."
214329312|NCT04910867|DIAGNOSTIC_TEST|APOL1 genetic testing|APOL1 genetic testing will be performed while live kidney donor candidates are undergoing donor evaluation to identify whether they are at elevated risk of kidney disease post-donation. This risk information is expected to better enable donor candidates to make meaningful informed decisions about donating.
214329313|NCT04910867|OTHER|EHR integration|APOL1 genetic test results will be integrated into the electronic health record to provide clinical decision support to transplant nephrologists in evaluating donor candidates.
214329314|NCT04948632|OTHER|Complete LeoMed application|Access to the complete LeoMed application on the participant's smartphone. The day before surgery, participants will receive notifications encouraging them to use the platform to help prepare for their surgery. Safety instructions will also be sent. Postoperatively, notifications will be sent to the participants every day during the first 4 days and on the 7th day. These notifications will direct them to online forms that aim to assess their condition. On the 15th and 30th postoperative day, the platform will send a follow-up form. The platform will collect this information and classify it for appropriate management of their condition.
214329315|NCT04948632|OTHER|Basic LeoMed application|Access to a partial version of the LeoMed application on the patient's smartphone during a visit to the preoperative clinic. Before surgery, participants will receive a phone call to be summoned to the hospital and to remind them of the safety instructions. Postoperatively, their follow-up will not be standardized and will vary depending on their surgeon. On the 15th and 30th postoperative day, the platform will send a follow-up form. In the event of an emergency, they will receive the contact details of the CHUM Health Infoline to ensure the continuity of their care.
214329316|NCT05607303|OTHER|Clinical estrogen therapy|No research interventions will be used as a part of the study since the research is observational. Estrogen treatment will be prescribed and followed by participant's clinical physician.
214329317|NCT05984888|BEHAVIORAL|MIND Diet Intervention Group|Participants will receive individually tailored nutrition counseling on adopting the MIND diet pattern from a registered dietitian nutritionist (RDN) for a total of 8 sessions spanning 12 weeks. After completing the counseling sessions participants will be followed up 6 months later to collect additional questionnaires and assessments.
214329318|NCT05984888|BEHAVIORAL|General Health Curriculum (GHC) Group|Participants will meet with trained study staff for 8 sessions spanning 12 weeks covering content on non-diet related health topics. After these sessions, participants will be followed up 6 months later to collect additional questionnaires and assessments. Once 6-month follow-up has been completed, participants will be offered to receive the MIND diet intervention offered in the MIND Diet Intervention Group.
214486235|NCT06734715|OTHER|Conservative oxygenation|Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
214486236|NCT06734715|OTHER|Liberal oxygenation|Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
214673426|NCT00685178|DRUG|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"
214931274|NCT04954794|COMBINATION_PRODUCT|TACE|TACE is performed by using drug-eluting beads or using microspheres combined with Lipiodol-pirarubicin emulsion per Investigator's decision. TACE treatment starts at day 0. Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after TACE.
214931275|NCT04121065|PROCEDURE|Blood withdrawal|Blood withdrawal of maximum 60 ml performed to each enrolled patient during the study for primary and secondary endpoints evaluation.
215071101|NCT06888258|PROCEDURE|Ultrasound guided Erector Spinae Plane block|"Group E: The block will be performed preoperatively with full aseptic precautions. The ultrasound probe will be placed on the back in a vertical orientation on the lateral side of the posterior median line to identify the transverse process of the 5th thoracic vertebra and erector spine muscle.~A skin wheal using 3ml of 1% lidocaine will be made 2 to 3 cm superior to the superior aspect of the transducer. The puncture will be performed using the intra-plane needling technique after local anaesthesia infiltration. A 20-gauge Tuohy needle connected to a syringe containing the anesthetic mixture or saline will be advanced. When the puncture needle touch the transverse process, with no blood, gas, or cerebrospinal fluid observed on aspiration, 20 mL of 0.25% bupivacaine will be administered between the erector spine muscle and transverse process.~Local anesthetic diffusion between the transverse process and erector spinae muscle is an indication of a successful puncture."
214931276|NCT06402448|DIAGNOSTIC_TEST|muscle pain , joint pain and nerve pain.|to discover the percentage of each tissue that causing pain even it is muscle, joint or nerve in patients with spinal disorders.
214329319|NCT05821309|DRUG|PEG 3350|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
214329320|NCT05821309|DRUG|PEG-3350 with electrolytes|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
214329321|NCT05821309|DRUG|Glycerin|Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
214329322|NCT06423612|BEHAVIORAL|POC urine assay informed enhanced ART adherence counselling for viral suppression|Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their ART adherence with provision of enhanced ART adherence counseling for viral suppression.
214329323|NCT06960707|RADIATION|Radiation therapy - 1 week|2600 cGy whole breast radiotherapy in five fractions (Arm 1) over 1 week
214329324|NCT06960707|RADIATION|Radiation therapy - 2 weeks|3200 cGy whole breast radiotherapy with a concomitant tumor bed boost to 3600 cGy in 10 fractions (Arm 2) over 2 weeks. In Arm 2, if no cavity is visible due to oncoplastic surgery, we will deliver 32 Gy to the whole breast only, without a boost.
214931277|NCT04639102|OTHER|PATH Intervention|"Patients will receive an enhanced level of care and service:~1. Discharge planning- PATH clinicians will develop an individualized treatment plan at time of ED discharge. Each patient will receive next-day phone call to monitor status. There will be additional patient and family education, triage of new or worsening symptoms, and additional telephone contact as determined in treatment plan. There will be communication with home health teams as needed.~2. Care coordination- PATH clinicians will arrange necessary primary medical doctor and specialty appointments. They will also communicate treatment plan to outpatient provider and arrange transportation for patients.~3. Home monitoring/ Home Health Services- If patients are eligible and consent to home health services, they will be enrolled in Penn Medicine Home Health (PMHH). This will include virtual home monitoring, skilled nurse care, home physical and occupational therapists, social work services, and wound care."
214931278|NCT05679531|OTHER|intervention|After filling out the patient information form, the patients who met the research criteria were chewed gum for an average of 15 minutes.
214329325|NCT05446909|BEHAVIORAL|IBMT mindfulness|IBMT is an effortless mindfulness technique; health education is a class including health-related topics - exercise, sleep, nutrition, lifestyle, stress management
214486237|NCT06735521|DIAGNOSTIC_TEST|Cardiac magnetic resonance stress-perfusion|"Included patients will be examined at the Karolinska University Hospital in a 1.5T Siemens Sola magnetic resonance camera at rest and during adenosine stress with specific CMR sequences (adenosine stress-perfusion, myocardial velocities, and tissue characterization) for non-invasive determination of macro- and microvascular dysfunction, global myocardial function, pulmonary artery pressure and scarring of the myocardium.~Adenosine or Regadenoson will be used as stress medication which is according to clinical routine. Adenosine will be infused over approximately 5 minutes (110-140 μg / kg/min), Regadenoson (5 ml) will be a 10-second injection (400 μg single dosage). Intravenous gadolinium-based contrast agents will be administered, Gadovist (1 mmol/ml, gadobuterol), 0.15 mmol/kg during stress and rest."
214931279|NCT03359330|OTHER|Degradable Conduit Small Gap Tublization|Degradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
215071102|NCT06888258|PROCEDURE|Ultrasound guided Mid-point to Pleura block|"Group M: The block will be performed preoperatively with full aseptic precautions. The ultrasound probe will be placed on the back in a vertical orientation on the lateral side of the posterior median line to identify the transverse processes of the 4th and 5th thoracic vertebrae and pleura.~A skin wheal using 3ml of 1% lidocaine will be made 2 to 3 cm superior to the superior aspect of the transducer. Using the in plane needling technique in the space between the transverse processes of the 4th and 5th thoracic vertebrae, the puncture needle needle tip will be placed at the mid-point between the transverse process and pleura, with no blood, gas, or cerebrospinal fluid observed on aspiration, 20 mL of 0.25% bupivacaine will be administered. The local anesthetic spread will be noted in the area midway between the transverse process and pleura is an indication of a successful puncture."
215071103|NCT06727903|OTHER|laboratory biomarker analysis|Results of laboratory biomarker analysis will be analyzed as predictors for mortality
215071104|NCT06886828|DEVICE|Virtual reality goggles during HFNC|HFNC oxygen therapy will be started with video demonstration accompanied by virtual reality glasses. Physiological parameters and anxiety level will be recorded 10 minutes after HFNC oxygen treatment. Video recording will be terminated. Since the parameters in the scales should be evaluated by 2 nurses independent of the study during the study, only the behaviours of the child during the procedure should be video recorded by a mobile phone. For the participants and parents who want to participate in the study but do not approve the video recording, the parameters will be evaluated instantly by a researcher independent from the study. The study will continue until the 30-person intervention group is completed.
215071105|NCT06886828|DEVICE|HFNC oxygen therapy with routine service application|HFNC oxygen therapy will be started with routine ward practice. Physiological parameters and anxiety level will be recorded 10 minutes after HFNC oxygen treatment. Video recording will be terminated. Since the parameters in the scales should be evaluated by 2 nurses independent of the study during the research, only the behaviours of the child during the procedure should be video-recorded by means of a mobile phone. For participants and parents who want to participate in the study but do not approve the video recording, the parameters will be evaluated instantly by a researcher independent from the study
214329326|NCT05446909|BEHAVIORAL|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
214329327|NCT03738826|BEHAVIORAL|Behavioral Intervention|Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
215071106|NCT06732141|BEHAVIORAL|Personalized Telephone-Based Psychological Support|"This intervention involves weekly, individualized 30-minute telephone sessions conducted over 8 weeks. The sessions are designed to address anxiety and improve adherence to inhaled corticosteroid (ICS) therapy in asthma patients. The intervention comprises four core components:~1. Medication Education: Detailed guidance on the benefits, mechanisms, and safety of ICS therapy, aiming to address misconceptions and reduce fears about side effects.~2. Lung Rehabilitation Guidance: Instructions for breathing exercises and tailored physical activity to improve respiratory health and overall well-being.~3. Motivational Interviewing (MI): A patient-centered approach that identifies barriers to adherence, enhances self-efficacy, and motivates behavior change.~4. Progressive Muscle Relaxation (PMR): A systematic relaxation technique to alleviate physical and emotional stress, tailored to each patient's anxiety levels."
214329328|NCT05560932|BEHAVIORAL|IMB-motivational interviewing (MI) techniques (IMB-MI)|The clinical pharmacist will employ MI in informational, participant-centered discussions in which the clinical pharmacist and participant collaboratively discuss the harms of drinking and polypharmacy (specifically alcohol interactive medications), symptoms associated with alcohol and specific medications, and how to mitigate these harms. Motivational elements include messages highlighting the participant's personal risk of bothersome symptoms from their use of alcohol and level of polypharmacy, attitude change elements to improve attitudes toward the intended behavior change, social normative support for the intended behavior change including identification of people who can support the participant in this process, and a menu of options for referrals for skill building (e.g. Social Work, meeting with the clinical pharmacist at their clinic, follow-up with the HIV clinician, alcohol-reduction programs, based on what is locally available as part of VA-based care).
214486238|NCT06734117|DIAGNOSTIC_TEST|Elecsys® Troponin T hs Gen 6|It is an immunoassay for the in vitro quantitative determination of cardiac troponin T (cTnT) in human serum and plasma using cobas e platforms. This investigational immunoassay is intended to aid in the diagnosis of myocardial infarction.
214931280|NCT01275508|DRUG|FITC-Adalimumab|The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
214931281|NCT06684015|DRUG|İNTRATECHAL MORPHİNE GROUP|Addition of intrathecal morphine as an adjuvant to local anesthesia in routine spinal anesthesia application and multimodal analgesia applications
214931282|NCT06684015|PROCEDURE|Erector Spinae Plane Block|Application of erector spinae plane block and multimodal analgesia applications at the end of the operation after routine spinal anesthesia application
214931283|NCT02890485|DEVICE|Dry Needling|Dry needling consists of small, monofilament needles that are administered directly into the tissue and manipulated to make the muscle relax for pain relief. This technique is used to treat dysfunctions in skeletal muscle and connective tissue to help diminish pain, reduce impairments of body structure and restore function. Dry needling will be performed in the gluteal or the quadriceps muscle groups depending upon group randomization.
214931284|NCT02890485|DEVICE|Sham Dry Needling|"The same overall procedures will be used as in the true dry needling groups and applied to the same muscle groups (gluteal or quadriceps) depending upon ground randomization. Sham dry needling will be performed using a commercially available sham needling system commonly.This set-up utilizes a blunt tipped needle. When the sham needle is pressed downward, the barrel of the needle retracts into the handle, giving the appearance of insertion of the needle through the skin. This also creates pressure on the subject's skin, increasing the sensation of dry needling. Patients will not be allowed to observe the areas being needled or sham needled."
214931285|NCT02890485|OTHER|Physical Therapy|Physical Therapy and exercise as determined by the examining clinician based on the patients specific impairments and functional limitations. All subjects enrolled in this study will receive an initial physical therapy (PT) evaluation and then 2 additional PT sessions a week a part. Interventions and prescribed home exercises will be specific to the patients' primary individual impairments as determined during the initial PT evaluation. These interventions reflect current evidence, but will not be restrictive to specific exercises; prescribed exercises will be deemed appropriate based on the treating PTs' examination, evaluation, and identification of each patients' primary deficits, impairments, functional limitations, and current literature.
214931286|NCT02938988|PROCEDURE|Antimicrobial photodynamic therapy|Described in arm/group
214931287|NCT02938988|PROCEDURE|Scaling and root planning|Described in arm/group
214931288|NCT02938988|DEVICE|red laser|658nm; 0.1W; 2229J/cm², 10s per point
214931289|NCT02938988|DRUG|methylene blue dye|
214931290|NCT03121196|OTHER|Epices score|Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression
214931291|NCT06575088|OTHER|Standard tourniquet pressure (250 mmHg)|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
214931292|NCT06575088|OTHER|Limb occlusion pressure|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
214931293|NCT06575088|OTHER|Cotton Pad|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
214931294|NCT06575088|OTHER|Elastic stockinette|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
214931295|NCT04865601|OTHER|resectomy of the colon|The patient scheduled for colon resectomy are included in the study
214931296|NCT06623123|DEVICE|Oto Smartphone Application (Oto Health Ltd)|The smartphone application delivers personalized tinnitus therapy combining evidence-based CBT with mindfulness, patient education as well as physical therapy such as stretches and exercises. There are additional sounds available to listen to from the sound library. There will be a structured programme that the participants can work through however they are encouraged to personalise their own therapy.
215071107|NCT06732141|BEHAVIORAL|Standard Care with Weekly Follow-Up Calls|Participants receive weekly telephone follow-up calls for 8 weeks. These calls include health status assessments, symptom monitoring, and general medication inquiries but exclude psychological or educational components.
214329329|NCT06323304|OTHER|Auricular acupressure|Auricular acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds, which is an herb in traditional medicine. The acupoints on the ear that will be treated with auricular acupressure therapy are Shenmen (TF4), Internal nose (TG4), Lung (CO14), Wind stream (SF1,2i), Adrenal gland (TG2p). These acupoints are believed to be effective in the treatment of allergic rhinitis. The patches will be kept on the auricle for one week.
214931297|NCT06623123|BEHAVIORAL|Tinnitus Retraining Therapy (TRT)|Tinnitus-retraining therapy will be offered in the control arm which represents the standard evidence-based intervention on the NHS. (2) Participants enrolled to this arm will undertake tinnitus retraining therapy with a trained audiologist. The sessions will last 30 minutes with the option for further sessions should the patient which to have more support with their tinnitus to mimic the NHS programme as much as possible. These sessions will encompass a brief audiological history followed by therapy tailored to the patient's needs allowing for patient-centred optimisation of tinnitus burden and secondary comorbidities. This may include relaxation, CBT and advice surrounding sound as well as white noise masking therapy.
214931298|NCT04797741|OTHER|IDEA3 Intervention|Delivery of IDEA3 intervention, a 12-hour online sexual assault resistance intervention for college women.
214931299|NCT02895113|DRUG|Aspirin|Patients suffering from type 2 diabetes will be randomized to receive 100 mg/day or placebo for one year
214931300|NCT02895113|OTHER|Placebo|Patients in this arm will be treated with placebo
214931301|NCT02878564|DRUG|Praziquantel|40 mg/kg, PO (orally administered tablets)
214931302|NCT02045862|DRUG|Solifenacin succinate|Participants received solifenacin 5 mg orally once a day at the same time each day.
214931303|NCT02045862|DRUG|Mirabegron|Participants received mirabegron 50 mg orally once a day at the same time each day.
214931304|NCT02045862|DRUG|Placebo to match solifenacin|Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
214931305|NCT02045862|DRUG|Placebo to match mirabegron|Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
214931306|NCT03721055|RADIATION|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
214931307|NCT04830384|DEVICE|Fully Active|7 subjects will be dispensed active treatment devices with light and music fully functional
214931308|NCT04830384|DEVICE|LLLT Only|7 subjects will be dispensed active treatment devices with only light functional
214931309|NCT04830384|DEVICE|Music Only|7 subjects will be dispensed placebo comparator devices with only music functional
214931310|NCT04830384|DEVICE|Placebo|7 subjects will be dispensed placebo or sham devices with no light or music functional
214931311|NCT03164564|DRUG|Oral CAB|CAB 30 mg tablet
214931312|NCT03164564|DRUG|Oral TDF/FTC|TDF/FTC 300 mg/200 mg fixed dose combination tablet
214931313|NCT03164564|DRUG|Placebo for oral CAB|Placebo tablets
214931314|NCT03164564|DRUG|Placebo for oral TDF/FTC|Placebo tablets
214931315|NCT03164564|DRUG|CAB LA|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
214931316|NCT03164564|DRUG|Placebo for CAB LA|Administered as one 3 mL intramuscular injection in the gluteal muscle
214931317|NCT04722744|PROCEDURE|screwmented metal frameworks|Intervention group: in which the edentulous area will be restored with 3-implant, screwmented CAD/CAM frameworks constructed based on planned implant positions
214931318|NCT04139512|PROCEDURE|guided surgery|placement of implant with local anesthesia using full guided surgery protocol versus free- hande one
214931319|NCT04139512|PROCEDURE|conventionnel implant placement|placement of dental implant with conventionnal freehand technic
214931320|NCT06059430|OTHER|no intervention|no intervention
214931321|NCT02449304|DEVICE|Endometrial ablation (4th gen)|Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining
214931322|NCT02691013|DRUG|Ramelteon|
214931323|NCT02691013|DRUG|Placebo|
214329330|NCT06323304|OTHER|Sham acupressure|Sham acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds. The acupoints that will be treated with auricular acupressure therapy are Helix 2 (HX10), Shoulder (SF4), Clavicle (SF6), Anus (HX5) and Tooth (LO1). These acupoints are not used to treat allergic immune-related problems or respiratory diseases. The patches will be kept on the auricle for one week.
214486239|NCT06734117|PROCEDURE|Blood sample collection|Blood will be collected from each recruited individual by a healthcare practitioner at five time points after emergency department presentation.
214486240|NCT06727396|DRUG|CKD-508 Tablet|Investigational drug
214486241|NCT06727396|DRUG|Placebo Tablet|Placebo
214931324|NCT04623879|DRUG|Lumacaftor, Ivacaftor Drug Combination|
214931325|NCT04306159|PROCEDURE|Subcostal TAP|Subcostal transversus abdominis plane block
214931326|NCT04306159|PROCEDURE|Modified RSB|Rectus Sheath Block under the guidance of surgical incision
214931327|NCT04306159|OTHER|General anesthesia|Traditional general anesthesia management
214931328|NCT01363752|DRUG|Advagraf|oral
214931329|NCT01363752|DRUG|Mycophenolate Mofetil|oral
214931330|NCT01363752|DRUG|Sirolimus|oral
214931331|NCT01363752|DRUG|Corticosteroids|i.v. and oral
214931332|NCT05169437|DRUG|Niraparib|Eligible participants will receive daily dosing of Niraparib.
214931333|NCT03539770|PROCEDURE|Posterior spinal fusion|Surgical procedure that involves placement of spinal rods to correct spinal curvature
214931334|NCT03544099|DRUG|Pembrolizumab|Pembrolizumab 200mg Intravenous Solution
214931335|NCT02357706|DEVICE|APAP A (ResMed AirSense AutoSet)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
214931336|NCT02357706|DEVICE|APAP B (Apex iCH Auto)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
214931337|NCT02856607|OTHER|determine the prognosis of threated patients according to the clinical care pathway.|
215071108|NCT06738082|BIOLOGICAL|Influenza vaccine|Standard, commercially available, quadrivalent split-vaccine against influenza is given to all study participants.
214931338|NCT05248256|OTHER|Evidence-based radiation dose limitation to the vertebral bone marrow|The only intervention that will occur during the radiation treatment planning process will be the application of evidence-based radiation dose limitations to the vertebral bone marrow during treatment plan optimization in order to attempt to limit Grade 3 Lymphopenia (G3L) toxicity.
214931339|NCT04743193|OTHER|2.5 %sevoflurane|for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration
214931340|NCT04743193|OTHER|8% sevoflurane low flow anesthesia|For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .
214931341|NCT00154778|DRUG|Taxol, UFT,Leucovorin|
214931342|NCT02327403|DRUG|Belatacept|Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.
214931343|NCT05035667|OTHER|Questionnaire Administration|Complete questionnaires
214931344|NCT04603768|OTHER|Theraband exercises|Group A performed theraband exercises for 6 weeks.In the first 2 weeks theraband with low resistance was used to perform exercises and then we proceeded gradually with higher resistance therabands.Theraband exercises was performed for Shoulder Flexion,Shoulder Extension Strengthening, Shoulder Internal Rotation Strengthening, Shoulder External Rotation Strengthening, Shoulder Abduction, Empty Can Exercise \& Rowing Exercise with 8-10 reps, 3sec hold and 2-3 sets With each of these exercises
214931345|NCT04603768|OTHER|Co-contraction exercises|"Muscle co-contraction is the simultaneous contraction of the muscles acting around a joint. Subject stood upright \& contracted both the groups (agonist and antagonist) simultaneously without bringing movement at shoulder joint with 6-8 reps , 3sets \& 5- 15 seconds duration of sustained self-arm bracing or stiffening was maintained.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
214931346|NCT04603768|OTHER|Isometric exercises|"Isometric exercises of shoulder were performed in subjects for 6 weeks which included isometric Shoulder flexion, shoulder abduction isometric exercise, isometric shoulder external rotation, isometric shoulder internal rotation \& isometric shoulder extension with 8-10 reps, 5 sec hold and 2 sets.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
214931347|NCT03734146|BEHAVIORAL|Aerobic Exercise|180 minutes of moderate-vigorous intensity aerobic exercise per week
214931348|NCT03734146|BEHAVIORAL|Resistance Exercise|180 minutes of resistance exercise per week
214931349|NCT03734146|BEHAVIORAL|Combined aerobic and resistance exercise|180 minutes of exercise per week with 90 minutes per week coming from moderate-vigorous intensity aerobic exercise and 90 minutes per week coming from resistance exercise
214931350|NCT04510246|BEHAVIORAL|Enhanced case management|"The health care worker will offer support to the GP for all aspects of the cascade of hepatitis C care including:~* Further testing advice~* Awareness that treatment can be prescribed by the general practitioner~* Conducting pre-treatment work-up assessment~* DAA prescription guidelines, including linkage to specialist consultation~* Providing treatment support~* Advising on testing process for cure~* Advising on post-cure management including methods of follow-up to manage risks (e.g. harm minimisation, reducing re-infection risk, opioid substitution therapy)~* Linking GP to resources for patients with cirrhosis or other concerns to specialist support for ongoing management.~The GP will be offered the option of the DoH specialist to contact the patient directly with the GP's consent to notify them of their result and to educate them on testing and treatment options and referral back to their GP."
214931351|NCT04751786|DRUG|PRECIOUS-01|Subjects will be enrolled in one of three dosing cohorts (three subjects per cohort for the planned dose escalation with a planned extension to a total of six subjects for the two highest dosing cohorts for the evaluation of the pharmacodynamic effects of PRECIOUS-01 for determination of the RP2D, if MTD is not reached).
214931352|NCT01075646|DRUG|ropivacaine|"Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.~Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.~Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h."
214931353|NCT01075646|DRUG|saline solution|"Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.~Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.~Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h"
215071109|NCT06885320|BEHAVIORAL|IMPROVE|IMPROVE is an individual manualized intervention. Session1 includes: • psychoeducation focusing on anxiety, its role in contributing to substance use, and the maintaining role of fear of bodily sensations • guided discussion of maladaptive thoughts about bodily sensations related to anxiety • how to challenge bodily sensations cognitively • generating three takeaways about the benign nature of anxiety Session 2 includes: • review of homework • psychoeducation focusing on the role of uncertainty in anxiety and identifying how new information can inform beliefs about uncertainty. • when to challenge thoughts related to uncertainty and when to use acceptance regarding uncertainty. Session 3 includes: • review interoceptive exposure (IE) and behavioral exercises (BE) for progress • revisit beliefs related to cognitive biases • discuss areas where skills can be used moving forward
214486242|NCT06741800|DRUG|ACARIZAX®️|ACARIZAX®️：The recommended dose for adults (18-65 years) is one freeze-dried tablet (12 SQ-HDM) daily, placed under the tongue.
214486243|NCT06743113|DEVICE|Hemanext ONE System|Hypoxic red blood cells
214486244|NCT06743113|DEVICE|Conventional RBCs|Conventional red blood cells
214931354|NCT02002312|DRUG|Lu-177-DOTA-girentuximab|"Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.~Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments."
214931355|NCT05186246|DRUG|Combination cream|Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate Cream combination (10 gram), were applied on one side of the face twice daily by participants.
214931356|NCT05186246|DRUG|Placebo cream|Cream that is identical looking were given to subjects to be applied on the other side of the face twice daily
214931357|NCT02048566|DEVICE|ImaCor PM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorPM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
214931358|NCT02048566|DEVICE|ImaCor SM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorSM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
214931359|NCT02048566|OTHER|Control PM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
214931360|NCT02048566|OTHER|Control SM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
214931361|NCT04318522|DEVICE|Transcranial Direct Current Stimulator|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
214931362|NCT02394496|DRUG|Fulvestrant|Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
214931363|NCT02394496|DRUG|Lapatinib|1500mg (TBD) O.S. qd
214931364|NCT02394496|DRUG|Aromatase Inhibitors|as indicated in the Summary Product Characteristic
214931365|NCT02394496|DRUG|Placebo Lapatinib|1500mg (TBD) O.S. qd
214931366|NCT00863473|PROCEDURE|Surgical treatment with LCP|
214931367|NCT04114331|OTHER|Manual therapy and exercise|Manual therapy consisting of soft tissue and joint mobilization to gain mobility. Therapeutic exercise was active motion and resisted motion to gain motor control and motor coordination in the new range.
214931368|NCT04562831|DIETARY_SUPPLEMENT|EH301 (Nicotinamide Riboside/Pterostilbene)|Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.
214931369|NCT04310631|DRUG|Ranibizumab Injection|Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections
214931370|NCT01943968|OTHER|Blood test|
214931371|NCT04151160|DIAGNOSTIC_TEST|Point of care ultrasound measurements|i. Ultrasound images will be obtained using a commercial, high frequency, linear Philips ultrasound probe attached to small, portable tablet. This tablet will have the capability of transferring the saved images to the secure MuscleSound cloud-based server.
214931372|NCT05285995|OTHER|Music Intervention|Before the operation, subjects were asked to choose their favorite music to listen so as to reduce the anxiety before the operation and before the induction of anesthesia.
214931373|NCT05285995|OTHER|The animation intervention|Before surgery, subjects were asked to choose their favorite cartoons to watch to reduce anxiety before surgery and induction of anesthesia.
214931374|NCT00220324|DRUG|Minisiston (SH D00342A)|Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
215071110|NCT06885320|BEHAVIORAL|HET|"Clinicians will administer HET using a PowerPoint presentation focused on healthy living habits, including healthy eating, water consumption, and sleep hygiene. Clinicians will guide participants through an exercise using the USDA food tracker to plan, record, and monitor nutritional information of meals. HET also includes a digital program that will include EDUCATION, MY CURRENT MOOD, and BEHAVIORAL ACTIVITY tabs."
214931375|NCT06097624|OTHER|synchronized tele-exercise|All evaluations and exercise interventions will be performed by via Google Meet, a video-conferencing application. The participation link will be sent to the individual by the researcher before each session. In case of any technological disruption, the session will be postponed to the nearest available time by phone. All interventions will be run by a blinded researcher.
214931376|NCT03648671|DRUG|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
214931377|NCT03648671|DRUG|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
214931378|NCT03648671|DRUG|rasagilina mesilato (12 weeks)|rasagilina mesilato
214931379|NCT03648671|DRUG|rasagilina mesilato (12 weeks)|rasagilina mesilato
214931380|NCT06550011|DRUG|ABI-110 Low Dose|Low dose. lower than the safety factor of 10 as recommended by the FDA
214931381|NCT06550011|DRUG|ABI-110 Medium Dose|Medium dose
214931382|NCT06550011|DRUG|ABI-110 High Dose|High Dose
214931383|NCT05380544|DEVICE|Extracorporeal Shockwave Therapy|ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
214931384|NCT04253639|OTHER|Questionnaires|"Patients must fill questionnaires to collect socio-demographics, aetiology and characteristics of pain, efficacy and tolerance regarding the TENS.~Study sites must fill questionnaires to collect information regarding the type of pain management centre, the characteristics of the clinician, the characteristics of the TENS prescribed."
214931385|NCT02683655|DRUG|Apatinib|Apatinib 500mg qd p.o.
214931386|NCT02683655|DRUG|Apatinib|Apatinib 750mg qd p.o.
214931387|NCT01895608|BEHAVIORAL|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
214931388|NCT01895608|BEHAVIORAL|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
214329331|NCT06323304|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of fluticasone propionate nasal spray as needed, and lifestyle modifications.
214329332|NCT06849830|BEHAVIORAL|Narrative Medicine (NM) Workshop Series|"The Narrative Medicine (NM) Workshop Series is a structured six-week behavioral intervention designed to enhance self-expression, reflection, and resilience in adolescents and young adults recovering from eating disorders. This intervention differs from traditional psychotherapeutic or psychoeducational approaches by integrating literary analysis, creative writing, and guided discussion as therapeutic tools.~Each one-hour weekly workshop includes:~* Close reading of visual or written texts related to themes such as self-definition, resilience, kindness, and possibility~* Creative writing exercises in response to structured prompts that encourage self-reflection and personal storytelling~* Facilitated group discussions to foster connection, self-expression, and emotional processing in a supportive environment"
214329333|NCT04958694|BEHAVIORAL|CEDARS|This intervention is intended to help adolescents cope with stress and improve positive affect.
214329334|NCT06461572|OTHER|conventional therapy|This group will receive conventional physiotherapy, which will consist of manual resistance-based neck strengthening exercises. The exercises will last 30 minutes apiece and cover cervical flexion, extension, side flexion, side flexion with rotation, and pure rotation with moderate resistance. The power ball's effect on proximal muscle control and refractive error in children with developmental delays will also be discussed.
214486245|NCT06894004|BEHAVIORAL|Ketogenic Diet|Participants will consume an isocaloric ketogenic diet for 4 weeks with all food provided as packed-out meals.
214486246|NCT06894004|BEHAVIORAL|Control Diet|Participants will consume an isocaloric control diet for 4 weeks with all food provided as packed-out meals.
214486247|NCT06744855|DEVICE|Non-invasive circulation gloves|Non-invasive class I medical device, circulation gloves with semiconductors embedded in the fabric.
214931389|NCT01895608|BEHAVIORAL|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
214931390|NCT01895608|BEHAVIORAL|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
214931391|NCT03829618|DRUG|Topical lidocaine|1% lidocaine topically applied in 4 mL aliquots
214931392|NCT03829618|DRUG|Nebuliser solution|2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer
214931393|NCT03829618|DRUG|Nebuliser Suspension|2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer
214931394|NCT01906021|PROCEDURE|CT/CBCT thermometry method|The study consists of acquiring one or maximum two additional CT or CBCT of the liver during hepatic RFA or MWA and analyzing the images to obtain a temperature map
214931395|NCT01906021|PROCEDURE|Ablation Probe|Temperature measured with thermocouples (current clinically approved method consisting of invasive needle placement for point measurement in area of concern)
214931396|NCT03395470|DRUG|PXL770|MAD
214931397|NCT03395470|DRUG|Placebo|MAD
214931398|NCT03395470|DRUG|Rosuvastatin|DDI
214931399|NCT03142542|DRUG|ZYDENA TAB.75mg(Udenafil 75mg)|ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks
214931400|NCT03142542|DRUG|Placebo Oral Tablet|Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
214931401|NCT03575299|BIOLOGICAL|The adoptive treatment of allogeneic γδT cells|Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.
214329335|NCT06461572|OTHER|conventional therapy along with standard therapy and stability exercises.|"Group B: In addition to standard care, this group will engage in power ball exercises for neck stability and strengthening. Gradually, the resistance will rise.~Three mints in each position for a total of fifteen mints of ball exercises. At first, Powerball progressively strengthened the muscle and reduced the pain , and with continued development, allowed them to move in a pain-free range."
214329336|NCT06048913|DRUG|Nimotuzumab|Nimotuzumab 400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses. The use of nimotuzumab is not interrupted due to interruption of radiotherapy during the administration until the end of radiotherapy.
214329337|NCT06048913|DRUG|S-1|Oral chemotherapy with the S-1 regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral S-1 course from Monday to Friday is synchronized with radiation therapy.
214329338|NCT06048913|RADIATION|Concurrent radiation therapy|Outline the target area layer by layer on the enhanced CT image, PGTV, PTV. The endangered organs are delineated layer by layer on the cross-section, and extended 0.3cm to form a corresponding plan to endanger the organs. The reverse intensity modulated radiotherapy plan was designed on the Monaco treatment plan system, with a prescribing dose of 56Gy/30F for PTV and 60Gy/30F for pGTV, and the target dose distribution and organ exposure dose were evaluated layer by layer on a cross-sectional surface, and combined with dose-to-volume histogram (DVH) evaluation and optimal treatment plan, the maximum dose of radiation in the spinal cord \< 40 Gy and lung V20\<30%. After the treatment plan is confirmed, the dose is verified on the treatment machine, and the treatment plan is executed after it is accurate. govern
214329339|NCT05971758|DRUG|Fimepinostat|The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.
214329340|NCT05151809|OTHER|Clinical information|The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.
214329341|NCT06472206|BEHAVIORAL|CHW Sessions|Sessions with a Community Health Worker (CHW).
214329342|NCT06472206|DEVICE|CleverCap|The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
214329343|NCT06228079|DRUG|Immunotherapy,Toripalimab Injection|Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
214329344|NCT06228079|DRUG|Chemotherapy,Gemcitabine based regimen|Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
214329345|NCT05768867|OTHER|FRAnçaise du PEYronie's Disease QUESTionnaire|Complete an online FRAnçaise du PEYronie's Disease QUESTionnaire
214329346|NCT05388942|PROCEDURE|Virtual reality hypnosis|VRH offers predefined hypnosis sessions with no need of trained physician or nurse or caregiver mobilization. Consisting of a headset including headphones and a virtual reality screen, VRH allow patients to select a visual and sound environment (e.g.: tropical beach, space, underwater…) into which the hypnotic speech is delivered. That way, the patient's attention is distracted and muscular relaxation is obtained, a major relaxation factor. HRV is simple, quick, and presumably safe.
214329347|NCT05388942|DRUG|Nitrous oxide|inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
214673427|NCT00685178|BEHAVIORAL|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
214673428|NCT00685178|DRUG|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
214673429|NCT04076124|DEVICE|Active rTMS-DLPFC|Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
214673430|NCT04076124|DEVICE|Active iTBS-DLPFC|Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
214673431|NCT04076124|DEVICE|Sham TBS-DLPFC or Sham rTMS-DLPFC|Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
214931402|NCT03575299|OTHER|Control|No allogeneic γδT cells will be administered to patients with MDR-TB.
214931403|NCT03575299|DRUG|Conventional treatment|Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
214931404|NCT03505593|DEVICE|ENVUE System|The ENvizion Medical™ ENVUE™ System is designed to aid qualified operators in the placement of the ENvizion Medical™ Enteral Feeding Tube™ into the stomach or small intestine.
214931407|NCT06604962|PROCEDURE|IMES using IEP|First group (n=12) received IMES using inverse electrode placement. The needle electrode inserted into the paraspinal region was connected to the active or cathode pole of the electrical stimulator. The reference or anode pole of the electrical stimulator was connected to the electrode that was inserted into the MTrP area of the UT muscle. The muscle was stimulated for 10 min with a tolerable intensity in a single session to induce muscle relaxation
214931408|NCT06604962|PROCEDURE|IMES using CEP|Second group (n=12) underwent IMES with conventional electrode placement. In this group, the cathode pole of the stimulator was connected to the needle inserted into the UT muscle, and the anode pole was connected to the needles of the paraspinal region of the cervical spine. Needle electrodes were connected using alligator clip connectors. The muscle was stimulated for 10 min with a tolerable intensity in a single session to induce muscle relaxation.
214931409|NCT06604962|OTHER|Sham-IMES|Third group (n=12) received sham-IMES. Similar to the experimental intervention groups, the cathode pole of the stimulator was connected to the needle inserted into the UT muscle, and the anode pole was connected to the needles of the paraspinal region of the cervical spine. However, the delivered IMES was very minimal intensity
214931410|NCT06472531|DRUG|INR101|• 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
214931411|NCT06472531|DRUG|INR101|"* 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT~* 7±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT"
214931412|NCT00893165|BEHAVIORAL|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
214931413|NCT04971148|OTHER|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level equal to patient peak tidal inspiratory flow
214931414|NCT04971148|OTHER|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.33 times of patient peak tidal inspiratory flow
214931415|NCT04971148|OTHER|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.67 times of patient peak tidal inspiratory flow
214931416|NCT04971148|OTHER|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set 2 times of patient peak tidal inspiratory flow
214931417|NCT02275780|DRUG|Doravirine|Doravirine 100 mg tablet administered p.o. q.d.
214931418|NCT02275780|DRUG|Darunavir|Darunavir 800 mg tablet administered p.o. q.d.
214931419|NCT02275780|DRUG|Ritonavir|Ritonavir 100 mg tablet administered p.o. q.d.
214931420|NCT02275780|DRUG|TRUVADA™ or EPZICOM™/KIVEXA™|The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
214931421|NCT03960866|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
214931422|NCT03960866|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
214931423|NCT00405522|DRUG|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
214931424|NCT00405522|DRUG|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
214931425|NCT04754438|BEHAVIORAL|e-CBT|Electronically delivered cognitive behavioural therapy
215071111|NCT06891495|OTHER|Expert Evaluation of Adapted Questionnaire|This intervention involves inviting a group of subject matter experts-including dental specialists, public health professionals, and communication experts-to evaluate the adapted questionnaire. The questionnaire, derived from the Questionnaire for Assessing Educational Podcasts (QAEP) and tailored for assessing an AI-generated health podcast, covers four dimensions: Access and Use, Design and Structure, Content Adequacy, and Value as an Aid to Learning. Experts will complete a structured online survey (via Google Form) to rate each item's clarity, relevance, and necessity. Their feedback is integral to refining and validating the instrument prior to its use with the general public.
215071112|NCT06891495|OTHER|AI-Generated Health Podcast Evaluation|Participants in this group will first listen to a 4-minute AI-generated health podcast on gum health and prevention. The podcast was produced using Google NotebookLM and is based on publicly available information from the American Academy of Periodontology, with appropriate source credit. After listening, participants will complete a validated questionnaire (administered via Google Form) that assesses the podcast's accessibility, design, content adequacy, and educational value. This intervention is designed to measure public perception, engagement, and overall feasibility of using AI-generated podcasts as an educational tool for health communication.
215071113|NCT06890754|DIAGNOSTIC_TEST|Diagnostic hysteroscopy|Diagnostic hysteroscopy. An IHC study of the expression of the plasma cell marker CD138 was systematically performed for all samples studied
215071114|NCT06632405|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
214486248|NCT06744855|DEVICE|Fabric gloves|These gloves will look and feel identical to the active circulation gloves, but will not have semiconductors embedded in the fabric.
214931426|NCT04754438|BEHAVIORAL|Mental Health Coaching|Electronically delivered mental health coaching
214931427|NCT02855359|DRUG|denintuzumab mafodotin|SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
214931428|NCT02855359|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
214931429|NCT02855359|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
214931430|NCT02855359|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
214931431|NCT02855359|DRUG|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
214931432|NCT02855359|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
214931433|NCT00797628|BEHAVIORAL|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
214931434|NCT00797628|BEHAVIORAL|Smoking Coach|"Control Patients will be referred by paper prescription to the control- Smoking Coach website."
214931435|NCT00775840|DRUG|Candesartan|Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
214931436|NCT00775840|DRUG|Placebo|Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
214931437|NCT03007290|OTHER|Therapeutic drug monitoring|Therapeutic drug monitoring for colistin
214931438|NCT00981045|DRUG|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
214931439|NCT00981045|DRUG|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
214931440|NCT05153200|DRUG|Upadacitinib|15 mg po daily
214931441|NCT05153200|DRUG|Adalimumab|40 mg sc every other week
214931442|NCT01241877|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin
214931443|NCT01241877|DIETARY_SUPPLEMENT|placebo|placebo
214931444|NCT05129475|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
214931445|NCT05129475|DRUG|Ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to PF-07321332/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours after PF-07321332/ritonavir dosing.
214931446|NCT00630175|DRUG|zolpidem-MR (modified release)|
214931447|NCT00630175|DRUG|zolpidem (SL800750)|
214931448|NCT00630175|DRUG|placebo|
214931449|NCT01469832|BIOLOGICAL|MA09-hRPE|"* Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells"
215071115|NCT06632405|DRUG|Nab paclitaxel|Nab paclitaxel 100mg/m2 will be administered as an intravenous infusion every 4 weeks in d1,8,15until unacceptable toxic effects or disease progression or other termination criteria appeared.
215071116|NCT06632405|DRUG|Levocetirizine Hydrochloride|5mg daily, start 3 days before the 1st administration
214486249|NCT06743646|DRUG|ZVS101e|subretinal injection of ZVS101e
214486250|NCT06893926|DIAGNOSTIC_TEST|Prenatal ultrasound examination with blood flow analysis|"For all patients who provide informed consent to participate in the study, an ultrasound examination is performed within 48 hours prior to delivery. This assessment includes:~1. Measurement of fetal anthropometric parameters and estimation of fetal weight.~2. Evaluation of blood flow using the pulsatility index (PI) in the UA, UtA, DV, and MCA."
214931450|NCT02190032|DEVICE|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
214931451|NCT02190032|DEVICE|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
214931452|NCT05702242|PROCEDURE|IUD removal with no visible strings|Removal with either alligator forceps or MVA
214931453|NCT05702242|DEVICE|Alligator forceps|IUD removal with alligator forceps
214931454|NCT05702242|DEVICE|Manual Vacuum Aspirator|IUD removal with MVA
214931455|NCT04181983|OTHER|Personalized exercise program|Home-based personalized exercise program using a smart phone app
214931456|NCT04181983|OTHER|WHO exercise guidelines|Standard exercise counselling according to WHO guidelines
214931457|NCT04430842|DRUG|QBS10072S|QBS10072S targets cancers with high LAT1 expression.
214931458|NCT05531578|DEVICE|INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)|Transfemoral implantation of the INOVARE® transcatheter valve
214931459|NCT01864915|DRUG|Prucalopride|Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
214931460|NCT01864915|PROCEDURE|Colon Capsule|Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
214931461|NCT03408470|DRUG|TD-1473 oral capsule|(Intervention description included in arm description)
214931462|NCT03408470|DRUG|[14C]-TD-1473 IV bolus|(Intervention description included in arm description)
214931463|NCT03408470|DRUG|[14C]-TD-1473 Oral Capsule|(Intervention description included in arm description)
214931464|NCT05482321|DRUG|Definity Suspension for Injection|"* DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided)."
214931465|NCT00003764|DRUG|cyclophosphamide|
214931466|NCT00003764|DRUG|fludarabine phosphate|
214931467|NCT03676114|DRUG|ketamine|0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
214931468|NCT03676114|DRUG|Normal saline|Same volume of normal saline will be administrated
214931469|NCT00738881|DRUG|Erlotinib Hydrochloride|Given PO
214931470|NCT00738881|DRUG|Pemetrexed Disodium|Given IV
215071117|NCT05844098|DEVICE|K-wire|K-wire No. 2.0 insertion was done additionally from arthroscopic assisted CC-stabilization by inserting K-wire from acromion process to distal clavicle.
215071118|NCT06894407|DEVICE|Device: Targeted Hyperthermia Therapy|Intra-tumoral gold nanorods (SivaRods) exposed to Near Infrared Light (860 +/- 10nm) mediated targeted hyperthermia therapy.
214329348|NCT04199299|DEVICE|Heart rate and respiration rate sensors|The use of sensors to monitor physiological variables (e.g. heart rate, sleep). The design is a before-and-after comparison with respect to whether the use of sensors has changed the caregivers' practice and their (perceived) understanding of the participant. The frequency of participants' self harm or aggressive behavior after as compared to before the introduction of pulse- and respiration monitors will also be charted.
214931471|NCT04202913|BEHAVIORAL|Coaching|Child will receive 1:1 coaching with health coach.
214931472|NCT00348790|DRUG|vatalanib|
214931473|NCT06410703|DRUG|CAN1012|CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W
214931474|NCT01044290|OTHER|Life Completion|Subjects discussed life review, issues of forgiveness and heritage and legacy.
214931475|NCT01044290|OTHER|Attention Control|Subjects listened to a non-guided relaxation CD
214931476|NCT01901354|OTHER|Low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
214931477|NCT01901354|OTHER|Airway Pressure Release Ventilation (APRV)|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
214931478|NCT02733354|DEVICE|watch viedo|
214931479|NCT04874233|DRUG|HU6|HU6 is active study drug
214931480|NCT04874233|DRUG|Placebo|Non-active study drug N = 20
214931481|NCT06158659|DIETARY_SUPPLEMENT|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
214931482|NCT06158659|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
214931483|NCT06158659|OTHER|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
214931484|NCT02809859|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
214931485|NCT00759785|DRUG|dalotuzumab (MK0646)|Single intravenous infusion
214931486|NCT00720512|BIOLOGICAL|bevacizumab|Given IV
214931487|NCT00720512|DRUG|fluorouracil|Given IV
214329349|NCT05651009|PROCEDURE|TKA|Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation
214329350|NCT06483269|PROCEDURE|PRP infiltration|"a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician.~It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site.~PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat.~PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations."
214329351|NCT01859715|DRUG|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
214329352|NCT01859715|DRUG|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
214329353|NCT01859715|DRUG|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
214329354|NCT01252290|DRUG|Lovaza™|4 capsules daily for 6 months
214329355|NCT01825369|DRUG|IV L-carnitine|See arm description
214486251|NCT06893926|DIAGNOSTIC_TEST|Umbilical cord blood gas analysis|A 0.5 mL blood sample is collected from the clamped section of the umbilical cord and immediately sent to the laboratory for cord blood gas analysis, including the determination of pH, base excess (BE), and lactate levels.
214673432|NCT03247907|DEVICE|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
214673433|NCT03247907|DEVICE|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
214673434|NCT03247907|DEVICE|Condition C: CPAP with Cold Passover|CPAP with Cold Passover with mouth leak
214931488|NCT00720512|DRUG|irinotecan hydrochloride|Given IV
214931489|NCT00720512|DRUG|leucovorin calcium|Given IV
214931490|NCT00720512|DRUG|oxaliplatin|Given IV
214931491|NCT05735314|OTHER|consultation with a specialist|The intervention consists of consultation with a specialist, use of a nurse navigator to help patients with appointments and help them understand their condition, and use of a data query of the electronic health record (EHR) to identify abnormal test results to make sure they are appropriately addressed.
214931492|NCT05735314|OTHER|Usual care|Usual care involves primary care physicians ordering additional tests and referrals to evaluate patients with new anemia and decreased glomerular filtration rate (GFR) .
214931493|NCT06051123|DIETARY_SUPPLEMENT|Probiotic|Participants will be taking 1 sachet a day.
214931494|NCT06051123|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day.
214931495|NCT04586738|PROCEDURE|non-perforating deep sclerectomy surgery|Non-penetrating deep sclerectomy is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma.This surgery is performed to facilitate the outflow of aqueous humour from the anterior chamber to the subconjunctival space through a natural membrane (trabeculo-Descemet's window). This enables a more physiological reduction of intraocular pressure to be achieved.
214931496|NCT06424990|OTHER|balance training with TENS|children will receive Biodex balance training with TENS for 30 minutes a day, 5 days per week for 4 weeks
214931497|NCT06424990|OTHER|Balance training with placebo TENS|children will receive Biodex balance training with placebo TENS for the same period.
214931498|NCT02032381|OTHER|late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.|
214931499|NCT05127850|BEHAVIORAL|Consultation audio recording app|Smartphone or tablet mobile application which allows for voice recording
214931500|NCT03074435|DEVICE|Indoor residual sprayings|Houses will be spayed with this formulation containing Pyrimiphos methyl.
215071119|NCT06896786|OTHER|dialysis assisted with the sodium management tool|"Sodium management tool is a modul of the fresenius 6008 dialysis machine. This model approximates changes in plasma electrolyte concentrations during dialysis and allows the estimation of sodium concentration based on dialysate conductivity. Na control biosensor continuously (every minute) monitors the dialysate side sodium balance based on measurements of fresh and spent dialysate conductivities and the application of a kinetic model to account for the typical influence of other ions on dialysate conductivity. In activated Na control, as zero diffusive mode, dialysate sodium is then adjusted continuously to minimize diffusive Na transfer. SMT is part of the 6008 Machine and its certification is included in the Fresenius 6008 Machine certification. Untill now there is no data if this modul benefits. in this study the investigator compares standard of care dialysis (Arm 1) with dialysis assisted with the SMT (Arm ) on clinical outcome"
214931501|NCT03074435|DEVICE|Larvicide|Larval breeding sites will be treated with larvicide
214931502|NCT03074435|BEHAVIORAL|BCC|
214931503|NCT03074435|BIOLOGICAL|Ivermectin|
215071120|NCT06895668|OTHER|None (cohort study)|None (cohort study)
215071121|NCT06896071|BEHAVIORAL|Project SOLVE|"Project SOLVE is a 30-minute self-guided online activity that includes an introduction to problem solving and which types of problems might be most appropriate for this skill; a description of how the brain facilitates problem solving; vignettes demonstrating how older adolescents have solved their problems; scientific evidence that problem solving can work; practice exercises; and activities to encourage the use of problem solving in daily life. The intervention teaches students how to solve problems via the SOLVE framework (i.e., Saying what the problem is; One goal to aim for; Listing some solutions; Voting for the best solution; Exploring what works)."
215071122|NCT06896071|BEHAVIORAL|Project Success|Project Success is comparable to Project SOLVE in format and length (i.e., a 30 minute online, self-guided intervention) and teaches young people three strategies to reach their academic goals: how to take effective notes, how to break big assignments down into smaller tasks, and how to ask trusted others for help.
215071123|NCT06896890|DRUG|CIS-DPI|"* Administration of cisplatin by inhalation (pulmonary route) using single-use RS01 capsule-based device and CIS-DPI hard capsules containing 2.5 mg, 5 mg, and 10 mg cisplatin.~* CIS-DPI, administered once-a-day, 5-days on followed by 2-days off. Daily dose to be administered will range from an initial dose of 2.5 mg cisplatin to a maximal theoretical dose of 30 mg (i.e., dose 1 to dose 7)."
214931504|NCT01646021|DRUG|Ibrutinib|560 mg once daily continuous (without interruption) by mouth for 21-day cycles
214931505|NCT01646021|DRUG|Temsirolimus|175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
214931506|NCT03268824|DEVICE|Electroencephalogram (EEG)|Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
214931507|NCT03268824|DEVICE|Diffusion Tensor imaging|We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
214931508|NCT03268824|OTHER|Language assessment|The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
214931509|NCT05888441|OTHER|Obstacle characteristics|"In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast."
214931510|NCT03256058|PROCEDURE|Reinflation after early deflation|the tourniquet would be inflated immediately before incision and deflated after the use of the cement , and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation. The total time of tourniquet inflation is controlled within 90 minutes.
214931511|NCT03256058|PROCEDURE|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
214931512|NCT04712019|DEVICE|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric at 125mmHg of continuous negative pressure on a closed surgical incision
214931513|NCT04712019|DEVICE|Standard Silver-containing Dressing|A standard silver-containing dressing applied to a closed surgical incision
214931514|NCT02589249|DIETARY_SUPPLEMENT|AyuFlex|Active product
214931515|NCT02589249|DIETARY_SUPPLEMENT|Placebo|Placebo
214931516|NCT00485043|BEHAVIORAL|Modified T'ai Chi: T'ai Chi for Arthritis|
214931517|NCT04521621|BIOLOGICAL|Gebasaxturev|Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.
214931518|NCT04521621|DRUG|Pembrolizumab|Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.
215071124|NCT06895278|DRUG|Methotrexate|Prevalent use of methotrexate in pediatric age
215071125|NCT06895278|DRUG|Biological Drug|Prevalent use of biological drugs in pediatric age
215071126|NCT06896305|COMBINATION_PRODUCT|CDED (Crohn's Disease Exclusion Diet) in addition to anti-TNF therapy|"Patients in the experimental group will receive professional dietary advice on how to adhere to CDED for 12 weeks, in addition to anti-TNF therapy while patients in the control group will receive only anti-TNF therapy for the entire duration of the study.~Diet adherence is completely voluntary and is not enforced in any way. CDED is divided into 3 phases, the first two, grouped as the induction phase, with 6 weeks of strict diet and 6 weeks to gradual food reintroduction, followed by 12 weeks of patients follow-up.~Five foods (chicken, eggs, potatoes, apple and bananas) are permitted at the start of the diet; the patient can then choose to consume a range of permitted foods at will, the variability of which increases after the first six weeks"
215071127|NCT06896305|DRUG|Anti-TNF Therapy|The control group will receive only anti-TNF therapy as per standard of care. This therapy is recommended by guidelines and is the cornerstone of treatment of Crohn's disease and ulcerative colitis.
215071128|NCT06896461|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|"The test consists of physical exertion performed on a stationary bike with a progressively increasing workload, continuing until specific electrocardiographic and/or clinical criteria are met or muscle fatigue occurs. The rate of workload increase (ramp) will be personalized and adjusted to ensure the exercise reaches its peak in approximately 10 minutes.~Throughout the test, a continuous electrocardiogram (ECG) will be recorded, and various physiological parameters will be measured. These include ventilation, oxygen consumption, carbon dioxide production, and related derived parameters, which will be assessed using a mouthpiece or a face mask through which you will need to breathe for the entire duration of the test. Blood pressure will also be measured at two-minute intervals."
214931519|NCT01282164|PROCEDURE|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
214329356|NCT00086580|BIOLOGICAL|FluCAM [Fludara + Campath]|"Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m\^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity."
214673435|NCT03247907|DEVICE|Condition D: CPAP with Modified humidifier|CPAP with Modified humidifier with mouth leak
214673436|NCT03247907|DEVICE|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
214931520|NCT01282164|PROCEDURE|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
214931521|NCT02220179|BEHAVIORAL|The Resilience Program|Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
214931522|NCT06540664|OTHER|Auricular Acupuncture needles|Auricular Acupuncture needles 5 days in 2 weeks
214931523|NCT06540664|OTHER|Sham Auricular Acupuncture needles|Sham Auricular Acupuncture needles 5 days in 2 weeks
214931524|NCT00559403|BEHAVIORAL|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
214931525|NCT00559403|BEHAVIORAL|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
214931526|NCT04525079|DRUG|CT-P59|CT-P59 will be administered
214931527|NCT04525079|DRUG|Placebo|Placebo-matching CT-P59
214931528|NCT01460654|DRUG|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
214931529|NCT01460654|DRUG|Alendronate|Alendronate (Fosamax) 70mg every week.
214931530|NCT01460654|DRUG|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
214931531|NCT01460654|DRUG|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
214931532|NCT06400459|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.1%|IVW-1001 Ophthalmic Eyelid Wipe 0.1%
214931533|NCT06400459|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.2%|IVW-1001 Ophthalmic Eyelid Wipe 0.2%
214931534|NCT06400459|DRUG|IVW-1001 Placebo|IVW-1001 Placebo
214931535|NCT01663779|PROCEDURE|Ultrasound guided radial artery catheterization.|Radial artery catheters will be placed with the assistance of bedside ultrasound.
214931536|NCT01663779|PROCEDURE|Blind insertion of radial artery catheterization|Radial artery catheters will be placed by the palpation technique only.
214931537|NCT00438100|DRUG|Capecitabine|1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
214329357|NCT00086580|BIOLOGICAL|fludarabine phosphate|Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m\^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
214329358|NCT02872922|OTHER|Low intensity therapeutic ultrasound|The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
214329359|NCT02965612|DEVICE|Injex|administration of Specific Immunotherapy (ITS) with car pressure injector without a needle
214329360|NCT02965612|PROCEDURE|SCIT|administration of Specific Immunotherapy (ITS) via traditional subcutaneous
214329361|NCT04409028|PROCEDURE|Coronal restoration|A restorative material like composite resin is condensed into the cavity of teeth.
214329362|NCT01670929|DRUG|Progesterone|
214931538|NCT00438100|DRUG|S-1|80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
214931539|NCT02465879|OTHER|Therapist Triage|An extended role occupational or physical therapist will triage each subject in the study to determine the urgency of their case and how soon they need to see the rheumatologist.
215071129|NCT06896461|DIAGNOSTIC_TEST|Lung function|"Assessment of both static lung volumes (vital capacity, total lung capacity, functional residual capacity, and residual volume) and dynamic lung volumes (forced vital capacity and forced expiratory volume in one second, or FEV1).~Additionally, the flow-volume curve is measured, generated by continuously recording airflow and volume using an electronic spirometer during a foThe diffusion capacity for carbon monoxide (DLCO) can be measured using the single-breath method (DLCOSB). The patient inhales a small, known concentration of carbon monoxide (CO), holds their breath for 10 seconds, and then exhales. A sample of alveolar gas (from the end of expiration) is analyzed to determine the amount of CO absorbed during the breath, expressed in ml/min/mm Hg.~By repeating the test with inhalation of gas mixtures containing different oxygen concentrations (approximately 20%, 40%, and 60%), it is possible to assess the diffusion subcomponents: the membrane component and capillary blood volume."
215071130|NCT06896461|DIAGNOSTIC_TEST|Biomarkers evaluation|"Samples of plasma will be collected for bimarkers quantification in heart failure.~Speecifically, plasma levels will be quantitatively assessed using plasma obtained from venous blood. Blood will be collected in tubes containing 0.129 M Na-citrate (9 volumes of blood to 1 volume of Na-citrate), immediately centrifuged at 3000 g for 15 minutes at 4°C. Circulating levels of both immature and mature SP-B will be analyzed via Tricine gel electrophoresis followed by immunoblotting with an anti-SP-B antibody, allowing for the detection of all SP-B isoforms (proprotein 42 kDa, intermediate 23 kDa, and mature 8 kDa).~To validate potential heart failure biomarkers, a quantitative, scalable, and cost-effective method-Multiple Reaction Monitoring (MRM)-will be used. MRM, based on triple quadrupole mass spectrometry, enables precise quantification of proteins/peptides and their isoforms in complex biological samples."
215071131|NCT05949697|DIETARY_SUPPLEMENT|Dry Eye Drink|Dry Eye Drink is a dietary supplement containing electrolytes, vitamins and natural anti-inflammatories.
214329363|NCT01670929|OTHER|Placebo|
214329364|NCT04863976|OTHER|Dynamic stretching|Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)
214329365|NCT04863976|OTHER|Passive stretching|passive stretching of the quadriceps muscle
214329366|NCT04863976|OTHER|Self-stretching|Self-stretching of the quadriceps muscle
214329367|NCT00807534|DRUG|ipratropium bromide|ipratropium bromide nebulization
214329368|NCT00807534|DRUG|placebo|placebo nebulization
214329369|NCT00807534|BEHAVIORAL|constant rate step test|nebulization of 500ug
214329370|NCT00807534|BEHAVIORAL|constant rate shuttle walk test|nebulization of 500ug
214329371|NCT04164147|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior Cruciate Ligament sacrificing or retaining implant
214329372|NCT04164147|DIAGNOSTIC_TEST|CT scan|CT scans of the affected knee joint before and after the surgical procedure
214329373|NCT04164147|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
214329374|NCT04164147|DEVICE|one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and NexGen PS total knee implant|Participant are randomly allocated to receive one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and the NexGen PS total knee implant for treatment of end-stage knee osteoarthritis.
214329375|NCT02645916|DRUG|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
214329376|NCT02645916|DRUG|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
214931540|NCT05182359|OTHER|SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test|The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) test is used to predict the four-year likelihood of myocardial infarction, stroke, hospitalization for heart failure or death. It will be provided to the participant's ordering provider.
214931541|NCT00046852|BIOLOGICAL|filgrastim|
214931542|NCT00046852|BIOLOGICAL|pneumococcal polyvalent vaccine|
214931543|NCT00046852|BIOLOGICAL|therapeutic autologous lymphocytes|
214329377|NCT04871334|DRUG|TWP-101|IV infusion Q2W for 4 weeks (28-day cycles)
214931544|NCT00046852|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214931545|NCT00046852|DRUG|carmustine|
214931546|NCT00046852|DRUG|cyclophosphamide|
214931547|NCT00046852|DRUG|melphalan|
214931548|NCT00046852|PROCEDURE|bone marrow ablation with stem cell support|
214329378|NCT00002816|DRUG|cytarabine|Given IV
214931549|NCT00046852|PROCEDURE|peripheral blood stem cell transplantation|
214931550|NCT05091736|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (BG-709b)
214931551|NCT05091736|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
214931552|NCT00875199|BEHAVIORAL|contingency management|Prize-based contingency management for weight loss
214931553|NCT00875199|BEHAVIORAL|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
214931554|NCT02316899|DRUG|linaclotide|Oral administration once daily
214931555|NCT02316899|DRUG|Placebo|Oral administration once daily
214931556|NCT03140332|OTHER|Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib|To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
214931557|NCT06618742|PROCEDURE|Cryotherapy|Focal cryoballoon ablation, 1-3 treatments with an interval of 1-3 weeks
214931558|NCT03108170|OTHER|perineal massage program|The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day
215071132|NCT06896773|OTHER|Impact of Normobaric Hypoxia on Cardiac Biomarkers in trained men|The intervention will consist of three series differing in terms of simulated altitude: S1 (normoxia), S2 (2000 m a.s.l.), and S3 (3000 m a.s.l.). Each research series will consist of one day of the measurements. All participants will perform two ergocycle tests (the graded exercise test GXT and constant-workload exercise test CXT at the individual lactate threshold workload (WRLT) until volitional exhaustion) with 10 minutes of active recovery break in different environment (S1, S2, S3- 3000). The order of the series will be randomized across all participants. The fraction of inspired oxygen (FIO2) will depend on the series and will be as follows: S1 (normoxia) = 20.9%; S2 (2000 m a.s.l.) = 16,5%; S3 (3000 m a.s.l.) = 14.4%. The hypoxic environment will be maintained using AirZone climate technology (AirSport). Between the series, there will be a one-week active rest break excluding exposure to hypoxia and performance of high-intensity exercise.
215071133|NCT06896773|OTHER|Effects of Hypoxic Endurance Training on Cardiac Biomarkers in the IHT group|The participants in IHT group will live in normoxic conditions, but part of their training will be performed in normobaric hypoxia in a hypoxic chamber. The experiment will consist of two series of testing: S1 (baseline) and S2 (after 3 weeks of training and 3 days of rest). All participants will perform the same testing protocol as in stage 1-albeit in a normoxic environment and after 72h of rest, all testing procedures will be repeated in a hypoxic environment.
214329379|NCT00002816|DRUG|dexamethasone|Given IV
214329380|NCT00002816|DRUG|etoposide|Given IV
214931559|NCT03108170|OTHER|Pelvic floor muscle exercise program|The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day
214931560|NCT03108170|OTHER|Educational pelvic floor dysfunction prevention program|This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
214931561|NCT02581475|PROCEDURE|Extending withdrawal time in the proximal colon|
214931562|NCT02581475|PROCEDURE|Segmental examination twice of the proximal colon|
214931563|NCT01570270|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
214931564|NCT03450785|OTHER|ultrasound examination|Doppler ultrasound examinations from the thyroid cartilage level to the supraclavicular region were used after CVC placement and on each of the following days until the catheter was removed.
214329381|NCT00002816|DRUG|idarubicin|Given IV
214329382|NCT00002816|DRUG|ifosfamide|Given IV
214329383|NCT00002816|DRUG|leucovorin calcium|
214329384|NCT00002816|DRUG|mesna|Given IV
214329385|NCT00002816|DRUG|pegaspargase|Given IV
214329386|NCT00002816|DRUG|therapeutic hydrocortisone|
214931565|NCT01967706|OTHER|mTHS|Single use of Tobacco Heating System 2.2 Menthol (mTHS)
214329387|NCT00002816|DRUG|thioguanine|
214329388|NCT00002816|DRUG|vincristine sulfate|Given IV
214329389|NCT00002816|RADIATION|low-LET cobalt-60 gamma ray therapy|
214329390|NCT00002816|RADIATION|low-LET electron therapy|
214329391|NCT00002816|RADIATION|low-LET photon therapy|
214329392|NCT00002816|DRUG|Methotrexate|Given IV
214329393|NCT05330650|DRUG|Coated Vicryl+|We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
214931566|NCT01967706|OTHER|mCC|Single use of subject's own menthol cigarette (mCC)
214931567|NCT01967706|OTHER|NRT|Single administration of 2 mg gum (Nicorette® 2mg)
214931568|NCT02777970|DRUG|Tramadol Hydrochloride/Dexketoprofen Trometamol|
214931569|NCT02777970|DRUG|Tramadol Hydrochloride/Paracetamol|
214931570|NCT02777970|DRUG|Placebo|
214329394|NCT05330650|DRUG|Vicryl|We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
214329395|NCT03710278|DEVICE|LPat Device|Performing Lumbar Puncture utilizing LPat device
214931571|NCT04001387|PROCEDURE|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the lateral position with the hip and knees flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance using dynamic needle tip positioning to administer the spinal anesthetic.
214931572|NCT03585153|OTHER|Non-contrast magnetic resonance imaging|subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
214931573|NCT02319967|BEHAVIORAL|CAPE|Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers
214931574|NCT02319967|BEHAVIORAL|CHW home visits|Home visits by community health workers (CHW) to assist children and their caregivers to implement the CAPE and other guideline-recommended competencies.
214931575|NCT00538044|DRUG|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
214329396|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with pediatric biopsy forceps|Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
214329397|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with cholangioscopy-directed biopsies|Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
214329398|NCT01038271|OTHER|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
214329399|NCT01038271|OTHER|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
214329400|NCT02561507|BEHAVIORAL|Survey|
214329401|NCT01978431|DRUG|cocaine hydrochloride|
214931576|NCT02347891|DRUG|Belimumab|Randomized phase: Week 0 - Week 40
214931577|NCT02347891|DRUG|Placebo|Randomized phase: Week 0 - Week 40
214931578|NCT05845567|DRUG|Givinostat|ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.
214931579|NCT05845567|DRUG|Clarithromycin|Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.
214931580|NCT01685489|DRUG|Docetaxel, PSK®|
214931581|NCT01685489|DRUG|Docetaxel, Placebo|
214931582|NCT00558662|DEVICE|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
214931583|NCT00558662|DEVICE|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
214329402|NCT01978431|DRUG|methylphenidate|
214329403|NCT05199857|BEHAVIORAL|WE BEAT Group Wellness Education program - phase 1|Participants will be assigned into a small group with 3-6 other participants and will participate in a weekly, 45-50 minute intervention session for 5 weeks, delivered by a licensed clinical psychologist or limited licensed clinical psychology fellow using University of Michigan (UM) Zoom. Each session will focus on a particular skill related to wellness and resiliency. There will also be a short battery of questionnaires to complete.
214329404|NCT05199857|BEHAVIORAL|HEART Club Home Exercise program - phase 2|This is an individualized home exercise program adapted from the exercise programs used in traditional, hospital-based cardiac rehabilitation. A complete cardiopulmonary exercise test (CPET) may be completed if needed for a baseline and one will be done at the last visit. The exercise physiology team will discuss participants exercise goals, interests, and available resources to help develop the exercise plan for the research study. Once the program is designed, participants will complete the exercise activities in the plan. Over time, participants will advance through various stages in the program and then will be gradually introduced to the principles of exercise rehabilitation and more intense physical exercise. Participants will be asked to wear a wearable activity tracker and have scheduled video check-ins with the exercise physiology team. Throughout the program participants will complete a short battery of surveys.
214329405|NCT02155595|OTHER|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
214329406|NCT02155595|OTHER|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
214329407|NCT02621970|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
214329408|NCT02621970|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1
214329409|NCT02621970|DRUG|Docetaxel|Docetaxel 60mg/m2, D1
214329410|NCT02621970|DRUG|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
214329411|NCT02621970|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
214931584|NCT06499168|DRUG|neoadjuvant chemotherapy: anthracycline based chemotherapy and taxans before surgery|"In locally advanced breast cancer patients who will receive neoadjuvant chemotherapy formalin fixed paraffin embedded tissue specimen of the baseline TCNB of locally advanced breast cancer will be obtained from pathology laboratory, Pathology Department, Assiut University.~* Histological diagnosis of H\&E stained sections will be confirmed.~* Immunohistochemical staining for CD10 .~* Baseline clinicopathological features of patients who will receive neoadjuvant chemotherapy will be collected from patients' records.~* Correlation between CD10 expression and the baseline clinicopathological features with the response to neoadjuvant chemotherapy."
214329412|NCT03829735|OTHER|Human biological samples|Collection of capillary blood for HbsAg testing. Collection of 12 mL of blood for HbsAg positive women and 1 mL for HbsAg positive children.
214329413|NCT06095843|PROCEDURE|placement of dental implants|placement of dental implants in mandibular reconstruction.
214329414|NCT00261716|BEHAVIORAL|IPS|Individual Placement and Support Evidence based supported employment
214329415|NCT00261716|BEHAVIORAL|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
214329416|NCT00261716|BEHAVIORAL|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
214329417|NCT04141462|GENETIC|blood sample|blood test
214329418|NCT02075437|BEHAVIORAL|Feeling and Body Investigators with Functional Abdominal Pain|"Investigator's ten session intervention trains children to be Feeling and Body Investigators. Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).~If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation."
214329419|NCT02075437|BEHAVIORAL|Treatment Strategies|"1. identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:~2. adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;~3. incorporate caregivers as role models and facilitators based on attachment research."
214329420|NCT05291390|DRUG|Pyronaridine Tetraphosphate|Via oral capsules.
214329421|NCT04793880|BEHAVIORAL|Medication Cost Information|This version of the HFrEF medication checklist includes patient-specific estimated monthly out-of-pocket cost for each medication. TailorMed, a company designed to provide financial counseling and planning for patients, will generate the patients' out-of-pocket cost based on insurance status. The costs for non-generic HFrEF medications will then be populated onto a checklist of recommended heart failure medications so that patients and their clinicians will have this information available during their clinical encounter.
214329422|NCT04793880|BEHAVIORAL|Heart Failure Medicines Checklist|The Heart Failure Medicines Checklist is an evidence-based medication checklist that describes guideline-recommended medications for HFrEF. This tool is used during the clinical encounter to facilitate a discussion about medications that may be most appropriate for the patient.
214329423|NCT04439240|DRUG|FGFR Inhibitor AZD4547|Given PO
214329424|NCT03844451|DRUG|Liposomal Bupivacaine|At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
214931585|NCT06098872|DRUG|Trametinib tablet|Drug is supplied in 2mg and 0.5 mg tablets
214673437|NCT03247907|DEVICE|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
214931586|NCT02541669|DRUG|TAK-491|TAK-491 tablets
215071134|NCT06896773|OTHER|Effects of Hypoxic Strength Training on Cardiac Biomarkers in the NRT group|The participants in the NRT group will perform resistance training in normoxia. The experiment will consist of two series of testing (S1 and S2), performed in a laboratory. S1 will involve baseline testing, while S2 will be performed after three weeks of training after 3 days of rest. Each research series will consist of three measurement days. The testing protocol and blood sampling will be the same as in the first and second stages of the research. After next 72h of rest, all participants will have their muscle strength assessed using the one-repetition maximum (1RM) test in normoxia environment. The tests will be conducted in two exercises: a barbell bench press and a barbell squat.
215077815|NCT04695028|OTHER|Data collection|"The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means."
214329425|NCT03844451|DRUG|Bupivacaine and Epinephrine|At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
214931587|NCT02541669|DRUG|TAK-491 placebo|TAK-491 placebo-matching tablets
214931588|NCT01070667|DRUG|Dronedarone|400mg orally once per day for 3 months
214329426|NCT01772498|BEHAVIORAL|heart rate variability biofeedback|
214329427|NCT00702130|DRUG|Pravastatin|pravastatin 40mg per os once daily
214329428|NCT05848388|OTHER|Molar incisor malformation presence|the presence of radiographic features of molar incisor malformation
214329429|NCT03380468|DRUG|cisplatin plus pemetrexed|cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
214329430|NCT05735002|DIAGNOSTIC_TEST|13C-butyrate breath test|breath test
214329431|NCT01650181|DRUG|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
214673438|NCT03247907|DEVICE|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
214931589|NCT01070667|DRUG|Placebo|1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
214931590|NCT00226668|DRUG|hCRF|hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
214931591|NCT00226668|DRUG|placebo hCRF|placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
214931592|NCT03861312|BEHAVIORAL|Neck Laterality|"Patients who belonged to the neck group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
214931593|NCT03861312|BEHAVIORAL|Foot Laterality|"Patients who belonged to the foot group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
214931594|NCT01757912|PROCEDURE|cuff pressure|The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
214931595|NCT04424212|BEHAVIORAL|Intervention group CoronaCope|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. Intervention's main purpose is to mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
214931596|NCT03580434|DEVICE|V-STRUT|Minimally invasive implantation of V-STRUT
214931597|NCT06420934|OTHER|Drying procedure after surgical handwashing|Participants will dry their hands with one surgical towel
214931598|NCT00000864|DRUG|Abacavir sulfate|
214931599|NCT00000864|DRUG|Zidovudine|
214931600|NCT06668675|OTHER|A serious game known as the 'Happy Heart' will be used as the intervention.|"The serious game known as 'Happy Heart' is a mobile game used for educational purpose in addition to entertainment. It focuses on healthy habits for the heart and is aimed at improving knowledge on diet and physical activity among school-going adolescents.~The game is developed in collaboration with the game development team from the School of Informatics, University of Skövde and the health team from Kathmandu Medical College, Nepal."
214931601|NCT00725608|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
214931602|NCT04558775|OTHER|Observational|no intervention
214931603|NCT06622915|DEVICE|Tissue Doppler imaging and Conventional Echocardiography|non-invasive cardiac imaging technique which measures the velocity of the longitudinal motion of the mitral annulus, tricuspid annulus and the basal part of interventricular septum
214931604|NCT00004087|BIOLOGICAL|filgrastim|as prescribed by physician
214931605|NCT00004087|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
214931606|NCT00004087|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
214931607|NCT00004087|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
214931608|NCT00004087|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
214931609|NCT00463762|DRUG|CP-75385-02 Cefoperazone/sulbactam|
214931610|NCT04697004|DEVICE|Investigational Arm: SMR Stemless Reverse|The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function.
214931611|NCT04697004|DEVICE|Control Arm: SMR Reverse Shoulder System|Conventional stemmed shoulder prostheses are commonly used in the clinical practice.
215077816|NCT00428220|DRUG|sunitinib|sunitinib
215077817|NCT02031224|BEHAVIORAL|Conventional low protein diet|
214673439|NCT03247907|DEVICE|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
214931612|NCT04775901|OTHER|CT-guided lung biopsy|Percutaneous transthoracic lung biopsy was conducted stepwise under the real-time guidance of CT scan. This kind of modality served as an effective method for diagnosing peripheral lung lesions (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
214931613|NCT04775901|DEVICE|Template-guided lung biopsy|A three-dimensional model consisting of participant's thoracic image information was initially reconstructed based on the CT scan data. Afterwards, a navigational template was customized, which accommodated well to the anatomical landmarks of the participant. The template was then printed by means of stereolithography from photopolymer material. Participants would receive navigational template-guided percutaneous transthoracic lung biopsy (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
214931614|NCT04558567|DRUG|Vogelxo|50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)
214931615|NCT05965635|OTHER|Ixodus scapularis nymphs|Tick challenge
214931616|NCT06623539|DRUG|Pemafibrate high dose|Pemafibrate 0.1 mg tablets shall be administered orally twice daily, two tablets per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 2 tablets 1 or 0.4 mg for 1 tablet 1 can be substituted.
214931617|NCT06623539|DRUG|Pemafibrate low dose|Pemafibrate 0.1 mg tablets shall be administered orally twice daily, one tablet per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 1 tablets 1 can be substituted.
214931618|NCT06623539|DRUG|Fenofibrate|Fenofibrate 53.3 mg tablets shall be administered orally once daily, one tablet per dose, after breakfast. Thereafter, the dose may be carefully increased to two tablets per dose at the physician\&amp;#39;s discretion.
214931619|NCT04402996|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
214931620|NCT04402996|OTHER|gingival crevicular fluid|"GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
214931621|NCT06622603|DRUG|Febuxostat|The minimal approved dose of febuxostat is 40 mg/day. We will use 0.5 tablet of febuxostat 40 mg or its placebo.
214931622|NCT01138358|OTHER|medical chart review|
215077818|NCT02031224|DIETARY_SUPPLEMENT|Very low protein diet supplemented with Ketosteril|
215077819|NCT02691403|DRUG|levo-bupivacaine|
215077820|NCT02691403|DRUG|normal saline|
215077821|NCT02024880|DEVICE|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
215077822|NCT02024880|DEVICE|Conventional catheter group|A standard embryo catheter
214673440|NCT06056739|DEVICE|Alio platform|Remote monitoring platform
214329432|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
214329433|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
214329434|NCT01650181|DRUG|Metformin|Patients with fatty liver treated with diet, exercise and metformin
214329435|NCT00545831|DEVICE|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
214329436|NCT00545831|DEVICE|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
214329437|NCT02138851|DIETARY_SUPPLEMENT|Ficus Carica (300g/day)|Ficus Carica (300g/day), parallel design
214931623|NCT01138358|OTHER|study of socioeconomic and demographic variables|
214931624|NCT01138358|OTHER|survey administration|
214931625|NCT01138358|PROCEDURE|quality-of-life assessment|
214931626|NCT00124007|BIOLOGICAL|VRC-HIVADV014-00-VP|
214931627|NCT00124007|BIOLOGICAL|VRC-HIVDNA016-00-VP|
214931628|NCT02728583|DIETARY_SUPPLEMENT|Margarine enriched with plant sterols and fish oil|
214931629|NCT02728583|DIETARY_SUPPLEMENT|Placebo margarine|
214931630|NCT00247078|BIOLOGICAL|widow spider antivenom|3 vials of antivenom capable of neutralizing 600 LD50 of L. mactans
214931631|NCT00247078|BIOLOGICAL|Placebo|
214931632|NCT03409107|DRUG|Daprodustat (GSK1278863)|Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.
214931633|NCT03409107|DRUG|Placebo|Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.
214931634|NCT03409107|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.
214931635|NCT04433715|DIAGNOSTIC_TEST|ICIQ-SF|All participants completed ICIQ-SF,
214931636|NCT04433715|DIAGNOSTIC_TEST|UDI-6|All participants completed UDI-6
214931637|NCT04433715|DIAGNOSTIC_TEST|IIQ-7|All participants completed IIQ-7
214329438|NCT02138851|DIETARY_SUPPLEMENT|Placebo (300g/day)|Placebo (300g/day), parallel design
214329439|NCT01190540|BEHAVIORAL|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
214329440|NCT01190540|BEHAVIORAL|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
214673441|NCT00077623|DRUG|epoetin alfa or beta|iv 3 times weekly, as prescribed
214673442|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
214931638|NCT04842188|PROCEDURE|L-PRF with aPDT|surgical open flap debridement followed by L-PRF with aPDT
214673443|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
214931639|NCT04842188|PROCEDURE|L-PRF|surgical open flap debridement followed by L-PRF alone
214931640|NCT02737631|DEVICE|"Chameleon Personal Lubricant"|
214931641|NCT00169715|PROCEDURE|Percutaneous Caliceal Diverticuli|Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
214931642|NCT06178731|DEVICE|rTMS|3 min rTMS delivery with iTBS to the left DLPFC
214931643|NCT06178731|OTHER|Virtual Reality|2-15 min VR viewing, 15 min descriptive and imaginal recounting
214931644|NCT00675168|RADIATION|PET/CT (low-dose)|400 mBq 18F-flour-deoxyglucose given iv. 60 min. before PET/CT-scan
214931645|NCT05698472|OTHER|questionnaire|"Use the Questionnaire on physical exercise of the elderly in Beijing community to collect the related information of the elderly."
214931646|NCT03912714|PROCEDURE|Laparoscopic appendectomy|Surgery will be performed under general anaesthesia. The laparoscopic appendectomy can be performed with the use of 3 trocars; one subumbilical, one suprapubic and one in the lower right quadrant of the abdomen. The appendix is removed using a laparoscopic endostapler enabling a safe and complete appendectomy with the cross stapling line at coecal base. Laparoscopic appendectomy will be performed by a gastrointestinal surgeon with sufficient experience in laparoscopic appendectomies (\>20).
214931647|NCT03912714|PROCEDURE|Endoscopic appendix biopsies|Appendix biopsies will only be taken when the scope easily slides into the lumen of the appendix (the scope will not be pushed into the appendix lumen)
214329441|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
214329442|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
214931648|NCT00690196|BEHAVIORAL|Tai Chi Chih|"Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up."
214329443|NCT03814694|DIETARY_SUPPLEMENT|CRHP Diet|Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat
214329444|NCT03814694|DIETARY_SUPPLEMENT|CD Diet|Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
214931649|NCT00690196|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
214931650|NCT06648616|OTHER|EBT|Elastic Band Resistance Training
214931651|NCT01118624|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes.~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
214931652|NCT01118624|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."
214931653|NCT01118624|DIETARY_SUPPLEMENT|Folic Acid|"1.0-1.25 mg orally~Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate."
214931654|NCT00752258|DRUG|Mentor Purified Toxin Botulinum Toxin Type A|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
215071135|NCT06896773|OTHER|Impact of Normobaric Hypoxia on Cardiac Biomarkers in untrained men|The intervention will consist of three series differing in terms of simulated altitude: S1 (normoxia), S2 (2000 m a.s.l.), and S3 (3000 m a.s.l.). Each research series will consist of one day of the measurements. All participants will perform two ergocycle tests (the graded exercise test GXT and constant-workload exercise test CXT at the individual lactate threshold workload (WRLT) until volitional exhaustion) with 10 minutes of active recovery break in different environment (S1, S2, S3- 3000). The order of the series will be randomized across all participants. The fraction of inspired oxygen (FIO2) will depend on the series and will be as follows: S1 (normoxia) = 20.9%; S2 (2000 m a.s.l.) = 16,5%; S3 (3000 m a.s.l.) = 14.4%. The hypoxic environment will be maintained using AirZone climate technology (AirSport). Between the series, there will be a one-week active rest break excluding exposure to hypoxia and performance of high-intensity exercise.
215071136|NCT06896773|OTHER|Effects of Hypoxic Endurance Training on Cardiac Biomarkers in the LHTL group|The participants from the LHTL group will be exposed to normobaric hypoxia (FIO2 = 14.4%, corresponding to an altitude of 3000 m a.s.l.) in a hotel room for 11 to 12 hours a day (evenings and nights). Participants in this group will perform interval training under normoxic conditions. The experiment will consist of two series of testing: S1 (baseline) and S2 (after 3 weeks of training and 3 days of rest). All participants will perform the same testing protocol as in stage 1-albeit in a normoxic environment and after 72h of rest, all testing procedures will be repeated in a hypoxic environment.
214329445|NCT01993264|OTHER|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
214931655|NCT05913635|BEHAVIORAL|Consumption of lunch and dinner, with no breakfast|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-breakfast intervention day, participants are instructed to fast and only be allowed to consume water until 1.00 p.m. and consume the above-designed lunch and dinner at 1.00 p.m. and 8.00 p.m. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. the following day.
214931656|NCT05913635|BEHAVIORAL|Consumption of breakfast and lunch, with no dinner|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-dinner intervention day, participants are instructed to consume the above-designed breakfast and lunch at 7.30 a.m. and 1.00 p.m., and no dinner. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. on the following day.
214329446|NCT04040101|DEVICE|smartphone-based balance training system|use smartphone application to training balance
214329447|NCT01291927|PROCEDURE|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
214931657|NCT06621706|DEVICE|Gastric ultrasonography|"Women will be requested to fast 2 hours for clear drinks, 6 hours for a light meal, and 8 hours for a meal high in fried or fatty content prior to their next antenatal clinic visit.~On the day of assessment, fasting and dietary compliance will be confirmed individually with each woman and Gastric ultrasonography will be performed after sex and eight hours of fasting food.~Women will be first scanned in a semi-recumbent (45 degrees head up) supine position, followed by a semi-recumbent (45 degrees head up) right lateral position (RLP). In both positions the gastric antrum will be identified in the sagittal plane with its internal anatomical landmarks identified, i.e. the left lobe of the liver anteriorly and the abdominal aorta posteriorly."
214931658|NCT05002894|OTHER|Pilates exercises|Pilates exercises for flexibility and stability
214931659|NCT05002894|DIETARY_SUPPLEMENT|medical standard care for fatigue|supplements and medical care
215071137|NCT06896773|OTHER|Effects of Hypoxic Endurance Training on Cardiac Biomarkers in the Control group|The participants in the C group will live and train in normoxic conditions. The experiment will consist of two series of testing: S1 (baseline) and S2 (after 3 weeks of training and 3 days of rest). All participants will perform the same testing protocol as in stage 1-albeit in a normoxic environment and after 72h of rest, all testing procedures will be repeated in a hypoxic environment.
215071138|NCT06896773|OTHER|Effects of Hypoxic Strength Training on Cardiac Biomarkers in the HRT group|The participants in the HRT group will perform resistance training in normobaric hypoxia (FIO2 = 14.4%, 3000 m a.s.l.). The experiment will consist of two series of testing (S1 and S2), performed in a laboratory. S1 will involve baseline testing, while S2 will be performed after three weeks of training after 3 days of rest. Each research series will consist of three measurement days. The testing protocol and blood sampling will be the same as in the first and second stages of the research. After next 72h of rest, all participants will have their muscle strength assessed using the one-repetition maximum (1RM) test in normoxia environment. The tests will be conducted in two exercises: a barbell bench press and a barbell squat.
215071139|NCT06895694|OTHER|examine the impact of education|Children in the research group were trained to create a positive hospital perception.
215071140|NCT06896357|PROCEDURE|Limbal relaxing incisions|A fixed depth diamond-guarded knife (Gemcision LRI 600 Microns Blade, Katalyst Surgical, chesterfield, MO, USA) will be used to create a paired circumferential corneal incision, following the limbal curvature, 1-1.5mm anterior to the limbus centered on the steep corneal meridian. The incision arc length will be ninety degree according to the Nichamin Age and Pachymetry Adjusted (NAPA) nomogram.
215071141|NCT06895785|DEVICE|Exalt Model D|Exalt Model D single-use duodenoscope will be used in ERCP
215071142|NCT06895785|DEVICE|Reusable|Standard reusable duodenoscope will be used in ERCP
214329448|NCT01291927|PROCEDURE|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
214329449|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #1|two most popular varieties of cowpea currently consumed in the selected geographic area
214329450|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #2|two most popular varieties of cowpea currently consumed in the selected geographic area
214329451|NCT05320653|DIETARY_SUPPLEMENT|Medical nutrition|Nutrition therapy of the critically ill patients
214329452|NCT00619697|DRUG|biphasic insulin aspart|
214329453|NCT00619697|DRUG|insulin glargine|
214329454|NCT00619697|DRUG|metformin|
214329455|NCT00619697|DRUG|glimepiride|
214329456|NCT02734017|OTHER|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
214329457|NCT00277602|DRUG|Riluzole|
214329458|NCT02479919|DEVICE|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
214329459|NCT02479919|DEVICE|Magstim® Sham TBS|Sham stimulation
214673444|NCT00974077|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
214931660|NCT00422344|DRUG|RAD001, Sunitinib|Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
214931661|NCT04417192|DRUG|Olaparib|Olaparib will be administered at a dose of 300mg as oral dose, twice a day.
214931662|NCT04417192|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
214931663|NCT01846481|DRUG|RBP-8000 100 mg|RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
214931664|NCT01846481|DRUG|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
214931665|NCT01846481|DRUG|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
214931666|NCT01846481|DRUG|RBP-8000 200 mg|RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
214931667|NCT05234086|COMBINATION_PRODUCT|InbioDerm + C plus advanced healing|For patients who are assigned to experimental treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section, through an enzymatic process and cell proliferation for a period of approximately fourteen days, the cells that are integrated in the InbioDerm+C will be obtained and used to treat the foot ulcer.
214931668|NCT05234086|PROCEDURE|Advanced healing|Patients who are assigned to active comparator correspond to the control treatment, which will be received advanced healing.
214931669|NCT00864825|DRUG|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
214931670|NCT06528535|OTHER|Health promotion intervention|Health promotion activities on nutrition with distribution of baskets of fresh fruits and vegetables
214931671|NCT04636385|OTHER|Observational study no intervention|No intervention
214931672|NCT03598920|DEVICE|AsspireAssist|Endoscopic bariatric procedure using the AsspireAssist device
214931673|NCT03598920|OTHER|Nutritional consulting|Nutritional consulting provided by a specialized consultant.
214931674|NCT00343785|DRUG|cyclophosphamide|Given IV
214931675|NCT00343785|BIOLOGICAL|anti-thymocyte globulin|Given IV
214931676|NCT00343785|DRUG|cyclosporine|Given IV or PO
214931677|NCT00343785|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
214931678|NCT00343785|DRUG|methotrexate|Given IV
214931679|NCT00343785|GENETIC|DNA analysis|Correlative studies
214931680|NCT00343785|OTHER|flow cytometry|Correlative studies
214931681|NCT00343785|GENETIC|polymorphism analysis|Correlative studies
215071143|NCT06896097|PROCEDURE|Ridge preservation|extraction of non restorable tooth in a traumatic way and socket preservation with the selected group
214329460|NCT04978038|DRUG|mRNA- COVID-19|Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
214329461|NCT04978038|DRUG|Prevnar13|Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
214329462|NCT04844385|DRUG|Toripalimab|Toripalimab 240 mg, d1, Q3w for two cycles
214329463|NCT04844385|DRUG|Paclitaxel-albumin|Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles
214329464|NCT04844385|DRUG|Nedaplatin|Nedaplatin 75mg/m2, d1, Q3w for two cycles
214673445|NCT00974077|OTHER|Waiting List Control|Patients receive MBCT with a delay of 6 months.
214931682|NCT00343785|OTHER|laboratory biomarker analysis|Correlative studies
214931683|NCT00828074|DRUG|sorafenib tosylate|Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.
214931684|NCT00828074|DRUG|vinorelbine ditartrate|Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
214931685|NCT00312065|DEVICE|Application of reflective heat shield to thermistor probe|
214931686|NCT04430231|OTHER|Wait list time|
214931687|NCT06682312|DEVICE|Non-invasive blood pressure|"Manual blood pressure via sphygmomanometer~Or~Non invasive blood pressure via earlyvue VS30 Monitor"
214931688|NCT00224146|DRUG|oxybutynin transdermal delivery system (Oxytrol(r))|
214931689|NCT03747068|DRUG|Anti-TNF Drug|
215071144|NCT06897098|BIOLOGICAL|Implantation of autologous cartilage mini-grafts (Cartibeads)|"1. st surgery: cartilage biopsy harvest by minimally invasive surgery (arthroscopy or mini arthrotomy).~2. nd surgery: Implantation of autologous cartilage mini-grafts (Cartibeads) by minimally invasive surgery (arthroscopy or mini arthrotomy). Cartibeads should entirely fill the defect zone, followed by a thin layer of surgical glue (TISSEEL Fibrin Sealant)."
215071145|NCT01777503|DRUG|prasugrel|prasugrel 5 mg o.d.
215071146|NCT01777503|DRUG|Clopidogrel|75 mg o.d.
215071147|NCT06897280|DEVICE|SCS Device Program Setting|A Pulse Dose setting specifies a brief duration of stimulation 'on' and stimulation 'off' durations, applied in a continuously cycled manner
214329465|NCT04844385|RADIATION|radiation therapy at a total dose 60 Gy|Radiation therapy at a total dose 60 Gy
214329466|NCT04844385|DRUG|Capecitabine|Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy
214329467|NCT04844385|RADIATION|radiation therapy at a total dose 50 Gy|Radiation therapy at a total dose 50 Gy
214329468|NCT03120650|OTHER|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
214329469|NCT03120650|OTHER|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
214329470|NCT00673452|DRUG|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
214329471|NCT00673452|DRUG|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
214329472|NCT05494255|OTHER|Recruitment maneuver|In Group RM (intervention group) after skin closure, mechanical ventilation settings will be set to FiO2:100%, I:E=1:1, respiratory rate: 6, and then tidal volume will be increased gradually by 150 ml until reaching a plato pressure of 30 mmHg. After 3 breaths in this state, RM will be considered accomplished. LUS evaluation will be made just before and after the RM.
214329473|NCT00351494|PROCEDURE|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
214329474|NCT00351494|PROCEDURE|embolization|Intervention is described in the case report form for each patient
214329475|NCT00813124|DRUG|Fludarabine|40 mg/m\^2 by vein over 60 minutes on Day -5 through Day -2.
214329476|NCT00813124|DRUG|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
214329477|NCT00813124|DRUG|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
214329478|NCT00813124|DRUG|Azacitidine|Start cycles of 32 mg/m\^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
214329479|NCT00813124|PROCEDURE|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
214931690|NCT03783130|BIOLOGICAL|VRC-HIVRGP096-00-VP|Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.
214931691|NCT03783130|OTHER|Alum Adjuvant|Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.
214329480|NCT03262272|DEVICE|VIE A Hemodialyzer|polysulfon membrane coated with vitamin E
214931692|NCT01505738|OTHER|bacterial samples|bacterial samples taken
214931693|NCT03219359|PROCEDURE|Autologous stem cell transplant|Hematopoietic stem cell transplantation
214931694|NCT03219359|DRUG|Cyclophosphamide|Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ \>20x104/ml then leukapheresis daily to collection goal
214931695|NCT03219359|DRUG|Cyclophosphamide|Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
214931696|NCT03219359|DRUG|Thymoglobulin|Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
214931697|NCT03219359|DRUG|Methylprednisolone|Day -3 to -1: 1 gram prior to each ATG dose
214931698|NCT03219359|DRUG|Vedolizumab|Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
214329481|NCT03262272|DEVICE|Rexsys 27H hemodialyzer|polyethersulfon membrane with large surface area : 2,7m²
214329482|NCT03262272|DEVICE|Leoceed 21HX hemodialyzer|polyslfon membrane with gamma sterilization
214329483|NCT03262272|DEVICE|Polypure 22S+ hemodialyzer|polysulfon membrane with steam sterilization
214329484|NCT04984655|DEVICE|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|All participants will go through the same intervention described above
214329485|NCT00365326|BIOLOGICAL|Catheter-based intracoronary injection|This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
214329486|NCT06440070|PROCEDURE|Loop Carpal Tunnel Release|Under the guidance of ultrasound, needles are inserted above and below the transverse carpal ligament, respectively, to form a loop around the ligament. Finally, the ligament is cut by pulling the looped thread.
214329487|NCT04929561|BEHAVIORAL|Video-conferencing group|No intervention
214329488|NCT03282084|DIAGNOSTIC_TEST|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
214329489|NCT03282084|DIAGNOSTIC_TEST|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
214329490|NCT01593618|BEHAVIORAL|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
214329491|NCT01593618|OTHER|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
214329492|NCT02535195|DIETARY_SUPPLEMENT|Ginger supplement|
214329493|NCT02535195|DIETARY_SUPPLEMENT|Placebo (starch)|
214329494|NCT01831310|DIETARY_SUPPLEMENT|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
214329495|NCT01831310|DIETARY_SUPPLEMENT|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
214329496|NCT01831310|DIETARY_SUPPLEMENT|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
214329497|NCT01831310|DIETARY_SUPPLEMENT|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
214329498|NCT00767676|DEVICE|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
214329499|NCT00079274|DRUG|irinotecan hydrochloride|Given IV
214931699|NCT05657600|BEHAVIORAL|Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments|Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.
214329500|NCT00079274|DRUG|oxaliplatin|Given IV
214329501|NCT00079274|DRUG|leucovorin calcium|Given IV
214329502|NCT00079274|DRUG|fluorouracil|Given IV
214329503|NCT00079274|BIOLOGICAL|cetuximab|Given IV
214329504|NCT00079274|DRUG|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
214329505|NCT02353481|OTHER|Heart Failure Management|
214329506|NCT01595620|OTHER|Thermal|Thermal sensation/pain testing
214931700|NCT05657600|OTHER|Video-based yoga|Video-based yoga
214931701|NCT05657600|OTHER|Face-to-face yoga|Face-to-face yoga
214931702|NCT05657600|OTHER|physical exercise|physical exercise
214931703|NCT03640975|OTHER|Endoscopy|The endoscopy will be performed under general anaesthesia using a flexible endoscope with an external diameter of between 4.9 and 9.2 mm, depending on the size of the child. In line with the guidelines, eight biopsies will be collected from the proximal, median and distal oesophagus for the routine analysis of esophageal remodelling and inflammation. Three of these biopsies will be used in the context of this study to analyse innate immune cells using flow cytometry and to determine the profile of cytokine expression. Two biopsies will be placed in sterile, 0.5 ml Nunc tubes containing a storage buffer (MACS® Tissue Storage Solution) and then stored in ice until the extraction of cells for cytometric analysis . The third specimen will be placed in a sterile tube and frozen immediately in liquid nitrogen for analyses of the esophageal microbiome.
214931704|NCT05225675|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
214931705|NCT05225675|OTHER|Placebo|Intravenous administration of placebo
214931706|NCT05784974|DRUG|Cadonilimab|15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
214931707|NCT03070340|DIAGNOSTIC_TEST|Breast Magnetic Resonance Imaging (MRI)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
214931708|NCT03070340|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEDM)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
214329507|NCT01595620|OTHER|Electrical|Electrical sensation/pain testing
214329508|NCT01595620|OTHER|Capsaicin|Intradermal Capsaicin
214329509|NCT01595620|DRUG|THC|Active THC (0.01 mg/kg) administered over 10 minutes
214329510|NCT01595620|DRUG|THC|Active THC (0.03 mg/kg) administered over 10 minutes
214329511|NCT01595620|DRUG|Placebo|Control: small amount of alcohol with no THC, administered over 10 minutes
214329512|NCT03919045|DRUG|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
214329513|NCT03919045|PROCEDURE|Placebo|Half of the group will be treated with needle stings without injections
214329514|NCT06309875|OTHER|PLAN CUIDARTE|Description Plan Cuidarte
214329515|NCT06309875|OTHER|Conventional care|Description Conventional care
214329516|NCT02652975|PROCEDURE|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
214329517|NCT02652975|PROCEDURE|SphygmoCor|"Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously."
214329518|NCT02652975|PROCEDURE|24hour blood pressure|24 hour blood pressure measurement
214329519|NCT02652975|PROCEDURE|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
214329520|NCT02652975|BIOLOGICAL|Laboratory blood samples|"Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen."
214329521|NCT00617240|DRUG|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
214329522|NCT00617240|DRUG|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
214329523|NCT03741959|PROCEDURE|Experimental group|"Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015)."
214329524|NCT03741959|PROCEDURE|Control group|Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
214329525|NCT02488512|DRUG|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) \[45-46\], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
214329526|NCT01611259|DRUG|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
214329527|NCT04936685|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Liquid solution for injection Intramuscular
214329528|NCT02527057|DEVICE|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
214329529|NCT02143622|BIOLOGICAL|LJM716|antibody
214329530|NCT02143622|BIOLOGICAL|cetuximab|antibody
214329531|NCT02717897|OTHER|No intervention|This study is not interventional
214329532|NCT02925975|DRUG|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
214329533|NCT02925975|DEVICE|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
214329534|NCT02925975|PROCEDURE|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
214329535|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
214329536|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
214329537|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
214329538|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
214931709|NCT01881880|DEVICE|Bilateral mammography with Tomosynthesis|no intervention pre specified to be administered to participants
214931710|NCT02120820|BEHAVIORAL|Multisensory environment (MSE)|Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
214931711|NCT02120820|BEHAVIORAL|Massage therapy (MT)|A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
214931712|NCT02120820|OTHER|Control group|Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
214329539|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
214329540|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
214329541|NCT00984854|DRUG|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
214329542|NCT04388332|PROCEDURE|Structural allograft|Subjects that have received ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and/or corticocancellous bone chips
214329543|NCT04388332|DEVICE|Tritanium C|Subjects will receive the Tritanium C anterior cervical cage which is intended to be used with autogenous or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft
214329544|NCT04870840|RADIATION|Proton Beam Radiation Therapy|Undergo radiation therapy
214329545|NCT04870840|OTHER|Quality-of-Life Assessment|Ancillary studies
214329546|NCT04870840|OTHER|Questionnaire Administration|Ancillary studies
214329547|NCT04326478|DRUG|Azithromycin|Enrolled children in the intervention arm of this study will receive a single weight-based dose of azithromycin (20 mg/kg, to a maximum dose of 1 gram) administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
214931713|NCT02120820|BEHAVIORAL|Massage therapy in multisensory environment (MT-MSE)|Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
214931714|NCT00258349|DRUG|vorinostat|Given orally
214931715|NCT00258349|DRUG|trastuzumab|Given IV
214931716|NCT01226368|OTHER|Biological Sample collection|Cervix cells
214931717|NCT01223469|DEVICE|Contact force assisted irrigated RF ablation|radiofrequency ablation of atrial fibrillation or SVT
214329548|NCT04326478|BIOLOGICAL|Placebo|Enrolled children in the placebo arm of this study will receive a single dose of non-antibiotic placebo administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
214329549|NCT00811564|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
214329550|NCT00811564|DRUG|latanoprost 0.005%|1 drop of study medication taken once daily
214329551|NCT05701137|OTHER|EMDR-RTE|The experimental group will have EMDR recent traumatic event.
214329552|NCT05701137|OTHER|TAU|The comparator group will have usual psychological intervention.
214329553|NCT06464939|DRUG|KH001|Applications of KH001 over a 1 or 2-week period, and application of placebo
214329554|NCT06464939|DRUG|Placebo|Applications of water for injection
214329555|NCT03969212|DRUG|Baloxavir Marboxil|IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.
214329556|NCT03969212|DRUG|Placebo|IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
214329557|NCT04457674|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
214329558|NCT04457674|BEHAVIORAL|Sleep Hygiene Education (SHE)|SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
214329559|NCT01451346|DIETARY_SUPPLEMENT|B. Infantis 35624|One sachet daily for 12 weeks
214329560|NCT02075320|DEVICE|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
214329561|NCT00075335|DRUG|AMD3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
214329562|NCT01147653|BIOLOGICAL|Autologous UCB Reinfusion|Autologous umbilical cord blood (UCB) reinfusion
214329563|NCT01147653|OTHER|Placebo|Placebo
214329564|NCT00353366|BIOLOGICAL|Rotarix|Two doses of the oral vaccine
214329565|NCT00353366|OTHER|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
214329566|NCT03467269|DIAGNOSTIC_TEST|Brush sign|presence of a brush sign in MRI image in acute cerebral ischaemia
214931718|NCT03664310|OTHER|FSET Anxiety and Sleep Treatment|Computerized anxiety and insomnia intervention.
214931719|NCT03664310|OTHER|Control|Physical health control
214931720|NCT03455010|OTHER|Increased load|Participants walk with 120% body weight achieved with a weight vest
214931721|NCT03455010|OTHER|Reduced load|Participants walk with 80% body weight achieved by a dynamic unloading system
214931722|NCT01692210|DRUG|Dexmedetomidine|After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
214931723|NCT02892604|DEVICE|insulin pump to inControl AP platform|Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.
214931724|NCT05261334|PROCEDURE|contour augmentation|early implant placement with contour bone augmentation
214329567|NCT02690961|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
214931725|NCT05997823|OTHER|kinesiotape|The button hole technique was used for area correction during the KT application (Figure 1). Two I-tapes were applied, one from the medial epicondyle to the proximal phalanx on the palmar side and the other from the lateral epicondyle to the proximal phalanx on the dorsal side. The area where the phalanges are located was marked, and two hole was drilled in the center.After cleaning the skin with alcohol, the tape to be applied to the palmar side was passed over the 3rd and 4th fingers, and the patient was asked to perform radial deviation and wrist extension
214931726|NCT05997823|OTHER|home exercises|home exercises
214931727|NCT04911335|COMBINATION_PRODUCT|Faringel plus and oral hygiene|The expected frequency of administration of the study product is 2 / day, 10 minutes 'before main meals, for patients without mucositis (grade 1 according to the OAG scale, total score = 8). The frequency of administration will increase to 3 / day for patients with mild or moderate mucositis (grade 2 on the OAG scale, total score 9-18) and up to 4 / day in cases of severe mucositis (grade 3 on the OAG scale, score total 19-24). Each administration will contain 7 ml of oral suspension, to be kept inside the oral cavity for 1-2 minutes and then swallowed slowly.
214931728|NCT02346110|DRUG|Bupivacaine-adrenaline|50 mg bupivacaine and 50 μg adrenalin
214931729|NCT02346110|DRUG|Dexamethasone|4 mg
214931730|NCT02346110|OTHER|Sodium chloride|1 mL of sodium chloride solution as placebo
214931731|NCT02831985|PROCEDURE|general practice follow-up|Post-surgery follow-up by general practitioner
214931732|NCT02831985|PROCEDURE|ear-nose-throat (ENT) specialist follow-up|Post-surgery follow-up by ear-nose-throat (ENT) specialist
214931733|NCT00157911|DRUG|MK0653; ezetimibe / Duration of Treatment: 12 weeks|
214931734|NCT00157911|DRUG|Comparator: simvastatin / Duration of Treatment: 12 weeks|
215071149|NCT06898502|DEVICE|Electrotherapy ( TENS, hot pack, and therapeutic ultrasound )|"Each participant will receive electrotherapy treatment three times a week for four weeks. Each treatment session will consist of 20 minutes of TENS, 20 minutes of hot pack, and 6 minutes of ultrasound therapy. Twelve weeks after the treatment, participants will be contacted by phone and asked about their improvement using the Global Rating of Change Scale (GRC). Pain intensity and disability level will be reassessed through phone interviews using the Numeric Pain Scale, the Oswestry Disability Index for low back pain, and the Neck Disability Index for neck pain at the 12th week. Thus, it will be evaluated whether there is any difference in patient satisfaction, pain intensity, and disability at the 12th week between participants who selected electrotherapy as the most effective method and those who chose other treatments."
215071150|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily for one month.
215071151|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
214329568|NCT02690961|DRUG|placebo multiple doses|
214329569|NCT06382233|DIAGNOSTIC_TEST|Identification of Diagnostic Biomarkers|Urinary single-cell and EVs screening to stage the intrarenal injury and repair processes in UPJO babies and identification of the whole blood gene expression profiling of babies with unilateral UPJO. Data deriving from patients with unilateral UPJO will be compared with data deriving from controls.
214329570|NCT03302481|OTHER|liver biopsy|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
214329571|NCT03296228|RADIATION|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
214329572|NCT03296228|RADIATION|Flexibility Radiographs (awake traction)|awake traction
214329573|NCT03296228|RADIATION|Flexibility Radiographs (STUGA)|supine traction under GA
214329574|NCT00365248|DRUG|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
214931735|NCT05884424|BEHAVIORAL|PARO Therapy Robot|"Participants allocated to the PARO Therapy Robot group will receive three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.~Robot therapy session will last 20 minutes. The sessions will be partially guided, intending to allow participants to interact with the robot seal freely for as long as possible, but redirecting the activity if necessary. The sessions will be conducted in group format, in groups of 4 users, with participants sitting in a circle around a table. The professional conducting the sessions will be a therapist with experience in NPT for people living with dementia, and who has attended the training session on the study intervention protocol.~The sessions will be structured as follows:~1. Welcome and presentation.~2. Main activity with PARO.~3. PARO cleaning.~4. End of session. A total of 13 different sessions are proposed, to be conducted in a cyclical manner (each session 3 times, except sessions 1 and 2)."
214931736|NCT01032421|PROCEDURE|IVF procedure|
214931737|NCT04339803|OTHER|rehabilitation intervention|we use lower limb mirror therapy after stroke for two weeks
215071152|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
215071153|NCT06895434|OTHER|Balneotherapy with physical therapy|"Balneotherapy applied in the thermal pools to patients for 20 minutes, at a temperature of 38-40°C. After resting for 30 minutes,physical therapy was applied.~A physical therapy program (5 days a week for 2 weeks, a total of 10 sessions) was applied to the painful area, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity."
215071154|NCT06895434|OTHER|Physical therapy|A physical therapy program (5 days a week for 2 weeks, a total of 10 sessions) was applied to the painful area, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.
214931738|NCT05308784|OTHER|Cellworks Singula and Ventura reports|Personalized drug match reports based on patients' genomic aberration.
214931739|NCT04875390|OTHER|Erector spina plane block|After the surgery is completed, intraoperative Erector spina plane block will be performed
214329575|NCT06269172|BEHAVIORAL|intereviews|"An individual's experience of their breathlessness is influenced by multiple factors including their medical condition, psychology, sociological and situational circumstances which will include ethnicity. There is currently a lack of evidence exploring the impact of ethnicity in the experience and presentation of breathlessness.~The non-medical management of breathlessness in respiratory diseases includes pulmonary rehabilitation (PR). PR is a highly evidenced exercise-based intervention to help manage breathlessness, improving health-related quality of life and improving survival. Recent audits in England and Wales showed 89% of patients attending PR were recorded as having a White British ethnicity which is in contrast to national ethnicity demographics. This may be because the cultural acceptability of PR components are not fully considered."
214329576|NCT00000439|DRUG|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
214329577|NCT03159884|DRUG|Conbercept|
214329578|NCT04845737|OTHER|sympathetic skin response measurement|"Sympathetic skin response(SSR) was studied with upper and lower extremity hand and foot recording of all participants, and amplitude and latency values will be recorded. SSR measurement will be made at room temperature of 25 ºC, while the patients are resting in the supine position. 6 mm silver disc electrodes will be used as the recording electrode.~The relationship between the patients' vitamin D levels and inflammatory response markers and their sympathetic skin responses will be investigated by statistical analysis."
214329579|NCT04925297|OTHER|No intervention|No intervention will be given
214329580|NCT02752295|BEHAVIORAL|stress-coping week|The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.
214329581|NCT02752295|BEHAVIORAL|additional two days follow-up weekend|A two-days follow-up which recapitulates previous treatment elements.
214329582|NCT00473720|DRUG|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
214329583|NCT00473720|DRUG|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
214329584|NCT03996785|BEHAVIORAL|Walking in Urban setting|Walking for 60 minutes as described above
214329585|NCT03996785|BEHAVIORAL|Walking in nature setting|Walking for 60 minutes as described above
214931740|NCT04875390|OTHER|local infiltration|After the surgery is completed, intraoperative local infiltration will be performed
214931741|NCT02129790|BEHAVIORAL|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
214931742|NCT06268405|GENETIC|Liquid Biopsy|Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing assays and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.
214931743|NCT06268405|DEVICE|Positron Emission Mammography (PEM)|PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.
214931744|NCT01825174|BEHAVIORAL|Ball games program|twice a week different ball games 90min
214931745|NCT01825174|BEHAVIORAL|Nutrition counseling|9 units of 90min each of nutrition counseling
214931746|NCT03694444|DRUG|AMY-101|C3 complement inhibitor
214931747|NCT03694444|OTHER|Water for injection|Placebo
214931748|NCT04221620|DEVICE|Zengar Electroencephalogram (EEG) Neurofeedback device|Electroencephalogram (EEG) Neurofeedback is a noninvasive way to allow the central nervous system to self regulate and calm the brain enough to allow the frontal cortex to function in an ideal state, which is the part of the brain that controls important functions including behavior, problem solving, memory, language, emotions, and judgment. EEG Neurofeedback is performed via a musical medley that lasts for about 34 minutes, with baseline numbers taken at the beginning and after the music finishes. During this time, the participant will wear headphones, sensory clips on the ears (3 total), and two sensors on their head while receiving traditional occupational therapy services.
214931749|NCT03482076|DIAGNOSTIC_TEST|transferrin receptor concentration|Sandwich radio-imunoassay
214931750|NCT06260267|DRUG|Microbiota suspension|Microbiota suspension
214329586|NCT04547062|DRUG|Tocilizumab|Administration of tocilizumab at day 8 of induction following a classical induction
214486252|NCT06893926|DIAGNOSTIC_TEST|Umbilical cord blood S100B protein level|A 1 mL sample of cord blood is collected in a labeled tube, which includes the mother's name, the child's gender, date of birth, and date of collection. The sample is then sent to the laboratory for centrifugation. The resulting serum samples are frozen, and once approximately 80 samples have been collected, they will be thawed and analyzed for S100B protein concentration. Any remaining material after laboratory processing will be properly disposed of.
214486253|NCT06893926|DIAGNOSTIC_TEST|Neonatal transfontanelle ultrasound assessment|A transfontanelle ultrasound examination is performed to assess for any abnormalities in the newborn.
214931751|NCT06260267|DRUG|Microbiota capsule|Microbiota capsule
214931752|NCT06260267|DRUG|Placebo suspension|Placebo suspension
214931753|NCT06260267|DRUG|Placebo capsule|Placebo capsule
215071155|NCT06896448|DIAGNOSTIC_TEST|Specialized sleep consultation and overnight recording using the APNEAL application|"A sleep consultation with a clinical examination. Completion of several questionnaires: Snoring and sleep quality questionnaire (AFSORL), EORTC Qulity of Life questionnary -C30, and H\&N35.~Providing the Apneal application pre-installed on a loaned smartphone for the patient to use at home for overnight recording."
214486254|NCT06894030|BEHAVIORAL|Gait Training Video|Personalized gait training videos featuring cued and non-cued gait for participants
214931754|NCT04218292|DEVICE|Micro Plug Set|The Micro Plug Set is indicated for arterial embolization in the peripheral vasculature.
214931755|NCT02691429|OTHER|Acai dye 10%|dye to be used during chromovitrectomy in humans
214931756|NCT03129191|DEVICE|Non-invasive bone conduction hearing aid A|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.
214329587|NCT00259857|DRUG|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
214931757|NCT03129191|DEVICE|Non-invasive bone conduction hearing aid B|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
214329588|NCT00000436|BEHAVIORAL|Self-efficacy and muscle strength training|
214329589|NCT00000436|PROCEDURE|High-intensity strength training|
214329590|NCT05554861|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
214329591|NCT05554861|DEVICE|Intermittent Theta Burst Stimulation (iTBS) Protocol|"It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTBS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
214329592|NCT05554861|DEVICE|Sham rTMS Protocol|"It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.~After the daily sham rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
214329593|NCT02968732|PROCEDURE|Radical Cystectomy|
214329594|NCT02545894|BEHAVIORAL|Cognitive therapy|"The tasks are:~* visually tracking a picture as it moves across the computer screen~* pressing a button every time a picture is seen on the screen~* pressing a button every time a specific picture is seen on the screen~* Pressing a button every time a specific sound is heard~* Matching objects to a picture~* Matching gestures to objects~* Matching two connected objects~* Sorting objects by categories~* Matching sounds to objects~* Complete the category and odd on out with objects~* Choosing target objects by pointing~* Choosing objects to complete the category by pointing"
214329595|NCT05081661|OTHER|Motor Imagery Program|The intervention group of the study will undergo standard postoperative physical therapy treatment at their therapist. Beginning on the third day after surgery, the participant will begin an motor imagery program to be performed three times a week for four weeks. A session lasts between fifteen and twenty minutes. It begins with a body awareness phase followed by a series of three to five one-minute exercises to be repeated three times, with a one-minute break between each exercise. The program is performed independently at home using a standardized audio tape.
214329596|NCT05081661|OTHER|Placebo program|"The control group of the study will undergo standard postoperative physiotherapy treatment at their therapist. On the third day after surgery, the participant will begin a relaxation program inspired by the mindfulness tool called Bodyscan that acts as a placebo mental imagery program. Nevertheless, the program created for this technique does not follow the Bodyscan guidelines (Jon Kabat-Zinn, 2005), as we do not want there to be any effects in favor of improved body perception on the participants, which could bring an additional biai to the study. For the sake of understanding, we have used the term body visualization in the various documents distributed to the participants. The program is to be performed three times a week for four weeks. A session lasts between ten and fifteen minutes. The program is performed independently at home using a standardized audio tape."
214329597|NCT06139627|OTHER|Best Practice|Receive usual care
214673446|NCT01240993|BEHAVIORAL|Mothers and Toddlers Program|This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.
214931758|NCT01196689|DRUG|AZD1981 100 mg twice daily for 61/2 days|100 mg tablets
214931759|NCT00278226|BEHAVIORAL|smoking cessation intervention|
214931760|NCT00278226|OTHER|educational intervention|
214931761|NCT02286648|DRUG|Formocresol|pulpotomy with formocresol
214931762|NCT02286648|DRUG|Mineral Trioxide Aggregate|pulpotomy with MTA
214931763|NCT05551520|DEVICE|Normative|ImPACT will be administered at baseline testing
214931764|NCT05551520|DEVICE|Reliability|ImPACT will be administered again within 60 days of baseline test
214931765|NCT01890226|BEHAVIORAL|Mobile Personal Health Record App.|
214329598|NCT06139627|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
214329599|NCT06139627|OTHER|Communication Intervention|Receive GA assessment summary and assessment-based recommendations
214329600|NCT06139627|OTHER|Comprehensive Geriatric Assessment|Complete GA
214329601|NCT06139627|OTHER|Electronic Health Record Review|Ancillary studies
214329602|NCT06139627|OTHER|Survey Administration|Ancillary studies
214486255|NCT06894030|BEHAVIORAL|Cognitive Cue|A verbal cue to be mentally rehearsed by each participant
214329603|NCT01083030|DEVICE|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
214329604|NCT01083030|COMBINATION_PRODUCT|DCB|Drug Coated Balloon Angioplasty
214329605|NCT00529932|OTHER|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
214329606|NCT00529932|OTHER|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
214329607|NCT01786694|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
214329608|NCT04406805|DIAGNOSTIC_TEST|Measurement of plasma and urine trimethylamine-N-oxide concentration|Information already included in arm/group descriptions.
214329609|NCT05764369|BEHAVIORAL|Parenting Wisely Residential Treatment (PWRT)|PWRT experimental intervention
214329610|NCT05764369|BEHAVIORAL|TAU|The TAU condition is the standard of care offered to parents in RT settings.
214329611|NCT06225258|DIETARY_SUPPLEMENT|Xanthohumol|Patients, who received Xanthohumol (Chmiel-Xn-Active, SALUTIS Pharmacy, Poland) as adjunctive therapy to treatment recommended by Surviving Sepsis Campaign. Xanthohumol is administrated by the nosogastric tube three times a day \*every 8 hours) at the dose of 2 mg.\\/kg body weight for 10 days. The first dose of Xanthohumol is administrated within 4 hours after the admission to the ICU.
214329612|NCT03666780|DEVICE|LAmbre Occluder|All patients are implanted with Lifetech LAmbre occluder device.
214329613|NCT01782651|DRUG|Lapatinib plus capecitabine|Lapatinib plus capecitabine
214329614|NCT05884099|PROCEDURE|Cryoanalgesia AND single-injection paravertebral block|CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
214329615|NCT05884099|PROCEDURE|Single-injection paravertebral block|Paravertebral block with Bupivacaine 0.5%
214486256|NCT06892730|DEVICE|Hybrid TEVAR combined with long bare-metal stent intervention|"\- Primary TEVAR: Primary TEVAR: Employ Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM 160-240mm endograft deployed with ≥2cm proximal landing zone coverage.~Concurrent bare-stenting: Post-TEVAR femoral access deployment of Fabulous® (45-150mm) long bare-metal stent with:~Proximal overlap ≥3cm with TEVAR graft. Distal extension 2-6cm below renal artery plane. Maximum distal limit: above iliac bifurcation.~\- Intraprocedural angiography with spinal reference mapping guides precise stent positioning relative to visceral arteries and infrarenal aorta."
214329616|NCT03689764|OTHER|interactive video game-based exercise|Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
214329617|NCT03689764|OTHER|no intervention|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
214329618|NCT06431828|OTHER|APP|The patients will download an app through which they will be able to report adverse events related to their cardiovascular health.
214329619|NCT02751151|OTHER|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
214329620|NCT00203203|DEVICE|Intramyocardial Injection of stem cells via NOGA Mapping|Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
214329621|NCT00203203|OTHER|Control, then Stem Cell Therapy|Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
214329622|NCT01893424|DRUG|Sativex buccal spray|buccal spray
214329623|NCT01893424|DRUG|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
214329624|NCT00449293|BEHAVIORAL|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
214329625|NCT00449293|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
214329626|NCT04670016|OTHER|This study does not include an intervention.|This study does not include an intervention.
214329627|NCT04856696|DIAGNOSTIC_TEST|PGT-A|trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
214329628|NCT04856696|DIAGNOSTIC_TEST|non-invasive PGT-A|cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
214329629|NCT00858390|DIETARY_SUPPLEMENT|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
214329630|NCT06779409|OTHER|Back squat|2 sets of 3 repetitions of a back squat, set to 85% of the 1 repetition maximum weight
214329631|NCT06779409|OTHER|Wingate test|30 second maximal effort cycling test, with resistance at 7.5% bodyweight
214329632|NCT03638986|OTHER|No intervention planned|No Intervention planned.
214673447|NCT01240993|BEHAVIORAL|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
214329633|NCT04471584|DEVICE|Insertion of ILR device|All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.
214329634|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
214329635|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
214329636|NCT00806468|DRUG|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
214329637|NCT04463381|PROCEDURE|choledochotomy techniques during LCBDE|
214329638|NCT06117462|OTHER|Assesment of CFS|Assesment of CFS
214329639|NCT03679260|OTHER|Carbohydrate restricted diet|20 grams total carbs/day
214329640|NCT03679260|OTHER|Non-restricted diet|Subject follows normal diet
214329641|NCT03679260|OTHER|Phone counseling with dietitian|Weekly calls with dietitian
214329642|NCT02633475|GENETIC|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
214329643|NCT04640025|DRUG|itacitinib|Participants will self-administer itacitinib orally using intact tablets with water and without regard to food.
214329644|NCT02144675|DRUG|choline magnesium trisalicylate|Given PO
214329645|NCT02144675|DRUG|idarubicin|Given IV
214329646|NCT02144675|DRUG|cytarabine|Given IV
214329647|NCT02144675|OTHER|laboratory biomarker analysis|Correlative studies
214931766|NCT01671566|BEHAVIORAL|Home based interval training|The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
214931767|NCT01659346|PROCEDURE|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication.
214931768|NCT01659346|DRUG|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
214931769|NCT00483210|DRUG|Fenofibrate|
214931770|NCT02028403|DRUG|BMS-936559|0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
214931771|NCT02028403|DRUG|Placebo for BMS-936559|Sodium chloride for injection 0.9%, USP, administered as an IV infusion
214931772|NCT03407703|DRUG|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|HCV treatment
214931773|NCT01818206|OTHER|Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.|Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
214931774|NCT05028413|BEHAVIORAL|Participants Shown their Breath Alcohol Content Measurement|Each time a Breath Alcohol Content (BrAC) Measurement is taken by the research team, the participant is shown the measurement before completing the paper visual analog scale scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
214931775|NCT00994695|BIOLOGICAL|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
214931776|NCT03912818|DRUG|Carboplatin|Given IV
214931777|NCT03912818|DRUG|Cisplatin|Given IV
214486257|NCT06894238|DIAGNOSTIC_TEST|Sub-hairline EEG Monitoring|Participants will receive standard postoperative care as per institutional protocols, including neuromonitoring, delirium screening, and ICU management. The study will not alter or assign any treatments but will analyze the association between sub-hairline EEG parameters and postoperative delirium (POD) outcomes
214673448|NCT06020976|DIAGNOSTIC_TEST|liver biobsy|all pationt will be subjected yo liver biobsy to confirm diagnosis
214931778|NCT03912818|PROCEDURE|Cystectomy|Undergo cystectomy
214931779|NCT03912818|DRUG|Doxorubicin|Given IV
214931780|NCT03912818|BIOLOGICAL|Durvalumab|Given IV
214931781|NCT03912818|DRUG|Gemcitabine|Given IV
214931782|NCT03912818|DRUG|Methotrexate|Given IV
214931783|NCT03912818|DRUG|Vinblastine|Given IV
214931784|NCT00006066|BIOLOGICAL|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
214673449|NCT02412644|DRUG|apremilast|
214931785|NCT00006066|BIOLOGICAL|Diphtheria and Tetanus Toxoids Adsorbed|
214931786|NCT00006066|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|
214486258|NCT06893718|OTHER|Compressions Stocking Group|"* Incline: Initially 5% incline and after 4 weeks an incline of 10% will be observed~* Speed: Constant speed of 3.4 mph.~* Warm up: Calf stretch 10 reps/ 2 sets."
214486259|NCT06893718|OTHER|Treadmill Training Group|"* Incline: Initially 5% incline and after 4 weeks an incline of 10% will be observed~* Speed: Constant speed of 3.4 mph.~* Warm up: Calf stretch 10 reps/ 2 sets."
214486260|NCT06892678|DRUG|DFMO|DFMO dose will be calculated based on the BSA measured within 14 days prior to the beginning of each cycle. Tablets may be swallowed whole, chewed, or crushed and mixed with soft food or liquid.
214931787|NCT00006066|DRUG|Bacteriophage phi X 174|
214931788|NCT00006066|DRUG|Aldesleukin|
214931789|NCT04398186|DIAGNOSTIC_TEST|Anogenital distance measurement|Measurements of AGD and perineal muscle strength
214931790|NCT00715728|DEVICE|Intraoperative warming with Bair Hugger forced air system|Intraoperative warming with Bair Hugger forced air system
214931791|NCT00715728|DEVICE|Intraoperative warming with Hotdog resistive heating system|Intraoperative warming with Hotdog resistive heating system
214931792|NCT05876793|DRUG|Remimazolam tosilate|The fixed dose of propofol in this study was 0.5mg/kg, with an injection time of 30 seconds. Subsequently, remimazolam was administered at an initial dose of 0.1mg/kg. After 1 minute of administration, sedation was evaluated using MOAA/S. When the MOAA/S score was ≤ 1, endoscopic examination could begin. If the patient did not show physical activity or coughing, sedation was considered successful, and the next patient's medication dose was reduced by 0.02mg/kg; On the contrary, if sedation fails, the next patient will receive an additional 0.02mg/kg of medication.Successful sedation results in a positive reaction, while failure results in a negative reaction. This study ends when 7 positive and negative reactions intersect
214931793|NCT03841539|BEHAVIORAL|Mediterranean Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.
214931794|NCT03841539|DIETARY_SUPPLEMENT|Study Supplement|Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
214931795|NCT03841539|BEHAVIORAL|Low-fat Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
214931796|NCT06366139|PROCEDURE|Radiofrequency thermocoagulation of the trigeminal ganglion|The patient is placed in the supine position and the foramen ovale is identified medial to the coronoid process of the mandible by giving the head a submental oblique position under fluoroscopic guidance. A 20-gauge, 5 mm active type, and 100 mm radiofrequency cannula is inserted 2 cm lateral to the commissura labialis and advanced towards the foramen. After entering the foramen ovale with a lateral fluoroscopic image, the radiofrequency cannula is connected to the radiofrequency generator and sensory and motor stimulations are performed to confirm the target maxillary and mandibular nerves. The radiofrequency lesion is applied at 60°C, 65°C and 70°C for 60-seconds periods. The patient is observed for side effects for 1 hour after the procedure.
214931797|NCT06366139|PROCEDURE|Maxillary/Mandibular nerve pulsed radiofrequency|The patient is placed in the lateral decubitus position with the affected side up. A 5-12 MHz linear ultrasound probe is placed in the infrazygomatic area above the maxilla at a 45° inclination in both the frontal and horizontal planes. The probe position allows visualization of the pterygopalatine fossa, which is limited to the maxilla anteriorly and the greater wing of the sphenoid posteriorly. Real-time ultrasound guidance allows direct localization of the internal maxillary artery and identification of the needle tip. The radiofrequency cannula was connected to the radiofrequency generator and PRF was applied at 42°C for 240 seconds after confirming the localization of the maxillary and mandibular nerve by obtaining appropriate responses to sensory and motor stimulation.
214931798|NCT02938624|DRUG|Pembrolizumab 200 mg IV single dose|Pembrolizumab 200 mg IV single dose, 21 days later surgery
214931799|NCT02938624|DRUG|Pembrolizumab 200 mg IV twice interval 21 days|Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery
214931800|NCT02938624|DRUG|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
214931801|NCT02938624|DRUG|Pembrolizumab 100 mg I.V single dose|Pembrolizumab 100 mg I.V single dose, surgery after 21 days.
214931802|NCT02938624|PROCEDURE|Surgical resection of tumor|Surgical resection of tumor by any of the acceptable procedures
214486261|NCT06893861|OTHER|Metabolomic profiling|Blood samples will be collected from these subjects, and following metabolomic profiling, the data will provide the foundation for training machine learning models capable of recognizing the metabolomic profiles of subjects with endometrial carcinoma and differentiating them from subjects with other conditions.
214673450|NCT03969433|DEVICE|TMSi Porti|Data collections
214931803|NCT02526875|DRUG|Telminuvo®Tab. 40/2.5mg|per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
214931804|NCT06463418|DEVICE|Ekoskeleton (Intervention)|Exoskeleton walking three times per week for 12 weeks.
214931805|NCT06463418|OTHER|Relaxation (Comparator)|Relaxation three times per week for 12 weeks.
214329648|NCT05913063|DEVICE|Structured Light Imaging Microscopy|Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
214931806|NCT05798013|BEHAVIORAL|Digital health management|The digital health management platform mainly includes reminding patients to take medication on time, monitoring and managing risk factors, reminding patients of regular review and regular follow-up, pushing personalized science according to patients' risk factors, etc., as well as following up and supervising patients' health management, and conducting regular formal medical science conferences.
214931807|NCT01200459|BEHAVIORAL|Social/mobile weight loss promotion intervention.|Social/mobile intervention for weight loss promotion, compared to control group.
214329649|NCT01813019|DRUG|AFQ056|mGluR5 antagonist
214931808|NCT01258075|DRUG|High-dose colesevelam|3.75 grams colesevelam hydrochloride in oral suspension
214329650|NCT01813019|DRUG|Placebo|Matched placebo
214329651|NCT01743937|PROCEDURE|Coronary occlusion with balloon inflation|
214329652|NCT05265949|BEHAVIORAL|diet and physical activity intervention|Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
214931809|NCT01258075|DRUG|Low-dose colesevelam|0.625 grams colesevelam hydrochloride in oral suspension
214931810|NCT01206413|DIETARY_SUPPLEMENT|Low glycemic index diet|
214931811|NCT01206413|DIETARY_SUPPLEMENT|High glycemic index diet|
214931812|NCT01206413|OTHER|Home-based exercise intervention|
214931813|NCT01206413|OTHER|Non-exercisers|
214931814|NCT02413242|OTHER|Various observed exposure(s) of interest|A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
214931815|NCT06057493|OTHER|Retinal Imaging with Optina4C Camera|"The study consists of 2 visits and 8 Imaging sessions:~The participant will go through four (8) imaging sessions in two visits with the Optina-4CTM cameras to get pictures of your retina. These imaging sessions will be done by three qualified operators who have been trained on the study device by Optina Diagnostics."
215071156|NCT06895655|DEVICE|MRI and Ultrasound Elastography|transcutaneous ultrasound elastography and MRI abdomen with diffusion to evaluate pancreatic mass as regard of probability of mass to be malignancy ,size of the mass ,relation to pancreatic duct and bile duct evaluation with their result will be compared to the pathologic finding.
214329653|NCT00647192|DRUG|Eplerenone|50 mg per day
214329654|NCT00647192|DRUG|Placebo|50 mg per day
214329655|NCT03377621|DEVICE|Whole Body Vibration|Whole Body Vibration Machine from the company Confidence Fitness
214931816|NCT01899807|DEVICE|OssDsign AB|
214931817|NCT03367559|BIOLOGICAL|ROTAVAC®|Rotavac® is in frozen form and is thawed till fully liquid prior to administration.
215071157|NCT06885216|PROCEDURE|Anterior cervical discectomy and fusion/ posterior decompression|
214329656|NCT01234623|OTHER|UCS eyedrops|1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
214329657|NCT03075644|DRUG|somapacitan|Once weekly subcutaneous injections (s.c., under the skin)
214329658|NCT03075644|DRUG|Norditropin|Daily subcutaneous injections (s.c., under the skin)
214329659|NCT06572956|BIOLOGICAL|CAR-T/CAR-NK cell injection|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
214329660|NCT06572709|DIAGNOSTIC_TEST|Parasternal intercostal muscle thickness with ultrasonography|Ultrasonographic measurements were performed of the bilateral parasternal intercostal muscle thickness in the supine position in the stroke patient group. Ultrasonographic measurements were performed of dominant side parasternal intercostal muscle thickness in the supine position in healthy individuals group. Spirometry evaluation was performed in both groups.
214329661|NCT02164396|DEVICE|Spectacle Lens|Spectacle Lens Only
214329662|NCT02164396|DEVICE|Habitual Soft Contact Lens|subject's own contact lens
214329663|NCT02164396|DEVICE|Test Lens|senofilcon A or narafilcon A
214329664|NCT01066559|PROCEDURE|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
214329665|NCT01066559|PROCEDURE|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
214329666|NCT01066559|BIOLOGICAL|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
214329667|NCT01066559|BIOLOGICAL|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
214673451|NCT03969433|DEVICE|Bloomlife sensor|Data collections
214931818|NCT00051441|DRUG|Benzydamine Hydrochloride 0.15% Oral Rinse|
215071158|NCT06896214|OTHER|Standardised nursing care intervention|Standardised nursing care intervention
215071159|NCT06897787|PROCEDURE|manuel positioning group|As Prof. Reyneke does, mandibular base and proximal segment leveling are performed first, followed by fixation.
215071160|NCT06897787|PROCEDURE|mandibular basis osteotomy|After the mandibular sagittal split, secure the proximal segment in its preoperative position and remove the bone piece for leveling. After that, fixation is performed.
215071161|NCT04696276|OTHER|ERAS protocol|special approaches in three phases preoperatively, intraoperatively and postoperatively, by an interdisciplinary team comprising of the surgeon, the anesthesiologist and the nurse. The combination of these techniques reduces the reaction to postoperative stress, relieves acute postoperative pain, restores the patient immediately to their original feeding and mobilization habits, thus reducing the time required for their complete recovery.
215071162|NCT05920811|OTHER|conventional obturator|restoration of midline maxillary defect with obturator made of cast metal , heat cure acrylic resin
215071163|NCT05920811|OTHER|3 d printed obturator|restoration of midline maxillary defect with obturator made of SLM metal , 3 d printed resin
214329668|NCT01458171|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06\_002CR (NCT01199705).
214329669|NCT03783559|DRUG|TACE|TACE
214931819|NCT04568525|DIAGNOSTIC_TEST|Passive Microwave Radiometry|The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
214931820|NCT01252862|DEVICE|iStent|Implantation of two iStents through a small temporal clear corneal incision
214931821|NCT01500213|DRUG|Rolapitant|200 mg PO
214329670|NCT03783559|DRUG|chemotherapy±target therapy|chemotherapy±target therapy
214329671|NCT01391117|DRUG|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
214329672|NCT01391117|DRUG|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
214329673|NCT01391117|DRUG|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
214329674|NCT01391117|DRUG|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
214329675|NCT01391117|DRUG|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
214329676|NCT01391117|DRUG|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
214329677|NCT01391117|DRUG|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
214329678|NCT01391117|DRUG|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
214329679|NCT01391117|DRUG|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
214329680|NCT01391117|DRUG|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
214329681|NCT02270060|OTHER|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
214329682|NCT02270060|OTHER|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
214329683|NCT06155045|PROCEDURE|Modified Carbo-dissection Technique|This technique comes the C02 blower with electrocautery. Thereby, producing vasodilatation due to the gas and dissection aided by the electrocautery.
215071164|NCT05325736|PROCEDURE|sleeve gastrectomy surgery|participants undergoing sleeve gastrectomy surgery
215071165|NCT05325736|PROCEDURE|gastric bypass surgery|participants undergoing gastric bypass surgery
214329684|NCT06155045|PROCEDURE|Conventional Arm|This technique uses only the electrocautery as conventional model
214329685|NCT05351008|OTHER|Cognitive Functional Therapy|A physicaltheapy approach combining cognitive techniques, func-tional movement training, functional integration and Lifestyle Changes.
214329686|NCT05351008|OTHER|Exercise program:|Core strengthening program
214329687|NCT00574860|DRUG|EN3285|Oral rinse
214329688|NCT00574860|DRUG|Placebo|Oral rinse
214329689|NCT00574860|OTHER|Standard of care|This will be the therapy most commonly used the the institution treating the patient
214931822|NCT01500213|DRUG|Granisetron|10 mcg/kg IV
214931823|NCT01500213|DRUG|Dexamethasone|20 mg PO and 8 mg PO
215071166|NCT05325736|PROCEDURE|control|cholecystectomy
215071167|NCT05325736|PROCEDURE|Pancreatectomy|Collecting a sample of an unidentified healthy pancreas to extract insulin-secreting beta cells from the sample
214329690|NCT03546374|PROCEDURE|Surgical Ablation|In addition to the concomitant surgery, subjects are required to have amputation or closure (with sutures or ligation) of the left atrial appendage.The Cox Maze IV lesion set is required to be performed.
214329691|NCT03546374|DEVICE|Cardioblate and Cryoflex hand held devices|The Cardioblate hand held devices consist of the Cardioblate iRF and Cryo surgical ablation devices.
214329692|NCT04604457|OTHER|Palliative care contacts primary care|Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
214329693|NCT02214121|DRUG|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
214329694|NCT02214121|DRUG|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
214931824|NCT01500213|DRUG|Placebo|(4 X 0 mg capsules) o mg PO
214931825|NCT01591551|DRUG|Natalizumab (Tysabri)|300 mg IV every 4 weeks
214931826|NCT01447875|OTHER|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before sedation
215071168|NCT06751602|DRUG|Belumosudil 200 mg QD|Belumosudil 200 mcg oral daily
215071169|NCT06751602|DRUG|Placebo|Placebo (once daily)
215071170|NCT03203941|BIOLOGICAL|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
215071171|NCT06895889|DEVICE|EB-OC Graft Implantation|The implantation of the EB-OC graft is completed via an arthrotomy, which is categorized as a minor surgery and is done on an outpatient basis, which means you can go home the same day. It is completed under general anesthesia and may last between one to two hours.
215071172|NCT06895889|PROCEDURE|Abrasion chondroplasty|Abrasion chondroplasty is a minimally invasive procedure in which the surgeon uses a rotary burr to scrape off the bone tissue from the surface of the joint.
214931827|NCT01447875|DRUG|propofol or mexmedetomidine|
214931828|NCT03083431|DRUG|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
214931829|NCT03083431|DRUG|Placebo|Oral solution containing the same excipients as propranolol solution
214931830|NCT00916968|DEVICE|Standard CR-Flex total knee|total knee implant used for joint replacement surgery of the knee
214931831|NCT00916968|DEVICE|Gender specific CR-Flex|TKA by Gender specific Nexgen CR-Flex
214931832|NCT00250536|DRUG|nandrolone decanoate|
214931833|NCT00250536|BEHAVIORAL|resistance exercise training|
214931834|NCT01733043|DRUG|Dexmedetomidine|
214931835|NCT01733043|DRUG|Placebo|
214931836|NCT06730243|PROCEDURE|"Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction"|"Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction"
215071173|NCT06895876|PROCEDURE|Deep parasternal intercostal plane block|The block is performed bilaterally in the 4th intercostal space. The probe is placed in the latero-median axis and a needle is placed latero-medially between the intercostal and transverse thoracic muscle. The solution is then injected under ultrasound control
215071174|NCT06896227|DIAGNOSTIC_TEST|transthoracic echocardiography|Each study patient will undergo transthoracic echocardiography, transesophageal echocardiography, and cardiac magnetic resonance imaging following transcatheter aortic valve replacement.
215071175|NCT02204046|DRUG|BIWA 4|
215071176|NCT00780143|DRUG|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
215071177|NCT04548700|DRUG|Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle."
215071178|NCT04548700|DRUG|Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day."
215071179|NCT06606288|DEVICE|Conduction system pacing|Implant with a Medtronic dual-chamber transvenous pacemaker on or after the study data with lead type and placement data indicating conduction system pacing
215071180|NCT06606288|DEVICE|Bi-ventricular pacing|Implant with a Medtronic bi-ventricular pacemaker (CRT-P) on or after the study date
214931837|NCT06730243|PROCEDURE|Standard Robot-Assisted Radical Prostatectomy|Standard Robot-Assisted Radical Prostatectomy
215071181|NCT06890221|DIETARY_SUPPLEMENT|B-Crobes intake complete nutrition|Contains whey and plant based proteins, enriched with prebiotics and probiotics, Ca-Hmb, minerals and multivitamins.
214931838|NCT06730243|PROCEDURE|Laparoscopic Radical Prostatectomy|Laparoscopic Radical Prostatectomy
214931839|NCT03488849|DEVICE|SureCRIC|SureCRIC is intended to be used as an accessory to cricothyrotomy and tracheotomy devices, helping to identify and stabilize anatomical landmarks for establishing an airway.
214931840|NCT03488849|OTHER|Freehand|Freehand palpation approach to identification of the cricothyroid membrane
214931841|NCT00669552|PROCEDURE|Percutaneous coronary intervention|PCI previously electively scheduled.
214931842|NCT02444975|DIETARY_SUPPLEMENT|Mineral water|1.5L/day of water on top of the normal fluid intake for 1 year
215071182|NCT06890221|DIETARY_SUPPLEMENT|Placebo|Contains full cream dairy milk
214931843|NCT02444975|OTHER|Coaching program|Coaching program to support increased water intake
214329695|NCT04460664|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214329696|NCT00715793|DRUG|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
214329697|NCT00715793|DRUG|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
214329698|NCT00715793|PROCEDURE|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
214931844|NCT02444975|OTHER|No intervention|No intervention
214931845|NCT03197870|DRUG|AKB-9778|Subcutaneous AKB-9778 15mg
214931846|NCT03197870|DRUG|Placebo|Subcutaneous Placebo
214931847|NCT00630084|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
214931848|NCT00630084|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
214329699|NCT04578847|DRUG|Imatinib|Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
214329700|NCT04578847|DRUG|Nilotinib|Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
214329701|NCT04578847|DRUG|Dasatinib|Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
214329702|NCT04578847|DRUG|Bosutinib|Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
214329703|NCT04856033|BEHAVIORAL|TM|Transcendental Meditation instruction, 12-sessions over 3-4 months with monthly follow-up
214931849|NCT00807391|PROCEDURE|TBCA, TBNA|One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
214931850|NCT03294291|PROCEDURE|Quadratus lumborum block|Postoperative pain procedure
214931851|NCT03294291|PROCEDURE|Caudal block|Postoperative pain procedure
214931852|NCT04940520|BIOLOGICAL|Drug recommended by the Brazilian Society of Dermatology|Using a drug recommended by the Brazilian Society of Dermatology, twice a day.
214931853|NCT04940520|COMBINATION_PRODUCT|Alpha bisabolol product and laser|Using alpha bisabolol-based product associated with low-level laser therapy. Alpha bisabolol-based product will be used twice a day, and laser therapy used once every fortnight.
214931854|NCT04940520|BIOLOGICAL|Alpha bisabolol product|Using alpha bisabolol-based product twice a day
215071183|NCT06895733|DRUG|Pazopanib Oral Tablet|Orally administered once daily (100mg)for 21 consecutive days, followed by a 7-day cessation of medication; Every 28 days is a treatment cycle.
215071184|NCT06895733|DRUG|Palbociclib|Oral treatment once a day, with a cycle of 28 days. In the safety introduction section, the initial dose of pazopanib is 400mg, and in the dose escalation queue, the dose of pazopanib is 600mg.
215071185|NCT01098253|BEHAVIORAL|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
215071186|NCT01402557|BEHAVIORAL|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
214329704|NCT04856033|BEHAVIORAL|PCT|Present Centered Therapy, 12-sessions over 3-4 months with monthly follow-up
214329705|NCT04942938|DEVICE|Neubie|The Neubie is a direct current neuromuscular electrical stimulation device. This system uses an exponential wave pattern to mimic the natural pattern neurologically to lengthen fibers of the sarcomere and engage force velocity of muscle with minimized protective co-contraction of nearby muscle groups. The golgi tendon and muscle spindles code for joint position and muscle/tendon stretch with 66% of fibers being intrafusal. Impacting these structures has direct impact on reticulospinal tract fibers and proprioceptive central fibers modulation of levels of spasticity. The Neubie direct current is designed to improve positioning of these stretch receptors.
214673452|NCT02947451|OTHER|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
214673453|NCT02947451|OTHER|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
214673454|NCT06956521|DRUG|Magnesium sulfate|Following MT and IA injection of MgSO4, patients will also receive a continuous infusion of 16g MgSO4 diluted in 240 ml of 0.9% normal saline, infusing at a rate of 10 ml per hour for 24 hours.
215071187|NCT01402557|BEHAVIORAL|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
215071188|NCT01402557|BEHAVIORAL|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
215071189|NCT01540526|DRUG|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
215071190|NCT00082368|DRUG|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
214329706|NCT01849588|DRUG|Sorafenib|
214329707|NCT00401336|DEVICE|Magnetic resonance imaging multiecho gradient-echo sequence|Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
214931855|NCT03725774|OTHER|GRIP (Getting Research into Practice) model|"The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.~The GRIP model is a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying the obstacles to improvements in clinical practice, and drawing up and implementing a plan of action for the purpose of improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the obstacles that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles."
214931856|NCT00313365|PROCEDURE|Surgical Lavage (Arthrotomy)|
214931857|NCT00313365|PROCEDURE|Arthrocentesis (Serial needle aspiration)|
214931858|NCT06545630|BIOLOGICAL|Tumor antigen-sensitized DC vaccine|subcutaneous administration
214931859|NCT06511362|PROCEDURE|Functional stabilization training|At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.
214931860|NCT06511362|PROCEDURE|perturbation exercises|At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.
214931861|NCT05304689|DIAGNOSTIC_TEST|test for quantitative index of interleukins in the oral fluid|collection of oral fluid and determination of the content of cytokines by test systems in patients with postoperative wound
214931862|NCT02604355|OTHER|Matching Placebo|Oral dosing with placebo capsules to match RO7020322.
214931863|NCT02604355|DRUG|RO7020322|Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
214931864|NCT04944303|DRUG|Sugammadex|Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium
214931865|NCT04944303|DRUG|Normal saline|Equal doseage of normal saline was injected to reverse the NMB.
214931866|NCT05267990|DIAGNOSTIC_TEST|Multi-Detector Computed Tomography|Coronary angiography calcium score via Multi-Detector Computed Tomography
215071191|NCT00082368|DRUG|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
215071192|NCT05271734|DEVICE|Lid retractor placement|Insertion of a lid retractor to find out if the corneal limbus is exposed in 360 degress
215071193|NCT00050206|DRUG|Olanzapine|
215071194|NCT00050206|DRUG|Placebo|
215071195|NCT07081893|OTHER|Conventional care with semi-structured interviews and focus groups|In semi-structured individual interviews, employees of healthcare organisations are asked about their experiences, opinions and knowledge on person-centredness. This makes it possible to gather in-depth insights. This approach will mainly be used when surveying e.g. board members, managers, representatives of patient organisations. In addition, focus groups (6 to 8 people) will be organised. This is especially valuable when surveying doctors, paramedics and nurses. Focus groups make it possible to survey several respondents at the same time, encourage spontaneous conversations and share experiences. The interaction between participants can also ensure that additional perspectives and insights are covered.
214329708|NCT02063997|DRUG|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
214329709|NCT02063997|DRUG|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
214329710|NCT02063997|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
214329711|NCT02063997|DRUG|Placebo|Placebo tablets once daily for 12 weeks
214329712|NCT02063997|DRUG|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
214673455|NCT00882713|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
214931867|NCT01570634|DRUG|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
214931868|NCT01618019|DIETARY_SUPPLEMENT|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
214931869|NCT01618019|DIETARY_SUPPLEMENT|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
214931870|NCT03380104|DEVICE|Intradural Spinal Cord Stimulation|The device will be placed percutaneously at the lumbar spine at L2-3 or L3-4 level into the intrathecal CSF space and advanced to the T8-10 disc space. After positioning of the intrathecal lead, the stimulation catheter will be run through a standardized experimental algorithm consisting on various frequencies.
214931871|NCT03380104|BEHAVIORAL|Administration of Questionnaires|Subjects will be administered questionnaires to evaluate pain, quality of life, and global function prior the study, at 1 hour after the completion of the study, and at 4 day follow-up appointment.
214931872|NCT01134679|BEHAVIORAL|Multi-disciplinary disease management approach|Follow up with phone calls
215071196|NCT07081893|OTHER|In-depth interviews with patients and relatives|The objective is to thoroughly understand what PEC means in rehabilitation. Although PEC can be understood as 'being responsive to the unique wishes and needs of the individual person', there still is a lack of consensus about its exact conceptualization in the rehabilitation context (Yun and Choi 2019). Prior work often only considers PEC in terms of shared decision making and goal setting, while the holistic perspective on the patient as a whole person is largely neglected (Yun and Choi 2019). This qualitative phase thus focuses on understanding PEC, its dimensions and the unique wishes and needs of patients in rehabilitation services. In addition, we gather insights regarding the potential enhancement of PEC in rehabilitation. The interviews are based on the Trajectory Touchpoint Technique (TTT; Sudbury-Riley et al. 2020a; 2020b) which allows us to uncover the unique experiences of respondents (i.e., patients, relatives, informal caregivers). The TTT is especially suited fo
214329713|NCT05941026|OTHER|Structured education|"The educational content of the research was created by the researcher in line with the literature and expert opinions and covers the following topics.~Educational subjects~1. Culture and Concepts Related to Culture~2. Culture/Cultural Characteristics and Cultural Elements in Terms of Social Structure~3. Cultural Factors Affecting Health and Disease~4. Concepts and Practices Related to the Field of Study~The training is an online training and continued via video conference, and a session invitation was sent to the participants before each session. In addition, after the training, brochures containing the training topics of each week were prepared and delivered to the participants. The trainings were conducted by the researcher in a total of four sessions (each session 20 minutes) once a week during the training process. During the training, the questions of the participants were answered."
214329714|NCT02132000|DRUG|toremifene or tamoxifen|
214329715|NCT04543552|DEVICE|Bladder scan|Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
214329716|NCT00914615|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
214329717|NCT06568003|DEVICE|Transcatheter Tricuspid Valve Intervention|Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
214329718|NCT06406738|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform newborn first-care.
214931873|NCT05174949|DEVICE|Transcranial direct current stimulation (high-definition)|"Three conditions (2 mA, 20 mins):~1. anodal stimulation over the ipsilesional primary motor cortex~2. cathodal one over the contralesional premotor cortex~3. Sham"
214931874|NCT06668298|DRUG|Oliceridine|The formula for postoperative analgesia pump is oliceridine 0.4mg · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
214931875|NCT06668298|DRUG|Sulfentanil|The analgesic regimen for the sufentanil group is sufentanil 2 µ g · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
214931876|NCT04699513|DEVICE|Mechanical Ventilation Mode (airway pressure release ventilation )|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
214931877|NCT06159556|OTHER|Peanut intake|Participants will consume 2 ounces of peanuts/peanut butter for 12 weeks
214931878|NCT05731037|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
214931879|NCT05589155|OTHER|Mobile health application|Intervention will be with mobile health application
214931880|NCT02971475|PROCEDURE|extracorporeal shock wave lithotripsy|People in this group would be treated with ESWL only.
214931881|NCT02971475|PROCEDURE|endoscopic drainage of the main pancreatic duct|People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.
214931882|NCT02971475|DRUG|Analgesics|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
214931883|NCT02683395|DRUG|PLX51107|
214931884|NCT03287284|DEVICE|Active Low Level Laser Therapy|Active application of Low Level Laser Therapy with a dose of 240 Joules
214931885|NCT03287284|BEHAVIORAL|Resistance Training|Resistance Training
214329719|NCT04594096|BEHAVIORAL|Telehealth visits|Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle
214329720|NCT04594096|BEHAVIORAL|Standard of Care|Receiving care as usual from the UC Davis Comprehensive Cancer Center
214329721|NCT02202928|BIOLOGICAL|DC-CIK|8×10\^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
214329722|NCT02202928|RADIATION|Radiotherapy|45\~50 Gy in 25-28 fractions.
214329723|NCT02202928|DRUG|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
214329724|NCT00002183|DRUG|Abacavir sulfate|
214329725|NCT00002183|DRUG|Amprenavir|
214931886|NCT03287284|DEVICE|Placebo Low Level Laser Therapy|Placebo application of Low Level Laser Therapy
214329726|NCT00002183|DRUG|Lamivudine|
214329727|NCT00002183|DRUG|Zidovudine|
214329728|NCT00094653|DRUG|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses
214329729|NCT00094653|BIOLOGICAL|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
214931887|NCT06333275|BIOLOGICAL|Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles|"First immunization course (6±1 months post CAR-T treatment):~1. Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b (as by the Swiss guidelines\[FOPH\] all of these are administered in one combined vaccine; INFANRIX DTPa-IPV+Hib Inj Susp®; GlaxoSmithKline)~2. Hepatitis B (Engerix B®, GlaxoSmithKline)~3. 13-valent Streptococcus pneumonia vaccine (Prevenar-13®; Pfizer)~4. Herpes zoster vaccine in patients with documented prior seropositivity or known varicella-infection in patient history (as by The Swiss guidelines; Shingrix®; GlaxoSmithKline)~5. Tick-borne encephalitis (as by The Swiss guidelines; FSME Immun CC®; Pfizer or Encepur N®, BavarianNordic; these vaccines can be used interchangeably)~Second immunization course (12±1 months post CAR-T treatment):~1. Mumps, measles, rubella (Priorix®, GlaxoSmithKline)~2. Varicella zoster vaccine (as by guidelines; Varilrix®, GlaxoSmithKline) If seronegative/patient history negative"
214931888|NCT02880865|BIOLOGICAL|Live attenuated SA 14-14-2 Japanese Encephalitis vaccine|Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
214931889|NCT02880865|BIOLOGICAL|Measles, mumps, rubella vaccine|Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
214931890|NCT05546346|DEVICE|wearable magnet tracking system|In this group, wearable magnet tracking system was used.
214931891|NCT05982483|PROCEDURE|Erector Spinae plane block using 20 ml of bupivicaine 0.25%|"Utilizing the in line approach, a 22 gauge 3.5 spinal needle was guided the the tip of the transverse process corresponding to the area of maximal tenderness or central to the reported area of spasm. 1% lidocaine with epinephrine was used for skin anaesthesia and for hydro-localization of the needle tip on approach to the tip of the transverse process. Once the needle tip made contact with the transverse process, 2-3 ml of 1% lidocaine with epinephrine was injected to open the ESP plane. If there was no reported tachycardia after approximately 45 seconds, 20 ml of 0.25% bupivicaine was injected into the ESP plane."
214931892|NCT05982483|DRUG|Usual care|Analgesia as dictated by the treating emergency physician
214931893|NCT03114527|DRUG|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
214931894|NCT03114527|DRUG|Everolimus|mTOR inhibitor
214329730|NCT03921411|BIOLOGICAL|Nemolizumab|Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
214329731|NCT04587622|DRUG|Icenticaftor|Single oral dose of 300 mg of icenticaftor (QBW251)
214329732|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led education module using virtual reality
214329733|NCT04278534|OTHER|Educational Intervention|Receive the usual verbal and written education materials
214931895|NCT02718170|PROCEDURE|Buried Intramedullary K-wire Fixation|
214329734|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led face-to-face education module
214329735|NCT04278534|OTHER|Survey Administration|Ancillary studies
214329736|NCT00330551|DRUG|Oral Risperidone|Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
214329737|NCT00330551|DRUG|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
214329738|NCT05664035|BIOLOGICAL|Diagnosis of SPAD using immunization with PPV23|Diagnosis of SPAD using immunization with PPV23
214329739|NCT05192577|OTHER|Electrical stimulation|At the beginning of the session, an electrode will be attached to the participant's ankle. Electrical stimulation will be applied to estimate the electrical perception threshold. This threshold will be used as condition stimuli when different thermal thresholds are assessed.
214329740|NCT03120013|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
214329741|NCT03120013|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
214329742|NCT03697811|DRUG|DE-117 Ophthalmic Solution|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
214329743|NCT00472134|DRUG|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
214329744|NCT00472134|DEVICE|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
214329745|NCT01826175|DRUG|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
214329746|NCT01826175|DRUG|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
214329747|NCT01826175|DEVICE|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
214329748|NCT03306888|OTHER|Physical Activity Coaching|Physical activity coaching over 4 months
214329749|NCT01192594|BEHAVIORAL|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
214329750|NCT01192594|BEHAVIORAL|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
214329751|NCT05053984|PROCEDURE|Percutaneous Echoguided Neuromodulation|Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
214329752|NCT00529841|DRUG|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
214329753|NCT05776108|DRUG|Cabotegravir IR Formulation (reference)|Cabotegravir IR Formulation (reference) will be administered.
214329754|NCT05776108|DRUG|Cabotegravir DT Formulation (test 1)|Cabotegravir DT Formulation (test 1) will be administered.
214329755|NCT05776108|DRUG|Cabotegravir DT Formulation (test 2)|Cabotegravir DT Formulation (test 2) will be administered.
214329756|NCT05487729|OTHER|ultrasonography and functional assessment and questionnaire survey|ultrasonography and functional assessment and questionnaire survey
214329757|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
214329758|NCT01541826|DIETARY_SUPPLEMENT|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
214329759|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
214329760|NCT04703452|OTHER|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
214329761|NCT00580424|DRUG|Norethindrone|Norethindrone 0.35 mg orally daily
214329762|NCT00169143|DRUG|Rituximab + ACVBP regimen plus Pegfilgrastim|
214329763|NCT00169143|PROCEDURE|Autologous stem cell transplant|
214329764|NCT00945984|PROCEDURE|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
214931896|NCT02718170|PROCEDURE|Plate and Screw Fixation|
214931897|NCT05521529|OTHER|no intervention, as this is an observational study|no intervention
214931898|NCT06847438|BEHAVIORAL|Optimized version of the EPIC-HF Checklist|The EPIC-HF checklist is a 1-page patient activation tool that contains approved and guideline-recommended medications and target doses for HFrEF. The EPIC-HF checklist allows patients to see recommended doses and categories of GDMT, which they can compare to their current medications and dosing. The EPIC-HF checklist has been refined and updated to include GDMT prescription and has been optimized for delivery through electronic medical record (EMR) systems. The checklist is being used as a patient activation/ discussion tool only and data entered on the checklist will not be collected for purposes of this study.
214931899|NCT06847438|BEHAVIORAL|Clinician-facing Decision Support|Information regarding GDMT (including target doses and medications) analogous to what is contained in the checklist will be provided to clinicians in intervention clinics. This information will be visible at the time of the encounter.
214329765|NCT00191997|DRUG|Olanzapine|
214329766|NCT06462690|OTHER|pre-mid-post test|(PIF) (DLQI) (GCS) Data Collection Forms Humidity measurement with DMM device
214329767|NCT06252675|BIOLOGICAL|Obinutuzumab|Given intravenously (IV)
214329768|NCT06252675|BIOLOGICAL|Glofitamab|Given IV
214329769|NCT06252675|DRUG|Pirtobrutinib|Given Orally (PO)
214329770|NCT06252675|PROCEDURE|Tumor Imaging|Undergo regular care imaging/scans
214329771|NCT06252675|PROCEDURE|Biospecimen Collection|Blood and tissue samples
214329772|NCT06252675|DEVICE|ClonoSeq Assay|ClonoSEQ is an FDA-cleared, Clinical Laboratory Improvement Amendments of 1988 (CLIA)-validated measure used to determine minimal residual disease (MRD). This helps uncover how much, if any, cancer remains in your body during and after treatment.
214329773|NCT06252675|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration.
214329774|NCT03440671|BIOLOGICAL|Hutox Inj|Hutox Inj(Clostridium botulinum type A)
214329775|NCT03440671|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
214329776|NCT02600637|BEHAVIORAL|MBSR|Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
214329777|NCT02600637|BEHAVIORAL|Brain Health class|An 8-week course on brain health will be administered to participants as an active control group.
214329778|NCT02627599|DEVICE|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
214329779|NCT01411306|OTHER|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
214673456|NCT00401973|DRUG|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
214931900|NCT06847438|BEHAVIORAL|Standard of Care|Patients of clinics that are not implementing EPIC-HF checklist will not have the checklist available to them through the electronic medical record (EMR).
214931901|NCT04773184|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
214931902|NCT04773184|PROCEDURE|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing. This is like a moving x-ray of the swallow.
214931903|NCT04773184|PROCEDURE|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
214931904|NCT04773184|PROCEDURE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
214931905|NCT04773184|PROCEDURE|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
214931906|NCT04773184|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
214931907|NCT04773184|OTHER|Voicing Tasks|Voicing tasks will be completed to assess vocal ability.
214931908|NCT05129293|BEHAVIORAL|Prospective Memory Intervention|Cognitive remediation focusing on prospective memory
214931909|NCT05129293|BEHAVIORAL|Educational|Psychoeducation
215071197|NCT07081893|OTHER|Semi-structured interviews and focus groups|In semi-structured individual interviews, employees of healthcare organisations are asked about their experiences, opinions and knowledge on person-centredness. This makes it possible to gather in-depth insights. This approach will mainly be used when surveying e.g. board members, managers, representatives of patient organisations. In addition, focus groups (6 to 8 people) will be organised. This is especially valuable when surveying doctors, paramedics and nurses. Focus groups make it possible to survey several respondents at the same time, encourage spontaneous conversations and share experiences. The interaction between participants can also ensure that additional perspectives and insights are covered.
215071198|NCT07081893|OTHER|Conventional care with additional focusgroups|In semi-structured individual interviews, students of healthcare organisations are asked about their experiences, opinions and knowledge on person-centredness. The focus groups will be supported by the Lego® Serious Play (LSP) will be used to collect in-depth insights from students. This design allows flexibility in questioning, while still following a consistent structure to explore common themes across focus groups. The use of Lego encourages participants to think in new ways.
215071199|NCT06644482|OTHER|Exercise group in a hospital setting|Participants will exercise in a group once a week for 16 weeks in a hospital setting.
215071200|NCT01794208|DRUG|Follitropin Epsilon|
214329780|NCT01411306|PROCEDURE|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
214329781|NCT06562881|OTHER|Scheduling Navigation|Participants will be connected to a scheduler to schedule a surgical consultation visit at time of recruitment. Participation does not guarantee or require surgery.
214673457|NCT00401973|DRUG|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
214931910|NCT03805451|BEHAVIORAL|Life Steps for PrEP for Youth|Life-Steps is a modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to pre-exposure prophylaxis.
214931911|NCT04908904|DIETARY_SUPPLEMENT|Cafestol|Capsule with 12 mg cafestol
214931912|NCT04908904|DIETARY_SUPPLEMENT|Placebo|Placebo capsule without cafestol
214931913|NCT00621595|DIETARY_SUPPLEMENT|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
215071201|NCT01794208|DRUG|Follitropin Alfa|
214931914|NCT06793527|DRUG|Celiac Plexus Block|During general anesthesia, a celiac plexus block will be performed intraoperatively (20 ml of 0.5% ropivacaine). The patient will not feel discomfort due to general anesthesia.
215071202|NCT00501722|DRUG|satavaptan (SR121463B)|
215071203|NCT06440954|DRUG|Intrathecal pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
215071204|NCT05969639|BEHAVIORAL|HEYA|The HEYA program is a 12-week app-delivered psychoeducational program that comprises of nutrition education, skills training on self-regulation, and weekly feedback.
214931915|NCT06793527|DRUG|ESP block|Before the procedure, a block of the erector spinae (ESP) compartment will be performed with approximately 20 ml of 0.25% ropivacaine at the Th4 level. The patient will be informed about the possibility of short-term discomfort if the block is performed before full induction of anesthesia.
214931916|NCT06793527|DRUG|Lidacaine|Instead of a regional block, an intravenous infusion of lidocaine will be used.
214931917|NCT06248359|DRUG|L-Arginine hydrochloride|Postoperative administration of L-Arginine hydrochloride before incidence of CS-AKI
214931918|NCT05810506|OTHER|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
215071205|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
214329782|NCT06562881|OTHER|Without Scheduling Navigation|Patients will work with clinic staff in the usual fashion for their treatment for primary hyperparathyroidism. They will not be connected directly to a scheduler to help schedule a surgical consultation visit at time of recruitment. With our crossover design, if patients have not yet received surgical consultation after 3 months, they will be called and connected with a scheduler at that time. Participation does not guarantee or require surgery.
214329783|NCT06461650|BEHAVIORAL|Nicotine cessation program|Participants will complete up to 4 sessions of a nicotine cessation program over either 12-24 weeks if receiving neoadjuvant therapy (i.e. chemotherapy or hormonal/endocrine therapy) prior to surgery or over 4-6 weeks if not receiving neoadjuvant therapy prior to surgery. Each session will be 30-60 minutes long. Participants receiving neoadjuvant therapy will also be eligible for nicotine replacement therapy; however, it must be stopped 6 weeks before surgery.
214329784|NCT01365273|DEVICE|Mepitel One|Dressing
214329785|NCT04043312|DEVICE|Magstim SuperRapid|Transcutaneous magnetic stimulation targeting the left stellate ganglion.
214329786|NCT04043312|DEVICE|Magstim SuperRapid|Sham transcutaneous magnetic stimulation.
214931919|NCT00860249|BEHAVIORAL|Letter Only|Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
214931920|NCT00860249|BEHAVIORAL|Letter and Educational DVD|Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
214931921|NCT03817957|DRUG|Polyglucoferron|intravenous administration
215071206|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
215071207|NCT07079748|DIETARY_SUPPLEMENT|Yeast Postbiotics|Participants in the intervention group will take two capsules of yeast postbiotics daily after meals, with each capsule containing 250 mg of yeast postbiotics, along with maltodextrin and silicon dioxide.
215071208|NCT07079748|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take an equal number of placebo capsules, identical in dosage form, taste, appearance, and packaging. The placebo contains only maltodextrin and a small amount of silicon dioxide. All participants will take two capsules once daily, swallowed with warm water after meals.
215071209|NCT06902701|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Endoscopic excision of the rectal lesion by submucosal injection and circumferential mucosal incision using an electrosurgical knife with en-bloc resection intent
215071210|NCT06902701|PROCEDURE|Transanal Endoscopic Surgery (TES)|Transanal endoscopic surgery procedures include Transanal Minimally Invasive Surgery (TAMIS) and Transanal Endoscopic Operation (TEO). TAMIS will be performed using a single-port transanal access platform with standard laparoscopic instruments, including a high-definition camera, an insufflation system, and endoscopic graspers. The lesion will be circumferentially excised using electrocautery or an energy device, ensuring full-thickness resection when necessary. The defect will be managed based on its size, with primary closure using absorbable sutures or left to heal by secondary intention. TEO will be conducted using a rigid transanal endoscopic platform with a stereoscopic optical system to enhance visualization. The lesion will be marked, and a full-thickness or submucosal excision will be performed using endoscopic instruments and electrosurgical devices. Post-resection, the rectal wall defect will be assessed, and primary closure will be performed when indicated to minimize post
214329787|NCT00504686|OTHER|manual therapy|manual therapy - thoracic spine thrust manipulation
214329788|NCT00504686|OTHER|exercise|therapeutic exercise
214329789|NCT00002188|DRUG|Alitretinoin|
214329790|NCT03499392|OTHER|psychological tests|psychological tests psychological interviews
214329791|NCT02188238|OTHER|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
214329792|NCT01339390|BEHAVIORAL|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
214329793|NCT01339390|BEHAVIORAL|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
214329794|NCT03886558|OTHER|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months.|The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
214329795|NCT04847674|DRUG|TEV-53275 Dose A|subcutaneous (sc) injection
214329796|NCT04847674|DRUG|TEV-53275 Dose B|subcutaneous (sc) injection
214931922|NCT03817957|DRUG|Ferric carboxymaltose|intravenous administration
214931923|NCT03817957|DRUG|Ferrous Sulfate|oral administration
214931924|NCT04935801|BIOLOGICAL|LD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
214931925|NCT04935801|BIOLOGICAL|LD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
214931926|NCT04935801|BIOLOGICAL|HD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
214931927|NCT04935801|BIOLOGICAL|HD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
214931928|NCT00432796|DRUG|Dalteparin|5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
214931929|NCT00432796|OTHER|Placebo|"patients will be randomized post-operative to receive either active treatment or placebo.~the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.~ie. 5,000 iu or 200 iu/kg"
214931930|NCT03574142|DRUG|Epanova|A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days.
214931931|NCT04481581|OTHER|Electronic Alerts|When FiO2 remains =\>0.4 and SpO2 =\>94% for more than 45 minutes, an electronic health record based alert will be sent to respiratory therapists to titrate oxygen per decision support tool.
214931932|NCT06078748|BEHAVIORAL|EX|"EX involves 2.5hrs of moderate intensity aerobic and resistance exercise per week. EX will be instructed by a clinical exercise physiologist (CEP) or registered kinesiologist (RKIN). The EX session will include a 5min warm-up, 20-30min of moderate intensity aerobic exercise, 20-30min of moderate intensity resistance training, and a 5min cool down. The virtual video session will be pre-recorded, have similar composition, and will be led by the same instructor as the group sessions. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on exercise in order to overcome barriers and increase maintenance of lifestyle changes."
214931933|NCT06078748|BEHAVIORAL|DIET|"DIET involves one session per week of diet education delivered by a Registered Dietitian. The DIET session will be 90 minutes during months 1-4, and 30 minutes in months 5 and 6. DIET was developed by our team, emphasizing foods identified as supporting executive function, memory, and other cognitive abilities. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on diet in order to overcome barriers and increase maintenance of lifestyle changes."
214931934|NCT06078748|BEHAVIORAL|STRETCH|STRETCH sessions will be time/frequency-matched to EX sessions (2.5hrs/week: 1.5hr in virtual group sessions; 1hr virtual video session) to control for social aspects and placebo effects of EX.Each STRETCH session will include a 5min warm-up, 5min of balance exercises, and 50min of stretching. Difficulty will not be progressed. STRETCH sessions will also be led by a CEP/RKIN instructor and video sessions will be pre-recorded by the same instructor.
214931935|NCT06078748|BEHAVIORAL|ED|ED sessions designed to be of equal intensity and social engagement to the DIET intervention. Participants will engage in group discussion and receive information on the brain and cognitive processes, the effect of age on cognition, and tips to promote healthy aging. This will include lectures, watching documentaries and participating in various games.
214931936|NCT03614260|DEVICE|Paradise Renal Denervation System|Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
214931937|NCT03614260|PROCEDURE|Renal Angiogram|Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure.
214931938|NCT01714843|DRUG|linaclotide|oral
214931939|NCT01714843|DRUG|placebo|oral
214931940|NCT06645782|BEHAVIORAL|Virtual, Group CF-CBT|Virtual, group CF-CBT is an online, tailored CBT program for adults diagnosed with CF. Participants will attend eight weekly sessions (90 minutes each) delivered online. The sessions include: Introduction to CBT; Relaxation Skills; Depression in CF: What Helps?; Adaptive Thinking Skills, Part 1; Adaptive Thinking Skills, Part 2; Taking Charge of My Health; Anxiety in CF: What Helps?; and Maintaining Positive Changes.
214931941|NCT06189729|BEHAVIORAL|Text reminder|Participants will receive trimonthly text reminders through instant messaging mobile applications or short message service.
214931942|NCT06189729|BEHAVIORAL|HIV self-test|Participants will receive trimonthly text messages asking them to choose a pickup point run by the delivery company to collect the free HIV self-test. Upon receiving the delivery instruction, the self-test kit with bilingual (Chinese and English) instructions would be delivered to the designated location.
214329797|NCT04847674|DRUG|Placebo|Matching subcutaneous (sc) placebo injection
214931943|NCT00174967|DRUG|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
214931944|NCT00174967|DRUG|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
214931945|NCT00174967|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
214931946|NCT00174967|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
214931947|NCT06234592|DRUG|Angiotensin II|Angiotensin II infusion
214931948|NCT06234592|DRUG|Vasopressin|Vasopressin infusion
214329798|NCT02281136|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
214931949|NCT06234592|DRUG|Norepinephrine|Standard care vasopressor therapy, norepinephrine infusion
214931950|NCT03625635|OTHER|Individualized food-based intervention|Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
214931951|NCT04250532|OTHER|Drowning|Measurement of pulse oximetry, after lifeguard immersion during their morning training
215071211|NCT00322452|DRUG|Gefitinib|oral tablet
214329799|NCT02281136|DEVICE|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
214673458|NCT00401973|DRUG|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
214673459|NCT00401973|DRUG|zonisamide|Zonisamide, 100-400mg, oral, daily.
214329800|NCT05716828|OTHER|Balint group activities|A Balint group is a working form that focuses on the professional doctor-patient relationship. Participants in the Balint group completed Balint training for a period of at least three months, which included two lectures and 10 small group discussion sessions held once a month for one hour at a time (on Thursdays from 12 to 1 PM). Balint group is a closed group including one to two group leaders and six to twelve participants, with sessions lasting 60 to 90 minutes.
214329801|NCT02563028|DEVICE|SightSaver Visual Stimulator|Evoked response photic stimulator
214329802|NCT01791361|OTHER|Other|No intervention other than routine medical care
214931952|NCT02004821|DIETARY_SUPPLEMENT|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.|
214931953|NCT06046625|OTHER|Regular care with additional administration of a semi-structured interview|"Patients receiving regular care. In addition, a semi-structured interview is conducted.~The semi-structured interviews take place once after completion of the care pathway (after all appointments for check-ups associated with the treatment). The interview contains questions about the experience of patients with the care, the needs in this care, the experiences with the information received, the support/guidance, the turnaround time, the treatment received and areas for improvement."
214931954|NCT02539966|DEVICE|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold|Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
215071212|NCT00322452|DRUG|Carboplatin|IV
215071213|NCT00322452|DRUG|Paclitaxel|IV
215071214|NCT03353363|DRUG|Bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.
215071215|NCT03353363|DRUG|Liposomal bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.
214329803|NCT03331068|BEHAVIORAL|online questionnaire of MAX-PC|Scale measuring of the anxiety specific of prostate cancer, French version.
214329804|NCT06416865|DRUG|AJU-C52L, AJU-C52|"AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.~AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks."
214931955|NCT02938403|BEHAVIORAL|In vivo counseling|Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.
214329805|NCT06416865|DRUG|C52R1L, C52R1M|"C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.~C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks."
214329806|NCT01462357|BIOLOGICAL|Cervarix|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6.
214673460|NCT00401973|BEHAVIORAL|Wellness education|weight management
215071216|NCT03353363|DRUG|Placebos|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
215071217|NCT05064020|DRUG|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.
215071218|NCT07079280|OTHER|Low Intensity Aerobic Exercise with Blood Flow Restriction (LIAE+BFR)|"In the LIAE+BFR condition, participants will walk on a treadmill for 20 minutes at 30-40% of heart rate reserve (HRR), with a pneumatic cuff inflated to 1.3 times the individual's ankle systolic blood pressure, using a 5cm wide x 75cm long commercial cuff around each upper thigh.~Treadmill speed will be adjusted dynamically to maintain target intensities, while the incline remains at 1%. Heart Rate, the Modified Borg Rate of Perceived Exertion scale, and the Rating of perceived discomfort will be continuously monitored throughout both exercise sessions to ensure adherence to the prescribed intensity levels."
215071219|NCT07079280|OTHER|High Intensity Interval Exercise (HIIE)|"In the HIIE condition, participants will perform a 20 minutes treadmill-based HIAE, alternating between 60-seconds high-intensity intervals at 60-89% HRR and 60-second active recovery intervals at 40-50% HRR.~Treadmill speed will be adjusted dynamically to maintain target intensities, while the incline remains at 1%. Heart Rate, the Modified Borg Rate of Perceived Exertion scale, and the Rating of perceived discomfort will be continuously monitored throughout both exercise sessions to ensure adherence to the prescribed intensity levels."
214329807|NCT01462357|BIOLOGICAL|Gardasil|2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
214931956|NCT02938403|BEHAVIORAL|Standard Smoking Cessation Counseling|Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
214931957|NCT06054061|BEHAVIORAL|Experimental: experimental wellbeing promotion group (Think and Cope Positively)|"Session 1: Welcome. 2: Identifying and amplifying positive emotions. 3: Experiencing positive emotions. 4: Identifying my negative trap thoughts. 5: Transforming my automatic thoughts into positive ones. Session 6: Experiencing my positive thoughts I. 7: Experiencing my positive thoughts II. 8: Learning to be kinder to myself. 9: Identifying a life project (Individual appointment).10: Identifying coping strategies I. 11: Identifying coping strategies II. 12: Identifying adaptive coping strategies linked to well-being. 13: Building my life purpose with my environment. 14: Helping me to build my life purpose? 15: Multi-family session, farewell and closing."
214931958|NCT06054061|BEHAVIORAL|TAU|The usual treatment in the intervention of people affected by severe mental disorder in the network of public and subsidized centers in Spain consists of improving psychosocial functioning. To this end, and depending on the characteristics of the user, work is done in groups and individually on social skills, psychoeducation about the disease, adherence to pharmacological treatment, improvement of daily living activities, promotion of independent leisure, support to families in the process of relapse prevention, and training for labor market insertion.
214931959|NCT03382301|DRUG|Ciclosporin A preconditioning before renal artery stenosis dilation|Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
214931960|NCT03382301|DRUG|NaCl preconditioning before renal artery stenosis dilation|NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
214931961|NCT02947204|OTHER|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
214931962|NCT02947204|OTHER|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
214931963|NCT05073029|OTHER|nutrition program and modification of physical activity|nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
214931964|NCT05073029|DIETARY_SUPPLEMENT|synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103, 4.0х109 colony forming units - CFU)|one synbiotic sachet (3g), BID, for 3 month traetment
214931965|NCT05073029|DIETARY_SUPPLEMENT|vitamin D3|vitamin D3, oral, 2000IU BID, for 3 month treatment
214931966|NCT02066818|DRUG|Lidocaine/tetracaine patch|
214931967|NCT02066818|DRUG|1% lidocaine|
214931968|NCT01668524|DRUG|ATS907|Single dose of each of three increasing concentrations
214931969|NCT06112652|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
214931970|NCT06112652|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
214931971|NCT06112652|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
214931972|NCT06112652|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
214329808|NCT01462357|DRUG|Placebo|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
214329809|NCT03366064|BIOLOGICAL|Pemetrexed and donor-derived NK cell infusion|Patients are administered with donor-derived NK cells one week after pemetrexed infusion
214329810|NCT05325463|PROCEDURE|conventional lung recruitment|The recruitment maneuver will be performed by pressure controlled mode maintaining a steady airway pressure of 15 cmH2O, with 5 cmH2O increments in positive end-expiratory pressure (PEEP) until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 sec. The peak airway pressure will be maintained for 10 sec or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings.
214931973|NCT06112652|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
214931974|NCT05295979|DRUG|Inflammatory skin disease formula|ISDF granules (10.85g twice daily) for 12 weeks
214931975|NCT05295979|DRUG|Placebo|Placebo granules (10.85g twice daily) for 12 weeks
214931976|NCT01585350|BIOLOGICAL|MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|"Cohort 1 will be divided into three sub-groups and will receive:~* Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)~* Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1~* Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations"
214329811|NCT05325463|PROCEDURE|ultrasound- guided lung recruitment|The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area was visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit was 40 cmH2O.
214673461|NCT05523362|DEVICE|Dexcom continuous glucose monitor|The investigational device used in this study is the Dexcom G6 Pro/Personal Continuous Blood Glucose Monitoring system.
214673462|NCT02971644|DEVICE|cobalt alloy pedicle screw implantation|The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
214673463|NCT03515538|DRUG|RRx-001|RRx-001 for injection
214329812|NCT06143475|DEVICE|FPS group|"Vibration frequency ranged from 0 to 100 Hz. There were 3 modes of FPS application during rehabilitation course. 1) anti-spasticity mode (FV): the stimulators were placed in the middle of the muscles of the affected limb (i.e. unilaterally); 2) bilateral mode of proprioceptive facilitation; and 3) the unilateral mode of the proprioceptive facilitation.~The 2 first sessions were realized with bilateral FPS stimulations plus the anti-spasticity FV mode to reduce the level of hypertonia. Then for 6 consecutive sessions unilateral FPS stimulations of the affected sides imitating the drawing of a straight lines (horizontal, vertical, diagonal), preparing for writing (drawing a circle, triangle, square, spiral) were realized. At last, the 4 remaining FPS sessions were realized unilaterally imitating and promoting the realization of everyday life activities."
214931977|NCT01585350|BIOLOGICAL|MELITAC 12.1 + Montanide ISA-51 + polyICLC|"Cohort 2 will be divided into three sub-groups and will receive:~* Group 2a: MELITAC 12.1 + polyICLC adjuvant~* Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1~* Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations"
214931978|NCT04615806|DRUG|Indocyanine green solution|ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.
215071220|NCT00494650|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
215071221|NCT00494650|BEHAVIORAL|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
215071222|NCT06896149|DIAGNOSTIC_TEST|Obstetric ultrasound|Ultrasound focus on fetal renal pelvis, amniotic fluid assessment, and fetal weight estimation.
215071223|NCT05667584|DEVICE|hypotension prediction index derived from non-invasive arterial pressure waveforms|The Hypotension Prediction Index (HPI) is an algorithm based on the complex analysis of features in high-fidelity arterial pressure waveform recordings developed to observe subtle signs that could predict the onset of hypotension in surgical and intensive care unit patients. HPI is a unitless number that ranges from 1 to 100, and as the number increases, the likelihood of a hypotensive event (MAP \<65 mm Hg for more than 1 minute) occurring in the near future increases. In a validation study on HPI conducted in patients under general anesthesia, the algorithm, at its optimal value, predicted hypotension with both sensitivity and specificity of 86% 5 minutes before the event. Measurement of the arterial pressure waveforms using a finger cuff (ClearSight) is well established.
215071224|NCT05667584|DEVICE|non-invasive arterial pressure waveforms|ClearSight is a non-invasive hemodynamic monitoring device using digital-cuff and volume-clamp technology to obtain a continuous arterial blood pressure waveform. Continuous finger blood pressure measurement is established by wrapping the cuff around the middle phalanx of a finger. The area under the waveform curve is analyzed using a unique algorithm that serves to calculate the arterial blood pressure, stroke volume (SV) and CO.
215071225|NCT06907680|DIETARY_SUPPLEMENT|M-Gard|One capsule containing 250mg of M-Gard Particulate EW is taken twice daily for 14 days.
215071226|NCT06907680|OTHER|Placebo|One capsule containing 250mg of MCC (Microcrystalline Cellulose) is taken twice daily for 14 days.
215071227|NCT01086956|DRUG|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
214329813|NCT06143475|OTHER|Conventional therapy group|Patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
214329814|NCT00096044|BIOLOGICAL|rituximab|IV
214329815|NCT00096044|DRUG|lenalidomide|Oral
214329816|NCT00496301|DRUG|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
214329817|NCT00004031|BIOLOGICAL|rituximab|375 mg/m2 IV every 21 days
214931979|NCT02641886|DRUG|Jian Pi Yi Shen Hua Tan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
214931980|NCT02641886|OTHER|the placebo group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
214931981|NCT02481271|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
214931982|NCT02481271|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
215071228|NCT03284333|DEVICE|other|no arm
215071229|NCT02243618|DRUG|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
215071230|NCT02243618|DRUG|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
215071231|NCT00882583|DRUG|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
215071232|NCT00882583|DRUG|Dasatinib|Oral Dasatinib Days 8 through 64.
215071233|NCT00882583|DRUG|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
215071234|NCT00882583|RADIATION|Radiation Therapy|Standard Radiation Therapy.
214329818|NCT00004031|DRUG|CHOP regimen|
214329819|NCT00004031|DRUG|carmustine|
214329820|NCT00004031|DRUG|cyclophosphamide|
214329821|NCT00004031|DRUG|doxorubicin hydrochloride|
214329822|NCT00004031|DRUG|etoposide|
214329823|NCT00004031|DRUG|prednisone|
214329824|NCT00004031|DRUG|vincristine sulfate|
214329825|NCT00004031|PROCEDURE|bone marrow ablation with stem cell support|
214329826|NCT00004031|PROCEDURE|peripheral blood stem cell transplantation|
214329827|NCT00004031|RADIATION|radiation therapy|
214329828|NCT00186004|DEVICE|Continuous Glucose Monitor|Subjects are fitted with a CGM system and perform self blood glucose measures three or more times per day for 3 days.
214931983|NCT01882881|OTHER|Healthy American Control Diet|The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (\~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
214931984|NCT01882881|OTHER|Dark Chocolate/Cocoa Diet|The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide \~33% of calories from fat. The SFA (\~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (\~9g).
214931985|NCT01882881|OTHER|Almond Diet|The Almond Diet will include 1.5 oz of almonds daily and provide \~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing \~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
214931986|NCT01882881|OTHER|Dark Chocolate/Cocoa + Almond Diet|This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at \~34-35% and the SFA will match that of the Almond Diet at \~8-9%. The fiber content of this diet will be highest (\~35g); cholesterol will remain ≤200 mg/day.
214931987|NCT06618131|OTHER|Exercise|Exercise program with virtual reality applications for lower extremities
214931988|NCT03117894|DRUG|Ropivacaine 5 mg/ml, 35 ml|Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.
214931989|NCT03117894|DRUG|Remifentanil 50 microg/ml|The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
214931990|NCT03117894|DRUG|Betamethason 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
215071235|NCT06220591|PROCEDURE|Superior trunk block|"The patient will receive selective supraclavicular nerve block, then will undergo blockage of superior trunk the fifth and sixth cervical nerves of the brachial plexus. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. Then ultrasound probe will be moved to scan the superior trunk the fifth and sixth cervical nerves in the scalene groove.15 cc of local anesthetics mixture will be injected in 0.5 cc aliquots to encircle the fifth \& sixth cervical nerve roots."
215071236|NCT06220591|PROCEDURE|Clavipectoral fascial plane block|"The patient will receive selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. The ultrasound probe will scan both the medial \& lateral ends of the clavicle. Then Local anesthetics mixture15 cc will be injected in 0.5 cc aliquots after negative aspiration between the periosteum of the clavicle and the clavipectoral fascia. The same technique will be conducted on both the lateral and medial ends of the affected clavicle."
215071237|NCT04753658|DRUG|lorlatinib|Oral
214329829|NCT04809909|PROCEDURE|Peripheral stimulation of acupuncture points (PSAP)|Electrode leads will be implanted at Bladder 25-bilateral (BL25), the acupoint commonly used for relief of chronic Low Back Pain in standardized acupuncture.
214329830|NCT04809909|PROCEDURE|Peripheral nerve field stimulation (PNFS)|Electrode leads will be implanted at the region of pain.
214329831|NCT04482296|DRUG|SSRI with Zinc Sulfate|Zinc sulfate (30 mg) once daily for 8 weeks SSRI
214931991|NCT03117894|DRUG|Paracetamol 1,5 g|Administered preoperatively to prevent pain postoperatively.
214931992|NCT03117894|DRUG|Propofol|The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
214931993|NCT03117894|DRUG|Arcoxia, 120 mg|Administered preoperatively to prevent pain postoperatively.
214931994|NCT03117894|DRUG|Ondansetron 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
214931995|NCT03117894|DRUG|Morphine|Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
214931996|NCT02031640|DRUG|Beclomethasone dipropionate|
214329832|NCT06114264|BEHAVIORAL|Multimodal + Resistance Programs|"Exercise: will focus on working the all body by performing functional tasks. Behaviour change: An 'idle alert' of the wrist-worn activity prompter will be set to vibrate after 45 min without movement. Participants will be encouraged to take a 1-2 min activity break.~Education: The basic contents will explain to the patient the main mechanism of chronic pain (pain as a protective system, consequences, etc).~The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group and a Mindfulness practice.~Resistance functional exercises will replicate functional movements, such as standing from a bed, carrying bags, picking up groceries from the ground, etc."
214329833|NCT06114264|OTHER|Control group|No experimental intervention. The group will receive the same multimodal intervention as the experimental group when the experimental period is over.
215071238|NCT04191759|DIAGNOSTIC_TEST|Test-Retest reproducibility|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
215071239|NCT04098432|DRUG|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
215071240|NCT04098432|RADIATION|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
215071241|NCT05969756|DRUG|Fluoride varnish|Thirty-eight permanent molars will receive 5% sodium fluoride varnish application every three months
215071242|NCT05969756|DRUG|Conventional etch and rinse sealant|Thirty-eight permanent molars will receive conventional etch and rinse sealant
214329834|NCT05028504|DRUG|Penpulimab|Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214329835|NCT05028504|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
214329836|NCT01556542|DEVICE|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
214329837|NCT01556542|DEVICE|nitinol stent implantation|nitinol stent implantation
214931997|NCT02031640|DRUG|Placebo|
214931998|NCT02031640|DRUG|Albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
214931999|NCT00635453|BEHAVIORAL|Dietary Advice|The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
214932000|NCT02940093|OTHER|Stem cell transplantation|Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
214932001|NCT01192113|DRUG|Mecobalamin IV Injection|Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks
214932002|NCT01192113|DRUG|Mecobalamin IM injection|Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks
215071243|NCT05969756|DRUG|Self-etch sealant|Thirty-eight permanent molars will receive self-etch sealant
214932003|NCT01192113|DRUG|Mecobalamin IV or IM injection|Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks
215071244|NCT05142254|DRUG|Tadalafil|2.5-5 mg/day
215071245|NCT05142254|DRUG|Hydroxyurea|20 mg/kg/day
215071246|NCT05142254|DRUG|Placebo|identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
215071247|NCT05949970|PROCEDURE|Radiofrequency denervation of the lumbar facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the lumbar facet joint with a three-tined expandable needle.
215071248|NCT06528418|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
215071249|NCT00113204|DRUG|IPI-504|
215071250|NCT03542903|DEVICE|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg)."
214932004|NCT03085238|DEVICE|M-Trap|Device(s) will be surgically implanted in the peritoneal cavity. Up to three (3) M-Trap devices will be surgically implanted via laparotomy in the right and left paracolic (pelvic) gutters and behind segment 6 of the liver within the peritoneal cavity of the patient at the time of surgical resection. Patients will receive standard platinum-based chemotherapy. If the cancer is diagnosed to have recurred, M-Trap devices with captured tumor cells will be removed via minimally invasive surgery (laparoscopy).
214932005|NCT05862883|DRUG|Rutan 25 mg|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 25 mg. Excipients: potato starch, calcium stearate, lactulose."
214932006|NCT05862883|OTHER|Control group|Taking basic therapy without Rutan
214932007|NCT02754687|DRUG|Placebo|Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients
214932008|NCT02754687|DRUG|11βmethyl nortestosterone dodecylcarbonate|Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
214932009|NCT03013907|BEHAVIORAL|UPLIFT|Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks
214932010|NCT03013907|BEHAVIORAL|Usual care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study
214932011|NCT04150211|DIETARY_SUPPLEMENT|Polyherbal Exten(d) vs Placebo|Supplementation during 4 weeks
214932012|NCT00535782|DRUG|Tocilizumab|Administered by intravenous infusion, 8 mg/kg every 4 weeks.
214932013|NCT00535782|DRUG|Placebo|Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
214932014|NCT00535782|DRUG|Methotrexate|Administered orally or parenterally, 7.5-25 mg weekly.
215071251|NCT03601039|DEVICE|Absnow Absorbable ASD Closure System|the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
215071252|NCT02845479|OTHER|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
214329838|NCT03314467|DIAGNOSTIC_TEST|polysomnography|"* classical polysomnography~* non invasive measurement of blood pressure~* blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes"
214329839|NCT01387607|DRUG|pregabalin|Pregabalin capsule, 300-450mg/day, twice daily
214329840|NCT01387607|DRUG|placebo|Placebo, twice daily
214329841|NCT01509794|OTHER|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
215071253|NCT00804752|DRUG|Adding vitamin D|Adding 1000IU/Vitamin D daily
215071254|NCT00804752|DRUG|Vitamin D|Addition of 1000IU/day Vitamin D
215071255|NCT00907608|DRUG|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
215071256|NCT00002705|DRUG|topotecan hydrochloride|
215071257|NCT00232284|DRUG|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
214329842|NCT01509794|OTHER|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
215071258|NCT00232284|BEHAVIORAL|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
215071259|NCT01530035|OTHER|physical training|training
214329843|NCT01164852|PROCEDURE|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
214329844|NCT02970838|OTHER|Structured weight-loss program|"During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling."
214932015|NCT06668857|DIAGNOSTIC_TEST|video-oculography|All participants will receive quantitative oculomotor and pupillomotor measurements using two different video-oculography devices. Thereby both pursuit eye movements, saccades and pupillary responses to light will be assessed. In addition, there will be a quantitative assessment of the angular vestibulo-ocular reflex (aVOR) by use of video-head-impulse testing and a hearing test.
214932016|NCT03764826|DEVICE|CAABT|The sound generators with CAABT will be used 15 min each session, three times a day
214932017|NCT03764826|DEVICE|TMT|The sound generators with TMT will be used 15 min each session, three times a day
214932018|NCT01570972|BEHAVIORAL|Group Cognitive Behavioral Therapy|weekly
214932019|NCT01570972|BEHAVIORAL|Multifamily Group Psychoeducation|twice monthly
214932020|NCT05561907|PROCEDURE|Surgical gastrojejunostomy (SGJ)|Laparoscopic gastrojejunostomy
215071260|NCT00218634|BEHAVIORAL|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
214329845|NCT05555381|BEHAVIORAL|young-D program|"* needs detection by means of survey and interviews (mixed-methods)~* 6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
214329846|NCT00501891|DRUG|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
214932021|NCT05561907|PROCEDURE|Endoscopic gastrojejunostomy (EGJ)|Endoscopic ultrasound (EUS) guided gastrojejunostomy
214932022|NCT06684171|PROCEDURE|Echocardiographic guidance|After detailed evaluation, patients randomized in this group will undergo TEER procedure under guidance of fully echocardiography but any fluoroscopy in the entire process.
214932023|NCT06684171|PROCEDURE|Fluoroscopic guidance|After detailed evaluation, patients randomized in this group will undergo TEER procedure under combined guidance of echocardiography and fluoroscopy in the entire process.
214932024|NCT02338219|OTHER|postpartum female pelvic floor muscle affection|"transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
214932025|NCT02338219|OTHER|postpartum sexual function in Egyptian women.|answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
214329847|NCT00501891|DRUG|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
214329848|NCT04921514|BEHAVIORAL|SASRQ questionnaire|"During an interview with a trained psychologist, the presence of acute stress will be assessed by the SASRQ test within one week of the occurrence of a sudden recovered death.~The diagnosis of acute post-traumatic stress disorder is made according to the presence of at least three dissociative symptoms out of five, and other symptoms of re-experiencing, avoidance or marked anxiety or hypervigilance. Each symptom is thus evaluated dichotomously. A symptom is present if the intensity of the response is 3 or more (0 from 0 to 2 and 1 from 3 to 5)."
214329849|NCT04921514|BEHAVIORAL|PCL-5 with LEC-5 questionnaire|"This questionnaire will be completed during an interview with a psychologist trained in the protocol, 3 months after the sudden death.~The PCL-5 is a 20-item self-report questionnaire that assesses the 20 symptoms of PTSD according to the DSM-V. It is associated with the LEC-5 questionnaire.~The self-reported scale uses ratings of 0 to 4 to assess each of the symptoms.~A threshold of 38 on the PCL-5 seems reasonable to suggest the presence of PTSD."
214329850|NCT01024400|BIOLOGICAL|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
214673464|NCT03515538|DRUG|Cisplatin for injection|Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
214932026|NCT06282224|DEVICE|Performing endoscopic transnasal skull base surgery with AR-integrated endoscope|To explore how to use augmented reality technology (AR) to highlight important anatomical structures in the neuroendoscopic field of view, optimize the endoscopic surgical field of view, make up for the shortage of simple endoscopic field of view, make it easier for surgeons to distinguish deep anatomical structures, and reduce the intraoperative and postoperative complications of transnasal endoscopic surgery.
214932027|NCT04392128|DRUG|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine is an anti-malarial drug also used as anti-inflammatory treatment for systemic lupus erythematosus and rheumatic disorders. HCQ also inhibits pH-dependant replication stages of diverse types of viruses including flavivirus, retrovirus and coronaviruses.
215071261|NCT00218634|BEHAVIORAL|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
215071262|NCT05243745|OTHER|3% PVM/MA + 5% KNO3 Combination|Toothpaste containing 3% PVM/MA + 5% KNO3 as combination will be used as test product.
215071263|NCT05243745|OTHER|3% PVM/MA only|Toothpaste containing 3% PVM/MA only will be used as comparator 1 product.
215071264|NCT05243745|OTHER|5% KNO3 Only|Toothpastes containing 5% KNO3 only will be used as comparator 2 product.
215071265|NCT05243745|OTHER|Regular Fluoride|Toothpaste containing regular fluoride will be used as negative control.
214932028|NCT04392128|DRUG|Azithromycin 250 MG Oral Capsule|Azithromycin is amacrolide antibiotic.
214932029|NCT04392128|DRUG|Placebo oral tablet|Placebo of Hydroxychloroquine Sulfate 200 MG \[Plaquenil\].
214932030|NCT04392128|DRUG|Placebo oral capsule|Placebo of Azithromycin capsules.
214932031|NCT03857451|DIAGNOSTIC_TEST|Clinical gait analysis|Three dimensional gait analysis consisting of joint kinematics, kinetics and dynamic EMG data will be introduced into the diagnostic scheme
214932032|NCT04613141|DEVICE|WalkingTall-PD|Smart garment (socks, insoles or ankle bands) delivering rhythmic haptic stimuli to the ankle timed with preferred cadence. Smart phone application delivers auditory cues synchronised with haptic stimuli. Smart phone application delivers a neurorehabilitation program.
215071266|NCT04011566|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
215071267|NCT05160168|DRUG|THE-630|Oral THE-630 administered once daily in a continuous regimen
215071268|NCT06339242|DRUG|Furmonertinib|After completion of all screening activities, eligible patients were confirmed to enter the study. All patients will receive study treatment, Furmonertinib tablets 160mg, oral, once daily, lateral ventricular chemotherapy with Ommaya capsule technique until disease progression, intolerable toxicity, death, withdrawal of informed consent.
214329851|NCT02705690|DEVICE|iOS Balance Application|"We have designed an iOS application and a belt. The application uses accelerometer data to calculate postural sway. Steps:~The phone is kept stable against the lower back of the participant using the belt.~The iOS application gives instructions to user to adopt the correct stance (eg: Standing Unsupported, legs side by side) Once the stance is adopted, the application turns on the accelerometer in the phone to sample acceleration along x (media lateral) and z (anterior posterior) axis.~These displacements from the mean are used to calculate the Root Mean Square of a person which acts a proxy score for Postural Sway. (Postural sway is defined as the phenomenon of constant displacement and correction of the position of the center of gravity within the base of support)"
214932033|NCT04613141|OTHER|Mobility-plus|Active 'pseudo placebo' comparator using a paper-based body weight exercise program.
214932034|NCT06337916|BEHAVIORAL|Cervical Stabilization Exercise|The cervical stabilization exercise group will receive cervical stabilization exercises 1 session a day, 3 days a week for 6 weeks. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).
214932035|NCT06337916|BEHAVIORAL|Cervical Standard Exercise Group|The patients in cervical standard exercise group will receive conventional cervical exercise for 6 weeks, 3 days a week, 1 session a day. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).
214329852|NCT06670339|OTHER|No Cooling|Participants will not be pre-cooled prior to completing a 60-minute moderate-intensity exercise bout in the heat.
214329853|NCT06670339|OTHER|Pre-Cooling|Participants will be immersed in cold (\~17°C) water to elicit a decrease in rectal temperature by 0.5°C from baseline values prior to completing a 60-min moderate-intensity exercise bout in the heat.
214329854|NCT06504082|DRUG|Letrozole|Patients in the MTX + letrozole group received letrozole tablets (Femara 2.5 mg) once daily for ten days starting from the day of MTX administration.
214329855|NCT06504082|DRUG|Methotrexate|After confirming the diagnosis of tubal ectopic pregnancy, each patient will receive a single dose of intramuscular MTX (50 mg/m² MTX) on the same day
214329856|NCT03013491|DRUG|CX-072|Solution for infusion
214329857|NCT03013491|DRUG|ipilimumab|Solution for infusion
214329858|NCT03013491|DRUG|vemurafenib|Tablet
214932036|NCT03645746|DRUG|REGN5069|REGN5069 will be administered by IV infusion or SC injection
214932037|NCT03645746|DRUG|Placebo|Placebo-matching REGN5069
214932038|NCT00401713|PROCEDURE|Transplantation of autologous RPE|RPE cell suspension
214932039|NCT00401713|PROCEDURE|Translocation of autologous RPE and Choroid|RPE patch
214932040|NCT06243367|OTHER|Placebo drink|Patients were instructed to be fasting for 6 hours before surgery and received only placebo drink (200 ml clear water) two hours before surgery
214932041|NCT06243367|DIETARY_SUPPLEMENT|Carbohydrate|Patients were given a meal of cup of yogurt (100 ml) with 2 spoonful of honey (42 gm) at midnight before surgery and 200 ml of a clear carbohydrate drink on the day of surgery, 2 h before anesthesia induction. This drink consisted of 200 ml water in which two spoonful of honey were dissolved.
214932042|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at high intensity (HI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 85% of the one-repetition maximum per exercise (high load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
215071269|NCT03732495|DRUG|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
214329859|NCT06672575|DRUG|Ivonescimab|Participante will recived an infusion by vein
214329860|NCT06616701|BEHAVIORAL|Follow up call|As part of the standard of care, caregivers of youths who present to the hospital with suicidal risk receive a follow up call approximately 5-10 business days after the hospital discharge to assist them with any challenges they may encounter in accessing mental health care, including medication access. The intervention group will receive a call 5 days after discharge. The non-intervention group will receive a call 10 days after discharge.
214329861|NCT06998056|DRUG|ARQ-151 cream 0.05%|ARQ-151 Cream 0.05% is applied once daily for 4 weeks in infants with atopic dermatitis (eczema).
214932043|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at moderate-high intensity (MHI-bands)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
214932044|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at moderate intensity (MI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 65-70% of the one-repetition maximum per exercise (moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
215071270|NCT01368172|BEHAVIORAL|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
215071271|NCT00372372|DRUG|risedronate|
215071272|NCT03842969|DRUG|RO7234292 (RG6042)|Intrathecal injection
215071273|NCT00146419|BEHAVIORAL|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
215071274|NCT01081704|DRUG|ustekinumab|Single dose of 45 mg subcutaneous injection
215071275|NCT01081704|DRUG|ustekinumab|Single dose of 90 mg subcutaneous injection
215071276|NCT00464373|DRUG|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
215071277|NCT00464373|DRUG|Placebo|4ml NaCl 0.9%
215071278|NCT03130621|DIAGNOSTIC_TEST|Gene detection|Next-generation sequencing
215071279|NCT04860557|OTHER|cognitive skill, dual task and physical activity assessment|Montreal Cognitive Assessment Test, Trail Making Test (TMT) A \& B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
215071280|NCT05296824|PROCEDURE|Cryoballoon ablation for the treatment of atrial fibrillation|Cryoballoon ablation for the treatment of atrial fibrillation
215071281|NCT00258232|DRUG|capecitabine|
215071282|NCT00258232|DRUG|celecoxib|
215071283|NCT00258232|DRUG|irinotecan hydrochloride|
215071284|NCT01044745|DRUG|rituximab|Given IV
214329862|NCT01223716|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
214329863|NCT01223716|BEHAVIORAL|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
214329864|NCT01223716|BEHAVIORAL|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
214329865|NCT03265119|DRUG|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
214329866|NCT03265119|DRUG|Placebo|Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
214329867|NCT07017816|DRUG|SGT-53|SGT-53 is a novel cationic liposome encapsulating a normal human wild type TP53 cDNA sequence in a plasmid backbone. The liposome is decorated on its surface with an anti- transferrin receptor (TfR) single chain antibody fragment (scFv) that is designed to target cancer cells through the binding of the TfRscFv to the transferrin receptor. This complex has been shown to efficiently and specifically deliver the TP53 complementary DNA (cDNA) to the tumor cells via receptor-mediated endocytosis of the cationic liposomal complex. Introduction of the TP53 cDNA sequence restores wild-type p53 (wtp53) function in the apoptotic pathway.
214329868|NCT07017816|RADIATION|hypofractionated radiotherapy with immunotherapy|Re-irradiation has rapidly grown into a primary consideration in the context of recurrent pediatric CNS malignancies. While not thought to be curative by itself, it has often resulted in temporary symptomatic improvement as well as occasional radiographic regression or stabilization, although as with any irradiation, may also cause some adverse events.
214932045|NCT06618469|BEHAVIORAL|Elastic tubes-based resistance training program at moderate-high intensity (MHI-tubes)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic tubes equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase)
214329869|NCT07017816|DRUG|Nivolumab|Given the poor prognosis for children with recurrent CNS malignancies and the importance of p53 function in these tumors, we propose a pilot study of SGT-53 in combination with re-irradiation and checkpoint inhibition followed by maintenance therapy with SGT-53 in combination with nivolumab to evaluate the safety, feasibility and preliminary efficacy. SGT-53 will be added to a salvage regimen utilized in patients with recurrent tumors of re- irradiation and nivolumab followed by combination therapy with SGT-53 and nivolumab.
214329870|NCT06875752|DRUG|no luteal support|In one arm of the study the patients receive no luteal support as part of their modified natural cycle frozen embryo transfer.
214932046|NCT06618469|BEHAVIORAL|Water-based resistance training program at moderate intensity (WMI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance leg extension and flexion, hip flexion and extension, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform in the poll the concentric and eccentric movements of each exercise at maximal velocity during 40 seconds (equivalent to working around 10 repetitions /75% 1RM each exercise). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4.
214329871|NCT06875752|DRUG|Vaginal Progesterone|In the 2nd arm the patient receives 2x200 mg vaginal progesterone as luteal support.
214329872|NCT06875752|DRUG|Progesterone plus HCG|In the 3rd arm the patients receive 2x200 mg vaginal progesteroen plus 125 mcg recombinant HCG s.c. on the day of embryo transfer and 62.5 mcg recombinant HCG s.c. 4 days later.
214329873|NCT05393713|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody IMC-001|Given intra-lymphatically via DoseConnect device
214329874|NCT05393713|PROCEDURE|Punch Biopsy|Undergo punch biopsy
214329875|NCT07025252|DEVICE|VersaWrap|VersaWrap is applied to the affected tendon to allow post-operative gliding.
214329876|NCT07025668|OTHER|Eccentric Exercise|In the eccentric exercise group, in addition to strengthening exercises for the periscapular muscles and stretching exercises for the biceps brachii muscle, eccentric strengthening exercises for the biceps brachii muscle will be given. Participants will do the exercises in the groups they were randomized to every day for 12 weeks. They will be called to the clinic once a week for exercise checks.
214329877|NCT07025668|OTHER|Combined Exercise|In the combined exercise group, in addition to strengthening exercises for the periscapular muscles and stretching exercises for the biceps brachii muscle, progressive isometric, isotonic and plyometric strengthening training will be given to the biceps brachii muscle. Participants will do the exercises in the groups they were randomized to every day for 12 weeks. They will be called to the clinic once a week for exercise checks.
214329878|NCT07025668|OTHER|Control Group Exercise|In the control group, strengthening exercises for the periscapular muscles and stretching exercises for the biceps brachii muscle will be given. Strengthening exercises for the biceps brachii muscle will not be given in this group. Participants will do the exercises in the groups they were randomized to every day for 12 weeks. They will be called to the clinic once a week for exercise checks.
214329879|NCT07023562|PROCEDURE|ABC suction sequence|Suction sampling should be conducted in the sequence of dry-suction, slow-pull and wet-suction.
214329880|NCT07023562|PROCEDURE|ACB suction sequence|Suction sampling should be conducted in the sequence of dry-suction, wet-suction and slow-pull.
214932047|NCT00880230|DEVICE|Scuba Iliac Stent System|The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
214932048|NCT00514644|OTHER|Carotid ultrasound examination|Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.
215071285|NCT01044745|DRUG|mycophenolate mofetil|Given IV or PO
215071286|NCT01044745|DRUG|tacrolimus|Given IV
215071287|NCT01044745|DRUG|anti-thymocyte globulin|Given IV
215071288|NCT01044745|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
215071289|NCT01044745|OTHER|laboratory biomarker analysis|Correlative studies
214329881|NCT07023562|PROCEDURE|BAC suction sequence|Suction sampling should be conducted in the sequence of slow-pull, dry-suction and wet-suction.
214329882|NCT07023562|PROCEDURE|BCA suction sequence|Suction sampling should be conducted in the sequence of slow-pull, wet-suction and dry-suction.
214329883|NCT07023562|PROCEDURE|CAB suction sequence|Suction sampling should be conducted in the sequence of wet-suction, dry-suction and slow-pull.
215071290|NCT01044745|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
215071291|NCT01044745|DRUG|cyclophosphamide|Given PO or IV
215071292|NCT01044745|DRUG|fludarabine phosphate|Given IV
215071293|NCT01044745|DRUG|busulfan|Given IV
215071294|NCT01044745|RADIATION|total-body irradiation|Undergo TBI
215071295|NCT01044745|BIOLOGICAL|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
215071296|NCT01044745|BIOLOGICAL|immunosuppressive therapy|Undergo immunosuppressive therapy
214329884|NCT07023562|PROCEDURE|CBA suction sequence|Suction sampling should be conducted in the sequence of wet-suction, slow-pull and dry-suction.
214329885|NCT07024394|DRUG|Luvometinib Tablets|5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, until disease progression or study completion, whichever occurs first
214329886|NCT07023991|DRUG|Bupivacaine|Bupivacaine will be used in an ESP block to provide postoperative analgesia.
214932049|NCT00514644|OTHER|Panorama examination|"Examination with the odontological radiological method Panorama, including a frontal verification image"
214329887|NCT07023991|DRUG|Dexmedetomidine|Dexmedetomidine will be added to bupivacaine in the ESP block to evaluate its effect on duration of postoperative analgesia.
214932050|NCT03494062|BEHAVIORAL|Exercise|Home-based exercise training
215071297|NCT04236180|OTHER|Specialised Paediatric Palliative Care (SPPC)|All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
215071298|NCT03290417|DIETARY_SUPPLEMENT|Vitamin D|5000 IU/cap; One cap by mouth daily
215071299|NCT03290417|DIETARY_SUPPLEMENT|Omega-3|720 mg/cap; one capsule by mouth 3 times per day
214932051|NCT06356844|DIETARY_SUPPLEMENT|Resolvin supplement|Transforaminal steroid injection will be administered to patients who are being followed up due to inflammatory low back pain. Patients will receive resolvin supplements for 6 months postoperatively.
215071300|NCT03290417|DIETARY_SUPPLEMENT|Turmeric|250mg/cap; two capsules by mouth 4 times per day
215071301|NCT05210582|DRUG|Afamelanotide|Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.
215071302|NCT02519894|BEHAVIORAL|Dietary Scanning Calculator|
215071303|NCT02890303|DEVICE|Zepto System|Anterior Capsulotomy using the Zepto System.
215071304|NCT06486493|OTHER|Conventional treatment|Conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.
214329888|NCT07024680|OTHER|Observational, None intervention|Observational, None intervention
214329889|NCT07025655|BEHAVIORAL|Multifaceted Mindfulness Program|Ten-week mindfulness classes
214329890|NCT07025655|BEHAVIORAL|Placebo|Regular daily activity
214329891|NCT07024238|DIETARY_SUPPLEMENT|SCFA|Participants randomized to this group will receive 1000 mg of sodium butyrate daily for 12 weeks. The intervention aims to evaluate the effect of high-dose SCFA supplementation on the gut microbiome and systemic/urinary metabolome in kidney transplant recipients.
214329892|NCT07024238|DIETARY_SUPPLEMENT|Placebo|Participants in this group will receive placebo capsules (sacharosis) identical in appearance to the active SCFA capsules, administered twice daily for 12 weeks. This arm serves as a control to evaluate the specific effects of SCFA supplementation.
214932052|NCT00731562|DRUG|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
214932053|NCT00731562|DRUG|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
214932054|NCT05730244|DRUG|Cassia alata extract|1 ml Cassia alata extract
214932055|NCT05730244|DRUG|Placebo|1 ml placebo solution
214932056|NCT02002039|DRUG|Erythropoietin|500 units /kg /day every other day for 5 doses
214932057|NCT06018896|DRUG|Ascorbate|For patients with baseline serum Vitamin C concentration \< 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
214932058|NCT02630225|BEHAVIORAL|Critical Time Intervention|"The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:~Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.~Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.~Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers."
214932059|NCT02630225|OTHER|Treatment as Usual|"Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~1. All necessary medical care and scheduled follow-ups with subspecialty services~2. Evaluation by social work with referral to appropriate community services~3. Screening for alcohol use~4. Discharge planning services~5. Financial counseling"
214932060|NCT02630225|BEHAVIORAL|Motivational Interviewing|A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.
215071305|NCT06486493|OTHER|Playful Family Education Strategy|"Workshop based on national and international guidelines for managing overweight and obesity in school-aged children, by the Food and Agriculture Organization (FAO). Monthly sessions over six months for parents and children, followed by an 18-month post-intervention follow-up.~For parents:~* First session focuses on raising awareness about childhood obesity through counseling and nutritional advice, promoting water consumption over sugary drinks.~* Subsequent sessions use 'case study' technique to discuss common food and nutrition challenges.~For children:~* Sessions follow the 'Nutritional Guidance Intervention Guide' by the National System for Integral Family Development (DIF).~* First session encourages healthy eating habits through activities and educational games.~* Later sessions emphasize healthy eating patterns and physical activity."
214932061|NCT02630225|OTHER|Multi-Agency Attention|Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
214932062|NCT03641625|DEVICE|Muscular tissue oxygen saturation guided care|Muscular tissue oxygen saturation monitored at flank and arm will be maintained \> 70% (absolute measurement) and \> baseline throughout the entire procedure.
214932063|NCT02729038|DRUG|Gepotidacin|Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
214932064|NCT02458339|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
214932065|NCT02458339|DRUG|Methotrexate|4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
214932066|NCT00402558|DRUG|Thymoglobulin|1.5 mg/kg By Vein Daily x 3 Days
214932067|NCT00402558|DRUG|Busulfan|130 mg/m\^2 By Vein Over 3 Hours x 4 Days
214932068|NCT00402558|DRUG|Fludarabine|40 mg/m\^2 By Vein Over 30 Minutes x 4 Days
214932069|NCT00402558|PROCEDURE|Alloreactive NK Infusion|Alloreactive NK infusion from haploidentical donor on Day -8. The alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7.
214932070|NCT00402558|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 x 109/L for 3 consecutive days.
214932071|NCT00402558|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.
214932072|NCT00402558|DRUG|Methotrexate|5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
214932073|NCT00402558|DRUG|Interleukin-2|0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4 only to participants receiving fourth dose level of NK cells.
214932074|NCT06375746|OTHER|Personalized video|After enrollment and assignment to the intervention group, patients will receive a link to a personalized video describing the different induction methods by a text message.
214932075|NCT03683693|DIAGNOSTIC_TEST|Procalcitonin group|"The ICU physician gets on regular base (day 0, d4, d7, d11, d15, d19, d23, d27) a PCT value and the according non-binding recommendation:~PCT \< 0.5 microgram/L of 80% drop of the peak value : antibiotic stop recommended.~PCT \< 0.25 microgram/L: antibiotic stop strongly recommended. The recommendation is not-binding and can be overruled by the ICU physician. The intervention is only set up for stopping antibiotics, not for initiating. PCT measurements only happens in case of still ongoing antibiotic course. In case of a second course of antibiotics, after interruption of the initial course, new PCT measurement will take place at this point followed by the continuation of the initial schedule of PCT measurement.~Intervention ends 28 days after inclusion."
214932076|NCT00451893|PROCEDURE|Lichtenstein operation with a heavy-weight mesh|Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
214932077|NCT00451893|PROCEDURE|Lichtenstein operation with a light-weight mesh|Johnson\&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
214932078|NCT01687465|PROCEDURE|Argon laser trabeculoplasty|With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
214932079|NCT01687465|PROCEDURE|Selective laser trabeculoplasty|Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
214932080|NCT01220765|DEVICE|Capnography|In the capnography arm, respiratory monitoring is performed with pulse oximetry and capnography. If the capnogram indicates sub-optimal ventilation and/or apnea, denoted as a flat line on the capnometer for ≥ 15 seconds, a respiratory rate ≤ 6, or a end-tidal CO2 \> 50 mmHg, medical staff will intervene by arousing the patient, performing chinlift or jawthrust, abandon from giving additional propofol, or provision of oxygen. The nurse qualified in sedation management will assess capnography him/ herself.
214932081|NCT05489263|OTHER|No intervention|No intervention
214932082|NCT00851916|RADIATION|CyberKnife Radiosurgery|CyberKnife Radiosurgery
214932083|NCT03078296|OTHER|survey respondents|all survey participants will be asked to complete a questionnaire
214932084|NCT00395941|DRUG|Pioglitazone|
214932085|NCT00395941|DRUG|Acitretin|Acitretin
215071306|NCT06486493|OTHER|Reinforced Playful Family Education Strategy|The previosuly created and INDAUTOR registered workshop, will be reinforced through two-week technological algorithms, such as videogames, educational videos, and digital challenges, for the children, that they must complete through their smartphone of tablet. Followed by an 18-month post-intervention follow-up.
214932086|NCT04737824|PROCEDURE|"An adaptation of the balloon-blowing exercise"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
215071307|NCT04014881|BIOLOGICAL|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
214329893|NCT07023692|BEHAVIORAL|Distraction with VR (Virtual Reality) headsets|VR headsets will be fitted and applied in consultation with the study participants. Distraction material will be selected from a range of options based on the participant's preferences, such as watching/listening to a story, an experience of being in nature, or mindfulness. When applying the VR headsets, care will be taken to ensure no light leaks into the eyes and that the headband and headphones are not perceived as too tight. This is especially important in terms of the risk for motion sickness (cyber sickness). The VR headsets will then be used throughout the examination procedure and removed once the bandage has been applied.
214329894|NCT07024446|OTHER|The time interval between PCI and NCS|Using 6 weeks post-PCI as the demarcation point, patients within 6 weeks were assigned to the observation group, while those beyond 6 weeks formed the control group.
214329895|NCT07023926|DEVICE|electroacupuncture|The supine position, the local skin of the acupoints was routinely sterilized, and the selected acupoints were pasted with Acupuncture auxiliary device. The main acupuncture points are DU20, bilateral EX-HN5, ST8, GB20, GB20, LI4, LR3, ST40. Select compatible acupoints based on the patient's accompanying symptoms: 1.Discomfort in the neck: EX-B2 of Cervical 3-4; 2.Emotional anxiety, depression or sleep disorders: GV29, HT7; 3.Stomach or abdominal discomfort: CV12, ST25 and CV6. The disposable acupuncture needles and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China.The specifications of acupuncture needles are Φ0.30×25mm, Φ0.30×40mm. The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
214486262|NCT06736639|PROCEDURE|Anchor Suture with Titanium Cable Cerclage|This intervention involves the use of \*\*anchor suture fixation combined with titanium cable cerclage\*\* for the treatment of inferior pole patellar fractures (IPPF). The anchor suture provides stable fixation of fracture fragments by anchoring directly into the bone, while the titanium cable cerclage offers additional reinforcement around the patella to enhance stability and minimize fragment displacement. This method is specifically designed to address the limitations of traditional Kirschner-wire tension band techniques, such as hardware irritation and infection, by using biocompatible and low-profile materials.
214486263|NCT06736639|PROCEDURE|Kirschner wire tension band + cerclage cable|This intervention uses \*\*Kirschner wire tension band combined with cerclage cable\*\* to treat inferior pole patellar fractures (IPPF). The Kirschner wires are positioned across the fracture site to form a tension band, which transforms tensile forces into compressive forces, promoting fracture stability. The cerclage cable is added to reinforce the fixation by encircling the patella, providing additional stability to comminuted or complex fractures.
214486264|NCT06738186|OTHER|Video-based exercise program|"The video-based exercise program - Bliib fit -mach mit! focuses on mobilization, muscle strengthening (focus on lower and upper extremities), coordination, balance, and relaxation. Each participant requires the use of a chair for support and to perform exercises in a seated position, if required. The group sessions are supervised by a care professional or registered activation specialist of the residential care facility."
215071308|NCT03789435|DIAGNOSTIC_TEST|Questionnaire|"A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)"
215071309|NCT04164017|DEVICE|EUS-guided FNB with Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
215071310|NCT04164017|DEVICE|EUS-guided FNB without Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
215071311|NCT00052611|DRUG|Celecoxib|
215071312|NCT01461928|DRUG|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
215071313|NCT01461928|DRUG|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
215071314|NCT04086693|DEVICE|Standard IV dressing|Polyurethane and clear tape dressing used to secure peripheral IV
215071315|NCT04086693|DEVICE|Standard IV dressing plus a tissue adhesive peripheral IV securement device|Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
215071316|NCT01159171|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
215071317|NCT01159171|DRUG|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
215071318|NCT01159171|DRUG|oxaliplatin|40 mg/m2 iv weekly
215071319|NCT05124652|DEVICE|Auto Adjusting Prosthesis|Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
215071320|NCT01892436|DRUG|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
215071321|NCT01892436|DRUG|Placebo|Placebo
215071322|NCT03263858|DEVICE|Stent|Implantation of coronary stent in de novo coronary artery lesions
215071323|NCT04112797|BIOLOGICAL|Allergovac himenoptera|Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula
215071324|NCT06488170|DRUG|Tildrakizumab|As provided in real world clinical practice.
214932087|NCT04737824|PROCEDURE|"An adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
214329896|NCT07023926|DEVICE|Sham electroacupuncture|"The SEA group will use Hua Tuo brand disposable blunt-tip sham needles (Φ0.3mm×25mm) and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China. Sham points 1-2, 3-4, 5-6, and 7-8 are bilaterally located at the midpoints between the following pairs of acupoints: SP19 and EX-UE12, SP6 and LR5, EX-UE1 and HT1, and HT7 and SI8. sham LI4: Bilateral of midpoint between acupoint LI4 and LU9; sham LR3: Bilateral of midpoint between acupoint LR3 and ST44; sham ST40: Bilateral of midpoint between acupoint ST40 and GB35. Compatible acupoints: EX-B2 of Cervical 3-4 horizontal side by 0.5 cun; sham GV29: midpoint between acupoint GV29 and BL2. sham CV12: midpoint between acupoint CV12 and ST21; sham ST25: Bilateral of midpoint between acupoint ST25 and SP15; sham CV6: 3 cun lateral to the level of the CV6; The width of the interphalangeal joint of the patient's thumb was 1 cun."
214932088|NCT06112158|BEHAVIORAL|Education Intervention|"The BSE training program for the early diagnosis of breast cancer will be offered to students in two ways: face-to-face and via web support.~Content of training Session 1: Topics such as the structure of the breast, the definition of breast cancer, its prevalence, risk factors and symptoms Session 2: Teaching the importance of early diagnosis in breast cancer, the importance and benefits of BSE, the technique of performing BSE, the obstacles to the application of BSE.~Session 3: Teaching the risk factors that cause breast cancer. Session 4: Discussion of case reports of patients diagnosed with breast cancer. Supporting education with web support"
214932089|NCT06014619|PROCEDURE|Mohs surgery|Treatment of a skin disease by Mohs micrographic surgery technique (frozen sections).
215071325|NCT02021617|DEVICE|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver-a small battery-powered drill-and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
215071326|NCT06046612|DRUG|Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment|The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
214932090|NCT06014619|PROCEDURE|Slow Mohs surgery|Treatment of a skin disease by Slow Mohs technique (formalin fixation and paraffin-embedded sections).
214932091|NCT01915667|DRUG|200 mg GLPG0634 as capsules, fasted|single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
214932092|NCT01915667|DRUG|200 mg GLPG0634 as tablets, fasted|single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
214932093|NCT01915667|DRUG|200 mg GLPG0634 as tablets, fed|single oral dose of 200 mg GLPG0634 given as tablets in fed condition
214932094|NCT01921192|DRUG|Folic Acid, vit B6 and B12|
214932095|NCT01921192|DRUG|Placebo|
214932096|NCT03562286|PROCEDURE|Fetoscopy|Performing a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair of the fetal neural tube defect.
215071327|NCT03549676|BIOLOGICAL|Fecal Microbiota Transplantation|For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
215071328|NCT00461149|DRUG|Octreotide-LAR|
215071329|NCT01965769|OTHER|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
215071330|NCT00583414|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
215071331|NCT00886886|DRUG|MDMA|125 mg, single dose
215071332|NCT00886886|DRUG|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
215071333|NCT00886886|DRUG|Placebo|capsules identical to MDMA or Reboxetine
214329897|NCT03238911|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
215071334|NCT00643786|DRUG|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
214932097|NCT06667102|BEHAVIORAL|Strategic and Interactive Signing Instruction|SISI centers on deaf children producing sign language compositions to communicate their messages with identified audiences, and teachers utilizing strategic and interactive approaches to bring attention to target sign language skills by consciously monitoring and manipulating language to create desired meanings grounded in socially shared understandings.
214932098|NCT05367284|DRUG|Testosterone|Testogel 16.2 miligrams/ gram (mg/g) gel
214932099|NCT02989779|DRUG|NK1 Antagonist|
214932100|NCT02989779|DRUG|Placebo Oral Capsule|
214932101|NCT00642096|DRUG|Metoprolol Succinate|
214932102|NCT00642096|DRUG|Hydrochlorothiazide|
214932103|NCT01129349|DRUG|Oprozomib|Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
214932104|NCT06194747|OTHER|Quality improvement bundle|(1) standardizing BZD default to intranasal or buccal midazolam; (2) targeting initial BZD treatment within 10 minutes of seizure onset; (3) relocating and bundling all administration items needed to the hospital unit medication room; (4) utilizing basic seizure first aid in the initial patient assessment; (5) developing and implementing SE-specific EHR documentation; (6) multidisciplinary QI teams
214932105|NCT06194747|OTHER|Quality improvement bundle and local PDSA cycles with central support|Sites will implement both the standard QI bundle as well as site-specific PDSA cycles with central data and methods support.
214932106|NCT06194747|OTHER|Quality improvement bundle and local PDSA cycles without central support|Sites will implement both the standard QI bundle as well as site-specific PDSA cycles without central data or methods support.
214932107|NCT06440356|OTHER|laser therapy|low level laser therapy applied
214932108|NCT06621888|DRUG|NTI164|This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164), specifically formulated to treat pediatric acute-onset neuropsychiatric syndrome (PANS). The dosing regimen is carefully structured to increase from an initial 5 mg/kg per day up to a maximum of 20 mg/kg, tailored to individual tolerance levels. This gradual titration and the option to extend treatment up to 54 weeks distinguishes it from other interventions that may use different concentrations of THC or shorter treatment durations. The efficacy of NTI164 is rigorously assessed through psychological evaluations and biomarker analyses.
214932109|NCT02822573|DRUG|Donepezil 5 mg|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
214932110|NCT02822573|DRUG|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
215071335|NCT00643786|DRUG|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
215071336|NCT04110951|BEHAVIORAL|Pranayama Breathing Technique|Yogic Breathing Technique
215071337|NCT04110951|BEHAVIORAL|Relaxation technique|Progressive relaxation technique
215071338|NCT00733291|DEVICE|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
215071339|NCT00733291|DEVICE|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
215071340|NCT00733291|DEVICE|FID 107027 solution|Commercially marketed solution for contact lens disinfection
215071341|NCT01018134|DRUG|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
215071342|NCT01018134|DRUG|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
215071343|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
215071344|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
215071345|NCT01018134|DRUG|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
215071346|NCT01018134|DRUG|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
215071347|NCT00063895|DRUG|erlotinib hydrochloride|Given PO
215071348|NCT00063895|OTHER|pharmacological study|Correlative studies
214329898|NCT03238911|DRUG|Ferric carboxymaltose|"Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial.~Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg)."
214329899|NCT03655236|DRUG|K0706|low dose, orally, once-daily
214329900|NCT03655236|DRUG|K0706|high dose, orally, once-daily
214329901|NCT03655236|OTHER|placebo|placebo, orally, once-daily
214329902|NCT07024407|DRUG|Andecaliximab|Participants will receive weekly subcutaneous injections of andecaliximab during inpatient hospitalization, clinic visit, or self-administration if discharged from the hospital
214329903|NCT06708897|DRUG|ZE 50-0134|oral capsules QD
214329904|NCT07038902|DEVICE|Group A: Modified Miniscrew-Assisted Rapid Palatal Expander (MARPE)|A skeletal anchorage-supported with miniscrews inserted into the palate using a self-drilling technique.
214932111|NCT05465265|BEHAVIORAL|Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)|Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
214932112|NCT04735692|OTHER|Full mouth or quadrant SRP|Full mouth or quadrant SRP
214932113|NCT06470035|DEVICE|Active VeNS Device|Battery powered non-invasive neurostimulation device
214932114|NCT06470035|DEVICE|Sham VeNS Device|Placebo comparator sham device (no active stimulation)
214932115|NCT01354392|DRUG|AZD1152|Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
215071349|NCT00063895|OTHER|pharmacogenomic studies|Correlative studies
215071350|NCT00063895|OTHER|laboratory biomarker analysis|Correlative studies
215071351|NCT01461265|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
215071352|NCT01064102|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
214329905|NCT07038902|DEVICE|Group B: Modified Rapid Palatal Expander (RPE)|A tooth-borne anchorage focusing on molar distalization .
214329906|NCT06887608|OTHER|Husband assisted rebozo application|At 4-5 cm, 6-7 cm and 8-9 cm, the pregnant woman will be given a rebozo by her husband.
214329907|NCT06887608|OTHER|Midwife assisted rebozo application|The midwife will apply rebozo to the pregnant woman at 4-5 cm, 6-7 cm and 8-9 cm.
214329908|NCT07065851|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|Non-invasive therapy delivering high-energy shock waves to stimulate healing in musculoskeletal tissues, targeting the hamstring muscles and related structures, administered 2 times per week for 4 weeks, alongside core exercises.
214329909|NCT07065851|BEHAVIORAL|Exercise Program|Structured exercises focusing on hamstring flexibility, lumbar stabilization, and core exercises, administered 3 times per week for 3 weeks, with sessions lasting 30-45 minutes.
214932116|NCT02853669|PROCEDURE|Ultrasound-guided Lumber Plexus Block|(30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
214932117|NCT02853669|PROCEDURE|adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
215071353|NCT06209138|DRUG|5 fluorouracil|5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
215071354|NCT06209138|OTHER|Saline|Normal saline solution contains 0.9 percent sodium chloride (salt)
215071355|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
215071356|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
215071357|NCT03438955|DRUG|Omacor|Omacor soft capsule 4000mg for 16days
214329910|NCT03865472|OTHER|Questionnaire Administration|Ancillary studies
214329911|NCT03865472|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
214329912|NCT03865472|PROCEDURE|Sham Intervention|Undergo sham rTMS
214329913|NCT06596252|DRUG|Budesonide|Twice daily intake of the tablet 30 min after a meal
214329914|NCT06858774|BEHAVIORAL|Circadian Reset Technology|Circadian reset technology is a software used on a VR headset in this intervention. The software is a passive viewing experience like a guided meditation that presents visual images.
214329915|NCT06858774|BEHAVIORAL|VR Headset|The software used on a VR headset in this intervention is a passive viewing experience like a guided meditation that presents neutral images that mimics the sequence used in the CRT software.
214329916|NCT07076264|OTHER|AquOTic|AquOTic is an evidence-based, occupational therapy-led intervention designed to enhance water competency and swim safety skills in children on the autism spectrum. The 10-week program consists of weekly 60-minute group sessions, each including six children paired in a 1:1 ratio with an interventionist. Sessions follow a structured routine involving six rotating stations, targeting various swim and safety skills, with the flexibility for individualized support by the interventionist.
214329917|NCT07085182|DRUG|SBRT combined with Tislelizumab followed by Tislelizumab|SBRT:3-10Gy/F, once daily, 5 times a week; Tislelizumab(200mg,iv,q3w):Tislelizumab was added after five sessions of SBRT radiotherapy.
214329918|NCT07087067|DRUG|Aspirin 75 mg|patients received aspirin 75 mg daily prior to 12 weeks gestation
215071358|NCT03438955|DRUG|Pritor|Pritor tablet 40mg for 7days
215071359|NCT03438955|DRUG|Omacor + Pritor|Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
215071360|NCT03438955|DRUG|Pritor + Omacor|Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
215071361|NCT02977936|DIETARY_SUPPLEMENT|Cartimotil Fort|1 to 4 capsules per day during 90 days
215071362|NCT05292911|DRUG|ALT-801|Injected subcutaneously (SC)
215071363|NCT05292911|OTHER|Placebo|Injected subcutaneously (SC)
214329919|NCT07085039|DRUG|Ruxolitinib|Participants will take the study drug in a tablet form, by mouth, every day for the next year, as long as it is helping with their disease and not causing unacceptable side effects.
214329920|NCT07086963|PROCEDURE|Repaired with standard TIP repair as described by Snodgrass|"Urethroplasty was performed over a 6-8 Fr Nelaton catheter (according to patient age and glans size) using 7/0 subcuticular continuous suture. Adequate meatus was left around the urethral catheter at the glans tip, followed by spongioplasty and a second-layer dartos fascia coverage.~Mucosal collar approximation and skin closure Glanular closure was then initiated with deep but superficial stitches using 7/0 or 6/0 polyglactin suture, and mucosal suture closure. Skin closure was achieved by preparing viable skin while avoiding midline skin closure by preparing a vascularized preputial skin flap to avoid skin coverage complications with subsequent UCF"
214329921|NCT07086963|PROCEDURE|Repaired with TIP with GIP using preputial graft|"The urethral plate was deeply incised from the glans tip, extending downwards beyond the junction between the plate and the hypospadiac meatus Graft fixation The graft was then spread to cover the raw area and fixed to the edges of the urethral plate.~Urethroplasty was performed over a 6-8 Fr Nelaton catheter (according to patient age and glans size) using 7/0 subcuticular continuous suture. Adequate meatus was left around the urethral catheter at the glans tip, followed by spongioplasty and a second-layer dartos fascia coverage.~Mucosal collar approximation and skin closure Glanular closure was then initiated with deep but superficial stitches using 7/0 or 6/0 polyglactin suture, and mucosal suture closure. Skin closure was achieved by preparing viable skin while avoiding midline skin closure by preparing a vascularized preputial skin flap to avoid skin coverage complications with subsequent UCF"
214673465|NCT03515538|RADIATION|Radiation Therapy|Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
214932118|NCT04738617|BEHAVIORAL|Inter and intra-individual variation in acute responses to two different warm-up types|Comparison of the acute effects of two different warm-up protocols on subsequent performance.
215071364|NCT03047356|BEHAVIORAL|"If-then plans"|"If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)"
215071365|NCT03047356|OTHER|Control|Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
215071366|NCT02222909|OTHER|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
215071367|NCT01981863|DRUG|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
215071368|NCT01981863|DRUG|Placebo|Placebo administered in same volume as in experimental arm.
215071369|NCT02242435|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
215071370|NCT02242435|DRUG|4 mL Injection of Placebo|
215071371|NCT03366558|DIAGNOSTIC_TEST|UPDRS questionnaires|UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
215071372|NCT03366558|DIAGNOSTIC_TEST|20-step walking test|20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
215071373|NCT00814697|DEVICE|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
215071374|NCT06236542|DEVICE|NextGen automated tracheostomy suctioning device|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctionings using an automated robotic suctioning device.
215071375|NCT06236542|DEVICE|NextGen mixed-reality tracheostomy tube change system|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy tube changes using the mixed reality tracheostomy tube change system.
215071376|NCT06236542|DEVICE|NextGen Tracheostomy Toolkit|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctioning using the robotic suctioning device; and tracheostomy tube changes using the mixed reality tracheostomy tube change system.
215071377|NCT03895086|OTHER|Specific Physical Activity|An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)
215071378|NCT03895086|BEHAVIORAL|Classic Physical Activity|"One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association"
215071379|NCT05617924|PROCEDURE|Physical Therapy|Therapy methods using physical agents in treatment
215071380|NCT05484531|DEVICE|CLEAR|Reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude
215071381|NCT01766492|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
215071382|NCT00002938|PROCEDURE|conventional surgery|Salvage prostatectomy
214932119|NCT06522555|DRUG|polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide|"Drug: Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab (Pola-ZR2)~Induction therapy:~The Pola-ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle; Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years."
214329922|NCT07086300|OTHER|Electroacupuncture (EA)|"In the electroacupuncture group, bilateral Zusanli (ST36) and Sanyinjiao (SP6) points were selected for needling. Upon achieving the deqi sensation, the electroacupuncture device was connected to the needles at both points. A dispersed-dense wave was applied with an intensity ranging from 0.5 to 2 mA, adjusted according to the patient's tolerance. The needles were retained for 20 minutes, after which they were removed."
214329923|NCT07086300|OTHER|Sham electroacupuncture|"In the sham electroacupuncture group, bilateral Zusanli (ST36) and Sanyinjiao (SP6) points were selected for sham electroacupuncture intervention, which did not receive manual manipulation. The electrode placement and other treatment settings were identical to those in the electroacupuncture group, but no skin penetration, electrical output, or needle techniques were applied to induce the sensation of deqi. No genuine electroacupuncture stimulation was administered in this group."
215071383|NCT04875507|BEHAVIORAL|Positive Psychology|This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
214329924|NCT07087288|OTHER|AI-supported case|In the artificial intelligence supported case analysis course, students will listen to the audio video prepared by artificial intelligence.
214932120|NCT06522555|DRUG|zanubrutinib, rituximab and lenalidomide|"Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)~Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years."
214932121|NCT05901012|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
214329925|NCT07087288|OTHER|Case Analysis|The case analysis will be made through the presentation prepared by the students in the group.
214932122|NCT05901012|DRUG|Placebo|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
215071384|NCT00117715|PROCEDURE|Genotyping and Phenotyping using dextromethorphan and caffeine as probes|Single doses of dextromethorphan (0.3 mg/kg)and caffeine (3.0 mg/kg) are administered and urine is collected overnight for measurement of drug and metabolites to determine drug biotransformation activity.
215071385|NCT05258214|OTHER|Mulligan Bent Leg Raise|Mulligan's bent leg raise, as well as the extreme Straight Leg Raise, can be used to relieve Low Back Pain. It can be used to treat leg discomfort that is above the knee. Bent Leg Raise methods are used where there is a restricted range of motion in the hip flexion joint, as well as low back pressure with or without referred leg pain.
215071386|NCT05258214|OTHER|Mulligan Traction Straight Leg Raise|Mulligan traction leg raise exercises are a non-invasive treatment that has been shown to help people with low back pain and reduced hip flexion range. Conservative sciatica therapy focuses on pain relief, but increasing Straight Leg Raise range will help restore normal mobility and reduce the severity of low back disability.
215071387|NCT05258214|OTHER|Neural Mobilization|These techniques are designed to mobilize a nerve with as little pressure down, resulting in a larger longitudinal excursion than techniques that actually lengthen the nerve bed, such as tensioning procedures.
215071388|NCT00952445|DRUG|T0903131 Besylate|Once daily, oral
215071389|NCT00952445|DRUG|Placebo|Once daily, oral
215071390|NCT05037448|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
215071391|NCT02104596|DEVICE|Xylitol|
215071392|NCT06485973|OTHER|Modified Dental Anxiety Scale (MDAS)|The MDAS is described as a scale to provide a more comprehensive assessment of dental anxiety. The MDAS has shown favorable psychometric properties with acceptable reliability and validity.
215071393|NCT01971749|PROCEDURE|Coronary stent procedure (CSP)|
215071394|NCT01971749|PROCEDURE|Coronary-artery bypass grafting (CABG)|
215071395|NCT04271371|OTHER|Not yet developed|A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.
215071396|NCT03218072|DRUG|HLX01|a potential rituximab biosimilar
215071397|NCT05563883|OTHER|event occurence|occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...
215071398|NCT02703012|OTHER|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
215071399|NCT01089413|DRUG|bevacizumab [Avastin]|As prescribed by physician
215071400|NCT01905345|PROCEDURE|Training|
214329926|NCT07086378|DEVICE|Oxygenating Bite Block|Oxygenating Bite Block will be used instead of the standard bite block.
214329927|NCT07086456|DRUG|Surufatinib|Administered orally at 200 mg once daily d1-d14, starting at the initiation of each radiotherapy phase, for 14 consecutive days. Six weeks after completion of concurrent chemoradiotherapy, patients meeting the eligibility criteria will receive consolidation therapy with surufatinib 200 mg orally once daily on Days 1-14 of each 21-day cycle
214329928|NCT07086456|DRUG|Tislelizumab|200 mg administered via intravenous drip one day prior to the start of each radiotherapy phase. Six weeks after completion of concurrent chemoradiotherapy, patients meeting the eligibility criteria will receive consolidation therapy with tislelizumab 200 mg administered via intravenous drip on Day 1 of each cycle (Q3W), for up to 12 months.
214329929|NCT07086456|DRUG|Concurrent Chemotherapy|Albumin-bound paclitaxel 50 mg/m² plus cisplatin 25 mg/m², administered weekly (QW).
214486265|NCT06738186|OTHER|Caregiver-led activation program|The caregiver-led activation program (DESKK- Demenzspezifisches Kurzzeitpflegekonzept) is instructed and carried out by care professionals (e.g., nursing staff) as optimized standard care conducted individually or in groups.
214932123|NCT04998279|DRUG|Granulocyte Colony-Stimulating Factor|Granulocyte-colony stimulating factors (G-CSF) is synthesized in the reproductive tract naturally, it is a hematopoietic lineage-specific cytokine which is known for its specific effects on the activation of intracellular signaling pathways that are associated with the cell proliferation, differentiation, and stimulation of hematopoietic cells of the neutrophilic granulocyte lineage; which act on macrophages of decidual cells and finally affect implantation
214329930|NCT07086456|RADIATION|Radiotherapy|definitive hypofractionated radiotherapy
214329931|NCT02128841|DRUG|Rivaroxaban|Direct Factor Xa Inhibitor
214329932|NCT05698095|DRUG|5-methoxy-N,N-dimethyltryptamine succinate salt|The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
214329933|NCT05698095|DRUG|Placebo|The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
214329934|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme|"A 12 week programme of exercise and education~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist only)"
214486266|NCT06736886|OTHER|Light application|Light application
214673466|NCT04075604|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
214932124|NCT04998279|OTHER|placebo|mock test without injection of G-CSF
214932125|NCT04403503|DRUG|Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group)
215071401|NCT03811847|DRUG|Methylphenidate Extended Release Oral Capsule|"Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg"
215071402|NCT03811847|OTHER|Placebo|Placebo comparator MPH Matched Placebo Tablet
215071403|NCT00269269|DRUG|antihypertensive drug|
215071404|NCT00269269|BEHAVIORAL|placebo|
215071405|NCT00062023|DRUG|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
215071406|NCT00062023|DRUG|Sulindac|Patients receive oral sulindac twice daily for 12 months.
215071407|NCT00062023|DRUG|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
215071408|NCT00062023|OTHER|Sulindac Placebo|Oral sulindac placebo twice daily.
215071409|NCT00795548|DRUG|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
214673467|NCT04075604|DRUG|Anastrozole|Specified Dose on Specified Days
214673468|NCT04075604|DRUG|Palbociclib|Specified Dose on Specified Days
214329935|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme and Behavioural Change|"A 12-week programme of exercise, education and behavioural change techniques to support exercise adherence and exercise self-efficacy~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist and participant)~Additional techniques addressing behavioural regulation include firstly, an exercise diary completed independently at home, secondly, the rationale and the intended functional benefit and expectations of the exercise programme clearly explained, thirdly individual weekly conversations to reflect on progress, expectations, solutions to barriers, and goals. Finally, peer support is strongly encouraged through the in-class support, and a social media networking group."
214329936|NCT03985553|BEHAVIORAL|Parenting Self-Management Program|
214329937|NCT05212259|DRUG|Collagen type II (40 mg/day)|4 capsules per day
214329938|NCT05212259|DRUG|Collagen type II (80mg/day)|4 capsules per day
214932126|NCT04403503|DRUG|Cyanoacrylate, Isobutyl|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group).
214932127|NCT01178879|BEHAVIORAL|Telehealth consultation|"The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.~The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line."
214932128|NCT04749654|OTHER|The Salivary pH measured|The saliva samples were obtained at 10-12 a.m. from all children. The saliva was collected into plastic cylinders and the salivary pH was measured with a pH meter (Compact pH meter B-212 twin pH, HORIBA, Osaka, Japan).
214932129|NCT04749654|OTHER|The saliva flow rate was measured|The saliva flow rate was estimated by during the first 30 s of paraffin chewing. The saliva was collected into plastic cylinders for a period of 5 minutes. Afterward, the saliva were weighed with a in a precision balance (Mettler PC 400, Zurich, Switzerland) and the flow rate was computed in gms/ml.
214932130|NCT04749654|OTHER|Streptococcus mutans and Lactobacillus counts in saliva were measured|The saliva samples were obtained according to described above. Numbers of colony-forming units (CFU) of S. mutans were counted on TSY20B agar and Lactobacilli were counted on Rogosa agar.
214932131|NCT01054300|DRUG|Ertugliflozin 2 mg single dose|Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose
215071410|NCT00803257|OTHER|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
214329939|NCT05212259|DRUG|Collagen type II (120 mg/day)|4 capsules per day
214329940|NCT05212259|DRUG|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day
214932132|NCT01054300|DRUG|Ertugliflozin 2 mg split into twice daily|Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
214932133|NCT01054300|DRUG|Ertugliflozin 4 mg single dose|Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose
214932134|NCT01054300|DRUG|Ertugliflozin 4 mg split into twice daily|Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day
215071411|NCT03735199|DEVICE|PCL-TCP scaffold|During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
214329941|NCT05212259|DRUG|Placebo|4 capsules per day
214329942|NCT00084695|BIOLOGICAL|anti-thymocyte globulin|Given IV
214329943|NCT00084695|DRUG|busulfan|Given orally
214329944|NCT00084695|DRUG|cyclophosphamide|Given IV
214329945|NCT00084695|DRUG|fludarabine phosphate|Given IV
214932135|NCT01054300|DRUG|Placebo|Placebo to ertugliflozin administered as a single dose
214932136|NCT00962975|DRUG|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
214932137|NCT00308087|DRUG|Sargramostim (Leukine)|Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
215071412|NCT03735199|DEVICE|Geistlich Bio-Gide collagen membrane|A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
215071413|NCT01472783|DRUG|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
215071414|NCT00182780|DIETARY_SUPPLEMENT|American ginseng|
215071415|NCT00182780|OTHER|Placebo|
215071416|NCT03626636|DRUG|Risuteganib|Subjects injected intravitreally with 1.0mg of Luminate®
214329946|NCT00084695|DRUG|melphalan|Given IV
214329947|NCT00084695|DRUG|methylprednisolone|Given IV
214329948|NCT00084695|RADIATION|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
214329949|NCT02263638|DRUG|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
214329950|NCT04857866|DRUG|XmAb27564|Single ascending dose of XmAb27564
214329951|NCT04857866|DRUG|Placebo|Single dose of placebo
214329952|NCT05937035|PROCEDURE|Customized allogenic bone block surgery|After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
214329953|NCT05857657|OTHER|: lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes for one session
214329954|NCT05857657|OTHER|propriocepticve neuromuscular facilitation|:Proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
214329955|NCT05857657|OTHER|propriocepticve neuromuscular facilitation with lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes with proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
214329956|NCT01272167|BEHAVIORAL|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
214329957|NCT03609294|DRUG|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
214486267|NCT06736925|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids (EPA plus DHA)|DHA+EPA capsules contain purified deep-sea fish oil, made from 100% wild-caught sardines and anchovies with a 3-year shelf life. The capsule shell is made from bovine limed bone with a size of 20 oblongs. Each soft gel capsule contains 480 mg of DHA, 205 mg of EPA, 145 mg of other omega-3 FA, and 10 mg of vitamin E. Participants in the DHA+EPA group will ingest 5 capsules daily \[a total of 3.4 g/d: DHA (2.4 g), EPA (1.0 g)\].
214486268|NCT06736925|DIETARY_SUPPLEMENT|Organic soybean oil|We will use organic soybean oil pills ) as a placebo condition for the DHA+EPA group. One capsule contains 485 mg of organic soybean oil, including negligible amounts of DHA (1.1 mg), EPA (1.7 mg), and vitamin E (10 mg). Participants will ingest 5 capsules daily. Soybean oil is one of the most widely used vegetable oils in the world. Soybean oil contains polyunsaturated fats and 18-carbon omega-3 FA (total omega-3 FA of 73.9 mg per capsule), but very low levels of DHA and EPA, which makes it an excellent placebo counterpart when evaluating the effects of DHA/EPA. The placebo capsule's shelf life, composition, shape, size as the DHA+EPA active comparator.
214673469|NCT05418608|DRUG|Radiotracer|A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans.
214932138|NCT00308087|DRUG|Rituximab|Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
214673470|NCT01954628|DRUG|AQX-1125|Synthetic SHIP1 activator
214329958|NCT03609294|DRUG|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
214329959|NCT05107986|PROCEDURE|laparoscopic repair|All patients of cohort underwent laparoscopic repair.
214329960|NCT00991302|BEHAVIORAL|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
214329961|NCT05190458|OTHER|High Velocity Nasal Insufflation|High velocity nasal insufflation (HVNI), a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than HFNC which uses large bore cannula, has the ability to accomplish complete purge of extra thoracic dead space at flow rates of 35 litres/min and may be able to provide ventilatory support in patients with respiratory failure in addition to oxygenation support in patients with overlap syndrome.
214329962|NCT05190458|OTHER|Non-invasive mechanical ventilation|Noninvasive ventilation (NIV) refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube).
214673471|NCT01954628|DRUG|Placebo|Placebo control
214673472|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-II|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
214932139|NCT01000532|DEVICE|SIELLO JT/T|Implantation of SIELLO and BPPU pacemaker leads
214932140|NCT01000532|DEVICE|Pacemaker therapy|Pacemaker therapy
214932141|NCT01000532|DEVICE|BPPU JT/T|Implantation of SIELLO and BPPU pacemaker leads
214932142|NCT02977611|DRUG|Iron sucrose|Iron sucrose will be infused at dose of 500 mg over a one hour period
214329963|NCT05299541|DIETARY_SUPPLEMENT|Food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
214329964|NCT05299541|DIAGNOSTIC_TEST|Indirect calorimetric|• The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
214329965|NCT05299541|DIAGNOSTIC_TEST|Bioimpedance|• The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
214329966|NCT05299541|BEHAVIORAL|Questioners|"At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM"
215071417|NCT03626636|OTHER|Sham|Sham injection
215071418|NCT02120170|PROCEDURE|Colon polypectomy|
215071419|NCT04268875|DEVICE|Optical Coherence Tomography (OCT)|"The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same."
215071420|NCT01587261|DRUG|Vitamin C|Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
215071421|NCT01587261|DRUG|Placebo|Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
215071422|NCT02715882|DRUG|CBLB502|
215071423|NCT02715882|DRUG|Placebo|
215071424|NCT02034175|DEVICE|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
215071425|NCT02034175|DEVICE|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
215071426|NCT00693823|PROCEDURE|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
215071427|NCT00693823|DEVICE|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
215071428|NCT04918953|DRUG|methylprednisolone|The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
215071429|NCT04918953|DRUG|budesonide atomization suspension|(3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
215071430|NCT04963140|OTHER|Optimized self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device
215071431|NCT04963140|OTHER|Conventional self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms
215071432|NCT04588012|BEHAVIORAL|The online self-help Program OurRelationship developed by prof. Brian Doss and prof. Andrew Christensen.|The OurRelationship program is developed by prof. Brian Doss and prof. Andrew Christensen.
215071433|NCT04588012|BEHAVIORAL|"The off line self-help course Pas på Parforholdet."|"The book Pas på parforholdet is written by Mattias Stølen Due."
215071434|NCT01746121|GENETIC|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
214932143|NCT00135798|DRUG|LADR Treatment|"PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was \<0.5 ug/kg, PEGIFN was permanently discontinued."
214932144|NCT01321138|PROCEDURE|Femoral nerve block|The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
214932145|NCT01321138|PROCEDURE|PCA morphine|Postoperative analgesia with self-administration iv morphine
214932146|NCT06365008|DRUG|Sintilimab+irinotecan+leucovorin folinate+fluorouracil|sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.
214932147|NCT04212208|DEVICE|IV cannulation|IV cannulation in the preoperative period
215071435|NCT03905031|DEVICE|InfraScanner 2000|The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD\>0.2 is abnormal and suggestive of intracranial hematoma.
215071436|NCT01971463|OTHER|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
215071437|NCT00301600|DRUG|Mycophenolate mofetil|MMF,1.0g/d
215071438|NCT04879394|OTHER|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
215071439|NCT02581956|BEHAVIORAL|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
215071440|NCT02581956|BEHAVIORAL|No walking exercise|no exercise
214329967|NCT05299541|DIETARY_SUPPLEMENT|Plated food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
214329968|NCT02553681|DEVICE|roflufocon D contact lenses|HPT treated rigid contact lenses
214329969|NCT02553681|DEVICE|RGP contact lenses made from roflufocon D|
214932148|NCT00387751|BIOLOGICAL|Bevacizumab|Given IV
214932149|NCT00387751|OTHER|Laboratory Biomarker Analysis|Correlative studies
214932150|NCT00387751|OTHER|Pharmacological Study|Correlative studies
214932151|NCT00387751|DRUG|Sorafenib Tosylate|Given orally
214932152|NCT04303533|DEVICE|Neuro-Feedback EFP|Neurofeedback (NF) - is a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Amygdala-EFP (EEG-finger-print, EFP) is an EEG-NF application that modulates amygdala response.
214932153|NCT06616051|OTHER|mHealth referral reminder to identified visually impaired school children|Intervention consists of a Multi-component health message which was framed with assistance from a panel of public health consultant and research supervisors. WHO health promotion and prevention messages library from has also been utilized. Two parts make up the computerized text message reminder system: an SMS application for text messaging that is sent automatically and a web-based application for child registration and automated reminder scheduling. The parents will get text messages written in Urdu, the native language, as part of the intervention. Mothers will receive instruction on how to access and interpret SMS text messages upon enrollment. The message consists of four parts and will be sent as an SMS: Health promotion message, visual depiction of a child vision, a customized action plan with details on how to get to the hospital including the location and a snapshot of the key location, how much money is needed.
215071441|NCT05273021|DIAGNOSTIC_TEST|TAPS|all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
215071442|NCT03018418|RADIATION|Proton therapy|Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
215071443|NCT03018418|DRUG|Chemotherapy|5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
215071444|NCT04902404|OTHER|First Pathways Game|The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
214932154|NCT04186806|DEVICE|3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray|20 ml bottle
215071445|NCT00362583|DRUG|Fentanyl|
214329970|NCT03787849|DRUG|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
214329971|NCT03787849|DRUG|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
214932155|NCT04186806|DEVICE|Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray|44.3 ml bottle
214932156|NCT03700333|DRUG|S-1 therapy|accept S-1(50mg, twice a day, morning and night, if\<1.5m2; 75mg, twice a day, morning and night,if \>1.5m2 )chemotherapy after finishing first-line therapy(\>21 days).
214329972|NCT01709318|DRUG|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
214329973|NCT01709318|DRUG|Etonogestrel (ENG)|Daily release of 75, 100, 120 or 125 μg
214329974|NCT01709318|DRUG|Ethinyl estradiol (EE)|Daily release of 15 μg
214329975|NCT01709318|DRUG|Estradiol (E2)|Daily release of 300 μg
214329976|NCT03062800|DRUG|Thalidomide|100-200mg/d,oral ,qn
214329977|NCT03062800|DRUG|pemetrexed|(500mg/m\^2) on day 1 of 21-days cycle,ivgtt
214329978|NCT03062800|DRUG|cisplatin|(75mg/m\^2) on day 1 of 21-days cycle, ivgtt
214329979|NCT03062800|DRUG|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
214329980|NCT02618330|DEVICE|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
214329981|NCT02127008|PROCEDURE|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
214329982|NCT02127008|PROCEDURE|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
214329983|NCT05832034|DRUG|Immune Globulin Intravenous (Human)|IVIg is 2 g/kg over 2 to 5 days at baseline, followed by 2 g/kg IV in 2 to 5 days after 4 and 8 weeks. The rate of infusion is controlled by means of an infusion pump. The first dosage (30 grams IVIg) will be administered on the neurology ward.
214329984|NCT05832034|DRUG|Placebo|Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
214329985|NCT04816357|OTHER|Questionaire|only questionaire
214329986|NCT03042312|DRUG|177Lu-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
214329987|NCT04250324|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
214329988|NCT01099124|DRUG|M2ES|polyethylene glycol rh recombinant endostatin
214329989|NCT01119261|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
214932157|NCT03700333|DRUG|Pemetrexed therapy|accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(\>21 days).
215071446|NCT00420004|DRUG|LY2216684|3-mg and 6-mg tablets
215071447|NCT00420004|DRUG|Placebo|
214329990|NCT01119261|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
214329991|NCT04499404|OTHER|Breastfeeding related information delivered by WeChat|Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.
214932158|NCT06646159|BEHAVIORAL|REThink Intervention|"At its core, the REThink game consists of seven levels, each focusing on a specific emotion-regulation skill crucial for emotional health. The game's story is based on the RETMAN character which helps the player fight the power of the Irrationalizer who personalizes irrational beliefs. The game is based on cognitive-behavioral psychotherapy - the unified protocol (Barlow et al., 2004) and well-supported Rational Emotive Behavioral Therapy (Ellis, 1995). Each level is composed of three sublevels, increasing in difficulty, and also has an embedded validated assessment system (composed of a sublevel for each level; David, Tomoiaga \& Fodor, 2024), and can function as a standalone intervention."
214932159|NCT03081559|BEHAVIORAL|Healthy Divas|Peer-based counseling to improve medication adherence and engagement in care
214932160|NCT00200109|DEVICE|Occipital Nerve Stimulation|Each group had a different plan
215071448|NCT00420004|DRUG|Escitalopram|10-mg capsules
215071449|NCT03929653|OTHER|Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing|This study is to observe this therapy model outcomes
215071450|NCT03452904|DEVICE|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
215071451|NCT03452904|DEVICE|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
215071452|NCT05989087|DIAGNOSTIC_TEST|CSF|Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.
214932161|NCT00622661|OTHER|Low Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
214329992|NCT04499404|OTHER|Non-breastfeeding related information delivered by WeChat|Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
214932162|NCT00622661|OTHER|High Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
214932163|NCT02416193|DRUG|Cholecalciferol|Participants will take randomly assigned high dose cholecalciferol once weekly for three months
214932164|NCT02416193|DRUG|Cholecalciferol|Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
214932165|NCT06621693|DEVICE|Transcutaneous electrical diaphragmatic stimulation intervention|It will be applied on diaphragm, 30 min per session ,3 days/week for 4 weeks at a stimulation frequency of 30 Hz, pulse width of 400 μs, the intensity was gradually increased until visible muscle contraction was observed.
214932166|NCT06621693|OTHER|traditional physiotherapy program|The participants will receive traditional physiotherapy ( postural drainage, percussion , diaphragmatic breathing, phase 1 cardiac Rehabilitation and balance training ) three times per week for 4 weeks
214932167|NCT03845361|PROCEDURE|Radial artery cannulation|Radial artery cannulation
214932168|NCT00177307|DRUG|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
214932169|NCT00177307|DRUG|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
214932170|NCT00177307|DRUG|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
215071453|NCT00309140|DRUG|enzastaurin|500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
215071454|NCT05778084|DRUG|Empagliflozin 10 MG|Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
214932171|NCT00895128|DRUG|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
215071455|NCT05081947|BEHAVIORAL|COMPASS|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
215071456|NCT05254405|DRUG|Brexanolone Injection [Zulresso]|Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
215071457|NCT00733772|DIETARY_SUPPLEMENT|flaxseed|30 grams/day of flaxseed for 12 weeks
214932172|NCT00895128|DRUG|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
214932173|NCT06022614|DRUG|Use Bupivacaine 0.25% Injectable Solution|Group A Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml normal saline.
214932174|NCT06022614|DRUG|Bupivacaine 0.25% Injectable Solution plus Dexmedetomidine|Group B Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml dexmedetomidine
214932175|NCT00286923|DRUG|Topiramate|
214932176|NCT00279617|DRUG|levetiracetam|open label levetricetam
214932177|NCT06577519|DRUG|Vicagrel|Vicagrel loading followed by Maintenance dose
215071458|NCT00733772|BEHAVIORAL|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
215071459|NCT05908071|DRUG|SHEN26 capsule|Capsule administered orally after meals.
215071460|NCT05908071|DRUG|SHEN26 placebo|Capsule administered orally after meals.
215071461|NCT00998673|DEVICE|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
215071462|NCT00998673|DEVICE|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
214932178|NCT06577519|DRUG|Clopidogrel|Clopidogrel loading followed by Maintenance dose
214932179|NCT04305249|DRUG|ATG-017|Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.
214932180|NCT04305249|DRUG|ATG-017+Nivolumab|With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be specified dose on specified days.
214932181|NCT06647602|DRUG|Euthyrox (levothyroxine)|Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.
214932182|NCT06647602|DRUG|Cytomel (liothyronine)|Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The pharmacoequivalent ratio of L-T3 to L-T4 is 1:3. The L-T4-cohort receive doses of 2 μg × kg body weight / day. The pharmacoequivalent L-T3 dose would be 1/3th of that namely: 0.67 μg × kg body weight / day. Cytomel will be given trice daily and available dosages are 5, 12.5 and 25 μg.
215071463|NCT00591149|DRUG|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
215071464|NCT00591149|DRUG|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
214932183|NCT01885286|PROCEDURE|circumcision with simple circumcision device|Circumcision performed with the device in the operating room using local anesthesia
215071465|NCT00591149|DRUG|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
215071466|NCT00441649|DRUG|Methylphenidate|
215071467|NCT05568914|DEVICE|Indirect Calorimetry|Indirect Calorimetry (Q-NRG Metabolic Monitor, COSMED) is performed to determine the Resting Energy Expenditure before hemodialysis.
215071468|NCT05568914|DEVICE|Bio-electrical Impedance Analysis (BIA)|Bio-electrical Impedance Analysis (BIA101/BIVA, Akern) is used to analyse the body composition (Fat Mass, Fat Free Mass, Phase Angle).
215071469|NCT05568914|OTHER|Nutritional assessments|The Nutritional assessments consist of a dietary anamnesis and a 3-day nutritional diary to determine the nutritional (caloric and protein) intake of the participants.
215071470|NCT02596373|DRUG|Mitoxantrone Hydrochloride Liposome Injection|
215071471|NCT00470093|BIOLOGICAL|recombinant interferon-α|
215071472|NCT00470093|BIOLOGICAL|recombinant interleukin-6|
215071473|NCT05901363|PROCEDURE|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones
215071474|NCT05901363|PROCEDURE|aparoscopic common bile duct exploration and laparoscopic cholecystectomy|laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
215071475|NCT01610440|BIOLOGICAL|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
214329993|NCT02383758|DRUG|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
214486269|NCT06736925|OTHER|Soccer Heading Model|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer (G-force tracker) embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 30 mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
214486270|NCT06737835|DEVICE|18 FDG|18 flurodeoxy glucose PET/CT
215071476|NCT01381003|GENETIC|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
215071477|NCT00989521|DRUG|PUR003|PUR003 for inhalation
215071478|NCT00989521|DRUG|Placebo|Normal saline for inhalation
215071479|NCT05325749|GENETIC|Screening|Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
215071480|NCT05325749|GENETIC|Family history record|Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
215071481|NCT05325749|OTHER|Questionnaire survey|Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
215071482|NCT05325749|GENETIC|Diagnostic|The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
215071483|NCT05325749|GENETIC|Selective screening|The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
215071484|NCT04205851|DRUG|KIN-1901|KIN-1901 is a fully human monoclonal antibody (mAb).
215071485|NCT04205851|DRUG|Placebo|Saline
215071486|NCT03263468|PROCEDURE|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
215071487|NCT03263468|PROCEDURE|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting \>48 hours to 45 days post primary PCI
215071488|NCT03411252|DRUG|Mirabegron 50 MG|Myrbetriq (Mirabegron) tablet
214932184|NCT06002139|BEHAVIORAL|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
215071489|NCT03411252|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron
215071490|NCT02429713|PROCEDURE|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
214932185|NCT06002139|BEHAVIORAL|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~* Two hours of kinesiotherapy (120 minutes, including gait training).~* Thirty minutes of ergotherapy.~* Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
215071491|NCT02429713|PROCEDURE|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
215071492|NCT05132257|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
215071493|NCT05978076|OTHER|data collection|data collection : mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications.
215071494|NCT01431937|DRUG|GSK2018682|Active Drug
215071495|NCT01431937|DRUG|Placebo|Placebo
214329994|NCT02383758|DRUG|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
215071496|NCT05752227|PROCEDURE|Transthoracic biopsy|Us guided transthoracic biopsy
215071497|NCT05752227|RADIATION|CT chest|Computed tomography
215071498|NCT00588172|DRUG|Metformin|1000mg bid for 1 week
214329995|NCT02383758|DRUG|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
214329996|NCT06469047|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-1β and NE levels were detected.
214329997|NCT00273364|PROCEDURE|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
214329998|NCT00273364|DRUG|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
214932186|NCT03726203|DEVICE|laparoscopic gynecologic surgery with the MiniLap System.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care, but using the MiniLap System instead of the conventional single-use trocars used usually.
215071499|NCT04113174|OTHER|Decision Analytic Modelling|Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
215071500|NCT04371640|DRUG|Sirolimus 1 MG/ML|Oral solution
215071501|NCT04371640|DRUG|Placebo|Oral solution
215071502|NCT05235347|BIOLOGICAL|Sotrovimab|500mg IV
215071503|NCT02332772|OTHER|Data Collection|Data collected from endoscopy procedures.
215071504|NCT01451229|DRUG|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
215071505|NCT00153829|BEHAVIORAL|Multifaceted outreach facilitation for chronic illness care|
215071506|NCT02456636|BEHAVIORAL|Fee-for-Service Model (FFS, In clinic individual visits)|To be performed by participant's doctor or other healthcare professional in their doctor's office.
215071507|NCT02456636|BEHAVIORAL|Patient Centered Medical Home (PCMH, In clinic group visits)|To be performed by a registered dietitian, a nurse or other healthcare professional in their local setting.
215071508|NCT02456636|BEHAVIORAL|Disease Management (DM, Phone group visits)|To be performed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling via telephone.
215071509|NCT04077294|OTHER|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
215071510|NCT04077294|OTHER|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
214932187|NCT03726203|DEVICE|laparoscopic gynecologic surgery with the conventional single-use trocars.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care using the conventional single-use trocars used usually.
214329999|NCT05166434|PROCEDURE|trans-crestal sinus lifting|this study will be divided in to three different groups, each group will receive a same technique of Crestal maxillary sinus lifting and implant placement at 2,4,6 mm heights.
214330000|NCT06085898|DRUG|Stryphnodendron Adstringens 3% - once daily post bath|Intimate Soap
214330001|NCT02753647|DRUG|Rituximab|
214932188|NCT03270475|OTHER|exercise training|subjects complete 4-5 weeks of training
214932189|NCT02999529|OTHER|Educational Video|Participants will be asked if they know the meaning of six words related to cancer treatment. Following the interview, participants will watch a video explaining the meaning of the six words. After viewing the video, participants will be re-interviewed about the meaning of the six words.
214932190|NCT06631482|DEVICE|Maintain HPI < 85|Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
214932191|NCT06631482|DRUG|Maintain MAP>=73|Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
214932192|NCT06623604|BEHAVIORAL|Experimental: Physical activity program|"In consultation with school administrators and classroom teachers, a physical activity program was implemented so that students\&amp;#39; classes would not be disrupted.~The exercises were carried out three days a week for 30 minutes in the school garden and gym by the same researcher, and the education was carried out in the classrooms one day a week.~During the program, students did a total of 180 hours of physical activity."
215071511|NCT05557552|RADIATION|standar thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
215071512|NCT05557552|RADIATION|decreased thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
215071513|NCT01040091|DRUG|Emtricitabine (FTC)|200 mg once a day
214330002|NCT02753647|DRUG|Cyclophosphamide|
214330003|NCT02753647|DRUG|Doxorubicin|
214330004|NCT02753647|DRUG|Vincristine|
214330005|NCT02753647|DRUG|Prednisone|
215071514|NCT01040091|DRUG|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
215071515|NCT01040091|DRUG|Efavirenz (EFV)|600 mg once a day
215071516|NCT01040091|DRUG|Truvada|200 mg emtricitabine + 300 mg TDF once a day
215071517|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
214330006|NCT02753647|DRUG|Chidamide|
214330007|NCT02305940|DRUG|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
214330008|NCT02305940|DRUG|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
214330009|NCT05894265|OTHER|ActiveMatrix® Dosage A|This group will receive ActiveMatrix® (AM) product dosage A (1cc AM diluted to 3cc with saline)
214330010|NCT05894265|OTHER|ActiveMatrix® Dosage B|Group 2 will receive ActiveMatrix® product dosage B (2cc AM diluted to 3cc with saline)
214330011|NCT05894265|PROCEDURE|Saline injection|Group 3 will receive saline injection
214330012|NCT03348267|DIETARY_SUPPLEMENT|Milk protein isolate|Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water
214330013|NCT03348267|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
214330014|NCT00646958|DRUG|Radezolid|450mg PO QD
214330015|NCT00646958|DRUG|Radezolid|450mg PO BID
214330016|NCT00646958|DRUG|Linezolid|600mg PO BID
214330017|NCT05134376|OTHER|During Episiotomy Repair, Women Will Be Watching Virtual Reality Glasses Accompanied by Music|Unlike the experimental group, only video and music application will not be applied to the pregnant women included in the control group. Other applications will be done exactly.
214330018|NCT04926753|DRUG|5-Fluorouracil, Cisplatin, Toripalimab|Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
214932193|NCT06471946|DRUG|Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT|"Patients were treated by VA Conditioning Regimen Allo-HSCT:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9"
215071518|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
214330019|NCT04771741|DRUG|Acetominophen|1,000 mg every 6 hours
214330020|NCT04771741|DRUG|Toradol|10 mg every 6 hours, days 0-3
214330021|NCT04771741|DRUG|Meloxicam|15 mg once daily, beginning post-op day 4
214330022|NCT04771741|DRUG|Cyclobenzaprine|10 mg every 8 hours
214330023|NCT04771741|DRUG|Lyrica|75 mg every 12 hours
214330024|NCT02537080|DRUG|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
214330025|NCT02537080|DRUG|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
214330026|NCT05495750|DRUG|Bupivacaine 0.25% Injectable Solution|ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg.
214330027|NCT02786615|BEHAVIORAL|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
214330028|NCT04801524|BEHAVIORAL|Self-benefit|Participants will be reminded that the vaccine helps protect themselves from COVID.
214330029|NCT04801524|BEHAVIORAL|Prosocial-benefit|Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID
214932194|NCT03042169|DRUG|Preoperative Chemotherapy|Standard chemotherapy regiments according to risk of recurrence
215071519|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
214330030|NCT04801524|BEHAVIORAL|Early access|Participants will be reminded that they have early access to COVID-19 vaccine.
214330031|NCT04801524|BEHAVIORAL|Fresh start|Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.
214330032|NCT03195413|PROCEDURE|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
214330033|NCT03195413|DRUG|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
214330034|NCT03195413|DEVICE|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
214330035|NCT04318210|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
214330036|NCT03175640|BEHAVIORAL|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
214330037|NCT01429896|OTHER|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
214330038|NCT03873285|GENETIC|Genetic diagnostic by mendeliome or genome|For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
214330039|NCT03085927|BEHAVIORAL|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
214330040|NCT03085927|BEHAVIORAL|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
214330041|NCT03475160|DRUG|Sildenafil Citrate vaginal suppositories|Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
214330042|NCT03475160|DRUG|Placebo vaginal suppositories|Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
214932195|NCT03042169|PROCEDURE|Surgery|the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.
214932196|NCT03042169|DRUG|Postoperative chemotherapy|Chemotherapy should be restarted between D1 and D30 post-randomization
214932197|NCT03254212|DEVICE|Titration of nocturnal oxygen needs to prevent desaturations|Oximetry recordings will be performed using a Pulse Oximeter. Two O2 titration sessions will be conducted at home in random order one week apart. One will consist of a stepwise night-to-night increase in O2 flow for up to 4 nights with supplemental O2, each at flow rates of 1L/min, 2L/min, 3L/min and 4L/min, respectively. During the other titration session, an automatic O2 delivery system will be used for 4 consecutive nights with O2 flow allowed to vary from 0 to 4 L/min with a 95 ± 2% SpO2 target. At the end of the titration periods, oxygen concentrators will be set at the lowest flow rate (1L/min to 4L/min) that maintained oxyhemoglobin saturation to \> 90% (Tsat90%) for ≥ 98% of the estimated sleep period and reduced the oxygen desaturation index 3% (ODI3) to \< 5/hour according to conventional O2 titration. If these targets are not reached, the lowest flow rate will be selected that minimizes the ODI3. These procedures will be repeated at week 5 and 11.
214330043|NCT03475160|PROCEDURE|Uterine artery Doppler before treatment|Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
214330044|NCT03475160|PROCEDURE|Uterine artery Doppler after treatment|Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
214932198|NCT06621381|BEHAVIORAL|Concentrated exposure and response prevention|The intervention consists of: Psychoducation for the patients (1 session, 2-3h in group format), psychoeducation for the legal guardians (1 session, 3h in group format), exposure and response prevention (3-4 sessions, 9-12h over the course of one week, individual format), group reunions for sharing experiences, motivational work and relapse prevention ( 2 sessions, 3h)
215071520|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
215071521|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
215071522|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
214330045|NCT02012387|BIOLOGICAL|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
214330046|NCT02012387|BIOLOGICAL|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
214330047|NCT02012387|BIOLOGICAL|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
214330048|NCT02692989|PROCEDURE|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
214330049|NCT02192450|DRUG|Insulin aspart/glargine|
214330050|NCT02192450|DRUG|Insulin aspart/degludec|
214486271|NCT06738875|DEVICE|manometre|Increases in peak and mean airway pressures of ETT cuff pressures will be monitored in patients undergoing laparoscopic bariatric surgery
214486272|NCT06739564|PROCEDURE|ICE PACKING|ICE PACKING ON LOWER LIMB AFTER AN EXHAUSTION EFFORT.
214486273|NCT06739564|PROCEDURE|DRY NEEDLING|DRY NEEDLING ON LOWER LIMB AFTER AN EXHAUSTION TRIAL
214330051|NCT03272594|OTHER|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
214330052|NCT03272594|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
214330053|NCT02039531|BIOLOGICAL|Plasma rich in growth factors|
214330054|NCT02039531|DRUG|Hyaluronic Acid|
214330055|NCT02346565|PROCEDURE|Exercise ECG|
214330056|NCT02346565|PROCEDURE|Stress Echocardiography|
214330057|NCT02037503|DRUG|Ketamine|
214330058|NCT02037503|DRUG|Saline|
214330059|NCT05050188|DRUG|H008|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.
214330060|NCT05050188|DRUG|H008 placebo|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
214330061|NCT05050188|DRUG|Lansoprazole|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
214932199|NCT02719912|DEVICE|mitral valve replacement|transcatheter mitral valve replacement
214932200|NCT04258540|BEHAVIORAL|Yoga group|The intervention group received yoga 2 times a week for 12 weeks (á 1.25 hr).
214932201|NCT04258540|BEHAVIORAL|yoga course|yoga course
214932202|NCT03170466|BEHAVIORAL|Primary Palliative Care|The intervention will span 4 domains: symptom management (e.g., dyspnea), psychosocial support (e.g., anxiety), advance care planning (e.g., understanding prognosis and electing a proxy) and care coordination (e.g., communication across providers).
215071523|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
215071524|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
214330062|NCT00785226|DRUG|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
214330063|NCT00785226|DRUG|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
214330064|NCT01023126|BEHAVIORAL|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
214330065|NCT06245070|DEVICE|Active transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Active stimulations will be delivered by a 9 MxN Soterix HD-tES device for 20 minutes( 2 mA) per day for 5 days.
214330066|NCT06245070|DEVICE|Sham transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Sham stimulations will be delivered by a 9 MxN Soterix HD-tES device. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
214330067|NCT04381104|DRUG|Paracetamol|The intervention arm will receive 2 capsules of paracetamols of 500mg.
214330068|NCT06531603|DRUG|bupivacaine wound infilteration|drug was given at the end of surgery
214330069|NCT06531603|DRUG|Bupivacaine plus dexmedetomidine wound infilteration|drug was given at the end of surgery
214330070|NCT03526224|DRUG|Dimethyl Fumarate|Individuals with MS treated with dimethyl fumarate (Tecfidera)
214330071|NCT03526224|DRUG|Teriflunomide|Individuals with MS treated with teriflunomide (Aubagio)
214330072|NCT02349711|DIETARY_SUPPLEMENT|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
214932203|NCT01459718|DRUG|Deferasirox|20-40 mg/kg/day orally, once daily
214932204|NCT01459718|DRUG|Deferoxamine (DFO)|40 mg/kg/day subcutaneous (sc) infusion, 3-4 days per week
214932205|NCT05353972|DRUG|IMG-007 or placebo|intravenously administered
214932206|NCT03840551|OTHER|Biomechanical analysis with inertial sensors (XSENS) and motion capture (BTS)|The kinematics of lower limbs, trunk and upper limbs will be calculated both with inertial sensors (XSENS) and motion capture marker-based system (BTS ). Inertial sensors and markers will be placed on the subjects clothes and on the skin (totally non-invasive) to identify body segments. Then subjects will perform their motor tasks normally. Lately, through the data post-processing, the kinematics evaluated with both the systems will be used to describe how well the task is performed in terms of ACL prevention, through derived biomechanical parameters.
214932207|NCT02387775|DEVICE|Esophageal temperature control|"Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.~All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit."
214932208|NCT03589963|BEHAVIORAL|Postnatal Lactation Support|In-home breastfeeding support delivered by professional lactation consultants and provision of a high-quality breast pump
214932209|NCT03897114|DIETARY_SUPPLEMENT|Cocoa group|Athletes perform the same training program and they take 5 g of cocoa (83 mg of flavonoids per gram of cocoa) mixed with low-fat milk for 10 weeks.
214932210|NCT03897114|DIETARY_SUPPLEMENT|Placebo group|The athletes perform the same training program and they take for 10 weeks 5 g maltodextrin mixed with low-fat milk for 10 weeks
214932211|NCT06254508|BEHAVIORAL|Online program that includes exercise guided by the FITT-VP principle and dietary advice|"1. Week 1: Children received 2 sessions of exercise initiation and 1 session of small group exercise training (45 minutes) with 4\~6 peers.~2. Weeks 2 to 16: 3 small group exercise sessions per week (45 minutes, 4-6 peers) of moderate-to-vigorous physical activity (MVPA). Effective exercise time was assessed by the time subjects reached the heart rate corresponding to the exercise intensity (64-95% of maximal heart rate), as measured by the instantaneous heart rate recorded during each exercise session. The type of exercise was a combination of aerobic, resistance, and flexibility exercises (time ratio 2.5:1:1).~3. Dietary guidance was provided concurrently during the 16-week intervention period: by establishing a WeChat group for caregivers and uploading daily pictures of the day's food to the group, the group's health coaches provided daily targeted dietary guidance."
214932212|NCT06254508|BEHAVIORAL|Conventional in-clinic nutrition and exercise advice and self-control|Physicians provide instructions on exercise and nutrition (total daily calorie intake) for the patients to conduct self-control for 16 weeks.
214932213|NCT00556634|DRUG|Efavirenz|"Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)"
214932214|NCT00651534|DRUG|Ronacaleret|
214932215|NCT01023841|DRUG|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
214932216|NCT01023841|DRUG|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
214932217|NCT05021289|BEHAVIORAL|guided imagery|guided imagery
214932218|NCT03347344|DRUG|Riluzole|50 mg will be administered (per os) twice a day
214932219|NCT03347344|DRUG|Placebo|50 mg will be administered (per os) twice a day
215071525|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
215071526|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
215071527|NCT04467658|DIAGNOSTIC_TEST|Korean ADHD rating scale|The KARS is a standardized screening tool for ADHD in Korean children and rating scale completed by the parents.
215071528|NCT04467658|DIAGNOSTIC_TEST|Korean Version of Diagnostic Interview Schedule for Children Version IV|The DISC-IV is a structured diagnostic tool that was developed for use in epidemiological studies in children and adolescents
215071529|NCT03267667|DIAGNOSTIC_TEST|2D Echocardiography and cardiac MRI|imaging of right ventricle by both modalities to assess right ventricle function accurately
215071530|NCT01900171|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
215071531|NCT01900171|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
215071532|NCT00150319|DRUG|Vfend®; I.V.|
215071533|NCT01948765|DRUG|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
214330073|NCT02349711|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
214330074|NCT03347994|DRUG|Minnelide|Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
214330075|NCT00194012|DRUG|Aripiprazole|Addressed in arm description.
214330076|NCT00194012|DRUG|Placebo|Addressed in arm description.
214330077|NCT01516268|DRUG|Sufentanyl|"As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block."
214330078|NCT01595516|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
214330079|NCT01595516|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
214932220|NCT03518970|OTHER|Nursing intervention|"The intervention was built on the components of the theory of uncertainty in illness and was designed to give in a face to face meeting with the caregiver education about advanced cancer in palliative care through an educational material.~Educational material: The educational booklet has the purpose of giving information to the family caregiver about palliative care. This material aims to be an easily accessible resource to understand the palliative care of the cancer patient. In addition, this booklet will be used to ensure the standardization of the intervention during the face-to-face meeting with the participants and the investigator.~Face-to-face meeting: The nursing intervention has a face-to-face meeting component between the investigator and the participant. This nursing educational session will be supported by the contents of the booklet and will have the purpose of discussing the contents of the booklet and resolving doubts on the part of the family caregivers."
214932221|NCT00392470|BIOLOGICAL|cetuximab|
214330080|NCT01595516|DRUG|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
214330081|NCT01595516|OTHER|Bradykinin|Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.
214330082|NCT01595516|OTHER|Saline|Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.
214330083|NCT01595516|OTHER|Vitamin C|The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (\~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.
214932222|NCT00392470|DRUG|irinotecan hydrochloride|
214932223|NCT00392470|PROCEDURE|conventional surgery|
214932224|NCT00392470|PROCEDURE|neoadjuvant therapy|
214330084|NCT01479036|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
214330085|NCT01479036|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
214330086|NCT04912505|DRUG|Aspirin|Run-in phase during one week with daily aspirin intake at 8 AM; visit 1: blood sampling at H24 and H2; intermediate phase (two weeks): daily aspirin intake at 8 PM; visit 2: blood sampling at H12; then daily intake of aspirin at the time preferred by the patient and study end visit 2 weeks after visit 2
214932225|NCT00392470|RADIATION|3-dimensional conformal radiation therapy|
214932226|NCT00392470|RADIATION|intensity-modulated radiation therapy|
214932227|NCT00460707|DRUG|Casopitant 150 mg|Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
214932228|NCT00460707|DRUG|Ketoconazole|Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
214932229|NCT00460707|DRUG|Casopitant 150 mg matching placebo|Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
214932230|NCT00460707|DRUG|Casopitant 50 mg|Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
214932231|NCT00460707|DRUG|Casopitant 50 mg matching placebo|Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
215071534|NCT01948765|DRUG|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
215071535|NCT04786704|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|A diagnostic device measuring syndecan 2(SDC2) methylation status in stool DNA to detect colorectal cancer
215071536|NCT04786704|DIAGNOSTIC_TEST|quantitative Fecal immunochemical test|A diagnostic device using immunoturbidimetric methods to measure fecal hemoglobin concentration
214330087|NCT05059158|RADIATION|positron emission tomography (PET)|18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.
214330088|NCT02497664|OTHER|Active Breathing Control|
214330089|NCT05786456|PROCEDURE|Discussion|Participate in group and web-based self-study sessions
214932232|NCT04647656|DEVICE|Hyperbaric oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
214932233|NCT04647656|DEVICE|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
214932234|NCT01542034|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
214932235|NCT01542034|DRUG|Placebo|Phosphate buffered saline placebo for injection
215071537|NCT03100240|PROCEDURE|Modified Supper Long Protocol|In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
215071538|NCT02606981|DEVICE|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
215071539|NCT02606981|DEVICE|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
215071540|NCT01663116|GENETIC|Stem cells|"1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
215071541|NCT01663116|GENETIC|Placebo|"1. first cohort: 20 ml administered at days 1, 8 and 15~2. second cohort: 40 ml administered at days 1, 8 and 15~3. third cohort: 80 ml administered at days 1, 8 and 15"
214932236|NCT05280899|OTHER|Weight-bearing As Tolerated|The WBAT group will be instructed to bear weight as tolerated immediately following their surgical procedure. The rehabilitation protocols provided will be identical beyond the initial weightbearing recommendations. Following the initial protection phase (three weeks), whereby the two weightbearing interventions will be provided, patients will progress through standardized phases including mobility and neuromuscular retraining, muscle balance and strengthening, functional training, and finally, advanced training for return to work and sport.
214330090|NCT05786456|OTHER|Informational Intervention|Receive handouts
214330091|NCT05786456|OTHER|Media Intervention|View videos
214330092|NCT05786456|OTHER|Questionnaire Administration|Ancillary studies
214330093|NCT05786456|BEHAVIORAL|Telephone-Based Intervention|Participate in check-in calls
214330094|NCT01019655|DRUG|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
214330095|NCT01285765|DRUG|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
214330096|NCT06393192|PROCEDURE|Epidural analgesia (EA) only group|The epidural needle will be inserted into the lumbar epidural space at the level of L2-3 intervertebral space.
214932237|NCT05280899|OTHER|Partial Weight-bearing|"The PWB group will be instructed to bear weight to a maximum of 20 lbs of bodyweight on the operative limb for the initial three weeks (termed toe touch), with graduated return to full weightbearing thereafter."
214330097|NCT06393192|PROCEDURE|Quadratus lumborum block (QL2)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side behind the QL muscle, resulting in a total of Sixty mL
214932238|NCT05020418|OTHER|Chart Review|Intervention sites will receive a multi-faceted implementation intervention, which will include external and internal blended facilitation, education materials for providers and patients, and audit and feedback about practices and outcomes with benchmarking to non-intervention sites.
215071542|NCT01029990|OTHER|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
214330098|NCT06393192|PROCEDURE|Quadratus lumborum block 3(QL3)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side among the QL muscle and the psoas major, resulting in a total of Sixty mL
214330099|NCT06393192|PROCEDURE|Quadratus lumborum block 2+3 QL(2+3)|0.2 percent bupivacaine solution of fifteen milliliters were administered at each injection site, with the needle being inserted once on each side
214330100|NCT04669210|DRUG|Ruxolitinib|Ruxolitinib administered during conditioning 5 mg tid before allogeneic hematopoietic stem cell transplantation, 5 mg tid days 5-21 and 5 mg bid days 22-150 after transplantation instead of tacrolimus and MMF.
214330101|NCT04669210|DRUG|Tacrolimus|Tacrolimus 0.03 mg/kg adjusted to concentrations 5-15 ng/ml from day+5 to +100
214330102|NCT04669210|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil 30 mg/kg from day +5 to +35
214330103|NCT04699994|DRUG|FLOT therapy|Preoperative FLOT therapy
214330104|NCT04731441|BEHAVIORAL|Home-based Exercise Program Prior to CRS-HIPEC|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
214330105|NCT04731441|BEHAVIORAL|Exercise Education|Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
214330106|NCT02200042|RADIATION|Image Guided Radiation Therapy|Patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days.
214330107|NCT03260816|BEHAVIORAL|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
214330108|NCT03260816|OTHER|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
214330109|NCT03637751|BEHAVIORAL|Behavioral|Trier Social Stress Test
214330110|NCT03637751|BEHAVIORAL|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
214330111|NCT02097134|DRUG|Melphalan|Given IA
214330112|NCT00218062|DRUG|D-Amphetamine 30mg|
214330113|NCT00218062|DRUG|D-Amphetamine 60mg|
214330114|NCT00218062|DRUG|Modafinil 200mg|
214330115|NCT00218062|DRUG|Modafinil 400mg|
214330116|NCT00218062|BEHAVIORAL|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
215071543|NCT01029990|OTHER|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
214932239|NCT06342583|OTHER|Advanced social relations training with technical device|15 participants from the experimental group will undergo a first part in which they will be guided through social stories to construct an appropriate conversation repertoire. In the first phase the participants will see 8 social stories with scenes from everyday life and after learning the correct mode of interaction and communication they will be asked to interact in the group by playing the roles previously seen in the social stories. These will be shown on a technological device. Participants will have the opportunity to choose the correct mode of interaction by selecting it directly on the technological device. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media. Slides will be shown to explain risks and correct use and the operator will show on the technological device (Smartphone) all the practical steps to be taken (e.g. privacy settings).
215071544|NCT02379221|DRUG|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
215071545|NCT02379221|DRUG|Topical|4% Topicaine gel
215071546|NCT05828394|PROCEDURE|DFGG|Depithelised free gingival graft harvesting technique
214330117|NCT00218062|DRUG|Placebo|
214330118|NCT04824534|OTHER|Motion analysis|Motion analysis is performed in the Motionlab using Vicon systems. Surgery (in case of SI patients) is performed with iFuse implant system for sacroiliac joint fusion
214330119|NCT06426797|DRUG|Cadonilimab plus anlotinib|cadonilimab (10mg/Kg, ivgtt, d1) and anlotinib (12mg, P.O., d1-d14) on a 21-day regimen for 3 cycles
214330120|NCT02839434|PROCEDURE|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
214330121|NCT01176825|BEHAVIORAL|cognitive-behavior therapy (CBT)|14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
214330122|NCT05567731|DRUG|ultrashort GnRHa|"the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm"
214486274|NCT06737211|DIETARY_SUPPLEMENT|Peripheral Parenteral Nutrition|2000 mL of peripheral parenteral nutrition with electrolytes (20 mL 7.45% KCl, 10 mL 20% MgSO4 and 20 mL 8.7% Na3PO4) will be administered via a peripheral venous catheter with a rhythm of 80cc/h from the time they will leave the operation room and will be transferred to the ward or the critical care unit (CCU) until the 5th postoperative day
215071547|NCT05828394|PROCEDURE|SCTG|Subepithelial connective tissue graft harvesting technique
215071548|NCT00100997|DRUG|tanespimycin|
215071549|NCT02660671|BEHAVIORAL|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
215071550|NCT02660671|BEHAVIORAL|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
215071551|NCT02660671|BEHAVIORAL|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
215071552|NCT02490995|OTHER|Movie|Besides the anesthesist explanations the children will have a movie explanation.
215071553|NCT02041975|DIETARY_SUPPLEMENT|Nutriose FB06|Wheat dextrin soluble fibre
215071554|NCT02041975|DIETARY_SUPPLEMENT|Placebo|
215071555|NCT02872896|PROCEDURE|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
215071556|NCT02192060|OTHER|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
215071557|NCT02192060|OTHER|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
215071558|NCT04347213|BEHAVIORAL|Regular lifestyle in different circumstances|Participants' lifestyle will be followed over the years.
214932240|NCT06342583|OTHER|Advanced social relations training without technical device|15 participants from the control group will undergo a first part in which they will be guided through social stories to build an appropriate conversation repertoire. In the first phase, the participants will see eight social stories illustrating scenes from everyday life and, after learning the correct modes of interaction and communication, they will be invited to interact in the group by playing the roles previously seen in the social stories. These will be shown in traditional mode (flashcards). Participants will have the opportunity to choose the correct mode of interaction by touching the card showing the appropriate mode. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media (facebook, instagram, TikTok, Whatsapp, YouTube). The trainer will show images on paper related to risks and correct use of social media.
214932241|NCT04823793|DIAGNOSTIC_TEST|Stool DNA methylation detection|Stool specimens are collected from participants in the outpatient department or the inpatient department. Both FIT and stool DNA real-time PCR are performed simultaneously. To improve the sensitivity and specificity of the colorectal cancer screening, this study enrolls multiple candidate genes to distinguish whether the participant has a high risk of colorectal cancer.
214932242|NCT02612610|DRUG|Gefapixant|Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
214932243|NCT02612610|DRUG|Placebo (for gefapixant)|
214932244|NCT05801900|DRUG|Ketorolac group|30 min preoperatively then every 8 hours postoperatively
214932245|NCT05801900|DRUG|Ibuprofen group|30 min preoperatively then every 8 hours postoperatively
214932246|NCT01612637|BEHAVIORAL|Pelvic floor muscle training and lifestyle advice|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
214932247|NCT01612637|BEHAVIORAL|Lifestyle advice|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
214932248|NCT00176644|DRUG|Transdermal Estradiol|"application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
214932249|NCT05236894|BEHAVIORAL|Cigarette Smoking|Smoke preferred brand of cigarette
215071559|NCT01739686|OTHER|CASA Intervention|"CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
215071560|NCT01322399|PROCEDURE|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
215071561|NCT01322399|PROCEDURE|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
215071562|NCT05617066|BEHAVIORAL|Cognitive behavioral therapy|With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
214330123|NCT05567731|DRUG|short GnRHa|"Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of \>18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture."
215071563|NCT01610557|DRUG|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
214330124|NCT05567731|DRUG|long GnRHa|In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
214486275|NCT06888622|DRUG|Eculizumab administration|Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks
214486276|NCT06889948|DRUG|Daratumumab|All patients will receive either fixed-dose daratumumab as a single agent therapy or fixed-dose daratumumab combined with stem cell transplantation.
214486277|NCT05166616|PROCEDURE|Biopsy|Correlative studies
214932250|NCT05236894|DRUG|Nicotine Oral Pouch|Given lower dose nicotine pouch
214932251|NCT05236894|DRUG|Nicotine Oral Pouch|Given higher dose nicotine pouch
214932252|NCT05236894|OTHER|Questionnaire Administration|Ancillary studies
214932253|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
214932254|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
214932255|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
214932256|NCT05109637|DEVICE|Konectom NMD Application|Administered as specified in the treatment arm.
214932257|NCT01801280|DRUG|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
214486278|NCT05166616|DRUG|Osimertinib|Given PO
214486279|NCT05166616|DRUG|Triptolide Analog|Given PO
214486280|NCT01553149|DRUG|Lenalidomide|Given PO
214486281|NCT01553149|OTHER|Pharmacological Study|Correlative studies
214486282|NCT06886178|DEVICE|STIL Orthosis|STIL Orthosis, a brace for the arm equipped with passive dampening designed to suppress high-frequency movements.
214486283|NCT06886178|DEVICE|Sham|A version of the STIL Orthosis that is visually indistinguishable from original, but which does not have the passive dampening mechanism.
214486284|NCT06747806|PROCEDURE|Cardiac Surgery and Procedures|To assess blood and tissue biomarkers of patients undergoing cardiac surgery
214932258|NCT01801280|DRUG|Pantoprazole|Daily dose: 40mg. Application together with CellCept® or Myfortic® .
214932259|NCT01801280|DRUG|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
214932260|NCT02149823|DRUG|Syntocinon 24 Intranasal Units (IU)|
214932261|NCT02149823|DRUG|Syntocinon 40 Intranasal Units (IU)|
214932262|NCT02149823|DRUG|Intranasal Placebo|
214932263|NCT02456389|OTHER|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
214932264|NCT02456389|OTHER|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
214932265|NCT02456389|OTHER|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
214932266|NCT02456389|OTHER|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
214330125|NCT01982422|BEHAVIORAL|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
214330126|NCT01982422|BEHAVIORAL|Standard of Care|Normal standard-of-care for pregnancy.
214330127|NCT04922801|DIAGNOSTIC_TEST|Nuclear Medicine whole-body|Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).
214330128|NCT04922801|DIAGNOSTIC_TEST|SPECT/CT imaging.|SPECT/CT scan at 24-48 hr post MRT
214330129|NCT04922801|DIAGNOSTIC_TEST|PET/CT imaging.|3-6 months Pre and post-therapy PET/CT imaging
214330130|NCT04922801|DEVICE|Patient-led radiation monitor (SELFIE)|"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."
214330131|NCT04922801|DIAGNOSTIC_TEST|LAB TEST|Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
214330132|NCT01086579|DEVICE|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
214330133|NCT01086579|DEVICE|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
214330134|NCT04693364|OTHER|Decision Aid|Use 3D printed breast model
214330135|NCT04693364|PROCEDURE|Discussion|Participate in consultation
214330136|NCT04693364|OTHER|Questionnaire Administration|Complete questionnaires
214330137|NCT03486041|BEHAVIORAL|Comprehensive Behavior Modification|Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.
214330138|NCT03486041|BEHAVIORAL|Attention|Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
214330139|NCT05241067|DRUG|Normal Saline|Placebo (Dose: equal volume saline) + Standard of care
214330140|NCT05241067|DRUG|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
214932267|NCT02456389|OTHER|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
214932268|NCT02456389|OTHER|Standard postoperative care|Routine postoperative care, as medically indicated
214932269|NCT04855214|OTHER|Qualitative Analysis|Mixed methods analysis of the user's experience with upper limb prosthetics.
214932270|NCT05384002|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Patients who underwent MRI with confirmed pathology data (either biopsy or prostatectomy)
214932271|NCT06014697|DIAGNOSTIC_TEST|Optical Coherence Tomography|Assessment of the lesion with a non-invasive OCT scan according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
214330141|NCT00287911|DRUG|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
214330142|NCT00287911|DRUG|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
214330143|NCT00287911|RADIATION|brachytherapy|Some patients may also undergo brachytherapy
214330144|NCT00287911|RADIATION|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
214330145|NCT04206163|DIAGNOSTIC_TEST|68Ga-DOTA-TOC PET/CT|Somatostatin receptor imaging
214330146|NCT04206163|BIOLOGICAL|Blood sample|Analysis of inflammatory biomarkers
214330147|NCT06358677|DRUG|Topical Tretinoin|Topical tretinoin will be applied to one half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
214932272|NCT06014697|OTHER|Clinical assessment|Clinical assessment of the lesion by a dermatologist according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
214673473|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-III|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
214673474|NCT02740153|OTHER|No Intervention Given|
214673475|NCT03976856|DRUG|GB226|Geptanolimab, 210mg，q2w，ivgtt.
214673476|NCT03976856|DRUG|Fruquintinib|Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
214673477|NCT00045838|DRUG|VCR-HIVDNA006-00-VP|
214932273|NCT04289909|OTHER|Adaptive Optics Ophthalmoscopy (AOO)|AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)
214932274|NCT06492733|DEVICE|FastWire System - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
214932275|NCT04261413|DRUG|RS-0139|RS-0139 will be administered for the indication of solid tumors.
214932276|NCT02463344|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
214932277|NCT02783729|DRUG|Lemborexant|Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
214932278|NCT02783729|DRUG|Lemborexant|Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
214932279|NCT02783729|DRUG|Lemborexant-matched placebo|Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
214932280|NCT02783729|DRUG|Zolpidem tartrate|Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
214932281|NCT02783729|DRUG|Zolpidem-matched placebo|Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
214932282|NCT02693171|DRUG|Dinutuximab|Unituxin was administered along with cytokines according to the prescribing information
214932283|NCT03583060|BEHAVIORAL|Mindful Awareness in body-oriented therapy|teaches interoceptive awareness skills for self care
214932284|NCT05127304|DEVICE|Trelegy Ellipta|Trelegy Ellipta with Furoate/Umeclidinium/Vilanterol
214932285|NCT05127304|DEVICE|Stiolto Respimat|Stiolto Respimat with Tiotropium Bromide/Olodaterol
214932286|NCT05127304|DRUG|Furoate/Umeclidinium/Vilanterol|Furoate/Umeclidinium/Vilanterol
214932287|NCT05127304|DRUG|Tiotropium Bromide/Olodaterol|Tiotropium Bromide/Olodaterol
214932288|NCT02310425|DRUG|S. boulardii|50 mg/kg twice daily
214932289|NCT02310425|DRUG|Placebo|he control group (group C) did not receive S. boulardii (nor other probiotics)
214932290|NCT06666803|OTHER|FNB sampling|A supplementary FNB will be performed during the EUS procedure. Sample will be processed to obtain organoids and assess their morphological, proliferative and genetics characteristics.
214932291|NCT06666803|BIOLOGICAL|blood sampling|A blood withdrawal will be performed during the EUS procedure. Sample will be processed to assess organoids morphological, proliferative and genetics characteristics.
214932292|NCT03830957|DRUG|Ivabradine|7.5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 7.5 mg
214932293|NCT03830957|DRUG|Metoprolol|5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 5 mg
214932294|NCT03261726|DEVICE|MedEl Test Electrode Placer|This study uses a sterile dummy (i.e., not working) cochlear implant electrode inserted at the time of tumor removal to keep the inner ear from scarring or filling with bone. The significance of this to you is that if you ever become eligible for a cochlear implant sometime after surgery, it may be possible to remove the dummy and insert a functioning cochlear implant.
215071564|NCT01610557|DRUG|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
215071565|NCT00584090|DRUG|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
214673478|NCT00950352|DRUG|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
215071566|NCT00584090|DRUG|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
215071567|NCT01349361|PROCEDURE|Daylight mediated photodynamic therapy|
215071568|NCT01657890|DRUG|isavuconazole|oral
215071569|NCT01598558|DRUG|Cu-64 Rituximab|Up to 14 mCi, iv
215071570|NCT05529277|OTHER|Dementia Care Management|Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
215071571|NCT06239246|OTHER|Behavioral|"Psychotherapy: Cognitive-behavioral therapy (CBT), Internet-based cognitive-behavioral therapy (I-CBT), cognitive-behavioral therapy for insomnia (CBT-I), self-management education for heart failure, blended intervention; Drug treatment (cardiovascular drugs: aspirin, clopidogrel, ticagrelor, statins; psychiatric drugs: SSRIs, SNRIs, etc.);"
215071572|NCT01938924|DEVICE|GekoTM|electrical neuromuscular stimulation
215071573|NCT00592228|DEVICE|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~1. FFR group: if FFR\<0.75~2. Routine DES group"
214673479|NCT00950352|DRUG|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
214673480|NCT00445055|DRUG|Droperidol|Intravenous injection
214673481|NCT04493710|DIAGNOSTIC_TEST|Sarcopenia estimation|Analysis of pre-existing CT imaging
215071574|NCT06345482|DRUG|MHB039A|a bispecific antibody
215071575|NCT00484393|DRUG|tetracaine 4% gel|tetracaine applied prior to 1 injection
214673482|NCT06145490|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 250 mg, oral intake
214673483|NCT06145490|DRUG|Placebo|Placebo capsule, oral intake
214673484|NCT00306436|PROCEDURE|comprehensive management|
214932295|NCT06662526|DRUG|Trace lithium dose plus treatment as usual|Subjects assigned to the active arm will receive 50 mg of lithium per day, for five years
214932296|NCT06662526|DRUG|Placebo pill plus treatment as usual|Patients will receive a placebo pill plus treatment as usual by their clinical providers
215071576|NCT00484393|DRUG|Placebo|placebo applied prior to 1 injection
215071577|NCT00519376|DRUG|GW642444M|drug
215071578|NCT00519376|DRUG|GW642444H|drug
215071579|NCT00519376|DRUG|placebo|
215071580|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.
214330148|NCT06358677|OTHER|Placebo|A placebo (topical moisturizer) will be applied to the other half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
214673485|NCT01650779|BIOLOGICAL|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
214673486|NCT00577330|DIETARY_SUPPLEMENT|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
214673487|NCT03406949|BIOLOGICAL|obrindatamab|B7-H3 x CD3 DART protein
214673488|NCT03406949|BIOLOGICAL|retifanlimab|anti-PD-1 antibody
214673489|NCT02352246|PROCEDURE|Physical activity programs steady-state exercise (SSE) program|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
214932297|NCT01421186|DRUG|MOR03087 phase 1 dose escalation|"Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.~In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1."
214932298|NCT01421186|DRUG|MOR03087|MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
214932299|NCT01421186|DRUG|Dexamethasone|Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
214932300|NCT01421186|DRUG|Pomalidomide|Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
214932301|NCT01421186|DRUG|Lenalidomide|Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
214932302|NCT03858725|DRUG|D569 Tab.|D569 Tab. 1T single oral administration under fasting condition
214932303|NCT03858725|DRUG|CKD-374 5mg Tab.|CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
214932304|NCT01866657|DRUG|Vasoconstrictor Agents|cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
215071581|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate plus vegetables|"The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables."
215071582|NCT06475209|DRUG|Adebrelimab combined with Apatinib|Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Atezolizumab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Apatinib is given orally at a dosage of 250mg daily from day 1 to day 14, every 3 weeks, with a one-week hiatus following two weeks of continuous intake. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
215071583|NCT00346450|PROCEDURE|Cultivated conjunctival transplantation|
215071584|NCT00549263|DRUG|SB797620|
215071585|NCT01398332|DEVICE|Stent graft (EXCLUDER)|Endovascular repair
215071586|NCT00978055|DRUG|1: Liothyronine Sodium Tablets|"Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
215071587|NCT00978055|DRUG|2: Cytomel® Tablets|"Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
215071588|NCT05687812|DIETARY_SUPPLEMENT|Cephalaria Syriaca flour-added bread|100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH).
214330149|NCT05027581|DRUG|Bone marrow mesenchymal stem cells|The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.
214673490|NCT02352246|PROCEDURE|Physical activity programs high intensity intermittent exercise (HIIE)|
214673491|NCT02279329|OTHER|Hyperpolarized Helium MRI|Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
215071589|NCT02813096|DRUG|folfox4 chemotherapy regimen|"Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
215071590|NCT02813096|OTHER|Placebo|"Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
215071591|NCT04360512|PROCEDURE|Posteriorization of the talus|Three sets of a 30-s grade IV mobilization
215071592|NCT05430191|OTHER|Cascade Screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
215071593|NCT02845622|DIETARY_SUPPLEMENT|Hazelnut|This dietary supplement contains 30 g of hazelnut.
215071594|NCT02845622|DIETARY_SUPPLEMENT|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
215071595|NCT02845622|DIETARY_SUPPLEMENT|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
215071596|NCT02845622|DIETARY_SUPPLEMENT|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
215071597|NCT02845622|DIETARY_SUPPLEMENT|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
214330150|NCT05027581|DRUG|hyaluronic acid|(60 mg/3 mL hyaluronic acid \[HA\])
214330151|NCT03125265|OTHER|dietary intake of omega-3 and omega-6 polyunsaturated fatty acids|
214330152|NCT03660046|DRUG|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
214330153|NCT03660046|DRUG|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
214330154|NCT03660046|DRUG|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
214330155|NCT00136487|DRUG|Celecoxib|
214330156|NCT01947400|OTHER|Hospitalists|AIDET Training
214330157|NCT00420550|BEHAVIORAL|Relaxation Response using Guided Imagery|
214330158|NCT05850871|DRUG|CAZ/AVI plus Aztreonam|Samples of the patients will be examined such as the routine blood test, blood culture et al.
214330159|NCT05850871|OTHER|Conventional treatment|Conventional treatment
215071598|NCT06399510|OTHER|Sterofundin fluid therapy|Sterofundin is known as balanced solution which has similar electrolytes content as per human plasma.
215071599|NCT02039219|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
215071600|NCT02039219|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
214330160|NCT03819868|PROCEDURE|High cost|Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
214330161|NCT03819868|PROCEDURE|Low Cost|Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
214330162|NCT06015698|PROCEDURE|Laparoscopic tubal disconnection|"1. The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~2. The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~3. The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~4. Then, the tube is severed in the middle of the burn area with laparoscopic scissors~5. Ensure adequate hemostasis"
214330163|NCT06015698|PROCEDURE|Laparoscopic salpingectomy|"1. The tube will be removed from its anatomical attachements by progressive bipolar coagulation~2. Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~3. Removal of the tube through one of the ancillary ports using artery forceps~4. Ensure adequate hemostasis"
214330164|NCT00394797|PROCEDURE|mitral valve annuloplasty|
214330165|NCT05577182|DRUG|INCA32459-101|solution for infusion
214330166|NCT06129812|DRUG|Neoadjuvant treatment|Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
214330167|NCT06312098|OTHER|remote ischemic preconditioning (RIPC)|After induction of anesthesia, the paired RIPC group took the RIPC intervention on the upper arm in the lateral position. The RIPC intervention was applied using a manual cuff inflator, which consisted of three cycles of 5-min inflation of the blood pressure cuff (to 250 mmHg, or to 50 mmHg higher than the preoperative SBP), followed by 5-min deflation of the cuff. In the no-RIPC group, a blood pressure cuff was also applied on the upper arm but was not inflated.
214330168|NCT01699425|DEVICE|Ajust sling|
214330169|NCT01699425|DEVICE|Classical transobturator sling|Control group
214330170|NCT06053216|OTHER|Indirect calorimetry|Weekly indirect calorimetry measurements using the Q-NRG+ device will be used to guide energy delivery up to day 28 of hospital admission.
214330171|NCT06053216|OTHER|Indirect calorimetry (Standard care nutrition arm)|Weekly indirect calorimetry measurements using the Q-NRG+ device will be conducted up to day 28 of hospital admission. In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry measurements.
214330172|NCT00518804|BEHAVIORAL|Functional Behavioural Skills Group and Parent Training|
214932305|NCT01866657|OTHER|Head/neck repositioning|Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
214932306|NCT01866657|OTHER|Increase ETCO2|Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
215071601|NCT05447195|DRUG|CAN008|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.
215071602|NCT05447195|DRUG|Placebo|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
215071603|NCT00834470|DRUG|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
214330173|NCT00594828|DEVICE|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
214673492|NCT00598962|DRUG|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
214932307|NCT01866657|OTHER|IV fluid bolus|Administer IV fluids to increase preload and cardiac output
214932308|NCT01866657|DRUG|Additional anesthesia|By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
214932309|NCT01866657|BIOLOGICAL|RBC transfusion|By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
214932310|NCT01866657|DRUG|Increase FiO2|Increase FiO2 to improve oxygen delivery to tissue
214932311|NCT00301301|DRUG|Gemcitabine|
215071604|NCT04552210|DIAGNOSTIC_TEST|blood sample|Whole blood was collected on EDTA (1mg/ml) to prevent clotting and DNA degradation.
215071605|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous (SC) injection
215071606|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
215071607|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
215071608|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
214932312|NCT00301301|DRUG|Cisplatinum|
214932313|NCT00301301|DRUG|Rituximab|
215071609|NCT00616382|DRUG|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
215071610|NCT00616382|DRUG|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
214330174|NCT00594828|DEVICE|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
214330175|NCT01178229|OTHER|Physiotherapy|"The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.~The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.~Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.~All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them."
214330176|NCT00000410|PROCEDURE|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
214330177|NCT00000410|PROCEDURE|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
214330178|NCT00731328|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
214932314|NCT00621166|DRUG|generic lopinavir/ritonavir|"Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.~Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional."
214932315|NCT04528212|DRUG|Glimepiride Tablets|Glimepiride (4 mg) per Day
215071611|NCT00129701|PROCEDURE|Telephone consultation|
215071612|NCT03120260|OTHER|Diet|Intervention 'Diet+ short sleep versus normal sleep
214330179|NCT02939404|OTHER|Cold exposure|23.25 hours inside respiratory chamber with the temperature set to19°C
214330180|NCT02939404|OTHER|Normal temperature|23.25 hours inside respiratory chamber with the temperature set to 24°C
214330181|NCT02939404|OTHER|Fixed diet|A diet that matches the participant's caloric needs
214330182|NCT02939404|OTHER|Ad libitum diet|Participants can eat as much as they want
214330183|NCT02939404|OTHER|Fasting|Participants do not eat for 12 hours before and 24 hours in chamber
214330184|NCT04055129|OTHER|No interventions|Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity
214330185|NCT00647855|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
214330186|NCT00647855|DRUG|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
214673493|NCT00598962|DRUG|Rifabutin/rifampin|
214932316|NCT04528212|DRUG|glimepiride plus fenofibrate|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
214932317|NCT04528212|DRUG|glimepiride plus curcumin|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
215071613|NCT02750345|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
215071614|NCT02750345|DRUG|Nitisinone Baked Tablet|A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
215071615|NCT02750345|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered.
215071616|NCT05271032|DIAGNOSTIC_TEST|use of Trasnpulmonary termodiluetion technique|All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
215071617|NCT00149695|BEHAVIORAL|Weekly home delivery of milk products|
215071618|NCT02947178|PROCEDURE|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
215071619|NCT02947178|BEHAVIORAL|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
215071620|NCT02947178|BEHAVIORAL|Pill Count|Patient reported as needed (prn) pain medication usage
215071621|NCT02947178|DRUG|Bupivacaine|
215071622|NCT02947178|DRUG|Liposomal Bupivacaine|
215071623|NCT03892083|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, including children with cerebral palsy.
215071624|NCT01447485|DRUG|Valsartan (VAL489)|
215071625|NCT00849615|DRUG|Docetaxel|50mg/m2 qd15
215071626|NCT00849615|DRUG|5-Fluorouracil|2600mg/m2 qd15
215071627|NCT00849615|DRUG|Oxaliplatin|85mg/m2 qd15
215071628|NCT00849615|DRUG|folinic acid|200mg/m2 qd15
215071629|NCT02966093|DRUG|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
214932318|NCT05522322|OTHER|COPD scoring ststems in ICU|SAPS \& APACH scoring systems in COPD ICU pts
214673494|NCT00358189|DEVICE|Deep Brain Stimulation|
214932319|NCT06621836|DRUG|ICPB H|"ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group H will receive 10 ml 0.25 % bupivacaine he technique will be repeated on the opposite side"
214932320|NCT06621836|DRUG|ICPB - L|"ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group L will receive 10 ml 0.125% bupivacaine. The technique will be repeated on the opposite side"
214932321|NCT05274841|OTHER|Support of relatives|Screening of the support needs of relatives
214932322|NCT01185743|DRUG|olanzapine|olanzapine 10mg od + placebo od
214932323|NCT01185743|DRUG|ziprasidone|ziprasidone 40mg td
214932324|NCT01185743|DRUG|placebo|placebo td
214932325|NCT03634995|DRUG|BMS-986256|Specified dose on specified days
214932326|NCT03634995|OTHER|Placebo|Specified dose on specified days
214932327|NCT01095900|PROCEDURE|conservative lateral internal sphincterotomy|
214932328|NCT01095900|PROCEDURE|Intra-sphincteric Botulinum-toxin injection|
214932329|NCT05600270|DEVICE|Angled guidewire|Cannulation of the common bile duct using an angled-tip guidewire during ERCP
214932330|NCT05600270|DEVICE|Straight guidewire|Cannulation of the common bile duct using an straight-tip guidewire during ERCP
214932331|NCT03107689|OTHER|administration of intravenous lipid emulsion|all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients
214932332|NCT02126267|PROCEDURE|Scaling and root planing|Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
214932333|NCT02126267|PROCEDURE|Full mouth disinfection|Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
214932334|NCT02126267|DRUG|Chlorhexidine gel and gluconate|application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)
214932335|NCT02126267|DRUG|Chlorhexidine gluconate solution|Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.
214932336|NCT02126267|DRUG|Azithromycin|Azithromycin (500 mg) once daily for 3 consecutive days.
214932337|NCT03777332|DRUG|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
214932338|NCT06684730|PROCEDURE|Hand Function Assessment Scales|The Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), The Box and Block Test (BBT) and Action Research Arm Test (ARAT) will be used as hand function assessment scales.
214932339|NCT06684730|OTHER|Prosthesis Satisfaction Scale|The Quebec Assistive Technology User Satisfaction Assessment (Q-YTKMD) Questionnaire will be used.
214932340|NCT06684730|OTHER|Quality of Life Scale|5Q-5D-5L will be used as quality of life scale.
214932341|NCT06684730|PROCEDURE|Kinematic Analysis|Kinematic analysis of shoulder abduction, elbow flexion, and cervical flexion will be performed during simulated tasks of drinking water from a glass and filling glass of water.
214932342|NCT06684730|PROCEDURE|Parkour Completion Time|A 10-item daily living activities parkour will be prepared for the participants. During the parkour, the participant will be given the following tasks: opening and closing 10 jar lids, slicing a 20cm cylindrical dough into 10 pieces, simulating drinking soup from a bowl 15 times with a spoon (standard bowl 150 ml, standard tablespoon 10 ml), simulating eating meatballs from a plate with a fork 10 times (approximately 6-10 meatballs per serving), simulating pouring water from a pitcher into a glass 10 times, simulating drinking water from a glass 10 times, simulating brushing teeth for 2 minutes, opening 10 clothespins attached to the edge of a cardboard box and attaching them to the other side, simulating opening and closing a zipper, and putting on shoes and tying shoelaces. The course completion time will be recorded.
214932343|NCT06684730|PROCEDURE|Fatigue Scale|A pre- and post-parkour will be employed, including a 5-point Likert scale for fatigue assesment, hand function assessment scales and kinematic analysis to participants. The results before and after the parkour will be compared.
214932344|NCT03374592|RADIATION|Volumetric Intensity-Modulated Arc Therapy|Advanced radiotherapy technique
214932345|NCT03374592|RADIATION|Conventional Radiotherapy|Conventional radiotherapy technique
214932346|NCT06269380|PROCEDURE|Esophagogastroduodenoscopy|During the procedure, endoscopic examination of the upper gastrointestinal tract was made. Biopsy sampling can be made during procedure if endoscopist deemed necessary.
214932347|NCT06269380|PROCEDURE|Endoscopic biopsy sampling|The obtaining of biopsy samples for control purposes despite the absence of endoscopic pathology during esophagogastroduodenoscopy.
214932348|NCT04360174|DRUG|OTX-TIC|OTX-TIC implant is injection in the anterior chamber of the eye
214932349|NCT02288091|DRUG|Inosine|Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
214673495|NCT02280681|OTHER|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
214330187|NCT03842787|OTHER|Biological analysis|"Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy"
214932350|NCT04081025|OTHER|EpiWux|A cross-sectional and longitudinal study including a questionnaire and a clinical examination
214932351|NCT00901017|DEVICE|Straumann BoneCeramic|Bone augmentation procedure performed with Bone Ceramic
214932352|NCT00901017|DEVICE|Bio-Oss|Bone Augmentation procedure performed with Bio Oss
214932353|NCT04021121|DRUG|LZD|LZD 1200 mg daily
214932354|NCT04021121|DRUG|High dose RIF|RIF 35 mg/kg/day
215071630|NCT02966093|DRUG|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
214330188|NCT04539028|PROCEDURE|Emergency Abdominal surgery|Emergency Abdominal surgery
214330189|NCT04212416|DRUG|Leflunomide|Given PO
214330190|NCT04871607|BIOLOGICAL|Basiliximab|Given IV
214330191|NCT04871607|DRUG|Carmustine|Given IV
214330192|NCT04871607|DRUG|Cytarabine|Given IV
214932355|NCT04021121|DRUG|Standard dose RIF|RIF 10 mg/kg/day
214932356|NCT00676312|DRUG|PTH134|
215071631|NCT03088436|DEVICE|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
215071632|NCT04477382|DIETARY_SUPPLEMENT|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.|Subjects suffering from house dust mite (HDM) allergic rhinoconjunctivitis who are reacting positively to chamber exposure with HDM are reevaluated in the exposure chamber 3 months after taking food supplements.
215071633|NCT04983836|PROCEDURE|Serratus anesthesia technique|locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml
215071634|NCT04983836|PROCEDURE|Paravertebral anesthesia technique|Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
215071635|NCT03785860|OTHER|Dietary Fiber|Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
214330193|NCT04871607|DRUG|Etoposide|Given IV
214330194|NCT04871607|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Given via infusion
214330195|NCT04871607|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC or IV
214330196|NCT04871607|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
214673496|NCT03828838|DRUG|Lu-177 PSMA-617|Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)
214673497|NCT06474741|BEHAVIORAL|in-app notification|Parents will receive bi-weekly prompts in a baby monitor app to change infant's orientation within crib, allow for tummy time several times per day, alternate the side from which infants are fed, alternate the side the infant faces during carrying, and in general note any side preferences of the infant so that positioning can assist in symmetry.
214330197|NCT06460168|OTHER|Mulligan(MWM) MobilizationTechnique|"Mulligan Mobilization program in MWM , a therapist-applied pain free accessory gliding force combined with active movement.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets."
214932357|NCT02891434|DEVICE|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
214932358|NCT02891434|DEVICE|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
214932359|NCT02891434|DEVICE|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
214932360|NCT02979912|BIOLOGICAL|Platelet Lysate|Eye drops of Platelet Lysate
214932361|NCT05660005|OTHER|Muscle Stretching|Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.
215071636|NCT03785860|OTHER|Placebo|Placebo will be given in a powder form to mix with a beverage of one's choice.
214330198|NCT06460168|OTHER|Maitland Mobilization technique|"will receive (Maitland mobilization program manipulative physiotherapy in which chain of oscillatory joint mobilization grades l-lV based on the pathological limit of tissue are used) In this, the exercises will be performed in 3 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session)"
214330199|NCT06350864|DEVICE|High-flow nasal cannula (HFNC)|high flow cartridge and adult size nasal cannula: (flow range: 5-40L/minute, oxygen concentration (FiO2): 21-100%, temperature range: 33-39◦ C, humidity minimum of 12mg/liter)
214932362|NCT05660005|OTHER|Self Myofascial Release|The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).
215071637|NCT04850976|DEVICE|Endotracheal intubation|Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation
214330200|NCT06350864|DEVICE|Conventional nasal oxygen therapy (COT)|Adult size, single use nasal cannula
214330201|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including gastroscopy|Upper gastrointestinal endoscopy (UGE) will be either diagnostic and/or therapeutic including variceal band ligation, endoscopic hemostasis as injection of bleeding peptic ulcers with adrenaline or bleeders control via either argon plasma coagulation (APC) or heater probe coagulation.
214932363|NCT05660005|OTHER|home exercises|The exercise brochure consists of 5 different exercises that include isometric and isotonic strengthening of the hip and surrounding muscles. Isometric contraction of gluteus maximus, hip march, external/internal rotation of hips with theraband, 4 sided straight leg raises were the exercises and prescribed 5 days a week, 10 repetitions, 3 sets. All participants were advised to use analgesics determined by the physician in case of unbearable pain and to apply a hot pack for 10-20 minutes before sessions.
214932364|NCT00819598|PROCEDURE|BLOOD PRESSURE MEASURMENT|Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.
214330202|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including Endoscopic ultrasound (EUA)|Upper gastrointestinal endoscopy (UGE) will be diagnostic
214330203|NCT01987323|DRUG|Subconjunctival injection of liposomal latanoprost|
214330204|NCT05136729|BEHAVIORAL|Self-Natural Posture Exercise training|SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
214673498|NCT03666143|DRUG|Sitravatinib|Administered orally as a capsule
214932365|NCT00819598|PROCEDURE|BLOOD PRESSURE MEASUREMENT|Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
214932366|NCT06480721|OTHER|Clinical management based on the index MRI and an additional [¹⁸F] FET PET scan|"Patients in the investigational arm will undergo the extra FET-PET scan, with use of the O-(2-~¹⁸F-fluoroethyl)-L-tyrosine (¹⁸F-FET) tracer. FET-PET scanning will be performed according to the joint European Association of Nuclear Medicine (EANM)/European Association of Neuro-Oncology (EANO)/Response Assessment in Neuro-oncology (RANO) guidelines. In most patients, a static scan (20-40 minutes post-injection) will performed. If the logistics of the research site allow for a dynamic scan (0-60 minutes post-injection), this will be performed. Interpretation will be done by an experienced nuclear medicine physician from the local center according to current European guidelines. Central review will be performed by a panel of nuclear medicine physicians from the study team. Clinical management is based on the index MRI and this additional \[¹⁸F\] FET PET scan."
214932367|NCT00832845|BEHAVIORAL|CBSST plus treatment as usual|Patients will receive CBSST in addition to their regular treatment for 36 weeks.
214932368|NCT00832845|BEHAVIORAL|Treatment as usual (TAU)|Patients will receive their regular treatment for 36 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians.
214932369|NCT06666634|DRUG|Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan|Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
214932370|NCT05542706|OTHER|Accompanying caregivers by paramedical team|At each study visit (baseline, one week after hospital discharge, 4-8 weeks after surgery, 8-12 weeks after surgery and 16-20 weeks after surgery), the paramedical team have a dedicated meeting with the caregiver of the patient (at hospital or remote) and teach them the care procedures needed in accompanying the patient and the evaluate the learning progress. The training is adapted to each caregiver, according to his/her motivation and his/her ability. The goal is to have the training regarding the enteral nutrition, prevention of dehydration, pain management.
214932371|NCT03451097|RADIATION|echocardiography|cardiac ultrasound
214932372|NCT05969964|BEHAVIORAL|Avoid second resection after initial complete resection|Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins won't undergo second look as endorsed by the guidelines.
214932373|NCT06444269|RADIATION|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
215071638|NCT02650128|DEVICE|Shockwave Coronary Rx Lithoplasty® System|The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
215071639|NCT02553980|BEHAVIORAL|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
215071640|NCT02553980|OTHER|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
215071641|NCT01385111|PROCEDURE|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
215071642|NCT01385111|PROCEDURE|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
214330205|NCT01552538|DEVICE|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
214330206|NCT02665728|DRUG|BLI400 Laxative|
214673499|NCT03666143|DRUG|Tislelizumab|Administered intravenously
214330207|NCT00375193|DRUG|Amrubicin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
214330208|NCT01178970|BEHAVIORAL|Resistance training|
214673500|NCT01489787|PROCEDURE|HIFU|"The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~* One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~* One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient."
214330209|NCT02028299|PROCEDURE|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
214330210|NCT02047110|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
214330211|NCT02047110|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
214330212|NCT00191893|DRUG|teriparatide|
214330213|NCT05219136|OTHER|Modified Fasting Group|a new fasting protocol is applied to subjects.
214932374|NCT06444269|DRUG|microbubble CEUS Contrast Enhanced Ultrasound (CEUS)|Microbubble Contrast non-FDA approved for route of administration
214932375|NCT00214149|RADIATION|brachytherapy|breast brachytherapy to 34 Gy
214932376|NCT01295463|OTHER|questionnaire administration|
214932377|NCT01295463|OTHER|study of socioeconomic and demographic variables|
214932378|NCT01295463|PROCEDURE|assessment of therapy complications|
214932379|NCT01295463|PROCEDURE|fertility assessment and management|
214932380|NCT01295463|PROCEDURE|psychosocial assessment and care|
214932381|NCT01295463|PROCEDURE|quality-of-life assessment|
215071643|NCT03006029|DRUG|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
215071644|NCT00635739|DIETARY_SUPPLEMENT|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
214932382|NCT01665222|DRUG|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
214932383|NCT02315495|DRUG|Saxagliptin|
214932384|NCT02315495|DRUG|Acarbose|
214932385|NCT01961895|PROCEDURE|Continuous lumbar plexus (LP) block analgesia|
214932386|NCT01961895|DRUG|Intravenous patient-controlled analgesia|
214932387|NCT01323010|DRUG|Albuterol - Experimental|The Experimental group will receive higher doses of albuterol in the first hour: 900 mcg (up to 15 kg), 1200 mcg (\> 15 to 20 kg), 1500 mcg (\> 20 to 25 kg) and 1800 mcg (\> 25 kg).
214932388|NCT01323010|DRUG|Albuterol - Control|The Control group will receive the following doses of albuterol in the first hour 600 mcg (up to 25 kg) or 1200 mcg (\> 25 kg)
214932389|NCT02538887|DEVICE|Radio Frequency Surgical Detection|
214932390|NCT00978250|DRUG|5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.
214932391|NCT00987870|DRUG|BFH772|
214932392|NCT00987870|DRUG|Placebo|
214932393|NCT00987870|DRUG|BFH772|
214932394|NCT00987870|DRUG|Placebo|
214932395|NCT00987870|DRUG|calcipotriol/betamethasone|
214932396|NCT01330394|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
215071645|NCT00635739|DIETARY_SUPPLEMENT|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
215071646|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
215071647|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|5.0 grams of PGX
215071648|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|0 grams of PGX
215071649|NCT05250050|DRUG|Esomeprazole|20mg bid
215071650|NCT05250050|DRUG|Bismuth potassium citrate|0.6g bid
215071651|NCT05250050|DRUG|Metronidazole|0.4g qid
215071652|NCT05250050|DRUG|Clarithromycin|0.5g bid
215071653|NCT05250050|DRUG|Levofloxacin|0.5g qd
215071654|NCT05250050|DRUG|Amoxicillin|1g bid
215071655|NCT05250050|DRUG|Tetracycline|0.5g qid
215071656|NCT03456791|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
215071657|NCT06038526|PROCEDURE|Biospecimen Collection|Undergo buccal, nasal, and blood sample collection
215071658|NCT06038526|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
215071659|NCT06038526|BIOLOGICAL|Canakinumab|Given SC
215071660|NCT06038526|PROCEDURE|Carbon Monoxide Measurement|Undergo CO testing
215071661|NCT06038526|OTHER|Survey Administration|Ancillary studies
215071662|NCT00608023|DRUG|Tesamorelin|
215071663|NCT00608023|DRUG|Placebo for Tesamorelin|
215071664|NCT06428565|DIAGNOSTIC_TEST|Low-level laser therapy (LLLT) or cold laser therapy|Low-level laser therapy (LLLT) or cold laser therapy
215071665|NCT06159881|PROCEDURE|Corneal Cross Linking|Total fluence adapted to thinnest point pachymetry
215071666|NCT03069287|BEHAVIORAL|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
215071667|NCT01432340|BIOLOGICAL|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
215071668|NCT02975999|DRUG|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
214330214|NCT05219136|OTHER|Conventional Fasting Group|a conventional fasting protocol is applied to subjects.
214673501|NCT01489787|PROCEDURE|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
214330215|NCT03150342|DIAGNOSTIC_TEST|myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201
214330216|NCT05304559|DRUG|S-Ketamine|S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
214330217|NCT05304559|DEVICE|Continuous iliac fascia space block|After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
214932397|NCT02047656|DRUG|LFF269|LFF269 capsules twice daily (b.i.d)
214932398|NCT02047656|DRUG|Placebo to LFF269|Placebo LFF269 b.i.d for 10 days in healthy volunteers
214932399|NCT02222233|DRUG|BI 671800 HEA delayed release (enteric coated) tablet|
214330218|NCT05304559|DRUG|Normal saline|Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
215071669|NCT02975999|DRUG|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
215071670|NCT05128786|BIOLOGICAL|CCT301-38|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT301-38. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single or multiple dose of CCT301-38 via intravenous injection.
215071671|NCT00648427|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
215071672|NCT00648427|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
214330219|NCT06021236|BEHAVIORAL|mindfulness-based intervention|Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing
214330220|NCT06021236|OTHER|CIED procedure routine care|CIED procedure home care guidance
214330221|NCT02630771|PROCEDURE|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
214330222|NCT04006158|DEVICE|LED bed|Low risk FDA cleared full body LED bed
214330223|NCT02247349|BIOLOGICAL|BMS-986012 (anti-fucosyl-GM1)|
214330224|NCT02247349|BIOLOGICAL|Nivolumab|
214330225|NCT01350206|PROCEDURE|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
214330226|NCT01350206|PROCEDURE|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
214330227|NCT02275286|DRUG|Trabectedin|"Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery."
214330228|NCT02275286|RADIATION|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
214330229|NCT02211833|DRUG|BI 2536|
214330230|NCT02211833|DRUG|Pemetrexed|
215071673|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
215071674|NCT02342717|DRUG|Itraconazole|multiple doses of Itraconazole capsules
215071675|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
215071676|NCT06303375|OTHER|Kinesio taping|"Kinesiotaping using inhibition technique in tight muscles and facilitation technique in weak muscles for LCS. Treatment sessions 3 days per week for almost 04 weeks.~10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
214330231|NCT04166305|GENETIC|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
214330232|NCT01248117|DRUG|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
214330233|NCT00821626|DEVICE|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
214330234|NCT00821626|OTHER|Control|No rapid flu test
214330235|NCT01271543|DEVICE|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
214330236|NCT01959581|DEVICE|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
214330237|NCT06341465|OTHER|Just Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
214330238|NCT06341465|OTHER|Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
214330239|NCT06341465|OTHER|Taping|Kinesiological taping will be applied as a tone enhancer or tone reducer according to the the concave and convex sides of the curve.
215071677|NCT06303375|OTHER|Conventional physical therapy|"10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
215071678|NCT04924530|DIETARY_SUPPLEMENT|Maltodextrin|Co-ingestion of maltodextrin with a high fat meal
215071679|NCT04924530|DIETARY_SUPPLEMENT|Sucrose|Co-ingestion of sucrose with a high fat meal
215071680|NCT04924530|DIETARY_SUPPLEMENT|Lactose|Co-ingestion of lactose with a high fat meal
215071681|NCT04274049|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
214932400|NCT02222233|DRUG|BI 671800 HEA solution|
215071682|NCT04274049|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
215071683|NCT06837935|DEVICE|Aluminum Foil Reflector|"The hyperbilirubinemia newborns will receive phototherapy with an Aluminum Foil Reflector around an incubator. The aluminum foil reflector, sewn inside a cloth that is 30 cm long and 3 mm thick, will be hung from the three sides of the phototherapy unit. The reflector will cover the whole incubator except for the foot part to allow infant observation during treatment. While receiving phototherapy, the lights will be continuously on, except during feeding, physical examination, and blood taking. All participants will dress only in nappies and eye masks during phototherapy treatment.~Serum bilirubin will be taken every 24 hours until phototherapy can be stopped according to AAP guidelines."
215071684|NCT02172573|DRUG|Pramipexole|
214330240|NCT02268097|PROCEDURE|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
214330241|NCT02268097|PROCEDURE|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
214330242|NCT04454385|DIAGNOSTIC_TEST|Patients with well controlled asthma|"Patients with well controlled asthma~The following parameters are to be evaluated:~Blood eosinophils FeNO Findings on lung function test"
214330243|NCT01228240|DRUG|Metformin|
214330244|NCT04054648|OTHER|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
214330245|NCT00870311|DRUG|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
214330246|NCT04054414|DRUG|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
214330247|NCT04054414|DRUG|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
214330248|NCT03808285|OTHER|mandibular osteomylitis|
214932401|NCT02222233|DRUG|BI 671800 HEA particulate|
214330249|NCT05000996|PROCEDURE|Bariatric Surgery|Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
214330250|NCT04833166|DEVICE|CMAC D-blade videolaryngoscope with full or partial glottic view|Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
214330251|NCT02003625|DRUG|GCSF|
214330252|NCT02003625|DRUG|meloxicam|
214330253|NCT02003625|DRUG|Placebo|
214330254|NCT04620148|DRUG|TAK-242|TAK-242 concentrate solution 80 mg/mL for dilution and infusion
215071685|NCT02172573|DRUG|Bromocriptine|
214932402|NCT04064970|BEHAVIORAL|patient acceptable symptom state (PASS)|The Severity Index for Urinary Incontinence, which documents incontinence frequency and severity, pelvic floor distress, patient global impression of severity and improvement, physical function, depression, sleep disturbance, anxiety, global health and ability to participate in social roles and activities.
214932403|NCT03141229|BEHAVIORAL|Mindfulness based stress reduction|
214932404|NCT02029989|DEVICE|Glucose and lipids|"Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids"
214932405|NCT02029989|DEVICE|Glycosylated Hemoglobin A1c|"Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c"
214932406|NCT02029989|DEVICE|Blood Pressure and Heart Rate|"Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate"
214932407|NCT02029989|DEVICE|Body mass index|Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
215071686|NCT02172573|DRUG|Placebo pramipexole|
215071687|NCT02172573|DRUG|Placebo bromocriptine|
214330255|NCT04620148|DRUG|Placebo|Matching placebo concentrate solution
214330256|NCT01140425|DRUG|PF-00232798|600 mg oral solution once daily x 7 days
214330257|NCT01140425|DRUG|PF-00232798|300 mg oral solution once daily x 7 days
214330258|NCT01140425|DRUG|Placebo|Oral solution once daily x 7 days
214330259|NCT01140425|DRUG|Moxifloxacin|400 mg tablet single dose
214330260|NCT03773757|BEHAVIORAL|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
214330261|NCT05138939|OTHER|Red wine A|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
214330262|NCT05138939|OTHER|Red wine B|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
214330263|NCT05138939|OTHER|Control|8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
214330264|NCT02617316|OTHER|Barefoot|barefoot running test was 20 minutes.
214932408|NCT02029989|DEVICE|Waist and Hip circumference|"Measurement for Central Obesity~Waist and Hip circumference"
214932409|NCT02029989|BEHAVIORAL|Comprehensive Medication Management|Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
214932410|NCT04351373|DRUG|Fluorescein Sodium|Intravenous administration 1 mg/kg initial dosing if insufficient additional doses of 1 mg/kg may be administered.
214932411|NCT04351373|DEVICE|YELLOW560 filter|Integrated fluorescence module serves to make fluorescent areas visible to assist in visualizing tumor during the resection.
214932412|NCT01075230|PROCEDURE|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
214932413|NCT04537910|DRUG|LY3819253|Administered SC.
215071688|NCT01591837|BIOLOGICAL|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
215071689|NCT06552793|BIOLOGICAL|autogenous partially demineralized dentin graft|tooth cleaning : form decay, tartar, soft tissue debris, fillings, cement then cut into fragments (5×5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). A disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.The decontamination of the granules will take place through UVA rays and ultrasounds, with temperature variations always lower than 43 ◦C to avoid damage to proteins. After 25 min, particle graft biomaterials will be obtained. The particles size will range from 815 µm with peaks up to 1110 µm.
215071690|NCT06552793|BIOLOGICAL|Xenograft|Cortico-cancallous Bovine powder
214932414|NCT04537910|DRUG|Placebo|Administered SC.
214932415|NCT03581734|BIOLOGICAL|Oral Polio Vaccine|OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
214932416|NCT03581734|BIOLOGICAL|Oral Cholera Vaccine|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
214932417|NCT05685134|DEVICE|Radiofrequency catheter ablation|Radiofrequency application via catheter to burn the electroanatomic substrate implicated in Brugada syndrome
214932418|NCT05685134|DEVICE|Sham procedure|Venous and epicardial punctions, catheter insertions, programmed electrical stimulation and electroanatomical mapping
214932419|NCT02683057|OTHER|International Physical Activity Questionnaire (IPAQ)|all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
214932420|NCT01463592|BIOLOGICAL|RENESSANS , INTERFERON ALPHA 2b, Ribavirin|ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
215071691|NCT05294289|OTHER|Alpelisib|There was no treatment allocation. Patients administered alpelisib by prescription that were involved in Novartis' alpelisib managed access program were enrolled
215071692|NCT05925452|DRUG|GenaKumab|GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w
215071693|NCT06339502|BEHAVIORAL|Jigsaw Technique|The jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
215071694|NCT04022226|DRUG|Ketamine|Induction agent that suppresses infra-slow waves
215071695|NCT04022226|DRUG|Methohexital|Induction agent that does not suppress infra-slow waves
214932421|NCT01463592|DRUG|Interferon Alfa-2b AND RIBAVIRIN|INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
215071696|NCT05894304|DEVICE|Suspension system|suspended from the handles of the straps by either their hands or feet while the non-suspended pair of extremities are in contact with the ground leading to muscle activation due to unstable base of support
215071697|NCT05894304|OTHER|Scapular training exercises|Scapular muscle strength by resistance
214932422|NCT01463592|BIOLOGICAL|RENESSANS|ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
214932423|NCT03091036|OTHER|Proactive healthcare intervention|There is an intervention in the coordination of health resources, and monitoring readmissions and know the benefit in total cost of care in 4 month.
214932424|NCT01528397|PROCEDURE|pedicled nerve graft|A pedicled nerve graft harvested from the dorsal branch of the PDN can be used for reconstruction of such defects. The graft is based on the second dorsal metacarpal artery.
214932425|NCT06630078|DEVICE|Wevosys acoustic analysis|Recording of voice signal of subjects enrolled
215071698|NCT03130439|DRUG|Abemaciclib|Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
215071699|NCT05775549|OTHER|None (Observational Study)|Not Applicable since observational study
215071700|NCT02509468|DRUG|Sirolimus|"* each patient will be followed during a 12-month-period~* each patient will start by an observational period and end being treated by sirolimus~* at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
214330265|NCT02617316|OTHER|In shoes|In shoes test was 20 minutes.
214932426|NCT05497388|OTHER|Serious Game|using Serious Game for HCV education
214932427|NCT06387706|OTHER|Gamified web-based pain management Program|"Gamified Program Development: The project aims to create a Gamified web-based pain management Program (GAP) tailored for older adults with chronic pain, enhancing engagement through gaming elements.~Inclusive Design Process: Older adults with chronic pain will actively participate in developing GAP, providing valuable feedback throughout the process.~Pilot Study Design: A pre and post study design will be employed, with a small pilot group of 4 participants to offer diverse perspectives in the program's development.~Educational Content \& Activities: GAP will feature interactive educational content on pain effects, medication, non-drug treatments, and exercises, delivered through a mobile-friendly web platform."
214330266|NCT00177424|DRUG|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
214330267|NCT00177424|DRUG|Placebo|matching placebo tablets
214330268|NCT00907283|DRUG|Deferiprone|15 mg/Kg/twice for 1 year
214330269|NCT01109316|DRUG|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
214330270|NCT01109316|DRUG|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
214330271|NCT01109316|DRUG|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
214932428|NCT02071810|DRUG|BIA 9-1067|
214932429|NCT02071810|DRUG|Placebo|
214932430|NCT03424902|DIAGNOSTIC_TEST|cardiac computed tomography and cardiac catheterization|assesment of certain predictors with CT and fluroscopy for paravalvular leakage
214932431|NCT03809767|DRUG|CS1003 monoclonal antibody|CS1003 will be administered intravenously every 3 weeks.
214932432|NCT00471718|DRUG|ABT-751|"Phase I:~Cohort \| Number of Patients \|Dose (mg) ABT-751 (BID)~* -1 \| 3-6 \|100 mg BID~* 1 \| 3-6 \|125 mg BID~* 2 \| 3-6 \|150 mg BID~* 3 \| 3-6 \|175 mg BID~* 4 \| 3-6 \|200 mg BID~Phase II:~Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle"
214932433|NCT05566834|DRUG|Minnelide|at the MTD dose level established for monotherapy or combination to confirm safety. With a sample of 12 patients, the probability is \> 80% that a serious adverse event with at least a 16% incidence will be detected.
214932434|NCT02224820|BIOLOGICAL|IdeS|Doses are administered in ascending doses
214932435|NCT01117675|OTHER|Virtual Hospital|A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients
214932436|NCT01117675|OTHER|Standard of Care|Standard of Care
214932437|NCT02501954|DRUG|Cisplatin|Given IV
214932438|NCT02501954|DRUG|Carboplatin|Given IV
214330272|NCT04955106|DIAGNOSTIC_TEST|SEM Scanner|They will perform 2 sets of 3 measures (1 on sacrum, 1 on the right heel and 1 on the left heel)for each patients
214330273|NCT01087424|DRUG|R mini CHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
214330274|NCT01936259|DEVICE|Mini Stem|The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments.
214330275|NCT01936259|DEVICE|Nano|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
214330276|NCT05354570|RADIATION|Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
214330277|NCT02269891|DIETARY_SUPPLEMENT|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
214330278|NCT02269891|OTHER|Placebo|
214330279|NCT06027749|DEVICE|Epitel's™ Remote EEG Monitoring System's (REMI™)|Ambulatory electroencephalography (EEG) monitoring
214330280|NCT00006482|DRUG|cisplatin|
214330281|NCT00006482|DRUG|gemcitabine hydrochloride|
214932439|NCT02501954|DRUG|Paclitaxel|Given IV
214932440|NCT02501954|RADIATION|Radiation Therapy|Undergo Radiation Therapy
214932441|NCT06523075|OTHER|Tumor Necrosis Factor|This study is a retrospective observational study, with Tumor Necrosis Factor being one of the exposure factors under investigation.
214330282|NCT02566915|DEVICE|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
214330283|NCT01721590|DRUG|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
214330284|NCT01721590|DRUG|placebo|3 capsules/time，3times/day for 1 year
214330285|NCT01404468|DEVICE|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
214330286|NCT01404468|OTHER|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
214330287|NCT01404468|DEVICE|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
214330288|NCT01302392|DRUG|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \[Days 1, 2, 8, 9, 15, 16\] for individual subjects).
214330289|NCT01302392|DRUG|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
214330290|NCT02224365|DIETARY_SUPPLEMENT|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
214330291|NCT02224365|DIETARY_SUPPLEMENT|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
214330292|NCT00670228|DRUG|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
214330293|NCT00670228|DRUG|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
214330294|NCT00670228|DRUG|Standard Therapy|Standard insulin therapy titrated to blood sugar control
214330295|NCT05609409|BEHAVIORAL|FlexED|Intervention consists of eight 20-30 minute sessions of a digital intervention based on Acceptance and Commitment Therapy (ACT). Participants learn skills of body image flexibility by following an avatar through a story line and completing interactive exercises.
214330296|NCT06163573|BIOLOGICAL|N-TEC|Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.
214330297|NCT06163573|BIOLOGICAL|Platelet rich plasma|"Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks.~Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks."
214330298|NCT02013323|DRUG|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
214330299|NCT02013323|DRUG|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
214932442|NCT06523075|OTHER|Interleukin-1β|This study is a retrospective observational study, with Interleukin-1β being one of the exposure factors under investigation.
214932443|NCT06523075|OTHER|Interleukin-12|This study is a retrospective observational study, with Interleukin-12 being one of the exposure factors under investigation.
214932444|NCT06523075|OTHER|Interleukin-18|This study is a retrospective observational study, with Interleukin-18 being one of the exposure factors under investigation.
214932445|NCT06523075|OTHER|Complement C3|This study is a retrospective observational study, with Complement C3 being one of the exposure factors under investigation.
214932446|NCT06523075|OTHER|Complement C5|This study is a retrospective observational study, with Complement C5 being one of the exposure factors under investigation.
214330300|NCT05071417|DRUG|Semaglutide|Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
214330301|NCT01702233|DRUG|Traumeel S inj|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
215071701|NCT04536480|BEHAVIORAL|Time Limited Eating|The TLE intervention arm will involve instructing participants to consume their usual kind and amount of food and beverages (all calories) within a pre-specified 8-hour period, fasting for the remaining 16-hours. They will be free to divide their food and beverage intake into as many meals or snacks as desired during the 8-hour period. Participants will be allowed to consume non-caloric beverages (water, tea, coffee) during the fasting period. No energy restriction will be required.
214932447|NCT03069261|DEVICE|Indocyanine green angiography|
214932448|NCT04278651|DRUG|Ferumoxytol|510mg infusion x 2 doses 3-8 days apart
214932449|NCT04278651|DRUG|Ferrous Sulfate|325mg oral twice daily
214932450|NCT01597375|DRUG|Placebo Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
214932451|NCT01597375|DRUG|Prasugrel Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
214932452|NCT02958280|BEHAVIORAL|Fit&Sober App|Fit\&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.
214932453|NCT02958280|BEHAVIORAL|Brief Advice|Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
214932454|NCT03867487|DRUG|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
214932455|NCT03867487|DRUG|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
214932456|NCT02591095|DRUG|ABT-263|
214932457|NCT04323033|DEVICE|PERS stent|"PERS® is a cobalt-chromium stent, made of cobalt-chromium alloy with drug (Sirolimus) and biodegradable polymer controlling drug elution.~The length of the stent is selected to cover the treated lesion with a margin of 5 mm proximal and distal, while the diameter of the stent will be selected based on the QVA measurement (balloon to vessel ratio 1:1)."
214932458|NCT04323033|DEVICE|NEPTUN C stent|Neptun C is balloon-expanding cobalt-chromium stent.
214330302|NCT01702233|DRUG|Fortecortin/Dexamethasone 8 mg/2 ml inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
214330303|NCT01702233|DRUG|Saline inj|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
214330304|NCT03396783|BIOLOGICAL|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
214932459|NCT02438605|DEVICE|Nellix|
214932460|NCT05516524|DIAGNOSTIC_TEST|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
214932461|NCT05516524|DIAGNOSTIC_TEST|PSG|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
214932462|NCT02059668|BIOLOGICAL|Biomarker analyses head & neck cancer tissue, blood specimen|For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
214932463|NCT05674123|PROCEDURE|Colonoscopy|Undergo colonoscopy
214932464|NCT05674123|PROCEDURE|Endoscopic Ultrasound|Undergo rectal endoscopic ultrasound
214932465|NCT05674123|OTHER|Medical Chart Review|Ancillary studies
214932466|NCT05674123|OTHER|Medical Device Usage and Evaluation|Undergo resection with the Flex Robotic System
214932467|NCT05674123|PROCEDURE|Resection|Undergo resection with the Flex Robotic System
214330305|NCT03396783|OTHER|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
214330306|NCT04410575|OTHER|Standard Pharmacist Care|Standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians)
214330307|NCT04410575|OTHER|Reviewed Questionnaire tool results with participant|Pharmacist reviews results of the patient-administered PHQ-9 and/or GAD-7 questionnaire tool, at the scheduled follow-up appointment
214330308|NCT04410575|OTHER|Patient Clinical Assessment|Pharmacist conducts clinical assessment of the participant's major depressive disorder and/or generalized anxiety, which can include: appearance, current mood, sleeping patterns, mental health, medical history, social history, family history, relationship with others, suicidal ideation, previous suicide attempts or hospitalizations, current employment status
214330309|NCT04410575|OTHER|Psychotherapy Referral|Pharmacist initiates collaboration with physician to arrange referral for psychotherapy, including: psychologist, social worker, counsellor, psychiatrist
214932468|NCT05703880|DRUG|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using United States Optum EHR data and OM1 RWDC databases.
214932469|NCT01662921|DRUG|NPH|Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
214932470|NCT01662921|DRUG|Insulin LISPRO|Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
214330310|NCT04410575|OTHER|Pharmacist initiated interim telephone follow-up with participant|Interim telephone follow-up conducted by the pharmacist since the last in-person follow-up \& a minimum of 1-2 weeks after the last in-person follow-up that involved a dose adjustment, prescribing of adjunctive medication, or discontinuation of therapy (Note: a telephone follow-up does not replace the scheduled in-person follow-up)
214932471|NCT01662921|DRUG|Insulin glulisine|Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
214932472|NCT01056198|DRUG|Santyl|2 mm Santyl applied once daily.
214932473|NCT01056198|PROCEDURE|Control|Daily gauze and optional sharp debridement
214932474|NCT06618456|BEHAVIORAL|VR dive (with Hypnosis)|Participants experience a VR dive through a friendly underwater world. They get a trance induction via audio.
215071702|NCT04536480|BEHAVIORAL|Components Common to All Study Arms.|All participants will receive two hours of standard nutrition counseling recommended for adolescents living with T2D. No specific caloric restriction will be recommended. All participants will maintain their usual lifestyle, including physical activity and sleep patterns. Physical activity and sleep recommendations consistent with the American Academy of Pediatrics guidelines for adolescents will be encouraged but not formally prescribed.
215071703|NCT04536480|BEHAVIORAL|Control|Participants assigned to the control arm will be instructed to consume food over a 12-h or more eating window. No energy restriction will be required.
214330311|NCT04410575|OTHER|Communication update with physician after participant contact|Pharmacist provides communication update (fax or electronic charting) with the participant's physician after contact with the participant
214330312|NCT04410575|OTHER|Medication Counselling and Educational Support|Pharmacist provides medication related counselling and educational support to participant
214673502|NCT01489787|PROCEDURE|HIFU|"Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient"
214932475|NCT06618456|BEHAVIORAL|VR dive (without Hypnosis)|Participants experience a VR dive through a friendly underwater world. They are informed that this part of the VR is a familiarization phase to the VR and they do not get a trance induction.
214932476|NCT06618456|BEHAVIORAL|Height exposure|The participants go through a height exposure. They start at the ground level of a virtual city and move upwards in 3 meter steps until they reach a height of 60 meters. Participants focus on a yellow spot on a balcony in front of them, so that they can recognise the depth perimeter.
214932477|NCT02046083|DRUG|arachid|
214932478|NCT03376256|DEVICE|Compuflo Epidural Instrument|Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.
214932479|NCT02229175|DRUG|bevacizumab|intravitreal injections of antibodies inhibiting vascular endothelial growth factor
214932480|NCT02229175|DEVICE|PASCAL Endpoint Management (EpM) laser treatment|This is an algorithm that is included in the PASCAL 577 mm yellow laser system (Topcon, Santa Clara, CA). This is FDA-approved for treatment of diabetic retinopathy and diabetic macular edema.
214932481|NCT03634436|DRUG|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
214932482|NCT03634436|DRUG|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
215071704|NCT04536480|DEVICE|Continuous Glucose Monitor|All participants will be trained to wear a blinded continuous glucose monitor sensor using manufacturer educational materials under the supervision of research staff. Participants will be asked to wear the CGM for the duration of the study. During each study visit, the CGM reader will be connected to the site database to create an individual participant report. Participants will be provided enough sensors to replace the sensor every 14 days. The participants and guardians will be educated on how to use the CGM and receive 1:1 coaching on how to change the sensor, which will be completed either independently or under study team guidance. At each weekly phone meeting, study staff will monitor any challenges related to CGM wear, including participant discomfort, skin adherence, and other issues.
215071705|NCT04758884|OTHER|Telemedicine|Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
215071706|NCT03896061|DEVICE|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
214673503|NCT00370786|DRUG|bevacizumab|
214932483|NCT06724900|BIOLOGICAL|KB304|Genetically modified herpes simplex type 1 virus
214932484|NCT06724900|DRUG|0.9% Normal Saline (NS)|Placebo
214932485|NCT01850147|DRUG|Sunitinib, chemotherapy|sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
215071707|NCT04019106|DRUG|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
215071708|NCT00634725|DRUG|capecitabine|
215071709|NCT00634725|DRUG|erlotinib hydrochloride|
215071710|NCT00634725|DRUG|gemcitabine hydrochloride|
215071711|NCT00634725|OTHER|laboratory biomarker analysis|
215071712|NCT00634725|RADIATION|radiation therapy|
215071713|NCT05511727|DEVICE|single versus double Foley's catheter in pre-induction cervical ripening|The single balloon catheter (i.e. Foley catheter \[FC\]) and Cook cervical ripening balloon have been the most commonly used mechanical method
215071714|NCT00678938|BEHAVIORAL|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
214673504|NCT03321786|OTHER|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
215071715|NCT00678938|BEHAVIORAL|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
215071716|NCT01109121|DRUG|Combination 400|Tranilast 300 mg QD; Allopurinol 400 mg QD
215071717|NCT01109121|DRUG|Allopurinol|Allopurinol 400 mg, QD
214673505|NCT01680406|DRUG|Artemether-lumefantrine combination|
214673506|NCT01680406|DRUG|Primaquine|
214673507|NCT01680406|DRUG|Chloroquine|
214932486|NCT02294175|DEVICE|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
214932487|NCT02294175|PROCEDURE|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
214932488|NCT04316442|BIOLOGICAL|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
214932489|NCT00792688|DRUG|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
214932490|NCT00792688|DRUG|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
214932491|NCT00792688|DRUG|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
214932492|NCT00438737|BIOLOGICAL|bevacizumab|
214932493|NCT00438737|BIOLOGICAL|cetuximab|
214932494|NCT00438737|DRUG|fluorouracil|
214932495|NCT00438737|DRUG|leucovorin calcium|
214932496|NCT00438737|DRUG|oxaliplatin|
214932497|NCT00438737|PROCEDURE|adjuvant therapy|
214932498|NCT00438737|PROCEDURE|conventional surgery|
214932499|NCT00438737|PROCEDURE|neoadjuvant therapy|
215071718|NCT01109121|DRUG|Combination 600|Tranilast, 300 mg QD; Allopurinol 600 mg QD
215071719|NCT00620256|DRUG|AL-37807 ophthalmic suspension, 0.1%|
215071720|NCT00620256|DRUG|Timolol gel forming solution, 0.5%|
215071721|NCT00620256|OTHER|AL-37807 ophthalmic solution vehicle|
215071722|NCT00620256|DRUG|Latanoprost ophthalmic solution|
214932500|NCT04991077|BIOLOGICAL|analyse of angiogenic, vasoactive and VEGF systems|the angiogenic, vasoactive and VEGF systems will be analysed through blood and urine sampling. These samples will be collected at the time of malignant hypertension diagnosis and repeated one month later, in 30 patients (patients group). The same tests will be performed once in 15 patients with severe non-malignant hypertension, constituting the control group.
214673508|NCT03642795|OTHER|Questionnaire|Patients are asked to complete several questionnaires
214932501|NCT04696354|DIAGNOSTIC_TEST|IVUS|Those who are randomized to the interrogation arm will have diagnostic imaging performed by IVUS to determine their treatment plan.
214932502|NCT04696354|OTHER|Continued Compression Therapy/Stockings|Those who are randomized to the deferred interrogation arm while continue compression therapy as prescribed.
214932503|NCT05238025|BIOLOGICAL|MVA-BN-RSV vaccine|One injection, suspension for injection, intramuscular use, 0.5mL MVA-BN-RSV virus with a titer of at least 3 x 10E8 infectious units (Inf.U)/0.5mL in a Tris buffer at pH 7.7.
215071723|NCT03150004|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|"Subjects will be started on CLAG-M regimen, which consists of the following:~* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 2 gm/m\^2 IV over four hours on days 1-5~* Mitoxantrone 10 mg/m\^2 IV on days 1-3;~* G-CSF at a dose of 300 μg on days 0-5."
215071724|NCT03150004|DRUG|Cladribine and Cytarabine (CLLDAC) Regimen|"* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 20 mg/m\^2 subcutaneous injection on days 1-10;"
215071725|NCT03981887|DRUG|Nafithromycin|Nafithromycin 200 mg as IV infusion
214330313|NCT04410575|OTHER|Non-medication Counselling|Pharmacist provides non-medication related counselling and educational support to participant
214330314|NCT04410575|OTHER|Identification of drug interaction|Pharmacist identification of drug interaction related to medication for major depressive disorder and/or generalized anxiety
214330315|NCT04410575|OTHER|Identification of drug adverse effect|Pharmacist identification of adverse effect related to medication for major depressive disorder and/or generalized anxiety
214673509|NCT00471380|DRUG|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
214673510|NCT00471380|DRUG|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
214932504|NCT05238025|BIOLOGICAL|Tris Buffered Saline (TBS)|One injection, solution for injection, intramuscular use, 0.5mL TBS, pH 7.7.
214932505|NCT04647396|OTHER|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"|"Implementation of the KDIGO bundle for at least 12 hours~1. discontinuation of all nephrotoxic drugs when possible~2. optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring)~3. close monitoring of serum creatinine, fluid balance and urinary output~4. avoidance of hyperglycemia~5. considerations of alternatives to radiocontrast agents~6. discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~7. avoidance of HES, gelatin, and chlorid-rich solutions"
214932506|NCT01559350|PROCEDURE|A right gastroepiploic artery in situ grafting|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
214932507|NCT01559350|PROCEDURE|A saphenous vein grafting|A saphenous vein grafting in the right coronary artery system during OPCAB
214932508|NCT03040804|RADIATION|Low dose Radiotherapy|Subjects in this protocol will only receive radiotherapy directed at one region, typically the region that is most bothersome to the patient. Patients will receive a total radiotherapy dose 7.5 Gy in five daily fractions of 1.5 Gy.
215071726|NCT03981887|OTHER|Placebo|placebo administered as IV infusion
215071727|NCT01350752|BEHAVIORAL|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
215071728|NCT01350752|BEHAVIORAL|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
214330316|NCT04410575|OTHER|Identification of severe deterioration|Pharmacist identification of participant severe deterioration (i.e. suicide attempt)
214330317|NCT04410575|OTHER|Pharmacist-to-physician recommendation for medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist collaborates, discusses, and makes recommendations to physician re: treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
214330318|NCT04410575|OTHER|Pharmacist initiated medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist initiated alteration to treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
214330319|NCT05235529|PROCEDURE|Aortic valve replacement|Surgery replacement od the aortic valve
214330320|NCT05235529|DEVICE|TAVI|Transcatheter aortic valve implantation
214330321|NCT02376907|PROCEDURE|Biliary drainage|EUS-BD or ERCP
214330322|NCT04310761|PROCEDURE|one single blastocyst transfer, both fresh and warmed|Ultrasound guided transvaginal embryo transfer.
214330323|NCT04630405|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
214330324|NCT04630405|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
214330325|NCT01539382|PROCEDURE|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow \>2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
214330326|NCT05035017|DEVICE|Test Lens|Daily disposable with modified lens design for 2 days
214330327|NCT05035017|DEVICE|Control Lens|Daily disposable lens for 2 days
214330328|NCT02875106|DEVICE|12-point-ECG|routine recording will be 300 seconds
214330329|NCT02875106|DEVICE|Polar V800|routine recording will be 300 seconds
214330330|NCT02875106|DEVICE|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
214932509|NCT04546139|OTHER|footwork|six-point footwork
214932510|NCT01902810|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization
214932511|NCT01902810|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization
215071729|NCT01350752|BEHAVIORAL|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
214330331|NCT02875106|DEVICE|Adidas Micoach smart run|routine recording will be 300 seconds
214486285|NCT06746922|DEVICE|Intermittent theta-burst stimulation|"Neuro-MS/D (Neurosoft) rTMS device will be used for stimulation with an angulated figure-of-eight coil. Neuronavigation system will be used to determine the application site. Before each session, active motor threshold (aMT) will be determined by obtaining a motor evoked potential with an amplitude of \>200μV in the EMG recording of the first dorsal interosseous muscle (FDI), which is slightly contracted (10-20% of maximum contraction) in at least five out of 10 stimuli delivered to the primary motor cortex. The handle will be held at a 45° angle to the sagittal plane, pointing backwards and laterally to create posterior-anterior current flow in the brain. The stimulation parameters are as follows:~Parameters:~Stimulation type:Burst Stimulus amplitude (% MT): 80 Burst frequency in sequence (Hz):5 Pulse frequency within burst (Hz):50 Number of bursts in the sequence: 10 Number of series:20 Interval between sequences: 8 sec Total time: 3min 47sec Total number of pulses: 600"
214932512|NCT03734302|DRUG|Brexpiprazole|Brexpiprazole , mutiple dose /oral/empty stomach
214932513|NCT04331977|DEVICE|Maxillary Expansion|2 appliances to expand the maxillary arch
214932514|NCT03628131|DRUG|Pazopanib|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
214932515|NCT03628131|DRUG|Ifosfamide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
214932516|NCT03628131|DRUG|Carboplatin|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
214932517|NCT03628131|DRUG|Etoposide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
214932518|NCT01265576|DRUG|Sorafenib|Participants will be on sorafenib at least 30 days before randomization into either the Treatment or Control Arms. Sorafenib will be administered according to the package insert unless contraindicated based on physician expertise.
214330332|NCT02875106|DEVICE|TomTom Runner Cardio HRM|routine recording will be 300 seconds
214330333|NCT04646616|OTHER|Community popular opinion leader (POL) based intervention|A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
215071730|NCT06205563|BEHAVIORAL|high-intensity interval training|High-intensity interval training (to significantly faster breathing, a significant increase in breathing depth, a significant increase in heart rate, sweating, and the need to stop exercising and adjust your breathing before you can speak; Energy expenditure (METy ≥6.00 in children) : Participants randomly assigned to HIIT will perform a 10-minute warm-up at 60-70% of their maximum heart rate (HRmax). After this, they will walk, run, or bike at 85-95% of their maximum heart rate for four sessions of four minutes each, with three minutes of active recovery (50-70% of their maximum heart rate) in between. The participants were given a five-minute cooling-off period at the end, for a total of 40 minutes of exercise. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
215071731|NCT06205563|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training (rapid breathing, rapid heart rate, slight sweating, but still able to talk easily; Energy expenditure (children METy) 3.00 to 5.99) : Participants randomly assigned to the MICT group will walk, run, or cycle continuously for 40 minutes at 60-70% HRmax. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
215071732|NCT04400019|DRUG|Hydroxychloroquine Only Product in Oral Dose Form|The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
214330334|NCT03049813|BEHAVIORAL|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
214330335|NCT03049813|OTHER|Supported Employment (Services as Usual)|Standard supported employment services.
214330336|NCT03976986|DEVICE|continuous-flow portable oxygen concentrator (cPOC)|SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
214330337|NCT03976986|DEVICE|pulsed-flow portable oxygen concentrator (pPOC)|InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
214330338|NCT00550836|BIOLOGICAL|panitumumab|Given IV
214330339|NCT00550836|DRUG|erlotinib hydrochloride|Given orally
214330340|NCT00550836|DRUG|gemcitabine hydrochloride|Given IV
214330341|NCT02369497|DEVICE|HRA|Humeral head resurfacing with the HRA device
214330342|NCT00179413|DRUG|PEG -Intron|
214330343|NCT00179413|DRUG|Colchicine|0.6mg twice a day
215071733|NCT03333096|DEVICE|Ocusweep test battery|"Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)"
215071734|NCT03333096|DIAGNOSTIC_TEST|Neuropsychological test battery|Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
215071735|NCT01140100|DRUG|propofol|
215071736|NCT01140100|DRUG|thiopental,propofol|
215071737|NCT03544476|BEHAVIORAL|Mobile phone TB treatment support app plus usual care|The behavioral intervention is delivered through a mobile phone TB support app. The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report. The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app. The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
215071738|NCT03544476|OTHER|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
214330344|NCT04698824|PROCEDURE|Hypnosis session|"At least one session of hypnosis in the internal medicine unit at the hospital Groupe Hospitalier Mutualiste de Grenoble"
214330345|NCT04053374|OTHER|Blood sampling|Blood sampling +/- CSF sampling
214330346|NCT01145079|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent
214330347|NCT01145079|DEVICE|Zotarolimus-eluting stent for ACS and DM|Zotarolimus-eluting stent for ACS and DM
214330348|NCT01145079|DEVICE|Everolimus-eluting stent for long lesion|Everolimus-eluting stent for long lesion
214330349|NCT01145079|DEVICE|Sirolimus-eluting stent for short lesion|Sirolimus-eluting stent for short lesion
214330350|NCT01512719|PROCEDURE|POEM|Per Oral Endoscopic Myotomy for achalasia
214330351|NCT02640729|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
214330352|NCT02640729|DRUG|Placebo|once daily, oral, matching tablets
214330353|NCT01072682|DEVICE|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
214330354|NCT00627679|DRUG|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
214330355|NCT00627679|DRUG|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
214330356|NCT00627679|DRUG|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
214330357|NCT00627679|DRUG|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
214932519|NCT01265576|DRUG|VT-122 (propranolol plus etodolac)|Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)\[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID\]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
214932520|NCT01265576|DRUG|Placebo|Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
214932521|NCT06604689|DRUG|third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)|EGFR-mutated NSCLC patients with brain metastases who met the inclusion and exclusion criteria, would receive first-line third-generation EGFR-TKI treatment (monotherapy or combined with upfront cranial radiotherapy)
214932522|NCT01730027|DRUG|ADC3680|ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
214932523|NCT01730027|DRUG|Placebo|Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
214932524|NCT01730027|DRUG|montelukast|montelukast for 12 weeks
214932525|NCT01081444|DEVICE|rTMS|effective and active cortical magnetic stimulations
214330358|NCT04897542|DRUG|Gallium-68 NODAGA-JR11|Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
214330359|NCT00626262|DRUG|Esomeprazole|Oral and Intravenous
214330360|NCT01696032|DRUG|SGI-110|
214330361|NCT01696032|DRUG|Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)|Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
214330362|NCT01696032|DRUG|Carboplatin|
214932526|NCT01081444|DEVICE|Placebo rTMS|non active cortical magnetic stimulation
215071739|NCT06029868|DIETARY_SUPPLEMENT|Black seed oil capsule|700 mg black seed soft gel capsule once a day from Gorgan Essential Oil Pharmaceutical Company,
215071740|NCT06029868|DIETARY_SUPPLEMENT|Placebo Black seed oil capsule|Placebo Black seed oil capsule
215071741|NCT01235845|BIOLOGICAL|Biological: DC activated CIK combined with DC|"Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations."
214932527|NCT00381732|DRUG|tadalafil|2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
214932528|NCT00381732|DRUG|placebo|Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
214932529|NCT02776891|DRUG|Gallium citrate|Ga-68 citrate will be administered on an outpatient basis at the Center for Molecular and Functional Imaging at China Basin. It will be administered a single time point intravenously prior to PET imaging. The one-time nominal injected dose will be up to 15 mCi containing 10 - 25 μg Ga-68. A simultaneous MRI (PET/MRI) of the head will be used for attenuation correction and anatomic localization of gallium-68 citrate uptake and standardized uptake value (SUV) calculation.
215071742|NCT04163861|DIAGNOSTIC_TEST|2d speckle tracking echocardiography|2d speckle tracking echocardiography
215071743|NCT04163861|DIAGNOSTIC_TEST|serum BNP level|serum BNP level of HFpEF study subjects
215071744|NCT00123162|DRUG|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
215071745|NCT00123162|DRUG|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
215071746|NCT02628431|DEVICE|Elfi tech monitor|
214330363|NCT02188576|DRUG|high dose TXA|
214330364|NCT02188576|DRUG|Low dose TXA|
214330365|NCT01192152|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
214330366|NCT01192152|DRUG|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
214330367|NCT01192152|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
214330368|NCT05902390|DEVICE|hydrogel spacer|Randomly assigned to either the treatment group, who were injected with hydrogel spacer, or the control group, who were not injected with hydrogel spacer.
214330369|NCT03945877|OTHER|No interventions|No interventions
214330370|NCT02625493|OTHER|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
214330371|NCT05013905|DRUG|PRA023 IV|PRA023 administered at timepoints as directed by the protocol
214330372|NCT05013905|DEVICE|Companion diagnostic (CDx)|CDx+ or CDx-
214330373|NCT03178617|OTHER|Educational Intervention|Attend standard of care LIP
214330374|NCT03178617|OTHER|Educational Intervention|Attend HIP
214932530|NCT02038855|BEHAVIORAL|Integrated Intervention for Dual Problems and Early Action|Integrated Intervention for Dual Problems and Early Action (IIDEA) includes psycho-education, Cognitive Behavioral Therapy and mindfulness; identifies triggers and challenging thoughts; provides motivational techniques for reducing substance use and/or smoking cravings; incorporates cognitive restructuring to identify and correct negative thinking patterns influenced by depression, anxiety and/or trauma; and includes self-monitoring of thoughts and risk behaviors that contribute to substance use, smoking and increased HIV risk.
214932531|NCT06619808|PROCEDURE|Hyperbaric oxygen therapy|Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in one month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).
214932532|NCT03565042|PROCEDURE|Arthroscopy|Arthroscopy of swollen joint (ankle/knee)
214932533|NCT03651427|DRUG|Estradiol|Induced hypogonadism and re-institution of CSHT
214932534|NCT00003762|DRUG|docetaxel|
214932535|NCT00003762|DRUG|gemcitabine hydrochloride|
214932536|NCT05140629|OTHER|Baobab fruit aqueous extract|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
214932537|NCT05140629|OTHER|Placebo OGTT|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
214932538|NCT06256692|OTHER|Pulse oximeter|No real intervention, but all study participants will have an additional pulse oximeter attached, to measure oxygen saturation.
214932539|NCT05352672|DRUG|Fianlimab|Intravenous (IV) infusion
214932540|NCT05352672|DRUG|Cemiplimab|IV infusion
214330375|NCT03178617|OTHER|Quality-of-Life Assessment|Ancillary studies
214330376|NCT03178617|OTHER|Questionnaire Administration|Ancillary studies
214932541|NCT05352672|DRUG|Pembrolizumab|IV infusion
214932542|NCT05352672|DRUG|Placebo|IV infusion
214932543|NCT00738790|RADIATION|Short course of radiotherapy|5 x 5 Gy plus boost 4 Gy
214932544|NCT00738790|RADIATION|Radiochemotherapy|28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)
215071747|NCT06072144|OTHER|Validity and reliability study|Test-retest method will be used to assess reliability. For this purpose, participants will be re-evaluated one week later with the Smart Speed device. For validity assessment, concurrent validity and agreement between measurements will be evaluated. Concurrent validity will be assessed by correlation analysis and agreement between measurements will be assessed by Bland Altman.
215071748|NCT00822627|DRUG|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
215071749|NCT00822627|BEHAVIORAL|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
215071750|NCT01684696|BEHAVIORAL|Virtual experience|
215071751|NCT01684696|BEHAVIORAL|Videos|
214330377|NCT05652088|PROCEDURE|Colonoscopy|Colonoscopy is a procedure where an instrument called colonoscope is inserted through the rectum to look at the entire internal surface of the intestine. Participants will be placed on a stretcher on the left side. A colonoscope will be advanced into the colon and into the terminal ileum. The entire procedure should take approximately 40 minutes
214330378|NCT01018459|BIOLOGICAL|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.
214330379|NCT01018459|DRUG|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
214932545|NCT06648356|OTHER|Neuromuscular electrical stimulation (NMES)|Neuromuscular electrical stimulation (NMES) is applied during an isometric contraction. The NMES uses a symmetrical biphasic rectangular pulse (50Hz frequency and 300 µs phase width) delivered through an Enraf Nonius TensMed S82 electrostimulator. Two 5x9 cm electrodes are placed on the hamstrings, and participants adjust the current to a moderate-strong, yet painless, contraction level. During the intervention, one researcher maintains the stretch position while another researcher controls the current intensity and monitors the timing of both stretching and contractions.
215071752|NCT06379802|BEHAVIORAL|Individualized physical activity and diet|Precision health
215071753|NCT00022204|DIETARY_SUPPLEMENT|vitamin E|
215071754|NCT00022204|DRUG|pentoxifylline|
215071755|NCT00022204|PROCEDURE|quality-of-life assessment|
215071756|NCT04838054|DRUG|Stabilized chlorine dioxide oral rinse|Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.
214330380|NCT06055426|OTHER|bed bath application|Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
214330381|NCT00028028|DRUG|temsirolimus|Given IV
214330382|NCT00028028|OTHER|pharmacological study|Correlative studies
214330383|NCT00028028|OTHER|laboratory biomarker analysis|Correlative studies
214330384|NCT06384547|DRUG|VRDN-001 10 mg/kg|5 infusions of VRDN-001 10 mg/kg
214330385|NCT06384547|DRUG|VRDN-001 3 mg/kg|5 infusions of VRDN-001 3 mg/kg
214330386|NCT05594342|DRUG|Ivabradine 7.5Mg Tab|Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.
214330387|NCT05594342|DRUG|DOBUTamine Injectable Solution|Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
214330388|NCT01349283|BIOLOGICAL|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
214330389|NCT01349283|BIOLOGICAL|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
214330390|NCT01624727|DIETARY_SUPPLEMENT|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
214330391|NCT00675116|DRUG|GW823296|
214330392|NCT02978690|DRUG|Spesolimab|Solution for infusion
214330393|NCT04606238|OTHER|Decision Aid|Oncologists and patients will use the decision aid in the same situation (change of treatment needs to be discussed with the patient - either because of disease progression or treatment toxicity or other reasons (e.g. change of care setting).
214330394|NCT04666259|DRUG|ABL001|Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
214330395|NCT06179082|COMBINATION_PRODUCT|Botox then threads|patients in which Botox injection then threads insertion were used
214330396|NCT06179082|PROCEDURE|threads only|patients in which threads insertion only was used
214330397|NCT01211275|BIOLOGICAL|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
214330398|NCT01211275|DRUG|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
214330399|NCT02659332|DEVICE|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
214330400|NCT04860310|PROCEDURE|Endometrial biopsy|Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.
214932546|NCT06648356|OTHER|Contract-Relax PNF (crPNF)|The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 20 seconds, followed by a 5-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.
214932547|NCT04684628|DRUG|68Ga-PSMA PET/CT|Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
214932548|NCT06585527|BIOLOGICAL|TS-2021|The participants meeting the criteria will undergo TS-2021 oncolytic virus (5×1011PFU/ml) intratumoral injection using stereotactic technique under MR Localization.
214932549|NCT03814720|BIOLOGICAL|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/1999 (H1N1) genetically fused to the ferritin protein from H. pylori. Purified H1ssF\_3928 particles display eight well-formed HA trimers that antigenically resemble the native H1 stem viral spikes.
215071757|NCT04838054|OTHER|Placebo|Patients received a rinse containing no active ingredients and periodontal basic therapy.
215071758|NCT00005841|BIOLOGICAL|MART-1 antigen|
214330401|NCT00572507|DEVICE|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
215071759|NCT00005841|BIOLOGICAL|gp100 antigen|
215071760|NCT00005841|BIOLOGICAL|incomplete Freund's adjuvant|
214330402|NCT06372847|DEVICE|Hypoglossal nerve stimulation implant|The hypoglossal nerve stimulation (HNS) implantation and therapy will be performed according to the standard clinical practice without additional procedures. Information about the surgical procedure will be collected. HNS implant information and settings will be collected throughout the study until the last study measurement (one year follow-up PSG and DISE) for that patient. No additional measures or interventions as part of the research project will be performed during implantation or treatment with HNS.
214330403|NCT06372847|DIAGNOSTIC_TEST|Polysomnography|A PSG at one-year follow-up is part of the standard follow-up pathway in patients receiving HNS therapy. In this study, PSG data will be collected from both baseline and one-year follow-up PSGs to assess treatment effect. Additionally, PSG data will be used for non-invasive prediction of the site and pattern of collapse using a novel, validated tool developed at our research group.
214486286|NCT06746922|DEVICE|Sham Intermittent theta-burst stimulation|In the sham application, the probe of the transcranial magnetic stimulation device will be placed in the vertical position and held perpendicular to the vertex and applied at an ineffective dose so that the patient hears the same sound. In order for the device to produce the same sound and warning sounds as the active application, it will be operated at the lowest operating power of 1 power. In the device operating at this power, there is no possibility of any warning due to the upright position of the probe.
214486287|NCT06746935|PROCEDURE|Collagen membrane.|Particulate bone mixture 1:1 autogenous and xenogenic bone covered with native collagen membrane.
215071761|NCT00005841|BIOLOGICAL|progenipoietin|
215071762|NCT00005841|BIOLOGICAL|tyrosinase peptide|
215071763|NCT00825942|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
215071764|NCT05922943|BEHAVIORAL|Harmony & Health program|Harmony \& Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
214330404|NCT06372847|PROCEDURE|Drug-induced sleep endoscopy (DISE)|"Drug-induced sleep endoscopy (DISE) is the clinical standard diagnostic test to assess site, pattern and degree of upper-airway collapse in OSA. Baseline DISE is part of the standard clinical pathway for HNS eligibility.~In this study, DISE data will be collected from routine baseline DISE without any additional procedures for the patient. They will undergo an additional DISE at one-year follow-up to assess the effect of HNS-therapy on site, pattern and degree of collapse. Both DISEs will be performed according to routine clinical practice in the operating theatre. Sleep will be induced using 1.5 mg bolus injection midazolam and target-controlled propofol infusion (2.0 - 3.0 μg). A flexible fiberoptic nasopharyngoscope will be transnasally inserted. Site, pattern and degree of collapse will be assessed using a standardized scoring system. Other maneuvers, including chin-lift, the use of a simulation bite or lateral position of the head will be performed according to clinical practice."
214330405|NCT01482260|PROCEDURE|Biopsy|Biopsy
214932550|NCT01257763|DEVICE|Transdermal Microchannel Skin System|A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.
214330406|NCT03199027|OTHER|Adherence Club|Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
214330407|NCT05894642|BEHAVIORAL|0|It is a case-control study, cross-sectional, so there is no intervention possible.
214330408|NCT00854581|BIOLOGICAL|PEG-interferon alfa-2b|Administered subcutaneously.
214330409|NCT00854581|BIOLOGICAL|Interferon alfa-2b|Administered intravenously.
214330410|NCT00854581|DRUG|Valproic Acid|Administered orally.
214330411|NCT00854581|DRUG|Zidovudine|Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
214932551|NCT01257763|DEVICE|Sham device|The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.
215071765|NCT04054869|OTHER|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
215071766|NCT04054869|OTHER|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
215071767|NCT04802135|OTHER|Survey|directive questionnaire administered during an individual face-to-face interview
215071768|NCT01801436|DRUG|Bortezomib|Bortezomib 1.3 mg per (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
214330412|NCT03884621|OTHER|EHP Group|The Enhanced post-discharge home-based care program (EHP) plus usual care
214330413|NCT01446731|BIOLOGICAL|mRNA transfected dendritic cell|"Autologous monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."
214330414|NCT01446731|DRUG|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
215071769|NCT04945707|DRUG|Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]|Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg
215071770|NCT04945707|DRUG|Placebo|Normal saline
215071771|NCT01895439|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
214330415|NCT03669445|DRUG|Ixazomib|21-day cycles induction and 28-day cycles consolidation
214330416|NCT03669445|DRUG|Lenalidomide|21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
214330417|NCT03669445|DRUG|Dexamethasone|21-day cycles induction and 28-day cycles consolidation
214330418|NCT03669445|DRUG|Daratumumab|21-day cycles induction and 28-day cycles consolidation
214330419|NCT00378703|BIOLOGICAL|Bevacizumab|Given IV
214330420|NCT00378703|OTHER|Laboratory Biomarker Analysis|Correlative studies
214330421|NCT00378703|OTHER|Pharmacological Study|Correlative studies
214330422|NCT00378703|DRUG|Sorafenib Tosylate|Given PO
214330423|NCT00378703|DRUG|Temsirolimus|Given IV
214486288|NCT06746935|PROCEDURE|Polytetrafluoroethylene membrane.|Particulate bone mixture 1:1 autogenous and xenogenic bone covered with polytetrafluoroethylene membrane.
214932552|NCT06667063|OTHER|Nasal swab/Nasopharyngeal swab/Blood sample collection|Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
214932553|NCT06667063|OTHER|Nasal swab/Nasopharyngeal swab/Blood draw|Visit 1/2/3：Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
215071772|NCT02694276|BEHAVIORAL|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
215071773|NCT04587843|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day)."
215071774|NCT04587843|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
215071775|NCT02293252|DEVICE|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
215071776|NCT03652857|DRUG|Apatinib Combined With Vinorelbine|Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
215071777|NCT02420288|BEHAVIORAL|Exercise Group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
215071778|NCT02899650|OTHER|exercise|acute downhill running
214330424|NCT01456442|DEVICE|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
214330425|NCT01456442|DEVICE|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
214330426|NCT00000537|BEHAVIORAL|meditation|
214330427|NCT00000537|BEHAVIORAL|relaxation|
214330428|NCT03856762|DIETARY_SUPPLEMENT|traditional Jiangnan diet|traditional Jiangnan diet supplement from Monday to Friday for six months
214330429|NCT03856762|DIETARY_SUPPLEMENT|Mediterranean diet|Mediterranean diet supplement from Monday to Friday for six months
214932554|NCT06667063|OTHER|Nasal swab/Nasopharyngeal swab/Blood draw|Visit 1/2/3：Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
214932555|NCT05721872|COMBINATION_PRODUCT|D-isoascorbic Acid (D-VC) With Arsenic Trioxide (ATO)|"After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.~Phase 1 - Scheme 1 - single intravenous administration in monotherapy with dose escalation (0.05, 0.1, 0.15 g/kg/day); Scheme 2 - single intravenous administration in the mode of sequential administration with arsenic trioxide with dose escalation of D-isoascorbic acid (0.05, 0.1, 0.15 g/kg/day).~Phase 2 - Study group 1: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I for at least 15 patients."
214330430|NCT03856762|DIETARY_SUPPLEMENT|Current Shanghai diet|current Shanghai diet supplement from Monday to Friday for six months
214330431|NCT00094874|PROCEDURE|Acupuncture|
214330432|NCT02705820|DRUG|Pembrolizumab|Switch maintenance pembrolizumab treatment
214330433|NCT05402995|DRUG|Irrisept (Irrigation Solution)|Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.
214330434|NCT05402995|DRUG|Saline|Saline irrigation
214330435|NCT04413578|DEVICE|Dexcom G6|Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.
214330436|NCT04413578|DEVICE|Contour NextOne|A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
214330437|NCT03870152|PROCEDURE|Electrocautery Ablation (EC)|For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
214330438|NCT04385784|OTHER|Balance exercise program.|Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
214330439|NCT04385784|OTHER|Home-based exercise program.|Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
214330440|NCT04779866|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
214330441|NCT04779866|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
214330442|NCT01913366|BEHAVIORAL|CM-PST|
214330443|NCT01913366|BEHAVIORAL|SG-PST|
214330444|NCT01823874|PROCEDURE|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
214330445|NCT03688321|DIETARY_SUPPLEMENT|Probiotic capsule GR-1 and RC-14|Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
214330446|NCT03688321|DIETARY_SUPPLEMENT|Placebo capsule|Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
214932556|NCT05721872|DRUG|FOLFOX/FOLFIRI regimen|"FOLFOX - oxaliplatin 85mg/m2 1 day Leucovorin 200mg/m2 IV 2h, 1, 2 days 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days~FOLFIRI Irinotecan 180 mg/m2 IV Leucovorin 400 mg/m2 IV Fluorouracil bolus 400 mg/m2 IV Fluorouracil infusional 2400 mg/m2 IV Courses are held every 2 weeks"
214932557|NCT01107808|DRUG|Calcium and Vit D|ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
214932558|NCT01107808|DRUG|Metformin, Vit D and Calcium|ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
214932559|NCT03418584|DEVICE|HybridAPC|HybridAPC is a device which combines submucosal fluid injection with APC
214932560|NCT03891043|DIETARY_SUPPLEMENT|Selenium|A 100 micrograms of Selenium was given to be taken twice a day.
214932561|NCT03891043|OTHER|Placebo|Placebo pill of 100 micrograms of starch was given to be taken twice a day.
214932562|NCT06348433|OTHER|Ketogenic diet|Ketogenic diet is a formula diet with high fat, low carbohydrate, proper amount of protein and other nutrients.
214330447|NCT01193491|DRUG|IPI-493|Capsules, ascending dose, multiple schedules
214330448|NCT01009099|OTHER|breathing retraining|breathing retraining using a metronome
214330449|NCT01009099|OTHER|exercise training|treadmill exercise training
214330450|NCT02702401|BIOLOGICAL|Pembrolizumab|IV infusion
214330451|NCT02702401|DRUG|Placebo|0.90% w/v sodium chloride IV infusion
214330452|NCT02702401|OTHER|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
214330453|NCT05092893|OTHER|Online parental questionnaires|"The SRS-2 is a parental 65-item questionnaire to detect difficulties in social responsiveness in children with autism spectrum disorder. Four different forms are available: preschoolers (2.5-4.5 years), school-aged children (4-18 years), adults (≥ 19 years) and adults self-report. In this study, only the form for school-aged children will be used.~The DCDQ'07 is a parental 15-item questionnaire to detect the risk of DCD in children between 5 and 15 years of age. Parents are asked to compare their child's motor performance to his/her peers using a 5-point Likert scale. The total sum score is compared to age-specific cut-off scores to determine the risk of DCD. Belgian norms are available since 2007."
214330454|NCT01800617|DRUG|Liothyronine, Sodium|
214330455|NCT02608112|DRUG|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
214330456|NCT02608112|DRUG|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
214932563|NCT04982211|DRUG|Propranolol|Oral propranolol hydrochloride capsules, dosed per participant weight
214932564|NCT04982211|DRUG|Placebo|Oral placebo capsules, dosed per participant weight
215071779|NCT01608698|DRUG|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
215071780|NCT01608698|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
215071781|NCT02294838|DEVICE|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
215071782|NCT02294838|OTHER|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
214330457|NCT06539026|OTHER|fluid therapy, 300 ml of crystalloid Ringer's solution.|"300 ml by dripping within 30 minutes, the fluid will be repeated by half the amount if needed to reach equal or less than 50% collapsibility.~the fluid that will be used is sterile Ringer's solution which is an isotonic intravenous solution with pH 5.0 - 7.5 and an osmolality of 308mOsmol/kg."
214330458|NCT03846258|DRUG|Low bicarbonate solution (22 mmol/L)|Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.
214330459|NCT03846258|DRUG|High Bicarbonate solution (32 mmol/L)|Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.
214932565|NCT01193465|DEVICE|Datex Ohmeda excel anesthesia machine|maintain one of following fresh gas flow, 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda excel anesthesia machine after draping complete
214932566|NCT01193465|DEVICE|Datex Ohmeda Avance anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda Avance anesthesia machine after draping complete
214932567|NCT01193465|DEVICE|Drager Cato anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Cato anesthesia work-station after draping complete
214932568|NCT01193465|DEVICE|Drager Primus anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Primus anesthesia work-station after draping complete
214932569|NCT06451562|DRUG|Lidocaine|a local anesthetic drug of the amino amide type
214932570|NCT00502892|DRUG|Topotecan|0.5 mg/m\^2 IV Daily x 3 Days
214932571|NCT00502892|DRUG|Ifosfamide|1.8 grams/m\^2 IV Over 1 Hour x 5 Days
214932572|NCT00502892|DRUG|Carboplatin|AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days \[for patients \> 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days\]
214932573|NCT02401516|DEVICE|Reprogramming insoles|1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
214932574|NCT06422104|DEVICE|Repetitive transcranial magnetic stimulation|10 Hz repetitive TMS will be delivered for 20 minutes per session and 0.7 Hz for 20 minutes per session
214932575|NCT02062073|DRUG|Abametapir Lotion 0.74% w/w|
214932576|NCT02062073|OTHER|0.1% sodium lauryl sulfate|
214932577|NCT02062073|OTHER|saline 0.9%|
214932578|NCT02062073|OTHER|Vehicle Lotion|
214932579|NCT03197324|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
215071783|NCT02294838|OTHER|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
215071784|NCT02858986|PROCEDURE|3D laparoscopy|
215071785|NCT02858986|PROCEDURE|4K laparoscopy|
215071786|NCT01126437|DRUG|tiotropium 18 mcg|HandiHaler
214330460|NCT05069922|OTHER|Fresh Frozen Plasma|Fresh Frozen Plasma
214330461|NCT00012051|BIOLOGICAL|filgrastim|
214330462|NCT00012051|BIOLOGICAL|rituximab|
214330463|NCT00012051|DRUG|carmustine|
214330464|NCT00012051|DRUG|cisplatin|
214330465|NCT00012051|DRUG|cytarabine|
214330466|NCT00012051|DRUG|dexamethasone|
214330467|NCT00012051|DRUG|etoposide|
214330468|NCT00012051|DRUG|ifosfamide|
214330469|NCT00012051|DRUG|melphalan|
214330470|NCT00012051|DRUG|methotrexate|
214330471|NCT00012051|PROCEDURE|bone marrow ablation with stem cell support|
214330472|NCT00012051|PROCEDURE|peripheral blood stem cell transplantation|
214330473|NCT00012051|RADIATION|radiation therapy|
214330474|NCT06082466|PROCEDURE|FRAMED Infrainguinal Venous Bypass|The harvested vein graft will be covered with a mesh.
214330475|NCT06082466|PROCEDURE|Conventional Autologous Bypass|The harvested vein graft will be used without a mesh coating.
214932580|NCT03197324|DRUG|Digoxin|2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)
214932581|NCT03308435|DIAGNOSTIC_TEST|Geriatric assessment|the assessment includes functional tests (hand grip strength, SPPB (Short Physical Performance Battery)) and questionaires Euro-QoL 5D, LUTS, GDS, ADL, iADL, dietary recall).
214932582|NCT03308435|DIAGNOSTIC_TEST|Psychiatric assessment|Psychiatric assessments includes HAMD-17 as well as Beck depression inventory, hospital anxiety and depression scale, SF36, PTSS-10
214932583|NCT03308435|DIAGNOSTIC_TEST|Inflammatory assessment|analysis will include arginase, ADMA, SDMA, homoarginine, aminoacids + metabolites, tryptophan, kynurenine, kynurenine acid, cortisol, ACTH, Metanephrine, myeloperoxidase,
214932584|NCT03308435|DIAGNOSTIC_TEST|Cardiological assessment|ECG, echocardiography
214932585|NCT01959763|BEHAVIORAL|Weight loss counseling program|Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.
214932586|NCT02957435|DRUG|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
215071787|NCT01126437|DRUG|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
215071788|NCT01126437|DRUG|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
214932587|NCT01630863|PROCEDURE|Photodynamic therapy|Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
214932588|NCT00965341|DRUG|Testosterone|Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
214932589|NCT00965341|DRUG|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
214932590|NCT02807506|DEVICE|Mobile Service Robot|The goal is to build a low-cost mobile service robot with an arm that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
214330476|NCT00247728|DRUG|PI-88|Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks
214330477|NCT01180738|BEHAVIORAL|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
214932591|NCT02807506|OTHER|Survey|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot.
214932592|NCT03057054|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
214932593|NCT03057054|BIOLOGICAL|Lactobacillus plantarum strain 299|Given PO or via NJ, NG or G tube
215071789|NCT01418703|DEVICE|Closed Loop Control (CLC)|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
214330478|NCT01180738|BEHAVIORAL|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
214330479|NCT03424031|PROCEDURE|Verticalization|To allow the verticalization of hemiplegic patients, we will use a device commonly used in rehabilitation: the standing (or standing) brand Thera Trainer . This device makes it possible to keep the patient standing despite the motor and postural deficits thanks to knee, buttocks and an anterior support for the upper limbs. Verticalization with this device requires the presence of one or two caregivers (including at least one re-educator), depending on the possibilities of participation of the patient.
214330480|NCT01440348|PROCEDURE|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
214932594|NCT03057054|BIOLOGICAL|Lactobacillus plantarum strain 299v|Given PO or via NJ, NG or G tube
214932595|NCT03057054|OTHER|Placebo Administration|Given PO or via NJ, NG or G tube
214932596|NCT04778462|DEVICE|extracorporeal shock wave and conventional treament|"Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band will be applied as low energy 2 sessions per week for 2 weeks The will be used as a radial type of shock wave therapy.~Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
214330481|NCT01106456|BEHAVIORAL|All Nations Breath of Life (ANBL)|ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
214330482|NCT01106456|BEHAVIORAL|Nontailored program (NT)|"The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence."
214330483|NCT01106456|DRUG|Pharmacotherapy|All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
214330484|NCT01930058|DRUG|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
214330485|NCT01924169|DRUG|Lenalidomide|"5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years."
214330486|NCT01924169|BIOLOGICAL|Influenza Vaccine|Administered as injection yearly, during the fall/winter season.
214932597|NCT04778462|DEVICE|high pain threshold ultrasound and conventional treatment for myofascial pain syndrome trigger points|"will be applied in continuous mode, with the probe placed directly on the TrP and held motionless. To elicit threshold pain, the US probe will be kept static on the TrP. Intensity gradually will be increased to the level of maximum pain the patient could bear. It will be kept at that level for 3 to 4 seconds, then will be reduced to the half-intensity level for another 15 seconds. This procedure was repeated 3 times.the intensity of US will be dependent on the patient's level of pain. intensity will be applied in the range of 0.5 to 2.0 Watt per/cm2. Patients continually report their pain level and its localization and nature High-power pain threshold US will be applied 4 times, with a 3-day interval 2 sessions per week for 2 weeks .~1)Isometric neck extensor exercise2)Isometric neck flexor exercise3)Isometric neck side bending muscle exercise,Stretching exercise:Passive stretching for the neck extensor muscles ,stretching of the neck side-bending muscles,Ischemic compression"
215071790|NCT01418703|DEVICE|Open Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
215071791|NCT03775343|DIAGNOSTIC_TEST|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
215071792|NCT03775343|DIAGNOSTIC_TEST|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
215071793|NCT00163943|BEHAVIORAL|Dietary weight loss +/- aerobic exercise|
215071794|NCT05971030|DEVICE|Cortical brain stimulation of mPFC and dlPFC|Left medial prefrontal cortex combined with dorsolateral prefrontal cortex electrical stimulation
215071795|NCT00615589|DRUG|Fludarabine/Busulfan x 4 days|"* Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~* Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day."
215071796|NCT00615589|PROCEDURE|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
215071797|NCT01220973|DRUG|atorvastatin calcium|
215071798|NCT01220973|DRUG|celecoxib|
215071799|NCT01220973|OTHER|laboratory biomarker analysis|
215071800|NCT02816593|DRUG|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
215071801|NCT02816593|DRUG|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
215071802|NCT02816593|DRUG|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
215071803|NCT01846663|DRUG|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
215071804|NCT01846663|DRUG|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months treatment
215071805|NCT02087618|OTHER|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
215071806|NCT02087618|OTHER|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
215071807|NCT02435290|BEHAVIORAL|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
215071808|NCT01215110|DRUG|TMC207|
215071809|NCT01215110|DRUG|Rifafour e-275 mg|
214932598|NCT04778462|OTHER|conventional treatment for myofascial pain trigger point|"Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
214932599|NCT02898727|OTHER|Local Therapy|"Neurosurgery: The decision whether or not to recommend neurosurgery will be made independently of this research study. The complexity and length of the surgery depends on the size and location of the tumour(s).~Stereotactic Radiosurgery: If the participant will be receiving stereotactic radiosurgery (either alone or in combination with neurosurgery), the Radiation Oncologist will organise for the participant to have a Radiotherapy planning. Single metastasis, smaller than or equal to 2cm, may require 1 fraction. Alternately, multiple metastasis, metastasis in the brain stem, or those bigger than 2cm will required multiple fractions to treat. The dose range for the study is 20Gy/1 fraction to 24Gy/3 fractions."
214932600|NCT02925182|DEVICE|Er,Cr:YSGG Laser|
214932601|NCT06667791|OTHER|Computer guided sodium hyaluronate injections|Patients will be treated with Computer guided sodium hyaluronate injections in superior TMJ space
214932602|NCT06667791|OTHER|conventional sodiumhyaluronate injections|Patients will be treated with conventional sodium hyaluronate injections in superior TMJ space
214932603|NCT01077739|DRUG|fluorouracil (5FU)|standard FOLFOX regimen
214932604|NCT01077739|DRUG|leucovorin|standard FOLFOX regimen
214932605|NCT01077739|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
214932606|NCT01077739|DRUG|capecitabine [Xeloda]|standard XELOX regimen
214932607|NCT01077739|DRUG|oxaliplatin|standard XELOX or FOLFOX regimen
214932608|NCT06407557|BEHAVIORAL|Accelerometer|Use of prompts to enable activity in older adults.
214932609|NCT00960986|DRUG|Duloxetine hydrochloride|po, QD
214932610|NCT00003829|DRUG|cyclophosphamide|
214932611|NCT00003829|DRUG|fludarabine phosphate|
214932612|NCT03108586|PROCEDURE|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
214932613|NCT03108586|PROCEDURE|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
214932614|NCT03097367|DIAGNOSTIC_TEST|bladder neck level on cystography|All patients had investigated by retrograde cystography after LRP and were grouped according their bladder neck position: Level 0: bladder neck at or above the superior margin of the symphysis pubis (SMSP), Level -1: bladder neck at \<2 cm below SMSP, and Level -2: bladder neck at \>2 cm below SMSP.
214932615|NCT04864340|DEVICE|CE marked medical device|Tetanic stimulation
214932616|NCT04864340|DEVICE|Algometer|Pressure stimulation
215071810|NCT03575845|BEHAVIORAL|Occupational Therapy Informed Yoga|Occupational therapy informed yoga met weekly for six, 60-minute sessions. Each session started with a seated warm-up to coordinate breath and movement and promote upper extremity mobility. Standing postures followed to target balance. Sessions closed with restorative postures in seated and supine variations.
215071811|NCT00374569|PROCEDURE|Gymnastic Routine|A combination of gymnastic movements are performed
215071812|NCT05333666|OTHER|Data collection|This investigation aims to collect and analyze the data from a cohort. During the cohort development, all participants received venous puncturing for NOAC concentration measurement. However, the standard treatment protocol was not changed after study enrollment. In this retrospective cohort study, we only collect data from the cohort without further intervention to the participants.
215071813|NCT06636019|DEVICE|Myopia control contact lens|Myopia control contact lens is placed on the study eye.
215071814|NCT04965948|OTHER|Novel food snack|Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks
215071815|NCT04965948|OTHER|Placebo snack|Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks
215071816|NCT04404790|DRUG|Anfibatide 5 IU/60kg|5 IU/60kg IV administration of Anfibatide with 5 minutes
215071817|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.002 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
215071818|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.004 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
215071819|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.008 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
215071820|NCT04404790|DRUG|Anfibatide 7 IU/60kg|7 IU/60kg IV administration of Anfibatide with 5 minutes
215071821|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.002 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
215071822|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.004 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
215071823|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.008 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
214932617|NCT04864340|PROCEDURE|Comparator|Non-nociceptive procedure (fine touch)
214932618|NCT01510600|GENETIC|DNA analysis|
214932619|NCT01510600|GENETIC|polymerase chain reaction|
214932620|NCT01510600|OTHER|laboratory biomarker analysis|
214932621|NCT01510600|OTHER|medical chart review|
214932622|NCT01766752|DEVICE|GlucoTab System|Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
214932623|NCT00539149|DRUG|Amoxycillin|50 mg/kg/day twice daily
214932624|NCT00539149|DRUG|Placebo equivalent to amoxycillin|50 mg/kg/d twice daily
214330487|NCT01924169|BIOLOGICAL|Pneumovax Vaccine|Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
214330488|NCT04056559|DEVICE|Adaptable mouthguards|Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).
214330489|NCT02334228|BEHAVIORAL|In SHAPE Lifestyles|In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
214330490|NCT02334228|BEHAVIORAL|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
214330491|NCT02994862|OTHER|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
214330492|NCT02994862|OTHER|Conventional Bonding|Normal Bonding Protocol
214330493|NCT05543785|DRUG|Ketorolac|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
214330494|NCT05543785|OTHER|Control|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
214330495|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
214932625|NCT02232828|PROCEDURE|Selective removal|Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
214932626|NCT02232828|PROCEDURE|Stepwise removal|"Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.~If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described."
215077823|NCT06056440|PROCEDURE|Virtual reality|"The VR intervention program for the experimental group will be carried out with a frequency of 3 sessions/week, duration of approximately 45 minutes, and for a total of 12 weeks, being performed in addition to the patient's usual treatment program.~The Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. Specifically, the specific functional rehabilitation program will be used, which comprises exercises that are easy to perform, with a playful component, and which encourage the patient's continuous attention to the task performed, acting as a distractor phenomenon in the face of restrictive movement factors such as fear of pain or movement. This software offers the possibility of adjusting the number of repetitions and characteristics of the exercises, thus allowing an individualized physical rehabilitation"
214330496|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
214330497|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
214330498|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
214330499|NCT03494036|DIETARY_SUPPLEMENT|Synbiotic|capsule
214330500|NCT03494036|DIETARY_SUPPLEMENT|Placebo|capsule
214330501|NCT05624099|DRUG|camrelizumab|200mg intravenous drip d1q3w
214330502|NCT05624099|DRUG|Paclitaxel drugs|150mg/m2 d1 q3w
214330503|NCT05624099|DRUG|Platinum drug|Cisplatin, carboplatin, nedaplatin and other platinum drugs
214330504|NCT05624099|RADIATION|Radiation|Dose: 5040cGy/28f
214330505|NCT04664504|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy Radiotherapy|50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.
214330506|NCT04664504|RADIATION|Short-course Radiotherapy|25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
214330507|NCT04664504|RADIATION|Local dose increase of Short-course Radiotherapy|25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
214330508|NCT04664504|DRUG|Consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses\*3 weeks per course.
214330509|NCT04664504|DRUG|Adjuvant chemotherapy|2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses\*3 weeks per course
214330510|NCT04664504|PROCEDURE|TME|Total mesorectal excision
214330511|NCT03947151|DRUG|Degarelix injection(s)|1 or 2 degarelix injection(s)
214330512|NCT04292730|DRUG|Remdesivir|Administered as an intravenous infusion
214330513|NCT04292730|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
214330514|NCT02694315|OTHER|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
214330515|NCT02694315|OTHER|cervical length|measuring cervical length by trans-vaginal ultrasound
214330516|NCT01527292|RADIATION|Stereotactic Radiation Therapy|SRT only
214330517|NCT01527292|RADIATION|SRT with Vertebral Augmentation Procedure|SRT with VAP
214330518|NCT02119546|OTHER|Aerobic exercise|Aerobic exercise and dual-task training
214955349|NCT06391229|BEHAVIORAL|Project Support|"Caregivers will receive up to four, 60- to 90-minute sessions focused on teaching two parenting skills - attentive listening and comforting. Attentive listening involves providing accurate and timely responses to show interest and keep the child engaged until they are ready to end the conversation. Comforting involves using the same attentive listening skills when the child is upset or distressed. Effective mastery of the listening and comforting skills also requires caregivers to withhold any non-listening or non-comforting responses (e.g., interruptions, criticisms).~The program is individually tailored such that caregivers with stronger skills could complete the program in less time (i.e., fewer sessions). Service providers educate caregivers about the skills, then engage in an iterative process of modeling the skills, engaging the caregivers in behavioral practice, and providing tailored, supportive feedback to help caregivers gain mastery."
215071824|NCT05688202|PROCEDURE|Simultaneous combination of fractional CO2 laser and subcision|"Fractional CO2 laser is performed immediately following subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
215071825|NCT05688202|PROCEDURE|Sequential combination of fractional CO2 laser and subcision|"Fractional CO2 laser conducted two weeks after subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
215071826|NCT05688202|DEVICE|Fractional CO2 laser|Fractional CO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) on both sides of the face sequentially with a two-week interval between sessions for each face's side by a single physician, with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes. At the first pass, only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density in the static operating mode. At the second pass, the whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density in the static operating mode with less than 10% overlap.
215077824|NCT06056440|OTHER|Control group|The control group will only receive their usual treatment program for the 12-week duration of the study.
215077825|NCT02335047|OTHER|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
215077826|NCT05125718|DRUG|0.85% synthetic antimicrobial peptide TAPS-18|commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
214330519|NCT02119546|OTHER|Stretch exercise|Stretch exercise \& sitting balance
214330520|NCT02501603|DRUG|afatinib|Afatinib 40mg daily oral administration
214330521|NCT02501603|DRUG|paclitaxel|Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
214330522|NCT01482767|DRUG|Pegylated-Interferon Alfa 2b (PEG-IFN)|1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
214330523|NCT01482767|DRUG|Ribavirin (RBV)|800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
214330524|NCT01482767|DRUG|Boceprevir (BOC)|800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
214330525|NCT05466227|OTHER|Implementation of Modified Valsalva maneuvre|"Modified Valsalva maneuvre:~* Patient is attached to 12-lead ECG monitoring~* The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~* Patient's legs are elevated (45°) for 15 seconds~* Afterwards, the patient is placed back in an upright position~* If not efficient, this maneuver can be repeated up to two times"
214330526|NCT03938142|OTHER|Filling in an online survey regarding goalsettings|Patients are asked to fill in an online survey regarding their individual goalsettings.
214330527|NCT01954485|PROCEDURE|Dental implant placement with a final prosthetic abutment|
214330528|NCT01261858|DEVICE|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
214330529|NCT02995785|OTHER|simulation-based training|simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).
214330530|NCT02995785|OTHER|traditional training|traditional training:Give TMS online lecture(15-min).
214330531|NCT01841814|RADIATION|Bone densitometry.|
214932627|NCT06354361|BEHAVIORAL|Trauma-Informed Goal Management Training (TI-GMT)|"Trauma Informed-Goal Management Training (TI-GMT) is a modified version of Goal Management Training (GMT), a cognitive remediation program that emphasises mindfulness and practice in planning and completing goal-oriented behaviours. TI-GMT enhances the standard GMT protocol with the addition of several trauma-informed adaptations and content that is sensitive and specific to public safety personnel with PTSD.~Participants are trained to interrupt ongoing disruptive behaviours through the resumption of executive control to help define goal hierarchies and monitor goal achievement. Mindfulness meditation helps develop attentional control and the skill of bringing one's mind to the present. Real-life examples are incorporated to illustrate goal attainment failures and successes, and participants practice solving complex, real-life tasks in sessions.~Sessions include instructional material, interactive tasks, discussion of real-life deficits, and homework/practice activities."
214932628|NCT06354361|BEHAVIORAL|Goal Management Training (GMT)|"Goal Management Training (GMT) is a cognitive remediation program that emphasises mindfulness and practice in planning and completing goal-oriented behaviours.~Participants are trained to interrupt ongoing disruptive behaviours through the resumption of executive control to help define goal hierarchies and monitor goal achievement. Mindfulness meditation helps develop attentional control and the skill of bringing one's mind to the present. Real-life examples are incorporated to illustrate goal attainment failures and successes, and participants practice solving complex, real-life tasks in sessions.~Sessions include instructional material, interactive tasks, discussion of real-life deficits, and homework/practice activities."
214330532|NCT04976192|COMBINATION_PRODUCT|TEV-45779|TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
214330533|NCT04976192|COMBINATION_PRODUCT|XOLAIR® Injection|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
214330534|NCT05130203|BEHAVIORAL|MouvMat Exergaming|Sessions engaging with exergaming device.
214330535|NCT05130203|BEHAVIORAL|Standard Recreational Programming|Conducted by recreational therapists.
214330536|NCT01856543|OTHER|Eucerin|
215077827|NCT05125718|DRUG|0.9% normal saline|commercially available normal saline Sodium Chloride irrigation solution
215077828|NCT01144975|DRUG|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
214330537|NCT01856543|OTHER|Mometasone Furoate 0.1%|
215077829|NCT01144975|DRUG|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
215077830|NCT02961933|OTHER|Apneic oxygenation|Nasal cannula apneic oxygenation
214330538|NCT01423448|OTHER|bulletin board|An asynchronous online bulletin board for people with experience of depression
214330539|NCT01622946|DRUG|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
214330540|NCT01622946|DRUG|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
214330541|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
214330542|NCT02102633|DRUG|Bosutinib|Bosutinib 500 mg orally
214330543|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
214330544|NCT05233410|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214330545|NCT05233410|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
214330546|NCT04325529|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
214330547|NCT05878548|PROCEDURE|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
214330548|NCT02788734|OTHER|Web-based survey|This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
214330549|NCT05827627|OTHER|simulation|Midwifery student directing the birth of a fetus with frank breech presentation.
214330550|NCT01148004|DRUG|Fenofibrate|
214330551|NCT01148004|DRUG|Ritonavir|
214330552|NCT01148004|DRUG|Lopinavir/Ritonavir|
214330553|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using custom 3D printed templates|A patient dental model is acquired by digital scan then digital waxing-up is performed using the Exocad software to 3D print clear templates for direct composite resin restoration.
214330554|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using conventional strip crowns|Direct composite resin restoration using celluloid crown forms
214330555|NCT02353091|DEVICE|Remote Microphone Hearing Aids|The ear receivers connect wirelessly with the microphone being worn by the teacher within a range of 25m.
214330556|NCT01374308|BIOLOGICAL|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
214330557|NCT01374308|DRUG|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
214330558|NCT04272398|OTHER|dynamic elastomeric fabric orthoses|Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
214330559|NCT01541930|DRUG|GK567|Once or twice daily, for 14 days, up to 30 g per day
214330560|NCT03416400|OTHER|Oocyte vitrification|Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
214330561|NCT06406127|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Single 600 mg daily dose
214330562|NCT02501096|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
214330563|NCT02501096|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
214330564|NCT05738200|OTHER|Nordic Hamstring Exercise|A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
214330565|NCT02148172|PROCEDURE|Standard Plyometric Training|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.
214932629|NCT05523193|OTHER|Formal treatment model|Formal treatment model , no further surgery or minimally invasive treatment was performed
214932630|NCT06276777|PROCEDURE|Tooth varnish (PRG Barrier Coat from Shofu)|Treatment of cervical dentin hypersensitivity with tooth desensitizers.
214330566|NCT02148172|PROCEDURE|Plyometric Training with BWS|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
214330567|NCT00534690|PROCEDURE|One-Lung ventilation|Low Vt, High PEP
214330568|NCT00534690|PROCEDURE|One-Llung ventilation|High Vt, low PEP
214330569|NCT04138407|OTHER|seated Tai Chi|Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair
214330570|NCT04138407|OTHER|Usual rehabilitation exercise|Regular rehabilitation exercise used in participating hospital
214330571|NCT03765294|DRUG|ACT-541468|Film-coated tablet for oral use
214330572|NCT03765294|DRUG|Placebo|Film-coated tablet for oral use
214330573|NCT01563068|DRUG|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
214330574|NCT03892811|OTHER|Three study conditions|Continuous fluoroscopy (at 30 frames/second) will be used for intermittent periods to capture 10 swallows in the initial sucking sequence of each of three study conditions: 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple.
214932631|NCT06276777|PROCEDURE|Tooth varnish (Clinpro white varnish 3M)|Treatment of cervical dentin hypersensitivity with tooth desensitizers.
214932632|NCT03229447|BEHAVIORAL|eLearning Modules|All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.
214932633|NCT03229447|BEHAVIORAL|Change Team Intervention|Courts selected for the experimental condition will participate in a hands-on change team intervention to provide instrumental assistance and to reinforce the information contained in the eLearning modules.
214932634|NCT00927511|DRUG|Fulvestrant|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
214330575|NCT04187196|DRUG|Propofol|Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved
214330576|NCT04187196|DRUG|Methohexital|Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved
214330577|NCT00360074|DRUG|Thyroxin, Triiodothyronine|
214932635|NCT06620393|DRUG|Dexmedetomidine|DEX 4 mcg/100 ml at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.
214932636|NCT06620393|DRUG|Placebo|NaCl 0.9% 100ml
214932637|NCT00877071|DRUG|LC Bead loaded with doxorubicin|LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
214932638|NCT05189327|OTHER|No intervention|Non-interventional study
215071827|NCT05688202|PROCEDURE|Subcision|Subcision is operated in all participants using an 1812G Nokor needle (BD Nokor™ Admix Needles, Becton, Dickinson and Company, New Jersey, United States). The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine. After obtaining appropriate anesthesia, a Nokor needle is inserted into the skin close to the depressed scars and progressed until it lays precisely under the scar. The insertion depth is at the dermal-hypodermal junction. Initially, the subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue. Once the fibrous mass has been sufficiently fractured, the needle is slid in a direction parallel to the skin's surface in order to detach the scar from its tethers. For densely fibrous scars, several needle insertion sites are used to undermine the defect from various angles.
214330578|NCT02437565|OTHER|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
214330579|NCT02437565|OTHER|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
214330580|NCT04537728|BEHAVIORAL|My Healthy Brain Version 2|multimodal lifestyle intervention incorporating mindfulness skills, behavioral principles, and recent research on brain disease risk factors
214932639|NCT00110227|BEHAVIORAL|12-week Tai Chi Program|24 tai chi sessions. 2 sessions/week for 12 weeks.
214932640|NCT00110227|BEHAVIORAL|12-week Education Program|24 Educational sessions. 2 sessions/week for 12 weeks.
215071828|NCT05688202|DRUG|Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream|Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
215071829|NCT05688202|DRUG|Paracetamol|A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
214330581|NCT04078776|OTHER|No intervention|There is no intervention in this study
214330582|NCT05149417|OTHER|SMS reminding|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
214330583|NCT05149417|OTHER|telemonitoring|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
214330584|NCT05314946|PROCEDURE|No feeding tube placed|The experimental arm will forego placement of a feeding tube.
214330585|NCT05314946|PROCEDURE|Placement of a percutaneous feeding tube|The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
214330586|NCT02099214|DEVICE|3Tesla cardiac MRI|
214330587|NCT02099214|DEVICE|Electrocardiogram (EKG)|
214330588|NCT02099214|BIOLOGICAL|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
214932641|NCT06621940|OTHER|High Protein Diet|Individuals will be placed on a high protein diet for 10 days.
214932642|NCT06621940|OTHER|Normal Protein Diet|Individuals will be placed on a normal protein diet for 10 days.
214932643|NCT05120531|OTHER|Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia|Use of an Ambulatory Monitoring System from Vuije University (VU-AMS) to record autonomic and cardiovascular activity of patients undergoing otolaryngologic surgery with anesthesia. This monitoring device will provide data of ANS activity and normoxic bradycardia among patients with Down Syndrome. This data will be compared to data from patients without Down Syndrome.
214932644|NCT04158882|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
214932645|NCT05407974|PROCEDURE|pleurectomy|"All patients will undergo resection of apical blebs with simultaneous pleurectomy or pleural abrasion.~Chest tube will be inserted in the pleural cavity and maybe connected on low-grade suction for first 24 h according to type of pneumothorax \& surgeons' preference, after which the suction is disconnected.~Post Operatively both groups will be compared regarding the postoperative drainage amount, persistence of air leak (chest tube removal time), length of hospital stay, mortality and risk of recurrence.~Follow up Chest x-ray will be done immediate postoperatively, then each patient will be followed up after 6 months."
214330589|NCT02099214|BIOLOGICAL|Pregnancy test|Beta-hCG
214330590|NCT02099214|DEVICE|Echocardiography at rest|Transthoracic echocardiograph
214330591|NCT02099214|BIOLOGICAL|Urinary pregnancy test|
214330592|NCT02099214|DEVICE|3Tesla abdominal MRI|
214330593|NCT01556204|PROCEDURE|Robotic surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
214330594|NCT01556204|PROCEDURE|Laparoscopic Surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
214330595|NCT05664724|BEHAVIORAL|Receives interdisciplinary sessions|"Along with usual care, participants receive six interdisciplinary sessions at 2 months and 1 month pre-operatively and 2 weeks, 6 weeks, 3 months, and 6 months post-operatively attended by an orthopedic surgeon, a physiotherapist, a patient navigator, and the patient. The pre-operative interdisciplinary sessions will outline expectations, explore patients' questions and concerns, set expectations for the next interdisciplinary session, and ensure goal congruence between all members of the team.~Along with usual care during the post-operative period, participants will receive interdisciplinary sessions that address safety and medical issues, revisit patient expectations, reinforce care team expectations, focus on a personalized rehabilitation plan, and ensure goal congruence between the various team members."
214330596|NCT00366392|DEVICE|Optical Aids|
214330597|NCT06175143|BIOLOGICAL|GR2002 injection|TSLP monoclonal antibody
214330598|NCT00688766|DRUG|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
214330599|NCT00688766|DRUG|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
214330600|NCT00688766|OTHER|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
214330601|NCT03139916|DRUG|Temozolomide|Temozolomide causes cell death and shrinks and kills the cancer cells
214932646|NCT01984892|DRUG|Poly-ICLC|"Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments."
214932647|NCT03886779|DRUG|Bromfenac|0.7 MG/ML \[Prolensa\]
214932648|NCT03886779|DRUG|Nepafenac|3 MG/ML \[Ilevro\]
214932649|NCT02964754|DEVICE|CT scan for internal fixation|In the observation group, digital three-dimensional models will be established by CT scan for internal fixation.
214932650|NCT02964754|PROCEDURE|conventional internal fixation|In the control group, patients will undergo conventional internal fixation.
214955350|NCT03836209|DRUG|Gilteritinib|"Induction: 120 mg orally daily x 14 days starting on day 8~Consolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)"
214955351|NCT03836209|DRUG|Midostaurin|"Induction: 50 mg orally twice daily x 14 days beginning on day 8~Consolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)"
214955352|NCT03836209|DRUG|Daunorubicin|"First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3~Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3"
214955353|NCT03836209|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles"
214955354|NCT05350813|PROCEDURE|Measurement of the PCT plasma levels|antibiotic treatment duration will be based on PCT plasma levels
215071830|NCT05688202|DRUG|Lidocaine 2% Injectable Solution|The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
215071831|NCT00574041|DRUG|Interferon beta-1a|injected, once a week
215071832|NCT02444546|OTHER|Laboratory Biomarker Analysis|Correlative studies
214330602|NCT03139916|DRUG|Bavituximab|Bavituximab may activate (cause) the immune system to attack the cancer cells
214330603|NCT03139916|RADIATION|Radiation|Radiation causes cell death and shrinks and kills the cancer cells.
214330604|NCT01620580|BEHAVIORAL|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3"
214330605|NCT01620580|BEHAVIORAL|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills \& adherence to renal diet and fluid restriction without discussing any intervention with the group.
214330606|NCT01957475|DEVICE|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
215071833|NCT02444546|BIOLOGICAL|Sargramostim|Given SC
215071834|NCT02444546|BIOLOGICAL|Wild-type Reovirus|Given IV
215071835|NCT02650271|DRUG|Entecavir|Patients will be received entecavir (10 mg/d) before liver resection.
215071836|NCT02650271|DRUG|Tenofovir|Patients will be received tenofovir before liver resection.
215071837|NCT00001766|DRUG|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
214330607|NCT01957475|DEVICE|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
214932651|NCT06450054|DIAGNOSTIC_TEST|Aerobic Exercise in diabetic post-stroke patients|The experimental group's members will use the treadmill for a five-minute warm-up and cool-down. Over 12 weeks, they will attend three 40-minute weekly sessions in groups of two to four. They will then perform aerobic exercise for thirty minutes at a heart rate reserve of 60% to 80%. Those with a low exercise tolerance will first be given small workouts lasting at least ten minutes, interspersed with rest periods until they can perform 30 minutes of exercise. They will progress to longer, continuous workouts punctuated by shorter rest periods as their tolerance to exercise grows. The degree of treadmill training intensity will be adjusted step-by-step according to each person's tolerance, heart rate, blood pressure responses, and perceived effort rate. If they exercise beyond their cardiovascular conditioning zone, participants will be instructed to raise their treadmill speed until they achieve it
215071838|NCT01321918|OTHER|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
215071839|NCT01321918|OTHER|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
214330608|NCT00003002|BIOLOGICAL|HER-2/neu peptide vaccine|
214330609|NCT00003002|BIOLOGICAL|sargramostim|
214330610|NCT05668065|BIOLOGICAL|CoronaVac/CoronaVac|Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
214330611|NCT05668065|BIOLOGICAL|CoronaVac/BNT162b2|"First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2"
214330612|NCT02591628|BEHAVIORAL|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
214330613|NCT03320239|BEHAVIORAL|HIV risk assessment and tailored suggestions|The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
214330614|NCT03320239|BEHAVIORAL|HIV risk behavior assessment|It only contains HIV risk behavior assessment and routine education
214330615|NCT03320239|BEHAVIORAL|placebo control|It only contains HIV/AIDS knowledge assessment and routine education
214330616|NCT04419116|PROCEDURE|tibial preservation bone cut|tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
214330617|NCT04473651|DRUG|Lu AG06479|capsules, orally (Part A and B)
214330618|NCT04473651|DRUG|Placebos|Placebo - capsules, orally (Part A only)
214330619|NCT01640730|DRUG|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
214330620|NCT03097419|PROCEDURE|Remote post-ischemic conditioning|"A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.~* The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.~* The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.~* Five (5) total iterations constitute the treatment.~* The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration."
214330621|NCT04587193|DEVICE|Robotic-assist gait training device|PD participants will walk while wearing a robotic-assist gait training device
214330622|NCT03869593|GENETIC|Sample analysis|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
214330623|NCT03407872|DRUG|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
214330624|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
214330625|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
214330626|NCT03407872|DRUG|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
214330627|NCT03343691|DIAGNOSTIC_TEST|Screening Population|Blood samples taken from screening population
214330628|NCT03343691|DIAGNOSTIC_TEST|Breast Cancer Population|Blood samples taken from Breast Cancer population
214330629|NCT03307668|DEVICE|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
214330630|NCT03307668|DEVICE|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
214330631|NCT03680274|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
215071840|NCT02791932|BEHAVIORAL|Exercise|See description above.
214330632|NCT03680274|OTHER|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
214330633|NCT02977234|DRUG|Isoamyl 2-Cyanoacrylate|
214330634|NCT01813318|DRUG|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
214330635|NCT01813318|DRUG|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
214330636|NCT02962037|OTHER|Melatonin and light therapy|
214330637|NCT00503386|DRUG|Palonosetron|
214330638|NCT00503386|DRUG|Granisetron|
214330639|NCT03567863|DEVICE|20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®|The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
214330640|NCT03567863|DEVICE|22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®|The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
214330641|NCT01552772|DRUG|Aripiprazole IM Depot|400 mg intramuscular injection of aripiprazole
214486289|NCT06746987|OTHER|Meditation|After the appropriate sample group for the research is created, study and control groups will be determined. Firstly, randomization of the study and control groups in the research will be done by an independent researcher on the randomizer.org website. Secondly, the Pitsburg Sleep Quality Scale and PERMA test will be applied to the study and control groups as a pre- test. Thirdly, theta healing meditation will be applied to the study group for 4 weeks, 2 days a week, 15- 30 minutes a day. After the 4 week meditation practice is completed with the study group, a final test will be given to the study and control groupsthe Pitsburg Sleep Quality Scale and PERMA test will be applied as the final test.
214932652|NCT06450054|OTHER|Aerobic Exercise in Non diabetic post-stroke patients|Group B will be managed aerobic exercise in non-diabetic post-stroke patients. Participants in the control group will walk outside comfortably while maintaining a heart rate reserve of less than 40%. They will be instructed to reduce their pace until their training zone reaches ≤40% if their heart rate reserve exceeds 40%. If the efficacy is demonstrated, participants in the control group will receive the experimental intervention
214330642|NCT03339375|DEVICE|esophageal Doppler|Goal directed fluid therapy using dynamic parameters from esophageal Doppler
214932653|NCT04116827|DRUG|Tamoxifen Oral Tablet|Patients who are scheduled for application of tamoxifen and goserelin
214486290|NCT06742866|DRUG|Amiodarone Injection|Administer 300 mg of intravenous amiodarone as a loading dose once daily (QD) and 200 mg of oral amiodarone twice daily (BID) within 24 hours postoperatively, and continue for 3 consecutive days.
214330643|NCT03369938|OTHER|exercise training intervention|structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
214486291|NCT06742866|DRUG|Sodium Chloride Injection 0.9%|Sodium chloride injection as a placebo in an amount equivalent to amiodarone injection.
214486292|NCT06743087|DIAGNOSTIC_TEST|Jamar handheld dynamometer|Jamar handheld dynamometer
214932654|NCT03568682|BEHAVIORAL|Nutritional counseling + urban gardening|Peer nutritional counseling and urban gardens
214932655|NCT04973631|GENETIC|Sex, Age|Evaluate the effect of sex and age on the incidence and survival of GC.
214932656|NCT04827082|OTHER|Diacutaneous fibrolysis|Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
214932657|NCT04464720|BEHAVIORAL|Cooking Ventilation Intervention|An educational video presentation for the families regarding the importance of ventilation use during and after cooking, and strategies for improving the ventilation during cooking, has been created by Dr. Holm, with input from Youth Research Assistants (YRAs) The youth involvement will help to ensure that the information is presented in a way that will resonate with the local community and will also provide the youth with exposure to developing health education tools. The educational video will be shown to families at the time of the intervention visit and they will receive printed reminder materials of what they have learned.
214932658|NCT02389569|PROCEDURE|Adhesive system|Etch-and-rinse and Self-etch adhesive system will be applied in volunteers that received different types of restoration protocol.
214932659|NCT02389569|PROCEDURE|Restoration protocol|Volunteers will be treated by two types of protocol restoration : 1) Biosilicate (powder) or 2) Control (without Biosilicate). In sequence, adhesive (self-etch or etch and rinse) and composite resin will be used for restoration.
214932660|NCT02511314|DEVICE|TENA Identifi|TENA Identifi
214932661|NCT00342563|DRUG|mecamylamine|mecamylamine 10mg/day
214932662|NCT00342563|DRUG|Placebo|Placebo
214955355|NCT05350813|PROCEDURE|Usual practice based on guidelines|antibiotic therapy duration will be determined by the type of infection, microbiological results and clinical, biological and/or radiological evolution, according to the usual practice based on guidelines.
214330644|NCT03279588|DIAGNOSTIC_TEST|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
214330645|NCT05491603|BIOLOGICAL|DBI-001|Topically administered
214330646|NCT05491603|BIOLOGICAL|DBI-002|Topically administered
214330647|NCT05491603|BIOLOGICAL|Aqueous Gel|Topically administered
214330648|NCT02994537|OTHER|Different biochemical results or pathogenesis.|Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
214330649|NCT04361526|DEVICE|Cytokine Adsorption|Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.
214932663|NCT05994521|PROCEDURE|ERCP alone|"ERCP with biliary stenting will be performed alone. ERCP is part of standard of care for biliary drainage. An endoscope is advanced to the small intestines and a metal stent is inserted through the tumor instead of bypassing the tumor to effectively drain the biliary system under x-ray guidance.~Management of MGOO will be on a wait-and-see approach, using endoscopic interventions performed only if obstruction is clinically diagnosed"
214932664|NCT05994521|PROCEDURE|ERCP +ProEUS-GE|ERCP is performed as described above. following the ERCP, the scoped is switched for an echoendoscope which is advanced to the stomach. A stent is then placed between the stomach and the small intestines, creating a connection (ProEUS-GE).
215071841|NCT01581749|RADIATION|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
214330650|NCT04449367|PROCEDURE|ultrasound guided erector spinae plane block|bilatral block given to patients under general anaesthesia for thoracic spine sugery to contorl post operative pain
214330651|NCT04143412|DRUG|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
215071842|NCT02439151|DEVICE|New lung ventilation strategy|New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
214330652|NCT02920983|DEVICE|somofilcon A|contact lens
214330653|NCT02920983|DEVICE|nelfilcon A II 2|contact lens
214330654|NCT02920983|DEVICE|omafilcon A ll 2|contact lens
214330655|NCT03620318|DRUG|Crenolanib besylate|
214330656|NCT02682420|DEVICE|everlinQ endoAVF System|
214330657|NCT06137443|DEVICE|Balance Training|Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
214330658|NCT00895180|BIOLOGICAL|olaratumab|Given IV
214330659|NCT00895180|BIOLOGICAL|ramucirumab|Given IV
214330660|NCT02839499|DEVICE|RU sleeping®|Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.
214330661|NCT02839499|OTHER|autonomy scale (ADL and AGGIR)|autonomy data
214330662|NCT02839499|OTHER|various activity scale (IADL)|activity of life data
214330663|NCT02531165|DRUG|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
214330664|NCT02531165|DRUG|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
214330665|NCT02531165|DRUG|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
214330666|NCT02531165|DRUG|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
214330667|NCT02531165|DRUG|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.
214330668|NCT02531165|PROCEDURE|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
214330669|NCT04269603|DEVICE|Take blood (TA-8V (Stago®)|Healthy volunteers will have 3 blood samples at M0, M3 and M6.
214330670|NCT02831270|PROCEDURE|Acute normovolemic hemodilution (ANH)|
215071843|NCT02439151|DEVICE|Conventional ventilation strategy|Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
214330671|NCT02831270|DRUG|hydroxyethyl starch (HES 130/0.6)|
214330672|NCT03497559|OTHER|Music|Classical music
214330673|NCT00998634|DRUG|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
214330674|NCT02617550|DRUG|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
214330675|NCT02617550|DRUG|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets \[o.d.\].
214330676|NCT02617550|DRUG|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat \[trough\] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat \[peak\] or placebo) on day 13, day 27 and day 41
214330677|NCT03895320|BEHAVIORAL|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
214330678|NCT03895320|BEHAVIORAL|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
214330679|NCT03895320|BEHAVIORAL|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
214330680|NCT03895320|BEHAVIORAL|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
214330681|NCT03895320|BEHAVIORAL|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
214330682|NCT03895320|BEHAVIORAL|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
214486293|NCT06742515|DRUG|Blinatumomab plus Reduced-dose Chemotherapy|Cycle 1: Reduced VCP on day1, IV and Blinatumomab for 2 weeks, IV. Cycle 2: Blinatumomab for 2 weeks, IV and Venetoclax for 2 weeks, oral.
214673511|NCT05363007|DRUG|nanoliposomal irinotecan|"Upfront SI (Arm A): Upfront nanoliposomal irinotecan (80 mg/m2, day 1) + 5-FU/leucovorin (2400 mg/m2, 400 mg/m2) plus SI~Add-on SI (Arm B): Add-on SI following limited progression to prior nanoliposomal irinotecan (last dose used) + 5-FU/leucovorin (last dose used)"
214932665|NCT02156895|DRUG|Axitinib|based on Axitinib approval
214932666|NCT04818606|OTHER|Mindfulness Oriented Recovery Enhancement|Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings.
214932667|NCT05723328|BEHAVIORAL|Group Music Therapy Advocacy Recording Intervention (MTAR)|Music Therapy Advocacy Recording Intervention (MTAR) is a sequence of group music therapy song-writing and recording sessions framed as a mental health awareness project to be shared with the general public.
214932668|NCT04531254|BEHAVIORAL|Wearing a face mask at all times|Children in this group will be asked to wear a face mask in the classroom and common areas during the simulation
214932669|NCT03805373|OTHER|Diet Assessment Survey|Participants will complete 2 different diet assessment tools separated by at least 1 week.
214932670|NCT03476174|DRUG|Pembrolizumab|Subjects will receive 200 mg pembrolizumab every 3 weeks for two cycles. Cycle length is 21 days (i.e., 3 weeks). On the last day of Cycle 2 (+/- 3 days), disease status will be assessed via imaging.
214955356|NCT05679349|OTHER|Survey Administration|Complete survey
215071844|NCT00813865|DRUG|afegostat tartrate|
215071845|NCT01184638|DRUG|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
215071846|NCT01184638|DRUG|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
215071847|NCT01028768|DRUG|Teduglutide|10 mg, one-time subcutaneous
214955357|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
214955358|NCT05679349|OTHER|Survey Administration|Complete survey
214955359|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
214955360|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
214955361|NCT05679349|OTHER|Counseling|Undergo shared decision making counseling
214955362|NCT05679349|OTHER|Survey Administration|Complete survey
214955363|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
214955364|NCT03739710|DRUG|Docetaxel|Docetaxel will be administered.
214955365|NCT03739710|DRUG|Feladilimab|Feladilimab will be administered.
214955366|NCT03739710|DRUG|Ipilimumab|Ipilimumab will be administered.
214955367|NCT03739710|DRUG|GSK4428859A|GSK4428859A/EOS884448 will be administered.
214955368|NCT03739710|DRUG|Dostarlimab|Dostarlimab will be administered.
214955369|NCT03739710|DRUG|GSK6097608|GSK6097608 will be administered.
215071848|NCT02339142|RADIATION|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
215071849|NCT02339142|DRUG|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
215071850|NCT00742287|DIETARY_SUPPLEMENT|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
215071851|NCT00742287|DIETARY_SUPPLEMENT|Placebo|placebo
214330683|NCT03895320|BEHAVIORAL|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
214330684|NCT01971138|OTHER|this is a survey|
214330685|NCT04596150|DRUG|CX-2009|Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)
214330686|NCT04596150|DRUG|CX-072|Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
214330687|NCT04423042|BIOLOGICAL|Tocilizumab|Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.
214330688|NCT04395716|BIOLOGICAL|ResCure™|Patients will be treated with nebulized ResCure™
214330689|NCT05961891|PROCEDURE|The Use of Composite Bone and Nail Bed Graft Combined With Cutaneous Flaps for Reconstruction of Finger Tip Amputations|"1. The amputated finger tip is cleaned and a composite graft including the nail bed and bone of distal phalanx is taken from the amputated part.~2. The bone of the amputated part is fixed to the remaining stump of the distal phalanx with an axial 21gauge needle or by a K-wire (0.8 mm).~3. The nail bed graft is sutured with 6-0 vicryl to the remaining nail bed.~4. A local or regional cutaneous flap is used to cover the volar aspect and tip of the distal phalanx bone e.g. V-Y advancement flap, thenar flap or cross finger flap .The flap should protrude beyond the tip, providing extra skin which is recontoured to a rounded tip.~5. The nail plate is inserted in the nail fold to prevent the formation of synechiae between the nail fold and the injured nail bed.~6. The finger is immobilized for two weeks in a below elbow dorsal slab.~7. Patients are followed up for 3 months. Postoperative complications and their management will be recorded."
214330690|NCT01813565|DRUG|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
214330691|NCT05731934|DRUG|HX301|At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
214330692|NCT00832351|PROCEDURE|Mobilisation|Mobilisation
214330693|NCT06104267|BEHAVIORAL|7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients|"The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group."
214330694|NCT00990483|DEVICE|3D mammograpgy system|In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition). The experimental imaging is compared to the standard of care imaging
214330695|NCT05911620|DEVICE|Magnetic resonance elastography (MRE)|Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
214330696|NCT03211195|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
214330697|NCT03212963|DRUG|Halobetasol Topical Lotion|Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
214330698|NCT03151356|DEVICE|Measurement of Prostate Health Index (PHI)|Use of a diagnostic tool to predict prostate biopsy outcome: measurement of total and free PSA as well as the \[-2\]proPSA and calculation of The Prostate Health Index according to the following formula: Prostate Health Index (PHI) = \[p2PSA /fPSA\] x √tPSA
214330699|NCT01632501|DEVICE|Coronary stent - Tsunami|A coronary angioplasty was done
214330700|NCT00976534|DRUG|AZD1386|90 mg, capsules, oral, during 3 weeks
214330701|NCT00976534|DRUG|Placebo|capsules, oral, during 3 weeks
214330702|NCT00649181|DRUG|Metolazone Tablets 5 mg|2x5mg, single dose fasting
214330703|NCT00649181|DRUG|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
215071852|NCT05928117|OTHER|Education|Pregnant women will be given training to cope with the fear of childbirth.
215071853|NCT06410261|BEHAVIORAL|Exercise rehabilitation program|"* The sessions will consist of a customized low-impact, resistance-base rehabilitation regime to increase muscle strength and functionality by focusing on isolating each targeted muscle, without increasing the participant's fatigue or pain level.~* The goal of phase one will be to start muscle activation without increasing fatigue or pain. Low intensity, single set of 30-35 repetitions for each of the targeted muscles will be performed by the participants, followed by stretching; the goal of phase two will be to progressively develop muscle strength, without increasing pain or fatigue. A single set of 20-25 repetitions for each muscle will be prescribed, followed by stretching; during phase three, the emphasis will be on further development of muscle strength, function, and endurance."
215071854|NCT04966312|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
215071855|NCT04966312|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
214932671|NCT03476174|DRUG|Interleukin-2|Following the pembrolizumab treatment, HD IL-2 treatment will commence. After completing the 2 cycles of pembrolizumab, High Dose Interleukin-2 (HD IL-2) will be administered. This will require a hospital stay of at least 5 days for each treatment cycle. Established guidelines will be followed for safely administering HD-IL-2 and managing toxicities from this treatment. Two treatment cycles will be administered, Cycle 2 being separated from Cycle 1 by approximately 9 days after completion (assuming subject has recovered from Cycle 1 adequately to proceed with Cycle 2). Four weeks after completion of the 2 cycles (called a course of HD IL-2 therapy), disease status will be monitored via CT of the chest and abdomen/pelvis using revised RECIST guidelines
214932672|NCT05537792|DEVICE|Robotic Knee/Ankle Prosthesis|The intervention is an experimental robotic knee/ankle prosthesis that has been previously developed by the team. It is used to improve walking gait performance.
215071856|NCT01984463|DRUG|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
215071857|NCT01984463|DRUG|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
215071858|NCT05201430|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
215071859|NCT05201430|DRUG|CapeOX|oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
215071860|NCT05120973|PROCEDURE|multispectral imaging|Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
215071861|NCT05120973|PROCEDURE|fluorescence for lymphatic mapping|Indocyanine green injected in abdominal wall
215071862|NCT00054951|DRUG|MTC-DOX for Injection|
215071863|NCT03150745|PROCEDURE|3- Cervical Pap smears|Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
215071864|NCT03150745|PROCEDURE|Colposcopic examination|"0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination"
215071865|NCT03150745|PROCEDURE|Office hysteroscopy|0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
215071866|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
215071867|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
215071868|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
215071869|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
215071870|NCT01031316|OTHER|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
215071871|NCT01031316|OTHER|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
215077831|NCT02961933|OTHER|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
215077832|NCT04623268|DIAGNOSTIC_TEST|Ultrasound and questionnaire|One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group
215077833|NCT01065051|DRUG|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
215077834|NCT01065051|DRUG|Placebo|Single oral dose
215077835|NCT02607241|DEVICE|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
215077836|NCT02607241|DEVICE|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR \> 0.8, residual diameter stenosis \< 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis \> 40% or FFR \< 0.8).
215077837|NCT00064766|DRUG|doxycycline|
215077838|NCT02068846|DRUG|Ciprofloxacin|Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
215077839|NCT02068846|DRUG|Placebo|Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
215077840|NCT04177485|BEHAVIORAL|SMS text reminders|SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
214330704|NCT02653677|OTHER|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
214932673|NCT06272136|DEVICE|Clinical Demo 2.0|During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)
214330705|NCT06008925|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
214330706|NCT06008925|DRUG|Nivolumab Injection|Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
214330707|NCT02720575|OTHER|Consumption of capsule/bread with vitamin D|
215071872|NCT03619707|DRUG|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
214330708|NCT01435005|OTHER|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
214330709|NCT01435005|OTHER|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
214932674|NCT06629298|OTHER|5Hz Stochastic Resonance Whole-Body Vibration Training|"Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 5 Hz."
215071873|NCT01191736|BEHAVIORAL|No training, assessed within 60 mins|Subjects receive no training in resuscitation
215071874|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
214330710|NCT05023694|OTHER|Video recordings|"In the first phase it will proceed to completion of the registration system by collecting data revivals and video recordings.~In a second phase, the video is displayed and analysis of the resuscitation performance will take place. We will identify and make a registration of incidents. At this point the observational descriptive analysis will take place.~Third phase: to develop preventive measures necessary to limit the number of incidents or to contain or minimize adverse effects resulting thereof: restructure and adapt the protocol."
214932675|NCT06629298|OTHER|2 Hz Stochastic Resonance Whole-Body Vibration Training|"Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 2 Hz."
215071875|NCT01191736|BEHAVIORAL|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
215071876|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
214330711|NCT05023694|OTHER|Video recordings after corrective measures in adverse events|"Fourth phase: Training department staff on improvements to optimize performance times protocol using simulation.~Fifth stage: final implementation of corrective measures of adverse events during the performance resuscitation.~Sixth stage: successive evaluations of impact of corrective measures. With this evaluation, it will be held another descriptive case series. With the secondary formulate hypothesis after analysis of the errors, the protocol is optimized and measured if errors are minimized: analytical observational prospective cohort study."
215071877|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
215071878|NCT01191736|BEHAVIORAL|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
214330712|NCT02553421|DEVICE|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
214330713|NCT05146128|OTHER|Strengthening exercises|The participants had to perform specific exercices 3 times a week during 8 weeks
214330714|NCT01814176|DEVICE|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
214330715|NCT03747081|DRUG|Rivaroxaban|Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.
214330716|NCT03747081|DRUG|Warfarin|Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
214330717|NCT00611702|PROCEDURE|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
214330718|NCT05287191|DRUG|Magnesium sulfate and then Digoxin|We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast Atrial Fibrillation persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance \<60 ml/min measured by the Modification of diet in renal disease formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
214330719|NCT05287191|DRUG|Amiodarone|We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
214330720|NCT02381080|DRUG|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
214330721|NCT02381080|DRUG|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
214330722|NCT02381080|DRUG|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
214330723|NCT01455324|DEVICE|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
214932676|NCT03410082|DEVICE|Titration under the guidance of BIS|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if BIS is greater than 80; The infusion rate is decreased by 0.1mcg/kg/h if BIS is less than 60.
214932677|NCT03410082|DIAGNOSTIC_TEST|Titration under the guidance of OAA/S|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if OAA/S is greater than 3; The infusion rate is decreased by 0.1mcg/kg/h if OAA/S is less than 3.
214932678|NCT01600274|DRUG|Dienogest-Ethinyl Estradiol (test product)|One tablet of Test
214330724|NCT05713123|OTHER|A SPECT-CT whole body is added in VERITON-CT camera|A SPECT-CT whole body in VERITON-CT camera is added after the conventional procedure recorded in Anger camera
214932679|NCT01600274|DRUG|Dienogest-Ethinyl Estradiol (reference product)|One tablet of Reference
215071879|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
215071880|NCT03957421|OTHER|aquatic exercise, land based exercise|general warm up and cool down. general exercises and treadmill training at self-selected intensity.
214932680|NCT01056991|OTHER|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
214932681|NCT01056991|OTHER|warming blanket|
215071881|NCT01408550|DRUG|NPB-01|Intravenous immunoglobulin
214932682|NCT06329960|OTHER|Ultrasound-guided injection combined with needle release|Ultrasound-guided PIT using D5W HD for dorsal scapular nerve combined with needle release of major and minor rhomboideus
215071882|NCT01408550|DRUG|Placebo|Physiological saline
215071883|NCT04339998|DIAGNOSTIC_TEST|Point-of-Care Ultrasonography (POCUS)|"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~1. B lines: absent (\< 3 lines), present (\> 3 lines), fused~2. Consolidation: yes or no~   a. Bilateral: yes or no~3. Pleural Effusion: yes or no~4. Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~1. Parasternal long axis~2. Parasternal short axis~   1. Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~  2. EPSS (E-point septal separation): normal (\<10 mm), abnormal (\>10 mm)~  3. Left ventricular (LV) mass approximation by septal thickness~  4. Left Ventricular Chamber Size by internal diameter at diastole"
215071884|NCT03927482|BEHAVIORAL|CARES mobile smart phone app|The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support
215071885|NCT03927482|BEHAVIORAL|Check Your Drinking|Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
214330725|NCT05176652|RADIATION|ultrasound|ultrasonographic assessment of optic nerve sheath diameter
214330726|NCT06884423|DEVICE|FETO with GoldBAL2 Balloon and BALTACCIBDPE100 Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
214330727|NCT06293482|DEVICE|Cochlear™ Nucleus® System|The Cochlear™ Nucleus ® System is a commercially available system intended for restoration of hearing sensation through electrical stimulation of the auditory nerve in adult patients with bilateral symmetrical sensorineural hearing loss.
214932683|NCT05972291|DIETARY_SUPPLEMENT|Oral Glutamine|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
214932684|NCT05972291|OTHER|Control Arm|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
214932685|NCT04913727|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging before the procedure|CMR image acquisition with previously mentioned analysis
214932686|NCT04913727|PROCEDURE|Transcatheter mitral edge-to-edge repair.|Included patients will undergo Transcatheter mitral edge-to-edge repair.
214932687|NCT05123092|OTHER|Ultrasound guided lumbar erectae spinae block|One group by using ultrasound for making erectae spinae block
215071886|NCT05764759|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
215071887|NCT05764759|BEHAVIORAL|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
215071888|NCT06755034|DEVICE|c-SIMO|Placement of an implant in the mandibular canine area and using it to stabilize a pre-existing mandibular complete denture.
215071889|NCT06755034|DEVICE|m-SIMO|Placement of an implant in the midline of the mandible and using it to stabilize a pre-existing mandibular complete denture.
215071890|NCT03255967|BEHAVIORAL|DSM-H|Multi-modal quality improvement program for improving the quality of care provided to person with dementia (PWD)-informal caregiver dyads through HHC
215071891|NCT03255967|BEHAVIORAL|Standard of Care|Subjects receive care through usual home healthcare assignment process.
215071892|NCT00519324|DRUG|Everolimus|10 mg/day (2 tablets of 5 mg each)
215071893|NCT00362271|DRUG|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
215071894|NCT01202188|DRUG|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
215071895|NCT01202188|DRUG|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
215071896|NCT01202188|DRUG|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
215071897|NCT01202188|DRUG|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
215071898|NCT01202188|DRUG|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
215071899|NCT06000683|BEHAVIORAL|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
215071900|NCT06000683|BEHAVIORAL|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
215071901|NCT06000683|BEHAVIORAL|Patient Reminders|Within 2 weeks prior to primary care appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss the LCS with their provider.
215071902|NCT06000683|BEHAVIORAL|Provider Reminers|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for LCS.
215071903|NCT02048644|DRUG|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
215071904|NCT02048644|DRUG|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
215071905|NCT02326168|DRUG|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
214330728|NCT05535907|DEVICE|Intravascular Lithotripsy|Enhancing percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium in below the knee lesions prior to full balloon dilatation at low pressures
214330729|NCT07039123|DIAGNOSTIC_TEST|Polygenic Risk Score for Coronary Artery Disease (PRS-CAD)|A polygenic risk score will be calculated based on genome-wide genotyping and combined with SCORE2 clinical risk factors to estimate personalized cardiovascular risk. The combined risk (PRS-CAD-SCORE2) will be communicated to participants and their healthcare providers using a standardized communication tool. Participants with elevated risk will be referred to a lipid clinic.
215071906|NCT03241277|PROCEDURE|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
215071907|NCT00937742|DIETARY_SUPPLEMENT|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
215071908|NCT07081880|OTHER|biological sampling|DNA and Cells will be sampled
215077841|NCT03222830|PROCEDURE|personal embryo transfer|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
215077842|NCT04134130|DRUG|Degarelix 120 MG [Firmagon]|Two doses of degarelix, 240 mg, subcutaneously once, at study start.
214330730|NCT07039123|BEHAVIORAL|Standardized Risk Communication Tool (SCORE2)|Participants will receive risk communication based solely on clinical risk factors using the SCORE2 algorithm. The same structured communication tool will be used (without genetic data), along with general lifestyle guidance.
214330731|NCT03108248|DRUG|ethiodized oil; doxorubicin;Gelfoam;|Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
214330732|NCT03108248|DEVICE|stent; idoine-125|In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
214330733|NCT06722170|GENETIC|EH002 administration|EH002 was administered into one or both ears via intracochlear injection.
214932688|NCT05123092|OTHER|Intrathecal Morphine injection|Injecting intrathecal morphine
214330734|NCT07049081|BIOLOGICAL|LUCAR-G79 T cells|Prior to infusion of the LUCAR-G79 T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
214932689|NCT03150992|DIETARY_SUPPLEMENT|Elemental 028 Extra Liquid|A nutritionally complete, liquid elemental diet consisting of a mixture of essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and flavourings with sugars \& sweeteners.
214932690|NCT01376466|OTHER|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
214932691|NCT06509750|OTHER|Carob-meal|A meal with carob-beverage
214932692|NCT06509750|OTHER|Non-carob-meal|A meal with orange-beverage
214932693|NCT00033202|DRUG|Gimatecan® (ST-1481)|
214932694|NCT00319384|DEVICE|Ultrafiltration therapy|
214932695|NCT01636154|DRUG|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
215077843|NCT04134130|DRUG|Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector|Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
215077844|NCT04134130|DRUG|Testosterone Undecanoate|One dose 1000 mg testosterone once, after 3 weeks.
214932696|NCT01636154|DRUG|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
215077845|NCT04650412|OTHER|Bundle of comorbidities care|Pulmonary function tests, blood gas analysis, transthoracic echocardiography, sleep study after stabilization of patient's index clinical condition, thus 1 month after hospital discharge
215077846|NCT06511739|DRUG|SYHX1901|SYHX1901 tablet
214330735|NCT06893809|PROCEDURE|Epidural injection via Tuohy needle|Local anesthetic was administered entirely through the Tuohy needle.
214330736|NCT06893809|PROCEDURE|Epidural injection via catheter|Local anesthetic was administered entirely through the epidural catheter.
214330737|NCT06893809|PROCEDURE|Combined epidural injection (needle and catheter)|Half of the total local anesthetic dose was administered through the needle and half through the catheter.
214330738|NCT06763705|DRUG|Midazolam|It will not be used alone but in combination with Fentanyl in the Midazolam + Fentanyl group.
214330739|NCT06763705|DRUG|Propofol|It will used alone in Propofol group and in combination with Fentanyl in the Propofol + Fentanyl group.
214330740|NCT06763705|DRUG|Fentanyl|Fentanyl will not be used in isolation but will be used in combination with either Midazolam or Propofol in Midazolam + Fentanyl group and Propofol + Fentanyl group, respectively.
214330741|NCT06893198|BEHAVIORAL|Storytelling intervention|"The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered via Computerized Intervention Authoring System (CIAS) on a biweekly basis. A supplementary Learn More module of didactic material (3 minutes) provides strategies for better patient-physician communication and is coordinated with the specific patient stories will be provided via CIAS as well."
214330742|NCT06893198|BEHAVIORAL|Home BP monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
214932697|NCT01636154|DRUG|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
214932698|NCT04614038|DIAGNOSTIC_TEST|DETEC® pH|DETEC® pH is a disposable diagnostic device that is used to indicate the alkalinity of the wound by testing wound exudate adsorbed onto wound dressing.
214932699|NCT01522287|BEHAVIORAL|Computer-Assisted Cognitive Behavior Therapy (BT STEPS)|BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
214932700|NCT03677336|DRUG|Dydrogesterone Oral Tablet|Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
214932701|NCT03677336|DRUG|Micronized progesterone|Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
214932702|NCT03677336|DRUG|Placebo Dydrogesterone oral tablet|Tablet, indistinguishable from dydrogesterone oral tablet
214932703|NCT03677336|DRUG|Placebo Micronized progesterone|Capsule, indistinguishable from micronized vaginal progesterone capsules
214932704|NCT03763461|DEVICE|HFNC|High flow nasal humidified oxygen HFNC is an air-oxygen blender, which provides high flow (up to 60 L/min) of warmed (36°C) and humidified gas through nasal cannula, allowing tighter control of FiO2 from 0.2 to 1.0.
214932705|NCT03763461|DEVICE|Oxygen Mask|Application of oxygen during conscious sedation
215077847|NCT06511739|DRUG|placebo|Oral tablet
215077848|NCT02676336|DIETARY_SUPPLEMENT|Violet™ Molecular Iodine (I2)|
215077849|NCT02676336|OTHER|Placebo|
214330743|NCT06893198|BEHAVIORAL|Expanded community health worker services|A training program will be implemented for community health workers for the intervention arm regarding hypertension management at the community level so that they can assist patients better managing their blood pressure at home.
214330744|NCT06893198|BEHAVIORAL|"Learn More module only"|"A supplementary Learn More module of didactic material (3 minutes) provides strategies for better patient-physician communication, which will be delivered via Computerized Intervention Authoring System (CIAS) at baseline and at 3, 6, and 9 months after enrollment."
214330745|NCT06761937|PROCEDURE|Thermotherapy|Thermotherapy will be given once a week after a radiotherapy fraction
214330746|NCT06761937|RADIATION|standard radiotherapy|standard radiotherapy
214330747|NCT06771843|BEHAVIORAL|Kisoboka|"Intervention activities:~Financial goal setting (developing delayed rewards), Text message reminders of savings goals (increase salience of delayed rewards), Substance-free activities (alternative reinforcers), Mobile money savings and work payments (constraints on buying alcohol), Social support \& role models for financial goals and substance-free activities (delayed rewards, alternative reinforcers), Financial literacy, Develop motivation \& confidence for change, Goal setting for alcohol reduction \& ART adherence, Alcohol harms \& defining low risk drinking Discuss challenges to change and maintain alcohol risk reduction and improved adherence, Developing \& reinforcing discrepancy between savings/life goals and drinking/poor adherence, Developing discrepancy activity: goals for savings and healthy living and weekly, monthly, yearly spending on alcohol Self-monitoring of savings \& spending Text message reminders to reinforce discrepancy between unhealthy behavior \& goals"
214330748|NCT06771843|BEHAVIORAL|Behavioral Economics|"Intervention activities:~Financial goal setting (developing delayed rewards), Text message reminders of savings goals (increase salience of delayed rewards), Substance free activities (alternative reinforcers), Mobile money savings and work payments (constraints on buying alcohol/ decrease reward value of alcohol), Social support \& role models for financial goals and substance free activities (delayed rewards, alternative reinforcers), Financial literacy"
214932706|NCT00846677|DIETARY_SUPPLEMENT|Vitamin D, cholecalciferol|Oral Quick Dissolve Strip, 400 IU once per day for 21 days
214932707|NCT00846677|DIETARY_SUPPLEMENT|Vitamin D, cholecalciferol|Oral Syrup, 400IU per day for 21 days
214932708|NCT03955081|DEVICE|Deep enteroscopy|A deep enteroscopy conducted with the new medical device PowerSpiral.
214932709|NCT06334653|OTHER|exercise|acute exercise bout
214932710|NCT03531528|OTHER|Diet|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
214932711|NCT00954512|DRUG|Carboplatin|
214932712|NCT00954512|DRUG|Epirubicin|
214932713|NCT00954512|BIOLOGICAL|Trastuzumab|
214932714|NCT00954512|DRUG|Everolimus|
215077850|NCT00746915|DEVICE|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
214330749|NCT06771843|BEHAVIORAL|Motivational Interviewing|"Intervention activities:~Develop motivation and confidence for change, Specific goal setting for alcohol reduction and ART adherence, Alcohol harms \& defining low risk drinking, Discuss challenges to change and to maintain alcohol risk reduction and improved adherence/care engagement"
214330750|NCT06771843|BEHAVIORAL|Screening and Referral|"Brief feedback on their Alcohol Use Disorders Identification Test (AUDIT) score per the AUDIT brief intervention manual, a referral for alcohol counseling, and brief guidance on the importance of HIV care engagement and adherence following the Ugandan Ministry of Health protocol. A referral coupon with details of the clinic name and location will be provided to each participant and participants will be asked to submit the referral note to the alcohol and/or HIV counselor."
214932715|NCT00954512|DRUG|Gemcitabine|
214932716|NCT00954512|BIOLOGICAL|Robatumumab|In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.
214932717|NCT00954512|BIOLOGICAL|Cetuximab|
214932718|NCT00954512|DRUG|Paclitaxel|
214932719|NCT00954512|DRUG|Cisplatin|
214932720|NCT00954512|DRUG|5-FU|
214932721|NCT00954512|DRUG|Erlotinib|
214932722|NCT00954512|DRUG|Irinotecan|
215077851|NCT01615055|DRUG|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
214932723|NCT00954512|DRUG|Folinic Acid|
214932724|NCT05073341|OTHER|Nurse-led family intervention|Nurse-led family intervention having three components first is infarmation about the patient's condition and guidance will be given to solve there queries and the emotional support will be given to the primary caregivers of CLD patient's admitted in HDU
214932725|NCT01751334|DEVICE|total knee arthroplasty|Mobile Bearing Total knee Arthroplasty
215077852|NCT01615055|OTHER|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
215077853|NCT01603797|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
214932726|NCT01751334|DEVICE|total knee arthroplasty|Fixed Total Knee Arthroplasty
214932727|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 10 mg PF-04427429 or placebo
214932728|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 30 mg PF-04427429 or placebo
214932729|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 100 mg PF-04427429 or placebo
214932730|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 300 mg PF-04427429 or placebo
214932731|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 1000 mg PF-04427429 or placebo
214932732|NCT01794793|DRUG|Pasireotide|Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
214932733|NCT01794793|DRUG|Cabergoline|Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
214330751|NCT06336343|DRUG|Bimekizumab|Bimekizumab 320 mg via subcutaneous injections. Bimekizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to and neutralizes the biologic functions of both interleukin-17A (IL-17A) and IL-17F, which are known to increase inflammation.
214330752|NCT06761131|DRUG|Linezolid (LZD)|compare the incidence and magnitude of Linezolid induced thrombocytopenia
214330753|NCT06794840|BEHAVIORAL|JomCare is a smartphone-based just-in-time adaptive intervention (JITAI) for chemsex-related harm reduction.|JomCare is a smartphone-based just-in-time adaptive intervention (JITAI) that uses an EMA-based machine learning (ML) algorithm to anticipate chemsex risk and deliver appropriate chemsex-related harm reduction and HIV prevention services when the risk is detected.
214330754|NCT07074353|DRUG|NALIRI|Irinotecan liposomes
214330755|NCT07074353|RADIATION|LCRT|Long-course concurrent chemoradiotherapy
214330756|NCT07074353|DRUG|FOLFOX|Fluorouracil/Leucovorin, Oxaliplatin (5-FU/LV, OX)
214330757|NCT07079254|PROCEDURE|Meniscus suture|The meniscus bucket-handle injury will either be treated with meniscus suture or partial meniscectomy
214330758|NCT07079254|PROCEDURE|Partial meniscectomy|The meniscus bucket-handle injury wil be treated with either meniscus suture or partial meniscectomy
214330759|NCT07077629|PROCEDURE|morbidity and mortality|Relationship of scoring systems with postoperative morbidity and mortality in geriatric patients undergoing gynecologic cancer surgery.
214330760|NCT07080580|BEHAVIORAL|Core exercises performed simultaneously on a whole body vibration platform|"It's a method where individuals stand on a vibration-generating platform and the vibration is transmitted from the soles of their feet to the entire body. Its use in combination with exercise has become popular in recent years due to the hypergravity it creates, aiming to increase muscle strength and reduce pain.~There is no standardized protocol for the frequency, amplitude, and frequency of vibration application. However, it is known that when applied at frequencies between 10-30 Hz, it has no negative side effects and is beneficial in managing pain. In our study, core exercises will be performed on a vibration platform at a frequency of 14 Hz with an amplitude of 8 mm."
214330761|NCT06786039|PROCEDURE|Non-invasive NAVA|"Initiate respiratory assist with NIV-NAVA within 48 hours. The setting of respiratory support will be adjusted based on clinical conditions of each subject. NIV-NAVA could be switched to nasal continuous airway pressure or high flow nasal cannula, and it also could be stopped after initial stabilization.~In cases of respiratory distress syndrome, lung surfactant will be administered via the less invasive surfactant administration (LISA) method and avoid endotracheal intubation whenever possible. For who intubated in the delivery room, extubation with NIV-NAVA should be considered as soon as possible. Endotracheal intubation with invasive ventilation could be applied when clinical deteriorations happens."
214330762|NCT06776783|COMBINATION_PRODUCT|APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)|Subjects in the APC-0101 group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface and APC-0101 treatment will be started.
214330763|NCT06776783|OTHER|Control|Subjects in the Control group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface but an empty vial will be used instead of APC-0101.
214330764|NCT07082387|OTHER|External oblique and rectus abdominis plane block|Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20ml of bupivacaine 0.25%.
214330765|NCT07082387|OTHER|Quadratus lumborum block|Patients will receive a quadratus lumborum block (QLB) using 20ml of bupivacaine 0.25%.
214330766|NCT07078825|OTHER|Training Supported by Metaverse and Virtual Reality (VR) in the Digital Breastfeeding Museum Group|The pregnant women in this group received training supported by Metaverse and virtual reality (VR) in the digital breastfeeding museum. The training began when pregnant women wore VR headsets (Meta Quest 2) and entered the digital museum using hand controllers. To prevent physical risks like falling or bumping, they navigated the environment safely from where they were seated. Educational content was accessed via personalized avatars. Participants moved between rooms by walking virtually or clicking on circular transition portals. The researcher provided guidance when needed. Video durations varied by topic, totaling around 40 minutes. Mothers could rewatch videos and pause/resume the training on the same day. They engaged with visual, auditory, and written materials, spending approximately one hour in the museum.
214330767|NCT07086326|DRUG|Ivonescimab+Chemo|Ivonescimab (AK112) + platinum-based doublet chemotherapy
214330768|NCT07086326|DRUG|Penpulimab+Chemo|Penpulimab (AK105) + platinum-based doublet chemotherapy
214330769|NCT07084974|DEVICE|Adjustment and practice session|During the adjustment and practice session, participants will perform the lifting task with each exoskeleton after they are properly fitted. They will also perform the measurement sequence as to limit learning effects during lifting task sessions. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
214330770|NCT07084974|DEVICE|No trunk assistance|This lifting task session is performed without any trunk assistance exoskeleton. Participants perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
214330771|NCT07084974|DEVICE|Uplift Lite exoskeleton|This lifting task session is performed with the Mawashi Uplift Lite trunk assistance exoskeleton. Participants will perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
214330772|NCT07084974|DEVICE|Biolift exoskeleton|This lifting task session is performed with the Biolift trunk assistance exoskeleton. Participants perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
214673512|NCT05363007|RADIATION|spleen irradiation|"Upfront SI (Arm A): upfront spleen irradiation (1 Gy/fx, day 1-4) in cycle 2~Add-on SI (Arm B): add-on spleen irradiation (1 Gy/fx, day 1-4) in cycle 1 following limited progression to prior nanoliposomal irinotecan + 5-FU/leucovorin"
214330773|NCT07084974|DEVICE|Laevo Flex exoskeleton|This lifting task session is performed with the Leavo Flex trunk assistance exoskeleton. Participants perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
214330774|NCT06787430|DRUG|nicorandil|In the nicorandil group, intracoronary nicorandil 3mg dissolved in 3ml saline was given within 30 seconds at two time points, one was when the guidewire or ballon passed the lesion and the blood flow was regained, and another was the time before the stent was implanted.
214330775|NCT06787430|DRUG|Saline (NaCl 0,9 %) (placebo)|In the control group, 3ml saline was given intracoronary through the guiding catheter within 30 seconds at the same time points in nicorandil group.
214330776|NCT07087223|DRUG|Vebreltinib combined with Furmonertinib|Vebreltinib 100mg/1500mg/200mg oral twice daily combined with Furmonertinib 80mg oral once daily
214330777|NCT07087223|DRUG|Vebreltinib combined with Furmonertinib|Vebreltinib 100mg/1500mg/200mg oral twice daily combined with Furmonertinib 80mg oral once daily. Based on the safety data from the completed dose cohorts, the investigators will involve the selection of 1-2 dose cohorts for further study. Approximately 10 additional subjects will be enrolled in the selected dose expansion cohort to determine the recommended dose for Phase II clinical trials.
214330778|NCT07087223|DRUG|Vebreltinib combined with Furmonertinib|RP2D of Vebreltinib as determined during Phase Ib oral twice daily combined with Furmonertinib 80mg oral once daily
214330779|NCT07086846|OTHER|Night splint|All participants will be treated conservatively by wrist splint in a neutral position.
214330780|NCT07086846|OTHER|Myofascial release technique|The participant will receive myofascial release using M2T blade. It will be applied on the carpal tunnel over and above the wrist creases on the ventral aspect of the forearm for 15 minutes, 3 sessions weekly for 6 weeks (total of 18 sessions).
214330781|NCT07086846|OTHER|Acupressure|"It will be applied on the pericardium 6 point (PC-6) for 3 minutes, three times per week for 6 weeks (total of 18 sessions).~It is located on the palm side of the wrist a couple of inches toward the body in between the two tendons (palmaris longus \& flexor carpi radialis) that run approximately down the center of the forearm."
214330782|NCT07086846|OTHER|Home advice|The participants will be asked to follow important advices like supporting the wrists during activity and ensuring proper posture, avoiding wrist flexion and extension, avoiding hard clutches, holding or carrying objects for a long time, catching with fingers, repetitive hand and wrist movement such as knitting or sewing, driving, activities and hobbies such as golf, tennis, table tennis.
214330783|NCT07086118|OTHER|0.9% normal saline|patients in group P will receive 0.9% normal saline
214330784|NCT07086118|DRUG|Metoclopramide 10mg|patients in group M will receive 10 mg metoclopramide
214330785|NCT07086118|DRUG|Dexamethasone|patients in group D will receive 8 mg dexamethasone
214330786|NCT07087119|BEHAVIORAL|utilization of artificial intelligence powered mental health support session through a web browser|utilization of artificial intelligence powered mental health support session with the software XAIA through a web browser for physicians in training to address symptoms related to depression and anxiety.
214330787|NCT07085910|DEVICE|Transcranial magnetic stimulation - dual coil|The dual coil stimulation will be applied using two MagPro X100 stimulators connected to two vertically oriented figure-of-eight coils designed for bilateral hemispheric stimulation.
214330788|NCT07085910|DEVICE|Transcranial magnetic stimulation|Single coil TMS will be performed using a TMS stimulator and the same stimulation coil (MC-B65-HO).
214330789|NCT06864819|OTHER|Blood Draw|Patients will have a single blood sample sent for PEth testing, blood draws will happen during standard of care blood draw.
214330790|NCT01626365|PROCEDURE|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
214673513|NCT05836961|OTHER|Benazir Nashonuma Program (BNP)|"Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy (1/4 of daily energy requirements for children in this age range)~Conditional Cash Transfers (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
215077854|NCT04316806|DIETARY_SUPPLEMENT|Probiotic|Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)
214330791|NCT01626365|PROCEDURE|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
214330792|NCT05123209|BIOLOGICAL|IM83 CAR-T cells|3×10\^9 CAR-T cells
214330793|NCT05123209|COMBINATION_PRODUCT|The second-line treatment of liver cancer|approved by NMPA
214330794|NCT01816620|DRUG|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
214330795|NCT03897608|BEHAVIORAL|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
214330796|NCT02453594|BIOLOGICAL|pembrolizumab|IV infusion
215077855|NCT04316806|DRUG|Rifaximin|Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
215077856|NCT03283098|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
215077857|NCT03283098|DRUG|Placebo|Placebo supplied to match active intervention.
214330797|NCT05239676|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells|The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient
214330798|NCT01323569|DRUG|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
214330799|NCT01323569|DRUG|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
214330800|NCT01323569|DRUG|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
214330801|NCT01323569|DRUG|Placebo|16 placebo sprays and 4 placebo capsules
214330802|NCT01323569|DRUG|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
214330803|NCT01323569|DRUG|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
214330804|NCT01837316|DRUG|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
214330805|NCT01837316|DRUG|Placebo|First strip: Inhalation powder of lactose
214330806|NCT05424471|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention lesson is taught to participants previously randomized into the FSN intervention group during the PECO 1 study. Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the 1 - 45 minute lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
214330807|NCT05424471|OTHER|Control Group - Vehicle Safety|The control (vehicle safety) lesson is taught to participants previously randomized into the control group during the PECO 1 study. Control group participants receive 1 - 30 minute lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
214330808|NCT04724239|DRUG|Sintilimab|200mg IV on Day 1 Q3W
214330809|NCT04724239|DRUG|Chidamide|30mg PO BIW each 3-week cycle
214330810|NCT04724239|DRUG|IBI305|7.5mg/kg IV on Day 1 Q3W
214330811|NCT02923375|BIOLOGICAL|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
214330812|NCT03266445|DRUG|buprenorphine/naloxone|The intervention will be to either continue taking buprenorphine/naloxone or to have the medication reduced perioperatively.
214330813|NCT02908997|OTHER|MindMate|A dementia-specific mobile reminding application
214330814|NCT04402827|DIAGNOSTIC_TEST|Susceptibility to infection|"ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed."
214330815|NCT01975844|OTHER|Individualized Anemia Mangement Protocol|"Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
214673514|NCT04767880|DIETARY_SUPPLEMENT|Whey|Doses of 10, 15, 20 and 30 gram protein of a regular whey protein compound (whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients))
214932734|NCT01794793|DRUG|Pasireotide LAR|Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
214330816|NCT01662869|DRUG|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
214330817|NCT01662869|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
214330818|NCT01662869|DRUG|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
214673515|NCT04767880|DIETARY_SUPPLEMENT|Placebo|The placebo contains \<1 kcal and 0 g protein
214673516|NCT03224962|DEVICE|fluorescence camera|drug - diagnostic test
214932735|NCT03495154|DEVICE|Parietene DS Composite Mesh|All subjects enrolled will receive the Parietene DS Composite Mesh
214932736|NCT05599139|BEHAVIORAL|Low iodine diet|Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake \< 50 mcg per day and thereby depleting the overall iodine store in the body.
214932737|NCT05685732|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
214932738|NCT05685732|OTHER|placebo|matching placebo
214932739|NCT02640404|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
215077858|NCT04128982|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
214330819|NCT01662869|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
214330820|NCT01662869|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
214330821|NCT02506114|BIOLOGICAL|PROSTVAC V/F|PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
214330822|NCT02506114|DRUG|Ipilimumab|
214330823|NCT03713489|PROCEDURE|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
214330824|NCT03599427|DRUG|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
214330825|NCT03599427|DRUG|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
214330826|NCT03778216|BEHAVIORAL|Family Based Treatment|
214330827|NCT00414752|DRUG|AFQ065|
214330828|NCT06462807|BEHAVIORAL|ARC|ARC is an evidence-based intervention that uses three strategies (ARC principles, ARC component tools, and ARC mental models) to create organizational social contexts (OSCs) that support the implementation of interventions to improve patient outcomes.
214330829|NCT06325774|RADIATION|Hypofractionated radiation therapy|54 Gy in 15 daily fractions of 3.6 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
214330830|NCT04101526|BEHAVIORAL|Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference|Six sessions of Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference. Sessions address topics such as sleep education, sleep hygiene, sleep restriction, stimulus control, relapse prevention, and cognitive restructuring.
214673517|NCT00251797|DRUG|Irinotecan|Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
215077859|NCT04866875|BEHAVIORAL|dieting|The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
215077860|NCT02725112|DRUG|Pregabalin ER|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
215077861|NCT02725112|DRUG|Pregabalin ER|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
215077862|NCT02725112|DRUG|Pregabalin ER|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
215077863|NCT02725112|DRUG|Pregabalin ER|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
215077864|NCT02725112|DRUG|Pregabalin ER|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
215077865|NCT02725112|DRUG|Pregabalin ER|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
215077866|NCT00000554|PROCEDURE|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
215077867|NCT00000554|PROCEDURE|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
215077868|NCT02029183|DEVICE|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
215077869|NCT02029183|DEVICE|bi-level positive airway pressure|
215077870|NCT03294096|DIETARY_SUPPLEMENT|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
215077871|NCT03294096|OTHER|Routine care|Routine post-op care
215077872|NCT03440723|DEVICE|DilaCheck|Measuring device for the measurement of cervical dilation
215077873|NCT03440723|DIAGNOSTIC_TEST|Cervical dilation examination|Sterile vaginal examination using subjective methods for measurement of cervical dilation
215077874|NCT02446470|PROCEDURE|Sinus Tarsi approach|A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
215077875|NCT02446470|PROCEDURE|Extensile Lateral approach|An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
215077876|NCT00666497|DRUG|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
215077877|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
215077878|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
215077879|NCT04160247|PROCEDURE|Immediate implant placement|Implants are placed in fresh socket
214330831|NCT01816464|BIOLOGICAL|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe."
214330832|NCT02692833|OTHER|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
214330833|NCT05410652|DIAGNOSTIC_TEST|Detection of fecal samples with diagnostic kit|The 23S rRNA mutation site of clarithromycin and gyrA mutation site of levofloxacin were detected by Helicobacter Pylori fecal Gene Mutation Detection Kit.
214330834|NCT05410652|DIAGNOSTIC_TEST|Sanger Sequencing group|Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing
214330835|NCT05410652|DIAGNOSTIC_TEST|Bacterial culture and drug sensitivity test of gastric mucosa samples|First, a sample of the patient's gastric mucosa will be obtained through gastroscopy. Then, Helicobacter pylori culture and drug sensitivity test can be carried out. Finally, the resistance data of Helicobacter pylori to clarithromycin and levofloxacin will be obtained.
214330836|NCT03675048|DIETARY_SUPPLEMENT|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
214330837|NCT03675048|DIETARY_SUPPLEMENT|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
214330838|NCT04744727|DRUG|paracetamol-pethidine|100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
214330839|NCT01574872|DEVICE|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
214330840|NCT01574872|DEVICE|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
214932740|NCT02640404|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular.
215071909|NCT01311115|BEHAVIORAL|Group commitment contract|"1. Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.~2. The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.~3. Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
215071910|NCT01311115|BEHAVIORAL|Smoking cessation education and counseling|Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
215071911|NCT02693054|DEVICE|HALO|Laser Treatment
215071912|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|Adequate dairy (\> 3 standard daily servings)
215071913|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|\< 1 standard dairy serving/day
215071914|NCT05610618|OTHER|Visual stimulation|Participants will be displayed with photographs of scenes and objects which predictability and sharpness will be manipulated
215071915|NCT01655121|DIETARY_SUPPLEMENT|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months."
214330841|NCT02932891|DRUG|DSXS topical|topical treatment
214330842|NCT02652624|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
214330843|NCT02652624|DRUG|E/C/F/TDF|150/150/200/300 mg FDC administered orally once daily with food
214330844|NCT02652624|DRUG|ATV|ATV 300 mg capsules administered orally once daily with food
214330845|NCT02652624|DRUG|RTV|RTV 100 mg tablets administered orally once daily with food
214330846|NCT02652624|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily with food
214330847|NCT02652624|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
214330848|NCT00865722|PROCEDURE|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
214330849|NCT01023659|DRUG|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
214330850|NCT01023659|DRUG|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
214330851|NCT01023659|BEHAVIORAL|motivational emails|brief motivational emails, sent weekly for 12 weeks
214330852|NCT05074550|DRUG|PPMX-T003|As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
214330853|NCT02310659|OTHER|No intervention|No intervention
214330854|NCT02343510|OTHER|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
214932741|NCT05244044|OTHER|Pulmonary rehabilitation in primary care|Pulmonary rehabilitation consists breathing exercises, exercise capacity, muscle strength and change towards an active lifestyle.
214932742|NCT05397171|DRUG|AZD8853|Monotherapy given until progressive disease or upon meeting other discontinuation criteria.
214932743|NCT05397171|DRUG|Zirconium-89 crefmirlimab berdoxam|CD8+ T cell tracer for positron emission tomography (PET) at two time points in addition to monotherapy AZD8853
214932744|NCT05354102|DRUG|BMC128|A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.
214330855|NCT02111616|BEHAVIORAL|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
214330856|NCT02111616|BEHAVIORAL|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
214330857|NCT03067779|OTHER|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
214330858|NCT05132335|OTHER|Imaging Biomarkers|"One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~\[18F\]-FTHA tracer injections \[15O\]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion"
214330859|NCT01560624|DRUG|Treprostinil Diolamine|Active
214330860|NCT01560624|DRUG|Placebo|Placebo
214330861|NCT00393172|BEHAVIORAL|exercise|5 days per week exercise for 4 months
214330862|NCT03409692|DIAGNOSTIC_TEST|Gene Expression Profiling|SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.
214330863|NCT05695157|DEVICE|Suture-TOOL|Suture device for fast and standardized closure of the abdominal fascia
214330864|NCT03863366|DRUG|Prucalopride|1mg prucalopride tablet, encapsulated in white capsule
214330865|NCT03863366|OTHER|Placebo|Lactose placebo tablet, encapsulated in white capsule
214330866|NCT01469325|OTHER|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
214330867|NCT01469325|OTHER|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
214330868|NCT03431194|DRUG|midodrine|oral midodrine tablets 5 mg
214330869|NCT03431194|DRUG|Placebo|
214330870|NCT03780179|BIOLOGICAL|MMRvaxpro|MMRvaxpro vaccine
214330871|NCT03780179|BIOLOGICAL|Placebo|Placebo
214330872|NCT05161676|DIETARY_SUPPLEMENT|Ketone monoester|Commercially available ketone supplement
214330873|NCT05161676|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
214330874|NCT02502357|OTHER|Healing Statements|"Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:~Following this operation, \[the participant\] will feel very comfortable and \[the participant\] will heal very well.~Toward the end of the surgery, the study staff member will say 5 times:~The operation has gone very well. Following the operation, \[the participant\] will be hungry. \[The participant\] will be thirsty and urinate easily."
214330875|NCT00501540|DRUG|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
214330876|NCT02150122|DIETARY_SUPPLEMENT|Vitamin D3|
214330877|NCT05555433|OTHER|NO INTERVENTION|no intervention
215071916|NCT06036017|OTHER|Earplugs|There are numerous studies that suggest using earplugs can regulate a patient's sleep and may reduce the risk of delirium (Locihova 2017) (Van Rompaey 2012). However, there is no hard and fast rule concerning the duration, timing, and preference of earplug use. The duration of earplug use may vary and will be determined based on the needs of the patient, and it will be ensured that they are used throughout the night (Rompaey 2012).
214330878|NCT01797536|DRUG|Elbasvir|
215071917|NCT06036017|OTHER|Music Therapy|Music therapy will be applied to help the patient relax and fall asleep. Moreover, the choice of music genre will be suitable for the patient's preferences, and it will be ensured that it is played at a low volume. Specific guidelines will be applied regarding the frequency and duration of music therapy, it will be performed twice a day after surgery at a low volume and via headphones, each session lasting 30 minutes (Sibenda A et al. 2019).
214330879|NCT00042094|BIOLOGICAL|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
214330880|NCT01376011|DIETARY_SUPPLEMENT|quercetin/placebo|Quercetin 500mg once per day versus placebo
214330881|NCT00231608|DRUG|topiramate|
214330882|NCT01379326|DRUG|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
214330883|NCT00098839|DRUG|L-asparaginase|Given IM
214330884|NCT00098839|DRUG|doxorubicin hydrochloride|Given IV
214330885|NCT00098839|DRUG|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
214330886|NCT00098839|DRUG|vincristine sulfate|Given IV
214330887|NCT00098839|BIOLOGICAL|epratuzumab|Given IV
214330888|NCT00098839|DRUG|cytarabine|Given IT
214330889|NCT00098839|DRUG|prednisone|Given orally
214330890|NCT00098839|DRUG|pegaspargase|Given IM
214330891|NCT00098839|DRUG|dexrazoxane hydrochloride|Given IV
214330892|NCT00098839|DRUG|methotrexate|Given IT
214330893|NCT00098839|DRUG|etoposide|Given IV
214330894|NCT00098839|DRUG|cyclophosphamide|Given IV
214330895|NCT00098839|DRUG|leucovorin calcium|Given IV
214330896|NCT00098839|BIOLOGICAL|filgrastim|Given SC
214330897|NCT04485481|DRUG|ADX-914|Single dose from 0.1mg/kg to TBD
214330898|NCT04485481|DRUG|Placebo|Matching single dose placebo
214330899|NCT04485481|DRUG|ADX-914|Multiple dose from TBD to TBD
214330900|NCT04485481|DRUG|Placebo|Matching multiple dose placebo
214330901|NCT00073905|DRUG|capecitabine plus gemcitabine|capecitabine plus gemcitabine
214932745|NCT05354102|DRUG|Nivolumab|A human monoclonal antibody that blocks programmed-death-1 (PD-1). It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
215071918|NCT06036017|OTHER|Presence of Family After Extubation:|According to the guidelines titled 'Family presence and visit in Adult ICU' published by the American Association of Critical Care Nurses (AACN) in 2012; it is recommended that a family member or friend chosen by the patient be present to provide 24-hour uninterrupted emotional and social support for patients in intensive care. Allowing the patient's family to visit helps maintain the patient's social connections and contributes to the psychological well-being of the patient with family support. In addition to routine visits, patients' families can spend longer periods with the patient during their intensive care process and information about the patient is conveyed to close family members. Research shows that family presence in the intensive care unit reduces the incidence of delirium (Eghbali-Babadi, 2017) (Rosa 2017).
214330902|NCT01040429|DRUG|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients \< 35 kg; 50 microgram (2 capsula) x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients \< 35 kg; 25 microgram (2 capsula) x 2/day for patients \> 35 kg."
214330903|NCT01040429|DRUG|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients \> 35 kg"
214330904|NCT05868694|DIAGNOSTIC_TEST|polysomnography|Polysomnography is mainly used to diagnose sleep breathing disorders, including sleep apnea syndrome, snoring, upper airway resistance syndrome, and also used for the auxiliary diagnosis of other sleep disorders, such as: narcolepsy, restless legs syndrome, insomnia classification, etc.
214330905|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
214330906|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
214330907|NCT02550964|PROCEDURE|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
214330908|NCT02321579|DIETARY_SUPPLEMENT|vitamin B-6|50 mg/d
214330909|NCT02321579|DIETARY_SUPPLEMENT|Glutathione|500 mg/d
214330910|NCT02321579|DIETARY_SUPPLEMENT|Dextrins|50 mg/d
214330911|NCT03447171|DEVICE|App Vision Screening|Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
214330912|NCT00305617|OTHER|antitumor drug screening assay|
214330913|NCT06021392|PROCEDURE|Z plasty and minimal excision of pilonidal sinus|"The investigators will perform a  Z plasty  procedure and Minimal excision procedure for patients complaining of pilonidal sinus and the investigators will compare the outcomes and rate of recurrence of these two procedures"
214673518|NCT00251797|DRUG|Thalidomide|Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
214932746|NCT04973540|DEVICE|Iron Bioresorbable Scaffold System (IBS Angel)|Subjects in this arm will be implanted with IBS Angel.
215071919|NCT05474638|DEVICE|Isometric Thumb Force (isometric mechanomyography) compared to TOF-Watch SX (acceleromyography)|Comparison of mechanomyographic measurements of thumb adduction's force induced by 100 versus 200 Hz 5 seconds tetanic ulnar nerve stimulation during neuromuscular block spontaneous recovery monitored by acceleromyography on the controlateral arm.
215071920|NCT00491946|DRUG|Actinomycin-D|
215071921|NCT00491946|DRUG|Vincristine|
215071922|NCT04448314|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
214330914|NCT02484105|BEHAVIORAL|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
214330915|NCT02484105|BEHAVIORAL|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
214673519|NCT04001686|OTHER|incidence aplastic anemia|Ambispective chart review
214673520|NCT04696835|DIAGNOSTIC_TEST|speech audiometry|65dB, 55dB or 75dB SPL speech audiometry
214673521|NCT00082082|DRUG|Thymalfasin (thymosin alpha-1)|
214673522|NCT00082082|PROCEDURE|Trans arterial chemoembolization (TACE)|
214673523|NCT00941980|BIOLOGICAL|Osteocel Plus|biologic
214932747|NCT00900549|DEVICE|CRT on|12 months
214932748|NCT00900549|DEVICE|CRT off|12-month
214932749|NCT06914986|PROCEDURE|Performed flexible and navigable suction ureteral access sheath combined with needle perc|Patients are performed flexible and navigable suction ureteral access sheath combined with needle perc or PCNL
214932750|NCT06914986|PROCEDURE|PCNL|Patients were performed flexible and navigable suction ureteral access sheath combined with needle perc or PCNL
215071923|NCT04659499|DRUG|Nab-paclitaxel in combination with pyrotinib|Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
215071924|NCT04607213|PROCEDURE|Advancement-rotation approach based on Millard' for repairing lip defect.|"patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill."
215071925|NCT04607213|PROCEDURE|Straight-line approach|"patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar."
214932751|NCT06915012|DEVICE|Tesla BioHealing(R) Biophoton Generators|Biophoton generators have been reported to reduce severe chronic pain significantly. This is to determine its efficacy.
214932752|NCT02720263|DRUG|ASP4345|Oral
214932753|NCT02720263|DRUG|Matching Placebo|Oral
214932754|NCT04459715|DRUG|Xevinapant (Debio 1143)|Xevinapant (Debio 1143) administrated as oral solution from Day 1 to 14, every 21-day cycle.
214330916|NCT01668316|BEHAVIORAL|Weight loss|"1. Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~2. Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~3. Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~4. Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
214330917|NCT05226962|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid supplement ingested in a dose intended to provide \~0.35 g of ketone monoester per kg body mass of the participant
214932755|NCT04459715|DRUG|Cisplatin|Cisplatin administered as an IV infusion every 3 weeks (Q3W).
214932756|NCT04459715|RADIATION|Intensity Modulation Radiation Therapy (IMRT)|70 Gy given in 35 fractions over 7 weeks.
214932757|NCT04459715|DRUG|Placebo|Matched placebo administrated as oral solution from Day 1 to 14, every 21-day cycle.
214932758|NCT02955095|DEVICE|Quit Smoking Phone Application|The app will be downloaded on participants' phones, and used by the participant for 30 days to make a quit attempt. Participants will be encouraged to use the app every day and to utilize all of its features, including features such as setting a quit date, taking the assessment section, and entering cigarette use and reasons for cravings
214932759|NCT06173037|DRUG|RC88|2.0 mg/kg Q3W IV
214932760|NCT02234596|DRUG|Nintedanib|Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
214932761|NCT05629494|DRUG|Ibuprofen 400 mg, TID|Participants will receive Ibuprofen 400 mg 3 times per day for 10 days.
214330918|NCT05226962|OTHER|Placebo|A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
214330919|NCT02180425|DRUG|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
214932762|NCT05629494|DIAGNOSTIC_TEST|PSA test|PSA test will be repeated in 6 weeks
214932763|NCT05206955|DRUG|Tadalafil|10 mg once daily orally week 1, 20 mg once daily orally during week 2, and 40 mg once daily orally during weeks 3 through 52
215071926|NCT02696733|DEVICE|Ultrasound|Ultrasound-guided obturator nerve localization
215071927|NCT02696733|DRUG|lidocaine 2%|local anesthetic used to block the obturator nerve
215071928|NCT02696733|DRUG|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
215071929|NCT02438384|BEHAVIORAL|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
214330920|NCT02180425|DRUG|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
214330921|NCT00797992|DRUG|Injection|Intravitreal injection of 1.25 mg bevacizumab
214330922|NCT00668681|DEVICE|EndoRefix|
214673524|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using water at room temperature|The use of water at room temperature to solve the 75g glucose.
214673525|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water|The use of hot water to solve the 75g glucose.
214932764|NCT05206955|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
214932765|NCT06951425|DRUG|TH-CART-027|3+3 dose escalation design: Dose Level 1: 0.3×10\^6 CAR+ T cells /kg; Dose Level 2: 1.0×10\^6 CAR+ T cells /kg; Dose Level 3: 3.0×10\^6 CAR+ T cells /kg
214932766|NCT05203848|PROCEDURE|Community Dance Intervention|The main dance instructor for the CDP is Yarra Ileto, who is the Artistic Director for NUS Dance Synergy. Yarra was trained at LASALLE College of the Arts, graduating with a First Class BA (Hons) Dance in 2008. Also, she has experience with crafting and conducting Community Dance Programs (CDP) for Seniors. Yarra will be developing the dance lesson plan and also training selected students from NUS Dance Synergy to guide the seniors during the dance sessions. Older adults will learn and practice the basic steps together for the first few weeks. Then, the student dance instructors will start teaching the dance formation. During each session, participants will need to warm up first to prevent injuries before practicing dance steps. Small group practicing is reserved for older adults to interact with each other. All the participants will do relaxation exercises before ending the session to cool down their bodies and release muscle tensions.
214932767|NCT05203848|OTHER|Control group|Control group
214932768|NCT05630040|DEVICE|Non-invasive vagus nerve stimulation|Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.
214932769|NCT05630040|DEVICE|Sham Intervention|Participants will take a placebo device home for 6 weeks and use daily.
214932770|NCT05633992|BIOLOGICAL|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
215071930|NCT02438384|BEHAVIORAL|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
215077880|NCT04160247|PROCEDURE|Angulated screw-retained crowns placement|To insert the restorations by angulated screw systems
214673526|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water|The use of cold water to solve the 75g glucose.
215077881|NCT04160247|PROCEDURE|Cemented crowns placement|To cement the restorations onto the implant abutment
215077882|NCT00617071|OTHER|medical chart review|
214330923|NCT04400305|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
214330924|NCT00323739|DRUG|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
214330925|NCT00323739|DRUG|RAD001|RAD001 10 mg by mouth daily
214330926|NCT00263523|DRUG|[11C] (-)-RWAY|
214330927|NCT03600168|DEVICE|PuraStat®|Synthetic haemostatic material
214330928|NCT03879681|DIETARY_SUPPLEMENT|Jelly confectionary Snakes|"The participants will be randomized by computer generated randomisation to receive either the jelly snake (n=120) or no intervention (n=120) apart from standard institutional management.~All children randomised into the snake group will be offered a chewy jelly snake once alert and cooperative in PACU or on the ward once University of Michigan Sedation Scale (UMSS) is 025,26. The UMSS is a simple observational tool that assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation).~The children randomized into the control group will receive a chewy jelly snake as a treat at discharge."
214330929|NCT02845271|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
214330930|NCT02845271|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
214330931|NCT02845271|DRUG|acetaminophen or paracetamol|"Pharmaceutical form: tablet~Route of administration: oral"
214330932|NCT02845271|DRUG|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule~Route of administration: oral"
214330933|NCT02845271|DRUG|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet~Route of administration: oral"
214330934|NCT06032286|DEVICE|Skinstylus microneedling device|Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.
214330935|NCT02514252|DRUG|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
214932771|NCT05633992|BIOLOGICAL|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
214932772|NCT04801147|BIOLOGICAL|Dendritic Cells Vaccine|"Right after the surgical resection of the tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Immunotherapy will follow radiochemotherapy and will comprise 4 vaccinations every second week (injections I, II, III, IV), 2 further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) 2 months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only. In correspondence to the third vaccine injection (week 13), mTMZ will start.~Vaccine doses will be injected in the forearm of the patient."
214330936|NCT02514252|BEHAVIORAL|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
214330937|NCT02514252|BEHAVIORAL|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
214330938|NCT02514252|BEHAVIORAL|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
214330939|NCT01117818|BIOLOGICAL|active: AFFITOPE AD02|vaccination
214673527|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water with tea bag|The use of hot water with tea bag to solve the 75g glucose.
214673528|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using room temperature water with tea bag|The use of room temperature water with tea bag to solve the 75g glucose.
214932773|NCT03634033|BEHAVIORAL|MiCAP with IF (Main Study)|"Sites will conduct MiCAP strategies described as follows. Relationship Building; Assess readiness to implement of the site; Internal Facilitator (IF) Champion Coalition Building, which will include IFs training in CAPABLE and facilitation and online IF coalition meetings; Facilitation by the IF, which will include training the clinicians, reviewing home visits with the clinician to assure CAPABLE was provided; IF developing a clinical team for implementation of CAPABLE and leading interdisciplinary coordination of individual beneficiary care; Intervention and implementation strategy fidelity data will be placed in a dashboard for audit and provided to IFs. IFs will use the data to provide feedback to clinicians; and develop action plans for improvement in training or care.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
214955370|NCT05346484|BIOLOGICAL|CF33-hNIS|CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)
214330940|NCT01117818|BIOLOGICAL|control: Placebo|vaccination
214955371|NCT05346484|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
214955372|NCT05346484|DRUG|Modified FOLFOX|"28 day cycle of:~* Leucovorin calcium/folinic acid~* Fluorouracil~* oxaliplatin"
214955373|NCT06098235|BEHAVIORAL|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and fat intake.
214330941|NCT05508061|DRUG|Insulin Lispro Cartridge [Lyumjev]|Administration of Lyumjev in combination with the AP system
214330942|NCT05508061|DRUG|Insulin Lispro Cartridge|Administration of Humalog in combination with the AP system (standard therapy)
214330943|NCT05621421|PROCEDURE|FFR and IVUS guided PCI|PCI to the long lesion guided with FFR and IVUS
214330944|NCT01558882|DEVICE|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
214932774|NCT03634033|BEHAVIORAL|MiCAP with IF and EF (Main Study)|"Sites will conduct MiCAP strategies described above in MiCAP with IF with an addition of External Facilitation. Centralized Oversight will be conducted by External Facilitators. External Facilitators will train in facilitation. The work of the External Facilitators will be tailored (i.e., type of discipline) to each site's needs. Intervention and implementation strategy fidelity data will be placed in a dashboard and will be provided to External Facilitators. External Facilitators will use the data to provide feedback to Internal Facilitators; and develop action plans for improvement in site clinician training or beneficiary care as needed.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
214330945|NCT05406544|OTHER|FD qualitative study on quality of life|Patients will be contacted and focus groups will be organized with 6 to 8 patients presenting different types of FD: monostotic, polyostotic, with or without craniofacial damage. Several focus-groups will be conducted with men only or women only. Patients will be led in a semi-directive manner by a moderator who will use an interview grid listing all the topics to be addressed: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The discussions will be recorded and transcribed verbatim. Data will be analyzed manually by 2 investigators and with the help of a semantic analysis software. The objective is to bring out common notions about the quality of life of patients, their psychological and emotional well-being, their difficulties in daily life and their coping strategies according to their condition. Differences or similarities between men and women will be investigated.
214330946|NCT05406544|OTHER|FD quantitative sudy on quality of life and olfaction.|Participants will receive 3 questionnaires to complete: the SF36 questionnaire (quality of life), the SELF-MOQ questionnaire (olfaction evaluation) and a demographic questionnaire. Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. For each questionnaire, scores will be calculated and compared between the different FD patient populations according to sex, age and type of FD.
214330947|NCT03228680|DRUG|Follitropin delta|Single daily subcutaneous administration through pre-filled injection pen
214330948|NCT03228680|DRUG|Follitropin beta|Single daily subcutaneous injection in the abdomen
214330949|NCT03821571|DIAGNOSTIC_TEST|Brain MRI|Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
214330950|NCT01177072|OTHER|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
214673529|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water with tea bag|The use of cold water with tea bag to solve the 75g glucose.
214955374|NCT06098235|BEHAVIORAL|ORIENT diet intervention|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
214330951|NCT01177072|OTHER|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
214330952|NCT03037151|DRUG|Grazaoprevir/Elbasavir|treatment naive
214330953|NCT03037151|DRUG|Grazaoprevir/Elbasavir/RBV|treatment experienced
214955375|NCT05054335|OTHER|Functional Assessment|Undergo walking function assessment with optical motion capture
214955376|NCT05054335|PROCEDURE|X-Ray Imaging|Undergo bi-plane dynamic X-ray imaging
214955377|NCT03606083|DEVICE|Endovascular repair|Endovascular repair of aorto-iliac or iliac aneurysms using an iliac branch device (IBD)
214955378|NCT01753115|BIOLOGICAL|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
214955379|NCT01753115|DRUG|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
214955380|NCT03642067|DRUG|Nivolumab|Nivolumab was administered IV on day 1 of each 28 day cycle.
214955381|NCT03642067|DRUG|Relatlimab|Relatlimab was administered IV on day 1 of each 28 day cycle.
214955382|NCT04146558|DRUG|Individualized internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
214955383|NCT04146558|OTHER|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
214955384|NCT02913781|PROCEDURE|polar body removal using zona drilling by laser then suction by injecting pipette|zona drilling with laser followed by polar body removal then ICSI procedure
214955385|NCT02913781|PROCEDURE|Classic ICSI|Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
214955386|NCT03927326|DRUG|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine
214955387|NCT03726307|BIOLOGICAL|DCreg: 0.5 million cells/kg+SOC|"DCreg 0.5 (±0.1) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
215077883|NCT00617071|OTHER|survey administration|
215077884|NCT00617071|PROCEDURE|fecal occult blood test|
215077885|NCT00617071|PROCEDURE|screening colonoscopy|
214330954|NCT02379949|BEHAVIORAL|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
214330955|NCT02379949|BEHAVIORAL|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
214330956|NCT03670589|RADIATION|Radiosurgery gammaknife|This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
214330957|NCT03670589|PROCEDURE|Microsurgery resection|Classical surgical approach with oto-neurosurgery procedures
214330958|NCT03318848|OTHER|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
214330959|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
214330960|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
214330961|NCT03962881|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
214330962|NCT02476396|PROCEDURE|Carotid Endarterectomy or Stenting|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing."
214330963|NCT04698005|DIETARY_SUPPLEMENT|25g Ketone monoester without added salts|oral supplementation of ketone monoester
214330964|NCT04698005|OTHER|Placebo|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
214330965|NCT01268644|DRUG|Leptin|weight based sub-cutaneous injection twice daily of Leptin
214330966|NCT05378386|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).
214330967|NCT03058068|BIOLOGICAL|Allo-hMSCs|1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)
214330968|NCT03058068|BIOLOGICAL|Placebo|1 peripheral intravenous infusion
214330969|NCT01416194|DRUG|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
214330970|NCT01416194|DRUG|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
214330971|NCT01416194|DRUG|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
214673530|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water at room temperature|The use of bubble water at room temperature to solve the 75g glucose.
214932775|NCT03634033|BEHAVIORAL|MiCAP with IF and Caregiver Engagement (Administrative Supplement)|A pilot study to examine use of informal caregiver engagement to provide CAPABLE to beneficiaries with Alzheimer's Disease or other Dementia using MiCAP with Internal Facilitation (implementation strategies from the (Main Study). External facilitator will be Champion, clinician, and an early adopters of CAPABLE.
214932776|NCT06516094|DRUG|Celecoxib+Pregabalin+Vitamin B fixed dose|One tablet of 200 mg / 150 mg / 100 mg / 50 mg / 0.50 mg + 1 capsule of placebo once a day
214330972|NCT03970434|OTHER|Venous blood collection|Venous blood collection
214330973|NCT03970434|OTHER|Peripheral blood collection|Peripheral blood collection
214330974|NCT04155996|DEVICE|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
214932777|NCT06516094|DRUG|Celecoxib + Vitamin B fixed dose|One capsule of 200 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
214932778|NCT06516094|DRUG|Pregabalin + Vitamin B fixed dose|One capsule of 150 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
214932779|NCT03689907|OTHER|Chimerism Evaluation|Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant.
214932780|NCT04323618|DEVICE|Breathe Well|
214932781|NCT06397365|OTHER|medical hypnosis|"The first hypnosis session (V2) consists of a safe place suggestion. Through this type of suggestions, patients will safely experience the dissociative state, and will be given tools (recordings of sessions) to perform self-hypnosis at home between the visits. The suggestions will help the patient to visualize an imaginary place where they feel well and safe, a protective place to rest. In this first session, CPAP treatment will be introduced during hypnosis, with specific suggestions relating to the use of this treatment.~The second session (V3) The second session will also use the safe place. We will adapt the suggestions according to the experience reported by the patient on the day of the visit. During this session, we'll focus on changes in the patient's perception of the CPAP machine.~Patients will also be given the recording of each session to perform self-hypnosis at home between the visits."
214330975|NCT02002897|DEVICE|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
214673531|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water|The use of cold bubble water to solve the 75g glucose.
214673532|NCT06060080|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|Lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
214673533|NCT03227926|DRUG|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
214330976|NCT02002897|DEVICE|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
214330977|NCT01222494|BEHAVIORAL|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
214673534|NCT03227926|DIAGNOSTIC_TEST|Molecular Screening|Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
214330978|NCT01222494|BEHAVIORAL|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
214932782|NCT05434182|PROCEDURE|Intradermal Suture|Skin closure with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
214932783|NCT05434182|PROCEDURE|Metallic Staples|Skin closure with metallic stapling using Visistat® (Weck®) 35W skin stapler.
214932784|NCT06366087|DRUG|Atropine Sulfate Ophthalmic Solution USP, 1%|Atropine Sulfate Ophthalmic Solution, USP 1% manufactured by Bausch \& Lomb Americas Inc., is a sterile topical anti-muscarinic indicated for mydriasis, cycloplegia, and penalization of the healthy eye to treat amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains the active ingredient atropine sulfate 10 mg, equivalent to 8.3 mg of atropine. Inactive ingredients are boric acid, hydroxypropyl methylcellulose, and water for injection, USP; hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0). Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in 0.4 mL single-dose vials and will be administered as a single dose to a single participant. 100 μL of Atropine Sulfate Ophthalmic Solution, USP 1% will be given sublingually by pipette to deliver 1.0 mg of atropine sulfate. Before administration, participants will be told to swallow. Once given, participants will be told to try not to swallow for 30 seconds and then swallow normally.
214932785|NCT06366087|DRUG|Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)|Atropine sulfate injection, USP is a muscarinic antagonist used for temporary blockade of severe/life-threatening muscarinic effects and to treat symptomatic bradycardia. Atropine Sulfate Injection, USP, 8 mg/20 mL (0.4 mg/mL) manufactured by Fresenius Kabi is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; and sodium chloride 9 mg; it may also contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8). Atropine Sulfate Injection, USP will be supplied in 8 mg/20 mL multidose vials (0.4 mg/mL). Each vial will be used to administer multiple doses to multiple participants. 2.5 mL will be injected into the mid-anterolateral thigh to deliver 1.0 mg of atropine sulfate. Vials will be dated/timed and will not be given after 24 hours of first entry.
214932786|NCT05342636|BIOLOGICAL|Pembrolizumab|200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)
214932787|NCT05342636|BIOLOGICAL|Coformulation favezelimab/pembrolizumab|800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W
214673535|NCT04595955|OTHER|CMyLife|CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
214673536|NCT03689231|OTHER|Volumetric measurements of liver metastases|"Depending on the available data and to be reproducible, patients will be divided into 2 sub-groups of follow-up imaging: CT only or MRI only, combined evaluation being not reliable for tumor detection~Patient follow-up at CT or MRI will be analyzed at baseline (date of discovery of hepatic metastatic disease), then 3-6 months after the start of the study, then annually.~At each assessment, a radiologist will analyze: the total volume of liver metastases (mm3), the estimated volume of the two target lesions chosen for RECIST follow-up (mm3), the number of liver lesions, and the evolution according to the RECIST criteria based on uni-dimensional measurements.~We will then correlate the following clinical data collected for patients: age, sex, presence of a carcinoid syndrome, Ki67 (%) and chromogranin A blood level (%) at diagnosis, number and location of other metastases, Octreoscan or Stereotactic Radio Surgery data if available."
214673537|NCT02127112|PROCEDURE|Block Allograft plus Matrix Allograft|A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
214932788|NCT05342636|BIOLOGICAL|MK-4830|800 mg administered via IV infusion Q3W
214932789|NCT05342636|DRUG|Lenvatinib|20 mg administered via oral capsules each day
214932790|NCT05342636|DRUG|Irinotecan|180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.
214330979|NCT04485533|DEVICE|VisuXL® Gel|"VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day."
214673538|NCT02127112|PROCEDURE|Moldable Matrix Allograft|The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
214673539|NCT00129077|PROCEDURE|plastic wrap over eye & lubrication applied q6 hrs|
214932791|NCT05342636|DRUG|Paclitaxel|80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
214932792|NCT03474744|DRUG|Copanlisib|Solution for IV infusion
214932793|NCT03474744|DRUG|Rituximab|Solution for IV infusion
214932794|NCT01515462|GENETIC|TLT003|TLT003 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
214932795|NCT05461677|DEVICE|SAIRE smart walker|Participants will walk along the 10-meter walkway 5 times using the SAIRE smart walker
214932796|NCT05461677|DEVICE|Standard 4-wheeled walker|Participants will walk along the 10-meter walkway 5 times using a standard 4-wheeled walker
214932797|NCT05461677|OTHER|No walking aid|Participants will walk along the 10-meter walkway 5 times without using a walking aid
214932798|NCT04501406|DRUG|Pioglitazone|An insulin-sensitizer FDA-approved to treat hyperglycemia caused by type 2 diabetes.
214673540|NCT00283712|DRUG|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
214673541|NCT00283712|OTHER|Placebo Comparator|Placebo administered in place of infliximab for control group
214932799|NCT04501406|OTHER|Placebo|Placebo looks just like pioglitazone and is given in the same way but has no active drug in it.
214932800|NCT00815815|BEHAVIORAL|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
214330980|NCT04485533|DEVICE|HYLO®|"HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day"
214330981|NCT05802381|DIETARY_SUPPLEMENT|protein supplement|20 gram protein supplement per day
214330982|NCT05802381|BEHAVIORAL|nutrition counseling|nutrition counseling for guidance of food intake
214330983|NCT00068055|DRUG|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
214330984|NCT00068055|DRUG|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
214330985|NCT00068055|DRUG|Placebo|Normal Saline.
215077886|NCT05379517|DEVICE|Pulsed ectromagnetid field therapy|Pulsed electromagnetic field therapy is an innovative therapy. The technology is based on a high intensity electromagnetic field, which positively influences human tissue. It is a form of non-invasive treatment, with good tolerance by patients. High-intensity electromagnetic fields excite neural and muscle cells, which stimulates the human body.
214932801|NCT00318851|DEVICE|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
214932802|NCT05092295|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
214932803|NCT05092295|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
214330986|NCT00283725|OTHER|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).
214330987|NCT03714633|BEHAVIORAL|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Post-discharge intervention to extreme premature infants and their parents
214330988|NCT05217797|BEHAVIORAL|Wearing glasses (any type)|Participants are asked to wear glasses in public spaces.
214330989|NCT05120167|DIAGNOSTIC_TEST|Endocervical liquid-base cytology|Endocervical sample collected by brushing and preserved in a liquid-base.
214673542|NCT03622411|DEVICE|speech app|language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
214673543|NCT03622411|DEVICE|brain games|language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
214673544|NCT03622411|BEHAVIORAL|aphasia therapy|language exercises provided by the speech therapist in hospital
214673545|NCT03989687|DEVICE|Fuji Triage|glass ionomer sealant
214673546|NCT03989687|OTHER|isolation|rubber dam or cotton roll isolation
214932804|NCT02326116|OTHER|Trachael Preparation Education|
214932805|NCT01296542|DRUG|Moxifloxacin Ophthalmic|
214932806|NCT01296542|DRUG|Besifloxacin Ophthalmic|
214932807|NCT03243344|DEVICE|Surgiflo|using device during the endonasal surgery.
214932808|NCT03243344|DEVICE|Floseal|using device during the endonasal surgery.
214932809|NCT03243344|DEVICE|Algosteril|using device during the endonasal surgery.
214932810|NCT01045083|DRUG|RO4917523|Oral single dose
214932811|NCT01045083|DRUG|escitalopram|Oral single dose
214932812|NCT01045083|DRUG|methylphenidate|Oral single dose
214932813|NCT01045083|DRUG|placebo|Oral single dose
214932814|NCT01649648|BIOLOGICAL|Autologous cord blood|Baby's own umbilical cord blood
214932815|NCT02819245|PROCEDURE|posterior correction and fusion|
215077887|NCT05379517|OTHER|Pulmonary rehabilitation program (PRP)|This type of physiotherapy program includes: respiratory muscle training, coughing exercises, diaphragmatic training, aerobic training and strength training.
215077888|NCT04525924|DEVICE|bright light therapy|please see arm description
214330990|NCT05120167|DIAGNOSTIC_TEST|Endocervical cell block|"Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology."
214330991|NCT05120167|DIAGNOSTIC_TEST|Endocervical curettage|Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
214330992|NCT01938534|DRUG|Helicobacter pylori eradication|
214330993|NCT05796544|BEHAVIORAL|Remote self-care education|The intervention group will receive a total of four remote educational sessions over 2 months.
214330994|NCT05796544|BEHAVIORAL|In-person self-care education|The active comparator group will receive a total of four in-person educational sessions over 2 months.
214330995|NCT02167035|DRUG|Combigan Two Times Daily (BID)|
214330996|NCT02167035|DRUG|Simbrinza Three Times Daily (TID)|
214330997|NCT05053386|DRUG|Idarubicin Hydrochloride for Injection|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
214330998|NCT05053386|DRUG|Epirubicin|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
214330999|NCT01618539|DRUG|propofol|varying intravenous dosages
214331000|NCT02148003|PROCEDURE|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
214331001|NCT02148003|PROCEDURE|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
214331002|NCT02148003|DEVICE|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
214331003|NCT02451826|DRUG|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
214932816|NCT05451433|DRUG|Saccharomyces Boulardii 250 MG|Normagut capsule twice a day
214932817|NCT05451433|DRUG|Placebo|Placebo capsule twice a day
214932818|NCT01668953|OTHER|Platelet Rich Plasma (PRP) Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.~4. Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.~5. The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations."
215071931|NCT03143907|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
214331004|NCT04662346|OTHER|Difficulty score system for robotic pancreatoduodenectomy|calculate the score for patient in you cohort
214331005|NCT03996928|OTHER|Exercise|
214331006|NCT04055636|DIAGNOSTIC_TEST|Echocardiography with speckle tracking analysis.|Transthoracic echocardiography with speckle tracking analysis.
214331007|NCT04055636|DIAGNOSTIC_TEST|48-hour ECG monitoring.|Ambulatory 48-hour electrocardiography monitoring.
214331008|NCT04055636|DIAGNOSTIC_TEST|Blood samples analysis.|Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
214331009|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
214331010|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
214331011|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S:~1. The probiotics, Duolac7S, consist of 7 bacteria.~2. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~3. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (30 min after morning and evening meal)~4. Duration: 4 weeks of treatment period"
214331012|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
214331013|NCT02489981|DRUG|Spiriva|60 puffs
214331014|NCT02358694|DIETARY_SUPPLEMENT|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
214331015|NCT02358694|OTHER|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
214331016|NCT04491630|BEHAVIORAL|Self-Hypnosis (SH)|"Participants assigned to this condition will listen to a 20-minute recording with instructions of SH adapted from one of our team member's proposed model. First, the audio recording will introduce and orient the participant to SH. Then instruction in SH will be provided, including: (a) how to self-induce a hypnotic induction; (b) specific self-suggestions for comfort and ability to manage intense sensations; and (c) post-hypnotic suggestions that the participant will be easily able to use these hypnotic strategies on their own at a later time (i.e., in this case, during the Cold Pressor Arm Wrap procedures that will follow).~A second 5-minute audio recording with instructions to guide the participant in SH will be provided during the second cycle of Cold Pressor Arm Wrap (CPAW)."
214932819|NCT01668953|OTHER|Whole Blood Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. 6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.~4. Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.~5. The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations."
214932820|NCT01668953|OTHER|Dry Needle Fenestration|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. A 22-gauge needle will then be placed into the tendon.~4. 15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon."
215071932|NCT05682287|DEVICE|448kHz capacitive resistive monopolar radiofrequency|Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
214331017|NCT04491630|BEHAVIORAL|Mindfulness Meditation (MM)|"Participants in the MM condition will listen to a 20-minutes recording with instructions in the use and application of Vipassana MM, adapted from the manual developed by one of our team members. First, the audio recording will focus on introducing the idea of attention to their breath, and of non-judgmental monitoring and acceptance of the all events and stimuli. Then a guided MM (body scan) experience will be provided.~A second 5-minute audio recording with instructions to facilitate the MM (body scan) experience taught in the first audio recording will be provided during the second cycle of CPAW."
214331018|NCT04491630|BEHAVIORAL|Christian Prayer (CP)|"Participants in this condition will listen to a 20-minute recording with CP instructions. These instructions will be adapted from the existing on-line biblical meditations from the Society of Jesus (www.passo-a-rezar.net). First, the recording will introduce and orient the participant to CP. Then, a text of the Bible will be read twice, followed by a brief suggestion of prayer.~A second 5-minute audio recording with instructions to facilitate the CP experience taught in the first audio recording, including the recording of a text of the Bible followed by a brief suggestion of meditation and relaxing music, will be provided during the second cycle of CPAW."
214673547|NCT03321617|DRUG|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
214673548|NCT04329923|DRUG|Hydroxychloroquine Sulfate 400 mg twice a day|Antimalarial compound
214673549|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg twice a day|Antimalarial compound
214673550|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg once a day|Antimalarial compound
215071933|NCT05682287|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
215071934|NCT03319953|DRUG|TAK-041|TAK-041 suspension
215071935|NCT03319953|DRUG|Placebo|TAK-041 placebo-matching suspension
215071936|NCT03319953|DRUG|Second Generation Antipsychotics (SGA)|Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
215071937|NCT00771706|DRUG|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
215071938|NCT00771706|DRUG|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
215071939|NCT06108193|DRUG|topical minoxidil in Acne Vulgaris|Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
215071940|NCT03459001|OTHER|Tube Feeding Product|a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
215071941|NCT02229305|BEHAVIORAL|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
215071942|NCT02229305|BEHAVIORAL|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita \& Weisz, 2010).
215071943|NCT00432328|DRUG|Avotermin|
215071944|NCT00992199|DRUG|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
215071945|NCT00729495|DRUG|celecoxib|dose form
215071946|NCT03315793|DRUG|Duloxetine Hydrochloride|Administered orally
215071947|NCT03315793|DRUG|Placebo|Administered orally
215071948|NCT05355259|DEVICE|GECKO Active Guidewire|The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.
214673551|NCT04329923|DRUG|Placebo oral tablet|Placebo
215071949|NCT04577300|DRUG|NT-501|Implant of Neurotech NT-501 device(s)
215071950|NCT04577300|OTHER|Sham comparator|Sham implantation
215071951|NCT06396169|OTHER|Yoga Exercise|Yoga Exercises
214331019|NCT05022810|DRUG|New Paracetamol Oral Suspension (24 mg/ml)|After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
214932821|NCT01668953|OTHER|Sham Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected."
214932822|NCT02134002|DRUG|Disulfiram|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
214932823|NCT02134002|DRUG|Placebo|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
214932824|NCT03931317|DRUG|Latanoprostene bunod 0.024% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
214932825|NCT03931317|DRUG|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
214932826|NCT01643733|DEVICE|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
214932827|NCT02804906|BEHAVIORAL|Home-based physical therapy|"Participants will be visited by a physical therapist 3 times a week for approximately 1 hour each day, for a duration of 4 weeks. These visits will serve to encourage adherence to the intervention, reinforce activities recommended at discharge, monitor safety under direct supervision, and adjust the exercise prescription if/as needed (e.g. advance recommended activity level) if necessary. Patients will also be provided with a tablet computer device installed with software, Moving Analytics, that will reinforce the cardiac rehabilitation program through daily reminders and easily accessible visual activity plans. This program will be updated by the physical therapist during home visits as the program advances. Daily patient-reported health status (Your Activities of Daily Living) 26 will be ascertained on the same tablet device by participants three times per week using open source software designed."
214932828|NCT02804906|BEHAVIORAL|Usual Care|"Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge. Participants will be provided with a tablet computer device to complete patient-reported health status (Your Activities of Daily Living) 26 three times per week using open source software designed. Participants will be visited by the Research Coordinator or member of the study team at one month post-hospital discharge to perform a follow-up assessment that will include ADLs, IADLs, SF-12 PCS, frailty measures, and questions on healthcare utilization (hospital readmissions)."
214932829|NCT01267084|DRUG|Trabectedin|Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
214932830|NCT01267084|DRUG|Ketoconazole|Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
214932831|NCT01267084|DRUG|Dexamethasone or equivalent steroid|Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
214932832|NCT01944670|DEVICE|Internal Joint Stabilizer - Elbow (IJS-E)|Device designed for internal stabilization of the elbow
215071952|NCT06396169|OTHER|Calisthenic Exercise|Calisthenic Exercises
214331020|NCT05022810|DRUG|Panadol B&I Oral Suspension (24 mg/ml paracetamol)|After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
214331021|NCT04428138|DIAGNOSTIC_TEST|In-office vascular visit|Every patient will undergo a complete physical examination in order to detect any clinical or sub clinical vascular disease.
214331022|NCT04428138|DIAGNOSTIC_TEST|Echo duplex scan of arterial system|Every patient will undergo a complete echo duplex scan in order to detect any morphological or hemodynamic alteration of aorta, carotid arteries and lower limb arteries.
214331023|NCT02529410|PROCEDURE|Cardiac Resynchronisation Therapy|
214331024|NCT01810978|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
215071953|NCT01331837|DRUG|Etanercept|Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
215071954|NCT01331837|DRUG|Tocilizumab|Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
215071955|NCT03345160|DRUG|Peanut Flour|open label oral immunotherapy
215071956|NCT04994912|DRUG|EI-001|EI-001 IV infusion
214331025|NCT01810978|DIETARY_SUPPLEMENT|Maltodextrin|same amount of maltodextrin per day will be given as placebo
214331026|NCT02771639|PROCEDURE|Hip arthroplasty|Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
214331027|NCT01860417|BIOLOGICAL|Allogenic Mesenchymal Stromal Cells|
214331028|NCT01860417|DRUG|Mepivacaine|
214331029|NCT03852316|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
214331030|NCT00349596|DRUG|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
214331031|NCT01989533|BIOLOGICAL|Ad4-mgag|Ad4 live virus vaccine with an HIV insert
214331032|NCT01989533|BIOLOGICAL|Ad4-EnvC150|Ad4 live virus vaccine with an HIV insert
214331033|NCT01989533|BIOLOGICAL|gp 120 Protein Boost|HIV protein boost
215071957|NCT04994912|OTHER|Placebo|Placebo IV infusion
214673552|NCT01702012|DIETARY_SUPPLEMENT|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
214673553|NCT01702012|BEHAVIORAL|Group-Based Lifestyle Intervention|
214673554|NCT03796741|OTHER|Data collection on Stable Ischemic heart disease|No intervention only description of management and treatment
214932833|NCT05850390|OTHER|Respiratory-Responsive Vocal Biomarker application|"A smartphone app that allows participants to receive a respiratory-responsive vocal biomarker (RRVB) score by recording a 6-second held ahh vowel elicitation. The applications returns the RRVB score which has previously been validated to correspond to the likelihood that the user's voice is similar to those of people diagnosed with asthma. This study will examine if the RRVB scores correlate with respiratory function and symptoms in asthma patients."
214673555|NCT03370367|DRUG|13-cis retinoic acid|Taken daily.
214673556|NCT03370367|OTHER|Placebo|Placebo
214673557|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
214673558|NCT01272180|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
214673559|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
214673560|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
214673561|NCT03609229|PROCEDURE|Burch|polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve
214932834|NCT05194995|DRUG|JAB-21822|JAB-21822 administered orally as a tablet.
214932835|NCT05194995|DRUG|Cetuximab|Cetuximab administered as an intravenous (IV) infusion.
214932836|NCT00289406|DRUG|S-amlodipine gentisate|
214932837|NCT00289406|DRUG|Amlodipine besylate|
214932838|NCT00743288|DRUG|Melphalan|Same as above
214673562|NCT03609229|PROCEDURE|Abdominal Sacrocolpopexy|"* By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~* The right-handed operator double gloves, and places the left hand in the vagina.~* With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~* Place three Ethibond J-shaped sutures on either side of the urethrovesical junction."
214932839|NCT00743288|DRUG|Panobinostat|
214932840|NCT01167556|BEHAVIORAL|Family Motivational Intervention|A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
215071958|NCT00969592|DRUG|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
215071959|NCT00969592|DRUG|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
215071960|NCT06837961|DIETARY_SUPPLEMENT|LC-Plasma|1 tablet containing 50mg LC-Plasma is taken daily for 4 weeks
215071961|NCT06837961|OTHER|Placebo|1 tablet containing 50mg MCC is taken daily for 4 weeks
215071962|NCT06894719|DRUG|tranexamic acid Oral-Short Arm|1.95g Tranexamic acid daily for post op days 1 to 3
214331034|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fed condition
214331035|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fasted condition
214932841|NCT05310318|PROCEDURE|Surgical treatment with and without fertility-sparing procedures|Patients accepted surgeries for LGESS and relevant adjuvant therapy if indicated.
214932842|NCT03060967|BEHAVIORAL|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
214932843|NCT05582044|OTHER|Lower-body Negative Pressure (-25 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
215071963|NCT06894719|DRUG|tranexamic acid Oral-Long Arm|1.95g tranexamic acid daily post op days 1-7
215071964|NCT06894719|DRUG|Control group placebo|Placebo for 3 days post-op
215071965|NCT00633373|DRUG|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
215071966|NCT00367718|DRUG|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
215071967|NCT01521871|PROCEDURE|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
214331036|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fed condition
214331037|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fasted condition
215071968|NCT01521871|PROCEDURE|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
215071969|NCT07080008|DEVICE|Lumitrace|Administered as a bolus intravenous injection over 30 - 60 seconds
215071970|NCT07080008|DEVICE|KARL STORZ POWER LED BLUE System|Imaging will be acquired within 30 minutes post Lumitrace administration. Following the initial endoscopic surgical incision, the surgeon will record the image assessments based on Likert Scales.
215071971|NCT03626688|DRUG|Ralinepag|Active
215071972|NCT03626688|DRUG|Placebo|Placebo
215071973|NCT06821061|BIOLOGICAL|Investigational Influenza Vaccine|Investigational Influenza Vaccine
215071974|NCT06821061|BIOLOGICAL|Investigational COVID-19 Vaccine|Investigational COVID-19 Vaccine
215071975|NCT06821061|COMBINATION_PRODUCT|Investigational Influenza and COVID-19 Combination Vaccine|Investigational Combined Influenza and COVID-19 Vaccine
215071976|NCT06821061|BIOLOGICAL|Licensed Influenza Vaccine 1|Licensed Influenza Vaccine 1
215071977|NCT06821061|BIOLOGICAL|Licensed Influenza Vaccine 2|Licensed Influenza Vaccine 2
215071978|NCT06821061|BIOLOGICAL|Licensed Influenza Vaccine 3|Licensed Influenza Vaccine 3
215071979|NCT06821061|BIOLOGICAL|Licensed COVID-19 Vaccine|Pfizer-BioNTech COVID-19 Vaccine
215071980|NCT06066918|DRUG|Pregabalin 75mg|Pregabalin 75 mg twice a day
214331038|NCT03794284|DIAGNOSTIC_TEST|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
214331039|NCT03050905|DRUG|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
214673563|NCT03466710|PROCEDURE|Colposcopy|"Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix."
215071981|NCT01877525|PROCEDURE|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
215071982|NCT05286476|COMBINATION_PRODUCT|Whole Body Vibration|vibration was administered for 1min, with a rest interval of 1min between each vibration set repeating 10 vibrations, with a frequency of 30 Hz and an amplitude of 0-2 mm and a speed of 50 m /s,18 and these sessions lasted for 6 weeks 3 days a week. whole-body vibration was induced by a noninvasive oscillation platform
215071983|NCT05286476|OTHER|pelvic floor exercises and static abdominal exercises in addition to diet instructions|"During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times."
215071984|NCT05208515|OTHER|independent obsteric operating center|send emergency cesarean section needing women from labor room to independent obstetric operating center
215071985|NCT05208515|OTHER|general operating center|send emergency cesarean section needing women from labor room to general operating center
215071986|NCT06929806|DRUG|Ferric Derisomaltose|100 mg/mL
214331040|NCT03050905|DRUG|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"
215071987|NCT04028167|DRUG|Sequential FLOT followed by chemoradiation|Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
214331041|NCT03592641|DRUG|Savolitinib|Given PO
214331042|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Ozone Injection|All procedures were performed under light sedation in a sterile operating room. Ozone was created by an ozone generator (Dr. J. Hänsler Ozonosan, Iffezheim, Germany). Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid plus ozone injection received additionally 5ml of ozone at a concentration of 28 g/ml for each transforaminal epidural injection level.
214331043|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|All procedures were performed under light sedation in a sterile operating room.Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid injection received two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level
214932844|NCT05582044|OTHER|Lower-body Negative Pressure (-15 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
215071988|NCT05184764|BIOLOGICAL|AP-SA02|Bacteriophage administered via intravenous bolus infusion
215071989|NCT05184764|OTHER|Placebo|Inactive Placebo administered via intravenous bolus infusion
215071990|NCT06937801|DIETARY_SUPPLEMENT|Collagen Peptide|10g Collagen Hydrolysate per sachet
215071991|NCT06937801|OTHER|Placebo|Placebo - active ingredients: N/A
214331044|NCT00149708|DRUG|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
214331045|NCT00040404|DRUG|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
214331046|NCT00040404|DRUG|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
214331047|NCT00040404|DRUG|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
214331048|NCT00040404|OTHER|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
214331049|NCT03370328|OTHER|Peppermint oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
214331050|NCT03370328|OTHER|Ginger oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
214331051|NCT00436280|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
214331052|NCT00436280|DRUG|gemcitabine|1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles
215071992|NCT06942429|BEHAVIORAL|Internet-delivered cognitive-behavioral therapy|Internet-delivered cognitive behavioral therapy (ICBT) is a 12-module intervention delivered over a maximum of 14 weeks. Two age-specific versions are available: \[1\] for children aged 8-12 years and \[2\] for adolescents aged 13-17 years. Both versions share the same core content, but the texts, illustrations, videos, and exercises are adapted to be developmentally appropriate. Each version focuses on exposure, along with psychoeducation, coping strategies, and relapse prevention. Caregivers have access to a parallel program that mirrors the structure of the youth program. Both patients and caregivers engage with a therapist through a secure digital platform, communicating via text messages similar to emails. Two scheduled telephone or videoconference calls are conducted approximately 3-4 and 7-8 weeks into treatment, respectively, to follow up on adherence and address questions related to the intervention. Additional telephone support will be available on demand.
215071993|NCT06942429|BEHAVIORAL|Personalized in-person cognitive-behavioral therapy|Personalized in-person cognitive-behavioral therapy (CBT) follows a manual drawing on previously published protocols and meta-analyses on effective components of CBT for pediatric anxiety disorders and results from our pilot study. It consists of 12 weekly one-hour sessions delivered over a maximum of 14 weeks. It follows a disorder-specific CBT approach, with a strong emphasis on therapist-led exposure tailored to the patient's principal anxiety disorder. Participants receive workbooks containing information on anxiety disorders, the treatment rationale, and the rationale for exposure therapy. The intervention has three phases: \[1\] 1-2 sessions of psychoeducation and symptom identification, \[2\] 8-10 sessions of therapist-led exposure with homework, and \[3\] 1-2 sessions of relapse prevention planning. Caregiver involvement is tailored to the individual needs of each participant, with a maximum of 2 additional hours allocated for caregivers beyond the standard treatment time.
215071994|NCT06943781|DIAGNOSTIC_TEST|Fecal Helicobacter pylori gastric cancer susceptibility gene test|In the early stage of the study, the team used genome-wide association analysis (GWAS) to identify H. pylori specific SNP that are significantly associated with gastric cancer in gastric cancer patients and controls; according to the mutation or not of the SNP loci, the strains were categorized into the high-risk group of gastric cancer (mutated group) and the low-risk group (un-mutated group). The mutation status of the SNP locus was detected in portable and non-invasive fecal samples from patients using molecular biology assays for early non-invasive screening and risk assessment of gastric cancer in H. pylori infected patients.
214331053|NCT00436280|DRUG|rituximab|375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles
214331054|NCT00436280|DRUG|oxaliplatin|100 mg/m², IV, once every two weeks, four to eight 2 week cycles
214331055|NCT04412941|BEHAVIORAL|Myofunctional exercises|"Myofunctional exercises: Respiratory rehabilitation exercises with diaphragmatic breathing, thoracic mobilization exercises and manual pompage techniques, followed by manual trigger point therapy techniques, that were identified by palpation following the guidelines provided by Travell and Simons trigger point manual, the accessory inspiratory muscles like pectoralis minor muscle, scapula elevator muscle, Sternocleidomastoid muscle.~Home oropharyngeal exercises: at every patient will be taught oropharyngeal exercises to perform at home twice a day (the duration of 15 minutes each session) involving in particular exercises for soft palate, tongue, facial and genio-glosso muscle.~The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep."
214331056|NCT04412941|BEHAVIORAL|The rules of sleep hygiene|The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.
214331057|NCT04875104|DEVICE|Orthodontic treatment with Invisalign system|Patients are going to receive an orthodontic treatment with Invisalign aligners.
214932845|NCT05582044|OTHER|Lower-body Neutral Pressure (0 mmHg)|In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
214932846|NCT05903924|DRUG|Tradipitant|Oral Capsule
214932847|NCT05903924|DRUG|Placebo|Oral Capsule
215071995|NCT06943807|DIAGNOSTIC_TEST|Fecal sample methylation detection for gastric cancer|Detection of gastric cancer-associated methylation sites in fecal samples
214331058|NCT04875104|DEVICE|Orthodontic treatment with Spark system|Patients are going to receive an orthodontic treatment with Spark aligners.
214932848|NCT03443765|DIAGNOSTIC_TEST|Detection of Plasma levels of 25(OH) vitamin D by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
214932849|NCT03443765|DIAGNOSTIC_TEST|Detection of Total serum immunoglobulin E by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
214932850|NCT03290534|DEVICE|CivaSheet|implanting CivaSheet for localized radiation dose delivery
214932851|NCT06331871|PROCEDURE|Ultrasound Guied Percutaneus Electrical Nerve Stimulation (US-PENS) and Manual physiotherapy protocol based on available evidence.|Intervention performed by needling in the vicinity of the peripheral nerves of the shoulder under ultrasound-guided control.
214932852|NCT06331871|PROCEDURE|Manual physiotherapy protocol based on available evidence.|Physiotherapy treatment based on the best scientific evidence available, based on manual therapy and passive and active kinesitherapy
214331059|NCT04875104|DEVICE|Orthodontic treatment with Quicksmile system|Patients are going to receive an orthodontic treatment with Quicksmile aligners.
214331060|NCT04875104|DEVICE|Orthodontic treatment with ClearCorrect system|Patients are going to receive an orthodontic treatment with ClearCorrect aligners.
214331061|NCT04904510|DIAGNOSTIC_TEST|INDICAID™ COVID-19 Rapid Antigen Test|The diagnostic assay will be compared to a EUA SARS-CoV-2 assay
214331062|NCT03752723|DRUG|GX-I7|i.m.
214331063|NCT03752723|DRUG|Pembrolizumab(KEYTRUDA®)|i.v.
214932853|NCT06411002|DRUG|DAXXIFY|Intramuscular injection of daxibotulintoxinA-lanm
214932854|NCT06162169|DRUG|JAB-21822|JAB-21822 was administered orally
214932855|NCT06162169|DRUG|Itraconazole|Itraconazole was administered orally
214932856|NCT06162169|DRUG|Omeprazole|Omeprazole was administered orally
214932857|NCT06162169|DRUG|Midazolam , Rosuvastatin calcium and digoxin|Midazolam , Rosuvastatin calcium and digoxin was administered orally
214932858|NCT06162169|DRUG|Rifampicin|Rifampicin was administered orally
214932859|NCT05494684|OTHER|Multisensoral Nature-based Intervention|The intervention includes a multi-sensory nature experience using natural materials and a virtually created natural environment.
214932860|NCT02988362|DRUG|HL068 16/10mg|Candesartan 16mg and Amlodipine 10mg
214932861|NCT02988362|DRUG|Candesartan 16mg and Amlodipine 10mg|
214932862|NCT05175196|DIAGNOSTIC_TEST|CandyCollect|The CandyCollect device is a novel, micro-engineered, lollipop-inspired platform. It has functionalized open microchannels for pathogen capture and concentration. It also has time-controlled flavoring release to make the platform more patient-centric.
214932863|NCT05175196|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Child participants are instructed to suck on the swab for 10 seconds, as they would suck on a lollipop. Participant will be asked to take this test twice."
214932864|NCT05486104|DRUG|Hemay005 tablets|Hemay005 tablets (15mg/tablet）will be orally administered twice daily.
214932865|NCT05486104|DRUG|Hemay005 placebo tablets|Hemay005 placebo tablets will be orally administered twice daily.
214932866|NCT04565210|OTHER|Music exposure|Participants will be offered individual sessions of music. They will be exposed for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
214932867|NCT04565210|OTHER|Silence|Participants in this group will be offered individual silence session for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
214932868|NCT05887843|DRUG|Mometasone + Azelastine|Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril
214932869|NCT05887843|DRUG|Mometasone Furoate|Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril
214932870|NCT05887843|DRUG|Azelastine Hydrochloride|Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril
214331064|NCT03752723|DRUG|Cyclophosphamide|i.v.
214331065|NCT02175069|PROCEDURE|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
214331066|NCT02175069|DRUG|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
214331067|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
214331068|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
214331069|NCT02175069|DRUG|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
214331070|NCT02175069|PROCEDURE|Shoulder Surgery|As per individual requirement (patient-dependent)
214331071|NCT03815162|DIETARY_SUPPLEMENT|High Flavanol Cocoa extract|Experimental group
214331072|NCT03815162|DIETARY_SUPPLEMENT|Alkalised cocoa|Control group
214331073|NCT05812482|PROCEDURE|Drug balloon dilatation|The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated
214331074|NCT05812482|PROCEDURE|Direct vision internal urethrotomy (DVIU)|A control subject will choose DVIU surgery until the desired effect is achieved
214331075|NCT01500824|DRUG|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
214331076|NCT01403090|DEVICE|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
214331077|NCT01049919|DEVICE|Bone marrow concentration device|Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
214331078|NCT01049919|PROCEDURE|Placebo procedure (sham)|Sham bone marrow aspiration, sham delivery to affected limb
214932871|NCT03185715|BEHAVIORAL|Oral and written counselling|Recipients were informed about success rates of SET and DET and also about the possible risks of DET. All the information was given orally and written.
214331079|NCT01663259|DRUG|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
214932872|NCT06668233|RADIATION|CT|CT Brain
214331080|NCT01663259|RADIATION|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
214331081|NCT00754247|DRUG|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
214331082|NCT00754247|DRUG|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
214932873|NCT06668233|RADIATION|CT scan|Neuroimaging in case with delayed development , focal neurological symptoms or seziures
214932874|NCT00465803|DRUG|Travoprost 0.004%/timolol 0.5% ophthalmic solution|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid
214932875|NCT00465803|DRUG|Travoprost ophthalmic solution, 0.004%|One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid
214932876|NCT00465803|DRUG|Timolol maleate ophthalmic solution, 0.5%|One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid
214932877|NCT00180492|DEVICE|RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System|
214932878|NCT06622980|OTHER|Education|"The educational intervention will take the form of a video explaining both general ergonomic principles and specific advice for laparoscopic surgeons. This video will be shown to surgeons at a time of their convenience and the research team will be available to answer any further questions at this time.~The educational video will cover both ergonomics principles and specific advice for laparoscopic surgeons. The principles will be relevant to any situation, including those outside the medical field. The laparoscopic-specific section will include tips for optimisation of operating theatre set-up and advice on posture and body position. The video content will be reviewed by experts experienced in surgical ergonomics education to ensure it covers all useful information and is in line with best practice."
214932879|NCT05098119|DRUG|Sintilimab, Nab-paclitaxel, Carboplatin|Neoadjuvant Therapy
214932880|NCT05098119|PROCEDURE|Surgical resection|Standard of care
214932881|NCT05098119|DRUG|Sintilimab|Adjuvant Therapy
214932882|NCT02983149|DEVICE|Double lumen tube|Use an double lumen tube to achieve one lung ventilation in thoracic surgeries
214932883|NCT02983149|DEVICE|Fuji blocker|Use the Fuji blocker to achieve one lung ventilation in thoracic surgeries
214932884|NCT02983149|DEVICE|EZ blocker|Use the EZ blocker to achieve one lung ventilation in thoracic surgeries
214932885|NCT00026442|DRUG|capecitabine|
214932886|NCT04338269|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.
214932887|NCT04338269|DRUG|Cabozantinib|Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
214932888|NCT05195047|DIETARY_SUPPLEMENT|1 week placebo(Week 1)|1 week of consecutively consuming oral placebo (1 time/day)
214932889|NCT05195047|DIETARY_SUPPLEMENT|1 week of probiotics(Week 1)|1 week of consecutively consuming oral probiotics (1 time/day)
214932890|NCT05195047|DIETARY_SUPPLEMENT|1 week placebo(Week 2)|1 week of consecutively consuming oral placebo (1 time/day)
215071996|NCT06943794|DRUG|recommendations for eradication treatment|"A high-risk Hp subtype guidance group consisting of the receiving physician + trial-related personnel conducts individualized assessment based on Hp infection, SNP test results, gastric mucosa condition, medical history and other factors, and provides subjects with medical explanations and recommendations for eradication treatment.~Eradication group protocol: standard quadruple therapy for H. pylori eradication program (PPI + bismuth + two antibiotics)~1. Omeprazole (or esomeprazole): 20mg, 2 times/day~2. Bismuth citrate: 220mg, 2 times/day~3. Metronidazole: 400mg, 3 times/day~4. Tetracycline: 500mg, 3 times/day~5. Treatment cycle: 10-14 days Eradication success was assessed after 1 month by urea breath test (UBT) or Hp fecal antigen test."
215071997|NCT06943768|DIAGNOSTIC_TEST|fecal methylation site-based testing and fecal Helicobacter pylori gastric cancer susceptibility gene-based testing|To establish an early diagnostic test system for gastric cancer based on the methylation site detection technology in feces, with or without the combination of Helicobacter pylori gastric cancer susceptibility gene detection, and then to evaluate the clinical diagnostic value of this test system.
215071998|NCT06950125|OTHER|Placebo|Bottle of 15 mL liquid (non-effective product) will be taken once a day for 12 weeks.
214331083|NCT00754247|DRUG|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
214331084|NCT06345508|DIAGNOSTIC_TEST|Quantitative Ultrasound|Research quantitative ultrasound
214331085|NCT06345508|DIAGNOSTIC_TEST|B-mode Ultrasound|B-mode US performed according to the clinical standard of care.
214932891|NCT05195047|DIETARY_SUPPLEMENT|1 week of probiotics(Week 2)|1 week of consecutively consuming oral probiotics (1 time/day)
214932892|NCT05195047|DIETARY_SUPPLEMENT|1 week placebo(Week 3)|1 week of consecutively consuming oral placebo (1 time/day)
214932893|NCT05195047|DIETARY_SUPPLEMENT|1 week of probiotics(Week 3)|1 week of consecutively consuming oral probiotics (1 time/day)
214932894|NCT06064825|OTHER|2 year follow-up of neurodevelopment using a parental questionnaire|A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
214331086|NCT06345508|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
214331087|NCT06345508|DIAGNOSTIC_TEST|Liver Biopsy|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
214331088|NCT00718172|PROCEDURE|Liver Biopsy|
214331089|NCT00718172|DRUG|Peginterferon &amp; Ribavirin for Hepatitis C|
214331090|NCT00718172|DRUG|Pre-treatment Ribavirin|
214331091|NCT04364633|OTHER|Voice Handicap Questionnaire (VHI)|Voice Handicap Index (VHI) self-questionnaire
214331092|NCT01540227|DRUG|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes"
214331093|NCT05059457|DEVICE|Blood source: single and pooled capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
214932895|NCT04838756|OTHER|AI screening modality|Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.
214932896|NCT04838756|OTHER|Conventional screening modality|Screen exams will be read by two radiologists without the support of AI.
214331094|NCT05059457|DEVICE|Blood source: single capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
214331095|NCT05059457|DEVICE|Blood source: pooled capillary and venous blood|"* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
214331096|NCT02558608|PROCEDURE|DIPL|dissection of the inferior pulmonary ligament
214331097|NCT02558608|PROCEDURE|WR|wedge resection of the lung bleb
214331098|NCT02558608|PROCEDURE|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
214331099|NCT05521893|OTHER|Telemedicine care|"In the telemedicine group, the appointments are performed online via scheduled videoconferences, on a monthly basis.~All women in the telemedicine group receive a smartphone with the installed application that enable transfer of the measured capillary glucose concentration."
214932897|NCT06409468|PROCEDURE|Subperiostal tunnel in conjunction with Novomatrix|An intrasulcular incision on the tooth with recession and on each adjacent tooth. Subperiosteal pouches dissected apically for about 6-8 mm facial to the 3 teeth and connected by extension of the subperiosteal dissection into the interdental areas to create a tunnel. NovoMatrix trimmed to a vertical dimension of 7-8 mm and a horizontal length to completely over the exposed roots and extend laterally to the root line angles of the adjacent teeth. The graft inserted into the tunnel and aligned. Both the overlying tissue and graft positioned 1mm coronally to the level of the cementoenamel junction and secured with a 6-0 resorbable sling suture.
214932898|NCT06061185|DEVICE|Multimodal CT|Non-contrast computed tomography, computed tomography angiography and computed tomography perfusion
214331100|NCT05521893|OTHER|Standard care|In the standard care group, visits are scheduled at the diabetes clinic on a monthly basis.
214331101|NCT01540370|OTHER|No Treatment|No treatment
214331102|NCT01412840|OTHER|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
214331103|NCT01412840|OTHER|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
214331104|NCT01849705|OTHER|No intervention|
214932899|NCT02454010|BIOLOGICAL|FF21101|(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
215071999|NCT06950125|OTHER|JUICE HA® supplement|Bottle of 15 mL JUICE HA® supplement will be taken once a day for 12 weeks.
215072000|NCT06947928|DRUG|IFx-Hu2.0|"Therapeutic Classification:~• Innate immune agonist~Route of Administration:~• Intralesional"
215072001|NCT06947928|DRUG|Placebo|"Route of Administration:~• Intralesional"
215072002|NCT06947928|DRUG|Pembrolizumab|"Therapeutic Classification:~• Immunotherapy (Immune checkpoint inhibitor)~Route of administration:~• Intravenous (IV) infusion"
215072003|NCT06949657|OTHER|the conventional treatment group|Patients received conventional mental health education once weekly for 6 weeks, covering schizophrenia symptoms, treatment, and prognosis. Standard nursing care and antipsychotic medications (e.g., olanzapine, quetiapine) were maintained without additional psychological interventions.
214331105|NCT04510116|BEHAVIORAL|Adults in the Making program|The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
214331106|NCT03533400|DEVICE|Jamboxx Respiratory Therapy Device|Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece containing a breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
214331107|NCT03533400|DEVICE|Jamboxx Musical Device|Jamboxx musical device is a hands free, breath controlled music device designed for people with quadriplegia. It resembles a common harmonica in that the user slides a mouthpiece along its horizontal axis to change the pitch of the instrument. The device connects to a personal computer via a mini USB to USB cable to interface with software that provides visual feedback for playing notes and sends the information to the computer speakers. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx musical device can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key
214331108|NCT01532687|DRUG|Gemcitabine|Given IV
214331109|NCT01532687|DRUG|Gemcitabine Hydrochloride|Given IV
214331110|NCT01532687|OTHER|Laboratory Biomarker Analysis|Correlative studies
214932900|NCT06038591|BEHAVIORAL|Sleep Tight|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
214932901|NCT05288205|DRUG|JAB-21822|KRAS G12C inhibitor
214932902|NCT05288205|DRUG|JAB-3312|SHP2 inhibitor
214932903|NCT04659707|DRUG|Hyperpolarized Xe129|Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
214932904|NCT04775342|DEVICE|smartphone|modern technology
214932905|NCT06391541|PROCEDURE|modified thoracolumbar interfacial plan block (mTLIP)|Injecting local anesthetic at L3 vertebral level between the longisimus and iliocostalis muscles within the erector spinae muscles.
214331111|NCT01532687|DRUG|Pazopanib|Given PO
214331112|NCT01532687|DRUG|Pazopanib Hydrochloride|Given PO
214932906|NCT06391541|PROCEDURE|Intertransverse process block (ITP)|injection of local anesthetic on the superior costotransverse ligament between the transverse process and the pleura.
214932907|NCT02988440|DRUG|PDR001|PDR001 will be administered intravenously
214932908|NCT02988440|DRUG|Sorafenib|Sorafenib is formulated as a tablet.
214932909|NCT06219291|OTHER|Observational|Observation of the natural course of the disease
214932910|NCT05269420|PROCEDURE|SAS-J|Single Anastomosis Sleeve Jejunal Bypass
214932911|NCT04722367|BEHAVIORAL|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
214932912|NCT00217074|OTHER|acupuncture|
214932913|NCT03868748|DIETARY_SUPPLEMENT|Beta-arbutin|Beta-arbutin capsules
214932914|NCT03868748|OTHER|Placebo|Placebo capsules containing non-medicinal ingredients
214932915|NCT02562638|OTHER|Non-fasting|Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
214331113|NCT01532687|OTHER|Placebo Administration|Given PO
214331114|NCT03844191|DRUG|RUC-4 Compound|single subcutaneous administration of RUC-4
214331115|NCT03861468|OTHER|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
214331116|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA\~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
214331117|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA\~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
214331118|NCT03160703|OTHER|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA\~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
214331119|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA\~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
214331120|NCT06562036|DRUG|Sildenafil|Patients were given oral sildenafil as 2 mg per kg per day, 6-hourly with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hour by nasogastric tube.
214331121|NCT06562036|DRUG|Milrinone|In this group, Milrinone was initiated at 0.5 ug per kg per minute using intravenous infusion through a syringe pump, and sildenafil was given in the same protocol mentioned for the Sildenafil Group.
215072004|NCT06949657|OTHER|the ACT group|"Patients received ACT-based nursing interventions tailored to risk factors (e.g., age ≥70, long disease duration), including:~ACT modules: Acceptance, cognitive defusion, mindfulness, values clarification, and committed action.~Adjunct strategies: Family therapy, Tai Chi, and crisis planning. Frequency: Daily practice + 1-2 group sessions/week for 6 weeks. Goal: Enhance psychological flexibility, reduce stigma, and improve cognitive function."
214331122|NCT06572696|DIAGNOSTIC_TEST|Shulder Ultrasound|"Ultrasound Shoulder Pathology Rating Scale (USPRS) will be used in the evaluation. While the participants are in a sitting position; A total of 5 variables, including bicipital tendinopathy, supraspinatus tendinopathy, greater tuberculum cortical surface irregularity, supraspinatus dynamic and subscapularis dynamic examination, are evaluated and scored according to the level of pathology; The total USPRS score is obtained by adding the scores of all variables.~Another parameter evaluated by ultrasonography in this study is the acromiohumeral distance measurement. In AH distance measurement with MSK-US, two measurements will be made with all participants in a neutral resting position and their hands at the top of the circle with the elbow angle of 110 °. In both positions, the probe will be placed longitudinally at the lateral point of the acromion determined by palpation, the distance determined between the acromion and the humeral head will be displayed and measured."
214932916|NCT05341336|PROCEDURE|total surgical excision|"patients will be operated under general anesthesia. Pressure is applied along the incision line while staying away from the palpable margin of the AVM lesion and used Raney clips to control bleeding.~Once the skin flap was raised, the lesion could be seen through the galea. The galea around the lesion is incised, and the lesion will be separated from the underlying skin using a combination of bipolar diathermy and sharp dissection.~The nidus is often located in galeal aponeurosis. Dilated arteries and veins extended into subcutaneous tissue, which was separated with special care to prevent accidental nidus rupture and avoid excessive cauterization to prevent postoperative scalp necrosis.~Ligation is applied on feeder arteries, then applied to veins with total excision of the lesion.~After excision of the lesion, the skin flap was replaced with interrupted stitches.~The wound was allowed to heal primarily along with intravenous administration of antibiotics."
214932917|NCT03322865|DRUG|Obinutuzumab|"Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15\*~\*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity"
214932918|NCT03290755|BEHAVIORAL|semi-directed interviews|semi-directed interviews in order to collect socio-behavioral data
214932919|NCT03580408|DRUG|Nivolumab|240 mg
214932920|NCT03580408|DRUG|Vinblastin|6mg/m²
214932921|NCT00670293|RADIATION|Positron Emission Tomography (PET) using [11C]raclopride|Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.
214932922|NCT00670293|DRUG|Methylphenidate|The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.
215072005|NCT06950775|OTHER|Residence in Agrihood Neighborhood|We are examining the effects of individuals who move into an agrihood neighborhood.
215072006|NCT06954584|DRUG|Bevacizumab|Bevacizumab : 15 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 15 months
215072007|NCT06954584|DRUG|Fluzoparib Monotherapy|150 mg orally bid (50 mg/capsule, 3 capsules/dose)
215072008|NCT06954584|BEHAVIORAL|Dietary Intervention|Control carbohydrate intake in the daily diet
215072009|NCT04481061|GENETIC|Electronic Decision Tool|Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.
215072010|NCT06360614|OTHER|Hand massage application|2 sessions of hand massage every day, 2 days a week (Monday and Friday) for 4 weeks
215072011|NCT06360614|OTHER|routine monitoring and nursing care|Routine monitoring and nursing care for 4 weeks
215072012|NCT06518317|DRUG|Aspirin|Short duration of aspirin (3 months) is compared to long duration of aspirin (12 months)
215072013|NCT06525896|DEVICE|NSSD|A robotically-controlled distractive force is applied to the lower back to produce decompression of the spinal column.
215072014|NCT06525896|DEVICE|Sham NSSD|A robotically-controlled distractive force (lower than the intervention) is applied to tension the belt and create a sense of decompression without producing decompression of the spinal column.
215072015|NCT06518655|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Detection of volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
215072016|NCT06470204|DRUG|Ropivacaine|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2ml 0.9% NaCl)
214331123|NCT03548870|OTHER|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
214331124|NCT03548870|OTHER|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
214331125|NCT04027660|DEVICE|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~1. Administration of Articain 1:200.000~2. No flap procedure~3. Place a Zirconia Implant on the alveolar post extraction socket~4. Place xenograft biomaterial in the jumping gap~5. Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~* Final Impression with a IOS~* Placement of the Final Crown~* 3 month post crown post op~  3 IOS will be made for volumetric evaluation :~ 1. before tooth extraction~ 2. 3 month of Osseointegration for final impression~ 3. 3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
214331126|NCT05691140|OTHER|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
214331127|NCT03424915|BEHAVIORAL|Harvard Health Professionals survey|Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.
214331128|NCT03424915|OTHER|Blood draw|Participant will provide a blood sample
214331129|NCT03424915|OTHER|CPET Procedures|CPET with 12-lead ECG
214331130|NCT03424915|OTHER|stool sample|Research stool sample (within ±1 week of surgery), if possible
214932923|NCT00670293|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.
214932924|NCT04387734|DRUG|Ocrelizumab|Ocrevus will be administered following the FDA's regulations.
214932925|NCT04387734|DRUG|Platform|The applications of the platform DMTs will follow the FDA-approved regulations.
214331131|NCT03424915|PROCEDURE|Research Tissue sampling|Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.
214331132|NCT06391827|DRUG|DA-7503 Single dose|Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).
214331133|NCT06391827|DRUG|DA-7503 Multiple dose|Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)
214932926|NCT06580613|OTHER|New model of Hypertension Management|Hypertension management based on cardiovascular risk assessment. For details see description of study arm intervention.
214932927|NCT06580613|OTHER|Control|Hypertension Management as usual
214932928|NCT03378414|PROCEDURE|Intravenous infusion|Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)
215072017|NCT06470204|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2mg Dexamethasone)
215072018|NCT03407053|DIETARY_SUPPLEMENT|Ultra-processed diet|Consuming ultra-processed diet over a 2-week period
215072019|NCT03407053|DIETARY_SUPPLEMENT|Unprocessed diet|Consuming unprocessed diet over a 2-week period
215072020|NCT01151605|DRUG|insulin infusion|insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
215072021|NCT01151605|DRUG|Dextrose infusion|Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl
214331134|NCT06391827|DRUG|Placebo Single dose|Oral administraion for once.
214331135|NCT06391827|DRUG|Placebo Multiple dose|Oral administration once daily for 7 days
214331136|NCT06131411|OTHER|Health promotion|Co-created culture-tailored intervention of health promotion aimed to increase healthy diet, physical activity and compliance with treatment protocols for diabetes.
214331137|NCT06131411|OTHER|Usual care|Health promotion activities routinely performed by Diabetes clinics at the recruiting centres.
214331138|NCT02984995|DRUG|Quizartinib|Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
214331139|NCT01061060|DRUG|Prostaglandin I2|oral
214331140|NCT01061060|DRUG|Placebo|oral
214932929|NCT03378414|PROCEDURE|Intrathecal injection|Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)
214932930|NCT03378414|BIOLOGICAL|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
214331141|NCT04077034|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis DE111®|Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
214331142|NCT04077034|DIETARY_SUPPLEMENT|Placebo comparator|Placebo comparator, once a day for 8 weeks
214932931|NCT06444308|OTHER|CommCare with Mobile Clinical Decision Support (CDS) Application|For those assigned to the CHW arm, management will be assisted by CDS from the CommCare application.
215072022|NCT01151605|DRUG|Saline Infusion|Saline will be infused at 100ml/hr
215072023|NCT03453255|DRUG|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
215072024|NCT01399632|BEHAVIORAL|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
214331143|NCT05356559|DIETARY_SUPPLEMENT|Intervention|12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
214331144|NCT05356559|OTHER|Control|Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
214331145|NCT02683759|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
214331146|NCT02683759|DRUG|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
214331147|NCT03122912|DIETARY_SUPPLEMENT|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
214331148|NCT03122912|DIETARY_SUPPLEMENT|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
214331149|NCT00014144|DRUG|gefitinib|
214331150|NCT05750693|GENETIC|PIK3CA analysis|"PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations."
214331151|NCT00248222|BEHAVIORAL|Supervised aerobic training|
214331152|NCT06142279|BIOLOGICAL|Sampling|At baseline, nasal, salivary and blood sampling will be taken for the participants.
214932932|NCT06444308|OTHER|Remote Supervision by Physicians|teleconsultation with a supervising physician
214932933|NCT06444308|OTHER|CommCare Application without CDS|The physician will have received training and orientation on the same clinical protocols followed by the CHWs, as well as access to reference materials for these protocols, but the version of the CommCare application used will not provide CDS, but will serve to record and review patient data only.
214932934|NCT05486117|DRUG|Delgocitinib|Cream for topical application 20 mg/g
214932935|NCT06163898|DRUG|Alnuctamab|Specified dose on specified days
214932936|NCT06163898|DRUG|Mezigdomide|Specified dose on specified days
214331153|NCT06142279|BIOLOGICAL|PCR (polymerase chain reaction) SARS-CoV-2|At baseline, this PCR SARS-CoV-2 will be taken for the participants.
214331154|NCT02533843|PROCEDURE|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
214331155|NCT01788501|DRUG|Tacrolimus|D-1\~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20\~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
214331156|NCT01788501|DRUG|Cyclosporine|D-1\~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20\~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
214932937|NCT06163898|DRUG|Dexamethasone|Specified dose on specified days
215072025|NCT01399632|BEHAVIORAL|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
215072026|NCT02096666|DRUG|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
214331157|NCT01788501|DRUG|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
214331158|NCT05191498|DEVICE|QuiremSpheres®|Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.
214932938|NCT01942044|DEVICE|Promus element, Xience prime, and Nobori|
214932939|NCT05670223|OTHER|Fit&Strong Exercise Program|The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
214932940|NCT05099614|COMBINATION_PRODUCT|Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system|1.2 mg of naloxone hydrochloride is administered to healthy adults using the SmartDose wearable auto injector and the mobile respiratory sensing system.
215072027|NCT01341717|DRUG|Sitagliptin|100 mg once daily for 6 months
215072028|NCT01341717|DRUG|Glimepiride|1 mg/2 mg/3 mg once daily
215072029|NCT01341717|DRUG|Metformin|\>=1000 mg twice daily
215072030|NCT01341717|DRUG|Insulin|TDD \> 10 IU once/twice daily
215072031|NCT05064176|OTHER|Usual care|"Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~\- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up"
215077889|NCT03908190|BEHAVIORAL|Personalized Support for Progress|Participants will receive the Personalized Support for Progress Intervention from a peer support provider including sessions with the peer support provider to complete a prioritization task, develop a personalized care plan, and receive support for implementing the personalized care plan.
215077890|NCT03356977|DRUG|Crisaborole ointment 2%|Applied BID
215077891|NCT00650455|DRUG|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
215077892|NCT00650455|DRUG|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
215077893|NCT00650455|DRUG|placebo|placebo tablet every morning and capsule every evening for 12 weeks
214331159|NCT06407778|OTHER|High Intensity Strength Training|"* High-intensity workouts to strengthen the quadriceps and enhance knee function;~* Knee flexion and extension 10 lbs.~* 10RM of hip flexion and extension~* 10RM hip adduction and abduction~* Standing with feet aligned for one minute\*2, standing on one leg's forefoot and the other leg's heel for two minutes\*2, standing on one foot for three seconds\*15, and walking ten meters in a straight line for four minutes~* 4-week program; 3 days/week; Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
214331160|NCT06407778|OTHER|Muscle Energy Technique|"The Muscle Energy Technique (MET) to strengthen and flex your quadriceps and hamstrings.~* After maintaining an isometric contraction for ten seconds, a little stretch was maintained for thirty seconds.~* Four contractions every treatment, separated by three seconds of rest. Standing with feet parallel for one minute\*2, standing on one leg's forefoot and the other leg's heel for two seconds\*2, standing on the forefoot for three seconds\*15~* Move in a 10 m by 4 straight line.~* 4-week program; 3 days/week Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
214331161|NCT02065128|OTHER|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
214331162|NCT02760394|DEVICE|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
214331163|NCT00226434|PROCEDURE|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
214331164|NCT00226434|PROCEDURE|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
214331165|NCT00047463|DEVICE|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
214331166|NCT00047463|DEVICE|Placebo-CPAP|Placebo-CPAP
214932941|NCT04916743|OTHER|Intradialytic exercise group|Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions. To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 5 Repetitions Maximum (5RM) for resistance protocols. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale). All protocols are tailor-made based on each individual's needs and physical abilities.
214331167|NCT00956150|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
214331168|NCT00956150|DRUG|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
214331169|NCT00956150|DRUG|Placebo|Placebo TID PO x 10 days
214331170|NCT04589559|BEHAVIORAL|Heart Rate Variability Biofeedback Training|First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
214331171|NCT01183793|RADIATION|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
214331172|NCT01401530|BIOLOGICAL|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
214932942|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
214932943|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
215072032|NCT05064176|PROCEDURE|Reconstructive lymphatic surgery|"For the procedure of LVA:~\- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~\- Aim:~1. Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~2. Placed lymph nodes induce lymphangiogenesis"
215072033|NCT03891004|PROCEDURE|Subcuticular Skin Closure|We will only close the subcuticular layer with suture
215072034|NCT03891004|DEVICE|Tissue Adhesives|No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
214331173|NCT03000465|PROCEDURE|Laparoscopic colorectal surgery|Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
214932944|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
214932945|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
214932946|NCT00102141|DRUG|Placebo|Placebo, given as tablets orally once daily in the morning for 8 weeks
215072035|NCT06454448|DRUG|Adebrelimab;decitabine;|Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
215072036|NCT02549625|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
215072037|NCT02509572|BEHAVIORAL|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
215072038|NCT01567501|DRUG|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
215072039|NCT01567501|DRUG|Levocetirizine Dihydrochloride|5 mg tablet once in a day
214932947|NCT06322953|DRUG|Direct-Acting Oral Anticoagulants (used as per local standard practice)|Direct-acting oral anticoagulants to be prescribed as per local standard practice at either 1 or 4 weeks.
215072040|NCT02640625|DIETARY_SUPPLEMENT|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
214331174|NCT02726815|OTHER|Questionnaire|Questionnaire based study using a symptom assessment tool
214331175|NCT00578773|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
214331176|NCT00578773|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
214331177|NCT00578773|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
214331178|NCT05632952|DEVICE|Intraperitoneal Onlay Mesh positioning Plus|"Intraperitoneal Onlay Mesh (IPOM) Plus with closure of the hernia defect will be performed according to the common recommendations.~The closure of the wall defect will be decided according to the surgeon evaluations: hernia size and choice of technique will be recorded in the database. The mesh will have an overlap of at least 5 cm on all sides of the defect. Dimension of the mesh will be sized to overlap the hernia orifice by at least five centimetres and placed in the intraperitoneal position. Using non-articulating laparoscopic fixation devices, 5.1-mm non-absorbable or absorbable tacks will be then positioned around the circumference of the prosthesis in a 3-row manner or 2-row manner based on the intraoperative findings, the patient's specific situation and the operating surgeon's decision."
214331179|NCT06068205|DIAGNOSTIC_TEST|Blood test - atomic force microscopy in the force spectroscopy mode|A single blood test to be analysed through atomic force microscopy in the force spectroscopy mode
215072041|NCT03511625|DRUG|Acthar Injectable Product|Acthar is a non-specific melanocortin receptor agonist
215072042|NCT03511625|DRUG|Depo medrol|Depo medrol is an anti-inflammatory glucocorticoid
214331180|NCT00451620|DRUG|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
214331181|NCT00451620|DRUG|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
214331182|NCT05541718|BEHAVIORAL|Reiki|Reiki will be provided by a trained Reiki master with the aim of balancing the flow of energy in the patient's body.
214331183|NCT05541718|BEHAVIORAL|Sham Reiki|Sham Reiki will be delivered by an individual trained to simulate the Reiki interventionist's movements, but they will not visualize patient healing
214932948|NCT05346211|DIETARY_SUPPLEMENT|Curcumin|Curcumin Supplementation
214932949|NCT02142361|DEVICE|enfilcon A|Silicone hydrogel toric lenses.
214932950|NCT05117554|DRUG|casdatifan|Capsule
214932951|NCT05117554|DRUG|Placebo|Capsule
214932952|NCT05117554|DRUG|Midazolam|Syrup solution
214932953|NCT02076737|DEVICE|Model-based iterative reconstruction (MB-IR VEOTM) on CT Discovery 750HD (GE Healthcare, Milwaukee, WI)|
214932954|NCT04932824|BIOLOGICAL|SCB-2019|a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.
214932955|NCT04932447|BEHAVIORAL|Inspiratory Muscle Strength Training|30 breaths/ day, 5 days/week for 24 weeks.
214932956|NCT06453876|DEVICE|Ultrasound assisted Thrombolysis|Please see Arms
214932957|NCT06453876|DEVICE|Percutaneous Embolectomy|Please see arms
214932958|NCT06453876|DRUG|Heparin|Active comparator
214932959|NCT05727787|RADIATION|Stereotactic Body Radiation Treatment|Single fraction SBRT 27 Gy
215072043|NCT01637363|BEHAVIORAL|Psychoeducation|6 x 2 hours of psychoeducation
215072044|NCT05420714|DEVICE|Dexcom Professional Continuous Glucose Monitoring|Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
214932960|NCT02610829|DIETARY_SUPPLEMENT|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
214932961|NCT00514826|OTHER|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
214932962|NCT05800587|DRUG|Carboplatin|Standard of care chemotherapy regimen
214932963|NCT05800587|DRUG|Pemetrexed|Standard of care chemotherapy regimen
214932964|NCT05800587|DRUG|Paclitaxel|Standard of care chemotherapy regimen
214932965|NCT05800587|DRUG|Nab paclitaxel|Standard of care chemotherapy regimen
214932966|NCT05800587|DRUG|Docetaxel|Standard of care chemotherapy regimen
214331184|NCT05541718|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation intervention will be adapted from a standardized mindfulness induction script validated in prior research. The mindfulness practice will guide patients to focus attention on breath and body sensations while monitoring and accepting discursive thoughts, negative emotions, and pain. The MM interventionist will be a trained mindfulness provider and have experience using MM in medical settings.
214331185|NCT00210652|DRUG|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
214331186|NCT02104557|OTHER|Non intervention|Non intervention
214331187|NCT02104557|OTHER|Non intervention|Non intervention
214932967|NCT05800587|DRUG|Gemcitabine|Standard of care chemotherapy regimen
214932968|NCT05800587|DRUG|Etoposide|Standard of care chemotherapy regimen
214331188|NCT03930017|BIOLOGICAL|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
214932969|NCT05800587|DRUG|Irinotecan|Standard of care chemotherapy regimen
214932970|NCT05800587|DRUG|Topotecan|Standard of care chemotherapy regimen
214932971|NCT05800587|DRUG|Lurbinectedin|Standard of care chemotherapy regimen
214932972|NCT02715700|DRUG|Methadone|Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
214932973|NCT02715700|DRUG|Doravirine|Doravirine 100 mg oral tablet once per day.
214932974|NCT04829110|OTHER|ETOH|Participants will consume Vodka
214932975|NCT04829110|OTHER|Sucrose|Participants will consume sucrose in solution with water
214932976|NCT02263248|DRUG|venlafaxine|slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
214932977|NCT02263248|DRUG|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
214932978|NCT02263248|DRUG|placebo|patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
214932979|NCT04166591|BEHAVIORAL|Overheard Speech|New words are introduced with the child as an observer rather directly taught.
214932980|NCT04166591|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
214932981|NCT06066697|BEHAVIORAL|SOVA Ambassador|"The SOVA Ambassador intervention includes:~adolescents will have access to the website specifically for adolescents: sova.pitt.edu These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion.~Participants that receive this intervention will contribute monthly articles and regular comments."
214932982|NCT06066697|BEHAVIORAL|Self-Reflection|Participant will be given an article from the sova.pitt.edu website and a prompt to write about privately.
214932983|NCT06356480|BIOLOGICAL|1% Acetic acid dressing|1% acetic acid dressing in chronic diabetic foot and wounds to see early epithelialization and later on graft application.
214932984|NCT05969548|DEVICE|active 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
214932985|NCT05969548|DEVICE|active 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
214932986|NCT05969548|DEVICE|active 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
214932987|NCT05969548|DEVICE|sham 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
215072045|NCT02524015|OTHER|Novel physical therapy|
215072046|NCT02524015|OTHER|Standard physical therapy|
215072047|NCT01025349|DRUG|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
215072048|NCT05034315|OTHER|Whole egg consumption|The participants in the whole egg group consumed two whole eggs immediately after exercise.
215072049|NCT04463628|BEHAVIORAL|Questionnaire|"The study questionnaire was constructed as follows:~* One part is composed of validated questionnaires: Cystic fibrosis specific self-questionnaire for quality of life, questionnaire for screening for anxiety disorder.~* The other part, which was not validated, was constructed as follows: questionnaire on knowledge of Covid-19 adapted to the new exceptional situation (Covid-19 pandemic) and specific questions adapted to the research objective on Covid-19 from the questionnaire of the French Public Health survey, to monitor changes in behaviour and mental health during lockdown"
215072050|NCT04463628|BEHAVIORAL|Interview|Two interviews in the human and social sciences, conducted by recorded video-conference, will be proposed to 15 patients during and after the lockdown.Two interviews will take place: one during the lockdown and one at 6 months from the first interview (or at the end of the confinement if it lasts more than 6 months). The interviews will be conducted independently of the results of the questionnaire.
215072051|NCT00511433|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles."
215072052|NCT00511433|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
214331189|NCT05271929|BIOLOGICAL|Current standard of care and COVID-19 convalescent and vaccinated plasma|ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
214932988|NCT05969548|DEVICE|sham 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
214932989|NCT05969548|DEVICE|sham 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
214331190|NCT05271929|OTHER|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~* Casirivimab~* Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~* Imdevimab~* Sotrovimab (Xevudy)~* Tixagevimab / Cilgavimab (Evusheld)~* Molnupiravir (MK-4482)~* Nirmatrevlir / Ritonavir (Paxlovid)~* Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
214331191|NCT04663555|DRUG|Dexamethasone|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.
214331192|NCT01045564|BIOLOGICAL|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
214932990|NCT03888651|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
214932991|NCT03888651|OTHER|Questionnaire Administration|Complete questionnaire
214932992|NCT02616965|DRUG|Romidepsin|Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
214932993|NCT02616965|DRUG|Brentuximab vedotin|Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
214932994|NCT04752761|BEHAVIORAL|Extrambulatory digital PROMs detection|An alternative PROMs evaluation method will be used in which the questionnaire will be administered to the patient digitally (Google Forms) in an outpatient environment
214932995|NCT03014128|OTHER|Clinical examination and data processing of questionnaires|xy
214932996|NCT04233346|DRUG|Ponatinib 30mg OD|Ponatinib 30mg OD
214932997|NCT04233346|DRUG|Ponatinib 45mg OD|Ponatinib 45mg OD
214331193|NCT05548608|OTHER|Reposition error (RE), pain at target positions of RE and flexibility of the TLF were assesed with iphone tiltmeter app, VAS and goniometric platform, respectively.|Target positions of reposition error were: 30º forward bending and 15º backward bending in sitting and standing.
214331194|NCT05326139|DRUG|Tranexamic acid|TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
214932998|NCT05234593|DIETARY_SUPPLEMENT|EmpowerPlus Lightning Sticks|multinutrient supplement containing vitamins, minerals, amino acids and antioxidants taken one Stick daily by dissolving the powder on or under the tongue
214932999|NCT04857814|DEVICE|ADAMM- RSM Device|All participants will wear the ADAMM- RSM device for a 6 month period
214933000|NCT06422312|DEVICE|Cystoscopy with RedPine flexible disposable cystoscope|Use of a disposable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents.
214933001|NCT06422312|DEVICE|Cystoscopy with standard of care flexible reusable scope|Use of a reusable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents
214933002|NCT05536895|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
214933003|NCT05536895|DIAGNOSTIC_TEST|Multi-detector Computed Tomography|Conventional, standard of care perfusion imaging for AIS
214933004|NCT02730377|DRUG|liraglutide|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
214933005|NCT02730377|DRUG|alpha-glucosidase inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
214933006|NCT02730377|DRUG|DPP-4 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
214933007|NCT02730377|DRUG|meglitinides|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
214933008|NCT02730377|DRUG|SGLT-2 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
214933009|NCT02730377|DRUG|sulphonylurea|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
214933010|NCT02730377|DRUG|thiazolidinediones|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
214331195|NCT05326139|OTHER|Isotonic saline|Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
214331196|NCT01150695|OTHER|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
214331197|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine \[approximately 1x10\^9 colony forming units (cfu)/mL\] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
214933011|NCT02441270|DRUG|Cyclophosphamide|
214933012|NCT02441270|RADIATION|Stereotactic body radiotherapy|
214331198|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10\^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
214933013|NCT05224960|BIOLOGICAL|UC-MSCs|3 doses of UC-MSCs intravenously at day 1, day 8, day 15.
214933014|NCT05224960|BIOLOGICAL|Placebo(solution without UC-MSCs)|3 doses of placebo intravenously at day 1, day 8, day 15.
214933015|NCT02111746|DRUG|Exparel|Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
214331199|NCT04586179|OTHER|Aerobic (treadmill) Exercise|"Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5."
214331200|NCT04586179|OTHER|Dynamic (Agility) Exercise|"Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5."
214933016|NCT02111746|DRUG|Bupivacaine hydrochloride|Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
214933017|NCT02111746|DRUG|Patient Controlled Analgesia (PCA)|Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
214933018|NCT02128347|OTHER|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
214933019|NCT06292585|PROCEDURE|MMA embolization plus medical therapy|Patients assigned to the intervention group will receive endovascular embolization treatment within 2 hours after enrollment. Patients will receive the best conservative treatment recommended by the guidelines after MMA, and conservative treatment will be the same in both groups
214933020|NCT06292585|DRUG|Medical therapy alone|Patients will receive the best conservative treatment recommended by the guidelines, and conservative treatment will be the same in both groups. Conservative treatment includes medication and general treatment. Drug therapy can be divided into hemostatic treatment, antihypertensive treatment, and symptomatic treatment. Specific local clinical diagnosis and treatment standards shall prevail or refer to corresponding clinical guidelines.
214933021|NCT03164473|DRUG|Rituximab|pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
214933022|NCT03164473|DRUG|Azathioprine|oral tablets : 2 mg/kg/day for 24 months
214933023|NCT03164473|DRUG|Placebo-rituximab|4 infusions for 18 months
214933024|NCT03164473|DRUG|Placebo-azathioprine|oral tablets for 24 months
214933025|NCT01618851|RADIATION|Radiotherapy with IMRT and CyberKnife Boost|"Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.~The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.~For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions."
214933026|NCT00331513|DRUG|vorinostat|Given orally
214933027|NCT00331513|DRUG|idarubicin|Given IV
214933028|NCT00331513|OTHER|laboratory biomarker analysis|Correlative studies
214933029|NCT00331513|OTHER|pharmacological study|Correlative studies
214933030|NCT02203851|DRUG|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
214933031|NCT04390672|DEVICE|SUPRAFLEX Cruz|Percutaneous Coronary Intervention for multivessel disease
214933032|NCT04390672|DEVICE|SYNERGY|Percutaneous Coronary Intervention for multivessel disease
214933033|NCT01701297|DRUG|cotrimoxazole|Cotrimoxazole 960mg orally each day (two 480mg tablets)
214933034|NCT01701297|DRUG|VSL#3 active|The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks
214933035|NCT01701297|DRUG|VSL#3 placebo|This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
214933036|NCT06263270|BIOLOGICAL|CYT-108, a recombinant protease inhibitor|"CYT-108 is a recombinant alpha-2-macroglobulin (A2M) variant engineered with increased potency against A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) substrates while possessing strong activity against Matrix Metalloproteinases (MMPs) and serine proteases. This A2M variant was engineered with amino acid modifications to the bait region (i.e., protease-binding region) of the A2M protein to make the variant at least two fold more effective in inhibiting ADAMTSs compared to wt-A2M without affecting its inhibitory activity toward other proteases (see Investigator Brochure). CYT-108 is not expected to cure osteoarthritis (OA), but it is expected to be the first treatment to slow disease progression by inhibiting cartilage breakdown, resulting in clinically significant outcomes such as pain reduction and improvement in mobility. This hypothesis is supported by our preliminary findings in multiple safety and efficacy studies conducted in rat and canine models of OA."
215072053|NCT00531076|BIOLOGICAL|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.~In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
215072054|NCT06162195|DEVICE|The H1 Implant|Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.
215072055|NCT06162195|DEVICE|Cementless total hip replacement|Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
215072056|NCT00762567|DRUG|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
214331201|NCT02832674|DEVICE|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
214331202|NCT05723367|PROCEDURE|lumbar ESPB group where ESPB is performed at L4 with local anesthetics 20ml|ultrasound guided fascial plane injection
214331203|NCT06027281|OTHER|Hamilton depression rating scale (HDRS)|Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.
214331204|NCT06027281|OTHER|Hamilton anxiety rating scale (HARS)|Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.
214331205|NCT06027281|OTHER|Mini international neuropsychiatric interview (MINI)|The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.
214331206|NCT06027281|OTHER|Minnesota Multiphasic personality Inventory (MMPI)|The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.
215072057|NCT01740089|DRUG|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
215072058|NCT01740089|DRUG|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
215072059|NCT01740089|DRUG|Ribavirin|800-1400 mg/day orally
214933037|NCT06263270|OTHER|Phosphate Buffered Saline (PBS)|Phosphate Buffered Saline (PBS)
214933038|NCT00046917|DRUG|alvocidib|Given IV
214933039|NCT00046917|DRUG|irinotecan hydrochloride|Given IV
214933040|NCT00046917|DRUG|cisplatin|Given IV
214933041|NCT04439305|DRUG|Dasatinib|Given PO
215072060|NCT01338077|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
215072061|NCT01338077|DRUG|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
215072062|NCT03369041|DRUG|Irinotecan-Eluting Beads|
215072063|NCT00006078|DIETARY_SUPPLEMENT|lycopene|
215072064|NCT05332249|PROCEDURE|Surgery|Patients who undergo spinal surgery for degenerative spinal disease
215077894|NCT01884493|DEVICE|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
215077895|NCT01884493|DEVICE|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
215077896|NCT06115694|DEVICE|TCI Articulating Introducer|use
215077897|NCT06115694|DEVICE|GlideRite® Rigid Stylet|use
214331207|NCT06027281|OTHER|The Symptom Check-List-90-R (SCL-90-R)|The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.
215072065|NCT05000268|OTHER|Progressive Myofascial Relaxation Exercise|"Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~* First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed."
215072066|NCT00906724|PROCEDURE|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
215072067|NCT05945732|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~Trastuzumab (T-DXd) to be administered according to the SmPC.~Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC."
215072068|NCT05209295|DRUG|Onureg|Specified dose on specified days
214331208|NCT06027281|OTHER|Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)|An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.
214331209|NCT06027281|OTHER|The female sexual function index (FSFI)|The female sexual function index is a brief multidimensional scale for assessing sexual function in women.
214331210|NCT04607226|OTHER|Active transcutaneous vagus nerve stimulation|respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes
214331211|NCT04607226|OTHER|Sham transcutaneous vagus nerve stimulation|stimulation of the auricle for 30 minutes
214331212|NCT01448850|BIOLOGICAL|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
214331213|NCT01448850|OTHER|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
214331214|NCT06014515|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
214331215|NCT06014515|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
214331216|NCT03860389|OTHER|Exercise|An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
214331217|NCT00222287|BEHAVIORAL|Feldenkrais Movement class|
214331218|NCT04634773|RADIATION|Low-dose CT|"A low-dose, or quantitative (q) CT scan will be performed on the shoulder. This CT scan will be done to assess the bony structure of the shoulder, as well as bone strength, which can influence the health of the cartilage.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
214331219|NCT04634773|OTHER|T1Rho MRI|"A T1Rho MRI will be performed on the shoulder. This imaging technique uses a special sequence and will be used to assess the muscles and tendons around the shoulder.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
214331220|NCT04634773|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
214933042|NCT00860041|BEHAVIORAL|pain questionnaires|
214933043|NCT06179732|COMBINATION_PRODUCT|Mesh - spatial repellent impregnated with transfluthrin (2500mg)|"Mesh is one of the first spatial repellent tools to provide long-lasting protection to users, with predicted efficacy of 6-months. The active ingredient of Mesh is transfluthrin, a fast-acting volatile pyrethroid with low persistency, which can act either by killing or via sublethal toxicity that causes deviation (repellency) in host attraction, reducing host-contact and risk of infectious bites. The chemical passively releases into the air and interacts with vector odour receptors causing irritation. The design of Mesh is simple with a transfluthrin-infused sheet protected by plastic mesh and encased in a plastic frame.~Mesh will be distributed to the intervention arm only."
214933044|NCT06179732|BEHAVIORAL|Information and Education Campaigns (IEC)|IEC campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home) using leaflets and word of mouth. IEC will be conducted in both arms.
215072069|NCT04525859|BIOLOGICAL|Safety|See previous Safety group description
215072070|NCT04525859|BIOLOGICAL|Expansion Cohort|See previous Expansion Cohort
215072071|NCT06052878|OTHER|"Parental telephone interview with standardized parental questionnaire from the Behaviour Rating Inventory of Executive Function (BRIEF)"|"The Behaviour Rating Inventory of Executive Function (BRIEF) is a parental questionnaire that assesses the executive functions of children aged 5 to 18 years old. It consists of 86 questions grouped into 8 scales: inhibition, flexibility, emotional control, initiation, material organization, working memory, planning/organization, and monitoring. It provides information on a global scale (score) regarding subtle and subclinical changes in various executive functions."
215077898|NCT05739695|DIAGNOSTIC_TEST|Virtual bronchoscopy navigation|It is planned to use VBN as the only navigation technique to compare it with rEBUS
215072072|NCT06052878|OTHER|Parental questionnaire about their child's cognitive functioning in their daily life and medical history.|Standardized questionnaire includes : The child's medical history and cognitive functioning (at school, parental home, and during extracurricular activities), home environment, parent's child socioeconomic status and emotional climate.
214331221|NCT05511844|DRUG|ORM-5029|Intravenous infusion
214331222|NCT02214147|DRUG|Alisertib|Alisertib will be supplied as enteric coated tablets.
214673564|NCT03466710|OTHER|Pap test|"Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (\>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (\</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or \>LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is \>/=CIN II. Results of \</=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization)."
214933045|NCT06179732|DIAGNOSTIC_TEST|test and treat malaria cases|All children in the cohort (both arms) will be tested by rapid diagnostic testing (RDT) monthly. If any children test positive, they will be treated with a course of 3-day artemisinin combination therapy (ACT) according to standard protocol and local guidelines. All children in the cohort will receive ACT to provide clearance of any malaria parasites during the baseline of the study.
214933046|NCT06022042|DEVICE|On1 two-stage abutment and one-stage abutment|the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.
214933047|NCT01069237|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
214933048|NCT01069237|DEVICE|Clear Care|Lens Care Solution for contact lenses
214933049|NCT01055405|DRUG|Sildenafil|Sildenafil 20mg TID orally
214933050|NCT01055405|OTHER|Placebo|Placebo TID orally
214933051|NCT05563012|DRUG|Sintilimal Injection|Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.
214933052|NCT05654090|DRUG|cefoperazone sodium and sulbactam sodium|Pharmacokinetic study under fasting conditions
214933053|NCT03523143|OTHER|early screening and intervention|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the IADPSG criteria. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks. The process of screening and intervention in the early screening group is all the same with that in the standard screening group. The only difference between two groups is the time of screening and intervention (18-20 weeks vs. 24-28 weeks of GA).
214331223|NCT03533075|BEHAVIORAL|Teachable Moment Brief Intervention|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
214331224|NCT02063165|DIETARY_SUPPLEMENT|High Linoleic Safflower Oil|2 tsp per day (\~10g of oil)
214331225|NCT06413225|DEVICE|Synergy cervical disc system|motion preservation disc
214331226|NCT06317636|DRUG|Ketamine|0.5 mg/kg ketamine infused intravenously over 40 minutes
214331227|NCT06317636|DRUG|Normal saline|0.9% normal saline infused intravenously over 40 minutes
214933054|NCT03523143|OTHER|standard screening and intervention|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria, ie. if one of the plasma glucose levels at fasting, 1-hour, and 2-hour during OGTT is above 92 mg/dL, 180 mg/dL, and 153 mg/dL, respectively. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks.
214933055|NCT00302484|DRUG|Zoledronate|
214933056|NCT01624857|DRUG|Rosuvastatin|Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
214933057|NCT01624857|DRUG|Placebo|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
214933058|NCT00697541|DRUG|0.18% COL-118 facial gel (1.8 mg brimonidine)|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
215072073|NCT01794078|DRUG|Aminophylline 400 mg|Xanthine derivative
215072074|NCT01794078|DRUG|Ambrisentan 5 mg|Endothelin receptor antagonist
215072075|NCT01794078|OTHER|Placebo|
215077899|NCT05739695|DIAGNOSTIC_TEST|radial EBUS|It is planned to use rEBUS as the only navigation technique to compare it with VBN
215077900|NCT01545232|BIOLOGICAL|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
214331228|NCT05761873|OTHER|Provision of audit and feedback via email and paper|Provision of A\&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
215077901|NCT01545232|BIOLOGICAL|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
215077902|NCT03433820|OTHER|Observation of wound healing|Observation of wound healing after skin biopsy
215077903|NCT03031392|DIAGNOSTIC_TEST|Sensitivity test|Routine clinical and radiographic examination
215077904|NCT05210634|DIETARY_SUPPLEMENT|THCv|THCv in MCT oil
215072076|NCT03886870|BEHAVIORAL|Lifestyle and work intervention|"The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes."
214331229|NCT05761873|OTHER|Provision of audit and feedback via paper only|Provision of A\&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
214331230|NCT06237153|DRUG|Triamcinolone Acetonide extended release suspension|Active steroid
214331231|NCT03098511|DIAGNOSTIC_TEST|Neurological Diagnostic Evaluation|"Clinical Data:~* Demographic data~* Daily data (clinical exams, laboratory data)~* Drug administration~* Additional clinical or ancillary neurological determination test~Diagnostic Intervention:~* CT-Perfusion~* CT-Angiography reconstructions~Reference Standard:~\- Clinical Neurological Exam~Blood Samples (Pharmacokinetics, Inflammatory \& Nanovesicles Parameters):~* At the time of patient enrolment~* 6 hours after patient enrolment~* At the time of the clinical neurological exam~Secondary Outcome measures at 6 months:~* extended Glasgow Outcome Scale (GOSe)~* modified Rankin Scale (mRS)"
214331232|NCT01046916|DRUG|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
214331233|NCT01125423|DRUG|Milnacipran|Subject with Fibromyalgia will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
214331234|NCT01125423|PROCEDURE|Skin biopsy|Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
214331235|NCT01125423|PROCEDURE|Skin Biopsy|Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
214331236|NCT06027827|PROCEDURE|Addition of fusion device lateral bone graft|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
214933059|NCT00697541|DRUG|0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
214933060|NCT00697541|DRUG|Advanced Eye Relief|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
214331237|NCT06249308|OTHER|Blood collection|Blood sample will be collected
214331238|NCT04981041|DRUG|Prasugrel or Ticagrelor|Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)
214331239|NCT04981041|DRUG|Clopidogrel|Clopidogrel and NOAC
214331240|NCT00691236|DRUG|Zoledronic acid|4mg IV 3 weekly for 6 doses
214331241|NCT00691236|DRUG|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
214331242|NCT02305303|PROCEDURE|Diary|A diary written prospectively during the ICU stay by the staff and relatives
214933061|NCT00697541|DRUG|COL-118 facial gel vehicle|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
214933062|NCT00005768|DRUG|Estrogen|
214933063|NCT03250481|DRUG|Propofol|Sedation targeted to RASS -3-0 or RI 20-40
214933064|NCT00402532|DRUG|Everolimus|Initial dosage 2 x 0.75 mg/d
214933065|NCT00402532|DRUG|Mycophenolatmofetil|Initial dosage 2 x 500 mg/d intravenous
215072077|NCT03886870|BEHAVIORAL|Lifestyle intervention|"The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home."
215072078|NCT00790868|DRUG|d-cycloserine|50mg
215072079|NCT00790868|DRUG|placebo|50mg
215072080|NCT01034566|RADIATION|Proton Beam Radiation Therapy|
215072081|NCT01380535|DRUG|ECP Methoxsalen|Methoxsalen delivered by ECP
214331243|NCT05256433|OTHER|Group-A|IASTM Certified IASTM practitioner will be performing the technique with emollient lubricant in which brushing and sweeping stroke will be applied for plantar fascia and fanning and sweeping stroke technique for calf muscles for the duration of 10 minutes to eliminate the inflammation. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury. The frequency stretching will be 5 repetitions for each with 10 seconds hold.
214331244|NCT05256433|OTHER|Group-B|Manual massage includes transverse friction massage for plantar fascia, flexor digitorum brevis, and deep massage for calf muscle for the duration of 10 minutes to eliminate the tightness and increase the blood flow. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury.
214331245|NCT00410696|DRUG|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
214331246|NCT00410696|DRUG|Pegfilgrastim|6 mg/day sc at day +1
214331247|NCT01374113|DRUG|50mg safinamide|50 mg safinamide on Day 1
214331248|NCT02671123|PROCEDURE|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
214331249|NCT02671123|PROCEDURE|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
214331250|NCT02621164|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
214331251|NCT02621164|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
214331252|NCT01897311|DEVICE|transcutaneous electrical nerve stimulation|
214331253|NCT03331874|DIAGNOSTIC_TEST|Reflectance Confocal Microscopy|In-vivo microscope
214331254|NCT06209112|DRUG|Sevoflurane|The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
214331255|NCT00485537|PROCEDURE|oocyte retrieval and ICSI procedure|
214331256|NCT03676049|DRUG|Cannabidiol|CBD will be administered as an adjunct to all current antiepileptic drugs. A dosing titration period will start with 100 mg/day, with 50mg BID dosing, and will be titrated monthly as tolerated based on clinical response, up to 300mg/day. This is based on a targeted dosing of 2.5 ---5---7.5 mg/kg/d.
214331257|NCT05856292|OTHER|Teach Back|Standard cancer pain educational intervention enhanced with teach-back method
214331258|NCT05856292|OTHER|Placebo|Standard cancer pain educational intervention without enhancement
214331259|NCT01487330|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
214933066|NCT04045132|BEHAVIORAL|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, in order to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. For each topic, we organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily, provides feedback to participants, and removes inappropriate postings if they occur. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed (engagement) and counts of sessions viewed and comments posted (dosage). Women in the intervention group will also be enrolled in the online depression treatment program, MoodGym.
214331260|NCT02878993|DEVICE|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
214331261|NCT00380640|DRUG|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
214331262|NCT00380640|DRUG|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
214331263|NCT01032941|DRUG|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
214331264|NCT04157829|DEVICE|Scintilling lamp|Lamp with a standardized scintilling
214331265|NCT04157829|DEVICE|Classic lamp|Lamp without a scintilling
214331266|NCT05924035|DEVICE|HBOT|HBOT treatment on a multiplace chamber (OXYHeal Hyperbaric Oxygen Chamber), 100% oxygen at 2.0 atmospheres for 90 minutes - on 4 consecutive days within 3 hours of completion of exercise training (as soon as practically possible). This will occur during week 2 of data collection.
214331267|NCT00003196|DRUG|chemotherapy|Undergo cytoreductive chemotherapy
214331268|NCT00003196|RADIATION|total-body irradiation|Undergo TBI
214331269|NCT00003196|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
214331270|NCT00003196|DRUG|cyclosporine|Given IV or PO
214331271|NCT00003196|DRUG|mycophenolate mofetil|Given PO
214331272|NCT00003196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
214331273|NCT00003196|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
214331274|NCT05251181|DRUG|Normal Saline|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
214933067|NCT04045132|BEHAVIORAL|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
214331275|NCT05251181|DRUG|Centhaquine|Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
214331276|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
214331277|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
214331278|NCT01267903|BIOLOGICAL|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
214331279|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
214331280|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
214331281|NCT00280566|DRUG|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
214331282|NCT00280566|DRUG|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
214331283|NCT03967470|BIOLOGICAL|Bacterial spray|Bacterial spray containing bacteria that do not cause underarm malodor
214331284|NCT02453295|BEHAVIORAL|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
214331285|NCT05234515|DIAGNOSTIC_TEST|Microbiology swab|Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery. Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021. Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
214331286|NCT05234515|OTHER|Questionnaire|Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days. These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
214933068|NCT00327743|DRUG|larotaxel|IV infusion on Day 1 of a 21-day cycle
214933069|NCT00327743|DRUG|capecitabine|oral, twice daily, Day 1-Day 14 of a 21-day cycle
214933070|NCT05210101|DRUG|Sotrovimab|Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.
214955388|NCT03726307|BIOLOGICAL|DCreg: 1.2 million cells/kg+SOC|"DCreg 1.2 (±02) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
215072082|NCT01380535|DRUG|Standard of Care|Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
215072083|NCT00898300|OTHER|biologic sample preservation procedure|
214331287|NCT03208374|BEHAVIORAL|Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire|Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
214331288|NCT03208374|BEHAVIORAL|Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)|The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
215072084|NCT00898300|PROCEDURE|biopsy|
215072085|NCT05381441|BEHAVIORAL|Safety Action Feedback and Engagement (SAFE) Loop|Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
214933071|NCT05581472|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention + Phone Coaching|"The intervention has 8 modules. The modules Away Moves and Letting Go of Control, help to establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. The modules Noticing Hooks and Stepping Back focus on diffusion, self as context, and mindfulness. While mindfulness is overtly addressed in the module Stepping Back, it is weaved through each module. The modules Your Values and How You Want to Act focus on helping participants identify their values. The modules Goal Setting and Making Commitments focus on committed action. Each module has a practice assignment which participants are asked to engage in over the next week.~During the phone coaching calls, the participant will be able to troubleshoot any technical difficulties and ask any questions about the material being taught in the intervention."
214331289|NCT03178058|OTHER|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
214331290|NCT03866174|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
214331291|NCT03866174|DRUG|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
214331292|NCT03866174|OTHER|Set and Setting (SaS) Protocol|The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
214331293|NCT06535724|PROCEDURE|Chronic plantar fasciitis endoscopic debridement coupled with heel spur resection|"1. Preoperative Preparation: popliteal nerve block, patient positioning supine with the operated limb fully externally rotated, spinal anesthesia, tourniquet application.~2. Surgical Procedure:~   * Initial Marking from the heel bone arch to the calcaneal bone to locate the entry point.~  * First Incision and Portal Creation: an initial incision at the palpated site using a size 11 blade; blunt dissection to reveal the plantar fascia; arthroscope entry.~  * Secondary Entry: 3 cm distally from the initial incision; positioning of the arthroscope; additional blunt dissection and obturator insertion.~  * Operative Technique: continuous irrigation with sterile saline; 3.5-mm shaver introduced through the distal portal; meticulous debridement of inflamed and pathological tissue; removal of calcaneal spurs; thinning of the plantar fascia~3. Postoperative Care • Careful monitoring and guided rehabilitation to support optimal healing and recovery."
214933072|NCT05581472|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention without phone coaching|"The intervention has 8 modules. The modules Away Moves and Letting Go of Control, help to establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. The modules Noticing Hooks and Stepping Back focus on diffusion, self as context, and mindfulness. While mindfulness is overtly addressed in the module Stepping Back, it is weaved through each module. The modules Your Values and How You Want to Act focus on helping participants identify their values. The modules Goal Setting and Making Commitments focus on committed action. Each module has a practice assignment which participants are asked to engage in over the next week."
214933073|NCT05809024|DRUG|letrozole|Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
214933074|NCT03180658|PROCEDURE|GTR + CGF + bone graft|Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
214933075|NCT03180658|PROCEDURE|CGF + bone graft|CGF combined with bone graft to treat mandibular furcation involvements
215072086|NCT02513290|DRUG|Bilastine|
215072087|NCT02513290|DRUG|Loratadine|
215072088|NCT02013206|DRUG|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
215072089|NCT02179736|DEVICE|Restylane|
215072090|NCT01018472|DIETARY_SUPPLEMENT|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
215072091|NCT01018472|OTHER|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
215072092|NCT03263728|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
214933076|NCT04463056|BIOLOGICAL|Elizaria®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
214933077|NCT04463056|BIOLOGICAL|Soliris®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
215072093|NCT05022199|DEVICE|SPY fluorescent angiography|This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
215072094|NCT00532025|DRUG|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
215072095|NCT02359357|DRUG|FDL169|
214331294|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
214331295|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
214331296|NCT00799812|DRUG|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
214331297|NCT00799812|OTHER|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
214331298|NCT00799812|OTHER|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
214331299|NCT06224920|DIAGNOSTIC_TEST|magnetic resonance imaging|MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.
214933078|NCT03198832|PROCEDURE|Non-surgical periodontal treatment|Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
214933079|NCT03796442|DEVICE|AVR with AVALUS|aortic valve replacement with AVALUS bioprosthesis
214933080|NCT03796442|DEVICE|AVR with CEPME|aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
214933081|NCT05487287|DEVICE|Kinematic computational analysis of the hand (Leap Motion device)|"Kinematic computational analysis exercises:~1. Finger extension~2. Wrist extension~3. Finger separation~4. Finger clamp"
214933082|NCT04519788|DRUG|AT-301B|Nasal Spray
215072096|NCT02359357|DRUG|Placebo|
215072097|NCT03217877|DIAGNOSTIC_TEST|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9\~15 months after the procedure according to the practice pattern of each participating center.
214331300|NCT06224920|OTHER|electroencephalography|A 20-channel resting EEG (Brain Products, Gilching, Germany) is recorded as part of routine clinical diagnostics in the Department of Psychiatry and Psychotherapy at the LMU to rule out focal neurophysiological pathologies. Within the scope of the present study, an extended examination will be carried out, which includes a 64-channel EEG, including a passive visual paradigm. After completion of the clinical evaluation, the neurophysiological changes in resting activity will be scientifically analyzed in comparison to the MRI and PET data.
214933083|NCT04519788|DRUG|AT-301A|Nasal Spray
214933084|NCT04995653|DRUG|Vancomycin Pre-Treatment|Four times daily dosing with Vancomycin
214933085|NCT04995653|DRUG|Vancomycin Placebo|Four times daily dosing with Vancomycin Placebo
214933086|NCT04995653|DRUG|SER-155|Once daily dosing with SER-155
214933087|NCT04995653|DRUG|SER-155 Placebo|Once daily dosing with SER-155 placebo
214933088|NCT05274581|OTHER|A new type of ultrasound course|All participants will receive the educational intervention. The educations intervention consists of three teaching seminars over three months, a curriculum of 10 point-of-care ultrasound applications, an online learning platform providing educational support before, during and after the teaching sessions.
214933089|NCT01878812|BIOLOGICAL|Fluarix/Influsplit Tetra® (2013-2014 season)|1 dose administered intramuscularly in the deltoid region of non-dominant arm
214933090|NCT02677038|DRUG|Olaparib|Given PO
214933091|NCT02523924|DRUG|18F-DCFPyL|18F-DCFPyL PET/CT
215072098|NCT03217877|DIAGNOSTIC_TEST|No Routine stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
215072099|NCT01588262|OTHER|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
215072100|NCT02791191|DRUG|LY3202626|Administered orally
215072101|NCT02791191|DRUG|Placebo|Administered orally
215072102|NCT04022785|DRUG|Azacitidine|Given IV or SC
215072103|NCT04022785|DRUG|BRD4 Inhibitor PLX51107|Given PO
215072104|NCT06357871|OTHER|No intervention|No intervention
215072105|NCT03474900|DEVICE|PLGA implant, Bioretec ltd. Finland|The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
215072106|NCT03474900|DEVICE|Titanium elastic stable nail|Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
215072107|NCT06389734|BEHAVIORAL|Manual soft tissue release|"The manual soft tissue release includes muscle energy techniques and passive stretching, targeting the anterior scalene, upper trapezius, pectoralis major, pectoralis minor, and diaphragm.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
214933092|NCT03819595|OTHER|Supervised exercise|a free 12-week, small-group (\~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
214933093|NCT03819595|OTHER|Personalized Program PVS|"a standardized promotion prescription of physical activity, balanced diet and smoking cessation, using the computer tool Promote Healthy Living integrated into the electronic medical record."
214933094|NCT03671564|DRUG|Milademetan|Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.
214933095|NCT02609100|PROCEDURE|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
214331301|NCT06224920|DIAGNOSTIC_TEST|blood and CSF biomarker|Aβ1-42 and 1-40, total tau protein and phosphorylated tau protein 181 (p-Tau), apolipoprotein E (APOE), soluble TREM2 protein, neurofilament light chain and glial fibrillary protein (GFAP) will be determined.
214933096|NCT02609100|PROCEDURE|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
215072108|NCT06389734|BEHAVIORAL|Myofascial release|"The myofascial release includes suboccipital muscle, anterior chest wall myofascial, and anterior neck myofascial.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
215072109|NCT06389734|BEHAVIORAL|Exercise training|The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.
214331302|NCT06224920|DIAGNOSTIC_TEST|positron emission tomography|According to an established and standardized protocol, PET scans are performed with the TSPO receptor ligand \[18F\]-GE-180, \[18F\]flutemetamol for assessment of fibrillar Aβ 162 accumulation and the Tau ligand \[18F\]-PI-2620. In brief, \[18F\]GE-180 TSPO PET images (mean dose: 177 ± 17 MBq) with an emission window of 60-80 min after injection will be acquired to measure the activation of glial cells. \[18F\]Flutemetamol Aβ PET images (average dose: 182 ± 11 MBq) are acquired with an emission window of 90-110 min after injection to assess fibrillar Aβ accumulation. Dynamic \[18F\]PI-2620 tau PET (average dose: 186 ± 14 MBq) with an emission window of 0-60 minutes after injection are performed for quantification of tau aggregation. Static images of the late phase (20-40 min) are reconstructed. These images are used for further processing and analysis.
214331303|NCT06224920|DIAGNOSTIC_TEST|neuropsychological test|Trained psychologists at the Memory Clinic of the LMU Hospital administered the CDR, CERAD-NB and Mini-Mental State Examination (MMSE). The CERAD-NB battery was used to generate a total score for the six subscales: semantic fluency (animals/60 s), modified Boston naming test, lexical items, construction practice, lexical items retrieval, and lexical items discrimination, with higher scores indicating better performance.
214331304|NCT01282593|OTHER|Impact of CD9 expression level on motility assays|"1\) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.~Adhesion results will be validated on patient samples of B-ALL."
214933097|NCT02609100|DEVICE|1.0 X 2.5 cm 'pill' containing a camera|
214933098|NCT02078375|DIETARY_SUPPLEMENT|Protein|whey protein plus casein protein
214933099|NCT02078375|DIETARY_SUPPLEMENT|Carbohydrate (Placebo)|The twice daily placebo will consist of a carbohydrate and a small amount of protein
214933100|NCT02078375|OTHER|Resistance Exercise Program|All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
214933101|NCT02339116|DRUG|fluoruracil|
214933102|NCT02339116|DRUG|Oxaliplatin|
214933103|NCT02339116|DRUG|Irinotecan|
214933104|NCT02339116|DRUG|Bevacizumab|
215072110|NCT01851486|DRUG|Clonidine|Clonidine 0.15 mg
215072111|NCT01851486|DRUG|Naloxone|naloxone 0.15 mg/kg
215072112|NCT01851486|DRUG|placebo|
215072113|NCT01851486|OTHER|saline|
215072114|NCT05452954|BEHAVIORAL|Brief behavioral parent training|In the newly developed intervention, both stimulus control and contingency management techniques will be offered in a brief behavioral parent training consisting of two intervention sessions and one booster session.
215072115|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
215072116|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
215072117|NCT00713921|DRUG|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
214933105|NCT00702442|DRUG|Droperidol|0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
214933106|NCT00702442|DRUG|Saline solution|Saline solution administrated i.v 30 min prior surgery
215072118|NCT05539560|OTHER|Olfactory training with essential oils|Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
214331305|NCT01282593|OTHER|Post-transcriptional regulation of CD9|"2\) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.~Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples."
214331306|NCT04542070|DRUG|Cabotegravir Tablets|CAB tablets were available as film coated tablets for oral administration.
214331307|NCT04542070|DRUG|Cabotegravir Injectable Suspension (CAB LA)|CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
214331308|NCT04542070|DRUG|Rilpivirine Tablets|RPV was administered as tablets for oral administration.
214933107|NCT04294706|DIETARY_SUPPLEMENT|Hemp arm|Hemp oil
214933108|NCT03703011|DEVICE|Accelerometers positioned at the wrinkle, the hip, and the ankle|Accelerometers are positioned at the wrinkle, the hip, and the ankle. The subject stands and walks 10 meters, followed up by a physiotherapist in the physiotherapy area. The accelerometers are triggered by a smartphone. The protocol is filmed (without the face), and 2 physicians will watch the film and count the steps blind to the results of the accelerometers (and blind to each-other steps counts)
214933109|NCT06411951|OTHER|Participation in the INTUK care offer at Klinik Zugersee|Person-centered treatment and care tailored to the individual patients needs by a team consisting of a senior physician, a nurse, social workers and peers.
214933110|NCT05502744|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis due to the advantages of small wounds, less use of abdominal drains , less need for antibiotics and analgesics and less postoperative hospital stay time.Laparoscopic cholecystectomy in acute cholecystitis may be performed as soon as begging of the symptoms called emergency or urgent and maybe scheduled in advance after controlling acute attack after 6-8weeks called elective.
215072119|NCT05539560|OTHER|Olfactory training with fragrance-free oils|Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
215072120|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets|Investigational Medicinal Product
215072121|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets|Evafem 20 (Trademark)
215072122|NCT03293433|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
214331309|NCT04542070|DRUG|Rilpivirine Injectable Suspension (RPV LA)|RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
214331310|NCT04542070|DRUG|BIKTARVY Tablets (BIK)|BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
214933111|NCT04739722|DIAGNOSTIC_TEST|ColoSense|"ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.~A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals."
214933112|NCT05860439|PROCEDURE|Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Patients previously treated were reassessed for long-term follow-up.
214933113|NCT01917812|DEVICE|Digital Activity Tracker|
214933114|NCT01917812|OTHER|Smart Text Messaging|
214933115|NCT06622174|RADIATION|Pulse radiotherapy|Pulsed radiotherapy combined with PD(L)-1 inhibitors targeting 2 to 5 progressive extracranial lesions per cycle
214933116|NCT03590535|DIAGNOSTIC_TEST|4th Gen cTnT|"Current Fourth Generation Cardiac Troponin T Enzyme Assay"
214933117|NCT03590535|DIAGNOSTIC_TEST|5th Gen cTnT|"New Fifth Generation (High-sensitivity) Troponin T Enzyme Assay"
214933118|NCT06523907|OTHER|Intervention Basic Nursing skills|Evaluating the effectiveness of the education program in improving paramedics' knowledge of essential nursing care principles, such as hygiene practice, infection control, safe administration of injection, blood draw, vital sign monitoring, respiratory rate
214933119|NCT06523907|OTHER|Control Present Knowledge about basic nursing skill|Assess the current and baseline knowledge status of the participants about the hygiene practice, infection control, safe administration of injection, blood draw, vital sign monitoring, respiratory rate
215072123|NCT01845584|DRUG|NPB-01|
215072124|NCT00672087|GENETIC|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
215072125|NCT04140955|PROCEDURE|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
215072126|NCT00842439|BEHAVIORAL|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
215072127|NCT00842439|DIETARY_SUPPLEMENT|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
215072128|NCT06300723|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
214331311|NCT04307238|DIAGNOSTIC_TEST|PLR|PLR measurements will be performed within the first 2 postoperative hours.
214331312|NCT04307238|DIAGNOSTIC_TEST|Alertness testing|Preoperative (baseline) and every 30 minutes postoperative computer based alertness testing will be performed.
215072129|NCT02378194|DRUG|Placebo|24 weeks, once daily oral administration
214933120|NCT01176695|DRUG|fish oil containing lipid emulsion|medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
214933121|NCT01176695|DRUG|MCT/LCT containing lipid emulsion|medium chain triglycerides, long chain triglycerides
214933122|NCT01185509|DRUG|trastuzumab|
214331313|NCT04307238|PROCEDURE|Propofol anesthesia|Maintenance of anesthesia will be performed using propofol.
214331314|NCT04307238|PROCEDURE|Sevoflurane anesthesia|Maintenance of anesthesia will be performed using sevoflurane.
214933123|NCT01185509|DRUG|vinorelbine|
214933124|NCT03687372|DRUG|A-101|hydrogen peroxide topical solution 45%
214933125|NCT03687372|OTHER|vehicle|vehicle as a topical solution
215072130|NCT02378194|DRUG|HD-003 (800mg/day)|24 weeks, once daily oral administration
215072131|NCT02378194|DRUG|HD-003 (1600mg/day)|24 weeks, once daily oral administration
215072132|NCT06036329|DEVICE|Group A : provided with 1 Whitsundays Nasal mask without a spare mask cushion|Group A will be provided with 1 Whitsundays Nasal mask without a spare mask cushion (replacement cushions will only be provided when requested)
215072133|NCT06036329|DEVICE|Group B : provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|Group B will be provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
215072134|NCT05018806|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
215072135|NCT05018806|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
215072136|NCT01356342|BIOLOGICAL|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections"
215072137|NCT03018470|OTHER|Analysis of data from NIV built-in software|Analysis of breathing pattern using data obtained from NIV built-in software
215072138|NCT05814198|DIAGNOSTIC_TEST|HALP score|we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
215072139|NCT05489653|BEHAVIORAL|mixed music|Learn about the effects of listening to music and doing activities with it on sleep.
215072140|NCT01068951|BIOLOGICAL|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
215072141|NCT01616940|BEHAVIORAL|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~* Introduction and Assessment~* HIV Transmission \& Viral Life Cycle~* Effective Communication and Self-Advocacy~* Understanding Lab Values~* HIV Medications~* Drug Resistance \& Adherence, and Understanding \& Managing Side Effects~* Disclosure and Stigma~* Harm \& Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~* Are any services needed?~* Have referrals or appointments been made?~* Does patient need accompaniment to a visit?~* Connect patient with services as needed.~* Appointment reminders.~* Overall well-being?~* Schedule next peer contact."
215072142|NCT01952665|DEVICE|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
214933126|NCT04884425|DEVICE|Pulsed Electromagnetic Frequency Device (Energy5)|A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
214933127|NCT00655148|BIOLOGICAL|DTaP-IPV vero vaccine|DTaP-IPV vero 0.5 mL solution for intramuscular injection at 2, 3½, 5 and 16 months of age
214933128|NCT00655148|BIOLOGICAL|DTaP-IPV mkc vaccine|DTaP-IPV mkc 0.5 ml solution for intramuscular injection at 2, 3½, 5 and 16 months of age
214933129|NCT05333939|DIETARY_SUPPLEMENT|Moringa leaf powder|capsule ingestion
214933130|NCT05333939|OTHER|Placebo|capsule ingestion
214933131|NCT03775122|DEVICE|TAES|TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity
214933132|NCT02779335|OTHER|Enteral Formula|pediatric subjects will be fed a standard pediatric enteral formula tube feeding
214933133|NCT03347734|BEHAVIORAL|Eye exercises group|"* 20 times hot water, 20 times cold water washing face in the morning and evening.~* Palming; 2 hands are rubbed together and warmed up, and the eyes are closed, and 8 digits are drawn with eyes in darkness.~* 20 blinks~* Looking at a clock in a circular shape, from 12 to 6, from 6 to 12, from 3 to 9, from 9 to 3, from 2 to 8, from 8 to 2, oblique from 10 to 4, from 4 to 10, and turning the eyes starting from 12 clockwise and counterclockwise. At the end of the exercises, 2-3 minutes of light massage around the eyes and on sunny days, sunbathing was recommended by closing the eyes for 3-5 minutes and swinging to the left and right."
214933134|NCT03347734|BEHAVIORAL|Convergence exercise group|"* Close eyes for 15 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 20 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Blink for 5 s,~* Close eyes for 5 s."
214933135|NCT03347734|BEHAVIORAL|Oculomotor Exercise Group (OMEG)|"* The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~* The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~* The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~* The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
214933136|NCT03991013|DRUG|Dolutegravir 50 mg|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
214933137|NCT03991013|DRUG|Placebo|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
214933138|NCT03380702|PROCEDURE|whitening photoactivation gel|35 subjects in active comparator group
214933139|NCT03380702|PROCEDURE|placebo|35 subjects in placebo comparator group
214933140|NCT04724902|OTHER|Elastic bandage compression|The compression will be applied with the volunteer in the supine position on a stretcher, with both lower limbs extended and relaxed. The intervention in the Compression group will be with elastic bandages involving the entire surface of the knee, positioned considering anatomical aspects: femoral condyles and the anterior tibial tuberosity. The level of compression must be maintained between 30 mmHg and 60 mmHg, according to the researched literature. The variations within these values will be stipulated according to the volunteer's self-report (comfortable and painless compression). The Shan Group will have the bandage wrapped around the knee without any compression force being exerted. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days. The Control group will be composed of volunteers who make up a study waiting list and will carry out the evaluations at the same time intervals as the other groups, but will not receive any type of intervention.
214933141|NCT02971436|DEVICE|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
214933142|NCT02971436|DEVICE|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
214933143|NCT02971436|DEVICE|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
214933144|NCT02971436|DEVICE|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
214933145|NCT02971436|DEVICE|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
214933146|NCT02971436|DEVICE|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
214933147|NCT01932736|OTHER|changing ear canal pressure|ear canal pressure changes: pressure varied from +/-40 decapascals
214933148|NCT05028075|BEHAVIORAL|Cobalt +|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
214331315|NCT00575848|DIETARY_SUPPLEMENT|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
214331316|NCT00575848|DIETARY_SUPPLEMENT|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
214331317|NCT06550570|BEHAVIORAL|QEVA questionnaire|QEVA questionnaire administered at 2 days pospartum (in hospital) and 4 weeks postpartum (phone call). (specific for the study)
214933149|NCT04790162|BEHAVIORAL|Heartfulness Meditation|Heartfulness meditation with a trainer provided virtually
214933150|NCT06426862|OTHER|Otago Exercise Program|"Otago exercise program~Strengthening Exercise Knee extensor, Hip adductors, heel and toe raising~Balance exercise Sit to stand, Knee bending, one leg standing, tandem stance, side walk, walk and turn around, tandem walk, backward walk, heel and toe walk, stair climbing"
214933151|NCT06426862|OTHER|Control Group|Routine physiotherapy like strengthening, stretching, postural awareness, gait and balance training.
214331318|NCT02657863|PROCEDURE|Urine collection and blood draw|
214331319|NCT02709395|DEVICE|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
214331320|NCT01108575|OTHER|IMST|inspiratory muscle strength training
214331321|NCT01108575|OTHER|Sham IMST|sham inspiratory muscle strength training
214933152|NCT04403646|DIETARY_SUPPLEMENT|ARBOX|dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg
214933153|NCT04403646|OTHER|PLACEBO|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX
215072143|NCT01952665|DEVICE|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
214331322|NCT05035771|DEVICE|Pressure wire measurement in peripheral vascular disease|The aim of IMPACT PAD is to examine the safety and feasibility of intraprocedural flow, pressure and resistance rate changes to help predict the success of a peripheral endovascular intervention.
214331323|NCT06967389|DRUG|Ozempic®|The study medication will be given in accordance with standard of care dosing schedule.
214331324|NCT01844635|DRUG|Thymoglobulin|
214331325|NCT02188485|BEHAVIORAL|ENGAGE|Up to 10 sessions delivered in the home.
214331326|NCT00768729|DRUG|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
214331327|NCT00768729|DRUG|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
214331328|NCT03367312|DRUG|Hyperpolarized 129Xenon gas|Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
214933154|NCT02350946|DRUG|Oxytocin|
214933155|NCT02350946|DRUG|Placebo|
214933156|NCT05221268|OTHER|Level walking exercise|treadmill exercise with 0 inclination
214933157|NCT05221268|OTHER|Downhill exercise|treadmill exercise with -20 inclination
214933158|NCT06648369|OTHER|MAX-ICH care bundle|The MAX-ICH care bundle is a comprehensive treatment approach for intracerebral hemorrhage (ICH). Patients receive 72 hours of care in a high-dependency unit like an ICU or hyperacute stroke unit. Intensive blood pressure control is used if systolic blood pressure exceeds 140mmHg, with rapid reduction to below 140mmHg within 60 minutes, and maintenance at or above 110mmHg for at least 75% of the time, with variability kept under 20%. The protocol includes rapid reversal of anticoagulation within 60 minutes, administration of tranexamic acid (1g bolus within 60 minutes, followed by 1g over 8 hours), and neurosurgical evaluation within 60 minutes. Additionally, family counseling is provided to avoid Do-Not-Resuscitate orders during the first 72 hours.
215072144|NCT01120314|DRUG|OTAMIXABAN (XRP0673)|"Form: solution for injection~Route: intravenous"
215072145|NCT01511328|OTHER|HPV testing|Testing for Human Papilloma Virus
215072146|NCT01537081|DRUG|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
215072147|NCT01537081|DRUG|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
215072148|NCT01537081|DRUG|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
215072149|NCT01022359|DEVICE|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
215072150|NCT01022359|DEVICE|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
214331329|NCT03756610|DEVICE|Active tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
214933159|NCT06648369|OTHER|Standard of care|The control group will be treated according to the hospital's standard protocol for patients with spontaneous intracerebral hemorrhage, based on the guidelines of the European Stroke Organisation (ESO). The ESO develops evidence-based recommendations for the optimal care of stroke patients. The recommended immediate measures include: immediate stabilization and assessment, blood pressure control and reduction, brain imaging, surgical intervention for large hemorrhages, coagulation control, and monitoring of intracranial pressure. The specific application of these measures varies depending on the hospital and the treating physicians.
214331330|NCT03756610|DEVICE|Sham tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
214331331|NCT03756610|DEVICE|Active boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.
214933160|NCT00878969|DRUG|valsartan (ARB)|
214933161|NCT00878969|DRUG|ramipril (ACE inhibitor)|
214331332|NCT03756610|DEVICE|Sham boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
214331333|NCT01461304|DRUG|triheptanoin|subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours; subjects who experience cardiomyopathy may receive doses up to 4 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
214331334|NCT01596764|DRUG|Loperamide placebo|200 ml apple juice
214331335|NCT01596764|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
214331336|NCT01596764|DEVICE|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
214331337|NCT01596764|DRUG|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
214331338|NCT01596764|DRUG|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
214331339|NCT01596764|DRUG|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
214331340|NCT01596764|DRUG|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
214331341|NCT01868633|DRUG|Dexamethasone|
214331342|NCT01868633|DRUG|Placebo|
214331343|NCT02489175|DEVICE|Stomaplasty KoringTM|In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
214331344|NCT03580096|OTHER|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
214331345|NCT03580096|OTHER|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
214331346|NCT02457325|DRUG|Surgery with 2%Articaine first, then Surgery with 4% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
214933162|NCT00878969|DRUG|Placebo|
214933163|NCT05831839|DEVICE|RehaCom|computerized cognitive training
214933164|NCT03698838|DEVICE|McDESPOT|MRI sequence, mcDESPOT (multicomponent driven equilibrium potential of T1 and T2) that utilizes a computer model that takes T1 and T2 sequences and derives a quantitative value for the myelin content in the myelin sheath
214933165|NCT04336449|DRUG|Eptinezumab|Eptinezumab - single intravenous infusion
214933166|NCT04336449|DRUG|Placebo|Placebo - single intravenous infusion
214933167|NCT00716352|BEHAVIORAL|Educational intervention programme|
215072151|NCT00689000|DRUG|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
215072152|NCT01463111|DRUG|Lithium|Open label treatment per standard of care for bipolar disorder for six weeks.
215072153|NCT01463111|DRUG|Valproate|Open label treatment per standard of care for bipolar disorder for six weeks.
215072154|NCT01463111|DRUG|Lamotrigine|Open label treatment per standard of care for bipolar disorder for six weeks.
214331347|NCT02457325|DRUG|Surgery with 4%Articaine first, then Surgery with 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
214331348|NCT04521491|DRUG|FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).|FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
214673565|NCT03466710|DIAGNOSTIC_TEST|HPV test|Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
214673566|NCT05718076|PROCEDURE|cataract surgery|Phacoemulsification combined trifocal lens implantation
214933168|NCT01152359|BEHAVIORAL|Choice|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
214933169|NCT01152359|BEHAVIORAL|Control|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
214933170|NCT06623552|OTHER|Neck Pain and Disability Scale (NPDS)|"The Turkish version of the Neck Pain and Disability Scale (NPDS), developed by Wheeler et al., was used for individuals with neck pain. The severity of neck pain is evaluated on a 5-point Likert scale; where 0 indicates no pain and 4 indicates very severe pain. The score is higher in those with upper extremity symptoms.The cut-off value of this scale was set to 15 to detect disability-related neck pain.The cut-off value is mandatory to evaluate a patient or a particular group of patients for clinically significant neck pain by distinguishing it from insignificant pain"
215072155|NCT01561547|BEHAVIORAL|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
215072156|NCT01561547|DIETARY_SUPPLEMENT|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
215072157|NCT01766063|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
215072158|NCT05962632|DRUG|Fluoride based varnish (Dentkist Charm Fill Varnish )|topical Fluoride varnish administrated professionally every 3 months in the clinic
215072159|NCT05962632|DRUG|pro care gel remineralizing agent|topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company
214331349|NCT00254007|DRUG|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
214331350|NCT02771262|OTHER|Pulmonary Rehabilitation|
214673567|NCT02962635|DEVICE|bioelectrical impedance measurement and biomarker measurement|Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
214673568|NCT03887572|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
214673569|NCT03288467|PROCEDURE|Root canal treatment with 5% NaOCl|
214673570|NCT03288467|PROCEDURE|Root canal treatment with 1% NaOCl|
215072160|NCT05962632|DEVICE|Mobile application|examine the impact of Mobile application on caries prevention
215072161|NCT05962632|COMBINATION_PRODUCT|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning,fluoride rinse OTC|interdental cleaning(dental floss),fluoride rinse OTC (B-FRESH MOUTH WASH )
215072162|NCT04140695|DRUG|Tradipitant|BID
215072163|NCT04140695|DRUG|Placebo|BID
215072164|NCT00283426|DRUG|Soluble beta-1,3/1,6-glucan|
215072165|NCT05345574|DRUG|dexmedetomidine infusion|dexmedetomidine as anaesthetic adjuvant
215072166|NCT05345574|DRUG|remifentanil infusion|remifentanil as anaesthetic adjuvant
215072167|NCT06403306|DRUG|Ferric Sulfate (Viskostat; Ultradent, Utah, USA)|Widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The metal-protein complex, formed due to contact with blood, creates a mechanical plug; thus, hemostasis occurs without clot formation.
215072168|NCT06403306|DRUG|Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)|Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).
214933171|NCT06623552|OTHER|Fonseca Anamnestic Index (FAI)|It is a questionnaire consisting of 10 questions, including pain during the period, parafunctional habits, movement restriction, clicking, malocclusion, emotional stress.In this study, clinical signs relevant to each severity category of Fonseca's anamnestic index were used to detect the frequency of symptoms and to characterize the symptoms and clinical findings of TMD.The Turkish version of Fonseca's Anamnestic Index (FAI) questionnaire was used to assess the symptom severity.
214331351|NCT02431208|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
215072169|NCT06403306|DEVICE|Er,Cr:YSGG laser (Waterlase MD, Biolase, USA)|Alternative technique introduced to clinical practice in recent years to provide hemostasis in vital pulp treatment is the usage of lasers in various wavelengths. Using lasers in pulpotomy provides many advantages such as tissue vaporization and coagulation, maintenance of a blood-free working field due to its property to close small blood vessels, minimal clot formation, and sterilization of the wound surface. Furthermore, laser systems were reported to induce cellular biostimulation. Er,Cr:YSGG lasers which belong to the Erbium laser family are the laser systems with the highest absorption rate by water, having a wavelength of 2780 nm. Besides, Erbium lasers manifest bactericidal effects.
215072170|NCT02821442|DEVICE|Acupuncture|Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
215072171|NCT02821442|DEVICE|Sham Acupuncture|Placebo needles appear to penetrate but do not actually penetrate the skin
215072172|NCT02596958|DRUG|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
215072173|NCT04202146|BEHAVIORAL|Contingency Management + Motivational Interviewing|Seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling on cannabis use and relapse.
215072174|NCT00355537|DRUG|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
214331352|NCT02431208|DRUG|Daratumumab|Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
215072175|NCT00355537|DRUG|0.9% saline|Saline injection intramuscular every 2 weeks
215072176|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
214331353|NCT02431208|DRUG|Lenalidomide|Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
214331354|NCT02431208|DRUG|Pomalidomide|Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
214331355|NCT02431208|DRUG|Dexamethasone|Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
214331356|NCT05855863|DRUG|Ginkgo Ketone Ester Tablets|Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
214331357|NCT05855863|DRUG|placebo|placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
215072177|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
215072178|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
214933172|NCT06623552|OTHER|Evaluation of Jaw Functional Limitation|The Jaw Functional Limitation Scale (JFLS) was developed as an 8-item scale for general functional limitation in the jaw. In the light of the obtained items and supporting psychometric data, it has been expanded and re-developed to include the verbal and non-verbal communication limitations that occur in a 20-item tool16 JFLS-20 is a tool with three structure contents (chewing, vertical mobility of jaw state and emotional and verbal statement) to evaluate functional state.Difficulty performing a determined task is graded from 0 (without limitation) to 10 (severe limitation). Higher scores are a more serious sign of functional limitation.
214331358|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg|
214331359|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg|
214933173|NCT00515359|PROCEDURE|Intermittent Propofol Sedation|Intermittent versus continuous dosage
214331360|NCT02667938|DRUG|HGP1201|
214331361|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg placebo|
214331362|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg placebo|
214331363|NCT02667938|DRUG|HGP1201 placebo|
214933174|NCT00515359|PROCEDURE|Continuous Propofol Sedation|intermittent vs continuous dosage
214933175|NCT05977075|OTHER|ApisMela protocol|The activities and games proposed by this protocol are offered in a sequence characterized by increasing complexity. The same function is stimulated with varied tasks because the repetitiveness of the same task negatively affects skill generalization. ApisMela training teaches to focus on the purpose of the task, check that you understand it, and make explicit the procedures to be implemented. Language plays a crucial role, participants are encouraged to use speech as a tool for attention regulation and cognitive processing. It's divided into 20 sessions: a weekly group meeting of one hour and thirty.
215072179|NCT01559259|DRUG|Ibuprofen|Two caplets of ibuprofen 200 mg
215072180|NCT01559259|DRUG|Placebo|Two caplets of placebo
215072181|NCT05425732|BIOLOGICAL|V116|0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
215072182|NCT05425732|BIOLOGICAL|PCV20|0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
215072183|NCT04516538|BEHAVIORAL|Mini Mental State Examination|test for evaluating a person's cognitive functions and memory capacity
215072184|NCT04516538|DIAGNOSTIC_TEST|6 Minutes Walk Test|a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
214331364|NCT05213858|DIAGNOSTIC_TEST|CAPS questionnaire|PTSD diagnosis and severity will be done using the CAPS-5 questionnaire.
214331365|NCT05213858|DIAGNOSTIC_TEST|Beck Depression Inventory|depression symptoms will be measured by the BDI-II. The BDI-II consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression.
214331366|NCT05213858|DIAGNOSTIC_TEST|The Fibromyalgia Impact Questionnaire|The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.
214331367|NCT05213858|DIAGNOSTIC_TEST|The Pittsburgh Sleep Quality Index|"sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates poor from good sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality."
214331368|NCT05213858|DIAGNOSTIC_TEST|Depression, Anxiety and Stress Scale-21 items|The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.
215072185|NCT04516538|DIAGNOSTIC_TEST|Timed up and go|A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
215077905|NCT01032317|DEVICE|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
215077906|NCT01057056|OTHER|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
215077907|NCT02291393|DEVICE|80 lead ECG|
215077908|NCT00873535|DRUG|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
215077909|NCT00873535|DRUG|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
215072186|NCT04516538|DIAGNOSTIC_TEST|Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest)."
214933176|NCT05977075|OTHER|"Unstuck and on Target protocol"|The protocol teaches people to be more flexible, skillful in planning and goal-oriented. It is useful for moving more easily from one topic to another and from one task to another, considering new ideas or another person's point of view, generalizing skills learned across contexts so that teachers, parents and therapists can focus more on educational aspects and less on behavioral management. It is divided into 20 sessions: a weekly group meeting of one hour and thirty minutes. A homework sheet is provided for each session to consolidate the skill learned and generalize it outside the work setting. Parents have an active role in performing the task.
214933177|NCT03721042|DEVICE|olfactory measuring device|Patients blowing into bags then analysis by olfadiag system
214933178|NCT01914575|DEVICE|Mapping with the Acutus Medical System followed by Ablation|
214933179|NCT02083185|DRUG|Relugolix|Relugolix tablets
214331369|NCT05213858|DIAGNOSTIC_TEST|Traumatic Events Questionnaire|"The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from not at all to severely/extremely. The TEQ has previously been used in Israel."
214933180|NCT02083185|DRUG|Leuprorelin|Leuprorelin subcutaneous injection
214933181|NCT04205409|BIOLOGICAL|Nivolumab|Given IV
214933182|NCT01609309|PROCEDURE|Laparoscopic gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
214933183|NCT01609309|PROCEDURE|Open gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience."
214933184|NCT02945397|BEHAVIORAL|Group-based activity|Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
214331370|NCT05213858|DIAGNOSTIC_TEST|Clinician Administered Dissociative States Scale|The CADSS is a 28-item structured clinical interview to assess state dissociation.
214331371|NCT05213858|DIAGNOSTIC_TEST|A diary will be used for seven consecutive nights|"A diary will be used for seven consecutive nights for the evaluation of:~* Mean sleep latency~* The number and duration of awakenings.~* Subjective total sleep time~* Subjective wake after sleep onset~* Sleep efficiency"
214331372|NCT05213858|DIAGNOSTIC_TEST|MRI|Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.
214331373|NCT05213858|DIAGNOSTIC_TEST|Functional brain imaging|Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.
214331374|NCT05213858|DIAGNOSTIC_TEST|EEG analysis|EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.
214331375|NCT05213858|DIAGNOSTIC_TEST|Autonomic nervous system monitors|"Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.~Data collected from the band will include:~ACC - Data from 3-axis accelerometer sensor in the range \[-2g, 2g\]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)"
214331376|NCT04028011|DIAGNOSTIC_TEST|Novel Wearable device|patient will wear novel wearable device overnight along with normal standard of care
214331377|NCT02809703|OTHER|Survey Questions|Subjects will receive surveys via direct mail. They will be given the opportunity to opt in to receive a phone call regarding quality of life.
214331378|NCT02320890|DEVICE|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
214331379|NCT02320890|DEVICE|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
214331380|NCT05630027|OTHER|Piroctone Olamine (PO), 2,4 Diaminopyrimidine oxide (2.4 DA) and Vichy mineralizing water|observational, prospective study
214331381|NCT05058313|DEVICE|Photobiomodulation|Six weekly photobiomodulation sessions (PBMT) using the MILTA ™ GYNECO vaginal probe.
214673571|NCT00850772|DIETARY_SUPPLEMENT|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
214331382|NCT00287768|DRUG|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
214331383|NCT00287768|DRUG|S-1|S-1 po days 1-28 every 6 weeks
214933185|NCT02945397|BEHAVIORAL|Individual activity|Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
214933186|NCT03419598|PROCEDURE|Opening wedge high tibial osteotomy|Realignment of knee by creating an opening wedge osteotomy in the upper part of the tibia. Since this is a virtual trial, the virtual patients were duplicated and enrolled into both arms
215072187|NCT04516538|DIAGNOSTIC_TEST|Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM)."
215077910|NCT00445939|BIOLOGICAL|adalimumab|160 mg at Week 0, 80 mg at Week 2
214673572|NCT04668378|OTHER|Time restricted eating|TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.
214673573|NCT04668378|OTHER|Normal Diet|ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
214673574|NCT03614715|DRUG|Interferon Beta-1A|A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
214933187|NCT03419598|DEVICE|Personalised subject specific custom HTO plate|Subject specific custom plate for stabilizing an open wedge HTO
214933188|NCT03419598|DEVICE|Generic HTO plate|Generic plate for stabilizing an open wedge HTO
214933189|NCT01740128|DEVICE|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
215077911|NCT00445939|BIOLOGICAL|adalimumab|80 mg at Week 0, 40 mg at Week 2
215077912|NCT00445939|BIOLOGICAL|placebo|Placebo at Week 0 and Week 2
215077913|NCT01246479|PROCEDURE|Blood draw|blood draw at Month 12, Month 24 and Month 36.
215077914|NCT01246479|BIOLOGICAL|IC51 has given in the parent study IC51-322|No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
215077915|NCT04921085|OTHER|Cross-sectional obeservational survey|Cross-sectional obeservational survey
215077916|NCT06427070|OTHER|Irrigating solution|Saline, sodium hypochlorite, chlorohexidine
214331384|NCT01392950|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
214331385|NCT01392950|DEVICE|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
214331386|NCT00009919|DRUG|semaxanib|Given IV
214331387|NCT05709171|DRUG|18F-FDG|PET/CT scan approximately 60 min after injection of 18F-FDG
214331388|NCT05709171|DRUG|64Cu-Dotatate|PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
214331389|NCT02378766|BEHAVIORAL|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
214331390|NCT02378766|OTHER|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
214331391|NCT04518891|BEHAVIORAL|Cognitive Functional Therapy (CFT)|Cognitive functional therapy (CFT) is an intervention that deals with potentially modifiable multidimensional aspects of pain (e.g. provocative cognitive, movement and lifestyle behaviours). Treatment with CFT will be individualised, the physiotherapist will listen to the complete patient pain history and the intervention will be focused on individual needs. A detailed examination will be crucial in identifying the modifiable multidimensional mediators of pain and disability (provocative cognitive, pain, movement and lifestyle behaviors) of each participant.
214331392|NCT04518891|DEVICE|Sham intervention|Due to the impossibility of applying placebo exercise, the control intervention in this study will be based on successful reports of placebo intervention in patients with chronic low back pain in the literature (Placebo photobiomodulation + neutral talking control)
214331393|NCT05582330|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke
214331394|NCT01393769|DRUG|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
214331395|NCT03736850|DRUG|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
214331396|NCT04349722|DRUG|Hyoscine Butylbromide|Intervention is given once a participant is in established labor
214331397|NCT04349722|OTHER|Placebo|Intervention is given once a participant is in established labor
214331398|NCT03818022|PROCEDURE|Cryoneurolysis (Iovera)|Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
214331399|NCT04001153|OTHER|Dental impressions|"Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state."
214933190|NCT01740128|OTHER|Harness-supported multimodal balance training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
214933191|NCT02952989|DRUG|SGN-2FF|SGN-2FF oral daily dosing.
214933192|NCT02952989|DRUG|pembrolizumab|200 mg every 3 weeks by IV infusion
214933193|NCT02474589|DRUG|tecovirimat|Study is based on Animal Regulatory Rule
214933194|NCT02474589|OTHER|Placebo|Does not apply
214933195|NCT06620692|DRUG|5% GM-XANTHO [GM-XAN003]|5% GM-XANTHO \[GM-XAN003\]
214933196|NCT06620692|DRUG|Placebo|The placebo
214933197|NCT01041976|BEHAVIORAL|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
214933198|NCT01041976|BEHAVIORAL|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
214933199|NCT04108494|PROCEDURE|Type of omentectomy|Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
214933200|NCT04388904|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.
214331400|NCT05447949|PROCEDURE|Adjuncts to levobupivacaine in Erector Spinae Plane Block|The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
214331401|NCT06383949|DEVICE|Synergy Cervical Disc system|motion preservation disc
214331402|NCT02515539|DEVICE|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
214331403|NCT01126164|BEHAVIORAL|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
214331404|NCT01818362|BIOLOGICAL|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
214331405|NCT01818362|BIOLOGICAL|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
214331406|NCT05443477|DIETARY_SUPPLEMENT|Hericium Erinaceus Mycelium|participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
214331407|NCT05443477|DIETARY_SUPPLEMENT|Probiotic|participants received two oral capsules containing Probiotic powder every day for the 3 months.
214331408|NCT05443477|DIETARY_SUPPLEMENT|control|participants received two oral capsules containing control powder every day for the 3 months.
214933201|NCT06385691|OTHER|myDIET software tool|"The tool is based on self-questionnaires completed by the patient. They are mainly filled in using visual analogue scales (from 0-10) or grades of symptoms/toxicities (Grades 0 to 4), based on the CTCAE V5. These scales will cover the following themes: food intake, weight changes, digestive symptoms, taste disorders, pain and fatigue. The system will be able to monitor data changes and the response given will be adapted according to the severity of symptoms:~* No signs of seriousness: general prevention or treatment documents/advice: toxicity management, nutritional advices targeted on symptoms, on digestive problems, on appropriate physical activity.~* Presence of signs of seriousness: action to be taken and alert to the coordinating nurse, oncologist or dietician.~In case of an alert, the coordinating nurse will call the patient back and either manage the symptom, schedule a nutritional consultation to initiate nutritional management, or refer the patient to the oncologist."
214331409|NCT04213898|DRUG|SHR-1210+Albumin-bound paclitaxel + epirubicin|Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
214331410|NCT04288622|OTHER|Weekly standardised, personalised feedback|The ESM-F group will receive standardised ESM-derived feedback immediately followed the weekly ESM data collection procedure, totalling 6 times in the entire intervention period. The feedback will be provided by the researcher in the format of written report and verbal explanation. The feedback on participants' momentary affective state in specific daily life contexts and the association with depressive symptoms will be given. The changes in positive affect level and the number of depressive complaints over the course of the ESM intervention will be shown.
214331411|NCT02489227|DRUG|CHS-1420|
214331412|NCT02489227|DRUG|Adalimumab|
214331413|NCT04099524|DEVICE|tDCS|tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (\~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.
214331414|NCT04652128|DRUG|Zoledronic acid|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
214331415|NCT04652128|DRUG|Placebo|Subject will receive a single infusion of physiological saline 100mL intravenously.
214933202|NCT05685862|DEVICE|Laser Speckle Contrast Imaging using the PerfusiX-Imaging device|Patient will undergo the standard-of-care gastric conduit procedure and in addition, peroperative Laser Speckle Contrast Imaging of the gastric conduit and eosophagus will be performed.
214933203|NCT00809640|BEHAVIORAL|Education (Back Comic-Book)|Through the Back Comic-Book the schoolchildren are taught prevention methods for low back pain.
214331416|NCT01826162|OTHER|acetate or placebo infusion|
214331417|NCT04230642|DEVICE|The Quantum Surgical device|Robotic platform for needle placement
214933204|NCT04018040|OTHER|Lacto-ovo vegetarian diet|Lacto-ovo vegetarian diet inclusive of dairy and eggs
214933205|NCT03814512|BEHAVIORAL|Extended Sleep Intervention|Participants will receive an Extended Sleep Intervention (ES). Participants will be prescribed a sleep schedule that allows them to obtain approximately 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively through discussion with participants and parents.
214933206|NCT05186038|DIAGNOSTIC_TEST|iVYCHECK GIP Urine|To determine the presence of Gluten Immunogenic Peptides (GIP) in urine samples using the immunochromatographic test iVYCHECK GIP Urine (Biomedal S.L).
214933207|NCT05186038|DIAGNOSTIC_TEST|CeliacDetect|To determine the presence of IgA anti-tTG antibodies in blood samples using the immunochromatographic test CeliacDetect (Biomedal S.L).
214331418|NCT03672903|DEVICE|Weight Vest|A vest with added weights up to a maximum of 15 kg.
214331419|NCT02326142|DRUG|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
214331420|NCT02326142|DRUG|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
214331421|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 14 days
214331422|NCT03555526|DRUG|Amoxicillin|amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
214331423|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, bid, for 7 days (day 8-14)
214331424|NCT03555526|DRUG|Levofloxacin 500mg|levofloxacin 250mg, bid, for 7 days (day 8-14)
214933208|NCT00380081|DRUG|zolpidem tartrate sublingual tablet 3.5mg|Zolpidem tartrate sublingual tablet 3.5 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
214933209|NCT00380081|DRUG|zolpidem tartrate sublingual tablet 1.75mg|Zolpidem tartrate sublingual tablet 1.75 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
215072188|NCT04516538|DIAGNOSTIC_TEST|Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest)."
215072189|NCT06145204|OTHER|questionnaire|anamnesis, OMSPQ, Brief Pain Inventory-short form, lymph-ICF-LL
214331425|NCT03555526|DRUG|Clarithromycin ER|clarithromycin 500mg, bid, for 7 days (day 8-14)
214331426|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 10 days
214331427|NCT03555526|DRUG|Dibismuth trioxide|Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
215072190|NCT06277700|OTHER|Chiropractic Manipulation (HVLA - high velocity low amplitude)|Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.
215077917|NCT00937989|OTHER|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
214331428|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, tid, for 10 days (day 1-10)
214331429|NCT03555526|DRUG|tetracycline|tetracycline 500mg, qid, for 10 days
214933210|NCT00380081|DRUG|Placebo|Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
214933211|NCT03679338|DEVICE|Ablation Therapy|Ablation Therapy With Bipolar Radio frequency
215077918|NCT00937989|OTHER|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
215077919|NCT00937989|OTHER|medical chart review|Baseline, 3, 6 and 9 months after starting the study
215077920|NCT00937989|OTHER|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
215077921|NCT00937989|OTHER|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
214331430|NCT00128258|PROCEDURE|Injection of bone marrow cells in the heart|Biological implant into the heart
214331431|NCT00128258|BIOLOGICAL|Biological bone marrow cell therapy|Biological implant into the heart
214331432|NCT06054048|OTHER|Telemedicine|"Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients."
214331433|NCT04675320|BIOLOGICAL|blood samples|Blood sampling during PARP inhibitor therapy
214331434|NCT01500148|DEVICE|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
214331435|NCT04095000|BEHAVIORAL|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
214331436|NCT04095000|BEHAVIORAL|Treatment as Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
214331437|NCT01546948|DRUG|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
214331438|NCT01546948|DRUG|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
214331439|NCT01731704|RADIATION|Stereotactic radiosurgery (SRS)|
214933212|NCT06622395|DIAGNOSTIC_TEST|Remote diagnosys|Remote Diagnostic Arm (Teleconsultation): First Teleconsultation (V1): A child psychiatrist or psychologist specializing in ASD conducts the ADI-R (short version) interview with the parents or legal guardian via teleconsultation. The professional will score the items from the algorithm. After the consultation, the professional completes a questionnaire assessing the technical aspects of the remote interview (e.g., video quality, connection stability). Second Teleconsultation (V2): During the BOSA remote assessment, the professional sends the parent/caregiver instructions and a video link. The parent watches the video and follows guidance on how to position themselves and the child for optimal visibility. The parent then carries out the BOSA activities under supervision. The professional observes the child's behavior and provides time guidance. Two questionnaires are completed: one on the technical aspects of the consultation and the second on parent-child interaction.
215072191|NCT06277700|OTHER|Dynamic Neuromuscular Stabilization|Participants in the groups receiving DNS exercise therapy will be given individualized exercises under the supervision of a physiotherapist. First, the participants were taught posterior diaphragm activation in the supine position and the ability to direct the intraabdominal pressure caudally, while preventing the cranial movement of the thorax, so that the chest and pelvis are in a neutral position and the thoracic diaphragm and pelvis are aligned in parallel. Participants will then be taught the ability to perform a chin tuck without disturbing the alignment of the rib cage. In this way, the cervical diaphragm, thoracic diaphragm and pelvic diaphragm will be aligned in parallel. Our aim in this alignment will be to activate the deep stabilizers as a reflex response to intra-abdominal pressure change with the correct diaphragm movement pattern. Participants will be asked to focus on and maintain this alignment throughout the entire DNS exercise pattern.
215072192|NCT01009944|DRUG|Lisinopril, Atenolol|once a day for 14 weeks
215072193|NCT02150551|BIOLOGICAL|Allogeneic bone marrow-derived mesenchymal stromal cells|This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; \<18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :\> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : \>34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
214331440|NCT01731704|RADIATION|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
214331441|NCT02206516|DEVICE|Transcranial Direct Current Stimulation|
214331442|NCT05721417|PROCEDURE|Tricuspid valve surgery|Surgical treatment of tricuspid regurgitation, that may be performed by repair or replacement
214331443|NCT00120432|DRUG|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
214331444|NCT04751305|BEHAVIORAL|Health Coaching|The weekly health coaching (HC) calls were structured to be participant-centered, built on a coach participant relationship, and include participant-determined goals, a self-discovery process to find solutions, patient accountability, and education. Before each HC call, the participants received a short questionnaire on fatigue, QOL, stress, loneliness, and social support which enabled tailoring the HC call to the individual. Educational topics are discussed in the following order: Goal Setting, Monitoring Behaviour, Barrier Management, Social Support, Stress Management, Adapting the Program, Self-Compassion, Sleep \& Nutrition, Reflection, Health Media, Remote Resources, and Maintaining Motivation. However, the order of the educational topics can be adjusted based on the specific participants' needs each week. At the half-way point of the intervention, the participant provided feedback on the HC calls, ensuring optimization of HC impact.
214331445|NCT04751305|BEHAVIORAL|Online delivered Exercise Classes|The group based remote exercise program was delivered over the Zoom application (2x/wk for first 2 weeks; 1x/wk for the remaining weeks). Classes were one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretch. Each class was followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
214331446|NCT04035720|OTHER|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
214331447|NCT01945515|DEVICE|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
214331448|NCT01945515|DEVICE|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
214331449|NCT05313516|DEVICE|OKKO Health app|Use of OKKO Health app for home monitoring.
214331450|NCT03079336|BEHAVIORAL|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
214331451|NCT03079336|BEHAVIORAL|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
214933213|NCT03186534|BEHAVIORAL|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
214933214|NCT03186534|BEHAVIORAL|Positive Affect Enhancement|coping skills for enhancing positive emotions, mindfulness
214933215|NCT02062424|OTHER|DIPI|
214933216|NCT03470558|OTHER|Dietary habits|Sleeve gastrectomy patients will be asked to monitor dietary habits before surgery and at 2, 6, and 12 months after surgery.
214933217|NCT01437917|OTHER|20% amylose bread|20% amylose bread
214933218|NCT01437917|DIETARY_SUPPLEMENT|10% amylose bread|10% amylose bread
214933219|NCT01437917|DIETARY_SUPPLEMENT|Carbohydrates|50g of carbohydrates ingested with 400 ml of water
214331452|NCT03079336|BEHAVIORAL|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
214331453|NCT03245021|DRUG|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
214331454|NCT03842475|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
214331455|NCT05379959|DRUG|MDMA|Participants will be given 125 mg of MDMA.
214331456|NCT05379959|DRUG|Methamphetamine|Participants will be given 20 mg of MA.
214331457|NCT05379959|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
214331458|NCT00773097|BIOLOGICAL|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
214331459|NCT01790906|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
214331460|NCT01790906|OTHER|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
214331461|NCT01970202|DRUG|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
214331462|NCT01970202|DRUG|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
214331463|NCT01970202|OTHER|Control|no treatment
214331464|NCT02707640|DRUG|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
214331465|NCT02707640|DRUG|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
214331466|NCT02707640|DRUG|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
214331467|NCT00216294|DRUG|RG1068 (Synthetic Human Secretin)|
214331468|NCT02517905|DRUG|Bupivacaine liposome|Local administration
214331469|NCT02517905|DRUG|Placebo|Local administration
214331470|NCT00690638|DRUG|PHX1149T|200 mg
214331471|NCT00690638|DRUG|PHX1149T|400 mg
214331472|NCT00690638|DRUG|Placebo|Placebo
214331473|NCT01206985|OTHER|Von Frey electronic|Change in pain threshold testing mechanical stimulation (von Frey electronic)
214331474|NCT03732066|BEHAVIORAL|Usual Text Messages|Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
214331475|NCT03732066|BEHAVIORAL|Personalized Reminders|"1. The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of \>180 mmHg or \<90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~2. Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days."
214331476|NCT03732066|BEHAVIORAL|Interactive Responses|"1. Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~2. The researchers will communicate with the patients every month."
214331477|NCT00466960|BIOLOGICAL|sargramostim|Given SC
214331478|NCT00466960|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214331479|NCT00466960|OTHER|laboratory biomarker analysis|Correlative studies
214331480|NCT00466960|OTHER|immunologic technique|Correlative studies
214331481|NCT04114058|DRUG|liposomal bupivicaine|local field infiltration
214331482|NCT04114058|PROCEDURE|Fascia iliaca blockade|fascia iliaca compartment blockade
214331483|NCT03014752|OTHER|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
214331484|NCT03014752|OTHER|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
214331485|NCT03087279|BEHAVIORAL|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
214331486|NCT01678534|DRUG|Allogenic mesenchymal stem cells from adipose tissue|
214331487|NCT01678534|DRUG|Placebo|
214331488|NCT00002082|DRUG|Azithromycin|
214933220|NCT04933084|BEHAVIORAL|Pre-operative Opioid Education|"The pre-operative education in the text handout and pre-recorded video will include the topics of:~1. Description of expected postoperative pain after robotic prostatectomy and typical opioid consumption after RARP.~2. Efficacy of non-opioid multimodal analgesia and recommendation to take nonopioid alternatives prior to prescribed opioids.~3. Adverse short- and long-term effects of opioids including nausea, vomiting, sedation, hypoventilation, hypotension, dizziness, constipation, depression, and addiction."
214933221|NCT02231879|DRUG|Plerixafor|Twice daily low dose injection for 14 months.
214933222|NCT02231879|DRUG|G-CSF|Twice daily low dose injection for 14 months.
214331489|NCT05451212|BIOLOGICAL|MuSK-CAART|Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.
214331490|NCT06154434|DRUG|Chlorpromazine HCl 100mg Tablets|single-dose administered after a 10-hour overnight fast.
214331491|NCT06243133|DRUG|clopidogrel for 90 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
214331492|NCT06243133|DRUG|clopidogrel for 30 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
214331493|NCT06348511|DEVICE|XTics|XTics is a gamified protocol of behavioral treatment for tic disorders. The participant's tics are monitored in real-time and they are reflected as achievements in a game that the participant plays at the same time. The rewards aim to counteract processes that consolidate the tic. XTics is compatible with ERP treatment, and it includes an introductory psychoeducation session and three behavioral training sessions.
214331494|NCT01221259|DRUG|E2212|single ascending doses ranging from 10mg to 250mg
214331495|NCT01221259|DRUG|placebo|a single dose of matching placebo
214331496|NCT01276899|PROCEDURE|Needle core biopsies|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
214331497|NCT01276899|PROCEDURE|Needle core biopsies of metastatic lesion|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
214331498|NCT01379092|DEVICE|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
214331499|NCT01379092|DEVICE|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
214331500|NCT01578044|BEHAVIORAL|Intervention|"1. Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~2. Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.~3. Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
214331501|NCT01578044|OTHER|Control|Usual care
214933223|NCT05203549|PROCEDURE|Tumor biopsy|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
214933224|NCT03867149|OTHER|neuroimaging|neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI
215072194|NCT05683938|DEVICE|Intermittent self-catheterisation|GentleCath™ Air intermittent catheter
215072195|NCT06343818|OTHER|The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff|Six month package of training and resources delivered to ward staff, including bite-sized audio, video and written materials. Face to face training will be provided weekly by a clinical psychologist. A staff group of 'compassion champions' will be responsible for embedding the intervention.
214933225|NCT03867149|OTHER|Neuropsychological assessment|neuropsychological assessment of memory, language, executive functions and mood
215072196|NCT00306293|DRUG|valacyclovir|valacyclovir
215072197|NCT01147887|DRUG|Drug combination/ 26489112|On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
214331502|NCT05301933|BEHAVIORAL|Behavioral Parent Training (BPT)|BPT is an evidence-based psychosocial intervention that is directed exclusively to parent of children with ADHD and related disorders. BPT focuses on instructing parents to use approaches to enhance the parent-child relationship (e.g., quality time, praise) and proactive discipline strategies (e.g., time out, reward systems) to reduce challenging child behavior.
214933226|NCT06072677|BEHAVIORAL|Healthy Minds Program|The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
214331503|NCT00885872|DRUG|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
214331504|NCT01795508|BEHAVIORAL|PMTO|Parent Management Training, Oregon
214331505|NCT01795508|BEHAVIORAL|TAU|Other kinds of family training
214331506|NCT00963729|DRUG|cyclophosphamide|Given IV
214331507|NCT00963729|DRUG|docetaxel|Given IV
214331508|NCT00963729|DRUG|epirubicin hydrochloride|Given IV
214331509|NCT00963729|DRUG|fluorouracil|Given IV
214331510|NCT00963729|DRUG|letrozole|Given orally
214331511|NCT01020916|PROCEDURE|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
214331512|NCT01020916|PROCEDURE|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
214331513|NCT03869190|DRUG|Atezolizumab|"For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle."
215077922|NCT00937989|PROCEDURE|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
215077923|NCT05683574|DRUG|FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo|Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
214331514|NCT03869190|DRUG|Enfortumab Vedotin|Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
214331515|NCT03869190|DRUG|Niraparib|Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
214331516|NCT03869190|DRUG|Magrolimab (Hu5F9-G4)|Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
214331517|NCT03869190|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
214331518|NCT03869190|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
214331519|NCT03869190|DRUG|Tocilizumab|Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
214331520|NCT03869190|DRUG|Cisplatin|Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
214933227|NCT02916394|RADIATION|68Ga-NODAGA-ZIGF-1R:4：40|No Intervention
214933228|NCT03165760|PROCEDURE|protective ventilation|the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
214933229|NCT02587572|BIOLOGICAL|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
214331521|NCT03869190|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
214331522|NCT05893277|BEHAVIORAL|Motivational Interviewing (MI) and Behavioral Couples Therapy (BCT)|Four Motivational Interviewing sessions with the husband (wife joins for last MI session) to reduce alcohol use dependency, followed by six Behavioral Couples Therapy session with the husband and wife together to improve their relation and communication and reduce intimate partner violence. Session 1: couple establishes daily trust contract and discusses strategies to cope with reduced alcohol use. Session 2: couple revisits these coping skills and builds on additional strategies, as necessary. Session 3: they shift to improving the relationship and communication. Session 4: activity to promote caring behavior between partners. Session 5: couple reviews communication strategies learned previously, learn active listening and address any ongoing communication challenges. Session 6: review session and plans to address challenges to create long-term change.
214331523|NCT05738278|BEHAVIORAL|HR-informed change in routine|"The intervention is given for a situation occuring at least ten times and accompanied by an increase in HR at least 80% of the time, during the two-week registration period. Change in care (intervention) is introduced from week 3.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
214331524|NCT05738278|BEHAVIORAL|Delayed HR-informed specific change in routine|"The intervention is given for a situation occuring at least twenty times and accompanied by an increase in HR at least 80% of the time, during the four-week registration period. Change in care (intervention) is introduced from week 5.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
214331525|NCT05382364|DRUG|Tucatinib|Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.
214331526|NCT06806228|BIOLOGICAL|S-Gboxin|Gboxin specifically inhibits the growth of human glioblastoma cells but not normal cells. Gboxin rapidly and irreversibly impairs oxygen consumption in glioblastoma cells. Its positive charge for binding to mitochondrial oxidative phosphorylation complexes is dependent on the proton gradient of the inner mitochondrial membrane, and it inhibits F 0 F 1 ATP synthase activity in tumor cells. S-Gboxin crosses the blood-brain barrier at therapeutically effective concentrations.
214331527|NCT05607953|DRUG|SD-101|SD-101 doses are administered via PRVI using the PEDD method of administration
214331528|NCT05607953|BIOLOGICAL|anti-PD-1|In the Phase 1b, anti-PD-1 will be administered together with SD-101
214486294|NCT06742177|PROCEDURE|Group Bi-level ESPB|The block procedure is performed immediately before surgery begins after general anesthesia induction, with the patient in the lateral decubitus position. For the block, sterile conditions are provided with USG, and the erector spinae muscle and vertebral process are visualized, and the in plane technique is used. The target vertebral level for bi-level ESPB is two levels, T5 and T7. The block needle is advanced in the caudo-cranial direction, and the potential area between the erector spinae muscle and the transverse process of the relevant vertebra is targeted. The block location is confirmed by injecting 2 ml of saline between the transverse process and the muscle. After the block location is confirmed, a total of 40 ml of 0.25% bupivacaine is applied, using 20 ml of 0.25% bupivacaine for a single level.
214933230|NCT03667872|PROCEDURE|Bilateral implantation of DBS system to Habeluna|Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
214933231|NCT01048112|BIOLOGICAL|Campylobacter jejuni strain CG8421|Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
214933232|NCT06623838|DIAGNOSTIC_TEST|Evolutionarily informed case conceptualization|Case conceptualization of personality functioning of a few transcripts of initial sessions and report of psychometric measures of patients diagnosed with personality disorder.
214933233|NCT03269084|OTHER|No intervention. DIPP is an observational study.|
214933234|NCT00904202|DRUG|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
214933235|NCT00904202|DRUG|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
214331529|NCT03734198|DRUG|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
214331530|NCT03734198|DRUG|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
214933236|NCT00904202|DRUG|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
214933237|NCT00904202|DRUG|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
214933238|NCT00904202|DRUG|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
214933239|NCT00904202|DRUG|Gabapentin 1800 mg/day + Lidoderm patch|
214933240|NCT03395717|DEVICE|Exoskeleton-Assisted Gait Training|
214933241|NCT05492487|DRUG|Mirena|Mirena Intrauterine System (Mirena-IUS) is a levonorgestrel-releasing intrauterine system. Mirena consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The reservoir consists of a white or almost white cylinder, made of a mixture of levonorgestrel and silicone (polydimethylsiloxane), containing a total of 52 mg levonorgestrel. Mirena is approved for intrauterine contraception and in 2009 to treat heavy periods for women who choose intrauterine contraception. Mirena is often used off-label for the treatment of endometrial hyperplasia. Levonorgestrel is a progestogen used in a variety of contraceptive products. Low doses of levonorgestrel can be administered into the uterine cavity with the Mirena intrauterine delivery system. Mirena has mainly local progestogenic effects in the uterine cavity.
214933242|NCT05492487|DRUG|Megace|Megestrol acetate (Megace) is a synthetic derivative of the natural occurring steroid hormone, progesterone. It is licensed for the treatment of anorexia, cachexia or unexplained weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) and palliative treatment of advanced breast or endometrial cancer. Megace is often used off-label for the treatment of endometrial hyperplasia. While the precise mechanism by which Megace produces its antineoplastic effects against endometrial carcinoma and endometrial hyperplasia is unknown at the present time, inhibition of pituitary gonadotrophin production and resultant decrease in estrogen secretion may be factors. There is evidence to suggest a local effect as a result of the marked changes brought about by the direct instillation of progestational agents into the endometrial cavity.
214933243|NCT04167124|BEHAVIORAL|multi-sensor lifestyle intervention|
214933244|NCT01949441|BIOLOGICAL|ToleroMune HDM|Intradermal injection 1 x 4 administrations 4 weeks apart
214331531|NCT03069625|BEHAVIORAL|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
214331532|NCT03069625|BEHAVIORAL|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
214331533|NCT01550874|BEHAVIORAL|Physical activity behavior-change counselling|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
214331534|NCT00463359|DRUG|Imiquimod cream|
214331535|NCT00463359|PROCEDURE|curettage and cautery|
214331536|NCT02513589|DRUG|18F-PBR06|Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
214331537|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
214331538|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
214331539|NCT06605950|DRUG|KarXT|Specified dose on specified days
214331540|NCT06605950|DRUG|KarX-EC|Specified dose on specified days
214331541|NCT06605950|DRUG|Placebo|Specified dose on specified days
214331542|NCT06605950|DRUG|Omeprazole|Specified dose on specified days
214331543|NCT01844258|PROCEDURE|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
214331544|NCT01844258|PROCEDURE|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
214331545|NCT01013233|BEHAVIORAL|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
214331546|NCT01013233|OTHER|control group|no intervention
214673575|NCT03412227|BEHAVIORAL|Individual Behavioral Activation Therapy (IBAT)|IBAT is a manual-based, individual behavioral activation plus exposure therapy aimed at treating youth with anxiety, depression, and anger. The program consists of 10-14 weekly 60 minute sessions. It uses behavioral activation (BA) strategies to target avoidance by helping youth identify stuck points in their lives through functional assessment of numerous life domains, including family and peer interactions, school, extracurricular activities, and health and self-care.
214933245|NCT01949441|BIOLOGICAL|Placebo|Intradermal injection 1 x 4 administrations 4 weeks apart
214933246|NCT03714854|DEVICE|transcranial magnetic stimulation|TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.
214933247|NCT03573219|RADIATION|Short-wave diathermy|The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.
214933248|NCT01726387|BEHAVIORAL|Psychosocial Counseling|Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
214933249|NCT01726387|BEHAVIORAL|Usual Care|Depending on the conditions, patients get usual care of their general practitioner
214933250|NCT00443664|DEVICE|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
214331548|NCT06663566|OTHER|Diagnose the patients right heart function as well as right heart fibrosis|Diagnose the patients right heart function as well as right heart fibrosis
214331549|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
214331550|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
214331551|NCT06664086|BEHAVIORAL|economic and psychological burden|measuring the economic and psychological burden of infertility
214331552|NCT06663124|DEVICE|EC-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are extreme capsule.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
214331553|NCT05419947|DRUG|VERDYE powder for solution for injection 25 mg|Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
214331554|NCT06663943|DRUG|CM313 (SC)|CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
214331555|NCT06663943|DRUG|Glucocorticoids|Patients in the control group receive azathioprine in combination with steroid therapy.
214331556|NCT06662552|DEVICE|whole body vibration using crazy fit machine|It will be applied on the whole body All subjects will be asked to stand in a squat position on the vibration platform with the knees bent 90 this position will be chosen because the vertical sinusoidal accelerations of the vibration platform had to be damped by the different muscles around the joints of the lower extremity) ,at a frequency of 30 Hz, 5 - 30 minutes per day, 3 times per week, for 6 weeks, and the physiotherapist will be standing beside the patient
214331557|NCT06662552|DEVICE|Pulsed electromagnetic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology. It consists of an appliance, motorized bed and solenoids. The appliance will be connected to electrical mains supplying230Vat frequency of 50 or 60 Hz with earth connection, Intensity 0-100. It will be used in the treatment of patient in group B. Subjects will be positioned in a supine position, and the treatment will be performed by placing the applicator centered over their thigh region (quadriceps muscle's area), for 15 minutes per day, 3 times per week for 6 weeks, the physiotherapist will be sitting beside the patient"
214331558|NCT06662552|OTHER|traditional physical therapy program|In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.
214331559|NCT06663111|OTHER|Blood samples for PK|Blood sampled for pharmacokinetic study
215072198|NCT02421406|BEHAVIORAL|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
215072199|NCT02421406|BEHAVIORAL|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
215072200|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
215072201|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
214331560|NCT06663111|OTHER|Blood samples for PK|Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.
214331561|NCT02869490|OTHER|Data collection|
214331562|NCT04935021|DRUG|ATTR-CM|Current treatment
214331563|NCT06661993|OTHER|Placebo|placebo film-coated tablet orally or via a nasogastric tube for seven days .
215072202|NCT00185380|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
214933251|NCT01815606|PROCEDURE|biopsy with 19 gauge needle|biopsy with 19 gauge needle
214331564|NCT06661993|DIETARY_SUPPLEMENT|Alpha-lipoic acid|Alpha-lipoic acid 1800 mg orally or via a nasogastric tube for seven days .
214331565|NCT06996132|DRUG|Glofitamab|Glofitamab is administered as monotherapy or in combination with investigator-selected agents (including but not limited to chemotherapy, ADCs, BTK inhibitors, etc.) for 2 cycles.
214933252|NCT01815606|PROCEDURE|biopsy with 25 gauge needle|biopsy with 25 gauge needle
214933253|NCT01266785|DRUG|Infliximab|Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.
214933254|NCT04889157|DRUG|PF-06882961|Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
214933255|NCT04889157|DRUG|Placebo|3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
214933256|NCT00522704|OTHER|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
214933257|NCT01546168|DEVICE|esophageal deviation with IDE device|esophageal deviation during AF ablation
214933258|NCT02370667|OTHER|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
214933259|NCT02370667|OTHER|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
215072203|NCT00515658|DEVICE|theta-burst rTMS|
215072204|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS plus GOS|
215072205|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS|
215072206|NCT05042323|BEHAVIORAL|TF-CBT-Short|Participants receive either 4-5 sessions of TF-CBT-Skills or TF-CBT-Narr. If the participant still has significant PTSS they are provided with step two which is the components provided in the arm they did not receive.
215072207|NCT00680355|DIETARY_SUPPLEMENT|golden rice|An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene
215072208|NCT00680355|DIETARY_SUPPLEMENT|corn oil 0g|0 g of corn oil in the golden rice meal
215072209|NCT00680355|DIETARY_SUPPLEMENT|corn oil 10g|10g corn oil in the golden rice meal
215072210|NCT00680355|DIETARY_SUPPLEMENT|coren oil 5 g|golden rice meal with 5 g corn oil
215072211|NCT04543266|PROCEDURE|Surgery|Resection of tumors
215072212|NCT04666103|PROCEDURE|Intraoperative thermal ablation|"After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
215072213|NCT01120236|DRUG|Bicalutamide|Given PO
215072214|NCT01120236|BIOLOGICAL|Cixutumumab|Given IV
215072215|NCT01120236|DRUG|Goserelin Acetate|Given SC
215072216|NCT01120236|OTHER|Laboratory Biomarker Analysis|Correlative studies
215072217|NCT01120236|DRUG|Leuprolide Acetate|Given IM
215072218|NCT01120236|OTHER|Pharmacological Study|Correlative studies
215072219|NCT03252444|OTHER|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
215072220|NCT03252444|OTHER|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
215072221|NCT02199314|DRUG|Desflurane|
215072222|NCT05978388|DIAGNOSTIC_TEST|Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation|Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.
215072223|NCT00606541|DRUG|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
215072224|NCT00606541|DRUG|Placebo|Placebo
214331566|NCT06996132|DRUG|Chimeric Antigen Receptor T Cells (CAR-T)|After two cycles of glofitamab-based salvage therapy, single-target or dual-target CAR-T cells directed against CD19, CD20, and/or CD22 are infused following lymphodepleting (fludarabine + cyclophosphamide) or myeloablative conditioning, at a dose of 2-4 × 10⁶/kg.
214486295|NCT06742177|PROCEDURE|Group M-TAPA block|The procedure is performed in the supine position immediately before surgery after general anesthesia induction and the in plane technique is used. The transversus abdominis, internal oblique and external oblique muscles are identified at the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. The block needle is advanced in the caudo-cranial direction and a deep angle is given with the probe in the sagittal direction to the costochondral angle at the edge of the 10th rib to visualize the lower surface of the costal cartilage in the midline. The block location is confirmed by injecting 2 ml of saline onto the transverse abdominis muscle under the 10th costal cartilage. After the block location is confirmed, 20 ml of 0.25% bupivacaine is used. This procedure is repeated for the opposite side and a total of 40 ml of 0.25% bupivacaine is used.
214486296|NCT01607853|DRUG|Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)|Once daily application, 3 weeks
214486297|NCT01607853|DRUG|Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)|Once daily application, 3 weeks
214486298|NCT01607853|DRUG|Daivobet® gel applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
214486299|NCT01607853|DRUG|Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
214933260|NCT02370667|OTHER|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
214933261|NCT00750412|BEHAVIORAL|TeenScreen Program|Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
214933262|NCT02034396|PROCEDURE|Blood Draw|One blood draw at enrollment
214933263|NCT05026047|OTHER|HPV self-sampling|HPV self-sampling in HIV-positive women
214933264|NCT02954653|BIOLOGICAL|PF-06747143|PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
214933265|NCT02954653|DRUG|Cytarabine|100-200 mg/m2 continuous infusion for 7 days)
214933266|NCT02954653|DRUG|Daunorubicin|60-90 mg/m2 daily for 3 days
214933267|NCT02954653|DRUG|Azacitidine|75 mg/m2 sub-cutaneous or intravenous for 7 days)
214933268|NCT02954653|DRUG|Decitabine|20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
214933269|NCT05725265|DEVICE|Large-area low-level laser therapy(Venusure)|The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions
214933270|NCT05725265|DEVICE|Conventional low-level laser therapy|The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.
214933271|NCT02026817|DRUG|HCP1201 750/10mg|750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
214933272|NCT02026817|DRUG|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
214933273|NCT02026817|DRUG|Rosuvastatin 10mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
214933274|NCT03054064|DEVICE|Indego Exoskeleton|Six study sessions including five Indego training sessions over two weeks.
214933275|NCT06439628|DRUG|Rimegepant|patients take rimegepant to treat migraine attack as needed
214933276|NCT00711828|DRUG|Bortezomib|Given IV
214933277|NCT00711828|BIOLOGICAL|Rituximab|Given IV
214933278|NCT00711828|DRUG|Cyclophosphamide|Given PO
214933279|NCT00711828|DRUG|Dexamethasone|Given PO
214933280|NCT00711828|OTHER|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
214486300|NCT06750003|PROCEDURE|3D versus 4K laparoscopic bilateral salpingo-oophorectomy|3D laparoscopy versus 4K laparoscopy for bilateral salpingo-oophorectomy performed by residents
214933281|NCT00711828|OTHER|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
214933282|NCT04228757|DIETARY_SUPPLEMENT|phytoestrogen herbal blend|phytoestrogen herbal blend
214933283|NCT04228757|OTHER|Placebo|Tablet without active ingredients
214933284|NCT06505135|BIOLOGICAL|Stem-cell treatment|"In the cell treatment group of patients, injection of the cell suspension will be performed at the end of the surgical procedure. Fluid is carefully aspirated via the anterior outflow cannula, and autologous micro-fragmented adipose tissue is injected in dry arthroscopy conditions from the lateral portal while maintaining a subacromial view from the posterior portal.~10 mL of the stem cells suspension will be injected into the supraspinatus muscle at four predefined sites at the musculo-tendinous junction of the supraspinatus muscle. For each injection site, 1.5 mL of the suspension will be injected using an 18-gauge syringe."
214331567|NCT06991699|OTHER|Milled PEEK Stent|A CBCT will be performed to assess the anatomy of the subnasal area and plan the position, size, shape and thickness of the PEEK Stent. These data will be transferred to a 3D planning software to generate a digital model. Eventually, the PEEK stents will be milled in a milling machine and sterilized in ethylene oxide before the surgery. Local anesthesia will be administered into the vestibular mucosa along the extension of the anterior maxilla. VISTA technique begins with a vestibular access incision in the midline frenum and 2 bilateral incisions at premolar area. A periosteal elevator will be introduced through the incision and inserted between the bone and periosteum to elevate the tissue, creating a subperiosteal tunnel, extending distally based on the dynamic of the smile. The PEEK stent will be in one piece. They will be placed onto the bone and stabilized with 2 bone graft screw for each side. The midline incision and the lateral incisions will be sutured primarily.
214486301|NCT06751095|OTHER|Maitland's Mobilization in End range|End-range mobilization will be performed individually in flexion and extension end range of the tibiofemoral joint .(0-135 degree)
214933285|NCT06505135|OTHER|Standard care|Standard treatment also includes intravenous injection preoperatively of 2 g of Cloxacillin In case of allergy 1.5 g of Cefuroxim is chosen. Tendon suture is performed arthroscopically under regional anaesthetic blockage and light sedation with standard double row technique using suture anchors
214933286|NCT05909813|BEHAVIORAL|Individualized Piano Keyboard Instruction|"During weeks two through seven, participants will receive a once a week, hour long, in-person individualized piano keyboard instruction as follows:~1. Warm-up~   1. Scales and Chords: Consisting of scales on seven major keys (C, D, E, F, G, A and B), chord progressions on I, IV, V, I. Two different keys will be learned every week.~  2. 5-finger exercises will be completed four times per week.~2. Piano Theory and Music~   1. Piano Theory: Playing through Alfred's Basic Adult All-in-One Course, Book 1, to be completed at the ability level of participant, with a least two new pages per lesson.~  2. Chosen Piece: Playing through an instrumental piece chosen by the participant.~Participants will be asked to practice homework from this lesson daily for 20 minutes per day, until their next weekly lesson."
214933287|NCT03787303|DRUG|Triiodothyronine (T3)|Participants will have their L-thyroxine (T4) discontinued and Triiodothyronine (T3)/liothyronine sodium initiated at 3: 1 and titrated.
215072225|NCT04826848|DIAGNOSTIC_TEST|Lactate|We will evauate the lactate clearance of the patients in 6 hours period. Lactate clearance = \[(Initial lactate - 6th hour lactate) / Initial lactate\] \* 100
215072226|NCT04540666|DRUG|Propofol|Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.
215072227|NCT04037631|DIAGNOSTIC_TEST|Diagnostic device|Diagnostic test
215072228|NCT03347526|DRUG|Cosyntropin Injectable Suspension, 1 mg/mL|Injectable
215072229|NCT03347526|DRUG|Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin|Injectable + oral solution
215072230|NCT03347526|DRUG|Vigabatrin|oral
215072231|NCT04187144|DRUG|Gepotidacin|Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
215072232|NCT04187144|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
214331568|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using single needle approach|The primary outcome is to study the efficacy of the described technique which creates a lesion that we estimate to be 11.0-mm wide and 11.6-mm long along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score. Responder status was defined as a 30% or greater improvement in VAS pain score from the pre-procedural VAS pain score. Outcomes were summarized by means and standard deviations for continuous outcomes, and frequencies (%) for categorical outcomes.
214331569|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using three needle approach|The primary outcome is to study the efficacy of the described technique by maximizing the lesion size (compared to control group) along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score.
214331570|NCT07017361|PROCEDURE|Conventional|Pre-operative fasting: NPO for solids and fluids from 00:00. No pre-emptive oral analgesia. Intra-operative: IV dexamethasone 5 mg at anaesthesia induction; IV acetaminophen 1 g about 1 h before wound closure. Post-operative nutrition: Levin tube removed in OR. POD1 morning-sips of water; POD3 morning upright abdominal X-ray; if normal, start soft fluid diet POD3 evening. POD4 pancreatobiliary CT; if normal, start soft bland diet at lunch. Drain management: two drains at hepaticojejunostomy and pancreaticojejunostomy; drain amylase measured POD1, 3 and 5; if POD4 CT normal, drains removable from POD5 per surgeon discretion (output, fever, pain). Analgesia: IV PCA until ≈POD3, then oral acetaminophen 650 mg every 8 h. No carbohydrate loading or NSAID/nefopam adjuncts.
214331571|NCT07017361|PROCEDURE|ERAS|Pre-op fasting: solids NPO from 00:00; clear fluids until 3 h pre-op; 300 mL carbohydrate drink 2-4 h pre-op with oral acetaminophen 650 mg + zaltoprofen 80 mg. Intra-op: IV dexamethasone 8 mg at induction; IV acetaminophen 1 g + ibuprofen 300 mg + nefopam 20 mg 1 h before closure. Post-op nutrition: Levin tube removed in OR. POD1 sips of water; POD2 morning upright abdominal X-ray-if normal, start soft fluid diet POD2 evening. POD3 pancreatobiliary CT-if normal, start soft bland diet at lunch. Drain mgmt: same placement; amylase POD1 \& 3; if POD4 CT normal and amylase ≤ 5 000 U/L trending down, remove drains POD4; otherwise per surgeon. Analgesia: IV PCA until ≈POD3; until POD1 morning, IV acetaminophen 1 g + ibuprofen 300 mg q8h; POD1-5, oral acetaminophen 650 mg + zaltoprofen 80 mg q8h.
214331572|NCT00001249|DRUG|Yttrium-90 radiolabeled anti-Tac antibody|
214331573|NCT07019168|BEHAVIORAL|Jump Squat with Blood Flow Restriction (BFR)|This intervention consisted of jump squat exercises performed with blood flow restriction applied using a non-automated, manually adjustable tourniquet placed on the proximal thighs. The restriction was applied during the exercise to partially limit venous return while maintaining arterial flow. The exercise protocol included 3 sets of 10 repetitions, performed 3 times per week for 4 weeks. A standardized warm-up preceded each session.
214331574|NCT07019168|BEHAVIORAL|Jump Squat without Blood Flow Restriction|This intervention consisted of the same jump squat protocol as the experimental group but without the application of blood flow restriction. Participants performed 3 sets of 10 repetitions, 3 times per week for 4 weeks. Each session was preceded by a standardized warm-up routine that included dynamic stretching and general activation exercises.
214331575|NCT07024290|BEHAVIORAL|HITT|The experimental group completed a 4-week HIIT-boxing protocol, in addition to regular boxing sessions. HIIT consisted of three weekly sessions, each including three blocks of five 30-second all-out punching intervals on a heavy bag, with 6-second rest between efforts and 1-minute rest between blocks. Heart rate was monitored throughout, confirming training intensities of 88-92% HRmax, consistent with high-intensity training standards in combat sports.
214486302|NCT06751095|OTHER|Maitland's mobilization in Mid range|Mid range Maitland's mobilization will be performed in (approx. 50-70° knee flexion) of the tibiofemoral joint
214933288|NCT01210495|DRUG|Axitinib (AG-013736)|Axitinib \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
214933289|NCT01210495|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
214933290|NCT01210495|DRUG|Placebo|Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
214933291|NCT01210495|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
214933292|NCT00228319|DIETARY_SUPPLEMENT|Oral Ascorbic Acid|4 grams per day for 12 months
214933293|NCT00228319|DRUG|Paclitaxel|Six cycles
214933294|NCT00228319|DRUG|Carboplatin|Six cycles
215072233|NCT04187144|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
214933295|NCT00228319|DRUG|Sodium Ascorbate|Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months
214933296|NCT00228319|DIETARY_SUPPLEMENT|Oral Mixed natural Carotenoids with Vitamin A|Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months
214933297|NCT00228319|DIETARY_SUPPLEMENT|Vitamin E|500 IU per capsule and participant to take 1 capsule daily for 12 months
214933298|NCT05870449|DEVICE|tunneled PICC|Tunneled PICC is a type of PICC catheterization technique that involves establishing a subcutaneous tunnel to keep the outlet of the catheter away from the puncture site
214933299|NCT05870449|DEVICE|routine PICC|Peripherally inserted central venous catheterization is a technique that involves inserting PICC through the peripheral vein and infusing drugs into the central vein through a catheter.
214933300|NCT00431665|DRUG|NG-monomethyl-L-Arginine (L-NMMA)|
214933301|NCT00431665|DRUG|triglycerides (Intralipid 20%)|
214933302|NCT00431665|DRUG|heparin|
214933303|NCT00431665|DRUG|somatostatin|
214933304|NCT00431665|DRUG|insulin|
214933305|NCT00431665|DRUG|glucose|
215072234|NCT04187144|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
215072235|NCT01980836|BIOLOGICAL|Seasonal influenza vaccine|
215072236|NCT02650804|DRUG|BPM31510 Nanosuspension Injection|
215072237|NCT02650804|DRUG|Gemcitabine|
214331576|NCT07024290|OTHER|Regular training|Participants in control groups followed a boxing training program for a period of four weeks, with sessions conducted three times per week. Each session lasted 90 min and was structured in alignment with the established training principles for amateur boxing. The training began with a 15-minute general warm-up phase, including dynamic mobility drills and calisthenics, to elevate core temperature and enhance neuromuscular readiness.
214933306|NCT00431665|DRUG|inulin|
214933307|NCT00431665|DRUG|paraamino hippurate (PAH)|
215072238|NCT05927675|BEHAVIORAL|Physical activity|"The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements."
215072239|NCT02187276|DRUG|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
215072240|NCT05979220|DRUG|Dalpiciclib combined with Letrozole|A multicenter, single arm, prospective Phase II clinical study
215072241|NCT00046293|DRUG|Reopro|
215072242|NCT00046293|DRUG|Retrovase|
215072243|NCT04355442|PROCEDURE|Facial fractures reduction or osteosynthesis|Facial fractures reduction or osteosynthesis
215072244|NCT00116701|DRUG|Aranesp®|
215072245|NCT01364883|BIOLOGICAL|Vaccination Schedule One|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
215072246|NCT01364883|BIOLOGICAL|Vaccination Schedule Two|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
215072247|NCT01364883|BIOLOGICAL|Vaccination Schedule Three|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
215072248|NCT01364883|BIOLOGICAL|Vaccination Schedule Four|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
214486303|NCT06748755|RADIATION|Group 1|To determine the sensitivity of ultrasound in detecting HCC
214933308|NCT01791946|PROCEDURE|Binocular Treatment|The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
215072249|NCT01364883|BIOLOGICAL|Vaccination Schedule Five|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
214933309|NCT01791946|PROCEDURE|Sham Binocular Treatment|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
214933310|NCT00766285|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.
215072250|NCT01364883|BIOLOGICAL|Vaccination Schedule Six|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
215072251|NCT01364883|BIOLOGICAL|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
214331577|NCT07024095|BEHAVIORAL|Inspiratory Muscle Training (IMT)|"Participants in the intervention group will receive, in addition to the standard postoperative follow-up for 8 weeks (3 days per week), a home-based exercise program including diaphragmatic breathing exercises, stretching exercises targeting kyphotic posture, and strengthening exercises for the thoracic region. These exercises will be taught to the patients and their caregivers by a licensed physiotherapist before hospital discharge.~In addition, inspiratory muscle training (IMT) will be performed every day for 8 weeks. To ensure progressive workload, maximal inspiratory pressure (MIP) will be reassessed weekly, and the IMT device will be adjusted accordingly."
214486304|NCT06749808|DIETARY_SUPPLEMENT|Carotenoid Nutritional Supplement|Carotenoid Nutritional Supplement: capsules with 500 mg Vitamin C, 200 IU Vitamin E, 25 mg Zinc, 2 mg Copper, 70 mcg Selenium, 10 mg Lutein, 2 mg Zeaxanthin, 3mg boron, 255mg calcium, 100mcg chromium, 0.9mg copper, 150mcg iodide, 180mg magnesium, 75mcg molybdenum, 2.3mg manganese, 140mcg selenium, 20mcg vanadium, 15mg zinc
214486305|NCT06749808|DIETARY_SUPPLEMENT|Placebo|Placebo Supplement: capsules with 500 mg Vitamin C, 200 IU Vitamin E, 25 mg Zinc, 2 mg Copper, 70 mcg Selenium, 3mg boron, 255mg calcium, 100mcg chromium, 0.9mg copper, 150mcg iodide, 180mg magnesium, 75mcg molybdenum, 2.3mg manganese, 140mcg selenium, 20mcg vanadium, 15mg zinc
214933311|NCT00766285|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
215072252|NCT06354413|PROCEDURE|CABG during myectomy|To explore the effect of CABG during myectomy. No control group
215072253|NCT00004248|BIOLOGICAL|aldesleukin|
214933312|NCT04631328|OTHER|Growing Together|Growing Together is a suite of free, online research-informed professional development modules to help early childhood educators promote deeper family engagement and enrich teacher-parent interactions.
214933313|NCT01914211|DRUG|Tranexamic Acid|100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.
214933314|NCT01914211|PROCEDURE|Acute Normovolemic Hemodilution|Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If \> 5Kg draw 20% of circulating blood volume without PRBC replacement)
214933315|NCT00215371|DRUG|Formoterol Fumarate|
215072254|NCT00004248|DRUG|doxorubicin hydrochloride|
215072255|NCT02759107|DRUG|Tirzepatide|Administered SC
215072256|NCT02759107|DRUG|Placebo|Administered SC
215072257|NCT02759107|DRUG|Dulaglutide|Administered SC
215072258|NCT02402894|OTHER|no intervention|
215072259|NCT00000273|DRUG|opiates|prescription opioids
215072260|NCT04984265|RADIATION|Stereotactic Body Radiation Therapy|SBRT targeting the area of the circuit of Ventricular Tachycardia
215072261|NCT04861467|DRUG|Camrelizumab|IV
215072262|NCT06229431|OTHER|The Carer Support Needs Assessment Tool Intervention (CSNAT-I)|"The CSNAT tool The tool includes 16 questions about the need for more support.~The five-stage person-centered approach~In the present study, the CSNAT-I consist of at least two meetings between the older spousal caregiver and the district nurse,1-4 weeks apart, following 5 stages:~1. Introduction of the CSNAT tool as a conversation starter.~2. Time for the spousal caregiver to consider the questions in which more support is needed.~3. An assessment conversation takes place.~4. A shared action plan is formed based on the assessment conversation.~5. Continuous shared review of the action plan."
215072263|NCT02383420|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
215072264|NCT01480804|OTHER|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
215072265|NCT02396771|PROCEDURE|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
215072266|NCT02396771|PROCEDURE|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
214331578|NCT07024095|BEHAVIORAL|control group|"Participants in the control group will receive, similar to the intervention group, a home-based exercise program for 8 weeks (3 days per week), including diaphragmatic breathing exercises, stretching exercises for kyphotic posture, and strengthening exercises for the thoracic region, in addition to standard postoperative follow-up. These exercises will be demonstrated to the patients and their caregivers by a licensed physiotherapist before hospital discharge.~Unlike the intervention group, participants in this group will not receive inspiratory muscle training (IMT)."
214933316|NCT06649474|BIOLOGICAL|assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy|assess the serum HMGB1 concentrations
214933317|NCT01695330|DRUG|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
214933318|NCT01772186|DEVICE|Real-time somatosensory cue|A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
214933319|NCT04502238|OTHER|Fluid restriction|Study participants will refrain from drinking fluids overnight to facilitate 1-2% fluid loss from baseline
214933320|NCT04939675|DRUG|Zonisamide 100mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
214933321|NCT04939675|DRUG|Levetiracetam 500mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
214933322|NCT04939675|DRUG|LamoTRIgine 50mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
214933323|NCT02851056|BIOLOGICAL|Survivin Vaccine|"Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered."
214933324|NCT02851056|PROCEDURE|Autologous Hematopoietic Cell Transplantation|The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
214933325|NCT02851056|BIOLOGICAL|Prevnar 13|13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
214933326|NCT02851056|DRUG|Granulocyte-colony Stimulating Factor|After the first survivin vaccination, participants will be mobilized with G-CSF.
214933327|NCT06253741|PROCEDURE|PARAVERTEBRAL BLOCK|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes
214331579|NCT07021365|DRUG|Phenol Injection|n patients diagnosed with chronic coccydynia, a ganglion impar block is initially performed following conservative treatment. In cases where this intervention provides limited benefit, ganglion impar phenol neurolysis is performed. A short-acting local anesthetic (3-4 mL of 1% prilocaine) will be administered into the skin and subcutaneous tissues. A 90 mm 22-gauge Quincke-tipped spinal needle will be advanced via the trans-coccygeal route under fluoroscopic guidance with intermittent imaging. The needle's position in the area anterior to the coccyx, where the ganglion impar is located, will be confirmed using 1-2 mL of contrast agent (iohexol). If the desired spread of contrast is observed, 5 mL of 7% phenol will be injected.
214331580|NCT07021365|DEVICE|Radiofrequency ablation alone|"In patients diagnosed with chronic coccydynia, a ganglion impar block is initially performed following conservative treatment. In cases where this intervention provides limited benefit, ganglion impar radiofrequency (RF) ablation-routinely used in clinical practice-will be performed by an experienced pain specialist (SŞ) with at least 10 years of expertise in this procedure.~Using fluoroscopic guidance and intermittent imaging, a 100 mm RF cannula with an injection tube will be advanced trans-coccygeally. After confirming the needle's position at the site of the ganglion impar in front of the coccyx with 1-2 mL of contrast agent (iohexol), sensory stimulation will be applied via the RF generator to confirm that the needle tip is at the patient's pain site. Motor stimulation will also be performed to ensure there is no muscle contraction. At this stage, 2 mL of lidocaine will be administered before initiating ablation at 80°C for 90 seconds."
214933328|NCT06253741|PROCEDURE|RHOMBOID INTERCOSTAL AND SUBSERRATUS PLANE BLOCK|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
214933329|NCT06253741|PROCEDURE|PLACEBO|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
214933330|NCT02619396|PROCEDURE|Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 4 on LA posterior wall
214331581|NCT07025213|OTHER|Diet and exercise.|The intervention group will receive recommendations to follow an anti-inflammatory diet. In addition, they will be instructed to increase their level of physical activity and will be asked to attend the institute to carry out a supervised exercise routine.
214933331|NCT02619396|PROCEDURE|Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 4 on LA posterior wall
215072267|NCT02502227|BEHAVIORAL|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
215072268|NCT02513485|DRUG|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
215072269|NCT02513485|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
215072270|NCT01088165|DRUG|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
215072271|NCT01088165|DRUG|Fumaric acid esters treatment group|"First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).~Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period."
215072272|NCT01088165|OTHER|Narrow band UVB radiation|"No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation"
215072273|NCT01704729|PROCEDURE|group1|Non-cycloplegic self-refraction +conventional glasses
215072274|NCT01704729|PROCEDURE|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
214331582|NCT07025213|OTHER|Diet.|The comparison group will be instructed to follow the anti-inflammatory diet intervention only.
214331583|NCT07025564|PROCEDURE|Biospecimen Collection|Undergo bone marrow and blood sample collection
214331584|NCT07025564|PROCEDURE|Echocardiography Test|Undergo ECHO
215072275|NCT01704729|PROCEDURE|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
215072276|NCT01704729|PROCEDURE|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
215072277|NCT02526524|DRUG|Met DR|metformin delayed-release tablets
215072278|NCT02526524|DRUG|Met IR|metformin immediate-release tablets
215072279|NCT02526524|DRUG|Placebo|
215072280|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
215072281|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
215072282|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
214331585|NCT07025564|DRUG|miR-126 Inhibitor miRisten|Given IV
214331586|NCT07041021|DIAGNOSTIC_TEST|Respiratory variation of the Internal Jugular Vein (IJV)|In the study group, the fluid therapy will be guided by the respiratory variation (RV) of the Internal Jugular Vein (IJV) throughout surgery. Fluid maintenance will be continued as long as the IJV diameter is less than 2 cm and the IJV RV is more than 18. If the IJV diameter exceeds 2 cm and the IJV RV is less than 18, fluids will be stopped.
214331587|NCT06889753|DIETARY_SUPPLEMENT|Graminex WSPE|Graminex Water Soluble Pollen Extract is standardized to 6% amino acids.
214331588|NCT06889753|DIETARY_SUPPLEMENT|Graminex LSPE|Graminex Lipid Soluble Pollen Extract is standardized to 7% phytosterols.
214933332|NCT02619396|PROCEDURE|Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 5 on LA posterior wall
214933333|NCT02619396|PROCEDURE|Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 5 on LA posterior wall
214933334|NCT01751581|BEHAVIORAL|Short Sleep|Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
214331589|NCT06889753|DIETARY_SUPPLEMENT|Placebo|Placebo
214331590|NCT06751147|OTHER|Group A|"It consists of 24 patients who were assessed by prone knee bend (PKB) test and knee range of motion was measured by goniometer. In addition to traditional physical therapy and muscle energy procedures, patients in this group received neural mobilization. The patient laid on their side with their knee bent to a 90-degree angle and the affected side looking up while neural mobilization was carried out. The therapist then performed the technique by abducting and extending the patient's hip. Five repetitions of the nerve stretch were performed, each with a 10-second hold and a 5-second rest in between.~METs were implemented in two positions using post-isometric relaxation (PIR): In this initial posture, the patient laid on their back with the affected leg just over the bed's edge. With one hand, the physiotherapist stood facing the affected side and pressed the contralateral ASIS to keep the patient from rolling off the bed. The therapist, however, simultaneously grabbed the femur dist"
214331591|NCT06751147|OTHER|Experimental Group B|It involves 24 patients who had received the neural mobilization described above along with traditional physical therapy that does not involve muscular energy techniques. The treatment took place in the outpatient physical therapy department and lasted around thirty minutes in total
214933335|NCT01751581|BEHAVIORAL|Habitual sleep|Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
214933336|NCT03768024|DRUG|GRT0151Y 50 mg capsule|GRT0151Y 50 mg capsule
214331592|NCT07063329|DRUG|PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy|For non-squamous NSCLC patients：Pemetrexed (500 mg/m2) plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily。 For squamous NSCLC subjects: Docetaxel（75 mg/m² ）or paclitaxel（175 mg/mg） plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily.
214331593|NCT07063329|DRUG|PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy|Multiple doses of PLB1004 for oral administration. Platinum-based chemotherapy is combined and administered on Day 1 of 21days（every 3 weeks).
214933337|NCT03768024|DRUG|Hydromorphone IR 4 mg|Hydromorphone IR 4 mg tablet (encapsulated)
214331594|NCT07063329|DRUG|RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy|RP2D of PLB1004 as determined during Phase Ib . Platinum-based chemotherapy is combined and administered on Day 1 of 21days（every 3 weeks）.
214331595|NCT07063329|DRUG|RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy|RP2D of PLB1004 as determined during Phase Ib，patients will undergo surgical treatment after 3 cycles of combination therapy with platinum-based chemotherapy. Post-surgery, they will receive an additional cycle of platinum-based chemotherapy followed by 13 cycles of maintenance therapy with PLB1004.
214331596|NCT07077278|DRUG|Low sodium oxybate (LXB)|Participants will continue take low sodium oxybate (LXB) for two weeks after completing an open-label titration and dose optimization period of low sodium oxybate (LXB).
214933338|NCT03768024|DRUG|Matching placebo|Matching placebo
214933339|NCT01194635|GENETIC|fluorescence in situ hybridization|
215072283|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
215072284|NCT01429428|OTHER|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
215072285|NCT01429428|OTHER|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
215072286|NCT05486000|DEVICE|Atrial shunt implant system|"Patients with chronic left heart failure who meet the conditions of the clinical trial undergo interventional surgery with the Atrial Shunt Implant System"
215072287|NCT02908646|PROCEDURE|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
215072288|NCT02908646|PROCEDURE|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
214933340|NCT01194635|GENETIC|gene expression analysis|
214933341|NCT01194635|GENETIC|polymerase chain reaction|
214933342|NCT01194635|GENETIC|protein analysis|
214933343|NCT01194635|GENETIC|protein expression analysis|
214933344|NCT01194635|OTHER|enzyme-linked immunosorbent assay|
214933345|NCT01194635|OTHER|immunohistochemistry staining method|
214933346|NCT01194635|OTHER|laboratory biomarker analysis|
214933347|NCT01094652|DIETARY_SUPPLEMENT|Whole grain diet|Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.
214933348|NCT01094652|DIETARY_SUPPLEMENT|Refined grain diet|The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
214933349|NCT02400866|DRUG|Olanzapine|
215072289|NCT03018795|PROCEDURE|Decontamination of implant surfaces|Decontamination of implant surfaces in combination with regenerative surgery
214331597|NCT07077278|DRUG|Placebo|Participants will take placebo for two weeks after completing an open-label titration and dose optimization period of low sodium oxybate (LXB).
214331598|NCT07076498|BIOLOGICAL|M032|M032 is a genetically engineered type 1 herpes simplex virus (HSV-1) that has been demonstrated to be aneurovirulent secondary to deletions of both copies of the γ134.5 gene and modified to express human interleukin-12 (IL-12). Each patient will receive a single intratumoral injection of M032.
214331599|NCT07086573|DIETARY_SUPPLEMENT|Algae oil 1|DHA Origins 550-Y oil (Fermentalg)
214331600|NCT07086573|DIETARY_SUPPLEMENT|Algae oil 2|Oleo H-02 (Microalgas)
214331601|NCT07086573|DIETARY_SUPPLEMENT|Fish oil (control)|Tuna oil
214331602|NCT07084766|PROCEDURE|ultrasonography, pelvic|Ultrasound measurements will be taken before and after bladder emptying. The axes of the uterine body, cervix and vagina will be marked out by tracing the 3 corresponding lines on the image.
214331603|NCT06908603|OTHER|Survey using a questionnaire.|The online, self-administered, 16-item questionnaire included several question styles (yes/no questions, closed-ended, multiple choice questions, and statements with Likert scale responses). The questionnaire was adapted from several published AI surveys . Questions were designed to assess three primary areas: AI knowledge, perceptions of AI integration into practice and challenges in implementing AI in the OR practice in Egypt.
214331604|NCT06908811|DIETARY_SUPPLEMENT|Novel Plant Protein Blend|Novel plant protein blend containing 30 grams of protein.
214331605|NCT06908811|DIETARY_SUPPLEMENT|Pea/Rice Protein Blend|Pea/Rice protein blend containing 30 grams of protein
214331606|NCT06908811|DIETARY_SUPPLEMENT|Whey Protein|Whey concentrate protein blend containing 30 grams of protein
214933350|NCT03343249|BEHAVIORAL|Smart Phone Based Smoking Cessation|The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system. The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time. The phone has 4G and is Wi-Fi and GPS capable. Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire. Thus, computer/typing skills are not required. Participants have the ability to call and receive calls from research staff through the smart phone free of charge. All phones will be equipped with Global Positioning Systems (GPS) capability. The smart phones are also equipped with a Secure Digital card to store data as it is collected.
214933351|NCT00570349|DRUG|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
214331607|NCT06908811|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Maltodextrin placebo
214331608|NCT07085169|DRUG|Trifluridine/tipiracil (TAS-102) plus bevacizumab|Trifluridine/tipiracil will be given at a 17.5 mg/m2 dose orally twice daily in a 14-day cycle consisting of 10 treatment days/4 rest days. Bevacizumab will be given at a 5mg/kg dose intravenously once at day 1 in a 14-day cycle. This is a single-arm study with all patients receiving these two drugs.
214331609|NCT07085104|GENETIC|ALLO-329|An allogeneic CAR T cell therapy targeting CD19 and CD70
214331610|NCT07085104|DRUG|Cyclophophamide|Chemotherapy for lymphodepletion
214331611|NCT07086404|DRUG|GC012F Injection infusion|GC012F Injection infusion will be performed within 48-72 hours after the end of lymphodepleting preconditioning.
214331612|NCT06908018|BIOLOGICAL|rDEN2Δ30-7169|rDEN2Δ30-7169 is a recombinat virus that could induce viremia and immunological responses with out serious adverse effect. The virus will be challenged after participants screening and consent for hospitalization. After virus challenge, the virological, immunological and clinical manifestation will be recorded and analyzed for the result from day 0-60 post-virus challenge.
214331613|NCT06909552|OTHER|Educational Video on Voiding Dysfunction|The educational video is a short 3-minute video which describes the condition in detail, at the level that a parent or child could understand without a medical background.
214331614|NCT06526390|PROCEDURE|f-URS|f-URS with S-UAS
214331615|NCT06526390|PROCEDURE|mini-PCNL|mini-PCNL
214331616|NCT04109846|OTHER|Non-euploid embryo transfer|Other than choice of embryo for transfer, all other medical interventions will be standard of care protocols
214331617|NCT04109846|OTHER|Euploid Transfer|Standard of Care Protocol
214331618|NCT06909123|DRUG|Cabergoline|Cabergoline
214331619|NCT06909630|OTHER|Driving pressure group|individual PEEP
214331620|NCT06908733|DRUG|3-4 cycles of Tislelizumab combined with platinum-based chemotherapy, evaluated by MDT and assigned to treatment strategies based on eligibility and patient preference.|Patients deemed eligible to surgery will receive standard lung cancer resection (excluding total pneumonectomy)
214331621|NCT06908993|DRUG|Tepotinib|Tepotinib will be given orally once daily at the dose of 500mg of tepotinib hydrochloride hydrate.
214933352|NCT00570349|DRUG|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
214933353|NCT00570349|DRUG|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
214331622|NCT06908993|DRUG|Pemetrexed (Alimta)|500 mg/m² every 3 weeks
214331623|NCT06908993|DRUG|Vinorelbine|25-30 mg/m² D1, D8, every 3 weeks
214331624|NCT06908993|DRUG|Gemcitabine alone|1250 mg/m² D1, D8, every 3 weeks
214331625|NCT06908993|DRUG|Docetaxel|75 mg/m² every 3 weeks
214331626|NCT06908993|DRUG|Paclitaxel|90 mg/m² D1, D8, D15 every 4 weeks If bevacizumab added: 10 mg/kg D1, D15 every 4 weeks
214331627|NCT06908993|DRUG|Pembrolizumab|200 mg every 3 weeks
214331628|NCT06908993|DRUG|Nivolumab|240 mg every 2 weeks
214331629|NCT06908993|DRUG|Atezolizumab|1200 mg every 3 weeks
214331630|NCT07086911|DRUG|Remimazolam|"Remimazolam group (Group R) : After intubation, remimazolam was maintained at a pump rate of 1-2mg/kg/h until ten minutes before the end of the operation.~Group C (remimazolam combined with propofol): After intubation, maintain with 0.3-1 mg/kg/h of remimazolam and 3-6 mg/kg/h of propofol until 10 minutes before the end of surgery."
214331631|NCT07086911|DRUG|Propofol|"Propofol group (Group P) : After intubation, propofol was maintained at a pump rate of 4-10mg/kg/h until surgery ten minutes before the end.~Group C (remimazolam combined with propofol): After intubation, maintain with 0.3-1 mg/kg/h of remimazolam and 3-6 mg/kg/h of propofol until 10 minutes before the end of surgery."
214331632|NCT06908785|DEVICE|Rotational thromboelastometry|rotem
214331633|NCT04965922|BEHAVIORAL|Multimodal intervention|"The intervention consists of identifying the individual needs of each caregiver and patient and identifying sources of improvement in the management of daily life, including the optimization of social support. This optimization requires the involvement of people in the environment (family, friends, neighbours) who can provide help, support of any kind, recurrent or punctual, minimizing negative family interactions and maximizing positive contributions by each in supporting and supporting the individual.~The intervention is personalized in the sense that the content of each session seeks to adapt itself to the specificities of the couple situation and its surroundings.~interviews/meetings involving a psychologist social worker."
214331634|NCT02543905|PROCEDURE|Prostate MRI and Biopsy|All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.
214331635|NCT06908798|DIAGNOSTIC_TEST|fecal calprotectin|fecal calprotectin test measures calprotectin protein in a stool sample. fecal calprotectin acts as a surrogate for gastrointestinal inflammation (e.g., inflammatory bowel disease, infectious gastroenteritis, acute appendicitis, peptic ulcer disease, coeliac disease, non-steroidal anti-inflammatory drugs (NSAID)-induced enteropathy)
214331636|NCT06909097|BEHAVIORAL|Sitting breaks|Participants will take 2 minute physical movement breaks throughout a sedentary work day.
214331637|NCT06908291|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of breat tomor and Ipsilateral axillary lymph nodes, in addition to real-time 2D PA/US imaging.
214331638|NCT04966000|BEHAVIORAL|Prism Adaptation Therapy|Participants wear goggles with built-in prisms (a 20-diopter lens) that shift the visual scene to the right. While wearing the googles they reach to and cross out 60 lines/circles, requiring them to learn to reach more leftward than the visual targets appear. Participants can only see the end of their movements.
214331639|NCT06428812|OTHER|Experimental: perineal package application group|This group includes those in the 2nd stage of labor upright position spontaneous pushing Hot application will be made
214486306|NCT06748833|BEHAVIORAL|SMILE Intervention App|The SMILE app, an iOS and Android compatible smartphone app, is based on effective CBT-based treatment features to help patients manage anxiety symptomology. Access requires a unique login. The SMILE app utilizes three relaxation features: calm breathing, mindfulness meditation, and deep muscle relaxation; one cognitive feature, thought journaling and the challenging of thoughts; one self-monitoring technique; a positive imagery game; and a feature aimed to reduce avoidance behaviour through exposure. The app will be self-guided, with no additional human involvement needed. Participants will be instructed to actively engage with at least one of the app's major functions for a minimum of 3 minutes per day.
214933354|NCT06731426|BEHAVIORAL|CBM-TAF|CBM-TAF aims to modify TAF by training participants to adopt an interpretation style that is inconsistent with TAF (i.e., having unwanted thoughts is not morally equivalent to acting upon them and/or having unwanted thoughts does not increase the likelihood of feared events happening in real life). To personalize the training, CBM-TAF is designed to address 4 subtypes of OCD (as defined by Dimensional Obsessive-Compulsive Scale; Abramowitz et al., 2010), each of which targets either TAF-moral or TAF-likelihood. Participants will indicate two OCD subtypes that are most relevant to their experiences and only complete scenarios that correspond to their chosen subtypes. For each scenario, participants are instructed to enter a missing letter in a fragmented word and resolve its emotional ambiguity. After then, participants will answer a True/False question related to the given scenario to verify their comprehension and consolidate their acquisition of healthier interpretation style.
215072290|NCT00473967|BIOLOGICAL|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
215072291|NCT02428621|DEVICE|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
215072292|NCT02428621|DEVICE|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
215072293|NCT01411358|BIOLOGICAL|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
215072294|NCT01411358|BIOLOGICAL|elderly aged over 60|one dose of 0.5mL AdimFlu-S
215072295|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
215072296|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
215072297|NCT04840563|DEVICE|Kalifon A|Commercially available kalifilcon A lenses
215072298|NCT04840563|DEVICE|Dailies Total1|Dailies Total1
214331640|NCT04659785|DRUG|Fluzoparib|Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
214331641|NCT04659785|DRUG|Apatinib|Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
215072299|NCT04840563|DEVICE|Precision1|Precision1
215072300|NCT01946672|PROCEDURE|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
215072301|NCT00003671|DRUG|asparaginase|
215072302|NCT00003671|DRUG|cyclophosphamide|
215072303|NCT00003671|DRUG|cytarabine|
215072304|NCT00003671|DRUG|daunorubicin hydrochloride|
215072305|NCT00003671|DRUG|dexamethasone|
215072306|NCT00003671|DRUG|leucovorin calcium|
215072307|NCT00003671|DRUG|mercaptopurine|
215072308|NCT00003671|DRUG|methotrexate|
215072309|NCT00003671|DRUG|thioguanine|
215072310|NCT00003671|DRUG|vincristine sulfate|
214331642|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation X|see Treatment Arms
214331643|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation Y|see Treatment Arms
214331644|NCT06938152|DRUG|Romosozumab followed by Denosumab|Romosozumab 210mg/month for 12 months, then Denosumab 60mg/6months for 12 months
214331645|NCT06938152|DRUG|Romosozumab and Denosumab Cycle Therapy|Romosozumab 210mg/month for 6 months then followed by Denosumab 60mg/6months once, and then repeat one more time after 6 months
214331646|NCT06050486|BEHAVIORAL|Mentalization-based treatment for children (MBT-C)|MBT-C is a time-limited intervention designed to resolve the child's emotional or behavioral problems and to promote resilience, by promoting the child's and parent's mentalizing capacities. It is composed by 1) an assessment phase, composed of 3 to 4 sessions, with the family, the child and the parent(s), 2) an intervention phase, composed of a minimum block of 12 individual sessions with the child and parallel sessions for the parent(s), that can be repeated up to three times (i.e., maximum of 36 sessions), and 3) a booster session 3 to 12 months after the last session. In this clinical trial, MBT-C will be composed of: 3 assessment sessions; 12 individual sessions with the child, plus 6 parallel individual sessions with the parent with BPD; 1 booster family session, 3 months after the last session.
214331647|NCT02742103|BIOLOGICAL|CSL_112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
214331648|NCT02742103|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
214331649|NCT03992105|OTHER|prospective cohort|"topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively"
214331650|NCT04113252|OTHER|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
214331651|NCT04113252|OTHER|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
214933355|NCT06731426|BEHAVIORAL|CBM-SMP|CBM-SMP is a comparable intervention to CBM-TAF (Siwiec et al., 2023), which aims to provide general education about stress and stress management techniques. It is identical to CBM-TAF in terms of its administration, except for the content of scenarios included in training sessions. For each scenario, participants are instructed to enter a missing letter in a fragmented word. After then, participants will answer a True/False question related to the given scenario in order to verify their comprehension.
214331652|NCT04113252|BEHAVIORAL|Coaching|Subjects will receive coaching prior to starting pain medication.
214331653|NCT03556631|DRUG|live combined Bifidobacterium and Lactobacillus Tablets|take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day
214331654|NCT04279444|DIETARY_SUPPLEMENT|BKR-017|BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
214331655|NCT00600821|DRUG|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
214331656|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
214933356|NCT02468128|DRUG|Sebacoyl Dinalbuphine Ester|Intramuscular injection 2mL/vial (75mg/mL)
214933357|NCT02468128|DRUG|Placebo|Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
214933358|NCT02172586|DRUG|Telmisartan|
215072311|NCT05281536|OTHER|Ppostural change from 45° to 10° in supine position|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
215072312|NCT03303859|DIAGNOSTIC_TEST|Bacterial vaginosis|
215072313|NCT03346265|OTHER|Treatment A combined exercise program and gait training with sensory cues|Treatment A consisted in a combined exercise program of 40 min duration RMP
215072314|NCT03346265|OTHER|Treatment B Conventional physiotherapy|Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
215072315|NCT02913430|DRUG|Fulvestrant|500mg IM Q28 days
214331657|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
214331658|NCT00600821|DRUG|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
214331659|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
214331660|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
214331661|NCT04949230|OTHER|No Intervention Used|There is no intervention in this study
214933359|NCT02172586|DRUG|Losartan|
214933360|NCT02172586|DRUG|Hydrochlorothiazide|
214933361|NCT00985959|DRUG|JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
214933362|NCT00985959|DRUG|JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
214933363|NCT00985959|DRUG|JNJ-26866138 1.3 mg/m2|Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
214933364|NCT00985959|DRUG|Melphalan|Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
214933365|NCT00985959|DRUG|Prednisolone|Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
215072316|NCT02913430|DRUG|Tamoxifen|20mg PO Qdaily
215072317|NCT02913430|DRUG|Palbociclib|Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
215072318|NCT01628484|OTHER|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
215072319|NCT01628484|OTHER|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
214331662|NCT04183400|BEHAVIORAL|Safety Awareness For Empowerment (SAFE)|SAFE is a mindfulness-based cognitive-behavioral intervention that aims to build risk-related attention skills.
214331663|NCT00467181|DRUG|Fenoldopam|
214331664|NCT06050421|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.
214331665|NCT06050421|OTHER|Treatment As Usual|he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
214331666|NCT06050421|OTHER|No intervention|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
214933366|NCT00383175|OTHER|Autorefractor, standard clinical instrument|Autorefractor, standard clinical instrument was used to assess the children's focusing power at near.
214933367|NCT01590732|DRUG|Carboplatin|Given IV
214933368|NCT01590732|DRUG|Etoposide|Given IV
214933369|NCT01590732|DRUG|Ifosfamide|Given IV
214331667|NCT00029835|DRUG|Rimonabant (SR141716)|
214933370|NCT01590732|DRUG|Romidepsin|Given IV
214933371|NCT06726837|OTHER|Postoperative pain - 6th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 6th hour.
214933372|NCT06726837|OTHER|Postoperative pain - 24th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 24th hour.
214933373|NCT06726837|OTHER|Postoperative pain - 48th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 48th hour.
214933374|NCT06726837|OTHER|Postoperative pain - 72nd hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 72nd hour.
214933375|NCT06726837|OTHER|Postoperative pain - 7 day|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 7 day.
214933376|NCT00976209|DRUG|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
214933377|NCT00976209|DRUG|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
214933378|NCT02097797|OTHER|Fecal Transplantation|Fecal microbiota (50-100g of stool from donor resuspended in 250-350ml of physiological serum and filtered) given by infusion in coecum during colonoscopy
214933379|NCT02097797|OTHER|Sham Transplantation|250-350ml of physiological serum given by infusion in coecum during colonoscopy
214933380|NCT03907930|PROCEDURE|percutaneous nephrolithotripsy|removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast
214933381|NCT06193148|DRUG|Jaktinib|Participants will receive Jaktinib orally for single dose
214933382|NCT06193148|DRUG|Placebo|Participants will receive Placebo orally for single dose
214933383|NCT05600062|DRUG|Racecadotril 100 milligram (MG) Oral Capsule|Licensed NEP inhibitor
214933384|NCT05600062|DRUG|Placebo|Placebo capsule
214933385|NCT02951039|DRUG|Edoxaban|Prescribed according to approved label
214933386|NCT01866267|DRUG|Maraviroc|HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
214331668|NCT02448303|DRUG|Pembrolizumab|
214331669|NCT02448303|DRUG|Acalabrutinib|
214331670|NCT00844454|PROCEDURE|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
214331671|NCT00844454|PROCEDURE|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
214933387|NCT05563402|DEVICE|Atalante|Atalante Gait training: Using the Atalante System (self-reliant walking system), participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute).
214933388|NCT04305106|DRUG|Bevacizumab|Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
214933389|NCT04305106|OTHER|Placebo|Placebo (7.5mg/kg BW) + Saline (100ml) The placebo drug will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
214933390|NCT04305106|OTHER|Standard care|Standard care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
214331672|NCT05457270|DRUG|AZD4831|Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
214331673|NCT01625052|DEVICE|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
214331674|NCT02229097|DRUG|Normal bolus|"During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period"
214331675|NCT02229097|DRUG|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
214331676|NCT02205619|DEVICE|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
214331677|NCT02205619|DEVICE|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
214331678|NCT02205619|DEVICE|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
214331679|NCT01566136|BEHAVIORAL|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
214331680|NCT03572491|BIOLOGICAL|influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
214331681|NCT03223818|OTHER|Fast-track peri-operative program|"Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.~All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia."
214331682|NCT01825551|DRUG|Granulocyte Colony Stimulating Factor|
214331683|NCT01825551|DRUG|Placebo|
215072320|NCT01628484|OTHER|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
214331684|NCT05346510|PROCEDURE|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
214331685|NCT04276272|OTHER|Imaging scan|PET/CT scan
214331686|NCT02864017|PROCEDURE|Enteral nutrition|
214331687|NCT02864017|DIETARY_SUPPLEMENT|L-Citrulline|
214331688|NCT02864017|DIETARY_SUPPLEMENT|Placebo|
214331689|NCT00637546|OTHER|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
214331690|NCT02656446|DEVICE|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
214331691|NCT02656446|DEVICE|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
214331692|NCT01629082|DRUG|Clofarabine|
214331693|NCT01629082|DRUG|Lenalidomide|
214331694|NCT02277626|DEVICE|Electro Flo 5000|Airway clearance device
214331695|NCT02277626|DEVICE|Incourage Vest System|Airway Clearance Device
214331696|NCT00659646|DRUG|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
215072321|NCT03855046|DRUG|IncobotulinumtoxinA 50 U Intramuscular Powder for Solution|"Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution."
215077924|NCT05683574|DRUG|etoricoxib 90 mg (Arcoxia®) +FDC placebo|Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
214933391|NCT00574249|BIOLOGICAL|adalimumab|subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
214933392|NCT00574249|DRUG|Calcipotriol/Betamethasone Ointment|Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
214331697|NCT00659646|DRUG|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
214331698|NCT02805842|DRUG|Tacrolimus BID|Administration of Tacrolimus BID
214331699|NCT02805842|DRUG|Advagraf QD|administration of Advagraf QD
214331700|NCT03063229|DEVICE|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
214331701|NCT03063229|OTHER|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
214331702|NCT03063229|PROCEDURE|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
214933393|NCT00574249|DRUG|placebo (vehicle ointment)|Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
214933394|NCT01734252|DRUG|Argatroban|Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
215072322|NCT03855046|PROCEDURE|Lateral subcutaneous sphincterotomy.|The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
215072323|NCT00116064|DRUG|intranasal lorazepam|
215072324|NCT00116064|DRUG|intramuscular paraldehyde|
215072325|NCT01353443|PROCEDURE|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
215072326|NCT05552794|DIAGNOSTIC_TEST|Optic nerve Sheath Diameter (ONSD)|ONSD and rSO2 monitoring will perform when the patients arrived in ICU.
215072327|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
215072328|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
215072329|NCT03752346|OTHER|exercise group|"A step aerobics exercise lasted a total 30 minutes, including:~1. a warm-up with 10 minutes of stretching exercises.~2. A step aerobics exercise (step aerobics for 30 minutes; step by step, step exercise, or stepping the ground repetitively)23,24 a total of 30 minutes then cool down (5 minutes).~3. Resistance training (10 minutes), stretching and relaxation for 10-15 minutes."
214331703|NCT03063229|DEVICE|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
214331704|NCT03063229|PROCEDURE|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
214331705|NCT03063229|OTHER|Food Diary|Participants will keep a 7 day weighed food diary.
214331706|NCT03063229|DEVICE|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
214331707|NCT03063229|OTHER|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
215072330|NCT04293510|PROCEDURE|renal biopsy and blood sampling|renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
215072331|NCT06415812|BEHAVIORAL|Evolutionary Systems Therapy|Evolutionary Systems Therapy is an individual form of psychotherapy (talk therapy) that has been previously tested trough a randomized controlled trial and a few cases series, confirming its feasibility and safety.
215072332|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
215072333|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
214331708|NCT03063229|PROCEDURE|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
214331709|NCT03063229|PROCEDURE|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
214933395|NCT04636294|DIAGNOSTIC_TEST|SARS-CoV-2 PCR|SARS-CoV-2 PCR of nasopharyngeal lysate.
214933396|NCT03449394|OTHER|Metacognitive Training|4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases
214933397|NCT01259375|DRUG|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
214933398|NCT00008775|DEVICE|Pressure support ventilation|
214933399|NCT03684824|DRUG|Long luteal phase GnRH agonist protocol|Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
214933400|NCT03684824|DRUG|Gonadotropins|Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
214933401|NCT03334318|OTHER|Mean blood glucose|Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
214933402|NCT03334318|OTHER|Blood glucose CV|Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
214933403|NCT03334318|OTHER|% time 70-180 mg/dL|Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
214331710|NCT03063229|DRUG|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
214331711|NCT03063229|DRUG|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
214331712|NCT05222568|BEHAVIORAL|Lateral positioning|After the DLT intubation, the patient is placed in lateral decubitus position
214331713|NCT05222568|DEVICE|Cuff pressure measurement|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning
214331714|NCT05007457|OTHER|Telerehabilitation|"Patients belonging to the experimental group will receive the brochure and, weekly a telematic comparison will take place lasting about 30 minutes, with a physiotherapist to be asked questions. The physiotherapist will be able to evaluate and modify the training program based on the patient's response.~The tele-rehabilitation sessions will take place: once / week for the first month, once every 2 weeks for the second month and from the third month from the third month the patient can contact the professionals in case of doubts or questions regarding the exercises he is taking place at home."
214331715|NCT02991209|DRUG|Testosterone|
214331716|NCT02991209|DRUG|Placebos|
214331717|NCT00023673|DRUG|carboplatin|
214331718|NCT00023673|DRUG|paclitaxel|
214933404|NCT03334318|OTHER|% time below 54 mg/dL|Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
214933405|NCT03334318|OTHER|% time above 180 mg/dL|Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
214933406|NCT03334318|OTHER|% time above 250 mg/dL|Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
214331719|NCT00023673|RADIATION|three-dimensional conformal radiation therapy|
214933407|NCT03334318|OTHER|MAGE (Mean amplitude of glucose excursions)|Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
214933408|NCT03334318|OTHER|LBGI (Low Blood Glucose Index)|Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
214331720|NCT05248893|DRUG|AGN-151586|Intramuscular Injection
214331721|NCT02497326|DRUG|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
214331722|NCT02497326|DRUG|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
214933409|NCT03334318|OTHER|HBGI (High Blood Glucose Index)|High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
214933410|NCT03334318|DRUG|Allopurinol|Oral allopurinol tablets administered in the PERL Clinical Trial
214933411|NCT03334318|DRUG|Placebo|Oral placebo tablets administered in the PERL Clinical Trial
214933412|NCT03124121|DRUG|Golimumab|A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
214933413|NCT02311556|DEVICE|dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging|
214933414|NCT03084068|OTHER|Human dehydrated umbilical cord allograft|human dehydrated umbilical cord allograft
214933415|NCT03084068|OTHER|Placebo|Open rotator cuff surgery with standard suture repair
214933416|NCT02999724|DRUG|Gabapentin|Gabapentin 300-600 mg 1 hour preop
214933417|NCT02999724|OTHER|placebo|placebo capsule(s) 1 hour preop
214933418|NCT02832141|PROCEDURE|Mobilization anterior|Participant in prone position. Central thoracic mobilization from posterior-to-anterior.
214933419|NCT02832141|PROCEDURE|Mobilization posterior|Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
214933420|NCT02470819|GENETIC|Genetic profiling|genetic profiling
214933421|NCT05827575|DEVICE|Transcutaneous Auricular Vagal Nerve Stimulation|stimulation on both ear within different area for 4 weeks；parameter：2s on，3s off,0.5ms，25hz
214933422|NCT01036659|DRUG|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
214933423|NCT03079037|DEVICE|Stimulation|Traditional deep brain stimulation
214933424|NCT00914706|OTHER|P-PROMPT|P-PROMPT is a web-based chronic disease management system. The system will help to ensure that all patients have up-to-date laboratory monitoring and visits as recommended by the Canadian Diabetes Association Guidelines.
214933425|NCT04060199|DRUG|Viltolarsen|IV infusion
214933426|NCT04060199|DRUG|Placebo|IV infusion
214933427|NCT00508937|OTHER|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
214933428|NCT00508937|OTHER|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
214331723|NCT02497326|DRUG|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score \>4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
214331724|NCT04332172|OTHER|General information|General information related to pregnancy is provided electronically.
215072334|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
214331725|NCT04332172|BEHAVIORAL|Baseline brief intervention|Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.
214331726|NCT04332172|BEHAVIORAL|Remote online booster sessions|Two \< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.
214331727|NCT04332172|BEHAVIORAL|SMS|Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
214331728|NCT03950024|DIAGNOSTIC_TEST|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
214331729|NCT04841564|PROCEDURE|ultrasound approach of serratus anterior block|After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.
214331730|NCT04841564|PROCEDURE|open approach of serratus anterior block|After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
214331731|NCT05737641|OTHER|water ingestion|ingestion of water after an 8h-fasting period
214331732|NCT05737641|DIETARY_SUPPLEMENT|jelly ingestion|ingestion of jelly after an 8h-fasting period
214331733|NCT00218192|BEHAVIORAL|Behavior Therapy|
214331734|NCT06663176|DRUG|RESP302|Nitric Oxide agent
214331735|NCT06663176|DRUG|RESP303|Nitric Oxide agent
214331736|NCT04442594|PROCEDURE|virtual reality session|"The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation."
214933429|NCT00508937|OTHER|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
214933430|NCT00508937|OTHER|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
214933431|NCT00508937|OTHER|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
214933432|NCT00478699|DRUG|Docetaxel/Cisplatin control|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
214933433|NCT00478699|DRUG|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
214933434|NCT00478699|DRUG|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
215072335|NCT02333682|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
215072336|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
215072337|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
215072338|NCT05312632|DRUG|Safinamide Mesilate|Safinamide Mesilate oral tablets.
215072339|NCT04660825|OTHER|A resistance band exercise programme|A resistance band based exercise programme lasting six months
215072340|NCT04660825|OTHER|Control|Maintained usual physical activity
215072341|NCT06197191|DEVICE|Fukuda Denshi Cardimax ECG device model FCP-7101|ecg and holter will be done one day before and one day after then after 1,6,12 month after transcatheter closure of ASD
214933435|NCT00478699|DRUG|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
214933436|NCT00044707|DRUG|Pramlintide acetate|Clear, colorless, sterile solution for SC injection.
214933437|NCT04308915|BEHAVIORAL|Game-based cognitive training|A suite of 5 games is presented to the participants for training working memory
214933438|NCT01629290|DEVICE|Enamel Pro|Varnish treatment containing 5% NaF
214933439|NCT01629290|DEVICE|Duraphat|Varnish treatment containing 5% NaF
214933440|NCT01629290|DEVICE|Vanish|Varnish treatment containing 5% NaF
214331737|NCT05683977|DRUG|durvalumab|Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
214331738|NCT05826964|DRUG|AI+CDK4/6i|"Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
214331739|NCT05826964|DRUG|SERD+CDK4/6i|"Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
214331740|NCT05826964|DRUG|mTOR inhibitor + AI|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
214331741|NCT05826964|DRUG|mTOR inhibitor + SERD|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
214331742|NCT05826964|DRUG|mTOR inhibitor + Selective estrogen receptor modulator|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
214331743|NCT05826964|DRUG|PI3K inhibitor + SERD|Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
214331744|NCT05826964|DRUG|PI3K inhibitor + AI|Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
214331745|NCT05826964|DRUG|Chemotherapy|Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
214331746|NCT05826964|DRUG|Oral SERD|Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
214331747|NCT05826964|DRUG|PARPi|For participants with germline breast cancer gene (BRCA) mutation(s). Participants will receive standard of care PARPi (Olaparib or Talazoparib) therapy in Step 2 and Step 3.
214331748|NCT05826964|DRUG|AKT inhibitor|For participants with tumors with one or more phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) or AKT serine/threonine kinase 1 (AKT1) or phosphatase and tensin homolog (PTEN) alterations. Participants in Step 2 and Step 3 will receive standard of care AKT inhibitor as an alternative therapy.
214331749|NCT05826964|OTHER|Step 3 Arm 2|Participants will receive third-line treatment standard of care as per their treating physician's choice according to National Comprehensive Cancer Network (NCCN) guidelines.
214331750|NCT03940209|BEHAVIORAL|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
215072342|NCT02019108|OTHER|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
215072343|NCT02019108|OTHER|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
214331751|NCT02438228|OTHER|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
214331752|NCT01326780|DRUG|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
214331753|NCT01326780|DRUG|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
214331754|NCT01326780|DRUG|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
214331755|NCT01326780|OTHER|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
214331756|NCT03882619|BEHAVIORAL|Calligraphy|Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
214933441|NCT01629290|DEVICE|Placebo|Bland varnish containing no NaF
214331757|NCT03341624|PROCEDURE|cataract surgery cataract extraction and intraocular implantation|
214331758|NCT04410692|OTHER|Prediction Market|"Participants bet on likely future outcomes using a prediction market"
214331759|NCT00253526|DRUG|bevacizumab|
214331760|NCT00253526|DRUG|gemcitabine hydrochloride|
214331761|NCT00253526|PROCEDURE|adjuvant therapy|
214331762|NCT00253526|PROCEDURE|anti-cytokine therapy|
214331763|NCT00253526|PROCEDURE|antiangiogenesis therapy|
214331764|NCT00253526|PROCEDURE|antibody therapy|
214331765|NCT00253526|PROCEDURE|biological therapy|
214331766|NCT00253526|PROCEDURE|chemotherapy|
214331767|NCT00253526|PROCEDURE|conventional surgery|
214331768|NCT00253526|PROCEDURE|growth factor antagonist therapy|
214331769|NCT00253526|PROCEDURE|monoclonal antibody therapy|
214331770|NCT00253526|PROCEDURE|surgery|
214933442|NCT02219789|DRUG|Alisertib|Given PO
214933443|NCT02219789|DRUG|Fulvestrant|Given IM
214933444|NCT02219789|OTHER|Laboratory Biomarker Analysis|Correlative studies
214933445|NCT00656851|DRUG|Pioglitazone|30mg/day for 16 weeks
214331771|NCT03146702|OTHER|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
214331772|NCT03859232|OTHER|Delta Dry® Waterproof Pantaloon|Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.
214331773|NCT03859232|OTHER|Cotton Padding|Cast with traditional cotton liner.
214331774|NCT06442267|DRUG|Enoxaparin Injectable Solution|Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily
214331775|NCT06442267|DRUG|Argatroban, 1 Mg/mL Intravenous Solution|Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.
214331776|NCT06442267|DRUG|Unfractionated heparin|Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.
214331777|NCT03394300|OTHER|iol power calculation|iol power calculation in high myopia
214331778|NCT02684591|DRUG|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
214331779|NCT02684591|DRUG|Placebo|Placebo
214331780|NCT05477004|DRUG|Ketamine|A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
214331781|NCT00424372|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
214331782|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
214331783|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
214331784|NCT03862976|DIAGNOSTIC_TEST|computerized cardiotocography|computerized cardiotocography (C-CTG)
214331785|NCT04622254|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214331786|NCT04622254|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
214331787|NCT00700791|DIETARY_SUPPLEMENT|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
214331788|NCT00700791|DEVICE|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
214331789|NCT00700791|OTHER|Placebo|Oral Placebo
214331790|NCT00700791|OTHER|Placebo Cream|Topical Placebo Cream
214331791|NCT03292822|DIETARY_SUPPLEMENT|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
214331792|NCT03292822|DRUG|Paclitaxel|chemotherapeutic drug
214331793|NCT00912405|DEVICE|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
214331794|NCT00796861|DRUG|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
214331795|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
214331796|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
214933446|NCT00656851|BEHAVIORAL|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
214933447|NCT00041106|DRUG|gemcitabine hydrochloride|Given IV
214933448|NCT00041106|DRUG|cisplatin|Given IV
214933449|NCT00041106|DRUG|gefitinib|Given PO
214933450|NCT00041106|OTHER|laboratory biomarker analysis|Correlative studies
214933451|NCT01391195|DEVICE|Phototherapy by low level laser therapy|Phototherapy by low level laser therapy during 9 weeks
214933452|NCT02348151|OTHER|Treadmill|The volunteers will perform the shuttle walk test on the treadmill
214933453|NCT02348151|OTHER|Corridor|The volunteers will perform the shuttle walk test on the corridor
214933454|NCT06601322|OTHER|Pacemaker Interrogation and Electrocardiogram (ECG):|Prior to the CMR study, subjects will undergo baseline interrogation of their dual chamber LBBAP to assess for appropriate device function. Lead capture characteristics will then be assessed with continuous intracardiac electrogram characteristics recorded from the atrial and ventricular lead with simultaneous 12-lead ECG rhythm strip recordings to assess for settings at which the investigators can differentiate aLBBAP, sLBBAP and nsLBBAP. Pacing output will be increased until left bundle branch area pacing with anodal capture is achieved, and then decreased until anodal capture is lost. These programming parameters will be recorded and utilized for Phase 2-3 of the CPET-CMR scan. 12-lead ECG rhythm strips of QRS morphology with each parameter set will be obtained and saved for later analysis.
214331797|NCT04136834|BIOLOGICAL|PT01 (Pegtomarginase)|PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
214331798|NCT03536728|DRUG|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
214331799|NCT03536728|DRUG|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
214331800|NCT05336500|OTHER|Pilates method exercises|Participants will be randomised into two groups that will be treated with Pilates exercises for 12 weeks (twice a week for 60 minutes). The control group will receive guidance on the specific activation of the center of strength (the powerhouse), while the experimental group will receive guidance to perform the exercises in a relaxed and smooth way.
214331801|NCT04963504|DIAGNOSTIC_TEST|Rest-to-exercise|Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)
214331802|NCT04963504|DIAGNOSTIC_TEST|Sitting-to-supine|Pulmonary diffusing capacity is assessed in the sitting and supine position
214331803|NCT04330079|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg once daily for 6 months.
214933455|NCT06601322|OTHER|Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR|Following ECG and pacemaker analysis as above for safety, subjects will be fitted with 2 sets of MRI-compatible ECG monitoring systems a BP monitoring system , and a finger-tip pulse gating system. Imaging will be performed on a Magnetom Vida 3 Tesla scanner by trained CRM radiology technologists.
214933456|NCT06601322|OTHER|Continuous pacemaker telemetry (CPT)|CPT will be established and supervised by a cardiac electrophysiologist to monitor for evidence of noise or artifact which may lead to inability to appropriately sense native atrial depolarization in DDD mode. Subjects with PM dependence are excluded. If noise is noted during scanning with NVP, then scanning will NOT be performed during P-synchronous pacing and will instead be performed during overdrive pacing at a rate above the patients maximal achieved heart rate with exertion during Phase 1. Thus, there is minimal risk to the subject from PM programming during CPET-CMR.
214933457|NCT01123941|BIOLOGICAL|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
214331804|NCT04330079|OTHER|Lifestyle modification|lifestyle modification (diet and exercise) for 6 months
214331805|NCT02829359|DRUG|Entecavir therapy|Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
214331806|NCT05163912|BEHAVIORAL|Virtual home intervention|Group classes with active videogames and discussions
214933458|NCT01123941|BIOLOGICAL|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
214933459|NCT05667974|BIOLOGICAL|PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried|PIKA rabies vaccine
214933460|NCT05667974|BIOLOGICAL|Chirorab|Active Comparator
214933461|NCT01058616|DRUG|LTX-315 (Oncopore™)|5 mg/ml-70 mg/ml. Dosing will be done as transdermal injection of a calculated volume at day 1 and 8. Additionally weekly injections up to a maximum of 4 injections.
214933462|NCT03841968|PROCEDURE|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
214933463|NCT03841968|PROCEDURE|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
214331807|NCT01266239|PROCEDURE|kissing balloon inflation|Kissing balloon inflation following the MV stenting
214331808|NCT01266239|DEVICE|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
214331809|NCT05446311|DRUG|Dinalbuphine sebacate|After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
214331810|NCT03952884|BEHAVIORAL|Resistance Exercise|Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
214331811|NCT03952884|BEHAVIORAL|No Resistance Exercise|Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
214331812|NCT03952884|DIETARY_SUPPLEMENT|Leucine|Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
214331813|NCT03952884|DIETARY_SUPPLEMENT|Dileucine|Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
214331814|NCT02267655|DRUG|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
214331815|NCT02267655|DRUG|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
214331816|NCT02267655|DRUG|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
214331817|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position
214933464|NCT06012955|DEVICE|Target-controlled infusion (TCI) systems|Target-controlled infusion (TCI) with propofol and remifentanil was used for anesthesia induction and maintenance
214331818|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position
214331819|NCT03018353|DRUG|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
214331820|NCT04854200|DEVICE|Medtronic HeartWare ™ HVAD™ System|The Medtronic HeartWare™ HVAD™ System includes a ventricular assist device (VAD) that helps the heart pump and increases the amount of blood that flows through the body in patients with advanced heart failure.
214331821|NCT01590823|DRUG|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
214331822|NCT02370888|DRUG|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
214331823|NCT04682600|DEVICE|Liver Incytes System|The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method. The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them. A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver. Ultrasound imaging through the patient ribs is used to track the displacements of these waves. Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated. The use of volumetric multi-frequency imaging increases the amount of liver scanned
214933465|NCT04601103|DRUG|No SLS toothpaste|Toothpaste no Sodium Lauryl Sulfate
215072344|NCT03380546|DRUG|Acarbose|Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.
215072345|NCT03380546|DRUG|Prandial insulin|Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
215072346|NCT01888536|DRUG|Limaprost|
214331824|NCT05951491|DEVICE|Wearable Shoulder Exoskeleton|The wearable shoulder exoskeleton prototype is under development at the University of Idaho to provide gravity support to the shoulder. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
214331825|NCT05951491|DEVICE|Wearable Hand Exoskeleton|The wearable hand exoskeleton prototype is under development at the University of Idaho to provide hand-opening support. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
214331826|NCT02556008|DRUG|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
214331827|NCT06571214|DRUG|Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)|As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.
214331828|NCT06571214|DRUG|Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)|This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
214933466|NCT04601103|DRUG|Medium SLS toothpaste|Less than or equal to X ppm Sodium Lauryl Sulfate
214933467|NCT04601103|DRUG|High SLS toothpaste|More than or equal to X ppm Sodium Lauryl Sulfate
215072347|NCT01888536|DRUG|Pregabalin|
215072348|NCT01888536|DRUG|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
215072349|NCT01888536|DRUG|Placebo(for Limaprost)|mimic Limaprost tablet
214933468|NCT04601103|DEVICE|Anti-plaque|Rinse prevents bacterial adherence to teeth
214933469|NCT01044511|BEHAVIORAL|Home visits|home visits by specialist nurse 2 times and 1 phonecall
214933470|NCT01044511|BEHAVIORAL|standard|hotline
215072350|NCT02324140|OTHER|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
215072351|NCT01084278|DRUG|Colchicine|Colchicine tablets
215072352|NCT04569136|OTHER|Education|The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
215072353|NCT04569136|OTHER|Therapeutic ultrasound|Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.
215072354|NCT04569136|OTHER|Sham ultrasound|Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.
215072355|NCT04569136|OTHER|Breast massage|Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
214331829|NCT05040412|DEVICE|difficult laryngoscopy|Patients will be intubated with the direct laryngoscope.
214331830|NCT00721994|DEVICE|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
214331831|NCT05044741|PROCEDURE|Emergency surgical enterostomy|Emergency surgical enterostomy
214331832|NCT03617809|PROCEDURE|Preoperative warming|The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
214331833|NCT02810834|BEHAVIORAL|Walking/Running program|"Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).~The intervention will run over two school years (approximately 16 months)"
214331834|NCT02810834|BEHAVIORAL|Classroom physical activity break program|"Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.~The intervention will run over two school years (approximately 16 months)"
214331835|NCT02507102|DEVICE|Voyager|Non-invasive RFE therapy
214331836|NCT06300541|PROCEDURE|Colectomy|Observational study.
214331837|NCT03081585|BEHAVIORAL|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
214331838|NCT04173143|DEVICE|Craniocervical flexion training with pressure biofeedback|Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training
214331839|NCT04173143|OTHER|Craniocervical flexion training without pressure biofeedback|Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
214331840|NCT00632697|DRUG|pentoxifylline|800 mg daily for six months
214331841|NCT00632697|DRUG|placebo|
214331842|NCT04085822|DEVICE|SMA-001|Intra-dermal injection of SMA-001 and control device.
214933471|NCT06619301|DRUG|Insulin glargine|Insulin Glargine is regularly used outside of pregnancy and its efficacy is well documented. It is a current medication we regularly use in pregnancy, however, there is limited data for comparison to the standard, NPH.
215072356|NCT04569136|OTHER|Usual obstetric care|Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
215072357|NCT03122821|OTHER|Real Transcranial direct stimulation+Mental Imagery|"The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
215077925|NCT05683574|DRUG|cyclobenzaprine hydrochloride + etoricoxib placebo|Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
215077926|NCT00798317|DRUG|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
215077927|NCT00798317|DRUG|Placebo|Intravitreal injection placebo.
214331843|NCT00261482|DRUG|norelgestromin + ethinyl estradiol|
214331844|NCT05829603|DRUG|Dimethyltryptamin (DMT) & Harmine|Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
214331845|NCT01670162|DRUG|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
214331846|NCT02232659|DEVICE|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
214331847|NCT03765307|DEVICE|SyMap Bronchial Ablation System|The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
214331848|NCT03765307|DEVICE|Boston Scientific Alair System|The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
214331849|NCT05573516|PROCEDURE|Open reduction and internal fixation|unicortical fully threaded 4mm screws will be used as positional screws after completely reducing the fracture
214933472|NCT06619301|DRUG|insulin NPH|Insulin NPH is a current medication used in pregnancy for diabetes mellitus. It has been used as the standard form of insulin.
214331850|NCT02260427|DEVICE|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
214331851|NCT02260427|DEVICE|Insertion of the air-Q sp|
214331852|NCT01840670|DRUG|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
214331853|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with L-PRF|"Partially edentulous patients in need of a single-tooth extraction in the premolar region\[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.~L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.~After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
214331854|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with Xenogenic bone and collagen membrane.|"Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.~In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.~The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .~After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
214331855|NCT04072484|OTHER|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
214331856|NCT03242499|DRUG|Lovastatin|Lovastatin 80mg or placebo use for 48 weeks.
214331857|NCT03242499|DRUG|Placebo|placebo for 48 weeks
214933473|NCT05686161|BIOLOGICAL|SW-BIC-213;SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
214933474|NCT05686161|BIOLOGICAL|Sinopharm (BIBP);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
215072358|NCT03122821|OTHER|Sham Transcranial Direct Stimulation +Mental Imagery|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
215072359|NCT00611468|DRUG|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
215072360|NCT00611468|DRUG|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
215072361|NCT01466660|DRUG|Afatinib|afatinib once daily
215072362|NCT01466660|DRUG|gefitinib|Gefitinib once daily
215072363|NCT02694913|OTHER|Non Interventional|This is a non therapeutic, pilot study.
215072364|NCT01742910|PROCEDURE|intraocular lens implantation|
215072365|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
215072366|NCT00191724|DRUG|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
215072367|NCT00191724|DRUG|Placebo|intravenous (IV), one infusion, over 12 hours
215072368|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
215072369|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
215072370|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
215072371|NCT06277986|OTHER|cachexia|Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
215072372|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
215072373|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
215077928|NCT02154048|DRUG|Ropivacaine|
214933475|NCT05686161|BIOLOGICAL|Pfizer(BNT162b2);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
214331858|NCT05082194|PROCEDURE|balance with open and closed eyes|"The UNTERBERGER TEST. The subjects performed the test once with their eyes open and then with their eyes closed. The participant's task was to assume a standing position with legs apart at hip-width and then walk in place (50 steps).~Static and dynamic balance testing on the Biodex SD balance platform. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. Before starting the tests, surface electrodes were glued to the patient's body (according to the SENIAM procedure). Five surface electrodes were used, consisting of three channels. They were placed on the abdomen of the right sternocleidomastoid muscle, two more were placed on the left longus colli muscle, and one reference electrode on the right shoulder process of the scapula. After each completed test, an ongoing test report was generated."
214331859|NCT02017691|DEVICE|Near Infrared Spectroscopy|If crSO2 is \<10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable \>10th centile, or if crSO2 is \> 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
214331860|NCT02017691|DEVICE|Pulse-oximetry|If SpO2 remains \<10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is \>90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
214331861|NCT00219934|DRUG|Antiretroviral therapy|HAART therapy
214331862|NCT01430585|DRUG|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
214331863|NCT01430585|DRUG|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
214933476|NCT06034925|DRUG|Maribavir|maribavir 400mg twice daily
214331864|NCT01430585|DRUG|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
214331865|NCT01324375|DEVICE|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
214331866|NCT03623737|DRUG|neoadjuvant chemoradiation|"Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection"
214331867|NCT04163744|DEVICE|Double balloon catheter|Induction of labour with double balloon catheter
214331868|NCT03376997|DRUG|Perampanel|IV infusion
214331869|NCT03376997|DRUG|Perampanel|Oral tablet
214331870|NCT06363916|DEVICE|Insulin Management System in Manual mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm not activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
214331871|NCT06363916|DEVICE|Insulin Management System in Automatic mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
214331872|NCT01280929|PROCEDURE|Panretinal Photocoagulation (PRP)|
214331873|NCT01280929|DRUG|Intravitreous injection of ranibizumab|
214331874|NCT03709550|DRUG|Decitabine|Given IV
214331875|NCT03709550|DRUG|Enzalutamide|Given PO
214331876|NCT00993785|DEVICE|Costar Coronary Stent Delivery System|
214331877|NCT05138380|DEVICE|Foot orthoses|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
214933477|NCT06034925|DRUG|Valganciclovir|valganciclovir 900mg once daily
214933478|NCT04198285|PROCEDURE|Retrograde bladder filling|The bladder will be filled with a large syringe through the urinary catheter (which is left in place for the surgery) with 200mL of sterile saline, and then the catheter will be removed.
214933479|NCT01203826|BIOLOGICAL|Asfotase Alfa|
214933480|NCT02094222|DRUG|RAVICTI|open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
214933481|NCT06452745|PROCEDURE|Colonoscopy|Colonoscopy performed as a regular practice during colorectal cancer screening.
215077929|NCT02154048|DRUG|Dexamethasone|
214331878|NCT05138380|DEVICE|Flat shoe insert|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
214331879|NCT05329740|DRUG|Methylprednisolone Injection|All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery. The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3. The daily dosage will be administered with two injections (12h interval).
214933482|NCT06452745|OTHER|Urine and FOBT collection|After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.
214331880|NCT04595487|PROCEDURE|Left ventricular septal pacing|"In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion."
214331881|NCT04595487|PROCEDURE|Right ventricular pacing|In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
214933483|NCT04473820|DRUG|Vapocoolant spray|The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.
214933484|NCT04473820|DRUG|Lidocaine-Prilocaine cream|A finger tip (0.5 gr) of the cream will be applied in 4 square cm at cannulation site and will be covered with closed dressing for 45 minutes.
215072374|NCT00803348|DRUG|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
215072375|NCT06305195|DIAGNOSTIC_TEST|heart rate variability test|"First, the patient is required to lie on their back to have a 5-minute continuous ECG recorded, without performing any maneuvers.~Following this, deep breath test, Valsalva and stand test are performed."
215072376|NCT04131205|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
215072377|NCT02583100|BEHAVIORAL|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
215072378|NCT02583100|BEHAVIORAL|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
214933485|NCT04576065|OTHER|WFIT|access to nurse practitioner for telehealth visits and activity monitor for 6 months after hospital discharge
214933486|NCT01838434|DRUG|lenalidomide|given PO
214933487|NCT01838434|DRUG|idelalisib|given PO
214933488|NCT03344575|PROCEDURE|Conventional defect closure|Laparoscopic suturing of the defect prior to placing an intraperitoneal Onlay Mesh
214933489|NCT03344575|PROCEDURE|Peritoneal bridging|Laparoscopic closure of the defect by using a peritoneal flap prior to placing an intraperitoneal Onlay Mesh
214933490|NCT03147859|BIOLOGICAL|Vedolizumab (brand name Entyvio)|IV infusion
214933491|NCT06643416|DRUG|Timolol 0.5% eye drops and betamethasone valerate 0.1% cream|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
214933492|NCT06643416|DRUG|Betamethasone valerate 0.1% cream|The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
214933493|NCT00091637|DRUG|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
214933494|NCT00091637|DRUG|Placebo infusion|bolus infusion over a 10 minute period once
214933495|NCT06011161|BEHAVIORAL|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
214933496|NCT02630849|PROCEDURE|intercostal muscle flap and pericostal no-compression suture|intercostal muscle flap and pericostal no-compression suture of the intercostal space
214933497|NCT02630849|PROCEDURE|Standard suture technique of the intercostal space|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
214933498|NCT04507919|DRUG|Dabrafenib|150 mg
214933499|NCT04507919|DRUG|Trametininb|2.0 mg
214933500|NCT01802736|BEHAVIORAL|Motivational intervention counselling plus SPP|
214331882|NCT00654524|DRUG|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.\& Livial 1.25-2.5mg p.o. q.d.) if needed.
214933501|NCT06604143|BEHAVIORAL|Quality Training|Participants will engage in piano playing tasks using their affected hand and fingers. The training focuses on specific aspects of finger movement, and participants will receive feedback related to their playing. They will wear a wrist brace for support, and their hand and arm positions will be monitored to ensure proper technique.
214933502|NCT06604143|BEHAVIORAL|Goal Training|Participants will engage in piano playing tasks using their affected hand and fingers. The training emphasizes learning to play and producing music. Feedback will be provided on various aspects of performance such as speed and accuracy, but specific details about finger movement or technique will not be given. The use of a wrist brace and monitoring of hand and arm positions will be consistent with standard practice.
214331883|NCT05709821|DRUG|IMM60|IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
214331884|NCT05709821|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
214331885|NCT06435247|BEHAVIORAL|With or without accompaniment in the recovery anaesthetic area|one grup will have family accompaniment in the recovery area and the other group will not in both groups the QoR15 scale will be used to measure the quality of anesthetic recovery
214331886|NCT05703399|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214331887|NCT05703399|OTHER|Questionnaire Administration|Complete questionnaire
214331888|NCT01890200|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
214331889|NCT01890200|DRUG|Ribavirin|conventional treatment of Hepatitis C
214331890|NCT01890200|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
215072379|NCT00474864|DRUG|GW856553|
214331891|NCT01890200|DRUG|Placebo|Placebo, without acting ingredient.
214331892|NCT02432794|PROCEDURE|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
214331893|NCT02197546|OTHER|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
214933503|NCT04197102|DRUG|CBD Isolate|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD isolate oil will be taken once daily for 8 weeks for participants randomized to the CBD Isolate arm.
214933504|NCT04197102|OTHER|CBD Broad Spectrum|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD Broad Spectrum oil will be taken once daily for 8 weeks for participants randomized to the CBD - Broad Spectrum arm.
214933505|NCT04197102|OTHER|Placebo oil|Placebo solution will be taken once daily for 8 weeks by participants randomized to the placebo arm.
214933506|NCT02212990|OTHER|Acetaminophen Arm|Blinded Therapy
214331894|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
214331895|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound in MV patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
214331896|NCT03850886|DIETARY_SUPPLEMENT|Niacinamide Oral Tablet|Nature's Life Niacinamide 1000 mg
214331897|NCT03850886|DRUG|Antidiabetic|Metformin or Sulphonylurea
214331898|NCT03946761|DEVICE|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
214933507|NCT02212990|OTHER|Placebo Arm|Blinded Therapy
215072380|NCT00461864|PROCEDURE|ultrasound examination of the hip|
215072381|NCT03546595|OTHER|Auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
215072382|NCT03546595|OTHER|Sham auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
215077930|NCT02154048|OTHER|Placebo|
214331899|NCT06573060|DEVICE|Continuous glucose monitoring|Subjects with T2DM and acute coronary syndrome (n=120) were fitted with continuous glucose monitors (CGM) to closely monitor their blood glucose levels continuously for 14 days.
214331900|NCT03063541|DRUG|Acetylsalicylic acid|100 mg daily as one tablet
214331901|NCT03063541|OTHER|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
214331902|NCT00237952|DRUG|EDTA chelating agents|
214331903|NCT01412424|DRUG|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
214331904|NCT03324165|OTHER|Proposed Algorithm|Proposed algorithm that uses Alvarado Score to guide CT utilization
214331905|NCT04660357|OTHER|survey study|survey study
215077931|NCT06507397|DRUG|hyperbaric bupivacaine and fentanyl|Patients received 3ml hyperbaric bupivacaine 0.5% combined with 25 microg of fentanyl.
215077932|NCT06507397|DRUG|plain bupivacaine and fentanyl|Patients received 15 mL mixture of (0.25% plain bupivacaine and 50 µg fentanyl) over 5 minutes, injected in the epidural space by epidural catheter at L3-L4 interspace, a dural puncture was created by the spinal needle. Braun's Espocan® combined spinal epidural kit before insertion of epidural catheter (needle-through-needle technique) but intrathecal medication administration was withheld.
214331906|NCT05631080|PROCEDURE|Anatomical Endoscpic enucleation of the Prostate|Transurethral endoscopic enucleation of the prostate adenoma
214331907|NCT04506554|DRUG|AMVAC + Nivolumab|Nivolumab 240mg will be administered intravenously for 3 doses - on days 1, 15 and 29. AMVAC will be dosed intravenously every 2 weeks for 3 doses on days 1, 15 and 29 with Neulasta or equivalent. Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.
214331908|NCT03175042|DEVICE|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
214331909|NCT03083496|DRUG|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
214331910|NCT03083496|DRUG|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
214331911|NCT04686097|PROCEDURE|treatment: puncture of coagulation|ultrasound-guided puncture of coagulation
214331912|NCT04686097|PROCEDURE|treatment: sclerosing agent injected|ultrasound-guided sclerosing agent injected
214331913|NCT04441450|DRUG|[14C]ICP-022|150mg suspension containing 100μCi of \[14C\]ICP-022
214331914|NCT03161314|PROCEDURE|Strengthening exercises|Conservative physical therapy treatment with home-based strengthening exercises (study 3)
214331915|NCT03161314|PROCEDURE|Stretching exercises|Conservative physical therapy treatment with home-based stretching exercises (study 3)
214331916|NCT00902200|DRUG|AR-12286|See arms
214331917|NCT00902200|DRUG|AR-12286 vehicle|See arms
214331918|NCT05294107|PROCEDURE|additional biopsies|"After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing."
214331919|NCT05814562|BEHAVIORAL|Remote Intervention|The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
214331920|NCT01590914|PROCEDURE|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
214331921|NCT01590914|PROCEDURE|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
214331922|NCT05919147|DRUG|Pioglitazone 45 mg|The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.
214331923|NCT05919147|DRUG|Placebo|Placebo will have the same appearance as the active drug.
214331924|NCT04304001|BEHAVIORAL|Community Health Advisor|"Intervention arm participants will receive one 45-minute face-to-face meeting followed by two phone calls in one-week intervals over a period of three weeks beginning within one month following baseline survey completion. These educational activities will include the use of National Cancer Institute colorectal cancer resources and materials, including a Screen to Save media presentation, and colorectal cancer brochures. The intervention will follow a conversation guide/standard script for intervention fidelity. Community Health Advisors will take notes following each interaction to document the call length and call details. Participants will receive an additional text message reminder once a week for an additional three weeks - with instructions for participants to text yes to confirm they received the message - for a total of six weeks of intervention delivery. The personalized text messages will include short messages about the benefits of colorectal cancer screening."
214331925|NCT04304001|BEHAVIORAL|Usual care|Control arm participants will receive a Fecal Immunochemical Test kit, a mailed targeted colorectal cancer brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
214331926|NCT06023095|DRUG|LY3502970|Administered orally.
214331927|NCT06023095|DRUG|Placebo|Administered orally.
214331928|NCT02500849|GENETIC|SB-728mR-HSPC Infusion 3 days following busulfan conditioning|
214331929|NCT06798012|BIOLOGICAL|TAK-411|TAK-411 IV infusion.
214331930|NCT02722668|DRUG|Fludarabine|Both Arms: 30 mg/m\^2 IV over 1 hour Day -6 to Day -2
214331931|NCT02722668|DRUG|Cyclophosphamide|Arm 1: 50 mg/kg IV over 2 hours Day -6
214486307|NCT06839820|OTHER|Infusion rate of infliximab|Infusion reactions of infliximab is compared between 30 and 60 minutes infliximab infusion-rates.
214933508|NCT02212990|OTHER|Ibuprofen Arm|Open Label Therapy
214933509|NCT04065451|DRUG|Epinephrine|Epinephrine in the submucosal injection fluid
214933510|NCT06442098|BEHAVIORAL|CAMP SMART Literacy Summer Camp|Multimodal approach to reading intervention
214933511|NCT04995250|OTHER|corrective exercise training for knee|All patients received 12 weeks (3 days per week) physiotherapy sessions with hot pack, TENS and Ultrasound session for 10 mints and knee isometric, quad strengthening, adductor and abductor strengthening, calf stretch, hamstring stretch, Maitland mobilization, Unconventional Corrective knee exercise protocol treatment: standing on one extremity, up and down on bosu exercise, walking to lateral direction, walking to anterio-posterior direction, walking to anterio-posterior and lateral for 20 mints. Data were collected at baseline, at week 4 and at post treatment (week 12).
214933512|NCT03266458|PROCEDURE|Primary percutaneous coronary intervention|Urgent percutaneous coronary intervention for ST- elevation myocardial infarction patients.
214933513|NCT06126835|DRUG|Ozanimod|Women with UC exposed to ozanimod during pregnancy
214933514|NCT06126835|DRUG|Conventional therapy|Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy
214933515|NCT06126835|DRUG|Advanced therapy|Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
214933516|NCT02585817|DEVICE|Remote CIED Management|Information Technology
214933517|NCT01683851|DEVICE|Isolite System|A type of isolation system used in dentistry. It protects soft tissues, and also has a mouth prop, which helps keep mouth open.
214933518|NCT01931943|DRUG|selatinib ditosilate tablets|
214933519|NCT03360851|DIAGNOSTIC_TEST|low-dose CT|see arm/group description
214933520|NCT03360851|DIAGNOSTIC_TEST|PoC-PCR|see arm/group description
214933521|NCT00000753|DRUG|Atevirdine mesylate|
214933522|NCT00000753|DRUG|Zidovudine|
214933523|NCT00000753|DRUG|Zalcitabine|
214933524|NCT00000753|DRUG|Didanosine|
214933525|NCT01999998|RADIATION|Radiotherapy|
214933526|NCT05001516|DRUG|LM-302|All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.
214933527|NCT01549561|BEHAVIORAL|Parent Training|16 weeks of parent training led by a trained group facilitator
214933528|NCT01549561|BEHAVIORAL|Youth Skills Training|16 weeks of one-on-one sessions with a trained youth skills coach
214933529|NCT05284708|DEVICE|Atalante|Powered Exoskeleton
215072383|NCT05385887|DRUG|Ciprofloxacin 500 mg|One tablet of 500mg Ciprifloxacine, twice a day
215072384|NCT05385887|DRUG|Metronidazole 500 mg|One tablet of 500mg Metronidazole, three times a day
215072385|NCT05385887|DRUG|Placebo|Placebo tablets
215072386|NCT03232814|BEHAVIORAL|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
215072387|NCT02430948|OTHER|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
215072388|NCT02430948|OTHER|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
215072389|NCT02430948|OTHER|Standard support|Screening recommendations presented in standard format
215072390|NCT02430948|OTHER|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
215072391|NCT06447779|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|"0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105.~Intramuscular injection"
215072392|NCT06447779|BIOLOGICAL|NaCl solution Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
215072393|NCT06157697|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Based on previous social transfer programs in Brazil, we will offer gift packages for mothers at 6 months. The options include: diapers, hygiene products, child developmental toys, transport vouchers, or a combination of these.
215072394|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
214933530|NCT06618170|DIAGNOSTIC_TEST|Tissue surface analysis with the device|Usage of the device to analyse the presence or absence of tumoral membrane marker at the surface of the removed tumoral specimen
214933531|NCT01258062|DRUG|GelVac™ nasal powder H5N1 influenza vaccine.|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
214933532|NCT01258062|DRUG|Placebo|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
214933533|NCT06328816|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
214933534|NCT06328816|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
214933535|NCT04159428|DIAGNOSTIC_TEST|HHIE-S survey score|"First, the patient will fill in the French translation of the HHIE-S questionnaire in the observation book.~* Secondly, he will perform the audiometry in silence test: for the tonal test in silence, we will test the frequencies 500, 1000, 2000 and 4000 hertz in each ear with pure tone sound. For the vocal in silence test, we will use the dissyllabic lists of words (Fournier's lists) at the intensities of 20, 30, 40, 50 and 60 decibels. This test will be in free-field conditions testing both ears.~* Thirdly, he will perform the speech in noise audiometry test that consists in repeating sentences pronounced at an equal intensity (60 decibels) while the intensity of the noise is increasing. This test will be in free-field conditions testing both ears."
214933536|NCT06164847|BEHAVIORAL|AERO Program|HEP, identification of barriers for exercise using the COM-B model. Interventions for these barriers: Review of HEP, review of method of delivery, cues, reminders, discussion of barriers and problem solving, motivational interviewing, decision balance sheets, behavioural contract, goal setting reviews, monitoring calls (detailed description in the link below).
215072395|NCT02068690|DRUG|Placebo|Placebo
215072396|NCT02068690|DRUG|Placebo|Placebo
215072397|NCT02068690|DRUG|BI 425809 tablet|BI 425809 tablet
215072398|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
215072399|NCT03322046|BEHAVIORAL|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
214933537|NCT06164847|OTHER|Standard Care|home exercise programs, mobilisations, soft tissue techniques, or training with gym equipment
214331932|NCT02722668|DRUG|MMF|"Both Arms:~Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, do not stop MMF."
214673576|NCT03412227|BEHAVIORAL|The PASCET Program for Youth Depressive Disorders|The Primary and Secondary Control Enhancement Therapy (PASCET; Weisz, Southam-Gerow, Gordis, \& Connor-Smith, 2003; Weisz, Southam-Gerow et al., 2009; Weisz, Thurber, Sweeney, Proffitt, \& LeGagnoux, 1997) is a brief (usually 11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of, and beneficial treatments for, youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b).
215072400|NCT03070639|BEHAVIORAL|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
215072401|NCT03070639|BEHAVIORAL|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
214933538|NCT01567345|DEVICE|Implantable pump with continuous flow|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Continuous morphine's flow is scheduled.
214933539|NCT01567345|DEVICE|Implantable pump with programmable flow.|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Programmable morphine's flow is scheduled.
214933540|NCT04697420|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block is a technique in which , the local anesthetic agent is injected in the paravertebral space to anesthetise the spinal nerves after emerging from the vertebral canal in order to provide analgesia in the thoracic and upper abdominal area .
214933541|NCT04697420|PROCEDURE|Transversus abdominis plane block|Transversus abdominis plane block is a technique is mostly done under ultrasound guidance to identify the transversus plane between the internal oblique muscle and the transverses abdominis muscle , the space in which the neurovascular supply of the anterior abdominal wall is present , and hence the injection of local anesthetic agent in this space results in anesthesia of the anterolateral aspect of the abdominal wall.
214933542|NCT03781258|DRUG|Warfarin|Anti-thrombotic monotherapy (ASA)-Warfarin withdrawal.
214933543|NCT00483197|DEVICE|VentrAssistTM Left Ventricular Assist Device|
214933544|NCT04713592|DRUG|Placebo for Risankizumab|Subcutaneous (SC) Injection
214933545|NCT04713592|DRUG|Risankizumab|Subcutaneous (SC) Injection
214933546|NCT03839290|PROCEDURE|Early neonatal cheiloplasty|
214933547|NCT03098498|PROCEDURE|Subgingival Debridement|Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions
214933548|NCT05104801|DRUG|sitravatinib|sitravatinib 100mg QD PO
215072402|NCT03940638|OTHER|Data collection|Data collection
214331933|NCT02722668|DRUG|Sirolimus|"Both Arms:~Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation.~Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m\^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines."
214331934|NCT02722668|RADIATION|TBI|Both Arms: 200 cGy on Day -1
214331935|NCT02722668|BIOLOGICAL|Umbilical cord blood cell infusion|Both Arms: Day 0
215072403|NCT01604577|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
214331936|NCT02722668|BIOLOGICAL|ATG|Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
214331937|NCT05112835|OTHER|brolucizumab|There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study
214331938|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose A)|Liquid formulation administered by intravitreal (IVT) injection
214486319|NCT06346379|BEHAVIORAL|Baduanjin exercise|Baduanjin has 8 movement forms, which are easy to learn without special equipment.These advantages make Baduanjin a suitable exercise for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully.During the exercise of Baduanjin, the knees are half bent and the body center of gravity is stable between the feet, which can effectively develop the strength and endurance of skeletal muscle groups, improving the physical fitness and Bone mineral density.
214486320|NCT06836193|OTHER|Emotional intervention|Negative emotional intervention
215072404|NCT03967028|PROCEDURE|cesarean section|lower segment cesarean section either elective or emergency
214331939|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose B)|Liquid formulation administered by intravitreal (IVT) injection
214331940|NCT05160805|PROCEDURE|Sham procedure|A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.
214331941|NCT04846140|DEVICE|transcranial electrical stimulation (tES)|Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
214331942|NCT04319315|OTHER|survey|online survey
214331943|NCT01915277|DRUG|Dexmedetomidine|
214486321|NCT06836193|OTHER|Emotional intervention|Positive emotional intervention
214486322|NCT06646549|OTHER|No intervention|No intervention
214933549|NCT05104801|DRUG|tislelizumab|tislelizumab 200mg Q3W IV
214933550|NCT06668753|DRUG|Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab|SGLT-2 inhibitors
214933551|NCT00321880|PROCEDURE|therapeutic touch|administration of healing touch in 30 minute sessions
214933552|NCT06202664|PROCEDURE|Erector Spinae Block|Erector Spinae block under ultrasound guidance will be administered bilaterally at T6 level. The block will be administered after induction of general anesthesia with 1mg of IV Midazolam, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. After induction patient will be placed in lateral position and then under ultrasound guidance Erector Spinae Block will be administered at T6 level. Drugs administered in the block will include 30ml of 0.25% Bupivacaine and 10ml of 1% Lignocaine (bilaterally). Skin incision for trocar insertion will be given 15 mins after administration of Erector Spinae Block.
215072405|NCT03155529|PROCEDURE|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
215072406|NCT03550443|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
215072407|NCT03550443|DRUG|Placebo|Capsules containing an inert placebo
215072408|NCT03211611|BEHAVIORAL|Questionnaire given to the two groups|"Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP"
215072409|NCT04974905|PROCEDURE|retrograde access for re-canalization of infra-inguinal arterial occlusive disease|after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
215072410|NCT02885740|OTHER|Quantification assay of adenosine and methionine cycle metabolites|
215072411|NCT02885740|GENETIC|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
215072412|NCT02885740|OTHER|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
215072413|NCT02885740|BIOLOGICAL|Blood sample|
215072414|NCT02876458|OTHER|Immediate coronary angiogram|An immediate coronary angiogram will be performed
215072415|NCT02876458|OTHER|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
215072416|NCT00280618|DRUG|Oxaliplatin|
215072417|NCT02301546|BEHAVIORAL|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
215072418|NCT01950793|DRUG|triamcinolone acetonide|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid"
215072419|NCT01950793|DRUG|Hyaluronic Acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
215072420|NCT01247025|OTHER|No intervention|This study will not contain a specific intervention
214933553|NCT06202664|DRUG|Opioid Analgesic|This group of patient will receive general anesthesia induction with 1mcg/kg of IV Fentanyl, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. 1g of IV paracetamol and 30 mg of IV Ketorolac will be given if intra-operative course suggest inadequate analgesia (Rise in Heart rate ± Blood Pressure by more than 20% from baseline).
214331944|NCT03204942|DEVICE|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
214331945|NCT03204942|DEVICE|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
214331946|NCT03204942|DRUG|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
214331947|NCT02316197|DRUG|MSC2490484A (M3814)|Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
214331948|NCT05234398|BIOLOGICAL|Blood and saliva samplings|At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.
214331949|NCT02664038|BEHAVIORAL|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
214331950|NCT06566274|DEVICE|thumbtack needle|As a kind of intradermal needle, thumbtack needle (TTN) is a method of shallow puncture and long-term needle.After the TTN is attached into the acupoints, it will be reserved in the acupoints for 3 days. After 3 days of retention of TTN, the patient is instructed to go to the hospital, where the doctor removes the needle, disinfect the local skin of acupoints and conducts the next TTN treatment. A total of 5 treatments were applied for a duration of 15 days.
214331951|NCT06566274|DEVICE|sham thumbtack needle|"The sham TTN used in the sham TTN group has no needle body and its appearance and shape are similar to the real TTN. But it does not produce a needle-like effect.~The acupoints of sham TN group are the same as those of TN group. The use of sham TN is the same as that of the TN group. After 3 days retention of sham TN, the patient will be instructed to go to the hospital, where the doctor remove the sham TN, and conduct the next treatment after local skin disinfection. A total of 5 treatments will be applied for a duration of 15 days."
214331952|NCT05116852|OTHER|Survey|All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.
214331953|NCT06349083|DRUG|Psilocybin|One 25 mg capsule and one 5 mg capsule (30 mg total) administered once orally
214331954|NCT06349083|OTHER|Inactive Placebo|Two matching placebo capsules administered once orally
214331955|NCT06349083|BEHAVIORAL|Supportive therapy sessions|Participants will receive three supportive therapy sessions of manual-based treatment from a Center for Psychedelic Medicine (CPM) clinician, accompanied by a Silver Hill Hospital (SHH) therapist who has an ongoing therapeutic relationship with the participant. The CPM clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be solely responsible for the content of the intervention. The SHH therapist will provide additional support and continuity with clinical treatment.
214331956|NCT05167695|BEHAVIORAL|Habit-based Sleep Health Intervention|A novel low-cost approach derived by leveraging the science of habit formation
214331957|NCT05167695|BEHAVIORAL|Text messaging intervention|In addition to the Habit-based Sleep Health Intervention, the participants will also receive the text messaging intervention.
215072421|NCT06166459|PROCEDURE|Drug-coated balloon combined with provisional drug-eluting stent implantation|(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).
215072422|NCT03053986|DIETARY_SUPPLEMENT|Apple polyphenols|1 tablet per day at evening before sleeping
214331958|NCT00103792|DRUG|mycophenolate mofetil|2000 mg mycophenolate mofetil per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
214331959|NCT00103792|DRUG|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
214331960|NCT04145791|OTHER|Ice|ice packs
214331961|NCT05464628|DRUG|Atorvastatin|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
214331962|NCT05464628|DRUG|ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
214331963|NCT02494700|RADIATION|External Beam Radiation Therapy|Undergo orbital EBRT
214486323|NCT06804590|DRUG|9MW0311|9MW0311 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
214933554|NCT05050734|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics - Enhanced (CBIT-E)|Behavioral treatment for persistent tic disorders.
214933555|NCT01292694|DRUG|Losartan|Oral, single-dose, 50 mg tablet
214933556|NCT01292694|DRUG|Captopril|Oral, single-dose, 50 mg tablet
214933557|NCT01292694|DRUG|Placebo|Oral, single administration, gelatin capsule filled with microcrystalline cellulose
215072423|NCT03053986|OTHER|Placebo|1 tablet per day at evening before sleeping
214331964|NCT02494700|DRUG|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
214331965|NCT05421078|DRUG|Obicetrapib|tablet
214331966|NCT05421078|DRUG|Placebo|No active ingredient
214331967|NCT06164873|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362
214331968|NCT06164873|DRUG|Placebo|Once-weekly injections of volume-matched placebo
214331969|NCT02917993|DRUG|Itacitinib|In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
214331970|NCT02917993|DRUG|Osimertinib|Osimertinib 80 mg once daily (QD)
214331971|NCT06169267|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration/biopsy
214331972|NCT06169267|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration/biopsy
214933558|NCT03277053|DEVICE|Mobile application|A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
214933559|NCT03277053|OTHER|Control.|Patient receive an ipad with no application.
214933560|NCT06618482|PROCEDURE|Kinesiotaping|Low back kinesiotaping
214933561|NCT06618482|PROCEDURE|Kinesiotaping|Transversus abdominis kinesiotaping
214933562|NCT05213884|DRUG|Camrelizumab|200 mg, intravenous infusion over 30 minutes (Q3W); 1\~3 cycles of camrelizumab before radiotherapy and camrelizumab are maintained for 16 cycles (1 year) after the end of radiotherapy.
214933563|NCT05213884|DRUG|Concurrent cisplatin chemotherapy|cisplatin is given at a dose of 40 mg/m2 via intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy every week for 6 cycles.
214933564|NCT05213884|RADIATION|Intensity-modulated radiotherapy (IMRT)|70 Gy/ 35 fractions/7 weeks, 5 fractions/week, 1 fraction/day.
215072424|NCT05716178|BEHAVIORAL|Maternal health education|The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion.
215072425|NCT04894344|BEHAVIORAL|Education group|Is taught to choose low-sodium foods
214331973|NCT06169267|PROCEDURE|Music Therapy|Listen to music
214331974|NCT06169267|OTHER|Questionnaire Administration|Ancillary studies
214331975|NCT02606136|DRUG|Pamrevlumab|Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials
214331976|NCT03296696|DRUG|AMG 596|Drug
214331977|NCT03296696|DRUG|AMG 404|Drug
214933565|NCT03118141|PROCEDURE|blastocyst morphologic score|Blastocysts will be scored by Gardner morphologic criteria.
214933566|NCT03118141|PROCEDURE|blastocyst biopsy and sequencing|Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
214933567|NCT03118141|PROCEDURE|freeze-all and single thawed blastocyst transfer|All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
214933568|NCT00813683|OTHER|Acupuncture stimulation|"Acupuncture by stimulation of 67 Bladder point"
214331978|NCT06013904|PROCEDURE|Difficult PIV placement personnel|Patients randomized to this group will have their difficult PIV placed following the usual protocol for pediatric ED patients.
214331979|NCT06013904|PROCEDURE|US-trained PEM Fellows|US-trained PEM Fellows
214331980|NCT05728892|DRUG|Melatonin 3 MG|Preopertive melatonin adminstration oral 0.2 mg /kg 45 min before general anaethesia.
214331981|NCT05728892|OTHER|Placebo|Placebo medication will be given to control group
214331982|NCT06051773|OTHER|muscle involvement|evaluation of muscle involvement
214331983|NCT06387784|DIETARY_SUPPLEMENT|Beetroot juice|In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate. Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
214331984|NCT06387784|DIETARY_SUPPLEMENT|Placebo juice|In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice. The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice. Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
214933569|NCT00813683|OTHER|Acupuncture stimulation|"Acupuncture stimulation of 45 Stomach point (sham)"
214933570|NCT05100368|OTHER|patients|Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
214933571|NCT05658055|DRUG|Vonoprazan|Potassium-competitive acid blocker
214933572|NCT05658055|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
215072426|NCT06098911|DEVICE|MI varnish|delivers a powerful dose of fluoride, with the added booster effect of the calcium and phosphate ions through its patented Recaldent™ technology. High initial fluoride release. Minimizes tooth sensitivity and strengthens enamel. Neutral pH of 6,6 enhances enamel and dentin acid resistance and inhibits demineralization
214331985|NCT05298605|BEHAVIORAL|Faith in Action! Church-based Navigation Model|Cancer screening education and navigation by identified trained navigators in faith based settings + American Cancer Society Screening Guidelines pamphlet
214933573|NCT05658055|DRUG|probiotics|Medilac-S; Enterococcus faecium 4.5\*10\^8 and Bacillus subtilis 5.0\*10\^7, Hanmi,Beijing, China
214933574|NCT01498224|DEVICE|ReSure Sealant|Comparison of ReSure Sealant to suture(s)
214933575|NCT01498224|PROCEDURE|Sutures|
214933576|NCT02511054|DRUG|Chloroquine (CQ)|Chloroquine Phosphate is a 4-aminoquinoline compound that is commercially available for oral administration. It is a white, odorless, bitter tasting, crystalline substance freely soluble in water; and widely used for the treatment andprophylaxis of malaria. It is supplied and manufactured in tablets of 500 mg (equivalent to 300 mg chloroquine phosphaste base)
215072427|NCT04404036|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
214331986|NCT05298605|OTHER|Control|Presentation on healthy behaviors (physical activity, nutrition) + American Cancer Society Screening Guidelines pamphlet
214331987|NCT05304949|OTHER|Lucentis|There was no treatment allocation. Patients administered Lucentis by prescription were enrolled.
214331988|NCT02409615|OTHER|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
214331989|NCT02409615|OTHER|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
214331990|NCT04694131|DEVICE|TMS|The intervention of interest will be TMS delivered to the region of the left posterior parietal cortex with the greatest connectivity with the left hippocampus derived from the baseline resting-state fMRI session. This region was chosen because of its dense connections with the hippocampus, allowing stimulation of this location to modulate function of the hippocampal-cortical network. The control intervention target will be vertex, a commonly used active control site which does not influence neural or behavioral activity.
214331991|NCT06559397|OTHER|Assessment of cervical proprioception|Cervical proprioception will be assessed using the 'head position error test' in both right and left rotation directions with the CROM device. Participants will be then divided into two groups based on the presence of proprioceptive errors (\>5°).
214331992|NCT04456699|DRUG|Olaparib|300 mg BID, oral until progressive disease or end of study
214331993|NCT04456699|DRUG|5-FU|2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion
214331994|NCT04456699|DRUG|Bevacizumab|5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
214331995|NCT04456699|DRUG|Capecitabine|1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
214331996|NCT04456699|DRUG|Leucovorin/ levoleucovorin|400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
214331997|NCT05607992|BEHAVIORAL|Brief exposure-based CBT|The 5-week intervention is psychologist-guided and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease. Key components include imaginal exposure of the ACS event, interoceptive exposure through at home physical activity that stimulats the CV system, exposure in-vivo to reduce avoided situations, and activities to enhance physical activity wellbeing. Labeling (i.e., describing cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure.
214331998|NCT06369571|DRUG|Atorvastatin 10mg|Atorvastatin 10mg daily by mouth
214331999|NCT06369571|OTHER|Modification of dietary fat composition|Replace 10% of saturated fat intake with polyunsaturated fat
214933577|NCT02511054|DRUG|Pyrimethamine (PYR)|PYR is a folic acid antagonist that is commercially available; and has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide. It is manufactured in tablets of 25 mg.
215072428|NCT01636063|DRUG|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
215072429|NCT01636063|DRUG|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
215072430|NCT06138015|BEHAVIORAL|Exercise and Time-Restricted Eating|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks and a time-restricted eating following 16:8 protocol for 12 weeks.
215072431|NCT06138015|BEHAVIORAL|Exercise only|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks only.
214933578|NCT02511054|BIOLOGICAL|Sanaria PfSPZ Challenge (NF54)|Sanaria PfSPZ Challenge are aseptic, cryopreserved P.falciparum sporozoites used for CHMI trials, produced by the biotechnology company; Sanaria Inc. In brief, manufacture includes the production, under traditional environmental conditions, of eggs from a colony of A. stephensi mosquitoes housed in a controlled environmental chamber. The sporozoites are purified, counted, and, at a specified concentration, cryopreserved. Cryopreservation commences with the addition of cryoprotective additives to the purified sporozoites to produce the Sanaria PfSPZ Challenge product. Sanaria PfSPZ Challenge is dispensed into screw-cap vials containing 15,000, 50,000, or 100,000 PfSPZ in a 20 L aliquot. Sanaria PfSPZ Challenge is stored in liquid nitrogen vapour phase at 140 (Infinite)C to -196 (Infinite)C.
214332000|NCT04112810|DRUG|Tildrakizumab|100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.
214332001|NCT05340686|BEHAVIORAL|Aerobic Physical Exercise|Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
214332002|NCT05340686|BEHAVIORAL|Relaxing Physical Exercise|Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
214332003|NCT05340686|BEHAVIORAL|Information about physical exercise|Written and oral information about physical exercise recommendations, on one occasion, by researcher
214933579|NCT01063270|DRUG|Clindamycin & Rifampin|Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
214933580|NCT01063270|PROCEDURE|Clindamycin + Rifampin along with NdYag Laser treatment|Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
214933581|NCT02513498|DRUG|Ixazomib Citrate|Given PO
214933582|NCT02513498|OTHER|Laboratory Biomarker Analysis|Correlative studies
214933583|NCT02513498|OTHER|Quality-of-Life Assessment|Ancillary studies
214933584|NCT02513498|OTHER|Questionnaire Administration|Ancillary studies
214933585|NCT06481111|DRUG|supplementary treatment with vitamin D|observational design
214933586|NCT02409745|PROCEDURE|endometrial scratch|local injury to the endometrium by Pipelle
214933587|NCT01171703|DEVICE|femoral-popliteal bypass|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
214933588|NCT01171703|DEVICE|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
214933589|NCT02770404|DRUG|Nafithromycin|100, 200, or 400 mg of nafithromycin
214933590|NCT02770404|DRUG|Placebo|IV matching placebo
214933591|NCT03922737|PROCEDURE|In-person office visit|Post-operative visit to occur in-person with provider
214933592|NCT03922737|PROCEDURE|Teleheath visit|Post-operative visit to occur via telehealth software platform with provider
214332004|NCT04548674|OTHER|Whiteness HP 35%|Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
214933593|NCT06038058|DRUG|BRY812 for injection|BRY812 for injection will be administered by intravenous drip, tentatively once per cycle spanning 3 weeks on D1 of each cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
214933594|NCT06664047|PROCEDURE|OTT ACLR|Patients in this group will undergo a reconstruction with the OTT technique which includes an intra-articular component and an extra-articular one, functioning as a LET.
214933595|NCT06664047|PROCEDURE|ACLR LET|Patients in this group will undergo a reconstruction with the conventional ACL technique accompanied by a routine LET, obtained from the iliotibial band.
214933596|NCT00494052|BEHAVIORAL|Heart to Heart (Web-Based Decision Aid)|Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
214332005|NCT04548674|DEVICE|Whiteness HP 35% + LASER|A dose of LASER (60 J / cm2, for 16 seconds) was applied at two points, one point in the cervical region and another in the center of the buccal surface of the third molars, using visible infrared LASER therapy (Photon III / DMC, São Carlos, SP, Brazil), with a wavelength of 808 nm, and AsGaAl, as an active medium.
214332006|NCT04548674|OTHER|Whiteness HP 35% + CPP|Topical application of casein phosphopeptide amorphous calcium phosphate fluoride CPP-ACPF (My Paste Plus, Recaldent, GC, USA) with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes.
214332007|NCT04548674|OTHER|Whiteness HP 35% + NANO|A topical application of nanohydroxyapatite (Nano P FGM, SC, Brazil) was performed with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes after teeth whitening.
214332008|NCT01333488|DEVICE|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
214332009|NCT01333488|DRUG|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
214332010|NCT04792112|BEHAVIORAL|Decision support tool|Decision support tool for late preterm antenatal corticosteroids
214933597|NCT00494052|BEHAVIORAL|Physician Education Session|A physician education session will be included in the program.
214933598|NCT00737347|BEHAVIORAL|Lifestyle modification|lifestyle intervention includes meal planning, food preparation, food label reading, dining out, and physical activity counseling
214933599|NCT05710991|BEHAVIORAL|Sleep Hygiene Workshop|Psychoeducation on the perinatal period and sleep difficulties including principles of sleep hygiene conducive environment for sleep, bedtime routine, food, beverage, and stimulant consumption, exercise
214933600|NCT05710991|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia Workshop|The CBT-I workshop group contains empirically supported strategies for insomnia modified to target the transitions and concerns faced by perinatal individuals. Content includes Sleep drive, stimulus control, sleep restriction, counter-arousal techniques, cognitive restructuring
214933601|NCT03951064|DEVICE|Esophageal balloon|All patients in both groups will have an esophageal balloon catheter inserted by a research investigator. The catheter will be inserted into their nare while upright (head of bed \>30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
214332011|NCT01112384|DRUG|SB939|Given orally 3 times per week
214332012|NCT01352494|DRUG|docetaxel|docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
214332013|NCT01352494|DRUG|gemcitabine|gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
214332014|NCT04488328|OTHER|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
214332015|NCT00000833|DRUG|Ribavirin|
214332016|NCT00000833|DRUG|Didanosine|
214332017|NCT05414903|BEHAVIORAL|Dynamic Visual Acuity|"First, participants will report the direction of the open portion of a Landolt C (right, left, up, or down) with the head still. Ten targets at 5 acuity levels (LogMAR -0.3, 0, 0.3, 0.7, 1.0, corresponding to Snellen visual acuity of 20/10, 20/20, 20/40, 20/100, 20/200) will be identified. Next, a rate sensor will be placed on the subject's head in the plane of the horizontal canals and htDVA will be measured. The Landolt C will be presented automatically when the examiner has moved the subject's head \> 150˚/sec. htDVA scores will be the LogMAR at which the subject fails to correctly identify 50% of the visual targets or reaches a LogMAR of -0.3. The overall htDVA score is calculated by subtracting the head still LogMAR from the htDVA LogMAR. htDVA scores will be calculated for right and left head movements separately."
214332018|NCT05414903|BEHAVIORAL|Reading Outcomes|"The TOSWRF will be used to assess reading fluency. Children get 3 minutes to identify as many words as possible by drawing boundaries between successive unrelated words.~The TOSCRF will be used to assess reading fluency. Children are allowed 3 minutes to identify as many contextually related words as possible by drawing boundaries between successive words.~The TILLS will be used to assess reading comprehension. Each subject will read a short passage and answer 3 yes/no questions assessing reading comprehension.~A computer based MNREAD Test will be used to assess reading acuity, critical print size and Reading Accessibility Index.~During the TILLS and MNRead test, eye tracking (Eye Link 1000+ eye tracker) will be used to record fixation duration, saccade length, regression frequency, and total time spent."
214332019|NCT05414903|BEHAVIORAL|Static Visual Acuity|"The subject's head will be in a headrest. Static visual acuity will be assessed in 9 domains (3 levels of visual target complexity x 3 levels of presentation complexity). The 3 levels of visual target complexity are identifying: 1) colors, 2) the direction of the open prongs of the Landolt C (right, left, up, or down), which does not require alphabet knowledge, and 3) single letters (C, D, H, K, O, N, S, R, V, and Z; NIH Toolbox, Li 2014)). The 3 levels of presentation complexity are identifying: 1) 1-visual optotype, 2) a successive row of 5 visual optotypes flashed for 3 seconds (Hillman 1999), and 3) successive rows of optotypes in paragraph form as quickly as possible (i.e., rapid automatized naming). Outcome parameters will be %-correct at each acuity level and reaction time. Fixation duration, saccade length, saccade frequency, regression frequency, and total time spent will be collected via an eye tracker (Eye Link 1000+ eye tracker \[SR Research, EyeLink, Ontario, Canada\])."
214332020|NCT01468896|BIOLOGICAL|Cetuximab|Given IV
214332021|NCT01468896|BIOLOGICAL|Edodekin alfa|Given SC
215072432|NCT03913026|BIOLOGICAL|Transplant with an expanded ECT-001 cord blood|"1. Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~2. The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~3. Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises."
215072433|NCT00936533|DRUG|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
215072434|NCT00936533|DRUG|Placebo|Placebo preparation without active compound, administered as the active drug.
214332022|NCT01468896|OTHER|Laboratory Biomarker Analysis|Correlative studies
214332023|NCT00390975|DRUG|Tegaserod|
214332024|NCT02915029|OTHER|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
214332025|NCT01637688|DIETARY_SUPPLEMENT|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
214332026|NCT01824745|OTHER|educational intervention|Receive the SCP-BCS template booklet
214332027|NCT01824745|OTHER|counseling intervention|Receive counseling sessions with a patient navigator
214332028|NCT01824745|PROCEDURE|standard follow-up care|Receive standard follow-up care
215072435|NCT02447250|DRUG|Varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning between 14 or more days from birth and at a corrected gestational age of 28w0d to 33w6d. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
214332029|NCT01824745|PROCEDURE|quality-of-life assessment|Ancillary studies
215072436|NCT02554149|RADIATION|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
214332030|NCT01824745|OTHER|questionnaire administration|Ancillary studies
214332031|NCT00754182|DEVICE|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
214332032|NCT00754182|DEVICE|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
214332033|NCT02075944|BEHAVIORAL|High intensity aerobic exercise|
214332034|NCT02075944|BEHAVIORAL|Low intensity aerobic exercise|
214332035|NCT02993679|PROCEDURE|reconstruction of the ACL and anterolateral ligament|reconstruction of the ACL and anterolateral ligament
214332036|NCT04911725|DEVICE|Elastic Compression Prototype|Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
214332037|NCT04487327|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
214332038|NCT05626881|DRUG|PRP|"It will include patients with melasma treated with PRP sessions every two weeks for three months. 10 ml of venous blood will withdraw by means of a wide bore needle and a vacutainer containing an anticoagulant (Acid citrate dextrose).~Double centrifugation will be done. First centrifugation, will be done for 10 minutes. After the first centrifugation, three layers will be seen , Second centrifugation will be done for 10 min, after which the platelets separate and form a grayish pellet at the bottom of the tube and the rest will be platelet-poor plasma. About 1 ml of this platelet-poor plasma will be decanted off and the platelet pellet will be resuspended in the remaining plasma to get PRP. With 10 ml blood, about 1-1.5 ml of PRP will be obtained.~PRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe."
214332039|NCT05626881|DRUG|sylimarin cream|Silymarin was manufactured with concentration of 1.4%
214332040|NCT06158880|BEHAVIORAL|Alcoholic Beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
214332041|NCT06158880|BEHAVIORAL|Non-alcoholic Beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
214332042|NCT06158880|BEHAVIORAL|Partner Negative Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
214332043|NCT06158880|BEHAVIORAL|Partner Positive Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
214332044|NCT04452188|OTHER|Normoxia (with controlled re-oxygenation)|"Participants will receive lower levels of oxygen during surgery and after surgery on the ventilator.~As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation with an FiO2 of 50% or less (unless clinically necessary) to achieve oxygen saturation and PaO2 goals that fit within the expected range for the participant's physiology:~1. Single ventricle patients (PaO2:35-45 and oxygen saturation 75%-85%)~2. Two ventricle patients (PaO2: 60-100 and oxygen saturation \>92%)"
214332045|NCT04452188|OTHER|Standard of care ventilation|As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation per standard protocols. Ventilation will be continued in the ICU and adjusted per standard goals per the intensivist.
214332046|NCT00650949|DRUG|CYT997|Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
214332047|NCT00650949|DRUG|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
214332048|NCT04438928|DIETARY_SUPPLEMENT|Elevit Pregnancy 2nd & 3rd Trimester|Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
214332049|NCT04438928|OTHER|Non-Supplement|Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
214332050|NCT01197469|DRUG|Tadalafil|Tadalafil 10mg once daily for 3 months
214332051|NCT01197469|DRUG|Placebo|
214486324|NCT06804590|DRUG|Prolia®|Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
214486325|NCT06877494|DIETARY_SUPPLEMENT|fish oil|Twice a day, with one dose of DHA 300mg: EPA 60mg, for a continuous intervention of 90 days
214486326|NCT06734520|DRUG|super-transplantation in 3 severe β -thalassemia pediatric patients.|Haplo-identical donors are mobilized with G-CSF and PBMCs that contain CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. Then the patients will be infused with the PBMC
214486327|NCT06891872|BIOLOGICAL|Vaicella Vaccine+DTaP on Day 0, MMR on Day 30|"Varicella vaccine: lyophilized powder, subcutaneous injection~DTaP: intramuscular injection~MMR: lyophilized powder, subcutaneous injection"
214486328|NCT06891872|BIOLOGICAL|Varicella vaccine+MMR on Day 0，DTaP on Day 30|"Varicella vaccine: lyophilized powder, subcutaneous injection~MMR: lyophilized powder, subcutaneous injection~DTaP: intramuscular injection"
214486329|NCT06891872|BIOLOGICAL|Varicella Vaccine|lyophilized powder, subcutaneous injection
214486330|NCT06891768|DIAGNOSTIC_TEST|Blood culture|Blood culture for bacteriological profile and antibiotic sensitivity
214332052|NCT02468466|BEHAVIORAL|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
214332053|NCT02468466|BEHAVIORAL|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
214332054|NCT04469361|OTHER|Navicular drop measurement|The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.
214332055|NCT04469361|OTHER|Measurement of venous return parameters in supine|Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position
214332056|NCT04469361|OTHER|Measurement of venous return parameters in standing|In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.
214332057|NCT04469361|OTHER|measurement of midfoot pressure distrubition|In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
214332058|NCT02357576|DRUG|Intralipid 20% I.V. Fat Emulsion|
214332059|NCT05598229|OTHER|Tik Tok|Encourage and do not restrict watching Tik Tok
214332060|NCT03661515|DRUG|Selinexor|"According to escalation level:~* Level -1: Selinexor 40 mg/day, once weekly~* Level 1: Selinexor 60 mg/day, once weekly~* Level 2: Selinexor 80 mg/day, once weekly~* Level 3: Selinexor 100 mg/day, once weekly"
214332061|NCT03661515|DRUG|fludarabine|fludarabine 30 mg/m2/day intravenously on days 1 to 4
214332062|NCT03661515|DRUG|idarubicin|idarubicin 10 mg/m2/day intravenously on days 1 to 3
214332063|NCT03661515|DRUG|cytarabine|cytarabine 2 g/m2/day intravenously on days 1 to 4
214332064|NCT03661515|DRUG|G-CSF|G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
214332065|NCT00128180|DRUG|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
214332066|NCT00128180|DRUG|Placebo|Placebo
214332067|NCT04820816|OTHER|pelvic tilt effect on balance, sensory integration and risk of fall|BIODEX balance system, Limits of stability test, Risk of Fall test, m-CTSIB test
214933602|NCT03951064|PROCEDURE|Intervention Spontaneous Breathing Trial (SBT) and Extubation|Patients in the Intervention group will undergo an SBT regardless of their PEEP level. The PEEP that generates a Ptp of 0 will be considered their optimal PEEP, and this will not be lowered for the SBT. The Intervention Group SBT will consist of a trial of a pressure support of 5 cm H2O and Optimal PEEP.
214933603|NCT03951064|PROCEDURE|Control Spontaneous Breathing Trial and Extubation|Patients in the Control group will undergo an SBT when they reach a PEEP ≤8 cm H2O. This is the current standard of care based on the SBT protocol at UNC Hospitals. SBT and extubation prior to meeting these criteria will be based on primary medical team's discretion and will be recorded for analysis and safety tracking.
215072437|NCT05804656|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
215072438|NCT05804656|DRUG|Botox®|Intramuscular injection Botox®
215072439|NCT02899507|DRUG|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
215072440|NCT01414023|BEHAVIORAL|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
214332068|NCT01073488|BEHAVIORAL|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
214332069|NCT01251484|DRUG|BIBF1120|Tablet 200 mg twice daily until progression
214332070|NCT02129361|BEHAVIORAL|Adapted Screening and Brief Intervention (Adapted SBI)|
214332071|NCT02129361|BEHAVIORAL|Screening & Education Attention Control|
214332072|NCT00567788|DRUG|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
214332073|NCT00567788|DRUG|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
214332074|NCT03363230|BEHAVIORAL|Mindfulness skills training|Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
214332075|NCT03363230|BEHAVIORAL|Interpersonal Effectiveness skills training|Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
214332076|NCT04613609|DEVICE|Electronic Cigarette containing nicotine|Non-smokers used an electronic cigarette containing nicotine
214332077|NCT04613609|DEVICE|Electronic Cigarette without nicotine|Non-smokers used an electronic cigarette without nicotine
214332078|NCT03266562|DIAGNOSTIC_TEST|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
214332079|NCT03266562|DIAGNOSTIC_TEST|F-18 FDG|Evaluate uptake of F-18 FDG in breast tissue
214486331|NCT06046898|DEVICE|non-invasive ventilation with or without resistance|non-invasive ventilation with or without resistance.
214332080|NCT00784446|DRUG|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
214332081|NCT01455116|PROCEDURE|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
214332082|NCT03101709|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
214332083|NCT03101709|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
214332084|NCT03101709|BIOLOGICAL|CART-19|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
214933604|NCT03951064|PROCEDURE|Intervention Weaning after Tracheostomy|Based on the use of optimal PEEP in this group, and the experience in the previous study protocol, the investigators will place patients in the Intervention group on Tracheostomy Collar Trial only with a speaking valve. This simulates the normal process of utilizing the upper airway to maintain lung inflation that is performed automatically when a patient does not have an artificial airway.
214332085|NCT00002335|DRUG|Emtricitabine|
214933605|NCT03951064|PROCEDURE|Control Weaning after Tracheostomy|The control group will be placed on Tracheostomy Collar Trial with no requirement for speaking valve. They may utilize a speaking valve if tolerated and desired, but there is no requirement as there is in the Intervention group.
215072441|NCT01414023|BEHAVIORAL|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
214332086|NCT03296163|DRUG|MB02 (Bevacizumab Biosimilar Drug)|15 mg/kg IV every 3 weeks on Day 1
214332087|NCT03296163|DRUG|EU-approved Avastin®|15 mg/kg IV every 3 weeks on Day 1
214332088|NCT03296163|DRUG|Carboplatin|Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles
214332089|NCT03296163|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
214332090|NCT00434668|DRUG|cisplatin/docetaxel|
214332091|NCT00434668|DRUG|cisplatin/vinorelbine|
214933606|NCT01198288|OTHER|domiciliary rehabilitation|a respiratory rehabilitation programme at the patient home
215072442|NCT00742989|OTHER|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
214332092|NCT05647512|DRUG|LM-305|Administered intravenously
214332093|NCT05647512|DRUG|Dexamethasone|Administered orally
214332094|NCT01000051|DRUG|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
214332095|NCT01000051|DRUG|Placebo|Once a day, orally for 8 weeks.
214332096|NCT03501797|BEHAVIORAL|Singing-based rehabilitation|The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.
214332097|NCT03501797|OTHER|Standard care|Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system
214332098|NCT00317681|DRUG|Tacrolimus ointment|
214332099|NCT04299711|OTHER|Exposed to the novel coronavirus disease 2019|Exposed to the novel coronavirus disease 2019
214332100|NCT05684679|OTHER|Incentive spirometer plus Chest physiotherapy|Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
214332101|NCT05684679|OTHER|Diaphragmatic breathing exercise plus Chest physiotherapy|Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
214332102|NCT04900103|OTHER|ITV-Pal|Use of new technologies for volunteering
214332103|NCT05596669|DRUG|Ketamine|to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
214332104|NCT00782652|DRUG|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
214332105|NCT00782652|DRUG|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
214332106|NCT04582422|OTHER|"Touch Therapy"|During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation
214332107|NCT00637169|OTHER|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
214332108|NCT02714049|BEHAVIORAL|sex therapy|60 minutes each time, in person or on the telephone
215072443|NCT00742989|OTHER|Sham OLT|Therapeutic massage performed
214332109|NCT02714049|DRUG|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
214332110|NCT05040763|DIAGNOSTIC_TEST|Buccal Swabc- Copan flocked swab|All participants will have a buccal swab sampled collected from the inside of the mouth either by themselves or by their caregiver
214332111|NCT05040763|DIAGNOSTIC_TEST|Standard of Care COVID-19 swab|All participants will receive a standard of care COVID-19 swab collected by a qualified healthcare professional
214332112|NCT05164705|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
214332113|NCT05164705|OTHER|Sham Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and breathe normal air (21 percent O2) for 30-minutes.
214332114|NCT03145727|DEVICE|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
214933607|NCT01198288|OTHER|Standard Care|As describe in the standard care arm
214933608|NCT00746707|DEVICE|1. Dermabond Topical Skin Adhesive 2-Octyl Cyanoacrylate|adhesive of perineal tears
214933609|NCT00746707|PROCEDURE|3. traditional suturing with vicryl rapid 2X0|suturing of perineal tears grade one with vicryl rapid 2X0
214332115|NCT03145727|DEVICE|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
214332116|NCT03145727|DEVICE|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
214332117|NCT05155735|PROCEDURE|Replantation|Surgical reattachment of a severed body part
214332118|NCT05155735|PROCEDURE|Primary wound closure|Primary wound closure with removal of exposed bone
214933610|NCT06187961|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
214933611|NCT06187961|DRUG|Lenvatinib plus cadonilimab|lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
214933612|NCT06620796|DRUG|Arm 1|Ivonescimab combined with Cadonilimab plus EC
215072444|NCT01497990|DRUG|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
214332119|NCT03840785|OTHER|Argentine tango|"Argentine tango sessions will consist of:~* Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~* Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling"
214332120|NCT04509700|DRUG|Parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
214332121|NCT04509700|DRUG|parsaclisib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
214332122|NCT04509700|DRUG|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
214933613|NCT06620796|DRUG|second-line group|AK112+AK104+paclitaxel
214933614|NCT00464516|DRUG|placebo|once daily for 14 days orally
214933615|NCT00464516|DRUG|Estetrol|once daily for 14 days orally
214933616|NCT05372055|OTHER|Semi-structure interviews|Semi-structured interview focusing on psychosocial impact of living with an IPC to be performed at 2 weeks and 6-8 weeks post IPC insertion
214933617|NCT02548351|DRUG|Obeticholic Acid|
214933618|NCT02548351|DRUG|Placebo|
214933619|NCT06142877|BEHAVIORAL|Social Media Use Reduction|Participants will be incentivized to reduce their social media use by a pre-specified percentage from baseline.
214933620|NCT01921712|DRUG|PUR0200|Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
214933621|NCT01921712|DRUG|PUR0200 Placebo|Randomized, single dose of inhaled placebo matched to PUR0200
214933622|NCT01921712|DRUG|Active comparator|Randomized single dose of inhaled active comparator product
214933623|NCT05040607|OTHER|Data Collection|"The first stage of the study:~Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL).~The second stage of the study~-Retrospective data of pulmonary function, respiratory muscle function, functional capacity before and after supervised inspiratory muscle training with POWERbreathe K5 device using tapered flow resistive loading and airway clearance techniques performed for 6 weeks in PCD with decreased respiratory muscle strength."
214933624|NCT05040607|OTHER|Data Collection|-Retrospective data collection of pulmonary function, respiratory muscle function, exercise capacity, physical fitness, and activities of daily living (ADL).
214933625|NCT01247051|PROCEDURE|Precoating|preoperative filling of heart lung machine with patients blood
214933626|NCT01247051|PROCEDURE|Standard priming|preoperative filling of heart lung machine with colloids
215072445|NCT00059943|DRUG|docetaxel|
215072446|NCT01345968|DRUG|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
215072447|NCT01345968|DRUG|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
215072448|NCT01885208|DRUG|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
215072449|NCT01885208|DRUG|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
215072450|NCT01974557|OTHER|Exercise|
215072451|NCT00673205|DRUG|Bicalutamide|150mg p.o. daily
215072452|NCT00673205|DRUG|Placebo|
215072453|NCT06643234|PROCEDURE|Ventral hernia repair|Comparative between both techniques
215072454|NCT01709422|DRUG|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
215072455|NCT01709422|DRUG|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
215072456|NCT01709422|DRUG|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
215072457|NCT01184313|PROCEDURE|aortic valve surgery with CPB|elective aortic valve surgery with CPB
215072458|NCT02164357|PROCEDURE|EVT (endovascular treatment )|
215072459|NCT02164357|PROCEDURE|IVT (intravenous thrombolytic therapy)|
215072460|NCT00370760|DRUG|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
215072461|NCT00370760|DRUG|placebo|
215072462|NCT06485856|BEHAVIORAL|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Evaluation of the pain level of patients who are followed in intensive care and cannot speak during the procedural procedure with 3 different methods.
215072463|NCT03004261|BIOLOGICAL|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
215072464|NCT03004261|DRUG|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
215072465|NCT03004261|DRUG|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
215072466|NCT00262236|DRUG|Aliskiren|
215072467|NCT05525091|OTHER|Feeding Evaluation|Feeding Evaluation with Device
215072468|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #1|Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
214933627|NCT00125242|BEHAVIORAL|Semantic Feature Analysis (SFA)Training|SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
214933628|NCT01664949|DRUG|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
214933629|NCT01664949|DRUG|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
215072469|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #2|Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
215072470|NCT04707989|OTHER|Ketone Free Placebo|Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
215072471|NCT04506216|OTHER|cohort|"During a regular follow-up visit, the following data will be collected:~* questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~* bio-electric impedance analysis~* insulin pump and sensor data collection"
215072472|NCT02539199|DRUG|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
214933630|NCT05577169|BEHAVIORAL|Mind-body skills|The purpose of mind-body medicine is to use conscious thoughts and actions to positively impact autonomic responses from the brain as well as coping mechanisms for life's stresses. Examples of mind-body skills include deep breathing exercises, meditation, drawing, guided imagery, journaling, affirmations, and biofeedback.
214933631|NCT05577169|BEHAVIORAL|Diabetes education|When children and adolescents are diagnosed with diabetes, education is typically focused on the parents; as our older adolescents prepare to transition to adult care with full responsibility of their health, the goal of short education sessions is to review the basics of T1D along with addressing each individual's needs and questions as they make this transition.
214933632|NCT00991757|DRUG|carisbamate|Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
214933633|NCT05220462|DRUG|Remimazolam|As per Remimazolam arm
215072473|NCT02539199|DRUG|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
215072474|NCT01320319|OTHER|Placebo|Capsule form, 960 mg to be taken three times a day.
215072475|NCT01320319|DIETARY_SUPPLEMENT|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
215072476|NCT05952765|PROCEDURE|Immediate implant|"* Local anesthesia Septanest special® will be administered prior to the procedure.~* Teeth extraction will be initiated by intrasulcular incision via 15 C blade without flap elevation.~* The tooth to be extracted will be luxated atraumatically using periotomes and thin straight elevator and delivered using forceps.~* The socket will be inspected for integrity, using a UNC graduated periodontal probe.~grafting material either experimental or control will be used to graft jumping gap."
215072477|NCT04883125|DRUG|Pioglitazone 15mg|pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
215072478|NCT06214130|DRUG|Sodium valproate 500 MG|oral intake
215072479|NCT06214130|DRUG|Valproic Acid 500 MG|oral intake
215072480|NCT03558334|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
214933634|NCT05220462|DRUG|Midazolam|As per Midazolam arm
214933635|NCT03003494|DRUG|Spiolto® Respimat®|observations taken in a period of approximately 6 weeks
214933636|NCT04447391|OTHER|Combined exercise program|Combined exercise programme, consisting of warm-up, aerobic exercise, resistance training, and cool-down, 3 days a week after school for 50 minutes from 17;30 under supervision by a trainer plus 300 kcal deficit diet
214933637|NCT04447391|OTHER|Control|300 kcal deficit diet only
214933638|NCT02414360|OTHER|Shortened Format|Shortened format of a systematic review
214933639|NCT02414360|OTHER|Full Length|Full length systematic review
215072481|NCT03558334|DRUG|No transplantation of mesenchymal stem cell|Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
215072482|NCT04131387|DEVICE|LIPUS-1|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
215072483|NCT04131387|DEVICE|LIPUS-2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
214332123|NCT04509700|DRUG|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
214332124|NCT06358079|PROCEDURE|Re-infusion of unwashed shed blood|Use of an isolated cardiotomy circuit for re-infusion of unwashed shed blood during off-pump coronary artery surgery
214933640|NCT04831827|OTHER|IVR Reminder|Participants will receive an interactive voice reminder (IVR) to complete mt-sDNA screening at day 7 and 21.
214933641|NCT04831827|OTHER|Phone call from research team|Patients will receive a scripted phone call from the research team to remind them to complete the mt-sDNA screening at day 7 and 21.
214332125|NCT00538005|BIOLOGICAL|bevacizumab|
214332126|NCT00538005|DRUG|oxaliplatin|
214332127|NCT00538005|DRUG|sorafenib tosylate|
214332128|NCT05151939|DIAGNOSTIC_TEST|Identification or discharge visualization of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos by an expert endoscopist|An expert endoscopist will select a dataset of mediastinal and abdominal EUS videos (one per patient). An expert endoscopist will identify or discharge visualization of the following organs correctly: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein.
214933642|NCT04831827|OTHER|EHR Portal message|Patients will receive an EHR patient portal message with a scripted message to remind them to complete the mt-sDNA screening at day 7 and 21.
214933643|NCT04687943|COMBINATION_PRODUCT|PELOID therapy, kinesio tape, exercise|126 patients diagnosed with lateral epicondylitis will be divided into 3 groups. Totally 15 sessions of peloid therapy for 42 patients in 1 group for 3 weeks, 5 days a week, 2 sessions of muscle and fascia correction techniques for 3 weeks in the second group for 3 weeks, and 3 sets per day for 42 patients in the third group for 3 weeks. You will be given 10 repetitive home workouts.
214933644|NCT03804229|DRUG|Butylphthalide soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills(100mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
214933645|NCT03804229|DRUG|Placebo soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
214933646|NCT01911481|OTHER|hydration|
214933647|NCT06260423|PROCEDURE|Experienced dentist using lateral compaction with bioceramic sealer.|Root canal treatment using bioceramic sealers.
214933648|NCT06260423|PROCEDURE|Unexperienced dentist using lateral compaction with bioceramic sealer.|Root canal treatment using bioceramic sealers.
214933649|NCT06260423|PROCEDURE|Experienced dentist using Single cone with bioceramic sealer.|Root canal treatment using bioceramic sealers.
214933650|NCT06260423|PROCEDURE|Unexperienced dentist using Single cone with bioceramic sealer.|Root canal treatment using bioceramic sealers.
214933651|NCT06682884|DRUG|Lorlatinib 100 mg|Eligible patients will be registered to receive oral lorlatinib 100mg qd for 6-8 weeks each during the neoadjuvant therapy phase
214933652|NCT03107364|OTHER|Hospital stay|Collection of hospital lengths of stay and readmissions
214933653|NCT00099684|DRUG|Ezetimibe|
214933654|NCT04898764|DRUG|Mometasone Furoate|Mometasone furoate nasal spray suspension, 50µg/actuation
215072484|NCT04527237|OTHER|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total. The session duration of an individual will be approximately 25 minutes.~Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application."
215072485|NCT04527237|OTHER|Placebo|Unlike acupressure, it will only be in contact with gloves, to reduce the electrical effect of touch, away from the actual acupressure points.
215072486|NCT01498575|BEHAVIORAL|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
214332129|NCT05151939|DIAGNOSTIC_TEST|Recognition of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos using artificial intelligence (AI)|Using the same previous dataset of mediastinal and abdominal EUS videos, the EUS-AI model will recognize the following organs: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein. Considering each patient (and not data frame videos) as the study unit, a contingency table per each mediastinal and abdominal organ/anatomic stricture will be designed.
214933655|NCT01131143|BEHAVIORAL|Provider Voice|A phone call with the pre-recorded doctor's voice will be made to their patients who have been pre-screened for obesity before the patient's appointments prompting the patients to ask about physical activity, nutrition, and weight loss.
214933656|NCT01131143|BEHAVIORAL|Generic Voice|A phone call with a pre-recorded neutral voice will be made to the doctor's patients who have been prescreened for obesity before their patient's appointments. The call will prompt them to ask ask their doctor about physical activity, nutrition, and weight loss.
214933657|NCT05231733|BIOLOGICAL|SPX-101|Subjects will receive SPX-101 on Day 1 of the first cycle, and will be evaluated for DLTs in the following 3 weeks. After the first cycle, subjects will continue treatment at dosing intervals as determined by safety and PK results. All patients will continue treatment until disease progression, development of unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion (maximum duration: 2 years).
214933658|NCT05969977|DRUG|PPI-1011|PPI-1011 is a liquid oil with light yellow to amber color, clear to slightly opalescent and flows readily at room temperature. It is insoluble in water and miscible with dichloromethane and liquid coconut oil. It is a synthetic glycerolipid derivative, comprised of an assembly of naturally-occurring products including glycerol backbone, an ether-linked hexadecyl group at sn1 position, an all-cis-4, 7, 10, 13, 16, 19-docosahexaenoyl group at sn2 position, and a lipoyl group at sn3 position. It was designed as a plasmalogen precursor and is similar in structure to naturally occurring alkyl-diacyl lipids with the primary difference being the presence of a lipoic acid moiety at the sn3 position. PPI-1011 is formulated in liquid coconut oil containing 0.1% 1-thioglycerol as an antioxidant.
214933659|NCT05969977|DRUG|Placebo|Placebo
214933660|NCT05641285|DEVICE|The OtoSight Middle Ear Scope|The OtoSight Middle Ear Scope is intended for use as an imaging tool for real-time visualization of the human tympanic membrane and fluid or air within the middle ear space. In the presence of middle ear fluid, the OtoSight Middle Ear Scope is used to visualize the fluid density. The OtoSight Middle Ear Scope is also used to provide surface images of the ear canal and tympanic membrane. It is indicated for use in children and adults.
214933661|NCT04517851|BIOLOGICAL|Elotuzumab|Given IV
214933662|NCT04517851|OTHER|Questionnaire Administration|Ancillary studies
215072487|NCT00396006|BIOLOGICAL|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
215072488|NCT01736072|PROCEDURE|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
214933663|NCT03792529|OTHER|detect gene mutations of ctDNA and ctRNA|Samples were collected from patients at baseline, during therapy and after disease progression, and gene mutations of ctDNA and ctRNA were detected in the samples.
214933664|NCT06649396|DIAGNOSTIC_TEST|Dried Blood Spot|Comparing analysis results between dried blood spot and plasma
214933665|NCT06649396|DIAGNOSTIC_TEST|Analysis on plasma|Analysis on plasma
215072489|NCT01736072|PROCEDURE|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
215072490|NCT00918164|DRUG|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
215072491|NCT02138409|DRUG|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
215072492|NCT02138409|DRUG|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
214933666|NCT06405789|OTHER|yoga practice|The researcher has a yoga certificate before the study. The intervention group participated in 15 weeks of yoga/awareness activities led by the researcher. The yoga curriculum for the use of yoga in the classroom had been previously studied with nursing students and permission was obtained for its use in this study \[11\]. The course content consists of 1.5 hours/per week (theoretical: 30 minutes; practical: 60 minutes) Each yoga session includes 5 minutes of breathing (pranayama) and warming up, 40 minutes of postures (asanas), 5 minutes of breathing (pranayama), 5 minutes of corpse pose (shavasana).In addition, to develop mindfulness, after the class, students were offered daily practices that enable a mindfulness-based approach to life events. The students participated in activities such as yoga practice, breathing and relaxation exercises, meditation practices with instructor notes and resources.
215072493|NCT06130774|OTHER|Retro walking and conventional|Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue his retro-walk for 20 minutes
215072494|NCT06130774|OTHER|conventional therapy|Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
215072495|NCT05369520|DEVICE|TESCoN device - Thoracic stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord (T7-T12, Group 1).
215072496|NCT05369520|DEVICE|TESCoN device - Lumbosacral stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord (L1 - L3, Group 2).
215072497|NCT04783779|DEVICE|Implant of STARgraft-2 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
214332130|NCT00414050|BIOLOGICAL|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
214332131|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
214332132|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
214332133|NCT01675180|OTHER|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
214332134|NCT01675180|OTHER|Control|No intervention
214332135|NCT01994512|PROCEDURE|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
214332136|NCT01994512|PROCEDURE|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
214332137|NCT06165068|DRUG|Aspirin 81Mg Ec Tab|Patients take aspirin 81 mg per day.
214332138|NCT06165068|DRUG|Clopidogrel|Patients take clopidogrel 75 mg per day.
214332139|NCT06165068|DRUG|N-acetylcysteine|Patients are given N-acetylcysteine 600 mg per day.
214332140|NCT06200805|BEHAVIORAL|tai ji quan|24-Style Taijiquan as an Intervention for College Students with Insomnia
214332141|NCT05731219|BIOLOGICAL|B7-H3 target, CAR gene modified gdT cell injection|After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
214955389|NCT03726307|BIOLOGICAL|DCreg:2.5 to 5.0 million cells/kg+SOC|"DCreg 2.5 to 5.0 million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
214332142|NCT04683055|PROCEDURE|Phacoemulsification combined with trabeculectomy|Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
214332143|NCT04683055|PROCEDURE|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
214332144|NCT03495908|DEVICE|VGo|Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
214332145|NCT02097992|DRUG|Roflumilast Placebo|Placebo pill
214332146|NCT02097992|DRUG|Roflumilast|500 Ug ORAL TABLET
214933667|NCT06621355|OTHER|Physical fitness test: Progressive intervalic test|"An incremental interval test of 4\&#39; of work for 1\&#39; of rest will be performed at an individual intensity below the aerobic threshold. At the end of the rest minute, the load shall be increased slightly. In order to be as adjusted and individualised as possible, the subjective physical condition level stated by the patient during the sociodemographic data collection shall be taken as a reference for the establishment of the initial load, being a value of power (W) in cycle ergometer and speed (km/h) in treadmill. Never less than 50W or 6 km/h, respectively.~The minimum incremental values will be 25W or 0.5km/h until you are unable to complete a full interval. An incomplete interval shall also be recorded and analysed.~During the one minute rest period, as will have been well emphasised during the explanation of the test, no part of the body may be moved at all, so at the end of the 4 minutes of work, the evaluator will count down for the patient to get ready and remain stil"
214933668|NCT05234125|BEHAVIORAL|Better|It is a nonpharmacologic sleep intervention to improve maternal glucose metabolism in African American Pregnant Women (AAPW). Sleep BETTER is composed of sleep hygiene practices and cognitive-behavioral principles.
214332147|NCT05389592|PROCEDURE|Active tDCS and cognitive training|Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
215072498|NCT03469986|DEVICE|Marcus Autism Center Investigational Device|This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.
215072499|NCT00764387|DRUG|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
215072500|NCT00764387|DRUG|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
215072501|NCT01419613|BEHAVIORAL|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
215072502|NCT01419613|BEHAVIORAL|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
215072503|NCT05960331|BEHAVIORAL|Autonomy supported learning|The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
215072504|NCT05960331|BEHAVIORAL|Practice with predetermined feedback|Learners practice the motor task, while the feedback is provided according to their counterpartner
215072505|NCT04723641|OTHER|functional training exercises|progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
214332148|NCT05389592|PROCEDURE|Sham tDCS and cognitive training|Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
214332149|NCT05854693|DEVICE|transCranial direct current stimulation|The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS
214332150|NCT05854693|DEVICE|sham stimulation|The sham group consisted of 10 daily 20-min sessions of sham stimulation
214332151|NCT03060824|OTHER|Blood sampling|To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.
215072506|NCT02347553|OTHER|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
215072507|NCT00569244|DRUG|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
215072508|NCT00569244|DRUG|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
215072509|NCT05080855|PROCEDURE|modified Millard technique vs Tennison-Randall technique|evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
215072510|NCT01571128|OTHER|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
215072511|NCT01571128|OTHER|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
215072512|NCT01571128|DRUG|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
215072513|NCT01571128|BEHAVIORAL|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
215072514|NCT01972308|BEHAVIORAL|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
214332152|NCT00451763|DRUG|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
214933669|NCT05234125|BEHAVIORAL|Birth Prep|The intervention involves training about pregnancy-related issues, and follow up
214332153|NCT00079547|BEHAVIORAL|Low-calorie diet|low-calorie diet
214332154|NCT00079547|BEHAVIORAL|low-carbohydrate diet|low-carbohydrate diet
214332155|NCT00062244|BIOLOGICAL|oblimersen sodium|Given IV
214332156|NCT05303805|DRUG|Sevoflurane|Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
214332157|NCT05303805|COMBINATION_PRODUCT|Cyteal|Rinsing and cleaning of ulcer.
214332158|NCT05468398|DEVICE|Soothe VR|The Soothe VR system is manufactured by Applied VR. It is a HIPAA-compliant platform and has been validated by randomized control trials. It has not yet been reviewed by the FDA.
214332159|NCT01862172|OTHER|Additional MRI|
214332160|NCT04634071|DRUG|Varenicline|Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.
214332161|NCT04634071|DRUG|Bupropion|Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.
214332162|NCT04634071|DRUG|Long-acting nicotine replacement therapy|Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.
214332163|NCT04634071|BEHAVIORAL|Low-intensity counseling|A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.
214332164|NCT04634071|BEHAVIORAL|High-intensity counseling|A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.
214332165|NCT04634071|OTHER|No nicotine replacement therapy|Participants in this group will not receive per required need nicotine replacement therapy.
214332166|NCT04634071|DRUG|Nicotine Replacement Products|Participants in this group will receive per required need nicotine replacement therapy.
214332167|NCT01397695|DRUG|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
214332168|NCT05065125|DEVICE|digital single-operator cholangioscopy|"1. Duodenoscope passes through esophagus and stomach to the papilla of Vater~2. SpyScope DS Catheter passes through the duodenoscope and into common bile duct~3. After direct visualization of anastomosis site stricture, guidewire is passed through SpyScope DS Catheter above the stricture site."
214332169|NCT02572050|PROCEDURE|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
214933670|NCT06145698|DEVICE|Cross-frequency transcranial alternating current stimulation via the Neuroelectrics Starstim 32 transcranial electric stimulation device|Stimulation will be delivered via the Neuroelectrics Starstim 32 transcranial electric stimulation device, an investigational electrical non-invasive brain stimulation device that is being used for clinical and translational research.
214933671|NCT02889198|BEHAVIORAL|Go NAP SACC|Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
214933672|NCT00326781|DRUG|Nicoderm Transdermal Patch|The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
214933673|NCT00326781|DRUG|Nicotine Nasal Spray|8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
214933674|NCT05288387|PROCEDURE|Spinal cord stimulation|High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord and this activation leads to blood pressure elevation.
214933675|NCT02768441|DRUG|Dexamphetamine|Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
214933676|NCT04169672|DRUG|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
214332170|NCT01158625|OTHER|Change of time of administration|Change of time of administration
214332171|NCT00203450|DRUG|Zonegran|zonisamide
214332172|NCT00203450|DRUG|Placebo|Placebo pill
214332173|NCT01769885|DRUG|tivozanib|Given PO
214933677|NCT04169672|DRUG|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
214933678|NCT00192101|DRUG|gemcitabine|
214933679|NCT00192101|DRUG|cisplatin|
214933680|NCT00606840|BEHAVIORAL|large changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
214933681|NCT00606840|BEHAVIORAL|small changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
215072515|NCT01972308|BEHAVIORAL|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
214332174|NCT01769885|PROCEDURE|therapeutic conventional surgery|Undergo nephrectomy
214332175|NCT02386943|DRUG|Sitagliptin|100mg po once.
214332176|NCT02386943|DRUG|Saxagliptin|5mg po once.
214332177|NCT02386943|DRUG|Blank control|No medication is taken.
214332178|NCT00940303|DRUG|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
214332179|NCT00940303|DRUG|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
214332180|NCT00940303|DRUG|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
214332181|NCT00940303|DRUG|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
214332182|NCT00940303|DRUG|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
214933682|NCT05160038|DEVICE|Embodied virtual reality|An immersive headmounted display visually depicts a relaxing woods scene, coupled with a virtual avatar that either shows bodily illusions or no bodily illusions
214933683|NCT02189655|PROCEDURE|bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
214933684|NCT04489849|DRUG|Apixaban 2.5 MG|apixaban 2.5mg BID for 3 months in experimental group
214933685|NCT04489849|OTHER|Active Control|Medication other than anticoagulation
214933686|NCT04264117|PROCEDURE|FlexAbility (Mesh-like irrigated tip catheter) group|"1. AF catheter ablation (PV isolation and linear ablations)~2. 30 sec ablation in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 13mL/min~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines"
214933687|NCT04264117|PROCEDURE|TactiCath (Contract force monitoring catheter) group|"1. AF catheter ablation (PV isolation and linear ablations)~2. contact force \>10g, target force-time integral 400 in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 15mL/min at 30W ablation, 30mL/min at 35W ablation~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines"
215072516|NCT03645525|DRUG|Human Umbilical Cord-derived Mesenchymal stem cell|The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10\^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
214933688|NCT00393263|DRUG|pimecrolimus and clobetasol|
214933689|NCT00393263|DRUG|clobetasol 0.05% cream|twice daily for three months
215072517|NCT03645525|DRUG|placebo|saline
215072518|NCT03691844|DRUG|AMZ001|diclofenac gel
215072519|NCT03691844|DRUG|Placebo|Placebo
215072520|NCT03691844|DRUG|Comparator|diclofenac gel
215072521|NCT02709187|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
215072522|NCT02709187|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
215072523|NCT02709187|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
215072524|NCT04991727|BEHAVIORAL|recruitment maneuvers|"Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery"
214332183|NCT02660918|DRUG|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
214332184|NCT02660918|OTHER|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
214332185|NCT02002234|PROCEDURE|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
214332186|NCT02002234|PROCEDURE|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
214933690|NCT05096260|BEHAVIORAL|Motivational Interviewing based SMS/MMS and web content|Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
214332187|NCT06482047|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
214332188|NCT06482047|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
214332189|NCT06482047|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
214933691|NCT01632150|BIOLOGICAL|Elotuzumab|Powder for solution, 400-mg vials, for infusion
214933692|NCT01632150|BIOLOGICAL|Thalidomide|50-mg capsules administered orally
214933693|NCT01632150|BIOLOGICAL|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
214933694|NCT01632150|BIOLOGICAL|Cyclophosphamide|50-mg tablets administered orally
214332190|NCT02643524|BEHAVIORAL|Nutrition and Exercise Counseling|Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
214332191|NCT02643524|BEHAVIORAL|Control|Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
214332192|NCT01493271|DRUG|Placebo|Placebo to RO5093151
214332193|NCT01493271|DRUG|RO5093151|oral doses twice daily for up to 28 days
214332194|NCT01093404|PROCEDURE|Thrombus aspiration|Aspiration of thrombus material before angioplasty
214332195|NCT05390489|DRUG|Cascara pulp arabica gayo coffee cream|extract of cascara pulp arabica gayo coffee
214332196|NCT01044810|DRUG|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
214332197|NCT00780572|BEHAVIORAL|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
214332198|NCT06323642|DIETARY_SUPPLEMENT|probiotic containing Lactobacillus rhamnosus GG.|probiotic containing Lactobacillus rhamnosus GG will be given daily for 3 days
214332199|NCT06323642|OTHER|placebo|milk as placebo
214332200|NCT02405416|PROCEDURE|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
214332201|NCT02405416|PROCEDURE|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
214933695|NCT03203408|DEVICE|OSTENIL PLUS|Injection into the joint cavity of the most painful knee
214933696|NCT03203408|DEVICE|SYNVISC-ONE|Injection into the joint cavity of the most painful knee
214933697|NCT04288141|OTHER|Acquisition of blood samples and tumour tissue samples (biopsies)|Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.
215072525|NCT02357693|DRUG|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
214332202|NCT02405416|PROCEDURE|Portal triad clamping|Portal triad are clamped in hepatectomy.
214332203|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
214332204|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
214332205|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
214332206|NCT01469065|DRUG|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
214332207|NCT01469065|DRUG|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
214332208|NCT03102476|DRUG|Humalog|Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
214332209|NCT00677495|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten-free diet
214332210|NCT05683600|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
214332211|NCT05683600|BIOLOGICAL|Placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
214332212|NCT00433693|DRUG|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25\~300μg(i.v.)/4 week
214332213|NCT02681874|BEHAVIORAL|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
214332214|NCT02681874|BEHAVIORAL|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
214332215|NCT01159418|DRUG|Panobinostat (LBH589), Carboplatin and Paclitaxel|"1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."
214332216|NCT05217368|OTHER|mandala painting|In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
214332217|NCT05217368|OTHER|antenatal education|Routine antenatal education will be given.
214933698|NCT05171244|BEHAVIORAL|virtual reality training|training of multisensory processing capacities in virtual reality in addition to usual program of interventions in usual care
214933699|NCT05171244|BEHAVIORAL|usual care|usual program of interventions in usual care
214332220|NCT03565185|OTHER|robot-assisted gait training|Investigators will use robot-assisted gait training for rehabilitation of stroke
214332221|NCT03565185|OTHER|placebo|Investigators will use only conventional treatment without robot-assisted gait training
214332222|NCT04595838|DEVICE|Chemo Mouthpiece|Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis
214332223|NCT04595838|OTHER|Best Supportive Care only|Standard Oral care for Chemotherapy
214332224|NCT02012946|DRUG|Levosimendan|patient receiving levosimendan
214332225|NCT02012946|DRUG|Dobutamine|patient receiving dobutamine
214933700|NCT00900640|PROCEDURE|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
214933701|NCT02607852|DEVICE|iPads|The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
214933702|NCT00219570|DRUG|clindamycin|
214933703|NCT00219570|DRUG|nadifloxacin|
214933704|NCT01170637|DRUG|Ibuprofen|200 mg oral administration (RhinAdvil(R))
214933705|NCT01170637|DRUG|Ibuprofen|200 mg oral administration (BI product)
214332226|NCT03957174|DRUG|Reboxetine|Single dose used to increase central norepinepherine
214332227|NCT03957174|DRUG|Rivastigmine|Single dose to increase central acetylcholine
214332228|NCT03957174|DRUG|Placebo oral tablet|Single dose as control condition
214332229|NCT02697019|BEHAVIORAL|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
214332230|NCT02432365|DRUG|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
214332231|NCT02432365|DRUG|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
214332232|NCT02432365|PROCEDURE|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
214332233|NCT03495024|DRUG|Varenicline|Oral medication approved to facilitate smoking cessation
214332234|NCT03835442|DRUG|Baclofen|baclofen 10mg tid for 4 weeks
214332235|NCT03835442|OTHER|Placebos|placebo tid for 4 weeks
214933706|NCT01170637|DRUG|Pseudoephedrine-HCl|30 mg oral administration (BI product)
214933707|NCT01170637|DRUG|Pseudoephedrine-HCl|30 mg oral administration (RhinAdvil(R))
214933708|NCT06620900|OTHER|Integrated Model of Care|The Integrated Model of Care was developed and piloted by the study team provide support for individuals seeking care in an interdisciplinary intensive outpatient program for mild traumatic brain injury to receive support for co-occurring substance use-related needs.
214933709|NCT01552148|OTHER|USguided bilateral TAP block|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
214332236|NCT00578565|DRUG|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
214332237|NCT01430065|DRUG|ASP015K|oral
214332238|NCT01430065|DRUG|Tacrolimus|oral
214933710|NCT01552148|DRUG|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8 min)
214933711|NCT01552148|DRUG|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8min)
214933712|NCT02143791|PROCEDURE|Burst and Tonic stimulation|
214933713|NCT04142320|DEVICE|closed-loop rTMS|Delivers patterned magnetic stimulation in closed-loop fashion
214332239|NCT05772065|BEHAVIORAL|CDC/NTCA guidelines only|The control group will have a link to US guidelines only.
214332240|NCT05772065|BEHAVIORAL|LTBI ASSIST and CDC/NTCA guidelines only|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool.
214332241|NCT01752933|DRUG|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
214332242|NCT01918475|DRUG|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
214332243|NCT01918475|DRUG|Placebo|1ml of NaCl 0.9% is administered intravenously
214332244|NCT06147505|BIOLOGICAL|XS005 Injection|Treatment on this study includes XS005 infusions over an 16 week period. Phase 1： dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D).
214332245|NCT02360618|DRUG|Metformin|See Group Description
214332246|NCT02360618|DRUG|Simvastatin|See Group Description
214332247|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
214332248|NCT05645627|DRUG|placebo /IBI112|placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
214332249|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
214332250|NCT02203591|DRUG|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
214332251|NCT02203591|DRUG|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
214332252|NCT02203591|DRUG|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
214332253|NCT02203591|DRUG|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
214332254|NCT03279276|PROCEDURE|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
214332255|NCT04629664|DRUG|FX-322|Active Comparator
214332256|NCT04629664|OTHER|Placebo|Placebo
214332257|NCT01142739|OTHER|Clinical variables|Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
214332258|NCT01142739|OTHER|Clinical variables|Demography, Biological variables.
214332259|NCT01142739|OTHER|Clinical variables|Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
214332260|NCT03832959|DEVICE|EnsoETM|The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
214332261|NCT00523185|DRUG|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
214332262|NCT00523185|DRUG|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
214332263|NCT04298710|BEHAVIORAL|Arm Cycling|20 minutes of arm cycling exercise at light to moderate intensity.
214332264|NCT04298710|BEHAVIORAL|Leg Cycling|20 minutes of leg cycling exercise at light to moderate intensity.
214332265|NCT04298710|BEHAVIORAL|Sitting|Remain seated for 20 minutes.
214332266|NCT02554110|DEVICE|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
214332267|NCT02554110|DEVICE|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
214332268|NCT06577298|BIOLOGICAL|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose|4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants
214332269|NCT06577298|BIOLOGICAL|VLP-Polio medium dose|4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants
214332270|NCT06577298|BIOLOGICAL|VLP-Polio high dose|1 dose of VLP-Polio vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants
214332271|NCT06577298|BIOLOGICAL|Vaccine Poliomyelitis Inactivated (IPV)|1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants
214332272|NCT05914727|DIAGNOSTIC_TEST|eNose|Collection of breath profile with eNose
214332273|NCT05914727|DIAGNOSTIC_TEST|Volatile exhaled breath sample|Collection of exhaled breath in Tedlar bag
214332274|NCT05914727|DIAGNOSTIC_TEST|Condensate sample|Collection of exhaled breath condensate with EcoScreen
214332275|NCT05228782|OTHER|HOW R U? Intervention|HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
214332276|NCT02743572|OTHER|iron sucrose-1|iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
214332277|NCT02743572|OTHER|iron sucrose-2|iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
214332278|NCT02743572|OTHER|iron sucrose-3|iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
214332279|NCT02743572|OTHER|iron sucrose-4|iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
214332280|NCT03022617|DRUG|Apremilast|
214332281|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
214332282|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
214332283|NCT01706250|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
214332284|NCT01706250|OTHER|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
214332285|NCT01706250|OTHER|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
214933714|NCT04142320|DEVICE|open-loop rTMS|Delivers patterned magnetic stimulation in open-loop fashion
214933715|NCT04142320|DEVICE|sham rTMS|Delivers placebo magnetic stimulation
214933716|NCT04516382|DRUG|PTG-300|Active drug
214933717|NCT06620991|DRUG|Phentolamine|A loading dose of 1-5 mg IV bolus over 1 minute is given followed by an IV infusion of a rate of 0.1-2 mg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over a volume of 10ml
214933718|NCT06620991|DRUG|Esmolol|A loading dose of 1 mg/kg IV infused over 1 minute is given followed by an IV infusion of 0.15-0.3 mg/kg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over total volume of 10ml
214332286|NCT01706250|OTHER|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
214933719|NCT06623760|DEVICE|Desk and chair adaptation interventions|Adjustment of the height of tables and chairs to the height of each pupil in accordance with Functional sizes and technical requirements of chairs and tables for educational institutions (GB/T 3976--2014）, with a duration of intervention of one year。
214933720|NCT05768191|DRUG|premix insulin human isophane suspension and insulin human|Sequence (Premix first, then Humulin N + Humulin R): Subjects randomized to this sequence will receive premix insulin, twice per day for 16 weeks. After the first 16 weeks, subjects will cross over to the Humulin N plus Humulin R sequence for a further treatment of 16 weeks
214933721|NCT05768191|DRUG|Humulin N plus Humulin R|Sequence (Humulin N + Humulin R first, then Premix): Subjects randomized to this sequence will receive basal bolus insulin scheme with Humulin N (twice daily) and Humulin R (before meals) for 16 weeks. After the first 16 weeks, subjects will cross over to the Premix sequence for a further treatment of 16 weeks
215072526|NCT01690559|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
215072527|NCT03546166|DRUG|Picato 0.05% Topical Gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
215072528|NCT05501886|DRUG|Gedatolisib|Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
215072529|NCT05501886|DRUG|Palbociclib|Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
215072530|NCT05501886|DRUG|Fulvestrant|Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
215072531|NCT05501886|DRUG|Alpelisib|Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
215072532|NCT05046717|DEVICE|ADAMTS13 Activity Assays|"In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits:~1. HemosIL AcuStar ADAMTS13 Activity Assay (Instrumentation Laboratory, Bedford, Massachusetts, United States)~2. ELISA, DG-EIA ADAMTS13 Activity (Diagnostic Grifols®, Spain)~3. FRETS-VWF73 for ADAMTS13 Activity Assay~Three kits will be used with all patients."
215072533|NCT00905762|DRUG|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
215072534|NCT00905762|DRUG|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
215072535|NCT00905762|DRUG|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
215072536|NCT04493541|DRUG|BMS-986256|Specified Dose on Specified Days
215072537|NCT04493541|OTHER|BMS-986256 Placebo|Specified Dose on Specified Days
215072538|NCT01062724|OTHER|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
215072539|NCT02851797|DRUG|givinostat|"The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below:~Givinostat or placebo starting dose~* \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid~* \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid~* \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid~* \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid~* \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid~* \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid~* \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid~* \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid~* \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid"
215072540|NCT02851797|DRUG|placebo|The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
215072541|NCT00203918|BEHAVIORAL|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
215072542|NCT00203918|BEHAVIORAL|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
215072543|NCT03086291|DRUG|Simvastatin|Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
215072544|NCT03897153|DEVICE|SONAS® Ultrasound Device|The SONAS® Ultrasound Device is intended for non-invasive transcranial ultrasound and used with a commercially approved contrast agent (e.g., Lumason®/SonoVue®).
214332287|NCT00871559|DRUG|REGN421(SAR153192)|
214332288|NCT03678181|BEHAVIORAL|Information Resources|The investigators will provide a HIV-related content as the attention-control condition.
214332289|NCT03678181|BEHAVIORAL|Social Support|The investigators will provide evidence-based answers to users' health questions, including linkage to care.
214933722|NCT04890977|BEHAVIORAL|Talking Story|A culturally grounded modular intervention to increase mental health treatment-seeking among Pacific Islanders.
215072545|NCT02894957|DRUG|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
215072546|NCT03852992|DRUG|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
214933723|NCT05548998|OTHER|General anesthesia with low fresh gas flow|General anesthesia with a fresh gas flow lower than 1L/min for the maintenance phase of anesthesia
215072547|NCT03852992|DRUG|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
215072548|NCT03852992|DEVICE|Laser|Fractional ablative, deep mode, 5% fractional coverage
215072549|NCT03852992|DRUG|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
215072550|NCT03852992|DRUG|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
215072551|NCT03852992|DRUG|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
215072552|NCT03386136|DRUG|100% Oxygen|To provide hospitalized ileus or pseudo-obstruction patient with 100% oxygen via non-rebreather face mask, for 6 hours
215072553|NCT05664659|DRUG|Oxytocin + misoprostol|600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
215072554|NCT05664659|DRUG|Carbetocin|100 micrograms carbetocin
215072555|NCT04361409|DRUG|Rituximab|375mg/m2 on Day-14 and Day-7
215072556|NCT04361409|DRUG|Cisplatin|70mg/m2 on Day1
215072557|NCT04361409|DRUG|Gemcitabine|1000mg/m2 on Day8
215072558|NCT04820010|DRUG|Topical Insulin|Patients were administered eyedrops enriched with insulin
215072559|NCT04564807|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
215072560|NCT04564807|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
215072561|NCT03570918|BIOLOGICAL|MGD014|HIV-1 x CD3 bispecific DART molecule
215072562|NCT00943475|PROCEDURE|circumcision|circumcision by plastbell
215072563|NCT06479265|OTHER|Phyical/Cognitve Exercise|Participants will report to the CERC and review informed consent with a study investigator. Eligibility assessments (PAR-Q, WCST64, Medical History) will be done post-consent. Data collected will include age, body composition, gender, aerobic capacity, chronic medication use, and treated pathologies. All measurements will occur during one visit. Participants will lay supine for 5 minutes to measure resting heart rate (HR) using an HR monitor. This resting HR, with age-predicted HR max, will determine HR reserve (HRR). Participants will master the WCST64 and identify walking pace on the Blue Goji treadmill. They will complete a baseline 10 Meter Walk Test, followed by the digital WCST64 under 7 conditions, ending with a post-intervention 10 Meter Walk Test.
215072564|NCT05912881|OTHER|Olfactory training|Participants perform olfactory training using sticks filled with scented essential oils.
215072565|NCT05912881|OTHER|Placebo training|Participants perform olfactory training using sticks filled with unscented medium chain triglycerides.
215072566|NCT04547907|DRUG|Nab-paclitaxel+ trastuzumab+ patuzumab|Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
215072567|NCT04547907|DRUG|Docetaxel+ carboplatin+ trastuzumab + patuzumab|Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
215072568|NCT04295681|DRUG|MMH-MAP|Oral administration
215072569|NCT04295681|DRUG|Placebo|Oral administration
215072570|NCT05718271|OTHER|Explicit instructions before extinction|"Shocks will no longer be administered during the next phase."
214933724|NCT05548998|OTHER|General anesthesia with high fresh gas flow|General anesthesia with a fresh gas flow equal to or higher than 1L/min for the maintenance phase of anesthesia
214933725|NCT05548998|DIAGNOSTIC_TEST|Mini mental state examination|6 category and 30-point test to inquire patient's cognitive function
214933726|NCT05548998|DIAGNOSTIC_TEST|Visual Analogue Scale|The patient's self-reported pain intensity according to a visual scale between 0 and 100
214933727|NCT03051516|OTHER|Laboratory Biomarker Analysis|Correlative studies
214933728|NCT03051516|OTHER|Placebo Administration|Given IM
214933729|NCT03051516|OTHER|Questionnaire Administration|Ancillary studies
214933730|NCT03051516|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
214933731|NCT05605639|DRUG|Bupivacaine|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
214933732|NCT05605639|OTHER|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
214933733|NCT05262712|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the feet of participants via C2 tactors (diameter: 3.05 cm, height: 0.79 cm, operating frequency: 200-300 Hz see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
215072571|NCT05718271|OTHER|Explicit instructions after extinction|"Tomorrow no shocks will be administered."
215072572|NCT04402632|PROCEDURE|Surgical Management|SDH Evacuation (Control)
215072573|NCT04402632|DEVICE|Surgical Management + Treatment|SDH Evacuation + Onyx™ LES Embolization
215072574|NCT04402632|OTHER|No Treatment|Observation Only (Control)
215072575|NCT04402632|DEVICE|Treatment|Onyx™ LES Embolization
215072576|NCT06554535|DRUG|Serplulimab，Platinum-based Chemotherapy，Aspirin|Participants will receive an induction therapy consisting of Serplulimab (4.5 mg/kg IV on Day 1), Carboplatin (AUC 5 IV on Day 1) or Cisplatin (75 mg/m² IV on Day 1), Etoposide (100 mg/m² IV on Days 1-3), and Bayer Aspirin (100 mg PO daily). This induction phase will be administered every 3 weeks for 4 cycles. Following the induction phase, participants will transition to a maintenance therapy phase where they will continue to receive Serplulimab (4.5 mg/kg IV on Day 1, every 3 weeks) and Bayer Aspirin (100 mg PO daily) until disease progression or intolerable toxicity.
215072577|NCT05221567|BEHAVIORAL|Psychotherapy|Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)
215072578|NCT01179828|DRUG|Oxycodone 15mg|15mg single administration p.o.
215072579|NCT01179828|DRUG|Clobazam|20mg single administration p.o.
215072580|NCT01179828|DRUG|Imipramine|75mg single administration p.o.
215072581|NCT01179828|DRUG|Tolterodine|1 mg single administration p.o.
215072582|NCT04353999|PROCEDURE|Socket sealing by diode laser photocoagulation|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed using 980 nm diode laser photocoagulation applied in a non-contact mode with a poer output of 1 watt in a continuous wave mode for 3-5 minutes
214933734|NCT05262712|OTHER|Placebo Control|Devices mounted, no stimulation
214332290|NCT03678181|BEHAVIORAL|HIV Testing|The investigators will provide opportunities for participants to get tested through HIV home test kits.
214332291|NCT01565291|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
214332292|NCT01416012|BEHAVIORAL|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
214673577|NCT03412227|BEHAVIORAL|The Coping Cat Program for Youth Anxiety Disorders|"The Coping Cat program (Kendall \& Hedtke, 2006; Kendall, Choudhury, Hudson, \& Webb, 2002) has received substantial empirical support for its efficacy in both children (9-13 years old) and teens (12 - 17 years old) (Kendall, 1994; Kendall et al., 1997; Kendall et al., 2008) and involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward."
214673578|NCT03412227|OTHER|14-week waitlist (WL) condition|Youth assigned to the 14-week WL will receive no specific therapeutic services from study therapists during the 14-week WL period. However, participants will be assigned a WL Liaison whom families can contact in the event of clinical deterioration. The Liaison will also be responsible for sending links to, and monitor completion of, weekly and mid-WL online surveys (Qualtrics). Independent Evaluators will conduct post-WL diagnostic interviews at the completion of the 14-week WL. WL participants will receive compensation for completion of assessments. After completion of the WL, participants will be invited to continue in the study and be randomly assigned to one of the three behavioral treatments (IBAT, PASCET, or Coping Cat).
214673579|NCT03606746|BIOLOGICAL|MDR-103|MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
214673580|NCT01183858|DRUG|Erlotinib [Tarceva]|Single daily oral dose
214673581|NCT00389415|DRUG|Vildagliptin|
214933735|NCT04477044|OTHER|Study Group|GoPro Hero4 to be mounted on the participant's forehead while performing intubation on a manikin.
214933736|NCT04308980|DIETARY_SUPPLEMENT|Specialized product for medical nutrition (SPP-1)|"Patients randomly allocated to this group will use specialized product for medical nutrition (SPP-1). This product contains: soy protein, whey protein concentrate, microcapsulated rapeseed oil, maltodextrin, inulin, Polydextrose, soy lecithin, potassium citrate, magnesium lactate, ω-3 PUFA (docosahexaenoic acid), sweetener mixture (stevia extract, erythritol), natural flavor Yogurt-vanilla, calcium carbonate, betaine hydrochloride, natural flavor raspberry, vitamin premix (vitamins a, e, C, D3, B1, B2, B6, B12, PP, folic acid, Pantothenic acid, K1, Biotin), beet juice concentrate, carrageenan, mineral premix (iron, zinc, copper, manganese, iodine, selenium, molybdenum, chromium), alpha-lipoic acid. The product is packed in approved by sanitary rules bags by 30 g. The instant drink obtained by the mixture of the bag content with warm (30-60C) water should be used immediately after being prepared. The daily dose is 1 pack TID"
214933737|NCT04308980|BEHAVIORAL|individualized diet|All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine
215072583|NCT04353999|PROCEDURE|socket sealing with dense polytetrafluroethylene membrane|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed by a non-resorbable dPTFE membrane that is stabilized by suturing to the soft tissue margins of the socket
215072584|NCT00803400|DRUG|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
214332293|NCT01416012|BEHAVIORAL|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
214332294|NCT01416012|BEHAVIORAL|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
214332295|NCT01416012|BEHAVIORAL|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
214332296|NCT06094348|PROCEDURE|Endonasal osteotomy|Patients will undergo median-oblique and lateral osteotomy, with conventional 2 mm guarded, straight osteotome.
214673582|NCT00098345|DRUG|ZD6474 (vandetanib)|oral once daily tablet
214673583|NCT00038194|DRUG|imatinib mesylate|
214673584|NCT00038194|DRUG|docetaxel|
214673585|NCT02241018|DRUG|CD25 monoclonal antibody|
214673586|NCT02241018|DRUG|calcineurin inhibitors|
214673587|NCT02241018|BIOLOGICAL|MSCs|
214673588|NCT02094105|PROCEDURE|Endoscopy examination with iodine staining|Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
214673589|NCT00887445|DRUG|SLV341|5 - 1000mg once daily
214673590|NCT00887445|DRUG|placebo|
214673591|NCT03690622|DRUG|Dexmedetomidine|Instillation of eyedrops
214673592|NCT03690622|DRUG|Balanced salt solution|instillation of eyedrop
214673593|NCT04332692|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
214673594|NCT04332692|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
214673595|NCT04332692|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital
214673596|NCT04332692|PROCEDURE|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital
214933738|NCT00401544|DRUG|darbepoetin alfa|Darbepoetin alfa administered by subcutaneous injection.
214933739|NCT00401544|DRUG|IV iron dextran|Administered by intravenous (IV) injection.
214332297|NCT06094348|DEVICE|Piezo assisted osteotomy|Piezo is a system for cutting bone with micrometric ultrasonic piezoelectric vibrations, with varying frequency and cutting energy. The device consists of a platform with a powerful piezoelectric hand piece and employs a functional frequency between 25-29 kHz. The device is fitted with a cooling irrigation system with a 0-60 cc/min variable sterile solution flow. Specific inserts and scalpels act in a linear vibration pattern, with a spatial range between 60 and 210 microns, moved by an ultrasonic power that exceeds 5 watts, reaching up to 16 watts.
214933740|NCT03621540|DEVICE|active tDCS|Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.
214332298|NCT04569461|DRUG|pembrolizumab|400 mg of pembrolizumab (KEYTRUDA) will be given by IV every 6 weeks for 9 cycles, for approximately one year of study drug administration.
214332299|NCT04569461|RADIATION|Low dose prostate radiation|A single dose of 2 Gy of radiation will be given to the prostate and seminal vesicles on approximately Week 7 for Arm A and approximately 2 weeks prior to the prostatectomy for Arm B.
214933741|NCT03621540|DEVICE|sham tDCS|Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.
214933742|NCT03621540|BEHAVIORAL|Adaptive working memory training|Adaptive spatial n-back training.
214332300|NCT04569461|PROCEDURE|Radical Prostatectomy|Robotic assisted laparoscopic prostatectomy (RALP) surgery will be performed at approximately Week 9 for Arm A and approximately 2 weeks after the low dose prostate radiation for Arm B. This surgery is part of the participants routine medical care.
214332301|NCT05811247|DRUG|AD109|Oral administration at bedtime.
214332302|NCT05811247|DRUG|Placebo|Oral administration at bedtime.
214332303|NCT03983473|OTHER|Microbiota Sequencing|virome, bacteriome, fungome NGS sequencing
214332304|NCT04584710|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
214332305|NCT04584710|DRUG|Placebo|Oral matching placebo once daily for 2 weeks
214332306|NCT00292357|PROCEDURE|Application of autologous bone marrow|
214332307|NCT04874506|DRUG|MBM-02|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
214332308|NCT04233970|BEHAVIORAL|web-based intervention programme|"The intervention will be designed as an individualized, dialogue-based system that will provide PwMS coordinated, individually tailored information based on the software platform broca®. The intervention programme will consist of three sections:~1. EBPI/decision aid (five modules plus decision aid in case of an acute relapse) provided by the broca® programme. The key element of the EBPI/decision aid is the information on glucocorticosteroids for the treatment of acute relapses.~2. A webinar led via WebEx by a trained MS nurse with questioning/chat session (approx. 60-75min).~3. A supervised chat room provided via the DMSG (https://www.dmsg.de/ms-connect). In addition, email reminders will be used to enhance involvement of participants."
214332309|NCT04233970|BEHAVIORAL|web-based information material offered via the same platform (broca®) in addition to usual care|Participants in the control group will have access to web-based information material offered via the same platform (broca®) in addition to usual care. The control group intervention will be based on material of the German Multiple Sclerosis Society (DMSG) on relapse management. The programme will accompany the participants over a period of 4 weeks and a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
214673597|NCT04332692|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
214933743|NCT00276185|DRUG|Time delay treatment of botulinum toxin|
214933744|NCT02564445|BEHAVIORAL|Gamification|All participants will be entered with their teammate into a game that includes points and levels
214933745|NCT02564445|BEHAVIORAL|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
214933746|NCT02564445|BEHAVIORAL|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
214933747|NCT02564445|BEHAVIORAL|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
214332310|NCT06178172|OTHER|Remote home monitoring|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
214933748|NCT04156945|BEHAVIORAL|Behavioural intervention|An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.
214332311|NCT04952194|DRUG|Stalevo|The dose of Stalevo initially ranges from (Levodopa/Carbidopa/Entacapone) 50/12.5/200 mg 3 times a day to a target dose of 100/25/200 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
214332312|NCT04952194|DRUG|Carbidopa and Levodopa Controlled Release Tablets|The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
214332313|NCT00481442|DRUG|Phenylephrine|
214332314|NCT01346267|PROCEDURE|Real Acupressure Band|Acupressure wristband
214332315|NCT01346267|PROCEDURE|Placebo Acupressure Band|Sham wristband
214332316|NCT03189394|BEHAVIORAL|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
214332317|NCT03189394|BEHAVIORAL|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
214332318|NCT03189394|BEHAVIORAL|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
214332319|NCT03149237|BEHAVIORAL|Couples-based services|Couples-based services, including treatment, counseling and peer mentoring in the community.
214332320|NCT00000540|DEVICE|defibrillators, implantable|
214332321|NCT02211469|DRUG|BMS-986104|
214332322|NCT02211469|DRUG|Placebo|
214933749|NCT04156945|DIAGNOSTIC_TEST|HCV RNA home-based test|An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
214332323|NCT04568122|DEVICE|Saliva test kit|Kit including tube with closed reagents using loop-mediated isothermal amplification (LAMP) assay to detect SARS-CoV-2 virus.
214332324|NCT01412775|BEHAVIORAL|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration."
214332325|NCT06078046|BEHAVIORAL|Mind-body interventions|Parallel randomized controlled trial
214332326|NCT02456922|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
214332327|NCT01227512|DRUG|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
214933750|NCT00598611|DRUG|desloratadine|singel dose, oral, 20 mg
214933751|NCT00598611|DRUG|desloratadine|single dose, oral, 5 mg
214332328|NCT01227512|OTHER|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
214332329|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
214332330|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|
214933752|NCT01429064|DRUG|ODM-201|ODM-201 administered orally daily
214332331|NCT03553316|DRUG|PK101-002|-(Single) PK101-002
214332332|NCT03553316|COMBINATION_PRODUCT|PK101|-(Combination) PK101-001, PK101-002
214332333|NCT03750734|DIAGNOSTIC_TEST|Bronchoscopy|Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
214332334|NCT03750734|DIAGNOSTIC_TEST|Blood test|Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
214332335|NCT01994304|BEHAVIORAL|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
214332336|NCT04497987|DRUG|Bamlanivimab|Administered IV.
214332337|NCT04497987|DRUG|Placebo|Administered IV.
214332338|NCT04497987|DRUG|Etesevimab|Administered IV.
214332339|NCT00512096|DRUG|Ifosfamide|1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3
214332340|NCT00512096|DRUG|Paclitaxel (Taxol)|175 mg/m\^2 By Vein Over 3 Hours on Day 1
214332341|NCT00512096|DRUG|Cisplatin|25 mg/m\^2 By Vein Over 2 Hours on Days 1-3
214332342|NCT02358824|DRUG|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)"
214332343|NCT02358824|DRUG|Telmisartan|"\- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)"
214332344|NCT02358824|DRUG|S-amlodipine|"\- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)"
214332345|NCT03091803|DEVICE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo GOCART DCE MRI
214332346|NCT03091803|DRUG|Gadobenate Dimeglumine|Given IV
214332347|NCT03091803|DRUG|Gadoterate Meglumine|Given IV
214332348|NCT03091803|DEVICE|Magnetic Resonance Imaging|Undergo QSM and T1WI imaging
214332349|NCT04196166|OTHER|preoperative blood tests|
214332350|NCT02134457|BIOLOGICAL|ranibizumab|
214332351|NCT00298038|DRUG|Rifaximin|Oral
214332352|NCT00298038|DRUG|Placebo|Oral
214332353|NCT02089750|OTHER|Orthotics|
214332354|NCT02089750|OTHER|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
214673598|NCT04637321|PROCEDURE|Solid organ transplant|Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018
214673599|NCT01501149|DRUG|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
214332355|NCT02089750|OTHER|Wait List|
214332356|NCT04197635|DIAGNOSTIC_TEST|Maximal functional capacity by cardiopulmonary exercise testing|It will be done with cycle ergometer (CORTEX Metamax3B), starting with 10W of power and increasing 10W every minute. During the test, heart rate, rhythm and blood pressure will be monitored. Gas exchange data shall be evaluated every 10 seconds and the peak oxygen consumption (peak VO2) shall be considered the maximum value obtained during the last 20 seconds of exercise. The main parameters to be determined are: maximum functional capacity, peak VO2, slope of the VE/VCO2 ratio, and chronotropic incompetence variables. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
214332357|NCT04197635|DIAGNOSTIC_TEST|Echocardiography|The following parameters will be evaluated: a)left ventricular volumes; b) left ventricular systolic function; and c)left atrial volume and E/e' ratio. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
214673600|NCT01501149|DRUG|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
214332358|NCT04197635|BEHAVIORAL|Evaluation of health related quality of life|Assessment of the quality of life through the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Spanish version. It will be completed at baseline and at 30 and 90 days after treatment initiation. The score of the questionnaire is 0 to 105 points.
214332359|NCT04197635|DIAGNOSTIC_TEST|Submáximal functional capacity assesment by 6 minutes walk test|It will be performed in an area equipped for cardiopulmonary resuscitation. Subjects will be asked not to perform a vigorous physical exercise in the previous 2 hours. They will be allowed to have a light meal before the test. Before the test, the vital signs will be determined in a seated position after a rest of 10 minutes. Subjects will be instructed to walk at their own pace to cover as much distance as possible in 6 minutes. It will be performed by a trained nurse blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
214332360|NCT04197635|OTHER|Clinical evaluation|Evaluation of signs and symptoms of heart failure
214332361|NCT05496725|DRUG|Micafungin|Pharmacokinetic study under fasting conditions
214332362|NCT02696096|OTHER|FMRI|all participants will complete 2 FMRIs
214332363|NCT02696096|DRUG|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
214332364|NCT01740583|DEVICE|percutaneous annuloplasty|plication of the mitral valve annulus
214332365|NCT02011048|PROCEDURE|Endoscopic components separation|Endoscopic components separation hernia repair
214332366|NCT00808600|BEHAVIORAL|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
214332367|NCT00808600|BEHAVIORAL|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
214673601|NCT04807569|OTHER|Peripheral magnetic neuromodulation|"Non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation"
214673602|NCT04807569|DRUG|Taking drug Tamsulosin|Tamsulosin at a dose of 0.4 mg x 1 time per day orally for 1 month.
214933753|NCT02787018|DRUG|Ropivacaine and Normal saline|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline
214332368|NCT00808600|BEHAVIORAL|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
214332369|NCT00808600|BEHAVIORAL|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
214332370|NCT00648297|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
214332371|NCT00648297|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
214332372|NCT00399334|DRUG|antipsychotic medications|as prescribed
214332373|NCT04733157|DRUG|Tranexamic acid injection|Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section
214332374|NCT04733157|OTHER|Normal saline placebo|10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group
214332375|NCT05408481|DIAGNOSTIC_TEST|Serum cortisol level|Biochemical test
214332376|NCT03788733|DRUG|Melatonin 3 mg|1 time a day for 8 weeks
214332377|NCT03788733|DRUG|Placebo Oral|1 time a day for 8 weeks
214332378|NCT02121691|BEHAVIORAL|Walk by Faith|The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
214332379|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 1|daily intake of the content of one 45 mL bottle containing the product
214332380|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 2|daily intake of the content of one 45 mL bottle containing the product
214332381|NCT02778581|DIETARY_SUPPLEMENT|Placebo|daily intake of the content of one 45 mL bottle containing olive oil
214332382|NCT06467526|DRUG|Hydroxychloroquine|Oral hydroxychloroquine (400mg/day) for 2 months
214332383|NCT06467526|DRUG|Steroid|Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)
214332384|NCT03289104|DEVICE|Steel Wires|Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
214332385|NCT03289104|DEVICE|ZipFix Sternal Closure System|Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
214332386|NCT02816216|BEHAVIORAL|CampAir|An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
214332387|NCT05293275|DEVICE|EaseVRx Virtual Reality Headset|Virtual reality device with 360 degree visualization of various scenery and interactive modules
214332388|NCT06419049|DEVICE|Altimate Medical EasyStand Bantam|Child will stand in stander 5 days per week for 60 min during each 8 wks intervention
214332389|NCT06572969|OTHER|Elastic-Resistance Kick Training|Athletes used tailored Elastic Resistance training
214332390|NCT06572969|OTHER|No Elastic-Resistance Kick Training|Regular Taekwondo regimen without Elastic Resistance training
214332391|NCT00742976|DRUG|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
214673603|NCT03015272|BEHAVIORAL|Auditory-Motor Mapping Training|AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.
214673604|NCT03015272|BEHAVIORAL|Speech-Repetition Therapy|SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
214673605|NCT01823796|OTHER|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
214673606|NCT01823796|OTHER|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
214332392|NCT00742976|DRUG|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
214332393|NCT00431249|DRUG|Cilostazol|
214673607|NCT04083911|DRUG|Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF|"Decitabine:20mg/m2/d, d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~9,intravenous infusion; Aclarubicin:10mg/d, d3\~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
214673608|NCT03477630|BIOLOGICAL|Platelet Rich Plasma|intra-articular infiltration of 8 ml of autologous PRP every 15 days.
214673609|NCT03477630|DRUG|Hyaluronic Acid|intra-articular infiltration of a single dose of HA
215072585|NCT00803400|DRUG|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association)."
215072586|NCT05837611|BEHAVIORAL|Deposit Contract|A deposit contract requires individuals to put down money that is earned back contingently upon meeting their goals.
215072587|NCT05837611|OTHER|Transdermal Alcohol Monitoring|Using a SCRAM-Cam device participants will be monitored for their alcohol use.
215072588|NCT02806219|DEVICE|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
215072589|NCT02806219|DEVICE|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
215072590|NCT03643341|BEHAVIORAL|Family Healthy Living|Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
215072591|NCT02302248|BEHAVIORAL|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
215072592|NCT02302248|BEHAVIORAL|Expressive writing intervention|3 week access to a web-based expressive writing platform.
215072593|NCT00210353|DRUG|chlorambucil (drug)|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
215072594|NCT00210353|DRUG|rituximab+chlorambucil|rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
215072595|NCT00210353|DRUG|rituximab|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
215072596|NCT02450461|OTHER|no intervention|
215072597|NCT01541943|DRUG|Atorvastatin|Once daily, administered orally, 8 week
215072598|NCT01541943|DRUG|Losartan|Once daily, administered orally, 8 week
215072599|NCT01541943|DRUG|Placebo|Once daily, administered orally, 8 week
215072600|NCT01541943|DRUG|HL-040XC|Once daily, administered orally, 8 week
215072601|NCT02529462|GENETIC|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
215072602|NCT02529462|DRUG|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
215072603|NCT00987428|PROCEDURE|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
215072604|NCT00987428|PROCEDURE|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
215072605|NCT02494518|BEHAVIORAL|Forced Exercise & Upper Extremity Repetitive Task Practice|
215072606|NCT02494518|BEHAVIORAL|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
215072607|NCT02494518|BEHAVIORAL|Stroke Education & Upper Extremity Repetitive Task Practice|
215072608|NCT05806034|OTHER|tractography MRI sequence protocol|tractography MRI sequence protocol does not require injection of contrast agent.
214332394|NCT03410225|BEHAVIORAL|CAMI-TPP|The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.
214332395|NCT03410225|BEHAVIORAL|CAMI-Fitness|The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
214332396|NCT03313362|DEVICE|SPEAC System|Seizure Monitoring and Alerting System
214332397|NCT03313362|DEVICE|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
214332398|NCT01755416|DRUG|Closed loop with sensor and Insulin|Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
214332399|NCT01755416|DRUG|Closed loop with sensor, Insulin and Liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
214332400|NCT03842176|PROCEDURE|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
214332401|NCT03842176|PROCEDURE|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
214332402|NCT05069012|DRUG|Morphine Sulfate|Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief
214332403|NCT02680184|DRUG|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
214332404|NCT02680184|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
214332405|NCT06976697|DEVICE|Transcranial direct current stimulation|In tDCS treatment session electrical current (2 mA) is applied for 30 minutes through two electrodes placed on top of scalp to modulate neural activity.
214332406|NCT06976697|DEVICE|Sham transcranial direct current stimulation|Sham treatment mimics the active device use and the experiences from the active stimulation while minimizing active effects.
214332407|NCT00758628|DRUG|Bromefenac|Bromfenac BID 3 months
214673610|NCT05167292|OTHER|Observational study|Routine clinical care was provided to all AKI cases presenting to the TTM Hospital in Samoa. This prospective observational study reviewed incidence, aetiology and outcomes for these cases.
214673611|NCT04546256|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
214673612|NCT04546256|DRUG|ADVAIR DISKUS® 500/50|2 inhalations of Test and Reference product in each study period
214673613|NCT01048125|DEVICE|Sympathetic Nerve Activity|Resting Sympathetic Nerve Activity
214673614|NCT01048125|BEHAVIORAL|Mental Stress Test (Color Word Test)|"A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure."
214673615|NCT01048125|DRUG|The Modified Oxford Technique for Baroreflex Sensitivity|Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
214673616|NCT01048125|OTHER|Cold Pressor Test|The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
214673617|NCT01048125|DEVICE|Echocardiographic evaluation|Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
214332408|NCT00758628|DRUG|Blink|Blink BID for 3 months
214673618|NCT02140918|DRUG|Fludrocortisone 100 μg|Fludrocortisone 100 μg/day
214332410|NCT03683381|BEHAVIORAL|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
214332411|NCT03683381|OTHER|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
214332412|NCT03723694|DIETARY_SUPPLEMENT|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
214332413|NCT03723694|DIETARY_SUPPLEMENT|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
214673619|NCT02140918|DRUG|Fludrocortisone 200 μg|Fludrocortisone 200 μg/day
214673620|NCT02140918|DRUG|Fludrocortisone 400 μg|Fludrocortisone 400 μg/day
214673621|NCT02140918|DRUG|Placebo|
214673622|NCT04146272|DEVICE|Hearing Aid Mermaid Current|The current hearing aid used to treat hearing loss.
214673623|NCT04146272|DEVICE|Hearing Aid Mermaid New|The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
214673624|NCT04146272|DEVICE|Power Hearing Aid Current|The current power hearing aid used to treat strong hearing loss.
214673625|NCT04146272|DEVICE|Power Hearing Aid New|The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
214933754|NCT02787018|DRUG|Ropivacaine and Dexamethasone|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone
214933755|NCT02787018|DRUG|Ropivacaine and Dexmedetomidine|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
214332414|NCT06239961|BEHAVIORAL|Social Connection|6 weekly Behavioral Activation Intervention calls with a 1 hour duration for each call.
214332415|NCT06239961|BEHAVIORAL|Nutritional Coaching|4 weekly nutritional coaching calls with a Registered Dietician with a 1 hour duration for each call.
214332416|NCT06239961|BEHAVIORAL|Physical Activity Coaching|4 weekly physical activity coaching sessions with a 1 hour duration for each call.
214332417|NCT06626490|DEVICE|Prevision Revision hip endoprosthesis stem implantation|"The Prevision hip endoprosthetic stem is a femoral part of a hip joint endoprosthesis. The system provides cementless and cemented variants. Prevision hip stems are modular with a short proximal and longer distal component, or monobloc hip stems. Modular components are coupled via a Prevision specific conical connection with a torque wrench and a tension nut to apply a predefined torsional moment on the connection. The distal component of modular Prevision stems can be combined with locking screws for additional bone fixation.~Both types, the monobloc and the modular, provide a 12/14 taper that serves as a connection for metal or ceramic prosthesis heads. Prevision hip stems are combined at the acetabulum with a cementless or cemented acetabular cup."
214332418|NCT06662929|RADIATION|Radiation|Radiotherapy for the Head \& Neck Cancer
214332419|NCT06663020|BEHAVIORAL|Smoking Cessation Duration|Participants are categorized based on their smoking status and the duration since they quit smoking prior to lung cancer surgery. This observational study focuses on evaluating the relationship between the duration of smoking cessation (measured in days or weeks) and the incidence of postoperative complications. Smoking cessation duration is recorded for each participant to determine its impact on surgical outcomes.
214332420|NCT06664749|OTHER|Three stair position pillow group|Preterm infants were monitored with three stair position pillows.
214332421|NCT06664749|OTHER|Positioning material group|Preterm infants were monitored with positioning material pillows.
214332422|NCT06662773|DRUG|TQB3616 capsule + itraconazole|C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors
214332423|NCT06662773|DRUG|TQB3616 capsule + rifampicin|C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer
214332424|NCT05894772|BEHAVIORAL|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the Power over Pain Portal for 4 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference. The overall objective is to determine the implementation (guided by Proctor's implementation conceptual framework) and clinical effectiveness of the PoP Portal in a sample of youth (12-18 years of age) who are on the waitlist for tertiary care consultation at any pediatric CP clinic in Canada.
214673626|NCT05195905|DEVICE|PMEG|All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.
214933756|NCT00888602|DIETARY_SUPPLEMENT|3.4 g psyllium|3.4 g psyllium served with meal
214933757|NCT00888602|DIETARY_SUPPLEMENT|6.8 g psyllium|6.8 g psyllium served with a meal
214933758|NCT00888602|DIETARY_SUPPLEMENT|6.8 g psyllium|6.8 g psyllium
214933759|NCT00888602|OTHER|Meal|meal
214933760|NCT00204503|DRUG|Depakote ER|
214933761|NCT04106362|BIOLOGICAL|Cetuximab|Given IV
214933762|NCT04106362|DRUG|Cisplatin|Given IV
214933763|NCT04106362|OTHER|Quality-of-Life Assessment|Ancillary studies
214933764|NCT04106362|OTHER|Questionnaire Administration|Ancillary studies
215072609|NCT01159925|PROCEDURE|Serum sample|Serum samples collected
215072610|NCT00227669|DRUG|docetaxel|
215072611|NCT00227669|DRUG|gemcitabine hydrochloride|
215072612|NCT04962841|OTHER|Nutraceuticals|To observe the effect on cognitive and physical impairment.
215072613|NCT02135029|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
214332425|NCT06021561|DIAGNOSTIC_TEST|Diagnosis of pain|Pain will be investigated - type, origin, level
214673627|NCT04919486|BEHAVIORAL|visual feedback with non-weight bearing exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
214933765|NCT04106362|RADIATION|Radiation Therapy|Undergo radiation therapy
214933766|NCT04587739|COMBINATION_PRODUCT|Surgery with Neoadjuvant stereotactic body radiation therapy|Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).
214933767|NCT02232854|BEHAVIORAL|Depression training/supervision program|"The intervention will be composed of:~* Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.~* After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.~* Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.~* Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment."
214933768|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
214933769|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
215072614|NCT02135029|DRUG|Atorvastatin|Atorvastatin PO QD
215072615|NCT02135029|OTHER|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
215072616|NCT02135029|OTHER|Placebo for atorvastatin|PO QD
215072617|NCT04695600|DRUG|Botulinum Toxin Type A Injection [Botox]|100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
214933770|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
214933771|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
214933772|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
214332426|NCT00880347|DEVICE|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
214332427|NCT03254901|OTHER|Screening test by Oraquick test|The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
214332428|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^6 cells/m2"
215072618|NCT00211393|DRUG|ketoconazole|600mg. /day for 6 weeks
214332429|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^7 cells/m2"
214332430|NCT02292628|DRUG|Infusion of mesenchymal stem cells from adipose tissue|
214332431|NCT02292628|OTHER|Infusion of placebo|
214332432|NCT04065347|DEVICE|Digital Pill|Digital Pill over encapsulating tenofovir alafenamide ART
214332433|NCT07010159|DRUG|KPL-387|administered by subcutaneous injection
214332434|NCT07010159|DRUG|Placebo|administered by subcutaneous injection
214332435|NCT03613896|PROCEDURE|conventional dentures|conventional dentures
214332436|NCT03613896|PROCEDURE|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
215072619|NCT02027467|DIETARY_SUPPLEMENT|StemAlive®|
214332437|NCT07024849|DIETARY_SUPPLEMENT|Ecological nutritional intervention|Patients in the intervention arm will receive a 4-week nutrition management program(1 week for patients more than 4 months post-surgery), which includes providing nutritional guidelines, home delivery of personalized care foods, encouragement of physical activity using a wearable device, and weekly phone calls to check on nutritional goals and symptoms. Management services are also available through the mobile application.
214332438|NCT07024576|OTHER|Preoperative casting intervention|A serial casting intervention protocol involving the application of heat, stretching, and massage before casting. This is repeated weekly for four weeks, with the cast removed and reapplied each time to promote gradual elongation of restricted tissue.
214673628|NCT04919486|BEHAVIORAL|elastic band exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
214673629|NCT00641147|DRUG|Curcumin|Given PO
214673630|NCT00641147|OTHER|Laboratory Biomarker Analysis|Correlative studies
215072620|NCT02027467|DIETARY_SUPPLEMENT|Placebo (For StemAlive®)|
215072621|NCT01558362|DRUG|123I-CMICE-013|2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections. All volunteers had a rest dose first followed by a stress dose.
215072622|NCT05898672|DRUG|Rosuvastatin|Single oral dose of rosuvastatin tablets
215072623|NCT05898672|DRUG|Nirmatrelvir/ritonavir|Twice daily oral doses of nirmatrelvir/ritonavir tablets
215072624|NCT01195376|DRUG|BEZ235|
215072625|NCT04645654|BEHAVIORAL|Hypnosis|Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
214332439|NCT07024043|DRUG|Dexamethasone versus Dexmedetomidine in IPACK Block to reduce pain post Arthroscopic knee surgeries|Blocks will be carried out with the patient supine with the operative leg externally rotated and slightly flexed at the knee or in prone position.with Ultrasound device with a high-frequency (6-13 MHz) linear probe using in plane lateral to medial approach and this will be done by a senior staff anaesthesia physician skilled in ultrasound guided regional anaesthesia.
214332440|NCT07024043|PROCEDURE|IPACK and multi-modal analgesic regimen|patients will be put in supine position, the procedure will be performed under complete aseptic precautions and All patients will be divided into three groups:(Group 1) for iPACK block with 0.25% bupivacaine only. (Group 2) for iPACK block with 0.25% bupivacaine and dexamthasone and (Group 3) for iPACK block with 0.25% bupivacaine and dexmedetomidine .
214332441|NCT07023523|BEHAVIORAL|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
214332442|NCT07023523|BEHAVIORAL|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
214332443|NCT07025135|BEHAVIORAL|comparison between use of mobile app|Patient-caregiver dyad receive standard care (optimal macrogol treatment) plus a mobile app featuring symptom tracking, medication reminders, dietary tips, and gamification elements.
214332444|NCT07025135|BEHAVIORAL|Patient-caregiver dyad using printed recommendations|Patient-caregiver dyad receives standard care ( optimal macrogol treatment) plus a non-interactive, educational-only printed version of recommendations.
214332445|NCT02420496|DRUG|Enteral fish oil|
214332446|NCT02420496|DRUG|Ursodeoxycholic Acid|
214332447|NCT02420496|DRUG|Placebo|
214673631|NCT00641147|OTHER|Placebo|Given PO
214673632|NCT05035186|DRUG|Amoxicillin|Anti-H. pylori regimens
214673633|NCT04879446|PROCEDURE|Concentrated growth factor(CGF)|Concentrated growth factor(CGF) liquid applied to the implant cavity and implant surface.
214673634|NCT04879446|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity and implant surface.
214673635|NCT04879446|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied.
214673636|NCT04879446|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied.
214933773|NCT02847923|OTHER|Presentation of alternative communication application|At this stage the purpose of the application is submitted, what its purpose and its features in a brief and clear manner.
214933774|NCT02847923|OTHER|Familiarization with the software interface|At this stage, the volunteer will be asked to use the application by himself for a short time so that he can get acquainted and learn to use it
214933775|NCT02847923|OTHER|Test of the software|"Then, the volunteer is instructed to use the application following a script task that will expose a simple and fast way all the application features. These tasks have easy actions to be executed, for example: The user must communicate through the application the phrase I want to drink water, so that he will be instructed to perform the actions to select the option and then drink the water option."
214933776|NCT02847923|OTHER|Answer the questionnaire|After performing all the tasks the user replies to a questionnaire to evaluate the usability of the application after you use.
214933777|NCT04511195|DIETARY_SUPPLEMENT|Standardized extract of Sphaeralcea angustifolia|Each patient will be treated topically with a gel containing the Sphaeralcea angustifolia extract three times a day for 4 weeks. Sphaeralcea angustifolia extract is standardized in its active compounds content: Sphaeralcic acid and scopoletin
214933778|NCT04511195|DRUG|Diclofenac Sodium Gel|Each patient will be treated topically with a gel containing 2% diclofenac three times a day for 4 weeks.
214933779|NCT06133946|GENETIC|Genetic screening test (Deafness gene variant detection array kit)|Infant participants were screened for fifteen variants in four genes (i.e., GJB2, SLC26A4, MT-RNR1 and GJB3).
214933780|NCT06057714|COMBINATION_PRODUCT|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing
215072626|NCT02262026|DRUG|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
215072627|NCT02262026|DRUG|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
215072628|NCT02262026|DRUG|Placebo|Placebo
215072629|NCT04955223|DRUG|Yinhu Qingwen Granules|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
215072630|NCT04190381|OTHER|FR-Mask|"The investigational medical product of this study is a biomedical repair mask, FR-MASK, acting like moisturizing lotion applied on breasts.~The FR-Mask is applied to users' radiation-irritated breast skin for 15 to 20 minutes every 3 days."
215072631|NCT05530395|DIAGNOSTIC_TEST|Testosterone levels|Blood sample to determine testosterone levels
215072632|NCT05455918|DRUG|TIP treatment (paclitaxel/ifosfamide/cisplatin)|Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
214673637|NCT01439958|DRUG|Inhalation|Twice daily inhalation for a maximum of three years.
215072633|NCT03634566|DRUG|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
215072634|NCT03634566|DRUG|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
215072635|NCT00115479|DRUG|intensive insulin therapy to maintain normoglycemia|
215072636|NCT02453165|PROCEDURE|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
215072637|NCT02453165|PROCEDURE|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
215072638|NCT00192049|DRUG|Gemcitabine|
215072639|NCT00192049|DRUG|mitomycin C|
215072640|NCT01024972|DRUG|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
215072641|NCT01024972|DRUG|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
215072642|NCT05129449|DEVICE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) conducted with motorized PowerSpiral in subjects presenting with surgically altered GI anatomy indicated for ERCP with biliary indication.
215072643|NCT01777217|DRUG|Solifenacin succinate|IGRT with VESIcare
215072644|NCT01777217|DRUG|Placebo|IGRT with placebo
215072645|NCT05071872|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
215072646|NCT01493102|DRUG|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
215072647|NCT01493102|DRUG|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
215072648|NCT03213782|OTHER|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
214933781|NCT05976308|DRUG|Bushen Huatan Decoction|The treatment group used Bushen Huatan Decoction, including Tusizi (the seed of Chinese dodder), Fupenzi (Raspberry), Bajitian (Morinda officinalis), Duzhong (Eucommia ulmoides), Shudi (prepared Rehmanniaroot), Fuling (Tuckahoe), Zelan (Aconitum gymnandrum), Zexie (Rhizoma alismatis), Guizhi (Cassia twig), Zhebeimu (Thunberg Fritillary Bulb), Taoren (Peach kernel) and Chuanxiong (Ligusticum wallichii). Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
215072649|NCT00754949|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
214332448|NCT07025525|DEVICE|Ultrasonic activated sodium hypochlorite|Using ultrasonic-activated sodium hypochlorite in the canals of primary molars can significantly enhance root canal disinfection by improving the irrigant's penetration and effectiveness. Primary molars often have complex and irregular canal anatomies, which can limit the reach of traditional irrigation methods. Ultrasonic activation creates acoustic streaming and cavitation effects, allowing sodium hypochlorite to better dissolve organic tissue and disrupt bacterial biofilms, especially in hard-to-reach areas. This leads to more thorough cleaning, reduced microbial load, and potentially better clinical outcomes in pediatric endodontics
214332449|NCT07025525|OTHER|Ultrasonic acivated saline|using ultrasonic-activated saline within the canals of primary teeth lies in its ability to enhance mechanical debridement and improve irrigation effectiveness without the risks associated with stronger chemical agents. Although saline lacks inherent antimicrobial properties, ultrasonic activation generates acoustic streaming and cavitation, which help dislodge debris, disrupt biofilms, and clean intricate canal anatomy more efficiently than passive irrigation. This makes it a safer alternative in pediatric patients, minimizing the risk of cytotoxic effects or damage to developing permanent tooth buds while still improving cleaning outcomes.
214332450|NCT07025525|OTHER|Sodium Hypochlorite Solution|using sodium hypochlorite (NaOCl) within the canals of primary molars is its excellent antimicrobial and tissue-dissolving properties, which are essential for effective root canal disinfection. Primary molars often have complex and irregular canal systems that harbor bacteria and necrotic tissue. Sodium hypochlorite not only helps eliminate a broad spectrum of microorganisms but also dissolves organic debris, improving canal cleanliness and reducing the risk of post-treatment infection. When used in appropriate concentrations, it can significantly enhance the success of pulpectomy procedures in pediatric patients while maintaining safety.
214332451|NCT07025525|OTHER|Saline|Saline is commonly used as an irrigant in the root canal treatment of primary molars due to its excellent biocompatibility and safety profile. It is a non-toxic, isotonic solution that poses no risk to the surrounding periapical tissues, which is particularly important in primary teeth where root resorption and open apices are common. This minimizes the chance of damaging the underlying permanent tooth germ, a critical consideration in pediatric dentistry. Saline is also safe if accidentally extruded beyond the apex or ingested, making it a suitable choice for young children.
214332452|NCT07025265|BEHAVIORAL|Breastfeeding Self-Efficacy-Based Education and Counseling|his intervention consists of breastfeeding self-efficacy theory-based education provided during the antenatal period. The education covers key factors affecting maternal breastfeeding self-efficacy, including previous experiences, vicarious learning, social support, and psychological responses. Weekly reminder and encouragement text messages will be sent until birth. Postpartum follow-up includes a home visit in the first week for counseling and phone-based follow-ups in the 2nd, 3rd, and 4th weeks.
215072650|NCT00754949|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
215072651|NCT00754949|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
215072652|NCT02839720|OTHER|Laboratory Biomarker Analysis|Correlative studies
214332453|NCT07023939|DRUG|ART: Atraumatic restorative treatment, SMART: Silver-Modified Atraumatic Restorative Treatment|"ART Group:~Selective caries removal was done using hand instruments-carious dentin was excavated from the axial walls with a spoon excavator, and unsupported enamel was carefully removed using a hatchet. On the pulpal floor, only soft, completely demineralized dentin was removed until firm dentin was reached.~SMART Group:~the surrounding gingival tissues and lips were protected with petroleum jelly to avoid staining and irritation (2) ) one drop of SDF (Advantage Arrest ™, Elevate Oral Care, USA) was placed into a disposable dish, (4) SDF was applied with a bended micro-sponge directly to the affected tooth surfaces for minimum of 60 seconds, (3) excess was blotted with a cotton pellet, (4)and the area was air-dried while maintaining isolation for up to three minutes."
214332454|NCT07023848|DRUG|89Zr-LNCab104|89Zr-LNCab104 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
214332455|NCT07023848|DRUG|89Zr-LNCab103|89Zr-LNCab103 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
214332456|NCT07023848|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg.
214933782|NCT05976308|DRUG|Placebo|The treatment group used Caramel pigment, Ku Ding Cha Extracts, Maltodextrin, Starch and 5% Bushen Huatan Decoction.
214933783|NCT01272141|DRUG|Lapatinib and Everolimus|"Lapatinib: 1250 mg by mouth daily~Everolimus: 5mg by mouth daily"
215072653|NCT02839720|DRUG|Selumetinib Sulfate|Given PO
215072654|NCT05798936|DRUG|Polidocanol|Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
215072655|NCT05798936|DRUG|Alcohol|Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
215072656|NCT01212679|DRUG|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
215072657|NCT01212679|DRUG|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
215072658|NCT04728152|OTHER|Blood and salivar test|"Saliva samples will be taken (concomitant with a visit carried out as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks).~Blood samples will be taken at two stages (concomitant with a blood test performed as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks)."
215072659|NCT03791281|BEHAVIORAL|BASIS|
214933784|NCT01819753|PROCEDURE|Percutaneous nephrolithotomy|The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
214332457|NCT07023406|BEHAVIORAL|Disfrutando|Disfrutando is a six-week, weekly intervention with a booster intervention at week 12. Intervention content includes glucose control with individual goals, glucose monitoring and glucometer practice, healthy eating demonstrations, benefits of physical activity, prevention and management of T2DM. The intervention has a strong focus on mitigating barriers and challenges to diabetes self-care management.
214332458|NCT07025408|DRUG|KJ101|"1. Clean the wound before applying medication.~2. Apply KJ101 (800U/mL) to the wound.~3. Apply a standard wound dressing after treatment.~4. Apply once daily until complete debridement of necrotic tissue has been achieved. After debridement, apply the medication every other day until the wound closes (maximum treatment duration: 28 days)."
214332459|NCT07025408|DRUG|Chymotrypsin|"1. Clean the wound before applying medication.~2. Apply Chymotrypsin (800U/mL) to the wound.~3. Apply a standard wound dressing after treatment.~4. Apply once daily until complete debridement of necrotic tissue has been achieved. After debridement, apply the medication every other day until the wound closes (maximum treatment duration: 28 days)."
214332460|NCT07025408|DRUG|Placebo (Sodium Chloride Injection 0.9%)|"1. Clean the wound before applying medication.~2. Apply Placebo (Sodium Chloride Injection 0.9%) to the wound.~3. Apply a standard wound dressing after treatment.~4. Apply once daily until complete debridement of necrotic tissue has been achieved. After debridement, apply the medication every other day until the wound closes (maximum treatment duration: 28 days)."
214332461|NCT07024121|DIAGNOSTIC_TEST|Patient consulting in spine surgery|Self-administered questionnaire quality of life scales
214332462|NCT07025161|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
214332463|NCT07025161|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
214332464|NCT07024602|DRUG|ASC50 tablets or matching placebo|Drug: ASC50 administered orally Drug: Placebo administered orally
214332465|NCT07025109|BEHAVIORAL|Peer support|Peer support counseling will include phone or text communication to assess goal progress, provide motivational counseling as needed, and to provide social support.
214673638|NCT06189443|OTHER|Group administered to individual telemedicine|A brochure containing incontinence patient information will be prepared and given, web-based training will be implemented, and informative/reminder messages will be sent via short messages every day.
214933785|NCT00572052|DEVICE|NovoFine® needle 6 mm|
214673639|NCT01966731|DRUG|Hydroxyurea|Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
214933786|NCT00572052|DEVICE|Ultra-Fine needle 12.7 mm|
214933787|NCT01131884|DRUG|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
214933788|NCT01131884|DRUG|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
214933789|NCT04543721|DEVICE|24-h-ABPM|24-h- blood pressure measurement and pulse wave analysis
214933790|NCT05574803|DEVICE|Active-tDCS|Active-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (20 minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program.
214933791|NCT05574803|DEVICE|Sham-tDCS|Sham-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (one minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program. Participants will receive initial stimulation for one minute, eliciting a tingling sensation on the scalp then it will be discontinued.
215072660|NCT03791281|BEHAVIORAL|Attention Control|
215072661|NCT03484507|DRUG|Chlorhexidine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
215072662|NCT03484507|DRUG|Povidone-Iodine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
215072663|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
215072664|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
215072665|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
215072666|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-5
215072667|NCT00883545|OTHER|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
215072668|NCT00883545|OTHER|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
215072669|NCT05705778|PROCEDURE|standard amblyopia treatment|amblyopia treatment following international guidelines and genetic tests.
215072670|NCT04561245|DRUG|ALT-801|Injected subcutaneously (SC)
215072671|NCT04561245|OTHER|Placebo|Injected subcutaneously (SC)
215072672|NCT01065194|DRUG|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
214332466|NCT07025109|BEHAVIORAL|Exercise Prescription|Women will be provided with an exercise prescription (Frequency, Intensity, Time, Type) which may be adjusted weekly for 6 weeks to goal of 150min/week of moderate to vigorous physical activity.
214332467|NCT07025109|BEHAVIORAL|Blood pressure self monitoring|Women will receive a home blood pressure monitor and encourage to record their readings in a log.
214332468|NCT07023952|PROCEDURE|Laser Treatment|Minimally invasive laser ablation procedure performed under local anesthesia for pilonidal sinus treatment. Laser energy is delivered through a fiber optic probe inserted into the sinus tract to achieve thermal ablation of the sinus cavity.
214332469|NCT07023952|DRUG|Crystallized Phenol|rystallized phenol is applied directly into the pilonidal sinus channels after cleaning and curettage. The phenol remains in contact for a specified duration before being neutralized with normal saline irrigation.
214332470|NCT05066841|DRUG|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) for 12 weeks
214332471|NCT05066841|DRUG|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks
214332472|NCT04849949|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
215072673|NCT01065194|DRUG|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
214332473|NCT04849949|OTHER|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
214332474|NCT04849949|OTHER|English walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
214332475|NCT06219655|PROCEDURE|thoracoscopic sympathectomy|sympathectomy
214332476|NCT02573324|DRUG|Temozolomide|Oral Capsule
214332477|NCT02573324|DRUG|Depatuxizumab mafodotin|Intravenous (IV) Infusion
214332478|NCT02573324|RADIATION|Radiation|
214332479|NCT02573324|DRUG|Placebo for ABT-414|IV Infusion (IV)
214332480|NCT03176810|DEVICE|OCT|OCT is used to guide PCI.
214332481|NCT03176810|DEVICE|Angiography|Angiography is used to guide PCI.
214332482|NCT03713567|BEHAVIORAL|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
214332483|NCT03509701|DIAGNOSTIC_TEST|VZV-specific antibody response from blood|Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
214332484|NCT01099995|OTHER|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
214332485|NCT01099995|OTHER|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
214332486|NCT01697384|DRUG|histrelin acetate|52 week implant
214332487|NCT03563040|DRUG|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
214332488|NCT03563040|DEVICE|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
214332489|NCT00129519|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
214332490|NCT02356835|DEVICE|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
214332491|NCT02356835|DEVICE|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
214332492|NCT03614026|BEHAVIORAL|Teachers and Parents as Partners|Family-school partnership intervention
214332493|NCT04132349|DRUG|Ulipristal Acetate 5 mg|Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
214673640|NCT02835729|DRUG|Idarubicin|Chemotherapy
214673641|NCT02835729|DRUG|Cytarabine|Chemotherapy
214673642|NCT02835729|DRUG|Indoximod Freebase|IDO pathway inhibitor
214673643|NCT02835729|DRUG|Indoximod HCL F1|IDO pathway inhibitor
214673644|NCT02835729|DRUG|Indoximod HCL F2|IDO pathway inhibitor
214933792|NCT05571202|PROCEDURE|General anesthesia plus local infiltration|The eligible patients underwent anorectal surgery under general anesthesia (GE, GM, IVG) plus locally injected analgesics.
214933793|NCT05571202|PROCEDURE|Spinal anesthesia|The eligible patients underwent anorectal surgery under spinal anesthesia alone.
214933794|NCT05024981|BEHAVIORAL|Videographic feedback|Twice a week during his classic re-education sessions, the patient will be filmed for 1 minute. After transferring the video to a tablet, he will watch the video once and decide what he wants to correct. During the second viewing, he will analyse his walk, the therapist being present to provide additional information. Finally, the patient will apply his analysis while being filmed and will compare the possible differences between the 2 videos. Depending on the time available, the patient may have to repeat the recordings, analyses and exercises.
214933795|NCT05024981|BEHAVIORAL|Classic reeducation|The patient will benefit twice a day for 30 minutes from re-education sessions.
214933796|NCT02537834|DRUG|Tofogliflozin|
214933797|NCT02537834|DRUG|GLP-1 analogue|
214933798|NCT02935582|DRUG|Enstilar® aerosol foam|Treatment according to local labelling
214933799|NCT02935582|DRUG|Other topical|Treatment according to local practise
214933800|NCT05556564|DRUG|observational study|No intervention, observational study
214933801|NCT03350308|OTHER|hemodialysis|The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration
215072674|NCT04221178|OTHER|Cessation of continuous matinenace therapy|Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation
214332494|NCT00134108|BEHAVIORAL|Cognitive Behaviour Therapy|
214332495|NCT01105533|DRUG|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
214332496|NCT01105533|DRUG|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
214332497|NCT01105533|DRUG|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
214332498|NCT01105533|DRUG|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
214332499|NCT01105533|DRUG|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
214332500|NCT01105533|DRUG|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
214332501|NCT01105533|DRUG|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
214332502|NCT01105533|DRUG|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
214332503|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
214332504|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
214332505|NCT01977911|OTHER|Stem cell based tissue engineered partial laryngeal implants|Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
214332506|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
214332507|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
214332508|NCT01917045|DRUG|Morphine|morphine 0. 5mg/ml
214933802|NCT02758444|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP) + 15 mg Zn|Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
214933803|NCT02758444|DIETARY_SUPPLEMENT|MNP + 10 mg Zn|Same as above except MNP will contain 10 mg Zn
215072675|NCT00150228|DRUG|CP-526,555 (varenicline)|
214332509|NCT02096835|DEVICE|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
214332510|NCT02096835|DEVICE|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
214332511|NCT02096835|DRUG|Tropisetron|will be given at the start of skin closure
214933804|NCT02758444|DIETARY_SUPPLEMENT|MNP + 5 mg Zn|Same as above except MNP will contain 5 mg Zn
214933805|NCT02758444|DIETARY_SUPPLEMENT|MNP without Zn|Same as above except MNP will not contain Zn
214933806|NCT02339155|BIOLOGICAL|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
214933807|NCT02339155|BIOLOGICAL|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
214933808|NCT02339155|DRUG|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
215072676|NCT04000607|DEVICE|APTURE transcatheter shunt|Transcatheter treatment of symptomatic left heart failure patients
215072677|NCT05695898|DRUG|XmAb22841|Given intravenously (IV)
214332512|NCT02096835|DRUG|Dexamethasone|will be given after induction
214332513|NCT02709967|OTHER|Material support|Writing materials
214332514|NCT02709967|OTHER|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
214332515|NCT02709967|BEHAVIORAL|Community dialogue|Community dialogue (youth club meetings, community and parent meetings)
214332516|NCT04852614|DIAGNOSTIC_TEST|Pharmacokinetic test|Blood samples will be collected 48 hours after the first dose on day 3 of the observed intake of the study medication at the following time points: t=0 (pre-dose), 1, 2, 3, 4, 8 and 12 hours post ingestion (7 samples) (3 mL each), Breast milk samples will be collected by emptying both breasts at 0, 2, 4, 8 and 12 hours (5 samples).
214332517|NCT03892889|COMBINATION_PRODUCT|Abilify MyCite®|Combination product of aripiprazole tablet embedded with sensor and wearable patch.
214332518|NCT03468439|OTHER|Femoral nerve block with phenol|
214673645|NCT05568745|DEVICE|Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)|Balloon catheter is inserted by a resident or a physician under visual control. The expected volume injected in the balloon probe is 60 mL. No traction is performed on the catheter. The catheter is left in place for a maximum of 12 hours.
214933809|NCT00162149|DRUG|Nevirapine|Tablets, Oral, 200 mg, Twice daily, 3 days.
214933810|NCT00162149|DRUG|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
214933811|NCT00162149|DRUG|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
214933812|NCT00162149|DRUG|Atazanavir + Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
214933813|NCT01214252|DEVICE|Permacol Surgical Implant|Permacol Surgical Implant
214933814|NCT02057913|DRUG|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
214933815|NCT05610800|DRUG|Exenatide 2 milligram (mg) Injection|Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
215072678|NCT05695898|DRUG|XmAb23104|Given intravenously (IV)
215072679|NCT00516906|DRUG|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
215072680|NCT00516906|DRUG|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
215072681|NCT02621151|BIOLOGICAL|Pembrolizumab|
214673646|NCT05568745|DRUG|Oxytocin|Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose\*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
214673647|NCT05568745|DRUG|Misoprostol Oral Tablet|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
214933816|NCT05610800|DRUG|Placebo|Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
214933817|NCT05610800|DRUG|Nicotine patch|"Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke \>10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14."
214933818|NCT05610800|BEHAVIORAL|Smoking Cessation Counseling|Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
214933819|NCT02703506|OTHER|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
214933820|NCT02703506|OTHER|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
214933821|NCT03250585|DIAGNOSTIC_TEST|Exhaled Breath Condensate (EBC)|Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
214933822|NCT03250585|DIAGNOSTIC_TEST|Plasma Sample|Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
214933823|NCT02322450|DRUG|QGC001|
214933824|NCT02322450|DRUG|Placebo|
214933825|NCT01827878|DRUG|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
214933826|NCT01827878|DRUG|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
215072682|NCT02621151|PROCEDURE|Transurethral Resection of Bladder Tumor|
214933827|NCT00360815|BEHAVIORAL|Insulin|
214933828|NCT02176083|BEHAVIORAL|Text message management prompts|
214933829|NCT02036671|DEVICE|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access|
214933830|NCT02957045|PROCEDURE|Cough pressure measurement|
214933831|NCT02957045|DEVICE|Pcough|
214933832|NCT04616105|DRUG|REGN6490|Single dose of REGN6490
214933833|NCT04616105|DRUG|Placebo|Placebo matching single dose of REGN6490
214933834|NCT04327661|DRUG|Tradipitant|Oral Capsule
214933835|NCT04327661|DRUG|Placebo|Oral Capsule
214933836|NCT02491125|DIETARY_SUPPLEMENT|soluble wheat bran fibre|12 weeks daily intake of 15g of soluble wheat bran fibre
214933837|NCT02491125|DIETARY_SUPPLEMENT|Placebo|12 weeks daily intake of 15g of maltodextrin
215072683|NCT02621151|DRUG|Gemcitabine|
215072684|NCT02621151|RADIATION|External Beam Radiation Therapy|
214933838|NCT03950141|DRUG|Apatinib and S-1|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
214933839|NCT02320682|DEVICE|Surgery for Total Hip Arthroplasty (THA)|THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
214933840|NCT02671825|DRUG|PUR0200|PUR0200 dry powder inhalation
214933841|NCT02671825|DRUG|Reference Product|Dry Powder Inhalation Reference Product
215072685|NCT05942053|DRUG|Placebo|Placebo match vitamin K2 capsules once per day.
215072686|NCT05942053|DRUG|Vitamin K 2|Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
215072687|NCT06482229|PROCEDURE|application for postoperative analgesia|three different methods will be applied to reduce patients' postoperative pain
215072688|NCT06433505|DRUG|BMS-986365|Specified dose on specified days
215072689|NCT06433505|DRUG|[14C] BMS-986365|Specified dose on specified days.
215072690|NCT06433505|DRUG|[14C] BMS-986409 + BMS-986410|Specified dose on specified days
215072691|NCT06433505|DRUG|[14C] BMS-986410 + BMS-986409|Specified dose on specified days
215072692|NCT01974206|BIOLOGICAL|ASP0113|intramuscular injection
215072693|NCT01974206|DRUG|Placebo|intramuscular injection
215072694|NCT06078202|DRUG|ABBV-903|Tablet; oral
215072695|NCT05235971|BEHAVIORAL|Episodic Future thinking|"During a visit with the study team, participants will identify personally-relevant reminders, or cues, that they will receive up to 3 messages a day via text-message over a two-week period.~The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected"
215072696|NCT05235971|BEHAVIORAL|Volitional choice|"Volitional choice creates structured if-then plans to dismantle context-linked alcohol use The messages sent over a two-week period facilitate alternative, healthier choices by identifying and linking risky cues with alternative actions. Participants will receive up to 3 messages a day for 14 days that include assessment and intervention messages.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
215072697|NCT05235971|BEHAVIORAL|Monitoring only|"Participants will receive general psychoeducation about alcohol use, mental health, resources, and a description of the assessments to be completed over a two-week field testing period.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
214933842|NCT02454374|PROCEDURE|Knee Loading protocol|The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
214933843|NCT02454374|PROCEDURE|Routine Physiotherapy Care|Routine Physiotherapy Care
215072698|NCT04356469|BIOLOGICAL|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
214332519|NCT05760092|COMBINATION_PRODUCT|Institutional standard treatment for xerostomia and Long Covid|(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages . When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
214332520|NCT05760092|RADIATION|Photobiomodulation Therapy|Application of Red LED in the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, for 36 seconds, twice a week for 06 weeks.
214332521|NCT05760092|RADIATION|Placebo Photobiomodulation Therapy|All parameters as the number of points, dose and place of application of the PBM will be the same as described in the item PBM therapy Intervention Group, however in the placebo PBM equipment will be turned off. The device activation noise will be recorded and used to mimic the irradiation.
214332522|NCT04260191|DRUG|AMG 910|IV Infusion
214332523|NCT02451345|BEHAVIORAL|Personalized risk model+website+coaching intervention|"A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care."
214332524|NCT04968067|DEVICE|App group|In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
214332525|NCT04968067|DEVICE|Nursing telephone advice (NTA) group|All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
214332526|NCT03650426|PROCEDURE|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
214332527|NCT03650426|PROCEDURE|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
214332528|NCT01643473|BEHAVIORAL|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
214332529|NCT01643473|OTHER|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
214332530|NCT01903694|DRUG|Sorafenib + Pravastatin|
214332531|NCT01903694|DRUG|Sorafenib|
214332532|NCT00789217|PROCEDURE|Immediate skin test|Intradermal test with immediate reading
214332533|NCT05990049|DRUG|Hyadent BG|Hyadent BG is a cross-linked hyaluronic acid. 1,6% cross-linked hyaluronic acid (xHA), 0,2% native hyaluronic acid (HA)
214933844|NCT02226926|DRUG|Aggrenox|
214933845|NCT02226926|DRUG|Persantin Retard|
214933846|NCT02226926|DRUG|Acetylsalicylic acid|
215072699|NCT05093335|DRUG|[68Ga]-Pentixafor|An intravenous bolus of 3 -5 mCi of \[68Ga\]-Pentixafor will be injected in all participants.
215072700|NCT05808179|DEVICE|Light|Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur every 20 s
215072701|NCT05808179|BEHAVIORAL|CBT|Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing
214933847|NCT05276011|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
214933848|NCT05276011|BIOLOGICAL|Placebo Control|2 mL normal saline injection
214933849|NCT02498509|DRUG|CKD-342|treatment for 4 weeks after randomization
215072702|NCT05808179|DEVICE|Sham Light|Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur once
214673648|NCT00353977|BIOLOGICAL|ALVAC-CMV (vCP260)|"ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.~Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.~Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)"
214332534|NCT02661906|OTHER|SKY|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
214332535|NCT00938925|PROCEDURE|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
214332536|NCT00938925|PROCEDURE|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
214332537|NCT03886038|BIOLOGICAL|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
214332538|NCT04946513|OTHER|Muscle volumes were measured on pre- and postoperative MRI scans.|Muscle volumes were measured on pre- and postoperative MRI scans.
214332539|NCT02294292|DRUG|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.
214332540|NCT02294292|DRUG|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
214332541|NCT02294292|PROCEDURE|Endoscopic Variceal Ligation|
214332542|NCT05595798|DIAGNOSTIC_TEST|Airmod breathing sound monitoring|Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
214332543|NCT01519518|DRUG|unfractionated heparin|70 units/kg body weight intravenous
214332544|NCT01519518|DRUG|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
214332545|NCT02517580|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|
214332546|NCT06211582|DEVICE|Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)|The Alkasite-Based Tooth-Colored Material
214332547|NCT06211582|DEVICE|Equia Forte HT ( GC, Tokyo, Japan)|Glass Hybrid Restorative Material
214332548|NCT06211582|DEVICE|Gradia Direct Posterior ( GC, Tokyo, Japan)|Conventional Composite Resin
214332549|NCT03757559|DRUG|Cebranopadol 100 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
214332550|NCT03757559|DRUG|Cebranopadol 400 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
214332551|NCT03757559|DRUG|Hydromorphone hydrochloride 4 milligrams|Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
214332552|NCT03757559|DRUG|Placebo matching hydromorphone|Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
214332553|NCT03757559|DRUG|Placebo matching cebranopadol|Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
214332554|NCT02864797|OTHER|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
214332555|NCT01973829|OTHER|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
214332556|NCT00030797|DRUG|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
214332557|NCT00030797|DRUG|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
214332558|NCT01312909|DRUG|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
214332559|NCT01312909|DRUG|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
214332560|NCT01312909|DRUG|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
214332561|NCT00753441|PROCEDURE|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
214332562|NCT00753441|PROCEDURE|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
214332563|NCT01151553|DEVICE|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
214332564|NCT02310438|OTHER|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
214673649|NCT00641940|BEHAVIORAL|Girls in Transition (GT) program|In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
214673650|NCT00641940|BEHAVIORAL|Waitlist Control|Participants in the waitlist control group will complete the GT program during the third year of the study.
214933850|NCT02498509|DRUG|Mometasone furoate|treatment for 4 weeks after randomization
214933851|NCT02498509|DRUG|Levocabastine HCL|treatment for 4 weeks after randomization
214332565|NCT04877301|DEVICE|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter
214332566|NCT04877301|PROCEDURE|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter
214332567|NCT04944342|OTHER|No intervention.|No intervention.
214673651|NCT03631329|DIAGNOSTIC_TEST|Doppler sonographic measurement|First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
214933852|NCT05848323|BEHAVIORAL|4-week Relaxation Training|A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, b) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery, and c) goal setting and problem-solving barriers focused on integrating relaxation practices into daily routine.
214933853|NCT05848323|BEHAVIORAL|4-week Behavioral Activation|A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
215072703|NCT05871476|BEHAVIORAL|Hospital Cohort Care Intervention at the hospital|There will be 3 different cohort groups for the patients: 1) Unknown CRE colonisation status with increased barrier precautions (all patients until screening results arrive will belong to this group unless there are available screening results from referral hospital), 2) CREpos, and 3) CREneg. CREpos patients (2) will be treated in one area of the ICUs by specially assigned nurses/personnel.
215072704|NCT05871476|BEHAVIORAL|, Household Education Communication Hygiene Intervention, Livestock Antibiotic Intervention|The intervention will focus on two main measurable outcomes: 1) Decrease feco-oral-animal transmission route to prevent in-HH and community spread of CRE +/- CoRE. 2) Decrease unindicated community use of ABs for humans and animals. This WP focuses on a one health intervention in collaboration with local health authorities, developing and implementing an HH Education Communication Hygiene Intervention (HECHI) to improve HH hygiene and health management and reduce the risk of transmission between humans and animals, a Provider Engagement Intervention (PEI) to improve case management of common infection and decrease unindicated AB, and and a Livestock AB Intervention (LAI) to reduce the use of AB in livestock through improved biosecurity conditions and animal husbandry.
215072705|NCT02517892|PROCEDURE|Biopsy|
215072706|NCT03192020|PROCEDURE|Percutaneous needle fasciotomy (PNF)|The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.
215072707|NCT03192020|DRUG|Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
214332568|NCT04365322|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
214332569|NCT04297046|DEVICE|PCA (patient controlled analgesia)|Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.
214332570|NCT03383432|DEVICE|Intrauterine device|Copper T 380 A
214332571|NCT03383432|RADIATION|Ultrasound|Transabdominal ultrasound
214332572|NCT03383432|PROCEDURE|uterine sounding sparing technique|we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
214332573|NCT00913159|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
214332574|NCT05684887|OTHER|Digital based contact tracing|"* Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~* Immediate access to the contact list in Mamal Pro once validated by the health care worker.~* Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~* Contacts will be invited to go to the nearest testing facilities/units to get tested.~* Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~* Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module."
214332575|NCT03548844|PROCEDURE|local excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
214332576|NCT03548844|PROCEDURE|total mesorectal excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
214332577|NCT06263777|OTHER|Nurses training program on early detection of disability|It included four main elements, which are: a booklet defining different disabilities, a list of the guidelines for early detection, a guide for family guidance for families of children with disabilities, a monitoring and follow-up form for 8 cases of children with disabilities). The program consisted of twelve training sessions with a total of 48 hours (4 hours per session) and was based on the techniques of lecture, dialogue, working groups, cooperative learning techniques and participatory learning
214332578|NCT05517239|DRUG|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
214933854|NCT05848323|BEHAVIORAL|4-week Cognitive Therapy|A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, b) labeling thoughts as helpful, unhelpful, or neutral, c) using distraction to cope with unhelpful thoughts, d) challenging and changing unhelpful thoughts, e) problem solving barriers to coping with or changing unhelpful thoughts.
214933855|NCT05390723|BEHAVIORAL|Communciation intervention|The investigators cannot reveal the manipulated communication as this might influence participant outcomes.
214332579|NCT03921268|DRUG|AZD1402|AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
214933856|NCT06851663|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
214933857|NCT06851663|DRUG|[68Ga]Ga-NOTA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RT4 injection.
214933858|NCT06851663|DRUG|[18F]F-RESCA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
214933859|NCT06851663|DRUG|[18F]F-RESCA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RT4 injection.
214933860|NCT05919849|BEHAVIORAL|Brief online writing intervention|Participants will be instructed to write for 20 minutes across 3 consecutive days. They will be writing based on the prompts given to them.
214933861|NCT05919849|OTHER|Control condition|Participants will be instructed to write in order to control for time and writing engagement.
215072708|NCT03192020|PROCEDURE|Limited fasciectomy (LF)|LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
214332580|NCT03527108|DRUG|Nivolumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of nivolumab will be fixed at 240 mg. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
214332581|NCT03527108|DRUG|Ramucirumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of ramucirumab will depend upon the patient weight as noted below. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
214332582|NCT04866134|DRUG|ERAS-007|ERAS-007 will be administered orally as specified in Arm description.
214332583|NCT04866134|DRUG|ERAS-601|ERAS-601 will be administered orally as specified in Arm description.
214933862|NCT05597917|DRUG|Trabectedin|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
214933863|NCT05597917|BIOLOGICAL|tTF-NGR|Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following day, q d 22 x until disease progression or contraindications against further application.
215072709|NCT03645941|BEHAVIORAL|Facebook Group|The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
214933864|NCT06272760|OTHER|Home-based hand-arm bimanual intensive training (Tele-HABIT)|Hand-Arm Bimanual Intensive Therapy (HABIT) is a therapeutic approach designed to improve the motor skills and functional use of both arms in individuals with conditions such as cerebral palsy. The core principle of HABIT is to encourage voluntary exercise by actively engaging the affected side, which may be weaker or partially paralyzed, in various activities. This approach aims to reduce physical and mental discomfort while maximizing the effectiveness of the training. HABIT has been adapted into a home-based format by ZOOM, referred to as Home-Based HABIT (H-HABIT).
214332584|NCT05727358|BEHAVIORAL|Group-based Acceptance and Commitment Therapy|G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
214332585|NCT01256775|DRUG|NCX-4016|NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
214673652|NCT03240640|PROCEDURE|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
214933865|NCT05756231|BEHAVIORAL|SIHT-16|a pencil-paper assessment tool.
214332586|NCT01256775|DRUG|NCX4016 placebo|NCX4016 placebo b.i.d. for 6 months
214933866|NCT04516343|DEVICE|Robotic Ankle Assist Device (RAAD)|The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP
214933867|NCT06330311|OTHER|Physiotherapy|Evidence-based multimodal physiotherapy treatment based on learning and motor control
214933868|NCT06146010|OTHER|No intervention|Once the patient or their legal guardian has given their written consent, a patient is included in the leptomeningeal disease register. Due to the rapid course of the disease and potential rapid deterioration, the documentation of the course of the disease of the individual patients is to be carried out retrospectively from the data recorded during the course of the clinical routine for the entire duration of the study or until the death of the participating patients after the written consent of the patients. The registry's data sources are the diagnostic findings made at the center and doctors' letters from routine clinical practice. The participating centers carry out the assessment of the participants' performance status so that the patients do not have to complete any study-related questionnaires.
214332587|NCT05105269|OTHER|Treatment from a physiotherapist|Any treatment provided by a physiotherapist e.g. exercise, advice and massage
214332588|NCT03738904|COMBINATION_PRODUCT|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
214332589|NCT03738904|COMBINATION_PRODUCT|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
214933869|NCT02179606|DEVICE|Dermalax Implant Plus|Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
215072710|NCT00726791|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
215072711|NCT02144688|DRUG|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
215072712|NCT06235593|BEHAVIORAL|Self-care Intervention|"The intervention will focus on self-care behavior of people with chronic diseases according to two distinct periods (through a longitudinal study - follow-up nursing interventions):~(i) baseline; and (ii) 4 months;"
214332590|NCT01383681|OTHER|No treatment|There was no treatment in this study.
214332591|NCT05487924|OTHER|SVV-GDHT|GDHT guided by SVV using Flotra/Vigileo monitor
214332592|NCT05487924|OTHER|O2ER-GDHT|GDHT guided by O2ER
214332593|NCT05487924|OTHER|conventional care|conventional fluid therapy without GDHT
214332594|NCT06168643|OTHER|Core stability|Physical therapy interventions will include core stability exercises which will be demonstrated and will be checked if they are being performed correctly. The exercises guided shall be performed 3 times daily and logbook will be provided to keep the record of exercise program.
214332595|NCT06168643|OTHER|Core stability with pregnancy support belt|Participants will receive same information and exercises as those in Group A. they will also receive pregnancy support belt. The logbook will be provided to keep the record of hours the belt has been worn along with exercise record.
214332596|NCT01266772|DRUG|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
214332597|NCT01266772|DRUG|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
214332598|NCT01312116|BEHAVIORAL|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
214332599|NCT01312116|BEHAVIORAL|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
214332600|NCT00337649|DRUG|Epothilone D|≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks
214332601|NCT00337649|DRUG|Herceptin|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
214332602|NCT03444857|DEVICE|Continuous positive airway pressure|The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
214332603|NCT00938431|DRUG|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
214332604|NCT04849975|OTHER|Pelvimetric measurements|The patients in this group are pregnant women after failure of external manual version (EMV) in case of breech fetal presentation. The participants will successively perform MRI pelvimetry (conventional management) and EOS imaging.
214332605|NCT05059392|BEHAVIORAL|Training for Awareness, Resilience and Action (TARA)|See arm description
214332606|NCT04962269|DIAGNOSTIC_TEST|MRI|monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
214933870|NCT02179606|DEVICE|Restylane Sub-Q|Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
214933871|NCT00419601|DRUG|Remifentanyl|Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
214933872|NCT00419601|DRUG|Fentanyl|start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
214933873|NCT02928783|BEHAVIORAL|Home-based cardiac rehabilitation|
214933874|NCT04927377|BEHAVIORAL|AI4DM|Those in the AI4DM intervention arm will receive weekly and bi-weekly calls for six months, access to home and online technology, diabetes-related multimedia educational content, a technology package including a voice-assistive device, wireless glucometer, and wrist-worn activity monitor
214933875|NCT04927377|BEHAVIORAL|Attention-control|Those in the Attention-control Group will receive telecoaching calls at the same frequency of the Intervention Group. Coaching calls will focus on general wellbeing, rather than diabetes-related topics. The Attention-control Group will serve as an untreated comparison group for the Intervention Group.
214933876|NCT03611231|DRUG|Chidamide|Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.
214933877|NCT01877551|DRUG|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
214933878|NCT01877551|OTHER|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
214933879|NCT01617772|DRUG|Atorvastatin|Atorvastatin 20 mg
214933880|NCT01617772|DRUG|L-Carnitine|1000mg L-carnitine
214933881|NCT01617772|DRUG|Placebo|Identically looking placebo
214933882|NCT04853342|DRUG|Drug: Furmonertinib 80 mg|The initial dose of Furmonertinib 80 mg once daily
214933883|NCT04853342|DRUG|Furmonertinib 80 mg placebo|The initial dose of Furmonertinib 80 mg once daily
214933884|NCT02697890|DEVICE|FDBA (MinerOss®) + Mucograft® seal|Collagen matrix membrane for soft-tissue regeneration
215072713|NCT06812026|OTHER|no melatonin and massage|receiving no melatonin and massage
215072714|NCT06812026|DIETARY_SUPPLEMENT|receive melatonin|receiving only melatıonin pills
215072715|NCT06812026|OTHER|receiving lymphatic drainage|receiving lymphatic drainage massage
215072716|NCT06655363|OTHER|Anatomical description|Anatomical description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
215072717|NCT06655363|OTHER|Radiological (MRI) description|Radiological (MRI) description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
215072718|NCT06601218|DRUG|Oral cannabis low THC|4 months daily dosing with oral cannabis low THC
215072719|NCT06601218|DRUG|Placebo Comparator|4 months of daily dosing with oral placebo
215072720|NCT06601218|DRUG|Oral cannabis high THC|4 months of daily dosing with oral cannabis with high THC
214933885|NCT02697890|DEVICE|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|Standard of Care
215072721|NCT06601218|DRUG|Oral cannabis THC/CBD|4 months of daily dosing with oral cannabis with THC and CBD
215072722|NCT06593184|DEVICE|Trans-spinal magnetic stimulation|Trans-spinal magnetic stimulation activates afferent spinal roots and increases cortical excitability.
215072723|NCT06593184|DEVICE|Sham Comparator|Sham trans-spinal magnetic stimulation involves masking, where the sound of stimulation persists even though no magnetic pulses are delivered
215072724|NCT06650748|DRUG|Dalpiciclib|Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.
215072725|NCT06650748|DRUG|Letrozole|2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
215072726|NCT03709745|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
215072727|NCT03709745|DRUG|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
215072728|NCT00081549|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
214332607|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 1|The performance of behavioral locomotion tasks is performed on 4 visits on pilot phase (2 in real condition and 2 in virtual reality in D1 and M1)
214332608|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 2|The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
214332609|NCT02734485|DEVICE|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
214332610|NCT02734485|DEVICE|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
214332611|NCT00796029|DRUG|14C-paliperidone|
214332612|NCT02086591|DRUG|Doxycycline|
214332613|NCT04791358|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
214933886|NCT06652438|DRUG|Revumenib|day 1- 28 per cycle
214933887|NCT06652438|DRUG|Placebo|day 1- 28 per cycle
215072729|NCT06984926|DRUG|BI 3810477|BI 3810477
215072730|NCT06984926|DRUG|Placebo|Placebo for BI 3810477
214332614|NCT05031624|DRUG|CDX-0159|Single subcutaneous dose of one of four dosages of CDX-0159
214332615|NCT05031624|DRUG|Normal saline|Single subcutaneous dose of normal saline
214933888|NCT06157164|OTHER|UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)|Simultaneous UroLift™ and Holmium Laser Enucleation of the Prostate (HoLEP) for the Treatment of BPH in Men with Prominent Median Lobe Desiring Preservation of Ejaculation
214332616|NCT03309436|DRUG|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
214332617|NCT03309436|PROCEDURE|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
214332618|NCT02509689|BEHAVIORAL|Global Z-Score Neurofeedback Training|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
214332619|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
214332620|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
214332621|NCT06739915|OTHER|TUTT-PT Intervention|All TUTT-PT arm participants who provide written informed consent will have sputum collected for TB testing (if sputum was not already collected by the clinic staff) and will receive a clinical evaluation for the presence of TB symptoms (cough, fever, weight loss, night sweats) and serious contraindications for TPT initiation (known liver disease, high alcohol intake (men: \>5 drinks/day or \>15 drinks/week; women: \>4 drinks/day or \>8 drinks/week), or strong clinical suspicion of TB disease as evidenced by severity of symptoms, including haemoptysis, or Karnofsky score ≤50. PLHIV for whom the study nurse does not have a strong clinical suspicion of TB nor evidence of serious TPT contraindications will be referred to clinic staff for TPT initiation, irrespective of the presence or absence of TB symptoms.
215072731|NCT04432064|DEVICE|Active TI-NDBS|In the active TI-NDBS condition, subjects will receive stimulation for 60 minutes applied to the brain through scalp electrodes. There will be a maximum of 2 mA per electrode pair and no single region will receive more than 2 mA because the currents will be administered to distinct regions. At the beginning of each stimulation period, the current will increase slowly at a constant rate for 30 seconds until it reaches the appropriate intensity. At the end of the stimulation, the current will decrease slowly for 30 seconds until it reaches zero.
214332622|NCT04320160|PROCEDURE|Platelet rich plasma|"Eight milliliters of blood sample will be aspirated from the patient's peripheral vein, and the sample will be centrifuged at 1,500 rpm for 5 minutes.~A 30-G needle will be used for superficial intradermal (ID) microinjections (0.1 mL per injection and space about 1 cm apart)"
214332623|NCT04320160|PROCEDURE|Fractional CO2 laser|"Fifteen lesions will be treated by Fr: CO2 laser (10,600 nm; KES Corporation, Beijing, China).~Scanner spot size will be adjusted based on the lesion size. Density selected will be 0.6 in the static mode.~Two passes with minimal overlap will be delivered. The laser will be applied to the vitiligo lesion and over a thin rim of healthy skin"
214933889|NCT05622071|DRUG|Tislelizumab|Tislelizumab 200 mg will be administered every 3 weeks IV for a maximum of 2 years
214933890|NCT05674916|DIAGNOSTIC_TEST|Point-of-care ultrasound-driven diagnostic pathway|Focused lung ultrasound will include 8 zones (anterior and lateral) and evaluate pneumothorax, interstitial syndrome, lung consolidation, and pleural effusion. Focused cardiac ultrasound will include four views (subxiphoid four-chamber view, parasternal long-axis view, parasternal short-axis view, and apical four-chamber view) and evaluate pericardial fluid, right ventricle dilation, and left ventricular systolic contractility.
214933891|NCT02659514|DRUG|Poziotinib|8 mg oral tablets, administered QD.
215072732|NCT04432064|OTHER|Sham TI-NDBS|This is the control condition in which participants will receive sham stimulation for 60 minutes.
215072733|NCT04432064|DEVICE|tDCS|This is a well established method of brain stimulation and will be used to compare against the efficacy of TI-NDBS in the reduction of nicotine craving and inhalation. Participants will receive stimulation for 60 minutes.
215072734|NCT06605651|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
215072735|NCT06605651|DRUG|0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
215072736|NCT06657651|PROCEDURE|immediate implant placement with dentin-derived membrane|immediate implant placement with dentin-derived membrane and allograft in mandibular molar area
215072737|NCT06657651|PROCEDURE|immediate implant with extended platelet rich fibrin membrane|immediate implant with extended platelet rich fibrin membrane and allograft in mandibular molar area
215072738|NCT00453609|DRUG|long-lasting injectable naltrexone|
214332624|NCT06247163|RADIATION|PET based Raditherapy boost|An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
214332625|NCT04390750|BEHAVIORAL|Care Partner-Assisted Intervention|Tailored teaching and coaching
214332626|NCT01899469|PROCEDURE|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
215072739|NCT06658002|DRUG|Cyclosporine A|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
214933892|NCT06059690|DIAGNOSTIC_TEST|pH Measurement of in vivo tissue|The investigator will identify multiple (2-5) 5-8mm diameter spherical targets on GI maps for use in stereotactic pH measurement and biopsy acquisition. All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target. After the pH probe is removed, the biopsy needle will be placed into the cannula and standard-of-care biopsy tissue will be obtained from the same area where pH measurements were recorded.
215072740|NCT06658002|OTHER|Placebo Comparator: Placebo|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
214332627|NCT01899469|PROCEDURE|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
214332628|NCT01899469|PROCEDURE|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
214332629|NCT04035785|DRUG|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
215072741|NCT06658652|DRUG|Enlicitide decanoate|Oral tablet
215072742|NCT06661551|PROCEDURE|Miniscrew insertion in dynamic-computer guided surgery|"The intervention more executed in the literature is by using static computer-guided systems (s-CAS) . However, the s-CAS has limitations, including the time and cost associated with guide production, furthermore, the guide's bulk prevents its use in patients with limited mouth opening, and reduced irrigation potentially leads to overheating and bone burns during implant placement. Additionally, the inability to adjust the surgical plan intraoperatively, the lack of real-time visualization during implant site preparation and implant insertion, and the requirement for specific surgical kits for each implant system present further challenges.~Dynamic navigation systems offer several benefits as highlighted in the literature, including: real-time feedback of the position of surgical drill or implant, allowing intraoperative changes adjusting the implant position during the surgery, reduction of risk of injury to adjacent anatomical structures, promotion of accuracy in novices"
215072743|NCT06658691|OTHER|Multidisciplinary approach|"The study investigated a multidisciplinary approach consisting of an endocrinologist, a diabetes specialized nurse, and a clinical pharmacist to assess and improve diabetic foot care by systematic screening, patients' risk categorization, therapy optimization, and tailored education.~Risk of Diabetic Foot Ulcer (DFU) occurrence was assessed and evaluated by the endocrinologist, and the nurse based on the 2019 International Working Group on Diabetes Mellitus (IWGDF). At that point, only the clinical pharmacist knew about patients' allocations.~According to risk stratification, the clinical pharmacist provided intervention patients with educational sessions and tailored materials during scheduled three months follow-up interviews at Jordan University Hospital (JUH) DFU-related clinics.~Moreover, the study evaluated the impacts of the multidisciplinary approach on health-related Quality of Life (QoL) at baseline and at the end of the study. Economic impacts were also further analyzed."
215072744|NCT04448392|DRUG|Valacyclovir|Upon completion of standard of care acyclovir for treatment of neonatal HSV disease, valacyclovir oral suspension (per ASHP recipe), 20 mg/kg every 8 hours, to be given for 2 (up to 7) days
215072745|NCT06660576|PROCEDURE|Cholecystectomy and histochemical analysis of Gallbladder stones|Cholecystectomy and histochemical analysis of Gallbladder stones
215072746|NCT06661408|BEHAVIORAL|Intervention group 1|The women assigned to this group will be shown the newborn bath application video prepared by the researchers in groups of 2-4 people in the form of a projection presentation.
215072747|NCT06661408|BEHAVIORAL|Intervention group 2|In groups of 2, the researcher will first explain the stages of newborn bathing application by the researcher in the form of a projection presentation, and then the pregnant women will be provided to perform the newborn bathing application on the newborn bathing model and tools simultaneously with the researcher.
215072748|NCT06608264|OTHER|stress ball intervention|Stress ball intervention; A medium hard, round, high quality stress ball of the same brand will be given to the patient\&amp;#39;s actively used hand 1-2 minutes before starting the continuous passive movement exercise by the researcher.The patient will be asked to squeeze and relax the stress ball for a count of 5 during continuous passive movement.After squeezing the stress ball, the patient should count to 5 and then relax it.The patient will be asked to continue this process until the continuous passive movement exercise is completed.
214332630|NCT03913143|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
214332631|NCT03913143|OTHER|Sham|Sham-Procedure (no experimental drug administered)
214332632|NCT01774903|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
214332633|NCT03411226|PROCEDURE|re-TREPP|repeated hernia repair via the TREPP technique
214933893|NCT04869319|BEHAVIORAL|MyChart message|Message subjects through MyChart to follow-up with their provider to schedule a follow up HbA1C test.
214332634|NCT01491477|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
214332635|NCT01491477|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
214332636|NCT05297045|DRUG|RGT001-075|Oral GLP1 Receptor Agonist
214332637|NCT05297045|OTHER|Placebo|Placebo comparator
214332638|NCT00741234|DRUG|SB939|SB939 taken orally in a 4-week cycle.
214332639|NCT00741234|DRUG|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
214332640|NCT00593372|BEHAVIORAL|Spaced Retrieval Training|Increasing time to remember important information.
214332641|NCT03855215|DIAGNOSTIC_TEST|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
214332642|NCT03188965|DRUG|Elimusertib (BAY1895344)|Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
214332643|NCT02782650|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences"
214332644|NCT05491707|OTHER|Music|Patients will choose a genre of music from the following list; pop, gospel, classical, jazz, and soul, at the preoperative visit. This will be played on disposable ear phones at a self-selected volume for the duration of the surgical procedure.
214332645|NCT02212730|DRUG|Pembrolizumab Pre-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
214332646|NCT02212730|PROCEDURE|Surgical Resection|Standard of care surgical resection of RCC tumor
214332647|NCT02212730|DRUG|Pembrolizumab Post-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
214332648|NCT03730935|DEVICE|Respiratory muscle endurance training|Respiratory muscle endurance training performed over the duration of 4 weeks
214332649|NCT04992949|DRUG|CPX-351|"Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study~Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.~Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle"
214332650|NCT00228891|PROCEDURE|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
214332651|NCT00228891|PROCEDURE|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
214332652|NCT04973761|OTHER|Zirconium crowns|Prefabricated pirmary anteroir teeth zirconium crowns
214332653|NCT04973761|OTHER|Strip composite crowns|Strip composite crowns
214332654|NCT05520671|OTHER|Gamified online quizzing platform|"TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days."
214933894|NCT00455559|DRUG|Perifosine|
215072749|NCT06608264|OTHER|hand holding intervention|Hand holding intervention will be performed by the person the patient prefers. Before the continuous passive movement exercise, the person concerned will sit next to the patient\&#39;s bed and warm their hands at a level that will not disturb the patient.1-2 minutes before the continuous passive motion exercise, the patient will hold the patient\&#39;s hand with one hand, without using gloves, with moderate pressure, without rubbing or squeezing to an uncomfortable level.Hand holding intervention will continue until the continuous passive movement exercise is completed.
215072750|NCT06662006|DRUG|nal-IRI,5-fu,LV, benmelstobart, anlotinib|liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
214933895|NCT00455559|DRUG|Imatinib Mesylate|
214933896|NCT03823079|DRUG|rhTPO|rhTPO 300u/kg, subcutaneous injection, qd
214933897|NCT03823079|DRUG|irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
214933898|NCT03823079|DRUG|Raltitrexed|3mg/m2 q3w
214933899|NCT03823079|RADIATION|radiotherapy|in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
214933900|NCT03823079|DRUG|rhIL-11|rhIL-11 50ug/kg, subcutaneous injection, qd
215072751|NCT06673667|DRUG|KT-621|Oral drug
215072752|NCT06673667|DRUG|Placebo|Oral drug
214933901|NCT00006007|DRUG|gemcitabine hydrochloride|
214933902|NCT00006007|DRUG|pemetrexed disodium|
214933903|NCT01504607|PROCEDURE|Congenital Cataract Surgery|Congenital cataract surgery with IOL implantation
214673653|NCT03240640|PROCEDURE|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
214933904|NCT03387228|OTHER|Pain education|"Pain education intervention we plan to use is based on Explain Pain developed by Moseley and Butler in 2003. The pain education handout and materials produced in Nepali will be proof-read and pre-tested in 5 - 10 Nepalese with LBP as needed, and corrected, if necessary.~Dosage: A single (approximately) one hour pain education will be delivered to the PEG.~Home advice: A printed handout of the pain education material will be provided only to the study participants in the PEG. Participants will be advised to read them (or have family members read them), followed by walking for 30 minutes."
214933905|NCT03387228|OTHER|Control group|"The control participants will receive physiotherapy care based on the recent clinical practice guidelines. This control group intervention will comprise of: (1) education (advice to remain active); (2) massage to back; (3) superficial heat; and (4) static cycling or (treadmill) walking with the aim to promote physical activity. Although superficial heat is recommended in the acute/subacute LBP, we included this as a common treatment for all types of LBP including chronic LBP, which could be a part of self-management.~Duration of treatment: 1 hour. Home advice: Participants will be advised to self-manage their back pain based on the information provided. Home exercise leaflet with emphasis on the value of exercise to increase strength and endurance, followed by a 30 minutes walking."
214933906|NCT04560283|DRUG|Vaginal gel HYALOGYN®|Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks
214933907|NCT04560283|BEHAVIORAL|Expectant management|Expectant management for 12 consecutive weeks
214933908|NCT02092480|BEHAVIORAL|If I Were Jack|The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
214933909|NCT00742872|DRUG|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
214933910|NCT00742872|DRUG|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
214933911|NCT06439966|DRUG|ABBV-787|Intravenous (IV) Infusion
215072753|NCT06606795|OTHER|Spinal Manipulation|For the treatment to be applied in the SMT group, segmental dysfunctions will be determined using static and dynamic palpation techniques and the applications will be applied with a chiropractic method, high-speed, low-amplitude spinal manipulation method, at the level of the dysfunctional spine.
215072754|NCT04505553|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
215072755|NCT04505553|PROCEDURE|Acupressure Therapy|Undergo acupressure
215072756|NCT04505553|PROCEDURE|Oral Cryotherapy|Undergo oral cryotherapy
215072757|NCT04505553|OTHER|Questionnaire Administration|Ancillary studies
215072758|NCT04505553|OTHER|Quality-of-Life Assessment|Ancillary studies
215072759|NCT06687668|OTHER|Short Leg Walking Plaster Cast|A short leg walking plaster cast that extends from the head of the metatarsal to the mid-calf. This cast provides stability to the fracture site while allowing limited weight-bearing, and is designed to restrict inversion and eversion movements, thereby reducing the risk of fracture displacement. Applied for six weeks.
215072760|NCT06687668|OTHER|Walking Foot Plaster Cast|A walking foot plaster cast that covers the foot from the metatarsal heads but leaves the toes exposed. This cast allows weight-bearing while restricting side-to-side movement, providing support to the fracture area without immobilizing the ankle. It will be used for six weeks.
215072761|NCT07028645|DRUG|desmopressin melt form 120 μg|Desmopressin 120 mcg will be used frist-line drug in the treatment of enuresis.
215072762|NCT07028645|DRUG|Desmopressin lyophilisate (Melt)|Desmopressin 240 mcg will be used for the patients who have not responsive to desmopressin 120 mcg.
215072763|NCT07028645|DRUG|Propiverine tablet|Propiverine (a dose of 0.8 mg/ kg) will be used for the patients who have -response to treatment with desmopressin 240 mcg
215072764|NCT04919889|OTHER|Exercise prescription|All individuals referred to the community-based Exercise on Prescription program
215072765|NCT07032701|OTHER|Best Practice|Undergo SOC non-adherent dressing wound care
215072766|NCT07032701|OTHER|Educational Intervention|Receive SNaP education
215072767|NCT07032701|OTHER|Educational Intervention|Receive SOC wound care education
215072768|NCT07032701|OTHER|Electronic Health Record Review|Ancillary studies
215072769|NCT07032701|OTHER|Follow-Up Care|Attend SNaP device follow-up visits
215072770|NCT07032701|OTHER|Follow-Up Care|Attend SOC wound care follow-up visits
215072771|NCT07032701|OTHER|Medical Device Usage and Evaluation|Undergo dNPWT with SNaP device
215072772|NCT07032701|PROCEDURE|Negative Pressure Wound Therapy|Undergo dNPWT with SNaP device
214332655|NCT05520671|OTHER|Conventional quizzing platform|"The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days."
214332656|NCT00064441|DRUG|OPC-6535 Tablets (drug)|
214332657|NCT03112434|DRUG|Botulinum toxin type A|Botox injection in upper extremity for spasticity in pediatric CP patients
214332658|NCT04518735|OTHER|Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19|Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
214332659|NCT01534468|BIOLOGICAL|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
214332660|NCT02880371|DRUG|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
214332661|NCT02880371|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
214332662|NCT00854087|DRUG|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
214332663|NCT00854087|DRUG|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
214332664|NCT01782677|PROCEDURE|Bilateral Surgical Resection of Carotid Bodies|
214332665|NCT01777997|DRUG|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
214332666|NCT02897739|PROCEDURE|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
214332667|NCT02897739|BIOLOGICAL|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
214332668|NCT02897739|RADIATION|PET CT|PET study for metabolic pathway study
214332669|NCT02897739|BEHAVIORAL|Psychological assessment|Assessment by a psychologist
214332670|NCT04667819|DRUG|Sodium Hyaluronate|We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
214933912|NCT05249322|OTHER|Follow-up alternating between face-to-face consultation and teleconsultation every three months.|"The intervention will be an alternate follow-up every three months with:~* A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine.~* An usual in-hospital consult of about 1h30 with paramedical and medical consult."
214933913|NCT06667323|OTHER|Integrated health service delivery for very young adolescent girls|The proposed HPV-VISION intervention will aim to increase girl-centered access to HPV vaccination and other VYA services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health post level.
214933914|NCT03264781|DRUG|Cyclofem|Intramuscularly injection 0.5 ml of Cyclofem or placebo
215072773|NCT07032701|OTHER|Photography|Ancillary studies
215072774|NCT07032701|OTHER|Questionnaire Administration|Ancillary studies
214332671|NCT00767546|DRUG|Botulinum toxin|60- 100 units Local injection to the rash area
214332672|NCT01787513|OTHER|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
214332673|NCT01787513|OTHER|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
214332674|NCT02660359|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
214673654|NCT01380093|DRUG|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
214673655|NCT01380093|DRUG|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
214673656|NCT01380093|DRUG|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
214933915|NCT02684409|DRUG|PROT-CL-NP101-015.01|
215072775|NCT07034144|OTHER|Drop Table Technique|"The Drop Table Technique is a chiropractic intervention that utilizes a segmented treatment table with adjustable sections that can be elevated slightly and then dropped.~During the procedure, a high-velocity, low-amplitude (HVLA) thrust is applied while the specific segment of the table drops slightly in coordination with the thrust.~This technique aims to reduce the resistance experienced during the adjustment and to enhance the mechanical effect on targeted spinal joints.~In this study, the Drop Table Technique will be specifically applied to the cervical spine to address mechanical neck pain.~All applications will be performed by a licensed chiropractor using standardized positioning and adjustment protocols to ensure consistency across sessions."
214332675|NCT02660359|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
214332676|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
215072776|NCT07034144|OTHER|Cervical Spine Manipulation|"Cervical spinal manipulation (SM) will be applied with the participant supine to restrictions found on motion palpation, following the technique described by Bergmann and Peterson. The participant's head and neck will be simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7)-to the end of passive range of motion (ROM).~Subsequently, a high-velocity, low-amplitude thrust will be delivered in the direction of restricted movement. Participants with greater ROM restriction in the lateral plane will receive more laterally-to-medially directed thrusts. Participants with more restriction in rotation will be given thrusts in the direction of restricted axial rotation, and those with more restriction in extension will receive more anteriorly directed thrusts."
214332677|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
214332678|NCT04498884|DRUG|Rinsulin® mix 30/70|one subcutaneous injection at a dose of 0.4 IU/kg
214332679|NCT04498884|DRUG|Humulin® M3|one subcutaneous injection at a dose of 0.4 IU/kg
214332680|NCT03394014|PROCEDURE|sciatic nerve block|blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
214332681|NCT02414087|DEVICE|ICB Medical insoles|"Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
214332682|NCT04978857|OTHER|autobiographic movie|viewing an autobiographic film through a virtual reality headset
214332683|NCT01842009|DEVICE|High Definition transcranial Direct Current Stimulation|
214332684|NCT01807130|OTHER|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
214332685|NCT01807130|OTHER|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
214332686|NCT03165201|DEVICE|LiverMultiScan|We will study participants who are due to be evaluated for possible liver transplant rejection. There will be no change to usual care as part of the study, but patients will get an additional MRI scan, so that the results can be compared to the biopsy results. Each centre has a consultant radiologist specialising in liver imaging with experience in post-transplant review; the radiologist will review the MRI scans and inform the patient's doctor if any structural liver abnormalities are found (e.g. abnormal vessels, haemangiomas, tumours or cysts) as this may have implications for the patient's planned biopsy.
214332687|NCT01546415|DRUG|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
214332688|NCT05453305|PROCEDURE|Control group: Traditional venipuncture, on the stretcher.|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.
214347164|NCT05244525|DRUG|Bupivacaine with Epinephrine|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
215072777|NCT07033312|DRUG|oral hyaluronate and injection|The patient receives oral hyaluronate and hyaluronate injection
215072778|NCT07033312|DRUG|hyaluronate injection|The patient receives hyaluronate injection only
215072779|NCT07034469|PROCEDURE|air|use of sterile air as a tamponade
215072780|NCT07034469|PROCEDURE|Gas SF6 (Sulfur Hexafluoride) and others|use of fluorinated gases such as SF6, C2F6 or C3F8 as a tamponade agent
215072781|NCT06887244|OTHER|Tele-consultation|Tele-consultation procedure is defined as a telephone consultation with the patient conducted by nursing staff with an appropriate level of experience in digestive endoscopy
215072782|NCT06895369|DRUG|Pucotenlimab|patients will receive 3 cycles of pucotenlimab combined with TP (cisplatin + docetaxel) as neoadjuvant therapy, followed by standard surgical treatment
215077933|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes
214332689|NCT05453305|PROCEDURE|Intervention group: DAK method venipuncture, simulating a hug|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
214332690|NCT03840161|DEVICE|non-invasive tissue glucose prediction|Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
214332691|NCT00907894|DRUG|LDT600 (Telbivudine)|LDT600 (Telbivudine)
214332692|NCT04375423|BEHAVIORAL|Ecological momentary assessment and intervention: Behaviorally-dependent messaging|In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks
214332693|NCT04375423|BEHAVIORAL|Ecological momentary assessment only|Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
214332694|NCT00127790|BEHAVIORAL|CBT for Insomnia (CBT-I)|
214332695|NCT00127790|BEHAVIORAL|CBT for Pain (CBT-P)|
214332696|NCT04734353|DRUG|Prasugrel 5mg|Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months
214332697|NCT04734353|DRUG|Ticagrelor 60mg|Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
214332698|NCT04751253|DEVICE|High Intensity Laser Therapy|different doses of energies of high-intensity LASER on pain and functional activity in patients with chronic knee OA.
214332699|NCT05880953|BEHAVIORAL|Parent-to-parent coaching|Parents and parent coaches will meet as needed via the family's preferred method. Engagement may include text messaging, phone conferencing, Zoom conferencing, or occasional in-home or hospital visiting as preferred. Coaching sessions will vary based on family desired frequency and location, but may include: on-site in the family home or hospital room, telephone or video conferencing, or asynchronous contacts via email or text messaging. The template for the intervention includes an initial introductory session which is intended to build rapport and orient the parent to our program. Subsequent session topics may include: addressing specific needs including topics of interviewing and selecting home health agencies, expectation setting for home based nursing care, recruiting for home health team from inpatient settings, and recruiting for home health team from professional and personal networks.
214332700|NCT01340989|PROCEDURE|alteration of the insufflation gas|addition of 4% oxygen
214332701|NCT01340989|PROCEDURE|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~* humidification~* set temperature of 32°C"
214332702|NCT01340989|PROCEDURE|standard pneumoperitoneum|no intervention besides the use of CO2
214332703|NCT06630637|BEHAVIORAL|Glucose-Ketone Index (GKI) monitoring|Ketone and blood glucose monitoring with Abbott Optium Neo up to 10 times per day to observe GKI dynamics for gamification of adherence.
214332704|NCT06630637|BEHAVIORAL|Continuous Glucose Monitoring (CGM)|Monitoring with an Abbott Freestyle Libre to observe glucose dynamics for gamification of adherence.
214332705|NCT06630637|OTHER|Digital dynamometer|Grip strength measurements, right and left hand, up to 20 readings per day per hand.
214332706|NCT06630637|DEVICE|Wearables|All Apple Watch 9 and Whoop data daily \[heart rate variability (HRV), resting heart rate, cardio recovery, sleep duration, composition (stages of sleep) and analogous scores, potential maximum rate of oxygen consumption attainable during physical exertion (VO2 max), basal metabolic rate and potential respiratory rate\].
214933916|NCT03825835|DRUG|30% oxygen group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
214332707|NCT06630637|DIAGNOSTIC_TEST|Blood tests|Pre- and Post-fast (48h) testing of lipid panel, ApoB, ApoA1, CRP, interleukin panel, omega 3:6 ratio, and autophagy analysis. Potential CBC, renal and liver panels to be taken where appropriate.
214933917|NCT03825835|DRUG|60% oxygen group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
214933918|NCT00003913|BIOLOGICAL|anti-thymocyte globulin|
214933919|NCT00003913|BIOLOGICAL|filgrastim|
214933920|NCT00003913|DRUG|busulfan|
214933921|NCT00003913|DRUG|cyclophosphamide|
215077934|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises|The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.
215077935|NCT06113224|PROCEDURE|Blood collection T0|2 blood samples will be taken in addition to the pre-operative check-up.
215077936|NCT06113224|PROCEDURE|Blood collection 6 months|1 blood sample will be taken 6 months after surgery.
214933922|NCT00003913|DRUG|methylprednisolone|
214933923|NCT00003913|PROCEDURE|umbilical cord blood transplantation|
214933924|NCT00003913|RADIATION|radiation therapy|
214332708|NCT06630637|DIAGNOSTIC_TEST|Stool tests|"15 g of stool will be collected from the subject pre- and post-fast for microbiome assessment and pre- and post- the first week (the three meal phase). After the first week, the maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast)."
214332709|NCT06630637|DIAGNOSTIC_TEST|Saliva tests|Saliva samples will be collected from the subject pre- and post-fast for microbiome assessment. Maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast).
214332710|NCT06630637|BEHAVIORAL|Fitness intervention|90 minutes of strength and/or cardiovascular training for a minimum of 5 days per week.
214332711|NCT06630637|BEHAVIORAL|Cold & heat intervention|"Cold plunge: at least 3 days per week, 2 sessions of maximum 5 minutes each (minimum 2 minutes between sessions) at a minimum of 6 degrees Celsius. Potential inclusion of GKI measurements before and after plunge.~Heat Therapy: maximum of 2 sessions of 20 minutes each of dry sauna blanket (minimum 5 minutes break between sessions) following the cold plunge intervention."
214332712|NCT06630637|DEVICE|Airofit|"Airofit is a smart breathing training device designed to improve respiratory strength and efficiency. It is used for enhancing sport performance, well-being, and overall health. The device works by providing adjustable resistance to breathing muscles.~5-10 minutes of daily use."
214332713|NCT06630637|BEHAVIORAL|18h fasting|Minimum of 18 hours fasting per day, with feeding window to occur between 5pm-8pm or 12pm-3pm. The fasting procedures will occur only after the Three Meal Phase.
214332714|NCT06630637|BEHAVIORAL|48h fasting|48h fasting maximum twice monthly, at least one week apart. Multivitamin and electrolytes with water, and black coffee or tea (0-calorie drinks) will be consumed.The fasting procedures will occur the Three Meal Phase.
214332715|NCT06630637|BEHAVIORAL|Three meal phase|During the first week of the study, the participant will follow a regime of three meals per day.
214332716|NCT06630637|BEHAVIORAL|Mediterranean-inspired diet|"Regimen of Mediterranean-inspired nutrition comprised of Olive Oil, Olives, Leafy Green Vegetables, Lean Protein (Beef, Chicken, Lamb, Pork, Duck, Salmon, Tuna), Chia Seeds, Pecans, Macadamia, Pumpkin Seeds, Walnuts, Greek Yogurt, Salt, Pepper, Paprika, Cumin, Garlic powder, onion powder; Fruit: Blueberry, Grapefruit; Carbohydrates: Rolled Oats; Hydration: Water, Black Coffee, Black Tea, Coke Zero and 100 Zero sparingly, Ultima electrolytes.~Photographs of meals will be taken to create a visual record of the diet followed. Photographs of the devices will be taken to create a visual record of the blood glucose and ketone concentration results."
214332717|NCT06630637|DIETARY_SUPPLEMENT|Supplements|Multivitamin (Centrum), Vitamin D (Up to 2000 IU per day), Creatine (Up to 2000mg), Fisetin (1 pill), Omega-3 (1 tablet), Turmeric, Pre-Probiotic, Blueberry Extract, Holy Basil Extract.
214332718|NCT06630637|BEHAVIORAL|Generative AI|Feeding ketone data, glucose data (from finger prick and/or CGM), any/all Apple Watch Data, and dietary images into a generative AI platform to convert data into images using any selected prompts, with the intent of the images serving as immediate, visual readouts as a function of activity and/or inactivity.
214332719|NCT06630637|OTHER|Interviews|Three interviews, of 30-60 minutes each one, at baseline, end of three meal phase and end of study, to gain insights into the participant's experience. Exploration of daily routines including diet, exercise and the use of technology and aspects of a healthy lifestyle.
214332720|NCT03292757|DRUG|Indocyanine Green|Fluorescent dye - indocyanine green
214332721|NCT03488381|DEVICE|Soccer Heading|"Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals."
214332722|NCT00388518|DRUG|Actos|45mg po daily
214332723|NCT00388518|DRUG|Placebo|po daily
214332724|NCT00388518|DRUG|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
214332725|NCT06337929|OTHER|CAPOEIRA TRAINING|The protocol of the capoeira training program and the movements (blows, dodges and flourishes) will be based on the Capoeira Abadá method.
214332726|NCT06337929|OTHER|CONTROL GROUP|The protocol of the control group will be based on an intervention with capoeira movements, however, without important cardiovascular, neuromuscular and metabolic demands, being an activity with stretching movements from positions of the capoeira modality itself.
214332727|NCT02464501|OTHER|Paclitaxel administration using the OPC|
214332728|NCT05718622|DEVICE|real EECP|Real EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 150 millimeters of mercury.
214332729|NCT05718622|DEVICE|sham EECP|Sham EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 75 millimeters of mercury.
214673657|NCT04062812|OTHER|the same citrate dosification in both types|match concentrated and dilute citrate protocol
214673658|NCT02365857|DRUG|Dexmedetomidine & Bupivacaine.|Intrathecal injection of Dexmedetomidine \& Bupivacaine.
214673659|NCT02365857|DRUG|Bupivacaine Only.|Intrathecal injection of Bupivacaine only.
214933926|NCT01968707|DRUG|ChloraPrep Hi-Lite Orange|Apply topically.
214933927|NCT01968707|DRUG|Normal saline|Apply topically.
214933928|NCT01968707|DRUG|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
214933929|NCT01968707|DRUG|3M CHG/IPA Prep Tint 26-mL|Apply topically
214933930|NCT00916344|DEVICE|EVIA Pacemaker|patient has standard indication for pacemaker therapy
214933931|NCT02395237|DRUG|: Amaryl® M IR 2/1000|
214933932|NCT05912231|RADIATION|Accelerated Proton Beam Radiation Therapy (PBT)|per protocol
214933933|NCT05912231|RADIATION|Accelerated Photon Radiation Therapy (XRT)|per protocol
214933934|NCT03936465|DRUG|BMS-986158|BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
214332730|NCT04244474|DRUG|A single one ml injection|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
214332731|NCT00857194|PROCEDURE|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
214332732|NCT00857194|PROCEDURE|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
214332733|NCT05746338|DEVICE|Ring-type wearable device|The ring-type wearable device is a slim, lightweight smart ring that continuously tracks blood oxygen saturation and heart rate throughout the day.
214933935|NCT03936465|DRUG|BMS-986378|BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
214933936|NCT03891472|DRUG|Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.|mFOLFIRINOX \> SBRT \> mFOLFIRINOX \> Surgical Intervention
214933937|NCT01679067|PROCEDURE|colonoscopy with endoscopic biopsies|
214933938|NCT02614222|DEVICE|Peripheral Nerve Blocks with CAIG|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
214933939|NCT04448067|BEHAVIORAL|Dietary Lentil Intake|Dietary intake of moderate or high dose of lentils at midday meals
214933940|NCT04448067|BEHAVIORAL|No Dietary Lentil CONTROL|Dietary intake of meals without lentils and matched to dietary lentil meals for total energy and protein
214933941|NCT06124248|BEHAVIORAL|RISE intervention|"The RISE intervention: a 15-weeks blended behavioral intervention, where a primary care physiotherapist coaches participants on striking the balance in their 24h activity pattern, with a focus on reducing and interrupting their sedentary time. This will subsequently lead to an increase in physical activity. Next to that, insights into their personal sleep pattern, sleep hygiene rules and advices will be provided.~Primary care physiotherapists coach people with a first-ever stroke in their home setting by using behavior change techniques and the RISE eCoaching system. The RISE eCoaching system consists of 1) an activity monitor, 2) a smartphone application that provides real-time feedback and contains e-learning modules, 3) a monitoring dashboard for the physiotherapist. Participants receive participatory support from someone from their social network (e.g., partner or close friend) who joins them in the intervention."
214933942|NCT04892212|DRUG|Sirolimus|The daily dose of sirolimus is divided twice.
214332734|NCT05746338|DEVICE|Overnight polysomnography|Overnight polysomnography is the gold standard for diagnosing OSAS.
214332735|NCT01478698|DRUG|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
214933943|NCT00984139|BIOLOGICAL|Engerix™-B Kinder|Intramuscular, one dose.
214933944|NCT06506019|DRUG|Psilocybin|25 mg psilocybin
214933945|NCT06506019|DEVICE|Functional MRI|The fMRI involving resting state measures and a facial affect task will be conducted one-day and one-month after the dosing session.
214933946|NCT02527759|BEHAVIORAL|Survey|
214933947|NCT00108485|DRUG|Extended release niacin|Extended release niacin 1500-2000mg once daily
214933948|NCT00108485|OTHER|Placebo|Placebo tablets
214933949|NCT00559780|BEHAVIORAL|Resistance training|12 weeks of resistance training (3/week)
214933950|NCT00559780|BEHAVIORAL|Neuromuscular electrical stimulation of the quadriceps muscle|12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
214933951|NCT00559780|BEHAVIORAL|Standard rehabilitation|12 weeks of standard physiotherapy exercises (1h/day)
214933952|NCT01097421|DRUG|Pramipexole Extended Release|
214933953|NCT04564469|DRUG|Furosemide|A number of different protocols exist in terms of the timing of furosemide injection, (F+0) protocol in which furosemide is injected at the same time of radiotracer administration \&( F - 15)protocol in which furosemide is administered 15 min before tracer administration
214332736|NCT01478698|DRUG|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
214332737|NCT01984723|DRUG|Experimental: EVP-6124|
214933954|NCT00372723|DRUG|Remicaide (infliximab)|a single dose infusion of 5mg/kg Remicade (Infliximab)
214933955|NCT03067688|DRUG|Temisartan+Amlodipine+Rosuvastatin (Combination drug)|PO, Once daily(QD), 8weeks
214933956|NCT03067688|DRUG|Temisartan+Amlodipine|PO, Once daily(QD), 8weeks
214933957|NCT03067688|DRUG|Temisartan+Rosuvastatin|PO, Once daily(QD), 8weeks
214933958|NCT00122538|DRUG|Efavirenz (EFV)|
214933959|NCT00122538|DRUG|Lamivudine (3TC)|
214933960|NCT00122538|DRUG|Didanosine (ddI)|
214933961|NCT05212701|DRUG|Reparixin|The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).
214933962|NCT05212701|DRUG|Placebo|The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
214933963|NCT02685501|OTHER|no intervention|
214933964|NCT02634268|BEHAVIORAL|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
214933965|NCT02381301|BIOLOGICAL|Venous blood sampling prior to CCTA.|
214933966|NCT00978939|OTHER|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
214933967|NCT00978939|OTHER|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
214332738|NCT00006508|PROCEDURE|Controlled hypoglycemia using insulin|
214332739|NCT00006508|PROCEDURE|formula meal|
214332740|NCT05309512|BIOLOGICAL|KN052|0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg, 9mg/kg, RP2D once every two or three weeks intravenously
214332741|NCT05660616|DRUG|Gemcitabine|"The study includes patients with unresectable malignant pleural mesothelioma who received at least 4 cycles of first line platinum (Cisplatin or Carboplatin) and pemetrexed combination chemotherapy~* Response after first line treatment will be assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 for pleural mesothelioma.~* Patients will be randomized according to a (1:1) ratio to either Arm 1: Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care Arm 2 (control arm): best supportive care alone.~* Cases will be evaluated every cycle clinically and every three cycles radiologically with CTs."
214933974|NCT05131087|DEVICE|Cadence implant|CADENCE Glaucoma Drainage Device System is a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach
214933975|NCT02985606|OTHER|Caffeine powder -60|
214933976|NCT02985606|OTHER|Caffeine powder -30|
214933977|NCT02985606|OTHER|Caffeine powder 0|
214933978|NCT02985606|OTHER|Placebo powder -60|
214933979|NCT02985606|OTHER|Placebo powder -30|
215077937|NCT00378599|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|"1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"
214332742|NCT05660616|OTHER|supportive care|supportive care
214332743|NCT00721526|DRUG|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
214332744|NCT02393495|DEVICE|intrauterine device TCu 380A|
214332745|NCT06266923|DRUG|SPH6516 tablets|SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle
214332746|NCT03851653|BEHAVIORAL|Lifestyle Intervention|Cognitive-behavioural intervention for weight loss and lifestyle change
214933980|NCT02985606|OTHER|Placebo powder 0|
214933981|NCT04908215|DRUG|INM-755 (cannabinol) cream|topical cream containing cannabinol for dermal application
214332747|NCT02944578|DRUG|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
214933982|NCT04908215|DRUG|Vehicle Cream|topical cream base for dermal application containing no active agent
214933983|NCT02289287|BEHAVIORAL|Self-Management group-intervention|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
214933984|NCT02289287|BEHAVIORAL|Standard Care|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
214933985|NCT00805870|DRUG|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
214933986|NCT00805870|DRUG|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
214933987|NCT03442478|OTHER|2D/3D Tomosynthesis|
214332748|NCT02944578|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
214332749|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
214332750|NCT02691455|PROCEDURE|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
214332751|NCT02691455|DEVICE|Ahmed Model FP7 Flexible Plate|
214332752|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
214332753|NCT06309082|PROCEDURE|Amputation|Amputation was performed on diabetic foot ulcer
214332754|NCT06309082|PROCEDURE|Debridement|Debridement of diabetic foot ulcers was performed
214332755|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
214332756|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
214332757|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
214332758|NCT01600300|DEVICE|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
214332759|NCT01600300|DEVICE|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
214332760|NCT01257204|DRUG|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
214332761|NCT01257204|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
214332762|NCT01257204|DRUG|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
214332763|NCT01257204|DRUG|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
214332764|NCT00284531|DRUG|Daclizumab|
214933988|NCT01701193|DRUG|L-Alanyl/L-Glutamine|Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
214933989|NCT01701193|DRUG|Physiologic saline|Placebo
214933990|NCT05526378|BEHAVIORAL|Sensory Interventions|"Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure."
214933991|NCT05735262|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
214933992|NCT05735262|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
214933993|NCT02062944|DRUG|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
214933994|NCT02956369|DIETARY_SUPPLEMENT|Control|Control granulates (maize starch and long-chain fatty acids) with powder
214933995|NCT02956369|DIETARY_SUPPLEMENT|SATIOSTAT|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder
214332765|NCT01878604|GENETIC|Gene analysis|Gene analysis
214332766|NCT01878604|OTHER|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
214332767|NCT01878604|OTHER|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
214332768|NCT06580821|PROCEDURE|mucogingigval surgery|Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.
214332769|NCT04162951|PROCEDURE|Ordinary approach paravertebral block|Ultrasound guided thoracic paravertebral block. At the appropriate dermatome, the needle (22-gauge, 8-10-cm, short bevelled spinal needle, or a Touhy needle if a catheter is to be placed) is inserted 2.5-3 cm lateral to the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process at a variable depth (2-4 cm) depending on the build of the individual. The needle is then walked above the transverse process and gradually advanced until a loss of resistance to air or saline, or a subtle 'click' is felt as the superior costotransverse ligament is penetrated, usually within 1-1.5 cm from the superior edge of the transverse process.
214673660|NCT06509061|OTHER|Physical Activity Self-Definition|6 week behavioural change program designed to increase PASD and PA
214933996|NCT06016569|DIAGNOSTIC_TEST|Exhaled breath condensate sampling|Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed.
214933997|NCT06016569|DIAGNOSTIC_TEST|Blood sampling|A venous blood sample will be taken for further biomarker analysis.
214933998|NCT06016569|PROCEDURE|LDCT|LDCT scan will be performed.
214332770|NCT04162951|PROCEDURE|Retrolaminar paravertebral block|In the retrolaminar approach to TPVB or retrolaminar block (RB), local anesthetic (LA) is injected into the retrolaminar plane to achieve a truncal sensory block like that of traditional TPVB. It has been postulated that during RB, LA spreads from the injection plane to the thoracic paravertebral space (TPVS) through the superior costotransverse ligament (SCTL). Retrolaminar block will be performed under ultrasound guidance, as a single injection.
214332771|NCT00215774|DRUG|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
214332772|NCT04569045|DEVICE|HA+Lidocaine|20 mg
214332773|NCT04569045|DEVICE|HA|20 mg
214332774|NCT01550939|DEVICE|Ophthalmic Biometer|One complete biometry examination
214332775|NCT03231904|DIAGNOSTIC_TEST|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
214332776|NCT04915859|OTHER|Hand Cooling at 12-15 degrees celsius|hand cooling at 12-15 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
214332777|NCT04915859|OTHER|Hand Cooling at 16-20 degrees celsius|hand cooling at 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
214332778|NCT04915859|OTHER|hand and back cooling at 12-15 or 16-20 degrees celsius|hand and back cooling at 12-15 or 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature while also wearing the back wrap cooling device set to this temperature
214332779|NCT04915859|OTHER|Passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
214332780|NCT04978792|BEHAVIORAL|Online self-compassion intervention|An online self-guided intervention that uses widely available exercises and information.
214332781|NCT04978792|BEHAVIORAL|Active Control|Participants will complete written exercises and breathing exercises that are not associated with self-compassion
214332782|NCT01086553|DRUG|budesonide|9mg budesonide OD
214486332|NCT06749938|OTHER|Holistic Intervention|"* Aerobic Exercise Prescription. Each participant will be given instruction on an exercise program to progress to perform a total of 150 minutes/wk of moderate-vigorous aerobic activity (including any yoga practice they choose to do) with two days of strengthening exercises using exercise bands.~* Yoga Protocol and Meditation Exercise. Participants will be asked to practice three 75-min session days per week. The program will focus on developing breath and body awareness/control (pranayama), focused concentration, meditation, muscular strength, muscular endurance, and mobility (flexibility) training that involves the mind body spirit connection.~* Diet Intervention. Coaching for diet modification will be incorporated into the psychosocial support messaging.~* Psychosocial Support. Motivational strategies to enhance exercise compliance comprise of electronic messaging using the BlueJay Mobile-Health, (Livermore, CA). This tele-health HIPPA compliant allows private communication."
214486333|NCT06747975|DRUG|Dexamethasone and Ondansetron|patients will receive Caudal epidural block (0.5 mL/kg of bupivacaine 0.25% plus dexa- methasone 0.1 mg/kg plus 4mg ondansetron ), and IV 5 mL normal saline
214486334|NCT06747975|DRUG|Bupivacaine + saline|patients will receive caudal epidural block (0.5 mL/kg of bupivacaine 0.25% only) and IV 5 mL normal saline
214933999|NCT06016569|DIAGNOSTIC_TEST|Vital signs|Blood pressure, weight, height, pulse, oxygen saturation will be measured.
214934000|NCT06016569|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed.
214934001|NCT06622460|OTHER|Hand Dexterity Assessment|to evaluate the reliability and sensitivity of the VET in healthy. Their performance helps define normal thresholds and behaviors in grip force modulation and manual dexterity.
214934002|NCT05107791|DRUG|Stulln Eyedrops|Stulln eyedrops will be applied to the anterior surface of cornea 3 times a day, 6 days a week. Half of participants (46) also receive accommodative training during the second stage (month) of the study while the rest maintains the Stulln eyedrops intervention.
214332783|NCT01086553|DRUG|budesonide|3mg budesonide TID
214332784|NCT03541733|OTHER|mid-gut tubing|mid-gut tubing at different time
214332785|NCT03511521|DRUG|NPH Insulin|Intermediate acting insulin
214332786|NCT03511521|DRUG|glargine|basal insulin
214332787|NCT03511521|DRUG|Insulin Aspart|prandial insulin
214332788|NCT01050595|DRUG|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance \<30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
214332789|NCT01050595|DRUG|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
214332790|NCT01766375|DRUG|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
214332791|NCT00439400|DRUG|doxycycline|
214332792|NCT00439400|DRUG|placebo|
214486335|NCT06752044|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
214673661|NCT06509061|OTHER|Control|6 week program designed to as an attention control, delivering content on general health behaviour.
214934003|NCT05107791|DRUG|Thera Tears|The eyedrops will be used in the identical manner as Stulln eyedrops.
214934004|NCT03499457|DRUG|Amoxicillin|chalange test of 50 mg, and after an hour 500 mg
214332793|NCT02538497|BEHAVIORAL|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
214934005|NCT01647191|BEHAVIORAL|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
214934006|NCT01647191|BEHAVIORAL|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
214934007|NCT00278148|DRUG|carboplatin|AUC2 weekly x 3 weeks
214934008|NCT00278148|DRUG|Erlotinib|Daily
215077938|NCT05849818|DEVICE|full-immersive VRapeutic software gaming technology|"* Children of the study group will receive VR training sessions 3 times per week for 8 successive weeks.~* Viblio VRapeutic fully immersive game will be used.~* Manual instructions of the game will be followed and features of the game will be customized.~* The child instructed to put back a pile of books on the floor into their shelves.~* Level II of the game we will use audio visual distractors , repeated parrot sound and the child is required to order the books by colors~* Level III distracting tasks during book ordering~* The complexity of the game depend on task duration, number of books and the nature of distractors"
214332794|NCT02538497|BEHAVIORAL|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
214332795|NCT02442921|DRUG|Colchicine|up to 2mg of Colchicine daily
214332796|NCT02442921|DRUG|Placebo|Daily placebo
214332797|NCT00451282|BEHAVIORAL|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
214332798|NCT04354259|DRUG|Peginterferon Lambda-1A|Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
214332799|NCT04354259|OTHER|placebo|injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
214332800|NCT00577122|DRUG|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
214332801|NCT00577122|DRUG|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
214332802|NCT05649605|DRUG|Testosterone treatment|Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
214934009|NCT00278148|DRUG|paclitaxel|50mg/m2/weekly x 3 weeks
214934010|NCT00278148|PROCEDURE|conventional surgery|conventional surgery
214934011|NCT00278148|RADIATION|radiation therapy|150 cGy bid
214934012|NCT01945801|DRUG|Lasilactone|Active drug (spironolactone 100 mg plus furosemide 20 mg).
214934013|NCT01945801|OTHER|Sodium-Restricted Diet|The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.
214934014|NCT01945801|DRUG|Placebo|The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
214934015|NCT02181322|DRUG|Meloxicam - low dose|
214934016|NCT02181322|DRUG|Meloxicam - medium dose|
214934017|NCT02181322|DRUG|Meloxicam - high dose|
214934018|NCT02035748|DRUG|Ocriplasmin|0.5 mg/0.2 mL solution for injection
214934019|NCT03246165|PROCEDURE|Cardiac surgery|Coronary bypass, heart valve replacement
214934020|NCT05856539|PROCEDURE|Erector spinae plane (ESP) block|ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
214934021|NCT02417922|OTHER|Saline|4 mls of saline is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
214934022|NCT02417922|OTHER|ACP|4 mls of ACP is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
214934023|NCT05149352|BEHAVIORAL|Treatment as usual (TAU) for depression|TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.
214934024|NCT05149352|BEHAVIORAL|Trauma-focused therapy (TFT)|The content of TFT, delivered by another therapist than the therapist that will provide TAU, depends on the type of CT the patient reports. If the patient predominantly reports experiences of abuse, there are often clear memories of this abuse ('target images') present and Eye Movement Desensitization and Reprocessing (EMDR) is recommended as the treatment strategy. If the patient predominantly reports experiences of neglect, memories are often less identifiable, although these experiences can have a big impact on the development of maladaptive schemas. In this case, imagery rescripting (ImRs) is recommended as treatment strategy. If the patient reports both experiences of abuse and neglect, the therapist will discuss with the patient which type of CT has the greatest impact on the current depressive symptoms and starts with the indicated therapy. If indicated, the therapist can switch between EMDR and ImRs after a minimum of 4 sessions.
214332803|NCT05649605|OTHER|Placebo treatment|Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
214934025|NCT05846399|DRUG|Amoxicillin/clavulanate|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 1 day or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 1 day
215072783|NCT06896812|DEVICE|The app-based treatment consists of a combination of physical exercise, graded activity, and pain journaling.|"The app-based treatment consists of a combination of physical exercise, graded activity, and pain journaling. The app will be installed on the participant's mobile device. The app will be used anonymously, and patients use their unique study code to activate the app.~The content and user-interface of the app-based treatment were developed in collaboration with healthcare professionals for relevant medical specialties, including orthopedic surgery, neurosurgery, neurology, physiotherapy, and rehabilitation. The content is based on expert opinion from these fields. Additionally, there is scientific evidence indicating that the treatments used within the app are safe and effective. The app has been tested for usability and functionality by both professionals and laypersons, including individuals with back pain."
215072784|NCT06895018|DIETARY_SUPPLEMENT|Supplementation with Polyphenol Rich Drink|Participants were instructed to consume, over a 6-week period, within the context of a Mediterranean diet, a polyphenol-rich drink RGPD (150 mL) containing 1.5 g of polyphenols. After this treatment period, participants underwent a two-week washout period before switching to the alternative treatment with control drink (Placebo) devoid of polyphenols. To evaluate metabolic responses during both fasting and postprandial states, participants participants consumed a standardized test meal at the end of the 6 weeks. This standard meal was preceded by the consumption of the RGPD 60 minutes prior.
215072785|NCT06895018|DIETARY_SUPPLEMENT|Supplementation with Control Drink (Placebo)|Participants were instructed to consume, over a 6-week period, within the context of a Mediterranean diet, a control drink (Placebo) (150 mL) containing 0 g of polyphenols. After this treatment period, participants underwent a two-week washout period before switching to the alternative treatment with a polyphenol-rich drink RGPD (150 mL) containing 1.5 g of polyphenols. To evaluate metabolic responses during both fasting and postprandial states, participants participants consumed a standardized test meal at the end of the 6 weeks. This standard meal was preceded by the consumption of the Control drink (Placebo) 60 minutes prior.
214332804|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
214332805|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel QD
214332806|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
214332807|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
214332808|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel BID
214332809|NCT02691767|DRUG|pazopanib|
214332810|NCT01064921|DRUG|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
214332811|NCT01064921|DRUG|cisplatin|Given IV
214332812|NCT01064921|RADIATION|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
214934026|NCT05846399|DRUG|Ciprofloxacin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
214934027|NCT05846399|DRUG|Clindamycin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
214332813|NCT01064921|PROCEDURE|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
214332814|NCT06018961|OTHER|Post-operative ileus surgery|Collection of ileus events, items of IFEED score and surgical complications
214332815|NCT00529386|DRUG|Botox|300 units
214332816|NCT03606798|OTHER|3 Home visits made by a psychologist|Patient and caregiver interviews with a psychologist at home
214332817|NCT01417832|DRUG|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
214332818|NCT01417832|DRUG|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
214332819|NCT04532112|DEVICE|Biocontainment Device For Aerosol Generating Procedures (Biobox)|The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
214332820|NCT04532112|DEVICE|Control for aerosol generating procedures|There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
214332821|NCT05225181|BEHAVIORAL|perform physical exercise|one 60-min session of physical training
214332822|NCT05225181|BEHAVIORAL|cognitive training|one 60-min session of cognitive training
214332823|NCT05225181|BEHAVIORAL|control group|perform body stretching(15min) and health education courses(90min)
214673662|NCT05654415|OTHER|Melatonin|Each enrolled patient will be subjected to two nap EEG recordings receiving in one occasion the melatonin-based solution under study at a dosage of 5 mg
215072786|NCT06897319|DEVICE|High-Flow Tracheal Therapy|Device: Airvo 2 (Fisher \& Paykel Healthcare) Settings: Flow rate start at 40L/min and will be adapted according to tolerance; temperature aimed at 37°C or 34°C according to tolerance, FiO₂ set (if needed) according to SpO2 target values.
214934028|NCT05846399|OTHER|Placebo (microcrystalline cellulose)|Placebo (microcrystalline cellulose) by mouth twice daily by mouth for 5 days
215072787|NCT06897423|OTHER|Education|"Midwifery students in the intervention group of the study will receive 8 weeks of disaster midwifery training. The training content will be covered in 8 main categories: safe prenatal, delivery and postnatal period, women's reproductive health services, family planning, immunization, violence and sexually transmitted infections and newborn and infant care, reproductive health in disadvantaged groups, emergency obstetric situations."
215072788|NCT06895642|OTHER|Exercise|After all of the participants perform a symptom-limited cardiopulmonary exercise test, they included a single session high intensity interval exercise created according to test results. They randomized to two gorups as video and treadmill-based or only treadmill-based high intensity interval exercise.
215072789|NCT06896409|COMBINATION_PRODUCT|PuraStat® combined with Adrenaline|PuraStat® application (mL) combined with Adrenaline injection (mL)
215072790|NCT06896409|COMBINATION_PRODUCT|Standard of Care|Adrenaline injection + second hemostasis modality (contact thermal, mechanical therapy, or injection of a sclerosing agent).
215077939|NCT00380419|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
214332824|NCT05613634|DEVICE|Repetitive transcranial magnetic stimulation|A high frequency (10 Hz) rTMs on the dominant dorsolateral prefrontal cortex (DLPFC) was applied with the Magstim Rapid Magnetic Stimulator, Magstim Company. Patients were seated in a chair, arms and legs relaxed, head stable, and no movement was allowed during the procedure. Motor threshold (MT) was determined before each session and was defined as the percent intensity output of the stimulator that generated a 50µV motor evoked response in the abductor pollicis brevis (APB) muscle in five out of 10 trials. The DLPFC of dominant hemisphere was localized on the scalp 5.5 cm anterior to the hot spot for the contralateral APB muscle along the parasagittal plane. The average MT was 50 % (range, 45-55%) of the maximal output of the stimulator. The initial mapping procedure was completed with the coil oriented at 45° lateral diagonal orientation roughly perpendicular to the central sulcus and the center of the coil applied tangentially to the scalp.
214332825|NCT05613634|OTHER|Cawthorne Cooksey exercises|Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.
214332826|NCT02285751|DRUG|acetylsalicylic acid|
214332827|NCT02285751|DRUG|clopidogrel|
214332828|NCT02285751|DRUG|prasugrel|
214673663|NCT05654415|OTHER|Deprivation|Each enrolled patient will be subjected to two nap EEG recordings,in one they will be subjected to sleep deprivation
214673664|NCT04734873|DRUG|CPI-006 2 mg/kg + SOC|IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
215077940|NCT00377559|DRUG|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
214332829|NCT02285751|DRUG|ticagrelor|
214332830|NCT01312402|DRUG|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
214332831|NCT01312402|DRUG|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
214332832|NCT01177033|OTHER|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
214332833|NCT06432010|OTHER|Group nutrition and physical activity coaching|Group nutrition and physical activity coaching consists of an initial health check-up, followed by nutrition and physical activity coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the group nutrition and physical activity coaching sessions.
214332834|NCT06432010|OTHER|Group cognition coaching|Group cognition coaching consists of an initial health check-up, followed by cognition coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the cognition coaching sessions.
214332835|NCT03745703|BEHAVIORAL|MOCHA|(see above)
214332836|NCT03621267|OTHER|Interactive Stepping Exercise|Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment
214332837|NCT03621267|OTHER|Home exercise program|Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
214332838|NCT00192179|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10\^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10\^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
214332839|NCT00192179|BIOLOGICAL|Placebo|The placebo consisted of physiologic normal saline.
214332840|NCT02736162|OTHER|No treatment (intervention) was administered|
214332841|NCT03348904|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
214934029|NCT05846399|PROCEDURE|Wound management|Wound management includes hemostasis, copious irrigation, removal of foreign bodies, and excisional debridement of devitalized tissue. If only punctures are present, lancing of the punctures is not typically required unless infection has already developed. Local anesthesia (1% lidocaine hydrogen chloride (HCl) with epinephrine 1:100,000; 200mg/20mL vial) will be used prior to irrigation (30mL of povidone-iodine in 1L of 0.9% sodium chloride (NaCl) solution and/or 118mL of 3% hydrogen peroxide) and debridement. Open wounds will be irrigated and debrided at bedside. Wounds will be covered with soft dressings in place until first follow-up at day 2.
215072791|NCT06895421|BEHAVIORAL|Cognitive behavior therapy based guided self help manual for psychosis plus treatment as usual|The Cognitive Behavior Therapy-Based Guided Self-Help (CBTp-GSH) manual is a structured intervention designed specifically for individuals with psychosis, particularly those diagnosed with Schizophrenia Spectrum Disorders. This manual offers a culturally adapted approach, providing participants with tools and strategies rooted in Cognitive Behavioral Therapy (CBT) principles, tailored to be delivered through guided self-help.
215072792|NCT06895421|DRUG|Treatment as usual|anti psychotic drugs which they are already using
215072793|NCT06897345|PROCEDURE|transversus abdominis plane block|The transversus abdominis plane (TAP) block is a regional anesthesia technique used primarily to provide pain relief for patients undergoing surgery in the abdominal region. The TAP block targets the nerves that supply sensations to the skin and muscles of the abdominal wall.
214332842|NCT03348904|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
214332843|NCT03348904|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
214332844|NCT03348904|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
214332845|NCT03348904|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
214332846|NCT03348904|DRUG|Gemcitabine|Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
214332847|NCT03348904|DRUG|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
215077941|NCT01762267|OTHER|nutrition intervention|DASH diet control diet
215077942|NCT00001724|DRUG|Flurbiprofen|
214332848|NCT03348904|DRUG|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
214332849|NCT05166291|DEVICE|Comfort-in injection system|local anesthesia applyed with comfort-in injection system
214332850|NCT05166291|OTHER|traditional anesthesia|local anesthesia applyed with dental syringe
214332851|NCT01076725|DEVICE|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
214332852|NCT01076725|DEVICE|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
214332853|NCT05882513|DRUG|Serplulimab and neoadjuvant therapy|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."
214332854|NCT05882513|PROCEDURE|surgical resection of lung cancer|radical resection of lung cancer
214332855|NCT05882513|OTHER|Tumour will be Collected from participant. Fate of sample is Destruction after use|Tumour sample will be collected after surgery
214332856|NCT01241734|DRUG|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
214332857|NCT02896231|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
214332858|NCT02565797|DEVICE|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
214332859|NCT01479634|DRUG|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
214332860|NCT01479634|DRUG|Study-Provided ART|"Study provided drugs:~1. Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]) PLUS~2. Efavirenz \[EFV\]"
214332861|NCT04555746|BEHAVIORAL|Physical activity|Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
214332862|NCT03614013|OTHER|Immunotherapy responders/non-responders|paraffin samples will be collected retrospectively along with clinical data
214332863|NCT04865835|DRUG|placebo|single dose of placebo
214332864|NCT04865835|DRUG|SEP-363856|single dose of SEP 363856 100 mg
214332865|NCT04865835|DRUG|metformin|metformin-HCl 850 mg
214332866|NCT03237923|DEVICE|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
214332867|NCT02755675|OTHER|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
214332868|NCT01867684|OTHER|Psychotherapy|
214332869|NCT06073327|DIETARY_SUPPLEMENT|dark chocolate|30g of dark or white chocolate was provided by the nutritionist for 30 days
214332870|NCT06073327|DIETARY_SUPPLEMENT|White chocolate|30g of white chocolate was provided by the nutritionist for 30 days
214332871|NCT01717417|DEVICE|miniscrew|
214332872|NCT01717417|DEVICE|TPA|
214332873|NCT03227380|OTHER|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
214332874|NCT04885517|DEVICE|Esophageal catheter|Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
214332875|NCT02039427|DRUG|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
215072794|NCT06897345|PROCEDURE|rectus sheat block|The rectus sheath block is a type of regional anesthesia used primarily for pain management in the abdominal area. It involves injecting local anesthetic into the rectus sheath, which is the fibrous sheath that envelops the rectus abdominis muscle. This block targets the lower intercostal nerves as they traverse through the sheath, thereby providing analgesia to the anterior abdominal wall.
215072795|NCT06895954|DIETARY_SUPPLEMENT|Genistein|Hyperlipidemia patients take a 125mg Genistein capsule daily, once a day.
214332876|NCT02039427|OTHER|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
214332877|NCT02039427|DRUG|Placebo|Normal saline 2 ml
214673665|NCT04734873|DRUG|CPI-006 1 mg/kg + SOC|IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
214673666|NCT04734873|DRUG|Placebo + SOC|IV placebo plus standard of care
214673667|NCT04824261|DRUG|Clotrimazol solution 1%|50 otomycosis randomized patients will receive Clotrimazol solution 1% The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
214673668|NCT04824261|DRUG|4%boric acid in distilled water|50 otomycosis randomized patients will receive 4%boric acid in distilled water The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
215072796|NCT06896253|DRUG|Pulse bolus corticosteroids|Treatment administration
215072797|NCT06896253|DRUG|Pulse bolus corticosteroids and IVIG|Treatment administration
215072798|NCT06896253|DRUG|Pulse bolus corticosteroids (G5%) and IVIG (G5 %)|Treatment administration
215072799|NCT06896851|OTHER|Su Jok|a type of acupressure includs hand massage
215077943|NCT00416715|DRUG|letrozole|Given PO
214332878|NCT05391217|OTHER|Remote assessment of patient reported outcomes and daily activity|Electronic patient-reported outcomes (NIH PROMIS) will be collected and combined with remotely monitored physical activity, heart rate, and sleep, as measured with a Fitbit (Sense).
214332879|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (90% triglycerides)|
214332880|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (60% triglycerides)|
214332881|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (ethyl esters)|
214332882|NCT00804427|DIETARY_SUPPLEMENT|Soy oil|
214332883|NCT03074721|DEVICE|PCI Suite Software|PCI with PCI Suite Software
214332884|NCT03074721|OTHER|conventional PCI|conventional PCI without PCI Software
214332885|NCT04448470|OTHER|Questionnaire for recording daytime sleepiness over the course of the day|Questionnaire for recording daytime sleepiness over the course of the day
214332886|NCT04448470|OTHER|Anamnesis and physicial examination|Anamnesis and physical examination, e.g. medication, comorbidities, complaints
214332887|NCT04448470|OTHER|Questionnaire for quantifying daytime sleepiness|the Epworth Sleepiness Scale (ESS) questionnaire and the STOP BANG Questionnaire
214332888|NCT04448470|DIAGNOSTIC_TEST|Pulmonary function test|The measured values of spirometry/body plethysmography, CO diffusion and blood gas analysis are documented, if available.
214332889|NCT04448470|DIAGNOSTIC_TEST|Polygraphy|Polygraphy is a non-invasive portable examination method that the patient uses in the home environment at night to measure possible sleep-related breathing disorders. Typically, the following measurement signals are recorded: nasal airflow, thoracic and abdominal breathing excursions, snoring and breathing sounds via a microphone, pulse, oxygen saturation and position. The evaluation results and the findings are checked by a physician. Essential parameters include the apnoea-hypopnoea index, the number of obstructive, central and mixed apnoea/hypopnoea, the number and duration of desaturation, snoring or the association with a certain position.
214332890|NCT06292143|OTHER|Advance Care Planning Toolkit|Participants or their caregivers will access the digital platform for advance care planning
214332891|NCT02851576|OTHER|Infusion of ADV specific T cells|Cell engineering
214934030|NCT01647984|DIETARY_SUPPLEMENT|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
214934031|NCT01647984|DIETARY_SUPPLEMENT|placebo|
214934032|NCT06098703|BEHAVIORAL|CARD (Comfort Ask Relax Distract)|CARD is a vaccine delivery framework/protocol to plan and deliver vaccinations
214934033|NCT03540303|DRUG|CAR19 T cells carrying cytoplasmic activated PD-1|"step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
214934034|NCT03873909|OTHER|Fruit Smoothie|Fruit Smoothie with 150-200 g mamey sapote fruit
215072800|NCT06896851|OTHER|Sham point using|unrelated point using for acupressing
215072801|NCT06762626|OTHER|Frozen embryo transfer according to endometrial receptivity analysis result|Frozen embryo transfer will be arranged according to endometrial receptivity analysis result, which will be shown in the form of P+X hours
215072802|NCT06086873|DEVICE|Implant Type|"Patients enrolled in the study will be allocated to one of three implant groups:~* Group 1: NGA Implant (NobelActive TiUltraNP, Nobel Biocare AG, Switzerland)~* Group 2: BLX implant (BLX) modSLA Surface (BLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)~* Group 3: TLX implant (TLX) modSLA Surface (TLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)."
215072803|NCT05539963|DRUG|STIMULAN VG|Participants will receive STIMULAN VG via implantation during debridement surgery on Day 1.
214332892|NCT02419716|DEVICE|Cologuard|Prescription of Cologuard for at-home stool collection
215072804|NCT05539963|DRUG|Systemic Antibiotics|Participants will receive Antibiotics per site-specific requirements.
215072805|NCT06896539|OTHER|Telemedicine|"Contraceptive Counselling using the LOWE Method and through Tele Health, Video Call with Midwife."
215072806|NCT06896539|OTHER|Counselling in person visit|"Contraceptive Counselling using the LOWE Method. In-person visit with midwife at Maternal Health Clinic."
215072807|NCT06895395|BEHAVIORAL|High intensive combined phonetic-phonological intervention|High intensity speech intervention 5 times 30' per week for 2 times 4 weeks
215072808|NCT06895395|BEHAVIORAL|Low intensive combined phonetic-phonological intervention|low intensity speech intervention 2 times 30' per week for 20 weeks
215072809|NCT06896721|DRUG|Preoperative sedation with dexmedetomidine was administered nasal before surgery|Do not drink or fast before operation. Before entering the operating room, 2 sprits of dexmedetomidine were administered intranasally (1-2ug/kg) with conventional open venous access
215072810|NCT06896721|DRUG|Preoperative sedation with normal saline was administered nasal before surgery|Do not drink or fast before operation. Before entering the operating room, 2 sprits of normal saline were administered intranasally (equal volume) with conventional open venous access
215072811|NCT06896487|OTHER|Surface EMG Biofeedback Muscle and Relaxation Training|We think that 6 weeks of superficial EMG Biofeedback muscle training and relaxation training given to the participants in this study will improve the patient's upper trapezius activation and voluntary contraction performance.
215072812|NCT06896487|OTHER|Conventional Rehabilitation|The conventional rehabilitation group of this study received ultrasound, TENS and hot pack application 3 days a week for 6 weeks.
215072813|NCT06896864|PROCEDURE|cochlear implantation|After the surgery, patients typically undergo a period of recovery and healing. several factors including age at implantation, pre- and post-operative therapy, and parental involvement
215072814|NCT06896747|BIOLOGICAL|Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes|"Mechanically engineered umbilical cord mesenchymal stem cell-derived exosomes (ME-UCMSC-Exo) are isolated from umbilical cord-derived mesenchymal stem cells (UCMSCs) subjected to mechanical stress conditioning during in vitro expansion. This process enhances exosome yield, bioactivity, and regenerative capacity. The exosomes are purified via ultracentrifugation and characterized for size, protein markers, and RNA content.~In this study, ME-UCMSC-Exo is administered via intra-endometrial injection under hysteroscopic guidance. Each participant in this intervention group will receive 1-1.5 mL of exosome solution (containing approximately5\*10\^10 particles/mL) per injection site during the proliferative phase (Day 3-7 of the menstrual cycle). The aim is to enhance endometrial thickness, receptivity, and pregnancy outcomes in patients with thin endometrium secondary to intrauterine adhesions."
215072815|NCT06896747|BIOLOGICAL|Umbilical cord mesenchymal stem cell-derived exosomes|Umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) are obtained from standard cultured UCMSCs without mechanical stress preconditioning. These exosomes undergo identical purification and characterization procedures as ME-UCMSC-Exo but lack biomechanical priming. UCMSC-Exo is also administered intra-endometrially via hysteroscopic injection at a dose of 1-1.5 mL (5\*10\^10 particles/mL) per site.
215072816|NCT06896747|BIOLOGICAL|platelet-rich plasma|"Platelet-rich plasma (PRP) is an autologous biological preparation obtained from centrifuged whole blood. It contains a high concentration of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), which promote endometrial regeneration.~In this study, PRP will be administered via hysteroscopically guided intra-endometrial injection at a dose of 1-1.5 mL per injection site, following standard PRP preparation protocols. This group serves as a positive control for evaluating the efficacy of exosome-based therapies."
215072817|NCT04739670|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody of IgG1 isotype PD-L1. It is used across a number of tumour types, both as a single-agent and in combination with other therapies such as chemotherapy.
215072818|NCT04739670|DRUG|Bevacizumab|Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
215072819|NCT04739670|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy drug
215072820|NCT04739670|DRUG|Carboplatin|Carboplatin is platinum based chemotherapy drug
215072821|NCT05463744|DRUG|Insulin Efsitora Alfa|Administered SC
214332893|NCT02509741|BEHAVIORAL|Education|
214934035|NCT03873909|OTHER|Matrix-Free Shake|Shake containing mamey sapote extracted carotenoids (2 g, 845 µg sapotexanthin and 1.21-1.51 mg cryptocapsin
214934036|NCT00245297|DRUG|Kogenate FS, reconstituted in a suspension of liposomes|
214934037|NCT06275711|BEHAVIORAL|Therapeutic communication methods|Drawing pictures, story completion, breathing and relaxation exercises
214934038|NCT00420277|DRUG|Hemospan (MP4OX)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
214934039|NCT00420277|DRUG|Voluven (HES 130/0.4)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
214934040|NCT05386277|DEVICE|TufTex Single Lumen Embolectomy Catheter|The SLC Embolectomy Catheter is indicated for the removal of arterial emboli and thrombi
214934041|NCT05331768|COMBINATION_PRODUCT|banding ligation plus terlipressin infusion|Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
214934042|NCT06619795|DEVICE|Anodal tDCS|In addition to anodal tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
214934043|NCT06619795|DEVICE|Sham tDCS|In addition to Sham tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
214934044|NCT00043030|PROCEDURE|psychosocial assessment and care|
214934045|NCT03998163|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
215072822|NCT05463744|DRUG|Insulin Degludec|Administered SC
214332894|NCT02509741|DIETARY_SUPPLEMENT|Food replacement|
214332895|NCT02509741|BEHAVIORAL|IOT monitoring|
215072823|NCT00003783|BIOLOGICAL|filgrastim|
215072824|NCT00003783|DRUG|asparaginase|
215072825|NCT00003783|DRUG|cyclophosphamide|
215072826|NCT00003783|DRUG|cytarabine|
215072827|NCT00003783|DRUG|daunorubicin hydrochloride|
215072828|NCT00003783|DRUG|dexamethasone|
215072829|NCT00003783|DRUG|etoposide|
215072830|NCT00003783|DRUG|idarubicin|
215072831|NCT00003783|DRUG|leucovorin calcium|
215072832|NCT00003783|DRUG|mercaptopurine|
215072833|NCT00003783|DRUG|methotrexate|
215072834|NCT00003783|DRUG|prednisone|
215072835|NCT00003783|DRUG|vincristine sulfate|
215072836|NCT00003783|RADIATION|radiation therapy|
215072837|NCT03524963|DRUG|Cilostan CR Tab.|Cilostan CR Tab. 200mg once a day for 5 days
215072838|NCT03524963|DRUG|Pletaal SR Cap.|Pletaal SR Cap. 200mg once a day for 5 days
215072839|NCT04743336|OTHER|Measuring pocket depth|Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
215072840|NCT01795495|DRUG|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
215072841|NCT01795495|DRUG|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
215072842|NCT01795495|DRUG|Remifentanil|
215072843|NCT06828185|PROCEDURE|Radical inguinal orchiectomy|External oblique fascia will be incised during orchiectomy
215072844|NCT06828185|PROCEDURE|Radical external oblique fascia sparing orchiectomy|External oblique fascia will be spared during orchiectomy
215072845|NCT05173610|RADIATION|Radiation: Stereotactic body radiotherapy (SBRT)|"Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma.~1. Target delineation The GTV is set using diagnostic CT, MRI, PET-CT, etc. CTV is delineated including the microscopic range in GTV and internal margin using 4D-CT. The PTV is expanded by considering the uncertainty of the daily patient posture setting and placement.~2. Radiotherapy All patients are treated using 3D-CRT, IMRT, or VMAT. Total dose and fractionations will be determined depending on the location and character of the metastasized tumor. Detailed radiation prescriptions is summarized in the following paragraph.~   i. Liver: 48-60 Gy in 4 fractions ii. Lung: 45-60 Gy in 3-4 fractions iii. Brain: 27-30 Gy in 3-5 fractions iv. bone: 24-40 Gy in 3-5 fractions v. adrenal gland: 30-60 Gy in 3-8 fractions vi. other organ: depending on the clinicians' decision"
215072846|NCT02772796|DRUG|SENS-218|Oral Administration
215072847|NCT05536622|DIAGNOSTIC_TEST|High resolution infrared imaging|High resolution infrared imaging of limb of concern and unaffected limb (control).
215072848|NCT03703310|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
215072849|NCT03703310|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
215072850|NCT00536016|DRUG|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
215072851|NCT04362475|BEHAVIORAL|Community Health through Engagement and Environmental Renewal (CHEER)|FYI and ESPI intervention activities will be implemented in the overall study, CHEER. It will also allow us to examine possible synergistic effects of both interventions when implemented in the same neighborhoods. Separate sets of participants will be selected for the FYI comparisons and for the ESPI comparisons. Because the FYI intervention focuses on mothers and their children, participants for the FYI comparisons will be selected by Respondent Driven Sampling of eligible families from the neighborhoods in all four cells. The ESPI intervention targets the whole neighborhood, and thus a random sample of neighborhood residents will be enrolled in each of the four cells. Because the primary outcomes for FYI and ESPI are connected but differ from each other, the FYI samples will be assessed for the FYI outcomes in all four cells and the ESPI samples will be assessed for the ESPI outcomes in all four cells.
215072852|NCT03074292|PROCEDURE|phototherapy|estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
215077944|NCT00416715|DIETARY_SUPPLEMENT|calcium carbonate|Given PO
215077945|NCT00416715|OTHER|laboratory biomarker analysis|Optional correlative studies
214934046|NCT03824886|OTHER|Implementation of skin care algorithm|Implementation of structured and standardized skin care regimen
214934047|NCT03813186|DRUG|ASTX727 + Day 2 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
214934048|NCT03813186|DRUG|ASTX727 + Day 4 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 4.
214332896|NCT00040040|DRUG|Bupropion|
214332897|NCT02875119|DRUG|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
214332898|NCT02875119|DRUG|Placebo Gel|Placebo Gel
214332899|NCT00666367|DRUG|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
214332900|NCT00666367|DRUG|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
214332901|NCT01019681|BIOLOGICAL|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
214332902|NCT05676697|DRUG|Linperlisib|The phosphatidylinositol 3-kinase delta (PI3Kδ) signaling pathway plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases. B cells play an essential role in immune system function and dysfunction (e.g., autoimmunity) by producing antibodies and by acting as antigen-presenting cells (APCs) for T cells. Signaling via PI3K controls many essential B cell functions and is therefore a promising target for preventing aberrant B cell activation.
214332903|NCT05416619|DEVICE|REMO®|The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
214332904|NCT04354831|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|"* SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion"
214673669|NCT04230850|OTHER|Static Cupping|Two cups will be applied unilaterally to the lumbar paraspinals. The skin will be elevated to 1.5 cm ensuring standardized pressure. Cups will remain on the treatment area statically for 4 minutes prior to removal. Another 4 minute bout of identical treatment to the contralateral side will follow. (Participants will be equally dispersed into three treatment groups via stratified randomization).
214934049|NCT02467257|DIETARY_SUPPLEMENT|Gum Arabic|oral ingestion of 30 gram every day for 12 weeks
214934050|NCT00095186|DRUG|Recombinant Human Lactoferrin|
214934051|NCT01088243|DRUG|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
214934052|NCT01088243|DRUG|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
214934053|NCT06622200|BEHAVIORAL|Mindfulness-based Intervention|"In the present research, the standardized, theory based MBI was introduced to the experimental group (Smith, 2005). This 30-minute protocol involves a series of activities, including paying attention to and being aware of breath, body sensations, thoughts, and sounds without judgment. This protocol is a widely recognized and utilized method due to its simplicity and accessibility, making it an ideal choice for this study.~Participants in the experimental group completed three weekly sessions of MBI for five weeks during their hemodialysis treatments (Alhawatmeh et al., 2022). Participants were provided with audio recordings of the MBI protocol, which they could practice during hemodialysis sessions. These recordings were delivered via email and WhatsApp, depending on their preference. This audio recording was developed based on the Smith's protocol by a certified study researcher who had a higher degree in nursing and extensive experience in practicing and delivering MBIs."
214934054|NCT02340442|OTHER|Obstetrical care parameters|
214934055|NCT02340442|OTHER|DVA measurements|
214934056|NCT02340442|OTHER|Fundus photographs|
214934057|NCT02763332|OTHER|Upper trunk group (UTG)|This bandage was placed over the upper trapezius muscle.
214934058|NCT02763332|OTHER|Global trunk group (GTG)|This bandage was placed globally along the back
214934059|NCT02119832|DEVICE|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
214934060|NCT00638742|DRUG|latanoprost|latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
214934061|NCT06288399|OTHER|No treatment given|No treatment given
214934062|NCT00028899|DRUG|asparaginase|
214934063|NCT00028899|DRUG|cytarabine|
214934064|NCT00028899|DRUG|gemtuzumab ozogamicin|
214934065|NCT00028899|DRUG|mitoxantrone hydrochloride|
214332905|NCT02973659|DRUG|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
214332906|NCT02973659|DRUG|Placebos|
214332907|NCT02732847|OTHER|A delayed prescription dated 2 days after clinical office visit|
214332908|NCT02732847|DRUG|Usual Dated|
214332909|NCT01198184|DRUG|temsirolimus|Given IV or PO
214332910|NCT01198184|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
214332911|NCT01198184|OTHER|laboratory biomarker analysis|Correlative studies
214332912|NCT01198184|OTHER|pharmacological study|Correlative studies
214332913|NCT00863538|DRUG|KPS-0373|
214934066|NCT00483106|DRUG|Ritalin|0.25 mg/kg bid, orally for 7 consecutive days
214934067|NCT00483106|DRUG|Placebo|taken orally twice a day for 7 consecutive days
214934068|NCT05672407|DRUG|Tranexamic acid|100 mg/mL Tranexamic acid with lidocaine with 1:100,000 epinephrine in 1:1 manner administered subcutaneously
214934069|NCT05672407|DRUG|Placebo|Lidocaine with 1:100,000 epinephrine mixed with 1:1 Basal Saline Solution (BSS) administered subcutaneously
214934070|NCT04341831|DRUG|Teicoplanin|We will be used 200mg Teicoplanin powder for each level of instrument.Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site.
214934071|NCT04653753|DEVICE|kneeSOFT500|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
214934072|NCT04504266|BEHAVIORAL|POWER|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
214934073|NCT00648934|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
214934074|NCT00648934|DRUG|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
214934075|NCT00065650|DRUG|Vedic Medicine|
214934076|NCT00065650|BEHAVIORAL|Vedic Medicine|
214332914|NCT01942382|DRUG|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
214332915|NCT02778529|DEVICE|Bilateral assessment robots (BiAS)|The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
214332916|NCT04027686|DEVICE|Laser Therapy|Adjunctive application of laser therapy in the periodontal pocket
214332917|NCT04027686|PROCEDURE|Non-surgical Scaling and Root Planing|Scaling to remove calculus deposits and root planing to smooth root surfaces
214332918|NCT02418260|PROCEDURE|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
214332919|NCT02418260|PROCEDURE|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
214332920|NCT02418260|PROCEDURE|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
214332921|NCT00002912|DRUG|etoposide|
214332922|NCT00002912|DRUG|mitoxantrone hydrochloride|
214332923|NCT00002912|DRUG|valspodar|
214332924|NCT04988165|DRUG|Traditional Chinese Medicine|It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
214332925|NCT00465166|PROCEDURE|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
214332926|NCT01673334|DEVICE|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
214332927|NCT02467101|OTHER|Corticosteroid/Saline|"Corticosteroid/Saline~Two groups were defined: group A and group B.~* Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head~* Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.~Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.~Each patient will be injected on half-head."
214934077|NCT00751257|DRUG|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
214934078|NCT00751257|DRUG|Placebo|"Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules"
214934079|NCT06602349|DRUG|Lidocaine 10 MG/ML|administration of lidocaine in posterior perineal block infiltration
215072853|NCT01579565|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
215072854|NCT01579565|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
215077946|NCT00416715|DIETARY_SUPPLEMENT|calcium citrate|Given PO
215077947|NCT00416715|DIETARY_SUPPLEMENT|calcium glucarate|Given PO
215077948|NCT00416715|DRUG|calcium gluconate|Given PO
215077949|NCT00416715|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
215077950|NCT00416715|PROCEDURE|assessment of therapy complications|Ancillary studies
215077951|NCT00416715|PROCEDURE|musculoskeletal complications management/prevention|Correlative studies
215077952|NCT04870541|DRUG|Ondansetron 8mg|Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
214934080|NCT06602349|DRUG|Saline|administration of salin solution in posterior perineal block infiltration
214332928|NCT06408467|OTHER|aMMP-8 diagnostic test|40 patients
214934081|NCT04895813|BEHAVIORAL|Education|The patient will be given pre-colonoscopy training and guidance by telephone.
214934082|NCT01471717|DRUG|INX-08189 50 mg QD X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
214934083|NCT01471717|DRUG|INX-08189 / Victrelis 800 mg TID X three days|Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
214934084|NCT01471717|DRUG|Victrelis 800 mg TID x 3 days|In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
214934085|NCT01471717|DRUG|Victrelis 800 mg TID with INX-08189 50 mg QD|Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
214934086|NCT01471717|DRUG|Placebo with Victrelis 800 mg|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
214332929|NCT03341130|DEVICE|Mandibular Repositioning Splint|The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.
214332930|NCT03341130|DEVICE|Mandibular Advancement Oral Appliance|Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
214332931|NCT05827497|DRUG|Baricitinib 2 MG|baricitinib 2 mg once daily
214332932|NCT05827497|DRUG|Methotrexate 25mg|25mg daily
214332933|NCT05575648|OTHER|10 meter walk test|To assess the dual task performance of children 10 meter walk test will be used.
214332934|NCT00111228|DEVICE|Guardian RT|
214332935|NCT00111228|DEVICE|SMBG only|SMBG only
214332936|NCT01325610|DIETARY_SUPPLEMENT|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
214332937|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System|Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
214332938|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems|Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
214934087|NCT01471717|DRUG|Cohort 2: Victrelis 800 mg with Placebo|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
214934088|NCT02189018|OTHER|Active Exercise|Active exercise on a treadmill
214934089|NCT02189018|OTHER|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
214934090|NCT02189018|OTHER|Weight loss and active exercise|Weight loss and active exercise on a treadmill
214934091|NCT02189018|OTHER|Ad lib activity at home|Ad lib activity at home
214934092|NCT02712021|OTHER|Lycra suit and physiotherapy treatment|Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
214934093|NCT02712021|OTHER|physiotherapy treatment|All the children will be involved in regular physiotherapy treatment (2-3/week).
215072855|NCT05087927|BEHAVIORAL|Gain framing plus demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
215072856|NCT05087927|BEHAVIORAL|Loss framing plus demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
214332939|NCT06142812|OTHER|Kahoot!™ Group|The theoretical concepts of each subject were taught over a period of four months, with a total duration of 30 hours. Of the total theoretical concepts of the subject, 50% were randomly selected to receive reinforcement through Kahoot! Each of the theoretical concepts chosen at random was consolidated through a Kahoot! questionnaire. which consisted of 15 questions, with three answer options. This questionnaire was administered at the end of the theoretical explanation of each section, with the objective of strengthening the learning of the contents just presented. After students answered each question in Kahoot!, the teacher clarified any questions related to that question and provided explanations as to why one answer was correct and the other two were incorrect. This process offered immediate feedback to students.
214332940|NCT03542643|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|1g of Eicosapentaenoic acid (EPA)
214332941|NCT03542643|DIETARY_SUPPLEMENT|Placebo|Olive oil ethyl esters
214332942|NCT05062668|PROCEDURE|cataract operation and istent|a cataract operation and the placement of one or two iStent inject or inject W at the same time
214332943|NCT05062668|PROCEDURE|cataract operation only|Patients have a classic postoperative treatment after cataract.
214332944|NCT04953767|DEVICE|Blue light therapy|Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.
214332945|NCT04953767|OTHER|White light|White light is used as sham control.
214332946|NCT05147857|DEVICE|Dilapan s|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
214934094|NCT03502018|DRUG|Bupivacaine liposome|A long-acting liposomal bupivacaine
214934095|NCT03502018|DRUG|Saline|Saline injection used as control
214934096|NCT00454818|GENETIC|MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
214934097|NCT00454818|PROCEDURE|Placebo Infusion|Saline; epicardial coronary artery infusion
214332947|NCT05147857|DRUG|Misoprostol|Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus. Misoprostol is taken by mouth when used to prevent gastric ulcers in persons taking NSAIDs.
214332948|NCT00951054|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
214332949|NCT04437394|DIAGNOSTIC_TEST|flexible endoscopic evaluation of swallowing|The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.
214332950|NCT04437394|DIAGNOSTIC_TEST|The analysis of voice|Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.
214332951|NCT03552887|PROCEDURE|Cardiac Surgery|Any type of cardiac surgery
214332952|NCT03552887|PROCEDURE|Physiotherapy|Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
214332953|NCT01147419|DEVICE|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
214332954|NCT01147419|DEVICE|femoral-popliteal bypass with artificial blood vessel|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
214934098|NCT00454818|GENETIC|MYDICAR Phase 2 (Placebo-controlled, Randomized Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
214332955|NCT01648309|OTHER|Neuropsychological testing|This is an observational study
214332956|NCT00073671|BEHAVIORAL|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
214332957|NCT00073671|OTHER|Usual care|Participants receive usual care
214332958|NCT02714452|BEHAVIORAL|Person-centred care|Person-centred and thriving promoting care
214332959|NCT00779766|BIOLOGICAL|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
214332960|NCT00779766|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
214332961|NCT03920397|BIOLOGICAL|Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation|The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 \[T3\], 6 \[T6\], 12 \[T12\], 18 \[T18\], and 24 \[T24\] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
214332962|NCT02124291|DEVICE|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
214332963|NCT00436306|BEHAVIORAL|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
214934099|NCT06620822|DRUG|IBI363|IBI363 is the worlds first PD-1/IL-2α bispecific antibody fusion protein with an IL-2 arm that has been designed and modified to retain CD25 (IL-2Rɑ) activity to maximize efficacy and high selectivity, and to reduce binding to IL-2Rβγ to reduce systemic toxicity, whereas the PD-1 binding arm allows for blockade of PD-1 and selective delivery of IL-2. Therefore, IBI363 has the ability to simultaneously block the PD-1/PD-L1 pathway and activate the IL-2 pathway, which can more effectively activate tumor-specific T cells. IL-2, as an important cytokine for activating tumor-specific CD8+ T cells, is mechanistically complementary to immune checkpoint inhibitors, and can reverse T-cell depletion, thereby overcoming immune resistance.
215072857|NCT05087927|BEHAVIORAL|Gain framing plus not demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
215072858|NCT05087927|BEHAVIORAL|Loss framing plus not demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
215072859|NCT02867813|BIOLOGICAL|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
214332964|NCT00436306|BEHAVIORAL|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
214332965|NCT03054909|BIOLOGICAL|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
214332966|NCT03054909|BIOLOGICAL|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
214332967|NCT06078397|DEVICE|remote programming|Remote programming (RP) is a new type of patient management method after DBS surgery, which allows physicians to understand the patient's movement symptoms and adjust parameters through video conferencing. At the same time, the RP system also includes device checks, medication adjustments, psychological counseling, and other contents. Compared to standard programming that requires going to the hospital, the application of RP can save the burden on patients and their caregivers.
214332968|NCT06078397|DEVICE|standard programming|Programming refers to a series of methods that set the parameters of the IPG after the implantation of DBS, and adjust the device parameters based on the patient's symptoms during subsequent follow-up to maintain the efficacy of electrical stimulation.
214332969|NCT00002312|DRUG|Delavirdine mesylate|
214332970|NCT00002312|DRUG|Zidovudine|
214332971|NCT01274637|DRUG|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
214934100|NCT06620822|DRUG|LM-108+Sintilimab|LM-108 is a humanized monoclonal antibody targeting the human chemokine CC receptor 8 (CCR8) and is able to modulate the tumor microenvironment by specifically removing tumor-infiltrating regulatory T cells (Treg) through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Treg.
214934101|NCT06620822|DRUG|IBI310+Sintilimab|The principle of CTLA-4 combined with PD-1 therapy is to fully relieve the inhibition of T cells by blocking both CTLA-4 and PD-1 immune checkpoints simultaneously.CTLA-4 inhibitors mainly work in the initial immune response stage by blocking the binding of CTLA-4 to B7 and enhancing the activation and proliferation of the initial T cells; whereas PD-1 inhibitors restore the anti-tumor activity of activated T cells by blocking the binding of PD-1 to its ligand PD-L1/PD-L2 and restoring their anti-tumor activity. and its ligand PD-L1/PD-L2 binding, lifting the functional inhibition of activated T cells and restoring their anti-tumor activity. Combination therapy can fully activate T-cells, improve the immune system\&amp;#39;s ability to recognize and attack tumors, enhance the anti-tumor immune response, and overcome the drug resistance of single therapy, thus improving the therapeutic effect.
214934102|NCT06620822|DRUG|Sintilimab|Sindilizumab (Sintilimab) is a humanized anti-PD-1 monoclonal antibody that has demonstrated promising anti-tumor activity in several cancer types. It works by blocking the binding of PD-1 to its ligands, PD-L1 and PD-L2, thereby lifting the inhibition of T-cells and restoring the immune system\&#39;s killing function against tumor cells.
214332972|NCT01497379|PROCEDURE|surgical implantation of subretinal device|surgical implantation of subretinal device
214332973|NCT01497379|PROCEDURE|surgical implantation of subretinal device|intra-individual implant OFF
214332974|NCT02321982|OTHER|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
214332975|NCT06461520|OTHER|Maze Balance board|Every child will have their balance evaluated using the SWOC tool, CTSIB, and Pediatric Balance Scale. Patients performed a range of proprioceptive exercises, such as static one-leg standing, board balancing, squatting, and 20 minutes of straight-line walking on a hard surface before moving to a foam surface. For 20 minutes each session, proprioceptive exercises were conducted with open eyes first, followed by closed ones. The training program for the maze balancing board will next take place. There will be seven phases to the maze balance board training; each stage will last for two days and there will be three sessions per day, each lasting an hour.
214332976|NCT06461520|OTHER|Proprioceptive training|This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
214332977|NCT06331208|DIAGNOSTIC_TEST|non-contrast chest CT|patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
214332978|NCT06331208|DIAGNOSTIC_TEST|spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
214332979|NCT06331208|DIAGNOSTIC_TEST|Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
214332980|NCT06331208|DIAGNOSTIC_TEST|supine bike exercise during right heart catheterisation|subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
214332981|NCT06331208|DIAGNOSTIC_TEST|Lung ventilation/perfusion SPECT|subgroup of HF subjects will undergo ventilation/perfusion SPECT
215072860|NCT03756363|PROCEDURE|Non-solvent|Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.
215072861|NCT03756363|PROCEDURE|Solvent|Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
215072862|NCT01448824|DRUG|LY2484595|Administered orally
215072863|NCT01448824|DRUG|Placebo|Administered orally
215072864|NCT01448824|DRUG|Ketoconazole|Administered orally
215072865|NCT00286195|DEVICE|Multi-Link Frontier Coronary Stent System|Bare metal stent
215072866|NCT00932620|DRUG|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
215072867|NCT00932620|DRUG|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
215072868|NCT00771732|DEVICE|light therapy|6 minute light therapy
214332982|NCT06156228|BEHAVIORAL|Multilevel Intervention|Clinic patients from the randomly assigned intervention clinics will be provided with additional vaccine information and will have the opportunity to ask any questions they might have about any of the 4 study focused vaccines (COVID-19, Shingles, Pneumococcal, Influenza). Health educators will provide them with additional information, address any misinformation and disinformation and will offer to schedule their vaccine appointment(s) for them.
214332983|NCT02100007|DRUG|ME-344|"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."
214332984|NCT02100007|DRUG|Topotecan|Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
214332985|NCT01194297|BIOLOGICAL|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
214332986|NCT01194297|BIOLOGICAL|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
214332987|NCT06167447|OTHER|questionnaire and examination|Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.
214332988|NCT06430541|DRUG|Psilocybin|A tryptamine that produces its behavioral effects primarily by acting as post-synaptic agonists at serotonin 5-HT2A and 5-HT2c receptors.
214332989|NCT05573295|OTHER|Diagnostic Test: Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
214332990|NCT05573295|OTHER|Diagnostic Test: Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
214332991|NCT05573295|OTHER|Diagnostic Test: London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
214332992|NCT05827302|DEVICE|Health Gauge AI-Based Wearable Device - Model: Phoenix|Wearable device
214934103|NCT06726902|DEVICE|GBT and SI with erythritol powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy~   * Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system.~  * Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with erythritol powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only."
214332993|NCT02170727|DRUG|DCV/ASV/BMS-791325|
214332994|NCT02181868|OTHER|Biodegradable and titanium fixation used in mandibular fractures.|
214332995|NCT03050086|DRUG|BPX-04 1% minocycline topical gel|once daily administration of topical minocycline gel to face
214332996|NCT03050086|DRUG|BPX-04 2% minocycline topical gel|once daily administration of topical minocycline gel to face
214332997|NCT03050086|DRUG|BPX-04 vehicle topical gel|once daily administration of topical minocycline gel to face
214332998|NCT02057107|RADIATION|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
214332999|NCT02057107|DRUG|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
214333000|NCT02057107|DRUG|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
214333001|NCT00720876|BIOLOGICAL|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
214673670|NCT04230850|OTHER|Dynamic Cupping|One cup will be applied ipsilaterally, raising skin to 1.2 cm of standard pressure. The cup will be continuously moved in a sweeping motion between L1 and L5 within a defined width. This process will be repeated on the other side. Each side will be treated for 4 minutes dynamically for a total treatment duration of 8 minutes. (Participants will be equally dispersed into three treatment groups via stratified randomization).
214673671|NCT04230850|OTHER|Stretching|The stretching program performed will involve a double knee to chest stretch, cat stretch, camel stretch, and pelvic tilts. Participants will receive a 30 second rest break between each of the four stretches. (Participants will be equally dispersed into three treatment groups via stratified randomization).
214673672|NCT00293280|DRUG|lomustine|
214934104|NCT06726902|OTHER|GBT and SI with glycine powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with glycine powder.~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only"
215072869|NCT00771732|DEVICE|light therapy|combination of wavelengths
215072870|NCT02036164|RADIATION|Pelvic radiation|"Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times"
215072871|NCT02036164|DRUG|Cisplatin|Cisplatin 40 mg/m2 i.v.
215072872|NCT02036164|DRUG|Paclitaxel|Paclitaxel 175 mg m2 i.v.
215072873|NCT02036164|DRUG|Carboplatin|Carboplatin AUC 5 i.v.
215072874|NCT04338724|DRUG|CS1002|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
215072875|NCT03128268|DEVICE|Imaging software for 4 dimensional images for Cardiac MRI|All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
215077953|NCT04870541|DRUG|Nefopam Injectable Solution|Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
215077954|NCT03333317|DRUG|Lumicitabine|Participants will receive oral administration of lumicitabine.
215077955|NCT03333317|DRUG|Placebo|Participants will receive oral administration of matching placebo.
214934105|NCT06726902|OTHER|GBT and SI with trehalose powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with trehalose powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only"
214934106|NCT06726902|OTHER|SRP and SI|conventional scaling and root planning (SRP) with subgingival instrumentation only will be performed
214934107|NCT03784118|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography is used to evaluate the change in artery size after arterial catheterization and to assess the complication in children
214333002|NCT00720876|DRUG|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
214934108|NCT03784118|DIAGNOSTIC_TEST|perfusion index|measurement of perfusion index immediately after arterial catheterization until surgery end, in arterial catheterization site and contralateral site.
214934109|NCT01384019|DEVICE|distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))|The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration
214333003|NCT03652324|OTHER|method|to compare the use of general anesthesia and deep sedation
214333004|NCT03666598|DEVICE|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
214333005|NCT01298284|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
214333006|NCT04720534|DRUG|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
214333007|NCT04720534|DRUG|Placebo|calculated volume to match active treatment by sc injection
214333008|NCT00286949|DRUG|Atomoxetine|Open Label uncontrolled active Drug intervention
214333009|NCT03198273|OTHER|Clinical pilates exercises|servical, lumbal, pelvic muscles
214934110|NCT01384019|PROCEDURE|c-PCI|conventional PCI without Guard wire
214333010|NCT03198273|OTHER|physiotherapy program|hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
214333011|NCT00260234|BIOLOGICAL|Allogeneic Cultured Islet Cells (human); Encapsulated|
214333012|NCT03767959|PROCEDURE|Chen's U-Suture|Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures
214333013|NCT03767959|PROCEDURE|Classic pancreatic duct to mucosa|A Classical anastomosis technique for Pancreaticojejunostomy
214333014|NCT05369221|DEVICE|ReSpace™|All of the subjects will be injected with ReSpace™ hydrogel.
214934111|NCT02824536|DRUG|3BNC117|Intravenous Infusion of 3BNC117
214934112|NCT02824536|DRUG|10-1074|Intravenous Infusion of 10-1074
214934113|NCT02824536|DRUG|Placebo|Intravenous Infusion of Sterile Saline (NaCl 0.9%)
214934114|NCT04324736|OTHER|no interventional study|no interventional study
214934115|NCT04151485|BEHAVIORAL|Mind/Body Program for Fertility (Domar et al., 2011)|see Arm Description
214934116|NCT04151485|BEHAVIORAL|Fertility Support Program|see Arm Description
214934117|NCT03639805|OTHER|Music therapy program MUSIC CARE® + standard care|Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.
214934118|NCT03639805|OTHER|standard care of vaso-occlusive crises|administration of standard care only
214934119|NCT06263881|DRUG|Raphamin|Tablet for oral use.
214934120|NCT06263881|DRUG|Placebo|Tablet for oral use.
214934121|NCT03259672|DRUG|Sevoflurane|Sevoflurane was used as a maintenance anesthetic agent.
214934122|NCT03259672|DRUG|Desflurane|Desflurane was used as a maintenance anesthetic agent.
214934123|NCT00772122|DRUG|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
214934124|NCT00772122|DRUG|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
214934125|NCT00767039|DRUG|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
214934126|NCT00767039|DRUG|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
214934127|NCT01826370|DRUG|Linagliptin|tablet
214333015|NCT02071576|DEVICE|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
214333016|NCT05769894|OTHER|No intervention given|No intervention is planned. Blood samples will be taken at different stages.
214333017|NCT03304379|DRUG|Fasinumab|Solution for injection in pre-filled syringe
214333018|NCT03304379|OTHER|Diclofenac|NSAID active comparator (capsule)
214333019|NCT03304379|OTHER|Celecoxib|NSAID active comparator (capsule)
214333020|NCT03304379|DRUG|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
214333021|NCT02873104|DEVICE|truSculpt rf device|radiofrequency device
214333022|NCT00099476|BEHAVIORAL|Effects of dark chocolate|
214347165|NCT05244525|DRUG|Bupivacaine alone|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
214934128|NCT01332279|DRUG|everolimus|Given PO
214934129|NCT01332279|DRUG|erlotinib hydrochloride|Given PO
214934130|NCT01332279|PROCEDURE|biopsy|Correlative studies
214333023|NCT03753958|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
214333024|NCT03753958|RADIATION|aPDT|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
214333025|NCT06152211|BEHAVIORAL|Choir|A choir for older adults is a musical/singing ensemble composed of individuals aged 65 and above. The choir rehearsals are weekly, 2 hours each and the length of the intervention is 16 weeks total.
214333026|NCT06152211|BEHAVIORAL|Group Music Listening|A weekly collective music listening, 2 hours each for 16 weeks.
214333027|NCT03097068|DRUG|Lucentis|0.3mg Lucentis
214333028|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
214673673|NCT03077048|DRUG|Ketosteril®|Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
214934131|NCT01332279|OTHER|laboratory biomarker analysis|Correlative studies
214934132|NCT01332279|OTHER|immunohistochemistry staining method|Correlative studies
214934133|NCT01332279|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
214934134|NCT01332279|OTHER|pharmacological study|Correlative studies
214934135|NCT01332279|RADIATION|external beam radiation therapy|Undergo EBRT
214934136|NCT01332279|GENETIC|microarray analysis|Correlative studies
214934137|NCT01575275|DRUG|aminolevulinic acid|Given PO
215072876|NCT06054516|DIAGNOSTIC_TEST|13C-enriched pyruvate|Before starting the hyperpolarization injection procedure, the patient will be scanned using the standard MR imaging defined in the clinical protocol and 13C prescriptions and a pre-scan will be completed. The clinical investigator will mount the administration syringe in the MR compatible power-injector with pre-adjusted injection volume calculated according to body weight (0.43 ml /kg bw). This setting is checked by the scanning operator and clinical investigator. The injection valve is set for agent delivery, and agent injected at a rate of 5 ml/s. The timings are monitored using a stopwatch on the SPINLAB. Following injection of hyperpolarized \[1-13C\]-Pyruvate , 20 ml of sterile saline in a separate syringe, already attached to the patient line, will be used to flush the IV line at the same injection rate (5 ml/s).
215072877|NCT01777555|DRUG|CVT-301|
215072878|NCT01777555|DRUG|Placebo|
214333029|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
214333030|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
214934138|NCT01575275|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214934139|NCT06622018|PROCEDURE|Seashell Nanoparticles and Gluma Desensitizer|Evaluation the effect of Seashell Nano Particles and Gluma desensitizer on sensitivity of the teeth for Intra coronal restoration at different times
214934140|NCT04587349|OTHER|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/ week)
215072879|NCT01760473|DRUG|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
214934141|NCT04587349|OTHER|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (3/ week)
214934142|NCT04587349|OTHER|Physiotherapy|Physiotherapy 2-years-long (3/week)
214934143|NCT04416737|DRUG|Ultra-rapid insulin|Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
214934144|NCT03332628|DEVICE|Microneedle patch|Each patch contains 50 microneedles.
214934145|NCT01821209|PROCEDURE|Placement of sling|Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
214934146|NCT01472757|DRUG|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
214934147|NCT01472757|DRUG|Placebo|Placebo delivered via a new dry powder inhaler
214934148|NCT06614296|PROCEDURE|Crenel Lateral Interbody Fusion|The Crenel Lateral Interbody Fusion (CLIF) is a surgical technique developed by the Department of Spine Surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine. Building on the traditional Lateral Lumbar Interbody Fusion technique, this series of technical improvements overcomes the shortcomings of previous surgical methods, enhancing the safety, operability, and effectiveness of the surgery while reducing complications.
214934149|NCT06614296|PROCEDURE|Crenel lateral interbody fusion plus second stage surgery|The patient was first admitted to undergo CLIF surgery and was discharged after the operation. The patient will return to the hospital for a second surgery at the scheduled time.
214934150|NCT05143008|BEHAVIORAL|SMART Intervention|Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.
214934151|NCT04489381|DRUG|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
215072880|NCT06467669|OTHER|Wrist denervation procedure|To summarize, a Wagner incision is made starting over the junction of the glabrous and non-glabrous skin overlying the thumb CMC joint extending toward the distal wrist crease. The branches of the superficial radial nerve are identified as lying perpendicular to the plane overlying the fascia of the thenar muscles. The branches of the lateral antebrachial cutaneous nerve are identified and resected within the anatomic snuffbox deep to the first compartment. Finally, the thenar muscle fibers are divided at their proximal origin to identify the articular branches of the posterior cutaneous branch of the median nerve.
214333031|NCT03223389|DIETARY_SUPPLEMENT|C-8 dietary oil|Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
214333032|NCT03223389|DIETARY_SUPPLEMENT|Tricaprylin|Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
214333033|NCT03223389|DIETARY_SUPPLEMENT|Olive oil|Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
214333034|NCT01714700|BEHAVIORAL|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
214486336|NCT06752044|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
214934152|NCT04489381|DRUG|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
214934153|NCT04489381|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
214934154|NCT02833935|BEHAVIORAL|Physical Activity Intervention|"The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants."
214934155|NCT03157739|BEHAVIORAL|MigraineManager: Individualized Self-Management Tool|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
214934156|NCT04007224|DRUG|Intranasal oxytocin|daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd
215072881|NCT04376840|OTHER|Blood sample and data record|Blood sample and data record
215077956|NCT02984449|BEHAVIORAL|Pre+post-operative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
215077957|NCT02984449|BEHAVIORAL|Postoperative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
214934157|NCT04007224|BIOLOGICAL|Autologous umbilical cord blood|patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth
214934158|NCT02266290|PROCEDURE|taping of ankle sprain|All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
214934159|NCT02266290|DEVICE|Sport tex® kinesiotape|
214934160|NCT02266290|DEVICE|Pretape Cramer®|
214934161|NCT04444128|DIAGNOSTIC_TEST|Cardiac Imaging|Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol/kg; mapping, volumes, function, strain and LGE); transthoracic echocardiography and blood testing.
214934162|NCT00760370|DRUG|Zoledronic Acid|4 mg intravenous (iv), one treatment
214934163|NCT02941796|DRUG|HCP1105|
214934164|NCT02941796|DRUG|HCP0918|
214934165|NCT02941796|DRUG|HCP0816|
214934166|NCT02062996|DRUG|Oxymetazoline|
214934167|NCT00070018|BIOLOGICAL|rituximab|250 mg/m\^2, as part of Zevalin regimen
214934168|NCT00070018|DRUG|Cyclophosphamide|750 mg/m\^2
214934169|NCT00070018|DRUG|doxorubicin hydrochloride|50 mg/m\^2
214934170|NCT00070018|DRUG|prednisone|100 mg
214934171|NCT00070018|DRUG|vincristine sulfate|1.4 mg/m\^2
214934172|NCT00070018|RADIATION|radiation therapy|4000-5000 cGy total
214934173|NCT00070018|BIOLOGICAL|Yttrium-90 ibritumomab tiuxetan|0.4 mCi/kg
214934174|NCT00070018|BIOLOGICAL|Indium-111 ibritumomab tiuxetan|5 mCi
214934175|NCT03861871|DRUG|Fenfluramine Hydrochloride|Oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. Manufactured by Andersonbrecon, Inc. on behalf of Zogenix International Limited.
214934176|NCT02961062|DRUG|SAF312|
214934177|NCT02961062|DRUG|Placebo|
214934178|NCT03567512|BEHAVIORAL|Smoking hygiene intervention|The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).
214934179|NCT03567512|BEHAVIORAL|Placebo intervention|"The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes)."
214934180|NCT02086825|DRUG|Rifaximin|(Xifaxin®, Salix Pharmaceuticals) 550mg tablet twice daily.
214934181|NCT02086825|DRUG|Lactulose|20g dose titrated
214934182|NCT02939716|OTHER|Rhubarb|300gm rhubarb
214934183|NCT02939716|OTHER|Bread|2 slices bread
214934184|NCT02939716|OTHER|Lettuce|300g lettuce
214934185|NCT03202537|DRUG|dexlansoprazole|dexlansoprazole treatment for Gastroesophageal Reflux symptoms
214934186|NCT00371644|BEHAVIORAL|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
214934187|NCT00371644|BEHAVIORAL|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
214934188|NCT06355089|DIETARY_SUPPLEMENT|Placebo Comparator|Low-protein milk product
214934189|NCT06355089|DIETARY_SUPPLEMENT|Whey protein hydrolysate milk product|Milk product with whey protein hydrolysate
214934190|NCT06355089|DIETARY_SUPPLEMENT|Postbiotic and whey protein hydrolysate milk product|Milk product with whey protein hydrolysate and Lacticaseibacillus rhamnosus GG
214934191|NCT02543892|BIOLOGICAL|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
214934192|NCT02543892|BIOLOGICAL|Placebo|Normal Saline
214333035|NCT01714700|BEHAVIORAL|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
214333036|NCT05718908|DIETARY_SUPPLEMENT|Food supplement|FibrofixPlus® is an authorized food supplement.
214333037|NCT01351129|DRUG|Formulation 1|150-mg immediate release tablet (single dose)
214333038|NCT01351129|DRUG|Formulation 2|150-mg modified release capsule, short duration (single dose)
214333039|NCT01351129|DRUG|Formulation 3|150-mg modified release capsule, long duration (single dose)
214333040|NCT04120389|DEVICE|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)|wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.
214333041|NCT04120389|PROCEDURE|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
214333042|NCT03246009|DRUG|rHSA/GCSF|single injection-1.8mg
214333043|NCT03246009|DRUG|rHSA/GCSF|single injection-2.1mg
214333044|NCT03246009|DRUG|rHSA/GCSF|single injection-2.4mg
214333045|NCT03246009|DRUG|rHSA/GCSF|multiple injection-1.8mg
214333046|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.1mg
214333047|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.4mg
214934193|NCT00598546|BEHAVIORAL|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
214934194|NCT00821223|PROCEDURE|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
214934195|NCT00821223|PROCEDURE|manual small incision surgery|
214934196|NCT00821223|PROCEDURE|phacoemulsification|cataract surgery
214934197|NCT00785213|DRUG|Rosiglitazone 4 mg Tablets|Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
214934198|NCT00785213|DRUG|Rosiglitazone 4 mg Tablets|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
214934199|NCT00785213|DRUG|Quinine Sulfate 324 mg Capsules|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
214934200|NCT00525902|DRUG|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
214333048|NCT05030142|PROCEDURE|Mechanical Thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
214333049|NCT05030142|DRUG|Best medical treatment alone|Best medical treatment alone (usual care)
214333050|NCT04616144|DEVICE|Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser|Fresh Corneal Lenticule Implantation using ReLex-Smile
214333051|NCT02054364|BEHAVIORAL|FBT and CRT|
214333052|NCT02054364|BEHAVIORAL|FBT and art therapy|
214333053|NCT03063827|DRUG|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
214333054|NCT03063827|DIAGNOSTIC_TEST|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
214333055|NCT00005638|DRUG|cisplatin|
214333056|NCT00005638|DRUG|irinotecan hydrochloride|
214333057|NCT00005638|RADIATION|radiation therapy|
214333058|NCT05899504|DEVICE|Over-The-Scope-Clip (OTSC) Stent Fix|A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. We will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure
214333059|NCT00144118|DRUG|sevoflurane or isoflurane|
214333060|NCT03843359|DRUG|GSK3745417|GSK3745417 will be administered.
214333061|NCT03843359|DRUG|Dostarlimab|Dostarlimab will be administered.
214934201|NCT02180997|DRUG|Tamsulosin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily
214333062|NCT01246726|PROCEDURE|CT SCAN|Prior to radiotherapy + after radiotherapy completion
214333063|NCT01246726|PROCEDURE|MRI scan|Prior to radiotherapy + after completion of radiotherapy
214333064|NCT01246726|PROCEDURE|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
214333065|NCT03970135|OTHER|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose \< 3mmol/L) or symptoms of hypoglycemia
214333066|NCT03747029|OTHER|No intervention is provided|No intervention is provided
214333067|NCT00395044|DRUG|Placebo|Placebo
214333068|NCT00395044|DRUG|Gabapentin|
214333069|NCT06096025|DRUG|pneumoniae bacteremia therapy|To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.
214333070|NCT04914572|OTHER|Therapeutic rainforest mindful walking|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by Mindfulness Practitioner who volunteered to be guides for this study.
214333071|NCT04914572|OTHER|Therapeutic rainforest walk|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by volunteer guides recruited by the research team.
214333072|NCT04914572|OTHER|Campus Green walk|A two-kilometer trail curated by the Office of Facility Management, NUS. The walk will be led by volunteer guides recruited by the research team.
214333073|NCT03464344|OTHER|neurological, neuropsychological and MRI evaluation|neurological, neuropsychological and MRI evaluation
214333074|NCT05821101|DEVICE|Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.|Bilateral implantation of IOLs such that dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters).
215072882|NCT03831906|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra (Ultra)|"The intervention will consist of the WHO standard of care for children with severe pneumonia plus the study intervention consisting in rapid detection of TB on the day of hospital admission using the Ultra assay performed on 1 NPA and 1 stool sample.~The sample flow will be organised to reduce time-to-results to 3 hours. Ultra will be performed at the hospital laboratory using a standard GeneXpert device, or implemented directly inward using a one-module, battery-operated GeneXpert device (G1 Edge).~Drugs will be available at the inpatient level to enable immediate initiation of TB treatment, as soon as a positive Ultra result is available."
214934202|NCT02180997|DRUG|Solifenacin|Tamsulosin and solifenacin: Solifenacin 10 mg, once daily
214934203|NCT02180997|DRUG|Tamsulosin and solifenacin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
214934204|NCT03667417|OTHER|Questionnaires|standardized data collection and 10-year prospective follow-up
215072883|NCT04599270|OTHER|PREVENTURE Program|Adolescents will be follow PREVENTURE program (2 session of 90 min).
215072884|NCT04599270|OTHER|Routine care|Adolescents will be follow routine care
214333075|NCT02263066|BIOLOGICAL|BAY14-2222_Kogenate-FS FVIII|Depends on Doctor's decision
214333076|NCT05056168|OTHER|Dermatology-Specific Treatment Satisfaction Instrument|Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients' preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.
214333077|NCT04047017|DRUG|Apatinib|250mg, po, qd
214333078|NCT04047017|DRUG|Camrelizumab|200mg, q2w
214333079|NCT05661292|DIAGNOSTIC_TEST|Fecal inmunochemical test|A fecal inmunochemical test will be performed prior to colonoscopy.
214333080|NCT05661292|DIAGNOSTIC_TEST|Colonoscopy|A colonoscopy will be performed. Any polyp identified will be resected (polypectomy) and analyzed histologically. NOTE: The subject and colonoscopist will be blinded to FIT test results and risk category.
214347166|NCT01962974|BIOLOGICAL|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
214347167|NCT06171113|DRUG|GSK4024484C|Doses administrated orally with 240 mL of water.
214347168|NCT06171113|DRUG|Placebo|Doses administrated orally with 240 mL of water.
214347169|NCT06137300|DRUG|Urinary kallidinogenase for injection|Urinary kallidinogenase 0.15PNA once daily for 7 days.
215072885|NCT03615872|DEVICE|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
215072886|NCT03817463|DRUG|Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
215072887|NCT03817463|DRUG|Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor|Dipeptidyl peptidase-4 (DPP-4) inhibitor
215072888|NCT04756999|BEHAVIORAL|massage therapy|Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.
215072889|NCT06373926|BIOLOGICAL|blood withdrawal|blood withdrawal
215072890|NCT01468948|DRUG|Octanoic Acid|
214333081|NCT05661292|BIOLOGICAL|Optional collection of tissue, blood and urine for future biomedical research|Subjects may optionally participate in the collection of tissue, blood, and urine samples for future biomedical research. This procedure consists of taking a 15 ml sample of venous blood and 20 ml of urine. The tissue samples to be used will be those that have been taken for diagnostic purposes during the colonoscopy. Additional biopsies not required for medical care will not be taken. These samples will be used as long as they are no longer required to establish a diagnosis.
214333082|NCT00890461|RADIATION|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
214333083|NCT06349044|RADIATION|Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）|RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.
214333084|NCT06349044|DRUG|Anti-PD-1 monoclonal antibody|Sintilimab 200mg d1 iv q3w
214333085|NCT06349044|DRUG|Oxaliplatin and Capecitabine|Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
214333086|NCT06349044|DRUG|Anti-VEGF 15mg/kg|Bevacizumab 15mg/kg d1 iv q3w
214333087|NCT06349044|DRUG|Anti-VEGF 7.5mg/kg|Bevacizumab 7.5mg/kg d1 iv q3w
214333088|NCT06349044|DRUG|Gemcitabine and Cisplatin|Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w
214333089|NCT02988063|DRUG|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
214333090|NCT05116735|PROCEDURE|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
214333091|NCT05241886|OTHER|anthoropometric measurement, SARC- F questionnare|SARC-F, CC, MUAC
214333092|NCT01482104|DRUG|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
214333093|NCT01482104|DRUG|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
214333094|NCT06113718|PROCEDURE|Abdominal Exercise (digital rectal stimulation, abdominal massage)|"The recommended bowel exercise program consisted of three steps:~1. Patients will perform a 2-3 minute massage starting from the cecum approximately 20-30 minutes after breakfast, moving along the colon.~2. Patients will assume a suitable position and perform circular massage on the anal walls with their finger for approximately 30 seconds (digital rectal stimulation).~3. Patients will try to defecate while sitting on the toilet."
214333095|NCT02066558|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
214333096|NCT02066558|OTHER|Placebo|
214934205|NCT05274542|OTHER|high intensity with blood flow restriction|Participants in high intensity with blood flow restriction group (n=12) will be given high-intensity resistance exercise training that restricts blood flow. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. A blood pressure cuff will be used to restrict blood flow. By applying the cuff to the proximal of the muscle, the blood flow will be restricted with a pressure of 150 mmHg and the muscle will be exercised in this way. After the exercise, the cuff will be removed and evaluations will be made after 2 minutes of rest.
214934206|NCT05274542|OTHER|high intensity without blood flow restriction group|Participants in high intensity without blood flow restriction group (n=12) will be given high-intensity resistance exercise training. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. After the exercise, after 2 minutes of rest, evaluations will be made.
214934207|NCT03098056|OTHER|PROG2|"Nutritional Supplements to be administered:~* Protein Shakes: one shake po twice daily~* Phytosterol supplement: one capsule po twice daily~* Cinnamon: one tablet twice daily~* Fiber supplement; one shake twice daily~* Antioxidant supplement: 2 capsules daily with dinner~* Fish Oil supplement: 1 capsule twice daily with food~* Probiotic supplement: 1 capsule twice daily with food"
215072891|NCT03092986|DRUG|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
215072892|NCT03092986|DRUG|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
215072893|NCT03092986|DRUG|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
215072894|NCT03092986|DRUG|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
215072895|NCT03092986|RADIATION|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
214333097|NCT04354922|BEHAVIORAL|Exercise intervention|Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
214333098|NCT03979716|DEVICE|fMRI|fMRI examination
214333099|NCT05815446|DEVICE|CT|NON CONTASR COMPUTED TOMOGRAPHY
214934208|NCT04373798|DIAGNOSTIC_TEST|C-reactive protein|Measurement of CRP value from blood sample taken at covid19 check point (baseline).
214934209|NCT04756128|DRUG|Colchicine 0.6 mg|"Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.~For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)"
214934210|NCT04756128|DRUG|Naltrexone|"Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.~For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension."
214934211|NCT01656278|PROCEDURE|Magnetic resonance imaging (MRI)|"Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28\>3.2 AND/OR MRI-detected bone marrow oedema score \> 0 (RAMRIS-score)"
215072896|NCT03447210|BEHAVIORAL|Assisted Partner Services|Contact tracing for sexual and drug-sharing partners to notify about exposure to HIV and offer HIV and hepatitis C testing with linkage to care and partner services for those who test positive.
215072897|NCT06481371|DRUG|zuojinwan|In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.
214333100|NCT00945516|DEVICE|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
214333101|NCT00945516|DEVICE|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
214333102|NCT03511560|DRUG|Tacrolimus Extended Release Oral Tablet|Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
214333103|NCT03511560|DRUG|Tacrolimus|Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
214333104|NCT03372408|OTHER|Chart review|Retrospective chart review of program participation and socio-demographic \& psychosocial characteristics
214333105|NCT03323268|DEVICE|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
214333106|NCT03026673|OTHER|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
214333107|NCT03487913|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
214333108|NCT02985736|DRUG|Topicort Topical Spray|
214333109|NCT00382733|DRUG|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
214333110|NCT02549144|DIETARY_SUPPLEMENT|Low fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.
214333111|NCT02549144|DIETARY_SUPPLEMENT|High fat/cholesterol diet|The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day
214333112|NCT06572488|DEVICE|Non-ablative SMOOTH mode Er:YAG laser|Four intravaginal treatments within four months.
214333113|NCT06573411|DRUG|ACEI/ARB+ finerenone|The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.
214333114|NCT06573411|DRUG|ACEI/ARB+ Placebo|Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
214333115|NCT05100875|BEHAVIORAL|"Social Skills and Emotion Regulation Training SSERT"|The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.
214333116|NCT04452357|RADIATION|PLDR|"PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows:~Dose level 1: 56 Gy; Dose level 2: 66 Gy Drug: Gemcitabine"
214333117|NCT06257784|PROCEDURE|Oxygen Therapy|Patients who have SpO2 \< 92% on room air will undergo oxygen therapy (nasal cannula or Venturi-mask).
214333118|NCT06257784|PROCEDURE|Non-Invasive Ventilation (NIV)|Patients with P/F \< 250 or Ph \< 7,35 with PCO2 \> 50 mmHg will undergo Non-Invasive Ventilation (NIV) (high flow nasal cannula or CPAP).
214333119|NCT06257784|PROCEDURE|Invasive Ventilation|Patients with P/F \< 150 associated to dyspnea at rest (moderate to severe, shortness of breath and/ or tachypnea (\>24 breaths/min) despite NIV for at least 2 hours or patients with Ph \< 7,2 with PCO2 \> 60 mmHg despite NIV for at least 2 hours will undergo invasive ventilation (intubation).
214333120|NCT04650828|DRUG|TDF|TDF combined with telbivudine (LDT) for 12 months
214333121|NCT04650828|DRUG|Tenofovir Disoproxil Fumarate 300 MG|TDF monotherapy was continued for 12 months
214333122|NCT05580575|DEVICE|Daily disposable toric soft contact lens|Daily disposable toric soft contact lens
214333123|NCT05580575|DEVICE|Monthly replacement toric daily wear soft contact lens|Monthly replacement toric daily wear soft contact lens
214333124|NCT05696015|BEHAVIORAL|Standard education|Without telehealth education, this group has only postdischarge education.
214333125|NCT05696015|BEHAVIORAL|Ampiled Education|With telehealth education, in addition of discharge education.
214347170|NCT06137300|OTHER|Guideline-prescribed medical therapy|Guideline-prescribed medical therapy
214333126|NCT01259193|DRUG|Sorafenib and Zoledronic Acid|Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
214934212|NCT01656278|OTHER|Conventional biochemical and clinical examinations|"Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28\>3.2"
214934213|NCT03851146|BIOLOGICAL|LeY CAR T cells|Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
215072898|NCT06481371|DRUG|Rabeprazole sodium enteric-coated tablets|For epigastric pain syndrome
215072899|NCT06481371|DRUG|mosapride citrate|Postprandial discomfort syndrome
215072900|NCT03167112|DRUG|Oxaliplatin|Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
215072901|NCT03167112|DRUG|Irinotecan|Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
214333127|NCT06453993|OTHER|Exhaled VOC breath test|To determine longitudinal variation in exhaled VOC concentrations during intended curative therapy for EC cancer.
214333128|NCT04260815|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
214333129|NCT05315388|OTHER|Immersion therapy in nature - Vitamin N|"Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements."
214333130|NCT03282955|DRUG|Lipidem|Lipoplus i.v. lipid emulsion for parenteral nutrition
214333131|NCT03282955|DRUG|Lipofundin MCT 20%|Lipofundin MCT 20% i.v. lipid emulsion for parenteral nutrition
214333132|NCT01665365|PROCEDURE|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
214333133|NCT05776030|DEVICE|Single Speed Ergonomic Wheelchair|"Ergonomic wheelchair. The ergonomic wheelchair was developed by the MADE program and has anterior placed hand rims that are connected with a bicycle chain. In Aim 1, Participants will use the ergonomic wheelchair to test 3 different gear ratios.~1. 2:3~2. 1:1~3. 3:2"
214333134|NCT05776030|DEVICE|Multi-Speed Ergonomic Wheelchair|The multi-speed ergonomic wheelchair will be developed by the MADE program and will use a two-hand rim design so the participant can change gears by changing hand rims.
214333135|NCT05404516|DRUG|Sorafenib|"Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year."
214333136|NCT05404516|DRUG|Idarubicin|"Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3."
214333137|NCT05404516|DRUG|Cytarabine|"Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3."
214333138|NCT02185768|DRUG|idarubicin|
214333139|NCT02185768|DEVICE|Dc- Beads 300-500µm|
214333140|NCT05957978|DRUG|LXE408|Film-coated tablets
214333141|NCT05957978|DRUG|sodium stibogluconate|Dosage/Administration: sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d.
214333142|NCT05957978|DRUG|Paromomycin|Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.
214333143|NCT00832429|PROCEDURE|Lymph Node Mapping|Undergo lymph node mapping
214333144|NCT00832429|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
214333145|NCT00832429|DRUG|Technetium Tc-99m Sulfur Colloid|Given ID
214333146|NCT05110001|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
214333147|NCT05110001|DRUG|Chlorhexidine Gluconate|Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.
214347171|NCT02266628|BIOLOGICAL|RSV-F Vaccine|
214347172|NCT02266628|BIOLOGICAL|Saline Placebo|
214347173|NCT01527201|PROCEDURE|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
214934214|NCT01777568|DRUG|30% oxygen|Inspired oxygen will be maintained at 30%.
214934215|NCT01777568|DRUG|80% oxygen|Inspired oxygen will be maintained at 30%.
215072902|NCT03167112|DRUG|Leucovorin|Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
215072903|NCT03167112|DRUG|Fluorouracil|Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
215072904|NCT05311943|DRUG|olverembatinib|olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
215072905|NCT04692649|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
215072906|NCT04692649|OTHER|cross body stretch|crossbody stretch performed by an individual
215072907|NCT00024024|DRUG|rebimastat|
215072908|NCT03789136|OTHER|Not applicable, observational study|Not applicable, observational study
215072909|NCT06006507|OTHER|control|no exercise will be given
215077958|NCT05490589|OTHER|EQUIPE Program|"EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home."
214934216|NCT03579628|DRUG|AsiDNA|"All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue."
214934217|NCT05008393|DRUG|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 daily for 10 days.
214934218|NCT05008393|DRUG|PJS-539 Dose 2|Patients will receive PJS-539 Dose 2 daily for 10 days.
214934219|NCT05008393|DRUG|Placebo|Patients will receive placebo daily for 10 days.
214333148|NCT05110001|DRUG|Natamycin|Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
214333149|NCT05110001|DRUG|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
214934220|NCT00103493|BEHAVIORAL|Motivational interviewing|
214934221|NCT00103493|BEHAVIORAL|Targeted DVD-based educational program|
214934222|NCT03760328|DEVICE|Upper Airway Stimulation|hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
214934223|NCT02744482|DRUG|risedronate|risedrante tablet (75 mg)
214934224|NCT02744482|DRUG|placebo|risedrante placebo tablet (75 mg)
214333150|NCT05110001|OTHER|Placebo|Study participants receive sham RB-PDT within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.
214934225|NCT00844480|DRUG|zoledronic acid|zoledronic acid, 5mg, iv
214934226|NCT00844480|DRUG|placebo|iv
214934227|NCT02858180|DRUG|Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)|1 pill once daily of SOF/LDV FDC
214934228|NCT06730880|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction (abbreviated PCR) is a laboratory technique for rapidly producing (amplifying) millions to billions of copies of a specific segment of DNA, which can then be studied in greater detail.
214934229|NCT00526331|DEVICE|Vigileo Monitor|Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
214934230|NCT00526331|DEVICE|FloTrac Sensor|Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
214934231|NCT02490748|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
214934232|NCT02490748|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
214934233|NCT01028248|DRUG|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
214934234|NCT03229148|PROCEDURE|General anaesthesia|Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
214934235|NCT03229148|PROCEDURE|Conscious Sedation|A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
214934236|NCT06242418|DRUG|FOLFOXIRI|Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
214934237|NCT06242418|DRUG|XELOX|Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
214934238|NCT00392522|DRUG|50% Nitrous Oxide and 50% Oxygen (MEOPA)|
214934239|NCT05009407|BIOLOGICAL|Immunohistochemistry and clinical analyses on patients and corneas|Immunohistochemistry and clinical analyses on patients and corneas
214934240|NCT01330056|PROCEDURE|FOPS|"* Functional organ preservation (FOPS) as a first-line treatment modality~* Postoperative RT or CRT may be included for the patients of this group."
214934241|NCT01330056|RADIATION|CRT|"* Concurrent chemoradiotherapy as a first-line treatment modality~* Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT"
214934242|NCT04808232|BEHAVIORAL|progressive muscle relaxation exercise|"We used the muscle relaxation audio CD produced by the Turkish Psychologists Association. The CD consists of three parts; the 10-min first part includes definition and purpose of relaxation, and points to take into consideration during relaxation, the 30-min second part includes instructions with river sounds, and the 30-min third part includes only relaxing music without instructions. We used the second part of the audio record in this study. Following the instructions on the CD, the students tensed each muscle group from hands to feet, and then, all muscles in their face and body for approximately 10 s. The women breathed in, tensed a specific muscle group, and then relaxed it while breathing out. The relaxation step took 10-20 s before tensing the next muscle group. Thus, the women relaxed by tensing and relaxing the muscle groups in hands, arms, neck, shoulder, chest, stomach, hips, foot and fingers, and all muscles in the face and body."
214934243|NCT01075906|DRUG|colchicine sprinkle capsules|0.3 mg
214934244|NCT01075906|DRUG|colchicine sprinkle capsules|0.3 mg
214934245|NCT04993599|DEVICE|Social robot interaction|The participants interact with the social robot which is controlled by the researcher behind the scene (wizard of oz. method).
214934246|NCT01005888|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
214934247|NCT01005888|DRUG|Placebo (saline)|
214934248|NCT04850573|OTHER|equine assisted activities|Participants interact with the horse and learn how to safely handle the horse.
214934249|NCT02371564|DEVICE|High flow humidified oxygen|
214934250|NCT02371564|DEVICE|Standard flow humidified oxygen|
214934251|NCT04115410|DRUG|PD-1 inhibitor|PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.
214934252|NCT04115410|DRUG|Chemotherapy Drugs, Cancer|Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
214934253|NCT03669718|BIOLOGICAL|ISA101b|Every 3 weeks for a total of 3 times
214934254|NCT03669718|DRUG|Cemiplimab|Every 3 weeks for up to 24 months
214934255|NCT03669718|OTHER|Placebo|Every 3 weeks for a total of 3 times
214333151|NCT02550652|DRUG|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
214333152|NCT02550652|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
214333153|NCT02550652|OTHER|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
214934256|NCT00669019|DRUG|saracatinib|
214934257|NCT02947906|OTHER|No intervention|No intervention
214934258|NCT02827435|DRUG|Rocuronium bromide|Pharmacokinetic-pharmacodynamic modeling blood sampling and Rocuronium bromide concentration measure muscle relaxation evaluation
214934259|NCT05921149|DIETARY_SUPPLEMENT|Fasting Mimicking Diet (Xentigen by L'Nutra)|L-Nutra Xentigen is a product which will provide all the food to be consumed by subjects during 3 days prior to chemotherapy and for 24 hours after chemotherapy. Xentigen is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients that are generally regarded as safe (GRAS) and comprises proprietary vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. The FMD consists of a 4-day regimen that provides approximately 1100 kilocalories for the first day and approximately 500 kilocalories per day for the second to the fourth day. Subsequently, a day 5 of transition diet (approximately 800 kilocalories) is provided to avoid the refeeding syndrome.
214934260|NCT05921149|DRUG|Carboplatin|Given IV
214934261|NCT05921149|DRUG|Paclitaxel|Given IV
214934262|NCT05921149|DIETARY_SUPPLEMENT|Standard diet|Normal diet
214934263|NCT06027307|DRUG|Enavogliflozin|All study patients will receive enavogliflozin in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
214934264|NCT06027307|DRUG|Placebo|All study patients will receive placebo in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
214934265|NCT05166720|BEHAVIORAL|NIDCAP care|NIDCAP care was performed according to the best evidence of NIDCAP
214934266|NCT02846870|OTHER|Visually enhanced prostate cancer educational presentation|Receive visually enhanced prostate cancer educational presentation
214934267|NCT02846870|OTHER|Standard prostate cancer education presentation|Receive standard prostate cancer education presentation
214934268|NCT01864213|DRUG|Ametop cream|
214934269|NCT00581542|DRUG|moxifloxacin|1-2 drops three times a day for 8-10 days.
214934270|NCT00581542|DRUG|polytrim|1-2 drops four times a day for 8-10 days.
214333154|NCT02550652|DRUG|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
214333155|NCT02550652|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
214333156|NCT04466163|BEHAVIORAL|Schema Therapy and the Healthy Adult|The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen \& Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
214333157|NCT03952793|OTHER|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
214333158|NCT04298528|DRUG|Dronabinol|2.5mg 2 times a day for 30 days after total knee replacement
214333159|NCT04298528|OTHER|Placebo|2 times a day for 30 days after total knee replacement
214333160|NCT03761251|BEHAVIORAL|Pet Fish|"Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~1. feed fish one pellet in the morning after waking; check and record BG reading at that time~2. feed fish one pellet in the evening before dinner; check and record BG reading at that time~3. feed fish one pellet at night before bedtime; check and record BG reading at that time~4. every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience."
214333161|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q4W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
215077959|NCT03812185|DEVICE|Suctioning orogastric tube which is attached to TEE probe cover|Suctioning orogastric tube which is atttached to TEE probe cover.
215077960|NCT03952715|DRUG|Ibuprofen 400 mg|Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
215077961|NCT03952715|DRUG|Placebo oral tablet|Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
215077962|NCT04172168|DIAGNOSTIC_TEST|Heart rupture|Left ventricular free-wall ruptrue after AMI
214934271|NCT04341350|DRUG|Propofol + analgesic drug|sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
214934272|NCT04341350|DRUG|Isoflurane + analgesic drug|sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
214934273|NCT06552962|DEVICE|Whole body vibration|The aim of this study is to reveal the effect of exercises performed with WBV on the myofascial tissue of the lumbar region and the tone of superficial back muscles, as well as to investigate the effects on pain, function, muscle strength, balance, proprioception and endurance parameters, compared to the exercise-only group.
214934274|NCT06552962|BEHAVIORAL|lumbar stabilization exercises|The control group will undergo lumbar stabilization exercises twice a week for 6 weeks.
214934275|NCT03783403|DRUG|CC-95251|Specified dose on specified days
214934276|NCT03783403|DRUG|Rituximab|Specified dose on specified days
215077963|NCT02707393|DRUG|Fludarabine|infusion
215077964|NCT02707393|DRUG|Thiotepa|infusion
214333162|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
214333163|NCT04630522|DRUG|Drug: JMT103- 180 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
214333164|NCT04630522|DIETARY_SUPPLEMENT|Dietary Supplement: Calcium Dietary Supplement: Vitamin D|Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
214333165|NCT05801627|DRUG|SAL067|SAL067 6mg(2 tablet) and Metformin ≥1500mg
214333166|NCT05801627|DRUG|Placebo|Placebo (2 tablet) and Metformin ≥1500mg
214333167|NCT03286140|PROCEDURE|Early endovenous ablation|
214333168|NCT03286140|PROCEDURE|Delayed endovenous intervention|
214333169|NCT01557075|DRUG|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~* Atorvastatin 40 mg daily for 12 months after randomization"
214333170|NCT01557075|DRUG|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization"
215077965|NCT02707393|DRUG|Melphalan|infusion
214333171|NCT03377348|PROCEDURE|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
214333172|NCT01527916|DRUG|placebo|Placebo Comparator
214333173|NCT01527916|DRUG|donepezil|Active Comparator
214333174|NCT01527916|DRUG|ABT-126|low dose, middle dose, high dose
214333175|NCT05525182|DRUG|ES16001 40 mg|Composition: Elaeocarpus extract 40mg tablet
214333176|NCT05525182|DRUG|ES16001 80 mg|Elaeocarpus extract 80 mg tablet
214333177|NCT05525182|DRUG|ES16001 160 mg|Elaeocarpus extract 160 mg tablet
215077966|NCT02707393|DRUG|ATG|infusion
215077967|NCT02707393|DRUG|Cyclosporine A|infusion, orally if possible
215077968|NCT02707393|DRUG|Mycophenolate mofetil|infusion
215077969|NCT02707393|BIOLOGICAL|bone marrow or peripheral blood stem cells|infusion
215077970|NCT05175768|OTHER|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
215077971|NCT05175768|OTHER|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
215077972|NCT05175768|OTHER|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
215077973|NCT05025098|DRUG|Standard therapy|"For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle."
214333178|NCT05525182|DRUG|Placebo|Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
214333179|NCT05066620|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
214333180|NCT02201797|OTHER|DCE MRI|
214333181|NCT00515827|DRUG|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
214333182|NCT00515827|DRUG|Placebo|400 mg placebo tablet taken orally twice daily
214333183|NCT02482350|BEHAVIORAL|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
214347174|NCT04701021|BIOLOGICAL|TENDU|The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.
214347175|NCT01692197|DRUG|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
214347176|NCT01692197|DRUG|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
214347177|NCT01692197|DRUG|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age \> 60 years).
214333184|NCT04401007|OTHER|Erector Spinae Plane Block with 1.5% lidocaine|Erector spinae plane (ESP) block is a new regional nerve block technique that involves a percutaneous injection of local anesthetic as a bolus through a needle or catheter into the fascial plane between the erector spinae muscle and the transverse processes in the upper or mid back.
214333185|NCT00099775|DRUG|Caspofungin|
214934277|NCT03783403|DRUG|Cetuximab|Specified dose on specified days
214333186|NCT02616003|DRUG|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
214333187|NCT02616003|OTHER|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
214333188|NCT02616003|DIETARY_SUPPLEMENT|Caloric diet with 1000 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)
214333189|NCT06084585|DIETARY_SUPPLEMENT|Study Product A (High-dose 2X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
214333190|NCT06084585|DIETARY_SUPPLEMENT|Study Product B (Low-dose X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
214333191|NCT06084585|DIETARY_SUPPLEMENT|Placebo|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
214934278|NCT03234517|DRUG|Vaginal Clindamycin Cream|Vaginal Clindamycin Cream
215072910|NCT06006507|OTHER|exercise|In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
214333192|NCT05494788|DRUG|CardiolRx|Pharmaceutically produced Cannabidiol
214333193|NCT05896150|PROCEDURE|Cryoanalgesia AND single-injection paravertebral block|CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
214333194|NCT05896150|PROCEDURE|Single-injection paravertebral block|Paravertebral block with Bupivacaine 0.5%
214333195|NCT04813770|BEHAVIORAL|Theory-based messages|COVID-19 vaccination information structured to address vaccination necessity and concerns.
214333196|NCT04813770|BEHAVIORAL|General messages|General messages about the COVID-19 virus and the vaccination programme.
214333197|NCT05429268|DRUG|Tafasitamab|Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
214333198|NCT05429268|DRUG|Lenalidomide|Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
214333199|NCT04630431|OTHER|Best Practice|Undergo standard of care follow-up
214333200|NCT04630431|OTHER|Educational Intervention|Undergo clinical trial education via a video and educational booklet
214333201|NCT04630431|OTHER|Electronic Health Record Review|Review of medical record
214333202|NCT04630431|BEHAVIORAL|Patient Navigation|Undergo clinical trial navigation
214333203|NCT04630431|OTHER|Questionnaire Administration|Complete questionnaire
214333204|NCT05462145|DEVICE|Globe Pulsed Field System|Ablation and atrial mapping with the Globe Pulsed Field System
214934279|NCT03234517|DRUG|Vaginal Probiotic|Vaginal Probiotic
214934280|NCT03337581|DRUG|Dexmedetomidine|see arms
214934281|NCT06619288|DRUG|B/F/TAF|Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.
215072911|NCT02964559|BIOLOGICAL|Pembrolizumab|Given IV
215072912|NCT01215643|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
215072913|NCT01215643|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
214333205|NCT06445842|OTHER|Exercise|The protocol involves a 10-minute warm-up and cool-down session, followed by two sets of high-intensity circuit training exercises (bench press, squats, overhead press, calf raising, barbell row, deadlifts) that last 12 minutes each (6 stations×2sets). There will be a 3-minute break between the exercise sets. The heart rate required during the exercise will be between 70-90% of their maximum capacity and a pre-scale rate of 7.5. The intensity of the exercise will be progressive each two weeks, commencing at 50% of their one rep max and increasing to 80% in their last week. During the initial phase, participants will be required to complete eight reps for each exercise. We will encourage them to increase their intensity level every two weeks.
214333206|NCT06445842|OTHER|No exercise|This group will need to maintain their sedentary lifestyle without changing their activity levels or diet
214934282|NCT06619288|DRUG|TDF+3TC+EFV|Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).
214934283|NCT06619288|DRUG|DTG/3TC|Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.
214934284|NCT06318052|DEVICE|The FemTouch delivery system|The FemTouch delivery system is used in conjunction with the AcuPulse CO2 laser system and the AcuScan120 microscanner to provide fractional treatments in gynecology
214934285|NCT06318052|DRUG|Gynomunal gel treatment|hormone/free, vaginal moisturizing gel for women with vaginal dryness
214934286|NCT01623037|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the each flank with a defined cooling rate and duration.
214934287|NCT02782299|OTHER|Decision Aid|Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
215072914|NCT01215643|DRUG|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
214333207|NCT02242357|DRUG|Micardis®|
214934288|NCT05960448|OTHER|Transcutaneous Spinal Cord Stimulation (TSCS)|This is electrical stimulation delivered to the spinal cord through the skin and tissue using a cathode electrode to deliver the stimulation and anode electrodes to ground the circuit.
214934289|NCT05960448|OTHER|Sham Transcutaneous Spinal Cord Stimulation|This is designed to appear like transcutaneous spinal cord stimulation without actually delivering the stimulation.
214333208|NCT02242357|DRUG|Micardis® Plus|
214333209|NCT00653354|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
214333210|NCT00653354|DRUG|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
214333211|NCT00653354|DRUG|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
214333212|NCT03973346|OTHER|Risk screening tool exposure|Risk screening tool is available to providers
214333213|NCT03181542|DEVICE|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
214333214|NCT03574545|BIOLOGICAL|ianalumab|Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
214333215|NCT01833403|OTHER|Hyperinsulinemic-euglycemic clamp|"Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~\--------------------------------------------------------------------------------"
214333216|NCT04138615|DRUG|Morphine|Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
214333217|NCT04138615|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
214333218|NCT00774631|PROCEDURE|Mild induced hypothermia (32-34°C)|"Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 \[6, 48\]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods."
214333219|NCT00774631|PROCEDURE|local recommendations and guidelines|"Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours."
214333220|NCT04520945|BIOLOGICAL|Chondrogen|Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid
214333221|NCT04520945|BIOLOGICAL|Placebo|Consist of saline and hyaluronic acid
214333222|NCT03099551|DEVICE|Group using manual toothbrush Curaprox 5460 Ultra Soft|Manual toothbrush usage with Bass technique twice a day during 2 minutes
214333223|NCT03099551|DEVICE|Group using sonic toothbrush Edel White|Sonic toothbrush usage twice a day during 2 minutes
214333224|NCT05090020|PROCEDURE|Treatment|Surgery and PAIR
214333225|NCT05611580|BEHAVIORAL|Chronic Disease Risk Reduction|The intervention involves education information about chronic diseases and way to reduce risk for developing chronic diseases and/or decrease worsening of existing conditions.
214333226|NCT04125316|OTHER|Observation, no intervention|Observational study, no intervnetion
214333227|NCT01585480|BEHAVIORAL|Weight Gain Prevention Intervention|"1. Behavioral Approaches~   1. Distribution of pedometers~  2. Traffic light labeling in worksite cafeteria and vending machines~2. Informational \& Persuasive Messages~   1. Stair use prompts~  2. Posters, pamphlets, table toppers~  3. Website~3. Social Approaches~   a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~4. Environmental Changes~   1. Traffic light labeling~  2. 1/2 portions at 1/2 price~  3. Walking routes~  4. Introduction of healthier foods~  5. Rearrangement of foods in the cafeteria~  6. Adjusting serving spoon size"
214333228|NCT03033472|DRUG|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
214934290|NCT00968058|PROCEDURE|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
214333229|NCT03033472|DRUG|Oral Placebo|Oral Placebo 30 minutes before treatment
214333230|NCT04623580|DEVICE|Surgical inguinal or femoral hernia repair|Surgical inguinal or femoral hernia repair (primary or mesh)
214333231|NCT03309280|OTHER|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
214333232|NCT03309280|DIAGNOSTIC_TEST|Evolution of the renal function|Evolution of the renal function in the next two days
214934291|NCT01729052|DEVICE|Acupuncture|
214934292|NCT02788370|DEVICE|a conical positive expiratory pressure device|The CPEP device will be connected to respiratory transducer for generating positive expiratory pressure with therapeutic rang (5 to 20 cm H2O).
214934293|NCT02788370|OTHER|Constant work load cycling test|"Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~1. sever breathlessness (\>5 /10 score of modified Borg scale)~2. leg fatigue (can not maintain speed between 50 to 60 rpm)~3. Hear rate (HR) \>80 % age-predicted maximum HR~4. Exercise time up to 10 minutes~5. Other symptom that stated by American thoracic Society(2002)"
214934294|NCT06618781|PROCEDURE|Sedation|Preoperatively, 2 mg intravenous midazolam was administered to the patients. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and when the Vizel analog score was \>4, intravenous 0.1-1 mcg/kg remifentanil was administered.
214934295|NCT06618781|PROCEDURE|Sedation + Quadratus Lumborum Block|Before the procedure, the patient was placed in the left lateral position and a Quadratus Lumborum Block was applied at the thoracic 8-10 level. A total of 20 cc blocking fluid consisting of 14 cc of 0.5% bupivacaine and 6 cc of 2% lidocaine was used for the block. A minimum of 30 minutes was waited after the block. 2 mg of intravenous midazolam was administered before being taken to the operating room. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and intravenous 0.1-1 mcg/kg remifentanil was administered when the Vizel analog score was \>4.
214934296|NCT04761406|DIETARY_SUPPLEMENT|Phaeosol group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
215072915|NCT01009437|DRUG|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
214333233|NCT04431037|DIETARY_SUPPLEMENT|Early oral feeding/Enhanced recovery after surgery protocols|Early oral feeding refers to NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
214333234|NCT00466765|DEVICE|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
214333235|NCT04814290|OTHER|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 [SF-36]).|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 \[SF-36\]).
214333236|NCT02553746|DEVICE|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
214333237|NCT02553746|PROCEDURE|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
214333238|NCT01812928|DRUG|Diclofenac|
215072916|NCT01009437|PROCEDURE|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
215072917|NCT04976673|DRUG|Triamcinolone Acetonide|The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
214333239|NCT03247439|DEVICE|Cartiva|Synthetic Cartilage Implant
214333240|NCT04055116|DRUG|Buffered Lidocaine|Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
215072918|NCT04976673|PROCEDURE|Photodynamic Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
215072919|NCT04122183|OTHER|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
215072920|NCT02834585|OTHER|Ultrasound|
214934297|NCT04761406|DIETARY_SUPPLEMENT|Placebo group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
214934298|NCT01513811|DRUG|Polyethylene glycol electrolyte solutions|Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
214934299|NCT01513811|DRUG|Itopride and Polyethylene glycol electrolyte solutions|Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
214934300|NCT01513811|DRUG|itopride and polyethylene glycol electrolyte solutions|Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
214934301|NCT02491801|OTHER|Dietary intervention|All arms are given to all participants, in a randomized order
214934302|NCT00718484|DRUG|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
214934303|NCT00718484|DRUG|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
214934304|NCT05336292|BEHAVIORAL|Meaningful life-focused intervention|The intervention works different skills to increase the meaningful life in the general population and specifically in the army.
214934305|NCT05336292|BEHAVIORAL|Meaningful life and emotional regulation-focused intervention|The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.
214934306|NCT05336292|BEHAVIORAL|Control Group|This group does not do any intervention
215072921|NCT04576039|DIAGNOSTIC_TEST|saline infusion sonography|Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
215072922|NCT05470543|BEHAVIORAL|Nurse-led supportive care|Nurse-led supportive care was given to primary caregivers of women with breast cancer. Nurse-led supportive care was applied to primary caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 30 minutes to interview with primary caregivers at the clinic.
215072923|NCT06497777|GENETIC|MicroRNA (mir-642b-3p)|A circulating microRNA in the blood of pancreatic cancer patients.
215072924|NCT02997553|DRUG|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
215072925|NCT02997553|DRUG|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node"
215072926|NCT02997553|DEVICE|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
214333241|NCT00003268|DRUG|amifostine trihydrate|
214333242|NCT00003268|DRUG|cytarabine|
214333243|NCT00003268|DRUG|idarubicin|
214934307|NCT03099694|PROCEDURE|noninvasive high-frequency ventilation (nHFOV)|NHFOV will be provided by a high frequency ventilator (CNO, Medin, Germany or SLE 5000, UK). NHFOV will be provided via binasal prongs.
214934308|NCT03099694|PROCEDURE|nasal continuous positive airway pressure (nCPAP)|Infants assigned to the NCPAP group will be started on a pressure of 6 cmH2O (range: 6-8 cmH2O) by CPAP system (CNO Medin, Germany, Carefusion, USA)
214934309|NCT04295057|OTHER|Non-intervention|Non-intervention
214934310|NCT05691959|DRUG|Placebo|Patients randomized to placebo group will receive Normal Saline 50ml IV.
214934311|NCT05691959|DRUG|Calcium|Patients randomized to the study group will receive Calcium 2gm in Normal Saline 50ml IV.
214934312|NCT03832790|OTHER|observation|observation
215072927|NCT02997553|DEVICE|Quest Camera|The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
215072928|NCT05319483|OTHER|No intervention|No intervention.
215072929|NCT00004446|DRUG|fluoxetine|
215077974|NCT05025098|DRUG|Precision therapy|Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.
214333244|NCT04150224|DRUG|PBTZ169 640 mg OD|Two administrations once a day with a wash-out period: food effect
214333245|NCT04150224|DRUG|PBTZ169 640 mg BiD|Twice a day fasted; 1 day of administration
214333246|NCT04150224|DRUG|PBTZ169 960 mg SD|Once a day fasted
214333247|NCT04150224|DRUG|PBTZ169 1280 mg SD|Once a day fasted
214333248|NCT04150224|DRUG|PBTZ169 1280 mg MD|Once a day after meal, 14 doses
214333249|NCT05556122|OTHER|intercostal nerve block|General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
214333250|NCT05556122|OTHER|lateral intercostal nerve block|lateral intercostal nerve block
214333251|NCT05556122|DRUG|ropivacaine + compound betamethasone|The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
214333252|NCT02774681|PROCEDURE|Cognitive Assessment|Ancillary studies
214333253|NCT02774681|DRUG|Palbociclib|Given PO
214333254|NCT02774681|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214333255|NCT02774681|BIOLOGICAL|Trastuzumab|Given IV
214333256|NCT03221985|OTHER|questionnaires|questionnaire with application on smartphone
214347178|NCT01692197|DRUG|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
215072930|NCT04463199|OTHER|Craniocervical flexion training|"PBU airbag was clipped together and folded in, fastened, and placed suboccipital. Uninflated pressure sensor was kept below the neck, so that it touched the occiput then inflated to a stable baseline pressure of 20 mmHg to just fill the space below the neck but not to push it into lordosis. Subjects were demonstrated the correct action of the deep cervical flexors that is gentle nodding of head as if saying yes."
214955390|NCT03326115|BEHAVIORAL|Peer Visitation Program|The Amputee Coalition's Peer Visitation Program (PVP) trains amputee peer supporters to properly navigate a new or less-experienced amputee through the process of rehabilitation. Peer support plays an important role, following the amputation of a limb, by allowing patients to meet other amputees and discuss lifestyle changes post-amputation. Subjects randomized to the PVP group will receive the intervention (visitation by a Certified Peer Visitor) immediately at amputation. Subjects randomized to the non-PVP group will not receive CPV visits immediately at amputation. Rather, they will receive delayed PVP intervention beginning 60 days after amputation and lasting a total of 60 days (or at 120 days post-amputation).
215072931|NCT03121677|BIOLOGICAL|Personalized tumor vaccine|"* Cycle 12 vaccine administration is optional~* The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection."
215072932|NCT03121677|DRUG|Poly ICLC|-The personalized tumor vaccine will be co-administered with poly-ICLC.
215072933|NCT03121677|BIOLOGICAL|Nivolumab|-Nivolumab will be administered at a dose of 240 mg intravenously
215072934|NCT03121677|PROCEDURE|Peripheral blood draws|-Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
215072935|NCT03121677|PROCEDURE|Leukapheresis|"* Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~* Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations."
215072936|NCT03121677|BIOLOGICAL|Rituximab|-Other anti-CD20 mAb treatment can be used
215072937|NCT03121677|PROCEDURE|Biopsy|-Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
215077975|NCT02460913|PROCEDURE|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
215077976|NCT02460913|DRUG|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
215077977|NCT05825924|DEVICE|E-Cigarette|E-cigarettes have been designed to resemble tobacco cigarettes. They include an aerosol generator, sensor, battery and storage area for liquid. They are either disposable or rechargeable. According to a study, e-cigarettes can deliver an average of 1.3 mg (range 0.4 to 2.6 mg) of nicotine from 15 puffs. Average Cmax after e-cigarette use is recorded as 8.4 ng/mL and Tmax achieved between 2 to 5 minutes
215077978|NCT05825924|DRUG|Nicotine patch|The nicotine patches are applied on the skin and nicotine is delivered at a steady rate. After administration, the peak blood levels are achieved within 6-10 hours. The levels remain constant, reducing by 25-40% with use of patches once daily. The patch is typically administered every 24 hours for no longer than 12 weeks. The dose of the patches is often determined by daily cigarette consumption and level of addiction.
215077979|NCT06408675|OTHER|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
215077980|NCT05749003|OTHER|sensorimotor training exercise|Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
215077981|NCT05749003|OTHER|conventional physical therapy program of exercise.|stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
215077982|NCT01509976|OTHER|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
215077983|NCT00258765|DRUG|Zoledronic Acid|
215077984|NCT00258765|DRUG|Docetaxel|
215077985|NCT02808195|OTHER|Constraint-induced therapy|
215077986|NCT02808195|OTHER|kinect-based constraint-induced therapy|
215077987|NCT01294306|DRUG|Akt Inhibitor MK2206|Given PO
215077988|NCT01294306|DRUG|Erlotinib Hydrochloride|Given PO
215077989|NCT01294306|OTHER|Laboratory Biomarker Analysis|Correlative studies
215077990|NCT01294306|OTHER|Pharmacological Study|Correlative studies
215077991|NCT00246051|BEHAVIORAL|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
214934313|NCT05994911|BEHAVIORAL|Mindfulness Training|"The application is planned as 8 sessions and one session per week. Each session corresponds to one lesson hour and is approximately 30-40 minutes. In the content of the application, the individual's attention, mind, attitude, intention, thought; It has basic concepts such as the separation and merging process of thoughts in our minds, the deep processes of awareness, staying in the moment, values, focusing process, self-compassion, integration of awareness with other situations in life, meditation practices developed with practice, and the content summarized around these concepts. It is a program that tries to enable individuals to focus on the moment they live in, within the framework of these basic concepts. The program is divided into session titles such as Introduction to Mindfulness, Mind Awareness, Body Awareness, Emotion and Behavior Awareness, Self Compassion, Stress Awareness, Eating Awareness."
214333257|NCT05430789|BEHAVIORAL|5As brief advice|"Participants will receive brief face-to-face advice following a 5As model at baseline:~1. Ask: Smoking patients will be asked about their smoking status.~2. Advise: Smoking patients will be advised to quit in a clear and personalised manner, with a focus on smoking-related diseases.~3. Assess: Smoking patients will be assessed for their readiness to quit by assessing their self-efficacy and perceived importance.~4. Assist: Those who are ready to quit will be assisted in setting a quit plan.~5. Arrange: Refer to smoking cessation services."
214934314|NCT06771622|DRUG|HCB101|QW
214333258|NCT05430789|BEHAVIORAL|Self-help e-booklet|"A 12-page generic self-help smoking cessation e-booklet via IM apps, including:~1. Highlights of the absolute risk of death due to smoking;~2. Smoking and diseases management;~3. Ten horrible pictorial warnings of health consequences of smoking and second-hand smoking;~4. Benefits of quitting;~5. Methods to quit and handle. withdrawal symptoms."
214333259|NCT05430789|BEHAVIORAL|Nurse-led mHealth intervention|Participants will receive real-time mHealth behaviour and psychosocial support for 12 weeks after baseline through IM apps. mHealth intervention consists of two main parts: regular instant messaging on smoking cessation and personalized real-time mHealth chatting on smoking and disease (including active referral to smoking cessation service)
214333260|NCT05430789|BEHAVIORAL|Regular intervention|Participants will receive text messages using IM app with content on general health and reminding the importance of participating in the follow-up surveys and biochemical validation for quitting.
214333261|NCT04407728|OTHER|early ultrasound screening|"Women whose fetus is at high risk of congenital heart disease at the end of the 1st trimester screening ultrasound (EchoT1), will benefit from an early heart-centered morphological ultrasound (EchoMorpho-T1) by a referring sonographer between 11 and 14 SA +/- an early fetal cardiac ultrasound (EchoCoeur-T1) between 11 and 15 SA by a cardio-paediatrician in case of EchoMorpho-T1 abnormality.~The results of the early morphological and cardiac ultrasounds will be compared with those of the 2nd trimester ultrasound at 18-22SA (EchoMorpho-T2) and +/- of the fetal cardiac ultrasound between 18SA and 24SA (Gold standard) or, failing this, with the anatomopathological examination when it is available if a medical termination of pregnancy took place before the EchoMorpho-T2."
214333262|NCT00003335|BIOLOGICAL|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
214333263|NCT00003335|DRUG|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
214934315|NCT06771622|DRUG|Trastuzumab|8 mg/kg IV loading dose on Day 1 of cycle 1, then 6 mg/kg IV every 21 days;
214934316|NCT06771622|DRUG|Pertuzumab|840 mg IV on Day 1, cycled every 21 days;
214934317|NCT06771622|DRUG|Oxaliplatin|130 mg/m2 IV on Day 1, cycled every 21 days
214934318|NCT06771622|DRUG|Capecitabine|1000 mg/m2 PO BID on Days 1-14, Cycled every 21 days
215072938|NCT03668938|OTHER|Occupational Therapy|The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
214934319|NCT06771622|DRUG|Ramucirumab|8 mg/kg IV on Days 1 and 15, Cycled every 28 days
214934320|NCT06771622|DRUG|Paclitaxel|80 mg/m2 IV on Days 1, 8, and 15, Cycled every 28 days
214934321|NCT06771622|DRUG|Bevacizumab|5 mg/kg IV on Day 1, Repeat every 2 weeks; or 7.5 mg/kg IV on Day 1, Repeat every 3 weeks.
214934322|NCT06771622|DRUG|Cetuximab|400 mg/m2 first infusion, followed by 250 mg/m2 IV weekly; or 500 mg/m2 IV over 2 hours on Day 1 every 2 weeks;
214333264|NCT00003335|DRUG|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
214333265|NCT00003335|DRUG|melphalan|melphalan IV for three days on days -4 to -2
214333266|NCT00003335|DRUG|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
214333267|NCT00003335|PROCEDURE|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
214934323|NCT06771622|DRUG|Irinotecan|180 mg/m2 IV over 30-90 minutes on Day 1 every 2 weeks
214934324|NCT06771622|DRUG|Leucovorin|400 mg/m2 IV on Day 1 every 2 weeks
214955391|NCT06364176|DRUG|Losartan|Treatment with losartan through week 12
214955392|NCT06364176|DRUG|Placebo|Treatment with placebo through week 12
214955393|NCT00604747|OTHER|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
214955394|NCT00003032|BIOLOGICAL|filgrastim|
214955395|NCT00003032|DRUG|cisplatin|
214955396|NCT00003032|DRUG|cyclophosphamide|
214955397|NCT00003032|DRUG|mitoxantrone hydrochloride|
214955398|NCT00003032|DRUG|tamoxifen citrate|
214955399|NCT04292067|BIOLOGICAL|Faecal sampling|Faecal sampling at baseline
214955400|NCT04292067|BIOLOGICAL|Blood sampling|Blood sampling at baseline
214955401|NCT05857124|DEVICE|Vielight Neuro RX Gamma active device|The Vielight Neuro RX Gamma active device is a home-use photobiomodulation (PBM) device designed to deliver near-infrared (810 nm) light (or photons) to the brain/scalp and nasal tissues.
214955402|NCT05857124|DEVICE|Vielight Neuro RX Gamma sham device|The Vielight Neuro RX Gamma sham device is a home-use device similar to the Vielight Neuro RX Gamma active device, but acting as a sham.
214955403|NCT02265939|DRUG|NPO-13|
214955404|NCT01381380|PROCEDURE|Manual therapy|Manual therapy, once a week for 8 weeks
214333268|NCT00003335|RADIATION|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
214934325|NCT06771622|DRUG|5-FU|400 mg/ m2 IV bolus on Day 1, followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks
214333269|NCT01069289|DRUG|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
215072939|NCT03668938|OTHER|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
215072940|NCT01995669|OTHER|Laboratory Biomarker Analysis|Correlative studies
214333270|NCT01069289|DRUG|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
214333271|NCT05543213|BEHAVIORAL|Action Observation Therapy|A video clip of a series of exercises is shown to the patients, then they practice them according to mirror neurons and observational learning.
214333272|NCT02505126|DEVICE|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
214934326|NCT06771622|DRUG|Toripalimab|240 mg/kg IV on Day 1 Cycled every 21 days
214333273|NCT02505126|DEVICE|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
214333274|NCT02490137|BEHAVIORAL|Race Car Video Game|Repeatedly playing a race car video game
214934327|NCT06771622|DRUG|Albumin-bound paclitaxel|125 mg/m2 IV on day 1 and Day 8 Cycled every 21 days
214934328|NCT06771622|DRUG|Pembrolizumab|200 mg IV day 1; given every 21 days
215072941|NCT01995669|DRUG|Lenalidomide|Given PO
215072942|NCT01995669|BIOLOGICAL|Obinutuzumab|Given IV
214934329|NCT06771622|DRUG|Gemcitabine|1000 mg/m2 IV days 1 and 8
214934330|NCT06595446|PROCEDURE|Early Stent removal|Ureteral JJ stents removed 5-7 days after radical cystectomy and ileal conduit formation
214934331|NCT06595446|PROCEDURE|Late Stent removal|Ureteral JJ stents removed 4-6 weeks after radical cystectomy and ileal conduit formation
214934332|NCT04368039|DEVICE|Normobaric Oxygen|40% FiO2 for 4 weeks
214934333|NCT04368039|DEVICE|Placebo|21% FiO2 for 4 weeks
214934334|NCT01454154|DRUG|Glyburide|Administered as specified in the Treatment Arm.
215072943|NCT02944864|DRUG|TQ-B3395|TQ-B3395 p.o. qd
215072944|NCT02871713|OTHER|Bilateral Quadratus lumborum block with 0.5% ropivacaine|Bilateral Quadratus lumborum block with 0.5% ropivacaine
215072945|NCT02871713|OTHER|Intrathecal Morphine with 100 mcg morphine|Intrathecal Morphine with 100 mcg morphine
215072946|NCT02998203|DIETARY_SUPPLEMENT|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
215072947|NCT02987361|DEVICE|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
215072948|NCT02017938|PROCEDURE|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
215072949|NCT03658200|OTHER|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
215072950|NCT03658200|OTHER|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
214333275|NCT06243497|PROCEDURE|Ultrasound CycloPlasty|All procedures were performed using the EyeOP1 device . The coupling cone was placed and adjusted on the centre of the patient's eye by visualising an equal white scleral ring surrounding the cornea. The coupling cone was kept in place via vacuum suction activated using a foot pedal and was then filled with a balanced salt solution to allow ultrasound transmission. The transducers were automatically activated at a frequency of 21 MHz and an acoustic power of 2.45 W, with an 8-s duration for each sector and a 20-s pause between each treatment to allow complete evacuation of heat.
214333276|NCT02047604|DRUG|SAN-300 0.5 mg/kg QW|
214333277|NCT02047604|DRUG|SAN-300 1.0 mg/kg QW|
214333278|NCT02047604|DRUG|SAN-300 2.0 mg/kg QOW|
214333279|NCT02047604|DRUG|SAN-300 4.0 mg/kg QOW|
214333280|NCT02047604|DRUG|SAN-300 4.0 mg/kg QW|
214333281|NCT02047604|DRUG|Placebo|
214333282|NCT05928702|PROCEDURE|temperature-elevating armbath|Hydrotherapeutic Approach
214333283|NCT02605512|OTHER|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
214934335|NCT01454154|DRUG|Placebo|Administered as specified in the Treatment Arm.
214934336|NCT03137901|DEVICE|Capstesia|Picture of the arterial waveform taken with a smartphone
214934337|NCT02291601|DRUG|Chlorhexidine Gluconate|comparison with other CHG products
214934338|NCT02291601|OTHER|Vehicle|Excipients of CHG product only.
214934339|NCT02291601|DRUG|DynaHex-2|2% CHG solution
214934340|NCT05230004|DEVICE|iFIT prosthesis|An adjustable modular prosthesis that can be fit in a single session. Fully adjustable by wearer.
214934341|NCT03411980|DRUG|Vilaprisan (BAY1002670)|Single oral dose (1 x 2 mg immediate-release, film-coated tablet)
214934342|NCT01639404|PROCEDURE|Umbilical Cord Blood Administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
214934343|NCT01639404|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
214333284|NCT02827292|OTHER|music|"A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained."
214333285|NCT02827292|OTHER|No music|Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
214333286|NCT02827292|PROCEDURE|Laparoscopic Surgery|Patients will undergo Laparoscopic Surgery as per the set protocol
214333287|NCT06573190|DIAGNOSTIC_TEST|Transient elastography|Liver Stiffness Measurement, Controlled Attenuation Parameter
214333288|NCT06573190|DRUG|Tenofovir Disoproxil Fumarate|Guided Therapy
214333289|NCT00315094|BEHAVIORAL|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
214934344|NCT01712867|OTHER|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
214934345|NCT01712867|OTHER|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
214934346|NCT06666894|OTHER|Intermittent fasting|subjects consumed 100 % of their energy needs in an 8-h period of time each day, with their caloric intake divided into three meals consumed at 1 p.m., 4 p.m., and 8 p.m. The remaining 16 h per 24-h period made up the fasting period. Subjects in the ND group consumed 100 % of their energy needs divided into three meals consumed at 8 a.m., 1 p.m., and 8 p.m. all patients will be subjected to 30 minutes mild aerobic exercise on treadmill.
214934347|NCT06666894|OTHER|Dietary approach to stop hypertension (DASH)|The USDA's 2015-2020 Dietary Guidelines for Americans recommend a healthy eating pattern, including a variety of vegetables, fruits, whole grains, fat-free dairy, protein, and oils. Limit saturated fats, trans fats, added sugars, and sodium to less than 10% daily calories, 10% saturated fat daily calories, and 2,300 mg sodium per day.
214934348|NCT02349919|DRUG|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
214934349|NCT02349919|DRUG|Placebo|Placebo twice daily for 4 weeks
215072951|NCT06032104|DIETARY_SUPPLEMENT|Dry beans|0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention. If patient cannot not tolerate 1.5 cup of canned cannellini bean, we will reduce per tolerance or offer the option of choosing a bean-based flour (100 gram/day, 23% fiber from Archer Daniels Midland)
215072952|NCT06032104|DIETARY_SUPPLEMENT|Usual diet|Usual diet without adding the bean smoothie
215072953|NCT05594927|DRUG|Icaritin|600 mg (6 x 100 mg capsules) icaritin administered orally twice daily (30 minutes after breakfast and dinner, respectively) until treatment discontinuation criteria are met.
215072954|NCT05594927|DRUG|Huachansu|1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
215072955|NCT00788099|DRUG|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
215072956|NCT00788099|DRUG|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
215072957|NCT05749510|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
215072958|NCT00198393|DRUG|Gefitinib|250 mg/day, until progression
215072959|NCT00198393|DRUG|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
215072960|NCT00198393|DRUG|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
215072961|NCT01181999|DRUG|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
215072962|NCT03854526|OTHER|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
215072963|NCT01649674|DRUG|polyethylene glycole (PEG) solution|
215072964|NCT01649674|DRUG|sodium picosulphate and magnesium citrate solution|
215072965|NCT03389555|DRUG|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
215072966|NCT03389555|DRUG|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
215072967|NCT03806556|DRUG|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
214333290|NCT04035486|DRUG|Osimertinib|"Drug: Osimertinib (Oral)~Other Names:~AZD9291"
214934350|NCT03099213|DRUG|RAMIPRIL HOE498|Pharmaceutical form:Tablet Route of administration: Oral
214934351|NCT00196729|DRUG|Thyrogen + Radioiodine (131I)|
214333291|NCT04035486|DRUG|Pemetrexed/Carboplatin|Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
214333292|NCT04035486|DRUG|Pemetrexed/Cisplatin|Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
214333293|NCT03113682|BEHAVIORAL|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
214333294|NCT03597516|DRUG|RP-G28|powder for reconstitution for oral administration
214333295|NCT03597516|DRUG|Placebos|powder for reconstitution for oral administration
214333296|NCT03995758|DEVICE|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
214333297|NCT03946163|DIETARY_SUPPLEMENT|cinnamon capsules|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
214333298|NCT03946163|DRUG|Placebo oral capsule|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
214333299|NCT04672005|DRUG|Folfirinox alternating with Gemcitabine-nab-Paclitaxel|modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
215072968|NCT03806556|DRUG|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
214333300|NCT03265626|BEHAVIORAL|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
214333301|NCT03265626|BEHAVIORAL|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
214333302|NCT03265626|OTHER|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
214934352|NCT04755413|OTHER|Medical/Behavioral therapy|"* Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.~* Overweight/Obese: Advise calorie reduction, dietician consultation.~* Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.~* High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.~  b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.~  d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of \<55mg/dl in diabetes~* Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.~* Diabetes management: HbA1c goal 6.5%"
214934353|NCT04755413|OTHER|Standard of Care|Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.
214934354|NCT04755413|OTHER|Registry|Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.
214934355|NCT03489018|BIOLOGICAL|PCV10|Experimental arms will receive a lower dose of the intervention than the marketed dose.
215072969|NCT02803177|BIOLOGICAL|BMC2012|
215072970|NCT02803177|DEVICE|beta-TCP Chronos® Synthes|
215072971|NCT00920218|BIOLOGICAL|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
215072972|NCT00920218|BIOLOGICAL|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
214934356|NCT03489018|BIOLOGICAL|PCV13|Experimental arms will receive a lower dose of the intervention than the marketed dose.
215072973|NCT01213147|DRUG|clomiphene citrate|100 mg per day oral for 7 days
215072974|NCT01213147|DRUG|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
215072975|NCT03109093|DRUG|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
215072976|NCT01847066|DEVICE|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
215072977|NCT01847066|DEVICE|Erbium 2940 plus cosmetics|laser
215072978|NCT04313374|DRUG|Morphine PCA 1 mg|PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
215072979|NCT04313374|DRUG|Morphine PCA 0,5 mg|PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
215072980|NCT04313374|DRUG|Placebo|the PCA will contain placebo
215072981|NCT03135769|DRUG|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
215072982|NCT00877786|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
215072983|NCT02130687|DRUG|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
215072984|NCT02130687|DRUG|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
215072985|NCT02130687|DRUG|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
215072986|NCT02130687|OTHER|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
214333303|NCT02556710|BIOLOGICAL|4 mL injection of AMPION™|4 mL Injection of Ampion
214333304|NCT02556710|DRUG|4 mL injection of Placebo|4 mL Injection of Placebo
214333305|NCT03116165|BEHAVIORAL|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
214333306|NCT03116165|BEHAVIORAL|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
214934357|NCT05262088|OTHER|video recording of general movements|"Video recording of general movements of children aged 3-5 days, then 4-5, 8-9, 12-13, 16-17, 20-22 weeks of life.~At the age of 12 weeks of life, an assessment will be made on the Motor Optimality Scale (MOS)."
214934358|NCT00381043|DRUG|Acamprosate (Campral)|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
214934359|NCT05625945|BEHAVIORAL|Physical activity monitoring|Physical activity patterns will be measured using the activPAL3 micro monitor
214934360|NCT01222754|DRUG|Lenalidomide|"1. With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.~2. Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course."
214934361|NCT01222754|RADIATION|XRT, 54-59.4 Gy|Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
214934362|NCT02704520|DIAGNOSTIC_TEST|High resolution MRI scan|MRI reporting of tumour but not mrTRG in the control arm = standard of care
214673674|NCT01939262|OTHER|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
214673675|NCT01939262|OTHER|Control|Participants assigned to the control group will be instructed to follow their usual diets.
214934363|NCT02704520|DIAGNOSTIC_TEST|mrTRG assessment|Watch and wait offered for good responders Consider further treatment for poor responders
214934364|NCT02688998|DEVICE|venous access PORT or PICC|Participants will receive a venous access prior to starting chemotherapy
214934365|NCT01978470|DEVICE|External Trigeminal Nerve Stimulation (eTNS)|External stimulation of the trigeminal nerve.
214934366|NCT01457586|BIOLOGICAL|Blood transfusion|Blood transfusion in perioperative period.
214934367|NCT01457586|BIOLOGICAL|No blood transfusion|No transfusion in the perioperative period.
214934368|NCT00536549|DEVICE|Guardian RT|
214934369|NCT00536549|BEHAVIORAL|Education about the self monitoring blood glucose|
214934370|NCT03045276|BEHAVIORAL|Behavioral Feedback and Economic Incentives: Arm 1|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 1, participants will not receive personalized feedback, nor will they receive the extra incentive of $10 for meeting their adherence goal."
214934371|NCT03045276|BEHAVIORAL|Behavioral Feedback and Economic Incentives: Arm 2|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 2, participants will receive personalized feedback, and an extra incentive of $10 for meeting their adherence goal."
214934372|NCT00347919|DRUG|pazopanib (GW786034) 400 mg|400 mg administered orally once daily
214934373|NCT00347919|DRUG|lapatinib (GW572016) 1500 mg|1500 mg administered orally once daily.
214333307|NCT01592513|DEVICE|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
214333308|NCT01138748|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
214333309|NCT01156324|BEHAVIORAL|Online Stress Management Group (Upliv)|Personalized online stress management program
214333310|NCT01156324|BEHAVIORAL|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
214333311|NCT02258152|DRUG|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
214673676|NCT04024410|OTHER|Evaluation of PEEP in prone position|Assessment of optimal Positive End-Expiratory Pressure (PEEP) in patients undergoing scheduled spine surgery in prone position.
214934374|NCT00347919|DRUG|lapatinib (GW572016) 1000 mg|1000 mg administered orally once daily
214934375|NCT00347919|DRUG|pazopanib (GW786034) 800 mg|800 mg administered orally once daily
214934376|NCT03379753|OTHER|music and positive images|The diad of misic and positive image will be administered to the standard care by adding a Bluetooth capable speaker with selections of music and a soothing nature landscape into the hospital room.
214934377|NCT00155766|BIOLOGICAL|HPV16 E7 peptide-pulsed autologous DCs|
214934378|NCT05263765|PROCEDURE|utilization of AO in the acute resuscitation of trauma and acute care surgery patients in shock.|AO to facilitate the acute resuscitation of trauma and acute care surgery patients in shock.
214934379|NCT02235051|BEHAVIORAL|exercise intervention|Undergo Curves exercise program
214934380|NCT02235051|OTHER|laboratory biomarker analysis|Correlative studies
214934381|NCT02235051|OTHER|questionnaire administration|Ancillary studies
214934382|NCT02235051|OTHER|quality-of-life assessment|Ancillary studies
214934383|NCT05665972|OTHER|Mandala coloring|Each participant will be given 12 colored felt-tip pen paint sets and 12 mandala coloring pages by the researchers. Participants will be asked to dye for 3 menstrual cycles, 14 days before the start of menstruation, 1 day a week, at any time of the day and for an average of 20-30 minutes each time.
214934384|NCT05062824|BEHAVIORAL|Baby Feed|Baby Feed web portals can (1) Quickly and easily evaluate infant diet using a validated Infant Food Frequency Questionnaire (infant FFQ) developed by our group14. \[Parental FFQ portal\]; (2) Provide automatic results to healthcare professionals on nutrients and foods/beverages consumed above or below the recommended levels to discuss with parents for improving the infant's diet. Also, to provide recommendations for amounts of foods/beverages that the infant should be consuming by age \[Clinician Portal\]; (3) Give online access to parents to these diet recommendations to implement at home, with an easy tracking component \[Parent's Portal\].
214934385|NCT01032239|DRUG|intrathecal baclofen|ITB test, implant, 6 months follow-up
214934386|NCT04611737|BEHAVIORAL|Interviewing|Self-Determination Theory within motivational interviewing
214934387|NCT04819503|DRUG|Spinal anaesthesia (sub-study 1)|We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.
214934388|NCT04819503|DEVICE|Repetitive transcranial magnetic stimulation (sub-study 2)|After sub-study 1, the same patients will enter sub-study 2 where they are randomly assigned to receive either first active rTMS (10 days over 2 weeks), and then after a 9 week washout period, sham rTMS (10 days over 2 weeks), or they first receive sham rTMS, and then after 9 weeks of washout, active rTMS. Thus, patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial with a 2 x 2 cross-over design, receiving both active and placebo stimulation
214934389|NCT04688528|RADIATION|Dose de-escalation and / or Volume de-escalation|The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.
214934390|NCT00383695|BIOLOGICAL|cetuximab|
214934391|NCT00383695|DRUG|capecitabine|
214934392|NCT00383695|DRUG|oxaliplatin|
214934393|NCT00383695|PROCEDURE|adjuvant therapy|
214934394|NCT00383695|PROCEDURE|conventional surgery|
214934395|NCT00383695|PROCEDURE|neoadjuvant therapy|
214934396|NCT00383695|RADIATION|radiation therapy|
214934397|NCT02097251|DRUG|UX003|Open Label
214934398|NCT02226705|PROCEDURE|Multiple transnasal endoscopic surgeries|Transnasal endoscopic surgery extended to the skull base
214934399|NCT02118142|DIETARY_SUPPLEMENT|Betaine|6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage
214333312|NCT02258152|DRUG|Placebo|Placebo QD
214333313|NCT02563340|OTHER|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
214333314|NCT02563340|OTHER|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
214347179|NCT05446415|OTHER|Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.|Preoperative and postoperative
214347180|NCT00587145|DRUG|S-1,Docetaxel|"* S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~* Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
214347181|NCT05658081|PROCEDURE|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
214333315|NCT04772092|BIOLOGICAL|Blood samples|"during the routine blood test, collection of additional blood samples:~* 1 x 5 mL heparinized tube for plasma collection and storage~* 1 heparinized 5 mL tube for immunophenotyping~* 4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation"
214934400|NCT02118142|DIETARY_SUPPLEMENT|Dextrose|6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage
214934401|NCT03173742|DRUG|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
214934402|NCT03173742|DRUG|T1,T3,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
214934403|NCT03173742|DRUG|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
214934404|NCT03173742|DRUG|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
214934405|NCT03173742|DRUG|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
214333316|NCT04772092|OTHER|Data collection|"* clinical examination data~* test results to measure the degree of geriatric fatigability~* Frailty screening questionnaire for neoplasia patients (G8 score)"
214333317|NCT06005259|DRUG|Spironolactone|Spironolactone 25 mg capsule
214333318|NCT06005259|DRUG|Placebo|Placebo capsule
214333319|NCT04258839|DRUG|Brexpiprazole|Oral tablet; taken once daily
214333320|NCT03082339|OTHER|Cortisone|Observation of QTc-interval
214333321|NCT03634592|PROCEDURE|Catheter ablation|Radiofrequency catheter pulmonary vein isolation
214333322|NCT04521010|OTHER|COVID-19 pandemic|The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
214934406|NCT03173742|DRUG|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
215072987|NCT02367274|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
214934407|NCT00002038|DRUG|Fluconazole|
214934408|NCT00582504|BIOLOGICAL|VEE TC-83|Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
214934409|NCT03178240|BEHAVIORAL|photoaging mirroring intervention|selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
214934410|NCT06368895|PROCEDURE|Fecal microbiota transplantation delivery through colonoscopy|Patients will receive 4 L of macrogol and salts solution the afternoon before FMT and remain fasting the night before the scheduled treatment. During colonoscopy, about 350 mL of donor fecal preparation will be infused in the cecum.
214934411|NCT06368895|DRUG|Fecal microbiota transplantation delivery through oral capsules|Intestinal gastro-resistant capsules (capacity 0.91 mL, overall 10\^8-9 bacteria per capsule) will be filled with the fecal slurry. From each donation weighing 100 g, it is expected to obtain 150 cps, which will be promptly frozen and stored at -80°C. At each monthly visit, the patient will receive 60 capsules, to be stored at -20°C at home. Capsules will be administered orally at the dose of 1 cps twice a day from month 1 post-colonoscopy to patients in the FMT group 1 (colonoscopy plus capsules), and from day 1 to patients in the FMT group 2 (capsules only).
214934412|NCT00624195|DRUG|FDA Approved Antiretroviral Therapy (see list below)|"Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
214934413|NCT02738255|DEVICE|Varnum mouthpiece|An adhesive mouthpiece with a central opening applied during sleep
215072988|NCT03134495|OTHER|all children with at least one prescription of PPI|all children with at least one prescription of PPI
215072989|NCT03134495|OTHER|all children with no prescription of PPI|all children with no prescription of PPI
214333323|NCT04498897|DRUG|Vortioxetine|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
214333324|NCT04498897|DRUG|Acamprosate|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
214333325|NCT02336984|BIOLOGICAL|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
214333326|NCT02336984|DRUG|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
214333327|NCT02336984|DRUG|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
214333328|NCT00263692|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
214333329|NCT01480115|OTHER|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
214347182|NCT05658081|PROCEDURE|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
214347183|NCT00147966|DRUG|rituximab|treatment with rituximab
214333330|NCT04905680|DEVICE|CGM lifestyle tracking and coaching|"Participants in the experimental group will go through a total of 5 lifestyle tracking sessions (including baseline), of which 1 will include CGM tracking. For this CGM lifestyle tracking session, experimental group participants will receive real-time feedback through the study applications, which will display the CGM trace.~The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans."
214333331|NCT00949013|OTHER|immunohistochemistry staining method|
214333332|NCT00949013|OTHER|laboratory biomarker analysis|
214333333|NCT04795505|BEHAVIORAL|Intervention|The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.
214333334|NCT04795505|BEHAVIORAL|Control|The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
214934414|NCT01040195|DRUG|Methotrexate, Hydroxychloroquine|Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
214934415|NCT01040195|DRUG|Placebo|Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
214934416|NCT06622447|DIETARY_SUPPLEMENT|βGluCnCs intervention|"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into βGluCnCs intervention (N=40).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."
214934417|NCT06622447|DIETARY_SUPPLEMENT|Placebo intervention|"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into placebo intervention (N=20).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."
214333335|NCT04292158|DEVICE|SomnoTouch|"The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis."
214333336|NCT04292158|DEVICE|MOX|"The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis."
214333337|NCT04135131|OTHER|pilates mat exercises and home exercises|Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
214333338|NCT02412267|DRUG|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
214333339|NCT01624545|OTHER|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
214333340|NCT04380584|DIAGNOSTIC_TEST|plasma Apelin level|blood sample for detection of plasma Apelin level
214333341|NCT02787356|DRUG|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic
214934418|NCT00602498|DRUG|Clarithromycin|
214934419|NCT01576445|PROCEDURE|Mid-vastus approach|Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
214333342|NCT02787356|DRUG|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD
214333343|NCT05747846|PROCEDURE|Carpal tunnel release, WALANT technique|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.
214333344|NCT05747846|PROCEDURE|Carpal tunnel release using a tourniquet|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
214333345|NCT02782819|DRUG|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
214333346|NCT02782819|DRUG|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
214333347|NCT01681082|BEHAVIORAL|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
214934420|NCT01576445|PROCEDURE|medial parapatellar approach|medial parapatellar approach
214934421|NCT02874079|OTHER|Blood sample and cotton skin swabs|
214934422|NCT05989074|DEVICE|ALLEGRA TAVI System TF|Patients receive ALLEGRA TAVI System TF. Patient will receive medication according to routine practice of the hospital
214673677|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
214673678|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
214673679|NCT00230490|DRUG|pradefovir mesylate|
214934423|NCT05989074|DEVICE|Ballon-expandable valve system|Patients receive any kind of CE-marked balloon expandable valve system, used at the hospital. Patient will receive medication according to routine practice of the hospital.
214934424|NCT05498103|DRUG|Methazolamide 25 MG|25 mg tablets
214673680|NCT00230490|DRUG|adefovir dipivoxyl|
214673681|NCT00564928|DRUG|IPI-504|IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
214934425|NCT05498103|DRUG|Methazolamide 50 MG|50 mg tablets
214333348|NCT04413318|DEVICE|Electronic device (VBM©)|Continuous control of tracheal cuff pressure using an electronic device (VBM©) for 6-hours followed by continuous control using a pneumatic device (Nosten©) for 6-hours.
214333349|NCT04413318|DEVICE|Pneumatic device (Nosten©)|Continuous control using a pneumatic device (Nosten©) for 6-hours followed by 6-hours of continuous control using an electronic device (VBM©).
214333350|NCT00147147|PROCEDURE|Gastrectomy with D2 or greater lymph node dissection|
214333351|NCT00147147|DRUG|Gastrectomy+ chemotherapy|
214333352|NCT02866578|PROCEDURE|Open lung protective ventilation strategy|
214333353|NCT02329405|DRUG|Rifampicin|
214333354|NCT02329405|DRUG|Placebo|
214673682|NCT01742923|BEHAVIORAL|Complex tailored intervention|
214673683|NCT01742923|BEHAVIORAL|Usual care|
214673684|NCT06443112|PROCEDURE|transvaginal cervical cerclage by Mc Donald technique|In the McDonald operation, a suture is is inserted around the exo-cervix as high as possible to approximate to the level of the internal os and thereby prevent second-trimester abortion.
214934426|NCT00744549|DIETARY_SUPPLEMENT|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
214934427|NCT00744549|DRUG|Placebo|Twice a day with meals.
214934428|NCT00161642|DRUG|CMD-193|
214934429|NCT01508052|DEVICE|sequential compression device|applying sequential compression device during the surgery
214934430|NCT01508052|DEVICE|elastic stockings|applying elastic stockings during the surgery
214934431|NCT01940900|DRUG|E10030|
214934432|NCT01940900|DRUG|ranibizumab|
214934433|NCT01940900|DRUG|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
214934434|NCT02225366|BIOLOGICAL|LL37|Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
214934435|NCT02225366|OTHER|Photographs|Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
214934436|NCT02835651|DIETARY_SUPPLEMENT|Palmitic acid|Experimental products are enriched with C16:0
214934437|NCT02835651|DIETARY_SUPPLEMENT|Stearic acid|Experimental products are enriched with C18:0
214934438|NCT00654992|DRUG|Erythropoietin-Beta|300 IU/kg of EPO or saline intravenously before surgery
214333355|NCT01306552|BEHAVIORAL|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
214333356|NCT01306552|BEHAVIORAL|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
214333357|NCT01306552|BEHAVIORAL|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
214333358|NCT01607905|DRUG|Selinexor|Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
214934439|NCT00654992|DRUG|Normal Saline|300 IU/kg of normal saline intravenously before surgery
214934440|NCT02481401|BEHAVIORAL|Intensive Individual Intervention Program|
214934441|NCT02481401|BEHAVIORAL|Peer-To-Peer Program Intervention|
214934442|NCT03992573|PROCEDURE|CGF application|CGF application into post-operative soft tissue and bone defects
214333359|NCT01607905|DRUG|Acetaminophen|Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
214333360|NCT05167838|PROCEDURE|fresh embryo transfer|55 patients undergoing fresh embryo transfer after ovarian stimulation followed by luteal phase support
214333361|NCT05167838|PROCEDURE|Frozen embryo transfer|55 patients undergoing frozen embryo transfer after ovarian stimulation followed by cryopreservation of all embryos and transfer in another cycle.
214333362|NCT01699399|PROCEDURE|water immersion|
214934443|NCT01310634|BEHAVIORAL|Comprehensive intervention|Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
214934444|NCT06376565|OTHER|Best Practice|Receive standard care
214934445|NCT06376565|OTHER|Communication Intervention|Complete clinic EHR interventions
214934446|NCT06376565|OTHER|Communication Intervention|Receive scheduling reminders
215072990|NCT03224507|DRUG|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
214333363|NCT01699399|PROCEDURE|water exchange|
214333364|NCT01699399|PROCEDURE|air insufflation|
214333365|NCT03492307|OTHER|Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)|A weight-based flow for HFNC.
214333366|NCT03492307|OTHER|Standard Flow for HFNC (Maximum 8L/minute)|Maximum flow of 8L/minute.
214333367|NCT06533618|DIAGNOSTIC_TEST|Continuous glucose monitoring system|All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.
214934447|NCT06376565|OTHER|Communication Intervention|Receive reminders and pending EHR orders
215072991|NCT03224507|DRUG|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
215072992|NCT05291988|OTHER|Educational Intervention|Receive S2S education
215072993|NCT05291988|OTHER|Fecal Immunochemical Test|Receive FIT kit
215072994|NCT05291988|OTHER|Questionnaire Administration|Ancillary Studies
214673685|NCT00002187|DRUG|Fomivirsen sodium|
214333368|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 1
214934448|NCT06376565|OTHER|Interview|Complete interview
214934449|NCT06376565|OTHER|Interview|Ancillary studies
214934450|NCT05709353|BEHAVIORAL|Prolonged exposure therapy|"COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure.~COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist."
215072995|NCT04916366|OTHER|Kinesio taping|Kinesio taping in a bandage to treat musculoskeletal pain.
215072996|NCT04916366|OTHER|Conventional bandage|It will be used a conventional bandage applicated in the same neck region than kinesio taping intervention.
214673686|NCT02175550|DEVICE|NR CC|
215072997|NCT01007435|DRUG|Tocilizumab|Tocilizumab was supplied in vials.
215072998|NCT01007435|DRUG|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
214333369|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 2
214333370|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 3
214333371|NCT01363323|DRUG|Placebo|
214333372|NCT01363323|DRUG|Moxifloxacin|
214333373|NCT01602315|DRUG|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
214333374|NCT01602315|DRUG|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
214333375|NCT01602315|BIOLOGICAL|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
214333376|NCT01602315|DRUG|BYL719 drink suspension|Oral alpha-specific PI3K inhibitor
214333377|NCT00011804|DRUG|Topiramate|
214333378|NCT03446703|BEHAVIORAL|SCIT|SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
214934451|NCT05709353|DRUG|MDMA|Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.
214934452|NCT05709353|DRUG|Niacin|Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions.
214333379|NCT03446703|BEHAVIORAL|TAR|TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
215072999|NCT01007435|DRUG|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
215073000|NCT01007435|DRUG|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
215073001|NCT04503135|DIAGNOSTIC_TEST|ultrasound|ultrasound of the central veins of the neck and chest and a (compression ultra-sound) CUS of the femoral veins will be performed bilaterally
214934453|NCT03492398|DRUG|HY209|6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
214934454|NCT03782298|DEVICE|Spyromite, Dynomite, Raptomite, Footprint Ultra PK SL|"PEEK Suture Anchors, which include:~* SPYROMITE™ 2.0 PK Suture Anchor with Needles~* DYNOMITE™ 2.0 PK Suture Anchor with Needles~* RAPTORMITE™ 3.0 Suture Anchor with Needles~* FOOTPRINT™ Ultra PK SL Suture Anchor"
214934455|NCT00852215|DEVICE|Taxus stent|Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with \> 50% diameter stenosis with ischemic symptoms or positive functional study, or \> 70% diameter stenosis without ischemic symptoms or positive functional study
214934456|NCT00852215|DEVICE|Vision stent|Stenting with VISION coronary stent system for coronary lesions with \> 50% diameter stenosis with ischemic symptoms or positive functional study, or \> 70% diameter stenosis without ischemic symptoms or positive functional study
214673687|NCT02533115|DRUG|CPX-351|"CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.~CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC."
214673688|NCT01172080|OTHER|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
214673689|NCT01683500|DEVICE|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
214673690|NCT00043147|DRUG|beclomethasone dipropionate|
214673691|NCT00043147|DRUG|methylprednisolone|
214673692|NCT00043147|DRUG|prednisone|
214673693|NCT00887081|DRUG|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
214673694|NCT03004560|PROCEDURE|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
214673695|NCT03004560|PROCEDURE|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
214673696|NCT04372264|DRUG|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb\_UK) intravenous (IV) was given 70 patients,
214673697|NCT04372264|DRUG|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
214673698|NCT04372264|DRUG|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
214673699|NCT04710589|RADIATION|CTV|According to the clinical conditions of the patients, they will be assigned to two groups based on the doctor's recommendations and their own wishes
214333380|NCT04660123|DRUG|Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication|"Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d."
214333381|NCT04746937|DRUG|Nitazoxanide|nitazoxanide adjuvant to standard therapy
214333382|NCT04746937|DRUG|Norfloxacin|Standard therapy
214333383|NCT05130775|OTHER|Transesophageal echocardiograpgy|3D acquisition of the right ventricle regurgitation volume
214333384|NCT02977949|DRUG|Raloxifene|
214333385|NCT03689127|DEVICE|Heated breathing circuit on|Heated breathing circuit will be turned on.
214333386|NCT03689127|DEVICE|Heated breathing circuit off|Heated breathing circuit will be turned off.
214333387|NCT00440271|DRUG|tipranavir|
214333388|NCT00440271|DRUG|ritonavir|
214333389|NCT00440271|DRUG|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
214333390|NCT00838305|DRUG|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
214333391|NCT00838305|DRUG|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
214333392|NCT03126981|OTHER|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
214333393|NCT03126981|OTHER|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
214333394|NCT00723801|DRUG|Atenolol|Atenolol 50mg PO QD
214333395|NCT00723801|DRUG|Losartan|Losartan 100mg PO QD
214333396|NCT03358576|DRUG|Ertapenem|Antibiotic for complicated intra-abdominal infection
214934457|NCT01512069|BEHAVIORAL|Web-based Health Planner on diet and exercise|"URL is closed~The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors."
214934458|NCT01512069|BEHAVIORAL|Non-tailored booklet on exercise and diet|The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
214934459|NCT06623929|DRUG|Etofenamat|E group: Etofenamate spray 100 mg/ml is applied to the painful area from a distance of approximately 10-15 cm in a maximum of 7 puffs. Each puff contains 18 mg etofenamate.
214673700|NCT02398123|OTHER|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
214673701|NCT02398123|OTHER|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
214673702|NCT02398123|DRUG|Bupivacaine|
214673703|NCT02609711|DRUG|Candesartan cilexetil|
214673704|NCT00824538|DRUG|sunitinib malate|
214673705|NCT00824538|OTHER|flow cytometry|
214673706|NCT00824538|OTHER|immunohistochemistry staining method|
214333397|NCT03358576|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic for complicated intra-abdominal infection
214333398|NCT03358576|DRUG|Ciprofloxacin|Antibiotic for complicated intra-abdominal infection
214333399|NCT03358576|DRUG|Metronidazole|Antibiotic for complicated intra-abdominal infection
214333400|NCT03358576|DRUG|Amoxicillin-Clavulanate|Antibiotic for complicated intra-abdominal infection
214333401|NCT03358576|DRUG|Sulopenem|Antibiotic for complicated intra-abdominal infection
214333402|NCT03424538|OTHER|Neurorehabilitation|5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
214333403|NCT03424538|OTHER|Physiotherapy|5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
214333404|NCT02848118|DEVICE|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
214333405|NCT02848118|OTHER|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
214333406|NCT02189187|BEHAVIORAL|Mindfulness|
214333407|NCT02189187|BEHAVIORAL|Psychoeducation|
214333408|NCT00628550|DRUG|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
214333409|NCT00628550|DRUG|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
214333410|NCT01565993|DEVICE|Hemoclip|"A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm"
214333411|NCT01565993|DEVICE|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
214333412|NCT01960231|OTHER|OGTT|
214333413|NCT02804165|GENETIC|Enterovirus vaccination|Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
214333414|NCT01824303|DRUG|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
214333415|NCT01824303|OTHER|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
214673707|NCT00824538|OTHER|laboratory biomarker analysis|
214673708|NCT00318708|DRUG|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
214673709|NCT00318708|DRUG|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
214673710|NCT00318708|DRUG|placebo clarithromycin|placebo clarithromycin twice daily
214673711|NCT00442312|DRUG|Combigan Ophthalmic Solutiom|
214673712|NCT03675399|OTHER|Supra-threshold isometric exercise|The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
214673713|NCT03675399|OTHER|Infra-threshold isometric exercise|The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
214673714|NCT02439385|DRUG|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
215073002|NCT04945278|OTHER|Double mirror device ALTER-EGO|"The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?"
215073003|NCT04945278|OTHER|EASE test|The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
215073004|NCT02503670|BEHAVIORAL|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
214673715|NCT02439385|DIETARY_SUPPLEMENT|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
214673716|NCT03342443|DRUG|Memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
214673717|NCT03342443|DRUG|Placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
214673718|NCT01373554|DRUG|Placebo|30mig/bid or 60mg/bid P.O
214673719|NCT01373554|DRUG|Oltipraz|30mig/bid or 60mg/bid P.O
214673720|NCT02225886|DRUG|Ascorbic Acid|300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
214673721|NCT02971696|DRUG|Sorafenib|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
214673722|NCT02971696|DRUG|Best Supportive care|Liver Support, pain management
214673723|NCT01819961|DRUG|MCT/LCT and fish oil|
214673724|NCT01819961|DRUG|MCT/LCT|
215073005|NCT02503670|OTHER|Control Group|Continue with standard care.
215073006|NCT00521690|DRUG|insulin detemir|
215073007|NCT04545190|DIETARY_SUPPLEMENT|Glucose|To investigate the effects of glucose intake during resistance training on muscle biological adaptations
215073008|NCT04154449|DRUG|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
214934460|NCT06623929|DRUG|Diclofenac|Group D: Diclofenac diethylammonium 1% spray was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
214333416|NCT03995004|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
214333417|NCT03995004|DRUG|Dexamethasone Sodium Sulphate 4mg/1mL|Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
214934461|NCT05665166|GENETIC|Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII|Autologous CD34+ haematopoietic stem cells from MPS II patients will be genetically modified ex vivo using CD11b.IDS-ApoEII Lentiviral Vector (LV), a self-inactivating (SIN) LV expressing the human codon-optimized IDS gene tagged with ApoEII and regulated by a human CD11b myeloid-specific promoter. These transduced CD34+ HSCs will then be cryopreserved until the time of infusion back to the patients
214934462|NCT06488209|DRUG|LAD191|LAD191 SC injection.
214333418|NCT03323905|DEVICE|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
214333419|NCT02624102|BEHAVIORAL|Trial based cognitive therapy|Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy
214333420|NCT02624102|BEHAVIORAL|Behavioral Activation|Patients with MDD, in use of antidepressants plus Behavioral Activation
214333421|NCT02624102|DRUG|Antidepressants|Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
214333422|NCT04086472|BIOLOGICAL|Clesrovimab|Single dose of clesrovimab administered via IV infusion.
214333423|NCT04086472|OTHER|Placebo|Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.
214333424|NCT04086472|BIOLOGICAL|RSV-A Memphis 37b|Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
214333425|NCT01495962|DRUG|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
214333426|NCT01495962|DRUG|Placebo|Placebo (Normal Saline)
214333427|NCT04273100|COMBINATION_PRODUCT|PD-1 mAb combined with TACE and lenvatinib|the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib)
214333428|NCT02210299|OTHER|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
214333429|NCT01584284|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
214934463|NCT06488209|OTHER|Placebo|Matching placebo SC injection.
214934464|NCT03475199|DEVICE|FabLife|"* A personnalized dietary program depending on the patient's phenotype and genotype~* The daily intake of a dietary supplement, developped in the context of male infertility."
214934465|NCT00785434|DRUG|escitalopram|Dose ranging up to 50mg
214934466|NCT01382225|DRUG|Sodium Hyaluronate Ophthalmic Solution, 0.18%|
214934467|NCT01382225|OTHER|Vehicle|Inactive ingredients used as run-in and placebo comparator
214934468|NCT03530813|OTHER|Ebook Asthma First Aid in School Training|Technology assisted, self-directed learning eBook resource
214934469|NCT03530813|OTHER|Face-To-Face Asthma First Aid in Schools Training|School Asthma First Aid Management Program 3 Hour Face to Face Training
215073009|NCT02613117|DEVICE|Potassium Oxalate Gel|Self applied
215073010|NCT02613117|DEVICE|Potassium Oxalate Liquid|Professionally Applied
214333430|NCT02690285|DRUG|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
214333431|NCT02690285|OTHER|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
214333432|NCT02950636|OTHER|Yoga|Restorative Yoga
214333433|NCT00844545|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
214333434|NCT04259190|BEHAVIORAL|interoceptive exposure|Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
214333435|NCT02872415|BIOLOGICAL|Blood puncture site|Blood puncture site
214333436|NCT05277467|OTHER|no intervention|no intervention
214333437|NCT01743092|BEHAVIORAL|Webinar|Some clients will receive a webinar as part of their treatment.
214333438|NCT01743092|BEHAVIORAL|Tutuorial workbook|A work book about their addiciton
214333439|NCT03925792|BEHAVIORAL|Lifestyle Medicine|diet, sleep, exercise and mindfulness
214333440|NCT03125889|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
214333441|NCT05165121|DEVICE|MDHearing smart hearing aid|air conduction hearing aid with app support
214333442|NCT04337567|PROCEDURE|radiofrequency ablation|ablative treatment as allocated to radiofrequency ablation
215073011|NCT02613117|DRUG|Stannous fluoride paste|SnF2 Paste
215073012|NCT01606683|OTHER|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
215073013|NCT01606683|OTHER|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
215073014|NCT01606683|OTHER|No intervention|
215073015|NCT02356419|DRUG|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
214333443|NCT04337567|PROCEDURE|ballon cryoablation|ablative treatment as allocated to ballon cryoablation
215073016|NCT01345591|PROCEDURE|Fat Grafting|
215073017|NCT03100916|DRUG|BI 690517|once daily
215073018|NCT03100916|DRUG|Placebo|once daily
214333444|NCT05750524|OTHER|reflexology hand massage|Reflexology massage methods applied randomly to both trial groups.
214333445|NCT05750524|OTHER|classical hand massage|Classical hand massage methods applied randomly to both trial groups.
214347184|NCT03032692|DEVICE|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
214347185|NCT03032692|OTHER|Exercise with biofeedback|
215073019|NCT03100916|DRUG|BI 690517 (Reference)|Fasting
215073020|NCT03100916|DRUG|BI 690517|Non- fasting
215073021|NCT05475210|DRUG|177Lu-DOTA-EB-TATE|Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.
215073022|NCT05475210|OTHER|Amino Acid Solution|The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
215073023|NCT02514694|DRUG|LEO32731|
215073024|NCT02514694|OTHER|Placebo|
215073025|NCT02163967|DEVICE|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
215073026|NCT03926000|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
215073027|NCT03926000|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
215073028|NCT03414255|BIOLOGICAL|Micronized DHACM|1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
215073029|NCT03414255|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
215073030|NCT00847665|OTHER|repositioning|Turning every 4 or 2 hours
215073031|NCT01820403|OTHER|portion size kcal of box lunch|
215073032|NCT03450694|DEVICE|ultrasound|ultrasound is a non-invasive and not expensive method, availiable at almost all institutions.
215073033|NCT03229772|DEVICE|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
215073034|NCT05302167|BEHAVIORAL|Molehill Mountain app|"The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study."
215073035|NCT05302167|DEVICE|Molehill Mountain app|As above.
215073036|NCT05439993|DRUG|Tepotinib plus paclitaxel|Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
215073037|NCT06368505|OTHER|ultrasound guided PRP injection|whole blood is initially collected in tubes that contain anticoagulants, such as citrate dextrose A to prevent platelet activation prior to its use. Then PRP is prepared by a differential centrifugation. Then 3ml of PRP will be delivered via the in-plane ulnar approach
215073038|NCT06368505|OTHER|ultrasound guided hydrodissection|5ml will be injected to detach the median nerve from the TCL (2ml saline, 2ml dexamethasone and 1ml lidocaine), the injectate will be delivered via the in-plane ulnar approach, and the median nerve will be hydrodissected from its undersurface while advancing the needle among the superficial surface of the median nerve and the TCL
215073039|NCT02545881|OTHER|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
215073040|NCT01357954|OTHER|Regular physiotherapy|The child's regular physiotherapy
215073041|NCT01357954|OTHER|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
215073042|NCT02660593|DIETARY_SUPPLEMENT|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
215073043|NCT03378609|OTHER|Vocal Fatigue Index (VFI)|collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
214347186|NCT03032692|OTHER|exercise without biofeedback|
214347187|NCT00476944|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
214347188|NCT03939273|DRUG|Vancomycin Oral|500 mg thrice per day for seven days
214347189|NCT03939273|DRUG|Metronidazole Oral|500 mg thrice per day for seven days
214347190|NCT03939273|DRUG|Ciprofloxacin Pill|500 mg twice per day for seven days
214673725|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
214673726|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
214673727|NCT05721885|BEHAVIORAL|nutrition management|Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score \> 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
214673728|NCT05446597|PROCEDURE|Symptom-specific Headache Treatment|Greater Occipital Nerve Block
214673729|NCT05446597|OTHER|Symptom-specific Dizziness &/or Neck Pain Treatment|Cervicovestibular Physiotherapy Treatment
215073044|NCT03385915|PROCEDURE|Aortic valve replacement|Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
215073045|NCT01150058|GENETIC|western blotting|
215073046|NCT01150058|OTHER|flow cytometry|
214673730|NCT05446597|BEHAVIORAL|Multimodal Concussion Treatment|Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
214673731|NCT04567836|OTHER|Investigation of the prevalence of test positivity|"The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses ."
214673732|NCT02928393|DRUG|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
214673733|NCT02928393|DRUG|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
214673734|NCT02194296|DRUG|Ambroxol hydrochloride - lozenge|
214673735|NCT02194296|DRUG|Ambroxol hydrochloride - syrup|
215073047|NCT01150058|OTHER|laboratory biomarker analysis|
215073048|NCT03927235|PROCEDURE|Transbronchial Cryobiopsy|Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
215073049|NCT03804567|OTHER|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs such as chronic pain that are troubling them.
215073050|NCT03804567|OTHER|Routine low back pain management|Standard low back persistent physiotherapy management as recommended by national guidelines.
215073051|NCT00094159|DRUG|SNS-595|
215073052|NCT01338350|DRUG|AZD5423|Inhalation, suspension
215073053|NCT01338350|DRUG|Placebo|Inhalation, solution
214333446|NCT01511380|BEHAVIORAL|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
214333447|NCT01511380|BEHAVIORAL|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
214333448|NCT04073316|DRUG|Rivaroxaban 20 MG|Rivaroxaban intake, 20mg/day
214333449|NCT04073316|DRUG|Warfarin|Warfarin intake, with target INR range between 2 and 3
214333450|NCT05572905|OTHER|Exercise|Patients after overnight fast will cycle on ergo-meter for 60 minutes. No per-oral food intake will be allowed during the test. Level of the intensity of exercise will be determined as individual range of heart frequency (HF), oxygen consumption (VO2) and respiratory quotient (RQ) just bellow the aerobic threshold of the given participant (close to anticipated fatmax). These values will be obtained during maximal capacity stress test on cyclo-ergo-meter. This maximum stress test will be performed at least one week prior to the 60 minutes exercise to eliminate potential carry-over effect. Power output will be modulated during the 60 minutes of exercise to ensure keeping participants values of HF, RQ and VO2 in the given range. Blood will be sampled at 5 time points with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-exercise.
214333451|NCT05572905|OTHER|Fasting control|The same participants will be monitored while resting for 120 minutes in calm environment. No peroral food intake will be allowed during the test. Fasting control will take place at least one week apart of the exercise. Blood will be sampled at 5 timepoints with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-control.
214347191|NCT03939273|DRUG|Fluconazole Oral Product|200 mg once per day for six days
214347192|NCT03939273|DRUG|Placebos|seven day course of placebo tablets and capsules identical in appearance and number to active treatment
214934470|NCT02012465|BIOLOGICAL|Insulin protocol|"Within 24 hours of admission for diabetic participants, the inpatient oncology team will consult the endocrine team to apply the following part of the protocol, confirm NPH insulin dosing, and ensure that oral hypoglycemics are held.~The following basal-bolus protocol is standard of care for inpatient diabetics requiring insulin at Barnes Jewish Hospital. The alternative practice has been to use 60-80% of the home insulin regimen while patients are hospitalized. For patients using home insulin, the admitting oncology team will enact one of these methods while awaiting the endocrine service's formal recommendations.~* Determine basal-bolus insulin requirement for the patient based on body weight: Patient weight (kg) x 0.5-0.7 Units/kg = Units of total insulin per 24 hours~* The TDD can be divided into 50% basal (glargine) and 50% meal time (lispro) insulin, plus sliding scale insulin (lispro)."
214934471|NCT06622811|OTHER|Students' Knowledge about Virtual Reality Questionnaire|"Part I: Personal Characteristics of Nursing Students:~It covers; age and gender.~Part II: Students' Knowledge about Virtual Reality Questionnaire:~This part will used to assess students' knowledge related to virtual reality that includes a definition of virtual reality, history of virtual reality, advantages and disadvantages of virtual reality on nursing education and equipment used for virtual reality and the effect virtual reality on future of education~Scoring system:~Respondents' answers will be scored (0) for incorrect answers, and (1) for correct answers. The overall items scores will be summed up and categorized according to the total percentages of unsatisfactory (\<60%) and satisfactory (≥60%)."
214934472|NCT06622811|OTHER|California Critical Thinking Disposition Inventory (CCTDI)|"It will consist of 24 items classify into 7 dimensions grouped as follows; truth-seeking (3 items); open-mindedness (4 items); analyticity (3 items); systematicity (4 items); critical thinking self-confidence (4 items); inquisitiveness (3 items); and cognitive maturity (3 items).~Scoring system:~Students asked to respond to all items with six points Likert scale as follows; strongly disagree = 1, disagree= 2, neutral = 3, sometimes agree = 4, agree = 5, and strongly agree= 6. The overall items scores will be summed up and categorized according to the total percentages of satisfactory critical thinking (≥75%) and unsatisfactory critical thinking (\<75%)."
214934473|NCT04159649|DRUG|Letrozole 2.5Mg Tablet|Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol
214934474|NCT04159649|DRUG|Gonadotropins|Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
214934475|NCT04159649|PROCEDURE|endometrial sample in the pretreatment cycle|All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
214934476|NCT02426749|DEVICE|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
214934477|NCT02426749|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
214934478|NCT03273725|OTHER|Dental examination including taking a saliva sample.|The main focus of the dental examination is enamel defects and caries. Saliva samples (stimulated) will also be taken.
214934479|NCT00697736|PROCEDURE|Echocardiography with myocardial tissular Doppler mode|Echocardiography with myocardial tissular Doppler mode during rest and exercise on a table equipped with a cyclo-ergometer
214934480|NCT01797081|BIOLOGICAL|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
214333452|NCT04592705|DEVICE|Therapeutic plasma exchange|"TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP."
214333453|NCT03058796|DEVICE|Contralaterally Controlled Functional Electrical Stimulation (CCFES)|The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
214333454|NCT03058796|DEVICE|Hand Therapy Video Games|The use of video games with CCFES to encourage therapeutic hand movement at home
214333455|NCT00568984|DRUG|repaglinide|
214934481|NCT01797081|BIOLOGICAL|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
214934482|NCT01797081|OTHER|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
214934483|NCT05731869|OTHER|epicondylitis band|An off-the-shelf lateral epicondylitis tape in S-M-L dimensions was used distal to the lateral epicondylitis.
214934484|NCT05731869|OTHER|wrist orhosis|Wrist orthosis of the shelf was used in sizes S-M-L, covering the hand and wrist.
214934485|NCT05463237|DIAGNOSTIC_TEST|oral glucose tolerance test|oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation
214934486|NCT05463237|DIAGNOSTIC_TEST|Blood sample|Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes
214673736|NCT06067646|BEHAVIORAL|Semistructured interview|Semistructured interview and validated quality of life assesment using EQ5-DL
214333456|NCT00568984|DRUG|metformin|
214333457|NCT00568984|DRUG|glicazide|
214333458|NCT06572410|DEVICE|EnVisio Navigation System|Patient will be undergoing BCS Breast Conserving Surgery treatment for DCIS or invasive breast cancer with EnVisio Navigation System.
214333459|NCT03586869|DRUG|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
214333460|NCT03586869|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214333461|NCT03586869|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
214333462|NCT03586869|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
214333463|NCT03586869|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
214333464|NCT03586869|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
214333465|NCT03586869|BIOLOGICAL|GI-4000|RAS yeast
214333466|NCT03586869|BIOLOGICAL|GI-6207|Carcinoembryonic Antigen (CEA) yeast
214333467|NCT03586869|BIOLOGICAL|GI-6301|Brachyury yeast
214333468|NCT03586869|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
214333469|NCT03586869|BIOLOGICAL|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
214333470|NCT03586869|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214673737|NCT03396471|DRUG|Pembrolizumab|200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
214673738|NCT03396471|RADIATION|External Beam Radiation Therapy|20-30 Gy over five fractions for up to two cycles.
214673739|NCT02252952|OTHER|Beverage Consumption|
214934487|NCT06517901|PROCEDURE|Software fusion prostate biopsy|Software fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using an image fusion platform such as UroNav or similar. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).
214934488|NCT06517901|PROCEDURE|Cognitive fusion prostate biopsy|Cognitive fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using visual estimation and/or measurements of lesion. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).
214934489|NCT05517824|PROCEDURE|microinsulated needle radiofrequency|A single treatment using a microinsulated needle radiofrequency device
214934490|NCT04859153|DIAGNOSTIC_TEST|central nerve sensory, motor control and various muscle mechanical characteristic and sport-related fitness test|To explore the sports performance of the adolescent sprinters, including analyzing the correlations between the results and central nerve sensory, and also between motor control and various muscle mechanical characteristic and sport-related fitness factor.
214934491|NCT00604942|PROCEDURE|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
214934492|NCT00604942|PROCEDURE|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
215073054|NCT03736057|OTHER|Delayed results of pharmacogenomic results|"1:1 randomization schedule for delayed knowledge of pharmacogenomic results to clinician and patient. Results are released to prescriber at \<1 week (unblinded) or 12 weeks (blinded). When genomic results are available upon receipt, unblinded clinicians select an FDA-approved drug from the recommended drugs when possible. Blinded prescribers provide the intended prescription when notified of blinded status. At 4 weeks, 1° outcome measures, NPI-Q and side effects ratings are collected. Clinicians make a GO/NO-GO decision for continuation based on those measures. A NO-GO decision is unblinding and an alternative drug may be prescribed. At 12 weeks, 1° outcomes are collected again. Previously blinded clinicians will be unblinded and may decide to continue or revise the treatment plan based on the clinical outcomes and the genetic results. After the 12 week visit, results of the genetic tests will be entered in the EHR. Further clinical follow-up is based on need."
214934493|NCT00604942|DRUG|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
214934494|NCT00604942|DRUG|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
214934495|NCT04174664|DIAGNOSTIC_TEST|1-minute sit to stand test|Childrens will complete 1-minute sit to stand test and 3 minute step test and quality of life questionnaire.
214934496|NCT01852201|DEVICE|Endovascular Mechanical Thrombectomy|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
214934497|NCT00760695|DRUG|dronabinol|tablets, twice daily, for 4 weeks
214934498|NCT00760695|DRUG|placebo|tablets, twice daily, for 4 weeks
214934499|NCT03657524|OTHER|echocardiography|Speckle tracking echocardiography
214333471|NCT03586869|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214934500|NCT06018298|OTHER|Treatment as usual (TAU)|the components of treatment as usual (TAU) are summarised and assessed by the items of the DUNDRUM-3: physical health, mental health, substance misuse, problem behaviours, self care and activities of daily living, education occupation and creativity, family and intimacy.
214934501|NCT00342381|DRUG|3,4-diaminopyridine|Single dose 3,4 diaminopyridine
214934502|NCT00342381|DRUG|Placebo|Single dose placebo treatment
214934503|NCT06148428|PROCEDURE|Laser in situ keratomileusis (LASIK)|"Patients were planned to undergo laser in situ keratomileusis. Local anesthesia was achieved by preservative-free oxybuprocaine hydrochloride 0.4% drops (a commonly used topical anesthetic due to its effectiveness in alleviating pain and ocular surface discomfort during the procedure). During surgery, the lights of the operating room were dimmed as much as possible and the surgeons spoke to the patients in a calm voice and explained what was happening. They also reassured the patients that the surgery was going as planned and would be over soon.~For patients undergoing (Microkeratome) MK-LASIK, a Moria 2 Microkeratome (Moria SA, Antony, France) was used to create the flap. For patients undergoing Femtosecond LASIK (FS-LASIK), the Allegretto Wave Light FS-200 femtosecond Laser (Alcon labs, Fort Worth, TX, USA) was used for flap creation.~Laser ablation was performed using WaveLight EX500 Excimer Laser (Alcon labs, Fort Worth, TX, USA) with a planned post-operative emmetropia."
214934504|NCT06101017|DIAGNOSTIC_TEST|Optical Coherence Tomography|Non-invasive imaging test that use light waves to take cross-section pictures of the eye.
214934505|NCT03762928|DRUG|PF-06651600|200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
214934506|NCT03762928|DRUG|midazolam|single administration of midazolam 2 mg oral solution
214934507|NCT03762928|DRUG|efavirenz|single administration of efavirenz 50 mg capsule
214934508|NCT04868851|BEHAVIORAL|Here for Health Only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
214934509|NCT04868851|BEHAVIORAL|mHealth technology assisted exercise counselling|Patients will complete the Here for Health intervention before completing a 3 month exercise and physical activity intervention supported by mHealth technology
214934510|NCT03480191|DRUG|Daptomycin|Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.
214934511|NCT02767492|DEVICE|BioD Restore|Investigational product, BioD Restore, will be injected into the articular space of the knee.
214934512|NCT02767492|DRUG|Kenalog|Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
214934513|NCT01177709|DRUG|Metformin|metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.
214934514|NCT03624062|DRUG|MAS-1 adjuvanted Insulin B-chain|MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.
214934515|NCT05077176|BIOLOGICAL|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
214934516|NCT05077176|BIOLOGICAL|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
214934517|NCT05669352|DRUG|CA-4948|Subjects on both the phase I and phase II portions will take 200 mg CA-4948 orally two times daily.
214934518|NCT05669352|DRUG|Pembrolizumab|Subjects on both the phase I and phase II portions will receive 400 mg pembrolizumab intravenously once every six weeks.
214934519|NCT04393064|DEVICE|fiberoptic endoscopic evaluation of swallowing|"intreventions name :-Fiberoptic endoscopic evaluation of swallowing(FEES) will be performed on all infants enrolled in this study.~interventions type: flexible nasopharyngeal laryngoscope 3,5 mm in size with portable camera \& light source \& video recording system will be used. Procedure will be done without anesthesia~."
214934520|NCT05627310|OTHER|Diagnostic|Training dataset was used to train the deep learning model, which was validated and tested by external dataset.
214934521|NCT05527847|BEHAVIORAL|Peers LEAD|Two group session focusing on beliefs about medicines and diabetes, discrimination/mistrust, and communication with providers, and 2 peer-based phone calls from Ambassadors to occur weekly for weeks 3-8, then bi-weekly for weeks 9-12.
214934522|NCT05527847|BEHAVIORAL|HLWD|Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
214934523|NCT04743583|DEVICE|Endosonography B-mode examination|Endobronchial ultrasound (EBUS) or Endoscopic with bronchoscope (EUS-B) B-mode examination and sampling, when indicated, of lymphadenopathy
214333472|NCT03586869|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214333473|NCT03586869|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
214333474|NCT03586869|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
214333475|NCT03586869|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
214333476|NCT03586869|BIOLOGICAL|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
214333477|NCT03586869|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
214333478|NCT04578314|BEHAVIORAL|Relating Therapy|Relating Therapy (RT) is a symptom-specific behaviourally oriented intervention that targets interpersonal relating as a key mechanism associated with auditory hallucination distress. The aim is that patients learn to relate more assertively within the difficult relationships they have with both the auditory hallucinations and other people. The RT will follow a treatment manual consisting of three phases: 1. Socialization to relating therapy and its implications; 2. Exploration of themes within the relational history of the participant and their experience of relationships with AH, and interpersonal relating within the family and social environment (identifying any prominent themes, such as abuse, disempowerment, or rivalry); 3. Exploration and development of assertive approaches to relating to AH and other people.
214333479|NCT04578314|OTHER|Treatment as usual|TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
214333480|NCT03037944|DRUG|Yasmin|(ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
214333481|NCT03037944|DEVICE|Metraplant-E|"Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013"
214333482|NCT01491321|PROCEDURE|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
214333483|NCT01491321|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
214333484|NCT01491321|PROCEDURE|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
214333485|NCT00403455|DRUG|Paroxetine|SSRI
214955405|NCT01233752|DRUG|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.~Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h)."
215073055|NCT00624585|DRUG|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~* Dose Level and Dose of dasatinib:~  1. Starting dose (1-8 weeks)= 100 mg orally (po) daily~ 2. +1 (\<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~* Dose Level and Dose of dasatinib:~  1. Starting dose = 100 mg po daily~ 2. -1 = 70 mg po daily~ 3. -2 = 50 mg po daily~OR~* Dose Level and Dose of dasatinib:~  1. Starting dose = 150 mg po daily~ 2. -1 = 120 mg po daily~ 3. -2 = 90 mg po daily~ 4. -3 = 50 mg po daily"
214333486|NCT05565612|DIETARY_SUPPLEMENT|Normodigest Classic|Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
214333487|NCT05565612|DIETARY_SUPPLEMENT|Placebo|Compound based on maltodextrin and other excipients
214333488|NCT06573892|DIETARY_SUPPLEMENT|Probiotic|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
214333489|NCT06573892|DIETARY_SUPPLEMENT|Placebo|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
215073056|NCT05774054|DRUG|Crystalloid|received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation
214333490|NCT06574204|DRUG|Erythromycin|The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.
214333491|NCT06574204|DRUG|Azithromycin|The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.
214347193|NCT04463901|PROCEDURE|Pterygium excision|Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
215073057|NCT05774054|DRUG|noradrenaline|received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
214333492|NCT06574204|OTHER|physiological saline|The researchers injected 10-20 μl of physiological saline into the inner left wrist of the subjects, which is a liquid dosage form.
214333493|NCT04805983|DRUG|BMS-984923|Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
214333494|NCT06573255|OTHER|Healthy group|Cardiopulmonary exercise test, respiratory function tests, respiratory muscle strength and physical activity assessment will be performed in this group.
214934524|NCT03873441|OTHER|Computer Games-Aided Balance Training Protocol|"1\) Sitting Balance exercises while playing the interactive computer games starting with bi manual object placed in hands for controlling the games, then using the head rotation movements to control the games progressing to use of trunk motions to control games while balancing on the compliant surfaces in order to progress by increasing the balance costs.~(2) Standing Balance exercises progressing from a fixed support surface to uneven, compliant surfaces like progression from standing over ground to sponge to air bladder as child tolerates increased balance costs.~(3) Progression then to balancing while performing the visuomotor and visuospatial game tasks such as playing the games starting with bi-manual object placed in hands for controlling the games, then using the head rotation movements to control the games and then progressing to use of trunk motions to control games while balancing on compliant surface.~(4) Progression to single-leg stance and stepping activities."
214934525|NCT03873441|OTHER|Conventional Balance Training Protocol|"The following is a summary of the conventional physical therapy balance training protocol:~1. Active-assisted stretching exercises for lower limb musculature focusing on postural control and improvement in dynamic stability,~2. Balance and weight bearing exercises with multi-directional reach outs associated with trunk movements on fixed surface gradually progressing to unstable movable and compliant surfaces,~3. Weight transfer exercises with multi-directional reach outs and~4. Stepping exercises in different directions on variety of surfaces."
214934526|NCT02013570|DRUG|Dexmedetomidine|2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
214934527|NCT02407132|BEHAVIORAL|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
214673740|NCT05760625|DIAGNOSTIC_TEST|analysis BDNF|We analysed consentration of BDNF in venous blood of patient with primary headache
214333495|NCT02809976|DRUG|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
214333496|NCT00087568|DRUG|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
214333497|NCT00087568|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
214333498|NCT02738021|BEHAVIORAL|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
214333499|NCT03771729|DRUG|LCZ 696|LCZ696 200mg twice daily
215073058|NCT03995056|BEHAVIORAL|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
214673741|NCT00562510|DRUG|Raltegravir|Raltegravir 400 mg BID added to stable HAART
214673742|NCT00562510|DRUG|Placebo|Placebo BID added to stable HAART
214333500|NCT00134368|DRUG|Etanercept|
214333501|NCT03009071|PROCEDURE|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
214333502|NCT03009071|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
214673743|NCT02563873|DEVICE|Tailored pacemaker settings|Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
214333503|NCT05071755|PROCEDURE|Gastrectomy|Radical Total Gastrectomy, Radical Partial gastrectomy (Proximal / Subtotal)
214333504|NCT05658926|BEHAVIORAL|Mindfulness|Patients will learn how to use diaphragmatic breathing with mindfulness
214333505|NCT05658926|OTHER|Education|Patients will be provided with education regarding the Gate Control Theory of Pain.
214333506|NCT04394351|DRUG|Dupilumab|Single-use, prefilled syringe
214333507|NCT04394351|DRUG|Matching Placebo|Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
214333508|NCT02591693|BEHAVIORAL|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
214333509|NCT04257877|PROCEDURE|Blood sampling|Blood samples for proteomic analysis in plasma of both groups
214673744|NCT05309070|DIETARY_SUPPLEMENT|N-acetyl cysteine|Study group will receive N-acetyl cysteine in unmarked boxes, in a daily dose of 1200 mg during two months
214673745|NCT05309070|OTHER|placebo|Control group will receive a placebo, in unmarked boxes, during two months
214673746|NCT02904967|BIOLOGICAL|Extra Blood Draw|
214673747|NCT00164905|DEVICE|Doppler ultrasound probe|Applying to ulcer base to assess the blood flow underneath the ulcer
214673748|NCT00718861|DRUG|Placebo|
214673749|NCT00718861|DRUG|Zoledronic acid|
214673750|NCT01690234|PROCEDURE|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
214673751|NCT01690234|PROCEDURE|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
214673752|NCT03237845|DRUG|Rimegepant|75 mg tablet QD
214934528|NCT02407132|BEHAVIORAL|Standard DSME|Active Comparator: Standard DSME Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
214955406|NCT03570203|DIAGNOSTIC_TEST|Serum Sodium|Measurement of serum sodium.
214955407|NCT01424241|DRUG|Sandostatin LAR|Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.
214333510|NCT00824317|DRUG|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
214934529|NCT05872100|BEHAVIORAL|MINDFULNESS BASED APPLICATION|"* The effectiveness of mindfulness practices in the field of health~* Breathing exercise~* Discussing and sharing about exercise~* Introduction of informal and formal mindfulness practices~* Communication exercise with conscious awareness~* Sounds and thoughts meditation~* The concept of compassion~* Biological foundations of compassion~* Self-compassion~* Barriers to compassion~* Coping with compelling emotions~* Coping with the intensity of compassion~* Compassionate mindfulness attitudes~* Admission stages and improving acceptance~* Compassion Meditation~* Courtesy Meditation~* My partner activity~* Body Scan~* Mindfulness Sitting Meditation~* Receiving feedback on the development of mindfulness skills and the content of the training program~* Integration of conscious awareness exercises in daily life for the future"
214934530|NCT01031745|BEHAVIORAL|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
214333511|NCT00824317|DRUG|Placebo|
214333512|NCT05068765|OTHER|Communication skills psychoeducation|Intervention explanations are explained in the groups section.
214333513|NCT05068765|OTHER|General psychoeducation|İntervention descriptions are explained in the intervention groups section.
214333514|NCT00058240|DRUG|alvocidib|Given IV
214333515|NCT00985348|DRUG|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
214333516|NCT03527992|DEVICE|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
214333517|NCT03527992|DEVICE|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
214333518|NCT05631639|DEVICE|PillSense System|The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
214934531|NCT01031745|OTHER|Prize bowl drawings|"Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives."
214934532|NCT03572400|DRUG|Gemcitabine|Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles
214934533|NCT03572400|DRUG|Durvalumab|Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year
214934534|NCT03617861|DRUG|Human Secretin|Injected once over one minute
214934535|NCT03617861|DRUG|Placebo|Injected once over one minute
214673753|NCT03237845|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
214673754|NCT05174689|DIAGNOSTIC_TEST|Exercise challenge in the cold chamber (ECC)|Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.
214673755|NCT05174689|DIAGNOSTIC_TEST|mRNA profile|Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
214673756|NCT05174689|DIAGNOSTIC_TEST|standard diagnostic|bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
214333519|NCT00018109|DRUG|glutamine|
214333520|NCT00018109|DRUG|creatine monohydrate|
214333521|NCT02578485|DEVICE|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
214333522|NCT02578485|DEVICE|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
214673757|NCT06343207|DEVICE|Percussive massage gun therapy|Between pre and post-test, there was a one and half minute period during which each participant were in a prone position on a medical examination bed. The experimental PT groups received a 30-second triceps surae massage on each limb, while the control group maintained the same prone position without massage. The massage gun was set to 2100bpm and 1 bar of surface pressure was indicated by the device. The massage gun movement was performed according to the manufactu'er's instructions.
214934536|NCT04253405|DEVICE|High Flow Nasal Catheter|"HFNC will be delivered through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize the patient´s comfort and SpO2"
214934537|NCT04253405|DEVICE|Noninvasive positive pressure ventilation (NIPPV)|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 according to the protocol.
214934538|NCT00623597|DRUG|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
214673758|NCT03037320|PROCEDURE|comparison of coronally advanced flap and semilunar vestibular incision technique for root coverage in maxillary teeth|
214934539|NCT00623597|DRUG|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
214934540|NCT01157000|DRUG|Canagliflozin|On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
214934541|NCT03309826|DEVICE|Positive Airway Pressure|Auto-PAP titration followed by fixed PAP treatment
214333523|NCT02578485|DEVICE|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
214934542|NCT03309826|DEVICE|Nasal Dilator Strip|Nightly use of nasal dilator strip
214934543|NCT02515994|DEVICE|senofilcon C|Investigational contact lens
214934544|NCT02515994|DEVICE|comfilcon A|Marketed Monthly Replacement Lens (Control)
214934545|NCT03790618|DRUG|3,4-Methylenedioxymethamphetamine|Participants will be given 0.75mg/kg of 1.5mg/kg MDMA
214934546|NCT03790618|DRUG|methamphetamine|Please see above.
214934547|NCT02642003|DRUG|Granulocyte Colony Stimulating Factor|
214333524|NCT02578485|DEVICE|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
214333525|NCT02578485|DEVICE|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
214934548|NCT04943302|DRUG|Bendamustine Hydrochloride|To be given by IV at 70mg/m2 on cycle days 1 and 8 for up to 6 cycles
214934549|NCT04943302|DRUG|Isatuximab|To be given by IV at10mg/kg IV on cycle 1 days 1,8,15, and 22; cycle 2-6 days 1,8; and cycle 7-12 days 1
214333526|NCT00654849|PROCEDURE|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
214333527|NCT00654849|PROCEDURE|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
214333528|NCT01537341|BEHAVIORAL|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
214333529|NCT01537341|BEHAVIORAL|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
214934550|NCT03384784|DRUG|Galantamine|The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
214934551|NCT03384784|DRUG|Placebo|Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
214934552|NCT01849068|DRUG|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
214934553|NCT01849068|DRUG|Placebo|Placebo for 12 weeks
214934554|NCT06284395|DRUG|Bortezomib|Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)
214934555|NCT06457360|DRUG|tranexamic acid|Application of sterile gauze after extraction for hemostasis
214934556|NCT06457360|DRUG|Ankaferd Blood Stopper|Application of sterile gauze after extraction for hemostasis
214934557|NCT06457360|DRUG|Chitosan|Application of sterile gauze after extraction for hemostasis
214934558|NCT02210286|DIETARY_SUPPLEMENT|Magtein|
214934559|NCT03161002|GENETIC|detection of genotype|detection of genotype by next generation sequencing
214934560|NCT03132870|OTHER|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions
214934561|NCT03653949|OTHER|Educational intervention|It will be an interactive lecture, 60 minutes long. The class will cover physiopathology, complications, treatment and prevention of exacerbations. Audiovisual resources and practical demonstrations of usual care will be used. Individual questions will be answered during the class.
214934562|NCT03653949|OTHER|Aerobic exercise|The aerobic exercise program will be performed at home, on a cycle ergometer for lower limbs between 24 and 35 minutes: 5 minutes of warm-up, 14 to 25 minutes of high-intensity interval exercise and 5 minutes of cool down.
214333530|NCT01826149|DRUG|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
214333531|NCT01826149|DRUG|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
214333532|NCT01826149|DRUG|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
214333533|NCT05322603|DRUG|Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)|A decrease in the pain severity (VAS);opioid-sparing effect
214934563|NCT04606992|PROCEDURE|CELS|CELS resection for early colon cancer is a compromised resection performed in frail patients
214333534|NCT05322603|DRUG|Analgesics|A decrease in the pain severity (VAS)
214333535|NCT02738775|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
214333536|NCT02738775|DRUG|Placebo|
214934564|NCT01668966|DRUG|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.
214673759|NCT06106165|OTHER|In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered in-person, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
214934565|NCT05392439|DEVICE|taVNS|transcutaneous auricular vagal nerve stimulation
214934566|NCT05392439|DEVICE|sham-taVNS|transcutaneous stimulation at the elbow area
214934567|NCT03203226|OTHER|FELDENKRAIS METHOD (FM)|They EG will receive the intervention of FM consisting of 30 lessons (1h-lesson per week; 30 weeks) verbal instructions provided by the therapist to participants. These instructions provide different options on how to perform a specific task with the purpose of leaving the decision on how to do the movement up to the performer, who has to focus on thinking, feeling, sensing and doing the movement as easily as possible.The lessons can be conducted sitting, standing or moving within a room.
214934568|NCT01712893|DRUG|Zoladex|Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
214673760|NCT06106165|OTHER|Online In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered online, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
214934569|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 0 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise
214934570|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 1 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise
214934571|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 1.5 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
214934572|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 2 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise
214934573|NCT02909881|BEHAVIORAL|Cycling exercise|Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
215073059|NCT04114643|BIOLOGICAL|Prothrombin Complex Concentrate|Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
215073060|NCT04114643|BIOLOGICAL|Frozen Plasma|Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
214673761|NCT06497725|DEVICE|Teleguidance-facilitated Airway Management|tele-guidence will be provided by an experienced airway expert
214673762|NCT04355117|DRUG|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
214673763|NCT01256619|DRUG|Marvelon|The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
214333537|NCT02992899|DEVICE|GammaCore/electroCore non-invasive VNS device|Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.
214333538|NCT02992899|DEVICE|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.
214347194|NCT04463901|PROCEDURE|Intraoperative mitomycin C|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
214347195|NCT04463901|PROCEDURE|Conjunctival autograft|A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
214333539|NCT02992899|DRUG|O-15 water|Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
214333540|NCT03587259|DIAGNOSTIC_TEST|Tomosynthesis|DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
214333541|NCT03587259|DIAGNOSTIC_TEST|2D mammography|2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
214333542|NCT03267238|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
214333543|NCT00965900|PROCEDURE|Endoscopic band ligation|"* Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
214333544|NCT00965900|DRUG|Propranolol|"* start with 20 mg of propranolol b.i.d~* Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
214333545|NCT00965900|PROCEDURE|EBL+Propranolol|"1. EBL~   * Perform EBL within 7 days after randomization~  * Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~  * Acid suppression using proton pump inhibitor until eradicated.~  * After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~2. Propranolol~   * start with 20 mg b.i.d~  * Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~  * After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
214333546|NCT05725603|OTHER|MRI imaging|Shoulder MRI will be performed at least 3 years after shoulder surgery
214333547|NCT05289102|OTHER|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.
214333548|NCT05289102|OTHER|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
214333549|NCT01578434|DRUG|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
214333550|NCT01578434|DRUG|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
214333551|NCT01578434|DRUG|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
214333552|NCT05800288|DRUG|Propofol|Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
214934574|NCT01594398|DRUG|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
214934575|NCT01594398|DRUG|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
214934576|NCT01594398|DRUG|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
214934577|NCT01594398|DRUG|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
214673764|NCT01546220|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
214673765|NCT05876572|DRUG|intradermal naloxone|One time 8 mg/0.1 mL dose of naloxone to be administered intradermally
214333553|NCT00515476|BEHAVIORAL|physical exercise|8 weeks of regular exercise training
214333554|NCT04468048|OTHER|"Music: Nada Himalaya performed by S. G. Sachchidananda"|"Music: Nada Himalaya performed by S. G. Sachchidananda"
214333555|NCT03228238|DRUG|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
214333556|NCT03228238|DRUG|Statin|Atorvastatin calcium 10mg
214333557|NCT03228238|DRUG|Standard medication for variant angina|Calcium Channel blocker or NG
214333558|NCT05176327|DEVICE|Exoskeleton training with Ekso NR|Walking exercise with Ekso NR
214934578|NCT01594398|DRUG|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
214934579|NCT01594398|DRUG|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
214934580|NCT00348426|DRUG|Botulinum AntiToxin|
214934581|NCT00348426|PROCEDURE|neuro-electrophysiologic study, repetitive nerve stimulation|
214934582|NCT00348426|PROCEDURE|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
214934583|NCT03955965|OTHER|Medication reconciliation|No intervention was performed other than collecting data on patients' medical files
214934584|NCT01542905|DIETARY_SUPPLEMENT|Korean Red Ginseng|Korean Red Ginseng Capsule (1g/day) for 8 Weeks
214934585|NCT01542905|OTHER|Placebo|Placebo Capsule (1g/day) for 8 Weeks
214934586|NCT03864666|DRUG|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
214934587|NCT03864666|DRUG|PMR 200 mg|Two PMR 200 mg at 08:00, single oral dose (total daily dose of 400 mg)
214934588|NCT01813734|DRUG|Ponatinib|28 day cycle
214333559|NCT04574362|DRUG|Rimegepant|One 75mg orally disintegrating tablet
214333560|NCT04574362|DRUG|Placebo|Matching placebo
214333561|NCT00003341|BIOLOGICAL|epoetin alfa|
214333562|NCT00003341|PROCEDURE|quality-of-life assessment|
214333563|NCT01709058|DRUG|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
214333564|NCT01709058|OTHER|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
214333565|NCT04013451|BEHAVIORAL|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
214934589|NCT00939406|DEVICE|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
214934590|NCT05588999|PROCEDURE|Cryotherapy Alone|"Patients in Group A were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart .~The liquid nitrogen was applied with a spray or a probe"
214934591|NCT05588999|COMBINATION_PRODUCT|Cryotherapy plus Salicylic Acid|Patients in Group B were subjected to cryotherapy plus with 50% salicylic acid to be properly applied for a maximum of eight weeks The liquid nitrogen was applied with a spray or a probe
214934592|NCT03357900|DEVICE|Automated titration of propofol and remifentanil|Calculation of Consumption of propofol and remifentanil
214934593|NCT00552032|DRUG|Mometasone Furoate nasal spray|Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
214934594|NCT00552032|DRUG|Placebo|Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
214333566|NCT00753324|DRUG|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
214333567|NCT04420026|RADIATION|Interact Active Tracker|Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
214333568|NCT00002526|BIOLOGICAL|filgrastim|
214673766|NCT05876572|DEVICE|microneedle injection|Intradermal delivery of naloxone using microneedle
214673767|NCT00092911|DRUG|DVS-233 SR|
214934595|NCT00345878|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
214934596|NCT00345878|BIOLOGICAL|HPV-16/18 L1 VLP AS04 (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
214333569|NCT00002526|DRUG|doxorubicin hydrochloride|
214333570|NCT00002526|DRUG|ifosfamide|
214673768|NCT04132752|OTHER|Motivation|Families were called via phone weekly and all questions were answered. Parents were motivated through phone.
214333571|NCT06298643|PROCEDURE|Red blood cell transfusion|≥2 units of red blood cell transfusion
214333572|NCT06298643|PROCEDURE|Red blood cell transfusion|0 units or \<2 units of red blood cell transfusion
214333573|NCT03991195|DIETARY_SUPPLEMENT|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
214333574|NCT03991195|DIETARY_SUPPLEMENT|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
214333575|NCT03147105|BEHAVIORAL|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
214333576|NCT01060384|DRUG|Lenalidomide|"Dose Cohort -1\^ 10mg daily on Days 1-21 every 28 days~Dose Cohort +1\^\^ 15mg daily on Days 1-21, every 28 days~Dose Cohort +2 20 mg daily on Days 1-21, every 28 days~Dose Cohort #3 25 mg daily on Days 1-21, every 28 days~\^Used only if Dose Cohort +1 requires further reduction~\^\^Starting Dose Cohort in Phase I"
214333577|NCT01060384|DRUG|ofatumumab|8 weekly infusions of ofatumumab 1000mg.
214934597|NCT00533052|BEHAVIORAL|Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
214934598|NCT02160028|OTHER|anesthetics and extended information before dental treatment|The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.
214333578|NCT02002767|DRUG|Velpatasvir|Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
214333579|NCT01866436|OTHER|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
214333580|NCT01866436|OTHER|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
214333581|NCT06094959|OTHER|Suicide Prevention Package|The implementation package consists of co-designed and culturally adapted suicide prevention elements including suicide crisis response planning, contact follow up phone calls, and healthcare provider support mechanisms to optimize implementation.
214333582|NCT00812929|DRUG|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
214333583|NCT00812929|DRUG|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
214333584|NCT00883389|DEVICE|Medical Alert Bracelet|Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
214333585|NCT02014961|PROCEDURE|Dermal biopsy|Skin biopsy
214333586|NCT02014961|BEHAVIORAL|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
214673769|NCT01889810|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
214673770|NCT05782413|OTHER|mechanical vestibular stimulation|Device produces mechanical vestibular stimulation. The child was placed in a sitting position on the swing and his hands grasping the ropes at the sides then the therapist stood behind him and begin pushing the platform in fast and jerky movements in back and front, side to side, and in spinning directions with the child trying to maintain his balance in all different directions.
214673771|NCT05782413|OTHER|The design exercise program|"A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand"
214934599|NCT02160028|OTHER|anesthetics and standard information before dental treatment|The standard information is short and concise, telling in neutral words what to expect.
214934600|NCT02384109|BEHAVIORAL|Shared decision-making with pharmacists|Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
214934601|NCT02384109|OTHER|Standard care from primary care providers|Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
214934602|NCT01796314|BEHAVIORAL|Therapeutic Educational Program|"The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.~These collective sessions focus on :~1. Knowledge of the disease~2. Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia~3. Crisis situations. Prevention of caregiver's exhaustion~4. Assistive devices and care pathways.~Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures."
214934603|NCT01402505|PROCEDURE|Transvaginal NOTES sleeve gastrectomy|transvaginal NOTES sleeve gastrectomy
214934604|NCT02719834|DRUG|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
214333587|NCT02014961|GENETIC|Whole-exome sequencing|Whole-exome sequencing (WES)
214333588|NCT00020410|BIOLOGICAL|filgrastim|
214333589|NCT00020410|PROCEDURE|peripheral blood stem cell transplantation|
214333590|NCT00020410|RADIATION|yttrium Y 90 monoclonal antibody B3|
214333591|NCT06569342|PROCEDURE|Intradetrusor BoNT-A|For intravesical injections, BoNT-A (Allergan, Irvine, CA, USA) was diluted in 0.9% saline to 10 93 international units/ml. Multiple injections were distributed throughout the detrusor, using a 94 transurethral 23-gauge injection needle under rigid cystoscopic guidance (9.8 Fr paediatric 95 cystoscope) at 10 units/kg to a maximum of 300 units. All injections were performed under general 96 anaesthesia with antibiotic prophylaxis given intra-operative as single dose intravenously.
214934605|NCT02719834|OTHER|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
214333592|NCT06572007|DIAGNOSTIC_TEST|Ultrasound|To investigate the thickness of the fascia tissue, the subjects will undergo an ultrasound examination using a clinical ultrasound system (S9, SonoScape Corporation, made in China) with a linear 5-14 MHz array of L14-5/38. The transducer with a cross-section of 6.24 cm2 will be aimed at points 2 cm lateral to the midline of the L2 and L3 vertebrae on both sides of the spine.
214333593|NCT02560129|OTHER|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
214673772|NCT03865407|DRUG|Allopurinol|Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
214934606|NCT05393934|OTHER|High dense nutrients formula|High dense nutrients formula: Powder based Infant formula with High Nutrients' Density with energy density of 100 kcal/100ml and for Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
214673773|NCT03877185|DIAGNOSTIC_TEST|Live birth rate|Live Birth Rate and Blastulation Rate according to the protocol of COS
214673774|NCT02117050|DRUG|Rebif®|Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
214673775|NCT04241003|DEVICE|SmartDrive Mx2+|Rear-mounted power assist
214673776|NCT04459299|DEVICE|Robotic-PCI (CorPath GRX System)|Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
214673777|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E2|The women undergoing Cesarean section are given high energy digestible food 300ml before surgery
214673778|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G2|The women undergoing Cesarean section are given glucose injection 300ml before surgery
214673779|NCT03747016|DIETARY_SUPPLEMENT|normal saline N2|The women undergoing Cesarean section are given normal saline 300ml before surgery
214673780|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E1|The women in delivery room are given high energy digestible food 300ml.
214934607|NCT05393934|OTHER|Pediatric Nutrition Care (PNC)|Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
214934608|NCT02519816|OTHER|Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.|
214673781|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G1|The women in delivery room are given glucose injection 300ml.
214673782|NCT03747016|DIETARY_SUPPLEMENT|normal saline N1|The women in delivery room are given normal saline 300ml.
214673783|NCT03855306|DRUG|Glibesyn|1 tablet contains 5 mg Glibenclamide
214673784|NCT03855306|DRUG|Daonil|1 tablet contains 5 mg Glibenclamide
214673785|NCT01140516|DRUG|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
214673786|NCT01140516|OTHER|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
214673787|NCT01645280|DRUG|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
214934609|NCT06712186|DRUG|Dexmedetomidine Group / Group D|In this study, the intervention involve administrating 0.5 mcg/kg of Inj dexmedetomidine intravenously over 10 min to patients in intervention group/group D 2 minutes prior to Endotracheal intubation using laryngoscopy aiming to asses its efficacy in attenuating the pressor response to laryngoscopy.
214934610|NCT06712186|OTHER|Normal Saline (Placebo)|The Placebo group / group C will be administer Normal Saline without any active medication over 10 min to patients, 2 minutes prior to Endotracheal intubation using laryngoscopy to compare its effect to those of Dexmedetomidine in attenuating the pressor response to laryngoscopy.
214934611|NCT05551689|DRUG|Psychostimulant|All enrolled patients should be receiving ADHD pharmacological treatment (psychostimulants)
214934612|NCT05551689|DEVICE|FOCUS ADHD App|FOCUS ADHD is a mobile health application to support ADHD treatment adherence, monitoring and psychoeducation. The App was developed by the Attention Deficit Hyperactivity Disorder Program (ProDAH) of the Hospital de Clínicas de Porto Alegre (HCPA) and the Federal University of Rio Grande do Sul (UFRGS)
214673788|NCT01645280|DRUG|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
215073061|NCT03549572|BEHAVIORAL|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
214333594|NCT01719965|OTHER|Interviews and Focus Group Discussions|
214333595|NCT00211081|DRUG|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
214333596|NCT02813031|OTHER|Functional meat products|
214333597|NCT02813031|OTHER|Traditional meat products|
214673789|NCT01645280|DRUG|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
214673790|NCT01645280|DRUG|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
214673791|NCT01645280|DRUG|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
214673792|NCT00916955|OTHER|Observation|Observe development of syndrome over time
214673793|NCT02723162|DRUG|Varenicline (VRN)|VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
214673794|NCT02723162|DRUG|N-Acetylcysteine (NAC)|NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
214673795|NCT02723162|DRUG|Placebo|Matched placebo
214934613|NCT06404944|PROCEDURE|implantation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech Implant EV Profile (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Placement healing abutment~4. Suturing the wound tightly"
215073062|NCT03017716|OTHER|Gluten free diet|The investigators will evaluate the effect of a gluten free diet (GFD) in IBP patients, randomly assigned to receive standard therapy for IBP or standard therapy for IBP plus GFD, for a period of at least one year.
215073063|NCT03957499|DRUG|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
215073064|NCT03957499|DRUG|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
215073065|NCT03957499|DRUG|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
215073066|NCT06179277|DEVICE|PrefGel® + Emdogain®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
215073067|NCT06179277|DEVICE|PrefGel®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
214333598|NCT06570967|DRUG|Methimazole(MMI)|The initial dose of methimazole was 0.2-0.8 mg/(kg▪d). This dose was subsequently reduced by 25% to 50% and adjusted to maintain euthyroidism, based on the results of serum thyroid hormone testing during follow-up.
214673796|NCT04174885|PROCEDURE|epicardial ablation|"In general anesthesia and left lung ventilation, authors will access the right thorax by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be visualized by trans esophageal echocardiography before the ablation."
214673797|NCT00973908|DRUG|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
214673798|NCT00973908|DRUG|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
214673799|NCT06024005|DRUG|Oral Solifenacin 5mg|Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
214673800|NCT06024005|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)|Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
214934614|NCT06404944|PROCEDURE|implantation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech OsseoSpeed® TX dental implant (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Guided bone regeneration with xenogeneic bone material Bio-oss® (Geistlich Pharma AG, Sweden) and collagen membrane Bio-Gide® (Geistlich Pharma AG, Sweden)~4. Suturing the wound tightly"
214673801|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
214934615|NCT04010864|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
214934616|NCT00223730|DRUG|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
214673802|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h|single application
214934617|NCT00223730|DRUG|Placebo|
214934618|NCT03566056|OTHER|Complications to Whipples procedure|Patients undergoing the Whipple procedure often tend to have a lot of complications. This study aims to investigate what complications these patients experience
214934619|NCT01844973|DRUG|M518101|Proper quantity twice a day
214333599|NCT01983800|DRUG|Isoflurane|
214333600|NCT01983800|DRUG|Propofol/midazolam|
214673803|NCT00234104|DRUG|OPC-41061(Tolvaptan)|
214673804|NCT02157272|DRUG|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
214673805|NCT05186558|DRUG|penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin|"Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~* Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~* lenalidomide: 10 mg, po, for 18 months."
214934620|NCT01844973|DRUG|Vehicle|Proper quantity twice a day
214934621|NCT01123772|DRUG|INO-8875|eye drops for 14 days in one eye
214934622|NCT01123772|OTHER|Placebo control|Matched placebo
214934623|NCT00002030|DRUG|Pentamidine isethionate|
214333601|NCT00917345|DRUG|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
214333602|NCT01332305|DRUG|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
214333603|NCT01332305|DRUG|Placebo|Placebo orally once daily
214333604|NCT04283734|DEVICE|iFR pullback with Syncvision software (Volcano company)|iFR pullback with Syncvision software permit us to analyze the vessel completely and to predict the physiological significance of every lesion and segment, to predict the benefit of the revascularization in terms of iFR improvement, and to predict the minimum stent length necessary to achieve this improvement.
214333605|NCT03615651|DIETARY_SUPPLEMENT|Probiotic|The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
214333606|NCT03615651|OTHER|Placebo|Placebo intervention.
214347196|NCT04463901|PROCEDURE|Limbal conjunctival autograft|A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
214673806|NCT04215354|DEVICE|Magnetic field|Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.
214934624|NCT06347445|OTHER|There is no intervention.|There is no intervention.
214934625|NCT01643798|PROCEDURE|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
214333607|NCT05501197|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
214333608|NCT05501197|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
214934626|NCT01643798|PROCEDURE|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
214934627|NCT02144636|DIETARY_SUPPLEMENT|herbalife protein shake|
214934628|NCT06471855|DEVICE|Multidisciplinary Conventional and Technology-based Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. According to their individualized rehabilitation project, patients will undergo non-immersive VR-based rehabilitation. VR-based rehabilitation will consist of one daily session (3 weeks) and will be conducted by the implementation of a single non-immersive VR device among the D-WallTM (TechnoBody SRL, Italy). Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants.
214333609|NCT02505516|OTHER|metformin|
214673807|NCT04215354|DEVICE|Virtual reality|Wii Fit plus machine which required balance board . It is a video game console designed by Nintendo 2009
214934629|NCT06471855|OTHER|Multidisciplinary Conventional Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to the patient's medical diagnosis, disability severity, and to consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
214934630|NCT06838871|BEHAVIORAL|Inspiratory Muscle Training (IMT) with Abdominal Drawing-In Maneuver (ADIM) training|"ADIM aims to enhance trunk stability by selectively activating the transversus abdominis. Participants begin in a supine position and practice drawing in their abdomen toward the spine while maintaining a stable trunk and pelvis. A therapist provides verbal instructions and manual guidance to ensure proper muscle activation.~IMT is performed using the Threshold RMT device (IMT, GH INNOTEK, Busan, South Korea). Participants wear a nose clip and start with 30% of Maximal Inspiratory Pressure (MIP), gradually increasing by 10% per week to reach 60% MIP by the final week. Each session consists of five sets of 10-15 repetitions, with a one-minute rest between sets."
214934631|NCT06838871|BEHAVIORAL|Sham Inspiratory Muscle Training (IMT) with Abdominal Drawing-In Maneuver (ADIM) training|Sham IMT with ADIM training performs the same ADIM protocol as the IMT with ADIM training but undergoes IMT with minimal resistance (0 cmH₂O) to prevent actual muscle strengthening. This design ensures that the effects observed can be attributed to IMT rather than ADIM.
214934632|NCT05045391|DIAGNOSTIC_TEST|Aspergillus IgG detection|Aspergillus IgG will be detected among pulmonary tuberculosis patients. 5 ml of vein blood will be collected for ELISA.
214934633|NCT01622205|OTHER|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
214934634|NCT01622205|OTHER|Ordinary rehabilitation|Ordinary rehabilitation
214934635|NCT05565781|DEVICE|ECG smartwatch|Testing ECG smartwatch to detect AF or potential signs of AF
214934636|NCT05565781|DEVICE|Insertable Cardiac Monitor (ICM)|Gold-standard cardiac monitor for comparison of testing device (ECG smartwatch)
214934637|NCT05565781|DEVICE|External ECG Monitoring|Regular cardiac monitor for diagnosis of AF
214934638|NCT03991923|DEVICE|XVIVO heart preservation devices|The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.
214934639|NCT03991923|DEVICE|Standard ICSS|Cold static preservation using standard preservation solution
214934640|NCT04178824|BEHAVIORAL|Discount Intervention|15% or 30% discount on fruits and vegetables
214673808|NCT00493948|DEVICE|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
214934641|NCT05651438|OTHER|Assessment|Assessment of pain, fatigue, sleep quality, and e-sports-specific features
215073068|NCT00676520|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
214333610|NCT01600040|RADIATION|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
214333611|NCT00129415|PROCEDURE|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
214333612|NCT00129415|PROCEDURE|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
214333613|NCT01163734|DRUG|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
214333614|NCT01163734|OTHER|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
214333615|NCT01152723|DRUG|Nicotine|2 mg, Single Dose
214333616|NCT01070927|DRUG|RO4929097|80mg po daily, 3 days on 4 days off schedule
214333617|NCT01070927|DRUG|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
214333618|NCT05663489|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|A concentrated and exposure-based psychological treatment over four consecutive days
214333619|NCT03888313|OTHER|Pretreatment group consultation|A consultation in group with several patients and one surgeon
214333620|NCT01083550|OTHER|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
214333621|NCT00734838|DEVICE|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
214673809|NCT01180140|DEVICE|Seamguard|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
214934642|NCT06188442|DRUG|DoxyODPrEP|Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex
214934643|NCT06188442|DRUG|DoxyPEP|Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
214934644|NCT05848882|DEVICE|Elastodontic Device|Removable device that embraces two dental archs
214934645|NCT03794661|DEVICE|Clinician programmer electrode screening mode tool|Provides a standardized workflow to guide clinicians or trained healthcare providers through the deep brain stimulation monopolar review screening process
214934646|NCT05542797|DRUG|Duphastone|dydrogesterone hormone
214934647|NCT01014897|DEVICE|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
214934648|NCT04810247|BEHAVIORAL|Body Project|The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised for use among adult women with weight/shape concern and higher body weight.
214934649|NCT04094272|DIAGNOSTIC_TEST|transthoracic doppler-echocardiography (TTE)|Transthoracic doppler-echocardiography (TTE) in patients with a new diagnosis of HCV before and after treatment with DAA medication.
214934650|NCT04773652|DIAGNOSTIC_TEST|speckle tracking echo|Two-dimensional and 3D Speckle tracking echocardiography and feature tracking CMR will be performed twice: within 48 hours of admission and 3 months following the index event.
214934651|NCT04932746|DRUG|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine or placebo) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~It begins with infusion of 4 ml within 10 minutes and then continues infusion, depending on the child's weight, at 1.6 ml / kg / h.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
214333622|NCT02360917|OTHER|Emerging from the Haze|A 6 week psycho-educational class
214333623|NCT00727389|BEHAVIORAL|Physiotherapy|Exercise two days a week for six month
214333624|NCT03294369|OTHER|Observational|This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
214673810|NCT05890638|DRUG|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
214673811|NCT05890638|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
214673812|NCT03120390|OTHER|Best Practice|Undergo usual care
214333625|NCT00966498|PROCEDURE|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
214333626|NCT04334603|OTHER|Exercise Training Program|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
214333627|NCT06107218|OTHER|Bioactive Glass Air Abrasion Particles.|Finishing of cavity walls by AquaCare Air Abrasion Device using Bioactive Glass Air Abrasion Particles.
214333628|NCT06107218|OTHER|Diamond Stone.|Finishing of cavity walls using Diamond Stone.
214673813|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo AE
214673814|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo RE
214673815|NCT03120390|OTHER|Laboratory Biomarker Analysis|Correlative studies
214673816|NCT03120390|DEVICE|Monitoring Device|Receive Polar heart rate monitor
214673817|NCT03120390|OTHER|Quality-of-Life Assessment|Ancillary studies
214333629|NCT00451425|BEHAVIORAL|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
214333630|NCT02205892|DRUG|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
214333631|NCT02205892|DRUG|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
214333632|NCT02929810|BEHAVIORAL|sleep extension|
214333633|NCT02929810|BEHAVIORAL|sleep maintenance|
214333634|NCT04713748|DEVICE|Tasso-SST on Demand|Participants will collect a small blood sample using the Tasso-SST OnDemand device during a serology blood draw visit already scheduled for the MURDOCK C3PI Study (Pro00105703). Participants will be provided a kit that includes written, step-by-step instructions that include pictures. Participants will also have the option to watch a brief video on using the device, available online, prior to collection. Both blood samples will be spun and processed for serum. Serum will be frozen and shipped to the lab at Duke for antibody testing. Antibody results will be compared between the two methods.
214333635|NCT04713748|OTHER|Regular Phlebotomy|Participants will have a small blood sample collected via regular venipuncture.
214333636|NCT00113516|DRUG|carboplatin|AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
214934652|NCT04932746|DRUG|Placebo|The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
214673818|NCT03120390|OTHER|Questionnaire Administration|Ancillary studies
214333637|NCT00113516|DRUG|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
214333638|NCT00113516|DRUG|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
214673819|NCT01411293|OTHER|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
214673820|NCT01411293|OTHER|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
214934653|NCT02472743|DEVICE|Custom-built phototherapy lamp|Described in the arm description
214934654|NCT02262598|DRUG|Telmisartan|
214333639|NCT02772016|DRUG|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
214333640|NCT03023735|OTHER|None. This is an observational study|
214333641|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type A mouldable adhesive|
214333642|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type B mouldable adhesive|
214333643|NCT03160430|DRUG|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
214333644|NCT03160430|DRUG|Placebos|matching placebo capsule
214333645|NCT01368458|OTHER|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
214333646|NCT00642304|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
214934655|NCT02262598|DRUG|Hydrochlorthiazide (HCTZ)|
214934656|NCT02262598|DRUG|Telmisartan/HCTZ fixed dose|
214934657|NCT00984061|DRUG|colchicine|0.6mg tablet administered at 9am on Day 1
214934658|NCT00984061|DRUG|clarithromycin|250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)
214934659|NCT00984061|DRUG|colchicine|0.6 mg tablet administered at 9am on Day 29
214333647|NCT01646671|DRUG|LCZ696|LCZ696 200 mg tablet once daily
214333648|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
214333649|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
214333650|NCT04475445|OTHER|Ultrasound-guided transforaminal epidural steroid injection|Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
214673821|NCT05130190|DEVICE|RF Treatment|ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
214934660|NCT06388863|DRUG|Healthy donor-derived FMT capsule|Participants will be treated with healthy donor-derived fecal microbiota transplantation in the form of oral capsules.
214934661|NCT06388863|DRUG|Placebo capsule|Capsules whose appearance and smell are identical as FMT capsules but contain milk powder
214934662|NCT05525585|DIETARY_SUPPLEMENT|Early HMF|Mom's milk or donor milk will be fortified between postnatal day 4 and 7
214934663|NCT05525585|DIETARY_SUPPLEMENT|Delayed HMF|Mom's milk or donor milk will be fortified between postnatal day 10 and 14
214934664|NCT05838742|DRUG|GSK3858279|GSK3858279 will be administered.
214934665|NCT05838742|DRUG|Placebo|Placebo will be administered.
214333651|NCT04475445|OTHER|Interlaminar epidural steroid injection|Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
214333652|NCT00982189|DRUG|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
214934666|NCT05896553|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
214934667|NCT05896553|DRUG|intranasal Placebo|Administration of intranasal Placebo
214934668|NCT06653465|DRUG|Acetaminophen|Acetaminophen, which has similarly effects with NSAIDs in terms of inhibition of cyclooxygenase COX1, COX2 and COX3, is widely used as adjuvant for perioperative multimodal analgesia.
214934669|NCT06653465|DRUG|Saline|Saline, a kind of crystalloid widely used in clinical treatment.
214934670|NCT05935007|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study.
214333653|NCT00982189|DRUG|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
214333654|NCT05932316|DIAGNOSTIC_TEST|spirometry|participants will undertake spirometry testing before and after bronchodilators and placebo
214934671|NCT04695262|PROCEDURE|EUS-FNB|Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB)
214934672|NCT04236518|BEHAVIORAL|Diets with either predominantly animal protein sources.|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from animal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
214934673|NCT04236518|BEHAVIORAL|Diets with predominantly plant protein sources|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from vegetal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
214934674|NCT05803213|OTHER|Virtual Reality 360 interactive video|Clinical scenarios revised and presented with 360 video, and interactive design on the learning platform that is available anytime and anywhere to the medical students
214934675|NCT05803213|OTHER|Traditional mini-lecture|Clinical scenario described according to the script as a mini-lecture to the medical students
214934676|NCT05365646|DEVICE|Hearing aids equipped with motion sensing abilities|Participants will wear hearing aids that will assess their movement, and fall risk.
214934677|NCT01240980|DRUG|BMS-903452|Solution, Oral, 0.1 mg, once daily, 1 day
214934678|NCT01240980|DRUG|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
214934679|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 3.0 mg, once daily, 1 day
214934680|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
214934681|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 30 mg, once daily, 1 day
214333655|NCT05932316|DRUG|Salbutamol|Salbutamol inhalation to determine bronchodilator response
214333656|NCT05932316|DRUG|placebo|placebo inhalation prior to repeating spirometry
214333657|NCT02074735|DRUG|Placebo|Inactive ingredient matching the active comparator in appearance
214333658|NCT02074735|DRUG|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
214333659|NCT03754257|PROCEDURE|Experimental Electrical Stimulation|Experimental Electrical Stimulation (100Hz) during 40 minutes
214934682|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 60 mg, once daily, 1 day
214934683|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
214934684|NCT01240980|DRUG|Placebo|Solution, Oral, 0 mg, once daily, 1 day
214934685|NCT01240980|DRUG|Placebo|Suspension, Oral, 0 mg, once daily, 1 day
214934686|NCT01240980|DRUG|BMS-903452|Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
214934687|NCT01240980|DRUG|BMS-903452|Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
214934688|NCT01240980|DRUG|Placebo|Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
214934689|NCT01240980|DRUG|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
214934690|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
214934691|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
214934692|NCT06215924|OTHER|Reverse Kegel exercise|In addition to the training given by the physician, patients will be taught the 'Reverse Kegel' exercise. The 'Reverse Kegel' exercise is an exercise that is used to relax the pelvic floor muscles. To practice the exercise, patients will be asked to lie in a supine position with a support under the knees. In this position, patients will be asked to relax the pelvic floor muscles while breathing through their nose, maintain this movement for 5 seconds, and tighten the pelvic floor muscles while exhaling. Patients will be advised to do this exercise for 5 sets, 10 repetitions during the day. On the day of the training, initial evaluations will be made to the patients before the exercise training is given. Evaluations will be repeated at the end of the second and fourth week.
215073069|NCT05483257|DEVICE|Multigene panel for next-generation sequencing|HLA-I genotyping based on next-generation sequencing for prognosis evaluation
215073070|NCT01425359|DRUG|Ranolazine|
215073071|NCT01425359|DRUG|Ranolazine placebo|
215073072|NCT04678986|OTHER|ER2|No intervention, data analysis only
215073073|NCT00338208|BEHAVIORAL|Training in the Use of Low Vision Devices|
215073074|NCT04419051|OTHER|Owlet Band|The Owlet Band is a wearable fabric band pregnancy tracker made up of small sensors that are able to detect natural low-level electrical signals normally produced by the mother's heart and baby's (fetal) heart.
214333660|NCT03754257|PROCEDURE|Sham Electrical Stimulation|Sham Electrical Stimulation (5Hz) during 40 minutes
214333661|NCT03754257|OTHER|Conventional Physiotherapy|Active and passive exercises, and walking.
214333662|NCT00812812|DRUG|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
214333663|NCT00812812|DRUG|paroxetine 20mg tablet|1 tablet once a day
214333664|NCT00812812|DRUG|matched placebo to paroxetine 10mg|2 tablets once a day
214333665|NCT00812812|DRUG|matched placebo to paroxetine 20mg|1 tablet once a day
214333666|NCT00471601|BEHAVIORAL|counseling intervention|
214333667|NCT00471601|BEHAVIORAL|questionnaire administration|
214333668|NCT00471601|BEHAVIORAL|psychosocial assessment and care|
214333669|NCT00471601|BEHAVIORAL|quality-of-life assessment|
214333670|NCT02721589|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
214333671|NCT01646034|DRUG|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
214333672|NCT01646034|DRUG|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|"* chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~* chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~* previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~* previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
215073075|NCT03525184|OTHER|Additional protein and multi-nutrient beverage|During SR+, participants will consume a multi-nutrient beverage and additional protein (\~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of \~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C \& D, zinc and omega-3 fatty acids (DHA and EPA).
214673822|NCT02703116|BEHAVIORAL|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
214673823|NCT02703116|BEHAVIORAL|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
214673824|NCT02282332|DRUG|Ticagrelor|
215073076|NCT03525184|OTHER|Placebo beverage|The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
215073077|NCT05460052|OTHER|Physical activity training program|"The physical activity training program will consist of 3 sessions per week for 6 weeks :~* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital~* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference."
214673825|NCT04096937|OTHER|Focus groups|Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.
214673826|NCT03558321|PROCEDURE|Hysteroscopic guided fractional curretage|Under general anaesthesia , evaluation of the endometrial cavity was done followed by biopsy of the whole endometrial tissue
214673827|NCT03558321|PROCEDURE|total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection|Through abdominal incision , removal of the whole uterus , both tubes and ovaries and in some cases pelvic lymph nodes removal was done
214333673|NCT06535581|PROCEDURE|surgery patient|patients with hypertension (group 2) and without (group 1) hypertension. The predictive ability of postoperative pain as a tool for measuring and assessing pain was examined by analysing the relative change in the Perfuston index.
214333674|NCT05937022|DEVICE|Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.
214333675|NCT05937022|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to the sham control group will receive 30 seconds of active stimulation over brain regions identical to either the left DLPFC or the right VLPFC experimental tDCS group.
214333676|NCT00529945|DEVICE|PFx Closure System|
214333677|NCT00351780|DEVICE|FFR measurement, side branch angioplasty|
214333678|NCT06136520|BEHAVIORAL|Baby massage|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
214333679|NCT03755765|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
214333680|NCT03755765|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
214333681|NCT03755765|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
214333682|NCT04800185|DRUG|Crisaborole 2% Top Oint|To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment
214347197|NCT04532892|DIETARY_SUPPLEMENT|Meta 18.06 Day and Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
214333683|NCT04800185|GENETIC|Skin Microbiome Swabs|At the baseline visit the investigator will identify sites for swabbing the skin including one affected distinct crisaborole-treated AD lesion, and one untreated AD lesion. The lesions will both be sampled at baseline, 14 days into treatment, 28 days into treatment, 3 months into treatment, and 4 weeks after treatment completion. Photographs of each lesion will be taken for reference. Skin swabs will be obtained in a sterile fashion using a BD Culture SwabsTM EZ Collection and Transport System (or equivalent) and soaked with sterilized 0.15 M NaCl and 0.1% Tween-20. The samples will be frozen at -80 C, kept at this temperature, and stored until analysis may be completed.
214333684|NCT02503280|DRUG|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\^8 (200 million) hMSCs.
214333685|NCT02503280|DRUG|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
214333686|NCT02503280|DRUG|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline \[PBS\] and 1% human serum albumin \[HSA\]).
214333687|NCT02503280|DEVICE|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
214333688|NCT04536844|DEVICE|Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)|An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
214934693|NCT06215924|OTHER|Postisometric Relaxation Technique|In addition to training given by the physican, internal digital Postisometric Relaxation method will be applied to the patients in this group from the anal region. Application will be made to the muscles where muscle spasm, movement restriction and pain are detected. The patient will be asked to perform a contraction against the digital resistance with maximum force and maintain this contraction for 5 seconds, actively relax after 5 seconds. During relaxation, stretching will be applied for 30 seconds by digitally supporting the movement of the pelvic floor muscles. The process will be performed with 5 repetitions. The application will be made 2 days a week for 4 weeks. On the day of the training, initial evaluations will be made to the patients before the exercise training is given.Evaluations will be repeated at the end of the second and fourth week.
214934694|NCT03519451|OTHER|Internet-Based Intervention|Given KickAsh smartphone mobile application
214934695|NCT03519451|OTHER|Internet-Based Intervention|Given Breathe2Relax smartphone mobile application
214934696|NCT03519451|OTHER|Questionnaire Administration|Ancillary studies
214934697|NCT02455258|OTHER|Dance/Movement Therapy (DMT)|Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.
214934698|NCT02455258|OTHER|Aerobics Exercise (AE)|The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
214934699|NCT06619158|PROCEDURE|Crown modification|Zirconia glaze removal and polish after crown removal to reduce roughness and prohibit plaque adhesion
214934700|NCT06666751|PROCEDURE|Cataract plus Microstent surgery|Both the Hydrus microstent and iStent Inject W are used in combination with cataract surgery, in order to help lower intraocular pressure for patients with open-angle glaucoma. The microstent is a small flexible device that is inserted into the eye during cataract surgery in order to improve the outflow of fluid from the eye.
214934701|NCT05296954|PROCEDURE|high resolution cartography|High-resolution electro-anatomical mapping will be performed in each group with the RHYTHMIA HDx system to obtain an activation and voltage map of the Koch triangle and surrounding areas.
214934702|NCT02075528|DRUG|Paliperidone ER|9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
214934703|NCT04197674|OTHER|Dialysis modality|This is a observational cohort study, and there is no intervention for all participants. Our aim is to evaluate dialysis modality (PD and HD) on patient survival
214934704|NCT00614120|DRUG|liraglutide|0.6 mg/day, s.c. (under the skin) injection
214934705|NCT00614120|DRUG|placebo|Glimepiride placebo, capsules
214934706|NCT00614120|DRUG|liraglutide|1.2 mg/day, s.c. (under the skin) injection
214934707|NCT00614120|DRUG|liraglutide|1.8 mg/day, s.c. (under the skin) injection
214934708|NCT00614120|DRUG|glimepiride|Capsules, 4.0 mg/day
214934709|NCT00614120|DRUG|metformin|Tablets, 1.5-2.0 g/day
214934710|NCT00614120|DRUG|placebo|Liraglutide placebo, s.c. (under the skin) injection
214934711|NCT03030144|OTHER|Evidence based nursing recommendations|The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
214934712|NCT03578458|OTHER|subjects will install a mobile app for use|novel mobile application
214333689|NCT04536844|OTHER|Conventional prescheduled follow-up|Patients will be followed in the outpatient clinic by prescheduled follow-up
214333690|NCT05991141|OTHER|Apnea|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.
214333691|NCT05991141|OTHER|Control Intervention|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
214333692|NCT05437146|BEHAVIORAL|puppet|pain and fear during blood collection
214673828|NCT06969781|DEVICE|MWA|Enrolled participants undergo microwave ablation (MWA) after comprehensive assessment of lesion location, size, and individual condition. CT or other imaging modalities are used to monitor changes in the ablation zone. The puncture needle is appropriately distributed within the lesion based on its morphology, and ablation duration is determined by imaging-confirmed coverage of the lesion. All procedures are performed under general anesthesia. Ablation time, power, and cycles are recorded intraoperatively, with continuous ECG monitoring throughout. Immediate post-procedure chest CT or other imaging is performed to document intraoperative complications (e.g., pneumothorax, bleeding). Participants are routinely observed for 24 hours post-procedure, followed by CT re-examination and documentation of any complications.
214673829|NCT06969781|DRUG|TKI|"1. Study Drug: Furmonertinib (Shanghai Allist Pharmaceuticals Co.,Ltd.);~2. Administration: Oral, 80 mg once daily. In the MWA-TKI group, targeted therapy is initiated post-MWA if no significant complications occur, continuing for up to 24 months without severe toxicity. In the TKI-MWA-TKI group, a 3-month induction with Furmonertinib is followed by CT re-evaluation; if no contraindications are present, MWA is performed, and targeted therapy resumes post-procedure, continuing for up to 21 months without severe toxicity."
214673830|NCT06969729|PROCEDURE|Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)|Implantation of a physician-modified fenestrated stent-graft using a patient-specific 3D-printed aortic template, performed via an endovascular approach.
214673831|NCT06971809|BEHAVIORAL|Pain resilience|A strengths-based approach to pain recovery
214934713|NCT05026099|OTHER|Boxing training|Boxing training: warm-up. Mitt hitting, sandbag hitting, in sitting, cool down, Assessment after 4 weeks boxing training: warm-up. Mitt hitting, sandbag hitting, below hips, cool down, Assessment after 6 weeks Boxing training: warm-up. Mitt hitting, sandbag hitting, both inn sitting and standing, cool down, Post assessment
214934714|NCT05026099|OTHER|Task Oriented Training|Task-oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 4 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 6 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Post assessment
214333693|NCT03091751|DRUG|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
214333694|NCT04455893|OTHER|Stratified Transplant Survival|The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs. Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ. excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
214333695|NCT00772174|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
214333696|NCT00772174|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
214333697|NCT06564376|DIAGNOSTIC_TEST|total magnesium|Treatment based on total Magnesium
214333698|NCT06564376|DEVICE|ionized magnesium|Treatment based on ionized magnesium
214333699|NCT05508529|DIETARY_SUPPLEMENT|Chaga Mushroom|Effect of chaga on immune/mood support
214333700|NCT05508529|DIETARY_SUPPLEMENT|Algae Extract|Effect of algae extract on immune/mood support
214333701|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil|Effect of black cumin seed oil on immune/mood support
214333702|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Astaxanthin|Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support
214333703|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Omega 3|Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support
214333704|NCT05508529|DIETARY_SUPPLEMENT|Placebo|Placebo control
214333705|NCT05115383|OTHER|VO2 Max test|The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.
214333706|NCT01161329|OTHER|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
214673832|NCT06971809|BEHAVIORAL|Pain education|A health literacy approach
214934715|NCT05069142|OTHER|Rehabilitation|Pre- and post-operative exercise and education.
214934716|NCT06664320|PROCEDURE|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
214934717|NCT06664320|DRUG|hydroxyethyl starch (HES 130/0.6)|hydroxyethyl starch (HES 130/0.6)
214934718|NCT02946073|DRUG|buprenorphine|
214934719|NCT02946073|OTHER|Placebo|
214934720|NCT03663465|OTHER|Hawthorn|Hawthorn tablet
214934721|NCT03663465|DRUG|SGAs|SGAs tablet
214934722|NCT04495504|DRUG|Ropivacaine|Administration of a bolus dose of 10 ml of ropivacaine 7, 5 mg/mL in each catheter Continuous infusion of ropivacaine 2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.
214333707|NCT05279521|BEHAVIORAL|pulmonary rehabilitation exercise|The lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
214333708|NCT00678691|DRUG|armodafinil|50-250mg/d
214934723|NCT03096769|OTHER|Ergonomist|The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
214934724|NCT02529904|BIOLOGICAL|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
214934725|NCT02454712|DRUG|PF614|PF614 is an oxycodone prodrug
214673833|NCT06969885|BEHAVIORAL|Intervention application with virtual reality glasses|In the preoperative period, approximately 1 hour before the procedure, a video will be watched for 15 minutes with virtual reality glasses. Approximately 10 minutes before the procedure, the patients will be administered the Physiological Parameters Monitoring Form, Distress Thermometer and VAS, and the data collection process will be completed.
214333709|NCT00678691|DRUG|placebo|matching placebo
214333710|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
214333711|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
214333712|NCT01529528|DRUG|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
214333713|NCT01689896|DRUG|Testosterone Gel|
214333714|NCT01689896|DRUG|Placebo Gel|
214934726|NCT02454712|DRUG|Oxycodone extended-release|Oxycodone extended-release is the comparator drug
214934727|NCT02454712|DRUG|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers
214333715|NCT01150838|DRUG|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
214333716|NCT02215590|DEVICE|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week."
214333717|NCT05315271|DRUG|Bupivacaine-ketamine injection|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
214486337|NCT06752044|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
214486338|NCT06754865|DRUG|Xiyanping injection+ antibiotic|Xiyanping injection+ antibiotic
214486339|NCT06754865|DRUG|Antibiotic|Antibiotic
214934728|NCT04376125|OTHER|Suboccipital inhibition in tension headache|Deep maneuver of myofascial induction in the suboccipital muscles
214934729|NCT05342922|PROCEDURE|Ultrasound group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
214934730|NCT05342922|PROCEDURE|Landmark group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
214934731|NCT05803096|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.
214333718|NCT05315271|DRUG|Bupivacaine injection with intravenous ketamine infusion|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
214333719|NCT05232448|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation and the development of personal coping strategies that target solving current problems.
214486340|NCT06745193|DRUG|chidamide+Camrelizumab+Apatinib|chidamide+Camrelizumab+Apatinib
214486341|NCT06745193|DRUG|Irinotecan or Docetaxel or Paclitaxel|Irinotecan Docetaxel Paclitaxel
214673834|NCT06969885|BEHAVIORAL|Standard application|No intervention will be made to the patients outside of the hospital routine, and approximately 10 minutes before the procedure, the Physiological Parameters Monitoring Form, Distress Thermometer and VAS will be applied again and the data collection process will be completed.
214673835|NCT06972251|BEHAVIORAL|TARDIS Photo Elicitation|Using visual-based qualitative methods to help identify and more robustly describe DD in Veterans.
214934732|NCT05803096|OTHER|Oxygen|Oxygen will be administered at 10 Liters/min for the duration of prostate biopsy.
214934733|NCT01655849|DRUG|z160|
214934734|NCT01655849|DRUG|Placebo|
214934735|NCT04865549|PROCEDURE|SNB + TAD + Lymphadenectomy|Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
214333720|NCT00653107|PROCEDURE|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
214333721|NCT00653107|RADIATION|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
214333722|NCT00653107|RADIATION|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
214333723|NCT04122833|OTHER|Next generation sequencing|observational study
214333724|NCT02894203|BEHAVIORAL|Mindfulness|
214333725|NCT02894203|BEHAVIORAL|Yoga|
214333726|NCT00367263|DRUG|Alvesco (Ciclesonide) 160 ug/day|
214333727|NCT03952533|DIETARY_SUPPLEMENT|Dav|Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
214333728|NCT06176833|PROCEDURE|Body Weight Supported Treadmill Training|For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
214333729|NCT01112085|DRUG|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
214934736|NCT04211532|OTHER|Surgery|Surgical risk is calculated according to the surgery performed.
214934737|NCT03602391|BEHAVIORAL|SCP Plus|The primary goal of the proposed project is to develop an in-home psychoeducational intervention (Senior Companion Program Plus, or SCP Plus) that is accessible, affordable, and sustainable for low-income African American ADRD caregivers. A weekly, 60 minute psychoeducational module will be delivered face-to-face across 9 weeks and will focus on education about ADRD, behavior management, communication skills, and aspects of providing care that enhance meaning such as spirituality. In order to provide an accessible intervention that is potentially sustainable, Senior Companions will be trained to provide the intervention in the homes of the African American ADRD caregivers.
214673836|NCT06972251|BEHAVIORAL|TARDIS Intervention|Design \& pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with T2D, to promote engagement in self-management behaviors.
214333730|NCT01112085|DRUG|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
214333731|NCT00354224|DRUG|capecitabine|
214333732|NCT00354224|DRUG|oxaliplatin|
214333733|NCT00058331|BIOLOGICAL|epoetin alfa|
214333734|NCT03624361|DEVICE|Glaucoma device implantation in a stand-alone procedure|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
214333735|NCT03162861|DRUG|sevoflurane inhalation for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
214333736|NCT03162861|DRUG|propofol for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
214333737|NCT01599650|DRUG|Ranibizumab|
214333738|NCT01599650|PROCEDURE|Laser|laser photocoagulation
214934738|NCT00227630|DRUG|cisplatin|
214934739|NCT00227630|DRUG|pemetrexed disodium|
214333739|NCT00491686|DRUG|AZD6765|intravenous infusion
214333740|NCT04549740|DIAGNOSTIC_TEST|salivary alpha amylase level measurement|Saliva samples will be obtained to estimate salivary alpha amylase
214333741|NCT03402243|OTHER|Menthol ban on cigarettes|Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes
214333742|NCT03402243|OTHER|Menthol ban on cigarettes and e-cigarettes|Participants will have neither menthol flavored cigarettes or e-cigarettes available
214333743|NCT03402243|OTHER|No menthol ban|Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
214333744|NCT03767491|DEVICE|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
214333745|NCT04163393|PROCEDURE|Percutaneous Coronary Intervention|PCI with robotic assistance
214333746|NCT04163393|DEVICE|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
214673837|NCT02820259|DRUG|Tacrolimus|
214673838|NCT03304951|DEVICE|Sinopsys® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid access.
214673839|NCT01568411|DRUG|TD-1211|Period 1
214673840|NCT01568411|DRUG|TD-1211+ itraconazole|Period 2
214673841|NCT01716169|DEVICE|Helicoll|Helicoll Collagen I Wound Dressing
214673842|NCT01716169|DEVICE|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
214673843|NCT03444025|DRUG|Goserelin|Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.
214673844|NCT00005037|DRUG|temozolomide|
214934740|NCT00227630|PROCEDURE|adjuvant therapy|
214934741|NCT00227630|PROCEDURE|conventional surgery|
214934742|NCT00227630|PROCEDURE|neoadjuvant therapy|
214934743|NCT00227630|RADIATION|radiation therapy|
214934744|NCT01588457|DRUG|Lithium|Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).
214934745|NCT01588457|DRUG|Divalproex|DV will be dosed to attain DV levels of ≥45mg/L.
214934746|NCT01588457|DRUG|Lamotrigine|LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
214333747|NCT06532903|OTHER|Selective muscle electrostimulation with exponential current|An electroevaluation will be performed, with an exponential current generator equipment, using Meditea® brand Neuromatic 700 equipment, which consists of a first application of the current, the pulse width (in milliseconds) in which a contraction is achieved will be sought. frank, visible and selective of the facial muscle that is being stimulated. The purpose is to identify the pulse width and the lowest intensity to obtain a frank, visible and selective contraction, understood as the best quality.
214934747|NCT01588457|DRUG|Quetiapine|QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
214934748|NCT03205735|DIAGNOSTIC_TEST|lymphocyte DPD dosage|lymphocyte DPD dosage in peripheral blood
214333748|NCT06532903|OTHER|Facial muscle reeducation in front of the mirror|"Muscle re-education: Symmetrical facial movements will be requested, activating the muscles of the affected side, avoiding the participation of the unaffected side. We will work with the patient sitting in front of a mirror, asking him to perform the following actions or gestures: raise his eyebrows, frown, close his eyes (tightly and blink), smell an unpleasant odor, show his fangs, blow a kiss, blow , fake smile (lip corner pulled back horizontally), frank smile (lip corner pulled back and up, showing teeth), kiss and pout. The functional capacity of the mouth will be trained, inflating the cheekbones and moving the air from one side to the other, avoiding compensations. Depending on the degree of facial dysfunction and its condition, the kinesiologist will perform a stretch reflex, facilitation of movement and/or inhibition of it. Three series of five repetitions of each gesture described will be done."
214333749|NCT03393611|DRUG|CPX-351|Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17
214333750|NCT03393611|DRUG|Fludarabine|Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)
214333751|NCT03393611|DRUG|Melphalan|Melphalan 140 mg/m2 (Day -2)
214333752|NCT03393611|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin|Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)
214333753|NCT03393611|BIOLOGICAL|Haplo-Cord Stem Cell Transplantation|Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
214333754|NCT06533605|DRUG|SSGJ-706|Bispecific antibody
214333755|NCT01318564|DRUG|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
214333756|NCT01318564|BEHAVIORAL|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
214333757|NCT01136824|OTHER|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic \& health Trait anxiety Quality of life Nausea Expectations Anxiety \& total mood disturbance Nausea \& vomiting Multiple symptoms"
214333758|NCT03691038|DRUG|Pregabalin 75mg bid|Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
214673845|NCT00005037|DRUG|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
214934749|NCT00293124|DRUG|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
215073078|NCT05460052|OTHER|Weekly phone call.|Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.
215073079|NCT05460052|OTHER|Personalized training plan.|After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.
214333759|NCT03691038|DRUG|Pregabalin 25mg, 50mg|Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
214673846|NCT01088412|DRUG|Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)|Dose, frequency and duration at discretion of attending physician.
214673847|NCT02700581|PROCEDURE|low PEEP conventional ventilation|
214673848|NCT02700581|PROCEDURE|moderate PEEP conventional ventilation|
214673849|NCT02700581|PROCEDURE|low PEEP protective ventilation|
214673850|NCT02700581|PROCEDURE|moderate PEEP protective ventilation|
214673851|NCT02031900|DEVICE|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
214673852|NCT01656616|DRUG|Cyanide antidote administration|
214673853|NCT02236585|PROCEDURE|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
214673854|NCT02236585|PROCEDURE|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
214934750|NCT02721524|PROCEDURE|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
215073080|NCT06367686|DEVICE|IscAlert sensor|Insertion of an IscAlert sensor at the nasal mucosa
215073081|NCT02959541|DRUG|Leucovorin|
214333760|NCT06170333|DRUG|8% sulphur and A. vera soap|Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
214333761|NCT02155439|DRUG|5-fluorouracil|antimitotic drug
214333762|NCT02155439|DRUG|Triamcinolone|
214486342|NCT06752447|DRUG|LNF2007|"LNF2007，9 dose groups:0.2μg/kg、1μg/kg、5μg/kg、20μg/kg、60μg/kg、120μg/kg、240μg/kg、360μg/kg、540μg/kg（0.2\~5μg/kg for accelerated titration, and i3+3 ramp-up starting from 20μg/kg dose group），IV, infusion time 60min±10min, Q4W, until disease progression 、intolerable toxicity or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first."
214486343|NCT06755905|PROCEDURE|ICGL-guided treatment|Indocyanine green lymphography guided resection combined with sclerotherapy
214673855|NCT01948934|PROCEDURE|Amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
214673856|NCT05938088|DRUG|Arm I (mirogabalin group)|Take two capsules of Mirogabalin 5 mg within 30 minutes before going to the operating room. Patients take 5 mg of mirogabalin twice daily at 12-hour intervals until POD 7 days.
214934751|NCT00516191|DRUG|Liposomal Doxorubicin/Melphalan/Bortezomib|"Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV~The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)"
214934752|NCT02032862|DRUG|Sage extract, 3400 mg , DER 1:17|
214934753|NCT00819780|DRUG|Panitumumab|Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
214934754|NCT00819780|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
214934755|NCT00819780|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
214673857|NCT05938088|DRUG|Arm II (placebo group)|It is performed in the same way as Arm l.
214673858|NCT06971029|DIETARY_SUPPLEMENT|Supplementation with Verisol®|Supplementation with Verisol® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.
214673859|NCT06971029|DIETARY_SUPPLEMENT|Supplementation with Peptech® 2.5G|Supplementation with Peptech® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.
214673860|NCT06971029|DIETARY_SUPPLEMENT|Supplementation with Peptech® 10.0G|Supplementation with Peptech® collagen will be administered at a dose of 10.0 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.
214673861|NCT06971029|DIAGNOSTIC_TEST|Control group|The control group will not receive supplementation.
214934756|NCT01793688|DRUG|Sulbactam Sodium/Ampicillin Sodium|"Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency))."
214673862|NCT06970379|OTHER|T-PRF|Patients received T-PRF placement at the fracture line.
214673863|NCT06970379|OTHER|T-PRF and Laser biomodulation|Subjects underwent the process of bio-stimulation of the fracture line using low-level laser therapy. Wavelength \[λ\]: 660 nm, Power: 100 mW, Spot size \[Ø\]: 0.06 cm2, and for 60 seconds
214333763|NCT03646422|OTHER|Registry of patients (exposure is Cutaneous Lymphoma)|
214333764|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT|Standard approach for SMC strategy used by the Ministry of Health (without directly-observed therapy) and without any interference of the study team. Implemented over 4 rounds, carried out in June-October 2023 with \~30 days between rounds.
214333765|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT|SMC will be implemented with the same number of rounds and the same timing as in active comparator arm but village health workers will visit the participants at home to administer each dose of study treatment (with DOT-directly-observed therapy)
214486344|NCT06755905|PROCEDURE|Conventional Treatment group|Resection with sclerotherapy
214486345|NCT06753890|DRUG|Changkang granules|7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
214486346|NCT06753890|DRUG|Changkang Granules placebo|7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
214486347|NCT06755346|DRUG|Cannabis plant (THC 20mg)|Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
214486348|NCT06755346|DRUG|Cannabis (0%/ THC / 0% CBD)|THC (0%) / CBD (0%) - Placebo marijuana
214486349|NCT06755346|DRUG|Cannabis plant (THC 40mg)|Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
214673864|NCT04914286|DRUG|GFH018|Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.
214673865|NCT04914286|DRUG|Toripalimab|Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
214486350|NCT06762145|DRUG|Methylprednisolone (Corticosteroid)|Intravenous Methylprednisolone 1mg/kg/d for 3 days started from the day on TAVR
214486351|NCT06762145|DRUG|Placebo|Placebo for 3 days started from the day on TAVR
214934757|NCT01753661|BEHAVIORAL|Linguistic Feedback Report|Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings
214934758|NCT01753661|BEHAVIORAL|Multimedia Education Sessions|Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.
214934759|NCT01753661|BEHAVIORAL|EI-As-Usual|The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
214333766|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT|SMC will be implemented as in arm 2 but age of participants is extended up to 10 years: each dose of study treatment (with DOT-directly-observed therapy) distributed at home by village health workers.
214333767|NCT05168007|DRUG|WID-RGC20(Cariprazine) 3mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
214333768|NCT05168007|DRUG|WID-RGC20(Cariprazine) 6mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
214333769|NCT05168007|DRUG|Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day|The placebo comparator is administered during the double-blind treatment period(6 weeks).
214333770|NCT03284216|PROCEDURE|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion."
214333771|NCT03284216|PROCEDURE|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
214486352|NCT03875001|DRUG|Placebo|For each dose group a placebo group was given matching placebo tablets, participants were randomized within each dose group in a 3:1 ratio (active drug:placebo), tablets taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
214486353|NCT03875001|DRUG|Dose group 1 - 50 mg BI 1358894|2 film-coated tablets of 25 milligram (mg) BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
214486354|NCT03875001|DRUG|Dose group 2 - 100 mg BI 1358894|1 film-coated tablet of 100 milligram BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
214486355|NCT03875001|DRUG|Dose group 3 - 200 mg BI 1358894|2 film-coated tablets of 100 milligram BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
214486356|NCT05680298|DRUG|Dupilumab|solution for injection, Subcutaneous injection
214486357|NCT06492057|DEVICE|Electromyostimulation (EMS)|EasymotionSkin body suit for digitally controlled electric impulses via Easymotion-2 software on crew iPad (frequency, impulse rate, duration) are transferred from integrated dry electrodes of the EMS- stimulation suit to activate surface muscle groups of the body (trunk), arms and legs
214934760|NCT02255318|DEVICE|Taurolock|
214934761|NCT02255318|DRUG|Placebo|
214333772|NCT03284216|BEHAVIORAL|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
214333773|NCT00431457|DEVICE|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
214934762|NCT05156762|PROCEDURE|Bariatric surgery|Patients randomized to the bariatric surgery study arm will undergo either a laparoscopic sleeve gastrectomy or a laparoscopic gastric bypass - this decision would be a joint decision made between the study participant and the bariatric surgeon after consideration of the patient's overall goals with weight loss and discussion of the risks and benefits of each procedure.
214333774|NCT00431457|PROCEDURE|amygddohyppocampertomy|Resective surgery
214333775|NCT04563312|PROCEDURE|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
214333776|NCT00684424|OTHER|Non-Interventional Study|Observational Only
214486358|NCT06492057|DEVICE|Myoton|The non-invasive Myoton technology collects data from passive muscle properties (tone and stiffness) obtained from selected anatomical surface muscle groups
214486359|NCT06492057|DIAGNOSTIC_TEST|Electromyography (EMG)|As a standard method, surface EMG collects data from nerve impulse-triggered active muscle contractions, pre/postflight only
214486360|NCT06492057|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI is a clinically standard (non-radiation) imaging method to study structural changes of the human body (organs, muscle, bones, tendons) at the macroscopic level, pre/postflight only
214486361|NCT06492057|DIAGNOSTIC_TEST|Dynamometry|Dynamometry is a standard functional and diagnostic method to test muscle strength in sports and rehabilitation. pre/postflight only
214333777|NCT04933851|BEHAVIORAL|ACT1VATE|ACT1VATE, informed by Acceptance and Commitment Therapy (ACT), will consist of five, 90-minute group-based telemedicine therapy sessions delivered by a Behavioral Health Provider.
214333778|NCT04933851|BEHAVIORAL|DSME/S|Diabetes self-management education and support (DSME/S) will be delivered by a Certified Diabetes Care and Education Specialist via one-on-one telemedicine format.
214333779|NCT02410811|OTHER|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
214333780|NCT05669443|DEVICE|conventional PEEP|Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
214486362|NCT05062057|DEVICE|Adhesive ambulatory ECG recording patches|All women in both groups will undergo sequential placement of two 14-day adhesive ambulatory ECG recording patches for a total of 28 days of ECG recording
214934763|NCT05156762|BEHAVIORAL|Medical weight loss|Study participants randomized to the medical weight loss study arm will have consultations with nutritionists, dieticians, and endocrinologists, and will make dietary and lifestyle changes in an effort to lower their BMI to ≤ 40 kg/m2. Patients may also be placed on pharmacotherapy to assist with weight loss.
214934764|NCT05156762|OTHER|Patient research surveys|Patients will have a telemedicine visit every 3 months with an orthopaedic surgery physician assistant to review their latest BMI and to complete a patient research survey to assess the patient's feelings regarding their progress. The telemedicine visits every 3 months are unique to the clinical trial and these visits would not otherwise occur if the patient was not enrolled in the trial. If patients are found to not be advancing toward the BMI goal of ≤ 40 kg/m2, these patient research surveys can be used to make individualized adjustments, based on recommendations from dieticians and the medical nutritionist.
214333781|NCT05669443|DEVICE|optimized PEEP|Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
214333782|NCT02371499|DIETARY_SUPPLEMENT|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
214333783|NCT02371499|DIETARY_SUPPLEMENT|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
214333784|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.5 Gy fx|Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
214333785|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.0 Gy fx|Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
214934765|NCT05156762|PROCEDURE|Total joint arthroplasty (TJA)|Once the study participant meets the target BMI goal of ≤ 40 kg/m2, they will undergo TJA. Patients will be followed for 2 years after undergoing TJA.
214333786|NCT00057746|RADIATION|Prophylactic cranial irradiation, 1.5 Gy fx|Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
214333787|NCT05984394|DIAGNOSTIC_TEST|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT
214934766|NCT05156762|OTHER|Usual standard of care|"Patients randomized to the usual standard of care study arm will be counseled on the importance of losing weight to optimize their BMI and will be provided with referral information (name and clinic number) to either the bariatric surgery or medical weight loss clinics. They will be urged to make an appointment or to seek any other interventions they choose to help lower their BMI, but no appointments will be made for them. A follow up visit in 6 months and 1 year will be made for them in the arthroplasty clinic to reassess their progress. Referral information will again be provided at 6 months if no progress has been made."
214934767|NCT00510016|DRUG|Clonidine HCL|Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
214934768|NCT04364113|OTHER|Usual Protein Diet|The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus
214333788|NCT05921773|DEVICE|AI-fNIRS neurofeedback device|The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness training through visual and auditory cues to help participants modulate their brain activity, and thus alleviates anxious states.
214333789|NCT05921773|DEVICE|AI-fNIRS neurofeedback device with sham signals|The sham control consists of playbacks of someone else's real AI-fNIRS neurofeedback and will be provided 3 times a week, for a total of 4 weeks.
214333790|NCT00403338|DEVICE|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
214333791|NCT05211622|DRUG|1. alpha acid lipoic - tables|600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days
214333792|NCT05211622|DRUG|2. ozonated oil - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks
214333793|NCT05211622|DRUG|3. chlorhexidine 0,2% - mouthwash|1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks
214333794|NCT05211622|DRUG|4. sodium bicarbonate 5% solution - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 3 weeks
214333795|NCT05257265|DRUG|Centanafadine Hydrochloride|Capsule
214333796|NCT05257265|OTHER|Placebo|Capsule
214333797|NCT02562313|DRUG|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
214333798|NCT02562313|DRUG|Humalog®|Humalog® bolus infusion followed by test meal intake
214934769|NCT04364113|OTHER|Low Protein Diet|The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus
214333799|NCT06050590|DEVICE|NeuroGlove|Study participant with PTSD will undergo daily at home treatment using the NeuroGlove.
214934770|NCT04364113|OTHER|Very Low Protein Diet|The very low protein diet contains 0.28 g/kg/day or protein, mg/kg/day of Phosphorus and a keto acid mixture.
214934771|NCT04364113|DRUG|Medications needed to maintain usual blood pressure|The MAP goal for the usual blood pressure group is \<=107 mm Hg for ages 18-60 and \<=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
214934772|NCT04364113|DRUG|Medications needed to maintain low blood pressure|The MAP goal for the low blood pressure group is \<=92 mm Hg for ages 18-60 and \<=98 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
214934773|NCT02517242|DEVICE|Pens Device|
214934774|NCT02517242|DEVICE|Syringe|
214934775|NCT02517242|OTHER|Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)|
214934776|NCT00356902|PROCEDURE|titration of oxygen during resuscitation|
214934777|NCT03762863|DEVICE|Tourniquet application skill retention|Tourniquet application following the procedure as learned in the Stop the Bleed curriculum.
214934778|NCT03596723|DRUG|KPI-121 1%|eye drops
214934779|NCT03596723|DRUG|Prednisolone acetate|eye drops
214934780|NCT03722953|OTHER|Control|"1. Ultrasound~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
214934781|NCT03722953|OTHER|Aerobic Exercise|"1. Ultrasound~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
214673866|NCT06971211|DRUG|Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.|Induction therapy, fluzoparib (150mg BID orally), abiraterone acetate tablets (II) (300mg QD orally), and prednisone (5mg BID orally). IMRT was administered as follows: For patients with low metastatic burden tumors: Prostate ± pelvic lymph node radiation + metastatic lesion radiation.For patients with non-low metastatic burden tumors: Prostate±pelvic lymph node radiation.IMRT dosage:Prostate: 70 Gy in 28 fractions (2.5 Gy/fraction, 5 fractions per week).Pelvic lymph nodes: 50.4 Gy in 28 fractions (1.8 Gy/fraction, 5 fractions per week).Fluzoparib and abiraterone acetate (II) were administered concurrently with radiotherapy. Maintenance treatment,patients received the same doses of fluzoparib,abiraterone acetate (II), and prednisone. Each treatment cycle lasted 28 days.
214673867|NCT05615870|OTHER|Winix 5500-2 HEPA filtration units|To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.
214673868|NCT06165419|RADIATION|SBRT to the spine|Stereotactic body radiation therapy (SBRT) administered to spine metastases
214333800|NCT06573099|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
214333801|NCT04313192|DEVICE|pulse rate of 2 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
214333802|NCT04313192|DEVICE|pulse rate of 10 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
214333803|NCT04313192|DEVICE|pulse rate of 150 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
214333804|NCT04363281|OTHER|preoperative questionnaire|"1. Three questions to predict acute pain:~   * Verbal numeric score Anxiety 0-10~  * Anticipated postoperative pain level~  * Anticipated analgesic requirements~2. Speilberger STATE-TRATE inventory index~3. Pain Catastrophizing Scale"
214333805|NCT04363281|OTHER|PACU questionnaire|parturients will be approached and requested to fill out a questionnaire regarding intraoperative pain, medication consumption, anxiety and nausea.
214333806|NCT04363281|OTHER|Postoperative questionnaire|Parturients will be approached at 24 hours postpartum and questioned regarding anxiety levels and medication consumption and requested to fill out the OBSQOR 11 questionnaire at 24 hours postpartum.
214673869|NCT02111811|OTHER|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
214673870|NCT02101008|DRUG|disulfiram and chelated zinc|
214673871|NCT05734937|OTHER|gastric assessment of gastric volume|ultrasound assessment of gastric volume is going to bel evaluted in the Preoperative and postoperative period while the patients lay in right lateral decubitus position.
214934782|NCT01433445|DRUG|panobinostat|Given 3 times a week, every other week in 28-day cycles.
214934783|NCT01433445|DRUG|ruxolitinib|Given twice daily in 28-day cycles.
214934784|NCT00533689|PROCEDURE|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
214934785|NCT02484651|DRUG|Sugammadex|Reversal of deep neuromuscular block
214934786|NCT02484651|DRUG|Rocuronium|Maintenance of deep neuromuscular block
214934787|NCT03785509|DRUG|DAPT, Statin|Compliance of DATP, Compliance of Statin, Drug Eluting Stent, Bare Metal Stent
214934788|NCT05097092|PROCEDURE|Orthopedic immobilization|Orthopedic immobilization will be performed with a sling and swathe.
214934789|NCT05097092|OTHER|Unilateral resistance training|Unilateral resistance training will be performed by the dominant arm of the immobilization + unilateral resistance training group during Phase 1.
214934790|NCT05097092|OTHER|Bilateral resistance training|Bilateral resistance training will be performed by both arms in both groups during Phase 2.
214934791|NCT03326128|DRUG|Bupropion Hydrochloride|Antidepressant that is also effective in smoking cessation
214934792|NCT01775358|DRUG|ALRN-5281 0.015 mg/kg|
214934793|NCT01775358|DRUG|ALRN-5281 0.05 mg/kg|
214934794|NCT01775358|DRUG|ALRN-5281 0.15 mg/kg|
214934795|NCT01775358|DRUG|Placebo 0.015 mg/kg|
214934796|NCT01775358|DRUG|Placebo 0.05mg/kg|
214934797|NCT01775358|DRUG|Placebo 0.15mg/kg|
214934798|NCT04917458|DRUG|Cholecalciferol 4000 IU Oral Capsule, Liquid Filled|-Vitamin D 25 (OH) or Cholecalciferol 4000 IU capsules, each capsules contain Vitamin D3 tablet @ 1000 IU Patients included into the study will be randomized into two groups and receive placebo (as control group) or cholecalciferol administered orally for 3 months.
214333807|NCT04363281|OTHER|Postoperative questionnaire- Obstetrician|The attended obstetrician will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
214333808|NCT04363281|OTHER|Postoperative questionnaire- anesthesiologist|he attended anesthesiologist will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
214333809|NCT06572527|BEHAVIORAL|Physical Activity Program|"Nurse-Led Coordinated Physical Activity Program for Child Health, developed as part of the Coordinated Approach to Child Health program for preschool children."
214333810|NCT02170753|PROCEDURE|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
214333811|NCT02170753|PROCEDURE|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
214333812|NCT01543269|DRUG|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
214333813|NCT01543269|DRUG|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
214934799|NCT04917458|DRUG|Placebo|Placebo will be given to control group. It would be administrated orally, one capsule once a day for 30 days of study period
214934800|NCT00865917|DRUG|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
214934801|NCT00865917|DRUG|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
214333814|NCT03212586|DRUG|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
214333815|NCT03212586|DRUG|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
214333816|NCT05769452|DEVICE|closed IV catheter system (BD Nexiva™)|There is a high-pressure extension set and a Q-syte split septum needle-free intervention device at the tip of the catheter. It creates a closed integrated system with this apparatus, reducing the risk of catheter-related bloodstream infection.
214333817|NCT05769452|DEVICE|open IV catheter (BD Insyte™ Autoguard™)|BD Instaflash™ needle technology improves initial entry success by confirming vascular access through the needle noch. It has flexible wings for secure cannula fixation.
214333818|NCT00427804|DRUG|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
214333819|NCT05435573|DRUG|1000 mL of ringer's acetate solution|1000 mL of ringer's acetate solution
214333820|NCT05435573|DRUG|250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)|500 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride plus 500 mL of ringer's acetate solution
214333821|NCT00439140|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
214333822|NCT00439140|DRUG|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
214333823|NCT04424121|DIAGNOSTIC_TEST|CCTA|Coronary Computed Tomography Angiography
214333824|NCT01522859|DEVICE|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
214934802|NCT00865917|DRUG|Placebo|matching appearance
214934803|NCT06452147|OTHER|Nerve block+standard anesthesia|"1. Receive nerve block as soon as possible after randomization;~2. Ultrasound-guided nerve block is recommended, with the iliacfascia block recommended as the blocking site;~3. It is recommended to use 1.33% bupivacaine liposome (long-acting), and the maximum dose should not exceed 133mg; or regular local anesthetic (bupivacaine or ropivacaine, etc.) with electronic analgesic pumping infusion; or multiple single injections of regular local anesthetics should be used to maintain the continuity of nerve block effect."
214333825|NCT04988022|DRUG|Dupilumab|300 mg prefilled syringe
214333826|NCT04988022|DRUG|Placebo|Matching placebo
214333827|NCT03384667|DRUG|Maekmoondong-tang|MMDT is a Herbal medicine consist of six herbs.
214333828|NCT03384667|DRUG|Placebo|The granules do not contain any active ingredients.
214333829|NCT03879629|DRUG|Carvedilol|oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day
214934804|NCT06452147|DRUG|Intravenous lidocaine+standard anesthesia|"1. Subjects randomly assigned to Lidocaine Group (Group L) will be given ECG monitoring, oxygen saturation monitoring, blood pressure monitoring and an open intravenous route on the morning of the surgery. It is recommended to start the infusion of Lidocaine as soon as possible in the ward.~2. It is recommended to use portable electronic infusion pump for drug delivery. The loading dose is 1mg/kg, and the maintenance dose range is 1\~2mg/kg/h. The specific dosage is determined by the anesthesiologist based on the patient's condition. The infusion ends when the patient leaves the Post-anesthesia care unit after surgery, and the infusion time and total amount should be recorded."
214934805|NCT06452147|DRUG|Bupivacaine liposome|1.33% bupivacaine liposome
214333830|NCT04154631|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
214333831|NCT04154631|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
214333832|NCT04154631|OTHER|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
214333833|NCT03734471|DEVICE|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
214333834|NCT03734471|PROCEDURE|Tube thoracostomy|Traditional chest tube placement
214333835|NCT04425330|OTHER|physiotherapy exercises|The evidence on the effectiveness of physical therapy in children with myelomeningocele is limited. The International Classification of Functionality, Disability and Health for Children and Youth is a useful tool to assist therapists in analyzing problems about the focus of the intervention. The evidence in physical therapy practice for individuals of all ages with neurological disorders, focuses on 5 Ps: prevention, prediction, participation, personalized and plasticity. Thus, neurological physiotherapists must perform the care with a focus on preventing the patient's disabilities, predicting the ideal response of an intervention, through measures of results of the movement system. In addition, it is of paramount importance that the goal of rehabilitation is that people with neurological disabilities are fully included and participate in life activities that are important to them and that their care is personalized. All of these measures facilitate the process of positive plasticity.
214333836|NCT04425330|OTHER|PBM|Photobiomodulation occurs from the application of low intensity light such as low intensity laser and light emitting diode (LED). The therapeutic effectiveness of phototherapy is based on the absorption of photons by photoreceptors or chromophores. Studies on the experimental model of spinal cord injury have shown that both wavelengths have the potential to be an effective and non-invasive means of therapy, promoting axonal appearance, increased concentration of glial cells and nerve connections, in addition to functional and sensitive. The findings of a clinical trial involving individuals diagnosed with spinal cord injury demonstrate that PBM exerted positive effects on motor function, especially during isotonic contraction of stimulated muscles assessed by electromyography, and there was a recovery in sensory perception and muscle strength.
214333837|NCT04425330|OTHER|SHAM PBM|SHAM PBM
214333838|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 30 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
214333839|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 15 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
214333840|NCT03461224|RADIATION|accelerated hypofractionated RT|
214333841|NCT03461224|RADIATION|conventional fractionated RT|
214673872|NCT06971575|DIAGNOSTIC_TEST|Magnetic resonance neurography|Patients will undergo a cervical MRI with specialized magnetic resonance neurography sequences to evaluate the extraforaminal cervical nerve roots.
214934806|NCT06452147|DEVICE|Ultrasound-guided nerve block|Ultrasound-guided nerve block
214934807|NCT02622763|BIOLOGICAL|Tolerogenic Dendritic Cells|Intralesional administration
214934808|NCT00150800|DRUG|Brivaracetam|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 10 mg and 25 mg~* Route of Administration: Oral"
214333842|NCT04890392|DRUG|PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)|S-1: 40\~60mg Bid，d1\~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
214333843|NCT03581110|DIAGNOSTIC_TEST|computed tomography|noncontrast-enhanced chest computed tomography
214333844|NCT03012386|DRUG|Sildenafil Citrate in G allele carrier|chronic use of phosphodiesterase 5 inhibitor in G allele carrier
214333845|NCT03012386|DRUG|Sildenafil Citrate in non G allele carrier|chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier
214333846|NCT01032135|BEHAVIORAL|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
214333847|NCT01032135|BEHAVIORAL|Telephone counseling|one telephone counseling session per week for 10 weeks.
214333848|NCT01032135|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
214333849|NCT01032135|DRUG|medication management|Prescription for naltrexone
214673873|NCT06971770|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214673874|NCT05161468|DRUG|Lidocaine injection|2ml of 1% lidocaine will be drawn into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
214333850|NCT01032135|BEHAVIORAL|Intensive OutPatient Therapy|Return to IOP, group therapy 3 times weekly for about three hours a day.
214333851|NCT00647621|DRUG|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
214333852|NCT00647621|DRUG|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
214333853|NCT01950546|DRUG|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
214333854|NCT01466192|DRUG|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
214333855|NCT01466192|DRUG|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
214333856|NCT01466192|DRUG|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
214333857|NCT04507958|DIAGNOSTIC_TEST|auscultation by using conventional stethoscope without PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
214347198|NCT04532892|DIETARY_SUPPLEMENT|Placebo Meta 18.06 Day and Placebo Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
214347199|NCT02804607|OTHER|questionnaire|
214347200|NCT02752620|OTHER|Osteopathic Manipulative Treatment|
214347201|NCT02752620|OTHER|Exercise Therapy|
214347202|NCT05758025|PROCEDURE|"Resection based on thymus-vascular-inferior parathyroid complex"|"Before clearing the central lymph nodes, looking for the thyro-thymic ligament first, looking for the inferior parathyroid along the thyro-thymic ligament. Dissect and leave the thymus-vascular-inferior parathyroid complex laterally; the inner side of this layer is the tissue of the central area. Then remove the central lymph nodes. Check for parathyroids in the removed specimen, transplant the parathyroids which are removed by accident."
214347203|NCT00765908|DEVICE|Angioplasty balloon|90 second balloon inflation x 2
214347204|NCT00765908|DEVICE|Angioplasty balloon|30 seconds or less balloon inflations x 2
214347205|NCT04533841|DRUG|Misoprostol|Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
214347206|NCT04533841|DRUG|Placebo|placebo
214347207|NCT04533841|DRUG|Propranolol|Propranolol
214347208|NCT02467777|DEVICE|Bair Hugger|
214347209|NCT02467777|DEVICE|VitaHeat|
214333858|NCT04507958|DIAGNOSTIC_TEST|auscultation by using electronic stethoscope in full PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
214333859|NCT00774488|OTHER|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
214333860|NCT01613339|OTHER|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
214934809|NCT01698879|DRUG|Mylotarg|"Cohort 1 version 1.0. GO: 6mg/m\^2 (maximum 10 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 1.0 version 2.0: GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 2: G-CSF: 150 mcg/m\^2, SC, days 0 to 7. GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO."
214934810|NCT01788189|DRUG|Lenalidomide|
214934811|NCT04972968|DRUG|ABBV-154|Subcutaneous Injection
214934812|NCT04972968|DRUG|Placebo|Subcutaneous Injection
214934813|NCT04972968|DRUG|Glucocorticoid|Oral Tablet
214934814|NCT06154395|PROCEDURE|OCT-guided PCI|The OCT guidance team routinely conducts OCT examinations on patients after standard angiography and/or thrombus aspiration. The OCT examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on OCT image features. After stent implantation, a follow-up OCT examination of the stent segment, as well as angiographic examination, is performed. Based on the OCT results, the operator decides whether post-dilation is necessary.
214934815|NCT06154395|PROCEDURE|60 MHz HD-IVUS-guided PCI|The IVUS guidance team routinely conducts IVUS examinations on patients after standard angiography and/or thrombus aspiration. The IVUS examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on IVUS image features. After stent implantation, a follow-up IVUS examination of the stent segment, as well as angiographic examination, is performed. Based on the IVUS results, the operator decides whether post-dilation is necessary.
214934816|NCT06154395|PROCEDURE|Angiography-guided PCI|After routine angiography and/or thrombus aspiration, the operator assesses the lesion based on treatment standards to determine whether stent implantation is necessary. For patients undergoing stent implantation, a follow-up angiography is performed postoperatively, and the decision for post-dilation is made by the operator based on experience.
214934817|NCT03421314|DIETARY_SUPPLEMENT|Zinc gluconate and/or Selenium yeast|30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast
214934818|NCT02389790|DRUG|MT-1303|
214333861|NCT06135662|PROCEDURE|CAF + CTG|Surgical techniques for mandibular gingival recession: coronally advanced flap + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
214347210|NCT03900936|DIAGNOSTIC_TEST|Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
214934819|NCT06056882|OTHER|CLE-guided cryobiopsy|During bronchoscopy, that is performed for suspicious pulmonary lesions, it is planned to use the CLE probe and cryoprobe simultaneously wafter detection of the round focus.
214934820|NCT05838443|OTHER|Self-directed mindfulness utilizing a multi-sensor EEG-supported device with neurofeedback-assisted and technology-supported meditation|Neurofeedback-assisted, technology-supported mindfulness via EEG-supported device delivered individually without the need for a facilitator or travel to training site. The device allows noninvasive neural activity recording from frontal and posterior brain regions. A dedicated smartphone application uses the EEG data to provide real-time adaptive feedback-modulating natural sounds to prompt user awareness of mind-wandering and intentional return to present experience. A smartphone app will guide patients through attention and focus on breath exercises. Patients will hear their distracted mind as the wind. Wind becomes stronger if their mind wanders, prompting patient's awareness of their wandering mind and guiding the patient back to focusing on their breath without judgment of how they are doing. Patients will be asked to practice mindfulness using the device for 20 minutes per day for 4 sessions prior to surgery.
214347211|NCT06535113|OTHER|Clinical Practice|"All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines.~There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures."
214347212|NCT04136938|OTHER|Social marketing campaign|A social marketing campaign of prevention workshop sessions will be performed.
214347213|NCT04297878|DIETARY_SUPPLEMENT|probiotic supplement Streptococcus salivarius K12 (Bactoblis®)|Probiotic food supplement
214347214|NCT01806337|DRUG|Alemtuzumab|Consolidation after CHOP induction
214333862|NCT06135662|PROCEDURE|Tunnel Technique + CTG|Surgical techniques for mandibular gingival recession: tunnel technique + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
214333863|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
214333864|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
214934821|NCT05838443|OTHER|Provider-directed mindfulness|"Patients will receive mental health support by a licensed social work provider who is trained in mindfulness through four 20-minute telehealth sessions. Patients will be taught cognitive behavioral therapy (CBT) techniques to reduce pain catastrophizing and increase coping efficacy, the clinician will review patient's current sleep routine and teach concepts and strategies to improve sleep. Patients will be guided through mindfulness and meditation exercises to improve pain and mood coping. Mindfulness-based instructions takes patients through quieting their mind by focusing on breath, expanding focus (i.e., at the tip of their nose full flow of the breath), with emphasis on acknowledgement of arising thoughts/emotions without judgement or emotional reaction, and return attention back to breath sensation. Principles of CBT and mindfulness will be reiterated at subsequent sessions."
214934822|NCT05838443|OTHER|Conventional Care|Control group, as defined by our institution's standard preoperative care for given procedure, which does not include psychological preparation.
214934823|NCT04637581|BEHAVIORAL|Wraparound|Wraparound is a 12-month family-driven intensive care coordination model.
214934824|NCT06099132|DIAGNOSTIC_TEST|Electromyographic measurements|HD and bipolar EMG were assessed from gastrocnemius medialis (GM), soleus (SO) and tibialis anterior (TA) at seated position, ankle at 0°, during isometric submaximal effort and maximal effort, knee flexed (90°) and knee extended (0°)
214934825|NCT00796705|DRUG|Adalimumab|40 mg injection of adalimumab administered subcutaneously
214934826|NCT00796705|DRUG|Adalimumab placebo|1.0 ml .9% saline placebo administered subcutaneously
214333865|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
214934827|NCT00796705|DRUG|Etanercept|50 mg dimeric fusion protein administered subcutaneously
214934828|NCT00831545|DRUG|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
214673875|NCT05161468|DRUG|Corticosteroid Injection|1 ml of triamcinolone acetonide (40 mg/ml) will be drawn with 1 ml normal saline into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
214673876|NCT05161468|DRUG|Protein Rich Plasma(PRP) Injection|30 ml of acid-citrate-dextrose (ACD) will be drawn into a 30 ml syringe to coat the syringe. 3 ml will be left in the syringe and then 27 ml of blood will be drawn via standard venipuncture. The 30 ml mixture of blood and ACD will then be prepared in the Peak PRP system as described in the manufacturer's instruction (PEAK® PRP System). After preparation, PRP will be withdrawn (2 mls) into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
214333866|NCT04430426|OTHER|Controlled Diet|Participants will consume a controlled low oxalate diet for five days.
214333867|NCT04430426|OTHER|Glycolate Administration|Participants will come to the UAB Clinical Research Unit (CRU) and be administered a glycolate load via intravenous (IV) catheter.
214333868|NCT00029731|DRUG|Arginine hydrochloride|
214333869|NCT00700011|DRUG|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
214333870|NCT00700011|DRUG|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
214333871|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
214333872|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
214333873|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
214333874|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
214333875|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
214333876|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
214333877|NCT00678561|DRUG|Placebo Vehicle|Topical treatment once daily for 28 days
214333878|NCT00678561|DRUG|Placebo Vehicle|Topical treatment twice daily for 28 days
214333879|NCT03419091|DEVICE|single-use flexible digital ureteroscope|Device being tested.
214333880|NCT03419091|DEVICE|Reusable Ureteroscope|Comparative device.
214333881|NCT03354494|DRUG|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa|
214333882|NCT04464642|DRUG|Methotrexate|Methotrexate 25 mg subcutaneous is given in group A
214333883|NCT04464642|DRUG|Tofacitinib|tofacitinib 10 mg given in group B
214333884|NCT01329510|DEVICE|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
214333885|NCT03580603|OTHER|Visualization tool|Visual representation of past microbiological culture data
214333886|NCT00437034|BIOLOGICAL|aflibercept|Given IV
214333887|NCT04118322|OTHER|aromatherapy (peppermint oil)|"The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)"
214333888|NCT03537118|PROCEDURE|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
214333889|NCT05883605|DEVICE|Measuring blood pressure|Measuring blood pressure using electronic device and using a mercury sphygmomanometer
214333890|NCT04612322|DEVICE|Assessment of microvascular function with intracoronary hemodilution|The pressure/temperature wire allows assessing coronary flow reserve, intracoronary pressure, and coronary flow to calculate multiple parameters of coronary macro- and microvascular function.
214333891|NCT01910064|DRUG|GK530G|
214333892|NCT00851175|DRUG|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
214934829|NCT02251106|DEVICE|Lumbar corset (Quickdraw, Aspen Medical Products)|The corset (a.k.a. brace) is made of webbing and elastic. It is wrapped around the trunk and tightened with Velcro and a series of cords (like tying shoes).
214333893|NCT00851175|DRUG|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
214333894|NCT01161758|OTHER|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
214333895|NCT01161758|OTHER|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
214333896|NCT00853658|DRUG|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
214333897|NCT00853658|DRUG|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
214934830|NCT06666790|DEVICE|Scan with elastic scattering spectroscopy device to assess risk of malignancy|Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology
214934831|NCT05565443|DEVICE|Blood Brain Barrier Disruption - Functional|Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
214934832|NCT02375555|DRUG|Lenalidomide|
214934833|NCT02375555|DRUG|Elotuzumab|
214673877|NCT06007170|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
214333898|NCT01532765|PROCEDURE|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
214934834|NCT02375555|DRUG|Bortezomib|
214934835|NCT02375555|DRUG|Dexamethasone|
214934836|NCT02375555|PROCEDURE|Stem Cell Mobilization|
214934837|NCT04926103|OTHER|Fecal Microbiota transplant (FMT)|Patients will come once a week for FMT for 8 weeks. FMT is the administration of the supernatant component of stool and water mixture from a healthy relative or an unrelated donor. The donor's stool and blood is rigorously screened to exclude known communicable diseases. Those that achieve remission with FMT will have the option of continuing FMT once per month for 3 years
214673878|NCT05937685|BEHAVIORAL|BP REACH Intervention|Educational materials, written and digital. Home blood pressure monitor and self management education from BP REACH coach. Monthly coaching calls from BP REACH coach. Medication management by pharmacist
214673879|NCT05514665|DEVICE|Diffuse Optical Tomography|Neonates once hemodynamically stable will undergo diffuse optical tomography measurements of functional brain connectivity at the bedside within 3-7 days after birth.
214673880|NCT03291379|DRUG|BTG-002814|BTG-002814 containing 100 mg vandetanib
214673881|NCT01165008|DRUG|Anakinra|
214934838|NCT02267772|DRUG|IV Acetaminophen|IV Acetaminophen
214333899|NCT01532765|PROCEDURE|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
214333900|NCT01532765|PROCEDURE|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
214333901|NCT02637843|DEVICE|Slender Sheath|Comparing outcomes for two different sheaths used during radial CAG/PCI
214333902|NCT01176552|DRUG|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
214333903|NCT06103942|DIAGNOSTIC_TEST|CO2 angiography|A supplemental CO2 angiography will be performed before and after the stent graft placement.
214333904|NCT02006238|DEVICE|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
214347215|NCT04317612|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
214934839|NCT02267772|DRUG|IV Morphine|IV Morphine
214934840|NCT03111472|OTHER|Self-management guide for people with Parkinson's who fall and their informal caregivers|The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.
214934841|NCT03809468|OTHER|phone call follow up|instead of a clinic visit, patients will be randomized to a phone call
214934842|NCT05253716|OTHER|ONS|Immunonutritional supplement
214934843|NCT05030909|BEHAVIORAL|transdiagnostic group treatment|The individual and group sessions will integrate core principles from Motivational interviewing (provide information, address barriers), Cognitive Behavioural Therapy (psychoeducation regarding emotions, enhancing emotional awareness, cognitive restructuring, behavioural experiments, relaxation) , Acceptance Commitment Therapy (mindfulness, grounding, emotional and body awareness, enhancing cognitive flexibility), and aspects of Islamic psychology.
214934844|NCT06712966|OTHER|EngageRx_SMBP|Patients in the EngageRx\_SMBP arm will be automatically registered in the CareSimple system and mailed a device they can use at home. They may also choose to install a smartphone application from CareSimple that will provide reminders about measuring their BP. The clinician will then manage the patient's hypertension according to the standard of care. The SMBP measurements from CareSimple will be available through EngageRx for them to use, and they will receive a weekly staff message to check EngageRx if there are new SMBP measurements for them to review. The clinician will also be able to indicate when they would like to stop using the CareSimple system.
214934845|NCT02141815|DIETARY_SUPPLEMENT|Arabinoxylan-oligosaccharides|
214934846|NCT02141815|DIETARY_SUPPLEMENT|Maltodextrine|
214934847|NCT03404349|BEHAVIORAL|Mindfulness for Adolescence Course|There are 6 topics that will each be presented over 2 weeks for the 12 week intervention. Individuals will participate in a one to 1.5 hours, once a week intervention for 12weeks. Mindfulness is the practice of becoming aware of one's present-moment experience with compassion and openness as a basis for wise action. This curriculum is intended to strengthen attention and emotion regulation, cultivate wholesome emotions like gratitude and compassion, expand the repertoire of stress management skills, and help participants integrate mindfulness into daily life. Each lesson includes age-appropriate discussion, activities, and opportunities to practice mindfulness in a group setting.
214934848|NCT04805580|PROCEDURE|unilateral intrathecal block|Quadratus lunborum block
214934849|NCT03065959|DRUG|reldesemtiv|oral
214934850|NCT03065959|DRUG|Placebo|oral
214934851|NCT01565369|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
214934852|NCT00224458|DRUG|Truvada|
214934853|NCT00224458|DRUG|efavirenz|
214934854|NCT06563544|DEVICE|FCV|90 minutes of FCV
214673882|NCT05569577|DRUG|Additional hCG injection|An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
214934855|NCT03136458|PROCEDURE|Ischemic preconditioning|Repeated remote ischemic preconditioning by arterial cuff insufflation.
214333905|NCT02006238|DEVICE|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
214333906|NCT02698358|DEVICE|Epic stent (Boston Scientific)|
214333907|NCT02803697|OTHER|Patients|
214934856|NCT03136458|DRUG|Endovenous normal saline|endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
214934857|NCT06505915|DIETARY_SUPPLEMENT|Pre op Carbohydrate drink|Lemon flavoured clear carbohydrate drink
214934858|NCT06505915|OTHER|Clear fluid as per sip til send policy|clear fluid such as water
214934859|NCT05928559|OTHER|OMRON BF511 Body Composition Monitor|The OMRON BF511 Body Composition Monitor is a digital scale and participants' body compositions will be evaluated with this device. The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test and the maximum oxygen consumption levels will be calculated with the help of the formula with the data obtained from this test. The trunk extensor muscle endurance of the participants will be evaluated with the Biering-Sorensen Test and the trunk flexor endurance will be evaluated with the Kraus-Weber Test. Participants' M. Quadriceps, M. Hamstring, M. Biceps Brachii and M. Triceps Brachii muscle strengths will be evaluated with MicroFET® 2 hand dynamometer.
214934860|NCT06886048|DIETARY_SUPPLEMENT|barley green|Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day
214673883|NCT05569577|DRUG|estrogen and dydrogesterone|estrogen and dydrogesterone
214673884|NCT01478347|BIOLOGICAL|Recombinant meningococcal B + OMV NZ|2 injections 2 months apart
214333908|NCT06103513|DRUG|Somatropin|The treatment of children with subcutaneous recombinant human growth hormone (rhGH) is the current gold standard of care for children with diagnosed GHD. This study will serve only to investigate the optimal dose of treatment in the first year of treatment with rhGH.
214347216|NCT04317612|OTHER|Reference product|Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
214673885|NCT00097266|DRUG|Placebo|Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
215073082|NCT04500080|BEHAVIORAL|PE Intervention|"Each single exercise session will last for one hour and will consist of a combination of the following elements:~* Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~* Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~* Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities"
215073083|NCT02453945|DEVICE|Adjustable Support Bra|A ClearPoint Medical support bra
214673886|NCT00097266|DRUG|Aripiprazole|Tablets, oral, 15-30 mg, once daily, 12 weeks.
214673887|NCT00097266|DRUG|Haloperidol|Capsule, oral, 5-15 mg, once daily, 12 weeks.
214934861|NCT01996410|DEVICE|Acupuncture|
214673888|NCT04219267|BEHAVIORAL|character strengths-based intervention|"Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths."
214934862|NCT02166411|PROCEDURE|myomectomy using barbed sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).
214934863|NCT02166411|PROCEDURE|myomectomy using conventional sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
214934864|NCT06124755|DEVICE|Viabahn endoprosthesis group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
214934865|NCT06124755|DEVICE|Drug-coated balloon group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
214934866|NCT00154232|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214934867|NCT06076018|DRUG|Group morphine|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally, and 120 mcg intrathecal morphine (ITM) will be administered to the morphine group. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
214934868|NCT06076018|OTHER|Group placebo|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
214934869|NCT05380284|OTHER|Senior Driving Simulation Training|The experimental group (Senior Driving Simulation Training: 30-mins training session two times per week for 5 weeks, with a total of 10 sessions) .
214934870|NCT05380284|OTHER|Waiting list control|The control group is waiting list control. They will also receive the (Senior Driving Simulation Training) after all research is done.
214333909|NCT05576116|PROCEDURE|Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)|"Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure."
214934871|NCT05545384|DRUG|Immediate Azathioprine (1st attack)|"Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
215073084|NCT05249933|DRUG|Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8|Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
215073085|NCT01854216|DRUG|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
215073086|NCT01854216|DRUG|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
215073087|NCT01854216|DRUG|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
215073088|NCT03172325|DRUG|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
214333910|NCT05576116|PROCEDURE|Combined Sleeve Gastrectomy and Pancreas transplantation|Simultaneous SG and pancreas transplantation
214333911|NCT05081739|DIAGNOSTIC_TEST|Prospera Transplant Assessment|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of dd-cfDNA in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available LDT developed by Natera, Inc. Natera is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA)."
214333912|NCT05081739|PROCEDURE|Endomyocardial biopsy|Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week in months 2 and 3, then monthly through month 6, then every 1-3 months through the end of month 12.
214333913|NCT04139590|DEVICE|Panda|
214333914|NCT04139590|DEVICE|Visual Analogue Scale - Original|
214673889|NCT04219267|BEHAVIORAL|early memories|In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
214934872|NCT05545384|DRUG|Immediate Rituximab (1st attack)|"Patients randomized in Immediate Rituximab group will benefit from immediate treatment with rituximab. Rituximab 375mg/m2 IV will be given at D1 and D15 and repeat every 6 months for 2 years.~Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
214333915|NCT03969342|DEVICE|Point of care ultrasound training|Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
214333916|NCT04947033|DRUG|TJ210001 Injection|The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
214333917|NCT02436512|DRUG|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
214333918|NCT05451576|DIETARY_SUPPLEMENT|Zelnite®|2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).
214934873|NCT05545384|DRUG|Standard of care|Patients in this group will be treated according to standard care
214934874|NCT05161208|DRUG|OC-01 (varenicline 0.6mg/ml) Nasal Spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
214934875|NCT05161208|DRUG|Placebo (vehicle) nasal spray|Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
214934876|NCT05238870|OTHER|Interviews for the needs analysis. No intervention.|To develop the education and training package, a needs-analysis is necessary. The clinicians' training needs will be established through interviews.
214934877|NCT04210388|DRUG|AZD5718 tablet, Formulation A|Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
214934878|NCT04210388|DRUG|AZD5718 tablet, Formulation B|Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
214934879|NCT04210388|DRUG|AZD5718 tablet, Formulation C|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
214333919|NCT05451576|DIETARY_SUPPLEMENT|Placebo|Placebo will be given for 7 weeks (5 days/week).
214333920|NCT02309281|DRUG|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
214333921|NCT04839497|COMBINATION_PRODUCT|Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees|Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.
214333922|NCT05940675|BEHAVIORAL|Food and Nutrition|A key element is that children receive a free of charge healthy do-it-yourself school lunch 4 days per week. The meals adhere to the Nordic Nutrition Recommendations and the Danish Food-Based Dietary Guidelines with focus on fish, wholegrains, fruits and vegetables and drinking water as well as stimulation of children's food literacy. Other intervention components involve the after school clubs, local retail stores and the parents.
214333923|NCT05940675|BEHAVIORAL|Physical Activity (FitFirst)|To ensure that all children reach the recommended 3x30 minutes of vigorous activity per week, we will implement three weekly 40-minute sessions in the school curriculum. These sessions will be carried out throughout the study period and will encompass modified and varied sporting activities and games, which promote motivation, physical literacy, active involvement of all children, and high training intensity.
214347217|NCT03510481|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
214934880|NCT04210388|DRUG|AZD5718 tablet, Formulation D|Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
214934881|NCT04210388|DRUG|AZD5718 film-coated tablet, Reference treatment|Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
214934882|NCT04907643|DEVICE|PICO G2 4k|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
214934883|NCT03005223|DRUG|Co-administration of DWC20155/DWC20156|
214934884|NCT03005223|DRUG|DWC20163|
214934885|NCT02559791|BIOLOGICAL|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
214934886|NCT02559791|DRUG|Placebo|Matching placebo once monthly for 2 months
214934887|NCT00940680|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
214934888|NCT00940680|DRUG|Losartan|losartan 100mg q.d.
214934889|NCT06373393|OTHER|STABILISE|"STABILISE technique: Stent assisted balloon induced intimal disruption and relamination in aortic dissection repair"
214934890|NCT01300299|RADIATION|Stereotactic Body Radiation Therapy|12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (\> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within \<2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
214934892|NCT02973113|BIOLOGICAL|EBVST Cells|EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
214673890|NCT02818634|PROCEDURE|Harvesting rib cartilage|
214673891|NCT04914130|OTHER|Study specific testing procedures|Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc
214673892|NCT01558817|BEHAVIORAL|Informed Assent|Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
214347218|NCT03510481|DRUG|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
214934893|NCT02973113|BIOLOGICAL|Nivolumab|Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
214934894|NCT06617247|DRUG|Intervention1: Cannabidiol|Os cuidadores randomizados para esta intervenção usarão CBD oral 300 mg (ou seja, 150 mg, duas vezes ao dia) por quatro semanas. A substância será fornecida gratuitamente pela empresa Ease Labs e será administrada em cápsulas para promover o cegamento. Esta posologia foi baseada no estudo, no qual o CBD nesta dosagem e forma de apresentação provou ser seguro e eficaz na redução de indicadores de burnout em profissionais de saúde da linha de frente da COVID-19. A segurança do uso do CBD também foi relatada em estudos anteriores conduzidos com humanos. Os efeitos colaterais do uso do CBD são raros, incluindo sintomas leves e toleráveis (por exemplo, tontura, sonolência, fadiga, letargia, náusea, dor de cabeça, febre e alterações sensoriais).
215073089|NCT03172325|DRUG|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
215073090|NCT03172325|DRUG|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
214673893|NCT01558817|BEHAVIORAL|Informational Brochure|An informational brochure about CPR will be given without a discussion with a physician.
214673894|NCT04630340|DEVICE|STEADES-2|In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
215073091|NCT03172325|DRUG|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
214347219|NCT03510481|DRUG|artemether 20mg/lumefantrine 120mg (AL)|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
214934895|NCT06617247|DRUG|Intervention 2: Placebo|In this group, the subjects will receive placebo intervention. For blinding purposes, caregivers in this group will use the vehicle of oral CBD 300mg (
215073092|NCT03962257|OTHER|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
214673895|NCT05294900|DRUG|paclitaxel/carboplatin|"Induction chemotherapy : total 2 cycle every 3weeks as below:~* Paclitaxel 175mg/m2~* Carboplatin AUC5"
214673896|NCT03709615|BEHAVIORAL|Internet delivered CBT for social anxiety disorder|"An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."
214673897|NCT06821126|BIOLOGICAL|LVT-001|Intranasal administration
214673898|NCT06821126|BIOLOGICAL|Cormirnaty|Intramuscular administration
214934896|NCT06808074|DRUG|Inhaled amikacin|Dosage of amikacin: 20 mg/kg based on ideal body weight, with a maximal dose of 2 g, once daily for 3 consecutive days.
214934897|NCT06808074|DRUG|Placebo|The equivalent volume of saline solution (0.9% sodium chloride \[NaCl\]) will be administered once daily for three consecutive days
214934898|NCT01744184|DRUG|Entonox|Entonox arm
214934899|NCT01744184|DRUG|Midazolam|up to 5mg midazolam as appropriate
214934900|NCT01945437|DRUG|Magnesium Sulfate|The magnesium group receive intravenous magnesium sulfate.
214347220|NCT00893659|DIETARY_SUPPLEMENT|wheat bread with beta-glucan|3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
214347221|NCT00893659|DIETARY_SUPPLEMENT|wheat bread without beta-glucan|Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
214934901|NCT01718834|BIOLOGICAL|prophylactic peptide vaccine|synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
214934902|NCT01718834|BIOLOGICAL|therapeutic peptide vaccine|therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
214347222|NCT02200822|DRUG|beta blockers|
214333924|NCT05940675|BEHAVIORAL|Sleep and screen media|The aim of this component is to promote healthy sleep and screen media behaviours. Sleep and screen media recommendations will be presented for parents at three parent workshops and in electronic infographics. Teachers/pedagogues will facilitate small assignments on screen media and sleep practices with children during school time. Children will talk about and reflect upon screen media and sleep practices in their family, based on assignments and material from e.g., Medierådet (The Danish Media Council). The results of the children's assignments will be presented to their parents at later workshops. This is done to integrate the children's perspective in the parent workshops, especially in relation to screen media habits.
214333925|NCT05940675|BEHAVIORAL|Community capacity building|Community capacity building in selected local communities. To promote healthier eating, children and families need to be supported within their local community by food environments that make the healthy choice the easy choice and not a challenge in their everyday life. To promote physical activity, the children will be invited to participate in activities in the local sports clubs including camps in the holidays.
214934903|NCT06860984|DRUG|Duloxetine|Duloxetine, a non-opioid neuromodulator, has been widely used to manage neuropathic pain. It possesses dual central and peripheral analgesic properties
214934904|NCT06860984|OTHER|Placebo capsule|Placebo will have the same look and appearance of active comparator
214934905|NCT05655286|DRUG|38% SDF treatment|Children with active caries will receive 38% silver diamine fluoride treatment
214934906|NCT05655286|BEHAVIORAL|not to rinse for at least 30 minutes after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked not to rinse their mouths for at least 30 minutes.
214934907|NCT05655286|BEHAVIORAL|rinse mouth immediately after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked to rinse their mouths immediately.
214934908|NCT06857825|BEHAVIORAL|Implementation of Infection Control Link Nurses (ICLNs)|"Infection Control Link Nurses (ICLNs) are clinical nurses, working in direct nursing care, with an interest and expertise on infection control practice. They work with constant and direct support by the IPC hospital team, and they are required to follow a training course with numerous scheduled meetings about IPC-related issues.~They will be selected via spontaneous application or identified by their Head Nurses. All ICLNs activities are to be completed during working hours, they still maintain their clinical nursing role, but in addition they implement and translate IPC-measures into clinical practice by observing, monitoring and analyzing data on compliance with hand hygiene, compliance with standard and isolation precautions, healthcare-associated infections and other IPC-related issues"
214934909|NCT06896630|DRUG|Tenofovir Disoproxil Fumarate (TDF)|ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION
214934910|NCT00606554|DEVICE|Computer-assisted weaning program|Closed-loop, knowledge-based, computer-assisted wean program initiated at the start of ventilator weaning.
214934911|NCT00606554|BEHAVIORAL|Standard of Care weaning|Evidence-based standard of care weaning process.
214934912|NCT03596606|PROCEDURE|Manual Treatment|"The manual treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~* Soft tissue techniques.~* Articulatory techniques applied at cervical level~* Osteopathic manipulation techniques applied at the affected jaw/s.~* Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis."
214934913|NCT03596606|PROCEDURE|Myofunctional Motor control exercises|"The protocol is a set of 8 exercises to improve the execution of the function in the stomatognathic and cervical area.~The therapist explains the objectives of the exercises and the patient performs it after each session and at home three times a day.~The first day before performing the myofunctional exercises, will be an explanatory talk prior to the exercises in order to educate the patient. The second day, before doing the exercises, will review the concept of memory of pain and the benefits of doing the exercises"
214934914|NCT00569647|DEVICE|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
214934915|NCT00569647|DEVICE|Placebo|no use of device
214934916|NCT04654754|DEVICE|high-flow high humidity oxygen device with tracheostomy adapter|This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.
214934917|NCT02496351|DEVICE|TENS INTERVENTION|24 hours of TENS treatment in the immediately postoperative of limb amputation
214934918|NCT00618943|BEHAVIORAL|Tobacco Use Cessation|The proposed intervention will proceed in three steps. Step 1, provided to all intervention participants, includes multimedia, stage-based, expert-system contacts at intake, 3- and 6-months follow-up supported with brief (15-min) motivational counseling sessions. Step 2, reserved for intervention participants interested in quitting, consists of 12-weeks of individual CBT sessions for smoking cessation. Step 3, a 12-week course of nicotine patch, will be offered to adolescents who enter the CBT Cessation Treatment, who do not have any medical contraindications, and who smoke an average of 5 cigarettes or more per day in the past month.
214934919|NCT02683278|BEHAVIORAL|Cognitive-behavioral|Seven sessions of group-based treatment targeting skills to improve dysfunctional pain-related thoughts and behaviors
214934920|NCT02683278|BEHAVIORAL|Mindfulness-acceptance|Seven sessions of group-based treatment targeting skills to improve mindful awareness and acceptance of pain and stress, and increase positive emotional experiences
214934921|NCT02683278|OTHER|Pain Education|Seven sessions of group-based education to provide information regarding managing a chronic pain condition, but with no exercises to promote skill development
214934922|NCT00003407|DRUG|amifostine trihydrate|
214934923|NCT00003407|DRUG|cytarabine|
214934924|NCT00003407|DRUG|mitoxantrone hydrochloride|
214934925|NCT04104217|BEHAVIORAL|Music therapy|Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.
214934926|NCT04104217|BEHAVIORAL|Interviews|Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
214934927|NCT04614610|DRUG|Lidocaine Iv|Lidocaine 1.5mg/kg (Max dose: 200mg) in Dextrose 5% 100mL over 10 minutes
214934928|NCT04614610|DRUG|Placebo|Dextrose 5% 100mL over 10 minutes
214934929|NCT04542421|DIAGNOSTIC_TEST|Lung ultrasound use in patients hospitalized with COVID|Hospitalists will be taught to use lung ultrasound in the management of their patients with COVID
214333926|NCT01976845|DRUG|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
214333927|NCT01976845|DRUG|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
214333928|NCT01976845|DRUG|Saline|Saline 2 ml IV, in the pre-op area as a premedication
214333929|NCT01521611|RADIATION|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
214934930|NCT03668847|DRUG|DM-CHOC-PEN|DM-CHOC-PEN administration by IV infusion
214333930|NCT05540886|BEHAVIORAL|TEACH CLEAN|"The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities."
214333931|NCT06983262|OTHER|Milled PEEK Stent|A CBCT will be performed to assess the anatomy of the subnasal area and plan the position, size, shape and thickness of the PEEK Stent. These data will be transferred to a 3D planning software to generate a digital model. Eventually, the PEEK stents will be milled in a milling machine and sterilized in ethylene oxide before the surgery. Local anesthesia will be administered into the vestibular mucosa along the extension of the anterior maxilla. VISTA technique begins with a vestibular access incision in the midline frenum and 2 bilateral incisions at premolar area. A periosteal elevator will be introduced through the incision and inserted between the bone and periosteum to elevate the tissue, creating a subperiosteal tunnel, extending distally based on the dynamic of the smile. The PEEK stent will be in one piece. They will be placed onto the bone and stabilized with 2 bone graft screw for each side. The midline incision and the lateral incisions will be sutured primarily.
214333932|NCT06983262|PROCEDURE|Lip repositioning surgery|Profound anaesthesia will be achieved. A marking pencil§ will be used to outline the apical, coronal, and lateral boundaries of the elliptical incision. The coronal boundary will be at the mucogingival junction and will be used as a reference point to mark the apical boundary at two times the amount of gingival display. The coronal and apical incisions will be parallel to each other, and the apical incision gradually angled downward to meet the coronal incision. A partial thickness dissection will be made. The epithelium will be excised, exposing the underlying connective tissue. The mucosal flap will be advanced and sutured at the mucogingival junction.
214333933|NCT06815432|GENETIC|15.GPC3-CAR T cells|"Four different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL1: 5x10\^6 DL2: 1x10\^7 DL3: 5x10\^7 DL4: 1x10\^8"
214934931|NCT00250874|DRUG|Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab|
214934932|NCT03907527|BIOLOGICAL|PRGN-3005 UltraCAR-T cells|Given IP
214934933|NCT03907527|BIOLOGICAL|PRGN-3005 UltraCAR-T cells|Given IV
214934934|NCT00200876|PROCEDURE|Hypertonic saline|To elicit pain
214934935|NCT00200876|PROCEDURE|Isotonic saline|Non-painful control
214673899|NCT06600698|DRUG|INM176|The active ingredient INM176 was prepared using a proprietary technology to extract AGN with ethanol and powderize with cellulose into a finished granular powder product that is 1/5 the weight of the raw herbal root. This product was chosen because its close match with the AGN extracts studied in the TRAMP model in the phytochemical profiles. It will be donated from the manufacturer Nutragen Co., Ltd. Korea.
214673900|NCT06667128|OTHER|Rapid Uptitration of Guideline-Directed Medical Therapy|Rapid up-titration of GDMT guided by protocol-specific guideline.
214934936|NCT05476627|DIAGNOSTIC_TEST|Biomarkers|Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
214934937|NCT04500964|DEVICE|TAVR|Trancatheter aortic valve replacement
214934938|NCT02857244|DRUG|Duloxetine|Patients will first receive Duloxetine for 4 weeks starting at 30mg, 60mg, 90mg then 120mg (if tolerated). Increases in dosage amounts will occur every week.
214934939|NCT02857244|DRUG|Donepezil|Patients will receive Donepezil after 4 weeks of dosing with Duloxetine. Patients will receive Donepezil in combination with the highest dose of Duloxetine that was tolerated. Patients will remain on this for 2 weeks with increasing doses at each week. One week of 5mg, one week of 10mg.
214934940|NCT02857244|DRUG|Modafinil|Patients will receive Modafinil after a 4 week washout period (after dosing with donepezil \& duloxetine in combination). Patients will receive Modafinil for two weeks with increasing doses at each week. One week at 100mg, one week at 200mg.
214934941|NCT02280746|OTHER|Gluten challenge|Intervention will be continued for at least 6 months
214934942|NCT01263782|DRUG|Carboplatin|AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
214934943|NCT01263782|DRUG|Pemetrexed|500 mg/m2 by vein on day 1 of each 21 day cycle.
214934944|NCT01263782|DRUG|Bevacizumab|15 mg/kg by vein on day 1 of each 21 day cycle.
214934945|NCT01263782|DRUG|Cixutumumab|20 mg/kg by vein on day 1 of each 21 day cycle.
214934946|NCT06682182|DRUG|Tislelizumab+SOX|"OX: S-1 dosing based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-\<1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 6 cycles.~Tislelizumab: 200mg IV, day 1, Q3W, for a total of 6 cycles. HIPEC: Docetaxel 75mg/m² in 3500ml normal saline, at 43°C for 60 minutes."
214934947|NCT06482294|DRUG|Salbutamol|One arm is a combination of salbutamol and fluticason as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
214934948|NCT06482294|DRUG|Fluticason either Beclometasone or Budesonide|One arm is a combination of salbutamol and an ICS as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
214934949|NCT02336360|DRUG|Flortaucipir F18|No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.
214347223|NCT02200822|DRUG|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
214934950|NCT05768230|DRUG|levosimendan|Levosimendan 12.5mg was injected intravenously in a 5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
214934951|NCT05768230|DRUG|5% glucose injection|5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
214934952|NCT01154348|DRUG|S-707106|Tablet, taken once daily with morning meal
214934953|NCT01154348|DRUG|Placebo|Placebo tablet, taken once daily with morning meal
214934954|NCT01154348|DRUG|Metformin, S-707106 plus metformin|Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily
214934955|NCT01154348|DRUG|Metformin, placebo plus metformin|Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
214934956|NCT02381730|DRUG|Intravitreal aflibercept|Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
214934957|NCT04381689|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Teratect Prefilled Syringe Inj. 0.5mL
214934958|NCT04381689|BIOLOGICAL|Fluarix Tetra Pre-filled Syringe|Fluarix Tetra Pre-filled Syringe 0.5mL
214673901|NCT06667128|DIAGNOSTIC_TEST|Elecsys® NT-proBNP - Roche Diagnostics|An assay provided by Roche (Elecsys® NT-proBNP - Roche Diagnostics) will be used to assess NT-proBNP levels in the Rapid Up-Titration GDMT Group with Point-of-Care (PoC) Monitoring, with the purpose of evaluating any differences in marker dosage between the indicated method and the monitoring by the hospital laboratory analysis.
215073093|NCT03520348|DRUG|PRO-167|"Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic"
214934959|NCT04742712|DEVICE|CoronaCheck Device|All participants breath normally into the device for up to 6 minutes
215073094|NCT03520348|DRUG|Corneregel|Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
214347224|NCT01303289|DIETARY_SUPPLEMENT|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
214347225|NCT01303289|DIETARY_SUPPLEMENT|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
214347226|NCT02276482|DRUG|Tedizolid Phophate|Tedizolid Phophate 200 mg, IV and/or oral for 6 days
214934960|NCT02339480|OTHER|Massage therapy|Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
214934961|NCT01877967|DIETARY_SUPPLEMENT|VSL#3|The intervention group will be asked to ingest two sachets (2x4.4g) of the food supplement (VSL#3) each day for 12 weeks, either both at the same time, or one in the morning and one in the evening. This food supplement is in powder form and can be ingested with either cold food or any non-carbonated cold drink. The control group will be given a placebo, although as it is a double-blind intervention, will not know it is a placebo. They will similarly to the intervention group be asked to take two sachets (2x4.4g) of a powder rach day for 12 weeks, either both at the same time, or one in the morning and one in the evening.
214934962|NCT01877967|DIETARY_SUPPLEMENT|placebo|
214934963|NCT04545567|DEVICE|RocketAP|Artificial pancreas system which is designed to be able to identify when you have eaten and provide insulin for this meal
214934964|NCT04545567|DEVICE|USS Virginia|Artificial pancreas system which responds to glucose fluctuations by modulating insulin delivery but does not specifically detect meal ingestion
214934965|NCT01864369|BEHAVIORAL|eCounseling + Usual Care|"This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12."
215073095|NCT03121235|DIAGNOSTIC_TEST|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
214934966|NCT05301179|OTHER|Protein quantity and quality|Participants will ingest Lacto-vegetarian and vegan diets providing different daily protein quantities. The parallel design will test for protein quantity and the cross-over design will compare the effects of the quality of the protein sources in the diet.
215073096|NCT02292758|BIOLOGICAL|Bevacizumab|Given IV
215073097|NCT02292758|BIOLOGICAL|Cetuximab|Given IV
215073098|NCT02292758|DRUG|Irinotecan|Given IV
215073099|NCT02292758|OTHER|Laboratory Biomarker Analysis|Correlative studies
215073100|NCT02292758|OTHER|Placebo|Given IV
215073101|NCT03075488|DEVICE|Accuro|spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
215073102|NCT03075488|PROCEDURE|cutaneous landmarks|spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
215073103|NCT00067964|BEHAVIORAL|small changes in physical activity and diet|
215073104|NCT00415337|PROCEDURE|endobronchial ultrasound|EBUS
215073105|NCT00273520|DRUG|Telithromycin|
214333934|NCT06593704|OTHER|PROSPERA-program|"The PROSPERA-program consists of the following components:~1. Health care provider training and education about U-Prevent and cardiovascular risk communication.~2. Risk stratification: proactive selection of cardiovascular patients through the PROSPERA-empanelment procedure - for the population with increased cardiovascular risk, prior to consultation.~3. Decision support tools: use of the Lifestylecheck and the U-Prevent clinical decision support tool to guide motivated shared decision making towards appropriate care matched to the care complexity of the patient - for the individual patient, during consultation."
214333935|NCT06986694|OTHER|Group A will receive Voodoo Flossing Technique along with aerobic and strengthening exercises & conventional physiotherapy protocol for Knee OA.|"Patient will sit or lie down comfortably with affected knee exposed and in extension. Start by wrapping voodoo floss band at the shin bone just below the knee joint with 50% tension in the band and 50% overlapping on each wrap by working your way up towards the thigh. Keep the flossing band on for at least 1-2 minutes and perform gentle knee movements to promote mobility.~* Knee flexion and extension in full range of motion in standing position 20-30 sec.~* Knee squats with/without support 20-30 sec.~* Abduction and Adduction 20-30 sec. Perform each exercise with 10-15 seconds of rest between each set. After completing ROM exercises, allow the knee to rest in comfortable position and then carefully unwrap the voodoo band from the knee joint. Also monitor the knee for any changes."
214934967|NCT06327087|OTHER|No intervention|Observational study in the late follicular and mid-luteal phase
214934968|NCT03979807|DRUG|Olodaterol/Tiotropium Bromide|(Stiolto®) delivered via Respimat inhaler
214934969|NCT03979807|DRUG|Umeclidinium/ Vilanterol|(Anoro®) delivered via Ellipta Inhaler
214934970|NCT04060277|DRUG|Letermovir|Given as SOC
214934971|NCT04060277|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
214934972|NCT04060277|OTHER|Placebo Administration|Given IM
214934973|NCT03586505|DEVICE|Light exposure|"The 6 lights used randomly are :~* 482nm =standard blue light illumination,~* 650nm,~* 675nm,~* 700nm,~* 750nm~* 800nm"
214934974|NCT05874427|PROCEDURE|Multimedia informed consent|A standard consent form on paper to explain the procedure, with an additional video to explain the procedure and risks.
214673902|NCT06667128|OTHER|Rapid Up-Titration GDMT Group with Hospital Monitoring|Rapid Up-Titration GDMT Group guided by protocol-specific guideline and hospital monitoring.
214673903|NCT05913401|BEHAVIORAL|Aerobic Exercise|20 minutes of supervised aerobic exercise on a treadmill prior to each TMS session
214934975|NCT05874427|PROCEDURE|Standard informed consent|A standard consent form, written on paper, used to explain a procedure to a patient face-to-face by a physician.
214934976|NCT05279976|OTHER|Visualized Education|The child assigned to intervention group 1 will be told the operation preparation room and the pre-anesthesia process through the picture booklet prepared immediately after the pre-test (first measurement). Children included in this group will be provided to touch the bonnet, mask, gloves and self-inflated balloon (representing the ambu device), and the questions of the child and the parent will be answered.
214934977|NCT05279976|OTHER|Distraction|Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.
214934978|NCT01177631|PROCEDURE|Operation|Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
214934979|NCT02644720|PROCEDURE|multifocal intraocular lens implantation|In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
214934980|NCT02644720|PROCEDURE|monofocal intraocular lens implantation|In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
214934981|NCT02644720|DRUG|Dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery
214934982|NCT02644720|DEVICE|multifocal intraocular lens (IOL) (Tecnis ZMB00)|
214934983|NCT02644720|DEVICE|monofocal intraocular lens (IOL) (Tecnis ZCB)|
214934984|NCT05379270|OTHER|Diet soda|Participants will be asked to drink 24 ounces of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
214934985|NCT05304793|OTHER|Best Practice|Receive usual management of dyspnea
214934986|NCT05304793|BEHAVIORAL|Cognitive Behavior Therapy|Receive TAB treatment
214934987|NCT05304793|OTHER|Questionnaire Administration|Ancillary studies
214934988|NCT00141245|DRUG|Pregabalin|
214934989|NCT04056845|DEVICE|Valgus knee brace (Medex K39-OA Corrector)|Valgus knee brace given to patients as part of the conservative management for knee osteoarthritis.
214934990|NCT04056845|OTHER|Physiotherapy and oral analgesic (diclofenac and panadol)|Physiotherapy and oral analgesic (diclofenac and panadol)
214934991|NCT02754674|PROCEDURE|type of anterior cruciate ligament reconstruction|comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation
214934992|NCT04570527|PROCEDURE|PCI|percutaneous coronary intervention
215073106|NCT04801433|OTHER|Boleda Supramolecular Active Zinc Conditioner|Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
215073107|NCT04801433|DRUG|Capotetriol scalp solution|Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
215073108|NCT04801433|OTHER|Supramolecular Hydrogel|Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
214333936|NCT06986694|OTHER|Group B will receive aerobic and strength training and conventional physiotherapy protocol for knee OA only.|"Aerobic Exercises: Walking or Stationary Cycling 2 times a week for 4 weeks Walking: On flat surface/Treadmill~* 10 minutes warm-up, 30 minutes brisk walking, 5 minutes cool down. Cycling: Ergometer cycling~* 10 minutes warm-up, 30 minutes on moderate loading (75% of max. heart rate), 5 minutes cool down. Strengthening Exercises: Quadriceps, Hamstrings, Hip Abductors, Adductors and Calf Muscles Strengthening and Balance Training 2 times a week for 4 weeks.~* Hip Abduction in standing 8-10\*2 RM~* Hip Adduction in standing 8-10\*2 RM~* Knee Flexion and Extension in standing 10\*2 RM~* Knee Squats 8-10\*2 RM~* Sit/stand from chair 10\*2 RM~* Step up and down 10\*2 RM~* Heel raises 10\*2 RM~* Hip Bridges 10\*2 RM Conventional Exercise Program: 2 times per week for 4 weeks Heat Therapy Ultrasound Therapy~* Static Quads activation 10\*2 RM~* SLR 10\*2 RM~* VMO activation 10\*2 RM~* Knee to Chest 5\*2 RM~* Quadriceps, Hamstrings and Calf stretches 5\*2 RM"
214333937|NCT06987162|OTHER|Percussive Therapy|PT will be performed by the same researcher using a hand-held massage gun, tapping at a frequency of 30 Hz (rotational speed 1800 rpm/min) with a flat massage head. Each percussive massage session will last for 15 minutes. This frequency of 30 Hz is chosen based on its effectiveness for myofascial release and previous studies have indicated that a 15-minute duration of back massage is beneficial
214333938|NCT06987162|OTHER|Instrument-Assisted Soft Tissue Mobilization|The Graston group performed as IASTM during 4 weeks. After warmup session, Friction free oil or gel was used to facilitate the device to move over the skin. Gua Sha tools were used. The instrument was kept at 45°, moved over the skin from cranial to caudal for 40-120 Sec on the back, while patients were lying in the prone position.The mobilization with sweeping strokes followed by fanning strokes were applied over the Erector spinae, quadratus lumborum, scrolling the device on the muscle belly from the posterior fascia and sacrum.
214333939|NCT06663644|OTHER|Muscle energy technique on iliotibial band|Post isometric relaxation involves the peripheral and central modulating mechanism by activating the muscles and joint mechanoreceptors. It can be effective for a variety of purposes including lengthening a shortened muscles, as a lymphatic or venous pump to aid the drainage of fluid or blood and increasing the range of motion. MET is a manual therapy intervention that can be used to stretch or lengthen muscles and fascia that lack flexibility.
214333940|NCT06663644|OTHER|Hamstring and abdominal muscle activation|The 90/90 exercises for abdominal and hamstring activation rotate the pelvis posteriorly in the sagittal and transverse plane, into a more neutral position. Hamstrings extend the hip, and therefore reciprocally inhibit hip flexors. Hamstrings and abdominals also aid in inhibiting paraspinal muscles via a posterior pelvic tilt / hip extension, a decrease in lumbar extension, and an increase in lumbar flexion.
214333941|NCT06663618|DRUG|prednison|Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.
214486363|NCT06833567|BEHAVIORAL|Brief mentalization-based group psychotherapy|"The intervention is an adaptation for anxiety and depression profiles of the introductory group program to Mentalization-Based Treatment for personality disorders.~Sessions program:~* Session 1: Building epistemic trust.~* Session 2: Introduction to mentalization.~* Session 3: Mentalization problems.~* Session 4: Emotions.~* Session 5: Mentalizing emotions.~* Session 6: Attachment relationships.~* Session 7: Attachment and mentalization.~* Session 8: Interpersonal relationships. Mentalizing relationships in the group.~* Session 9: Anxiety, attachment and mentalization.~* Session 10: Depression, attachment and mentalization.~* Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing~* Session 12: Final balance and closing."
214673904|NCT05913401|BEHAVIORAL|Video Watching|20 minutes of watching documentaries or educational videos prior to each TMS session
214934993|NCT05351879|BIOLOGICAL|GAD-alum (Diamyd) 40 μg/mL|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) adsorbed to Alhydrogel at a concentration of 40 μg/mL and is given as a sterile solution for intralymphatic injection
214673905|NCT04579393|DRUG|Placebo|Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
214673906|NCT04579393|DRUG|fostamatinib|The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
214934994|NCT05128890|PROCEDURE|Resection techniques for pancreatic and liver tumors|to compare open versus minimally invasive pancreatic resection techniques and analyze the different outcome variables from the clinical standpoint
214934995|NCT01826565|PROCEDURE|Rotational technique|90 degree rotation
214934996|NCT02419612|DRUG|Saxagliptin|
214934997|NCT02419612|DRUG|Dapagliflozin|
214934998|NCT02419612|DRUG|Glimepiride|
214934999|NCT02419612|OTHER|Placebo|
214935000|NCT02329067|OTHER|walnuts|consumption of 43 g walnuts per day
214333942|NCT06663618|DRUG|Mycophenolate mofetil|Oral Mycophenolate mofetil 0.75g bid for 6 months.
214333943|NCT06662565|BEHAVIORAL|Behavioral modification|"It includes:~.- Reducing or eliminating smoking and carbonated drinks.~* Weight loss in overweight or obese individuals.~* Caffeine Reduction: Limiting caffeine intake, especially for those consuming at least 400 mg per day.~* Consume Adequate Water: 6 to 8 glasses of water per day.~* Refrain from consuming fluids 2 to 3 hours before bedtime.~* Identify Bladder Irritants: such as sugar substitutes, citrus fruits, and tomato.~* Increasing fiber intake like fruits, and vegetables to reduce constipation with adequate hydration to make stools softer and easier to pass"
214333944|NCT06662565|OTHER|Pelvic floor down-training|"Pelvic floor down training exercises aimed at promoting relaxation and deconditioning of the pelvic floor muscles (PFM). It will be practiced three sessions per week for 8 weeks.~Biofeedback-Assisted pelvic floor down-training:~Procedure:~* Rectal biofeedback will be inserted.~* The therapist asks the woman to focus on consciously relaxing and releasing the PFM after each contraction or exercise while watching biofeedback screen.~* Then, breathe deeply and fully into her abdomen, allowing her pelvic floor to naturally relax and lengthen.~* And to incorporate relaxation techniques such as visualization, or progressive muscle relaxation to promote overall muscle relaxation and reduce PFM tension.~* Exercises are typically repeated around 10-20 times per session. This number can vary depending on the patient's condition and tolerance, as well as the therapist's assessment and treatment plan."
214935001|NCT06668844|PROCEDURE|Endoscopic direct Draf IIa|Endoscopic direct Draf IIa (Carolyn' window approach) frontal sinusotomy
214347227|NCT02276482|DRUG|Antibiotic comparator|Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
214347228|NCT02276482|DRUG|Aztreonam|In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.
214935002|NCT06668844|PROCEDURE|Endoscopic angled Draf IIa|Group BFrontal sinusotomy using angled endoscopeand instruments
214935003|NCT01033955|DRUG|Rosuvastatin|Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
214935004|NCT01033955|DRUG|Placebo|identical appearing encapsulated placebo.
214935005|NCT01740908|OTHER|Hyperbaric Oxygen Treatment|"Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle.~All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days."
214935006|NCT04210908|OTHER|Visual biofeedback|Patient will observe the descent of the fetal head as they push during contractions
214935007|NCT06482684|DRUG|KTE-X19|See description of treatment arms
214935008|NCT06482684|DRUG|Ibrutinib|See description of treatment arms
214935009|NCT02827019|OTHER|questionnaire|a questionnaire made puerperium the 2nd day of life during the interview with the parents on the basis of a semi-structured interview about the progress of the birth and the immediate postpartum period using the memories of parents
214935010|NCT04411979|OTHER|treatment-as-usual plus aerobic walking|aerobic walking
214935011|NCT06664138|DRUG|Remimazolam|Remimazolam is a recently approved medication used for the induction of general anesthesia and maintenance of sedation. There have been no prior studies using remimazolam for the induction of anesthesia in ECT, and this research aims to investigate the feasibility of using remimazolam as an induction agent for ECT.
214935012|NCT06664138|DRUG|Etomidate|Etomidate is widely used in ECT due to its rapid onset, stable hemodynamic profile, and quick recovery. In this study, remimazolam will be used as the experimental group, while etomidate will serve as the control group.
214935013|NCT01754961|DRUG|Vitamin D|Vitamin D 500,000 IU given orally on Day 1
214935014|NCT01754961|DRUG|Placebo|Placebo given orally on Day 1
215073109|NCT03305419|DRUG|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
215073110|NCT03305419|DRUG|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
214935015|NCT01095978|DRUG|Clarithromycin (Klacid SR)|Klacid SR in a dose of 1000 mg once daily
214935016|NCT06666933|BEHAVIORAL|Time restricted eating|TRE (eating is allowed from 8am to 4pm without limitation in calories) with metformin 1g bid po for 6 weeks
214935017|NCT06666933|DRUG|Metformin|Taking metformin 1g bid po only for 6 weeks as control
214935018|NCT02135107|DRUG|Rabeprazole|Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
214935019|NCT02135107|DRUG|Rabeprazole|Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
214935020|NCT02135107|DRUG|Rabeprazole|Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
214935021|NCT02135107|DRUG|Rabeprazole|Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
214935022|NCT00474045|DRUG|insulin detemir|Treat-to-target, dose titration, s.c. (under the skin) injection
214935023|NCT00474045|DRUG|NPH insulin|Treat-to-target, dose titration, s.c. (under the skin) injection
215073111|NCT03162484|BEHAVIORAL|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
215073112|NCT00075946|BIOLOGICAL|rituximab|Given IV
214935024|NCT00474045|DRUG|insulin aspart|Treat-to-target, dose titration, s.c. (under the skin) injection
214333945|NCT06664463|OTHER|Arousal enhancment protocol|"Auditory stimulation: Playing familiar music or personalized playlists tailored to the patient's preferences evokes emotional responses and promotes arousal.~Olfactory stimulation: Using essential oils or fragrances associated with calming or invigorating properties fosters emotional connections and evokes nostalgia through scents linked to positive memories.~Visual stimulation: Displaying photographs of family members or significant events provides comforting visual stimulation and stimulates visual awareness.~Tactile stimulation: Gentle touch or therapeutic massage engages the patient through tactile input, promoting physiological and emotional responses.~Besid thsi protocl also the will recivce routine care throughout study period The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive s"
214333946|NCT06664463|OTHER|Routine Care|The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive supportive care, including pain management, hydration, and nutrition, as well as physical, occupational, or speech therapy as needed based on their recovery progress
214333947|NCT06594705|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
214333948|NCT01157533|DRUG|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
214935025|NCT03083561|DRUG|LY3337641|Administered orally.
214935026|NCT03083561|DRUG|Placebo|Administered orally.
214935027|NCT05523011|DRUG|Exosome ointment|100 µg MSC exosomes/g ointment
214935028|NCT02009397|DRUG|Ipilimumab|
214935029|NCT02009397|DRUG|GM-CSF|
214935030|NCT03280082|OTHER|MUAC Program|All children admitted to the PB program will receive standard care according to the national Protocol and that of MSF, including preventive and therapeutic care at admission as well as hospital care in case of clinical complications. There will be no change in the Protocol for the hospital care to the CRENI (Center of Intensive Nutritional Rehabilitation). RUTF (Ready-to-Use therapeutic food) will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
214935031|NCT03280082|OTHER|Standard Program|All children admitted to the standard program will receive standard care according to national and MSF protocols, including preventive and therapeutic care on admission as well as hospital care in case of clinical complications. RUTF will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
214673907|NCT04022369|BEHAVIORAL|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. The program was established on evidence-based recommendations for the cardiac rehabilitation of patients with HF. Each session included warm-up and cool-down exercises, moderate walking, and balance exercises.
214935032|NCT05204173|DRUG|sintilimab, paclitaxel and S-1|Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days with one week rest.
215073113|NCT03913832|DEVICE|sirolimus drug coated balloon (SCB)|"Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology Nanolute. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions \& de novo lesions."
214935033|NCT06323746|DEVICE|Denneroll cervical traction orthodontic|The duration of each session will start at approximately three minutes and increase by one minute per session until reaching the goal of 20 minutes per session. The intervention will be repeated three times per week for 10 weeks in the supervised setting.
214333949|NCT05121116|BEHAVIORAL|Online Mindfulness-Based Stress Reduction (MBSR)|Participation in an 8-week MBSR program consisting of pre-recorded mindfulness practices, including a guided body scan in week 1, guided sitting meditation in week 2, mindful yoga practices in week 3 and 4, meditation on difficult emotions in week 5, visualization meditation in week 6, lovingkindness meditation in week 7, and a silent meditation in week 8. Most practices last approximately 30 minutes and participants were encouraged to engage in a mindfulness practice daily or as often as possible. In weeks 2 - 8 participants could choose to alternate the practice introduced each week with practices from previous weeks. Participants had immediate access to all practices but were asked to complete them sequentially and in the order described above over a period of eight weeks. The MBSR program also encourages participants to employ mindfulness in their daily lives, and gives access to educative readings and videos related to the weekly mindfulness practices.
214935034|NCT05221346|DIETARY_SUPPLEMENT|Plant food supplement|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
214935035|NCT05221346|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
214935036|NCT02987374|BIOLOGICAL|2011-2012 Fluzone IIV3 (IM)|2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
214935037|NCT05839782|PROCEDURE|Mitral valve repair (PLM)|A mitral valve plasty is performed to treat mitral regurgitation
214935038|NCT05839782|PROCEDURE|Mitral valve replacement|A mitral valve replacement with a prosthesis is performed to treat mitral regurgitation
214935039|NCT01312168|DEVICE|Therapeutic CPAP|CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months
214935040|NCT01312168|DEVICE|Subtherapeutic CPAP|Subtherapeutic CPAP ventilator, pressure \<3 cmH2O, daily use at sleep, six months
215073114|NCT03913832|DEVICE|paclitaxel releasing coronary balloon catheter|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.
215073115|NCT02443194|DRUG|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
215073116|NCT02443194|DRUG|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
214333950|NCT06981156|DIAGNOSTIC_TEST|pNANO Assessment|"pNANO assesses patient gait, strength, cerebellar function, visual fields, visual acuity, facial strength, level of consciousness, extraocular movement, dysarthria, and dysphagia~The patient will be assessed by 2-3 different clinicians during each of 2 visits."
214935041|NCT02175082|OTHER|Cycling at Forced rate|
214935042|NCT02175082|OTHER|Cycling at self-selected rate|
214935043|NCT02278120|DRUG|Ribociclib|Ribociclib (600 mg, in three 200 mg hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.
214935044|NCT02278120|DRUG|Tamoxifen|Tamoxifen (20 mg, tablets) was administered orally on a continuous daily schedule (days 1-28 of each 28-day cycle)
214935045|NCT02278120|DRUG|Letrozole|Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
214935046|NCT02278120|DRUG|Anastrozole|Anastrozole (1 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
214935047|NCT02278120|DRUG|Goserelin|Goserelin (3.6 mg, subcutaneous implant) was administered on day 1 of every 28-day cycle
214935048|NCT02278120|DRUG|Placebo|Placebo (hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.
214935049|NCT02057029|BEHAVIORAL|BCI Assay Results|The nature of the intervention is to utilize the BCI results in the decision making process for ER-positive breast cancer patients and their physicians.
214935050|NCT00006280|DRUG|Tobramycin for Inhalation|
214935051|NCT02441127|DEVICE|diode laser group|the laser tip was used to remove all visible epithelium in the outer side of the defined graft area. The treatment was performed from the coronal to the apical aspect in parallel paths, and care was taken to avoid any laser contact to the palatal bone and periosteum by aiming the laser beam at a 450 angle to the palatal soft-tissue. The resultant layer on the surface was totally removed with knife and moist gauze. Then, the graft was harvested from the de-epithelized area with a 15c blade.
214935052|NCT02441127|PROCEDURE|scalpel control group|In the control group tissue was obtained by two horizontal and two vertical incisions defining the area to be harvested. The blade was oriented perpendicular to the bone along the coronal horizontal incision and once an adequate soft tissue thickness was obtained; it was rotated in order to be parallel to the superficial surface. The thickness of the graft was maintained uniform while proceeding apically with the blade until the FGG was harvested. The palatal wound was protected with equine-derived collagen maintained by compressive sling 5-0 sutures
214935053|NCT00287989|DRUG|Carboplatin|
214935054|NCT00287989|DRUG|erlotinib hydrochloride|150mg
214935055|NCT00287989|DRUG|Paclitaxel|200mg/m2
214935056|NCT00287989|DRUG|erlotinib hydrochloride|1500mg
215073117|NCT00380029|DRUG|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
214673908|NCT02757495|DRUG|Dexmedetomidine|Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
214673909|NCT04146532|DRUG|Aspirin 500 MG|Single 500mg aspirin capsule.
214673910|NCT04146532|DRUG|Placebo|Single 500mg placebo capsule.
214673911|NCT00002828|DRUG|fluorouracil|
214673912|NCT00002828|DRUG|raltitrexed|
214673913|NCT02426866|DRUG|Efavirenz|
214673914|NCT05828940|DRUG|Losartan Potassium|oral tablet, over-encapsulated
215073118|NCT00380029|PROCEDURE|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
215073119|NCT06321198|BIOLOGICAL|iMSC|Subjects will receive 4 or more times of iMSC injection
214673915|NCT05828940|DRUG|Placebo|oral tablet, over-encapuslated
214333951|NCT06663865|DIETARY_SUPPLEMENT|Active|"40g bio-active whey protein concentrate powder containing dairy phospholipids~Other Names:~Active Treatment"
214333952|NCT06663865|DIETARY_SUPPLEMENT|Placebo|"Around 40g pea protein powder not containing dairy phospholipids~Other Names:~Placebo Treatment"
214347229|NCT02276482|DRUG|Metronidazole|Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
214673916|NCT02343328|BIOLOGICAL|Fecal Microbiota Transplant|
214673917|NCT02343328|BIOLOGICAL|Placebo|
214673918|NCT06405204|DRUG|Myoinositol|an enzymatic isoform of inositol and belongs to the vitamin B complex family
214673919|NCT06405204|DRUG|Co-Enzyme Q10|a lipid-soluble quinone, acting as an effective antioxidant,
215073120|NCT03082183|DRUG|Rifampicin|once daily
215073121|NCT03082183|DRUG|BI 425809|once daily
215073122|NCT06584331|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days
215073123|NCT06584331|DIETARY_SUPPLEMENT|2 doses of Beetroot juice intake|This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.
214333953|NCT06662981|BEHAVIORAL|preoparative information and education|The intervention will include oral and written education about the operation, nursing and active participation in self-care. The intervention will take place in 3 phases: One week before THA, one day before THA after patient admission and postoperatively, before patient discharge. After a rough description of the operation, the anatomy and functionality of the joint will be presented, underlining the necessity of the operation. Instructions for recognizing and managing potential complications will be given. Patients will be informed about the appropriate post-operative walking aids, walking style, sitting up techniques, standing-up techniques, lying down techniques and getting in and out of the car. There will be a demonstration of muscle strengthening exercises, isometric quadriceps and gluteal exercises, Patients will also be informed about the necessity of prophylactic postoperative antithrombotic and antibiotic treatment.
214935057|NCT03545594|OTHER|Patient-centered in home rehabilitation|Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts before the Corona pandemic and eight sessions with up to six of them video delivered if necessary during the Corona pandemic ) delivered over a 4-month period in three phases
214673920|NCT06405204|DRUG|Melatonin|an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant
214673921|NCT06405204|DRUG|Folic acid|control
214673922|NCT02904564|DRUG|MMP with 5-FU|MMP with 5-FU using tattoo device
214673923|NCT02904564|DRUG|MMP with Saline infusion|MMP with saline infusion using tattoo device
214333954|NCT06663488|PROCEDURE|Thoracic epidural anesthesia|The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .
214333955|NCT06663488|PROCEDURE|Thoracic spinal anesthesia|Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
214333956|NCT06663267|OTHER|NOT|This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.
214333957|NCT06659315|BEHAVIORAL|Couples Problem Solving Therapy|A couples-based problem solving program to deal with depression, PMTCT adherence, and couple communication.
214333958|NCT06990295|PROCEDURE|Focused Ultrasound Spleen Neuromodulation|A portable focused ultrasound device is used to stimulate the spleen area under real-time imaging guidance. Each session lasts approximately 20 minutes, repeated twice daily for five days.
214333959|NCT03246529|DRUG|BL-8040 1.25 mg/kg + G-CSF|Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
214673924|NCT05275413|BEHAVIORAL|family-based mHealth Intervention|The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.
214935058|NCT03545594|OTHER|Control|Usual follow-up in the municipality
214935059|NCT00489229|DRUG|Rosiglitazone|
214935060|NCT00489229|DRUG|Ramipril|
214935061|NCT02262689|DRUG|GSK2256294|GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
214935062|NCT02262689|DRUG|Placebo|Matched Placebo will be supplied as gelatin capsule to be administered orally
214935063|NCT00254176|DIETARY_SUPPLEMENT|Parenteral cysteine-HCl supplementation|cysteine-HCl supplementation 121 mg per kg per day
214935064|NCT00254176|DIETARY_SUPPLEMENT|Placebo - added premasol|Premasol 121 mg per kg per day
215073124|NCT06584331|DIETARY_SUPPLEMENT|Placebo|In this group, the participants will receive 70ml of low-nitrate beetroot juice to consume in the morning.
215073125|NCT03440567|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
215073126|NCT03440567|DRUG|Avelumab|Given IV
215073127|NCT03440567|DRUG|Carboplatin|Given IV
215073128|NCT03440567|DRUG|Etoposide Phosphate|Given IV
215073129|NCT03440567|DRUG|Ibrutinib|Given PO
215073130|NCT03440567|DRUG|Ifosfamide|Given IV
215073131|NCT03440567|OTHER|Laboratory Biomarker Analysis|Correlative studies
214333960|NCT03246529|DRUG|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
214333961|NCT02777346|DEVICE|Absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
214333962|NCT02777346|DEVICE|Non absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
214333963|NCT06989983|DRUG|AZD5462 film-coated tablet|Oral, fasted
214673925|NCT05275413|BEHAVIORAL|mother-only mHealth Intervention|The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.
214333964|NCT06989983|DRUG|[14C]AZD5462 Solution for Infusion|Intravenous, fasted
214333965|NCT06989983|DRUG|[14C]AZD5462 Oral Solution|Oral, fasted
214333966|NCT00006347|RADIATION|indium In 111 monoclonal antibody MN-14|
214673926|NCT05275413|OTHER|Health education|The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
214673927|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate|Participants have a one in three chance of consuming a carbohydrate beverage between two bouts of high-intensity exercise.
214673928|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate-Protein|Participants have a one in three chance of consuming a carbohydrate-protein beverage between two bouts of high-intensity exercise.
214673929|NCT04859491|DIETARY_SUPPLEMENT|Placebo|Participants have a one in three chance of consuming a placebo beverage between two bouts of high-intensity exercise.
214935065|NCT01846429|DRUG|Sodium Bicarbonate|Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
214935066|NCT06605989|PROCEDURE|Nasotracheal intubation|For nasotracheal intubation, the nasal RAE tube will be first inserted through the left nostril for patients in the left nostril side arm. For nasotracheal intubation, the nasal RAE tube will be first inserted through the right nostril for patients in the right nostril side arm.
214935067|NCT00920127|DIETARY_SUPPLEMENT|AKL1|"Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm."
214673930|NCT04936880|DEVICE|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
214673931|NCT04936880|DRUG|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
214673932|NCT01326962|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
214673933|NCT01788085|DEVICE|Bravo pH monitoring procedure|Bravo pH monitoring procedure
214673934|NCT03750162|DEVICE|VDW Ultra|supplementary disinfection technique
214673935|NCT03750162|DEVICE|AMD picasso|supplementary disinfection technique
214673936|NCT03750162|DEVICE|ProtaperNext X3 gutta-percha|supplementary disinfection technique
214673937|NCT02153515|OTHER|Your own ( autologous) finger prick of blood produced with a diabetic lancet|
214673938|NCT01399827|DRUG|ADHD Medication|For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
214673939|NCT01399827|DRUG|Omega-3 Fatty Acids|Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
214673940|NCT04232501|DEVICE|Cirvo Compression device|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
214673941|NCT02369510|DRUG|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
214673942|NCT02369510|DRUG|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
214673943|NCT02369510|DRUG|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
214673944|NCT04661813|OTHER|EXTRA-CVD Virtual Care|"The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination."
214333967|NCT00006347|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
214333968|NCT05473312|BEHAVIORAL|Community Sensitization|One event will be developed and delivered for households in each cluster area. Approach and content will be informed by the formative research and CAC input (may include drama and nutrition fairs).
214673945|NCT00010023|DRUG|capecitabine|
214673946|NCT00010023|DRUG|cisplatin|
214673947|NCT04283877|DRUG|Methylphenidate|3 x 10 mg oral tablets. Single acute dose for all participants
214673948|NCT04283877|DRUG|Placebo oral tablet|3 x 10 mg oral lactose tablet for all participants
214673949|NCT06863558|DRUG|PPA Intervention|"Participants in this group will receive a pharmacological cocktail (PPA) for five days in addition to standard medical treatment for acute ischemic stroke. The regimen includes terazosin or urapidil, and propranolol or esmolol, with individualized blood pressure management. The specific protocol is as follows:~* Terazosin (no less than 1 mg orally or via nasogastric tube, nightly) or Urapidil (100 mg in 30 mL saline, IV infusion at no less than 2 mL/h)~* Propranolol (10 mg orally or via nasogastric tube, three times daily) or Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond 48 hours, switch to Propranolol)"
214333969|NCT05473312|BEHAVIORAL|28-day PD/Hearth Sessions|Mothers will come together in a home-like setting to rehabilitate their malnourished child (8 dyads/Hearth), learn and practice new feeding and childcare behaviours (during Covid-19: 4 dyads/Hearth). Curriculum and activities will be informed by CAC, CORE Guide and formative research. Two female facilitators will demonstrate, encourage, convey key messages and guide practices.
214333970|NCT05473312|BEHAVIORAL|Supplemental Print Information|The content will be informed by the formative research and CAC, will reinforce Hearth messages, and be adapted for each gender group. Material will be locally produced, engaging, user friendly, and target an illiterate audience (i.e. culturally relevant images with minimal text).
214333971|NCT05059015|DIAGNOSTIC_TEST|CERVICAL HPV|A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.
214333972|NCT05059015|DIAGNOSTIC_TEST|SELF SAMPLING HPV|A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
214333973|NCT06043310|DRUG|Nω-nitro-L-arginine methyl ester (L-NAME)|L-NAME will be infused locally through microdialysis catheters.
214333974|NCT06043310|DRUG|Acetylcholine|ACh will be infused locally through microdialysis catheters.
214673950|NCT04936425|DEVICE|OTSC Stentfix|The OTSC stentfix will be placed during upper endoscopy after a self-expanding metal stent has been deployed.
214673951|NCT01982201|DRUG|Lesinurad 400 mg|
214935068|NCT05071040|BEHAVIORAL|Home-based physical activity|Participants will follow a strength exercise program
214935069|NCT06667986|OTHER|artificial intelligence models (YOLO and Mask-RCNN)|machine learning model will used to detect secondary caries around restorations by comparing the results with digital bitewing radiography
214935070|NCT01966068|OTHER|MyAsthma Web Portal|Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
214673952|NCT01982201|DRUG|Tums 500 mg and 750 mg|
215073132|NCT03440567|BIOLOGICAL|Rituximab|Given IV
214673953|NCT01982201|DRUG|MINTOX 10 mL|
214935071|NCT01486901|DRUG|isophane human insulin|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
214935072|NCT02266472|DRUG|metformin|single dose of metformin given as tablets
215073133|NCT03440567|BIOLOGICAL|Utomilumab|Given IV
214935073|NCT02266472|DRUG|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
214935074|NCT02266472|DRUG|empagliflozin|single dose of empagliflozin given as tablet
214935075|NCT00808639|DRUG|Methotrexate|intravenously 30mg/m2 over 30 minutes
214935076|NCT00808639|DRUG|Doxorubicin|intravenously 30mg/ms over 15 minutes
214935077|NCT00808639|DRUG|vinblastine|intravenously 3mg/m2 over 30 minutes
214935078|NCT00808639|DRUG|cisplatin|intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
214935079|NCT00808639|DRUG|Pegfilgrastim|Given subcutaneously 24 hours after last chemotherapy dose
215073134|NCT06232980|PROCEDURE|urological surgical intervention|Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.
215073135|NCT03639623|DRUG|Saroglitazar|Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
215073136|NCT05392855|OTHER|Symptom driven performance of airway clearance|Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
215073137|NCT05392855|OTHER|Continuous daily performance of airway clearance|Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
215073138|NCT00889603|DRUG|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
215073139|NCT05963412|OTHER|Meaning Centered Coping Program|"Meaning Centered Coping Program is a psychological intervention program developed for women diagnosed with breast cancer, based on the Meaning Making Model (Park, 2010; Park and Folkman, 1997) and Wong's (2010) principles of Meaning Therapy. Each weekly session had specific topics. These are:~Session 1: Guiding patients to tell the story of their breast cancer and psycho-education; Session 2: Encouraging patients to talk about the effects of breast cancer on their lives and learning to accept their difficult emotions; Session 3: Focusing on cognition through the meaning attributed to breast cancer; Session 4: Learning to take alternative perspectives and defusing their negative thoughts; Session 5: Exploring personal strengths; Session 6: İdentifying important life values and moving toward value-based actions; Session 7: Finding meaning in breast cancer and life; Session 8: Focusing on Future plans and hopes"
215073140|NCT04005508|DIAGNOSTIC_TEST|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
214333975|NCT06043310|DRUG|Sodium Nitroprusside|SNP will be infused locally through microdialysis catheters.
214333976|NCT03117387|DIAGNOSTIC_TEST|Measurements of the level of neuromuscular blockade|Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.
214333977|NCT06995144|DRUG|Extended Release Torsemide Tablets|Extended release torsemide vs Immediate release torsemide
214333978|NCT06995144|DRUG|Immedate Release Torsemide Tablets|Immediate release torsemide vs Extended release torsemide
214333979|NCT06321484|BIOLOGICAL|Cytokine-Induced Memory-like Natural Killer Cells|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.
214673954|NCT01507246|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
214673955|NCT01507246|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
214935080|NCT06667024|DRUG|Hyperbaric bupivacaine|Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only
214935081|NCT06667024|DRUG|Dexmedetomidine and Hyperbaric bupivacaine|Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient height) hyperbaric bupivacaine
214935082|NCT05781516|DRUG|Prednisolone|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.
214673956|NCT05508568|DIAGNOSTIC_TEST|ADXBLADDER|ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.
214673957|NCT02762864|OTHER|platelet (P2Y12) reaction units|VerifyNow P2Y12 assay point-of-care testing
214673958|NCT02762864|DRUG|ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
214935083|NCT05781516|DRUG|Baricitinib|Oral Baricitinib 2mg daily for 12 months.
214935084|NCT06173635|DEVICE|Maxi Move 5|4 comparative devices will be used to evaluate the MM5 device
214935085|NCT00432224|PROCEDURE|photodynamic therapy|
214935086|NCT02009124|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
214935087|NCT01151202|DRUG|AG NPP709syrup|
214935088|NCT05793450|DRUG|IBI362|2.0mg, SC, single dose
214935089|NCT00207558|DRUG|folic acid|
214935090|NCT04430764|PROCEDURE|non-surgical periodontal treatment|Non-surgical periodontal treatment program was as following: First, motivation and oral hygiene instructions were given to all participants with periodontitis. The modified-Bass tooth brushing technique with a given dentifrice and toothbrush twice a day, and dental flossing/ interdental brushing once a day was advised to all patients with periodontitis. Second, scaling using an ultrasonic device and root planning by hand instruments under local anesthesia was performed.
214333980|NCT06321484|DRUG|Interleukin 2|Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion
214935091|NCT00020943|BIOLOGICAL|filgrastim|5 ug/kg subQ daily day 4 until ANC \>10,000 (or ANC\> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3
214333981|NCT06996015|OTHER|Cognitive behavior therapy|The treatment session will begin with a 10-minute conventional therapy, including a 5-minute hot pack applied to the cervical region and a 5-minute Myofascial Release (MFR) using skin rolling and cross-hand techniques to relax and stretch the fascia layers. This will be followed by a 10-minute application of Sustained Natural Apophyseal Glides (SNAGs), where the physiotherapist will guide the patient's active neck movements with accessory glides to improve joint ROM and reduce pain. Lastly, a 20-minute Cognitive Behavioral Therapy (CBT) session will include visual aids, explanations of cervical spine biomechanics, pain pathways, ergonomics, and posture management. Patients will receive manuals summarizing key points and be encouraged to engage actively. The 40-minute session will be conducted twice weekly for four weeks
214333982|NCT06996015|OTHER|Cervical Stabilization Exercises|"The treatment session will last 40 minutes, twice a week for 4 weeks. It begins with a 10-minute conventional treatment: a 5-minute hot pack application to the cervical region followed by a 5-minute Myofascial Release (MFR) using the skin rolling technique. Natural wax will be applied for smooth strokes. MFR will engage all fascia layers with superficial strokes, progressing to deeper fascia using cross-hand stretch, depending on the pain tolerance.~Next, SNAGs (Sustained Natural Apophyseal Glides) will be applied for 10 minutes. The patient, seated, will actively move the painful joint through its range of motion while the therapist applies a glide force. This will be repeated 10 times for 3 sets.~Then session includes 20 minutes of Cervical Stabilization Exercises (CSE) with bracing in neurodevelopment stages (supine, prone, quadrupedal, bipedal), holding each position for 10 seconds. Isometric exercises and functional training with elastic bands and exercise balls follow."
214333983|NCT04169295|OTHER|Gynecologists' feedback on ART-Birth rates|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
214333984|NCT04169295|OTHER|Control group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
214333985|NCT00441337|BIOLOGICAL|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
214333986|NCT06996002|OTHER|Rhomboids Strengthening Exercise|"1. Seated Bent Row in Sitting position,3 sets of the exercise program with 12 repetitions per set, 3 times per week.~2. Bent Over Row in standing position, 3 sets, 12 repetitions, 3 times per week.~3. Lat Pull Down in sitting position with 12 repetitions per set, 3 times per week.~4. Shoulder Horizontal Abduction in lying position with 3 sets of the exercise program with 12 repetitions per set, 3 times per week.~5. Band pull apart performed 4sets, 12 repetitions, and 10 seconds rest for 2 mints, 3 times per week.~6. Prone lateral raise with 3 sets of the exercise program with 12 repetitions per set, 3 times per week.~Conventional treatment Modalities:~Trans-cutaneous Electric Nerve Stimulation (TENS) and Hot pack, postural exercises and stretching exercises"
214333987|NCT06996002|OTHER|Conventional Exercises|"Conventional Treatment~1. hot pack for 10 min,~2. Trans-cutaneous Electric Nerve Stimulation (TENS) will be applied, with pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the sub occipital region and the trapezius bilaterally.~3. Stretching exercises of tight muscles 2 sets of 15 min.~4. Posture correction exercises:~releasing muscles of anterior part of the trunk, neck, shoulder."
214673959|NCT02762864|DRUG|Comparator|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
214673960|NCT06260150|DEVICE|Intermittent Pneumatic Compression Devices|During use, the pressure is gradually reduced from large to small, and pressure is applied in steps, starting from the calf and moving up to the thigh. Every 30 minutes, the patient's skin color of the lower extremities is observed for any abnormalities, and the blood supply status of the distal ends of both lower limbs (palpation of the dorsalis pedis artery pulse) is noted. If any special conditions occur, the procedure must be immediately stopped.
214935092|NCT00020943|BIOLOGICAL|rituximab|375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 \& 12 Tx 3, and weekly for 2 doses Tx 5
214935093|NCT00020943|DRUG|carmustine|15 mg/kg IV infusion over 2 hours Day 6, Tx 4
214935094|NCT00020943|DRUG|cyclophosphamide|2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 \& 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
214935095|NCT00020943|DRUG|cytarabine|2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
214935096|NCT00020943|DRUG|doxorubicin hydrochloride|50 mg/sq m IVP Day 3, Tx 1\& 2
214935097|NCT00020943|DRUG|etoposide|40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
214935098|NCT00020943|DRUG|leucovorin calcium|50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels \<0.05 uM, Tx 1 \& 2
214935099|NCT00020943|DRUG|methotrexate|300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 \& 2
214935100|NCT00020943|DRUG|prednisone|100 mg/sq m PO Days 3-7, Tx 1 \& 2
214935101|NCT00020943|DRUG|vincristine sulfate|1.4 mg/sq m IVP Day 3, Tx 1 \& 2
214935102|NCT00020943|PROCEDURE|peripheral blood stem cell transplantation|Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
214935103|NCT05303766|DEVICE|Radio-frequency ablation|Radiofrequency thermocoagulation of the genicular nerves
215073141|NCT03481166|OTHER|Education on breastfeeding pain|A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
215073142|NCT01229254|DRUG|Amiodarone|Patients on Amiodarone
215073143|NCT01229254|DRUG|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
214935104|NCT05303766|DRUG|Intra-articular steroids|Intra-articular steroids for Knee osteoarthritis
214935105|NCT05303766|DEVICE|Pulsed Radio-frequency|Intraarticular Pulsed Radiofrequency of the knee
215073144|NCT01229254|DRUG|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
214333988|NCT07002567|OTHER|Implicit motor imagery|Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).
214333989|NCT07002567|OTHER|Explicit motor imagery|In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
214935106|NCT00004406|DRUG|human parathyroid hormone|
214935107|NCT06262945|DIAGNOSTIC_TEST|Diagnoses|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
214935108|NCT06262945|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
214935109|NCT06262945|BIOLOGICAL|platelet rich fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
214673961|NCT02730702|DEVICE|LEBS - Low coherence enhanced backscattering|Unprepped patients will have the LEBS probe brought into contact with the rectal mucosa, upon which 10 random readings will be obtained.
214673962|NCT04358913|DEVICE|MR scan with the Alberta linac-MR P3 system|Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
214673963|NCT06117592|OTHER|Education, training and assessment intervention|Staff competence assessment documents for acute oncology knowledge and skills
214935110|NCT06262945|DRUG|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
214673964|NCT02975648|BEHAVIORAL|educational model + follow up|Orientation from health professionals at discharge, educational program with explanation of booklets and telephone follow-up (three calls)
214333990|NCT03967418|BEHAVIORAL|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychiatric and addictive comorbidities)
214333991|NCT07009457|DRUG|SHR-1316 (sc) Injection|SHR-1316 (sc) injection.
214333992|NCT07009457|DRUG|SHR-1316 Injection|SHR-1316 injection.
214673965|NCT02975648|BEHAVIORAL|usual care|Hospital health professionals offered orientation on care after discharge
214673966|NCT04224987|DRUG|Azithromycin|"Azithromycin will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight or age-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
215073145|NCT01229254|DRUG|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
215073146|NCT04497103|OTHER|control|The traditional therapy included immersing the hand in paraffin for 10 min; soft massaging with a moisturizing gel for 5 min; passive mobilization of the wrist, MP, PIP, and DIP joints; active/passive ROM and stretching exercises; strengthening exercises (done in static mode initially and progressed in the second month to dynamic strengthening using elastic bands); desensitizing sensory stimulation of hypertrophic scars, occupational therapy.
215073147|NCT04497103|OTHER|Xbox kinect|The traditional plus Xbox Kinect games were related to five target activities determined according to the person-centered analysis results were chosen for each patient.
215073148|NCT04497103|OTHER|task oriented training|The traditional plus the target activities involved training with the materials (clothes, spoons, pencils, buttons, rope, etc) needed for the activity as well as Velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
215073149|NCT05140304|DEVICE|OCT angiography|OCT angiography of foveal avascular zone in diabetic retinopathy
215073150|NCT03853382|BEHAVIORAL|Cognitive analytic informed brief therapy|"The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings."
215073151|NCT00472316|BEHAVIORAL|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
215073152|NCT05610826|PROCEDURE|cytoreductive surgery|Cytoreductive surgery is an operation to remove as much tumor tissue as possible.
215073153|NCT05610826|DRUG|Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)|"PRRT is a form of targeted treatment (think of a lock and key) done by the use of a small molecule (Lutathera). Lutathera acts as a key to lock onto certain areas your tumor cells called receptors when injected into a vein and travels through blood."
215073154|NCT05610826|PROCEDURE|Peptide receptor radionuclide therapy (PRRT)|PRRT is a molecular targeted therapy used to treat neuroendocrine tumors (NET). Molecular targeted therapies use drugs or other substances to identify and attack cancer cells while reducing harm to healthy tissue. PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects.
215073155|NCT02231892|DEVICE|TMS|HAC coil (real rTMS or sham rTMS)
215073156|NCT02780583|DRUG|kineret|anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
214333993|NCT07009457|DRUG|Carboplatin Injection|Carboplatin injection.
214333994|NCT07009457|DRUG|Etoposide Injection|Etoposide injection.
214333995|NCT06680102|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
214333996|NCT06680102|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
214333997|NCT05247190|BEHAVIORAL|Treating self-criticism|A psychological treatment given i a group format targeting self-criticism. The treatment is based on treatment principles from Cognitive behavior therapy, Self-compassion, Acceptance and Commitment Therapy and also contains psychoeducation. The group treatment consists of 8 sessions delivered once a week for 2 hrs during 8 weeks in a child- and adolescent psychiatric outpatient setting.
214333998|NCT03071796|DIETARY_SUPPLEMENT|multivitamin supplement|supplement includes 97 natural extracts
214333999|NCT03071796|DIETARY_SUPPLEMENT|Placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
214334000|NCT06684041|DRUG|HRS-5965 capsule|HRS-5965 capsule
214334001|NCT06684041|DRUG|HRS-5965 capsule placebo|HRS-5965 capsule placebo
214334002|NCT07016750|BIOLOGICAL|KB803|Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein
214334003|NCT07016750|DRUG|Placebo|Vehicle
214334004|NCT06271772|DRUG|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
214334005|NCT06271772|DRUG|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 3-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
214334006|NCT06271772|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
214334007|NCT07022756|BEHAVIORAL|Honoraria|A $20 honorarium for each appointment attended with completed bloodwork if requested.
214334008|NCT07022756|BEHAVIORAL|Outreach|A personalized outreach service specific for rheumatic disease.
214334009|NCT06690398|DRUG|Lumateperone high dose|Lumateperone administered orally once daily
214334010|NCT06690398|DRUG|Lumateperone low dose|Lumateperone administered orally once daily
214334011|NCT06690398|DRUG|Placebo|Matching Placebo administered orally once daily
214334012|NCT06086535|PROCEDURE|Intercostal nerve cryoanalgesia vs BRILMA blockade|For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery
214935111|NCT06262945|DEVICE|low laser therapy, bicure laser|There are studies in the literature that low-energy lasers have positive effects on the biological and biochemical processes of wound healing. Acceleration of local circulation, increase in cell proliferation and collagen synthesis are among the various effects of laser application. B Cure Dental Pro Laser application will be applied to the patient for the first 3 days. Low dose laser application will be applied to the angulus area, covering the surgical area for 8 minutes. Before this laser procedure, the patient will be asked to fill out a pain scale. This pain scale and the number of analgesics used will be monitored for 3 days.
214673967|NCT04224987|OTHER|Placebo|"Placebo will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
214334013|NCT07023432|DRUG|Belzutifan|Given by PO
214673968|NCT05588284|DEVICE|AngioJet device|A device can be used for thrombus aspiration and thrombolysis.
214673969|NCT05588284|OTHER|anticoagulation alone|a medicine for anticoagulation therapy
214673970|NCT04603378|OTHER|KB195|KB195 is a novel glycan
214935112|NCT06262945|DRUG|Analgesic|Analgesics are prescribed for the patients.
214935113|NCT01720498|DRUG|remifentanil|The effect site concentration of remifentanil
214935114|NCT00041977|DRUG|doxycycline hyclate 20 mg twice daily|
214673971|NCT04603378|OTHER|Polydextrose|Polydextrose is an oligosaccharide
214673972|NCT04603378|OTHER|Pullulan|Pullulan is an oligosaccharide
214673973|NCT04603378|OTHER|Maltodextrin|Maltodextrin is a digestible carbohydrate
214673974|NCT06626789|BIOLOGICAL|Amygdala neurofeedback|Real-time fMRI neurofeedback from amygdala's blood oxygenation level dependent (BOLD) signal + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
214673975|NCT06626789|BEHAVIORAL|Sham neurofeedback|Recorded neurofeedback from a different participant + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
214673976|NCT06877988|DEVICE|AI|Retinal photography-based deep learning algorithm for detection of disease-related visual impairment cases
214673977|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
214334014|NCT07023432|OTHER|Active Surveillance|Given by Observation
214334015|NCT07024316|DRUG|ATL-001 (Ciclopirox oral solution)|Daily administration of oral ATL-001
214334016|NCT07025616|BEHAVIORAL|Buteyko|The Buteyko breathing exercise is a method that encourages nasal breathing, reducing breathing volume, and using breath-holding exercises to normalize breathing pattern
214334017|NCT07025616|DRUG|Asthma reliever and controller|Asthma reliever and controller according to GINA (Global Initiative for Asthma) guideline
214334018|NCT06511869|DRUG|AZD4205|AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
214334019|NCT07025174|DRUG|PD-1/CTLA-4 Dual Functional Antibody|"PD-1/CTLA-4 Dual Functional Antibody (iparomlimab and tuvonralimab injection):~5 mg/kg intravenous infusion every 3 weeks (day 1 of each 21-day cycle) for up to 6 cycles, with potential for maintenance therapy continuation. Used in combination with GP regimen in experimental arm only. This is a novel dual-functional antibody targeting both PD-1 and CTLA-4 pathways simultaneously."
214334020|NCT07025174|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m² d1,8+Cisplatin 25mg/m² d1,8
214334021|NCT07025174|DRUG|Anlotinib|10mg po d1-14 q3w
214334022|NCT07025174|DRUG|Oxaliplatin + 5-Fluorouracil/Leucovorin|XELOX (oxaliplatin 130mg/m² d1+capecitabine 1000mg/m² d1-14 q3w) or FOLFOX6 (Oxaliplatin 85 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² intravenous bolus followed by fluorouracil 2400 mg/m² 46 hours, q2w)
214334023|NCT07024914|DRUG|Oxygen|Oxygen supplementation via nasal cannula at a rate of 3 lit/min during 30sec Sit-To-Stand Test among COPD patients without resting hypoxemia
214334024|NCT07024914|DRUG|medical air|Medical Air supplementation via nasal cannula at a rate of 3 lit/min during 30sec Sit-To-Stand Test among COPD patients without resting hypoxemia
214334025|NCT07025538|OTHER|Best Practice|Receive SOC treatment
214334026|NCT07025538|OTHER|Biomarker Analysis|Undergo GHVD biomarker analysis
214334027|NCT07025538|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214334028|NCT07025538|OTHER|Questionnaire Administration|Ancillary studies
214334029|NCT07025538|DRUG|Ruxolitinib|Given PO
214334030|NCT07023458|DIAGNOSTIC_TEST|Brief-P|Executive function test in preschool children with OSA
214334031|NCT07025681|BIOLOGICAL|Erythropoietin alfa|Erythropoietin 4000 IU Injection, for subcutaneous injection.
214486364|NCT06833567|BEHAVIORAL|Acceptance and Commitment Therapy group intervention|"The intervention includes 12 sessions based on Acceptance and Commitment Therapy. Sessions program:~* Session 1: Presentation.~* Session 2: Cognitive defusion~* Session 3: Uncontrollability of thought, emotions and behavior.~* Session 4: Creative Hopelessness.~* Session 5: Mindfulness and acceptance.~* Session 6: Values.~* Session 7: Values and action.~* Session 8: Vital goals.~* Session 9: Goal achievement plan.~* Session 10: Implementation.~* Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing~* Session 12: Final balance and closing."
214334032|NCT07024186|PROCEDURE|Xenogeneic Collagen Matrix|Xenogeneic Collagen Matrix The xenogeneic collagen matrix is a biomaterial used to promote soft tissue regeneration and support healing in dental implant procedures.
214334033|NCT07024186|PROCEDURE|subepithelial connective tissue graft|ubepithelial Connective Tissue Graft The subepithelial connective tissue graft is a biological tissue taken from the patient's own palate or other donor sites to promote healing and aesthetic outcomes around dental implants.
214334034|NCT03614949|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
214334035|NCT03614949|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
214334036|NCT07025486|BEHAVIORAL|HabitWorks|Smartphone delivered interpretation bias exercises, symptom tracking
214334037|NCT07025486|BEHAVIORAL|Symptom TRacking|Self-assessment via symptom surveys
214334038|NCT07025590|BEHAVIORAL|Moderate-intensity continuous movement and Antipsychotics intervention|On the basis of Antipsychotics intervention, Patients in the exercise group should start exercise intervention as soon as possible after completing baseline examination, and need to complete a training plan of at least 36 times, 3 times/week. At the beginning of each training session, patients need to warm up for 5-10 minutes, mainly jogging and stretching exercises. After the warm-up, the patient enters the training phase, the heart rate reserve is 70% to 85%, and after the training, the patient performs 10-15 minutes of recovery exercise, mainly jogging, slow walking and stretching. The specific exercise plan is formulated according to the patients' own aerobic capacity assessment, and the principle of formulation is gradual and individual. At each training session, patients were asked about their perceived fatigue level to adjust the training intensity.
214334039|NCT07025590|DRUG|Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine)|Patients maintained regular medication during the intervention period, and returned to the doctor every two weeks, and the psychiatrist decided whether to maintain the current dose or gradually reduce the dose based on the patient's symptoms and diagnosis. Psychiatrists, unaware of patient groupings, use supportive measures to help manage adverse reactions.
214334040|NCT07024342|DEVICE|Liner perforated with very small diameter holes|A commercially available, elastomeric liner perforated with very small holes (approximately 0.3 mm diameter) to allow perspiration to drain. This liner is worn between the skin and the participant's prosthetic socket.
214334041|NCT07024342|DEVICE|Liner perforated with somewhat larger diameter holes|A commercially available, elastomeric liner perforated with somewhat larger holes (approximately 1.5 mm diameter) to allow perspiration to drain. This liner is worn between the skin and the participant's prosthetic socket.
214334042|NCT07024342|DEVICE|Liner-liner|A thin, special purpose half-ply sock which may reduce the effects of perspiration. The liner-liner is worn between the skin and the participant's as-prescribed liner.
214935115|NCT01187498|BEHAVIORAL|Behavioral training|Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
214935116|NCT01187498|DRUG|Oxybutynin chloride, extended-release|Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
214935117|NCT05043597|PROCEDURE|Thrombus aspiration|Thrombus aspiration
214935118|NCT01585753|DRUG|NRTI + PI|tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
214935119|NCT01585753|DRUG|maraviroc + PI|maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
214334043|NCT07024342|DEVICE|As-prescribed liner|A commercially available, elastomeric liner with no perforations. This liner is worn between the skin and the participant's prosthetic socket.
214935120|NCT01585753|DRUG|maraviroc + NRTI|maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
214935121|NCT04794374|OTHER|Telerehabilitation|Telerehabilitation will consists of physiotherapist-guided exercises. Exercises will be designed by physiotherapists for COVID-19 survivors using the current guidelines. Exercise brochure will be prepared and will be sent to participants. Repetitions and sets of exercises will be modified according to the patients.
214935122|NCT01717482|DRUG|Metformin|
214935123|NCT01717482|OTHER|Placebo Comparator|Standard of Care Observation
214486365|NCT06018701|DEVICE|"A dental device made of zirconia. This is a new invention and does not exist generically. The given generic name of the invention (dental device) is Dantya Nikhan."|Dental device is surgically placed and cemented with PMMA bone cement on edentulous region.
214935124|NCT00409968|PROCEDURE|Tumor Biopsy|A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
214935125|NCT01736774|OTHER|Usual care intervention|The usual care intervention will include appropriate primary care as required including medication
214935126|NCT01736774|OTHER|Physiotherapy treatment|Exercise and manipulative therapy treatment for 10 weeks:The treatment intervention consists of two visits per week for the first four weeks (8 treatments) and one visit per week for the last six weeks (6 treatments)
214935127|NCT00191282|DRUG|Insulin lispro|Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
214935128|NCT00191282|DRUG|Human insulin isophane suspension (NPH)|Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \>8.0%
214935129|NCT00191282|DRUG|Insulin glargine|Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
214935130|NCT00191282|DRUG|Human insulin isophane suspension|Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
214935131|NCT00191282|DRUG|Human insulin 30/70|Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \>8.0%.
214935132|NCT00102531|DRUG|Cisplatin liposomal|
214935133|NCT00288067|DRUG|fenretinide|Given PO
214935134|NCT00288067|DRUG|rituximab|Given IV
214935135|NCT02628457|PROCEDURE|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
214935136|NCT02429024|DEVICE|OneTouch Reveal® Mobile APP|Diabetes management application for use on a mobile phone.
214486366|NCT06754735|DEVICE|Topical Wound Oxygen Therapy|The active intervention is the application of the Topical Wound Oxygen device that supplies cyclical oxygen pressure directly to the wound site within a sealed environment.
214935137|NCT02429024|DEVICE|OneTouch Verio® Flex BGMS|Blood Glucose Monitoring System (BGMS)
214935138|NCT06414824|DEVICE|Intermittently Scanned Continuous Glucose Monitoring|FreeStyle Libre, 4 weeks
214935139|NCT06414824|DEVICE|Standard Blood Glucose Monitoring|Standard blood glucose monitoring with glucose meters
214935140|NCT04635124|BEHAVIORAL|Dog visit|An visitor visits the participant with a dog
214935141|NCT04635124|BEHAVIORAL|Encourage to engage in activity|In each visit the visitor invites the participant to engage in an activitty
214935142|NCT06163742|DEVICE|Product X|The investigational device is a polyethylene glycol-based biomaterial. It can be applied to donor sites on the arms, torso, and legs.
214935143|NCT06163742|DEVICE|Standard-of-Care|The active comparator includes the current standard-of-care treatment: hydrocellular polyurethane dressing covered with TegadermTM film for 48 hours, followed by an occlusive gauze impregnated with 3% Bismuth Tribromorphenate in petrolatum.
214935144|NCT03004170|BEHAVIORAL|Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training|
214935145|NCT03004170|BEHAVIORAL|Telephone-Administered Coping Effectiveness Training|
214334044|NCT06420336|PROCEDURE|Quadratus lumborum block|After induction of anesthesia and securement of appropriate airway device, the patient will be placed in position for the QL block. Using ultrasound guidance, the pediatric anesthesiology attending will perform unilateral QL block on the side of the anterior iliac bone graft harvest. The dose will be 0.2% ropivacaine, 1 mL per kilogram to a max of 20 mL with an additive of dexamethasone 4 mg. Ultrasonography will be used to identify external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A 50 mm-150 mm block needle will be advanced under ultrasound guidance. Ropivacaine will be injected slowly with frequent aspiration to rule out incorrect needle placement. The anesthetic is deposited at the lateral edge of the QL after penetrating the transversus abdominus aponeurosis. Injection will continue to be observed with real time US guidance.
214334045|NCT06420336|PROCEDURE|Local anesthetic infiltration|After induction of anesthesia and securement of appropriate airway device the patient will be turned over to the surgical team to proceed with the operation. The surgeon will proceed with usual injection of local anesthetic as their standard of care; this medication will be charted by the circulating nurse in the Medication Administration Record with local anesthetic type and amount. At the conclusion of the procedure, to maintain the blind, the patient will have a bandage placed where the QL block would have been performed.
214334046|NCT07024433|PROCEDURE|Tubeless anesthesia|"1. Anesthesia Induction: Implement TCI with propofol and remifentanil; insert a laryngeal mask for SIMV ventilation, and monitor vital signs including IBP and end-tidal CO2.~2. Nerve Blocks: Perform ultrasound-guided paravertebral, pleural surface, and vagus nerve blocks using local anesthetics.~3. Anesthesia Maintenance: Adjust remifentanil for spontaneous breathing; maintain propofol and BIS levels; manage heart rate and blood pressure with fluids and medication as needed, without using inhaled anesthetics.~4. Postoperative Analgesia: Provide PCIA with morphine for pain management."
214935146|NCT03494400|OTHER|Aerobic Training Presential|The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days, more follow-up.
214334047|NCT07024433|PROCEDURE|Traditional tracheal intubation|"1. Anesthesia induction using propofol, sufentanil, and rocuronium is performed, with DLT or single-lumen tube insertion at BIS≤60 for single-lung ventilation, maintaining appropriate oxygen and ventilation parameters.~2. Anesthesia is maintained with sevoflurane, propofol, and remifentanil, supplementing rocuronium every 30-40 minutes for muscle relaxation, with BIS maintained at 40-60.~3. Post-surgery, ultrasound-guided thoracic paravertebral block and PCIA are used for analgesia, with extubation following standard recovery procedures."
214334048|NCT07025642|DRUG|Urodynamic evaluation before and after solifenacin treatment.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
214334049|NCT07025642|DRUG|Urodynamic evaluation before and after mirabegron treatment.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
214935147|NCT03494400|OTHER|Aerobic Training Home-based|The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities, more follow-up.
214935148|NCT05468242|DRUG|Neoadjuvant chemo-immunotherapy|The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab \[200 mg, once every 3 weeks (Q3W)\].
214935149|NCT05468242|DRUG|Bevacizumab|The Bevacizumab was administrated concurrently with neoadjuvant chemo-immunotherapy (7.5mg/kg) once every 3 weeks (Q3W).
214935150|NCT05468242|RADIATION|Radiotherapy|Definitive radiotherapy to the thoracic lesions.
214935151|NCT05468242|DRUG|Tislelizumab|Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.
214935152|NCT06370871|DRUG|Brigimadlin|Brigimadlin
214935153|NCT06370871|DRUG|Ezabenlimab|Ezabenlimab
214935154|NCT06370871|DRUG|Gemcitabine|Solution for infusion
214935155|NCT06370871|DRUG|Docetaxel|Solution for infusion
214935156|NCT05462132|DRUG|SYNB1353|SYNB1353 IMP is formulated as a nonsterile solution intended for oral administration. SYNB1353 is subsequently lyophilized to form the bulk drug product. The lyophilized product is sieved into powder form and filled into high-density polyethylene (HDPE) bottles. Placebo will be manufactured using an inactive powder that is color matched to the SYNB1353 drug product. L-Methionine will be supplied as dry powder and will be suspended in a diluent prior to use.
214935157|NCT06204471|DEVICE|Helite hip protector|hip protector
214935158|NCT06204471|DEVICE|Wolk hip protector|Hip protectdor
214935159|NCT00596128|BEHAVIORAL|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
215073157|NCT02780583|DRUG|placebo|placebo injection administered every 6 hours along with intravenous methylprednisolone
214334050|NCT07025642|DRUG|Urodynamic evaluation before and after combined treatment with solifenacin and mirabegron.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
214334051|NCT07025642|DRUG|Urodynamic evaluation before and after Botulinum toxin (Botox) injection.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
215073158|NCT00170768|DRUG|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
215073159|NCT00170768|DRUG|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
215073160|NCT00170768|DRUG|Placebo|Placebo once daily tablet (sham titration)
215073161|NCT00799227|DRUG|Dexamethasone|700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
215073162|NCT04845009|BEHAVIORAL|progressive muscle relaxation|progressive muscle relaxation
215073163|NCT04845009|BEHAVIORAL|Usual care|Usual care
215073164|NCT01897350|OTHER|Cardiac magnetic resonance imaging|
215073165|NCT03228459|DIAGNOSTIC_TEST|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
214334052|NCT07025083|BEHAVIORAL|Adapted Family Check-Up Online|The Family Check-Up Online is a digital intervention that includes an assessment, computer-generated feedback, and intervention modules that focus on improving family relationships and parenting skills in order to reduce child mental health problems and to improve child self-regulation. These modules include Healthy Behaviors for Stressful Times, Positive Parenting, Rules and Consequences, Supporting School Success, and Communication. In addition, two modules for Latinx families are being added in the adapted version. This version represents a deep adaptation.
214334053|NCT07025083|BEHAVIORAL|Original Family Check-Up Online|This version is the original Family Check Up Online translated into Spanish without the adaptions. This represents a surface-level adaptation.
214334054|NCT06878937|BEHAVIORAL|Peer Delivered Psychoeducation Program|The peer delivered psychoeducation program is the only intervention being tested in this pilot evaluation study.
214334055|NCT07023497|DRUG|Intrathecal morphine|Intrathecal morphine with fixed-dose fentanyl and ropivacaine
214334056|NCT05987462|OTHER|Green walking|The researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups. The first subgroup had their 50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval between green walks for both groups.
214334057|NCT07033793|BEHAVIORAL|GApp|Participants receive only digital support with health information, self-assessment tests, preventive advices and games. No educational sessions are provided, and the focus is solely on digital preventive advice used autonomously.
214334058|NCT07033793|BEHAVIORAL|GappE|"Participants receive preventive interventon delivered via digital support (smartphone app) including health information, self-assessment tests, preventive advices and games).~In addition to the App used autonomously, they will participate in 5 group educational sessions proposed by a physiotherapist (once every two weeks)."
214334059|NCT07039344|OTHER|Conventional method of Palliative care Training (Group A)|Group A receive training through the 2-step Conventional method. The first step comprises 1 didactic lecture / week (1 hour) for 10 weeks leading towards the second step of 1 skill session / week for 1 hour under instructor supervision for 6 weeks.
214334060|NCT07039344|OTHER|Pedagogical (LWPPR) method of Palliative care Training (Group B)|Group B will receive training through the 5-steps pedagogy method including: the 1st step (learn), in which didactic lectures will be given to the students leading to the 2nd step (video watch), a 30 minutes video on Palliative care. The students first see the video in the class on multimedia with explanation and then share to the students in what's up group for frequent watching as per need. In the 3rd step (practice), students practiced their skills on a low fidelity simulator under instructor supervision on a scheduled day of the week in the nursing skill lab for 6 weeks. The errors will be corrected on the spot. A total of 11 groups will make with a ratio of 5 in each group. In the 4th step (perform), students perform their skill in real-life situations through the clinical rotation under supervision. Finally, the 5th step (Retain) will be established through self-directed learning in which an additional one-hour skill session / week will be provided to the students.
214334061|NCT06717438|DRUG|BPN14770|Capsules for oral administration
214334062|NCT06717438|DRUG|Placebo|Capsules for oral administration
214334063|NCT07038239|DIAGNOSTIC_TEST|Skin biopsy|under the arm using a 3 mm punch, with local anaesthesia, in the investigating centres.
214486367|NCT06754735|DEVICE|Sham Control Topical Wound Oxygen|The sham control intervention is the application of Topical Wound Oxygen device that supplies topical room air to the wound site within a sealed environment.
214334064|NCT07038239|DIAGNOSTIC_TEST|Blood sample|"3 classical 4ml tubes samples per patients, using the routine blood sampling technique, in the investigating centres.~For children, blood sampling volume will be adapted to the patient's weight according to L.1121-1 of the French public health code."
214334065|NCT06721949|DRUG|Taurine|Taurine is a naturally occurring amino sulfonic acid commonly found in the body. It is marketed as a natural health product/supplement and plays an important role in the body.
214334066|NCT06721949|DRUG|Placebo|The placebo capsule is visually identical to the taurine capsule.
214334067|NCT02802280|OTHER|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
214935160|NCT04894552|PROCEDURE|Laparoscopic Hysterectomy and Sentinel Lymph Node Biopsy for Endometrial Carcinoma|Patients with endometrial carcinoma will undergo laparoscopic hysterectomy and sentinel lymph node biopsy. The patient will be positioned in a modified lithotomy position with the hips flexed 30 degrees. Blue dye is injected at the cervix. The round ligament will be transected. Sentinel lymph nodes will be detected, dissected and isolated. Then standard lymphadenectomy will be done. Then the infundibulopelvic ligament will be transected. Ligation of the uterine vessels. The cardinal ligaments will be transected, and the vaginal fornices will be opened laparoscopically. The whole specimen will be removed through the vagina. The vaginal cuff will be then closed trans-vaginally. Intraoperative and early postoperative complications will be assessed. The isolated sentinel lymph node will be sent for pathological study as well as the standard lymphadenectomy specimens. Both specimens will be compared to assess the diagnostic reliability and sensitivity of the sentinel lymph node.
214935161|NCT04756154|DRUG|CHG/IPA Surgical skin preparation|Apply topically to the inguinal region for 2 minutes
214935162|NCT04756154|DRUG|Normal saline|Apply topically to the inguinal region for 2 minutes
214935163|NCT05599087|BIOLOGICAL|Acellular system|Regenerative Endodontic Procedure Tissue engineering procedure
214935164|NCT02288078|OTHER|General condition|Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
214935165|NCT02288078|OTHER|Blood pressure|systolic blood pressure (SBP)/diastolic blood pressure (DBP)
214935166|NCT02288078|OTHER|Patient Reported Outcome|Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
214935167|NCT02288078|OTHER|Clinical findings|"* Blood and lymphatic system disorders: febrile neutropenia~* Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting~* General disorders and administration site conditions: fatigue and malaise~* Immune system disorders: allergic reaction~* Metabolism and nutrition disorders: anorexia~* Nervous system disorders: dysgeusia and peripheral sensory neuropathy~* Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)~* Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome~* Vascular disorders: hypertension~* Symptomatic pancreatitis"
214334068|NCT07048392|BEHAVIORAL|Retrieval-based word learning: Repeated Spaced Retrieval condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated spaced retrieval. In this condition, they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. This procedure will occur on two consecutive days."
214486368|NCT06752785|DRUG|CAR-T Therapy|CD19/CD22 CAR-T cell therapy
214935168|NCT02288078|OTHER|Hematology/blood chemistry|White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
214935169|NCT02288078|OTHER|Coagulation and fibrinolysis system|international normalized ratio (INR)
214935170|NCT02288078|OTHER|Urinalysis|Proteinuria (qualitative)
214935171|NCT02288078|OTHER|Medication check|Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
214935172|NCT02288078|OTHER|Adverse event|CTCAE ver.4.0
214935173|NCT02288078|OTHER|Thyroid function test|Thyroid-stimulating hormone (TSH), T4, and T3
214935174|NCT02288078|OTHER|Contrast-enhanced torso CT|It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
214935175|NCT02288078|OTHER|Brain MRI|If any symptom of brain metastasis is suspected
214935176|NCT02288078|DRUG|Dexamethasone|Capsule filled with dexamethasone and lactose
214935177|NCT02288078|DRUG|Regorafenib|Film-coating tablet contains 40 mg of regorafenib
214935178|NCT02288078|DRUG|Placebo|Capsule filled with lactose
214935179|NCT02288078|DRUG|Proton pump inhibitor|PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
214935180|NCT02694354|DRUG|BI 685509|
214935181|NCT02694354|DRUG|Placebo|
214935182|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days."
214935183|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
214935184|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours."
214935185|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
214334069|NCT07048392|BEHAVIORAL|Retrieval-based word learning: Repeated Study condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated study trials only (with no retrieval practice). In this condition, they will simply hear the information (word \& meaning) as part of the story. This procedure will occur on two consecutive days."
214334070|NCT06732375|BEHAVIORAL|Mindset Moments|"MM™ includes: 1) CBT; 2) resilience training; 3) mindfulness-based stress reduction; 4) peer support; and 5) family conversations delivered in small virtual groups, with a mentor who facilitates resilience-building conversations prompted from Skill of the Week lessons."
214334071|NCT07045896|DRUG|Fucoidan|Background Therapy: Continued pre-existing conventional RA treatment at stable doses Intervention: Oral fucoidan Dosage Form: Size-0 gelatin capsules containing 1000mg fucoidan powder Dosage: 2000mg (2 capsules) per dose, twice daily (BID) Duration: 12 weeks continuous treatment
214334072|NCT07045896|DRUG|Corn starch|Background Therapy: Continued pre-existing conventional RA treatment at stable doses Intervention: Oral Corn starch as Placebo Dosage Form: Size-0 gelatin capsules containing 1000mg Placebo powder Dosage: 2000mg (2 capsules) per dose, twice daily (BID) Duration: 12 weeks continuous treatment
214334073|NCT04206982|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
214935186|NCT05028127|DRUG|Bimekizumab|Subjects will be receiving bimekizumab at pre-specified time-points.
214935187|NCT05040672|BEHAVIORAL|questionare online application|questionare online application
214334074|NCT04206982|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
214334075|NCT04206982|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
214334076|NCT07042425|OTHER|Computer based cognitive telerehabilitation|An intervention group received computer-based cognitive training with online monitoring and a control group that received conventional cognitive training by an occupational therapist
214334077|NCT07048028|DRUG|Chitosan Low Molecular Weight (20-200 Mpa.S)|A 0.2 % (w/v) low-molecular-weight chitosan solution (50-190 kDa, ≥75 % deacetylation) prepared fresh in 1 % acetic acid, pH ≈ 6.0. Ten mL is delivered into the root canal over 30 s and left in situ for an additional 30 s (total contact 60 s), followed by a 5 mL sterile saline flush
214935188|NCT00454220|OTHER|Placebo|33 patients to placebo + 131-I arm
214935189|NCT00454220|DRUG|MRrhTSH|33 patients to 0.01 mg MRrhTSH + 131-I arm
214935190|NCT00454220|DRUG|MRrhTSH|33 patients to 0.03 mg MRrhTSH + 131-I arm
214935191|NCT04737395|DEVICE|"upper extremity training program (Meditouch,MSQUARE)"|40 hours of therapy with the Hand Tutor (MediTouch) device and a wearable vest (EkssoUE, Ekso Bionics) for arm rehabilitation
214334078|NCT07048028|DRUG|Sodium Hypochlorite|Commercial 2.5 % (w/v) sodium hypochlorite endodontic irrigant. Ten mL is delivered over 30 s and left for 30 s (total contact 60 s), then flushed with 5 mL sterile saline
214334079|NCT07048028|DRUG|EDTA chelating agents|Ready-to-use 17 % EDTA solution (pH ≈ 7.3) for smear-layer removal. Ten mL is delivered over 30 s and left for 30 s (total contact 60 s), then flushed with 5 mL sterile saline
214334080|NCT06741397|DRUG|CAB LA|Injections administered IM gluteal.
214334081|NCT06741397|DRUG|New formulation of CAB LA|Injections administered IM gluteal.
214334082|NCT06893822|DIETARY_SUPPLEMENT|Griffonia simplicifolia|Griffonia simplicifolia 1x/day
214334083|NCT06893822|OTHER|Placebo|Placebo 1x/day
214486369|NCT06754111|BEHAVIORAL|ideal birth environment|"ideal birth room While designing a single room without unnecessary medical equipment, your own bed linen, bed linen, It will be a pillow case, a photo frame, he will be able to listen to the music he wants, he will be able to make a photo of his own choice.~There will be a companion, a birthing ball and chair, and the room will allow freedom of movement.~It will be designed to allow"
214334084|NCT06550427|DIAGNOSTIC_TEST|ctDNA analyzed by phased variant|this observational cohort study is to investigate the correlation between ctDNA analyzed by phased variant and the early outcome of the disease.
214935192|NCT02345460|DRUG|Irinotecan Hydrochloride|Given IV
214935193|NCT02345460|DRUG|Oxaliplatin|Given IV
214935194|NCT02345460|DRUG|Leucovorin Calcium|Given IV
214334085|NCT07051486|DRUG|SHR-A1811 Injection|SHR-A1811 for injection.
214334086|NCT07051785|DRUG|Fruquintinib+Irinotecan Liposome+Capecitabine|"Stage 1: Participants received fruquintinib, irinotecan liposome, and capecitabine for 6-8 cycles. If no disease progression was observed after the initial treatment, patients were transitioned to maintenance therapy with fruquintinib and capecitabine.~Stage 2: if the primary endpoint of progression-free survival (PFS) was met in the first stage, participants were eligible for the second stage. Participants were randomly assigned to two groups (A and B), Group A: Fruquintinib + irinotecan liposome + capecitabine. After 6-8 cycles of treatment, patients who had no disease progression were transitioned to maintenance therapy with Fruquintinib + capecitabine"
214486370|NCT06759623|DRUG|Different drug type for conduction of general anesthesia|Patients will be randomly divided into two groups: patients for whom general anesthesia will be performed with sevoflurane and patients for whom general anesthesia will be performed with desflurane.
214486371|NCT06760234|DIAGNOSTIC_TEST|No Interventions|The high-throughput extraction of quantitative image features from medical images
214486372|NCT06760234|DIAGNOSTIC_TEST|No Interventions|Immunohistochemical analysis
214935195|NCT02345460|DRUG|Fluorouracil|Given IV
214935196|NCT02345460|OTHER|Laboratory Biomarker Analysis|Correlative studies
214935197|NCT04779580|PROCEDURE|Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
214935198|NCT04779580|PROCEDURE|Subcostal Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
214935199|NCT00639574|DRUG|Néfopam|"There are two groups :~* a group N : néfopam~* a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes."
214334087|NCT07051785|DRUG|Bevacizumab+Irinotecan Liposome+Capecitabine|Stage 2: if the primary endpoint of progression-free survival (PFS) was met in the first stage, participants were eligible for the second stage. Participants were randomly assigned to two groups (A and B), Group B: Bevacizumab + irinotecan liposome + capecitabine. After 6-8 cycles of treatment, patients who had no disease progression were transitioned to maintenance therapy with bevacizumab + capecitabine
214334088|NCT06748040|OTHER|Timing of return of results|Participants will be randomized to immediate versus delayed return of PGx results.
214935200|NCT04497376|PROCEDURE|upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo EI-VOM, followed by the '2C3L' ablation step. The details include: (1). EI-VOM procedure: An 8.5-French-long sheath or a steerable long sheath is sent to the coronary sinus (CS) via the femoral vein. A JR4.0 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a BMW wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated with 6 to 8 atm in the VOM. A selective venogram of the VOM is obtained by slowly injecting 1 mL of contrast medium. Then, ethanol is slowly injected into the VOM and selective venography of the VOM is repeated. (2) . After EI-VOM, radiofrequency ablation was performed to achieve bilateral pulmonary vein isolation and bidirectional block of mitral isthmus line, roof line, and cavotricuspid isthmus line. (3). Any organized AT observed during the procedure will be targeted as well.
214935201|NCT04497376|PROCEDURE|pulmonary vein antral isolation|After reconstructing the left atrial geometry, PVI will be performed (the right PV antrum (PVA) will be ablated first, followed by the left PVA. ) in a wide area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished. The endpoint of the circumferential PVA ablation procedure is to achieve electrical bilateral PV isolation, that is, the PV potentials associated with atrial electrical activity cannot be recorded during sinus rhythm or CS pacing (entrance block). A waiting period of at least 20 min (after the last PV is isolated) will be used during which spontaneous PV reconnection will be related. , and tDemonstration of exit block (he by pacing in the PV cannot be and proving the absence of transmitted conduction to capture the atrium) may be performed but is not mandatory. Any organized AT observed during the procedure will be targeted as well.
214935202|NCT04025931|DRUG|chidamide and toripalimab|"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
214935203|NCT06342622|DIAGNOSTIC_TEST|Using routine clinical data and machine learning models.|This study used clinical data and machine learning model to screen young-onset colorectal cancer.
214935204|NCT02562222|PROCEDURE|anodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
214935205|NCT02562222|PROCEDURE|cathodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
214334089|NCT06895837|OTHER|Severe-energy restriction|The participants will receive only 25% of their estimated energy needs.
214334090|NCT06895837|OTHER|Severe-energy restriction with exercise|The participants will run on the treadmill for 30 minutes and receive 25% of their estimated energy needs.
214334091|NCT01752205|DRUG|Paclitaxel|45mg/m2/w,total 6 weeks
214334092|NCT01752205|DRUG|Erlotinib|150mg/d,days 1-42,total 6 weeks
214334093|NCT01752205|RADIATION|Radiation therapy|
214334094|NCT06768918|OTHER|remote physical rehabilitation|In this multisite international study, we feasibility test implementation of 4 different digital solutions for delivering interactive physical rehabilitation during or after systemic anticancer treatment. The contents of the intervention follows international recommendations for exercise during or after treatment for cancer.
214334095|NCT05436418|DRUG|Melphalan|"Matched HCT: 100 mg/m\^2 IV on day -2 over 30 minutes. Haplo HCT:~100 mg/m\^2 IV on day -6 over approximately 20-30 minutes."
214334096|NCT05436418|DRUG|Sirolimus|Sirolimus: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg)\^d, then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +80 with no taper. Doses should be modified as appropriate for drug interactions and may be modified based on institutional practice.
214334097|NCT05436418|RADIATION|Total Body Irradiation (TBI)|Haplo HCT only: A dose of 200 cGy will be administered on day -1.
214334098|NCT05436418|DRUG|Cyclophosphamide|based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.
214334099|NCT05436418|DRUG|Mycophenolate Mofeti|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
214334100|NCT05436418|DRUG|Fludarabine|Matched HCT: 25 mg/m\^2/day infused IV over 60 minutes from day -7 to day -3. Haplo HCT: 40 mg/m\^2/day infused IV over approximately 30-60 minutes from day -5 to day -2
214334101|NCT05436418|PROCEDURE|Allogeneic HSCT|Stem cell transplant
214334102|NCT05436418|DRUG|Mesna|equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.
214334103|NCT05436418|DRUG|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.
214334104|NCT07084935|DEVICE|Connecting all patients to the nociception level index(NOL) and the surgical pleth index (SPI)|All patients will be connected to the NOL and SPI during surgery after induction of general anesthesia.
214935206|NCT02562222|PROCEDURE|anodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
215073166|NCT03228459|DIAGNOSTIC_TEST|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
215073167|NCT03228459|DIAGNOSTIC_TEST|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
214673978|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
214673979|NCT06710405|DRUG|Lidocaine (drug)|a single bolus dose of lidocaine 1.5 mg/kg is administered concurrently with the induction of anesthesia, followed by a continuous infusion of lidocaine at a rate of 1.5 mg/kg/hr.
215073168|NCT03228459|DIAGNOSTIC_TEST|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
215073169|NCT03228459|DIAGNOSTIC_TEST|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
215073170|NCT03228459|DIAGNOSTIC_TEST|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
215073171|NCT03228459|DIAGNOSTIC_TEST|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
214673980|NCT06710405|DRUG|Saline infusion (placebo)|Continuous infusion of normal saline in the same volume as that administered to the lidocaine group.
214673981|NCT04634123|OTHER|Pulpotomy therapy by White Portland Cement|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined using a sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White Portland Cement
214673982|NCT04634123|OTHER|Pulpotomy therapy by White MTA|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined usinga sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White MTA
214673983|NCT02903511|DRUG|Metformin|Monitoring of safety and tolerability
214673984|NCT02903511|DRUG|Placebo|Monitoring of safety and tolerability
214334105|NCT07084935|DEVICE|All patient will receive a tetanic stimuli (60mA, 100hz) of 5 seconds before start of incision|All patient will receive a tetanic stimuli (60mA, 100hz) of 5 seconds before start of incision.
214334106|NCT06453941|OTHER|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion)|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion) is a newly compiled routine developed on the foundation of the traditional Baduanjin (Eight Pieces of Brocades), which is a traditional Chinese medical health exercise consisted of eight movements to be practiced by oneself.
214334107|NCT04839705|DEVICE|WEB|"Device: WEB The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~Other Names:~• WEB Aneurysm Embolization Device"
214673985|NCT01613235|OTHER|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
214673986|NCT06710444|PROCEDURE|ultrasound-guided erector spinae plane block|ESPB
214673987|NCT06710444|PROCEDURE|ultrasound-guided retrolaminar plane block|RLB
214673988|NCT06887543|OTHER|Meal timing|Participants either eat all of their daily calories between 8 AM and 4 PM with 16 hours fasting for six days, or they eat the same meals ad lib daily for six days. After post-testing, they crossover to the other arm.
214935207|NCT02562222|PROCEDURE|cathodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
214673989|NCT06887543|OTHER|Time restricted eating|Eating restricted to 8 AM - 2 PM for 80% of caloric intake, the remaining 20% consumed by 4 PM, subsequent 16-hour fasting (4 PM-8 AM) each day for six days while on Time Restricted Arm.
214673990|NCT06887543|OTHER|Usual feeding pattern.|Participant consumes usual diet ad lib without enforced fasting period for six days while on Usual Feeding Pattern arm.
214673991|NCT06706258|DRUG|Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days|Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 2 more days.
214673992|NCT06706258|DRUG|Pepcid (Famotidine) 20 mg q 12 hrs for 3 days|Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 2 more days.
214334108|NCT06878118|DEVICE|Single-vision contact lens|Standard single vision contact lens
214334109|NCT06878118|DEVICE|A.R.R.E.S.T.® contact lens|Contact lens with edge pattern
214334110|NCT06677190|DRUG|Belzutifan|A Hypoxia-Inducible Factor-2 alpha inhibitor, 40 mg immediate-release tablet, taken orally per protocol.
214334111|NCT06905873|DRUG|FB102|Route of administration- Intravenous (IV)
214334112|NCT06905873|DRUG|Placebo|Route of administration- Intravenous (IV)
214334113|NCT06646458|OTHER|Healthy Elderly Volunteers|Take the elderly milk power 2 times every day up to 28 days
214334114|NCT06908057|OTHER|Blood Draw|We will draw blood to measure islet-related autoantibodies and celiac disease markers with a combined research method, blood sugar, C-peptide (an indicator of insulin production that controls sugar levels) and hemoglobin A1c. Additional blood will be collected for the study of biomarkers of T1D and for long-term storage for potential future use.
214334115|NCT05181007|DRUG|Mefanamic Acid|mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
214334116|NCT05181007|DRUG|Valproate|valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
214334117|NCT06908148|DEVICE|Electrolysed water|Electrolysed water is a novel antiseptic produced by passing an electric current through a mixture of tap water and salt. Microbiocidal activity is due to the presence of hypochlorous acid at neutral Ph. Irrigation of chronic wounds reduces bacterial load and appears to encourage wound healing. We propose to compare electrolysed water against conventional management.
214334118|NCT06908148|DEVICE|Conventional irrigant|The irrigant (Prontosan™) that is currently 'in-use' in the conventional management of diabetic foot wounds
214334119|NCT06466005|OTHER|UnityPhilly app|UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.
214334120|NCT02078583|DRUG|Fentanyl|
214673993|NCT03401489|DEVICE|PACESETTER|Patients will be given a Viaca electronic pill tray \& blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational \& reinforcement messages guided by self-determination theory constructs of competence \& autonomous regulation. In addition to personalized messages, PACESETTERs will receive text messages 2 times per week on HTN/stroke facts, importance of med adherence, and tips on expressing questions/concerns with a physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
214673994|NCT00969618|DRUG|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
214673995|NCT06884293|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC): starting dose is 2.0 mg, after 4 weeks of administration, increase to 4.0 mg; After another 4 weeks, increase to 6mg; After another 4 weeks, increase to the maximum dose 9mg for 36 weeks
214334121|NCT02078583|DRUG|Remifentanil|
214334122|NCT02078583|DRUG|Normal saline|
214334123|NCT06907134|BEHAVIORAL|Smartphone delivered internet-based Cognitive Behavioural Therapy|The intervention is 9 week long were partipants use an smartphone app based on CBT-principles with while having access to an internet platform where extra working material and therapist support is available on demand.
214334124|NCT06928168|OTHER|Total sleep deprivation|This group will perform an incremental running test, conducted until exhaustion, in: - a control condition (usual sleep) - a one-night condition of partial sleep deprivation - a one-night partial sleep deprivation condition with 5 nights of prior extension. The order of conditions will be randomized.
214334125|NCT06928168|OTHER|partial sleep deprivation|This group will perform an incremental running test, conducted until exhaustion, in: - a control condition (usual sleep) - a one-night condition of partial sleep deprivation - a one-night partial sleep deprivation condition with 5 nights of prior extension. The order of conditions will be randomized.
214334126|NCT06928168|OTHER|Reproductibility|This group will perform an incremental running test, driven to exhaustion, after a night of total sleep deprivation twice, at least two weeks apart.
214334127|NCT05162976|BIOLOGICAL|Nivolumab|Given IV
214935208|NCT02562222|PROCEDURE|anodal tDCS on M1 and cathodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
214935209|NCT02562222|PROCEDURE|cathodal tDCS on M1 and anodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
214935210|NCT02562222|PROCEDURE|sham tDCS|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
214935211|NCT03430401|BEHAVIORAL|Perceptual-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
214935212|NCT03430401|BEHAVIORAL|Semantic-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
214935213|NCT03430401|BEHAVIORAL|Cognitive stimulation|The frequency, duration and the number of sessions will be consistent with the experimental interventions.
214935214|NCT06622746|PROCEDURE|Endoscopic Hand Suturing|Endoscopic Hand Suturing is a technique of the wound closure after advanced endoscopic third-space resections I the upper and lower gastrointestinal tract. In this technique, the needle is held on the opposite side from the tip with the needle holder. The needle is pierced perpendicularly into the tissue at the side of the wound with an appropriate margin, then driven through the tissue with rotation and grasped at the bottom of the defect. The same steps are repeated from the middle of the wound to create a symmetrical structure.
214935215|NCT03579186|DEVICE|OKS|Optokinetic stimulation
215073172|NCT03228459|OTHER|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
215073173|NCT03228459|OTHER|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
215073174|NCT03228459|DIAGNOSTIC_TEST|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
215073175|NCT01755962|OTHER|Glycemic Load|
215073176|NCT01755962|OTHER|Resistance Training|
214334128|NCT05162976|DRUG|Oral Azacitidine|Given PO
214334129|NCT00669357|DEVICE|Abiocor Implantable Replacement Heart|Replacement of heart
214935216|NCT04641663|DIETARY_SUPPLEMENT|Multi-target Dietary Supplement (MTDS)|"The Multi-Target Dietary Supplement (MTDS) is comprised of 51 ingredients designed to simultaneously target and support the cellular processes implicated in the progression of the aging phenotype (oxidative stress, inflammatory processes, insulin resistance, and membrane and mitochondrial deterioration). The MTDS is unique in that it was specifically designed as a multi-target intervention to support the complex cellular perturbations associated with aging. Components of the formulation were chosen based on scientific consensus of documented effectiveness for one or more of the targeted processes, long-term evidence of safety, and synergistic or additive interactions between components.~The MTDS is divided into morning and evening doses to maximize availability of the components to the peak activity level of the cellular processes that require those components."
214334130|NCT01297218|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
214334131|NCT00320281|DRUG|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
214334132|NCT00320281|OTHER|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
214334133|NCT01184352|DEVICE|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
214334134|NCT04747938|DEVICE|Energy accumulator|All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
214334135|NCT04747938|BEHAVIORAL|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
214334136|NCT01876121|DRUG|Celecoxib|oral
214334137|NCT00113113|DRUG|Rubitecan|
214334138|NCT03981406|BEHAVIORAL|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
214334139|NCT03981406|BEHAVIORAL|Standard of Care|Control group will receive standard of care treatment for IPF.
214935217|NCT03349554|OTHER|body-scan meditation|15 minutes audio-guided body-scan meditation
214935218|NCT03349554|DIAGNOSTIC_TEST|Psychological evaluation|"NPI (Neuropsychiatric symptoms Inventory) - PAS (Parkinson's disease Anxiety Screening Questionnaire) - VAS measuring pain, anxiety and discomfort Before and after body-scan meditation"
214935219|NCT05393115|OTHER|Square wave breathing|difference in time to failure from the two breathing modes
214334140|NCT02522897|DRUG|Ranibizumab|
214334141|NCT02522897|DEVICE|Laser|
214334142|NCT01856140|BIOLOGICAL|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
214334143|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists.
214334144|NCT05534282|BEHAVIORAL|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
214334145|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
214334146|NCT06468644|DRUG|chemoradiotherapy （CRT）+sintilimab 1|radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
214935220|NCT01790828|DRUG|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
214935221|NCT00525811|OTHER|patient dialogue|Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
214935222|NCT00525811|OTHER|patient information|Information on acute low back pain, information on depression
214935223|NCT05680051|DEVICE|Drug-eluting balloon|Drug eluting balloon was used in the experimental group
214334147|NCT06468644|DRUG|CRT+sintilimab 2|radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
214334148|NCT02352324|OTHER|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
214334149|NCT03794765|DRUG|Ceftriaxone|Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
214334150|NCT03794765|DRUG|Metronidazole|Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
214334151|NCT03794765|OTHER|Placebo infusion|Similar placebo infusion
214334152|NCT02690246|OTHER|questionnaire|a questionnaire based study
214673996|NCT06884293|DRUG|semaglutide|Once-weekly injections of gradually increased doses, subcutaneously (SC): starting dose is 0.25 mg, after 4 weeks of administration, increase to 0.5 mg; After another 4 weeks, increase to 1mg; After another 4 weeks, increase to 1.7mg; After another 4 weeks, increase to the maximum 2.5mg for 32 weeks
214673997|NCT06738446|DIETARY_SUPPLEMENT|Multicomponent dietary supplement group|Participants in supplement group were asked to take a capsule content are eicosapentaenoic acid 45 mg, docosahexaenoic acid 30 mg, lutein 30 mg, and zeaxanthin1.8 mg every day for 12 weeks
214935224|NCT05680051|DEVICE|Drug-eluting stent|Drug eluting stent was used in the control group
214935225|NCT04973371|DIAGNOSTIC_TEST|Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test|Those who screen positive for TB using the standard 4-question screener will be offered a GeneXpert® \[Cepheid, Sunnyvale, CA\] MTB/RIF test in their home with referral for clinic-based TB treatment initiation for those who receive a positive MTB/RIF test result.
214935226|NCT05622877|DRUG|Qushi Formula|Qushi Formula are decoction granules composed 8 traditional Chinese medicines, such as poria cocos, Macrocephalae Rhizoma, Polyporus, cassia twig, dried ginger and licorice, Etc.
214935227|NCT05622877|DRUG|Zhu's Wenban Formula|Zhu's Wenban granules are decoction granules composed of leech, panax notoginseng, Atractylodes Lancea and rhizome
214935228|NCT05622877|DRUG|placebo|The placebo was composed of dextrin, powdered sugar, starch, and liquid caramel in the same color as the other two groups.
214935229|NCT05622877|OTHER|Basic treatment|Basic diseases except hyperlipidemia were treated in accordance with the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack. Basic treatment includes conventional treatment such as comprehensive prevention and treatment (actively controlling basic diseases such as hypertension and diabetes and suggesting a good lifestyle), drug therapy (anti-inflammatory, lipid-regulating, anti-platelet aggregation, calcium channel blockers) and so on according to individual conditions of patients.
214673998|NCT01039168|BEHAVIORAL|Workplace dialogue|
214673999|NCT01039168|OTHER|Care as usual|
214334153|NCT02629146|DRUG|Midazolam|
214334154|NCT02629146|DRUG|Fentanyl|
214334155|NCT02629146|DRUG|Isotonic saline|
214334156|NCT03554122|PROCEDURE|Shotblocker|Patients spinal injections were performed with Shotblocker placed onto injection site
214334157|NCT03554122|PROCEDURE|Placebo|Patients spinal injections were performed without Shotblocker
214334158|NCT03258476|DRUG|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
214334159|NCT03258476|BEHAVIORAL|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
214334160|NCT03258476|DRUG|Placebo|Placebo oral capsule
214674000|NCT00542347|DRUG|Esomeprazole first|"* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
214674001|NCT00542347|DRUG|Generic omeprazole first|"* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
214674002|NCT05980026|DRUG|oral omega-3 fatty acids supplementation|oral omega-3 fatty acids supplementation
214674003|NCT05980026|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
214334161|NCT04932174|OTHER|High-intensity Interval Training|"Consisting of the following program:~* Warming up period for 10 minutes at 60-70% of HR max.~* Training phase 4x4 min intervals at 85-90% of HRmax with a 3 min active recovery at 70% of HRmax between each interval.~* Duration of HIIT 4 minute~* Number of interval per session 4~* Duration of rest interval 3 minute 3-10 min cool-down period, giving a total of 60 min."
214334162|NCT04932174|OTHER|Low-intensity Continuous Training|"Consisting of the following program:~* Warming up period for 10 minutes.~* Training phase for 60-minute walking on a treadmill at intensity 40-50% HRR (1- 6) weeks then 60-70% HRR (7-12) weeks.~* cooling down period for 10 minutes."
214334163|NCT05708079|PROCEDURE|Endovascular thrombectomy|An endovascular thrombectomy is the removal of a thrombus (blood clot) under image guidance. A thrombectomy is most commonly performed for an arterial embolism, which is an arterial blockage often caused by atrial fibrillation, a heart rhythm disorder.
214334164|NCT05916755|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
214334165|NCT05916755|DIAGNOSTIC_TEST|RNA-Sequencing|RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
214334166|NCT05916755|DIAGNOSTIC_TEST|Microbiome analysis|Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
214334167|NCT05916755|DIAGNOSTIC_TEST|ctDNA analysis|ctDNA analysis will be performed in plasma before and during NACT.
214334168|NCT05916755|DIAGNOSTIC_TEST|TCR-β repertoire sequencing|TCR-β repertoire sequencing will be performed in plasma before and during NACT.
214334169|NCT05916755|DIAGNOSTIC_TEST|PBMCs phenotyping|PBMCs phenotyping will be performed in plasma before and during NACT.
214334170|NCT05916755|DRUG|Pembrolizumab|Pembrolizumab will be given in combination with standard NACT.
214334171|NCT05916755|DRUG|Chemotherapy|Standard NACT will be given.
214334172|NCT00827372|DRUG|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
214334173|NCT01111656|DRUG|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
215073177|NCT05407649|RADIATION|Radiotherapy Combined with GM-CSF|Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
214674004|NCT06748664|DRUG|Rimegepant|Take 75mg qd of oral sulfate remigipan orally disintegrating tablets
214334174|NCT01111656|DRUG|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
214334175|NCT00001631|PROCEDURE|Magnetic resonance imaging|
214334176|NCT04876027|DRUG|GLP-1 RAs|GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
214334177|NCT04876027|OTHER|calorie restricted diet|Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
214334178|NCT02293005|DRUG|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
214334179|NCT02642913|DRUG|Enzalutamide|
214334180|NCT02642913|DRUG|Enzalutamide with Sorafenib|
214334181|NCT05507710|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
214334182|NCT04011475|DRUG|Tiotropium + Olodaterol|Spiolto®
214334183|NCT04011475|DRUG|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
214334184|NCT04011475|DRUG|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
214334185|NCT02595567|DEVICE|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
214334186|NCT02248584|DIETARY_SUPPLEMENT|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
214334187|NCT00941733|DEVICE|IN.PACT Amphirion|Balloon Angioplasty
214334188|NCT00941733|DEVICE|Standard PTA|Balloon Angioplasty
214334189|NCT02376426|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.
214334190|NCT02376426|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.
214334191|NCT02376426|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
214674005|NCT06748664|DRUG|Placebo|Take 75mg qd of oral Rimegepan oral tablets with placebo
214674006|NCT06757504|DRUG|TTYP01 Tablets (12mg or 18mg)|Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
214674007|NCT06757504|DRUG|Placebo (Simulant TTYP01 Tablets)|Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
215073178|NCT01748708|DEVICE|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
215073179|NCT01748708|DEVICE|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
215073180|NCT01557777|DRUG|Navitoclax|QD
214334192|NCT01889589|OTHER|Surveillance|
214935230|NCT02855229|DRUG|Methylphenidate|cross-over, single-dose intervention
214935231|NCT00790231|DEVICE|urodynamic procedure|introduction of the urodynamic catheter into the bladder and assessment of the bladder function
214935232|NCT06463392|OTHER|No Intervention: Observational Cohort|No intervention is scheduled for this observational study.
214935233|NCT02101931|DRUG|Amino levulinic Acid|The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
214935234|NCT04271319|DEVICE|BEST™ HVPC microcurrent electrical stimulation PRO-SPORT Ultra® Device|"Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
214935235|NCT04271319|DEVICE|Sham PRO-SPORT Ultra® Device|"Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Sham PRO-SPORT Ultra® device will be used. The built in electrodes and the accessory port for connecting the lead wire to the electrode pads will be disconnected internal to the device. The device will power on with the same sounds and indications."
214334193|NCT05036642|DEVICE|Compliant Passive Arm Support|The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
214334194|NCT00612066|DRUG|rosiglitazone maleate|
214334195|NCT00630877|DRUG|Niacin extended-release (NER)|Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
214334196|NCT00630877|DRUG|Niacin extended-release (NER) placebo|Tablets administered once daily for 6 weeks
214334197|NCT00630877|DRUG|Aspirin (ASA)|Tablets (325 mg) administered once daily for 6 weeks
214334198|NCT00630877|DRUG|Aspirin (ASA) placebo|Tablets administered once daily for 6 weeks
214334199|NCT04681521|OTHER|Hot and Cold compress, nursing interventions|using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
214334200|NCT05631067|BEHAVIORAL|Remote blood pressure monitoring|Participants will receive a blood pressure monitor to check daily BPs for two weeks post partum
214674008|NCT06768164|PROCEDURE|Billroth 2 (B2)|B2 technique requires a single anastomosis (gastro-jejunostomy) after distal gastrectomy
215073181|NCT06117969|DRUG|Tibolone|1.25mg po qd
215073182|NCT06117969|DRUG|Xiangshao granules|4g po tid
214334201|NCT05631067|DIAGNOSTIC_TEST|NT proBNP assessment|Participants will have biomarker assessment at 0-2 days postpartum
214334202|NCT00487110|DRUG|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
214674009|NCT06768164|PROCEDURE|Roux-En-Y (REY)|REY technique requires 2 anastomoses (gastro-jejunostomy and entero-enterostomy) after distal gastrectomy
214334203|NCT00487110|DRUG|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
215073183|NCT06117969|DRUG|Tibolone plus Xiangshao granules|Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid
214334204|NCT06367374|DRUG|Sonrotoclax|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days).~Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
214334205|NCT06367374|DRUG|Zanubrutinib|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
214334206|NCT02114242|OTHER|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
214334207|NCT02114242|OTHER|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
214334208|NCT04896957|BEHAVIORAL|Interview|Face to face semi-directed interviews about perceptions, representations and experiences of Covid-19 vaccination, including six opened-questions
214334209|NCT04190745|DRUG|Toripalimab+Apatinib mesylate|Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
214334210|NCT04190745|DRUG|paclitaxel|paclitaxel 80mg/m2, q3w
214674010|NCT00362388|PROCEDURE|Intramyocardial injection of autologous bone marrow cells|
214674011|NCT06891729|DEVICE|Delivery Lumen Access Device|Delivery Lumen Access Device use prior to Vasectomy
214674012|NCT06891729|DEVICE|DLAD|Participants will be exposed to the DLAD during their planned vasectomy
214674013|NCT06901063|DEVICE|ultrasound|Using ultrasound probe to scan and record the bilateral interscalene brachial plexus
214674014|NCT05136885|DRUG|SLS-005|Administration: Infusion Dose: 0.75 g/kg weekly
214674015|NCT05136885|DRUG|Matching Placebo|Administration: Infusion Dose: equivalent weight-based volume as described for trehalose
214674016|NCT04892797|OTHER|Covid-19+ observational|This is observational--there is no intervention
214935236|NCT06506643|DRUG|Zinc-64 Aspartate|KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).
214935237|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
214935238|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
214334211|NCT01124890|DEVICE|early percutaneous coronary intervention|
214334212|NCT01124890|DEVICE|late percutaneous coronary intervention|
214935239|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
214935240|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
214935241|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
214935242|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
214935243|NCT03128320|DRUG|BAY1193397|Single dose of 1 mg BAY1193397 given in the fasted state
214935244|NCT03128320|DRUG|BAY1193397|Single dose of 5 mg BAY1193397 given in the fasted state
214334213|NCT01513772|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
214334214|NCT01513772|DRUG|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
214334215|NCT03689010|DRUG|Azelaic acid foam 15%|Azelaic acid foam 15%
214334216|NCT03689010|DRUG|Finacea® (Azelaic acid Foam) 15%|Azelaic acid foam 15%
214334217|NCT03689010|DRUG|Vehicle of the test product|Vehicle of the test product
214334218|NCT01529645|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
214334219|NCT01529645|BIOLOGICAL|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
214334220|NCT01529645|BIOLOGICAL|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
214334221|NCT01529645|BIOLOGICAL|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
214334222|NCT01529645|OTHER|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
214334223|NCT02699905|OTHER|phlebotomy|phlebotomy
214334224|NCT05114603|DRUG|HLX208|level 1:600mg po Bid level 2:900mg po Bid
214935245|NCT03128320|DRUG|Placebo|Single dose of placebo given in the fasted state
215073184|NCT02824770|BEHAVIORAL|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
214334225|NCT05060419|DRUG|Meropenem- FL058|"Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h"
214334226|NCT05060419|DRUG|Piperacillin -tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
214334227|NCT05060419|DRUG|Saline|180min
214935246|NCT00129727|DRUG|Paclitaxel|Given intravenously
214334228|NCT05060419|DRUG|Saline|30min
214334229|NCT02879097|BIOLOGICAL|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
214334230|NCT02879097|BIOLOGICAL|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
214334231|NCT02879097|DRUG|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
214334232|NCT02879097|DRUG|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
214334233|NCT02030678|DRUG|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
214334234|NCT04891549|PROCEDURE|Tension band fixation|Fracture fixation of the patella fracture with tension band.
214334235|NCT04891549|PROCEDURE|Plate fixation|Fracture fixation of the patella fracture with a plate.
214935247|NCT00129727|DRUG|Carboplatin|Given intravenously
214935248|NCT00129727|DRUG|Bevacizumab|Given intravenously
214935249|NCT06083727|OTHER|rate of cesarean section|rate of primary cesarean section in primigravida and multigravida
214935250|NCT04483492|DRUG|Caffeine citrate|diaphragm contractility after administration
214935251|NCT01833624|DIETARY_SUPPLEMENT|Peptamen® AF|Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
214935252|NCT01833624|DIETARY_SUPPLEMENT|Sondalis® HP|
214935253|NCT01328899|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx's)|Lung Volume Reduction Coil
214935254|NCT01312233|OTHER|Medical Care|Participants allocated to all three treatment groups receive medical care over a 12-week period. Medical treatments are standard therapies for back pain. Medical and osteopathic physicians follow clinical practice guideline recommendations for back pain: focused history and physical exam; limited diagnostic imaging; self-management education; maintaining physical activity as tolerated and local heat/cold application; pharmacotherapy with analgesics and anti-inflammatory agents. Participants not responding to treatment may receive additional therapies such as physical therapy or specialist referral.
215073185|NCT02824770|DRUG|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
215073186|NCT02824770|DRUG|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
214935255|NCT01312233|OTHER|Dual Care|Participants allocated to Dual Care receive medical care as described plus chiropractic care over a 12-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach based upon a participant's clinical presentation. Treatments may include spinal or extremity joint manipulation, such as: high velocity-low amplitude or low velocity-variable amplitude maneuvers; mechanical device assisted adjustments; or passive mobilization. Recommendations for exercise, lifestyle modifications, or other therapies may be provided.
214935256|NCT01312233|OTHER|Shared Care|Participants allocated to Shared Care receive co-managed medical care from a medical or osteopathic doctor and chiropractic care from a doctor of chiropractic over a 12-week period. The medical and chiropractic treatments are standard therapies for back pain, as described under Medical Care and Dual Care.
214935257|NCT04567927|OTHER|Ultrasonography|Venous compression ultrasonography using real-time B-mode and colour doppler in transverse and longitudinal views
214935258|NCT06621680|DRUG|Multivitamins|All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.
214935259|NCT06621680|OTHER|Connective tissue massage|Connective tissue massage will be applied on (Sacral, lumbar, last thoracic vertebrae-T12, and subcostal regions), 2 sessions/week for 20 minutes each session for 12 weeks. Treatment will begin 3 days before menstruation to the 4th day of menstruation for 3 successive menstrual cycles.
214935260|NCT06649513|DIAGNOSTIC_TEST|eye drops (Tropicamid)|Mydriatic + cycloplegic eye drops are given to measure refractive error and to image the full retina.
214935261|NCT00260598|PROCEDURE|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
214935262|NCT06620354|DRUG|Selumetinib|Patients without indications for surgical excision were evaluated with 6 cycles of daily oral smetinib capsules (20-50mg bid) for 30 days, individually calculated based on patient body surface area (BSA)
214935263|NCT06158997|DEVICE|EyePeace|EyePeace a commercially available for enhancing meibum expression. The flexible, handheld device is made of silicone and provides regulated vertical pressure on closed eyelids (https://www.eyepeace.de). EyePeace will be used to assess its usefulness in improving evaporative dry eye signs and symptoms.
214935264|NCT06158997|DEVICE|Heated Eye Mask|Heated Eye Mask will be used once a day to assess its usefulness in improving evaporative dry eye signs and symptoms.
214935265|NCT05803447|OTHER|Interview questionnaire|"An Interview questionnaire concerning an assessment of the intensity suicidal behavior, M.I.N.I. 7.0.2 was used.~M.I.N.I. interview was conducted with each patient to verify the intensification of suicidal behaviour."
214935266|NCT05803447|DIAGNOSTIC_TEST|biochemical parameters|"The concentrations of the following parameters were determined from the:~* blood serum: vitamin D3, B12, folic acid, sodium, potassium, calcium, magnesium, chlorine, total cholesterol, LDL and HDL fractions, TG~* plasma: metabolites of the oxidative stress"
214935267|NCT05803447|DIAGNOSTIC_TEST|cognitive function|The participants completing cognitive function were assessed using computer CogState Test. The following cognitive functions were assessed: psychomotor drive (DET), metastability of attention (IDN), verbal memory, retrieval of learned material (ISLR) and verbal learning and memory (ISL), visual learning and memory (OCL), processing speed (GMCT), visual memory including deferred retrieval (GMR), executive functions (SETS and GML), working memory (ONB, TWOB).
215073187|NCT02824770|PROCEDURE|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
215073188|NCT02340208|DRUG|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
215073189|NCT05553340|OTHER|Education for caregivers|The intervention will aim to equip the family caregiver to assist the elderly in activities of daily living after discharge, and will be carried out by two researchers, through an online course. The course includes the skills required and included in the scales that assess the caregiver's knowledge and performance. The course is divided into 12 modules that can be accessed as many times as needed by caregivers, in random order, according to the care needs of the elderly and the caregiver.
214674017|NCT06743828|OTHER|Fermented meat alternative|Participants incorporate a novel fermented product into their habitual diet for three weeks. The product replaces the main protein source of the meal(s). Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
214334236|NCT00143858|DEVICE|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
214674018|NCT06743828|OTHER|Unfermented meat alternative|Participants incorporate an unfermented product into their habitual diet for three weeks. The product replaces the main protein source of the meal(s). Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
214674019|NCT06888414|DIAGNOSTIC_TEST|transvaginal ultrasound|Fifty perimenopausal women presenting with AUB were recruited from the outpatient clinic. Baseline data, including demographic, obstetric, and medical history, BMI, and laboratory investigations (CBC, renal and liver function tests, coagulation profile), were collected. All patients underwent transvaginal 3D ultrasonography and hysteroscopy.
215073190|NCT02775591|DRUG|DA-9701|DA-9701 30mg Tablet
215073191|NCT02775591|DRUG|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
214334237|NCT03475641|DRUG|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
214334238|NCT03475641|PROCEDURE|The current standard treatment|Tumescent anesthesia.
214334239|NCT02908568|DEVICE|Spring device|Brisk dilatation of fhe mouth.
214334240|NCT02908568|DEVICE|Mandible stimulator|Stimulation of fhe mouth.
214334241|NCT04543422|DIETARY_SUPPLEMENT|Green tea|Green tea extract capsules
214334242|NCT04543422|OTHER|Placebo|Placebo containing inert material.
214486373|NCT06760078|DRUG|intravenous tranexamic acid (TXA) infusion|Intravenous tranexamic acid will be administered as an initial dose of 1 g (10mL: 1g, diluted in 90 mL normal saline) over 10 minutes, followed by a maintenance dose of 1 g over 8 hours (10mL: 1g, diluted in 240 mL normal saline). Intensive blood pressure lowering will be maintained throughout the treatment period until 24 hours after onset.
214334243|NCT01319734|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C supplementation 500mg
214935268|NCT04015076|DRUG|Inzomelid|Active Drug
214334244|NCT01319734|DRUG|glyburide|this group receiving glyburide 5 mg alone
214334245|NCT05733988|PROCEDURE|Bailout edge to edge|Edge to edge repair is the suture of the mitral valve leaflets in the regurgitant spot. It can be used as a bailout procedure when the first attempt of mitral valve repair with other surgical techniques is not satisfactory at intraoperative echo control. In this case, a second run of cardiopulmonary bypass is carried out, the heart is reopened and an edge-to-edge is performed.
214334246|NCT04546204|OTHER|vaginal delivery|normal vaginal spontaneous delivery
214334247|NCT02112786|DEVICE|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
214334248|NCT01980849|DRUG|Nadroparin, long term|
214334249|NCT01980849|DRUG|Nadroparin: short-term|
214334250|NCT03144570|OTHER|None, non-interventional study|Not applicable, non-interventional study
214334251|NCT00023816|DRUG|carbendazim|
214334252|NCT00048724|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
214935269|NCT04015076|DRUG|Placebo|Placebo to Match
214935270|NCT01007331|BEHAVIORAL|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10\^10 colony forming units pr day of probiotics
214334253|NCT01103297|DEVICE|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
214935271|NCT01594892|RADIATION|Radiosurgery|Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
214334254|NCT02568410|PROCEDURE|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
214334255|NCT05734092|DEVICE|Traditional orthodontic treatment|As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
214334256|NCT05734092|DEVICE|Low-Level Laser|"The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage."
214334257|NCT05914467|DRUG|Teicoplanin|Dose will be adjusted in the study arm using MIPD guided TDM- dosing
214935272|NCT03026530|PROCEDURE|Pulmonary recruitment maneuver|The participants in the experimental arm receives 1 minute of ventilator-piloted pulmonary recruitment with positive inspiratory pressure set to 40 cm H2O, at the end of laparoscopic bariatric surgery.
214935273|NCT03026530|PROCEDURE|Laparoscopic bariatric surgery|
214935274|NCT03026530|DEVICE|Ventilator|
214935275|NCT00006357|DRUG|imatinib mesylate|
214935276|NCT01746498|PROCEDURE|Direct current stimulation using Anodal electrode|11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
214935277|NCT01746498|PROCEDURE|direct current stimulation using cathodal electrode|11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
214935278|NCT01746498|PROCEDURE|Sham direct current stimulation|11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
214935279|NCT06395298|OTHER|Experimental group PIOMI|A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)+PIOMI
214334258|NCT02595684|DRUG|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
214334259|NCT02595684|DRUG|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
214334260|NCT02863354|DRUG|Aflibercept|Intravitreal injection
214334261|NCT03389646|DEVICE|CERAMENT G V|"During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU)."
214334262|NCT03235024|BIOLOGICAL|B244|B244 suspension
214935280|NCT06395298|OTHER|Control group NIDCAP|A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)
214935281|NCT03108404|OTHER|Validation of a diagnostic test|Validation of a diagnostic test
214935282|NCT02744664|PROCEDURE|Cryotherapy|After entering the group subject receive Cryotherapy on lung cancer
214935283|NCT02744664|DRUG|Icotinib|After Cryotherapy, subjects begin Icotinib administration
214935284|NCT00519233|DRUG|AGS-1C4D4|IV
214935285|NCT04756583|OTHER|Notification system|Email and page notification sent to clinicians for patients at high-risk of mortality in 30 days and 6 months
214935286|NCT00444041|DRUG|Bevacizumab|neoadjuvant therapy prior to elective surgery
214935287|NCT00468754|DEVICE|Insulin pumps|
214935288|NCT00478114|DRUG|sorafenib|sorafenib in the patients with advanced Renal Cell Carcinoma
214935289|NCT06429215|DEVICE|Multi-component Intervention (MC-I): VR Cognitive training and Psychoeducation on health and lifestyle|"In a period of 5 consecutive weeks, participants will receive:~* an interactive immersive virtual reality cognitive training for 30 minutes, 3 days per week. It consists in different tasks implemented in virtual real-like scenarios of daily living situations that target the following cognitive processes: long-term associative memory, relational binding, spatial pattern separation and pattern completion;~* an interactive immersive virtual reality health and lifestyle education program for 30 minutes, 1 day per week. It consists in 360° videos aimed at advancing awareness and knowledge of the various health conditions associated with an increased risk of cognitive decline and dementia and helping participants to develop a healthier lifestyle."
214935290|NCT06429215|DEVICE|Cognitive-only intervention (CO-I): VR Cognitive training (+ Psychoeducation active control)|"In a period of 5 consecutive weeks, participants will receive:~* the interactive immersive virtual reality cognitive training as described in the MC-I condition, for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for 30 minutes, 1 day per week."
214935291|NCT06429215|DEVICE|Active control intervention (AC-I): VR Cognitive active control + Psychoeducation active control|"In a period of 5 consecutive weeks, participants will receive:~* an active control of the immersive virtual reality cognitive training (participants will be requested to virtually carry out daily actions, in the same setting as those performed in cognitive immersive VR training, but they will follow prearranged instructions requiring very low cognitive demands) for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for about 30 minutes, 1 day per week."
214935292|NCT04824391|BIOLOGICAL|ERUCOV-VAC 3 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
214935293|NCT04824391|BIOLOGICAL|ERUCOV-VAC 6 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
214935294|NCT04824391|OTHER|Placebo|Two IM applications on Days 1 and 28
214935295|NCT03721835|DEVICE|CONQUEST FN Femoral Neck Fracture System|Fracture fixation device consisting of a single plate and three screws
214935296|NCT03211923|DIAGNOSTIC_TEST|Transcranial magnetic stimulation (TMS)|Single pulse, monophasic transcranial magnetic stimulation
214334263|NCT03235024|BIOLOGICAL|Vehicle|Vehicle suspension
214935297|NCT06618248|COMBINATION_PRODUCT|Sirolimus coated balloon angioplasty|This study involves the use of a Sirolimus-Coated Balloon (SCB) for the treatment of coronary artery disease, specifically targeting coronary bifurcation lesions. The SCB is coated with sirolimus, an antiproliferative drug that helps to prevent restenosis by inhibiting smooth muscle cell proliferation. The balloon is inflated at the target lesion site, delivering the drug directly to the arterial wall. This intervention aims to achieve vessel dilation while reducing the risk of restenosis, providing a potential alternative to stent placement.
214935298|NCT06618248|COMBINATION_PRODUCT|Paclitaxel coated balloon angioplasty|This study involves the use of a Paclitaxel-Coated Balloon (PCB) for the treatment of coronary artery disease, specifically targeting coronary bifurcation lesions. The PCB is coated with paclitaxel, an antiproliferative drug that helps to prevent restenosis by inhibiting smooth muscle cell proliferation. The balloon is inflated at the target lesion site, delivering the drug directly to the arterial wall. This intervention aims to achieve vessel dilation while reducing the risk of restenosis, providing a potential alternative to stent placement.
215073192|NCT00422630|BEHAVIORAL|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
214674020|NCT06826404|DEVICE|Training provided with a wearable ostomy model and standardized patient|"The subjects of what is stoma, nursing care after stoma surgery, and care of the peristomal area will be explained to the students participating in the study theoretically by the responsible director in a session and for a maximum of 30 minutes with plain narration and discussion methods, not exceeding 30 slides. Both groups will receive this training at the same time. After this explanation, stoma care will be performed on a wearable colostomy model by a volunteer student who is doing her doctorate in Surgical Diseases Nursing in accordance with the skill guide Changing the Ostomy Bag and Nursing Care of the Peristomal Area developed by the director of the study based on literature, and nursing students will be given the opportunity to ask questions, and then the skill will be demonstrated twice on the wearable stoma model by following the steps in the learning guide."
214334264|NCT01281488|PROCEDURE|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
214334265|NCT01281488|PROCEDURE|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
214334266|NCT01281488|DRUG|indocyanine green|Given IV
214334267|NCT01173562|DRUG|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
214334268|NCT01632800|DEVICE|High pulsed magnetic fields|Magnetic fields will escalate in strength
214334269|NCT04614766|DRUG|Lutathera|intravenous administration
214334270|NCT04614766|DRUG|Azedra|intravenous administration
214334271|NCT00726115|DRUG|SAM-531|
214334272|NCT00726115|DRUG|placebo|
214334273|NCT03178656|DRUG|Sorafenib|continuous application of the drugs
214334274|NCT03178656|PROCEDURE|surgery|curative resection
214334275|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
214334276|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
214334277|NCT02968199|BEHAVIORAL|A brief intervention|The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
214334278|NCT03667339|PROCEDURE|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
214334279|NCT01642394|BEHAVIORAL|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
214334280|NCT04358484|BEHAVIORAL|Incredible Years - ASD and Language Delay®|"The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language."
214334281|NCT01623440|COMBINATION_PRODUCT|Placebo and fMRI|Pill form, participant dosed one time an hour before fMRI.
214334282|NCT01623440|COMBINATION_PRODUCT|Naltrexone and fMRI|50 mg pill given one time, one hour before fMRI
214334283|NCT06383039|DEVICE|Transcranial Direct Current Stimulation|"Evaluations will be made in the presence of a physiotherapist. Individuals; For demographic information~• Demographic Information Form~For Static Balance Evaluation:~* Wii-Fit~* Balance Error Scoring System~For Dynamic Balance Assessment:~* Star Balance Test~* Timed Get Up and Go Test"
214334284|NCT06302387|PROCEDURE|Acellular Dermal Matrix|The ADM arm involved vertical soft tissue augmentation using an acellular dermal matrix. This process included the placement of a porcine dermal collagen graft (Mucoderm®, Institut Straumann AG, Switzerland) atop the dental implant site. The graft, measuring 15x20 mm, was hydrated in a 0.5% Metronidazole solution for 20 minutes before application, then trimmed and placed to extend 10 by 5 mm beyond the implant margins in both buccal and lingual directions. The primary wound closure was achieved using double mattress suturing with 6-0 Prolene (Ethicon, USA).
214674021|NCT06826404|OTHER|Training low fidelity simulator|"The subjects of what is stoma, nursing care after stoma surgery, and care of the peristomal area will be explained to the students participating in the study theoretically by the responsible facilitator in one session and for a maximum of 30 minutes, using plain narration and discussion methods, not exceeding 30 slides. Both groups will receive this training at the same time. After this explanation, skill training will be carried out on a lifeless mannequin in accordance with the skill guide Changing the Ostomy Bag and Nursing Care of the Peristomal Area developed by the facilitator of the study based on literature."
214935299|NCT01845168|OTHER|Computer-alert|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids
214935300|NCT01845168|DEVICE|A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids
214935301|NCT01845168|DEVICE|Computer-alert|
214935302|NCT06598384|DRUG|Venetoclax combined with Azacytidine|"Patients were treated by venetoclax and azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg/m2 subcutaneous injection qd d1-5."
214935303|NCT04198584|BEHAVIORAL|VC-CBCS|A 14-module stress management and lifestyle group-based intervention delivered via videoconferencing WebEx technology to participants who have/had chronic hepatitis C and experience symptoms, stress or lifestyle requirements to promote liver health.
214935304|NCT01560533|BEHAVIORAL|Interviews|Interviews will be done with patients
214674022|NCT06892704|DRUG|Dupilumab - Standard Dose|24 weeks of dupilumab 300mg q2 weeks
214674023|NCT05363293|DRUG|AL001|a crystal engineered lithium-salicylate-proline lithium delivery product
214935305|NCT02152553|DRUG|Hydrocortisone|
214334285|NCT06302387|PROCEDURE|Soft Tissue Expansion using Tenting Technique|The Tenting Technique arm involved soft tissue expansion using a submerged healing abutment to promote soft tissue growth. After implant placement, 2 mm healing abutments were set on the implants. Flaps were mobilized using vertical releasing incisions, and tension-free wound closure was achieved with horizontal mattress sutures followed by suturing the incision line with interrupted sutures for primary and submerged healing. This method aimed to create a subepithelial healing space for soft tissue expansion and augmentation.
214334286|NCT05458193|DRUG|Daridorexant|Film-coated tablet for oral use
214334287|NCT05458193|DRUG|Placebo|Film-coated tablet for oral use
214334288|NCT03430466|DRUG|Durvalmab&Tremelimumab&Fulvestrant|Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks
214334289|NCT04316624|DRUG|C-CAR066|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
214334290|NCT00698958|PROCEDURE|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
214935306|NCT02152553|DRUG|Placebo|
214935307|NCT04323865|DIAGNOSTIC_TEST|fetal heart rate variability|No direct intervention, as the study is observational.
214674024|NCT05363293|OTHER|Placebo|matching placebo formulation
214935308|NCT03445234|DIETARY_SUPPLEMENT|Blueberry|26 g/day freeze-dried powder, 2 weeks duration
214935309|NCT03445234|DIETARY_SUPPLEMENT|Placebo|Placebo powder
214935310|NCT03445234|DIETARY_SUPPLEMENT|banana|Acute ingestion of bananas 0.2 g carb/kg every 15 min exercise with water
214935311|NCT03445234|DIETARY_SUPPLEMENT|No banana|water only
214935312|NCT01834716|BEHAVIORAL|Aerobic vs. Non-Aerobic exercise|
214935313|NCT05072964|DEVICE|FARAPULSE Pulsed Field Ablation System|A pulmonary vein isolation will be performed using catheter ablation
214935314|NCT03081143|DRUG|FOLFIRI|Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin\* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
214935315|NCT03081143|DRUG|Ramucirumab|8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
214935316|NCT03081143|DRUG|Paclitaxel|80 mg/m2 on day 1, 8, 15
214674025|NCT06321419|BEHAVIORAL|Advanced Trauma Life Support training|Advanced Trauma Life Support (ATLS) is a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. The programme was developed by the Committee of Trauma of the American College of Surgeons. The course includes intial treatment and resuscitation, triage and interfacility transfers. Leaning is based on practical scenario-driven skill stations, lectures and includes a final performance proficiency evaluation. Physicians will be trained in an accredited ATLS training facility in India.
214334291|NCT00698958|PROCEDURE|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
214935317|NCT06408064|OTHER|Music therapy|Music therapy is a non-pharmacological therapeutic intervention that will be implemented through two modalities: live and pre-recorded instrumental lullabies music.The volume control will be conducted within the groups through the use of a decibel regulator, with a maximum volume of 70 dB. During the intervention and for a period of 30 minutes following its conclusion, singing will be prohibited by the music therapist or the parents. Both live and pre-recorded music will be instrumental in nature, lacking any lyrics.
214935318|NCT05250687|PROCEDURE|MR- High intensity focused ultrasound|The intervention treatment is MR-HIFU, which will be given as a standalone treatment. MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastasesThe ExAblate focused ultrasound device operates in conjunction with an MRI machine. Gadavist is being administered intraveneously as contrast medium for MRI.
214935319|NCT05250687|RADIATION|External beam radiotherapy|Standard of care for pain palliation of bone metastases consists of single fraction external beam radiotherapy of 8-16 Gray (Gy) or a multi-fraction regime of 20 Gy in 5 fractions, 24 Gy in 6 fractions or 30 Gy in 10 fractions. The radiation schedule is at the discretion of the treating radiation oncologist.
214935320|NCT03211143|DRUG|CKD-381|Test drug: CKD-381
214935321|NCT03211143|DRUG|Nexium|Reference drug: Nexium
214935322|NCT03690973|DRUG|Alveolar socket preservation with graft and flap surgery|Alveolar socket preservation with xenogenic bone graft and flap surgery
214935323|NCT03690973|DEVICE|Immediate implant placement with bone using flapless surgery|Immediate implant placement with xenogenic bone graft using flapless surgery
214935324|NCT03690973|DEVICE|Immediate implant placement with bone using flap surgery|Immediate implant placement with xenogenic bone graft using flap surgery
214935325|NCT03690973|DRUG|Alveolar socket preservation with graft and flapless surgery|Alveolar socket preservation with xenogenic bone graft and flapless surgery
214935326|NCT02744027|OTHER|Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)|Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight. Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min. One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories \[TWIST\]) sequence. The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds. This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence. In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.
214334292|NCT05174975|BEHAVIORAL|App-based Positive Psychological Intervention|The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
214334293|NCT01336465|DRUG|placebo|Repeating subcutaneous injection
214334294|NCT01336465|DRUG|rhuMAb Beta7|Repeating subcutaneous injection
214334295|NCT02358746|OTHER|combined endo/epicardial approach|
214935327|NCT02744027|OTHER|Heavy Weighted T2 Imaging (T2W)|Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters. Scan time varies from 2-5 min depending upon the size of the subject.
214935328|NCT02744027|OTHER|Lymph Node Access|"The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old.~Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite."
214935329|NCT01726036|DEVICE|Gomco Circumcision Clamp|Neonatal male circumcision utilizing the Gomco Circumcision Clamp
214674026|NCT04715802|PROCEDURE|Immediate breast reconstruction with implant|Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
214334296|NCT02358746|OTHER|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
214334297|NCT01727531|DRUG|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
214334298|NCT02035007|DEVICE|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
214334299|NCT03357458|BEHAVIORAL|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
214334300|NCT05267067|OTHER|respiratory exercises|Manual respiratory exercises versus respiratory exercises with pressure meter
214334301|NCT02168166|BEHAVIORAL|Executive Function Training|
214334302|NCT02168166|BEHAVIORAL|Placebo|Placebo version of executive function training
214935330|NCT01726036|DEVICE|Mogen Circumcision Clamp|Neonatal male circumcision utilizing the Mogen Circumcision Clamp
214674027|NCT04715802|PROCEDURE|delayed breast reconstruction with implant|The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
214334303|NCT03428516|DEVICE|Fixed CPAP|CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep
214935331|NCT02042300|DEVICE|XIENCE Xpedition/Alpine/Sierra|
214935332|NCT05636007|DEVICE|Huawei Watch|pulse rate variability measured by a smartwatch
214334304|NCT03428516|DEVICE|Auto-adjusting CPAP|Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
214334305|NCT04687956|PROCEDURE|LYMPHA|Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
214935333|NCT00779532|DRUG|Moxifloxacin|Capsules containing 400 mg moxifloxacin, on Day 14 only
214935334|NCT00779532|DRUG|NOMAC-E2 (Org 10486-0 + Org 2317)|Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
214334306|NCT04687956|PROCEDURE|control|In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
214334307|NCT01243944|DRUG|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
214334308|NCT01243944|OTHER|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
214334309|NCT01166984|DRUG|AB103|Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes
214334310|NCT01166984|DRUG|Placebo|Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
214334311|NCT06271096|DRUG|Intra muscular Midazolam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
214334312|NCT06271096|DRUG|Intravascular Diazepam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
214334313|NCT00161928|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
214334314|NCT03480555|DIETARY_SUPPLEMENT|Replenish Protein|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
214334315|NCT03480555|DIETARY_SUPPLEMENT|Standard protein|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
214334316|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
214935335|NCT00779532|DRUG|Moxifloxacin placebo|Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
214935336|NCT00779532|DRUG|NOMAC-E2 placebo|Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
214935337|NCT05461456|DRUG|Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)|"Intervention:~The amount of study lotion (OP2101) used is 11 grams per subject, equivalent to 22 fingertip units (FTU). The lotion is applied to the subject on back and front of the trunk, both hands (palm and back) and both arms. An SOP for handling and application of the lotion ensures the 11 grams covers 54% of the body surface area (BSA) evenly without residue.~Comment:~The treatment is single-dose and single-treatment. The FTU is used to standardize the amount of cream being applied in clinical research. It is also used in clinical practice and hence connects the objectiveness of the trial to the clinical situation."
214935338|NCT06622733|BEHAVIORAL|Questionnaire|Attitude towards the concept of CS on demand
214935339|NCT02763397|DEVICE|NBM-DBS|DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
214334317|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
214334318|NCT03962972|OTHER|Frailty evaluation|"It will be used a questionnaire that is called:The Centre of Excellence Self-Administered questionnaire (CESAM). The score of this questionnaire and its stratification of frailty in four levels with incident adverse health events in older community dwellers will be compare with validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index, Rockwood frailty index, 6-ietm brief geriatric assessment (BGA), Program of Research on the Integration of Services for the Maintenance of Autonomy (PRISMA-7) and b) two other frailty index developed over the COVID-19 pandemic which are Évaluation SOcio-GÉriatrique (ESOGER) and CriblAge et REcommandations (CARE)."
214334319|NCT02681926|PROCEDURE|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
214935340|NCT02763397|DEVICE|DBS|DBS will be switched off
214935341|NCT04787796|DEVICE|a 28-channel ECG (MECG) system|To test if a 28-channel ECG (MECG) system would efficiently differentiate the patients suspected to have CAD or ACS with acceptable sensitivity and specificity, and optimize this portable self-built-in multichannel ECG recorder system with various algorithms.
214935342|NCT05519059|DRUG|Pelareorep|Pelareorep at 1.5×10\^10 TCID50, 3×10\^10 TCID50, 4.5×10\^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m\^2 on Day 1/8/15 per cycle
214935343|NCT00703794|DEVICE|The AXIUM Progressive Coil System|Embolization of aneurysm
214935344|NCT05341206|DRUG|Herbal gargle|The treatment group receive Herbal gargle 150ml and are instructed to hold the gargle in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
214935345|NCT05341206|OTHER|Normal saline|The control group receive Normal saline 150ml and are instructed to hold the normal saline in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
214674028|NCT04715802|PROCEDURE|delayed breast reconstruction with autologous fat transplantation|Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
214674029|NCT06906471|DRUG|AS1986NS|Single dose, IV, 100 µg of AS1986NS
214674030|NCT03673787|DRUG|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
214674031|NCT03673787|DRUG|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
214674032|NCT02726750|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214674033|NCT02726750|OTHER|Laboratory Biomarker Analysis|Correlative studies
214674034|NCT04109079|PROCEDURE|Axillary lymph node dissection|Participants will undergo removal of at least level I and II axillary lymph nodes.
214674035|NCT04109079|RADIATION|Axillary radiotherapy|Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
214674036|NCT04109079|RADIATION|Breast or chest wall radiotherapy|Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
214674037|NCT01318902|DRUG|Ixazomib|Ixazomib capsules.
214674038|NCT01318902|DRUG|Dexamethasone|Dexamethasone tablets.
214674039|NCT06912607|BEHAVIORAL|Balance in Motion Exercise class|8 weeks of 2 meetings/wk exercise class, with a once weekly homework exercise, delivered entirely in ASL
214674040|NCT06828692|COMBINATION_PRODUCT|Group A (clinical guideline+machine learning)|Group A (CG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG) and machine learning (ML) approach.
214674041|NCT06828692|COMBINATION_PRODUCT|Group B (clinical guideline+impedance cardiograph+machine learning)|Group B (CG+ICG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG), hemodynamic parameters measured by impedance cardiograph (ICG), and machine learning (ML) approach.
214674042|NCT06828692|OTHER|Group C (usual care)|Control group, the physicians manage the hypertensive patients according to their knowledge and experiences.
214935346|NCT02343445|DRUG|P-1037|P-1037 is a novel ENaC inhibitor
214935347|NCT02343445|DRUG|Hypertonic Saline|4.2% saline solution
214935348|NCT02343445|DRUG|Saline|0.17% saline solution
214935349|NCT01190358|DIETARY_SUPPLEMENT|Placebo|Sugar pill containing maltodextrin.
214935350|NCT01190358|DIETARY_SUPPLEMENT|Grape seed extract|Meganatural Gold® contains 300mg of grape seed extract.
214935351|NCT03646214|DEVICE|Midline traction oral appliance|Device positions the mandible forward to open airway; device can be titrated to gradually advance the mandible.
214935352|NCT04010747|BEHAVIORAL|Motivational Interviewing for Loved Ones (MILO)|4 sessions of behavioral coaching in motivational interviewing communication techniques
214334320|NCT05440682|PROCEDURE|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
214334321|NCT04174677|DRUG|Inebilizumab|Infusion of Inebilizumab
214935353|NCT04010747|BEHAVIORAL|Mental Health Services Consultation and Waitlist|1 session of individualized consultation on relevant mental health services for the IP and participating PCSO and 6 weeks on a waitlist, followed by opportunity to participate in MILO sessions.
214334322|NCT04174677|DRUG|VIB4920|Infusion of VIB4920
214935354|NCT03635385|PROCEDURE|Apheresis technics|Blood draw will be performed for anti bodies dosages
214935355|NCT03055494|BIOLOGICAL|Secukinumab|Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
214935356|NCT03055494|BIOLOGICAL|Placebo|Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
214674043|NCT05303675|OTHER|exercise and training|"Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
214334323|NCT04174677|DRUG|Inebilzumab+VIB4920|Infusion of Inebilizumab and VIB4920
214334324|NCT06569576|BEHAVIORAL|Wellness program|It combines seated yoga exercises, mindfulness, and social participation activities and discussions, and can be delivered in-person or via tele-health.
214674044|NCT06735131|RADIATION|radiotherapy 5 Gy × 5 fractions, once a day|5 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
214674045|NCT06735131|RADIATION|radiotherapy 8 Gy × 5 fractions, once a day|8 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
214674046|NCT06735131|RADIATION|radiotherapy 8 Gy × 3 fractions, once every other day|8 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
214674047|NCT06735131|RADIATION|radiotherapy 10 Gy× 3 fractions, once every other day|10 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
214674048|NCT06735131|RADIATION|radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)|0.5 Gy twice-a-day × 2 days, on the first 2 days of the first 4 cycles of toripalimab and chemotherapy (total 8Gy)
214674049|NCT06735131|DRUG|Toripalimab|Toripalimab (240 mg IV, d1, Q3W)
214674050|NCT06735131|DRUG|chemotherapy regimen selected by the investigator|Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)
214674051|NCT06920537|OTHER|Postpartum Cardio-obstetric Rehabilitation Program|The intervention consists of an 8-week exercise and education program with a hybrid format (in person, virtual and pre-recorded sessions). The aerobic exercise intensity will progressively increase from 50 to 85% of Targeted Heart Rate Range (THRR), calculated for middle-aged women using the maximal heart rate (HR) estimated as 206 - (0.88 x age) . First and second weeks training will target an intensity of 50-65% THRR, third and fourth weeks will target 65 to 75% of THRR, fifth to seventh weeks will target 75 to 80%, and eighth week will target 85%. Participants will use Fitbit Charge-6 to monitor THRR during exercise sessions. Pelvic floor, body alignment/core stability, balance, and low back pain prevention exercises will be added to each in-person session and repeated during the online session. Participants from the intervention group will receive recommendations to progressively reach daily 10,000 steps throughout the intervention period.
214674052|NCT06922357|DRUG|HRS-6719|HRS-6719
214334325|NCT02317640|DRUG|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
214334326|NCT02317640|OTHER|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
214674053|NCT04857645|DRUG|ASTX727|Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
214935357|NCT05984173|DRUG|Vitamin E application|patients received vitamin E inside the socket after extraction
214935358|NCT05907031|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
214935359|NCT05907031|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
214935360|NCT00662428|OTHER|Symptom based discharge management|Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
214334327|NCT02317640|DEVICE|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
214935361|NCT00662428|OTHER|Treatment as usual|Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
214935362|NCT04692324|PROCEDURE|Biospecimen Collection|Undergo collection of CSF samples
214935363|NCT04692324|OTHER|Electronic Health Record Review|Review of medical records
214935364|NCT04692324|OTHER|Survey Administration|Ancillary studies
214935365|NCT03953027|OTHER|Survey Administration|Ancillary studies
214935366|NCT05732116|OTHER|PTSD|Series scales, including GHQ-12, PCL-6, and CAPS-5 will be used to screen and diagnose the development of PTSD in surgeons and anesthesiologists at 3 time points, baseline (time 0), 3 m, and 6 m.
214935367|NCT05079750|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
214935368|NCT06337786|DEVICE|Digital app RB4.1|Standard care and the digital app RB4.1
214935369|NCT06337786|OTHER|Control arm|Standard care alone
214935370|NCT06065007|OTHER|No intervention|This is a cross-sectional observational study, no intervention will be implemented or exposure studied. Data for outcomes of interest will be collected via questionnaires
214935371|NCT05878925|OTHER|Aroma|The study intervention is an olfactory stimulation with vanilla or strawberry aroma. The aroma will be applied to the inner surface of the nCPAP mask of preterm infants using designated scent pens every 3-4 hours over a period of 12 hours. The two aromas will be applied in blocks of 5 consecutive infants (5 infants vanilla, 5 infants strawberry, and so forth).
214935372|NCT05878925|OTHER|Placebo|During the control intervention, identically looking placebo pens will be used to apply a colored carrier solution (without aroma) to the inner surface of the nCPAP mask of preterm infants in the same manner.
214935373|NCT06280066|OTHER|Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers|The content of the Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers will include the Psychological Resiliency Program for Children and Adolescents developed by Akar (2018), laughter yoga, meditation, breathing exercises and therapeutic story sessions.
214935374|NCT03605771|OTHER|Daily Clinical Practice|The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
214935375|NCT03383081|BIOLOGICAL|Low dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);
214935376|NCT03383081|BIOLOGICAL|High dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)
214935377|NCT03383081|PROCEDURE|Intraarticular injection|Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
214334328|NCT05795387|OTHER|Video-based self-regulated training on the mental status exam|Authentic patient videos for self-regulated training as well as written e-course material, both on the mental status exam
214334329|NCT05795387|OTHER|E-course with written material on the mental status exam|Written material on the mental status exam
214347230|NCT00318006|PROCEDURE|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
214674054|NCT04857645|OTHER|Donor Lymphocyte Infusions|In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
214674055|NCT06509932|DEVICE|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
214935378|NCT04867967|BEHAVIORAL|Iyengar Yoga|Classical Iyengar Yoga intervention, especially designed for headache patients. Note: First administered face-to-face, due to Covid-restrictions changed to online classes
214935379|NCT04867967|BEHAVIORAL|Mindfulness-based stress reduction|Standardazied Mindfulness-based stress reduction intervention Note: First administered face-to-face, due to Covid-restrictions changed to online classes
214935380|NCT04220814|RADIATION|MRI|MRI protocol is different, a little bit longer than MRI in routine for patients. For healthy volunteer, a specific MRI for this study is done
214674056|NCT06509932|DEVICE|MoliCare Premium Bed Mats|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
214935381|NCT04220814|OTHER|Electrophysiology|Electrophysiology will be done during routine visits for patients and during inclusion visit to healthy volunteers
214935382|NCT06354920|BEHAVIORAL|Bonding Bundle|Doctors in the intervention arm will be asked to use suggested approaches while meeting with their hospitalized patients. The goal of these strategies is to improve the relationship and interactions between patients and physicians.
214935383|NCT06346847|DIETARY_SUPPLEMENT|Postbiotic|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
214935384|NCT06346847|DIETARY_SUPPLEMENT|Placebo|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
214674057|NCT02747628|DRUG|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
214674058|NCT02747628|DRUG|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
214334330|NCT01416805|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
214334331|NCT01416805|BEHAVIORAL|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
214334332|NCT01813526|OTHER|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
214334333|NCT01955876|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
214334334|NCT03976440|OTHER|Renal Replacement Therapy (RRT) start|At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy
214334335|NCT04480164|DRUG|NDMC|Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
214334336|NCT00951067|OTHER|Exercise, Elevation, and Compression Garment|"Patients will be asked to daily:~* exercise~* elevate arm~* wear an arm compression garment"
214334337|NCT00951067|DEVICE|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
214334338|NCT00951067|DEVICE|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
214334339|NCT00951067|DEVICE|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
214334340|NCT00951067|DEVICE|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
214334341|NCT03280277|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
214334342|NCT03280277|DRUG|Ferumoxytol|Given IV
214334343|NCT02802345|DRUG|Nintedanib|
214334344|NCT02802345|DRUG|Placebo|
214334345|NCT02802345|DRUG|Sildenafil|
214334346|NCT05236790|DIAGNOSTIC_TEST|Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye|Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
214334347|NCT05323305|PROCEDURE|ultrasound guided regional block|Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.
214935385|NCT05201144|DRUG|Sildenafil Oral Suspension|Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
214334348|NCT06531668|DIETARY_SUPPLEMENT|Beyond Hormone|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
214334349|NCT06531668|OTHER|Placebo|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
214334350|NCT04632940|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
214334351|NCT04632940|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
214334352|NCT04632940|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
214334353|NCT04803929|BIOLOGICAL|anti-ILT3 CAR-T|Autologous T cells genetically modified with anti-ILT3 CAR
214334354|NCT02661828|OTHER|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
214334355|NCT02661828|OTHER|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
214334356|NCT05224947|OTHER|Infant Formula|Two infant formulas differing in composition
214674059|NCT02747628|DRUG|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
214935386|NCT05201144|OTHER|Placebo|Equal volume of placebo
214334357|NCT01804556|PROCEDURE|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 \~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
214334358|NCT03291912|PROCEDURE|Chuna Manual Therapy|"* Unique manual therapy in traditional Korean medicine~* Mandatory techniques for neck part and selective techniques for other part (if necessary)~* Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
214334359|NCT03291912|PROCEDURE|Usual care|"1. Physical therapy based on traditional Korean medicine theory~   * Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~  * Heat stimulation: either Hot pack or Infrared lamp~2. Patient education~   * Physical and pathological explanation of cervicogenic dizziness~  * Cause and risk factors of cervicogenic dizziness~  * Functions of muscles related to cervicogenic dizziness~  * Home exercising to self-manage cervicogenic dizziness"
214334363|NCT06227780|OTHER|Alpha Auditory Entrainment|"Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers"
214334364|NCT06227780|OTHER|Sham|"Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers"
214334365|NCT00199862|DRUG|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
214334366|NCT01826500|OTHER|blood test|blood test
214334367|NCT05673720|DEVICE|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session for 5 times via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session for 5 times by a recorded meditation.
214334368|NCT05673720|DEVICE|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
214334369|NCT06406205|DRUG|Voclosporin（QL1074）|QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
214334370|NCT06406205|DRUG|Placebo|Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
214334371|NCT00088296|PROCEDURE|Blood Draw|
214334372|NCT00947583|BIOLOGICAL|Osteocel Plus|biologic
214334373|NCT04313166|DRUG|Cu(II)ATSM|cooper-containing synthetic small molecule
214334374|NCT03395431|OTHER|Fingerprick autologuos blood (FAB)|Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
214334375|NCT03973242|DEVICE|Dual focus with narrow band imaging|dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
214334376|NCT03521492|DIAGNOSTIC_TEST|serum vitamin D , calcium , parathyroid hormone and albumin level|measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
214334377|NCT05104372|OTHER|Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)|Nasal washout and gargles
214334378|NCT05857527|COMBINATION_PRODUCT|Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in lab|Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session. Phase 1 will occur in the lab, and ongoing notifications will be made to the EMG system to test feasibility of automatic stimulation
214347231|NCT00318006|PROCEDURE|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
214935387|NCT06315517|OTHER|Conventional lactose-free cow's milk|"Participants will receive conventional lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
214334379|NCT05857527|COMBINATION_PRODUCT|Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in home|Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session. Phase 2 will occur in the home and will assess the quality of the CIMT therapy provided with the automated EMG system.
214334380|NCT06268821|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
214334381|NCT05281731|DEVICE|Sonobiopsy|Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy
214334382|NCT05281731|PROCEDURE|Research blood|No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)
214334383|NCT05281731|GENETIC|Cancer Personalized Profiling|Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.
214334384|NCT05281731|DEVICE|Definity®|Being used off-label in this trial
214334385|NCT01772953|DRUG|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
214334386|NCT02737566|BEHAVIORAL|Standard Care + Financial Incentives|Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
214334387|NCT02737566|OTHER|Standard Care|Tobacco cessation counseling plus pharmacotherapy.
214334388|NCT04212507|DIAGNOSTIC_TEST|The serum level of Claudin-3 and intestinal Fatty acid binding protein|The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.
214334389|NCT02799082|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
214334390|NCT02799082|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
214334391|NCT00694460|BIOLOGICAL|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
214334392|NCT00694460|BIOLOGICAL|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
214334393|NCT00694460|BIOLOGICAL|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
214935388|NCT06315517|OTHER|Nonconventional (A2) cow's milk|"Participants will receive nonconventional (A2) cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
214935389|NCT06315517|OTHER|Nonconventional (A2) lactose-free cow's milk|"Participants will receive nonconventional (A2) lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
214334394|NCT00694460|BIOLOGICAL|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
214334395|NCT00694460|BIOLOGICAL|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
214334396|NCT01778192|DRUG|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
214334397|NCT01778192|DRUG|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
214334398|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
214334399|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
214334400|NCT05038137|BEHAVIORAL|Time restricted feeding|Participants will eat all food during a self selected 8 hour eating window prior to 8:00 PM.
214334401|NCT05038137|BEHAVIORAL|Control|Participants will have a daily eating period equal to or greater than 12 hours.
214334402|NCT01187238|DRUG|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
214334403|NCT06536166|DRUG|Ruxolitinib|IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.
214334404|NCT06536166|DRUG|Placebo|IBM patients treated by placebo, twice a day, during 12 months.
214334405|NCT00144573|DRUG|MRA(Tocilizumab)|
214334406|NCT00245557|DRUG|Sertraline|"Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day.~Duration of treatment was 12 weeks."
214334407|NCT01348529|BEHAVIORAL|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
214334408|NCT02242786|RADIATION|External beam radiation therapy|
214334409|NCT04922593|DRUG|LY03010; paliperidone palmitate|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
214334410|NCT04922593|DRUG|INVEGA SUSTENNA|INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
214334411|NCT01564225|DRUG|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
214334412|NCT03174977|DRUG|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
214334413|NCT05884034|OTHER|Telerehabilitation|Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.
214334414|NCT05884034|OTHER|Education|Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.
214334415|NCT05904964|DRUG|Disitamab vedotin|Disitamab Vedotin 2mg/kg was injected every 2 weeks,
214334416|NCT05904964|OTHER|Endocrine therapy|Doctors choose endocrine therapy independently
214334417|NCT04701268|OTHER|Device: Hemiverse|Implantation of the hemiverse shoulder prothesis
214334418|NCT04705077|DRUG|SR419|2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
214334419|NCT05900947|OTHER|analysis of carotid atherosclerotic plaque|To assess the presence of air pollutants (benzene, toluene, xylene, and ethylbenzene) or of microplastics within tissues from atherosclerotic plaques by Chromatographic analyses.
214674060|NCT06503991|BEHAVIORAL|Community Health Worker (CHW)-delivered Hypertension Management Pilot (CHAMP)|Clinic-based hypertension educational intervention delivered by a Community Health Worker.
214334420|NCT01748994|DRUG|Pioglitazone|30mg per day for four months
214334421|NCT01748994|DRUG|Placebo|
214334422|NCT03178071|DRUG|Lorlatinib|oral tablets, administered daily, continuously
214334423|NCT05015894|DRUG|NNC0480-0389|"A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days"
214334424|NCT04901884|DRUG|PET/MR with 18F-FDG|(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
214334425|NCT01887431|OTHER|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
214334426|NCT01887431|OTHER|Conventional therapy|3-month routine clinic visits
214334427|NCT00658346|DRUG|Treatment initiation for HIV-1 group O infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
214334428|NCT00658346|DRUG|Treatment initiation for HIV-1 group M infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
214334429|NCT01628276|BEHAVIORAL|Cog Rehab|Cognitive rehab for MS patients
214334430|NCT04378933|DEVICE|Amber Glasses|Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.
214334431|NCT04378933|DEVICE|Clear Lens Glasses|Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.
214347232|NCT00172510|PROCEDURE|blood drawing|
214674061|NCT06503991|BEHAVIORAL|Control of Blood Pressure and Risk Attenuation (COBRA)|Multi-component counseling program addressing patient education, provider training, coordination of care, and subsidizing care costs.
214935390|NCT04104412|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2\*10\^7
214935391|NCT01109628|DIETARY_SUPPLEMENT|Protein drink|Twice a day during 6 months
214935392|NCT01109628|DIETARY_SUPPLEMENT|Placebo drink|Twice a day during 6 months
214935393|NCT05961930|BEHAVIORAL|Questionnaire|Surgeons will be asked to fill in a short questionnaire after surgery on risk of postoperative infection
214334432|NCT05907356|OTHER|sciatic nerve slider technique in slump lying position|The patient will be sitting at the edge of the couch with the posterior aspect of the knee at the edge, the thighs parallel to each other, and flexion at the thoracic and lumbar spines (slouch position). The therapist will be standing at the bedside of the patient with a proximal arm over the patient's shoulder and one hand guiding the neck movements of the patient and the other hand guiding the knee movements, passively performing cervical neck flexion with knee flexion (stretching the nerve proximally and relaxing at the distal end) and then moving into cervical extension with knee extension. Provide five sets in every session: the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions; and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes
214347233|NCT06268912|PROCEDURE|Cold Mepivacaine|change the temperature, 3% at 5ºC
214347234|NCT06268912|PROCEDURE|Mepivacaine at room temperature|no change the temperature of anesthesia
214935394|NCT05399043|OTHER|Multidisciplinary Conventional Neuromotor Rehabilitation|Patients will receive conventional treatment consisting of two daily one-hour session (4 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
214935395|NCT05399043|DEVICE|Technology-based Rehabilitation|"According to their individualized rehabilitation project, patients will undergo RAT or non-immersive VR-based rehabilitation.~RAT will consist of three times a week one-hour session (4 weeks) and will be conducted by the implementation of an exoskeleton device for the upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™).~VR-based rehabilitation will consist of one daily one-hour session (4 weeks) and will be conducted by the implementation of a single non-immersive VR device among the Riablo™ (Corehab, Italy), the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), the Walker View™ (TechnoBody SRL, Italy).~Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants."
214935396|NCT05897827|BEHAVIORAL|PLANTS|PLANTS intervention is an online-delivered training program, including asynchronous and synchronous activities. This intervention was informed by the Information-Motivation-Behavior theory to target skills, self-efficacy, knowledge, and outcome expectations. There are 3 asynchronous online modules that cover a variety of topics including lessons on LGBTQ+ terminology, names and pronouns, resources, antibullying, gender neutral bathrooms, student confidentiality, active empathic listening, and school policies. Module include recorded presentations, student testimonials, activities, and downloadable resources for future reference. Every month, 7-9 lessons are opened. There are 2 synchronous group events delivered via Zoom and are 1.5 hours each.
214935397|NCT05897827|BEHAVIORAL|EMAILS|The active control arm is an email-based intervention, EMAILS, in which existing public resources for supporting, affirming, and protecting LGBTQ+ students are emailed to participants.
214935398|NCT05342753|DEVICE|Restylane Kysse|Hyaluronic Acid: Injectable gel for lip augmentation and the correction of upper perioral rhytids
214935399|NCT05999318|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
214935400|NCT05999318|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
214674062|NCT04735835|OTHER|Dietary Intervention|To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.
214674063|NCT06384989|OTHER|Child restraint system with load leg feature|The primary objective is to assess the usability of the load leg design for caregivers who must install the child safety seat into a vehicle. The specific aims are to quantify any errors committed by the participants while installing the car seat (especially related to the use of the load leg) and to assess participants' opinions on the car seat's load leg design.
214674064|NCT05287893|DRUG|Pyronaridine|Single dose
214674065|NCT05287893|BIOLOGICAL|P. falciparum IBSM infection|Induced Blood Stage Malaria
214347235|NCT02267382|DRUG|VT-1161|
214674066|NCT05520619|DRUG|Paclitaxel, Cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.
214674067|NCT05520619|DRUG|tislelizumab|Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
214935401|NCT06069154|DEVICE|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or for the Varian: 5.5-minute \[all but 5 participants\] or 3-minute \[5th - 12th participants; changes based on new laboratory and subsequently clinical data\] argon activation (2000 psi starting at 100% power but decreased to keep return gas flow temperature warmer than -100C) followed by a 30-second helium defrost. For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
214334433|NCT05907356|OTHER|sciatic nerve slider technique in supine position|.The patient will be in a supine position. The therapist will hold the patient's limb passively and then move the hip into flexion with the ankle in plantar flexion and the knee in extension, stretching the nerve at the hip and relaxing at the ankle, Then reversing the movement with the hip into extension, maintaining the knee in extension and the ankle in dorsiflexion, relaxing the nerve at the hip and stretching at the ankle. Provide five sets in every session; the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions, and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
214935402|NCT06069154|PROCEDURE|Local anesthetic peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks. The injectate through the introducer will depend on the treatment group: for participants of the control group, ropivacaine 0.5% or bupivacaine 0.375% (both with epinephrine 1:400,000) will be injected (volume determined by institutional standard-of-care). This will provide a peripheral nerve block for the control group.
214935403|NCT06069154|DEVICE|Sham Cryoneurolysis|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or for the Varian: 1 cycle of 5.5 minutes \[all but 5 participants\] or 3 minutes \[5th - 12th participants; changes based on new laboratory and subsequently clinical data\] of argon and 30 seconds of helium. However, for the sham comparator, the gas will NOT be deployed to the tip, there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
214935404|NCT06069154|PROCEDURE|Sham peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks: for participants allocated to the cryoneurolysis group (experimental group), normal saline will be injected for the peripheral nerve block. This will result in a sham/placebo nerve block for the experimental group.
214935405|NCT05441033|OTHER|Fetal Heart Sounds (FHS) Listening Intervention|Pregnant women and their partners listened to fetal heart sounds (also referred to as angel sounds) for 20 minutes before bedtime on three consecutive nights using a fetal heart rate monitoring device. The intervention aimed to enhance prenatal attachment and reduce anxiety by increasing awareness of the fetus through auditory stimulation.
214935406|NCT05441033|OTHER|Guided Imagery Technique (GIT) Intervention|Pregnant women and their partners listened to guided imagery audio recordings for 20 minutes before bedtime on three consecutive nights. The recordings were developed to support bonding with the baby, reduce anxiety, and improve sleep quality. The intervention was delivered via audio files prepared by the research team based on structured imagery scripts.
214935407|NCT05199662|DRUG|Intravenous tenecteplase|Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).
214935408|NCT05199662|DRUG|Placebo|Placebo matching IV TNK
214935409|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in Bangladesh|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
215073193|NCT00422630|BEHAVIORAL|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
215073194|NCT00422630|BEHAVIORAL|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
215073195|NCT03370380|DRUG|Aflibercept|Patients are treated according to authorization of Aflibercept
215073196|NCT00140283|PROCEDURE|Educational interactive intervention|
215073197|NCT05403372|DEVICE|PAS-C System|The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
215073198|NCT03536780|DRUG|Avelumab and Gemcitabine|"* Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~* Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"
215073199|NCT04982328|DIAGNOSTIC_TEST|Th17 cytokine profile|Screening for the components of metabolic syndrome
215073200|NCT04982328|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
214347236|NCT02267382|DRUG|Placebo|
214347237|NCT05046457|DIETARY_SUPPLEMENT|Beta-cryptoxanthin (BCX)|Subjects will be randomised into one of the three study treatment arms.
214347238|NCT01165281|DRUG|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
214347239|NCT01165281|DRUG|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
214334434|NCT05907356|OTHER|Conventional physiotherapy|The patient will receive conventional physiotherapy, which includes: a moist hot pack, TENS, and back strengthening exercises (as a home program).
214334435|NCT00727857|DRUG|Pioglitazone and metformin|Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
214334436|NCT00727857|DRUG|Pioglitazone|Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
214334437|NCT00727857|DRUG|Metformin|Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
214334438|NCT05937074|OTHER|Weight loss (%)|Change in body weight from cancer diagnosis to study enrollment
214334439|NCT03128697|BEHAVIORAL|Satiating diet|
214334440|NCT03128697|BEHAVIORAL|Control diet|
214334441|NCT02658110|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
214935410|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in Uganda|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
214935411|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in India|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
214935412|NCT02548559|DRUG|Full-Spectrum Cannabidiol|Full-Spectrum Cannabidiol; total daily dose of 30 mg.
214935413|NCT02548559|DRUG|Single-Compound Cannabidiol|Single-Compound Cannabidiol; total daily dose of 30 mg.
214674068|NCT05520619|RADIATION|Radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
215073201|NCT04982328|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
215073202|NCT05905224|DEVICE|Invisalign 7-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 7-day wear protocol
215073203|NCT05905224|DEVICE|Invisalign 3-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 3-day wear protocol
214334442|NCT02658110|OTHER|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
214334443|NCT02658110|OTHER|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
214674069|NCT05417971|OTHER|Fludarabine|Reduced-intensity fludarabine with intermediate-dose TBI
214674070|NCT05243550|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
214674071|NCT05667428|DRUG|leuprorelin|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of leprorelin in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
214674072|NCT05667428|DRUG|normal saline|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
214334444|NCT02112565|DRUG|RNR inhibitor COH29|Given PO
214334445|NCT02112565|OTHER|laboratory biomarker analysis|Correlative studies
214674073|NCT03729869|DRUG|Progesterone|200 mg of exogenous progesterone twice a day
214674074|NCT03729869|DRUG|Placebo|One dose of matched placebo twice a day.
214674075|NCT03444363|DEVICE|Laser group|Laser application in addition to SRP
214674076|NCT03444363|DEVICE|Control group|Placebo laser application in addition to SRP
214674077|NCT04340869|OTHER|Theobromine|Natural extract from Cocoa
214674078|NCT04340869|OTHER|Remin Pro|Remin Pro
214334446|NCT02112565|OTHER|pharmacological study|Correlative studies
214334447|NCT02510846|BEHAVIORAL|Intensive educative management|5 hours a week
214334448|NCT01455675|DRUG|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
214334449|NCT01455675|DRUG|Placebo|Placebo, 70 ml gargling solution, once daily
214334450|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (active C-tDCS)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
214334451|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (sham stimulation)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
214674079|NCT05337267|DRUG|sintilimab (after the change)|0.3mg/kg，I.V.，single dose
214674080|NCT05337267|DRUG|sintilimab (before the change)|0.3mg/kg，I.V.，single dose
214674081|NCT02806427|OTHER|Enteral Formula|
214935414|NCT02548559|DRUG|Placebo|Placebo solution.
214935415|NCT04190368|OTHER|Team Clinic Care|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient.~Selected providers will be trained in the Team Clinic Care protocol for completing medical appointments. Team Clinic Care key components:~(1) Shared decision making: Providers, AYA, parent/caregiver will mutually agree on priorities for each medical visit using a shared decision making tool (2) Autonomy supportive care: Providers will be trained in skills building, patient centered key elements, intervention bites, reviewing plans, designed to support AYA autonomy and intrinsic motivation. AYA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach AYA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate. (4) Fidelity Review and process for self-assessment"
214935416|NCT04190368|OTHER|Standard Care|Participants attend quarterly visits (1 visit every 3 months) and see their diabetes care provider. They do not participate in Team Clinic group visits but if they need diabetes education or supportive services they will be referred for necessary care per usual methods.
214935417|NCT06796335|OTHER|RIGht|The final intervention consists of five components; 1) education of nurses 2) a dialog tool used in a single session intervention and follow- up 3) a relative- to- relative list 4) video material 5) guidelines on how to document the relative involving plan in the patient's electronic journal.
214935418|NCT00197002|BIOLOGICAL|GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)|Two doses, administered intramuscularly in the right anterolateral thigh.
214935419|NCT00197002|BIOLOGICAL|Prevnar™|One dose, administered intramuscularly in the left anterolateral thigh.
214935420|NCT06840873|DEVICE|wearable device|Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation, including 3 aerobic and 2 strengthening exercise sessions per week at a moderate intensity, 30 min/session.
214935421|NCT06840873|BEHAVIORAL|Healthy consulation|Participants received routine outpatient health education.
214935422|NCT02017717|BIOLOGICAL|Nivolumab|specified dose on specified days
214935423|NCT02017717|BIOLOGICAL|Bevacizumab|specified dose on specified days
214935424|NCT02017717|BIOLOGICAL|Ipilimumab|specified dose on specified days
214935425|NCT05635227|DRUG|Dexamethasone phosphate|See description of arms
214935426|NCT05635227|DRUG|Isotonic sodium chloride (0.9%)|See description of arms
214935427|NCT05635227|DRUG|Olanzapine 10 MG|Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
214935428|NCT05635227|DRUG|Placebo capsule|capsule identical to capsule containing olanzapine
214935429|NCT05635227|PROCEDURE|Flow-targeted hemodynamic management|See description of arms
214935430|NCT05635227|PROCEDURE|Pressure-targeted hemodynamic management|See description of arms
214935431|NCT05635227|PROCEDURE|Low tidal-volume ventilation|See description of arms
214935432|NCT05635227|PROCEDURE|No ventilation|See description of arms
214935433|NCT05687747|DRUG|Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI|68Gallium-FAPI-46 PET/MRI is a novel radioactive diagnostic tracer used with Positron Emission Tomography imaging. It defects Fibroblast Activation Protein positive cancer cells and cancer associated fibroblasts.
214334452|NCT02417454|DIETARY_SUPPLEMENT|ProbioStick|"One sachet daily, without or without meals (3 x 10\^9 CFU per sachet)~(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)"
214935434|NCT05956886|BEHAVIORAL|sleep chatbot|Personalized intervention algorithms will be developed based on CBT-I guidelines, focus group data, individual sleep baseline information and self-reported prioritized sleep goals. The CBT-I intervention will focus on principles of sleep restriction and stimulus control, with other CBT-I components used as on-demand content. The sleep chatbot system will facilitate sleep goal-setting with the participant and communicate weekly behavioral prescriptions and educational modules. After baseline data collection, the research coordinator will provide intervention orientation and set up the first-week sleep modification goal during the in-person/Zoom meeting. Sleep modification goals in the remaining weeks will be developed through the participant-chatbot interaction. The Chatbot system will send sleep-related information and behavioral reminders/feedback based on the interactive conversation with participants. Participants will also complete a sleep diary prompted by a chatbot.
214674082|NCT03856073|BEHAVIORAL|Novice|Using the simulate device, the novices in bronchoscopy are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
214334453|NCT02417454|OTHER|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
214334454|NCT04766879|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
214334455|NCT04766879|DEVICE|Placebo|Passive emanator with formulated inert ingredients
214334456|NCT02181231|DRUG|venlafaxine XR|slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
214334457|NCT02181231|DRUG|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
214334458|NCT02181231|DRUG|Placebo|patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
214334459|NCT05559619|DRUG|Calcium carbonate|1000 mg of natural calcium carbonate once daily for 12 weeks
214334460|NCT05559619|DRUG|Vitamin D3|1000 IU vitamin D3 once daily for 12 weeks
214347240|NCT00058266|DIETARY_SUPPLEMENT|genistein|Given orally
214935435|NCT06847906|OTHER|Iteratively designed (new) clinical decision support tool for virtual visits|The new, iteratively designed clinical decision support tool includes the traditional CDS along with links to supportive tipsheets, which include one for providers on how to add an order for patients to upload vitals in their electronic health record, and one that walks patients through how to upload vitals on their own.
214935436|NCT06847906|OTHER|Traditional clinical decision support tool|The traditional CDS tool is the usual care intervention, and does not include links to tipsheets to support virtual patient care.
214935437|NCT05940402|DRUG|Emraclidine|Oral tablets
214935438|NCT05371496|DRUG|Semaglutide|3.0 mg/ml (titrated to 2.4 mg) subcutaneous once weekly for 12 months
214935439|NCT05371496|DRUG|Placebo|Matched placebo with no active drug once weekly for 12 months
214935440|NCT05371496|BEHAVIORAL|Counselling on healthy lifestyle intervention|All participants will receive counselling on healthy lifestyle intervention including limiting consumption of salt, red meat, saturated or trans fats, sweets, and sugar-sweetened beverages, and how to restrict calorie intake (500 kcal/day deficit) in consultation with a trained study dietician. Regular physical activity \>150 minutes per week will be encouraged.
214935441|NCT03527264|DRUG|Nivolumab induction|2 doses Nivolumab 240mg IV
214935442|NCT03527264|DRUG|Cisplatin|40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.
214935443|NCT03527264|RADIATION|Radiation|"Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field"
214935444|NCT03527264|DRUG|Nivolumab with chemoradiation|Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.
214935445|NCT03527264|DRUG|Nivolumab maintenance|Nivolumab 480 mg IV every 4 weeks for 2 years
214935446|NCT04016896|BEHAVIORAL|WIdowed Elders' LIfestyle after Loss (WELL)|Digital monitoring; motivational health coaching; personalized feedback
214935447|NCT04016896|OTHER|Enhanced Usual Care|psychoeducation plus study assessments controlling for time and attention
214935448|NCT06072430|DRUG|VBI-S|VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
214935449|NCT05920941|DRUG|[14C]JAB-21822|Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
214935450|NCT06527287|OTHER|Neurocognitive Ankle Training for Instablity to Optimize Neuromusculoskeletal outcomes (NATION)|The NATION rehabilitation protocol will serve as the true intervention group. NATION is a 6-week evidence-based chronic ankle instability (CAI) rehabilitation protocol that incorporates neurocognitive exercises. Participants will complete up to 18 unsupervised home sessions and up to 12 supervised sessions. Treatment volume and exercises may vary based on participant progress and study team member guidance.
214935451|NCT06527287|OTHER|Evidence-Based|The Evidence-Based rehabilitation protocol will serve as the active comparator group. The Evidence-Based protocol will be similar to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants assigned to the Evidence-Based protocol will complete up to 18 unsupervised home sessions and up to 12 supervised sessions over the course of 6-weeks. Treatment volume and exercises may vary based on participant progress.
214935452|NCT05962164|BEHAVIORAL|Passive Heat Therapy|The intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
214935453|NCT05962164|BEHAVIORAL|Sham Immersion|The sham intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
214334461|NCT05559619|DEVICE|laser acupuncture therapy|The patient was in crock lying for stimulation of acupoints in abdomen and lower limbs then asked to be in side lying for stimulation of acupoints in the back. After disinfection of the skin and careful localization of the acupoints, low level laser therapy (LLLT) (model: Lis 1050, SN: EM 13481014, manufactured by EME srl, Italy) was applied bilaterally on Dazhu (BL 11), Ganshu(BL 18), Pishu (BL20), Shenshu (BL23), Zusanli (ST 36), Sanyinjiao (Sp6), Jingmen(GB25), Yanglingquan (GB34) andXuanzhong (GB39) acupoints, while it was applied in the midline on Guanyuan (CV4) andMingmen (GV4) acupoints. Each acupoint was irradiated for 60 sec, with total duration of 20 min, wave length of 905 nm, average radiant power output of 12 mW, energy density of 2 J/cm2, pulse radiation of 200 ms and pulse frequency of 5000 Hz
214334462|NCT01728467|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
214334463|NCT01728467|DRUG|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
214935454|NCT04236414|DRUG|Olaparib|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to \<18 years. AAF available for ≥0.5 to \<6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.
214935455|NCT05684055|DRUG|First-line antihypertensive single-pill combination (SPC)|In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
214935456|NCT05684055|OTHER|Standardized counselling and referral to the closest health facility|In control villages, participants diagnosed with aHT receive a standardized counselling by the CC-VHW and are referred to the closest health facility for initiation or continuation of antihypertensive treatment.
214334464|NCT00393549|DEVICE|NeuroPath|
214334465|NCT02520531|DEVICE|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
214334466|NCT02520531|DEVICE|Scorpio NRG PS|Implantation of total knee prosthesis
214347241|NCT00058266|PROCEDURE|conventional surgery|Patients undergo surgery
214347242|NCT00005853|BIOLOGICAL|anti-thymocyte globulin|
214347243|NCT00005853|BIOLOGICAL|etanercept|
214347244|NCT01700608|DRUG|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
214347245|NCT06536075|RADIATION|Sialoscintigraphy|Sialoscintigraphy
214347246|NCT01154634|DRUG|AZD2516, 5 mg|Capsule, oral
214347247|NCT01154634|DRUG|AZD2516, 16 mg|Capsule, oral
214347248|NCT01154634|DRUG|AZD2516, 40 mg|Capsule, oral
214935457|NCT02984566|DEVICE|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
214935458|NCT06579755|BIOLOGICAL|TDV|TDV SC injection.
214935459|NCT06579755|OTHER|Placebo|Placebo SC injection.
214334467|NCT04112693|PROCEDURE|Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020.~The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse."
214334468|NCT04740606|DEVICE|Augmented Reality Navigation System|Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.
214334469|NCT04865094|OTHER|cyclic merocyanine|long-UVA absorber
214334470|NCT04865094|OTHER|placebo|placebo
214935460|NCT03848663|BEHAVIORAL|Traditional Remapping|Shifting text outside of scotoma
214935461|NCT03848663|BEHAVIORAL|Personalized Remapping|Shifting text based on individual letter-based perimetry
214935462|NCT04367857|OTHER|COVID-19 Serology|Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19
214935463|NCT04367857|BEHAVIORAL|Health Care Worker Survey|The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
214935464|NCT04488419|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
214935465|NCT04488419|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
214935466|NCT05380687|DIAGNOSTIC_TEST|Inspiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of inspiration. It is used to asses expiratory force generation (maximal expiratory pressure, MEP) and frequently used in clinical practice.
214935467|NCT05380687|DIAGNOSTIC_TEST|Expiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of expiration. It is used to asses static PEEP and inspiratory force generation (maximal inspiratory pressure, MIP \& occlusion pressure, ∆Pocc) and is frequently used in clinical practice.
214935468|NCT05380687|DIAGNOSTIC_TEST|Ultrasound of respiratory muscles|Ultrasound of the diaphragm, parasternal intercostal muscle and internal oblique muscle will be performed during each block. Thickening fractions, calculated as thickness at end-inspiration minus thickness at end-expiration divided by thickness at end-expiration, are used to assess the contribution of the muscle to the tidal volume. A median over 5 breaths will be calculated.
214935469|NCT05380687|OTHER|PEEP 10|Positive End-Expiratory Pressure of 10cmH2O for 30 minutes
214935470|NCT05380687|OTHER|PEEP 5|Positive End-Expiratory Pressure of 5cmH2O for 30 minutes
214935471|NCT05380687|OTHER|PEEP 0|Positive End-Expiratory Pressure of 0cmH2O for 30 minutes
214935472|NCT04642430|DRUG|Apixaban|Refer to Apixaban group
214935473|NCT04642430|DRUG|Rivaroxaban|Refer to Rivaroxaban group
214935474|NCT01089933|PROCEDURE|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
214334471|NCT01159067|DRUG|deferasirox|Given orally
214935475|NCT01089933|PROCEDURE|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
214486374|NCT06760078|DRUG|Placebo|An intravenous placebo (10mL NS, diluted in 90mL NS) matching the specification and appearance of TXA will be administered as an initial bolus over 10 minutes, followed by a continuous infusion of placebo (10mL NS, diluted in 240mL NS) over 8 hours, with intensive blood pressure lowering maintained throughout the treatment period and continued until 24 hours after symptoms onset.
214486375|NCT06439160|OTHER|Participants will be asked to complete a series of questionnaires at t0, t1 and t2|"Individuals will be people who voluntarily will take part in a residential three to six weeks multidisciplinary inpatient intensive rehabilitation treatment targeting the improvement of psychological well-being, body image, and psychopathology for anorexia nervosa.~Therefore, at T0 (at the beginning of the treatment) and T1 (at the end of the rehabilitation programme), participants will fill out some self-report questionnaires to evaluate the effect of the multidisciplinary inpatient intensive rehabilitation treatment on different outcomes (i.e. psychological well-being, eating pathology, body image, and comorbidities), among which their social components/skills. Moreover, we will ask participants to complete 3 months after discharge the questionnaires related to the social components/skills only. Participants will be contacted by email, within the email participants will find a link to click on for the completion of the questionnaires."
214334472|NCT04417491|DEVICE|Dry Needling|Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
214674083|NCT01378390|DRUG|Expanded autologous adipose-derived adult stem cells (eASCs)|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
214935476|NCT04652908|BIOLOGICAL|Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix|As in the current standard fetal surgery, under sonographic guidance, initial uterine entry will be accomplished by uterine stapling device or similar. The fetus will be given an intramuscular injection of pain medications and paralytic. The myelomeningocele will be closed in a standardized manner under magnification. As in the standard fetal operation, the spinal cord will be dissected from surrounding tissue and allowed to drop into the spinal canal. The PMSC-ECM product will then be tailored to the size of the spinal cord and applied topically, cell side down. The PMSC-ECM product will be sutured in place to the dura. Finally, the fetal skin will be closed in the standard fashion. The amniotic fluid volume will be replaced and antibiotics will be added. The uterus will be closed. The abdominal fascial layer and skin will be closed in routine fashion.
214935477|NCT04652908|OTHER|Untreated contemporaneous cohort|The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.
214935478|NCT02999230|OTHER|Caries Free 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
214935479|NCT02999230|OTHER|Caries Free Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
214935480|NCT02999230|OTHER|Caries Active 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
214935481|NCT02999230|OTHER|Caries Active- Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
214935482|NCT00177281|DRUG|S CKD602|
214935483|NCT05199194|DRUG|Tenecteplase|Intravenous thrombolysis with tenecteplase 0.25mg/kg
214935484|NCT05199194|DRUG|Placebo|Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg
214935485|NCT06467656|OTHER|Individualized, periodized endurance training for ultra-endurance triathlon.|Endurance exercise consisting of swimming, cycling and running training for a minimum of 3 hours /week up to a maximum of 20 hours/week with regular rest days and intensities being fluctuated throughout the program to optimize training stimulus and adaptation. Strengthening exercises to complement the aerobic training, enhance conditioning and prevent injury will also be performed 1-2 hours/week for the first 9-months of the program.
214935486|NCT06467656|OTHER|Time-Aligned Control|Participants will receive no specific intervention and will continue to live their lives as if they were not in a study.
214935487|NCT06620263|OTHER|Pre-education period (PreEd)|No intervention. ). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024).
214334473|NCT04417491|DEVICE|Sham Needling|Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
214334474|NCT04003597|OTHER|Usual-salt diet|Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
214347249|NCT01154634|DRUG|Placebo|Capsule, oral
214347250|NCT00985218|DEVICE|SMART System|microfluidic embryo culture system
214347251|NCT00985218|DEVICE|Culture dish|Standard IVF culture dish
214347252|NCT02069600|DEVICE|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
214347253|NCT03591744|DRUG|Bortezomib|Given SC
214347254|NCT03591744|BIOLOGICAL|Daratumumab|Given IV
214347255|NCT03591744|DRUG|Dexamethasone|Given IV and PO
214347256|NCT03591744|DRUG|Lenalidomide|Given PO
214347257|NCT03591744|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214347258|NCT05868083|DRUG|SNC-109 CAR-T Cells|SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
214347259|NCT01220908|DEVICE|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
214347260|NCT01220908|DEVICE|Coils|Lung Volume Reduction Coil(s)
214347261|NCT05806762|DEVICE|BioIntellisense|Enrolled patients will have a Fitbit placed on their wrist. There is no comparator group enrolled.
214347262|NCT03860194|DIETARY_SUPPLEMENT|Protison with High Protein 51(Original Flavor)|Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
214347263|NCT00171977|DRUG|Imatinib Mesylate|
214347264|NCT00326378|DRUG|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
214674084|NCT01378390|DRUG|Placebo|Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
214674085|NCT01394029|DRUG|deferasirox|
214935488|NCT06620263|OTHER|Post-education period (PostEd)|In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed.
214935489|NCT00663897|DRUG|lansoprazole|lansoprazole, 30 mg, once daily for 14 days
214935490|NCT00663897|DRUG|mosapride|mosapride, 5 mg, thrice daily for 14 days
214935491|NCT05197985|BEHAVIORAL|IECD Intervention|The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
214935492|NCT05930886|OTHER|Focus Group|Black or Hispanic/Latino parents, caregivers or family members of children with ADHD symptoms and/or emotional dysregulation, will discuss: (1) impact of child's mental health, treatments, care received; (2) perceived and actual barriers to future study participation, including discussion about acceptability of bio-specimen collection methods for urine and blood. Each group will comprise individuals who self-identify as Hispanic/Latino, Black, or mixed race. Groups are anticipated to comprise individuals who identify with one or the the other race/ethnicity in order to create space to hear perspectives that may differ between these broadly defined groups.
214935493|NCT06320457|OTHER|Brief case management intervention|"The brief case management intervention aims to support patients during the difficult phase of involuntary hospitalisation and reduce the impact of this short-term event on their long-term recovery process. The intervention starts during the hospital stay, at the latest one week after admission, and lasts for a maximum of one month after discharge. The intervention consists of five sessions, the order of which may vary according to the specific needs of the patient:~1. Personal account of involuntary hospitalisation and its consequences~2. Presentation of the personal recovery model and the tools to promote it and prevent coercion~3. Introduction to the personal recovery plan~4. Network meeting and discussion on dignity of risk~5. Personal recovery plan"
214935494|NCT03976336|DIETARY_SUPPLEMENT|Berberine|500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
214935495|NCT03976336|OTHER|Identical Placebo|500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
214935496|NCT05488509|DRUG|Cannabis|Participants will inhale vapor from cannabis containing either 20mg THC or 40mg THC.
214935497|NCT05488509|DRUG|Placebo|Participants will inhale vapor from a placebo product.
214334475|NCT04003597|OTHER|Reduced-salt diet|Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (\<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
214334476|NCT01849341|DRUG|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
214334477|NCT01849341|DRUG|Roflumilast 500 mcg per day|
214334478|NCT01581203|DRUG|Asunaprevir (ASV)|
214935498|NCT06838416|DRUG|Finerenone|Treatment will continue for 48 weeks.
214935499|NCT06480227|DEVICE|Solyx Single-incision Sling|Minimally invasive mesh device placed to treat stress urinary incontinence.
214935500|NCT06480227|DEVICE|Bulkamid Transurethral Bulking Agent|Minimally invasive bulking agent injections used to bulk up the tissue surrounding the urethra to treat stress urinary incontinence. Up to 2 treatments within 12 months are allowed
214935501|NCT06529523|DRUG|Tislelizumab|Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).
214334479|NCT01581203|DRUG|Daclatasvir (DCV)|
214334480|NCT01581203|DRUG|Pegylated-interferon alfa 2a (PegIFN)|
214334481|NCT01581203|DRUG|Ribavirin (RBV)|
214674086|NCT01815710|OTHER|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
214334482|NCT03154697|OTHER|Data collection of sleep disturbances in individuals with SMS|Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey
214334483|NCT06560541|OTHER|UKMRC9|UKMRC9 is a low glycemic index and polyphenol-rich red pigmented rice
214334484|NCT06560541|OTHER|White rice|White rice refers to a local polished rice
214334485|NCT00077259|DRUG|epothilone D|
214334486|NCT03074734|OTHER|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
214334487|NCT04487340|BEHAVIORAL|Education|Provide each center with relevant education of guidelines, and help the clinicians to improve medical quality.
214334488|NCT03265028|BEHAVIORAL|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
214486376|NCT06760962|BEHAVIORAL|Reflective Mindfulness and Emotional Regulation training|The RMERT program consisted of six weekly 90-minute sessions facilitated by researchers trained in cognitive behavioral therapy (CBT) and transactional analysis (TA). The training employed the ABC model of CBT (Activating events, Beliefs, and Consequences) to address maladaptive cognitive patterns, along with TA techniques such as empathic inquiry and reflection. Relaxation strategies, including diaphragmatic breathing and progressive muscle relaxation, were also integrated. The sessions focused on enabling students to reflect on their mental and emotional states, process their feelings, and apply cognitive reappraisal-a healthy emotional regulation strategy-instead of relying on expressive suppression, which is maladaptive.
214334489|NCT04336969|BEHAVIORAL|4T Education and Care|CGM data will be used to create customized weekly or monthly feedback to the participant/family by secure MyChart message.
214674087|NCT01815710|OTHER|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
214334490|NCT05352139|PROCEDURE|Resection (removal) of the degenerative tissue using the Hydrocision TenJet system|During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.
214935502|NCT06485427|PROCEDURE|Selective Intra-arterial Cooling Infusion (IA-SCI)|"Pre-recanalization: During the procedure, the micro-catheter is advanced over a micro-guide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4 ℃) is infused intro into the ischemic territory at a rate of 10 mL/min via the micro-catheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~Post-recanalization: After recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL/min for 10 min, repeated twice with a 10-minute interval between infusions."
214935503|NCT05276726|DRUG|JAB 21822|Administered orally
214935504|NCT05756894|DEVICE|Neurostimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
214674088|NCT05238896|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg/d oral route for 42 days
214674089|NCT05238896|DRUG|Placebo|Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
214674090|NCT01438710|DRUG|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
214674091|NCT01438710|DRUG|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
214334491|NCT05352139|DEVICE|Hydrocision Tenjet System|The TenJet system will be used during surgery to remove the damaged tissue from the joint
214334492|NCT00762489|OTHER|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
214674092|NCT05484986|OTHER|A questionnaire with 47 items|A form consisted of questions on introductory characteristics (age, sex, and class, among others), Big Five Inventory (BFI) to evaluate personality traits, and Management of Workplace Violence Competence Scale for Nursing Students in Areas of Clinical Practice.
214674093|NCT01775488|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
214935505|NCT05756894|OTHER|Repiratory training|Respiratory exercises will be completed immediately after completing neurostimulation. Respiratory exercises will involve inspiratory muscle training performing four sets of 6-10 breaths per day with two minutes of rest.
214935506|NCT05299333|OTHER|Exercise|High repetition muscle endurance and strengthening exercises Walking
214935507|NCT04330664|DRUG|MRTX849|KRAS G12C Inhibitor
214334493|NCT01723904|DRUG|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
214334494|NCT02488044|DRUG|AEB1102|modified human arginase I
214334495|NCT04989257|DRUG|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
214334496|NCT04989257|DRUG|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
214334497|NCT00374777|DRUG|zolpidem MR|oral
214935508|NCT04330664|DRUG|TNO155|SHP2 Inhibitor
214935509|NCT06160258|BEHAVIORAL|Ready to Eat (RTE)|Participants will be provided precooked and individually packaged whole grains in the ready-to-eat (RTE) condition for reheating and consumption at home.
214334498|NCT00374777|DRUG|nitrazepam|oral
214334499|NCT00374777|DRUG|placebo|oral
214334500|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based assessments|Motor and cognitive testing in virtual reality
214674094|NCT02452970|DRUG|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
214334501|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based serious games|Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
214674095|NCT02452970|DRUG|Gemcitabine and cisplatin|RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
214935510|NCT06160258|BEHAVIORAL|Dried|Participants will be provided with dried whole grains for home preparation and consumption
214334502|NCT03251924|DRUG|BMS-986226|specified dose on specified days
214334503|NCT03251924|BIOLOGICAL|Nivolumab|specified dose on specified days
214334504|NCT03251924|BIOLOGICAL|Ipilimumab|specified dose on specified days
214935511|NCT00005005|DRUG|PTH|
214935512|NCT00005005|DRUG|Alendronate|
214334505|NCT03251924|BIOLOGICAL|Tetanus Vaccine|specified dose on specified days
214334506|NCT01256905|DRUG|Armodafinil|Armodafinil 150 mg
214935513|NCT06275074|PROCEDURE|Dry Needling|Insertion of filiform needles into cervicothoracic multifidi, upper trapezius, and suboccipital muscles
214334507|NCT00834301|DIETARY_SUPPLEMENT|Oral Multivitamin|Oral Multivitamin
214334508|NCT06533839|PROCEDURE|Permanent colostomy|A long-term (permanent) colostomy will be performed in the diseased colon or rectum.
214334509|NCT05316857|DRUG|Orelabrutinib + Rifampin|Orelabrutinib + Rifampin
214334510|NCT05316857|DRUG|Orelabrutinib + Itraconazole|Orelabrutinib + Itraconazole
214334511|NCT03086798|PROCEDURE|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
214334512|NCT03086798|PROCEDURE|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
214334513|NCT01025700|DRUG|Cesemat|1 mg capsule per day for 21 days
214334514|NCT03030612|DRUG|ARGX-110|ARGX-110 will be administered intravenously.
214334515|NCT03030612|DRUG|AZA|AZA will be administered subcutaneously/intravenously.
214334516|NCT02041455|DRUG|Melatonin and Placebo|
214334517|NCT02041455|DRUG|Amitriptyline and Placebo|
214334518|NCT02041455|DRUG|Melatonin and Amitriptylin|
214935514|NCT06275074|OTHER|Therapeutic Exercise|Therapeutic exercise program provided to all participants with the aim of addressing periscapular strength and postural edurance.
214935515|NCT05553223|BEHAVIORAL|Microdoses of activity|Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
214935516|NCT06003023|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to participants in both arms.
214935517|NCT06003023|BEHAVIORAL|Tailored Exercise Prescription|Participants in both arms will receive the results of their exercise stress test, which includes information on the duration, frequency, and intensity of their physical activity.
214935518|NCT06003023|BEHAVIORAL|Healthy Lifestyle Education|Participants in both arms will receive information on healthy living, including topics such as physical activity, sleep, stress management, and diet.
214935519|NCT06003023|BEHAVIORAL|Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior|Participants randomized to the CHD-PAL arm will receive coaching to: 1) change attitudes towards physical activity; 2) increase perceptions of other people's approval of physical activity; 3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance and will be accompanied by goal-setting.
214935520|NCT04483284|DRUG|TACE combined with Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
214935521|NCT04483284|PROCEDURE|TACE plus Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
214334519|NCT01544244|PROCEDURE|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
214935522|NCT06372899|OTHER|E-cigarettes|Participants randomized to ECIGS are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. They will be provided with an e-cigarette device and nicotine pods.
214935523|NCT06372899|OTHER|Oral nicotine pouches|Participants randomized to ONPS are instructed to switch from smoking combustible cigarettes to using nicotine pouches for 6 weeks. They will be provided with nicotine pouches.
214935524|NCT01190059|DRUG|Ex vivo lung perfusion with Steen Solution™|The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
214935525|NCT05573672|COMBINATION_PRODUCT|Dietary Counselling combined with Omega-3 Supplementation|"Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner.~Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal."
214935526|NCT03570372|BEHAVIORAL|Internet-based treatment for adults with autism spectrum|Internet-based CBT. The intervention includes 18 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies and stress management
214935527|NCT03570372|BEHAVIORAL|Psychoeducation about autism spectum disorder|"Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö \& Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half."
214935528|NCT05957445|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, and subsequently a 600-pulse cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
214674096|NCT03554499|PROCEDURE|Bichectomy with hydrodissection|Intraoral removal of buccal fat pads using hydrodissection technique
214674097|NCT03554499|PROCEDURE|Bichectomy|Intraoral removal of buccal fat pads using conventional technique
214674098|NCT02372292|DRUG|intravenous furosemide|Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
214674099|NCT02091622|OTHER|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
214674100|NCT06177834|DEVICE|Alisklamp|Alisklamp
214674101|NCT06177834|OTHER|Dorsal slit circumcision technique|In this group, included the patients who will operated with dorsal slit circumcision technique
214334520|NCT01544244|PROCEDURE|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
214334521|NCT00151645|DRUG|activated lymphocytes|
214334522|NCT03374124|DIAGNOSTIC_TEST|sinonasal outcome test-22|Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
214334523|NCT05337501|OTHER|Collecting data|Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
214334524|NCT06205290|BIOLOGICAL|Liso-cel|Specified dose on specified days
214674102|NCT00293072|DRUG|Rituximab|
214674103|NCT05087602|DRUG|Toripalimab and Anlotinib|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
214674104|NCT04561843|DIAGNOSTIC_TEST|pelvic floor ultrasound|2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons
214334525|NCT06205290|DRUG|Idelalisib|Specified dose on specified days
214334526|NCT06205290|DRUG|Rituximab|Specified dose on specified days
214334527|NCT06205290|DRUG|Bendamustine|Specified dose on specified days
214334528|NCT06205290|DRUG|Fludarabine|Specified dose on specified days
214334529|NCT06205290|DRUG|Cyclophosphamide|Specified dose on specified days
214334530|NCT01798446|DRUG|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
214334531|NCT01193556|DEVICE|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
214334532|NCT01193556|DEVICE|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
214935529|NCT05957445|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences，including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, and subsequently a 600-pulse sham cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
214935530|NCT05515887|DRUG|Shenqu Xiaoshi Oral liquid|The dosage was determined by age: 3-4 years old, 5 ml/dose; 5-14 years old 10 ml/dose. Taken half an hour after meals, three times a day.
214935531|NCT04128501|DRUG|Azacitidine|Given SC
214935532|NCT04128501|DRUG|Venetoclax|Given PO
214935533|NCT05613868|DRUG|TPN-101|100 mg/ day up to 400mg/day of TPN-101
214935534|NCT04542499|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
214935535|NCT04542499|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
214674105|NCT05480137|PROCEDURE|NSE scoring balloon and plain balloon angioplasty|Using NSE scoring balloon or plain balloon in BPA surgery.
214674106|NCT03518229|DEVICE|Microsoft Band 2 + UV messaging|wearable device (wrist) and associated mobile application; UV sensor and messaging activated
214674107|NCT03518229|DEVICE|Microsoft Band 2|wearable device (wrist) and associated mobile application; UV messaging not activated
214674108|NCT03095534|BEHAVIORAL|3-Step Workout for Life|a 10-week moderate exercise program
214674109|NCT00004106|DRUG|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
214674110|NCT02009137|DEVICE|EVERA|EVERA apply for 12 weeks
214674111|NCT02009137|DEVICE|ESTES|ESTES apply for 12 weeks
214674112|NCT01247818|DRUG|PH-10 (0.002% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
214674113|NCT01247818|DRUG|PH-10 (0.005% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
214674114|NCT01247818|DRUG|PH-10 (0.01% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
214334533|NCT04509531|BEHAVIORAL|Wise Intervention (SA, ITP and resilience)|The intervention will be based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. This will include activities such as reading scientific information about social behavior and its role in people's well-being and mental health, the meaning of online victimization experiences and ways to react to them, experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change. Furthermore, it provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
214674115|NCT01247818|DRUG|Vehicle|PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
214674116|NCT01383200|DRUG|Tetracaine drop|0.5% Tetracaine Right eye / 2% Lidocaine Left eye
214674117|NCT01383200|DRUG|Lidocaine gel|0.5% Tetracaine Left eye / 2% Lidocaine Right eye
214674118|NCT00128206|DRUG|Isoniazid|Isoniazid 900 mg twice weekly
214334534|NCT04509531|BEHAVIORAL|Standard preventive intervention|The control intervention will involve scientific information and education about internet risks such as sexting and grooming.
214674119|NCT00128206|DRUG|Rifampin|Rifampin 600mg once per day
214674120|NCT00250471|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
214674121|NCT03958682|DEVICE|AR smart wearing equipment combined with 4G + satellite information transmission system|"We are going to add a pair of wearable smart glasses with AR function to the original flight helmet .During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.~It can not only transmit the patient's information in the cabin to the ground medical institutions in real time, but also transmit the rescue plan of the ground medical experts to the rescue helicopter in real time to ensure the safety of patients in transit ,which will save the time for medical staff to hand over after landing and reduce errors."
214334535|NCT05855629|DIETARY_SUPPLEMENT|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|Lactobacillus Rhamnosus 1,5 х 10\*9, Inulin 25mg, D-chiro-inositol 250mg
214334536|NCT05855629|DRUG|Topical Adapalene, Benzoyl Peroxide Gel|Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
214334537|NCT06408285|DRUG|TQC3927 powder for inhalation|TQC3927 is a targeted inhibitor.
214935536|NCT01320345|DRUG|Fenofibrate|145 mg tablet of fenofibrate administered once daily for 36 months.
214334538|NCT06408285|DRUG|TQC3927 powder for inhalation placebo|TQC3927 powder for inhalation placebo contains no active substance.
214334539|NCT01067079|OTHER|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
214334540|NCT02264834|DRUG|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
214334541|NCT02264834|DRUG|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
214334542|NCT02264834|PROCEDURE|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
214334543|NCT02617589|DRUG|Nivolumab|
214334544|NCT02617589|DRUG|Temozolomide|
214334545|NCT02617589|RADIATION|Radiotherapy|
214334547|NCT02711657|OTHER|Fibrocyte measurement and lung function test.|
214334548|NCT01149304|DRUG|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
215073204|NCT04917952|DEVICE|Blood Flow Restriction (BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, 80% at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the intervention group will receive an exercise protocol with blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Blood flow restriction will be applied at 80% by using pressure cuffs. The cuffs will be applied to the proximal thigh. Cuff pressure needed for a 100% vascular occlusion will be determined for each individual at a seated and relaxed position."
214334549|NCT01149304|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
214334550|NCT01149304|DRUG|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
214334551|NCT05754086|BEHAVIORAL|Clear Speech|"This behavioral modification asks participants to speak more clearly, as if they were speaking to someone with a hearing loss."
214334552|NCT05754086|BEHAVIORAL|Less Clear Speech|"This behavioral modification asks participants to speak less clearly, as if they were in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear."
214334553|NCT03089190|DIETARY_SUPPLEMENT|DC7-2|Effects on appetite
214334554|NCT03089190|DIETARY_SUPPLEMENT|DC7-2 + potato protein isolate|Effects on appetite
214334555|NCT03089190|DIETARY_SUPPLEMENT|Potato protein isolate|Effects on appetite
214334556|NCT03089190|DIETARY_SUPPLEMENT|Placebo|Inactive whey protein, not expected to affect appetite.
214334557|NCT02523833|DRUG|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
214334558|NCT06216951|PROCEDURE|Vital Pulpotomy|Vital pulpotomy involves the removal of the coronal pulp, while MTA is used to seal the root orifices. It is clear that vital pulp treatments for symptomatic pulpitis are a more reliable, cost-effective, and generally easier option than root canal treatment (RCT) once the mineral trioxide aggregate (MTA) is introduced in dentistry. In vital pulpotomy, as opposed to RCT, tooth healing and symptoms are diminished while the vitality of the tooth is maintained. Furthermore, vital pulpotomy is a significantly more practical and economical treatment alternative than RCT.
214334559|NCT04819360|DRUG|VESIcare 10Mg Tablet|"Vesicare® 10 mg per day for 12 weeks~Vesicare 10mg 12 weeks"
214334560|NCT04819360|DRUG|Botox 100 UNT Injection|1 injection of Botox® 100 UNT
214334561|NCT03544983|BEHAVIORAL|Web + Streamlined Telephone Genetic Information|Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
214334562|NCT06078735|DEVICE|Vascular closure with LockeT device|For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.
214347265|NCT00326378|DRUG|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
214347266|NCT05159752|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
214674122|NCT00896519|BIOLOGICAL|rituximab|
214674123|NCT00896519|BIOLOGICAL|sargramostim|
214935537|NCT01320345|DRUG|Inert lactose placebo|Insert lactose tablet matching active tablet administered once daily for 36 months.
214935538|NCT05957354|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive a combination of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
214935539|NCT05957354|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive a combination of stimulation sequences, including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
214674124|NCT00896519|DRUG|cyclophosphamide|
214935540|NCT05711381|DRUG|HM15912|Singe subcutaneous administration of HM15912 0.5 mg/kg
214935541|NCT05868226|DRUG|ALX148|CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
214334563|NCT06028061|PROCEDURE|Adjuvant-free Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
214935542|NCT05868226|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
214935543|NCT05868226|DRUG|Zanidatamab|Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
214935544|NCT05868226|DRUG|Tucatinib|Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
214935545|NCT05651022|DRUG|Decoy20|Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
214935546|NCT05651022|DRUG|Tislelizumab|Tislelizumab is a PD-1 inhibitor.
214935547|NCT04335487|BEHAVIORAL|PSP PTSD Course|A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
214935548|NCT04335487|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
214935549|NCT03337360|DIETARY_SUPPLEMENT|Impryl|Food supplement with betaine, cystine, zinc, niacin, folic acid (5MTHF-glucosamine), Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (riboflavin)
214674125|NCT00896519|DRUG|doxorubicin hydrochloride|
214674126|NCT00896519|DRUG|prednisone|
214334564|NCT06028061|PROCEDURE|Quadratus lumborum block III with Adjuvant|The same block was applied to this group too, but a different local anesthetic mixture was used.Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
214674127|NCT00896519|DRUG|vincristine sulfate|
214674128|NCT00896519|GENETIC|gene expression analysis|
214674129|NCT00896519|GENETIC|gene rearrangement analysis|
214674130|NCT00896519|GENETIC|polymerase chain reaction|
214674131|NCT00896519|OTHER|R-CHOP regimen|
214674132|NCT00896519|OTHER|laboratory biomarker analysis|
214674133|NCT00397956|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
214674134|NCT05429515|PROCEDURE|HFR-SUPRA|HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.
214674135|NCT05429515|PROCEDURE|hemodialysis|hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.
214674136|NCT05429515|DRUG|Chemotherapy|chemotherapy protocol will be made by hematologists.
214674137|NCT02688855|DEVICE|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
214674138|NCT02688855|DEVICE|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|Sham CMF OL1000
214674139|NCT06408090|OTHER|IDECIDE-HOSPICE|12-pg educational booklet detailing information about hospice including what hospice is, why someone would use hospice, who pays for hospice, and where hospice services are delivered
214935550|NCT03337360|OTHER|Placebo|Inactive ingredients, placebo
214935551|NCT02228304|DRUG|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
214935552|NCT02228304|DRUG|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
214935553|NCT05519332|PROCEDURE|percutaneous vertebral-disc plasty|percutaneous vertebroplasty combined percutaneous cement discoplasty
214935554|NCT05935891|DRUG|CBD-dominant|product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
214674140|NCT04286308|OTHER|electrophysiological data collection|Electrophysiological data collection at the time of DBS surgery.
214935555|NCT05935891|DRUG|THC dominant|contains 375mg THC and less than 20mg CBD per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
214334566|NCT03815422|PROCEDURE|Regional anesthesia|Short lasting sciatic nerve block and long lasting plantar block with distal deep peroneal block
214334567|NCT02678039|DEVICE|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
214334568|NCT02678039|PROCEDURE|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
214334569|NCT04719910|OTHER|Visual exposure to taped food preparation|Patients in the study group can watch the preparation of the the type of food she prefers to eat normally.
214935556|NCT04797949|DRUG|Low-dose aspirin|Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
214935557|NCT05470283|DRUG|OBX-115|Given by IV
214935558|NCT05470283|DRUG|Acetazolamide|Given by PO
215077992|NCT00246051|OTHER|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~1. Positive on the Berlin Questionnaire~2. Clinic visit, exam with a physician, given a home diagnostic device (HDD)~3. High risk on HDD, seen by physician, given a CPAP machine~4. Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~5. Contacted by a sleep health clinic at 3, 6, 12 months~6. After 12 months subject will be referred to their primary care physician"
214674141|NCT01654575|DRUG|Methotrexate|Methotrexate 25mg/week for 16 weeks
214334570|NCT04719910|OTHER|Visual exposure to topics not related to food|Patients in the placebo group can choose a video that is relaxing but not related to food.
214334571|NCT01121211|DRUG|Testosterone|Testosterone 300mcg transdermal patch x 24 weeks.
214674142|NCT01654575|DRUG|Placebo|Placebo tablets once a week for 16 weeks
214674143|NCT06211283|DRUG|Sodium valproate|fasted
214935559|NCT05470283|DRUG|Cyclophosphamide|Given by IV
214935560|NCT05470283|DRUG|Furosemide|Given by IV
214935561|NCT05470283|DRUG|Mesna|Given by IV
214935562|NCT05470283|DRUG|Fludarabine Phosphate|Given by IV
214935563|NCT00800813|BEHAVIORAL|Penile Exam, Peyronie's Plaque and Erectile function assessment|"At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level."
214935564|NCT04161079|DEVICE|Medtentia Annuloplasty Ring (MAR)|Mitral valve repair using the MAR performed in clinical investigation 2010-040
214935565|NCT00079300|DRUG|imiquimod|
214935566|NCT00079300|PROCEDURE|conventional surgery|
214935567|NCT06158568|OTHER|Percutaneous Electrical Nerve Stimulation|Application of a electrical current percutaneously (at the motor response intensity) targeting the suprascapular and axillar nerves
214935568|NCT06158568|OTHER|Placebo Percutaneous Electrical Nerve Stimulation|Application of sham electrical current (no intensity) percutaneously targeting the suprascapular and axillar nerves
214935569|NCT06158568|OTHER|Exercise|Application of three weeks of progressive exercises targeting the shoulder musculature
214935570|NCT00072540|DRUG|celecoxib|
214935571|NCT00072540|PROCEDURE|anti-cytokine therapy|
215073205|NCT04917952|DEVICE|Sham Blood Flow Restriction (sham BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, Sham BFR, 10mm Hg at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the control group will receive an exercise protocol with sham blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Sham technique for blood flow restriction will be applied by using pressure cuffs inflated at 10mm Hg. The cuffs will be applied to the proximal thigh. Cuff pressure will be applied for each individual at a seated and relaxed position."
215073206|NCT01979666|DRUG|nitrate patch|patients in the study group will get a nitrate patch
215073207|NCT01979666|DRUG|placebo patch|control group patients will get a placebo patch
214334572|NCT01121211|DRUG|Placebo|Placebo transdermal patch x 24 weeks
214334573|NCT03697954|DEVICE|full stage implantation of sacral neuromodulation|full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence
214334574|NCT06105307|BEHAVIORAL|RN-SLEEP|RN-SLEEP is a training program delivered via mobile application and designed to help improve the sleep of nurses who engage in shift work. RN-SLEEP aims to include training on strategies for sleeping while working shift work, basics of sleep science and physiology, behavior change components (i.e., goal setting), and components of cognitive behavioral therapy for insomnia (i.e., relaxation).
214334575|NCT06105307|BEHAVIORAL|Healthy Habit - Educational Control|Healthy habit app (i.e., exercise tracking) to act as a control arm for the RN-SLEEP intervention
214334576|NCT00098215|BEHAVIORAL|Pediatric residency training on tobacco|
214334577|NCT00835406|DRUG|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
214334578|NCT00835406|DRUG|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
214334579|NCT01494233|DRUG|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
214334580|NCT01494233|DRUG|Placebo tablet|Matching placebo tablet administered orally
214334581|NCT00733343|DEVICE|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
214334582|NCT05210036|DEVICE|Ultrasound Therapy (US)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
214334583|NCT05210036|DEVICE|High-Intensity Laser Therapy (HILT)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
214334584|NCT03428776|BEHAVIORAL|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
214334585|NCT03428776|BEHAVIORAL|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
214334586|NCT03428776|OTHER|Record keeping|Electronic immunization records on cloud-based software platform and use of biometric identification
214334587|NCT04865796|OTHER|Lactoferrin products|Patiens will use a toothpaste and 2 tablets per day (between foods) for home oral care.
215073208|NCT01979666|DEVICE|MRI scan|MRI scan after 6 weeks of treatment
215073209|NCT03008668|OTHER|acupuncture|a stimulation of the body or auricular points
214334588|NCT04865796|OTHER|Probiotics products|Patiens will use a toothpaste and a chewing-gum (for 10 minutes a day) for home oral care.
214334589|NCT04865796|OTHER|Standard home oral care|Patiens will use a normal toothpaste for home oral care.
214674144|NCT06211283|DRUG|Sodium valproate|fed
215073210|NCT02779088|OTHER|exercise and nutrition|Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
214334590|NCT02138214|PROCEDURE|Thyroidectomy|Undergo total thyroidectomy
214334591|NCT02138214|PROCEDURE|entral lymph node dissection (CLND)|Undergo total thyroidectomy with ipsilateral prophylactic CND
214334592|NCT02138214|OTHER|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
214674145|NCT03957083|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
214674146|NCT01223911|DRUG|NNC 0151-0000-0000|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
214935572|NCT00072540|PROCEDURE|antiangiogenesis therapy|
214935573|NCT00072540|PROCEDURE|biological therapy|
214935574|NCT00072540|PROCEDURE|cancer prevention intervention|
214935575|NCT00072540|PROCEDURE|chemoprevention of cancer|
214935576|NCT00072540|PROCEDURE|enzyme inhibitor therapy|
214935577|NCT00072540|PROCEDURE|growth factor antagonist therapy|
214334593|NCT02550613|DEVICE|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
214935578|NCT06431685|RADIATION|Whole Brain Low Dose Radiotherapy|Whole brain LDRT will be administered at 3 cohorts with increasing dose fractions: Group 1: 4 Gy/2f of one cycle; Group 2: 4 Gy/2f of two cycles (Q3w); Group 3: 4 Gy/2f of three cycles (Q3w). WB-LDRT will be administered in a 4 Gy of 2 fractions over two days, starting from Day 1 in the first cycle (a daily dose of 2 Gy, 4 Gy/2f for one cycle, once per three weeks, at minmum in one cycle and maximum in four cycles in total).
214935579|NCT06431685|DRUG|Pemetrexed|Pemetrexed, 30 mg, intrathecal injection, once per three weeks, 4 cycles in total
214935580|NCT06431685|DRUG|Sintilimab|PD-1 inhibitor (Sintilimab, dose as recommended in the instruction manual), intravenous infusion, once per three weeks, 4 cycles in total
214935581|NCT06431685|DRUG|Chemotherapy|Pemetrexed at a dose of 500 mg/m\^2, intravenous infusion, once per three weeks, 4 cycles in total
215073211|NCT04104191|DEVICE|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
214674147|NCT01223911|DRUG|placebo|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
214674148|NCT02533960|OTHER|not applicable (observational study)|Observational study without study related intervention.
215073212|NCT02121106|BEHAVIORAL|Cognitive Remediation|
215073213|NCT02121106|BEHAVIORAL|Sham Cognitive Remediation|
215073214|NCT02350413|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
215073215|NCT00092703|DRUG|MK0663, etoricoxib|
214334594|NCT05443984|DRUG|JP-1366 20mg|1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
214334595|NCT05443984|DRUG|Esomeprazole 40mg|1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
214334596|NCT05731284|PROCEDURE|Platelet rich plasma (PRP) Injection|Randomly picked (like the flip of a coin) by a computer to receive either platelet-rich plasma (PRP) or normal saline. This is a double-blind study. During vaginal prolapse surgery, the surgeon will inject PRP into the vaginal tissue at the surgical site.
215073216|NCT00092703|DRUG|Comparator: Diclofenac sodium|
214334597|NCT05731284|PROCEDURE|Placebo|Normal saline Injection
214334598|NCT00793442|DIAGNOSTIC_TEST|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
214334599|NCT06440772|DRUG|Ringer's Lactate Crystalloid Solutions|7 ml/kg ml of Ringer's Lactate is given in 10 min amongst initially tolerant fluid responders.
214334600|NCT00881075|DRUG|SeeMore(TM)|single dose intravenous injectable
214334601|NCT03517267|DIAGNOSTIC_TEST|ultrasound and FNA|The nodule to undergo FNA will be chosen according to TIRADS ACR criteria and the ATA risk criteria ( if there is a disagreement between the methods whether to perform FNA the FNA will be performed ) If both methods do not recommend FNA , but the referring doctor has requested the procedure or the patient is unable to stay on follow up , the FNA will be performed .
214334602|NCT01362907|DEVICE|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
214334603|NCT01362907|DEVICE|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
214674149|NCT02501356|DIETARY_SUPPLEMENT|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
214935582|NCT04401761|DRUG|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
214935583|NCT04401761|DRUG|Acetylsalicylic acid|75 - 100 mg once daily at the discretion of the investigator
214935584|NCT02535234|DEVICE|Novel System|A Novel full Continuous Positive Airway Pressure (CPAP) system - Prototype Device, Mask + Accessories
214935585|NCT02535234|DEVICE|Traditional System|A Traditional full Continuous Positive Airway Pressure (CPAP) system- Released Device + Accessories, Prototype Mask
214935586|NCT00842075|DRUG|pramlintide|subcutaneous injection (15 mcg initial dose)prior to meals
214935587|NCT05008809|DRUG|mFOLFOX6|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
214935588|NCT05008809|DRUG|mFOLFOXIRI|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
214935589|NCT05008809|DRUG|FOLFIRI|Folinic acid: 400mg/m², 1-2h IV Infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Irinotecan: 180 mg/m², 90-120 min IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles is administered.
214935590|NCT05008809|DRUG|CAPOX|Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.
214935591|NCT02954185|OTHER|WellClub|
215073217|NCT04463693|DRUG|Etonogestrel implant|Insertion of the contraceptive implant at an alternative insertion site located over the scapula
214334604|NCT06966323|BEHAVIORAL|Hold me Tight / Let me Go|"Hold Me Tight / Let Me Go (HmT/LmG) is a manualized, group-based behavioral intervention for parents of adolescents aged 12 to 18. Grounded in Emotionally Focused Therapy (EFT) and Hold me Tight for couples. HmT/LmG aims to improve the parent-adolescent relationship by enhancing emotional validation, secure attachment, and effective communication.~The intervention consists of four group sessions for parents, supplemented by three structured individual or dyadic sessions involving both parents and adolescents. Key components include psycho-education, role plays, emotion-focused conversations, and exercises targeting validation, apologizing, and supportive limit setting. Families complete pre- and post-intervention questionnaires and a follow-up assessment to evaluate changes in relationship quality and psychological well-being."
214334605|NCT02158039|DRUG|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
214334606|NCT02158039|DRUG|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
214334607|NCT01196871|DRUG|Migalastat HCl|Oral capsules, single dose
214334608|NCT01196871|BIOLOGICAL|Agalsidase Beta|IV infusion, single dose
214334609|NCT01196871|BIOLOGICAL|Agalsidase Alfa|IV infusion, single dose
214334610|NCT01744730|DRUG|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
214334611|NCT00844441|OTHER|medical chart review|
214334612|NCT00844441|OTHER|questionnaire administration|
214334613|NCT00844441|PROCEDURE|quality-of-life assessment|
214334614|NCT02669186|DRUG|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
214935592|NCT02954185|BEHAVIORAL|Standard Therapy|
214935593|NCT04062071|OTHER|no intervention|no intervention
215073218|NCT02565264|OTHER|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
215073219|NCT02667041|DEVICE|NeuroQore rTMS Device|
214334615|NCT02669186|DRUG|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
214334616|NCT02747316|OTHER|Stable iron isotope 57 (57Fe) labeled iron solution|test meal labeled with 12 mg 57Fe
214334617|NCT02747316|OTHER|Stable iron isotope 58 (58Fe) labeled iron solution|test meal labeled with 12 mg 58Fe
214334618|NCT03509948|DRUG|cytisine|cytisine 1.5 mg film-coated tablets
214334619|NCT03437200|DRUG|Nivolumab|Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
214334620|NCT03437200|DRUG|Ipilimumab|Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
214935594|NCT04927871|BEHAVIORAL|Total Diet Replacement (TDR)|The nutritionist will provide a total diet replacement (TDR) with Low-Energy Liquid-Diet (LELD - 811 kcal/day, 64 g protein, 132 g carbohydrate, 6 g fat) and the food reintroduction for two months.
214935595|NCT04927871|BEHAVIORAL|Medical Nutritional Therapy (MNT)|The nutritionist will provide Medical Nutritional Therapy (MNT) using the transcultural Diabetes Nutritional Algorithm (tDNA) Toolkit adapted for Venezuela for four months.
214935596|NCT04927871|BEHAVIORAL|Diabetes Prevention Program 4 months|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 4-months.
215073220|NCT06553300|PROCEDURE|Autotransplantation with PRF|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth with the application of PRF
214674150|NCT02501356|DIETARY_SUPPLEMENT|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
214935597|NCT04927871|BEHAVIORAL|Diabetes Prevention Program|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 6-months.
214935598|NCT02817698|DRUG|cannabis|All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
214935599|NCT00361166|DRUG|ACP-103|
214935600|NCT03427268|DRUG|PM060184|"PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point.~PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle)."
215073221|NCT06553300|PROCEDURE|Autotransplatation Only|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth.
215073222|NCT04835220|OTHER|Telehealth Calls|The telehealth nurse will record data in a case report form within the VA REDCap electronic data capture system that is stored within the VA firewall.
214935601|NCT03702491|DRUG|Apatinib|Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
214935602|NCT03702491|DRUG|Tegafur|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
215073223|NCT01694121|BEHAVIORAL|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
215073224|NCT01694121|BEHAVIORAL|Comparison|general health intervention for men, not inclusive of HIV or relationship health
214334621|NCT03437200|OTHER|Chemoradiation|All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
214334622|NCT02072967|OTHER|Ribomustin|Routine practice
214334623|NCT02072967|OTHER|rituximab|Routine practice
214334624|NCT01334866|PROCEDURE|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
215073225|NCT00759265|OTHER|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
215073226|NCT00980512|BEHAVIORAL|Parent Training|16 weeks of parent training led by trained group facilitator
215073227|NCT03878381|COMBINATION_PRODUCT|Skin Care Cream|The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
215073228|NCT03878381|DRUG|Placebo|The placebo will be a formula with no active ingredients
214674151|NCT03946306|DRUG|5,25% NaOCl with syringe needle irrigation alone|In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
214674152|NCT03946306|DEVICE|EDDY|In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
214674153|NCT00683553|DRUG|I5NP|Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
214334625|NCT00113256|DRUG|Rubitecan|
214334626|NCT03994770|DIAGNOSTIC_TEST|Balanced Reach Assessment and Training Protocol|Three one-hour training sessions for one week in the Balanced Reach Training Protocol
214334627|NCT00113737|DRUG|fluoxetine|
214334628|NCT00113737|BEHAVIORAL|cognitive behavioral therapy|
214674154|NCT00683553|DRUG|Placebo|Single IV injection of saline
214674155|NCT02340104|DRUG|Baricitinib|4 milligrams (mg) administered orally
214674156|NCT02340104|DRUG|[^13C4D3^15N]-baricitinib|4 micrograms (μg) administered intravenously (IV)
214334629|NCT00495716|DRUG|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
214334630|NCT00495716|DRUG|acyclovir|400 mg acyclovir orally twice daily for 1 year
214334631|NCT05859295|DEVICE|Red Low-Level Light Therapy|Visible red light (633nm) projected onto the face using an light emitting diode (LED) mask
214935603|NCT00998348|BEHAVIORAL|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
214935604|NCT03541434|DIAGNOSTIC_TEST|Complete Blood Count|White blood cell subgroups count
214935605|NCT03541434|DIAGNOSTIC_TEST|Tympanometry|Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance
214334632|NCT02865031|DRUG|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
214334633|NCT04519658|DRUG|CIN-107|CIN-107 tablets by mouth once daily
214334634|NCT04519658|DRUG|Placebo|placebo tablets by mouth once daily
214334635|NCT04185168|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone (as 2 tablets)
214334636|NCT04185168|OTHER|control|2 tablets of placebo
214935606|NCT03541434|PROCEDURE|Tonsillectomy and/or adenoidectomy|Excision of palatine and/or pharyngeal tonsils.
215073229|NCT05958394|BEHAVIORAL|SkillFlix for Parents|A Microskills video training library on communication skills for talking to youth about relationships and sexual health topics.
214334637|NCT02989207|PROCEDURE|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
214334638|NCT02989207|DEVICE|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
214334639|NCT02989207|DRUG|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
214334640|NCT02210429|PROCEDURE|Elbow Fracture Fixation|
214334641|NCT02751177|GENETIC|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|Mutation in plasma DNA vs tumor tissue
214334642|NCT01071512|DRUG|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
214334643|NCT01427296|DRUG|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
214334644|NCT01427296|DRUG|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
214935607|NCT03391232|BIOLOGICAL|PolyPEPI1018 CRC Vaccine|Colorectal Cancer Vaccine
214935608|NCT00507351|BEHAVIORAL|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
214935609|NCT00148655|DEVICE|Decision Board|Decision board that explains the risks and benefits of treatment options
214935610|NCT01995175|PROCEDURE|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
215073230|NCT02337998|OTHER|load carriage|
215073231|NCT01700998|DRUG|Magnesium|
215073232|NCT01700998|DRUG|Placebo|
215073233|NCT02047773|OTHER|Duration|If bacterial load checked on day 7 is less than 10\^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10\^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
215073234|NCT02047773|DRUG|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
215073235|NCT02047773|DRUG|Meropenem|
215073236|NCT02680041|DRUG|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
215073237|NCT00521599|DRUG|Mometasone furoate dry powder inhaler|
215073238|NCT00521599|DRUG|Placebo|
215073239|NCT01237457|DRUG|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
215073240|NCT05227560|OTHER|Complementary Therapies|The emotional freedom technique was applied to the experimental group.
215073241|NCT01747408|DRUG|Human Albumin|"25% human albumin given in four escalating doses:~1. Group 1: .625g/kg infused over 3hrs daily X 7day~2. Group 2: 1.25g/kg infused over 3hrs daily X 7day~3. Group 3: 1.875g/kg infused over 3hrs daily X 7day~4. Group 4: 2.5g/kg infused over 3hrs daily X 7day"
215073242|NCT04611958|DRUG|ERCP with Bupivacaine infusion|"Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom."
214334645|NCT04596540|DRUG|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR"
214334646|NCT04596540|DRUG|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR"
214334647|NCT04596540|OTHER|Placebo|Normal saline
214935611|NCT01995175|PROCEDURE|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
214935612|NCT01995175|OTHER|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
214935613|NCT06042361|BEHAVIORAL|Smokefree Implementation Framework and Toolkit|"Framework and toolkit that includes Implementation Guide, Action Plan, and Implementation Checklist that supports the needs of Permanent Supportive Housing communities."
214935614|NCT03348475|BEHAVIORAL|Binge Focused Therapy (BFT) Intervention|The intervention, Binge Focused Therapy, is a 3-session, 8-week, non-expert guided self-help program. Participants will attend sessions at Week 1, Week 2, and Week 8 at the Nova Scotia Health Authority Eating Disorder Clinic. Each session will be approximately 2 hours in length.
214486377|NCT06795854|OTHER|Aerobic training|Sessions will be conducted 3 times per week. Each 40-minute session will include a 5-minute warm-up involving fast walking, slow running, and stretching, followed by an active phase of continuous running. The running period will start at 15 minutes and increase by 2 minutes every two sessions until reaching 30 minutes. The session will conclude with a 5-minute cool-down of slow running and stretching. Exercise intensity will be maintained at 13-15 on the Borg Rate of Perceived Exertion, with continuous walking performed on a treadmill.
214935615|NCT01380717|DRUG|Beta-blocker, ACE-inhibitor|Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
214935616|NCT01380717|DRUG|Calcium Channel Blockers, ACE-Inhibitor|Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
214935617|NCT03828110|DEVICE|Robotic Assisted Gait Training (Lokomat)|The RAGT treatment consisted of sessions lasting 45 minutes each performed with the commercially available Lokomat device. The same exercises were offered to the children with preset duration, speed, and difficulty. For all patients, the initial body-weight support was set at 50%, and was then gradually decreased according to the individual functional capacity. The guidance force was initially set to 100% for all children, and then gradually reduced.
214935618|NCT03828110|PROCEDURE|Physiotherapy|The physiotherapic sessions aimed at strengthening the gluteus and quadriceps muscles, stretching the hip flexor and hamstrings muscles, increasing static balance, increasing dynamic balance, increasing functional abilities, improving ground gait and climbing stairs.
214935619|NCT05245721|DRUG|Nalbuphine|Caudal nalbuphine injection in pediatrics undergoing infra-umbilical surgeries
214935620|NCT05245721|DRUG|Bupivacain|Caudal bupivacaine in pediatrics undergoing infra-umbilical surgeries
214935621|NCT03928808|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Nasogastric administration of OpenBiome 25 g/mL solution administered nasogastrically once weekly for 4 consecutive weeks
214935622|NCT05923775|PROCEDURE|Impacted third molar surgey|The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.
214935623|NCT06608875|BEHAVIORAL|Hyper-personalized feedback (HPF intervention)|For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
214935624|NCT06608875|BEHAVIORAL|Targeted auditory stimulation during sleep (TASS verum intervention)|The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
214935625|NCT06608875|BEHAVIORAL|Control targeted auditory stimulation during sleep (TASS sham intervention)|Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
214935626|NCT01628653|DEVICE|U-SMART|4-weeks' training
214334648|NCT03126799|DRUG|Erlotinib plus Bevacizumab|Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
214334649|NCT03126799|DRUG|Erlotinib|Erlotinib 150mg, po, daily, Q weeks
214334650|NCT05068973|DEVICE|NOVATECH® LUCIOLA™ EB - (Fiducial Marker)|Bronchoscopic implantation in the lung of the NOVATECH® LUCIOLA™ EB fiducial marker
214935627|NCT03352193|DIETARY_SUPPLEMENT|Wheat spaghetti|Wheat oral immunotherapy
214334651|NCT03228004|BEHAVIORAL|Glooko MeterSync|The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
214334652|NCT05961774|DEVICE|Transcranial magnetic stimulation|The stimulation point is the lumbar multifidus hotspot. The parameters will be set at frequency 10 Hz, 50 number of pulses, 40 train of stimulation (5 seconds stimulation and 25 seconds inter-stimulation interval). The position of coil will be placed tangentially at 45 degrees on the LM hotspot. The stimulation will be 20 minutes.
214935628|NCT05390151|PROCEDURE|Laser treatment of anal fistula|using a radial laserprobe to treat transsphincteric fistula
214935629|NCT05390151|PROCEDURE|RAF|current golden standard in transsphincteric fistula surgery
214334653|NCT05961774|DEVICE|Neuromuscular electrical stimulation|The neuromuscular electrical stimulation will be set as interferential current 6000 Hz, amplitude 20-50 Hz with scanning mode, duration 20 minutes, intensity to elicit the LM contraction.
214334654|NCT02794272|DEVICE|tDCS|
214334655|NCT02794272|DEVICE|sham-tDCS|
214334656|NCT05267171|OTHER|Web access|The intervention group will have access to the website where the information is provided. The control group will not have this access.
214334657|NCT01122966|DRUG|intraocular injections of bevacizumab|intracameral and subconjunctival injections
214334658|NCT04341974|DIAGNOSTIC_TEST|Serum creatinine|Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
214935630|NCT00268567|DRUG|leflunomide combined with prednisone|
214935631|NCT06621108|OTHER|Focus group session|Participants will take part in a focus group, which includes sharing their experience of the four-week feeling tone mindfulness course in an online group session. The focus group session will be led by trained moderator, and attended by several other course participants who completed the four-week feeling tone mindfulness course. The session will be audio-recorded as the research team will analyze the qualitative feedback offered by participants.
214935632|NCT01021761|DRUG|Ketorolac Tromethamine|ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
214334659|NCT02674022|DIETARY_SUPPLEMENT|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
214334660|NCT00499135|OTHER|Computed Tomography|Correlative studies
214334661|NCT00499135|OTHER|Fluorothymidine F-18|Correlative studies
214334662|NCT00499135|OTHER|Laboratory Biomarker Analysis|Correlative studies
214935633|NCT01021761|DRUG|Bromfenac|Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
214935634|NCT01021761|DRUG|nepafenac|drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
214935635|NCT03047720|DEVICE|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
215073243|NCT04761679|BEHAVIORAL|Applying the Mepilex foam|Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
215073244|NCT02695368|DEVICE|Novaerus NV800 on|The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.
215073245|NCT02695368|DEVICE|Novaerus NV800 off|The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.
215073246|NCT02695368|DEVICE|Novaerus NV800 on or off|Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
214334663|NCT00499135|OTHER|Pharmacological Study|Correlative studies
214334664|NCT00499135|OTHER|Positron Emission Tomography|Correlative studies
214334665|NCT00499135|DRUG|Sunitinib Malate|Given PO
214334666|NCT02076412|DRUG|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
214334667|NCT02076412|DRUG|Placebo|Placebo tablet PO bid (morning and evening)
214334668|NCT02665975|BEHAVIORAL|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
214334669|NCT02665975|BEHAVIORAL|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
215073247|NCT05059821|BIOLOGICAL|Peptide cancer vaccine|Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
215073248|NCT02949986|BEHAVIORAL|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
215073249|NCT04958044|DRUG|Calcium Gluconate|Calcium electroporation
214347267|NCT00363766|DRUG|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
214347268|NCT05016492|DEVICE|Visual-perceptual interactive game system|Subjects received 30-min interactive digital game training session per week. The game system contain 7 skills training, each of which was named according to the corresponding TVPS-3.
214347269|NCT05016492|BEHAVIORAL|standard rehabilitation|Subjects received the standard 4-week course of rehabilitation delivered in one 30-min session per week. The course of rehabilitation included: sensory integration therapy, cognitive function training and visual perception/auditory attention training.
214347270|NCT00221793|PROCEDURE|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
214347271|NCT02706457|OTHER|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
214334670|NCT00799149|DRUG|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
214935636|NCT03047720|DEVICE|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
214935637|NCT02353494|DRUG|Dihydroartemisinin-Piperaquine|Treatment according to national guidelines with follow up.
214935638|NCT06620497|PROCEDURE|stress free implant bar|SFI bar was sectioned and adjusted on the model for more convenience and to save the time of the appointment. The bar (Cendres Metaux, Switzerland) abutments were screwed to the implant analogues.
214935639|NCT06620497|PROCEDURE|milled bar|bar abutments were attached to the analogues and scan bodies were threaded into the bar abutments. The cast was scanned using a lab scanner (Ceramill, Amann Girrbach, Germany). The milled bar was selected from the software (Exocad DentalCAD) and designed digitally to connect the implants.
214935640|NCT03289598|BEHAVIORAL|A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals|"The intervention consists of two parts:~1. Education of the health care staff with three day's education focusing of aspects of food, meals and nutrition to old people.~2. The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication."
214935641|NCT04736927|DRUG|GLPG3667|From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.
214935642|NCT04736927|DRUG|Midazolam|On Day 1 and Day 7 as liquid formulation, orally in fed state.
214935643|NCT03544931|PROCEDURE|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
214935644|NCT03544931|DEVICE|EMD Application|Application of Enamel Matrix Derivatives on the root surface after debridement in sites with probing depth deeper than 5 mm
214935645|NCT00536224|BEHAVIORAL|Full counseling|"The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling."
214935646|NCT00536224|BEHAVIORAL|Minimal counseling|"Patients assigned to the minimal counseling intervention received brief counseling (\<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.~Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal."
214935647|NCT06213896|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
214674157|NCT03337841|DRUG|Pembrolizumab|Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
214334671|NCT01760148|DRUG|interferon alpha 2b|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
214334672|NCT00799617|DRUG|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
214334673|NCT00799617|DRUG|Placebo|Testosterone levels will be measured at regular intervals.
214334674|NCT04495088|DRUG|mFOLFOX (neoadjuvant)|neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
214334675|NCT04495088|DRUG|XELOX (neoadjuvant)|neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
214674158|NCT00449059|DRUG|acute infusion of nitroglycerine into the pulmonary artery|
214674159|NCT01067638|DRUG|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
214674160|NCT01915875|OTHER|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
214334676|NCT04495088|DRUG|mFOLFOX (adjuvant)|adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
214935648|NCT06213896|PROCEDURE|Color Fundus Photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
214935649|NCT06213896|DEVICE|EyeCheckup v2.0|Screening for existence of eye diseases
214935650|NCT03555864|DEVICE|infrared transluminescent device|use of infra red for venous access for second intravenous access
214935651|NCT00022243|DRUG|batabulin sodium|
214935652|NCT04690790|PROCEDURE|Thoracoscopy|Patients who are indicated for thoracoscopic nodulectomy.
214935653|NCT06622382|PROCEDURE|Bariatric endoscopic antral myotomy|A mucosal incision is performed using a triangle-tip knife J at the level of the incisura along the level of the greater curvature. Submucosal tunneling is then performed and stopped immediately proximal to the pylorus. Two parallel lines of partial thickness myotomy are then performed from the distal to proximal antrum using the same endoscopic knife. The myotomy is stopped approximately 2 cm distal to the mucosal incision site. Finally, the mucosal incision is closed using endoclips after haemostasis is confirmed.
214935654|NCT02012933|DRUG|3,4-diaminopyridine|10mg tablets for up to 100mg per day
214935655|NCT05803070|DRUG|Topical Cetirizine 1 %|topical cetirizine belongs to anti histamines group
214935656|NCT05803070|DRUG|Topical betamethasone valerate 0.1%|topical betamethasone valerate belongs to corticosteroids group
214935657|NCT05288894|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|A routine cardiac magnetic resonance imaging with biventricular function evaluation, atrial volumes, LGE acquisitions, and pulmonary and aortic assesment.
214674161|NCT04510922|DRUG|Droxidopa 100 MG [Northera]|droxidopa taken three times a day titrated up to a maximum of 600 mg.
214334677|NCT04495088|DRUG|XELOX (adjuvant)|adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
214334678|NCT04495088|DRUG|Capecitabine (adjuvant)|adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
214347272|NCT02206802|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
214935658|NCT05387460|DIAGNOSTIC_TEST|radiomics|Radiomics refers to high-throughput mining of quantitative image features from medical imaging. Radiomics derived data, when combined with other pertinent clinicopathological features, can produce accurate and robust evidence-based decision-making systems. Multimodal radiomics can provide more imaging feature information than single modal radiomics, which showed better diagnostic performance in previous study of kinds of cancer diseases.
214334679|NCT04495088|DRUG|"infusional 5-FU/FA AIO regimen (adjuvant)"|adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
214334680|NCT04495088|DRUG|"infusional 5-FU/FA de Gramont (adjuvant)"|adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
214334681|NCT04545515|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
214935659|NCT04789291|DRUG|BI 1595043|Single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet).
214935660|NCT06523023|BEHAVIORAL|An integrated online program|Our integrated online program combines validated psychoeducational materials on dissociation with components of strucutred writing therapy.
214935661|NCT02101372|BEHAVIORAL|treatment as usual|case management
214935662|NCT02101372|BEHAVIORAL|Psychoeducation group treatment|Psychoeducation therapy problem solving focus
214935663|NCT05015140|OTHER|musıc therapy|calm music with nature sounds set by the music therapist
214935664|NCT01013844|BEHAVIORAL|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter \> or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
214935665|NCT02673801|OTHER|Orthopedic assessment in the outpatient clinic|Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
214674162|NCT00688493|DRUG|Dapagliflozin|3 x 50 mg tablets, single oral dose
214674163|NCT00688493|DRUG|Dapagliflozin|2 x 10 mg capsules, single oral dose
215073250|NCT06424158|OTHER|Massage Therapy|Massage therapy (MT) has been proven as an alternative non-opioid pain management intervention, particularly towards reducing pain, diminishing depression, improving immune function, and increasing alertness in the adult population. MT raises the temperature of local tissues, dilates capillaries, accelerates the circulation of blood and lymph, promotes the absorption of local tissue metabolism and mass inflammation, improves the nutritional supply of surrounding muscle groups, promotes their growth and development, and relieves pain.
215073251|NCT01689870|DRUG|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
215073252|NCT01689870|DRUG|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
214334682|NCT04545515|DRUG|IVA|Tablet for oral administration.
214334683|NCT02164552|DIETARY_SUPPLEMENT|Vitamin D3 pills|Dietary supplement
214334684|NCT02164552|OTHER|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
214334685|NCT01934634|DRUG|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
214674164|NCT00688493|DRUG|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
214674165|NCT00688493|DRUG|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
214935666|NCT03249246|OTHER|No intervention|
214935667|NCT02018172|DRUG|somatropin|
214935668|NCT05102825|DIAGNOSTIC_TEST|1H and Xe-129 MRI|Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).
214935669|NCT05146986|DEVICE|Non surgical and Surgical|"For non-surgical group, patients will receive non-surgical treatment (analgesia and symptomatic management treatment).~For surgical group, patients will receive surgical treatment using RibFix Blu Thoracic Fixation System."
214935670|NCT03479359|BEHAVIORAL|Routine review of DRE results by attending doctors|Let the internship regularly compare DRE result and the pathology outcome of prostate biopsy of each patient.
215073253|NCT02867943|OTHER|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
215073254|NCT02183480|DRUG|Linagliptin, low dose|
215073255|NCT02183480|DRUG|Linagliptin, medium dose|
215073256|NCT02183480|DRUG|Linagliptin, high dose|
215073257|NCT02186652|DRUG|Pantoprazole|
214674166|NCT01348178|PROCEDURE|Follow-up|Follow-up
214674167|NCT03474523|OTHER|Experimental group|"Cavitation: 70% intensity, 30 minutes apply plane electrode and 10 minutes focal electrode.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
214674168|NCT03474523|OTHER|Control group|"Diathermy-Radiofrecuency: 30 minutes at 70% intensity (40-43ºC) in manual resistive modality and 10 minutes in automatic capacitive modality.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
214674169|NCT06497426|OTHER|Study intervention|Participants will be asked to drink water. Water intake will be supervised by a nurse/nurse assistant/dietitian team to ensure adherence, and registered to assess intervention compliance.
214674170|NCT04457726|BIOLOGICAL|SARS-CoV-2 Specific T Cells|Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.
214674171|NCT00366834|DRUG|Casopitant (GW679769) oral tablets|
214674172|NCT00366834|DRUG|Casopitant (GW679769) intravenous|
214674173|NCT00366834|DRUG|Dexamethasone intravenous|
214334686|NCT01934634|DRUG|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
214334687|NCT01934634|DRUG|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
214935671|NCT03729570|OTHER|ePrEP|Participants will have a baseline teleconsultation with a site study clinician who will be responsible for prescribing PrEP as indicated. They will be offered a 1-month check-in and telemedicine consultations at 3, 6, 9 and 12 months. Participants will complete home specimen collection for laboratory tests for each consultation. The virtual study visit consists of surveys, specimen collection, and a telemedicine consultation.
214334688|NCT06050408|DEVICE|1hz repetitive transcranial magnetic stimulation|1hz rTMS applied over P3 EEG 10-20 location. Total of 1200 pulses administered. Figure of eight coil used to stimulate, held tangential to the scalp.
214334689|NCT00958880|BEHAVIORAL|Group Cognitive Behavioral Therapy|"5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy."
214334690|NCT00958880|DRUG|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
214334691|NCT00958880|DRUG|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
214334692|NCT01876264|PROCEDURE|Extended resection|
214334693|NCT01876264|PROCEDURE|Conventional resection|
214935672|NCT05523232|OTHER|Vibration training with 42 Hz|Vibration exposure was given using a handheld vibration device.
214935673|NCT05523232|OTHER|Vibration training with 63 Hz|Vibration exposure was given using a handheld vibration device.
214935674|NCT00740909|BEHAVIORAL|Cognitive Behavioral Therapy|A therapy designed to help patients with response prevention skills.
214935675|NCT01608815|BIOLOGICAL|Typhoid Vi polysaccharide|0.5 mL, Intramuscular
214334694|NCT01848990|DRUG|Commercial Hylenex® recombinant (hyaluronidase human injection)|
214674174|NCT00366834|DRUG|Ondansetron oral tablets|
214674175|NCT00366834|DRUG|placebo|casopitant placebo
214935676|NCT00368693|DEVICE|Dermal - Living Skin Replacement (Dermal-LSR)|The only experimental procedure is the application of the study device, Dermal - Living Skin Replacement (Dermal - LSR), to the foot ulcer. All others are regular or standard procedures. Dermal - LSR is a gel containing living human skin cells. This gel is applied directly to ulcers to help repair the skin. The cells used in this study device have come from one foreskin (skin covering the tip of the penis) taken from a baby boy shortly after his birth for reasons unrelated to this study. All cells that will be used have been tested to be healthy and safe. The amount of the study device you will receive depends on the size of your ulcer at each treatment visit. You will receive less than a 1/4 teaspoon of Dermal - LSR for about every dime-size area of your ulcer as measured and calculated by the research investigator.
214935677|NCT01820507|DEVICE|Optiflow (Fisher&Paykel)|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
214935678|NCT01820507|DEVICE|Nasal cannulae or controlled oxygen concentration mask|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
215073258|NCT00744978|DRUG|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
214935679|NCT00410020|BEHAVIORAL|Alpha-linolenic enriched diet|
215073259|NCT00744978|DRUG|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
215073260|NCT01218958|DRUG|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
215073261|NCT01218958|DRUG|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
214334695|NCT01848990|DRUG|Precommercial Hylenex recombinant (hyaluronidase human injection)|
214334696|NCT01848990|DRUG|Insulin lispro|
214334697|NCT01848990|DRUG|Insulin aspart|
214334698|NCT01848990|DRUG|Insulin glulisine|
214334699|NCT04106791|DEVICE|closed-loop system for vasopressor administration|The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
214334700|NCT03359733|DRUG|TAK-659|TAK-659 tablet.
214334701|NCT01144156|DRUG|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
214334702|NCT02657811|DEVICE|Miri, Benchtop Multi-room incubator|Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
214334703|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
215073262|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
215073263|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
215073264|NCT03311139|DRUG|Antithrombotic agents|Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
215073265|NCT03094364|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
215073266|NCT00381511|DRUG|low molecular weight heparin|
215073267|NCT03580642|DEVICE|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
215073268|NCT04000308|DRUG|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
215073269|NCT04000308|DRUG|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
215073270|NCT02140008|DEVICE|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
214334704|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
214334705|NCT06031571|PROCEDURE|dry cupping massage|Dry cupping is a form of massage therapy that involves using Hijamat cups without skin injury while applying suction and then performing circular and transverse movements
214935680|NCT01619644|DRUG|sodium valproate|sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
214935681|NCT01619644|DRUG|Placebo|Placebo with an oral dosage of 30 mg/kg/jour
214935682|NCT04282291|PROCEDURE|fascial block as postoperative analgesia|The tissue damage induced by the surgery generates a nociceptive pain which is accompanied by inflammatory mechanism (somatic pain), visceral and neuropathic pain, and why the treatment must be adapted to each surgical procedure. As the innervation of the upper abdominal wall depends mainly on the last intercostal nerves, the block of these nerves should be considered a good analgesic strategy to avoid the somatic pain. The placement of the local anesthetic in the serratus intercostal plane at the eighth rib (serratus intercostal plane block, SIPB) in the middle axillary line, managed to block the lateral and anterior cutaneous branches of the last intercostal nerves (T7-11). The results were satisfactory in the postoperative pain control of the patients with open cholecystectomy.
214935683|NCT04282291|DRUG|Morphine|The continuous (basal) dose
214334706|NCT06031571|PROCEDURE|Myofacial release|Myofascial release is a form of manual therapy using hands-on techniques to regain tissue extensibility and elasticity
214935684|NCT04282291|DEVICE|PCA CADD Smith Medical pumps|perfusion
214935685|NCT02340260|BEHAVIORAL|High intensity interval training|High intensity exercise during 12 weeks with three weekly training sessions
214935686|NCT02340260|BEHAVIORAL|Sprint interval training|Sprint interval exercise during 12 weeks with three weekly training sessions
214935687|NCT01482962|DRUG|Alisertib|Alisertib enteric coated tablets
215073271|NCT02140008|DEVICE|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
214935688|NCT01482962|DRUG|Pralatrexate|Pralatrexate IV infusion
214334707|NCT00364780|DRUG|XL647|XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 \& 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
214935689|NCT01482962|DRUG|Gemcitabine|Gemcitabine IV infusion
214935690|NCT01482962|DRUG|Romidepsin|Romidepsin IV infusion
214334708|NCT06109428|DRUG|HTX-011|400 mg
214674176|NCT01685294|BEHAVIORAL|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
214674177|NCT01008930|PROCEDURE|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
214674178|NCT04797975|BIOLOGICAL|KDS-1000|"Non-randomized part of study:~* At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~* Cohort 1: Low Dose, 2x10E8 cells/dose~* Cohort 2: High Dose, 1x10E9 cells/dose"
214334709|NCT06109428|DRUG|Bupivacaine Hydrochloride|125 mg
214674179|NCT04797975|OTHER|Placebo|0.9% Normal Saline
214674180|NCT04315363|BEHAVIORAL|Motivational MRI and Behavioral Intervention|Motivational messaging delivered during a functional brain MRI scan and with daily messaging
214674181|NCT04315363|BEHAVIORAL|Control MRI and Behavioral Intervention|Control messaging delivered during a functional brain MRI scan and with daily messaging
214674182|NCT02952066|PROCEDURE|Bronchial biopsy|Bronchial tissue taken during biopsy
214935691|NCT05759520|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (multivalent conjugate)|the 2-month-old experimental group and the 3-month-old group received the experimental vaccine
214935692|NCT05759520|BIOLOGICAL|Prevenar 13|the 2-month-old control group received the active control vaccine
214935693|NCT00522691|PROCEDURE|sacral nerve stimulation|sacral nerve stimulation for fecal incontinence
214935694|NCT04393220|DRUG|Bevacizumab Injection|15mg/kg (Q3W)
214935695|NCT04393220|DRUG|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
215073272|NCT04254367|BEHAVIORAL|Learn-to-Cope|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
215073273|NCT02647541|DIETARY_SUPPLEMENT|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
215073274|NCT03424954|BEHAVIORAL|EpxOstomy|A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
215073275|NCT00866047|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
214334710|NCT06109428|DRUG|Ibuprofen|400 mg
214334711|NCT06109428|DRUG|Acetaminophen|1 g
214935696|NCT02407457|DEVICE|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
214334712|NCT06109428|DEVICE|Luer lock applicator|Applicator for instillation
214334713|NCT00360776|DRUG|tipifarnib|Given orally
214334714|NCT00360776|OTHER|laboratory biomarker analysis|Correlative studies
214334715|NCT06149637|PROCEDURE|Traditional neck dissection approach|.1. A transverse cervical incision is made with horizontal extension towards the affected side. 2. It is dissected through the subplatysmal plane, the posterior edge of the sternocleidomastoid muscle is dissected along its entire length. 3. Identification and dissection of the spinal nerve at Erb's point. 4. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it 5. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level 6. Identification and dissection of level III nodes 7. Identification and dissection of level IIA and IIB ganglia with identification and preservation of the accessory nerve.
214334716|NCT06149637|PROCEDURE|Anterior neck dissection approach|"1. A transverse cervical incision is made with horizontal extension towards the affected side.~2. It is dissected through the subplatysmal plane, the anterior edge of the sternocleidomastoid muscle is dissected along its entire length.~3. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it~4. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level~5. Identification and dissection of level III nodes~6. Identification and dissection of level IIA and IIB nodes with identification and preservation of the accessory nerve."
214334717|NCT04369248|OTHER|hepassocin|hepassocin levels in polycystic ovary syndrome
214334718|NCT06415643|OTHER|Islet organoids transplantation|autologous transplantation of ex vivo expanded islet organoids.
214334719|NCT05262205|OTHER|measuring depth of anesthesia and its relation to the globe|measuring feasibility of BIS monitor in detecting depth of anesthesia in pediatric population and whether it will be beneficial as a tool for helping anesthesiologist in maintaining central globe alignment
214334720|NCT04888975|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
214334721|NCT06402058|DEVICE|DMSB01|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
214334722|NCT06402058|DEVICE|Rejuran®|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
214334723|NCT06316739|BEHAVIORAL|Ganchero intervention|"The Ganchero intervention is an HIV, hepatitis C virus (HCV) and overdose prevention intervention for migrant people who inject drugs (PWID) from Puerto Rico who are living in New York City. The intervention has two core components, both centered around the key migrant PWID role of the Ganchero, an individual who provides expert injection services in exchange for money or drugs. First, a sample of Gancheros will be trained in foundational HIV, HCV and overdose risk-reduction knowledge and outreach strategies (over 6 2-hour, in-person, small group sessions facilitated by an Interventionist). Second, during a 4-month outreach period, trained Gancheros will disseminate risk-reduction messages learned in the training, and associated resources (e.g., sterile syringes and other injection equipment, naloxone), to migrant PWID in their neighborhood as they deliver their regular Ganchero services."
214334724|NCT01060267|DRUG|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
214935697|NCT02407457|DEVICE|FDA Approved EVAR AAA Graft Systems|
214334725|NCT01060267|DRUG|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
214334726|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
214334727|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
214935698|NCT03275259|DEVICE|THORK Shock Wave® (Extracorporeal shock waves)|Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
214935699|NCT06478849|OTHER|QUESTIONNAIRES|QUESTINNAIRES / WEBINARS
214334728|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
214334729|NCT00955266|DRUG|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
214334730|NCT00955266|DRUG|Placebo|Normal saline, 50cc delivered over 5 minutes
214935700|NCT04446845|DRUG|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
214935701|NCT04446845|DRUG|Conventional Stimulation (Elonva+rFSH) in follicular phase|From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
214334731|NCT04383821|DEVICE|Double-Trunk Mask|The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
214334732|NCT04383821|DEVICE|Non-Rebreather mask|The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
214334733|NCT02972528|BIOLOGICAL|Platelet Lysate|Direct injection of allogenic Platelet Lysate
214334734|NCT02972528|BIOLOGICAL|Platelet Poor Plasma|Direct injection of allogenic Platelet Poor Plasma
214334735|NCT04294004|COMBINATION_PRODUCT|TGplPTH1-34 in fibrin|TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage
214334736|NCT04294004|OTHER|Autologous Bone Graft|Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.
214334737|NCT03992807|OTHER|A patient decision aid|Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
214334738|NCT03992807|OTHER|A usual education booklet|Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
214935702|NCT04357912|BEHAVIORAL|Activity Tracker Group|In addition to the standard of care exercise education, participants in the activity tracker group will be provided a Fitbit physical activity tracker at no cost to the participants. They will be asked to download the Fitbit application (app) to their personal smartphone device to allow them to see their own data collected by the Fitbit. They will also be asked to download the Stridekick app for the purpose of sharing their activity tracker data electronically with the study team and having the opportunity to participate in fitness challenges through the app. App accounts will be created by the participants with usernames that do not contain the participant's identifiable personal information. Optional fitness challenges will be created once per month by the study investigators, and participants will also receive a weekly message of encouragement from the study team.
214935703|NCT04357912|BEHAVIORAL|Standard of Care Group|Participants will receive standard of care exercise education.
214935704|NCT02895308|BEHAVIORAL|Online psychoeducation|The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
214935705|NCT02895308|BEHAVIORAL|Face-to-face psychoeducation|The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
214334739|NCT03837795|DEVICE|Neurofeedback treatment|A treatment that developed to train adults with sensory modulation disorder by applying EEG (Curry 7 EEG system, Neuroscan-Compumedics). This treatment will aim to normalize the Alpha power (amplitude).
214334740|NCT00803127|DEVICE|vs-sense|detection swab
214334741|NCT06137456|DEVICE|Exoskeletal robotic therapy for walking.|Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.
214334742|NCT06137456|OTHER|Conventional exercise therapy|Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
214334743|NCT02755831|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
214334744|NCT02755831|OTHER|Pre-natal care|Standard Pre-Natal Care
214935706|NCT01583075|PROCEDURE|Circumferential pulmonary vein ablation|Circumferential pulmonary vein ablation
214334745|NCT05244031|PROCEDURE|superficial erector spina plane block|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
214935707|NCT01583075|PROCEDURE|single ring pulmonary vein ablation|single ring pulmonary vein ablation
214334746|NCT05244031|PROCEDURE|Standard (opioid-based) analgesia|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
214347273|NCT05108337|PROCEDURE|Superficial cervical plexus block|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml 0.5% ropinacaine.
214347274|NCT05108337|OTHER|Control group|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
214334747|NCT03989193|DEVICE|Computer guided alveolar ridge splitting technique|"The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm."
214334748|NCT00557791|DRUG|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
214334749|NCT00557791|DRUG|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
214334750|NCT01720069|DRUG|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
214334751|NCT03445416|BEHAVIORAL|POL arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
214334752|NCT03445416|BEHAVIORAL|Comparison arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
214334753|NCT05588596|BEHAVIORAL|Trauma Resiliency Mindfulness-Informed Intervention|The total duration of the intervention was once a week for eight weeks. The aim of the intervention was to teach patients a range of trauma recovery mindfulness skills
214674183|NCT03131297|PROCEDURE|treatment by radiofrequency|Radiofrequency might destroy fistula tract without lesion of anal sphincter.
214674184|NCT06097585|DRUG|SGLT2 inhibitor|case control study in which group will receive SGLT2I and group will not , to detect impact of the drug in changing NYHA class for heart failure and echographic parameter
214935708|NCT06424600|OTHER|Gingival Index|The G-I index ranging between 0.5-2 was used to calculate the occurrence of severe gingival issues in participants with smoking habits. The G-I index between 0.50-1.00 displayed light gingival inflammation, G-I between 1.10-2.00 revealed moderate gingival inflammation and G-I \> 2.00 confirmed severe gingival inflammation.
214334754|NCT00508742|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
214334755|NCT00508742|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
214334756|NCT00650039|DRUG|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
214334757|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
214334758|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
214334759|NCT01228929|OTHER|Environmental Chamber Condition Change Intervention|For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
214334760|NCT03072173|DRUG|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
214334761|NCT03072173|DRUG|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
214334762|NCT00412165|BEHAVIORAL|Cell Phone|The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
214334763|NCT00412165|BEHAVIORAL|Weekly access to interactive web site|This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
214334764|NCT00412165|BEHAVIORAL|Group|The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
214334765|NCT03941210|OTHER|Detection of molecular Biomarkers|MicroRNA expression profile analysis by flow cytometry
214334766|NCT00656253|DRUG|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
214674185|NCT04904042|DEVICE|Use of plasma of neutral argon|"Evaluation of the mesentery or peritoneum area infiltrated by miliary implants that is going to be treated. Determination of the PCI. Collection of several samples of the mesenteric peritoneum or parietal peritoneum with tumor involvement (implants between 1-2.5mm of diameter).~It will established a matrix which will be divided into 12 quadrants where the tissue with implants will be placed and it will be treated according to specific power (80-100%), and for an action time of 2-4 seconds or until macroscopic tumor destruction. For each power, application of Plasmajet at 1, 2 and 3 cm from the target tumor tissue.~The in-vivo effect will be evaluated with the use of ball-tip in terms of damage to the serosa or vascularization of the mesentery."
214334767|NCT00656253|DRUG|Placebo|12 months period of placebo plus 1 month period without placebo
214334768|NCT06804603|DRUG|Tradipitant|Oral capsule
214334769|NCT06804603|DRUG|Placebo|Oral capsule
214334770|NCT04903691|BEHAVIORAL|Cardiac Exercise Program|Participants who enrolled in cardiac exercise program
214334771|NCT03273036|DRUG|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
214334772|NCT03273036|DRUG|Placebos|no injected agent
214334773|NCT01900613|BEHAVIORAL|Ninos Sanos Familia Sana|
214334774|NCT01486017|DRUG|ASP015K|oral
214334775|NCT01221974|DEVICE|Essure Micro Insert|
214334776|NCT03778970|OTHER|Pain Neuroscience Education|Pain neuroscience education (2 sessions during 40 minutes) administered by an interactive workshop
214334777|NCT03778970|OTHER|Self-Management Education|A self-management education (2 sessions during 40 minutes) administered by an interactive workshop
214935709|NCT03219606|OTHER|Organized education course of Modified Rodnan Skin Scoring|"1. Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).~2. Demonstration: Master instructor demonstrate the patient assessment without revealing his score.~3. Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course."
214935710|NCT01798407|DEVICE|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
214674186|NCT01790061|PROCEDURE|Standardized FMT|Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut or whole colon
214334778|NCT03778970|OTHER|Movement Control Exercises|Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.
214674187|NCT01790061|DRUG|Traditional treatments|Medications
214674188|NCT01977534|DEVICE|Absorb BVS|The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating \[formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating\].
214334779|NCT04302467|PROCEDURE|fluid therapy during operation|ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.
214334780|NCT03072212|OTHER|Observational study|No intervention
214334781|NCT03053895|PROCEDURE|CSDH - Bedside twist drill technique|For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic
214334782|NCT03053895|PROCEDURE|CSDH - Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
214334783|NCT02420106|PROCEDURE|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
214334784|NCT00963690|DEVICE|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
214334785|NCT00963690|PROCEDURE|Standard compression|Use standard compression to achieve hemostasis
214935711|NCT01798407|OTHER|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
214674189|NCT03839433|DRUG|Ciclesonide|
214674190|NCT03835208|BEHAVIORAL|High/low carbohydrate distribution|A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
214334786|NCT02002494|OTHER|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
214334787|NCT02460224|DRUG|LAG525|LAG525 was administered via intravenous (i.v.) infusion
214935712|NCT02049840|DEVICE|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
214674191|NCT03661385|DRUG|Nitric Oxide|Addition of nitric oxide 20ppm into bypass circuit
214674192|NCT04373122|DEVICE|REBOA|Resuscitative Endovascular Balloon Occlusion of the Aorta
214674193|NCT06032403|BEHAVIORAL|flexible patient centred consultations|In the intervention group, the set-up will be flexible patient-centred consultations. The first consultation for the participant will be with the doctor and depending on the participant's need, the following consultations can be scheduled as either a doctor- or a nurse consultation. After each consultation, it will be decided in collaboration between the healthcare professionals and the participant whether a nurse or a doctor consultation will be relevant next. The consultations (whether it is with the doctor or nurse) will be centered around the participant's choice of topics by use of an atopic dermatitis dialogue tool developed in the department. Additionally, the nurse consultation will focus on therapeutic patient education (TPE) in atopic dermatitis. The interval between consultations will depend on the participant's need
214334788|NCT02460224|DRUG|PDR001|PDR001 was administered via i.v. infusion
214334789|NCT03797638|DEVICE|Finger Force Manipuladum (FFM)|Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
214334790|NCT04103528|OTHER|morning surgery|31 patients will be operated on between 8:00 and 12:00 in the morning.
214674194|NCT02349906|DRUG|Treosulfan|
214674195|NCT02349906|DRUG|Busilvex|
214334791|NCT04103528|OTHER|afternoon surgery|31 patients will be operated on between 14:00 and 18:00 in the afternoon.
214334792|NCT04918680|DEVICE|EcoFit® Total Hip System with implacross® E Polyethylene|The EcoFit® Total Hip System is a primary hip replacement system indicated for patients who are candidates for a primary cementless hip replacement. implacross® E Polyethylene is one of the components in the EcoFit® system.
214334793|NCT04648930|DRUG|Xolair|There was no treatment allocation. Patients administered Xolair by prescription that started before inclusion of the patient into the study were enrolled.
214334794|NCT01384084|PROCEDURE|POP repair plus mini-sling|"For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh."
214334795|NCT01384084|PROCEDURE|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
214334796|NCT02065674|DRUG|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
214334797|NCT06805903|OTHER|TRansanal Irrigation Adherence scaLe|new trans-anal irrigation self-assessment questionnaire in French
214334798|NCT01620606|BEHAVIORAL|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy \& Social Learning
214334799|NCT01620606|BEHAVIORAL|Education and Support|Education about the GI system, nutrition and food safety
214334800|NCT03876730|OTHER|ICF CP Core Set|Core set
214334801|NCT04783129|OTHER|Education program based on 10 monthly lectures|The education program consist of 10 lectures on the management of motor and non-motor alterations associate with PD will be offered by a nurse, physiotherapist, occupational therapist, speech therapist, neurologist, lawyer, nutritionist, and psychologist.
214334802|NCT04783129|OTHER|No intervention|Participants will follow no education program (lecture) and will be instructed to follow their usual routine for the treatment of the disease
214334803|NCT00286416|DRUG|omalizumab (Xolair)|
214935713|NCT06299904|BEHAVIORAL|Modified Air-pulse Stimulation|Connected the oxygen humidification bottle to a fibreoptic endoscope, then inserted the terminal into the nasal cavity and the pulse sensation stimulation generated by oxygen was transmitted through the internal port of the fibreoptic endoscope to the anterior wall of the pyriform recess or to the folds of the arytenoepiglottis. (5 min once a day for 2 weeks)
214935714|NCT06299904|BEHAVIORAL|Conventional air-pulse stimulation|The terminal airway of the air pulse was placed in the oral cavity, specifically in the patient's palatoglossal arch, pharyngeal posterior wall, tongue base, and other areas. The airbag was quickly squeezed to generate airflow and stimulate the mucosa.(5 min once a day for 2 weeks)
214935715|NCT01325116|BEHAVIORAL|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
214935716|NCT05207618|DIETARY_SUPPLEMENT|ARBOX (QUEBRACHO AND CHESNUT EXTRACT)|ARBOX TWICE A DAY FOR 60 days
214334804|NCT03069027|PROCEDURE|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
214334805|NCT03069027|DRUG|saline adrenaline|
214334806|NCT03069027|DRUG|Xylocaine, adrenaline|
214334807|NCT01043965|DRUG|Metformin|Metformin 850mg
214334808|NCT02192944|DRUG|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
214334809|NCT02192944|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
214334810|NCT03640065|DRUG|freeze-dried probiotic sachets|"* The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~* This procedure will be repeated once daily for the following 4 weeks.~* 4 weeks supply will be given to the participants."
214334811|NCT03640065|DIETARY_SUPPLEMENT|fermented dairy product ( yogurt)|"* The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~* 4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home"
214334812|NCT06184334|DRUG|Solfenacin|pills taken once day
214334813|NCT06184334|DRUG|Mirabegron|pills taken once day
214334814|NCT06184334|DRUG|Tadalafil 5mg|pills taken once day
214334815|NCT03893266|OTHER|Interviews|An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.
214334816|NCT05593796|BEHAVIORAL|cognitive behavioral therapy|12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .
214334817|NCT05617846|OTHER|Anti-osteoporosis therapy|Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.
214334818|NCT01394926|DRUG|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
214334819|NCT03146650|BIOLOGICAL|Ipilimumab|Given IV
214334820|NCT03146650|OTHER|Laboratory Biomarker Analysis|Correlative studies
214334821|NCT03146650|BIOLOGICAL|Nivolumab|Given IV
214334822|NCT01684384|RADIATION|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
214334823|NCT01632371|DEVICE|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
214334824|NCT01632371|DEVICE|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
214334825|NCT00573963|DRUG|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
214334826|NCT00573963|DRUG|saline solution|2 injections of 20mL plain saline solution - one on each side.
214334827|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
214334828|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
214334829|NCT01502722|BEHAVIORAL|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
214334830|NCT03176732|DEVICE|Positive Airway Pressure|Participants will use Positive Airway Pressure (PAP) treatment
214334831|NCT06182267|DRUG|L Arginine|toothpaste
214334832|NCT06182267|DRUG|Sodium Fluoride|toothpaste
214334833|NCT02905305|DEVICE|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
214334834|NCT02905305|DEVICE|Contour Advance electrode|Standard Contour Advance electrode
214334835|NCT03258372|DRUG|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
214334836|NCT05198492|OTHER|Impact of air pollution|To assess the short- and long- term impact of air pollution
214334837|NCT04390152|DRUG|Wharton's jelly derived Mesenchymal stem cells.|IV Wharton's jelly derived Mesenchymal stem cells, two doses
214334838|NCT04390152|DRUG|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)|Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
214935717|NCT05645419|BEHAVIORAL|personalized chronoprevention|Chronobiological variables: dynamic and static position of the planets of the solar system, moon, sun, constellations; angles/degrees of celestial objects above/below the horizon; angular interactions between celestial objects; the moment/time of the patients' birth; moment/time of MI occurrence; latitude / longitude of the place of birth of the patients, as well as the occurrence of MI (event); the degree of influence of celestial objects in relation to the constellations, where they were at a particular personal event / points of the patient.
214935718|NCT03111199|OTHER|Cryotherpy|Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
214334839|NCT05491629|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|"The quantitative part of the study is a descriptive study with the Perceived Perioperative Competence Scale-Revised to determine the perceptions of operating room nurses about their competencies.~It is a case study in order to reveal the opinions of the surgical team members about the competencies of the operating room nurses and the affecting factors through individual in-depth interviews and to better explain the current situation at the qualitative stage, which is carried out simultaneously."
214334840|NCT01175655|OTHER|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
214334841|NCT03333486|DRUG|Cyclophosphamide|Given IV
214334842|NCT03333486|DRUG|Fludarabine Phosphate|Given IV
214334843|NCT03333486|OTHER|Laboratory Biomarker Analysis|Correlative studies
214334844|NCT03333486|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
214334845|NCT03333486|RADIATION|Total-Body Irradiation|Undergo TBI
214334846|NCT05443425|DRUG|Cholestyramine|Given PO
214334847|NCT05443425|DRUG|Leflunomide|Given PO
214334848|NCT05443425|DRUG|Steroid Therapy|Given steroid therapy
214334849|NCT01062685|DIAGNOSTIC_TEST|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
214334850|NCT06664736|BEHAVIORAL|Exercise|The exercise group performed a home-based exercise program consisting of aerobics 3 days a week with videos and strengthening and stretching exercises 2 days a week with infographics, for 8 weeks.
214334851|NCT06664736|BEHAVIORAL|Physical activity|The control group was advised to increase physical activity
214334852|NCT06601270|OTHER|There are no interventions as the study is purely observational.|There are no interventions as the study is purely observational.
214935719|NCT03111199|OTHER|TENS Burst|The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
214334853|NCT01985516|OTHER|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
214935720|NCT03111199|OTHER|TENS Burst Placebo|The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
214334854|NCT01985516|OTHER|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
214334855|NCT06987175|OTHER|sadante neo therapy|SAN machine having 3 tube cords on both sides. Each tube cord contains 2 pairs of flat suction cups. We will use 4 pair of flat suction cups in this study. We will place 2 pair on left and two on right para spinal muscles of lumber in prone lying. Due to its automatic suctioning capability, these cups can easily stick to skin. After placing the cups on lumber each patient of group A will receive its stimulation for about 10 minutes every day for about 4 weeks along with conventional exercises.
214334856|NCT06987175|OTHER|Conventional exercises|receive conventional exercises only. Conventional exercises will be performed for 20 minutes, each exercise will be performed 20 times with 10 seconds hold.
214334857|NCT06493513|DEVICE|40Hz stimulation|Exogenous 40Hz stimulation is a physical intervention that induces gamma oscillations, oscillations and pulsations at the corresponding frequency, and may lead to a significant reduction in β-amyloid, reversal of tau protein hyperphosphorylation, and consequently improvement of cognitive function in patients.
214334858|NCT04923958|DIAGNOSTIC_TEST|Novel mycobacterial culture techniques|We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
214334859|NCT04923958|DIAGNOSTIC_TEST|Novel sputum smear microscopy techniques|We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
214334860|NCT04923958|DIAGNOSTIC_TEST|Sputum-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
214334861|NCT04923958|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
214334862|NCT04923958|DIAGNOSTIC_TEST|Urine LAM assays|We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
214334863|NCT04923958|DIAGNOSTIC_TEST|Blood-based host immune response assays|We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
214334864|NCT04923958|DIAGNOSTIC_TEST|Breath-based assays|We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
214334865|NCT04923958|DIAGNOSTIC_TEST|Artificial intelligence-based digital health tools|We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
214334866|NCT04923958|DIAGNOSTIC_TEST|Phage-based assays|We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
214334867|NCT04923958|DIAGNOSTIC_TEST|Cartridge-based molecular assays for detecting drug resistance|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
214334868|NCT04923958|DIAGNOSTIC_TEST|Sequencing-based assays for detecting drug resistance|We will evaluate targeted and whole genome sequencing assays.
214334869|NCT00774995|BIOLOGICAL|EngerixTM-B|Intramuscular injection, one dose.
214334870|NCT02143518|BIOLOGICAL|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
214334871|NCT02143518|BIOLOGICAL|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
214334872|NCT06994143|DRUG|CLN-978|Specified dose on specified days
214334873|NCT04862468|COMBINATION_PRODUCT|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
214334874|NCT04862468|COMBINATION_PRODUCT|Perivascular sham|Saline delivery around target vein segment(s)
214334875|NCT00452335|DRUG|Lubiprostone|12 mcg capsule once daily (QD)
214334876|NCT00452335|DRUG|Lubiprostone|12 mcg capsule twice daily (BID)
214674196|NCT06555094|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
215073276|NCT05824039|DIETARY_SUPPLEMENT|Tea infusion|Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
214334877|NCT00452335|DRUG|Lubiprostone|24 mcg capsule twice daily (BID)
214334878|NCT04069793|DEVICE|Commercially available device|A commercially available and registered with the FDA prosthesis equipped with a powered single-degree of freedom wrist and powered hand.
214334879|NCT04069793|DEVICE|Non FDA registered device|An experimental, non FDA registered prosthesis equipped with a multi function wrist and a powered hand.
214334880|NCT07000201|DRUG|One hour prior to admission to the operating room, patients will receive the study medication (as premedication) by mouth with a sip of water;|group I patients will receive two capsules of pregabalin (Lyrica) 75 mg (total = 150 mg), group II patients will receive two capsules of gabapentin (Conventin) 300 mg (total = 600 mg), and group III patients will receive a matching placebo in the form of two capsules of powdered multivitamin by mouth.
214334881|NCT00535886|DIETARY_SUPPLEMENT|Man-made Trans FA|EA as 6% of total energy
214334882|NCT00535886|DIETARY_SUPPLEMENT|Natural Trans FA|VA as 6% of total energy
214334883|NCT00535886|DIETARY_SUPPLEMENT|Oleic Acid|OA as 6% of total energy
214674197|NCT06555094|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
214674198|NCT06555094|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
214334885|NCT06681142|OTHER|Pharmacy-Physiotherapy Intervention|"Pharmacists will provide comprehensive 1:1 patient care, including a complete patient assessment and medication review, provide specific drug therapy recommendation(s) using shared decision making (SDM), and provide patient education, including further written materials.~Participants will be offered either individual or group physiotherapy sessions at the a private clinic."
214935721|NCT03111199|OTHER|Education|After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
214935722|NCT00813670|DRUG|XPF-001|Single oral dose, or 6 days of repeated oral doses.
214334886|NCT07012213|DRUG|Patients in group A received .5 g/kg/h dexmedetomidine infusion after general anesthesia, in group B received 1 ml (100 mic) dexmedetomidine intranasal spray before induction.|Patients in group A received .5 g/kg/h dexmedetomidine infusion after general anesthesia, in group B received 1 ml (100 mic) dexmedetomidine intranasal spray before induction.
214334887|NCT07013045|OTHER|Structured Neuromuscular Exercise Group|In the Structured Neuromuscular Exercise group, the exercise program will be administered to patients diagnosed with FMF twice a week for 12 weeks under the supervision of a physiotherapist. The exercises will be performed using a balance board and will include sitting, standing, lunge, modified push-up, and plank positions.
214334888|NCT07013045|OTHER|Neuromuscular Exergaming Program Group|In the Neuromuscular Exergaming group, patients diagnosed with FMF will perform the same exercises as those in the structured neuromuscular exercise program, delivered in an exergaming format using the Smart Exercise Board (SEG-Board). The program will be conducted under the supervision of a physiotherapist, twice weekly for 12 weeks, and will include exercises performed in sitting, standing, lunge, modified push-up, and plank positions.
214334889|NCT05242978|OTHER|Nutrition|acute single dose nutrition intervention
214334890|NCT06694701|DRUG|Emapalumab-Izsg|The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
214334891|NCT06694701|DRUG|Emapalumab-Izsg|The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
214674199|NCT05321797|OTHER|Aerobic Training|This group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 12-week period
214674200|NCT05321797|OTHER|Conventional Physiotherapy|This group will be administered with Conventional Physiotherapy that includes 5 minutes of stretching exercises for quadriceps, hamstrings and gastrocnemius, 5 minutes of trunk control training, 5 minutes walking in the hall with and without the therapist assistance, walker or crutches, and finally 5 minutes of breathing exercises for Relaxation
214674201|NCT01263535|DEVICE|SENSIMED Triggerfish|Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
214935723|NCT04892628|OTHER|Progressive resistance training|Resistance training of upper limb and lower limb muscles. Resistance will be increased on a weekly basis. Dumbbells and therabands will be used to provide resistance.
214935724|NCT04892628|OTHER|Aerobic training|The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.
214935725|NCT03714646|DIETARY_SUPPLEMENT|beta glucan and resistant starch|12g per day the day before the CID Resistant starch 7.5 g
214935726|NCT03714646|DIETARY_SUPPLEMENT|Placebo|isocaloric maltodextrin before the CID
214334892|NCT06694701|DRUG|Placebo|250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply
214334893|NCT07024303|DRUG|Psychotropic medication (at discretion of psychiatrist)|The timing and dose of medication will be determined by the prescribing provider. Most medications are delivered daily and some medications may be delivered more than once per day. Providers are expected to adhere to professional guidelines for prescribing.
214334894|NCT07024303|BEHAVIORAL|Behavioral therapy|Functional communication training (FCT) will be delivered for 1 hour every week in-vivo or via telehealth. This timing and dosage has been shown effective in previous research. However, caregivers will be encouraged to practice the treatment procedures as often as possible on their own. Treatment will be delivered by a therapist and/or caregiver for those receiving in-vivo therapy and caregivers will deliver treatment with coaching from a therapist when using telehealth.
214334895|NCT07023796|PROCEDURE|Autologous fat filtration|Patients who underwent a surgical procedure and autologous fat processing for subsequent fat filtration.
214334896|NCT07035067|OTHER|No intervention|No specific intervention is assess in this study.
214334897|NCT06878443|OTHER|Vaginal probiotics|Probiotics from Canadian company Lallemand Health Solutions are stored at room temperature and administered vaginally.
214334898|NCT07043023|DRUG|Lidocaine (drug)|Lidocaine 2%, bolus of 0.075 ml/kg real weight (i.e. 1.5 mg/kg) then IVSE at 0.05 ml/kg/h (i.e. 1 mg/kg/h) for 48 hours
214334899|NCT07043023|DRUG|Placebo|Placebo (sodium chloride 0.9%), bolus of 0.075 ml/kg of real weight then IVSE at 0.05 ml/kg/h for 48h
214334900|NCT07051057|DIAGNOSTIC_TEST|Survey using a questionnaire.|A survey was constructed to collect the data of oral hygiene and nutritional habits and obesity
214334901|NCT07050641|DRUG|SCTB39-1|SCTB39-1, IV
214334902|NCT07051590|DEVICE|cad cam|Occlusion assessment in CAD CAM restorations
214334903|NCT07051590|DEVICE|3D printer|Crowns produced with 3D technology
214334904|NCT07051434|OTHER|Regional Analgesic Block|Preoperative regional analgesic block performed as part of routine clinical care in selected patients undergoing mastectomy (e.g., PECS block, paravertebral block, or other truncal blocks).
214334905|NCT07051772|OTHER|mobility skills testing session|A mobility skills testing session using the Qualisys system (Trinoma), when carrying out specific tasks plus 7-day recording of activity using an accelerometer.
214334906|NCT06620133|OTHER|Pain education and patient-led goal setting|8 week program delivered via five, up to 1-hour telehealth sessions. The sessions will be scheduled at approximately fortnightly intervals. Participants will also be prescribed approximately 30 minutes of online activities with each session. Pain education will be based on Explain Pain and the curriculum will have specified learning objectives adapted for each individual participant. Participants will access the online education curriculum through Pathwright. For patient-led goal setting, the healthcare practitioner will take an initial history of the participants physical activity behaviours and problems related to their back pain. The participant will prioritise their problems according to impact in their life. Strategies will then be discussed, and the participant will, in collaboration with the healthcare practitioner, set goals and strategies to work on independently between sessions.
214334907|NCT06620133|OTHER|Guideline-based written advice|Participants will receive guideline-based written information for the management of chronic low back pain. This will include information about the prognosis of low back pain and treatment options to consider.
214334908|NCT07051161|PROCEDURE|bronchoscope|procedure performed by bronchoscopy
214334909|NCT06855147|DRUG|[14C]HRS9531|A single dose of \[14C\]HRS9531 injected subcutaneously.
214334910|NCT06830005|DEVICE|Rho AI software|Rho is a AI enabled opportunistic pre-screening computer-aided detection and notification software for low bone mineral density.
214334911|NCT06491394|DRUG|Lactoferrin|an iron-binding protein
214334912|NCT06491394|DIAGNOSTIC_TEST|iron|Iron in kidney and heart tissues
214334913|NCT06491394|DIAGNOSTIC_TEST|MDA, TAC, and GSH|Oxidative stress levels in kidney and heart tissues
214334914|NCT06491394|DIAGNOSTIC_TEST|Nrf2|Nrf2 expression in kidney and heart tissues
214334915|NCT06491394|DIAGNOSTIC_TEST|AMPK|AMPK levels in heart and kidney tissues
214334916|NCT06491394|DIAGNOSTIC_TEST|HO-1|HO-1 levels in kidney and heart tissues
214334917|NCT06491394|DRUG|glycerin|GLY intramuscular injection for rhabdomyolysis induction
214674202|NCT01936649|DRUG|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
214674203|NCT06326840|DRUG|Metformin|All participants were administered 1500 mg/day of metformin for eight weeks. The trial design is single-group with no masking.
214674204|NCT01748396|DRUG|Calcitriol|
214674205|NCT01748396|DRUG|Calcium Carbonate|
214935727|NCT03714646|DIETARY_SUPPLEMENT|beta gluten|12 g beta gluten there day before the CID
214935728|NCT05896722|OTHER|Core muscle endurance|Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.
214935729|NCT05896722|OTHER|Upper extremity muscle strength|Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.
214935730|NCT05896722|OTHER|Grip strength|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
214935731|NCT05896722|OTHER|Pinch strength|Pinch strength will be evaluated with a pinchmeter in three positions.
214935732|NCT05896722|OTHER|Alternate hand-wall toss test|To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.
214674206|NCT04103372|DIAGNOSTIC_TEST|MRI scan|MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy.
214674207|NCT04103372|OTHER|Radiologist training|Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer.
214674208|NCT02991300|DEVICE|BioPoly RS Partial Resurfacing Patella Implant|
214674209|NCT03510143|DEVICE|Neoveil (Polyglycolic Acid Mesh)|Apply the Neoveil (Polyglycolic Acid Mesh) in the neck node dissection area in thyroid cancer surgery.
214674210|NCT01215318|DEVICE|modified vaginal tampon|modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
214334920|NCT04097067|RADIATION|Radiation Therapy|Low dose radiotherapy with 20 Gy (10x2Gy)
214334921|NCT03578484|DIAGNOSTIC_TEST|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
214334922|NCT06945575|OTHER|Opus loop|17X25SS will used to fabricate opus loop which is L shaped loop with helix
214334923|NCT06945575|OTHER|T loop|17X25SS wire will be used to fabricate T-loop which is a T shaped loop
214334924|NCT00043693|BEHAVIORAL|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
214334925|NCT00043693|BEHAVIORAL|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
214347275|NCT03130582|DRUG|high-dose etoposide|an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
214674211|NCT01900275|OTHER|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
214674212|NCT05575804|DRUG|GQ1001+pyrotinib|GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.
214674213|NCT05575804|DRUG|pyrotinib+capecitabine|pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
214674214|NCT04655586|DRUG|rNAPc2|two dose levels of rNAPc2
214674215|NCT04655586|DRUG|Heparin|standard of care heparin per institution (therapeutic or prophylactic regimen)
214674216|NCT02345369|DEVICE|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
214674217|NCT02345369|DEVICE|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
214674218|NCT04818450|DRUG|Gabapentin|Gabapentin 100-300 mg is given to the intervention group
214334926|NCT06306118|DEVICE|Multiple stereotactic Tumor Biopsies during a Brain Tumor Resection|For pre-resection biopsy cases (3 target per patient), the targets will be selected from metabolite hotspots on MR-spectroscopy imaging and/or amino acid tracer uptake hotspots on PET imaging. Depending on the tumor location and surgical procedure, all biopsies will be performed via one single or multiple entry points.
214935733|NCT00175032|DRUG|Lansoprazole and naproxen and aspirin|Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
214935734|NCT00175032|DRUG|Celecoxib and aspirin|Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
214935735|NCT01156649|DEVICE|PAP therapy|Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
214935736|NCT01156649|DEVICE|Sham PAP therapy|During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
214935737|NCT00897962|OTHER|Healthy Controls|One blood draw (2 teaspoons)
214674219|NCT03291002|BIOLOGICAL|CV8102|CV8102 alone
214674220|NCT03291002|BIOLOGICAL|CV8102 + anti-PD-1 therapy|CV8102 in combination with standard of care anti-PD-1 therapy
214674221|NCT05425771|PROCEDURE|Anti Reflux Mucosa Ablation|Mucosa ablation with Argon plasma coagulation performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm in patients with refractory reflux symptoms
214674222|NCT04637451|PROCEDURE|Root coverage treatment|Gingival unit graft Connective tissue graft
214674223|NCT04996576|PROCEDURE|infrazygomatic approach sphinopalatine ganglion block|"A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
214674224|NCT04996576|PROCEDURE|intranasal injection approach of sphinopalatine ganglion block|method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
214674225|NCT01772979|DRUG|Trabectedin|
214334927|NCT01818336|DRUG|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
214334928|NCT00014534|BIOLOGICAL|filgrastim|6 mg sub Q
214334929|NCT00014534|DRUG|cisplatin|60 mg/sq m IV
214334930|NCT00014534|DRUG|doxorubicin hydrochloride|50 mg/ sq m IV
214334931|NCT00014534|DRUG|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
214334932|NCT02120339|DRUG|Carvedilol|
214334933|NCT02612207|DEVICE|Bilirubin Binding Capacity by Hematofluorometry Validation|Observation study
214334934|NCT02010424|OTHER|control group|standard IVF protocol
214334935|NCT02010424|DEVICE|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
214334936|NCT04251559|OTHER|oral glucose loading test|oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
214334937|NCT03849638|OTHER|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~* 5 minutes of heating at a comfortable speed for the patient~* Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
214334938|NCT02993601|DEVICE|Heartfelt-1|The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
214334939|NCT02993601|DEVICE|Weighing scales|The patient will be asked to stand on standard medical weighing scales, to measure their weight.
214334940|NCT02993601|OTHER|Medical grading of oedema|A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
214334941|NCT02993601|OTHER|Baseline assessements|At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
214674226|NCT00201201|OTHER|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
214674227|NCT00201201|OTHER|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
214674228|NCT00000110|PROCEDURE|magnetic resonance spectroscopy|
214674229|NCT00000110|DRUG|dietary fat|
214674230|NCT05573685|DEVICE|DiNaMo Study App|Study App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
214935738|NCT00897962|OTHER|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
214935739|NCT00897962|OTHER|Non-cancer medical illness|One blood draw (2 teaspoons)
215073277|NCT04842630|DRUG|SHR-1916|All participants receive SHR-1906 alone
215073278|NCT02185430|DRUG|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
215073279|NCT02185430|DRUG|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
215073280|NCT04755166|PROCEDURE|Lateral ridge augmentation|
215073281|NCT05607082|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
214334942|NCT02993601|DEVICE|Water displacement method|This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
214334943|NCT02993601|DEVICE|Callipers measurements|This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
214334944|NCT02993601|DEVICE|Measuring tape|The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
214334945|NCT00944775|BEHAVIORAL|Exercise training|10-month exercise training program during hemodialysis sessions
214334946|NCT02453451|OTHER|2D-/3D-TTE|recording of 3 cardiac cycles
214334947|NCT02453451|OTHER|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
214334948|NCT02453451|OTHER|Walking Test|for 6 minutes
214334949|NCT02453451|PROCEDURE|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
214334950|NCT00123240|BEHAVIORAL|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
214334951|NCT00123240|BEHAVIORAL|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
214334952|NCT01747681|PROCEDURE|Microfracture|
214334953|NCT04741659|DEVICE|Ventimask|The patients will be asked to breathe spontaneously using their actual low oxygen flow
214334954|NCT04741659|DEVICE|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe using high flow nasal cannula (HFNC). Air flow will set up to 60 l/m, temperature according to patient's comfort and FiO2 in order to obtain SpO2 values \>/= 92%
214334955|NCT04741659|DEVICE|Helmet CPAP|The patients will be asked to breathe with Helmet. CPAP will set at 10 cmH2O and FiO2 in order to obtain SpO2 values \>/= 92%
214334956|NCT04741659|DEVICE|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
214334957|NCT01313234|BEHAVIORAL|Education|Theory based education and systematic daily assessment
214935740|NCT04346212|DIAGNOSTIC_TEST|Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)|We will assess dysphagia, nutritional status and needs of compensatory treatment (fluid and nutritional adaptation) in patients with COVID-19 disease. We will also collect clinical data, information about swallowing and nutritional status and needs through the electronical medical history of the patients and by telephone call at 3 and 6 months follow-up, as well as clinical complications.
214334958|NCT02366572|OTHER|Control|Non pulse extruded cereal
214334959|NCT02366572|OTHER|Pea protein|Pulse extruded cereal
214334960|NCT02366572|OTHER|Pea starch|Pulse extruded cereal
214334961|NCT02366572|OTHER|Pea fibre + pea starch|Pulse extruded cereal
214334962|NCT02366572|OTHER|Pea protein + pea starch|Pulse extruded cereal
214334963|NCT02366572|OTHER|Pea fibre + pea starch + pea protein|Pulse extruded cereal
215073282|NCT02125851|OTHER|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
215073283|NCT02125851|OTHER|Honey|esophageal mucosal contact time of honey vs sucralose slurry
214334964|NCT02139644|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
214334965|NCT02139644|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
214334966|NCT02139644|DRUG|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
214334967|NCT02139644|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
214334968|NCT02139644|DRUG|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
214334969|NCT05378867|BIOLOGICAL|TRS003|"* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period"
214334970|NCT05378867|BIOLOGICAL|China-approved Bevacizumab|• Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle
214334971|NCT05378867|DRUG|mFOLFOX6|"The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus."
214334972|NCT01123018|BEHAVIORAL|Memtrax Memory screening test|Memory Screening test
214935741|NCT02662400|BIOLOGICAL|MNCs|200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
214935742|NCT01778699|DIETARY_SUPPLEMENT|lozenges|"The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.~The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study)."
214935743|NCT04495816|DRUG|Omega-3 Fatty Acid Supplement|Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks. They will receive softgels containing 1,000 mg of omega-3 fatty acid. 1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid
214935744|NCT04495816|DRUG|Placebo/Control|Patients randomized to this arm will also be instructed to take two of the softgels they received per day for 6 weeks. They will receive placebo softgels that are indistinguishable from those containing fish oil.
214935745|NCT05399017|DEVICE|EZVent|EZVent Ventilator System is designed for respiratory support in hospitalized mechanical ventilated patients. The Ventilator is designed to be used for adults patients. It is designed to be a stationary product suitable for service in hospitals, critical care situations to provide continuous positive pres- sure respiratory support to the patient. The ventilator met EDA, ISO 80601-2-12 requirements on essential performance of critical care ventilator and other applicable international standards.
214935746|NCT04662788|DRUG|NK cells/Combined Monoclonal Antibodies|Each subject receive NK cells/Combined Monoclonal Antibodies
214935747|NCT02678585|DRUG|Nalbuphine|53 patients received intravenous regional lidocaine plus nalbuphine
214935748|NCT02678585|DRUG|Lidocaine|53 patients received intravenous regional lidocaine
214935749|NCT05448287|BEHAVIORAL|Health and family planning|Promotion of health and family planning behaviors
214334973|NCT02784314|PROCEDURE|Robotic-Assisted Radical Prostatectomy|
214334974|NCT02784314|PROCEDURE|Laparoscopic Radical Prostatectomy|
214334975|NCT05038059|DRUG|ethanolic extract of sapindus mukorossi|ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.
214334976|NCT05038059|DRUG|ethylene diamine tetra acetic acid|used as final endodontic irrigant in root canal therapy
214334977|NCT05897359|BEHAVIORAL|bCBTMI|This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.
214334978|NCT05897359|BEHAVIORAL|Control|The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
214334979|NCT03889717|DIETARY_SUPPLEMENT|vitamin D|vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age
214334980|NCT00760279|DRUG|Azithromycin|
214674231|NCT05573685|DEVICE|Placebo App|Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
214935750|NCT05448287|BEHAVIORAL|Nutrition|Promotion of maternal, infant, and young child feeding behaviors and nutrition
214935751|NCT05448287|BEHAVIORAL|Agriculture and homestead food production|Promotion of knowledge and practices about homestead food production
214935752|NCT05448287|BEHAVIORAL|Water, sanitation, and hygiene|Promotion of behaviors to improve water, sanitation, and hygiene
214674232|NCT01342640|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
215073284|NCT02512601|DRUG|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
214334981|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
214334982|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
214334983|NCT00045994|DRUG|ALT-711|
214334984|NCT05173467|PROCEDURE|Robot-assisted Invasion-controlled Surgery|The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
214334985|NCT05173467|PROCEDURE|Traditional-open Surgery|This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
214334986|NCT03102099|PROCEDURE|contrast-enhanced ultrasound group|The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
214334987|NCT03102099|PROCEDURE|conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
214935753|NCT03249597|DIAGNOSTIC_TEST|Blood test: Glukos, SuPAR, Laktat and HBP|"Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP."
214334988|NCT02588118|DRUG|propofol|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
214935754|NCT03889470|DRUG|NTG 1 MG/ML Injectable Solution|administered after sheath placement
214935755|NCT04891211|DIETARY_SUPPLEMENT|Vitamin D deficiency|Ocular significance of vitamin D deficiency in pediatric cases
214334989|NCT02588118|DRUG|Cisatracurium|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
214334990|NCT03508089|OTHER|Ocular fundus on patient with Multiple Sclerosis|Ocular fundus on patient with Multiple Sclerosis
214334991|NCT03508089|OTHER|Ocular Fundus on voluntary person|Ocular Fundus on voluntary person
214334992|NCT00002181|DRUG|Cidofovir|
214334993|NCT04245735|DIAGNOSTIC_TEST|perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.
214334994|NCT00672880|BEHAVIORAL|Self-System Therapy|12 sessions of structured Self-System Therapy
214935756|NCT02707315|DRUG|Gemcitabine|
214935757|NCT02707315|RADIATION|Stereotactic Radiosurgery|
214935758|NCT06477068|COMBINATION_PRODUCT|Mobile medical reminder application|"Experimental group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department, in addition to being supported through the telemedicine medication reminder app on smartphones.~Control group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department."
214935759|NCT00558896|DRUG|dexamethasone|40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
214935760|NCT00558896|DRUG|pomalidomide|2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
214935761|NCT01112410|OTHER|Hypertonic saline|"Hypertonic saline (6%) nebulised twice a day for 4 weeks.~(Randomised crossover trial)"
214674233|NCT04885738|OTHER|no intervention|"For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD."
214334995|NCT00672880|BEHAVIORAL|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
214334996|NCT00672880|OTHER|Standard Care|Study participants continue with their usual medical care, no changes.
214674234|NCT05399693|PROCEDURE|platelet transfusion|platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
214674235|NCT04918693|DEVICE|Ultrasound scanning|All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
214674236|NCT03863938|DRUG|Tegoprazan 50mg|K-CAB
214334997|NCT01010984|DEVICE|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
214334998|NCT02192684|DRUG|Pioglitazone|45 mg daily Insulin sensitizing
214334999|NCT02192684|DRUG|placebo|Compare with pioglitazone
214335000|NCT00608829|DEVICE|GORE TAG® Thoracic Endoprosthesis|Implant
214674237|NCT01745055|DRUG|CP-690,550 (tofacitinib)|CP-690,550 30 mg q12h for 5 days
214674238|NCT01745055|DRUG|Methotrexate (MTX)|individual dose of methotrexate (stably dosed)
214935762|NCT01112410|OTHER|Isotonic saline|Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.
214935763|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
214935764|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
214935765|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
214935766|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
214935767|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
214935768|NCT01168310|DRUG|Formoterol Fumarate|Inhalation Solution
214935769|NCT01168310|DRUG|Placebo|Inhalation Solution
214935770|NCT01759810|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
214935771|NCT01759810|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
214935772|NCT05410041|BIOLOGICAL|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/kg (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/kg (D-5\~D-3), determined by tumor burden at baseline.
214935773|NCT05964517|OTHER|Fascial Distortion Model|Facial Distortion is a manual therapy technique applied by model physiotherapists. It is a deep tissue massage to the fascial tissue.
214935774|NCT06119334|BEHAVIORAL|Online intervention|Phone counselling for 1 hour/week over 16 weeks and access to the online platform with health promotion materials (videos, text, audios)
214935775|NCT06620341|BEHAVIORAL|drug education|"* Training: Train emergency doctors every month on how to use antibiotic infusion reasonably; The prescription, cancellation, or method of use of antibiotics is decided by doctors.~  * Implementation of intervention cards: When the C-reactive protein (CRP) of patients is exceed 10mg/L, the doctor should determine whether to use antibiotics based on the clinical status of patients.~    * Promotion: Promote reasonably use of intravenous antibiotics through public accounts and posters.~      * Patient education: Distribute educational flyers to patients about how to use antibiotics reasonably."
214335001|NCT06463847|DRUG|UC-MSCs|"In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials."
214335002|NCT04098692|DRUG|Derazantinib capsule|300 mg derazantinib oral administration (3x100 mg capsules)
214335003|NCT04098692|DRUG|[14C]-Derazantinib solution for infusion|100 μg \[14C\]-derazantinib intravenous administration
214335004|NCT04098692|DRUG|[14C]-Derazantinib capsule|300 mg \[14C\]-derazantinib oral administration (3x100 mg capsules)
214335005|NCT01330940|DIETARY_SUPPLEMENT|Orange soda|32 ounces per day
214335006|NCT00310687|PROCEDURE|BLOOD DRAW|
214335007|NCT03531593|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
214335008|NCT02602288|BEHAVIORAL|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
214335009|NCT02602288|BEHAVIORAL|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
214335010|NCT02602288|BEHAVIORAL|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
214335011|NCT02602288|DEVICE|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
214335012|NCT02602288|DEVICE|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
214335013|NCT02602288|DRUG|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
214335014|NCT03874000|BIOLOGICAL|Sintilimab|Given IV
214335015|NCT03874000|DRUG|Metformin Hydrochloride|Given PO
214335016|NCT00185133|DRUG|Olmesartan medoxomil|
214335017|NCT00185133|DRUG|Amlodipine|
214335018|NCT01310413|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
214674239|NCT01065480|BEHAVIORAL|Live teleconference supervision|Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
214674240|NCT01065480|BEHAVIORAL|Taped Review Supervision|Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
214335019|NCT01310413|BIOLOGICAL|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
214335020|NCT02564471|DRUG|Chloroquine|FDA approve dosing schedule
214335021|NCT02564471|DRUG|Atovaquone and Proguanil|FDA approve dosing schedule
214335022|NCT02564471|DRUG|Doxycycline|FDA approve dosing schedule
214335023|NCT02564471|BIOLOGICAL|Rabies Vaccine|FDA approve dosing schedule
214335024|NCT04870567|RADIATION|Stereotactic ablative radiotherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
214335025|NCT04870567|RADIATION|High dose rate brachytherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
214335026|NCT04307758|OTHER|Muscle Strength Assesment-Make Test|For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
214674241|NCT01225783|OTHER|Self measurement of limb volume +water displacement|Comparison will be made between self measurement is two types of tape measure compared with water displacement
214674242|NCT04396912|PROCEDURE|Total thyroidectomy|Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
214674243|NCT04689646|BEHAVIORAL|Mind Body Intervention 1|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
214935776|NCT00150124|DRUG|MTZ+LT4|
214935777|NCT00150124|DRUG|Methimazole|
214335027|NCT04307758|OTHER|Muscle Strength Assesment-Break Test|For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
214335028|NCT01183091|PROCEDURE|Ablation of atrial fibrillation|Ablation of atrial fibrillation
214335029|NCT04502160|PROCEDURE|Vascular Access Creation|arteriovenous fistula creation
214335030|NCT00815126|PROCEDURE|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
214335031|NCT03724604|DIAGNOSTIC_TEST|Neuron-Specific Enolase to Albumin Ratio|Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
214335032|NCT02471924|OTHER|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
214335033|NCT03405467|OTHER|general and specific data|General and specific data collected
214674244|NCT04689646|BEHAVIORAL|Mind body intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
214674245|NCT02251223|DRUG|Tipranavir low dose|
214935778|NCT03509870|BIOLOGICAL|mesenchymal stromal cells|mesenchymal stromal cells in a collagen scaffold
214935779|NCT06620211|PROCEDURE|promontofixation, prolapse cure|Patient who underwent surgery to place the Sacromesh® medical device (promontofixation) for a prolapse cure, between 2009 and 2018
214935780|NCT01881997|DRUG|Fentanyl|Fentanyl Intramuscular (IM), 1ugm/kg, x1
214335034|NCT03141502|DEVICE|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
214335035|NCT03141502|PROCEDURE|Skin grafting|the standard technique of skin grafting after wound preparation.
214335036|NCT05745740|DRUG|RC48-ADC|RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
214335037|NCT05745740|DRUG|Pyrotinib|Pyrotinib 400 mg by oral once a day.
214674246|NCT02251223|DRUG|Tipranavir medium dose|
214674247|NCT02251223|DRUG|Tipranavir high dose|
214674248|NCT02251223|DRUG|Ritonavir low dose|
214674249|NCT02251223|DRUG|Ritonavir high dose|
214935781|NCT01881997|DRUG|Normal Saline|IM normal saline
214935782|NCT00463216|BEHAVIORAL|A multidisciplinary diagnostic evaluation|
214935783|NCT04399408|DEVICE|Obstetrics Ultrasound (non invasive)|Participants are instructed to preform 1-3 short (3 minuets) ultrasound scans a day according to pre-defined steps.
214335038|NCT04538014|DRUG|Lu AF88434|Oral solution
214335039|NCT04538014|DRUG|[11C]-Lu AF88434|\[11C\]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
214935784|NCT02160847|BEHAVIORAL|DRIVE Program|The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
214935785|NCT01971762|BEHAVIORAL|Follow recommendations based on scientific evidence to S. aureus bacteremia management|
214935786|NCT01971762|BEHAVIORAL|Not to follow recommendations based on scientific evidence to S. aureus bacteremia management|
214935787|NCT02550392|BEHAVIORAL|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
214935788|NCT04329091|DRUG|Dexmedetomidine|All subjects will receive Dexmedetomidine to induce sedation between their pre-sedation and post-sedation perceptual learning tests.
214935789|NCT02594189|OTHER|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
214935790|NCT05473689|DEVICE|Continuous positive airway pressure (CPAP) therapy|Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
214935791|NCT03122613|DIETARY_SUPPLEMENT|Curcumin|3g of Curcumin per day
214935792|NCT03122613|DRUG|Placebo|3g of Curcumin Placebo per day
214935793|NCT04649918|OTHER|pulmonary rehabilitation|COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
214935794|NCT03837119|OTHER|pregnancy outcome|descriptive statistics of variables
214935795|NCT01985438|PROCEDURE|percutaneous endoscopic gastrostomy tube placement|A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.
214935796|NCT01985438|PROCEDURE|nasogastric tube placement|All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
214935797|NCT06166043|BEHAVIORAL|NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION|An online training consisting of 10 sessions in total for 5 weeks will be given to the patients in order to improve their fatigue management skills. In addition to this training, they will receive a nurse support program.
214935798|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
214935799|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
214935800|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
214935801|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
214935802|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
214935803|NCT01527487|DRUG|Eribulin|1.4 mg/m2 IV (Days 1 \& 8), given short (≤15 minute) IV infusion, per institutional standard
214935804|NCT01527487|DRUG|Cyclophosphamide|Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
214935805|NCT01527487|DRUG|Docetaxel|Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
214935806|NCT00108342|DRUG|Nicotine gum - 2 mg and 4 mg|
214935807|NCT00108342|DRUG|Nicotine lozenges - 2 mg and 4 mg|
214935808|NCT00108342|DRUG|"Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing"|can yield 4 mg from 10 mg device - infrequent and frequent puffing
214935809|NCT00108342|OTHER|Computer learning|
214335040|NCT02731001|RADIATION|Proton therapy|
214335041|NCT02731001|RADIATION|Photon therapy|
214335042|NCT05251792|OTHER|Ocular examination|All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
214335043|NCT02805257|DRUG|Mitomycin-C|Intraoperative and postoperative injections of mitomycin-c/Mitosol
214674250|NCT04101422|BEHAVIORAL|Augmented Reality 1|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) and non-smoking related stimuli (pens, notebook, eraser).
214935810|NCT05631522|OTHER|foot reflexology|"Warm-Up Phase:~Pre-reflexology foot massage and all-over foot squeeze will be performed for two minutes.~Mini-Reflexology Session:~Specific reflexology will be performed with special attention to two important foot reflex areas that include:~Diaphragm and Solar Plexus Reflex Areas are located in the distance between the upper and middle third of the sole.~The Heart and Lung Reflex Areas are located below the chest of the foot. The heart pumps the oxygen-rich blood around the body"
214935811|NCT04147624|DRUG|Souvenaid|Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.
214674251|NCT04101422|BEHAVIORAL|Augmented Reality 2|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of smoking related AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.). They will also be presented with real smoking (e.g., ashtray) and non-smoking (e.g., pencil) items. Their urge to smoke rating following each presentation will be compared for AR images vs. vivo items, and smoking-related vs. non-smoking related.
214935812|NCT04147624|OTHER|Placebo|The Placebo used in this study is an oral beverage vitamin mixture containing Vitamins A, B1, B2, B3 and B5.
214935813|NCT02255136|OTHER|Individualized homeopathic medicines|5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year
214935814|NCT02255136|OTHER|Placebo|Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
214935815|NCT02283736|OTHER|Lactobacillus rhamnosus SP1|Tablet containing Lactobacillus rhamnosus SP1
214935816|NCT02283736|OTHER|Talc powder|Tablet containing talc powder
214935817|NCT02283736|PROCEDURE|Periodontal treatment|Scaling and root planning
214935818|NCT04970472|BIOLOGICAL|collection of blood, urines, stool and tumor samples|blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
214935819|NCT02326922|DEVICE|Metraplant-E levonorgestrel-releasing intrauterine device|Metraplant-E insertion and follow up for 6 months
214935820|NCT04042922|DEVICE|GENUS device (Active Settings)|Participants in the experimental group will use the GENUS device configured to active settings for 30 - 60 minutes.
214935821|NCT04042922|DEVICE|GENUS device (Sham Settings)|Participants in the control group will use the GENUS device configured to sham settings for 30 - 60 minutes.
214335044|NCT02805257|OTHER|Balanced Salt Solution|Intraoperative and postoperative injections of BSS
214335045|NCT02805257|PROCEDURE|Ahmed Glaucoma Valve Implant|Implantation of Ahmed Valve in study eye
214335046|NCT01621373|DRUG|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
214335047|NCT00905333|DRUG|Candesartan (test)|16 mg oral tablet, single dose
214335048|NCT00905333|DRUG|Felodipine (test)|5 mg oral extended release tablet, single dose
214335049|NCT00905333|DRUG|Candesartan Cilexetil|16 mg oral tablet, single dose
214335050|NCT00905333|DRUG|Felodipine|5 mg oral extended release tablet, single dose
214935822|NCT01491750|BEHAVIORAL|GUIDED IMAGERY|DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
214935823|NCT01491750|BEHAVIORAL|PLACEBO|DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
214935824|NCT02277158|DRUG|Chemoradiotherapy|S-1 CCRT
214335051|NCT00927446|PROCEDURE|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
214935825|NCT05984693|BEHAVIORAL|Video Assisted Instruction|Video Assisted Instruction
214935826|NCT03257878|OTHER|validated Korean version of the SF36 and EQ-5D|"This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS)."
214935827|NCT04695951|DIETARY_SUPPLEMENT|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
215073285|NCT02512601|OTHER|Compression therapy|"Compression:~* With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~* With a bandage: 7-10 m long and 10 cm wide.~* Both strategies (orthosis vs bandage) are equally applicable."
215073286|NCT02928029|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
215073287|NCT02928029|DRUG|Placebo|Matching placebo
214674252|NCT04101422|BEHAVIORAL|Augmented Reality 3|Participants will use an Augmented Reality )AR) application on smart phones in locations and situations where they typically smoke. the application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays). Participants will have a goal of using application at least 5 times per day for 7 days. Usage and rating data will be collected in real-time.
214674253|NCT04101422|BEHAVIORAL|Augmented Reality 4|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.) Their urge to smoke rating following each presentation will be compared from baseline urge to smoke. The post-test urge to smoke will be compared between control group and extinction group.
214674254|NCT02640612|DRUG|BI 695501|
214674255|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, low dose
214674256|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, high dose
214674257|NCT04824872|DRUG|Placebo|placebo for dasiglucagon
214674258|NCT06007430|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
214674259|NCT06007430|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
214674260|NCT03472534|DRUG|diacerein 1% ointment|diacerein 1% ointment applied to the skin of the infrascapular area of the back under occlusive patch for 21 days.
214674261|NCT03714412|DEVICE|Implantation|Implantation of the Cardiovalve transfemoral mitral valve replacement system
214674262|NCT00552305|DRUG|lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
214674263|NCT05197101|PROCEDURE|balloon catheter combined with oxytocin induction|Balloon catheter for 12 hours and oxytocin for up to 3days.If failed , they will be treated ceacrean.
215073288|NCT02928029|DRUG|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
214674264|NCT00005860|DRUG|floxuridine|
214674265|NCT00005860|DRUG|leucovorin calcium|
215073289|NCT02928029|DRUG|Dexamethasone|Dexamethasone is administered orally at 40 mg
214674266|NCT00005860|DRUG|oxaliplatin|
214335052|NCT05464147|DEVICE|DynamX Drug-Eluting Coronary Bioadaptor System|DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
214335053|NCT00452504|DRUG|SRA-444|
214335054|NCT01965067|DRUG|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state"
214335055|NCT01804959|DIETARY_SUPPLEMENT|Vivomixx probiotics|
214674267|NCT06293092|DEVICE|leg pedaling cycling device|Intradialytic aerobic cycling exercise program ,each patient will receive the treatment program three times per week for three months.
214674268|NCT06293092|DEVICE|sand bags|Intradialytic resistive exercise program , each patient will receive the treatment program three times per week for three months.
214674269|NCT06293092|DEVICE|hemodialysis sessions|hemodialysis sessions ,each patient will receive the treatment program three times per week for three months.
214674270|NCT05091801|BEHAVIORAL|Intervention|Participants will have one week of increased chewing time (chew food until they reach an apple sauce consistency)
214674271|NCT04820478|DIETARY_SUPPLEMENT|Beta Hydroxybutyrate Ester (KetoneAid KE4)|see arm/group description
214674272|NCT04820478|DIETARY_SUPPLEMENT|Placebo|see arm/group description
214674273|NCT03013751|DRUG|Udenafil|Active drug
214674274|NCT06274333|DRUG|Dexmedetomidine 0.5 mic/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,
215073290|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
215073291|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
215073292|NCT02609230|DRUG|ONC-201|
215073293|NCT00515294|DRUG|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
214335056|NCT05561998|DEVICE|TalkingMats|TalkingMats is a low-technology communication framework, to help people with communication difficulties to express their views. It uses a simple system of picture symbols, placed on a textured mat, that allow people to indicate their feelings about various options within a topic by placing the relevant image below a visual scale. Three sets of symbols are used, one set for the topics of the conversation, one set for the options within each topic and one set consisting of the value scale under which the options are placed.
214335057|NCT05561998|OTHER|Usual conversation method|The standard procedure during needs-assessment conversation and conversations planning the provision of home care services.
214335058|NCT05095480|DRUG|Red Yeast Rice Pill|Taking Lesstat
214335059|NCT05095480|DRUG|Placebo|Placebo receiving group
214335060|NCT01575340|DIETARY_SUPPLEMENT|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
214335061|NCT04660981|BEHAVIORAL|Antenatal education|Training Program on Fear of Childbirth Based on Motivational Interview Method
214335062|NCT04756219|OTHER|Contact Video|No additional information necessary.
214335063|NCT04756219|OTHER|Contact Text|No additional information necessary.
214335064|NCT04756219|OTHER|Education Video|No additional information necessary.
214335065|NCT04756219|OTHER|Education Text|No additional information necessary.
214335066|NCT03173222|PROCEDURE|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
214335067|NCT04599881|DRUG|PTR-01|IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
214335068|NCT02657850|OTHER|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
214935828|NCT04695951|OTHER|Placebo|A total of 35 patients treated with Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
214935829|NCT04723563|DRUG|Heparin|25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
214335069|NCT02657850|OTHER|head neck self reporting|head and neck patient self reports dysphagia symptoms
214335070|NCT02657850|OTHER|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
214335071|NCT04824547|OTHER|exercise|All exercises programs will applied two sessions per week, totally eight week..
214335072|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate|Zinc Picolinate (50 mg PO TID x 5 days)
214935830|NCT04723563|DRUG|0.9%sodium chloride|5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization
214674275|NCT06274333|DRUG|Tramadol 1mg/kg|Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
214335073|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2 grams po BID x 5 days
214335074|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate Placebo|Zinc Picolinate Matched Placebo PO TID x 5 days
214335075|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol Placebo|Resveratrol Matched Placebo PO BID x 5 days
214335076|NCT04527263|DIAGNOSTIC_TEST|measurement of urinary 5-HIAA|urinary assessment of 5-HIAA
214335077|NCT00209313|DRUG|Acyclovir|Acyclovir 800 mg twice daily or placebo
214335078|NCT03942718|OTHER|Exercise|Participants will obtain an individualized exercise program based on entrance examination on treadmill.
214335079|NCT03052985|PROCEDURE|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
214335080|NCT03735966|DRUG|Pyrotinib plus trastuzumab and docetaxel and carboplatin|pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles
214335081|NCT04557722|PROCEDURE|0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.
214335082|NCT04557722|PROCEDURE|New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
214674276|NCT06274333|DRUG|Paracetamol 10mg/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
214674277|NCT02542449|DIETARY_SUPPLEMENT|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
214674278|NCT02542449|DIETARY_SUPPLEMENT|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
214335083|NCT00030589|DRUG|bexarotene|
214335084|NCT00030589|DRUG|methoxsalen|
214335085|NCT00030589|PROCEDURE|UV light therapy|
214335086|NCT04593992|DEVICE|HTEMS|high-tone external muscle stimulation
214335087|NCT04593992|DEVICE|Placebo|Placebo stimulation
214335088|NCT02670590|BEHAVIORAL|diet|diet
214335089|NCT01690403|DRUG|rifapentine (M000473)|"Pharmaceutical form:tablet~Route of administration: oral"
214335090|NCT01690403|DRUG|EFZ EMT TDF|"Pharmaceutical form:tablet~Route of administration: oral"
214335091|NCT06069492|OTHER|Wheat-containing food|One daily serving of 38 grams wheat-containing pasta contains either 5000 mg wheat protein (standard-dose group) or 650 mg wheat protein and 4350 gluten-free flour (low-dose group)
214674279|NCT01947673|OTHER|Mindfulness Meditation|
214674280|NCT01947673|OTHER|Health Education|
214935831|NCT00273468|DRUG|Granisetron|
214935832|NCT00291772|DRUG|Pramlintide|Basal and bolus pramlintide subcutaneous infusion
214335092|NCT02033889|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
214335093|NCT02033889|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
214335094|NCT02033889|DRUG|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
214935833|NCT02865590|DEVICE|sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)|
214935834|NCT02865590|DEVICE|Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)|
214935835|NCT03295123|OTHER|phone interview with the mother|it's a telephone survey about children's health
214935836|NCT01270386|DRUG|apatinib|Apatinib 750 mg p.o. once daily
214335095|NCT02033889|OTHER|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
214335096|NCT02033889|DRUG|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
214935837|NCT01270386|DRUG|placebo|placebo p.o. once daily
214935838|NCT00667186|OTHER|Targeted Screening|Selection method for screening is based on risk
214935839|NCT00667186|OTHER|Routine Screening|Selection method for screening is not based on risk
214935840|NCT02258542|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously
214935841|NCT02258542|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously
214935842|NCT00986986|DRUG|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
214935843|NCT06154161|DIETARY_SUPPLEMENT|Whey protein supplement|A monthly supply of 35 g of whey protein isolate will be provided to participants in individual sachet packets with instructions of preparation. Every month, participants will come to the center to provide the standard monthly blood sample. At this time, the PI will have participants complete the quality-of-life instrument, ask if there have been any changes in their dietary habits, and collect weights for up to 6-months. Additionally, participants will indicate if they had consumed the protein daily and/or bring back their empty/full satchel packets. As this is a feasibility trial, it is necessary to determine the compliancy of consuming protein daily and the amount. Furthermore, understanding how protein markers may be affected by consumption of the protein daily vs less frequently throughout the week is important to establish improved recommendations for consumption of protein supplements.
214935844|NCT06514053|PROCEDURE|Full pulpotomy|A full pulpotomy will be performed by removing the entire roof of the pulp chamber and the remaining pulp tissue will be covered by Biodentine.
214335097|NCT02033889|BIOLOGICAL|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
214335098|NCT02033889|DRUG|Metformin|Metformin \>=1500 mg/day, orally, once a day
214335099|NCT04632446|OTHER|Early diagnosis|Early diagnosis. Upgrade program implementation.
214335100|NCT02507089|BEHAVIORAL|Tailored sleep health education materials.|Tailored sleep health materials.
214935845|NCT06514053|PROCEDURE|Root canal treatment|The regular procedure of root canal treatment will be performed on teeth with irreversible pulpitis
214935846|NCT01630408|DRUG|Paricalcitol|Paricalcitol oral capsules 1 mcg/day for 48 weeks
214935847|NCT00501124|DRUG|Clevudine|
214935848|NCT00501124|BIOLOGICAL|Purified hepatitis B surface antigen|
214335101|NCT02507089|BEHAVIORAL|Generic sleep health education materials.|
214335102|NCT03613857|DRUG|Clopidogrel|8 tablets 75 mg clopidogrel loading dose before PCI
214335103|NCT03613857|DRUG|Ticagrelor 90mg|2 tablets 90 mg brilique before PCI
214335104|NCT00297453|BEHAVIORAL|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
214935849|NCT04144036|BIOLOGICAL|Neihulizumab, 3 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
214935850|NCT04144036|DRUG|Neihulizumab, 6 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
214935851|NCT04144036|DRUG|Neihulizumab, 9 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
214935852|NCT04144036|DRUG|Neihulizumab|This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
214935853|NCT06618937|OTHER|Treatment medication withdrawal strategy|The study aims to compare early biomarkers-guided versus conventional unguided drugs withdrawal strategy.
214935854|NCT06895252|OTHER|Sham transplantation|Sham FMT will involve saline infusion via colonoscopy
214935855|NCT06895252|OTHER|Anti inflammatory diet|The modified diet plan will be given to each study participant
214935856|NCT06895252|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
214935857|NCT06895252|OTHER|Sham diet|Dietary counselling alone
215073294|NCT00515294|OTHER|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
215073295|NCT00515294|DRUG|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
215073296|NCT00515294|OTHER|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
214935858|NCT02550600|PROCEDURE|iLA activve treatment|"iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P\_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P\_peak - PEEP) ≤15 cm H2O and P\_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow)."
214935859|NCT02550600|PROCEDURE|Control group|"The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group."
214335105|NCT00297453|BEHAVIORAL|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
214335106|NCT00297453|BEHAVIORAL|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
214335107|NCT00977262|OTHER|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
214674281|NCT05934760|OTHER|High intensity interval training (HIIT)|"Each HIIT session last 15 minutes. Participants will be asked to measure their own heart rate during their rest periods and provided with an estimated max heart rate which they should be aiming to achieve within the final 2 exercises. Participants will be provided with a logbook to record the heart rate achieved in each exercise. The regimen will include:~* 2 min warm-up: jogging on the spot~* Each of the following exercises performed for 60seconds, interspaced by 90 seconds rest~  * Star jumps~ * Standing squats~ * On-the-spot sprints~ * Standing squats~ * Star jumps~* 2 min cool-down: jogging on the spot"
214674282|NCT05934760|OTHER|Resistance based training (RET)|"Each RET session lasts an estimated 20minutes. Participants will be provided with a set of resistance bands to provide resistance to their workout, and a logbook to record the number of repetitions and band used.~Each session will include:~* 2 min warm-up jogging on the spot~* 2 sets of 12-15 repetitions of:~* Squats~* Hip flexion~* Hip extension~* Hip abduction~* Seated row~* Bench press~* Lateral raises~* 2 min jogging on the spot cooldown.~Each exercise will be separated by 1-minute rest, with participants encouraged to workout to mild fatigue on their final repetition in each set. If able to perform more than the allocated maximum of 15 repetitions prior to fatigue, then participants will be informed to increase the resistance by using a tougher resistance band."
214935860|NCT02433925|DIETARY_SUPPLEMENT|Resveratrol|
214335108|NCT00977262|OTHER|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
214486378|NCT06795854|OTHER|Relaxation techniques|Relaxation techniques will include slow deep breathing and mindfulness meditation exercises. The breathing exercise will involve six cycles per minute, with a 4-second inhalation and a 6-second exhalation, repeated for 30 minutes, three sessions per week. Mindfulness meditation will include a stress and pain management program with sessions starting at 10-15 minutes and gradually increasing to 20-30 minutes, three times per week. Sessions will be conducted in a quiet, comfortable space, focusing on breath awareness, body scanning, thought observation, and optional loving-kindness meditation, concluding with a reflection period.
214935861|NCT02433925|DIETARY_SUPPLEMENT|Placebo|
214335109|NCT00977262|OTHER|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
214486379|NCT06795854|OTHER|Low fodmap diet|All groups will follow a low-FODMAP diet (LFD). The LFD will exclude foods that commonly aggravate IBS symptoms, such as those containing lactose (dairy), fructose (e.g., apples, pears), and sweeteners like sorbitol and xylitol. Female participants with a BMI of 25 to 29 will aim for a daily calorie intake of 1,800 to 2,200 calories, adjusted based on age, activity level, and metabolism, to maintain weight while managing IBS symptoms effectively.
214335110|NCT02843789|DRUG|Tocilizumab|
214335111|NCT02609126|DRUG|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
214335112|NCT02609126|DRUG|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
214335113|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (immediate group)|Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.
214335114|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period)|"Four week waitlist period during which participants receive treatment as usual. Following the waitlist period, participants will receive the telemedicine pain management intervention:~Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management."
214335115|NCT02676206|OTHER|Classical music|Classical music will be played over the headphones
214335116|NCT02934139|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
214335117|NCT02934139|OTHER|Placebo|Matched placebo
214335118|NCT05239806|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
214335119|NCT05239806|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
214335120|NCT05239806|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
214335121|NCT05239806|BIOLOGICAL|Comirnaty|Day 0; intramuscular injection
214335122|NCT05239806|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
214335123|NCT05449639|DEVICE|Relief implantation|The device will be implanted by endoscopic procedure by a standard resectoscope.
214935862|NCT06494410|PROCEDURE|High versus Low Fraction of Inspired Oxygen|to compare the effect of high oxygen fraction (FiO2 1.0) vs. low oxygen fraction (FiO2 0.4) on clinical outcome on intraoperative and postoperative atelectasis and PPC. We will asses the impact of FiO2, especially during RM, on atelectasis development, using modified LUSS in obese patients with atelectasis undergoing laparoscopic bariatric surgery.
214335124|NCT03540927|BEHAVIORAL|PM+ for entrepreneurs|The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
214335125|NCT03540927|OTHER|Cash transfer to the Entrepreneurs|The entrepreneurs in the control arm will receive cash transfer only for their businesses.
214335126|NCT05058274|DEVICE|Implant of the AT-TORBI 709 lens|Implant of the AT-TORBI 709 lens
214335127|NCT01031823|BEHAVIORAL|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
214335128|NCT01679119|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
214335129|NCT01679119|DRUG|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
214335130|NCT01679119|DRUG|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
214335131|NCT01679119|DRUG|Rituximab|Rituximab 375mg/m2 IV given day 1
214335132|NCT01679119|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
214335133|NCT01679119|DRUG|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
214335134|NCT05073536|DEVICE|mini-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
214335135|NCT05073536|DEVICE|normal-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
214674283|NCT00692705|DRUG|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
214935863|NCT05981261|OTHER|inducement of experimental pain|Inducement of experimental pain
214935864|NCT05408871|DRUG|adnectin 18F-BMS-986192 Head and Neck Cancer|Head and Neck Cancer: PET imaging will be performed after initial diagnosis and within 2 weeks of MRI or CT of the neck done as standard of care. MRI will include T1 weighted pre and post gadolinium spin echo, diffusion weighted imaging, and T2 weighted imaging. CT of the head and neck with contrast will be performed per standard clinical protocol. Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
214335136|NCT03936491|DRUG|Methylphenidate|Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
214335137|NCT03936491|DRUG|Atomoxetine|Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).\[6\] Use is only recommended in those who are at least six years old.\[6\] It is taken by mouth.\[6\]
214335138|NCT01091311|DEVICE|Blephasteam|Eye lid warming goggles
214674284|NCT00692705|DRUG|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
214674285|NCT01652677|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
214674286|NCT04706390|BIOLOGICAL|covid-19 vaccine|vaccination
214335139|NCT04488731|BEHAVIORAL|Normal BMI and moderate coffee consumption|Normal BMI and moderate coffee consumption
214335140|NCT04488731|BEHAVIORAL|Normal BMI and heavy coffee consumption|Normal BMI and heavy coffee consumption
214335141|NCT04488731|BEHAVIORAL|overweight and moderate coffee consumption|overweight and moderate coffee consumption
214335142|NCT04488731|BEHAVIORAL|overweight and heavy coffee consumption|overweight and heavy coffee consumption
214335143|NCT05083767|OTHER|Experimental|The study protocol of WBV includes twelve weeks of whole-body vibration training provided to the Type 2 diabetic patients. It was recommended to all participants that they follow their regular diet and medication during the training. Two sets of six 1-minute vibration squats were designed with 20 seconds of rest, 3 times weekly for a duration 12 weeks (total workout time 36 minutes a week), using a vertical vibration machine. The six static positions consisted of (a) a deep squat position (knee angle 900) (b) an elevated squat position (knee angle 1250) (c) an elevated squat position (with elevated heels) (d) a slight knee flexion1 (hand straps with shoulder bending) (e) a slight knee flexion (hand straps with shoulder abduction) and (f) a slight knee flexion 3 (hand straps with elbow flexion). The training load steadily increased from the initial vibration of 30 Hz and the platform amplitude was raised from 2 mm at week 1 to 40 Hz and from 4 mm at week 5 to the completion of training.
214335144|NCT05083767|OTHER|Control|The control group was advised to their normal physical activity level, diet, and medication.
214335145|NCT01899924|BEHAVIORAL|Event Related Potentials recording|
214335146|NCT01471535|DRUG|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
214335147|NCT01641887|OTHER|Decision Aid|Patients will use a decision aid administered on a computer.
214935865|NCT05408871|DRUG|adnectin 18F-BMS-986192 Brain Metastases|Brain Metastases: Recruited patients will undergo standard clinical MRI within 2 weeks prior to PET, including T1 weighted pre- and post-gadolinium spin-echo and gradient-echo imaging, diffusion weighted imaging, susceptibility weighted imaging (2D SWI), T2 weighted imaging, 3D FLAIR, and combined DCE and dynamic susceptibility contrast (DSC) perfusion (DCE perfusion will be performed first, DSC perfusion will utilize T2 spin echo images). DCE perfusion will be processed on syngo Tissue 4D software (Siemens). DSC perfusion will be processed with syngo MR Perfusion Engine (Siemens). Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
214935866|NCT00270270|DRUG|epoetin alfa|
214935867|NCT05005585|PROCEDURE|immediate implant|immediate implant placement with VST technique versus early implant placement with contour augmentation technique
214935868|NCT04373811|DIAGNOSTIC_TEST|Lung ultrasound|"Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax.~Lung Ultrasound Score (lung aeration) will be recorded using a convex probe with a transverse view. Presence of pleural thickening and subpleural consolidations will be recorded."
214935869|NCT04373811|DIAGNOSTIC_TEST|Muscle ultrasound|"Diaphragm ultrasound will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness and thickening and subcostal anterior view with convex probe to assess diaphragm excursion.~Thickness of vastus intermedius, rectus femori and tibialis anterior will be measured using ultrasound linear probe. Cross-sectionnal area and echogeneicity of rectus femori and tibialis anterior will be measured using ultrasound linear probe. Penation angle of rectus femori will be assessed using ultrasound linear probe."
214935870|NCT01344993|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
214935871|NCT03103373|DEVICE|Conventional monitor|Patients underwent non-cardiac surgery will be monitoring by regular monitors
214335148|NCT01361412|BIOLOGICAL|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
214335149|NCT01361412|BIOLOGICAL|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
214335150|NCT01877447|DEVICE|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
214335151|NCT03143829|OTHER|eSSET-CINV|This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
214335152|NCT02717949|DRUG|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
214335153|NCT02717949|DRUG|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
214335154|NCT02717949|DRUG|Ribavirin|ribavirin 1200 mg given orally in divided dose for those \>75kg and 1000 mg in divided dose for those \<75 kg.
214335155|NCT04101799|BEHAVIORAL|For Our Children's Sake|Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
214935872|NCT03103373|DEVICE|Echocardiography|Patients will be monitoring by regular monitors plus echocardiography
215073297|NCT01331382|DIETARY_SUPPLEMENT|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
214674287|NCT06498102|OTHER|Intermittent Fasting: Time Restricted Feeding During 6 Weeks|Thirty-one healthy, young males (age: 27.5±6 years, body mass: 76.5±8.4 kg, and maximal oxygen uptake \[V̇O2max\]: 43.9±6.6 mL/kg/min) were randomly assigned to either TRF (n=14) or control group (n=17). TRF group followed an 16:8 intermittent fasting diet program for 6 weeks. Body composition, insulin sensitivity, resting substrate oxidation, and fat oxidation during cycling at 40% V̇O2max were assessed before and after the diet program.
214674288|NCT03430882|DRUG|Carboplatin|Given IV
214674289|NCT03430882|DRUG|Paclitaxel|Given IV
214335156|NCT04101799|OTHER|Active control|Participating in everyday activities that may include parenting activities in the control prisons
214486380|NCT04506255|DEVICE|Silicone tape|Medical grade tape with silicone adhesive
214674290|NCT03430882|DRUG|Sapanisertib|Given PO
214674291|NCT01082913|DEVICE|SSE|Use of SSE or not use of SSE
215073298|NCT01331382|OTHER|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
214335157|NCT03529526|DRUG|KN046|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg."
214335158|NCT04971382|DRUG|Curcumin|Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
214335159|NCT01918345|BEHAVIORAL|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
214335160|NCT01918345|BEHAVIORAL|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
214335161|NCT03843502|DRUG|Kava Dietary Supplement|Participants will be given three 75mg kava capsules.
214335162|NCT04268017|DEVICE|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
214674292|NCT01883882|BEHAVIORAL|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
214674293|NCT02361749|DRUG|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
215073299|NCT00776672|DRUG|Fosinopril 40mg Tablets|
214674294|NCT02361749|PROCEDURE|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
215073300|NCT03335072|DRUG|Azithromycin|Mass Drug Administration
215073301|NCT01647243|OTHER|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
214335163|NCT00278707|DRUG|GTA: Glyceryltriacetate|
214335164|NCT03975348|DEVICE|High flow nasal cannula|High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
215073302|NCT01858142|BEHAVIORAL|Parental presence decision tool|
215073303|NCT01858142|BEHAVIORAL|Standard preparation|
214674295|NCT01819922|DRUG|PF-05175157|600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
214674296|NCT01819922|DRUG|Placebo|Placebo powder in capsule, one dose within 5 minutes prior to AM meal
214674297|NCT00084422|DRUG|lestaurtinib|Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
214674298|NCT00546819|BIOLOGICAL|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
214674299|NCT00546819|BIOLOGICAL|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
215073304|NCT00626509|DRUG|sunitinib malate|
214335165|NCT03975348|DEVICE|Continuous positive airway pressure|Positive airway pressure applied through a sealed face mask
214335166|NCT03975348|DEVICE|Facemask|Oxygen therapy through a conventional facemask
214335167|NCT00059657|DRUG|Ecraprost in lipid emulsion|
214335168|NCT03855722|PROCEDURE|RIPC|Remote Ischaemic Preconditioning
214335169|NCT03855722|PROCEDURE|Sham-RIPC|Sham procedure
215073305|NCT00626509|PROCEDURE|adjuvant therapy|
215073306|NCT00626509|PROCEDURE|neoadjuvant therapy|
215073307|NCT00626509|PROCEDURE|therapeutic conventional surgery|
215073308|NCT02471560|DRUG|dimethyl fumarate|As per the prevailing local label.
215073309|NCT02471560|DRUG|injectable MS DMT|As described above.
215073310|NCT02778555|BEHAVIORAL|Questionnaires|
215073311|NCT01829633|PROCEDURE|Physiotherapy|Shoulder physiotherapy with exercises
215073312|NCT06489184|DRUG|Zanubrutinib|patients with treatment naive or R/R CLL who treatment with Zanubrutinib
214935873|NCT06522282|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
214335170|NCT04352010|BEHAVIORAL|Res-Up!|Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
214335171|NCT04352010|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
214335172|NCT04352010|OTHER|Wait-Control Group|In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
214335173|NCT02886572|RADIATION|Stereotactic radiosurgery|Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
214335174|NCT00670124|DEVICE|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
214335175|NCT02873624|PROCEDURE|Laparoscopic cholecystectomy|
214335176|NCT00519480|DRUG|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
214335177|NCT00519480|DRUG|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
214335178|NCT00519480|DRUG|Placebo|Placebo will be available as an oral tablets.
214335179|NCT01176591|DRUG|Placebo session 1, Aprepitant session 2|placebo in session 1, Aprepitant 80 mg in session 2, oral administration.
214335180|NCT01176591|DRUG|Placebo session 1, Placebo session 2|Placebo, one per session, oral administration
214335181|NCT05395377|BEHAVIORAL|Registered Dietitian/Nutritionist|Participants received a FitBit Flex and Intensive Lifestyle Intervention coaching via telephone with Registered Dietitian/Nutritionist.
214335182|NCT05395377|BEHAVIORAL|Diabetes Prevention Program|Modified DPP group classes lead by a Registered Dietitian and Exercise Physiologist.
214335183|NCT05395377|BEHAVIORAL|Weight Watchers, Reimagined|Participants in this group were provided with an online access code to enroll in WW and could choose the format of their choice- group, online, and/or smartphone app.
214335184|NCT05395377|BEHAVIORAL|DPP or RDN Counseling + Medication|Participants met with a weight management specialist to receive weight loss medications, as well as, receiving either the DPP or Registered Dietitian coaching. Medications utilized in this study were Phentermine and Metformin. Metformin was prescribed if the participant could not tolerate Phentermine.
214335185|NCT05395377|OTHER|Bariatric Surgery Evaluation|Participants (BMI \> 40) were offered a consultation with the bariatric surgical program that requires lifestyle weight management during the first 6 months. Participants were also able to choose to receive one of the other 4 intervention options in the first six months prior to consideration for bariatric surgery.
214335186|NCT03229330|PROCEDURE|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
214335187|NCT03229330|COMBINATION_PRODUCT|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
214335188|NCT03286959|PROCEDURE|PCR with calcium hydroxide|
214335189|NCT03286959|PROCEDURE|PCR with RMGIC|
214335190|NCT03286959|PROCEDURE|PCR with direct composite|
214935874|NCT06522282|COMBINATION_PRODUCT|Standard stroke unit|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
214935875|NCT05757427|DEVICE|Wavelia #2|Patients who are eligible and consent to have an MBI breast scan procedure will be asked to confirm their willingness to participate on the day of the breast scan. The patient will first have an OBCD scan, to reconstruct the external surface of the breast with high-precision, measure the total volume and the vertical extent of the breast before the MBI scan. The MBI scan will be performed on both breasts. The process will include optimization of breast positioning and breast cleaning to remove any transition liquid remaining on the skin.
214335191|NCT01466816|DIETARY_SUPPLEMENT|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
214486381|NCT06755593|PROCEDURE|Electroacupuncture|We use acupuncture needles of size 0.30 \* 25 mm and electroacupuncture machine KWD808-1 manufactured by Gujin Greatwall (Frequency 100Hz)
214935876|NCT04009668|DRUG|adalimumab|Adalimumab will be dosed based on weight
214935877|NCT06126029|DRUG|Metformin 500 Mg extended release Oral Tablet|34 patients of experimental group will get metformin 500mg extended release oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.
214935878|NCT06126029|DRUG|Placebo oral tablet|34 patients of placebo group will get placebo oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.
214486382|NCT06755593|DEVICE|Intravenous laser|We use intravenous laser with the iBIO-ILIB He-Ne laser device Mini-630 with 635 nm wavelength manufactured by Vietnam Laser Technology Center.
214935879|NCT06569173|DEVICE|LaiKai anti-reflux ureteral stent|Ureteral stents are serving to support the ureter and facilitate urine drainage with an anti-reflux valve.
214935880|NCT06569173|DEVICE|LaiKai Ureteral Stent|Ureteral stents are serving to support the ureter and facilitate urine drainage.
214935881|NCT00847769|OTHER|High velocity, low amplitude stretch|This group (n=9) will receive talocrural traction manipulation. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
214935882|NCT00847769|OTHER|Slow, mobilization stretch|This group (n=9) will receive talocrural traction mobilization. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating investigator's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
214935883|NCT00847769|OTHER|Passive Positioning|This group (n=9) will receive the manual therapy control intervention. This will consist of the same patient and clinician preparation for the mobilization/manipulation techniques. However, a single standardized treating investigator will simply maintain passive ankle positioning for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force characteristic of the intervention received by the other 2 comparison groups.
214935884|NCT03573531|OTHER|Laboratory analysis|Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity
214935885|NCT03344692|DRUG|Alirocumab|prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution
214935886|NCT03344692|OTHER|Placebo|prefilled pen containing 1 ml of solution without Praluent
214935887|NCT05146544|OTHER|Heart Rate Recording|During the APA session, HR was digitized at 1Hz (using custo guard, Custo Med GmbH). The ratio between the APA session HR and exercise test HRpeak was used to assess the intensity of effort.
214935888|NCT04427163|GENETIC|Blood sample analysis|Nucleic acids sequencing, presence of proteins and metabolites.
214935889|NCT04427163|OTHER|Health status|Health status will be examined by a physician and subject will complete a health status questionnaire.
214935890|NCT04427163|OTHER|Race and ethnicity|Subject will complete race and ethnicity questionnaire to make sure subjects are from the Czech population.
214935891|NCT06647667|OTHER|HIITS|"Frequency: HIIT will be in 2 supervised sessions per week for 12 weeks on the treadmill.~session duration from 30-40 min including the waming up and cooling down Intensity: HIIT included 4 minute intervals aiming 60-85% of heart rate reserve"
214935892|NCT06647667|OTHER|MICT|"Frequency: Moderate continuous training is scheduled 2 times per week for 12 weeks.~Intensity: exercise had been applied on the treadmill with 40%-59% of heart rate reserve) session duration from 30-40 min including the warming up and cooling down"
214335192|NCT03431077|DRUG|Angiotensin II|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
214335193|NCT05466318|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
214335194|NCT05466318|DRUG|Cladribine|6 mg/m2 intravenously once daily @ Day -7 \~ -3
214935893|NCT05935163|PROCEDURE|Conventional therapy for hamstring tightness|Conventional Physical therapy will include TENS , hot pack , Hamstring self stretch , Calf self stretching , bridging exercise , piriformis stretch , prone on hands and prone on elbows.
214935894|NCT05935163|PROCEDURE|Bowen Technique|"Bowen Technique:~1. The patient will assume a full prone-lying position on the plinth.~2. Sequence of short gentle moves will be applied over hamstrings. Firstly, the thumbs will be placed on top of the hamstrings muscle and the tightness is assessed.~3. Then, the muscle will be hooked by the thumbs from its lateral edge. Then, gentle pressure will be applied to the point of resistance to challenge the muscle in medial direction, as the thumbs will be flattened in medial direction, the muscle will pluck under the thumbs.~4. First with the thumbs, then will be followed by the fingers. Often, the hands are placed with a distance of inch of space between the thumbs and fingers so that the hands performed the technique on the muscle easily.~5. The whole procedure will be repeated again. The treatment time for each session will be 20 minutes for each side."
214935895|NCT05935163|PROCEDURE|Dynamic Soft Tissue Mobilization (DSTM):|"1. To access the hamstring muscle group, the subject will be asked to attain prone position and deep longitudinal strokes will be applied to the entire muscle group. Once the specific area of hamstring muscle tightness will be located, the remaining treatment will be limited to this target area.~2. To execute the dynamic intervention, the subject will be requested to move in the supine position with the hip and knee flexed to 90 degree.~3. Deep longitudinal strokes will be applied in a distal to proximal direction to the area of hamstring tightness and the leg will be passively moved to knee extension. Five strokes will be applied and 20 seconds of shaking is performed at the completion of this technique.~4. This treatment will be given for 20 minutes on each side."
214935896|NCT00581347|OTHER|outreach services|Tracking/reminder/recall/home visit strategy.
214335195|NCT05466318|DRUG|Gemcitabine|2500 mg/m2 intravenously @ Day -7, -3
214335196|NCT05466318|DRUG|Busulfan|3.2 mg/kg intravenously once daily @ Day -7 \~ -4
214335197|NCT05466318|DRUG|Carmustine|300 mg/m2 intravenously @ Day -8
214335198|NCT05466318|DRUG|Etoposide|200 mg/m2 intravenously once daily @ Day -7 \~ -4
214335199|NCT05466318|DRUG|Cytarabine|400 mg/m2 intravenously once daily @ Day -7 \~ -4
214335200|NCT05466318|DRUG|Melphalan|140 mg/m2 intravenously @ Day -3
214335201|NCT05466318|PROCEDURE|Autologous hematopoietic stem cell transplant|autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy
214935897|NCT03186274|BEHAVIORAL|Facilitated Group Session|Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.
214335202|NCT00520416|PROCEDURE|Carbon dioxide angiogram|see description of procedure
214335203|NCT06282627|OTHER|Observational study|No intervention. Observational study
214335204|NCT00357864|DRUG|carbachol|
214335205|NCT05836038|BEHAVIORAL|Visio-Tactile Stimulation|They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
214335206|NCT04812353|OTHER|Follow-up of Io-Fix type fixation|Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
214335207|NCT00000571|DEVICE|ventilators, negative pressure|
214335208|NCT03412643|DRUG|Doxorubicin|60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
214335209|NCT03412643|DRUG|Cyclophosphamide|600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
214335210|NCT03412643|DRUG|Weekly Paclitaxel|80 mg/m2 IV weekly for 12 doses
214335211|NCT03412643|DRUG|Trastuzumab|loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4
214335212|NCT03412643|DRUG|Pertuzumab|loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4
214335213|NCT03412643|DIAGNOSTIC_TEST|Celcuity CELx HSF|Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
214935898|NCT03186274|BEHAVIORAL|CELA Session|Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
214935899|NCT03391544|PROCEDURE|V4c toric ICL implantation surgery|The size and power of the V4c toric ICL were determined following the manufacturer's guidelines using a modified vertex formula. Emmetropia was the target refraction following surgery in all cases. Before surgery, three centration points were marked using the slit lamp while the patient, in sitting position, fixated on the center of the slit-lamp beam, which was narrowed as much as possible.
214935900|NCT04183140|PROCEDURE|primary percutaneous coronary intervention|primary percutaneous coronary intervention via transulnar or transradial access
214935901|NCT05688033|RADIATION|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
215073313|NCT01179217|DRUG|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
215073314|NCT01179217|DRUG|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
215073315|NCT02112474|DEVICE|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
214335214|NCT01347021|PROCEDURE|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
214335215|NCT00982319|DRUG|Broccoli sprout extract|100 µmols of sulforaphane (dissolvable)
214335216|NCT00982319|DRUG|Mango juice|150 mL of mango juice
214335217|NCT06573515|DEVICE|high tone power therapy|female patients will receive high-tone power therapy using a device (HiTop 191 Medizintechnik, Rimbach, Germany) duration 30 minutes at 2 sessions per week for 6 weeks
214335218|NCT06573515|DEVICE|interferential current therapy|female patients will receive interferential current therapy using Enraf-Nonius (ENDOMED 484, Germany)The electrode pairs will placed at a distance of at least 2.5 cm from each other. The utilized parameters will have a base frequency of 4,000 Hz, a modulation frequency range of 10 Hz-20 Hz, spectrum mode triangular, and slope 1/1 in a quadripolar manner with a beat frequency of 80 Hz. duration of treatment session 20 minutes 2 sessions per week for 6 weeks
214335219|NCT06573515|DEVICE|conventional physical therapy|female patients will receive conventional physical therapy modalities in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
214335220|NCT01892475|BEHAVIORAL|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~1. Accurately predicting step target attainment the following months (SGD10)~2. Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
214335221|NCT01892475|BEHAVIORAL|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
214335222|NCT01922596|DRUG|Ropivacaine|
214335223|NCT01922596|DRUG|Placebo|
214335224|NCT03847181|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban at a dose of 15 or 20 mg once daily
214335225|NCT03847181|DRUG|Apixaban (Eliquis)|Apixaban at a dose of 2.5 or 5 mg twice daily
214335226|NCT03847181|DRUG|Warfarin|Warfarin dose as prescribed by medical practitioner
214335227|NCT03084328|DIETARY_SUPPLEMENT|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
214335228|NCT00000465|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
214335229|NCT00000465|PROCEDURE|coronary artery bypass|
214335230|NCT02479425|PROCEDURE|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
214335231|NCT04025918|DEVICE|Vasopressor automated delivery system|"Novel closed-loop system incorporating:~1. Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~2. Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~3. Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm."
214935902|NCT03109665|DIAGNOSTIC_TEST|SD-OCT Angiography|SD-OCT Angiography
214335232|NCT04025918|DRUG|Phenylephrine|Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
214335233|NCT04025918|DRUG|Ephedrine|Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
214935903|NCT03109665|DIAGNOSTIC_TEST|SD-OCT|SD-OCT
214935904|NCT06561360|DRUG|Vemurafenib|Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.
214935905|NCT06561360|DRUG|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.
214935906|NCT06561360|DRUG|Cladribine|Cladribine IV on days 1-5 concurrently with rituximab.
215073316|NCT02112474|DEVICE|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
214335234|NCT04025918|DEVICE|Manual vasopressor delivery system|"Manual dosing system consisting:~1. Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~2. Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm."
214335235|NCT03704545|OTHER|Pharmaceutical consultation at the hospital|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
214935907|NCT06561360|DRUG|Rituximab|Rituximab on days 1-5 concurrently with rituximab.
214935908|NCT04054973|DRUG|L-arginine|6000mg of L-arginine daily for 14 days
214935909|NCT04054973|DRUG|Sapropterin Dihydrochloride|800mg of Kuvan daily for 14 days
214335236|NCT03704545|OTHER|Pharmaceutical consultation at the pharmacy|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
214486383|NCT06754969|PROCEDURE|Peripheral Nerve Regenerative Interface (RPNI) and Nerve/Muscle Biopsy|RPNI is a surgical technique which wraps denervated muscle targets around severed nerve ends.
214486384|NCT06754969|PROCEDURE|Biopsy Alone|Sural nerve and muscle biopsy performed in the standard fashion.
214674300|NCT04547296|DRUG|Sodium Bicarbonate Ringer's Solution|After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.
214935910|NCT04648982|OTHER|Admission to inpatient psychiatric unit|All persons in the study are hospitalized at the only inpatient mental health hospital in Rwanda - Ndera. Data will be collected when the person is being discharged.
214935911|NCT05896462|OTHER|10% povidone iodine|The apposed skin edge was covered with 10% povidone iodine-soaked gauze dressing
214935912|NCT04092673|DRUG|eFT226|eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
214935913|NCT04092673|DRUG|Sotorasib|Recommended dosage: 960 mg orally once daily
214935914|NCT04092673|DRUG|Fulvestrant|500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter
214935915|NCT04092673|DRUG|Abemaciclib|Dose in combination with fulvestrant: 150 mg twice daily
215073317|NCT02112474|DEVICE|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
215073318|NCT01849575|BEHAVIORAL|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
215073319|NCT04597216|DEVICE|sample of blood and saliva|sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
215073320|NCT01887613|DRUG|Regnite|oral
215073321|NCT01713673|DRUG|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
215073322|NCT01713673|DRUG|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
214935916|NCT04092673|DRUG|Trastuzumab|600 mg every 3 weeks
214674301|NCT05646641|OTHER|Strength exercise|The protocol consists of 8 weeks of training, consisting of 16 sessions of 50 minutes, twice a week on alternate days.
214335237|NCT03704545|OTHER|Follow-up pharmaceutical consultation at the pharmacy|During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
214335238|NCT01923181|DRUG|semaglutide|Once-daily oral administration as tablets.
214935917|NCT00070382|DRUG|darbepoetin alfa|darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period
214935918|NCT00070382|DRUG|epoetin alfa|epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
214674302|NCT03048721|PROCEDURE|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
214935919|NCT03628989|BEHAVIORAL|Use of Virtual Technology|If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
214935920|NCT03931772|BEHAVIORAL|Automated Self-Hypnosis|Self-Hypnosis will be delivered through an interactive application administered through Amazon Alexa or Reveri.com.
214935921|NCT05115227|BEHAVIORAL|Education|The team will educate the patient about low back pain and how this can be self-managed.
214935922|NCT05115227|BEHAVIORAL|Exercise|The team will advice the patient to conduct relevant exercises and to stay physical active.
214935923|NCT06144320|OTHER|Acupuncture|Acupuncture is performed using acupuncture points recorded in traditional Chinese medicine books as helpful for cognitive impairment.
214935924|NCT02814227|DEVICE|Zansors® sleep screening device|Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
214935925|NCT03589976|DRUG|Sirolimus 2 MG|Dose will be adjusted throughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose will be 6mg/day.
214335239|NCT01923181|DRUG|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
214935926|NCT03589976|OTHER|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
215073323|NCT04659174|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
215073324|NCT04945850|PROCEDURE|routine care intraocular sx|Fluid was collected during routine intraocular surgery
214335240|NCT01923181|DRUG|oral placebo|Once-daily oral administration as tablets.
214335241|NCT00279123|DRUG|pantoprazole infusion|
214335242|NCT00279123|DRUG|pantoprazole bolus|
214674303|NCT03048721|PROCEDURE|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
214674304|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with a marked tip
214674305|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with an unmarked tip
214335243|NCT00279123|DRUG|no treatment|
214335244|NCT06205511|DIAGNOSTIC_TEST|Oral HPV Sample|The study participant will be asked to provide an oral swish and spit sample. This sample collection will follow the procedure published by (Herrero et al 2013). The specimen is collected by a 15-second rinse followed by a 15-second gargle using 15 ml of an alcohol-based mouth wash such as a commercially available product, Scope. The 15-ml samples will then be stored at -20 and then shipped on dry ice to Dr. Anna Giuliano's laboratory in Tampa Florida for HPV testing. At present Dr. Giuliano's laboratory is using the DDL SPF10 LiPA assay for sample analysis. An oral exam will be performed for each patient by the Vivent Dentist within 30 days of the collection of the HPV sample. If a referral is needed to an oral surgeon or Ears, Nose, and Throat specialist this will be done within 60 days of the dentist visit. The HPV results will not be shared with the participants as these are research study results and not part of standard of care.
214335245|NCT06461104|BEHAVIORAL|Structured Physical Activity Programme|A somatic examination will also be conducted by a sports physician, which will include the assessment of muscle strength, cardiorespiratory fitness, walking gait, blood pressure, and body mass index (BMI). Based on this evaluation, the sports physician will design a personalised physical activity programme for the participants in the intervention group.
214335246|NCT06461104|BEHAVIORAL|Psychoeducational Programme|The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.
214335247|NCT00295672|DRUG|Vinorelbine|
214935927|NCT01780402|BEHAVIORAL|Hand feeding techniques|"Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.~Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.~Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position."
214935928|NCT05854303|BEHAVIORAL|Opioid cessation|opioid cessation will occur during pain rehabilitative program over approximately 3 weeks
214935929|NCT05854303|OTHER|No opioid cessation|Subjects will not stop taking opioids
214486387|NCT06754228|DIETARY_SUPPLEMENT|Probiotic Agent|Bacillus coagulans JBI-YZ6.3 (BC4U)
214486388|NCT06754228|DIETARY_SUPPLEMENT|Probiotic Agent|An escalating dose cross-over design: Participants are fed 0 mg, 100 mg, 200 mg, and 400 mg on different clinic visits.
214486389|NCT06840353|OTHER|Experimental group (Pecha Kucha training)|Ventrogluteal injection training given to students using the Pecha Kucha training method
214486390|NCT06019728|DRUG|AGALSIDASE BETA (GZ419828)|Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
214486391|NCT06019728|DRUG|Acetaminophen|Tablet or solution; Oral
214486392|NCT06019728|DRUG|Diphenhydramine|Tablet or solution; Oral
214486393|NCT06019728|DRUG|Dexamethasone|Tablet or solution; Oral
214486394|NCT06019728|DRUG|Montelukast|Tablet or chewable tablet or oral granules; Oral
214335248|NCT01863446|DEVICE|Lighting1|Ocular light exposure to a red wavelength light
214335249|NCT01863446|DEVICE|Lighting2|Ocular light exposure to a blue/green wavelength light
214486395|NCT06019728|DRUG|Loratadine|Tablet or chewable tablet; Oral
214486396|NCT06019728|DRUG|Cetirizine|Tablet or oral solution; Oral
214486397|NCT06019728|DRUG|Fexofenadine|Tablet or oral suspension; Oral
214486398|NCT05699018|DIAGNOSTIC_TEST|eLIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry ≥ 8 kPa and \< 15 kPa)
214486399|NCT06769113|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214335250|NCT04993352|DRUG|recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
214935930|NCT02900105|DRUG|Letrozole|Letrozole 2.5mg (1 tablet) once a day for 4 months
214935931|NCT06558747|PROCEDURE|Tooth Preperation|After the caries were removed, the teeth were prepared by shaving according to the manufacturer's recommendations for NuSmile ZR.
214935932|NCT06558747|PROCEDURE|Cementation|Pediatric zirconia crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
214935933|NCT00346047|DRUG|Placebo|Corresponding placebo is applied for 12weeks
214674306|NCT03088904|BIOLOGICAL|FluMist® Quadrivalent|LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
214674307|NCT03088904|BIOLOGICAL|Fluzone® Quadrivalent vaccine|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
214674308|NCT00282958|DRUG|Botulinum Toxin type a (Botox)|
215073325|NCT04077996|DEVICE|Peritonitis treatment placed in APD|Antibiotic treatment of peritontiis placed in bags of Automated peritoneal dialysis.
214674309|NCT04825093|DIETARY_SUPPLEMENT|Vitamin D supplementation in pregnant women|Intervention group will be administered 1,000 UI of vitamin D and a control group will be administered 400 UI of vitamin D. Participants will take the supplementation from the enrollment to delivery.
214674310|NCT05967234|BEHAVIORAL|Telehealth solution|Telehealth solution offered for breastfeeding education.
214674311|NCT03476018|DRUG|Z-100|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
214674312|NCT03476018|DRUG|Placebos|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
214335251|NCT06133621|OTHER|dosage dRVVT|Blood test dRVVT assay on two tubes of blood in the haemostasis laboratory of the Center de Biologie et de Pathologie Est
214335252|NCT03993418|DIETARY_SUPPLEMENT|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
214335253|NCT04725175|DRUG|PIPE-307|Single and multiple ascending oral doses of PIPE-307 tablets
214335254|NCT04725175|DRUG|Placebo oral tablet|Single and multiple ascending oral doses of matching Placebo tablets
214335255|NCT05571501|DEVICE|Gait assessment using the GAITRIte walkway|10-20 walking assessment using the GAITRite walkway
214335256|NCT01738152|OTHER|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
214335257|NCT01738152|BEHAVIORAL|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
214335258|NCT04401124|OTHER|no intervention|no intervention
214335259|NCT02312310|DIETARY_SUPPLEMENT|Cocoa Flavanol|12 weeks administration of cocoa flavanol
214335260|NCT01702792|BIOLOGICAL|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
214335261|NCT00094380|DRUG|CTLA4-IgG4m (RG2077)|
214335262|NCT00094380|DRUG|Cyclophosphamide|
214935934|NCT00346047|DRUG|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
214935935|NCT06624098|PROCEDURE|Early TIPS|TIPS was performed within 72 hours after the endoscopic hemostasis.
214935936|NCT04662528|DRUG|Placebo|4 x 1g capsules/day
214935937|NCT04662528|DRUG|MAT9001 (omega-3 pentaenoic acid)|4 x 1g capsules/day
215073326|NCT04077996|DEVICE|Peritonitis treatment with one exchange in CAPD|Antibiotic treatment of peritontiis placed in one bag of Continuos ambulatory peritoneal dialysis per 6 hours each day.
215073327|NCT03824678|DRUG|CC-220|CC-220
215073328|NCT01532284|OTHER|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
215073329|NCT01945411|DEVICE|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
214935938|NCT03454828|DIETARY_SUPPLEMENT|obese carbohydrate diet|The experimental diet will consist of 30% carbohydrates (CHO), 35% protein, and 35% fat. Since the experimental diet is lower in CHO, the fiber and sugar content will be calculated based on total CHO in the same percentage as the control (0.25 g fiber per each kcal of CHO and 18.2% sugar for total CHO).
214935939|NCT03454828|DIETARY_SUPPLEMENT|lean carbohydrate diet|The control diet composition will follow the American Dietary Guidelines of 55% carbohydrates (CHO), 15% protein, and 30% fat. CHO content will be primarily complex CHO of high quality (14 g fiber/1,000 kcals and \<10% of total kcals in the form of sugar).
214935940|NCT06064838|DIETARY_SUPPLEMENT|Flavonoids|1 capsule every 12h for 90 days
214935941|NCT06124027|DEVICE|Monitoring tcPCO2 and mitoPO2|Monitoring tcPCO2 using SenTec and mitoPO2 using COMET
214935942|NCT00774527|DRUG|Cyclophosphamide-fludarabine-anti thymocyte globulin|"* Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~* Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~* Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2."
214935943|NCT06602427|OTHER|Shoulder proprioception measurement using isokinetic dynamometer|A Cybex brand isokinetic dynamometer \[Cybex NORM®, Humac, CA, USA\] was used for shoulder proprioception assessment. Active Joint Position Sensation (AJPS) was evaluated to examine proprioception. AJPS was measured in the sitting position. The target angle was 30° external and 30° internal rotation. The participant was positioned with the elbow in 90° flexion and the wrist in the neutral position. The dynamometer was fixed at 0° to ensure the same starting position for each participant during trials and evaluations. Before starting the test, 3 trials were performed and then the participants were asked to find the target angle 3 times. The amount of error between the target angle and the angle found by the participant was used to describe the accuracy of the AJPS. The arithmetic mean of the result of the 3 tests was recorded for use.
214935944|NCT01601327|DRUG|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
214935945|NCT01601327|DRUG|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
214935946|NCT01601327|DRUG|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
214935947|NCT00163982|DRUG|Norfloxacin|
214935948|NCT01875627|DIETARY_SUPPLEMENT|Konjac noodles|Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
214935949|NCT01875627|DIETARY_SUPPLEMENT|Carbohydrate and Konjac Noodles|
214674313|NCT04686734|OTHER|No active intervention (observational only)|No active intervention (observational only)
215073330|NCT01945411|DEVICE|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
215073331|NCT06362473|DRUG|Lipid-lowering treatments|
215073332|NCT05718167|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
215073333|NCT05718167|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
215073334|NCT05718167|DRUG|Tislelizumab injection|Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
214674314|NCT01386099|DRUG|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
214335263|NCT03333005|DRUG|APX001 with Standard of Care anti-fungal agent|safety assessment
214335264|NCT00927017|OTHER|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
214674315|NCT01386099|DRUG|Placebo|Placebo twice a day for 12 weeks.
214935950|NCT01875627|DIETARY_SUPPLEMENT|Carbohydrate noodles|
214935951|NCT01003704|PROCEDURE|Lower extremity amputation|
214935952|NCT05737576|DRUG|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.
214935953|NCT05737576|DRUG|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.
214935954|NCT05737576|DRUG|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.
214935955|NCT05737576|DRUG|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.
214935956|NCT05737576|DRUG|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 3. NovoRapid®, administered subcutaneously in dose 3.
214335265|NCT00927017|OTHER|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
214335266|NCT04575402|OTHER|Wearable Activity Monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
214335267|NCT02571894|OTHER|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
214335268|NCT03603964|DRUG|Guadecitabine|Guadecitabine
214935957|NCT05737576|DRUG|HR011408 injection; NovoRapid®|NovoRapid®, administered subcutaneously in dose 3. HR011408 injection, administered subcutaneously in dose 3.
214935958|NCT03062527|OTHER|Dietary Intervention: Low vs. moderate glycemic index|
214935959|NCT04441840|DIETARY_SUPPLEMENT|Active Probiotic Culture|Both conditions matched in appearance and serving size
214935960|NCT04441840|DIETARY_SUPPLEMENT|Inactive Probiotic Culture|Both conditions matched in appearance and serving size
214935961|NCT00514904|BIOLOGICAL|Nimenrix|Single dose, intramuscular injection
214935962|NCT00514904|BIOLOGICAL|Mencevax|Single dose, subcutaneous injection
214935963|NCT00001044|BIOLOGICAL|Aluminum hydroxide|
214935964|NCT00001044|BIOLOGICAL|QS-21|
214935965|NCT00001044|BIOLOGICAL|rgp120/HIV-1MN|
214935966|NCT01486472|DRUG|S-1|Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
214935967|NCT01687569|OTHER|Control Cracker Snack|Base cracker snack
214935968|NCT01687569|OTHER|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
214935969|NCT01687569|OTHER|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
214935970|NCT01562301|DRUG|Carboplatin|AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.
214935971|NCT01562301|DRUG|Docetaxel|75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.
214674316|NCT05933291|DRUG|steroid|Moderate- or high-dose steroids
214674317|NCT00055419|BIOLOGICAL|Cetuximab|400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
214674318|NCT04399967|BEHAVIORAL|Chat-based support|Participants will receive three months of chat-based support through IM apps (e.g. WhatsApp, WeChat). The regular messages and instant messaging on psychosocial support aim to provide hygienic advice to reduce the risk of exposure to SARS-cov2, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
214674319|NCT04399967|BEHAVIORAL|AWARD plus COVID-specific advice|Ask about smoking history, Warn about the risks associated with the COVID-19 and smoking (with a COVID-related health warning leaflet), Advise to quit as soon as possible during the COVID-19 pandemic, Refer smokers to SC services (with a referral card, see below for information), and Do it again: to repeat the intervention
214935972|NCT01562301|DRUG|Anvirzel|"Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.~Expansion Cohort Starting Dose: Maximum tolerated dose from"
214935973|NCT01562301|BEHAVIORAL|Questionnaires|Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
214935974|NCT02580669|OTHER|Neuropsychological assessment|A neuropsychological assessment is done
214335269|NCT00563797|DRUG|Mecamylamine|mecamylamine 10mg/day for 12 weeks
214335270|NCT00563797|DRUG|Placebo|Placebo pill
214335271|NCT04317586|DEVICE|Trident II Tritanium Acetabular Shell for Revision|A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
214335272|NCT02341196|PROCEDURE|CEA|Patients in both groups received an intra-operative angiography
214335273|NCT05809895|DRUG|Ociperlimab|900 mg intravenously (IV) every 3 weeks (Q3W)
214335274|NCT05809895|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
214335275|NCT05809895|DRUG|Paclitaxel|90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
214335276|NCT05809895|DRUG|Nab-paclitaxel|100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
214335277|NCT05809895|DRUG|Carboplatin|AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
214335278|NCT05809895|DRUG|Placebo|normal saline intravenously (IV) Q3W
214335279|NCT05809895|DRUG|Pembrolizumab|200 mg intravenously (IV) Q3W
214335280|NCT05809895|DRUG|Gemcitabine|1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
214335281|NCT00901329|DEVICE|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
214335282|NCT00901329|DEVICE|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
214486400|NCT06769113|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214935975|NCT02580669|OTHER|Neurologic consultation|A neurologic consultation is done
214935976|NCT02580669|OTHER|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
214935977|NCT03465501|RADIATION|Brachytherapy|Brachytherapy
214935978|NCT02557204|PROCEDURE|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
214935979|NCT02557204|PROCEDURE|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
214935980|NCT02557204|PROCEDURE|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
214935981|NCT02557204|PROCEDURE|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
214935982|NCT00721344|DRUG|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
214935983|NCT00721344|DRUG|Moxifloxacin|Tablets 400mg
214335283|NCT00807092|DRUG|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
214935984|NCT00721344|DRUG|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
214935985|NCT00721344|DRUG|Placebo|Placebo cartridges
214935986|NCT03820219|DEVICE|Prevena™ system|The Prevena™ System acts by removing exudate from a clean, closed incision. It helps hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
214935987|NCT03820219|OTHER|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room.
214935988|NCT02247635|BEHAVIORAL|Healthy lifestyle and adherence|"Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake \<30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.~The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care"
214935989|NCT06620224|DEVICE|Virtual Reality|we only use single group in this study, before the acupuncture treatment, let the participant wear the virtual reality to realize the course of the acupuncture treatment
214935990|NCT06620484|DEVICE|Musculoskeletal Ultrasound with elastography|Musculoskeletal Ultrasound with elastography
214935991|NCT03430895|DRUG|durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.
214935992|NCT00084318|BIOLOGICAL|cetuximab|400 mg/m\^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m\^2 intravenously over 60 minutes in weeks 2 through 7.
214935993|NCT00084318|DRUG|cisplatin|30 mg/m\^2 intravenously infused over over 60 minutes in weeks 2 through 7.
214935994|NCT00084318|DRUG|docetaxel|15 mg/m\^2 intravenously infused over 30 minutes in weeks 2 through 7.
214935995|NCT00084318|RADIATION|radiation therapy|60 Gy (2 Gy once a day, 5 times a week)
214935996|NCT06575179|DRUG|Dexmedetomidine low-dose|The low-dose dexmedetomidine group received a 75 μg/h loading dose over 15 minutes, followed by 60 μg/h maintenance infusion intravenously.
214935997|NCT06575179|DRUG|normal Saline|The control group received volume-matched 0.9% saline infusions at identical rates.
214935998|NCT06575179|DRUG|Dexmedetomidine high-dose|The high-dose dexmedetomidine group received a 150 μg/h loading dose over 15 minutes, followed by 120 μg/h maintenance infusion intravenously.
214674320|NCT04399967|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
214674321|NCT04399967|BEHAVIORAL|COVID-19 related health warning leaflet|The 2-sided color printed A4 leaflet, which covers the risk of COVID-19 and smoking and the most important messages to motivate smoking cessation
214674322|NCT04399967|BEHAVIORAL|Health warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation.
214674323|NCT04399967|BEHAVIORAL|SMS-based support|Participants will receive regular SMS with similar frequency to Intervention group but with generic information on smoking cessation.
214335284|NCT00807092|DRUG|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
214335285|NCT00807092|DRUG|metformin|Metformin dose must remain the same as that used prior to the trial.
214935999|NCT04186702|PROCEDURE|INTRAVITREAL RANIBIZUMAB INJECTION|interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)
214335286|NCT04116229|PROCEDURE|Oral glucose tolerance test|After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
214335287|NCT04116229|BEHAVIORAL|Cognitive testing|For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
215073335|NCT05137171|DRUG|AK105 and anlotinib|AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
214335288|NCT04116229|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
214335289|NCT01794949|DEVICE|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
214335290|NCT01581346|OTHER|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
214936000|NCT04477590|DRUG|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.
214936001|NCT03837366|BEHAVIORAL|Activity tracker and health coaching|Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.
215073336|NCT01382303|DRUG|Pentoxifylline|Pentoxifylline 400mg three times a day
215073337|NCT01382303|DRUG|Placebo|placebo tablet three times a day
214936002|NCT00754208|DRUG|methylphenidate|Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
214936003|NCT04570852|OTHER|LiDCO|"We plan to elucidate the pathophysiology and molecular subtypes of acute pancreatitis in order to develop specific biomarkers and identify new drug targets. The evaluation will include an analysis of the impact of obesity and the metabolic profile during the disease course of acute pancreatitis.~Supportive treatments will be registered including an assessment of the fluid balance based on the fluid intake and loss and weight. Bioimpedance will be assessed at admission/day1, day 2, day 3,"
214936004|NCT01759849|OTHER|Allergen|Allergen extract is administered by inhalation.
214936005|NCT04627532|DRUG|PF-07304814|Participants will receive PF-07304814
214936006|NCT04627532|DRUG|Placebo|Participants will recieve placebo
214936007|NCT06622837|PROCEDURE|implant overdenture|With the assistance of these stereolithographic surgical guides and submerged surgical technique, 4 dental implants (IS III Active Implant, Neo BioTech) were placed in the canines and premolars regions of the maxillary arch, and 2 dental implants were placed in the canines region of the mandibular arch.
214936008|NCT03747315|OTHER|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.
214936009|NCT03747315|OTHER|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.
214936010|NCT06617156|OTHER|RSBI Value Evaluation|"Spirometer Measurement: The traditional method for calculating RSBI involves the use of a spirometer (Wright MK20; Ferraris Medical Ltd., Hertford, England), equipped with a disposable bacterial filter at the front end, connected to the artificial airway to measure the minute ventilation of the patient's spontaneous breathing over one minute.~Three Measurement Methods from the Ventilator: A. PSV at 5 cmH2O with PEEP at 5 cmH2O B. CPAP at 5 cmH2O C. CPAP at 0 cmH2O.~Electrical impedance tomography (EIT) will be secured around the patient's thorax using a silicone belt, positioned at the fifth or sixth intercostal space, with 16 evenly spaced electrodes. Measurement data will be obtained by passing a small electrical current around the chest, utilizing the principle of resistance."
214936011|NCT03597009|DRUG|Talimogene laherparepvec (TVEC)|Talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles, with or without nivolumab
214936012|NCT03597009|DRUG|Nivolumab|Nivolumab (240 mg IV) will be co-administered with talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles in the Dose Level 2 cohort
214936013|NCT00182598|PROCEDURE|computer-based psychoeducational intervention|
214936014|NCT00182598|PROCEDURE|community-based substance abuse counseling|
214936015|NCT01317797|DRUG|namilumab (MT203)|administered three times, subcutaneous in the abdomen
214936016|NCT01317797|DRUG|Placebo|administered three times, subcutaneous in the abdomen
215073338|NCT01639339|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
215073339|NCT01639339|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
214335291|NCT06573541|DEVICE|Use of ultrasound|Use of ultrasound in the initial management of patients in shock
214335292|NCT06561113|OTHER|Caffeine intake|One cup of Turkish coffee contains 60 mg/65 ml (1 Turkish coffee cup) of caffeine. Participants will be instructed to sit for 10 minutes before drinking coffee. To prepare the Turkish coffee, 5 g of ground dry coffee will be mixed in 100 mL of tap water and left to boil in a coffee machine. When the first boil starts, it will be removed from the machine and poured into the cup. Then, 65 ml of Turkish coffee will be given to the subjects to ensure oral caffeine intake.
214335293|NCT05989399|DIAGNOSTIC_TEST|circulating neutrophils|evaluation of circulating neutrophils level
214335294|NCT06573645|DRUG|Rituximab|Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).
214936017|NCT06667154|DRUG|Low-dose nivolumab combined with platinum-based doublet chemotherapy|Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3 mg/kg every 21 days for 3 cycles.
215073340|NCT01639339|DRUG|Standard therapy|"The standard therapies allowed in this study are:~\- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~\- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
215073341|NCT02132923|BIOLOGICAL|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
214335295|NCT04832555|RADIATION|Non elective radiotherapy|Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.
214335296|NCT03775005|RADIATION|standard treatment|3000 cGy in 10 daily fractions
214335297|NCT03775005|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
214335298|NCT03003676|BIOLOGICAL|ONCOS-102|Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)
214335299|NCT03003676|DRUG|Cyclophosphamide|Pre-treatment
214335300|NCT03003676|DRUG|Pembrolizumab|PD1 blockade
214335301|NCT05269524|BEHAVIORAL|Internet-delivered tailored cognitive behavior therapy|Therapists-supported tailored 10-week treatment for depression in older adults.
214335302|NCT00215293|DEVICE|Cervical I/F Cage|
214335303|NCT00215293|DEVICE|Autograft or allograft with a plate, or autograft alone.|
214335304|NCT01306136|BEHAVIORAL|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
214335305|NCT01306136|BEHAVIORAL|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
214335306|NCT05209191|BEHAVIORAL|Student Athlete Wellness Portal|A web-based design that illustrates various opioid misuse and diversion resistance strategies.
214335307|NCT06269328|OTHER|Total ıntravenous anesthesia with propofol and remifentanil for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia maintained with propofol iv 75-100 µg kg-1 min-1 and remifentanyl iv 0.05-0.2 µg kg-1 min-1 infusion.
214335308|NCT06269328|OTHER|Inhalation anesthesia with sevoflurane for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2% )
214335309|NCT00399438|DRUG|Placebo|Tablets, Oral, once daily, 2 weeks
214335310|NCT00399438|DRUG|BMS-562086|Tablets, Oral, once daily, 2 weeks
214335311|NCT02990663|OTHER|Use of blood pressure lowering medication at bedtime|Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
214335312|NCT02990663|OTHER|Use of blood pressure lowering medication in the morning|Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
214335313|NCT01229228|DRUG|Naproxen Test|200-mg single dose
214335314|NCT01229228|DRUG|Naproxen Test|400-mg (2 x 200-mg)
214335315|NCT01229228|DRUG|Naprosyn|single dose
214335316|NCT01229228|DRUG|Naprosyn|single dose
214936018|NCT03064854|DRUG|PDR001|Powder for solution for infusion
214936019|NCT03064854|DRUG|Cisplatin|Intravenous infusion
214936020|NCT03064854|DRUG|Gemcitabine|Intravenous infusion
214936021|NCT03064854|DRUG|Pemetrexed|Intravenous infusion
214936022|NCT03064854|DRUG|Carboplatin|Intravenous infusion
214335317|NCT01229228|DRUG|Placebo|single dose
214335318|NCT00426075|DEVICE|Elastic stockings|
214335319|NCT01675713|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
214335320|NCT00007800|BEHAVIORAL|Behavioral Group Weight Loss Intervention|
214335321|NCT00007800|BEHAVIORAL|Motivational Interviewing|
214936023|NCT03064854|DRUG|Paclitaxel|Intravenous infusion
214936024|NCT03064854|DRUG|Canakinumab|Subcutaneous injection
214936025|NCT06617845|DEVICE|Stimulation Set A and B|Subjects will receive one stimulation parameter set first for 3 months and then the other for three months. Sets will include Set A (145 Hz high frequency stimulation) and Set B (Low frequency stimulation less than 40 Hz, which is similar to stimulation frequencies used during cortical stimulation). The 145 Hz stimulation will be set to cycling (1 min on, 5 min off) while the low frequency setting will be continuous. Both sets include stimulation parameter sets that have been used in clinical practice as a part of standard of care. However, it is unclear which set is better or whether they are similarly effective.
214335322|NCT00268749|DRUG|glycine|0.8 g/kg/day
214335323|NCT00541047|DRUG|bicalutamide|
214335324|NCT00541047|DRUG|goserelin acetate|
214335325|NCT00541047|DRUG|leuprolide acetate|
214936026|NCT01378377|DRUG|Pimasertib|Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
214936027|NCT01378377|DRUG|Pimasertib|Pimasertib will be administered in fasted state at a dose of 75 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
214936028|NCT01378377|DRUG|Temsirolimus|Temsirolimus will be administered at a dose of 12.5 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
214335326|NCT00541047|PROCEDURE|adjuvant therapy|
214335327|NCT00541047|PROCEDURE|quality-of-life assessment|
214335328|NCT00541047|RADIATION|radiation therapy|
214335329|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
214335330|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
214335331|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
214335332|NCT00828646|DRUG|Placebo|Capsules, Oral, once daily, 14 days
214335333|NCT01788540|DRUG|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
214335334|NCT01850199|OTHER|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
214335335|NCT01850199|OTHER|Usual management|Usual care will be provided, including face-to-face visits
214936029|NCT01378377|DRUG|Temsirolimus|Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
214936030|NCT01550705|DRUG|Isoniazid|Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
214936031|NCT01113645|PROCEDURE|Cerebral perfusion evaluation|The patient who received a craniectomy is included in the study and an information notice given to him. All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores 1 week prior and 6 and 24 weeks post cranioplasty. Furthermore, hemodynamic monitoring is performed by CT perfusion scan (with quantitative assessment of global and local cerebral flow) 1 week prior and 6 weeks post cranioplasty, as well as by trans-cranial Doppler 1 week prior and 6 and 24 weeks post cranioplasty.
214936032|NCT02893176|DRUG|macitentan|
214936033|NCT02893176|DRUG|placebo (for macitentan)|
214335336|NCT03711123|BEHAVIORAL|Group metacognitive therapy|10 weekly Group session of 90 minutes duration
214335337|NCT03711123|BEHAVIORAL|Clinical management|10 weekly individual sessions With clinical management including guided self-help
214335338|NCT00621439|DRUG|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
214335339|NCT00621439|DRUG|Placebo|Patients will receive placebo.
214335340|NCT06571461|DRUG|Liposomal Irinotecan|Liposomal Irinotecan：i.v. infusion
214335341|NCT06571461|DRUG|Oxaliplatin|Oxaliplatin;：i.v. infusion
214936034|NCT06624280|PROCEDURE|single-event multilevel surgery|surgical orthopedic approach where multiple deformities are corrected in one solution, often involving both lower limbs, to improve walking performance
214335342|NCT06571461|DRUG|S-1|S-1: Oral
214335343|NCT06571461|DRUG|Gemcitabine|Gemcitabine: i.v. infusion
214335344|NCT06571461|DRUG|Capecitabine|Capecitabine: Oral
214335345|NCT06358924|OTHER|Potassium nitrate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of the desensitizing agent recommended by the manufacturer (After Whitening Mousse), once for 10 minutes.
214335346|NCT06358924|OTHER|Casein phosphopeptide-amorphous calcium phosphate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Mi Paste Plus once for 3 minutes.
214335347|NCT06358924|OTHER|Hydroxyapatite with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Hydroxyapatite and Fluoride (ReminPro) once for 3 minutes.
214335348|NCT06358924|OTHER|PAMAM-carboxylic acid dendrimer|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of PAMAM once for 30 minutes.
214936035|NCT03756727|DRUG|Ascorbic Acid|Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).
214936036|NCT03756727|DRUG|Saline|Patients in Control Comparator group received saline 10ml at the night before surgery, during the surgery and five days after surgery (once a day).
214936037|NCT01430780|DRUG|nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
214936038|NCT01430780|DRUG|control group|placebo
214936039|NCT00000592|PROCEDURE|blood transfusion|
215073342|NCT01174537|BIOLOGICAL|New Castle Disease Virus|Patients will receive IV 1\*10\^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
214674324|NCT04399967|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
214674325|NCT04399967|BEHAVIORAL|COSH Self-help smoking cessation booklet|A general smoking cessation self-help booklet
214674326|NCT00175006|OTHER|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
214335349|NCT06128135|OTHER|Technology acceptance questionnaire for prostheses users.|One questionnaire, which is for prosthesis users, where will be 15 questions to identify what kind of activities the person uses the prosthesis, how much is the use time and what is the main problem with the device.
214335350|NCT06128135|OTHER|Technology acceptance questionnaire for relatives of prostheses users.|One questionnaire, where there will be between 8 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
214335351|NCT06128135|OTHER|Technology acceptance questionnaire for therapists|One questionnaire, where there will be between 9 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
214335352|NCT02443298|DRUG|placebo|Matching placebo for risankizumab
214335353|NCT02443298|DRUG|risankizumab|Monoclonal IgG antibody
214335354|NCT01116089|DRUG|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
214335355|NCT01116089|DRUG|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
214335356|NCT00922610|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
214335357|NCT04627727|OTHER|low FODMAP diet|low FODMAP diet
214335358|NCT04986618|OTHER|One-way Nordic Exercise|Participants in this group will be given the standard Nordic Hamstring exercise.
214335359|NCT04986618|OTHER|Two-way Nordic Exercise|In addition to the standard Nordic Hamstring exercise, participants in this group will do the same exercise backwards for the quadriceps.
214335360|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.
214335361|NCT03759223|BEHAVIORAL|Healthy Living Messages (HLM)|Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.
214335362|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST) (non-randomized)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.
214936040|NCT06590389|OTHER|mandala activity|A descriptive patient form, VAS and STAI-I were applied before surgery. After the surgery, VAS and STAI-I were applied before and after the mandala activity until the patient was discharged. The VAS form was applied every 4 hours until the patient was discharged. This process was repeated in the same way for the entire intervention group.
214936041|NCT01645891|DEVICE|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
214936042|NCT01645891|DEVICE|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
214936043|NCT00754520|DEVICE|Ceramic On Metal|Ceramic on Metal articulation using M2a-38™ mm cup
214936044|NCT00754520|DEVICE|Metal on Metal|Metal on Metal articulation using M2a-38™ mm cup
214936045|NCT02884557|OTHER|collection of gut biopsies collection of blood samples|Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
214936046|NCT02339129|DRUG|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
214936047|NCT02339129|DRUG|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
214936048|NCT00212472|DRUG|Factor VIII concentrates|To be determined at the discretion of the investigator.
214936049|NCT00212472|OTHER|Low-dose treatment|50 FVIII u/kg three times a week.
214936050|NCT00212472|OTHER|High-dose treatment|200 FVIII u/kg per day.
215073343|NCT01282307|BEHAVIORAL|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
215073344|NCT03745443|PROCEDURE|increase and decrease positive end-expiratory pressure|20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
214335363|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
214335364|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
214335365|NCT02700230|PROCEDURE|Computed Tomography|Undergo CT scan
214335366|NCT02700230|OTHER|Laboratory Biomarker Analysis|Correlative studies
214335367|NCT02700230|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
214486401|NCT06769113|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214486402|NCT06759454|DRUG|Glutaraldehyde-Based Desensetizing Agent|A glutaraldehyde-based desensitizing agent applied to the cervical area of affected teeth using a micro-brush, left undisturbed for 30 seconds, and air-dried. Both interventions aim to reduce pain associated with dentinal hypersensitivity by either occluding dentinal tubules or reducing nerve excitability
214335368|NCT02700230|OTHER|Quality-of-Life Assessment|Ancillary studies
214335369|NCT02700230|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT imaging
214335370|NCT02700230|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214335371|NCT02700230|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
214335372|NCT02700230|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214335373|NCT02700230|PROCEDURE|Biopsy|Undergo tissue biopsy
214335374|NCT02700230|OTHER|Questionnaire Administration|Ancillary studies
214335375|NCT05505981|OTHER|Immediate PT|Patients will start PT immediately
214335376|NCT05505981|OTHER|Rest until pain resolves|Patients will wait to start PT until their pain resolves
214486403|NCT06759454|DEVICE|Low Level Laser Therapy|Low-level laser therapy (LLLT) using a diode laser set to a low power level (e.g., 100 mW, continuous wave mode). Each affected tooth will be treated for three minutes, targeting apical, cervical, and middle points
215073345|NCT05986968|DRUG|Ticagrelor|Ticagrelor monotherapy for 12 months
215073346|NCT05986968|DRUG|Aspirin|Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
215073347|NCT04161443|OTHER|physiotherapy|"* Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention)."
215073348|NCT00809991|RADIATION|hypofractionation|3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T
215073349|NCT04690907|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy and 2 virtual dietary counseling sessions.
214335377|NCT05547464|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
214335378|NCT05547464|BIOLOGICAL|BNT164b1|Multi-antigen RNA vaccine for active immunization against tuberculosis administered as intramuscular injection
214335379|NCT05547464|OTHER|Placebo|Placebo
214335380|NCT03698773|OTHER|Access to routine information|Access to routine pain-control information
214335381|NCT03698773|OTHER|Access to website|Access to informational website: thepainlesspush.com
214335382|NCT00908960|DRUG|Enoxaparin|
214335383|NCT05074433|DRUG|casirivimab+imdevimab|Co-administered sequentially subcutaneous (SC)
214335384|NCT05074433|DRUG|Placebo|Administered SC
214335385|NCT02592473|DEVICE|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
214335386|NCT01377974|DRUG|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
214335387|NCT01377974|DRUG|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
214335388|NCT03746821|DIETARY_SUPPLEMENT|Biotin|Biotin supplements (2) to be taken daily
214335389|NCT01158924|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
214335390|NCT05796128|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|In this group, infants will receive NIPPV during LISA procedure.
214335391|NCT05796128|PROCEDURE|Nasal continuous positive airway pressure (NCPAP)|In this group, infants will receive NCPAP during LISA procedure.
214936051|NCT06590025|BEHAVIORAL|INtegral Cognitive REMediation program|This comprehensive functional remediation program includes a traditional CR component with a specialized therapist (based on the compensation model) and a CCT component adapted to the difficulties of each patient. The inclusion of both aspects allows adapting the intervention to the present difficulties by forming new strategies with compensation techniques and promoting translation to everyday life. Therefore, the intervention aims at improving cognitive functioning (beyond a mere training) so as to facilitate the improvement and maintenance of psychosocial functioning for patients with MDD.
214936052|NCT06590025|BEHAVIORAL|Psychoeducation for depression|Psycho-education refers to educating individuals about depression and the various treatment options. It is a form of therapy that aims to provide individuals with the knowledge and skills to manage their mental health symptoms effectively.
214335392|NCT03768739|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
214335393|NCT01014507|DRUG|8 cycles BEACOPPesc plus oral contraceptive|
214335394|NCT01014507|DRUG|8 cycles BEACOPPesc plus Goserelin|
214335395|NCT02857127|BEHAVIORAL|Walking program|To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
214335396|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 2 saliva samples at inclusion.
214335397|NCT05928442|BEHAVIORAL|Completion of a self-questionnaire|Completion of a self-questionnaire on symptom and quality-of-life at inclusion.
214335398|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 1 saliva sample at the follow-up visit.
214335399|NCT05914584|DRUG|Baricitinib 4 MG|Reference drug
214335400|NCT02233231|DRUG|Varenicline|Varenicline 2 mg x 1 day 7 to week 12
214335401|NCT02233231|DRUG|Placebo|similar tabl
214335402|NCT03795922|DRUG|MT10109L|MT10109L will be injected into the GL.
214335403|NCT03795922|DRUG|Placebo|Placebo will be injected into the GL.
214335404|NCT00705575|DRUG|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
214335405|NCT00705575|DRUG|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
214936053|NCT00138073|DEVICE|Web-based waveform interpretation guide|Use of an educational website.
214936054|NCT06621043|DRUG|NTI164|Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC, administered orally starting with a dose of 5 mg/kg, titrated up to 20 mg/kg based on tolerance, followed by a maintenance phase at the maximum tolerated dose, and concluding with a gradual dose reduction.
214936055|NCT05759624|DRUG|rhGH|Hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
214674327|NCT04217902|OTHER|Description of patients' experiences of diabetes care delivery and planning|Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).
214936056|NCT03301740|OTHER|UF profiling during HD|"Experimental arm: Linear UF profiling (linearly decreasing UF rate with a UF rate starting at 1.33 times the rate that would be needed at a constant UF rate to achieve the desired post-weight; pre-programmed profile 2 on a Fresenius 2008K machine, the machine used in all participating clinics). Ultrafiltration profiling will be performed using Fresenius 2008K dialysis machines in accordance with manufacturer instructions."
214936057|NCT03301740|OTHER|Conventional HD|Control arm: Conventional HD (routine care) is the participant's standard HD prescription without UF profiling.
214936058|NCT04982458|DIAGNOSTIC_TEST|68Ga-FAPI|68Ga-FAPI injection is a radiopharmaceutical used for positron emission tomography (PET) diagnosis. This product is used for PET, qualitative and localized diagnosis and evaluation of abnormal expression of fibroblast-activated protein in focus-associated fibroblasts.
215073350|NCT03897725|OTHER|Telehealth Coaching|Telehealth coaching to promote adherence
214335406|NCT00934271|RADIATION|fractionated stereotactic radiotherapy|Audit of outcome
214335407|NCT00036920|DRUG|canfosfamide hydrochloride|
214936059|NCT01239212|DRUG|levetiracetam|50 mg/kg single loading dose of IV levetiracetam
214936060|NCT03707119|OTHER|Educational programme|the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
214936061|NCT05496413|DEVICE|STARSTIM|In order to evaluate the working memory ability of schizophrenic participants, a task was designed that needs to be performed by them. Firstly, a stimulus of six different color circles of same size in a gray background would be given for 500ms. This would be followed by 2000ms delay phase and then a test array would be appeared. The test array would be exactly same to the stimulus array but with or without change in color of only one circle. The test array would appear on the screen till the participants record their response and they would be asked to respond if the test array matches to the stimulus or not.
215073351|NCT05460364|DRUG|BR1018-1|"Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
215073352|NCT05460364|DRUG|BR1018-2|"Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
215073353|NCT02980146|OTHER|Non interventional study|
214335408|NCT03413878|OTHER|Breathing in the simulated avalanche snow|Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
214335409|NCT04083872|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
214335410|NCT04083872|DRUG|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
214335411|NCT03140891|DEVICE|NHFOV|NHFOV is used as the noninvasive mode after extubation
214335412|NCT03140891|DEVICE|NCPAP|NCPAP is used as the noninvasive mode after extubation
214335413|NCT02248922|DRUG|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
214335414|NCT02351752|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR\>60)
214335415|NCT02822794|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
214936062|NCT00687349|BEHAVIORAL|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
214936063|NCT05662059|DEVICE|RAVANS|Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation
214936064|NCT05662059|DEVICE|RAVANS-sham|RAVANS sham device
214936065|NCT01852552|DEVICE|transcatheter aortic valve implantation|Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
214936066|NCT01852552|PROCEDURE|Aortic Valve Replacement|Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
215073354|NCT06066021|OTHER|health educational sessions in diabetic patients type 2.|Professionals from different areas will be invited to carry out the sessions at Visit 2, namely on: mental health, physical activity, nutrition and self-care.
215073355|NCT02042053|DEVICE|PET/CT|
215073356|NCT02042053|DEVICE|PET/MRI|
215073357|NCT03022097|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
215073358|NCT03022097|DRUG|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
215073359|NCT03022097|DRUG|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
215073360|NCT03022097|DRUG|Placebo|Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
215073361|NCT05126797|OTHER|Questionnaire Administration|Ancillary studies
215073362|NCT05126797|DEVICE|Stent Device|Wear customized 3D printed oral stent
214335416|NCT02822794|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
214335417|NCT00035906|DRUG|DEX PS DDS®|
214335418|NCT01698697|DRUG|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
214335419|NCT00588913|BIOLOGICAL|aldesleukin|
214335420|NCT00588913|BIOLOGICAL|therapeutic autologous lymphocytes|
214335421|NCT00588913|DRUG|zoledronic acid|
214335422|NCT00529828|PROCEDURE|Consumption of CLA enriched food|
214335423|NCT05933837|DIAGNOSTIC_TEST|Troponin I|Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.
214335424|NCT01592630|DRUG|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
214936069|NCT05740176|DEVICE|Anterior Cervical Discectomy and Fusion|Anterior cervical discectomy is a surgical procedure that was developed to treat damaged cervical discs by relieving pressure on the nerve roots or on the spinal cord by removing the ruptured disc. The operation is performed by reaching the cervical spine through a small incision in the front of the neck. The soft tissues of the neck are then separated allowing for the disc to be removed. Anterior cervical discectomy has proven to be a safe and effective procedure for the treatment of degenerative disc disease. The anterior approach allows direct visualization of the entire interspace and wide decompression of the anterior aspect cervical spinal cord and nerve roots. It may be undertaken in cases of multilevel disease and interbody fusion may be performed if required
214936070|NCT03440762|BEHAVIORAL|AF awareness education|Participants will receive education about a description of AF, complications, recognition of signs and symptoms of AF, pulse taking, and how to recognize an irregular pulse
214936071|NCT05977127|BIOLOGICAL|Comirnaty|Administration of Comirnaty vaccine
214335425|NCT01592630|DRUG|Saline|On-Q pumps containing saline to be attached to TAP catheters
214335426|NCT03973190|PROCEDURE|Immediate alveolar regeneration after exodontia|The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
214335427|NCT03973190|PROCEDURE|installation of dental implant and collection of biological material|The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
214335428|NCT03973190|DEVICE|ISQ analysis|The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
214335429|NCT01817972|BIOLOGICAL|Certolizumab pegol|Subcutaneous injection
214335430|NCT01817972|DRUG|Azathioprine|50mg tablets
214335431|NCT05026957|DEVICE|SharedHeart|A smartphone application
214335432|NCT03056690|DRUG|ASP0819|Oral capsule
214674328|NCT04217902|OTHER|Description of health care professionals needs and experiences in diabetes care delivery and planning|Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
214674329|NCT01543451|DRUG|Elsiglutide|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
214335433|NCT03056690|DRUG|Placebo|Oral capsule
214674330|NCT01543451|DRUG|Placebo|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
214674331|NCT04445467|DRUG|Favipiravir|Favipiravir
214335434|NCT00002010|DRUG|Fluconazole|
214335435|NCT02047617|DEVICE|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
214335436|NCT02047617|DEVICE|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
214335437|NCT02809495|OTHER|use of app in smartphone|
214936072|NCT05484076|OTHER|breastfeeding counseling|"A breastfeeding booklet will be created by the researchers by taking expert opinion. This booklet will explain everything about breastfeeding in five sessions.~At 34-38 weeks of pregnancy, the first interviews will be done face-to-face at the hospital. The second interview will be made face-to-face or online, depending on the conditions, in the first 1-5 days after the birth. Subsequent interviews (postpartum 1-4 weeks, postpartum 5-12 weeks, postpartum 13-24 weeks) will be held online. The scales used in the research will be applied twice, before and after the training."
214936073|NCT02211963|DRUG|BI 44847|
214936074|NCT02211963|DRUG|Placebo|
214936075|NCT02010658|OTHER|Cognitive Aid|
214936076|NCT05613608|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
214936077|NCT05613608|DRUG|Placebo|Placebo arm.
214936078|NCT05610384|DRUG|Ketorolac Injectable Solution|ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively
214936079|NCT05610384|DRUG|Ibuprofen 800 mg|ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
214936080|NCT00334633|DRUG|tinidazole, metronidazole|Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
214936081|NCT00962364|BIOLOGICAL|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
214936082|NCT06271603|DIAGNOSTIC_TEST|diagnosis based on deepLive™ LC-OCT device|Management of BCC with an initial diagnosis based on the deepLive™ device using LC-OCT technology.
214936083|NCT06271603|DIAGNOSTIC_TEST|diagnosis based on skin biopsy|Control Arm: Standard management with an initial diagnosis based on skin biopsy
214674332|NCT01729910|BEHAVIORAL|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
214936084|NCT00773578|DEVICE|Measurement of exhaled nitric oxide (eNO)|Chemiluminescence NO analyzer Measurement of lung function (spirometry)
214936085|NCT00773578|DEVICE|Measurement of biomarkers of nasal inflammation|Nasal lavage
215077993|NCT00246051|OTHER|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
215077994|NCT00416663|PROCEDURE|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
214335438|NCT05483244|OTHER|discontinuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
214936086|NCT03484936|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
214936087|NCT03484936|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.
215077995|NCT04028765|DRUG|Misoprostol|Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated
215077996|NCT04028765|DRUG|Oxytocin|IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
214936088|NCT00790998|DRUG|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
214936089|NCT00790998|DRUG|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
214936090|NCT06448533|OTHER|No intervention|No intervention
214936091|NCT06473454|OTHER|aerobic exercise and basic body awareness therapy ( exercise)|exercise
214936092|NCT03909113|DIETARY_SUPPLEMENT|amino acid based formula|amino acid based formula
214936093|NCT02747797|DRUG|Lucitanib|10 mg orally daily
214936094|NCT05923411|DRUG|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
214936095|NCT05923411|DRUG|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
214936096|NCT05923411|DRUG|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level
214936097|NCT05923411|DRUG|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
214335439|NCT05483244|OTHER|continuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
214335440|NCT03032003|OTHER|Cysticlean|2 BID for 15 days
214335441|NCT03032003|OTHER|Placebo|2 BID for 15 days
214674333|NCT01729910|BEHAVIORAL|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
214936098|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet Formulation|A single dose of PF-07220060 as a tablet formulation administered under fed conditions
214936099|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration).
214936100|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|A 2-treatment fixed sequence of a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal followed by a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)
214936101|NCT05923411|DRUG|Single dose of PF-07220060 as third tablet formulation|A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
214936102|NCT00756392|PROCEDURE|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
214936103|NCT05467618|PROCEDURE|Maxillofacial surgery|An incision on the skin over the mandible versus incision on the gingivae inside the mouth
214936104|NCT04080674|OTHER|Feed-back controlled deep brain stimulation|Feed-back controlled deep brain stimulation
214936105|NCT00504491|DRUG|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
214936106|NCT01768845|GENETIC|umbilical cord blood (UCB)|Infusion will occur after preparative regimen in one or two UCB unit(s). If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis.
214936107|NCT01908933|DEVICE|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
214936108|NCT02650947|DIETARY_SUPPLEMENT|Sucralose|Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
214674334|NCT02052960|DRUG|CetuGEX™|60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
214936109|NCT02650947|DIETARY_SUPPLEMENT|Placebo|Consumption of empty capsule everyday for 4 weeks
214936110|NCT01730651|RADIATION|Tomotherapy|"IMRT boost of gross LNs~1. Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~2. Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
215077997|NCT06537297|DRUG|Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab|"* Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly;~* Furmonertinib(160mg QD);~* bevacizumab(5mg/kg，once monthly) until progressive disease."
214674335|NCT02052960|DRUG|Cetuximab|400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
214936111|NCT02342548|DRUG|20 mg BID of PF-02545920|All subject who completed A8241021 will receive 20 mg BID (with or without titration)
214936112|NCT01047332|DEVICE|Partially Covered Wallstent|Partially covered wallstent
214936113|NCT01047332|DEVICE|Uncovered Wallstent|Uncovered wallstent
214936114|NCT00291161|BEHAVIORAL|Partners in Dementia Care|"Partners in Dementia Care is facilitated by the VA Dementia care coordinator (VA DCC) that is with the study. The role of the VA DCC includes conducting initial assessments with the subject and caregiver that leads to:~Arranging for further assessment or attention from VA health care system/providers about dementia related concerns or about co-morbid health issues; for example: VA driving evaluation, congestive heart failure medication adherence; Ensuring education is provided about particular health, safety issues; Following up with patient/caregiver on health promoting activities he/she is committed to do; and Sharing care plan actions/outcomes with other VA providers as agreed upon by patient."
214936115|NCT01471509|OTHER|water, glucose with or without amino acid|240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
214936116|NCT06902532|BEHAVIORAL|coconut oil pulling with clove oil|Participants will swish 10 mL of coconut oil mixed with 2 drops of clove oil once daily for 4 weeks. This intervention is designed to assess its antimicrobial efficacy in reducing Streptococcus mutans levels in children and improving oral hygiene.
215077998|NCT00839449|DRUG|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
215077999|NCT02284529|DRUG|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
215078000|NCT02801279|OTHER|Conventional bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
214674336|NCT02052960|DRUG|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
214674337|NCT01380496|DRUG|doxycycline monohydrate|tablet, 100 mg, single, oral dose
214674338|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
214936117|NCT06902532|BEHAVIORAL|coconut oil pulling|Participants will swish 10 mL of pure coconut oil once daily for 4 weeks. This intervention aims to evaluate the effectiveness of coconut oil alone in reducing Streptococcus mutans levels and its potential role in maintaining oral health.
214936118|NCT06902532|DRUG|Fluoride Mouthwash|Participants will rinse with 10 mL of fluoride mouthwash three times daily for 4 weeks. This intervention serves as the active comparator, as fluoride mouthwash is a well-established method for reducing Streptococcus mutans levels and preventing dental caries.
215073363|NCT03306979|DRUG|N Acetylcysteine|Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
215078001|NCT02801279|OTHER|Kinect-based bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
214674339|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
215078002|NCT01495130|PROCEDURE|ultrasound imaging|Undergo transrectal ultrasound
214674340|NCT02648048|DRUG|Pirfenidone|Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
214674341|NCT02648048|DRUG|Vismodegib|Vismodegib will be administered as per the dosage schedule mentioned in arm description.
214674342|NCT03166358|BEHAVIORAL|Hatha yoga|8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
214674343|NCT02166593|DRUG|Pravastatin40mg/Fenofibrate160mg|Pravafenix(Pravastatin40mg/Fenofibrate160mg)
214674344|NCT02166593|DRUG|Atorvastatin Sodium 10mg|Lipitor 10mg(Atorvastatin Sodium)
215078003|NCT01495130|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
214335442|NCT01956175|DEVICE|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
214936119|NCT00633776|DRUG|formoterol fumarate|Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
215078004|NCT05384418|RADIATION|HDP-Tc99m bone scintigraphy|HDP-Tc99m bone scintigraphy
215078005|NCT02944357|DRUG|Cisplatin|Given IV
215078006|NCT02944357|DRUG|Gemcitabine Hydrochloride|Given IV
215078007|NCT02944357|PROCEDURE|Radical Cystectomy|Undergo cystectomy
215078008|NCT02944357|BIOLOGICAL|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
215078009|NCT04857437|DRUG|PF-07202954 Repeat Dose|10, 30, 100, 300, 600, 1200 milligrams (mg)
215078010|NCT04857437|DRUG|PF-07202954 Single Dose|10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
214335443|NCT01956175|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
214674345|NCT00303342|BEHAVIORAL|mind body treatment|regulation of attention, respiration and posture
214674346|NCT00303342|BEHAVIORAL|desensitization|mentation on insomnia behaviors and cognitive activity
214674347|NCT06284018|OTHER|Progressive Muscle Relaxation Exercises|"* Focus on the targeted muscle group.~* Take a slow, deep breath while squeezing on muscle group as hard as she can (not to the point of strain). Keep the muscle tensed for 5 seconds.~Hands and arms, forehead ,Eyes and Cheek, Mouth and Jaw , Neck and Shoulder ,Stomach , Leg and Toes"
214674348|NCT06284018|OTHER|Pilates Exercises|Pilates exercise program consisted of floor exercises on a rubber mat, including the following exercises: a- Pelvic Curl. b- Single-Leg Lift. c- Chest Lift. d- Supine Spine Twist. e- Basic Back Extension.
214674349|NCT02126644|DRUG|70% glycolic acid|
214674350|NCT04180813|DRUG|Linagliptin|drug
214674351|NCT04180813|DRUG|Acarbose|drug
214674352|NCT03849560|BIOLOGICAL|Grippol® Quadri|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Quadri into the upper third of the outer surface of the shoulder (the deltoid muscle).
214674353|NCT03849560|BIOLOGICAL|Grippol® Plus, trivalent (Yamagata lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Yamagata lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
214674354|NCT03849560|BIOLOGICAL|Grippol® Plus, trivalent (Victoria lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Victoria lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
214674355|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy|Derazantinib was administered orally at a dose of 300 mg once daily
215078011|NCT04857437|DRUG|Placebo|Matching Placebo
214674356|NCT04045613|DRUG|Derazantinib 200 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
214674357|NCT04045613|DRUG|Derazantinib 300 mg once daily+ atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
215078012|NCT03515226|BEHAVIORAL|ITS based training|Training using computerized adaptive training in addition to role play
215078013|NCT03515226|BEHAVIORAL|Traditional Training|Training using didactics and role plays
215078014|NCT05091697|BEHAVIORAL|Multicomponent treatment VIRTUAL FIBROWALK + TAU|To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
214936120|NCT04727034|DRUG|Remimazolam tosylate|Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.
214936121|NCT04727034|DRUG|Propofol|Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.
214335444|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
214335445|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule|Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
214335446|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
214335447|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule|Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
214335448|NCT01809626|DRUG|Zolpidem|
214335449|NCT01809626|OTHER|Placebo|
214335450|NCT02442700|DRUG|pitavastatin|Treatment A = administration pitavastatin for 12 weeks
214936122|NCT03521817|OTHER|Alcohol|"The ethanol group will consume a 30% energy restriction diet that will also include \~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). In the United States, one standard drink contains roughly 14 grams of pure alcohol."
214936123|NCT03521817|OTHER|No Alcohol|This group will not consume alcohol. Thus 0 kcal/d will come from alcohol
214936124|NCT03702712|BEHAVIORAL|Aerobic Exercise and Relaxation|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of mindfulness training.
214936125|NCT03702712|BEHAVIORAL|Aerobic Exercise Only|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of quiet rest.
214936126|NCT03702712|BEHAVIORAL|Relaxation Only|This intervention will combine 20 minutes of mindfulness-based relaxation training followed by 20 minutes of quiet rest.
214936127|NCT03066856|OTHER|Dietary intervention|"The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:~* reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.~* reducing high glycemic index food and high insulinemic foods.~* reducing sources of saturated fat (red and processed meat, milk and dairy products).~* eating mostly food of plant origin, with a wide variety of seasonal products."
214936128|NCT03153982|DRUG|Ruxolitinib|Given orally
214936129|NCT06084715|OTHER|Nutritional support|The hospitals in Benin already provide nutritional support for patients with pulmonary TB which will continue throughout the study.
214936130|NCT00203944|BEHAVIORAL|Behavioral, Development|
214936131|NCT05740683|DIAGNOSTIC_TEST|RT-QuiC|RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.
214936132|NCT01848743|DRUG|Tenofovir|
214936133|NCT01848743|DRUG|lamivudine|
214936134|NCT00082017|DRUG|UCN-01 (7-hydroxystaurosporine)|"UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 21 days."
214936135|NCT06910917|BEHAVIORAL|Roy Adaptation-Based Nursing Interventions|"After the research groups were formed, a six-session interview program was created for the participants in the experimental group. Individual goals were set for the participants in the experimental group by combining the evaluations of the areas related to the psychosocial adaptation brought by the disease (physiological, self-concept, role function, interdependence) and the stimuli that would disrupt the adaptation (focus, affecting and possible) and nursing interventions were determined in line with these goals.~applied. In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. It was applied to the participants as standard."
214335451|NCT02442700|DRUG|placebo|Treatment B = administration placebo for 12 weeks
214335452|NCT02304094|DRUG|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
214936136|NCT02286570|DEVICE|Glidescope|videolaryngoscope used for endotracheal intubation
214335453|NCT02304094|OTHER|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
214936137|NCT02286570|DEVICE|Airtraq|videolaryngoscope used for endotracheal intubation
214936138|NCT02286570|DEVICE|Fastrach|intubating laryngeal mask airway used for blind endotracheal intubation
215078015|NCT02576535|PROCEDURE|Fractionated stereotactic radiosurgery|
215078016|NCT02576535|DEVICE|Leskell gamma unit|FDA approved device
214335454|NCT05430386|DRUG|HS-10241|"Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy."
214674358|NCT04045613|DRUG|Derazantinib 200 mg twice daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
214674359|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy (QD)|Derazantinib was administered orally at a dose of 300 mg once daily
214674360|NCT04045613|DRUG|Derazantinib 300 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
214674361|NCT04045613|DRUG|Derazantinib 200 mg twice daily monotherapy|Derazantinib was administered orally at a dose of 200 mg twice daily
214674362|NCT04983901|DRUG|Imipenem/Cilastatin/Relebactam|Given IV
214674363|NCT04983901|DRUG|Cefepime|Given IV
214674364|NCT04983901|DRUG|Meropenem|Given IV
214674365|NCT04983901|DRUG|Piperacillin-Tazobactam|Given IV
214936139|NCT03264378|BEHAVIORAL|Physical Exercise Intervention|The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.
214936140|NCT04229602|DRUG|Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
214936141|NCT04229602|DRUG|EFEXOR® XR|EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
214674366|NCT04983901|DRUG|Vancomycin|Given IV
214936142|NCT03970148|PROCEDURE|Nd: YAG laser|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
214936143|NCT05743062|BEHAVIORAL|Virtual Reality|Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds. Participants will be asked to fill out a survey before the intervention to collect the baseline data, after each session of VR intervention and a final survey at the end of the study.
214674367|NCT04983901|DRUG|Daptomycin|Given IV
214936144|NCT05743062|OTHER|Control|For case control, participants will service as their self control and no VR intervention will be given at first. Participants will be asked to fill out a survey before the intervention to collect the baseline data.
214674368|NCT04983901|DRUG|Linezolid|Given IV or PO
214674369|NCT01243593|PROCEDURE|Transversus Abdominis Plane Block|A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
214674370|NCT01243593|PROCEDURE|Standard Anesthesia|Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
214674371|NCT01189773|DRUG|ibuprofen and codeine|ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
214674372|NCT00813839|OTHER|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
214674373|NCT01057121|DRUG|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
214674374|NCT03845283|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.
214674375|NCT03845283|BEHAVIORAL|Physical Activity Intervention|An program designed to help participants gradually increase their physical activity and maintain an active lifestyle. The program encourages bouts of moderate-to-vigorous physical activity. Participants in this group will receive a Fitbit Versa to help them monitor their physical activity that they will be advised to wear daily. Participants will receive brief (5-10 minute) lessons weekly for the first 3 months and monthly for the last 3 months.
214674376|NCT03845283|BEHAVIORAL|Bite Counter|Participants will receive a Bite Counter device to help them monitor and reduce their within-meal consumption. Participants will be asked to wear the device daily.
214674377|NCT03845283|BEHAVIORAL|Virtual Reality|This program allows participants to practice behavioral weight loss skills using a virtual reality system compatible with their home device. This program helps patients practice these skills in the following artificial settings: at home, at work, at the gym, and at a party. Each participant will be asked to play through each scene at least once during their participation, though they are encouraged to use the program regularly.
214674378|NCT03845283|BEHAVIORAL|Virtual Meetings|Participants will attend virtual meetings using their own device. Each virtual meeting focuses on a specific topic that will help patients lose weight. Participants are asked to virtually attend at least 6 meetings during their participation. There is no limit to how many they can attend. The meeting topics will rotate and repeat on a schedule.
214674379|NCT05986656|PROCEDURE|Atlas-Standard method|Hardware acupressure of the suboccipital muscles according to the Atlas-Standard method for the reduction of chronic subluxation of the first cervical vertebra.
214674380|NCT00827619|DEVICE|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
214674381|NCT03576027|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
214335455|NCT05383846|OTHER|Experimental Narrative Exposure Therapy|"NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for complex trauma, aiming to reduce symptoms of traumatic stress in individuals. NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.~This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included."
214335456|NCT02061241|PROCEDURE|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
214335457|NCT02061241|PROCEDURE|Pacing in other suitable vein|Pacing in other suitable vein
214335458|NCT00059475|DRUG|Glycoprotein 100 (GP100): 209-217 (210M)|
214335459|NCT00059475|DRUG|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
214335460|NCT00059475|DRUG|Montanide ISA 51|
214335461|NCT00059475|DRUG|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
214335462|NCT00059475|DRUG|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
214936145|NCT01390428|DRUG|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
214936146|NCT02800915|OTHER|Service innovation with focus on multidisciplinary collaboration|The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
214936147|NCT05299398|DRUG|Trazodone|Trazodone capsule once daily
214936148|NCT05299398|DRUG|Placebo|Placebo capsule once daily
214936149|NCT04602026|OTHER|Best Practice|Receive standard of care
214335463|NCT00059475|DRUG|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
214335464|NCT02678611|DIETARY_SUPPLEMENT|Basis 250|
214335465|NCT02678611|DIETARY_SUPPLEMENT|Basis 500|
214936150|NCT04602026|BEHAVIORAL|Exercise Intervention|Complete home exercise intervention
214936151|NCT04602026|PROCEDURE|Physical Therapy|Undergo physical therapy
214936152|NCT04602026|OTHER|Questionnaire Administration|Ancillary studies
214335466|NCT02678611|DIETARY_SUPPLEMENT|Placebo|
214335467|NCT03176108|BEHAVIORAL|Cognitive Behavorial Therapy (CBT)|Cognitive Behaviorial Therapy (CBT)
214335468|NCT03176108|BEHAVIORAL|Body mediation|Body mediation (theatre)
214335469|NCT01492140|PROCEDURE|Subdermal Injection|Injection of dermal filler
214335470|NCT01492140|DEVICE|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
214335471|NCT02774109|DIETARY_SUPPLEMENT|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
214335472|NCT02774109|DIETARY_SUPPLEMENT|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
214335473|NCT02774109|PROCEDURE|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
214335474|NCT02774109|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
214335475|NCT00002980|DRUG|decitabine|
214335476|NCT00463450|DRUG|Gynodian® Depot (BAY86-5032)|Injection monthly
214335477|NCT00463450|DRUG|BAY86-4980|orally
214335478|NCT05234346|DRUG|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
214335479|NCT05234346|OTHER|Placebo|No Description for the intervention
214335480|NCT02015234|DRUG|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
214335481|NCT01591681|DEVICE|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
214335482|NCT06293417|DRUG|Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin|Treatment group
214936153|NCT03941197|BEHAVIORAL|Ready and Healthy for Kindergarten Family Literacy program|Participants will participate in 8 parent-child health-themed literacy workshops. Participants will receive 2-3 text messages per week for 8 weeks.
214936154|NCT03050541|DRUG|MDMA|This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.
214936155|NCT03050541|DRUG|Placebo|
214936156|NCT02104349|BEHAVIORAL|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
214936157|NCT04369040|DEVICE|High-flow nasal oxygen therapy using a specific nasal cannula|Patient in this arm will received high-flow nasal oxygen therapy ventilation during the ENT surgery
214936158|NCT04369040|DEVICE|Flow Controlled Ventilation using a laryngeal tri-tube|Patient in this arm will received a laryngeal tri-tube ventilation during the ENT surgery
214936159|NCT06062199|PROCEDURE|Training in the A-DIVA scale and its failure prediction score|Nurses are trained in the A-DIVA scale and its predictive failure score. This score enables them to adapt their approach to peripheral venous line insertion.
214936160|NCT05339841|OTHER|Mobile health application|The mHealth app delivers a personalized support program of digital health. Specifically, using ad hoc designed algorithms which uses the data self-reported by the subject and/or collected by the recruiter at baseline, the App delivers periodic messages with advice, motivational reminders and support to improve lifestyle habits and risk factor control.
215078017|NCT05787093|DEVICE|transabdominal rectal ultrasound|transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol
215078018|NCT02962271|DEVICE|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
215078019|NCT03563677|OTHER|dual expert guidance structure|Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
215078020|NCT06065319|DEVICE|Wearable Sensors|Participants will wear smartwatches and smartrings and this data will be used to design algorithms which seek to find associations between device data and recovery.
214335483|NCT06293417|DRUG|Dose escalation of moderate-intensity statin|Control group
214335484|NCT05942456|DIAGNOSTIC_TEST|ELISA: enzyme-linked immunosorbent assay|enzyme-linked immunosorbent assay
214335485|NCT00179647|DRUG|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
214335486|NCT00179647|DRUG|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
214335487|NCT01747759|OTHER|Kruskal-Wallis and qualitative parameters|
214335488|NCT04273464|PROCEDURE|Brava-group|Breast reconstruction by external tissue expansion and multiple fat transplantations(Brava group); Breast reconstruction with microsurgical DIEP-flap transfer.
214335489|NCT04273464|PROCEDURE|DIEP-group|Microsurgical reconstruction by DIEPO method
214335490|NCT06040346|DRUG|Meplazumab for Injection|Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
214335491|NCT04558736|DRUG|Anti-Thymocyte Globulin (Rabbit)|Given intravenously (IV)
214335492|NCT04558736|DRUG|Fludarabine|Given intravenously (IV)
214335493|NCT04558736|DRUG|Cyclophosphamide|Given intravenously (IV)
214936161|NCT05103176|DEVICE|TMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
214936162|NCT05103176|BEHAVIORAL|Object directed grasping|"Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After \~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every GO cue in order to modulate cortical activity during both the planning and execution phase of the action."
214936163|NCT06100770|DEVICE|Aveir AR Leadless Pacemaker|This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.
214936164|NCT06100770|DEVICE|Single-chamber atrial transvenous pacemaker|This study will utilize real-world data from patients implanted with a single-chamber atrial transvenous pacemaker as a comparator to the Aveir AR LP study arm. No device intervention is required in this study
214936165|NCT06210789|PROCEDURE|Surgical excision|Periodontal plastic reconstruction of the subsequent soft tissue dehiscence after the surgical excision of the localized gingival enlargement
215073364|NCT03306979|OTHER|Placebo oral capsule|Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
215073365|NCT01451931|OTHER|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
215073366|NCT01451931|RADIATION|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
214335494|NCT04558736|DRUG|Mesna|Given intravenously (IV)
215073367|NCT01451931|OTHER|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
215073368|NCT06508177|OTHER|İnterfascial plane block|Interfascial plane blocks will be added to the routine analgesia plan as part of multimodal analgesia.
215073369|NCT06508177|OTHER|Standart analgesia plan|This is the routine analgesia plan applied in our clinic.
215073370|NCT05295121|DRUG|XC221 100 mg tablets|XC221, 3 discrete doses separated by 7-day wash-out periods
214335495|NCT04558736|DRUG|G-CSF|Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days, or as clinically indicated
214335496|NCT04558736|RADIATION|Total Lymphoid Irradiation (TLI)|TLI will be given at 800 cGy total dose in 4 fractions.
214335497|NCT04558736|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
214335498|NCT04558736|BIOLOGICAL|HPC, A Infusion|Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)
214335499|NCT04558736|BIOLOGICAL|CD45RA-depleted DLI|CD45RA-depleted DLI will be given at least ONE week after engraftment
214335500|NCT04034589|DRUG|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
214335501|NCT05949983|OTHER|APA Program|Patients treated and monitored for their breast cancer following the 6-month APA program.
214335502|NCT05949983|OTHER|Recommendations for physical activity|Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
215078021|NCT04907149|DRUG|GLPG3970 film-coated tablet|Participants will receive a single oral dose of GLPG3970.
215078022|NCT04907149|DRUG|[14C]GLPG3970 solution for infusion|Participants will receive an i.v. microtracer microdose.
214335503|NCT05055674|BEHAVIORAL|Motherly app|The Motherly app is organized in four different modules: 1) Library: a collection of brief texts on several topics related to health and pregnancy, 2) Health: journeys with varying degrees of interactivity designed to teach and engage participants in well-established psychological techniques (behavioral activation, cognitive restructuring, emotion regulation, stress management techniques, mindfulness and meditation, sleep hygiene techniques), 3) Pregnancy and motherhood: a module to help mothers keep track of their health care visits, medical exams, and their childrens' development, and 4) Profile: a module allowing participants to keep track of activities and goals completed in the Health module journeys, and to assess depression and anxiety symptoms with brief questionnaires, with results displayed graphically in a timeline and in the the form of short feedback texts.
214335504|NCT05055674|BEHAVIORAL|COMVC app|The COMVC displays over 30 brief psychoeducational videos on several topics related to general mental health, such as depression, anxiety, stress, sleep, problem solving techniques, among others. Psychoeducation is limited to video only (no interactivity). The content of these videos was developed by clinicians, researchers, and professors from the Psychiatry Department of the Medical School of the University of Sao Paulo and from the Federal University of Rio Grande do Sul. Mental health monitoring is delivered by means of brief questionnaires assessing depression and anxiety symptoms, which can be filled at users' discretion. Users' responses are displayed graphically in a timeline and they receive short feedback texts based on assessment results.
214335505|NCT05918679|BEHAVIORAL|Effects of speech variability on speech motor learning|This intervention will examine whether reducing normal variability of speech could improve error detection and speech motor learning. We will design training tasks to change subjects' speech variability. We will train subjects to decrease/decrease their speech variability. Upon completing the training tasks, subjects will complete a motor learning task.
214936166|NCT06052137|DEVICE|Active TBS-DLPFC|"Participants will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
214335506|NCT05918679|BEHAVIORAL|Effects of error-detection training on speech motor learning|This intervention will examine whether improving subjects' ability to detect and estimate auditory perturbation could improve speech motor learning. For this purpose, we will design training tasks to change subjects' estimation of the perturbation magnitude. After completing the training tasks, subjects will complete the motor learning task.
214335507|NCT05918679|BEHAVIORAL|Contributions of error awareness to speech motor learning|This intervention will examine the contributions of error awareness to speech motor learning. Subjects will produce a target word while receiving perturbed auditory feedback with different magnitudes. Subjects will be trained to indicate the magnitude of the error they perceived with or without visual feedback.
214335508|NCT05918679|BEHAVIORAL|Enhancing auditory-to-motor mapping with augmented visual feedback|This intervention will determine the contributions of enhanced auditory-to-motor mappings to speech motor learning. We will design training tasks in which we will use visual feedback to provide feedback regarding subjects' accuracy of auditory-to-motor mapping.
214674382|NCT06399549|DIAGNOSTIC_TEST|Dead bug exercise|the participant in supine, lying on a mat with shoulders, hip joints and knees flexed to 90°. With the lumbopelvic region being maintained in the neutral position, the participant will be instructed to draw in the abdomen, lower two contra lateral limbs (opposite arm and leg) toward the floor, hold for the stipulated time, then return to starting position. The same movement will be repeated with the opposite limbs. In the DBG, both pairs of limbs will be moved an equal number of times withinthe stipulated time. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises.
214674383|NCT06399549|DIAGNOSTIC_TEST|The McGill Curl Up|"Lie down on your back. Extend one leg and bend the knee of the other leg. The Side Bridge. Lie on your side, with your forearm on the floor and elbow underneath your shoulder.~The Bird Dog. Assume a hands-and-knees position on the floor. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises. The exercise program includes a warm-up session of five exercises (awareness of the back, pelvic tilt, lumbar rotation, arm movements, whole-body movement in standing), well-known exercises targeting the muscles of the back extensors, abdominals, lateral buttocks, trunk rotators, posterior buttocks, leg muscles, oblique abdominals (e.g. the plank, diagonal arm and leg lift), as well as exercises for flexibility. The exercises will be taught to the patients at the end of the first session in both groups."
214674384|NCT02859415|DRUG|Mithramycin|Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
214674385|NCT03705923|PROCEDURE|Bariatric surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
214674386|NCT01174784|DEVICE|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
214936167|NCT06052137|DEVICE|TBS-DMPFC|"Participants will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
215073371|NCT04301128|OTHER|Experimental|Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
215073372|NCT04301128|OTHER|control|Patients in the control group were informed same informations verbally and given an education book.
215073373|NCT01956747|PROCEDURE|venapunction|
215073374|NCT01956747|PROCEDURE|bone marrow punction|
215073375|NCT01726400|DRUG|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
215078023|NCT04907149|DRUG|[14]GLPG3970 oral solution|Participants will receive a single oral dose \[14C\]GLPG3970.
215073376|NCT01726400|DRUG|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
214674387|NCT01678846|BEHAVIORAL|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good\_school\_toolkit.php).
214335509|NCT05918679|BEHAVIORAL|Effects of enhanced auditory-motor awareness on speech motor learning|In this intervention, subjects will be trained to control their articulators more accurately and be more aware of their articulators' position and their auditory consequences. After the training tasks, subjects will complete a motor learning task.
214335510|NCT03027466|BEHAVIORAL|Self-affirmation induction|Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
214674388|NCT01300377|DRUG|Bupivacaine / Lidocaine|5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
214674389|NCT01300377|DRUG|Lidocaine|10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
214674390|NCT02046135|DRUG|Sodium Bicarbonate|
214936168|NCT04783220|BEHAVIORAL|Comprehensive structured parent intervention|"1. Educational sessions and coaching on infants' behavior cues~2. Skills on motor stimulation~3. Written instructions for play and stimulation activities at discharge~4. Multidisciplinary follow-up~5. Developmental tracking and advice via a mobile app"
214936169|NCT05348837|PROCEDURE|Deep brain stimulation|Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.
214936170|NCT00462176|PROCEDURE|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
214936171|NCT00462176|OTHER|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
214936172|NCT03891784|DRUG|Abemaciclib|Given PO
214674391|NCT02046135|DRUG|Sodium Chloride|
214335511|NCT03251248|DRUG|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
214335512|NCT03251248|DRUG|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
214335513|NCT06852742|OTHER|Facial Cream A|The participants will use the Facial Cleanser twice daily (morning and evening). The Facial Cream A will be applied topically evenly over the entire face after cleansing and drying face in the morning and in the evening. The Sunscreen will be applied evenly over the entire face after Facial Cream A in the morning and re-applied after 80 minutes of swimming or sweating, immediately after towel drying, and at least every 2 hours during sun exposure.
214674392|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist|anti-IL6 alone
214674393|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist and corticosteroids|anti-IL6 + corticosteroid combination
214674394|NCT04486521|DRUG|corticosteroid alone|"dexamethasone, hydrocortisone, methylprednisolone, prednisone. All steroids  other than dexamethasone will be converted to dexamethasone equivalent"
214674395|NCT00802165|DEVICE|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
214674396|NCT00802165|DEVICE|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
214674397|NCT00005628|BIOLOGICAL|vitespen|
214674398|NCT01666873|PROCEDURE|patients that undergo a total knee prosthesis|
214936173|NCT05863520|BEHAVIORAL|Zones of Regulation|ZOR is rooted in CBT principles and uses a metacognitive framework to increase awareness of feelings and to build regulation, prosocial skills, and overall wellness.
214936174|NCT05863520|BEHAVIORAL|Facing Your Fears - School Based|FYF-SB is a CBT program for managing anxiety in autistic youth.
214936175|NCT04381195|DIAGNOSTIC_TEST|REALS Development|Complete drafting of an item pool (adults with ASD, parents, adult service providers); Assign items to all parts of our conceptual framework to ensure sufficient construct coverage across employment, social, and independent living domains; and Conduct cognitive interviews with 25 caregivers of adults with ASD and 25 self-reporting adults with ASD.
215073377|NCT03126058|PROCEDURE|enhanced recovery after surgery|Patients will undergo enhanced recovery after surgery programs.
215073378|NCT00503581|PROCEDURE|Biopsy|Undergo biopsy
215073379|NCT00503581|OTHER|Laboratory Biomarker Analysis|Correlative studies
215073380|NCT00503581|DRUG|Megestrol Acetate|given orally
215073381|NCT00503581|OTHER|Pharmacological Study|Correlative studies
215073382|NCT00503581|OTHER|Quality-of-Life Assessment|Ancillary studies
215073383|NCT00503581|PROCEDURE|Therapeutic Conventional Surgery|undergo hysterectomy
215073384|NCT03979014|BIOLOGICAL|Gardasill 9™ vaccine|3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
214335514|NCT06852742|OTHER|Facial Cream B|The participants will use the Facial Cleanser twice daily (morning and evening).The Sunscreen will be applied evenly over the entire face after cleansing in the morning and re-applied after 80 minutes of swimming or sweating, immediately after towel drying, and at least every 2 hours during sun exposure. The Facial Cream B will be applied in the evening after washing and drying face.
214335515|NCT05620290|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
214335516|NCT05620290|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
214335517|NCT04542629|DRUG|RiTUXimab Injection [Rituxan]|375 MG/M2 /WEEK INFUSION
214335518|NCT05004922|OTHER|Embryo transfer into upper cavity|Transfer of embryos in upper cavity
214335519|NCT05004922|OTHER|Embryo transfer into midcavity|Transfer of embryos in mid cavity
214335520|NCT01563250|DEVICE|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
214335521|NCT01790412|BEHAVIORAL|Exercise group|Combined two land aerobic sessions and one aquatic activities session
214335522|NCT06567652|DEVICE|catheter ablation|All patients underwent pulmonary vein isolation (and eventually left atrial posterior wall isolation) with the POLARx™ cryoballoon system
214335523|NCT05699668|DEVICE|OCT Angiography|"2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds."
214335524|NCT06211647|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.
214335525|NCT05327790|DRUG|Lyophilized fecal microbiota (LFMT)|vedolizumab or ustekinumab + FMT vs placebo
214335526|NCT05327790|OTHER|Placebo|Placebo
214936176|NCT04381195|DIAGNOSTIC_TEST|REALS Testing|A national sample of proxy reporters (e.g., parents, clinicians, group home staff) for 1000 autistic adults and self-reporting autistic adults and adults with other IDD will complete the REALS draft items and a co-calibration battery to establish psychometrics, generate short-forms, and ensure applicability across adults with ASD.
214674399|NCT02508714|DEVICE|Orsiro|stents will be implanted in case of significant coronary artery disease
214335527|NCT01440946|DRUG|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
214335528|NCT01440946|DRUG|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
214335529|NCT06139952|DRUG|Atorvastatin 80mg|Atorvastatin 80mg taken Once before coronary angiography
214335530|NCT06139952|DRUG|N-acetyl cysteine|200mg 3 times daily 2 days before coronary angiography
214335531|NCT06139952|OTHER|Normal Saline|adequate hydration using Normal Saline (1ml/kg/hr)
214335532|NCT03221413|DEVICE|transcranial alternating current stimulation (tACS)|
215073385|NCT04470908|DRUG|Zanubrutinib|Single oral dose of 320 mg
215073386|NCT04470908|DRUG|Rifabutin|Oral dose of 300 mg once daily
214335533|NCT06230887|BEHAVIORAL|Building Spiritual Strength|Spiritually Integrated group intervention for moral injury
214335534|NCT06230887|BEHAVIORAL|Present Centered Group Therapy|Active control, manualized evidence-based coping skills intervention for PTSD
214674400|NCT02508714|DEVICE|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
214674401|NCT00364039|DRUG|AV650|
214674402|NCT01507545|DRUG|MORAb-004|MORAb-004 8mg per kg IV once a week
214674403|NCT01507545|DRUG|Placebo|Placebo - normal saline IV once a week
214674404|NCT01507545|OTHER|Best supportive care|Best supportive care to improve quality of life
214674405|NCT00193674|DRUG|Dydrogesterone|20 mg/day, oral
214674406|NCT00193674|DRUG|Placebo|Placebo
214674407|NCT00450866|BIOLOGICAL|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
215073387|NCT06056336|DRUG|Tislelizumab|Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
215073388|NCT03197987|DEVICE|Endocuff|Endocuff-assisted colonoscopy
215073389|NCT03197987|DEVICE|cap|Cap-assisted colonoscopy
215073390|NCT05339750|DEVICE|AI-based smartphone application|AI-based smartphone application to record and interpret the patch test results
215073391|NCT05339750|DIAGNOSTIC_TEST|Allergen patch|Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.
215073392|NCT03326921|BIOLOGICAL|CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|Given IV
215073393|NCT03326921|OTHER|Laboratory Biomarker Analysis|Correlative studies
215078024|NCT01842165|DRUG|Intravenous injection of 177Lu-octreotate|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
214674408|NCT03545152|BEHAVIORAL|Exercise|"Prescription exercise: frequency, intensity, type, time, and progression (FITT-PRO).~150 min/week (the intensity will be moderate). exercise routine: warming up, resistance training and aerobic exercise training(range of motion and flexibility exercises)"
214674409|NCT03545152|BEHAVIORAL|Cognitive training|Cognitive training intervention consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
214674410|NCT03545152|BEHAVIORAL|New life-style|Combination of exercise and cognitive interventions
214674411|NCT02035072|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2
214674412|NCT02035072|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2
214674413|NCT02035072|RADIATION|Hypofractionated RT|Hypofractionated radiotherapy (35 Gy in 7 fractions)
214674414|NCT02183298|DRUG|BI 1356 BS - intravenous|
214674415|NCT02183298|DRUG|BI 1356 BS - Tablet|
214674416|NCT02183298|DRUG|Placebo|
214936177|NCT04281784|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page Jumpstart Guide provides information to the clinician about prior advance care planning documentation and code status derived from the EHR. The Jumpstart Guides includes tips to improve goals-of-care communication.
214936178|NCT05998161|BEHAVIORAL|reviga|Participants will receive access to the digital health intervention reviga in addition to TAU.
214936179|NCT03247088|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT IV
214936180|NCT03247088|DRUG|Busulfan|Given IV
214936181|NCT03247088|DRUG|Cyclophosphamide|Given IV
214936182|NCT03247088|BIOLOGICAL|Filgrastim|Given SC
214936183|NCT03247088|DRUG|Fludarabine|Given IV
214936184|NCT03247088|DRUG|Mycophenolate Mofetil|Given PO
214936185|NCT03247088|DRUG|Sorafenib|Given PO
214936186|NCT03247088|DRUG|Tacrolimus|Given PO
214674417|NCT04877782|DEVICE|Transcutaneous vagus verne stimulation|Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.
214674418|NCT02225067|DRUG|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
214674419|NCT05297305|DEVICE|Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
214674420|NCT05297305|DEVICE|Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
214674421|NCT03869073|DRUG|Evolocumab|Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
214674422|NCT03869073|DRUG|Placebo|Preservative free 0.9% sodium chloride. Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
214674423|NCT06970639|DRUG|Furmonertinib Mesilate Tablets|Usage and dosage: 80mg, 240mg, or 160mg QD orally Medication duration: A cycle of 21 days until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs
214936187|NCT04322539|DRUG|Fruquintinib|Oral VEGFR inhibitor
214936188|NCT04322539|DRUG|Placebo|Placebo capsule
214936189|NCT06052748|DRUG|AD-223A|PO, Once daily(QD), 8weeks
214936190|NCT06052748|DRUG|AD-223B|PO, Once daily(QD), 8weeks
214936191|NCT06052748|DRUG|AD-223C|PO, Once daily(QD), 8weeks
214936192|NCT06052748|DRUG|AD-223A Placebo|PO, Once daily(QD), 8weeks
214936193|NCT06052748|DRUG|AD-223B Placebo|PO, Once daily(QD), 8weeks
214936194|NCT06052748|DRUG|AD-223C Placebo|PO, Once daily(QD), 8weeks
214936195|NCT03548961|DRUG|FOLFOX regimen|FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy
214936196|NCT00918775|OTHER|Follow-Up Care|Undergo follow-up
214936197|NCT00918775|OTHER|Laboratory Biomarker Analysis|Correlative studies
214936198|NCT06075329|BEHAVIORAL|Contemplative Practice|Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.
214335535|NCT03280355|BEHAVIORAL|Singing training|"Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology."
214936199|NCT05899491|PROCEDURE|ARMA|Patients will be instructed to fast for 6 hours pre-ARMA, the Procedure will be performed under propofol-based sedation. Patients will be in the left lateral decubitus position. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
214335536|NCT03280355|BEHAVIORAL|Physical Training|"Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres."
214335537|NCT05016102|OTHER|Exercise type|Aerobic exercise and Resistance exercise
214335538|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline + L-arginine|L-citrulline + L-arginine - sachet dissolved in water
214335539|NCT03378596|DIETARY_SUPPLEMENT|L-arginine|L-arginine - sachet dissolved in water
214335540|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline - sachet dissolved in water
214335541|NCT03378596|DIETARY_SUPPLEMENT|Placebo|Placebo (corn starch) - sachet dissolved in water
214335542|NCT01511887|DRUG|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
214335543|NCT02486406|DRUG|Ombitasvir/paritaprevir/ritonavir|Film-coated tablet for oral use
214335544|NCT02486406|DRUG|Dasabuvir|Film-coated tablet for oral use
214335545|NCT02486406|DRUG|Ribavirin|Film-coated tablet for oral use
214335546|NCT02486406|DRUG|Ombitasvir mini tablet|Film-coated tablet for oral use
214335547|NCT02486406|DRUG|Paritaprevir mini tablet|Film-coated tablet for oral use
214335548|NCT02486406|DRUG|Ritonavir mini tablet|Film-coated tablet for oral use
214936200|NCT05899491|PROCEDURE|UGI Endoscopy|"UGI Endoscopy will be performed under propofol based sedation with scope kept inside for atleast 5 minutes.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry, reflux questionnaire."
214936201|NCT03203928|BEHAVIORAL|Occupational Therapy Intervention for Women with ADHD|"The intervention will run for 7 weeks and consist of the following 1-hour sessions. Each intervention session will be facilitated by two CUMC occupational therapy students in each participant's home environment (or another environment of the participant's choosing such as the work or school environment).~Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments."
214936202|NCT01315041|DRUG|Capsicum frutescens fruits, homeopathic medicine|5 drops, PO, 3 times a day, during 16 weeks
214335549|NCT02486406|DRUG|Dasabuvir mini tablet|Film-coated tablet for oral use
214335550|NCT02486406|DRUG|Ribavirin solution|Oral solution
214335551|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
214335552|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
214335553|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
214335554|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
214335555|NCT02705131|DEVICE|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
214335556|NCT02705131|DEVICE|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
214335557|NCT01826825|BEHAVIORAL|Cognitive Screen|Cognitive Screen
214335558|NCT01826825|BEHAVIORAL|Mini-Cog|Cognitive Screen
214335559|NCT01769794|DRUG|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
214335560|NCT01769794|DRUG|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
214335561|NCT01769794|DRUG|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
214335562|NCT01858194|DEVICE|Renal sympathetic denervation|"* The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~* After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
214936203|NCT01315041|DRUG|Inert alcoholic solution|5 drops, PO, 3 times a day, during 16 weeks
214936204|NCT00743938|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
214936205|NCT00743938|DRUG|Erlotinib|Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
214936206|NCT01702532|DRUG|Nicotine|Comparison of different dosage forms of nicotine
214936207|NCT02544295|BEHAVIORAL|Clinical interview|
214936208|NCT02544295|BEHAVIORAL|Virtual reality task|
214936209|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for banking
214674424|NCT06970639|DRUG|Carboplatin Injection|"Usage and dosage: Administer via IV infusion, with a dosage of AUC5, not exceeding 750 mg.~Medication schedule: every 3 weeks as a cycle, D1 administration per cycle, immediate administration of carboplatin upon completion of pemetrexed infusion, intravenous infusion, carboplatin can be used for up to 4 cycles."
214936210|NCT05770531|PROCEDURE|Computed Tomography|Undergo CT
214936211|NCT05770531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214936212|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for ctDNA evaluation
214936213|NCT05770531|BIOLOGICAL|Sacituzumab Govitecan|Given by IV
214936214|NCT04549376|DRUG|Povidone-Iodine 0.4% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%
214936215|NCT04549376|DRUG|Povidone-Iodine 0.5% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5%
214674425|NCT06970639|DRUG|Cisplatin for injection|Usage and dosage: Administer via IV infusion at a dose of 75 mg/m2. Medication schedule: Every 3 weeks as a cycle, with D1 administration per cycle. Cisplatin is administered approximately 30 minutes after the infusion of pemetrexed, via intravenous infusion. Adequate hydration therapy must be received before and after cisplatin treatment. Cisplatin can be used for up to 4 cycles.
214674426|NCT06970639|DRUG|Pemetrexed Disodium for Injection|Usage and dosage: Intravenous (IV) infusion administration, dosage of 500 mg/m2 Medication schedule: Administer on the first day of each cycle (21 days per cycle, i.e. every 3 weeks) until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs.
214674427|NCT06970639|DRUG|Osimertinib Mesylate Tablets|Usage and dosage: 80mg, QD administration Medication duration: A cycle of 21 days until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs
214674428|NCT06970197|OTHER|simülation group|İncludes high reality simulation applications.
214674429|NCT06970197|OTHER|out-of-class educational activities group|"It includes a tour of the sales facility, a sapling planting activity and an action for the environment activity to provide experiential learning."
214674430|NCT06970899|DEVICE|PATH EX CycloPE® Device|Participants in this arm will receive two extracorporeal blood filtration treatments using the PATH EX CycloPE® device. The first treatment will be initiated following baseline assessments, and the second treatment will occur 24-36 hours after the start of the first treatment. Each treatment will last up to 4 hours. The device is designed to target and remove bacteria from the bloodstream. All participants will also receive standard-of-care treatment for sepsis, including IV antibiotics, as determined by the treating physician.
214674431|NCT06969742|OTHER|Psycho-education and Psychological intervention_After cancer treatment|"The intervention program consists of Psycho-education and Psychological intervention that includes cognitive behavioral therapy sessions and interventions for patients and caregivers.~It integrates and applies various evidence-based theories; mindfulness theory, solution-focused theory, resilience theory, and family intervention theory.~The intervention is divided into two sessions; core sessions and elective sessions. The after cancer treatment group undergoes 7 core sessions and 3 elective sessions, a total of 10 sessions.~The sessions are conducted 1:1, either face-to-face or remote, and 1 to 2 times a week, approximately 50 minutes per session."
214936216|NCT04549376|DRUG|Povidone-Iodine 0.6% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6%
214936217|NCT04549376|DRUG|Povidone-Iodine 0.5% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.5%
214335563|NCT01858194|DEVICE|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
214335564|NCT02322697|DRUG|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
214936218|NCT04549376|DRUG|Povidone-Iodine 0.6% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.6%
214936219|NCT04549376|OTHER|Placebo comparator: DW-NI|Nasal irrigation will be provided by Distilled water
214936220|NCT04549376|OTHER|Placebo comparator: DW-NS|Nasal spray will be provided by Distilled water
214936221|NCT04030260|DRUG|Regorafenib and PD-1 antibody in Combination with Radiotherapy|Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and PD-1 antibody
214936222|NCT04030260|RADIATION|Radiation therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
214936223|NCT04291326|DIAGNOSTIC_TEST|Transfontanelle ultrasound|cerebral blood flow measurement using transfontanelle ultrasound
214936224|NCT05103436|OTHER|TENS|Electrical nerve stimulation
214936225|NCT01451164|DRUG|OPC-34712|orally administered once daily
214936226|NCT01451164|DRUG|OPC-34712|orally administered once daily
214936227|NCT01451164|DRUG|OPC-34712|orally administered once daily
214936228|NCT01451164|DRUG|Placebo|orally administered once daily
214936229|NCT03606694|DRUG|Dihydromyricetin|The intervention wiil be 300 mg, two times per day before break-fast and dinner during 12 weeks.
214936230|NCT03606694|DRUG|Metformin|The intervention wiil be 850 mg, two times per day before break-fast and dinner during 12 weeks.
214936231|NCT03751436|DRUG|Enzalutamide|Given PO
214936232|NCT03751436|DRUG|Venetoclax|Given PO
214936233|NCT05258799|DRUG|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
214936234|NCT04222842|DRUG|CM082|Subjects will receive CM082 orally for two weeks followed by two weeks off in four-week cycles.The total treatment period is tentatively set at 3 cycles (12 weeks).
214936235|NCT00297050|DRUG|Peramivir|
214936236|NCT05250531|BEHAVIORAL|multicomponent therapy|patient education,Exercise training,Private Psychotherapy,relaxation
214936237|NCT06537076|DRUG|AR1005|AR1005 inhibits sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.
214936238|NCT06537076|DRUG|Placebo|Matching placebo for AR1005 to be administered BID for 20 weeks
214936239|NCT06537076|DRUG|Rivastigmine 3 mg|3mg Rivastigmine will be administered BID for both active and placebo groups
214936240|NCT01846221|DRUG|Clonidine|Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
214936241|NCT01846221|DRUG|Fentanyl|Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
214936242|NCT02533102|DRUG|E7050|100 mg tablet administered orally
215073394|NCT06303440|OTHER|Routine Physical Therapy+ Balance Training|Each session will be begun with routine PT treatment and lasted for 45 minutes in total. To start, the participants will be asked to do warm-up exercises, sitting comfortably on a chair with their backs and feet well supported, the participants will be instructed to breathe in and out. Warm-up exercises will be carried out for 5 minutes. Stretching exercises will be performed for 15 minutes per session, and stretches were held for 30 seconds with four repetitions of each of the following areas, shoulder flexors, elbow and wrist flexors, hip flexors, hip adductors, knee flexors, and calf, 10 seconds of rest period will be added after stretching of one muscle group. Participants will have a 15 minutes session of exercises neck holding on form roller for 1 minute with two repetitions, astride-sitting on foam roller for 2 minutes with four repetitions, weight on both hands on gym ball for 1 minute with two repetitions and hip adductors strengthening for 1 minute with three repetitions.
214936243|NCT02967913|PROCEDURE|Bladder flap|bladder is separated from the lower uterine segment prior to making the uterine incision at time of cesarean delivery
214936244|NCT02920541|DRUG|S 055746|S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
214936245|NCT01848236|DIETARY_SUPPLEMENT|Vitamin D2|Ergocalciferol vitamin D2
214936246|NCT01848236|DIETARY_SUPPLEMENT|Vitamin D3|Cholecalciferol vitamin D2
214936247|NCT02686242|PROCEDURE|spinal anesthesia|bupivacaine injected by spinal puncture
214936248|NCT02686242|PROCEDURE|general anesthesia|general anesthesia with intubation
214936249|NCT01609166|DRUG|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
214936250|NCT01609166|DRUG|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
214936251|NCT06649526|OTHER|endotracheal intubation with videolaryngoscope|The present study will compare the images of two different VLs with Macintosh blades (the McGrath videolaryngoscope and the Hugemed videolaryngoscope) in both indirect (screen images) and direct (images viewed through the mouth) laryngoscopy.
214936252|NCT01639066|DRUG|Tenofovir|Tenofovir 300mg daily Oral
214936253|NCT01639066|DRUG|Entecavir|Entecavir 1 mg daily Oral
214936254|NCT01639066|DRUG|Tenofovir|Tenofovir 300mg daily Oral
214936255|NCT02027662|DRUG|Osvaren Granules|
214936256|NCT02027662|DRUG|Osvaren film-coated tablets|
214936257|NCT02824016|BIOLOGICAL|biological sample|T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured
214936258|NCT02824016|RADIATION|supraclavicular irradiation|Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions
214936259|NCT06309420|DEVICE|Cryogenic treatment of warts (Pixie CO2)|Treatment of common and plantar warts by cryotherapy treatment.
214936260|NCT06309420|DEVICE|Cryogenic treatment of warts (Wortie®)|Treatment of common and plantar warts by cryotherapy treatment.
214936261|NCT06620081|OTHER|Performance Tests|Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.
214936262|NCT06620081|OTHER|Functional Tests|Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.
214936263|NCT02712762|OTHER|Cross-sectional study|
214936264|NCT04146675|DEVICE|TRICOT JERSEY VANISE DOUBLE FACE|"Short sleeve t-shirt : TRICOT JERSEY VANISE DOUBLE FACE  THERMOLACTYL EVOLUTION  with ceramic fibers.~A Tinetti test will be performed while wearing the T-shirt, as well as an evaluation of the equilibration on posturography platform under static conditions and an assessment of dynamic equilibrium and locomotion in motion analysis."
214936265|NCT04146675|DEVICE|TRICOT JERSEY SIMPLE|Short sleeve t-shirt : TRICOT JERSEY SIMPLE The comparator T-shirt has the same weight, the same appearance, and will be used by patients in the same way and under the same conditions as the T-shirt with ceramic fibers.
214936266|NCT04326868|DRUG|Benzimidazole Anthelmintic|The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
214936267|NCT03652233|DRUG|Nivolumab|Given by vein every 14 days for up to 12 months
214936268|NCT03652233|DRUG|Afatinib|Taken by mouth daily for up to 12 months
214936269|NCT02879994|OTHER|Laboratory Biomarker Analysis|Correlative studies
214335565|NCT04926675|BEHAVIORAL|Psychological Therapy|Participants will be receiving their one-to-one psychological therapy from IAPT as usual. They typically receive between 6 and 12 sessions with a psychological practitioner.
214936270|NCT02879994|BIOLOGICAL|Pembrolizumab|Given IV
214936271|NCT06095635|OTHER|Placebo Protocol|ingestion of 500 mg of starch following 30 minutes of exercise (treadmill)
214936272|NCT06095635|OTHER|Protocol Beet|ingestion of 500 mg of beet extect following 30 minutes of exercise (treadmill)
214335566|NCT04926675|BEHAVIORAL|Debt Advice|Participants will receive one-to-one support from a Citizen's Advice (CA) money advisor for as long as needed to resolve any money worries currently affecting their mental health.
214674432|NCT06969742|OTHER|Psycho-education and Psychological intervention_In cancer treatment|"The intervention program consists of Psycho-education and Psychological intervention that includes cognitive behavioral therapy sessions and interventions for patients and caregivers.~It integrates and applies various evidence-based theories; mindfulness theory, solution-focused theory, resilience theory, and family intervention theory.~The intervention is divided into two sessions; core sessions and elective sessions.~The intervention is divided into two sessions; core sessions and elective sessions. The in cancer treatment group undergoes 4 core sessions and 1 elective session, which is selected out of the given three topics, a total of 5 sessions.~The sessions are conducted 1:1, either face-to-face or remote, and 1 to 2 times a week, approximately 50 minutes per session."
214936273|NCT06095635|OTHER|Protocol Resveratrol|ingestion of 500 mg of resveratrol following 30 minutes of exercise (treadmill)
214936274|NCT06095635|OTHER|Protocol Beet and Resveratrol|ingestion 500 mg of beet extect and 500 mg of resveratrol following 30 minutes of exercise (treadmill)
214936275|NCT02741791|DRUG|AXS-05|AXS-05 taken daily for 6 weeks.
214936276|NCT02741791|DRUG|Bupropion|Buproprion taken daily for 6 weeks.
214936277|NCT02750605|DEVICE|DEB|Intervention with drug eluting balloon.
214936278|NCT02750605|DEVICE|POBA|Intervention with old technology as comparison
214936279|NCT04585399|BEHAVIORAL|Contingency management|Financial incentives for attending bup appointments and demonstrating opioid abstinence. Rides will also be provided for up to two clinic visits per week.
214936280|NCT04132089|BEHAVIORAL|capABILITY|All participants utilized the designed capABILITy application. The application consisted of education material and persuasive messaging. There were two types of messaging components named facilitators and sparks. This created three groups consisting of: control, facilitators and sparks. Participants spent 1 month in each group (total duration of the study was three months).
214936281|NCT05821790|OTHER|Surgical waste and Data collect|Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection. Data necessary for the study will be collected from the patient's medical records, MRI examinations, and data specific to the characteristics of the surgical waste.
214936282|NCT04096898|DEVICE|Senofilcon A contact lens|Senofilcon lenses will be tested in moderate to severe dry eye patients to determine their efficacy in reducing discomfort associated with dry eye.
214335567|NCT05067075|DEVICE|Blinded CGM|CGM that records blood glucose but is not visible to patient or provider in real-time
214335568|NCT00517920|DRUG|ABT-869|0.25 mg/kg QD
214335569|NCT05501509|PROCEDURE|Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Using a 3-hole third plate and high resistance sutures across the acromioclavicular joint to achieve horizontal and vertical stability of the joint
214335570|NCT05501509|PROCEDURE|Coracoclavicular fixation for the management of an unstable acromiclavicular luxation|Isolated coracoclavicular repair using a 3 hole third plate.
214335571|NCT04057495|OTHER|further fasting|2 hours of fasting
214335572|NCT04057495|OTHER|white bread consumption|113 grams of white bread consumption
214335573|NCT04057495|OTHER|mango consumption|330 grams of mango consumption
214936283|NCT06077149|BIOLOGICAL|RSV vaccine|"All participants will get either the Pfizer RSV vaccine (RSVpreF (ABRYSVO)) or the GSK RSV vaccine (RSVpreF (AREXVY)) at 120 ug of the RSV prefusion F antigen intramuscularly in the the non-dominant deltoid muscle.~Long-term care facility residents will get whichever vaccine is available at the facility as part of standard of care. Community cohort will be matched proportionally"
214936284|NCT03568032|DIAGNOSTIC_TEST|Measurement of intima media thickness of carotid artery|IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.
214936285|NCT03568032|DIAGNOSTIC_TEST|Detection and measurement of carotid plaques|Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound
214936286|NCT03568032|DIAGNOSTIC_TEST|Carotid Color Flow Duplex Testing|Velocity measurement of carotid artery to determine carotid stenosis
214936287|NCT03568032|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Cognitive assessment
214936288|NCT03568032|OTHER|Medical history of cardiovascular risk factors and cardiovascular diseases|Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
214936289|NCT06129136|OTHER|Nature-based exposure by biodiversity component in lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
214936290|NCT06129136|OTHER|Placebo group using colored lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
214936291|NCT06116552|BEHAVIORAL|More Social Stories|Children listen to four stories while looking at accompanying images that contain more social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
214936292|NCT06116552|BEHAVIORAL|Less Social Stories|Children listen to four stories while looking at accompanying images that contain less social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
214936293|NCT05310500|DIAGNOSTIC_TEST|Finishing files of ProTaper Gold (F2) without effect to NaOCL|Finishing files of ProTaper Gold (F2) without effect to NaOCL
214936294|NCT05310500|DIAGNOSTIC_TEST|Finishing files of ProTaper Gold (F2) with effect to NaOCL|Finishing files of ProTaper Gold (F2) with effect to NaOCL
214936295|NCT05310500|DIAGNOSTIC_TEST|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
214936296|NCT05310500|DIAGNOSTIC_TEST|Finishing files of Dia-X ProTaper (D4) with effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
214936297|NCT00428051|OTHER|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
214936298|NCT06269016|OTHER|expremental pre and post test|effect of strengthening exercise of combined hip strengthening exercises and pelvic floor exercises
214936299|NCT02052596|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
214936300|NCT02052596|BIOLOGICAL|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
214936301|NCT00705718|DEVICE|Endurant Stent Graft System|Abdominal Aortic Aneurysm Repair
214936302|NCT00497978|DIETARY_SUPPLEMENT|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
214936303|NCT00497978|DIETARY_SUPPLEMENT|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
214936304|NCT00182728|PROCEDURE|surgery|conventional
214674433|NCT05468957|DEVICE|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
214936305|NCT00182728|PROCEDURE|therapy|neoadjuvant
214936306|NCT00182728|RADIATION|radiation therapy|intraoperative radiation therapy
214936307|NCT06649461|PROCEDURE|ozone injections|Ozone injections (5 mL/10 μg/dL) were administered under aseptic conditions, with the wrist fixed in dorsiflexion, and with the insulin injector, a 23-gauge needle was inserted between the palmaris longus and flexor carpi radialis muscles at a 45-degree angle from the palmar distal line (Salutem/19147884379).
214936308|NCT06649461|OTHER|Splint|hand splint for night
214936309|NCT05562765|OTHER|Survey|A descriptive characteristics form, the General Comfort Scale and Quality of Life Index Cardiac Version-IV was used to collect data.
214936310|NCT02402634|OTHER|Mechanical ventilatory lung care|
214936311|NCT06041425|DRUG|Oxycodone|The patients were given 0.1mg/kg oxycodone 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
214936312|NCT06041425|DRUG|Sufentanil|The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
214936313|NCT02161003|PROCEDURE|Stem Cells Injection Technique|Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.
214936314|NCT02161003|PROCEDURE|Stem Cell Isolation|From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
214936315|NCT06137703|DRUG|Zavegepant 100mg non-enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule
214936316|NCT06137703|DRUG|Zavegepant 100mg immediate release tablet|Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet
214936317|NCT06137703|DRUG|Zavegepant 2 x 100mg immediate release tablets|2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg
214335574|NCT04496609|DEVICE|Stimulation and automated rehabilitation / automated rehabilitation|Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
214936318|NCT06137703|DRUG|Zavegepant 4 x 25mg enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg
214936319|NCT04794205|DRUG|Low Dose Beta-Caryophyllene|5 mg BCP
214936320|NCT04794205|DRUG|Medium Dose Beta-Caryophyllene|30 mg BCP
214936321|NCT04794205|DRUG|High Dose Beta-Caryophyllene|150 mg BCP
214936322|NCT04794205|DRUG|Placebo|Placebo drug.
214936323|NCT02115074|DRUG|Fluvastatine|"Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
214936324|NCT02115074|DRUG|Celebrex|"Dose levels : 100 mg twice a day (\< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (\> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
214936325|NCT04106089|BEHAVIORAL|Extended time between vitals check|Participants will have 6 hours protected sleep time (vitals checks moved from every 4 to every 6 hours)
214936326|NCT00741091|DEVICE|Carotid WALLSTENT Monorail Endoprosthesis|A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
214936327|NCT00741091|DEVICE|FilterWire EZ™ System™|Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
214936328|NCT06620094|OTHER|diabetes education videos|In the initial meeting during the preparation phase, participants in the experimental group were informed about the notifications and diabetes education videos that would be sent to their phones. Afterward, the patients received three notifications daily, every day of the week. The first notification requested them to ;measure and record their fasting and postprandial blood sugar in the morning; The second notification instructed them to ;exercise for at least 30 minutes a day.; The third notification asked them to ;record the foods they consumed and their quantities, and to measure and record their evening fasting and postprandial blood sugar, as well as their blood sugar before going to bed.; Additionally, during their routine outpatient follow-ups, the results of their tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides), blood pressure, and weight measurements were recorded. Furthermore, three times a week, participants were asked to ;measure and record their blood pressur
214936329|NCT01801358|DRUG|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
214936330|NCT01801358|DRUG|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
214936331|NCT03059706|DEVICE|RegenoGel-OSP™|intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery
214936332|NCT03059706|OTHER|saline|intra-articular injection of saline after arthroscopic surgery
214936333|NCT00292110|DRUG|Methadone|100 mg/day orally
214936334|NCT00292110|BEHAVIORAL|Contingency Management|Incentives given for cocaine abstinence
214936335|NCT00292110|DRUG|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
214936336|NCT00292110|BEHAVIORAL|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
214936337|NCT01070836|DRUG|natalizumab|Administered as specified in the treatment arm
214936338|NCT01967641|DRUG|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
214936339|NCT00723190|DRUG|CLONICEL (Clonidine HCl sustained release)|0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
214936340|NCT04660318|DEVICE|Remote photoplethysmography for physiological parameters|physiological parameters will be acquired using the Remote photoplethysmography software simultaneously for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
214936341|NCT04660318|DEVICE|standard acquisition system for physiological parameters|physiological parameters will be acquired using the standard acquisition system for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
214936342|NCT02400567|DRUG|Fluorouracile|
214936343|NCT02400567|DRUG|Epirubicin|
214936344|NCT02400567|DRUG|Cyclophosphamide|
214936345|NCT02400567|DRUG|Letrozole|
214936346|NCT02400567|DRUG|Palbociclib|
214936347|NCT06620913|OTHER|Description of clinical, immunological and tumor features of patients harboring CV2 Abs|This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.
214335575|NCT04496609|DEVICE|Automated rehabilitation / Stimulation and automated rehabilitation|Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
214335576|NCT04798300|PROCEDURE|Newly Introduced Gradient Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Newly Introduced Gradient Monolithic Zirconia to measure wear
214335577|NCT04798300|PROCEDURE|Full Strength Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Full Strength Monolithic Zirconia to measure wear
214936348|NCT06615713|DEVICE|Steerable Ureteroscopic Renal Evacuation (SURE) with CVAC System|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
214936349|NCT03181503|DRUG|CD14152 Dose A|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
214936350|NCT03181503|DRUG|CD14152 placebo|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
214335578|NCT05540392|PROCEDURE|Acupuncture|10 treatments of acupuncture over the course of 10 weeks
214936351|NCT06649084|BEHAVIORAL|Multicomponent Lexical Retrieval Training (Multi-LRT)|In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing names of personally relevant target in multiple communication modalities. Treatment focuses on the use of strategies which capitalize on residual linguistic ability and autobiographical memory to support word retrieval. The participant completes two one-hour-long sessions per week plus daily homework. The participant also meets 4 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.
214335579|NCT05540392|OTHER|Waitlist Control|The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
214936352|NCT06649084|BEHAVIORAL|Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA)|In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing personally relevant scripts of 3-5 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician are held which target clear and accurate script production, script memorization, and conversational usage of the script and multimodal communication. The participant also meets 6 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.
214936353|NCT06649084|BEHAVIORAL|Multicomponent Communication Partner Training (Multi-CPT)|In person or via teletherapy: A multi-component treatment incorporating elements of compensatory and care-partner focused interventions. Biweekly (one hour each) sessions with a clinician are held which target use of communication strategies including multimodal communication for the participant and study partner (e.g., spouse). The participant also completes regular assignments meant to increase generalization of communication strategies and progress on personal goals.
214936354|NCT04930042|DRUG|Stelara|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
214936355|NCT04930042|DRUG|AVT04|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
214335580|NCT05540392|OTHER|Questionnaires|Patients will complete Patient Reported Outcomes (PRO)
214335581|NCT00260052|DRUG|Erythropoietin administration|
214335582|NCT05768503|DRUG|Experimental drug|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
214335583|NCT05768503|DRUG|Control Rx|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
214335584|NCT03550963|OTHER|rice-richen meal|Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.
214335585|NCT03550963|OTHER|wheaten-richen meal|Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
214335586|NCT03062891|PROCEDURE|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
214335587|NCT02873169|OTHER|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
214936356|NCT05547607|DIAGNOSTIC_TEST|advanced cardiac imaging|In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
214335588|NCT01485952|DRUG|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
214335589|NCT01485952|DRUG|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
214335590|NCT01485952|DRUG|Placebo|Once daily administration (immediate release capsule)
214936357|NCT04673656|DIETARY_SUPPLEMENT|BKR-017|Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.
214936358|NCT00001656|DRUG|Olanzapine|tablet; 5-20mg/day; 8 weeks
214674434|NCT05468957|DRUG|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
214674435|NCT04471220|DEVICE|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
215073395|NCT06303440|OTHER|Virtual Reality+ Routine Physical Therapy|The exercises will be selected, and the difficulty level will be gradually increased according to participant's performance. Starting from the penguin slide, they will progress to table tilt. Initially, each game will be played for 2 minutes per session. With the progression of performance, 4 minutes of table tilt will be added. While playing this game, a typical mobility pattern will be initiated, and balance will be improved. In the same week, the subjects performed single-leg extensions for 1 minutes. In the following weeks, Balance Bubble, Advanced step, and Basic Run will be added to the plan. The participants will perform these activities for 7 minutes per session. Treatment sessions then progressed to motor function games, including bowling, tennis, kicking, and boxing (least challenging to most challenging), with most treatment sessions ending with boxing will be provided for 7 minutes and routine physical therapy for 30 minutes as explained in control group.
214674436|NCT04010422|DIAGNOSTIC_TEST|no intervention|no intervention
214674437|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 1 gram|after a blood draw 1 gram of vitamin c will be consumed followed by 3 additional blood draws
214674438|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 2 grams|after a blood draw 2 grams of vitamin c will be consumed followed by 3 additional blood draws
214674439|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 5 grams|after a blood draw 5 grams of vitamin c will be consumed followed by 3 additional blood draws
214674440|NCT04463030|DIETARY_SUPPLEMENT|Placebo|after a blood draw placebo will be consumed followed by 3 additional blood draws
214335591|NCT05323383|BEHAVIORAL|Mindfulness Meditation|Participants in the mindfulness meditation condition will listen to a 20minute guided mindfulness meditation practice that holds the breath and body as the object of meditation.
214335592|NCT05323383|BEHAVIORAL|Self-hypnosis|Participants in self-hypnosis will listen to a 20-minute audio-guided hypnosis practice with an induction phase, followed by suggestions tailored towards shifts in affect and decentering, and then a re-alerting with post-hypnotic suggestions phase.
214335593|NCT05323383|OTHER|Attention Control|Control participants will listen to a 20-minute natural history recording which was chosen as past research has found that individuals who listen to it report this to be a neutral, but relaxing passage, and it has been used as an effective control condition in previous research.
214674441|NCT00553787|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
214936359|NCT00001656|DRUG|Clozapine|tablet; 12.5-900mg/day; 8 weeks
214936360|NCT01523015|OTHER|preoperative chemo- and chemoradiotherapy|2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
214936361|NCT01523015|PROCEDURE|Surgical resection|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
214936362|NCT00000207|DRUG|Buprenorphine|
214936363|NCT06079307|OTHER|Oxygenated Mouthwash|Will be comparing the impact of using oxygenated mouthwash with other groups.
214335594|NCT06009952|OTHER|Cryolipolysis and cavitation devices with vegan diet|"Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months)."
214936364|NCT06079307|OTHER|Oxygenated mouth foam|will be comparing the impact of using oxygenated foam to other groups.
214936365|NCT06620315|COMBINATION_PRODUCT|RBM|Resorbable Blast Media (RBM) implant surfaces can enhance osseointegration and implant stability
214936366|NCT06620315|COMBINATION_PRODUCT|sand blasted implant|sand blasted implant
214936367|NCT05451615|DRUG|Janus Kinase Inhibitor|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
214936368|NCT05451615|DRUG|Abatacept|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
214936369|NCT06021756|DRUG|Intervention: Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
214674442|NCT00553787|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
214674443|NCT00553787|DRUG|VI-0521|placebo
214674444|NCT02011503|PROCEDURE|Multi-layer compression therapy|Application of multi-layer compression therapy.
214674445|NCT02011503|OTHER|Application of dHACM|Application of dHACM to ulcer.
214674446|NCT02285010|DRUG|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
214674447|NCT02285010|DRUG|Pregabalin|"Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed."
214674448|NCT02851446|OTHER|measure dyspnoea> Borg 7|
214674449|NCT04204681|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
214674450|NCT02844608|OTHER|Quality of Life Questionnaires|Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
214674451|NCT02261740|BEHAVIORAL|Yoga Therapy|"A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).~Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice."
214674452|NCT02997189|DRUG|OTO-104|12 mg dexamethasone administered intratympanically
214674453|NCT04568174|DRUG|PPSGG|an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies
214674454|NCT04568174|DRUG|Placebo|A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
214936370|NCT06730971|PROCEDURE|Total thyroidectomy|Post operative specimen after total thyroidectomy
214936371|NCT06730971|PROCEDURE|Total thyroidectomy|Remove of both thyroid lobes and isthmus
214936372|NCT03141983|DRUG|Anakinra|Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). It is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) but differs from human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. It is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.
214936373|NCT03141983|DRUG|Placebo|Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
214335595|NCT05585216|DRUG|platelet-rich plasma|intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
214335596|NCT03411525|BEHAVIORAL|Commitment Invitation for Clinicians (Clinician Intervention)|Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
214335597|NCT03411525|OTHER|Health Education Materials to Patients (Patient Intervention)|During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
214335598|NCT04614259|DRUG|Bupivacain|"The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). \[104\] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis"
214674455|NCT05597566|PROCEDURE|modified electroconvulsive therapy|The patient underwent MECT therapy. The treatment instrument is Xingmaitong IV ECT multifunctional treatment instrument (USA, SOMATICS THYMATRON company), fasting for 6 hours before surgery, emptying urine. Routine preoperative preparations were made, followed by intravenous injection of atropine, propofol, and succinylcholine chloride injection, artificial respiration, placement of dental pads, and electroconvulsive therapy. The whole process is completed by an anesthesiologist and a therapist in cooperation with each other. The first 3 times are once a day, and the next 5 times are once every other day. A total of 8 courses of treatment.
214335599|NCT04614259|COMBINATION_PRODUCT|i.v. analgesia|"Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes"
214335600|NCT05073406|OTHER|Altitude exposure in hypobaric normoxic condition|Altitude exposure with oxygen supplementation to achieve normoxia at altitude
214335601|NCT05073406|OTHER|Altitude exposure in hypobaric hypoxic condition|Altitude exposure with air supplementation to obtain a sham comparator arm
214335602|NCT06404996|DEVICE|Smart-phone Voiding Diary|Smart-phone Voiding Diary
214335603|NCT06404996|DIAGNOSTIC_TEST|Paper voiding diary|Conventional Paper voiding diary
214674456|NCT00006168|DRUG|Methotrexate|
214674457|NCT01919372|DEVICE|Telemedic assistance with a technological system|
214674458|NCT01919372|OTHER|Standard care|
214335604|NCT03065881|DEVICE|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
214335605|NCT05087017|OTHER|Intervention group|Patients with medical condition to follow the rehabilitation program will be asked to answer questionnaires to assess their sleep quality.
214335606|NCT03001895|DRUG|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
214335607|NCT03529630|OTHER|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
214335608|NCT01334931|RADIATION|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
214335609|NCT01334931|RADIATION|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
214335610|NCT04720859|DRUG|Canagliflozin 300 MG Oral Tablet|Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
214335611|NCT03221257|DRUG|Pirfenidone (PFD)|Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
214936374|NCT06730009|BIOLOGICAL|SLOG + Allogeneic NK cell|"Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)~Biological:~Allogeneic Magicell-NK contains NK cells suspended in 100 mL of normal saline Ph I dose starts at 10 × 10\^8 cells (Cohort 1) and escalates to 20 × 10\^8 cells (Cohort 2).~Ph II dose will be determined lower than or equal to Ph I MTD/MFD."
214936375|NCT06730009|DRUG|SLOG chemotherapy|Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)
214936376|NCT03839771|DRUG|AG-120|250mg tablets
214674459|NCT00521963|BIOLOGICAL|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
214674460|NCT05110586|OTHER|Electrotherapy|Applications will be applied for 4 weeks, 5 days a week
214674461|NCT00939263|OTHER|assessment of disease activity using the EEsAI|disease activity index
214674462|NCT02400112|DRUG|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
214335612|NCT03221257|DRUG|Placebo (Plac)|Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
214335613|NCT03221257|DRUG|Mycophenolate Mofetil (MMF)|Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
214347276|NCT04708873|OTHER|High intensity interval training|4x4 min intervals of high intensity treadmill running (80-95% of HRR, RPE 7-10 on Borg's category ratio scale of perceived exertion) interspersed with active recovery (slow jogging or fast walking at 50-70% HRR). HIIT-Resistance exercises 2 sessions per week, RPE 5 (hard) 6-8 RM, 1-3 sets of as many repetitions as possible in 60 seconds, active recovery 20-60 seconds b/w exercises,
214674463|NCT05215210|OTHER|Bitter-gourd|12-week intervention of 3.6 grams of dried bitter-gourd supplements
214674464|NCT05215210|OTHER|Cucumber|12-week intervention of 3.6 grams of cucumber supplements
214674465|NCT02231203|DRUG|Omegaven|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
214674466|NCT02231203|DRUG|Placebo|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
214674467|NCT00611793|DRUG|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
214674468|NCT00754767|DRUG|L-carnitine L-tartrate|Given orally
214674469|NCT00754767|OTHER|placebo|Given orally
214936377|NCT03839771|DRUG|Placebo for AG-120|250mg tablets
214936378|NCT03839771|DRUG|AG-221|100mg tablets
214936379|NCT03839771|DRUG|Placebo for AG-221|100mg tablets
214936380|NCT00391157|DRUG|Velcade/Dexamethasone|Velcade 1,3 mg/m2 on days 1, 4, 8 and 11
214936381|NCT02300350|DRUG|Treatment A digoxin|0.5 mg digoxin administered on Day 1 and Day 20
214936382|NCT02300350|DRUG|Treatment B LX4211|400 mg LX4211 administered daily on Day 14 through Day 25
214936383|NCT02300350|DRUG|Treatment C Digoxin + 400 mg LX4211 administered concomitantly|0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
214936384|NCT02036658|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
214936385|NCT02036658|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
214335614|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 8-session version|Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
214347277|NCT04708873|OTHER|Moderate Intensity Continuous Training|Moderate intensity continuous Aerobic exercises (Stationary cycling for 15-20 min followed by treadmill walking for 15-20 min) at 55-70% 55-70% of HRR, RPE 3-4 on Borg's category ratio scale of perceived exertion. The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
214347278|NCT00558285|DRUG|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
214347279|NCT00558285|DRUG|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
214347280|NCT00558285|DRUG|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
214936386|NCT01886742|DRUG|Standard Dose Group|The standard dose of Cefazolin will be administered intravenously.
214936387|NCT01886742|DRUG|Weight Based Group|The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
214936388|NCT03785899|DEVICE|SPOCnew|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The revised new algorithm is turned on."
214936389|NCT03785899|DEVICE|8s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 8s.
214936390|NCT03785899|DEVICE|SPOCold|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The former old algorithm is turned on."
214936391|NCT03785899|DEVICE|2s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 2s.
214936392|NCT00001783|DRUG|0-15 Water|
214936393|NCT00640653|BEHAVIORAL|Abstinence-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.
214936394|NCT00640653|BEHAVIORAL|Safer-sex-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
214936395|NCT00640653|BEHAVIORAL|Long comprehensive HIV/STD risk-reduction intervention|Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).
214936396|NCT00640653|BEHAVIORAL|Short comprehensive HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.
214936397|NCT00640653|BEHAVIORAL|Health promotion control intervention|"Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for Hawthorne effects to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention."
214936398|NCT00745511|DRUG|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
214936399|NCT00745511|DRUG|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
214936400|NCT01729533|OTHER|ICSI|ICSI Sperm selection in the ICSI group is analyzed under a magnification of 400x using an inverted microscope. ICSI is performed in a micro-injection dish prepared with 4 µL droplets of buffered medium and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
214936401|NCT01729533|OTHER|IMSI|Sperm selection in the IMSI group is analyzed at high magnification using an inverted microscope equipped with high-power differential interference contrast optics. The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei (\[1\] smooth, \[2\] symmetric, and \[3\] oval configuration) and \[4\] normal nuclear chromatin content (if it contained no more than one vacuole, which occupies \<4% of the nuclear area) are selected for injection.
214936402|NCT03672448|OTHER|Naturalistic observation|Naturalistic observation
215073396|NCT06303440|OTHER|Motor Imagery+ Routine Physical Therapy|"The 15 minutes of Motor Imagery session will be provided to participants. It's a three step process that will be used to incorporate the technique.~Step I, The self-recorded videos of the principal researcher performing a normal movements will be shown to participant.~Step II, The participants will be asked to imagine movement with eyes closed, and breathe deeply.~Step III The participants will be asked to perform the movement you watched in video and routine physical therapy of 30 minutes will be provided.~During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video."
214335615|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 16-session version|Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
214335616|NCT06171867|DEVICE|PNEUMACRIT|Monitoring of breathing
214335617|NCT00725426|DRUG|Bosutinib|
214335618|NCT06491550|DRUG|AZD4144- Part A|Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.
214335619|NCT06491550|DRUG|Placebo- Part A|Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.
215073397|NCT03354546|DIAGNOSTIC_TEST|Frailty index|A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
214335620|NCT06491550|DRUG|AZD4144- Part B|"Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion.~Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion."
214936403|NCT01058486|BEHAVIORAL|Self-Management and Motivational Interviewing|"Post hospital discharge, patients will be referred (\<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.~A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.~Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts."
214335621|NCT06491550|DRUG|Placebo- Part B|Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.
214936404|NCT03843424|BEHAVIORAL|eSOC program|American Medical Association (AMA) recommended staged approach to childhood obesity screening and counseling
214674470|NCT04149522|DEVICE|Mepitel Film®|As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
215073398|NCT02713997|DRUG|etanercept|50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT
215073399|NCT02713997|DRUG|Alpha 1-Antitrypsin|90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant
214335622|NCT06491550|DRUG|Rosuvastatin and Furosemide- Part C|Participants will be administered a single oral dose of 10 mg Rosuvastatin and 1 mg Furosemide.
214335623|NCT06491550|DRUG|Rosuvastatin, Furosemide, and AZD4144 Part C|Participants will be administered a single oral dose of 10 mg Rosuvastatin, 1 mg Furosemide and a single dose of AZD4144 via IV infusion.
215073400|NCT05368285|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
215073401|NCT05368285|DRUG|Matching Placebo|Subcutaneous Administration
214347281|NCT00558285|DRUG|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
215073402|NCT06107985|OTHER|Structured exercise program|This intervention will be based on shoulder kinetic control, load modification exercises and lumbopelvic stabilization with core stability exercises which is not a part of conventional exercise program for shoulder impingement syndrome patients.
215073403|NCT06107985|OTHER|Conventional Exercise Program|Conventional exercise program for shoulder impingement syndrome patients
215073404|NCT06274996|DRUG|Upadacitinib|Upadacitinib, a selective Janus kinase (JAK) inhibitor taken orally, is being assessed for its unique capacity to attenuate inflammatory pathways in IBD at a cellular level by selectively inhibiting JAK1, a pathway integral to inflammatory cytokine production. This study focuses on its use as monotherapy for Chinese patients unresponsive to conventional IBD treatments, such as aminosalicylates and corticosteroids. By centering on a demographic typically underrepresented in research, the study aims to provide new insights into dosing, treatment frequency, and duration, thus enhancing the understanding of Upadacitinib\&#39;s safety and efficacy. The retrospective analysis of patient data is anticipated to inform more personalized treatment approaches, potentially improving IBD management and patient quality of life.
215073405|NCT01039545|DRUG|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
215073406|NCT01039545|DRUG|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
215073407|NCT01263418|DRUG|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
214347282|NCT01274546|DEVICE|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
215073408|NCT03321864|PROCEDURE|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
214335624|NCT02338752|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
214335625|NCT02338752|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
214486404|NCT06739538|DIAGNOSTIC_TEST|Bobath exercises|Bobath concept, are therapeutic techniques designed to improve motor control and function in individuals with neurological conditions, particularly those with cerebral palsy. These exercises focus on facilitating normal movement patterns, enhancing postural stability, and reducing muscle spasticity. The approach emphasizes individualized treatment, utilizing hands-on techniques to promote movement awareness and encourage the development of functional skills. By reinforcing weak movements and inhibiting overactive ones, Bobath exercises aim to enhance overall motor abilities and improve the quality of life for affected individuals.
214936405|NCT03843424|BEHAVIORAL|FBT program|An intensive,comprehensive, behavioral intervention aligned with the US Preventive Services Task Force recommendations for childhood obesity screening and counseling.
214936406|NCT04380012|DRUG|Pyrotinib|Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer
214936407|NCT04380012|DRUG|Pyrotinib in combination with trastuzumab|Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer
214674471|NCT06496503|BEHAVIORAL|Physical activity Protocol|The children included in the experimental group will undergo 12 weeks of physical activity sessions, and it is mandatory that all children complete a minimum of two weekly sessions of physical activity for 50-60 minutes. The activities will consist of content such as motor and cognitive games, sports, dance, and gymnastics. The intensity of the sessions will be checked using accelerometry. The physical activity protocol is adapted from a previously described protocol (CMSP, 2021; Klem, Filha, Monteiro, 2017; Mazzoccante et al.; 2020; Paiano, 2019; Rodrigues, 2018; Rosini et al., 2014). Acceptance of the exercise program in the pediatric population has been previously observed in a pilot study.
214936408|NCT04276610|BEHAVIORAL|Low Vision Reading Rehabilitation|Following Time 1, participants will receive the full complement of vision rehabilitation services available and deemed suitable by their clinical staff and rehabilitation professionals of either rehabilitation centre, according to the provision of assistive devices and services regulated by the Quebec Health Insurance (RAMQ). These services are include but are not limited to: a full optometric exam to determine functional vision, including refraction and the prescription of appropriate near and distance glasses and optical devices, an assessment by a low vision therapist and/or occupational therapist, the loan provision of hand-held optical magnification devices, electronic non-optical magnification devices (e.g., portable or table-top closed-circuit televisions), or computer software for screen content magnification (e.g., ZoomText), with appropriate training and follow-up sessions in the home, if required.
214936409|NCT02505334|DRUG|liraglutide|Injected subcutaneously s.c. (under the skin) once daily.
214936410|NCT02433041|DRUG|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
214936411|NCT02433041|DRUG|Ketamine|Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
214936412|NCT02433041|DRUG|Haloperidol + Ketamine|Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
214936413|NCT02433041|DRUG|Saline solution (NaCl 0.9%)|Placebo being used in one of the four groups
214936414|NCT05110521|BEHAVIORAL|PROMPTS|PROMPTS is a two-way Short Message Service (SMS) digital health platform that connects mothers with information, advice and referrals to care during the prenatal and postnatal period. The platform also collects information from women on care experience that is reported back to maternity facilities.
214936415|NCT05110521|BEHAVIORAL|MENTORS|MENTORS is a program in which in facility nurse-mentors are trained and supported to offer training to nurses, midwives and other maternity facility staff on aspects of basic and emergency obstetric and newborn care.
214936416|NCT01835275|BEHAVIORAL|Enhanced Audio|
214936417|NCT01835275|BEHAVIORAL|Audio|
214335626|NCT04699331|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
214335627|NCT02315235|BIOLOGICAL|Normal saline|Normal saline is injected in one leg of patient.
214335628|NCT02315235|BIOLOGICAL|stem-cell|"Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient."
214335629|NCT04905056|OTHER|Ablation therapy|Ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
214335630|NCT02072850|DEVICE|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
214335631|NCT02072850|OTHER|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (\~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (\< 12 hours, days 2, 7-10 and at 6 months).
214335632|NCT05892848|DIAGNOSTIC_TEST|serum ostecalcin,serum sclerostin and parathroid profile|evaluation of bone turnover markers in blood
214335633|NCT06034158|DRUG|single-dose madopar, single-dose propranolol, and single-dose placebo by order|Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
214936418|NCT03409900|OTHER|LPB|The LPB will be performed in a lateral position, but modified to utilize ultrasound guidance to enhance our ability to quickly and safely locate the lumbar plexus as well as to avoid unblinding with regard to the traditional landmark LPB technique. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
214936419|NCT03409900|OTHER|QLB|The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
214936420|NCT06494306|BEHAVIORAL|European Test of Olfactory Capabilities (ETOC)|Investigators will collect the ETOC score in patient of both arms
214936421|NCT06494306|BEHAVIORAL|Standardized Hedonicity Test|To smell 20 odorant solutions and for each odor and evaluate it along five dimensions: familiarity, hedonicity, edibility, desire to smell again, perceived intensity). Each dimension is assessed with a Likert scale (from 1 (not at all) to 9 (extremely))
214936422|NCT06494306|BEHAVIORAL|Questionnaires|Patients with PTSD will have the following questionnaires : PTSD Checklist for Diagnostic and Statistical Manual (DSM)-V (PCL-5), Peri-trauma Dissociation Experience Questionnaire (PDEQ), Patient Health Questionnaire-9 (PHQ9), Snaith-Hamilton Pleasure Scale (SHAPS), Childhood Trauma Questionnaire (CTQ) and Apathy Evaluation Scale (AES)
214936423|NCT06494306|BEHAVIORAL|Odor / trauma association questionnaire|Patients with PTSD will have Odor / trauma association questionnaire
214936424|NCT00100191|PROCEDURE|uterine artery embolization|
214936425|NCT00100191|PROCEDURE|hysterectomy|
214936426|NCT03199612|DRUG|Sildenafil|To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.
214936427|NCT03199612|DRUG|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.
214936428|NCT00154401|DRUG|liraglutide|
214936429|NCT05228925|OTHER|Maternal vitamin D status|Maternal vitamin D status (serum 25-hydroxyvitamin D) was collected during the GraviD study, while the woman was pregnant with the child now being followed-up in the GraviD-child study
214936430|NCT02284763|OTHER|EtCO2|Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
214936431|NCT06339216|DRUG|Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)|"Adebrelimab injection：Intravenous infusion, fixed dose 1200 mg, Day 1, Q3W. Until disease progression or intolerable toxicity occurs, the infusion should be administered over 30 to 60 minutes and over a maximum of 2 hours. When adalimumab is administered in combination with chemotherapy, Adebrelimab should be administered as an intravenous infusion first, followed by chemotherapy at least 30 minutes apart.~Apatinib mesylate：Administered orally, 250 mg/time, once daily, orally, half an hour after meals (the time of daily administration should be as same as possible), with warm boiled water, the missed dose of Apatinib during the course of treatment cannot be supplemented.~Paclitaxel for Injection(Albumin Bound)：Intravenous infusion, 250 mg/m2, day 1, Q3W, intravenous drip over 30 minutes."
214936432|NCT05359510|PROCEDURE|prophylactic mesh repair at different sites for prevention of incisional hernia after various abdominal incision versus primary abdominal suturing|before closure of the abdominal layers prophylactic mesh will be used for prevention of incisional hernia. another patient with abdominal incision , primary closure of abdominal layer will occur.
214335634|NCT06034158|DRUG|single-dose madopar, single-dose placebo, and single-dose propranolol by order|Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
214936433|NCT01931241|DRUG|AHRO-001|Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
214335635|NCT06034158|DRUG|single-dose propranolol, single-dose madopar, and single-dose placebo by order|Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
214335636|NCT06034158|DRUG|single-dose propranolol, single-dose placebo, and single-dose madopar by order|Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
214335637|NCT06034158|DRUG|single-dose placebo, single-dose propranolol, and single-dose madopar by order|Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
214335638|NCT06034158|DRUG|single-dose placebo, single-dose madopar, and single-dose propranolol by order|Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
214335639|NCT00898976|OTHER|immunohistochemistry staining method|
214335640|NCT00898976|OTHER|laboratory biomarker analysis|
214335641|NCT02149342|DRUG|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
214335642|NCT02149342|DRUG|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
214335643|NCT03887039|OTHER|clinical examination|clinical examination for all the oral findings
214335644|NCT00000707|DRUG|Pentamidine isethionate|
214335645|NCT03467633|BEHAVIORAL|High-intensity interval training|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the UOHI prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
214335646|NCT03658083|PROCEDURE|Thoracotomy|Open surgery
214335647|NCT03658083|PROCEDURE|Robotic-assisted thoracic surgery|Minimally invasive surgery
214335648|NCT00038922|DRUG|rhIL-11|
214335649|NCT05940974|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the surgery and after the surgery (on 4 dates over a 1-year period); the DASH and ASES questionnaires to measure their functional outcomes before the surgery and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the surgery and after the surgery (on 4 dates over a 1-year period).
214335650|NCT01129141|PROCEDURE|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
214335651|NCT01129141|PROCEDURE|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
214335652|NCT05626946|OTHER|Observation|Observation
214335653|NCT05902208|DRUG|Antiviral treatment with conventional non-surgical treatment|Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
214335654|NCT05902208|DRUG|Placebo with conventional non-surgical treatment|Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
214335655|NCT02419846|OTHER|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
214674472|NCT04635644|PROCEDURE|Erector Spinae Plane Block|Patients will be turned into the prone position. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T8 spinous process. The erector spinae muscles will be identified superficial to the tip of the T8 transverse process. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine, a 21G 10 cm needle will be inserted using an in-plane approach in a cranial to caudal direction to contact the T8 transverse process. The location of the needle tip will be confirmed by hydrodissection with 2 mL of lidocaine 2% and visualizing linear fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of 0.25% Bupivacaine is injected will be injected at this point. The same procedure will be repeated for the opposite side.
214674473|NCT04635644|PROCEDURE|Intrathecal morphine|Patients will be placed on their right side. An intrathecal injection of morphine 200 μg (0.2 mL of morphine sulfate 1 mg/mL) diluted in 1.8 mL normal saline will be administered at the L3-L4 or L4-L5 level with a 25 G Whitacre spinal needle.
214674474|NCT03809286|DEVICE|active rTMS|rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.
214674475|NCT03809286|BEHAVIORAL|Inpatient admission|All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.
214335656|NCT02419846|PROCEDURE|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
214674476|NCT03809286|DEVICE|sham rTMS|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
214335657|NCT02419846|OTHER|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
214335658|NCT02419846|OTHER|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
214335659|NCT02419846|OTHER|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
214335660|NCT02419846|OTHER|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
214335661|NCT00180856|PROCEDURE|Radiofrequency ablation|
214335662|NCT04084353|OTHER|Intrapartum fetal monitoring training and quality improvement project|Intrapartum fetal monitoring training
214335663|NCT05209685|OTHER|Resistance exercise on the lower extremities|Resistance exercise mainly on the lower extremities will be executed by carrying weight according to each participant's tolerance while performing certain movements, such as side step-up, sit-to-stand, and tip-toe-standing.
214335664|NCT05209685|OTHER|Resistance exercise on the lower extremities with blood flow restriction|Blood flow restriction on the thigh of the dominant leg will be used in combination with resistance exercise.
214335665|NCT01492634|OTHER|Prescription of post-dialytic weight based on BCM device|"Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).~The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.~Prescription steps will be calculated weekly for all study patients. TAFO \< -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO \> 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week."
214674477|NCT06971380|BIOLOGICAL|HBI0101 CART|HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART may be provided fresh or cryopreserved.
214674478|NCT06969625|PROCEDURE|(SHAC) block|The shoulder anterior capsular block targets interfacial and pericapsular space. A 25-gauge 80-mm insulated stimulating needle will be used for injections and in-plane needling will be from lateral to medial side. After aspiration is negative, 10 ml of 0.5 % bupivacaine plus dexamethasone 4 mg as adjuvant will be injected in the interfacial plane. Once the injection into the fascial space is achieved, the operator can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle and the second injection after negative aspiration will be 10 ml 0.5 % bupivacaine plus dexamethasone 4 mg in pericapsular space.
214674479|NCT06969625|PROCEDURE|(SSNB-ANB) block|"Suprascapular Nerve Block (SNB): Using an in-plane ultrasound guidance from the medial side, 10 mL of 0.5% bupivacaine plus dexamethasone 4 mg as adjuvant will be injected after contacting the lateral aspect of the supraspinous fossa and negative aspiration confirmed. The LA should spread beneath the supraspinatus, lifting up the muscle.~Axillary Nerve Block (ANB):~The ANB is performed from behind the patient with the patient seated. The axillary nerve will be identified within the quadrilateral space by placing high frequency linear probe (Sono site M turbo) parallel to the long axis of the humeral shaft. The nerve was identified next to the circumflex artery. The skin will be anesthetized with 1% lidocaine (3mL). 10 mL of 0.5% bupivacaine plus dexamethasone 4 mg will be injected against the surface of the humerus, just posterior and lateral to the artery after confirming negative aspiration."
214674480|NCT06970834|DIETARY_SUPPLEMENT|bitter melon peptides|Momordica charantia extract
214674481|NCT06970171|DEVICE|MAD of the Scheu Dental type with lateral guidance wings (MAD-1)|The vertical dimension is raised to achieve an incisal edge distance (IED) of 5 mm using a George Gauge, with a mandibular advancement of 5 mm at insertion, progressing to final titrated advancement during the treatment phase.
214674482|NCT06970171|DEVICE|MAD of the Panthera X3 type with lateral guidance wings (MAD-2)|The vertical dimension is raised to achieve a minimum 2 mm interocclusal cusp distance and the lowest possible IED, with a mandibular advancement of 5 mm at insertion, progressing to final titrated advancement during the treatment phase.
214674483|NCT06971471|DEVICE|Integration of Artificial Intelligence (AI) assistance to screening gastroscopy|"Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems."
214674484|NCT06972082|DEVICE|VEXUS|Goal-directed fluid and drug therapy according to VEXUS measurements to minimize AKI
214674485|NCT05279092|DRUG|Bupivacaine-Liposomal Bupivacaine|Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
214674486|NCT05279092|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
215073409|NCT03430024|OTHER|Association of Myosin VI with oestrogen receptor|"1. Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~2. Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~3. Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues."
215073410|NCT02403934|DEVICE|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
215073411|NCT01661777|DRUG|Nasal steroid|
215073412|NCT01661777|PROCEDURE|Myringotomy tube placement|
215073413|NCT01661777|DRUG|Diuretic|
215073414|NCT01661777|DRUG|Antihistamine|
215073415|NCT01661777|BEHAVIORAL|Low salt diet|
215073416|NCT05301257|BEHAVIORAL|Intervention group SOSteniamoci|Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
215073417|NCT02370485|DRUG|LY2801653|Administered orally
215073418|NCT05909410|OTHER|Survey investigating the CHC use and patients' perception about the relationship between CHC and cancer, diseases and symptoms|This survey investigated the CHC use (type and timing of administration) and patients' perception about the relationship between CHC and cancer, diseases and symptoms
214936434|NCT02747849|DEVICE|TENS|Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
214335666|NCT00482079|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
214335667|NCT00482079|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
214936435|NCT05468749|DRUG|CTP-543|Single 12 mg oral dose administered on Day 1
214674487|NCT06095674|DRUG|Anti-PD-1 antibody balstilimab|Both antibodies will be neoadjuvantly administered around the cervical tumor.
214674488|NCT01670851|DEVICE|Strattice|Perineal reconstruction and stoma reinforcement with Strattice
214674489|NCT05848713|DRUG|Heparin|"Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement."
215073419|NCT05007496|BIOLOGICAL|AV-COVID-19|DCL previously loaded with varying quantity of S-protein
215073420|NCT05666843|BEHAVIORAL|Personalized Dietary Advice|Personalized dietary guidance to increase the intake of fibre-rich foods on top of usual care.The dietary guidance is implemented by dieticians and is personalized based on current adherence to the dietary guidelines, usual dietary intake, gender and personal goals and preferences.
214674490|NCT01030042|DRUG|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
214936436|NCT03644836|DRUG|Amino Acids|Sweet taste cocoa flavored drink
214936437|NCT03644836|DRUG|Placebos|Sweet taste cocoa flavored drink
214936438|NCT06238661|DIAGNOSTIC_TEST|Urology visit with Risk Calculator and MRI|Patients with PSA ≥3 ng/ml will undergo urology visit with risk calculator and MRI assessment of the prostate
214936439|NCT01368107|DRUG|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
215073421|NCT04363697|DRUG|Dapagliflozin|Dapagliflozin
214335668|NCT03212625|DRUG|Urea Cream 20%|Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
214936440|NCT01368107|DRUG|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
214936441|NCT01368107|DRUG|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
214335669|NCT03212625|DRUG|Placebos|Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
215073422|NCT04363697|DRUG|Placebo|Matched placebo
215073423|NCT06107803|DRUG|Roluperidone 64 mg|64 mg/day oral
215073424|NCT06107803|DRUG|Olanzapine 10 MG|10 mg/day oral
214335670|NCT04089267|DRUG|TPO|
214335671|NCT00075829|PROCEDURE|One Autologous Transplant|Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive \~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) \> 500/mm3 for two days.
214347283|NCT03538535|BEHAVIORAL|Go/No-Go Active Learning (GOAL)|Behavioral Activation psychotherapy adapted to engage go/no-go learning
214347284|NCT03384758|DEVICE|Compression Therapy|Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
215073425|NCT05392114|DRUG|Donidalorsen|Donidalorsen will be administered by SC injection.
215073426|NCT06503848|DRUG|Sumatriptan|Register the response to treatment and headache characteristics.
214347285|NCT03248284|PROCEDURE|Tendon biopsy procedure|Two tendon biopsy specimens will be obtained from one Achilles tendon with enthesitis.
214347286|NCT03066531|BEHAVIORAL|ACT-based intervention|
214347287|NCT03066531|BEHAVIORAL|CBT-based intervention|
215073427|NCT05129072|DEVICE|kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D|kalifilcon A Daily Disposable Toric LD213001 lens
214335672|NCT00075829|PROCEDURE|Non-Myeloablative Allogeneic Transplant|Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
214335673|NCT00075829|PROCEDURE|Second Autologous Transplant|Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
214335674|NCT00075829|DRUG|Thalidomide|Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
214335675|NCT00075829|DRUG|Dexamethasone|Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
214335676|NCT00075829|BEHAVIORAL|Observation|One year of observation post-transplants.
214335677|NCT01387204|DRUG|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
214335678|NCT02044536|OTHER|No intervention|retrospective data review
214335679|NCT00694980|DRUG|placebo|Intravenous and subcutaneous escalating doses
214674491|NCT01030042|DRUG|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
214674492|NCT04238845|DRUG|AQSP Administration|Three days treatment of all children with AQSP for SMC
214674493|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Plumpy'Doz|Daily supplementation of children with Plumpy'Doz
214936442|NCT01368107|DRUG|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
214936443|NCT05702411|OTHER|Air Stacking Technique|Air Stacking lung reexpansion technique after aspiration with expiratory pause in a closed system.
214936444|NCT05702411|OTHER|No Air Stacking Technique|Aspiration technique in a closed system of aspiration with an expiratory pause of 10 seconds.
215073428|NCT06585293|DEVICE|Mitra Microsampling Device|Microsampling tool for finger-prick blood collection
214674494|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Vitamin A|Single dose supplementation with Vitamin A to all children
214674495|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Zinc|Daily supplementation with Zinc
214674496|NCT01334112|DRUG|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
214674497|NCT03912467|OTHER|Pressure Ulcer Evaluation|Patient was evaluated according to presence of pressur ulcer or not
214674498|NCT01101724|BEHAVIORAL|Mandated Rest, Intervention|"In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury."
214674499|NCT06971159|DEVICE|Systemic vibratory therapy|Systemic vibratory therapy is an intervention in which mechanical vibration, generated by the vibrating platform, is transmitted to the whole-body of the individual generating whole-body vibration exercise.
214936445|NCT02938949|DRUG|alirocumab|
215073429|NCT02380664|DEVICE|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
215073430|NCT02380664|BEHAVIORAL|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
214936446|NCT02938949|DRUG|placebo|
214936447|NCT03266692|BIOLOGICAL|ACTR087|Autologous T cell product
214936448|NCT03266692|BIOLOGICAL|SEA-BCMA|B-cell maturation antigen (BCMA)-directed antibody
214335680|NCT00694980|DRUG|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
214335681|NCT01122511|DRUG|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
214335682|NCT01122511|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab into study eye
214335683|NCT01122511|OTHER|sham|Sham needle-less injection administered in the study eye
214335684|NCT00447928|DRUG|OrthoDerm transdermal nitroglycerin patch|
214335685|NCT00685932|DEVICE|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
214335686|NCT00355446|DRUG|Bimatoprost 0.03%|
214335687|NCT03413332|OTHER|E-Talkcare|Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.
214936449|NCT04754620|OTHER|real time online video visit|Participants have received an online visit by a smartphone application
214674500|NCT06971159|OTHER|Osteopathic manipulative treatment|Osteopathic manipulative treatment is defined by the WHO as a diagnostic and therapeutic method that uses manual contact for these purposes. It concerns the relationship between body, mind and spirit in health and illness, emphasizing the structural and functional integrity of the body and the body's intrinsic tendency to direct itself towards healing.
214674501|NCT06971159|OTHER|Sham|In the sham group, the interventions are simulated, as described in the sham group protocol.
214674502|NCT02186327|BEHAVIORAL|Integrative Health Coaching|Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
214674503|NCT02195648|OTHER|Suboccipital inhibition|"Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles."
214674504|NCT01661647|DEVICE|3D knee kinematic assessment under local anesthesia|3D knee kinematic assessment under local anesthesia
214936450|NCT03685292|BEHAVIORAL|Behavioral Advisory System|Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.
214347288|NCT04182022|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.
214936451|NCT03685292|DRUG|Behavioral Treatment|This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
214936452|NCT03685292|DEVICE|Behavioral Division|This study is relative to minimal contact control (MCC).
214936453|NCT03542591|OTHER|"Questionnaire on the topic Supplementation of critical nutrients in a plant-based diet"|No active intervention, only survey as mentioned above.
214936454|NCT01319240|DRUG|insulin degludec|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
214936455|NCT01319240|DRUG|insulin degludec/liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
214936456|NCT01319240|DRUG|liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
214936457|NCT00201240|BIOLOGICAL|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ \>5 x 10\*6/kg and CD3+ \< 1 x 10\*5/kg
214936458|NCT03724266|DRUG|Chitosan|chitosan will be used as intracanal medication
214936459|NCT03724266|DRUG|Calcium Hydroxide|intracanal medication
214936460|NCT01870674|DRUG|YH12852|
214674505|NCT04170621|DEVICE|Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
214674506|NCT03856450|DEVICE|DTS|Subjects undergo wrist imaging using DTS.
214674507|NCT03856450|DEVICE|X-ray|Subjects undergo wrist imaging using standard X-ray imaging.
214674508|NCT03856450|DEVICE|MRI or CT|Subjects may undergo wrist imaging using MRI or CT.
214335688|NCT03413332|OTHER|Usual Care|Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
214335689|NCT05449028|DRUG|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
214335690|NCT05449028|DRUG|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
214335691|NCT05449028|DRUG|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
214936461|NCT01870674|DRUG|Prucalopride|
214335692|NCT05449028|DRUG|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
214936462|NCT01870674|DRUG|Placebo|
214936463|NCT02182466|DEVICE|Colon capsule endoscopy|
214936464|NCT06288269|OTHER|Severity of Stroke and 1 year survival|Evaluated from NIHSS and clinical outcome 1 year survival death
214674509|NCT00987766|DRUG|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
214674510|NCT00987766|DRUG|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
214674511|NCT00987766|DRUG|oxaliplatin|Given through a vein in the arm 1 time every other week.
214674512|NCT00987766|OTHER|laboratory biomarker analysis|Blood and tissue collection.
214335693|NCT05449028|DRUG|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
214335694|NCT01037478|DRUG|Resminostat (4SC-201)|oral administration
214335695|NCT03550924|PROCEDURE|low flow passive oxygenation|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
214335696|NCT03550924|PROCEDURE|high flow passive oxygenation|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
214335697|NCT03781076|BEHAVIORAL|Sleep Intervention|The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
214335698|NCT01687166|DEVICE|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
214335699|NCT01687166|DEVICE|FDA Approved Open-Irrigated Ablation Catheter|
214674513|NCT00810160|DIETARY_SUPPLEMENT|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
214674514|NCT00810160|DIETARY_SUPPLEMENT|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
214936465|NCT00081731|DRUG|Atacand/HCT, Caduet|Atacand/HCT and caduet or optimal medical therapy for hypertension
214936466|NCT00081731|PROCEDURE|GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)|Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
214936467|NCT02841566|OTHER|questionnaire|
214936468|NCT00829816|DRUG|Dimebon|
214936469|NCT00829816|DRUG|Placebo|
214936470|NCT03860714|DIAGNOSTIC_TEST|Neuropsychological tests|We do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Clinical Dementia Rating(CDR),Quality of Recovery Score - 40 (QoR-40),Geriatric Depression Scale (GDS),CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
214936471|NCT05240469|DEVICE|Automated sperm selection software|"The software measures both morphology and motility similar to an embryologist but provides a more accurate and consistent measure of sperm characteristics. Embryologists use their experience to qualitatively judge if an individual sperm is suitable for injection based on morphology and motility. Similarly, the software follows a two-step process: firstly, a computer vision algorithm measures characteristics of all sperm in a given field, including motility and morphology; secondly, the software algorithm then uses a set of quantitative criteria to categorize and identify the most developmentally competent sperm with normal characteristics. All the characteristics that the software calculate are defined by the WHO guidelines, and the software does not propose or define new parameters."
214936472|NCT02096068|DRUG|Dexmedetomidine (Dexdor®)|Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
214936473|NCT02096068|DRUG|0.9% Sodium Chloride|Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
214936474|NCT01135069|DRUG|Tretinoin microsphere 0.1%|Treatment of acne vulgaris
214335700|NCT04958733|PROCEDURE|Autologous bone grafting|Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
214335701|NCT04958733|PROCEDURE|Absence of autologous bone grafting|Donor sites will be left unfilled
214335702|NCT02966171|DRUG|HMPL-453|oral administration
214335703|NCT05371535|DEVICE|MatrixOssTM Bone Graft plus Bio-Gide membrane|To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
214335704|NCT02296112|DRUG|trametinib|Given PO
214335705|NCT02296112|OTHER|laboratory biomarker analysis|Correlative studies
214335706|NCT02296112|OTHER|pharmacological study|Correlative studies
214936475|NCT01135069|DRUG|Brand Retin-A Micro tretinoin microsphere gel 0.1%|Treatment of acne vulgaris
214936476|NCT01135069|DRUG|placebo microsphere gel|treatment of acne vulgaris
215073431|NCT02378298|DRUG|Rituximab|Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
215073432|NCT02378298|DRUG|Iv Methylprednisolone|Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
215073433|NCT02378298|DRUG|peroral methylprednisolone and Methotrexate|Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
214674515|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
214674516|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
215073434|NCT04934254|OTHER|Attitude Scale|26-item related to scale will construct and apply to nurses for creating scale
215073435|NCT04730635|DRUG|Donepezil|Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.
214335707|NCT02348528|DRUG|Lenalidomide|
214335708|NCT02348528|DRUG|Dexamethasone|
214335709|NCT06197451|OTHER|Turkish Version of M. D. Anderson Dysphagia Inventory|Turkish Validation and Cultural Adaptation of M. D. Anderson Dysphagia Inventory in Neurologic Patients
214335710|NCT04317248|DRUG|Cyclophosphamide|Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
214335711|NCT04317248|BIOLOGICAL|Multiple Signals loaded Dendritic Cells Vaccine|one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;
214335712|NCT02543931|DRUG|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
214335713|NCT02543931|DRUG|placebo|Placebo capsules containing inert ingredients
214335714|NCT02645994|DEVICE|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
214674517|NCT02243566|DRUG|MicardisPlus®|
214936477|NCT01241617|DEVICE|Duet TRS|Endo GIA stapler with integrated Duet TRS
214936478|NCT01241617|DEVICE|Endo GIA|Endo GIA stapler with Single Use Loading Units
214936479|NCT00909714|DEVICE|DC-Stimulator to apply tDCS|Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
214936480|NCT00909714|DEVICE|DC-Stimulator to apply Sham tDCS|Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
214936481|NCT03451110|DRUG|lemborexant|oral tablet
214936482|NCT03451110|DRUG|Loestrin|oral tablet
214936483|NCT03451110|DRUG|famotidine|oral tablet
215073436|NCT04730635|DRUG|Placebo|Dose matched placebo capsule QD, orally for Days 1-56.
215073437|NCT06397703|DRUG|Leuprolide, Degarelix or Relugolix|Patients assigned to the androgen deprivation therapy (ADT) arm will be treated with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.
215073438|NCT06397703|RADIATION|Stereotactic body radiation therapy/radiosurgery (SBRT)|SBRT will be directed to the prostate and delivered with a prescription dose of 40 Gy in 5 fractions prescribed to the 95% isodose line encompassing the planning target volume. Intra-fraction motion targeting and target position corrections will be utilized for each of the 5 treatment fractions.
215073439|NCT05389514|DRUG|Cyclophosphamide|Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
215073440|NCT05389514|DRUG|Gemcitabine|Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
214936484|NCT03451110|DRUG|fluconazole|oral tablet
214936485|NCT03625310|DRUG|Sodium Fluoride|
214936486|NCT03625310|DRUG|Sodium Fluoride with TCP|
214936487|NCT03625310|DRUG|Sodium Fluoride with CXP|
214936488|NCT03625310|DRUG|Sodium Fluoride with CPP-ACP|
214936489|NCT02356510|PROCEDURE|Primary PCI|
214335715|NCT02645994|DEVICE|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
214936490|NCT02948010|DEVICE|Auto CPAP + comfort feature A|Auto CPAP + comfort feature A using Fisher \& Paykel Healthcare CPAP Device
214936491|NCT02948010|DEVICE|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
214936492|NCT02948010|DEVICE|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
214936493|NCT02948010|DEVICE|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher \& Paykel Healthcare CPAP Device
214936494|NCT02948010|DEVICE|CPAP with comfort feature A|CPAP with comfort feature A using Fisher \& Paykel Healthcare CPAP Device
214936495|NCT02948010|DEVICE|CPAP with comfort feature B|CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
214936496|NCT02948010|DEVICE|CPAP with no comfort feature|CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
214936497|NCT02948010|DEVICE|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher \& Paykel Healthcare CPAP Device
214936498|NCT02948010|DEVICE|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher \& Paykel Healthcare CPAP Device
214936499|NCT04462523|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
214936500|NCT04462523|DRUG|Topical Prednisolone|Standard of care topical drop treatment
214936501|NCT03069456|DEVICE|BIS|
214936502|NCT03069456|DEVICE|ADMS|
214936503|NCT00874328|DRUG|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
215073441|NCT05389514|DRUG|Pembrolizumab|Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
214936504|NCT00874328|DRUG|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
214936505|NCT00874328|DRUG|TS-1 (S-1)|TS-1 po D1\~D14 q 3 weeks until maximum 6 cycles
214936506|NCT00110916|DRUG|Intra-articular metHuIL-1ra (anakinra)|anakinra
214936507|NCT00110916|DRUG|placebo|placebo
215073442|NCT05389514|BIOLOGICAL|Cell Infusion|"Patient's T cells will be administered at a dose of between 1 x 10\^9 to 5.0 x 10\^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be safely administered and is capable of mediating tumor regression in some patients with metastatic cancers.~The cells are to be infused intravenously over approximately 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping."
214335716|NCT04540861|DRUG|Siponimod|1 or 2 mg film-coated tablets. The tablets have to be taken orally once daily and swallowed whole with water, with or without food.
214335717|NCT06481059|RADIATION|Head and Neck cancer post-radiotherapy|Head and Neck Cancer patients who received radiotherapy after 6 months
214335718|NCT02442830|DEVICE|Early Video Capsule Endoscopy|"The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue."
214936508|NCT00134641|DRUG|gemcitabine|
214936509|NCT00134641|DRUG|vinorelbine|
214936510|NCT00038896|DRUG|Venlafaxine ER|
214936511|NCT03437876|OTHER|intestinal microbiota transplant|All participants take 4 times IMT by gastroduodenoscopy with 2-week intervals
214936512|NCT01917357|BIOLOGICAL|Quinvaxem in Uniject|
214936513|NCT01917357|BIOLOGICAL|Quinvaxem in single dose vials|
214936514|NCT06658886|OTHER|No intervention|No intervention
214936515|NCT03404258|OTHER|Research Blood Sampling|Blood samples will be collected at specified time points and research assays will be performed.
214936516|NCT04886206|BIOLOGICAL|DLI|the patients will receive the injection of donor lymphocytes from haplo-identical donor (the son or daughter or possibly nephew or niece of the patient). No immunosuppressive drugs will be used. The HLI dose levels are 1) 1x107 CD3+/kg 2) 5x107 CD3+/kg 3) 7.5x107 CD3+/kg 4) 1x108 CD3+/kg.The CRM method (Continual Reassessment Method) was chosen to specify the dose of cells to be injected, each patient being assigned a dose that is believed to be associated with the target toxicity corresponding to the maximum tolerated dose (MTD). The dose-toxicity curve will be readjusted after assessing the toxicity of each patient.
214936517|NCT02947542|DEVICE|One-catheter concept|Coronary angiography will be performed using the one-catheter concept.
214936518|NCT02947542|DEVICE|Standard catheter|Coronary angiography will be performed using a standard catheter.
214936519|NCT03654105|DRUG|Cytisine|"Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects."
214936520|NCT03654105|DRUG|Acetylsalicylic acid|The treatment will consist of Acetylsalicylic acid at 100mg once a day
214936521|NCT03654105|OTHER|Diet Modification and Physical Activity Increase|"It will be proposed:~1. an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~2. a regular and sustainable physical activity program with periodic verification of the results."
214936522|NCT03654105|DIAGNOSTIC_TEST|early lung cancer detection|standard treatment for early lung cancer detection with ultra low dose CT
214936523|NCT03654105|DIAGNOSTIC_TEST|spirometry with CO test|spirometry with CO test
214936524|NCT03654105|OTHER|anthropometic data collection|anthropometic data collection
214936525|NCT03654105|OTHER|blood test|blood test to assess the metabolic and inflammatory profile
214936526|NCT05842564|OTHER|Blood samples|Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)
214936527|NCT05842564|OTHER|Biopsies|5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy
214936528|NCT06061055|DEVICE|Intubation with VentiBronc Anchor endobronchial double-lumen tube|Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).
214936529|NCT06061055|DEVICE|conventional double-lumen intubation|Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
214936530|NCT05867693|DIETARY_SUPPLEMENT|palmithoylethanolamide/polydatin|"Palmitoyl-ethanolamide, a saturated fatty acid amide of palmitic acid commonly found in egg yolk and peanuts, is chemically related to anandamide but exhibit low affinity for cannabinoid receptors, and participate in the control of inflammation and nociception mainly via down-regulation of mast cell activity. In addition, palmitoylethanolamide is able to reduce human colonic permeability both in vitro and in vivo. Interestingly, palmithoylethanolamide may act as mast cell modulator as a possible agonist for cannabinoid 2-like receptors; and as agonist for PPAR-α, transient receptor potential vanilloid type 1 (TRPV1), and 'orphan' G protein-coupled receptor 55.~For these reasons, palmithoylethanolamide has emerged as potential regulators of nociception. Polydatin, a resveratrol glucoside, is a common dietary component derived from grapes which may act synergistically with palmithoylethanolamide in reducing mast cell activation and local oxidative stress."
215073443|NCT05591066|BEHAVIORAL|PFC I-PASS Intervention|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
214335719|NCT03955042|DRUG|Pemetrexed|Pemetrexed 900 mg/m\^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
215073444|NCT05591066|BEHAVIORAL|PFC I-PASS+ Intervention|PFC I-PASS+ builds on PFC I-PASS to make it better and focus on the special needs of patients who speak languages other than English. PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters during and after rounds, cultural humility training, and provider communication skills training.
215073445|NCT05014464|DRUG|Crizotinib|Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
214674518|NCT00954577|BEHAVIORAL|Nutrition, health, and exercise education|The classroom intervention is part of the routine science curriculum and consists of 14 sessions taught by the investigators. Topics covered include the development of type 2 diabetes, nutrition education, exercise education, and overall healthy lifestyle education (both at home and in school). The intervention is offered in each year to all grades and to all students, regardless of whether or not they are enrolled in the study. The exercise intervention is optional and consists of 2-3 sessions per week of aerobic exercise (dancing) taught by pediatric trainers and offered in lieu of regular gym classes.
214335720|NCT02451566|DEVICE|Ovation Prime Abdominal Stent Graft System|
214936531|NCT05867693|DIETARY_SUPPLEMENT|placebo|After the screening phase, eligible patients will be randomly assigned to equivalent placebo
214674519|NCT01134484|DRUG|Velcade|"* INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~* REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)"
214936532|NCT04610450|DEVICE|HEARO|Robotic system for otological procedures
214936533|NCT04610450|DEVICE|OTOPLAN|Otological surgical planning software
214936534|NCT02979080|OTHER|Eisensulfat LOMAPHARM 50 mg|Eisensulfat LOMAPHARM 50 mg administration for 120 days
214936535|NCT04686786|DRUG|CVL-865|Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
214936536|NCT01526876|DRUG|clevidipine butyrate|intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
214936537|NCT00563160|DRUG|gemcitabine, carboplatin|
214936538|NCT00563160|PROCEDURE|surgery|
214936539|NCT06148675|OTHER|No Intervention|No intervention,data collection
214335721|NCT05936255|BEHAVIORAL|Give to Others Module|Negative interpersonal beliefs are targeted via cognitive-behavioral strategies, including evaluation of cognitive distortions, and activity planning and tracking.
214335722|NCT03940378|DRUG|Levamisole Hydrochloride|Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
214335723|NCT03940378|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
214335724|NCT01516879|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
214335725|NCT01516879|BIOLOGICAL|Placebo|Administered by subcutaneous injection once a month
214335726|NCT01516879|DRUG|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
214335727|NCT01516879|DRUG|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
214936540|NCT05181254|BEHAVIORAL|health dialogue|The visual health assessment formulary is based on detailed questions about food, physical activity, heredity, smoking, alcohol, stress and mental illness and measurements such as BMI, blood pressure and blood fats. Patients fill in a web-based questionnaire resulting in a visual colorful scale showing a risk assessment (Figure 1). The Health Dialogue is a prognostic tool that provides an estimate of the increase in risk with current lifestyle habits. The use has shown improvement of lifestyle habits such as smoking cessation, lower intake of fat and higher physical activity level as well as reduced mortality in a long-term follow-up.
214936541|NCT04263480|DRUG|Carfilzomib + Ibrutinib|"Carfilzomib:~Cycle 1, day 1: 20 mg/m² i.v. Cycle 1, day 8, day 15: 70 mg/m² i.v. Cycle 2 - 12, day 1, day 8, day 15: 70 mg/m² i.v. Cycle 13 - 24, day 1, day 15: 70 mg/m² i.v.~Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
214936542|NCT04263480|DRUG|Ibrutinib|"Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
214936543|NCT03413956|PROCEDURE|Surgeries|Surgeries
214335728|NCT01516879|OTHER|Diet Only|Diet only, no lipid lowering background drug given
214335729|NCT00183872|DRUG|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
214335730|NCT04380207|DRUG|QPX7728|antibiotic
214335731|NCT04380207|DRUG|Placebo|Placebo comparator
214335732|NCT04380207|DRUG|QPX2014|antibiotic
214335733|NCT06147011|OTHER|3D printed educational model|Slide-based presention plus 3D printed thyroid fine needle aspiration model
214347289|NCT04182022|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
214347290|NCT02276300|DRUG|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
214335734|NCT06413199|OTHER|Hyper Training|Experimental group will perform 2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, 4 sets with a goal of 8-12 Reps with 90 seconds rest between sets. 1.5 second concentric and 1.5 second eccentric contraction of bench press, The elbows had to be fully locked out to be counted as a repetition.
214335735|NCT06413199|OTHER|1 Repetition maximum training group|2 training session per week for 8 weeks, 1 set of 10 unloaded repetitions in arms as a warm-up, 1 Repetition maximum training group consisted of 5 attempts to lift as much weight as possible one time for that training visit with 90 seconds of rest between attempts, the load was progressively increased each attempt to try to reach or exceed their previous 1 repetition maximum.
214335736|NCT03784950|BEHAVIORAL|Rating tool|eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
214335737|NCT03784950|BEHAVIORAL|Feedback|eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
214335738|NCT00379470|DEVICE|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
214347291|NCT02276300|DRUG|Sargramostim|Sargramostim is part of Her2 vaccination
214347292|NCT02276300|DRUG|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
214347293|NCT02276300|DRUG|Imiquimod|Imiquimod is part of Her2 vaccination
214936544|NCT01942356|PROCEDURE|TIVA - Hypotension|"Defined as: MAP \< 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1. Give 200 mL Fluid Bolus~2. If not successful, give ephedrine 5 mg bolus~3. Repeat from 1.) if even is not resolved after 3.)"
214936545|NCT01942356|PROCEDURE|TIVA - Hypertension|"Defined as: SBP \> 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1.) Labetalol 5 mg IV will be administered"
214936546|NCT01942356|PROCEDURE|TIVA - Bradycardia|"Defined as: Heart rate \< 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
214936547|NCT01942356|PROCEDURE|TIVA - Tachycardia|"Defined as: Heart Rate \> 90 beats/min~1. If associated with normal NIBP (MAP \> 60 mmHg and SAP \< 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required.~2. If associated with hypertension (SAB \> 140 mmHg): proceed with the management of the hypotention during maintenance protocol.~3. If associated with hypotension (MAP \< 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol."
214936548|NCT01942356|PROCEDURE|INH - Hypotension|"Defined as: MAP \< 70 % of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~1. give a 200 ml fluid bolus (crystalloid).~2. If not successful, give ephedrine 5 mg bolus.~3. If not successful decrease volatile by 0.1 MAC.~4. Repeat from 1) if event is not resolved after step 3) for maximum of 2 iterations"
214936549|NCT01942356|PROCEDURE|INH - Hypertension|"Defined as: SBP \> 130% of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~1. increase Sevoflurane by 0.1 MAC~2. If not successful after 3 minutes (SBP \>130% of baseline), increase Sevoflurane again by 0.1 MAC. Maximum of 1.2 allowed.~3. If still not successful (SBP \>130% of baseline), Labetolol 5mg IV will be administered."
214936550|NCT01942356|PROCEDURE|INH - Bradycardia|"Defined as: Heart Rate \< 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
214936551|NCT01942356|PROCEDURE|INH - Tachycardia|"Defined as: Heart rate \> 90 beats/min~1. if associated with normal NIBP (MAP \> 70% of baseline and SBP \<130% of baseline) : give fluid bolus of 200 ml, repeat once if required. (look for bleeding and treat if required).~2. If associated with hypertension (SBP \>130% of baseline) : proceed with the management of the hypertension during maintenance protocol.~3. If associated with hypotension (MAP \< 70% of baseline) : proceed with the management of the hypotension during maintenance protocol."
214936552|NCT05440435|DIAGNOSTIC_TEST|digital radiography (DR)|Patients with bone injury received routine and mobile DR sequential examination.
214674520|NCT01134484|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70"
214936553|NCT04010526|COMBINATION_PRODUCT|local co-administration of autologous ADIpose|local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging.
214936554|NCT04010526|OTHER|placebo|local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV
215073446|NCT05661981|DEVICE|GLYCAR Pericardial Patch|The Glycar patches are intended to be used by surgeons specialized in the field of cardiovascular surgery. The patch is intended to be used for pericardial closure, or repair and/or reconstruction of cardiovascular structures by replacing missing tissue, reinforcing weakened tissue and providing extra strength to repair tissue during healing.
215073447|NCT04934800|DRUG|Cladribine|No intervention will be administered as a part of this study. Participants who had switched from first-line DMD treatments to treatment with cladribine tablets in routine clinical practice will be assessed for 2 years in this study.
215073448|NCT05787899|OTHER|Hypothermia Protocol|Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
214936555|NCT06353126|PROCEDURE|DEB-TACE|"DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).~During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells."
214936556|NCT04050124|DEVICE|Promogran Prisma|Promogran+SOC; composite collagen, silver-oxidized regenerated cellulose matrix
215073449|NCT05897619|BEHAVIORAL|Experimental: Maya Perinatal Cognitive Behavioral Skills App|The intervention includes the completion of a mobile skills app teaching evidence-based strategies tailored for perinatal mood and anxiety. Modules include psychoeducation, skill information, practice exercises, and homework.
215073450|NCT04603495|DRUG|Pelabresib|"Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF."
214674521|NCT01134484|DRUG|Dexamethasone|"* INDUCTION THERAPY~  1. VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~ 2. TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~* AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~  1. VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~ 2. TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)"
214335739|NCT06250101|BEHAVIORAL|Enhanced Conversational Recast treatment|In the context of child-friendly activities, the clinician prompts the child to attempt to use the grammatical form targeted in the treatment. The clinician immediately restates the child's attempt (i.e., the recast), correcting any ungrammatical elements. Clinicians elicit and recasts 24 utterances per session.
214936557|NCT04050124|DEVICE|Standard of care (SOC) dressings|standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
214936558|NCT03188068|DRUG|Sirolimus|Oral administration
214936559|NCT03188068|DRUG|Prednisolone|Oral administered with sirolimus
214936560|NCT06668272|BEHAVIORAL|Small Changes program|"Participants will be asked to track their compliance with their Small Changes diet plan using a simple checklist record . Participants will be asked to follow their diet plan every day. They are encouraged to create a diet plan that is as close to their current diet as possible. Meal options include make-from-scratch recipes, quick grab-and-go options,and restaurant options. There may be some time involved in learning the recipes and the routine of their new diet. It also may alter their grocery spending and habits somewhat"
214936561|NCT06668272|BEHAVIORAL|Standard behavioral therapy for weight loss|Participants will be provided guidance on cutting and counting calories, setting goals, reading labels, and portion sizes.
214674522|NCT01134484|PROCEDURE|Peripheral Blood Stem Cell (PBSC) collection|"* Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~* G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection"
214674523|NCT01134484|PROCEDURE|First Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
214674524|NCT01134484|PROCEDURE|Second Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
214674525|NCT01426386|DRUG|FE 999049|
214674526|NCT01426386|DRUG|Gonal - F|
214674527|NCT02772380|DEVICE|Defibrillation following induction of VT/VF|Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
215073451|NCT04603495|DRUG|Ruxolitinib|Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
214335740|NCT02231242|BIOLOGICAL|Autologous Stem Cell Transplantation|"Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.~Intrathecal Autologous Bone Marrow TNC"
214936562|NCT05502146|DRUG|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
214936563|NCT05502146|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
214936564|NCT05502146|DRUG|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.
214936565|NCT05502146|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
214335741|NCT00150020|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
214335742|NCT03454438|PROCEDURE|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
214335743|NCT01067703|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
214335744|NCT01067703|PROCEDURE|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
214335745|NCT02797262|DEVICE|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
214335746|NCT01985737|OTHER|Sample collection|
214335747|NCT01600586|DEVICE|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
214335748|NCT01588912|DRUG|Telbivudine|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
214335749|NCT01588912|DRUG|Tenofovir|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
214335750|NCT01588912|DRUG|Entecavir|Maintain the entecavir through the study period
214335751|NCT01800071|DRUG|MVA-EBNA1/LMP2 vaccine|
214335752|NCT02669290|OTHER|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
214335753|NCT02669290|OTHER|Non-guided|LV lead placement will be conventional posterolateral placement
214335754|NCT03563768|PROCEDURE|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
214335755|NCT01898793|DRUG|Fludarabine|
214335756|NCT01898793|DRUG|Cyclophosphamide|
214936566|NCT04271839|COMBINATION_PRODUCT|fluticasone/formoterol k-haler (medium strength)|2 inhalations every 12 hours
214936567|NCT04271839|COMBINATION_PRODUCT|Standard of care (ICs/LABA high strength)|Depend of the ICs/LABA combination
214936568|NCT04281901|DRUG|Platelet- and extracellular vesicle-rich plasma|ear wick soaked in platelet- and extracellular vesicle-rich plasma
214936569|NCT04281901|DRUG|Standard conservative treatment|standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
214936570|NCT01551719|BEHAVIORAL|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
214936571|NCT01841450|DEVICE|iStent|Implantation of one iStent in conjunction with cataract surgery
214936572|NCT01841450|PROCEDURE|Cataract surgery|Cataract surgery alone
214335757|NCT01898793|PROCEDURE|Leukapheresis|
214335758|NCT01898793|BIOLOGICAL|Cytokine-induced killer cells|
214936573|NCT04669964|PROCEDURE|Intravenous Hydration|Patients will receive daily intravenous hydration of normal saline based on their ileostomy output.
214936574|NCT04989634|BEHAVIORAL|Intensive dietary and weight management|health education , nutritional analysis and individualized dietary guidance
215073452|NCT04603495|DRUG|Placebo|Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
215073453|NCT05866029|DRUG|Denosumab|Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
215073454|NCT05866029|DRUG|Teriparatide|Teriparatide was sequentially treated with Denosumab
214335759|NCT01898793|BIOLOGICAL|IL-2|
214335760|NCT01898793|DRUG|ALT-803|
214335761|NCT01898793|PROCEDURE|Peripheral blood for correlative studies|-Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
214335762|NCT01898793|PROCEDURE|Bone marrow for correlative studies|-Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
214335763|NCT02877550|DRUG|Obinutuzumab|Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
214335764|NCT02877550|DRUG|Venetoclax|p.o. once daily according to dose level (DL) or MTD
214335765|NCT05596526|BIOLOGICAL|recombinant zoster vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
214936575|NCT04989634|BEHAVIORAL|Standard care|Standard prenatal education on diet, nutrition and physical activity
214335766|NCT01941953|DRUG|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
214335767|NCT05281250|OTHER|Supervised physical exercise|A supervised exercise is randomized. Although this intervention is not standard in our setting, it is a recommended practice, since it is known that rehabilitation strategies in hospitalized patients have different benefits.
214335768|NCT04391010|OTHER|Surgical masks|Surgical masks will be applied in health care providers
214335769|NCT04391010|OTHER|Filtering respirators|Filtering respirators will be applied in health care providers
214335770|NCT01935011|OTHER|PD, DBS|PD DBS frequency on swallowing function
214335771|NCT03198611|DIAGNOSTIC_TEST|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
214335772|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
214335773|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
214335774|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
214486405|NCT06739538|COMBINATION_PRODUCT|Gasotransmitters|such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S), are small gaseous signaling molecules that play key roles in various physiological functions, including the regulation of muscle tone and neuroinflammation. In the context of spastic diplegic cerebral palsy (CP), gasotransmitters may help reduce spasticity and pain. Gasotransmitters help reduce spasticity and pain in children with spastic diplegic cerebral palsy through multiple mechanisms: Muscle relaxation and improved blood flow reduce muscle tightness, Anti-inflammatory and neuroprotective properties help minimize the damage that exacerbates spasticity.They also modulate pain pathways, both centrally and peripherally, reducing pain perception.
214486406|NCT06758271|DRUG|Avacopan|oral administration
214936576|NCT03584464|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 5.0 mm
214335775|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
214335776|NCT01196728|DRUG|CM3.1-AC100|SAD study with single ascending subcutaneous doses
214335777|NCT03300245|RADIATION|Maxillofacial CT|clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
214335778|NCT02240888|BIOLOGICAL|0,5 mg Prevenar i.m.|
214335779|NCT02240888|BIOLOGICAL|0,5 mg seasonal influenza vaccine i.m.|
214335780|NCT01346384|DEVICE|laryngeal tube (VBM Medizintechnik)|laryngeal tube number 4
214335781|NCT02367313|DRUG|Vapendavir|Vapendavir 264 mg twice daily
214335782|NCT02367313|DRUG|Vapendavir|Vapendavir 528 mg twice daily
214335783|NCT02367313|DRUG|Placebo|Placebo twice daily
214335784|NCT00931307|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
214335785|NCT04932265|DIETARY_SUPPLEMENT|HRG80™ Red Ginseng|Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product
214335786|NCT04932265|COMBINATION_PRODUCT|HRG80™ Red Ginseng + gamma cyclodextrin|Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
214335787|NCT00983814|DRUG|Droxidopa+Carbidopa|3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo
214335788|NCT01201252|PROCEDURE|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
214936577|NCT03119623|DRUG|sacubitril/valsartan|Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
214936578|NCT03119623|DRUG|Enalapril|enalapril 5mg, titrated up to 10mg po BID
214936579|NCT05163821|DIAGNOSTIC_TEST|Manchester Somali Cognitive Assessment Tool|Cognitive screen for dementia
214936580|NCT05163821|DIAGNOSTIC_TEST|ACE-III Somali Translation|Cognitive screen for dementia
214936581|NCT01292421|BIOLOGICAL|hepatitis B antigen peptide|Given PO
214936582|NCT01292421|OTHER|placebo|Given orally (PO)
214674528|NCT06092502|OTHER|Graded Motor Imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
214674529|NCT06092502|OTHER|Traditional Physiotherapy Program|This protocol included stretching and strengthening exercises
214674530|NCT00765479|DIETARY_SUPPLEMENT|soy protein isolate|Given orally
214674531|NCT00765479|OTHER|placebo|Given orally
214674532|NCT03831503|BIOLOGICAL|INO-A002|Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
214674533|NCT03831503|DEVICE|CELLECTRA® 2000|Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
214674534|NCT03831503|DEVICE|Dengue Fever Antibodies (IgG)|To determine if the subject is Dengue seronegative at baseline
214335789|NCT06574243|BEHAVIORAL|Social media education|"The intervention consisted of daily positive messages about aging posted on an Instagram account (@laetapaplateada), created specifically for this study, and was conducted over the course of a week. Examples included The ability to make decisions improves with age and Emotional regulation improves with age (David, 2017). These posts were accompanied by their respective author references"
214335790|NCT01103531|BEHAVIORAL|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
214936583|NCT01292421|OTHER|immunoenzyme technique|Correlative studies
214936584|NCT00732979|PROCEDURE|Infrahepatic inferior vena cava clamping|The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
214936585|NCT00732979|PROCEDURE|No infrahepatic inferior vena cava clamping|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below \< 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
214936586|NCT05168878|BEHAVIORAL|30-second BeSMART video|30 second video focused on education about child gun deaths and responsible gun storage
214936587|NCT05168878|BEHAVIORAL|3-minute BeSMART video|3-minute video focused on education about child gun deaths and responsible gun storage
214936588|NCT01577615|BEHAVIORAL|Patterned Experience|"* The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.~* Nonnutritive sucking will be offered to infants.~* Blood work will be collected for inflammatory cytokines.~* Saliva will be collected for genetic analysis~* Saliva will be collected in 10 infant sub study for cortisol pre and post feedings~* All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.~* Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.~* Follow up visits will occur at 2,6and 24 months corrected age."
214936589|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
214936590|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
214936591|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
214936592|NCT01914159|DRUG|Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)|Monthly intravitreal injections
214936593|NCT01633008|BEHAVIORAL|ACT Workshop|The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
214936594|NCT06413056|DRUG|Micafungin|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive either micafungin or amphotericin B
215073455|NCT05849584|OTHER|Transperineal ultrasound|A 2D scan will be performed of one experienced clinician. The average of 3 2D levator hiatal anteroposterior measurements will be stored. Then, a 3D/4D ultrasound examination of the pelvic floor will be performed using a Voluson S10, E8 or E10 (GE healthcare, Zipf, Austria) device with a RAB 4-8 MHz curved array transducer with the acquisition angle set at 85 degrees. Offline analysis of the ultrasound volumes will be performed using the 4D view (GE Healthcare, Austria) software, blinded to all clinical data. Hiatal anteroposterior diameter will be measured in both 2D and 3D. Hiatal area and hiatal transverse diameter will be measured in the 3D volume
215073456|NCT06315140|OTHER|Nutrition|The intervention will build on the 11-year Tribal-academic partnership with the Ramapough Nation of northern NJ to advance tradition-centered farming practices and management strategies supporting sustainable food systems to relieve local food insecurity. Working with the Ramapough-leased Munsee Three Sisters Medicinal farm (growing produce/crops on clean soil) will provide the tribe with nutrition-rich foods and recipes for nutritious cooking. The interventions aims to return healthy soil on the farm allowing for healthy plant production.
214335791|NCT01103531|BEHAVIORAL|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
214335792|NCT00909805|DEVICE|cutaneous suture (Surjet)|cutaneous surjet suture
214335793|NCT00909805|DEVICE|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
214936595|NCT06413056|DRUG|Amphotericin B|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups.
214936596|NCT00802061|BEHAVIORAL|Sleeping position in glaucoma patient|
214936597|NCT01907061|DRUG|N-acetylcysteine|drug will be administered via IV,NG
214936598|NCT01907061|DRUG|Placebo|placebo or NAC will be given
214936599|NCT03336268|BEHAVIORAL|POINT|A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
214936600|NCT03183934|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.~This study is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
214936601|NCT04476121|PROCEDURE|PRF application|PRF application into post-operative wound.
214936602|NCT04476121|DRUG|Nipas application|Nipas application into post-operative wound.
214936603|NCT02396303|DRUG|Carbetocin|
214936604|NCT03688958|DRUG|Placebo|Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
214936605|NCT03688958|DRUG|iodine|Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).
214936606|NCT03688958|DRUG|FEC/TE Placebo|The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).
214936607|NCT03688958|DRUG|FEC/TE iodine|The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
214936608|NCT03576534|OTHER|Use of prebypass ultrafiltration (PBUF)|In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.
214936609|NCT01537068|DRUG|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
214936610|NCT01537068|DRUG|Placebo|Matching placebo pills
214936611|NCT02574702|PROCEDURE|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
215073457|NCT05623319|DRUG|Pembrolizumab/Olaparib|Patients will receive pembrolizumab 200 mg 1q21 and chemotherapy -platinum compound (cisplatin 75 mg/m2 or carboplatin area under the curve of 5 mg per milliliter per minute) 1q21 plus etoposide 100 mg/m2 1-3q21- for 4 cycles (Induction Phase). In case of responsive or stable disease, patients will receive pembrolizumab 200 mg 1q21 plus olaparib 300 mg twice daily until progression (Maintenance Phase) or up to a maximum of 35 cycles.
215073458|NCT05893160|DRUG|JAN101 SR|The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
214674535|NCT03495505|DEVICE|WiSE-CRT|Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
215073459|NCT05893160|OTHER|Placebo|Inert placebo formulation
214936612|NCT04512313|DRUG|Rocuronium 0,3mg/kg|Rocuronium 0,3mg/kg at induction
214936613|NCT04512313|DRUG|Rocuronium 0,9mg/kg|Rocuronium 0,9mg/kg at induction
214936614|NCT01664832|DEVICE|S-nIMV|Synchronization of nasal breaths to infant's own respiratory effort
214335794|NCT02109588|BEHAVIORAL|A supervised physical exercise program|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
214335795|NCT00829621|OTHER|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
214335796|NCT00829621|OTHER|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
214335797|NCT05747677|DRUG|HH-120 Nasal Spray|HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
214936615|NCT03871816|OTHER|Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis|Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.
214936616|NCT05002517|DRUG|Tociliziumab group|Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology.
214936617|NCT05002517|DRUG|Methylprednisolone group|Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
214936618|NCT00483704|DRUG|Telcagepant 140 mg|Telcagepant 140 mg tablets
214936619|NCT00483704|DRUG|Talcagepant 280 mg|Telcagepant 280 mg tablets
214936620|NCT00483704|DRUG|Placebo|Placebo tablets
214936621|NCT02589353|DRUG|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain \~484 microgram acarbose; total maximum exposure of each subject to acarbose will be \~14-30 mg each session (1-20 sessions)
214936622|NCT04442269|DRUG|dupilumab|Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
214936623|NCT04442269|DRUG|Placebo|Matching placebo
214936624|NCT01948583|DRUG|Hyaluronic Acid|Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
214936625|NCT03968250|BEHAVIORAL|Cognitive Behavioral Therapy for Treating Fatigue|"The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.~The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed."
214936626|NCT03407183|PROCEDURE|intradetrusor injection of botulinumtoxinA (Botox)|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.
214936627|NCT05409079|DEVICE|Abilitech Assist|The Abilitech™ Assist is an externally worn device supported by a body frame, which is designed to support and assist the arms in activities of daily living (ADL's). The Abilitech Assist is comprised of three parts: a modular body vest that adjusts to accommodate different body sizes, a single arm orthosis that attaches to the body vest, and an external power pack and controller for tensioning the arm's internal springs to adjust the arm's level of assist. The device augments a user's native arm function to provide lift assistance. Software customizes the spring tension for the level of assist required. The user can turn the system ON/OFF and toggle and adjust the level of assist (e.g., low, medium or high assist) using a pushbutton controller.
214335798|NCT02520245|DRUG|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
214335799|NCT00787410|DRUG|ZD1839|250mg tablet, once daily, orally administered
214335800|NCT06572215|DRUG|Dapagliflozin|On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
214335801|NCT00572650|DRUG|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
214335802|NCT06660667|BIOLOGICAL|SAR402663|Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection
214335803|NCT06660667|DRUG|Diluent|Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection
214335804|NCT07024732|BIOLOGICAL|PST-611|PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle
214335805|NCT06620757|DRUG|Single antiplatelet therapy (SAPT)|Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding
214335806|NCT04356716|DRUG|Sildenafil|Initial Sildenafil dosage will be weight dependent. Participants will start at 40 mg daily (20mg in the morning, 20 mg in the evening) or 60 mg daily (40mg in the morning and 20 mg in the evening). Sildenafil dosage may be increased to up to 80mg daily (20-40mg in the morning and 20-40mg in the evening) based on the response to lower doses. If the participant has not had improvement after initial treatment, the dose may be increased, at the discretion of the study physician.
214335807|NCT04356716|OTHER|Standard of Care Sildenafil|Medical record review of participants that receive Sildenafil as part of standard of care.
214335808|NCT04356716|DIAGNOSTIC_TEST|Ocular Coherence Tomography-Angiography (OCT-A)|Retinal photographs will be taken at each study visit.
214335809|NCT04356716|OTHER|Visual Acuity (VA)|Visual acuity will be measured with Snellen Eye Chart at each study visit.
214335810|NCT01132521|DRUG|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
214335811|NCT01132521|DRUG|placebo|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
214335812|NCT05527028|OTHER|Occupational Therapy Services|Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
214335813|NCT02908438|DRUG|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
214335814|NCT04832204|DRUG|Apatinib and Camrelizumab for Injection|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
214335815|NCT00745732|DRUG|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
214335816|NCT00745732|RADIATION|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
215073460|NCT03784911|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.
215073461|NCT03784911|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
214335817|NCT00614029|DEVICE|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
214335818|NCT03910335|DIAGNOSTIC_TEST|LSS Screen|Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)
214335819|NCT00057915|BIOLOGICAL|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
214335820|NCT03007316|PROCEDURE|VIP graft|surgical soft tissue grafting concomitant to implant placement
214486407|NCT06891963|OTHER|Acupuncture-like TENS|"The first experimental group will receive 20-minute sessions of TENS, where participants adjust the amplitude to achieve strong muscle twitching beneath the electrodes at an intensity below the pain threshold. Acupuncture-like TENS uses high-frequency pulsed currents at two trains per second with an internal pulse frequency of 100 pps. The pulse pattern is set to burst, with an asymmetrical biphasic waveform and a pulse duration of 200 µs. Minor fluctuations in pulse rate between 100 and 104 pps were noted using a cathode ray oscilloscope before the experiment."
214674536|NCT05176028|OTHER|conventional physiotherapy|For individuals of control group, hot pack applied for 20 minutes in the sitting position, Interferential Current was applied for the analgesic effect at a constant 100 Hz frequency on the anterior, posterior, superior and inferior part of the operated shoulder. By increasing the current slowly, the dosage of the current was adjusted to such a degree that the patient could tolerate it.
214674537|NCT05176028|OTHER|fascial release|Fascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the cervical, thoracolumbar and upper extremity areas until tissue loosening and releasing were felt.
214674538|NCT00196937|BIOLOGICAL|Cervarix|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
214674539|NCT05115318|DRUG|Medical Cannabis|Patients with GTS were assessed before, 4 and 12 weeks after Medical cannabis initiation for consumption habits, efficacy and side effect profile
214674540|NCT04575129|OTHER|No intervention will be applied|No intervention will be applied
214674541|NCT05413694|OTHER|telephone interview 24 months after hospitalization for Covid-19|telephone interview 24 months after hospitalization for Covid-19
214674542|NCT01769521|DEVICE|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
214335821|NCT03319043|DRUG|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
214674543|NCT01112215|DRUG|Azathioprine|Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
214674544|NCT01112215|DRUG|Enteric-Coated Mycophenolate Sodium|Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
214674545|NCT01096667|DRUG|Placebo to Ertuglilflozin 1 or 5 mg|Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
214335822|NCT02160873|OTHER|chocolate milk|12 oz, 7-8 hours prior to exercise trial (night before)
214335823|NCT02160873|OTHER|flavor-matched placebo|12 oz, non-caloric flavor-matched placebo
214335824|NCT03994861|DIAGNOSTIC_TEST|Assessment of disability and behavior (by questionnaires)|Assessment of disability and behavior (by questionnaires)
214335825|NCT00000435|DRUG|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
214335826|NCT00000435|DRUG|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
214335827|NCT00270491|DRUG|Paclitaxel|
214335828|NCT00270491|DRUG|Capecitabine|
214335829|NCT02766608|DRUG|BFF MDI 320/9.6 μg|Blinded Treatment
214335830|NCT02766608|DRUG|BFF MDI 160/9.6 μg|Blinded Treatment
214335831|NCT02766608|DRUG|FF MDI 9.6 μg|Blinded Treatment
214335832|NCT02766608|DRUG|BD MDI 320 μg|Blinded Treatment
214674546|NCT01096667|DRUG|Ertugliflozin 1 mg|Ertugliflozin tablet 1 mg once daily for 28 days
214674547|NCT01096667|DRUG|Ertugliflozin 5 mg|Ertugliflozin tablet 5 mg once daily for 28 days
214674548|NCT01096667|DRUG|Ertugliflozin 25 mg|Ertugliflozin tablet 25 mg once daily for 28 days
214674549|NCT01096667|DRUG|HCTZ 12.5mg|Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
215073462|NCT06404515|OTHER|Telehealth Group Counseling|Group counseling for women via telehealth to provide educational materials about atherosclerotic heart disease and provide information about risk factors and modification of risk factors. Women then have an opportunity to discuss / ask questions.
215073463|NCT04776187|DRUG|Gadodiamide|Gadodiamide Injection(OMNISCAN™)
215073464|NCT04776187|DRUG|Gadoteric Acid Meglumine Salt|Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
215073465|NCT02118766|DRUG|AN2728 Topical Ointment, 2%|
215073466|NCT02118766|DRUG|Matching vehicle control|
214335833|NCT02766608|DRUG|Symbicort® TBH 400/12 μg BID|Open Label
214335834|NCT06161909|DRUG|sintilimab|200mg fixed dose Q3W,1 year
214335835|NCT04612270|OTHER|Venous blood collection|Two venous blood collections in within one week. No drug-related intervention in-vivo.
214335836|NCT00855829|DEVICE|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~1. The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~2. Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
214335837|NCT00855829|DEVICE|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
214335838|NCT04368936|GENETIC|Isolated DNA, Real Time PCR|"We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele."
214335839|NCT00667784|BEHAVIORAL|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
214335840|NCT02066298|DRUG|Mometasone 220mcg BID|Mometasone is an ICS
214674550|NCT01096667|DRUG|Placebo to HCTZ|Placebo to HCTZ 12.5 mg capsule once daily for 28 days
214674551|NCT01096667|DRUG|Placebo to ertuglilflozin 25 mg|Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
214674552|NCT03260738|DEVICE|Rehabilitation program with Poppy robot|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.
214674553|NCT03260738|OTHER|Usual rehabilitation program|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
214674554|NCT01612910|DRUG|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
214674555|NCT01612910|OTHER|laboratory biomarker analysis|Correlative studies
214674556|NCT03085732|DRUG|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
214674557|NCT00918762|PROCEDURE|assessment of therapy complications|
214674558|NCT00918762|PROCEDURE|diagnostic endoscopic surgery|
214674559|NCT00918762|PROCEDURE|quality-of-life assessment|
214674560|NCT00918762|PROCEDURE|therapeutic conventional surgery|
214674561|NCT00918762|PROCEDURE|therapeutic endoscopic surgery|
214674562|NCT00918762|PROCEDURE|transoral robotic surgery|
214674563|NCT00918762|PROCEDURE|video-assisted surgery|
214674564|NCT02556762|RADIATION|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
214674565|NCT02556762|RADIATION|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
214674566|NCT02556762|DRUG|PF|Chemotherapy: Cisplatin and 5fluorouracil
214674567|NCT02657239|BEHAVIORAL|MOVE UP|Weight management behavioral program
215073467|NCT01924273|DRUG|Talaporfin sodium|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
214335841|NCT02066298|DRUG|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
214335842|NCT02066298|DRUG|Placebo|
214335843|NCT05981651|OTHER|non-intervention|non-intervention
214335844|NCT03616210|PROCEDURE|Protective ventilation|Protective ventilation strategy with tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O.
214335845|NCT06454513|PROCEDURE|general anesthesia|Different anesthesia methods
214335846|NCT01963689|OTHER|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
215073468|NCT05413512|OTHER|Acute psychological stress|Experimental: Acute psychological stress Two, acute-psychological stress tasks known to reliably elicit a cardiovascular responses (Multi-source interference task; Stroop).
215073469|NCT06570512|DEVICE|transcutaneous posterior tibial nerve stimulation|Over three weeks, the TPTNS group underwent ten sessions of electrical stimulation along the course of the posterior tibial nerve behind the medial malleoli using cup electrodes, with a width pulse of 250 microseconds, and a frequency of 20 Hz. The TENS group used a sham device with the same parameters, but the electrodes were placed behind the lateral malleoli with underpowered amplitudes.
215073470|NCT06651775|DEVICE|High intensity laser therapy|lumbosciatalgia mode of the HILT device
215073471|NCT06651775|DEVICE|Sham Comparator|sham mode of the HILT device
215073472|NCT06341881|BEHAVIORAL|Transitional Care Training Program|A nursing based transitional care training intervention would be carried out to prepare the family caregivers to take care of their elderly stroke survivors at home. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the family caregivers at their homes after hospitalization. The study participants would be evaluated after 8 weeks of the intervention. A structured, validated and literature based assessment checklist will be devised to assess the usefulness and feasibility of the intervention. Assistance of senior nurses and health professionals, specialized in stroke care will be taken during the training part of the program.
215073473|NCT06119789|DRUG|Imatinib|imatinib treatment based on molecular alterations
214335847|NCT01963689|OTHER|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
214335848|NCT01963689|OTHER|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
214335849|NCT05699863|BEHAVIORAL|Lifestyle intervention|"Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months."
214335850|NCT02284828|DRUG|BIA 2-093|
214335851|NCT02261818|BEHAVIORAL|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
214335852|NCT06428747|DIAGNOSTIC_TEST|b. Detection of micro particles and their subtypes by flow cytometery on(BECKMAN COULTER CytoFLEX flow cytometer).|detection of micro-particles
214335853|NCT00598689|DRUG|0.3% hypromellose|0.3% hypromellose four times a day for 5 days prior to LASIK surgery
214335854|NCT01169857|DRUG|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
214335855|NCT03542227|OTHER|First-void urine collection|Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.
214335856|NCT03542227|OTHER|Blood draw|Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
214335857|NCT02343458|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
214335858|NCT02343458|DRUG|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
215073474|NCT06119789|DRUG|Trametinib|According to biomarkers
215073475|NCT06119789|DRUG|Dabrafenib|According to biomarkers
215073476|NCT05709704|DIAGNOSTIC_TEST|Self-palpation via telehealth|This will be used to determine if the participant has the diagnosis
215073477|NCT05709704|DIAGNOSTIC_TEST|Real-time Ultrasound|This will be used in a subgroup of participants to confirm/rule out a diagnosis
215073478|NCT02844244|BEHAVIORAL|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
215073479|NCT04717024|DEVICE|Observational Study - no intervention|Observational Study - no intervention
215073480|NCT02723552|BEHAVIORAL|Aerobic Exercise|40 minute aerobic exercise sessions 3x/week.
215073481|NCT01581528|GENETIC|gene expression analysis|
215073482|NCT01581528|OTHER|cell culture procedure|
215073483|NCT01581528|OTHER|flow cytometry|
215073484|NCT01581528|OTHER|laboratory biomarker analysis|
215073485|NCT01581528|OTHER|metabolic assessment|
215073486|NCT04094259|BEHAVIORAL|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
215073487|NCT03219034|DEVICE|oral appliance - A ; washout; oral appliance B|Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
215073488|NCT03219034|DEVICE|oral appliance - B; washout; oral appliance A|Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
215073489|NCT00210457|DRUG|Lanreotide (Autogel formulation)|
215073490|NCT02521233|DRUG|Candesartan + Chlorthalidone (8mg+12,5mg)|
214335859|NCT02343458|DRUG|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
214936628|NCT06619938|BEHAVIORAL|Mindfulness With Biofeedback|The intervention includes two weekly 90-minute sessions of brief mindfulness training, covering mindfulness practices, psychoeducation on caregiving, and group sharing. After the first session, participants receive a wearable device for biofeedback on RR, HR, HRV, EDA, and sleep patterns to support mindfulness practice and reduce stress. A 30-minute session teaches caregivers how to use the devices and understand the parameters. The study uses Fitbit Sense with Fitbit apps, employing PPG sensors. The Fitbit Sense connects to smartphones with the apps installed. Caregivers can: (1) view real-time RR, HR, HRV, and EDA on the device and trends on their phone; (2) receive mindfulness practice reminders; (3) access audio coaching; (4) set personal goals (e.g., 30 minutes of daily practice); (5) track practice duration; (6) rate daily stress; and (7) review sleep quality. After the second session, caregivers practice mindfulness for 30 minutes daily over eight weeks.
214936629|NCT06619938|BEHAVIORAL|Mindfulness Without Biofeedback|The control group will receive two weekly sessions of brief mindfulness training, the same as the intervention group. After the 1st brief mindfulness training, the control group will receive a 30-minute briefing session on goal setting for mindfulness practice. Each caregiver will be asked to develop an action plan for continuous mindfulness practice. A mindfulness therapist will also discuss the challenges and solutions for developing a habit of mindfulness practice with the caregivers in the second session. Caregivers in the control group will be advised to practice mindfulness daily for 30 minutes over the course of eight weeks.
215073491|NCT02521233|DRUG|Candesartan + Chlorthalidone (8 mg + 25 mg)|
214335860|NCT02343458|DRUG|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
214335861|NCT04691479|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|"1. MEntA: Educational \& Training Program~2. Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~3. Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~4. Identification of Care plan and Schedule next visits~5. Follow-up D30-D60-D90-D180 depending of the care plan, through the channel that belong for each care plan"
214335862|NCT04691479|BEHAVIORAL|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
214335863|NCT03379025|OTHER|Electronic cigarette|electronic cigarette and cartridge refills (also known as pods)
214335864|NCT02227160|BEHAVIORAL|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
214936630|NCT03279796|BIOLOGICAL|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
215073492|NCT02521233|DRUG|losartan+hydrochlorothiazide|
215073493|NCT02438683|DRUG|BI 409306|high dose, single dose, oral administration
215073494|NCT02438683|DRUG|BI 409306|low dose, single dose, oral administration
215073495|NCT02438683|DRUG|Placebo|single dose, oral administration
215073496|NCT04778631|DEVICE|Heat therapy|Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
215073497|NCT04778631|DEVICE|Cryotherapy|Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
215073498|NCT04654221|DIAGNOSTIC_TEST|mGFR by iohexol clearance|Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
215073499|NCT02302092|DRUG|Flomoxef|Flomoxef intravenous infusion
215073500|NCT02302092|DRUG|Cefepime|Cefepime intravenous infusion
214674568|NCT06034730|DEVICE|Portable GC device for brath analysis|Patients were asked to orally exhale 1-2 L breath into a 5 L Tedlar bag via a one-way mouthpiece and Nafion filter for moisture removal, as shown in Figure 1B. The process usually takes about a few minutes. The breath analysis took place either in-situ immediately after the breath sample collection or within 24 h of breath collection. The Tedlar bags were stored under ambient condition until analyzed. During the breath analysis, the Tedlar bag was connected to the sampling port of the portable GC (Figure 1C). Approximately 350 mL of breath was pulled from the Tedlar bag into the GC for analysis. The GC operation was controlled using LabView via a laptop. The total assay time was 30 min, including 5 min of breath sampling time from the Tedlar bag at a flow rate of 70 mL/min (see the blue path in Figure 1A), 5 min of desorption/transfer time, 10 min of chromatographic separation time (see the orange path in Figure 1A), and 10 min of GC system cleaning time.
214335865|NCT02227160|BEHAVIORAL|Outpatient counseling and support groups|Usual mental health care
214335866|NCT06177340|DEVICE|visualization of the sacrospinous ligament|visualization of the sacrospinous ligament by the Nanoscope system during sacrospinofixation
214335867|NCT02629510|DRUG|Tachosil|
214335868|NCT04315389|DEVICE|(1) Mobile Assistant Balance Robot|MRBA: Robotic wheelchair with a planar compliant robotic arm to provide balance assistance to the user at the pelvis and hip, during sit to stand, standing and walking tasks in indoor and controlled outdoor level environments.
214335869|NCT04315389|DEVICE|(2) Transfer Assistive Cobot|TAC: Intelligent powered wheelchair equipped with a robotic arm that is capable of lifting payload up to 110kg, and perform a totally dependent transfer in a semi- autonomous fashion
214335870|NCT02599792|DRUG|CTP-656|
214674569|NCT03330691|BIOLOGICAL|Patient-derived CD19- and CD22 specific CAR|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
215073501|NCT06981065|PROCEDURE|Simple Sling and Physiotherapy|Non-surgical treatment with a simple sling and physiotherapy according to standardized program.
214335871|NCT02599792|DRUG|Placebo for CTP-656|
214335872|NCT02599792|DRUG|Kalydeco|
214335873|NCT01305967|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, Intravenous route, 16times for 2.5 months
214335874|NCT05014009|BEHAVIORAL|FIFA11+ and multidirectional training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time."
214335875|NCT05014009|BEHAVIORAL|FIFA11+ and linear sprint training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time."
214335876|NCT03655158|DEVICE|ozone device ( Ozonytron XL )|The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
214674570|NCT00001737|DRUG|Cyclosporin A Implant|
214674571|NCT01894282|PROCEDURE|Manual Therapy|Manual Therapy Arm
214674572|NCT01894282|PROCEDURE|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
214674573|NCT03427840|PROCEDURE|Procedure/Surgery: superior hypogastric block|superior hypogastric blockade during surgery
214674574|NCT01462292|DRUG|GSK2402968 3mg/kg/week|Comparison of 2 doses of GSK2402968
214674575|NCT01462292|DRUG|GSK2402968 6 mg/kg/week|Comparison of 2 doses of GSK2402968
214674576|NCT01462292|DRUG|Placebo to match GSK2402968 3 mg/kg/week|Matched placebo
214335877|NCT02326103|DRUG|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
214335878|NCT02326103|DRUG|Placebo|
214674577|NCT01462292|DRUG|Placebo to match GSK2402968 6 mg/kg/week|Matched Placebo
214674578|NCT01094483|DRUG|PN400|naproxen 500 mg/esomeprazole 20 mg oral tablet
214674579|NCT01094483|DRUG|ASA|Asprin 81 mg enteric coated tablet
214674580|NCT01094483|DRUG|Placebo|
214674581|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
214674582|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
214674583|NCT04172025|DIAGNOSTIC_TEST|Analysis of Bacterial Genome|genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
214674584|NCT03224533|DIAGNOSTIC_TEST|Diabetes Outcome|based on self report definition, fasting plasma glucose, and hemoglobin A1c
214674585|NCT02997514|BEHAVIORAL|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
214674586|NCT02997514|BEHAVIORAL|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
214674587|NCT03156153|DRUG|Bumetanide|bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
214674588|NCT03156153|DRUG|Placebo|placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
214335879|NCT04623294|PROCEDURE|Oxygen supply of high-low-high procedure|"The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
214335880|NCT04623294|PROCEDURE|Oxygen supply of low-high-low procedure|"The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
214335881|NCT05831293|BEHAVIORAL|Mindfulness Based Stress Reduction Program|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
214335882|NCT03002181|OTHER|Education|70 minute education session.
214335883|NCT03300388|DIETARY_SUPPLEMENT|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
214335884|NCT03300388|DIETARY_SUPPLEMENT|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
214335885|NCT03300388|OTHER|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
214335886|NCT05189574|PROCEDURE|Endoscopic negative pressure therapy|Endoscopic placement of a sponge in/at staple line leaks under negative pressure.
214335887|NCT04209582|DEVICE|measurement of TcPO2 with skin electrode|measurement of TcPO2 with skin electrode
214335888|NCT00475826|DRUG|Statins and Ezetimibe|
214335889|NCT02174536|BIOLOGICAL|Decidual stromal cells|Decidual stromal cells (approximately 1x10\^6 cells/kg) will be infused intravenously.
214335890|NCT02174536|BIOLOGICAL|Placebo|
214335891|NCT03865277|RADIATION|dose-escalated radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm.~Radiotherapy is always applied with 5 fractions per week."
214335892|NCT03865277|RADIATION|dose-escalated radiochemotherapy with carbon ion boost|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm using a carbon ion boost.~Radiotherapy is always applied with 5 fractions per week."
214936631|NCT03279796|DRUG|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
214936632|NCT01647919|DIETARY_SUPPLEMENT|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
214936633|NCT01647919|DIETARY_SUPPLEMENT|Placebo|4 capsules of placebo identical to cogniVida™ once a day
214335893|NCT03865277|RADIATION|standard radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.~Radiotherapy is always applied with 5 fractions per week."
214335894|NCT03961594|OTHER|expansion volémique|cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
214335895|NCT00820768|DRUG|ABI-010|17-AAG and ABI-007
214335896|NCT03293823|BEHAVIORAL|VSOP training|a computerized cognitive training of attention and processing speed
214335897|NCT03293823|BEHAVIORAL|MLA control|a computerized cognitive intervention of multiple mental leisure activities
214936634|NCT04392388|BIOLOGICAL|Non applicable|to collect data from questionnaires and to collect serological samples
215073502|NCT06981065|PROCEDURE|Surgical treatment|Surgical treatment with plate and screws (lateral clavicle plate, clavicle plate or hook plate with/without coracoclavicular fixation).
215073503|NCT03520751|DRUG|scAAV1.tMCK.NTF3|gene vector
214335898|NCT02873923|DRUG|undefined|Chemotherapy drug (meta-analyses of randomized trials)
214335899|NCT00001663|DEVICE|Magstim Super Rapid Stimulator|
214335900|NCT01265953|DRUG|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
214335901|NCT01265953|DIETARY_SUPPLEMENT|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
214335902|NCT04092426|OTHER|opthalmologic examination|opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
214335903|NCT05069662|OTHER|Directive Interview|One directive interview conducted by telephone
214335904|NCT03414138|BEHAVIORAL|Mindfulness Training|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] will be used to teach patients to independently practice mindfulness meditation.
214335905|NCT03414138|BEHAVIORAL|Book Listening Control|Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
214335906|NCT02687152|OTHER|N-hydroxy-nor-L-arginine|
214335907|NCT05875324|DEVICE|virtual reality application|VR was used for 10 minutes a day in the sitting position for three weeks, twice a week, by watching a walking video before beginning the exercises. Patients were instructed to imagine themselves walking while concentrating on walking and watching the video. The patients were asked to stop watching video by removing their VR glass if they experienced discomfort such as dizziness and nausea during the VR application. They were told to continue watching the video when the discomfort was gone. In cases where similar discomforts recurred, the treatment was terminated.
214335908|NCT05875324|OTHER|exercise|activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were provided an exercise program for at-home practice.
214335909|NCT01610700|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
214335910|NCT01610700|DRUG|Placebo|Each actuation of placebo delivered the excipients only.
214335911|NCT03137862|OTHER|Gluten free bread|patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
214335912|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 3g/day|"patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks"
214486408|NCT06891963|OTHER|Dry needling|The second experimental group will receive 20-minute sessions of dry needling. Patients will be positioned in a prone, relaxed position, and the overlying skin will be cleaned with alcohol. The muscle will be palpated to locate the trigger point (MTrP), with the muscle grasped between the thumb, index, and middle fingers. A solid filiform needle within a guide tube will be inserted into the MTrP using a tapping motion at an oblique angle. The upper trapezius muscle will be palpated for trigger points, with needle insertion depths ranging from 10-15mm. After obtaining a local twitch response, the needle will be moved vertically 3-5mm until no more twitch responses occur. This group will also receive 20 minutes of conventional physical therapy.
214674589|NCT00495846|DRUG|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
214936635|NCT01157650|OTHER|Autologous mesenchymal stem cells|"The trial is divided in three phases:~I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.~II.- Treatment phase includes:~1. Liposuction procedure to obtain adipose tissue.~2. Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)~3. ASCs implant~III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant."
214674590|NCT00495846|OTHER|Locoregional treatments|
214674591|NCT00997685|DRUG|Capecitabine plus oxaliplatin|"Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles"
214674592|NCT02335450|BEHAVIORAL|Motivational Interviewing|The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
214674593|NCT02335450|DEVICE|Wristband physical activity monitor|The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
214674594|NCT01475292|DRUG|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
214674595|NCT01475292|DRUG|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
214936636|NCT03369028|OTHER|2D and 3D image of infants´ faces|2D and 3D image of infants´ faces
214674596|NCT01475292|DRUG|Placebo|Placebo administered via a nebuliser once daily for 14 days
214674597|NCT04211324|DEVICE|TENS|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
214674598|NCT04211324|DEVICE|electro-acupuncture|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
214936637|NCT02815124|OTHER|Standard of Care|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
214936638|NCT02815124|OTHER|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
214936639|NCT00140270|BEHAVIORAL|PEP program|
214936640|NCT00005046|DRUG|chemotherapy|
214936641|NCT00005046|DRUG|paclitaxel|
214936642|NCT01772849|BEHAVIORAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
214335913|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 6g/day|"patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
214936643|NCT05814536|DRUG|AB-218 capsule|Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.
214936644|NCT02293759|PROCEDURE|HoLEP|Holmium laser enucleation of the prsotate
214936645|NCT02293759|PROCEDURE|Greenlight laser PVP|Greenlight laser (532nm) Photoslective vaporization of the prostate
214936646|NCT05141916|PROCEDURE|Endoscopic Retrograde Cholagiopancreatography (ERCP)|Endoscopic procedure employed to manage biliary and pancreatic diseases
214936647|NCT06622707|OTHER|kinesio taping|Despite the increasing indications and new application techniques developed all over the world, it is believed that there is a need for evidence regarding the mechanisms of action and effectiveness of kinesio taping. As a result of the literature review, no study was found in which kinesio taping was applied for 72 hours as a non-pharmacological complementary method to reduce postoperative pain after cesarean section and increase postpartum comfort. In this study, it is planned to apply kinesiotaping for 72 hours after cesarean section.
214936648|NCT06622707|OTHER|Routine clinical care|As routine clinical care; Analgesic treatment protocol applied after cesarean section, postnatal care and discharge services are provided
214936649|NCT05585125|DRUG|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol"
214335914|NCT06131918|DRUG|Resveratrol, Alpha lipoic acid, Super oxide dismutase|Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
214335915|NCT06131918|DRUG|Resveratrol|Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
214335916|NCT06131918|DRUG|Alpha lipoic acid|Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
214335917|NCT06131918|DRUG|Super Oxide Dismutase|Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
214335918|NCT03866993|BIOLOGICAL|AK105|IV infusion
214335919|NCT03866993|DRUG|Paclitaxel|IV infusion
214335920|NCT03866993|DRUG|Carboplatin|IV infusion
214335921|NCT03866993|DRUG|Placebo|IV infusion
214335922|NCT02818205|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
214335923|NCT04414670|PROCEDURE|C/S|laparoscopic or robotic metroplasty
214347294|NCT04827199|DEVICE|Artificial Urinary Sphincter implantation|"Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~* Perineal approach and bulbar urethral dissection~* Inguinal approach~* Cuff implantation around the urethra~* Transmission cable passing~* Surgery test procedure~* Implantation of the Control Unit~* Closure of the inguinal incision~* Closure of the perineal incision~* Implant disabled mode activation"
214347295|NCT03068403|PROCEDURE|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
214936650|NCT05585125|DRUG|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol"
214936651|NCT02611128|OTHER|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
214936652|NCT04450407|DRUG|LY3209590|Administered SC
214936653|NCT04450407|DRUG|Insulin Degludec|Administered SC
214936654|NCT03061656|DRUG|Cyclophosphamide|1st HDCT
214936655|NCT03061656|DRUG|Carboplatin|1st HDCT
214335924|NCT05186324|OTHER|Interview|"During each interview, patients will be asked questions to collect demographic and clinical information, and asked a set of open-ended questions with probes to describe their experiences with Fabry disease (symptomology and impacts on patient's lives \[i.e., activities of daily living, school/work, ability to take holidays/vacation\]), and pegunigalsidase alfa treatment (experience of infusions and schedule) and their experience of change in symptoms and impacts over the BRIGHT-F51 clinical study.~A semi-structured discussion guide will be used to conduct the approximately 60-minute interviews. The use of open-ended questions avoids bias and questions will not be read verbatim to allow for a free-flowing discussion."
214335925|NCT00001022|DRUG|Zidovudine|
214335926|NCT00001022|DRUG|Zalcitabine|
214335927|NCT00001022|DRUG|Didanosine|
214335928|NCT06529367|OTHER|Snellen chart|"Patients will be asked to use the 5 feet distance for standardization, which allows for visual acuity assessment from 20/16 to 20/200.~Patients will be asked to wear their current corrective lens for distance, to take the test at home in a place with good lighting and to test each eye separately.~Office-based vision testing will be performed by a trained ophthalmic technician in a dimmed room with the Snellen chart illuminated on a screen. Patients will be asked to wear their current corrective lens for distance and an eye occluder will be used to test each eye separately."
214335929|NCT01971398|BEHAVIORAL|Positive FASD education brochure|Exposure to a positive FASD education brochure
214335930|NCT01971398|BEHAVIORAL|Negative FASD education brochure|Exposure to a negative FASD education brochure
214335931|NCT01971398|BEHAVIORAL|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
214335932|NCT00302224|DRUG|2S, 4R Ketoconazole (DIO-902)|
214335933|NCT06044298|OTHER|procedural sedation|"Participants, adverse events during and after gastrointestinal procedures with sedation administered were observed and recorded. No intervention was performed."
214347296|NCT00098124|DRUG|milnacipran hydrochloride|
214674599|NCT05677945|DRUG|3Mixtatin paste: Simvastatin mixed with modified triple antibiotic|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
214936656|NCT03061656|DRUG|Etoposide|1st HDCT
214936657|NCT03061656|RADIATION|131I-MIBG|2nd HDCT
214936658|NCT03061656|DRUG|Thiotepa|2nd HDCT
214936659|NCT03061656|DRUG|Melphalan|2nd HDCT
214936660|NCT00301496|DEVICE|Coban 2 Layer Compression System|
214936661|NCT06618261|DIETARY_SUPPLEMENT|Caffeine + Resistance exercise|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
214936662|NCT06618261|DIETARY_SUPPLEMENT|Placebo + Resistance exercise|Acute placeb intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
215073504|NCT06651385|OTHER|Remote digital therapeutic exercise program|Participants will be introduced to the digital therapeutic exercise program during Screening and Consent (Visit 0, V0). Participants will be provided with an orientation to the Vitala platform and assistance will be offered in the download and access to the application, as needed. The study team will ensure access has been obtained via the health care professionals' dashboard on the Vitala app. Information obtained in the assessments outlined above will inform the tailored exercise prescription to meet the participant's needs. Participants will be encouraged to complete a total of 150 minutes of remote exercise sessions each week for 12 weeks via the Vitala platform. Participants will receive daily notifications to remind them to complete their assigned daily exercises.
215073505|NCT06658444|OTHER|Phonophoresis|Pulsed ultrasound will be used at a frequency of 1 MHz with an intensity of 0.5 W/ cm2 for 5 minutes.
215073506|NCT06658444|OTHER|sham ultrasound|sham ultrasound
214936663|NCT04483375|BIOLOGICAL|SCTA01|recombinant humanized anti-SARS-CoV-2 monoclonal antibody
214936664|NCT04483375|OTHER|Placebo|Placebo
214936665|NCT00097955|DRUG|aliskiren|
214936666|NCT06903585|DRUG|Naproxen (Proxen S)|Naproxen will be given for 5 days starting from the day subjects first receive palliative radiotherapy, it will be taken as an initial dose of 500mg then as 250mg every 8 hours for a total of 5 days.
214936667|NCT06903585|DRUG|Placebo|Placebo will be given for 5 days starting from the day subjects first receive palliative radiotherapy, it will be given every 8 hours for a total of 5 days.
214936668|NCT06903585|DRUG|Esomeprazole 20mg once daily|Esomeprazole will be given to all subjects as 20mg once daily starting from the day they start palliative radiotherapy and for a total of 5 days.
214936669|NCT05659979|OTHER|Comprehensive geriatric assessment|A detailed comprehensive geriatric assessment will be given to all the participants randomized to this group, including the administration of multidimensional prognostic index (MPI), a tool derived from the CGA and consisting of eight different domains.
214335934|NCT04317300|DRUG|Varenicline|Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
214335935|NCT04317300|OTHER|brief behavioral therapy|brief behavioral therapy
214335936|NCT04841343|DRUG|Triamcinolone|Triamcinolone in sinus
214335937|NCT01199081|DRUG|Dronedarone|"Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily"
214335938|NCT02648698|DRUG|Antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
214936670|NCT01574638|DRUG|Rifapentine (RPT)|Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
214936671|NCT06903923|DRUG|GLP-1 receptor agonist|Participants prescribed a GLP-1 receptor agonist (semaglutide) by their physician will be enrolled in this arm of the study. All participants will receive study provided calcium \& vitamin D supplement to support bone health and to reduce this as a confounding factor in overall outcomes
214936672|NCT06903923|BEHAVIORAL|Lifestyle Management|Participants receiving usual lifestyle interventions will be enrolled in this arm of the study. All participants will receive study provided calcium \& vitamin D supplement to support bone health and to reduce this as a confounding factor in overall outcomes
214936673|NCT04190498|DIAGNOSTIC_TEST|Nocturnal oximetry|Diagnosis of OSA will be based on the 3% Oxygen Desaturation Index (IDO) obtained by home nocturnal oximetry. The oximetry recordings will be centralized in sleep laboratory of the University Hospital of Grenoble Alpes. Oximetry data will be analyzed by a technician from the sleep laboratory of the University Hospital of Grenoble Alpes
214936674|NCT03087097|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal microbiota delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (MAM or SAM) who are in the rehabilitation phase of treatment and have failed to respond to at least 4 weeks of standard therapy.
214936675|NCT00923182|DRUG|alemtuzumab|
214936676|NCT01712165|DIETARY_SUPPLEMENT|ANMUM Materna|
214936677|NCT01712165|DIETARY_SUPPLEMENT|Control (milk powder)|
214936678|NCT01921244|OTHER|Decision Aid|"Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters."
214936679|NCT00792246|DRUG|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
214936680|NCT00792246|DRUG|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
215073507|NCT06660251|OTHER|Egg intervention|Oral administration of three hard-boiled eggs to be ingested within 15 minutes on one occasion.
215073508|NCT06660251|OTHER|Meatball intervention|Oral intervention with 170 g meatballs to be ingested within 15 minutes on one occasion.
215073509|NCT06659497|BEHAVIORAL|web-based patient education|"The web-based training, which will provide the following information about the IUI treatment process, will last a total of 60 minutes.~MODULE 1: General Information About Fertility MODULE 2: Diagnostic and Therapeutic Methods in Infertility / Insemination Treatment MODULE 3: Drugs Used in Insemination Treatment and Their Application MODULE 4: Things to Consider After Insemination"
215073510|NCT06388148|DRUG|Medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
215073511|NCT06388148|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
215073512|NCT06821009|OTHER|mPATH-CRC|Individuals will receive an automated text message inviting them to use the mPATH-CRC WebApp. The WebApp takes approximately 5 to 8 minutes to complete. The WebApp verifies patients are due for routine CRC screening, educates them about their options, and lets them request a screening test via the program.
215073513|NCT06821009|OTHER|Usual Care (Control)|"Patients randomized to the control arm will receive usual care, which includes the organizations' standard procedures for addressing CRC screening. In the participating Fee-for-Service and Value-Based settings, the EHR flags patients who are overdue for CRC screening as a care gap that is visible to all primary care providers."
215073514|NCT06600763|OTHER|Ice pack|The temperature of the area where the ice pack is applied will be measured at one minute intervals, and when the relevant area reaches a temperature of 13.6 0C, the physician will be informed and the drain removal procedure will be initiated.
214335939|NCT06280365|OTHER|Mulligan Mobilization with Movement Technique|Mobilization Technique
214335940|NCT01640301|BIOLOGICAL|Aldesleukin|Given SC
214335941|NCT01640301|DRUG|Cyclophosphamide|Given IV
214335942|NCT01640301|DRUG|Fludarabine Phosphate|Given IV
214335943|NCT01640301|OTHER|Laboratory Biomarker Analysis|Correlative studies
214335944|NCT01640301|BIOLOGICAL|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
214335945|NCT03103529|OTHER|Active Rehabilitation|
214335946|NCT06534515|DEVICE|Tomatis auditory stimulation|Traditional Tomatis Method Protocol
214335947|NCT02451657|OTHER|No Intervention|No intervention was administered in this study
214347297|NCT04398524|DRUG|ISA101b|ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
214347298|NCT00768274|DRUG|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
214347299|NCT00768274|DRUG|Placebo|Placebo twice daily (b.i.d.) for 28 days
214936681|NCT03784144|DIAGNOSTIC_TEST|Biering-Sorensen Test and Prone Plank Test|All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.
214335948|NCT01716247|OTHER|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
214335949|NCT02791139|OTHER|Cardiovascular Magnetic Resonance Imaging (MRI)|Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
215073515|NCT06600763|OTHER|warm gel pad|Gel pads kept at room temperature will be applied to the drain area of the pediatric patient whose surgical drain indication is decided to end, in a sheath designed to wrap around the drain. After waiting for 10 minutes in the application area, the drainage system will be removed by the physician.
214936682|NCT01748422|DRUG|Qutenza|Transdermal patch
214936683|NCT05001295|PROCEDURE|Physical Activity|Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
214936684|NCT02188472|DRUG|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
214936685|NCT02188472|DRUG|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
214936686|NCT02188472|DRUG|Placebo|Placebo: 2 tablets should be taken twice daily
214335950|NCT02791139|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
214335951|NCT02791139|OTHER|Tonometry|Tonometry is a noninvasive method to obtain arterial pressure waveform
214936687|NCT02089334|DRUG|RX-0201|"RX-0201 will be administered in a dose up to 250mg/m\^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles."
214335952|NCT02791139|OTHER|Genetic Testing (Blood)|The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
214335953|NCT02791139|OTHER|Hand-Grip Strength Measurement|We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
214335954|NCT02791139|OTHER|Body Fat Mass Analysis|Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
214486409|NCT06891963|OTHER|Conventional treatment|All participants in the three groups will receive conventional treatment in the form of hot pack treatment followed by active range of movement (AROM) exercises. A hot pack will be placed on the patients cervical, paraspinal, and upper thoracic areas (including the upper trapezius muscle with aMTrP) for 20 minutes. This will be followed by AROM exercise for cervical spine joints. Participants were asked to actively flex the neck so that the head dropped toward the contralateral trapezius muscles. Patients then rotated the head toward ipsilateral side. This exercise will be repeated five times.
214936688|NCT02613039|DRUG|Combined Estrogen-Progestin Oral Contraceptives|All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
214936689|NCT01604863|DRUG|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
214936690|NCT01604863|DRUG|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
214936691|NCT01604863|DRUG|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
215073516|NCT06605768|DIETARY_SUPPLEMENT|Complex with Biotin, Collagen, Keratin, Hyaluronic Acid.|"Biotin, Collagen \&amp;amp; Keratin Beauty Complex 25,000 mcg, 60 capsules, oral route of administration."
215073517|NCT06605768|DIETARY_SUPPLEMENT|Placebo product|Placebo, 60 capsules, oral route of administration
215073518|NCT06606509|DEVICE|Continuous Glucose Monitoring System (GX-01S)|Patients with Type 1 Diabetes Mellitus (T1DM) will receive Continuous Glucose Monitoring System (GX-01S) for seven days.
214335955|NCT03096548|BEHAVIORAL|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
214936692|NCT01179841|BEHAVIORAL|Playgroup|The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.
214936693|NCT01179841|BEHAVIORAL|Parent Training|The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.
214936694|NCT01179841|BEHAVIORAL|Parent Training|In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
214936695|NCT05546216|OTHER|Determination of the Effect of Raised Supine Position and Back Support on Back Pain, Anxiety and Comfort Level in Coronary Angiography Patients|The study was conducted between 01 September 2021 and 30 January 2022 as a randomized single-blind interventional study with a pre-test post-test control group. The sample of the study consisted of patients who underwent coronary angiography. Data; The patient information form was collected with the visual analog scale, state anxiety and immobilization comfort scale. Back support was provided to the intervention group with a pillow at the exit of the angiography and the head of the bed was raised 30 degrees. Back pain intensity at 0, 2 and 4 hours, anxiety and comfort level at 0 and 4 hours were measured. The control group was given routine nursing care.
214936696|NCT02215863|BIOLOGICAL|Fluad and Prevenar13|
214936697|NCT02215863|BIOLOGICAL|Fluad|
215073519|NCT06607666|DRUG|Lanreotide autogel|Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
215073520|NCT06607419|DRUG|Blinatumomab|Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.
215073521|NCT05097677|OTHER|Not applicable (observational study)|Not applicable (observational study)
214335956|NCT03096548|BEHAVIORAL|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
215073522|NCT06606834|DIAGNOSTIC_TEST|sonoelastography|Elasticity is defined as the ability of an organ or tissue to return to its original shape after being deformed by an applied force or stress. Based on this principle, sonoelastography is a technique used to assess the elasticity of tissues and organs during ultrasonography. This assessment allows measurement of changes in stiffness of soft tissues following physiological or pathological processes.
215073523|NCT06163703|BEHAVIORAL|Family Life Skills Triple P|The intervention is a 12-session program that combines parenting support with trauma-informed life skills coaching. It includes content related to positive parenting strategies, self-regulation, coping with emotions, effective communication, dealing with the past, and developing healthy habits.
215073524|NCT03537248|DEVICE|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
215073525|NCT03537248|DEVICE|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
214486410|NCT06892535|DRUG|Albumin infusion, 2g/L of ascitic fluid aspiration.|Albumin infusion lower than the standard dose, either 2g/L or 4g/L of ascitic fluid aspiration is termed as low dose.
215073526|NCT06753669|BEHAVIORAL|health education and social network building|The investigators will use techniques from the social network literature to build each treatment group as a cohesive social network and will diffuse educational messages through these groups.
215073527|NCT06753669|BEHAVIORAL|dental referral and educational materials|Control arm will receive a referral to vetted dentist and educational materials on child health
215073528|NCT04669262|DRUG|BGB-DXP604|Administered as intravenous (IV) infusion over 30 to 60 minutes
215073529|NCT04669262|DRUG|BGB-DXP593|Administered as intravenous (IV) infusion over 30 to 60 minutes
215073530|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP593
215073531|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP604
215073532|NCT01191645|DRUG|naloxone|Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
215073533|NCT01191645|DRUG|remifentanil|Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
214674600|NCT05677945|DRUG|3Mix: Modified triple antibiotic mix in propylene glycol|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
215073534|NCT01191645|DRUG|Sodium Chloride|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
214674601|NCT03940170|DEVICE|vistacam proof|Light fluorescence device
214335957|NCT02334735|BIOLOGICAL|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10\^6 cells)"
214335958|NCT02334735|BIOLOGICAL|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
214335959|NCT02334735|BIOLOGICAL|Poly-ICLC|1.4 mg
214335960|NCT03746860|DRUG|Tablet, Dispersible|1 tablet/day with 12 SQ-HDM per lyo-tablet
214335961|NCT01389908|DRUG|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
214335962|NCT03884283|DEVICE|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)
214335963|NCT02397395|DRUG|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
214335964|NCT02397395|DRUG|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
214335965|NCT03047616|OTHER|Blood and Urine Collection|
214936698|NCT02215863|BIOLOGICAL|Prevenar13|
214936699|NCT03177434|DRUG|polyethylene glycols (PEG) 3350|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
215073535|NCT01191645|DRUG|metoclopramide|Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
214335966|NCT06138574|DRUG|Dexmedetomidine|After the induction of general anesthesia, one group (Group: 1) will be administered dexmedotomidin infizyon and group (Group :2)remifentanil
214335967|NCT06138574|DRUG|Remifentanil|Remifentanil
214936700|NCT03177434|DRUG|Lactulose Oral Product|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
214936701|NCT01355198|DIETARY_SUPPLEMENT|Cysteine (as n-acetylcysteine) and glycine|Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each
214936702|NCT01355198|DIETARY_SUPPLEMENT|Cysteine/glycine|Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)
214936703|NCT06620705|DEVICE|Left bundle branch area pacing|Pacing of the left bundle branch area using a transvenous pacemaker lead
214936704|NCT06620705|DEVICE|Biventricular pacing|Pacing of the right and left ventricle using transvenous pacemaker leads
214674602|NCT03940170|OTHER|ICDASII|visual examination
214674603|NCT03940170|PROCEDURE|fissurotomy|histological validation
214936705|NCT02510105|DEVICE|VDR4 ventilator (Intrapulmonary Percussive Ventilation)|
214335968|NCT05754320|DEVICE|Tension band wire fixation|Tension band wire fixation
214335969|NCT05754320|DEVICE|Plate fixation|Tension band wire fixation
214335970|NCT05203029|OTHER|Online exercise|Patients in each group will be added to the specific group on Whatsapp, and the schedule and information about the exercise will be explained there. Furthermore, patients will be joined to particular pages on Instagram, and exercises will be performed through Live on that pages. All the patients will exercise for 12 weeks, two or three times every week.
214335971|NCT03028168|OTHER|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
214335972|NCT03028168|OTHER|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
214936706|NCT02510105|DEVICE|CT scan|
214936707|NCT02510105|DEVICE|Servo-i|
214936708|NCT02510105|DEVICE|- Intubation|
214936709|NCT02510105|DEVICE|Ventilation ( with an ICU conventional ventilator)|
214936710|NCT01993498|PROCEDURE|blood sampling|blood samples collection
215073536|NCT06875518|PROCEDURE|BTLH with bilateral uterine artery ligation from its origin|The round ligament close to the pelvic side wall is first coagulated and separated before the procedure is applied. Further incision is then made in the peritoneum. The bladder fold is pulled downward by opening the anterior leaf of the wide ligament. It shows the ureters lateralized and the posterior leaf of the wide ligament. After that, the ureters' path is shown, the retroperitoneal area is revealed, and the location where the uterine artery leaves the iliac artery is seen.
215073537|NCT06875518|PROCEDURE|Conventional TLH|The conventional TLH technique involved division of the corneal pedicles and securing the uterine pedicles. Preoperative Preparation of bowel wasn't routinely done to improve enhanced recovery of patients. Antibiotic prophylaxis with 3rd generation cephalosporin and metronidazole was given one hour preoperatively. Obese patients received subcutaneous low molecular weight heparin and compression devices after surgery. Under general anesthesia, patients were placed in a Lloyd Davis position.
215073538|NCT06874517|OTHER|no intervention|no intervention
215073539|NCT04428190|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
215073540|NCT04428190|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
215073541|NCT01638013|DRUG|Peficitinib|Oral Tablet
214335973|NCT03028168|OTHER|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
214936711|NCT05108077|BIOLOGICAL|cytokine-induced killer cells|Autologous cytokine-induced killer cells injected intravenously
214936712|NCT05108077|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of bladder/renal cancer according to the Clinical protocols
215073542|NCT06877104|OTHER|Healing @ Home Program (H@H 2.0)|Healing @ Home 2.0 is a clinically used comprehensive technology-based postpartum support program, which provides 24/7 support to individuals through use of a text message based chatbot for six weeks postpartum. Content of H@H 2.0 includes anticipatory guidance regarding physical recovery, infant care and feeding, clinical algorithms to respond to urgent patient needs.
215073543|NCT07033403|DEVICE|Low Level Laser Therapy|low-level laser therapy (LLLT) at a wavelength of 660nm (SiroLaser Blue, Dentsply Sirona, USA) after extraction
215073544|NCT07033403|BEHAVIORAL|Placebo plus Treatment As Usual|placebo (Sham) with only the aiming beam of thelow-level laser therapy (LLLT)
214674604|NCT04371510|OTHER|blood sample|a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
214674605|NCT00203645|BEHAVIORAL|Self-help treatment|"Workbook Becoming a Winner,"
214674606|NCT02827552|OTHER|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
214674607|NCT02973815|BEHAVIORAL|NU-HOME Intervention|The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
214674608|NCT03690258|DEVICE|Variable load exercise|This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
214335974|NCT02842060|BEHAVIORAL|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
214936713|NCT02133794|DEVICE|Tomosynthesis|
214936714|NCT03815591|DEVICE|smokeSCREEN web-based game|smokeSCREEN tobacco use reduction/prevention web-based game. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
214936715|NCT06621927|OTHER|Diet|The Ideal Food Pyramid, which has not been applied before, is used to observe disease activities and especially changes in intestinal microbiota in rheumatoid arthritis.
214335975|NCT02842060|BEHAVIORAL|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
214335976|NCT04944875|PROCEDURE|Group headphone|The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
214936716|NCT06621927|OTHER|Control (Standard treatment)|We chose a control group to show the effect of the intervention we would apply to the diet group and did not apply any intervention to the control group.
214936717|NCT00792376|DRUG|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
214936718|NCT00792376|DRUG|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
214936719|NCT00791362|OTHER|National programme for accreditation and improvement of GP|The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
214936720|NCT02584894|DEVICE|rTMS 1Hz|trauma exposure + repeated transcranial magnetic stimulation at 1Hz
214674609|NCT02124720|BEHAVIORAL|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
214674610|NCT02613572|DRUG|alpha lipoic acid|
214335977|NCT04944875|PROCEDURE|Group music|The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
214674611|NCT02613572|DRUG|Placebo|
214674612|NCT03993743|BIOLOGICAL|CD147-CART|Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
214335978|NCT04944875|PROCEDURE|Group maternal voice|The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
214335979|NCT02855502|DRUG|Prednisolone|
214335980|NCT02855502|DRUG|Placebo|
214335981|NCT05870280|BEHAVIORAL|nurse coaching|Group coaching will be applied to individuals with diabetes, 5-8 people.
214335982|NCT00377767|BEHAVIORAL|To change structure and roles of primary care teams to optimize prevention of obesity|
214335983|NCT00672477|DRUG|Methylnaltrexone|
214335984|NCT00672477|DRUG|Placebo|
214335985|NCT05840653|OTHER|psychotherapeutic intervention|The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation
214335986|NCT01657201|DRUG|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
214674613|NCT00907725|OTHER|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
214674614|NCT00907725|OTHER|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
214674615|NCT00953121|DRUG|bevacizumab and CPT-11 and Carboplatin|Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
214335987|NCT01657201|DRUG|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
214335988|NCT01858454|PROCEDURE|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
214335989|NCT01858454|PROCEDURE|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere \[Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.\].
214335990|NCT04946240|OTHER|Supervised (BRACE) Group|Supervised (BRACE) protocol include static, dynamic and anticipatory balance exercises, chair rise, stair climbing and floor transfer comes under the category of resistance exercises. 6 minutes walk test, marching in space and cycling comes in aerobic. count reverse for 50 remember 5 words, 5 animals, repeat 5 words, spell forward and backwards and cont even numbers comes in cognitive exercises.
214335991|NCT04946240|OTHER|Conventional Balance Exercises Group|The home plan included Balance and Resistance exercises of BRACE protocol were provided to the control group but that was not supervised. Control group participants were also same assessed as the S-BRACE group. Before giving the training plan for home, it was elaborated in detail. For the convenience of participants, the BRACE protocol was also translated into Urdu and was given in the printed form. The data were collected at baseline, after 3 weeks, 6, 9 and then after 12 weeks of training
214335992|NCT03230279|PROCEDURE|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
214335993|NCT03230279|PROCEDURE|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
214335994|NCT06213597|OTHER|routine swallowing rehabilitation|Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.
214335995|NCT06213597|DEVICE|real repetitive transcranial magnetic stimulation|In the rTMS group, 5 Hz rTMS was applied to the hot spot of the supraglottic motor cortex of the affected hemisphere at a treatment intensity of 80% resting motor threshold for 10 min, with a total of 250 pulses (with an interval of 11 s for every 1 s of continuous stimulation), and the treatment was performed once a day for 6 d per week for 2 weeks.
214335996|NCT06213597|DEVICE|sham repetitive transcranial magnetic stimulation|The sham rTMS group supplemented pseudomagnetic stimulation at the hotspot of the representative area, tilted the magnetic stimulation coil at 90°, and the same noise was emitted by the instrument during the treatment, but no stimulation was performed, and the group was treated once a day, 6d per week, for 2 weeks.
214335997|NCT00333034|DRUG|Etanercept|
214335998|NCT03808506|DIAGNOSTIC_TEST|Fecal calprotectin|Stool test to look at baseline burden of inflammation
214335999|NCT06525883|OTHER|No intervation|No intervention was made to the groups
214336000|NCT00381394|DRUG|sitamaquine|
214336001|NCT00612612|DRUG|obatoclax mesylate|Given IV
214936721|NCT02584894|DEVICE|rTMS 10Hz|trauma exposure + repeated transcranial magnetic stimulation at 10Hz
214936722|NCT02584894|BEHAVIORAL|psychoneurological assessment|psychoneurological assessment
214936723|NCT02584894|DEVICE|conductivity meter|electrodermal conductance measure
214936724|NCT02584894|DEVICE|electrocardiogram|heart rate measure
214336002|NCT00612612|DRUG|fludarabine phosphate|Given IV
214336003|NCT00612612|BIOLOGICAL|rituximab|Given IV
214936725|NCT06295627|OTHER|There were no interventions in retrospective analysis|A retrospective analysis method was used to analyze the causes of catheter-related urinary tract infection and the infecting bacteria of the two groups of patients. A single factor analysis was performed on various factors and other related factors, and corresponding nursing strategies were summarized and proposed.
214674616|NCT00731029|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2002/2003|Single dose, intramuscular injection
214936726|NCT00847782|PROCEDURE|Blood draw|1 day
214936727|NCT01862939|DRUG|DS-7309|1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
214936728|NCT01862939|DRUG|placebo|placebo to match part 2 DS-7309
214936729|NCT02402023|BEHAVIORAL|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
214336004|NCT00612612|OTHER|laboratory biomarker analysis|Correlative study
214674617|NCT00731029|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003|Single dose, intramuscular injection
214674618|NCT00847717|PROCEDURE|Selective neck dissection|Level IIb preserving neck dissection
214674619|NCT00847717|PROCEDURE|Conventional Neck dissection|Conventional neck dissection (MRND type III or Supraomohyoid)
214674620|NCT03992300|DEVICE|Clinical adjustment|Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
214936730|NCT02402023|BEHAVIORAL|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
214936731|NCT02718690|DEVICE|TENS|TENS transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214936732|NCT02718690|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
214936733|NCT06050655|DEVICE|Lingual aligners|orthodontic treatment with lingual aligners
214336005|NCT05982743|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota fermented milk|Participants will take one bottle (65 ml) of Yakult® drink daily, containing at least 6.5 x 10\^9 CFU of Lactobacillus casei strain Shirota, for a period of 4 weeks. Subsequently, there will be a two-week follow-up period.
214336006|NCT00884481|OTHER|Natalizumab|Participants treated with Tysabri
214336007|NCT02632149|DEVICE|PINS Vagus Nerve Stimulator|
214336008|NCT03888144|DRUG|Oxycodone|5 mg of oxycodone taken by mouth every 6 hours for 5 days
214336009|NCT03888144|DRUG|Ketorolac|10 mg of ketorolac taken by mouth every 6 hours for 5 days
214336010|NCT02348489|DRUG|SGI-110 (guadecitabine)|Investigational medicinal product
214336011|NCT02348489|DRUG|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
214336012|NCT02188017|DRUG|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
214336013|NCT01957189|DRUG|Dutasteride and Tamsulosin|0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
214336014|NCT01639001|DRUG|Crizotinib|250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
214936734|NCT03794102|OTHER|Water|Sterile water irrigation from standard sterile water bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
214936735|NCT03794102|OTHER|Saline|0.9% saline irrigation from standard saline bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
214936736|NCT06514716|PROCEDURE|Geniculate Artery Embolization with Intra-articular Corticosteroid Injection (GAE with IACI)|Participants will undergo geniculate artery embolization (GAE) followed by an intraoperative intra-articular corticosteroid injection (IACI). This combination aims to alleviate post-procedural pain and improve early functional outcomes in patients with knee osteoarthritis (OA).
214936737|NCT06514716|PROCEDURE|Geniculate Artery Embolization alone (GAE alone)|Participants will undergo geniculate artery embolization (GAE) without the additional intraoperative intra-articular corticosteroid injection. This procedure aims to serve as a control to evaluate the effectiveness and safety of GAE with IACI in comparison.
214936738|NCT04507802|DEVICE|Non invasive ventilation via helmet|Patients requiring long hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet
214936739|NCT03755843|DIAGNOSTIC_TEST|PASSIVE LEG RISING|"Pasive Leg Rising: In the supine method, the legs are lifted passively from the horizontal position to a 30° to 45° elevation while the head of the bed is flat.~Fluid Challenge: Fluid responsiveness is generally defined as an increase in SV or CO of 10% to 15% in response to a 250 mL crystalloid fluid bolus"
214936740|NCT03425266|OTHER|Interactive decision support tool|PainApp 1) assesses patient treatment goals (a structured values clarification exercise) and preferences, including decision making and communication preferences; 2) presents structured educational modules tailored to the user's stated goals and preferences; 3) presents educational information addressing identified gaps in care and communication; 4) assesses pain, pain interference, function, and other clinical factors; 5) generates succinct individualized summaries of patient treatment preferences and medical history, tailored to different clinical settings; 6) generates a personalized report for the patient, based on their goals and interests; 7) transmits the clinical summary to the patient and their provider(s), with patient permission.
214936741|NCT02368379|OTHER|Low dose (1 mcg) ACTH stimulation test|Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
214936742|NCT02368379|OTHER|Overnight metyrapone test|Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
214936743|NCT03060343|BIOLOGICAL|Zeushield Cytotoxic T Lymphocytes|"Three dose levels will be evaluated. Dose Level One: 1.0×10\^5 cells/kg, Dose Level Two: 1.0×10\^6 cells/kg, Dose Level Three: 1.0×10\^7 cells/kg.~At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals."
214336015|NCT01639001|DRUG|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
214336016|NCT01639001|DRUG|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
214336017|NCT00272701|DRUG|Esomeprazole|
214336018|NCT00272701|DRUG|Other PPI marketed in Sweden|
214336019|NCT02784418|PROCEDURE|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
214336020|NCT02784418|PROCEDURE|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
214336021|NCT02866682|DRUG|Prograf|Brand Drug for the duration of the study.
214336022|NCT02866682|DRUG|Tacrolimus|Generic
214336023|NCT04552782|BEHAVIORAL|Alcohol CBM|Trains approach or avoidance responses to alcohol cues.
214336024|NCT04552782|BEHAVIORAL|PTSD CBM|Trains approach or avoidance responses to trauma cues.
214336025|NCT04552782|BEHAVIORAL|Alcohol Sham|Will not train approach or avoidance responses.
214336026|NCT04552782|BEHAVIORAL|PTSD Sham|Will not train approach or avoidance responses.
214336027|NCT00671281|DRUG|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
214336028|NCT00671281|DRUG|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
214336029|NCT01794325|OTHER|Trans-radial|Coronary angiography performed through trans-radial access
214336030|NCT01794325|OTHER|Trans-femoral|Coronary angiography performed through trans-femoral access
214336031|NCT01201434|DIETARY_SUPPLEMENT|Bio-25 probiotic|2 tablets per day for 6 months
214336032|NCT03207412|BIOLOGICAL|hAECs|human amniotic epithelial cells
214336033|NCT03207412|PROCEDURE|Minimally invasive implantation|Minimally invasive implantation with ultrasound guidance
214936744|NCT00356252|DRUG|mixed carotenoids|
214336034|NCT02687880|PROCEDURE|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
214336035|NCT06067074|PROCEDURE|Volar Locking Plate|Surgery
214336036|NCT06067074|PROCEDURE|Plaster Cast|Non-operative treatment with a plaster cast
214336037|NCT06491004|DIAGNOSTIC_TEST|PTX3 assay|PTX3 dosage by the in vitro medical device in evaluation.
214336038|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
214336039|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
214336040|NCT01016795|DRUG|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
214936745|NCT06628752|DEVICE|Deep brain stimulation|Stimulation through a device implanted bilaterally into deep brain structures.
214336041|NCT04418882|OTHER|management and follow up of all open fractures|to evaluate the development of sepsis after an open fracture and then, if there is a development of a pseudarthrosis too.
214936746|NCT04490642|OTHER|Questionnaire|Final version Childhood Bladder and Bowel Dysfunction for 5-12 years old questionnaire in Korean language to patients who never encountered beforehand in other available languages (Dutch, English).
214936747|NCT02832375|DRUG|stannous fluoride|0.454% w/w stannous fluoride containing 1100ppm of fluoride
214936748|NCT02832375|DRUG|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
214936749|NCT00468442|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|transplant of islet cells injected into the portal vein of the liver
214336042|NCT03792594|OTHER|arthroscopic repair with bone marrow concentration|arthroscopic repair with bone marrow concentration
214336043|NCT03792594|OTHER|arthroscopic repair|arthroscopic repair only
214336044|NCT01112995|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
214336045|NCT01112995|DIETARY_SUPPLEMENT|Sugar pill (placebo)|placebo identical to the active product will be given
214336046|NCT01793064|BEHAVIORAL|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
214336047|NCT01793064|BEHAVIORAL|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
214336048|NCT05652751|DRUG|nerve growth factor|The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
214336049|NCT05652751|DRUG|physiological saline|Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
214347300|NCT00838344|OTHER|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
214347301|NCT02730819|DRUG|Illuminate Cream|Topical compound applied daily
214936750|NCT00468442|BIOLOGICAL|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
214936751|NCT00468442|BIOLOGICAL|Daclizumab|Will replace antithymocyte globulin in all islet transplantations after the first one
214936752|NCT00468442|BIOLOGICAL|Rituximab|Depletes transient B-cells
214936753|NCT00468442|DRUG|Sirolimus|Maintenance immunosuppressive therapy
214336050|NCT05652751|DEVICE|EA|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
214336051|NCT05652751|DEVICE|sham EA|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
214336052|NCT00201006|BEHAVIORAL|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
214336053|NCT00201006|BEHAVIORAL|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
214336054|NCT00201006|OTHER|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
214336055|NCT03869775|DEVICE|perfusion index monitor|perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor
214674621|NCT01145105|PROCEDURE|neural dynamics techniques treatment|Treatment group- will receive neural mobilizations techniques, to improve movement of the sciatic nerve.
214674622|NCT01145105|PROCEDURE|placebo treatment|Control group- will receive placebo treatment that will include mobilization to the upper limb. After the placebo treatment, these patients will receive neural mobilizations techniques.
214674623|NCT02342561|DEVICE|Ioban 2 incision drape, 3M|The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
214674624|NCT01143597|OTHER|Arm and hand training|Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.
214336056|NCT03869775|DIAGNOSTIC_TEST|ewing test|ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis
214336057|NCT00004129|RADIATION|brachytherapy|
214336058|NCT00004129|RADIATION|phosphorus P32|
214336059|NCT03348891|OTHER|Tumor biopsy specimens and blood samples|Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.
214674625|NCT05228912|DRUG|COVID-19 Vaccines|Each group will receive a complete scheme of the vaccine according to local government assignation
214674626|NCT04634968|BEHAVIORAL|Brief Motivational Interviewing interaction|Telephone peer counselling+ Brief Motivational Interviewing interaction, and telephone-based interview after receiving all information.
214674627|NCT04634968|BEHAVIORAL|General health communication|Telephone peer counselling+ General health communication, and telephone-based interview, and telephone-based interview after receiving all information.
214936754|NCT05407428|OTHER|NeuraLight software-based platform|NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including ALS patients
214336060|NCT03556657|OTHER|Music Therapy|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
214336061|NCT00101855|PROCEDURE|An evidence based tailored web site|
214336062|NCT00470951|PROCEDURE|open rectal resection|open rectal resection
214936755|NCT05311228|DRUG|Azithromycin Powder|Azithromicyn intravena for 14 days
214936756|NCT00201461|DEVICE|STARFlex septal closure system|transcatheter placement of STARFlex device to close a patent foramen ovale
214674628|NCT04494711|BEHAVIORAL|Physical Functional Literacy for Adults|A 5 week physical literacy for program focused on virtual knowledge translation strategies to improve function and mobility for adults with multiple chronic conditions. This is a population -based approach to rehabilitation
214674629|NCT06657534|PROCEDURE|Push-pull technique|push-pull technique as described by McBride et al, J Infus Nurs 2018
214674630|NCT06657534|PROCEDURE|SOC (Standard of care)|Standard of care method to obtain blood with waste blood
214674631|NCT06656741|BEHAVIORAL|Resting State|Resting state is a mental state and a research paradigm that people do nothing and idle as much as possible to show their baseline neuro signals. In this task, we instructed participants to rest with their eyes opened for 6 minutes. The VR environment of blue sky and swaying meadow was presented to the participants throughout this task.
214674632|NCT06656741|BEHAVIORAL|Mindful Breathing|Mindful breathing is a state that people focus on their inner sensation. In this task, the meadow's motion in the VR environment corresponded to the participants' inhalation and exhalation, as detected by the respiration belt. The participants were instructed to focus mentally on their bodily sensations as they breathed, with the meadow's sway as a visual cue.
214336063|NCT00470951|PROCEDURE|laparoscopic rectal resection|laparoscopic assisted rectal resection
214336064|NCT04271930|BEHAVIORAL|Mindfulness Awareness Practices for Insomnia|MAP-I is a curriculum-based intervention that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
214674633|NCT06656741|BEHAVIORAL|Guided Breathing|Guided breathing refers to the breath training technique that trainees are guided to inhale and exhale according to a fixed tempo. In this task, meadow swayed in a fixed tempo of 4 seconds back and 6 seconds forth. The participants were instructed to synchronize their inhalation with the meadow's backward motion (lasting 4 seconds) and their exhalation with its forward motion (lasting 6 seconds).
214336065|NCT04271930|BEHAVIORAL|Sleep Health Information|A video SHE seminar will serve as active comparator for nonspecific treatment elements that pose rival explanations for the effectiveness of MAP-I.
214336066|NCT01490177|DRUG|Food proteins|Oral ingestion of Food proteins
214674634|NCT06656741|BEHAVIORAL|Breath Counting|Breath counting refers to the breath training technique that trainees mentally count the numbers of breath cycles they have finished in a certain period of time. In this task, similar to the mindful breathing task, the meadow's motion was synchronized with the participants' breathing patterns. During the 6 minutes, we instructed the participants to breathe naturally and mentally count their breathing cycles.
214336067|NCT06404580|PROCEDURE|R anastomosis|R anastomosis
214336068|NCT01954654|DEVICE|Custom-made compression sleeve and -gauntlet|Device: Compression garments worn for a minimum of six hours per day
214336069|NCT01954654|OTHER|Educational information, recommendation and instruction|Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
214336070|NCT01448746|DRUG|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
214674635|NCT06326229|OTHER|ICF entities assessment|A visual analog scale will be used by the participants to evaluate the relevance of the ICF entities in relation to their musculoskeletal condition. The scale will range from 0 (no problem) to 100 (complete problem).
214674636|NCT03997630|DEVICE|High flow Oxygenation|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
214674637|NCT03997630|DEVICE|Standard oxygen|Control group: All patients included in this group will receive a low flow oxygenation (flow rate \< 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
214936757|NCT00201461|DRUG|Best medical therapy|aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
214936758|NCT03817411|DRUG|Telatinib|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
214936759|NCT03817411|DRUG|Capecitabine|1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).
214936760|NCT03817411|DRUG|Oxaliplatin|130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.
214936761|NCT03817411|DRUG|Placebos|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
214936762|NCT06350461|OTHER|Discontinuation of hypertonic saline (HS)|Discontinuation of current hypertonic saline (HS) therapy during 6-week study period.
214936763|NCT06350461|OTHER|Continuation of hypertonic saline (HS)|Continuation of current hypertonic saline (HS) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily). The concentration of HS is according to clinical prescription (e.g., 7% sodium chloride or 3.5% sodium chloride) and at least 3%.
214936764|NCT03385044|PROCEDURE|MOVT|ETT cuff will be inflated till the disappearance of audible air leak on auscultation, while abdominal carbon dioxide (CO2) inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
214936765|NCT03385044|PROCEDURE|VE/VI ratio of Spirometer|ETT cuff will be inflated till the VE/VI ratio meets the initial VE/VI ratio, while abdominal CO2 inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
214674638|NCT00853905|DRUG|Triesence|At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.
214336071|NCT02837744|DEVICE|Axiostat®|Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
214336072|NCT01304888|OTHER|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
214336073|NCT01304888|OTHER|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
214336074|NCT01304888|OTHER|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
214674639|NCT00853905|DRUG|balanced salt solution BSS|At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
214674640|NCT04538950|DIAGNOSTIC_TEST|PET/CT|Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
214674641|NCT04538950|DRUG|radioactive drug (tracer)|A radioactive drug (tracer) is used in the PET scan.
214936766|NCT03411694|OTHER|Survey|Survey in patients from the Jessa Hospital that are planned for elective surgery, both ambulatory and inpatient.
214936767|NCT03071731|DRUG|Bronchodilators|Administration of a nebulized combination of bronchodilators before the administration of a functional test.
214936768|NCT03071731|DRUG|Placebos|Administration of a nebulized placebo before the administration of a functional test
214936769|NCT00274079|DRUG|SPIRIVA|
214936770|NCT05484154|BIOLOGICAL|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given at 100 mL IV infusion
214336075|NCT01304888|OTHER|Control|No benefits were provided
214336076|NCT04543734|DEVICE|HemoScreen hematology analyzer|The use of HemoScreen for self-testing of blood values
214674642|NCT00974779|DEVICE|HCO1100 dialyzer|Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
214936771|NCT05484154|OTHER|Placebo|Matching placebo, 0.9% sodium chloride in water, given at 100 mL IV infusion
214936772|NCT05871398|DRUG|Tegoprazan|Novel, potent, and highly selective potassium-competitive acid blocker which was developed in Korea
214674643|NCT00974779|DEVICE|regular dialysis polyamide|Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
214936773|NCT05871398|DRUG|Placebo|Placebo
214936774|NCT02520882|DRUG|68Ga-NOTA-Aca-BBN|68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
214936775|NCT02520882|DEVICE|PET/CT|
214936776|NCT06731582|DIETARY_SUPPLEMENT|Nicotinamide Tablet|1.5 grams/day
214936777|NCT06731582|DIETARY_SUPPLEMENT|Nicotinamide Placebo|2 tablets
214936778|NCT06621082|DRUG|Selumetinib|After surgical resection，based on the patient's body surface area (BSA), the patient was given an oral dose of Simetinib bisulfate capsule (20-50mg bid) daily for 30 days for 6 cycles
214936779|NCT03273465|OTHER|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
214936780|NCT01461720|OTHER|Standard medical care|Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
214336077|NCT02157311|DRUG|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
214336078|NCT03696121|DRUG|Desmopressin Injection|Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes
214336079|NCT03696121|DRUG|Normal saline|Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
214336080|NCT05123248|DEVICE|Blinded Group|Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
214336081|NCT05123248|DEVICE|Unblinded group|Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
214347302|NCT06099171|DRUG|Cannabidiol and β-Caryophyllene Patch|Cannabidiol with its decongestant activity has a soothing action in the area of application, thanks to the association with B-caryophyllene which assists its activity
214674644|NCT04940598|OTHER|high intensity interval exercise|HIIT training will be delivered two times per week for 16 weeks (32 sessions). Each session will be separated by at least 24-hrs. Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule. The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test. HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.
214936781|NCT01461720|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
214936782|NCT02191176|DRUG|Dextromethorphan syrup - low dose|
214936783|NCT02191176|DRUG|Dextromethorphan syrup - high dose|
214936784|NCT02191176|DRUG|Placebo|
214936785|NCT01537627|OTHER|Physical training|"Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.~Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months."
214936786|NCT01537627|OTHER|Physical training|Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
214936787|NCT04921527|DRUG|chiauranib|50mg orally once daily
214936788|NCT04921527|DRUG|Placebo|50mg orally once daily
214936789|NCT04921527|DRUG|Paclitaxel|at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
214936790|NCT00215527|DRUG|laronidase|0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
214936791|NCT06906536|OTHER|Acute Intermittent Hypoxia (AIH)|4 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
214936792|NCT06906679|DEVICE|Experimental Group|"The EG will follow 20 sessions of robot-assisted therapy for the upper limb. Exercises will be performed using a handpiece to support the weight of the upper limb during therapy and to assist (or resist) movements according to the patient's needs. These modalities are presented to the patient through visual and motor feedback (force feedback).~The exercises will focus on rehabilitating upper limb performance, for example:~Elbow: flexion-extension; Shoulder: horizontal adduction/abduction, flexion-extension.~The software includes serious games for:~* Motor control (both movement control and force control);~* Coordination;~* Cognitive training;~* Simulation of daily activities. The exercises will be defined by specialized personnel based on the patient's characteristics. Each rehabilitation session lasts 45 minutes, including 5 minutes for device setup, 20 minutes for the right upper limb and 20 minutes for the left upper limb."
214936793|NCT06906679|OTHER|control group|The CG will last 20 sessions (3 days/week) of conventional rehabilitative treatment without the use of technological devices for the upper limb. Each session will last 45 minutes. The motor exercises will focus on upper limb rehabilitation and will be performed with a therapist who will personalize the treatment based on the patient's characteristics and needs. Specifically, the upper limb treatment will include exercises for mobility (shoulder, elbow, wrist, and hand), coordination, and manual dexterity.
214936794|NCT03148457|DRUG|Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Early treatment will be started within 48 hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after symptom onset (major ischaemic stroke)
214674645|NCT04940598|OTHER|No-exercise control group|No-exercise control group
214674646|NCT01004146|PROCEDURE|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
214674647|NCT04138706|DRUG|Vancomycin|Extension of initial vancomycin regimen for the treatment of C. diff from 14 days to 28 days (i.e. an additional 14 days of vancomycin treatment)
214674648|NCT04138706|DRUG|Placebos|Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.
214936795|NCT03148457|DRUG|Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Patients in the control arm will receive late treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day, moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2 day).
214674649|NCT06661759|BEHAVIORAL|Clinic-based and technology-supported sleep intervention|CATS sleep intervention: The in-person sleep education and consultation will consist of 3 face-to-face, one-on-one sessions held 3 months apart during the child's routine clinic visit.The digital component of the sleep intervention will extend in-person education by providing ongoing support. Participants will receive one digital session per week for four weeks after the baseline, 3-month, and 6-month clinic visits, totaling 12 sessions.
214336082|NCT02044887|OTHER|physical activity|The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
214336083|NCT04010617|DEVICE|Pharyngeal Electrical Stimulation (PES)|PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
214674650|NCT06859554|DRUG|Glyceryl Trinitrate (GTN) 0.2% Ointment|Participants will apply 0.2% Glyceryl Trinitrate (GTN) ointment to the anal region twice daily for four weeks. GTN functions as a nitric oxide donor, reducing internal anal sphincter tone to improve blood flow and promote fissure healing. The study aims to assess its effectiveness in symptom relief, fissure healing, and associated side effects such as headaches and dizziness.
214336084|NCT01764100|GENETIC|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
214336085|NCT00423436|BEHAVIORAL|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
214336086|NCT00423436|BEHAVIORAL|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
214336087|NCT00423436|BEHAVIORAL|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
214336088|NCT00274716|DRUG|MK0736|
214936796|NCT03247491|BEHAVIORAL|Mindfulness|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
214936797|NCT06174376|DEVICE|GORE Synthetic Cornea Device|Treatment with GORE Synthetic Cornea Device
214936798|NCT02464891|DRUG|CCX168|
214336089|NCT00274716|DRUG|MK0916|
214336090|NCT00274716|DRUG|Placebo|
214336091|NCT01162005|DRUG|Tacrolimus|dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
214674651|NCT06859554|DRUG|Glyceryl Trinitrate (GTN) 0.4% Ointment|Participants will apply 0.4% Glyceryl Trinitrate (GTN) ointment twice daily for four weeks. This increased concentration aims to determine dose-dependent efficacy and adverse effects in treating acute anal fissures. GTN acts by relaxing smooth muscle, decreasing sphincter tone, and enhancing mucosal blood flow to promote healing.
214936799|NCT03250091|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for histopathological examination, including H.pylori detection
214936800|NCT03250091|PROCEDURE|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination, serum biomarkers
214936801|NCT03250091|PROCEDURE|Biopsies for gastric microbiota|During upper endoscopy biopsies for gastric microbiota analysis will be obtained
214936802|NCT03250091|PROCEDURE|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
214936803|NCT00847392|PROCEDURE|Ultrasound prior to bladder catheterization|Bedside ultrasound to estimated volume of urine in bladder
214936804|NCT00375050|DRUG|Riluzole|
214936805|NCT00375050|DRUG|Placebo|placebo
214674652|NCT06859554|DRUG|Nifedipine 0.2% Ointment|Participants will apply 0.2% Nifedipine ointment twice daily for four weeks. Nifedipine, a calcium channel blocker, reduces sphincter tone by inhibiting calcium influx into smooth muscle cells, leading to improved fissure healing. This arm will assess its effectiveness in symptom relief and healing rates, with a focus on side effects such as local irritation or hypotension.
215073545|NCT07032896|BEHAVIORAL|Nurse-led Patient Education|The training program will be implemented in line with patient needs determined by the researcher. In order to overcome this lack of information, existing research findings and evidence-based treatment guidelines were extensively reviewed. The training program will be based on the following guidelines. The program will start with a 30-minute individual training session on patients' self-efficacy level, self-care behaviors, medication and diet compliance processes. This training will be carried out in the hospital in accordance with the patient's plan. Discharged intervention group patients will then be interviewed by telephone six times over a period of three months, and two interviews will be scheduled for each of these monthly periods. In order to measure the impact of the intervention, data will be collected twice, before and after the training for the intervention group
214336092|NCT01322204|DRUG|Codeine|One single oral dose of 1 mg/kg of codeine
214336093|NCT05427149|DRUG|25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)|It will be evaluated whether there is postpinal shivering in the cases.
214336094|NCT02680691|OTHER|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
214336095|NCT02680691|OTHER|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
214336096|NCT02762409|OTHER|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
214336097|NCT02762409|OTHER|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
214336098|NCT03946332|BEHAVIORAL|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
214336099|NCT03946332|BEHAVIORAL|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
214674653|NCT06859554|DRUG|Nifedipine 0.5% Ointment|Participants will apply 0.5% Nifedipine ointment twice daily for four weeks. This higher concentration is used to evaluate whether increased potency provides superior symptom resolution and healing rates compared to 0.2% Nifedipine. The study will also assess any potential adverse effects, including local irritation, dizziness, and hypotension.
214674654|NCT02107664|RADIATION|Palliative RT for bone cancer pain|
214936806|NCT06328244|BEHAVIORAL|Simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
214936807|NCT06153186|DRUG|Flunarizine Hydrochloride|Flunarizine tablet
214936808|NCT05908435|BEHAVIORAL|Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors|The study intervention is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
214336100|NCT02912351|OTHER|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
214674655|NCT01240018|DIETARY_SUPPLEMENT|Probiotic|Parallel, randomized, controlled 2 arms study.
214674656|NCT06217406|DRUG|Intravenous acyclovir (ACYCLOVIR )|Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).
214936809|NCT03333902|PROCEDURE|QLB|QLB, quadratus lumborum block.
214674657|NCT06217406|DRUG|Saline bags|Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).
214936810|NCT03333902|PROCEDURE|Intravenous patient controlled analgesia (PCA)|Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
214936811|NCT03398512|PROCEDURE|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical colorectal resection and cytoreductive surgery
214936812|NCT03398512|PROCEDURE|HIPEC|Normal saline 3000ml-4000ml, Raltitrexed 4mg, 43°C, 60min.
214336101|NCT04795271|OTHER|Orthopedic intervention|"In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~1. Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~2. Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~3. Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~4. Insole type and lining material~5. Materials of the added corrections~6. Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite."
214336102|NCT00975975|DRUG|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
214336103|NCT04848285|OTHER|Early Mobilization|Additional 2 or more sessions of out-of-bed activity to the standard stroke care, focused in active sitting, standing and walking assisted by physiotherapists
214336104|NCT04848285|OTHER|Standard care|Standard protocol of mobilization in acute stroke patients admitted to the Stroke Unit at the discretion of the nursing and physiotherapy staff
214336105|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
214336106|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
214336107|NCT00961259|DRUG|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
214336108|NCT00665119|DRUG|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
214336109|NCT00665119|DRUG|placebo|NaCl 0.9 %
214336110|NCT00843791|DRUG|placebo|treatment with placebo for 3 months
214486411|NCT06761274|OTHER|peripheral blood sampling|"It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics:~* in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification).~* newly diagnosed (stage II b, III or IV, Ann Arbor Classification)."
214674658|NCT03526640|DEVICE|The BioSentry Tract Sealant System|The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
214936813|NCT03398512|DRUG|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. Capecitabine: 1500mg, twice daily for two weeks, and then suspend for one week
214936814|NCT01173055|DRUG|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
214674659|NCT03556696|DEVICE|ANI-REMI-loop|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
214674660|NCT03556696|DEVICE|remifentanil pK/pD target administration device|standard practice, remifentanil administration using Minto's pK/pD model
214674661|NCT03556696|DRUG|Remifentanil|Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
214674662|NCT03556696|DRUG|Propofol|propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range
214336111|NCT00843791|DRUG|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
214336112|NCT01252251|DRUG|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
214336113|NCT03611803|DEVICE|Physiotherapy + Robotic-device|Daily use of an exoskeleton (robotic-device) on 5 successive days as well as daily physiotherapy sessions
214336114|NCT03611803|OTHER|Physiotherapy only|Participants will engage in daily physiotherapy sessions (without the exoskeleton) and/or home-based sit-to-stand exercises
214336115|NCT03868436|DRUG|Methoxyflurane 3mL|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
214336116|NCT01324024|DRUG|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
214336117|NCT01324024|DRUG|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
214336118|NCT04965779|DEVICE|Abdominal Binder|Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
214674663|NCT03556696|DEVICE|ANI monitor|"ANI (Analgesia Nociception Index) value is used in the std\_practice arm for guidance of the remifentanil Ce target"
214936815|NCT01173055|DRUG|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
214936816|NCT00456508|DRUG|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
214936817|NCT03335423|DRUG|Oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
214936818|NCT03335423|DRUG|Intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
214936819|NCT03335423|DRUG|Oral codeine and oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
214936820|NCT03335423|DRUG|Oral codeine and intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
214936821|NCT05922319|OTHER|Computerized cognitive training with different training doses|The training dose was defined as training frequency (number of training days per week) and average training duration per training day. The daily dose was divided into 13 categories with an interval of 5 minutes and the training frequency has 7 categories according to the number of training days per week.
214936822|NCT02021136|DEVICE|Rebel Reliever|Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations
214936823|NCT02021136|OTHER|Control|Usual antalgic treatment + physical exercises recommendations
214936824|NCT06623318|DEVICE|Remote therapeutic monitoring device|IV Ensure proprietary remote therapeutic monitoring device is used to record and transmit data associated with date, time, and duration of IV medications administered in the home setting post-acute.
214936825|NCT05994118|OTHER|NaCl 0.9% (normal saline)|Subcutaneous normal saline injection
214936826|NCT05994118|OTHER|Magnetized Normal Saline|Magnetized Normal Saline
214936827|NCT00126100|DRUG|G-CSF Granulocyte-Colony Stimulating Factor|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
214936828|NCT00126100|OTHER|Placebo|Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
214936829|NCT03126006|PROCEDURE|NSPT plus oral hygiene|Non-surgical periodontal therapy under local anesthesia to remove plaque and calculus
214936830|NCT03126006|OTHER|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
214936831|NCT01829178|DRUG|Silymarin|Silymarin 420 mg in 3 divided dose plus standard chemotherapy
214936832|NCT01829178|DRUG|Placebo|placebo tablets: 420 mg in 3 divided dose
214936833|NCT01829178|DRUG|chemotherapy|All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
214936834|NCT02351193|OTHER|transvaginal Ultrasound|
214936835|NCT02757937|BEHAVIORAL|Health & Wellness Website|Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
214936836|NCT02757937|OTHER|Control Arm|Continue with standard diabetes care without getting access to the intervention website.
214486412|NCT06761950|DEVICE|Low Level laser therapy|The patient received low-level laser therapy three times per week for four weeks, with immobilization maintained. The Mustang 2000 Laser device was used with an infrared laser probe to accelerate tendon healing. The device's specifications include peak power output of 15W, power density of 15W/cm2, wave length of 890nm, pulse frequency of 100Hz, spherical size of 0.002cm2, pulse duration of 130 ns, exposure duration of 60 sec, and energy density of 5.85J/cm2.
214674664|NCT03854487|BEHAVIORAL|Mirror therapy|A mirror is placed at the midsagittal plane of the patient. The patients in the mirror therapy group watched the mirror illusion of the non-affected arm in the mirror and moved together with the affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
214936837|NCT06621628|OTHER|stretching, strengthening exercises and active exercises|Bioptron light therapy device, resisted exercises and stretching exercises
214936838|NCT00743015|DRUG|BI 44370 TA tablet|
214936839|NCT06618833|OTHER|Collection of medical data|Collection of medical data focused on the history of atrial fibrillation by the principal investigator
214936840|NCT06618833|BEHAVIORAL|Collection of global health elements|Collection of global health elements (physical and mental) by the principal investigator by discussion with the patient
215073546|NCT07033806|OTHER|Exercise Tabata Protocol|more effective
214936841|NCT06618833|BEHAVIORAL|PROMIS global questionnaire|"The patient completes the global PROMIS questionnaire which collects data on their overall health.~The questionnaire consists of 10 questions about the patient\&#39;s overall health, and for each question, the patient has a possible choice of 5 answers varying between different propositions depending on the question:~Excellent to poor or Totally to not at all, or Always to never or None to very intense"
214936842|NCT06618833|BEHAVIORAL|Collection of sociological data|Collection of patient sociological data (territorial, economic, professional, ethnic) by the principal investigator
215073547|NCT07034456|DEVICE|Tape with mangetic particles|An elastic adhesive tape containing magnetic particles, designed to be applied directly to the skin. In this study, the tape is applied to the lumbar region. The tape remains in place during standardized sensory and vascular measurements
214936843|NCT06906588|DEVICE|Experimental|The experimental group (EG), in addition to the standard rehabilitation treatment, will perform one upper limb BRAT session per day through the Arm Light Exoskeleton Hybrid (Alex RS - Wearable Robotics) robotic system.. Each participant will perform a total of 16+/-3 treatment sessions with a frequency of 4 times a week for 4 consecutive weeks. During the first session, the device should be adjusted according to the patient's bilateral size and suspension angle. The selection of personalized exercises will be based on each patient's motor skills and the difficulty can be gradually increased during the treatment period. These modalities are shown to the patient with visual and motor feedback (force feedback). The duration of the single rehabilitation treatment is 45 minutes, of which 5 minutes are used for setting up the device, 10 minutes for assembly/disassembly, 10 minutes for unilateral treatment with the affected upper limb and 20 minutes for bilateral treatment.
214336119|NCT04965779|OTHER|Postpartum nursing care|Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
214336120|NCT02129179|DRUG|Glucagon-Like Peptide 1|
214336121|NCT05711069|OTHER|Core Stability Exercise Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
214336122|NCT05711069|OTHER|Routine Football Training Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
214936844|NCT06906588|OTHER|Control|The control group (GC), in addition to the standard routine rehabilitation treatment, will follow 45 minutes of conventional rehabilitation of the upper limbs without the use of technological devices. Each participant will perform a total of 16+/-3 conventional upper limb treatment sessions with a frequency of 4 times a week for 4 weeks. The motor exercises will concern the rehabilitation of the upper limb and will be performed with a therapist who will personalize the treatment based on the clinical characteristics and needs of the patient. Specifically, the treatment of the upper limb will be characterized by motor exercises (shoulder, elbow, wrist and hand), coordination and manual dexterity. Each session will consist of passive, active-assisted and active exercises.
214336123|NCT01159496|DRUG|PF-05212377 (SAM-760)|Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
214936845|NCT04250233|DEVICE|Respiratory Monitor|All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.
215073548|NCT07034456|DRUG|Topical Anesthetic Cream|EMLA®, a topical anesthetic cream containing lidocaine and prilocaine, will be applied under occlusion prior to tape application during 30 minutes with the aim of anesthetize the cutaneous sensory receptors
215073549|NCT07034456|DEVICE|Control KinesioTape|An elastic adhesive tape, designed to be applied directly to the skin. In this study, the tape is applied to the lumbar region. This tape does not content magnetic particles, thus is used as a comparator. The tape remains in place during standardized sensory and vascular measurements
215073550|NCT07034456|DEVICE|Moisturizing Cream (control)|A neutral moisturizing cream (control) will be applied under occlusion prior to tape application during 30 minutes. The application will be blind and use as a placebo vs the anesthetic cream.
214674665|NCT03854487|BEHAVIORAL|Sham mirror|A transparent glass wall is placed at the midsagittal plane of the patient. The patients in the sham mirror group watched the movements of the affected arm through the transparent glass wall and moved together with the non-affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
214674666|NCT03854487|BEHAVIORAL|Covered mirror|A covered mirror is placed at the midsagittal plane of the patient. The patients in the control group watched the movements of the non-affected arm and moved together with the affected arm behind the covered mirror. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
215073551|NCT07033533|DRUG|Allopurinol Tablet|allopurinol 300
215073552|NCT07033533|DRUG|Placebo|placebo tablet
215073553|NCT06718426|DRUG|Fertitonex capsule|Fertitonex which contains L- carnitine L-tartarate 300 mg, L-arginine 241mg, vitamin B6 1.1 mg, vitamin B12 1.7 mcg, vitamin D3 2 mcg, vitamin E 6.5 mg, vitamin C 60 mg, selenium 28 mcg, zinc 7.5 mg, folic acid 300 mcg and CoQ 10 enzyme 7.5 mg in each capsule. The dose will be one capsule twice daily for 3 months.
215073554|NCT06718426|DRUG|Placebo Oral Capsule|placebo oral capsule. the dose is twice daily for 3 months
214336124|NCT01159496|DRUG|Placebo|Oral capsule, once daily for 14 days
214336125|NCT04361357|OTHER|whey protein|whey protein powder was added on the basis of standardized enteral nutrition preparation.
214336126|NCT05689840|PROCEDURE|Receiving inpatient surgical intervention|Receiving inpatient surgical intervention in Peking Union Medical College Hospital
214336127|NCT02666235|PROCEDURE|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
214336128|NCT02666235|PROCEDURE|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
214336129|NCT00856024|BIOLOGICAL|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
214336130|NCT00856024|DRUG|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
214336131|NCT06467266|DIAGNOSTIC_TEST|Acute Haemodynamic Study|Multisite temporary pacing
214336132|NCT01531959|DRUG|Midodrine|Patients will be randomized to blinded to 20 mg of midodrine
214336133|NCT01531959|DRUG|Placebo|Patients will be randomized to blinded placebo control
214336134|NCT03837691|DEVICE|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
214336135|NCT03837691|BEHAVIORAL|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
214336136|NCT06456294|BEHAVIORAL|MHC Outreach Intervention|Adult PC clinics are randomized to receive the MHC Outreach Intervention early (n=7 clinics) vs. delayed (n=7 clinics). In early intervention clinics, patients prescribed chronic opioid therapy, on a chronic opioid registry, and receiving their medication from the intervention clinic are sent emails and letters inviting them to schedule an MHC appointment. Clinical staff at the early intervention clinic are educated to encourage attendance. During MHC visits, MHC staff assess patients prescribed Chronic Opioid Therapy (COT), educate them about overdose, prescribe naloxone, and order guideline-concordant opioid monitoring.
214336137|NCT02375412|PROCEDURE|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
214336138|NCT00145366|DRUG|Recombinant human thyrotropin (Thyrogen)|
214336139|NCT01484470|BIOLOGICAL|StemEx|"For patients allocated to StemEx® arm:~* Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~* Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~* Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~* Day 1: StemEx® transplantation.~* Day 2 to 3 years: Post transplant follow-up."
214336140|NCT03616756|BEHAVIORAL|Authentic Connections|Authentic Connections support groups for nurse leaders who are also mothers. Meetings occur once a week for one hour.
214336141|NCT03616756|BEHAVIORAL|Protected time|Participants have one hour per week protected time scheduled on their calendar to do with what they choose.
214336142|NCT01160965|DRUG|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
214336143|NCT01160965|DRUG|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
214486413|NCT06761950|DEVICE|Placebo low level laser therapy|Same as in the study group except turning on the device with covering probe by aluminum foil and ask patient to wear sun glasses to obtain the placebo effect 3 sessions per week for 4 weeks.
214486414|NCT06761950|OTHER|medical treatment|the patients received their drugs from their treating physicians
214936846|NCT04325698|DRUG|PF-06439535 (CN)|15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
214336144|NCT04619316|DRUG|Trametinib 2 MG [Mekinist]|Monotherapy with Trametinib is given in patients with BRAF wildtype.
214936847|NCT04325698|DRUG|Bevacizumab-EU|15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
214336145|NCT04619316|DRUG|Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]|Combination therapy is given in patients with BRAF V600E mutation.
214336146|NCT02057757|DRUG|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
214336147|NCT02057757|DRUG|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
214486415|NCT06761950|OTHER|physical therapy program|patients received the traditional program after flexor tendon repair involving isometric exercise, stretching and mobilizations
214486416|NCT06782308|OTHER|Survey using a questionnaire.|patients preferences survey
214486417|NCT06765265|DRUG|Rosuvastatin 20 mg/day|Rosuvastatin 20 mg / Day for 24 weeks
214486418|NCT06765265|DRUG|Atorvastatin 40 mg|Atorvastatin 40mg / Day for 24 weeks
214674667|NCT03163238|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
214674668|NCT03163238|DRUG|Normal saline|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
214674669|NCT00661765|DRUG|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
214936848|NCT04325698|DRUG|Paclitaxel|175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
214936849|NCT04325698|DRUG|Carboplatin|AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
214936850|NCT02225327|BIOLOGICAL|Fluad alone|Fluad
214936851|NCT02225327|BIOLOGICAL|Fluad and PPV23 on the different arms|Fluad and Prodiax
214936852|NCT02225327|BIOLOGICAL|Fluad and PPV23 on the same arm|Fluad and Prodiax
214674670|NCT00661765|DRUG|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
214674671|NCT00649961|DRUG|Melatonin injection|"A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr."
214347303|NCT06099171|DEVICE|Oxygen-Ozone Therapy|Ozone (O3) is a molecule consisting of 3 atoms of oxygen in a dynamically unstable structure. O3 has the capacity to modulate inflammation. O3 when in contact with human fluids and tissues rapidly reacts, generating many reactive oxygen species, as hydrogen peroxide (H2O2), superoxide ion, and hydroxyl radical (OH-). It is suggested that through moderate oxidative stress generated by these reactive byproducts, O2O3 might produce positive effects in several pathologies, including musculoskeletal affections. Moreover, O2/O3 may directly regulate prostaglandins (PGS) and bradykinin, and suppress several proinflammatory mediators, such as IL-6, IL-8 and TNF-α
214936853|NCT02225327|BIOLOGICAL|PPV23 alone|Prodiax
214674672|NCT00934063|DRUG|somatropin|For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214936854|NCT04253782|OTHER|Team Intervention|"The Team will meet with participants (remotely/electronically and/or by phone) and will ask that they select one of three options that may help with opioid addiction:~1. treatment with buprenorphine/naloxone (BUP),~2. inpatient, 12-step, or methadone regimens, or~3. education only (materials provided by the CT Community for Addiction Recovery (CCAR)).~Throughout the study, participants may switch to any other option."
214936855|NCT00962091|DRUG|Alisertib|Alisertib OS Alisertib PIC Alisertib PIC
214936856|NCT02939027|DEVICE|Electronic Brachytherapy (6,1 Gy)|A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
214674673|NCT00934063|OTHER|No treatment given|Control group not receiving treatment
214674674|NCT03744234|PROCEDURE|PRP|Autologous platelet-rich plasma
214674675|NCT03744234|PROCEDURE|Steroid Injection|Steroid injection
214674676|NCT02218203|DRUG|Dextromethorphan|Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)
214674677|NCT02218203|DRUG|Lidocaine|0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)
214674678|NCT02218203|DRUG|Placebo (Dextromethorphan)|0mg Dextromethorphan
214674679|NCT02218203|DRUG|Placebo (Lidocaine)|0mg/kg LBM Lidocaine
214936857|NCT02939027|DEVICE|Electronic Brachytherapy (7 Gy)|A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
214936858|NCT00481260|PROCEDURE|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
214936859|NCT04206176|DRUG|Ticagrelor|Ticagrelor 45mg twice daily per oral administration
214936860|NCT05425043|BIOLOGICAL|Granulocytes|Receive granulocytes for 7 consecutive days after engraftment post transplant
214936861|NCT01063920|DRUG|LT-NS001|1200 mg b.i.d. p.o. for 12 weeks
214936862|NCT01063920|DRUG|Naprosyn®|500 mg b.i.d. p.o. for 12 weeks
214936863|NCT03890627|DEVICE|Thoracic bio-reactance|Cardiac output variation measured by thoracic bio-reactance, between inclusion and one year after hemodynamic evaluation by right cardiac catheterization, to discriminate stable patients from those that degrade.
214936864|NCT04216589|DRUG|Semaglutide|Administered subcutaneously
215073555|NCT06716619|BIOLOGICAL|Tumor Associated Lymph node T cell|At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells . After lymphodepletion, patients are infused with TAL-T.
215073556|NCT06716619|DRUG|Serplulimab Injection|Srulizumab injection was given intravenous infusion both before and after the TAL-T cells infusion.
215073557|NCT07034534|BEHAVIORAL|Three typical yoga poses|duration for both group includes 10 mins 5 sec, rest period will be included
215073558|NCT07034534|BEHAVIORAL|Deep breathing technique|duration for both group includes 10 mins 5 sec, rest period will be included
215073559|NCT06887920|DEVICE|Acuvue Oasys for Presbyopia|ACUVUE OASYS for PRESBYOPIA contact lenses will be prescribed to children with myopia to be worn in one eye for 10 hours a day for one year.
215073560|NCT06887920|DEVICE|MiSight 1 Day|MiSight 1 Day contact lenses will be prescribed to children with myopia to be worn in one eye for 10 hours a day for one year.
215073561|NCT06897332|BEHAVIORAL|Real-world manual dexterity task|Participants will perform a manual dexterity task involving the displacement of physical cubes
215073562|NCT06897332|BEHAVIORAL|Immersive virtual reality with controllers|Participants will perform a manual dexterity task in an immersive virtual reality environment, requiring them to move virtual cubes using controllers
214336148|NCT01160107|DRUG|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR \> 50%; 2. The study stop (if PR \<40% and grade 3-4 adverse events \>25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are \< 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are \> 50% and PR rate \> 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
214336149|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
214336150|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
214336151|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
214336152|NCT00066196|BIOLOGICAL|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
214336153|NCT00066196|BIOLOGICAL|Integrin + Dacarbazine|supplied in other formulations
214336154|NCT03614793|PROCEDURE|Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome|Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
214336155|NCT02082522|DRUG|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
214336156|NCT02082522|PROCEDURE|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
214336157|NCT02082522|DRUG|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
214336158|NCT02036905|OTHER|Cervical and thoracic mobilization|Described in arm description
214336159|NCT02036905|OTHER|cervical and thoracic manipulation|described in arm description
214336160|NCT05833984|DRUG|IMM01|IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
214336161|NCT05833984|DRUG|Tislelizumab|Tislelizumab 200mg Q3W IV
214936865|NCT06371729|PROCEDURE|DEEP mapping|"The Substrate-based DEEP Mapping aims to identify the arrhythmogenic substrate of VT in sinus rhythm (SR). A standardized VT mapping and ablation procedure in SR has been proven effective in reducing VT recurrences in a multicenter setting by targeting late potential (LP) abolition. Regions with LPs and LAVAs that displayed decremental behavior evoked during right ventricular (RV) pacing with extra stimuli (decrement-evoked potential; DEEP), colocalized with the regions of the initiation and diastolic pathway of the VT more accurately than those areas displaying non decremental LPs.~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)"
214936866|NCT06371729|PROCEDURE|Activation Mapping|"VT Activation Mapping can localize reentry circuits, and the diastolic pathway isthmus is the desirable target for ablation when possible because it can eliminate the elements required for reentry. In fact, activation mapping of the entire diastolic pathway is associated with higher freedom from VT recurrences compared to substrate modification~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)"
214936867|NCT04530591|OTHER|Survey|Participants will complete a survey about their opioid use history, its impact on their lives, their current strategies for preventing or reversing opioid overdoses, and their preferences for a device-based intervention.
214936868|NCT04530591|OTHER|Interview|"Participants will participate in a semi-structured interview, during which they will provide feedback on non-functional, looks-like prototypes of a naloxone delivery device."
214336162|NCT00004357|DRUG|Methylprednisolone|IV
214336163|NCT00004357|DRUG|Prednisolone|Oral
214347304|NCT02446561|DRUG|MRXXX|
214347305|NCT02446561|DRUG|MR1XXX|
214347306|NCT02446561|DRUG|MR2XXX|
214347307|NCT02446561|DRUG|MR3XXX|
214347308|NCT01674036|DRUG|Genz-682452|Capsules for oral administration.
214347309|NCT01674036|DRUG|Placebo|Placebo to Genz-682452
214336164|NCT04768036|OTHER|IMPROVE DD VTE Tool|"Universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow."
214936869|NCT05157620|OTHER|Yoga-based Exercise (YE)|The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
214936870|NCT05157620|OTHER|Wellness Lifestyle Program (WLP)|The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
214936871|NCT03491631|DRUG|SHR9146+SHR-1210|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W
214674680|NCT00989703|DRUG|placebo|oral solution, daily for 14 days
215073563|NCT06897332|BEHAVIORAL|Immersive virtual reality with hand-tracking|Participants will perform a manual dexterity task in an immersive virtual reality environment, requiring them to move virtual cubes using the hand-tracking technology
214336165|NCT04140994|DEVICE|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
214336166|NCT02698501|DRUG|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
214336167|NCT02698501|DRUG|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
214336168|NCT00456092|DRUG|Apremilast|Capsules for oral administration
214336169|NCT00456092|DRUG|Placebo|Capsules for oral administration
214336170|NCT06168175|DRUG|Sodium lactate|2 mmol/kg, intravenous, daily for 5 consecutive days
214336171|NCT06168175|DRUG|Placebo|intravenous, daily for 5 consecutive days
214336172|NCT00191061|DRUG|duloxetine hydrochloride|
214336173|NCT04901117|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
214336174|NCT04901117|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
214336175|NCT04901117|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
214336176|NCT04901117|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
214336177|NCT04901117|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
214674681|NCT00989703|DRUG|GLPG0259|oral solution
214336178|NCT04901117|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
214336179|NCT04901117|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
214674682|NCT00989703|DRUG|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
214674683|NCT04718090|PROCEDURE|PENG Block|Pericapsular nerve group block in shoulder surgery.
214674684|NCT00298571|DRUG|.5% bupivacaine with epinephrine|
214336180|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
214336181|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
214936872|NCT03491631|DRUG|SHR9146+SHR-1210+Apatinib|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
214336182|NCT02112097|DRUG|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
214674685|NCT02650011|OTHER|Acute deterioration of liver function|development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
214336183|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
214336184|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
214336185|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
214336186|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
214336187|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
214936873|NCT03187067|DEVICE|Lung ultrasound|Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.
214936874|NCT06559384|OTHER|Interviews|semi-structured individual interviews
214936875|NCT01690910|DEVICE|Rifton Gait Trainer|
214936876|NCT01690910|DEVICE|Front Wheeled Walker|
214936877|NCT00003910|DRUG|Cyclophosphamide|Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
214936878|NCT00003910|DRUG|Methotrexate|Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
214936879|NCT00003910|DRUG|Prednisone|Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
215073564|NCT06896760|DRUG|[14C]ABSK011|The standard meal was taken the night before administration, and the patient was fasted for at least 10 h without drinking water overnight. The next morning, eat a low-fat meal, finish the meal within 30 minutes, and take the test drug with warm water 30 minutes (±5 minutes) after the beginning of the meal. The total volume of warm water and suspension liquid is about 240 mL. Except for meals and administration, no water was allowed 1 hour before and 1 hour after medication. No food is allowed for 4 hours after taking the medication. Throughout the study, participants received meals provided by the center at approximately the same time each day.
214674686|NCT04044638|OTHER|Resistance trainining|Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G \* Tech-branded automatic digital device (MASTER model).
214936880|NCT04875312|DEVICE|Ultrasound cavitation in group A|"Group A:~twenty obese infertile patients with PCO who will be treated by ultrasound cavitation, 2 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)"
214936881|NCT04875312|DEVICE|Electro acupuncture in group B|"Group B:~twenty obese infertile patients with PCO who will be treated by electroacupuncture, 3 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)"
214336188|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
214336189|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
214336190|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
214936882|NCT01979471|OTHER|Advanced Care|"The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:~* Patient assessment~* Laboratory assessment of HbA1c and lipids~* Individual assessment of CVD risk and education about this risk~  * Calculation of cardiovascular risk will be facilitated by an online tool~ * Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options~* Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.~* Regular communication with the patient's family physician after each contact with the patient~* Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months."
214936883|NCT02253771|DEVICE|shockwave therapy|Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
214936884|NCT02253771|DEVICE|placebo shockwave therapy|sham shockwave therapy by an identically looking device without any function
214936885|NCT02953106|DRUG|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
214936886|NCT02953106|DRUG|Placebos|Placebo nasal spray
214936887|NCT02326298|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
214936888|NCT02326298|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
214936889|NCT02008747|DRUG|Magnesium sulphate|Continuous application of magnesium sulphate applied 40 mg/kg ideal body weight by bolus before the operation started, followed by a continuous infusion of 10 mg/kg ideal body weight/h for 24 hours
214674687|NCT00465738|DRUG|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
214674688|NCT00649298|PROCEDURE|haemodialysis|Comparison of different weekly duration of haemodialysis treatment
214674689|NCT02234011|DRUG|Ketamine|
214674690|NCT02234011|DRUG|Placebo|
214674691|NCT01902160|DRUG|Brentuximab Vedotin|Given IV
214674692|NCT01902160|OTHER|Laboratory Biomarker Analysis|Correlative studies
214336191|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
214336192|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
214336193|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
214674693|NCT01902160|DRUG|Temsirolimus|Given IV
214336194|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
214336195|NCT02112097|DRUG|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
214347310|NCT02559908|DEVICE|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
214674694|NCT02489630|DRUG|Ketamine|0.1mg/kg ketamine IV
214674695|NCT02489630|DRUG|Normal Saline|1ml/kg normal saline placebo
214674696|NCT02489630|DRUG|opiate analgesic|0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
214674697|NCT03077295|OTHER|High Fibre|High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
214674698|NCT03077295|OTHER|High Protein|• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
214936890|NCT01446276|DIETARY_SUPPLEMENT|Resveratrol|500 mg 3 times daily for six month
214936891|NCT01446276|OTHER|Placebo|1 placebo tablet 3 times daily for six month
214674699|NCT02054650|OTHER|Osteopathic Manual Treatment (OMT)|Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.
214936892|NCT04751773|BEHAVIORAL|Exercise training|Perioperative exercise training
214936893|NCT01501773|BIOLOGICAL|Autologous bone marrow stem cell|Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
214336196|NCT02112097|DRUG|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
214936894|NCT00534079|DRUG|Dornase alfa (Pulmozyme)|1 x 2,5 ml per day, inhalation use, for 28 days
214936895|NCT00534079|DRUG|isotonic saline|1 x 2,5 ml per day, inhalation use, for 28 days
214336197|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
214336198|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
214936896|NCT03191864|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
214936897|NCT03191864|DRUG|Placebo|Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
214936898|NCT03144843|DRUG|Apatinib|Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
214336199|NCT02112097|DRUG|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
214336200|NCT00507052|DRUG|N-acetylcysteine|
214674700|NCT02054650|OTHER|Sham OMT|Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
214936899|NCT03144843|DRUG|Placebos|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
214936900|NCT05738876|PROCEDURE|CORONARY ANGIOGRAPHY|coronary angiography by femoral or radial artery access
214936901|NCT01765829|DRUG|Discontinuation antipsychotic treatment|Dose reduction until withdrawal
214936902|NCT01765829|DRUG|Antipsychotic treatment|Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
214936903|NCT04687020|DRUG|Viltolarsen|Received during weekly intravenous infusions
214936904|NCT00583882|OTHER|Routine change of central venous catheters|Changeing CVCs on a regular basis to decrease infection rate.
214936905|NCT03962231|OTHER|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid reeducation exercises, assisted arm elevation and scapular control exercises.
214936906|NCT03962231|OTHER|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises focusing on lateral rotation, medial rotation and arm elevation.
214336201|NCT02501330|DRUG|Bosutinib|The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.
214336202|NCT01329497|OTHER|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
214336203|NCT05904600|DEVICE|Respiratory muscle training|The training of the intervention group will have an initial workload of 30% of maximal inspiratory and expiratory pressures, which will be increased weekly by 10% according to tolerance, if not tolerated by 5%. In addition, patients will be instructed to maintain a normal respiratory rate (12-16 breaths per minute). Moreover, they will continue their usual treatment.
214336204|NCT05904600|DEVICE|Control group|In the control group, the respiratory muscle training will be simulated by using the device without load throughout the study period using an opaque adhesive tape surrounding the device to mask the valve position.
214336205|NCT03891082|PROCEDURE|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
214336206|NCT03891082|PROCEDURE|BALLOON INSERTION|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
214336207|NCT00722644|BEHAVIORAL|Cognitive Behavioral Stress Management|
214936907|NCT03399682|DIAGNOSTIC_TEST|cystography|observationnal study
214936908|NCT01563367|DRUG|Iron isomaltoside 1000 (Monofer®)|All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
214336208|NCT00000415|PROCEDURE|Physical activity|
214936909|NCT01563367|DRUG|Natriumklorid 9 mg/ml, Fresenius Kabi|All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
214936910|NCT04948034|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
214936911|NCT04948034|DRUG|Fruquintinib|Starts within two weeks upon SABR completion: 5mg, d1-14, qd; Continued until disease progression, unacceptable toxicity or patient withdrawal.
214936912|NCT04948034|DRUG|Tislelizumab|Starts within one week upon SABR completion: 200mg, d1, q3w; the dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
214936913|NCT01389479|BIOLOGICAL|Fluviral™|Intramuscular, single dose
214674701|NCT03614624|DEVICE|Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips|Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
214674702|NCT03403244|PROCEDURE|US-MR image fusion-guided PTED|patients diagnosed with lumbar disc herniation undergoing US-MR image fusion-guided PTED
214674703|NCT03403244|PROCEDURE|fluoroscopy-guided PTED|patients diagnosed with lumbar disc herniation undergoing fluoroscopy-guided PTED
215073565|NCT06896318|DEVICE|Virtual Reality Therapy|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR TierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
214674704|NCT03619785|DRUG|Bupivacaine|Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.
214674705|NCT03619785|DRUG|Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen|Oral or IV pain medication as needed.
214674706|NCT00033839|DRUG|Civamide (Zucapsaicin)|
214336209|NCT00000415|DRUG|Calcium supplement|
214674707|NCT03550144|BEHAVIORAL|Awe Walk|To examine the effect of weekly awe walks in cognitively healthy older adults.
214936914|NCT01389479|BIOLOGICAL|Fluzone®|Intramuscular, single dose
214936915|NCT05708677|BIOLOGICAL|EB-101|This is non-interventional and follows patients treated with EB-101
214936916|NCT02410083|DRUG|Clopirin 1|
214936917|NCT02410083|DRUG|Clopidogrel-Aspirin(co-administration) 1|
214936918|NCT02410083|DRUG|Clopirin 2|
214936919|NCT02410083|DRUG|Clopidogrel-Aspirin(co-administration) 2|
214936920|NCT00659698|DEVICE|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
214936921|NCT03031574|DRUG|SUVN-D4010|Tablets
214936922|NCT03293082|DEVICE|CGM ON|The period of time when continuous glucose monitoring was used, in edition to SMBG
214936923|NCT03293082|DEVICE|CGM OFF|The period of time when continuous glucose monitoring was not used, only SMBG
214936924|NCT04919876|DIETARY_SUPPLEMENT|fruit/vegetable supplement (FVS)|The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.
214674708|NCT03550144|BEHAVIORAL|Control Walk|To examine the effect of weekly walks in cognitively healthy older adults.
214336210|NCT02840877|BEHAVIORAL|DOT Adherence Monitoring|Study participants will meet with a study-employed DOT worker daily during weekdays throughout the course of their TB treatment
214336211|NCT01459406|DIETARY_SUPPLEMENT|Glucose|500 ml water drink containing 40g glucose
214936925|NCT04919876|DIETARY_SUPPLEMENT|Placebo|The product does not contain nutrients present in the FVS.
214936926|NCT04231396|OTHER|Audiobooks for hearing loss App|Same as Arm 1
214936927|NCT00787917|DRUG|Omalizumab|Omalizumab subcutaneous injections of 600 mg daily.
214336212|NCT01459406|DIETARY_SUPPLEMENT|Fructose|500 ml water drink containing 40g fructose
214336213|NCT01459406|DIETARY_SUPPLEMENT|Fructan|500 ml water drink containing 40g fructan
214336214|NCT01459406|DIETARY_SUPPLEMENT|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
214336215|NCT05479175|DRUG|Ibuprofen|Ibuprofen
214336216|NCT05479175|DEVICE|Diode laser|Diode laser
214336217|NCT05479175|DEVICE|Nonactive Diode laser|Nonactive Diode laser
214336218|NCT04554433|DRUG|Ethanol with Asprin|"Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~1. Inhaling alcohol vapor through nostrils .~2. Inhalation of Alcohol vapor driven by Oxygen .~3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results ."
214336219|NCT00650533|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fed
214336220|NCT00650533|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fed
214336221|NCT00145834|BEHAVIORAL|community based trial|
214336222|NCT02100267|DRUG|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
214936928|NCT00787917|DRUG|Placebo|Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
214936929|NCT00787917|DRUG|Itraconazole|Itraconazole twice daily with a maximum daily dose of 400 mg.
214936930|NCT06907992|DRUG|Antifungal treatment|Short-course antifungal therapy (7 days) versus standard of care antifungal therapy (14 days)
214936931|NCT02672358|DRUG|Dabrafenib|Oral Dabrafenib 150 mg BID
214936932|NCT02672358|DRUG|Trametinib|Oral Trametinib 2 mg QD
214936933|NCT05631106|BEHAVIORAL|High Intensity Interval Resistance Training|During each group exercise session, the participants will be guided through a 5-minute warm-up, supervised to perform two sets of machine-based leg press, chest press, seated row, and shoulder press exercises at 30% of 1-RM, and guided through a cool-down. Each exercise set will be 40 -seconds in length with instructions to perform as many repetitions as possible followed by a 20-second rest in between sets and a three-minute rest between exercises.
214936934|NCT05631106|BEHAVIORAL|Stretching, Balance, and Range of motion|The stretching, balance, and range of motion intervention will include a rotating and varied routine of stretching exercises for large and small muscle groups, and activities to improve balance and range of motion. Participants will attend this intervention twice a week with each session lasting 30 minutes.
214936935|NCT01485445|DRUG|Fluticasone Furoate (200mcg unit strength)|inhalation powder
214674709|NCT05960955|DRUG|Cadonilimab|IV infusion,Specified dose on specified days
214674710|NCT05960955|DRUG|AK117|IV infusion,Specified dose on specified days
214674711|NCT05960955|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
214674712|NCT05960955|DRUG|Tegafur-gimeracil-oteracil potassium|Oral,Specified dose on specified days
214674713|NCT05960955|DRUG|Docetaxel|IV infusion,Specified dose on specified days
214336223|NCT02660736|DRUG|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
214336224|NCT02660736|DRUG|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
214674714|NCT05960955|DRUG|5-Fluorouracil|IV infusion,Specified dose on specified days
214674715|NCT05164523|DIAGNOSTIC_TEST|24-hour rhythm Holter|Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.
214936936|NCT01485445|DRUG|Fluticasone Furoate/Vilanterol (200/25mcg unit strength)|inhalation powder
214336225|NCT02660736|DRUG|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
214674716|NCT05164523|DIAGNOSTIC_TEST|36 item Short Form Survey (SF-36)|Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.
214936937|NCT05421052|OTHER|Unmet health needs|The students who have unmet health needs during the last 6 months will respond to the questionnaire to assess the causes and other factors
214336226|NCT02660736|DRUG|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
214936938|NCT04588727|DRUG|AZD3366|In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
214936939|NCT04588727|DRUG|Placebo|In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
214936940|NCT04588727|DRUG|Ticagrelor|In Part B, subjects will receive oral ticagrelor tablets.
214936941|NCT04588727|DRUG|acetylsalicylic acid (ASA)|In Part B, subjects will receive oral ASA chewable tablets.
214936942|NCT06912321|OTHER|No Intervention: Observational Cohort|No intervention：all participants did not receive any intervention measures throughout the study
214936943|NCT06911645|OTHER|Immediate access to customized version of GPT-4|Group is given immediate access to a customized version of GPT-4 to support their diagnostic reasoning for each case.
214936944|NCT06911645|OTHER|Access to customized version of GPT-4 following use of conventional resources|Group is first encouraged to reason through diagnostic cases with the support of conventional resources. After they submit a case's answers they are then given access to a customized version of GPT-4 and have the opportunity to change their initial answers.
214936945|NCT06911151|DEVICE|innovative footwear|HDC shoe
214936946|NCT06905834|DRUG|Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC|Subconjunctival injection is a widely used technique in ophthalmology due to its effectiveness, minimal invasiveness, and ease of administration. In a subconjunctival injection the cells adult adipose tissue-derived mesenchimal cells are delivered into the subconjunctival space, the area between the conjunctiva and sclera.
214336227|NCT03243916|RADIATION|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
214336228|NCT01168999|OTHER|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
214336229|NCT01168999|OTHER|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
214336230|NCT01168999|OTHER|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
214336231|NCT00136708|PROCEDURE|Neonatal Resuscitation|
214936947|NCT05778032|OTHER|Multidisciplinary metabolic rehabilitation program|Multidisciplinary metabolic rehabilitation program with a duration of 3 weeks
214936948|NCT00992628|DEVICE|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
214936949|NCT00992628|DEVICE|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
214936950|NCT03185806|DEVICE|Puncture and drainage|The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
214936951|NCT03244670|OTHER|Observation study only, no specific intervention|Observation study only, no specific intervention
214936952|NCT03946878|DRUG|Acalabrutinib|Given PO
214936953|NCT03946878|DRUG|Venetoclax|Given PO
214936954|NCT00800306|DRUG|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
214936955|NCT00800306|DRUG|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
214936956|NCT05191589|OTHER|Haptic|Trainees are randomized in this group to use the haptic device.
215073566|NCT06896318|BEHAVIORAL|Cardiac rehabilitation|A three-week, hospital-based cardiac rehabilitation program for all participants, incorporating structured group exercises and activities. The conventional cardiac rehabilitation program includes morning warm-up exercises, afternoon group sessions, interval training on stationary bikes, and relaxation activities. Morning sessions consist of 20 minutes of standing cardiovascular exercises accompanied by music, while afternoon sessions include 45 minutes of seated activities, divided into cardiovascular, equipment-based, and breathing exercises.
215073567|NCT06896370|OTHER|observational study|By prospectively following a population of asymptomatic carriers carrying high-risk Hp SNP subtypes and non-high-risk subtypes, the incidence of gastric cancer and progression of gastric precancerous lesions were compared between the groups.
214674717|NCT01056523|DRUG|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
214674718|NCT01056523|DRUG|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
214674719|NCT04760132|BIOLOGICAL|COMIRNATY - BioNTech Manufacturing GmbH|Vaccination as part of the the Danish national government programme
214336232|NCT00318487|PROCEDURE|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
214336233|NCT02984397|DRUG|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
214336234|NCT02984397|DRUG|Placebo|
214936957|NCT06912490|OTHER|Amniotic Fluid Proteomic Analysis Using Capillary Electrophoresis-Mass Spectrometry (CE-MS)|This intervention consists of analyzing the amniotic fluid proteome using capillary electrophoresis coupled with mass spectrometry (CE-MS). The goal is to evaluate a predefined 98-peptide signature that predicts postnatal kidney function in fetuses with bilateral congenital anomalies of the kidney and urinary tract. Unlike standard prenatal assessments based on ultrasound and fetal biochemistry, this method provides a molecular-based prognostic tool to improve decision-making regarding pregnancy management and neonatal care
214936958|NCT01328548|DRUG|Zostavax|
214936959|NCT06910085|BEHAVIORAL|kettlebell-training|15 min of body weight or kettlebell loaded strength training
214674720|NCT04760132|BIOLOGICAL|COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|Vaccination as part of the the Danish national government programme
214336235|NCT02984397|OTHER|Standard of Care|
214336236|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
214336237|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
214336238|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
214336239|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
214936960|NCT05766618|PROCEDURE|Injectable platelet rich fibrin (i-PRF): in acceleration of orthodontic tooth movement|"Preparatory phase~* Space closure will be done on a 17x25 stainless steel wire~* Both molars will be indirectly anchored to the miniscrew~* Extend closing coil spring of suitable length from the canine hock to the first molar hock for retraction.~* Apply a force of 150gm for each side. The force is measured by a force gauge and activated each visit to keep it constant all over the retraction phase. PRF Injection protocol~* The First injection will be 3 weeks before extraction~* By the end of the fourth week the patients will be referred for pre-intervention records. Upper arch CBCT will be obtained to take preintervention measurements of the alveolar bone.~* At the time of canine retraction patient will receive another injection immediately and an alginate impression will be taken~* follow up every month and injection will be repeated month after month with an observational period of 5 months."
214936961|NCT05890690|DIAGNOSTIC_TEST|Urea|"Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~\- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g."
214936962|NCT05890690|DIAGNOSTIC_TEST|Placebo|"Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~\- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®."
215073568|NCT06896552|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic Diet as an Adjunct to Immunotherapy: Unlike many trials focused on chemotherapy or targeted therapies, this study specifically investigates the synergistic effects of the ketogenic diet with immune checkpoint inhibitors (ICIs), a promising approach for enhancing immunotherapy efficacy. The diet's high-fat, low-carbohydrate regimen is designed to shift metabolism towards ketone bodies and fatty acid utilization, potentially modulating immune responses and tumor immunogenicity in a way that standard diets do not.
215073569|NCT06897059|OTHER|Vuka+ application|The Vuka+ smartphone app included PrEP daily reminders, tracking for pill taking, resources for sexual reproductive health including quizzes and articles, and chat access to other Vuka+ users and medical expert.
215073570|NCT06896084|DEVICE|da Vinci Xi System|A group of surgeons will make determinations as to the material within identical balloons while using the da Vinci Xi System
214674721|NCT04760132|BIOLOGICAL|COVID-19 Vaccine AstraZeneca suspension for injection|Vaccination as part of the the Danish national government programme
214336240|NCT06572878|OTHER|Cognitive training|Cognitive training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The cognitive training task components will specifically focus on attention, learning and memory, executive function, perceptual-motor skills, and language.
214336241|NCT06572878|OTHER|Physical training|Physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The physical training task components will specifically focus on strength, balance, agility, gait, low-volume aerobic, and flexibility.
214336242|NCT06572878|OTHER|Combined cognitive and physical training|Combined cognitive and physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The combined cognitive and physical training components will specifically focus on a single cognitive task and simultaneously handle a single physical task.
214336243|NCT06572878|OTHER|Passive information activities|In passive informational activities, which include a variety of puzzles, audiobooks, and diverse reading materials such as newspapers or listening to news content.
214336244|NCT05520216|DEVICE|Spinal mouse (idiag m360)|A noninvasive Spinal Mouse device will be used to measure the thoracic kyphosis and lumbar lordosis angle of the spinal column in the sagittal plane. It will be displayed on the computer aided software screen where the thoracic and lumbar region angles are calculated by swiping over the spinal processes from top to bottom with the Spinal Mouse (IDIAG m360) device. Measurements will be taken while standing on a flat surface. The volunteer will take off his upper clothes and shoes during the examination. Relax your arms and torso will be positioned next to you. The distance between the feet will be approximately waist width and parallel to each other, the knees will be straight and face motionless. He will stand where he feels comfortable. A Spinal Mouse examination will be performed and data will be recorded.
214936963|NCT00073983|BIOLOGICAL|filgrastim|filgrastim
214936964|NCT00073983|BIOLOGICAL|pegfilgrastim|pegfilgrastim
214936965|NCT00073983|DRUG|docetaxel|docetaxel
214936966|NCT00073983|DRUG|gemcitabine hydrochloride|gemcitabine hydrochloride
214936967|NCT00073983|GENETIC|microarray analysis|microarray analysis
214936968|NCT00073983|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
214936969|NCT00073983|OTHER|pharmacokinetic study|pharmacokinetic study
214936970|NCT00774254|BEHAVIORAL|A|Intervention
214674722|NCT02648815|PROCEDURE|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
214936971|NCT00774254|BEHAVIORAL|B|Intervention
214936972|NCT04684758|OTHER|Self-completion of a questionnaire|The questionnaire will be translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service, if necessary.
214936973|NCT03800836|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28 day cycle for all arms except for arms F1/F2 where it will be administered at a dose of 300 milligrams (mg) orally daily for the first two cycles and 400 mg for the remaining three cycles.
214936974|NCT03800836|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion on Days 1, 8, and 15 of each 28 day cycle for all arms, with the exceptions of Arms F1, F2, G1 and G2, where it will be also administered on Day 22 as well, of each 28 day cycle.
214347311|NCT01173393|PROCEDURE|PARAMEDIC COOLING|"For patients randomised to paramedic cooling:~* LMA/ Intubation and ventilation with 100% oxygen~* Measure temperature using tympanic probe and record~* Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR~* If temperature \>34.5ºC, infuse further 10mL/kg stat~* After ROSC, infuse further (max 2 litres) ice-cold saline~* If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg."
214347312|NCT04019847|DEVICE|STAK Tool|Medical stretching device
214674723|NCT02648815|PROCEDURE|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
214936975|NCT03800836|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28 day cycle for all arms, although in Arms C1/C2, it will be administered on Day 15 of Cycle 1 followed by Days 1 and 15 in subsequent cycles.
214936976|NCT03800836|DRUG|Nab-Paclitaxel|Nab-paclitaxel will be administered by IV infusion at a dose of 100 mg/m\^2 on Days 1, 8, and 15 of each 28 day cycle.
214674724|NCT04786288|OTHER|massage with lavender essential oil mixed in a carrier oil|22 elderly participants received a one session M technique hand massage that lasted 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the M technique hand massage
214674725|NCT04786288|OTHER|massage with odourless baby oil|odourless baby oil was used for the application of one session M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.
214674726|NCT03429556|BIOLOGICAL|Botulinum Neurotoxin Serotype E|Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
214674727|NCT03429556|DRUG|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
214936977|NCT03800836|DRUG|AC|AC (Doxorubicin and Cyclophosphamide) will be administered by IV infusion at 60 mg/m\^2 and 600 mg/m\^2 respectively on Days 1 and 15 of Cycles 1 and 2 for Arms F1, F2, G1 and G2.
214936978|NCT04412187|DIAGNOSTIC_TEST|[18F]-GE-180 PET|serial \[18F\]-GE-180 PET imaging to assess microglia activation
214936979|NCT04412187|DIAGNOSTIC_TEST|3T MRI|serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness
214936980|NCT04412187|DIAGNOSTIC_TEST|immune cell profiling in blood|Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.
214936981|NCT03197467|DRUG|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
214936982|NCT06326190|DRUG|Local standard of Care|According to local standard practice, treatment or no treatment in the control arm is left to the investigator's discretion.
214936983|NCT06326190|DRUG|177Lu-DOTATATE|Intravenous injection of 177Lu-DOTATATE
214336245|NCT05520216|BEHAVIORAL|chest circumference measurement|Measurements will be taken from the axillary (4th rib level - two fingers below the axilla), epigastric (xiphoid process level) and subcostal (9th rib level) regions at the time of normal, maximal inspiration, and maximal expiration using a tape measure while the patient is in a sitting position. The tape measure will be placed in the area to be measured. Care will be taken that there is no folding or horizontal level difference in the tape measure and that the fingers are not under the tape measure. Normal respiration will be measured first and recorded in centimeters (cm). The patient will then be asked to take a deep, long breath towards the bottom of the tape measure. The value obtained will be recorded as the deep inspiration value. Immediately after deep inspiration, the patient will be asked to make a deep and long expiration. The obtained value will be recorded as deep expiration.
214336246|NCT05520216|BEHAVIORAL|Maximum Breath Hold Test|During the breath-hold measurement, the subject will sit in a chair with a backrest. He will take a deep breath through his nose. We do not want maneuvers (Valsalva and Müller) and diaphragm contractions that will affect the breath-hold time, so volunteers will be observed throughout the test. The test will be terminated as soon as involuntary diaphragm contractions are seen. This test will be applied 3 times by resting the volunteer with breaks for 5 minutes. The average of 3 test results will be taken (Lin, Y. C.: Effect of O2 and CO2 on breath hold breaking point. In The Physiology of Breath Hold Diving. (eds): CEG Lundgren, M Ferringo, Undersea and Hyperbaric Medical Society Inc, Bethesda, Maryland, p: 75-87 1987.).
214336247|NCT05520216|BEHAVIORAL|Sit and Reach|While the participant is sitting on the floor with his back to the wall and his legs are fully extended in front of him, his knees should be in full contact with the floor. The box will be placed on the sole of the participant's feet (without shoes) in full contact with the volunteer's feet. The participant will be instructed to lean forward as slowly as possible, keeping their fingertips level with each other and their legs straight on the floor. He will be asked to slowly lie down along the ruler three times, and on the third attempt the volunteer will be instructed to reach out as far as possible and hold for 2 seconds. This value will be saved
214336248|NCT03893227|OTHER|Questionnaire|Patients and healthy controls will fill out a questionnaire
214336249|NCT05864339|BEHAVIORAL|A designed empathy intervention|Students watch 4 smokers' videos, read the textual materials, fill out the HEMs and discuss a quit counseling plan for an assigned smoker using the 5As counseling skilll.
214336250|NCT05864339|BEHAVIORAL|Smoking cessation counseling tutorial|Students watch 4 smokers' videos, read the textual materials, and discuss a quit counseling plan for an assigned smoker using the 5As counseling skill.
214936984|NCT06226844|DEVICE|Music therapy walking program|In the experimental group (PEMA BeatMove), patients will benefit from an outpatient walking training program with app-based performance monitoring, combined with music therapy (BeatMove device). The program comprises 36 walking training sessions, with 30
214936985|NCT06372015|OTHER|Nutritional Approach|Nutritional Approach
214936986|NCT06372015|OTHER|Surgery Approach|Bariatric surgery
214936987|NCT05502770|DIAGNOSTIC_TEST|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
214936988|NCT05502770|OTHER|Physical development and General Health|Physical development and General health examination
214936989|NCT05502770|DIAGNOSTIC_TEST|Developmental Red flags|Developmental Red flags Questionnaires
214936990|NCT05565586|DIETARY_SUPPLEMENT|High-Fiber Diet (HFD)|Participants are assigned to the high fiber diet, all meals and snacks will be provided to participants during the study. This diet includes fruits, vegetables and whole grains, a maximum of 18 oz. cooked red meat (including beef, pork, and lamb) per week, and little or no processed meats or added sugars.
214936991|NCT05565586|DIETARY_SUPPLEMENT|Prebiotic Food-Enriched Diet (PreFED)|Participants are assigned to the prebiotic food enriched diet, participants will receive 2 prepared snacks and 1 meal component (a key prebiotic ingredient to incorporate into meals and simple recipes) each day. Participants will also receive a handout that includes key prebiotic foods to incorporate into your own diet.
214936992|NCT00626236|DRUG|SPN-810|1.67mg capsule taken TID
214936993|NCT00626236|DRUG|SPN-810|3.33mg capsule taken TID
214936994|NCT00626236|DRUG|SPN-810|5mg capsule taken TID
214936995|NCT00626236|DRUG|SPN-810|6.67 mg capsule taken TID
214936996|NCT02559856|DRUG|Apixaban|
214936997|NCT02559856|DRUG|Rivaroxaban|
214936998|NCT00715104|BIOLOGICAL|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
215073571|NCT06897384|DRUG|Saline (NaCl 0,9 %)|The control group involves only adding 50ml of normal saline to a 50ml syringe, without any labels to ensure identical appearance, and the method of administration and dosage are the same with vitamin C group.
214336251|NCT02097875|DRUG|BLZ-100|
214336252|NCT00393445|DRUG|GLP-1 control|intravenous infusion of GLP-1
215073572|NCT06897384|DRUG|Vitamin C (Ascorbic Acid)|Vitamin C at dose of 500mg/kg/24h, 2g/h
214336253|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
214336254|NCT00393445|DRUG|saline control|intravenous infusion of saline
214336255|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
214336256|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
214336257|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
214336258|NCT04416035|BIOLOGICAL|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
214336259|NCT04416035|BIOLOGICAL|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
214336260|NCT04416035|DRUG|Carboplatin|Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
214336261|NCT04416035|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
214336262|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
214336263|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
214336264|NCT01047683|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
214336265|NCT06019858|OTHER|Vitamin Energy Shot|"Vitamin Energy® shot is a naturally-caffeinated functional energy shot that contains:~Vitamin B3 Vitamin B6 Vitamin B12 Natural Caffeine (green tea extract) L-Carnitine Tartrate Potassium Sorbate Taurine Sucralose"
214336266|NCT02137200|PROCEDURE|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
214336267|NCT02137200|PROCEDURE|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
214336268|NCT05867394|OTHER|Stress ball|Stress ball squeeze
214336269|NCT03611634|OTHER|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
214936999|NCT00715104|BIOLOGICAL|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
214336270|NCT00544245|BEHAVIORAL|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
214336271|NCT03732248|DRUG|Rapamycin|Immunosuppressive drug
214336272|NCT03732248|DRUG|Placebo|Inert drug
214937000|NCT04721704|DRUG|Clarithromycin+ Amoxicillin + Omeprazole|In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children
214937001|NCT04721704|DRUG|Metronidazole +Amoxicillin + Omeprazole|Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI
214937002|NCT00427206|DRUG|acetaminophen (4g/day)|
214336273|NCT00733824|DRUG|AMD3100|
214336274|NCT00733824|DRUG|G-CSF|
214336275|NCT00733824|PROCEDURE|Apheresis|
214336276|NCT03032926|BEHAVIORAL|Open Trial|Behavioral Intervention
214336277|NCT02477384|PROCEDURE|8mm-TIPS|
214336278|NCT02477384|PROCEDURE|Endoscopic variceal ligation|
214336279|NCT02477384|DRUG|Propranolol|
214336280|NCT02477384|DEVICE|8mm ePTFE-covered stent|
214336281|NCT01463605|DRUG|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
214336282|NCT05460624|OTHER|Egg-containing breakfast|Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
214336283|NCT05460624|OTHER|Typical American-style breakfast excluding eggs|Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
214336284|NCT04241939|BEHAVIORAL|Numberless BDS|Participants perform daily weighing using a numberless BDS with feedback from app (color codes, challenges), in conjunction with modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
214336285|NCT04241939|BEHAVIORAL|Digital Scale|Participants perform daily weighing using a digital scale (number readout), in conjunction with standard adolescent weight loss program
214336286|NCT04241939|BEHAVIORAL|Modified Motivational Interviewing|Modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
214336287|NCT03167294|DEVICE|AquaBeam System|Aquablation
214336288|NCT05676242|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
214336289|NCT00131287|DRUG|Extract of Agaricus blazei Murill|
214336290|NCT05540223|DEVICE|DREAMS 3G RMS|Subject undergoes implantation of DREAMS 3G RMS
214336291|NCT05540223|DEVICE|Xience DES|Subject undergoes implantation of Xience DES
214937003|NCT00427206|DRUG|placebo|
214937004|NCT04283292|DRUG|Capsaicin|Topical Capsaicin for the treatment of Cannabinoid Hyperemesis Syndrome
214937005|NCT04283292|DRUG|Placebo|Placebo cream that is applied once topically
214937006|NCT05373992|BEHAVIORAL|Screen Time Restriction (ST-Restricted)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. Following the first 72-hours of restricted screen-time, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
214674728|NCT03425656|DRUG|Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide|Trastuzumab (8 mg/kg IV loading dose at cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for four 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)
214937007|NCT05373992|BEHAVIORAL|Aerobic Exercise (AE)|Engage in 30-minutes of aerobic exercise daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
214336292|NCT04590755|BEHAVIORAL|Interactive father-child sessions and website|The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
214336293|NCT02708745|BEHAVIORAL|Intervention Survey|
214336294|NCT02708745|BEHAVIORAL|Placebo Survey|
214674729|NCT04560101|DRUG|botulinum toxin A|Intramuscolar injection of botulinum toxin in affected muscles
214674730|NCT03636412|OTHER|Ambulation|An ambulator will walk with a patient three times a day, based on physical therapy recommendations.
214937008|NCT05373992|BEHAVIORAL|Screen-time restricted plus aerobic exercise (STR+AE)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) while concurrently engaging in daily aerobic exercise in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed STR+AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
214674731|NCT03461965|BEHAVIORAL|3D printed model|A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery
214674732|NCT03461965|BEHAVIORAL|Verbal Counselling|Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
214674733|NCT00486980|DRUG|Peramivir 150mg|
214336295|NCT02540239|DRUG|2L PEG|
214336296|NCT02540239|DRUG|2L PEG+simethicone|
214336297|NCT00411307|DRUG|OROS hydromorphone HCI|
214674734|NCT00486980|DRUG|Peramivir 300mg|
214674735|NCT00315601|DRUG|Telithromycin|800 mg once a day for 5 days
214674736|NCT00315601|DRUG|azithromycin|500 mg on day 1, and then 250 mg once-daily on days 2 through 5
214674737|NCT00315601|PROCEDURE|bronchoalveolar lavage|One bronchoscopy with bronchoalveolar lavage with each drug administration
214674738|NCT00315601|DRUG|Telithromycin|Telithromycin 800 mg once a day
214674739|NCT04362267|OTHER|self-administered questionnaire|Every14 days, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
214674740|NCT04362267|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every14 days, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
214674741|NCT02409498|DRUG|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
214674742|NCT02409498|DRUG|no pudendal block|preemptive pudendal nerve blockade with 10 ml of normal saline to each side
214674743|NCT05466110|DEVICE|Spinal Cord Stimulation|Epidural application of electrical current to the spinal cord
214674744|NCT05466110|PROCEDURE|Spinal Fusion Surgery|screw-rod system based spinal instrumentation
214674745|NCT03248466|BIOLOGICAL|PRG combined with BMMSCs transplantation|PRG combined with BMMSCs transplantation
214674746|NCT01863758|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
214674747|NCT02603640|DEVICE|MRI scanning|
214674748|NCT02232646|DRUG|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
214674749|NCT05799144|BIOLOGICAL|DNA Vaccine|Given pBI-11 IM
214674750|NCT05799144|BIOLOGICAL|Human Papillomavirus Tumor Antigen Vaccine|Given into a muscle
214674751|NCT05799144|BIOLOGICAL|Pembrolizumab|Given into vein
214674752|NCT05799144|PROCEDURE|Computed Tomography (CT)|Undergo a CT
214674753|NCT05799144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo an MRI
214674754|NCT05799144|PROCEDURE|Magnetic Resonance Imaging|Undergo blood sample collection
214674755|NCT05799144|PROCEDURE|Biopsy|Undergo tumor biopsy
214674756|NCT05885685|DRUG|Nabilone Oral Capsule|Each oral capsule contains a 0.25 mg dose of nabilone. Participants begin by taking 1 capsule at night then 1 capsule in the morning and 1 at night for the next 2 days. On the 4th day, the dose is doubled. On the 6th day, the dose is doubled again.
214674757|NCT05209243|RADIATION|SBRT|SBRT (all metastatic lesions)
214937009|NCT05373992|BEHAVIORAL|Stretching Only|Participants will be instructed to follow a prescribed stretching program for the first 72-hours following the initial clinic visit. Following the first 72-hours of prescribed stretching, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
214336298|NCT02480621|DRUG|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
214336299|NCT04181710|PROCEDURE|Kidney transplant|Organ preserved in preservation solution
214336300|NCT05273892|BEHAVIORAL|Diet + Activity + Sleep|Personalized lifestyle behavior change counselling
214336301|NCT05273892|BEHAVIORAL|Diet + Activity|Personalized lifestyle behavior change counselling
214336302|NCT06529328|OTHER|core stability|"In this study the experimental group will perform core stability exercises 3 times per week for an 8-week period and each session of 30 to 45 minutes, the core stability exercises will work on abdominals and trunk muscles with challenges.Subjects received 25 min conventional therapy in addition to 30 30-minute trunk stabilization exercise program conducted for 3 days\\week on non-consecutive days.~Passive stretching exercises are applied to all tight muscles, including the hamstrings and calf muscles in the lower limb. It is performed five times initially, building up to ten repetitions, stretching for 5 times, and then allowing relaxation for 5time. Strengthening exercises for back, hip, and knee extensor muscles (for 10 minutes)."
214336303|NCT06969027|DRUG|JS207|JS207 (10 mg/kg or 15 mg/kg, IV, d1)
214336304|NCT06969027|DRUG|Pemetrexed injection|Pemetrexed (500 mg/m2 IV, D1)
214336305|NCT06969027|DRUG|Platinum|Platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1)
214937010|NCT05709119|DIAGNOSTIC_TEST|Quantification of human DNA retrieved and DNA fragmentation profile.|The sample will be analysed for material quality and have no impact on the patient's future care.
214336306|NCT06969027|DRUG|Paclitaxel|Paclitaxel (175 mg/m2 IV, D1)
214336307|NCT03342664|DEVICE|Artemis + Medical Management|Subject will receive best MM in addition to the MIS procedure with Artemis.
214336308|NCT03342664|OTHER|Best Medical Management Alone (MM)|Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.
214336309|NCT01825408|DRUG|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
214336310|NCT01825408|DRUG|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
214336311|NCT01825408|DRUG|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
214336312|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
214674758|NCT05209243|RADIATION|STANDARD OF CARE|ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
214336313|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
214336314|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
214336315|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
214336316|NCT05638373|OTHER|One shade universal composite|A resin composite with new smart chromatic technology and chameleon effect. It has the ability to match the new lighter shade of the bleached teeth unlike the conventional composite
214336317|NCT05638373|OTHER|Nanohybrid resin composite|A conventional resin composite with multiple shades
214336318|NCT05321394|DRUG|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
214336319|NCT05321394|DRUG|Tixagevimab Cilgavimab|"2 subsequent injections:~1. tixagevimab 300mg/3mL (100mg/mL)~2. cilgavimab 300mg/3mL (100mg/mL)"
214336320|NCT05321394|DRUG|Nirmatrelvir Ritonavir|300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
214674759|NCT01019590|DRUG|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
214937011|NCT01455246|DRUG|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of \> 30 ml/min and \< 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of \>50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
214674760|NCT01019590|DRUG|Benicar HCT ® Tablets 40 mg/25 mg|
214336321|NCT00178191|OTHER|Bladder diary|3-day bladder diary
214336322|NCT00178191|OTHER|Questionnaires|Incontinence Quality of Life questionnaires
214336323|NCT00178191|PROCEDURE|Urodynamics|Urodynamics
214336324|NCT00178191|OTHER|Pad weight|Pad weight
214336325|NCT00983580|DRUG|Aspirin|Given PO
214336326|NCT00983580|DRUG|Eflornithine|Given PO
214336327|NCT00983580|OTHER|Laboratory Biomarker Analysis|Correlative study
214336328|NCT00983580|OTHER|Placebo|Given PO
214336329|NCT00983580|OTHER|Telephone-Based Intervention|Ancillary studies
214336330|NCT05321862|DRUG|[68Ga]Ga-PentixaFor|Tomography by Emission of Positons (PET) with the radiopharmaceutic \[68Ga\]Ga-PentixaFor
214336331|NCT03430752|OTHER|questionnaires|Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
214336332|NCT02734316|OTHER|endoscopic procedure|Evaluation of adverse events in patients on DOACs undergoing GI endoscopy
214336333|NCT05566340|PROCEDURE|mitral valve repair|Repair of mitral valve concomitant to aortic valve replacement.
214674761|NCT04952389|DEVICE|Acupuncture Therapy|Consists of two treatments per week for five weeks
214674762|NCT04952389|DRUG|Budesonide|Twice daily nasal rinses with steroid medication (budesonide)
214674763|NCT04952389|OTHER|Olfactory Training|involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
214674764|NCT05331989|OTHER|patient group/ healthy group|Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
214674765|NCT06512480|PROCEDURE|colonic resection|colonic resection with the Hugo RAS robotic platform.
214674766|NCT03442426|OTHER|Integrated model of primary care|Intervention includes: 1) consistent risk screening and assessment; 2) care coordination and system navigation; 3) patient/caregiver engagement and shared decision-making; and 4) enabling technology supports.
214336334|NCT01690390|DRUG|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
214336335|NCT01690390|DRUG|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
214336336|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
214336337|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
214336338|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
214336339|NCT01971346|DRUG|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
214336340|NCT02136875|DRUG|Double dose of Salmeterol + Fluticasone Propionate|
214674767|NCT02500030|PROCEDURE|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
214336341|NCT02136875|BEHAVIORAL|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
214336342|NCT02136875|DRUG|Self-administered prescription|"An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1\) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days"
214336343|NCT01652716|DRUG|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
214336344|NCT01652716|DRUG|Exenatide twice daily|5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
214336345|NCT03735862|BIOLOGICAL|Hepatic derived surgical matrix|Hiatal hernia repair with MIROMESH
214336346|NCT01514318|DEVICE|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
214336347|NCT04121325|DEVICE|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
214336348|NCT00381420|DEVICE|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
214336349|NCT00381420|DEVICE|bare-metal stent|un-coated Bx VELOCITY Stent
214674768|NCT02500030|PROCEDURE|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
214336350|NCT00676442|DRUG|PN400|naproxen/esomeprazole
214336351|NCT03641352|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
214336352|NCT03641352|DRUG|Placebo|Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
214336353|NCT00360334|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
214336354|NCT00360334|DRUG|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
214336355|NCT05927233|DRUG|Methylprednisolone|30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
214336356|NCT05927233|DRUG|Saline|30 ml Normal saline
214336357|NCT05493995|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
214336358|NCT05493995|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
214336359|NCT05493995|DRUG|Nab paclitaxel|125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.
214336360|NCT05493995|DRUG|Gemcitabine|1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
214336361|NCT05770466|DRUG|P1101 (Ropeginterferon alfa-2b)|"1. Name: P1101 (Ropeginterferon alfa-2b)~2. Dosage form: pre-filled syringe~3. Strength: A single dose of 250 mcg/0.5 mL~4. Dosage and administration: 250 mcg per subcutaneous injection~5. Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities.~6. Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines"
214336362|NCT05770466|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
214347313|NCT04019847|OTHER|Standard treatment|Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain AROM and function
214336363|NCT00594256|DRUG|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
214336364|NCT03982329|DEVICE|navigated repetitive transcranial magnetic stimulation|
214336365|NCT03982329|PROCEDURE|physical therapy|
214336366|NCT02923518|OTHER|Questionnaire|Observational study without any intervention described under intervention type
214336367|NCT02066012|OTHER|dysmetabolic iron overload syndrome|
214937012|NCT01455246|DRUG|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of \>50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
214937013|NCT05575037|DRUG|Dupilumab|8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
214937014|NCT03958214|BEHAVIORAL|Recipe 4 Success|Home visitors teach parents about children's self-regulation skills and healthy eating habits. The home visitors then teach parents how to sensitively scaffold the development of their toddlers' self-regulation skills in the context of cooking and snack preparation lessons. Prior research shows that self-regulation skills in early childhood predict long-term health indicators, such as BMI. Prior research also shows that children who are involved in the preparation of healthier foods are more likely to eat them.
214937015|NCT03958214|BEHAVIORAL|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
214937016|NCT01877356|PROCEDURE|bilateral spinal anesthesia|prilocaine plain 2% 50 mg
214937017|NCT01877356|PROCEDURE|unilateral spinal anesthesia|prilocaine 2% hyperbaric 30 mg
214937018|NCT00077441|DRUG|bortezomib|Given IV
214937019|NCT00077441|OTHER|laboratory biomarker analysis|Correlative studies
214937020|NCT06612099|OTHER|Aerobic Exercise|Individuals in this group will perform aerobic exercise training on a treadmill/bicycle under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 training sessions. Moderate intensity aerobic exercise training will be set by calculating the target heart rate range. During the training session, individuals will receive a total of 50 minutes of training, consisting of a 10-minute warm-up, 30 minutes of moderate walking/cycling and a 10-minute cool-down period. In addition to the aerobic exercise training group, on the days he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, with weights of 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
214937021|NCT06612099|OTHER|Mat Pilates Exercise|Individuals in this group will perform mat pilates exercises under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 exercise sessions. During the exercise sessions, individuals will undergo a 50-minute mat pilates exercise program. In addition to the mat pilates exercise group, on the days when he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
214937022|NCT04991363|PROCEDURE|Bleaching|Digital images for each patient will be taken once with the camera fixed on the classic tripod and again when the camera was fixed on the ISD , then horizontal and vertical measurements of the canines will be recorded by using a computer software on the digital images, then bleaching will be fine for all patients, then a second set of images will be taken again with the tripod and then with ISD, then measurements will be repeated and compared with the first set of images
214937023|NCT01308112|DIETARY_SUPPLEMENT|iron|Daily supplementation with iron (60 mg) as ferrous sulphate
214937024|NCT00088959|DRUG|erlotinib hydrochloride|Given orally
214937025|NCT00088959|DRUG|celecoxib|Given orally
214937026|NCT00088959|OTHER|laboratory biomarker analysis|Correlative studies
214937027|NCT06511570|DRUG|sabirnetug (ACU193)|sabirnetug by intravenous infusion
214937028|NCT06511570|COMBINATION_PRODUCT|Sabirnetug + rHuPH20|sabirnetug + rHuPH20 by subcutaneous injection
214336368|NCT00169637|DRUG|rhGH|
214336369|NCT04160260|DRUG|Omadacycline|Omadacycline: PO Tablets
214336370|NCT03113591|PROCEDURE|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
214336371|NCT03113591|PROCEDURE|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
214336372|NCT01445392|BIOLOGICAL|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \&amp; 5 of a 21 day cycle for 2 cycles
214336373|NCT01445392|DRUG|Pemetrexed|500 mg/m\^2 on day 1 of each 21 day cycle until disease progression
214336374|NCT01445392|DRUG|Cisplatin|75 mg/m\^2 on day 1 of each 21 day cycle until disease progression
214336375|NCT01445392|BIOLOGICAL|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
214336376|NCT01978184|DRUG|gemcitabine|
214336377|NCT01978184|DRUG|abraxane|
214336378|NCT01978184|DRUG|hydroxychloroquine|
214336379|NCT03837496|OTHER|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
214336380|NCT03837496|OTHER|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
214336381|NCT00448058|DRUG|GSK372475|daily administration during the 10-week treatment phase
214937029|NCT04599933|DRUG|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
214937030|NCT04599933|DRUG|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
214937031|NCT05366985|PROCEDURE|Socket shield technique with computer guided sectioning of the root|"A computer guide was used to section the root, leaving the coronal 2/3 of its labial part attached to the socket. An implant was then placed.~Preoperative and Postoperative (5 months later) intraoral scans were superimposed with a digital software to assess the dimensional changes of the labial alveolar ridge. Linear changes at 1,3 and 5 mm from the gingival margin and mean linear changes in a specified Area Of Interest (AOI) were measured"
214937032|NCT01424046|DRUG|basal insulin glargine|Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
214937033|NCT01424046|DRUG|standard therapy|Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
214937034|NCT01289756|DRUG|Clomiphene|clomiphene once 100 mg oral
214937035|NCT01289756|DRUG|clomiphene and paroxetine|clomiphene 100mg and paroxetine 3x40mg
214937036|NCT01289756|DRUG|clomiphene and clarithromycin|clomiphene 100mg and clarithromycin 9x500mg
214336382|NCT00448058|DRUG|venlafaxine|daily administration during the 10-week treatment phase
214336383|NCT00448058|DRUG|placebo|daily administration during the 10-week treatment phase
214336384|NCT03330535|BEHAVIORAL|Reminders once a week|Participants in this group will receive active oral hygiene reminders through text messaging once a week.
214336385|NCT03330535|BEHAVIORAL|Verbal oral hygiene instructions|Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
214336386|NCT03330535|BEHAVIORAL|Reminders three times a week|Participants in this group will receive active oral hygiene reminders through text messaging three times a week.
214937037|NCT05450926|PROCEDURE|Ultrasound-guided selective cervical nerve root block|The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
214937038|NCT05098067|DRUG|Capsaicin Topical Cream|5g 0.075% applied once
214937039|NCT05098067|DRUG|Metoclopramide|10mg IV once
214937040|NCT05098067|DRUG|Ondansetron|8mg IV once if needed
214937041|NCT05098067|DRUG|Lactated Ringers, Intravenous|1000cc once
214937042|NCT02411604|DRUG|Tacrolimus|Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.
214937043|NCT00072436|DRUG|gemcitabine hydrochloride|Given IV
214937044|NCT00072436|DRUG|alvocidib|Given IV
214336387|NCT03330535|BEHAVIORAL|Daily reminders|Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
214336388|NCT01115426|DRUG|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
214336389|NCT04913428|OTHER|Interdigital exercise|Patient asked to sit in upright position interlocking their fingers with inhaling deeply bringing the arms up and exhaling through mouth while bring the arm down.
214336390|NCT04913428|OTHER|Blow-Bottle technique|For blow bottle 20cm of bottle filled with 10cm of water in which a tube of length 35- 40cm inserted with the inner diameter of ≥8mm(21).Patient is asked to form bubbles in bottle by exhaling in bottle performing Forced Expiratory Techniques.
214336391|NCT05716711|OTHER|LAVENDER OIL|IT WILL BE APPLIED TO 60 PATIENTS, 20 IN EACH GROUP, WITH A COLOSTOMY
214336392|NCT01915368|BEHAVIORAL|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
214336393|NCT01915368|BEHAVIORAL|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
214937045|NCT00072436|OTHER|pharmacological study|Correlative studies
214937046|NCT01825356|PROCEDURE|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
214937047|NCT01825356|PROCEDURE|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
214336394|NCT01915368|BEHAVIORAL|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
214336395|NCT02812667|DRUG|Nivolumab + Plinabulin|
214336396|NCT03968952|OTHER|SMARThealth Pregnancy|Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
214336397|NCT03811730|DIAGNOSTIC_TEST|Transesophageal echocardiography|Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
214336398|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
214336399|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
214336400|NCT02268981|DEVICE|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
214336401|NCT01900470|BEHAVIORAL|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
214336402|NCT00131781|BEHAVIORAL|Cognitive Therapy|
214336403|NCT00131781|BEHAVIORAL|Supportive Therapy|
214937048|NCT03219151|DEVICE|eMAR game|The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process
214937049|NCT03219151|OTHER|Normal pre-work|Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
214937050|NCT01333358|DRUG|Alemtuzumab|Alemtuzumab 12mg given intravenously each day for five days and again twelve months later for an additional three days
214674769|NCT02050048|OTHER|Administration of Lactated Ringer's (LR) Solution|"Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes"
215073573|NCT06897371|OTHER|Games-based education|"A 5-question trial test on Kahoot usage will be applied to the students in the intervention group (questions must be prepared in advance, students must have full internet connection, students must enter the Kahoot application with their phones, students must enter the code required to enter the platform, etc.). The questions that make up the trial test will be created independently of the subject covered in the theoretical training and students will be adapted to Kahoot. After the 2-hour theoretical training is completed, reinforcement will be provided using the 25-question game-based learning method on the Kahoot platform. Brief explanations will be made to reinforce the subject and the reinforcement session will last for 30 minutes. The Self-Confidence/Competence Scale in Patient Intervention, Postpartum Hemorrhage Management Information Form and Motivation Scale Regarding the Teaching Material will be applied to both groups as a post-test."
214674770|NCT00934531|DRUG|Donepezil|"Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline."
214674771|NCT00360516|BEHAVIORAL|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
214674772|NCT02664246|DEVICE|percutaneous coronary intervention|
214336404|NCT00236938|DRUG|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
214336405|NCT00236938|DRUG|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
214336406|NCT05075616|PROCEDURE|Percutaneous endoscopic gastrostomy|Percutaneous endoscopic gastrostomy (PEG) is a minimally-invasive endoscopic procedure that creates a passage from the patient's stomach to the abdominal wall via a feeding tube and provides a means of feeding if oral intake is not adequate.
214336407|NCT06236035|DEVICE|Analgesia nociception index|a device to assess patient's pain during surgery
214674773|NCT06279585|OTHER|Physical therapy|Health education sessions and combined therapeutic exercise sessions, based on muscular strength training and cardiorespiratory endurance.
214674774|NCT04591665|OTHER|swallowing examination|patients received swallowing examination, including high resolution impedance manometry and Video-Fluoroscopic swallowing study.
214937051|NCT02915536|OTHER|Natural exposure of high iodine|Natural exposure of high iodine intake from drinking water
214937052|NCT02872857|DRUG|Placebo|Placebo will match drug capsules.
214937053|NCT02872857|DRUG|8mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
214937054|NCT02872857|DRUG|12mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
214336408|NCT04232163|BEHAVIORAL|Arm Boot Camp|The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.
214336409|NCT01218997|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
214937055|NCT05108740|DRUG|everolimus|Self-administered as a daily dose of 10mg orally
214336410|NCT01218997|DRUG|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
214336411|NCT00059904|BIOLOGICAL|aldesleukin|
214336412|NCT00059904|BIOLOGICAL|rituximab|
214336413|NCT01815671|PROCEDURE|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
214336414|NCT04589585|DEVICE|DiVeRt|DiVeRt - Vascular Reconstruction Device and Delivery System
214336415|NCT03390907|DEVICE|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
214674775|NCT06336824|DRUG|Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
214336416|NCT02791815|DRUG|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
214336417|NCT02791815|DRUG|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
214937056|NCT03443310|PROCEDURE|Ultrasound assessment of DVT|Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
214674776|NCT06336824|DRUG|IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
214674777|NCT06670677|OTHER|Lifestyle survey completion|For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.
214674778|NCT06670677|OTHER|Unlimited on-demand blood pressure measurements with G2C|For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated
214937057|NCT04142164|OTHER|MacInfo presentation|Presentation about intravitreal drug injection
214937058|NCT04142164|OTHER|Placebo presentation|Placebo presentation
214937059|NCT02663752|PROCEDURE|Bone marrow aspirate|Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
214937060|NCT02663752|DRUG|Deferasirox|Patients are already on commercial deferasirox before entering the study.
214336418|NCT01222585|DRUG|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with \>=14 postnatal days and every 24 hours for infants \<14 postnatal days.
214336419|NCT06075602|DEVICE|Impact of current PCI techniques/ devices in complex coronary artery lesions|To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
214336420|NCT00349492|DRUG|IP|irinotecan+cisplatin
214347314|NCT02897804|BEHAVIORAL|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.
214347315|NCT02897804|BEHAVIORAL|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214347316|NCT02897804|BEHAVIORAL|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214336421|NCT01767792|DRUG|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
214336422|NCT04891679|DRUG|Oral misoprostol solution (OMS)|"Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity."
214336423|NCT00674141|DRUG|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
214336424|NCT05848635|DRUG|Hydromorphone Hydrochloride|Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation
214937061|NCT04392167|DEVICE|a/LCI-OCT imaging probe|a/LCI and OCT imaging measurements of several locations in the esophagus
214937062|NCT04392167|PROCEDURE|esophageal biopsy|biopsies of esophageal tissue imaged by a/LCI-OCT probe
214336425|NCT05848635|DRUG|Morphine hydrochloride|Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation
214937063|NCT06010420|DEVICE|insoles|Insoles are support devices that take the shape of the foot structure and enable the foot to press in a correct form.
214674779|NCT06670677|OTHER|Continual blood pressure measurements with G1|For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project.
214937064|NCT01652326|DRUG|Diazepam|
214937065|NCT02395263|DRUG|Yuxintine|
214937066|NCT00955045|DRUG|istradefylline|
214937067|NCT01071239|DEVICE|CliniMACs device|Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
214674780|NCT02855814|OTHER|Body Composition|No intervention. This is an observational, normative study of body composition variation in preterm infants
214674781|NCT02417220|BEHAVIORAL|Weight Watchers Online 2015 Program|Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.
214937068|NCT01071239|DRUG|Busulfan|Chemotherapy administered as a part of the HSCT conditioning regimen.
214674782|NCT02417220|OTHER|Electronic Scale with Feedback|Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
214674783|NCT05880758|BEHAVIORAL|Intermittent Short Sleep (ISS)|Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
214674784|NCT05880758|BEHAVIORAL|Social Jetlag (SJL)|2-hour delayed sleep timing.
214674785|NCT05880758|BEHAVIORAL|Sustained Adequate Sleep (SAS)|Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
214674786|NCT03619148|DEVICE|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen
214674787|NCT03536429|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
214937069|NCT01071239|DRUG|Fludarabine|Chemotherapy administered as a part of the HSCT conditioning regimen.
214937070|NCT01071239|DRUG|Cyclophosphamide|Chemotherapy administered as a part of the HSCT conditioning regimen.
214937071|NCT01071239|DRUG|ATG|Chemotherapy administered as a part of the HSCT conditioning regimen.
214937072|NCT05057117|DEVICE|Microwave thermolysis|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
214937073|NCT05057117|DRUG|Botulinum toxin A|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
214937074|NCT05734950|OTHER|Translational study|Non-interventional, translational study
214937075|NCT04518969|DEVICE|CytoSorb|"CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
214937076|NCT01831323|DIETARY_SUPPLEMENT|VSL#3|VSL#3
214937077|NCT01831323|DRUG|Rifaximin|Rifaximin
214937078|NCT01831323|DRUG|Mesalazine|Mesalazine
214937079|NCT01831323|DIETARY_SUPPLEMENT|Psyllium|psyllium
215073574|NCT06897111|BIOLOGICAL|Implantation of allogeneic cartilage mini-grafts (Allogeneic Cartibeads)|Implantation of allogeneic cartilage mini-grafts (Cartibeads) by minimally invasive surgery (arthroscopy or mini arthrotomy). Cartibeads should entirely fill the defect zone, followed by a thin layer of surgical glue (TISSEEL Fibrin Sealant).
215073575|NCT06817512|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2 (MK-7) 300µg/d for 2 year
214937080|NCT05391581|OTHER|GIPR antagonist / study tool|Selective antagonist of the GIPR, GIP(3-30)NH2
214937081|NCT05391581|OTHER|GLP-2R antagonist / study tool|Selective antagonist of the GLP-2R, GLP-2(3-33)
214937082|NCT05391581|OTHER|Placebo|Saline
214937083|NCT06731738|DRUG|Gadoteric acid|A gadolinium-based contrast agent (authorised auxiliary medicinal product (AMP)) will be injected i.v. at a dose of 0.2 mmol Gd/kg bw and T1 mapping and ECV measurement will be done.
215073576|NCT06817512|DIETARY_SUPPLEMENT|Zinc|Zinc, 15mg/d for 2 year
215073577|NCT06817512|DIETARY_SUPPLEMENT|Placebo|Placebo for 2 year
214937084|NCT06731738|DRUG|Mangafodipir trisodium injection|Mangafodipir trisodium injection (IMP) will be administered i.v. at a dose of 5 µmol/kg bw and T1 mapping, Saturation Recovery T1 weighted imaging for measurement of the uptake rate, and T2 mapping, will be done.
214937085|NCT05597579|DIAGNOSTIC_TEST|DAPAR Tests (IQ equivalent test)|This study will compare DAPAR scores before and after the onset of the psychotic illness.
214937086|NCT02165475|BEHAVIORAL|Biofeedback|
214336426|NCT02851238|OTHER|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
214336427|NCT00220818|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
214336428|NCT00220818|DRUG|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
214937087|NCT02165475|DRUG|Loperamide|
214937088|NCT02165475|DRUG|Stool bulking agent (stericulia or isphagula husk)|
214674788|NCT03536429|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
214336429|NCT04284189|OTHER|Transition model|Transition of follow-up care of childhood cancer survivors to adult care
214937089|NCT02165475|OTHER|Combination of biofeedback and medical treatment|
214674789|NCT02088216|DRUG|N-acetylcysteine|600mg po twice a day for 12 months
214336430|NCT00879671|DIETARY_SUPPLEMENT|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
214937090|NCT04382144|DRUG|Liposomal bupivacaine|Patient will receive a single injection of a local anesthetic into the common extensor origin.
214937091|NCT04063657|PROCEDURE|External fixator|Patients will be placed in an external fixator followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
214937092|NCT04063657|PROCEDURE|Splinting|Patients will be placed in a short leg splint followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
214937093|NCT03336723|DEVICE|Dental Implant|Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken
214336431|NCT00879671|DIETARY_SUPPLEMENT|placebo|Placebo capsules identical in taste and appearance
214336432|NCT04546854|BEHAVIORAL|Appeals|Written text motivating participants to take up the seasonal influenza vaccination
214336433|NCT02584309|DRUG|Dexrazoxane|
214336434|NCT02584309|DRUG|Doxorubicin|
214336435|NCT00546143|DRUG|Omalizumab|
214336436|NCT00546143|DRUG|Omalizumab|
214674790|NCT02088216|OTHER|On-demand treatment|receive as-needed therapy
214674791|NCT01477216|OTHER|ELSA 1-9|Measuring GI and II values for Finnish foods
214937094|NCT06454916|DEVICE|Small Bowel Anastomosis with Flexagon SFM Device with OTOLoc|This study will investigate one type of intervention: small bowel anastomosis creation in subjects undergoing laparoscopic small bowel surgery. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically into two different sections of small bowel that are intended to be anastomosed. An OTOLoc device will be deployed into the small bowel wall in one section of the small bowel to provide access for the deployment of a Flexagon SFM into that section of bowel. The process is repeated at the second section of bowel. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two sections of bowel until the anastomosis is fully formed.
214937095|NCT06528795|OTHER|Scenario-based high-reality hybrid simulation method|"Intervention group students will be practiced with the Lactation Simulator, a high-reality simulator, in the simulation laboratory, accompanied by a scenario."
214937096|NCT05452733|BEHAVIORAL|differences of behavior between sleepwalking and non sleepwalking patient|movement registry done by camera when low intensity sound are send to patient during sleep.
214674792|NCT06143631|DRUG|Letrozole 2.5mg|Oral letrozole 2.5mg/day
214674793|NCT06143631|OTHER|Placebo|Placebo capsule
214674794|NCT01804595|OTHER|Sunscreen|
214674795|NCT01804595|BEHAVIORAL|Text-Message Reminders|
214674796|NCT01804595|OTHER|Sunscreen and Text Message Reminders|
214336437|NCT00546143|DRUG|Omalizumab|
214336438|NCT05381792|DIAGNOSTIC_TEST|Bacterial gene markers test|Bacterial gene markers test using qPCR
214336439|NCT05821010|COMBINATION_PRODUCT|Lyophilized fecal microbiota transplantation capsules|Oral administration (capsule)
214336440|NCT05821010|COMBINATION_PRODUCT|Placebo capsules|Oral administration (capsule)
214336441|NCT05821010|DIETARY_SUPPLEMENT|A. soehngenii|Oral administration (capsule)
214336442|NCT05821010|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Oral administration (capsule)
214336443|NCT05821010|DIETARY_SUPPLEMENT|B. animalis subsp. lactis|Oral administration (capsule)
214336444|NCT05821010|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Oral administration (dissolved in water)
214336445|NCT06449573|OTHER|Exercise capacity|cardiopulmonary exercise test used assessment of exercise capacity
214336446|NCT04431232|DEVICE|Endoscopic Band Ligation|Band ligation of the gastric body for weight loss
214336447|NCT06573164|DRUG|Bacillus clausii tablets（Qipian®）|Take 4 tablets (0.3 mg each) orally three times daily.
214336448|NCT06573164|DRUG|conventional medication|Use conventional medication as needed based on the patient's condition.
214674797|NCT01804595|BEHAVIORAL|Education|
214674798|NCT00813475|DRUG|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
214674799|NCT00813475|DRUG|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
214937097|NCT03408444|DEVICE|EMO-114|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
214937098|NCT03408444|DEVICE|EMO-116|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
214937099|NCT03408444|DEVICE|EMO-118|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
214937100|NCT03408444|DEVICE|EMO-117|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
214937101|NCT04984681|BEHAVIORAL|Mindfulness|The traditional mindfulness intervention consists of the following: (1) orientation; (2) a series of eight weekly session of 2.5 to 3 hours; (3) a silent retreat during the between weeks 4 and 6; (4) daily home assignments including formal and informal mindfulness practices; and (5) didactic presentations on stress and the consequences of stress.
214937102|NCT04984681|OTHER|Usual Care|The control condition will continue receiving usual care or standard of care.
214937103|NCT00357136|BEHAVIORAL|password usage|
214937104|NCT03141775|OTHER|Treatment of CDI|Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
214937105|NCT00001736|DRUG|Cysteamine|
214937106|NCT02267213|DRUG|Lipotecan|Administer 40mg Lipotecan at D1, D8, D15 of each cycle.
214937107|NCT00957749|DRUG|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
214937108|NCT00568256|BEHAVIORAL|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
214937109|NCT01823172|PROCEDURE|Methylene blue dye injection of sentinel lymph node|Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
214937110|NCT01473394|DRUG|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
214937111|NCT01473394|DRUG|Vilazodone|Vilazodone was supplied as tablets.
214937112|NCT02847026|BIOLOGICAL|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
214674800|NCT04285723|OTHER|alpelisib|Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.
214674801|NCT04036617|DRUG|NaQuinate|SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
214674802|NCT04036617|DRUG|Placebo|SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
214674803|NCT03118843|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
214674804|NCT00474227|BEHAVIORAL|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
214674805|NCT02001350|OTHER|Ultrasonography|
214937113|NCT02847026|BIOLOGICAL|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
214937114|NCT02847026|BIOLOGICAL|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
214937115|NCT02847026|BIOLOGICAL|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
214937116|NCT02847026|BIOLOGICAL|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
214937117|NCT02847026|BIOLOGICAL|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
214937118|NCT02847026|BIOLOGICAL|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
214674806|NCT04439578|DRUG|SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin|600 mg rifampicin was administered in the morning.
214674807|NCT00372164|PROCEDURE|American Society of Interventional Pain Physician Guidelines|
214674808|NCT06209957|DRUG|Local corticosteroid injection|Local corticosteroid injection;1 ml of triamcinolone acetonide 40 milligram/1.0 mL
214937119|NCT02847026|BIOLOGICAL|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
214937120|NCT03057223|DEVICE|3D-printed patient-specific titanium plates|3D-printed patient-specific titanium plates will be used in patients.
214336449|NCT06573177|OTHER|Referral to the gender identity service.|Referral to the national gender identity service consisting of the Sexological Clinic, Child and Adolescent Mental Health Center, and Department of Growth and Reproduction in the Capital Region of Denmark.
214336450|NCT05797805|DRUG|Tegavivint|"The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle"
214336451|NCT05797805|DRUG|Lenvatinib|"In the second part of the study, the combination of tegavivint plus lenvatinib will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus lenvatinib combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 and 22 of a 28-day cycle; lenvatinib 8 mg (patients \< 60 kg) or 12 mg (patients ≥ 60 kg) will be administered once daily on days 1-28 of a 28-day cycle ."
214336452|NCT05797805|DRUG|Cabozantinib|"In the second part of the study, the combination of tegavivint plus cabozantinib will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus cabozantinib combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 and 22 of a 28-day cycle; cabozantinib 60 mg (patients with Child-Pugh A) or 40 mg (patients with Child-Pugh B) will be administered orally once daily on days 1 through 28 of each 28-day cycle"
214336453|NCT02746614|OTHER|Psychomotor Therapy|Psychomotor Therapy
214336454|NCT06327126|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
214336455|NCT06327126|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
214336456|NCT02287415|DRUG|BIA 2-093|
214336457|NCT02287415|DRUG|Warfarin|
214336458|NCT03211741|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
214336459|NCT02206126|BEHAVIORAL|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
214336460|NCT00265811|DRUG|Folfox|
214336461|NCT00265811|DRUG|Cetuximab|
214336462|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 1|"Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
214336463|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 1|"Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
214937121|NCT06215755|DRUG|VRG50635|"Part 1, no study drug will be administered.~Part 2, the starting dose is 400 mg for 8 weeks (Treatment Period 1) and doses will be escalated to 600 mg for 8 weeks (Treatment Period 2) and 800 mg for 8 weeks (Treatment Period 3).~Part 3, each participant will continue receiving treatment with the highest tolerated dose achieved in Part 2 for up to 40 weeks."
214336464|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 2|"Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
214674809|NCT06209957|DRUG|Platelet-rich Plasma Local injection|Platelet-rich Plasma (From 2-step centrifugation of patient blood) Local injection.
214674810|NCT06345040|BEHAVIORAL|Virtual-reality intervention|For the experimental condition, participants will receive seven individual sessions of Virtual Reality Therapy conducted by a therapist trained in both eating disorder psychotherapy and virtual reality-based therapy, including avatar therapy. In the initial stage of therapy participants create a virtual avatar embodying their eating disorder voice. This enables the person to engage in real time face to face dialogue with the eating disorder voice. The main goal of the intervention is to encourage participants to stand up to the negative comments and commands made by the eating disorder voice and hereby increase their power and agency in the context of the eating disorder voice.
214937122|NCT02732405|DRUG|MK5172 /MK8742|tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
214937123|NCT00865267|DRUG|Ultravate® 0.05% ointment, single exposure|A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
214937124|NCT03769597|DRUG|Iohexol Inj 300 MG/ML|After injecting a loading dose of 5ml of iohexol bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
214937125|NCT01538992|DEVICE|Standard steerable Marinr RF ablation Catheter (5F or 7F)|Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
214937126|NCT00546455|DRUG|Fenretinide|200 mg/day
214937127|NCT00546455|DRUG|Placebo|2 capsules/day
214937128|NCT03117881|BEHAVIORAL|DirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
214336465|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 2|"Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
214336466|NCT06333626|DIETARY_SUPPLEMENT|multi-vitamin carbohydrate|oral multi-vitamin carbohydrate beverage
214336467|NCT06428201|DIAGNOSTIC_TEST|Control Group|The control group receives standard care, which includes routine medical management and general physical rehabilitation exercises. This involves regular consultations with healthcare providers and exercises aimed at maintaining mobility and physical function. The control group also follows a schedule of three 45-minute sessions per week for 12 weeks, ensuring a consistent comparison with the experimental group.
214674811|NCT06345040|BEHAVIORAL|TAU - specialized treatment|The control condition encompasses treatment as usual comprising seven sessions of specialized treatment, such as individual or group psychotherapy and dietary guidance, provided by interdisciplinary health professionals.
214336468|NCT06428201|COMBINATION_PRODUCT|Experimental Group|The experimental intervention involves tele-rehabilitation-based task-specific training to enhance cognitive functions in multiple sclerosis (MS) patients. This program includes cognitive exercises targeting memory, attention, executive function, and processing speed, conducted remotely via a tele-rehabilitation platform. Patients participate in three 45-minute sessions per week for 12 weeks. Each session is guided by a trained therapist, ensuring personalized support and real-time feedback.
214336469|NCT05468840|DRUG|Ketamine Hydrochloride|see study arm description
214336470|NCT05468840|DRUG|Normal saline|see study arm description
214336471|NCT06024954|OTHER|aromatherapy|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
214336472|NCT06024954|OTHER|music therapy|"The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes."
214336473|NCT06024954|OTHER|aromatherapy and music therapy|Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
214336474|NCT00951210|BIOLOGICAL|PLX-PAD|IM injection
214336475|NCT04713384|DEVICE|Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games|20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
214336476|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
214336477|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
214336478|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
214336479|NCT01035879|DRUG|Sitagliptin|tablets and capsule once daily
214937129|NCT03117881|BEHAVIORAL|TeleCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
214937130|NCT03117881|BEHAVIORAL|rDirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks by a therapist via videoconferencing technology. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
214937131|NCT00574223|DRUG|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
214674812|NCT04627350|OTHER|Response to pulmonary finding (nodule, mass)|Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
214937132|NCT00574223|DRUG|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
214937133|NCT04182438|DIETARY_SUPPLEMENT|Low potassium content vegetables|use low-potassium content vegetables
214937134|NCT04577534|DRUG|iv Tocillizumab (TCZ)|Participants are randomized (2:1) to receive TCZ or Standard of Care
214674813|NCT05552638|OTHER|Telecare|The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
214674814|NCT03078725|DRUG|Glyburide|oral hypoglycemic agent
214336480|NCT01035879|DRUG|placebo|tablets and capsule once daily
214336481|NCT03128749|BEHAVIORAL|Mindfulness Based Intervention|"The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams \& Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013)."
214674815|NCT03078725|DRUG|Metformin|oral hypoglycemic agent
214674816|NCT04128657|DIAGNOSTIC_TEST|MA_LARS|Validation of the MA\_LARS and MA\_Wexner
214674817|NCT02204540|BEHAVIORAL|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
214937135|NCT05795205|BEHAVIORAL|Normal dinner|Participants will consume breakfast at 0830-0855 am, lunch at 1230-1255 pm, followed by dinner at 1800-1825 pm. Snacks will be consumed at 2130-2140 pm.
214937136|NCT05795205|BEHAVIORAL|Delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Dinner will be consumed at 21:30-21:55 pm.
214674818|NCT03175380|BIOLOGICAL|bacillus Calmette-Guérin|BCG injection for prevention of tuberculosis
214674819|NCT06672263|DRUG|TQB3911 tablets|TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor. By occupying the myristyl binding site, TQB3911 recovers the inhibition of BCR::ABL1 fusion protein kinase activity, and ultimately inhibits the proliferation of tumor cells.
214336482|NCT03128749|DRUG|Treatment as Usual|The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
214336483|NCT02575664|DRUG|Buprenorphine|Buprenorphine 5 microg/h/7 days
214674820|NCT06594640|DRUG|Mitoxantrone Hydrochloride Liposome|assigned dose according to the 3+3 dose-escalation design in part 1, RP2D in part 2, D2
214674821|NCT06594640|DRUG|Rituximab (R)|375mg/m2, D2
214674822|NCT06594640|DRUG|Cyclophosphamide (CTX)|750mg/m2, D2
214674823|NCT06594640|DRUG|Vincristin|1.2mg/m2, maximum 2mg， D2
214674824|NCT06594640|DRUG|Prednisolone|60mg/m2, D2-6
214674825|NCT03044665|DRUG|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
215073578|NCT04863300|BEHAVIORAL|Collaborative stepped care and peer support|"Case identification will be done through open referral and outreach activities such as street booth, talks, and home visits.~For older adults with mild depressive symptoms (PHQ-9 score 5-9), 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided by the project social workers in DECC. For participants with moderate depressive symptoms (PHQ-9 score 10-14), 6-8 weeks high-intensity clinical intervention, mainly group cognitive behavioral therapy (CBT), would be provided by project social workers from DECC and ICCMW. For those with moderately severe depressive symptoms (PHQ-9 score 15-19), 8-10 weeks individual CBT or group CBT at higher frequency would be provided by the project social workers from ICCMW.~In the progress review when a client is assessed to meet the discharge criteria, a 2-month exit plan involving a Peer Supporter follow-up is invoked."
214674826|NCT03044665|DRUG|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
214336484|NCT02575664|DRUG|Placebo|Placebo patch
214674827|NCT02597595|OTHER|spirulina|oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
214674828|NCT03063073|DRUG|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection \[Precedex\]
214674829|NCT03063073|DRUG|Bupivacaine|
214674830|NCT00213018|DRUG|Carraguard (PC-515)|
214336485|NCT06534021|DRUG|IASO-782 injection|Each subject will be given only one dose of IASO-782. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
214347317|NCT02897804|BEHAVIORAL|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214674831|NCT04902950|DRUG|Tranexamic acid|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
214674832|NCT04902950|DRUG|Saline|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
214674833|NCT04411238|OTHER|interview|interview
214674834|NCT06673173|OTHER|Implant|A long cone paralleling approach with a specially made film holder will be used to assess each patient's vertical marginal bone loss to ensure standardized radiography analysis and avoid any magnification errors. The linear distance between the proximal crestal bone level and the implant shoulder will be measured at the mesial and distal aspects of the implant measured in millimeters (mm). Measurements will performed using image measurement software patient satisfaction comparison between 2 groups
214674835|NCT06869642|BEHAVIORAL|Doing Pasat-Test|PASAT-Test either with or without doing chest compressions
214674836|NCT06869642|PROCEDURE|Chest compressions|Performing chest compressions as desribed in the ERC Guidelines
214937137|NCT05795205|BEHAVIORAL|Exercise with delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Participants will exercise for 45 min at moderate-intensity 45 min prior to the delayed dinner at 21:30-21:55 pm.
214937138|NCT02018978|BEHAVIORAL|Comprehensive Triaged HIV Prevention (CTHP)|"1. HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~2. Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~3. Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~4. Incentives \& Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
214336486|NCT06534021|DRUG|placebo|Each subject will be given one dose of placebo. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
214336487|NCT04262258|DIETARY_SUPPLEMENT|Blueberry enriched diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
214336488|NCT02447991|DRUG|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
214336489|NCT02447991|DRUG|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
214336490|NCT01243385|DRUG|Metformin|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
214336491|NCT04108039|DRUG|GnRh antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS
214336492|NCT04108039|DRUG|Micronized progesterone|Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
214336493|NCT01769157|DRUG|L-carnitine|
214336494|NCT01769157|DRUG|Placebo|
214336495|NCT00810121|DRUG|ketoprofen 100 mg|100 mg b.i.d. for 5 days
214336496|NCT00810121|DRUG|ketoprofen|150 mg b.i.d. for 5 days
214336497|NCT03966235|DRUG|Melatonin 3 mg|Melatonin was taken daily for 6 months.
214336498|NCT03966235|DRUG|Placebo|Placebo tablet was taken daily for 6 months.
214336499|NCT05544877|BEHAVIORAL|Integrated 5-day Gratitude Exercise and Behavioral Activation Program|The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
214336500|NCT03765957|BIOLOGICAL|Mesenchymal Stem Cells|After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.
214336501|NCT06531460|DIETARY_SUPPLEMENT|Fish oil enteral supplementation|Omega-3 (4.2 g), administered through an enteral feeding tube, three days before surgery
214336502|NCT06531460|DIETARY_SUPPLEMENT|Fish oil oral supplementation|Omega-3 (4.2 g), orally administered enriched nutritional formula, drinking at home three days before surgery
214336503|NCT06531460|DIETARY_SUPPLEMENT|Enteral nutrition without fish oil|Enteral formula without omega-3 administered through an enteral feeding tube, three days before surgery
214336504|NCT06531460|DIETARY_SUPPLEMENT|Oral nutritional supplement without fish oil|Oral nutritional supplement without omega-3 orally administered, drinking at home three days before surgery
215073579|NCT06896591|PROCEDURE|Deep posterior post gluteal nerve block|One injection with ultrasound guidance injection of 5, 10 or 15 mL of naropeine 0.35 % Procedure : injection below the piriformis muscle in front of the head of the femur.
214674837|NCT05178901|BIOLOGICAL|PHV02|live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection
214336505|NCT03046680|OTHER|Health Coaching|
214336506|NCT03046680|OTHER|Multiprofessional Team|
214336507|NCT00459134|DIETARY_SUPPLEMENT|ArginMax|Given orally
214336508|NCT00459134|DIETARY_SUPPLEMENT|Placebo|Given orally
214336509|NCT05781035|PROCEDURE|dexmedetomidine|patients will recieve moderate sedation by dexmedetomidine as study group
214674838|NCT05178901|OTHER|Placebo|Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection
214674839|NCT03199092|BEHAVIORAL|RRT+sat|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.
214336510|NCT05781035|PROCEDURE|general anesthesia|general anesthesia with neuromuscular blockade under controlled ventilation as control group.
214336511|NCT00125554|DRUG|Metyrapone|
214336512|NCT04455386|DIAGNOSTIC_TEST|Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy|All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.
214336513|NCT01260441|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
214336514|NCT04523129|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
214674840|NCT03199092|BEHAVIORAL|Abilmente|'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
214937139|NCT02204358|PROCEDURE|autologous bone marrow stem cells|"Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.~If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits."
214937140|NCT03346304|OTHER|Photodynamic Therapy (PDT)|Photodynamic Therapy (PDT) using photosensitiser drug Fotolon
214674841|NCT00003803|DRUG|cisplatin|
214674842|NCT00003803|DRUG|gemcitabine hydrochloride|
214336515|NCT04523129|DRUG|Vehicle topical ocular, eye drops|Vehicle
214336516|NCT00578370|DRUG|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
214336517|NCT00578370|DRUG|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
214336518|NCT00578370|DRUG|0.1% betamethasone|Solution 200µl once a day (26 days)
214336519|NCT00578370|DRUG|0.005% calcipotriol|Solution 200µl once a day (26 days)
214336520|NCT00578370|DRUG|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
214336521|NCT01813500|OTHER|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
214336522|NCT01640158|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
214336523|NCT01640158|OTHER|Commercially available computerized training|Commercially available computerized training, up to 65 hours
214336524|NCT03289962|DRUG|Autogene cevumeran|Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.
214336525|NCT03289962|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
214336526|NCT05453474|GENETIC|Whole genome amplification|DNA is amplified by whole genome amplification
214674843|NCT00003803|RADIATION|radiation therapy|
214674844|NCT03826992|DRUG|Vyxeos|Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
214674845|NCT03826992|DRUG|Venetoclax|"Venetoclax Dose:~1. Dose Level 0 - weight based daily dosing for 21 days~2. Dose Level -1 - weight based daily dosing for 14 days~3. Dose Level -2- weight based daily dosing for 10 days~4. Dose Level -3- weight based daily dosing for 7 days"
214336527|NCT05870176|BEHAVIORAL|Enhanced Referral|The enhanced referral uses an electronic referral and patient decision aid to provide choices to 3 different physical activity programs.
214336528|NCT05870176|BEHAVIORAL|Standard Referral|"The standard referral period will serve as the usual care comparator. Patients will receive a paper referral and Fitbit monitor."
214336529|NCT04742595|BIOLOGICAL|SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes|Given IV
214674846|NCT02979067|PROCEDURE|Nasal oxygen flow|Nasal oxygen flow during apnoea
214674847|NCT01900548|DIETARY_SUPPLEMENT|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
214674848|NCT01900548|DIETARY_SUPPLEMENT|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
214674849|NCT01900548|DIETARY_SUPPLEMENT|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
214336530|NCT02087462|OTHER|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
214336531|NCT02087462|OTHER|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
214336532|NCT02087462|DRUG|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
214336533|NCT02087462|DRUG|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
214336534|NCT04582552|DRUG|PARP inhibitors|Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
214336535|NCT01612546|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
214336536|NCT01612546|OTHER|Laboratory biomarker analysis|Correlative studies
214336537|NCT01612546|OTHER|Pharmacological studies|Correlative studies
214336538|NCT05226650|OTHER|Regular meal pattern|6 meals every day
214336539|NCT05226650|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
214674850|NCT01900548|OTHER|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
214336540|NCT03813615|BEHAVIORAL|treadmill walking (Proof-of-Concept)|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology. setting.
214336541|NCT03813615|BEHAVIORAL|treadmill walking Dose-Finding / Escalation|Six doses of aerobic training ( 90mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/wk \& 450mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity \& duration) or non-linear (i.e., exercise dose is continually altered \& progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 3 to 6 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented \& may be monitored using TeleEx. Patients may also perform up to three aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided a plan for their unsupervised session(s) verbally or via Portal Secure Messaging (PSM), as appropriate.
214336542|NCT05755373|OTHER|No treatment given|No treatment given
214336543|NCT00234884|BIOLOGICAL|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
214336544|NCT00208377|DEVICE|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
214336545|NCT03541746|BIOLOGICAL|Platelet Rich Plasma|After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
214336546|NCT03541746|DEVICE|Intrauterine Foley's Catheter|After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
214336547|NCT01947504|BEHAVIORAL|education and support intervention|
214336548|NCT01016834|DEVICE|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
214336549|NCT01016834|DRUG|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
214336550|NCT06653257|OTHER|Active surveillance|a non-operative management strategy aimed at avoiding unnecessary surgery in patients with thyroid nodules with a cytopathological diagnosis of Bethesda IV-VI, who do not present clinical or imaging characteristics suggesting malignancy and/or aggressiveness.
214336551|NCT06655935|PROCEDURE|Ordinary Transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO inside the left atrial cavity over stiff wire into the pulmonary veins
214336552|NCT06655935|PROCEDURE|modified transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO over the multipurpose catheter inside the left atrial cavity which might help in the shortage of the duration \& the cost of the procedure with less complication rate
214347318|NCT02897804|BEHAVIORAL|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
214674851|NCT01105351|DIETARY_SUPPLEMENT|folic acid plus B6 and B12|folic acid 400 µg plus vitamin B12 plus B6
214674852|NCT01105351|DIETARY_SUPPLEMENT|folic acid|folic acid 400 µg
214674853|NCT06752811|DRUG|paclitaxel polymeric micelles for injection|Paclitaxel polymeric micelles for injection at a dose of 300 mg/m2 (based on body surface area), administered on Day 1, with intravenous infusion for ≥ 3 hours, every 3 weeks as a cycle.
214674854|NCT06752811|DRUG|Gemcitabine Hydrochloride for Injection|The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1 and D8 every 3 weeks.
214937141|NCT06730828|COMBINATION_PRODUCT|The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)|Intervention includes a topical, atrial-specific, amiodarone infused CardiaMend patch in the operating room and applied onto the epicardial surface biatrially
214937142|NCT01027897|DRUG|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
214937143|NCT03870529|DRUG|Vitamin A Compound|Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection
214937144|NCT03870529|PROCEDURE|Therapeutic Conventional Surgery|Participants randomized to this arm will receive surgical resection
214937145|NCT05562141|BIOLOGICAL|Blood sample|Blood sample before induction, 1h after induction and 24h after the start of procedure
214937146|NCT02265757|BEHAVIORAL|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
214937147|NCT02265757|BEHAVIORAL|Computer Brain Fitness Training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program and will be encouraged to maintain 250 minutes of computerized brain training per week for 18 months post program. Each participant's adherence and progress will be tracked through the clinician portal provided by Posit Science both during HABIT and for 18 months post-program.
214937148|NCT02265757|BEHAVIORAL|Support Group (patient and partner)|Patient: The patient support group will meet for 45-60 minutes daily. It will use the LifeBio Memory Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
214937149|NCT02265757|BEHAVIORAL|Wellness Education|The education component will involve daily 60-minute group sessions with topics including Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition and Exercise, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
214937150|NCT02265757|BEHAVIORAL|Physical Exercise|The HABIT physical exercise intervention is intended to initiate and sustain a schedule rather than a type of physical activity. HABIT will provide a customized DVD as a supplement for continued use and practice after the program to those that opt to continue yoga. Will use an activity log completed by the partner to track activity level of the participants during the 18 month follow-up period.
214937151|NCT05914389|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 for inducing chemotherapy on Day 1 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
214937152|NCT05914389|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
214937153|NCT05914389|DRUG|Anti-PD-L1 Monoclonal Antibody|The incidence of adverse events with Anti-PD-L1 Monoclonal Antibodies is relatively low. Based on phase I clinical trial data of Envafolimab, a dose reduction design was conducted to minimize the incidence of adverse events while ensuring therapeutic efficacy. In the two cohorts of the efficacy-enhancing design, a reduced dose of 100mg/0.5ml IH QW will be used for 6 weeks. The PD-L1 monoclonal antibody (Envafolimab) dose adjustment was implemented according to the prescribing information.
214937154|NCT05914389|DRUG|Clostridium butyricum|Clostridium butyricum is treated with Miyarisan 588 powder, 160mg/day (4 packets/day) taken orally for a total of 6 weeks.There have been no reports of adverse reactions for Lactobacillus. There is no predetermined reduction plan.
214937155|NCT05914389|PROCEDURE|Colectomy|The specific surgical approach, whether it be laparoscopic or open surgery, is determined by the surgeon. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
214674855|NCT06752811|DRUG|Paclitaxel for Injection (albumin bound )|Patients in the control group will receive intravenous infusion of paclitaxel for Injection (albumin bound ) at a dose of 125 mg/m2 (based on body surface area), administered at D1, D8, and D15, every 4 weeks as a cycle.
214674856|NCT06752811|DRUG|Gemcitabine Hydrochloride for Injection|The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1, D8, and D15 every 4 weeks.
214674857|NCT02653092|DRUG|Insulin|
214674858|NCT02653092|DRUG|Intralipid|
214674859|NCT02653092|DRUG|Dextrose|
214674860|NCT02653092|DRUG|Heparin|
214674861|NCT02653092|DRUG|GnRH|
214674862|NCT02653092|PROCEDURE|Hyperinsulinemic Euglycemic Clamp|
214937156|NCT00473824|BIOLOGICAL|Hepatitis C Immune Globulin Intravenous (Human) 5%|Hepatitis C Immune Globulin Intravenous (Human) 5%, \[Civacir\]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
214937157|NCT00755950|DIETARY_SUPPLEMENT|Silymarin|280 mg three times daily for four weeks
214937158|NCT00755950|DIETARY_SUPPLEMENT|Silymarin|420 mg three times daily for four weeks
214937159|NCT00755950|OTHER|Lactose monohydrate|Lactose monohydrate 326.95 mg three times daily for four weeks
214937160|NCT05337917|PROCEDURE|Surgical of the digital nerve|All patients (cases and controls) were subject to surgical repair of digital nerve injury.
214937161|NCT02673294|OTHER|balance virtual rehabilitation|
214937162|NCT02795468|PROCEDURE|Radial arterial cannulation|Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
214937163|NCT02560623|PROCEDURE|Biopsy|Undergo biopsy
214937164|NCT02560623|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214937165|NCT02560623|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
214674863|NCT06528873|COMBINATION_PRODUCT|Concurrent optical and magnetic stimulation (COMS) treatment|"COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps:~Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1)~If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device."
214674864|NCT06908031|RADIATION|Short-Course Radiotherapy|Patients undergo SCRT at a dose of 5Gy × 5 fractions
214336553|NCT03802097|PROCEDURE|No use of antimicrobial prophylaxis|Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
214336554|NCT03802097|PROCEDURE|Use of antimicrobial prophylaxis|Use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
214336555|NCT06664216|BEHAVIORAL|incorrect trocar placement marks.|Participants in the experimental group will perform trocar placements on laparoscopic models that have been pre-marked with incorrect insertion sites by previous participants. These marks simulate procedural steps or anatomical landmarks that are intentionally incorrect.
214336556|NCT06664008|DRUG|PPI (proton pump inhibitor)|It reduces stomach acid production and manage GERD symptoms
214336557|NCT06664008|DRUG|Probiotic|Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.
214336558|NCT06664008|DRUG|Zinc|Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
214336559|NCT06663800|OTHER|Ujjayi Paranayama|Inhale or breathe in slowly while taking a deep, prolonged breath through both nostrils. As you inhale, attempt to tighten your throat and feel the air in your throat. Air should not come into contact with the interior of the nose. When air enters the throat, an odd sound is made. Allow the breath to be loose and easy while you slightly tighten the back of your throat and hiss lightly as you breathe in and out. The sound isn't forced, but it should be loud enough for someone to hear you if they were close. Now close your right nostril and release the breath through your left. As you exhale, try making the sound HHHHHAAAA
214674865|NCT06908031|DRUG|PD-1 monoclonal antibody|Patients complete immune therapy with PD-1 monoclonal antibody for 4 cycles.
214674866|NCT06908031|DRUG|mFOLFOX6 regimen|Patients complete chemotherapy with mFOLFOX6 regimen for 4 cycles.
215073580|NCT06770673|BEHAVIORAL|TOD Great Plains|The adapted TOD intervention is rooted in the original TOD structure, delivery system, and home-visiting teaching schedule. Local enhancements include intervention topics and activities to address local adult caregivers' diabetes management and to promote families' modifiable risk and protective factors targeted by this proposal and informed by the Wicozani wellness concept and measurement. The TOD intervention includes targeted content taught approximately bi-weekly by family health coaches over a 16-week period.
215073581|NCT06770673|BEHAVIORAL|Waitlist Standard of Care|Participants who are waitlisted to receive the TOD intervention will receive Standard of Care.
214937166|NCT02560623|DEVICE|Swallowable Sponge Cell Sampling Device|Undergo swallowable sponge cell sampling assessment
215073582|NCT06769425|DRUG|HS-10502 + NHA|HS-10502 + NHA
214937167|NCT01337323|DRUG|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
215073583|NCT06769425|DRUG|HS-10502 + HS-20093|HS-10502 + HS-20093
215073584|NCT06769425|DRUG|HS-10502+ Apatinib|HS-10502+ Apatinib
214937168|NCT05230745|DEVICE|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
214937169|NCT06850116|PROCEDURE|Retzius-sparing robot-assisted radical prostatectomy|Retzius-sparing robot-assisted radical prostatectomy
214937170|NCT04527003|DRUG|Cannabidiol (CBD) Extract|Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.
214937171|NCT04527003|DRUG|Norethindrone Acetate|Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
214937172|NCT04527003|OTHER|Placebo|a substance or treatment which is designed to have no therapeutic value
214937173|NCT06020612|OTHER|Assessment by dermatopathologists|Histological assessment of the cSCCs by eight dermatopathologists.
215073585|NCT06769425|DRUG|HS-10502 + HS-20089|HS-10502 + HS-20089
215073586|NCT06769425|DRUG|HS-10502 + Platinum + Bevacizumab|HS-10502 + Platinum + Bevacizumab
215073587|NCT06769425|DRUG|HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan|HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
215073588|NCT06769425|DRUG|HS-10502 + Bevacizumab|HS-10502 + Bevacizumab
215073589|NCT02307097|PROCEDURE|Cognitive-Behavioural Bibliotherapy|
215073590|NCT02307097|PROCEDURE|Cognitive-Behavioural Therapy|
215073591|NCT02307097|OTHER|WAIT|
215073592|NCT00059930|DRUG|FOLFOX regimen|
215073593|NCT00059930|DRUG|dexamethasone|
215073594|NCT00059930|DRUG|floxuridine|
215073595|NCT00059930|DRUG|fluorouracil|
215073596|NCT00059930|DRUG|leucovorin calcium|
215073597|NCT00059930|DRUG|oxaliplatin|
214336560|NCT06663800|OTHER|Standard Protocol|Control Group will perform Deep Breathing Adhering to a FITT model protocol, with a frequency of 5 days. Intensity set at 8 repetitions, duration range from 10 to 15 minutes
214336561|NCT06986707|OTHER|Strain counterstrain technique|"Group A: Conventional treatment will be given for 45 minutes (repeated 2 sets in each session)~* 1 day per week~* 4 weeks protocol"
214336562|NCT06986707|OTHER|Graston technique|"GROUP B: Conventional treatment will be given for 45 minutes Before starting procedure, brisk walking or stretching is done for 4- 5 minutes~* Applying heat for 3-4 minutes to warm the area~* 40 seconds on right side~* 40 seconds on left side~* 1 day per week~* 4 weeks protocol After treatment, apply Ice for 2 minutes"
214336563|NCT02969928|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
214937174|NCT01276691|DRUG|81 mg enteric coated aspirin|81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
214937175|NCT06619119|OTHER|Excape room simulation|"Application of Research:~Preparation and Implementation of the Escape Room The escape room game scenario prepared by the relevant faculty members consists of the subjects of Triage, Basic Life Support, Advanced Life Support and Traumas, which are included in the Emergency Nursing course curriculum. Students who will participate in the escape room game were given 30 minutes to solve the puzzles in the room, follow the clues, find the exit key and escape. To solve puzzles, unlock padlocks, and find specific objects in the escape room, students had to answer questions on Triage, Basic Life Support, Advanced Life Support, and Traumas and manage to exit the room in time."
214937176|NCT00532272|DRUG|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
214937177|NCT00376272|DRUG|Valsartan|
214937178|NCT00376272|DRUG|Placebo|
214937179|NCT03140956|DRUG|Levodopa, carbidopa, ODM-104|Crossover design. Study treatments will be administered in randomized order 4 times a day.
214937180|NCT03410732|BIOLOGICAL|activated DCs|autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.
214937181|NCT03410732|PROCEDURE|radical surgery only|Only radical surgery is given to the control group
214937182|NCT01160835|PROCEDURE|total knee arthroplastyinstruments|Quadriceps-sparing arthrotomy with side-cutting instruments
214937183|NCT05227703|DRUG|CVL-231 15 mg|CVL-231 15 mg, oral (tablet), once per day for 6 weeks
214674867|NCT06908031|DRUG|Cetuximab|Patients with RAS/BRAF wild-type receive targeting therapy with Cetuximab for 4 cycles.
215073598|NCT00059930|PROCEDURE|adjuvant therapy|
214336564|NCT02969928|DRUG|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
214336565|NCT02969928|DRUG|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
214336566|NCT02969928|DRUG|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
214336567|NCT02610699|OTHER|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
214937184|NCT05227703|DRUG|Required CVL-231 30 mg|CVL-231 30 mg, oral (tablet), once per day for 6 weeks
215073599|NCT00059930|PROCEDURE|conventional surgery|
214937185|NCT05227703|DRUG|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
214937186|NCT05667649|BIOLOGICAL|RB-ADSC|Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)
214937187|NCT05341947|BIOLOGICAL|Activated T cells|Activated T cells (ATC) administered intravenously at one timepoint
214937188|NCT04983667|DIETARY_SUPPLEMENT|Zn-AA|Oral supplementation of either 30 mg daily or Zinc-AA complex or placebo, from the study recruitment during first trimester of pregnancy, all through pregnancy and up to the sixth month after giving birth.
214937189|NCT05336396|OTHER|BMI|Longitudinal data will be collected to determine the effectiveness of BMI compared to traditional OHI to maintain and improve periodontal health.
215073600|NCT06890689|PROCEDURE|Scaling and root planing|Retrospective study to evaluate the outcome of scaling and root planing
214674868|NCT06908031|DRUG|Bevacizumab|Patients with RAS/BRAF mutations receive targeting therapy with Bevacizumab for 3 cycles. (Bevacizumab is not used in the last cycle of the bevacizumab group)
214674869|NCT06908031|PROCEDURE|Surgical resection|Surgery either local excition or total mesorectal excision is performed 8-10 weeks after the completion of short-course radiotherapy.
214674870|NCT01859351|DRUG|WX-037|
215073601|NCT05557162|OTHER|AI ECG Amyloid algorithm|Artificial intelligence enabled electrocardiogram screening tool used to identify the predictive model that best differentiates those at greatest risk for an amyloidosis diagnosis
215073602|NCT06890000|OTHER|Scapular Exercise|"Scapular exercise includes scapular clock exercise (3 sets of 10 repetitions), rowing exercise (3 sets of 10 repetitions), resisted external rotation (3 sets of 10 repetitions), resisted punching exercise (3 sets of 10 repetitions).~The rowing, external rotation and punching exercises will do with theraband. When participants complete the elastic band exercises easily and do not report any muscle fatigue, they will move on to the next level of difficulty. The color order of the bands is yellow, red, green and blue. The exercises will begin with the yellow elastic band, which provides the least resistance.~The intervention will last for 6 weeks, with 2 training sessions per week and each training session lasting 15-20 minutes."
214336568|NCT02610699|OTHER|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
214336569|NCT03620851|OTHER|effect of age|effect of age on the efficiency of enhanced recovery program
214674871|NCT01859351|DRUG|WX-554|
214674872|NCT06140966|DRUG|Daratumumab|Given by vein: days 1 and 8 of each Induction cycle; days 1 and 15 of each Consolidation cycle; and day 1of each Maintenance cycle.
214674873|NCT06140966|DRUG|Carfilzomib|Given by vein: days 1,2,8 and 9 of each Induction cycle; days 1, 2, 8, 9,15, and 16 of each Consolidation cycle; days 1, 2,15, and 16 of each Maintenance cycle.
214937190|NCT05054361|DIAGNOSTIC_TEST|MAIT cells analysis|For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.
214937191|NCT05054361|DIAGNOSTIC_TEST|MAIT cytokines production analysis|Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
214937192|NCT05054361|DIAGNOSTIC_TEST|Lactulose/Mannitol Test|After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
214937193|NCT05054361|PROCEDURE|UGI Endoscopy|Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
214937194|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
214937195|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
214937196|NCT02996552|PROCEDURE|M & T Repair Group|After the mitral valve repair a device for tricuspid annuloplasty will be implanted.
214937197|NCT02996552|PROCEDURE|Mitral-Only Group|Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
214937198|NCT05889585|OTHER|quality of life questionnaire|EORTC-QLQ C-30 questionnaire The Impact of Events Scale (IES-R) Multi-Dimensional Fatigue Inventory The EORTC-QLQ C-30 Vers. 3
214674874|NCT06140966|DRUG|Lenalidomide|Given by mouth: days 1-7 of each Induction cycle; days 1-14 of each Consolidation cycle.
214336570|NCT02539875|BEHAVIORAL|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
214336571|NCT06624514|BEHAVIORAL|Training Group|Implicit approach bias is the behavioral action tendency to be faster to approach rather than avoid cues for a stimulus category. The Approach-Avoidance Task (AAT)is a computerized program in which participants make approach or avoidance movements in response to an irrelevant feature of an image presented on a computer screen (e.g., push when in portrait, pull when in landscape). The intervention in this study is a treatment version of the AAT used as an Approach Bias Modification (ABM) intervention, to retrain participants' implicit biases toward or away from stimuli by presenting the target stimuli predominantly in one format (e.g., push or pull).
214336572|NCT06624514|BEHAVIORAL|Sham Training Group|A sham-training control condition
214674875|NCT06140966|DRUG|Dexamethasone|Given by mouth or by vein: days 1, 8, 15, and 22 of each Induction cycle; days 1, 8, 15, and 22 of each Consolidation cycle; and days 1 and 15 of every cycle during Maintenance
214674876|NCT06140966|DRUG|Cisplatin|Given by vein: days 1-4 of each Induction cycle
214674877|NCT06140966|DRUG|epirubicin|Given by vein: days 1-4 of each Induction cycle
214674878|NCT06140966|DRUG|Cyclophosphamide|Given by vein: days 1-4 of each Induction cycle
214674879|NCT06140966|DRUG|Etoposide|Given by vein: days 1-4 of each Induction cycle
214674880|NCT06140966|DRUG|Melphalan|Given by vein: day -1 of Transplant
214674881|NCT06140966|PROCEDURE|ASCT|day 0 of Transplant
214674882|NCT06140966|DRUG|bortezomib|given by subcutaneous injection: days 1, 4, 8, and 11 of pretrial induction chemotherapy
214674883|NCT05383157|BEHAVIORAL|Brief mindfulness|Training in mindfulness focused on breathing and pain sensations to enhance decentering, meta-awareness, and interoceptive awareness.
214937199|NCT02375490|BEHAVIORAL|Healthy Start|Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal, interpersonal, organizational, community and physical environment and political levels. These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
214937200|NCT00181350|DEVICE|Relocatable fixation system|
214674884|NCT05383157|OTHER|Usual care|Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
214937201|NCT02899559|BEHAVIORAL|Message|Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
214937202|NCT03606538|DRUG|Midomafetamine HCl|80 mg midomafetamine HCl
214937203|NCT02836964|DEVICE|Crown placement|Dental implant
214937204|NCT03364764|DRUG|Sirolimus|On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
214937205|NCT00850304|DRUG|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
214937206|NCT00850304|DRUG|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
214937207|NCT01661933|BIOLOGICAL|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
214937208|NCT01661933|BIOLOGICAL|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
214674885|NCT05872438|DIAGNOSTIC_TEST|Vaginal, Oral and anal sampling|The patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed.
214674886|NCT00608335|DRUG|Micafungin|IV
214674887|NCT04570943|COMBINATION_PRODUCT|Gabrinox|"Regimen: GEMBRAX~Other Names:~Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²~Regimen: FOLFIRINOX~Other Names:~Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²~Gembrax + Folfirinox = GABRINOX"
214674888|NCT04570943|RADIATION|MRI-GUIDED STEREOTACTIC RADIOTHERAPY|"Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox.~Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended."
214674889|NCT05043116|DIETARY_SUPPLEMENT|Cholecalciferol D3|2000 IU of Vitamin D provided as oral suspension for one year
214674890|NCT05043116|OTHER|Oral placebo suspension|Oral suspension with no active substance tasting like the active supplement.
214674891|NCT05720910|OTHER|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway
214674892|NCT02699515|DRUG|MSB0011359C|Subjects with metastatic or locally advanced solid tumors received intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
214674893|NCT06523426|DIAGNOSTIC_TEST|Patient treated by spinal endoscopy|Questionnaire administered by surgeon; assessment of level of autonomy for activities of daily living
214674894|NCT06362408|DRUG|Dexmedetomidine|Older patients who have used dexmedetomidine(safe use range: 0.2\~1.0 μg/(kg·h)) for anesthesia induction or maintenance during surgery were classified as the DEX group. On the contrary, patients who did not use dexmedetomidine throughout the entire anesthesia process were identified as the Non-DEX group.
214674895|NCT06099717|DEVICE|Dual-cantilevered implant bridge|A 3-unit supported by one implant in the middle
214674896|NCT06099717|DEVICE|3-unit iFDP|3-unit fixed dental prosthesis supported by two implants
214336573|NCT07023679|DRUG|Morphine|Morphine (10 mg, 10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
214336574|NCT07023679|DRUG|saline placebo|Saline (10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
214336575|NCT07029347|DEVICE|Strength of the dominant and non-dominant hip muscles using hydraulic pusj pull dynamometer|fleksor, ekstensor, abductor, adductor, internal rotasi, eksternal rotasi
214336576|NCT07029347|DEVICE|Static balance parameters using stabilometry|Center of Pressure (COP) range sway, velocity sway, dan weight distribution
214336577|NCT07032961|OTHER|Collect epidemiological, diagnostic, and follow-up data after MCG examination.|MCG System: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd.
214336578|NCT07040332|OTHER||No intervention
214937209|NCT05353582|DRUG|Preoperative systematic therapy|6 cycles of mFOLFOXIRI±Bev is administrated before CRS+HIPEC. Irinotecan165mg/m2 IV day 1, oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted. Bev will not be administrated in at the last two cycles for minimizing surgery complications.
214937210|NCT05353582|PROCEDURE|CRS+HIPEC|CRS+HIPEC aims to achieve CC0/CC1 resection. Oxaliplatin or mitomycin C is determined by the treating physician.
214336579|NCT07042763|PROCEDURE|Cutaneous Suture|Subciliary incision followed by closure using skin sutures only. The skin was closed with 5-0 nylon using subdermal interrupted sutures. No closure of the periosteal plane was performed.
214336580|NCT07042763|PROCEDURE|Periosteal Suture|Subciliary incision followed by closure of both the periosteum and skin layers. The periosteum was closed with absorbable 4-0 Vicryl sutures, and the skin was closed with 5-0 nylon using subdermal sutures.
214336581|NCT07046520|BEHAVIORAL|High intensity interval training|HIIT protocol was performed three times per week over a 10-week period, totaling 30 sessions. HIIT sessions included: (1) a standardized warm-up of five minutes of continuous jogging at 50%MAS, followed by five minutes of dynamic mobility and activation drills such as high-knee skips, high-knee running, and butt kicks. (2) a HIIT training session, consisted of four series of 15-second runs at 90-105% of the maximal aerobic speed (MAS) interspersed with 15 seconds of active recovery and (3) a cool-down of five minutes of static stretching.
214336582|NCT07042685|DRUG|Fruquintinib Combined With Chemotherapy|The intervention in this trial involves administering a combination of 5FU-based chemotherapy and fruquintinib to patients with locally advanced unresectable or metastatic colorectal cancer. Patients receive either the FOLFIRI or mFOLFOX6 regimen, both of which include 5-fluorouracil (5FU), leucovorin (LV), and either irinotecan (FOLFIRI) or oxaliplatin (mFOLFOX6). Fruquintinib is given orally once daily for 21 days in each 28-day cycle. The initial dose of fruquintinib is 4 mg daily for the first three patients to assess safety; if no dose-limiting toxicities are observed, the dose is increased to 5 mg daily for subsequent participants. Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal. After six months, patients with stable disease or better transition to a maintenance phase with 5FU and fruquintinib alone.
214937211|NCT05353582|DRUG|Postoperative chemotherapy|6 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
214937212|NCT05353582|DRUG|Postoperative chemotherapy|12 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
214937213|NCT06605222|DRUG|SHR-7787 injection|Firstly Dose Escalation and Dose Expansion of SHR-7787 injection monotherapy should be conducted.
214937214|NCT05725408|BEHAVIORAL|Dialectical behavior therapy-informed group eating intervention protocol (telehealth)|A 10-week, skills-based group eating intervention. Online/telehealth meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
214336583|NCT06705764|DRUG|Tezepelumab|"Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.~Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90"
214336584|NCT06705764|DRUG|Placebo|Placebo 1.91 ml subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.
214674897|NCT06265532|DRUG|EGCG 300 mg|"Participants will be administered EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
214336585|NCT07047872|PROCEDURE|Computer-Aided Diagnosis|Undergo CAD development for patient-specific external breast prosthesis model
214336586|NCT07047872|PROCEDURE|Prosthetics Intervention|Undergo measurements for external breast prosthesis
214674898|NCT06265532|DRUG|Placebo for EGCG 300 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
214937215|NCT05725408|BEHAVIORAL|Dialectical behavior therapy-informed group eating intervention protocol (in-person)|A 10-week, skills-based group eating intervention. In-person meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments, online) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
214937216|NCT06307691|PROCEDURE|Conventional drilling|Atraumatic extraction, followed by sequential drilling using conventional drills
214937217|NCT06307691|PROCEDURE|Osseodensification drilling|Atraumatic extraction, followed by osteotomy prepared using densah bur (sequential drilling)
214937218|NCT04154462|OTHER|Scribes|Section 507 of the MISSION Act of 2018 mandates a two-year pilot of medical scribes in VA specialty clinics and emergency departments. Medical scribes assist health care providers by helping to administratively expedite an episode of care through the recording of patient information and updating patient records. Scribes are trained but non-licensed professionals, often deployed in emergency departments and outpatient clinic settings, that observe and document patient encounters but do not participate in clinical care.
214336587|NCT07047872|PROCEDURE|Prosthetics Intervention|Undergo fitting for 3D-printed external breast prosthesis
214336588|NCT07047872|PROCEDURE|Prosthetics Intervention|Receive 3D-printed external breast prosthesis
214336589|NCT07047872|OTHER|Questionnaire Administration|Ancillary studies
214336590|NCT07047131|BIOLOGICAL|GTO® (fully resorbable bone substitute)|Collagenated heterologous cortico-cancellous porcine bone mix + thermogelling copolymer with collagen (GTO®, OsteoBiol®, Tecnoss®)
214937219|NCT05161455|BIOLOGICAL|platelet rich fibrin|we would like to measure the effect of PRF on soft and hard tissue healing
214937220|NCT03731559|DRUG|DTG 50 mg OD with food|Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
214937221|NCT03731559|DRUG|DTG 50 mg BID|Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
214937222|NCT06511206|DIETARY_SUPPLEMENT|25g MCT-based nutrient mix|The 25g MCT-based nutrient mix will be consumed two hours after breakfast.
214937223|NCT06511206|DIETARY_SUPPLEMENT|25g MCT-based nutrient mix + cofactors|The 25g MCT-based nutrient mix + cofactors will be consumed two hours after breakfast.
214937224|NCT06511206|DIETARY_SUPPLEMENT|non-ketogenic control|The non-ketogenic control will be consumed two hours after breakfast.
214937225|NCT06142942|OTHER|Exercise Intervention|Participants will complete an exercise intervention where they will exercise 2, 3, or 4 days per week for 4 weeks.
214937226|NCT03238885|DIAGNOSTIC_TEST|pelvic MR examination|All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.
214937227|NCT05398185|DEVICE|CleverCap|The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
214937228|NCT05477485|BEHAVIORAL|Experimental: AIMS program - patient|Patient-level support will be offered to eligible Virginia Medicaid enrollees who have a late ART prescription refill(s) by \>30 days. Support will come from the provider, pharmacy, managed care organization or the community. Patient-level support will involve direct linkages and referrals for participants with a late ART prescription refill(s) \>30-60 days. Support will intensify as the gap in ART prescription(s) fills increases. For those with a late ART prescription refill(s) for \>60 days, added patient-level support will include warm health technology via PositiveLinks, a mobile app program promoting better health through self-monitoring tools, educational resources, direct messaging with program staff and a confidential user community board.
214937229|NCT05477485|OTHER|No Intervention/Usual care|Participants in the usual care arm will receive standard state-level care for late ART prescription refill(s) for Virginia Medicaid enrollees living with HIV.
214937230|NCT06602271|DRUG|PF614 capsule|Experimental oxycodone prodrug
214937231|NCT06602271|DRUG|Placebo|Inactive medication
214937232|NCT06602271|DRUG|Oxycodone HCl 10 mg|Active comparator
214937233|NCT05983120|OTHER|Education|Educate the patients who suffer from Type 2 Diabetes Mellitus
214937234|NCT02720744|DRUG|FT218|
214937235|NCT02720744|DRUG|Placebo|
214937236|NCT06328881|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214336591|NCT07047131|BIOLOGICAL|Apatos® (partially resorbable bone substitute)|Porcine cortical bone granules (Apatos Cortical®, OsteoBiol®, Tecnoss®) stabilized with TSV Gel®, a thermogelling copolymer with collagen.
214336592|NCT06722586|DRUG|Sirolimus|Sirolimus two pills (1mg) per day
214336593|NCT06722586|DRUG|Placebo|Placebo two pills per day
214336594|NCT07041814|DRUG|Oral estradiol valerate|Progynova is an oral hormone replacement therapy containing the active ingredient estradiol valerate, a synthetic ester of 17β-estradiol that, upon ingestion, is rapidly converted to bioidentical estradiol. Each film-coated tablet delivers either 1 mg or 2 mg of estradiol valerate, with inactive excipients including lactose monohydrate, maize starch, povidone, magnesium stearate, and hypromellose. In terms of pharmacokinetics, oral estradiol valerate undergoes first-pass metabolism in the liver, yielding a peak serum estradiol concentration within 4-8 hours of dosing and a biological half-life of approximately 20 hours. Progynova tablets are supplied in blister packs of 28 tablets, with recommended storage at room temperature (15-30 °C), protected from moisture and direct sunlight.
214336595|NCT07041814|DRUG|Transdermal 17β estradiol|Oestrogel® is a transdermal hormone replacement therapy containing 17β-estradiol in a hydroalcoholic gel formulation designed for topical application. Each pump actuation delivers 0.75 mg of estradiol in a 1.25 g dose of gel, which is formulated with excipients including ethanol, propylene glycol, carbomer, sodium hydroxide, and purified water to ensure consistent hormone release and skin penetration. Upon application to intact skin-typically the forearm or thigh-the gel allows for direct systemic absorption of estradiol, bypassing first-pass hepatic metabolism. Peak serum estradiol levels are generally reached within 6-12 hours post-application, with a half-life of approximately 10-20 hours, resulting in more physiological, steady- steady-state estradiol exposure compared to oral formulations. The gel is supplied in multi-dose pump bottles (150 g), each providing up to 120 actuations.
214336596|NCT03568461|BIOLOGICAL|tisagenlecleucel|Tisagenlecleucel is single infusion.
214336597|NCT07048769|DRUG|Lidocaine|10cc of 1% lidocaine buffered with 1cc 8.4% sodium bicarbonate, injected at 4 and 8 o'clock paracervical positions.
214336598|NCT07048769|PROCEDURE|Sham paracervical block|A capped needle is pressed at 4 and 8 o'clock positions to mimic lidocaine block without injection.
214347319|NCT02897804|BEHAVIORAL|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214674899|NCT06265532|DRUG|EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
214674900|NCT06265532|DRUG|Placebo for EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
214674901|NCT04185610|OTHER|Qi Gong|Guided Qi Gong class
214937237|NCT06328881|DEVICE|Intermittent Oro-esophageal Tube|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214937238|NCT06328881|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214937239|NCT05525442|PROCEDURE|percutaneous cholecystostomy|Transhepatic gallbladder drainage was performed under ultrasound guidance after local anesthesia was administered by interventional radiology to patients with acute cholecystitis. Subsequently, an 8-10 Fr pigtail catheter was inserted into the gallbladder using a guide wire under fluoroscopy.
214937240|NCT02406300|PROCEDURE|Subarachnoid Anesthesia|
214937241|NCT02406300|PROCEDURE|PNB/GA|
214937242|NCT02406300|DRUG|ropivacaine|
214937243|NCT02406300|DRUG|sevoflurane or desflurane|
214937244|NCT02406300|DRUG|bupivacaine or levobupivacaine|
214937245|NCT01520142|DRUG|JNJ-26528398|In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
215073603|NCT06890000|OTHER|Control (Standard treatment)|"Conventional Treatment includes TENS (100 Hz) with hotpack (20 minutes), Stretching exercises (posterior capsule and pectoral muscle), resisted flexion and abduction exercises.~The rowing, external rotation and punching exercises will do with theraband. When participants complete the elastic band exercises easily and do not report any muscle fatigue, they will move on to the next level of difficulty. The color order of the bands is yellow, red, green and blue. The exercises will begin with the yellow elastic band, which provides the least resistance.~The intervention will last for 6 weeks, with 2 training sessions per week and each training session lasting 30-45 minutes."
215073604|NCT06896955|OTHER|PMR+VR Education|PMR and VR education
214674902|NCT01783522|DRUG|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
214674903|NCT01783522|OTHER|quality-of-life assessment|Ancillary studies
214674904|NCT01783522|OTHER|placebo|Given PO
214674905|NCT02948231|DEVICE|Mistral implantation|Mistral Implant is implanted in the Mitral valve
215073605|NCT06896955|OTHER|PMR Education|PMR education
214937246|NCT01520142|DRUG|Placebo|In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
215073606|NCT06838663|PROCEDURE|Robotic assisted Cruciate-Retaining (CR) TKA procedures|Patients who underwent Cruciate Retaining (CR) total knee arthroplasty (TKA)
214674906|NCT00375934|DRUG|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
214937247|NCT01942499|OTHER|Community-based exercise program|
214937248|NCT01447446|DRUG|Peg-IFN Alfa-2a|Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
214937249|NCT01447446|DRUG|Peg-IFN Alfa-2b|Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
214937250|NCT01447446|DRUG|Ribavirin|Ribavirin according to standard of care and in line with local labeling.
214937251|NCT01447446|DRUG|Boceprevir|Boceprevir according to standard of care and in line with local labeling.
214937252|NCT01447446|DRUG|Telaprevir|Telaprevir according to standard of care and in line with local labeling.
214937253|NCT03530787|OTHER|Acetyl Zingerone Topical Cream|Topical cream with an active acetyl zingerone component.
214937254|NCT03530787|OTHER|Topical cream|Topical cream without an active acetyl zingerone component and just the carrier cream.
214937255|NCT03494972|DRUG|Tetracyclin ointment|During 3rd molar surgery
214674907|NCT00375934|DRUG|Placebo|Oral placebo capsule, every 6 hours
214674908|NCT02645747|DRUG|Aflibercept (Eylea, BAY86-5321)|"Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency."
214674909|NCT06029816|DRUG|Neratinib tablets|Neratinib tablets
214674910|NCT06378658|DRUG|BAY2927088|Oral administration
214674911|NCT06378658|DRUG|Esomeprazole|Oral administration
215073607|NCT06838663|PROCEDURE|Robotic assisted Bi-Cruciate Stabilized (BCS) TKA procedures|Patients who underwent Bi-Cruciate Stabilized (BCS) total knee arthroplasty (TKA)
215073608|NCT06860490|DRUG|Sintilimab|Sintilimab will be administered by IV, 200 mg on day 1 of each 21 day cycle.
214674912|NCT06378658|OTHER|Food|light low-fat meal or high fat, high calorie meal
214674913|NCT00893113|DRUG|Placebo|Alfuzosin-matched One tablet once daily
214674914|NCT00893113|DRUG|Alfuzosin|10 mg once daily
214674915|NCT02654327|DEVICE|VV-ECCO2R to enable lower tidal volume mechanical ventilation|In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
214937256|NCT05774795|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement to treat mitral regurgitation
214937257|NCT05774795|PROCEDURE|Aortic valve surgery|Aortic valve replacement to treat aortic regurgitation
214937258|NCT02961322|OTHER|lobo-isthmectomy assisted robot|
214674916|NCT01025180|OTHER|Procalcitonin level|"The duration of antibiotic treatment is based on PCT level:~* \< 0.25 ng/ml: antibiotic should be stopped~* 0.25 \< PCT \<0.5: antibiotic prescription is not recommended~* \> 0.5 ng/ml: antibiotic should be used"
214674917|NCT04192448|OTHER|Alcohol Administration|The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).
214674918|NCT04192448|OTHER|Mood Induction|The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
214674919|NCT01842061|BEHAVIORAL|Active Living Program|
214674920|NCT01842061|BEHAVIORAL|Education|
214674921|NCT01959867|DEVICE|SurgiMend® PRS|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
214674922|NCT01959867|OTHER|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
214937259|NCT00403650|DRUG|Iloprost|Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
214937260|NCT04938219|OTHER|Gloves filled with warm tap water|The intervention in the treatment group will consist of nonsterile gloves, filled with regular tap water at a comfortable warm temperature and sealed with a plastic clip. The temperature of the water will not be measured, the investigators will take a temperature that feels comfortable in their hands
214937261|NCT02174913|DEVICE|bispectral index|Bispectral index (BIS) is one of several technologies used to monitor depth of anesthesia.
214937262|NCT02174913|DRUG|Target controlled infusion of propofol|TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups
214937263|NCT02174913|DRUG|Fentanyl|Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.
214937264|NCT02174913|DRUG|Atracurium|Atracurium 0.6 mg/kg is used for endotracheal intubation
215073609|NCT06860490|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle.
215073610|NCT06860490|PROCEDURE|HAIC|FOLFOX regimen (oxaliplatin, 85 mg/m2 from hour 0-2 on day 1; leucovorin, 400 mg/m2 from hour 2-3 on day 1; and ﬂuorouracil, 400 mg/m2 bolus at hour 3 on day 1 and 2,400 mg/m2 over 24 hours) via infusion via the hepatic artery. HAIC was repeated once every 3 weeks for up to four cycles. Sintilimab plus bevacizumab will be administered 1-3 days after HAIC.
215073611|NCT06888869|OTHER|Other: Clinical rehabilitation group|Rehabilitation training for twice a week, total 12 weeks in hospitals.
215073612|NCT06888869|OTHER|Other: Home-based rehabilitation group|Rehabilitation training for twice a week, total 12 weeks at home.
214937265|NCT05168332|BEHAVIORAL|patellar taping combined with isometric strength training|patellar taping combined with isometric strength training
214937266|NCT05168332|BEHAVIORAL|sham patellar taping combined with isometric strength training|sham patellar taping combined with isometric strength training
214937267|NCT02262000|RADIATION|Image Guided Stereotactic Ablative Radiotherapy|
214937268|NCT02750007|DRUG|HS-20004|
214937269|NCT06621069|DRUG|Bisphosphonates|Alendronate Sodium or Zoledronic acid
214937270|NCT06621069|OTHER|Control|control without BP
215073613|NCT06897176|DRUG|Cerebrolyisin|This intervention uses Cerebrolysin, which is a treatment aimed at improving language abilities and providing neuroprotection for patients with non-fluent aphasia following a stroke. Cerebrolysin is administered via intravenous injection, with the goal of improving language skills and promoting brain function recovery. The treatment is evaluated based on improvements in language abilities, neurological function recovery, and safety.
214336599|NCT07044804|DEVICE|Active Group (Active Anodal tDCS to the left IFG or Cathodal tDCS to the left IFG)|Participants in the active tDCS group (Anodal tDCS or Cathodal tDCS) will receive stimulation set at 1 mA (milliampere), with a duration of 20 minutes per session. The stimulation will be administered in five consecutive sessions per day, five days a week, for two weeks, totaling 10 sessions, while participants will also undergo logopedic treatment for 20 minutes. The training protocol will consist of 10 minutes of training in motor planning and programming abilities and 10 minutes of training on the lexical, morphosyntactic, and functional aspects of language and communication.
214336600|NCT07044804|DEVICE|Sham Group|For the sham condition, the same electrode placement will be used as in the anodal tDCS condition, but the current will be applied for 30 s and will be ramped down without the participant's awareness. Stimulation intensity will be set at 1 mA; the duration of stimulation will be 20 min and will be held five consecutive daily session per week for two weeks, for a total of 10 sessions. During the tDCS sessions participant will sit in a comfortable chair and a language training will be administered
214336601|NCT07051525|DRUG|Early antibiotic cessation alert|For all patients, antibiotics will be commenced at onset of fever. For those in the intervention arm an alert will fire in the electronic medical record once a patient is afebrile for 48-96 hours and clinically stable.
214937271|NCT01752153|DRUG|Desferrioxamine, Legalon® (Silymarin)|Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
214937272|NCT01752153|DRUG|Silymarin (Legalon)|
214937273|NCT02564640|DEVICE|videolaryngoscope|patients intubated by using the videolaryngoscope
214937274|NCT02564640|DEVICE|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
214937275|NCT05704335|OTHER|Questionnaire administration|A trained physician will administer a structured questionnaire
214937276|NCT01230424|DRUG|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
214937277|NCT01230424|DRUG|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
214937278|NCT05449535|DRUG|JYB1904|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
214674923|NCT01757639|BIOLOGICAL|Ipilimumab|Given IV
215073614|NCT06897176|DRUG|Placebo|The placebo is administered alongside standard language therapy to the patients with non-fluent aphasia following a stroke. This allows for comparison with the Cerebrolysin group to assess the impact of the treatment on language abilities and neurological function recovery. The goal is to evaluate the improvements in language skills, neurological function recovery, and safety, comparing the effects between the active treatment and placebo.
214674924|NCT01757639|OTHER|Laboratory Biomarker Analysis|Correlative studies
214674925|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV + 320 mg LNG|DPV VR, containing 200 mg DPV
214674926|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV|DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
215073615|NCT06894069|DRUG|Dexamethasone|a 2 ml solution of dexamethasone (3.3mg/ml) will be flushed in the root canal and intentionally extruded to the periradicular tissues to assess its potnetial sedative effect
215073616|NCT06894069|OTHER|Placebo|2ml of normal saline will be used as placebo to be flushed and extruded through the canals to the periradicular tissues
214347320|NCT02897804|BEHAVIORAL|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214937279|NCT05449535|DRUG|Omalizumab|Dosage form: injection, powder, lyophilized, for solution； Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.
214937280|NCT05449535|DRUG|JYB1904 Placebo|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
214937281|NCT01128218|DRUG|Tumor fluorescence|"Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2"
214937282|NCT02813005|PROCEDURE|Jet ventilation group|MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
214937283|NCT02813005|PROCEDURE|Standard ventilation group|apnea made by the anesthesiologist to the request of the radiologist
215073617|NCT02902302|DRUG|Ibuprofen 400 mg/10 mL oral suspension|
215073618|NCT02902302|DRUG|MOMENT 400 mg coated tablet|
215073619|NCT01846299|OTHER|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
215073620|NCT01846299|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
215073621|NCT06112080|DEVICE|RESP™ Biosensor|The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
215073622|NCT06149221|DEVICE|NTAP|Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline
215073623|NCT04974827|DRUG|Camrelizumab|200mg/3weeks
214937284|NCT06623045|OTHER|Pelvic floor muscle training intervention|"The training program consisted of 12 weeks of PFM exercises, 3 times per week, with each session lasting between 10 and 15 minutes. The program followed different stages through the weeks: (1) proprioception of pelvic floor muscles activation and integration with diaphragmatic breathing, (2) stabilization and strengthening of the pelvic floor musculature through progressive overloading, and (3) transference of these exercises to FFT practice. During the 12 weeks, short contractions (2) were combined with longer ones (5 to 10), carrying out the progressive overload by increasing the number of contractions, the duration of the contraction, or by evolving the execution position towards more upright postures and sporting movements."
214937285|NCT04395612|DRUG|niraparib combined with brivanib|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
214937286|NCT04395612|DRUG|niraparib combined with toripalimab|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.
214937287|NCT05148403|DRUG|glibenclamide|Glibenclamide was given orally or by nasal feeding
214937288|NCT06521255|DRUG|Tafasitamab|Tafasitmab was infused intravenously
214937289|NCT06521255|DRUG|Lenalidomide|Lenalidomide orally
214937290|NCT06521255|DRUG|Gemcitabine|Gemcitabine was infused intravenously
214937291|NCT06521255|DRUG|Oxaliplatin|Oxaliplatin was infused intravenously
214937292|NCT06521255|DRUG|Rituximab|Rituximab was infused intravenously.
215073624|NCT04974827|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
214674927|NCT03387904|DRUG|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
214937293|NCT05642624|DRUG|Deoxycholic acid amphotericin B|Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
214674928|NCT03387904|DRUG|Irinotecan|Irinotecan Day 1,8 ivgtt
214674929|NCT01724606|RADIATION|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
215073625|NCT03023774|DRUG|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
215073626|NCT00725192|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
215073627|NCT00725192|BEHAVIORAL|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
215073628|NCT01730326|DRUG|Paracetamol|1000 mg
215073629|NCT01730326|DRUG|Dexketoprofen|50 mg
215073630|NCT02251561|DEVICE|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
215073631|NCT02251561|DEVICE|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
214937294|NCT03536949|DRUG|RVL-1201|RVL-1201 ophthalmic solution, 0.1%
214937295|NCT03536949|OTHER|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
215073632|NCT02251561|DEVICE|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
214674930|NCT01724606|DRUG|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
214937296|NCT03932149|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|The target is left DLPFC and the iTBS protocol is: 70% of RMT; triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
214937297|NCT03932149|DEVICE|Sham stimulation|The target is right DLPFC and the sham stimulation protocol is: triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
214937298|NCT00435435|DRUG|Disulfiram|
214937299|NCT00435435|DRUG|Acamprosate|
214937300|NCT00435435|DRUG|Naltexone|
214937301|NCT04815499|DIETARY_SUPPLEMENT|Food supplement|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
214937302|NCT04815499|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
214937303|NCT06623500|DIETARY_SUPPLEMENT|Iodine excess|Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration (median urinary iodine levels in children aged 8-10 years old)≥300μg/L
214937304|NCT06623500|DIETARY_SUPPLEMENT|Iodine suitable|Iodine suitable areas：water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
214937305|NCT01425970|DRUG|INX-08189|Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
214937306|NCT01425970|DRUG|INX-08189|Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
215073633|NCT04741958|DIAGNOSTIC_TEST|Ultrasound Guided Peripheral Thoracic Tumors|Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
215073634|NCT01961856|DRUG|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
215073635|NCT01961856|DRUG|Ticagrelor|Ticagrelor 180mg loading dose
215073636|NCT00496483|DRUG|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
214937307|NCT01425970|DRUG|INX-08189|Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
214937308|NCT01425970|DRUG|Placebo matching with INX-08189|Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
214336602|NCT07051616|BEHAVIORAL|Child laughter video|1 hour after the chemotherapy treatment was started, the video monitor was placed at a height where the patient could see comfortably while lying down and the video, which was checked and prepared beforehand, was turned on full screen. The appropriate volume was adjusted and the patient was allowed to watch the video for 10 minutes without any other intervention. The video was then stopped and the etagere was removed from in front of the patient. Chemotherapy was continued. At the 2nd hour of chemotherapy, the disinfected etagere and computer were placed in a position where the patient could see them comfortably and the 2nd video was started and the patient was allowed to watch the video for 10 minutes.
214937309|NCT01425970|BIOLOGICAL|Pegylated interferon alfa-2a|Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
214937310|NCT01425970|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
214937311|NCT01425970|DRUG|INX-08189|Tablet, Oral, 200 mg, QD, 12 weeks
214937312|NCT01425970|DRUG|Daclatasvir|Tablet, Oral, 60 mg, QD, 12 weeks
214674931|NCT02400346|DRUG|Adjunct brexpiprazole|"Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.~Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg."
214674932|NCT02400346|DRUG|ADT|Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
214674933|NCT01269125|DRUG|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
214937313|NCT04058106|PROCEDURE|A patient who need the cerebral artery aneurysm clipping surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
214674934|NCT01269125|PROCEDURE|IVF|Assisted Reproduction Technique.
214674935|NCT04579081|DEVICE|Contour Neurovascular System|Intrasaccular flow disruptor/divertor
214674936|NCT06573489|DRUG|Fospropofol|Use fospropofol for general anesthesia maintenance
214937314|NCT06293118|DEVICE|Ischemic conditioning group|The ischemic conditioning protocol will consist of a period of 12 weeks (24 sessions) with a frequency of 2 weekly sessions lasting between 15 and 20 minutes each. Therapy will be performed bilaterally on the upper limbs. The ischemic conditioning group will perform 4 times, 8 cycles with 30 seconds of ischemia (80 - 200 mmHg) with 5 seconds of reperfusion in each cycle. Ischemia cycles are controlled by a device (KAATSU C3 - KAATSU GLOBAL / USA) with customized ischemia programs, partially restricting blood flow through special pressure cuffs that are internally valved, providing greater comfort and safety for these patients who typically have stiffness in the affected limb and localized muscle pain. In the first cycle, participants will be subjected to pressures of 80 to 150 mmHg. In the 3 subsequent cycles, pressures from 130 to 200 mmHg will be applied.
214937315|NCT06293118|DEVICE|Sham group|Participants in the control group (Sham) will perform 4 cycles of 5 minutes of ischemia (30 mmHg) with 4 subsequent cycles of reperfusion (rest) bilaterally in the arms with a sphygmomanometer
214937316|NCT01721915|DRUG|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
214937317|NCT01721915|DRUG|Placebo|
214937318|NCT05471570|DEVICE|tDCS stimulation|The study examines the effect of excitatory stimulation of right inferior frontal gyrus (IFG) on naming abilities of people with aphasia (PWA) as compared to sham stimulation to examine the compensatory versus interference role of right hemisphere in language recovery after stroke.
214937319|NCT03441607|DRUG|mHACMb|Active ingredient
214937320|NCT03441607|OTHER|placebo|inactive ingredient
214674937|NCT06573489|DRUG|Propofol|Use propofol for general anesthesia maintenance
214674938|NCT00318838|DRUG|Azimilide dihydrochloride|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
214674939|NCT00318838|DRUG|Placebo|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
214674940|NCT03556722|DEVICE|Repetitive Transcranial Magnetic Stimulation.|High frequency rTMS on left dorsolateral prefrontal cortex.
214674941|NCT03556722|DEVICE|Sham rTMS|Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
214674942|NCT01283581|DRUG|Delafloxacin|300mg IV every 12 hours for 5-14 days
214674943|NCT01283581|DRUG|Linezolid|600mg IV every 12 hours for 5-14 days
214674944|NCT01283581|DRUG|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
214674945|NCT01682369|BIOLOGICAL|TIV (Aggripal)|
214937321|NCT06648109|DEVICE|Electric Blanket|Participants were randomized to groups A and B. When the subject\&#39;s group cohort went through the intervention phase (instead of the control phase), they received a 7-day, 8-hour intervention with an electric blanket +5±1°C above room temperature.
214336603|NCT07051278|DEVICE|Method Comparison|Quantifying the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for ctBil and FHbF in heparinized capillary whole blood samples in capillary measuring mode (C65).
214336604|NCT07051876|DEVICE|Mouthguard and Physiotherapy|The mouthguard and physiotherapy group will receive a custom-fitted mouthguard along with a physiotherapy program. The home-based physiotherapy exercises will include posture improvement routines, relaxation techniques, and targeted therapy for the muscles of the head, neck, and shoulders. These sessions will be performed daily at home for a duration of six weeks. Each participant will sign a consent form approved by the Ethics Committee of Saint Joseph University.
214336605|NCT07051876|DEVICE|Mouthguard Only|The mouthguard only group will receive a custom-fitted mouthguard, which will be fabricated by a qualified dentist. The mouthguard will be worn during sleep for 6 weeks. Participants will be instructed to clean the mouthguard daily and to store it in a cool, dry place.
214336606|NCT07052227|DEVICE|Delfi blood flow restriction cuff|Leg press exercise with Delfi blood flow restriction cuff
214336607|NCT07052227|DEVICE|Fitcuffs|Leg press exercise with Fitcuff blood flow restriction cuff
214336608|NCT07052227|OTHER|Control|Leg press exercise with no blood flow restriction cuff
214336609|NCT07051369|DIAGNOSTIC_TEST|Portal Hypertension diagnostics|his study aims to determine the frequency of portal hypertension among patients with cirrhotic liver using ultrasound.A cross-sectional study will be conducted at Sheikh Zaid Medical College and Hospital, Rahim Yar Khan,
214336610|NCT07051603|DRUG|SAL0140|In this part, SAL0140 tablets will be administered as a single or multiple oral dose.
214937322|NCT02901275|DRUG|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
214937323|NCT02378415|DRUG|Ketamine|IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
214937324|NCT02378415|DRUG|Placebo|Normal Saline Infusion
214937325|NCT04888715|DRUG|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
214937326|NCT04888715|DRUG|Pirfenidone|Pirfenidone
214937327|NCT04888715|DRUG|Nintedanib|Nintedanib
214937328|NCT02063178|BEHAVIORAL|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
214336611|NCT07051603|DRUG|SAL0140 placebo|In this part, SAL0140 placebo tablets will be administered as a single or multiple oral dose.
214937329|NCT02063178|BEHAVIORAL|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
214937330|NCT02063178|BEHAVIORAL|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
214674946|NCT01682369|BIOLOGICAL|ATIV (Fluad)|
214674947|NCT00959296|DEVICE|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
214336612|NCT07052643|OTHER|Image and data collection|Evaluation of the photographs by four independent raters
214336613|NCT07051889|PROCEDURE|Lower Trapezius Tendon Transfer|This procedure is performed arthroscopically. The lower trapezius tendon is harvested from the back of the shoulder blade. A donor tendon is then used to extend the lower trapezius tendon so that it can reach the top of the arm bone. The tendon graft is then attached to the top of the arm bone, while the other end remains attached to the lower trapezius tendon itself. Any additional concomitant procedures (e.g. debridement, biceps release…etc.) may be performed as well.
215073637|NCT00496483|DRUG|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
215073638|NCT06320548|DIETARY_SUPPLEMENT|Low-residue diet|Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.
215073639|NCT06320548|DIETARY_SUPPLEMENT|Free diet|Patients had free diet.
214674948|NCT00486226|DEVICE|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
214674949|NCT05682807|DRUG|Caffeine|5-10 mg/kg/day IV maintenance dose given after 24 h for 2 months.
214674950|NCT05682807|DRUG|Probiotic Formula|probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months.
214674951|NCT02983903|PROCEDURE|transbronchial biopsy|
214937331|NCT02063178|BEHAVIORAL|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
214937332|NCT02063178|BEHAVIORAL|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
214937333|NCT02063178|BEHAVIORAL|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
214937334|NCT02063178|BEHAVIORAL|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
214336614|NCT07051889|PROCEDURE|Partial Rotator Cuff Repair|This procedure is performed arthroscopically. The massive rotator cuff tear will be repaired by securing the loose tendon ends to the bone with suture anchors. The surgeon may also conduct a debridement of the area to remove any broken-down cartilage and tissues. Finally, the biceps tendon in will be further inspected for any damage or inflammatory changes, and the tendon may be released at the discretion of the surgeon (known as a biceps tenodesis or tenotomy depending on technique).
214674952|NCT01869894|PROCEDURE|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
214937335|NCT02063178|BEHAVIORAL|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
214937336|NCT02063178|BEHAVIORAL|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
214937337|NCT02063178|BEHAVIORAL|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
214937338|NCT02063178|BEHAVIORAL|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
214937339|NCT03023111|DRUG|Sbv|Standard treatment for CL, parenteral drug used during 20 days.
214937340|NCT03023111|DRUG|Miltefosine plus placebo|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
214937341|NCT03023111|DRUG|Miltefosine plus GM-CSF|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
214937342|NCT02718183|OTHER|Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)|bleaching teeth gel to intracameral use.
214937343|NCT02718183|OTHER|carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).|bleaching teeth gel to intracameral use.
214937344|NCT02657577|OTHER|There is no intervention|There is no intervention
214336615|NCT07052487|PROCEDURE|Post-Isometric Relaxation (PIR)|A manual physiotherapy technique applied to the gluteus maximus, iliopsoas, piriformis, and hamstrings. Each session begins with 10 minutes of transcutaneous electrical nerve stimulation (TENS) and moist heat (hot-pack), followed by three cycles per muscle group of: a 10-second isometric contraction against the therapist's counterforce, 5-second relaxation, and 30-second passive stretch. Sessions are delivered thrice weekly for eight weeks (24 sessions total).
214336616|NCT07052487|PROCEDURE|Simple Stretching Exercises (SSE)|A set of four static stretches targeting the gluteus maximus, iliopsoas, piriformis, and hamstrings. Each session begins with 10 minutes of TENS and hot-pack application, followed by ten repetitions of each stretch held for 10 seconds. Sessions are delivered thrice weekly for eight weeks (24 sessions total).
214336617|NCT07052253|DRUG|TT-00420 (tinengotinib)|oral
214336618|NCT07052253|DRUG|AK104|intravenous
214336619|NCT07052253|DRUG|AK112|intravenous
214937345|NCT04669951|OTHER|uPAR immunohistochemistry|Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
214937346|NCT06622577|DIETARY_SUPPLEMENT|Cysteine|Cysteine supplementation would be given according to the 2001 ROSS guidelines for the HCU. Cys amino acid supplements are available in the form of powder, each sachet containing 4gm which provides 500mg of Cys per sachet that is available in HMC medical store from where patients receive the medical formula and food at free of cost. The dosage of cysteine will be calculated according to the weight of the patient with the age specific recommendation and prescribed by the metabolic dietitian which will be approved by the metabolic physician prior to the supply of cysteine supplements to the patients. It is not known to have any serious adverse events that is life threatening. A single arm interventional study is opted as the intervention involves all the participants without withholding the treatment. Moreover, a single arm interventional study on cysteine supplementation aims to provide evidence on its efficacy contributing to the advancement of clinical practice in HCU management.
214336620|NCT07051291|DIETARY_SUPPLEMENT|Instant Coffee Capsule|Participants received 1.7 grams of instant coffee in the form of three capsules. 200 mL of plain water was provided to participants to swallow the three capsules.
214336621|NCT07051291|DIETARY_SUPPLEMENT|Instant Coffee Beverage|Dissolved 1.7 grams of instant coffee in 200 mL of hot water to make a coffee beverage.
214937347|NCT06463483|DEVICE|Medtronic 780G System|Automated insulin delivery using Medtronic 780G system
214937348|NCT06463483|DEVICE|Continuous Glucose Monitoring|Usual care with continuous glucose monitoring
214937349|NCT03149120|BIOLOGICAL|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
214937350|NCT03149120|DRUG|Pazopanib|Pazopanib given at a dose of 800 mg by mouth daily.
214937351|NCT03265548|DEVICE|Video Laryngoscope|The use of video laryngoscopy
215073640|NCT01925495|OTHER|varied middle-ear pressure|
215073641|NCT01925495|DRUG|varied middle-ear gas composition|
215073642|NCT01925495|OTHER|varied ear-canal pressure|
215073643|NCT00230802|DRUG|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
215073644|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
215073645|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
215073646|NCT03095027|DEVICE|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
215073647|NCT03095027|DEVICE|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
214336622|NCT07052019|DEVICE|Virtual Reality Distraction|Children wear virtual reality glasses during restorative dental treatment to reduce pain and anxiety.
214336623|NCT07052019|BEHAVIORAL|Tell-Show-Do Technique|Conventional behavioral technique where the dentist tells, shows, and then performs the procedure to reduce anxiety and build cooperation.
214336624|NCT06797518|DRUG|Iptacopan|LNP023 oral capsule 200 mg b.i.d
214336625|NCT07051447|OTHER|PKRxHD|The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).
214336626|NCT07051447|PROCEDURE|Dialysis|Standard of care dialysis.
214937352|NCT06461065|DEVICE|AIDS|mylife CamAPS application, marketed by CamDiab Ltd, in conjunction with YpsoPump, marketed by by Ypsomed, Dexcom G6 blood glucose sensor, Orbit Infusion sets and Orbit Infusion sets and Orbit inserter (used in their indications)
214937353|NCT06461065|OTHER|Brain MRI|To evaluate the neuroanatomical damage to gray matter associated with type 1 diabetes in young children according to their glycemic profile (AIDS use or not) and compared with an age-matched control subject
214336627|NCT07052383|BIOLOGICAL|DIT309 cell injection|3+3 dose escalation design： Dose Level 1: 4.0×10\^6/kg CAR+ T cells；Dose Level 2: 1.0×10\^7/kg CAR+ T cells；Dose Level 3: 2.0×10\^7/kg CAR+ T cells.
214336628|NCT07052617|DEVICE|Continuos renal replacement therapy|Different modalities of CRRT: continuous veno-venous hemofiltration; continuous veno-venous hemodialysis and continuous veno-venous hemodiafiltration Different doses of CRRT: low effluent dose (\<15 ml/kg/h); medium-low effluent dose (15-25 ml/kg/h); standard effluent dose (25-30 ml/kg/h); high effluent dose (\>30 ml/kg/h
214336629|NCT07052162|DRUG|Single dose tafenoquine (10 mg/kg) given with water|Participants will receive single-dose TQ as 10 mg/kg taken with water and a low-fat meal (3 plain cracker biscuits; 2% fat). Food (low-fat meal) is taken with both regimens to attenuate any gastrointestinal adverse effects that are related to taking TQ on an empty stomach. Combinations of full or half-tablets will be swallowed whole or crushed lightly (tablets) or dissolved in boiled water (if dispersible tablets are available), as directly observed treatment. Children vomiting within the first 30 minutes of treatment will be withdrawn
214336630|NCT07052162|DRUG|Single dose tafenoquine (10 mg/kg) given with fat|Single-dose TQ as 10 mg/kg taken with 250 mL chocolate flavoured milk (9% fat) and a low-fat meal (3 plain cracker biscuits). Food (low-fat meal) is taken with both regimens to attenuate any gastrointestinal adverse effects that are related to taking TQ on an empty stomach. Combinations of full or half-tablets will be swallowed whole or crushed lightly (tablets) or dissolved in boiled water (if dispersible tablets are available), as directly observed treatment. Children vomiting within the first 30 minutes of treatment will be withdrawn
214674953|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
214674954|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
214674955|NCT04704882|OTHER|omental patchwork|the omental flaps were sewn to lesser omentum and hepatorenal ligament to cover all the vessels
214674956|NCT01259492|DRUG|Placebo|Placebo Comparator: Placebo
214674957|NCT01259492|DRUG|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
214937354|NCT02632240|OTHER|Surgery:The tunnel technique for covering gingival recession|The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
214937355|NCT05314140|DIAGNOSTIC_TEST|Coronary artery calcium score evaluation|The evaluation of the coronary artery calcium score will be performed with chest CT scan
214937356|NCT01440140|OTHER|Closed-loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
214937357|NCT01440140|OTHER|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
215073648|NCT04363255|DRUG|Etoposide Injection|Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
214937358|NCT03260517|DEVICE|Medtronic Coronary Drug-Coated Balloon Catheter|Medtronic Paclitaxel Coronary Drug-Coated Balloon Percutaneous transluminal coronary angioplasty
214937359|NCT02553434|DEVICE|Pigtail catheter|Insertion of pigtail catheter
215073649|NCT04363255|DRUG|Carboplatin Injection|Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
215073650|NCT04363255|DRUG|Cisplatin injection|Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
214674958|NCT01259492|DRUG|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
214674959|NCT01062646|BEHAVIORAL|Multimodal music therapy|
214674960|NCT01062646|BEHAVIORAL|Community treatment as usual|
214674961|NCT04413240|DEVICE|Telerehabilitation|"* VRRS is a medical device to perform cognitive telerehabilitation and home speech therapy in online or offline mode.~* K-Wand is an additional device to VRRS for motor telerehabilitation of the upper limb and trunk. It works with a set of motion sensors through light recognition technology.~* Khymu is a set of sensors added to the VRRS used to carry out motor telerehabilitation activities of the lower limb. The use in combination with the K-Wand is able to allow full-body motor telerehabilitation.~Patients will have at their home a special workstation connected to the internet. The same equipment will also be present in the reference structure. Only the online telerehabilitation mode will be used, including an audio and video teleconference. The rehabilitator will be able to remotely control the patient's system. The patient, will see on his screen the exercises to be performed, their realization and the results achieved."
214937360|NCT04855617|DRUG|Ocrelizumab|"Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.~* Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.~* Subsequent doses: single 600 mg intravenous infusion every 6 months.~* Observe the patient for at least one hour after the completion of the infusion"
214937361|NCT00250458|DRUG|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
214674962|NCT04413240|OTHER|Conventional rehabilitation|It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated.
215073651|NCT04363255|DRUG|Toripalimab|After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.
215073652|NCT04363255|DRUG|Anlotinib hydrochloride|After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
215073653|NCT01255813|DEVICE|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
214336631|NCT06575712|BEHAVIORAL|Step Up|A hybrid in-person and mHealth (mobile health) coping skills training and activity coaching intervention.
214674963|NCT02773758|OTHER|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
214674964|NCT02773758|OTHER|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
214937362|NCT00250458|DRUG|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
214937363|NCT02333721|PROCEDURE|D2 lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
214937364|NCT02333721|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
214937365|NCT01103102|DRUG|Iocide Oral Rinse|Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
214937366|NCT01103102|DRUG|Placebo|Placebo
214937367|NCT05573490|DEVICE|Cognitive Training|Participants will be asked to complete approximately 45 minutes of training, 4-5 sessions per week for 14 weeks (corresponding to approximately 40 hours of training total). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
214937368|NCT05573490|BEHAVIORAL|Tai Chi- Qi Gong|Participants will be asked to complete 14 hours of training total (in 30-minute sessions, 2 days per week for 14 weeks).
214937369|NCT05573490|DEVICE|Brain Games|Participants will be asked to complete 40 hours of training total (in 45-minute sessions, 4 to 5 days per week for 14 weeks). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
215073654|NCT01255813|DEVICE|Stimulation (Full)|Stimulation applied above the perception threshold
215073655|NCT01255813|OTHER|Control|No stimulation applied
215073656|NCT03876691|OTHER|Patients|Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.
215073657|NCT03876691|OTHER|Physician|The current emergency medical department departments within the preparation of the attending physician
214336632|NCT06575712|OTHER|Usual Care Plus (UC+)|Usual medical care plus videos delivering educational content via an app.
214336633|NCT07052149|OTHER|cervical muscle stabilization exercises|deep cervical muscle stabilization exercises, 15 minutes, 3 sessions per week for two months
214336634|NCT07052149|OTHER|Proprioceptive training|proprioceptive training, 15 minutes, 3 sessions per week for two months
214336635|NCT06738719|BIOLOGICAL|CT-P13 SC Auto-Injector|Subcutaneous(SC) Injection
214336636|NCT06738719|BIOLOGICAL|Placebo Auto-Injector|Subcutaneous(SC) Injection
214336637|NCT06926985|BIOLOGICAL|anti-CD19/BCMA CAR NK cells|Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3. Multiple doses of anti-CD19/ BCMA CAR NK cells will infused using the dose-escalation strategy.
214336638|NCT03964454|BEHAVIORAL|WIC support + home-based individual support + Breastfeeding Incentives (SC+BFI)|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives (Breastfeeding Incentives, BFI) contingent on observed breastfeeding.
214336639|NCT03964454|BEHAVIORAL|WIC support + home-based individual support (SC)|Participants randomized into SC will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
214336640|NCT05131100|DRUG|Somavert|As provided in real world practice
214336641|NCT03934268|GENETIC|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
214336642|NCT00358241|PROCEDURE|Nerve block|
214336643|NCT05297994|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
214336644|NCT05297994|BIOLOGICAL|Inactivated influenza split vaccine|solution for intramuscular injection, 0.5 ml
214336645|NCT04866394|RADIATION|SBRT|Patients will be planned with the aim of delivering 30 Gy in 5 fractions.
214336646|NCT00687505|DRUG|FP-1039|Intravenous weekly administration
214336647|NCT04198779|DEVICE|APPLI|The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
214674965|NCT05720611|BEHAVIORAL|Digitally delivered gardening and healthy eating course|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
214674966|NCT05615597|PROCEDURE|Para-discal injection of corticoid|In this pilot study, all patients underwent the same procedure: a corticosteroid infiltration via a para-discal approach. The infiltrations were performed under CT or scopy.
214937370|NCT05573490|BEHAVIORAL|Stretching|Participants will be asked to engage in stretching exercises twice per week, for approximately 15 minutes per session. This will total of approximately 7 hours over the course of 14 weeks.
214674967|NCT04473261|DRUG|Iodine Complex|Iodine Complex capsule (200mg) will be given three times a day
214937371|NCT05213793|DIAGNOSTIC_TEST|multi-delay arterial spin labeling|Multi-delay arterial spin labeling is a new method to evaluate the degree of the cerebral perfusion. It can obtain three parameters including CBF,CBV and ATT without radiation,which is similar to the traditional technology. Multi-delay ASL can provide more information of the acute stroke patients.
214336648|NCT04064697|DRUG|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
214336649|NCT01055392|DRUG|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
214336650|NCT01055392|DRUG|Placebo|Identical placebo tablets were administered twice-a-day for two years.
214336651|NCT02360540|OTHER|Gestalt estimation|
214336652|NCT03120091|DEVICE|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
214336653|NCT03328897|DRUG|Omalizumab|injection of 150mg or 300 mg
214336654|NCT03328897|DRUG|Placebo|Injection of placebo
214336655|NCT00971971|PROCEDURE|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
214336656|NCT00971971|PROCEDURE|Standard SLED|
214336657|NCT05706259|DIETARY_SUPPLEMENT|Soft gelatin 200000 IU vitamin D3 capsule|Weekly single dose for 3-weeks
214937372|NCT05051605|BIOLOGICAL|COVID-19 Vaccine|Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.
214336658|NCT05706259|DIETARY_SUPPLEMENT|Orodispersible (sachet) 200000 IU vitamin D3|Weekly single dose for 3-weeks
214937373|NCT01756105|DRUG|Metformin|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
214336659|NCT03219944|PROCEDURE|Platelet Rich Fibrin|: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone
214336660|NCT03219944|PROCEDURE|sub epithelial connective tissue graft|sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
214336661|NCT00548769|DRUG|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
214336662|NCT00548769|DRUG|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
214336663|NCT00548769|DRUG|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
214336664|NCT00548769|DRUG|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
214937374|NCT01756105|DRUG|Rapid acting analog insulin Intermediate acting NPH Insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is \> to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is \> 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is \> 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
214937375|NCT05666128|DRUG|HD-6277|HD-6277 100mg
214937376|NCT05666128|DRUG|HD-6277|HD-6277 50mg
214937377|NCT05666128|DRUG|Placebo|Placebo
214937378|NCT00735293|DEVICE|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
214937379|NCT03051698|DRUG|C1-inhibitor|100 Unit/kg IV, one gift prior to broncho provocation.
214937380|NCT03051698|OTHER|Saline|0.9% NaCl
214937381|NCT03051698|DRUG|Antibiotics|vancomycin, ciprofloxacin, metronidazole
214937382|NCT04442451|OTHER|Control Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) without blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
214937383|NCT04442451|OTHER|Blood Flow Restriction Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) with blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
214937384|NCT01972451|PROCEDURE|Colonoscopy with enhanced dye|
214937385|NCT01729520|OTHER|Knee extension strength training|"Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for~Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for"
214937386|NCT01255462|BIOLOGICAL|LFG316|
214937387|NCT01255462|BIOLOGICAL|LFG316|
214336665|NCT02454426|DRUG|Vortioxetine|open label treatment
214336666|NCT06531733|DEVICE|Sleep Promoting (pink noise)|Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.
214674968|NCT04473261|DRUG|Iodine Complex|Iodine Complex syrup form (40ml) will be given three times a day
214674969|NCT04473261|DRUG|Placebo|Empty capsule will be given as placebo
214937388|NCT01255462|BIOLOGICAL|LFG316|
214937389|NCT01255462|BIOLOGICAL|LFG316|
214937390|NCT01329926|PROCEDURE|Harvesting of neural stem cells|During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.
214937391|NCT05814692|DIAGNOSTIC_TEST|blood and urine samples|blood and urine samples
214937392|NCT03085992|DRUG|FOLFOXIRI plus Bevacizumab|"* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
214937393|NCT03085992|OTHER|Chemoradiotherapy plus Bevacizumab|"* FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~* BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
214937394|NCT00449943|PROCEDURE|Computed Tomographic Angiography|CT scan
214937395|NCT00449943|PROCEDURE|Myocardial Perfusion Imaging Scan|SPECT
214336667|NCT06531733|DEVICE|Wake Promoting (blue enriched light plus a nap)|Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.
214336668|NCT04787666|PROCEDURE|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure
214336669|NCT01428492|DRUG|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
214336670|NCT01428492|DRUG|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
214336671|NCT01428492|DRUG|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
214336672|NCT02393313|PROCEDURE|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
214336673|NCT02393313|DEVICE|Rayner T-flex Toric IOLs|
214336674|NCT05158946|BEHAVIORAL|Future Oriented Group Training|This study's experimental condition consisted of a Future Oriented Group Training (FOGT), originally developed in 2008 by van Beek et al. (2009). Participants followed this training weekly, over a period of 9 weeks in groups of 6 to 10 participants. The sessions, which lasted one and a half hours each, were each led by one trainer.
214336675|NCT03391843|DRUG|FOLFOXIRI+Cetuximab regimen|FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle
214336676|NCT06054646|BIOLOGICAL|Amnion collagen|A collagen extract sourced from the human amniotic membrane
214336677|NCT06054646|BIOLOGICAL|Platelet-rich plasma|Autologous preparation of PRP
214336678|NCT00013897|DRUG|Atazanavir|
214336679|NCT00013897|DRUG|Lamivudine/Zidovudine|
214336680|NCT00013897|DRUG|Efavirenz|
214674970|NCT04473261|DRUG|Idoine Complex|Iodine Complex spray form 2 puffs will be given three times a day
214937396|NCT03796819|PROCEDURE|lymphadenectomy|Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection
214336681|NCT01024127|OTHER|Laboratory Biomarker Analysis|Correlative studies
214336682|NCT06532682|DRUG|dapagliflozin|dapagliflozin 5 MG/10 MG once daily
214336683|NCT06532682|DRUG|ACE inhibitor|ACE inhibitor
214336684|NCT01323699|BEHAVIORAL|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
214336685|NCT03540901|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
214336686|NCT03540901|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
214937397|NCT04303936|DEVICE|SenseWear® armband device|"Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life, sleep"
214937398|NCT06648902|DRUG|meldonium|500 mg (Arm A) or 1,000 mg (Arms B and C) orally daily, weeks 1-6
214336687|NCT05750381|OTHER|Micrococcus luteus Blis Q24 balm|Balm formulation containing probiotic bacteria Micrococcus luteus Q24 for topical applications.
214674971|NCT01107977|BEHAVIORAL|Iyengar yoga|Iyengar yoga twice/week for 6 weeks
214674972|NCT02046031|DRUG|Ginkgolides Meglumine Injection|25 mg, ivdrip, once.
214937399|NCT06618404|OTHER|No intervention - cross-sectional cohort analysis|Observational
214937400|NCT05906186|BEHAVIORAL|kiwifruit|eating two kiwifruits a day
214937401|NCT01238718|DRUG|Lidocaine|lidocaine 1.5 mg/kg intravenously
214937402|NCT01238718|DRUG|Placebo|normal saline
214937403|NCT02273271|OTHER|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
214937404|NCT01892085|BEHAVIORAL|Early initiation|Initiation of breast milk expression \<1 hour following delivery.
214937405|NCT01892085|BEHAVIORAL|Intermediate expression|Initiation of milk expression 1-\<3 hours following delivery.
214937406|NCT01892085|BEHAVIORAL|Late initiation|Initiation of milk expression \>3-6 hours following delivery.
214937407|NCT02585271|DEVICE|Transanal decompression tube|22 Fr transanal decompression tube
214937408|NCT02585271|DEVICE|Stent|self-expandable colorectal nitinol alloys stent
214937409|NCT05659511|DIAGNOSTIC_TEST|MRI|MRI data was acquired with a GE discovery MR750 3.0 T scanner using an eight-channel phased- array head coil. Foam padding was used to restrict head movement and ear plugs were used to eliminate scanner noise. During the acquisition period, all participants were asked to keep their eyes closed and not to think anything.
214937410|NCT06622265|DEVICE|Electrocardiogram recording|ECG recording with investigational device
214937411|NCT05205148|DEVICE|Percutaneous coronary intervention with the following platforms: Orsiro; Mistent; BioMime; Supraflex Cruz|Patients treated with ultrathin coronary stents (namely stents with strut thickness \< 70 um) for specific coronary disease scenarios: unprotected left main stenosis; Bifurcation coronary stenosis (with side branch diameter ≥ 2.5 mm); Chronic total coronary occlusion; In-stent restenosis
214937412|NCT02212548|DEVICE|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
214674973|NCT04749108|DRUG|Induction chemotherapy - modified FOLFIRINOX regimen|An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
214336688|NCT05750381|OTHER|Placebo balm|Placebo balm formulation for topical applications.
214336689|NCT00158379|DRUG|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
214937413|NCT00673725|DRUG|Locobase® REPAIR|emollient
214937414|NCT04801472|OTHER|Optimisation of dental implant sites protection from irradiation|"Optimal treatment plan validation after two dosimetric computer-tomography scans (with or without radiological guide) and visualisation of virtual dental implants on scanner images.~Evaluation of toxicity, quality of life and dental implant survival rate"
214336690|NCT04156308|OTHER|Osteopathic Manipulative Treatment (OMT) - Temp1|A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.
214336691|NCT04156308|OTHER|Combined Exercises|A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
214336692|NCT01750268|BEHAVIORAL|Medical Management Counseling|Brief alcohol and medication counseling
214336693|NCT01750268|DRUG|Topiramate|Experimental medication
214336694|NCT01750268|DRUG|Placebo|Placebo comparator
214336695|NCT04830449|DRUG|HCP1904-2|Take it once daily for 8 weeks orally.
214336696|NCT04830449|DRUG|RLD2001-2|Take it once daily for 8 weeks orally.
214937415|NCT06054243|BEHAVIORAL|CBT-I|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psychoeducation about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
214937416|NCT06054243|BEHAVIORAL|CBT-A|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The CBT-A treatment is modified from the Coping Cat programme, which incorporates psychoeducation and the core behavioural strategies and cognitive skills for managing anxiety (e.g. exposure, relaxation training, cognitive restructuring).
214336697|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine|Subjects will be coadministered with inactivated SARS-CoV-2 vaccine and varicella vaccine.
214336698|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with MMR|Subjects will be coadministered with SARS-CoV-2 vaccine and MMR.
214336699|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine administered alone|Subjects will be immunized with inactivated SARS-CoV-2 vaccine alone
214674974|NCT04749108|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
214674975|NCT04749108|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or Intensity-Modulated RadioTherapy (IMRT) (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of radiotherapy treatment (2 daily intake).
214674976|NCT04749108|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
214336700|NCT02359396|DRUG|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
214937417|NCT05074446|OTHER|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/she belongs.~Stereotype threat manipulation will be performed on the intensivist and non-intensivist participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare the cardiopulmonary resuscitation performance between intensive care units and other branches. The other participants (Control Group) will not be given any prior information."
215073658|NCT01762956|OTHER|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
215073659|NCT02592616|BEHAVIORAL|CON|No exercise intervention.
215073660|NCT02592616|BEHAVIORAL|CW|One hour of continuous walking on a treadmill.
215073661|NCT02592616|BEHAVIORAL|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
214674977|NCT04510857|DEVICE|MOVE-IT Intervention|The MOVE-IT device comprises a custom smart toy and therapy game software to enable repetitive task practice involving the arm and hand.
214336701|NCT03959865|DRUG|Long-acting GLP-1RA|Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg
214336702|NCT03959865|DRUG|Short-acting GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.
214336703|NCT03959865|DRUG|Human-based GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or dulaglutide 0.75 or 1.5 mg / week
214336704|NCT03959865|DRUG|Exendin-based GLP-1RA|Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.
214937418|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation|Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. No adjunctive therapies were applied in this group.
214937419|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and chlorhexidine irrigation|The participants in the mechanical instrumentation with chlorhexidine (MC) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were irrigated with 0.2% chlorhexidine digluconate solution for 1 minute.
214937420|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and ozone application|The participants in the mechanical instrumentation with ozone (MO) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, gaseous ozone was applied to the peri-implant pockets using an ozone-generating device and a specialized glass fiber probe. The ozone gas was delivered to four sites (mesial, distal, buccal, and lingual) for 15 seconds per site, resulting in a total application time of 1 minute per implant. The device operated at a power of 3 watts and 80% oxygen concentration, as recommended by the manufacturer.
214937421|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and air abrasion|The participants in the mechanical instrumentation with glycine powder air abrasion (MA) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were treated with glycine powder-based air abrasion using an air-abrasion device (AIR-FLOW® handy 3.0 PERIO HANDPIECE, EMS, Nyon, Switzerland) and a flexible Perio-Flow® nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant.
214937422|NCT06730568|PROCEDURE|Air abrasion monotherapy|The participants in the glycine powder air abrasion monotherapy (A) group were treated exclusively with glycine powder-based air abrasion. Local anesthesia was applied before the procedure. The peri-implant pockets were instrumented with an air-abrasion device using glycine powder and a flexible nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant. .
214937423|NCT02380495|OTHER|Data Collection|
214937424|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 1
214937425|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 2
214937426|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 3
214937427|NCT01367496|DRUG|IV Methylnaltrexone (MNTX)|
214937428|NCT02425722|DRUG|ASP0456|oral
214937429|NCT02425722|DRUG|Placebo|oral
215073662|NCT00199251|DRUG|RUPATADINE|
215073663|NCT06176872|DIAGNOSTIC_TEST|Cardiac Computed Tomography Angiography|Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
214336705|NCT03959865|DRUG|Fixed ratio BI/GLP-1RA combination|Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)
214336706|NCT03959865|DRUG|Flexible BI/GLP-1RA combination|GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
214336707|NCT00021307|DRUG|carboplatin|
214336708|NCT00021307|DRUG|temozolomide|
214937430|NCT05276622|OTHER|Comprehensive Geriatric Assessment|"A modified Cancer and Aging Research Group (CARG) Geriatric Assessment that includes validated measures of 7 geriatric domains: functional status, comorbidity, cognition, psychological state, social activity, and support, nutritional status, and medications will be performed at baseline (pre-treatment), every 3 months for a total of 3 assessments. The modified comprehensive Geriatric Assessment includes patient-reported surveys and research staff assessments.~Cognitive Testing: The National Institutes of Health Toolbox Cognition Battery (objective) and PROMIS Short Form v2.0 - Cognitive function 8a (subjective)"
214336709|NCT00509197|DRUG|Placebo (sham inhaler)|
214336710|NCT00509197|DRUG|Fluticasone|Fluticasone 250mcg bid for one month
214336711|NCT00000189|DRUG|Gepirone|
214937431|NCT05276622|OTHER|Qualitative patient-care partner interviews|Semi-structured Interviews: Baseline and again at 3 months.
214937432|NCT05276622|OTHER|Surveys on well-being and function|Care partner's Surveys on well-being and function: Baseline and again at 3 months
214937433|NCT05919095|DRUG|Carrilizumab plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment."
214674978|NCT04510857|BEHAVIORAL|UCT Control|Participants assigned to the UCT control group will continue to receive their previously prescribed therapy services.
214674979|NCT05241171|DEVICE|Fitbit|The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.
214674980|NCT06169748|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
214674981|NCT06169748|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
214674982|NCT06169748|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
214674983|NCT04744415|OTHER|Epidemiology of admissions|Cardiology Intensive Care Unit admission
214674984|NCT02571361|DRUG|Paracetamol (1g x 4)|Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively
214336712|NCT05075317|BEHAVIORAL|Standard cardiac rehabilitation|Standard, multi-dimensional cardiac rehabilitation program.
214336713|NCT05075317|BEHAVIORAL|Time-Restricted Eating|Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day
214937434|NCT06496022|DIAGNOSTIC_TEST|Frail scale|FRAIL scale for determining frailty (tired most of the time in the last 4 weeks; the presence of more than 5 diseases; difficulty or inability when climbing stairs and walking around the block; weight loss of more than 5% of the previous weight in the last 6 months).
214674985|NCT02571361|DRUG|Ibuprofen (400 mg x 4)|Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
214674986|NCT02571361|DRUG|Paracetamol (0,5 g x 4)|Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively
214674987|NCT02571361|DRUG|Ibuprofen (200 mg x 4)|Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
214674988|NCT02571361|DRUG|Placebo (x4)|Given in 6 hour intervals the first 24 hours postoperatively
214674989|NCT06451237|DRUG|Isotretinoin capsules|A one year follow up for patients on three maintenance regimens after acne clearance, including weekend isotretinoin and adapalene gel.
214674990|NCT05746780|PROCEDURE|Elective bilateral neck dissection in cN0 patients|Radical modified type 3 selective bilaterale elective neck dissection
214336714|NCT04175262|DRUG|sunitinib|Patients to receive sunitinib as second line therapy for mRCC
214336715|NCT01969838|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
214336716|NCT01969838|DRUG|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
214336717|NCT01969838|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
214674991|NCT02778880|DRUG|Ketamine|
214674992|NCT02778880|DRUG|Fentanyl|
214674993|NCT01818375|PROCEDURE|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
214674994|NCT01818375|OTHER|Standard fluid therapy|
214336718|NCT01969838|DRUG|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
214336719|NCT06077006|OTHER|questionnaires Only|questionnaires Only
214336720|NCT03087591|OTHER|Laboratory Biomarker Analysis|Correlative studies
214336721|NCT03087591|BIOLOGICAL|siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401|Given IV
214336722|NCT02497768|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
214336723|NCT01003431|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|\[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)\] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
214336724|NCT01003431|BIOLOGICAL|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
214937435|NCT06496022|DIAGNOSTIC_TEST|Barthel scale|The Barthel scale is used to determine the degree of independence in daily life, the patient's household activity, the assessment of the quality of life and the necessary care.
214937436|NCT06496022|DIAGNOSTIC_TEST|SARC-F|The SARC-F scale is used to identify muscle dysfunction (difficulty lifting things over 4.5 kg, walking around the room, difficulty climbing from a chair and up 10 steps, whether the respondent has fallen in the last year).
214937437|NCT06496022|DIAGNOSTIC_TEST|FRAX|FRAX Scale (Kazakhstan platform) fracture and osteoporosis risk assessment on the website https://frax.shef.ac.uk/FRAX/tool.aspx?country=72
214937438|NCT06496022|DIAGNOSTIC_TEST|Mini-Cog scale|The Mini-Cog scale defines cognitive impairment (cognitive impairment - when scoring less than 3 points based on remembering three words and evaluating the task of drawing a clock).
214937439|NCT06496022|DIAGNOSTIC_TEST|dynamometry|carpal dynamometry (sarcopenia is exhibited at values below 26 units for men and below 16 units for women).
214937440|NCT04318639|COMBINATION_PRODUCT|Donepazil|"Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.~Cognitive remediation therapy (CRT): This study employs a computerized program (BrainHQ) for cognitive enhancement. Participants use their program for one hour per session, up to five sessions per week, over 13 weeks (maximum of 65 sessions). They may training on site or at another quiet location of their choice."
214937441|NCT00645125|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL
214336725|NCT01003431|BIOLOGICAL|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
214336726|NCT02348138|OTHER|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
214336727|NCT02855294|DRUG|COC containing 30 μg of EE and 3mg of drospirenone|treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
214336728|NCT05912946|DRUG|Interferon|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.
214336729|NCT05912946|DRUG|Sodium Hyaluronate|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.
214937442|NCT00645125|DRUG|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
214937443|NCT00881439|DRUG|Aliskiren|Oral, 300 mg, once daily, 6 months
214674995|NCT01374581|DRUG|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~Weight in kg Number of tablet per dose Age 5 to \< 15 kg 1 tablet per dose 15 to \< 25 kg 2 tablets per dose 25 to \< 35 kg 3 tablets per dose"
214674996|NCT01374581|DRUG|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to \< 9kg):1 tablet (25 mg/675mg) for 3 days~1 to 5 years (= 9 kg to \< 18 kg)1 tablet(25mg/67,5mg)for 3 days"
214674997|NCT01374581|DRUG|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to \< 11 kg: ½ tablets 12 to \< 19 kg: 1 tablets per dose 20 to \< 27 kg: 1½ tablets per dose 28 to \< 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily"
214937444|NCT00881439|DRUG|Placebo|Matching Placebo once daily, 6 months
214937445|NCT00274313|DRUG|552-02|
214937446|NCT05285722|BEHAVIORAL|Cognitive Behavioral Therapy form for dental anxiety|Message to Dentist form
214336730|NCT05912946|DRUG|Sodium Chloride Injection|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
214336731|NCT05968612|DRUG|Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet|Film-coated tablet administered orally.
214336732|NCT05968612|DRUG|Lumacaftor 200 mg Film-Coated Tablet Formulation|Film-coated tablet administered orally.
214336733|NCT04506450|PROCEDURE|Peripheral nerve block|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected."
214486419|NCT06766682|BEHAVIORAL|The Skill Development Program for Emotion Regulation|The Skill Development Program for Emotion Regulation to be carried out with the intervention group was planned as 6 sessions. The aim of this study was to investigate The Skill Development Program for Emotion Regulation Program on oncology nurses' emotion regulation difficulties, emotion regulation skills, experiential avoidance, and compassion fatigue.
214937447|NCT03619759|DRUG|Sugammadex|Sugammadex injection as a reverse agent of neuromuscular blocking
214937448|NCT01255410|BIOLOGICAL|10^6 PFU rHMPV-Pa vaccine|Single dose of 10\^6 PFU rHMPV-Pa vaccine delivered intranasally
214937449|NCT01255410|BIOLOGICAL|10^5 PFU rHMPV-Pa vaccine|Single dose of 10\^5 PFU rHMPV-Pa vaccine delivered intranasally
214937450|NCT01255410|BIOLOGICAL|Placebo Vaccine|Single dose of placebo vaccine delivered intranasally
214937451|NCT01573416|OTHER|ASSIST-linked brief intervention for hazardous and harmful substance use.|ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
214937452|NCT01573416|OTHER|Observation|Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
214937453|NCT06477835|BIOLOGICAL|SIM0718 Injection|Subjects who meet entry criteria will be randomized in a 1:1 ratio to receive either SIM0718 or matching placebo,Q2W, SC until Week 16. At the Week 16 visit, subjects in the placebo group will be transferred to SIM0718 300 mg Q2W after completing safety and efficacy assessments. Subjects who were originally treated with 300 mg Q2W of SIM0718 will continue on their original treatment regimen.
214937454|NCT05137535|OTHER|Questionnaire|Family-based questionnaire
214674998|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
214937455|NCT05783024|OTHER|Data collection|retrospective data collection
214937456|NCT03989934|BEHAVIORAL|The Mind in Action|Mindfulness program for adolescents
214937457|NCT03989934|BEHAVIORAL|Healthy Topics|Health education program for adolescents
214937458|NCT01549041|DRUG|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
214937459|NCT01549041|DRUG|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
214937460|NCT06619002|PROCEDURE|Sentinel lymph node sampling|video analysis
214937461|NCT02521779|OTHER|Low-fat Treatment Meal|Isocaloric test meal that provided 20% fat.
214937462|NCT02521779|OTHER|Saturated-fat Treatment Meal|Isocaloric test meal that provided 35% fat with saturated fat (16 g).
215073664|NCT03723538|DRUG|Dexmedetomidine|patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.
214937463|NCT02521779|OTHER|N-3 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)
215073665|NCT04039711|PROCEDURE|Vaginal self-sampling|The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
214336734|NCT04506450|PROCEDURE|Spinal anesthesia|"In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected."
214336735|NCT01415505|DRUG|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
214937464|NCT02521779|OTHER|N-6 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
214937465|NCT03047096|DRUG|hyaluronic acid|intra-Articular injection
214937466|NCT03047096|DRUG|hyaluronic acid and corticosteroids|intra-Articular injection
214937467|NCT05583279|BEHAVIORAL|Dialetical Behavioral Therapy for Adolescents|DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.
214937468|NCT02440321|BEHAVIORAL|Parent-child interactive program|
214937469|NCT02440321|OTHER|written materials|
214937470|NCT03247764|OTHER||observational study
214937471|NCT00063479|DRUG|Zoledronic Acid|
214937472|NCT02089100|RADIATION|stereotactic body radiation therapy|
214937473|NCT02089100|RADIATION|Systemic treatment|
214937474|NCT06295887|OTHER|Educational Program using VR or simulator designed to improve medical intern's performance managing emergency situation|Simulation program using VR or simulator that mimics patient's desaturation
214937475|NCT04972370|OTHER|Patients with Unilateral Cleft Lip with or without Cleft Palate|2 dimensional Photographs of patients with unilateral cleft lip with or without cleft palate
214937476|NCT00597506|DRUG|Bevacizumab|10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
214937477|NCT00597506|DRUG|Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28
214937478|NCT00210600|DRUG|PROCRIT (Epoetin alfa)|
214937479|NCT00324142|DRUG|Oral tinidazole|
214937480|NCT01622270|OTHER|Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index|Indirect calorimetry test by a indirect calorimeter (OHMEDA) body composition by a DEXA machine blood tests, 3 days food records, Crohns disease activity index
214937481|NCT04211974|DIAGNOSTIC_TEST|whole-exome sequencing|"Fresh frozen or formalin-fixed, paraffin-embedded samples were obtained from patients following resection along with matching peripheral blood samples.~whole-exome sequencing will be performed to identify mutations in tumor tissue and matching blood"
214336736|NCT04932304|DEVICE|Transcranial direct current stimulation (tDCS)|
214937482|NCT05236101|BEHAVIORAL|survey research|Children with dental treatment were asked to draw pictures.
214937483|NCT02034812|OTHER|Decipher Questionnaire|Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
214937484|NCT04912219|DEVICE|Microneedling|"Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.~Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.~Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.~This will be repeated for a total of four treatments one month apart"
214937485|NCT00239213|DRUG|catechin extracts (health food)|
214937486|NCT05914038|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.
214937487|NCT03740321|DEVICE|Embolization with tri-acryl gelatin (Embosphere) particles|Left, right and posterior branches of superior rectal artery will be embolized with tri-acryl gelatin particles in 500-700 and 700-900 micrometers in size until homeostasis will be achieved.
214937488|NCT00027677|DRUG|halofuginone hydrobromide|
214937489|NCT05615805|OTHER|OSDI questionnaire|Ocular Surface Disease Index
214937490|NCT05615805|OTHER|SPEEDII questionnaire|Standardized Patient Evaluation of Eye Dryness II questionnaire
214937491|NCT05742893|DIAGNOSTIC_TEST|Measurement of pragmatic and discourse test scores in the two scales.|The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .
214937492|NCT00006994|DIETARY_SUPPLEMENT|glutamine|20 cc three times daily for 60 days
214937493|NCT00006994|RADIATION|radiation therapy|Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
214937494|NCT00006994|DRUG|l-glutamine placebo|20 cc three times daily for 60 days
214937495|NCT00941694|BEHAVIORAL|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
214937496|NCT00941694|BEHAVIORAL|placebo group|3 phone calls not related to asthma self-management
214336737|NCT04932304|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham Transcranial direct current stimulation (tDCS)
214336738|NCT00408993|DRUG|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
214937497|NCT01291576|PROCEDURE|Rectal/colorectal segmental resection|Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
214937498|NCT01291576|PROCEDURE|Rectal nodule excision|Either full thickness excision or rectal shaving
214937499|NCT04066296|DRUG|Liposomal bupivacaine|Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
214937500|NCT02609724|OTHER|Information|During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
214937501|NCT02609724|OTHER|Skin care|The skin is hydrated during the session. If wounds are present, the wound is cared.
214937502|NCT02609724|OTHER|Compression therapy|During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
214937503|NCT02609724|OTHER|Fluoroscopy-guided MLD|Fluoroscopy-guided MLD is applied on patient-specific lymphatic system (known from lymphofluoroscopy) by applying cleaning techniques on lymph nodes, resorption techniques to stimulate resorption of lymph by lymph capillaries and gliding technique to stimulate transport of lymph through lymph collectors
214937504|NCT02609724|OTHER|Traditional MLD|Traditional MLD is applied without knowledge of the patient-specific lymphatic architecture. During MLD no cream or oil is used. A pressure with the hands up to 40 mmHg is applied. Drainage is performed at the level of the jugular and occipital region and the belly (in the depth). Draining techniques are applied on the retroclavicular lymph nodes, axillary lymph nodes, humeral lymph nodes and cubital lymph nodes. At the level of the hand, arm, shoulder and trunk, hand movements are applied to stimulate lymphatic transport through the lymph collectors. The therapist's hands perform 'pumping-movements' while stretching the skin.
214336739|NCT00408993|DRUG|Placebo|Placebo every day (QD), by mouth (PO)
214336740|NCT02654080|BIOLOGICAL|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
214937505|NCT02609724|OTHER|Placebo MLD|During placebo MLD a superficial massage with massage cream is performed on the patient's contralateral arm and on the belly.
214937506|NCT03077659|DRUG|NanoPac®|Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
214937507|NCT06363032|DIAGNOSTIC_TEST|elastography|When routine renal ultrasound is arranged, patients will be invited to receive elastography at the same time.
214937508|NCT04940715|OTHER|Passive joint mobilization|Dosage: 5 sets of 2 minutes with 30 seconds of rest were applied, with a strong force (\>50% of maximum therapist strength), according to patient's irritability and severity.
214937509|NCT04940715|OTHER|Mobilization with movement|Dosage: 3 sets of 10 repetitions were performed, with 1-2 minutes of rest between sets.
214937510|NCT04353388|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
214937511|NCT00709007|BEHAVIORAL|Directly Administered Antiretroviral Therapy (DAART)|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
214937512|NCT00709007|BEHAVIORAL|SAT|Participants take their HIV medications by themselves.
214937513|NCT01537978|OTHER|Video gaming for enhanced function after spinal cord injury.|Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
214937514|NCT04872556|DEVICE|Laser acupuncture device|The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
214674999|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
214336741|NCT02654080|BIOLOGICAL|rVSV HIV envC vaccine|1 × 10\^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
214336742|NCT02654080|BIOLOGICAL|Placebo|"Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
214336743|NCT05643066|DRUG|0.1 mg/kg esketamine|Esketamine 0.1 mg/kg was intravenously injected first.
214336744|NCT05643066|DRUG|0.2 mg/kg esketamine|Esketamine 0.2 mg/kg was intravenously injected first.
214336745|NCT05643066|DRUG|0.9% saline|0.9% saline was intravenously injected first.
214336746|NCT05643066|DRUG|Propofol|Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
214336747|NCT03738865|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
214336748|NCT03738865|DRUG|Novo Glucagon|1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
214336749|NCT06141798|OTHER|Hemodialysis|Number of weekly hemodialysis treatment
214937515|NCT04872556|DEVICE|Pseudo-laser acupuncture|The experiment group would arrange Pseudo-laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
214937516|NCT03957811|OTHER|Whole body Vibration exercise|Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
214937517|NCT03767556|PROCEDURE|Inspiratory muscle training|Powerbreathe® K5
214336750|NCT01006044|BIOLOGICAL|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
214336751|NCT05809518|DRUG|Propofol injection|sedation after cardiac surgery
214336752|NCT05809518|DRUG|Dexmedetomidine injection|sedation after cardiac surgery
214336753|NCT05809518|DRUG|Dexmedetomidine and Propofol|sedation after cardiac surgery
214336754|NCT04532697|OTHER|Uncaria Rhynchophylla (Gou-Teng)|Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
214336755|NCT04532697|OTHER|Placebo|All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
214336756|NCT00010218|DRUG|karenitecin|
214336757|NCT02621606|DRUG|[11C]MK-6884|IV bolus dose of \~370 MBq \[11C\]MK-6884
214336758|NCT06004310|BEHAVIORAL|Pulmonary Rehabilitation|Participants will be participated a 06 weeks comprehensive outpatient pulmonary rehabilitation which includes endurance training, strength training, patient education, relaxation techniques, psychological support and nutritional counselling.
214336759|NCT02048384|DRUG|metformin alone (Arm A)|metformin alone
214336760|NCT02048384|DRUG|metformin (Arm B)|rapamycin + metformin
214336761|NCT02048384|DRUG|rapamycin (Arm B)|rapamycin + metformin
214336762|NCT01278459|DRUG|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
214336763|NCT02764749|DIETARY_SUPPLEMENT|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
214336764|NCT02764749|DIETARY_SUPPLEMENT|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
214336765|NCT06309147|DRUG|BMS-9894923|50 mg capsules, oral administration
214336766|NCT02309385|DRUG|8% Dexamethasone Sodium Phosphate - Visulex|
214675000|NCT00680420|PROCEDURE|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
214937518|NCT00674856|DRUG|naproxcinod|750mg
214937519|NCT00568360|DEVICE|Oximeter|
214675001|NCT06529289|OTHER|Training|"We conducted one day of training for FCHVs and four different groups of FCHVs from two municipalities. We conducted training on hypertension knowledge and blood pressure measurement skills for FCHVs. Studies from Nepal show that with appropriate training, FCHV has the potential to promote hypertension education and conduct hypertension screening. Access to essential equipment such as digital blood pressure monitors, would improve FCHV performance on measuring blood pressure. Therefore, our training was to provide hypertension knowledge and to train FCHVs to measure blood pressure.~The training had two objectives referring to enhancing knowledge and building skills."
214675002|NCT01949064|DEVICE|Grindcare|
214675003|NCT01949064|DEVICE|Michigan-type occlusal splint|
214336767|NCT02309385|DRUG|15% Dexamethasone Sodium Phosphate - Visulex|
214336768|NCT02309385|DRUG|Prednisolone Acetate (1%) Eye Drops|
214336769|NCT05702320|OTHER|the heating procedure|The patients will undergo a heating procedure.
214336770|NCT05971212|BEHAVIORAL|Behavioural sleep clinic access|Access to behavioural Sleep Clinic
214336771|NCT02126254|DEVICE|Hemodynamic group|NICAS guided treatment
214336772|NCT00111644|DRUG|Ceftriaxone|1000mg iv daily
214336773|NCT00111644|DRUG|beta-lactam|750mg iv q 23h for 3-14 days
214336774|NCT00111644|DRUG|beta-lactam|1500mg iv q 12h for 3-14 days
214336775|NCT00134277|PROCEDURE|Infragenual dilatation|Infragenual dilatation
214675004|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
214937520|NCT01139099|BEHAVIORAL|Group Psychotherapy|integrated group psychotherapy, including the interpersonal and cognitive group therapy
214937521|NCT02844907|DRUG|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
214937522|NCT02844907|DRUG|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
214937523|NCT02844907|OTHER|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
215073666|NCT03232242|DIAGNOSTIC_TEST|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
215073667|NCT01368783|DRUG|atazanavir|400 mg/day for 2 days
215073668|NCT01368783|DRUG|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
215073669|NCT01368783|DRUG|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
215073670|NCT01368783|DRUG|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
215073671|NCT02252549|DEVICE|SPIES+WLI assisted TURB|
215073672|NCT02252549|DEVICE|WLI assisted TURB|
215073673|NCT04378829|DIAGNOSTIC_TEST|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
214675005|NCT00569920|DRUG|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
214937524|NCT04982978|BEHAVIORAL|PMT Threat Appraisal|"The first half of the PMT present video will include narration by Science Insider producer, Benji Jones, including dialogue regarding the risks associated with vaping by Chief Pediatric Pulmonology at the NYU Winthrop Hospital, Dr. Melodi Pirzada, and information on nicotine by the Director of Pediatric Pulmonology at NYU's Langone Hassenfeld Children's Hospital, Dr. Mikhail Kazachkov. The second half of the PMT present video will include personal experiences and narratives by students at the University of Utah with information regarding our current knowledge of vaping health effects through research by Dr. Sean Maddock and Dr. Sean Callahan from the University of Utah to highlight the susceptibility of vaping for a population of young adults in university."
214937525|NCT04982978|BEHAVIORAL|General Nutrition and Lifestyle|The first half of the PMT absent video will be presented by the Alliance for Aging Research, including an immersive video design, explaining the impact that nutrition may have as the participants age, reviewed by Dr. Steven Austad and Senior Nutritionist Johanna Dwyer. The second half of the PMT absent video will be presented by TED-Ed with narration by Addison Anderson, including a similar immersive video design, explaining how the food the participants eat may affect our brain and overall health. The nutrition and lifestyle information design will be administered as a control because it provides informative lifestyle choices regarding nutrition that can help promote the participants overall health without having an underlying link to vaping behaviour and its subsequent effect on the status of health.
214937526|NCT03024528|BEHAVIORAL|CPOT assessment|Polish version of Critical care pain observation tool validation.
214937527|NCT06720077|OTHER|Acupressure|"It will be applied for the experimental group only. Before starting the first treatment session, the participants will be instructed briefly about the nature of the treatment to gain their confidence and cooperation. Each participant in this group will be asked to lie in supine position and the acupressure will be applied by using the therapist's fingers on the following acupoints (san jio 6/ spleen 15/ stomach 25/ joining vally  intestine 4) 1 minute for each point with 3 repetitions on both sides (about 30 minutes as total time), 3 times per week for 6 weeks."
215073674|NCT04143165|DRUG|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
214675006|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
215073675|NCT03843944|DRUG|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
215073676|NCT04021524|DRUG|Benzoyl Peroxide 10% Bar|Patients will wash with Benzoyl Peroxide 10% Bar
214675007|NCT02098317|DRUG|DHA plus Vitamin D|DHA 500 mg plus Vitamin D 800 IU
214675008|NCT02098317|DRUG|Placebo|Placebo pearls mimicking pearls with DHA and Vitamin D
214675009|NCT02615106|DRUG|Endostar|7.5 mg/m2/day, day 1-14
214675010|NCT02615106|RADIATION|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
215073677|NCT04021524|DRUG|Chlorhexidine Gluconate|Patients will wash with Chlorhexidine Gluconate
215073678|NCT05275010|DRUG|Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)|A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).
215073679|NCT05275010|DEVICE|Handheld Syringe with Hypodermic Needle|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using a handheld manual syringe.
214675011|NCT03454048|DRUG|Piperaquine (low dose)|subcurative regimen (480 mg)
214675012|NCT03454048|DRUG|Piperaquine (high dose)|Curative regimen (960mg)
214675013|NCT03454048|DRUG|Sulfadoxine pyrimethamine|Curative regimen (1000mg/50mg)
214675014|NCT03454048|DRUG|Atovaquone Proguanil|Curative regimen (1000/400 mg, for 3 days)
214675015|NCT03454048|OTHER|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
214675016|NCT03454048|OTHER|Blood stage malaria challenge infection, P. falciparum 3D7|P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
214675017|NCT06332144|BEHAVIORAL|Structural vs. Random sequences of stimuli|Participants will see or listen to sequences of sounds and images either in a structured condition or a random condition.
214675018|NCT06332144|BEHAVIORAL|Intact vs. Degraded speech|"Participants will listen to an audiobook Alice in Wonderland in the MRI scanner. The speech is either intact or degraded."
214675019|NCT06332144|BEHAVIORAL|Repeating 5-syllable nonwords or 2-syllable nonwords|Participants will listen to nonwords (either 5-syllable or 2-syllable) and then repeat them as accurately as possible in the MRI scanner.
214675020|NCT06332144|BEHAVIORAL|Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data.|Participants will read (orthographic serial recall) or listen to (phonological serial recall) strings.
214675021|NCT01008254|BEHAVIORAL|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
214675022|NCT01008254|BEHAVIORAL|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
214675023|NCT01008254|OTHER|No musical prompt|No intervention.
215073680|NCT05275010|DEVICE|On-Body Delivery System|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using the on-body delivery system (OBDS).
214675024|NCT05197868|PROCEDURE|Intubation with traditional laryngoscope|Participants will be invited to intubate the mannequin with a traditional laryngoscope
214675025|NCT05197868|PROCEDURE|Intubation with a straight blade video laryngoscope|Intubation with a straight blade video laryngoscope
214336776|NCT00134277|PROCEDURE|Infragenual dilatation with stenting|Infragenual dilatation with stenting
214336777|NCT00134277|PROCEDURE|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
214675026|NCT05197868|PROCEDURE|Intubation with a hyper-angulated video laryngoscope|Participants will be asked to intubate the mannequin with a hyper-angulated video laryngoscope
214937528|NCT06720077|OTHER|Diaphragmatic breathing exercises|A modified exercise will be used to achieve normal diaphragmatic breathing while the woman is lying on her back, with one hand placed on her abdomen and the other on her thorax. She will then be instructed to breathe in deeply, slowly, and gradually for 4 seconds, hold the air for 2 seconds, and exhale slowly through pursed lips for 6 seconds. Three series of ten repetitions will be completed with rest in between; the woman will be advised to rest longer if she feels dizzy or lightheaded. The patient will ensure the exercise is performed successfully if the hand placed on the abdomen shows greater mobility compared to minimal or no mobility of the hand on the thorax. From that point, the series of repetitions will begin.
214937529|NCT06720077|OTHER|General bowel care advise|All women in both groups will receive bowel care advice, including encouraging fiber intake (20-35 g/day) from sources like whole grains, fruits, vegetables, and legumes, with a focus on soluble fiber. They will be advised to limit meat, dairy, and low-fiber foods and avoid caffeine-containing products like chocolate and coffee. Adequate hydration (1.5-2.0 L/day) with water or juices will be recommended, along with daily exercise, such as 20-30 minutes of walking. Proper toilet posture will be emphasized, including sitting with knees higher than hips (using a stool if needed), leaning forward, placing elbows on knees, relaxing, and maintaining a straight spine.
214937530|NCT02888353|DEVICE|Device: MRI|Perform MRI in patients with cardiac devices
214937531|NCT00426660|DRUG|maraviroc|The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
214937532|NCT02064465|DRUG|Lamotrigine Dispersible/Chewable tablet|Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1
214937533|NCT02064465|DRUG|Lamotrigine Compressed tablet|Single dose of lamotrigine compressed 100mg tablet at Day1
214937534|NCT03862768|PROCEDURE|surgery|Surgery requires at least removal of all drug-resistant lesions.
214937535|NCT03862768|DRUG|Imatinib 400 MG|Imatinib 400 MG/d should be taken once the patients resume oral diet
214937536|NCT03862768|DRUG|Imatinib escalation|Imatinib 600 MG/d
214937537|NCT03862768|DRUG|Sunitinib|Sunitinib 37.5 MG/d
214675027|NCT06328075|OTHER|non interventional study|non interventional study
214675028|NCT00000615|BEHAVIORAL|diet, reducing|
214675029|NCT04713020|OTHER|Intervention:APP educational programs|Use mobile device education programs to improve disease knowledge and self-efficacy of stroke patients, and reduce depression
214675030|NCT04713020|OTHER|No Intervention:general care|general care
214675031|NCT01166659|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
214937538|NCT02232152|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
214937539|NCT02232152|DRUG|fluorouracil|Given IV
214937540|NCT02232152|OTHER|pharmacological study|Correlative studies
214937541|NCT02232152|OTHER|laboratory biomarker analysis|Correlative studies
214937542|NCT01675375|DEVICE|Eye Shield|one application following refractive surgery
214675032|NCT01257126|DRUG|diclofenac potassium|
214675033|NCT01257126|DRUG|nimesulide|
214675034|NCT00813553|DIETARY_SUPPLEMENT|placebo|daily
214675035|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
214336778|NCT00134277|PROCEDURE|Laser therapy|Laser therapy
214336779|NCT06146244|PROCEDURE|sinus lift|Implant placement on grafted sinus vs antral autogenous bone
214336780|NCT06146244|DEVICE|resonance frequency analysis|analysis of the ISQ evolution and its changes after 3 months of placing the implant in native or regenerated bone, always in the antral area
214336781|NCT00099697|DRUG|DHEA|
214336782|NCT02164682|PROCEDURE|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
214336783|NCT02164682|PROCEDURE|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
214675036|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
214675037|NCT06027320|BEHAVIORAL|Brain Health Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
214675038|NCT06027320|BEHAVIORAL|Alzheimer Disease Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
214675039|NCT02024711|DEVICE|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
214937543|NCT06030830|BEHAVIORAL|SMaRT Mom|"SMaRT Mom intervention that we have developed is based on several approaches to digital addiction detection, prevention, and intervention aimed to help breastfeeding mothers to manage and reduce smartphone use during breastfeeding. The SMaRT Mom intervention results will be measured in changes in two main outcomes: 1) reduced maternal reports of their infants' negative emotionality, and 2) increased maternal self-efficacy as distal outcomes as well as two proximal outcomes: 1) breastfeeding as a rewarding experience, and 2) maternal attention towards their infant during breastfeeding. We will then assess changes in breastfeeding mothers' neural activity, physiology and behavior before and after the implementation of the SMaRT Mom intervention, as potential mechanisms underlying changes in the main outcomes of the intervention."
214937544|NCT00061022|DRUG|NXY-059|
214937545|NCT01393132|DRUG|Thymosin Beta 4 eye drops|Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
214937546|NCT01393132|DRUG|Vehicle Control|Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
214937547|NCT01658449|OTHER|Inhalable Hypertonic saline 7% + Hyaluronan 0.1%|Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
214937548|NCT01658449|OTHER|Inhalable Hypertonic saline 7%|Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
214675040|NCT02024711|DEVICE|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
214675041|NCT02889510|DRUG|liraglutide|7-week subcutaneous liraglutide once daily
214336784|NCT04666649|DRUG|Venetoclax and pegcrisantaspase|Therapeutic
214336785|NCT00804297|DRUG|Octreotide (drug)|
214336786|NCT05637151|OTHER|clamp time of umbilical|The umbilical cord was clamped immediately or late for more than 30s
214336787|NCT04231344|DEVICE|Laryngoscopy|Laryngoscopic examination of patients with GERD by two physicians
214336788|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training With Visual and Auditory Cues|Comparison of Effects of Treadmill Training With Visual and Auditory Cues
214336789|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training Without Visual and Auditory Cues|Comparison of Effects of Treadmill Training Without Visual and Auditory Cues
214336790|NCT02527720|BEHAVIORAL|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at \~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
214336791|NCT04100226|DIETARY_SUPPLEMENT|Vitamin D3 (1.25 (OH)2 cholecalciferol)|"Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients."
214937549|NCT01794598|BEHAVIORAL|Receiving educational material of depression care|The educational material provides patients about depression management
214937550|NCT01110668|DRUG|Nilotinib|
214937551|NCT04064255|OTHER|Practical Body Image (session 1 - 7)|Practical body image therapy
214937552|NCT04064255|OTHER|Practical Body Image (session 8 - 14)|Twice weekly mirror exposure plus ending session
215073681|NCT06024850|OTHER|Datas collected|"Datas collected by medical record: medical data (weight, height, smoking status, history) and socio-demographic data (age, occupation, type of injury) information, assessment of knee function before surgery, at 6 months and 1 year after surgery, magnetic resonance imaging (MRI) and radiological imaging at 1 year after surgery, results of the Iso-kinetic Muscle Assessment Test at 1 year after surgery to objectively determine the recovery of muscle function~The data collected will be used to perform a statistical analysis to evaluate the factors predicting a good long-term post-surgical evolution"
215073682|NCT05706155|BEHAVIORAL|Control Diet|Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
215073683|NCT05706155|BEHAVIORAL|Plant-based Diet|Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
214675042|NCT02889510|DRUG|placebo|7-week subcutaneous placebo once daily
214336792|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
214336793|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
214336794|NCT01694706|DRUG|omeprazole|medium dose of omeprazole
214336795|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
214336796|NCT00054002|PROCEDURE|adjuvant therapy|Lung surgery
214336797|NCT00054002|PROCEDURE|conventional surgery|Lung surgery
214336798|NCT00054002|DRUG|porfimer sodium|iv
214336799|NCT02229955|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
214336800|NCT04790149|OTHER|Conventional Rehabilitation|Motor Imagery Training combined with Active functional exercises
214336801|NCT04790149|OTHER|NEUROM + tDCS|NEUROM combined to tDCS
214336802|NCT04790149|OTHER|NEUROM|protocol to induce motor recovery
214937553|NCT03486678|DRUG|SHR-1210+GEMOX|28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond chemotherapy until the disease progression or untolerable toxicity.
214937554|NCT06370728|DRUG|Orforglipron|Administered orally
214937555|NCT06370728|DRUG|Carbamazepine|Administered orally
214937556|NCT06660745|OTHER|telenursing-based family empowerment program|"The intervention was conducted in two sections. The first part included a one-day educational workshop conducted through Skype for the child and their caregiver and was planned to introduce the members of the intervention group to each other and provide information on how to deliver and receive the content. In the second part of the intervention, the content was prepared based on a scheduled plan. It was in the form of a 5-10-minute audio file, video, or educational text and was uploaded on the SendBig website. Once the upload is complete, a link is provided to the user. The link was sent to the phone numbers of children with cystic fibrosis and their caregivers so that they could watch the weekly content over three months. Once it was confirmed that the link had been received (acknowledged in the Cystic Fibrosis Companions group) and the content had been viewed, remote follow-ups were scheduled twice a week, on Sundays and Tuesdays between 6:00 PM and 8:00 PM, using Skype messenger."
214675043|NCT01959386|DRUG|Trastuzumab|Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
214336803|NCT03779997|BEHAVIORAL|Video-based DOT Application|Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine. Clinical staff (i.e. physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
214336804|NCT05589545|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
214937557|NCT05728853|RADIATION|Assessment of body composition|Assessment of body composition using BIA and DXA
214937558|NCT05264519|OTHER|foot bath intervention|Students in this group will have their feet soaked in water with a temperature of 38-42 degrees for 20 minutes, half an hour before bedtime.
214336805|NCT01641588|BEHAVIORAL|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
214937559|NCT03456999|BIOLOGICAL|MAU868|MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.
214937560|NCT03456999|BIOLOGICAL|Placebo|Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
214937561|NCT00955981|DRUG|RDEA594|Uricosuric agent for the treatment of gout
214937562|NCT00955981|DRUG|Placebo|Matching placebo
214937563|NCT02290600|DEVICE|Continuous Glucose Monitor|CGM sensor calibration individualization
214675044|NCT04536324|PROCEDURE|Subcutaneous parenteral hydration|Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.
214937564|NCT04326439|DRUG|Cytarabine|100 mg/m²/dose every 12 hours IV Days 1-10
214937565|NCT04326439|DRUG|Daunorubicin|50 mg/m²/dose IV Days 1, 3, 5
214336806|NCT03899116|OTHER|deflation of pneumatic tourniquet|gradual deflation with variable degrees
215073684|NCT01397110|OTHER|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
215073685|NCT02355652|DEVICE|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
215073686|NCT02355652|DEVICE|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
214937566|NCT04326439|DRUG|Erwinase|25,000 International Units/m²/dose IM Days 2, 9
214937567|NCT04326439|DRUG|Etoposide|150 mg/m²/dose IV Days 1-5
214937568|NCT04326439|DRUG|Gemtuzumab ozogamicin|Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.
214937569|NCT04326439|PROCEDURE|Stem cell transplantation (SCT)|Transplantation of multipotent hematopoietic stem cells from bone marrow
214937570|NCT04326439|DRUG|Sorafenib|200 mg/m2/dose daily, rounded to accommodate tablet size. The maximum dose will be 400 mg. Days 7 through 34.
214937571|NCT04291677|OTHER|intervention musical|Intervention group in which musical intervention will be applied the first or third day of mechanical ventilation.
214937572|NCT04291677|OTHER|Without intervention musical|Control group with standard treatment without musical intervention.
215073687|NCT01420692|DRUG|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
215073688|NCT01420692|DRUG|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
215073689|NCT01183520|DIETARY_SUPPLEMENT|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
214937573|NCT03643913|PROCEDURE|Deep neuromuscular block|Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).
214937574|NCT03643913|PROCEDURE|Moderate neuromuscular block|Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).
214937575|NCT03643913|DRUG|Neuromuscular Blocking Agents and reversing agents|Deep neuromuscular block versus moderate neuromuscular block.
214937576|NCT05805085|DEVICE|Lens A|Hydrogel Daily Disposable Toric Contact Lens for 15 minutes
214937577|NCT05805085|DEVICE|Lens B|Silicone Hydrogel Daily Disposable Toric Contact Lens for 15 minutes
215073690|NCT00730041|DEVICE|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
214675045|NCT02706093|OTHER|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at \~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
214675046|NCT02706093|OTHER|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
214675047|NCT02706093|OTHER|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax \[25min; \~150kcals; 4d/wk\]
214675048|NCT02706093|OTHER|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax \[15min; \~90kcals; 4d/wk\]
214937578|NCT04108949|BEHAVIORAL|Tuning in to Kids|A psychosocial intervention focusing on emotion socialization and emotion coaching.
214937579|NCT04108949|BEHAVIORAL|Treatment as usual|See description included in arm/Group description.
214675049|NCT02751307|DRUG|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
214675050|NCT02751307|DRUG|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
214675051|NCT03463265|DRUG|nab-sirolimus|nab-sirolimus, single agent
214675052|NCT03463265|DRUG|nab-sirolimus + temozolomide|temozolomide, combination
214937580|NCT06136598|DRUG|Opevesostat|Tablets to be taken orally.
214675053|NCT03463265|DRUG|nab-sirolimus + bevacizumab|bevacizumab, combination
214675054|NCT03463265|DRUG|nab-sirolimus + lomustine|lomustine, combination
214937581|NCT06136598|DRUG|Dexamethasone|Tablets to be taken orally
214937582|NCT06136598|DRUG|Fludrocortisone|Tablets to be taken orally.
214937583|NCT06136598|DRUG|Hydrocortisone|Tablet to be taken orally as a rescue medication.
214937584|NCT03046901|DRUG|Vancomycin|Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
214937585|NCT05451784|DRUG|PD1+ TILs (NUMARZU-001) product infusion|"The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute.~Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following:~* Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion.~* Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist.~Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction)."
214675055|NCT03463265|DRUG|nab-sirolimus + marizomib (MRZ)|marizomib (MRZ), combination
214675056|NCT03463265|DRUG|nab-sirolimus + temozolomide + radiotherapy|temozolomide + radiotherapy, combination
214675057|NCT03952546|DEVICE|Saline-coupled Bipolar Sealer|The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.
214675058|NCT03952546|DEVICE|Unipolar electrocautery|The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
214675059|NCT00416351|DRUG|clofarabine|
214675060|NCT00218244|OTHER|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
214675061|NCT00218244|OTHER|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
214336807|NCT06401681|OTHER|Balance training|The balance exercises consist of single limb stances with eyes open and closed, single-leg hops with stabilization, and single-leg hops and reach. Thirty-second breaks will be provided between exercise sets. Progressions for single-leg stance exercises involve longer durations and introduction of unstable surfaces. Progressions for hopping exercises involve longer hopping distances. To progress to the next level, participants must complete a balance training session without any errors. Errors include 1) touching the floor or bracing with the opposite limb, 2) excessive lateral trunk flexion or hip abduction, 3) hands coming off hips (hop tasks) or shoulders (stance tasks), 4) missing the landing target, 5) using the reach leg for a substantial amount of weight bearing.
214336808|NCT01469676|DEVICE|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
214937586|NCT06683053|DRUG|empagliflozin|Comparing the benefits of both doses of empagliflozin (10 mg versus 25 mg) in terms of heart ejection fraction and quality of life.
215073691|NCT00730041|DEVICE|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
214336809|NCT00229684|DRUG|Tesaglitazar|2 mg once daily in oral form
214336810|NCT00229684|DRUG|pioglitazone|45 mg once daily in oral form
214336811|NCT03574025|OTHER|Questionnaire|To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
214675062|NCT04936672|BEHAVIORAL|Brisk walking and Tai Chi Chuan|This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.
214675063|NCT04137172|PROCEDURE|laparoscopic (IPOM) hernioplasty without repair|"Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap ."
214937587|NCT01702675|DRUG|ACH15 50 mg|ACH15 50mg capsule
214937588|NCT01702675|DRUG|ACH15 250 mg|ACH15 250mg capsule
214937589|NCT01702675|DRUG|ACH15 500mg|ACH15 500 mg capsule
215073692|NCT06277414|OTHER|collection of laboratory test results, imaging results and symptoms|collection of laboratory test results, imaging results and symptoms
215073693|NCT03564522|PROCEDURE|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
215073694|NCT03564522|RADIATION|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
214336812|NCT02252081|DRUG|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min
214336813|NCT02252081|DRUG|Placebo|placebo pill(s) orally per day for 16 weeks
214336814|NCT00009230|DRUG|Celecoxib|
214336815|NCT04407897|RADIATION|Stereotactic radiotherapy|Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
215073695|NCT03966963|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|Trauma-Focused Therapy
214336816|NCT01297842|DRUG|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
215073696|NCT05970003|OTHER|Copenhagen exercises|"Group A performs copenhagen exercises~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
214937590|NCT01702675|DRUG|ACH15 - 1000mg|ACH15 500mg capsule - two 500mg capsules in single dose
214937591|NCT01702675|DRUG|ACH15 - 2000mg|ACH15 500mg capsule (four 500mg capsules in one dose)
215073697|NCT05970003|OTHER|Holmich exercises|"The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period.~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
214336817|NCT01297842|DRUG|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
214336818|NCT04412902|DRUG|adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy
214336819|NCT01498926|DRUG|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
214336820|NCT01498926|DRUG|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
214937592|NCT01702675|DRUG|ACH15 - 500mg|ACH15 - 500mg twice a day for 7 days
214937593|NCT01702675|DRUG|Placebo 250 mg|Capsule manufactured to mimic ACH15 250 mg capsule
215073698|NCT05809050|DIAGNOSTIC_TEST|BM aspirate|Bone Marrow aspiration \& Examination
215073699|NCT06329063|DRUG|Vasopressin|Administration of vasopressin (20 IU) (oral spray)
214937594|NCT01702675|DRUG|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule
214937595|NCT01702675|DRUG|Placebo 1000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
214336821|NCT00491244|DRUG|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
214336822|NCT00491244|DRUG|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
214937596|NCT01702675|DRUG|Placebo 2000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
215073700|NCT06329063|DRUG|Placebo|Administration of placebo (oral spray)
215073701|NCT05526781|DEVICE|Clareon monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
215073702|NCT00043355|DRUG|interferon gamma-1b|500 mcg, oral, three times weekly
214675064|NCT04137172|PROCEDURE|aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS|"Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation"
214675065|NCT04137172|PROCEDURE|laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0|The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
215073703|NCT04085458|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
215073704|NCT04549779|PROCEDURE|Low volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
215073705|NCT04549779|PROCEDURE|Intermediate volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
215073706|NCT04549779|PROCEDURE|High volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
215073707|NCT03632993|DRUG|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
214675066|NCT03796169|BEHAVIORAL|Personal notification|Baseline quality indicators of each endoscopist were measured and those were notified individually.
214675067|NCT03796169|BEHAVIORAL|Open notification|Quality indicators were measured for 3 months after 1st interventions and those were notified openly
214937597|NCT01702675|DRUG|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
214937598|NCT00095745|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
214937599|NCT04840420|OTHER|social prescribing|as above
214336823|NCT05548075|DRUG|Psilocybin|Up to 25mg of Psilocybin on 2 occasions.
214336824|NCT05548075|BEHAVIORAL|Therapeutic support|Psychological and physical therapeutic support
214336825|NCT03189251|OTHER|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
214336826|NCT00510029|DRUG|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
214336827|NCT05448001|DRUG|JP-1366 20mg|JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
214336828|NCT05448001|DRUG|Lansoprazole 30mg|JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
214937600|NCT04840420|OTHER|usual care|as above
214937601|NCT05741853|BEHAVIORAL|Video-Implemented Script Training for Aphasia (VISTA)|Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
214336829|NCT02802553|DEVICE|Smart Goggle|Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The Smart Goggles is a non-invasive imaging system that does not require contact with patients.
214937602|NCT05741853|BEHAVIORAL|Lexical Retrieval Training (LRT)|Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.
214336830|NCT02802553|OTHER|Cardio-Green|Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
214336831|NCT02802553|DEVICE|SPY Elite Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
214336832|NCT02802553|DEVICE|Quest near-infrared (NIR) Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
214336833|NCT02802553|DEVICE|PDE Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
214336834|NCT02802553|DEVICE|Gamma probe|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
214336835|NCT02802553|OTHER|Blue Dyes|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
214336836|NCT06573151|DRUG|Selinexor, anti-PD-1 antibody and P-GemOx|Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);
214336837|NCT00207441|BEHAVIORAL|Arthritis Self management program|
214336838|NCT00207441|BEHAVIORAL|Chronic Disease Self Management Program|
214336839|NCT04151862|DEVICE|tight eye bandage|sterile eye pad made of 100% cotton
214937603|NCT00323401|OTHER|Antenatal classes|3 sessions of 3 hours each
214937604|NCT05999617|OTHER|Rehabilitation|Conventional rehabilitation (stretching, strengthening, balance) and dual task exercise training (simple math during active stretching, carrying the ball without dropping child while on the balance pad) will be applied 3 days a week for 12 weeks. Interventions will be implemented individually. Patients will be evaluated before and 12 weeks after the interventions.
214937605|NCT02233920|DRUG|Ventilat® - metered dose inhaler|
214937606|NCT00204477|DIETARY_SUPPLEMENT|soy milk|Each drink contained soy protein, fat, and carbohydrates calcium and phosphorous to give a total energy of 177.8 kcal. Subjects took two drinks per day.
214937607|NCT00204477|DIETARY_SUPPLEMENT|cow's milk|Each drink contained casein, fat, carbohydrates, calcium and phosphorous to give a total energy of 178.6 kcal. Subjects took two drinks per day.
214937608|NCT05036057|OTHER|Questionnaire|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
214937609|NCT06618196|BIOLOGICAL|LR20062|DTaP-HepB-IPV-Hib vaccine
214937610|NCT06618196|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Control hexavalent vaccine
214937611|NCT00632684|BEHAVIORAL|Interviews with a single treatment planning session|Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
214336840|NCT04151862|DEVICE|Soflex Soft Contact Lens|Therapeutic contact lenses (TCL)
214336841|NCT04193813|OTHER|Observational|Observational study
214336842|NCT06449911|PROCEDURE|HIFU|300 lines and 10,200 dots will be performed to each half lower two-thirds of the face and submental area of every participant.
214336843|NCT05008510|DRUG|Sabizabulin|Sabizabulin (Veru-111)
214336844|NCT05008510|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan-hziy
214336845|NCT05008510|DRUG|Sabizabulin/Sacituzumab govitecan-hziy Combo|Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
214336846|NCT02121145|BIOLOGICAL|Vivotif|3 oral doses
214336847|NCT02121145|BIOLOGICAL|Typherix|one intramuscular dose
214336848|NCT03766646|DEVICE|Optiflow|45l.min oxygen
214336849|NCT00928317|DRUG|ART621|3.0mg/kg s.c.
214336850|NCT00928317|DRUG|ART621|1.5mg/kg s.c.
214336851|NCT00928317|DRUG|ART621|0.75mg/kg s.c.
214336852|NCT00928317|DRUG|Placebo|Placebo s.c.
214336853|NCT00759967|PROCEDURE|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
214336854|NCT00759967|PROCEDURE|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
214336855|NCT02966080|DRUG|HEP-IV|
214336856|NCT06034366|DRUG|0.01% atropine|0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
214336857|NCT06034366|OTHER|0.9% sodium chloride|placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks
214937612|NCT00632684|BEHAVIORAL|Adaptive treatment model|The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
214336858|NCT00994916|DRUG|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
214937613|NCT05189067|DRUG|Paclitaxel|i.v. 80mg/m\^2
214937614|NCT05189067|DRUG|Trastuzumab|i.v. loading dose of 8 mg/kg, followed by 6mg/kg
214937615|NCT05189067|DRUG|Docetaxel|i.v. 100mg/m2
214937616|NCT04543318|PROCEDURE|Deep temporal nerves|"Surgical procedure:~Group A Exploration on the affected side a facelift-type incision will be performed, and an anterior subcutaneous flap is then will be lifted for several centimetres. In the inferior zygomatic region, the plane of elevation is deepened into the sub-SMAS plane and a composite flap elevated for several centimetres. Following elevation in this plane, the distal facial nerve branches will be identified. The distal portion of the zygomatic nerve is usually located midway between the oral commissure and the helical root. and was confirmed by nerve stimulator.~The deep temporal fascia and temporalis muscle will be incised along the temporal fusion line and will be reflected from the skull to expose the divisions of the deep temporal nerves and the longest branch was traced and prepared for anastomosis end to end with the zygomatic branch after confirming the eyelid supply."
214937617|NCT04543318|PROCEDURE|massteric nerve|group B The same procedure as group A except tracing the masseteric nerve related to masseter muscle and anastomosis will be the same
214937618|NCT01185223|DRUG|Valganciclovir|Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
214336859|NCT03264157|DRUG|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
214336860|NCT03264157|DRUG|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
214937619|NCT01185223|DRUG|Ganciclovir|2x5mg/kg/d intravenous ganciclovir
214937620|NCT00388336|DRUG|Epoetin Alfa|
214937621|NCT06648551|DIAGNOSTIC_TEST|CONUT|It is a scale that uses albumin, lymphocytes, and cholesterol for the diagnosis of malnutrition
214937622|NCT02147951|DRUG|Talimogene Laherparepvec|Up to 4ml of talimogene laherparepvec per cycle visit
214937623|NCT06498466|OTHER|myofascial release|Myofascial release therapy (MRT) is a manual therapy technique that involves gradual stretching by a therapist or the individual, acting on the muscles and surrounding fascia. Its effects include increasing joint range of motion and mobility of soft tissues, eliminating imbalances in muscle tone, reducing muscle pain, reducing stress on joints, and increasing neuromuscular efficiency.
214937624|NCT00827749|DEVICE|respiratory plethysmography by inductance|contribution of respiratory plethysmography by inductance and informatic tool
214937625|NCT01500408|DRUG|Interferon beta-1a (current approved manufacturing process invloving FBS)|Single dose of 60 mcg given Intramuscularly (IM)
214937626|NCT01500408|DRUG|Interferon beta-1a (new process, manufactured without FBS)|Single dose of 60 mcg given Intramuscularly (IM)
214937627|NCT01981343|DIETARY_SUPPLEMENT|A-F Betafood|
214937628|NCT01981343|OTHER|Placebo|
214336861|NCT03264157|BIOLOGICAL|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
214336862|NCT00288496|DRUG|polyethylene glycol bowel lavage solution|
214937629|NCT00359736|DRUG|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
214336863|NCT00191321|DRUG|Teriparatide|
214336864|NCT05673694|DRUG|EG017|According to the dosage group of the program, once a day.
214336865|NCT01037309|DRUG|PRO044 SC|Subcutaneous injection, once a week, for five weeks
214336866|NCT01037309|DRUG|PRO044 IV|Intravenous injection, once a week, for five weeks
214336867|NCT02411721|BEHAVIORAL|Animal Assisted Intervention|"1. Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.~2. The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.~3. Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination."
214336868|NCT00268125|DEVICE|Acupression's bracelet|
214336869|NCT00268125|BEHAVIORAL|Hygiene and dietetic advices|
214675068|NCT03796169|BEHAVIORAL|Education|Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
214336870|NCT00786916|DRUG|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
214937630|NCT06583447|BEHAVIORAL|Calorie-restricted diet (CRD)|"Standardized lifestyle interventions for all obese children and their parents will be constructed by endocrinologists and dietitians to increase physical activity and healthy eating habits. Physical activity interventions include decreasing time spent in sedentary activities, increasing the amount of physical activity, and recommending at least 60 minutes of moderate-intensity exercise per day. Individualized dietary counseling is provided to address the comorbidities in obese children.~Based on the standardized lifestyle intervention, the study subjects in the control group will be treated with CRD. Total daily energy intake will be restricted to 80% of the energy requirement for each age group in the Dietary Reference Intakes of Nutrients for Chinese Residents DRIs 2013. A daily food diary will be kept for at least one weekday and one weekend per week."
214937631|NCT06583447|BEHAVIORAL|Time-restricted eating (TRE)|Based on the standardized lifestyle intervention mentioned by the calorie-restricted diet (CRD) intervention, TRE is administered to the study subjects in the intervention group. The eating window is limited to 12 hours per day, with the last meal no later than 7:00 p.m., and the study subjects are free to choose their eating window. Energy intake is not restricted during the eating period, and calorie-free, sugar-free beverages (water, tea, coffee) are allowed during the fasting period. A daily food diary will be kept for at least one weekday and one weekend per week.
214937632|NCT04272606|DRUG|Tranexamic Acid|Antifibrinolytic Agent
214937633|NCT04272606|DRUG|Saline Solution|Placebo
214937634|NCT04272606|DIAGNOSTIC_TEST|Visual Acuity Exam|Supplemented into standard of care daily neurological exam on day of surgery and day after
214937635|NCT04272606|DIAGNOSTIC_TEST|3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)|3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
214937636|NCT05926752|DEVICE|SoLá therapy|SoLá therapy is a photobiomodulation device that works by stimulating mitochondria, soothing tense muscles, and promotes healing.
214937637|NCT05926752|OTHER|Pelvic floor physical therapy|Physical therapy is manual myofascial release, muscles stretches, and exercises designed to help myofascial pelvic pain
214937638|NCT06375096|OTHER|evaluate bone mineral density|observation effect of graves' in bone mineral density in children
214937639|NCT02432391|BEHAVIORAL|GEM|GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.
215073708|NCT02657655|DEVICE|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
215073709|NCT01552551|BEHAVIORAL|Assessment and education|PA Healthy Steps program
215073710|NCT01552551|BEHAVIORAL|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
215073711|NCT01552551|BEHAVIORAL|Healthy Steps in Motion|Group exercise program
215073712|NCT02645643|OTHER|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
215073713|NCT01372943|BIOLOGICAL|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
214336871|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
215073714|NCT00453037|BEHAVIORAL|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
214675069|NCT05319951|DRUG|Oral Rehydration Salts power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
215073715|NCT00453037|BEHAVIORAL|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
214675070|NCT05319951|DIETARY_SUPPLEMENT|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
214675071|NCT05319951|DIETARY_SUPPLEMENT|water|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
214675072|NCT01371838|DRUG|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
214675073|NCT01371838|DRUG|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
214675074|NCT01334125|DRUG|Metformin|Metformin 1000 mg once daily by mouth for 9 months
214675075|NCT01334125|DRUG|Placebo|2 capsules once daily by mouth for 9 months
214675076|NCT02698592|DEVICE|CelsiusTMDS® 8 mm catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
214937640|NCT04466761|DIETARY_SUPPLEMENT|Monosaccharide Powder|Monosaccharide powder dissolved in water.
214937641|NCT04466761|OTHER|Placebo Comparator|Placebo (cellulose powder).
214937642|NCT05644821|OTHER|complex intervention|"The intervention has several elements:~1. Regular symptom monitoring via ePROMs~2. Alarm when defined thresholds of EPIC-26 or PHQ-4 are reached or exceeded, 3.) In case of alarm, standardized telephone contact by a study nurse at the treating center with the offer to coordinate a urological consultation at the center, 4.) if requested by the patient: a urological consultation at the treating prostate cancer center by urologists trained in the PRO-P study,~4\) content of the consultation: if necessary, the guideline-compliant initiation of further diagnostics and therapy including in this context necessary follow-up contacts and 5) postal communication of the ePROM results in case of an alarm as well as postal dispatch of a report of the findings in case of a urological consultation at the treating prostate cancer center to the practicing, treating urologist."
214937643|NCT05644821|OTHER|current clinical practice|current clinical practice
214937644|NCT03090724|DRUG|BIA 5-453|100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
214937645|NCT04064021|PROCEDURE|Acupunture|Patient will receive 12 acupuncture treatments over 6 weeks (2x per week)
214937646|NCT01258179|OTHER|Analysis of PSP and PAP from venous blood samples|to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery
214937647|NCT05428202|DRUG|GN037|GN-037 cream containing urea, salicylic acid, retinoic acid and clobetasol 17-propionate and matching placebo
214937648|NCT05428202|DRUG|Placebo|Placebo cream containing base without active ingredients
214937649|NCT04028622|OTHER|TCAD (telemedicine anesthesia consultation)|Patients in the TCAD (telemedicine anesthesia consultation) group, arrange their bookings on a website and realise their anesthesia consultation from a platform from home
214937650|NCT06767748|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
214937651|NCT06767748|DRUG|insulin degludec|insulin degludec s.c.,once-daily，treat-to-target dose
214937652|NCT02250482|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
214937653|NCT00057304|DRUG|RO 205-2349|
214937654|NCT02012790|OTHER|Diet|The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
214675077|NCT02698592|DEVICE|Thermocool® 3.5 mm catheter of irrigated tip|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
214675078|NCT02698592|DEVICE|Thermocool® SF catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
214675079|NCT01275261|BEHAVIORAL|Nursing protocol to avoid Foley catheter placement|A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
214675080|NCT00292292|DEVICE|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
214675081|NCT00292292|DEVICE|Charite Artificial Disc|Insertion of the Charite
214675082|NCT02734992|BEHAVIORAL|ACT+ MTAU|Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou \& Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.
215073716|NCT02743949|DRUG|Vonoprazan|Vonoprazan over-encapsulated capsules
214675083|NCT02734992|BEHAVIORAL|Waitlist Control +MTAU|Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
214937655|NCT03378297|DRUG|Metformin|Metformin tablets 850 mg x 2 orally
214937656|NCT03378297|DRUG|Acetylsalicylic acid|Acetylsalicylic acid tablets 160 mg x1 orally
214937657|NCT03378297|DRUG|Olaparib|Olaparib capsules 300 mg x 2 orally
214937658|NCT03378297|DRUG|Letrozole|Letrozol tablets 2.5 mg x 1 orally
214937659|NCT05916859|OTHER|Group 2 PDT (10 s)|\- Conventional endodontic treatment associated with PDT (10 s)
214937660|NCT05916859|OTHER|Group 3 PDT 20 s|Conventional endodontic treatment associated with PDAT (20 s)
214937661|NCT05916859|OTHER|Group 1. Placebo|Conventional endodontic treatment
214937662|NCT02923362|PROCEDURE|Laparoscopic Fundoplication|The gastric fundus of the stomach is wrapped or plicated around the lower end of the esophagus and and stitched in place reinforcing the closing function of the lower esophageal sphincter. The hiatus is also narrowed down with sutures or mesh to prevent or treat a concurrent hiatal hernia.
214937663|NCT02923362|DEVICE|LINX Antireflux|The LINX is a flexible band of interlocked titanium beads with a magnetic core. The LINX is placed around the lower esophageal sphincter to help restore the function of the LES by preventing reflux into the esophagus.
214937664|NCT03943264|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
214937665|NCT03185754|PROCEDURE|Sublobar resection|Sublobar resection
214937666|NCT03185754|PROCEDURE|lobectomy|lobectomy
215073717|NCT02743949|DRUG|Esomeprazole|Esomeprazole over-encapsulated tablets
215073718|NCT02743949|DRUG|Esomeprazole Placebo|Esomeprazole placebo-matching capsules
215073719|NCT01404793|DRUG|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
215073720|NCT03549208|BIOLOGICAL|LBVE01|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
215073721|NCT03549208|BIOLOGICAL|LBVE02|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
214336872|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
214336873|NCT00636454|BEHAVIORAL|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
214336874|NCT00636454|OTHER|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
214486420|NCT06768593|PROCEDURE|RIFP Block|After aseptic conditions are ensured, with high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) bilateral block will be applied to Group R. As the patient is in supine position, the USG probe is placed in transverse plane on the sternum and will be directed downwards and laterally and rotated to determine the xiphoid and just below the rectus abdominis muscles. Costal cartilage and rectus abdominis muscle sonographically will be shown. This region corresponds to the 3-4 cm lateral and 3-4 cm caudal region of the xiphoid. Using the in-plane technique, the block needle will be advanced in the caudal-cephalic direction, and 5 ml saline will be injected into the area between the rectus muscle and costal cartilage to verify the block location. 30 ml of 0.25% bupivacaine (Buvacaine, Polifarma ®) will be injected to each side, which corresponds to 60 ml total local anesthetic-saline mixture in Group R.
214675084|NCT01509586|DRUG|Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product|The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
214675085|NCT06957002|DRUG|Bosentan|Bosentan : 62.5 mg twice a day for 4 weeks and 125 mg twice a day during 9 weeks (treatment length 3 months)
214675086|NCT06957002|DRUG|Glucocorticoids|prespecified GC tapering schedule
214675087|NCT03416582|BEHAVIORAL|Symptom Management Education and Nurse Coaching|"The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the Cancer Treatment Symptom Management Education Toolkit geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration."
214675088|NCT03416582|BEHAVIORAL|Drinks Diary|The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
214937667|NCT05705154|BEHAVIORAL|Psychology interventions|"Based on clinical expertise and theory, it is anticipated the following elements may be included in the intervention:~* Progressive breathing pattern retraining, including education, self-observation, relaxation, body scanning, postural re-alignment~* Identifying the connections between body and mind to address anxiety and breathlessness~* Coping skills for managing anxiety using principles from narrative therapy and mindfulness~* Online materials to improve self-efficacy with home practice~* Social connection with other CYP for peer support, and resource sharing~* Activities to help CYP reconnect with their usual activities, skills, abilities, interests, support systems."
214937668|NCT02683382|DEVICE|Moisturizing Eye Product in Liquid Formula|Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
214937669|NCT05720494|DRUG|JZP441|Oral study drug administered for up to 4 weeks
214675089|NCT04901026|OTHER|An in-house manikin|Participants obtain an in-house manikin
214675090|NCT03525977|PROCEDURE|Fascia iliaca block arm|The fascia iliaca block will be performed by the anesthesiologist on call
214675091|NCT05265013|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m\^2 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion
214675092|NCT05265013|BIOLOGICAL|pembrolizumab|200 mg every three weeks on days 1 and 22 of each 6-week cycle, 30 minute IV infusion
214336875|NCT03185624|DRUG|Rifaximin|Antibiotics
214336876|NCT03243331|DRUG|Gedatolisib|Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
214675093|NCT03341104|DRUG|Bupivacaine liposome|Replace bupivacaine with bupivacaine liposome
214675094|NCT00124540|DRUG|misoprostol|
214937670|NCT05720494|DRUG|Placebo|Oral placebo administered for up to 4 weeks
214336877|NCT03243331|DRUG|PTK7-ADC|PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
214336878|NCT01734746|PROCEDURE|Tracerinjection|The intervention concerns the tracerinjection for detection of the sentinel node.
214937671|NCT05157542|DRUG|Durvalumab|Day 1 and 22, 1500mg
214937672|NCT05157542|DRUG|nanoparticle albumin bound paclitaxel|Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5
215073722|NCT03549208|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
215073723|NCT01611363|DRUG|ASP1941|Oral
215073724|NCT01611363|DRUG|Placebo|Oral
215073725|NCT01581489|PROCEDURE|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
215073726|NCT05005845|DRUG|NFX-179 gel|NFX-179 topical gel is the active investigational product being studied
215073727|NCT05005845|DRUG|Vehicle gel|NFX-179 vehicle gel is the placebo comparator for this study
215073728|NCT04553744|OTHER|Survey Administration|Complete survey
215073729|NCT00308412|BIOLOGICAL|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
215073730|NCT00308412|BIOLOGICAL|Placebo|Placebo for rHPIV3cp45 vaccine
214937673|NCT05157542|RADIATION|low dose radiation therapy|10 Gy in 5 fractions, 20 Gy in 10 fractions, 30 Gy in 15 fractions respectively in our three groups from Day1
214937674|NCT02486640|DRUG|Interferon beta-1b (Betaferon, BAY86-5046)|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
214675095|NCT00124540|DRUG|placebo|placebo resembling misoprosotl
214675096|NCT04102891|OTHER|Microbiota modulation diet|The Collect\&Go shopping carts of the 400 participants will be adapted by replacing food products by healthier alternative ones based on the Flemish food-based dietary guidelines and the microbiota modulation diet guidelines for the control and study arm respectively. Based on these guidelines, and the habitual dietary pattern and level of food literacy of the participant, personalized dietary advice will be provided. A dietitian helpline will be available for further nutritional issues as well.
214675097|NCT02612090|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry
214675098|NCT02612090|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|Placebo
214336879|NCT04279925|DEVICE|ORIF (Open reduction internal fixation): locally-made miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia. The plate used in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.
214336880|NCT04279925|DEVICE|ORIF: Imported miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using Biomet® miniplate 1.5 produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate used in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog. Biomet® screw 1.5 utilized in this study is also produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws.
214336881|NCT02410681|DEVICE|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.~1. 3 recordings after the baseline visit~2. 3 recordings 6 weeks after the baseline visit~3. 3 recordings one year after the baseline visit"
214675099|NCT04013737|DEVICE|EPIC IMPOC|Clinical Decision Support System for antibiotic prescribing.
214675100|NCT01264133|DRUG|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
214675101|NCT02242071|BIOLOGICAL|Stem Cell|intrathecal autologous bone marrow mononuclear cell transplantation
214675102|NCT00641043|DRUG|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
214675103|NCT00641043|DRUG|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
214675104|NCT02584634|DRUG|Avelumab|Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
214675105|NCT02584634|DRUG|PF-06463922|Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
214675106|NCT02584634|DRUG|Crizotinib|Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
214675107|NCT01629342|BEHAVIORAL|Standardized activities|"All patients do each of the following standardized activities over a course of 2 days:~* treadmill walking (5 minutes, 1 and 2km/h)~* staircase walking (1 floor, normal pace)~* cycling with fixed load (5 minutes)~* standing up from sitting position and sitting down again (x5)~* standing up from supine position~* turning from left to right and back while lying in bed~* raising outstretched arm 90° (x5, standing position)~* eating (5 minutes, sitting position)~* drinking a glass of water~* sleeping (6 hours)"
214937675|NCT02486640|DEVICE|Betaconnect Autoinjector|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
214937676|NCT02290236|DEVICE|Pulseoximetry|Peripheral saturation will be recorded continuously
214937677|NCT03577977|DRUG|Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)|Betaferon was injected subcutaneously as prescribed by the treating physician.
214937678|NCT03140072|DRUG|AZD9898|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
214675108|NCT01613469|DRUG|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
214937679|NCT03140072|DRUG|Matching Placebo|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
214937680|NCT06090643|OTHER|Best Practice|Receive CRC screening usual care
214937681|NCT06090643|OTHER|Consultation|Receive consultation with clinic staff
214937682|NCT06090643|OTHER|Educational Intervention|Receive education and training on CRC screening
214937683|NCT06090643|OTHER|Electronic Health Record Review|Ancillary studies
214937684|NCT06090643|OTHER|Fecal Immunochemical Test|Receive FIT kit with culturally tailored instructions
214937685|NCT06090643|BEHAVIORAL|Feedback|Receive feedback on CRC screening
214937686|NCT06090643|BEHAVIORAL|Health Education|Receive CRC screening recommendations
214937687|NCT06090643|OTHER|Support Education Activity|Utilize clinical decision support tool
214675109|NCT06192199|DIAGNOSTIC_TEST|2018 edition of the Guidelines for Diagnosis|According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group
214675110|NCT00077181|DRUG|cytarabine|Given IV
214675111|NCT00077181|DRUG|triapine|Given IV
214937688|NCT06090643|OTHER|Text Message-Based Navigation Intervention|Receive text message reminders
214937689|NCT03370575|DRUG|ethiodized poppyseed oil|Hysterosalpingography using ethiodized poppyseed oil
215073731|NCT03327220|DEVICE|iovera°|The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
214675112|NCT00077181|OTHER|laboratory biomarker analysis|Correlative studies
214675113|NCT03976232|DEVICE|Trans cranial Direct Current Stimulation (tDCS)|Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.
214675114|NCT03976232|OTHER|Craniosacral therapy (CST)|Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.
215073732|NCT03336801|PROCEDURE|Back Surgery|All patients undergo basic back surgery.
215073733|NCT03336801|DRUG|Propofol|Anesthesia on propofol alone.
215073734|NCT03336801|DRUG|Sevoflurane|Anesthesia on sevoflurane alone.
214675115|NCT03976232|OTHER|tDCS+ CST|This group will receive tDCS along with CST
214675116|NCT03345212|OTHER|Exercise training|The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
214937690|NCT03370575|DRUG|the second-generation non-ionic monomer contrast|Hysterosalpingography using the second-generation non-ionic monomer contrast
214937691|NCT01869621|DRUG|Metformin|6 days treatment with metformin to steady-state
214937692|NCT02750475|DRUG|Sunscreen Sport Lotion (BAY987516)|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)
214937693|NCT02750475|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
214937694|NCT01037127|DRUG|GSK1120212|Daily oral dosing
214937695|NCT02622373|DEVICE|PEA POD Infant Body Composition System|The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
214937696|NCT00826592|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
214675117|NCT04275310|BEHAVIORAL|Microeconomic Intervention|The intervention will consist of six sessions on six different days. Sessions will be held at VCU or at one of VCU's community partners. Each session will last for around 2 ½ hours (around 15 hours total). There will be breaks and food will be provided. During the sessions the facilitators will provide education on a variety of topics, including economic services that are available to people living in Richmond, job skills (such as creating a resume and dealing with discrimination at work), personal finance education, gender transition ideas, and HIV prevention. The sessions will occur in a group of about 4-10 transgender women.
214336882|NCT02410681|RADIATION|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
214937697|NCT00507078|PROCEDURE|Surgical treatment for OSA|
214336883|NCT02410681|OTHER|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:~1. At the baseline visit~2. Three months after the baseline visit~3. One year after the baseline visit"
214336884|NCT01284647|DRUG|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
214336885|NCT01284647|DRUG|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
214336886|NCT01736280|OTHER|Standard of Care|Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
214937698|NCT05930028|DRUG|Fimasartan|Subjects take the investigational products once a day for 8 weeks.
214937699|NCT05930028|DRUG|Ezetimibe/Atorvastatin|Subjects take the investigational products once a day for 8 weeks.
214937700|NCT05930028|DRUG|Fimasartan Placebo|Subjects take the investigational products once a day for 8 weeks.
214336887|NCT03983590|OTHER|Visual Analogic Scale|VAS are collected in the first 24 hours after inclusion, 15 minutes, during and 15 minutes after the bed bath. Each time of collection are noted.
214336888|NCT01645475|DRUG|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
214336889|NCT00028834|DRUG|gemcitabine hydrochloride|Given IV
214486421|NCT06768593|OTHER|Postoperative pain management|"Ibuprofen 400 mg (Ibuprofen, Polifarma ®) and tramadol 100 mg (Contramal, Abdi İbrahim ®) IV single bolus dose will be given 20 minutes before the end of the surgical procedure for postoperative analgesia.~NRS scores at rest and while moving will be evaluated and recorded and if the NRS score is ≥ 4, meperidine 0,5 mg/kg (Aldolan®) IV will be administered as a rescue analgesic."
214486422|NCT06769321|DEVICE|Automatic Thermo-mechanical Massage Bed|The MASTER V6 (Master series, CGM MB-1701, CERAGEM Co. Ltd., Cheonan, Korea) used in this study is a commercially available automated thermo-mechanical therapy device that combines mechanical spinal stimulation with far-infrared (FIR) heat treatment.
214937701|NCT05930028|DRUG|Ezetimibe/Atorvastatin Placebo|Subjects take the investigational products once a day for 8 weeks.
214937702|NCT06646328|PROCEDURE|Central venous access|Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein.
214937703|NCT06646328|DEVICE|Pump-assisted circuit|The pump-assisted circuit to be used will be Fresenius multiFiltrate (Fresenius Medical Care GmbH, Bad Homburg v.d.H., Germany). EMIC2® Fresenius Medical Care high-flux synthetic membrane will be used
214937704|NCT06646328|DRUG|Heparin sodium|Non-fractional heparin will be used in one arm with an initial dose of 500-1000 IU/hour with adaptation of the infusion to the patient and the clotting time.
214937705|NCT06646328|OTHER|Regional citrate anticoagulation|Regional citrate anticoagulation will be used in the other arm with an initial dose of 3 mmol/L and with a calcium reinfusion solution at an initial dose of 2 mmol/L, with adaptation of both infusions to the patient ionic calcium levels.
214937706|NCT06646328|PROCEDURE|Blood and ultrafiltrate samples|"Blood samples will be taken from the prefilter (inlet filter plasma concentration \[Ci\]) and postfilter (outlet filter plasma concentration \[Co\]) sites of the extracorporeal circulation circuit. The ultrafiltrate will be collected directly from the outlet of the hemofilter (ultrafiltrate concentration \[Cuf\]).~The samples will taken at the beginning of CRRT (T0) and at the following times: T0, Ci; after 60 min (T1) and after 24 hours (T2) of CRRT, Ci, Co and Cuf.~Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein."
214336890|NCT00028834|BIOLOGICAL|bevacizumab|Given IV
214336891|NCT00028834|OTHER|laboratory biomarker analysis|Correlative studies
214336892|NCT04777279|BEHAVIORAL|individual physical exercise group|The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.
214336893|NCT04777279|DIETARY_SUPPLEMENT|individual Branched-Chain Amino Acids supplements group|The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.
214336894|NCT04777279|OTHER|combination of physical exercise and nutrition supplements group|The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
214336895|NCT03264625|DRUG|Cholecalciferol (2000iu qd)|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
214336896|NCT03264625|OTHER|Routine therapy for PD|Patients randomized to the placebo group will receive routine therapy for PD.
214336897|NCT05927441|DEVICE|DragonFly Transcatheter Mitral Valve Repair System|Edge-to-edge repair with DragonFly System
214336898|NCT05495503|DEVICE|Prototype (814A-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
214336899|NCT05495503|DEVICE|Prototype (814B-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
214336900|NCT05495503|DEVICE|Prototype (814C-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
214336901|NCT05495503|DEVICE|Prototype (814D-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
214937707|NCT02584998|OTHER|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
214937708|NCT02584998|OTHER|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
214937709|NCT03101852|DIETARY_SUPPLEMENT|Plumpy Nut|
214937710|NCT03101852|DIETARY_SUPPLEMENT|Plumpy Sup|
214937711|NCT02637713|DEVICE|Stretta|Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter. It is approved for the management of GRED.
214937712|NCT02637713|PROCEDURE|Radiofrequency (RF) Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under moderate sedation or general anesthesia which uses radiofrequency (RF) energy applied to the lower esophagus over 14 minutes per FDA approved procedures.
214675118|NCT05506371|DRUG|Az+SRP|Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis
214675119|NCT05506371|DRUG|SRP|Scaling and root planning (SRP) treatment of periodontitis
214675120|NCT05506371|DRUG|No interventions|Diagnostocs to confirm the healthy state of the gingiva
214336902|NCT04087057|OTHER|Interview|Participate in interview
214336903|NCT04087057|OTHER|Medical Chart Review|Patients' medical records are reviewed
214336904|NCT04087057|BEHAVIORAL|Questionnaire|Complete questionnaires
214336905|NCT03678948|DEVICE|Radiofrequency-Based Debridement|In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
214336906|NCT03678948|DEVICE|Mechanical Debridement|Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
214336907|NCT04598516|DIAGNOSTIC_TEST|serum creatinine assay|peak change in serum creatinine in a period of 5 days from baseline (day 0) will be determined
214336908|NCT05106868|DEVICE|acupuncture|Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.
214336909|NCT06175728|DEVICE|S-Press|Leg Strengthening Device that can be used in supine and seated positions
214486423|NCT06768788|BEHAVIORAL|Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 1|Intervention: need support, two-month face-to-face and web-based need-supportive intervention program for PE teachers.
214675121|NCT03088605|DRUG|TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
214675122|NCT03088605|DRUG|Placebo to TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
214675123|NCT00241111|DRUG|zoledronic acid|
214675124|NCT00243893|DRUG|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
214675125|NCT00243893|DRUG|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
214675126|NCT00051688|DRUG|tezacitabine|
214675127|NCT00051688|DRUG|oxaliplatin|
214675128|NCT01709877|PROCEDURE|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
214937713|NCT02847182|BIOLOGICAL|Cord Blood Infusion|
214937714|NCT02847182|BIOLOGICAL|Placebo|
214937715|NCT02345889|DEVICE|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
214937716|NCT02345889|DEVICE|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
214937717|NCT02345889|DEVICE|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
214937718|NCT02345889|DEVICE|Standard Colonoscopy|Current standard of care colonoscopy
214937719|NCT00855205|DRUG|Rituximab|Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
214937720|NCT00312481|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
214937721|NCT00312481|DRUG|NA picosulfate magnesium citrate|150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.
214937722|NCT06619054|DRUG|KP-001|Oral single dose 50mg.
214937723|NCT00688311|DIETARY_SUPPLEMENT|Synbiotic 2000|A preparation consisting of 4 species of probiotic bacteria (10\^10 each) combined with 4 types of dietary fiber (2.5g each).
214937724|NCT00688311|DIETARY_SUPPLEMENT|Placebo|Placebo
214937725|NCT02405975|OTHER|SCRIPT|An online tool designed to train doctors in all areas of prescribing
214675129|NCT01713985|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
214675130|NCT01713985|DEVICE|Thermage|Radiofrequency treatment focusing radiofrequency energy
214336910|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
214336911|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
214336912|NCT00659269|DRUG|Chemotherapy|"Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800"
214336913|NCT01158222|DRUG|sunitinib malate|Given orally
214336914|NCT00783536|DRUG|Etanercept + Methotrexate|
214336915|NCT00783536|DRUG|DMARDS|
214336916|NCT04723433|OTHER|Oxygen gas -Conservative|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.
214937726|NCT03399903|DRUG|Pentasa vs Align|We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
214937727|NCT05311566|COMBINATION_PRODUCT|Camrelizumab plus Concurrent chemoradiotherapy|Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6\~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.
214937728|NCT01725932|BEHAVIORAL|Culturally adapted CBT based Self Help|Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
214937729|NCT05669898|BEHAVIORAL|Pain scores (numerical rating scale at rest and motion): will be assessed with numerical rating scale at both rest and motion on both knees.|Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
215073735|NCT04434625|DRUG|Polyethylene glycol|Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group and those in the control group underwent colonoscopy directly
215073736|NCT03227952|DEVICE|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
214675131|NCT00987051|PROCEDURE|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
214675132|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
214675133|NCT00856752|DRUG|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
214675134|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
214675135|NCT05164952|DRUG|Zoledronic Acid 4 MG|(4 mg via 15-min infusion every 6 months) for 24 months
214675136|NCT04471103|OTHER|Participation in a Delphi survey|Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.
214675137|NCT01759784|BIOLOGICAL|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
214675138|NCT03952923|BIOLOGICAL|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
214675139|NCT02225223|DEVICE|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
214675140|NCT02225223|DEVICE|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
214675141|NCT05132738|DRUG|Ripretinib treatment|"Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters.~The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen."
214675142|NCT05272059|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
214336917|NCT04723433|OTHER|Oxygen gas -Liberal|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
214336918|NCT06035926|OTHER|questionnaire|questionnaire
214336919|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI|
214336920|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI|
214336921|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
214336922|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
214336923|NCT02359292|DRUG|Placebo pMDI|
214937730|NCT05669898|OTHER|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale|For the functional assessment both before and after TKA surgery.
214937731|NCT05669898|BEHAVIORAL|Rehabilitation physiotherapy|Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.
214937732|NCT05479591|DRUG|IDegLira|Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.
214937733|NCT00416676|DRUG|carboplatin|
214937734|NCT00416676|DRUG|cisplatin|
214937735|NCT00416676|DRUG|cyclophosphamide|
214937736|NCT00416676|DRUG|etoposide|
214937737|NCT00416676|DRUG|vincristine sulfate|
214937738|NCT00416676|PROCEDURE|adjuvant therapy|
214937739|NCT00416676|PROCEDURE|conventional surgery|
214937740|NCT00416676|PROCEDURE|neoadjuvant therapy|
214937741|NCT00416676|RADIATION|radiation therapy|
214937742|NCT03424629|BIOLOGICAL|Low-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
214937743|NCT03424629|BIOLOGICAL|High-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 3×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
214937744|NCT03424629|DRUG|Methotrexate|Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
214937745|NCT00382395|DEVICE|SOLX Gold Shunt GMS-plus|Single use implant
214937746|NCT00382395|DEVICE|Ahmed FP7 Glaucoma Valve|Single use implant
214937747|NCT00077116|DRUG|busulfan|
214937748|NCT00077116|DRUG|cyclophosphamide|
214937749|NCT00077116|DRUG|cytarabine|
214336924|NCT04116554|DRUG|0.25% bupivacaine.|20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
214937750|NCT00077116|DRUG|gemtuzumab ozogamicin|
214937751|NCT00077116|DRUG|idarubicin|
214937752|NCT00077116|PROCEDURE|allogeneic bone marrow transplantation|
214937753|NCT00077116|PROCEDURE|peripheral blood stem cell transplantation|
214937754|NCT00077116|RADIATION|radiation therapy|
214675143|NCT05272059|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
214336925|NCT04116554|DEVICE|0.9%saline|20 ml of 0.9%saline will be injected on each side
214336926|NCT03135223|BEHAVIORAL|Co-created intervention to promote physical activity|A working group of girls and researcher co-created a school-specific intervention to promote physical activity
214675144|NCT02687113|DEVICE|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
214675145|NCT03952364|OTHER|PredictSURE IBD™|To evaluate a test called PredictSURE IBD™ in the US population
214675146|NCT03586804|OTHER|dual task|mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
214937755|NCT01113138|DIETARY_SUPPLEMENT|Mablet (Magnesium-supplement)|Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS
214937756|NCT01113138|DRUG|Magnesium Sulfate|Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
214336927|NCT05864027|BEHAVIORAL|Peer-led Oral Health Recovery Group|"The interactive Oral Health Recovery group will be centered around the tailored materials previously developed, with topics such as it's never too late to make a change, oral health and whole health, taking care of your teeth, and going to the dentist."
214336928|NCT05864027|BEHAVIORAL|Educational Video about Oral Health|The video comparison will be pulled from Toothflix 2.0 Patient Education DVD Series, which are patient education videos developed by the American Dental Association.
214937757|NCT01230684|PROCEDURE|Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)|The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
214937758|NCT05329051|BIOLOGICAL|SCTV01E|intramuscular injection
214937759|NCT05329051|BIOLOGICAL|Comirnaty|intramuscular injection
214937760|NCT00778102|DRUG|5-FU|Bolus 400mg/m2, day 1 every 2 weeks
214937761|NCT00778102|DRUG|5-FU|3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
214937762|NCT00778102|DRUG|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
214937763|NCT00778102|DRUG|Irinotecan|165mg/m2 1-hour iv infusion, day 1 every 2 weeks
214937764|NCT00778102|DRUG|Leucovorin|400mg/m2 2-hour iv infusion, day 1 every 2 weeks
214937765|NCT00778102|DRUG|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
214937766|NCT00778102|DRUG|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
214937767|NCT00778102|DRUG|bevacizumab [Avastin]|5mg/kg iv day 1 every 2 weeks
214937768|NCT06912386|DEVICE|taVNS|"Intervention Name: Transauricular Vagus Nerve Stimulation (taVNS)~Intervention Description:~Participants will receive transauricular vagus nerve stimulation on the tragus. Frequency: 2 sessions per day (one at 10 AM and one at 6 PM). Duration: Each session will last 15 minutes. Treatment Cycle: Stimulation will be applied for 5 days each month, starting 2 days before the expected beginning of the menstrual cycle, for a total of 2 months. The participants will adjust the level of maximum stimulation they considered painless."
214336929|NCT01132144|PROCEDURE|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~* Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~* Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~* Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
214336930|NCT01132144|PROCEDURE|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
214336931|NCT00962429|DRUG|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
214336932|NCT05966025|DRUG|Itopride|itopride will be taken by pateints one time per day by dose 100 mg
214336933|NCT05966025|DRUG|conventional therapy|will taken by patient in control group
214336934|NCT01970332|PROCEDURE|Revascularization Surgery|
214336935|NCT01970332|OTHER|Supervised exercise therapy|
214336936|NCT01842828|OTHER|Standard care plus electronic cigarettes|
214336937|NCT01842828|BEHAVIORAL|Standard care|
214336938|NCT01639898|DRUG|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
214336939|NCT01639898|DRUG|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
214336940|NCT03103867|DEVICE|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
214336941|NCT03103867|DEVICE|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
214937769|NCT06912386|DEVICE|SHAM stimulation|"Intervention Name: SHAM stimulation of the earlobe. Participants will receive SHAM stimulation on the earlobe, which does not stimulate the vagus nerve.~Frequency: 2 sessions per day (one at 10 AM and one at 6 PM). Duration: Each session will last 15 minutes. Treatment Cycle: Placebo stimulation will be applied for 5 days each month, starting 2 days before the expected beginning of the menstrual cycle, for a total of 2 months. The participants will adjust the level of maximum stimulation they considered painless."
214937770|NCT05368415|DRUG|Norepinephrine|mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
214937771|NCT06912568|DEVICE|Miniscrew insertion|four or two miniscrews insertions using computer-guided minimally-invasive and flapless approach
214937772|NCT06912568|DEVICE|Expander|In the TB group, the tooth-borne hyrax appliance was designed with bands on the maxillary first molars; in the BB4 group, the bone-borne expander was supported by 4 miniscrews inserted both in paramedian and parapalatal position of the palatal vault; in the BB2 group, the bone-borne expander was supported by 2 miniscrews inserted in the paramedian region of the palate. The same type of expansion screw and expansion protocol were used in all groups. Specifically, a 10mm hyrax click screw (Dentaurum, Bologna, Italy) was activated by 4 quarter-turns on the first day and by 3 quarter-turns per day during the active phase of treatment (0.20mm per turn, 0.6mm daily) until an 8mm screw opening was achieved.
215073737|NCT03857360|DIETARY_SUPPLEMENT|Pentabiocel|Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.
215073738|NCT03857360|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.
214336942|NCT01490060|DRUG|Fosaprepitant|150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
214336943|NCT01490060|DRUG|Dexamethasone|Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
214336944|NCT01490060|DRUG|5HT3 receptor antagonist|5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
214336945|NCT01490060|DRUG|Ifosfamide-based chemotherapy (AI)|Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
214336946|NCT01490060|DRUG|Doxorubicin|25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
214336947|NCT01490060|DRUG|Mesna|Prior to ifosfamide (Day 1) - 500 mg/m\^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m\^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m\^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
214336948|NCT01490060|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m\^2).
214336949|NCT01490060|DRUG|Vincristine|2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
214336950|NCT01877421|DRUG|2 mg KSL-W|
214336951|NCT01877421|DRUG|4 mg KSL-W|
214336952|NCT01877421|DRUG|6 mg KSL-W|
214336953|NCT01877421|DRUG|10 mg KSL-W|
214336954|NCT01877421|DRUG|20 mg KSL-W|
214336955|NCT01877421|DRUG|30 mg KSL-W|
215073739|NCT02762656|DRUG|Lidocaine|Lidocaine drip during surgery
214336956|NCT01877421|DRUG|50 mg KSL-W|
214336957|NCT01877421|DRUG|75 mg KSL-W|
214336958|NCT01877421|DRUG|100 mg KSL-W|
214336959|NCT01877421|OTHER|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
214336960|NCT04614428|BEHAVIORAL|RESILIENCE Program|"In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective."
214336961|NCT05497908|PROCEDURE|TAP block via lateral approach|TAP block via lateral approach
214336962|NCT05497908|PROCEDURE|TAP block via posterior approach|TAP block via posterior approach
214336963|NCT01831687|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
214336964|NCT01831687|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
214336965|NCT02566837|PROCEDURE|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
214336966|NCT02566837|PROCEDURE|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
214336967|NCT06216236|OTHER|Kinect intervention system combined with aerobic exercise training|A Kinect intervention system was used in the experimental group. The video displayed a skeletal simulation of the action. The participants could see their own actions and those of the teacher. After the video was completed, an accurate score for each action was displayed.
214486424|NCT06768788|BEHAVIORAL|Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 2|Intervention: autonomy or competence or relatedness support, one-month face-to-face and web-based need-supportive intervention program for PE teachers.
214937773|NCT06912568|RADIATION|CBCT|"All patients underwent CBCT examinations before the application of the RME device (T0) and post-treatment, after the 6-month retention period (T1). The exposure settings were as follows: 10 mA, 90 kV, total scanning time of 15.0 seconds, effective radiation time of 4.0 seconds, voxel size of 0.2 mm, scanning area of 14 x 16.5 cm, and an effective radiation dose of approximately 524 mGy/cm2.~The CBCT images analyzed in this study were not acquired specifically for this research but were part of an ongoing prospective randomized clinical trial aimed at evaluating the skeletal and dentoalveolar effects of three different orthodontic devices. The imaging protocol was established in accordance with ethical guidelines and was approved by the relevant institutional review board."
214486425|NCT06757088|DEVICE|M1 Stimulation Group|For M1, the anodal electrode will be placed over M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region.
214937774|NCT06910410|BEHAVIORAL|BodyScreen App|The BodyScreen App uses behavioural interventions along with haptic interruptions in social media app usage. The app will engage participants by sending them notifications, reminders, and activities to complete throughout the day and the week.
214937775|NCT00282906|DEVICE|hybrid PET-CT imaging system|15 mCi of FDG
214937776|NCT05481229|OTHER|nutritional interventions|Nutritional intervention will be initiated in patients at risk of overweight and obesity. A targeted nutritional intervention will be carried out, which will include consultation on dietary habits and physical activity as determined by diet and physical activity records. Consultations will be aimed at improving lifestyle and maintaining an adequate body weight.
214937777|NCT06909916|OTHER|Periprosthetic Fracture Knee Repaired CT Scans|The investigators will be assessing the use of weight-bearing CT and conventional CT, specifically its imaging, with RSA-like software, for analyzing fracture healing for a periprosthetic distal knee fracture.
214937778|NCT06910345|OTHER|A skin patch (2.1 mg melatonin) was applied to the melatonin group. The melatonin patches will be placed at 8:00 PM (on the upper chest or forearm, as determined by the patient) before going to sleep|A skin patch (2.1 mg melatonin) was applied to the melatonin group.
214937779|NCT06910735|OTHER|Control|Participants will receive the standard care that includes setting a weight-loss target based on the weight achieved at 12 months post-bariatric surgery following the standard multidisciplinary follow-up at the inclusion center
214937780|NCT06910735|BEHAVIORAL|Threshold financial incentive|Participants will receive the standard care with an additional financial incentive of 300 € if they successfully achieve the weight loss target corresponding to their weight at 12 months after bariatric surgery. This financial incentive will be awarded 12 months after their inclusion in the study.
214937781|NCT06910735|BEHAVIORAL|Proportional financial incentive|Participants will receive the standard care with an additional financial incentive, which will be determined based on the proportion of their actual weight loss in relation to the predefined weight loss target corresponding to their weight at 12 months after bariatric surgery. The financial incentive can be up to 300 € if the weight loss target is achieved 12 months after their inclusion in the study.
214937782|NCT05963451|OTHER|No intervention|No intervention will be given in our study since, the investigators are recruiting people who will receive already a facet thermal ablation.
215073740|NCT04845659|DRUG|Doptelet Pill|40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
215073741|NCT00201448|BIOLOGICAL|Hepatitis A Vaccine|Single dose give IM
215073742|NCT00201448|BIOLOGICAL|Towne CMV Vaccine|Single dose given subcutaneously
215073743|NCT01846676|BEHAVIORAL|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
214937783|NCT06329882|DRUG|Sitagliptin 100mg|Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
214937784|NCT06329882|DRUG|Doxycyclin|Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
214937785|NCT05919992|DRUG|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on empty stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
214937786|NCT05919992|DRUG|Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7 in a total daily dose of 19.9mg
214937787|NCT05919992|DRUG|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
215073744|NCT01846676|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
215073745|NCT00564863|BIOLOGICAL|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
214675147|NCT04284644|DRUG|Induction using propofol|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.
214336968|NCT06216236|OTHER|aerobic dance training|The control group used a video that did not show a skeletal simulation of the action and only saw the teachers movements.
214336969|NCT05410912|PROCEDURE|Great saphenous vein stripping and ambulatory phlebectomy|All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
214336970|NCT05500976|OTHER|Semi-controlled dietary intervention - Western|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Western diet foods (eg, beef, potatoes, bread, sour cream) provided during each intervention and will be repeated twice.
214336971|NCT05500976|OTHER|Semi-controlled dietary intervention - MiniMed|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Mediterranean foods (eg, oatmeal, salmon, nuts, basil, olive oil, fruits) provided during each intervention and will be repeated twice.
214336972|NCT05798507|DRUG|Avutometinib|Given PO
214336973|NCT05798507|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214937788|NCT05919992|DRUG|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7
214937789|NCT06911593|DIAGNOSTIC_TEST|Doppler ultrasonography|The delay time was determined as the time difference between the onset of the Doppler waveform and the R-wave on the electrocardiogram(ECG) of the USG device. The distance between the carotid and femoral arteries, where imaging was performed, was then measured. This distance was divided by the delay time to calculate the carotid-femoral pulse wave velocity(PWV) in meters per second, which was considered a measure of arterial stiffness.
214937790|NCT04852796|OTHER|Patients with hemopathy|optimal humoral response at 1 month after COVID-19 vaccination
214937791|NCT05903053|BEHAVIORAL|Early Self-Regulation Intervention|"Participants enrolled in a separate protocol (UC Davis IRB ID#1077801) will be invited to participate upon meeting eligibility criteria. All participants will receive the intake and exit assessment battery, with the intake assessment battery being completed as part of IRBNet ID#1077801. A multiple baseline design across participants will be used with varying introduction of treatment elements for a subset of enrolled intervention participants. An intense intervention phase will follow the baseline phase in which 45-60 minute intervention sessions will occur two times per week for approximately 4-6 weeks for a total of 8 sessions. At the conclusion of the intense intervention phase, coaches will provide booster sessions once weekly for a month (4 sessions total)."
215073746|NCT00551148|DRUG|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
215073747|NCT00551148|DRUG|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
215073748|NCT00551148|DRUG|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
215073749|NCT00551148|DRUG|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
215073750|NCT00551148|OTHER|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
215073751|NCT00523705|DRUG|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
215073752|NCT00523705|OTHER|placebo|Placebo tablets matched to drug
214937792|NCT03655223|DIAGNOSTIC_TEST|Confirmatory Testing|If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
214937793|NCT04641260|DRUG|Fezolinetant|Oral
214937794|NCT01896947|DIAGNOSTIC_TEST|MRI|evaluating to see if 3T MRI is as effective as MR arthrogram to diagnose labral pathology
214937795|NCT05519488|BEHAVIORAL|Rubato Life Music|Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
215073753|NCT00651495|BEHAVIORAL|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
214336974|NCT05798507|DRUG|Defactinib|Given PO
214336975|NCT06404177|DRUG|Dexketoprofen|An intravenous perfusion of eunantyum with an intramuscular isotonic saline
214486426|NCT06757088|DEVICE|Cerebellar Stimulation Group (CbSG)|For the Cerebellar Stimulation Group, active anodal electrode will be placed over the cerebellum bilaterally about 1-2 cm below the inion occipital protuberance, whereas the returning cathodal electrode will be placed on right buccinator muscle
214486427|NCT06757088|COMBINATION_PRODUCT|M1 + Cerebellar Stimulation Group|In M1, the anodal electrode will be placed over the M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region whereas simultaneously for the CbSG, active anodal electrode will be placed over the cerebellum bilaterally about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode will be placed on right buccinator muscle.
214486428|NCT06757088|DEVICE|Sham Stimulation Group|In Sham stimulation, Electrodes will be placed according to M1 Stimulation i.e., the anodal electrode will be placed over M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region.
214486429|NCT06770881|DRUG|JSKN033|JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle
214675148|NCT04284644|DRUG|Induction using sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 8% inhalational sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen.
215073754|NCT01275612|BIOLOGICAL|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
215073755|NCT02383654|PROCEDURE|Autologous Adipose-Tissue Derived Stem Cells|"1. Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~2. Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
215073756|NCT00368836|DEVICE|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
214336976|NCT06404177|DRUG|Piroxicam|intramuscular injection of piroxicam with a perfusion of isotonic saline intravenous
214336977|NCT05686304|BEHAVIORAL|Internet-based self-help money management program|The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
214675149|NCT04284644|DRUG|Induction using propofol and sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 4% sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
215073757|NCT01933438|OTHER|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
215073758|NCT01933438|OTHER|Control|Standard treatment
215073759|NCT04351464|OTHER|physical therapy and reflexology|
215073760|NCT02460354|DRUG|Metformin|Metformin 500 mg pill dispensed once orally
215073761|NCT00820794|DRUG|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
215073762|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
215073763|NCT00820794|DRUG|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
215073764|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
215073765|NCT04044599|DRUG|Gynoflor|VAGİNAL GYNOFLOR
215073766|NCT02878525|PROCEDURE|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
215073767|NCT02878525|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
215073768|NCT04040595|PROCEDURE|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
215073769|NCT00849706|OTHER|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
215073770|NCT02410473|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
215073771|NCT02410473|OTHER|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
214675150|NCT06435715|OTHER|10 Repetitions of Deep Breathing Exercise|Respondents in the intervention group performed 10 repetitions of deep breathing exercises every 3 hours for 3 days.
214336978|NCT04146480|DIAGNOSTIC_TEST|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4\. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5\. Upon completion of the scan, will be released without any restrictions."
214336979|NCT02842268|DRUG|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
214336980|NCT03887091|OTHER|Postwire|Postwire© is a web-based, video platform
214675151|NCT06435715|OTHER|3 Repetitions of Deep Breathing Exercise|Respondents in the control group performed 3 repetitions of deep breathing exercises for 3 days.
214937796|NCT05519488|BEHAVIORAL|Music of their desire|patients will be asked to listen to a minimum of 45 minutes per day of music (or a total of 12 hours), of their desire, which the participant considers as stress relief music for a period of a 2 weeks (or a total of 12 hours)
215073772|NCT02607917|OTHER|Mass Media plus clinic intervention.|
215073773|NCT02607917|OTHER|Media|
214336981|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for experimental vaccine is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
214336982|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 1 is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
214336983|NCT06344065|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 2 is through intramuscular injection of 0.5ml into the anterolateral side of the thigh or the upper arm.
215073774|NCT05190029|DIAGNOSTIC_TEST|Series of questions to parents of children in a virtual form.|A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).
215073775|NCT05190029|OTHER|Intervention by teachers|"The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas."
215073776|NCT05190029|PROCEDURE|Physiotherapeutic evaluation|"A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1)."
214675152|NCT03413644|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer
214675153|NCT02584985|PROCEDURE|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
214675154|NCT02584985|PROCEDURE|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
214675155|NCT04239560|DRUG|Boron-based Gel (Fibore)|During each radiotherapy session, 15 minutes before radiotherapy, the gel used and patients followed up.
214336984|NCT01611571|DRUG|Risedronate|weekly risedronate
214336985|NCT01611571|DRUG|Teriparatide|daily teriparatide
214336986|NCT01611571|DRUG|Placebo Teriparatide|daily placebo of teriparatide
215073777|NCT00725348|DRUG|Talarozole|1.0 mg oral dose per day
214675156|NCT04239560|DRUG|Placebos|During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
214675157|NCT04635735|DRUG|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
215073778|NCT01602783|OTHER|11C Acetate Imaging|Single scan
214675158|NCT02078622|OTHER|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
214675159|NCT06338865|OTHER|Carbon dioxide|Gas used for insufflation pressure
214675160|NCT06338865|DRUG|Bupivacaine|Local subcutaneous infiltration of all port sites with 0.25% bupivacaine will be performed prior to each incision. Remaining local anesthetic will be administered into the incision sites prior to the conclusion of the case (30cc total).
215073779|NCT00338832|BEHAVIORAL|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
214675161|NCT06338865|DRUG|Oxycodone|All patients will be prescribed a total of 10 pills of oxycodone 5mg, which is the standard amount that our practice prescribes for patients after laparoscopic surgery.
214937797|NCT04047134|OTHER|Action Observation Treatrment|Participants will be asked to carefully observe the videos showing different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes, totally lasting 12 min/video. At the end of each motor act presentation, participants will be asked to execute with the affected hand the observed motor sequence for 2 minutes (20 minutes/session). 10 daily actions will be recorded. Each video will be presented to participants twice a day, in order to complexity as judged by the experimenter. Only 1 typology of motor task per day for each condition, starting from the easiest and ending with the most complex action throughout 15 sessions spread on 5 weeks (3 sessions/week). Tasks will be based on some relevant activities of daily living belonging to at least one between feeding, self-care or external actions category on the affected side. Each session will last about 15 minutes and will be repeated twice a day, at least 60 minutes apart.
214675162|NCT04297163|OTHER|Telemedicine|Remote CPAP monitoring, mobile app and voice mail
214675163|NCT04297163|OTHER|In Hospital|Face-to-face follow up
214675164|NCT00402974|DRUG|menaquinone 7|
214675165|NCT06430749|DEVICE|Microtaze|Targeted Microwave Tissue Coagulation
214675166|NCT05255562|PROCEDURE|Combined Serratus Anterior Plane Block|Combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
214675167|NCT05255562|DRUG|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
214675168|NCT01576861|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
214675169|NCT00006270|DRUG|cosyntropin|
214675170|NCT00006270|DRUG|metyrapone|
214675171|NCT03136705|DRUG|Nicotinamide|Nicotinamide tablet
214675172|NCT03136705|DRUG|Lanthanum Carbonate|Lanthanum Carbonate tablet
214675173|NCT03136705|DRUG|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
214675174|NCT03136705|DRUG|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
214336987|NCT01611571|DRUG|placebo Risedronate|weekly placebo of Risedronic Acid
214336988|NCT00724451|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
214336989|NCT00724451|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
214336990|NCT00724451|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
214336991|NCT02651623|DRUG|Sertraline|Multiple doses of sertraline for 14 days
214336992|NCT02651623|DRUG|Moxifloxacin|A single dose of 400 mg Moxifloxacin
214336993|NCT02651623|DRUG|Drug - Placebo|Placebo administered for 14 days
214675175|NCT03859999|DIAGNOSTIC_TEST|Analysis of primary radiograph and available demographics|Multivariate analysis of the fracture x-ray features measured by computer, together with the database demographic and outcome data will be used to develop the best model /decision rule to predict likelihood of MUA success
214675176|NCT06637826|BEHAVIORAL|Quaternary Ammonium Compound Disinfectants|"Participants are instructed to use quaternary ammonium compound disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
214675177|NCT06637826|BEHAVIORAL|Alcohol-based Disinfectants|"Participants are instructed to use alcohol-based disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
214336994|NCT03992690|DEVICE|Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol|Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
214336995|NCT03992690|DEVICE|Training with traditional physiotherapy protocol|Stretching
214336996|NCT04055194|DRUG|Tranexamic acid tablets|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
214336997|NCT04055194|DRUG|Placebo oral tablet|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
214675178|NCT02267512|DRUG|ATG-F|Intravenous (IV)
214675179|NCT04470752|DRUG|Capsaicin 1% oral solution|Capsaicin 1.0 micrograms/ml
214675180|NCT04470752|DRUG|InOrpha Solution|glycerol based suspension vehicle
214937798|NCT04047134|OTHER|Observation of videos with Non Motor contents|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
214937799|NCT05930795|PROCEDURE|pectopexy|pectopexy: surgery performed by suspending prolapsed uterus or vault to the pectineal ligament
214937800|NCT05930795|PROCEDURE|lateral suspension|lateral suspension: surgery performed by suspending prolapsed uterus or vault to the lateral walls of the abdomen corresponding to the 3 cm anterior superior to the iliac crest
214937801|NCT06667882|DRUG|Alteplase Injectable Product|The 2019 ESC guideline for the diagnosis and management of acute pulmonary embolism (PE) recommended thrombolytic therapy only in high-risk PE cases because of the bleeding risk. The most often used drug for thrombolysis is the rtPA and the recommended dose is 100 mg over two hours. According to the literature, the risk of major haemorrhage is 10-13% and fatal or intracranial bleeding is 1.7-3.6% among patients receiving thrombolysis.
214937802|NCT05569928|OTHER|Administration of deuterated compounds for kinetic study|Participants will be submitted to a standardized oral-fat load and kinetic study will be performed
214937803|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
214937804|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
214937805|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
214937806|NCT04655092|BIOLOGICAL|P1101 (Ropeginterferon alfa-2b)|The subjects who have completed the 52-week treatment duration in Study A19-201 will be treated with P1101, starting at the dose at Week 50. The dose during this study may be increased or decreased up to 500 μg depending on the condition. This study will be continued as a post-marketing clinical study after acquisition of the marketing approval of P1101.
214937807|NCT03376971|PROCEDURE|Biopsy|Undergo lung biopsy
214937808|NCT03376971|OTHER|Laboratory Biomarker Analysis|Correlative studies
214937809|NCT01399489|BEHAVIORAL|Exercise training|Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
214937810|NCT00634686|DIETARY_SUPPLEMENT|DHA/EPA|1.2 gram capsule daily for 6 months
214937811|NCT00634686|DIETARY_SUPPLEMENT|Placebo capsule|daily for 6 months
214937812|NCT00634686|DIETARY_SUPPLEMENT|Calcium with vitamin D|1000 mg of calcium with 1000 IU vitamin D daily for 6 months
214336998|NCT06158737|DRUG|JS010 injection|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
214336999|NCT06158737|DRUG|Placebo|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
214337000|NCT03835260|DEVICE|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
214937813|NCT00538512|BIOLOGICAL|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
214937814|NCT00538512|BIOLOGICAL|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
214937815|NCT00538512|OTHER|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
214337001|NCT06003725|BEHAVIORAL|Culturally Adapted Adolescent Substance Use Treatment|The Cannabis Youth Treatment Series (CYT) (MET/CBT12 model) aims to reduce alcohol and cannabis use.
214337002|NCT00947622|DEVICE|Transcranial direct current stimulation|Transcranial Direct current stimulation
214937816|NCT04889599|DRUG|BH009 (Docetaxel injection)|75mg/m2
214937817|NCT04889599|DRUG|Docetaxel injection|75mg/m2
214937818|NCT05863793|OTHER|Acupuncture|The obligatory acupoints include Zhongwan (CV12), bilateral Weiwanxiashu (EX-B3), bilateral Ganshu (BL18), bilateral Pishu (BL20), bilateral Shenshu (BL23), bilateral Zusanli (ST36), bilateral Yanglingquan (GB34), bilateral Sanyinjiao (SP6), bilateral Taixi (KI3), and Bafeng (EX-LE10). Additional acupoints Baxie (EX-UE9) will be added when patients' symptoms appear not only in the lower limbs but also in the upper limbs. After skin disinfection, disposable, stainless steel acupuncture needles will be inserted into the skin of acupoint (approximately 10-20 mm depth), and then manipulations of twirling, lifting, and thrusting will be performed on all needles for at least 10 s to reach De qi (a compositional sensation including soreness, numbness, distention, and heaviness), which is believed to be an essential component for acupuncture efficacy. Needles will be retained in these acupoints for 20 min.
214937819|NCT05863793|OTHER|Sham Acupuncture|Patients in the SA group will receive sham acupuncture. The procedure and duration of treatment in the SA group will be identical in the MA group except the needles are blunt tip and there will be no skin penetration and needle manipulation for De qi.
214937820|NCT05404633|DEVICE|Ergogycle prototype testing for acceptability|The objective was to assess the acceptability of the ergogycle prototype (device) while used in a clinical settings by both the patients and the professionals.
214937821|NCT02417961|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
214937822|NCT02624128|DRUG|Valproic Acid|Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
214937823|NCT02624128|DRUG|Cisplatin|administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
214937824|NCT02624128|DRUG|Cetuximab|administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
214937825|NCT03765853|OTHER|Physiotherapy|Usual prevention methods (ergonomic education) and Stretching Postural® postures.
214937826|NCT05645328|OTHER|Iowa Cancer Affiliate Network (ICAN)|Each hospital in the intervention has undergone interviews in which the investigators elicited program goals, challenges, and readiness for change. Prior to the intervention, the cancer centers will be provided a document specifying current status for meeting Commission on Cancer (CoC) accreditation standards, gaps identified, suggestions and resources for the next steps to meet goals, and progress toward fulfilling CoC accreditation standards. The hospitals will be offered support, expertise, and resources to facilitate them in achieving the CoC standards. Support will be offered in the form of education/training regarding the standards and provision of cancer services, regular in-person/zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation/educational resources regarding standard requirements. The intervention actions will be tailored to the needs of each hospital based on standards they currently do not meet and choose to work toward.
214937827|NCT03843645|PROCEDURE|general anesthesia|surgical procedure under general anesthesia
214937828|NCT03843645|PROCEDURE|regional anesthesia|surgical procedure under regional anesthesia
214937829|NCT04796350|DEVICE|AGN1 LOEP treatment|the implantation site is injected with the AGN1 implant material
214937830|NCT06652204|OTHER|questionnaire|Caregivers must reply to the French version of the QASCI questionnaire, the ZBI (Zarit Burden Interview) questionnaire, HADS (Hospital Anxiety and Depression Scale), and WHOQOL-Bref (World Health Organization Quality of Life Instrument - Short Form). After 15 days, they wil reply to the French version of the QASCI questionnaire (to asse the reliability).
214937831|NCT06539949|BEHAVIORAL|Rapid Planning Method (RPM)|RPM is a three day immersive seminar. Subjects will be exposed to a variety of mind-body exercises and psycho educational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
214937832|NCT06539949|BEHAVIORAL|Journaling|Subjects will be keeping a weekly to-do list.
214937833|NCT05354427|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with implantabale spacers.
214937834|NCT05397210|DEVICE|Infinity-Lock Button System|Infinity-Lock Button System
214675181|NCT04610242|DIAGNOSTIC_TEST|skin test|"For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours."
214337003|NCT05194176|DEVICE|Virtual Reality|For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
214337004|NCT01260922|DRUG|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
214937835|NCT00642603|DRUG|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
214675182|NCT02604719|DRUG|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
214675183|NCT02777840|DEVICE|face mask oxygen|oxygen given by face mask as per routine practice
214675184|NCT02777840|DEVICE|High flow oxygen|High flow oxygen given via optiflo machine / device
214675185|NCT01466114|DRUG|estriol|4 capsules of 2 mg (total of 8 mg) PO QD
214337005|NCT01260922|DRUG|Aricept®|10 mg Orally Disintegrating Tablet
214337006|NCT04701775|DIETARY_SUPPLEMENT|Only Lactobacillus rhamnosus GG strains|1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule
214675186|NCT01466114|OTHER|Placebo|4 capsules PO QD
214675187|NCT01466114|DRUG|Norethindrone|Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
214675188|NCT01466114|OTHER|Progestin Placebo|Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
214937836|NCT00642603|DRUG|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
214937837|NCT00642603|DRUG|bevacizumab [Avastin]|5 mg/kg taken intravenously on Day 1 of each 2 week cycle
214937838|NCT00642603|DRUG|oxaliplatin|85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
214937839|NCT00642603|DRUG|irinotecan|135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
214937840|NCT06531798|DRUG|Breztri Aerosphere|Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg
214937841|NCT06148337|DIETARY_SUPPLEMENT|unhydrolyzed eggshell membrane|an unhydrolyzed, minimally processed chicken eggshell membrane powder.
214937842|NCT06148337|DIETARY_SUPPLEMENT|Placebo|psyllium husk fiber powder
214675189|NCT04050904|DEVICE|ExpHeart|ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the Information System. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System.
214937843|NCT05047172|DRUG|Ticagrelor + Aspirin|ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
214937844|NCT05047172|DRUG|Rivaroxaban + Aspirin|low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
214937845|NCT05047172|DRUG|Clopidogrel + Aspirin|clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily)
214937846|NCT05047172|OTHER|Risk Factor Management|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.
214937847|NCT04871308|DRUG|Dexmedetomidine|"Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins."
214937848|NCT04871308|DRUG|Control|During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
214937849|NCT05195398|DEVICE|Anodal transcranial Direct Current Stimulation (A-tDCS)|Participants randomized to tDCS will undergo 5 weeks of A-tDCS + CCT.
214937850|NCT05195398|DEVICE|Sham Intervention|Participants randomized to sham-intervention will undergo 5 weeks of sham + CCT.
214937851|NCT04851613|DRUG|Afuresertib|The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
214937852|NCT04851613|DRUG|Afuresertib/placebo|afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
214937853|NCT05172258|PROCEDURE|Biopsy Procedure|Undergo biopsy
214937854|NCT05172258|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214937855|NCT05172258|PROCEDURE|Computed Tomography|Undergo CT
214675190|NCT01924715|BEHAVIORAL|ISTDP|An emotion focused brief psychotherapy format.
214675191|NCT02243124|DRUG|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
214675192|NCT02243124|DRUG|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
214675193|NCT02016742|DRUG|RDC5|
214337007|NCT04701775|COMBINATION_PRODUCT|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains|combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule
214337008|NCT04701775|OTHER|Placebo|Placebo probiotic capsule
214337009|NCT03652103|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block Catheterisation|After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.
214337010|NCT03652103|DRUG|Bupivacaine 0.25% Injectable Solution|Perineural Injection
214675194|NCT02405039|DRUG|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
214675195|NCT02405039|DRUG|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
214675196|NCT03988777|DEVICE|Preoperative localisation technique|Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
214675197|NCT03952286|DRUG|ED-Dispensing home and school supervision|"1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~2. 360 ug of budesonide inhalation powder once-daily for at-home use, and~3. albuterol sulfate as needed for relief of acute respiratory symptoms."
214937856|NCT05172258|DRUG|Ipatasertib|Given PO
214937857|NCT05172258|BIOLOGICAL|Pembrolizumab|Given IV
214937858|NCT06417775|DRUG|Ubrogepant|Oral Tablets
214937859|NCT06417775|DRUG|Placebo for Ubrogepant|Oral Tablets
214937860|NCT04113421|DIAGNOSTIC_TEST|Contrast-enhanced chest CT|A single follow-up contrast-enhanced chest CT to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
214937861|NCT05619653|DRUG|Prednisolone|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
214937862|NCT05619653|DRUG|Losartan|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
214937863|NCT04057352|DEVICE|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
214937864|NCT06203210|DRUG|Ifinatamab deruxtecan|12 mg/kg intravenous dose on Day 1 of each 21-day cycle
214937865|NCT06203210|DRUG|Topotecan|Topotecan will be administered per local SoC.
214937866|NCT06203210|DRUG|Amrubicin|Amrubicin will be administered per local SoC.
214937867|NCT06203210|DRUG|Lurbinectedin|Lurbinectedin will be administered per local SoC
214937868|NCT06829615|DEVICE|Shen.AI|Contactless measurement of heart rate, heart rate variability, breathing rate, and blood pressure using Shen.AI software and reference methods.
214937869|NCT02823821|OTHER|Default dialysate sodium concentration of 137mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
214937870|NCT02823821|OTHER|Default dialysate sodium concentration of 140mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
214937871|NCT06625320|DRUG|RMC-6236|Oral Tablets
214937872|NCT06625320|DRUG|Gemcitabine|intravenous (IV) infusion
214937873|NCT06625320|DRUG|nab-paclitaxel|IV infusion
214937874|NCT06625320|DRUG|Irinotecan|IV infusion
214937875|NCT06625320|DRUG|Liposomal irinotecan|IV infusion
214675198|NCT00404443|DEVICE|Acupuncture|Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
214675199|NCT00002516|BIOLOGICAL|dactinomycin|
214675200|NCT00002516|DRUG|cyclophosphamide|
214675201|NCT00002516|DRUG|doxorubicin hydrochloride|
214337011|NCT04165291|BEHAVIORAL|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
214337012|NCT04165291|BEHAVIORAL|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
214337013|NCT05577897|OTHER|Education|"A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet COPD Guide on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method."
214337014|NCT04791800|DIAGNOSTIC_TEST|Malaria/CRP combination test|Testing with a malaria/CRP combination test, in parallel with a standard malaria RDT (to guide case management), preparation of thin/thick films for expert malaria microscopy, and collection of venous blood for subsequent CRP quantification.
214337015|NCT02220010|DEVICE|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
214337016|NCT00151359|DEVICE|SoleSensor|
214337017|NCT04603859|PROCEDURE|Elective induction of labor at 39 gestational weeks and 0 to 3 days|Elective induction of labor (eIOL) according to local policies
214675202|NCT00002516|DRUG|etoposide|
214337018|NCT03626129|PROCEDURE|Oximetry guided deflation|"At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A."
214337019|NCT04408443|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 + Vitamine D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
214337020|NCT04408443|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
214337021|NCT01813604|BIOLOGICAL|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
214337022|NCT01813604|BIOLOGICAL|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
214337023|NCT01813604|BIOLOGICAL|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
214675203|NCT00002516|DRUG|ifosfamide|
214675204|NCT00002516|DRUG|mesna|
214675205|NCT00002516|DRUG|vincristine sulfate|
214675206|NCT00002516|PROCEDURE|conventional surgery|
214675207|NCT00002516|RADIATION|low-LET cobalt-60 gamma ray therapy|
214675208|NCT00002516|RADIATION|low-LET photon therapy|
214675209|NCT02910778|DRUG|Atorvastatin|Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
214675210|NCT02910778|DRUG|Placebo|Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
214675211|NCT02910778|DRUG|Ticagrelor|
214675212|NCT03827876|DRUG|Enstilar 0.005%-0.064% Topical Foam|Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
214675213|NCT02296346|DRUG|SoluMedrol|Infusion of drug subcutaneously, once a month.
214937876|NCT06625320|DRUG|5-fluorouracil|IV infusion
214937877|NCT06625320|DRUG|leucovorin|IV infusion
214937878|NCT06625320|DRUG|Oxaliplatin|IV infusion
214937879|NCT06055920|DEVICE|FlowTriever System|Mechanical Thrombectomy for pulmonary embolism
214937880|NCT06055920|DRUG|Anticoagulation Agents|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
214937881|NCT00819208|BEHAVIORAL|exercise intervention|3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36
214937882|NCT00819208|OTHER|counseling intervention|Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.
214937883|NCT00819208|OTHER|educational intervention|Once at the beginning of the program
214937884|NCT00819208|OTHER|laboratory biomarker analysis|Every 12 months
214937885|NCT00819208|OTHER|questionnaire administration|Every 6 months
214937886|NCT00819208|OTHER|study of socioeconomic and demographic variables|Every 6 months
214937887|NCT00819208|PROCEDURE|fatigue assessment and management|Every 6 months
214937888|NCT00819208|PROCEDURE|quality-of-life assessment|Every 6 months
214937889|NCT00819208|OTHER|Educational Intervention|For Arm 2 just once at beginning of program.
214937890|NCT00819208|OTHER|Fitness testing|Objective fitness testing for both arms
214937891|NCT06300450|BEHAVIORAL|Computer Alert|On-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease
214937892|NCT05729282|DRUG|Diazoxide oral suspension, 1 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).
214675214|NCT02296346|DEVICE|Extracorporeal Photopheresis|This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
214675215|NCT00631319|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
214675216|NCT00631319|DRUG|Placebo|Placebo
214675217|NCT04331301|PROCEDURE|Bipolar Vapo-Enucleation of the prostate|group A: Patient will be subjected to bipolar endoscopic enucleation of the prostate by vaporization electrode (vapoenucleation).
214675218|NCT04331301|PROCEDURE|Bipolar Needlescopic Enucleation of the prostate|group B: Patient will be subjected to bipolar endoscopic enucleation of the prostate by hot knife electrode (Needlescopic Enucleation ).
215073780|NCT00338832|BEHAVIORAL|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
215073781|NCT05121454|DEVICE|Serenno Sentinel, model Alpha 2.0, software version: 8.0|intra-abdominal pressure measurements compared to a Foley Manometer at different insufflation pressures between 5 and 25 cmH20 at 30seconds intervals.
214337024|NCT01813604|BIOLOGICAL|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
214337025|NCT01813604|BIOLOGICAL|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
214675219|NCT01037712|DRUG|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
214675220|NCT01037712|DRUG|Placebo|placebo
214937893|NCT05729282|DRUG|Diazoxide oral suspension, 2 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
214937894|NCT05729282|DRUG|Placebo|Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
214937895|NCT05729282|DEVICE|FreeStyle Libre Pro|All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.
215073782|NCT01988532|OTHER|No treatment given|Subject will only fill out a questionnaire
215073783|NCT02442310|DRUG|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
214675221|NCT00891657|DEVICE|SprayShield™|Anti-adhesion barrier
214675222|NCT00326261|PROCEDURE|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
214675223|NCT00326261|PROCEDURE|Ultrasound|
214675224|NCT04207073|DEVICE|Mobilization of median nerve|Neural mobilization
214675225|NCT05171738|DEVICE|skeletally anchored distal jet|used from day one and activated every month
214675226|NCT04707144|DEVICE|MRI 1.5 tesla|"* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), o 3D STIR sequence.~* 3D PSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes)"
214675227|NCT02739698|DRUG|Paclitaxel|
214675228|NCT02739698|PROCEDURE|Radical surgery-peritonectomy|
214675229|NCT02927171|OTHER|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
214937896|NCT05729282|DRUG|Deuterated water (2H2O/D2O)|All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.
214937897|NCT04759274|DEVICE|Diuretic Tuner|Mobile device application for diuretic dose titration
214937898|NCT05814016|DRUG|Danavorexton|Danavorexton IV infusion.
214937899|NCT05814016|DRUG|Placebo|Placebo matching danavorexton IV infusion.
214937900|NCT06524115|DEVICE|Comparator device, Closed-field autorefractometer without cycloplegia|Objective refraction without cycloplegia
214937901|NCT06524115|OTHER|Distance visual acuity check using objective refraction without cycloplegia|Distance visual acuity is checked, using objective refraction without cycloplegia
214675230|NCT02808715|OTHER|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
214337026|NCT03143244|DRUG|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
214337027|NCT03143244|DRUG|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
214337028|NCT03143244|DRUG|Control group (Normal Saline) (C)|Patients received normal saline in two sets
214675231|NCT01789073|DIETARY_SUPPLEMENT|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
214675232|NCT04530825|OTHER|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
214675233|NCT04530825|OTHER|PREVENT Tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
214937902|NCT06524115|DEVICE|Comparator device, Closed-field autorefractometer with cycloplegia|Objective refraction with cycloplegia
214937903|NCT06524115|OTHER|Distance visual acuity check using objective refraction with cycloplegia|Distance visual acuity is checked, using objective refraction with cycloplegia
214937904|NCT06964087|DRUG|OPT101|Subcutaneous injection.
214937905|NCT06964087|OTHER|OPT101 Placebo to Match (PTM)|5% Dextrose (w/v)
214675234|NCT03870022|DEVICE|Pivot Breath Sensor System|Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
214675235|NCT03870022|DEVICE|Similar Carbon Monoxide breath sensor system|Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
214675236|NCT01589120|BEHAVIORAL|Video decision aid|Video decision aid of the goals of care
215073784|NCT02442310|DRUG|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
215073785|NCT05332587|DRUG|Rituximab|The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
215073786|NCT01022957|GENETIC|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
215073787|NCT05055258|DRUG|KVD824|KVD824 300 mg Modified-Release Tablets
214675237|NCT05170139|DIETARY_SUPPLEMENT|Caffeine|Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates
214675238|NCT05170139|DIETARY_SUPPLEMENT|Placebo drink|Participants will ingest the exact same drink without caffeine
215073788|NCT05055258|DRUG|Placebo to KVD824|Placebo to KVD824 300 mg Modified-Release Tablets
214937906|NCT06092216|DRUG|Spesolimab|"900 mg of spesolimab intravenously (IV) administered every 4 weeks at Visits 2, 3, 4, 5, 6, 7, 8, 9.~If at visit 4 dosing schedule changes to every 3 weeks, Spesolimab will be administered at Visits 2, 3, 4, 5, 6, 8, 9, 10 and 11."
215073789|NCT00481559|DRUG|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
215073790|NCT04264650|BEHAVIORAL|an mHealth intervention|The Care \& Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
215073791|NCT04111016|BEHAVIORAL|Integrated child stimulation, nutrition, lead, arsenic, WASH intervention|The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
214675239|NCT03909685|BEHAVIORAL|Mobile Mental Health App|The Mobile Mental Health App is an app that utilizes artificial intelligence to identify symptoms and provides targeted, tailored solutions for its users.
214937907|NCT06246487|BEHAVIORAL|Occupational Therapy Intervention|Children randomized to the intervention condition will receive a sensory enriched intervention 2x's per week, 60-minutes per session, for 16 weeks. The intervention will follow a codified protocol developed by Dr. Bodison that is theoretically grounded in neurodevelopmental research. The interveners will be occupational therapists who will be trained by Dr. Bodison to deliver the codified, intervention protocol to provide a personally customized set of therapeutically guided environmental interactions. Because, at its core, the intervention emphasizes playful interaction with a sensory enriched environment, the intervention room will be equipped with swings, scooter boards, climbing equipment, bolsters, and large carpeted barrels. Within this setting, using the codified manual of intervention developed by Dr. Bodison, the intervener will structure activities to provide tactile and proprioceptive input to address the child's individualized areas of need.
214675240|NCT01720667|DRUG|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
215073792|NCT00067847|BEHAVIORAL|State-directed nutrition policy change|
215073793|NCT03661424|DRUG|HER2 BATs|A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
215073794|NCT06466941|PROCEDURE|regional anesthesia|Patients who underwent surgery and received an epidural or peripheral nerve block
215073795|NCT06466941|PROCEDURE|no regional anesthesia|Patients who underwent surgery and did not received an epidural or peripheral nerve block
214337029|NCT04436094|PROCEDURE|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
214675241|NCT01720667|DRUG|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
214675242|NCT01472237|OTHER|Nutritional intervention|Modification of diet
215073796|NCT06466941|OTHER|acute pain consultation|Patients who underwent surgery and had a perioperative (preop, intraop, or postop) acute pain consultation
215073797|NCT06466941|OTHER|no acute pain consultation|Patients who underwent surgery and did not have a perioperative (preop, intraop, or postop) acute pain consultation
215073798|NCT04174300|PROCEDURE|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
215073799|NCT00727142|PROCEDURE|Surgical treatment|Insertion of a functioning shunt
214675243|NCT01977144|OTHER|Comprehensive Chromosomal Screening|
214675244|NCT01675037|OTHER|Biological evaluation|Complete hypothalamic-pituitary hormonal evaluation
214675245|NCT01579201|DRUG|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
214675246|NCT02012972|BEHAVIORAL|Referral for NCD care|Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
214675247|NCT04002323|DRUG|Dolutegravir 50mg Tab|The subjects starts their ART with this drugs, once a day
214675248|NCT04002323|DRUG|Lamivudine 300 mg|The subjects starts their ART with this drugs, once a day
214675249|NCT02558699|PROCEDURE|physician's personal experience|physician's personal experience
214675250|NCT02558699|PROCEDURE|Virtual rotor mapping|Virtual rotor mapping
214937908|NCT06519071|OTHER|Tryptophan Intake|Each hourly meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 Resting Energy Expenditure and adequate protein (at 1.5 g.kg.d), to maintain a metabolic steady state. The liquid shake contains protein-free powder orange-flavored drink crystals, corn oil, and water.
214937909|NCT04789148|DRUG|Intranasal Oxytocin (IN-OXT)|6 IU single dose
215073800|NCT04023357|OTHER|PEEK|New polyetheretherketones material
215073801|NCT04023357|OTHER|Emax|standard etchable glass ceramic used for Endocrowns
215073802|NCT04392141|DRUG|Standard Treatment|Standard Treatment for COVID-19 based on National Recommendations
214337030|NCT04436094|PROCEDURE|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
214337031|NCT05586867|PROCEDURE|Blood test|15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
214337032|NCT02658851|DEVICE|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
214337033|NCT05569785|OTHER|Resistance Exercise Therapy|"4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only."
214937910|NCT04789148|DRUG|Intranasal Oxytocin (IN-OXT)|IN-OXT 6 IU three times a day for 2 weeks
214937911|NCT04789148|DRUG|Placebo|Intranasal placebo three times a day for 2 weeks
214937912|NCT04789148|DRUG|Intranasal Oxytocin (IN-OXT)|24 IU single dose
214937913|NCT04789148|DRUG|Placebo|placebo single dose
214937914|NCT06079970|DEVICE|Neelde Based Confocal Laser Endomicroscopy|Confocal microscopy through the TBNA needle before tissue sampling using the Cellvizio system and AQ flex probe (Mauna Kea Technologies)
214937915|NCT06079970|PROCEDURE|Conventional diagnostic bronchoscopy|Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope
214937916|NCT02224781|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214937917|NCT02224781|PROCEDURE|Computed Tomography|Undergo CT
214937918|NCT02224781|DRUG|Dabrafenib Mesylate|Given PO
214937919|NCT02224781|PROCEDURE|Echocardiography Test|Undergo ECHO
214675251|NCT03232723|DIAGNOSTIC_TEST|Whole-cortex MEG System (with optional EEG)|"Whole-Cortex MEG System non- invasively measures the magnetoencephalographic (MEG) signals (and, optionally, electroencephalographic EEG signals) produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The location may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain."
214675252|NCT05212532|DRUG|EOM613|peptide nucleic acid (PNA)
214675253|NCT02393599|DRUG|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
214675254|NCT02393599|DRUG|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
214937920|NCT02224781|BIOLOGICAL|Ipilimumab|Given IV
214337034|NCT06467318|DRUG|Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
214937921|NCT02224781|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214937922|NCT02224781|BIOLOGICAL|Nivolumab|Given IV
214937923|NCT02224781|OTHER|Quality-of-Life Assessment|Ancillary studies
214937924|NCT02224781|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214937925|NCT05155163|BEHAVIORAL|SC-POWR|Patients assigned to SC-POWR receive 12 Cognitive Behavioral Therapy (CBT) sessions over 24 weeks.
214937926|NCT00006113|BIOLOGICAL|MART-1 antigen|
214937927|NCT00006113|BIOLOGICAL|aldesleukin|
214937928|NCT00006113|BIOLOGICAL|gp100 antigen|
214937929|NCT00006113|BIOLOGICAL|recombinant CD40-ligand|
214937930|NCT00006113|BIOLOGICAL|recombinant interferon gamma|
214937931|NCT00006113|BIOLOGICAL|recombinant interleukin-4|
214937932|NCT00006113|BIOLOGICAL|sargramostim|
214937933|NCT00006113|BIOLOGICAL|therapeutic autologous dendritic cells|
214937934|NCT00006113|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214937935|NCT00006113|BIOLOGICAL|tyrosinase peptide|
214937936|NCT00006113|RADIATION|Candida albicans skin test reagent|
214937937|NCT05619211|BEHAVIORAL|Sprint-Intensity Interval Training with Telecoaching|Maximal intensity exercises that use the arms.
214937938|NCT06229132|BEHAVIORAL|LGBTQ-affirmative CBT for transgender individuals|The intervention addresses unique stressors encountered by transgender individuals due to discrimination and lack of adequate and affirming healthcare resources.
214937939|NCT03666533|OTHER|Active transcranial Direct Current Stimulation|Active tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
214337035|NCT06467318|DRUG|NSAID, Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
214337036|NCT02572271|PROCEDURE|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
214337037|NCT02572271|PROCEDURE|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
214337038|NCT06165003|OTHER|Use of broselow tape|"In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses."
214937940|NCT03666533|OTHER|Sham transcranial Direct Current Stimulation|Sham tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
214937941|NCT05402033|BEHAVIORAL|Survey / Interview Group|Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.
214937942|NCT05845996|DRUG|SAR441344|Solution for intravenous/subcutaneous injection
214337039|NCT00764348|OTHER|no treatment|
214337040|NCT02005341|DEVICE|nanOSS|
214337041|NCT02005341|DEVICE|Autograft|
214937943|NCT05845996|DRUG|placebo|Solution for intravenous/subcutaneous injection
214937944|NCT05845996|BIOLOGICAL|Keyhole limpet hemocyanin|Subcutaneous Lyophilized powder for reconstitution
214937945|NCT04056884|BEHAVIORAL|SIBS intervention|SIBS is a manual-based group intervention for siblings and parents of children with chronic illness
214937946|NCT04057898|DRUG|MN-166|Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.
214937947|NCT04057898|DRUG|placebo|Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.
214937948|NCT02159495|DRUG|cyclophosphamide|Given IV
214937949|NCT02159495|BIOLOGICAL|Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
214937950|NCT02159495|OTHER|laboratory biomarker analysis|Correlative studies
214675255|NCT02393599|DRUG|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
215073803|NCT04392141|DRUG|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions|Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
214675256|NCT05777811|PROCEDURE|Vertically coronally advanced flap combined with connective tissue graft.|The exposed root surfaces are planed with Gracey 1-2 curettes. An intrasulcular incision is made with a blade on the buccal aspects of the involved teeth. The incision is extended horizontally to the adjacent papilla. Then, slightly divergent vertical releasing incisions are carried 2 mm beyond the mucogingival junction. A full-thickness flap is raised with a periosteal elevator towards the mucogingival junction. After that, a partial-thickness dissection is carried out in the apical direction to release muscle tension and provide coronal advancement of the flap. The adjacent papillae are de-epithelialized. The connective tissue graft (CTG) is harvested from the lateral palate using the de-epithelialized gingival graft technique. After harvesting, the connective tissue graft is sutured to the recipient bed. Finally, the flap is positioned 2 mm over the cementoenamel junction and sutured with 6-0 polypropylene sutures. No periodontal dressing is applied.
214337042|NCT04636892|OTHER|MindMics earbud|Novel noninvasive wearable infrasound sensor
214937951|NCT02159495|BIOLOGICAL|Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Given IV
214937952|NCT02159495|DRUG|Fludarabine Phosphate|Given IV
214937953|NCT05390944|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
214937954|NCT05390944|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
214937955|NCT06789666|BEHAVIORAL|ARTCan App|"The ARTCan App is an art therapy technology application program. The application can be accessed via the web (via computer, phone, or on a device such as an iPad). With the use of the application, participants complete weekly sessions that culminate in an art piece. Note that participants are not required to have expertise in drawing; developing art skills or assessing the quality of art pieces is not the focus of the ARTCan program.~Subjects will upload a photo of the art they created to this application to show proof of completion of art therapy. They will also answer questions specific to the art therapy theme for the week."
214937956|NCT05892432|DRUG|Semaglutide 3 MG [Rybelsus]|Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.
214937957|NCT05892432|DRUG|Semaglutide 7 MG [Rybelsus]|Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.
214937958|NCT05892432|DRUG|Placebo|A medically inert placebo medication will be taken for 8 weeks.
214937959|NCT06493578|DRUG|VYN201 Gel|VYN201 Gel is a topical formulation applied as a thin layer to affected areas.
215073804|NCT06397027|DRUG|Ziftomenib|Given by IV
215073805|NCT06397027|DRUG|Venetoclax|Given by PO
215073806|NCT06397027|DRUG|Azacitidine|Given by PO
214937960|NCT06493578|DRUG|Vehicle Gel|Vehicle gel (placebo) is matching in appearance to VYN201 gel and is to be applied in the same manner as VYN201 gel.
214337043|NCT03251703|PROCEDURE|Ultrasound-Guided Suprascapular Pulsed Radiofrequency .|The ultrasound-Guided Suprascapular Pulsed Radiofrequency was administered under operating room conditions while the patient was monitored in a sitting position.An ultrasound-guided 22 G 5-mm active-tip 100-mm radiofrequency needle (SC-K; Top Neuropole, Tokyo, Japan) was pushed forward towards the suprascapular notch until it passed the transverse scapular ligament using an in-plane approach.
214937961|NCT06633224|PROCEDURE|Blood Specimen Collection|Blood samples will be obtained throughout the course of the study
214937962|NCT06633224|OTHER|Stool Specimen Collection|Stool samples will be obtained throughout the course of the study
214937963|NCT06633224|OTHER|Quality of Life (QOL) Questionnaires|Surveys will be given throughout the course of the study.
214937964|NCT04762602|DRUG|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
214937965|NCT06369415|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3 and behavioural screening according to Strength and Difficulties Questionnaires (SDQ's)|"Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones. The ASQ-3 covers five developmental domains: communication, gross motor, fine motor, problem-solving and personal-social behaviour.~The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire for 2-17-year-olds. It exists in several versions to meet the needs of researchers, clinicians and educationalists. The SDQ asks about 25 attributes, some positive and others negative. These 25 items are divided between 5 scales: emotional symptoms, conduct problems; hyperactivity/inattention, peer relationship problems, and prosocial behaviour"
214937966|NCT04533698|OTHER|Assessment of reason for resternotomy|No intervention is performed. Reasons for resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
214937967|NCT04533698|OTHER|Assessment of reason for avoidance of resternotomy|No intervention is performed. Reasons for avoidance resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
214937968|NCT01827969|PROCEDURE|ablathermy focused ultrasound|ablathermy focused ultrasound
214937969|NCT06032143|BEHAVIORAL|Online educational phthalate course|This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
214675257|NCT05777811|PROCEDURE|Free gingival graft|A partial-thickness flap is elevated (using a blade #15c) with horizontal incisions at the cemento-enamel junction (CEJ) level of the adjacent teeth. Then, two vertical incisions extending to the apical are made from the two ends of the horizontal incision. The epithelium in the framed region is removed with a scalpel, and the underlying connective tissue is exposed. To achieve the best vascularization of the free gingival graft from the recipient site, bed preparation is completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region. The free gingival graft is stabilized using interrupted sutures and a sling suture.
215073807|NCT06121141|DRUG|Full strength lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000
215073808|NCT06121141|DRUG|Dilute lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
214337044|NCT04262999|OTHER|effect of sodium valproate on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.
214337045|NCT04262999|OTHER|effect of levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.
214937970|NCT06032143|BEHAVIORAL|Control environmental education|Participants in the control group will receive access to environmental exposures other than phthalates.
214937971|NCT06032143|BEHAVIORAL|Phthalate conversation|Participants in the intervention groups will be asked to engage in conversations about phthalates between doulas/pregnant individuals.
214937972|NCT06032143|BEHAVIORAL|Environmental exposures conversation|Participants in the intervention groups will be asked to engage in conversations about environmental exposures (other than phthalates) between doulas/pregnant individuals.
214937973|NCT06628362|DRUG|Placebo|Placebo will be volume-matched and administered subcutaneously (SC) once weekly.
214937974|NCT06628362|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
214937975|NCT04655508|DRUG|Seretide|"For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~\- For children between 12 to 17 years (\> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
214937976|NCT04655508|DRUG|Placebo|For children between 6 to 11 years (\< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (\> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
214937977|NCT06470282|DRUG|Enfortumab Vedotin|Given intravenously (IV)
215073809|NCT05970133|PROCEDURE|Colectomy with NOSE procedure|The specimen will be extract from the anus.
214937978|NCT06470282|BIOLOGICAL|Pembrolizumab|Given IV
215073810|NCT05401929|DEVICE|iTBS|Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
215073811|NCT05401929|DEVICE|iTBS|Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
214937979|NCT06470282|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Undergo standard of care, IMRT
214937980|NCT06470282|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
214937981|NCT06470282|PROCEDURE|Cystoscopy (CS)|Undergo cystoscopy
214937982|NCT06470282|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
214937983|NCT06470282|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
214937984|NCT06470282|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET Scan, may be combined with CT (PET/CT)
215073812|NCT04372147|PROCEDURE|MMA embolization|Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
214937985|NCT02389244|DRUG|Regorafenib|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
214337046|NCT04262999|OTHER|effect of sodium valproate+levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.
214337047|NCT04262999|OTHER|control group|Control group individuals will be systemically healthy.
214337048|NCT05515302|OTHER|Audio Clip|Selected Audio clips will be introduced to the study subjects during the Burns Dressing Changes. The Audio Clips will be selected as per subjects preference.
214337049|NCT01807273|OTHER|Walking test|
214337050|NCT06294002|OTHER|Dynamic neuromuscular stabilisation group|DNS group protocol involved 5 min a moderate intensity warm-up, 40 minutes of DNS movements according to the DNS approach, different diaphragmatic breathing, mobility and controlled movement exercises and 5 minutes of cool-down. Exercises gradually increased in complexity and difﬁculty level regarding DNS training principles. The participants were instructed to refrain from engaging in high-intensity anaerobic or anaerobic resistance training throughout the study period to prevent potential disruptions in the study results.
214337051|NCT06294002|OTHER|Whole body vibration group|WBV was performed on the Power Plate Next Generation vibration platform (Power Plate North America, Chicago, IL). All training routines were approximately 50 minutes long, commencing with 5 minutes of moderate-intensity warm-up and concluding with a cool-down period. The program consisted of 8-10 static and dynamic exercises for PS that progressively increased in difficulty and complexity. During the training process, the frequency increased from 20 to 35 Hz in the last week of the experiment; the exercise duration was from 20 - 60 seconds (in the previous week), followed by 1-minute seated rest. Moreover, the complexity and difficulty of exercise increased over the experimental period. The resting period between sets was constant from the start to the end of the training process. During the experiment, the WBV intervention group performed three weekly training sessions.
214337052|NCT06294002|OTHER|Dynamic neuromuscular stabilisation with whole body vibration group|The MIX group underwent a two-month training program consisting of three weekly sessions, including a 50-minute exercise program with a 5-minute warm-up and cool-down period. The training included 20 minutes of WBV and 20 minutes of DNS training, following previous research and training recommendations. VIBRO exercises were performed on the Power Plate Next Generation vibration platform, with 6-8 exercises for balance and PS. Participants were advised not to engage in high-intensity anaerobic or anaerobic resistance training. The training protocol was adapted from previous research.
214337053|NCT01170897|DRUG|PEGPH20|PEGylated Recombinant Human Hyaluronidase
214337054|NCT03951129|PROCEDURE|hemodialysis catheter insertion|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) scoring will be performed after informing all groups and after the procedure
214937986|NCT02389244|DRUG|Placebo|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
214937987|NCT06286748|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice + exercise. Patients will ingest 200ml of beet juice (Beta vulgaris) containing approximately 300mg of nitrate (NO3-), and after 2 hours they will be instructed to perform an exercise protocol.
214937988|NCT06286748|OTHER|Placebo|Placebo + exercise. Patients will ingest 200ml of placebo (water, without nitrate (NO3-)), and after 2 hours they will be instructed to perform an exercise protocol.
214937989|NCT06008171|OTHER|Patient Decision Aid|A designed tool (by us) that help patients and providers talk and decide together about field-directed treatment options for actinic keratosis.
214937990|NCT05965063|DIETARY_SUPPLEMENT|Bifidobacterium M-16V|Bifidobacterium M-16V was dosed at 10 billion colony forming unit (CFU) (equal to 6 drops)/day for 12 weeks.
214937991|NCT05965063|OTHER|allergy food avoidance|strict avoidance of the specific allergenic food
214937992|NCT05934253|DRUG|Chloroprocaine ophthalmic gel 3%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
214937993|NCT06091904|DRUG|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
214937994|NCT06091904|DRUG|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
214937995|NCT04240886|DRUG|fosmanogepix|IV and oral fosmanogepix
215073813|NCT05552261|DRUG|Cenegemin in the DEFENDO Study|"Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial."
215073814|NCT04154345|OTHER|Exercise therapy (exercising into pain)|The intervention consists of 12 weeks of progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, in which the pain allowed ranges between 4 and 7 on a verbal NPRS for 9 weeks, then pain ratings are 0-2 for the remaining 3 weeks. Every physiotherapy session includes also 15 minutes of manual therapy.
215073815|NCT05466292|OTHER|Survey1|Closed-ended survey on the level of knowledge, use, and dissemination of the CEC.
214337055|NCT04959084|OTHER|Laser acupuncture therapy and pelvic floor training|The laser will be applied directly to the skin over acupuncture points and each point receive a shoot of 65 seconds followed by Pelvic floor exercises for 15 min.
214337056|NCT03653429|DRUG|Tranexamic Acid|administered prior to surgical incision
214337057|NCT03653429|DRUG|Normal saline|administered prior to surgical incision
214337058|NCT04170647|DRUG|Plasminogen Activators|standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion
214337059|NCT05438953|BIOLOGICAL|Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)|Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart
214337060|NCT06530316|DRUG|RET Inhibitor|RET inhibitors for neoadjuvant treatment
214337061|NCT06530316|PROCEDURE|Surgery|Operable patients receive surgery after neoadjuvant therapy
214337062|NCT06377839|BIOLOGICAL|Advanced platelet-rich fibrin in the ekstraction socket|Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.
214337063|NCT05826236|DEVICE|Periarticular compression|Periarticular knee compression using a sphygmomanometer.
214337064|NCT04719585|DRUG|Duloxetine vs. Opioid|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
214337065|NCT05623709|DEVICE|Positive airway pressure with continuous positive airway pressure or noninvasive ventilation|CPAP or NIV prescribed by the treating respirologist for long-term use at home
214337066|NCT01525082|DRUG|Capecitabine|Capecitabine by mouth twice daily on Days 1 to 14
214937996|NCT03740139|OTHER|The Police-Mental Health Linkage System|When, during an encounter, the police officer decides to call the number provided in the notice, the Linkage Specialist (a licensed mental health provider from the mental health service where the subject was recruited, who has access to the clinic's EMR) can provide telephonic support to the officer.
214937997|NCT02459847|BEHAVIORAL|Mindfulness Training|
214937998|NCT02459847|BEHAVIORAL|Sonographic Biofeedback|
214937999|NCT02459847|OTHER|Standard Care|
214938000|NCT04743804|BIOLOGICAL|Ravulizumab|Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
214938001|NCT04743804|OTHER|Placebo|Matching placebo
214938002|NCT04743804|OTHER|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
214938003|NCT05709444|DRUG|Bremelanotide|Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).
214938004|NCT05709444|DRUG|RAAS inhibition therapy|RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
214938005|NCT03547362|DIETARY_SUPPLEMENT|Casein|See arm description
214938006|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 1|See arm description
214938007|NCT03547362|DIETARY_SUPPLEMENT|Whey protein|See arm description
214938008|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 2|See arm description
214938009|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 3|See arm description
214938010|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 4|See arm description
214938011|NCT01632904|DRUG|Ruxolitinib|Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
214938012|NCT01632904|DRUG|Hydroxyurea (HU)|Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
214938013|NCT01632904|DRUG|HU-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently."
214938014|NCT01632904|DRUG|Ruxolitinib-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently."
214938015|NCT03163056|BEHAVIORAL|Cognitive-behavioral treatment (CBT)|The CBT was implemented in group-based sessions of four patients. Sessions were carried out once a week over a 8-week period, with quite date occurring at fifth session. The main component was nicotine fading. From the first to the fourth week, patients were asked to gradually reduce their nicotine intake based on a weekly reduction of 30%. A maximum number of cigarettes per day and also specific cigarette brands with lower nicotine levels were recommended. Other components of the CBT program included information about tobacco, a behavioral contract, self monitoring and graphical representation of cigarette smoking, stimulus control, strategies for controlling nicotine withdrawal symptoms, physiological feedback, training in alternative behaviors, and relapse prevention strategies.
215073816|NCT05466292|OTHER|semi-structured interview_1|the semi-structured interview concerns participants'motivations/expectations for implementing CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered
215073817|NCT05466292|OTHER|semi-structured interview_2|semi-structured interview concerns participants motivations and expectations to be a member of the CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered.
215073818|NCT05466292|OTHER|semi-structured interview_3|semi-structured interview concerns participants' experiences with the ethics consultation service provide by the Clinical Ethics Committee
215073819|NCT05466292|OTHER|survey_2|survey of 20 multiple-choice questions and supplemented by free-text questions.
214938016|NCT03163056|BEHAVIORAL|CBT+Behavioral Activation (BA)|This intervention was provided as in the above CBT condition, that is, eight group-based sessions of four patients. Nevertheless, this treatment included a BA component for addressing both smoking cessation and depression management. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
214938017|NCT03163056|BEHAVIORAL|CBT+BA+ Contingency Management (CM)|This intervention was provided in the same manner as the above mentioned treatment protocols but with the addition of a contingency management procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
214938018|NCT02059434|DRUG|LAS190792 Dose 1|
214938019|NCT02059434|DRUG|LAS190792 Dose 2|
214938020|NCT02059434|DRUG|LAS190792 Dose 3|
214938021|NCT02059434|DRUG|LAS190792 Dose 4|
214938022|NCT02059434|DRUG|LAS190792 Dose 5|
214938023|NCT02059434|DRUG|LAS190792 Dose 6|
214938024|NCT02059434|DRUG|LAS190792 Dose 1 (Part 2)|
214938025|NCT02059434|DRUG|LAS190792 Dose 2 (Part 2)|
214938026|NCT02059434|DRUG|Tiotropium 18 μg|
214337067|NCT01525082|DRUG|Temozolomide|Temozolomide by mouth daily on Days 10 to 14
214337068|NCT01525082|BIOLOGICAL|Bevacizumab|Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15
214938027|NCT02059434|DRUG|Indacaterol 150 μg|
214938028|NCT02059434|DRUG|Placebo|
214938029|NCT04965441|PROCEDURE|Computer-assisted surgery|Preoperative head and neck computed tomography (CT) and lower extremity CT angiography were acquired for all patients. In the CAS group, CT images (slice thickness\<1 mm) were imported into a 3D surgical planning software (Proplan, Version 2.0/3.0 Materialise, Leuven, Belgium). Virtual surgical planning was performed to determine the mandibular and fibular resection and cut margins with localization of the optimal angles for performing osteotomies. After that, surgical guides were designed utilizing a 3D designing software (3-Matic, Version 9.0-13.0, Materialise, Leuven, Belgium). The generated virtual templates were exported in Standard Tessellation Language (STL) format and printed with a professional 3D printer (Connex 350, Stratasys, Eden Prairie, MN, USA). The reconstructive plates were pre-bent on a 3D printed planned mandibular model.
214938030|NCT01942317|OTHER|Balneotherapy|
214938031|NCT06374277|OTHER|Med AAAction intervention|The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.
214938032|NCT03978247|DIAGNOSTIC_TEST|NASHMIR|An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
214938033|NCT02956447|DRUG|Kisspeptin 112-121|0.313 ug/kg - 2 ug/kg IV or SC
214938034|NCT02956447|DRUG|GnRH|0.075 ug/kg IV
214337069|NCT04823845|DRUG|Topical Adapalene Gel 0.1%|applying Adapalene Gel 0.1% to plantar warts topically
214337070|NCT02048956|OTHER|Hydrotherapy intervention|Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
214938035|NCT00310206|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
214337071|NCT02048956|OTHER|Control group|Standard exercises of hydrotherapy
214337072|NCT01385059|DRUG|axitinib|Given PO
214938036|NCT00310206|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
214938037|NCT00771264|DEVICE|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
214938038|NCT02634034|DRUG|A: NK-104-CR 8 mg|NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
214938039|NCT02634034|DRUG|B: Pitavastatin IR 4 mg|Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
214938040|NCT02634034|DRUG|C: Pitavastatin IR 8 mg|Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
214938041|NCT06189391|DRUG|MK-1045|IV infusion
214938042|NCT05852574|DRUG|CP-101|"CP101 is an investigational oral microbiome drug designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent CDI.~CP101 contains live microbial communities, derived from rigorously screened human donor stool that is tested, stabilized, characterized, and formulated into capsules designed specifically for delivery into the small bowel for release, to avoid potential degradation by gastric acid."
214337073|NCT01385059|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy and pelvic lymph node dissection
214337074|NCT01385059|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214337075|NCT01385059|OTHER|laboratory biomarker analysis|Correlative studies
214337076|NCT01294995|DIETARY_SUPPLEMENT|Tea-flavor Liquor|30 mL of Tea-flavor Liquor(45% alcohol content)
214337077|NCT01294995|DIETARY_SUPPLEMENT|Guizhou Meijiao Liquor|30 mL of Guizhou Meijiao Liquor (45% alcohol content)
214337078|NCT03360292|OTHER|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
214337079|NCT05383170|DRUG|CyPep-1|Intratumoral injection
214337080|NCT05383170|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
214938043|NCT05852574|DRUG|CP-101 + Placebo|The placebo in this trial will be presented in capsules that are identical in size, smell, texture, and appearance to those of the CP101 capsules. These will be produced by the BWH investigational drug service
214337081|NCT05087043|DEVICE|Oral motor stimulation (OMS) and The supplemental nursing system (SNS)|OMS and an SNS were applied to preterm infants in the experimental group. Oral stimulation intervention provides assisted movement to activate muscle contraction and provides movement against resistance to build strength. The cheeks (internal and external), lips, gums, tongue, and palate were stimulated by finger-stroking following the protocol. OMS consisted of intra (oral region) and peri-oral stimulation (around the oral region). The OMS was administered three times a day by a nurse, from the day of initiation of oral feeding to the day of independent oral feeding 15 minutes before the feeding schedule. A bottle/container was filled with breast milk before the process and given to the baby via SNS while the baby was holding the mother's breast. The SNS consists of a syringe/container and a feeding catheter. One end of the feeding probe is inside the syringe/container, while the other end of it is fixed to the mother's nipple using plaster.
214337082|NCT01852890|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
214337083|NCT01852890|DRUG|Gemcitabine|Intravenous chemotherapeutic
214337084|NCT01852890|RADIATION|Radiation therapy|
214337085|NCT03239652|DEVICE|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
214337086|NCT02015377|OTHER|High sugar versus low sugar meals|Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
214337087|NCT01767116|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
214337088|NCT01767116|DRUG|Ribavirin|Capsule
214337089|NCT01767116|DRUG|Placebo for ribavirin|Capsule
214337090|NCT03025620|DIETARY_SUPPLEMENT|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
214337091|NCT03025620|DIETARY_SUPPLEMENT|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
214337092|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
214337093|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
214337094|NCT04508803|DRUG|HX008，Niraparib，Trastuzumab|Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
214337095|NCT04508803|DRUG|HX008，Niraparib，Pyrrolitinib|"HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle."
214337096|NCT03732287|DEVICE|Cooling Anesthesia|Application of cooling anesthesia device prior to intravitreal injection
214337097|NCT05795933|DRUG|Vitamin D3|A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
215073820|NCT04683146|DRUG|Hand antisepsis with Propanolol- 1 60%.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later"
214337098|NCT06222476|DRUG|Dorzagliatin|Dorzagliatin will be initiated and maintained at 75mg twice a day
214337099|NCT06222476|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg once a day
214337100|NCT06568146|DIETARY_SUPPLEMENT|Multivitamin Supplement|: Participants will take 2 capsules of the multivitamin supplement daily with the first meal of the day in the morning.
214337101|NCT00355875|PROCEDURE|titration of oxygen during resuscitation|
214337102|NCT01403103|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
214337103|NCT01403103|PROCEDURE|biopsy|Correlative studies
214337104|NCT01403103|GENETIC|protein expression analysis|Correlative studies
214337105|NCT01403103|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214337106|NCT01403103|OTHER|laboratory biomarker analysis|Correlative studies
214337107|NCT01403103|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
214337108|NCT01182077|DRUG|ASP015K|Oral
214337109|NCT01182077|DRUG|Midazolam|Oral
214337110|NCT01132079|DRUG|cream treatment|
214337111|NCT02826889|DEVICE|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
214337112|NCT02826889|DEVICE|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
214337113|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
214337114|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
214337115|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
214337116|NCT04007536|OTHER|No Intervention|No Intervention
214337117|NCT01792661|OTHER|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
214337118|NCT01792661|OTHER|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
214337119|NCT01792661|OTHER|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
214938044|NCT01004406|DEVICE|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks
214938045|NCT01004406|DRUG|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
214938046|NCT03211442|RADIATION|Radiotherapy|Breast cancer patients treated with radiotherapy
214938047|NCT04355806|DRUG|PD-1/PD-L1 inhibitors|Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
214938048|NCT04355806|BIOLOGICAL|Inactivated trivalent influenza vaccine|Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
214938049|NCT06637423|DRUG|Sacituzumab tirumotecan|Intravesical administration
214938050|NCT06637423|DRUG|Rescue medication|Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
214938051|NCT06637423|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
214938052|NCT00631085|DRUG|gamma tocopherol|Maxi Gamma softgels 1200mg QD
214938053|NCT02928770|DEVICE|Nastent|Use of the device while at home and in the sleep lab
214938054|NCT03393429|OTHER|DAVID assisted training|DAVID device assisted training under supervision
214938055|NCT03393429|OTHER|training recommendation|"training recommendation to stay active"
214938056|NCT00403741|BEHAVIORAL|motivational interviewing|
214675258|NCT03197675|OTHER|Acupuncture|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
214675259|NCT01319929|DRUG|LY2828360|Administered orally
215073821|NCT04683146|DRUG|Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later."
214337120|NCT01856972|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
214675260|NCT01319929|DRUG|Placebo|Administered orally
215073822|NCT03625869|DEVICE|PiCSO|After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
214675261|NCT00306566|BIOLOGICAL|CYT004-MelQbG10|
214675262|NCT02004990|PROCEDURE|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
214675263|NCT01749735|DEVICE|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
214675264|NCT01749735|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
214675265|NCT01749735|DEVICE|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
214675266|NCT02337504|OTHER|community-based care|Will receive HIV care in the community and not in the clinic which is the normal standard of care
214938057|NCT03201874|BEHAVIORAL|Pain self-management|The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
214938058|NCT03201874|BEHAVIORAL|Education|Education about sickle cell disease to increase disease knowledge
214337121|NCT01856972|PROCEDURE|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
214337122|NCT01856972|OTHER|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
214938059|NCT01738841|BIOLOGICAL|Priorix-Tetra™|Single dose, subcutaneous injection
214938060|NCT01738841|OTHER|Safety data collection|Recording of adverse events, using diary cards
214938061|NCT00929474|DEVICE|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
214938062|NCT00929474|DEVICE|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
214938063|NCT05936541|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium Bifidum PRL2010|Probiotic supplement
214938064|NCT05936541|OTHER|Control group|No probiotic supplementation
214938065|NCT03248518|BEHAVIORAL|Usual Care|Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
214938066|NCT03248518|BEHAVIORAL|Cognitive behavioural approach|A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities
214938067|NCT03248518|BEHAVIORAL|Personalised Exercise Programme|PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
214938068|NCT04857918|BEHAVIORAL|Virtual running group program|The intervention will include an eight-week virtual running group program hosted on online platforms such as Zoom and the fitness application Strava. Participants will be placed in running groups of 6 people, and each running group will have the collective goal to run/walk the distance across the province of B.C., (940 km) and will meet weekly over Zoom to socialize and discuss running topics and their progress towards the group goal. Participants will receive a t-shirt with the STRIDE logo and a phone armband for carrying their smart phone during runs and walks.
214938069|NCT04857918|BEHAVIORAL|Attention Control: Fitness Application Strava|The attention control condition will be instructed to record their exercise using the Strava application, and will be encouraged to participate in 150 minutes of moderate-to-vigorous exercise each week of the intervention.
214938070|NCT05837728|BEHAVIORAL|Health promoting assessment of older adults living at home|Based on the results of the first assessment of the older person's health determinants, healthcare professionals will recommend and tailor measures to the individual's needs to reduce the risk of functional decline and maintain their health while living at home.
214938071|NCT00436098|BEHAVIORAL|Motorpedagogic exercise|physical training
214938072|NCT03440294|DIAGNOSTIC_TEST|resting standard spirometry|The subject (seated, bust straightened) should perform, after a slow and maximum inspiration, a forced and complete exhalation followed by a new inspiration to the total lung capacity.
214938073|NCT03440294|DIAGNOSTIC_TEST|maximum exercise testing|Incremental exercise on cycle ergometer with 100W start for men (80W for women) for 4 minutes as part of the warm-up. Then, step increment of a 50W power for men (40W for women) lasting 2 minutes each.
214938074|NCT02428374|DRUG|Rosuvastatin plus clopidogrel|Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
214938075|NCT02428374|DRUG|Rosuvastatin plus ticagrelor|Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
214938076|NCT02428374|DRUG|Simvastatin plus clopidogrel|Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
214938077|NCT02428374|DRUG|Simvastatin plus ticagrelor|Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
214938078|NCT04205461|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation before pulmonary valve replacement. Voltage and activation mapping of right ventricle in a subset of patients.
214938079|NCT01100216|OTHER|Nicotine Lozenge|4 mg for 12 days
214337123|NCT03884972|DRUG|Trabectedin|Given IV
214938080|NCT01100216|OTHER|Stonewall Dissolvable Tobacco Pieces|5.6 mg nicotine pieces for 12 days
214938081|NCT01100216|OTHER|Camel Snus Frost|pouches, 6.2 mg nicotine, for 12 days
214938082|NCT01100216|OTHER|Skoal Wintergreen|Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
214938083|NCT01651338|PROCEDURE|acupuncture|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
214938084|NCT02427438|OTHER|Video|A video with moving demonstration and verbal instruction of the exercise to strengthen low back
215073823|NCT03984890|DRUG|Vitamin D3|Vitamin D3 drops 800IU/d for 3 months
215073824|NCT03984890|DRUG|Traditional treatment of CGD and TB|Anti-tuberculosis drugs, interferon-gamma
215073825|NCT05584111|DRUG|STC-15|STC-15 oral capsules various dosing regimen in 3-week cycles
215073826|NCT04253106|GENETIC|Liquid biopsies (blood, gastric fluid).|Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.
214337124|NCT03884972|DRUG|Venetoclax|Given PO
214337125|NCT03376204|OTHER|No intervention|No intervention
214938085|NCT02427438|OTHER|Handout|A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
214938086|NCT01831505|DRUG|Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them|
215073827|NCT02405247|OTHER|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
214337126|NCT05389124|BEHAVIORAL|Partial abstinence from oral hygiene|One quadrant of the dentition will be protected from oral hygiene for 3 weeks.
214337127|NCT02340559|BEHAVIORAL|Meta-cognitive Training|
214337128|NCT02340559|BEHAVIORAL|Psychoeducational group|
214337129|NCT02930434|DIETARY_SUPPLEMENT|cholecalciferol|Administration of vitamin D3
214337130|NCT06554574|DRUG|LTG-305|Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
214337131|NCT03354676|OTHER|MetS+|Data processing from Patient Medical Files
214337132|NCT03354676|OTHER|MetS-|Data processing from Patient Medical Files
214337133|NCT02449759|BEHAVIORAL|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
214337134|NCT01258205|DRUG|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
214938087|NCT06094101|BIOLOGICAL|Peptide vaccine IPX|"Peptide vaccine is a combination of~1. class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~2. class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~3. control peptide derived from Survivin.~4. adjuvant: toll like receptor (TLR) 1/2 ligand XS15."
214938088|NCT02907593|DRUG|Budesonide in Calfactant|Budesonide in Calfactant
214938089|NCT05104879|OTHER|Biosketch Card|The experimental group received a biosketch card during rooming, pre-clinician encounter that gave an overview of the midlevel providers qualifications.
214938090|NCT04139837|BEHAVIORAL|Health screening, community health talks or activities on frailty|Screening for frailty using the FRAIL scale to categorize participant's status as robust, prefrail and frail. A series of community health talks or activities on frailty will be provided to each category of participants for the prevention or management of frailty.
214938091|NCT00104065|DRUG|CG53135-05, velafermin|
214938092|NCT02071602|DRUG|CD-NP|Randomized 1:1:1
214337135|NCT03731494|BIOLOGICAL|Nickel oral hyposensitization treatment|Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
214337136|NCT03675659|DRUG|intra-articular injection|intra-articular injection with magnesium sulfate with four injections at weekly intervals
214347321|NCT02897804|BEHAVIORAL|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214938093|NCT00322361|BIOLOGICAL|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
214938094|NCT00322361|BIOLOGICAL|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
215073828|NCT01117298|DRUG|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
215073829|NCT01117298|DRUG|Placebo|Tab Placebo every alternate day for 8 weeks
215073830|NCT05431387|DRUG|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
215073831|NCT05431387|DRUG|Placebo|film-coated oral tablets containing matched placebo
215073832|NCT05431387|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
215073833|NCT05072223|PROCEDURE|Pericapsular nerve group block|A new nerve block guided by ultrasound that aims to block articular branches of the shoulder.
215073834|NCT05072223|PROCEDURE|Interscalene block|A common and rapid-onset nerve block method guided by ultrasound for pain control of patients undergoing shoulder surgery.
215073835|NCT04975412|DIAGNOSTIC_TEST|Whole blood zinc level|whole blood zinc levels determined through ashing acid digestion-inductively coupled plasma (ICP) using Shimadzu ICPS-7510, an inductively coupled plasma emission spectrometer.
215073836|NCT02936310|BEHAVIORAL|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
215073837|NCT02305472|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
215073838|NCT00204594|DRUG|rM28|
215073839|NCT00204594|DRUG|autologous PBMCs|
215073840|NCT01803191|DRUG|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
215073841|NCT01803191|DRUG|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
215073842|NCT04282265|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks
215073843|NCT04282265|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
215073844|NCT03179254|DRUG|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
214337137|NCT02744924|BEHAVIORAL|Physical activity intervention|"The intervention is comprised of 5 steps:~1. Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~2. Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~3. Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~4. Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~5. Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project"
214337138|NCT00153101|DRUG|Telmisartan|
214337139|NCT00153101|DRUG|Combination of Telmisartan and Ramipril|
214337140|NCT00153101|DRUG|Ramipril|
214337141|NCT02610140|DRUG|Anetumab ravtansine (BAY94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
214337142|NCT02610140|DRUG|Vinorelbine|Starting dose: 30mg/m\^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
214337143|NCT02589119|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
214337144|NCT03169153|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
214337145|NCT03169153|DEVICE|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
214337146|NCT00000601|DRUG|estrogen replacement therapy|
214337147|NCT00000601|DRUG|estrogens|
214675267|NCT04549038|OTHER|12-16 hour nutrition|Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.
214938095|NCT04405284|OTHER|use and exposure to disinfectants during the coronavirus pandemic|The use of disinfecting products in deep house cleaning by women during the coronavirus lockdown.
214938096|NCT05963828|BEHAVIORAL|Post-hospital management based on WeChat applet|The brain and heart health manager uses the exclusive QR code in the WeChat applet to receive and manage patients. Patients can register and use the WeChat applet by scanning the QR code. The functions of WeChat applet include making medication plan for patients, daily medication reminder, targeted health education, health index monitoring, online consultation and so on.
214938097|NCT05963828|BEHAVIORAL|Routine post-hospital follow-up management|The brain and mental health managers routinely followed up the patients in the standard group for 1, 3, 6 and 12 months by telephone or outpatient follow-up, the main content of which was to inquire about the medication of patients and the management of stroke risk factors. Targeted health education was carried out according to the risk factors of patients.
214938098|NCT06462469|DRUG|Ruxolitinib|Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.
214337148|NCT00000601|DRUG|progesterone|
214337149|NCT00000601|DRUG|hormone replacement therapy|
214337150|NCT05264805|DRUG|0.25% Bupivacaine|20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
214337151|NCT00224159|BEHAVIORAL|Drug and Dietary behavior|
214337152|NCT01336127|BEHAVIORAL|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
214337153|NCT01169324|OTHER|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
214337154|NCT03103620|DEVICE|COBRA PzF Coronary Stent System|COBRA PzF Coronary Stent System
214337155|NCT01470755|DRUG|salbutamol|Metered dose inhaler, 100µg+300µg per puff, administered one day
214938099|NCT05442606|OTHER|Ultrasound Therapy|Using an Enraf Nonius Sonoplus 490 from the Netherlands, the patients were asked to lie supine while the therapist stood at the level of the patient's head. The patients received pulsed (duty cycle 50%) US therapy with intensities of 1 and 0.5 W/cm2 for maxillary and frontal sinus, respectively, and a collimating beam frequency of 1MHz. To deliver US to the treatment area, a small probe US applicator (0.8 cm2) with an effective radiating area (ERA) of 0.6 cm2 and a beam non-uniformity ratio (BNR) of 6:1 was used. The skin around the cheeks was used for the maxillary sinus and the forehead for the frontal sinus. Between the applicator and the skin, ultrasound transmission gel was employed, and a full contact technique in slow circular motion was used for 5 minutes over the maxillary sinuses and 4 minutes over the frontal sinuses on each pair of sinuses
214938100|NCT05442606|OTHER|Manual Drainage Techniques|Manual Drainage Techniques for the frontal and maxillary sinuses
214938101|NCT05442606|OTHER|Self Sinus Massage Technique|Patients will also encouraged to self-massage their frontal and maxillary sinuses while resting supine
214938102|NCT01232621|OTHER|Physician Introduction of research personnel|Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
214938103|NCT05994313|DIETARY_SUPPLEMENT|Habitual potato consumption|Potatoes are to be consumed in the evening meal, every evening for 12-weeks.
215073845|NCT03179254|DRUG|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
215073846|NCT00970892|DRUG|Warfarin dose titration|Dosage
215073847|NCT04137588|DRUG|Antiangiogenesis Agents|antiangiogenesis agents plus chemotherapy as first line treatment
215073848|NCT04137588|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor plus chemotherapy as first line treatment
215073849|NCT03800446|DIAGNOSTIC_TEST|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
215073850|NCT03221868|BEHAVIORAL|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
214337156|NCT01470755|DRUG|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
214337157|NCT01470755|DRUG|Salbutamol -dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
214337158|NCT01470755|DRUG|salbutamol -dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
214938104|NCT05994313|DIETARY_SUPPLEMENT|Habitual non-nutrient-dense staple consumption|White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.
214938105|NCT05739942|DRUG|[177Lu]Lu-NeoB|Radiopharmaceutical solution for infusion
214938106|NCT05739942|DRUG|[68Ga]Ga-NeoB|Either provided as Kit for the radiopharmaceutical preparation of \[68Ga\]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
214938107|NCT05739942|OTHER|Temozolomide|Capsules/ lyophilized powder in single-dose vial for reconstitution.
214938108|NCT04261959|OTHER|myoActivation|myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.
214938109|NCT04896437|PROCEDURE|non-centrifuge fat graft application to the wounds|Autologous fat grafts were harvested from abdominal or gluteal regions of the patients and injected into the wound bed and wound environment. Clinical observation and photograph records were used to follow the wounds.
214938110|NCT04427137|DEVICE|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single LFR treatment, with 360 pulses of LFR delivered in one continuous train of 6 minutes at 1Hz at 120% of the patient's resting motor threshold.
214938111|NCT02398370|BIOLOGICAL|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
214938112|NCT01074723|DIETARY_SUPPLEMENT|b-cryptoxanthin and phytosterols|Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
214938113|NCT04618471|DEVICE|Boston Scientific WaveWriter SCS System|WaveWriter SCS Programming
214938114|NCT04508114|BEHAVIORAL|Technology-assisted Index|The participant will be informed the ATP testing result and explanation in pretest.
214938115|NCT05853211|COMBINATION_PRODUCT|Aligner and inter-arch elastics|Correction of class II malocclusion by class II elastics on clear aligners
214938116|NCT03859180|BEHAVIORAL|Focused breathing|Focused breathing is a series of focused, controlled breaths that aid in relaxation. Each participation in this group will be taught how to do focused breathing by the study investigator. Once determined to be able to perform focused breathing, participants will be asked to practice it for 4 minutes, twice a day, for 6 weeks. If they choose to do so, they may practice focused breathing if they become anxious at other times. They will be asked to keep a diary of each time they practice and/or use focused breathing.
214675268|NCT04182191|DRUG|Tenoxicam|After extraction of at least one third molar, 89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed.
214675269|NCT01221233|OTHER|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
214675270|NCT01221233|OTHER|Moist Heat|"For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
214675271|NCT04618497|DRUG|Methoxyflurane|Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
214938117|NCT02800941|DRUG|Oral anticoagulant treatment|The treatment is delivered according to the usual practice.
214938118|NCT02376296|DRUG|docetaxel|3-weekly docetaxel therapy (starting dose of 75 mg/m2)
214938119|NCT02376296|OTHER|Blood draws|Blood draws for determination of docetaxel plasma levels and exposure (AUC)
214938120|NCT01080729|DRUG|Recombinant-follicle stimulating hormone (r-FSH)|"The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml \[22 micrograms/0.5 ml\]; 450 IU/0.75 ml \[33 micrograms/0.75 ml\]; or 900 IU/1.5 ml \[66 micrograms/1.5 ml\].~The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG)."
214938121|NCT03954717|BEHAVIORAL|Shepherd CAN DO Program|CAN DO Shepherd is a four-day participatory program held at the Shepherd Center, in Atlanta, Georgia or people with MS. The four-day program comprises evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a health life beyond their MS.
214938122|NCT01752634|DRUG|Secukinumab (AIN457)|Secukinumab (AIN457)
214938123|NCT01752634|DRUG|Placebo|Placebo PFS for s.c. administration.
214938124|NCT00727987|DRUG|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.
214938125|NCT00727987|DRUG|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
214938126|NCT00727987|DRUG|Methotrexate (MTX)|6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
214938127|NCT03071679|DRUG|Omiganan|Omignan 1%, 2.5%
214337159|NCT02885233|BEHAVIORAL|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
214337160|NCT02885233|BEHAVIORAL|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
214337161|NCT04995380|PROCEDURE|Early Cholecystectomy|Cholecystectomy performed within 10 days from onset of symptoms
214337162|NCT00004327|DRUG|octreotide|
214337163|NCT04023006|DEVICE|Removable prostheses|Full dentures created by Additive manufacturing (Carbon Printers)
214337164|NCT05405673|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|A kind of stool test
214337165|NCT02327208|DIETARY_SUPPLEMENT|Control|
214938128|NCT03071679|DRUG|Imiquimod|Imiquimod 15mg
214938129|NCT03071679|DRUG|Omiganan 1% and Imiquimod|Omiganan 1% and Imiquimod
214938130|NCT03071679|DRUG|Omiganan 2.5% and Imiquimod|Omiganan 2.5% and Imiquimod
214938131|NCT03071679|DRUG|Placebo|Vehicle
214938132|NCT00516802|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
214938133|NCT00516802|DRUG|dacarbazine|intravenous injection over at least 20 minutes
214938134|NCT01250171|BIOLOGICAL|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
214938135|NCT01250171|BIOLOGICAL|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
214938136|NCT01250171|BIOLOGICAL|Placebo|The placebo solution for infusion contained 5% glucose.
214938137|NCT01196936|DRUG|Tamoxifen Citrate|5 mg PO Daily
214938138|NCT01196936|DRUG|Placebo|1 tablet daily
214938139|NCT01196936|PROCEDURE|Digital mammography|Correlative studies
214938140|NCT01196936|OTHER|immunohistochemistry staining method|Correlative Studies
214675272|NCT04618497|DRUG|Ketorolac|Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
214675273|NCT03336398|DRUG|Ketamine Hydrochloride in saline|0.5 mg/kg IV of ketamine hydrochloride in saline will be administered with one of the MRS Scan
214675274|NCT03336398|DRUG|Saline|Saline will be administered with the other MRS scan
215073851|NCT03221868|BEHAVIORAL|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
214337166|NCT02327208|DIETARY_SUPPLEMENT|Protein|
214337167|NCT02327208|DIETARY_SUPPLEMENT|Carbohydrate|
214337168|NCT01464528|DRUG|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
214337169|NCT04955626|BIOLOGICAL|BNT162b2|Intramuscular Injection
214337170|NCT04955626|OTHER|Placebo|Intramuscular Injection
214337171|NCT04955626|BIOLOGICAL|BNT162b2 OMI|Intramuscular Injection
214938141|NCT01196936|OTHER|pharmacological study|Correlative Studies
214938142|NCT01196936|OTHER|laboratory biomarker analysis|Correlative Studies
214938143|NCT01196936|GENETIC|protein expression analysis|correlative studies
214938144|NCT01196936|OTHER|pharmacogenomic studies|correlative studies
214938145|NCT01196936|OTHER|questionnaire administration|Ancillary studies
214938146|NCT01196936|PROCEDURE|Fine needle aspiration|
214938147|NCT01196936|OTHER|Quality of Life Assessment|Ancillary Studies
214938148|NCT06556095|DRUG|Dexamethasone 4mg/ml solution|The study intervention dexamethasone solution (4mg/ml) is used to hydrate bone allograft.
214938149|NCT05748873|DRUG|SPVN06|AAV-RdCVF-RdCVFL
214337172|NCT04955626|BIOLOGICAL|Combination BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection"
214337173|NCT04955626|BIOLOGICAL|Combination (Bivalent) BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection"
214347322|NCT02897804|BEHAVIORAL|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
214675275|NCT05180305|DIAGNOSTIC_TEST|Mitomic Prostate Test|Mitomic Prostate Test
214675276|NCT01439529|OTHER|Device programming: nominal|CRT device is programmed to nominal values
214675277|NCT01439529|OTHER|Programming optimization by QRS|CRT device is programmed by QRS optimization
214675278|NCT00984464|BIOLOGICAL|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
214675279|NCT00984464|DRUG|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
214675280|NCT00984464|DRUG|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
214675281|NCT03789773|DEVICE|Millimeter-Wave Holographic Imaging|Undergo mm-wave holographic imaging
214675282|NCT03743584|PROCEDURE|Targeted temperature management|Target temperature management at 33°C
214938150|NCT06254898|BEHAVIORAL|Child life standard of care|Standard preparation and support provided to the participant by a Certified Child Life Specialist.
215073852|NCT00218816|BEHAVIORAL|Nebulizer Education Intervention|Asthma Education
215073853|NCT00218816|BEHAVIORAL|Standard Asthma Education Groups|Asthma Education
214938151|NCT06254898|BEHAVIORAL|Child life standard of care + incentives provided with conditional agreement.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. Before the procedure the child life specialist discusses earning a prize with the patient if they demonstrate the agreed upon coping goal (i.e. holding arm still, taking deep breaths, engaging in distraction.) At the end of the procedure the patient is provided with the prize if they earn the prize based on the agreed upon coping plan.
214938152|NCT06254898|BEHAVIORAL|Child life standard of care + incentive provided unconditionally.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. After the procedure is complete the patient is provided with a prize. The patient does not need to do anything to earn the prize.
214938153|NCT01110369|DIETARY_SUPPLEMENT|Protein drink|Protein drink twice a day during 6 months.
214337174|NCT02290587|OTHER|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :~* Questionnaire for depression and anxiety~* Evaluation of executive functions~* Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~* morphological MRI~* functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
214337175|NCT02290587|DEVICE|MRI|
214337176|NCT00051116|DRUG|CC-5013|
214337177|NCT01167946|DRUG|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
214337178|NCT01167946|DRUG|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
214337179|NCT01167946|DRUG|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
214337180|NCT05283096|OTHER|Questionnaire|A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
214337181|NCT04558476|BIOLOGICAL|Convalescent Plasma|2 units of convalescent plasma
214938154|NCT01110369|OTHER|Resistance exercise training|Resistance exercise training twice per week during 6 months.
214938155|NCT01110369|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink twice a day during 6 months.
214675283|NCT03743584|PROCEDURE|Standard care, early treatment of fever|Standard of care with early treatment of fever
214675284|NCT03099369|BEHAVIORAL|Daily Step-based Exercise|A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.
214337182|NCT04558476|OTHER|Standard of Care|Gold Standards
214337183|NCT01399359|BEHAVIORAL|Counseling session|
214337184|NCT01399359|OTHER|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
214675285|NCT03099369|BEHAVIORAL|Symptom-based Exercise|A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.
214337185|NCT01399359|OTHER|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
214337186|NCT01399359|OTHER|online questionnaire|
214337187|NCT01336478|PROCEDURE|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
214337188|NCT01336478|PROCEDURE|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
214337189|NCT03812718|DEVICE|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
214337190|NCT03812718|DEVICE|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
214337191|NCT04893889|DIAGNOSTIC_TEST|Shear-wave elastography|Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
214337192|NCT03835858|OTHER|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
214675286|NCT03099369|OTHER|Fitbit Fitness Monitor|Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
214675287|NCT00416637|BIOLOGICAL|Bevacizumab (Avastin)|
214938156|NCT06104449|DRUG|Opevesostat|Tablets to be taken orally.
214938157|NCT06104449|DRUG|Dexamethasone|Tablets to be taken orally.
214938158|NCT06104449|DRUG|Fludrocortisone acetate|Tablet to be taken orally.
214938159|NCT06104449|DRUG|Hydrocortisone|Tablets to be taken orally as a recue medication.
214938160|NCT06581211|PROCEDURE|Aromatherapy and Essential Oils|Inhale LA
214938161|NCT06581211|OTHER|Electronic Health Record Review|Ancillary studies
214938162|NCT06581211|OTHER|Jojoba Oil|Inhale jojoba oil aromatherapy
214938163|NCT06581211|OTHER|Lavender Oil|Inhale LAO
214938164|NCT06581211|OTHER|Questionnaire Administration|Ancillary studies
214938165|NCT06581432|DRUG|Zongertinib|Zongertinib
214938166|NCT06474078|DRUG|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
214938167|NCT05242510|PROCEDURE|Patching|The subject will occlude the non-dominant eye for 24 hours.
214938168|NCT05242510|PROCEDURE|Prism Adaptation|The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
214675288|NCT04748276|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary.
214675289|NCT01241513|DRUG|NAC|NAC provided to determine if beneficial at altitude
214938169|NCT05596318|DEVICE|Digital CBT-I|The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.
214938170|NCT05596318|DEVICE|Digital SHE|The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
214675290|NCT01241513|DRUG|Placebo|Placebo
214675291|NCT00611455|DRUG|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
215073854|NCT03178123|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
215073855|NCT03178123|BIOLOGICAL|high-dose recombinant interferon a-2B|15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
214938171|NCT04523857|DRUG|Abemaciclib|Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
214938172|NCT04523857|DRUG|Hydroxychloroquine|Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
214938173|NCT06101940|DIAGNOSTIC_TEST|MRI scan|Brain MRI scan to evaluate the integrity of the nervous system; lower limb muscle MRI scan to evaluate fat infiltration in skeletal muscles of the lower limb
214938174|NCT06101940|DIAGNOSTIC_TEST|Electrocardiography|Standard 12-lead electrocardiography or Holter monitoring performed to assess cardiac conduction abnormalities and arrhythmias in patients with DM1.
215073856|NCT01940250|DRUG|Magnesium Sulphate|MgSO4 IV infusion
215073857|NCT01940250|DRUG|Sterile water|H2O IV infusion
214938175|NCT06101940|DIAGNOSTIC_TEST|Pulmonary function test|Comprehensive pulmonary function testing including spirometry to assess respiratory muscle weakness and restrictive lung disease in DM1 patients.
214938180|NCT04019964|DRUG|Nivolumab|Nivolumab 480mg intravenously every 4 weeks
214938181|NCT04033081|DEVICE|CivaSheet|Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
214938182|NCT04478773|PROCEDURE|MRI|MRI with or without contrast
214938183|NCT06346509|DRUG|PORT-77|Healthy adult participants will receive a single oral dose of PORT 77.
214938184|NCT06346509|DRUG|Placebo|Healthy adult participants will receive matching placebo on Day 1.
215073858|NCT04740281|BEHAVIORAL|Footwear|Assessment of footwear
215073859|NCT03848208|DRUG|cytisine|cytisine film-coated oral tablet
215073860|NCT03848208|DRUG|placebo|matching placebo oral tablet
214675292|NCT00611455|DRUG|Placebo|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
214675293|NCT00858702|DRUG|olmesartan medoxomil and a CCB|olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks
214675294|NCT00858702|DRUG|olmesartan medoxomil and a diuretic|olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
214675295|NCT02676310|DRUG|Bimatoprost|
214675296|NCT02602236|DEVICE|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
214675297|NCT04850040|DRUG|Apatinib Mesylate|250 mg, oral every other day. Approximately half an hour after a meal (the daily dose should be taken at the same time as possible) with warm boiled water.
214675298|NCT04850040|DRUG|Camrelizumab|200 mg, 30 minutes intravenous drip (overall dosing time no shorter than 20 minutes and no longer than 60 minutes, including tube flush time) once every 2 weeks, with the first dose administered concurrently with Apatinib Mesylate Tablets.
214675299|NCT04850040|DRUG|Oxaliplatin|85 mg/m2, once every 2 weeks, to be administered half an hour after Camrelizumab injection.
214675300|NCT06435195|PROCEDURE|Surgical Removal|Resection of pituitary pathologies.
214675301|NCT06435195|PROCEDURE|Biopsy|Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis
214675302|NCT01670630|PROCEDURE|Sheathed speculum examination|
214938185|NCT05317754|BEHAVIORAL|Mindful breathing|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
214938186|NCT05317754|BEHAVIORAL|Prostrations, according to Tibetan Buddhist tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
214675303|NCT01670630|PROCEDURE|Standard speculum examination|
214675304|NCT05187195|OTHER|Home-based telerehabilitation with exercise videos|Balance, walking, strengthening, posture videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
214675305|NCT05187195|OTHER|Exercise brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening, posture etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
214675306|NCT00491530|DRUG|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
214938187|NCT05317754|BEHAVIORAL|The Koan Mu, according to Zen Buddhist tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
214938188|NCT05317754|BEHAVIORAL|The mirror exercise, according to Toltec tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
214337193|NCT03717337|PROCEDURE|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
214337194|NCT03717337|PROCEDURE|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
214337195|NCT04524962|BIOLOGICAL|Descartes 30|Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
214938189|NCT01900132|DEVICE|EIM testing|EIM device is placed on the muscle and a high frequency current is delivered to the skin.
214938190|NCT01900132|DEVICE|Nerve &amp; muscle ultrasonography|Ultrasound waves to examine the muscles and nerves
214337196|NCT04010942|DRUG|Vit D|Injection
214337197|NCT04010942|DRUG|Metformin|tablets
214337198|NCT04010942|DRUG|Clomiphene|Tablet
214337199|NCT04181918|BEHAVIORAL|AOT|During action observation, participants observe different daily actions (e.g. reading a newspaper; drinking an espresso) divided into up to four motor segments.
214337200|NCT04181918|BEHAVIORAL|MI|During motor imagery, participants imagine themselves performing the same daily actions as in AOT in the absence of motor output
214337201|NCT00271336|DRUG|Pentoxifylline|
214337202|NCT02233049|DRUG|Erlotinib|
214337203|NCT02233049|DRUG|Everolimus|
214337204|NCT02233049|DRUG|Dasatinib|
214337205|NCT06394128|DRUG|Cangpo Liujun Prescription|Based on the diagnostic criteria of spleen deficiency and dampness excess syndrome, Cangpo Liujun Prescription could be used to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy.
214938191|NCT01900132|DEVICE|Nerve conduction studies|Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.
214938192|NCT01900132|DEVICE|Electromyography (EMG)|Thin needle placed into muscles to record electrical activity-adults only
214938193|NCT05608772|PROCEDURE|revision surgery|revision procedure after failed sleeve gastrectomy
214938194|NCT06487403|RADIATION|Standard of care external beam radiotherapy (single integrated boost)|70Gy in 35 fractions, 56 Gy in 35 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
214938195|NCT06487403|RADIATION|Standard of care external beam radiotherapy (two-phase treatment)|70Gy in 35 fractions, delayed 40 Gy in 20 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
214938196|NCT04216784|DRUG|Furosemide Injection|Patient will receive furosemide intravenously
214938197|NCT04216784|DRUG|Albumin Human|Patient will receive albumin (25%) 12.5 gm intravenously
215073861|NCT03106844|DRUG|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
215073862|NCT03195244|OTHER|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
215073863|NCT00201357|DRUG|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
215073864|NCT04151927|DEVICE|Normobaric Hypoxia|Low oxygen exposure to mimic \~8500 feet elevation.
215073865|NCT04151927|DEVICE|Normobaric Normoxia|Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).
214675307|NCT00491530|DRUG|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
214938198|NCT05482880|OTHER|Regular care with additionally administration of questionnaires|"Patients receiving regular care. In addition, validated questionnaires are administered at two measurement points:~1. after the multidisciplinary consultation, a baseline questionnaire\*, the decision conflict scale and the EQ-5D-5L questionnaire are administered by phone.~2. 1 month after completion of the treatment program (care pathway) the EQ-5D-5L, the BaSQoL and the EORTC IN-PATSAT32 questionnaires will be administered by phone.~Completing the questionnaires takes about 30 minutes each time.~\*Baseline questionnaire: gender, age, marital status, education level, World Health Organization (WHO) performance status, presence of informal care, stage and treatment of cSCC, history of skin cancer, presence of current other skin cancer, and average travel time to hospital."
214675308|NCT00491530|DRUG|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
214938199|NCT06660407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214938200|NCT06660407|PROCEDURE|Computed Tomography|Undergo CT
214938201|NCT06660407|OTHER|Immunotherapy|Given immunotherapy
214938202|NCT06660407|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
214938203|NCT06660407|RADIATION|Spatially-fractionated Radiation Therapy|Undergo grid radiation therapy
214938204|NCT02887040|RADIATION|Radiation|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.
214938205|NCT02887040|DRUG|Atengenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
214938206|NCT02887040|DRUG|Astugenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
214938207|NCT04159727|OTHER|stool and blood analysis|High throughput sequencing and quantitative PCR
214938208|NCT04977388|DRUG|Droxidopa|Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.
214938209|NCT04977388|OTHER|Placebo|Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.
214938210|NCT06961370|DRUG|RO7669330|RO7669330 will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
214938211|NCT06961370|DRUG|Syfovre™|Syfovre™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
214938212|NCT06961370|DRUG|Izervay™|Izervay™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
214938213|NCT00962949|DRUG|Angiotensin II|Angiotensin II infusion for 1 hour
214938214|NCT03155906|OTHER|Health care delivery|Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
214938215|NCT06831461|RADIATION|Proton Beam Therapy|Patients randomized to the experimental arm will be treated with proton beam therapy.
214938216|NCT06831461|RADIATION|Photon Radiotherapy|Patients randomized to standard arm will be treated with photon therapy.
214938217|NCT05904496|DRUG|BGB-30813|Specified dose administered on specified days
214938218|NCT05904496|DRUG|Tislelizumab|Specified dose administered on specified days
214675309|NCT00491530|DRUG|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
214675310|NCT02417623|BEHAVIORAL|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
214675311|NCT01738035|DRUG|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
214938219|NCT06909955|OTHER|Exercise|"Relaxation Exercises (Progressive Muscle Relaxation Exercises):~Progressive muscle relaxation exercises, one of the relaxation techniques, will be used in this study. Participants will be instructed to sit in a comfortable position on a chair during the exercises. Clear and precise instructions will be provided to ensure proper execution. The exercise program will be conducted for 8 weeks, 3 days a week, for 30 minutes, under the supervision of an expert physiotherapist."
214938220|NCT06910423|BEHAVIORAL|Psychosocial intervention|Culturally relevant psychosocial intervention for people with insomnia
214675312|NCT01738035|OTHER|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
214675313|NCT05094440|BEHAVIORAL|Dialectical behavioral therapy skills training (DBT-ST)|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
215073866|NCT05098964|DEVICE|pedometer home based rehabilitation|Home based pulmonary rehabilitation for 6 weeks using pedometer Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan)
215073867|NCT05098964|OTHER|Exercise training|Hospital based exercise training for 6 weeks
215073868|NCT02357082|RADIATION|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
215073869|NCT06105086|OTHER|Semi-structured interview|Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
215073870|NCT05816642|DRUG|sunitinib or pazopanib|Single targeted therapy
214337206|NCT01975389|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
214938221|NCT06912555|OTHER|Diet|The nutritional plan will be initially based on a protein intake of 1.3 to 1.5 g per kilogram of body weight. From this, the total daily calorie intake is calculated, with 30% of the calories allocated to fats. The remaining calories will be assigned to carbohydrates, depending on the protein intake. Protein distribution will be approximately 40% at breakfast and lunch, and 60% at dinner. Caloric restriction will be moderate, reducing the total energy expenditure by 30%-calculated individually-which translates to an approximate decrease of 400 to 600 kcal per day compared to the participant's usual energy needs. It is important to note that the diet will never provide less than 1200 kcal per day to ensure that the minimum nutritional requirements are met.
214938222|NCT06912555|OTHER|Diet|The macronutrient plan will include a protein intake of 1.3 to 1.5 g per kilogram of body weight. Based on this protein amount, the total daily caloric intake will be determined, allocating 30% of the calories to fat consumption. The remaining calories will be assigned to carbohydrates, proportional to the protein intake. Protein distribution will be approximately 85% during breakfast and lunch and 15% at dinner. The caloric restriction will be moderate, with a 30% reduction in total energy expenditure calculated individually, resulting in an approximate decrease of 400 to 600 kcal per day compared to the participant's usual energy needs. It is important to note that the diet will never contain fewer than 1200 kcal per day, ensuring that the participant's nutritional requirements are met.
214938223|NCT06912555|OTHER|Diet|The macronutrient plan will include a protein intake of 0.8 g per kilogram of body weight. From this protein amount, the total daily calorie intake will be calculated, with 30% of the calories allocated to fats. The remaining calories will be assigned to carbohydrates, depending on the protein intake. Caloric restriction will be moderate, reducing the total energy expenditure by 30%-calculated individually-which translates to an approximate decrease of 400 to 600 kcal per day compared to the participant's usual energy needs. It is important to note that the diet will never contain fewer than 1200 kcal per day, ensuring that the participant's nutritional requirements are met.
214938224|NCT06503159|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR) Program|The study intervention is a 9-week MBSR intervention once per week in-person or remotely (via an NIH approved remote platform used in compliance with policy, including HRPP Policy 303). The MBSR will be delivered to groups of 8-12 participants. Only the vaping adolescents will receive MBSR training.
214938225|NCT06085560|BEHAVIORAL|Usual Care Message|Usual care is provided by the FQHC for the screening option chosen.
214938226|NCT06085560|BEHAVIORAL|Implementation Intention Intervention: Standard Message|Implementation Intention Intervention module includes standard messaging in addition to the usual care provided by the FQHC for the screening option chosen.
214938227|NCT06085560|BEHAVIORAL|Implementation Intention Intervention: Culturally-Targeted Message|Implementation Intention Intervention module includes culturally-targeted framing of health information messages in addition to the usual care provided by the FQHC for the screening option chosen.
214938228|NCT04936048|BEHAVIORAL|Music Therapy|Music therapy will use rhythmic cues, music instruments (piano, drums, djembe, xylophone, harmonica), songs, and stories accompanied by songs or musical instruments to target common goals.
214938229|NCT04936048|BEHAVIORAL|Play therapy|Play therapy is designed as a play-based active comparison condition to control for factors such as support, therapist attention, positive expectancies, and emotional engagement. It will use verbal interaction, toys (Lego, finger puppets, Play Doh, puzzles), and the same stories as in MT, but without a musical component, to target common goals.
214938230|NCT02338167|PROCEDURE|Blood sampling|A blood sample will be taken during a routine blood draw
214938231|NCT04557124|BEHAVIORAL|USS|social cognitive training
214337207|NCT01975389|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
215073871|NCT05816642|DRUG|PD-1 inhibitor combined with axitinib|targeted therapy combined with immunotherapy
214675314|NCT02741531|OTHER|Bladder filled with saline solution|Patients in this arm will have their bladders filled with 150 cc of saline solution.
214675315|NCT02741531|OTHER|saline solution|Saline solution will be used to partially fill patients' bladders
214675316|NCT02061137|DRUG|fingolimod (FTY720)|0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
214675317|NCT02894073|DEVICE|skin transilluminator|VeinViewer
214675318|NCT02542345|PROCEDURE|magnetic resonance imaging|
214675319|NCT03644797|GENETIC|Exome sequencing|Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
214675320|NCT01580475|OTHER|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
214938232|NCT04557124|BEHAVIORAL|MovingForward|problem solving training
214337208|NCT04904523|DIAGNOSTIC_TEST|Diagnostic Test:Blood test|Drop of blood for RNA and metabolic analysis
214337209|NCT06459557|PROCEDURE|cast|children with displaced distal radius fractures would be managed by a cast in the emergency room
214337210|NCT06459557|PROCEDURE|surgical reduction|anatomical reduction of pediatric displaced distal radius fractures under general anesthesia in the operating room
214337211|NCT00333606|BEHAVIORAL|Acupuncture|Body acupuncture of 1 specific point per trial session
215073872|NCT02072460|OTHER|electromyography|
214337212|NCT05249725|DRUG|Irsogladine Maleate|Orally administration of irsogladine maleate 4mg/day, for 8 weeks.
215073873|NCT02072460|OTHER|electroencephalography|
215073874|NCT02072460|OTHER|approaches from psychophysics|
214337213|NCT05249725|DRUG|Hydrotalcite|Patients were given 1 g hydrotalcite every morning, afternoon and evening for 8 weeks.
214337214|NCT04139785|OTHER|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
214938233|NCT06359652|DEVICE|Prehabilitation Program (Apple Watch Series 6 with exercise flipbook)|We will evaluate whether use of a personal device (the Apple Watch) could help medical professionals assess patients' pre-surgery prehab state. It will also assess whether patients are willing to use a personal device and engage in prehab exercise and whether the device can enhance prehab uptake. The intervention is to also offer patients the Exercise Flipbook, to send them a reminder to exercise and to send them notifications to track their exercise.
214938234|NCT06387498|PROCEDURE|Testicular tissue biopsy and cryopreservation|Surgical Procurement of Testicular Tissue: At early stages of technology development, simple orchiectomy (removal of one entire testicle) may give the best chance of preserving sufficient cells for effective therapy. However, incisional biopsy of up to 25% of tissue from one testis (wedge resection) will also be presented to the patient as an alternative option. The amount of testicular parenchyma removed will be at the discretion of the surgeon.
214938235|NCT06182332|OTHER|Electronic Health Record Review|Undergo medical record review
214938236|NCT06182332|OTHER|Internet-Based Intervention|Use AI algorithm
214938237|NCT06377098|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor
214938238|NCT06377098|DRUG|Placebo Oral Tablet|Placebo table given orally every eight hours up to three times while mother is in labor
214938239|NCT04431895|DRUG|Tofacitinib 5 MG|tofacitinib 5 mg tablet administered twice a day for 6 months
214938240|NCT05409131|DEVICE|Omnipod 5 System|Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.
214938241|NCT06109571|DEVICE|Connections App|The Connections app was developed for patients with substance use disorders or unhealthy substance use and adapted to include HIV support. For this study, it has been modified to provide additional resources to support patients engaged in HIV care. Connections' core features include agency-specific informational resources compiled in a resource center, patient self-monitoring through weekly check-in surveys, discussion rooms, and private messaging.
214938242|NCT05564403|DRUG|Binimetinib|Given PO
214675321|NCT03247998|DRUG|General Anesthesia|Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
214675322|NCT03247998|DRUG|Conscious Sedation with Remifentanil|Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
214938243|NCT05564403|PROCEDURE|Biopsy Procedure|Undergo biopsy
214337215|NCT03333746|OTHER|Laboratory Biomarker Analysis|Correlative studies
214337216|NCT03333746|DRUG|Lenalidomide|Given PO
214337217|NCT03333746|BIOLOGICAL|Nivolumab|Given IV
214337218|NCT03333746|OTHER|Pharmacological Study|Correlative studies
214337219|NCT02311049|RADIATION|Hypofractionation|
214337220|NCT01485601|BIOLOGICAL|MT10109|Single dose intramuscular injection MT10109 vs Botox®
214337221|NCT02709070|PROCEDURE|resection|hepatectomy for HCC
214337222|NCT02709070|PROCEDURE|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
214337223|NCT02279810|BEHAVIORAL|survey|Survey
214337224|NCT05552703|PROCEDURE|surgical evacuation of extradural hematoma|evacuation of extradural hematoma by craniotomy
214938244|NCT05564403|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214938245|NCT05564403|PROCEDURE|Bone Scan|Undergo bone scan
214938246|NCT05564403|PROCEDURE|Computed Tomography|Undergo CT
214938247|NCT05564403|PROCEDURE|Echocardiography Test|Undergo ECHO
214938248|NCT05564403|DRUG|Fluorouracil|Given IV
214938249|NCT05564403|DRUG|Leucovorin Calcium|Given IV
214938250|NCT05564403|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214938251|NCT05564403|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214938252|NCT05564403|DRUG|Oxaliplatin|Given IV
214938253|NCT03596671|DEVICE|RENOVA iStim™ System|Tibial implantable neuromodulation device
214337225|NCT02510157|DRUG|Dexamethasone|active comparator
214337226|NCT02510157|DRUG|Normal Saline|placebo controlled intervention
214337227|NCT02510157|DRUG|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
214337228|NCT06346561|DRUG|Dexmedetomidine|the reduction of controlled hypotension and the control of hemodynamic responses of the body
214337229|NCT06346561|DRUG|Labetalol|the reduction of controlled hypotension and the control of hemodynamic responses of the body
214337230|NCT00930358|DRUG|MEOPA|anaesthetic gaz inhalation
214337231|NCT00930358|DRUG|general anaesthesia|Anaesthetic intravenous route
214337232|NCT01929356|PROCEDURE|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
214337233|NCT06431620|DRUG|Recombinant Human Thyroid Stimulating Hormone|recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
214337234|NCT05795023|OTHER|NeuraLight|NeuraLight software-based platform
214337235|NCT03119103|DEVICE|Functional Bed Sheet|All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
215073875|NCT02924194|DEVICE|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
214675323|NCT04880057|OTHER|Resistance+Aerobic training|"The RT focuses on lower extremity workout, including leg press, hamstring curls, and calf raises. The participants start with intensity at 12 RM and finished with intensity at 8 RM after 3 weeks. There are 8 repetitions, 2 sets for each action. It will take 15 minutes to complete RT.~The AeT is composed by cycling on stationary bikes in the first week, stepping on steppers in 2nd week, and running on treadmills in the last week. Participants are asked to wear a portable heart rate monitor throughout the experiments. They have to maintain their heart rates in 60%-75% of predicted maximal heart rate (moderate intensity exercise), which has been shown to be benefit on cognition\[3\]. It took the participants 25 minutes to complete AeT."
214675324|NCT04880057|OTHER|Agility training|AT program consists of three parts: technical drills, pattern running and reactive agility training. There will be nine sessions over 3 weeks and progress the intensity, complexity or velocity every week.
214337236|NCT06176027|DRUG|Azacytidine plus CAOLD regimen|Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)
214337237|NCT06414109|BEHAVIORAL|BREATHE-Migraine|"The BREATHE-Migraine intervention was adapted from the research-supported curriculum, Learning to BREATHE (Broderick, 2021), based on qualitative feedback from adolescents with migraine, their parents, and pediatric headache providers. BREATHE-Migraine includes experiential and didactic exercises designed to address emotion regulation and the stress of living with frequent migraine."
214337238|NCT04278417|BIOLOGICAL|Brolucizumab 6 mg|3 x q6w loading injections, followed by q12w maintenance through Week 90
214337239|NCT04278417|PROCEDURE|Panretinal photocoagulation laser|initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
214337240|NCT01973985|OTHER|Pleural Manometry|Intrapleural pressure will be monitored with the use of an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device).
214675325|NCT00933946|DRUG|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
214938254|NCT02672332|DRUG|SB204 4%|Once daily
214938255|NCT02672332|DRUG|Vehicle Gel|Placebo comparator
214938256|NCT06229548|DRUG|SYH2053|subcutaneous injection
214938257|NCT06229548|DRUG|Placebo|subcutaneous injection
214938258|NCT01779167|DRUG|Thalidomide|Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 \& 27)
214938259|NCT01779167|DRUG|Lenalidomide|Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 \& 28). Lenalidomide will be initiated at a starting dose of 5 mg.
214938260|NCT01779167|DRUG|Rituximab|Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
214337241|NCT01973985|OTHER|Thoracic ultrasonography|"Thoracic ultrasound scan will be done before drainage of pleural effusion - all participants.~Thoracic ultrasound scans will also be done during drainage of pleural effusion and the results will be recorded after every 100mL of pleural fluid drained - all participants.~Thoracic ultrasound scan will be done after drainage of pleural effusion - all participants.~Thoracic ultrasound scan will also be be done during clinic follow-up as part of routine clinical care - all participants."
214337242|NCT01973985|PROCEDURE|Pleural aspiration catheter OR chest drain (standard care)|Insertion of pleural aspiration catheter OR intercostal chest drain under ultrasound guidance - all participants (standard care).
214337243|NCT01973985|PROCEDURE|Talc slurry pleurodesis via chest drain (standard care)|Talc slurry pleurodesis via intercostal chest drain where/when clinically indicated as part of routine clinical care participants with intercostal chest drain only (standard care).
214675326|NCT00107107|DRUG|pramlintide acetate|Syringe vial and Pen-cartridge
214938261|NCT01644526|DEVICE|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
214938262|NCT00497848|BEHAVIORAL|motivational interviewing|"An individual intervention building on the Motivational Interviewing by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy"
214675327|NCT03320148|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"1. Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~2. Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~3. Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~4. Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
214675328|NCT03320148|OTHER|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
214675329|NCT02278146|DEVICE|ParaPatch|A device for the treatment of urinary incontinence
214938263|NCT00497848|OTHER|The System-Orientated Intervention|"Principles in this intervention come from Clinical Risk Managing and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on."
214337244|NCT00850031|DEVICE|AcuFocus Corneal Inlay|Inlay implanted in cornea for improvement of near vision
214337245|NCT02008500|OTHER|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
214938264|NCT04281316|DEVICE|Nasal High Flow installation|"Participants randomized in NHF group will receive the nasal high flow (NHF) treatment delivered by myAirvo2.~Nasal High-Flow (NHF) is a treatment delivering heated, humidified, and optionally oxygen-enriched, air at high flow rates through a nasal cannula. The physiologic effects of NHF are an improvement in gas exchanges including a reduction in hypercarbia an optimization in breathing patterns with a reduction of work of breathing and high compliance as delivered via a comfortable nasal interface"
214938265|NCT04281316|DEVICE|Non Invasive Ventilation|Participants randomized in the Non Invasive Ventilation group will receive treatment as in their usual care.
214938266|NCT04281316|OTHER|Training session|The patients in the Nasal High Flow (MyAirvo) arm will receive two hours training adaptation session in the hospital
214938267|NCT04281316|OTHER|Education session|Participants randomized in the Non Invasive Ventilation group will receive an additional educational session of one hour for improving compliance.
214938268|NCT03722940|DRUG|Magnesium sulphate|Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.
214938269|NCT03722940|OTHER|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.
214938270|NCT02428803|OTHER|Telemedicine|Patients will be administered the KDQOL-SF and the IIRS and will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. At the end of 6 months the KDQOL-SF and IIRS will again be administered. The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely
214938271|NCT01503398|DRUG|Olanzapine|Olanzapine Tablets, 5 mg
214938272|NCT04731025|DRUG|Gentamicin, Cefazolin and Vancomycin|The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in a 500 mL isotonic saline solution. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
214938273|NCT04731025|OTHER|Placebo|500 mL of sterile isotonic (9%) saline. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
214938274|NCT03251794|DIAGNOSTIC_TEST|three dimensional ultrasound|evaluation of the suprarenal glands
214938275|NCT03251794|DIAGNOSTIC_TEST|color Doppler|Doppler evaluation of the suprarenal artery
214938276|NCT00050817|DRUG|clopidogrel (SR25990)|
215073876|NCT02924194|DEVICE|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
215073877|NCT00668382|BIOLOGICAL|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
215073878|NCT05215860|BEHAVIORAL|Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|WHO toolkit for Tobacco cessation (5A's and 5R's model)
215073879|NCT05215860|OTHER|visual exposure to personal intraoral photographs of oral lesions at baseline and review|Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
214337246|NCT02008500|OTHER|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
214337247|NCT02008500|OTHER|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
214337248|NCT00112203|DRUG|Itopride|
214337249|NCT01479803|PROCEDURE|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
214337250|NCT06075680|PROCEDURE|Non-Surgical Periodontal Treatment|The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease
214938277|NCT05507827|DRUG|Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)|CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
214938278|NCT05507827|DRUG|Treg CD34+HSPC (Orca-T)|Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
214938279|NCT03652649|OTHER|3:1 ratio Ketogenic diet|Type 2 Diabetic subjects with BMI greater than or equal to 30 are started on 3:1 ratio ketogenic complete meal replacement program and weight loss and glycemic control is tracked over 6 month intervention period
214938280|NCT06647875|BEHAVIORAL|Complementary Feeding Education|"This training program has been designed in accordance withWHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age. The training will be delivered both in-person and via tablet, and will be supported by infographics and visuals created using WHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age and the Basic Information for Families on Child Health and Safety in the First 5 Years booklet published by the Child Health Association, specifically the section on Healthy Eating. At the end of the training, participants will be provided with a booklet containing the Healthy Eating section of the Child Health Association's booklet."
214938281|NCT00960349|DRUG|Cediranib|Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
214938282|NCT00960349|DRUG|Cisplatin|Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
214938283|NCT00960349|DRUG|S-1|Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
214938284|NCT00960349|DRUG|Cisplatin|60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
214938285|NCT00960349|DRUG|Capecitabine|Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
214938286|NCT03447600|BEHAVIORAL|Alternate Day Fasting|25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.
214938287|NCT03447600|BEHAVIORAL|Continuous dietary restriction|25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.
214938288|NCT04628078|OTHER|Use of echocardiography guidance for LAAC|Since August 2015, the echocardiography is routinely used by majority of operators to guide LAAC
214675330|NCT04408157|BEHAVIORAL|Self-management booklet (SWitCh: Stay well during COVID-19)|The purpose of this booklet is to support adjustment to the current circumstances of the COVID-19 pandemic and facilitate the development and maintenance of healthy behaviours at home. The booklet covers a range of topics, including understanding bodily sensations and symptoms of COVID-19, managing the uncertainty surrounding COVID-19, physical activity, sedentary behaviour, sleep, social support and isolation, nutrition and alcohol consumption, sex and intimate relationships, and coping with children at home. The booklet will provide structured guidance on the various topics through the use of effective behaviour change techniques, in particular self-monitoring, goal setting, and problem solving and signposting to additional helpful resources, such as drinking or nutrition tracking apps.
214938289|NCT03226678|DRUG|APL-2|Complement (C3) Inhibitor
214938290|NCT00336388|DEVICE|Paracheck Device|
214938291|NCT00619164|DRUG|E5555|E5555, 50 mg (tablet), taken orally, once a day.
214938292|NCT00619164|DRUG|E5555|E5555, 100 mg (tablet), taken orally, once a day.
214938293|NCT00619164|DRUG|E5555|E5555, 200 mg (tablet), taken orally, once a day.
214337251|NCT03275558|DRUG|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
214337252|NCT03275558|DRUG|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
214938294|NCT00619164|DRUG|Placebo|Placebo tablet taken orally, once a day.
214938295|NCT01279564|DEVICE|ETview TVT endotracheal tube|intubation
214938296|NCT01279564|DEVICE|Endotracheal tube|Intubation
214938297|NCT02608008|DEVICE|Data analysis|data parameters Analysis
214938298|NCT00287391|DRUG|Rabeprazole|
214938299|NCT05675514|OTHER|Myofascial Release Therapy|The increasing number of basketball players also increases the risk of sports-related injuries. Basketball has the highest injury risk of all sports because the game is so powerful and fast moving. Myofascial release therapy; ıt is a form of manual therapy applied on the muscle fascia complex to restore optimal length, reduce pain and improve functions. It is known to be effective in providing rapid relief of pain and tissue sensitivity. By restoring the length and health of the restricted connective tissue with the myofascial release therapy, it aims to relieve pressure on pain sensitive structures such as nerves and blood vessels, as well as improves sports performance.
214938300|NCT00782691|OTHER|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
214938301|NCT03182634|DRUG|Fulvestrant|
214938302|NCT03182634|DRUG|Neratinib|
214938303|NCT03182634|DRUG|AZD5363|
214938304|NCT03182634|DRUG|Olaparib|
214938305|NCT03182634|DRUG|AZD6738|
214938306|NCT05083052|OTHER|Propolis 15%|oothpaste formulation with 15% propolis.
214938307|NCT05083052|OTHER|Propolis 10%|Toothpaste formulation with 10% propolis.
214938308|NCT05083052|OTHER|Placebo|Formulation of toothpaste without active ingredient.
214938309|NCT00032422|PROCEDURE|Acupuncture|
214938310|NCT01911780|DRUG|placebo|placebo matching amlodipine capsule
214938311|NCT01911780|DRUG|telmisartan + HCTZ|FDC tablet
214938312|NCT01911780|DRUG|telmisartan + HCTZ|FDC tablet
214938313|NCT01911780|DRUG|amlodipine|capsule
214938314|NCT05303402|BIOLOGICAL|PHH-1V|COVID-19 Vaccine HIPRA, 40 mcg/dose
214938315|NCT02045732|BIOLOGICAL|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
214938316|NCT02045732|BIOLOGICAL|Placebo|Bi-Weekly Subcutaneous Injections X 6
214938317|NCT02045732|BIOLOGICAL|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
214938318|NCT02045732|BIOLOGICAL|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
214938319|NCT05737121|DRUG|VNX001|VNX001 (alkalinized lidocaine HCl and heparin sodium)
214938320|NCT05737121|DRUG|Placebo|Inactive placebo for VNX001
214938321|NCT05737121|DRUG|Lidocaine|Alkalinized lidocaine hydrochloride
215073880|NCT05808946|DRUG|Alpha-Lipoic Acid|1200 mg of ALA daily (given as two 600 mg capsules once daily)
215073881|NCT05808946|DRUG|Sepsis Supportive Care|Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
214337253|NCT03275558|DRUG|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
214337254|NCT02269462|DRUG|Efavirenz|600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
214337255|NCT02269462|DRUG|Nevirapine|200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
214337256|NCT01603875|BIOLOGICAL|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
214337257|NCT03306342|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
214337258|NCT02199418|DRUG|Paclitaxel|
214675331|NCT03671369|OTHER|Safety data collection (following routine vaccination) by a continuous surveillance method.|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS."
214938322|NCT05737121|DRUG|Heparin|Alkalinized heparin sodium
214938323|NCT06096779|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle.
214938324|NCT06096779|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21-day cycle.
214938325|NCT01412697|BEHAVIORAL|Fruit and vegetable intake in rural youth|A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
214938326|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Intermediate Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
214938327|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Low Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
214938328|NCT05014815|DRUG|Ociperlimab|900 mg intravenously (IV) once every 3 weeks (Q3W)
215073882|NCT01896076|OTHER|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
215073883|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
215073884|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
214938329|NCT05014815|DRUG|Tislelizumab|200 mg IV Q3W
214938330|NCT05014815|DRUG|Carboplatin|Area under the concentration-time curve (AUC) of 5 or 6, administered on Day 1 of each 21-day cycle
214938331|NCT05014815|DRUG|Paclitaxel|75 or 200 mg per square meter (mg/m²) of body surface area, administered on Day 1 of each 21-day cycle
214938332|NCT05014815|DRUG|Nab paclitaxel|100 mg/m², administered intravenously on Days 1, 8, and 15 of each 21-day cycle
214938333|NCT05014815|DRUG|Cisplatin|75 mg/m², administered intravenously on Day 1 of each 21-day cycle
214938334|NCT05014815|DRUG|Pemetrexed|500 mg/m² administered intravenously on Day 1 of each 21-day cycle
214938335|NCT05014815|DRUG|Placebo|Administered intravenously Q3W to match ociperlimab
214938336|NCT06261827|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
214938337|NCT06261827|DRUG|200-ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
214938338|NCT04247880|BEHAVIORAL|Mentoring program|Apprentice-level female construction workers will be assigned to a mentor who has gone through a rigorous mentorship training. Participants will be asked to meet with a mentor at least 4 times/year in person to discuss the challenges of being a female in construction, learn coping mechanisms, and otherwise discuss the unique challenges of the job environment.
214337259|NCT02199418|DRUG|Cisplatin|
214337260|NCT01482780|DEVICE|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
214337261|NCT04749290|OTHER|Study Formula|Study infant formula for term infants containing OPO and CPP
214337262|NCT02143570|DRUG|Darifenacin|Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
214337263|NCT02143570|PROCEDURE|Physiotherapy|All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
214337264|NCT02499393|DRUG|Magnesium Sulfate|intravenous infusion of magnesium sulphate
214337265|NCT00298831|DRUG|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
214938339|NCT00568997|DRUG|Pimecrolimus|Pimecrolimus 1% cream
215073885|NCT05818917|DRUG|FHND5071|"The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data."
214675332|NCT04828876|BEHAVIORAL|Yoga practice|"Yoga basically consists of breathing techniques, asanas (postures) and relaxation phases.~Practiced Yoga Stages; 10 min. standing breathing exercise, 10 min. breathing exercise with seated asana, 10 min. lying down breathing exercise with asana, 20 min. sitting breathing exercise, 10 min. The session will be completed in 60 minutes, including deep relaxation stages by lying down. At the end of each session, patients' feedback about yoga practice will be received."
214675333|NCT00002993|DRUG|cisplatin|
214337266|NCT00298831|DRUG|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
214337267|NCT04691466|PROCEDURE|Joint replacement|Routinely performed hip- or knee replacement
214337268|NCT06046638|DRUG|Cyclopofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
214337269|NCT06046638|DRUG|Propofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
214337270|NCT01999010|DEVICE|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
214938340|NCT05692635|DIAGNOSTIC_TEST|MRI of the Brain|An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
214938341|NCT05692635|OTHER|Blood draws|Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
214938342|NCT05692635|OTHER|Quality of Life Questionnaires|Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.
214938343|NCT05692635|DRUG|Gadolinium|Given intravenously
214938344|NCT04198766|DRUG|INBRX-106 - Hexavalent OX40 agonist antibody|The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
214938345|NCT04198766|DRUG|pembrolizumab 200 mg|pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
214938346|NCT04198766|DRUG|pembrolizumab 400 mg|pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
214675334|NCT00002993|DRUG|doxorubicin hydrochloride|
215073886|NCT04802512|PROCEDURE|validity and reability study|validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)
215073887|NCT03622112|DRUG|AZD7594 DPI 55μg/50μg.|A non-steroidal and selective modulator of the GR.
215073888|NCT03622112|DRUG|AZD7594 DPI 99 µg/90 µg|A non-steroidal and selective modulator of the GR.
215073889|NCT03622112|DRUG|AZD7594 DPI 198 µg/180 µg|A non-steroidal and selective modulator of the GR.
215073890|NCT03622112|DRUG|AZD7594 DPI 396 µg/360 µg once daily.|A non-steroidal and selective modulator of the GR.
215073891|NCT03622112|DRUG|AZD7594 DPI 792 µg/720 µg|A non-steroidal and selective modulator of the GR.
215073892|NCT03622112|DRUG|Placebo for AZD7594 once daily.|Placebo for AZD7594
215073893|NCT03622112|DRUG|FF 100 µg once daily (open-label)|Fluticasone furoate
214675335|NCT00002993|DRUG|mitomycin C|
214675336|NCT02060708|DEVICE|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
214675337|NCT04971811|OTHER|Snack with energy density less than 1.5 kcal/g|Snack meal with snack food having energy density less than 1.5 kcal/g
214337271|NCT05108181|OTHER|Muscle typology + exercise training|Exercise training: Participants perform 9 weeks of strength training at 60% of their 1RM.
214337272|NCT05108181|OTHER|Muscle typology + training frequency|Training frequency: leg A and arm A of the participants train 3 times per week, leg B and arm B train 2 times per week.
214337273|NCT01886794|DRUG|Postmenopausal, topical vaginal estrogen cream|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
214337274|NCT01886794|DRUG|Placebo Comparator: Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
214337275|NCT01306617|DRUG|ABT-450|tablets
214337276|NCT01306617|DRUG|ABT-333|tablets
214675338|NCT04971811|OTHER|Snack with energy density greater than 1.5 kcal/g|Snack meal with snack food having energy density greater than 1.5 kcal/g
214938347|NCT04198766|DRUG|Carboplatin AUC-5|carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
214938348|NCT04198766|DRUG|Carboplatin AUC-6|carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
214938349|NCT04198766|DRUG|Pemetrexed 500 mg/m2|pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles
214938350|NCT04198766|DRUG|Cisplatin 75mg/m2|cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
214938351|NCT04198766|DRUG|Paclitaxel 200mg/m2|paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
214337277|NCT01306617|DRUG|ribavirin|tablets
214337278|NCT01306617|DRUG|ritonavir|capsules
214337279|NCT04688281|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
214938352|NCT04198766|DRUG|Nab paclitaxel 100mg/m2|Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4
214938353|NCT05617716|RADIATION|Conventional external beam radiation therapy dose (EBRT)|Participants will undergo 8 Gray in 1 fraction of EBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.
214938354|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy standard dose|Participants will undergo 24 Gray in 2 fractions of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.
214938355|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy high dose|Participants will undergo 19 Gray in 1 fraction of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.
214938356|NCT05962177|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging
214938357|NCT05962177|OTHER|Blood withdrawal|Blood withdrawal
214938358|NCT05962177|OTHER|Neuropsychological tests|Neuropsychological tests
214337280|NCT04688281|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
214337281|NCT05506020|PROCEDURE|indocyanine green (ICG) fluorescence cholangiography|indocyanine green (ICG) fluorescence cholangiography during operation
214337282|NCT02259491|OTHER|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
214337283|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|"* Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~* Health education sessions and relaxation sessions: one per week.~* Smoking and diet checking: as recommended by doctor."
214938359|NCT06303167|PROCEDURE|Biopsy Procedure|Undergo biopsy
214938360|NCT06303167|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214938361|NCT06303167|PROCEDURE|Echocardiography Test|Undergo ECHO
214675339|NCT02360943|OTHER|4 blood samples|PK and / or PD measurements during hospitalization
214675340|NCT02732912|DEVICE|Ear plugs|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
214675341|NCT02732912|DEVICE|Eye Mask|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
214675342|NCT02732912|DRUG|Zopiclone|This night sedation will be given to any patient requesting it, in either group
214337284|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
214337285|NCT05280119|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
214337286|NCT05280119|DEVICE|Ultrasound device routinely used in the department.|Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
214337287|NCT05280119|PROCEDURE|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
214337288|NCT01435668|BEHAVIORAL|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
214337289|NCT01435668|BEHAVIORAL|Simple written advice|Patients receive an information leaflet.
214337290|NCT04028388|DRUG|Docetaxel in Parenteral Dosage Form|Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily
214938362|NCT06303167|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214938363|NCT06303167|DRUG|Osimertinib|Given PO
214938364|NCT06303167|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
214938365|NCT06271837|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
214938366|NCT06271837|DRUG|Bevacizumab|Bevacizumab by intravenous infusion
214938367|NCT04795193|PROCEDURE|Minimal invasive coronary surgery|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
214938368|NCT04795193|PROCEDURE|Off-pump coronary artery bypass surgery|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
214938369|NCT02716233|DRUG|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
214938370|NCT02716233|DRUG|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
214938371|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)|
214938372|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)+Tremelimumab|
214938373|NCT02453282|DRUG|Paclitaxel + Carboplatin|Chemotherapy Agents
214938374|NCT02453282|DRUG|Gemcitabine + Cisplatin|Chemotherapy Agents
214938375|NCT02453282|DRUG|Gemcitabine + Carboplatin|Chemotherapy Agents
214938376|NCT02453282|DRUG|Pemetrexed + Cisplatin|Chemotherapy Agents
214938377|NCT02453282|DRUG|Pemetrexed + Carboplatin|Chemotherapy Agents
214938378|NCT02453282|BIOLOGICAL|Tremelimumab|
214337291|NCT04028388|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
214675343|NCT00539786|DRUG|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
214675344|NCT04382651|DRUG|MAS825|MAS825 liquid solution for intravenous infusion
214675345|NCT04382651|OTHER|Placebo|Placebo liquid solution for intravenous infusion
214675346|NCT04382651|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
214675347|NCT00004048|BIOLOGICAL|filgrastim|
214675348|NCT00004048|DRUG|doxorubicin hydrochloride|
214938379|NCT06338657|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214938380|NCT06338657|PROCEDURE|Computed Tomography|Undergo CT scan
214938381|NCT06338657|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214938382|NCT06338657|DRUG|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
214337292|NCT04929301|OTHER|Antenatal milk expression|Hand-expression of breast milk in pregnancy
214337293|NCT04929301|OTHER|Education handouts|Educational breastfeeding handouts
214337294|NCT05845125|OTHER|Physiotherapy alone|Physiotherapy focusing on increasing the shoulder range of motion.
214337295|NCT05845125|DRUG|Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy|"The patient will lie supine on the radiology table. Proper skin disinfection will be done with Soluprep x 3 and sterile draping will be applied. An anterior view of the shoulder will be obtained with the fluoroscopic C-arm. Location of the injection site will be obtained with a radio-opaque stylus. Proper local anesthesia will be performed using approximately 1cc of 0.5% Bupivacaine intradermal. A 22G 3.5 spinal needle will be placed in the glenohumeral joint under fluoroscopic guidance using the anterior approach. A small amount (1cc) of iodine-based contrast agent (Omnipaque) will be injected under live fluoroscopic imaging to confirm the intra-articular position of the needle in the glenohumeral joint. In the event of a known iodine contrast allergy, no contrast agent will be used. A combination of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine will be injected into the glenohumeral joint."
214337296|NCT04862091|DRUG|Abiraterone Acetate Tablets (I)|Abiraterone Acetate Tablets (I)
214337297|NCT04862091|DRUG|ZYTIGA®|ZYTIGA®
214337298|NCT01406691|DEVICE|Flashes|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
214337299|NCT02995395|DEVICE|Mucosal Impedance Balloon catheter|"During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded."
214337300|NCT01114516|DRUG|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
214337301|NCT00797615|BEHAVIORAL|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
214337302|NCT00797615|BEHAVIORAL|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
214337303|NCT00129259|BIOLOGICAL|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
214337304|NCT00129259|OTHER|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
214337305|NCT00129259|DIETARY_SUPPLEMENT|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
214675349|NCT00004048|PROCEDURE|autologous bone marrow transplantation|
214938383|NCT06338657|PROCEDURE|Tumor Resection|Undergo surgical resection
214337306|NCT06347354|DRUG|Indocyanine green|Subdermal injection of 2,5 mg (1 cc) of ICG
214675350|NCT00004048|PROCEDURE|peripheral blood stem cell transplantation|
214675351|NCT00004048|RADIATION|indium In 111 monoclonal antibody MN-14|
214675352|NCT00004048|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
214675353|NCT00090649|DRUG|DVS-233 SR|
214675354|NCT00211822|PROCEDURE|fMRI|fMRI
214675355|NCT05669885|DRUG|Sildenafil|Study participants will be allocated to receive oral administration of 100 mg sildenafil.
214675356|NCT05669885|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
214675357|NCT03414918|DRUG|Clarithromycin|Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
214675358|NCT04569305|PROCEDURE|Negative Pressure Wound Therapy|NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.
214675359|NCT04569305|PROCEDURE|Conventional treatment|In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
214675360|NCT02881307|DIETARY_SUPPLEMENT|Whey Protein&Prebiotic Supplement|Dietary supplement (protein drink) commercially available protein shakes
214675361|NCT02881307|BEHAVIORAL|Dietary Counseling|Dietary Counseling
214938384|NCT02496104|BEHAVIORAL|Package n°1 of the APIB|
214938385|NCT03813784|DRUG|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
214938386|NCT03813784|DRUG|Capecitabine|1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
214337307|NCT03049059|DEVICE|Fractional Picosecond 1,064 nm laser|Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
214337308|NCT03049059|DRUG|4% hydroquinone cream|
214337309|NCT03766321|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
214337310|NCT03766321|BIOLOGICAL|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
214337311|NCT02758236|OTHER|No Intervention|No Intervention
214938387|NCT03813784|DRUG|Oxaliplatin|130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
214337312|NCT05789875|OTHER|aDOT-CEI|For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.
214337313|NCT06486545|DRUG|Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)|"Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first)."
214938388|NCT03813784|DRUG|Apatinib|250 mg administered as continuous oral once daily (QD) of each 3-week cycle.
214938389|NCT06559137|DRUG|Ropivacaine 0.2% Injectable Solution|Patients who are randomized to the peripheral nerve block group will receive a pre-operative perineural injection of 0.2% plain Ropivacaine regardless of weight.
214938390|NCT06365047|DEVICE|8% Arginine toothpaste|Investigative
214938391|NCT06365047|DRUG|1000 ppm F toothpaste|Control
214938392|NCT06283992|OTHER|Digital Navigation|1:1 educational support at the bedside about the functions of the patient portal and telehealth that can help with care transitions.
214938393|NCT06973928|DEVICE|Measures of jaw activity using the Jawac|At the inclusion visit (V1), informed consent will be obtained from one parent or legal guardian of each participant, who will then complete questionnaires about their children's quality of life and sleep-related symptoms. Participating children will undergo PSG combined with Jawac measurements of jaw activity. Patients will undergo adenotonsillectomy during the surgical visit (V2). Three months later, at the follow-up visit (V3), patients will again undergo PSG with Jawac measurements, and the same parent or legal guardian will complete the same questionnaires.
214938394|NCT03902522|DRUG|PRO 140|2 injections of PRO 140 (2 X 2 mL/inj.) Subjects who were previously enrolled and receiving 350 mg dose had the option to move to the 700mg dose for the remainder of the trial.
214337314|NCT04693663|PROCEDURE|Relex-Smile surgery|surgery using Relex-Smile
214337315|NCT06574334|PROCEDURE|Proprioceptive exercise|"* The first session was included an orientation to the exercises and its purpose to geriatric participants in the first week. Also, pretest was done in the first session before implementing exercises to assess geriatric KOA pain and QOL, each session started by revision about what was given during the previous session and the objectives of the next session.~* The 2nd session about exercises.~* The 3rd session for repetition of exercises to ensure that the patient has learned it well in the second week.~* The 4th session after six weeks later (from wk. (3) to wk. (8) to make posttest after implementation session.~* The 5th session after two-month later (from wk. (9) to wk. (16) to do follow up test."
214337316|NCT06572319|DRUG|Disitamab Vedotin(RC48) Plus Tratuzumab|Disitamab Vedotin: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Tratuzumab: RP2D，ivgtt，D1, every 2 weeks for a treatment cycle.
214337317|NCT06572761|DRUG|Combination of antibiotics|Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally
214337318|NCT06572761|DEVICE|Emergency cerclage|Emergency cerclage
214337319|NCT06572761|DRUG|Vaginal progesterone|Vaginal progesterone
214337320|NCT06573593|DRUG|Tofacitinib|In the real-world settings, patients with AA treated with tofacitinib.
214337321|NCT06573593|DRUG|Baricitinib|In the real-world settings, patients with AA treated with Baricitinib.
214337322|NCT06573593|DRUG|Ruxolitinib|In the real-world settings, patients with AA treated with Ruxolitinib.
214675362|NCT02881307|BEHAVIORAL|Dietary recommendations|recommendations for one meal per day including lean protein and vegetables
214675363|NCT00126451|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|
214938395|NCT06037460|DRUG|Tocilizumab treatment|"* 1 injection/2 weeks from W0 to W12: W0, W2, W4, W6, W8, W10, W12~* Then 1 injection/4 weeks until W24: W16, W20, W24"
214938396|NCT06037460|OTHER|questionnaires|HAQ, SF-36, FACIT-Fatigue score
214938397|NCT06037460|BIOLOGICAL|Blood samples|Additionnal blood samples for immunomonitoring
214675364|NCT00126451|DRUG|Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles|
214675365|NCT06480071|DRUG|Oxymetazoline, 0.05% Nasal Spray|2 sprays each nostril before the excercise test.
214675366|NCT01873742|OTHER|STIC feedback system|This condition includes the use of the STIC feedback system.
214675367|NCT03739983|DEVICE|Vaginal Renewal Program|Therapeutic vibrating wand.
214675368|NCT05839990|PROCEDURE|Surgery|Replacement of the ascending aorta in case of anerysm and dilatation
214675369|NCT05700344|DRUG|Avelumab|Single Group Assignment
214675370|NCT00790296|DRUG|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
214675371|NCT00790296|DRUG|Placebo|Saline
214938398|NCT06037460|PROCEDURE|18FDG PET scan|PETVAS calculation (to be performed between W0 and W8) (optional).
214938399|NCT01920737|DRUG|Daunorubicin|In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
214938400|NCT01920737|DRUG|Vincristine|
214938401|NCT01920737|DRUG|Prednisone|
214938402|NCT01920737|DRUG|PEG-Asparaginase|
214938403|NCT01920737|DRUG|Methotrexate|
214337323|NCT06573593|DRUG|Upadacitinib|In the real-world settings, patients with AA treated with Upadacitinib.
214938404|NCT01920737|DRUG|6-MP (6-Mercaptopurine)|
214938405|NCT01920737|DRUG|Cyclophosphamide|
214675372|NCT05837312|BEHAVIORAL|Reconnecting to Internal Sensations and Experiences|Reconnecting to Internal Sensations and Experiences (RISE) is a novel, self-guided interoceptive intervention designed to be accessible and convenient. RISE is hosted on Qualtrics and accessed on any internet-enabled device. RISE consists of four interactive 30-minute modules: (1) Progressive Muscle Relaxation and Body Functionality, (2) Understanding, Noticing and Managing Emotions, (3) Self-care and Communication, and (4) Body Sensations. The training consists of a mix of audio clips, psychoeducation, self-guided reading, and interactive writing prompts. Intervention materials are separated by multiple free-response prompts so that participants can relate the materials to their own lives, practice the introduced skills, and problem-solve difficulties implementing the skills.
214675373|NCT04704765|OTHER|abdominal breathing training|The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
214337324|NCT06573593|DRUG|Abrocitinib|In the real-world settings, patients with AA treated with Abrocitinib.
214337325|NCT06573593|DRUG|Ritlecitinib|In the real-world settings, patients with AA treated with Ritlecitinib.
214337326|NCT01994395|DEVICE|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
214337327|NCT01994395|OTHER|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
214337328|NCT01940705|OTHER|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
214675374|NCT05541692|BEHAVIORAL|Sleep Hygiene Toolkit|The sleep hygiene toolkit includes multiple resources including assistive devices (ie. eye masks and ear plugs), sensory-based tools (ie. aromatherapy, music, meditation, and breathing techniques), cognitive behavioral therapy (CBT) activities (ie. addressing anxiety and worry), and education and training on sleep hygiene.
214675375|NCT05699460|OTHER|This is an observational study.|This is an observational study.
215073894|NCT05887544|OTHER|Exposure: Plant-based diet pattern|From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.
215073895|NCT05887544|OTHER|Intervention: Fermented dairy products|1000g of the product to be consumed 1-2 days prior to spot urine sample.
214337329|NCT01940705|OTHER|Hearing-Aid DVD|Take-home DVD about hearing aids
214337330|NCT01940705|BEHAVIORAL|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
214337331|NCT01940705|OTHER|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
214337332|NCT03105050|OTHER|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
214337333|NCT00139997|DEVICE|Litebook treatment devices|Litebook LED phototherapy device used for 30 min before 8 am
215073896|NCT05887544|OTHER|Exposure: individual foods and food groups|From the dietary records, average intake of specific foods or food groups will be calcualted.
215073897|NCT06318806|OTHER|Psychotherapy|Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.
214675376|NCT01671488|BIOLOGICAL|Treatment|ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.
214675377|NCT01671488|DRUG|5FU|1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
214675378|NCT01671488|DRUG|Mitomycin|10 mg/m2, day 1 and 29 (day 29 can be + 7 days)
214337334|NCT00139997|DEVICE|Inactivated negative ion generator|Equivalent exposure to inactivated negative ion generator
214337335|NCT01632579|DRUG|LY3023703|Administered orally
214938406|NCT01920737|DRUG|Cytarabine|
214938407|NCT01920737|DRUG|Leucovorin|
214938408|NCT01920737|DRUG|Dexamethasone|
214938409|NCT01920737|OTHER|Blood draw|
214938410|NCT01920737|DEVICE|CT/PET scans|PET or CT scan every 6 months for 3 years
214938411|NCT06463652|PROCEDURE|Cervical cerclage|Cervical cerclage using the McDonald technique under anaesthesia.
214938412|NCT06463652|DRUG|Vaginal progesterone|Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
214938413|NCT06621212|DRUG|mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day 1, every 4 weeks
214938414|NCT06621212|DRUG|Cytarabine|Cytarabine (100 mg/m\^2 ) on day 1-7, every 4 weeks
214675379|NCT01671488|RADIATION|IMRT|54 Gy in 30 fractions at 1.8 Gy per fraction.
214675380|NCT01914445|DRUG|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
214938415|NCT06621212|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-8, every 4 weeks
214337336|NCT01632579|DRUG|Placebo|Administered orally
214337337|NCT01632579|DRUG|Celecoxib|Administered orally
214337338|NCT03841643|DEVICE|patient-specific implant|solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect
214337339|NCT03841643|DEVICE|cement|norian cement for reconstruction of the cranial defect
214337340|NCT00175474|PROCEDURE|knee surgery|
214337341|NCT02186964|PROCEDURE|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
214337342|NCT02186964|PROCEDURE|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
214337343|NCT02186964|PROCEDURE|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
214337344|NCT01187589|DEVICE|Pulsehaler|
214337345|NCT01187589|DRUG|Nebulizer & Albuterol 0.5ml|Albuterol aerosolized by a nebulizer
214337346|NCT02678546|OTHER|Other|case review of diagnosed disease
214337347|NCT04689113|BEHAVIORAL|Incontinence Health Belief Development Program|After the applied interventions, it is desired to develop kegel exercise behavior in women.
214938416|NCT02545361|DRUG|KAHR-102|"KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days)."
214938417|NCT03385304|DRUG|10% povidone-iodine (1% free iodine) in purified water|Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all open fracture surgeries for a two-month period.
214938418|NCT03385304|DRUG|4% chlorhexidine gluconate (CHG) in purified water|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all open fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
214938419|NCT01120249|DRUG|everolimus|Given orally
214938420|NCT01120249|OTHER|placebo|Given orally
214938421|NCT04612881|DRUG|fitostimoline vaginal pessaries|vaginal pessaries
214938422|NCT04612881|OTHER|standard of care|standard of care
214938423|NCT01021475|PROCEDURE|Visceral Manipulation|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
214938424|NCT01021475|DRUG|PPIs and/or Domperidone|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
214938425|NCT01007136|DEVICE|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
214938426|NCT01007136|DEVICE|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
214938427|NCT00705458|PROCEDURE|Coronary Computed Tomography Angiography|64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
214938428|NCT00705458|PROCEDURE|Stress Nuclear Myocardial Perfusion Imaging|Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
214938429|NCT06393257|DEVICE|Oscillation and Lung Expansion|A novel airway clearance technology
214938430|NCT06393257|BEHAVIORAL|Postural drainage|A type of physical therapy used to treat respiratory diseases by changing the patient's body position so that sputum is drained down the respiratory tract so that it can be more easily expelled from the body.
214938431|NCT06393257|DRUG|Anti-infective therapy|Antibiotics were used in these patients.
214675381|NCT01312350|DRUG|neoadjuvant docetaxel/cisplatin/fluorouracil|2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
214337348|NCT05455567|DIAGNOSTIC_TEST|OCTA|Choriocapillary vessel density calculated with OCTA
214337349|NCT01364064|DRUG|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
214938432|NCT06393257|DRUG|Mucolytic|Mucolytics were used in these patients.
214938433|NCT06317844|BEHAVIORAL|Behavioral Writing Intervention|This behavioral intervention will require participants to write about certain aspects of their lives.
214938434|NCT06300476|GENETIC|JWK006|Subretinal administration of gene therapy vector JWK006 to one eye.
214938435|NCT02563262|OTHER|body angles measurements during weightlessness|
214938436|NCT03274557|PROCEDURE|RFM|
214337350|NCT00818441|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
214938437|NCT05974644|OTHER|Registry|The purpose of this registry is to collect and store health information from people who are carriers of the gene known to cause hereditary amyloidosis and those with a confirmed diagnosis of the disease.
214675382|NCT01312350|DRUG|No treatment before definitive CCRT|concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
214675383|NCT00247910|DRUG|Hydrochlorothiazide|Not recorded in detailed description.
214938438|NCT05136313|BEHAVIORAL|Time-restricted eating|16 weeks of TRE consisting of an 8-hour eating window.
214938439|NCT06462235|DRUG|Part A: ATM-AVI Single Dose, Cohorts 1-4|Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.
214675384|NCT02612077|OTHER|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
214938440|NCT06462235|DRUG|Part B: Multiple-dose ATM-AVI, Cohorts 1-4|Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.
214938441|NCT01511718|DRUG|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
214938442|NCT01511718|DRUG|Ondansetron Hydrochloride|Zofran Tablets 8 mg
214938443|NCT05168163|BIOLOGICAL|Atezolizumab|Given IV
214938444|NCT05168163|DRUG|Cabozantinib|Given PO
214938445|NCT05168163|DRUG|Lenvatinib|Given PO
214938446|NCT03308318|PROCEDURE|The supratemporalis approach|The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
214938447|NCT05220059|DIETARY_SUPPLEMENT|Polyphenol extract|Single dose
214938448|NCT05220059|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214337351|NCT00818441|DRUG|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
214337352|NCT05334108|DRUG|Ecopipam|ecopipam HCl \~2mg/kg/day
214337353|NCT05334108|COMBINATION_PRODUCT|Cohort 1 Probe Substrate Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
214337354|NCT05334108|DRUG|Cohort 2 Probe Substrate|bupropion
214337355|NCT05334108|COMBINATION_PRODUCT|Cohort 3 Probe Substrate Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
214337356|NCT03705754|DEVICE|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
214938449|NCT02636101|DRUG|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
214938450|NCT02697565|BEHAVIORAL|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
214938451|NCT02697565|BEHAVIORAL|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
214938452|NCT01890616|DEVICE|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
214938453|NCT01696149|DEVICE|transcutaneous electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
214938454|NCT03284138|DEVICE|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
214938455|NCT03284138|DEVICE|placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
214938456|NCT01629823|DEVICE|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
214675385|NCT02612077|DRUG|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
214675386|NCT05055635|RADIATION|Pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day
214675387|NCT02251730|BEHAVIORAL|Smoking cessation|Refer for smoking cessation
214675388|NCT01022853|DRUG|BI 6727|intravenous each 21 days
214675389|NCT01022853|DRUG|BIBF 1120|oral continuously
214675390|NCT05588362|OTHER|Fitz Frames 3-D Printed Glasses|The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
214337357|NCT04442516|OTHER|Questionnaire, sampling of blood, urine and saliva|We are following patients who are receiving Cisplatin as part of their cancer therapy.
214337358|NCT01390558|PROCEDURE|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
214337359|NCT03540342|PROCEDURE|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
214337360|NCT01295606|DRUG|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
214337361|NCT00720954|PROCEDURE|Ct-guided pleural needle biopsy|Biopsy of pleura
214337362|NCT00720954|PROCEDURE|Thoracoscopy|Biopsy of pleura
214337363|NCT02695238|PROCEDURE|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
214337364|NCT05463224|DRUG|Lazertinib group|Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
214938457|NCT04112095|DRUG|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
214938458|NCT05673096|BEHAVIORAL|PACT|Paediatric Autism Communication Therapy
214938459|NCT05673096|BEHAVIORAL|MAU|Management as usual
214938460|NCT00919997|GENETIC|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
214938461|NCT00919997|GENETIC|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
214938462|NCT00919997|OTHER|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
214938463|NCT00919997|OTHER|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
214938464|NCT00919997|OTHER|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
214938465|NCT00919997|PROCEDURE|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
214938466|NCT01451242|OTHER|no intervention is made|no intervention is made
214938467|NCT00480493|BEHAVIORAL|STEP|Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
214938468|NCT00738062|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
214938469|NCT00738062|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
214938470|NCT05915676|DIAGNOSTIC_TEST|Leukocyte Immunoglobulin-like receptors A3|Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.
214938471|NCT00550862|DRUG|INT-747|Once a day (QD) by mouth (PO)
214938472|NCT00550862|DRUG|Ursodeoxycholic Acid (URSO)|Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
214938473|NCT00550862|DRUG|Placebo|Placebo
214938474|NCT00980174|DRUG|60 mg denosumab|60 mg denosumab (SC injection every 6 months)
214675391|NCT02807116|DRUG|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
214675392|NCT02807116|DRUG|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
214675393|NCT02807116|DRUG|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
214675394|NCT04846153|OTHER|Human-based Quantification of Airway Stenosis|Human-based Quantification of Airway Stenosis From Bronchoscopic Images.
214675395|NCT04846153|DEVICE|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
214675396|NCT03391011|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while monitored by clinically approved system.
214675397|NCT01753518|DEVICE|Subcuticular suture|subcuticular Monocryl suture closure
214337365|NCT04309435|BEHAVIORAL|Self-esteem intervention|See relevant study arm for description
214675398|NCT01753518|DEVICE|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
214938475|NCT00980174|OTHER|Placebo|Placebo for denosumab (SC injection every 6 months)
214938476|NCT03207074|DIAGNOSTIC_TEST|iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry|The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
214675399|NCT01962259|BEHAVIORAL|Physical activity|
214675400|NCT01220310|BEHAVIORAL|Online diabetes workshop observation and learning sessions|We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
214675401|NCT01720511|DIETARY_SUPPLEMENT|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
214675402|NCT01720511|DIETARY_SUPPLEMENT|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
214938477|NCT06032520|BEHAVIORAL|FAST|FAST includes around 3 hours of face-to-face direct treatment time weekly and consists of a maximum of 10% online direct treatment time (i.e., treatment via phone, video-calling or texting). The treatment stage of FAST lasts five to nine months depending on the individual goals of the juvenile and the caregiver(s) and is followed by a period of aftercare.
214337366|NCT04309435|BEHAVIORAL|Self-stigma intervention|See relevant study arm for description
214337367|NCT04309435|BEHAVIORAL|Jumping to conclusions intervention|See relevant study arm for description
214337368|NCT04309435|BEHAVIORAL|Control procedure (assessment only)|See relevant study arms for description
214337369|NCT06534294|OTHER|reflexology|Reflex therapy was done for each patient for 30 minutes, first for the right foot and then for the left foot (15 minutes each) and breathing exercises in 3 stages
214938478|NCT03216148|DIAGNOSTIC_TEST|FET-PET|All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
214938479|NCT06731569|DEVICE|Advanced intelligence drill|"The AI drill is an innovative surgical tool designed specifically for Maxillary Sinus Floor Augmentation (MSFA) procedures. It incorporates advanced technology to enhance safety, precision, and efficiency during lateral window preparation.~It has an Automated Pressure-Sensing Mechanism which makes the drill automatically stops rotating when it detects contact with the Schneiderian membrane, minimizing the risk of perforation.~The OLA kit consists of Hydraulic Lift which is compatibility with the drill connected to a saline-filled syringe to gently elevate the Schneiderian membrane from the sinus floor.~It involves a Multi-Step Drilling Process using different drill tips designed each for a specific task including the pilot drill for initial window creation and the non-cutting ball-end drill for lateral wall thinning and smoothing.~It works at a controlled high-Speed Performance of 6000 RPM with irrigation system included."
214337370|NCT06534294|OTHER|breathing exercise|breathing exercise done as 3 stages,stage one for 5 minutes, stage two for 10 minutes end stage ; Close eyes and focus your present feelings, Then Relax the whole body for 5 minutes.
214337371|NCT06534294|OTHER|standard care|standard medical care no other treatment
214337372|NCT02386202|OTHER|No intervention|No interventions
214337373|NCT01242904|DRUG|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
214337374|NCT01242904|DRUG|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
214337375|NCT06117267|DEVICE|Anatase Spine Surgery Navigation System|Collect images with the probe touching the target position before screw implantation
214337376|NCT05703529|BEHAVIORAL|Positive Psychotherapy|A 6-week group-based positive psychotherapy was conducted in this group. The themes of each week include positive introduction, three good things and positive reactions, gratitude, positive memory, identifying personal strengths and utilizing strengths.
214337377|NCT05703529|OTHER|Usual Care|Usual Care means treating as usual, including a regular home visit.
215073898|NCT06362655|BEHAVIORAL|Intervention|Intervention study. In this intervention study for teachers, a 5-month continuous training program will be included that will improve teaching style and promote teaching training. It will also strengthen teaching competencies to create teaching improvement strategies affecting PEaH and interpersonal and personal factors. This is expected to improve schoolchildren's AB, even when they are not directly influenced. The program will be designed according to the results of the cross-sectional study. The greatest associations found between the three proposed factors (school, interpersonal and personal factors) and schoolchildren AB will be sought. In addition, the characteristics of the schools and the possibilities of time and physical spaces available will be taken into account. This information will be recorded through validated questionnaires and interviews in the pre-test, post-test 1 and after follow-up post-test 2.
214675403|NCT03629626|PROCEDURE|ERAS protocol|"preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function."
214675404|NCT03726216|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
214675405|NCT02060396|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
214675406|NCT03927534|BEHAVIORAL|Mindful Eating|The ME group will be composed by 7 weekly group sessions with a minimum duration of two hours, mixing theoretical contents with practices. Sessions will always be the same day of the week, except for bank holidays or eventualities, and will be conducted by a psychologist specially trained and certified in ME with experience in leading mindfulness groups. Group sizes will range between 10 and 12 participants. At the end of each session, participants will receive theoretical contents and homework activities to be practiced along the week.
214675407|NCT04045223|OTHER|Blood samples|Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
214675408|NCT01971476|DRUG|volasertib|intravenous administration on day 1of a treatment course
214675409|NCT02498080|PROCEDURE|DEB PTA|paclitaxel drug eluting balloon PTA
214675410|NCT02498080|PROCEDURE|Standard PTA|Standard PTA
214675411|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
214337378|NCT01745029|DEVICE|Motilis-3D-transit|
214337379|NCT00612313|DRUG|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
214337380|NCT00612313|BEHAVIORAL|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
214675412|NCT02075255|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 24 inclusive.
214347323|NCT02897804|BEHAVIORAL|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214938480|NCT06731569|DEVICE|Traditional rotary instrument|"Traditional Rotary Drill~The traditional rotary drill is a commonly used surgical tool in Maxillary Sinus Floor Augmentation (MSFA) procedures, employing conventional drilling techniques for lateral window preparation. It is a widely recognized method due to its accessibility and effectiveness in skilled hands.~It Uses a rose-head bur attached to a surgical straight handpiece that operates at speeds of 800-1200 RPM with irrigation to prevent overheating and ensure efficient bone cutting.~It is a manual operator control that requires the surgeon's skill and experience to control the depth and force of drilling. And relies on visual and tactile feedback to identify when the Schneiderian membrane is close to exposure.~It is versatile and can be adapted to varying bone densities and anatomical complexities. It is effective for creating the window for sinus access.~It comes with an irrigation system to avoid necrosis of the bone."
214938481|NCT05763368|DIAGNOSTIC_TEST|Clinical tests and proprioception evaluation|Each patient will be evaluated using clinical scales (BBS, HHS, HOOS, SF12) and ''Delos Proprioceptive System'' to assess postural stability and proprioception.
214938482|NCT01811836|DIETARY_SUPPLEMENT|Zinc|Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
214938483|NCT06036784|DRUG|MBX 1416 (Part A)|Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg
214938484|NCT06036784|DRUG|MBX 1416 (Part B)|Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
214938485|NCT06036784|DRUG|Placebo|Single dose or repeated subcutaneous (SC) dose of placebo.
214938486|NCT06036784|DRUG|MBX 1416 (Part C)|Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
214938487|NCT04056000|DIETARY_SUPPLEMENT|Caffeine|200 mg of caffeine, 60 minutes before exercise
214938488|NCT04056000|DIETARY_SUPPLEMENT|High-carbohdyrate breakfast|Ingestion of a high-carbohydrate breakfast 60 minutes before exercise
214938489|NCT04056000|BEHAVIORAL|60-minutes of steady state exercise|See intervention name
214938490|NCT02335749|DEVICE|The ZELTIQ System|The CoolSculpting System with a Small Area Applicator will be used to deliver treatments.
214938491|NCT05040620|DRUG|Olive Oil Topical Oil|the effect of olive oil local application in decreasing orthodontic alighment phase
214938492|NCT00324389|DRUG|Interferon alpha|
214938493|NCT03337594|DRUG|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
214938494|NCT03337594|DRUG|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
214938495|NCT03337594|PROCEDURE|Surgery|Cardiac surgery
214938496|NCT00156039|BEHAVIORAL|Follow-up Strategy for Breast Cancer|
214938497|NCT03808025|BEHAVIORAL|opioid education|see arm/group descriptions
214337381|NCT06572176|BEHAVIORAL|With fluorescent concretization group|"Nurses were given the fluorescent lotion and asked to apply it all over their hands. The CE-certified test lotion is in gel form and is safety-approved. The lotion disperses particles the same size as bacteria on the skin. These particles settle on the skin, similar to the behavior of microorganisms, but disappear with hand washing under the influence of fluorescent light. They were then asked to wash their hands with 4 ml of soap. Two researchers marked the hand washing steps independently using the Hand Washing Skill Checklist. The duration of hand washing was recorded with a mobile stopwatch for each participant. Hand washing efficiency was evaluated using the Derma Litecheck device. UV rays were used after using the test lotion and drying the hands. Since any fluorescent material left on the hands would shine under UV light, it was possible to judge how well the hands were cleansed. The dirty spots were shown to the participants, and the reason for this was discussed."
214337382|NCT05446350|PROCEDURE|transcranial alternating current stimulation (tACS)|transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception
214337383|NCT05446350|PROCEDURE|electroencephalography (EEG)|analyse rhythmic electroencephalography responses that outlast the stimulation
214337384|NCT05446350|PROCEDURE|brain imaging (fMRI)|Using brain imaging (fMRI) to predict optimal stimulation protocols for individual participants
214938498|NCT00191425|DRUG|Teriparatide|
214938499|NCT00191425|DRUG|Raloxifene|
214938500|NCT00943176|DRUG|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
214938501|NCT01683422|RADIATION|Proton, Gemcitabine, Erlotinib, Capecitabine|"Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.~Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles."
214938502|NCT01683422|RADIATION|Proton Radiation|
214938503|NCT05548491|DRUG|AZR-MD-001 ointment/semi-solid drug|ointment/semi-solid drug
214938504|NCT00112255|BEHAVIORAL|Practice nurse-led partner notification|
214938505|NCT00112255|BEHAVIORAL|Referral to specialist genitourinary clinic|
214938506|NCT05055934|DRUG|SHR-1314 injection|SHR-1314 injection
214938507|NCT05055934|DRUG|placebo|placebo
214938508|NCT03774225|OTHER|Virtual Reality with Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.
214675413|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
214675414|NCT00020930|BIOLOGICAL|cetuximab|
215073899|NCT00535704|BEHAVIORAL|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
214337385|NCT05446350|PROCEDURE|electroencephalography (EEG) with neurofeedback|Using neurofeedback to teach participants to enhance their own neural entrainment
214938509|NCT03774225|OTHER|Virtual Reality with No Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.
214938510|NCT03774225|OTHER|Physical Therapy|Patients of the control group will be trained with balance exercises by a experient physiotherapist.
214938511|NCT02672007|DEVICE|SensiumVitals|The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
214938513|NCT05890430|BIOLOGICAL|Blood draw, Urine draw|Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time
215073900|NCT00535704|BEHAVIORAL|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
214938514|NCT04719130|OTHER|Multimodal circuit exercise|A structured and supervised multimodal exercise circuit twice a week, under 12 weeks program. The circuit workout program consists of 8 exercises, divided into motor coordination, balance, strength, and aerobic exercises. The exercises will be employed in a reserved room inside of the Basic Health Units. The sessions of exercises will last approximately 50 minutes,
214938515|NCT04719130|OTHER|Multidisciplinary lectures|Multidisciplinary lectures on pain and usual care provided by the Basic Health Units. A cycle of multidisciplinary lectures on pain will be offered by professionals in physical education, nursing, physiotherapy, medicine, psychology and social work that will take place in the Basic Health Units every 15 days.
214938516|NCT04809948|BIOLOGICAL|viral vector vaccine|AstraZeneca vaccine
214938517|NCT00047216|DRUG|tipifarnib|
214938518|NCT04660708|BEHAVIORAL|manual physical therapy|Previously described in the arm description
214938519|NCT06338618|PROCEDURE|liver treatment protocol|The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks
214938520|NCT04217005|DEVICE|Sensory Feedback|Subjects will receive a sensory feedback provided by electrical stimulation
214675415|NCT05895825|DRUG|EOC237|EOC237 for orally
214675416|NCT00000539|DRUG|niacin|
214675417|NCT00000539|DRUG|pravastatin|
214675418|NCT00000539|DRUG|beta-carotene|
214675419|NCT00000539|DRUG|vitamin E|
214675420|NCT00000539|BEHAVIORAL|dietary supplements|
214675421|NCT00000539|DRUG|vitamin C|
214347324|NCT02897804|BEHAVIORAL|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214675422|NCT00000539|DRUG|warfarin|
214675423|NCT03994926|DEVICE|Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye|Device measures smooth eye pursuit and response to light flash after pt smokes cannabis
214675424|NCT03994926|DRUG|Cannabis cigarette - 4.0% THC|smoked cannabis 4.0% THC
214675425|NCT04742517|DRUG|ASP1128|Intravenous
214938521|NCT05245734|DRUG|Human Anti-D (rh) immunoglobulin|prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
214938522|NCT02073318|OTHER|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
214938523|NCT02073318|OTHER|Upper extremities exercise|"4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks"
214938524|NCT02430103|DRUG|Goserelin 3.6 MG|In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
214938525|NCT04631107|DRUG|AD109 dose1- A|Oral administration at bedtime
214938526|NCT04631107|DRUG|AD109 dose2- B|Oral administration at bedtime
214938527|NCT04631107|DRUG|Placebo- C|Oral administration at bedtime
214938528|NCT06482177|DRUG|Cyclosporine ophthalmic solution|Cyclosporine BID in the study eye
214675426|NCT04742517|DRUG|Placebo|Intravenous
214675427|NCT05864157|OTHER|Gait training without rhythmic auditory cues|Gait training on treadmill and overground without any rhythmic auditory cues
214675428|NCT05864157|OTHER|TRAC|Metronome set to 85% on treadmill and 115% when walking overground
214675429|NCT05864157|OTHER|dTRAC|Metronome set around 85% on treadmill and around 115% when walking overground
214675430|NCT03503773|DRUG|Alcohol|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
214675431|NCT03503773|OTHER|Sham control|endovascular, renal angiography
214675432|NCT06369467|DRUG|linvoseltamab|Administered by intravenous (IV) infusion
214675433|NCT06369467|DRUG|dupilumab|Administered by subcutaneous (SC) injection
214675434|NCT03145857|DRUG|[68]Ga-HA-DOTATATE|All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
214675435|NCT02624700|DRUG|Experimental Arm A: Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
215073901|NCT01080066|OTHER|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m\^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m\^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
215073902|NCT00599391|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
214938529|NCT02003963|BEHAVIORAL|Klub Kinect|"Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.~The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention."
214938530|NCT02621658|OTHER|Clear Liquid Diet|Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.
214938531|NCT02621658|OTHER|Full Liquid Diet|Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
214938532|NCT01192035|DRUG|Efavirenz or Nevirapine|"2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count \>250 cells/mm3. Females beyond childbearing age will be treated with efavirenz."
214675436|NCT02624700|DRUG|Experimental Arm A: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.
214938533|NCT01192035|DRUG|Ritonavir-boosted lopinavir|2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
214938534|NCT05148845|BIOLOGICAL|Booster vaccine|"To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen) COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonke participants~In addition we will continue to evaluate VE of the Sisonke Boost compared to:~i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa."
214938535|NCT04294433|BIOLOGICAL|Infanrix-hexa, Twinrix-Junior|Vaccines administrated according to product monographs' recommendations
214938536|NCT01797159|RADIATION|Hippocampal-sparing Prophylactic Cranial Irradiation|Hippocampal-sparing Prophylactic Cranial Irradiation
214675437|NCT02624700|DRUG|Experimental Arm B: Pemetrexed|Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
214675438|NCT02624700|DRUG|Experimental Arm B: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
214938537|NCT02766452|BEHAVIORAL|"You and your child in the recovery room DVD"|
215073903|NCT01975662|DRUG|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
215073904|NCT01975662|DRUG|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
215073905|NCT01480518|GENETIC|DNA analysis|
215073906|NCT01480518|GENETIC|comparative genomic hybridization|
214675439|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
214675440|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
214675441|NCT00004177|BIOLOGICAL|filgrastim|as prescribed by physician
214675442|NCT00004177|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks from treatment
214337386|NCT04176796|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
214337387|NCT06098599|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
214675443|NCT00004177|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
214675444|NCT00004177|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
214675445|NCT01801397|DRUG|osteoanabolic therapy|
214675446|NCT02675517|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
214675447|NCT00425438|DRUG|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
214675448|NCT00425438|DRUG|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
214675449|NCT00425438|DRUG|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
214337388|NCT02928328|DRUG|GABA oral solution|Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
214337389|NCT02928328|DRUG|Intramuscular GABA|The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
214337390|NCT02928328|DRUG|Pain modulation|The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
214337391|NCT01736566|OTHER|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~1. The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~2. The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~\*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
214337392|NCT01736566|OTHER|Family History Only|Doctors and their patients receive a Family History report.
214337393|NCT06325995|RADIATION|Conventional radiation therapy|66-74 Gy in 33-37 daily fractions of 2 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
214675450|NCT00425438|DRUG|Cyclophosphamide|0.75 g/m\^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m\^2 to maintain a minimum WBC count of ≥ 2500 per mm\^3 from Weeks 5 through 24
214675451|NCT03988816|DRUG|Roflumilast|500Mcg Tab, once daily
214675452|NCT03988816|DRUG|Placebo oral tablet|once daily
214675453|NCT06065956|DRUG|Intravenous morphine|"Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.~The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation."
214675454|NCT05762822|DIETARY_SUPPLEMENT|3-OHB (KE4)|60 ml (30 g) of 3-OHB
214675455|NCT05762822|DIETARY_SUPPLEMENT|water|60 ml water (added bitter taste)
214675456|NCT00276289|DRUG|Spironolactone|
214675457|NCT00959244|OTHER|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
214675458|NCT00959244|OTHER|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
214675459|NCT00959244|OTHER|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
214675460|NCT00959244|OTHER|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
214675461|NCT02764840|OTHER|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
215073907|NCT01480518|GENETIC|gene expression analysis|
215073908|NCT01480518|GENETIC|mutation analysis|
215073909|NCT01480518|GENETIC|polymerase chain reaction|
215073910|NCT01480518|GENETIC|polymorphic microsatellite marker analysis|
215073911|NCT01480518|OTHER|laboratory biomarker analysis|
215073912|NCT00453115|DRUG|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
215073913|NCT00453115|DRUG|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
215073914|NCT05499455|DEVICE|Positional Sleep Belt|Rematee Positional Sleep Belt
215073915|NCT05499455|DEVICE|Control|Control Device
215073916|NCT03579472|DRUG|Bintrafusp Alfa|Given IV
214337394|NCT06325995|RADIATION|Hypofractionated radiation therapy|57.5-65 Gy in 23-26 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
214337395|NCT06884501|BEHAVIORAL|Latin dance, MIND diet, and Strength training|This will be a 6 month remote-delivered BAILAMOS™ dance program, MIND diet and strength training intervention.
214675462|NCT02764840|OTHER|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
214337396|NCT06884501|BEHAVIORAL|Latin dance and MIND Diet|This will be a 6 month remote-delivered BAILAMOS™ dance and MIND diet program.
214337397|NCT00568308|DRUG|PI-88|160mg subcutaneous injection
214337398|NCT00568308|DRUG|placebo|matched placebo
214337399|NCT04160299|BEHAVIORAL|Dance-based exergaming|Dance sessions
214337400|NCT07042256|RADIATION|Low-field MR-informed adaptive marker-less SBRT for definitive treatment of localized prostate cancer in patients with bilateral hip prostheses|Low-field MR-informed adaptive marker-less SBRT
214337401|NCT07045883|DRUG|Vitamin D Supplementation+ standard treatment|The experimental group was tested for 25(OH)D concentration after enrollment, and the experimental group was divided into vitamin D deficiency group and vitamin D normal group. In the vitamin D-deficient group, participants will receive standard treatment plus oral vitamin D3 supplementation (800 IU daily for 4 weeks), whereas the vitamin D normal group will receive standard treatment alone
214337402|NCT07045883|OTHER|standard treatment|The experimental group was tested for 25(OH)D concentration after enrollment, and the experimental group was divided into vitamin D deficiency group and vitamin D normal group. The vitamin D normal group will receive standard treatment alone
214337403|NCT07052058|BIOLOGICAL|Tocilizumab|Single infusion tocilizumab, 8 mg/kg, diluted in 100 mL of normal saline
214337404|NCT07052058|DRUG|Normal Saline (0.9% NaCl)|Placebo, same volume as intervention
214337405|NCT07051681|OTHER|Individualized Medical Nutrition Therapy|Pregnant women with GDM received individualized nutrition therapy during pregnancy. No intervention was applied to the control group.
214675463|NCT05191082|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
214675464|NCT05191082|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
214675465|NCT05191082|DEVICE|Palatal Wound treated with Neurotensin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with neurotensin and 4.0 silk sutures.
214675466|NCT01729832|PROCEDURE|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
214675467|NCT01729832|PROCEDURE|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
214675468|NCT05321953|OTHER|Standard Physical Therapy Care|Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.
214938538|NCT02766452|BEHAVIORAL|Standard pre-operative preparation|Attendance to the Pre-anesthetic assessment clinic to meet with registered practical nurse and anesthesiologist (physical assessment and medical history). Completion of the Surgery Virtual Tour.
214938539|NCT04592289|PROCEDURE|Full bowel preparation|MBP+OA
214938540|NCT04592289|PROCEDURE|Mechanical bowel preparation only|MBP
214938541|NCT06264674|DRUG|CHF5993 200/6/12.5 μg pMDI HFA-152a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
214938542|NCT06264674|DRUG|Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
214938543|NCT01217125|DRUG|Sirolimus|plasma levels between 4 and 8
214938544|NCT04392830|DRUG|ALZ002 DS|Administered orally
214938545|NCT04392830|DRUG|Placebo|Administered orally
214938546|NCT00990067|DRUG|3,4-Methylenedioxymethamphetamine|125 mg, single dose
214938547|NCT00990067|DRUG|Duloxetine|120 mg two doses 12h and 2h before MDMA
214337406|NCT07051265|BEHAVIORAL|Transcutaneous Electrical Nerve Stimulation (TENS)|Participants received TENS therapy at two specific acupoints - Hegu (LI4) and Lieque (LU7). Surface electrodes were placed over the acupoints, and stimulation was delivered using a standard TENS device.
214337407|NCT07051265|BEHAVIORAL|Acupressure|The acupressure group placed the acupoint patches on the Hegu and Lieque points on both hands and pressed each acupoint with the index finger and thumb for 1 minute, 3 times a day, each time for about 4 minutes.
214337408|NCT07051499|DRUG|TAP Block Group|Bilateral ultrasound-guided TAP block with 0.25% levobupivacaine and 75 mcg clonidine per side, plus standard intraoperative intravenous analgesia (ketorolac, tramadol, ondansetron).
214337409|NCT07052175|BEHAVIORAL|Standard Multidisciplinary Treatment|Comprehensive intervention including structured phases: initial assessment, detoxification, withdrawal management, psychological and psychiatric therapy, rehabilitation, and follow-up care. Delivered by a multidisciplinary team according to established clinical protocols.
214337410|NCT07052175|BEHAVIORAL|Digital Monitoring Tool|In addition to standard care, participants will use a mobile application that monitors clinical indicators, detects early signs of relapse risk, and provides personalized alerts and intervention prompts. The tool is designed to support both patients and clinicians in decision-making and therapeutic follow-up.
214337411|NCT07051395|DIAGNOSTIC_TEST|Road Traffic Accidents Patient|Coagulation Profiles And Injury Severity In Road Traffic Accidents Patients at Dera Ismail Khan
214337412|NCT07052396|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.
214938548|NCT00990067|DRUG|Placebo|capsules identical to MDMA or duloxetine
214938549|NCT01273714|PROCEDURE|thyroid resection|bilateral subtotal versus total thyroidectomy
214938550|NCT01935128|DRUG|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
214938551|NCT02706171|RADIATION|CyberKnife|
215073917|NCT03579472|DRUG|Eribulin Mesylate|Given IV
214337413|NCT07051382|DIAGNOSTIC_TEST|Transcranial Sonographic Examination (Cranial Ultrasound)|"No evidence of intracranial abnormalities such as intraventricular hemorrhage, germinal matrix hemorrhage, periventricular leukomalacia, hydrocephalus, or infarction.~Brain structures were assessed to be age-appropriate for gestational development."
214337414|NCT07052123|DEVICE|MultiSense® Non-Invasive Hemodynamic Monitoring Device|The MultiSense® device is a wireless, non-invasive monitoring system designed to continuously measure blood pressure, microcirculation, central body temperature, and detect arrhythmias in ICU patients. It aims to reduce risks associated with invasive monitoring, improve patient comfort and mobility, and decrease alarm fatigue through intelligent alert algorithms.
214337415|NCT07051512|DRUG|dexmedetomidine 4μg|patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 4μg)
214337416|NCT07051512|DRUG|dexmedetomidine 8 μg|patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 8 μg)
214337417|NCT07051512|DRUG|dexmedetomidine 10 μg|patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 10 μg).
214337418|NCT07051213|DIAGNOSTIC_TEST|Whole exome sequencing|Whole exome sequencing using Illumina short read sequencing
214337419|NCT07051213|DIAGNOSTIC_TEST|Whole genome Sequencing|Whole genome sequencing using Illumina short read sequencing
214337420|NCT07051629|BIOLOGICAL|SIF001|SIF001 intravenous infusion every two weeks
214938552|NCT04172922|DRUG|Topical Sirolimus|Open label, topical sirolimus (1%) cream will be applied to cutaneous component of complicated vascular anomalies twice daily for 4 weeks and once daily thereafter- for the duration of study.
214938553|NCT05173285|DIAGNOSTIC_TEST|Baseline Assessment|At baseline (i.e. Pre-intervention) participants will complete several questionnaires online via Qualtrics.
214938554|NCT05173285|BEHAVIORAL|Brief Online ACT Intervention|Participants will complete the 4-week online intervention via Qualtrics
215073918|NCT04841161|BEHAVIORAL|Balance function, gait ability, weight- distribution and weight-shifting|Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.
214675469|NCT05321953|OTHER|Aerobic and Inspiratory Muscle Training|The exercise-based 3 times per week for 8 weeks intervention will consist of aerobic interval training and inspiratory muscle training (IMT) for a total duration of 30 minutes. Aerobic-based intervals will be performed at a moderate intensity. Aerobic modes of exercise will include upper extremity ergometer, treadmill, bike, or elliptical.
214675470|NCT06136338|BEHAVIORAL|Mindfulness training|Women in the experimental group underwent four sessions of mindfulness training. The mindfulness training started at the 28th week of pregnancy for the women, the second training was at the 30th week of pregnancy, the third was at the 32nd week of pregnancy, and the last was at the 34th week of pregnancy, with each session lasting 45 minutes.
214337421|NCT07051629|DRUG|Placebo|Placebo
214675471|NCT04446143|BEHAVIORAL|Mindfulness meditation|Mindfulness meditation
214675472|NCT05773157|BEHAVIORAL|Online Modules|Participants receive modules to improve responsive feeding practices of caregivers
214675473|NCT02619253|DRUG|Pembrolizumab|
214675474|NCT02619253|DRUG|Vorinostat|
214675475|NCT06970717|DEVICE|M5Stick Programmable watch|This smart watch is fashioned using a M5StickC, an IOT platform which is programmable and allows us to measure specific exercises.
214675476|NCT05562570|BEHAVIORAL|Physical activity intervention coupled with standard post-cancer directed treatment care|AYACS will participate in a 16-week physical activity program. AYACS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize AYACS' success. AYACS will receive a Fitbit at the beginning of the intervention.
214938555|NCT05173285|DIAGNOSTIC_TEST|Post-Intervention Assessment (i.e. between 4-6 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
214938556|NCT05173285|DIAGNOSTIC_TEST|Follow-up Assessment (i.e. between 8-12 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
214938557|NCT01375582|DRUG|B & L Soothe Lubricant Eye Drops|Eye Drop
214938558|NCT01375582|DRUG|Liposic EDO|Eye Drop
214938559|NCT01375582|DRUG|OcuFresh Eye Wash|Saline drop
214337422|NCT07051551|DEVICE|tooth restoration|restoration of class ııı cavities
214337423|NCT07051551|DEVICE|tooth restoration|restoration of class ııı cavities
214337424|NCT06700356|DEVICE|Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoring|Epilepsy monitoring unit evaluation will follow standard of care practices for seizure characterization, and antiseizure medications may be reduced to facilitate the recording of seizures. Patient clinical management, and video-EEG interpretation will be completed by the clinical epilepsy monitoring unit team which consists of physicians, nurse practitioners, registered nurses, and in-house 24-hour 7-days-per-week EEG technicians. Continuous full-bandwidth thalamus recordings (250 Hz) will be acquired by the research study team using a standard clinician programmer and telemetry module. Hospital monitoring will last up to 4 days.
214938560|NCT03330366|DIETARY_SUPPLEMENT|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
214938561|NCT03330366|DIETARY_SUPPLEMENT|Placebo|take two capsules per day
214938562|NCT01440569|DRUG|COBI|150 mg tablet administered orally with food once daily
214938563|NCT01440569|DRUG|DRV|800 mg (2 x 400 mg tablets) administered orally with food once daily
214675477|NCT05562570|OTHER|Standard post-cancer directed treatment care control|AYACS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Exercise Guidelines for Cancer Survivors will be offered to AYACS following completion of 16-week follow-up. Moreover, AYACS will receive a Fitbit following completion of 16-week follow-up
214675478|NCT04557904|OTHER|Craniocervical flexion exercises|Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible. Subject has to slightly raise his/he skull a few centimeters. Fingers should be touching the cranium but not supporting it. Subject had to respire and hold the position. Subject has the move out the chin. Stop exercise and restart again. Perform this exercise for 10 times by holding this position for 20 sec at the start of the exercise, increasing it by 10 seconds every session commonly underwent pectoralis minor stretching before every session of exercise of 4 sets with 30 second's hold
214337425|NCT06700356|DEVICE|Phase 2-DBS Stimulation with Medtronic Percept DBS device-Out Patient|Patients will then transition to the ambulatory phase. In the outpatient setting, patients will have constrained ambulatory thalamus recordings using recording parameters determined by Phase 1. DBS treatment stimulation will be programmed in the clinical epilepsy neuromodulation lab using typical high frequency (\>50 Hz) stimulation. High frequency stimulation is the conventional approach to DBS for epilepsy, as was used in the pivotal study leading to premarket approval (SANTE study)2 of anterior nucleus of the thalamus (ANT) DBS for focal epilepsy, which is typical for epilepsy DBS practice3, and several studies of DBS for generalized epilepsy4-6, in a sensing friendly electrode configuration. Patients will keep a detailed seizure diary. Ambulatory thalamus recordings by the DBS system and patient reported seizure diaries will be collected during routine clinical DBS programming visits (q3-9 months).
215073919|NCT04841161|BEHAVIORAL|Weight- distribution and weight-shifting training program|The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
214337426|NCT06898749|OTHER|canine mediation|"Animal mediation consists of bringing an animal into contact with a specific audience to improve the mental or physical health of a person. The dog and beneficiaries interact through various activities, in which the animal participates, offered during the sessions. The dog plays a particularly important role as a mediator through the bonds it forms with the human, as well as a non-judgmental partner in interaction.~The canine educator will be accompanied by a healthcare professional during interventions. The sessions are organized based on the expertise and suggestions of both professions (canine educator and psychomotor therapist).~The canine educator will be a state-certified professional educator with a specialization in animal mediation.~The dog used is trained by the educator, with two types of learning being worked on: emotions and commands on cue."
214337427|NCT06898749|OTHER|standard psychomotor therapy|standard sessions of psychomotor therapy
214337428|NCT06576297|OTHER|Inspiratory Muscle Training (IMT)|IMT using a PrO2™ inspiratory training device will incorporate the Test of Incremental Respiratory Endurance (TIRE)9 technology to achieve an optimized exercise training regimen.
214938564|NCT01440569|DRUG|NRTIs|Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
214938565|NCT02254122|DRUG|BEA 2180 BR|
214938566|NCT02254122|DRUG|Placebo|
215073920|NCT01901523|BEHAVIORAL|Reporting of discrepancy to journal|
214938567|NCT02254122|DEVICE|Respimat®|
214938568|NCT04928469|OTHER|No intervention performed|Collection of clinical and laboratory data
215073921|NCT03505294|OTHER|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks."
215073922|NCT02019446|DEVICE|Laser Treatment YAG laser|YAG Laser / FOX Laser
214938569|NCT00596726|DEVICE|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
214938570|NCT05889208|DEVICE|Prophylactic pacemaker implantation|Pacemaker implantation prior the TAVI-procedure
214938571|NCT00382902|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
214938572|NCT01412892|DRUG|RAD001: Everolimus|10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
215073923|NCT02019446|DRUG|Standard Treatment (control group) terbinafine hydrochloride tablets|Terbinafine hydrochloride tablets tablets
215073924|NCT04793230|DIAGNOSTIC_TEST|biopsying|The procedure was carried out under general or local anesthesia. An otolaryngologist conducts the endoscopic intranasal operation, while an eye surgeon removes tissue from the sac and lacrimal tubes using lacrimal probes passed through the canaliculi.
215073925|NCT01418131|DRUG|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
215073926|NCT01418131|DRUG|Placebo|Placebo
215073927|NCT04947345|DRUG|Remimazolam Besylate|Remimazolam Besylate are used as sedatives for subjects in this arm.
215073928|NCT04947345|DRUG|Propofol|Propofol are used as sedatives for subjects in this arm.
215073929|NCT03773133|DRUG|Satoreotide tetraxetan|Radioactivity delivered in 2 administrations (cycles): one loading dose followed by a lower maintenance dose, 6 weeks apart until progression or unacceptable toxicity (up to 4 additional cycles could be administered depending on efficacy and tolerability).
215073930|NCT03773133|DRUG|Satoreotide trizoxetan|Imaging companion: 1 administration at screening and one administration at End of core Trial cycle.
214337429|NCT06576297|OTHER|Standard of Care|Standard of Care Participants in the usual care group will be telephoned at 4 and 8 weeks, and AE/SAE will be reviewed.
214337430|NCT06830096|DRUG|10 mg glipizide ingestion|A single dose of 10 mg glipizide will be ingested
214337431|NCT05274022|OTHER|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. As part of the study, all patients will receive the same exercise program. Exercises will include lower extremity strengthening, balance, and mobility exercises with the use of modalities as needed
214337432|NCT05274022|OTHER|Speed Walking Intervention|The 4-6 week program will consist of a warm up of active stretching. Following the warm up, subjects will perform a 2 minute warm up followed by 1 minute of walking at their fastest comfortable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing for 4cycles and then a 2 minute cool down. The program will be performed 12 visits over 4-6 weeks.
214337433|NCT05955560|DEVICE|PureWick Male External Catheter|The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.
214337434|NCT05955560|DEVICE|Sage PrimoFit|The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
214337435|NCT06786130|OTHER|observational study|This is an observational study in which participants complete PRO questionnaires via a web platform. No medical intervention or medication is involved.
214675479|NCT04557904|OTHER|Scapular stabilization exercises|The scapular stabilization exercises were made up of four stages: (1) In supine position, the patient was commanded to deep respire for the sake of relaxation by maintain the cervical and shoulder in relaxing position to take a deep breath to relax the body while holding her shoulders and neck in relaxing position. (2) The patient then flex her knees and placed her feet flat on the plinth, and maintain the pose without any cervical movement. Then the patient asked to raise her dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. This position was sustained for 10 seconds before going to initial position. Three laps of 10 repetitions with one-minute interval in between were performed. (3) In quadruped position, the patient raise her arms alternatively with shoulder abduction and 120 ° flexion. That posture was held for 10 seconds before returning to the starting position. (4) In sitting position
214938573|NCT05020366|BEHAVIORAL|Promoting Health through Parent Empowerment and the Activation of Routines|Parents will receive a report of their child's current performance and adherence to World Health Organization recommendations in each intervention area. Parents will be coached to build consistent family mealtime routines, in which children are involved in meal preparation, food exploration, and play. They will receive education on appropriate serving sizes for young children and basic information nutrition recommendations. Predictable bedtime routines will be designed to incorporate calming sensory input to improve the transition to bed. Parents will be educated on screen time recommendations and help families brainstorm alternatives to screens, including family-based routines of movement and activity. Finally, parents will be coached to incorporate play into all newly adopted routines, as young children learn though play.
214938574|NCT05020366|BEHAVIORAL|Enhanced Usual Care|For the control group, usual care will be enhanced by providing parents with a report of their child's performance and adherence to World Health Organization recommendations in the areas of healthy eating, physical activity, sedentary behavior and sleep. This report will consolidate data based on parent report, written logs, and actigraphy at baseline.
214938575|NCT04748848|DRUG|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.
214938576|NCT04748848|DRUG|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.
214675480|NCT06971900|DRUG|PORT-77|Active oral dose form
214337436|NCT03522142|DRUG|INCB081776|INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
214675481|NCT06971900|DRUG|Placebo|Matching inactive oral dose form
214675482|NCT02172612|OTHER|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
214675483|NCT05761951|DRUG|DKN-01|Given by IV (vein)
214938577|NCT04748848|DRUG|Azacitidine|Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2
214938578|NCT04748848|DRUG|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle
214675484|NCT05761951|DRUG|Pembrolizumab|Given by IV (vein)
214938579|NCT04748848|DRUG|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.
214938580|NCT03471234|DEVICE|Angioplasty|Inspiron Drug Eluting stent implantation
214675485|NCT03925428|DRUG|Entinostat|Given PO
214675486|NCT03925428|DRUG|Molibresib|Given PO
214675487|NCT05840705|PROCEDURE|Small curved incision with apex lateral|Small curved incision with apex lateral
214337437|NCT03522142|DRUG|INCMGA00012|INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
214337438|NCT06749288|DIETARY_SUPPLEMENT|Radicle Revive Placebo Control Form 4.1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214938581|NCT00392496|DRUG|sunitinib malate|Given orally
214938582|NCT05477628|OTHER|Childcare Navigator|"Participants will be contacted by the CN to assist with access to centre-based childcare after enrolment. The CN will: a) educate the family on the benefits of centre based childcare; b) facilitate placement of the child on waiting lists for funding and centre based childcare placement in their neighbourhood with the aim of having full-time centre based childcare start at 1 year of age; and c) work with the family to overcome barriers to childcare placement prior to and during childcare. It is expected that the child will be in full-time centre-based childcare for a minimum of 12 months.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare according to the Rourke Baby Record."
214938583|NCT05477628|OTHER|Lactation Consultant|"Participants will be contacted by the LC on the same day as their first primary healthcare visit. They will also receive age-appropriate nutrition recommendations according to the Rourke Baby Record. The LC will be an International Board Certified Lactation Consultant (IBCLC) who will provide scheduled and on-call visits, along with phone calls, video conferencing, and text messaging as needed to support exclusive breastfeeding (using virtual care modalities as appropriate during COVID-19). The LC will contact the family once per week for the first 4 weeks to support breastfeeding technique and help with breastfeeding problems such as latching difficulties, painful nursing, and low milk production, monthly thereafter and provide on-call support as required to support exclusive breastfeeding through 6 months of age.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare."
214938584|NCT05477628|OTHER|Lactation Consultant Support and Childcare Navigator Support|This intervention is a combination of the two interventions described above.
214938585|NCT05477628|OTHER|Control Group|All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare.
214337439|NCT06749288|DIETARY_SUPPLEMENT|Radicle Revive Active Study Product 4.1 Usage|Participants will use their Radicle Revive Active Study Product 1.1 as directed for a period of 6 weeks.
214337440|NCT04804735|DEVICE|REV : local anesthesia and virtual reality|REV : local anesthesia and virtual reality in Implanted Venous Access Device (IVAD) procedure under local anesthesia
214337441|NCT04804735|DEVICE|MUS : local anesthesia and music therapy|MUS : local anesthesia and music therapy in Implanted Venous Access Device (IVAD) procedure under local anesthesia
214337442|NCT04621500|DRUG|cholecalciferol|Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
214337443|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq|RNA-seq analysis will be used to (a) identify changes in transcriptional profiles and biological pathways in the prostate between African American and Caucasian men and (b) compare Allostatic Load results to determine stress response and (c) identify changes in the molecular signature in relation to vitamin D levels
214337444|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation|Pathology results of the prostate biopsies will be analyzed for changes in the (a) Gleason Score (b) the number of positive cores (0 to 12) and (c) the highest percentage of positive core involvement (0 to 100%).
214337445|NCT04621500|DIAGNOSTIC_TEST|Allostatic Load|"Diagnostic Test: Allostatic Load Measurements at baseline and after one year vitamin D3 supplementation Allostatic Load measurements to determine body stress compared at baseline and after one year of vitamin D3 supplementation. Also compared with RNA-seq results to determine stress response.~Other Names:~Bloodwork for HgbA1c, lipid profile, creatinine, albumin and vitamin D levels. Body measurements: Ht. Wt, BMI, waist and hip measurements for waist/hip ratio. Measurements of systolic and diastolic blood pressure and heart rate"
214337446|NCT06911619|DIETARY_SUPPLEMENT|Dietary management|The intervention consists of a personalized dietary management with a nutritional follow-up pending transplantation. Teleconsultation appointments are scheduled with the dietician for dietary coaching and a re-evaluation of the nutritional strategy every month. Follow-up visits in person, carried out by the dietitian at the 3rd and 6th month waiting for transplant and are coupled with the usual consultations with the referring hepatologist. The visits allow the realization of LFI (Liver Frailty Index), the collection of interrelated events and the reassessment of hepatic disease as well as the re-evaluation of the nutritional strategy (CNO, enteral or parenteral nutrition)
214675488|NCT05464277|OTHER|Oxygen|Oxygen to achieve assigned SpO2 (or FiO2) targets will be administered to study subjects. The treating clinician can alter oxygenation targets at any time if deemed necessary. The oxygenation goal will be based on SpO2 rather than arterial oxygen saturation (SaO2) or arterial pressure oxygen (PaO2) from arterial blood gases. However, PaO2 can be used instead in situations where the treating clinician considers that peripheral perfusion is poor or SpO2 readings are unreliable. Assigned SpO2 targets will apply to the study subjects for a total duration of 6 hours from intubation or until death or until transfer to the operating theater (whatever comes first).
214938586|NCT05801419|DEVICE|RETI-port/scan 21|Pattern visual event-related potential and pattern electroretinogram on right eye (non-dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
214938587|NCT05801419|DEVICE|Zilia Ocular|Eye fundus tissue oximetry measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
214938588|NCT05801419|DEVICE|OCT-A|Optical coherence tomography angiography measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
214675489|NCT02694029|DEVICE|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
214675490|NCT02694029|DEVICE|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.
214675491|NCT02879500|OTHER|Diet beverages|
214675492|NCT05677789|DIAGNOSTIC_TEST|Medical observation|Likely suitable for home treatment
214675493|NCT05677789|DIAGNOSTIC_TEST|Supportive treatment (BSC)|Consider hospital supervised treatment
214675494|NCT05677789|DIAGNOSTIC_TEST|Intensive care management|Manage in hospital as severe pneumonia
214938589|NCT05801419|COMBINATION_PRODUCT|Electronic cigarette without nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial without nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
214938590|NCT05801419|COMBINATION_PRODUCT|Electronic cigarette with nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial with nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
214938591|NCT01782560|DRUG|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
214938592|NCT01782560|DRUG|Placebo|
214938593|NCT00288808|DEVICE|Hemosense (PT/InR point of care device)|
214938594|NCT00282386|DRUG|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
214938595|NCT00282386|DRUG|Placebo/ Duration of Treatment: 156 weeks|
214938596|NCT01044758|DRUG|Levetiracetam 62.5mg|62.5mg twice daily (2 weeks)
214938597|NCT01044758|DRUG|Levetiracetam 125mg|125mg twice daily (2 weeks)
214938598|NCT01044758|DRUG|Levetiracetam 250mg|250mg twice daily (2 weeks)
214938599|NCT01044758|DRUG|Placebo|placebo capsule twice daily (2 weeks)
214938600|NCT01009255|DRUG|GSK239512|Histamine H3 Antagonist
214938601|NCT01009255|DRUG|Placebo|Placebo to match GSK239512
214938602|NCT00870610|PROCEDURE|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
214938603|NCT01072981|BIOLOGICAL|HyperAcute-Pancreas Immunotherapy|Up to 18 immunizations of 300 million immunotherapy cells
214938604|NCT01072981|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2/day once a week for 3 weeks
214938605|NCT01072981|RADIATION|5FU Chemoradiation|5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
215073931|NCT03872830|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
214938606|NCT05887752|OTHER|Standard rehabilitation|"Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~* physiotherapy;~* occupational therapy;~* sports rehabilitation."
214938607|NCT05887752|DEVICE|Hunova® rehabilitation|Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
214938608|NCT03737279|BEHAVIORAL|Meditation|Routine care + twice daily meditation per schedule, to start on the day of randomization
214938609|NCT03737279|BEHAVIORAL|Routine Care|"Routine care including ACOG educational pamphlets:~* Day 1: Nutrition in Pregnancy~* Day 2: Heart Health for Women~* Day 3: Exercise after Pregnancy"
214938610|NCT00714584|DRUG|Naltrexone HCl.|
214938611|NCT00677859|BIOLOGICAL|MultiStem®|Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
214938612|NCT00677859|BIOLOGICAL|MultiStem®|Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
215073932|NCT03872830|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
215073933|NCT01500603|DEVICE|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
215073934|NCT01500603|DEVICE|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
215073935|NCT00151710|DRUG|Pioglitazone|
215073936|NCT03794206|DEVICE|Vesair Balloon|Treatment with Vesair Balloon for one year
215073937|NCT03371407|OTHER|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
215073938|NCT04248920|BEHAVIORAL|Clinic to Community Education Program|The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
214337447|NCT06911619|OTHER|No dietary management|The patient will be followed up by his reference hepatologist every 3 months. Follow-up visits at 3 months and 6 months waiting for liver transplantation will be performed by Clinical Research assistant on the same day as the follow-up consultation with his hepatologist with the completion of the Liver Frailty Index test and the collection of intercurrent events and the reassessment of liver disease.
214938613|NCT05667207|DIAGNOSTIC_TEST|Point-of-care microscopy and dipstick guided management|"GPs will be encouraged to apply the following diagnosis and treatment algorithm (figure 1) to consenting women, taking their preferences into account:~1. If POCTs are positive for bacteria by microscopy and/or for erythrocytes by dipsticks the GP issues, at his/her own clinical judgement, a delayed or immediate prescription for an antibiotic.10 In the MicUTI intervention, delayed prescription is defined as issuing an antibiotic prescription with the advice to take the medication only when symptoms do not improve or worsen in 48 hours.~2. If POCTs are negative for bacteria and erythrocytes, the GP advises for self-help remedies according to guidelines and to do without antibiotics Study specific training in point-of-care microscopy will be provided to intervention practices."
214938614|NCT04150705|DEVICE|FDG PET/MRI|-All patients will undergo a simultaneous list mode PET and MR acquisition beginning 55-65 minutes after administration of FDG according to a standard weight-based scale.
214938615|NCT00041210|BIOLOGICAL|bleomycin sulfate|
214938616|NCT00041210|DRUG|ABVD regimen|
214938617|NCT00041210|DRUG|Stanford V regimen|
214938618|NCT00041210|DRUG|dacarbazine|
214938619|NCT00041210|DRUG|doxorubicin hydrochloride|
214938620|NCT00041210|DRUG|etoposide|
214938621|NCT00041210|DRUG|mechlorethamine hydrochloride|
214938622|NCT00041210|DRUG|prednisone|
214938623|NCT00041210|DRUG|vinblastine sulfate|
214938624|NCT00041210|DRUG|vincristine sulfate|
214938625|NCT00041210|RADIATION|radiation therapy|
214938626|NCT00055510|DRUG|BO-653|
214938627|NCT01065714|DRUG|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
214938628|NCT01065714|DRUG|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
214938629|NCT06435546|DIAGNOSTIC_TEST|Blood samples|Ferritin, Transferrin Saturation (TSAT), Serum iron, Haemoglobin, Albumin
214938630|NCT06435546|OTHER|Adherence to anti-cancer therapies questionnaires|GIRERD questionnaire, AdOT questionnaire, Use of social networks and alternatives and complementary medicines using patient questionnaire, EORTC QLQC30, HADS, MNA, MSPSS
214938631|NCT01768091|PROCEDURE|POEM|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~4. Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.~(Inoue H et al. POEM for esophageal achalasia… Endoscopy 2010; 42: 265-271)"
214938632|NCT01768091|PROCEDURE|Pneumatic dilation|"A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.~(N Engl J Med 2011;364:1807-16.)"
214938633|NCT02085226|OTHER|Creative Engagement Intervention|"The CEI has 5 component stages which map the participant's journey with the Artist~1. Meeting with Artist, discuss interests, stroke and explore initial creative goals.~2. Introduction to materials and mark making to create interpretations of established images.~3. From mark making and interpretations to developing personal project ideas.~4. Turning personal project ideas into creative finished pieces.~5. Review of completed work, mounting and display of work, future plans.~It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes."
214938634|NCT02085226|OTHER|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
214938635|NCT01244217|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
214938636|NCT04315844|DEVICE|Ewata balloon guiding|The balloon guide catheter is coaxial cavity and reinforced braided catheter with varying stiffness echelon.The distal end is marked by an impermeable ray, the proximal end has a bifurcated ruhr interface, and the end is embedded with a compliance balloon.The product label indicates the size of the balloon guide catheter and the maximum volume of the balloon.
215073939|NCT01610713|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
214337448|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration|The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
214675495|NCT01417286|RADIATION|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
214337449|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only|The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
214938637|NCT03886389|DIETARY_SUPPLEMENT|PreOP|Mixture of Carbohydrates; standard amount designed for enhanced recovery after surgery (ERAS) i.e. preoperative carbohydrate loading before long standing surgery to enhance recovery.
214337450|NCT01343160|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
214337451|NCT06922604|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
214675496|NCT02533648|DRUG|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
214938638|NCT00003394|DRUG|carboplatin|
214938639|NCT00003394|DRUG|endocrine-modulating drug therapy|
214938640|NCT00003394|DRUG|estramustine phosphate sodium|
214938641|NCT00003394|DRUG|goserelin acetate|
214938642|NCT00003394|DRUG|leuprolide acetate|
214938643|NCT00003394|DRUG|paclitaxel|
214938644|NCT06305260|DIAGNOSTIC_TEST|Lumbar Ultrasound|Investigators will utilize our ultrasound machine to complete a pre-procedural lumbar ultrasound prior to epidural placement.
214938645|NCT03502694|DRUG|Lumicitabine|Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.
214938646|NCT03502694|DRUG|Placebo|Participants will receive matching placebo tablets orally.
214938647|NCT01025466|DRUG|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
214938648|NCT01025466|DRUG|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
214938649|NCT05710692|DRUG|PRX-102 1 mg/kg every 2 weeks|PRX-102 1 mg/kg every 2 weeks
214337452|NCT06922604|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214337453|NCT06922604|BIOLOGICAL|Glofitamab|Given IV
214337454|NCT06922604|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214938650|NCT05710692|DRUG|PRX-102 2 mg/kg every 4 weeks|PRX-102 2 mg/kg every 4 weeks
214938651|NCT02787057|DRUG|vancomycin|IP vancomycin 1g every 5 days
214938652|NCT02787057|DRUG|moxifloxacin|oral moxifloxacin 400mg QD
214938653|NCT02787057|DRUG|ceftazidime|IP ceftazidime 1g QD
214938654|NCT01260272|OTHER|Alternative Snack Comparator|Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers
214337455|NCT06922604|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
214337456|NCT06922604|BIOLOGICAL|Obinutuzumab|Given IV
214337457|NCT06922604|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214337458|NCT03645200|DRUG|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
214675497|NCT02533648|DRUG|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
214675498|NCT01062451|DRUG|Perindopril|8 mg taken orally from days 0 through 7.
214938655|NCT01260272|OTHER|Raisins|Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
214938656|NCT04774848|DEVICE|High Frequency Jet Ventilator|HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
214938657|NCT04774848|DEVICE|High Frequency Oscillatory Ventilator|HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
214938658|NCT04951713|DRUG|XZP-3287 combined with clarithromycin|Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21
214938659|NCT04951713|DRUG|XZP-3287 combined with rifampicin|Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19
214938660|NCT03442699|BEHAVIORAL|Cognitive Behavioral Therapy|Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
214938661|NCT05995951|DEVICE|Deep Bran Stimulation (DBS)|Deep brain stimulation (DBS) surgery targeting the antero-medial Sub-Thalamic Nucleus (amSTN)
214938662|NCT05995951|DEVICE|Sham-stimulation|Deep brain stimulation (DBS) surgery - Sham stimulation
214938663|NCT02268682|OTHER|Patient-Guided|"The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program."
214938664|NCT02268682|OTHER|Educator-Guided|The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
214938665|NCT06316388|PROCEDURE|vitrectomy|pars plana vitrectomy
214938666|NCT04079166|BIOLOGICAL|SCIB1 or iSCIB1+ DNA vaccine|"Participants receive up to 11 doses of either SCIB1 or iSCIB1+ up to 85 weeks, in combination with nivolumab with ipilimumab or SCIB1 with pembrolizumab.~Nivolumab with ipilimumab or pembrolizumab treatment will be started 1 week after the first dose of SCIB1 or iSCIB1+ and given as per standard treatment."
214938667|NCT04396600|BEHAVIORAL|MinnRAP Peer Support Program|"The behavioral intervention consists of 1) pairing healthcare workers into Battle Buddies who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals."
214675499|NCT01062451|DRUG|Placebo|Placebo treatment daily.
214337459|NCT06935435|OTHER|Pink Beans|Pink beans consumed for 2 weeks, at an amount of ½ cup/day for week 1 and 1 ½ cups/day for week 2.
214675500|NCT01062451|DRUG|Candesartan|16 mg taken orally from days 0 through 7.
214675501|NCT03411733|OTHER|Blood and stool samples collection|Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection
214337460|NCT06935435|OTHER|Great Northern Beans|Great northern beans consumed for 2 weeks, at an amount of ½ cup/day for week 1 and 1 ½ cups/day for week 2.
214337461|NCT06935435|OTHER|Five-Bean Mixture|Five-bean mixture made of pinto, kidney, black, pink, and great northern beans consumed for 2 weeks, at an amount of ½ cup/day for week 1 and 1 ½ cups/day for week 2.
214938668|NCT06329310|DEVICE|aXess-E conduit|The aXess-E conduit is a sterile, regenerative biodegradable polymer-based vascular conduit, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess-E conduit is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
214938669|NCT05461898|OTHER|Inpatient Rehabilitation|Standard inpatient rehabilitation program with a interdisciplinary team that included a physiotherapist who ensured muscle strength, balance, aerobic and functional training, an occupational therapist who provided training of basic and instrumental activities of daily living and education of energy conservation techniques and a a speech and language therapist for swallowing training.
214938670|NCT05461898|OTHER|Inspiratory muscle training|Inspiratory muscle training protocol during 6 weeks with a electronic-controlled valve device
214938671|NCT05121168|DRUG|Active bupivacaine 0.25% via an erector spinae plane perineural catheter|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
214938672|NCT05121168|DRUG|Placebo normal saline via an erector spinae plane perineural catheter|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
214938673|NCT06257017|DRUG|gemcitabine|1,000 mg/m2 intravenous gemcitabine on day 1 and day 8
214938674|NCT06257017|DRUG|Cisplatin|70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)
214938675|NCT05109832|DRUG|14C-IMP4297|14C marked IMP4297
215073940|NCT02959827|DRUG|Iodinated contrast agents|Use of iodine contrast agents and doses following the decision of the treating physician.
214337462|NCT06938672|DEVICE|Placebo Transcranial Direct Current Stimulation (tDCS)|Placebo Transcranial direct current stimulation (tDCS): Participants will experience a 20-minute session of placebo tDCS on two consecutive days.
214337463|NCT06938672|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Active transcranial direct current stimulation (tDCS). Participants will experience a 20-minute session of active tDCS (1.2 mA) on two consecutive days.
214337464|NCT04560504|OTHER|Control Group|Leisure activities
214337465|NCT04560504|OTHER|Oculomotor Training Group|Eye movement training
214337466|NCT05932914|PROCEDURE|Liver Biopsy|Standard transjugular liver biopsy under moderate sedation
214938676|NCT01727544|PROCEDURE|cartilage cap occlusion surgery|placement of a cartilage cap over the dome of the superior semicircular canal through a combined transmastoid and tegmen mini- craniotomy approach.
214938677|NCT03589326|DRUG|Ponatinib|Ponatinib Tablets.
214938678|NCT03589326|DRUG|Imatinib|Imatinib Tablets.
214337467|NCT06940219|PROCEDURE|Delayed Sequence Induction|Delayed Sequence Induction - fractional dosing of Ketamin and Midazolam until a dissociative status is achieved. Dosing should follow the clinical effect. - start of preoxygenation with Bag-Valve-Mask Device or NIV when dissociative status is achieved for at least 3 minutes. - after completion of preoxygenation: neuromuscular blockade with Rocuronium - after application of Rocuronium: Intubation via standard of care. - should apnoea occur during preoxygenation, the continuation of ventilation via Bag-Valve-Mask or NIV is recommended, but not mandatory.
214337468|NCT06940219|PROCEDURE|Modified Rapid Sequence Induction|Modified Rapid Sequence Induction - Preoxygenation FiO2 100% with Bag-Valve-Mask-Device or NIV for at least 3 Minutes. - After completion of Preoxygeniation: application of Midazolam, Ketamin and Rocuronium. - The dosing of medication is determined in advance by the operating physician. - Ventilation via Bag-Valve-Mask-device or NIV after application of rocuronium is allowed. - After application of medication: Intubation via standard of care.
214337469|NCT06947135|DRUG|Morphine|Morphine (10 mg, 10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
214337470|NCT06947135|DRUG|saline placebo|Saline (10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
214337471|NCT06954337|OTHER|Usual practice pattern (UPP)|Patient follows usual practice pattern for routine care
214337472|NCT06954337|OTHER|Experimental: Enhanced Telehealth (ET)|Patient follows enhanced telehealth practice pattern. As clinically appropriate, patients given option to shift routine care from face-to-face to at-home services available at institution: telehealth visits, home phlebotomy, and educational support for home administration of injection medications
214337473|NCT03657641|BIOLOGICAL|Pembrolizumab|Given IV
214337474|NCT03657641|DRUG|Regorafenib|Given PO
214337475|NCT05751135|DEVICE|Focal muscle vibration|Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.
214337476|NCT05751135|PROCEDURE|Stretching|Stretching of shortened lower extremity muscle
214938679|NCT03589326|DRUG|Vincristine|Vincristine IV injection.
215073941|NCT05540249|DIETARY_SUPPLEMENT|carbohydrates|Patients will orally consume 355mL CHO after 20:00 the evening before surgery.
215073942|NCT05237791|DRUG|Magnesium sulfate|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
215073943|NCT05237791|DRUG|Placebo|normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
214337477|NCT05751135|PROCEDURE|Strengthening|Strengthening exercises for weak lower extremity muscles
214337478|NCT05751135|PROCEDURE|Positioning|Positioning of participant to maintain a good body posture
214337479|NCT03129347|DRUG|Nalmefene|Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
214938680|NCT03589326|DRUG|Dexamethasone|Dexamethasone Tablets.
214938681|NCT03589326|DRUG|Cytarabine|Cytarabine IV infusion.
214938682|NCT03589326|DRUG|Methotrexate|Methotrexate IV infusion.
214938683|NCT03589326|DRUG|Prednisone|Prednisone Tablets.
215073944|NCT04183127|OTHER|No intervention|ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
215073945|NCT05149651|DRUG|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
215073946|NCT05149651|DRUG|MTA|ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
214337480|NCT03299140|BEHAVIORAL|Family Focused Therapy|
214337481|NCT01337089|DRUG|Nabiximols|
214337482|NCT05601479|DRUG|Acetyl-L-carnitine|At the beginning of the first chemotherapy of the oxaliplatin regimen, Acetyl-L-carnitine 500mg will be given orally three times daily for 24 weeks. If subjects discontinue oxaliplatin-containing chemotherapy for various reasons (e.g., allergy to oxaliplatin), they will continue taking acetyl-L-carnitine until 24 weeks (unless acetyl-L-carnitine intolerance or other conditions interfere with medication).
214337483|NCT03574129|BEHAVIORAL|Adolescent Transition Package|Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
214337484|NCT04890340|DIAGNOSTIC_TEST|ARNA Breast|Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method
214675502|NCT06249542|OTHER|Care Delivery Improvement Intervention|"KPWA clinical leaders and clinicians in each clinic implemented all aspects of the care delivery improvement intervention, including screening, assessment, and shared decision-making followed, as appropriate, by treatment. The implementation strategy, which was refined during the pilot phase, included:~1. Identification of a clinical champion and local implementation team~2. Participatory design~3. Training of primary care providers and medical assistants~4. Use of EHR clinical decision support tools~5. Weekly facilitated local implementation team meetings~6. Performance monitoring with feedback, including monthly meetings with the local implementation team and clinic leaders~7. Learning sessions for primary care providers during implementation~8. Social worker use of an EHR registry with weekly supervision~9. Use of a video and informational handouts to shift attitudes and reduce stigma associated with unhealthy substance use"
214938684|NCT00435487|DRUG|Dalteparin ( Fragmin)|Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.
214938685|NCT00435487|DRUG|Unfractionated heparin|Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg \[units per kilogram\] and initial infusion of 12 U/kg/h \[units per kilogram per hour\]).
215073947|NCT05534659|DEVICE|Programmable valve|Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
215073948|NCT05534659|DEVICE|Non-programmable valve|Non-programmable valve used in the study was Medtronic CSF-flow control valve.
215073949|NCT01213459|PROCEDURE|Cervical samples|Human papillomavirus detection and typing in cervical samples.
215073950|NCT01213459|OTHER|Data collection|Questionnaire completion
214938686|NCT02627326|PROCEDURE|open flap debridement|periodontal surgery in the form of open flap debridement was done in both the groups
214938687|NCT06525025|OTHER|Observational study, non intervention|Observational study, non intervention
214938688|NCT03301844|COMBINATION_PRODUCT|Blephapad Combo|"Blephapad Combo is used to cleanse, soften, sooth and decongest inflamed eyelids and cilia.~The combo also presents an applicator with a heatable tablet that is applied to the eyelid in order to clean and open occluded Meibomian glands, thereby allowing the production of lipids necessary for a healthy tear film. The heatable tablet is to be used prior to cleansing with Blephapad wipes."
214938689|NCT03301844|OTHER|Standard treatment|Standard treatment, twice daily for one month, consisting in eyelid hygiene using wet, warm gauze.
214938690|NCT01198561|DEVICE|repetitive Transcranial Magnetic Stimulation|10 times repetitive TMS, high frequency
214938691|NCT01935856|DRUG|KHK7580|Oral administration
214337485|NCT04959045|OTHER|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
214938692|NCT02730767|BEHAVIORAL|partially supervised exercise intervention|
215073951|NCT02390440|DRUG|EXPAREL|
214337486|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent coextruded with doxazosin|Placement of drug-coated ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
214337487|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent|Placement of a commercially available ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
214938693|NCT05087966|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
214938694|NCT04695574|PROCEDURE|Some clinical evaluation performance tests together with procedure of Closed Kinetic Chain Lower Extremity Stability Test|Clinical evaluation methods
214938695|NCT04703374|DRUG|CKD-382(formulation I)|1 tablet administered under fasting condition for 7days
214938696|NCT04703374|DRUG|CKD-382(formulation II)|1 tablet administered under fasting condition for 7days
214938697|NCT04703374|DRUG|D026|1 tablet administered under fasting condition for 7days
214938698|NCT03934723|BEHAVIORAL|Exercise|The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.
214938699|NCT02543372|BEHAVIORAL|Behavioral Couples Therapy (BCT)|BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
214938700|NCT02543372|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
214938701|NCT03495739|DRUG|RDG-17012 Capsule|Dabigatran Etexilate tosylate 150mg
214938702|NCT03495739|DRUG|Dabigatran Etexilate Mesylate 150 MG Oral Capsule|Dabigatran Etexilate mesylate 150mg
214675503|NCT04984226|DRUG|Sodium bicarbonate|Sodium bicarbonate will be dosed at 0.8meq per kilogram of ideal body weight daily (1meq is approximately 84mg). We will use the Devine formula to determine ideal body weight. Investigational Drug Services at both UC Davis and Vanderbilt will compound the sodium bicarbonate. Sodium bicarbonate 650 mg tablets will be over-encapsulated and matching placebo capsules will be prepared. Participants will be limited to a maximum of 9 capsules daily (maximum dose = 5850mg of sodium bicarbonate). Capsules will be dispensed to patients in two separate 8-week allotments. The dose will be rounded to the nearest whole capsule and depending on participant preference may be divided into portions taken twice or thrice daily. Given the high probability of interruption in sodium bicarbonate supply and availability, we may need to change brands of sodium bicarbonate intermittently.
214675504|NCT04984226|DRUG|placebo|The placebo and filler for for sodium bicarbonate capsules will be comprised of microcrystalline cellulose. Capsule appearance for control and sodium bicarbonate will be the same.
214675505|NCT00310505|DRUG|Amphotericin B deoxycholate given as daily administration|
214675506|NCT00607750|DRUG|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
214675507|NCT00607750|DRUG|Placebo|Placebo eyedrops, BID, 48 weeks
214675508|NCT04697147|BEHAVIORAL|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
214675509|NCT03520049|DRUG|Oseltamivir|
214337488|NCT03339076|DEVICE|"M3 MINI CATHETER"|"Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter."
214938703|NCT00993759|DRUG|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
214938704|NCT05839405|OTHER|None - Cross Sectional.|There is no intervention, this is cross-sectional only.
214938705|NCT05402124|DRUG|acetylsalicylic acid delayed release tablets, 81mg|acetylsalicylic acid delayed release tablets, 81mg taken once per day for 90 days
214938706|NCT01886586|BEHAVIORAL|Problem Solving Therapy|6-12 sessions of Problem Solving Therapy (both members of dyad)
214337489|NCT03783351|GENETIC|CYP2C19 genotype testing|CYP2C19 genotype testing will be conducted in a designated central laboratory.
214675510|NCT03520049|DRUG|Placebo|
214675511|NCT05086237|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who missed their well child visits.
214675512|NCT03622645|DEVICE|Assessment of Range of Motion with Leap Motion sensor|An ROM measurement method called as HandROM by us will be developed with leap motion sensor
214675513|NCT04706598|DRUG|Camrelizumab|Solution for Infusion (Intravesical)
214675514|NCT02785757|OTHER|Thrombin Generation Assay|
214675515|NCT03929042|DEVICE|Posture correction girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
214675516|NCT03466762|OTHER|Non applicable|Non applicable
214675517|NCT01172171|DRUG|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
214675518|NCT01172171|DRUG|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
214675519|NCT01208181|DRUG|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
214675520|NCT01208181|DRUG|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
214938707|NCT01886586|BEHAVIORAL|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
214938708|NCT01886586|OTHER|Enhanced Usual Care|Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
214938709|NCT04985175|BEHAVIORAL|Question prompt list|The specific QPS was a one page leaflet for chronic kidney disease which developed by applied literature and public QPL from the National Health Agency. It contains 3 domains 25 questions related to treatment, dialysis, and Kidney transplant. The QPL group participants were asked to read and mark those questions they concerned or write down additional problems.
214938710|NCT00501059|DRUG|Aspirin (Acetylsalicylic acid, BAYE4465)|100mg enteric coated Aspirin, taken daily
214675521|NCT01208181|DRUG|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
214675522|NCT01208181|DRUG|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
215073952|NCT05295784|DRUG|Caffeine citrate|A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
215073953|NCT03585036|DRUG|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
215073954|NCT03585036|DRUG|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
215073955|NCT03585036|DRUG|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
214675523|NCT02427581|BIOLOGICAL|Personalized synthetic long peptide vaccine (Poly ICLC)|
214675524|NCT02427581|DRUG|Poly ICLC|
214675525|NCT00943878|BIOLOGICAL|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
214675526|NCT00943878|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
214337490|NCT05481021|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
214675527|NCT00943878|DRUG|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
214337491|NCT04028375|OTHER|No intervention|No intervention
214337492|NCT02761564|OTHER|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
214337493|NCT02761564|OTHER|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
214675528|NCT02443844|PROCEDURE|Transurethral Resection|Endoscopic treatment of bladder cancer
214675529|NCT02443844|DRUG|Tamsulosin|Medical treatment for benign prostate hyperplasia
214675530|NCT01457339|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
214337494|NCT02595203|DRUG|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
214337495|NCT02595203|DRUG|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
214337496|NCT06573840|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand. NeuroGlove provides sensory stimulation in the form of pneumatic puffs of air.
214337497|NCT02262429|OTHER|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
214675531|NCT01457339|DRUG|Placebo|Placebo Capsule(s) for oral use taken once daily for 30 days
214675532|NCT02660658|DRUG|Intrathecal dexmedetomidine|The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
214675533|NCT02730247|DRUG|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
214675534|NCT02730247|DRUG|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
214675535|NCT04155385|OTHER|Measurement|The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
214675536|NCT04155385|OTHER|Feedback|The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
214675537|NCT00002423|DRUG|Indinavir sulfate|
214675538|NCT00002423|DRUG|Abacavir sulfate|
214675539|NCT00002423|DRUG|Amprenavir|
214675540|NCT00002423|DRUG|Nelfinavir mesylate|
214675541|NCT00002423|DRUG|Lamivudine|
214675542|NCT03890224|DEVICE|home ventilators|The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
214675543|NCT03694522|BIOLOGICAL|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
214675544|NCT03694522|DRUG|Placebo|Administered by intravenous infusion over approximately 30 minutes
214938711|NCT00501059|DRUG|Placebo|Placebo, taken daily
215073956|NCT05386862|BEHAVIORAL|Reduce THC Use|Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
215073957|NCT01644006|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
215073958|NCT01242410|DEVICE|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
214938712|NCT00517894|DRUG|CEOP/IMVP-Dexa chemotherapy|Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
214938713|NCT02237209|BIOLOGICAL|RSV LID ΔM2-2 Vaccine|10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
214938714|NCT02237209|BIOLOGICAL|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
214938715|NCT05949424|DRUG|Olaparib|Starting dose of 200mg 2dd.
214675545|NCT03694522|DRUG|Modified FOLFOX6|"mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours"
214675546|NCT03940144|DEVICE|the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device|Stroke volume variation (SVV)-guided fluid therapy
214675547|NCT02320331|BEHAVIORAL|PILI Lifestyle Program|A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
214675548|NCT02976467|DRUG|Fulacimstat (BAY1142524)|25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
214337498|NCT02262429|OTHER|ONS Standard Feeding|Standard of care
214337499|NCT04459611|BIOLOGICAL|sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
214337500|NCT04459611|DRUG|pemetrexed|500 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
214337501|NCT04459611|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.
214337502|NCT04459611|DRUG|albumin-bound paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
214337503|NCT00204191|DRUG|tacrolimus|
214337504|NCT05417711|DEVICE|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
214675549|NCT02976467|DRUG|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
214675550|NCT05427630|DRUG|THC ~2.5%|Cannabis flower containing THC \~2.5%
214675551|NCT05427630|DRUG|THC ~5%|Cannabis flower containing THC \~5%
214675552|NCT05427630|DRUG|THC ~10%|Cannabis flower containing THC \~5%
214675553|NCT05427630|DRUG|Sham Cannabis|Cannabis flower from which the THC and CBD have been extracted
214675554|NCT05999305|OTHER|Teaching the critical care nursing course with an Escape Room game|A teacher will begin with a 1.5-hour lecture, followed by an escape room game to reinforce learning through case studies for another 1.5 hours. The first section of the game will be a ten-minute pre-brief. The game will then begin promptly at a designated time and will be played in groups of six to seven students, with each group seated separately in a classroom. The game will last up to fifty minutes, during which all groups will be assisted to complete puzzles within the time limit. After the game, a fifteen-minute debriefing session will be held by the teacher, during which the students will reflect on their performance and what they learned about the cases and related topics. The teacher will finally provide feedback and support to the groups during this session.
214675555|NCT05999305|OTHER|Teaching the critical care nursing course with a case-based learning|Students in the comparison group will also receive a 1.5 hour lecture which is the same as those in the intervention group. Another 1.5 hour is a case-based learning session, with six sessions in total over six weeks. The case-based learning sessions will include a pre-brief, teamwork, and debrief, and will be facilitated by the same teacher and teaching assistant and will primarily be provided with paper-based case studies.
214675556|NCT01748760|BEHAVIORAL|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
214675557|NCT01748760|OTHER|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
214675558|NCT05374356|DRUG|Intrathecal bupivacaine and morphine|Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).
214938716|NCT05949424|DRUG|Lenvatinib|Starting dose of 10mg 1dd.
214938717|NCT05949424|DRUG|Sunitinib|Starting dose of 25mg 1dd 28/42 days.
214938718|NCT05949424|DRUG|Palbociclib|Starting dose of 75mg 1dd 21/28 days.
214938719|NCT05949424|DRUG|Pazopanib|Starting dose of 200mg 1dd.
214938720|NCT05949424|DRUG|Olaparib|Starting dose of 300mg 2dd.
215073959|NCT01900301|DRUG|Scopolamine|Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
215073960|NCT01900301|DRUG|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
215073961|NCT00178919|DRUG|L-NMMA|IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
214675559|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
214938721|NCT05949424|DRUG|Lenvatinib|Starting dose of 20mg 1dd for RCC or endometrial carcinoma, starting dose of 24mg 1dd for thyroid carcinoma.
214938722|NCT05949424|DRUG|Sunitinib|Starting dose of 50mg 1dd 28/42 days.
214938723|NCT05949424|DRUG|Palbociclib|Starting dose of 125mg 1dd 21/28 days.
214938724|NCT05949424|DRUG|Pazopanib|Starting dose of 800mg 1dd.
214938725|NCT02201095|DEVICE|Forced air warming|
214938726|NCT02201095|DEVICE|Conduction warming mattress|
214938727|NCT04482595|DRUG|BIO 300 Oral Suspension|Suspension of genistein nanoparticles
214938728|NCT04482595|DRUG|Placebo|Matched placebo for BIO 300 Oral Suspension
214938729|NCT03559868|DRUG|Digoxin|Participants will receive 3 mcg/Kg/day doses of oral digoxin
214938730|NCT03559868|OTHER|Placebo|Oral placebo
214938731|NCT03559868|DRUG|Digoxin|Participants will receive 0.15 mcg/Kg/day doses of oral digoxin
214938732|NCT03152825|PROCEDURE|PCI|percutaneous coronary intervention attempt
214938733|NCT00876226|DRUG|Citalopram|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
214938734|NCT05084365|DRUG|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
214938735|NCT05084365|DRUG|Placebo|Placebo
214938736|NCT00430352|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv every 8 weeks
214938737|NCT05177900|DEVICE|Study Tool Computer|Nonconventional pulses delivered with custom-ware designed by Boston Scientific
214938738|NCT04511949|DIAGNOSTIC_TEST|COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)|"* The rapid test is performed using a drop of blood obtained at the fingertip (10 microliters) using a lancet.~* The dropper pipette, held vertically, collects the drop of whole blood up to the sample line~* Place 1 drop of whole blood (10 μL in the sample well (S) of the cassette.~* Immediately add 2 drops (80μL) of buffer to the well (B) of the cassette.~* Avoid air bubbles; if there is an air bubble, add a 3rd drop of buffer.~The reading is taken after 10 minutes at most by the healthcare professional under medical supervision.~In case of sepositivity of the rapid test, it may be offered to index cases and adult contacts, a blood sample of 5 ml of blood for a serothèque allowing a characterization of the antibodies and in particular of the neutralizing antibodies."
214675560|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
214675561|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
214938739|NCT04947995|DEVICE|ctDNA multi-omics test|The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.
214938740|NCT02331849|DEVICE|High resolution manometry (HRM)|High resolution manometry of the esophagus
214938741|NCT06730516|DRUG|Latanoprost (Xalatan)|latanoprost 0.005
214938742|NCT06730516|DRUG|Brimonidine 0.2 %|Brimonidine0.2
214938743|NCT00565669|DRUG|Cyclosporin A Restasis®|
215073962|NCT00178919|DRUG|Trimethaphan|IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
215073963|NCT00520702|PROCEDURE|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
214675562|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
214675563|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
214675564|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
214675565|NCT01235533|DIETARY_SUPPLEMENT|N-3 polyunsaturated fatty acids|Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
214337505|NCT05417711|DEVICE|Tailor-made Notched Music Training|Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.
214337506|NCT02445079|OTHER|This is an observational study only|Observational study only
214337507|NCT02011841|DRUG|Rifaximin|rifaximin 1200 mg/day orally for 6 months
214337508|NCT02011841|DRUG|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
214337509|NCT03324061|DRUG|Fulvestrant for Injectable Suspension|Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
214337510|NCT03324061|DRUG|Faslodex (Reference)|Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
214675566|NCT02522377|DRUG|Ketamine|inter venous injections
214938744|NCT00565669|DRUG|Blink tears|blink tears to be used twice a day
214938745|NCT00565669|DRUG|Systane|systane to be used twice a day
214938746|NCT02930525|OTHER|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
214938747|NCT02930525|OTHER|Standard respiratory care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
214938748|NCT02689310|OTHER|Leptospermum scoparium honey|No information available- PI left- study being withdrawn.
214938749|NCT02689310|OTHER|Standard of Care Treatment|No information available- PI left- study being withdrawn.
214938750|NCT05603156|DRUG|the usage of Olverembatinib combined with Inotuzumab Ozogamicin|patients in this arm will accept a 28 days treatment regimen: Olverembatinib 40mg QOD (d1 to d28 )and Inotuzumab Ozogamicin 1.2mg/m2 (divided into 2 days, d1 and d8, 0.6mg/m2, respectively).
214938751|NCT03653091|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
214938752|NCT03653091|DEVICE|Duodenal Mucosal Resurfacing Sham (Sham)|The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.
214938753|NCT01785849|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
214938754|NCT01785849|DRUG|Placebo|Administered intravenously (IV) three times per week.
214938755|NCT06288204|DIETARY_SUPPLEMENT|Propolis associated with Royal Jelly|The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis together, for 2 months.
215073964|NCT00520702|PROCEDURE|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
215073965|NCT05263986|DRUG|MRTX849|"Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1."
214337511|NCT02760186|PROCEDURE|Altitude Exposure|Altitude Exposure
214675567|NCT02522377|DRUG|Midazolam|inter venous injections
214675568|NCT00581607|DRUG|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
214675569|NCT00581607|DRUG|Placebo|Placebo twice a day
214675570|NCT00581607|DRUG|Bosentan|drug given for 16 weeks
214675571|NCT00581607|DRUG|Placebo|placebo
214675572|NCT05465681|DRUG|HR20013 for injection；dexamethason|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
214938756|NCT06288204|DIETARY_SUPPLEMENT|Royal Jelly|The participants will consume 1 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
214938757|NCT06288204|DIETARY_SUPPLEMENT|Placebo|The participant will consume 4 capsules a day of placebo, for 2 months.
214938758|NCT05452616|OTHER|ART first- Therapeutic use trial|ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease. The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
214938759|NCT05452616|OTHER|TB results first- Therapeutic use trial|Deferral of ART initiation until active TB has been refuted or confirmed. PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations. Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
214938760|NCT06620549|DIAGNOSTIC_TEST|gastric ultrasonograppy|Patients will be scanned in both supine and right lateral decubitus position (RLD)s. If the antrum is visible, it will be judged if the antrum is empty in both positions or the antrum is empty in supine position and fluid apparent in RLD position suggesting a low fluid volume (\<1,5 ml/Kg). The third option is fluid apparent in both supine and RLD position, suggesting a higher fluid volume (\>1,5ml/Kg) and the last option is solid food in one or both positions.
214938761|NCT06811480|OTHER|Conventional Physiotherapy|"Participants in the first group underwent conventional physiotherapy interventions for 6 weeks, 5 days per week. These interventions included Ultrasound (US), Transcutaneous Electrical Nerve Stimulation (TENS), wrist joint range of motion exercises, stretching exercises, and strengthening exercises using Digiflex, Powerweb, and dumbbells. The number of repetitions and sets of the exercises was adjusted based on the patients' conditions, following a progressive approach.~US was applied to the affected wrist for a total of 30 sessions, 5 days a week, once daily, for 6 minutes at an intensity of 1.5 W/cm², using an underwater application method. TENS was administered at a frequency of 100 Hertz for 20 minutes. All participants received manual stretching exercises for wrist flexion, extension, ulnar and radial deviation, supination, and pronation. These stretches were performed by a physiotherapist, with 5 repetitions in each direction, holding the end position for 20 seconds."
214938762|NCT06811480|OTHER|Closed Kinetic Chain Exercise|Participants in the second group received a treatment protocol that included closed kinetic chain exercises (CKCE) in addition to conventional physiotherapy. CKCE exercises were performed with 15 repetitions each and involved stabilizing a ball between the hand and the wall in different arm positions, rolling it in multiple directions. Participants also performed weight-shifting exercises against a wall and on a table, holding positions for 6 seconds. Additionally, in a crawling position, they moved their unaffected arm diagonally on both a firm surface and a cushion.
214938763|NCT05996003|DRUG|NS-089/NCNP-02|"Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1"
215073966|NCT05576168|BIOLOGICAL|overexpression STRA6/miRNA3|RBP4 express in patients with T2DM or not
215073967|NCT03130387|DEVICE|Office Hysteroscope|Diagnosis of C.S niche in patients wit AUB by office hysteroscope
215073968|NCT01317576|BEHAVIORAL|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
215073969|NCT03943550|DRUG|RO7049665|Multiple ascending doses of RO7049665 will be administered SC.
215073970|NCT03943550|DRUG|Placebo|Matching placebo will be administered SC.
215073971|NCT05397041|DRUG|BMB-101|Participants will receive one of several different oral doses of BMB-101 once or twice daily
214938769|NCT06802094|OTHER|Single-session balance intervention in virtual reality|Single-session balance intervention (30 minutes) in a virtual reality environment, the Gait Real-time analysis Interactive Lab (GRAIL) or the Computer Assisted Rehabilitation Environment (CAREN) in children with and without Developmental Coordination Disorder (Motek Medical, The Netherlands).
214938770|NCT00646945|DRUG|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
214938771|NCT00646945|DRUG|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
215073972|NCT05397041|DRUG|Placebo|Matched Placebo
215073973|NCT03359785|DRUG|Luvadaxistat|TAK-831 Tablets.
215073974|NCT03359785|DRUG|Matching Placebo|Matching Placebo Tablets.
214938772|NCT06103864|DRUG|Dato-DXd|Provided in 100mg vials. IV infusion. Experimental drug.
215073975|NCT00527683|DRUG|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
214938773|NCT06103864|DRUG|Durvalumab|Provided in 500mg vials. IV infusion. Experimental drug.
214938774|NCT06103864|DRUG|Paclitaxel|IV infusion. Active comparator.
214938775|NCT06103864|DRUG|Nab-paclitaxel|IV infusion. Active comparator.
215073976|NCT00527683|DRUG|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
215073977|NCT00527683|BEHAVIORAL|Group therapy|Participants attend group sessions once a week
215073978|NCT03267719|DEVICE|laser therapy|Transvaginal erbium-laser treatment
215073979|NCT03118427|PROCEDURE|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
215073980|NCT03118427|PROCEDURE|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
215073981|NCT02864186|DEVICE|control|Women wont use support bra 24 hours a days for six months
215073982|NCT02864186|DEVICE|surgical support bra|Women will use surgical support bra 24 hours a day for six months
214337512|NCT02148094|DRUG|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
214337513|NCT01569334|BIOLOGICAL|blood samples|
214337514|NCT02541721|DEVICE|LabiaStick#01|"This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area."
214337515|NCT03395535|PROCEDURE|Primary Selective Laser Trabeculoplasty Treatment Pathway|"Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
214938776|NCT06103864|DRUG|Gemcitabine|IV infusion. Active comparator.
214938777|NCT06103864|DRUG|Carboplatin|IV infusion. Active comparator.
214938778|NCT06103864|DRUG|Pembrolizumab|IV infusion. Active comparator.
214938779|NCT05234983|BEHAVIORAL|LifeFirst SWASTH brief advice intervention|This intervention will support tobacco cessation among patients of high-reach, low-resource community healthcare settings in Mumbai (TB clinics, dental practices, and NGO-run health centers). The intervention will also use technology to build the capacity of practitioners in these settings to use evidence-based practices in their work and allow them to network and exchange best practices with one another.
214938780|NCT04242147|DRUG|KD033 (SAR445710)|Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
214938781|NCT06236451|DRUG|Aripiprazole|Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.
214938782|NCT06236451|DRUG|Risperidone|Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
214938783|NCT05745714|DRUG|Ruxolitinib|oral
214938784|NCT05745714|DRUG|Venetoclax|oral
214938785|NCT05745714|DRUG|Dexamethasone|oral/intravenous
214938786|NCT05745714|DRUG|Cyclophosphamide|intravenous
214938787|NCT05745714|DRUG|Cytarabine|intravenous
214938788|NCT05745714|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
214938789|NCT06557785|BIOLOGICAL|CH505M5 N197D mRNA-gp160|To be administered intramuscularly as a split dose
214938790|NCT06557785|BIOLOGICAL|CH505 TF mRNA-gp160|To be administered intramuscularly as a split dose
214938791|NCT06022120|BEHAVIORAL|An integrated health literacy intervention|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish contexts among students at risk of poorer health outcomes compared to their peers with stronger literacy skills.
215073983|NCT02864186|DEVICE|common support bra|Women will use common support bra 24 hours a day for six months
215073984|NCT04449393|DEVICE|Emdogain® FL|Emdogain® FL is an enamel matrix derivative intended for subgingival and topical application in conjunction with scaling and root planing procedures to provide regeneration of tooth support lost due to periodontal disease. Emdogain® FL has been shown to be effective in residual pockets with probing depths from 5mm to 9mm with no furcation involvement in patients with adequate plaque control. Emdogain® FL has also been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
214938792|NCT04550832|DRUG|Delpazolid|Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.
214938793|NCT04550832|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
214938794|NCT05455450|OTHER|Eye movement desensitisation and reprocessing therapy|Up to 16 EMDR sessions (minimum of 8 sessions), and 1-month follow-up session, as well as attending neuropsychiatric appointments (NPC). Participants will be given the choice of attending EMDR physically face-to-face or virtually via a video-consultation platform. Sessions will normally be attended weekly, with treatment completed within 6 months. Sessions will be 60-90 minutes long. EMDR will follow the standard 8-phase protocol, with additions so that it is tailored for FND presentations. The FND-specific EMDR therapy protocol has been developed for the trial by the chief investigator.
214938795|NCT05455450|OTHER|Neuropsychiatric care|Standard medical care consisting of 1-3 30 minute appointments with neuropsychiatrist over the course of the 9-month trial period.
214938796|NCT05794178|BEHAVIORAL|Education|Education about health benefits of physical activity, 2018 US Physical Activity Guidelines, assigned goals tailored to baseline step counts, and worksheet to develop action and coping plans (three of each)
214938797|NCT05794178|BEHAVIORAL|Activity tracker|Fitbit activity tracker and mobile app to provide ad libitum behavioral feedback and self-regulatory support
214938798|NCT05794178|BEHAVIORAL|Text messaging (random timing and selection)|Four text messages/day at random times within a participant's availability window and drawn at random from one of three content libraries (move more \[40%\], sit less \[40%\], inspirational quotes \[20%\])
214938799|NCT05794178|BEHAVIORAL|Text messaging (precision dosing)|Up to four text messages/day within a participant's availability window, timed and selected from one of three content libraries (move more, sit less, inspirational quotes) based on a person-specific dynamic model and contextual data
214938800|NCT04823130|DRUG|Dupilumab (SAR231893)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
215073985|NCT04449393|OTHER|Scaling and root planing|Scaling and root planing procedures as part of non-surgical periodontal therapy involves mechanical removal of dental plaque and calculus using curettes and sonic scalers.
214938801|NCT06599502|DRUG|AZD0022|AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.
214938802|NCT06599502|DRUG|Cetuximab|Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands
214938803|NCT05264389|DEVICE|Poly-Tape Devices|Poly-Tape Devices, 10mm Poly-Tape or 5mm Infinity-Lock Tape, for Medial Patellofemoral Ligament (MPFL) Reconstruction
214938804|NCT06546618|BEHAVIORAL|pictorial warning and no flavor|LCC Package with pictorial warning and no flavor
214938805|NCT06546618|BEHAVIORAL|pictorial warning and 'sweet' flavor|LCC Package with pictorial warning and 'sweet' flavor
214938806|NCT06546618|BEHAVIORAL|text-only warning and no flavor|LCC Package with text-only warning and no flavor
214938807|NCT06546618|BEHAVIORAL|text-only warning and 'sweet' flavor|LCC Package with text-only warning and 'sweet' flavor
214938808|NCT06802263|DIAGNOSTIC_TEST|at-home quantitative urine b-hCG test|"Cases will begin performing urine and serum hCG testing 24 hours after the initial hCG level. Urine hCG testing will be performed on the first morning urine at home and participants will limit water for at least 8 hours before testing. Serum hCG testing will occur at a UCHealth laboratory before 10 am and within 2 hours of the urine test to allow for the comparison of the values. Both urine and serum hCG testing will then occur daily x 7 days, or until a medical or surgical intervention is indicated. If serum testing is indicated on a weekend, patients will present to the UCH Infusion Center.~Non-pregnant controls will test the first morning urine at home and undergo serum hCG testing in a UCHealth lab on the 4th and 6th day of the menstrual cycle. All urine hCG values will be recorded in the Mira home kit and evaluated in comparison to serum hCG levels."
214938809|NCT06374290|DRUG|Naltrexone (Vivitrol)|At week 1 the Nurse Practitioner will administer extended-release naltrexone via intramuscular gluteal injection supplied as a standard single-use kit containing 380-mg vial of Vivitrol microspheres. Only one naltrexone injection will be administered over the course of the study
214938810|NCT06374290|DRUG|Bupropion|Oral bupropion will be titrated to 450 mg over the course of 3 days. One week's supply of the study medication will be dispensed at each visit. Cell-phone assisted remote observation of medication adherence (CAROMA) will be used to assess compliance. Following Week 3, participants will be provided with enough pills to titrate the dose of bupropion over a period of 4 days. Therefore, participants will receive bupropion pills 3 weeks plus 4 additional days to titrate down the dose.
214938811|NCT06533462|DIETARY_SUPPLEMENT|Multiallergen powder|OIT multiallergen powder.
214938812|NCT06474923|BEHAVIORAL|Face image and voice audio|Take photographs of the front, left and right side of the patient's face. Recording the patient's voice during doctor-patient communication.
214337516|NCT03395535|DRUG|Primary Medical Treatment Pathway|"Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
214337517|NCT02710630|DRUG|Dabigatran etexilate tablet E1|
214337518|NCT02710630|DRUG|Dabigatran etexilate tablet D1|
214337519|NCT02710630|DRUG|Dabigatran etexilate tablet C1|
214337520|NCT02710630|DRUG|Dabigatran etexilate tablet B1|
214337521|NCT02710630|DRUG|Dabigatran etexilate tablet A1|
214337522|NCT02710630|DRUG|Dabigatran etexilate capsule|
214337523|NCT02232529|DRUG|MIN-101|
214938813|NCT03315455|DRUG|Emicizumab|Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
214938814|NCT03711058|DRUG|Copanlisib|"Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV"
214938815|NCT03711058|DRUG|Nivolumab|"Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV"
214938816|NCT03991091|DRUG|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.
214938817|NCT03991091|DRUG|continuation of oxytocin administration|continuation of oxytocin administration
214938818|NCT06521554|DRUG|NVL-330|Oral Tablet of NVL-330
214938819|NCT05343481|BIOLOGICAL|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus immunotherapeutic
214938820|NCT05343481|BIOLOGICAL|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus immunotherapeutic
214938821|NCT05343481|BIOLOGICAL|Nivolumab|Human immunoglobulin G4 monoclonal antibody
214938822|NCT05441514|DRUG|Cobimetinib|Given PO
214337524|NCT02232529|DRUG|Placebo|
214337525|NCT02409485|BEHAVIORAL|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
214337526|NCT04790045|DRUG|Venetoclax|Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
214337527|NCT00036166|DRUG|FK463|
214337528|NCT06173817|DEVICE|isocapnic hyperventilation|isocapnic hyperventilation (iHV) increases the elimination of methanol to the extent that it could replace haemodialysis for elimination purposes when haemodialysis is not required for the correction of acidosis, and alcohol dehydrogenase (ADH) is completely blocked by an antidote.
214938823|NCT05441514|DRUG|Enasidenib Mesylate|Given PO
214938824|NCT03513770|OTHER|Wrist-to-elbow (W-E) occlusion|"An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated."
214938825|NCT03513770|DRUG|ketorolac tromethamine|In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( \~40-60 ml) will be infused into the occluded forearm at a rate of \~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.
214938826|NCT03513770|DRUG|saline control|In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
214938827|NCT06291415|DRUG|HMPL-523|Syk inhibitor
214938828|NCT05507931|DIETARY_SUPPLEMENT|1 Serving of broccoli sprouts|Participants will take 1 serving of broccoli sprouts daily for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
215073986|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
215073987|NCT05383443|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
214675573|NCT01513915|OTHER|Group cognitive behavioral intervention|A Group cognitive behavioral intervention \_based on parent training component of FRIENDS program\_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
214337529|NCT02461589|DRUG|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
214337530|NCT02461589|DRUG|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
214337531|NCT02461589|DRUG|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
214337532|NCT00426023|DRUG|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
214337533|NCT00426023|DRUG|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
214337534|NCT01259986|PROCEDURE|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
214337535|NCT01717235|DRUG|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
214337536|NCT04591834|OTHER|Observational|An observational study in subjects with the severe form of MPS II.
214337537|NCT06533124|DEVICE|The ultrasonic cardiac output monitor 1A system (USCOM Ltd., Sydney, Australia) is a non-invasive Doppler stroke volume (SV) technique derived from echocardiography.|In the USCOM + ultrafiltration group, cardiac output was monitored using a non-invasive ultrasonic cardiac output monitor, which employed transaortic or transpulmonary Doppler flow tracing and estimated the valve area using a patient's height to estimate their cardiac output. The monitored parameters include, SV index (SVI), SV variation (SVV), cardiac output (CO), cardiac index (CI), inotropy (INO), systemic vascular resistance index (SVRI), systemic vascular resistance (SVR), flow time corrected (FTC) and velocity time integral (VTI) .
214337538|NCT06390735|BEHAVIORAL|Mommy ReachOut Intervention|The momy reachOut intervention is a web-based psycho-education with 4 sessions, released over a two week period.
214337539|NCT01079221|BEHAVIORAL|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at \< 90 % of peak power, 3 days/week for 6 weeks
214337540|NCT01978119|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
214337541|NCT01978119|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
214337542|NCT03295201|OTHER|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
214675574|NCT00306891|DRUG|Cediranib|45 mg oral dose
214675575|NCT00306891|DRUG|Cediranib 30 - 90 mg|oral tablet dose escalation
214938829|NCT05507931|DIETARY_SUPPLEMENT|3 Servings of broccoli sprouts|Participants will take 3 servings of broccoli a day for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
214938830|NCT06246357|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PentixaFor will be injected intravenously approximately 60 minutes prior to scanning at a dose of 150 +/- 50 MBq (4 mCi +/- 1.4).
214938831|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (high-dose)|140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
214938832|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (low-dose)|140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
214938833|NCT06021223|OTHER|Placebo|140ml of placebo to be consumed daily for 2 weeks
214938834|NCT06131749|OTHER|No intervention|No intervention, observational cohort study
214938835|NCT06474767|BEHAVIORAL|P-CGS (Pediatric Collaborative Goal Setting)|Electronic questionnaire sent to participants ahead of a pediatric primary care well child visit, assessing goals for themselves and the child's health with prompt to share with providers during visit
214938836|NCT04775355|PROCEDURE|Biospecimen Collection|Undergo collection of stool and urine
214938837|NCT04775355|OTHER|Electronic Health Record Review|Medical records are reviewed
214938838|NCT04775355|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
214938839|NCT04775355|OTHER|Questionnaire Administration|Complete questionnaires
214938840|NCT06511193|DRUG|Budenoside/Glycopyrronium/Formoterol|Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria
214938841|NCT05685602|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
214938842|NCT05685602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214938843|NCT05685602|PROCEDURE|Computed Tomography|Undergo a CT scan
214938844|NCT05685602|BIOLOGICAL|Emavusertib|Given PO
214938845|NCT05685602|DRUG|Gemcitabine Hydrochloride|Given IV
214938846|NCT05685602|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214337543|NCT03295201|OTHER|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
214337544|NCT04908891|OTHER|Clinical Scapular protocol (ClinScaP)|the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS and healthy controls.
214337545|NCT04908891|OTHER|the prevalence of trunk, scapula and upper limb impairments.|To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.
214337546|NCT04908891|OTHER|the interaction between trunk, scapula and upper limb impairments.|To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.
214337547|NCT01224262|BIOLOGICAL|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)|A single vaccination of Fluzone alone
214938847|NCT05685602|DRUG|Nab-paclitaxel|Given IV
214938848|NCT05685602|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
214938849|NCT05685602|PROCEDURE|X-Ray Imaging|Undergo an x-ray
214938850|NCT06378268|DRUG|Dydrogesterone 10 mg|Dydrogesterone 10mg orally 2 times daily, starting on the day of gonadotropin injection to the oocyte maturation trigger night.
214938851|NCT06378268|DRUG|Cetrorelix 0.25 mg|Cetrorelix 0.25mg is injected subcutaneously once a day. It is given from day 5 or day 6 of stimulation by the oocyte maturation trigger day.
214337548|NCT01224262|BIOLOGICAL|LIQ001 (0.45mg)|A single vaccination of 0.45 mg LIQ001
214337549|NCT01224262|BIOLOGICAL|LIQ001 (1.8mg)|A single vaccination of 1.8 mg LIQ001
214337550|NCT05571943|DRUG|Difamilast|Difamilast Ointment 1%
214337551|NCT01465334|DRUG|Ofatumumab|
214337552|NCT01465334|DRUG|High-Dose Methylprednisolone|
214337553|NCT01465334|DRUG|Alemtuzumab|
214337554|NCT03495336|OTHER|coffee abstention phase|no coffee consumption for 2 weeks
214337555|NCT03495336|OTHER|LR Coffee consumption|for 4 weeks participants consumed only LR Turkish coffee
214337556|NCT03495336|OTHER|DR Coffee consumption|for 4 weeks participants consumed only DR Turkish coffee
214675576|NCT01757457|DRUG|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
214938852|NCT04847466|DRUG|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every 4 weeks (1 week after starting treatment with the PDL-1 CAR-NK cells).
214938853|NCT04847466|DRUG|Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30-minute IV infusion every 6 weeks. Pembrolizumab will be administered on the same day as the PD-L1 CAR-NK cells.
214938854|NCT04847466|BIOLOGICAL|PD-L1 t-haNK|PD-L1 CAR NK cells (2x109) will be administered by IV infusion over approximately 30 minutes every week. After the week 6 treatment, these cells will be given every 2 weeks.
214938855|NCT05713253|DEVICE|ELITA System|Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
214938856|NCT06394999|DRUG|Mifepristone 50 mg|Once-weekly oral mifepristone 50 mg
214938857|NCT06122779|DRUG|BMS-986435|Specified dose on specified days
214938858|NCT06122779|OTHER|Placebo|Specified dose on specified days
214938859|NCT06351566|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol), 1600 IU per day.
214938860|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics|Prebiotics (inulin), 10g per day.
214938861|NCT06351566|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
214938862|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics placebo|Prebiotics placebo, 10g per day.
215073988|NCT05383443|BEHAVIORAL|Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
214675577|NCT01757457|DRUG|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
214675578|NCT02367612|DIETARY_SUPPLEMENT|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
214938863|NCT05880680|DEVICE|SEAL Device|Using standard interventional endovascular techniques, the device is navigated via the push wire delivery system through compatible neurovascular microcatheters to the aneurysm lumen or target site. The device is positioned into its target aneurysm lumen and is electrically detached by the operator with a hand-held, battery-powered detachment handle designed specifically for the SEAL Embolization System.
214938864|NCT06512623|DEVICE|Hemoadsoprtion|The hemoadsorption treatment will be performed during the entire duration of the CPB. Blood flow within the cartridge is standardized at 250 ml/min.
214938865|NCT03030118|DRUG|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
214938866|NCT03030118|DRUG|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
214938867|NCT00001029|DRUG|Zidovudine|
215073989|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
214938868|NCT00001029|DRUG|Zalcitabine|
214938869|NCT00001029|DRUG|Didanosine|
214938870|NCT02170467|OTHER|assessment of the intestinal permeability|
214938871|NCT01903681|DRUG|Circadin 2 mg|First arm lower dose
214938872|NCT01903681|DRUG|Circadin 10 mg|Second arm higher dose
214938873|NCT04051099|PROCEDURE|Bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 16 ml)|bilateral superficial cervical plexus
215073990|NCT05383443|OTHER|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
214938874|NCT04051099|DRUG|Dexmedetomidine plus propofol infusion|Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion
215073991|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (once a week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
215073992|NCT05383443|BEHAVIORAL|Physical exercise|In-person group training (monthly): 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher.
214938875|NCT04051099|PROCEDURE|Local infiltraion analgesia|local infiltration analgesia with 2%lidocaine with adrenaline 5 ug/ml 10 ml
214938876|NCT04051099|PROCEDURE|General anesthesia with endotracheal tube|Induction with Propofol and intubation with cisatracurium
214938877|NCT05390463|OTHER|PERformance guided Fracture Rehablitation Method (PERFoRM) protocol.|A structured rehabilitation protocol for surgically treated peri-articular fractures of the upper extremity (proximal humerus and distal radius fractures).
214675579|NCT02367612|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
215073993|NCT05383443|BEHAVIORAL|Nutrition education|In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants. The participants will have the opportunity to consume the prepared meals at home.
215073994|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|In-person group 60-minute sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
214675580|NCT00673673|DRUG|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
214675581|NCT00673673|DRUG|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
215073995|NCT05383443|BEHAVIORAL|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
214675582|NCT02263365|DRUG|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
214938878|NCT05710094|DRUG|SoftOx Biofilm Eradicator (Groups 1 to 7)|SBE is a water-based formulation containing hypochlorous acid (HOCl) at concentrations of 500-1000 µg/mL and acetic acid (HAc) at concentrations of 1-3 %. Both active ingredients are naturally occurring molecules and have a long history of safe use in medicinal products and in solutions approved as medical devices. Both molecules, exhibit broad-spectrum antimicrobial activity at the concentrations present in SBE. The antimicrobial effect of HOCl is rapid and powerful by acting on and disrupting the function of key microbial molecules such as proteins, lipids, and nucleic acids, while remaining safe to mammalian cells and not promoting the emergence of new resistant microbes. Moreover, HOCl is active against biofilms, and some studies suggest that HOCl may also increase oxygenation of the wound site leading to improved healing.
214938879|NCT05710094|DEVICE|Sterile isotonic saline (Groups 1 to 4)|Sterile isotonic saline was used as placebo because it is part of standard of care, used as an irrigation solution at dressing change and has the same appearance as SBE
214938880|NCT05196113|BEHAVIORAL|sipIT|Participants receive education and digital tools to monitor their fluid intake and just-in-time text messages to remind them when they have lapsed in regular fluid intake.
214938881|NCT05399732|DRUG|Luspatercept|Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
214938882|NCT05399732|DRUG|Cyclosporine|Cyclosporine was administered at a 3-5 mg/(kd/d) and maintained at a 100-200 ng/ml trough plasma concentration.
214938883|NCT06153316|OTHER|School shooting incident|The school has experienced a gun shooting incident within the past 2 years of the study (for 3 case schools) and prior to 2 years (for 3 case schools). Incidents where a gun was displayed but no shot was fired, or where a shot was fired by police or security officer will not be included.
214938884|NCT01032070|DRUG|erlotinib|oral
214938885|NCT01032070|DRUG|etoposide|oral
214938886|NCT00937248|DEVICE|prone pillow and simple ankle fixation device|Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
214938887|NCT00937248|DEVICE|Customized Vacuum Immobilization Device (CVID)|This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
214938888|NCT05839184|DEVICE|therapeutic toy|Neonates in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
214938889|NCT02645552|DRUG|Tranexamic Acid|Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
214938890|NCT02645552|OTHER|Sodium chloride|Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
214938891|NCT05409430|DEVICE|Neurothrombectomy|"The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction.~The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion."
214675583|NCT03891277|DRUG|Ferrous succinate|"Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks."
214675584|NCT04345939|DIAGNOSTIC_TEST|Detection method|Different methods for pathogen diagnosis
214938892|NCT04858594|OTHER|Planned Chemotherapy|standard oncologic supportive care including antibiotic prophylaxis
214938893|NCT04405622|DRUG|Toripalimab plus gemcitabine|Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
214938894|NCT01541839|DEVICE|Septal Stapler|This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.
214938895|NCT03488225|DRUG|Cyclophosphamide|Given IV
214675585|NCT02435628|OTHER|Questionnaires|All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
214675586|NCT03078517|DEVICE|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
214675587|NCT03078517|DEVICE|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
214675588|NCT03115255|DRUG|intravitreal ranibizumab|0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
214675589|NCT03672617|OTHER|No treatment given|"No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion."
214938896|NCT03488225|DRUG|Cytarabine|Given IT or IV
214938897|NCT03488225|DRUG|Dexamethasone|Given IV or PO
214938898|NCT03488225|DRUG|Doxorubicin Hydrochloride|Given IV
214938899|NCT03488225|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214938900|NCT03488225|OTHER|Laboratory Biomarker Analysis|Correlative studies
214938901|NCT03488225|DRUG|Leucovorin Calcium|Given IV
214938902|NCT03488225|DRUG|Mercaptopurine|Given PO
214938903|NCT03488225|DRUG|Methotrexate|Given IT, IV or PO
214938904|NCT03488225|BIOLOGICAL|Ofatumumab|Given IV
214938905|NCT03488225|DRUG|Prednisone|Given PO
214938906|NCT03488225|BIOLOGICAL|Rituximab|Given IV
214938907|NCT03488225|DRUG|Vincristine Sulfate|Given IV
214938908|NCT03619824|DRUG|Sintilimab|Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
214675590|NCT01224899|PROCEDURE|Left cervico-thoracic sympathetic blockade|Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
214938909|NCT03619824|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
214675591|NCT04760795|OTHER|PTSD Check List (PCL) scale|PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.
214938910|NCT03619824|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
214337557|NCT06071000|BEHAVIORAL|Neuro-developmental stimulation (Neuro-vývojová stimulace).|Neuro-developmental stimulation is exercise based intervention program that is focused on repeating reflex movements and thus inhibiting reflexive response.
214337558|NCT02323919|BEHAVIORAL|SystemCHANGE|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
214337559|NCT02323919|BEHAVIORAL|CHANGE+|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
214675592|NCT04760795|OTHER|Brief COPE scale|Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.
214938911|NCT03619824|RADIATION|intensity-modulated radiotherapy|Definitive IMRT of 66-70Gy will be given in six to seven weeks.
214675593|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (during containment)|GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
214675594|NCT04760795|OTHER|Analog scale|Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
214938912|NCT00894790|DRUG|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
214675595|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (post containment)|GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.
214675596|NCT04760795|OTHER|Big Five Inventory (BFI) scale|Big Five Inventory (BFI) will be realized to evaluated personality.
214675597|NCT04760795|OTHER|Relationship Scales Questionnaire (RSQ)|Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.
214675598|NCT01804361|DRUG|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
214675599|NCT01804361|DRUG|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
214675600|NCT00018863|DRUG|Methylphenidate|
214675601|NCT03078985|PROCEDURE|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
214675602|NCT03078985|DEVICE|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
214938913|NCT00894790|DRUG|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
214938914|NCT06730802|DRUG|PCSK9 inhibitor|the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
214938915|NCT06730802|DRUG|Statin|the control group will receive standard statin therapy.
214938916|NCT02482064|OTHER|Flexible resin|This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
214938917|NCT05680506|PROCEDURE|Pain neuroscience education|Pain neuroscience education will be given in form videos,pictures, stories and metaphors for 2 times per week for 4 weeks.
214938918|NCT05680506|PROCEDURE|Standard Therapy|Hot pack,TENS, Kaltenborn grade 1 and 2 mobilizations, stretchings and lumbar stabilization exercises
214938919|NCT03203460|BEHAVIORAL|High-intensity aerobic interval training (HIIT)|A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
214337560|NCT02323919|BEHAVIORAL|Usual Care|Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
214938920|NCT05714475|PROCEDURE|Pancreas surgery|"Criteria~Inclusion Criteria:~* Isolated pancreatic metastases from Colorectal cancer~* Previous surgery for colorectal cancer~* Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas~pancreaticoduodenectomy total-pancreatectomy distal-pancreatectomy other metastases resection"
214938921|NCT04093492|OTHER|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
214938922|NCT04093492|OTHER|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
214938923|NCT04105894|DEVICE|MSCT of nose and PNs|MSCT of nose and PNs axial, coronal and sagittal cuts without contrast to evaluate the state of the sinuses at the beginning of evaluation and after 2 months duration of medical treatment for GERD
214938924|NCT04105894|DIAGNOSTIC_TEST|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin at the at the beginning of evaluation and after 2 months duration of medical treatment for GERD
214938925|NCT04105894|DRUG|medical treatment of GERD t|medical treatment of GERD only for 2 months as described by gastroenterology department
214938926|NCT00248144|DRUG|Famciclovir|
214675603|NCT00945191|DRUG|CS-1008|CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6
214675604|NCT00945191|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
214675605|NCT00945191|DRUG|Carboplatin|Carboplatin (target area under the concentration versus time curve of 6.0 mg/mL/min using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
214675606|NCT00165568|DRUG|Bevacizumab|
214675607|NCT01052285|PROCEDURE|Transversus abdominis plane block|UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
214675608|NCT01052285|PROCEDURE|Saline|UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
214337561|NCT00572572|DRUG|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
214337562|NCT00572572|DRUG|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
214675609|NCT01052285|PROCEDURE|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
214938927|NCT05480865|DRUG|BBP-398|BBP-398 administered orally
214938928|NCT05480865|DRUG|sotorasib|sotorasib administered orally
214938929|NCT05724108|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214938930|NCT05724108|PROCEDURE|Computed Tomography|Undergo CT
214938931|NCT05724108|DRUG|Lutetium Lu 177 Dotatate|Given IV
214938932|NCT05724108|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214675610|NCT02083250|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
214675611|NCT02083250|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
214675612|NCT02083250|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214675613|NCT02083250|DRUG|Busulfan|Given IV
214675614|NCT02083250|DRUG|Clofarabine|Given IV
214675615|NCT02083250|DRUG|Fludarabine Phosphate|Given IV
214675616|NCT02083250|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
214675617|NCT02083250|OTHER|Pharmacological Study|Correlative studies
214675618|NCT02083250|DRUG|Vorinostat|Given PO
214675619|NCT03048097|DRUG|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
214938933|NCT05724108|DRUG|Triapine|Given PO
214938934|NCT03005457|BEHAVIORAL|Hemiparesis Therapy with VR|An in-home therapist-as-consultant model of CI therapy in which motor practice with shaping and the Motor Activity Log with problem solving were delivered via a custom avatar-based video game called Recovery Rapids
214938935|NCT02110030|DEVICE|Transcutaneous nerve stimulation|"The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain."
214337563|NCT03395795|DEVICE|NAVA|"The study has 3 phases:~1. Phase 1:~   The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~2. Phase 2:~   Switch to NAVA mode (1h).~  * Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~  * NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~3. Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording."
214337564|NCT01831089|DRUG|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
214337565|NCT01480700|OTHER|Nutritional study|subjects consume 2 eggs per day during 4 months
214938936|NCT02110030|DEVICE|Interferential Currents|"The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and V deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain)."
214938937|NCT02370030|DIETARY_SUPPLEMENT|Citrulline malate|Active comparator: 10 g/day citrulline malate during 7 days
214938938|NCT01053130|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
214938939|NCT01053130|BEHAVIORAL|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
214938940|NCT02303990|DRUG|Pembrolizumab|
214938941|NCT02303990|RADIATION|Radiotherapy|
214938942|NCT06433934|DEVICE|Oxy2mask|Open design oxygen mask
214938943|NCT05031637|BEHAVIORAL|treatment of BP by using night-time BP|titration of BP medications to target according to night-time SBP
214938944|NCT05031637|BEHAVIORAL|treatment of BP by using daytime BP|titration of BP medications to target according to daytime SBP
214938945|NCT03102307|OTHER|Not suitable for TAD|Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done
214938946|NCT03102307|PROCEDURE|Suitable for TAD|Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
214938947|NCT00848978|BEHAVIORAL|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity \~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
214938948|NCT05156645|DRUG|SCTA01 and SCTA01C|Diluted by 0.9% normal saline
214675620|NCT03048097|DRUG|Rubidium|used in PET scans
214938949|NCT05156645|DRUG|Placebo|Diluted by 0.9% normal saline
214337566|NCT00363714|DRUG|AGN211745|100microgram single intravitreal injection
214337567|NCT00363714|DRUG|AGN211745|200microgram single intravitreal injection
214337568|NCT00363714|DRUG|AGN211745|400microgram single intravitreal injection
214337569|NCT00363714|DRUG|AGN211745|800microgram single intravitreal injection
214337570|NCT00363714|DRUG|AGN211745|1200microgram single intravitreal injection
214938950|NCT04130048|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography aims to assess the stiffness of a tissue, submitting it to an ultrasound impulse.
214938951|NCT05220748|COMBINATION_PRODUCT|RM-1995|RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts
214938952|NCT05220748|BIOLOGICAL|Pembrolizumab|Pembrolizumab (200 mg) will be administered by intravenous (IV) infusion one week before the first RM-1995 PIT treatment and the second dose three weeks later for patients in the combination arm. Once the DLT window is complete, pembrolizumab dosage will be maintained at either 200 mg Q3w, or shift to 400 mg Q6w, per investigator discretion.
214938953|NCT01537016|DEVICE|PROMOGRAN|PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
214938954|NCT01537016|DEVICE|Tielle|Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
214938955|NCT06412458|BIOLOGICAL|IM83 CAR-T Cells|IM83 CAR-T Cells, 5×10\^8 cells, 1×10\^9 cells, and 2×10\^9 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
214938956|NCT05289024|BEHAVIORAL|Mindful Awareness in Body-Oriented Therapy|Up to 8 individually delivered clinical sessions
214938957|NCT05949541|DRUG|Everolimus 10 mg|Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
214938958|NCT05949541|DRUG|CDK4/6 Inhibitor SHR6390|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
214675621|NCT03048097|DIAGNOSTIC_TEST|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
214938959|NCT05949541|DRUG|Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
214938960|NCT00958607|BEHAVIORAL|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care \& by telephone during inpatient rehabilitation and community discharge. SSP provides support, information \& guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
214938961|NCT00958607|BEHAVIORAL|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
214938962|NCT00627809|DRUG|Streptokinase|intracoronary infusion, 250.000 Units
214938963|NCT00627809|PROCEDURE|primary percutaneous coronary intervention|balloon catheter, stent
214938964|NCT04394793|RADIATION|Low dose radiation therapy|Patient will be treated with a dose of 70 cGy in one fraction radiation therapy in addition to standard therapy
214938965|NCT04150302|OTHER|Exploratory interviews|Exploratory interviews to generate an interview guide
214938966|NCT04150302|OTHER|Semi-directive interviews|Semi-directive interviews to collect qualitative data that will be used for questionnaire item generation
214675622|NCT05585385|DEVICE|Backward Walking Training|The subjects in this group will receive BW training program on an electric treadmill. The subject will be asked to walk, arms beside, in a backward manner on a level treadmill, zero inclination, with a warming up and cooling down period (5 minutes for each period). The subject walks at his self-selected and comfortable walking speed. A warm-up and cool-down period, in form of light jogging on a treadmill, will be done at speed of 1-2 m/sec. The total training is 30 minutes, three times a week for six consecutive weeks.
214675623|NCT05585385|DEVICE|Balance Training|"Subjects in this group will receive balance training on Biodex Balance System for 3 sessions/ week, over 6 weeks period. Each subject will be instructed to stand with both legs on the locked platform. The researcher advances the platform to an unstable state while instructing the subject to focus on the visual feedback screen. Arms are free at the side of the body and not grasping handrails.~After selecting the stability training program (dynamic balance training), Stability levels are changed depending on the subject's ability to maintain balance, and subjects are instructed to maintain their Center of Pressure (COP) in the smallest concentric rings (balance zones) of the Biodex Balance System monitor, named A zone.~The stability level of the platform is set at level plate stability 8 (the most stable) for the first two sessions. After that, the plate stability is decreased by one level every two sessions to increase the difficulty in training."
214675624|NCT05585385|OTHER|Conventional treatment|Patients in this group will receive the traditional physical therapy program only for 3 sessions/ week, over 6 weeks period. The traditional physical therapy program is (evertors strengthening, short foot ex, heel raise ex, and calf stretch).
214675625|NCT02937610|PROCEDURE|percutaneous endoscopic gastrostomy|PEG tube inserted with pull technique
214675626|NCT05313919|DIAGNOSTIC_TEST|Comprehensive functional diagnostics of coronary circulation|"Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~* echocardiography with assessment of diastolic function~* flow-mediated dilation of brachial artery~* coronary angiography~* functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~* provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~* laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~* serum level of inflammatory cytokines and chemokines"
214938967|NCT04150302|OTHER|Delphi Process|Cotation of newly developed items pertinence on a 4 points likert scale.
214938968|NCT04150302|OTHER|Think aloud interviews|Debriefing session for the newly developed items: final possibility to adjust the tool before validating the psychometric proprieties of the questionnaire.
214938969|NCT04150302|OTHER|Psychometric validation|Psychometric properties study
215073996|NCT05476237|BEHAVIORAL|Group Interpersonal Therapy for Adolescents (IPT-AG)|IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.
215073997|NCT05476237|BEHAVIORAL|Treatment as Usual (TAU)|Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
215073998|NCT04907773|OTHER|Capillary blood sampling|Each subject will have one to two capillary blood collections.
215073999|NCT04907773|OTHER|Venous blood sampling|Each healthy subject will also have a reference venous blood collection.
214337571|NCT00363714|DRUG|AGN211745|1600microgram single intravitreal injection
214337572|NCT00422539|DRUG|70% trichloroacetic acid|
214337573|NCT01058200|DEVICE|iCup|new vacuum extractor: sterile disposable plastic cup
214337574|NCT01058200|DEVICE|reference cup|reference cup of the obstetrical ward: metallic cup
214337575|NCT00664144|DRUG|Rasburicase (SR29142)|
214938970|NCT01197170|DRUG|Anastrozole|1 mg by mouth daily of a 28 day cycle.
214938971|NCT01197170|DRUG|Bevacizumab|Starting dose 10 mg by vein on day 1 of a 21 day cycle.
214938972|NCT01197170|DRUG|Everolimus|Starting dose 5 mg by mouth daily for a 28 day cycle.
214938973|NCT01197170|DRUG|Sorafenib|Starting dose 200 mg by mouth twice a day of a 28 day cycle.
214938974|NCT01197170|DRUG|Erlotinib|Starting dose 75 mg by mouth daily for a 28 day cycle.
214938975|NCT02476370|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week programm, one introductory session and daily home practice"
214938976|NCT02476370|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
214938977|NCT01277809|BEHAVIORAL|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
214675627|NCT06389370|OTHER|HU-DBI questionnaire|a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.
214675628|NCT01004107|DEVICE|Radiesse Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
214675629|NCT04542291|DRUG|Dapagliflozin|Dapagliflozin will be provided for this trial
214675630|NCT04542291|DEVICE|BIOSENSE meters|-Being used in this trial to evaluate utility for assessing breath ketones
214675631|NCT01716260|DRUG|Chloroquine|
214675632|NCT01716260|DRUG|Primaquine|
214675633|NCT01258829|OTHER|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
214675634|NCT01258829|OTHER|ECHO optimisation|Standard ECHO optimisation method
214675635|NCT05064345|DRUG|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
214675636|NCT05064345|DRUG|Placebo|Palcebo
214938978|NCT01277809|BEHAVIORAL|Walking Program|Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
214938979|NCT04016246|DRUG|Propofol-Lipuro|sedation of babies \< 32wGA with propofol / placebo before a LISA Procedure
214938980|NCT04016246|DRUG|Placebos|injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
214337576|NCT00013793|BEHAVIORAL|Motivational enhancement and ultrasound|
214337577|NCT01958918|DRUG|Ranibizumab|0.5 mg intravitreal injection
214337578|NCT01958918|DRUG|Aflibercept|2 mg intravitreal injection
214337579|NCT05954897|DRUG|Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC|RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
214938981|NCT00588081|BEHAVIORAL|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
214938982|NCT02669914|DRUG|MEDI4736|
214938983|NCT04728555|PROCEDURE|Game about radiotherapy|A digital pedagogical game about radiotherapy
214938984|NCT04800614|DRUG|sitravatinib|100 mg sitravatinib on Day 1 of each of 3 periods
214938985|NCT04878458|PROCEDURE|phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
214938986|NCT04878458|PROCEDURE|phacoemulsification with intraocular lens implantation combined with trabeculectomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
214938987|NCT01857700|OTHER|Compensation for transport cost|
214938988|NCT01857700|OTHER|Compensation for lost wages|
214938989|NCT01857700|OTHER|Compensation for transport cost and lost wages|
214938990|NCT01857700|OTHER|Standard of Care|Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
214938991|NCT03650296|DEVICE|ePER vs PS vs PaedER|see detailed description of methods
214938992|NCT05366218|BIOLOGICAL|Tafasitamab|Antibody vaccination
214938993|NCT03539185|DEVICE|Videolaryngoscope Airtraq|Awake orotracheal intubation with laryngeal nerve block and remifentanil sedation
214337580|NCT01925183|DRUG|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
214337581|NCT01925183|DRUG|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally
214337582|NCT01925183|DRUG|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
214337583|NCT02114892|DRUG|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
214337584|NCT02114892|DRUG|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
214938994|NCT03539185|DEVICE|Fiberoptic bronchoscope|Awake nasotracheal intubation with laryngeal nerve block and remifentanil sedation
214938995|NCT04365478|PROCEDURE|Radial Extracorporeal Shock Wave Therapy|rSWT group: One radial shock wave therapy session a week for 8 weeks (parameters: 1.5 bar, 10 Hz, 2000 shots for each muscle group treated) administered daily during the morning for 40 minutes of conventional rehabilitation treatment.
214675637|NCT04095910|BEHAVIORAL|Planet Nutrition program|"1. \- Nutritional education sessions: The study team previously worked on the development of a handbook called Planet Nutrition which contains around 26 topics of nutrition and health. Interns from the Nutritional Sciences Degree of the University of Sonora implemented the sessions. 2 classes of 1 hour were given weekly, adding 18 sessions in total, during regular school hours. The program contemplates the establishment of different objectives.~2. \- Physical activity: The classes were designed and implemented by interns from the Bachelor of Physical Culture and Sport from the University of Sonora along with a teacher from the study team. 3 weekly sessions of 1 hour were provided. The activities were held on the schoolyard court during normal school hours, independent of the physical activity classes of the school.~3. \- Indirect family participation: Six information brochures with different nutrition and health topics were sent to parents."
214675638|NCT03760380|DEVICE|Sole 1 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.
214337585|NCT01392352|DRUG|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
214337586|NCT00277264|DRUG|Tiotropium (Spiriva®)|
214337587|NCT01881451|DRUG|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
214337588|NCT01881451|PROCEDURE|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
214337589|NCT02084953|DRUG|BMS-791325|
214675639|NCT03760380|DEVICE|Sole 1 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
214675640|NCT03760380|DEVICE|Sole 2 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.
214675641|NCT03760380|DEVICE|Sole 2 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
214675642|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
215074000|NCT04907773|OTHER|Arterio-venous blood sampling|Each hemodialysed subject will also have a reference arterio-venous blood collection.
215074001|NCT04324996|BIOLOGICAL|NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells|The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
215074002|NCT03539211|OTHER|Rotation Exercises|The subjects received 7 trunk rotation stability exercises x 10 reps each
215074003|NCT03539211|OTHER|Control Exercises|The subjects received 7 traditional exercises x 10 reps each
214675643|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + soybean oil|Meal containing canned tuna + soybean oil
214675644|NCT04338945|BEHAVIORAL|COVID-surgRES questionaire|The questionaire gives a multidimensional assessment of residents' impression with regard to impact of COVID emergency on Italian specialist training programs
215074004|NCT03273647|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
215074005|NCT05097651|DRUG|Cannabidiol oral solution|Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.
214675645|NCT01746992|DRUG|Cyclophosphamide 750mg/m2|day 1 in both arms
214675646|NCT01746992|DRUG|Vincristine 1.4mg/m2|day 1
214675647|NCT01746992|DRUG|Doxorubicin 50mg/m2|day 1
214675648|NCT01746992|DRUG|prednisone 60mg/m2|day1-day5
215074006|NCT05097651|DRUG|Inert sesame seed oil|Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.
214675649|NCT01746992|DRUG|ifosfamide 2000mg/m2|day 22-day 24
214675650|NCT01746992|DRUG|pirarubicin 50mg/m2|day 1
215074007|NCT03822455|DRUG|OligoG DPI|OligoG Dry Powder for Inhalation
214675651|NCT01746992|DRUG|pirarubicin 25mg/m2|day 22
214675652|NCT01746992|DRUG|Etoposide phosphate 100mg/m2|day 22-day 24
214675653|NCT01746992|DRUG|methotrexate 1500mg/m2|day 43
214675654|NCT00148590|DRUG|Memantine|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
214337590|NCT02084953|DRUG|Moxifloxacin|
214337591|NCT02084953|DRUG|Placebo matching BMS-791325|
214337592|NCT00162851|DRUG|alemtuzumab|
214675655|NCT00148590|DRUG|Placebo|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
214675656|NCT01748695|DRUG|V158866|
214675657|NCT01748695|DRUG|Placebo|
214675658|NCT00970294|BEHAVIORAL|Health Promotion Program|10 week health promotion program 3-4 times per week
215078025|NCT05076916|BEHAVIORAL|The effectiveness of the web-based education programme among cancer patients|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
214337593|NCT05156229|BIOLOGICAL|CDK-003|CDK-003 administered subcutaneously
214938996|NCT04365478|PROCEDURE|Conventional physiotherapy|Control group: 40-minutes of conventional rehabilitation treatment 5 days per week in the morning (strength exercise, trunk control exercise, stretching exercise, occupational therapy, and neurodevelopmental facilitation techniques) for 8 weeks
215074008|NCT05285215|PROCEDURE|Integrated psychological program (IPP)|"Patients will listen to the music for 30 minutes before delivery, and resume music listening once they are comfortable after delivery. Upon discharge, they will be asked to have music listening at least 30 minutes per day until 8 weeks postnatal survey.~Mindfulness training via mobile application is administered before delivery. After delivery, they are asked to perform mindfulness training for 10 minutes daily, until last follow-up at 8 weeks post-delivery.~Mobile electronic survey will be used to assess patients' EPDS scores fortnightly, until the last follow-up at week 8 post-delivery. If the EPDS scoring is found to be equal to or more than 10, video counselling and/or face-to-face consultation will be arranged.~Video counselling sessions will be offered if patients are found to have EPDS score of 10-12. For women found to have EPDS≥13, a face-to-face initial psychiatry consultation will be conducted."
214337594|NCT01542112|OTHER|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
214337595|NCT01542112|OTHER|No treatment|Patients in this arm receive the usual routine in the department.
214337596|NCT04327934|DRUG|GnRH antagonist|GnRH antagonist up to 16 days.
214938997|NCT00503997|DRUG|oxaliplatin|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
214337597|NCT04327934|DRUG|GnRH antagonist + MethylTESTOSTERone 5 MG|GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
214938998|NCT00503997|DRUG|pemetrexed disodium|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
214938999|NCT00001569|DRUG|Cisplatin|
214939000|NCT00001569|DRUG|Paclitaxel|
214939001|NCT00001569|DRUG|5-FU|
214939002|NCT06361615|OTHER|Single-Task|Single-task (ST) training group developed an exercise program based on Functional Exercise Circuit (FEC) protocol. This exercise program has been published previously12, which considered 15 different exercises in a functional exercise circuit.
214939003|NCT06361615|OTHER|Dual-Task|DT training (multicomponent physical exercise + cognitive tasks)
214337598|NCT04239534|DEVICE|Convergence Of Epicardial And Endocardial RF Ablation|The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
214337599|NCT05294263|DRUG|Varenicline|Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
214337600|NCT05294263|DRUG|Placebo|Matching, inactive medication
214337601|NCT06072066|DIETARY_SUPPLEMENT|Skin Barrier Oral Supplement|Supplment powder
214939004|NCT02035397|DRUG|Botulinum Toxin Type A|
214939005|NCT02035397|DRUG|Saline solution|
214347325|NCT02897804|BEHAVIORAL|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214675659|NCT05717738|PROCEDURE|TACE|Procedure of TACE is standardized.
214939006|NCT01195844|BIOLOGICAL|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children \< 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
214939007|NCT06071572|OTHER|Biological samples collected specifically for the IBD Biobank|Biological samples will include: material intestinal biological waste (surgical leftover), 30 ml of peripheral blood, one sample stool standards and a saliva sample.
215078026|NCT03167970|DEVICE|Pill cam|Patient is asked to swallow the esophageal capsule.
215078027|NCT03167970|OTHER|EGD|Patient will undergo standard EGD
215078028|NCT02545517|BIOLOGICAL|Rabipur|Participants in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm.
215078029|NCT02545517|PROCEDURE|Blood sampling|Blood samples were drawn from all participants at Day 1 and then at subsequent year intervals from extension study Day 1 onwards.
215078030|NCT02545517|BIOLOGICAL|Purified Chick-Embryo Cell Rabies Vaccine|1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM).
214939008|NCT04510389|DIETARY_SUPPLEMENT|Maltodextrin|Bariatric patients with or without sarcopenia receiving maltodextrin
214939009|NCT04510389|DIETARY_SUPPLEMENT|Whey|Bariatric patients with or without sarcopenia receiving whey protein
214939010|NCT03745040|DRUG|Liposomal bupivacaine|20ml bupivacaine liposome injectable suspension 1.3% (266mg) + 50ml 0.25% Bupivacaine (150mg) + 70ml preservative-free 0.9% neutral saline
214939011|NCT04414189|DIAGNOSTIC_TEST|HostDx Sepsis|Blood collection for mRNA analysis
215074009|NCT03782207|DRUG|Atezolizumab|Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
214675660|NCT05717738|DRUG|Lenvatinib|8mg; p.o.; q.d.
214939012|NCT00240825|DRUG|Ibuprofen|
214675661|NCT05717738|DRUG|Anti-PD-1 monoclonal antibody|Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
214675662|NCT05717738|DRUG|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
215074010|NCT03324529|DEVICE|Tako Breath|Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (\<10 breaths/min) with prolonged exhalation.
215074011|NCT02745067|BEHAVIORAL|enhanced cognitive behavioral therapy|
214675663|NCT05717738|DRUG|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
214337602|NCT03528330|DEVICE|Rehabilitation with dental implant with internal hexagon connection|"All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
214337603|NCT03528330|DEVICE|Rehabilitation with dental implant with conical connection|"All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
214675664|NCT05717738|DRUG|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
214675665|NCT05717738|DRUG|Sorafenib|400mg; p.o. bid
214675666|NCT05717738|DRUG|Donafenib|200mg; p.o. bid
214939013|NCT00240825|DRUG|Placebo|
214675667|NCT05717738|DRUG|Regorafenib|160 mg; p.o.; q.d.
215074012|NCT02178852|DEVICE|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
214675668|NCT00307229|BIOLOGICAL|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
214675669|NCT03235908|OTHER|Observation only|Observation only
215074013|NCT06183294|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
214675670|NCT04783207|DIETARY_SUPPLEMENT|Mitopure|Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily
214675671|NCT04783207|DIETARY_SUPPLEMENT|Placebo|Softgel containing only excipients. 4 soft-gels to be taken daily
214675672|NCT00847561|BEHAVIORAL|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
214939014|NCT00240825|DRUG|Acetaminophen|
214939015|NCT05170230|DRUG|Terlipressin|intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy
214939016|NCT05833828|PROCEDURE|on-pump surgery|"the surgery will be performed on-pump"
214939017|NCT05833828|PROCEDURE|off-pump surgery|"the surgery will be performed off-pump"
214939018|NCT05385224|DIAGNOSTIC_TEST|PillSense|The PillSense System is intended to detect the presence of blood in the stomach for the evaluation of upper gastrointestinal bleeding.
214939019|NCT01910220|DRUG|REGN1033 (SAR391786)|
214939020|NCT01910220|OTHER|placebo|
214939021|NCT00776802|DRUG|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
214939022|NCT00776802|DRUG|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
214939023|NCT02733575|OTHER|Compassion Focused Therapy|Up to 26 sessions of Compassion Focused Therapy
214939024|NCT01846468|DRUG|LHW090|1 mg, 12.5 mg, 100 mg capsules
214939025|NCT01846468|DRUG|Placebo|Matching placebo capsules
215074014|NCT00709293|DRUG|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
215074015|NCT00709293|DRUG|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
215074016|NCT01124123|DRUG|Bilastine|20 mg oral tablet
215074017|NCT01124123|DRUG|Bilastine|10 mg endovenous bilastine
215074018|NCT01083979|DRUG|Liposomes|Intravesical instillation
214337604|NCT00501449|BEHAVIORAL|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
214939026|NCT00551161|DRUG|memantine|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
214939027|NCT03516006|DRUG|UCMSC|infusion of aUCMSC at day 0, 7, 14, and 21
214939028|NCT03516006|DRUG|UDCA|oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d
214939029|NCT06529172|OTHER|Resistance training|RG performed RT with an elastic band (yellow, force of 9-11 pounds when stretched twice the original length). They performed eight movements. Each movement was performed for 3-5 sets at 8 times/sets with 30 s of rest between groups. The movements included upright rows, reverse curls, standing shoulder rotations, neck-elbow extensions, elbow bends, downward lunges, standing leg lifts, side lifts and standing back kicks. All participants completed the RT movements according to the regular rhythm (1-2-1) provided by the experimenter, which ensured that all participants had similar movements completion rates.
214939030|NCT06529172|OTHER|Yijinjing|YG performed 12 movements . These movements included extending the hands upwards and slowly lowering them; extending the torso by stretching the hands straight up and bending the body to the left or right; squatting with the hands on the knees and standing up slowly; bending the body to the left or right side, extending the arms and waist; getting down on the knees, leaning forward, extending the hands forward and slowly pulling them back; bending forward, placing the hands around the knees and standing up slowly; placing the hands on the hips; and leaning back to stretch the back and waist.
214939031|NCT06529172|OTHER|Baduanjing|BG performed eight movements . These movements included holding the hands straight up, slowly bringing the hands down and turning the waist while in a standing position; bending the body to the left or right side and extending the arms; extending one hand straight up, placing the other hand on the waist, then switching arms and repeating the movement; tilting the head back and looking back while stretching the neck and back; squatting the body, swinging the head and hips from side to side and moving the spine and waist; bending the body forward, touching the hands to the toes and standing up slowly; making fists with the hands and moving the arms and shoulders; and gently bouncing the body to relax the whole body in a standing position.
214939032|NCT06529172|OTHER|Control|The CG group maintained their original lifestyle without engaging in regular exercise
214337605|NCT03427372|BEHAVIORAL|anxiety scale, depression scale|post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
214337606|NCT03525834|DRUG|Everolimus|Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
214337607|NCT01223079|DRUG|r-hFSH|r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
214337608|NCT01223079|DRUG|r-hFSH and r-hLH|Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
214337609|NCT04886921|BEHAVIORAL|Abdominal muscle training|Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
214337610|NCT02960880|DRUG|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
214337611|NCT02960880|DRUG|Phenprocoumon (branded and generics)|Individually adjusted dose
214337612|NCT06573710|DEVICE|sonic activator|Polyamide EDDY tips 28mm long is inserted in the canal 2mm short of the working length operated at 6,000 Hz. Activation is done for three cycles each for 20sec. The tip is moved vertically in up and down motion, 1ml is used for each activation cycle followed by 2ml 17% EDTA20
214337613|NCT06573710|DEVICE|LASER activation|Diode laser 980nm is used to activate the irrigant using fiber optic tip of (200micrometer) and power of 1.5w continuous mode. The tip is placed 2 mm shorter than the working length. Laser irradiation is done for each canal for 20 secs repeated over three cycles for total time of 60 secs and 10 secs pauses between each cycle
214337614|NCT06573710|DEVICE|Ultrasonic activation|ED60tip is used with ultrasonic device operated on mode E and inserted in the canal 2mm short of the working. Activation is done for three cycles each for 20 sec. The tip is moved vertically in up and down motion,1ml is used for each activation cycle followed by 2ml 17% EDTA
214337615|NCT06573710|DEVICE|passive irrigation with Endodontic needle|Each canal is irrigated with side vented endodontic needle 30G Placed 2mm short of the working length with total time of 60 secs followed by 2ml 17% EDTA
214337616|NCT05371210|OTHER|SAIF|Participants interacted with SAIF system at least 2-3 times per week; each session took up to 20 minutes.
214337617|NCT01202838|DEVICE|Composite Implant|Subjects receiving composite implants
214939033|NCT05547061|DRUG|Lu-177-DGUL|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
214939034|NCT05547061|DRUG|Ga-68-NGUL|Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.
214939035|NCT05369494|OTHER|Hydrolyzed protein infant formula with oligosaccharides|Hydrolyzed protein infant formula with oligosaccharides
214939036|NCT03566875|PROCEDURE|Total knee arthroplasty with the Stryker's MAKO™ system|The robot assisted surgery is performed using the Stryker's MAKO™ system. The precision with this system is very accurate. It should help the surgeon to improve the positioning accuracy of prosthetic implants compared to the conventional method.
214939037|NCT03566875|PROCEDURE|Total knee arthroplasty with mechanical ancillary|The arthroplasty is performed with the mechanical ancillary refering to the the conventional method.
214939038|NCT04632056|DRUG|Beovu|There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study were enrolled.
214337618|NCT03206021|DRUG|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
214337619|NCT04611997|DRUG|Indocyanine Green|Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
214337620|NCT00390390|DRUG|Lansoprazole|
214337621|NCT05933915|OTHER|group-based laughter yoga|"Midwives in the intervention group of the research will apply 8 sessions of laughter yoga, 2 sessions a week. Laughter yoga will be practiced by researchers with leadership certification. Each session will take an average of 45 minutes. Laughter Yoga sessions will be held on the web through the Zoom program. Each session will consist of groups of 8 people."
214337622|NCT04133935|PROCEDURE|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
214939039|NCT02897388|OTHER|breast milk consume promotion|(1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling \& promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
214939040|NCT00477997|DEVICE|Physiological Bolus of Growth Hormone|0,5 mg Norditropin
214939041|NCT02100137|OTHER|vaginal ultrasound|vaginal ultrasound performed at a routine gyn examination
214939042|NCT00096993|DRUG|Placebo|Placebo was provided as a single-use formulation for infusion.
214939043|NCT00096993|DRUG|Gemcitabine|Gemcitabine was provided as a solution for infusion.
214939044|NCT00096993|DRUG|Pertuzumab|Pertuzumab was provided as a single-use formulation for infusion.
214939045|NCT03040505|OTHER|questionnary|Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
214939046|NCT02658383|OTHER|Cleaner cookstove received after visit 2|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).
214939047|NCT02658383|OTHER|Cleaner cookstove received after visit 4|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
214939048|NCT00231283|DEVICE|CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
214939049|NCT00287677|BIOLOGICAL|recombinant human Growth Hormone|Growth Hormone during 6 months (30UG/KG/DAY)
214939050|NCT00287677|BIOLOGICAL|Vaccination|Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
214337623|NCT04133935|PROCEDURE|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
214337624|NCT02998294|DEVICE|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
214939051|NCT00287677|DRUG|HAART|HAART all over the trial
214939052|NCT00772005|DRUG|armodafinil|150 mg/day armodafinil
214939053|NCT00772005|DRUG|placebo|placebo
214939054|NCT00772005|DRUG|armodafinil|200 mg/day armodafinil
214939055|NCT00772005|DRUG|armodafinil|250 mg/day armodafinil
214675673|NCT00847561|BEHAVIORAL|Information Monitoring|Packet providing information on strategies for coping with anxiety
214675674|NCT03899740|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
214337625|NCT02998294|DEVICE|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
214337626|NCT01159301|DRUG|entinostat|Given orally (PO)
214337627|NCT01159301|DRUG|sorafenib tosylate|Given PO
214337628|NCT01159301|OTHER|pharmacological study|Correlative studies
214337629|NCT01159301|OTHER|laboratory biomarker analysis|Correlative studies
214337630|NCT03095417|BEHAVIORAL|Physical Exercise Intervention|In home exercise intervention.
214675675|NCT03899740|OTHER|Ranking - Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
214675676|NCT03899740|OTHER|Ranking - Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
214939056|NCT03280225|OTHER|External facilitation|"Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation."
214939057|NCT01828216|DEVICE|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
214939058|NCT01828216|DEVICE|conventional polysomnography|conventional type I sleep study according to international guidelines
214939059|NCT06261541|DEVICE|ABLE Exoskeleton|Participants with MS will undergo a training program with the ABLE Exoskeleton device: a total of 10 sessions, distributed 1-2 sessions/week for up to 11 weeks.
214939060|NCT04420819|DEVICE|Ischemic Preconditioning|The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff
214939061|NCT06482333|OTHER|Time for resumption of DOAC|Time for resumption of DOAC
214939062|NCT00316407|DRUG|lapatinib (GW572016)|1000 mg po qd
214939063|NCT00316407|DRUG|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
214939064|NCT00316407|DRUG|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
214939065|NCT03030885|DRUG|131I-MIP-1095|"First Therapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
214939066|NCT02379507|OTHER|DEC033 Study Product|Apply twice daily
214939067|NCT01159288|BIOLOGICAL|Dex2|"* Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.~* Induction immunotherapyIntradermal injections of Dex once a week during 4 consecutive weeks.(Peptides pulsed onto DC, sources of Dex: PRS pan-DR, MAGE-3 DP04, MAGE-1 A2, MAGE-3 A2, NY-ESO-1 A2 et MART-1 A2)~* Continuation Immunotherapy: Intradermal injections of Dex every two weeks during 6 weeks."
214939068|NCT05679180|DEVICE|micropulse laser|treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
214337631|NCT03095417|BEHAVIORAL|Cognitive Training Intervention|Online cognitive training modules.
214337632|NCT03095417|BEHAVIORAL|Stretching Control|In home stretching.
214337633|NCT03095417|BEHAVIORAL|Cognitive Control|Online control puzzles and games.
214337634|NCT03120975|OTHER|Computerized decision support and audit & feedback|"* suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~* mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~* suggestion of standard antimicrobial treatment duration according to indication"
214337635|NCT03120975|OTHER|Audit & Feedback|\* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
214337636|NCT03120975|OTHER|Standard antibiotic stewardship|"* Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)"
214337637|NCT04071873|DIAGNOSTIC_TEST|Point-of-care HIV testing|Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
214337638|NCT04071873|BEHAVIORAL|HIV testing education|Participants will be provided with education on community based HIV resources.
214337639|NCT01405157|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
214939069|NCT01836991|PROCEDURE|surgery|
214939070|NCT02338466|DRUG|rt-PA|0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
214675677|NCT03899740|OTHER|Ranking - Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
214675678|NCT00233571|BIOLOGICAL|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
215074019|NCT03650803|DEVICE|3D MR Fingerprinting scan|"3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast.~MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan."
214675679|NCT00006072|DRUG|Rituxan|
214675680|NCT02620540|DEVICE|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
215074020|NCT06539858|OTHER|massage|General back massage from the base of the neck to the sacrum. Classical massage techniques such as stroking and kneeding will be applied. To be performed by a specialist physiotherapist.
214337640|NCT01405157|DRUG|methylprednisolone|tablets 16 mg single dose
214337641|NCT04118621|DEVICE|chest ultrasound|detection of postoperative pulmonary complications after cardiothoracic surgery
214337642|NCT03022851|DEVICE|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
214337643|NCT06396728|DIETARY_SUPPLEMENT|GI BIOTICS 100B UFC|Consumption of GI BIOTICS 100B UFC.
214337644|NCT06396728|DIETARY_SUPPLEMENT|Placebo Consumption|Consumption of a placebo capsule.
214337645|NCT02755493|BEHAVIORAL|Sleep deprivation|
214337646|NCT06515860|DIAGNOSTIC_TEST|Liquid biopsy for MPNST development|Participants will be asked to complete a blood sample (liquid biopsy) at baseline (15 mL, approximately 1 tablespoon) and every 6 months (10 mL) for the five-year follow-up period.
214337647|NCT06073405|DEVICE|Colonic Polyp Measurement Assessment Via Artificial Intelligence|In this study, we collect colonoscopy video clips of polyps and, among the related clinical information, their estimated size using the gold standard technique, and we use them offline to evaluate the measurement performances of the novel virtual polyp sizing tool
214337648|NCT05038488|DRUG|MIB-626|Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
215074021|NCT00979342|DEVICE|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
214337649|NCT05038488|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
214347326|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
214675681|NCT00408681|DRUG|lithium carbonate|Given orally
214675682|NCT00408681|OTHER|laboratory biomarker analysis|Correlative studies
215074022|NCT02965742|DEVICE|Stratos|A machine made by DMS group.
215074023|NCT02965742|DEVICE|"Hologic QDR 4500A"|A machine made by Hologic inc.
214337650|NCT05038488|OTHER|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
214337651|NCT00548782|OTHER|Paleolithic diet|diet
214939071|NCT02338466|DRUG|tenecteplase|"Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg)."
214939072|NCT03933722|DEVICE|Caretaker|Application of Caretaker device to subjects that have septic shock and that have an invasive arterial pressure monitor placed.
214939073|NCT05821465|DEVICE|HeartWatch|The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
214939074|NCT02612350|GENETIC|ctDNA Analysis for the Detection of Genetic Mutations|Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
214939075|NCT01652066|DIETARY_SUPPLEMENT|Mixture of probiotics|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
214939076|NCT01652066|DIETARY_SUPPLEMENT|Mixture of probitiocs|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
214939077|NCT05389826|DEVICE|mHealth App|We will compare the degree of improvement in phosphate control with respect to baseline values and report any adverse event. Nephrologist will use a web management system to provide results of phosphorus levels and medical recommendations to the patient, mediated by a cloud IT environment. In addition, patients will receive alerts, suggestions, and general information. They will also be able to communicate with nephrologists and interact with their corresponding group of fellow patients.
214939078|NCT01606202|DRUG|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
214939079|NCT01606202|DRUG|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
214939080|NCT02190409|DEVICE|Dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
214939081|NCT01082393|DRUG|topical tacrolimus treatment|4 applications (day 1,day 3, day 6 and day10)
215074024|NCT02965742|DEVICE|"Hologic HORIZON A"|A machine made by Hologic inc.
214337652|NCT00548782|OTHER|ADA ( American Diabetes Association) recommended diet|diet
215074025|NCT01818739|PROCEDURE|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
215074026|NCT01818739|DRUG|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
215074027|NCT01818739|DRUG|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
215074028|NCT01818739|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
215074029|NCT01217879|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
214675683|NCT03490786|DRUG|GT-001|PK, PD Study to Determine Safety of Escalating Doses of GT-001
214675684|NCT01367743|DRUG|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
214675685|NCT01367743|DRUG|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
214675686|NCT00652587|PROCEDURE|hepatectomy and transcatheter arterial chemoembolization|partial hepatectomy with adjuvant transcatheter arterial chemoembolization
214675687|NCT00652587|PROCEDURE|hepatectomy|hepatectomy alone
214939082|NCT01082393|DRUG|topical pimecrolimus treatment|4 applications (day 1, day 3, day 6 and day 10)
214939083|NCT01082393|DRUG|local mometasone furoate treatment|4 applications (day 1, day 3, day 6 and day 10)
214939084|NCT01082393|DRUG|cold cream|4 applications (day 1, day 3, day 6 and day 10)
214337653|NCT05580718|BEHAVIORAL|MI-CBT|"* Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~* Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~* Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
214337654|NCT06126549|BEHAVIORAL|Building Better Caregivers|Peer-led, group intervention for caregivers focused on problem-solving
214337655|NCT06126549|BEHAVIORAL|Problem Solving Training|Clinician-led, one-to-one intervention for caregivers focused on problem-solving
214939085|NCT04092088|DEVICE|tDCS-r|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).
214939086|NCT04092088|DEVICE|TENS-r|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..
214939087|NCT04092088|DEVICE|tDCS-s|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).
214939088|NCT04092088|DEVICE|TENS-s|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).
214939089|NCT03197740|DRUG|Donepezil patch|Treatment
214939090|NCT03197740|DRUG|aricept Tab|Comparator
214939091|NCT06370546|OTHER|Low intensity|Low intensity group: participants will be requested to perform the following exercises: 1)squat, 2) rowing, 3)deadlift and 4)bench press. All exercises will be performed with low intensity (40% of the maximum velocity used in one-repetition maximum) and will be supervised by a researcher.
214939092|NCT06370546|OTHER|high intensity|High intensity group: participants will be requested to perform the following exercises: 1)squat, 2)rowing, 3)deadlift and 4)bench press. All exercises will be performed with high intensity (80% of the maximum velocity used in one-repetition maximum) and will be supervised by a researcher.
214939093|NCT00707876|DRUG|ferumoxytol|Dose 1 versus non-contrast MRA
214939094|NCT00707876|DRUG|ferumoxytol|Dose 2 versus non-contrast MRA
214939095|NCT00707876|DRUG|ferumoxytol|Dose 3 versus non-contrast MRA
214939096|NCT03126565|OTHER|Lifeline CareSage Flagging|Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
214939097|NCT05406505|DRUG|Dapagliflozin 10mg Tab|patients will receive once daily dapagliflozin 10 mg orally in addition to standard care
214939098|NCT05406505|OTHER|Placebo|patients will receive placebo and standard care.
214939099|NCT02105714|PROCEDURE|Stool culturing for pathogenic bacteria|
214939100|NCT02105714|PROCEDURE|Kato-Katz technique|
214939101|NCT02105714|PROCEDURE|Baermann technique|
214675688|NCT04986527|PROCEDURE|Chest tube suction|The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.
214675689|NCT05558345|BEHAVIORAL|Contingency Management|A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.
214675690|NCT02471417|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
214675691|NCT02471417|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
214939102|NCT02105714|DEVICE|Mini-FLOTAC|
214337656|NCT06126549|BEHAVIORAL|Usual Care|Usual discharge training and support offered to family caregivers of ABI patients
214939103|NCT02105714|DEVICE|Crypto/Giardia Duo Strip|
214939104|NCT02105714|PROCEDURE|Formalin-ether concentration technique|
215074030|NCT03982719|OTHER|Brief protocol|This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
214337657|NCT01470287|BIOLOGICAL|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
214939105|NCT02105714|DEVICE|CCA RDT|
214939106|NCT02105714|PROCEDURE|Koga agar plate culture|
214337658|NCT00485875|DRUG|Atomoxetine Hydrochloride|
214337659|NCT04111341|DRUG|TCM (Gan-Lu-Yin)GLY|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
214337660|NCT04111341|DRUG|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
214337661|NCT06535698|DIETARY_SUPPLEMENT|Perelel Health Hormonal Balance Support|The supplement contains Myo-inositol (1000 mcg), Metabolic balance blend (200 mcg) including Berberine HCl, Alpha lipoic acid, DIM (33'-Diindolylmethane), and D-chiro-inositol (25 mg). Other ingredients include Vegetable cellulose (capsule), plant cellulose, and L-leucine.
214939107|NCT02105714|PROCEDURE|Kinyoun staining|
214939108|NCT02105714|DEVICE|Multiplex PCR|
214939109|NCT02105714|PROCEDURE|Metagenomics analysis|
214939110|NCT04561024|DIAGNOSTIC_TEST|AI model|Deep Learning CNN model
214337662|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in Sodium chloride|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in sodium chloride
214337663|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in dextrose 5%|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%
214337664|NCT06534697|DRUG|Dextrose 10 % in Water|Preoperative fascia iliaca block with 40 ml volume of dextrose 10%
214939111|NCT04658524|DIAGNOSTIC_TEST|Thyroid function|laboratorial thyroid tests
215078031|NCT02746601|BEHAVIORAL|Risk Assessment, Counselling & Resources|A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
214939112|NCT03193658|PROCEDURE|Thoracolumbar Interfascial Plane (TLIP) block|"A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.~The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally."
214939113|NCT03193658|DRUG|I.V drug based multimodal approach|A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
214939114|NCT01267201|DRUG|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
214939115|NCT01267201|DRUG|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
214939116|NCT01267201|DRUG|methylprednisolone|tablet 32 mg single dose
214939117|NCT05060146|OTHER|Structured medico-pharmaceutical collaboration|Reconciliation of drug treatments; Writing of the prescription for discharge from hospital for the pneumococcal vaccine; Pharmaceutical interview at discharge; Drafting of the discharge letter and transmission to the attending physician; Writing of the pharmaceutical discharge letter and transmission to the pharmacist; Pharmaceutical dispensing in the pharmacy; Administration of the vaccine by the attending physician or a nurse at home.
214939118|NCT01338961|PROCEDURE|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
214939119|NCT03812562|BIOLOGICAL|Nivolumab|Given IV
214939120|NCT03812562|RADIATION|Yttrium Y 90 Glass Microspheres|Given IV
214939121|NCT05661630|OTHER|EDUCATION AND COUNSELING WITH EX-PLISSIT MODEL|"In addition to the routine procedure, the women in the experimental group of the research will be given sexual education and counseling with the EX-PLISSIT model. The steps to be followed in accordance with this model are as follows; Session 1 Permission Limited Information The Specific Suggestions The IT-Intensive Therapy Session 2 At the beginning of the interview, the data forms will be reapplied, and then the homework given in the first session will be discussed. The information that the patient needs in line with his questions will be given within the steps of the Ex-PLISSIT model, within the steps of allowing, limited information, special recommendations and, if necessary, intensive therapy.~Session 3 At the beginning of the interview, the data forms will be applied for the last time and the patient's questions, if any, will be answered and the session will be ended."
214939122|NCT06142175|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
215074031|NCT03982719|OTHER|Intense protocol|This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
215074032|NCT02815046|DRUG|Botulinum toxin type A|Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.
215074033|NCT02815046|DEVICE|Polyacrylamide hydrogel|Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.
215078032|NCT03010137|PROCEDURE|Incisional Negative Pressure Wound Therapy|
215078033|NCT03010137|PROCEDURE|Standard Closure with Skin Glue|
215078034|NCT03010137|DEVICE|PICO (Smith&Nephew)|Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
215078035|NCT03010137|DEVICE|Dermabond|Final wound closure with skin glue.
215078036|NCT01529515|DRUG|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
215078037|NCT01529515|DRUG|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
215078038|NCT01529515|DRUG|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
214675692|NCT01668069|DRUG|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
215078039|NCT01529515|DRUG|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
215078040|NCT01529515|DRUG|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
214675693|NCT00447421|DRUG|pemetrexed|"Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)~Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles"
214675694|NCT00447421|DRUG|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
214675695|NCT00447421|RADIATION|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
214675696|NCT06482879|DEVICE|Oxygen delivery|Oxygen is delivered with high flow nasal canula or simple nasal canula to prevent hypoxia during procedures under deep sedation.
214675697|NCT02765893|OTHER|No Foley|Patients will have Foley catheter removed 6 hours post-op.
214675698|NCT02203682|DRUG|Doxycycline hyclate|Tab. Doxycycline 50 mg PO per day for 12 weeks
214675699|NCT02203682|DRUG|Placebo|Tablet placebo for 12 weeks
214939123|NCT05481268|OTHER|Kinesiotaping Group|In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius. The tension of the tape was adjusted between 20 and 25% and the application was performed in the longest position of the muscle. The inhibition technique was applied from the insertion to the origin of the muscle. The tape was applied to cover the trigger points where pain was felt. For upper trapezius, the muscle was taped in the opposite direction on the cervical region in lateral flexion, slight flexion, shoulder depression and using the muscle technique with the I tape. For SCM muscle, the tape was applied on the muscle in the opposite direction on the cervical region with positioning in lateral flexion, extension and ipsilateral rotation using the muscle technique with I tape Taping was applied every 3 days and totally in 4 cycles.
214939124|NCT05481268|OTHER|Stretching Group|In our application, 3 cycles of 20 seconds of stretches were applied to upper trapezius and SCM muscle. The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching. For the SCM muscle, stretching was achieved in the positions of contralateral lateral flexion, ipsilateral rotation and extension. For upper trapezius, stretching was performed in flexion and lateral flexion. Stretching was performed every 3 days in 4 cycles in total.
214939125|NCT05481268|OTHER|Control Group|Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed. The assessment was performed before treatment, at the end of week 1 and at the end of week 2.
214939126|NCT01312714|DRUG|Cholecalciferol|3 tablets of 1000 IU daily for 26 weeks
214939127|NCT01312714|DRUG|Placebo|3 tablets of 1000 IU daily for 26 weeks
214939128|NCT02811588|DEVICE|Non-invasive ventilation|
214939129|NCT02978859|DRUG|MGCD516|Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
214675700|NCT03610412|OTHER|Cinnamomum Cassia|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
214337665|NCT05574348|OTHER|Osteopathic Protocol in 2 Sessions (PO2S)|"PO2S works on the principle that there is a concordance between the author's Preferential Torsion Pattern (PTP) and the rotatory direction of osteopathic dysfunctions.~The PO2S consists of two sessions of 30 minutes each, one week apart. A 13-item clinical examination is performed at the first session. It focuses on caused pain tests, and classifies patients in left or right PTP. During the first session 14 normalizations of joint, muscular, ligament and visceral dysfunctions are performed systematically. During the second session 10 normalizations of joint, muscular, ligament and visceral dysfunctions are performed .~PO2S is an innovative osteopathic protocol for back pain."
214337666|NCT01410110|BEHAVIORAL|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
214337667|NCT01410110|BEHAVIORAL|Work Therapy|20 hours per week of work therapy
214337668|NCT03560219|DIAGNOSTIC_TEST|Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis|"Key variables that will be recorded include the following:~* Clinical~  * Age~ * Gender~ * BMI~ * Diabetes Mellitus~ * Hypertension~ * Heart Failure~ * Ischemic Stroke / TIA~ * Thromboembolism~ * Coronary Artery Disease~ * Peripheral Arterial Disease~ * Glomerular Filtration Rate~* Contrast-enhanced MRI~  o Presence and extent of atrial fibrosis~* Biomarkers~  * IL-6~ * CRP~ * D-dimer~ * Fibrinogen~* Transthoracic Echocardiography~  * LA Volume Index (LAVI)~ * LA Strain, Global~ * LA Strain rate, Positive peak, Global~ * LA Strain rate, early negative peak, Global~ * LA Strain rate, late negative peak, Global~ * LA Emptying Fraction (LAEF)~ * LVH~ * LVEF~* Endothelial function o FMD"
214337669|NCT03310541|DRUG|AZD5363|AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
214675701|NCT03610412|OTHER|Placebo (calcined magnesia)|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
214939130|NCT02622841|PROCEDURE|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
214675702|NCT00467883|DRUG|Liposomal Amphotericin B|high dosage
214675703|NCT03551899|OTHER|Different ventilation parameters|mode of ventilation, tidal volume per body weight and PEEP settings
214675704|NCT02449564|DRUG|sirolimus|sirolimus 1mg daily
214675705|NCT00184847|DRUG|acetylcholine|
214675706|NCT00184847|PROCEDURE|twenty minutes of forearm ischemia|
214675707|NCT00184847|PROCEDURE|three 5-minute periods of forearm ischemia|
214939131|NCT01046032|DRUG|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
214939132|NCT01046032|DRUG|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
214939133|NCT02719938|BEHAVIORAL|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
214939134|NCT01885715|DRUG|Injection of neostigmine|"At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms."
214939135|NCT06080906|BIOLOGICAL|IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero Cells) of 320EU/0.5ml on Day 0, 28
215078041|NCT04597021|DEVICE|use of a wiresless US transducer|to (evaluate the practicability of applying a wireless US transducer for central venous catheter-placement in these patients.
214675708|NCT00184847|DRUG|adenosine|
214675709|NCT00184847|DRUG|caffeine|
214675710|NCT01707147|DRUG|Trajenta tablet|Linagliptin
214939136|NCT06080906|BIOLOGICAL|IRV on a 0-, 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on Day 0, 28, 56
214939137|NCT06080906|BIOLOGICAL|Placebo on Day 0, 28|Two doses of placebo at the vaccination schedule of Day 0, 28
214939138|NCT06080906|BIOLOGICAL|Placebo on Day 0, 28, 56|Three doses of placebo at the vaccination schedule of Day 0, 28, 56
214939139|NCT04529512|DRUG|DEXTENZA®|DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.
215074034|NCT04031664|DRUG|Qianjin Capsule of Gynaecology|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
215074035|NCT02035436|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
215074036|NCT02035436|OTHER|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
214337670|NCT03310541|DRUG|Enzalutamide|Enzalutamide 160 mg PO once daily
214337671|NCT03310541|DRUG|Fulvestrant|500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
214337672|NCT03898245|DEVICE|apply tDCS|Intensity 2mA, 20minues, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
214337673|NCT03898245|DEVICE|Sham tDCS|Intensity 0mA, 40 seconds, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
214337674|NCT05726656|OTHER|traditional physical therapy session|manual lymph drainage-pneumatic compression and skin care
214337675|NCT05726656|OTHER|wii console based exercise|execise session using the wii console video games
214337676|NCT00764140|BIOLOGICAL|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
214675711|NCT02792777|OTHER|Interviews|Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo software for coding and analysis.
214675712|NCT02792777|OTHER|Concept Mapping (CM)|"The CM process consists of 3 steps that take place over 3 sessions:~Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.~Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.~Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.~Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group."
214675713|NCT02355093|PROCEDURE|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
215074037|NCT04011826|DEVICE|Device: Trial nasal mask (F&P)|This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
215074038|NCT00350363|DRUG|Zymar|zymar qid
214337677|NCT03619733|OTHER|no intervention|this is an observational study. no intervention is planned
214939140|NCT00955968|DRUG|Highly active antiretroviral therapy (HAART)|"A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant."
214939141|NCT01455181|DRUG|NPSP558|50, 75, 100 μg
214939142|NCT02041650|DRUG|Ticagrelor|
214939143|NCT06712849|DEVICE|Sham Transcranial Random Noise Stimulation|Sham transcranial random noise stimulation will be applied over the primary visual cortex (area V1) with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2.0 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 40 minutes.
214939144|NCT06712849|DEVICE|High Frequency Transcranial Random Noise Stimulation|Non-invasive brain stimulation will involve the use of high-frequency transcranial random noise stimulation (100-640 Hz) to apply a 2.0 milliamp current over the primary visual cortex (area V1) for approximately 40 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
214939145|NCT00117624|DRUG|darbepoetin alfa|
214939146|NCT01528657|OTHER|Ventricular Pace Suppression (Vps)|Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.
214939147|NCT01528657|OTHER|Intrinsic rhythm support (IRSplus)|All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
214939148|NCT06731686|OTHER|Retrospective study|Collection of children's datas
214939149|NCT05020899|BEHAVIORAL|Sessions with a trained counselor|4 sessions will be provided with a trained counselor who will discuss the participant's' smoking habits with them and strategies to help them quit. The first session is in-person, lasts for 20 minutes, and typically happens when the participant comes to the HIV clinic to pick up their medication. Sessions 2 through 4 are over the telephone and last for 15 minutes each. These occur 1 week, 4 weeks, and 8 weeks after the first session.
214939150|NCT05020899|OTHER|Cell phone messages|Brief messages that give tips to help quit smoking will be sent to participants' cell phones using WeChat. 3 messages per day will be sent for the first week, 2 messages per day for the next 3 weeks, 1 message per day for the next 1 week, and 1-2 messages per week for the rest of the time
214939151|NCT05020899|OTHER|Offered nicotine replacement therapy|Participants will be offered nicotine replacement therapy (gum or patch, depending on which one is available).
214337678|NCT05169294|OTHER|Telerehabilitation Program|Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.
214337679|NCT05169294|OTHER|Written Home Program|Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
214337680|NCT00286143|DRUG|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
214337681|NCT00647231|DRUG|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
214337682|NCT00647231|OTHER|Placebo Patch|Treatment with placebo patch
214939152|NCT05020899|OTHER|Self-help guide for quitting smoking|Participants will be offered a self-help guide with information about quitting smoking.
214337683|NCT00881725|DRUG|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
214337684|NCT00539526|DRUG|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
214337685|NCT00539526|DRUG|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
214337686|NCT00539526|DRUG|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
214337687|NCT06317792|OTHER|online exergaming-based physiotherapy programs|The online exergaming-based physiotherapy programs focus on training in shoulder, hip, and knee ROM balance, weight-bearing, strength, weight shifting, and walking based on RF in machine learning to the features selection in patients with PIGD. The training tasks consist of a set of 10 pieces of training (20 min per session, five sessions every week, for 8 weeks). Five exergaming programs were used for training, designed to incorporate an appropriate level of challenge to match the ability and fitness of patients with PD.
214337688|NCT04083989|OTHER|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
214337689|NCT04574544|DRUG|Zinc Supplementation|The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
214337690|NCT04574544|BEHAVIORAL|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
214337691|NCT04868201|DEVICE|0-anxiety|0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
214337692|NCT03830671|DRUG|18-month regimen containing 6 anti-TB drugs|Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
214337693|NCT00354926|BIOLOGICAL|AME-133v (LY2469298)|IV 4X weekly X 4
214337694|NCT02211989|DRUG|BI 14332 CL|
214337695|NCT02211989|DRUG|Placebo|
214939153|NCT03938649|RADIATION|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
214939154|NCT03938649|DRUG|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
214939155|NCT04383340|BEHAVIORAL|Mother-Infant Transaction Program|Parent sensitivity training for mothers of premature infants
214939156|NCT04383340|BEHAVIORAL|Treatment as usual|Standard hospital care and parental support
214939157|NCT04907500|DEVICE|Intraocular lens|Cataract surgery
214939158|NCT00822575|DEVICE|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
214939159|NCT03075202|DEVICE|e-cigarette, brand name JUUL|This is not an experimental study/trial, rather a prospective observational study. Device will be offered to cohort, but they are not mandated to take or use the device.
214939160|NCT04657081|DRUG|Decitabine and Cedazuridine (ASTX727)|Route of administration: oral in the form of a tablet
214347327|NCT02897804|BEHAVIORAL|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214939161|NCT04657081|DRUG|Venetoclax|Route of administration: oral in the form of a tablet
214939162|NCT06983353|DEVICE|transphyseal screw|transphyseal screw in proximal femoral physis
214337696|NCT03686774|DRUG|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
214337697|NCT03686774|OTHER|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
214337698|NCT04870801|DRUG|Respirogen Micro-Oxygen|Enteral (rectal) delivery of Respirogen Micro-Oxygen
214337699|NCT02533882|BEHAVIORAL|Movement to Music|
214337700|NCT02533882|BEHAVIORAL|Adapted Yoga|
214337701|NCT05284045|OTHER|Detailed information|Subjects in this arm will receive usual information + detailed information on side effects
214337702|NCT05239091|DRUG|Dextrose solution|A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.
214337703|NCT05239091|DRUG|Lidocain|A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.
214939168|NCT01342250|BIOLOGICAL|conventional therapy plus low dose hUC-MSCs treatment|patients will receive the conventional therapy plus low dose hUC-MSCs treatment
214939169|NCT01342250|BIOLOGICAL|conventional therapy plus medium dose hUC-MSCs treatment|patients will receive conventional therapy plus medium dose hUC-MSCs treatment
214675714|NCT02355093|PROCEDURE|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
214337704|NCT04076228|DRUG|Pembrolizumab|pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
214337705|NCT05720832|OTHER|WINGS-IP1 Smartphone Application|"The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content."
214337706|NCT04689737|DRUG|Doravirine|Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
214337707|NCT05447988|DEVICE|Breast Tissue Expander|tissue expander based breast reconstruction
214337708|NCT06276478|OTHER|AI-video|Video administration for the explanation of the dental procedures followed by verbal instructions.
214337709|NCT06276478|OTHER|Verbal instructions|Only verbal instructions will be administered for the explanation of the dental procedures
214337710|NCT04411043|BEHAVIORAL|Molecular caracterization|Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T
214337711|NCT03895853|OTHER|Best Practice|Receive standard of care
214337712|NCT03895853|DIETARY_SUPPLEMENT|early metabolic resuscitation|Given Intravenous
214337713|NCT06301165|DRUG|TPC induction chemotherapy|TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).
214337714|NCT06301165|DRUG|GP induction chemotherapy|GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)
214337715|NCT05215574|DRUG|NGM831|Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
214939170|NCT01342250|BIOLOGICAL|conventional therapy plus high dose hUC-MSCs treatment|patients will receive conventional therapy plus high dose hUC-MSCs treatment
214675715|NCT02355093|DRUG|ropivacaine|
214675716|NCT00025649|BIOLOGICAL|filgrastim|
214675717|NCT00025649|DRUG|busulfan|
214675718|NCT00025649|DRUG|carboplatin|
214675719|NCT00025649|DRUG|cyclophosphamide|
214675720|NCT00025649|DRUG|doxorubicin hydrochloride|
215074039|NCT03172962|BEHAVIORAL|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
215074040|NCT03172962|BEHAVIORAL|Usual care (control)|Will receive the usual care at the hospital
214675721|NCT00025649|DRUG|etoposide|
214675722|NCT00025649|DRUG|melphalan|
214337716|NCT05215574|DRUG|NGM831 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle."
214337717|NCT05215574|DRUG|NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle."
214337718|NCT04231630|OTHER|Prolacta|Will receive outpatient supplementation with donor human milk product added to mother's own milk
214675723|NCT00025649|DRUG|vincristine sulfate|
214675724|NCT00025649|PROCEDURE|autologous bone marrow transplantation|
214675725|NCT00025649|PROCEDURE|conventional surgery|
214939171|NCT05619536|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
214939172|NCT05619536|DRUG|Saline placebo|Sterile normal saline for injection
214939173|NCT02691728|DRUG|LDV/SOF FDC|
214337719|NCT02279303|BEHAVIORAL|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
214337720|NCT02279303|BEHAVIORAL|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
214939174|NCT06007963|PROCEDURE|Treatment with impella device.|Impella percutaneous mechanical supported patients will be included after revision to support.
214337721|NCT06535906|OTHER|kinesio taping|The 5 cm wide Kinesio tape (Kinesio® Tex Gold™, Albuquerque, NM) applied to the participants has the ability to stretch up to 140% of its original length. Moreover, it provides comfortable use for 3 to 5 days thanks to its latex-free, cotton, hypoallergenic and porous features. The skin will be cleaned with alcohol before applying Kinesio tape. To prevent muscle tension, the physiotherapist will apply the kinesio tape inhibition technique to the wrist flexor muscles with light tension (15-25% of the current tension) from the end point to the origin. We will use this inhibition technique to prevent muscle spasm. Kinesio taping will be applied immediately after exercise
214939175|NCT06588400|DEVICE|AOSEPT Plus and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
214939176|NCT06588400|DEVICE|AOSEPT Plus with HydraGlyde and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus with HydraGlyde) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
214939177|NCT06588400|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
214939178|NCT04482075|OTHER|segmental stability training|SEGMENTAL STABILISATION TRAINING (SST): This part of the therapy shall involve Isometric co-contraction of Lumbar Transversus abdominis and Lumbar Multifidus. The patient shall perform 10 repetitions of abdominal drawing-in manoeuvre with 30-40% Maximal Voluntary Contraction (MVC) with a 10-second hold in specific prescribed positions.
214939179|NCT04450134|OTHER|Lactose|Placebo: Lactose capsules
214939180|NCT04450134|DRUG|Fexofenadine Hydrochloride|H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
214939181|NCT04450134|DRUG|Famotidine|H2 receptor antagonist: 40 mg Famotidine
214939182|NCT04450134|OTHER|High-intensity interval training (HIIT)|6 weeks HIIT
214939183|NCT05665140|DRUG|Isatuximab|i.v. Induction Phase (Arm A and B): Induction Cycle 1 10 mg/kg D 1, 8, 15, 22, 29. Induction Cycle 2-3 10 mg/kg D 1, 15, 29 Consolidation Phase (Arm B): Consolidation Cycle 1-3 10 mg/kg D 1, 15, 29 Maintenance Phase (Arm A and B): Maintenance Cycle 1 and subsequent cycles 10 mg/kg D 1, 15, 29
214939184|NCT05665140|DRUG|Lenalidomide|hard capsule for oral use. Induction Phase (Arm A and B): Induction Cycle 1-3 25 mg D1-14, 20-35. Consolidation Phase (Arm B): Consolidation Cycle 1-3 25 mg D1-14, 20-35. Maintenance Phase (Arm A and B): Maintenance Cycle 1-2 10 mg D1-28. Maintenance Cycle 3 and subsequent cycles 15 mg D1-28 if tolerable
214939185|NCT05665140|DRUG|Bortezomib|s.c. injection. Induction Phase (Arm A and B): Induction Cycle 1-3 1,3 mg/m² D1, 4, 8, 11, 22, 25, 29, 32. Consolidation Phase (Arm B): Consolidation Cycle 1-3 1,3 mg/m² D1, 4, 8, 11, 22, 25, 29, 32
214939186|NCT05665140|DRUG|Dexamethasone|orally and i.v. Induction Phase (Arm A and B): Induction Cycle 1 20 mg p.o. D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. D1, 8, 15, 22 and 29. Induction Cycles 2 and 3 20 mg p.o. D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. D1, 15 and 29. Consolidation Phase (Arm B): Consolidation Cycle 1-3 20 mg p.o. on D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. on D1, 15 and 29
214939187|NCT05665140|OTHER|autologous stem cell transplant|autologous stem cell transplant
214939188|NCT06509971|DRUG|QL1706|"The Order of Drug Administration was: QL1706→ bevacizumab → albumin-binding paclitaxel, and each drug was administered at least 30 minutes apart.~QL1706: 5 mg/kg Q3W. The infusion time was 30 minutes + 5 minutes. No dose adjustment was allowed for QL1706 during treatment, but delayed administration was allowed, with a delay of no more than 4 weeks from the previous dose.~Albumin-binding paclitaxel: 260 mg/m 2 Q3W, IV, for 30 min + 5 min. During treatment, albumin-binding paclitaxel allows for dose adjustments.~Bevacizumab: 15 mg/kg Q3 W, iv. The first infusion should last 90 minutes. If the first infusion was well tolerated, the second infusion could be shortened to 60 minutes. If the patient is also well-tolerated for a 60-minute infusion, then all subsequent infusions can be completed in 30 minutes, no dose adjustment is allowed for bevacizumab."
214939189|NCT06729541|OTHER|Multigenetic Pharmacogenomics-Guided Treatment (MPGT)|In the guidance group, drug types and dosages were adjusted based on the results of Pharmacogenetic TESTING.
214939190|NCT06995677|DRUG|TYRA-300 60mg|Self-administered 60mg dose Oral tablet(s) given daily
214939191|NCT06995677|DRUG|TYRA-300 50mg|Self-administered 50mg dose Oral tablet(s) given daily
214939192|NCT06995677|DRUG|TYRA-300 Dose TBD|To Be Determined Dose: Self-administered Oral tablet(s) given daily
214939193|NCT04626024|OTHER|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal|Stop taking TKI medication
214939194|NCT04626024|DRUG|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation|Re-start TKI medication
214939195|NCT06033196|DRUG|Tocilizumab|"The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more"
215078042|NCT00751309|OTHER|Non-interventional|Post-transplantation observational study
214337722|NCT06535906|OTHER|placebo kinesio taping|5 cm wide and 0.5 mm thick I-shaped Kinesio tape (Kinesio Tex® Gold) will be used. The tape will be applied in a plus-shaped, tension-free and technical sitting position. Kinesio taping will be applied immediately after exercise
214675726|NCT00025649|PROCEDURE|peripheral blood stem cell transplantation|
214675727|NCT04205422|PROCEDURE|BIPAP|Biphasic Intermittent Positive Airway Pressure
214675728|NCT04205422|PROCEDURE|APRV|Airway Pressure Release Ventilation
214337723|NCT06535906|OTHER|manual lymph drainage|Participants will lie in a supine position with their knees bent. Manual lymphatic drainage will begin with abdominal lymph drainage followed by central lymph stimulation. Then, bilateral axillary lymph nodes will be stimulated and the fluid in the exercised arm will be directed to the axillary lymph nodes. While the patients are in the prone position, the axillary lymph nodes will be stimulated in the same way and each manual lymphatic drainage will be performed from the back to the axillary lymph node. Each treatment session will last approximately 30 minutes
214337724|NCT06535906|OTHER|placebo manual lymph drainage|Participants will lie in a supine position with their knees bent. It will only be moved in a stroking style with hand contact from the fingers towards the armpit.
214939196|NCT06033196|DRUG|Placebo for Tocilizumab|"Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses"
214337725|NCT03783923|DRUG|Deflazacort|Deflazacort tablet will be administered as per the dose and schedule specified in the arm.
214337726|NCT03397901|PROCEDURE|Transverse colostomy|Transverse double-cavity colostomy
214337727|NCT00127959|DRUG|tenofovir|
214337728|NCT00127959|DRUG|emtricitabine|
214337729|NCT00127959|DRUG|zidovudine|
214337730|NCT00127959|DRUG|efavirenz|
214337731|NCT02842567|DRUG|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
214337732|NCT02842567|DRUG|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
214337733|NCT02543346|DRUG|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
214939197|NCT00398437|BIOLOGICAL|trastuzumab|
214939198|NCT00398437|DRUG|chemotherapy|
214939199|NCT00398437|PROCEDURE|magnetic resonance imaging|
214939200|NCT05614180|PROCEDURE|Percutaneous coronary intervention|Patients with a diagnose of coronary chronic total occlusions will be treated by percutaneous coronary intervention, as indicated by the heart-team.
214939201|NCT01876537|DEVICE|Hardware wound healing|
214939202|NCT01876537|DEVICE|Usual Surgery|
214337734|NCT02543346|OTHER|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
214337735|NCT02966067|DEVICE|Microneedle Device (Experimental)|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
214337736|NCT02966067|DEVICE|30-gauge Short Hypodermic Needle|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
214337737|NCT06303765|OTHER|Practice Resource for Driving After Stroke (PReDAS)|"1. Provision of written copy of PReDAS for occupational therapist to review~2. 1:1 online training session to use the PReDAS (1 hour in length)"
214337738|NCT05705102|OTHER|Coronary intervention|Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for \<24h.
214337739|NCT04015193|PROCEDURE|Single-port thoracoscopic sympathicotomy (patient care)|Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
214337740|NCT01242527|DRUG|placebo|4 capsules (1g) daily for 12 weeks
214337741|NCT01242527|DRUG|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
214337742|NCT01242527|DRUG|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
214337743|NCT01242527|DRUG|omefas|4 capsules (1g)daily for 12 weeks
214337744|NCT04345848|DRUG|Enoxaparin|Two different doses of anticoagulation
214337745|NCT04834011|PROCEDURE|Laparoscopic right colonic resection with Complete Mesocolic Excision (CME)|
214337746|NCT04834011|RADIATION|3D CT angiography|
214337747|NCT00763542|BEHAVIORAL|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
214337748|NCT00763542|BEHAVIORAL|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
214675729|NCT00575796|DRUG|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
214675730|NCT02729129|OTHER|Diesel exhaust exposure with filtered facemask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a filtered facemask.
214675731|NCT02729129|OTHER|Diesel exhaust exposure with sham mask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a sham facemask.
214337749|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
214337750|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
214939203|NCT06948981|BIOLOGICAL|GT719 Injection|GT719 Injection
214939204|NCT01444729|DRUG|Xiapex|Xiapex administration will follow SMPC
215078043|NCT01706497|DEVICE|Cerebral tissue oxygen saturation monitoring, blinded|
215078044|NCT01536665|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
215078045|NCT01536665|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
215078046|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
215078047|NCT00798239|OTHER|Iliac crest autograft|autograft
215078048|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
215078049|NCT03172065|DRUG|Normal saline|intravenous flluid
215078050|NCT03172065|DRUG|Dexmedetomidine|anaesthetic adjuvants and pain killer medication.
215078051|NCT06289920|DRUG|BR3005|One tablet administered alone, Once a day
214939205|NCT01444729|PROCEDURE|surgery|Non-pharmacological treatment
214337751|NCT03653754|DIAGNOSTIC_TEST|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
214939206|NCT02144480|BEHAVIORAL|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
214939207|NCT02144480|BEHAVIORAL|traditional training|usual care: conventional rehabilitation
214939208|NCT03776643|DRUG|ILT-101 ld-(IL2)|Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
214939209|NCT03713008|DIAGNOSTIC_TEST|Fluid bolus|All patients included in the study will receive 5 ml/kg fluid bolus of a balanced crystalloid solution.
215074041|NCT00518648|OTHER|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
215074042|NCT00518648|OTHER|Usual care|Usual care
215074043|NCT04742348|DRUG|Carbidopa Levodopa|Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
215074044|NCT04742348|DRUG|Placebo|Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
215074045|NCT02559323|OTHER|Survey|
214675732|NCT02035423|DIETARY_SUPPLEMENT|120 IU milk|Daily consumption of milk fortified with 120 IU vitamin D
214337752|NCT00004317|DRUG|Leucovorin calcium|See arm descriptions
214337753|NCT00004317|DRUG|Pyrimethamine|See arm descriptions
214337754|NCT00004317|DRUG|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
214337755|NCT00004317|DRUG|Sulfadiazine|See arm descriptions
214337756|NCT04584567|DRUG|Doxycyclin|daily (100mg)
214675733|NCT02035423|DIETARY_SUPPLEMENT|200 IU Milk|Daily Consumption of milk fortified with 200 IU vitamin D
214337757|NCT01251796|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
214337758|NCT03726112|DEVICE|SpotOn Specs|SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field
214337759|NCT03726112|DEVICE|Sham Specs|Sham device
214675734|NCT02035423|DIETARY_SUPPLEMENT|Non-Fortified Milk|Daily consumption of non-fortified milk
215074046|NCT03802305|DEVICE|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~* anesthesia of the interdental papilla,~* positioning of the needle and perforating of the interdental space,~* Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
215074047|NCT03802305|DEVICE|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
215074048|NCT02901054|DRUG|Ondansetron|A single 15-min intravenous infusion of ondansetron
215078052|NCT06289920|DRUG|BR3005-1|One tablet administered alone, Once a day
215078053|NCT06289920|DRUG|BR3005-2|One tablet administered alone, Once a day
214337760|NCT04341922|BEHAVIORAL|Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic|The intervention focuses on 1) teaching participants how to discriminate between functional and dysfunctional worry (what are solvable problems vs. what is worry, i.e. unsolvable thoughts?) 2) providing participants with skills to solve functional worry topics (e.g. set time and make a workable plan to be prepared for possible negative outcomes \[e.g. becoming unemployed\]), 3) helping participants to reduce unhelpful behaviors that may reinforce worry (e.g., limit excessive news consumption, refrain from assurance seeking behaviors), 4) providing participants with skills to approach dysfunctional worry (e.g., not engage in worrisome thoughts, just leave them), and 5) increase the behavioral repertoire (take walks, engage in activities that promote health without putting oneself at risk to become infected).
214337761|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
214337762|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
214337763|NCT00103649|DRUG|xaliproden (SR57746A)|
214347328|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214939210|NCT06308302|OTHER|Group A (Inspiratory Muscles Training + Aerobic Interval Training)|"Performed Inspiratory muscle training on a breather device (20), (10 inhales with maximum 3-sec hold), 3 sets with a 1-minute interval between each set, for 6 days a week along with aerobic interval training on alternate days (3 days a week for 20-25 minutes in 1st week, 30-35 minutes in 2nd week, 40 minutes in 3rd week, 45-60 minutes in 4th week each session). (120)~Baseline treatment given is Aerobic interval training and COPD medications."
214939211|NCT06308302|OTHER|Group B (Expiratory Muscles Training +Aerobic Interval Training)|"Performed Expiratory muscle training along with aerobic interval training on alternate days (3 days a week for 20-25 minutes in 1st week, 30-35 minutes in 2nd week, 40-45 minutes in 3rd week, 45-60 minutes in 4th week per session). (120)~Baseline treatment given is Aerobic interval training and COPD medications."
214337764|NCT05375513|OTHER|PMI@Home|"Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control."
214337765|NCT05375513|OTHER|Brain Health Pro|"Online Modules:~* Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~* Physical Activity~* Cognitively Stimulating Activities~* Diet~* Sleep~* Social and Psychological Health~* Vascular health~* Vision and Hearing~* Lifestyle Risk Impact Surveys~* Goal Setting"
214337766|NCT05961293|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand of a stroke victim during acute, subacute, or chronic phases of a stroke. NeuroGlove provides sensory stimulation in the forms of pneumatic puffs of air. There is some early evidence that early peripheral sensory stimulation may improve neurological outcomes following an ischemic stroke.
214939212|NCT05973019|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|6 times/per week for 2 weeks, total 12 times rTMS with 10 Hz.
214939213|NCT01277653|DEVICE|tumor maker interval shortly|tumor maker interval every 3 month
214939214|NCT02131818|DRUG|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
214939215|NCT02131818|DRUG|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
214939216|NCT01910987|DRUG|bortezomib (optimized retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
214939217|NCT01910987|DRUG|dexamethasone (optimized retreatment)|Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6
214939218|NCT01910987|DRUG|bortezomib (standard retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression
214939219|NCT01910987|DRUG|dexamethasone (standard retreatment)|Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
214675735|NCT05596825|DEVICE|Mandibular Advancement Device|"To analyze the phenotypic characteristics of different subgroups of patients with obstructive sleep apnea syndrome who respond better (complete responders) or worse (partial responders or non-responders) to treatment with mandibular advancement devices.~Responders will be defined as a post-treatment AHI of less than 10/h and at least a 50 percent reduction in their AHI. Partial responders will be defined as a post-treatment AHI greater than 10/hour but at least a 50 percent reduction in AHI, and non-responders as less than a 50 percent reduction compared to baseline."
214675736|NCT05979844|DRUG|3,4-methylenedioxymethamphetamine (MDMA)|2 MDMA sessions; PTSD+ Veteran partner only
215074049|NCT03215992|DEVICE|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
215074050|NCT04674111|DEVICE|Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)|The Vortex System is intended to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
214675737|NCT05979844|BEHAVIORAL|Brief Cognitive Behavioral Conjoint Therapy (bCBCT)|8 bCBCT sessions; Both partners
214939220|NCT01353690|BIOLOGICAL|AMDC|Cell Treatment
214939221|NCT06662864|OTHER|Patients reported outcomes|Patients reported outcomes were collected via telephone
214939222|NCT06662864|OTHER|questionnaire global Pittsburgh Sleep Quality Index (PSQI)|Patients reported outcomes were collected via telephone
214939223|NCT04446650|DRUG|Fedratinib|Oral
214939224|NCT05260385|DRUG|KC1036|KC1036 are administered orally QD or BID in 21-day cycles.
214939225|NCT04251728|DEVICE|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
214939226|NCT04251728|OTHER|Physical Exercise|The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.
214939227|NCT04251728|DEVICE|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
214939228|NCT05996640|OTHER|This is study does not use an intervention|This is study does not use an intervention. A survey will be used to collected data on patients' experiences and preferences about waiting list for heart surgery.
214675738|NCT04762290|OTHER|Dance|The intervention is a series of expressive dance movements.
214675739|NCT05457829|DRUG|Doxorubicin Hydrochloride Liposome+Irinotecan|Q3W, 2 cycles.
214675740|NCT05457829|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 2 cycles.
214675741|NCT05339308|OTHER|Magnesium oil (BetterYou) dermal application|10 sprays (200 mg) of magnesium oil (BetterYou) will be applied to skin covering knee extensor muscles. The magnesium oil will be applied only once
214675742|NCT05339308|OTHER|Placebo Control|Natural mineral-free oil (10 sprays) will be applied as the control condition. This will be done only once
214675743|NCT05738252|DIAGNOSTIC_TEST|Clinical Frailty Scale|A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
214675744|NCT05738252|DIAGNOSTIC_TEST|Frailty Phenotype|Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
214939229|NCT04451616|DIAGNOSTIC_TEST|Blood sample collection|Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.
214337767|NCT06572553|DRUG|Faricimab|Faricimab (faricimab-svoa; Vabysmo), a bispecific antibody that inhibits both VEGF-A and Ang-2, was developed by Roche/Genentech, and dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease relative to anti-VEGF therapy alone.
214337768|NCT06171152|DRUG|Liraglutide Pen Injector [Saxenda]|A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.
214337769|NCT06171152|OTHER|Medication Diary|Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.
214337770|NCT03588169|DIETARY_SUPPLEMENT|semi-structured interviews|"About 30 minutes and touching on the following subjects:~* perception of hospital meals~* patient representation of ONS~* taking ONS and feelings about it"
214337771|NCT02811198|OTHER|No intervention|
214337772|NCT06410105|DEVICE|CLEAR ALIGNERS|The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm
214337773|NCT05476003|PROCEDURE|Ultrasound-guided Bilateral superficial cervical plexus block|"This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus."
214337774|NCT05476003|DRUG|Midazolam|All patients will be premedicated with Midazolam (0.02mg/Kg).
214337775|NCT02879838|OTHER|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
214337776|NCT06321705|DRUG|CS1|CS1 delayed release capsules will be supplied with 160 mg active pharmaceutical ingredient (API) per capsule. Three dose levels will be administered in this expanded access study at the same dose the patient received in the parent study (CS1-003) of 480 mg, 960 mg, or 1920 mg. All patients will later have the option to be titrated to the most efficacious and safe dose determined from the ongoing CS1-003 study when completed.
214337777|NCT01739322|BIOLOGICAL|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
214939230|NCT04451616|DIAGNOSTIC_TEST|Hair sample collection|Hair sample collection will be performed. Hair mineral analysis will be performed.
214939231|NCT04451616|DIAGNOSTIC_TEST|Urine sample collection|Urine sample collection will be performed. Urine mineral analysis will be performed.
214939232|NCT04451616|DIAGNOSTIC_TEST|Body composition analysis|Body composition analysis with the use of electric bioimpedance will be performed.
214939233|NCT04451616|DIAGNOSTIC_TEST|Questionnaires|Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.
214939234|NCT04451616|DIAGNOSTIC_TEST|Blood pressure, pulse and blood oxygen saturation measurement|Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.
214675745|NCT04115033|DEVICE|Alpha-stim|The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
214675746|NCT03277170|DRUG|Montelukast Oral Granules|Montelukast granules, 30 mg, mixed with applesauce
214939235|NCT03065764|DRUG|89Zr-Pembrolizumab|"eligible subjects will undergo two whole body immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with and one without a preceding cold therapeutic dose of pembrolizumab."
214337778|NCT02928692|DRUG|Minocycline|
214337779|NCT02928692|DRUG|Placebo|
214675747|NCT06027463|PROCEDURE|Head and neck vascular recanalization|Head and neck vascular recanalization
214675748|NCT05217069|DRUG|5-FU|400 mg/m2 (i.v. bolus) 2400 mg/m2 (i.v. 46h)
214939236|NCT06715683|DRUG|BMS-986278 Batched method, Dose A|Specified dose on specified days
214939237|NCT06715683|DRUG|BMS-986278 Batched method, Dose B|Specified dose on specified days
214939238|NCT06715683|DRUG|BMS-986278 Continuous method|Specified dose on specified days
214939239|NCT05701956|DRUG|Tenecteplase|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy
214675749|NCT05217069|DRUG|Folinic Acid|400mg/m2
215074051|NCT01534260|DRUG|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
215074052|NCT03252886|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
214675750|NCT05217069|DRUG|Irinotecan|180 mg/m2
214939240|NCT05701956|PROCEDURE|Endovascular thrombectomy|The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.
214939241|NCT05538767|DRUG|Emodepside|Treatment with Emodepside 30 mg
214337780|NCT05350293|OTHER|Molded abutment|"The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner."
214939242|NCT05538767|DRUG|Albendazole 400mg|Treatment with Albendazole 400 mg
214939243|NCT06592755|PROCEDURE|single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection|The included patients chose to undergo single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection via the subclavian approach based on patients preference.
214939244|NCT06592755|PROCEDURE|conventional open surgery|These patients chose to undergo total thyroidectomy with central compartment neck dissection via conventional open surgery based on patients preference.
214939245|NCT01789580|OTHER|Gambling moderator|
214939246|NCT05094089|DEVICE|Hernia repair with mesh|Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery
214675751|NCT05217069|DRUG|Cetuximab|400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w
214675752|NCT05217069|DRUG|Avelumab|10mg/kg IV (day 1 q2w)
214337781|NCT05350293|OTHER|3D printed abutment|A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
214675753|NCT01429246|DIETARY_SUPPLEMENT|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
214675754|NCT01429246|DIETARY_SUPPLEMENT|Salt Substitute|Estimated 30 grams per day per household member
214675755|NCT05782920|DEVICE|Platelet rich plasma|PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.
214939247|NCT02923245|OTHER|point-of-care ultrasound|
214939248|NCT06828601|DRUG|IV Lidocaine|Participant receives IV Lidocaine during surgery. Infusion continues for 48 hours. An initial bolus dose of 1.5 mg/kg ideal body weight (IBW) of IV study infusion will be given at the start of surgery, followed by infusion rate of 2.0 mg/kg/hr IBW intraoperatively.This will be reduced to 1.5 mg/kg/hr IBW postoperatively for 48 hours - once the patient has reached recovery.
214939249|NCT06828601|DRUG|IV Saline|Participant receives IV Saline (placebo) during surgery. Infusion continues for 48 hours. An initial bolus dose of 1.5 mg/kg ideal body weight (IBW) of IV study infusion will be given at the start of surgery, followed by infusion rate of 2.0 mg/kg/hr IBW intraoperatively.This will be reduced to 1.5 mg/kg/hr IBW postoperatively for 48 hours - once the patient has reached recovery.
214939250|NCT02976675|BIOLOGICAL|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
214939251|NCT02976675|BIOLOGICAL|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
214939252|NCT00362713|DRUG|Ipilimumab|Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
214939253|NCT06898177|BEHAVIORAL|mCBT-AR|mCBT-AR is an 8-week virtual treatment for avoidant/restrictive food intake disorder delivered via mobile application
214939254|NCT06763146|DRUG|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using the investigator or a delegate at the study site collects secondary/historic data of finerenone usage (patient demographic and clinical characteristics, diagnosis-related, treatment-related, and laboratory data) from clinic specific medical records.
214939255|NCT07064473|DRUG|Vicadrostat|Vicadrostat
214939256|NCT07064473|DRUG|Empagliflozin|Empagliflozin
214675756|NCT05782920|DEVICE|non cross-linked hyaluronic acid|HA filling is a known modality for rejuvenation
214675757|NCT05782920|DEVICE|topical HA gel|the standard treatment of vaginal atrophy and dryness
214939257|NCT07064473|DRUG|Placebo matching Vicadrostat|Placebo matching Vicadrostat
214939258|NCT07071558|BIOLOGICAL|RSV vaccine formulation 1 dose|Suspension for injection. Route of administration: IM injection
214939259|NCT07071558|BIOLOGICAL|RSV vaccine formulation 2 dose|Suspension for injection. Route of administration: IM injection
214337782|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
214337783|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
214337784|NCT02362399|DRUG|sildenafil citrate|single oral dose of 50 mg
214337785|NCT02362399|OTHER|placebo|single oral dose of placebo tablet
214939260|NCT07071558|BIOLOGICAL|RSV vaccine formulation 3 dose|Suspension for injection. Route of administration: IM injection
214337786|NCT02323191|DRUG|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
214337787|NCT02323191|DRUG|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
214337788|NCT04369027|DIAGNOSTIC_TEST|passive leg raising|"passive leg raising: to raise the legs of the patients by adjusting the angle of the patient's bed during one minute.~Tidal volume challenge: an increas by 2ml/Kg of the tidal volume during one minute"
214337789|NCT02752997|OTHER|Pharmacist discharge medication services|Included in arm descriptions
214337790|NCT06158633|DRUG|Prevora|"Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant.~All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months."
214337791|NCT04148079|OTHER|physical therapy|low frequency currents (galvanic or TENS), medium frequency currents (interferential) and high frequency currents (short wave diathermy), all combined with an individualized exercise program and massage therapy
214337792|NCT03006406|DRUG|Long term GnRH-a (3.75mg)|patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
214337793|NCT01979653|DRUG|dexmedetomidine alone or dexmedetomidine + midazolam|
214337794|NCT02154815|OTHER|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, 24, 36, 48, 72 months
214337795|NCT04877197|BEHAVIORAL|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
214337796|NCT04877197|OTHER|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
214337797|NCT04512274|DEVICE|Test Article|Omeza Collagen Matrix
214337798|NCT01649856|DRUG|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
214337799|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
214337800|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
214337801|NCT04230382|DIAGNOSTIC_TEST|Diagnosis of diabetes (OGTT)|Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
214337802|NCT04162704|DEVICE|EpiCheck|If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.
214337803|NCT00622635|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
214337804|NCT00622635|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
214337805|NCT00622635|DRUG|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
214939261|NCT07071558|BIOLOGICAL|RSV vaccine formulation 4 dose|Suspension for injection. Route of administration: IM injection
214939262|NCT07071558|BIOLOGICAL|RSV vaccine formulation 5 dose|Suspension for injection. Route of administration: IM injection
214939263|NCT07071558|BIOLOGICAL|RSV vaccine formulation 6 dose|Suspension for injection. Route of administration: IM injection
214939264|NCT07071558|BIOLOGICAL|RSV vaccine formulation 7 dose|Suspension for injection. Route of administration: IM injection
214939265|NCT07071558|BIOLOGICAL|RSV vaccine formulation 8 dose|Suspension for injection. Route of administration: IM injection
214939266|NCT06766851|OTHER|Procedure: TMJ Arthrocentesis|Temporomandibular joint arthrocentesis
214939267|NCT06834373|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214939268|NCT06834373|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214939269|NCT06834373|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214939270|NCT06834373|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Undergo standard of care CAR-T therapy
214939271|NCT06834373|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214939272|NCT06834373|DRUG|Golcadomide|Given PO
214939273|NCT06834373|PROCEDURE|Leukapheresis|Undergo leukapheresis
214939274|NCT06834373|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214939275|NCT06834373|BIOLOGICAL|Rituximab|Given IV
214939276|NCT05138276|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of NEC
214337806|NCT00281840|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
214337807|NCT00281840|DRUG|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
214337808|NCT00281840|PROCEDURE|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
214939277|NCT05138276|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
214939278|NCT04404920|OTHER|Questionnaire|"Novel questionnaire about oral symptoms (Oral symptom assessment scale / OSAS), and validated questionnaire about physical and psychological symptoms (Memorial Symptom Assessment Scale / MSAS)."
214939279|NCT06561464|DEVICE|EzPAP®|EzPAP® is a portable, single-use respiratory exercise device that provides positive expiratory pressure during expiration while supporting respiration during inspiration. Its use has been increasing in recent years as an oxygenation device. It is portable, single-use, easy to use, well-tolerated, and cost-effective. EzPAP® helps increase functional capacity in the lungs and reduces atelectasis. With EzPAP®, an oxygen flow of 5-8 L/min reaches the patient as 35-42% fractionated oxygen, thus quadrupling the oxygen flow.
214939280|NCT06561464|DEVICE|Non-invasive mechanical ventilation (NIMV)|NIMV provides respiratory support during both expiration and inspiration through continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP). Treatment success can be monitored within the first 2 hours by the improvement in oxygenation and reduction in pCO2 levels
214939281|NCT02893982|RADIATION|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
214939282|NCT06519344|BIOLOGICAL|anti-CD20/CD30-CAR-T Cells|Before cell infusion,researchers may decide, based on necessity, whether to administer prophylactic medication,which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others. Subjects are allowed to receive adequate supportive care after anti-CD20/CD30-CAR-T cell infusion,including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesice,etc.
214939283|NCT02715505|DRUG|Umbilical cord blood transplantation with HSC835|Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
214939284|NCT01963377|DEVICE|O2 through nasal cannulae|supplementation of O2 through nasal cannulae during bronchoscopy
214939285|NCT01963377|DEVICE|O2-channel|supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy
214939286|NCT02520427|DRUG|AMG 330|0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.
214939287|NCT00655473|DRUG|Dalcetrapib (RO4607381)|600mg po daily for 24 months
214939288|NCT00655473|DRUG|Placebo|po daily for 24 months
214939289|NCT02048917|DRUG|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
214939290|NCT02048917|DRUG|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
214337809|NCT00281840|RADIATION|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
214337810|NCT00341224|BEHAVIORAL|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
214337811|NCT00006411|OTHER|corneas assigned by donor age group|A web-based computer program was used to select and assign a cornea by donor age group from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors \>=66 and \<66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
214337812|NCT04229719|DRUG|N-acetyl-5-methoxytryptamine|1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
214675758|NCT03215472|OTHER|DASH Cloud|With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.
214939291|NCT02048917|DRUG|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
214939292|NCT02048917|DRUG|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
214939293|NCT02048917|DRUG|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
214337813|NCT03383588|DRUG|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
214939294|NCT02048917|DRUG|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
214939295|NCT02048917|DRUG|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
214939296|NCT02048917|DRUG|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
214939297|NCT02048917|DRUG|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
214939298|NCT02048917|DRUG|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
214939299|NCT02048917|DRUG|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
214939300|NCT02048917|DRUG|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
214939301|NCT03324516|PROCEDURE|Re-Suspension of the temporal muscle after a craniotomy.|The temporal muscle cuff will be used to re-suspend the temporal muscle after a traditional craniotomy.
214939302|NCT03324516|PROCEDURE|Traditional re-suspension of the temporal muscle|The temporal muscle will be re-suspended to the bone plate that is used to fixate the temporal bone that is removed for the craniotomy.
214939303|NCT00793624|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
214939304|NCT00793624|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
214939305|NCT00793624|DRUG|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
214939306|NCT00793624|DRUG|Placebo|Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
214939307|NCT00793624|DRUG|Placebo|Placebo for comparison Formoterolon safety and efficacy in COPD patients
214939308|NCT00710684|DRUG|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
214939309|NCT00710684|DRUG|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
214939310|NCT00710684|DRUG|Placebo|Placebo added to existing donepezil
214939311|NCT00710684|DRUG|donepezil 5-10mg|existing donepezil treatment
214939312|NCT04778059|DRUG|USB002|USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
214939313|NCT04778059|DRUG|Placebo|The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
214939314|NCT06433661|DRUG|Etavopivat|Participants will receive single dose of oral Etavopivat in each treatment period.
214675759|NCT03215472|OTHER|Nutritionix Track app|DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
214675760|NCT02605863|DRUG|Enzalutamide|160 mg by mouth daily for 12 months
214939315|NCT05659862|BEHAVIORAL|Digitally assisted behavioral physical activity intervention|"Digitally Assisted Behavioral Physical Activity Intervention Each week, the step count target will be renewed and an average of 20 minutes of phone calls will be made, including motivational interviews guided by Social Cognitive Theory. Motivational interviews will last 8 weeks.~Outcome Expectations - Informing about the positive results when the physical activity level is increased and the dose-effect relationship Self Efficacy - Individuals' previous physical activity/exercise experiences will be evaluated and discussed.~Social Support - A WhatsApp group will be created. Self Regulation - Self-monitoring ; Goal setting; Feedback, Self-reward"
214939316|NCT05659862|BEHAVIORAL|Education|"Patient Education~* Definition of fibromyalgia syndrome~* Symptoms of fibromyalgia syndrome~* Exercise and physical activity~* Recommendations to improve the quality of life~* Sleep quality and sleep hygiene~* Pain management~* Fatigue and energy conservation techniques All patient education content will also be available on the website."
214939319|NCT02683044|PROCEDURE|Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)|Sessions of shocks to the body of the penis
214675761|NCT04290650|BEHAVIORAL|Modified CBT for insomnia|Nurses who are working closely with the patients around the clock will perform an adjusted and modified version of CBT for sleep disturbances, in addition to standard evidence based treatment for psychosis and affective disorders as per today.
214939320|NCT01553240|DEVICE|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
214939321|NCT00688233|DEVICE|Seifi's Functional|Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
214939322|NCT01665846|DRUG|Ferumoxytol|A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
214939323|NCT05843058|BEHAVIORAL|laughter yoga|The effect of laughter yoga on psychologıcal wellness ın women wıth gynecologıcal cancer has been evaluated.
214939324|NCT00247169|DRUG|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
214675762|NCT04290650|BEHAVIORAL|Treatment as usual|All patients on the two other psychosis wards will receive standard evidence based treatment for psychosis and affective disorders as per today.
214675763|NCT04089605|DRUG|dexamethasone implant|intravitreal dexamethasone implant injections in vitrectomized patients with DME
214675764|NCT04089605|DRUG|Ranibizumab|intravitreal ranibizumab injections in vitrectomized patients with DME
214939325|NCT06648343|OTHER|Intensive cognitive and physical training|The cognitive and physical training program consists of 25-35 minutes of cognitive training (memory, attention, visuospatial orientation) and 10-15 minutes of physical training (stretching, strength training, coordination, and aerobic exercise). Additionally, participants will be instructed to perform 30-40 minutes of aerobic exercise 3-4 times per week
214675765|NCT02222727|DRUG|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
214675766|NCT02041715|DRUG|TKM-100802 for Injection|IV infusion
214675767|NCT02041715|DRUG|Placebo|IV infusion
214939326|NCT04909749|GENETIC|Oneome RightMEd Pharmacogenomic testing Kit|The RightMed test is an end-to-end solution which includes sample collection, pharmacogenomic (PGx) testing services, data analysis, and clinical interpretation that helps physicians select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on Food and Drug Administration (FDA) medication labels. The OneOme RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1.) Green - use as directed; 2.) Yellow - use with caution; and 3.) Red - adjust dose or choose alternative mediation and can be used proactively or reactively
214939327|NCT01828333|OTHER|No intervention|No intervention
214939328|NCT01506154|DRUG|MRX-7EAT|Once daily application of a patch for 14 days
214939329|NCT01623973|OTHER|specific training of paretic upper limb|nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
214939330|NCT07088653|DRUG|MicroRepair ABX mouthwash|Participants begin at T0 (baseline) with clinical assessments, oral hygiene instruction, and the start of a 14-day home regimen using MicroRepair® ABX mouthwash. The formulation contains zinc-hydroxyapatite with antibacterial agents (cetylpyridinium chloride, magnolol, honokiol). Mouthwash is used twice daily (10 mL for 30 seconds) without rinsing, and participants avoid food or drink for 1 hour afterward. All participants use the same sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®) throughout the study.
214939331|NCT07088653|DRUG|Chlorhexidine 0.12% mouthwash|Participants begin at T0 (baseline) with clinical assessments, oral hygiene instruction, and the start of a 14-day home regimen using 0.12% chlorhexidine (CHX) mouthwash. Mouthwash is used twice daily (10 mL for 30 seconds) without rinsing, and participants avoid food or drink for 1 hour afterward. All participants use the same SLS-free toothpaste (Biorepair®) throughout the study.
214939332|NCT04216446|BEHAVIORAL|Mobile Health Intervention|A mobile based application will be developed that will function on android as well as the iPhone operating system. The application will be provided to eligible pregnant women randomized to the intervention group. The dietary, supplement use and physical activity coaching will be provided over the period of 6 months through the application.
214939333|NCT06623578|PROCEDURE|robotic-assisted surgery|robotic-assisted surgery via single-incision transaxillary approach
214939334|NCT06623578|PROCEDURE|Open Surgery|conventional open surgery
214939335|NCT00656487|DRUG|rimonabant|double blind, placebo controlled, single 90 mg dose
214939336|NCT00656487|DRUG|placebo|matched placebo
214939337|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
214675769|NCT01040832|DRUG|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
214675770|NCT01040832|DRUG|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram \[mg/kg\] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
214675771|NCT03311178|DRUG|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
214675772|NCT03492450|OTHER|Treadmill training|Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.
214939338|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
214939339|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
214939340|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
214939341|NCT03439540|DIETARY_SUPPLEMENT|Plantago major|Individuals receive Plantago major daily, for 12 weeks
214939342|NCT03439540|DIETARY_SUPPLEMENT|Placebo|Individuals receive placebo daily, for 12 weeks
214939343|NCT01518231|PROCEDURE|autologous hematopoiesis stem cell transplantation|Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
214939344|NCT01518231|DRUG|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
214939345|NCT01518231|DRUG|Warfarin|warfarin 2\~6mg,qd,po(patients with fibrillation atrial);
214939346|NCT01518231|DRUG|Atorvastatin|atorvastatin 20mg,qd,po
214939347|NCT01518231|DRUG|Edaravone|edaravone 30mg,bid,ivgtt.
214939348|NCT01518231|DRUG|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
214939349|NCT01518231|DRUG|Warfarin|warfarin 2\~6mg,qd,po(patients with fibrillation atrial)
214939350|NCT01518231|DRUG|Atorvastatin|atorvastatin 20mg,qd,po
214939351|NCT01518231|DRUG|Edaravone|edaravone 30mg,bid,ivgtt
214675773|NCT06332053|DRUG|SY-5007|SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11
215074053|NCT04587414|BEHAVIORAL|eHealth +counselling contacts|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
214939352|NCT02319720|BIOLOGICAL|Bone Marrow Aspirate|Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
214939353|NCT02319720|BIOLOGICAL|Cultured Bone Marrow Cells|The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
214675774|NCT06332053|DRUG|Itraconazole|Itraconazole 200 mg, Capsules, Day 8-Day 18
214675775|NCT06332053|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16
214939354|NCT02319720|PROCEDURE|Control|The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
214939355|NCT00264160|DRUG|AMN107|
214939356|NCT05960227|DRUG|Iron dextran|Administration of 1.2g of iron dextran in infusion bolus as a loading strategy.
214939357|NCT05960227|DRUG|Placebo|250ml of saline 0,9% for 4 hours insusion.
214939358|NCT06906523|OTHER|Blood flow restriction training|The intensity of the work will be set at around 40% of the maximum intensity that can be executed in a single repetition (1RM). To reach the established intensity, weights, weighted ankle supports and rubber bands of different resistances will be used. Three sets of 8-10 repetitions will be performed with breaks of 1-2 seconds between repetitions and 2-3 minutes between sets. The intensity of the work will be established by applying the rate of perceived exertion. A blood flow restriction device will be used (Akrafit, Valencia, Spain model).
214675776|NCT06332053|DRUG|Rifampin|Rifampin 600 mg, Capsules, Day 8-Day 21
214675777|NCT00005655|BIOLOGICAL|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
214675778|NCT00005655|BIOLOGICAL|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
214939359|NCT06351098|BEHAVIORAL|nap|Children are nap promoted
214939360|NCT00731757|DRUG|Humira|80 mg at week 0, then 40 mg weekly from week 1-week 23.
214939361|NCT02681757|DEVICE|triple antibiotic ointment dressing|used for control group under soft cast
214939362|NCT02681757|DEVICE|Mepitel Ag|used for variable/experimental group under soft cast
214939363|NCT04101929|DRUG|Apatinib|Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
214939364|NCT04101929|DRUG|S-1 capsule|Patients receive S-1 capsule According to the body surface area \<1.25m2 60mg/d, 1.25 \~ 1.5 m2 80 mg/d, \> 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
214939365|NCT04101929|DRUG|Irinotecan|"Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded."
214939366|NCT04655040|DRUG|Caffeine|100milligram (mg) tablet taken orally in period 1 and period 2
214939367|NCT04655040|OTHER|Ritlecitinib|200 milligrams (mg) taken orally once a day(QD) for 8 days
214939368|NCT04395092|BIOLOGICAL|K-NK002|"K-NK002 will be administered intravenous (IV) on Day -2, Day +7 and Day +28.~Part One (Safety run-in):~An initial safety run-in to confirm the starting dose, and safety and tolerability of K-NK002;~* Dose cohort 1 will include 3 patients who will receive a dose of K-NK002 at 1 x 10E7 NK cells per kg.~* Dose cohort 2 will include 3 patients who will receive K-NK002 at 1 x 10E8 NK cells per kg.~Part Two (Open Enrollment):~Enrollment into the second part of the study (Open Enrollment) can begin following Part One, confirmation of dose and safety."
214939369|NCT04395092|PROCEDURE|Conditioning Regimen|"From Day -7 to Day -3:~* Melphalan: 140 mg/m2 (100mg/m2 in patients ≥ 60) on Day -7.~* Fludarabine: 40 mg/m2 daily for 4 doses starting on days -7.~* TBI: 2 Gy on Day -3."
214939370|NCT04395092|PROCEDURE|HaploBMT|Bone marrow is the only allowed graft source for patients enrolled in this clinical trial
214939371|NCT03702114|DEVICE|auricular point detection|This device is only for auricular detection. No additional intervention will be delivered.
214939372|NCT03258970|OTHER|Observational cohort study|taking vitamin supplements
214939373|NCT00108511|DRUG|Gemfibrozil|
214939374|NCT06249854|DRUG|Bojungikki-tang(BJIKT)|"Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~1. Protective effect of intestine and hematopoietic organs against radiation damage~2. Improving localized radiotherapy-induced immune deterioration~3. Improving cancer-related fatigue and QOL~4. Reducing radiation or chemotherapy induced side effects"
214939375|NCT06249854|DRUG|Pembrolizumab|It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.
214337814|NCT03383588|DRUG|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
214337815|NCT03383588|DRUG|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
214337816|NCT03383588|DRUG|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
214337817|NCT03383588|OTHER|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
214337818|NCT00580905|DRUG|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
214337819|NCT00580905|DRUG|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
214337820|NCT00580905|DRUG|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
214337821|NCT00874744|DRUG|Bevacizumab|1.25mg bevacizumab (0.05ml)
214337822|NCT00874744|DRUG|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
214337823|NCT05632809|DRUG|NKTR-255|Given by IV (vein)
214337824|NCT05632809|DRUG|Durvalumab|Given by IV (vein)
214337825|NCT02130375|PROCEDURE|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
214939376|NCT04724577|RADIATION|carbon ion radiotherapy|dose escalation radiotherapy with five levels of dose from 54GyE/12Fx to 58.8GyE/12Fx
214939377|NCT02209805|DRUG|BIRB 796 BS, low dose|
214939378|NCT02209805|DRUG|BIRB 796 BS, high dose|
214939379|NCT02209805|DRUG|Placebo|
214939380|NCT06237244|DIAGNOSTIC_TEST|triglyceride to glucose ratio|Ratio of triglyceride level to glucose
214939381|NCT06237244|DIAGNOSTIC_TEST|triglycerdie to HDL ratio|Ratio of triglyceride to HDL cholesterol
214939382|NCT07088666|DRUG|MicroRepair ABX mouthwash|"At baseline (T0), participants receive clinical assessments, oral hygiene instruction, and begin a 14-day home regimen with MicroRepair® ABX mouthwash, which contains zinc-hydroxyapatite microcrystals and antibacterial agents (cetylpyridinium chloride, magnolol, honokiol). The mouthwash is used twice daily (10 mL for 30 seconds) after toothbrushing, without rinsing, and participants avoid food or drink for 1 hour. All participants use a sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®) throughout the study.~At 1 month (T1), participants undergo professional supragingival prophylaxis following the Guided Biofilm Therapy (GBT) protocol, which includes plaque disclosure, ultrasonic debridement with an EMS Piezon piezoelectric device, and air-polishing with glycine powder.~At 3 months (T2) and 6 months (T3), additional GBT sessions and a repeated 14-day mouthwash cycle are performed only if the Full-Mouth Bleeding Score (FMBS) remains greater than 10%."
214939383|NCT07088666|DRUG|Chlorhexidine 0.2% mouthwash|"At baseline (T0), participants undergo clinical and photographic assessments, receive oral hygiene instruction, and begin a 14-day home regimen with 0.2% chlorhexidine digluconate mouthwash, used twice daily (10 mL for 30 seconds) after toothbrushing. The solution is not rinsed away, and participants avoid food or drink for 1 hour. All participants use a standardized sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®).~At 1 month (T1), participants receive professional supragingival prophylaxis following the Guided Biofilm Therapy (GBT) protocol, which includes plaque disclosure, piezoelectric ultrasonic scaling with an EMS Piezon device, and air-polishing with glycine powder.~At 3 months (T2) and 6 months (T3), additional GBT sessions and repetition of the 14-day home regimen are performed only if the Full-Mouth Bleeding Score (FMBS) remains greater than 10%."
214939384|NCT05985473|OTHER|audiological measurements|audiological measurements
214939385|NCT05985473|OTHER|Objective and subjective audiological measurements|Objective and subjective audiological measurements
214939386|NCT05985473|OTHER|Evaluation of the denoising methods REFINED|Evaluation of the denoising methods REFINED
214939387|NCT05428163|OTHER|Biological sampling|3ml of blood
214939388|NCT02863510|DEVICE|Renal Sympathetic Denervation|Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
214939389|NCT01243502|DRUG|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
214939390|NCT01243502|DRUG|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
214939391|NCT05801510|BEHAVIORAL|Cognitive Muscular Therapy for knee pain|Psychologically informed physiotherapy which uses biofeedback training to reduce muscle overactivity and improve postural control and also encourages people to change the way they react to pain.
214675779|NCT01565629|BEHAVIORAL|Computer assisted cognitive behavioral therapy.|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
214337826|NCT00078390|DRUG|S-3304|S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
214939392|NCT01254851|BEHAVIORAL|goal-augmented post-operative care|Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
214939393|NCT01903785|DRUG|Salbutamol|60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
214939394|NCT01903785|DRUG|Placebo|
214939395|NCT02222597|DEVICE|infrascanner|
214939396|NCT05724628|PROCEDURE|Laparoscopic appendectomy|Subjects will receive surgery (using 3 port Laparoscopic appendectomy) to remove appendix
214939397|NCT05724628|DRUG|Antibiotics (IV transitioned to oral)|"Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course.~Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin"
214939398|NCT06459505|OTHER|Routine or standard Physical Therapy|Participants will undergo physical therapy to stop abnormal movement patterns and restore control over output in the developmental sequence. Therapists will provide cues to elicit basic posture and movement patterns, inhibiting aberrant patterns. The therapy aims to promote normal posture and movement patterns, incorporating the hemiplegic side for symmetry and functional use. Active usage and targeted strengthening activities will be emphasized, with motor performance practice included.
214939399|NCT06459505|OTHER|Adapted Physical Activity|For Upper extremities, Manual Ability Classification Scale (MACS) is a tool designed to support individuals with hemiplegic cerebral palsy by providing structured support through activities focusing on strength, flexibility, balance, and coordination. Participants at different MACS levels receive tailored treatments, including adaptive tools, task-specific training, assistive gadgets, and functional training. For lower extremities, the therapy will begin on stable support surfaces before progressing to more challenging surfaces such as inflatable cushions, foam pads, or balance discs, focusing on slow and controlled motions for improved body alignment and coordination.
214939400|NCT01306045|DRUG|AZD6244|Cycle = 21 days AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours
214939401|NCT01306045|DRUG|MK-2206|Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week
214939402|NCT01306045|DRUG|Lapatinib|Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)
214939403|NCT01306045|DRUG|Erlotinib|Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)
214939404|NCT01306045|DRUG|Sunitinib|Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28
214939405|NCT01306045|PROCEDURE|Molecular Profiling|Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled
214939406|NCT04103827|OTHER|usability assessment|"Usability of Le Qoos will be assessed using a validated usability questionnaire"
214939407|NCT00026429|BIOLOGICAL|denileukin diftitox|
214939408|NCT03944733|DIETARY_SUPPLEMENT|Iron|65 mg of iron (ferrous sulfate)
214939409|NCT03944733|DIETARY_SUPPLEMENT|Gelatin|600 mg gelatin
214939410|NCT04948554|BIOLOGICAL|MK-2225|Administered Subcutaneously (SC)
214939411|NCT04948554|BIOLOGICAL|Placebo|Administered SC
214939412|NCT00153127|DRUG|polyethyleneglycol3350|
214939413|NCT03647774|DRUG|Extended release naltrexone|380mg injectable extended release naltrexone every four weeks
214939414|NCT04907331|BIOLOGICAL|Vaxzevria|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty
214675780|NCT02123017|DRUG|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses
214675781|NCT02123017|DRUG|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
214675782|NCT02123017|DRUG|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses
214337827|NCT00078390|OTHER|Chemo-irradiation|Standard of care chemo-irradiation
214939415|NCT04907331|BIOLOGICAL|Comirnaty|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria
214939416|NCT05930834|BEHAVIORAL|exercise|All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max
214939417|NCT06043479|OTHER|Fever Management Education|The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.
214939418|NCT02381938|BEHAVIORAL|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
214675783|NCT01592851|DRUG|Stannous Fluoride|dentifrice containing stannous fluoride
214675784|NCT01592851|DRUG|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
214939419|NCT02381938|OTHER|Healthy Finances|6-month intervention to educate and improve financial health
214939420|NCT02432859|PROCEDURE|Electrical Stimulation|Direct current with sensory intensity for one hour
214939421|NCT02432859|PROCEDURE|Placebo|Direct current with zero intensity for one hour
214939422|NCT06730477|OTHER|observational study|Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.
214337828|NCT02501889|BEHAVIORAL|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
214939423|NCT03750747|DEVICE|Pulse Oximeter|SpO2 will be measured using a handheld PO device (selected for this study) applying the low noise cabled sensor. For patients weighing \<10 kg, the sensor will be placed on the big toe. For patients weighing \>10 kg, the sensor will be placed on an index finger. In case of failure in the first attempt, the alternate toe or index finger will be tried (second attempt). First, the sensor will be placed on toe or index finger and then the PO will be powered-on. A stable Sp02 reading will be considered to be obtained if SpO2 reading is stable by ±1 % for at least 10 seconds and the device signal strength is displayed to be adequate (green signal). Second attempt will be warranted if a stable reading is not obtaining within 1-2 minutes.
214939424|NCT07094412|OTHER|Educational content on statin side effects|Participants will view educational content that will include written material, graphics and video. The content will explain side effects and benefits of statin medications. The content will also explain placebo and nocebo effects and how they may impact people taking statins.
214939425|NCT03863327|OTHER|No intervention|There will be no intervention as a part of this protocol.
214939426|NCT02987972|BIOLOGICAL|V114 Lot 1|Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
214939427|NCT02987972|BIOLOGICAL|V114 Lot 2|Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
214939428|NCT02987972|BIOLOGICAL|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
214675785|NCT01058369|DRUG|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
214675786|NCT00483288|OTHER|educational intervention|
214675787|NCT00483288|OTHER|questionnaire administration|
214939429|NCT02359799|DEVICE|IntelliStretch|The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
214939430|NCT06906458|OTHER|Paresthesia|Patients experiencing paresthesia during the interscalene nerve block
214939431|NCT06906458|OTHER|No paresthesia|Patients not experiencing paresthesia during the interscalene nerve block
214337829|NCT02501889|BEHAVIORAL|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
214337830|NCT02534610|DRUG|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
214337831|NCT02534610|DRUG|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
214337832|NCT01079234|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily
214337833|NCT01079234|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
214337834|NCT01079234|DRUG|insulin aspart|At least three daily doses at meal-time
214337835|NCT01037790|DRUG|PD-0332991|Given orally, 125 mg QD on a 21-day
214337836|NCT04412135|OTHER|spirituality|Patients will take three questionnaires (FACIT-Sp, Euroqol 5 dimensions and ESAS)
214939432|NCT05679817|OTHER|Dose-graded aerobic exercises|The D-GAE group received a 12-week aerobic training, three times in addition to the traditional physical rehabilitation. The D-GAE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The D-GAE program included a warm-up for 5 minutes and a cool-down for 5 minutes
214337837|NCT04300400|OTHER|Delphi questionnaire|Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
214337838|NCT01312961|DRUG|Dupilumab|Solution for injection, one subcutaneous injection.
214675788|NCT00483288|OTHER|study of socioeconomic and demographic variables|
214675789|NCT00483288|OTHER|survey administration|
214675790|NCT05682664|OTHER|Luchtbrug Junior (online monitoring)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
214675791|NCT05682664|OTHER|Usual care|Routine outpatient clinical visits every 3 months.
214675792|NCT00815984|PROCEDURE|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
214939433|NCT05679817|OTHER|Traditional physical rehabilitation|The control group received the traditional physical rehabilitation only, 45 minutes per session, three times a week for 12 consecutive weeks. The program consisted of flexibility exercises, strengthening exercises, balance training, and general conditioning exercises.
214939434|NCT02568228|DIETARY_SUPPLEMENT|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
214675793|NCT02940886|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
214337839|NCT01312961|DRUG|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
214337840|NCT01312961|DRUG|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
214939435|NCT02568228|OTHER|Lean and fatty fish|The fish group will be open labeled.
214939436|NCT02568228|DIETARY_SUPPLEMENT|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
214939437|NCT04494763|DRUG|Propanolol|Non-selective Beta-blocker
214939438|NCT04494763|OTHER|Placebo|Inactive drug
214939439|NCT06912438|OTHER|Fill out questionnaire|"After signed consent all patients will be asked to fill a series of questionnaires in print. The questionnaires administered are standardized and validated in Hebrew.~Patients will be asked to fill out:~Diagnostic Criteria for Temporomandibular Disorders (DC-TMD) questionnaire.~Patient Health Questionnaire 9 PHQ-9-HEB~Emotion Regulation Questionnaire (ERQ)~Toronto Alexithymia Scale (TAS - 20)~At each injection session, all patients will be asked to fill out the Profile of Mood States Hebrew translation (POMS-H) before and after trigger point injections."
214939440|NCT06907654|DEVICE|well-being app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
214939441|NCT06907654|BEHAVIORAL|List of well-being resources|Participants will be given a list of resources that promote well-being.
214939442|NCT06912451|DEVICE|Sport custom mouthguard|This mouthguard will be made using two 3mm vinyl acetate ethylene sheets in a vacuum machine, following the recommendations for an appropriate mouthguard regarding trauma prevention and patient comfort. The patients will be monitored after 1, 3, and 6 months of using the mouthguard.
214939443|NCT07091864|OTHER|Best Practice|Receive SOC treatment
214939444|NCT07091864|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214939445|NCT07091864|OTHER|Dietary Intervention|Attend dietary counseling sessions
214939446|NCT07091864|OTHER|Glucose Measurement|Undergo intermittent glucose monitoring
214939447|NCT07091864|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214939448|NCT07091864|OTHER|Monitoring|Undergo CGM
214337841|NCT01312961|DRUG|Fluticasone monotherapy|Oral inhalation twice daily.
214939449|NCT07091864|OTHER|Questionnaire Administration|Ancillary studies
214939450|NCT07091864|OTHER|Supportive Care|Receive endocrinology-guided interventions
214939451|NCT07133646|OTHER|Rib Mobilization Technique and Diaphragm Release Technique|The RMT, adapted from Henderson et al10 and Abdelaal et al,15 was carried out in 2 different participant positions: supine and seated. In the supine position, the therapist was placed next to the participant and positioned the last 4 fingertips of both hands at the rib angles. The therapist mobilized the costal angles in the postero anterior direction accompanying the participant's normal inspiration The movement was performed in 2 series of 10 respiratory cycles in each hemi thorax, with a 1-minute interval between sets.
214939452|NCT07133646|OTHER|Diaphragm Release Technique|The DRT was performed according to the protocol described by Rocha et al.13 In this protocol, the participant remains in the supine position so that the therapist is able to maintain manual contact with the bottom edge of the rib cage. During inspiration, the therapist exerts traction after the natural rib-cage movement, then deepens the manual contact and maintains the resistance exerted in the previous phase throughout exhalation. The technique was applied in 2 series of 10 deep respiratory cycles, with a 1-minute interval between the series, under the therapist's verbal command.
214939453|NCT07095270|DEVICE|Circadian OS software|Circadian OS is a software program that runs on existing iPads. It utilizes the iPad capabilities to control and deliver circadian-effective light.
214939454|NCT06910488|OTHER|Daily Living Activities Mobile Application|mobile application was used for three months
214337842|NCT01312961|DRUG|Albuterol|Oral inhalation as needed.
214939455|NCT06910488|OTHER|Individual interviews|"The individual's daily living activities are assessed using forms and scales that evaluate disability, functional level, and the ability to perform skill-based activities.~Factors affecting daily living activities, such as strengths and weaknesses, barriers, accessible healthcare services, and social support networks, are examined.~The client's independent, semi-dependent, and dependent daily living activities are evaluated together.~Implementation steps are created to achieve the identified goals. Barriers to achieving the goals and supporting factors are identified."
214337843|NCT01312961|DRUG|Levalbuterol|Oral inhalation as needed.
214337844|NCT03511482|DEVICE|myAsthma Application|myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.
214347329|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214939456|NCT06910488|OTHER|Group education|"Information is provided about the symptoms of schizophrenia and bipolar disorder, their causes, and treatment.~The early warning signs are explained, along with the importance of recognizing that they can lead to an emergency situation.~The importance of prior planning for what to do in case of an emergency is discussed. As homework, the family is asked to make this plan together.~Information is provided about the importance of daily living activities and what they entail.~Information is provided about self-care skills, healthy nutrition, movement planning, good sleep hygiene, the importance of body temperature regulation, and elimination issues.~Information is provided about communication skills. Information is given about what to pay attention to in order to establish effective communication."
214939457|NCT06910488|OTHER|Routine rehabilitation program|It includes psychiatric rehabilitation services that are part of the clinic's program.
214939458|NCT04064541|OTHER|Virtual Visit|Virtual Visit
214939459|NCT07100080|DRUG|Iza-bren|Specified dose on specified days
214939460|NCT07100080|DRUG|Carboplatin|Specified dose on specified days
214939461|NCT07100080|DRUG|Cisplatin|Specified dose on specified days
214939462|NCT07100080|DRUG|Pemetrexed|Specified dose on specified days
214939463|NCT07099365|DEVICE|Orbi|Orbi is adapted from COMPASS, a web-based cognitive behavioural therapy (CBT) intervention based on the Transdiagnostic Model of Adjustment in Long-Term (physical) Conditions Model. Orbi is made up of 13 topics, each exploring a different challenge faced by individuals with a LTC(s). Orbi is a self-guided CBT programme with no therapist involvement.
214939464|NCT06830720|DRUG|ribociclib + NSAI ± LHRH|ribociclib in combination with an aromatase inhibitor ± LHRH as described in the summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
214939465|NCT06830720|DRUG|abemaciclib + ET ± LHRH|abemaciclib in combination with an endocrine therapy ± LHRH as described in the summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
214939466|NCT06830720|DRUG|ET mono ± LHRH|endocrine monotherapy ± LHRH. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
214939467|NCT06908109|DEVICE|Yankauer Suction Device|The Yankauer suction device is a hollow, curved and flexible tube that has a suction tip surrounded by a bulbous head to allow effective suctioning without damaging the surrounding tissue. It has been frequently used in multiple settings that range from minor dental procedures to large surgeries. It is also frequently used in the intensive care units to suction oropharyngeal secretions and prevent aspiration. Throughout this study, and regardless of the study group (control or intervention group), the Yankauer suction device is attached to a distinct suction port and placed, at the other end, inside the oral cavity of the patient.
214939468|NCT06908109|PROCEDURE|Bronchoscopy|Flexible bronchoscopy done for the following indications: presence of a lung mass or collapse, persistent pulmonary infiltrates, pulmonary infection in the setting of immunosuppression, hemoptysis, or other rare causes like chronic cough. Flexible bronchoscopy (FB) is a medical procedure that has been used for more than five decades for the diagnostic evaluation and/or therapeutic intervention in a multitude of pulmonary and bronchial diseases
214939469|NCT04862897|OTHER|Patient-controlled admissions|Patients are allowed to admit themselves to inpatient care when needed (standard procedure, four days of inpatient care at a time, up to three times a month)
214939470|NCT06620653|OTHER|Telemonitoring|Patients assigned to the intervention group will receive a tablet (if the patients do not have a tablet, computer or smartphone), a weight scale and a blood pressure monitor. The patients will provide daily biometric data (weight, heart rate and blood pressure) and report symptoms through four questions to capture worsening symptoms of the cardiac condition.
214939471|NCT06620653|OTHER|Standard Care|patients with a recent admission for heart failureare seen in a first face-to-face appointment within two weeks of discharge as per current 2021 ESC Heart Failure Guidelines with face-to-face follow up at 6 and 12 weeks.
214939473|NCT06696443|DRUG|Suzetrigine|Tablets for oral administration.
214347330|NCT02897804|BEHAVIORAL|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
214939474|NCT04084730|RADIATION|Accelerated Partial Breast Irradiation|Treatment will consist of APBI delivered using external beam RT techniques to a dose of 24 Gy in 3 fractions of 8.0 Gy delivered on consecutive weekdays
214939475|NCT06395103|BIOLOGICAL|Zilovertamab vedotin|Administered via IV infusion
214939476|NCT06731452|BEHAVIORAL|Strategic Memory Advanced Reasoning Training teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance|"Online SMART is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~Stress Solutions extends the SMART principles to relevant domains of stress and resilience."
214939477|NCT07109609|DRUG|Topical application of 20% menthol solution in MCT oil.|To facilitate reproducible and correct application of the solution, the subject wears glasses while the product is applied. The solution is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers about 12 mg solution, i.e. 2.4 mg menthol to one cheek. Or this method delviers 12 mg of placebo oil. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
214939478|NCT07109609|DRUG|Topical Placebo Oil rolled onto the cheek.|To facilitate reproducible and correct application of the Placebo oil, the subject wears glasses while the product is applied. The Placebo oil is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers zero active agent. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
214939479|NCT00673751|DRUG|GLP-2|450 nmol subcutaneous
214939480|NCT00673751|DRUG|Placebo|
214939481|NCT06911437|OTHER|treatment group|"Xiaoyu Zhitong Formula: 10g of long pepper, 10g of cloves, 10g of borneol, 10g of papaya, 10g of white peony, 10g of licorice, 15g of chicken blood vine, 10g psoralen, 10g of cistanche, powdered petroleum jelly, wrapped in gauze and heated and applied to the affected area.~Freehand lymphatic drainage technique: the patient is in the supine position, first use the thumb to press the deep lymph nodes of the trunk for 3-5 min, which are lymph nodes in the groin, neck, lumbosacral spine and supraclavicular fossa, and then perform freehand lymphatic drainage at the lymphatic vessels or superficial lymph nodes, according to the clockwise circle method, all the way to the outside of the thigh, and then to the lateral malleolus of the calf, and then press the medial malleolus of the inner calf to the inner thigh. 20min each time, 1 time every other day. 3 times a week for a total of 9 treatments for 3 weeks."
214939482|NCT06911437|OTHER|control group|External application of Diclofenac Diethylamine Emulgel（Manufacturer: Switzerland,Haleon CH SARL） combined with lymphatic drainage technique for treatment，Freehand lymphatic drainage technique: the patient is in the supine position, first use the thumb to press the deep lymph nodes of the trunk for 3-5 min, which are lymph nodes in the groin, neck, lumbosacral spine and supraclavicular fossa, and then perform freehand lymphatic drainage at the lymphatic vessels or superficial lymph nodes, according to the clockwise circle method, all the way to the outside of the thigh, and then to the lateral malleolus of the calf, and then press the medial malleolus of the inner calf to the inner thigh. 20min each time, 1 time every other day. 3 times a week for a total of 9 treatments for 3 weeks.
215074054|NCT04587414|BEHAVIORAL|eHealth|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
215074055|NCT04587414|BEHAVIORAL|Usual care|Usual care and councelling given to type 2 diabetics within the primary health care setting.
215074056|NCT01792713|DRUG|Sertaconazole 2% cream|
215074057|NCT01792713|DRUG|Placebo|
215074058|NCT00642434|DRUG|carvedilol|variable
215074059|NCT00642434|DRUG|metoprolol|variable
214675794|NCT02940886|DRUG|Iron sucrose|"Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial.~Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended."
214347331|NCT02897804|BEHAVIORAL|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214347332|NCT02897804|BEHAVIORAL|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214675795|NCT00502905|DRUG|Busulfan|130 mg/m\^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
214675796|NCT00502905|DRUG|Fludarabine|40 mg/m\^2 through a central venous catheter over one hour, once a day, for four days.
215074060|NCT01407471|DRUG|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
214675797|NCT05492383|DEVICE|TAVI|Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
214675798|NCT01969175|OTHER|Low-glycemic-load and milk-free diet|
214675799|NCT05413967|OTHER|Mills manipulation in addition to myofasical release therapy|Group A will receive Mills manipulation in addition to myofasical release therapy as baselin
215074061|NCT01407471|DRUG|Clobetasol + Placebo|One application 6 days a week during 4 weeks
214939483|NCT06910215|OTHER|Elastic therapeutic taping|Elastic therapeutic taping is a non-invasive method that uses a specially designed elastic cotton tape applied directly to the skin. In this study, it is used to support pain management after open-heart surgery (CABG via sternotomy). The tape is applied near the surgical site to gently lift the skin, which may help reduce pain, improve circulation, and support healing. The application is done by a trained physiotherapist following a standardized taping protocol. The tape remains on the skin for up to 48 hours.
215074062|NCT01407471|DRUG|Placebo + Spironolactone|One application 6 days a week during 7 weeks
214675800|NCT05413967|OTHER|Nirschl exercises in addition to myofascial release therapy|Group B will receive Nirschl exercises in addition to myofascial release therapy as baseline
214675801|NCT01306058|DRUG|TRC 105|15 mg/kg intravenous (IV) every 2 weeks
214675802|NCT01306058|DRUG|Sorafenib|400 mg twice a day (bid) continuously in a 28 days cycle
214675803|NCT01666444|DRUG|pegylated liposomal doxorubicin (PLD)|
214675804|NCT01666444|DRUG|VTX-2337|TLR8 Agonist
214939484|NCT06910215|OTHER|Placebo Elastic Therapeutic Taping|In this group, the same type of elastic tape used in the therapeutic group is applied to the skin near the surgical area, but without any stretch or therapeutic technique. The tape does not provide physical support or intended therapeutic effects. It is used to help researchers understand whether any improvements are due to the taping itself or simply from receiving an intervention. The tape remains in place for up to 48 hours and is applied by trained personnel using a standardized, non-therapeutic method.
214939485|NCT06910215|OTHER|Therapeutic Taping on Non-Surgical Areas|In this group, elastic therapeutic tape is applied to body areas not directly related to the surgery, such as the shoulder, back, or rib area. The purpose is not to treat pain at the surgical site, but to simulate the experience of receiving a physical intervention. This approach helps researchers understand the potential impact of attention, expectation, or psychological support related to being part of a study. The tape is applied gently without therapeutic intent and stays on for up to 48 hours
214939486|NCT06912256|BEHAVIORAL|Sleep restriction|During the intervention period (i.e., 9 consecutive days), the intervention group started the sleep protocol, sleeping only the quantity of hours defined for their individual chronic partial sleep restriction (15% of the usual sleep time). The amount and quality of sleep obtained were daily monitored through actigraphy devices, and all the players filled in a sleep diary when they woke up. During this period, players performed the SSGs in two different moments (moment 1 and moment 2), interspersed by 4 days.
214939487|NCT06910553|OTHER|Non-exposed group|Pregnant individuals with IBD who are not exposed to an IBD pharmacotherapy during pregnancy
214675805|NCT01666444|DRUG|Placebo|
214675806|NCT01947374|PROCEDURE|Matrix encapsulated chondrocyte implantation|Each implant contains 6,000,000 autologous chondrocytes.
214675807|NCT01947374|PROCEDURE|Microfracture awl|Is an awl that allow perforation of the subchondral bone.
214675808|NCT02158143|DIETARY_SUPPLEMENT|vitamin D3|
214675809|NCT01390701|DEVICE|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
214675810|NCT01390701|DRUG|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
214675811|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
214939488|NCT06910553|DRUG|Exposed to IBD pharmacotherapy during pregnancy|Pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy
214939489|NCT06909851|PROCEDURE|Adductor Canal Block (ACB)|Evaluation of postoperative analgesic effectiveness of ACB block in participants undergoing arthroscopic knee surgery under spinal anesthesia.
214939490|NCT06909851|PROCEDURE|Genicular Nerve Block (GNB)|Evaluation of postoperative analgesic effectiveness of GNB block in participants undergoing arthroscopic knee surgery under spinal anesthesia.
215074063|NCT01407471|DRUG|Placebo + Placebo|One application 6 days a week during 7 weeks
215074064|NCT03898466|DRUG|Fluticasone furoate|Inhaled corticosteroid
215074065|NCT03898466|OTHER|Matching placebo|Placebo inhaler
215074066|NCT00003603|DRUG|cyclophosphamide|
215074067|NCT00003603|DRUG|dexamethasone|
215074068|NCT00003603|DRUG|idarubicin|
215074069|NCT00003603|DRUG|lomustine|
215074070|NCT00003603|DRUG|melphalan|
215074071|NCT00003603|DRUG|prednisolone|
215074072|NCT04703816|OTHER|Interpersonal Skills Multifaceted Training Program for the physician-patient relationship|The training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations based on communication theory like Process-Com® and the Four Habits Model.
215074073|NCT01551576|DEVICE|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
215074074|NCT03092830|GENETIC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
215074075|NCT01818258|DRUG|ZDV+3TC+LPV/r|
215074076|NCT00159328|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
215074077|NCT03619096|PROCEDURE|tunnel technique for Root coverage with Porcine collagen Matrix|Tunnel technique for root coverage for multiple gingival recessions, using porcine collagen matrix
215074078|NCT03619096|PROCEDURE|extended fla technique for Root coverage with Porcine collagen Matrix|Extended flap technique for root coverage for multiple gingival recessions, using porcine collagen matrix
215074079|NCT02708849|DRUG|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
215074080|NCT02708849|DRUG|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
215074081|NCT02708849|DRUG|Placebo|oral dose placebo
215074082|NCT05559840|DEVICE|S-Condom Uterine Tamponade|The condom catheter will be inflated with air
214939491|NCT07112391|OTHER|Observational Invasive Hemodynamic Assessment|Collection and analysis of invasive hemodynamic data obtained through routine cardiac catheterization performed as part of standard care. No intervention is mandated by the study protocol.
214939492|NCT04149574|DRUG|nivolumab|Specified Dose on Specified Days
214939493|NCT04149574|OTHER|Placebo|Specified Dose on Specified Days
214939494|NCT04149574|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Specified Dose on Specified Days
214939495|NCT05305547|DRUG|S-217622|Administered as a round tablet.
214939496|NCT05305547|DRUG|Placebo|Administered as a round tablet.
214939497|NCT06136650|DRUG|Opevesostat|Administered orally
214939498|NCT06136650|DRUG|Dexamethasone|Administered orally
214939499|NCT06136650|DRUG|Fludrocortisone acetate|Administered orally
214939500|NCT06136650|DRUG|Hydrocortisone|Administered orally or IM as a rescue drug
214939501|NCT06136650|DRUG|Abiraterone acetate|Administered orally
214939502|NCT06136650|DRUG|Prednisone acetate|Administered orally
214939503|NCT06136650|DRUG|Enzalutamide|Administered orally
214939504|NCT07111078|BIOLOGICAL|VRC-FLUMOS0122-00-VP (SteMos1) with and without Army Liposome Formulation containing saponin QS-21 (ALFQ) Adjuvant|"FLUMOS0122-00-VP (SteMos1) is a sterile, aqueous buffered solution supplied in 3 mL single-dose glass vials containing 0.7 +/- 0.1 mL with a vaccine concentration of 1080 mcg/mL.~The ALFQ drug product is a sterile suspension that contains 240 mcg of monophosphoryl 3-deacyl Lipid A (3D-PHAD) and 120 mcg QS-21 that is vialed at 0.6 mL/vial in 3.0 mL glass vials. 0.5 mL of ALFQ adjuvant will be mixed with the 60 or 180 mcg dose of SteMos1 during preparation in the pharmacy prior to"
214939505|NCT02826668|OTHER|Ultrasound|A baseline lumbar ultrasound in a standardized lateral position (by bed markings) will be performed with the midline and L3-L4 interspace marked, and estimated depth to the epidural space recorded. A second lateral lumbar ultrasound will be performed immediately prior to placement at the time of epidural request. The bed position will be standardized with lines drawn down the back, at the flexion of the knee, and heel of the foot. The sonographic measurements will include the midline, the L3-4 interspace, (both marked at the skin surface), and the measured depth to the ligamentum flavum (in centimeters).
214939506|NCT07113054|DRUG|Edoxaban 60 MG [Lixiana]|Single administration of edoxaban
214939507|NCT07113054|OTHER|Edoxaban 60 MG [Lixiana] + Grapefruit Juice|Coadministration of edoxaban and grapefruit juice
214939508|NCT05319743|OTHER|Medicaid Expansion|Expansion of Medicaid, 01/01/2014
214939509|NCT03175692|DIAGNOSTIC_TEST|Whole Exome Sequencing|Using next generation sequencing to analysis patient's whole exome. To explore the pathogenic gene variation.
214939510|NCT04824794|BIOLOGICAL|GEN3014|GEN3014 is administered by IV infusion.
214939511|NCT04824794|DRUG|Daratumumab|Daratumumab is administered by SC injections.
214939512|NCT06937762|DEVICE|Intra capsular coblation tonsillotomy|Tonsils were dissected from the surface inward with the wand set at Coblate 7 setting. The wand skims the tonsil surface with continuous saline irrigation. Ablation was performed without penetrating the tonsillar capsule. Retraction of the tonsillar pillars is done to define the margins for near complete ablation. When the capsule is approached, the wand is turned down to Coblate 3 setting. Thin layer of tonsillar tissue is left to protect the capsule. Bleeding does not occur in most cases, but when it occurs, the wand was used in the Coagulate 5 setting for homeostasis
214939513|NCT06937762|DEVICE|Extracapsular cold knife dissection tonsillectomy|Begin by retracting the anterior tonsillar pillar to expose the tonsil, use a cold knife (scalpel or tonsil dissector) to make an incision along the anterior pillar near the mucosal margin of the tonsil, identify the plane between the tonsillar capsule and the underlying pharyngeal muscle, then carefully dissect the tonsil away from the surrounding tissues, following the plane to avoid trauma to the underlying structures, proceed from the superior pole of the tonsil to the inferior pole, ensuring that the entire tonsil is removed, use gauze or sponges to control minor bleeding during the procedure, for more significant bleeding, apply direct pressure or use ligatures and cold packs, achieve final hemostasis using absorbable sutures or electrocautery if needed
214939514|NCT06937762|DEVICE|Extra capsular Radiofrequency tonsillectomy|Radiofrequency bipolar forceps, connected to a radiofrequency apparatus model Ellman Surgitron 4 MHz (Ellman International, New York, USA) by which cutting and dissection with coagulation were done in the same time with minimal diffuse heating to the surrounding tissue. The power was adjusted to a power grade 40 in a bipolar mode.
214939515|NCT06940713|DEVICE|Imaging Time|"fUS:~transfontanellar functional ultrasound imaging, performed using the CONEXUS system.~fUS-EEG:~transfontanellar functional ultrasound imaging, performed using the CONEXUS system, performed simultaneously with an EEG examination.~The fUS examinations consist of recording brain activity for a few minutes in one of the imaging planes (Posterior Coronal, Median Coronal, Frontal Coronal, Right Para-sagittal, Right/Left Para-sagittal, 3-plane Antero-posterior Coronal) including structures involved in brain functional connectivity networks (somatosensory, auditory, visual, salience).~These fUS examinations are conducted to perform longitudinal follow-up of patients in the 5 different groups."
214939516|NCT07143487|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214939517|NCT07143487|OTHER|Genetic Testing|Undergo genetic testing
214939518|NCT07143487|OTHER|Communication Intervention|Receive proband-mediated communication
214939519|NCT07143487|OTHER|Survey Administration|Ancillary studies
214939520|NCT06945640|DEVICE|RUS NE|RUS NE is a surgical navigation system designed for use in robot-assisted partial nephrectomy. It reconstructs CT images into 3D models, providing visualization of tumor and vascular structures to enhance surgical precision and optimize resection planning. This system aids in reducing resection volume and improving operative outcomes by integrating anatomical insights into the surgical workflow.
214939521|NCT06948656|OTHER|fitting a blood glucose sensor|automatic, continuous collection by the blood glucose sensor for 14 days
214939522|NCT06948656|OTHER|food collection|14-day dietary record in a notebook for the patient
214939523|NCT06948656|OTHER|tests and questionnaires|measurement of muscle strength using a hand-held dynamometer, animal enumeration test, self-questionnaire on the frequency of consumption of the main food groups
215074083|NCT05559840|DEVICE|Traditional condom catheter|The condom catheter will be inflated with saline following national protocol
214939524|NCT07146230|DRUG|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD 1 on T cells and CD80 (B7.1) on immune cells.
214337845|NCT03511482|DEVICE|Lloyds Pharmacy Online Doctor|"Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare."
214337846|NCT02052479|OTHER|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
214337847|NCT04003727|DEVICE|Mcgrath Mac Videolaryngoscope|Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
214939525|NCT07146230|DRUG|Monalizumab|Monalizumab is a humanized mAb of the IgG4 subtype that specifically binds and inhibits Cluster of Differentiation 94 (CD94)/NK cell protein group 2 A(NKG2A).
214939526|NCT07146230|DRUG|Oleclumab|Oleclumab is a human IgG1λ mAb that selectively binds to and inhibits the ectonucleotidase activity of CD73.
214939527|NCT07146230|RADIATION|Radiotherapy|PET based dose painted radiotherapy. If these treatment techniques are not available for some reason treatment may be delivered using a sequential boost technique (2.75 Gy x 17 to the low-risk PTV followed by 2.75 Gy x 3 to the high-risk planning target volume).
214939528|NCT07071051|OTHER|Non-Interventional Study|Non-interventional study
214939529|NCT07174700|OTHER|Questionnaire|An online questionnaire will be used to assess the prevalence of internet addiction, gaming addiction, and porn addiction, and their relation with stress, anxiety and depression
214939530|NCT07175493|BIOLOGICAL|CM336 Injection|subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol
214939531|NCT07174492|DRUG|Masitinib 4.5 mg/kg/day|masitinib + riluzole
214939532|NCT07174492|DRUG|Placebo|Placebo + riluzole
214939533|NCT07176312|DRUG|Zanidatamab|Zanidatamab 1,200 mg (patients \<70 kg at baseline) or 1,600 mg (patients ≥70 kg at baseline), administered i.v. on day 1 of each 2-week cycle (Q2W)
214939534|NCT07176312|DRUG|Pembrolizumab|Pembrolizumab 400 mg, administered i.v. on day 1 of every third cycle (Q6W)
214939535|NCT07176312|DRUG|mFOLFOX|modified FOLFOX with Oxaliplatin 85 mg/m2 i.v. on day 1; Folinic Acid 400 mg/m2 i.v. on day 1; 5-FU 2,400 mg/m2 i.v. continuous infusion over 48 hours (no bolus!) on days 1 and 2 of each 2-week cycle (Q2W)
214939536|NCT07176845|OTHER|Observational|This study is observational of nature: multidimensional data is collected and no interventional is imposed
214939537|NCT07176468|OTHER|Neuronavigation-guided individualized iTBS|"Participants will receive individualized iTBS for 14 consecutive days in addition to their usual medication regimen.~iTBS parameters: 50 Hz bursts every 200 ms (5 Hz), 2s on/8s off, total 600 pulses per session;6 sessions/day (3 in morning, 3 in afternoon, 3600 pulses/day); 100% RMT intensity; Neuronavigation: Brainsight system (Rogue Research, Canada)"
214939538|NCT07175168|OTHER|No medical or experimental intervention will be administered|Laboratory procedures (blood sampling for karyotyping, basic investigations such as echocardiography, thyroid function tests, abdominal ultrasound) are part of standard diagnostic assessment, not rese
214939539|NCT07176637|BEHAVIORAL|A-B-C Program|"The purpose of this study is to assess the effectiveness of the 4-week A-B-C program in implementing and maintaining daily PA. We will explore outcomes for the effectiveness of the program, on (1) increasing the weekly duration of PA, and (2) reducing baseline depressive symptoms and other mental health outcomes among sedentary older adults with depressive symptoms at baseline. Specifically, we will evaluate the change in depressive symptoms, stress, and self-esteem from baseline, at the end of the 4-week intervention, and after additional 4 weeks from the end of the intervention (at follow-up). The intervention will be 4 weeks overall, with total of 8 sessions: the duration of each session will be 60 minutes each, and the frequency will be twice weekly for 4 weeks."
214337848|NCT04051892|DEVICE|FixNip™ NRI|The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
214337849|NCT02390583|BEHAVIORAL|CBT treatment of internet dependence|CBT treatment of internet dependence
214337850|NCT02390583|BEHAVIORAL|CBT treatment of sleep disorders|CBT treatment of sleep disorders
214939540|NCT07176637|OTHER|Physical Activity Educational Program|"The control group will serve as an sham active comparator, designed to control for group format, scheduled sessions, and social interaction. The agenda for the control group was designed to specifically function as a control to compare the A-B-C program. These participants will also attend twice-weekly 60-minute sessions over four weeks, focusing on educational content about the health benefits of physical activity and current physical activity guidelines.~The difference between the two interventions is that the control program is strictly educational, whereas the A-B-C program focuses on challenging cognitive biases that change decision making related to physical activity. To reiterate, the control program simply provides education on the effects of physical activity with physiological evidence."
214337851|NCT00628602|DEVICE|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
214337852|NCT03422120|OTHER|Natural Killer Cell Activity Assay|Subjects had a blood test to measure NK cell activity (NKA) at different time points
214337853|NCT02166983|OTHER|computer-assisted cognitive training|Complete Lumosity cognitive exercises
214337854|NCT02166983|OTHER|cognitive intervention|Complete Active Journaling cognitive exercises
214939541|NCT07174817|BEHAVIORAL|weight loss|The weight loss intervention group underwent dietary and exercise programs for three months prior to initiating IVF treatment. These interventions included consuming foods with a low glycemic index (GI), achieving a daily net energy expenditure of 500-750 kcal, and engaging in moderate-intensity exercise 3-5 times per week. After the three-month period, weight maintenance was managed according to each patient's preferences.
215074084|NCT03655301|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
215074085|NCT03655301|DRUG|Metformin|Single dose of 1000 mg is administered orally.
214337855|NCT02166983|PROCEDURE|mind-body intervention procedure|Complete relaxation exercises
214337856|NCT02166983|OTHER|memory intervention|Complete compensatory strategies
214337857|NCT02166983|OTHER|questionnaire administration|Ancillary studies
214939542|NCT07175805|PROCEDURE|Bariatric Surgery|Patients in this arm plan to undergo gastric sleeve or gastric bypass surgery.
214939543|NCT07175805|DRUG|GLP1 receptor agonist|Patients in this arm plan to start a GLP-1 receptor agonist.
214939544|NCT07176689|DRUG|Nirogacestat|Nirogacestat oral tablet
214939545|NCT07175714|OTHER|Methodologies to induce gait perturbations|Method 1: Obstacles deployed at the frond end side of the treadmill Method 2: Obstacles deployed on the side of the treadmill Method 3: Spit-bell treadmill to induce slip perturbations Method 4: String method
215074086|NCT01410175|DEVICE|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
215074087|NCT03227653|DRUG|Efavirenz|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
215074088|NCT03227653|DRUG|Nevirapine|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
215074089|NCT03227653|DRUG|Lopinavir-Ritonavir Drug Combination|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
215074090|NCT04296175|DRUG|Epirubicin|90mg/m2, d1 every 2 or 3 weeks
215074091|NCT04296175|DRUG|CTX|600mg, d1 every 2 or 3 weeks
214337858|NCT02212821|DRUG|Erythromycin|
214337859|NCT02212821|DRUG|Placebo|physiological saline
215074092|NCT04296175|DRUG|Paclitaxel|80mg/m2,d1,d8,d15, every 3 weeks
215074093|NCT04296175|DRUG|ddEpirubicin|90mg/m2, d1 every 2 weeks
214337860|NCT04898231|DRUG|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
214337861|NCT04898231|DRUG|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
214337862|NCT04898231|DRUG|Methylprednisolone|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
214337863|NCT05676385|DIETARY_SUPPLEMENT|First concept product (containing 50 grams of carbohydrates)|Fasted intake of First concept product (randomised)
214337864|NCT05676385|DIETARY_SUPPLEMENT|Second concept product (containing 50 grams of carbohydrates)|Fasted intake Second concept product (randomised)
214337865|NCT05676385|DIETARY_SUPPLEMENT|Reference product (containing 50 grams of carbohydrates)|Fasted intake of Reference product (randomised)
214337866|NCT03282552|DEVICE|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
214337867|NCT03291613|OTHER|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
214337868|NCT00205712|DRUG|Ketamine|Ketamine without dexmedetomidine
215074094|NCT04296175|DRUG|ddCTX|600mg, d1 every 2 weeks
215074095|NCT04296175|DRUG|Paclitaxel(with carbo)|80mg/m2,d1,d8,d15, every 4 weeks
215074096|NCT04296175|DRUG|Carboplatin|AUC=2,d1,d8,d15, every 4 weeks
215074097|NCT06127381|DRUG|Glycolic acid tetrasubstituted piceatannol (TGKP)|A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.
215074098|NCT06172803|BEHAVIORAL|Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise|8 week exercise program. 20 minutes of home aerobic exercise most days, phone- based motivational exercise coaching and supervised exercise with our team exercise physiologist.
214337869|NCT00205712|DRUG|Dexmedetomidine|Ketamine plus dexmedetomidine
214337870|NCT00006095|DRUG|irinotecan hydrochloride|
214939546|NCT07176624|PROCEDURE|Enteral nutrition is reduced before the prone position|Before the prone position, the gastric contents are aspirated with a syringe, and the dose of enteral nutrition reduction is determined based on the different amounts of gastric residue. If the residual volume in the stomach is less than 200ml, the enteral nutrition intake will be reduced by one third. Gastric residual volume 200-500ml: Reduce enteral nutrition by half. If the residual gastric volume is greater than 500ml: Stop enteral nutrition and consider post-pyloric feeding
215074099|NCT06172803|BEHAVIORAL|Light Stretching/Breathing Exercises|The control group will receive 8-week, attention-matched, stretching and breathing exercises, supervised by a rehabilitation clinician (via 20-minute weekly video visits). Exercises performed 5 days a week will not increase HR significantly. Participants will record and track their HR with Apple watch and app; like RESToRE, fidelity of treatment will be objectively measured using HR data.
215074100|NCT02052336|DRUG|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
214675812|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
214675813|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
214675814|NCT05163561|BIOLOGICAL|Sii Licensed IPV|Poliomyelitis Vaccine (Inactivated), produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Poliomyelitis Vaccine (Inactivated) is a highly purified, inactivated poliovirus vaccine.
215074101|NCT02052336|DRUG|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
214675815|NCT00935857|DEVICE|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
215074102|NCT02052336|DRUG|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
215074103|NCT04812119|DIAGNOSTIC_TEST|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F; Robins, Fein, \& Barton, 2009) is a 2-stage parent-report screening tool to assess risk for Autism Spectrum Disorder (ASD). It is valid for children 16-30 months old.
215074104|NCT04812119|DIAGNOSTIC_TEST|The Autism Spectrum Quotient-Children's Version (AQ-Child)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 4-11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
215074105|NCT04812119|DIAGNOSTIC_TEST|The Autism-Spectrum Quotient (AQ)-Adolescent Version (AQ-Adolescent)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 12-15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
215074106|NCT04812119|DIAGNOSTIC_TEST|The Viking's Speech Scale|The Viking Speech Scale (Pennington, Virella, Mjøen, da Graça Andrada, Murray, Colver, … \& Andersen, 2013) is used to classify children's speech production, specifically the ease at which children can make themselves understood using different methods of communication. The scale has four levels and is ordinal. The four levels include: (1) speech is not affected by motor disorder (2) speech is imprecise but usually understandable to unfamiliar listeners (3) speech is unclear and not usually understandable to unfamiliar listeners out of context (3) no understandable speech. It is intended for children above the age of 4 years.
214337871|NCT00006095|DRUG|vincristine sulfate|
214337872|NCT01331694|DRUG|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
214337873|NCT01331694|DRUG|tiotropium|patients initiating treatment with tiotropium
214337874|NCT01331694|DRUG|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
214337875|NCT04796831|DRUG|Quizartinib dihydrochloride|Single oral dose of 60 mg quizartinib (2 x 30 mg tablets)
214337876|NCT04796831|DRUG|14C-Quizartinib solution for infusion|50 μg solution for infusion containing NMT 22.84 kBq 14C in 5 mL; administered once as a 15-minute infusion
214337877|NCT04977843|PROCEDURE|EARLY BRONCHOALVEOLAR LAVAGE|E-BAL done with instillation of 100cc normal saline and sucked out
214337878|NCT01856816|OTHER|Meal Pattern Treatment A|"In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
214337879|NCT01856816|OTHER|Meal Pattern Treatment B|"In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
214337880|NCT01856816|OTHER|Meal Pattern Treatment C|"In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
214337881|NCT02582099|DRUG|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
214939547|NCT07174765|OTHER|Person-level linkage of the database looking for relationship with septic shock survival and comorbidities, previous intake of medication, and previous dependence on health services.|"A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted with septic shock to hospitals in the region will be carried out.~The overall data of patients admitted to hospitals will be analysed. The survival data of patients will be compared with their previous individual drug consumption and inhospital survival to septic shock. In addition, drug dependence and dependence on health services of survivors will be studied in comparison with their situation prior to sepsis.~The objective is to establish the Registry of Administrative Data Automatically Recorded for Septic Shock (RADAR-Septic Shock), leveraging administrative data to characterize septic shock incidence, describe patient profiles, identify population-specific healthcare needs, and provide benchmark values for performance assessment in Catalonia's public health system."
214337882|NCT02582099|DRUG|Normal saline nasal irrigation|Nasal wash with normal saline solution
214939548|NCT07175428|DRUG|REGN7508|Administered per the protocol
214939549|NCT07175428|DRUG|REGN9933|Administered per the protocol
214939550|NCT07175428|DRUG|Apixaban|Administered per the protocol
214675816|NCT00935857|DEVICE|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
214675817|NCT03843658|OTHER|There is no intervention, but a diagnosis.|Cohorts will be determined by the primary rheumatology diagnosis.
214675818|NCT01143350|OTHER|Bras A (EHPAD Training and stimulation)|"EHPAD of the group of Training / Stimulation will benefit:~* after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~* of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
214675819|NCT01143350|OTHER|EHPAD Control|EHPAD of the reference group, will have their habitual functioning
214675820|NCT00592358|DRUG|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
214675821|NCT00084682|DRUG|romidepsin|Given IV
214675822|NCT04011436|OTHER|Strengthening program|"Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises"
214675823|NCT03152136|DEVICE|Cala ONE device|The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
214337883|NCT04618055|DEVICE|NiTiDent Tuah Porous NiTi Dental Implants|A newly developed NiTiDent Tuah porous NiTi cylindrical bone level dental implant measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations produced by Nitium Technology Sdn Bhd.
214337884|NCT04618055|DEVICE|Control Dental Implant Systems|A market approved bone level dental implant systems measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations
214337885|NCT03709537|BEHAVIORAL|Mental Health Peer Workforce Support|"Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency."
214337886|NCT01180712|DIETARY_SUPPLEMENT|Mirtoselect|"Male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days."
214347333|NCT02897804|BEHAVIORAL|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214675824|NCT03623984|DRUG|Gallium Dotatate|Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
214675825|NCT01587872|PROCEDURE|Fujinon EC-450BI5 double-balloon colonoscope|Colonoscopy with the test instrument
214675826|NCT02657252|DRUG|Glucose|Sclerotherapy of telangiectasis in one lower limb.
214939551|NCT07176416|DEVICE|Veritas Vision System|Veritas Vision System
214939552|NCT07177261|BEHAVIORAL|Fast Friends|"Participants will interact with another person while both have their EEG recorded. They will ask and answer 12 questions with the other person that become increasingly personal in nature, e.g., When did you last cry in front of another person? By yourself?"
214675827|NCT02657252|DRUG|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
214675828|NCT05826197|OTHER|Radiomics|PET Radiomics
214939553|NCT07177261|BEHAVIORAL|Small Talk|"Participants will interact with another person while both have their EEG recorded. They will ask and answer 12 impersonal questions with the other person , e.g., Do you prefer digital watches and clocks or the kind with hands? Why?"
214939554|NCT07174947|DRUG|Fluoxetine (drug)|Fluoxetine: Maintain at 20mg per day, orally, until disease progression or intolerance
214939555|NCT07174947|DRUG|Placebo|Placebo: 1 placebo tablet per day for maintenance, orally.
214337887|NCT05996861|BEHAVIORAL|ICU sleep protocol|"Adjusting sound intensity, as well as reducing noise: efforts will be made to minimize staff conversation volume during the night.~Earplugs will be offered, along with the provision of eye masks for lucid patients, and thermal comfort adjustments will be made, such as providing blankets and/or adjusting room temperature.~Dimming of lights starting from 10 PM. Reduced circulation of external services between 11 PM and 6 AM, and rationalization of sample collections and/or patient transfers between beds during the 11 PM to 6 AM interval.~Optimization of analgesics for better pain control; optimization of medication use during wakefulness when clinically feasible; adjustment of intervals for capillary blood glucose measurement; maintaining and/or resuming the use of chronic sleep medications. If the patient has been unable to sleep, a hypnotic medication will be offered.~Other considerations include suggesting ventilatory support measures for selected patients."
214337888|NCT03619421|DIETARY_SUPPLEMENT|Zinc supplement|25 mg
214337889|NCT05705622|OTHER|Oral mukositis nurse's education for patients|Education given to patients by nurses on the prevention, treatment and care of oral mucositis
214337890|NCT01749891|DRUG|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
214939556|NCT07176858|OTHER|brain gym exercise|specially designed physical therapy program in addition to brain gym exercises for 60 min (30 min designed P.T program and other 30 min for brain gym exercises), 3 sessions/ week for 3 successive months. eight Brain Gym exercises will be selected: Cross Crawl, Lazy 8s, Hook-ups, Brain Buttons, The Elephant, The Owl, Neck Rolls, Double Doodle
214939557|NCT07176858|OTHER|specially designed pt program|conventional physical therapy program including reinforcement of the normal motor development, reflex inhibiting patterns, postural reaction, stretching, strengthening exercises, and gait training was applied to children in the control group
214939558|NCT07175207|BIOLOGICAL|UCB-MNCs|UCB-MNCs will be administered via intravenous infusion three times, once per week, with a dose of 3×10⁸ cells per infusion.
214939559|NCT07174791|DEVICE|cone beam computed tomography|-Implant marginal bone height changes will be measured by cone beam radiograph after one and two years of loading
214939560|NCT07174791|DEVICE|photogrammetric scan using elite scanner (shining 3d)|implant placement accuracy will be evaluated using photogrammetric scan after implant insertion
214939561|NCT07175974|BEHAVIORAL|Feldenkrais Method - Awareness Through Movement (ATM)|Participants attended eight consecutive sessions of the Feldenkrais Method, each lasting 90 minutes, over 8 days (total 12 hours). Sessions focused on enhancing upper limb functionality, trunk integration, posture, coordination, body awareness, and somatic regulation through slow, mindful, guided movements.
214939562|NCT07175077|DEVICE|7t MRI|7t brain MRI followed by up to 12 months of standard of care 1.5t/3t MRI scans
214939563|NCT07177157|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|2000 IU of Vitamin D daily (1 pill)
214939564|NCT07175064|BEHAVIORAL|Nursing-Led Livelihood Programs|A set of community-based livelihood initiatives introduced in 2016 and facilitated by nursing faculty in partnership with local leaders. Activities included bracelet making, rag making, and liquid dishwashing. The programs aimed to provide sustainable income, build women's confidence and skills, and indirectly improve health outcomes by addressing poverty-related social determinants of health.
214939565|NCT07174713|BIOLOGICAL|Biologic Therapy|Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (\~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years.
214939566|NCT07176650|DRUG|HLX13|Patients will receive HLX13 (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.
214939567|NCT07176650|DRUG|Yervoy|Patients will receive US-sourced YERVOY® (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.
214939568|NCT07176650|DRUG|OPDIVO|Patients will receive EU-sourced OPDIVO® (EU-sourced nivolumab) (1 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles. Subjects who may continue to benefit from OPDIVO® treatment as assessed by investigators will be subsequently treated with local-sourced OPDIVO® monotherapy every 4 weeks, up to 2 year after randomization.
214939569|NCT07175883|PROCEDURE|Redon drain|Patients in group A will have a Redon drain placed at the end of the procedure following the usual technique
214939570|NCT07176741|DIAGNOSTIC_TEST|TREM-1 expression (via immunohistochemistry) between SAH patients and controls|"this is the first study to focus on hepatocyte-specific TREM-1 expression in human liver tissue~What Distinguishes This Study Tissue-Level Focus: Unlike most studies that assess blood biomarkers or systemic inflammation, this research directly measures TREM-1 expression in liver tissue (hepatocytes), offering localized insights into disease severity and immune response.~Retrospective Biobank Utilization: Leverages a rich biobank of archival biopsies spanning 10 years, ensuring real-world data and long-term clinical follow-up-rarely combined at this scale in similar research.~Dual Purpose (Diagnostic \& Prognostic): Most biomarkers are evaluated for either diagnostic or prognostic value-this study uniquely addresses both in a single, comprehensive framework.~Therapeutic Translation Potential: TREM-1 is already a target for pharmacological inhibition (e.g., with peptide inhibitors tested safely in humans for other conditions). This positions the study for rapid clinical translation,"
214939571|NCT07177053|DRUG|non fluoridated hydroxyapatite tooth paste (KAREX KINDER tooth paste)|"arm 1 : hydroxyapatite tooth paste \[ HAP\] (study group): assessment will involve Quantitative Light-Induced Fluorescence- QLF at baseline, 3, 6, 9, and 12 months. The images were analyzed using a commercial software program (Inspektor QLF 1.97, Inspektor Research Systems, Amsterdam, The Netherlands) to determine the change in fluorescence~(ΔF, %) and extension of the lesion (area; mm2)."
214939572|NCT07177053|DRUG|fluoridated toothpaste (Colgate Total PROTECTION ACTIVE)|"Arm 2 :Fluoride-containing tooth paste \[1450ppm fluoride\] (control group):~assessment will involve Quantitative Light-Induced Fluorescence- QLF at baseline, 3, 6, 9, and 12 months. The images were analyzed using a commercial software program (Inspektor QLF 1.97, Inspektor Research Systems, Amsterdam, The Netherlands) to determine the change in fluorescence (ΔF, %) and extension of the lesion (area; mm2)."
214337891|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
214337892|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / LMA ETT™|After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
214337893|NCT03109678|DEVICE|Crossover FASTRACH™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
214337894|NCT03109678|DEVICE|Crossover FASTRACH™ / LMA ETT™|After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
214939573|NCT07176273|BEHAVIORAL|Modular Cognitive Processing Therapy|"CPT is a first-line treatment for PTSD that includes the following core elements: (a) identification of stuck points in thinking that interfere with recovery and (b) using Socratic questioning and a series of Contains the same core elements of CPT, but content is repackaged into modules instead of sessions so that clinicians can select and dose treatment elements according to patient need. Modular CPT contains the same core elements of CPT, but content is repackaged into modules instead of sessions so that clinicians can select and dose treatment elements according to patient need."
214939574|NCT07176273|BEHAVIORAL|Modular Prolonged Exposure Therapy|PE is a first-line treatment for PTSD that includes the following core elements: (a) in vivo exposure and (b) imaginal exposure to the trauma memory. Modular PE is comprised of the same elements of standard PE, but clinicians select and dose modules (i.e., imaginal exposure, in vivo exposure) based on individual patient need.
215074107|NCT04812119|DIAGNOSTIC_TEST|The Functional Communication Classification System (FCCS)|The Functional Communication Classification System (Barty, Caynes \& Johnston, 2016) was designed to classify how children with cerebral palsy communicate on a daily basis. The tool focuses on how children typically communicate with familiar and unfamiliar communication partners. There are five classifications a child can be categorized in: (1) effective communicator in most situations (2) effective communicator in most situations, but does need some help (3) an effective communicator in most situations and can communicate small ranges of messages and topics to most familiar people (4) assistance is required in most situations, especially with unfamiliar people and environments. Communicates daily needs and wants to familiar people (5) communicates using undirected movement, vocalisation and/or behaviour, for interpretation by familiar people. The FCCS is valid for use in children up to 13 years.
214675829|NCT04346069|OTHER|PCIT (parent child interaction therapy)|Parent child interaction therapy is a treatment strategy that nurture parent child relationship and teach effective parenting strategies to decrease child non compliance behavior (BodifordMcNeil; Hembree-Kigin, 2010).Parent-Child Interaction Therapy (PCIT; Eyberg; Robinson, 1982 ; Zisser; Eyberg, 2008 ) is a manualized parent training intervention that has received substantial empirical support in the treatment of disruptive behavior across multiple reviews (e.g., Brestan; Eyberg, 1998 ; Gallagher, 2003 ; Thomas \&amp; Zimmer-Gembeck, 2007 ). PCIT established strong relation among parenting, social learning, and attachment theories and proceeds.
214675830|NCT03455478|DEVICE|spectacles|dispending spectacles for uncorrected refractive error
214675831|NCT05070273|DIAGNOSTIC_TEST|Hypoglossal nerve conduction study|"NCS of nervus hypoglossus (evaluation of M-response parameters) was carried out using a 4-channel electromyographic machine. The stimulation will be carried out from three points:~1. angle of the lower jaw (proximal point),~2. the area of the carotid triangle (distal point),~3. directly from the electrode of St. Mark when it is localized on the muscles of the tongue.~The initial stimulation parameters: strength of an electric current 20 mA, stimulus duration 0.2 ms, and frequency 1 Hz. To achieve supramaximal stimulation, the stimulation strength will be increased with a step of 1-2 mA to a maximum of 35 mA, the duration of the stimulus will be increased to 0.3 ms."
214337895|NCT01045304|DRUG|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214337896|NCT01045304|DRUG|Gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214337897|NCT01045304|DRUG|Carboplatin|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214337898|NCT01725568|DEVICE|BioMonitor|Implantable cardiac monitor
214337899|NCT01337297|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
214337900|NCT02316717|BIOLOGICAL|IMM-124E|IMM-124E
214337901|NCT02316717|OTHER|Placebo|Matched placebo
214939575|NCT07176273|BEHAVIORAL|Step Down Treatment|Self-managed treatment will involve receiving a self-help version of the remaining treatment materials and ongoing use of the intervention companion app (CPT Coach or PE Coach).
214939576|NCT07176273|BEHAVIORAL|Digital Interventions|The prompt will be a text message delivered through VA-approved technology (e.g., PETALS).
214939577|NCT07176273|BEHAVIORAL|Cognitive Processing Therapy (CPT)|"CPT is a first-line treatment for PTSD that includes the following core elements: (a) identification of stuck points in thinking that interfere with recovery and (b) using Socratic questioning and a series of progressive worksheets to examine stuck points, develop balanced beliefs, and facilitate the experience of natural emotions."
214939578|NCT07176273|BEHAVIORAL|Prolonged Exposure (PE)|PE is a first-line treatment for PTSD that includes the following core elements: (a) in vivo exposure and (b) imaginal exposure to the trauma memory. In imaginal exposure, participants repeatedly, systematically approach their trauma memory and related thoughts and feelings. In in vivo exposure, participants repeatedly, systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma.
214337902|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution as a single dose.
214337903|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution given twice daily.
214337904|NCT03541694|BIOLOGICAL|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
214337905|NCT00462956|DRUG|Tykerb|lapatinib 1500mg daily
214337906|NCT00648531|DRUG|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
214337907|NCT00648531|DRUG|Colazal® Capsules 750 mg|3x750mg, single dose fasting
214337908|NCT04122443|DRUG|Acetaminophen|Acetaminophen 650mg
214939579|NCT07177300|DRUG|PK-optimized oral hydroxyurea at MTD until 15 years of age.|Because people are different, we will measure how each participant's body absorbs and eliminates the medicine, hydroxyurea, using blood tests. This information will be used to determine the best dose for each participant (rather than using the same weight-based dose for everyone).
214939580|NCT07176390|DRUG|Tulisokibart|Subcutaneous (SC) administration
214939581|NCT07176390|DRUG|Placebo|SC Injection
214939582|NCT07176390|DRUG|Methotrexate|Background Therapy - SC injection or oral administration. Per protocol, parenteral administration is allowed.
214939583|NCT07174778|BEHAVIORAL|Episodic future thinking|Participants will engage in episodic future thinking prompted via text-based cues and picture-based cues to help them adhere to oral anticoagulants. Participants will also receive health education on atrial fibrillation-related stroke prevention.
214939584|NCT07174778|BEHAVIORAL|attention control|The control group will receive standard care, including routine health education from ward nurses and one post-discharge telephone follow-up. In additon, participants will receive a message from the researcher at the same time point each day, but the message will only involve daily greetings.
214939585|NCT07176221|PROCEDURE|endoscopic cardia constriction ligation|The experimental group used disposable endoscopes to perform ECCL, while the control group used traditional endoscopes to perform ECCL. ECCL involves ligating and fixing the mucosa and partial muscle layer above the dentate line under direct endoscopic visualization to create folds. Post-procedure, the ligated mucosa undergoes ischemic necrosis and heals to form scar tissue, thereby reducing the cardia diameter, increasing LES pressure, and alleviating reflux symptoms.
214939586|NCT07175350|OTHER|PROFFIT|The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire is a 30-item questionnaire that measures health-related quality of life (HRQOL) in cancer patients ; PRO-CTCAE is a short list of 43 symptoms relevant for ovarian cancer
214939587|NCT07176702|DRUG|HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy|"Drugs: HLX22 (15 mg/kg IV) + trastuzumab (8 mg/kg loading dose → 6 mg/kg maintenance) + nab-paclitaxel (125 mg/m² IV) + gemcitabine (1000 mg/m² IV).~Administration: Administered every 3 weeks until disease progression, unacceptable toxicity, or withdrawal."
214939588|NCT07176169|PROCEDURE|Muscle Energy Technique for Sacral torsion|"Conventional management including Electrotherapy by application of Thermotherapy or Cryotherapy, Transcutaneous Electrical Nerve Stimulation (TENS) for 20 minutes, Core-stabilization Exercises,~* Clamshells~* Four Point Kneeling~* Bridging/Side Bridges~* Bird-Dog Pose~* Dead Bugs~* Dynamic Core Stability (Unstable Surfaces) For Sacral Torsions, Six MET protocols address Forward and Backward torsions on Left and Right Oblique axis using patient generated force in Prone or Side-lying positions. Left-on-Left (LOL) Forward Torsion, Right -on-Right (ROR) Forward Torsion, Right-On-Left (ROL) Backward Torsion, Left-on-Right (LOR) Backward Torsion, Bilateral Sacral Nutation, Bilateral Sacral Counternutation"
214939589|NCT07176169|PROCEDURE|Muscle Energy Technique for Innominate rotation|Conventional management including Electrotherapy by application of Thermotherapy or Cryotherapy, Transcutaneous Electrical Nerve Stimulation (TENS) for 20 minutes, Core-stabilization Exercises, • Clamshells • Four Point Kneeling • Bridging/Side Bridges • Bird-Dog Pose • Dead Bugs • Dynamic Core Stability (Unstable Surfaces). Anterior Innominate Rotation and Posterior Innominate Rotation.
214939590|NCT07175337|BEHAVIORAL|Surah Maryam group|Pregnant women who came for birth were taught Surah Maryam. They were monitored throughout the labor process, and in addition to routine midwifery care, Surah Maryam was played twice during labor to provide spiritual support.
214939591|NCT07175337|BEHAVIORAL|Virgin Mary's Hand Plant Group|he pregnant woman was monitored throughout labor; in addition to routine midwifery care, she was given spiritual support by placing the Virgin Mary's Hand plant in water and watching the plant unfold, encouraging her to believe that the birth canal also opens in the same way.
214939592|NCT07176494|PROCEDURE|Patients who underwent surgery under general anesthesia|Patients undergoing surgery under general anesthesia will undergo general anesthesia induction. During the skin closure, patients received 50 mg of dexketoprofen. Additionally, a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered intravenously for multimodal analgesia.
214939593|NCT07176494|PROCEDURE|Patients who underwent surgery under regional anesthesia|"25 cc (15 cc 0.5% bupivacaine + 5 cc 2% lidocaine + 5 cc isotonic) local anesthetic solution is prepared. 10 cc of the medication is administered into the interpectoral plane, and 15 cc into the pectoserratus plane.~During the skin closure, patients received 50 mg of dexketoprofen. Additionally, a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered intravenously for multimodal analgesia."
214939594|NCT07174401|DRUG|Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.|The eye not selected as the study eye will be used for comparison so both eyes will be imaged with the study devices to assess blood flow changes.
215074108|NCT04812119|DIAGNOSTIC_TEST|Brief Infant Sleeping Questionnaire (BISQ)|The Brief Infant Sleep Questionnaire (BISQ; Sadeh, 2004) is used to assess sleep patterns, parent perception, and sleep-related behaviors in young children (0-36 months). The BISQ has been validated against actigraphy, daily logs, and has high sensitivity in documenting expected developmental trends in sleep.
214337909|NCT04122443|DRUG|Oxycodone|Oxycodone 10mg
214337910|NCT03553628|OTHER|Chlorhexidine, Propolis and Clove Oil mouthwash|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash
214337911|NCT03553628|OTHER|Chlorhexidine mouthwash|Chlorhexidine HCL 0.12% mouthwash
214337912|NCT02333916|OTHER|overfeeding + exercise pre-training|
214337913|NCT02333916|BEHAVIORAL|fitness training|
214337914|NCT02333916|OTHER|overfeeding + exercise post-training|
214337915|NCT01659424|RADIATION|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
214337916|NCT03632291|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
214939595|NCT07174401|DEVICE|Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.|One OCT device is FDA-cleared while the other is still experimental. Both devices assess blood flow in different ways.
214939596|NCT07176351|DRUG|Buprenorphine|Weekly or monthly extended-release subcutaneous injection
214939597|NCT07177248|BEHAVIORAL|Family-Based 12-Week Multicomponent Program|Weekly digital materials to parents (email/WhatsApp) + three on-site sessions (\~90 min each: functional training; modified games; outdoor trekking); 12 weeks total; delivered by a Physical Education teacher; attendance and delivery logs for fidelity.
214939598|NCT07175311|DIAGNOSTIC_TEST|Multimodal imaging findings|Fundus photography, Optical Coherence Tomography, and Fluorescein Angiography will be performed 7 days after meeting the criteria for inactivation of endophthalmitis, as outlined in the MEX-ESG guidelines. These imaging tests will be repeated one month after meeting the inactivation criteria.
214939599|NCT07175688|DEVICE|Abdominal Ultrasound|Standard abdominal ultrasonography performed to evaluate pancreatic steatosis by comparing pancreatic echogenicity to liver and kidney tissue.
214939600|NCT07175688|DEVICE|Transient elastography|Non-invasive transient elastography used to assess hepatic steatosis and liver stiffness in patients with chronic hepatitis B.
214939601|NCT07175688|DIAGNOSTIC_TEST|Waist Circumference|The midpoint between the superior aspect of the iliac crests and the lower lateral margins of the ribs using an inelastic tape (TBW Import Ltd) that was 0.5 cm in width and 200 cm in length, according to World Health Organization (WHO) recommendations. Abdominal obesity, determined as a waist circumference of ≥94 cm in males or ≥80 cm in females according to the recommendations of the International Diabetes Federation group
214939602|NCT07175688|DIAGNOSTIC_TEST|Body mass index|"It was calculated by the equation dividing the weight in kilograms by height in meters squared.~BMI=〖mass〗\_kg/(〖height〗\_m\^2 )"
214939603|NCT07175558|OTHER|Reiki|"The patient will be explained about reiki (life energy recovery) and the application environment will be kept quiet.~Metal objects on the patient and the researcher will be removed. The researcher will wash and warm their hands. The patient's privacy will be ensured. The patient will be given a flat lying position with their arms and legs on both sides and comfortable. The patient will be asked to close their eyes. The researcher's fingers will be straight, side by side and closed, and energy will be provided to the application areas; crown chakra (top of the head), forehead chakra (top of the forehead), throat chakra (top of the throat), heart chakra (middle of the chest), solar plexus (under the chest, above the navel), sacral chakra (below the navel) and root chakra (upper back). Reiki application will be applied to the points on the 7 chakra regions for 4 minutes each, for a total of 28 minutes. The patient will be asked to open their eyes at the end of the application."
214939604|NCT07176429|DEVICE|Measurement of refractive error and amplitude of pseudoaccommodation|We will be using an assessor, masked as to which participant received what particular lens implant to determine the range of pseudoaccommodation in each eye. This will be done for each eligible eye and the 3 cohorts will be studied and compared.
214939605|NCT07177144|OTHER|anti müllerian hormone|participants were checked for amh levels preoperatively
214337917|NCT01257594|DRUG|erlotinib|"For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room."
214939606|NCT07177144|DIAGNOSTIC_TEST|anti müllerian hormon|participants were checked for amh levels at 3 months postoperatively.
214939607|NCT07172386|DRUG|Toripalimab and axitinib|Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for four consecutive cycles combined with axitinib administered for four consecutive cycles before surgery, and followed by 17 cycles' toripalimab for adjuvant therapy.
214939608|NCT07177066|DRUG|EDG-15400|EDG-15400 is administered orally
214939609|NCT07177066|DRUG|Placebo|Placebo is administered orally
214939610|NCT07174908|DRUG|IN10018 in combination with D-1553|IN10018 100mg QD PO and D-1553 600mg BID PO, 21days per cycle
214939611|NCT07174908|DRUG|anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed|Tislelizumab 200mg Q3W IV + Carboplatin AUC 5 mg/mL/min or Cisplatin 75mg/m² Q3W IV+ Pemetrexed 500mg/m² Q3W IV
214939612|NCT07177170|OTHER|Differentiated screening delivery|More flexibility in the screening delivery will be offered. A decision aid process will be implemented to help the participants deciding between the two options.
214939613|NCT07177170|OTHER|Single visit|All the steps of the screening (using HPV test) and of the treatment will be performed in a single visit (when possible).
214939614|NCT07175909|DEVICE|The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology|The device has received EC certification as a medical device for the treatment of ocular surface disorders. It will deliver a low-intensity alternating electrical current (ranging from 4 MHz to 64 MHz) to targeted biological tissue via contact electrodes. Previous studies have shown the effectiveness of this treatment in alleviating dry eye symptoms, both subjectively and objectively.
214939615|NCT07176208|DRUG|Dronabinol (Marinol®)|Subjects in this arm will receive one dose of 5 mg THC (Dronabinol) with a placebo beverage in one of the assigned treatment days.
214939616|NCT07176208|DRUG|Dronabinol (Marinol®)|Subjects in this arm will receive one dose of 10 mg THC (Dronabinol) with a placebo beverage in one of the assigned treatment days.
214939617|NCT07176208|DRUG|Dronabinol (Marinol®) + Alcohol|Subjects in this arm will receive one dose of 5 mg THC (Dronabinol) with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.
214939618|NCT07176208|DRUG|Dronabinol (Marinol®) + Alcohol|Subjects in this arm will receive one dose of 10 mg THC (Dronabinol) with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.
214337918|NCT01257594|PROCEDURE|Cytoreductive Surgery|Standard procedure
214337919|NCT01072201|DRUG|Triclosan and Fluoride|Brush twice daily
214337920|NCT01072201|DRUG|Fluoride|Brush twice daily
214337921|NCT03724825|DIAGNOSTIC_TEST|lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))|blood samples will be collected after 10 hours fasting
214939619|NCT07176208|DRUG|Alcohol beverage|Subjects in this arm will receive placebo capsule with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.
214939620|NCT07176208|DRUG|Placebo|Subjects in this arm will receive a placebo capsule with a placebo beverage in one of the assigned treatment days.
214939621|NCT07176923|BIOLOGICAL|CS-121|CS-121 is a in vivo base editing therapy formulated in lipid nanoparticles for targeted editing of the APOC3 gene in hepatocytes. In this study, participants receive a single intravenous infusion of CS-121 at escalating dose levels. The investigational product is designed to reduce ApoC3 protein expression and serum triglyceride levels in adults with familial chylomicronemia syndrome (FCS).
214939622|NCT07176676|OTHER|Lavanda Angustifolia essential oil|Administration of Lavender Angustifolia essential oil by inhalation in reducing nausea after abdominal, vascular, neurosurgical and gynaecological surgery under general anaesthesia during the 24-hour postoperative period.
214939623|NCT07176676|OTHER|Usual Care|Patients in the Usual Care group will follow the standard procedure, which consists of administering antiemetics if provided in therapy or reporting to the doctor with a subsequent treatment decision
214939624|NCT05769868|DRUG|Esmolol Injection [Brevibloc]|"Brevibloc® will be administered intravenously by infusion pump following the administration schedule:~Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes.~If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute.~The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg.~The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min)."
214939625|NCT06787924|DIETARY_SUPPLEMENT|Collagen hydrolyzed peptides|bovine collagen peptides
214939626|NCT06787924|DIETARY_SUPPLEMENT|Starch|Starch placebo
214939627|NCT03436212|DEVICE|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device
214939628|NCT05523947|DRUG|YH32367|"Dose Escalation Part: 8 Cohorts. In this part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose and the dose being escalated/de-escalated in adjacent dose cohorts will be up to Dose level 8.~Dose Expansion Part: 2 Cohorts(Cohort 1: Biliary tract cancer, Cohort 2: Solid tumors). The part will consist of multiple cohorts in patients who were treated with at least 1 prior gemcitabine- and/or cisplatin-based therapy, HER2 positive biliary tract cancer(Cohort 1); in patients who were treated with all available standard therapies and have no available options, HER2 positive solid tumor malignancies other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer(Cohort 2). Each cohort will enroll 65 and 40 patients, respectively."
214939629|NCT02295059|DIETARY_SUPPLEMENT|omega 3 fatty acids|supplied as soft gelatin capsules for oral administration
214939630|NCT05698147|DRUG|Selinexor|"Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death."
214939631|NCT05698147|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
214939632|NCT05698147|DRUG|Methotrexate|high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
215074109|NCT04812119|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire (PSQ)|Pediatric Sleep Questionnaire (PSQ; Chervin, Hedger, Dillon, Pituch, 2000) has been designed to screen for sleep problems in children. The scale consists of 22 parent-reported items examining snoring and breathing problems, daytime sleepiness, inattention, hyperactivity, and other signs and symptoms of apnea including obesity and nocturnal enuresis. Those questions specifically relate to sleep-disordered breathing (SDB) in children. PSQ has been validated for children 2-18 years old.
215078054|NCT01761318|DRUG|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
214675832|NCT05070273|DIAGNOSTIC_TEST|Transcranial magnetic stimulation of hypoglossal nerve|"TMS will be carried out using a Magstim 200 magnetic stimulator connected with a BiStim module (Magstim Co. Ltd., Whitland, Wales, UK). The generated magnetic pulses will be delivered by the coil 65 mm in diameter tangentially located relative to the scalp in the F7 projection - T3 and F8-T4 (according to the international scheme 10-20). The area of cortical stimulation will be localized by supplying single pulses with gradual increase, with a coil displacement with a step of 1 cm, until the contraction of the facial muscles will be obtained, followed by the determination of the MEP threshold value. Analysis of conduction by cortical-lingual pathway will be performed at TMS with magnetic stimulus intensity 20-30% above the MEP threshold."
214337922|NCT03724825|DIAGNOSTIC_TEST|Total testosterone|blood samples will be collected after 10 hours fasting
214675833|NCT01366222|DIETARY_SUPPLEMENT|food concentrates: fruit, vegetable, fish oil and probiotics|comparison the effect of food concentrate
214337923|NCT03724825|DIAGNOSTIC_TEST|Adropin|blood samples will be collected after 10 hours fasting
214337924|NCT03724825|DIAGNOSTIC_TEST|Adiponectin|blood samples will be collected after 10 hours fasting
214337925|NCT00581958|OTHER|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
214337926|NCT04814069|DRUG|Tislelizumab|Tislelizumab 200mg q3w
214347334|NCT02897804|BEHAVIORAL|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
214675834|NCT06105879|DEVICE|covered or open skin|transcutaneous mesarument of covered or open skin area
214939633|NCT02345265|PROCEDURE|Biopsy Procedure|Undergo biopsy of tumor
214939634|NCT02345265|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214939635|NCT02345265|DRUG|Cediranib Maleate|Given PO
214675835|NCT00120445|PROCEDURE|air|0.3 ml of filtered air
214675836|NCT00120445|PROCEDURE|expansile gas|0.3 ml of perfluoropropane gas
214675837|NCT04343170|DRUG|Placebo|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
214675838|NCT04343170|DRUG|ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
214939636|NCT02345265|PROCEDURE|Computed Tomography|Undergo CT scan
214337927|NCT03268967|BEHAVIORAL|Structured admission procedure|A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
214337928|NCT03822728|DIAGNOSTIC_TEST|3D-DESS MRI (3 dimensional double echo steady state MRI)|3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
214337929|NCT00003380|DRUG|etoposide|
214939637|NCT02345265|PROCEDURE|Echocardiography Test|Undergo echocardiogram
214939638|NCT02345265|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
214939639|NCT02345265|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214939640|NCT02345265|DRUG|Olaparib|Given PO
214939641|NCT02345265|OTHER|Questionnaire Administration|Ancillary studies
214939642|NCT06282757|OTHER|Video placebo communication|The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
214939643|NCT06282757|OTHER|Video nocebo communication|The nocebo communication video comprises of an educational VR video containing nocebo stimulating verbal language.
214939644|NCT06583941|DIETARY_SUPPLEMENT|Low Dose Virtiva Plus|Participants will consume a low dose of Virtiva Plus (120mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (120mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.
214939645|NCT06583941|DIETARY_SUPPLEMENT|High Dose Virtiva Plus|Participants will consume a high dose of Virtiva Plus (240mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (240mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.
214939646|NCT04497779|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or nasopharyngeal swabs
214939647|NCT04497779|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214939648|NCT04497779|OTHER|Electronic Health Record Review|Donors and recipients have their medical records reviewed.
214939649|NCT04497779|OTHER|Questionnaire Administration|Ancillary studies
214939650|NCT05328180|OTHER|Sodium bicarbonate|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5% is buffered with 7.5% sodium bicarbonate in 1:10.
214939651|NCT05328180|OTHER|Control arm|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5%.
214939652|NCT02567422|DRUG|Berzosertib|Given IV
214939653|NCT02567422|DRUG|Cisplatin|Given IV
214939654|NCT02567422|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214675839|NCT04843111|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
214675840|NCT03238248|DRUG|Azacitidine Subcutaneous Injection or Intravenous Infusion|75 mg/m2
214675841|NCT03238248|DRUG|Pevonedistat Infusion|20 mg/m2
214675842|NCT03238248|PROCEDURE|Bone Marrow Biopsy & Aspirate|Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
214675843|NCT05462587|DRUG|AVTX-803 (L-Fucose)|L-fucose crystalline powder
214675844|NCT04730323|DRUG|Tocilizumab|"Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded."
214939655|NCT02567422|OTHER|Laboratory Biomarker Analysis|Correlative studies
214939656|NCT02567422|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214939657|NCT02567422|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214939658|NCT02567422|RADIATION|Radiation Therapy|Undergo radiation therapy
214939659|NCT04356677|DRUG|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
214939660|NCT04356677|DRUG|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
214939661|NCT05773781|OTHER|PuraBond|Application of PuraBond to surgical field
214939662|NCT05488691|BEHAVIORAL|EMDR|The first session consists of recording the patient's history. In the second session the therapist evaluates the presence of coping mechanisms of the patient and, if necessary, suggests extra coping techniques. The following sessions are devoted to the reprocessing process. During these sessions, a target memory is identified and processed using EMDR. After a total of 8-10 sessions, it is expected that the patient will have achieved physiological reconciliation, relieved distress, and the ability to reformulate negative beliefs.
214939663|NCT05488691|BEHAVIORAL|TAU|treatment as usual for substance use disorders
214939664|NCT05391048|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
214675845|NCT05874245|DRUG|oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
214675846|NCT05874245|DRUG|oral ketamine|will receive 6 mg/kg oral ketamine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia
214675847|NCT05874245|DRUG|oral Midazolam|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
214675848|NCT02860468|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
214939665|NCT05391048|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
214939666|NCT06040502|BEHAVIORAL|The DICE Approach|Systematic guidance for care partners through assessment and management of the behavioral and psychological symptoms of dementia
214939667|NCT04497350|DEVICE|Transcranial Magnetic Stimulation|5,000 pulses (120-140% MT, continuous temperature of 24C) will be delivered per session (see Appendix A for timing parameters). Patients will have one TMS session per day, five days a week, until their treatment is completed (approximately four weeks).
214939668|NCT04497350|DEVICE|Theta Burst Stimulation|One session of iTBS will deliver 1,800 pulses (120-140% MT, continuous temperature of 22ºC) over an 9-minute-40-second period. The minimum break period between iTBS sessions is 25 minutes.
214939669|NCT00098202|DRUG|Low phytic acid maize|
214939670|NCT00098202|DRUG|Zinc|
214939671|NCT05490823|DEVICE|A smartphone app for anemia screening|This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
214939672|NCT01229813|DRUG|bevacizumab, erlotinib|bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily
214939673|NCT01229813|DRUG|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week
214675849|NCT02860468|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
214337930|NCT00003380|DRUG|pegylated liposomal doxorubicin hydrochloride|
214939674|NCT01229813|DRUG|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week.
214337931|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
214337932|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
214337933|NCT03200613|DRUG|Apixaban|2.5 mg orally twice daily
214337934|NCT03200613|DRUG|Low molecular weight heparin|Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
214337935|NCT00964691|DRUG|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
214337936|NCT00964691|DRUG|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
214337937|NCT00304785|DRUG|latanoprost 0.005%|
214337938|NCT00304785|DRUG|Fotil|
214939675|NCT01229813|DRUG|low dose capecitabine|capecitabine 500 mg twice daily
214939676|NCT03129113|DRUG|Maraviroc|1:1:1:1 randomisation to one of four arms for 48 weeks
214939677|NCT03129113|DRUG|Metformin|1:1:1:1 randomisation to one of four arms for 48 weeks
214939678|NCT02525302|DRUG|HT-100|HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
214939679|NCT05015764|OTHER|Fluid Management|Removal of excess extracellular fluid using diuretics
214939680|NCT05015764|DEVICE|Reprieve Cardiovascular System|System with Fluid Management Module
214939681|NCT06959394|OTHER|Ultrasound|Participants will receive ultrasound at 1.5 W/cm2 for 6 minutes (transmitter agent aquasonic gel) 5 sessions per week for 2 weeks.
214337939|NCT00304785|DRUG|placebo|
214939682|NCT06959394|OTHER|Phonophoresis|Participants will receive ultrasound with 1.5 W/cm2, 6 min (transmitter diclofenac gel) for 5 sessions per week for 2 weeks.
214939683|NCT06959394|OTHER|Placebo|Participants will receive 0 W/cm2, 6 min ultrasound, 5 sessions per week for 2 weeks.
214939684|NCT06165341|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
214939685|NCT06165341|DRUG|Placebo|Fazirsiran matching placebo.
214939686|NCT06743191|BEHAVIORAL|Access Nourish|A total of 65 participants with hypertension and low access to high quality food will be enrolled to test the feasibility of using commercially available grocery delivery services, simultaneous to a robust behavioral intervention, to improve adherence to the DASH eating pattern. The behavioral intervention will include skills training, nutrient goal setting, self-monitoring via dietary tracking, personalized text message feedback, and adaptive health coaching. Participants will also receive a membership to Instacart+ and weekly grocery list recommendations from a health coach. Participants will be able to complete all intervention components via smartphone. The intervention period for participants will be 4 months.
214939687|NCT05468203|DRUG|Dapagliflozin 10mg Tab|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
214939688|NCT05468203|DRUG|Placebo|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
214675850|NCT04020237|BEHAVIORAL|Education about particulate matter practice score|"For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~* 1\) Start air purifier~* 2\) Do not go out and make it to the minimum when absolutely necessary~* 3\) It is recommended to wear a mask when going out.~* 4\) The investigators recommend a lot of water, fresh fruit and vegetables.~* 5\) Prepare an inhaler and use it when symptoms get worse."
214337940|NCT03098446|BEHAVIORAL|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
214939689|NCT04917120|DEVICE|Virtual Reality|The procedure will consist of a virtual reality program associated with suggestions of hypnoanalgesia, be added to usual care. Included patients will benefit from the Virtual Reality program combined with hypnoanalgesia suggestions for a period of 20 minutes. We will use a helmet with a built-in screen and an audio headset connected to a control room. Patients will watch an Virtual Reality sequence while listening to narratives designed for the hypnoanalgesia of the present pain.
214337941|NCT03098446|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
214337942|NCT00595582|DIETARY_SUPPLEMENT|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
214337943|NCT03612037|DIETARY_SUPPLEMENT|alpha lipoic acid|600 mg/day oral dose of alpha lipoic acid
214337944|NCT03612037|DIETARY_SUPPLEMENT|Cellulose|600mg/day oral dose of placebo cellulose
214337945|NCT04409041|DRUG|Low-Dose Naltrexone|Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.
214939690|NCT04343274|DRUG|Tozuleristide|
214939691|NCT04983862|DRUG|Illuminare-1|Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Dose levels of the agent will be administered starting at 0.25mg/kg, with increases in dose between cohorts of no more than 0.75 mg/kg until a maximum dose of 3.0mg/kg is reached, if needed. At the dose identified to have the acceptable NMR and no associated DLTs, Illuminare-1 will be studied in up to 20 additional patients at this dose to optimize the imaging protocol and provide additional safety data.
214939692|NCT04983862|DEVICE|Karl Storz D-Light C photodynamic diagnostic (PDD)|The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.
214939693|NCT06514898|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|"After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.~up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment)"
214939694|NCT06514898|BIOLOGICAL|TTRNA-xALT|All participants will receive a single infusion of T-cells.
214675851|NCT04827056|DRUG|Placebo|Placebo will be administered orally, as individual films in the SL space.
214337946|NCT01049659|BEHAVIORAL|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
214675852|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the SL space.
214939695|NCT06514898|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #5, #7 and #9.
214675853|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space.
214675854|NCT04827056|PROCEDURE|Ethanol Infusion|Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
214939696|NCT06514898|BIOLOGICAL|autologous HSCs|All participants will receive a single intravenous infusion of autologous HSCs.
214675855|NCT04827056|BEHAVIORAL|PTSD Reactivity Condition|Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
214939697|NCT06514898|DRUG|Pembrolizumab|Participants will receive PD-1 blockade IV starting with ACT continuing for up to 2 years as long as tolerable and without disease progression.
214337947|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-free diet|The probiotic and gluten-free diet group (PRO-GFD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses, comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
214337948|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-free diet|The placebo and gluten-free diet group (PLA-GFD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
214337949|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-containing diet|The probiotic and gluten-containing diet group (PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
214337950|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-containing diet|The placebo and gluten-containing diet group (PLA-GD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
214337951|NCT05322317|OTHER|ADVANCE-PC training via ECHO|To assess the feasibility of using a technology-based platform to deliver the ADVANCE-PC program to multiple primary care clinics. This model will be based on the ECHO program, a tele-mentoring program which uses communications technology to provide facilitated education, case review, and peer-to-peer problem solving remotely. Our working hypothesis is that the use of ECHO will be efficient (allowing several clinicians and teams to be supported simultaneously while creating a community of practice), feasible (that clinicians will enroll and share experiences via mentoring, guidance, feedback, and didactic education), and have the potential to impact patients as clinicians perceptions shift to favor ACP, their skills increase, and they are able to integrate ACP for patients with dementia into their clinic.
214337952|NCT03819231|DRUG|Oxytocin|A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.
214337953|NCT03819231|BEHAVIORAL|Mindfulness|Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
214337954|NCT03819231|DRUG|Saline Solution|A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
214337955|NCT03819231|BEHAVIORAL|Sham mindfulness|The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
214337956|NCT00965848|DRUG|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
214337957|NCT04284696|DIETARY_SUPPLEMENT|Pregnan-C-Gum(R) chewing gum|"Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days ad libitum"
214939698|NCT03385109|DEVICE|Surgery|Patients are approached surgically with the Senhance Surgical System
214939699|NCT03961854|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
214939700|NCT03961854|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
214939701|NCT05673460|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg
214939702|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A1|Suspension for injection. Route of administration: IM injection
214939703|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A2|Suspension for injection. Route of administration: IM injection
214939704|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A3|Suspension for injection. Route of administration: IM injection
214939705|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B1|Suspension for injection. Route of administration: IM injection
214939706|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B2|Suspension for injection. Route of administration: IM injection
214939707|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B3|Suspension for injection. Route of administration: IM injection
214939708|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C1|Suspension for injection. Route of administration: IM injection
214675856|NCT04827056|BEHAVIORAL|Alcohol Cue Reactivity|Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
214675857|NCT01369693|PROCEDURE|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
214675858|NCT01187797|OTHER|Emotional stimulation|Increase of the physical correlates of an emotion
214675859|NCT02241512|DRUG|Ibuprofen|
214675860|NCT02241512|DRUG|placebo|
214675861|NCT01970579|DEVICE|Paclitaxel coated balloon|"* Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting"
214675862|NCT01970579|DEVICE|uncoated PTA catheter|"* Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting."
214675863|NCT02203253|DRUG|Thalidomide|100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
214675864|NCT02203253|DRUG|Placebo for thalidomide|Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
214675865|NCT02203253|DRUG|Palonosetron and Dexamethasone|Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
214675866|NCT00455247|DRUG|Glutamine|
214675867|NCT00474630|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
215074110|NCT04812119|DIAGNOSTIC_TEST|The Eating and Drinking Ability Classification System (EDACS)|The Eating and Drinking Ability Classification System (EDACS; Sellers, Mandy, Pennington, Hankins, Morris, 2013) has been developed for people with cerebral palsy to describe five distinct levels of ability using the key features of safety and efficiency. The patient can be categorized in: (1) eats and drinks safely and efficiently, (2) eats and drinks safely but with some limitations to efficiency, (3) eats and drinks with some limitations to safety; maybe limitations to efficiency, (4) eats and drinks with significant limitations to safety or (5) unable to eat or drink safely - tube feeding may be considered to provide nutrition. The EDACS is valid for use in children above the age of 36 months.
214675868|NCT00474630|DRUG|Placebo|
214675869|NCT00474630|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
214337958|NCT04284696|DIETARY_SUPPLEMENT|Placebo chewing gum|"Using a chewing gum without vitamin C (per piece/gum) for 14 days ad libitum"
214675870|NCT04685603|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
215074111|NCT04812119|DIAGNOSTIC_TEST|Mini Manual Ability Classification System (Mini-MACS)|The Mini Manual Ability Classification System (Mini-MACS; Eliasson, Krumlinde-Sundholm, 2013) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 1-4 years of age.
214675871|NCT00538603|DRUG|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
214675872|NCT00538603|DRUG|Paclitaxel & Carboplatin|Chemotherapy
214675873|NCT05696366|DRUG|Sotagliflozin|Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
214675874|NCT05696366|DRUG|Volagidemab|Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
214675875|NCT00352781|DRUG|nicotine replacement therapy|nicotine transdermal patches as per product monograph
214675876|NCT00352781|BEHAVIORAL|behavioural intervention|Smoking cessation counselling and relapse prevention
214939709|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C2|Suspension for injection. Route of administration: IM injection
214939710|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C3|Suspension for injection. Route of administration: IM injection
214939711|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 1|Suspension for injection. Route of administration: IM injection
214939712|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 2|Suspension for injection. Route of administration: IM injection
214939713|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 3|Suspension for injection. Route of administration: IM injection
214939714|NCT06583031|BIOLOGICAL|Monovalent RSV Vaccine|Suspension for injection. Route of administration: IM injection
214939715|NCT05128773|DRUG|Amcenestrant|tablet, oral
214939716|NCT05128773|DRUG|Tamoxifen|tablet, oral
214939717|NCT05128773|DRUG|Amcenestrant-matching placebo|tablet, oral
214939718|NCT05128773|DRUG|Tamoxifen-matching placebo|tablet, oral
214337959|NCT00882011|OTHER|Latest generation chemotherapies for T-LBL + transplant|"1. Standard doses of one of the following chemotherapies:~   * Holzer~  * LSA2-L2 modified~  * Stanford regimen~  * Hyper CVAD~  * Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~  * Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~2. Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
214337960|NCT00396734|DRUG|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
214337961|NCT00396734|DRUG|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
214337962|NCT01130740|BEHAVIORAL|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
214337963|NCT02069561|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
214337964|NCT03077165|DRUG|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
214337965|NCT03077165|DRUG|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
214337966|NCT03077165|DRUG|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
214337967|NCT03077165|DRUG|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
214337968|NCT03077165|DRUG|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
214337969|NCT03077165|DRUG|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
214337970|NCT05800054|DIETARY_SUPPLEMENT|Nutritional Support Team|Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
214939719|NCT05365958|BEHAVIORAL|HIV Podcast for Heterosexual African American Adults|"The video podcast will deliver HIV prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
214337971|NCT05800054|DRUG|Docetaxel|60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
214337972|NCT05800054|DRUG|cisplatin|cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
214939720|NCT04023331|DRUG|67Cu-SARTATE|67Cu-labelled MeCOSar-Tyr3-octreotate
214939721|NCT04023331|DRUG|64Cu-SARTATE|64Cu-labelled MeCOSar-Tyr3-octreotate
214939722|NCT06961760|DRUG|zervimesine|Zervimesine (CT1812) was shown to be safe and well tolerated in a study of healthy volunteers and in Phases 1 and 2 studies of participants with mild to moderate AD and DLB. This is an open label expanded access program designed to provide access to CT1812 and to evaluate the long-term safety of CT1812 administered once daily for 12 months in adults aged 50 to 86 who have been diagnosed with mild to moderate DLB (the targeted clinical indication for CT1812). Participants will receive 100 mg of CT1812 once daily for 360 days.
214939723|NCT05941442|DRUG|Darigabat|Oral tablets
214939724|NCT05941442|DRUG|Placebo|Oral tablets
214939725|NCT04250714|DEVICE|Boston Scientific Cardiac Cryoablation System|cryoablation of atrial fibrillation consisting in electrical isolation of the pulmonary veins
214939726|NCT06115824|DRUG|Orelabrutinib|Combination of orelabrutinib on a methotrexate-based chemotherapy regimen with a starting dose of 150 mg/d
214675877|NCT01810159|OTHER|Integrated collaborative care|
214675878|NCT01810159|OTHER|Education and Resources|
214939727|NCT05738798|DIETARY_SUPPLEMENT|oral immunotherapy|oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
214939728|NCT06254326|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment
214939729|NCT06254326|BIOLOGICAL|Autologous Hematopoietic Stem cells (HSCs)|Participants will receive a single infusion of autologous CD34+ HSCs
214939730|NCT06254326|BIOLOGICAL|TTRNA-xALT|Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells
214939731|NCT06254326|DRUG|Td vaccine|All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.
214939732|NCT04048655|DRUG|Neostigmine, Combinations|All patients have neostigmine induced recovery of neuromuscular block.
214939733|NCT04676412|BIOLOGICAL|Pembrolizumab|IV infusion
214939734|NCT04676412|DRUG|Lenvatinib|oral capsule
214939735|NCT04676412|DRUG|Placebo for lenvatinib|oral capsule
214939736|NCT04697056|DRUG|Imsidolimab|Humanized Monoclonal Antibody
214939737|NCT04697056|BIOLOGICAL|placebo|placebo
214939740|NCT05691530|DRUG|rDENdelta30/31-7164|The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.
214939741|NCT05820087|DEVICE|HistoSonics Edison System|Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
214675879|NCT00355589|DRUG|Ramipril and hydrochlorothiazide|
214675880|NCT02538146|DIETARY_SUPPLEMENT|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
214675881|NCT00004033|DRUG|liposomal NDDP|
214675882|NCT00004033|PROCEDURE|therapeutic thoracoscopy|
214675883|NCT03267329|DRUG|Duowell®|telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
214675884|NCT03267329|DRUG|Telmisartan|telmisartan 80mg
214675885|NCT02028689|DRUG|Lesinurad 400 mg|
214337973|NCT05800054|RADIATION|Radiotherapy|image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); Irradiation targets include primary lesions, clinical targets, positive lymph nodes, and lymph node drainage areas. Dose splitting/prescription dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/23-25 times.
214337974|NCT00555438|DRUG|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
214337975|NCT00061048|BIOLOGICAL|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
214337976|NCT03243734|DEVICE|trūFreeze® System spray cryotherapy|Subjects where trūFreeze® System spray cryotherapy is performed
214939742|NCT06459180|BIOLOGICAL|Sacituzumab Tirumotecan|IV infusion
214939743|NCT06459180|DRUG|Pemetrexed|IV infusion
214939744|NCT06459180|BIOLOGICAL|Tisotumab Vedotin|IV infusion
214939745|NCT06459180|DRUG|Topotecan|IV infusion
214939746|NCT06459180|DRUG|Vinorelbine|IV infusion
214939747|NCT06459180|DRUG|Gemcitabine|IV infusion
214939748|NCT06459180|DRUG|Irinotecan|IV infusion
214675886|NCT02028689|DRUG|Metformin 850 mg|
214675887|NCT02028689|DRUG|Furosemide 40 mg|
214675888|NCT03318107|DEVICE|Transvaginal probe using photoacoustic and ultrasound imaging|-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
214675889|NCT02711670|DRUG|chlorthalidone|
214675890|NCT02711670|DRUG|Hydrochlorothiazide|
214675891|NCT03827577|PROCEDURE|Surgical removal of primary and/or of all oligometastases|Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).
214675892|NCT03827577|RADIATION|Non-surgical LAT|Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.
214675893|NCT03827577|DRUG|Standard medical therapy|platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
214675894|NCT03399539|DRUG|Dexamethasone|Given PO
214675895|NCT03399539|DRUG|Ixazomib Citrate|Given PO
214675896|NCT03399539|OTHER|Laboratory Biomarker Analysis|Correlative studies
214675897|NCT03399539|DRUG|Venetoclax|Given PO
214337977|NCT06038682|DRUG|Argatroban Injection|Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
214337978|NCT06038682|DRUG|Heparin|Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
214337979|NCT01431508|DRUG|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
214337980|NCT03313596|DRUG|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
214337981|NCT03313596|PROCEDURE|LT|Orthotopic LT and subsequent immunosuppression therapy
214337982|NCT04897581|BEHAVIORAL|Brief Behavioral Therapy for Insomnia, BBTI|BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.
214337983|NCT04897581|BEHAVIORAL|Physical Self-Regulation, PSR|PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
214337984|NCT02755935|DEVICE|Cochlear Nucleus CI532|cochlear implantation
214337985|NCT02629406|OTHER|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
214337986|NCT03436472|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
214337987|NCT03436472|DRUG|placebo|normal saline infusion
214337988|NCT01092195|BIOLOGICAL|Gardasil|3 separate 0.5 ml intramuscular
214337989|NCT01609556|DRUG|Mirvetuximab soravtansine|Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
214337990|NCT01866189|OTHER|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
214337991|NCT06573021|DRUG|Near-infrared fluorescent cholangiography|For intra-operative fluorescent cholangiography, 2.5 mg indocyanine green (ICG, Pulsion Medical Inc., Irving, Tx) was administered intravenously 45-60 min prior to surgery, according to the recent guidelines from the International Society for Fluorescence Guided Surgery (ISFGS) and the latest consensus conference published in 2021.
214337992|NCT03336008|OTHER|no intervention|No intervention but clinical assessement for all recruited subjects
214337993|NCT04452344|DRUG|opioid-containing analgesic|hydrocodone/ acetaminophen combination product
214337994|NCT04452344|DRUG|two over-the-counter analgesics|combination of over-the-counter analgesics (ibuprofen/acetaminophen)
214337995|NCT06573320|OTHER|physical exercise|physical exercise
214337996|NCT06573775|DEVICE|pulsed ultrasound|treatment of myofacial trigger points with therapeutic ultrasound
214337997|NCT06573775|OTHER|myofascial release|manual massage and range of motion exercises
214337998|NCT06573775|DEVICE|lidocaine phonophoresis|transdermal tranmission of lidocaine molecules via ultrasound
214337999|NCT00023452|DRUG|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT)."
214939754|NCT05686330|DEVICE|Apple Watch|Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
214338000|NCT00023452|DRUG|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
214338001|NCT06572202|BEHAVIORAL|Positive Psychology Intervention|The 14-session intervention program is designed to enhance various internal resiliency factors. It begins with an orientation to positive psychology and setting group guidelines. Cognitive resilience is developed through identifying personal and signature strengths, reappraising memories, and learning savoring techniques. Emotional resilience is strengthened by focusing on forgiveness, managing decision fatigue, and fostering positive communication. Spiritual resilience is cultivated through gratitude practices and exploring hope and optimism. Behavioral resilience is addressed by recognizing strengths in others and engaging in altruism. The final session integrates all these elements to promote lasting positive changes in engagement, relationships, meaning, and accomplishments. Mid-session feedback ensures the program's effectiveness and responsiveness to participants' needs.
214939755|NCT06638632|BEHAVIORAL|Decision aid|Patients with dementia and care partners will receive an iteration of the decision aid and provide feedback.
214939756|NCT06645366|DEVICE|Treatment with BTL-785F|Three (3) treatment sessions will be applied to the subjects' face and neck using the BTL-785F system equipped with the BTL-785-4-4 tip on BTL-785-4 applicator, lasting from 20 to 60 minutes depending on the size of the treated area. Each treatment will be spaced 2 - 6 weeks apart, after the complete healing of scabs.
214939757|NCT03760835|DRUG|Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)|Treatment of congenital adrenal hyperplasia
214939758|NCT03760835|DRUG|Dual release hydrocortisone (plenadren)|Treatment of congenital adrenal hyperplasia
214675898|NCT04715724|OTHER|Positioning and Attachment video-based simulation (telesimulation)|Participants will teach a standardized patient actor (SP) to position and attach the baby doll at the breast of the Lactation Simulation Model in a video-based simulation (telesimulation)
214939759|NCT05751044|DRUG|Dasatinib|Oral
214939760|NCT05751044|DRUG|Venetoclax|oral
214939761|NCT05751044|DRUG|Dexamethasone|oral/intervenous
214939762|NCT05751044|DRUG|Cyclophosphamide|intravenous
214939763|NCT05751044|DRUG|Cytarabine|intravenous
214939764|NCT05751044|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
214939765|NCT03945162|COMBINATION_PRODUCT|Ruvidar® (TLD-1433) Bladder infusion and PDT|Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
214939766|NCT05904119|DRUG|Lomustine|Oral administration of Lomustine
214939767|NCT05904119|RADIATION|Reirradiation|Given at least 6 months after the end of prior radiotherapy
214338002|NCT05314153|DRUG|Brexanolone|Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
214338003|NCT00132444|DRUG|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
214939768|NCT06193954|DEVICE|VasoStar guidewire system|The VasoStar Vibrational Guidewire System vibrates longitudinally at the distal segment of a wire with an electromagnetic source.
214939769|NCT04064359|DRUG|OBT076, a CD205-directed antibody-drug conjugate|Intravenous (IV) infusion of OBT076 every 3 weeks.
214939770|NCT06630234|DRUG|DCC-3009|Administered orally
214675899|NCT00404781|DRUG|cilostazol in addition to aspirin and clopidogrel|
214675900|NCT03912571|DIAGNOSTIC_TEST|Structural 3T MRI|measures of global and hippocampal atrophy)
214675901|NCT03912571|DIAGNOSTIC_TEST|MRI Based Perfusion Imaging|brain blood flow
214675902|NCT03912571|DIAGNOSTIC_TEST|VR-CO2 MRI Scans|reduced vaso reactivity to carbon dioxide
214675903|NCT00000800|DRUG|Methadone hydrochloride|
214675904|NCT00000800|DRUG|Zidovudine|
214939771|NCT05831176|DRUG|Dupilumab|Administered as described in the protocol
214939772|NCT03819296|OTHER|Best Practice|Receive standard of care
214939773|NCT03819296|OTHER|Biospecimen Collection|Undergo collection of stool, blood, and tissue samples
214939774|NCT03819296|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
214939775|NCT03819296|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
214939776|NCT03819296|BIOLOGICAL|Infliximab|Given intravenously (IV)
214939777|NCT03819296|OTHER|Laboratory Biomarker Analysis|Ancillary studies
214939778|NCT03819296|DRUG|Prednisone|Given orally
214939779|NCT03819296|BIOLOGICAL|Vedolizumab|Given IV
214939780|NCT05558397|DEVICE|Interventional Group (Epidural morphine)|Implantation of an epidural catheter for administration of morphine and ropvacaine
214939781|NCT05558397|DRUG|Control Group (Oral morphine)|Oral administration of morphine, pregabalin or duloxetin
214939782|NCT05989997|DRUG|68Ga-NOTA-SNA002|68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
214939783|NCT03260491|DRUG|HER3-DXd (FL-DP)|HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).
214939784|NCT03260491|DRUG|HER3-DXd (CTM-1 Lyo-DP)|HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.
214939785|NCT03260491|DRUG|HER3-DXd (CTM-3 Lyo-DP)|HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.
214939786|NCT03729544|BEHAVIORAL|On-screen computerized decision support alert|On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
214939787|NCT04609839|OTHER|Follow-up of patients with COVID-19|"The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.~The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients."
214939788|NCT04590872|BIOLOGICAL|Tolerogenic Dendritic Cell Vaccine|PIpepTolDCs
214939789|NCT06800248|DRUG|emodepside (BAY 44-4400)|Treatment with single dose of oral 15 mg emodepside
214939790|NCT06800248|DRUG|Mebendazole 100 MG|Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
214939791|NCT06800248|DRUG|similar placebo to mebendazole|Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
214939792|NCT06800248|DRUG|matching placebo of emodepside|Treatment with single dose of oral emodepside matching placebo
214939793|NCT06797531|DRUG|ribociclib|This is an observational study. There is no treatment allocation. The decision to initiate ribociclib will be based solely on clinical judgement.
214939794|NCT04162353|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
214939795|NCT05599984|DRUG|ABBV-706|Intravenous (IV) Infusion
214338004|NCT02939105|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform treatments.
214338005|NCT04948944|DEVICE|transcranial direct current stimulation|the tDCS stimulator delivers very low (2mAmp) current with surface electrodes to the skull
214338006|NCT04091841|DRUG|protein supplement|Three sachet of protein supplement to be mixed in with water used daily.
214675905|NCT04897503|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
214675906|NCT03645837|OTHER|Compression clamp release|Standard compression clamp is used and will be released at different times according to randomization
214675907|NCT02381756|DEVICE|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
214675908|NCT04241237|PROCEDURE|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
214675909|NCT00434850|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
214675910|NCT00434850|DRUG|Deoxyspergualin|An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
214675911|NCT00434850|BIOLOGICAL|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
214675912|NCT00434850|BIOLOGICAL|Daclizumab or basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
214675913|NCT00434850|DRUG|Sirolimus|Maintenance immunosuppressive therapy
214675914|NCT00434850|DRUG|Tacrolimus|Maintenance immunosuppressive therapy
214675915|NCT00434850|BIOLOGICAL|Etanercept|Blocks TNF-alpha which is toxic to islet cells
214939796|NCT05599984|DRUG|Cisplatin|Intravenous infusion
214939797|NCT05599984|DRUG|Budigalimab|IV Infusion
214939798|NCT05599984|DRUG|Carboplatin|Intravenous infusion
214939799|NCT05204147|DRUG|Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A|Given IV
214939800|NCT05204147|PROCEDURE|Biospecimen Collection|Correlative studies
214939801|NCT04210349|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
214939802|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 1 SP Shz TIV1|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
214939803|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 2 SP Shz TIV2|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
214939804|NCT04089189|DRUG|IMP4297|IMP4297 100mg PO QD
214939805|NCT03312595|DEVICE|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
214939806|NCT06507618|DRUG|Tamoxifen, Letrozole, Anastrozole, or Exemestane|Choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist.
214939807|NCT03657394|OTHER|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
214939808|NCT06522854|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor
214939809|NCT06522854|DRUG|Placebo Oral Tablet|Placebo tablet given orally every eight hours up to three times while mother is in labor
214939810|NCT04439357|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214939811|NCT04765722|DRUG|Mepolizumab|Mepolizumab subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
214939812|NCT04765722|DRUG|Normal Saline|Placebo subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
214939813|NCT06244771|DRUG|FMC-376|Oral Capsule
214939814|NCT05175131|DRUG|Mebeverine+Simethicone|fixed-dose combination, film-coated tablets, 135 mg + 80 mg
214939815|NCT05175131|DRUG|Mebeverine|Duspatalin®, coated tablets 135 mg
214939816|NCT05175131|DRUG|Simethicone|Espumisan® capsules 40 mg
214939817|NCT05502237|DRUG|Zimberelimab|Administered intravenously
214939818|NCT05502237|DRUG|Domvanalimab|Administered intravenously
214939819|NCT05502237|DRUG|Pembrolizumab|Administered intravenously
214939820|NCT05502237|DRUG|Carboplatin|Administered intravenously
214939821|NCT05502237|DRUG|Cisplatin|Administered intravenously
214939822|NCT05502237|DRUG|Paclitaxel|Administered intravenously
214939823|NCT05502237|DRUG|Nab-paclitaxel|Administered intravenously
214939824|NCT05502237|DRUG|Pemetrexed|Administered intravenously
214939825|NCT03859063|BEHAVIORAL|Intervention|Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
214338007|NCT04091841|OTHER|Carbo Mass|Three sachet of Carbo Mass supplement to be mixed in with water used daily.
214338008|NCT01626976|DRUG|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
214939826|NCT03859063|BEHAVIORAL|Control|Community based follow-up as usual
214939827|NCT05991323|DRUG|Dupilumab|Injection solution; subcutaneous
214939828|NCT04537416|OTHER|No intervention|No intervention
214939829|NCT05906836|DRUG|Rosuvastatin|Administered orally.
214939830|NCT05906836|DRUG|Selpercatinib|Administered orally.
214939831|NCT03233191|PROCEDURE|Digital Mammography|Undergo DM
214939832|NCT03233191|PROCEDURE|Digital Tomosynthesis Mammography|Undergo TM
214939833|NCT03233191|OTHER|Laboratory Biomarker Analysis|Correlative studies
214939834|NCT04087291|OTHER|Chiropractic Care|"Chiropractic interventions:~1. Patient education.~2. Passive interventions, such as spinal manipulation and myofascial therapies which include thrust type (high velocity-low amplitude) spinal manipulation for the low back, non-thrust manipulation (joint mobilization), and use of manually held instruments, such as an Activator. Myofascial therapies are also commonly used, such as myofascial release and trigger point therapy.~3. Transitional interventions, such as therapeutic exercise.~4. Recommendations for active interventions, such as general exercise and mind-body therapies.~5. Self-management advice, which refers to advice given to build the capacity of a person to self-monitor, control, and/or reduce the impact of a condition over time."
214338009|NCT01626976|DRUG|Placebo|Solution, single dose
214338010|NCT01626976|DRUG|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
214939835|NCT03672318|DRUG|CAR138 T Cells|"The MTD is defined as the dose at which approximately 0.20 of subjects experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10\^6 cells/m\^2 Dose level 2: 1X10\^7 cells/m\^2 Dose level 3: 2.5X10\^7 cells/m\^2 Dose level 4: 5X10\^7 cells/m\^2 Dose level 5: 1x10\^8 cells/m\^2 Dose level 6: 2x10\^8 cells/m\^2~Six subjects will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m\^2 and fludarabine 30 mg/m\^2 given once daily for three days."
214939836|NCT01303341|OTHER|Laboratory Biomarker Analysis|Correlative studies
214939837|NCT01303341|OTHER|Pharmacological Study|Correlative studies
214939838|NCT01303341|DRUG|Riluzole|Given PO
214338011|NCT01626976|DRUG|Placebo|suspension, single dose
214338012|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
214338013|NCT01626976|DRUG|Placebo|suspension, single dose
214338014|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
214939839|NCT01303341|DRUG|Sorafenib Tosylate|Given PO
214338015|NCT01626976|DRUG|Placebo|suspension, single dose
214338016|NCT01626976|DRUG|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
214338017|NCT01626976|DRUG|Placebo|suspension, single dose
214338018|NCT04420806|OTHER|HIT-exercise|13 months of high intensity endurance and resistance exercise, 3x 45 min/week - 3 months of COVID-19 induced exercise break
214338019|NCT04420806|OTHER|Sham intervention|Types of exercise (flexibility, relaxation) that did not affect the present outcomes
214338020|NCT04751916|DIETARY_SUPPLEMENT|Essential Amino Acid Protein Supplement|Proprietary essential amino acid protein supplement
214338021|NCT04751916|DIETARY_SUPPLEMENT|Beneprotein®|Whey protein supplement
214939840|NCT04109131|OTHER|Samples collection: Plasma|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Every 3 months (+/- 1 month)"
214939841|NCT04109131|OTHER|Samples collection: CSF|Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice
214939842|NCT04109131|OTHER|Samples collection: Non-CNS Metastatic Tumour Tissue|Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis
214939843|NCT04109131|OTHER|Brain MRI|"Part A:~* Brain MRI at inclusion is allowed within 45 days before enrolment~* Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)"
214939844|NCT04109131|OTHER|Samples collection: Serum|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis for cohorts 1-5."
214939845|NCT04281199|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
214338022|NCT03779841|DRUG|AGN-151607|Injections were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
214338023|NCT03779841|DRUG|Placebo|Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
214338024|NCT01164748|RADIATION|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
214338025|NCT02563041|DRUG|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
214338026|NCT02563041|DRUG|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
214338027|NCT05163145|OTHER|TPN|early detection of comlications of prolonged TPN on neonatal liver
214939846|NCT04281199|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214939847|NCT04281199|RADIATION|Tomotherapy|Undergo IMRT with tomotherapy
214338028|NCT00162136|DRUG|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
214338029|NCT02765945|OTHER|Supervised exercise program|Subjects were enrolled in a hospital-based wellness center where, after analysis of their medical history and previous levels of physical activity ands documentation of a normal exercise stress test, they chose individually tailored exercise programs
214939848|NCT04281199|RADIATION|Total-Body Irradiation|Undergo TBI
214939849|NCT04281199|RADIATION|Volume Modulated Arc Therapy|Undergo IMRT with VMAT
214939850|NCT04728516|DRUG|Vonoprazan-based dual eradication therapy for two weeks|Patients with ACS after PCI, associated with positive Hp need a long-term DAPT treatment. We conducted a study on the prevention of gastrointestinal bleeding between vonoprazan-based dual eradication therapy for two weeks and pantoprazole for six months of a rountine therapy.
214939851|NCT04728516|DRUG|amoxicillin|amoxicillin
214939852|NCT04728516|DRUG|Pantoprazole|Pantoprazole
214939853|NCT04227028|BIOLOGICAL|Bevacizumab|Given IV
214939854|NCT04227028|DRUG|Brigatinib|Given PO
214939855|NCT04107038|PROCEDURE|General Endotracheal Anesthesia|Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.
214939856|NCT04107038|PROCEDURE|Monitored anesthesia care|Participants receive monitored anesthesia care for their procedure.
214939857|NCT04801290|PROCEDURE|TIPS insertion|Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
214939858|NCT06103877|BIOLOGICAL|AZD1163|"In Part 1, Participants will receive AZD1163 through IV infusion or SC injection on Day 1.~In Part 2, participants will receive AZD1163 through SC injection on Days 1 and 15."
214338030|NCT02788175|BIOLOGICAL|Entyvio (Vedolizumab)|A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
214939859|NCT06103877|OTHER|Placebo|"In Part 1, Participants will receive matching placebo through IV infusion or SC injection on Day 1.~In Part 2, participants will receive matching placebo through SC injection on Days 1 and 15."
214939860|NCT05691504|PROCEDURE|Biopsy Procedure|Undergo biopsy
214939861|NCT05691504|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214939862|NCT05691504|DRUG|Cobimetinib|Given PO
214939863|NCT05691504|PROCEDURE|Computed Tomography|Undergo CT
214939864|NCT05691504|PROCEDURE|Echocardiography Test|Undergo ECHO
214939865|NCT05691504|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214939866|NCT05691504|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214939867|NCT05691504|DRUG|Pelcitoclax|Given IV
214939868|NCT02542293|BIOLOGICAL|Durvalumab +Tremelimumab|
214939869|NCT02542293|DRUG|Paclitaxel + carboplatin|Chemotherapy Agents
214939870|NCT02542293|DRUG|Gemcitabine + cisplatin|Chemotherapy Agents
214939871|NCT02542293|DRUG|Gemcitabine + carboplatin|Chemotherapy Agents
214939872|NCT02542293|DRUG|Pemetrexed + cisplatin|Chemotherapy Agent
214338031|NCT02886533|OTHER|Antithrombotic|Collection of clinical, biological data
214338032|NCT04620434|DEVICE|Video laryngoscopic view|The glottic view on the screen of the video laryngoscope during laryngoscopy with a C-MAC video laryngoscope, which installed with Macintosh blade.
214338033|NCT04620434|DEVICE|Direct laryngoscopic view|The glottic view evaluated by the anesthesiologist who performing tracheal intubation, by direct laryngoscopy with C-MAC installed with Macintosh blade.
214939873|NCT02542293|DRUG|Pemetrexed + carboplatin|Chemotherapy Agent
214939874|NCT06432764|DRUG|AZD7798|Each participating patient will receive the study drug as specified in the study protocol.
214939875|NCT06432764|DRUG|[11C]AZ14132516|A single microdose (≤ 10 μg) of radiopharmaceutical \[11C\]AZ14132516 will be extemporaneously prepared and administered to each participant prior to each PET examination
214939876|NCT06196008|OTHER|Educational Intervention|Attend telephone-based coaching sessions
214939877|NCT06196008|OTHER|Educational Intervention|Receive written educational materials on physical activity and standard preoperative care
214939878|NCT06196008|OTHER|Exercise Intervention|Receive a personalized physical activity program, set fitness goals
214939879|NCT06196008|OTHER|Medical Device Usage and Evaluation|Wear activity monitor
214939880|NCT06196008|OTHER|Physical Performance Testing|Ancillary studies
214939881|NCT06196008|OTHER|Quality-of-Life Assessment|Ancillary studies
214939882|NCT06196008|OTHER|Questionnaire Administration|Ancillary studies
214939883|NCT04822688|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
214939884|NCT06057142|BEHAVIORAL|Fun activities for reciting Tang poems|The students will participate in three weekly sessions of Tang poem classes and one session of performance show. Each session lasts for 1.5 hours. Parents can sit in the class. A total of six poems will be taught by two experienced Chinese teachers.
214939885|NCT03297606|DRUG|Olaparib|300mg taken twice daily
214939886|NCT03297606|DRUG|Dasatinib|100mg administered orally once daily
214939887|NCT03297606|DRUG|Nivolumab plus Ipilimumab|"* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.~* Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks."
214939888|NCT03297606|DRUG|Axitinib|5mg orally twice daily
214939889|NCT03297606|DRUG|Bosutinib|500mg orally once daily
214939890|NCT03297606|DRUG|Crizotinib|250mg orally twice daily
214939891|NCT03297606|DRUG|Palbociclib|125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
214939892|NCT03297606|DRUG|Sunitinib|50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
214939893|NCT03297606|DRUG|Temsirolimus|25mg infused over a 30-60 minute period once a week
214939894|NCT03297606|DRUG|Erlotinib|150mg orally, once daily
214939895|NCT03297606|DRUG|Trastuzumab plus Pertuzumab|"Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.~Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes."
214939896|NCT03297606|DRUG|Vemurafenib plus Cobimetinib|"Vemurafenib = 960 mg orally every 12 hours.~Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest"
214939897|NCT03297606|DRUG|Vismodegib|150mg taken orally, once daily
214939898|NCT03297606|DRUG|Tucatinib|300mg taken orally, twice daily
214675916|NCT00958568|DRUG|Olanzapine and Fluoxetine combination (OFC)|"Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.~Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.~Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks."
214675917|NCT00958568|DRUG|Fluoxetine|25 or 50 mg/day fixed dosing for 27 weeks
214675918|NCT03517046|DRUG|CartiLife|Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
214939899|NCT04044534|DRUG|Intranasal insulin|Subjects in this arm will receive intranasal insulin (80 IU per day).
214939900|NCT04044534|DRUG|Placebo|Subjects in this arm will receive placebo.
214939901|NCT06307496|OTHER|Smoking cessation intervention|Receive links to smoking cessation videos
214939902|NCT06307496|OTHER|Informational intervention|"Receive NCI's Clearing the Air booklet"
214939903|NCT06192992|OTHER|Peripheral heating of 2 feet|Heating of both feet
214939904|NCT06192992|OTHER|Sham|No heating
214939905|NCT04104932|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation
214939906|NCT03919500|DRUG|EPO|Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.
214338034|NCT02703935|BEHAVIORAL|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
214338035|NCT02703935|BEHAVIORAL|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
214338036|NCT03930745|OTHER|Placebo|Placebo vaginal inserts.
214338037|NCT03930745|DRUG|TOL-463|TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
214338038|NCT03156231|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
214338039|NCT03156231|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
214939907|NCT03919500|DRUG|Normal saline|Infants in control group are administered normal saline with the same volume and period as EPO.
214939908|NCT04529850|DRUG|Drug: GC4419|GC4419 60 Minute Infusion
214338040|NCT01587183|BEHAVIORAL|Educational material control|Participants will be given educational materials on starting a running program using a run/walk approach.
214338041|NCT01587183|BEHAVIORAL|Group running style B|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
214338042|NCT01587183|BEHAVIORAL|Group running style A|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
214338043|NCT01693601|DRUG|Panobinostat|PO TIW QOW or PO TIW QW
214338044|NCT01693601|DRUG|Ruxolitinib|PO BID x 28 days
214338045|NCT06532539|DRUG|Paclitaxel and Cisplatin|"Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Duration: 6-8 cycles, until disease progression or intolerable adverse effects as judged by the investigator.~Alternative: If contraindicated for cisplatin, or if there is an allergy to paclitaxel and/or cisplatin, alternative drugs such as different types of paclitaxel or carboplatin can be used."
214338046|NCT06532539|DRUG|Cadonilimab|Cadonilimab: 5-10 mg/kg, intravenous infusion, Day 1, every 3 weeks (Q3W). Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
214338047|NCT06532539|RADIATION|Radiotherapy|"Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases.~Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases.~Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 2-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions.~echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy."
214338048|NCT01200381|OTHER|Quarterly remote follow ups and remote monitoring|Quarterly remote follow ups and remote monitoring
214338049|NCT01200381|OTHER|Quarterly remote follow ups + additional phone calls and remote monitoring|Quarterly remote follow ups + additional phone calls and remote monitoring
214338050|NCT01200381|OTHER|Quarterly in clinic follow ups and remote monitoring|Quarterly in clinic follow ups and remote monitoring
214338051|NCT03196765|DRUG|Sobetirome (NV1205)|Once a day oral dose of the study drug
214338052|NCT06531707|DRUG|Ibuprofen + Loratadine fixed dose|Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day
214338053|NCT06531707|DRUG|Ibuprofen|Suspension 2,000 mg / 100 mL, 20 mL twice a day
214338054|NCT06531707|DRUG|Loratadine|Suspension 1 mg / 1 mL, 5 mL twice a day
214338055|NCT03856229|DRUG|Conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
214338056|NCT03856229|DRUG|Shortened steroid regimen|"* Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
214939909|NCT04529850|RADIATION|Intensity-modulated radiation therapy (IMRT)|2.0 to 2.2 Gy daily over 7 weeks
214939910|NCT04529850|DRUG|Cisplatin|100mg/m2 once every 3 weeks or 40mg/m2 once weekly for 6-7 doses
214939911|NCT00310466|BIOLOGICAL|Sublingual immunotherapy|once daily intake of sublingual drops
214939912|NCT00310466|BIOLOGICAL|Placebo|once daily intake of sublingual drops
214939913|NCT02269254|DEVICE|Persona PS Knee Prosthesis by Zimmer|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
214338057|NCT00002453|DRUG|Tenofovir disoproxil fumarate|
214675919|NCT00845923|DRUG|Civamide Patch|Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
214675920|NCT01340235|DRUG|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
214347335|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214675921|NCT02917187|DRUG|BIIB074|Administered as specified in the treatment arm
214939914|NCT02269254|DEVICE|NexGen PS Knee Prosthesis by Zimmer|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
214939915|NCT03787199|DEVICE|Andago|The Andago is a body-weight supporting device with which a patient can walk overground
214939916|NCT03787199|OTHER|Treadmill|Bodyweight supported treadmill walking
214939917|NCT01458951|DRUG|tofacitinib|10 mg oral BID
214939918|NCT01458951|DRUG|Placebo|Placebo oral BID
214939919|NCT00928655|DRUG|acetazolamide|acetazolamide 250mg 1/0/2
214939920|NCT00928655|PROCEDURE|nocturnal continuous positive airway pressure|continuous positive airway pressure
214939921|NCT00928655|DRUG|placebo|placebo capsules
214939922|NCT06007794|OTHER|JUMP group|patients will have a femoral ultrasound and blood tubes in addition to the blood sample taken as part of the treatment
214939923|NCT06553729|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol), 1600 IU per day.
214939924|NCT06553729|DIETARY_SUPPLEMENT|Prebiotics|Prebiotics (inulin), 10g per day.
214939925|NCT06553729|DIETARY_SUPPLEMENT|Prebiotics placebo|Prebiotics placebo.
214939926|NCT06553729|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
214347336|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214675922|NCT02917187|DRUG|Placebo|Matched placebo
214939927|NCT00585013|DRUG|Nitric Oxide|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
214939928|NCT05014841|BEHAVIORAL|Speech Tasks|Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
214939929|NCT03664830|DRUG|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
214939930|NCT00669643|DRUG|PB 6 doses - Rifampicin and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone"
214939931|NCT00669643|DRUG|PB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
214939932|NCT00669643|DRUG|MB 12 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
214338058|NCT06328959|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214939933|NCT00669643|DRUG|MB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
214939934|NCT06459570|BEHAVIORAL|Virtual reality based exercises|one experimental group with Virtual reality-based exercises. Subjects in the VR-based exercises will receive 12 sessions of the VR-based exercises treatment, administered four times a week over 3 weeks, with each session lasting approximately 60 minutes.
214939935|NCT06459570|OTHER|standard physical therapy|"Second control group with standard physical therapy and occupational therapy treatment.Subjects in the control group will receive 12 sessions of physical therapy treatment involving passive and active range of motion exercises, muscle strengthening, and therapeutic stretching, administered four times a week over a span of 3 weeks, with each session lasting approximately 60 minutes."
214939936|NCT00293371|DRUG|docetaxel|
214939937|NCT00293371|DRUG|prednisone|
214338059|NCT06328959|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214338060|NCT04095858|DRUG|Efprezimod alfa|IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
214338061|NCT04095858|DRUG|Placebo|IV infusion, 100 ml at Day -1, Day 14, and Day 28.
214338062|NCT04095858|DRUG|Methotrexate|IV, 15 mg/m\^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
214338063|NCT04095858|DRUG|Tacrolimus|Begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted
214338064|NCT02932631|OTHER|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
214675923|NCT05426148|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®|The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.
214675924|NCT00262106|DRUG|PRO 2000/5|Gel
214675925|NCT00262106|DRUG|Placebo|Placebo
214675926|NCT04978376|BEHAVIORAL|Time restricted eating|We will compare the effects of time restricted eating alone and combined with resistance exercise of endurance exercise versus a no intervention control group.
214675927|NCT04210973|DRUG|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
214675928|NCT04210973|DRUG|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
214675929|NCT02383394|OTHER|follow up antenatal care|ultrasound follow up of pregnancy
214939938|NCT00293371|DRUG|vatalanib|
214939939|NCT02882880|DEVICE|The Luco Hybrid OSA Appliance|Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
214939940|NCT06531772|DRUG|Antitubercular Agents|Full regimen of antitubercular drugs for 6 month period or longer as justified by patient condition
214939941|NCT02963558|DEVICE|cycle ergometry|The cycler will provide 3 different possible modes of cycling-passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
214939942|NCT01194934|DRUG|NOX-A12|4 mg/kg daily IV for 5 days
214939943|NCT01194934|DRUG|NOX-A12|2 mg/kg daily IV for 5 days
214939944|NCT01194934|DRUG|Filgrastim|5 µg/kg SC daily for 5 days
214939945|NCT01194934|DRUG|NOX-A12 in combination with Filgrastim|Safe and efficacious dose regimen according to results of groups A and B
214939946|NCT03309696|DEVICE|sham tDCS and sham rTMS|Both combinations of tDCS and rTMS in this intervention are sham.
214347337|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214939947|NCT03309696|DEVICE|sham tDCS and active rTMS|tDCS in this intervention is sham and rTMS is active
214939948|NCT03309696|DEVICE|active tDCS and active rTMS|Both combinations of tDCS and rTMS in this intervention are active
214939949|NCT06202625|DRUG|avatrombopag|The avatrombopag 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase avatrombopag dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within avatrombopag dosage at 40 mg/d, decrease avatrombopag dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop avatrombopag; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping avatrombopag , reuse avatrombopag at 40 mg/d.
214939950|NCT06202625|DRUG|Placebo|The placebo 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase placebo dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within placebo dosage at 40 mg/d, decrease placebo dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop placebo; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping placebo, reuse placebo at 40 mg/d.
214939951|NCT01087580|DRUG|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
214939952|NCT01087580|DRUG|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
214939953|NCT01087580|DRUG|Radiation Therapy|"GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index \< 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
214939954|NCT06004492|BEHAVIORAL|blended learning program|blended learning program: 8 hours of workshops and four months of practical learning on technology platforms.
214939955|NCT02495194|BEHAVIORAL|Horticultural Therapy|The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
214939956|NCT05320107|DRUG|Ketamine|0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study
215074112|NCT04812119|DIAGNOSTIC_TEST|Manual Ability Classification System (MACS)|The Manual Ability Classification System (MACS; Eliasson, Krumlinde Sundholm, Rösblad, Beckung, Arner, Öhrvall, Rosenbaum, 2006) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 4-18 years.
214939957|NCT05320107|DRUG|Placebo|0.9% NaCl
214939958|NCT03176615|DIETARY_SUPPLEMENT|Experimental diet|The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
215074113|NCT04812119|DIAGNOSTIC_TEST|The Gross Motor Function Classification System - Expanded and Revised (GMFCS - E&R)|The Gross Motor Function Classification System - Expanded \& Revised (GMFCS - E\&R; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to \< 4 years, 4 to \< 6 years, 6 to \< 12 years, and 12 to 18 years.
215074114|NCT04812119|DIAGNOSTIC_TEST|The Visual Function Classification System (VFCS)|The Visual Function Classification System (Baranello et al, 2019) is a valid and reliable 5-level classification system of visual functioning for children with Cerebral Palsy. It describes the use of visual abilities in daily life, focusing on activity and participation.
215074115|NCT04812119|DIAGNOSTIC_TEST|The Early Childhood Oral Health Impact Scale (ECOHIS)|The ECOHIS measures the impact of oral problems and/or experience of dental treatment on the quality of life in children under 5 years old and their parents or other family members. It has 13 questions divided into two domains: one related to impact on the child (9 questions), and another to impact on the family (4 questions), measured using the Likert scale. In children with cerebral palsy and/or the ECOHIS has been validated for ages up to 6,5 years, in children with intellectual disability for ages up to 5 years and in children with special need for ages up to 9 years.
215074116|NCT04812119|DIAGNOSTIC_TEST|The Family Impact Scale (FIS)|The FIS evaluates the impact of a child's oral condition on family life. It consists of 14 items divided into three subscales: parental/family activity (PA), parental emotions (PE), and family conflict (FC). The financial burden subscale (FB) is the only one that is evaluated separately, since it comprises a single item and addresses economic rather than psychosocial or behavioural impact. It has been validated for children above the age of 12 years.
214675930|NCT00915967|DRUG|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
214675931|NCT00915967|DRUG|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
214675932|NCT03964012|BIOLOGICAL|NmCV-5|Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
214675933|NCT03964012|BIOLOGICAL|Menactra|Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
214939959|NCT01432821|OTHER|Apomorphine (Experimental product)|"Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~* Sequence A during visit 2 followed by sequence B during visit 3~* or sequence B during visit 2"
214939960|NCT01573767|DRUG|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
214939961|NCT01573767|DRUG|Placebo|Placebo inhalation powder during treatment period
214939962|NCT01573767|DRUG|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
214939963|NCT00476892|PROCEDURE|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
214939964|NCT05473741|DRUG|Second Generation Long-Acting Injectable Antipsychotic Medications|Patients who have been stabilized on long-acting injectable formulations of paliperidone palmitate, risperidone and aripiprazole will be followed for 48 weeks to determine the rate of relapse when adherence is established. Blood samples to measure plasma antipsychotic levels and prolactin levels, and urine samples for drug screen will be collected at baseline and at the 24-week and 48-week time points.
214939965|NCT00013000|BEHAVIORAL|Test strategy for implementation guideline|
214939966|NCT00112021|DRUG|pramlintide acetate|
214939967|NCT00769535|GENETIC|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR\_RFLP
214939968|NCT04989972|DRUG|PSIL428|1 mg of psilocybin
214939969|NCT04989972|DIETARY_SUPPLEMENT|Oyster mushroom|1 mg of oyster mushroom
214939970|NCT04989972|DRUG|PSIL428|1 mg psilocybin
214939971|NCT03721588|OTHER|Clinical interviews, psychometric scales were applied.|
214939972|NCT04482166|OTHER|Training|20-times training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
214675934|NCT02605733|DEVICE|EEG|amplitude integrated electroencephalography
214675935|NCT02605733|DEVICE|NIRS|regional tissue oximetry
214675936|NCT01903239|PROCEDURE|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
214939973|NCT04482166|DEVICE|supraglottic airway device|supraglottic airway device
214939974|NCT04604964|OTHER|Evaluation of anastomotic leakage occurrence|Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum
214939975|NCT00383682|DRUG|morphine and mexiletine|
214675937|NCT04356105|DRUG|Minimal stimulation protocol|Letrozole, Recombinant FSH, GnRH antagonist
214675938|NCT04356105|DRUG|Microflare protocol|OCP, GnRH agonist, Recombinant FSH
214939976|NCT05611996|BEHAVIORAL|Peers plus|Peer support intervention in which peer mentors who have experiential knowledge of depression deliver social support through video chats and texting to older adults with depression.
214939977|NCT01534806|DRUG|Ketorolac|Ketorolac(0.5mg/kg) IV push
214939978|NCT01534806|DRUG|Placebo|Sodium Chloride 0.9% - 10 mL IV push
214939979|NCT02368210|DRUG|122-0551 Foam|Topical Foam
214939980|NCT02368210|DRUG|Vehicle Foam|Topical Foam
214939981|NCT00078949|BIOLOGICAL|rituximab|Given IV
214675939|NCT04356105|PROCEDURE|IVF/ICSI cycle|Involving ovum pickup and embryo transfer
214675940|NCT00126542|BIOLOGICAL|bevacizumab|Given IV
214675941|NCT00126542|DRUG|erlotinib hydrochloride|Given orally
214675942|NCT00126542|OTHER|laboratory biomarker analysis|Correlative studies
214675943|NCT01591018|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
214675944|NCT01591018|PROCEDURE|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
214939982|NCT00078949|DRUG|cisplatin|Given IV
214939983|NCT00078949|DRUG|cytarabine|Given IV
214939984|NCT00078949|DRUG|dexamethasone|Given IV
214939985|NCT00078949|DRUG|gemcitabine hydrochloride|Given IV
214939986|NCT04214405|PROCEDURE|fixation of tripodal zygomatic fractures|One point versus two point fixation of tripodal zygomatic fractures
214939987|NCT01290497|DRUG|Hyaluronic acid 5 x 2.5 ml|5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)
214939988|NCT01290497|DRUG|Hyaluronic acid 1 x 5 ml|1 intraarticular administration of Adant® 5ml
214338065|NCT03095989|BEHAVIORAL|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
214338066|NCT03265405|DRUG|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
214338067|NCT03265405|DRUG|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
214338068|NCT05889936|BEHAVIORAL|Lev|Lev includes three sessions using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev also include two homework assignments. The second session can be repeated if needed. Lev-s and Lev are described in two manuals.
214338069|NCT00522210|DRUG|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
214338070|NCT00522210|OTHER|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
214338071|NCT03545126|OTHER|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
214338072|NCT04292301|DEVICE|STrategically Acquired Gradient Echo (STAGE)|The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
214338073|NCT03740217|DRUG|GKT137831|oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
214338074|NCT05494879|BEHAVIORAL|microkinesitherapy treatment|"The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions."
214939989|NCT01290497|DRUG|Hyaluronic acid 2 x 5 ml|2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
214939990|NCT01046357|DRUG|AZD7687|Single oral dose
214939991|NCT01046357|DRUG|Placebo|Single oral dose
214939992|NCT01153789|PROCEDURE|orthoptic rehabilitation|Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.
214939993|NCT01153789|OTHER|Orthoptic diagnostic|postural, oculomotor and orthoptics tests
214939994|NCT00362531|DRUG|tacrolimus combined with prednisone|
214939995|NCT05477992|PROCEDURE|Endovascular embolization|Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels.
214939996|NCT03529344|DIETARY_SUPPLEMENT|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
214939997|NCT03529344|DIETARY_SUPPLEMENT|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
214939998|NCT05279768|BIOLOGICAL|UC-MSCs|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
214338075|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
214939999|NCT05279768|BIOLOGICAL|Secretomes|Treatment with tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
214940000|NCT05279768|BIOLOGICAL|UC-MSCs and Secretomes|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
214940001|NCT05279768|BIOLOGICAL|Control|Treatment with Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
214940002|NCT04577222|PROCEDURE|Technical modification during radical prostatectomy|Covering the NVB with fat
214940003|NCT06035939|BEHAVIORAL|Voice Crisis Alert V2|The mHealth self-management intervention consists of the following components: 1) condition-specific electronic educational materials; 2) pain/symptom monitoring and tracking; 3) health history information documentation; 4) medication tracking; 5) secure messaging with a provider; 6) functioning monitoring and tracking; and 7) transmission of health information (graphs with recorded pain and functioning histories) to a provider.
214940004|NCT06035939|BEHAVIORAL|Electronic educational materials|The control arm will receive enhanced usual care, which will consist of usual educational materials distributed at the clinic plus a version of the intervention (Voice Crisis Alert V2) that only includes the electronic educational materials.
214338076|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
214338077|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
214338078|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
214338079|NCT00928148|DRUG|SPD465|50 or 75 mg once daily for 7 days
214940005|NCT02510300|DRUG|Sofosbuvir (SOF)|Exposure of interest for participants who received a SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
214940006|NCT02510300|DRUG|Ledipasvir/Sofosbuvir (LDV/SOF)|Exposure of interest for participants who received a LDV/SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
214338080|NCT00928148|DRUG|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
214940007|NCT02510300|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|Exposure of interest for participants who received a SOF/VEL-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
214338081|NCT00928148|DRUG|Placebo|Once daily for 7 days
214940008|NCT02510300|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)|Exposure of interest for participants who received a SOF/VEL/VOX-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
214940009|NCT02534519|OTHER|Whole Genome Sequencing (WGS)|There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
214940010|NCT06398392|DRUG|[18F]PBR111|\[18F\]PBR111 is a radiotracer produced at University Hospital of Geneva in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 10 mL (max) of formulated product, the maximal applicable dose being 200 MBq.
214940011|NCT06398392|PROCEDURE|PBR111 injection|\[18F\]PBR111 will be administered once, intravenously in the antecubital fossa at a dose of 200 MBq
214940012|NCT06398392|DEVICE|PET scan|Upon administration of the radiotracer, a 120-minute PET/CT scan will be initiated.
214338082|NCT04917198|PROCEDURE|median sternotomy|median sternotomy
214940013|NCT06398392|RADIATION|PBR111 dosimetry|to establish the exposure of the organs/tissues to a standard radioactive dose (200 MBq) of \[18F\]PBR111
214940014|NCT06558136|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214338083|NCT03483623|OTHER|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
214338084|NCT03483623|OTHER|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
214338085|NCT03483623|OTHER|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
214338086|NCT03483623|OTHER|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
214338087|NCT05014100|DRUG|Orelabrutinib tablet|Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
214940021|NCT03758976|DIAGNOSTIC_TEST|Biopsies, blood|We will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer
214940022|NCT06342453|PROCEDURE|Art Therapy|Participate in CrA
214940023|NCT06342453|PROCEDURE|Discussion|Participate in art focus group, art-making
214940024|NCT06342453|OTHER|Media Intervention|Watch videos
214940025|NCT06342453|OTHER|Survey Administration|Ancillary studies
214940026|NCT04088708|OTHER|Aerobic Exercise Training|Each session will last 20 to 60 minutes depending on the stage of progression (shorter duration in the first few weeks). Sessions will occur on nonconsecutive days of the week. Moderate-intensity, continuous aerobic exercise will be used to target large muscle groups (e.g., legs) with the principal goal of increasing cardiorespiratory fitness. Exercise intensity will be gradually increased. To mitigate stagnation and support continued improvement of cardiorespiratory fitness, high-intensity interval exercise will be added in later weeks of the intervention.
214940027|NCT04088708|OTHER|Attention Control|The flexibility/toning control condition will be delivered using the same frequency as the aerobic condition (i.e., 3 times per week) and use light resistance bands of least difficulty. The flexibility/toning sessions will last about 40 minutes, be led by trained exercise specialists. Flexibility/toning activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands (i.e., Thera-bands) that provide minimal resistance.
214940028|NCT02929251|DRUG|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
214940029|NCT02929251|DRUG|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
214338088|NCT05014100|DRUG|Lenalidomide|"Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up"
214338089|NCT04198610|PROCEDURE|Non surgical periodontal therapy|Procedure/Surgery: non surgical periodontal therapy and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
214338090|NCT04471259|OTHER|Classification statistics|We classified patients by gender, age, recovery time,etc
214338091|NCT00523029|BEHAVIORAL|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
214338092|NCT06520748|OTHER|Hand rehabilitation program using the computerized glove|The patient extended finger to reach from grey to green to red colour and heard the beep providing knowledge of result (KR), whereas the increase of range of finger extension reached every session provides knowledge of performance (KP). As the patient's performance improved, the range of their finger's movement will also be increased due to the augmented feedback provided to the patient and the therapist through the glove software
214338093|NCT06520748|OTHER|Selected hand program|Distal key point of Bobath, approximation of affected arm, to control spasticity of wrist/ finger flexor (5 minutes). Dynamic splint to facilitate wrist and finger extension (10 repeat\*5 sets). Passive range of motion exercise (10 repeat\*5 sets) for each joint. Mud exercise (spherical, clyndrical , hook). Thera band exercises.
214338094|NCT00039767|DRUG|Lepirudin|
214338095|NCT04446663|DRUG|Toripalimab|Toripalimab 240mg ivdrip, every 3 weeks for 6 cycles, with 3 cycles combined with induction chemotherapy, 3 cycles combined with concurrent chemoradiotherapy
214940030|NCT02929251|DRUG|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
214940031|NCT06006546|BIOLOGICAL|426c.Mod.Core-C4b|100 mcg and 300 mcg
214940032|NCT06006546|OTHER|Adjuvant 3M-052-AF+Alum|5 mcg
214940033|NCT04511988|OTHER|Diagnostic Test|blood sample (20 ml) and biopsy
214940034|NCT04751409|PROCEDURE|Chest Radiography|Undergo CXR
214940035|NCT04751409|PROCEDURE|Computed Tomography|Undergo CT-chest
214940036|NCT04751409|PROCEDURE|Follow-Up|Undergo intense follow-up
214940037|NCT04751409|PROCEDURE|Follow-Up|Undergo limited follow-up
214940038|NCT04751409|PROCEDURE|Imaging Technique|Undergo imaging
214940039|NCT04751409|OTHER|Questionnaire Administration|Ancillary studies
214940040|NCT05412095|OTHER|Ultrasound of the abdominal wall muscles|the measurements will be performed during inspiration and expiration to take into account variability during the respiratory cycle. The examination is performed bilaterally and comparatively and lasts between 3 and 5 minutes.
214940041|NCT05412095|OTHER|Ultrasound quadricipital|The examination is performed bilaterally and comparatively and takes between 3 and 5 minutes.
214940042|NCT05412095|OTHER|Ultrasound of the diaphragm|The examination is performed bilaterally and comparatively and takes between 5 and 10 minutes.
214940043|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|measurements performed bilaterally on a patient in a half-sitting position at 45° and in spontaneous ventilation
214940044|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|In spontaneous ventilation, lying down, arms by the side of the body, palms up, head down
214940045|NCT06102044|DIETARY_SUPPLEMENT|Zinc Supplements|Dispersible zinc citrate tablets
214940046|NCT06102044|DIETARY_SUPPLEMENT|Placebo Supplements|Dispersible placebo tablets
214940047|NCT06394830|DRUG|VNX001|Intravesical administration of VNX001
214940048|NCT05853289|OTHER|Maternal Opioid use Disorder Management and Care Resources (MOM CARE) in Custody|MOM CARE is a web-based implementation resource designed for jail staff to help the staff provide evidence-based, trauma-informed and patient-centered care and support to pregnant people with opioid use disorder in and leaving custody. MOM CARE's content will include medical guidance and best-practices from intake to discharge, reentry steps and recommendations, and implementation 'how to' content. There will be specific content for jail administrators, medical and custody staff. Content will be curated from existing resources regarding this topic with new original tools specific to pregnant people with OUD in jail.
214940049|NCT06242691|BIOLOGICAL|MK-1200|IV Infusion
214940050|NCT06242691|DRUG|Antiemetic|One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion
214675945|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more"
215078055|NCT01761318|DRUG|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
215078056|NCT03920293|BIOLOGICAL|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams \[mg\]/milliliter \[mL\]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
214338096|NCT04446663|DRUG|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 260 mg/m2, d1 of every cycle, every 3 weeks for 3 cycles before radiotherapy
214338097|NCT04446663|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiotherapy Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiotherapy
214675946|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off
214940051|NCT02497261|PROCEDURE|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
214940052|NCT04852770|BEHAVIORAL|Trial-Based Cognitive Therapy|TBCT is an approach that includes psychoeducation and cognitive restructuring techniques concerning automatic thoughts, underlying assumptions and core beliefs related to the traumatic events. It is conducted in a therapeutic setting that makes use of experiential techniques, allowing the patient to refer to him/herself in the third person and thus taking distance from him or herself. One of TBCT techniques for dealing with guilt and shame, emotions that provoke great limitation to patients with PTSD, is the participation grid (PG). Another important technique is the consensual role-play (CRP), designed to help patients resolve ambivalence and make decisions. In addition, the most important TBCT technique, the Trial, was developed to help patients change dysfunctional negative core beliefs. Therapists who will conduct this approach have a specialization level in CBT. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
215078057|NCT03920293|DRUG|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
215078058|NCT03804463|PROCEDURE|endometrial cancer radical surgery|Take hysterectomy and bilateral adnexectomy.
214338098|NCT04446663|RADIATION|intensity-modulated radiotherapy|Definitive IMRT of ≥66 Gy will be given .
214338099|NCT02770391|DRUG|Leuprolide acetate|Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
215078059|NCT03804463|PROCEDURE|fertility-sparing surgery|Take endometrectomy , preserve uterus and bilateral ovaries.
215078060|NCT03804463|PROCEDURE|ovarian preservation surgery|Take hysterectomy,preserve bilateral ovaries.
214675947|NCT01733069|DEVICE|APTIMA COMBO 2 Assay (AC2 Assay)|APTIMA COMBO 2 Assay (AC2 Assay
214338100|NCT02770391|DRUG|Apalutamide|Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.
214338101|NCT02770391|PROCEDURE|Radical prostatectomy|
214675948|NCT03268746|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject
214675949|NCT06129994|OTHER|Observational|Participants will complete an in-person baseline study visit with fasting blood draw, medical and health history, anthropometrics and vital signs, and surveys. If participants are not currently using a CGM, one will be placed. The LifeData study mobile app will be installed on the participant's smartphone. Over the two-week home monitoring period, participants will be asked to wear the CGM and respond to EMA questions three times daily. After the end of the home monitoring period, a remote visit will be performed in which the CGM will be removed by the study participant at home; the study team will obtain all data available from the CGM and insulin pump (if available); and surveys will be collected.
214940053|NCT04852770|BEHAVIORAL|Mindfulness-Based Health Promotion|"The MBHP protocol is a structured program developed over 8 sessions, in group, where participants (8-15 people) meet every week for 2 hours (standard duration of one session), to experience the concepts and techniques of mindfulness. Participants are also given suggestions of daily activities to be implemented at home or in the workplace, that last in average 15-20 minutes, but may last up to 45 minutes in the case of more motivated and compliant participants. They are also encouraged to incorporate the idea of Mindfulness in their daily lives (the so-called informal practice), so that all daily activities somehow become opportunities to practice Mindfulness. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line."
214940054|NCT04852770|BEHAVIORAL|Positive psychotherapy|PPT is the clinical and therapeutic work derived from PP. PPT consists of 15 specific practices that have been empirically validated, either separately, or in conjunction with two or three practices. After empirical validation, these practices were organized in a cohesive protocol of 15 sessions called PPT. Many of these practices have been studied through online interventions. In the present study, the protocol will be reduced to 14 sessions, with sessions called positive relationships, positive communication, and practical wisdom removed. It was understood that the other 12 would be more easily adapted to the moment of the study. (DUCKWORTH; STEEN; SELIGMAN, 2005; MONGRAIN; ANSELMO-MATTHEWS, 2012; RASHID; SELIGMAN, 2019). In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
214940055|NCT06541158|OTHER|Best Practice|Receive usual care
214940056|NCT06541158|OTHER|Discussion|Participate in a CAB
214940057|NCT06541158|OTHER|Educational Intervention|Receive PAF pamphlet
214940058|NCT06541158|BEHAVIORAL|Health Promotion and Care|Receive the TRACT program
214675950|NCT05795465|DRUG|GEn-1124|Intravenous infusion
214675951|NCT05795465|DRUG|Placebo|Intravenous infusion
214675952|NCT04418583|DIAGNOSTIC_TEST|Three-dimensional imaging|Three-dimensional surface images, acquired by the Artec Leo
214338102|NCT03357042|OTHER|Aerobic exercise and balance retraining|Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.
214338103|NCT03357042|OTHER|Standard of care|Normal concussion treatment; physical and cognitive rest
214338104|NCT01418300|DRUG|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
214338105|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
214675953|NCT02432677|DRUG|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
214675954|NCT02432677|DEVICE|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
214675955|NCT02432677|DEVICE|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
214675956|NCT02432677|DRUG|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
214940059|NCT06541158|OTHER|Media Intervention|Receive transportation awareness brief video
214675957|NCT02945761|PROCEDURE|High concentration of sugar solution|
214675958|NCT02945761|PROCEDURE|conventional surgical dressing change|
214675959|NCT05671120|PROCEDURE|Transcutaneous levator recession|recession of the upper and lower eyelid retractors can improve the upper eyelid contour if the patient has lateral flare (common in TED). The choice of procedure depends on severity of lid retraction and associated features like proptosis, status of extraocular muscles, and corneal condition
214675960|NCT06498271|DEVICE|Personalized and automated digital coaching using a mobile application|Participants allocated to the experimental group will be invited to download a smartphone application which will appraise their motivation and automatically propose: 1) exercises to be performed at home and adapted to their pain levels; 2) audio recordings for pain management; and 3) educational and coaching content adapted to their motivation. In addition, the smartphone application enables users to plan their home exercises
214338106|NCT02199691|BIOLOGICAL|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, IM
214338107|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
214338108|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
214338109|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
214338110|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
214338111|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
214338112|NCT06249100|PROCEDURE|flexible mini percutaneous nephrolithotomy|In Group A (flexible mini-PCNL cases), a puncture will be done under fluoroscopic guidance medial to the posterior axillary line using an 18-gauge puncture needle. The puncture will be directed horizontally or with a slight upward inclination towards the lower or middle calyx. After a successful puncture, a 0.035 Fr Super Stiff guidewire will be inserted. Tract dilatation with amplatz dilator followed by access sheath insertion. Stone disintegration will be done with the flexible mini-nephroscopy (WiScope Digital Endoscope System by OTU Medical, California, USA) which has a shaft length of 38 cm, distal tip diameter is 15.3 F tapering to 10 F, working channel inner diameter is 6.6 F, and the angle of deflection of the distal tip is 210 degrees.
214338113|NCT06249100|PROCEDURE|Retrograde intrarenal surgery|n Group B, Flexible ureteroscopy will be used with a ureteral access sheath and laser fragmentation of renal stones will be done
214338114|NCT02276495|OTHER|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
214338115|NCT02276495|DRUG|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
214338116|NCT02276495|DRUG|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
214338117|NCT03154710|DEVICE|MOOVCARE|web-mediated follow up
214338118|NCT01912248|OTHER|strength training|strength training, lower limb.
214338119|NCT00903838|DRUG|pardoprunox|1.5 to 12 mg/day
214338120|NCT00903838|DRUG|pramipexole|0.75-4.5 mg/day
214338121|NCT01294618|DRUG|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
214338122|NCT06652035|DIETARY_SUPPLEMENT|Quevir® (Quercetin Phytosome®)|500 mg Quevir® (Quercetin Phytosome®) tablet
214338123|NCT06652035|DIETARY_SUPPLEMENT|Bactoblis®|Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)
214338124|NCT00424905|DRUG|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
214338125|NCT00836875|DRUG|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (\<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing \<50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
214338126|NCT05741918|DIAGNOSTIC_TEST|Fick's method|Cardiac output measurement by Fick method
214338127|NCT05741918|DIAGNOSTIC_TEST|Echocardiography|Cardiac output measurement by echocardiography
214338128|NCT00273403|BEHAVIORAL|Maintenance in Care Services|
214675961|NCT02410369|DRUG|S-588410|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
214675962|NCT02410369|DRUG|Placebo|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
214675963|NCT02677701|DRUG|azithromycin|500mg tablet over-encapsulated to match placebo
214675964|NCT02677701|DRUG|placebo (for azithromycin)|
214940060|NCT06541158|OTHER|Questionnaire Administration|Ancillary studies
214940061|NCT01143064|DRUG|Progesterone|Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
214940062|NCT01143064|DRUG|Lipid emulsion without progesterone|Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
214940063|NCT00323037|DRUG|carvedilol controlled release|Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
214940064|NCT00323037|DRUG|carvedilol immediate release|Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
214940065|NCT04933396|DIAGNOSTIC_TEST|ultrasound diagnostic criteria|evaluate using the recent consensus based definition for FGR using biometric and Doppler parameters to identify fetuses at risk of adverse perinatal outcomes compared to using solely biometric based parameter (EFW \<10th percentile according to the Hadlock growth standard).
214940066|NCT05943184|BEHAVIORAL|Cognitive Behavioral Nursing Model|(1)Psychological intervention was accessible to those who felt resistant to their treatment plans or developed inferior feelings due to visual impairment to establish a good relationship with patients and help them better cope with unhealthy emotions. (2) Health education was provided through self-developed booklets and question-and-answer sessions to publicize the fundamental knowledge and make sure all patients have a full understanding of the disease and related treatments. (3) Dietary guidelines were set out to encourage a light, healthy diet with fruits and vegetables, free of irritating food, and containing a limited amount of oily food. (4) Behavioral guidelines were developed to address the importance of quitting tobacco use and prevent eye strain due to excessive eye use with tailored eye care plans.
214940067|NCT06277271|OTHER|E-cigarette|Participants will be supplied with an e-cigarette along with a 4-week supply of e-liquid. Participants will receive training on how to use the device and practice puffing with the e-cigarette during the research visit. They will be instructed to self-regulate administration according to their craving and withdrawal symptoms and to refrain from using other nicotine and tobacco products.
214338129|NCT00273403|BEHAVIORAL|Access to Care Services|
214338130|NCT02927691|DEVICE|EMST|
214940068|NCT05265091|DRUG|KL590586 Capsule|Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule
214940069|NCT03603951|DRUG|SHR2554|SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
214940070|NCT00230022|BEHAVIORAL|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
214940071|NCT05044949|OTHER|Probiotic|The study product is a probiotic strain
214940072|NCT05044949|OTHER|Placebo|The study product is a placebo to the probiotic strain
214940073|NCT06622967|DIAGNOSTIC_TEST|CadAI-B|"The ultrasound is performed following the usual process. If there are any lesions or areas of concern identified by the patient, a more detailed analysis is conducted on the affected area.~When a lesion is confirmed, the examiner verifies the results through the frozen image, while also securing the results displayed on CadAI-B.~The examiner uses the analysis from CadAI-B as a reference to make the final BI-RADS classification.~Static images and cine clips are captured from the most suspicious areas."
214675965|NCT02677701|DRUG|inhaled tobramycin|clinically prescribed inhaled tobramycin used by subjects participating in the study
214338131|NCT02927691|BEHAVIORAL|smTAP|
214338132|NCT04990986|OTHER|Complex intervention|Will be co-developed during the study.
214940074|NCT05866367|DRUG|Low dose Regular Insulin|Regular insulin administered intranasally at either 40 IU
214675966|NCT00147628|DRUG|sildenafil citrate|
214675967|NCT00147628|DRUG|placebo for sildenafil citrate|
214940075|NCT05866367|DRUG|High dose Regular insulin|Regular insulin administered intranasally at either 80 IU
214940076|NCT02107287|RADIATION|IMRT Technique|
214940077|NCT03801824|OTHER|Standard Nutrition Therapy|Subjects will be advised on standard diet appropriate for the management of Gestational Diabetes Mellitus (GDM) designed to be high in fiber and have moderate to high dietary glycemic index
214940078|NCT03801824|OTHER|Low Glycemic Index|Subjects will be advised to eat low glycemic index foods
214940079|NCT06473025|BEHAVIORAL|Information on Relative Nutritional Status|The intervention involves providing information on the height-for-age and weight-for-age percentiles of children relative to a reference group of healthy children based on WHO standards
214940080|NCT06473025|BEHAVIORAL|Information on Returns to Child Nutrition|The intervention involves providing information on the effects of child undernutrition on long-term health, education, and labor market outcomes.
214940081|NCT05248334|DRUG|Ranibizumab Injection|"The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed."
214940082|NCT05248334|PROCEDURE|PPV|Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
214940083|NCT05936216|BIOLOGICAL|TVI-Brain 1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
214940084|NCT01942031|BEHAVIORAL|structured collegial feed back|Collegial feed back to primary care physicians at randomized primary care centers
214338133|NCT06573216|DEVICE|Wrist Ambulatory Blood Pressure Monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
214338134|NCT06662851|DIAGNOSTIC_TEST|UDFF|Ultrasound-Derived Fat Fraction (UDFF) is a quantitative ultrasound technique used to assess hepatic steatosis by measuring the amount of fat in the liver tissue. UDFF estimates fat content using specific ultrasound parameters, namely the attenuation coefficient (AC) and backscatter coefficient (BSC). The AC measures the rate at which ultrasound waves weaken as they pass through the liver, which correlates with fat content, while the BSC quantifies the amount of reflected ultrasound signal, providing additional insights into liver tissue characteristics.
214338135|NCT06664190|DIAGNOSTIC_TEST|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)
214338136|NCT06662721|DRUG|Baricitinib 4 MG|The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.
214675968|NCT00816972|DRUG|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
214675969|NCT00816972|DRUG|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
214675970|NCT00816972|DRUG|Placebo for Desloratadine 2.5 mg|Placebo BID
214675971|NCT00816972|DRUG|Placebo for Oxybutynin 2.5 mg|Placebo BID
214940085|NCT06197412|DRUG|Yunnan Baiyao|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
214675972|NCT06512090|DIETARY_SUPPLEMENT|LGI steam bread|"LGI Steam bread called Mangusteam bread"
214675973|NCT06512090|DIETARY_SUPPLEMENT|Diabetic diet|the calorie intake of Diabetic diet will by recommended by nutritionist
214675974|NCT02265211|BEHAVIORAL|Self-Help App|
214675975|NCT02201823|DRUG|ABTL0812|ABTL0812. Five cohorts and one extension phase.
214675976|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 25 mg tablet
214675977|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 50 mg tablet
214675978|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 100 mg tablet
214675979|NCT01970150|DEVICE|rTMS real|
214675980|NCT00850499|DRUG|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
214675981|NCT00850499|DRUG|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
214675982|NCT00850499|DRUG|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
214940086|NCT00081796|DRUG|larotaxel (RPR109881, XRP9881)|
214675983|NCT05391763|PROCEDURE|Fascia pectoralis preservation|A total mastectomy will be performed in the control breast: a procedure which includes removal of the breast glandular tissue including the PF and subcutaneously excision of the nipple-areolar complex, while the pectoralis muscle will be spared. As much of the healthy skin envelope will be preserved to enable the performance of an effective breast reconstruction afterwards. When a nipple-sparing mastectomy is performed, the skin envelope together with the nipple-areolar complex will be spared. The investigational part of the operation is preservation of the PF. Dissection of cutaneous flaps and the breast with or without the PF will be performed with electrocautery.
214675984|NCT05810779|OTHER|dynamic surface exercise|Optimal arousal Physio ball Make the child bounce, active/passive on the Swiss ball, slow/fast 5 times 5 sets Combined frontal and transverse plane movements Physio ball/ bolster High sitting: one hand weight bearing followed by trunk rotation to reach the toy on opposite side 5-7 each side 1 set Combined frontal and transverse plane movements Platform swing Reaching the toy with both the hands kept overhead and 45°-60° diagonal to the mid line 5-7 times each side 1 set
214675985|NCT05810779|OTHER|trunk targeted training|"trunk training group (TTG) consist of exercises and activities focusing on the activation of the trunk muscles, pelvic control and proximal stabilization and these were combined with the trunk and gluteal muscle strengthening exercises.~The trunk elongation activities, the facilitation of spinal extension, weight shifting and weight-bearing activities The children in the TTG received 45-75-minute of physiotherapy twice a week for 8 weeks"
214675986|NCT04765462|BIOLOGICAL|Allogeneic γδ T cells|"Phase 1:Enrolled patents will be administered allogeneic γδ T cells from 2x10\^6/kg, 1 x10\^7/kg to 5x10\^7/kg every 2-4 weeks to determine the recommended dose level.~Phase 2: Enrolled patents will be administered allogeneic γδ T cells at the recommended dose level to confirm the efficacy.~Whether or not in combination with other therapies will be determined by research physicians according to the disease status of enrolled patients."
214675987|NCT01984112|DEVICE|Locked plate|Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
214675988|NCT01984112|DEVICE|Intramedullary locked nail|Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
214338137|NCT06662708|DIAGNOSTIC_TEST|Accurate Prediction Artificial Intelligence Models|Diagnostic Test: Accurate Prediction Artificial Intelligence Models Post-operative pathology, precise pre-operative diagnosis (including benign and malignant, invasive, grading, subtypes) or 3D lesion modelling will be predicted based on the AI predictive model in response to the information provided
214338138|NCT06663410|DEVICE|SPG block with the use of the Tx360 device|A SPG block was performed using the Tx360 nasal applicator according to the manufacturer's instructions bilaterally, injecting 0.3cc of lidocaine 2% into each nostril.
214338139|NCT06664268|BIOLOGICAL|Plasma rich in growth factors (PRGF-Endoret)|Plasma Rich Fibrin (PRF) is a newer modality in regenerative medicine derived from the patient's own blood. PRF does not use anticoagulants during processing, leading to a natural fibrin matrix that supports prolonged release of growth factors and cytokines .This matrix has been shown to enhance wound healing and improve scar texture and appearance .
214338140|NCT06664268|DEVICE|Fractional CO2 laser assisted PDT|Fractional CO2 laser therapy is a well-established technique for scar treatment, including postburn scars. This technology utilizes laser energy to create microthermal zones in the skin, which stimulates collagen production and skin remodeling while minimizing damage to surrounding tissues .
214338141|NCT06663150|BEHAVIORAL|health intervention with a socio-community approach|"The intervention consists of five components, including education, cognitive stimulation, physical activity, nutrition, and socio-community aspects. The duration of the intervention will be 6 months and will be conducted in either in-person or virtual format, individually or in groups, depending on the nature of each component. Mode of Delivery:~The intervention will be offered in both in-person and synchronous virtual formats. Participants who are unable to attend in person or who face difficulties doing so on any occasion will have the option to join the sessions through a real-time videoconferencing platform. In both modalities, the professionals in charge will supervise and guide the activities, ensuring proper execution and adherence to the study's objectives. The research team will maintain a detailed record of attendance and participation using the RedCap platform for appropriate tracking."
214940087|NCT00081796|DRUG|capecitabine|
214940088|NCT02026336|OTHER|electronic nose|"Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L Tedlar bag. Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile."
214940089|NCT02707471|BEHAVIORAL|SM-AET|self-management for improving adherence and reducing symptom interference (SM-AET)
214940090|NCT02707471|BEHAVIORAL|general health education|general health education intervention that focuses on improving overall health.
214940091|NCT05680831|BIOLOGICAL|0.070 ppm ozone concentration|The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.
214940092|NCT05680831|BIOLOGICAL|Clean air (0.0 ppm ozone)|Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.
214940093|NCT01004601|DRUG|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
214940094|NCT01004601|DRUG|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
214940095|NCT01681316|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
214338142|NCT06664580|OTHER|Metabolic Bariatric Surgery Procedures|Observational analysis of various metabolic bariatric surgeries, including LSG, RYGB, and OAGB, focusing on long-term outcomes related to weight maintenance, nutritional health, and patient satisfaction.
214338143|NCT06661980|DRUG|Dexmedetomidine Injectable Solution|Dexmedetomidine 200 mcg/ 2 mL IV.
214940096|NCT01681316|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
214940097|NCT01681316|DRUG|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
214940098|NCT00240955|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
214940099|NCT03258008|DRUG|Utomilumab|Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
214940100|NCT03258008|BIOLOGICAL|ISA101b|ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
214940101|NCT06500923|OTHER|Oral rehabilitation by means of implant-supported single unit crowns|Surgery: Implant placement; Prothetic rehabilitation: single unit crown
214940102|NCT01763138|BEHAVIORAL|oral health education|oral health education in the form of a pictorial pamphlet.
214940103|NCT01763138|BEHAVIORAL|reminder phone call|a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
214940104|NCT01199822|BIOLOGICAL|Olaratumab|Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
214940105|NCT02553707|DRUG|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
214940106|NCT02156375|DRUG|Ustekinumab|Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
214940107|NCT02156375|DRUG|Ustekinumab|Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
214940108|NCT03374670|DRUG|Zimura|Zimura in combination with Eylea
214940109|NCT03374670|DRUG|Eylea|Zimura in combination with Eylea
214338144|NCT06661980|OTHER|Placebo|Normal Saline IV.
214338145|NCT06664060|DRUG|osteoimplant|30 lower third molars will be selected and prescribed preoperative treatment with two units of Osteoimplant Complex® 5 days prior to surgery and postoperative treatment with one unit of Osteoimplant® for 8 weeks from the time of surgery. Both nutritional supplements will be administered every 24 hours.
214338146|NCT06664060|DRUG|Placebo|30 lower wisdom teeth will be selected and prescribed placebo, both preoperatively 5 days prior to surgery and postoperatively for 8 weeks from the time of surgery.
214338147|NCT06663228|DIAGNOSTIC_TEST|MMS|miniature mass spectrometry with AI assistance
214338148|NCT06662903|PROCEDURE|Cranioplasty with Titanium mesh|Cranioplasty using titanium mesh
214940110|NCT04996511|DEVICE|PulseOn|Postoperative HRV measurement
214940111|NCT03803228|DRUG|DUOSTIM|2 consecutive stimulations by Fertistartkit® on the same cycle
214940112|NCT03803228|DRUG|Conventional stimuli|2 stimulations by Fertistartkit® performed on 2 different cycles
214940113|NCT03644056|DRUG|IMC-001|Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)
214940114|NCT02013856|DIETARY_SUPPLEMENT|Low Epicatechin and procyanidin|70 mg epicatechin and 65 mg procyanidins once daily for 28 days
214940115|NCT02013856|DIETARY_SUPPLEMENT|High Epicatechin and procyanidin|140 mg epicatechin and 130 mg procyanidins once daily for 28 days
214940116|NCT02013856|DIETARY_SUPPLEMENT|High procyanidin|No epicatechin and 130 mg procyanidins once daily for 28 days
214940117|NCT02013856|DIETARY_SUPPLEMENT|Placebo|Placebo control once daily for 28 days
214338149|NCT06662903|PROCEDURE|Cranioplasty with bone cement|Cranioplasty using bone cement
214338150|NCT06663839|DRUG|Biological NILK-2301|Treatments will be administered every two weeks in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Should evidence emerge showing that treatment beyond one year may prolong benefit in responding patients, the protocol will be amended to ensure that these responding patients may continue with the study treatment beyond 12 months until disease progression.
214338151|NCT06663254|DRUG|Hydroxyethyl starch 130/0.4|Individualized goal-directed administration of 6% Hydroxyethyl starch (HES) 130/0.4: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min. If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. If the use of HES exceeds 30 ml/kg, sodium acetate Ringer will be replaced. In addition, patients will have a background infusion of sodium acetate Ringer's solution at 4 ml/kg/h to satisfy the maintenance fluid requirements during surgery.
214940118|NCT05958745|BEHAVIORAL|Aerobic Exercise|Aerobic exercise training Program
214940119|NCT05958745|BEHAVIORAL|Aerobic + resistance exercise|Aerobic + resistance exercise training Program
214940120|NCT03284645|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
214940121|NCT03284645|DRUG|Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
214940122|NCT03284645|DRUG|Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily|Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
214940123|NCT00204282|BEHAVIORAL|Educational presentation, group discussion, questionnaires|
214940124|NCT04375501|OTHER|Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail|If fit for anaesthesia patients may undergo relevant procedure for fractured neck of femur as per NICE guidelines within limitations of resources as defined by BOAST
214940125|NCT03747302|OTHER|Social Media Message about HPV and HPV vaccine|Messages educate parents with facts about HPV vaccination.
214940126|NCT03747302|OTHER|Social media message about risk of electronic cigarettes.|Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.
214338152|NCT06663254|DRUG|Sodium acetate Ringer|"Individualized goal-directed administration of crystalloid alone: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min.~If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. In addition, patients will have a background infusion of sodium acetate, the maintenance fluid requirement during surgery."
214338153|NCT06664723|DEVICE|high tone external muscle stimulation|Device HiToP®: Parameters of (HTEMS), Voltage: 230-V Pulse widths: ≤350 mA. Electrical Frequency: Frequencies continuously scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 m W. Intensity: the electrical stimulation will be adjusted to a pleasant level that will not produce any pain or discomfortable paraesthesia, Duration 30 minutes per session. Electrodes will be placed around ulcer. It will be introduced 3 times per week, for 8 weeks Prior to intervention, skin sensation will be assessed using warm water in a test-tube (temperature), pin prick (pain) and cotton wool (light touch) to ascertain the skin sensitivity
214338154|NCT06664723|OTHER|Standard medical treatment (SMT)|The Standard care of diabetic foot ulcers includes good glycemic control, adequate nutrition, off-loading (via bed rest or casts), local care (moist dressings and topical management), lessening of edema, surgical debridement of devitalized wound tissue and antibiotic therapy.
214338155|NCT06661109|OTHER|Intervention (Kinesio Taping) group|No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.
214338156|NCT06663891|OTHER|Functional MRI with EEG per MRI|"2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.~Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,"
214338157|NCT06662838|OTHER|Ergonomics Awareness and First Aid Training Program|The ergonomic awareness and first aid training program includes training on possible situations that children of seasonal agricultural worker families may encounter in the field.
214338158|NCT06663085|DIETARY_SUPPLEMENT|Enteral feeding|intervention group received enteral feeding breastmilk during transfusion
214338159|NCT06663215|OTHER|School Based Bullying Prevention Program|Three forms were administered to the adolescents: Personal Information Form, Bullying and Cyberbullying Scale for Adolescents (BCE-A) and Adolescent Future Expectations Scale. Adolescents were included in a school-based bullying prevention program the next day. One month later, the forms were administered again.
214338160|NCT06661837|OTHER|Clinical examination and mobile photo|Children were both clinically examined and a mobile photo was taken for assessment
214940127|NCT05123469|DEVICE|Electroencephalography|Simultaneous recording of electroencephalogram by conventional EEG device and the Zeto EEG device
214940128|NCT05795920|DRUG|Utidelone injection in combination with gemcitabine|Utidelone injection: 30mg/m2, for days 1-5, once a day, 21 days for a treatment week Period; Gemcitabine: 1000mg/m2, Q3W on day 1 and day 8, 21 days for a treatment cycle
214940129|NCT04160572|BEHAVIORAL|Morning sleep schedule|sleep right after night shifts
214940130|NCT04160572|BEHAVIORAL|Evening sleep schedule|sleep before night shifts
214940131|NCT05362240|PROCEDURE|Four corner fusion|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denuded the articulating surfaces between lunate , capitate , hamate and triquetrum . Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones
214338161|NCT06662578|OTHER|Traditional memory workshop|The participants received 8 weekly sessions of 60 minutes of neurocognitive stimulation, based on French memory workshops.
214338162|NCT06662578|OTHER|Equine assisted therapy memory workshops|The participants received 8 weekly sessions of 60 minutes, based on traditional memory workshops (French type of neurocognitive stimulation) with the mediation of a horse (example : working on associative memory by selecting which object is used for the horse between 2 presented objects).
214338163|NCT06663787|DRUG|Trastuzumab (Herceptin)|Continuing anti-HER2 treatment
214338164|NCT06663787|DIAGNOSTIC_TEST|SIgnatera|A personalized, tumor-informed test.
214338165|NCT05318638|DEVICE|Soft robotic glove|The soft-robotic glove used in the study is the Carbonhand system (Bioservo Technologies, Sweden). It is a CE-marked medical device and it consists of a glove that supports finger flexion via sewn-in tendons and a control unit housing the actuators that pull on the tendons and the batteries. The grip support is activated by applying very light pressure on sensors in the fingertips of the glove, and de-activated by releasing the pressure on the sensors.
214338166|NCT05943860|DIETARY_SUPPLEMENT|Pantovigar® vegan|Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months
214338167|NCT06669013|DRUG|dinutuximab beta|Chemotherapy + Immunotherapy (dinutuximab beta)
214940132|NCT05362240|PROCEDURE|three corner fusion without triquetrum excision|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denude the articulating surfaces between lunate , capitate , hamate and don not include triquetrum. Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones.
214940133|NCT03769675|DEVICE|High Frequency Spinal Cord Stimulator|The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .
214940134|NCT02745912|DRUG|Naltrexone/Bupropion|Naltrexone/Bupropion extended-release tablets.
214940135|NCT02745912|DRUG|Metformin|Metformin immediate-release tablet.
214940136|NCT02240303|PROCEDURE|Quantitative Sensory Testing (QST)|Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
214940137|NCT02240303|PROCEDURE|Physical Performance|Participants in both groups will have a Physical Performance test.
214338168|NCT06621121|OTHER|Tenecteplase|The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg/kg, up to a maximum of 25 mg, based on their clinical condition and the preferences expressed by the patients and their families.
214338169|NCT06621121|OTHER|Alteplase|The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg/kg, up to a maximum of 90 mg, based on their clinical condition and the preferences expressed by the patients and their families.
214338170|NCT06620237|DEVICE|Implantation of the Solia CSP S pacing lead for LBBAP|Left bundle branch area pacing using a Solia CSP S lead
214347338|NCT02897804|BEHAVIORAL|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
215074117|NCT04812119|DIAGNOSTIC_TEST|The Achenbach System of Empirically Based Assessment (ASEBA)|The Achenbach System of Empirically Based Assessment (ASEBA; Achenbach) is a collection of questionnaires used to assess adaptive and maladaptive behavior and overall functioning in individuals. The system includes report forms for multiple informants - the Child Behavior Checklist (CBCL) is used for caregivers to fill out ratings of their child's behavior, the Youth Self Report Form (YSR) is used for children to rate their own behavior, and the Teacher Report Form (TRF) is used for teachers to rate their pupil's behavior. The ASEBA seeks to capture consistencies or variations in behavior across different situations and with different interaction partners. The ASEBA exists for multiple age groups, including preschool-aged children, school-aged children, adults, and older adults. Scores for individuals in each age group are norm-referenced.
214940138|NCT02240303|PROCEDURE|Magnetic Resonance Imaging (MRI)|Participants in both groups will have an magnetic resonance imaging (MRI).
214940139|NCT02240303|PROCEDURE|Blood Sample|Participants in both groups will have blood samples taken.
215074118|NCT04812119|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System Third Edition (ABAS-3)|The ABAS-3 (Harrison, Oakland, 2015) is a rating scale useful for assessing skills of daily living in individuals with developmental delays, autism spectrum disorder, intellectual disability, learning disabilities, neuropsychological disorders, and sensory or physical impairments. Rating forms are filled out by the parent and a teacher. The ABAS-3 covers three broad domains: conceptual, social, and practical, using 11 skill areas within these domains. Tasks focus on everyday activities required to function, meet environmental demands, care for oneself, and interact with others effectively and independently. On a 4-point response scale, raters indicate whether, and how frequently, the individual performs each activity.
214347339|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214940140|NCT02635542|DRUG|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
214675989|NCT05646771|BEHAVIORAL|Partner support|Remotely delivered, partner-supported weight management counseling delivered in group visits every two weeks over 14 weeks (8 sessions)
214940141|NCT02635542|DRUG|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
214940142|NCT06245967|DEVICE|Frequency specific microcurrent therapy|Concussion protocol
214940143|NCT06245967|DEVICE|Sham Frequency specific microcurrent therapy|Shan concussion protocol
214940144|NCT00851773|DRUG|semaglutide|0.1 mg once weekly, s.c. injection
214940145|NCT00851773|DRUG|semaglutide|0.2 mg once weekly, s.c. injection
214940146|NCT00851773|DRUG|semaglutide|0.4 mg once weekly, s.c. injection
214940147|NCT00851773|DRUG|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
214940148|NCT00851773|DRUG|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection
214940149|NCT00851773|DRUG|placebo|0.1 mg once weekly, s.c. injection
214940150|NCT00851773|DRUG|placebo|0.2 mg once weekly, s.c. injection
215074119|NCT00002873|RADIATION|brachytherapy|
215074120|NCT01226641|DEVICE|Telemedicine|CPAP treatment with telemedicine system
214940151|NCT00851773|DRUG|placebo|0.4 mg once weekly, s.c. injection
214940152|NCT00851773|DRUG|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
214940153|NCT00851773|DRUG|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
214940154|NCT03632226|DRUG|18F-OGA-1|
214940155|NCT05433480|DRUG|BPI-16350|BPI-16350 400 mg, orally once daily
214940156|NCT05433480|DRUG|placebo|Placebo 400 mg, orally once daily
214338171|NCT01997775|DRUG|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 \> 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
214940157|NCT05433480|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
214338172|NCT03403634|DRUG|Celecoxib|Given PO
214338173|NCT03403634|OTHER|Laboratory Biomarker Analysis|Correlative studies
214338174|NCT03403634|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
214338175|NCT03403634|DRUG|Rintatolimod|Given IV
214940158|NCT05037539|DRUG|Fentanyl Citrate 50Mcg/Ml Inj_#1|Injectable Fentanyl in Sublingual Route 50 mcg
214940159|NCT05037539|DRUG|Morphine|Oral Morphine Syrup 2.5 ml ( 5 mg)
214940160|NCT03361436|DRUG|Eribulin Mesylate|Given IV
214940161|NCT03361436|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214940162|NCT03361436|OTHER|Laboratory Biomarker Analysis|Correlative studies
214940163|NCT03361436|OTHER|Quality-of-Life Assessment|Ancillary studies
214940164|NCT03361436|OTHER|Questionnaire Administration|Ancillary studies
214940165|NCT03361436|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214940166|NCT03453996|OTHER|Intervention|"Computerized clinical decision support intervention. This intervention consists of 2 decision support components for CI-AKI prevention:~1. Estimation of safe contrast limit to reduce the relative risk of CI-AKI by 20% (ePRISM Acute Kidney Injury Model with Contrast Sensitivities and Dialysis Risk software from Health Outcomes Sciences)~2. Patient weight and left ventricular end diastolic pressure (LVEDP) based intravenous crystalloid fluid recommendation."
214940167|NCT03453996|OTHER|Control|Usual procedural care provided by cardiologist without introduction of the computerized clinical decision support information.
214338176|NCT00321035|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
214940168|NCT01432275|DEVICE|ADC blood glucose meter|Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
214940169|NCT01432275|DEVICE|Comparator blood glucose meter|Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
214940170|NCT01432275|DEVICE|ADC blood glucose meter with insulin calculator active|Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
214940171|NCT01048970|OTHER|Nutritional Assessment|Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
214940172|NCT01048970|DIETARY_SUPPLEMENT|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
214940173|NCT02565706|BEHAVIORAL|WIC Fresh Start Program|The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
214940174|NCT02565706|BEHAVIORAL|Existing Online Health Education|Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
214338177|NCT07042464|PROCEDURE|Modified poco-poco exercises|Participants performed modified poco-poco exercises three times weekly for 12 weeks
214338178|NCT06820697|BEHAVIORAL|Low HIVST kit subsidy|"The two study groups are the high and low subsidy groups. The high subsidy group will start off with a 90% subsidy while the low subsidy group will start off with a 50% subsidy. Both study groups will experience decreasing subsidies at each phase of the study."
214338179|NCT06820697|BEHAVIORAL|High HIVST kit subsidy|"The two study groups are the high and low subsidy groups. The high subsidy group will start off with a 90% subsidy while the low subsidy group will start off with a 50% subsidy. Both study groups will experience decreasing subsidies at each phase of the study."
214338180|NCT06889740|OTHER|NMNH|Reduced Nicotinamide Mononucleotide
214338181|NCT06889740|OTHER|Placebo|Starch powder
214338182|NCT06743750|DIAGNOSTIC_TEST|RT-PCR in different respiratory tract samples|RT-PCR on saliva, orrobuccal swab and nasal swab will be performed. Nasopharyngeal swab will be performed independently of the study as standard of care.
214675990|NCT02958163|PROCEDURE|Trans-arterial Chemo-Embolization|Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.
214940175|NCT02623842|DEVICE|Tonederm® (Radiofrequency non ablative)|The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
214940176|NCT00803309|DRUG|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
214940177|NCT00803309|DRUG|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
214940178|NCT00803309|DRUG|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
214940179|NCT00803309|DRUG|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
214940180|NCT03623971|DEVICE|Cataract AI agent|An artificial intelligence to make comprehensive evaluation and treatment decision of different types of cataracts.
215074121|NCT01226641|DEVICE|Standard care|Standard care, including CPAP
214940181|NCT03315611|DRUG|'Eucerin AtopiControl Lotion' (for the body)|Treatment with Eucerin AtopiControl Lotion
214940182|NCT03315611|OTHER|Allergen challenge chamber|Exposure to Dactylis glomerata pollen in an environmental challenge chamber
214940183|NCT02253732|BEHAVIORAL|3 months exercise intervention program|3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength \& aerobic exercises
214940184|NCT06294873|DIAGNOSTIC_TEST|A screening device for the detection of colorectal and other aerodigestive tract cancers|DNA test to screen to detect colon cancer and precancerous lesions
214940185|NCT01935700|DRUG|Colchicine|"Adjustment the dosage of colchicine during study:~The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day."
214940186|NCT03985189|DRUG|ME-401|"\[Phase 1 study (DLT evaluation)\] ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.~\[Roll over study\] 60 mg ME-401 will be administrated on intermittent schedule (1 week on and 3 week off in every 4-week cycle)and will continue until the prescribed mediation in ME-401-004 study is completed or discontinuation criteria are met."
214940187|NCT01551706|DIETARY_SUPPLEMENT|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract
214940188|NCT01551706|OTHER|Placebo|Placebo
214940189|NCT05956405|BEHAVIORAL|AIR + Mindfulness|AIR + Mindfulness program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
214940190|NCT05956405|BEHAVIORAL|Relaxation condition|Relaxation program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
214940191|NCT04952207|DRUG|Direct-acting antiviral agents|The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
215074122|NCT05594121|DRUG|Extended Release Subcutaneous Buprenorphine|Monthly subcutaneous injections of long-acting buprenorphine
214675991|NCT02958163|DRUG|Doxorubicin|Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
214675992|NCT02958163|RADIATION|Stereotactic Ablative Radiotherapy|"SABR schemes will be adapted according to the CP score and the vicinity of surrounding organs at risk. These are the different schemes proposed in this trial:~48Gy = 3x16Gy BED 124.8Gy ( α/β=10) 50Gy = 5x10Gy BED 100Gy ( α/β=10) 48Gy = 6x8Gy BED 86.4Gy ( α/β=10) 40Gy = 5x8Gy BED 72Gy ( α/β=10)~For patients with Child-Pugh (CP) A cirrhosis : the choice of the scheme will be left to each physician. The highest BED should be favored if dose constraints to the organs at risk are respected.~For patients with CP B cirrhosis : only the latter scheme will be allowed: 40Gy = 5x8Gy."
215074123|NCT05594121|DRUG|Immediate Release Sublingual Buprenorphine|Daily sublingual fast-acting buprenorphine
214675993|NCT03501355|DEVICE|Inspiratory muscle strength training|"Treatment group will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 50% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 50% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
214940192|NCT04471571|OTHER|Resin infiltration and microabrasion for MIH-affected incisors|MIH-affected incisors will be treated with microabrasion followed by resin infiltration as a combined treatment
214347340|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214940193|NCT04471571|OTHER|Resin infiltration for MIH-affected incisors|MIH-affected incisors will be treated with resin infiltration alone
214940194|NCT04246645|OTHER|CORE STABILITY EXERCISES|SELECTED CORE EXERCISES
214940195|NCT01225289|DIETARY_SUPPLEMENT|Vitamin A|25000 IU/day (one capsule per day) Vitamin A for 6 months
214940196|NCT01225289|DRUG|Placebo|1 capsule per day for six months
214940197|NCT02428894|DEVICE|LVAD|
214940198|NCT02859688|GENETIC|pyrosequencing|
214940199|NCT02859688|GENETIC|Methylome|
214940200|NCT05658640|DRUG|Trametinib|Oral
214940201|NCT05658640|DRUG|Dexamethasone|Oral/ Intravenous
214940202|NCT05658640|DRUG|Cyclophosphamide|Intravenous
214940203|NCT05658640|DRUG|Cytarabine|Intravenous
214338183|NCT07051824|DIETARY_SUPPLEMENT|Probiotic and Prebiotic|"This synbiotic intervention aims to minimize postoperative gastrointestinal symptoms in sleeve gastrectomy patients. The 5 g sachet contains:~* Partially hydrolyzed guar gum (PHGG; 4.9 g): Clinically shown to reduce diarrhea and improve stool consistency,~* Lactobacillus rhamnosus GG (LGG; 1×10⁹ CFU): Evidence-based for alleviating abdominal pain and bloating,~* Maltodextrin (0.1 g): Excipient for stability.~Administered daily in yogurt for 12 weeks post-surgery, this combination directly targets:~① Diarrhea and constipation (via PHGG's soluble fiber),~② Abdominal pain and bloating (via LGG's anti-inflammatory effects),~③ Overall GI symptom burden.~\*\*Distinctive features vs. other studies:~* Symptom-specific formulation: PHGG (high-dose fiber) + LGG (symptom-targeted probiotic) synergy,~* Surgical context: Optimized for rapid gastric transit post-sleeve gastrectomy,~* Delivery innovation: Yogurt matrix protects probiotics against surgical gut pH changes."
214338184|NCT07051759|PROCEDURE|Back contouring surgery|Back rolls are assessed, and the type of surgery is determined according to grade of back rolls.
214338185|NCT07051811|PROCEDURE|Intravascular Ultrasound Ablation Therapy|"The single-use intravascular ultrasound ablation catheter is used in conjunction with the ultrasound ablation device to remove renal sympathetic nerves.~Standardized medication regimen."
214338186|NCT07051811|PROCEDURE|Renal Artery Angiography|Only undergo renal artery angiography. Standardized medication regimen.
214940204|NCT05658640|DRUG|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
214940205|NCT01634451|OTHER|Bespoke on-line sedation education package|A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
214940206|NCT01634451|OTHER|Sedation specific outcome process feedback|Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
214940207|NCT01634451|DEVICE|Responsiveness monitoring; novel sedation monitor|Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
214940208|NCT00444860|BIOLOGICAL|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
214940209|NCT04116541|DRUG|HDM201|HDM201 120mg, Every 3 weeks, Per os
214940210|NCT04116541|DRUG|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
214940211|NCT04116541|DRUG|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
214940212|NCT04116541|DRUG|Alectinib|Alectinib, 600mg twice daily, Per os
214940213|NCT04116541|DRUG|Regorafenib|Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
214940214|NCT04116541|DRUG|Trametinib|Trametinib 2 mg/day, continuous, Per os
214940215|NCT04116541|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily, Per os
214940216|NCT04116541|DRUG|Avapritinib|300 mg/day,continuous, Per os
214940217|NCT00840736|PROCEDURE|Laparoscopic adjustable gastric banding|Laparoscopic adjustable gastric banding
214940218|NCT00840736|PROCEDURE|vertical banded gastroplasty|vertical banded gastroplasty
214940219|NCT06509490|DRUG|KD-025 cell injection|This is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of KD-025 cell infusion in patients with advanced NKG2DL+ solid tumor. In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be undergo screening, pre-treatment (cell product preparation;lymphodepleting chemotherapy), treatment and follow up
214940220|NCT06441695|DIETARY_SUPPLEMENT|xumXR extended release caffeine|proprietary capsule for extended release of caffeine
214940221|NCT06441695|DIETARY_SUPPLEMENT|immediate release caffeine|immediate release caffeine capsule
214347341|NCT02897804|BEHAVIORAL|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214940222|NCT05023551|DRUG|DSP-0390|DSP-0390 administered orally
214940223|NCT05323747|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
214940224|NCT05326126|DEVICE|coronary physiology|To evaluate the association between microvascular disfunction and myocardial fibrosis identified per computed tomography among subjects undergoing TAVI for severe, symptomatic aortic stenosis.
214940225|NCT03019003|DRUG|Oral Decitabine|DNA methyltransferase inhibitor
214940226|NCT03019003|DRUG|Durvalumab|anti-PD-L1
214940227|NCT03019003|DRUG|5' Azacitidine|DNA methyltransferase inhibitor
214940228|NCT03019003|DRUG|Tremelimumab|anti-CTLA4
214940229|NCT06153173|DRUG|Mirdametinib|Mirdametinib is administered by mouth twice daily on a continuous schedule, with each cycle being 4 weeks. Patients are instructed to take consecutive doses separated by a minimum of 6 hours and a maximum of 14 hours.
214940230|NCT06350643|OTHER|Quit and Screen Project training|This online course will be developed for healthcare providers and will fill gaps in knowledge and attitudes toward lung cancer screening and smoking not covered by the G02 (Global Knowledge Center for Lung Cancer) Lung Cancer Screening training.
214675994|NCT03501355|DEVICE|Inspiratory muscle endurance training|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
215074124|NCT00904098|DRUG|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~1. A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~2. An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
215074125|NCT00904098|DRUG|Usual Care|Current treatment used to treat all migraine headaches
214675995|NCT04068389|PROCEDURE|Pulmonary Tissue Collection|Pulmonary Tissue Collection
214675996|NCT00659685|DRUG|Ondansetron|ODT, single-dose, fasting
214338187|NCT07052110|OTHER|Digital storytelling|DST is an intervention that can potentially mitigate the psychological impact of traumatic experiences. People can usually find positive meaning in a traumatic experience by communicating their experience using narratives like storytelling. In particular, by externalising the traumatic experience in the form of a narrative, the individual can become an objective agent, distancing themselves from negative meanings attached to the experience. This lowers people's resistance to and defence against the experience, assisting them to explore alternative perspectives regarding the experience and to identify its positive aspects, which boost self-esteem. Likewise, storytelling engages different areas of the brain, including those responsible for visual, language, and hearing functions, to reorganise the disorganised traumatic experience into a coherent story, facilitating integration of the experience into existing memories.
214940231|NCT06350643|OTHER|G02 (Global Knowledge Center for Lung Cancer) Lung Cancer Screening training|The G02 (Global Knowledge Center for Lung Cancer) Lung Cancer Screening training is an online course that covers disparities in lung cancer and smoking, patient barriers to lung cancer screening, and provider resources for addressing common barriers.
214940232|NCT05808764|DRUG|Risdiplam|Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
214940233|NCT05211895|DRUG|Durvalumab|Durvalumab IV (Intravenous infusion)
214940234|NCT05211895|DRUG|Domvanalimab|Domvanalimab IV (Intravenous infusion)
214940235|NCT05211895|OTHER|Placebo|Placebo IV (Intravenous infusion)
214940236|NCT05245331|DEVICE|Peristeen® Transanal irrigation system with the conic catheter|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
214940237|NCT05245331|DEVICE|Standard reusable enema|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
214940238|NCT06234956|BIOLOGICAL|BIMERVAX|BIMERVAX
214338188|NCT07052357|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver push notifications. The notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of five therapeutic approaches: 1) CBT-Behavioral, 2) CBT-Cognitive, 3) Distanced Self-Talk, 4) Mindfulness, 5) Motivational Interviewing.
214940239|NCT05735184|DRUG|Ziftomenib|Oral Administration
214940240|NCT05735184|DRUG|Venetoclax|Oral Administration
214675997|NCT00659685|DRUG|Zofran ODT|
214675998|NCT00020852|PROCEDURE|conventional surgery|
214675999|NCT00020852|PROCEDURE|cryosurgery|
214676000|NCT04174963|BEHAVIORAL|eToke + TPsy|Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
214676001|NCT05930873|BEHAVIORAL|Immersive room|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented on one of the four walls of the immersive room and a set of stimuli, including the target stimulus, which the subject will have to touch within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
214940241|NCT05735184|DRUG|Azacitidine|Subcutaneous or Intravenous Administration
214940242|NCT05735184|DRUG|Daunorubicin|Intravenous Administration
214940243|NCT05735184|DRUG|Cytarabine|Intravenous Administration
214940244|NCT05735184|DRUG|Quizartinib|Oral Administration
214940245|NCT05840406|DRUG|Postoperative pain management with acetaminophen|During the 24 hours postoperatively, participants will receive 1 g acetaminophen intravenously (i.v.) three times a day. On the second and third postoperative days, participants will receive 1g acetaminophen per os three times a day.
214940246|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine will be administered to the participant on each side.
214940247|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine and dexmedetomidine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine with the addition of 0,5 μg/kg dexmedetomidine will be administered to the participant on each side.
214940248|NCT05840406|DRUG|Postoperative pain management with tramadol|During the 24 hours postoperatively, participants will receive 500 mg tramadol + 500 ml 0,9% NaCl i.v. continuously 30ml/h.
214940249|NCT05840406|DRUG|Postoperative pain management with ketoprofen|During the 24 hours postoperatively, participants will receive 100 mg ketoprofen + 100 ml of 0,9% NaCl i.v. twice a day. The first dose will be administered in the theatre at the end of the surgical procedure.
214940250|NCT05840406|DRUG|Postoperative pain management with ibuprofen|On the second and third postoperative days, participants will receive 600 mg ibuprofen per os three times a day.
214940251|NCT05844735|DRUG|SAR441566|Tablet
214940252|NCT05844735|DRUG|Placebo|Tablet
214940253|NCT05844735|DRUG|Ciprofloxacin|Tablet
214940254|NCT05732701|OTHER|Algorithm-guided DAPT duration|"PRECISE-DAPT score ≥25~* Chronic Coronary Syndromes (CCS): Aspirin + clopidogrel for 1 month, followed by clopidogrel monotherapy~* Acute Coronary Syndromes (ACS): Aspirin + ticagrelor for 1 month, followed by ticagrelor monotherapy~PRECISE-DAPT score \<25:~* Non-complex CCS: Aspirin + clopidogrel for 6 months, followed by clopidogrel monotherapy~* Non-complex ACS: Aspirin + potent P2Y12 inhibitor for 6 months, followed by potent P2Y12 inhibitor monotherapy~* Complex CCS or ACS: Aspirin + P2Y12 inhibitor for 12 months, followed by P2Y12 inhibitor monotherapy (potent P2Y12 inhibitor mandatory for ACS)"
214940255|NCT05732701|OTHER|Standard-of-care DAPT duration|DAPT strategy at the operators´ discretion in accordance with applicable guidelines
214940256|NCT03910452|DRUG|Busulfan|3 days of IV Busulfan. An alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of conditioning regimen for myelosuppressive properties as per package insert and standard of care.
214940257|NCT03910452|DRUG|Alemtuzumab|5 days of IV Alemtuzumab. A humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complement-mediated lysis and antibody-dependent cellular toxicity. For this study, being used as part of the conditioning regimen per package insert and standard of practice.
214940258|NCT03910452|DRUG|Cyclophosphamide|2 days of IV Cyclophosphamide. This is an antineoplastic, and for this study is bine used for its immunosuppressive mechanism of action per package insert and standard of care
214940259|NCT03910452|DRUG|Sirolimus|Post Peripheral blood stem cell infusion. It is used for its immunosuppressive mechanism of action.
214940260|NCT03910452|RADIATION|Total Body Irradiation|2 fractionated doses on -2 day. It is used for its immunosuppressive mechanism of action. It is SOP for conditioning for transplant.
214940261|NCT03910452|BIOLOGICAL|Allogeneic peripheral blood stem cell|IV infused donor peripheral blood stem cell. Stem cells are cells that give rise to the blood cells - red blood cells that carry oxygen, white blood cells that help the body to fight infections, and platelets that help make the blood clot. Collected and infused per the standard of operating procedures established by the Department of Transfusion Medicine.
214940262|NCT06484452|DEVICE|No Intervention|No Intervention
214940263|NCT04840602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214940264|NCT04840602|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214940265|NCT04840602|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214940266|NCT04840602|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214940267|NCT04840602|DRUG|Ibrutinib|Given PO
214940268|NCT04840602|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214940269|NCT04840602|BIOLOGICAL|Rituximab|Given IV
214940270|NCT04840602|DRUG|Venetoclax|Given PO
214940271|NCT04020081|OTHER|Yoga breathing exercises and Meditation|"8 Breathing exercises.The first set of 6 exercises is of the Upper Lobe breathing (Upper and Middle Lobe of the Lungs) while 7th exercise is abdominal breathing,8th exercise is yogic breathing.~6-steps Nirmal Dhyan (meditation).Step 1: Breath awareness,Step 2: Body awareness,Step 3: Thought awareness,Step 4: Refreshing awareness,Step 5: Gap awareness,Step 6: Expanding awareness."
214940272|NCT06443801|OTHER|THE GROUP THAT WILL TAKE WEB-BASED BREASTFEEDING EDUCATION IN PREGNANCY|"The data of the study will be applied to both groups at the same time. No training will be given to the control group, and web-based breastfeeding training consisting of 4 modules will be given to the experimental group during their pregnancy. As data collection tools; Pregnant data collection form, Postpartum information form, IOWA infant feeding attitude scale, IMDAT scale, Edinburgh depression scale, Breastfeeding motivation scale, Insufficient milk perception scale, Breastfeeding self-efficacy scale and System usability scale will be used. Data collection tools will be applied to women at pregnancy, postpartum 7th day, PP 3rd month and PP 6th month.~Appropriate methods will be used in the evaluation of the data. The significance level will be determined as α=0.05.~The sample of the study consisted of 90 primiparous pregnant women, 45 of whom were in the control and 45 in the experimental group, who met the inclusion criteria."
214940273|NCT05745467|DRUG|Povidone Iodine 5% Soln,Top,Kit|5% povidone iodine will be swabbed in patients nares of the experimental group.
214940274|NCT03994614|OTHER|TEAS|Patients in the experimental group will be given TEAS treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26).
214940275|NCT06620367|PROCEDURE|conventional guided bone regeneration|10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) covered with bilayer collagen membrane stabilized by tacks
214940276|NCT06620367|PROCEDURE|digital guided bone regeneration|10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) placed by digital designed guide covered with bilayer collagen membrane stabilized by tacks
215074126|NCT02174029|PROCEDURE|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
214676002|NCT05930873|BEHAVIORAL|stimuli in a paper format|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented in a paper format and a set of stimuli, including the target stimulus, which the subject will have to indicate within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
214676003|NCT03531268|OTHER|PGx Testing|Pharmacogenomic (PGx) testing will be administered to all subjects. The results of PGx testing will be evaluated for clinical utility. Subjects will be evaluated based on whether PGx testing has clinical utility or has no clinical utility.
214338189|NCT07052448|DRUG|sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies|sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies
214940277|NCT00270283|DRUG|epoetin alfa|
214940278|NCT01740869|BIOLOGICAL|Autologous Intrathecal Hematopoietic Stem Cells|Patients will be stimulated with granulocyte colony-stimulating factor (G-CSF) for 3 consecutive days. Bone marrow will be harvested, processed to isolate CD34+ hematopoietic stem cells and reduce red blood cells. An inoculum of 5-10 mL will then be infused intrathecally into the cerebrospinal fluid.
214940279|NCT01740869|OTHER|Observation with IDEA and CARS Scales|Participants will be observed for 6 months without active intervention. They will be evaluated using the Childhood Autism Rating Scale (CARS) and the IDEA scale at baseline, 30 days, and 180 days. After 6 months, participants may crossover to the experimental arm.
214940280|NCT00274443|DRUG|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
214940281|NCT06331195|OTHER|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol.
214940282|NCT06331195|OTHER|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil.
214940283|NCT06331195|DIETARY_SUPPLEMENT|Phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
214940284|NCT06331195|DIETARY_SUPPLEMENT|Krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
214940285|NCT06521580|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation of those with osteopetrosis and weight bearing fractures
214676004|NCT01834326|BIOLOGICAL|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
214676005|NCT01834326|BIOLOGICAL|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
214676006|NCT03881163|DRUG|N-acetylcysteine (NAC)|Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
214676007|NCT00029315|DRUG|Recombinant Tissue Plasminogen Activator (rt-PA)|
214676008|NCT02891993|OTHER|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
214940286|NCT03802565|DRUG|Tolperisone|TID
214940287|NCT03802565|DRUG|Placebo|Placebo
214940288|NCT07119229|DEVICE|Implantable Artificial Bronchus|The Implantable Artificial Bronchus (IAB) is a tapered, flexible and fenestrated polymer-based airway stent that is implanted bronchoscopically using a proprietary delivery system into diseased lungs of patients with emphysema.
214940289|NCT00055861|BIOLOGICAL|bevacizumab|Given IV
214940290|NCT00055861|DRUG|docetaxel|Given IV
214940291|NCT00055861|OTHER|laboratory biomarker analysis|Correlative studies
214940292|NCT05619406|DEVICE|Riskometer Application|The intervention group participants at baseline will be assessed by installing a riskometer app on their mobile phones to calculate their global stroke risk score. They will be shown their risk scores and the specific risk factors identified through the screening. They will be counselled and supported to manage their risk factors through lifestyle changes and visit their healthcare provider for appropriate care.
214940293|NCT05619406|BEHAVIORAL|Routine Clinic Therapy|After their assessment by the blinded adjudicator, the controls will visit the study doctor to obtain the routine clinic therapy and then will be allowed to go home.
214940294|NCT04314375|DRUG|Low Dose Budesonide|3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
214940295|NCT04314375|DRUG|High Dose Budesonide|6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
214940296|NCT04314375|DRUG|Placebo|Matching placebo once daily.
214940297|NCT03433313|DRUG|EG12014|EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
214940298|NCT03433313|DRUG|Herceptin|Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
214940299|NCT02124759|DRUG|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
214940300|NCT02124759|DRUG|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
214940301|NCT02124759|DRUG|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
214940302|NCT02124759|OTHER|High Fat diet|The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
215074127|NCT02174029|PROCEDURE|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
215074128|NCT02174029|PROCEDURE|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
214338190|NCT07052500|DIETARY_SUPPLEMENT|Seed Cycling|Daily consumption of 1 tablespoon each of flax and pumpkin seeds during the follicular phase and 1 tablespoon each of sunflower and sesame seeds during the luteal phase
214676009|NCT02891993|OTHER|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
214676010|NCT04109443|BEHAVIORAL|Young Men & Media Program|The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.
214676011|NCT04109443|BEHAVIORAL|Available websites on safe sex and preventing STIs|Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
214676012|NCT02004340|DEVICE|ear vagus nerve stimulator|
214676013|NCT03921892|BEHAVIORAL|Parenting Education|Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
214676014|NCT00483951|DEVICE|Toshiba Aquilion ONE CT|The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.
214676015|NCT00483951|DEVICE|SWiemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
214338191|NCT07052539|OTHER|High protein and sodium meal|Meal with 1g/kg protein content and 3900mg sodium
214338192|NCT07051421|PROCEDURE|EARLY WARNING SCORE|In the RECO-EWS scoring system we designed; 0-7 low risk, 7-10 medium risk, ≥10 high risk, postoperative stay findings of high-risk patients and, if necessary, new cut-off values are determined for each parameter in the scoring system according to the analysis results.
214338193|NCT07051720|DEVICE|Bilateral implantation of CT ASPHINA 409M|Patients will be implanted with CT ASPHINA 409M during catarct surgery. The CT Asphina 409M has been commercially available for several years and is widely used in clinical practice. Designed with aberration-neutral optical properties, it could improve contrast sensitivity and visual quality. This monofocal aspheric IOL features four-point plate haptics and a one-piece design made from hydrophilic acrylic material with hydrophobic surface properties. It also has an overall diameter of 11 mm and a 6 mm optical diameter. The lens has a sharp posterior optic edge to minimize posterior capsule opacification. It is ideally suited as a comparative referent lens to new EDOF IOLs.
214338194|NCT07051720|DEVICE|Bilateral implantation of TECNIS Eyhance ICB00|Patients will be implanted with TECNIS Eyhance ICB00 during catarct surgery. TECNIS Eyhance ICB00 is a one-piece, posterior chamber lens with an overall diameter of 13.0 mm and an optic diameter of 6.0 mm. The lens has a spherical posterior surface and a modified aspheric anterior surface that offers a smooth and continuous change in power from the periphery to the center of the lens, without a demarcation zone.
214338195|NCT07051720|DEVICE|Bilateral implantation of AcrySof® IQ Vivity®|Patients will be implanted with AcrySof® IQ Vivity® during catarct surgery. The AcrySof® IQ Vivity® is a single-piece, hydrophobic acrylic IOL that utilizes non-diffractive wavefront-shaping technology (X-wave™) on its anterior surface to achieve an extended range of vision. Its aspheric anterior surface features a 2.2 mm central zone composed of two smooth transition elements: the first forms a slightly elevated plateau (\~1 µm) that stretches the wavefront, while the second shifts the wavefront to create a negative extended focal range. Together, these elements could create advanced and delayed wavefronts resulting in a continuous extended focal range instead of multiple focal points, while optimizing light transmission. This UV-absorbing and blue light filtering foldable IOL has a refractive index of 1.55 at 35 °C, an optic diameter of 6 mm and an overall length of 13 mm. The lens is available in spherical powers ranging from +10.0 to +30.0 diopters.
214940303|NCT02124759|OTHER|Low Fat diet|The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
214940304|NCT00693342|BIOLOGICAL|immunological adjuvant OPT-821|Given subcutaneously
214940305|NCT00693342|BIOLOGICAL|polyvalent antigen-KLH conjugate vaccine|Given subcutaneously
214940306|NCT05014269|PROCEDURE|Phacoemulsification in eyes with corneal opacities|senile cataract extraction using lens emulsification under the slit illuimnation of the surgical microscope
214940307|NCT00006486|DRUG|carboxyamidotriazole|Given orally
214940308|NCT00006486|OTHER|placebo|Given orally
214940309|NCT05262868|DEVICE|rTMS|The stimulus intensity will be 80% of the motor threshold and the frequency will be 20 Hz for all patients. The total number of pulses will be 1200 for a single treatment session. We plan a total of 15 sessions distributed over 5 days a week for 3 consecutive weeks.
214676016|NCT06498375|DIAGNOSTIC_TEST|Bioelectrical impedance|Fluid distribution measured by bioelectrical impedance Bodystat Multiscan 5000 Bodystat Ltd, Isle of Man, British Isles
214676017|NCT02049528|DRUG|CC-122|CC-122
214676018|NCT02049528|DRUG|CC-122|CC-122
214676019|NCT02049528|DRUG|CC-122|CC-122
214940310|NCT06523439|DEVICE|MagPro X100 edition (MagVenture, Skovlunde, Denmark)|10 daily sessions (50 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
214338196|NCT07051720|DEVICE|Bilateral implantation of LuxSmart™|Patients will be implanted with LuxSmart™ during catarct surgery. The LuxSmart™ intraocular lens is a single-piece, acrylic hydrophobic and aspheric IOL with an overall diameter of 11 mm, an optical diameter of 6 mm, and a 4-point fixation haptic design. This non-diffractive IOL utilizes a technology known as Pure Refractive Optics (PRO), incorporating a 2.0 mm central EDOF zone that combines fourth- and sixth-order spherical aberrations of opposite signs designed to improve perceived depth of focus. The paracentral region, on the other hand, is a transition zone meant to gradually decrease the optic vergence from the center to the monofocal periphery. It has also a 360° continuous square edge on the posterior surface to prevent epithelial lens cells migration and posterior capsule opacification.
214338197|NCT07051720|DEVICE|Bilateral implantation of Eyecryl SERT|Patients will be implanted with Eyecryl SERT during catarct surgery. EyeCryl-SERT (Biotech) is a new advanced monofocal, single-piece hydrophobic IOL with an aspheric surface, continuous vision from distance to intermediate, spectacle independence for intermediate vision, an extended range of vision: \>1.75 D at spectacle plane with visual acuity 0.2 LogMAR or better, an intermediate vision up to 57 cm and a design for fast neural adaptation.
214940311|NCT06523439|DEVICE|MagPro X100 edition (MagVenture, Skovlunde, Denmark)|5 daily sessions (25 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
214940312|NCT03860116|BEHAVIORAL|APP-based case management service|The intervention consists of 4 parts, educational articles, online communication with case managers, supportive service information and visit reminder. Educational articles are both delivered automatically and retrieved by participants. Online communication can also be initiated by participants and case managers. Case managers are request to respond to questions from participants as well as care about medication taking behaviors of each patients during the first month. Supportive service information, which include time, location and charges of service providers will be retrieved by participants, with reminders of available service information scheduled at the beginning of every month. Visit reminders are scheduled at one week before due date.
214940313|NCT03860116|BEHAVIORAL|Standard-of-care followup service|When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.
215074129|NCT06420856|OTHER|Assessment of the musculoskeletal system and its functions|Measurement of sub sole pressure sense, light touch sense, vibration sense and two-point discrimination sense. will be evaluated with. For the evaluation of proprioception, active joint position sense technique was used in plantar flexion (PF): 7°, 14° and 21°; In dorsiflexion (DF), 7° target angles will be used. An Dr. Goniometer will be used to determine target angles. To measure plantarflexion and dorsiflexion muscular strength and endurance will be used with the isokinetic system. Weight-Bearing Lunge test will be used to evaluate ankle mobility. For balance assessment, the Modified Star Excursion Balance Test will be measured using the anterior, posteromedial and posterolateral directions. American Orthopedic Foot and Ankle Society midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score , which are subjective evaluation methods, will be used to determine the functional level. A heel lift test will be performed to evaluate physical performance.
215074130|NCT01882426|OTHER|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
215074131|NCT01882426|OTHER|Usual Care|usual step care practice
215074132|NCT03702348|OTHER|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
214338198|NCT07051720|DEVICE|Bilateral implantation of RayOne EMV|Patients will be implanted with RayOne EMV during catarct surgery. RayOne EMV (Rayner) is a new EDOF lens that has recently emerged in the market. It is a truly non-diffractive, single-piece hydrophilic IOL which does not use light splitting technology like many IOLs which increase depth of focus, resulting in low levels of dysphotopsia, similar to standard monofocal lenses. RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration. Compared to a lens with zero spherical aberration, the carefully controlled positive spherical aberration induced by RayOne EMV spreads light along the visual axis, elongating the focal range from far into intermediate with up to 1.5 D of depth of focus (per lens on the spectacle plane).
214338199|NCT07051564|BIOLOGICAL|CNK-UT009 cell injection|CNK-UT009 cell injection
214338200|NCT07051174|DIAGNOSTIC_TEST|MIMS|This study is an extension follow up study conducted in continuation of the prior MIMS® study (see: STUDY ID: MMS EEU-1), in which the long-term (i.e., 28, 36, 42 months) clinical outcomes of Minimally Invasive Micro Sclerostomy System \[MIMS® System\] \[CE Marked device\] are evaluated.
214338201|NCT07051694|DEVICE|taVNS|Transcutaneous Auricular Vagus Nerve Stimulation
214338202|NCT07051694|DEVICE|sham-taVNS|sham transcutaneous auricular vagus nerve stimulation
214338203|NCT07051343|OTHER|designed artificial intelligence Chatbot education about electronic fetal monitoring|effect of using designed artificial intelligence Chatbot about electronic fetal monitoring on maternity nursing students' performance
214338204|NCT07051343|OTHER|traditional teaching method|the traditional learning method (online meeting).
214940314|NCT06272045|BEHAVIORAL|ENRICH|In the ENRICH intervention, home visitors will incorporate heart health information and activities into routine home visits beginning in pregnancy and continuing until children turn 2 years old. The intervention includes 1) Information and resources on topics such as healthy eating, physical activity, weight management, tobacco use, healthy sleep and stress reduction, 2) tools like scales, Fitbits, and blood pressure monitors to facilitate self-monitoring, and 3) activities and information focused on infant nutrition, feeding, healthy growth, sleep, play and emotions and soothing.
214940315|NCT06272045|BEHAVIORAL|Usual Home Visiting|Usual home visiting without cardiovascular health promotion content
214338205|NCT07051200|BEHAVIORAL|Peer Support Services Recovery|A program of mental health recovery through one-on-one and small group meetings with a PSS and RCOs for individuals recently discharged from an acute care psychiatric facility.
214940316|NCT03648554|DRUG|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
214940317|NCT03648554|OTHER|reinforced dietary monitoring|moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
214940318|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214676020|NCT05721625|OTHER|Aerobic exercise|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
214338206|NCT07052422|DRUG|Venetoclax (VEN)|Venetoclax (VEN) was administered at 400mg/day on days -10 to -4.
214338207|NCT07052422|DRUG|Decitabine (DAC)|"Decitabine (DAC) was administered at 20mg/m2/day on days~-10 to -8."
214338208|NCT07052422|DRUG|Busulfan (Bu)|"Busulfan (Bu) was administered at 3.2 mg/kg/day on days~-5 to -4."
214338209|NCT07052422|DRUG|Fludarabine (Flu)|Fludarabine (Flu) was administered at 30mg/m2/day on days -5 to -2.
214338210|NCT07052422|DRUG|Fludarabine (Flu)|Fludarabine (Flu) was administered at 30mg/m2/day on days -6 to -2.
214338211|NCT07052136|DRUG|Levetiracetam|Patients were treated with intravenous levetiracetam (LEV) 20 mg/kg over 15 minutes, followed by 60 mg/kg/day in two divided doses over 24 hours.
214338212|NCT07052136|DRUG|Valproic acid|Patients received intravenous valproic acid at 15 mg/kg over 15 minutes, followed by 20 mg/kg/day in two divided doses over 24 hours.
214338213|NCT07051941|OTHER|Validation of a satisfaction questionnaire for robotic surgeon|"The primary endpoint is to validate a questionnaire to assess user satisfaction among expert surgeons utilizing various surgical robotic systems, including - but not limited to - the Da Vinci®, Hugo™ RAS, Versius®, and Toumai® platforms.~Based on these domains, an initial pool of items was generated; items were formulated as Likert-scale questions (5-point) and grouped into thematic sections.~The validation of the Questionnaire will be developed with a 2-step process.~1. Test for Content Validity and Face Validity: a pilot test will be performed with 5-10 surgeons from FPG to ensure content and face validity, item comprehension, and usability.~2. Validation from external users:"
214338214|NCT07051460|OTHER|Baseline Condition (No Stimuli)|Participants underwent baseline evaluation using the Vertical Maddox Test with no auditory or oral proprioceptive stimulation. This phase was used to confirm the absence of spontaneous visual pseudo-scotomas and served as an internal control condition for each participant.
214338215|NCT07051460|OTHER|Auditory Stimulation only|Participants received bilateral auditory stimulation consisting of 500 Hz tones (500 ms duration, 50 dB) delivered through wireless headphones, without any accompanying oral stimuli. This condition was used to assess the isolated effect of sound on visual perception using the Vertical Maddox Test.
214940319|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214940320|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214338216|NCT07051460|OTHER|Auditory and Oral Proprioceptive Stimulation (OPS)|Participants received simultaneous auditory and oral proprioceptive stimuli while undergoing the Vertical Maddox Test. - Auditory: 500 Hz tones (500 ms, 50 dB) via headphones. - Oral Proprioceptive Stimuli (OPS): included Combined Oral Stimuli (e.g., tongue and lip self-administered positions) and Dental Stimuli (mechanical pressure or traction on central incisors using a calibrated probe). This condition aimed to assess whether OPS could modulate or eliminate sound-induced visual pseudo-scotomas.
214940321|NCT01068626|DRUG|Rosuvastatin|10 mg once daily
214940322|NCT01068626|DRUG|Placebo for rosuvastatin|once daily
214940323|NCT03342131|OTHER|Circulating wnt 2 and wnt 4 concentration|"Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission."
214940324|NCT01110213|BEHAVIORAL|Physical activity|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for physical activity.
214940325|NCT01110213|BEHAVIORAL|Fruit and vegetable|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for fruit and vegetable consumption.
214940326|NCT05461937|BEHAVIORAL|Getting things done after stroke|A two-session, online rehabilitation intervention focussing on cognitive executive functions supplemented with weekly homework tasks.
214676021|NCT05721625|OTHER|Connective tissue massage|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While the patients are in the sitting position, this massage will be applied on whole back.
214676022|NCT00909090|DIETARY_SUPPLEMENT|12 mg Lutein + Zeaxanthin|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year
214676023|NCT00909090|DIETARY_SUPPLEMENT|Visually identical placebo|Visually identical placebo, taken once daily for one year
214338217|NCT07051460|OTHER|Oral Proprioceptive Stimulation Only (OPS)|Participants received oral proprioceptive stimuli alone, without auditory input, during the Vertical Maddox Test. - Combined Oral Stimuli (COS): self-administered tongue/lip positions. - Dental Stimuli (DS): applied by the operator to central incisors. This condition was used to evaluate the independent effect of OPS on visual perception.
214338218|NCT06765863|DIETARY_SUPPLEMENT|Human Milk Fortifier|"Human milk fortifier added to expressed human milk (mother's own milk or pasteurized donor human milk) per feed per manufacturer's instructions for a minimum of 21 days (in-facility provision only)~* Clinical feeding guideline including targets for initiation and advancement of breast milk feeding~* Provision of guideline-driven standard of care \[facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps\]"
214338219|NCT06765863|OTHER|Volume targets|"* Clinical feeding guideline including targets for initiation and advancement of breast milk feeding~* Provision of guideline-driven standard of care \[facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps\]"
214338220|NCT05069831|DRUG|Abrocitinib|Abrocitinib daily for 4 months
214338221|NCT06618352|OTHER|Simulated indoor overheating exposure|Young adults exposed to a multi-day extreme heat event
214940327|NCT05461937|BEHAVIORAL|Stroke psychoeducation|A two-session, online stroke psycho-education intervention supplemented with weekly homework tasks.
214940328|NCT05118061|DIAGNOSTIC_TEST|Ketone|compare diagnostic tests to reference methods
214940329|NCT05929248|DRUG|Telitacicept|160mg once a week for 48 weeks
214940330|NCT05929248|DRUG|conventional therapy|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
214940331|NCT05929248|DRUG|Placebo|Used once a week in combination with standard treatment
214940332|NCT04958759|OTHER|Functional Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 4 weeks of foundation inspiratory muscle training and 6 weeks of functional inspiratory muscle training
214940333|NCT04958759|OTHER|Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 10 weeks of foundation inspiratory muscle training
214940334|NCT04958759|OTHER|Breathing exercises|The program will be consist of 10 weeks of breathing exercises
214940335|NCT05546658|DRUG|Psilocybin|Psilocybin administration under supportive conditions
214940336|NCT01110785|BIOLOGICAL|panitumumab|
214940337|NCT01110785|DRUG|simvastatin|
214940338|NCT01110785|OTHER|laboratory biomarker analysis|
214940339|NCT06853886|OTHER|blood sample HBV patient|"During a boold sample at only one follow up visit:~* 3 tubes EDTA 10 ml per patient~* 1 tube Paxgene 1ml~* 2 dry tube per patient"
214940340|NCT06853886|OTHER|blood sample healthy volunteers|"* 3 tubes EDTA ideally age and sex matched to CHB patient.~* 1 tube Paxgene 1ml~* 2 dry tube"
214940341|NCT05551273|DRUG|Selgantolimod|1.5 mg tablet
214940342|NCT05551273|DRUG|Placebo|Matching placebo tablet
214940343|NCT04340843|DRUG|Belinostat|Given IV
214940344|NCT04340843|PROCEDURE|Biopsy Procedure|Undergo biopsy
214940345|NCT04340843|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214940346|NCT04340843|PROCEDURE|Computed Tomography|Undergo CT
214940347|NCT04340843|DRUG|Decitabine and Cedazuridine|Given PO
214940348|NCT04340843|DRUG|Guadecitabine|Given SC
214940349|NCT04340843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214940350|NCT04249622|OTHER|Best Practice|Given standard of care pertuzumab-based chemotherapy
214940351|NCT04249622|OTHER|Questionnaire Administration|Ancillary studies
214940352|NCT04249622|DRUG|Rifaximin|Given PO
214940353|NCT06654466|DEVICE|Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.|The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.
214940354|NCT00779688|DEVICE|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
214338222|NCT06866054|DRUG|SPSIPB block|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
214940355|NCT06977568|DRUG|Zilretta|triamcinolone acetonide, extended release injectable suspension
214940356|NCT06977568|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide, Immediate Release (TCA-IR)
214940357|NCT04250298|DIETARY_SUPPLEMENT|sucrosomial iron|oral intake of iron as sachets or capsules
214940358|NCT06241560|DRUG|BI 1015550|BI 1015550
214338223|NCT06866054|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
214940359|NCT06241560|DRUG|Pirfenidone|Pirfenidone
214940360|NCT06806995|DRUG|Zidebactam-Cefepime|(1) ZID-FEP 3g IV (ZID 1 g plus FEP 2 g) administered over 1 hour (h)
214940361|NCT06806995|DRUG|Metronidazole|(2) metronidazole 0.5 g IV alone administered over 1 h
214940362|NCT06806995|DRUG|FEP-ZID|(3) metronidazole 0.5 g IV over 1 h, followed by ZID-FEP 3g IV over 1 h over 3 treatment periods separated by a 48 h washout period.
214940363|NCT05296798|DRUG|Phesgo|Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
214940364|NCT05296798|DRUG|Giredestrant|A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
214676024|NCT05978895|OTHER|Targeted canteen menus|"The nutritional intervention consisted in the development of targeted menus aiming at the needs of individuals with ASD and in assessing their acceptance of the targeted menus.~The revision of the standard menus was carried 1) balancing energy and macronutrient content, according to LARN 2014; 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus according to CREA 2018; 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population was evaluated through meal evaluation forms. These results were compared with the ones collected during the first observational phase (WP1). In fact, referring to the results of WP1, new canteen menus were drafted according to the nutritional and sensory needs of the population."
214676025|NCT05497505|DEVICE|Pacmed Critical|For patients in the On-period, Pacmed Critical will be available as decision support after initial eligibility screening for ICU discharge by treatment team
214676026|NCT02786459|DEVICE|ProxiScan|ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.
214676027|NCT02786459|DEVICE|Magnetic Resonance Imaging|Used as a comparative to ProxiScan.
215074133|NCT03267043|BEHAVIORAL|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
214676028|NCT02786459|DEVICE|SPECT-CT|Used as a comparative to ProxiScan.
214676029|NCT05068596|OTHER|expermintal|progressive resistive functional strength training in the plantigrade foot position plus designed physical therapy program
214676030|NCT05068596|OTHER|CONTROL|Designed physical therapy program
214676031|NCT02057237|DRUG|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
214676032|NCT00644319|DRUG|ibuprofen|
214338224|NCT06230367|BEHAVIORAL|Sexual health advocacy for guys|5 month HIV prevention program delivered via text messaging
214338225|NCT06230367|BEHAVIORAL|Healthy lifestyle control|5 month control group program delivered via text messaging
215074134|NCT03267043|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
215074135|NCT02613468|OTHER|collection of periodontal records|"1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester."
215074136|NCT02613468|OTHER|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
214338226|NCT03586479|BEHAVIORAL|Interactive storybook reading|Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.
214338227|NCT00756509|DRUG|Nilotinib|800 mg/d orally
214338228|NCT06405230|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
214338229|NCT06405230|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
214338230|NCT06405230|DRUG|Pemetrexed+ (carboplatin or cisplatin)|PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered.
214338231|NCT05089656|GENETIC|OAV101|Gene therapy
214338232|NCT05089656|PROCEDURE|Sham control|The sham procedure will consist of a small needle prick on the lower back at the location where the LP injection is normally made. The needle will break the skin, but no needle insertion for lumbar puncture will occur.
214338233|NCT06304337|DEVICE|New oropharyngeal airway group|Oropharyngeal airwayIt is composed of nasal plug, bite mouth, oropharyngeal passage, oxygen supply tube, rope and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.For patients undergoing endoscopic surgery/examination to prevent airway obstruction caused by backtongue fall, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time, JK model can monitor oropharyngeal end-expiratory carbon dioxide collection.
214676033|NCT00644319|DRUG|morphine sulfate|
214940365|NCT05296798|DRUG|Docetaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
214940366|NCT05296798|DRUG|Paclitaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
215074137|NCT02613468|OTHER|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
214676034|NCT00644319|PROCEDURE|management of therapy complications|
214676035|NCT00644319|PROCEDURE|pleurodesis|
214676036|NCT01742351|BEHAVIORAL|Guided internet-based cognitive behavior therapy|
214676037|NCT05000606|OTHER|A home visit program|A home visit program including education and counseling was applied. A total of five home visits over three months were performed.
214940367|NCT05296798|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
214940368|NCT05296798|DRUG|Optional Endocrine Therapy of Investigator's Choice|For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
214940369|NCT06981936|DRUG|Balance Tablet|Each Balance tablet contains a broad range of vitamins and trace minerals at doses designed to prevent deficiencies (including but not limited to vitamins A, B-complex, C, D, E, K, calcium, iron, zinc, magnesium, selenium, and others, per standard multivitamin composition).
214940370|NCT06981936|DRUG|Control (placebo)|The placebo is an inert pill formulated to be indistinguishable from the Balance tablet in appearance, weight, and taste.
214940371|NCT03604705|DRUG|APX001|APX001
214940372|NCT06657222|DRUG|TUB-030|A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
214940373|NCT06453473|OTHER|TSBR|"The intervention consists of 20 training sessions on the PerStBiRo system (\~ twice a week within 3 months period). Each session lasts for 20 minutes and includes three parts: stage 1) warm up, stage 2) main exercise and stage 3) cool down.~Stage 1 contains 3 minutes of self-paced pedalling with the same bicycle resistance. At Stage 2, the main exercise, all participants will perform a 15-minute hands-free cycling training on the PerStBiRo system with a pulse watch to maintain moderate-intensity training, corresponding to 64-76% of the predicted maximal heart rate (Borg scale 12-14), including cognitive tasks projected at a screen in front of the participant. Stage 3 includes the cool down with 2 minutes of self-paced pedalling without bicycle resistance and cognitive tasks. During the training sessions, all participants will wear a loose safety harness that can arrest falling using the PerStBiRo system, but still allow comfortable pedalling."
214940374|NCT06453473|OTHER|PerTSBR|Participants of the intervention group will receive a combination of lateral and medial tilting unannounced perturbations during stage 2 of the TSBR training. This will be provided by roll and pitch angles (tilt) balance perturbations that aim to evoke trunk and arm balance recovery responses.
214940375|NCT06878807|BEHAVIORAL|eye movement|Participants underwent EM tasks during the first 30 seconds of the extinction phase. All participants in this group experienced identical EM conditions in terms of speed and duration.
214940376|NCT06878807|BEHAVIORAL|TMT-B|Participants performed the Trail Making Test B (TMT-B).
214940377|NCT06652633|GENETIC|GLPG CAR T-cell therapy|No investigational products will be administered to participants in this study.
214940378|NCT06592521|DEVICE|OPTI-FREE EXPRESS MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
214940379|NCT06592521|DEVICE|OPTI-FREE PureMoist MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
214940380|NCT06592521|DEVICE|OPTI-FREE REPLENISH MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
214940381|NCT06592521|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
214676038|NCT01355991|DRUG|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
214676039|NCT01355991|DRUG|Salmeterol|50mcg inhalation twice daily for two weeks
214676040|NCT01782183|DEVICE|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
215074138|NCT04452071|RADIATION|periapical xray|periapical xray on the middle phalanax of the middle finger
215074139|NCT03420391|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
214676041|NCT02345434|OTHER|Informative letter|The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
214676042|NCT00674336|PROCEDURE|High Hydrostatic Pressure Processing|High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
214676043|NCT03824977|DIAGNOSTIC_TEST|Six minutes stepper test (6MST)|"The 6MST is done using a stepper (Stepper essential, Decathlon(TM), France), with a walking height of 20 cm, placed in front of a wall or parallel bars, so patients can hold on if necessary.~Patients are instructed to make the maximum number of steps possible in 6 minutes, and are given a time check at one minute intervals."
215074140|NCT04816136|OTHER|Sleep recording (already done)|Sleep recording (already done)
215074141|NCT05783310|BEHAVIORAL|Psychoeducation Intervention|The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
214940382|NCT06158074|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 60 minutes targeted the pudendal nerve, thrice weekly for a total of 4 weeks.
214940383|NCT06158074|PROCEDURE|sacral neuromodulation|In the prone position, patients undergo sacral nerve root localization through MRI and CT fusion analysis. A 3D-printed sacral foramen puncture template is crafted for precision. Using local anesthesia, a 20G needle at a 60° angle enters the S3 sacral foramen along the template. A temporary stimulator, delivering square waves (14-35 Hz, 210-360 μs), tests motor and sensory responses to confirm accuracy. Self-fixating electrodes are then implanted, validated, and tunneled subcutaneously. External connection to a temporary stimulator provides a 4-week therapeutic experiential stimulation.Patients are administrated by antibiotics peri-operatively to prevent lead site infection.
214940384|NCT06819592|DRUG|Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride|2 grams of Ceftriaxone diluted in \>200ml of 0.9%sodium chloride are administered intravenously once following randomisation
214940385|NCT06819592|DRUG|Placebo comparator - no ceftriaxone|placebo: \>200ml 0.9% sodium chloride given as an intravenous infusion once after randomisation
214940386|NCT06816446|DEVICE|Myopia control spectacle lens|The intervention group will wear specially designed lenses that aim to slow the progression of myopia. Follow-up visits will take place at regular intervals.
214940387|NCT06816446|DEVICE|Single-vision lens|The control group will wear single vision lenses for one year. They will then switch to the myopia control lens for a further year. Follow-up visits will take place at regular intervals.
214940388|NCT04923685|OTHER|Trier Social Stress Test|The TSST is a standardized test to induce acute psychological stress in humans. Participants will abstain from caffeine for 12 hours and nicotine for 2 hours prior to the test. An IV butterfly catheter will be placed in an arm vein and flushed with saline. Participants will rest for 15 minutes. A 10ml baseline blood sample will be drawn. They will perform the TSST task and then have 10ml of blood drawn at 0, 15, 30, 60, and 90 minutes post-TSST.
214940389|NCT05241847|BEHAVIORAL|PeLTQL delivery via electronic means|Delivery of PeLTQL scoring information to clinicians via electronic means.
214940390|NCT05548868|DEVICE|E4W mobile app|Eating for Wellness (E4W) is a mobile application that analyzes photos of meals taken by the user and determines the nutritional profile. Nutritional content is then directly transmitted to the dietitian.
214940391|NCT05548868|BEHAVIORAL|Standard Care|Patients will receive standard dietary counselling as part of the weight management program.
214940392|NCT02913014|OTHER|No AAD post Ablation.|Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
214676044|NCT03824977|DIAGNOSTIC_TEST|Sit to stand test (STST)|The STST is done using a chair measuring 47 cm in height. The patient are instructed to sit in the chair and then to do the maximum number of lifts possible from the chair, in 1 minute, with arms folded and without leaning against the chair.
214676045|NCT03538873|BEHAVIORAL|Physical activity|
214676046|NCT00062738|DRUG|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
214676047|NCT00062738|DRUG|Nortriptyline|nortriptyline 25 - 75 mg q hs
214338234|NCT00428610|DRUG|LY573636-sodium|LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
214338235|NCT05147103|DEVICE|Low-Intensity Focused Ultrasound|LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
214338236|NCT06939816|DRUG|Vonafexor low dose|Oral tablets
214338237|NCT06939816|DRUG|Vonafexor high dose|Oral tablets
214338238|NCT06663033|PROCEDURE|colorectal surgery|surgery for colorectal cancer
214338239|NCT03977844|OTHER|Technical Assistance|"TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery."
214347342|NCT02897804|BEHAVIORAL|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
214676048|NCT00062738|OTHER|placebo|matching placebo
214676049|NCT02796950|DRUG|Acipimox|P.o. administration of 250 mg acipimox
214676050|NCT03084159|BEHAVIORAL|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
214676051|NCT05197972|OTHER|cardiac coherence program coupled with hypnosis|"At home the patient will perform the cardiac coherence sessions between 7 days and a maximum of 15 days before the surgery through the application Respirelax: 3 sessions per day, lasting 5 minutes with a breathing frequency of 6 cycles/min for a period of 7 days minimum and maximum 15 days.~An audio tape read in a hypnotic tone can be listened to by the patient during the cardiac coherence program or at another time of the day (see the text of the audio tape)."
214940393|NCT01229033|PROCEDURE|Ablation|Ablation of atrial tachycardia
214338240|NCT03977844|OTHER|Community Engagement and Planning|CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles \[48, 64\]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.
214338241|NCT03977844|OTHER|Community Resources (CR)|The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
214676052|NCT00956644|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
214940394|NCT01229033|PROCEDURE|Cardioversion|Cardioversion of atrial tachycardia
214940395|NCT06097689|DEVICE|Lab Demo 1.0|"Lowering of the participants blood glucose with the application of insulin to induce hypoglycaemia, followed by the application of glucose to induce hyperglycaemia and finally insulin to restore euglycemia.~During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)."
214940396|NCT02252471|BEHAVIORAL|Choices-Teen|Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
214940397|NCT06597188|DEVICE|VitaFlow Liberty|All subjects randomized to the TAVR group will receive transcatheter aortic valve replacement (TAVR) with the study device of VitaFlow Liberty
214940398|NCT06597188|DEVICE|Commercially available surgical bioprosthetic valve|All subjects randomized to the SAVR group will receive surgical aortic valve replacement (SAVR) with the control device of a commercially available surgical bioprosthetic valve.
214940399|NCT06988371|BEHAVIORAL|Reduced nicotine regulatory environment|In this regulatory environment, participants' usual combustible cigarette will not be available in the Experimental Tobacco Marketplace and reduced nicotine content cigarettes will be the only available combustible cigarette.
214940400|NCT06988371|BEHAVIORAL|Restriction on characterizing flavors in combustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in combustible nicotine products will not be available in the Experimental Tobacco Marketplace. Tobacco- or no-flavored combustible nicotine products will be the only combustible nicotine products available.
214940401|NCT06988371|BEHAVIORAL|Restriction on characterizing flavors in noncombustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in noncombustible nicotine products will not be available in the Experimental Tobacco Marketplace. Tobacco- or no-flavored noncombustible nicotine products will be the only noncombustible nicotine products available.
214940402|NCT06664671|OTHER|Experimental|Patients will inhale thyme oil via inhaler sticks with instructions on proper usage, supervised by the researcher. Each patient will complete the Patient Introduction Form, Asthma Control Test, and pre-test sections of the Asthma Symptom and Respiratory Parameters Form. Measurements of FEV1 and FEV1/FVC will be recorded. On the fourth day of hospitalization, post-test data will be collected.
214676053|NCT00956644|DRUG|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
214676054|NCT02477865|DRUG|PEX168(100µg)|100µg,Subcutaneous injection,once a week. continued for 52 weeks
214940403|NCT06664671|OTHER|Placebo|Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
214940404|NCT06664671|OTHER|Control (Standard treatment)|Patients will complete pre- and post-test forms without any intervention.
214940405|NCT04555655|DIETARY_SUPPLEMENT|Chicken extract supplement|70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
214940406|NCT04555655|DIETARY_SUPPLEMENT|Peptide Supplement|70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.
214940407|NCT04555655|OTHER|Placebo|70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
214940408|NCT06994364|OTHER|Trigger point release|"Ischemic compression technique is based on the application of manual pressure to treat trigger points.~The patient was asked to lie in the supine position on the examination table. The osteopath identified the muscle through deep palpation and movement-based muscle differentiation, then applied 90 seconds of tolerable pressure to the trigger point on both sides."
214676055|NCT02477865|DRUG|PEX168(200µg)|200µg,Subcutaneous injection,once a week. continued for 52 weeks
214676056|NCT02477865|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
214676057|NCT00006386|DRUG|carmustine|
214676058|NCT00006386|RADIATION|radiation therapy|
214676059|NCT00006386|RADIATION|stereotactic radiosurgery|
214676060|NCT00999128|DRUG|GDC-0941|Oral repeating dose
214676061|NCT00999128|DRUG|rabeprazole|Oral repeating dose
214676062|NCT02125929|PROCEDURE|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
214676063|NCT02125929|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
214940409|NCT06994364|OTHER|Simulation of the intestinal listening technique.|The patient will be asked to lie in a supine position on the treatment table to simulate the listening technique for assessing the mobility and motility of the small intestine without influencing the final results, with the sensory hand placed below the umbilicus.
214676064|NCT02125929|PROCEDURE|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
214676065|NCT02307305|DRUG|Duloxetine|"1. Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~2. Phase II (titration): POD#1\~6 (30mg for another 6 days)~3. Phase III (maintenance): POD#7\~13(60mg for 7 days)~4. Phase IV (tapering-1): POD#14\~20 (30mg for 7 days)~5. Phase V (tapering-2): POD#21\~27 (30mg another every day for 7 days)"
214940410|NCT06530706|DRUG|Esketamine|Esketamine 0.2mg/kg was pumped slowly after intubation, followed by 0.1mg/kg pumped until the end of the operation. In the PCIA pump, esketamine 1mg/kg was added to the sufentanil.
214940411|NCT06530706|DRUG|normal saline|Same volume of normal saline was pumped slowly after intubation, followed by the same volume of NS until the end of the operation. In the PCIA pump, only sufentanil was used.
214940412|NCT07001657|PROCEDURE|SPSIP Block|Patients in this group will receive an ultrasound-guided Serratus Posterior Superior Intercostal Plane (SPSIP) block with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus posterior superior muscle and the third rib, 30 minutes before surgery.
214940413|NCT07001657|PROCEDURE|PECS II Block|Patients in this group will receive an ultrasound-guided PECS II block with 30 mL of 0.25% bupivacaine hydrochloride (20 mL between the pectoralis minor and serratus anterior muscles, and 10 mL between the pectoralis major and minor muscles), 30 minutes before breast cancer surgery.
214940414|NCT06863142|BIOLOGICAL|VRC-FLUMOS0116-00-VP|The VRC-FLUMOS0116-00-VP (FluMos-v2) vaccine is composed of de novo engineered pentamer assembled with de novo engineered trimeric domains to an icosahedral core, projecting 20 HA ectodomain trimers from influenza strains: Influenza A (H1-H3) and Influenza B (Victoria lineage and Yamagata lineage)
214940415|NCT06863142|OTHER|ALFQ|The ALFQ adjuvant is a sterile suspension that contains monophosphoryl 3-deacyl Lipid A \[3D-PHAD(R)\] and QS-21
214940416|NCT06864806|OTHER|Genetic profile|Filiation analysis between the fetus and his father
214940417|NCT06671925|BEHAVIORAL|Strengthening COnnections to Overcome Pain (SCOOP)|Each week for 7 weeks, SCOOP intervention group participants will watch a brief video on the study website teaching a pain management or social connectedness skill and have a session with a community health worker, where they will receive support with behavioral goal-setting related to pain management and/or social connections. Participants will be screened for unmet social needs and connected to appropriate resources.
214940418|NCT06594562|DIAGNOSTIC_TEST|Telementored eFAST|Ultrasound examination guided in real-time by a remote expert for detecting free fluid.
214940419|NCT04339777|DRUG|Busulfan test dose|0.8 mg/kg IV infusion over 2 hours
214940420|NCT04339777|DRUG|Fludarabine|40 mg/m2 IV infusion over 30 min once daily for 4 days
214940421|NCT04339777|DRUG|Busulfan|"AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 10/10 Matched Related and Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 4 days (-6, -5, -4, and -3).~For Intermediate Intensity Arm, the busulfan dose will be given for 3 days (-6,-5, and -4).~For Low Intensity Arm, the busulfan dose will be given for 2 days on days (-6 and -5). 9/10 HLA Matched Related or Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 3 days (-6,~-5, and -4). For the the Intermediate Intensity Arm, the busulfan dose will be given for 2 days (-6 and -5).~For the Low Intensity Arm, the busulfan dose will be given for 1 day on day (-6)."
214940422|NCT04339777|DRUG|Alemtuzumab|Alemtuzumab will be given if there is evidence of immune dysregulation 10 mg/m2 SC divided over three days (-14, -13, and -12)
214676066|NCT02307305|DRUG|celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone|Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
214676067|NCT02178618|DEVICE|Deployment of Partially covered biliary self expandable metal stent|
214676068|NCT02178618|DEVICE|Deployment of uncovered biliary self expandable metal stent|
214676069|NCT03482310|DEVICE|Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
215074142|NCT03387007|BEHAVIORAL|Psychosocial support training for school teachers|The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
215074143|NCT00659100|DRUG|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
214338242|NCT03977844|OTHER|Community Resources + eBT|"The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities \[65\]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app."
214676070|NCT02221739|DRUG|Ipilimumab|
214940423|NCT04339777|RADIATION|Total body Irradiation|200 cGy Transplant Day -1 (Only for 9/10 HLA Matched Related or Unrelated Donor Recipients )
214940424|NCT04339777|PROCEDURE|Allogeneic HSCT|Stem cell transplant
214940425|NCT04339777|DRUG|Tacrolimus (Tacro)|Tacrolimus 0.02 mg/kg IV continuous infusion over 24 hours starting on day +5
214940426|NCT04339777|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 15 mg/kg IV over 2 hours three times a day starting on day +5 will continue until Approximately+35 (+/- two days)
214940427|NCT04339777|DRUG|Cyclophosphamide (Cytoxan)|Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight
214940428|NCT03405389|PROCEDURE|MatrixWAVE MMF System|Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion
214676071|NCT02221739|RADIATION|Radiotherapy (IMRT or 3-D CRT)|
214676072|NCT02206711|DRUG|BMS-955176|Single dose of drug on Day 1
214676073|NCT02592304|DEVICE|Dual energy computed tomography|one extra scanning with a dual energy ct.
214676074|NCT04370249|OTHER|pulmonary ultrasound|pulmonary ultrasound on admission
215074144|NCT03651856|DRUG|ATM FOG in PD|open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
215074145|NCT01812200|DRUG|Dabigatran, Ticagrelor, ASA|
215074146|NCT01812200|DRUG|Rivaroxaban, Ticagrelor, ASA|
215074147|NCT01812200|DRUG|Phenprocoumon, Ticagrelor, ASA|
214338243|NCT04204421|OTHER|Experience Sampling Method (ESM)|Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
214338244|NCT04832763|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214338245|NCT04832763|OTHER|Medical Chart Review|Review of medical charts
214338246|NCT04832763|OTHER|Physical Performance Testing|Undergo physical function testing
214338247|NCT04832763|OTHER|Quality-of-Life Assessment|Ancillary studies
214338248|NCT04832763|OTHER|Questionnaire Administration|Complete questionnaire
214338249|NCT06503120|BEHAVIORAL|Mediterranean-diet intervention group|Dietitian-guided Nutritionist Education Process
214338250|NCT06503120|BEHAVIORAL|Standard care|A 10-minute talk on the epidemiology of MASLD and balanced diet, resembling routine clinical practice.
214940429|NCT06733584|BEHAVIORAL|Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention without Mutual Gaze|Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.
214940430|NCT06733584|BEHAVIORAL|Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention|Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.
214940431|NCT06720974|OTHER|AquaReBal|"The interventions will be delivered one-on-one, in person at the KITE Research Institute by a trained and licensed physiotherapist. We will follow an RBT program previously developed by co-investigators. The interventions will be matched as closely as possible for frequency, intensity and time. The exercise interventions will be based on internal and external perturbations. Therapist-applied perturbations and multiple perturbation types and directions are of most benefit in terms of reactive balance control, so our study will focus on manual perturbations; the perturbations will be strong enough to cause stepping reactions. Interventions will be tailored to the individual participants' abilities.~Each session will include a 10 min warm-up, at least 40 min of perturbations and a 10 min cool-down. Internal perturbations will be achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task."
214940432|NCT04836481|OTHER|Serum Sample Collection|Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.
214940433|NCT05565144|OTHER|None, pure observational study|None, pure observational study
214940434|NCT07041008|BEHAVIORAL|Digital intervention|Individual cognitive stimulation sessions will be delivered using RehaCom software, which provides adaptive, computerised exercises targeting specific cognitive domains.
214940435|NCT07041008|BEHAVIORAL|Physical/Analogue Intervention|Individual cognitive stimulation sessions will employ structured physical materials, specifically the 'Memories from North to South©' and 'Cognitive Domains' resources, applied on an alternating basis.
214940436|NCT05876767|DRUG|SAR444336|Single or repeated dose subcutaneous injection
215074148|NCT04171791|DRUG|ABT-199 (venetoclax)|Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
214338251|NCT05582941|OTHER|No intervention will be performed.|No intervention will be performed.
214338252|NCT06295549|BIOLOGICAL|LUCAR-G39P cells product|LUCAR-G39P cells product Prior to infusion of the LUCAR-G39P, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
214338253|NCT05317936|DRUG|Pirtobrutinib|Given by PO
214338254|NCT05317936|DRUG|Venetoclax|GIven by PO
214338255|NCT03609060|DRUG|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
214338256|NCT00126048|DRUG|Atorvastatin|40mg tablet
214338257|NCT00126048|DRUG|Placebo|Placebo tablet
214338258|NCT00217789|PROCEDURE|Bronchoalveolar Lavage and Venipuncture|
214338259|NCT04844164|DRUG|Cholecalciferol 15000 UNT/ML Oral Solution|A single dose (150,000 IU) of cholecalciferol aqueous solution per os
214338260|NCT04634201|DIETARY_SUPPLEMENT|Oral probiotics (L. reuteri)|administration of probiotic containing tablets twice daily after tooth brushing for 3 months
214338261|NCT04634201|DIETARY_SUPPLEMENT|Placebo|administration of a placebo twice daily after tooth brushing for 3 months
214338262|NCT00647920|BIOLOGICAL|adalimumab|40 mg adalimumab sc, every other week
214338263|NCT00647920|BIOLOGICAL|placebo|placebo sc, every other week
214338264|NCT01043874|DRUG|Nilotinib|400 mg BID
214338265|NCT02818738|DRUG|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
214338266|NCT02818738|OTHER|Placebo|matching verum
214338267|NCT03894449|COMBINATION_PRODUCT|Prebiotic + Iron Forificant|A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
214338268|NCT03176160|OTHER|Palliative regimen consisting of LITT|Minimally invasive technique to necrotize intracranial lesions
214338269|NCT01653431|DEVICE|Transcranial direct current stimulation|
214940437|NCT05876767|DRUG|Placebo|Single or repeated dose subcutaneous injection
214940438|NCT06729060|OTHER|Combination of Motor Imagery and Physical Performance|"For 15 minutes you will physically eliminate targets by clicking on them in the Aim Lab Trainer (Physical Performance Part).~Then, on a screen divided into 60 squares, the target will appear and disappear in a random square for 5 seconds. At the same time, the metronome will give a warning sound at each new target. The stimulus will come every five seconds and each time the stimulus comes, the target will imagine that it has disappeared. In the next 5 seconds, the stimulus will come again in a different place and he will imagine that he has destroyed it again. In the first two weeks, this will happen for 60 stimuli with 5 second intervals.~(60target\*5sec=300sec \*3=900sec/60 =15 min). In the next 2 weeks, the interval will be reduced by 1 second and in the last two weeks it will not be reduced. But the duration will always be 15 minutes (Motor Imagery Part)."
214940439|NCT06729060|OTHER|Physical Performance|For 30 minutes, they will eliminate the Aim Lab Trainer test by clicking quickly and accurately with their dominant hands. The physical performance practice to be applied both in this group and in the Motor Imagery and Physical Performance Combination Group is the same and will be applied in the same way for 8 weeks
214940440|NCT07049952|DEVICE|taVNS|Active or inactive non-invasive vagus nerve stimulation of the auricular branch of the vagus nerve paired with 2 oral feedings/day for 14d
214940441|NCT07049952|COMBINATION_PRODUCT|NAC and taVNS|NAC 100 mg/kg diluted 1:3 with sterile water (or equal volume sterile water), q6h NG 1h before a feed for 4d prior to delivering active or sham taVNS paired with 2 feeds/day for 14d with NAC (or sterile water).
215074149|NCT04816656|OTHER|ePROMs assessment|"At inclusion the patient received a unique login code which he/she used to start the care path. After signing the informed consent on the digital pathway, the patient needed to fill in the questionnaires that were presented at fixed time points throughout this study.~Based on the data collected from the questionnaires the patient received customized information and advice. In case of COVID-19, the information and advice was based on the guidelines from Sciensano and the Belgian government. If the patient suffered from side effects from the cancer therapy, they received tips and tricks how to manage these complications. The collected data was forwarded to the patient medical file. As such health care workers were be able to use this information in the patients' follow up consultations."
214338270|NCT04134663|DRUG|vasoconstrictor and oxytocin treatment|intransal administration of vasoconstrictor and oxytocin
215074150|NCT03610945|DRUG|Fluconazole|Subjects will receive fluconazole once daily from Day 5 to Day 18
215074151|NCT03610945|DRUG|Quinidine|Subjects will receive quinidine twice daily from Day 5 to Day 12
215074152|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 14
215074153|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
214338271|NCT04134663|DRUG|vasoconstrictor's placebo and oxytocin treatment|intransal administration of vasoconstrictor's placebo and oxytocin
214338272|NCT04134663|DRUG|vasoconstrictor and oxytocin's placebo treatment|intransal administration of vasoconstrictor and oxytocin's placebo
214338273|NCT00182689|DRUG|sorafenib tosylate|Given orally
214338274|NCT01405391|DRUG|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
214486430|NCT06777225|OTHER|breathing exercises|"This study is to examine the effects of breathing exercises on nausea, vomiting and anxiety levels in patients with gynecological cancer.~1 Exercise:~* Find a quiet, calm and comfortable place for yourself.~* Lie on your back in a comfortable place (flat surface, bed or couch) and bend your knees or sit in a comfortable place (chair or armchair).~* Close your eyes.~* Place your left hand on your belly and your right hand on your chest.~* Take a deep breath through your nose for 4 seconds.~* Feel your hand on your belly rise and your belly swell as you breathe in.~* Make sure your chest is not swollen.~* Hold your breath for 4 seconds. Breathe out in 4 seconds.~* Do this 10 times every day, morning and evening, 3 times."
214940442|NCT07049952|DEVICE|inactive taVNS|inactive transcutaneous auricular vagus nerve stimulation with 2 feeds/day x 14 days
214940443|NCT07049952|COMBINATION_PRODUCT|sterile water and inactive taVNS|Sterile water per NG tube every 6h for 4 days, then continuing with 14days of inactive taVNS paired with oral feeding
214940444|NCT06735664|PROCEDURE|Biopsy|Undergo ultrasound guided biopsy
214940445|NCT06735664|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215074154|NCT01663324|DEVICE|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS"
214676075|NCT00349791|DRUG|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
214676076|NCT00349791|DRUG|Placebo patch|placebo patch replaced twice a week for two years
214676077|NCT03614429|DRUG|Chlorhexidine gel will be prepared according to an international product Instillagel®|"Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol\* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not."
214676078|NCT01985685|DRUG|Thiamine|200 mg IV thiamine
214338275|NCT00123227|DRUG|Rosiglitazone|
214676079|NCT01214434|DEVICE|Promiseb Topical Cream|topical non steroidal cream, twice daily
214338276|NCT03422003|RADIATION|Radiation Therapy|"For the conventional fractionation arm: Each fraction will consist of 200 cGy per day. Total dose = 5000 cGy to the chest wall and 4600-5000 cGy to the lymph nodes.~For the hypofractionation arm: Each fraction consists of 266 cGy per day. Total dose = 4256 cGy to the chest wall and 3990 cGy to the lymph nodes."
214338277|NCT04382118|OTHER|Data collection from routine medical records|Data collection from routine medical records (clinical and radiological data)
214338278|NCT00664612|DEVICE|AirTraq|Laryngoscopy with AirTraq
214940446|NCT06735664|PROCEDURE|Bone Marrow Biopsy|Undergo optional bone marrow biopsy
214940447|NCT06735664|PROCEDURE|Computed Tomography|Undergo CT
214940448|NCT06735664|PROCEDURE|Echocardiography|Undergo ECHO
214940449|NCT06735664|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214940450|NCT06735664|BIOLOGICAL|Odronextamab|Given IV
214940451|NCT06735664|PROCEDURE|Positron Emission Tomography|Undergo PET
214940452|NCT06735664|PROCEDURE|Ultrasound Imaging|Undergo ultrasound guided biopsy
214940453|NCT06735664|DRUG|Zanubrutinib|Given PO
214940454|NCT06633861|DEVICE|spot-check measurement|Spot-check measurement: different Philips SpO2 sensors and Philips FAST pulse oximeter system, capnography
215074155|NCT01663324|DEVICE|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS"
214676080|NCT01214434|OTHER|Bland emollient|Eucerin cream twice daily
214338279|NCT04054583|OTHER|Renovation of long-term residential care living spaces|Living spaces of the long term care facility will be renovated.
214338280|NCT02579642|DRUG|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
214940459|NCT06745804|DRUG|68Ga-R10602 injection|68Ga-R10602 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions in hormone receptor positive breast cancer
214940460|NCT03619902|BIOLOGICAL|Imsidolimab|Humanized monoclonal antibody
214940461|NCT06894394|BEHAVIORAL|UP-A|The UP-A (Ehrenreich-May et al., 2018, 2020, 2022) is a transdiagnostic intervention with eight modules targeting neuroticism. It improves emotion regulation and reduces avoidance, with summaries after each module and a Parent Module (P). The intervention is a group adaptation of the Spanish version of UP-A that consists of 16 weekly sessions, each lasting 60 to 90 minutes, held in person at a Day Hospital within the Spanish public healthcare system. Due to the complexity of the setting, parent sessions are not viable. However, parents receive summaries of the modules covered with the adolescents, as well as the Parent Module (Parenting the Emotional Adolescent), to support their understanding of the treatment content.
214676081|NCT01641016|DRUG|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
214676082|NCT03100435|DEVICE|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
214338281|NCT02579642|DRUG|Placebo|Normal saline administered with usual induction drugs for ECT
214338282|NCT01515085|PROCEDURE|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
214338283|NCT02341716|PROCEDURE|WA|Walk advice with Nordic Poles and best medical treatment
214338284|NCT02341716|PROCEDURE|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
214338285|NCT02341716|PROCEDURE|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
214338286|NCT01311830|BEHAVIORAL|Telephone Counseling|
214338287|NCT01311830|BEHAVIORAL|Written Materials|
214338288|NCT05025293|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|100ml Zoledronic acid (5mg/100ml) administered intravenously
214338289|NCT05025293|DRUG|sodium chloride|100ml NaCl 9mg/ml administered intravenously
214338290|NCT06168708|PROCEDURE|Transurethral resection of the prostate (TURP)|TURP with addition of gentamicin on irrigation fluid to reduce infectious complications
214338291|NCT06168708|DRUG|Gentamicin|gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)
214676083|NCT03100435|OTHER|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
214676084|NCT03792750|DRUG|BMS-986205|Specified Dose on Specified Day
214940462|NCT06738641|BEHAVIORAL|Pro2col Health|The Pro2col Health application is a smartphone application that provides users with health behavior guidance, personalized feedback, and assessments designed to estimate their current healthspan and biological age.
214940463|NCT06738641|BEHAVIORAL|Control|The control group will receive subject-facing materials depicting current general activity recommendations as published by the American Heart Association (AHA) and current dietary guidelines provided by the United States Department of Agriculture (USDA).
214940464|NCT02742883|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
214940465|NCT07054489|OTHER|Beta blocker|Participants randomized to intervention will be dosed and titrated on beta blocker according to study protocol.
214940466|NCT04835428|DEVICE|Treatment Group: AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
214940467|NCT04835428|DEVICE|Control Group: PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
214940468|NCT06497582|OTHER|zhan-zhuang|zhan-zhuang as a fundamental type of qigong
214940469|NCT06497582|OTHER|self-acupressure|Self-acupressure as a common type of traditional Chinese medicine therapies
214940470|NCT05803382|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214940471|NCT05803382|PROCEDURE|Biopsy Procedure|Undergo biopsy
214940472|NCT05803382|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214940473|NCT05803382|DRUG|Capecitabine|Given PO
214940474|NCT05803382|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
214940475|NCT05803382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214940476|NCT05803382|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214940477|NCT06747845|DRUG|Niraparib|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle.
214676085|NCT03792750|BIOLOGICAL|Nivolumab|Specified Dose on Specified Day
214676086|NCT00138151|BIOLOGICAL|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
214676087|NCT00138151|DRUG|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
214676088|NCT00138151|DRUG|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
214940478|NCT06747845|DRUG|FOLFIRI|Standard chemotherapy FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) will be administered intravenously every 14 days of a 28-day cycle.
214940479|NCT06747845|DRUG|Ipilimumab|Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
214940480|NCT06752850|DRUG|Efanesoctocog alfa|50 IU/kg once weekly, Intravenous injection
214940481|NCT03449381|DRUG|BI 907828|Film-coated tablet
214940482|NCT05201066|DRUG|decitabine|Solution for intravenous infusion
214940483|NCT05201066|DRUG|spartalizumab|Solution for intravenous infusion
214676089|NCT05216991|OTHER|TetraGraph on dominant hand|Using standard of care TetraGraph device on dominant hand
215074156|NCT04903873|DRUG|EU101|EU101 will be administered via intravenous infusion.
215074157|NCT01183052|OTHER|Training|20 sessions of training
215074158|NCT02649218|BIOLOGICAL|Ligelizumab|QGE031 240 mg s.c. q4w
214676090|NCT05216991|OTHER|TetraGraph on non-dominant hand|Using standard of care TetraGraph device on non-dominant hand
214338292|NCT06168708|DRUG|normal saline|normal saline (2 ml) on the irrigation solution (placebo)
214338293|NCT03077282|DRUG|Prasaprohyai|Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
214338294|NCT06535269|PROCEDURE|Monopolar Hemorroidecotmy|Hemorrhoidectomy with monopolar diathermy
214338295|NCT06535269|PROCEDURE|Caiman Hemorroidectomy|Hemorrhoidectomy with Caiman® bipolar energy
214676091|NCT06453447|DRUG|Prednisone|40 mg PO once daily for 14 days starting day of surgery
215074159|NCT02493257|DRUG|Capsaicin|
215074160|NCT02493257|DRUG|Placebo|
214338296|NCT04173221|OTHER|Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
214338297|NCT04173221|OTHER|Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
214338298|NCT05080582|BEHAVIORAL|Mother-Scented Simulated Hand|Preterm neonates wrapped with a warm Mother-Scented Simulated Hand during the invasive procedures
214676092|NCT06453447|DRUG|Placebo|Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
214676093|NCT00607828|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
214676094|NCT06392100|BEHAVIORAL|Mindfulness-Based Intervention|Mindfulness-based stress reduction interventions include: breathing awareness, loving-kindness meditation, body scan, walking meditation, sitting body awareness, eating meditation, and deep breathing exercises.
214940484|NCT05201066|DRUG|sabatolimab|Solution for intravenous infusion
214940485|NCT05201066|DRUG|azacitidine|Solution for subcutaneous injection or intravenous infusion
214940486|NCT05201066|DRUG|venetoclax|Tablet for oral administration
214940487|NCT05201066|DRUG|INQOVI (oral decitabine)|Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
214940488|NCT06403046|DRUG|intraarticular injection|all patients will be subjected to routine (TMJ) arthrocentesis followed by Tenoxicam injection into the superior joint space in the (Tx group) and Meloxicam injection among the patients of (Mx group).
214940489|NCT07109739|DEVICE|POWERbreathe K5|The POWERbreathe K5 is portable, battery-powered, and commercially available. No modifications to the FDA-approved design are being made. Its use in this study is consistent with prior published human research and does not constitute a significant deviation from labeled use in terms of safety or function.
214940490|NCT03982446|GENETIC|Mutations|
214940491|NCT04440891|DEVICE|TMS stimulation with X-Torp task|TMS-Stimulation with X-Torp task
214940492|NCT04440891|DEVICE|TMS-Stimulation with MindMotion Go|TMS-Stimulation with MindMotion Go
214940493|NCT04440891|DEVICE|TMS-Sham with X-Torp task|TMS-Sham with X-Torp task
214940494|NCT04440891|DEVICE|TMS-Sham with MindMotion Go|TMS-Sham with MindMotion Go
214940495|NCT06910371|BEHAVIORAL|smartphone screen time reduction|Smartphone screen time has to be reduced to less-equal 2 hours per day for 3 consecutive weeks.
214940496|NCT04506905|DRUG|MK-8189|MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
215074161|NCT01456208|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
215074162|NCT01456208|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
215074163|NCT01456208|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
215074164|NCT02082457|DRUG|YKP10811 5mg|
214940497|NCT04506905|DRUG|Placebo|Oral tablets of dose-matched placebo to MK-8189 according to randomization
214940498|NCT06225271|BEHAVIORAL|the combined intervention of exercise, fruit, and vitamin supplementation|"Group intervention~After each intervention, investigators will hold a 15-minute communication and discussion session for the participants. Besides, community health workers will organize at least one health education activity per week during the intervention for no less than 45 minutes.~Individual intervention~Physical activity~The participants will be gathered at the community activity center or day care center. The participants will be allowed to exercise in a way that interests them. The duration of exercise should be longer than 30 minutes.~Fruit supplementation~Consideration of seasonal supply situation and the participants' diabetic status, various types of fruit will be prepared. The fruit will be divided into 50g/100g servings. Participants will be required to eat on site.~Vitamin supplementation~During the intervention, the participants will be required to take 1 tablet of vitamin B complex plus 1 tablet of vitamin C every day."
214940499|NCT00602290|DRUG|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were \> 2 until treatment completion.
214940500|NCT00602290|DRUG|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
214940501|NCT00602290|DRUG|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
214940502|NCT07128199|DRUG|Cisplatin|IV infusion.
214940503|NCT07128199|DRUG|Carboplatin|IV infusion.
214940504|NCT07128199|DRUG|Pemetrexed|IV infusion.
214940505|NCT07128199|DRUG|TAS6417|Oral tablets.
215074165|NCT02082457|DRUG|YKP10811 20mg|
214676095|NCT02596490|BEHAVIORAL|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
214676096|NCT02596490|BEHAVIORAL|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
215074166|NCT02082457|DRUG|YKP10811 placebo|
215074167|NCT04640493|DRUG|Dapagliflozin|If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.
215074168|NCT04640493|DEVICE|WatchPat|HF patients undergo SDB testing with the WatchPat device. (non-experimental)
215074169|NCT00895752|DRUG|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
215074170|NCT05145322|DEVICE|Composite with 90 degree cavosurface angle|Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the preparation will be restored with a bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
214940506|NCT07128199|DRUG|Zipalertinib Matching-placebo|Oral tablets.
214940507|NCT07095894|DRUG|Atropine|Daily 0.05% atropine eyedrops
214940508|NCT07095894|DEVICE|Spectacles with HAL|Spectacle lenses with highly aspherical lenslets (HAL)
214676097|NCT02596490|BEHAVIORAL|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
214940509|NCT07095894|DRUG|Placebo Eyedrops|Daily placebo eyedrops
214676098|NCT06260176|BEHAVIORAL|exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
214940510|NCT07144527|DIETARY_SUPPLEMENT|NMN, betaine, low-dose hydrogen peroxide (EGA)|Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.
215074171|NCT05145322|DEVICE|Composite with wide bevel|Lesion-specific cavity design with wide bevel throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the cavity will be restored in with a pre-warmed (using Bioclear Heatsync Kit) bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
214338299|NCT05080582|BEHAVIORAL|NICU Standard Care|Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture.
214338300|NCT03946943|DRUG|Anlotinib|Once a day dosing of anlotinib alone for the first 7 days, Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
214338301|NCT03946943|DRUG|Toripalimab|Toripalimab 240mg shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
214338302|NCT03946943|PROCEDURE|Blood Draw|Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
214338303|NCT03946943|PROCEDURE|Tumor Specimen Collection|Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
214940511|NCT07144527|DIETARY_SUPPLEMENT|Nicotinamide Mononucleotide (NMN)|Conventional NMN supplement.
214940512|NCT07144527|DIETARY_SUPPLEMENT|Placebo|Organoleptically matched inert control.
214940513|NCT07152548|OTHER|Task-oriented exercises and mirror therapy|Patients in this group will receive task-oriented exercises 3 sessions per week for 6 weeks.Therapy will include the following functional tasks: reaching, grasping or holding, lifting, placing objects, and counting fingers.Mirror therapy group: 3 sessions per week for 6 weeks.A mirror will be placed on the learning table, and exercises will be carried out by the patient looking into the mirror, where an unaffected limb would be placed in front of the mirror. Through looking into the mirror, the patient will assume the reflection of the unaffected limb is the affected limb. Exercises will be performed by hand opening and closing, wrist extension and flexion, squeezing, opposition, calculation, and finger flexion and extension.
214940514|NCT07152548|OTHER|Task-oriented exercises|Patients in this group received task-oriented exercises 3 sessions per week for 6 weeks.Therapy included the following functional tasks: reaching, grasping or holding, lifting, placing objects, and counting fingers.
214338304|NCT04691869|DEVICE|Achilles EXPII|Portable ultrasound machine that measures a patient's bone density at the calcaneus.
214940515|NCT07152548|OTHER|Mirror Therapy|Mirror therapy group 3sessions per week for 6 weeks. Mirror will be placed on the learning table and exercises will be carried out by the patient looking into the mirror where an unaffected limb would be placed in front of the mirror, through looking into the mirror patient will assume the reflection of the unaffected limb as the affected limb. Exercises will be performed hand opening and closing, wrist extension and flexion, squeezing, opposition, the calculation, finger flexion and extension.
214940516|NCT07153263|PROCEDURE|Ultrasound-guided retro-SCTLB|Patients undergoing CT-guided lung nodule localization were selected for the study. Before the surgery, the retro-SCTLB was performed under ultrasound guidance.
214940517|NCT07153263|PROCEDURE|Ultrasound-guided TPVB|Patients undergoing CT-guided lung nodule localization were selected for the study. Before the surgery, the TPVB was performed under ultrasound guidance.
214940518|NCT07150702|OTHER|Conventional physical therapy program|Conventional physical therapy program that includes hot packs, transcutaneous electrical nerve stimulation, ultrasound, and core stabilization exercises
214940519|NCT07150702|BEHAVIORAL|Close follow-up by a physician|Daily physician-patient meetings during the sessions
214940520|NCT07157800|OTHER|ergonomics training|"Each of the control group participants will receive separate ergonomics training. The content of this training will include the topics of what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk factors."
214338305|NCT04194190|DRUG|Individual Patient TCR-Transduced PBL|
214338306|NCT03435393|PROCEDURE|Catheter ablation|Mapping of the epicardium and ablating areas of long fractionated potentials
214338307|NCT05947448|DRUG|Azilsartan Medoxomil Potassium Tablet|Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month
214338308|NCT05947448|DRUG|Nifedipine Sustained -release Tablets|Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；
214338309|NCT05947448|DRUG|Levoamlodipine Maleate Table|Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；
214338310|NCT05306067|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
214338311|NCT05306067|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests
214338312|NCT03151265|DEVICE|ThermaCare Low Back Heat Wrap|The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
214338313|NCT01040871|DRUG|VELCADE|VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
214338314|NCT01040871|DRUG|Rituximab|Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
214338315|NCT01040871|DRUG|Cyclophosphamide|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
214338316|NCT01040871|DRUG|Doxorubicin|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
214338317|NCT01040871|DRUG|Prednisone|Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
214338318|NCT01040871|DRUG|Vincristine|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
214338319|NCT04186962|OTHER|Behavioral: Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
214338320|NCT02833740|DEVICE|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
214338321|NCT05561686|DRUG|Pyrotinib|This study adopted a prospective, multicenter, observational design. From October 1, 2022, 100 patients with HER2-positive breast cancer scheduled to receive neoadjuvant therapy with pyrotinib were enrolled. The treatment regimen was determined according to the patient 's condition, physician' s treatment experience, evidence-based evidence and other factors to assess the clinical benefit (pCR, ORR) and safety of different neoadjuvant therapy modalities containing pyrotinib. Exploratory analysis was performed to investigate the correlation between the level of TMB and the pCR rate of neoadjuvant therapy in HER2-positive breast cancer patients, and the effect of pyrotinib on intestinal flora.
214338322|NCT01273831|DRUG|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
214676099|NCT06260176|BEHAVIORAL|exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
214676100|NCT06260176|BEHAVIORAL|exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
214676101|NCT06260176|BEHAVIORAL|exposure to sweetened beverage tax messaging|Message reminding consumers to make healthier choices
214676102|NCT02018250|DRUG|MMB4 DMS|Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
214338323|NCT01273831|DRUG|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
214338324|NCT00004867|PROCEDURE|conventional surgery|
214940521|NCT07157800|OTHER|exercise + ergonomics training|"Each of the control group participants will receive separate ergonomics training. The content of this training will include the topics of what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk factors.~Other: exercise program stretching exercises strengthening exercises waist exercises core exercises relaxation exercises"
214940522|NCT07153497|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214940523|NCT07153497|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214940524|NCT07153497|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214940525|NCT07153497|DRUG|Decitabine and Cedazuridine|Given PO
214940526|NCT07153497|DRUG|Olutasidenib|Given PO
214940527|NCT07153497|DRUG|Venetoclax|Given PO
214940528|NCT05652205|DRUG|Linaclotide|Capsule; oral
214940529|NCT05652205|DRUG|Placebo for Linaclotide|Capsule; oral
214940530|NCT07157540|BEHAVIORAL|Personalized Feedback on Cannabis Protective Behavioral Strategies, Cannabis Use, Cannabis Expenditures, and Cannabis-Related Consequences (PF)|"PF comprises the following content:~* Self-reported PBS questionnaire, personalized feedback on PBS, possibility to select strategies to start using or use more often, possibility to set a reminder to use PBS strategies.~* Short questionnaire on cannabis use (frequency/number of hours under the influence) and normative feedback on participant's cannabis use as compared to people of same age and gender in the general population and among Cann-L participants.~* Question on money spent for cannabis purchase, personalized feedback (total amount spent and corresponding number of grams of cannabis over one year), gamified gauge to picture potential yearly savings, reflection on how to use the saved money, and possibility to set a reminder for money saving objectives.~* Questionnaire on cannabis-related consequences, feedback on the level of consequences met, question about which consequence(s) participant might want to think about, and possibility to set a reminder to think about consequences."
214940531|NCT07157540|BEHAVIORAL|Imagining the Future Using Counterfactual Thinking and Episodic Future Thinking (IMAGIN)|"Two-task intervention including:~1. Counterfactual thinking:~   * Description of a recent negative situation related to cannabis use encountered by the participant~  * Identification of a preventive strategy that would have addressed this situation~  * Writing a sentence formatted as If only +preventive strategy, then + description on how the specific past problem would have improved~  * Assessment of participant's intention and confidence in using the preventive strategy~  * Imagining a future situation using this preventive strategy~  * Possibility to set a reminder of the preventive strategy.~2. Episodic future thinking:~   * Description of a significant positive event that might occur in the short-term (3 months) and that does not involve cannabis use~  * Assessment of the importance and enjoyment of this positive event~  * Encouragement to imagine it as vividly as possible~  * Suggestion to describe the positive event in detail and to write it down~  * Possibility to set a reminder of the positive event."
214676103|NCT02018250|DRUG|Placebo|Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
214676104|NCT00187161|DRUG|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
214676105|NCT02440724|DEVICE|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
214338325|NCT00004867|PROCEDURE|positron emission tomography|
214338326|NCT00004867|PROCEDURE|radionuclide imaging|
214338327|NCT00004867|RADIATION|fludeoxyglucose F 18|
214338328|NCT00004867|DRUG|chemotherapy|
214338329|NCT00004867|RADIATION|Radiotherapy|
214338330|NCT02451748|OTHER|Lab Work|Lab work to measure IL-7 and IL-7R
214338331|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)|"Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
214338332|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)|"rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
214338333|NCT02451748|DRUG|Hydroxychloroquine|some patients are on 400mg/day of hydroxychloroquine.
214338334|NCT02451748|DRUG|Sulfasalazine|some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
214676106|NCT02440724|DEVICE|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
215074172|NCT04479475|BEHAVIORAL|Supportive care through community support persons|The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks: (1) Introduction, (2) Working in a social network-based setting, (3) Setting drinking and drug use goals, (4) Coping skills 1, (5), Coping Skills 2, (6) Making lifestyle changes, (7) Generating income. Social support persons attend up to five sessions over the course of six weeks.
214338335|NCT02451748|DRUG|Medrol|some patients are on 8mg/day of medrol
214940532|NCT07157540|BEHAVIORAL|Behavioral Economics-Informed Exercises to Increase Motivation to Engage in Substance-Free Activities (SFAS)|"SFAS includes:~* A questionnaire on how participant value different aspects of their life, and feedback on valued domains.~* Two open-ended questions on short- and long-term life goals.~* A questionnaire assessing time allocation (hours per week allocated to different activities, e.g. socializing, working, etc.), and personalized feedback including the time spent using substances and recovering from their effects.~* Gamified exercise to imagine allocating time in a different way.~* List of substance-free recreational activities in the region of Lausanne, with possibility to select activities on a wish-list including internet hyperlinks.~* Possibility to set a reminder of the selected activities.~* Single-item questionnaire on stress and mood, and feedback on stress and mood level.~* Open-ended question on coping strategies currently used for stress and mood.~* List of coping strategies that can be selected.~* Possibility to set a reminder of stress/mood coping strategies."
215074173|NCT01349322|RADIATION|Standard fractionation whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
214338336|NCT02451748|DRUG|Prednisone|some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
214940533|NCT07157540|BEHAVIORAL|Information|Minimal intervention (Control Intervention), consisting of simple, text-only web pages containing information on cannabis effects and health-related risks, cannabis consumption modes, cannabis harm reduction and protective behavioral strategies, as well as hyperlinks to additional resources and online help.
214940534|NCT07161141|DEVICE|Immersive Virtual Reality Platform to Support Birth Preparedness and Mental Wellbeing|"The VR-based intervention will be grounded in a childbirth education framework designed to enhance women's awareness of their attitudes toward childbirth, their readiness for the birthing process, and their expectations related to labor, delivery, and the postpartum period. The program aims to strengthen emotional insight and coping capacities by guiding participants to reflect on their feelings and thoughts throughout the childbirth journey. The intervention will integrate key components such as breath awareness exercises, coping techniques, and motivational messages. While participants receive structured childbirth education, they will simultaneously be supported in developing psychological preparedness through immersive and reflective experiences tailored to foster emotional resilience and self-efficacy.~The digital labyrinth will be designed both visually and functionally to facilitate immersive navigation. It will be set in an expansive virtual landscape enriched with natural elem"
214940535|NCT07161102|OTHER|Reflexology|A complementary technique that involves applying pressure to reflexology points on the feet. In this study, foot reflexology will be applied in 10 sessions, twice a week, for 30 minutes, aiming to reduce anxiety symptoms.
214940536|NCT07161102|OTHER|Sham Reflexology|A simulated procedure consisting of superficial and random maneuvers on the feet, without stimulation of specific reflexology points. Ten sessions will be conducted twice a week, each lasting 30 minutes, for placebo control purposes.
214940537|NCT07158541|PROCEDURE|tunneled coronally advanced flap with connective tissue graft|The gum at the recession site is undermined, only partially detached and reattached higher (combined withh a connective tissue graft).
214940538|NCT07158541|PROCEDURE|modified tunnel with connective tissue graft|At the recession site, the gingiva is undermined to create a tunnel, and a connective tissue graft is inserted through the sulcus into this space before advancing the flap coronally.
214940539|NCT07164664|PROCEDURE|External Oblique Intercostal Block|Bilateral ultrasound-guided External Oblique Intercostal Block (30 mL, 0.25% bupivacaine, bilaterally) will be performed. All patients will receive multimodal analgesia, including a single dose of IV tenoxicam 20 mg. Additionally, 15 mg/kg IV paracetamol (based on IBW) will be administered at skin closure and continued every 6 hours postoperatively. A standardized IV PCA protocol will be initiated using a PCA device programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum of 0.1-0.15 mg/kg (IBW). Upon arrival in the PACU, patients with a resting NRS ≥4 will receive titrated IV morphine boluses of 0.03 mg/kg (IBW; max 10 mg) every 10 minutes until pain is controlled. In the surgical ward, patients with breakthrough pain (NRS ≥4) despite PCA use will receive IV tramadol 1-1.5 mg/kg (IBW) in 50-100 mg slow doses, not exceeding 400 mg/day.All patients will receive 8 mg dexamethasone and 0.15 mg/kg ondansetron (IBW) for PONV prophylaxis.
215074174|NCT01349322|RADIATION|Hypofractionated whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
214338337|NCT02451748|DRUG|Triamcinolone|some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly
214338338|NCT02451748|DRUG|Naproxen|some patients are on 1000 mg/day of naproxen
214338339|NCT02451748|DRUG|Leflunomide|some patients are on 20mg/day of leflunomide
214338340|NCT02451748|DRUG|Methotrexate|some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
214940540|NCT07164664|PROCEDURE|Port-Site Infiltration|Before port placement, 0.25% bupivacaine solution will be injected into the laparoscopic port insertion sites (5 mL at each port site).
214940541|NCT07164664|DRUG|ıv morphine PCA|A standardized IV PCA protocol will be initiated for all patients using a PCA device (Body Guard 575 pain manager, UK), programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/ kg (IBW). No basal infusion will be used.
214940542|NCT07169214|DRUG|BT-114143 Injection at low dose|A total of 10 subjects were enrolled. All of them received BT-114143 Injection at low dose. BT-114143 will be administered twice daily for three consecutive days.
214940543|NCT07169214|DRUG|BT-114143 Injection at Medium-dose|A total of 10 subjects were enrolled. All of them received BT-114143 Injection at Medium-dose. BT-114143 will be administered twice daily for three consecutive days.
214940544|NCT07169214|DRUG|BT-114143 Injection at High-dose|A total of 10 subjects were enrolled. All of them received BT-114143 Injection at High-dose. BT-114143 will be administered twice daily for three consecutive days.
214940545|NCT07169214|DRUG|control group|The ratio of subjects in the experimental group to those in the control group is 10:3, with 3 placebo - treated control subjects corresponding to each dose group. The subjects will receive placebo treatment twice a day for 3 consecutive days.
214940546|NCT07167030|BEHAVIORAL|Virtual Reality Digital Storytelling|Participants in the intervention group will receive digital storytelling modules using virtual reality (VR) headsets once a week for four weeks, starting at 28 weeks of gestation. Each module will include three topics (2-10 minutes). After each topic, there will be a rest period followed by an interactive session. The final two modules will be administered during the NST recording, and mother and baby status will be monitored. Each module, including the interactive session, will last 45-50 minutes. Participants will receive an educational brochure after the module and will be reminded via WhatsApp.
214940547|NCT07165340|COMBINATION_PRODUCT|Indocyanine Green near infrared fluorescence imaging|A total of 10 intradermal injections of 25 ug indocyanine green (ICG) in 0.1 mL saline are administered in the feet, medial ankles, lateral calves, and thigh. The total dose of ICG will not exceed 250 ug. After injection, the legs will be illuminated by the dim output of a 780 nm laser diode, and the resultant fluorescent signal emanating from ICG-laden lymph will be collected by a custom built near-infrared fluorescent lymphatic imager.
214940548|NCT07165340|DEVICE|advanced pneumatic compression|The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy. Daily treatment will be prescribed for approximately 30 days.
214940549|NCT07165340|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound to measure venous reflux will be done at each visit.
215074175|NCT01349322|RADIATION|Concurrent boost|15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.
215074176|NCT01349322|RADIATION|Sequential boost|6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
215074177|NCT06053112|OTHER|New infant formula with 6 HMOs blend|Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
214338341|NCT02451748|DRUG|humira|some patients are on Humira 40mg q2weeks
214338342|NCT05634681|RADIATION|Plan of the day|Several treatment plans are prepared and the appropriate plan is used at each treatment session.
214338343|NCT05634681|RADIATION|Standard plan|One treatment plan
214338344|NCT02106338|OTHER|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
214338345|NCT02106338|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
214338346|NCT01353339|DRUG|Levofloxacin|500mg, PO, once daily for 3 months
214338347|NCT03604718|BIOLOGICAL|Beltavac® Polymerized with Alternaria alternata|Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice
214338348|NCT00173667|DRUG|Nifedipine 30 mg GITS|
214338349|NCT03637998|BEHAVIORAL|Problem-solving Pain to Enhance Living Well (PROPEL)|PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.
214338350|NCT05361473|DEVICE|The NeoHilda Point of care method|This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
214338351|NCT05361473|PROCEDURE|Traditional evaluation|Traditional way of evaluation
214338352|NCT00750945|OTHER|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
214338353|NCT00750945|OTHER|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
214338354|NCT00750945|OTHER|Home program|Home walking program 6 days/wk x 4 weeks
214338355|NCT02486224|DIETARY_SUPPLEMENT|Kona Deep|Subjects will receive Kona Deep post exercise
214940550|NCT07165340|DEVICE|compression wrap|A compression wrap, to provide 20-40 mm Hg of pressure, will be provided for daily use between visits (approximately 30 days).
215074178|NCT06053112|OTHER|Standard infant formula without 6 HMOs blend|Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
214676107|NCT04199754|DRUG|Omnipaque 300mg/mL Solution for Injection|Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
214676108|NCT04199754|RADIATION|Cone Beam CT|60 seconds after contrast administration, a Cone Beam CT will be performed.
215074179|NCT03127774|DRUG|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
215074180|NCT03127774|DRUG|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
214676109|NCT04199754|RADIATION|Radiation Therapy|Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.
214676110|NCT04199754|DRUG|0.9% Saline|50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
215074181|NCT03127774|PROCEDURE|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
214940553|NCT05934903|DEVICE|Transcranial Direct Current Stimulation|Cathodal direct current stimulation at 0 or 2mA will be applied to subjects
215074182|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living. This therapy has shown impressive improvements in children with PC."
214676111|NCT05734547|BEHAVIORAL|Stepping Together for Children after Trauma (ST-CT)|ST-CT is Step One of Stepped Care CBT for Children after Trauma (previously called Stepped Care Trauma-focused Cognitive Behavioral Therapy; Salloum et al., 2014). It consists of five components: psychoeducation, stabilization, trauma narrative, in-vivo exposures and consolidation. The parent and child have 11 at-home-meetings and complete tasks in a workbook, Stepping Together (from the Preschool PTSD Treatment by Michael Scheeringa et al), over 6-9 weeks. In addition, there are weekly calls and five sessions with the therapist. Children who meet responder-criteria (i.e., no more than four symptoms of PTSS) continue to a 6-week maintenance phase, after which treatment is complete if the child still meets responder criteria. For those who do not meet responder-criteria, or are not able to complete the workbook, the responsibility for the treatment is transferred from the municipal service level to the corresponding child and adolescent mental health service (BUP).
214676112|NCT05734547|BEHAVIORAL|Usual care|Therapists in the control group will provide the treatment they usually provide, and develop a treatment plan in collaboration with the parents. This may consist of individual sessions with the child, parent sessions, group treatment, meetings with the school and other collaborating services, or referral to the second line mental health centres (BUP).
214676113|NCT04102839|OTHER|Interview|Qualitative Interview
214676114|NCT01963052|DRUG|AGS15E|intravenous (IV) infusion
214676115|NCT06972160|OTHER|Arm1: intervention 1 (SMS+call)|The intervention will consist in two text messages (one and two weeks after received the screening test, respectively), an automated non-human call or a call made by the administrative assistant (three weeks after received the screening test), and a phone call made by a physician (four weeks after received the screening test)
214676116|NCT06972160|OTHER|Control group|The control group will not be subjected to any interventions to increase the adherence to screening.
214676117|NCT06970678|DRUG|Dexmedetomidine infusion|Patients will receive intravenous loading dose of dexmedetomidine at 0.5 μg/kg ideal body weight (concentration 2 μg/ml) over 15 minutes prior to anesthesia induction, followed by 10 ml of 0.9% sodium chloride over 60 seconds during anesthetic induction. Post-intubation, Dexmedetomidine will be maintained at 0.5 μg/kg/h ideal body weight via a syringe pump until trocar removal.
214676118|NCT06970678|PROCEDURE|paragastric autonomic neural block|Paragastric autonomic neural block (PGANB) will be administered using a 25-gauge needle attached to a venous catheter extension, introduced through the left 12 mm port. Infiltration of 20 mL undiluted 0.5% bupivacaine will be performed at six levels in the fatty tissue of the paragastric area, including the lesser omentum, vagus nerve, esophagogastric junction, proximal stomach, mid-stomach, distal antrum, hepatic artery, and left gastric artery, with the needle cap removed under direct vision throughout the procedure.
214676119|NCT05144022|BEHAVIORAL|Bungee jump|Bungee jump from a cran
214676120|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|
214676121|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|
214940554|NCT07170267|OTHER|Transversalis fascia plane block|Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.
214940555|NCT07170267|DRUG|Intrathecal dexmedetomidine|Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) + (5 µg intrathecal dexmedetomidine diluted in 0.5ml saline) with a sham block at the end of surgery.
214940556|NCT07175896|BEHAVIORAL|Immediate delivery of low-sodium DASH diet group coaching plus hand-on cooking program|Low-sodium DASH diet group coaching enhanced by cooking classes
214940557|NCT07175896|BEHAVIORAL|Delayed delivery of low-sodium DASH diet group coaching plus hand-on cooking program|Low-sodium DASH diet group coaching enhanced by cooking classes
214940558|NCT07176572|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated + NS IV Infusion 100 ml
214940559|NCT07176572|DRUG|Dexketoprofen Trometamol|50 mg dexketoprofen trometamol in 100 ml normal saline solution + Transcutaneous electrical nerve stimulation treatment will not be activated.
214338356|NCT02486224|DIETARY_SUPPLEMENT|Spring Water|Subjects will receive Spring Water post exercise
214338357|NCT02486224|DIETARY_SUPPLEMENT|Sports Drink|Subjects will receive Sports Drink post exercise
214338358|NCT00673049|DRUG|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
214338359|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
214338360|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
214940560|NCT07177092|PROCEDURE|Surgery|① Preoperative evaluation must confirm resectability. Thoracoscopic minimally invasive surgery will be performed, with the surgical approach selected according to disease conditions, such as lobectomy, segmentectomy, wedge resection, or sleeve resection; ② Systematic mediastinal lymph node dissection or lymph node sampling (based on preoperative imaging and intraoperative evaluation) must be performed; ③ Postoperative recovery must be adequate (postoperative complications ≤ Clavien-Dindo grade II).
214338361|NCT02241226|BEHAVIORAL|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
214940561|NCT07177092|DRUG|Osimertinib|Dose: 80 mg orally, once daily, until disease progression or the occurrence of unacceptable toxicity. The dose should be administered at approximately the same time each day, at 24-hour intervals.
214940562|NCT07175389|DRUG|JDB153|JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.
214940563|NCT07175389|DRUG|Serplulimab|Serplulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).
214338362|NCT05266911|BEHAVIORAL|high-intensity functional strength training|HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.
214338363|NCT05266911|BEHAVIORAL|Lower extremity stretching|Lower extremity stretching program to be completed by participants at home 3 days per week.
214338364|NCT05522803|DEVICE|TMS followed by sham TMS|Transcranial Magnetic Stimulation followed by sham TMS
214338365|NCT05522803|DEVICE|Sham TMS followed by TMS|Sham Transcranial Magnetic Stimulation followed by TMS
214338366|NCT01175824|DRUG|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
214338367|NCT01175824|DRUG|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
214940564|NCT07174596|DEVICE|B+L Infuse spherical soft contact lenses|Test lens
214940565|NCT07174596|DEVICE|J&J ACUVUE OASYS 1-Day spherical soft contact lenses|Control lens
214940566|NCT07177196|DRUG|nL-PRPH2-001|Personalized antisense oligonucleotide
214940567|NCT07175675|PROCEDURE|Operative treatment of surgeons choice|treatment of single finger amputation with revision amputation, local or micro-vascular flap as best befits each specific injury
214338368|NCT01175824|DRUG|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
214338369|NCT06532695|OTHER|No intervention will be provided.|no intervention will be provided.
214338370|NCT04749264|BEHAVIORAL|Mindfulness meditation retreat|6 to 7-days mindfulness retreat (Vipassana/insight meditation). The retreats are held in silence and led by senior teachers with many years of experience in teaching meditation. The focus of the retreat is the practice of mindfulness meditation while sitting and walking. Retreats include focused attention and open monitoring mindfulness meditation practices. Each retreat has a similar practice schedule thus the amount and nature of formal practice is mostly the same.
214940568|NCT07175675|PROCEDURE|Semi-occlusive film|The film is placed on a cleansed wound surface. bone is shortened to the level of injury. Visible nerves, arteries and tendons are cut and allowed to retract. The film is to be changed once weekly until the wound has closed.
214940569|NCT07175571|PROCEDURE|Intracytoplasmic Sperm Injection (ICSI)|Mature oocytes are injected with a single frozen-thawed donor sperm cell using micromanipulation under a microscope. This fertilization method is performed shortly after oocyte retrieval. Sperm used are pre-screened and standardized for post-thaw motility and morphology. ICSI is conducted in accordance with standard embryology lab protocols. The oocyte allocation to ICSI is randomized within each participant's cycle.
214940570|NCT07175571|PROCEDURE|Conventional Insemination (IVF)|Oocytes are inseminated by co-incubation with frozen-thawed donor sperm in a culture dish for 16-18 hours. Sperm are washed and prepared according to lab protocol to ensure motility and concentration suitability. This method does not involve direct sperm injection. Oocytes are randomly assigned to this method within each participant's retrieved cohort.
214940571|NCT07175220|DRUG|SHR2554; SHR-A2102|SHR2554 tablets combined with SHR-A2102 for injection, with a cycle of 21 days
214940572|NCT07175220|DRUG|SHR2554; Adabelimumab|SHR2554 tablets combined with Adabelimumab, with a cycle of 21 days
214338371|NCT03844893|PROCEDURE|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
214338372|NCT06489808|DRUG|Linperlisib|Linperlisib RP2D D1-14
214338373|NCT06489808|DRUG|Rituximab|rituximab 375 mg/m2 D0
214338374|NCT06489808|DRUG|Gemcitabine|gemcitabine per regimen dosage
214940573|NCT07175220|DRUG|SHR2554; SHR-1701|SHR2554 tablets combined with SHR-1701 injection, with a cycle of 21 days
214940574|NCT07174531|PROCEDURE|Transcatheter valve in Valve implantation|Transcatheter valve-in-valve implantation for patients with degenerated aortic/mitral/tricuspid bioprosthetic valves who are at high-risk to redo surgical valve replacement.
214940575|NCT07177040|PROCEDURE|Maitland|Maitland technique therapy, which consists of passive mobilizations applied to the lumbar facet joints in an anterocranial direction while the patient is in a prone lying position
215074183|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities at home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
215074184|NCT05740605|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 4 hours per week in autonomy and 1 hour per week under supervision.
215074185|NCT05740605|BEHAVIORAL|Usual Care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
214338375|NCT06489808|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1
214940576|NCT07177040|PROCEDURE|SNAG|The technique involves applying a sustained glide to the lumbar facet joints while the patient is in a sitting position, and the pelvic girdle will be stabilized by a belt. Then the therapist will ask the patient for active forward flexion of the spine while the pressure on the facet joint is maintained during the movement till its end
215074186|NCT03522038|PROCEDURE|percutaneous coronary intervention|PCI was performed using standard techniques. Antiplatelet and antithrombotic agents were prescribed according to current PCI guidelines. A procedure was considered successful when achieving TIMI flow grade 3 with \<30% angiographic residual stenosis in the CTO vessel. All patients received drug-eluting stents and were discharged on dual antiplatelet therapy with duration of at least on year.
214676122|NCT04674163|BIOLOGICAL|Blood sample and Cerebrospinal fluid (CSF) collection.|An additional blood sample (25 ml) and a cerebrospinal fluid (CSF) sample (2 ml) will be taken.
214940577|NCT07176897|DIAGNOSTIC_TEST|Normal Toric IOL implantation with digital marking|Digital marking was compared to bedside marking, but there was no change in clinical practice. The difference in the marks was measured.
214940578|NCT07175025|BEHAVIORAL|Narrative Exposure Therapy (NET)|Narrative Exposure Therapy (NET) is the PTSD intervention for the treatment group.
214676123|NCT05176678|DIETARY_SUPPLEMENT|1 gram of a protein hydrolysate|After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
214676124|NCT05176678|DIETARY_SUPPLEMENT|2 grams of a protein hydrolysate|After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
214676125|NCT05176678|DIETARY_SUPPLEMENT|4 grams of a protein hydrolysate|After 4 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
214676126|NCT05176678|DIETARY_SUPPLEMENT|8 grams of a protein hydrolysate|After 8 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
214676127|NCT00009867|DRUG|arsenic trioxide|Given IV
214676128|NCT02902809|BIOLOGICAL|Tralokinumab open-label|Subcutaneous injection; fixed dose; 300 mg
214676129|NCT00167908|DRUG|Ethyol (drug)|
214676130|NCT00532259|DRUG|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
214676131|NCT00169468|DRUG|Rituximab -CHOP plus Velcade|
214676132|NCT00793104|PROCEDURE|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
214676133|NCT05701852|OTHER|reward learning task|during usual follow-up patients will complete a remard learning task questionnaire. This questionnaire cannot be assimilated to a clinical intervention.
214676134|NCT03453086|PROCEDURE|Thoracic paravertebral block(TPVB) group|"Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior"
214338376|NCT06489808|DRUG|Ifosfamide|Ifosfamide 5g/m2 D2
214676135|NCT04535570|OTHER|Indirect Calorimetry|In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
214676136|NCT03421223|OTHER|No intervention|No intervention
214676137|NCT01910506|DRUG|RDEA3170 10 mg|
214676138|NCT03320733|DIAGNOSTIC_TEST|Dual energy CT scan with subtraction imaging|"The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT."
214676139|NCT01920139|PROCEDURE|Fine needle aspiration and core biopsy of lymph node|Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
214338377|NCT06489808|DRUG|Carboplatin|Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)
214940579|NCT07177027|BEHAVIORAL|Music intervention|Participants listened to 12 relaxing music tracks introduced during prenatal childbirth classes at 36 weeks of gestation. The tracks were shared via WhatsApp to encourage regular listening during pregnancy. During labor, participants were encouraged to listen to music whenever they wished. At cervical dilations of 4 cm, 6 cm, and 8 cm, participants listened to their preferred tracks from the playlist for 20 minutes. Pain intensity was measured before and after each session using the Visual Analog Scale (VAS).
214940580|NCT07177027|BEHAVIORAL|Breathing Exercise|Participants were trained in Lamaze breathing techniques during prenatal childbirth classes. They practiced guided breathing exercises during labor at cervical dilation points of 4 cm, 6 cm, and 8 cm. Pain intensity was assessed before and after each session using the Visual Analog Scale (VAS).
214940581|NCT07175857|DEVICE|Lyv Endo app|Lyv Endo is a CE-marked Class I therapeutic digital medical device offering a patient-centered, integrative approach. Its innovation lies in its ability to deliver personalized content based on symptoms, surpassing the limits of traditional care.
214940582|NCT07176247|DRUG|Aztreonam-Avibactam|Antibiotic therapy with Aztreonam-Avibactam
214940583|NCT07174570|DRUG|Celecoxib|Receive by mouth (PO).
214940584|NCT07174570|BIOLOGICAL|Durvalumab|Receive intravenously (IV).
214940585|NCT07174570|BIOLOGICAL|Tremelimumab|Given intravenously (IV).
214940586|NCT07174570|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214940587|NCT07174570|PROCEDURE|Computed Tomography|Undergo Computed Tomography (CT).
214940588|NCT07174570|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging (MRI).
214940589|NCT07174570|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy.
214940590|NCT07175363|DRUG|An postoperative analgesic pump was used|The drugs in the analgesic pump include butorphanol, hydromorphone, tramadol, and other medications.
214940591|NCT07174895|DRUG|Intra-articular Tranexamic Acid + Suction Drainage|Patients received intra-articular injection of 3 g tranexamic acid in 100 mL normal saline after wound closure, along with a closed suction drain inserted intra-articularly and subcutaneously, activated two hours postoperatively.
214940592|NCT07174895|DRUG|Intra-articular Tranexamic Acid|Patients received intra-articular injection of 3 g tranexamic acid in 100 mL normal saline after wound closure. No suction drain was used.
214940593|NCT07174895|DEVICE|Suction Drainage Only|Patients had a closed suction drain inserted intra-articularly and subcutaneously, activated two hours postoperatively. No tranexamic acid was administered.
214940594|NCT07175246|DIAGNOSTIC_TEST|Polysomnography (PSG)|Polysomnography (PSG) is the gold standard, multi-parametric diagnostic test used to comprehensively assess sleep architecture and diagnose sleep disorders. This objective, overnight recording captures simultaneous physiological data channels, including electroencephalography (EEG) to stage sleep, electrooculography (EOG) to detect eye movements, electromyography (EMG) to measure muscle tone, electrocardiography (ECG) for heart rhythm, respiratory effort (via thoracic and abdominal belts), nasal airflow, and pulse oximetry for blood oxygen saturation. As the primary/secondary outcome measure, PSG will be administered to quantitatively evaluate the intervention's effect on key sleep parameters such as total sleep time (TST), sleep efficiency (SE), wake after sleep onset (WASO), latency to sleep onset, and the frequency of sleep-disordered breathing events (e.g., Apnea-Hypopnea Index, AHI) or periodic limb movements.
214940595|NCT07174960|BEHAVIORAL|Life-Skills Training Program|This study aims to assess the impact of a life-skills training program on self-efficacy in patients with substance use disorders. The program is designed to prevent relapse by equipping individuals with crucial skills for managing triggers and challenges. It focuses on developing constructive coping strategies, effective stress and craving management techniques, social competencies like assertiveness, and emotional regulation abilities including anger control. By enhancing these domains, the intervention seeks to strengthen patients' confidence in their capacity to resist substance use and make adaptive decisions, thereby reducing relapse risk.
214940596|NCT07175870|PROCEDURE|Non-cardiac surgery followed by postoperative PCI|Patients undergo the planned time-sensitive non-cardiac surgery first in a hybrid operating room, with PCI standby available in case of an intraoperative acute coronary event. If such an event occurs, immediate PCI will be performed. Additional PCI will be performed postoperatively if clinically indicated.
214940597|NCT07175870|PROCEDURE|Preoperative PCI followed by delayed non-cardiac surgery ~3 months later|Patients undergo PCI first. The planned non-cardiac surgery will then be performed approximately 3 months after PCI, in accordance with current guideline recommendations for the timing of non-cardiac surgery following PCI.
214338378|NCT06489808|DRUG|Etoposide|Etoposide 100mg/m2 D1-3
214338379|NCT06489808|DRUG|Dexamethasone|Dexamethasone 40mg D1-4
214940598|NCT07176884|PROCEDURE|nurse-performed coronary catheterization|nurse-performed coronary catheterization
214940599|NCT07176884|PROCEDURE|interventional cardiologist-performed coronary catheterization|interventional cardiologist-performed coronary catheterization.
214338380|NCT06489808|DRUG|Cisplatin|Cisplatin 100mg/m2 D1, continuous intravenous infusion
214338381|NCT06489808|DRUG|Ara-C|Ara-C 2g/m2 q12h D2
214338382|NCT06489808|DRUG|Vinorelbine|Vinorelbine 20mg/m2 D1
214338383|NCT06489808|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 18mg/m2 D1
214338384|NCT00924950|DRUG|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
214338385|NCT00924950|DRUG|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
214338386|NCT05089396|OTHER|Maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
214940600|NCT07176533|PROCEDURE|Suprazygomatic maxillary nerve block (SZMN) with ropivacaine|Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of 0.25% ropivacaine (local anesthetic), up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.
214940601|NCT07176533|PROCEDURE|Suprazygomatic maxillary nerve block (SZMN) with placebo|Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia. which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of saline (placebo) up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.
214940602|NCT07174921|PROCEDURE|Laparoscopic Lateral Suspension|Participants in this arm will undergo laparoscopic lateral suspension for post-hysterectomy vaginal cuff prolapse. The procedure involves attaching a synthetic mesh from the vaginal cuff to the lateral abdominal wall to provide support and restore normal vaginal anatomy. Standard perioperative care, including anesthesia and postoperative pain management, will be provided.
214940603|NCT07174921|PROCEDURE|Laparoscopic Sacrocolpopexy|Participants in this arm will undergo laparoscopic sacrohysteropexy for post-hysterectomy vaginal cuff prolapse. The procedure involves suspending the vaginal cuff to the sacral promontory using a synthetic mesh, restoring vaginal support. Standard perioperative care, including anesthesia and postoperative pain management, will be provided.
214940604|NCT07176182|DRUG|mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group|"The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy.~Treatment Protocol~Preoperative (4-6 cycles) and Postoperative (6-8 cycles):~Each 14-day cycle includes:~Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1.~Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1.~5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours.~Citrus flavonoid tablets (Alvenor) : 500 mg orally three times daily (Days 1-14), administered with or without the chemotherapy regimen (depending on group assignment)."
214940605|NCT07176182|DRUG|mFOLFOX regimen neoadjuvant therapy group|"The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy.~Treatment Protocol~Preoperative (4-6 cycles) and Postoperative (6-8 cycles):~Each 14-day cycle includes:~Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1.~Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1.~5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours."
214940606|NCT07175701|BEHAVIORAL|Behavioral: Nutritional education and diet counselling|"All participants will be asked to visit the study site after the 10-day baseline monitoring period. They will receive a 30-minute nutrition education focusing on reducing UPF intake; and personalized counselling session based on their dietary intake observed during the baseline monitoring period.~Participants allocated to the intervention group will receive nutrition education and personalized counselling aimed at reducing ultra-processed food (UPF) intake by encouraging the substitution of UPFs with unprocessed/minimally processed foods, thereby improving overall diet quality. Participants will be educated on the definition of UPFs, how to identify them, practical strategies for reducing UPF intake, UPF-reducing recipes, and the associations between UPF intake and health outcomes. The content related to UPFs was developed based on previous studies exploring the health effects of UPF intake, while the content on diet quality was based on the 2020 Korean Dietary Reference Intakes."
214940607|NCT07175701|BEHAVIORAL|Conventional nutrition education and diet counseling|All participants will be asked to visit the study site after the 10-day baseline monitoring period. Participants in the control group will receive a conventional nutrient-based education and personalized diet counseling developed based on the 2020 Korean Dietary Reference Intakes.
214940608|NCT07175727|DEVICE|Pulmonary vein isolation|Pulmonary vein isolation for paroxysmal atrial fibrillation
214940609|NCT07175727|RADIATION|cerebral magnetic resonance tomography|A subset of consecutive patients of each group (n=25 of each group) receives cMRI on the day after the procedure to asses silent cerebral lesions. A control cMRI is scheduled in case of positive findings.
214940610|NCT07175727|DIAGNOSTIC_TEST|Biomarker assessment (C-reacitve Protein, troponine)|A subset of patients of each group (n=25 of each group) received blood tests to asses inflammation and troponine release.
214940611|NCT07176234|BEHAVIORAL|Treatment|The Linking Exercise for Advancing Daily Stress (LEADS) Management intervention integrates a family-based intervention to address chronic stressors to promote behavioral skills for increasing PA in overweight AA adolescents and their parents. Based on Lazarus and Folkman's Stress and Coping Model, Family Systems, and Social Cognitive Theories, the proposed intervention integrates components that build coping skills (mindfulness, deep breathing, active coping, cognitive reframing), self-esteem (self-affirmation), and positive parenting practices (parent support, nurturance, family routines).
214940612|NCT07176234|OTHER|Health Education|Attention Control Comparator
214338387|NCT05793905|COMBINATION_PRODUCT|Buffered lidocaine in inferior alveolar nerve block injection|Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars
214338388|NCT05793905|DRUG|lidocaine 2% in inferior alveolar nerve block injection|Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
214338389|NCT04117828|DIETARY_SUPPLEMENT|Dates|Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
214940613|NCT07174505|DEVICE|Mechanical Thrombectomy using the CONDA Stent Retriever|Intravenous sedation, local or general anesthesia, and anticoagulation management will be administered following the institution's standard of care to ensure subject safety and comfort. These procedures should be applied to the target population at the discretion of the investigator and in accordance with clinical guidelines. The use of CONDA is no different than that established for other CE marked stent retrievers. The use of supportive devices including, long sheaths, guide catheters with our without balloons, distal access catheters, ANA funnel catheter, microcatheters and microwires, along with the CONDA device, will be guided by operator preference and/or center established practices. Operators are required to use these devices according to their labeling and instructions for use.
214940614|NCT07176260|OTHER|Patients with pre-Capillary pulmonary hypertension|Patients will be followed for 3 years with routine clinical, hemodynamic, and laboratory assessments. Blood samples for oxidative stress and mitochondrial function analyses will be collected during scheduled follow-up visits or catheterization procedures. No intervention beyond standard care will be performed.
214940615|NCT07176715|OTHER|Same-Day Colectomy|"study, they will undergo extensive education during their preoperative visit. Perioperative education includes management of perioperative medications, bowel prep and perioperative antibiotics. Perioperative education will include that of the patient and their designated caregiver.~Perioperative nursing staff will go over postoperative discharge instructions again. A custom discharge instruction sheet will be made and given to all patients upon discharge. On days 1 and 3 postoperatively, patients will receive a phone call or virtual visit from a member of the research team. Questions will be asked of patients based on a script made. Patients will then be seen in the clinic between postoperative day 5-7.~Patients' medical record will be followed for six months postoperatively to track emergency department visits, readmissions, and postoperative complications. Postoperative complications will include surgical site infection, deep surgical infection, bleeding requiring transfusion, ana"
214338390|NCT03574792|DRUG|Gabapentin|Given PO
214338391|NCT03574792|DRUG|Methadone|Given PO
215078061|NCT05306561|PROCEDURE|Systane iLux thermal pulsation treatment|Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
215078062|NCT06204692|PROCEDURE|dental implant|consisted of 6 patients where computer guided dental implant placement
214338392|NCT03574792|DRUG|Oxycodone|Given PO
214338393|NCT03574792|OTHER|Quality-of-Life Assessment|Ancillary studies
214338394|NCT03574792|OTHER|Questionnaire Administration|Ancillary studies
214338395|NCT03574792|DRUG|Venlafaxine|Given PO
214338396|NCT03574792|DRUG|Venlafaxine Hydrochloride Extended Release|Given PO
214338397|NCT01579123|PROCEDURE|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
214338398|NCT01579123|PROCEDURE|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
214338399|NCT06077396|PROCEDURE|radial artery cannulation|radial artery cannulation
214338400|NCT06432712|DRUG|Dexamethasone 4mg|2.5ml of Dexamethasone 4mg/ml will be administered via periapical infiltration with a 23 gauge needle to the experimental group.
214338401|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Day 0, Months 6 and 12
214338402|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Months 1, 7, and 13
214338403|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
214338404|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
214338405|NCT01519713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
214338406|NCT06636474|OTHER|patients with mental disorders|administration of standardized questionnaires and scales, upon entering the research, then annually, and finally upon leaving the research
214338407|NCT01179594|DRUG|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
214338408|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
214338409|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
215078063|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
214676140|NCT01920139|PROCEDURE|Axillary surgery|Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.
214338410|NCT01179594|DRUG|placebo|orally daily, 24 weeks (weeks 12-36)
214676141|NCT01920139|OTHER|Titanium marker|A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
214338411|NCT01042964|DRUG|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
214338412|NCT05430516|OTHER|No intervention|No intervention
214940616|NCT07176754|DRUG|Infliximab|"The TNF-α antagonist (infliximab) used by the experimenter was manufactured by Hisun Biopharmaceuticals Ltd. under the trade name anbaite.The dosage was administered at 5 mg/kg, dissolved in 250 mL of 0.9% sodium chloride injection, and delivered via intravenous infusion over 2 hours."
214338413|NCT02311595|PROCEDURE|reduced port laparoscopic distal gastrectomy|
214338414|NCT02237105|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
214940617|NCT07176754|DRUG|Sodium chloride injection USP, 0.9% (placebo)|Patients in the control group received 250 mL of 0.9% sodium chloride injection as a placebo, administered via intravenous infusion over 2 hours.
214940618|NCT07176728|DRUG|BAY 3389934|Solution for intravenous infusion
214940619|NCT07176728|DRUG|Matching Placebo / Diluent|Solution for intravenous infusion
214940620|NCT07175948|OTHER|Standard Medical Therapy|All enrolled children will receive standard medical therapy tailored to clinical status. This includes inotropes (e.g., dopamine, dobutamine, milrinone), ACE inhibitors, beta-blockers, and/or diuretics as indicated. Treatment is supportive and adjusted according to severity of cardiac dysfunction and hemodynamic status. The goal is to stabilize heart failure, improve cardiac output, and prevent progression to dilated cardiomyopathy.
214338415|NCT02999308|OTHER|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
214338416|NCT05578404|DRUG|Cholecalciferol|Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
214338417|NCT05578404|DRUG|Placebo|matching placebo to Vit D
214338418|NCT00679991|DRUG|PRT-201|Applied topically to AVF during surgery
214940621|NCT07175948|DRUG|Standard Medical Therapy|"All enrolled children will receive standard medical therapy tailored to clinical status. This includes inotropes (dopamine, dobutamine, milrinone), ACE inhibitors, beta-blockers, and/or diuretics as indicated. Therapy is supportive and adjusted according to severity of cardiac dysfunction and hemodynamic status to stabilize heart failure, improve cardiac output, and prevent progression to dilated cardiomyopathy.~2️⃣ Intervention 2"
214940622|NCT07175545|DEVICE|Independent use of the Mobili® Device by patients, overseen by pharmacists|"After recruitment each participant will be subject to a type I medication review.~After allocation to the intervention group, pharmacists will provide initial training to participants, and during the course of the intervention whenever necessary (e.g. when delivering the eDosette with the therapeutic regime). Pharmacists will prepare the eDosette in the pharmacy and deliver it directly to participants with no further intervention.~Participants will receive the number of eDosettes their therapeutic regime allows, to minimize visits to the pharmacy. For the control group, pharmacists will also provide the number of DAAs the therapeutic regime allows. Upon finishing the intervention, a new type II medication review will be performed for all participants (intervention and control) and information related to their personal therapeutic regime will be provided, ensuring a safe exit of the study."
215074187|NCT02666495|OTHER|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement \& stabilisation; phase 2 - developing trust \& understanding; phase 3 - developing awareness \& acceptance; phase 4 - testing change \& strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
214676142|NCT03057873|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|Dry powder to be mixed with 10 ounces of cold water
214338419|NCT00679991|DRUG|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
214338420|NCT02406144|DRUG|MLN9708|
214338421|NCT02406144|DRUG|Lenalidomide|
214338422|NCT02406144|DRUG|Dexamethasone|
214338423|NCT05219201|DEVICE|partial-body cryotherapy chamber session|"The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions)."
214338424|NCT05953194|BEHAVIORAL|Exposure to counter-marketing messages|Counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
214338425|NCT05953194|BEHAVIORAL|Exposure to traditional health messages|Traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
214338426|NCT05953194|BEHAVIORAL|Exposure to control (neutral) messages|Control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
214338427|NCT04221516|DRUG|Camrelizumab|Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
214338428|NCT03322306|GENETIC|Genechip screening kit|10 ml blood for genetic screening by specific genetic screening kit
214338429|NCT06129292|BEHAVIORAL|EFT group|"Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held."
214338430|NCT02585739|GENETIC|blood sample|
214676143|NCT03057873|DIETARY_SUPPLEMENT|Placebo|Dry powder to be mixed with 10 ounces of cold water
214338431|NCT05908240|OTHER|Care Coordinator Model|A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
214338432|NCT06573268|DEVICE|robot surgery device|SPRA used da-Vinci SP system (SPRA) BABA used da-Vinci Xi system (BABA)
214338433|NCT06560268|DRUG|Sevoflurane; In our study, the effects of sevoflurane in different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.|Low-flow anaesthesia is generally adminstered as nitrogen wash-out, a period of higher flow rate in combination with a high vaporizer setting for initial saturation, and subsequent reduction of fresh gas flow and adjustment of the vaporizer to maintain the desired end-tidal anesthetic agent concentration (Etaa).In the initial wash-in phase, the vaporizer setting is adjusted to 6% for desflurane and 2.5-3% for sevoflurane, with FGF=4 L/min, until the Etaa concentration is 1-1.3 MAC. In another method, the vaporizer setting is adjusted to 12-18% for desflurane and 6-8% for sevoflurane, with FGA=1 L/min. Reducing the FGF during the wash-in period prevents unnecessary depth of anesthesia and reduces the consumption of inhalational anesthetics. In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 min before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero.
214338434|NCT06573918|DIAGNOSTIC_TEST|EMG-based assessment of paratonia|EMG-assessed paratonia was analyzed and compared to assess motor response efficiency in three groups of healthy young adults with different levels of physical activity: professional athletes engaged in closed and open skills sports, amateurs, and sedentary individuals. To analyze EMG-assessed paratonia, two surface electrodes were attached to the biceps and triceps brachii muscles during passive flexion-extension movements of the elbow while the participant remained in a state of maximum relaxation. Any EMG activity detected during these movements was attributed to an inability to relax, thereby reflecting their degree of paratonia.
214338435|NCT06573398|COMBINATION_PRODUCT|SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin|Stereotactic body radiation therapy (SBRT): 30 \~ 40 Gy/5f, Week 1, Day 1 \~ Day 5, 6-8 Gy/time, once a day; 3 weeks as a cycle, for 4 cycles Tislelizumab: 200 mg, i.v., single infusion, 21 days as a cycle for 4 cycles, on Day 1 of each treatment cycle; Thymalfasin: 4.8 mg, subcutaneous injection, twice a week, on Day 1 and Day 4 of each week during Weeks 1 \~ 13; Albumin-bound paclitaxel: 125 mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; Gemcitabine: 1000mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; After 4 cycles of preoperative neoadjuvant therapy, radical surgery will be evaluated by the MDT team within 2-4 weeks after completion of chemotherapy + immunotherapy.
214338436|NCT01583725|PROCEDURE|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
214338437|NCT01583725|BEHAVIORAL|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
214338438|NCT03503968|DRUG|MDG1011|PRAME-T-Cell Receptor Gene Modified Autologous T Cells
214338439|NCT03503968|OTHER|Investigator Choice therapy|Any intervention/therapy chosen by the investigator
214676144|NCT02349230|OTHER|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
214940623|NCT07174752|PROCEDURE|Non-Submerged De-Epithelialized Free Gingival Graft|The Free gingival graft will be de-epithelialized and fixed at the recipient site in a non-submerged manner to increase the keratinized mucosa
214940624|NCT07174752|PROCEDURE|Conventional FGG|The Free gingival graft will be fixed at the recipient site to increase the keratinized mucosa
214940625|NCT07174830|DRUG|Allisartan Isoproxil Tablets 240mg or placebo|Allisartan Isoproxil Tablets 240mg or placebo, QD
214940626|NCT07174830|DRUG|Allisartan Isoproxil Tablets 480mg or placebo|Allisartan Isoproxil Tablets 480mg or placebo, QD
214940627|NCT07174830|DRUG|Allisartan Isoproxil Tablets 720mg or placebo|Allisartan Isoproxil Tablets 720mg or placebo, QD
214940628|NCT07176819|BEHAVIORAL|Gait retraining|The intervention is a wearable device-assisted gait retraining program designed specifically for female runners with patellofemoral pain (PFP). Unlike conventional physiotherapy or exercise-based interventions, this program integrates real-time biofeedback through a commercially available smartwatch and its mobile application. Participants are instructed to increase their step rate by 10% above their preferred cadence. The smartwatch provides auditory metronome cues and real-time cadence feedback to ensure accurate step-rate modification.
214940629|NCT07176819|BEHAVIORAL|Education|PFP education, load management strategies, symptom-based training modifications, and strengthening exercises.
214940630|NCT07177079|DRUG|Azacitidine|A chemotherapy drug known as a hypomethylating agent
214940631|NCT07177079|DRUG|Venetoclax|Targeted cancer therapy used to treat certain blood cancers. It specifically targets a protein called BCL-2 to trigger the self-destruction of cancer cells.
214940632|NCT07177079|DRUG|High-dose ascorbate|Administering vitamin C intravenously to achieve very high concentrations in the bloodstream. In contrast to low doses, which act as antioxidants, these pharmacological doses can function as a pro-oxidant, killing cancer cells while leaving healthy cells unharmed.
214940633|NCT07177079|DRUG|Decitabine|Azacitidine may be substituted with decitabine 20 mg/m2 daily, on days 1-5, at PI discretion in the event of toxicity/drug supply shortage.
215078064|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
215078065|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
215078066|NCT04007237|DRUG|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
215078067|NCT04966494|DIETARY_SUPPLEMENT|BOSB|BOSB consisted on a oats (26 %), common beans (30 %), water and emulsifier-based snack bar, administered daily (50 g/day) during 8 weeks.
214676145|NCT05069363|DEVICE|Whole-Body Photobiomodulation Therapy|"* All participants entering the trial will receive a course of whole-body PBM therapy~* The NovoTHOR Whole-Body PBM therapy device consists of a hinged, clamshell design with light-emitting diodes (LEDs) arranged to emit near-infrared and visible red light therapy is delivered to the entire body at once.~* Participants will be expected to lie horizontal in the device with the lid as closed as they are comfortable with.~* 18 sessions is the currently recommended and widely instituted and accepted practice with the NovoTHOR device.~* The LED equipment delivers red and near infrared light therapy to the participant~* Session 1 = 6 minutes~* Session 2 = 12 minutes~* Sessions 3-18 = 20 minutes~* Timescale: 3 treatments/week for 6 weeks~* The dosage of LED light (also known as 'fluence') will be equivalent to 25J/cm2. The device will supply a dual wavelength of red and near-infrared light with a 50:50 ratio; 660nm and 850nm respectively"
214338440|NCT00165282|BEHAVIORAL|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
214338441|NCT00165282|BEHAVIORAL|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
214338442|NCT02044081|DRUG|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
214338443|NCT02044081|DRUG|Placebo|Placebo is the vehicle without C16G2
214338444|NCT02044081|DRUG|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
214338445|NCT03750136|DRUG|Hypertonic saline|high dose furosemide with hypertonic saline 3x daily
214940634|NCT07174635|BEHAVIORAL|Intervention-telenursing|The first researcher sent an educational booklet prepared on the educational topics or the topics the patient needed to the patients in the experimental group as a message. The patient was then called by phone and informed about the educational booklet. After the main interview, the patients were called 2 more times for follow-up. The intervention group was given education on topics such as reducing pain complaints, increasing activity level, exercise, and coping with stress. The education of the intervention group lasted approximately 4 weeks.
214940635|NCT07177001|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will receive a non-specific spine exercise program provided in a handout. The interventional group (Group B) will be asked to keep the standardised spine-specific exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain.
214940636|NCT07177001|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine-specific exercise program will be provided in a handout and given only to the intervention group (Group B), and will include specific spine basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study and referred for evaluation and treatment if necessary.
214940637|NCT07175597|DIETARY_SUPPLEMENT|Hibiscus sabdariffa drink|A daily dose of Hibiscus sabdariffa drink that provides 9.6 mg of anthocyanins
214940638|NCT07176013|BEHAVIORAL|Voice therapy|All patients will receive a course of voice therapy as normal.
214676146|NCT02795598|PROCEDURE|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
214940639|NCT07176013|BEHAVIORAL|Meditation|Meditation at the start of each session. (each session is 30 minutes)
214940640|NCT07176013|DEVICE|Virtual Reality|TRIPP application in the Meta Quest 2 Virtual Reality Headset.
214940641|NCT07175090|COMBINATION_PRODUCT|Coconut oil|The rinse is used three times a day during three weeks
214940642|NCT07175090|OTHER|Placebo|Inactive ingredients with same taste and colour
214338446|NCT03750136|DRUG|Furosemide Injection|high dose furosemide
214338447|NCT02972697|RADIATION|11C-acetate ligand|
214338448|NCT02972697|RADIATION|FDG ligand|
214338449|NCT04635046|PROCEDURE|Transfer or extirpation of the peroneus longs tendon|Tendon transfer or extirpation of peroneus longus or brevis tendon, ligamental reconstruction +/- calcaneal osteotomy
214338450|NCT02543541|BEHAVIORAL|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
214338451|NCT02543541|BEHAVIORAL|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
214338452|NCT02640794|DRUG|Clopidogrel|Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
214338453|NCT02640794|DRUG|Aspirin|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
214347343|NCT02897804|BEHAVIORAL|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214940643|NCT07176039|RADIATION|High-Intensity Laser Therapy (HILT)|will be administered to active myofascial trigger points in the neck and shoulder region. The laser device used is an 808 nm gallium-aluminum-arsenide (GaAlAs) diode laser in continuous mode. Parameters: power output of 8-10 W, frequency of 2000 Hz, and application time of 60 seconds per trigger point, targeting 5-6 trigger points per session. Treatment will be delivered twice weekly for 4 consecutive weeks, totaling 8 sessions.
214940644|NCT07176039|OTHER|Extracorporeal Shockwave Therapy (ESWT)|ESWT will be applied to active myofascial trigger points using a radial shockwave device. Parameters: Energy flux density 0.1-0.2 mJ/mm², 2000 shocks per session, frequency of 2 sessions per week for 4 weeks (8 sessions).
214940645|NCT07174427|BIOLOGICAL|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.
214940646|NCT07174427|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
214338454|NCT01911533|PROCEDURE|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
214338455|NCT01911533|PROCEDURE|No extracorporeal CO2-removal|Patients are their own control group.
214338456|NCT00734526|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
214940647|NCT07174427|DRUG|Fludarabine|Fludarabine (30mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
214940648|NCT07174843|BIOLOGICAL|CD19/CD22/BCMA CAR-T cells(BZE2204)|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of BZE2204 CAR T cells.~On day0 subjects will receive a single dose BZE2204 CAR T cells by intravenous (IV) injection."
214940649|NCT07176910|OTHER|conduct angiopuncture on perforator points|conducted angiopuncutre on patients of intervention group, and compare those patients pain scores before and after angiopuncture therapy.
214940650|NCT07176403|OTHER|intradialytic exercise|"50 patients will undergo Exercise training program for twelve weeks during hemodialysis session.~1. Type of exercise: aerobic exercise training sessions using a lower limb ergometer.~2. Frequency: three times per week.~3. Duration: thirty minutes per session."
214940651|NCT07176403|OTHER|control group|50 patients will not perform exercise during hemodialysis session
214940652|NCT07176078|OTHER|Osteopathic care|"Participants allocated to the osteopathic care group will receive 4 weekly consultations of person-centered osteopathic care. Each consultation will last approximately 45 minutes and consist of a careful medical history, a clinical examination, treatment, and advice (e.g. exercise, dietary, lifestyle).~The osteopathic treatment protocol could be labeled as 'custom tailored': the determination of the treatment was left to the clinical judgment of the osteopath, meaning that no predefined, standardized osteopathic protocol would be implemented. Standard osteopathic techniques (Glossary of Osteopathic Terminology) can be applied, including diagnostic techniques (e.g. observation, neurological tests, palpation, and motion testing) and therapeutic direct (e.g. high-velocity low-amplitude, muscle energy), indirect techniques (e.g. strain counter strain, balanced ligamentous tension, balanced membranous tension), or combined techniques."
214940653|NCT07176078|OTHER|Sham Osteopathic care|"For this trial, sham intervention will mimic the osteopathic care according to the touch equality assumption. Therefore, it mimics a clinical examination and treatment. The sham clinical evaluation involves a full evaluation of the position and mobility of the spine.This screening of the patient will be performed using conventional osteopathic manual tests, without any intention to make a diagnosis. Sham treatment will involve light manual contact, with the subject lying supine on the treatment table."
214940654|NCT07176078|BEHAVIORAL|Flexi-FODMAP Diet|"In addition to the real or sham osteopathic care, all participants will follow a 4-week flexi-FODMAP diet delivered online. Participants will receive structured dietary instructions via a customized online platform, based on the NHS Gentle-FODMAP diet guidelines and informed by expert input from dieticians. This modified FODMAP-gentle approach involves a targeted, less restrictive elimination of selected high-FODMAP foods."
214940655|NCT07175298|PROCEDURE|conventional opioid-based technique|Control Group: Participants will receive general anaesthesia with a conventional opioid-based technique
214338457|NCT00734526|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
214338458|NCT00734526|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
214338459|NCT06145828|DEVICE|Cytokine Adsorption|During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
214338460|NCT00506935|DRUG|GVG|5 grams GVG
215078068|NCT02421731|DEVICE|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
214338461|NCT00506935|DRUG|placebo|placebo
214338462|NCT04962971|DIETARY_SUPPLEMENT|X|exocyan
214338463|NCT04962971|DIETARY_SUPPLEMENT|Y|exocyan
214338464|NCT04962971|DIETARY_SUPPLEMENT|Z|exocyan
214338465|NCT06204393|OTHER|Thyroid metabolic index|"The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.~Psychological evaluations (using the 7-item Generalized Anxiety Disorder Questionnaire, GAD-7, and the Patient Health Questionnaire 9, PHQ-9) and interventions."
214338466|NCT00550784|BIOLOGICAL|filgrastim|
214338467|NCT00550784|DRUG|cisplatin|
214338468|NCT00550784|DRUG|cyclophosphamide|
214338469|NCT00550784|DRUG|melphalan|
214338470|NCT00550784|DRUG|paclitaxel|
214338471|NCT00550784|DRUG|topotecan hydrochloride|
214338472|NCT00550784|GENETIC|TdT-mediated dUTP nick end labeling assay|
214338473|NCT00550784|GENETIC|gene expression analysis|
214338474|NCT00550784|OTHER|immunohistochemistry staining method|
214338475|NCT00550784|OTHER|pharmacological study|
214338476|NCT00550784|PROCEDURE|peripheral blood stem cell transplantation|
214940656|NCT07175298|PROCEDURE|SPSIPB Group|SPSIPB Group: Participants will receive an ultrasound-guided Serratus posterior superior intercostal plane block with 30 ml 0.25% bupivacaine per side pre-incision and general anaesthesia with opioid based fentanyl
214940657|NCT03647163|BIOLOGICAL|VSV-IFNβ-NIS|Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
214940658|NCT03647163|BIOLOGICAL|Pembrolizumab|Pembrolizumab
214338477|NCT00000597|DRUG|antilymphocyte serum|
214940659|NCT03647163|BIOLOGICAL|ipilimumab + nivolumab|Intravenous ipilimumab 1mg/kg in combination with nivolumab 360mg, or Intravenous ipilimumab 1mg/kg in combination with nivolumab 3mg/ kg for 4 cycles, followed by fixed dose nivolumab 480mg
214940660|NCT06508515|BEHAVIORAL|Unadapted Research Units in Behavioral Intervention (RUBI) implementation strategy|"The unadapted RUBI IS involves weekly, one hour educational meetings where sessions involve discussion of homework from the week prior (5 minutes), didactic instruction on targeted behavioral strategies (40 minutes), coaching and consultation around the newly learned strategy (10 minutes), and fidelity review, where RUBI implementation is observed (5 minutes). Finally, Attend\| Behavior® is a HIPAA-compliant mobile application support that is designed to support RUBI delivery and implementation."
214940661|NCT06508515|BEHAVIORAL|RUBI in Educational Settings (RUBIES)-Team|RUBIES is an 8-module intervention that provides educators a range of skills to support the building of a behavioral management toolbox to be used, as needed, with autistic children and disruptive behavior. The program emphasizes: 1) tailoring the intervention to the specific child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice; 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to modify behaviors. All educators will receive RUBIES training across 24 weeks via Zoom.
214338478|NCT00000597|DRUG|nandrolone|
214338479|NCT02530619|DRUG|Alisertib|Given PO
214338480|NCT02530619|OTHER|Laboratory Biomarker Analysis|Correlative studies
214338481|NCT02530619|OTHER|Pharmacological Study|Correlative studies
214338482|NCT03019497|BEHAVIORAL|Specific Modules|Educational session about a specific related problem
214338483|NCT03019497|BEHAVIORAL|Cognitive behavioral therapy|PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
214338484|NCT00259753|DRUG|Bevasiranib|
214338485|NCT02747940|DRUG|flunarizine and/or pregabalin|
214338486|NCT00188097|BEHAVIORAL|Diagnosis of variceal bleeding and dits control in cirrhosis|
214338487|NCT06103981|OTHER|Acute Liver Injury|To evaluate the impact of acute liver injury in patients with pneumonia on hospital stay and outcome.
214338488|NCT00009737|DRUG|5-Fluorouracil|425mg/m2 iv daily from day 1 to day 5 every 28 days.
214338489|NCT00009737|DRUG|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
214338490|NCT00009737|DRUG|Capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
214338491|NCT01097226|OTHER|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
214338492|NCT01097226|OTHER|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
214338493|NCT01097226|OTHER|Apple granules delivering 70 mg epicatechin|Delivered as a puree
214338494|NCT01097226|OTHER|Water delivering no epicatechin|Delivered as flavoured water
214338495|NCT00997997|DRUG|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
214338496|NCT00189085|DRUG|simvastatin and ezetimibe|
214338497|NCT00110240|DRUG|vildagliptin|
214338498|NCT01807585|DEVICE|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
214338499|NCT01807585|DEVICE|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
214338500|NCT01807585|DEVICE|Roll-in (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
214338501|NCT04840095|DRUG|Ketones|Sports supplement that is administered mid-scan.
214338502|NCT04840095|DRUG|Glucose|Supplement is administered mid-scan.
214338503|NCT03813303|DRUG|Midazolam|Administration of midazolam by anesthesiologist for sedation.
214338504|NCT03813303|DRUG|Fentanyl|Administration of fentanyl by anesthesiologist for sedation.
214338505|NCT03813303|DRUG|Propofol|Administration of propofol by anesthesiologist for sedation.
214338506|NCT05622773|OTHER|Mat use application|In the research, repeated measurements will be made by using mats and foot baths in a single group and the data will be recorded.
214338507|NCT01699997|DRUG|Oxytocin|Intranasal spray with 40 IU of OXT
214940662|NCT05670314|DIETARY_SUPPLEMENT|Inulin Fibre supplement|20g/ day. Inulin is easily dissolvable in liquid and can be incorporated into the usual diet - by adding to water, juice, smoothies, cereal, yogurt etc.
214940663|NCT05670314|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|10g/ day which can be consumed by adding to breakfast cereal/ smoothie/ yogurt or drink of choice
214940664|NCT05670314|BEHAVIORAL|Exercise|Joint Academy An app-based exercises platform (Joint Academy®) will be used as an intervention given to the treatment arm. The programme consists of a mixture of open and close chain exercises, a combination of concentric, eccentric and focusing on the global strength of legs including the muscles around the hips and knee joints as well as balance enhancement exercises.
214940665|NCT05622279|PROCEDURE|Percutaneous tenotomy + PRP|The patients will receive a percutaneous ultrasound-guided treatment including a needle tenotomy followed by a PRP injection in the plantar fasciitis.
214338508|NCT01699997|DRUG|Placebo|Intranasal spray with placebo solution
214338509|NCT00334659|DRUG|apricitabine|
214338510|NCT01163682|DEVICE|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
214338511|NCT01163682|DEVICE|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The electro-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
214338512|NCT04031339|PROCEDURE|Standard treatment|e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance
214338513|NCT03021759|BEHAVIORAL|Active choice|Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
214338514|NCT03021759|BEHAVIORAL|Social comparison feedback|Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
214940668|NCT06558214|DRUG|Pembrolizumab|Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.
214940669|NCT06558214|DEVICE|Optune GIO®|".~. Optune GIO® TTFields treatment will begin 3-7 days prior to MLA for Arm1 and 3-10 days prior to MLA for Arm 2."
214940670|NCT06558214|DEVICE|NeuroBlate®|Treatment with NeuroBlate will occur one time at the beginning of the study.
214940671|NCT06529029|DEVICE|Sigma-Stim|Right Ultra-Brief Low Amplitude Seizure Therapy at 600mA or 700mA vs Right Unilateral Ultra-Brief Standard ECT at 800mA.
214940672|NCT06352827|BEHAVIORAL|Survey|All participants will complete a baseline survey and have medical information collected.
214940673|NCT06095479|DEVICE|2D ultrasound scan and MRI examination|All subjects will undergo a 2D ultrasound scan and MRI examination.
214940674|NCT03254667|BIOLOGICAL|Brodalumab|Brodalumab
214940675|NCT03254667|DRUG|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
214940676|NCT05174286|BEHAVIORAL|SBIRT|"SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~The investigators will utilize the Culturally-adapted Alive! Program - a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
214940677|NCT05174286|BEHAVIORAL|Referral as Usual (RAU)|Referral as Usual will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
214940678|NCT05337410|BEHAVIORAL|YES IDEAS|YES IDEAS is an adapted version of the evidence based YES (Youth Empowerment Solutions) program. Through the YES program, youth design and implement their own projects to help improve their own communities. The adapted YES IDEAS curriculum empowers youth from various backgrounds to address bullying and promote positive behaviors as a way to reduce violent behavior. Over the course of the program, youth carry out a community change project aimed at promoting non-violence in their community.
215078069|NCT02421731|OTHER|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
214338515|NCT02815111|DRUG|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
214338516|NCT02815111|DRUG|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
214338517|NCT02815111|DRUG|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
214338518|NCT02815111|DRUG|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
214940679|NCT03900832|OTHER|Without Heating|Subject will complete walking protocol without any heating procedure
214940680|NCT03900832|OTHER|Warm Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 38-41°C. Subjects will remain in the tub for ≤ 30 minutes. If the HR increases more than 15 -20 bpm, or a significant BP drop occurs (e.g. BP \>20 mmHg), the subject will be removed from the bath even if the time is \<30 min."
214940681|NCT03900832|OTHER|Neutral Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 35 - 37°C. Subjects will remain in the tub for ≤ 30 minutes."
214940682|NCT03900832|OTHER|Heating Suit|The mean skin temperature Tsk will be controlled with a water-perfused suit worn by subjects. Whole-body heating will be accomplished by perfusing warm water (\~ 45 - 50 °C) through the suit to elevate the Tsk to ≤ 38 °C (100 oF). Warm water is through plastic tubes, and subjects' skin will not directly touch warm water. The heating will be continued until the ∆Tcore reaches \~ 0. 6 - 1.0 °C. This may take approximately 60 - 90 min.
214940683|NCT03900832|OTHER|Lower limb warm water immersion|Subjects will sit on a chair and put their lower legs and feet in a bucket with warm water. The water level will be just below the knees (depth of approximately 40 cm). The water temperature will be monitored and controlled at \~38 - 42 °C throughout the 30 minutes. BP, HR, Tcore, the skin temperature and skin blood flow (e.g. on a thigh and/or forearm) will be measured before, during and after the lower limbs warm water immersion.
214940684|NCT03900832|OTHER|Gardner walking protocol|The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.
214940685|NCT03240809|BIOLOGICAL|Brodalumab|140 mg SC dose
214940686|NCT03240809|BIOLOGICAL|Brodalumab|70 mg SC dose
214940687|NCT05935735|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|4 in-person sessions; 1 individual and 3 group sessions
214940688|NCT05503719|PROCEDURE|Surgical wound closed with an absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with an absorbable suture according to their respective study group.
214940689|NCT05503719|PROCEDURE|Surgical wound closed with a non-absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with a non-absorbable suture according to their respective study group.
214940690|NCT04726839|OTHER|Standard of care for stroke management and evaluation of functionnal outcome at 3 months|Additional tubes at inclusion (maximum 13 mL) Collection of the mRS data during a routine visit if planned at 3 months +/-15 days or, if not during a specific research phone call at 3 months
214940691|NCT05072106|DRUG|Lurbinectedin|3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
214940692|NCT05072106|DRUG|Bosentan|Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).
214940693|NCT03839459|DRUG|Denosumab|120mg of Denosumab will be administered subcutaneously once every 4 weeks
214940694|NCT03713983|OTHER|Observational study|Observational study
214940695|NCT05400512|BEHAVIORAL|Cognitive Training|Computerized cognitive training targeting the underlying cerebral networks associated with depression.
214940696|NCT05400512|DEVICE|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system).
214940697|NCT05400512|DEVICE|tDCS (sham stimulation)|Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
214940698|NCT06100809|BEHAVIORAL|Personalized coaching|Personalized fatigue mitigation coaching.
214940699|NCT06100809|BEHAVIORAL|Nutrition handout|Nutrition handout
214940700|NCT06298864|BEHAVIORAL|Internet-CBT|"* Common reactions following ACS. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation, i.e., labeling. General lifestyle advice on e.g., physical activity, diet.~* Identifying life areas impaired by ACS-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Gradual exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms.~* Gradual exposure to avoided situations, activities and increase in physical activity.~* Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
214940701|NCT06298864|BEHAVIORAL|Internet-CL|"* Education on ACS, risk factors, its treatments and medication.~* Education and advice promoting healthy habits regarding diet, alcohol and tobacco.~* Education and advice regarding physical activity and the beneficial effects on health.~* Education regarding common emotional reactions following ACS.~* Prevention of relapse and plan forward to maintain a healthy lifestyle."
214940702|NCT01604317|PROCEDURE|Resuscitation-torso plastic bag|Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
214940703|NCT01604317|PROCEDURE|Resuscitation-partial-head plastic bag|Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
214940704|NCT06370832|OTHER|IMT and exercise training group|Participants will perform supervised exercise training per usual care and will be provided with a personalized prescription for an IMT program during the pre-transplant phase. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session) 5 days per week in their home environment or in-person visits. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
214940705|NCT04802447|DRUG|SurVaxM|Each participant will receive 4 doses of SVN53-67/M57-KLH (SurVaxM) spaced two weeks apart. This phase of treatment is known as the prime-boost phase and will take 6 weeks to complete. After completion of the prime-boost phase of treatment, the participant will receive a dose ofSVN53-67/M57-KLH (SurVaxM) every 3 months for up to two years
214940706|NCT05139056|BIOLOGICAL|Neural Stem Cells-expressing CRAd-S-pk7|Given intracerebrally
214940707|NCT05139056|PROCEDURE|Resection|Undergo surgical resection
214940708|NCT04313725|DEVICE|Tangible Boost|Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.
214940709|NCT04313725|OTHER|Placebo|Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
214940710|NCT06191887|BIOLOGICAL|Autologous BAFFR-targeting CAR T Cells|Given IV
214940711|NCT06191887|DRUG|Bendamustine|Given IV
214940712|NCT06191887|PROCEDURE|Biopsy|Undergo biopsy
214940713|NCT06191887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214940714|NCT06191887|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy/aspirate
215074188|NCT05137457|OTHER|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal."
215074189|NCT05137457|OTHER|Sleep diary|The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
214940715|NCT06191887|PROCEDURE|Computed Tomography|Undergo CT scan
214940716|NCT06191887|DRUG|Cyclophosphamide|Given IV
214940717|NCT06191887|PROCEDURE|Echocardiography|Undergo echocardiography
214940718|NCT06191887|DRUG|Fludarabine|Given IV
214940719|NCT06191887|PROCEDURE|Leukapheresis|Undergo leukapheresis
214940720|NCT06191887|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214940721|NCT06191887|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214940722|NCT06161025|DRUG|R-DXd|R-DXd will be administered as an intravenously (IV) infusion
214940723|NCT06161025|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion
214940724|NCT06161025|DRUG|Paclitaxel|Paclitaxel will be administered as an IV infusion
214940725|NCT06161025|DRUG|Topotecan|Topotecan will be administered as an IV infusion
214940726|NCT06161025|DRUG|PLD|PLD will be administered as an IV infusion
214940727|NCT05077384|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
214940728|NCT04569240|DEVICE|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor will be applied to the upper outer arm before cardiovascular surgery. Data will be collected for 10 days or upon discharge from the ICU.
214940729|NCT02785848|OTHER|Interviews and Surveys|The investigators will perform semi-structured interviews and surveys on this cohort
214940730|NCT06484335|BIOLOGICAL|VRC07-523LS|VRC07-523LS (VRC-HIVMAB075-00-AB) is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site
214940731|NCT06484335|BIOLOGICAL|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region.
214940732|NCT06484335|BIOLOGICAL|ChAdOx1.tHIVconsv1|ChAdOx1.tHIVconsv1 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv1.
214338519|NCT03109834|DIETARY_SUPPLEMENT|Meal replacement (MR)|"MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
214338520|NCT03109834|OTHER|Control (C)|"During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
214486431|NCT06777225|OTHER|scale|The patient received standard nursing care and the scale was applied after the intervention. The 21-question inventory developed by Dr. Aaron T. Beck was used. The reliability and validity of the Beck Depression Inventory (BDI), which is used to measure the severity of depression, was performed in our country by N. Hisli in 1989. (Cronbach's alpha value was calculated as 0.85). Each question takes a value between 0-3 points. When evaluating the results; 0-10 points are normal; 11-16 points are mild mood disorder; 17-20 points are borderline clinical depression; 21-30 points are moderate depression; 31-40 points are severe depression and over 40 points are very severe depression (Çiçekçe et al, 2023).
214486432|NCT06777225|OTHER|scala|The scale was developed by Rhodes and McDaniel (1999), and its Turkish validity and reliability were carried out by Fatma Genç and Mehtap Tan. The scale, which evaluates the number and severity of nausea-vomiting-retching episodes in the last 24 hours, consists of eight items. The scale has three sub-dimensions: Symptom Experience, Symptom Formation, and Symptom Distress. The responses to the items on the five-point Likert-type scale are scored as 0 = minimum 22 distress level, 4 = maximum distress level. When evaluating the scores, items 1, 3, 6, and 7 are reversed. The highest score that can be obtained from the scale is 32, and higher scores mean that nausea-vomiting symptoms have increased in patients (Odabaşı et al, 2021).
214940733|NCT06484335|BIOLOGICAL|ChAdOx1.HIVconsv62|ChAdOx1.HIVconsv62 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv62.
214940734|NCT06484335|BIOLOGICAL|MVA.tHIVconsv4|MVA.tHIVconsv4 is a recombinant, non-replicating Modified Vaccinia Ankara (MVA) virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated tHIVconsv4.
214940735|NCT06484335|BIOLOGICAL|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine.
214940736|NCT06484335|BIOLOGICAL|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic
214940737|NCT06484335|OTHER|Placebo|Normal saline (0.9% sodium chloride for injection) will be used as a placebo.
214940738|NCT05111392|BIOLOGICAL|Placebo|Ingestion of one (1) liter of beverage with observation for 2 h
214940739|NCT05111392|BIOLOGICAL|Oral Rehydration Solution 1|Ingestion of one (1) liter of beverage with observation for 2 h
214940740|NCT05111392|BIOLOGICAL|Oral Rehydration Solution 2|Ingestion of one (1) liter of beverage with observation for 2 h
214940741|NCT02849392|OTHER|Pistachio added 20% of kcals to diet|Pistachio added 20% of kcals to diet
214940742|NCT04529304|DEVICE|Bilateral Bispectral Index and EEG|"raw-EEG and spectrographic EEG-visualization based on the Medtronic Device Bilateral BiSpectral Index"
214940743|NCT01920256|OTHER|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
214940744|NCT01920256|OTHER|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
214940745|NCT04298255|OTHER|Round Spermatid Injection (ROSI)|In Vitro Fertilization using Round Spermatid Injection (ROSI)
214940746|NCT04298255|OTHER|Half ROSI-half Sperm Donor Fertilization|Half ROSI-half Sperm Donor Fertilization
214940747|NCT06156137|OTHER|Glucose variability|A retrospective cohort study was conducted in hospitalized T2DM patients with NCP who were discharged or died. Clinical data and blood glucose variability parameters were collected by computer blood glucose monitoring technology (CGM). Time in range (TIR), time above target range (TAR), time below target range (TBR), mean amplitude of glycemic excursions (MAGE), absolute mean daily difference (MODD) and other indicators were used.
214940748|NCT01733485|DRUG|Aspirin|500 mg/8 h for 5 days
214940749|NCT01733485|DRUG|Indomethacin|25 mg/8 h for 5 days
214940750|NCT00850096|OTHER|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
215074190|NCT02063867|DRUG|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
215074191|NCT04700657|DIAGNOSTIC_TEST|corneal sensation test|Thorough ocular surface study including corneal sensation test in the GVHD group, comparing to the normal control group
215074192|NCT02572505|DRUG|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
215074193|NCT05463718|DEVICE|Virtual Reality|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
215074194|NCT06179134|BEHAVIORAL|Goal Management Training|"The main objective of GMT intervention are to train individuals to periodically STOP what they are doing, attend to task goals, evaluate their performance and monitor or check outcomes as they proceed (Levine \& Stamenova, 2017)."
214676147|NCT02795598|PROCEDURE|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
214676148|NCT05308095|OTHER|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Initially, a euglycaemic state (5.0 - 8.0 mmol/L) is established and blood glucose is then declined to hypoglycaemia (3.0 - 3.5 mmol/L) by administering insulin. Thereafter, blood glucose is raised again to euglycaemia (5.0 - 8.0mmol/L). During the procedure, driving data is recorded. Additionally, eye movement, head pose, facial expression, heart rate, skin conductance, and CGM values are recorded throughout the glycemic trajectory. Participants are blinded to the blood glucose values during the procedure.
214940751|NCT00850096|DRUG|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
214940752|NCT01323036|DIETARY_SUPPLEMENT|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
214676149|NCT06510465|DRUG|utidelone|utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；
214676150|NCT06510465|DRUG|Cisplatin|cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.
214676151|NCT06510465|DRUG|Trastuzumab|Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d
214676152|NCT06510465|DRUG|Pertuzumab|Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase
214676153|NCT00939172|DRUG|TTP607|3.3 mg/m\^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
215074195|NCT01335724|DRUG|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
215074196|NCT01335724|DRUG|Placebo gel|Placebo gel
215074197|NCT00156988|DRUG|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
214676154|NCT06135818|DIAGNOSTIC_TEST|IRISA-TB|ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.
214676155|NCT00317070|DRUG|dimethyl sulfoxide|intravesical installation 50 ml
214338521|NCT03109834|DIETARY_SUPPLEMENT|Verum|"Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)"
214940753|NCT01323036|DIETARY_SUPPLEMENT|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
214940754|NCT06665971|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dosage form: Subcutaneous injection Dosage: 300 mg/ 2ml Dosage frequency: Once a week Duration: 12 weeks
215074198|NCT04300361|GENETIC|Sequencing of DPYD gene|The DPYD gene of non-Western patients will be sequenced to identify DPYD variants that are possibly associated with an increased risk of developing severe fluoropyrimidine-related toxicity.
215074199|NCT03922347|DIAGNOSTIC_TEST|Screening program including 2 consecutive tests|visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)
215074200|NCT03922347|DIAGNOSTIC_TEST|Screening program with mobile health|Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)
215074201|NCT00665054|DRUG|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
215074202|NCT00665054|DRUG|Placebo|Matching placebo tablets orally prior to sexual activity
215074203|NCT02918461|BEHAVIORAL|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
214338522|NCT03109834|OTHER|Placebo|"Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)"
215074204|NCT06412705|PROCEDURE|Tooth extraction, guided bone regeneration and dental implant|The arm received tooth extraction and contextual guided bone regeneration. After 4 months, a dental implant was inserted.
215074205|NCT03494530|DRUG|Edoxaban 60 MG|Anticoagulant used to treat atrial fibrillation
215074206|NCT03494530|DRUG|Edoxaban 30 mg|Anticoagulant used to treat atrial fibrillation
215074207|NCT04376684|BIOLOGICAL|Otilimab|Otilimab will be administered once via IV route.
215074208|NCT04376684|BIOLOGICAL|Placebo 1|Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
215074209|NCT04376684|BIOLOGICAL|Placebo 2|Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
215074210|NCT04376684|DRUG|Standard of care|All participants will receive standard of care as per institutional protocol.
214940755|NCT05161078|DEVICE|CARPEDIEM|CARPEDIEM treatment as per local standard of care
214940756|NCT01371877|DRUG|High Dose Vitamin D3|Vitamin D 4000 IU per day for 3 months
214676156|NCT00317070|DRUG|IC Cocktail|"* Heparin 10,000 units~* Gentamicin 80 mg~* Hydrocortisone sodium succinate (Solucortef) 100 mg~* Lidocaine hydrochloride 1% 10 ml~* Sodium Bicarbonate 8.4% 5 ml"
214676157|NCT02928237|DEVICE|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
214676158|NCT05938881|PROCEDURE|self-cut mesh procedure|transvaginal mesh procedure using self-cut mesh
214940757|NCT01371877|DRUG|Low Dose Vitamin D3|Vitamin D 600 IU per day
214940758|NCT00553982|PROCEDURE|Patellar component|Resurfacing with onlay technique
214940759|NCT00553982|PROCEDURE|No patellar component|Trimming of osteophytes when appropriate
214940760|NCT06294665|DRUG|Pericapsular Nerve Group (PENG) Block|The PENG block will be performed ,the patient is placed in the supine position , the procedural leg is slightly abducted, the curvilinear low-frequency ultrasound probe will be placed over the line parallel to the inguinal ligament. It will subsequently rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly. Following negative aspiration, by one of the two syringes each one has a serial number corresponding to each group.
214940761|NCT05024526|DRUG|edaravone dexborneol or edaravone|Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.
214940762|NCT00869557|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
214676159|NCT05938881|PROCEDURE|mesh-kit procedure|transvaginal mesh procedure using mesh-kit
215074211|NCT05231577|PROCEDURE|7.5fr ultra-fine ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 1 patients used 7.5fr ultra-fine ureteroscopy
215074212|NCT05231577|PROCEDURE|9.2fr Ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 2 patients used 9.2fr Ureteroscopy
215074213|NCT05179603|DRUG|THOR-707|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
215074214|NCT05179603|DRUG|Pembrolizumab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
214940763|NCT00869557|DRUG|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
214940764|NCT01625208|PROCEDURE|Combined nerve block|Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
214940765|NCT01625208|PROCEDURE|Supraclavicular block|Standard supraclavicular brachial plexus block
214940766|NCT04498416|DIAGNOSTIC_TEST|Quantitative and qualitative assessments of mental health|Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale
214940767|NCT03246841|OTHER|Genetic testing|A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
214940768|NCT06091592|OTHER|Serum autotaxın levels|Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.
214940769|NCT02666638|OTHER|Control Volunteers|MRI on up to a 7T scanner without contrast.
214940770|NCT02666638|OTHER|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
215074215|NCT02244840|DEVICE|Electronic bidet|commercial electronic bidet
215074216|NCT02244840|DEVICE|Sitz bath|Conventional sitz bath
215074217|NCT02950155|DRUG|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
215074218|NCT02950155|DRUG|Sodium Chloride solution|A single infusion of Placebo/Sham.
214940771|NCT03013608|PROCEDURE|Simple relocation of the nail plate in nailbed injuries in paediatric population|Repositioning the nail bed without sutures
214940772|NCT04842799|OTHER|Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform|"Participants will receive a link to the digital pre-test information. This will consist of text covering: Genetics and cancer risk; Genetics testing; What will happen if your test is positive; What will happen if your test is negative; Implications for insurance.~Where relevant, parts of the text will be linked through to additional information, such as insurance advice from the Association of British Insurers. Participants will be able to call a genetic counsellor on the hotline during weekday office hours, should they have any questions or require further information."
214338523|NCT00710333|DRUG|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
214338524|NCT00710333|DRUG|placebo|placebo
214338525|NCT01394861|DEVICE|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
214338526|NCT02504645|DRUG|IPP-201101|
214940773|NCT04842799|OTHER|Digital Delivery of Genetic Test Results via the BRCA-DIRECT Platform|Participants will receive a digital message that their results are available. When they click this, they will receive digital notification of their negative (normal) result in short form. Full details will be provided in an individualised letter.
214940774|NCT05940077|BEHAVIORAL|Exercise|Community-based exercise involving non-contact boxing and individualized balance training
214940775|NCT06059729|DEVICE|Al-Lisaan|Al-Lisaan is a digital application for the self assessment and management of adult stutters.
214940776|NCT02683148|DRUG|DHEA|
214940777|NCT02683148|OTHER|FACT-67 validated survey|"* Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~* 7 questions with answers ranging from 0=Not At All to 4 = Very Much."
214940778|NCT00097305|BEHAVIORAL|Body-Oriented Therapy|
214940779|NCT00097305|BEHAVIORAL|Standardized Massage Therapy|
214940780|NCT03218605|OTHER|physical activity|Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
214940781|NCT01580345|DIETARY_SUPPLEMENT|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.
214338527|NCT02504645|DRUG|Placebo|
214338528|NCT02504645|OTHER|Standard of Care|
214940782|NCT01580345|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.
214940783|NCT05974956|OTHER|Mastitis care teaching protocol|It was developed by the authors based on previous similar studies, articles and library resources. It was introduced to the study group in the form of face to face sessions plus a hand out copy. It consisted of three parts; (1): Theoretical part about mastitis (definition, types, clinical manifestation, possible causes, diagnosis and management). (2):Self-care practices, and (3):Recommendations regarding dietary measures, rest, medication and follow up.
214940784|NCT02532114|DRUG|Enzalutamide|Given PO
214940785|NCT02532114|OTHER|Laboratory Biomarker Analysis|Correlative studies
214940786|NCT02532114|DRUG|Niclosamide|Given PO
214338529|NCT00991601|PROCEDURE|FNAC (fine needle aspiration cytology)|UL guided biopsy
214338530|NCT00338351|BIOLOGICAL|Pneumococcal (vaccine)|
214338531|NCT03462667|BEHAVIORAL|Stoma Boot Camp|Educational session designed to prepare people for living life with a stoma.
214338532|NCT03462667|OTHER|Standard of Care|Patients receive normal pre-surgery standard of care.
214338533|NCT05153018|OTHER|Blood collection|a 4-mL blood sample collected in a dry tube
214338534|NCT00530023|DEVICE|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
214338535|NCT00359762|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
214338536|NCT00359762|DRUG|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
214338537|NCT02829034|DRUG|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
214338538|NCT02829034|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks
214338539|NCT01141361|PROCEDURE|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
214338540|NCT05158062|BIOLOGICAL|pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
214338541|NCT05158062|DRUG|olaparib|olaparib 300 mg twice daily (BID) during maintenance period
214338542|NCT05158062|BIOLOGICAL|bevacizumab|bevacizumab 15 mg/kg Q3W
214940787|NCT02532114|OTHER|Pharmacological Study|Correlative studies
214940788|NCT06009809|DIAGNOSTIC_TEST|transesophageal echocardiogram|To measure mean blood velocity at the level of the right renal and superior mesenteric artery
214940789|NCT05450185|PROCEDURE|Critically ill patients with continuous renal replacement therapy|Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.
214940790|NCT00181649|DRUG|Recombinant human prolactin|
214940791|NCT05105516|PROCEDURE|Ablation|Ablation of ectopic foci causing PVCs
214940792|NCT03065036|DRUG|prestudy topical glaucoma medications|Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
214940793|NCT01967095|DRUG|erlotinib|Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 \& D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 \& D2, \& will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 \& 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 \& 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
214940794|NCT04424771|BEHAVIORAL|Maslach Burnout Inventory (MBI)|The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
214940795|NCT00840593|PROCEDURE|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
215074219|NCT00964340|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
214940796|NCT00840593|PROCEDURE|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
214940797|NCT04027075|BEHAVIORAL|Qlarity app users|Use of the Qlarity app involves completing 12 modules and 12 practice sessions over 30 days.
214940798|NCT00583375|DEVICE|Augment® Bone Graft|Augment® Bone Graft
214940799|NCT00583375|PROCEDURE|Standard of Care|Autologous Bone Graft
214940800|NCT05411094|PROCEDURE|Biopsy Procedure|Undergo biopsy
214676160|NCT03494725|DIETARY_SUPPLEMENT|Lpc-37|Lacticaseibacillus paracasei Lpc-37 at 1.75 x 10\^10 colony forming units (CFU) per day, microcrystalline cellulose, magnesium stearate, silicon dioxide
214676161|NCT03494725|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, magnesium stearate, silicon dioxide
214676162|NCT03267095|BEHAVIORAL|music therapy sessions .|In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
214676163|NCT00337298|DRUG|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
214940801|NCT05411094|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal samples
214940802|NCT05411094|PROCEDURE|Computed Tomography|Undergo CT scan
214940803|NCT05411094|BIOLOGICAL|Durvalumab|Given IV
214940804|NCT05411094|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214940805|NCT05411094|DRUG|Olaparib|Given PO
214940806|NCT06073275|DIETARY_SUPPLEMENT|Beetroot juice ingestion|Beetroot juice ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
214940807|NCT06073275|DIETARY_SUPPLEMENT|Placebo ingestion|Placebo ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
214940808|NCT05356975|BEHAVIORAL|Superset|"A strength circuit training will be performed in a supersets fashion. Three strength circuit training in three blocks.~1. One leg squat, side plank, and push up.~2. Deadlift, lumbar extension stretch, and row.~3. Glute bridge, crunches, and front raise."
214940809|NCT05356975|BEHAVIORAL|Concurrent|Six resistance exercises in a traditional fashion: three exercises for the lower body (one leg squat, deadlift, and glute bridge). Three exercises for the upper body (push up, row, and front raise). And three aerobic exercises (floor tap squat, jumping jacks, and skaters).
214940810|NCT05914675|DRUG|Letermovir|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen would start between +7\~+14d after transplantation. The total duration of dosing was approximately 100 days or 14 weeks.
214940811|NCT06450639|DRUG|Satralizumab|Satralizumab will be administered SC in the abdominal or femoral region on Day 1, Weeks 2 and 4 (loading doses) and then Q4W from Weeks 8 to 104 (maintenance doses) until the study completion visit.
214940812|NCT00586287|OTHER|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
214940813|NCT00586287|OTHER|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
214940814|NCT00586287|DRUG|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
214940815|NCT04306887|DRUG|TQ-B3101 capsule|Escalating doses starting at 200 mg bid.
214940816|NCT00956631|PROCEDURE|Interlaminar Decompression|The MILD® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompression.
214940817|NCT02772276|DRUG|MB-102-- single dose of 4 µmol/kg|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
214940818|NCT02772276|DRUG|MB-102-- single dose of 130 mg|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
214940819|NCT02772276|DRUG|MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
214940820|NCT02772276|DRUG|MB-102-- two doses of 130 mg 24 hours apart|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
214940821|NCT02772276|DRUG|Iohexol|5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
214940822|NCT02772276|DEVICE|QuantumLeap|Optical Renal Function Monitor (ORFM)
214940823|NCT02772276|DEVICE|Radiance|Optical Renal Function Monitor (ORFM)
214940824|NCT02772276|DEVICE|Brilliance (1 or 2 sensors)|Optical Renal Function Monitor (ORFM)
214940825|NCT02772276|DEVICE|Brilliance (2-part sensor)|Optical Renal Function Monitor (ORFM)
214940826|NCT06525662|PROCEDURE|Endotracheal intubation using an endotracheal tube with a 30 degree straight to cuff shape|Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
214940827|NCT06525662|PROCEDURE|Endotracheal intubation using an endotracheal tube with an arcuate cuff shape|Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
214940828|NCT00455520|DRUG|CG5503|100, 150, 200, 250 mg twice daily given for up to 15 weeks
214940829|NCT00455520|DRUG|placebo|matching placebo twice daily for 12 weeks
214940830|NCT00109876|PROCEDURE|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
214940831|NCT00791830|DRUG|Irbesartan|Tablets, 300 mg \* 1 daily, 1 year
214940832|NCT00791830|DRUG|Placebo matching irbesartan 150 mg|Tablets, 300 mg \* 1 daily, 1 year
214940833|NCT05591924|PROCEDURE|Phelebotomy|Collection of 10mL of heparin anticoagulated blood, 10mL of EDTA anticoagulated blood, and 3mL of blood in a PAX gene tube
214940834|NCT05591924|PROCEDURE|Broncheoalveolar Lavage|Bronchioalveolar lavage fluid (BALF) samples will be obtained from participants who are mechanically ventilated, and a bronchoscopy is indicated as part of routine clinical care. The BALF will be collected by a qualified ICU physician using standard clinical practice. Briefly, patients will receive appropriate sedation and analgesia, a flexible video-bronchoscope will be inserted into the patient's airway, and bronchial segments will be identified. The bronchoscope will be wedged in the most appropriate lung segment and 40-100mL of sterile normal saline (NS) as clinically indicated, will be injected into the bronchoscope port with using a 50mL syringe. Next, the instilled NS (i.e.: lavage fluid) will be collected in a sterile container using gentle suction. The BALF will then be partitioned and sent to clinical laboratories, and the remaining BALF (10-20mL) will be used in the ESTABLISH research study.
214940835|NCT05591924|PROCEDURE|Tracheal Aspirate|Tracheal Aspirate (TA) will be obtained from participants who have an endotracheal tube or a tracheostomy in situ at the time of ICU admission through out the ICU admission on the study days, as long as distal airway access is available.
214940836|NCT05591924|PROCEDURE|Rectal Swab|A Rectal will be obtained at the time of ICU admission and on all study days during the ICU admission
214940837|NCT06214702|DIAGNOSTIC_TEST|ELISA|ELISA estimation of PLGF, sFlt-1 and Serpin C
214940838|NCT03059199|BEHAVIORAL|Single-Arm Feasibility Study|Participants are provided with the HAT TRICK Playbook, a resource manual including weekly healthy eating and physical activity challenges and tracking logs. Each face-to-face session is facilitated by trained research staff, community partners, and health care professionals. Weekly sessions include information on physical activity, healthy eating, and behaviour change techniques (e.g., social support, goal setting, self-monitoring) and include an opportunity to be active/exercise.
214940839|NCT04837599|DEVICE|Discovery TM of Pentax medical on/off in colonoscopy|on the monitor artificial integlligence Discovery can be switched on or off.
214940840|NCT00919906|DEVICE|My Scrivener(R)|Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
214940841|NCT01477294|DRUG|Caffeine|5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
214940842|NCT01477294|DRUG|Placebo|Malt dextrin (5 mg/kg body mass) twice a day during 4 days
214940843|NCT01752894|DEVICE|Angio-guided PCI with EES or BES|Angio-guided intervention
214940844|NCT01752894|DEVICE|OCT-guided PCI with EES or BES|OCT-guided intervention
214940845|NCT01752894|DEVICE|PCI with BES under angio-guide or OCT guide|biolimus A9-eluting stent.
214338543|NCT05158062|DRUG|carboplatin|carboplatin AUC=5 or 6 Q3W during treatment period
214338544|NCT05158062|DRUG|paclitaxel|paclitaxel 175 mg/m2 Q3W during treatment period
214338545|NCT05158062|DRUG|docetaxel|docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
214940846|NCT01752894|DEVICE|PCI with EES under angio-guide or OCT guide|everolimus eluting stent.
214940847|NCT01752894|DRUG|Keep DAPT|maintain DAPT for 12 months according to level of uncovered strut (\>6%) at 3months OCT follow up after stent implantation.
214940848|NCT01752894|DRUG|Discontinue DAPT|discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
214940849|NCT02248974|OTHER|LVAD Decision Aid|"Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE)."
214940850|NCT03138694|OTHER|BHCG monitoring|Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
214940851|NCT06498089|DRUG|Prednisone|This drug will be used in both arms. Patients' initial daily prednisone dose will be calculated according to their weights (0.6mg \* weight(kg), maximum 50mg/day), and then tapered gradually during the study course.
214940852|NCT06498089|DRUG|Methotrexate|This drug will be used in the traditional arm. A dose of 15mg per week will be used.
214940853|NCT06498089|DRUG|Tocilizumab|This drug will be used in the precise treatment arm. For patients in constitutional type a dose (8mg/kg weight) will be used every 2 weeks (iv drip) for 12 weeks, then a dose (8mg/kg weight) will be used every 4 weeks (iv drip). For patients in vascular inflammation type, a dose (8mg/kg weight) will be used every 4 weeks (iv drip).
214940854|NCT06498089|DRUG|Tofacitinib|This drug will be used in the precise treatment arm. A sustained release tablet will be used (11mg per day).
214940855|NCT06498089|DRUG|Adalimumab|This drug will be used in the precise treatment arm. A dose of 40mg (ih) will used every 2 weeks.
214940856|NCT01122940|DRUG|Epamin: Reference Drug|Single dose of 75 mg (10 ml in suspension) of Epamin
214940857|NCT01122940|DRUG|Phenytoin: Study Drug|Single dose of 75 mg (10 ml in suspension) of Phenytoin
214940858|NCT02848989|OTHER|Qigong Mind-Body Exercise|An exercise program that involves gentle movements combined with breathing/relaxation techniques
214940859|NCT00199329|DRUG|ondansetron adding in PCA|
214940860|NCT02887222|DRUG|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
214940861|NCT05859022|OTHER|Roux-en-Y gastric By-pass (RYGB) surgery|RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J\& company.
214338546|NCT02652780|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
214338547|NCT02652780|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
214338548|NCT02162628|DEVICE|Exair Prolapse Repair System|
214940862|NCT05859022|OTHER|Bariatric Arterial Embolization (BAE) procedure|use of Embosphere Microspheres (EM) that are designed to offer controlled, target embolization.
214940863|NCT05143216|OTHER|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Canula)|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Cannula)
214940864|NCT05143216|OTHER|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)
214676164|NCT00337298|DRUG|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
214676165|NCT05870501|DRUG|Ketamine|0.5mg/kg IV infusion
214676166|NCT05870501|DRUG|Midazolam|0.045mg/kg IV infusion
214676167|NCT03285880|BEHAVIORAL|Napping|Children nap during the nap opportunity
214676168|NCT06672380|OTHER|Remote Physical Exercise Program for Breast Cancer Survivors|Structured and remotely guided physical exercise program The participants in the intervention group took part in a remote physical exercise program for 12 weeks. The telepresence sessions, conducted three times a week via Google Meet®, lasted 60 minutes and consisted of three phases: warm-up (10 minutes), multi-joint functional exercises (40 minutes) and stretching (10 minutes). The exercises were progressively intensified over the weeks, using the Borg scale to monitor effort. The intensity was adjusted in three cycles: in the first 4 weeks (60 seconds of exercise/90 seconds of rest), in weeks 5 to 8 (75 seconds of exercise/60 seconds of rest) and in weeks 9 to 12 (90 seconds of exercise/30 seconds of rest).
214676169|NCT06672380|OTHER|Initial Consultation and Exercise Guidance via Ebook for Women Surviving Breast Cance|Participants in the Ebook group received an illustrated manual containing detailed guidelines for practicing simple physical exercises at home, using only their body weight. The manual suggested a frequency of 3 to 5 times a week, with 30 to 60 minutes of activities such as stretching, squats and exercises for the upper and lower limbs. The participants were encouraged to follow these guidelines and, 30 days after receiving the ebook, an additional stimulus was sent by text message, reinforcing the importance of following the protocol.
214676170|NCT06672380|OTHER|Initial Incentive for Eating Habits in Women Surviving Breast Cancer|The control group only received general guidance on the importance of regular physical activity. The recommendations followed health guidelines, suggesting between 150 and 300 minutes of moderate-intensity physical activity per week.
214338549|NCT02162628|PROCEDURE|Total Native Tissue Repair|
214338550|NCT04049994|DRUG|Uro-Vaxom|Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
214338551|NCT04049994|DRUG|Placebo oral tablet|Placebo oral tablet
214338552|NCT05029648|OTHER|Cohort|Cohort
214338553|NCT03211936|PROCEDURE|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
214338554|NCT03211936|DEVICE|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
214486433|NCT06778421|PROCEDURE|Intramuscular injection|Injection performed using method for aesthetic facial rejuvenation procedure with neuromuscular chemodenervation agents
214486434|NCT06778421|DRUG|OnabotulinumtoxinA (Botox®) Injections|"Injection of 64 units of active drug at a ratio of 4 units to 0.1 mL of sterile, preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only~\- Abbvie/Allergan drug."
214940865|NCT03511716|DEVICE|HRT Mitral Bridge Mitral Valve Repair|Surgical mitral valve implant intended to reduce mitral regurgitation by direct reduction of the septo-lateral mitral annular diameter, promoting early coaptation of the valve leaflets and restraining the leaflets below the intra-annular plane
214676171|NCT01111981|DRUG|Clobetasol Propionate 0.05% Emollient Foam|Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
214940866|NCT03448939|DRUG|S5G4T-1|Once a day topical cream
215074220|NCT00964340|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
214676172|NCT04983940|DRUG|Jatenzo|237 mg soft gel capsule taken twice a day by mouth with food.
214940867|NCT03448939|DRUG|S5G4T-2|Once a day topical cream
214940868|NCT03595358|DIAGNOSTIC_TEST|Ellume Home Flu Test|The Ellume Home Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples.
214940869|NCT03595358|DIAGNOSTIC_TEST|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is a rapid in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples.
215074221|NCT06035393|DRUG|HRG2005 inhalation|Drug 1: dose 1; dose 2; dose 3
215074222|NCT06035393|DRUG|Placebo to match HRG2005 inhalation|Drug 2
214338555|NCT03211936|DEVICE|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
214338556|NCT03211936|OTHER|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
214338557|NCT03211936|OTHER|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
214338558|NCT01411189|DRUG|Menthol|20 mL NPO-11 in prefilled syringe
214338559|NCT01172938|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
214338560|NCT01172938|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
214338561|NCT01172938|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
214338562|NCT01172938|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
214338563|NCT00002408|DRUG|Crofelemer|
214338564|NCT00548821|DRUG|Cisplatin|
214338565|NCT04168749|COMBINATION_PRODUCT|Numeta G13|10 days
214338566|NCT00003498|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214940870|NCT03595358|DIAGNOSTIC_TEST|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT\_PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
214940871|NCT03595358|DIAGNOSTIC_TEST|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
214940872|NCT03461016|BEHAVIORAL|Exposure Therapy|"Exposure therapy is a form of behavior therapy that is widely used to treat anxiety disorders, including specific phobia. It involves systematic and repeated confrontation with a feared stimulus. It works by (a) implosive therapy, habituation, in which repeated exposure reduces anxiety over time by a process of extinction; (b) disconfirming fearful predictions; and (c) increasing feelings of self-efficacy and mastery. In vivo exposure \[is\] a type of exposure therapy, generally used for treating individuals with phobias, obsessive compulsive disorder, and other anxiety disorders, in which the client directly experiences anxiety-provoking situations or stimuli in real-world conditions. (VandenBos, 2015)"
214940873|NCT00040235|PROCEDURE|magnesium|
214940874|NCT05525234|DRUG|Thalidomide|Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
214338567|NCT04188041|OTHER|TB Infection ECHO|A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
214940875|NCT05525234|DRUG|Placebo|Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
214940876|NCT02970019|DRUG|K0706|Once a day administration after fast
214940877|NCT02970019|DRUG|Placebo|Once a day administration after fast
214940878|NCT03013764|BEHAVIORAL|normal protein diet|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
214940879|NCT03013764|BEHAVIORAL|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
214940880|NCT01744002|OTHER|Shoulder treatment and neck mobilization|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
214940881|NCT01744002|OTHER|Control|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
214940882|NCT05691764|DRUG|Cyclosporin|Cyclosporin was administered intravenously with the dose of 3 mg/ kg body weight
214940883|NCT05691764|PROCEDURE|remote ischemic preconditioning|Performed by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval
214940884|NCT05691764|DRUG|Placebo|Intravenous placebo
214940885|NCT06380803|OTHER|A educational program|A educational program using cadaver or porcine models for robotic brest surgery
214940886|NCT01733459|DRUG|DLBS3233|1 DLBS3233 capsule 100 mg once daily for 6 months
214940887|NCT01733459|DRUG|Metformin XR|1 Metformin XR caplet 750 mg twice daily for 6 months
214940888|NCT01733459|DRUG|Placebo caplet of Metformin XR|1 placebo caplet of Metformin XR twice daily for 6 months
214338568|NCT00038493|DRUG|Temozolomide and SCH66336|
214338569|NCT03396744|DEVICE|Light|Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
214338570|NCT04823338|BEHAVIORAL|Conectar Jugando Online Program|Online play sessions with modern board and card games guided by the study researchers
214338571|NCT02823925|DRUG|Pamidronate or Zoledronate|
214338572|NCT04575779|DRUG|Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h|To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.
214338573|NCT06534138|BEHAVIORAL|Physical exercise|The CP-exercise group was categorized based on patients' self-reported daily exercise time into four levels: 15 minutes/day, 30 minutes/day, 45 minutes/day, and ≥60 minutes/day. Additionally, resistance exercise and endurance exercise were distinguished based on patients' self-reported exercise modalities, including swimming, jogging, brisk walking, practicing Tai Chi, and dumbbell training.
214338574|NCT05282004|DRUG|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
214940889|NCT01733459|DRUG|Placebo capsule of DLBS3233|1 placebo capsule of DLBS3233 once daily for 6 months
214940890|NCT00504959|DRUG|ranibizumab|
214940891|NCT04575259|DRUG|ANAVEX2-73|Oral capsules
214940892|NCT03039491|BIOLOGICAL|Pneumococcal polysaccharide vaccine 23 valent|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
214940893|NCT03039491|BIOLOGICAL|13 valent conjugated pneumococcal vaccine|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
214940894|NCT02317770|DRUG|Lidocaine Spray|5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
214940895|NCT02317770|DRUG|Nebulized Lidocaine|The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
214338575|NCT04564352|DIETARY_SUPPLEMENT|Adansonia digitata|Juice of AD fruit
214338576|NCT00165724|DRUG|Donepezil Hydrochloride|
214338577|NCT05306106|OTHER|Glucose|Each subject will consume the reference product during visits V1 and V5. A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume the glucose solution. The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
214338578|NCT05306106|OTHER|truffle match|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 221.2 g of truffle match (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
214338579|NCT05306106|OTHER|hazelnut chocolate cookie|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 142.8 g of hazelnut chocolate cookie (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
214347344|NCT02897804|BEHAVIORAL|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214486435|NCT06778421|OTHER|Sodium Chloride|Placebo injection of the same volume of preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only.
214940896|NCT02698644|DRUG|Isoamyl-2-cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
214940897|NCT04812340|OTHER|High intensity circuit training|6 series with 3 minutes rest between the series. each series will consist of 30 seconds each of burpees, skipping, lunges, 1- legged squat, leg levers, and push-ups with 30 seconds rest in between. the volume of exercise will be increased progressively over a period of 8 weeks.
214940898|NCT04812340|OTHER|Low intensity interval training|4 series with 3 minutes rest in between. each series will consist of 10 minutes of jogging and 5 minutes walking with 30 seconds recovery in between. the volume of exercise will be increased progressively over a period of 8 weeks.
214940899|NCT00002644|DRUG|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
214676173|NCT03651999|OTHER|"participation in a workshop: dream workshop animated by a nurse anesthesist"|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; the nurse anesthetist will take care to explain to them the progress of the hospitalization and help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...) ; he can customize his mask and choose the blanket he wants to take; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
214940900|NCT00002644|OTHER|Placebo|Placebo 20Mg Tab
214940901|NCT00140530|DEVICE|Paclitaxel-eluting stent (Taxus)|patients has been implanted the Paclitaxel-eluting stent.
214940902|NCT00140530|DEVICE|Rapamycin-eluting stent|patients has been implanted the Rapamycin-eluting stent.
214940903|NCT03707366|BEHAVIORAL|FHF-T|FHF-T employs mentoring, consisting of relationship development, advocating for and empowering youth, and skill-building activities to promote positive youth development. Mentors meet individually for 2-3 hours per week for 30 weeks with each teen they mentor, in order to engage teens in positive youth development activities and provide skills training in areas including emotion recognition, perspective-taking, problem solving, effective communication, managing anger, healthy coping and resisting peer pressure for deviant activities. Youth also attend group workshops over the course of the program, in which they engage with other participants and mentors in skill-building activities.
214940904|NCT01472965|DRUG|ethanol|70% ethanol catheter lock therapy
214676174|NCT02008929|BIOLOGICAL|MG4101|Ex vivo expanded allogeneic NK cell
214676175|NCT05346952|DRUG|TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection|PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
214676176|NCT03112837|OTHER|Lactobacillus, Bifidobacterium and Enterococcus|3 pills two times a day during the whole treatment
214338580|NCT05306106|OTHER|Paris Brest style eclair|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 277.7 g of Paris Brest style eclair (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
214338581|NCT05306106|OTHER|hazelnut chocolate finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 312.5 g of hazelnut chocolate finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
214940905|NCT01472965|DRUG|heparin-saline placebo|heparin-saline placebo catheter lock therapy
214940906|NCT05995457|OTHER|"Intramuscular injection of Haloperidol decanoate using the Z-track and Airlock techniques"|"Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the Z-track and Airlock techniques"
214940907|NCT05995457|OTHER|Intramuscular injection of Haloperidol decanoate using standard techniques|Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique.
214940908|NCT01897610|DRUG|Immuncell-LC|intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour
214940909|NCT00628095|DRUG|CE-224,535|500 mg po BID
214940910|NCT00628095|DRUG|Placebo|no active ingredient
214940911|NCT05234034|OTHER|online survey|participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.
214676177|NCT06971185|DRUG|Luspatercept|As per product label
215074223|NCT06035393|DRUG|Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 3
215074224|NCT06035393|DRUG|Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 4
215074225|NCT03099174|DRUG|Xentuzumab|Once weekly administrated through one hour intravenous infusion
215074226|NCT03099174|DRUG|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
214486436|NCT06862583|PROCEDURE|surgery|Open heart surgery
214486437|NCT06862583|PROCEDURE|endovascular intervention|Aortic endovascular intervention
214676178|NCT06971185|DRUG|Erythropoiesis-stimulating agent (ESA)|As per product label
214676179|NCT06969417|DRUG|Pregabalin|o Group A will receive Cap Pregabalin 150mg oral OD for 4 weeks
214676180|NCT06969417|DRUG|Lacosamide|o Group B will receive Tab Lacosamide 100mg oral BD for 4 weeks
214676181|NCT05470790|OTHER|patient reported outcome measures|Activity Rating Scale, Knee Stability in Sports/Cutting-Pivoting Ability scale, Knee Injury and Osteoarthritis Outcome Score, Lysholm Knee Score, and International Knee Documentation Committee Subjective Knee Form.
214676182|NCT05852171|DRUG|Baricitinib|Baricitinib administered orally
214940912|NCT02555124|DRUG|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
214940913|NCT02555124|DRUG|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
214940914|NCT02555124|DRUG|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
214940915|NCT02555124|DRUG|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
214940916|NCT00189319|DRUG|Flecainide controlled release|
214940917|NCT01576003|DRUG|Glutamine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
214940918|NCT01576003|DIETARY_SUPPLEMENT|L-alanine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
214940919|NCT04352218|DEVICE|"PTA + Stenting using Petalo stent"|PTA and Petalo's Stenting are a minimally invasive endovascular procedures, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
214940920|NCT04352218|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|PTA is a minimally invasive endovascular procedure, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
215074227|NCT03099174|DRUG|Letrozole|Once a day
215074228|NCT03099174|DRUG|Anastrozole|Once a day
214338582|NCT05306106|OTHER|lemon finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 263.1 g of lemon finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
214338583|NCT05306106|OTHER|elderflower madeleine|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 294.1 g of elderflower madeleine (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
214940921|NCT06721221|DEVICE|Point-by-point PVI with the QDot Micro catheter in QMODE+ setting with the Svtag software|PVI will be performed via femoral access after transseptal puncture, guided by fluoroscopy pressure monitoring, intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE). A fast anatomical left atrial map will be created; then, point-by-point PVI will be performed with QDot Micro catheter in QMODE plus with the Svtag software. Inter-tag distance should be ≤ 6 mm on the posterior wall and ≤ 4 mm on the anterior wall. All applications' duration should be 4 seconds. After creating the isolation circle, the presence or absence of first-pass isolation will be assessed on each side by the presence of entrance block. If PVI is complete, this is defined as first-pass isolation. If PVI is not complete at this point, touch-up lesions will be delivered to reach the isolation of all pulmonary veins. After that, acute PV reconnections will be evaluated during a 20 minutes waiting period.
214940922|NCT03235115|DEVICE|Methafilcon A IV|Contact Lens
214940923|NCT03235115|DEVICE|Ocufilcon B|Contact Lens
214940924|NCT03235115|DEVICE|Omafilcon A|Contact Lens
214940925|NCT05654506|DRUG|Daratumumab|1800 mg subcutaneous (SC) injection (total amount 15 mL) into the right/left abdominal area once weekly for 8 doses followed by once every 2 weeks for an additional 8 doses
214940926|NCT02271711|OTHER|Laboratory Biomarker Analysis|Correlative studies
214940927|NCT02271711|BIOLOGICAL|Natural Killer Cell Therapy|Given autologous ex-vivo expanded NK cells IV
214940928|NCT00771511|DRUG|capsaicin|capsaicin cream 0.1% 10 ml applied to cervix
214676183|NCT00514449|DRUG|Valacyclovir|1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
214676184|NCT00514449|DRUG|Placebo|2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
214676185|NCT05117710|DRUG|Ebselen|Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).
214676186|NCT05117710|DRUG|Placebo|Matched placebo capsules
214676187|NCT05227651|DRUG|AK104|IV infusion,Specified dose on specified days
214676188|NCT04116502|DRUG|Ruxolitinib|10mg of ruxolitinib twice daily (bd)
214676189|NCT04116502|DRUG|Hydroxycarbamide|Via standard hospital mechanisms
214676190|NCT04116502|DRUG|Interferon-Alpha|Any formulation, via standard hospital mechanisms
214676191|NCT04353947|DIAGNOSTIC_TEST|Mini Cognitive Examination (MCE)|This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.
214676192|NCT04353947|DIAGNOSTIC_TEST|Beck Depression Inventory-II (BDI-II)|This test evaluates the absence or presence of depressive symptoms.
214676193|NCT04353947|DIAGNOSTIC_TEST|Global Deterioration Scale (GDS)|This scale measures the level of deterioration of the subject.
214676194|NCT04353947|DIAGNOSTIC_TEST|Memory alteration test (M@T)|In this test different memory subtypes are evaluated.
214940929|NCT00771511|DRUG|Placebo|Only lidocaine gel will be appled to the cervix
214940930|NCT05209711|PROCEDURE|Femoral nerve block under ultrasound control with a electrostimulator peripheral nerves 7.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (7.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
215074229|NCT03099174|DRUG|Fulvestrant|Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock
215074230|NCT03099174|DRUG|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
215074231|NCT04173260|DRUG|Deutetrabenazine 6 MG|Increasing doses of Deutetrabenazine
215074232|NCT02308163|DRUG|Peficitinib|oral
215074233|NCT02308163|DRUG|Placebo|oral
215074234|NCT02308163|BIOLOGICAL|Etanercept|subcutaneous injection
215074235|NCT05517980|DRUG|KP104|Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
214676195|NCT04353947|DIAGNOSTIC_TEST|Spanish-Complutense Verbal Learning Test (TAVEC)|This test is used to assess immediate memory, deferred memory and learning ability.
214676196|NCT04353947|DIAGNOSTIC_TEST|Barcelona test (BT)|"This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category animals in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter p in 3 minutes."
214676197|NCT04353947|DIAGNOSTIC_TEST|Rey-Osterrieth Complex Figure Test (ROCFT)|In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated.
214338584|NCT04808609|DEVICE|Lumme mobile phone application|Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
214676198|NCT04353947|DIAGNOSTIC_TEST|Frontal assessment battery (FAB)|This test is a composite tool for assessing executive functions related to the frontal lobe.
214338585|NCT04808609|BEHAVIORAL|Standard of Care|Smoking cessation counseling and nicotine replacement therapy
214338586|NCT06571357|BEHAVIORAL|Pranic Healing|The Pranic Healing intervention will be applied according to the advanced protocol by Master Choa Kok Sui, involving seven key techniques: sensitizing the hands, scanning the aura, cleansing the aura, increasing receptivity, energizing with prana, stabilizing the projected prana, and releasing. The intervention will take place in three stages: 5 minutes before, during, and 5 minutes after venipuncture.
214676199|NCT04353947|DIAGNOSTIC_TEST|Positive and Negative Affect Scale (PANAS)|It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale).
214676200|NCT04353947|DIAGNOSTIC_TEST|Auto-Assessment Manikins (SAM)|It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
214676201|NCT03464097|DRUG|Ozanimod|Specified dose on specified days
214676202|NCT03464097|OTHER|Placebo|Specified dose on specified days
214338587|NCT02202135|DRUG|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
214338588|NCT02202135|DRUG|Vancomycin|IV vancomycin 15mg/kg every 12 hours
214338589|NCT02202135|DRUG|Aztreonam|IV aztreonam 1 g every 8 hours
214338590|NCT01554046|DRUG|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~* Ages 6-12, up to 25Kg - 35mg maximum per day.~* Ages 6-12, above 25Kg - 50mg maximum per day.~* Ages 12-65, above 25Kg - 80mg maximum per day."
214338591|NCT00600964|DRUG|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
214338592|NCT00600964|DRUG|GX15-070MS|GX15-070MS at various doses and schedules
214940931|NCT05209711|PROCEDURE|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (7.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
214940932|NCT01928797|DEVICE|Cardiac output monitor data|The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
214940933|NCT02933905|DRUG|Intravitreal Ranibizumab injection|
214940934|NCT00006305|PROCEDURE|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
214940935|NCT00006305|PROCEDURE|Coronary Artery Bypass|Coronary Artery Bypass
214940936|NCT00006305|DRUG|Biguanides, thiazolidinediones|Biguanides, thiazolidinediones
214940937|NCT00006305|DRUG|Insulin, sulfonylurea|Insulin, sulfonylurea
214338593|NCT03649126|BEHAVIORAL|Implementation tools|Implementation tools developed by experts in order to increase the use of SSR in pathology
214338594|NCT02256111|DRUG|Enzalutamide|
214338595|NCT02256111|DRUG|Androgen deprivation therapy|
214338596|NCT02256111|BEHAVIORAL|Supervised exercise training|
214338597|NCT01993719|DRUG|Aldesleukin|720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
214338598|NCT01993719|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days
214338599|NCT01993719|DRUG|Fludarabine|30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.
214338600|NCT01993719|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV)
214940938|NCT00006305|DRUG|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
214940939|NCT00648505|DRUG|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
214940940|NCT00648505|DRUG|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
214940941|NCT05207904|DRUG|Tislelizumab, paclitaxel, Carboplatin|Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
214940942|NCT01569750|DRUG|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
214940943|NCT01569750|DRUG|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
214676203|NCT05564624|OTHER|Fasting mimicking diet (FMD)|The ProLon(TM) Fasting Mimicking Diet regimen is a meal replacement plan that mimics water only fasting. It consists of 100% natural ingredients, which are generally regarded as safe (GRAS). It is comprised of bars, soups, and beverages aiming to achieve consistent and effective short-term calorie restriction, while providing adequate micronutrients. The very low protein and very low sugar content are essential characteristics of the diet. Complex carbohydrates and polyunsaturated fatty acids are its main components.
214676204|NCT04916197|DRUG|Dexmedetomidine prolonged sedation|Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
214676205|NCT04916197|DRUG|0.9% saline|An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
214676206|NCT01430221|BEHAVIORAL|Mindfulness-based Personalized Health Planning|
214338601|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
214338602|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.
214940944|NCT01569750|DRUG|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
214940945|NCT01569750|DRUG|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
214940946|NCT01569750|DRUG|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
214338603|NCT01993719|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV)
214338604|NCT01993719|DRUG|Pembrolizumab|2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
214338605|NCT06238505|OTHER|Virtual|application will be made with virtual reality device
214338606|NCT06238505|OTHER|biodex|application will be made with biodex device
214338607|NCT05546606|DEVICE|ECCO2R|ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.
214338608|NCT05331742|DRUG|Vaccine|patients who have received vaccine against coronavirus disease infection
214940947|NCT01350440|BIOLOGICAL|IVIG|Intravenous Immune Globulin
214940948|NCT06188104|DRUG|Trichloroacetic acid|Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
214940949|NCT05526222|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
214940950|NCT00662558|DRUG|celecoxib|200 mg capsules BID for 6 weeks
214940951|NCT00662558|DRUG|tramadol HCL|50 mg capsules QID for 6 weeks
214940952|NCT04940416|DEVICE|Neurofit (oculometric testing)|The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.
214940953|NCT04814316|DIAGNOSTIC_TEST|Blood and urine specimens|Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.
214676207|NCT01430221|OTHER|Structured & Guided Education|
214676208|NCT06430255|OTHER|Global Postural Re-education|Program for treatment
214676209|NCT06430255|OTHER|Laser-guided Supervised Exercise|Program for treatment
214676210|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
214676211|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
214676212|NCT00145340|DRUG|pioglitazone|30 Mg/day
214676213|NCT05878444|DIETARY_SUPPLEMENT|Probiotic|Resistant gastrointestinal capsules will be provided daily to the participants.
214676214|NCT02894983|OTHER|Flexion-ulnar cast|The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
214338609|NCT04177693|DIETARY_SUPPLEMENT|Epigallocatechin gallate (EGCG)|800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
214338610|NCT04177693|DRUG|Clomiphene Citrate|100 mg for 5 days
214338611|NCT04177693|DRUG|Letrozole|5 mg for 5 days
214338612|NCT05296616|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
214338613|NCT02436382|OTHER|change in temperature|increase in ambient room temperature
214338614|NCT05826821|DRUG|Pirfenidone|Intervention drug
214338615|NCT04382326|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
214338616|NCT04382326|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
214940954|NCT00975858|PROCEDURE|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
214940955|NCT03035435|OTHER|fast-track rehabilitation|
214940956|NCT03035435|OTHER|standard care rehabilitation|
214940957|NCT04970017|RADIATION|Cardiac MRI, Echocardiography|Magnetic resonance imaging, Echocardiography
214338617|NCT02259530|BEHAVIORAL|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
214940958|NCT05136534|PROCEDURE|spinal anesthesia|subarachnoid anesthesia with 2% hyperbaric pilicaine
214676215|NCT02894983|OTHER|Functional cast|The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
214338618|NCT00970086|DRUG|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
214338619|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
214338620|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
214338621|NCT01679535|BEHAVIORAL|nutrition and hygiene education|Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
214338622|NCT01326520|DIETARY_SUPPLEMENT|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
214338623|NCT01326520|DIETARY_SUPPLEMENT|diary product|The patients will consume daily 250 mL of a common dairy product.
214338624|NCT00497120|DRUG|acetazolamide|
214338625|NCT00497120|DRUG|placebo|
214338626|NCT00497120|PROCEDURE|uvulopalatopharygoplasty|
214338627|NCT03923127|OTHER|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
214338628|NCT01771276|DEVICE|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
214338629|NCT02919852|PROCEDURE|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
214338630|NCT00277017|DRUG|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."
214338631|NCT04978246|BEHAVIORAL|Neuropsychometric Test|Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
214338632|NCT00690547|OTHER|muscle activation|activation of the muscle quadriceps femoris
214338633|NCT00365859|DRUG|Aripiprazole|Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
214940959|NCT05136534|PROCEDURE|local anesthesia|(Mepivacaine 2%) performed by the surgeon before skin incision
214940960|NCT06285734|DIAGNOSTIC_TEST|Breath test|The concentration of methane and hydrogen in the exhaled gas of patients with Abdominal distention is measured by a breath test to determine the presence of SIBO and abnormal OCTT.
214338634|NCT00770016|DRUG|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
214940961|NCT05646758|DRUG|TQB2934 injection|TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
214940962|NCT00329641|DRUG|carboplatin|Given IV
214940963|NCT00329641|DRUG|paclitaxel|Given IV
214676216|NCT01914133|DRUG|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
214676217|NCT01914133|DRUG|Placebo|Placebo given prior to meal the standardized meal
214676218|NCT01898312|DRUG|Mifepristone|Randomised controlled trial of Mifepristone and placebo comparator Triobe
214676219|NCT01516801|OTHER|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
214338635|NCT03934229|DIETARY_SUPPLEMENT|Daily intake of study product|Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
214338636|NCT03224468|DRUG|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
214338637|NCT03681301|OTHER|virtual reality simulator|Additional self-directed learning and practice using virtual reality simulator
214338638|NCT04284423|DIAGNOSTIC_TEST|joint fluid lactate|Analysis of lactate level in joint fluid to determine presence of septic joint
214676220|NCT02609893|OTHER|modified directly observed therapy (mDOT)|
214676221|NCT02609893|OTHER|unobserved dosing|
214338639|NCT03200392|DEVICE|laser root surface conditioning & laser DGG harvesting|laser root surface bio-modification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
214338640|NCT03200392|DEVICE|laser root surface conditioning & blade DGG harvesting|laser root surface bio-modification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
214338641|NCT03200392|PROCEDURE|blade DGG harvesting|De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
214338642|NCT04067141|DEVICE|somofilcon A|Contact Lens
214940964|NCT00329641|DRUG|sorafenib tosylate|Given orally
214940965|NCT04629924|DEVICE|sleeper one|anesthesic injection with sleeper one device
214940966|NCT04629924|DEVICE|conventional technis|anesthesic injection with the conventional technic
214940967|NCT01934075|BEHAVIORAL|Mental health treatment|6 sessions of individual mental health counseling.
214940968|NCT05771818|OTHER|Falls Prevention Program|The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session focuses on falls strategies training and walking and balance exercises. Each session lasts approximately 1.5 hours.
214940969|NCT03375515|DRUG|Hydromorphone|"1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes."
214940970|NCT03375515|DEVICE|PCA pump|"1. For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone.~2. For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs."
214940971|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
214940972|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
214940973|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
214940974|NCT05704777|BEHAVIORAL|Exercise|A 24-weeks concurrent exercise training program
214940975|NCT05704777|OTHER|Control|Usual care
214940976|NCT06730308|RADIATION|Radiotherapy|Hypofractionated radiotherapy
214940977|NCT06730308|DRUG|Concurrent chemotherapy|weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)
214676222|NCT02609893|OTHER|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
214940978|NCT06730308|DRUG|Methylprednisolone|Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy
214940979|NCT02709681|OTHER|Physician standard-of-care in SCD patients|
214940980|NCT02259634|BEHAVIORAL|Patient Navigation|Motivational Interviewing
214940981|NCT00783224|DRUG|Placebo for MF|Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
214338643|NCT04067141|DEVICE|nelfilcon A|Contact Lens
214338644|NCT03566641|DEVICE|Negative pressure wound therapy|The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.
214338645|NCT03566641|OTHER|standard care dressing|The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
214338646|NCT03868904|DEVICE|OCS Lung System|No active interventions are part of this study. This study will collect long-term survival and BOS data in subjects who were part of the INSPIRE trial.
214338647|NCT01038921|DRUG|Melatonin|8 mg dose of Melatonin
214338648|NCT01038921|DRUG|Placebo|Placebo
214338649|NCT02352493|DRUG|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
214338650|NCT02352493|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
214338651|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
214940982|NCT00783224|DRUG|Placebo for FP|Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
214940983|NCT00783224|DRUG|Mometasone|Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
214940984|NCT00783224|DRUG|Fluticasone|Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
214940985|NCT04946019|COMBINATION_PRODUCT|Unity-based MR-Linac guided FSRT|The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
214940986|NCT01711619|DEVICE|subcutaneous nerve stimulation|subcutaneous nerve stimulation plus optimized medical management
214940987|NCT01711619|OTHER|Optimized Medical Management|Optimized medical management
214940988|NCT01601002|DRUG|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
214940989|NCT01325259|OTHER|neuropsychologic assessment|Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
214940990|NCT01325259|RADIATION|[18F]AV-45 PET|intravenous injection of 4 MBq/kg of \[18F\]AV-45
214940991|NCT01325259|RADIATION|18-FDG PET|intravenous injection of 100 to 120 MBq of FDG
214940992|NCT01325259|OTHER|MRI|Magnetic Resonance Imaging
214940993|NCT04127175|DEVICE|Volpara|This tool represents a physics-based model which extract pixel-wise information from the FFDM or DBT images, and combine it with metadata information from the DICOM header and appropriate linear attenuation coefficients of both adipose and glandular tissue.
214940994|NCT02732236|OTHER|Rituximab|Cohort observation study
214940995|NCT04018807|OTHER|Resource pamphlet|The pamphlet will list violence prevention, mental health, and substance abuse services.
214940996|NCT04018807|BEHAVIORAL|Remote Therapy|Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
214940997|NCT05940896|DRUG|Disitamab vedotin|Disitamab Vedotin intravenously combined with radiotherapy (concurrent)
214940998|NCT02799173|BIOLOGICAL|RANKL/OPG ratio|
214940999|NCT02799173|DEVICE|bone densitometry|
214941000|NCT02799173|DEVICE|fan beam CT scan|
214941001|NCT02799173|DEVICE|Doppler ultrasound|
214941002|NCT00104468|DRUG|Troxatyl™ (Cytotoxic Chemotherapeutic)|
214941003|NCT00081926|DRUG|Gleevec|
214941004|NCT02991014|BEHAVIORAL|researcher-selected frequency-modulated music|Music pieces have been selected in advance by the researchers. Furthermore, musical frequencies have been artificially modulated.
214941005|NCT02991014|BEHAVIORAL|researcher-selected non-modulated music|The same music pieces as in the active comparator arm have been selected in advance by the researchers, but no artificial frequency modulation.
214941006|NCT02991014|BEHAVIORAL|participant-selected non-modulated music|Participants bring their own choice of personally preferred music pieces and listen to them during the intervention sessions. There is no frequency modulation in this condition.
214941007|NCT03217019|PROCEDURE|Guidewire-assist|catheter insertion with guidewire-assist(catheter over guidewire)
214941008|NCT03217019|PROCEDURE|Direct|catheter insertion without guidewire assist(catheter over needle)
214941009|NCT02851979|OTHER|Olfactory stimulations|"Odors are disseminated using a portable fragrance device, a prototype developed by a research unit, CNRS UMR5292. The device is outside the incubator, the only part inside is a disposable Teflon tube. The odor flux stimulates distally the NBs' nostrils. Odoriferous compounds are placed in glass tubes. This allows the olfactometer to deliver three distinct odors (to avoid habituation) in a random scheme: spearmint odor, vanilla odor, and grapefruit odor (chemicals registered by Chemical Abstracts Service), while controlling for intensity (amount of compound), duration, and odor sequence. For the vehicle period, the glass tubes remain empty.~Stimulations occur every 5 minutes, for 5 seconds, they are mixed in medical gas to avoid infection. There are three 24-hour periods, and two 24-hour wash out periods, followed by a maximum of 3 days of surveillance."
214941010|NCT01676506|DRUG|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
214941011|NCT01676506|PROCEDURE|Ranibizumab Injection|
214941012|NCT01118988|BEHAVIORAL|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
214941013|NCT02479971|DRUG|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
214941014|NCT02479971|DRUG|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
214941015|NCT04220099|PROCEDURE|Electroconvulsive therapy(ECT)|Patients recieve 8-sessions ECT treatments and those kinds of drugs they take since they were recruited remain unchanged during this study.
214941016|NCT04620694|DEVICE|Choice of arterial cannulation site at the beginning of the surgery|Choice of arterial cannulation site at the beginning of the surgery is at the discretion of the anesthesia physician.
214486438|NCT05298904|DIAGNOSTIC_TEST|Genetic Health Screen Panel|This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).
214486439|NCT06411522|DEVICE|Mouthwash containing 0.12% CHX (Chlorhexidine)|Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.2% CHX mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).
214941017|NCT04012307|DRUG|Candesartan Cilexetil 32mg|Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
214941018|NCT04012307|DRUG|Atacand® PROTECT|Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
214941019|NCT06510920|BEHAVIORAL|Aerobic exercise|The mixed design scheme of football and volleyball sports technology and competition will be adopted.aerobic exercise intensity will be moderate-intensity aerobic exercise load , and the intervention time was 12 weeks, 60 minutes each time, twice a week. The main preparation activities were jogging and special preparation activities (10 minutes), and the main part was technical teaching combined with competition (60 minutes).The end part is mostly jogging and stretching (10 minutes). Two subjects in each group were selected to wear Decathlon Bluetooth heart rate band, and the exercise intensity was controlled by detecting the heart rate of the subjects.
214941020|NCT06091930|DRUG|BI 765049|BI 765049
214941021|NCT06091930|DRUG|Ezabenlimab|Ezabenlimab
214941022|NCT05112757|OTHER|Smartphone application use|Use of a smartphone application
214338652|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
214941023|NCT01395173|PROCEDURE|Position change|Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
214941024|NCT01395173|PROCEDURE|Standard|Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
214941025|NCT03646149|BEHAVIORAL|Housing Skills Training Group|12-session social skills training group for persons with homeless experiences and serious mental illness delivered once a week for 12 weeks
214941026|NCT00475878|DRUG|escitalopram|10mg escitalopram/day for 3 months
214941027|NCT00475878|DRUG|placebo|placebo capsule/day for 3 months
214941028|NCT04678401|RADIATION|Radiation|Total Myeloid and Lymphoid Irradiation (TMLI) delivered through Radiation Oncology institutional standards
214941029|NCT04678401|DRUG|Fludarabine|Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)
214941030|NCT04678401|DRUG|Thiotepa|Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)
214941031|NCT04678401|DRUG|Cyclophosphamide|Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)
214941032|NCT04678401|DRUG|Mesna|Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)
214676223|NCT04194593|OTHER|PCR (Polymerase Chain Reaction)|"Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes).~A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm."
214676224|NCT04726267|DEVICE|Wide-field optical coherence tomography|Merged 4 images of wide-field optical coherence tomography, 2 images of vertical scan and 2 images of horizontal scan.
214676225|NCT05873140|BEHAVIORAL|application LINE|Online lifestyle modification education for weight loss
214676226|NCT05955859|PROCEDURE|Samplings from patient's affected paranasal sinus|Samplings from patient's affected paranasal sinus during endoscopic surgery.
214338653|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
214338654|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
214338655|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
214941033|NCT04678401|BIOLOGICAL|Treg-enriched donor cell|Given intravenously -4 day prior to hematopoietic stem cell transplant (HSCT)
214941034|NCT04678401|BIOLOGICAL|Unmodified donor T Cell|Given intravenously -1 day prior to hematopoietic stem cell transplant (HSCT)
214941035|NCT04678401|PROCEDURE|CD34+ Haplo Peripheral Blood Stem Cell|CD34+ Haplo Peripheral Blood Stem Cell Transplantation
214941036|NCT05016297|DRUG|Baricitinib|baricitinib 4mg per day
214941037|NCT05016297|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg twice a day
214338656|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
214338657|NCT00192725|OTHER|rapid tryptophan depletion|Amino-acid mixture without tryptophan
214338658|NCT06017284|DRUG|Thalidomide|Thalidomide 100 mg/day, once a day, orally intake at night.
214338659|NCT06017284|DRUG|Nab paclitaxel|nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.
214338660|NCT06017284|DRUG|Gemcitabine|gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
214338661|NCT06017284|DRUG|Placebo|Placebo, 100 mg/day, once a day, orally intake at night.
214338662|NCT03188640|PROCEDURE|Laparoscopic gastric-bypass surgery|Female participants with BMI \>30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
214338663|NCT06061458|DIAGNOSTIC_TEST|speech auditory brainstem response|A diagnostic objective test to evaluate the speech process in hearing impaired children
214338664|NCT02652728|DRUG|Enalapril Orodispersible Minitablet|Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
214338665|NCT06129058|DEVICE|At-home transcranial direct current stimulation (tDCS)|30 minutes session 5 days/week for 3 weeks.
214338666|NCT06129058|DEVICE|Sham at-home tDCS|30 minutes session 5 days/week for 3 weeks.
214338667|NCT00651989|OTHER|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
214941038|NCT00567697|DRUG|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
214941039|NCT00567697|DRUG|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
214338668|NCT02723617|OTHER|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
214338669|NCT02723617|OTHER|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
214338670|NCT02723617|OTHER|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
214338671|NCT02723617|OTHER|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
214338672|NCT02579291|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
214338673|NCT02579291|OTHER|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
214338674|NCT02804919|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
214338675|NCT05163860|OTHER|Survey|Participants will complete an online survey.
214338676|NCT03494257|DRUG|Brinzolamide-Brimonidine fixed combination|Simbrinza 0.2%-1% Ophthalmic Suspension
214338677|NCT00725166|OTHER|Skeletal muscle aging|"W1 - Blood test~* Maximal voluntary contraction of quadriceps~* Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy"
214338678|NCT05940285|DIAGNOSTIC_TEST|Dynamic 99mTc-Tetrofosmin CZT-SPECT|Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
214338679|NCT05413538|BEHAVIORAL|Mindfulness training|The intervention recordings will teach the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording has the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
214338680|NCT04954365|DRUG|Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)|Rescue Post-Operative Nausea and Vomiting (PONV) treatment
214338681|NCT04954365|DRUG|Amisulpride|Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
214338682|NCT00889421|DRUG|Apremilast|oral dose of 30 mg BID for 6 months
214941040|NCT00019422|DRUG|carboplatin|
214941041|NCT00019422|DRUG|lobradimil|
214338683|NCT04344821|DIETARY_SUPPLEMENT|Curves Calcium|"Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)"
214338684|NCT04344821|DIETARY_SUPPLEMENT|Placebo|Dextrose Placebo
214338685|NCT05787769|DRUG|P shot arm ( Autologous Platelet Rich Plasma)|Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum
214338686|NCT05787769|DRUG|PDE5i arm|Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
214338687|NCT00652457|DRUG|Memantine|10 mg BID x 3 months
214338688|NCT01547572|PROCEDURE|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
214941042|NCT05555316|DRUG|TACE combined with Lenvatinib|Three days after the first TACE treatment, when the liver function was evaluated as grade A / B, Lenvatinib was taken orally, 8mg / day (body weight less than 60kg) or 12mg / day (body weight equal to or more than 60kg). Lenvatinib reduction standard: 8mg / day; 4mg / day; 4mg, the next day.
214941043|NCT04015778|BIOLOGICAL|Nivolumab|240mg Q2W or 360mg Q3W
214941044|NCT04015778|DRUG|carboplatin|AUC 5, d1 every three weeks
214941045|NCT04015778|DRUG|nab-paclitaxel|135 mg/m2, d1, 8
214941046|NCT01741571|DEVICE|EBUS guided FNA with and without suction|"Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied."
214941047|NCT04494594|BEHAVIORAL|Drinks:Ration app|Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.
214941048|NCT00017680|DRUG|Melphalan|100 mg/m2 twice a day from Days -2 and -1 as induction therapy
214941049|NCT00017680|PROCEDURE|Autologous Stem Cell Transplantation|Bone marrow and peripheral blood stem cells harvested
214338689|NCT01547572|PROCEDURE|The control group will receive a leaflet only|The control group will receive a leaflet only
214338690|NCT05786677|OTHER|Physiotherapy protocol|"the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~1. Suboccipital release~2. Diaphragm release~3. Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise"
214338691|NCT05786677|DRUG|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRIs)
214338692|NCT01699594|DRUG|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
214338693|NCT01699594|DRUG|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
214338694|NCT00418392|PROCEDURE|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
214941050|NCT00401960|DRUG|Daptomycin|daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
214338695|NCT00418392|PROCEDURE|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
214347345|NCT02897804|BEHAVIORAL|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214347346|NCT01649284|DRUG|afatinib|40, 30, and 20 mg film-coated tablets
214941051|NCT00022880|DRUG|Iodine-131 Anti-B1 Antibody|
214941052|NCT04670380|OTHER|Posture and movement analysis during a simulated forceps vaginal operative delivery|It will be request from each volunteer to perform a vaginal operative delivery using a Suzor's forceps on a mannequin. The condition will be standardized (anterior occiput low fetal presentation). Each participant will be equipped with 34 reflecting markers allowing to record their movement using infra red cameras (VICON system).
214941053|NCT03173365|DRUG|Brimonidine Tartrate|1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
214941054|NCT02649426|DEVICE|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
214941055|NCT02649426|DEVICE|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
214941056|NCT06308757|DIETARY_SUPPLEMENT|Very-low-calorie ketogenic diet (VLCKD) with meal replacements|The VLCKD study arm will receive an experimental diet therapy with very-low-calorie ketogenic meal replacements (VLCKD) consisting of 5 successive phases (600 - 1500 kcal/day).
214941057|NCT06308757|DIETARY_SUPPLEMENT|Mediterranean low-calorie diet (LCD)|The Control arm LCD will receive standard Mediterranean type low-calorie diet (LCD) therapy by the most recent guidelines on MAFLD/NAFLD (1200-1500 kcal/day).
214941058|NCT00135902|DRUG|17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement|Participants receive a weekly progesterone injection (17 alpha hydroxyprogesterone caproate) up to 37 weeks gestation and take daily Omega-3 supplements.
214941059|NCT00135902|DRUG|17 alpha-hydroxy progesterone caproate and Placebo supplement|Participants receive a weekly progesterone injection (17P) up to 37 weeks gestation and take daily placebo supplements
214941060|NCT06730451|OTHER|Washed Microbiota Transplantation|Washed microbiota suspension delivered through mild-gut and lower-gut
214941061|NCT06302023|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) 1000 mg|Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age
215074236|NCT03926572|OTHER|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
215074237|NCT05732935|BEHAVIORAL|Time Restricted Eating intervention|"In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
215074238|NCT05732935|BEHAVIORAL|Successful Aging Comparison Group (LEARN)|"In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
215074239|NCT05434338|DIAGNOSTIC_TEST|HPV detection test|Samples taken from the squamocolumnar junction using swabs (UTM Copan)
215074240|NCT04414046|BIOLOGICAL|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
215074241|NCT05563805|DEVICE|Virtual Reality-based physical activity intervention|The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 6-8-weeks (1-2 days/week, 30 minutes/session) totaling 6 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.
215074242|NCT05441163|OTHER|APA and nutrition intervention|"\- APA intervention: weekly supervised sessions at home with the APA professional combined with unsupervised sessions, alone or with the APA partner, for 8 weeks.~The supervised session will be broken down as follows: warm-up block (approximately 10'), aerobic block (15'), muscle strengthening/resistance block (15') and stretching/relaxation block (10'). The remaining 10' will be used to review the session and the individual sessions. This program can be adapted to the needs and abilities of the patient if necessary.~\- Nutritional intervention: dietitian weekly visits at home during 8 weeks with dietetic counseling; decision of oral, enteral and/or parenteral feeding validated by the clinical steering committee according to the Société Francophone de Nutrition Clinique et Métabolisme (SFNCM) guidelines."
215074243|NCT05312749|OTHER|progressive relaxation exercises|progressive relaxation exercises
214676227|NCT00301067|DIETARY_SUPPLEMENT|Calcitriol|The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle
214676228|NCT00301067|DRUG|Temozolomide|The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
214941062|NCT05756361|BEHAVIORAL|Family-Based Treatment for T1D|"Our FBT curriculum, which has been delivered successfully in the specialty and primary care settings, has 3 components: 1. Meal planning including quality of carbohydrates and glycemic index for both parents and children while ensuring that youth have a balanced meal plan with adequate amounts of carbohydrates for optimal growth. Our FBT has a focus on Food Literacy including healthy food selection and sourcing of affordable healthy food, food preparation and preplanning, social engagement tailoring the meal plan to the needs to the family in socio cultural appropriate way and also feasibility based on logistics and economic aspects; 2. Physical activity (PA) component with shaping strategy to allow for a progressive shaping of easy PA starting, if needed, with as little as with 10 minutes of walking/day and strategies to incorporate PA in daily routines, family, and social activities; 3. Extensive behavioral component which has been shown to be very powerful in obesity treatment"
214941063|NCT05133414|OTHER|Selective left subclavian ansae stimulation|Percutaneous, transarterial approach for target stimulation
214941064|NCT05846113|DIAGNOSTIC_TEST|Renasight|"The Renasight™ test is a next generation sequencing (NGS) gene mutation assay for patients with chronic kidney disease (CKD) which utilizes genomic DNA from patient blood or buccal swab samples to analyze over 380 genes that are associated with autosomal dominant, autosomal recessive and X-linked disorders.~Patients undergoing Renasight™ testing are offered optional genetic information sessions in addition to their test results.~RenasightTM is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
214941065|NCT02495818|PROCEDURE|Lidocaine|Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
214941066|NCT02495818|PROCEDURE|Saline solution|Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
214941067|NCT02495818|OTHER|Homemade exercises|Codman and Hughston exercises.
214941068|NCT00164502|BEHAVIORAL|Community-based eight session group self-management program|
214941069|NCT00609713|BEHAVIORAL|Comprehensive behavioral weight control program|Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.
214941070|NCT00609713|OTHER|Individual 12-month nutrition education program|The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
214941071|NCT02030496|PROCEDURE|open reduction and internal fixation|The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
215074244|NCT01894048|DRUG|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
215074245|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
215074246|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
214676229|NCT03662152|DEVICE|Foam roller|Foam roller massage after DOMS
214676230|NCT03662152|DEVICE|Vibration foam roller|Foam roller massage with vibration after DOMS
214676231|NCT00149825|DRUG|Escitalopram|5 to 20 mg for 12 weeks
214676232|NCT00149825|BEHAVIORAL|CBTI|Cognitive Behavioral Treatment for Insomnia
214676233|NCT00149825|BEHAVIORAL|CTRL|Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
214941072|NCT02030496|OTHER|Closed reduction and plaster|Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
214941073|NCT01678703|DEVICE|Laminaria, MedGyn Products, Inc. USA.|Insertion of Hygroscopic laminarias into the cervical canal for preparation prior to late surgical abortion. The number of laminarias is according to the cervical compliance.
214941074|NCT01678703|DRUG|Misoprostol|Cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
214941075|NCT00865579|DRUG|Safinamide|"The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning."
214941076|NCT04309903|OTHER|Manual therapy|Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 \* 10 repetitions, 20 sec of per reps and 10 sec of interval.
214941077|NCT00771979|DRUG|AZD0530|of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
214941078|NCT00771979|DRUG|AZD0530|Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
214941079|NCT05559684|PROCEDURE|Erector spinae plane block|Under strict aseptic precautions, The T3 spinous process will be located. A high-frequency 12 MHz linear US transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process. Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle. Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.
214941080|NCT05559684|PROCEDURE|Transversus thoracis plane block|Under strict aseptic precautions, the T4-T5 intercostal space is identified under US using the US probe in the longitudinal plane 1 cm lateral to the sternal border. A high-frequency linear transducer is used. Next, a parasternal sagittal view of the intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib is visualized above the pleura and a 22G, 5-10 cm needle is inserted in-plane (according to patient's body habitus and relevant anatomy) to the transducer with bevel up until the tip of the needle is located in the transverses thoracis muscles. After excluding intravascular and intrapleural placement, local anesthetic is adminstred bilaterally by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side.
214941081|NCT01957943|DIETARY_SUPPLEMENT|SMOFLipid|
214941082|NCT01957943|DIETARY_SUPPLEMENT|equivalent volume of 10% glucose solution|Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
215074247|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
215074248|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
215074249|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
215074250|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
214676234|NCT06387719|DIAGNOSTIC_TEST|Magnetic resonance imaging|"* Basic sequence for ethical consideration: evaluation of casual findings.~* Structural MRI.~* Functional MRI (fMRI) in the Resting-state~* fMRI- task based. Presented in a computer screen on a magnetically compatible googles."
214676235|NCT01359982|DRUG|RRx-001|Dose level 1 (10 mg/m2)
214338696|NCT06387563|PROCEDURE|Abdominal activation using pressure biofeedback|"PBF assisted abdominal muscle activation training (30 min, 3x /week /4 weeks) Progressive Muscle Relaxation for 5 min Pressure biofeedback assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Progression criteria in training: Maintaining 3 - 5 mmHg pressure on PBF dial while performing abdominal muscle activation.~Exercises for Group For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
214347347|NCT02331992|BEHAVIORAL|Adherence program|Participants will receive supportive messages while enrolled in the program.
214676236|NCT01359982|DRUG|RRx-001|Dose Level 2 (16.7 mg/m2)
214676237|NCT01359982|DRUG|RRx-001|Dose Level 3 (24.6 mg/m2)
214676238|NCT01359982|DRUG|RRx-001|Dose Level 4 (33 mg/m2)
214347348|NCT02121847|DRUG|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
214347349|NCT02121847|DRUG|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
214347350|NCT01660906|DRUG|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
214676239|NCT01359982|DRUG|RRx-001|Dose Level 5 (55.0 mg/m2)
214338697|NCT06387563|PROCEDURE|Abdominal activation using SEMG biofeedback|"SEMG-BF assisted abdominal muscle activation training (30 min, 3x/ week/ 4 weeks) Progressive Muscle Relaxation for 5 min Surface EMG-BF assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Maintaining minimal volumetric contraction of abdominal muscle activation (as per person) on SEMG device with abdominal muscle activation for set frequency~Exercises for Group B For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
214338698|NCT02362880|RADIATION|Florbetaben|single dose of Florbetaben followed by PET scan
214941083|NCT04116606|DRUG|Active JNJ-54175446|JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
214338699|NCT02872064|DRUG|Verteporfin|Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
214941084|NCT04116606|DRUG|Placebo|Matching placebo containing the same excipients
214676240|NCT01359982|DRUG|RRx-001|Dose Level 6 (83 mg/m2)
214676241|NCT06244368|DRUG|GVM±R regimen|"Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician."
214676242|NCT06518863|BEHAVIORAL|Education|Educational handouts on how to adhere to the corresponding diet.
214676243|NCT02165852|PROCEDURE|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
214676244|NCT02165852|PROCEDURE|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
214486440|NCT06411522|DEVICE|Mouthwash containing 0.05% CHX (Chlorhexidine) and 0.05% CPC (Cetylpyridinium Chloride)|Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.05% CHX + 0.05% CPC mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).
214486441|NCT05457725|BEHAVIORAL|Contingent rtfMRI neurofeedback training|Contingent rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about real-time brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
214486442|NCT05457725|BEHAVIORAL|Non-contingent/sham rtfMRI neurofeedback training|Non-contingent/sham rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about non-contingent/sham brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
214676245|NCT06483633|BEHAVIORAL|MICT + CPT, HIIT + CPT, SIT + CPT|Single acute intervention, each exercise mode had a washout period of at least 7 days.
214941085|NCT04015752|DIAGNOSTIC_TEST|culture from infected site|ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
214941086|NCT02584959|DRUG|C1 esterase inhibitor [human] liquid|C1 Esterase Inhibitor \[Human\] Liquid administered Subcutaneously as specified on specified days
214676246|NCT00346515|DEVICE|FiberNet Emboli Protection System|
214676247|NCT01634347|DRUG|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
214676248|NCT01634347|DRUG|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
215074251|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
214676249|NCT05646550|DRUG|CC-1 Infusion|Short term (3h) infusion of CC-1
214676250|NCT04036266|PROCEDURE|medial open wedge high tibial osteotomy|opening of medial aspects of the proximal tibial metaphysis and change the coronal alignment of the tibia in order to shift the center of force passing axially through the knee from the arthritic region of the knee towards the unaffected side then fixation with a plate (the standard plate is the T-locked plate )
215074252|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
214941087|NCT02584959|DRUG|Placebo|Placebo
214941088|NCT04849585|OTHER|semi-directed entretien|semi-directed entretien
214941089|NCT02364154|OTHER|Control group-Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
214941090|NCT02364154|OTHER|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
214941091|NCT04909814|BIOLOGICAL|The performance of colposcopy in vaccinated women|Evaluating the performance of colpscopy in HPV vaccinated women by comparing vaccinated and unvaccinated women taking their first test within the organized screening program
215074253|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
215074254|NCT00964912|DRUG|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
215074255|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
215074256|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
214676251|NCT02680067|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
214676252|NCT02680067|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
214676253|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
214676254|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
214941092|NCT03526055|DEVICE|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
214941093|NCT03008278|DRUG|Olaparib|Give PO
214941094|NCT03008278|BIOLOGICAL|Ramucirumab|Given IV
214941095|NCT00195494|DRUG|Etanercept|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
214941096|NCT00195494|DRUG|Methotrexate|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2"
214941097|NCT00195494|DRUG|Placebo|"Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
215074257|NCT03526237|BEHAVIORAL|24 week community based DPP Group Lifestyle Balance Program|a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
215074258|NCT03526237|BEHAVIORAL|Wait-List Control community based DPP Group Lifestyle Balance Program|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
214676255|NCT03777930|DRUG|Chemotherapy drugs|According to the NCCN Guidelines
214676256|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
214676257|NCT03777930|OTHER|optimal support treatment|Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
214676258|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
214338701|NCT03175653|OTHER|Oxycodone Pill A|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
214338702|NCT03175653|OTHER|Oxycodone Pill B|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
214338703|NCT02574975|DRUG|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
214338704|NCT02574975|DRUG|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
214338705|NCT02574975|DRUG|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
214941098|NCT03252366|DEVICE|GELFOAM|"* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
214941099|NCT03252366|DEVICE|xenograft|"* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
214941100|NCT00513357|DRUG|Melatonin|20 mg by mouth daily for 4 Weeks
214941101|NCT00513357|DRUG|Placebo|Capsule by mouth daily for 4 Weeks
214941102|NCT06730269|BEHAVIORAL|Face-to-Face Rehabilitation Program|The Face-to-Face Rehabilitation Program is a structured rehabilitation regimen designed to improve posture, reduce pain, and strengthen back extensor muscles in children with thoracic hyperkyphosis. Participants in this group engaged in the Thoracic Corrective Exercise Program, which included four specific exercises targeting thoracic spine correction. The exercises were performed three times per week over six weeks, under the direct supervision of a trained therapist. This setup ensured real-time feedback, personalized adjustments, and guidance during each session, optimizing the effectiveness of the rehabilitation process.
214941103|NCT06730269|BEHAVIORAL|Telerehabilitation Program|The Telerehabilitation Program is a structured rehabilitation regimen designed to improve posture, reduce pain, and strengthen back extensor muscles in children with thoracic hyperkyphosis. Participants in this group followed the Thoracic Corrective Exercise Program, which included four specific exercises targeting thoracic spine correction, performed three times per week over six weeks. The program was delivered remotely through the Fiziu platform, allowing therapists to provide virtual guidance, feedback, and monitoring during the sessions. This approach offered flexibility for families and ensured accessibility to rehabilitation services from the comfort of their homes.
214941104|NCT00753844|BIOLOGICAL|URLC10|Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
214941105|NCT02624622|PROCEDURE|Chlorhexidine application to cord by mother|
214941106|NCT02624622|PROCEDURE|Chlorhexidine application by CHW|
214941107|NCT00878605|DRUG|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
214941108|NCT00878605|DRUG|Placebo|Placebo control
214941109|NCT04573166|PROCEDURE|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation|After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
214941110|NCT03353948|DRUG|MET|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
214941111|NCT03353948|DRUG|COMBI|In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
214941112|NCT04535128|OTHER|No intervention|No intervention
214941113|NCT06234371|BEHAVIORAL|Financial Incentive|The intervention is offering a $500 gift card as an incentive for completing 6 counseling sessions to eligible individuals randomized into the treatment group. Another $500 gift card will be given after completing 12 counseling sessions, and another $500 gift card will be given after completing 18 counseling sessions.
214941114|NCT03023540|DRUG|PXT3003|Liquid oral solution, twice 5 mL (Dose 1) bid
214941115|NCT01527708|PROCEDURE|Corneal Collagen Cross-linking (CXL)|Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
214941116|NCT05691621|DRUG|Standard Reagents, Whole Blood|All patients receive standard treatment, only their blood and urine samples are needed
214941117|NCT02453659|BEHAVIORAL|Distress Tolerance Treatment for Weight Concern (DT-W)|
214941118|NCT02453659|BEHAVIORAL|Health Education (HE)|
214941119|NCT02453659|BEHAVIORAL|Smoking Cessation counseling|
214338706|NCT02574975|DEVICE|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
214338707|NCT02574975|DRUG|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
214941120|NCT02453659|DRUG|Transdermal Nicotine Patch|
214941121|NCT01133496|DRUG|Alendronate Sodium Tablets, 70 mg|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
214941122|NCT01756508|DRUG|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
214941123|NCT00898495|GENETIC|loss of heterozygosity analysis|
214941124|NCT00898495|GENETIC|polymerase chain reaction|
214941125|NCT00898495|GENETIC|polymorphism analysis|
214486443|NCT06875037|DEVICE|Electric stimulation removable appliance|The device will be used with the fixed appliance to accelerate orthodontic tooth movement (i.e., canine retraction).
214941126|NCT05571696|BEHAVIORAL|Immune Strength|Immune Strength is a 12 week online program that provides content, strategies, and guidance on how to improve your immune system and increase your mental wellbeing, with a focus on stress, sleep, nutrition, and exercise. In addition to the online program, each participant will be paired with a Cleveland Clinic Coach who will communicate with the participant via email. The Coach will help guide the participant throughout the program and provide encouragement and guidance for making behavior changes for making a more resilient immune system.
214941127|NCT02300961|BEHAVIORAL|Cognitive rehabilitation program|
214941128|NCT05599347|DRUG|Azithromycin Pill|Tablet - 500 mg azithromycin (as dihydrate)
214941129|NCT05599347|OTHER|Placebo|Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
214941130|NCT05463757|DRUG|Vismodegib|Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)
214941131|NCT05463757|DRUG|Sonidegib|Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)
214941132|NCT06094894|OTHER|sucralose|Food additive used to replace sugar providing a sweet taste without calories.
214941133|NCT06094894|OTHER|placebo|Cornstarch without significant physiological effects
214941134|NCT02171013|DRUG|Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)|
214941135|NCT02171013|DRUG|Dabigatran polymorph I|
214941136|NCT01217385|PROCEDURE|DOSI|Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
214941137|NCT04912388|OTHER|Lumbal stabilization excercises|The stabilization group will perform lumbal stabilization exercises in lying, sitting, standing and on a swisball 3 times a week during 6 weeks.
214941138|NCT04912388|OTHER|Conventional exercises|The general exercise group will perform conventional exercises 3 times a week during 6 weeks.
214941139|NCT01734915|DEVICE|Circulating tumor cell chip|three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
214941140|NCT00090987|DRUG|imatinib mesylate|400 mg orally once a day for up to 6 months.
214941141|NCT02464761|DRUG|Visudyne|
214941142|NCT02292186|DRUG|Revusiran (ALN-TTRSC)|
214941143|NCT04788225|OTHER|Balance assessment|"Static balances will be measured with the Biodex-BioSway 950-462 static balance device according to 3 different standard test procedures (Postural Stability Test, Stability Limit Test and Modified Sensori Organization Test) in single foot stance and double foot stance.~Dynamic balances will be evaluated with the Y balance test."
214941144|NCT04788225|OTHER|Functionality assessment|Functionality will be evaluated with the Lower Extremity Functional Scale and AOFAS (American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale)
214941145|NCT04788225|OTHER|Performance assessment|Performance evaluation will be made with a single leg jump test and time up and go test.
214941146|NCT04788225|OTHER|ROM assessment|Range of motion (ROM) of the ankle will be measured with an electrogonyometer in dorsi-plantar flexion.
214941147|NCT04053985|COMBINATION_PRODUCT|TAI combine lenvatinib|TAI combine lenvatinib
214941148|NCT04053985|DRUG|Lenvatinib|lenvatinib only
214941149|NCT00370981|DRUG|pagoclone|
214941150|NCT00835679|BIOLOGICAL|cetuximab|Given IV
214941151|NCT00835679|DRUG|dasatinib|Given orally
214941152|NCT00835679|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214941153|NCT00835679|OTHER|laboratory biomarker analysis|Correlative studies
215074259|NCT03760016|BEHAVIORAL|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
215074260|NCT03760016|BEHAVIORAL|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
215074261|NCT06423664|BEHAVIORAL|Play and Learn Strategies (PALS) Program|Monthly modules and personalized coaching sessions designed to strengthen maternal responsiveness and sensitivity which, in turn, improves infant social-emotional behavior and development outcomes.
215074262|NCT06650878|PROCEDURE|Desarda|This technique prevent from using a mesh to surgical repair of a inguinal hernia
215074263|NCT06650878|PROCEDURE|Lichtenstein|This technique implies using a mesh to surgical repair of a inguinal hernia
215074264|NCT03848130|OTHER|Mulligan Knee Taping with Home Exercises|Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings \& ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).
215074265|NCT03848130|OTHER|Lateral wedge insoles with Home Exercises|Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)
214676259|NCT05263882|DRUG|Gemcitabine combined with eribulin|"* Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~* Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~* The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
214676260|NCT05777525|COMBINATION_PRODUCT|"application of cream La Chinata"|application of cream enriched with essential oil
215074266|NCT03848130|OTHER|Traditional Physiotherapy with Home Exercises|Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors \& abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
214676261|NCT00705510|DRUG|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
214676262|NCT00411515|DRUG|Mycophenolate Mofetil 2x 1g|
214941154|NCT04441684|DIAGNOSTIC_TEST|Blood sample for serological test|"Serology tests:~* By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~* ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed."
214941155|NCT01443494|OTHER|NE|norepinephine
214676263|NCT00451087|PROCEDURE|leg press training|quadriceps muscle strengthening. 30min/ 3times/ week
214676264|NCT00451087|PROCEDURE|isokinetic training|quadriceps muscle training. 30 min/ 3 times/ week
214676265|NCT00527852|DEVICE|Flocked swab|
214941156|NCT06011304|DRUG|[18F]Florastamin Injection|"The subjects who participate in phase 3 study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 110 min after the injection.~Subjects who participate in pilot study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 5 min, 30 min, 60 min, 110 min, 160 min after the injection."
214941157|NCT05998434|BEHAVIORAL|Improving Low Back Pain Through Motor Control Training|In the digital healthcare group, participants utilized app-based online motor control training. In contrast, participants in the traditional treatment group underwent motor control training under the guidance of healthcare professionals at the hospital.
214941158|NCT06052540|DIETARY_SUPPLEMENT|Probiotic supplement|"* Stick: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Maltodestrins~* Drops: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Medium chain triglycerides, vegetable fats, emulsifier, and maltodextrin."
214941159|NCT06052540|DIETARY_SUPPLEMENT|Placebo|"* Drops: Medium Chain Triglycerides, vegetal oil, E471, and maltodextrin~* Stick: Maltodextrin."
214941160|NCT04417140|BIOLOGICAL|dHACM (AmnioWrap)|Dehydrated human amnion-chorion membrane (dHACM) is a healing adjunct that has been applied in a broad range of disease, and is FDA registered for wound healing.
214941161|NCT04683354|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. It will be given twice or three times daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative antitumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
214941162|NCT06402591|DRUG|Cefazolin|cefazolin extended prophylaxis 5 days (15 doses)
214941163|NCT05152654|DEVICE|Tacker|metallic staples used to fix the mesh
214676266|NCT02354001|DRUG|Raloxifene hydrochloride|120mg daily- 1 capsule for 12 week trial
214676267|NCT02354001|DRUG|Placebo|1 capsule daily for 12 week trial - lactose
214676268|NCT04598438|BEHAVIORAL|Music behavioral early intervention program|The program consists of carefully designed play-based enhancement strategies implemented in the form of hybrid online/in-person playgroups. Following a teach-model-coach-review approach, parents will learn to implement various skills that are expected to enhance infant's language and communication skills through singing and engaging in musical play with their child at home.
214676269|NCT04598438|BEHAVIORAL|Arts and crafts early enhancement program|The program follows the same general structure with the music intervention program. Parents will learn how to implement a series of arts and crafts activities at home, with an aim to enhance infant's visual-perceptual, motor, and sensory integration development.
214676270|NCT01430195|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
214941164|NCT06618365|DRUG|Vitamin D Deficiency|"The first phase will involve studying 4 groups with the outcome (percentage of patients attaining Vitamin D levels \&gt;30ng/ml) at 3 months to show the superiority of any of the groups. Vitamin D levels will be checked at baseline then 6 and 12 weeks. The second phase will include only patients who achieve the target level above 30ng/ml after the first phase and will be randomized to receive either oral Vitamin D2 or oral Vitamin D3 every 2, 3 or 4 weeks for another 3 months.~For patients that achieved normal level in phase 1, we will keep a maintenance dose of the oral Vitamin D for 2 groups with 3 sub-groups under each."
214941165|NCT02994758|OTHER|Personalised treatment|Treatment based on NGS or DSRT
214941166|NCT00911209|BEHAVIORAL|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
214941167|NCT03056365|PROCEDURE|Advanced Nurse (AN)|Protocoled AN-based management of detox
214941168|NCT03056365|PROCEDURE|General Practitioner (GP)|'As usual' medical management of detox
214941169|NCT01572467|GENETIC|RNA analysis|
214941170|NCT01572467|GENETIC|gene expression analysis|
214941171|NCT01572467|GENETIC|mutation analysis|
214941172|NCT01572467|GENETIC|reverse transcriptase-polymerase chain reaction|
214941173|NCT01572467|OTHER|laboratory biomarker analysis|
214941174|NCT01572467|OTHER|medical chart review|
214941175|NCT06348121|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study had last 56 days, and each patient will make 3 visits (d0, d28, d56).
214941176|NCT05436678|DRUG|PrimeC 748 mg|PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
214941177|NCT05436678|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
214941178|NCT05436678|DRUG|Celecoxib 200mg|Celecoxib
214338708|NCT04080973|DIAGNOSTIC_TEST|CT scan|non contrast spiral CT of the urinary tract including the bony structures of the spine and pelvis
214338709|NCT04080973|DIAGNOSTIC_TEST|24 hour urine collection|24 hours collection of urine and measurement of the concentration of calcium, phosphorous, uric acid, oxalate and citrate
214941179|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
214941180|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
214941181|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
214941182|NCT06124586|PROCEDURE|Percutaneous transluminal angioplasty|Percutaneous transluminal angioplasty of the leg
214338710|NCT00585754|DRUG|Guanfacine|1.5mg BID
214338711|NCT00585754|DRUG|Placebo|placebo
214338712|NCT00003945|DRUG|cisplatin|
214338713|NCT00003945|DRUG|topotecan hydrochloride|
214338714|NCT02691858|DRUG|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
214338715|NCT02691858|DRUG|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
214338716|NCT04979221|DRUG|Cyproheptadine|Cyproheptadine 8mg three times a day during 10 days
214338717|NCT06100614|DIAGNOSTIC_TEST|Presepsin|"Umbilical cord blood or blood from the first routine venous puncture within four hours after birth will be used for presepsin determination. Presepsin measurement can be performed in 100 μl plasma with PATHFAST™ Presepsin which is a rapid chemiluminescent enzyme immunoassay (Mitsubishi Chemical Medience corporation, Tokyo, Japan) with results available within 15 minutes."
214941183|NCT04118556|BIOLOGICAL|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
214941184|NCT04118556|DRUG|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
214941185|NCT01839305|OTHER|Hydrotherapy|Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
214941186|NCT03759145|OTHER|Exergame|Participants use exergame with the therapist in the rehabilitation center. Several games are available, the therapist adjusts the choice of game and level of difficulty according to the participant's abilities and interests.
214676271|NCT01430195|PROCEDURE|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
214941187|NCT03759145|OTHER|usual care|participants continued their planned rehabilitation sessions
214941188|NCT02702141|DRUG|SGN-CD19B|Given intravenously Day 1 of 28-day or 42-day cycles
214941189|NCT04174937|DRUG|Potentiator of antibiotics (PA)|Intervention is administered to patients in this Arm
214941190|NCT04174937|OTHER|Placebo PA|Intervention is administered to patients in this Arm
214941191|NCT04769739|OTHER|CO2|using CO2 insufflation to help insertion
214941192|NCT04769739|OTHER|Water|using water instead of traditional gas to help insertion
214941193|NCT04769739|OTHER|50% saline|using 50% saline solution instead of traditional gas to help insertion
214338718|NCT06100614|DIAGNOSTIC_TEST|Standard Care|Standard care according to the Dutch EOS guideline
214338719|NCT03586999|DRUG|Nivolumab|Nivolumab injection is to be administered as an IV infusion.
214941194|NCT04769739|OTHER|25% saline|using 25% saline solution instead of traditional gas to help insertion
214941195|NCT01669200|OTHER|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
214941196|NCT01669200|OTHER|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
214941197|NCT01922154|DRUG|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
214941198|NCT01922154|PROCEDURE|Trabeculectomy with mitomycinC|All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
214941199|NCT02657070|BEHAVIORAL|Reinforcement-Induced Movement Therapy (RIMT)|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
214941200|NCT02657070|BEHAVIORAL|VR-based motor rehabilitation in RGS without augmented feedback|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
214941201|NCT02081664|BEHAVIORAL|lifestyle intervention|
214941202|NCT06977724|DRUG|ABBV-319|Intravenous (IV) Infusion
214941203|NCT06679257|DIAGNOSTIC_TEST|cell-free dNA|Blood samples taker per protocol, analyses performed by a lab blinded to the status of the respective patients
214941204|NCT06678893|DEVICE|Acupuncture Needle on an adhesive|This study utilizes acupuncture needs on small adhesives which will be placed according to the 5NP NADA Auricular Acupuncture Protocol.
214941205|NCT06678893|DEVICE|Adhesives|For those randomized to the placebo arm, adhesives without needles will be placed according to the 5NP NADA Auricular Acupuncture Protocol placement
214941206|NCT06347068|BIOLOGICAL|iC9-CAR.B7-H3 T Cell Therapy|iC9-CAR.B7-H3 T cells will then be administered intravenously
214941207|NCT06347068|DRUG|cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
214941208|NCT06347068|DRUG|fludarabine|fludarabine 30 mg/m2 IV will be given.
214941209|NCT03689543|DRUG|Estradiol|Estradiol patch 0.1 mg transdermal every three days for three weeks
214941210|NCT03689543|DRUG|ER Beta Agonist|Lilly Compound LY500307, a selective estrogen receptor (ER) beta agonist
214941211|NCT03689543|OTHER|Placebo|Placebo orally once daily
214941212|NCT03689543|DRUG|Provera|Provera 5 mg orally once a day for one week after completion of randomization
214338720|NCT03586999|DRUG|Etoposide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
214338721|NCT03586999|DRUG|Prednisolone|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
214338722|NCT03586999|DRUG|Oncovin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
214338723|NCT03586999|DRUG|Cyclophosphamide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
214486444|NCT06875037|PROCEDURE|Traditional orthodontic fixed appliance without accleration|The traditional method of canine retraction will be employed using fixed appliances. No additional appliances will be used to activate orthodontic tooth movement.
214941213|NCT05921578|DIAGNOSTIC_TEST|Pre-operative planning based on CBCT|Pre-operative planning based on CBCT
214941214|NCT01451632|DRUG|MM-121|escalating doses MM-121 IV QW
214941215|NCT01451632|DRUG|Irinotecan|180 mg/m2 IV Q2W
214941216|NCT01451632|DRUG|Cetuximab|escalating doses cetuximab IV QW
214941217|NCT00005604|BIOLOGICAL|recombinant interleukin-12|Given IV
214941218|NCT00005604|BIOLOGICAL|aldesleukin|Given SC
214941219|NCT00005604|OTHER|laboratory biomarker analysis|Correlative studies
214941220|NCT05764746|DRUG|Artemether-lumefantrine and Amodiaquine Drug Combination|AL and AQ will be given together for three days then followed by placebo for three days
214941221|NCT05764746|DRUG|Artemether-lumefantrine then Artesunate amodiaquine|AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days
214941222|NCT05764746|DRUG|Artemether-lumefantrine|This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
214941223|NCT05538975|OTHER|Physiotherapy Treatment|Pulmonary Rehabilitation Techniques
214941224|NCT05843201|DEVICE|The AquaPass System|The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.
214941225|NCT04891406|OTHER|A|Use of product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes
214941226|NCT04891406|OTHER|B|Use of product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 minutes
214941227|NCT04891406|OTHER|C|Use of product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 minutes
214941228|NCT04891406|OTHER|D|Use of product D (Nicotine pouch, 10.6 mg/pouch) for 20 minutes
214941229|NCT04891406|OTHER|E|Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes
214941230|NCT02966119|DRUG|Clopidogrel or Aspirin and/or Dypyridamole|"The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart"
214941231|NCT00585715|DEVICE|1064 nm Nd:YAG laser|3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms
214941232|NCT05717764|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
214941233|NCT05717764|DRUG|Capecitabine|Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
214941234|NCT06258317|PROCEDURE|fixation of conventional polypropylene mesh|"By fixation of the polyprolene mesh,patients will be divided into two groups:~Group 1 includes patients with fixation of conventional polypropylene mesh. Group 2 includes patients without fixation of the mesh."
214941235|NCT01920659|BEHAVIORAL|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
214941236|NCT01920659|BEHAVIORAL|REHIT|6 weeks 3 x week (20sec intervals)
214941237|NCT01634659|DEVICE|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
214941238|NCT01634659|DEVICE|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
214941239|NCT03969303|DEVICE|Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)|OCT SCAN
214941240|NCT02431806|DRUG|Placebo|Matched over-encapsulated placebo capsules administered orally on Day 1 to Week 8.
214941241|NCT02431806|DRUG|Levomilnacipran|Over-encapsulated levomilnacipran ER capsules administered orally on Day 1 to Week 8.
214941242|NCT02431806|DRUG|Fluoxetine|Over-encapsulated fluoxetine tablets administered orally on Day 1 to Week 8.
214338724|NCT03586999|DRUG|Hydroxydaunorubicin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
214338725|NCT04096560|DRUG|TAK-994|TAK-994 tablets.
214338726|NCT04096560|DRUG|Placebo|TAK-994 placebo-matching tablets.
214338727|NCT01142258|DRUG|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
214338728|NCT01142258|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
214338729|NCT00501605|DRUG|AZD2171|
214338730|NCT04779957|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.
214338731|NCT02464969|DRUG|Apixaban|Tablet or Solution
214338732|NCT02464969|DRUG|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
214338733|NCT04589065|DEVICE|Selective Cytopheretic Device|SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
214338734|NCT05898399|DRUG|ART6043|ART6043 will be given orally.
214486445|NCT06782815|DEVICE|Acupuncture|acupuncture Baihui, Sishencong ; acupuncture bilateral Qimen, Zhangmen, Hegu, Taichong, reinforcing and reducing, until the acid swelling is obvious,stopped ferforming acupuncture, the needle was retained for 30 min.
214486446|NCT06782815|DEVICE|Acupuncture|（1）Acupuncture bilateral Tianrong points, obliquely 45 ± 5 ° backward, 1-1.5 inch deep, reinforcing and reducing horizontally, and stop the needle when the auricle has a heat sensation ; （2）Acupuncture at bilateral Tianyou points, pointing to the tip of the nose, with a depth of 0.5-1 inches, flat reinforcing and reducing, until the sense of soreness and distension obviously stops, and the needle is retained for 30 minutes.
214941243|NCT01246037|DRUG|Bisoprolol|In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
214941244|NCT03108872|DEVICE|left atrial appendage occlusion|Percutaneous exclusion of left atrial appendage with Watchman or ACP devices
214941245|NCT03108872|DRUG|New oral anticoagulants|Include dabigatran, rivaroxaban, apixaban and edoxaban
214941246|NCT06098963|DEVICE|sacral neuromodulation|sacra neuromodulator implantation outcomes
214338735|NCT05898399|DRUG|Olaparib|Olaparib will be given orally.
214338736|NCT05898399|DRUG|Niraparib|Niraparib will be given orally.
214338737|NCT03380923|BEHAVIORAL|Moderate Intensity|Exercise prescription intensity is moderate
214941247|NCT06080880|DRUG|Ondansetron every 3 weeks|Ondansetron, Po, 24mg/d, 3 days' application every 3 weeks
214941248|NCT06080880|DRUG|Aprepitant|aprepitant, Po, 125mg/d, 1day' application every 3 weeks
214941249|NCT06080880|DRUG|Dexamethasone|dexamethasone, iv, 10mg/d, 1day' application every 3 weeks
214941250|NCT06080880|DRUG|Ondansetron weekly|Ondansetron, Po, 24mg/d, 3 days' application weekly
214338738|NCT03380923|BEHAVIORAL|High Intensity|Exercise prescription intensity is high
214338739|NCT00534352|DRUG|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
214338740|NCT04143347|OTHER|No Intervention|
214338741|NCT01591746|DRUG|Botulinum Toxin Type A|
214338742|NCT01591746|DRUG|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
214338743|NCT03450551|DEVICE|Twin Block, Herbst, Frog distalising appliance|To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
214941251|NCT03363451|DRUG|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment
214941252|NCT03627416|DEVICE|rTMS|high frequency rTMS to induce the long term potentiation of primary motor areas for the muscles of lower extremities
214941253|NCT01795092|OTHER|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
214941254|NCT03227172|PROCEDURE|apicoectomy|After flap elevation and osteotomy , peri-apical lesion and the root tip were located: after root-end resection using a fissure bur, the resected root tip and the pathological tissue were removed and immediately preserved in 1% formaldehyde solution.
214941255|NCT06624033|OTHER|amino acids kinetics|"After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured."
214941256|NCT04760288|DRUG|Pralsetinib|Participants will receive pralsetinib at a dose of 400 mg, as per the dosing schedule described above.
214941257|NCT04760288|DRUG|Cabozantinib|Adult participants will receive cabozantinib at a dose of 140 mg, as per the dosing schedule described above.
214941258|NCT04760288|DRUG|Vandetanib|Adult participants will receive vandetanib at a dose of 300 mg and adolescent participants will receive vandetanib as per the dosing schedule described above.
214941259|NCT02968433|DRUG|Infusions of young plasma|Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
214941260|NCT01916603|BEHAVIORAL|Normative Intervention|Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
214941261|NCT00043667|DRUG|Daclizumab|
214941262|NCT04291664|DRUG|Abiraterone Acetate|Abiraterone Acetate 1000mg will be administered orally once daily
214941263|NCT04291664|DRUG|Prednisone 5Mg Tab|"Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped"
214941264|NCT04291664|DRUG|DST-2970 (Abiraterone)|DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped
214941265|NCT06647901|DRUG|ICG (Indocyanine Green)|Patients will be receive intravenously administrated at a dose of 2 mg/kg on the day before surgery. The drug was dissolved into 250 mL of normal saline and administered using a light-proof infusion apparatus. The time course of administration was 60 min. NIR imaging will be performed during surgery to help identify small tumor residuals.
214941266|NCT00877149|DRUG|telbivudine/LDT600|
214941267|NCT02079636|DRUG|Abemaciclib|Administered orally
214941268|NCT02079636|DRUG|Pemetrexed|Administered IV
214941269|NCT02079636|DRUG|Gemcitabine|Administered IV
214941270|NCT02079636|DRUG|Ramucirumab|Administered IV
214941271|NCT02079636|DRUG|LY3023414|Administered orally
214941272|NCT02079636|DRUG|Pembrolizumab|Administered IV
214941273|NCT06234696|OTHER|entrepreneurial intervention|The experimental group will be given psychoeducation for 4 weeks.
214941274|NCT06184113|PROCEDURE|Aortic valve replacement surgery|Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.
214941275|NCT06184113|DIAGNOSTIC_TEST|Computed tomography|All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.
214941276|NCT06184113|DIAGNOSTIC_TEST|Echocardiography|All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.
214941277|NCT00006013|DRUG|semaxanib|
214941278|NCT03058224|DRUG|IGN-ES001|Only active product will be compared with placebo as described in Arms and Interventions.
214941279|NCT03058224|DRUG|Parol 500 mg Tablets (acetaminophen)|Analgesic Rescue Medication
214941280|NCT06252701|BEHAVIORAL|Reduction of Ultra-processed foods|Reduction of Ultra-processed foods for four weeks.
214941281|NCT04096443|BIOLOGICAL|Fecal microbial transplant (FMT)|Oral fecal microbial transplant capsules
214941282|NCT05593536|BEHAVIORAL|Breastfeeding Education|Biological feeding and classical breastfeeding trainings will be given to pregnant women by a trained nurse.
214941283|NCT02437032|DRUG|recombinant FSH|Controlled ovarian stimulation with 150-300 UI recombinant FSH
214941284|NCT02437032|DRUG|Urinary FSH|Controlled ovarian stimulation with 150-300 UI urinary FSH
214941285|NCT02437032|DRUG|hMG|Controlled ovarian stimulation with 150-300 UI hMG
214941286|NCT00875433|DRUG|BIBW 2992|patients to receive continuous oral daily dosing of BIBW 2992
214941287|NCT00689559|DRUG|AZD3480|AZD3480 capsules qd, oral, 22 days
214941288|NCT00689559|DRUG|Placebo|Placebo qd, 12 days
214941289|NCT00689559|DRUG|Aripiprazole|single dose on day 5
214941290|NCT04781829|DIAGNOSTIC_TEST|BioFire Pneumonia Panel|Treatment based on an algorithm that recommends antibiotic choices based on bacteria/virus detected by BioFire Pneumonia Panel
214941291|NCT01167049|DRUG|CAPECITABINE|Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
214941292|NCT03604991|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214941293|NCT03604991|DRUG|Carboplatin|Given IV
214941294|NCT03604991|PROCEDURE|Computed Tomography|Undergo CT scan
214941295|NCT03604991|BIOLOGICAL|Ipilimumab|Given IV
214941296|NCT03604991|BIOLOGICAL|Nivolumab|Given IV
214941297|NCT03604991|DRUG|Paclitaxel|Given IV
214941298|NCT03604991|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214941299|NCT03604991|RADIATION|Radiation Therapy|Undergo radiation therapy
214941300|NCT06594016|DRUG|Fosigotifator|Oral
214941301|NCT06592768|DRUG|Briquilimab|Subcutaneous Administration
214941302|NCT06592768|OTHER|Placebo Comparator|Subcutaneous Administration
214941303|NCT06668922|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
214338744|NCT04594512|OTHER|Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery|A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
214338745|NCT03539380|DRUG|TRx0237|Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)
214941304|NCT06865495|OTHER|Handwashing Hardware and Supply Provision|Households will be given a locally available handwashing facility called the Kalingalinga bucket. Intervention delivery workers will set-up the handwashing facility, and demonstrate how it works, including where to place soap on the stand. Households will also be given supplies and materials to make their own liquid soap from locally available soap products (soapy water). Discussions will also be held on HWF maintenance. This component of the intervention should take no longer than 30 minutes. Intervention delivery workers will return to households after three months (one visit) to ensure there are no issues with the handwashing station (e.g., broken stand or tap), to bring more liquid soap and to remind households how to make soapy water.
214941305|NCT06865495|BEHAVIORAL|Hand Hygiene Behavioural Promotion|"The hand hygiene behavioural promotion intervention employs interactive storytelling and visual aids to promote handwashing with soap. Intervention delivery workers will act as storytellers, narrating stories about three characters with different handwashing habits.~The intervention progresses through five bi-weekly visits, with a final sixth visit 4 weeks after the fifth visit. The 30-minute visits progress through different stages: (1) identifying behaviours, (2) understanding disease risks, (3) encouraging practical solutions and (4) promoting practice. The penultimate stage of the intervention focuses on reflection and commitment, encouraging participants to assess their behaviours and pledge to adopt improved hygiene practices. The final visit allows participants to reflect on the whole intervention and covers information participants would like to revisit."
214941306|NCT05617079|OTHER|Survey|an electronic survey will be conducted
214941307|NCT06992362|DRUG|Perioperative treatment|RC48+SOX+Sindilizumab
214941308|NCT06255379|DRUG|Fuquinitinib+Tegafur Gimeracil Oteracil|Fuquinitinib:5 mg once daily, 2 weeks on/1 week off,q3w; Tegafur Gimeracil Oteracil:BSA(body surface area)\< 1.2m2,40mg/m2,p.o,bid,2 weeks on/1 week off,q3w; 1.2m2 \< BSA （body surface area）\< 1.5m2,50mg/m2,p.o,bid,2 weeks on/1 week off,q3w;BSA（body surface area） \>1.5m2,60mg/m2,p.o,bid,2 weeks on/1 week off,q3w;
214941309|NCT00622336|DRUG|CC-5013|Oral 25mg daily on Days 1-21 every 28 days.
214941310|NCT00622336|DRUG|Lenalidomide|Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
214941311|NCT06998524|DRUG|Emicizumab|"Participants will receive emicizumab 3 milligrams per kilogram (mg/kg) subcutaneous (SC) injections every week (QW) for the first 4 weeks as loading doses, followed by maintenance doses of emicizumab 3 mg/kg SC once every 2 weeks (Q2W).~During the extension period, participants may remain on maintenance dose of emicizumab 3 mg/kg Q2W, or change their emicizumab maintenance regimen to 1.5 mg/kg once every week (QW) or 6 mg/kg once every 4 weeks (Q4W), if they prefer and if agreed by the investigators."
214941312|NCT06998524|DRUG|von Willebrand Factor (VWF) Concentrates|Used according to local labeling or local treatment guidelines.
214941313|NCT06998524|DRUG|Factor VIII (FVIII) Concentrates|Used according to local labeling or local treatment guidelines.
214941314|NCT06998524|DRUG|von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates|Used according to local labeling or local treatment guidelines.
214941315|NCT06998524|DRUG|Bypassing Agents|Used according to local labeling or local treatment guidelines.
214941316|NCT04520516|DEVICE|Active VAGUSTIM device|Settings: 25 Hz stimulation, 100 microsec pulse width, intensity escalation up to 8 mA or below if tingling sensation, 20 min/day of stimulation in one daily session
214941317|NCT04520516|DEVICE|Sham VAGUSTIM device|The sham device : no electrical signal for VNS will be delivered.
214941318|NCT07003386|DRUG|Galantamine|Start within 24 hours of hospitalization, administer 5.0 mg of galantamine via intramuscular injection once daily, and continue the treatment for 10 days.
214941319|NCT07003386|DRUG|Standard treatment for acute ischemic stroke|Standard treatment for acute ischemic stroke
214941320|NCT07004790|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|A non-invasive bedside diagnostic procedure used to measure cerebral blood flow velocities and pulsatility index in intracranial arteries, primarily the middle cerebral artery (MCA). The test is performed within the first 24 hours of symptom onset using standard ultrasound equipment with a 2-MHz probe. The data collected is used solely for prognostic evaluation and does not influence treatment decisions.
214941321|NCT04837547|BIOLOGICAL|Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)|There will be two immunotherapy products manufactured and administered to subjects enrolled on this trial. The first product will be autologous dendritic cells (DCs) loaded with total tumor messenger ribonucleic acid (mRNA) (TTRNA) derived from malignant tumors. The second product will be autologous T lymphocytes stimulated ex vivo against TTRNA antigens for autologous transfer (TTRNA-xALT). DCs are professional antigen-presenting cells critical for the initiation of B and T-cell responses in vivo.
214941322|NCT04858880|RADIATION|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.
214941323|NCT06542432|GENETIC|Disclosure of integrate risk score for coronary artery disease|Participants will receive their integrated risk score for coronary disease along with an optional genetic counseling visit to discuss the results.
214941324|NCT07006948|DIAGNOSTIC_TEST|Autism Diagnostic Observation Schedule, the 2nd edition(ADOS-2)|The toddlers diagnosed with ASD will receive the ADOS-2 evaluation to confirm the diagnosis.
214676272|NCT05207267|DEVICE|driving pressure guided tidal volume|Volume control mode without spontaneous breathing, PEEP will be set according to best respiratory compliance method, and tidal volume (VT) will be set to reach three levels of driving pressure (High 14-15cmH2O, moderate 10-11 cmH2O, and low 7-8 cmH2O). Each level of VT was maintained 10 minutes in supine and/or prone position.
214676273|NCT00855712|DEVICE|Organ Care System|The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
214338746|NCT03735420|DRUG|Xanthohumol|The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
214338747|NCT03735420|DRUG|Placebo oral capsule|The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
214941325|NCT07006948|DIAGNOSTIC_TEST|Griffiths Developmental Scales, Chinese edition(GDS-C)|The toddlers diagnosed with ASD, GDD, LD, and typically developing will receive the GDS-C evaluation to confirm the diagnosis.
214338748|NCT05234944|BEHAVIORAL|Type 1 Diabetes and Life|Brief behavioral intervention, delivered remotely by certified diabetes care and education specialists, targeting diabetes-specific health-related quality of life for people with type 1 diabetes across the lifespan and for their parents and partners.
214338749|NCT02399085|DRUG|Tafasitamab|12 mg/kg
214338750|NCT02399085|DRUG|Lenalidomide|25 mg
214338751|NCT01969071|DRUG|Levosimendan|The effects of levosimendan on renal function
214338752|NCT01969071|DRUG|Dobutamine|Standard Inotropic agent
214338753|NCT04245488|OTHER|taste test|rate intensity of sour solutions and fatty acid solutions
214941326|NCT06868264|DRUG|Bemnifosbuvir-Ruzasvir (BEM/RZR)|BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
214941327|NCT06868264|DRUG|Sofosbuvir-Velpatasvir (SOF/VEL)|SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
214941328|NCT07003789|BEHAVIORAL|Women-Centered HIV Prevention Program|This behavioral intervention consists of a participatory, youth-designed HIV prevention program that uses Human-Centered Design (HCD) principles and WhatsApp-based engagement. It includes information and support for HIV self-testing and PrEP, with the goal of increasing awareness, improving uptake, and reducing stigma among young women in Ghana.
214941329|NCT05186974|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
214941330|NCT05186974|DRUG|Pembrolizumab|Administered intravenously
214941331|NCT05186974|DRUG|Carboplatin|Administered intravenously
214941332|NCT05186974|DRUG|Cisplatin|Administered intravenously
214941333|NCT07008378|BIOLOGICAL|P-CD19CD20-ALLO1 Cells|P-CD19CD20-ALLO1 Cells will be administered intravenously as per the schedule specified in the protocol.
214941334|NCT07008378|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
214941335|NCT07008378|DRUG|Fludarabine|Fludarabine will be administered intravenously.
214941336|NCT04739813|BIOLOGICAL|obinutuzumab|administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214941337|NCT04739813|DRUG|prednisone|administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214941338|NCT04739813|DRUG|Revlimid|administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214338754|NCT00902356|DRUG|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
214338755|NCT00902356|DRUG|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
214338756|NCT01144104|BEHAVIORAL|Public Service Announcement|
214338757|NCT01144104|BEHAVIORAL|Interactive Multi-Media Computer Program|
214338758|NCT01144104|BEHAVIORAL|Sleep Hygiene Video|
214941339|NCT04739813|BIOLOGICAL|Polatuzumab|administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214941340|NCT04739813|DRUG|ibrutinib|administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214941341|NCT04739813|DRUG|venetoclax|administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
214941342|NCT06870591|DEVICE|Cardiac Performance System (CPS)|CPS is a non-invasive platform for hemodynamic assessment that uses acoustic sensors and electrocardiogram electrodes.
214676274|NCT00855712|DEVICE|Cold Cardioplegia Solution|This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
214941343|NCT07009210|BEHAVIORAL|AI Assisted Personalized Legacy Program|AI Assisted Personalized Legacy Program will be facilitated by a clinician trained in legacy work.
214676275|NCT00256555|DRUG|Nutropin AQ|
214676276|NCT01115712|DRUG|Placebo|Placebo (to match pioglitazone 30 mg) once daily
214338759|NCT01260987|DRUG|Conventional photodynamic therapy|Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
214338760|NCT01260987|DRUG|Fractional CO2 laser assisted PDT|Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
214338761|NCT02782481|DRUG|ND0612|
214338762|NCT02782481|DRUG|Placebo|
214338763|NCT05167344|BEHAVIORAL|Healthy Relationships Program-Enhanced|The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
214338764|NCT04428632|DRUG|Berotralstat|One 150mg capsule administered orally once daily
214338765|NCT05441059|DRUG|Mepolizumab 100 MG|Treatment with mepolizumab for severe asthma
214338766|NCT03104504|BEHAVIORAL|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
214338767|NCT03104504|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
214338768|NCT03104504|BEHAVIORAL|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
214941344|NCT04794322|DIAGNOSTIC_TEST|Uterine lavage, or a wash of the womb|Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.
214941345|NCT04794322|DIAGNOSTIC_TEST|Blood sample|Participants undergo two blood draws (one required, one optional) up to 31 days before surgery
214941346|NCT04794322|DIAGNOSTIC_TEST|Pap smear|Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.
214338769|NCT03104504|BEHAVIORAL|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
214941347|NCT07011342|DRUG|18F-rhPSMA-7.3|Utility of 18F-rhPSMA-7.3 in the diagnosis of prostate cancer after Focal Gland Treatment (SCOUT)
214676277|NCT01115712|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg once daily
214676278|NCT01115712|DRUG|Comparator: Hyperinsulinemic Euglycemic Clamp|Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
214676279|NCT06232122|DIAGNOSTIC_TEST|68Ga-FAPI-46|Intravenous injection of one dosage of 2 mCi 68Ga-FAPI-46
214676280|NCT06232122|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 5-10mCi 18F-FDG
214676281|NCT00942708|DRUG|Fluoxetine|"Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID"
214676282|NCT05082870|BEHAVIORAL|Supportive-expressive group therapy (SEGT)|The SEGT approach fosters mutual support, promotes openness and emotional expression. SEGT will be delivered and co-facilitated by a psychiatrist and an allied healthcare professional. It is a 6-module program held over a 3-week period (approximately 2 hour sessions X 2 week) that is framed within social cognitive theory, whereby resilience to adversity (limb loss in this instance) relies on personal enablement.
214676283|NCT01975025|PROCEDURE|Short daily dialysis for 2 weeks|
214676284|NCT03836521|DEVICE|Transcatheter aortic valve replacement|
214338770|NCT02634658|OTHER|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
214676285|NCT02355379|DRUG|LV5FU2 or capectitabine|
214676286|NCT02355379|DRUG|FOLFOX4 or XELOX|
214676287|NCT02355379|OTHER|Observation|
214676288|NCT02355379|DRUG|LV5FU2 or capecitabine|
214676289|NCT00156078|DRUG|pregabalin|
214676290|NCT02596880|DRUG|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
214338771|NCT02634658|OTHER|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
214676291|NCT02596880|DRUG|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
214676292|NCT02596880|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
214676293|NCT00974662|DRUG|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 \& 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
214941348|NCT06394557|PROCEDURE|In-office Dental Bleaching Conventional|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 7 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
214941349|NCT06394557|PROCEDURE|In-office Dental Bleaching Alternative|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 2 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
214941350|NCT07008456|DRUG|APHD-012|12 g dextrose beads
214941351|NCT07008456|DRUG|APHD-002|2 g dextrose beads
214941352|NCT07008456|DRUG|APHP-012|12 g placebo beads
214941353|NCT07008456|DRUG|APHP-002|2 g placebo beads
214941354|NCT07005362|BEHAVIORAL|Fitbit and AI Chatbot|Participants will wear their Fitbit devices daily for 12-weeks and will receive personalized messages from the AI Chatbot every week with a new exercise recommendation based on their previous week's activity level. Additionally, they can engage with the AI Chatbot through text message for further support and education.
214941355|NCT07005362|OTHER|Routine Care|The control group will consist of patients with type 2 diabetes who meet the study's inclusion criteria but have not participated in the intervention.
214941356|NCT03964506|DRUG|Hyperbaric oxygen|Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
214941357|NCT06619860|DRUG|VX-993|Tablets for oral administration.
214941358|NCT06619860|DRUG|Pregabalin|Capsules for oral administration.
214941359|NCT06619860|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
214941360|NCT06619860|DRUG|Placebo (matched to VX-993)|Placebo matched to VX-993 for oral administration.
214941361|NCT06624059|DRUG|Alectinib|"Cohort B1: participants will receive oral alectinib twice daily (BID) for up to 5 years.~Cohort B2: Participants will receive oral alectinib BID for 3 cycles (cycle length = 3 weeks) prior to surgery, and for up to 5 years after surgery."
214941362|NCT06624059|DRUG|Cisplatin|"Cohort B1: Participants will receive intravenous (IV) cisplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV cisplatin on Day 1 of each cycle for up to 3 cycles (cycles length = 3 weeks) prior to surgery."
214941363|NCT06624059|DRUG|Carboplatin|"Cohort B1: Participants will receive IV carboplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV carboplatin on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery."
214941364|NCT06624059|DRUG|Pemetrexed|"Cohort B1: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery."
214941365|NCT07012291|DEVICE|Whole Blood Clotting Time|"Fresh whole blood samples from patients on rivaroxaban or apixaban taken at various times during the day to obtain samples from DOAC patients that represent the entire analytical range to the extent possible, as opposed to a strict trough/peak testing schedule."
214941366|NCT07012291|DEVICE|Whole Blood Clotting Time|Fresh whole blood samples, non-citrated, are drawn and loaded onto a cuvette free of any biological reagents, to obtain a whole blood clotting time value.
214941367|NCT07021248|DIETARY_SUPPLEMENT|Elan Believe|Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Believe for SG addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.
214941368|NCT07021248|DIETARY_SUPPLEMENT|Elan Compass|Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Compass for RYGB addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.
214941369|NCT07021248|DIETARY_SUPPLEMENT|Elan Supreme|Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Supreme for OAGB addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.
214941370|NCT05497960|BEHAVIORAL|Vivo workout|2 days a week for 12 weeks of a live, interactive virtual strength training program. Each class is 45 minutes long and lead by a certified trainer.
214941371|NCT07021170|DIETARY_SUPPLEMENT|Elan Believe|Elan Believe is formulated specifically for patients undergoing SG and contains 18 mg of elemental zinc.
214941372|NCT07021170|DIETARY_SUPPLEMENT|Elan Compass|Elan Compass is tailored for RYGB and contains 24 mg of zinc.
214941373|NCT07021170|DIETARY_SUPPLEMENT|Elan Supreme|Designed for OAGB, provides 36 mg of zinc.
214941374|NCT07021170|DIETARY_SUPPLEMENT|Standard Multivitamins|Over-the-counter multivitamin containing 100% of the recommended daily allowance (RDA) for essential vitamins and minerals. Unlike the specialized formulations, the standard multivitamin is not designed to accommodate the altered gastrointestinal absorption characteristics of post-MBS patients.
214941375|NCT04148287|DRUG|APX001|Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
214676294|NCT03389672|PROCEDURE|spinal anesthesia|For conventional spinal anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
214676295|NCT03389672|PROCEDURE|epidural anesthesia|For conventional epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
214941376|NCT05410145|DRUG|D3S-001|Oral
214941377|NCT05410145|DRUG|Pembrolizumab|Intravenous
214941378|NCT05410145|DRUG|Cisplatin|Intravenous
214941379|NCT05410145|DRUG|Carboplatin|Intravenous
214338772|NCT02634658|OTHER|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
214338773|NCT03639155|DRUG|vadadustat reference tablets|oral tablet
214338774|NCT03639155|DRUG|vadadustat test tablets|oral tablet
214338775|NCT06368128|BEHAVIORAL|Indoor Rock Climbing Exercise Training Program|Training will occur 2-3 days per week for 60 minutes; ratings of perceived exertion between 3-7 on a scale of 0-10 will be targeted for the desired intensity throughout the program. Minutes of rock climbing will also be monitored to develop the progression strategy.
214338776|NCT01645709|DRUG|Verapamil|
214338777|NCT01645709|DRUG|Placebo|
214338778|NCT03290716|OTHER|SS|Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
214338779|NCT03290716|OTHER|SSSC|A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
214338780|NCT01180075|DRUG|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
214338781|NCT01180075|DRUG|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
214338782|NCT01180075|DRUG|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
214338783|NCT01180075|DRUG|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
214338784|NCT01180075|PROCEDURE|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
214338785|NCT02673697|DEVICE|Perceval valve|Sutureless Aortic Biological Valve
214338786|NCT02673697|DEVICE|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
214338787|NCT03821428|PROCEDURE|Acupuncture|Needling of P6 and CV24 points
214338788|NCT03821428|PROCEDURE|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
214338789|NCT05185024|DIETARY_SUPPLEMENT|Ferrous Sulfate Capsules|Once daily dose of one Ferrous Sulfate Capsule for 12 weeks in total.
214338790|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Capsules|Once daily dose of one \>Your\< Iron Forte Capsule for 12 weeks in total.
214338791|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Liquid|Once daily dose of 5 ml of \>Your\< Iron Forte Liquid for 12 weeks in total.
214338792|NCT05185024|OTHER|Blank Capsules|Once daily dose of one Blank Capsule (excipients only) for 12 weeks in total.
214338793|NCT05185024|OTHER|Blank Liquid|Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.
214338794|NCT04886141|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
214941380|NCT05410145|DRUG|Pemetrexed|Intravenous
214941381|NCT05410145|DRUG|Cetuximab|Intravenous
214941382|NCT06253117|DRUG|Pirfenidone|"Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day~Duration of treatment- total 6 months"
214941383|NCT06253117|DRUG|Placebo|Placebo
214941384|NCT06694688|DIAGNOSTIC_TEST|the supine/standing postural change test|The prevalence of orthostatic hypotension will be characterized by the percentage of patients with a decrease of ≥ 20mmHg in systolic blood pressure or ≥ 10mmHg in diastolic blood pressure following the supine/standing postural change position.
214941385|NCT06631768|OTHER|Casual labor subsidy|Eligible participants will be offered a voucher that can be redeemed for a set number of days of agricultural labor from casual laborers hired by local One Acre Fund offices. Casual laborers receive standard training in line with the trainings currently offered by the organization to participating farmers.
214941386|NCT06685965|DRUG|RE03|Buccal Dexmedetomidine
214941387|NCT06685965|DRUG|Placebo|Matching Placebo
214941388|NCT06492486|RADIATION|Adaptive radiotherapy|Volumetric and biological adaptive radiotherapy will be delivered based on interval imaging with MRI and PET scan during treatment.
214941389|NCT06686251|DEVICE|App LuAna|Inclusion of chest x-ray images in the LuAna app to receive feedback on lung findings.
214338795|NCT02573987|DRUG|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
214338796|NCT02573987|DRUG|Lidocaine|standard strategy by local injection anesthesia of lidocaine
214338797|NCT03632161|DRUG|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
214338798|NCT03632161|DRUG|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
214338799|NCT00002684|DRUG|cisplatin|
214338800|NCT00002684|DRUG|ifosfamide|
214338801|NCT00002684|DRUG|paclitaxel|
214338802|NCT01551862|PROCEDURE|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
214941390|NCT06185205|DRUG|Accelerated partial breast irradiation|High Dose Rate treatment delivery
214941391|NCT06702332|DRUG|MSD-001|MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications
214941392|NCT06702332|DRUG|Placebo Comparator|Matching Placebo
214941393|NCT06702592|BEHAVIORAL|Virtual support|Subjects will use a virtual support platform that was built for their needs.
214676296|NCT03389672|PROCEDURE|combined spinal-epidural anesthesia|For conventional combined spinal-epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
214676297|NCT01784549|DRUG|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
214676298|NCT01157858|DRUG|Everolimus|2.5 mg every day orally
214676299|NCT01157858|DRUG|Octreotide LAR|40 mg every 28 days IM
214676300|NCT04803786|DRUG|Transition from Xyrem to Xywav|This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
214676301|NCT05450861|OTHER|SF DNA extraction composition|the composition of small fragments of DNA from fish
214676302|NCT05450861|OTHER|Placebo|the scalp conditioning solution without SF DNA extraction composition
214676303|NCT00950417|DRUG|Nimotuzumab|
214676304|NCT05310383|COMBINATION_PRODUCT|Tislelizumab plus radiotherapy|During the period of radiotherapy, patients receiveTislelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Tislelizumab 200mg q3W was administered for up to 35 cycles (up to approximately 2 years) after radiotherapy until disease progression or toxicity.
214676305|NCT03378206|DEVICE|hinged 8-figure plate|Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.
214676306|NCT03378206|DEVICE|conventional 8-figure plate|Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
214338803|NCT01260233|OTHER|Smoking cessation program|"Smoking cessation program includes:~* brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~* smoking cessation brochures~* referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~* free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day"
214338804|NCT01070810|DRUG|D5W|Dextrose 5%
214338805|NCT01070810|DRUG|Thiamine|Thiamine 200mg in 50ml D5W
214338806|NCT02012374|BEHAVIORAL|Intensive Language Action Therapy|
214941394|NCT06702592|BEHAVIORAL|Patient educational material|Participants will have access to patient educational material.
214941395|NCT02144207|DEVICE|Glidescope|
214941396|NCT07044687|DRUG|Venetoclax|Oral Tablet
214941397|NCT07044687|DRUG|Azacitidine|Subcutaneous (SC) Injection
214676307|NCT02391727|BIOLOGICAL|SYN004|subjects who have received effective treatment for their cancers are eligible
214338807|NCT05281692|DIAGNOSTIC_TEST|Enhanced Preservation Media (EPM-IX)|EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.
214338808|NCT04897516|DRUG|Short regimen of benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.
214338809|NCT04897516|DRUG|Short treatment with benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks.
214338810|NCT04897516|DRUG|Standard treatment with benznidazole|Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks
214676308|NCT05121597|DEVICE|HugeMed Videolaryngoscope|Macintosh laryngoscope
214676309|NCT02760407|DRUG|Olokizumab 64mg q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
214676310|NCT02760407|DRUG|Olokizumab 64mg q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
214676311|NCT02760407|DRUG|Adalimumab 40mg q2w|0.4 or 0.8 mL prefilled, single-dose syringe
214941398|NCT07044687|DRUG|Azacitidine|Intravenous (IV) Injection
214941399|NCT06482437|DRUG|NMD670|Tablets taken twice daily for 21 days
214941400|NCT06482437|DRUG|Placebo|Tablets taken twice daily for 21 days
214941401|NCT07059078|BEHAVIORAL|Brief Motivational Interviewing-based Alcohol Intervention|"Participants in both arms (BMAI and BMAI + MT) will receive a brief motivational interviewing-based alcohol intervention (BMAI) delivered by a pediatric clinician in the primary care setting.~BMAI is adapted from the Provider Guide: Adolescent SBIRT Using the S2BI-CRAFFT Screening Tool, grounded in the stages of change model and motivational interviewing (MI). It consists of one or more brief sessions involving structured feedback, advice, and goal setting to help adolescents recognize links between substance use and health outcomes and develop personalized change plans. The intervention is face-to-face, delivered during routine or follow-up visits, and modeled after the brief negotiated interview. The first session lasts 10-30 minutes and includes six MI-based steps. This is followed by one or more additional brief MI sessions lasting 5-15 minutes where the patient's goals are reviewed, gains or barriers are addressed, and ongoing support is provided."
215074267|NCT03941964|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
215074268|NCT03941964|DRUG|Azacitidine|The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
215074269|NCT03941964|DRUG|Decitabine|The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
215074270|NCT01805908|OTHER|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
214941402|NCT07059078|BEHAVIORAL|Smartphone App-delivered Mindfulness Training|"In addition to BMAI, participants in the BMAI + MT arm will receive 8 weeks of smartphone-delivered mindfulness training using the Healthy Minds Program (HMP) app.~The HMP app provides self-guided, self-paced mindfulness and meditation training designed to improve psychological well-being, reduce stress/anxiety, and enhance self-regulation. It includes podcast-style teachings and guided meditations. The app features four modules-Awareness, Insight, Connection, and Purpose-based on neuroscience research. Each module offers 27 practices (5-30 minutes each). This study focuses on the Awareness and Insight modules, which teach breath and body awareness and emotion noting to support mindfulness in daily life. Participants will be asked to use the app 5-30 minutes per day, following 4 weeks of Awareness content, then 4 weeks of Insight. After 8 weeks, they will have open access to all modules and be encouraged to explore additional practices as they find helpful during follow-up."
214941403|NCT07059234|BEHAVIORAL|Non-exercise activity|The 5-week intervention to assess the effects of non-exercise activity on the activity-subjective energy association incorporates two high-intensity Ambulatory Assessment (AA) weeks at the beginning and end, with a tapered 3-week Ecological Momentary Intervention (EMI) phase in between. Momentary targeted micro interventions (JITAIs) with a Within-Person-Encouragement Design (WPED) are used to tailor the activity to the individual situation and phenotype of each participant.
214941404|NCT07054190|DRUG|Inavolisib|Inavolisib will be administered as per the schedule specified in the arms
214941405|NCT07054190|DRUG|Ribociclib|Ribociclib will be administered as per the schedule specified in the arms
214941406|NCT07054190|DRUG|Letrozole|Letrozole will be administered as per the schedule specified in the arms
214941407|NCT07058909|DEVICE|ELISIO™-HX Dialyzer|Following consent, participants will undergo a baseline hemodialysis treatment with their currently used dialyzer, the ELISIO-H™, and following the baseline visit will receive hemodialysis with the investigational device, ELISIO™-HX, three times a week for 12 weeks.
214941408|NCT07058623|PROCEDURE|Nurse-Led Telehealth Consultation|Participants receive scheduled postoperative nursing consultations delivered remotely via the HA Go mobile application, a secure, hospital-approved telehealth platform. Consultations occur approximately two weeks after total knee replacement surgery, with additional sessions arranged as clinically needed within the first month post-surgery. Each telehealth session lasts about 20 to 30 minutes and includes assessment of recovery progress, monitoring for complications, patient education, and guidance on rehabilitation exercises. Patients receive technical support to facilitate effective use of the telehealth platform. This intervention leverages virtual care technology to provide convenient, accessible nursing follow-up without requiring in-person clinic visits.
214941409|NCT07058623|PROCEDURE|Traditional In-Person Nursing Consultation|Participants receive scheduled postoperative nursing consultations in person at the Specialist Outpatient Department. Each consultation lasts approximately 20 to 30 minutes and includes physical assessment, monitoring for complications, patient education, and rehabilitation guidance. Follow-up visits are typically scheduled two weeks after total knee replacement surgery, with additional visits as clinically indicated. This intervention represents standard postoperative nursing care delivered face-to-face.
214941410|NCT06897839|OTHER|Air-sham|Room air for intratracheal administration
214941411|NCT06897839|DRUG|Zelpultide alfa|Reconstituted Zelpultide alfa for intratracheal administration
214941412|NCT06795581|DRUG|18F-PF-06445974|Injected IV followed by PET scanning
214338811|NCT00032292|DRUG|Visilizumab|
214338812|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via face to face|The exercises are performed by the participants under the supervision of a physiotherapist via face-to-face.
214941413|NCT06778863|DRUG|CLSP-1025|CLSP-1025 will be administered by IV infusion
214676312|NCT02760407|DRUG|Placebo q2w|sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
214676313|NCT00434460|BEHAVIORAL|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
214676314|NCT06335940|OTHER|Videoregulation|"To encourage the use of video-regulation, several measures will be taken to reinforce its use as much as possible:~* Posters visible to all in the dispatch room.~* Regular mailings to all dispatching physicians.~* On-site presence of interns and the study investigator to help doctors who are not used to video-regulation to get to grips with the computer tool.~* Involvement of ARMs to remind doctors to use video-regulation."
214338813|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via video conference|The exercises are performed by the participants under the supervision of a physiotherapist via video conference.
214338814|NCT01899976|DEVICE|X-Suit NIR Covered Biliary Stent|
214338815|NCT03373591|DRUG|Liposomal Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
214338816|NCT03373591|DRUG|Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
214676315|NCT05914220|DEVICE|AI Insights Application|Predictive AI Model Risk score
214676316|NCT01533155|DRUG|Nektar 118|Oral 25 mg tablet
214676317|NCT01533155|DRUG|Quinidine|Oral 200 mg tablet
214676318|NCT01533155|DRUG|Quinidine placebo|Oral Tablet
214676319|NCT01533155|DRUG|Morphine|10 mg/ml, intravenously
214676320|NCT03768401|OTHER|Education|Seminars about wellness and exercise, and resulting therapeutic programs, while living with a neurological physical disability.
214676321|NCT03768401|BEHAVIORAL|Trial Exercise Modalities|Wellness/exercise clinics located at Mayo Clinic, Rochester will be offered to persons with neurological physical disabilities on a regular basis, at least monthly, during the last half of the trial period.
214941414|NCT06917456|DEVICE|Virtual Reality Headset|Participants will use either a Meta Quest VR device, or a Pico headset. Both of these devices are standard non-medical hardware items.
214941415|NCT06901245|DRUG|Tirzepatide|Subjects will take Tirzepatide for 48 weeks
214941416|NCT04874116|BEHAVIORAL|Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging|Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
214941417|NCT04874116|BEHAVIORAL|Mobile text messaging|Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
214941418|NCT03911557|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.
214941419|NCT03912428|DRUG|11C-MC1|PET radioligand for Cyclooxygenase-2 (COX-2)
214941420|NCT03912428|DRUG|Celecoxib|Cyclooxygenase-2 (COX-2) inhibitor
214676322|NCT01288378|DRUG|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
214338817|NCT03735550|DEVICE|Contact thermographic breast examination device|A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
214338818|NCT01172548|DRUG|imatinib mesylate|
214338819|NCT06155617|OTHER|Upper Extremity Rehabilitation|Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
214338820|NCT06023784|PROCEDURE|left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
214338821|NCT06023784|PROCEDURE|right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
214338822|NCT02749903|DRUG|enzalutamide|oral
214338823|NCT04266457|OTHER|No Intervention|No Intervention
214338824|NCT05813054|DIETARY_SUPPLEMENT|HA matrix ingredient|1 capsule/day
214338825|NCT05813054|DIETARY_SUPPLEMENT|Placebo|1 capsule/day
214338826|NCT05210920|OTHER|Nail polish application|After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
214338827|NCT03345459|OTHER|ICare Prevent (internet-based treatment for depression in college students)|ICare Prevent (internet-based treatment for depression in college students): 7 weekly sessions and 1 booster session. Each session requires about 30-45 minutes to complete. All sessions are accessed online, and it is a guided treatment (i.e., each patient provided an eCoach).
214338828|NCT02041429|DRUG|Ruxolitinib|
214338829|NCT02041429|DRUG|Paclitaxel|
214338830|NCT06504017|PROCEDURE|COG-TB: Cognitive Fusion guided prostate targeted Biopsy|Cognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
214941421|NCT03912428|DRUG|[11C]ER176|Radioligand for 18-kDa Translocator Protein
214941422|NCT03912428|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)/computed tomography (CT) Scan|Whole body or brain PET/CT scans
214941423|NCT06427798|DRUG|68Ga-DOTATATE|68Ga-DOTATATE PET/CT whole-body scanning will be done at target dose of 5 mCi. The whole-body PET/CT scan will be started approximately 60 minutes after the tracer injection and will take up to 2 hours.
214941424|NCT06427798|DRUG|[203Pb]VMT-alpha-NET|\[203Pb\]VMT-alpha-NET (6 mCi) will be given IV at 7 days prior.
214338831|NCT06504017|PROCEDURE|FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy|MRI-TRUS Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
214338832|NCT02445235|OTHER|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
214338833|NCT03508557|BEHAVIORAL|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
214338834|NCT05154903|DRUG|Citicoline 500 MG|Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.
214338835|NCT00861341|DRUG|Aspirin|81 mg
214941425|NCT06427798|DRUG|[212Pb]VMT-alpha-NET|\[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during Phase II. One cycle is 8 weeks.
214941426|NCT06860932|BEHAVIORAL|Palliative care video comprises the conversation and advance directives.|The palliative care video was done in a way that facilitates discussion and minimizes anxiety or any psychological risk/burden. The video is narrated by a young adult who opens with an empathic statement regarding the situation the young adult/adult patient finds themselves in. Then, there is a transition to contemplating what the future might hold and decisions about medical care and introducing the concept of ACP. There is acknowledgment that decision making is difficult, and that the presence of caregivers often helps. There is an explicit statement regarding values and spiritual beliefs and how that might impact decision making. The video then attempts to translate the preceding conversation into actionable medical orders using the most common three-goal framework that is based on the Physician Orders for Life Sustaining Treatment (POLST) paradigm: life-prolonging care, limited/blended care and comfort care.
214338836|NCT00861341|DRUG|Pioglitazone|30mg Pioglitazone x1
214338837|NCT05030922|OTHER|Antiatherogenic diet|Participants instructed in antiatherogenic diet during pregnancy with frequent follow-ups to ensure compliance
214338838|NCT03011216|BEHAVIORAL|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
214338839|NCT03011216|BEHAVIORAL|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
214941427|NCT06860932|BEHAVIORAL|Palliative care written material|Written materials about palliative care conversation and advance directives.
214338840|NCT05712226|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 35 minutes.
214676323|NCT03744169|DIAGNOSTIC_TEST|Lung ultrasound|A point-of-care lung ultrasound exam will be performed on admission (no later than 14 hours following admission, allowing for participant stabilization and care) to the PICU and within 6 hours of any escalation in mechanical ventilatory support without interrupting clinical care, by study investigators blinded to participant history, physical examination, and diagnostic testing/imaging and who are not involved in the clinical management of the participant. Investigators will use a six-zone standardized scanning protocol with pattern analysis to form a diagnosis for the cause of the participant's respiratory failure. Images will be acquired by pediatric critical care trainees and saved online; accuracy of diagnoses based on the ultrasound exam will be evaluated by a expert sonographer offline.
214676324|NCT03744169|DIAGNOSTIC_TEST|Clinical exam|Following morning ICU rounds, the PICU fellow or attending physician caring for the participant will be asked for his/her interpretation of the most recent chest radiograph and his/her diagnosis concerning the etiology of the participant's acute respiratory failure. This clinical diagnosis will be compared to ultrasound findings.
214941428|NCT06192758|DEVICE|TheraSphere PCa|Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
214941429|NCT06844669|DRUG|Carvedilol|6.25 mg with food
214941430|NCT06844669|DRUG|Empagliflozin|10 mg in the morning with or without food
214941431|NCT06439576|DRUG|Faricimab|The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
214941432|NCT06537999|DRUG|DNTH103|"* Day 1: IV loading dose~* Week 1 to Week 15: DNTH103 administered SC every 2 weeks"
214941433|NCT06537999|DRUG|Placebo|"* Day 1: IV infusion of placebo~* Week 1 to Week 15: placebo administered SC every 2 weeks"
214941434|NCT04522973|OTHER|Beverage with ethanol and E-cigarette liquid with ethanol|Beverage with ethanol and E-cigarette liquid with ethanol
214941435|NCT04522973|OTHER|Beverage with ethanol and E-cigarette liquid without ethanol|Beverage with ethanol and E-cigarette liquid without ethanol
214941436|NCT04522973|OTHER|Beverage without ethanol and E-cigarette liquid with ethanol|Beverage without ethanol and E-cigarette liquid with ethanol
214941437|NCT04522973|OTHER|Beverage without ethanol and E-cigarette liquid without ethanol|Beverage without ethanol and E-cigarette liquid without ethanol
214941438|NCT00545389|DRUG|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
214941439|NCT06243783|BEHAVIORAL|Montreal Imaging Stress Test|In the Montreal Imaging Stress Test, participants are required to solve basic mathematical tasks, but the allowed reaction time is set lower than their average.
214941440|NCT06735534|DEVICE|FARAPULSE™ Pulsed Field Ablation System|"The FARAPULSE™ Pulsed Field Ablation System is indicated for the treatment of symptomatic atrial fibrillation.~The FARAWAVE Catheter is indicated for the isolation of pulmonary veins and posterior wall in the treatment of drug-refractory, recurrent, symptomatic paroxysmal and persistent atrial fibrillation. The FARAWAVE Catheter is also indicated for the for the isolation of pulmonary veins and posterior wall in the treatment of persistent atrial fibrillation as an alternative to anti-arrhythmic drug (AAD) therapy as an initial rhythm control strategy.~The FARAPOINT™ PFA Catheter is indicated for use as an adjunctive device for 1) the creation of an ablation line between the inferior vena cava and the tricuspid valve and/or 2) Mitral Isthmus, when the FARAWAVE Catheter is used in the endocardial treatment of persistent atrial fibrillation (episode duration no greater than 12 months)."
214941441|NCT06881277|BEHAVIORAL|Mobile phone based intervention|The PRIMI intervention is a 6-month smartphone-based digital health program designed to promote a healthy diet and physical activity among migrant women after pregnancy.
214941442|NCT06840483|DRUG|Zelenectide pevedotin (BT8009)|Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.
214338841|NCT06194903|DEVICE|isopropyl alcohol wipes|cellphones will be sanitised with isopropyl alcohol wipes and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
214338842|NCT06194903|DEVICE|UVC box|cellphones will be sanitised in a UVC box and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
214338843|NCT03933293|DRUG|AK102|450mg, Q4W, subcutaneous injection
214338844|NCT03933293|DRUG|Statins|Lipid-lowering therapies
214338845|NCT03933293|DRUG|Ezetimibe|Lipid-lowering therapies
214338846|NCT02264223|DIETARY_SUPPLEMENT|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
214338847|NCT02264223|DIETARY_SUPPLEMENT|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
214941443|NCT06620965|PROCEDURE|Mulligan Mobilization Technique|NAGs (Natural Apophyseal Glides) involve passive oscillatory movements of a spinal facet joint in an anterocranial direction, performed with the patient seated. SNAGs (Sustained Natural Apophyseal Glides) maintain facet glides during active movements, aiming to reach the joint\&#39;s end range. In SNAGs, the patient actively participates, and overpressure is applied at the end of movements to enhance the range of motion. Techniques include increasing rotation, lateral flexion, flexion, and extension. These were applied by a certified physiotherapist three times a week for four weeks, aiming to improve joint mobility without causing pain.
214941444|NCT06620965|PROCEDURE|Proprioceptive Neuromuscular Facilitation (PNF) Technique|"Proprioceptive Neuromuscular Facilitation (PNF) Technique: PNF consists of four movement patterns in two diagonals:~Flexion-left rotation and extension-right rotation Flexion-right rotation and extension-left rotation 3 PNF techniques were applied.~Combined Isotonic Contractions: This technique involves concentric, eccentric, and stabilizing contractions of a muscle group (agonist). The goal is to increase active range of motion (ROM), strength, and improve control and coordination.~Dynamic Stabilization (Stabilizing Reversal): This involves applying resistance in various directions to prevent movement, aiming to enhance dynamic stability, strength, and agonist-antagonist coordination.~Hold-Relax Technique: This relaxation method involves isometric contractions against maximum resistance without movement to increase passive ROM and reduce pain. These were applied by physiotherapist three times a week for four weeks, aiming to improve joint mobility without causing pain."
214941445|NCT01639547|DRUG|Peginterferon alfa-2a plus Ribavirin|Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000\~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
214941446|NCT05031416|COMBINATION_PRODUCT|LTQ|The investigators will test the LTQ-Connect application and a standard 10-week course of nicotine replacement therapy (NRT) nicotine patches, and Facebook groups, which will run for a total of 3 months with research study participants
214941447|NCT03885180|DRUG|Warfarin Sodium|Extending warfarin anticoagulation
214941448|NCT02280616|DRUG|low dose budesonide tablet|1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
214941449|NCT02280616|DRUG|high dose budesonide tablet|2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
214941450|NCT02280616|DRUG|high dose budesonide suspension|placebo tablet twice daily AND 5ml \[0.4mg budesonide/ml\] suspension twice daily
214941451|NCT02280616|DRUG|Placebo|placebo tablet twice daily AND 5ml placebo suspension twice daily
214941452|NCT05210114|DEVICE|Skin Hydration Sensor|The device is a skin hydration sensor. The sensor is placed on the skin at the inner arm. It is non-invasive and measures in seconds the percent water content of the dermis by quantifying its dielectric constant.
214941453|NCT06483815|DIAGNOSTIC_TEST|Culture, İsolation|Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.
214941454|NCT06461715|OTHER|Machine learning with artificial intelligence software program|This is a retrospective observational study using cardiac MRI, cardiac CT and x-ray fluoroscopy images to develop a 3D hybrid guidance system with the use of deep learning methods.
214941455|NCT00059605|GENETIC|DOTAP:Chol-fus1|Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.
214941456|NCT04417972|DRUG|SHR7280|treatment
214941457|NCT04417972|DRUG|Placebo oral tablet|blank control
214941458|NCT00867828|DIETARY_SUPPLEMENT|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
214941459|NCT00867828|DIETARY_SUPPLEMENT|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
214941460|NCT00867828|DIETARY_SUPPLEMENT|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
214941461|NCT07110441|DRUG|Single Dose G1090N|Subjects will receive single ascending doses of G1090N up to 1200mg.
214941462|NCT07110441|DRUG|Multiple dosing of G1090N|Subjects will receive multiple ascending doses of G1090N up to 1200mg twice daily for 7 consecutive days.
214338848|NCT03755063|OTHER|Speech therapy apps|Speech therapy apps loaded on tablets
214941463|NCT07110597|OTHER|Statement communicating 1 source of uncertainty|It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
214941464|NCT07110597|OTHER|Statements communicating 2 sources of uncertainties|"It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.~Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her."
214941465|NCT07110597|OTHER|Statements communicating 3 sources of uncertainties|"It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.~Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.~Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live."
214676325|NCT03744169|DIAGNOSTIC_TEST|Chest x-ray|Results of chest x-ray will be collected for comparison with ultrasound findings.
214676326|NCT01645930|DRUG|Ixazomib|Ixazomib capsules
215074271|NCT04190407|BEHAVIORAL|Intravenous access|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
215074272|NCT01753869|PROCEDURE|Airways clearance and Hypertonic saline inhalation|
214338849|NCT01835782|DRUG|L-Serine|
214338850|NCT00510666|DRUG|Saline|Saline infusion adjunct to morphine PCA pump
214338851|NCT00510666|DRUG|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
214338852|NCT00510666|DRUG|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
214338853|NCT00510666|DRUG|Saline|Preemptive saline as a control group to tramadol one
214338854|NCT01070290|DRUG|ARQ 197|120 mg capsule administered twice daily
214338855|NCT01070290|DRUG|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
214676327|NCT01645930|DRUG|Lenalidomide|Lenalidomide capsules
214676328|NCT01645930|DRUG|Dexamethasone|Dexamethasone tablets
214941466|NCT07110597|OTHER|Statements communicating 4 sources of uncertainties|"It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.~Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.~Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.~Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown."
214941467|NCT07110597|OTHER|Control group|No information about uncertainty
214941468|NCT07175272|DRUG|Holy basil extract|"Holy basil extract (Ocimum sanctum) will be provided as an oral capsule formulation. Each capsule contains 300 mg of standardized holy basil extract with defined amounts of active compounds including ursolic acid (≥0.10 mg) and rosmarinic acid (≥0.50 mg). Participants will be instructed to take one capsule once daily for 28 consecutive days.~The capsules will be dispensed in blister packs, with labeling according to clinical trial regulatory requirements. Participants will be asked to record daily intake in a study diary, and compliance."
214338856|NCT03299192|BEHAVIORAL|Tai Chi|Yang Style Tai Chi
214338857|NCT03299192|BEHAVIORAL|Health Education|Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
214338858|NCT03299192|OTHER|Usual Medical Care|Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
214338859|NCT00177437|BEHAVIORAL|home testing kit|
214338860|NCT01418209|DRUG|Low-dose 17-ß-estradiol with progesterone taper|Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
214941469|NCT07177209|DRUG|Non-Interventional Study|As provided in real world practice
214941470|NCT07174973|OTHER|Balance training with FES|"Participants assigned to this group complete a standardized balance training program while receiving FES to the lower limb muscles. Training sessions involve standing in a safety harness and performing interactive, game-based balance tasks on a force plate that provides real-time visual feedback of body sway.~FES will be applied bilaterally to specific leg muscles (e.g., tibialis anterior, quadriceps, gastrocnemius) using surface electrodes. Stimulation parameters (pulse width, frequency, and amplitude) are individually adjusted to produce visible yet comfortable muscle contractions that support functional standing and balance activities. Stimulation is delivered in synchrony with balance exercises to augment muscle activation during postural adjustments."
215074273|NCT01210963|DEVICE|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
215074274|NCT05712109|OTHER|Follow-up after Anterior cruciate ligament reconstruction|The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8.months after the surgery
215074275|NCT02945358|PROCEDURE|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
215074276|NCT00014989|DRUG|magnesium sulfate|
214676329|NCT01809366|PROCEDURE|seminal plasma insemination|
214676330|NCT03319550|DIETARY_SUPPLEMENT|Casein|see experimental description
214338861|NCT01418209|DRUG|Venlafaxine XR|Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
215074277|NCT03404063|DRUG|Cardiac Drug|"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
214676331|NCT03319550|DIETARY_SUPPLEMENT|Whey|see experimental description
214676332|NCT03319550|DIETARY_SUPPLEMENT|Leucine-enriched whey|see experimental description
214676333|NCT06035718|DRUG|Probiotic Blend Capsule|By a probiotic blend capsule a specific product is intended which contains the following: Lactobacillus rhamnosus Lactobacillus plantarum Lactobacillus casei Lactobacillus helveticus Lactobacillus acidophilus Lactobacillus bulgaricus Lactobacillus gasseri Bifidobacterium bifidum Bifidobacterium lactis Bifidobacterium breve Bifidobacterium longum Streptococcus thermophile Fructooligosaccharides (FOS).
214676334|NCT06035718|DEVICE|tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp.
214338862|NCT01418209|DRUG|Placebo|The placebo is an inactive pill that looks like the active medication.
214338863|NCT01920815|OTHER|No interventions|
214338864|NCT06429306|DRUG|Dexycu|5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
214338865|NCT06429306|DRUG|Placebo|Acetyl triethyl citrate
214941471|NCT07174973|OTHER|Balance training wiith combined neuromodulation (TSCS+FES)|Participants in this group complete the standardized balance training program while receiving both FES and TSCS. Training sessions take place in a safety harness and involve interactive, game-based balance exercises performed on a force plate with real-time visual feedback of body sway.FES is delivered bilaterally to lower limb muscles (e.g., tibialis anterior, quadriceps, gastrocnemius) through surface electrodes. Stimulation parameters (pulse width, frequency, amplitude) are individualized to produce visible, comfortable contractions that facilitate muscle activation during postural tasks.TSCS is applied simultaneously via electrodes placed over the thoracolumbar spinal region to modulate spinal excitability and enhance neuromuscular control. Standardized stimulation parameters are used across participants, with adjustments made to ensure tolerance and safety.
214941472|NCT07174973|OTHER|Balance training only|Participants in this group complete the standardized balance training program without electrical stimulation. Sessions are conducted in a safety harness and consist of interactive, game-based balance exercises performed on a force plate, which provides real-time visual feedback of body sway. Tasks are designed to challenge postural control by requiring weight shifting in multiple directions, maintaining stability during perturbations, and progressively increasing task difficulty.
214941473|NCT07176975|DRUG|BI 1831169|BI 1831169
214941474|NCT07176975|DRUG|nivolumab|nivolumab
214941475|NCT07174661|BEHAVIORAL|Advance Care Planning|Attend ACP appointment
214941476|NCT07174661|OTHER|Educational Intervention|Watch on-demand early ACP educational video
214941477|NCT07174661|OTHER|Electronic Health Record Review|Ancillary studies
214941478|NCT07174661|OTHER|Survey Administration|Ancillary studies
214941479|NCT07176091|DEVICE|Combined treatment of tDCS and rTMS|Bilateral pre-treatment with tDCS is carried out for 10 minutes. The current is 2 mA, and the electrodes are spaced 5 cm apart. The current gradually rises and falls in the first and last 30 seconds. Subsequently, the bilateral primary motor cortex (M1 area) of the patient is stimulated with iTBS at a frequency of 5 Hz. The magnetic field intensity is set at 80% of the resting motor threshold. Each train contains 10 pulses, and each pulse consists of 3 bidirectional pulses at 50 Hz. The interval between each train is 8 seconds. There are 60 trains per session (1800 pulses per session), and the treatment lasts for 5 days in total.
214941480|NCT07176091|DEVICE|sham-tDCS combined with real TMS|Participants received sham transcranial direct current stimulation combined with intermittent theta burst stimulation for a total of 5 days
214941481|NCT07176338|DIAGNOSTIC_TEST|Blood and lens capsule samples for PK testing|Blood samples and lens capsule tissue will be collected from patients for PK testing
214941482|NCT07175012|DEVICE|ELECTROVEST|A wearable vest device that delivers airway clearance therapy through high-frequency chest wall oscillation (HFCWO) combined with surface neuromuscular electrostimulation (EEM). The session includes a 2-minute warm-up phase at 4 Hz, 16 minutes of active stimulation at 8 Hz, and a 2-minute recovery phase at 4 Hz (total duration: 20 minutes). The intervention is administered during supervised physiotherapy sessions to promote mucociliary clearance and respiratory muscle activation in patients with chronic respiratory diseases.
214941483|NCT07175012|DEVICE|The Vest® Model 105|A conventional airway clearance therapy using a commercial high-frequency chest wall oscillation (HFCWO) device (The Vest® Model 105 or AffloVest®). The session includes a 2-minute warm-up phase at 13 Hz, 16 minutes of treatment at 20 Hz, and a 2-minute cool-down at 13 Hz (total duration: 20 minutes). This intervention serves as the active comparator in the crossover trial.
214941484|NCT07174414|DRUG|Cilostazol 100 mg|Cilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability.
214338866|NCT04710251|DEVICE|Speedometer|We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
214941485|NCT07174414|DRUG|Placebo|Placebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability.
214941486|NCT07176481|BEHAVIORAL|Diné Parents Taking Action Program|A culturally adapted parent training program delivered by trained Navajo Family Advisors, focused on teaching parents/guardians evidence-based strategies to support their child's development and family well-being.
214941487|NCT07174466|OTHER|Standard Referral to 211|Participants receive a standard referral to United Way 211 for assistance with social needs. 211 specialists contact referred patients, provide available service referrals, and follow up in an ad-hoc manner as per standard 211 protocols.
214338867|NCT00658112|DRUG|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
214338868|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
214338869|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
214338870|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
214338871|NCT04737538|OTHER|Experimental Dentrifrice|Toothpaste containing sodium bicarbonate, sodium hyaluronate and sodium fluoride
214338872|NCT04737538|OTHER|Positive control dentifrice|Dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride
214338873|NCT04737538|OTHER|Negative control dentifrice|Dentifrice containing 1100ppm fluoride as sodium fluoride (Crest Cavity Protection)
214941488|NCT07174466|BEHAVIORAL|e-SINCERE (Phone Support)|Participants receive a study-provided cellphone to ensure stable phone access. Using this device, participants are connected to United Way 211 specialists, who provide referral services for identified social needs. This intervention focuses on overcoming communication barriers that might otherwise prevent successful service connection.
214941489|NCT07174466|BEHAVIORAL|e-SINCERE (Digital Navigation)|Participants receive a study-provided TracFone and direct support from a trained Digital Navigator. The Digital Navigator assists participants with accessing United Way 211 services, troubleshooting barriers to phone or internet use, and reinforcing follow-through on referrals. This arm is designed to provide enhanced, structured navigation support to address digital access barriers and increase successful service connections.
214941490|NCT07176130|OTHER|No Intervention: Observational Cohort|Not applicable, No intervention. Observational study.
214941491|NCT07176988|OTHER|Hierarchical method|"Participants in the hierarchical version of Conversation Training Therapy (CTTH) will receive four weekly sessions of voice therapy. This approach gradually increases the difficulty of speaking tasks-from simple sounds to full conversations-based on the participant's progress. The therapy begins with basic awareness and speech sounds (e.g., consonant-vowel pairs), then progresses through words, phrases, and sentences, culminating in natural conversation. Each level must be completed with at least 80% accuracy before proceeding to the next one.~The structure is modeled after traditional voice therapies like resonant voice and aims to help participants succeed early and reduce mental fatigue. Daily homework includes seven short (2.5-minute) practice sessions, aligned with prior research showing this is a realistic and effective amount of practice."
214941492|NCT07176988|OTHER|Non Hierarchical method|"The therapy includes four weekly sessions and several key techniques:~Clear Speech: Speaking clearly, like leaving an important voicemail.~Awareness Training: Paying attention to how the voice sounds and feels in the mouth and face.~Negative Practice: Switching between their bad voice and good therapy voice to recognize and improve differences.~Embedded Gestures: Briefly holding certain speech sounds to reduce vocal strain and boost clarity.~Prosody and Projection: Working on pitch, rhythm, and speaking louder through better technique.~Participants practice these skills throughout the day using a mobile app to track their progress and record a weekly sample. Unlike hierarchical models, components in CTT can be introduced in any order based on individual needs, making it flexible and personalized"
214941493|NCT07176936|DEVICE|Cymba Conchae stimulation|Electrical stimulation applied to the cymba conchae region of the outer ear
214941494|NCT07176936|DEVICE|Earlobe stimulation|Electrical stimulation applied to the earlobe region of the outer ear
214941495|NCT07174934|BIOLOGICAL|application of injectable platelet-rich fibrin on the wound area .|Injectable platelet-rich fibrin will be prepared using low speed centrifugation technique, after centrifugation, the I-PRF in the upper part of the tube will be collected via an injector and will be transferred to a metal godet. It will be left for 15-20 min for polymerization of the I-PRF ,Then the polymerized I-PRF will be applied to the secondary wound of test area.
214941496|NCT07177222|PROCEDURE|laparoscopic esophagocardiomyotomy|Heller myotomy, is a minimally invasive surgical procedure that involves cutting the muscle at the lower end of the esophagus to treat achalasia, a condition where this muscle (esophageal sphincter) fails to relax and hinders food passage into the stomach.
214941497|NCT07177222|PROCEDURE|open surgery|Open surgery, or traditional surgery, involves a surgeon making one large incision to directly access and view the internal organ or body part being operated on.
214941498|NCT07171801|DEVICE|Three-Dimensional Endoscopic Visualization|Use of a stereoscopic 3D high-definition endoscopic system with dual optical channels, projecting to a stereoscopic monitor viewed with polarized glasses, to perform standardized spinal simulation tasks.
215074278|NCT03404063|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
214676335|NCT06035718|DEVICE|Sham tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp. At this arm the electric current will be applied for a very short time (30 s) after which the device will turn off, thus providing the initial tingling sensation over the scalp but not interfering with the ongoing brain activity.
214676336|NCT02085655|DRUG|pegaspargase|pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214676337|NCT02085655|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214676338|NCT02085655|DRUG|Oxaliplatin|100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
215074279|NCT03478254|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~\- Received at least one Influenza vaccine dose in the last year."
214338874|NCT03492697|DRUG|PF-06882961 Immediate Release Tablet|Immediate Release Tablet
214338875|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (long)|Controlled Release tablet (long)
214338876|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (short)|Controlled Release tablet (short)
214338877|NCT03492697|DRUG|PF-06882961 Immediate Release Solution|PF-06882961 Immediate Release solution
214338878|NCT03998007|DEVICE|IRIS System|A QEEG based pain biomarker that scales with the patient reported NRS
214338879|NCT03427385|DRUG|Ropivacaine 0.5%|The volume of local anesthetic Ropivacaine 0.5% will be determined by the response (success or failure of block, 30 minutes after local anesthetic injection) of the previous patient in that group. Block success is defined as an absence of ice sensation in the knee within 30 min of ropivacaine administration accompanied by tolerance to tetanic electrical stimulation (TES) at 60 mA(milliamp) for 5 seconds.
214676339|NCT02085655|DRUG|Methotrexate|3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214338880|NCT01544972|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
214338881|NCT01544972|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
214486447|NCT06782698|BEHAVIORAL|Home-based exercise program|"The home-based program follows the National recommendations on Physical Exercise for Cancer Patients \[Bruno RC, 2023\]. It is logbook-guided and technology-enabled.~It consists of:~* Two initial supervised explanatory sessions, in the Physic and Rehabilitation Medicine Gym of our institution.~* Followed by 2 muscular training sessions + 3 additional periods of aerobic exercise per week in their home environment until the end of neoadjuvant treatment. Patients are given a logbook with instructions and a sports bracelet for heart rate monitoring.~The training sessions will be monitored by smartwatch heart rate measurements and self-notion of effort according to Borg Categorization \[Borg GA, 1982\] and recorded by the participants in the Mi Fitness application or an Exercise Diary.\[Nilsen TS, 2018\]"
214941499|NCT07171801|DEVICE|Two-Dimensional Endoscopic Visualization|Use of the same high-definition endoscopic system with stereoscopic function deactivated, providing conventional monoscopic two-dimensional visualization, to perform standardized spinal simulation tasks.
214941500|NCT07175103|BEHAVIORAL|Nurses' Stress Self-Care Educational Program (NSSCEP)|A control intervention consisting of four 1-hour sessions over one month, focusing on general technical skills relevant to pediatric oncology nursing (e.g., procedural updates, equipment use). The program does not include stress management content. Participants complete weekly checklists and pre- and post-intervention surveys to measure burnout and stress levels.
214941501|NCT07175103|OTHER|General Technical Skills Program|A control program with four 1-hour sessions over one month, focusing on technical skills (e.g., procedural updates, equipment use) without stress management content. Includes weekly checklists and pre/post surveys to measure burnout and stress.
214941502|NCT07174804|OTHER|Yoga (IAYT) Intervention|Yoga practice for a period of three months
214941503|NCT07175766|DIETARY_SUPPLEMENT|Dachundou No Sugar Added Soymilk|Participants will consume two bottles of Dachundou No Sugar Added Soymilk daily (375 mL each; total 750 mL per day) for 8 consecutive weeks. The product is packaged in 375 mL cartons and made from non-GMO soybeans, containing approximately 4.2 g of soy protein per 100 mL. The soymilk is unsweetened and stored at 0-7°C.
214941504|NCT07175038|DRUG|ROC-101|Oral, daily administered Rho kinase inhibitor
214941505|NCT07174856|DRUG|Misoprostol-only medication abortion regimen|This intervention is an updated misoprostol-only regimen that involves being counseled on and receiving medications for a medication abortion using 3-4 doses of 800μg misoprostol administered sublingually every 3 hours.
214941506|NCT07174856|DRUG|Combined regimen|This intervention will involve participants being counseled on and receiving medications for a medication abortion regimen of mifepristone (200mg orally) followed 24-48 hours later by misoprostol (800μg b/v) with a second dose of misoprostol (800μg b/v) taken 3 hours later only for those 64-77 days.
214941507|NCT07176143|PROCEDURE|Delivering human bone marrow mesenchymal stem cells via the uterine artery|"Interventional Uterine Artery Infusion of Human Bone Marrow Mesenchymal Stem Cells (hBMSCs):~Subjects in the experimental group will undergo iodine allergy testing and groin area shaving/disinfection preoperatively. The procedure is performed on Day 10 of the endometrial proliferation phase.~Step-by-Step Procedure:~1. Positioning \& Anesthesia: (Patient placed in supine position; Local infiltration anesthesia administered)~2. Arterial Access: (Femoral artery punctured using Seldinger technique; Vascular sheath and catheter inserted)~3. Catheterization: (Catheter/microcatheter advanced into one uterine artery; Position confirmed by angiography)~4. Stem Cell Infusion: (Under fluoroscopic guidance, slowly inject 15mL solution containing 1×10⁶ cells/kg hBMSCs via microcatheter)~5. Postoperative Care: (Hospital observation for 48 hours)~6. Concurrent Treatment: (Hormone replacement therapy cycle maintained during the procedure month)~Treatment Frequency: Single intervention"
214941508|NCT07176832|DRUG|Stiripentol capsule (Diacomit®)|Single oral administration of 1,000 mg stiripentol (2 × 500 mg capsules) at the end of breakfast.
214941509|NCT07176832|DRUG|Stiripentol oral suspension (Diacomit®)|Single oral administration of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL) at the end of breakfast.
214941510|NCT07176065|DRUG|Ropivacaine + saline solution|0.5% ropivacaine (19 mL) + 1 mL normal saline administered intraoperatively via periarticular injection.
214941511|NCT07176065|DRUG|Ropivacaine + Dexmedetomidine|0.5% ropivacaine (19 mL) + dexmedetomidine 100 µg in 1 mL administered intraoperatively via periarticular injection.
214676340|NCT02085655|DRUG|Dexamethasone|40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214676341|NCT02085655|DRUG|Thalidomide|100-200mg, PO, after chemotherapy
215074280|NCT03478254|BIOLOGICAL|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~* One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~* One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~* One PPSV 23 dose in the last 5 years.~* One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
215074281|NCT03478254|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
215074282|NCT04202406|DRUG|Acetaminophen and codeine and caffeine|The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
214676342|NCT03245814|BEHAVIORAL|Service Dog|A service dog trained to perform tasks that are specific to PTSD
214676343|NCT01665638|DRUG|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
214676344|NCT01665638|DRUG|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
214676345|NCT01665638|DRUG|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
214338882|NCT06019416|BEHAVIORAL|culturally tailored mindfulness-positive psychological intervention|"This 3-week culturally tailored mindfulness-positive psychological intervention instructs techniques to enhance positive emotions and meditation exercise lasting approximately 30 minutes. The culturally tailored mindfulness-positive psychological intervention consists of four modules: 1) noticing positive events, 2) amplifying positive events, 3) gratitude, and 4) mindfulness and meditation. This 3-dimensional software includes gamification features, including a virtual living room, Japanese garden, art gallery, and meditation garden.~A private office and/or space was utilized to implement the culturally tailored mindfulness-positive psychological intervention for older Korean Americans/immigrants, provided by the recruitment sites such as non-profit organization and church. The private room at the sites had a desktop (or laptop) computer, a virtual reality device (Oculus Quest 2), a chair, and a desk."
214338883|NCT01533610|PROCEDURE|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
214338884|NCT02036099|OTHER|Driving in Mild Dementia Decision Tool|
214338885|NCT01384435|DRUG|KPS-0373|
214338886|NCT01384435|DRUG|KPS-0373|
214941512|NCT07175844|OTHER|Vocal exercises|"Participants performed six weekly sessions of 30 minutes, guided by videos focusing on diaphragmatic breathing and contemporary singing techniques. Initial exercises (weeks 1-2) included sustained s sounds, lip trills, humming, melodic vowel sequences, and Ja exercises. Weeks 3-6 included advanced solo exercises such as short and long S, humming variations, mum vocalizations, rhythmic patterns (cha-cha-cha), melodic sequences (Niemak 1-3), and counting exercises. Exercises were performed standing, preferably in front of a mirror."
214941513|NCT07175844|OTHER|Breathing exercises|"Participants in the breathing exercises group were given access to a 30-minute instructional video, in which a licensed physiotherapist demonstrated how to perform the exercises. Participants were instructed to complete the exercises twice per week at a time convenient for them. They could reflect on the exercises and submit questions to the physiotherapist within a closed social media group. Two weeks after the start of the intervention, participants were advised to increase the intensity of the exercises: lengthening inhalation, exhalation, and breath-holding during square breathing, and increasing the number of exhalations during Kapalabhati breathing from 20 to 60 per series, while respecting individual comfort and tolerance."
214941514|NCT07176052|PROCEDURE|cancer surgery|All surgery will be performed at Copenhagen University Hospital, Rigshospitalet, Denmark
214941515|NCT07176156|OTHER|No intervention|Observational one-time questionnaire study without intervention
214941516|NCT07176949|DRUG|0.01% atropine eye drops|Participants will use 0.01% atropine eyedrops nightly for myopia control.
214941517|NCT07176949|DRUG|0.05% atropine eye drops|Participants will use 0.05% atropine eyedrops nightly for myopia control.
214941518|NCT07176949|DEVICE|Spectacle lenses with highly aspherical lenslets|"These are a special type of eyeglass lenses designed primarily to slow down the progression of myopia (nearsightedness) in children. The center of the lens provides a clear correction for distance vision, just like regular glasses. The surrounding area contains hundreds of tiny, invisible, and highly aspherical (complex curved) microlenses. These microlenses create a special optical effect. While the child looks straight ahead clearly, peripheral light rays are focused in front of the retina. This is called myopic defocus. Research suggests that this myopic defocus signal helps to control the excessive elongation of the eyeball, which is the main cause of myopia getting worse."
214941519|NCT07177118|DRUG|Ustekinumab|Ustekinumab group (induction phase with intravenous equivalent doses at weeks 0 and 8, maintenance phase with 90 mg subcutaneously every 8 weeks)
214941520|NCT07177118|DRUG|Risankizumab|Risankizumab group (induction phase with intravenous 600 mg at weeks 0, 4, and 8, maintenance phase with 360 mg subcutaneously every 8 weeks)
215074283|NCT04202406|DRUG|Acetaminophen|The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
215074284|NCT04202406|DRUG|Placebo|The patient will receive placebo (starch) 1hour before treatment.
215074285|NCT05484934|PROCEDURE|Regenerative post mastectomy surgery|Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
214676346|NCT01665638|DRUG|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
214676347|NCT02122289|DEVICE|Application of Smartphone|Weekly questionnaire on smartphone
214676348|NCT02122289|OTHER|No application Smartphone|No weekly questionnaire on smartphone
214338887|NCT01384435|DRUG|KPS-0373|
214338888|NCT01384435|DRUG|KPS-0373|
214338889|NCT01384435|DRUG|Placebo|
214338890|NCT01867034|OTHER|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
214338891|NCT01867034|OTHER|Bare Metal Stent|
214338892|NCT00261924|DEVICE|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
214338893|NCT04534842|DRUG|SYNB1618|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
214338894|NCT04534842|DRUG|SYNB1934|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
214338895|NCT04015661|DRUG|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
214338896|NCT00797953|DRUG|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
214338897|NCT01916304|DRUG|Levothyroxine sodium new formulation|Levothyroxine tablets
214338898|NCT04341038|DRUG|Tacrolimus|the necessary dose to obtain blood levels of 8-10 ng / ml
214338899|NCT04341038|DRUG|Methylprednisolone|120mg of methylprednisolone daily for 3 consecutive days
214338900|NCT01863472|DEVICE|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
214338901|NCT01863472|DEVICE|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
214676349|NCT04302181|DRUG|Ropivacaine injection|6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
214676350|NCT02846675|BIOLOGICAL|autologous SVF|SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.
214676351|NCT02846675|BIOLOGICAL|Placebo|a Placebo treatment without SVF cells
214676352|NCT01708564|BIOLOGICAL|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
214941521|NCT07177183|DIETARY_SUPPLEMENT|Dietary supplement creatine|Dietary supplement creatine. The dosage of creatine will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.
214941522|NCT07177183|DIETARY_SUPPLEMENT|Dietary supplement - placebo|Dietary supplement polydextrose as a placebo. The dosage of placebo will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.
214338902|NCT05457309|PROCEDURE|malignant fungating wounds care regimen|1\) Preliminary construction of regimen: The researchers summarized the literatures and guidelines about malignant fungating wounds care, and then formed a preliminary draft of the regimen.2) Expert consultation: Experts in malignant fungating wound care, breast cancer and rehabilitation were consulted by email, and the researchers revised the protocol according to the experts' comments, and the final draft was determined after multiple rounds of consultation with experts. 3) Pre-experiment: The researchers investigated the enrolled patients to assess the feasibility of the protocol, and adjusted the content based on the feedback.4) Final Determining: including health records establishment, the intervention time, implementers, location, method and frequency. A wound care team was formed, interventions were carried out in terms of somatic care, wound home care, psychological support, and rehabilitation guidance, and the enrolled patients would be regularly followed by the researchers.
214941523|NCT07177183|OTHER|No intervention|Patients in Group 1 will serve as controls and will receive no intervention, only standard care.
214941524|NCT07174557|OTHER|MoodTriggers Application|"The Mood Triggers application, developed by Dr. Jacobson, will be used for collecting smartphone sensor data. This HIPAA-compliant app has been incorporated into various projects at Dartmouth, Stanford, and MGH/Harvard, with development supported by NIDA, NIMHD, NCI, and the Department of Veterans Affairs. The Mood Triggers app will capture a wide range of metrics, including psychomotor agitation, sleep disturbances, low behavioral activation, social contact, exposure to natural light, heart rate, heart rate variability, and screen time. The app also tracks the patient's screen time and app usage data. The Mood Triggers App will be installed on the smartphones at time of informed consent for all 120 patients enrolled in Phase 1 and for 100 clinical trial participants randomized to the early warning system (intervention arm) in Phase 2. Data will be collected from the Mood Triggers App starting on day of discharge from care and for 6 months post-discharge date."
214941525|NCT01777139|DRUG|Retigabine IR|Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
214941526|NCT03876769|BIOLOGICAL|CTL019|"Based on the subject's weight, one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects \> 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
214941527|NCT05625477|BIOLOGICAL|TNM002 (low dose)|Single dose of TNM002 administered by intramuscular injection
214941528|NCT05625477|BIOLOGICAL|TNM002 (medium dose)|Single dose of TNM002 administered by intramuscular injection
214941529|NCT05625477|BIOLOGICAL|TNM002 (high dose)|Single dose of TNM002 administered by intramuscular injection
214941530|NCT05625477|BIOLOGICAL|HTIG|Single dose of HTIG administered by intramuscular injection
214941531|NCT05625477|BIOLOGICAL|Placebo|Single dose of placebo administered by intramuscular injection
214941532|NCT05414396|BEHAVIORAL|Behavioral Intervention|Attend EML program sessions
214941533|NCT05414396|OTHER|Questionnaire Administration|Ancillary studies
214676353|NCT04320303|BIOLOGICAL|expanded NK cells|Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
214941534|NCT04088721|BIOLOGICAL|AD17002|LTh(αK) as immunomodulator
214941535|NCT04088721|OTHER|Formulation Buffer|Formulation buffer
214338903|NCT05793385|OTHER|operative intervention|all patients were operated after being admitted to surgical ward for acute abdomen
214676354|NCT05449353|BEHAVIORAL|Trauma-informed Cognitive Behaviour Therapy (TiCBT)|Group: Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
214941536|NCT02502266|DRUG|Cediranib|Given PO
214941537|NCT02502266|DRUG|Cediranib Maleate|Given PO
214941538|NCT02502266|PROCEDURE|Computed Tomography|Undergo CT
214941539|NCT02502266|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214941540|NCT02502266|DRUG|Olaparib|Given PO
214941541|NCT02502266|DRUG|Paclitaxel|Given IV
214941542|NCT02502266|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214676355|NCT01158950|DRUG|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
214676356|NCT01158950|OTHER|Placebo|Placebo (200mg) administered at study visit
214676357|NCT02814214|DEVICE|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
214941543|NCT02502266|OTHER|Questionnaire Administration|Ancillary studies
214941544|NCT02502266|DRUG|Topotecan|Given IV
214941545|NCT02502266|DRUG|Topotecan Hydrochloride|Given IV
214941546|NCT02707406|OTHER|NEOX®CORD 1K|use of human tissue product wound covering
214941547|NCT02707406|OTHER|standard of care|standard wound coverings
214941548|NCT02921750|DEVICE|Exufiber Gelling Fibre Dressing|Gelling fibre dressing
214941549|NCT02921750|DEVICE|Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre|Hydrofiber® Dressing with Strengthening Fibre
214941550|NCT03298659|DIAGNOSTIC_TEST|iFR|Treatment guided by instantaneous wave-free ratio
214941551|NCT03298659|DIAGNOSTIC_TEST|CMR|Treatment guided by stress perfusion CMR
214941552|NCT04295213|OTHER|oligosaccharides|1 dose a day of oligosaccharides or placebo
214941553|NCT05201040|DEVICE|JETKNEE Synovial Fluid Supplement|2mL of JETKNEE Synovial Fluid Supplement
214941554|NCT05201040|DEVICE|Normal saline|2mL of normal saline
214941555|NCT03824821|OTHER|No intervention|No intervention
214941556|NCT03310294|DIETARY_SUPPLEMENT|Placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
215074286|NCT05026840|PROCEDURE|GDM screening criteria|difference in risk factors and clinical outcomes between groups
214347351|NCT03372226|BEHAVIORAL|Online self-help program|The program consists of 10 modules with many interactional exercises and homework-sheets. Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse.
214941557|NCT03310294|DIETARY_SUPPLEMENT|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
214941558|NCT00554541|OTHER|Ankle Brachial Index Venous physiologic study|Assessment of lower extremity venous disease
214941559|NCT03219905|DEVICE|Therapeutic Kinesio-taping|"The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees."
214941560|NCT03219905|DEVICE|Sham Kinesio-taping|"The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg."
214941561|NCT03734900|OTHER|Saline injection|5ml Placebo infusion of 0.9% Sodium Chloride
214941562|NCT03734900|BIOLOGICAL|PRP injection|"Device: Aeon Acti-PRP~5ml autologous platelet rich plasma injection"
214941563|NCT03734900|BIOLOGICAL|PL injection|"Device: Aeon Acti-PRP~5ml autologous platelet lysate injection"
214941564|NCT02323737|DRUG|Irinotecan and cisplatin|
214941565|NCT02323737|DRUG|Etoposide and cisplatin|
214941566|NCT02065063|DRUG|Trametinib|Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.
214941567|NCT02065063|DRUG|Palbociclib|Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
214941568|NCT01535586|DEVICE|CPAP versus MAD|Cross over design
214941569|NCT04140916|DEVICE|Midline catheter|Peripherally inserted short intravenous catheter
214941570|NCT04140916|DEVICE|PICC-line catheter|Peripherally inserted long intravenous catheter
214941571|NCT05422768|BEHAVIORAL|Warrior Renew|Warrior Renew is a program for military sexual trauma (MST).
214941572|NCT05422768|BEHAVIORAL|Warrior Renew + EAL|Warrior Renew and EAL are combined into one program for military sexual trauma (MST).
215074287|NCT00597311|RADIATION|radiotherapy|"1. Short term radiotherapy 5x5 Gy during 5 days~2. Chemoradiotherapy 50 Gy + 5Fu/Lv"
214676358|NCT06512324|DEVICE|Ampa One TMS System|Transcranial Magnetic Stimulation
214676359|NCT00206518|DRUG|Taxotere/Docetaxel|Taxotere
214676360|NCT00206518|DRUG|Adriamycin/Cytoxan|Adriamycin/Cytoxan
214941573|NCT06002256|PROCEDURE|Mostafa Maged maneuver|While the patient is on the lithotomy position , The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)
214676361|NCT00206518|DRUG|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
214941574|NCT06002256|PROCEDURE|Bimanual uterine compression|the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands.
214941575|NCT02398513|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
214941576|NCT06731829|DRUG|HRS-9231|HRS-9231
214941577|NCT06731829|DRUG|Gadobutrol|Gadobutrol
214676362|NCT03709433|BEHAVIORAL|ACT groups and mobile app|See arm description.
214347352|NCT02524704|DEVICE|CT scan|Applied only when part of the patient's standard care
214941578|NCT03605849|DRUG|Centanafadine SR|200mg, BID, oral tablets
214941579|NCT04087616|BEHAVIORAL|ICBIT|The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.
214941580|NCT04087616|BEHAVIORAL|waiting list|Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
214941581|NCT04959214|BEHAVIORAL|progressive relaxation egzersize|Performing exercises in a quiet environment for 45 minutes with the Turkish Psychologists Association CD. Filling the PSQI and FSS before and 1 month after the application
214941582|NCT02488590|DRUG|LABA + LAMA|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
214941583|NCT02488590|DRUG|ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
214347353|NCT01538745|DRUG|Ketamine|0.3 mg/kg ketamine Intravenous push (IVP) over 5 minutes. Total of two possible doses.
214676363|NCT01269034|DRUG|Exenatide|1.25 mcg before the boost sub-cutaneously.
214676364|NCT01269034|DRUG|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
214676365|NCT01269034|DRUG|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
214347354|NCT01538745|DRUG|Morphine|0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.
214676366|NCT06670924|PROCEDURE|Running suture for vesico-urethral anastomosis in open radical prostatectomy|The surgical technique of the RS followed the description of Van Velthovens, was applied with slight modifications. Two 3/0 absorbable monofilament (polydioxanone) sutures were used. The first needle is started from bladder neck at 3 o'clock, and terminated in the urethra at 9 o'clock. After completion of the posterior anastomosis, a transurethral catheter is placed. The second sutures' needle is passed from the bladder at 9 o'clock and ended in the urethra at 3 o'clock. The bladder neck and urethra are merged by gentle traction of the anterior and posterior sutures at 3 and 9 o'clock.
214676367|NCT06670924|PROCEDURE|interrupted suture for vesico-urethral anastomosis in open radical prostatectomy|The technique described by Walsh for interrupted anastomotic suturing was applied with minor modifications. Six 3/0 absorbable monofilament (polydioxanone) sutures were placed at 1, 3, 5, 7, 9 and 11 o'clock to accomplish the vesicourethral anastomosis.
214676368|NCT05969210|OTHER|Toe strengthening exercise|12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.
214676369|NCT05969210|OTHER|Control Group|12 participants will be in control group they will do only there running training.
214676370|NCT06010667|DRUG|Envafolimab|With or without Envafolimab
214676371|NCT03004846|DRUG|GSK2981278 ointment|"GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas ."
214676372|NCT03004846|DRUG|Vehicle ointment|It will be supplied as white to off-white vehicle ointment for topical application.
214676373|NCT03790735|DIAGNOSTIC_TEST|FISH|Targeted chromosomal aberrations detection
214676374|NCT01050660|OTHER|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
214676375|NCT01050660|OTHER|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
214676376|NCT02928640|DEVICE|ClariCore System|Data collection to build the prostrate tissue classification algorithm.
214676377|NCT03566966|BIOLOGICAL|Non-organ-specific Ab positive|Antiviral administration and evaluation of SVR24 and side effects
214676378|NCT03566966|BIOLOGICAL|Non-organ-specific Ab negative|direct-acting antiviral agents
214676379|NCT00248677|BEHAVIORAL|Behavioral Family-Based Intervention|Behavioral family intervention
214676380|NCT00248677|BEHAVIORAL|Behavioral Parent-Based Intervention|Behavioral Parent-Only Intervention
214676381|NCT02106208|OTHER|Cheese diet|
214676382|NCT02106208|OTHER|Butter diet|
214676383|NCT02106208|OTHER|CHO diet|
214676384|NCT02106208|OTHER|MUFA diet|
214676385|NCT02106208|OTHER|PUFA diet|
214676386|NCT01652833|OTHER|Physician Survey|Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
214676387|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
214676388|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
214676389|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
214676390|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
215078070|NCT01069861|DRUG|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
214347355|NCT06040489|DRUG|Miltefosine 50mg|Oral Miltefosine 50mg bid
214347356|NCT06040489|DRUG|Pentoxifylline 400mg|Oral Pentoxifylline 400mg tid
214347357|NCT06040489|DRUG|Liposomal Amphotericin B|Intravenous 25 to 40mg/kg
214347358|NCT05997004|DRUG|Normal Saline|After surgical creation of umbilical port Control group received injection normal saline 1ml.
214676391|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
214676392|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
214676393|NCT03364998|DRUG|Damoctocog (Jivi, BAY94-9027)|60 international units (IU)/kg, given as a 10 minute injection, 1 dose
214676394|NCT03364998|DRUG|Elocta|60 IU/kg, given as a 10 minute injection, 1 dose
214676395|NCT04905329|DRUG|Empegfilgrastim|Extimia®
214676396|NCT05171530|DRUG|Lenvatinib plus taxane drugs|"* Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA"
214676397|NCT02011022|DRUG|3g MTX|The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
214676398|NCT02011022|DRUG|5g MTX|The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
214676399|NCT04330625|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for four weekly doses
214676400|NCT05873530|OTHER|Grape|Reconstituted whole grape powder
214676401|NCT03863496|PROCEDURE|Scoliosis surgery|All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
214676402|NCT05127772|DRUG|HEC93077|Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
214676403|NCT05127772|DRUG|Placebo|Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
214676404|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
214941584|NCT02488590|DRUG|LABA + LAMA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
214941585|NCT02488590|DRUG|LABA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
214941586|NCT02488590|DRUG|other|An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
214941587|NCT05717803|PROCEDURE|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
214941588|NCT01172964|DRUG|flucytosine|Given orally
214941589|NCT01172964|OTHER|polymerase chain reaction|Correlative studies
214941590|NCT01172964|OTHER|immunohistochemistry staining method|Correlative studies
214941591|NCT01172964|BIOLOGICAL|gene therapy|Injected at the time of the surgery to resect the tumor
214941592|NCT01172964|OTHER|pharmacological study|Correlative studies
214941593|NCT01172964|OTHER|3-Tesla magnetic resonance imaging|Correlative studies
214941594|NCT01172964|OTHER|laboratory biomarker analysis|Correlative studies
214941595|NCT01172964|PROCEDURE|therapeutic conventional surgery|Surgery to resect the tumor
214941596|NCT01172964|BIOLOGICAL|E. coli CD-expressing genetically modified neural stem cells|Injected at the time of the surgery to resect the tumor
214941597|NCT02507843|DRUG|Cholecalciferol|Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
214941598|NCT02507843|DRUG|Placebo|Placebo will be administered in placebo group monthly for 6 months.
215074288|NCT02879643|DRUG|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
214941599|NCT04283474|DRUG|XG005-03|3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation
215074289|NCT05924698|OTHER|Electrostimulation|Consisting of the use of NMES (biphasic symmetrical pulse, bipolar mode, 50Hz frequency, pulse duration 300 μs at 1:1 ratio) (S82®; Enraf-Nonius BV, Rotterdam, The Netherlands). The self-adhesive electrodes (8x5 cm2 Pals Platinum © type, Axelgaard Manufacturing Co. Ltd, Fallbrook, CA, USA) were placed on the quadriceps muscle. The positives electrodes placed distally on the rectus anterior and vastus externus and negative electrodes were placed proximally on the rectus anterior and vastus internus. The over current program consisted of 8 seconds (s) of work (ON phase) and 8 seconds of rest (OFF phase). The overcurrent program in the ON phase had a rise time of 2 s, a hold time of 4 s and a fall time of 2 s. The intensity of the electric current was increased to the maximum perceived tolerance, achieving a clear contraction without producing fatigue.
215078071|NCT02760771|OTHER|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
215078072|NCT02760771|OTHER|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
215078073|NCT00544453|DRUG|[123I] MNI-308|Injection of \[123I\] MNI-308 and SPECT scanning
215078074|NCT00504504|DRUG|Rituximab|375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
214941600|NCT04283474|DRUG|Placebo|Placebo topical formulation
214941601|NCT00053508|BIOLOGICAL|ACAM1000|Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
215078075|NCT00504504|DRUG|Adriamycin|25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
214941602|NCT00053508|BIOLOGICAL|vaccinia virus (calf lymph) smallpox vaccine: Dryvax|group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
214941603|NCT04128891|DRUG|Sacubitril-Valsartan|Cardiomagnetic Resonance Imaging
214941604|NCT04478500|DRUG|Minocycline|"Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase."
214941605|NCT02102100|DRUG|nicotine|In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
214941606|NCT02102100|DRUG|menthol|In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
214941607|NCT03006263|PROCEDURE|Totally Laparoscopic Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
215078076|NCT00504504|DRUG|Bleomycin|10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
215078077|NCT00504504|DRUG|Vinblastine|6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
215078078|NCT00504504|DRUG|Dacarbazine (DTIC)|375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
215078079|NCT06358781|OTHER|Whole grain wheat flour|Group A: whole grain flour: 0 g Group B: Whole grain flour: 25 g Group C: Whole grain flour: 50 g Group D: whole grain flour: 100g
215078080|NCT01304212|DRUG|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
214347359|NCT05997004|DRUG|Glycopyrrolate|After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
214941608|NCT03006263|PROCEDURE|Laparoscopy Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
214941609|NCT02278692|DIETARY_SUPPLEMENT|Vitamin K|Oral vitamin K
214941610|NCT02278692|OTHER|Placebo|Oral placebo tablet
214941611|NCT00962936|DRUG|CT-011|CT-011
214941612|NCT02003989|OTHER|ophthalmologic examination and MRI|thorough investigation of patients, not included in usual care.
214941613|NCT06397989|DIETARY_SUPPLEMENT|Ready-to-use school food|80 grams of peanut paste-based food containing skim milk powder, cowpea, peanuts, vegetable oil, and multiple micronutrients
214941614|NCT06397989|DIETARY_SUPPLEMENT|Standard meal|300ml of porridge made with rice/millet flour
214941615|NCT01483989|OTHER|SYSTANE® Gel Drop lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
214941616|NCT00328094|DRUG|continuous intravenous insulin infusion|Tight glucose control versus standard of care
214941617|NCT03241433|OTHER|High intensity interval training|exercise by use of stationary cycles
214941618|NCT03241433|OTHER|Moderate intensity continuous training|exercise by use of stationary cycles
214941619|NCT03241433|OTHER|No Exercise|no exercise training will be given and no exercise will be added to subjects routine
214941620|NCT05470855|BIOLOGICAL|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
214941621|NCT01142765|BIOLOGICAL|AdCh63 MSP1, MVA MSP1, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
215074290|NCT05924698|OTHER|Blood flow restriction therapy|To attain partial vascular occlusion, a PTS ii portable tourniquet system (Delphi Medical, Vancouver, BC, Canada) with a corresponding size-specific tourniquet was placed around the patient's proximal thigh. This system allows for precise control of cuff pressure throughout training despite the changes in muscle volume that naturally occur while performing exercises. Total limb occlusion pressure (LOP) was identified by determining the pressure required to eliminate a detectable pulse using Doppler ultrasound. Partial vascular occlusion was achieved by setting the tourniquet to 80% of the LOP. This ensured that venous occlusion was obtained while still allowing arterial inflow and was personalized to each patient despite variations in thigh girth, cuff size, and systolic blood pressure. An Easy-Fit Tourniquet Cuff (Delfi Medical, Vancouver, VC, Canada) was used with the PTS ii system.
214676405|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
214676406|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
215074291|NCT00050531|DRUG|Gleevec|400 mg orally twice daily.
215074292|NCT00050531|DRUG|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
215074293|NCT00050531|DRUG|Sargramostim (GM-CSF)|125 mcg/m\^2 three times per week subcutaneously.
214941622|NCT01142765|BIOLOGICAL|AdCh63 AMA1, MVA AMA1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose MVA AMA1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
214941623|NCT01142765|BIOLOGICAL|AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose AdCh63 MSP1 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA AMA1 2.5 x 108 pfu intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
215074294|NCT06104878|OTHER|No Intervention|No Intervention will be administered in this study.
214347360|NCT01028573|DRUG|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
214347361|NCT01028573|DRUG|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
214347362|NCT01028573|DRUG|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
214347363|NCT01028573|DRUG|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
215074295|NCT02684877|OTHER|Questionnaire|
215074296|NCT04319380|BIOLOGICAL|Tetanus/diphtheria toxoids|One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.
215074297|NCT04319380|DRUG|SMC with SP+AQ|Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
215074298|NCT04319380|BIOLOGICAL|RTS,S/AS01|One booster dose of RTSS/AS01 (June) in year 1 and 2.
214941624|NCT01142765|BIOLOGICAL|AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose AdCh63 ME-TRAP 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA MSP1 2.5 x 108 pfu intramuscularly and 1 dose MVA ME-TRAP 2 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
214941625|NCT01142765|BIOLOGICAL|Sporozoite challenge|Non-vaccinated controls for sporozoite challenge
214941626|NCT04616846|DIAGNOSTIC_TEST|Peripheral venous ultrasound|Screening for VTE from D7 to 42
214338904|NCT06142916|OTHER|Vırtual Realıty Traınıng On Mental Health Lıteracy And Stıgma|Nurses in the intervention group will be taken to a suitable room on the ward and virtual reality glasses will be worn. Mental health literacy training prepared by researchers by scanning the literature will be given using virtual reality glasses. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. Animations will be prepared for each topic. The training is planned to last 45 minutes.
214338905|NCT06142916|OTHER|Classical Education|Nurses in the control group will be given mental health literacy training using the classical method using brochures. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. The training is planned to last 45 minutes.
214338906|NCT00296556|DRUG|Rivenprost (drug)|
214338907|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) active stimulator|In tDCS the electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
214338908|NCT06155786|DEVICE|transcranial random noise stimulation (tRNS)|Here, an alternating electrical current is applied at a mix of frequencies it is called transcranial random noise stimulation (tRNS), which can be delivered in low (between 0.1-100 Hz) or high (between 101-640 Hz) frequency stimulation
214338909|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) sham stimulator|Here a sham electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
214347364|NCT05729074|DRUG|IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
214676407|NCT02053246|DRUG|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
214941627|NCT02441751|PROCEDURE|intra-operative blood loss|surgery in the urology and orthopedics
214941628|NCT04023305|DRUG|Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts|Pharmacokinetic of inhaled sevoflurane used for sedation
214676408|NCT03403972|DRUG|Vancomycin 250Mg Capsule|Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
214941629|NCT06083545|BEHAVIORAL|App|The low-protein diet app introduces the perceived significant efficacy of low-protein diets for patients with chronic kidney disease.
214941630|NCT03994757|BEHAVIORAL|MRBI|The activities content is designed according to the children's daily routine and goals. It mainly involves bathing activities, eating activities, dressing activities, game activities, social and communication activities, and according to the needs of parents. In the treatment room, after the therapist and parents discuss the intervention methods and suggestions, they will demonstrate the intervention strategies and methods, and let the parents practice the practice, and the therapist will guide them. After discussing with parents, the therapist will give parents a homework related to children's daily routine, let the parents implement at home, and discuss with parents and record before each intervention.
214941631|NCT03994757|BEHAVIORAL|Control|Traditional treatment was directly performed for children in the treatment room by the therapist. The activity content was designed according to the children's goals. After each end of treatment, therapist will give parents a homework related to traditional treatments, let the parents perform at home, and know the parents' performance at home and record before each treatment begins.
214941632|NCT04787861|OTHER|motorized movement therapy|The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
214941633|NCT00590538|DRUG|Sodium 4-Phenylbutyrate|The standard oral adult dose is 20 g/day (tablets) for 4 days.
214941634|NCT00590538|DRUG|Genistein (Unconjugated Isoflavones 100)|Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
214941635|NCT00590538|DRUG|Placebo|The placebo is given to match the active comparator for four days.
214941636|NCT00381329|BEHAVIORAL|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
215074299|NCT04319380|DRUG|SMC placebo|Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
215074300|NCT03871010|DEVICE|Midline catheter|Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.
215074301|NCT03447899|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
214338910|NCT02960984|OTHER|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
214941637|NCT00381329|BEHAVIORAL|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
214941638|NCT02411981|OTHER|Autogenic drainage|
214941639|NCT02309723|DEVICE|Beta amyloid imaging|
214941640|NCT03718195|OTHER|Pediatric Formula|One week intake diary, one week tolerance diary, product intake
214941641|NCT01125813|BIOLOGICAL|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
214941642|NCT06433817|RADIATION|Spectral computed tomography scan|Spectral CT scans acquisition performed during the arterial phase and venous phase for cervical cancer
214941643|NCT06346574|BEHAVIORAL|Experimental|Participants will receive access to health and wellness app and guide
214941644|NCT03811210|BEHAVIORAL|portion size|"Smaller than normal portion size - the intervention is the main meal component size perceived as 'smaller than normal' that participants are provided with during lunch and dinner in the laboratory.~Small-normal portion size - the intervention is the main meal component size perceived as 'small-normal' that participants are provided with during lunch and dinner in the laboratory.~Large-normal portion size - the intervention is the main meal component size perceived as 'large-normal' that participants are provided with during lunch and dinner in the laboratory."
214941645|NCT06289998|DRUG|Tamibarotene|Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.
214941646|NCT06289998|DRUG|Placebo|Subjects are administrated to placebo in daily for 52 weeks.
214941647|NCT00128804|BEHAVIORAL|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
214941648|NCT00006033|BIOLOGICAL|gene therapy|
214941649|NCT00006033|BIOLOGICAL|interleukin-2 gene|
214941650|NCT00006033|DRUG|methotrexate|
214941651|NCT05122533|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
214941652|NCT05122533|DIAGNOSTIC_TEST|Clinical limb length measurements|"Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~* bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~* tape measuring:~  * Spina iliaca anterior superior - medial malleolus~ * umbilicus - medial malleolus~ * greater trochanter - lateral malleolus~ * in standing, sitting, resupinate and side position"
214941653|NCT00985426|BIOLOGICAL|HEPLISAV-B|Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24
214338911|NCT02283502|DEVICE|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
214941654|NCT00985426|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
214338912|NCT01236404|DRUG|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
214338913|NCT01236404|DRUG|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
214338914|NCT06359405|BEHAVIORAL|drug safety simulation|"The intervention's purpose is to develop a simulation program to increase nursing students' crisis management skills regarding medication safety. This simulation program will provide students with the opportunity to develop skills in recognizing, evaluating, and effectively intervening in medication errors in real-world scenarios.~The simulation program will include interactive case scenarios, virtual patients, and simulation sessions led by an instructor providing feedback to students. Also, medicine Learning materials covering preventing, recognizing, and correcting errors will also be provided."
214676409|NCT02795156|DRUG|Afatinib|40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
214338915|NCT00139126|BEHAVIORAL|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
214338916|NCT01719692|DRUG|Rituximab|
214338917|NCT05641740|DEVICE|Single-session of Radiofrequency|"The experimental group continue with their usual conservative and pharmacological treatment and will receive a single-session of monopolar dielectric capacitive radiofrequency in their hands. An Biotronic Advance Develops® (ABD-S25v) with a carrier wave frequency of 800-900 KHz of 850 KHz will be used. Patients will be placed in a seated position, with the forearms supinated and resting on a wooden table. An almond oil conductor will be applied to the hands. The application will be carried out with a circular head of 5 cm2 and for a total of 10 minutes on each of the palms of the hands.~They will be evaluated at baseline and post-session."
214941655|NCT00985426|OTHER|Placebo|Placebo(saline) intramuscular (IM) injection at Week 8
214676410|NCT02795156|DRUG|Regorafenib|160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
215074302|NCT06658379|DIAGNOSTIC_TEST|CD8+TEMRA|
214347365|NCT05729074|DRUG|IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
214941656|NCT02327013|DRUG|vortioxetine 10 mg tablet|Oral tablets, once daily
214941657|NCT02327013|DRUG|vortioxetine 20 mg tablet|Oral tablets, once daily
214941658|NCT02327013|OTHER|Placebo tablet|Oral tablets, once daily
214941659|NCT01565668|DRUG|AC220|oral
214941660|NCT03192618|PROCEDURE|adjuvant transarterial chemoinfusion (TAI)|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
214941661|NCT03192618|DRUG|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
214941662|NCT06029933|BIOLOGICAL|Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)|Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.
215074303|NCT06658990|PROCEDURE|buccal acupuncture|ultrasound positioning assisted buccal acupuncture
215074304|NCT06658990|DRUG|control|Sufentanil is used after surgery
214338918|NCT05641740|DEVICE|Control Placebo single-session of Radiofrequency|"The control placebo group continue with their usual conservative and pharmacological treatment and will receive a placebo single-session of radiofrequency. This group will follow the same protocol and treatment time, but they will receive a placebo treatment (the device remains in paused mode), so that radiofrequency will not be applied.~They will be evaluated at baseline and post-session."
214941663|NCT06029933|BIOLOGICAL|High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)|Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.
214941664|NCT00160225|DRUG|Daglutril|
214941665|NCT04258254|BEHAVIORAL|Multimodal|Multimodal intervention will involve hello songs, warm up mainly involve sensory and stretching games, music time involves playing instruments, moving game involves use of music or songs to move the whole body, yoga involves themes/songs to perform yoga poses, and good bye involves a goodbye song and reflections about the session. In all movement conditions, trainers emphasize complex and multilimb coordination (asymmetrical and ipsi/contralateral movements) and balance.
214941666|NCT04258254|BEHAVIORAL|General|The general exercise group will begin with hello games/set up and end with reflections and cleanup. Children will engage in limb and body warmup routines, specific strengthening exercises (single-joint/single-limb/symmetrical), moderate intensity endurance exercises involving various obstacle courses, and a cool down routine.
214941667|NCT04258254|BEHAVIORAL|Standard of Care|The seated play group will also begin with hello/icebreaker games and end with goodbye and cleanup. In between, they will read books and review the story line and overall message and engage in fine-motor activities involving building supplies and art-craft.
214941668|NCT05000203|BEHAVIORAL|Online prenatal specific education|"The sessions will start around 30 weeks of gestation with the intention that around 35-37 weeks all pregnant women have had the opportunity to attend all the sessions.~Five specific online group sessions have been established for the fear of childbirth, each divided into three parts, and lasting approximately 60 minutes. In the first part, the aspects that are most relevant according to the reported experience of women with fear of childbirth will be discuss. In a second part, videos will be displayed starring midwives who will collaborate in specific intrapartum support with the aim of presenting the personnel involved in the care of women during delivery and immediate postpartum, and where the procedures and options available in the obstetric service of HUMIC. The session will end with brief therapy tasks. After each session, written documentation on the topics discussed will be made available to the participants."
214941669|NCT05000203|BEHAVIORAL|Intrapartum specific support|"At first, a group of expert midwives will be formed in support of pregnant women with fear of childbirth. The objective is that three midwives from each work group shift will include the women from the experimental group in the intrapartum support team. The working group will receive a seminar given by the researcher where the study protocol and an update on fear of childbirth will be explained, which will include information on: concept and prevalence, risk factors, consequences, diagnosis and treatment.~For the follow-up of the participants, an instant messaging group will be formed where the collaborating midwives and the main researcher will be able to find out the existence of a participant within the emergency area or in the maternity ward, facilitating continued care in the changes of guard"
214941670|NCT05000203|BEHAVIORAL|Prenatal usual education|The participants in this group will follow the development of the usual interventions by midwives and obstetricians according to the established protocol for monitoring the pregnancy and / or by the private care system, as well as additional consultations for complications in pregnancy or consultations on demand that are considered necessary Group maternal education is offered in primary care center starting at week 28 of gestation. Although its content is supported by the Affective-Sexual and Reproductive Health Care Program, midwives are responsible for preparing the sessions according to their criteria to adapt them to the population. In addition to group interventions, pregnant women in the intervention environment also receive individualized educational attention in follow-up and control visits. After delivery, an inquiry will be made about the maternal education received by pregnant women during their current pregnancy.
215078081|NCT01304212|DRUG|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
215078082|NCT01304212|DRUG|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
214338919|NCT01651572|DRUG|Cisatracurium|"Cisatracurium (Nimbex):~* initial dose: 0.2 mg/kg~* maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
214676411|NCT02795156|DRUG|Cabozantinib|60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
214676412|NCT03985137|OTHER|mucocutaneous sampling by swab at the balano-preputial furrow.|the sample is made by the patient
214676413|NCT05478915|PROCEDURE|discectomy of the TMJ disc|removal of the TMJ disc
214676414|NCT05478915|PROCEDURE|TMJ discopexy|fixation of the TMJ disc
214676415|NCT06187415|BEHAVIORAL|Mobile app to reduce harm of chemsex|Access to the mobile app which includes PrEP diary, demistification of chemsex urban legends, information on the location of needle and syringe services program, and alert sending to emergency contact.
214676416|NCT00395785|DEVICE|Carotid Stent Implantation|
214676417|NCT00395785|DEVICE|Embolic Protection|
214676418|NCT05798962|PROCEDURE|Biopsies|Biopsies from the pathological muscle and healthy, unaffected muscle
214338920|NCT01651572|DRUG|Rocuronium|"Rocuronium (Esmeron):~* initial dose: 0.6 mg/kg~* maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
214347366|NCT05729074|DRUG|IN-A002 Ointment 1% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
214676419|NCT05910593|DIAGNOSTIC_TEST|Dexterity Assessment Tool|Measures finger dexterity using pressure sensor pads.
214338921|NCT05388890|DRUG|MLD|Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
214338922|NCT05388890|DRUG|WFC|Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
214338923|NCT05668793|DIAGNOSTIC_TEST|GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
214338924|NCT01974050|BEHAVIORAL|Text message surveillance|
214941671|NCT05000203|BEHAVIORAL|Intrapartum usual support|A routine detection of fear of childbirth or a protocolized practice for this problem is currently not contemplated in the trial setting. The different professionals who pay their attention to the pregnant woman can detect the fear of childbirth thanks to their experience or different indicators such as the expression of fears by the pregnant woman, being able to offer individualized attention and resources for the approach, according to their awareness of the problem .
214338925|NCT06232733|BEHAVIORAL|Healthy Lifestyles Project e-intervention|Virtual lifestyle behaviour change support.
214338926|NCT03538340|PROCEDURE|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
214338927|NCT03538340|PROCEDURE|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
214338928|NCT00338195|BEHAVIORAL|Individualized caffeine cessation instructions|Intervention is described in the protocol
214338929|NCT00602303|DRUG|Torsemide|
214338930|NCT02284997|DEVICE|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
214338931|NCT00748943|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
214338932|NCT01338116|OTHER|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
214676420|NCT03322137|DRUG|SNA-120|Pegcantratinib ointment
214676421|NCT03322137|DRUG|Vehicle|Placebo ointment to mimic Pegcantratinib ointment
214676422|NCT05888337|DEVICE|Contoura LASIK with Phorcides planning strategy|Bilateral treatment with topography guided LASIK
214676423|NCT05888337|DEVICE|Contoura LASIK with manifest refraction planning strategy|Bilateral treatment with topography guided LASIK
214676424|NCT00404040|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
214338933|NCT02460198|BIOLOGICAL|Pembrolizumab|IV infusion
214338934|NCT00536367|OTHER|No intervention - observational study only|
214338935|NCT00841126|DRUG|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
214338936|NCT00841126|DRUG|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
214338937|NCT00841126|DRUG|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
214338938|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
214338939|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg|Amlodipine 10mg+Valsartan 160mg
214338940|NCT03639480|DRUG|Valsartan 160mg+Atorvastatin 40mg|Valsartan 160mg+Atorvastatin 40mg
214338941|NCT04382612|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
214338942|NCT04645212|BIOLOGICAL|ADVM-022|Long term follow-up of subjects that received ADVM-022
214338943|NCT03969771|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program was developed by the University of Massachusetts Medical School.
214338944|NCT04666441|DRUG|REGN10933+REGN10987 combination therapy|Administered IV or SC single dose
215078083|NCT01304212|DRUG|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
214338945|NCT04666441|DRUG|Placebo|Administered IV or SC single dose to match
214338946|NCT04908813|DRUG|HLX22|IV Q3W D1
214676425|NCT00404040|DRUG|Lactulose|
214676426|NCT04663620|BEHAVIORAL|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
215078084|NCT00308893|GENETIC|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
215078085|NCT04165187|OTHER|Body Awareness Therapy|Body scanning, stretch-release movements, centralization, contact with the ground, postural stability, movement flow and free breathing will be performed during sessions in lying, sitting and standing positions.
215078086|NCT04165187|OTHER|Home exercise program|Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
215078087|NCT00311194|BEHAVIORAL|6 months readmission rate to hospital|
214338947|NCT04908813|DRUG|Placebo|IV Q3W D1
214941672|NCT02113995|OTHER|ACERTO protocol vs Traditional care|Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.
214941673|NCT05913206|BEHAVIORAL|Ambiguity|The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
214941674|NCT05913206|BEHAVIORAL|Complexity|The intervention is a novel communication approach to communicate complexity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
214941675|NCT05913206|BEHAVIORAL|Normalizing language|The intervention is a novel communication approach to normalize and explain the inherent uncertainty faced by parents of children with medical complexity during clinical decision making.
214941676|NCT05913206|BEHAVIORAL|Narrative|Parent and caregiver narratives about their decision making experiences for the care of their child with medical complexity.
214338948|NCT04908813|DRUG|Trastuzumab|IV Q3W D1
214338949|NCT04908813|DRUG|Oxaliplatin|IV Q3W D1
214338950|NCT04908813|DRUG|Capecitabine|PO Q3W D1-D14
214338951|NCT06364826|DRUG|Sintilimab, bevacizumab, gemcitabine|This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
214338952|NCT06364826|RADIATION|IMRT|IMRT
214338953|NCT06377735|PROCEDURE|BAI-BACE|Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
214338954|NCT02672371|DEVICE|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
214941677|NCT02255552|DRUG|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
214941678|NCT03570606|DEVICE|bone graft substitute|orthopaedic or spine bony defects
214941679|NCT03593421|DRUG|synthetic PreImplantation Factor|peptide
214941680|NCT02895724|DRUG|Medical Oxygen|Hyperbaric oxygen therapy
214941681|NCT03613558|DRUG|Dexmedetomidine|Dexmedetomidine is an alpha-2 agonist that provides both sedation and analgesia
214941682|NCT03613558|DRUG|Placebo|saline solution
214676427|NCT04663620|BEHAVIORAL|No Saving Babies Lives Programme|No comprehensive neonatal healthcare package
214676428|NCT03994640|COMBINATION_PRODUCT|Cannabis Cream|Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
214338955|NCT02672371|DEVICE|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
214338956|NCT00788866|DIETARY_SUPPLEMENT|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
214338957|NCT00788866|DIETARY_SUPPLEMENT|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
214338958|NCT01085175|DRUG|LMI 1195|Single bolus intravenous injection of LMI 1195
214338959|NCT03149328|OTHER|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
214676429|NCT03994640|COMBINATION_PRODUCT|Placebo Cream|Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
214676430|NCT02707757|DRUG|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
214676431|NCT02707757|DRUG|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
214676432|NCT04874740|OTHER|No intervention|No intervention
214676433|NCT01539265|DRUG|silodosin|
214676434|NCT01539265|DRUG|silodosin|
214941683|NCT02918903|PROCEDURE|Minimal caries removal|the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
214941684|NCT02918903|PROCEDURE|Complete caries removal|the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
214941685|NCT00361920|DRUG|prednisone|
214941686|NCT04829331|DEVICE|Restrata|Restrata is a sterile, single use device intended for use in local management of wounds
214941687|NCT03221140|DRUG|Outpatient parenteral antimicrobial therapy|Administration of intravenous antimicrobials on an outpatient basis
214676435|NCT01539265|DRUG|placebo|
214676436|NCT05446246|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
214676437|NCT04132544|OTHER|standardized gerontological evaluation (EGS)|Evaluation (EGS): initially, the patient benefits from a complete EGS and a complete fall balance realized by a Gerontological Assessment Nurse (initial visit V0) in the 7 working days following the intervention of the SAMU for fall. This assessment is based on the EGS and the assessment of risk factors for falls (HAS, INPES).
214676438|NCT04132544|OTHER|Proposal for a personalized intervention plan (PIP)|"A PIP containing personalized recommendations to improve the patient's state of health, treatment and environment as well as risk factors for falls is proposed during the multi-professional consultation and discussed by telephone with the attending physician (pre-arranged telephone appointment). with the latter).~The PIP validated by the attending physician is delivered and explained to the patient by the Gerontological Assessment Nurse in the week following the Multidisciplinary Team Meeting (MDTM) during the V1 visit to the patient's home."
214676439|NCT04132544|OTHER|Follow-up|"Four follow-up visits at 6, 12, 18 and 24 months (V2, V3, V4, V5) are performed at the patient's home. During these visits, the Gerontological Assessment Nurse reassesses the person from the gerontological point of view and from the point of view of risk factors for falls.~A mail containing the elements of interest is sent to the attending physician after each visit. The patient is also contacted by telephone by the Gerontological Assessment Nurse at 2, 4, 9, 15 and 21 months of follow-up to maintain a link, identify possible difficulties and encourage him / her to apply the PIP recommendations."
215078088|NCT02632279|DIETARY_SUPPLEMENT|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
215078089|NCT02632279|DIETARY_SUPPLEMENT|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
215078090|NCT02632279|DEVICE|Stimulator ON|Participants will be tested while their stimulator is turned ON
214338960|NCT04530682|BIOLOGICAL|Biological samples|Serum and plasma samples. At baseline, 6, 12 and 24 months
214676440|NCT04132544|OTHER|Usual care|"The patients included in the control group will benefit from the usual care as well as documentation on general recommendations to be put in place to prevent falls and to age in good health \[series of brochures published by INPES for the elderly. They are informed by telephone of their home group by the Gerontological Assessment Nurse. The documents are sent by mail to the patient's home address."
214941688|NCT03041103|OTHER|Food Product 1|50 grams of fortified nutritious product from legumes
214941689|NCT04363918|DEVICE|bioelectric stimulation|bioelectric stimulation
214941690|NCT03425357|OTHER|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
214941691|NCT03160222|OTHER|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
215078091|NCT02632279|DEVICE|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
215078092|NCT04018560|BEHAVIORAL|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
215078093|NCT03581539|PROCEDURE|Transverses Abdominis Plane (TAP) block|TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
215078094|NCT03581539|PROCEDURE|Quadratus Lumborum (QL) block|QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
215078095|NCT03581539|PROCEDURE|Surgeon Infiltration using Exparel|SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
215078096|NCT03739489|PROCEDURE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
215078097|NCT02906215|BEHAVIORAL|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
215078098|NCT00898924|GENETIC|molecular diagnostic method|
215078099|NCT00898924|GENETIC|mutation analysis|
215078100|NCT00016367|BIOLOGICAL|Trastuzumab|"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."
215078101|NCT00016367|DRUG|Cisplatin|"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1."
214338961|NCT03756766|DIAGNOSTIC_TEST|RSV point of care testing|Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
214676441|NCT04430530|BIOLOGICAL|Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
214676442|NCT01666522|DRUG|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
214941692|NCT01397539|DRUG|BIIB037|Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
214941693|NCT01397539|OTHER|Placebo|Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
214941694|NCT03588078|DRUG|APR-246|Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
214941695|NCT03588078|DRUG|Azacitidine|azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
214941696|NCT01276522|DRUG|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
214941697|NCT01067625|DEVICE|TOGA® System|Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
214941698|NCT04566133|DRUG|Trametinib|orally 2 mg once a day
214338962|NCT01328002|DRUG|Milnacipran|"Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing"
214338963|NCT01328002|DRUG|Placebo|matching placebo tablets daily
214338964|NCT04315285|BEHAVIORAL|Treadmill gait training with verbal instruction|Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
214338965|NCT03579199|DEVICE|exploration of abdominal cavity and liver using a NIR/ICG camera|exploration of abdominal cavity and liver using a NIR/ICG camera
214338966|NCT00813761|DEVICE|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
214338967|NCT00813761|DEVICE|Proclear contact lens|control contact lens to be worn for entire length of study.
214486448|NCT06782698|BEHAVIORAL|Promotion of Healthy Physical Activity|"The short counseling consists of at least one opportunistic talk for promotion of physical activity, taking up to 5 minutes, during the Medical Oncology appointment or during Physical Assessments at T0. It should follow the instructions of the Portuguese Directorate-General of Health, Short Counselling for the Promotion of Physical Activity, including the delivery of a Physical Activity Guide plus a Auxiliar of Decision or a Plan of Action or Maintenance.\[Mendes R, 2020\] All patients will receive a Guide about Nutrition for Cancer Patients \[Capela AM, 2023\] and may be offered Nutritional, Psychological or other additional consultations according to clinical judgement of the Medical Oncologist."
214676443|NCT01666522|OTHER|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
214676444|NCT04701255|PROCEDURE|phacoemulsification with intraocular lens implantation|treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
214338968|NCT00813761|DEVICE|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
214338969|NCT00813761|DEVICE|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
214941699|NCT04566133|DRUG|Hydroxychloroquine|orally 600 mg twice a day-1,200 mg total dose
214941700|NCT03570554|DRUG|Naproxen Sodium (Aleve, BAY117031)|660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)
214941701|NCT03570554|DRUG|Acetaminophen ER|3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)
214941702|NCT03570554|DRUG|Celecoxib|200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)
214941703|NCT03570554|DRUG|Placebo|Over-encapsulation capsule, 4 days, oral (Treatment D)
214941704|NCT00176436|BEHAVIORAL|Diet support group|Diet support group weekly and exercise sessions 3 times/week, placebo medication
214941705|NCT00176436|BEHAVIORAL|Group counseling and exercise|Support group weekly and exercise sessions 3 times/week for 24 weeks
215078102|NCT00016367|DRUG|Gemcitabine Hydrochloride|"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."
215078103|NCT03272828|DEVICE|Nobel Biocare titanium dental implants|
214338970|NCT03435094|DRUG|Binosto 70Mg Effervescent Tablet|Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
214338971|NCT03435094|DRUG|Fosamax 70Mg Tablet|Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.
214676445|NCT04701255|DEVICE|ocular aberrometer assesment|evaluate total ocular wavefront, corneal wavefront \& internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
214941706|NCT02222675|PROCEDURE|Sonography assisted breast surgery|
214676446|NCT04214795|OTHER|Observational study. Postnatal variables are recorded|Postnatal evolution is analyzed in both groups
214941707|NCT02222675|PROCEDURE|Conventional breast surgery|
214941708|NCT05865275|DEVICE|Low-level laser treatment|a single preliminary treatment for a few seconds for each tooth using low level diode laser before of tooth bleaching could reduce risk to arise of tooth sensitivity
214941709|NCT05865275|OTHER|tooth bleaching procedure|The gingival tissues of the teeth to be bleached were isolated from the bleaching gel using a light-cured resin dam (OpalDam Kit, Ultradent; Milan, Italy). A 38 % ready-to-use Hydrogen peroxide-containing gel (The Smile® Strong, Italy) was applied from the first premolar right to the first premolar left of both jaws for a total period of 20 minutes for a 1 single whitening session.
214338972|NCT01384058|DRUG|ezetimibe|ezetimibe 10 mg per day for six weeks
214338973|NCT01384058|DRUG|simvastatin|Simvastatin 20 mg per day for six weeks
214338974|NCT01384058|DRUG|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
214338975|NCT04231435|DRUG|Fedratinib|Oral
214338976|NCT04231435|DRUG|Digoxin|Oral
214338977|NCT04231435|DRUG|Rosuvastatin|Oral
214338978|NCT04231435|DRUG|Metformin|Oral
214941710|NCT04960852|OTHER|a single shade structurally colored universal resin composite|Omnichroma is a single shade composite that is claimed to have blending effect with the tooth color, thus eliminate shade matching procedures during restorative treatment
214338979|NCT00691210|DRUG|Vorinostat|"Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
214338980|NCT00691210|DRUG|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
214676447|NCT04541823|DRUG|Desﬂurane|Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
214676448|NCT04541823|DRUG|Propofol|Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
214338981|NCT00691210|DRUG|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
214338982|NCT02716844|OTHER|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
214338983|NCT01494311|DRUG|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
214338984|NCT01494311|DRUG|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
214338985|NCT01494311|DRUG|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
214338986|NCT01494311|DRUG|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
214338987|NCT01507428|DRUG|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
214338988|NCT01507428|DRUG|Carboplatin|Given IV
214338989|NCT01507428|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
214338990|NCT01507428|PROCEDURE|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
214338991|NCT01507428|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
214338992|NCT01507428|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
214338993|NCT01507428|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
214338994|NCT01507428|OTHER|Laboratory Biomarker Analysis|Correlative studies
214338995|NCT01507428|DRUG|Paclitaxel|Given IV
214338996|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
214338997|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
214338998|NCT02114970|OTHER|Randomized- paper consent|
214338999|NCT02114970|OTHER|Randomized- Tablet-delivered consent|
214941711|NCT00801437|DRUG|Xalacom|Xalacom 1 drop into the affected eye daily
214941712|NCT00355706|PROCEDURE|Thoracic facet joint nerve blocks|Thoracic medial branch blocks
214941713|NCT03180515|DEVICE|Activa PC+S Neurostimulator|Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
214941714|NCT01642485|DRUG|Moxifloxacin 400 mg fasted|"Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.~This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies."
214339000|NCT02114970|OTHER|Focus Group- paper and tablet consent|
214339001|NCT02125539|BEHAVIORAL|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
214339002|NCT02125539|BEHAVIORAL|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
214339003|NCT03049163|DRUG|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
214339004|NCT00999349|DRUG|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
214339005|NCT00999349|DRUG|Placebo|
214339006|NCT01208233|DRUG|PF-03049423|1 mg of PF-03049423 daily for 90 days
214339007|NCT01208233|DRUG|PF-03049423|3 mg of PF-03049423 daily for 90 days
214339008|NCT01208233|DRUG|PF-03049423|6 mg of PF-03049423 daily for 90 days
214339009|NCT01208233|OTHER|Placebo|Placebo of PF-03049423 daily for 90 days
214339010|NCT05063097|OTHER|urine test|The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol \[THC\]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
214339011|NCT05063097|OTHER|Fagerström questionnaire|Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
214941715|NCT01642485|OTHER|FDA breakfast|Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.
214941716|NCT01642485|OTHER|Continental breakfast|High carbohydrate breakfast (\>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.
214941717|NCT01642485|DRUG|Moxifloxacin 400 mg fed|Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.
214676449|NCT02940665|OTHER|ERAS|Patients in the ERAS group received the ERAS protocol
214676450|NCT00456937|DRUG|Escitalopram|
214676451|NCT01379586|DRUG|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
214339012|NCT05063097|OTHER|Exhaled carbon monoxide (CO) measurement|Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of \> 3 parts per million (ppm) signifying active smoking.
214339013|NCT05889858|OTHER|Data collection|Data collection
214339014|NCT01751503|PROCEDURE|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
214339015|NCT01751503|PROCEDURE|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
214339016|NCT05053282|OTHER|endurance running exercise|regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
214339017|NCT01947803|DRUG|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
214339018|NCT04739748|DIAGNOSTIC_TEST|complete blood picture|Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
214339019|NCT05729022|DEVICE|Ultrasound microendoscopic technique|Ultrasound-guided microendoscopic lumbar transforaminal epidural steroid injection
214339020|NCT05729022|RADIATION|Fluoroscopy|Fluoroscopy-guided lumbar transforaminal epidural steroid injection.
214339021|NCT03361410|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 12 months
214339022|NCT03361410|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 12 months
214339023|NCT00199745|DRUG|atorvastatin|
214347367|NCT05729074|DRUG|IN-A002 Ointment 3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
214676452|NCT01379586|DRUG|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
214941718|NCT01642485|PROCEDURE|Insulin Clamp|A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.
214941719|NCT01642485|DRUG|Placebo|Comparison of different meals effect on Moxifloxacin PK profile
214941720|NCT06154642|DIAGNOSTIC_TEST|Determination of arterial compliance using blood pressure waveform analysis|Measurement of arterial stiffness using a non-invasive pressure transducer placed on the skin of the wrist, which records the pulse wave at the level of the radial artery in order to analyze the characteristics of the arterial wall. The parameters of interest are the arterial stiffness of large- and small-caliber arteries (ml/mmHg).
214941721|NCT06154642|DIAGNOSTIC_TEST|Measurement of plasma Vascular Endothelium Growth Factor|Measurement of plasma Vascular Endothelium Growth Factor levels by ELISA
214941722|NCT06154642|DIAGNOSTIC_TEST|Skin temperature gradient|Measurement of skin surface temperature gradient, defined as the difference in temperature between the skin surface of the forearm and that of the fingertip (forearm-to-fingertip)
214941723|NCT06154642|DIAGNOSTIC_TEST|Vaso-occlusion test|Measurement of endothelial function by a vaso-occlusion test performed by inflating a cuff on the arm to occlude arterial flow for 3 min. Reactive hyperemia on deflation of the cuff is measured by photoplethysmography placed on the index finger, and tissue oxygen saturation (StO2) by near-infrared spectroscopy (NIRS). The amplitude of the reperfusion flow corresponding to the peak of the perfusion index (ΔPI Peak) and the time to reach this peak (time to peak) are the parameters recorded by photoplethysmography. Tissue resaturation rate (rStO2) is the parameter recorded by NIRS.
214941724|NCT06154642|DIAGNOSTIC_TEST|Transthoracic echocardiography|The diameter of the left ventricular outflow tract is measured in the tele systolic parasternal long-axis view. The pulsed Doppler flow profile is acquired at the level of the left ventricular chamber in the apical five-chamber view. The time-velocity integral of the aortic flow is then calculated. Left ventricular end-diastolic and end-systolic volumes are also measured using Simpson's method in the 4-cavity monoplane view. Measurements of vena cava diameter and respiratory variability of vena cava diameter provide an estimate of right atrial pressure. These measurements estimate cardiac output and systemic vascular resistance.
214941725|NCT06154642|DIAGNOSTIC_TEST|Photoplethysmography|The perfusion index (PI) is derived from the signal and represents the ratio between the absorbance or reflectance of pulsatile and non-pulsatile light of the photoplethysmography signal. PI is measured non-invasively using a photoplethysmographic sensor placed on the earlobe or finger.
214676453|NCT05205707|DIAGNOSTIC_TEST|ACE serum levels|Circulating ACE2 level will be measured
214676454|NCT04370262|DRUG|SOC + Intravenous Famotidine|Standard of Care treatment plus IV famotidine
214676455|NCT04370262|DRUG|SOC + Placebo|Standard of Care treatment plus IV placebo
214676456|NCT03320512|BEHAVIORAL|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
215078104|NCT05712304|DIAGNOSTIC_TEST|second examination of the proximal colon|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
215078105|NCT04358705|OTHER|Aim 1: Online survey|"This survey will evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users. This survey will be used to inform survey design for further aims.~As a proxy for biological verification of tobacco use status, data on brand, frequency, and pricing will be collected to confirm user status~Participants will rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions. Participants will also complete purchase and substitution tasks."
215078106|NCT04358705|BEHAVIORAL|Eye Tracking Activity|The eye tracking activity consists of a single in-person eye tracking activity that will take place in a private office in Columbus, Ohio where the participant will be seated in a chair within a typical viewing distance from a computer monitor equipped with an infrared camera on the monitor to capture precise eye movements. Participants will have their gaze monitored continuously by the camera on the computer monitor while a randomized set of stimuli (e.g., tobacco product images) are viewed (n=30) for 10 seconds per image. Following each image, an on-screen closed response question will re-center the participant's gaze for standardization prior to the next image.
214339024|NCT04401228|OTHER|predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?|"patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact \< one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded"
214339025|NCT00132769|DRUG|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
214339026|NCT00132769|DRUG|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
214339027|NCT03735394|DIAGNOSTIC_TEST|ultrasonic probe|apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
214941726|NCT06154642|PROCEDURE|Transcatheter aortic valve insertion (TAVI)|TAVI is a treatment for aortic valve stenosis. A new valve is inserted with minimally invasive procedure without removing the old, damaged valve.
214941727|NCT06547242|DRUG|Levothyroxin|Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
214941728|NCT06547242|DRUG|Levothyroxin|Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
214941729|NCT03008993|BEHAVIORAL|HQIS implementation|
214941730|NCT00148577|DEVICE|Transcutaneous Electrical Nerve Stimulation|
214941731|NCT06292793|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
214941732|NCT06292793|BEHAVIORAL|Cyclical Sighing|A 4-minute audio recording consisting of a 1-minute introduction to cyclical sighing followed by a 3-minute cyclical sighing practice.
214941733|NCT02718248|DEVICE|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
214941734|NCT02718248|BEHAVIORAL|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
214941735|NCT03546010|BEHAVIORAL|Neuropsychological tests|WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test
214941736|NCT03546010|BEHAVIORAL|Oculometric tests|When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.
214941737|NCT02863081|OTHER|Survey|Administered to healthcare providers
214941738|NCT02863081|OTHER|interview|Administered to patients and LAR (i.e., interviews)
215074305|NCT06659666|DEVICE|COPD Optimiser|Patients will receive enhanced usual medical care as determined by their physician. The study visit is a standard consultation supported by the COPD Optimiser webtool. The extra elements added to the COPD consultation are the use of the COPD Optimiser and a short questionnaire directly following the consultation on the patient's experience with the COPD Optimiser. Patients can additionally consent to two optional elements: 1) a determination of blood eosinophil count using a point of care test and 2) a brief interview on their experience with the COPD Optimiser. this tool creates an overview of fac- tors and characteristics that may be associated with suboptimal COPD and provides GOLD guideline-based management suggestions. Implementation of the COPD Optimiser will sup- port healthcare professionals in providing optimal care for their COPD patients by providing individualized GOLD-guided management suggestions.
214676457|NCT03320512|BEHAVIORAL|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
214339028|NCT06573138|DRUG|Selinexor, anti-PD-1 antibody plus Golidocitinib|Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.
214339029|NCT06105476|OTHER|Alcohol|Test drink with 12 g alcohol (30 g vodka 40%) in water
214339030|NCT06105476|OTHER|Alcohol+protein|Test drink with 12 g alcohol (30 g vodka 40%) and 25 g whey protein in water
214339031|NCT06105476|OTHER|Alcohol+retinol|Test drink with 12 g alcohol (30 g vodka 40%) and 1000 μg retinol in water
214941739|NCT02223819|DRUG|Crizotinib|"An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.~Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration."
214941740|NCT06840080|OTHER|Placebo|Single dose of 2 capsules. Capsules contain the same excipients as the active arms, except for the OEA with LipiSperse in capsules that appear identical to the OEA with LipiSperse capsules
214941741|NCT06840080|DIETARY_SUPPLEMENT|125mg OEA with LipiSperse|Single dose of 2 capsules. 1 capsule contains 125mg of OEA and 13.9mg of LipiSperse, the other capsule is a placebo.
214941742|NCT06840080|DIETARY_SUPPLEMENT|250mg OEA with LipiSperse|Single dose of 2 capsules. Each capsule contains 125mg of OEA and 13.9mg of LipiSperse.
214941743|NCT02307084|PROCEDURE|Ultrasound imaging of the long saphenous vein|Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
214941744|NCT00566956|PROCEDURE|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
214941745|NCT01284387|BIOLOGICAL|ACC-001 (vanutide cridificar)|Comparisons of 2 different doses of ACC-001 or placebo for 24 months
214676458|NCT03320512|BEHAVIORAL|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
214676459|NCT01460836|DRUG|Tobramycin solution for inhalation|
214676460|NCT01460836|DRUG|Aztreonam lysine for inhalation|
214339032|NCT06105476|OTHER|Retinol|Test drink with 1000 μg retinol in water
214339033|NCT06572735|OTHER|QoL surveys|2 quality of life surveys (OV28 and ELD14) will be completed by patients every 3 months during a 12-month period
214339034|NCT06572735|OTHER|Geriatric assessment (G-CODE)|A geriatric assessment (G-CODE) will be performed by the research staff every 3 months during a 12-month period
214339035|NCT06572735|BIOLOGICAL|Blood sampling|A supplementary volume of blood will be collected from a routine blood sample (8 mL) at 3 different time points : one at inclusion, one 6 and 12 months after the beginning of PARP inhibitors treatment. Genetic lab test will be performed to assess whether there is a specific genetic signature for PARP inhibitors toxicity.
214339036|NCT05635747|DEVICE|Relizorb Enzyme Cartridge|Tube feeds run across device to digest fats.
215074306|NCT06661707|PROCEDURE|Sonar guided Quadratus Lumborum block|The probe will be tilted down the lateral abdomen to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg
214941746|NCT05265156|OTHER|Plant based formula for children aged between 12 and 36 months|Daily intake of plant based formula for 3 weeks (400ml-600ml per day).
214941747|NCT03652948|BEHAVIORAL|Meru Health Ascend Program|Cognitive-behavioral skills, mindfulness
214941748|NCT02849067|OTHER|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
214941749|NCT02849067|OTHER|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
214941750|NCT00266591|DRUG|topiramate|
214941751|NCT03466125|PROCEDURE|Cardiac surgery|Retrospective cohort study
214941752|NCT02956057|DRUG|Polyethylene Glycols|
214941753|NCT02956057|DRUG|Natrium picosulfate / Magnesium citrate|
215074307|NCT06661707|PROCEDURE|Sonar guided Ilioinguinal/Iliohypogastric block|"The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles.~After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg"
214941754|NCT02956057|DRUG|Polyethylene glycol / Ascorbic acid|
214941755|NCT00565916|DRUG|Estrogen|"Estrogen only plus placebo: estradiol topical patch 0.3 mg placed on the lower abdomen for 3 days plus an oral placebo.~Other procedures: heart metabolism tests which includes a positron-emission tomography (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO)."
214941756|NCT00565916|DRUG|Progesterone|Estrogen plus progesterone: estradiol with oral progesterone (Prometrium, 200 mg/day) for 3 days, instead of placebo. Progesterone therapy involves taking a daily oral pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.
214676461|NCT02307968|OTHER|insulin injection site|insulin injected site between inner thigh and out thigh
214676462|NCT00046826|DRUG|docetaxel|
214676463|NCT00046826|DRUG|estramustine phosphate sodium|
214676464|NCT00046826|DRUG|thalidomide|
214676465|NCT00487812|PROCEDURE|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
214676466|NCT02139410|PROCEDURE|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
214676467|NCT04248010|DEVICE|neuroConn DC-Stimulator MR|standard tDCS, active \& sham
214676468|NCT04248010|DEVICE|Soterix MxN HD-tES|HD-tDCS, active \& sham
214941757|NCT00565916|DRUG|Placebo|Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
214941758|NCT01667939|BEHAVIORAL|Healthy Eating Index (HEI) in supervised pregnancies|Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
214941759|NCT01764724|BEHAVIORAL|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
214941760|NCT03435224|DEVICE|INVSENSOR00012|Noninvasive pulse oximeter sensor
214941761|NCT00972634|OTHER|computer-assisted intervention|symptom assessment
214339037|NCT02710526|DRUG|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
214339038|NCT02741947|DRUG|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
214339039|NCT02741947|DRUG|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
214339040|NCT00497926|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
214339041|NCT02977377|OTHER|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
214339042|NCT02977377|OTHER|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
214339043|NCT05943301|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care
214339044|NCT03481946|DRUG|BAY1093884|0.3 mg/kg given intravenously
214339045|NCT03481946|DRUG|BAY1093884|1 mg/kg given intravenously
214339046|NCT05012592|BEHAVIORAL|Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children|This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
214339047|NCT01606982|DRUG|MDV3100|oral
214339048|NCT02286882|DRUG|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
214339049|NCT05060224|DEVICE|EasyLaser: Low Level Laser therapy|
214941762|NCT00972634|OTHER|questionnaire administration|Symptom assessment
214941763|NCT00972634|PROCEDURE|assessment of therapy complications|Symptom assessment
214676469|NCT05249595|DEVICE|Surface electromypgraphy-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the sEMG signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
214941764|NCT00972634|PROCEDURE|quality-of-life assessment|Symptom assessment
214339050|NCT02939222|DEVICE|Implant placement|Routine implant placement in the ideal three dimensional implant position
214339051|NCT00233025|DRUG|Duloxetine|
214339052|NCT00233025|DRUG|Placebo|
214339053|NCT05820750|DEVICE|photodynamic therapy|root canal treatment of primary molars using photodynamic therapy
214339054|NCT05820750|PROCEDURE|pulpectomy with metapex|root canal treatment using standard technique
214339055|NCT04663815|BEHAVIORAL|Animal-assisted activity|The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
214339056|NCT04663815|OTHER|Control intervention|The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
214339057|NCT02766491|OTHER|Strengthening and stretching|"Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
214339058|NCT02766491|OTHER|conventional stretching|"This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
214339059|NCT00090012|DRUG|Olanzapine|
214339060|NCT00090012|DRUG|Quetiapine|
214339061|NCT00228449|DRUG|peginesatide|
214339062|NCT03145272|DRUG|Oxycodone|A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
214339063|NCT00974428|DIETARY_SUPPLEMENT|Wobenzym® N|4 tablets TID, 6 weeks
214339064|NCT00974428|DIETARY_SUPPLEMENT|Placebo|4 tablets TID
214339065|NCT04090814|DEVICE|HeatTens (HV-F311-E)|(1) 2\~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
214347368|NCT05729074|DRUG|IN-A002 Ointment 5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
214347369|NCT05729074|DRUG|IN-A002 Ointment 1%|Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
214347370|NCT05729074|DRUG|IN-A002 Ointment 3%|Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
214941765|NCT05146063|DIAGNOSTIC_TEST|Take the patient's subcutaneous fat tissue to detect the expression of LNK|Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.
214941766|NCT00002063|DRUG|Zidovudine|
214941767|NCT02523235|DRUG|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
214941768|NCT04984317|DRUG|onabotulinumtoxin A|One-time injection of 100U BOTOX
214941769|NCT06607835|BEHAVIORAL|Mindful- compassion|Online mindful-compassion weekly for four weeks
214941770|NCT06607835|BEHAVIORAL|Mindful-compassion and cannabis suppositories|Cannabis suppositories and online mindful-compassion for vaginal pain
214676470|NCT05249595|DEVICE|Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
214941771|NCT01420679|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 30 mg/m2~Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met."
214941772|NCT06514703|PROCEDURE|CT-Guided Genicular Nerve Ablation|This procedure involves using computed tomography (CT) imaging to guide the precise placement of a needle for the ablation of genicular nerves in the knee. The goal is to disrupt the pain signals caused by osteoarthritis, providing long-term pain relief. The intervention is performed under local anesthesia and is aimed at patients who have not responded adequately to conservative pain management strategies.
214941773|NCT06514703|PROCEDURE|Fluoroscopic-Guided Genicular Nerve Ablation|This procedure utilizes fluoroscopy to accurately guide the needle placement for the ablation of genicular nerves associated with osteoarthritis knee pain. The technique focuses on minimizing pain and improving functional mobility by disrupting nerve pathways that transmit pain signals. Like the CT-guided approach, it is intended for use in patients whose symptoms have not been sufficiently managed with non-invasive treatments.
214941774|NCT05259384|PROCEDURE|Robotic pancreaticoduodenectomy|The Intervention of MIPD-ROB group
214941775|NCT05259384|PROCEDURE|Laparoscopic pancreaticoduodenectomy|The Intervention of MIPD-LAP group
214941776|NCT05259384|PROCEDURE|Robotic Distal Pancreatectomy|The Intervention of MIDP-ROB group
214941777|NCT05259384|PROCEDURE|Laparoscopic Distal Pancreatectomy|The Intervention of MIDP-LAP group
214941778|NCT00367484|BIOLOGICAL|Rebif® (clone 484-39)|s.c. administered Rebif®
214676471|NCT05249595|DEVICE|Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by combining sEMG and ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
214676472|NCT02128581|DRUG|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
214676473|NCT02128581|OTHER|Saline|
214941779|NCT03678896|BEHAVIORAL|CrewD Program|The CrewD Program - Creative reading and writing in Diabetes Program - is a Diabetes self-management education and support program to help people with Diabetes coping with the disease.
214941780|NCT03678896|BEHAVIORAL|Classical structured education|The Classical educational approach consists in an educational method based on the presentation of relevant theoretical information to help people with Diabetes coping with the disease.
215074308|NCT06660017|DRUG|Placebo|Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
215074309|NCT06660017|DRUG|Ketamine Topical|Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
214339066|NCT03261557|BEHAVIORAL|CBT + SST|"It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
214339067|NCT03261557|BEHAVIORAL|Psychoeducation, habits and healthy lifestyle|"Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
214339068|NCT01713777|DRUG|"Lamotrigine Generic A"|
214339069|NCT01713777|DRUG|"Lamotrigine generic B"|
214339070|NCT01343706|DRUG|Placebo|Solution for oral administration
214339071|NCT01343706|DRUG|Placebo|Immediate release solid oral dosage (film-coated tablet)
214339072|NCT01343706|DRUG|BI 409306|Immediate release solid oral dosage (film-coated tablet)
214339073|NCT01343706|DRUG|BI 409306|solution for oral administration
214339074|NCT05829408|BEHAVIORAL|KOPPeling|KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.
214941781|NCT03415659|DRUG|HWH340 tablet|"1. single escalating dose study starts from 20 mg as the initial dose until the maximum dose group (520mg) or maximum tolerated dose (MTD) has been reached.~2. multiple-dose study conducted on oral HWH340 tablet BID. The DLTs evaluating period is 4 weeks and the safety evaluation period lasts till 4 weeks after drug withdrawal.~3. dose-expansion study conducted on oral HWH340 tablet BID in 2 to 4 dose groups. Patients with BRCA mutation OR HRD will be assigned to 2 cohort in each dose group."
214941782|NCT03757637|OTHER|NLSCP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in this groups will further receive either NLSCP (Exp-1). Patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). This group will receive a face-to-face education or counseling by trained research nurse.
214941783|NCT03757637|OTHER|ICT supported HAP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in the groups will further receive ICT supported HAP (Exp-2) intervention. For this groups, patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). The group will receive the interactive mobile phone App.
214941784|NCT04605432|DRUG|PEG-FFI|"Patients with risk factor : on the day before the colonoscopy at 20:00- 21:00 hours, 60gPEG-4000 was mixed with 1L water; 4-6 h before colonoscopy, 120gPEG-4000 was mixed with 2L water.~Patient without risk factor: 4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by experienced researcher."
214941785|NCT04605432|DRUG|PEG-nonFFI|"All patients on the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by ward nurse."
214941786|NCT05400031|BIOLOGICAL|propolis|"After obtaining written consent, oral identification of all participants will be performed prior to randomization. Oral diagnosis of children receiving chemotherapy will be repeated on day 0, day 5, and day 10, and the difference between the Oral Mucositis Rating Scale mean scores of the children in the groups will be examined.~Oral Mucositis Assessment: Oral Mucositis Rating Scale will be used. The oral mucosa of children will be evaluated using the World Health Organization Oral Mucositis Classification."
214941787|NCT05400031|BIOLOGICAL|Placebo|Placebo
214941788|NCT05046431|DRUG|BAT2506|50mg/0.5mL
214941789|NCT05046431|DRUG|EU Simponi|50mg/0.5mL
214941790|NCT03479593|DIAGNOSTIC_TEST|CMR and OCT in NSTEMI patients with MVD|Lesions \>50% stenosis i patients with NSTEMI are examined by OCT. All patients will have CMR performed prior to angiography
214941791|NCT02745691|OTHER|Surgery|Thoracic surgery for lung cancer
214941792|NCT02745691|OTHER|Radiochemotherapy|Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
214941793|NCT02745691|OTHER|Targeted therapy|New targeted therapies for lung cancer
214941794|NCT02745691|OTHER|Immunotherapy|New immunotherapies for lung cancer
214941795|NCT02616315|DRUG|Naltrexone HCl/Bupropion HCl Placebo|Naltrexone/bupropion placebo-matching tablets
214941796|NCT02616315|DRUG|Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
214941797|NCT00111371|DRUG|Levodopa|
214941798|NCT01313494|DRUG|Roflumilast|Roflumilast tablets
214941799|NCT01313494|DRUG|Placebo|Placebo tablets
214941800|NCT01313494|DRUG|Salbutamol|Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
215074310|NCT06659406|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 will be given once daily, 200mg for the period of 3 months
215074311|NCT06658587|DIAGNOSTIC_TEST|No interventions|No interventions
215074312|NCT01916252|DRUG|bortezomib (Velcade ®)|
214339075|NCT02490813|DIETARY_SUPPLEMENT|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
214339076|NCT02490813|DIETARY_SUPPLEMENT|Placebo|Placebo will be starch with colorings
214339077|NCT00560833|DRUG|esmirtazapine|
214339078|NCT00560833|DRUG|Placebo|
214339079|NCT04402333|PROCEDURE|Robotic Interval Debulking Surgery|Interval debulking surgery carried out in a minimally invasive manner using the Da Vinci Robot.
214347371|NCT05729074|DRUG|Elidel Cream 1% (pimecrolimus)|Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
214941801|NCT02253550|DRUG|Simeprevir|Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.
214941802|NCT02253550|DRUG|Sofosbuvir|Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
214941803|NCT02604550|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
214941804|NCT02604550|DRUG|Percocet 7.5/325|Percocet 7.5/325 will taken as needed up to every four hours.
214941805|NCT02604550|DRUG|Naprosyn 500 mg|Naprosyn 500 mg will be taken twice daily.
214941806|NCT04472026|BEHAVIORAL|Counseling using the electronic conversation aid|This conversation aid will help you and your doctor discuss ways to care for your thyroid nodule. We will evaluate the acceptability of the conversation aid and barriers to implementation in clinical practice. Post visit semi structured interviews and recordings of the clinical visits will be qualitatively analyzed. We hypothesize that the conversation aid will be accepted and facilitate the decision making process.
214941807|NCT04742166|PROCEDURE|Reconstruction|Lateral gastrojejunal Terminolateral gastrojejunal
215074313|NCT01916252|DRUG|lenalidomide (Revlimid®)|
215074314|NCT01916252|DRUG|busulfan (Busilvex ®)|
215074315|NCT01916252|DRUG|Dexamethasone acetate|
215074316|NCT01916252|DRUG|Melphalan|
215074317|NCT02136680|OTHER|CASA Education|Basic palliative care competencies for outpatient use.
214339080|NCT05360524|PROCEDURE|Laminectomy alone versus laminectomy and fusion|"laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.~Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis."
214941808|NCT04288336|OTHER|Food Diary|Ancillary studies
214941809|NCT04288336|OTHER|Preventative Dietary Intervention|Follow intermittent fasting
214941810|NCT04288336|OTHER|Questionnaire Administration|Ancillary studies
214941811|NCT00801697|BIOLOGICAL|DNA Vaccine|4 mg VRC-HIVDNA044-00-VP administered as 1 mL
214941812|NCT00801697|BIOLOGICAL|DNA Vaccine placebo|1 mL VRC-PBSPLA043-00-VP
214347372|NCT02099006|DRUG|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
214941813|NCT00801697|BIOLOGICAL|rAd35|VRC-HIVADV027-00-VP 1 x 10\^10 PU administered as 1 mL
214941814|NCT00801697|BIOLOGICAL|rAd35 placebo|1 mL VRC-PBSPLA043-00-0VP
214941815|NCT00801697|BIOLOGICAL|rAd5|4 mg VRC-HIVADV038-00-VP administered as 1 mL
214941816|NCT00801697|BIOLOGICAL|rAd5 placebo|1 mL VRC-DILUENT013-DIL-VP
214941817|NCT01021488|DRUG|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
214941818|NCT01021488|DRUG|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
214941819|NCT04134065|DRUG|Vitamin D|patients with refractory Crohn disease and a serum 25(OH)D concentration \<75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100e125 nmol/L.
214941820|NCT04134065|DRUG|Placebo oral capsule|the capsule contain nothing
214941821|NCT01720329|DIETARY_SUPPLEMENT|Probiotics|Active comparator Arm. XXmls of XXX supplemented with XX of L. rhamnosus GG on a daily basis for six months
214941822|NCT01720329|OTHER|probiotic placebo|Placebo comparator arm -Participants randomized to placebo will receive XXmls of XXX G on a daily basis for 6 months.
214941823|NCT01273740|PROCEDURE|External support|Bypass surgery with externally supported graft
214941824|NCT03906721|DRUG|Placebo|Sugar pill used to condition patients.
214941825|NCT03906721|DRUG|Oxycodone|An opioid used for analgesia.
214941826|NCT03906721|OTHER|Essential Oil|An aromatic oil used for conditioning.
214941827|NCT03713840|BEHAVIORAL|Healthy Beverages in Child Care|12-week intervention promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
214941828|NCT03484221|DRUG|FOLFOXIRI|IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
214941829|NCT03484221|RADIATION|Short-Course Radiation Therapy(5Gy*5)|Patients received a short-course radiation therapy(5Gy\*5) after 4 cycles of FOLFOXIRI.
214941830|NCT03484221|DRUG|XELOX|OXALIPLATIN 130 mg/m\^2 IV over 2-h, day 1 Capecitabine 1000 mg/m\^2 twice daily days 1-14 every 3 weeks for 4 cycles.
214941831|NCT03844594|DRUG|Eptifibatide Injection|Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
214941832|NCT01398189|DRUG|clozapine|C-11 clozapine
214941833|NCT05483894|DRUG|Atorvastatin 10mg|Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group
214941834|NCT05483894|DRUG|Placebo|Placebo once daily for 12 weeks and than Atorvastatin(Lipinon Tab. 10mg) for 12 weeks for control group
214941835|NCT03165474|OTHER|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
214941836|NCT03165474|OTHER|Didactic health information|Didactic health information and resources by email and/or text
214941837|NCT00000865|DRUG|Abacavir sulfate|
214941838|NCT00000865|DRUG|Lamivudine|
214941839|NCT00000865|DRUG|Stavudine|
214941840|NCT00000865|DRUG|Zidovudine|
214941841|NCT00000865|DRUG|Didanosine|
214941842|NCT00079872|DRUG|Pemetrexed|
214941843|NCT01488669|PROCEDURE|robot assisted neck dissection via retroauricular approach|A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.
214941844|NCT01488669|PROCEDURE|Conventional neck dissection|A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
214941845|NCT00112281|DRUG|Tilarginine Acetate Injection intravenous infusion|
214941846|NCT04053010|BIOLOGICAL|Sabin-IPV and DTaP|Sabin-IPV +DTaP at the age of 3/4/5 months old respectively
214941847|NCT04053010|BIOLOGICAL|Sabin-IPV|Sabin-IPV only at the age of 3/4/5 months old respectively
214941848|NCT04053010|BIOLOGICAL|DTaP|DTaP only at the age of 3/4/5 months old respectively
214941849|NCT00000710|DRUG|Didanosine|
214941850|NCT04824755|PROCEDURE|Yune Zhao|Yune Zhao did congenital cataract surgeries
214941851|NCT06620523|DRUG|CoQ10 1200 mg orally with Glutathione 1000 mg orally|This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury
214339081|NCT05433883|PROCEDURE|sleep surgery|Thirty severe OSA patients (AHI\>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.
214339082|NCT05350449|BEHAVIORAL|Loving-kindness Meditation|Loving-kindness meditation is a type of mindfulness practice where the focus is on love/compassion and kindness for self and others. The guided meditation will be provided via recording device. The intervention is 4 week long.
214941852|NCT06620523|DRUG|Group B: Placebo CoQ10 orally and Placebo Glutathione orally|A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
214941853|NCT01404208|DRUG|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
214941854|NCT01404208|DRUG|Placebo|Sugar pill
214941855|NCT02962323|DRUG|Torrent's Rosuvastatin Calcium Tablets 40 mg|Oral, crossover
214941856|NCT02962323|DRUG|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA|Oral, crossover
215074318|NCT06660537|PROCEDURE|Balloon-blowing exercises in 90/90 bridge position with a ball.|In this group patients will undergo balloon-blowing exercises in the 90/90 bridge position with a ball. In this intervention, patients lie on back with feet against a wall and knee bent at 90 degrees, holding a ball between their knees. While extending one arm overhead and holding a balloon in the other hand, perform a pelvic tilt without lifting their back off the mat. Inhale through the nose, exhale into the balloon for four breaths, then remove the balloon and repeat the sequence four times. The 4-week protocol includes three supervised sessions per week, each supervised by a physiotherapist. Progress will be monitored regularly to evaluate improvements throughout the intervention.
215078107|NCT04358705|OTHER|Eye tracking survey|Other Names: Participants will complete a survey using Qualtrics immediately after the eye tracking activity and one week following completion of the activity via email to measure recall of brand name, product flavors, perceptions of cigarillo harm, and tobacco use behaviors and intentions.
214676474|NCT01498510|BEHAVIORAL|Web-based CBT for chronic pain|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
214676475|NCT04640246|BIOLOGICAL|TBX-3400|Autologous transfusion
214347373|NCT02099006|DRUG|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
214676476|NCT06449261|OTHER|Spinal Manual therapy used in Physiotherapy Practice|C5-C6 and thoracic spine mobilization with postural correction
214676477|NCT04076761|DRUG|Trifluridine/Tipiracil|FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
214941857|NCT02769039|OTHER|No intervention. Observational studies of sleep, movement and brain imaging|Participants will be asked to visit the University for 3 baseline visits which include a screening visit \& sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
214941858|NCT02456038|DRUG|Asfotase Alfa (ALXN1215)|
214941859|NCT03240224|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
214941860|NCT03240224|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
214941861|NCT02570139|DEVICE|Cavilon Advanced Skin Protectant|The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.
214941862|NCT02570139|DEVICE|ConvaTec Sensi-Care Protective Barrier|Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
214941863|NCT00634595|DRUG|E10A|E10A 1\*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
214347374|NCT02099006|DRUG|Ketoprofen|To be applied topically at a 10% concentration
214347375|NCT02099006|DRUG|Ketamine|To be applied topically at a 10% concentration
214347376|NCT02099006|DRUG|Loperamide|To be applied topically at a 5% concentration
214347377|NCT02099006|DRUG|Gabapentin|To be applied topically at a 6% concentration
214347378|NCT02099006|DRUG|placebo|Compounding base to be used alone as a placebo
214676478|NCT03844971|PROCEDURE|Computer assisted arthrocentesis of|Under general anesthesia : patients specific preoperative prefabricated surgical guide will be used intraoperative for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction
214676479|NCT01667744|DRUG|Citalopram|10 mg/day
214676480|NCT00638846|DEVICE|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
214676481|NCT00638846|DEVICE|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
214676482|NCT01070615|DRUG|Prucalopride|
214941864|NCT00634595|DRUG|Cisplatin|25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
214941865|NCT00634595|DRUG|Paclitaxel|160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
214941866|NCT02651519|DRUG|0.25% ropivacaine hydrochloride|stellate-ganglion block with 0.25% ropivacaine hydrochloride
214941867|NCT02651519|DRUG|saline|stellate-ganglion block with saline
214941868|NCT04794413|DRUG|Pimavanserin|Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
214941869|NCT02308813|OTHER|Braking and functionality|
214339083|NCT01076400|DRUG|adavosertib|Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
214941870|NCT06478602|BIOLOGICAL|Fecal microbiota transplantation|Performing a colonoscopy with fecal microbiota transplantation at the level of the cecum.
214941871|NCT00693602|DRUG|Erwinase|Chemotherapy
214941872|NCT06027502|BEHAVIORAL|Passive Heating|20 minutes of baseline data collection, up to 45 minutes of immersion in the hot tub to achieve a core temperature of 38.5 degrees celsius, followed by up to 90 minutes of recovery.
214941873|NCT00339196|DRUG|5 azacytidine - VALPROIC acid- Retinoic acid|5 azacytidine - VALPROIC acid- Retinoic acid
214941874|NCT02322502|DRUG|Desflurane|inhalation with laryngeal mask to maintain anaesthesia
214941875|NCT02322502|DRUG|Sevoflurane|inhalation with laryngeal mask to maintain anaesthesia
214941876|NCT02322502|DRUG|propofol|intravenous injection to maintain anaesthesia
214941877|NCT03499405|BEHAVIORAL|Family Navigator Intervention|Caregivers will be paired with a culturally matched family navigator.
214941878|NCT03684551|OTHER|The CHW-led health system|During the study period, all CHWs, regardless of treatment arm, performed proactive case detection, the process of conducting at least two hours per day of door-to-door home visits to proactively identify - through health history inquiry and/or disease diagnostics - patients who need care. For all patients identified, CHWs provided doorstep counselling, evaluation, diagnostics, treatment, referral to appropriate health facilities, and follow-up. CHWs provided care in the community without user fees, and were able to refer patients to the reinforced government primary health centres for care without user fees as well. CHWs were residents of the communities they served, and they were required to be available at home or by phone for consultation at any time.
214941879|NCT03684551|OTHER|The CHW Supervision model|CHWs in both study arms received monthly individual supervisory sessions and weekly group supervisory sessions from their dedicated CHW supervisor. An individual monthly session of 360 Supervision included: (i) solicitation of patient perspectives of CHW care; (ii) direct observation of CHW doorstep care; and (iii) a one-on-one feedback discussion with or without the CHW Performance Dashboard depending on treatment arm.
214941880|NCT03684551|OTHER|The CHW Performance Dashboard|"The CHW Performance Dashboard was a graphic display of a CHW's performance along three indicators defined as follows: (i) Quantity of care: the number of homes visited during the month; (ii) Timeliness of care: the percentage of sick children under five treated within 24 hours of symptom onset during the month; (iii) Quality of care: the percentage of sick children under five treated without protocol error among 23 potential errors during the month. The Dashboard displayed an individual CHW's quantity, timeliness, and quality of care indicators from the previous month, using absolute numbers, percentages, and visual graphics, alongside those of the highest performing CHW. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month."
214941881|NCT05578105|OTHER|no intervention|No intervention, only observation
214941882|NCT06385197|DEVICE|App randomizing dosing regimen|patients will receive their dimethyl fumarate treatment and the dose and time of administration will be determined using a designated app.
214339084|NCT01076400|DRUG|Topotecan|Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.
214339085|NCT01076400|DRUG|Cisplatin|Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.
214339086|NCT01076400|DRUG|Placebo to adavosertib|Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
214339087|NCT01032694|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
214339088|NCT01032694|DRUG|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
214941883|NCT05094544|RADIATION|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
214941884|NCT00564044|PROCEDURE|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm\*5mm\*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
215074319|NCT06660537|PROCEDURE|Buteyko breathing exercises management|In this group, patients will receive Buteyko breathing exercises, which consist of two main exercises; the control pause and the maximum pause. For control pause, patients exhale, plug the nose, and hold their breath until they feel the urge to breathe, then inhale and breathe normally for 10 seconds. In Maximum pause, patients exhale, plug their nose, and hold their breath as long as possible, aiming for double the control pause time, then inhale and breath normally for 10 seconds. This is a 4-week protocol with three sessions per week. Pre- and post-intervention values will be recorded to assess progress.
214339089|NCT00698529|BEHAVIORAL|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
214339090|NCT00698529|BEHAVIORAL|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
214339091|NCT00698529|BEHAVIORAL|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
214339092|NCT02751281|PROCEDURE|Pneumatic percutaneous nephrolithotomy|Pneumatic percutaneous nephrolithotomy is type of surgery that we use pneumatic lithotripter to treat kidney stone
214339093|NCT02751281|PROCEDURE|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery that we use ultra-sonic lithotripter to treat kidney stone
214676483|NCT05431686|BEHAVIORAL|SMA visits|SMA visit once every 3 months over a 12 month period
214941885|NCT00782600|DRUG|suspension IR|50 mg IR suspension once daily for one day
214941886|NCT00782600|DRUG|CR 1|50 mg shorter release CR once daily for one day
214339094|NCT04474184|PROCEDURE|Biospecimen Collection|Receive vaginal kit for biospecimen collection
214941887|NCT00782600|DRUG|CR 2|50 mg medium release CR once daily for one day
214941888|NCT00782600|DRUG|CR 3|longer release SR formulation once daily for one day
214941889|NCT03768700|OTHER|Data gathering|Questionnaires and collection of medical data on patients during hospitalization, at D28, at 90 and at 1 year
214941890|NCT03125187|BIOLOGICAL|Sodium heparin UQ Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
214941891|NCT03125187|BIOLOGICAL|Sodium heparin FK Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
214941892|NCT03356899|DRUG|Low dose bupivacaine 0.5% (8mg)|8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml
214941893|NCT03356899|DRUG|High dose bupivacaine 0.5% (10mg)|10 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.5
214941894|NCT05422209|PROCEDURE|Mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.
214339095|NCT04474184|BEHAVIORAL|Focus Group|Attend focus group
214339096|NCT04474184|OTHER|Survey Administration|Ancillary studies
214339097|NCT04916639|DEVICE|Device: Physiomer undiluted seawater nasal spray|"In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~* Nasal wash four times every day~* These washes are to be carried out in each nostril~* By continuously pressing the spray for 3 seconds in each nostril~* Subjects are recommended to distribute the 4 nasal washes as follows:~  * 1st : morning~ * 2nd : midday~ * 3rd : afternoon~ * 4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other symptoms."
214339098|NCT05884060|OTHER|No intervention|No interventions
214339099|NCT01130766|PROCEDURE|stereotactic radiosurgery (SRS)|Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
214339100|NCT01390012|DRUG|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
214676484|NCT05519943|BEHAVIORAL|The Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
214941895|NCT05422209|PROCEDURE|Mesh-augmented sacrospinal fixation with posterior colporrhaphy.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy.
214941896|NCT03847415|DIAGNOSTIC_TEST|ultrasound|to evalute abnormal uterine bleeding in postmenopausal women using 3D(dimensional) ultrasound assessment of endometrial volume .Doppler assessment of endometrium and hysteroscopy and to correlate this finding with pathological finding of endometrial biopsy
214941897|NCT04007107|DRUG|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
214941898|NCT04007107|DRUG|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
214941899|NCT00002756|BIOLOGICAL|filgrastim|
214941900|NCT00002756|DRUG|asparaginase|
214941901|NCT00002756|DRUG|cyclophosphamide|
214941902|NCT00002756|DRUG|cytarabine|
214941903|NCT00002756|DRUG|daunorubicin hydrochloride|
214941904|NCT00002756|DRUG|etoposide|
214941905|NCT00002756|DRUG|leucovorin calcium|
214941906|NCT00002756|DRUG|mercaptopurine|
214941907|NCT00002756|DRUG|methotrexate|
214941908|NCT00002756|DRUG|prednisone|
214941909|NCT00002756|DRUG|therapeutic hydrocortisone|
214941910|NCT00002756|DRUG|vincristine sulfate|
214941911|NCT04022356|DEVICE|Feetme Connected Soles|"Walk for 10 meters (and 30meters):~* By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~* By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely."
214941912|NCT05100498|DEVICE|Web-based oncofertility support tool|The website structure was developed to satisfy the needs of reproductive-age women was investigated based on four domains of social support, as developed by Cohen and Syme (1985). The important needs of patients can be classified as emotional, informational, appraisal, and instrumental support.
214941913|NCT02689882|DIETARY_SUPPLEMENT|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
214941914|NCT05910060|DIAGNOSTIC_TEST|OTTAWA ANKLE RULES|count the ottawa score and do an x-ray if the score is greater than or equal to 1
214941915|NCT05648175|BEHAVIORAL|e-CBT|The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.
214941916|NCT05648175|BEHAVIORAL|e-CBT + Phone Call|In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.
214339101|NCT01390012|DRUG|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
214339102|NCT05168774|DRUG|Elamipretide|Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.
214339103|NCT03719872|DIAGNOSTIC_TEST|Pre-Operative Transabdominal Ultrasound|Pre-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
214941917|NCT05648175|BEHAVIORAL|e-CBT + Phone Call + Pharmacotherapy|In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.
214941918|NCT06472999|PROCEDURE|Nephroprotective measures|Due to the observational design of the study, no study specific interventions are performed. The treatment of the patients is completely guided by the responsible physicians.
214941919|NCT05720624|DRUG|Anhydrous Enol-oxaloacetate|Given PO
214941920|NCT05720624|OTHER|Best Practice|Receive standard of care therapy
214941921|NCT05720624|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood
214676485|NCT05519943|BEHAVIORAL|TAU condition|A TAU waitlist condition during which participants received routine care services tailored to each child individually.
214676486|NCT02758145|OTHER|Flu vaccination information in 3 phases|"An oral information is given by the nurse during the recruitment visit at the occupational medicine unit. She initiates the discussion on flu and asks the employee if he usually receives the vaccine. Then she provides a brief standardized information on recommendations concerning flu vaccination, and the annual influenza vaccination campaign in CHUV and PMU. She responds to questions.~After the interview, she gives an informative document with key messages (information about the disease, benefits to be vaccinated, vaccine safety, etc.). The document includes frequently asked questions, website address, and the email address of the occupational medicine unit in case of questions.~The third phase consists of sending to the employee shortly after the start of the next campaign of flu vaccination (November 2016), a postal mail recalling the information provided during the recruitment examination and inviting them to get vaccinated."
215074320|NCT06607497|OTHER|Intervention using an AI enabled risk communication tool (PERDICT.AI)|Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.
214339104|NCT03719872|DIAGNOSTIC_TEST|Post-Operative Transabdominal Ultrasound|Post-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
214339105|NCT04536636|DRUG|Docohexanoic acid|Patients received 650 mg DHA/3 times/wk/post-HD session
214941922|NCT05720624|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRS imaging
214941923|NCT05720624|OTHER|Questionnaire Administration|Ancillary studies
215074321|NCT06607497|OTHER|Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)|The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.
215074322|NCT06604793|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate
215074323|NCT06604793|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214339106|NCT04536636|DRUG|Control-No drug|Patients received usual medical care with no DHA
214339107|NCT05625906|OTHER|Multi-media experiential training programme|"1. Webpage and mobile applications of training material on ACP, to be offered four weeks before the workshop~2. A three-hour multimedia workshop (8-10 nurses per group) including enhanced lectures and a role play encounter with standardised patients. Immediate feedback on their quality of decision support skills will be given. The workshops will be delivered by an experienced advance practice nurse with a palliative care specialty.~3. Writing a reflective journal after the role play with standardised patients"
214339108|NCT06459609|DIETARY_SUPPLEMENT|protein supplementation|Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
214339109|NCT00258986|PROCEDURE|Living donornephrectomy|
214339110|NCT01696630|DRUG|Xenon|
214339111|NCT01696630|DRUG|Desflurane|
214339112|NCT05905185|DRUG|Tocotrienol-rich fraction vitamin E (TRF)|The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
214339113|NCT05905185|DRUG|Placebo|50mg of Placebo
214339114|NCT03042806|BEHAVIORAL|questionnaire|all the COPD patients will be ask to complete the questionnaire
214676487|NCT04589494|DRUG|Tramadol Hydrochloride|tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
214676488|NCT01910662|OTHER|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
214676489|NCT01910662|OTHER|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
214339115|NCT05838222|BEHAVIORAL|Solution Focused Intervention|A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges
214941924|NCT04068688|BEHAVIORAL|Early Start Denver Model (ESDM)|"Twelve one hour sessions, skill is introduced by Help is in your hands Community ESDM videos. Session skills include specific strategies caregivers can use to increase their child's attention to people and their child's communication; strategies to identify, create and use joint activity routines to engage with and teach their child; in addition to ways to use the ABCs of learning to teach their child new behaviors. Help is in your hands Community ESDM materials also provide video examples of other caregivers using the session skill with their child. The early childhood development practitioner then coaches the caregiver in the session skill, in at least two activities. The goal of coaching was to provide enough support for the caregiver to experience success in implementing the new skill with their child. Coaching is followed by caregiver reflection and a discussion of generalization of the new skill across various daily activities, using a daily activities visual aid."
214941925|NCT04068688|BEHAVIORAL|Telehealth coaching|The telehealth coaching intervention was informed by the Community-Early Start Denver Model (C-ESDM) materials. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) were developed by the research team. Over 12, 1-hour asynchronous caregiver coaching sessions that are delivered by non-specialists, caregivers were coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors. The session itself being delivered via phone. Prior to the coaching session staff shared session materials with the family via WhatsApp. Prior to the session the caregiver shared a 6-min video of an interaction with their child. During the session, the caregiver and coach reviewed the video, and the caregiver completed a self-reflection checklist.
214941926|NCT01901861|DRUG|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
214941927|NCT01901861|DRUG|Placebo|Placebo is given before meal ingestion
214941928|NCT04679051|BEHAVIORAL|Sleep duration|Participants will be asked to alter time in bed to achieve specified sleep durations.
214941929|NCT05956353|BEHAVIORAL|Digital Storytelling Intervention|Culturally tailored narrative-based videos created by individuals to promote colorectal, breast and cervical cancer screening among eligible participants in a primary care practice.
214941930|NCT05676476|DRUG|Antihypertensive treatment|Antihypertensive treatment to goal of less than 140/90 mmHg
215074324|NCT04522102|DRUG|Start antiplatelet monotherapy|Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation
215074325|NCT06608524|BEHAVIORAL|Self-regulated learning strategy|The experimental group uses self-regulated strategy.This program selects classroom performance , homework quality , experimental operation, and test score as academic performance (score) evaluation variables.
215074326|NCT06608524|BEHAVIORAL|Standard learming method|The control group uses standard learming method. The program selects classroom performance, homework quality, experimental operation, and test score evaluation form as academic performance (score) evaluation variables.
214676490|NCT01910662|OTHER|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
214676491|NCT01910662|OTHER|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
214676492|NCT06126445|DEVICE|Battery operated toothbrush|Device on plaque removal efficacy
215074327|NCT06660303|BEHAVIORAL|Comprehensive Preoperative Education for Enhanced Recovery in Colorectal Surgery|The intervention in this study involves preoperative patient education aimed at improving outcomes for individuals undergoing colorectal surgery. Patients in the study group will receive targeted educational sessions that focus on setting expectations, managing anxiety, understanding pain control, and preparing for the surgical process as part of the Enhanced Recovery After Surgery (ERAS) protocol. This educational approach is designed to empower patients, reduce anxiety, enhance satisfaction, and potentially improve post-surgical recovery compared to those receiving routine hospital care.
214339116|NCT05838222|OTHER|Treatment as Usual|The patient receives standardized care from primary care team without the SFBT intervention
214339117|NCT04877912|DIAGNOSTIC_TEST|MRI Abbreviated Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
214347379|NCT02389543|DRUG|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
214347380|NCT02389543|DRUG|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
214676493|NCT06126445|DEVICE|Manual toothbrush|Device on plaque removal efficacy
214941931|NCT05123976|DRUG|Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
214941932|NCT05123976|DRUG|Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
214941933|NCT05939791|OTHER|Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518|The commercial probiotic dairy product has been provided to PALL along with physical training once a day for 8 weeks. Each serving contained 20 billion CFUs of Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518 (Lactobacillus casei CNCMI-1518). Each patient's legal representative was advised to follow a normal diet when preparing and providing food for children.
214941934|NCT05939791|OTHER|Physical exercise|The individual online (MS Teams) training program for PALL in the length of 8 weeks included 25-45 minutes of moderate-to-vigorous physical exercise, twice a week, under the supervision. The structure of the exercise program was developed to improve endurance and gradually rebuild muscular strength. The exercise program's structure was created to increase endurance and gradually rebuild muscular strength. Large muscle groups were the focus of training sessions, which also placed a strong emphasis on proper technique. A strength exercise squat was given consideration as a movement required to meet necessities. (e.g., sitting or standing). Each exercise consisted of between 10 and 15 repetitions in each series and 2 to 3 series overall.
215074328|NCT06660303|OTHER|Routine hospital care|The control group, designated as Group II, will receive standard hospital care, encompassing the usual preoperative and postoperative procedures provided by the hospital. This includes typical preparation and recovery guidelines without any added specialized preoperative education or targeted nursing instructions. This routine hospital care serves as a baseline, allowing for a direct comparison of outcomes against the intervention group, which will receive comprehensive preoperative education aimed at enhancing recovery and improving surgical outcomes.
215074329|NCT06606756|OTHER|Patient Registry without intervention|This is a patient registry that collects real world data without intervening with therapeutic decision
215074330|NCT06606756|OTHER|Digital Registry and Feedback on clinical data|The data is entered via a validated online platform and is provided back to the center in aggregated form
215074331|NCT06608004|OTHER|test taking|Measurement of VAS for sensation of hunger, LFQP-France test, 24-hour semi-quantitative dietary recall, Assessment of energy expenditure linked to physical activity using the IPAQ (International Physical Activity Questionnaire) (only at inclusion), Screening for undernutrition risk factors using the SSQ (Social Support Questionnaire) (only at inclusion), Measurement of body composition by impedancemetry, Measurement of isometric grip strength by handgrip test, Measurement of quality of life (SF36), Study of olfacto-gustatory sensoriality (olfaction via the Sniffin\&#39; Sticks test, gustation via lingual application of impregnated strips and AHSP self-questionnaire) (carried out every other visit) and Measurement of gustatory evoked potentials in response to sugar.
215074332|NCT06606938|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4
215074333|NCT06606938|PROCEDURE|Normal Saline (Placebo)|Placebo at baseline, week 2, week 4
215074334|NCT05403437|OTHER|Evaluation of pain|Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).
215074335|NCT05403437|DIAGNOSTIC_TEST|Evaluation of pelvic girdle pain diagnostic tests|Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.
215074336|NCT05403437|OTHER|Evaluation of activity limitation|The Pelvic Girdle Questionnaire will be filled.
214676494|NCT05767957|OTHER|Rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist using conventional technique alone.
214676495|NCT05767957|OTHER|Cognitive-behavioral therapies in addition to rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist according to conventional technique, with the addition of techniques from cognitive-behavioral therapies.
214676496|NCT05502848|BEHAVIORAL|Internet Cognitive Behavior Therapy|ICBT helps change patterns of thinking (cognitions) and behaviors of psychological distress, including relaxation, stress management, while using ICBT can increase personal tolerance for negative thoughts and negative emotions, help patients reduce negative perception of the disease due to long-term recurrent itching, and break the vicious cycle
214339118|NCT04877912|DIAGNOSTIC_TEST|Abbreviated MRI Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
214676497|NCT00390923|DRUG|Selegiline + nicotine replacement therapy|Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
214676498|NCT00390923|DRUG|placebo + nicotine replacement therapy|Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
214339119|NCT06452459|OTHER|No interventinon|No intervention is anticipated. This is an observational study.
214339120|NCT02696850|DRUG|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
214339121|NCT02696850|DRUG|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
214339122|NCT05600608|DIETARY_SUPPLEMENT|Oral Stimulant Drink|please see description of the drink in the arm/ group section
214941935|NCT06622291|DRUG|Nitric Oxide|Exogenous nitric oxide is directly administered to the oxygenator in the cardiopulmonary bypass circuit at a concentration of 60 ppm. Nitric oxide is also directly administered to the ventilator at a concentration of 60 ppm for 12 hours post-operation.
214676499|NCT01171521|DEVICE|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
214339123|NCT03196648|OTHER|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
214339124|NCT03196648|OTHER|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
214339125|NCT03196648|OTHER|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
214339126|NCT05680025|BEHAVIORAL|Physical exercise intervention|"The intervention group will have access to training videos through social networks (WhatsApp and YouTube) and infographics. The mobile phone of each of the participants will allow send dates of workshops, link for videos, messages reminding to perform exercise routines.~The training plan will be designed so the participants will achieve being physically active at the end of 6 months of intervention. Training will be planned to gradually, through 3 levels, increase the duration and intensity of exercises; they will have an important component of aerobic exercises and others for muscular strength. Each level of training will last two months; at each level the participants will be given 4 specific trainings and will be asked to perform two per week at level 1 and 2; and at the 3 level, 3 trainings per week.~The strategy for promoting physical exercise is based on the social cognitive theory, in which the bases of the transtheoretical model are found."
214339127|NCT05680025|BEHAVIORAL|Workshops|Six workshops to promote the performance of physical activity. The workshops will be held with groups of 15 participants. During them, the work will be to promote motivation to perform physical exercise, sharing information about the health benefits, benefits for control of the disease, together creating planning of measurable, realistic goals; reinforcing behavior when the desired advances are made, monitoring progress (using a monthly self-report of exercise performed). The participants will be motivated and congratulated each time for goals reached, self-sufficiency will be reinforced as well as greater evaluation of the advantages of performing exercise against the barriers or negative aspects perceived by the participants. These activities will be performed according to the level of exercise performed by the individuals (stage of change).
214339128|NCT02569697|OTHER|HEC Placebo gel|
214941936|NCT06622291|OTHER|Placebo|This is the placebo group. The standard CPB protocol involves delivering an air-gas mixture to the cardiopulmonary bypass circuit during cardiac surgery and avoiding the use of nitric oxide within 12 hours after surgery.
214941937|NCT03994744|DRUG|PD-1 inhibitor|Intravenous administration of Sintilimab (1200mg/3weeks)
214941938|NCT03994744|DRUG|Metformin|"Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week."
214941939|NCT02332239|BEHAVIORAL|iDOVE Intervention (ED+text)|"1. In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~2. Eight-week longitudinal tailored text-message program"
214941940|NCT02332239|BEHAVIORAL|Control (EUC)|"1. In-ED brief session, discussing home safety \& nutrition~2. Eight-week longitudinal home safety \& nutrition text-message program"
214941941|NCT00115037|DRUG|Naltrexone|100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
214941942|NCT00115037|DRUG|placebo|placebo comparer for 16 weeks in phase 2.
214339129|NCT02569697|OTHER|Placebo Intravaginal Ring|
214339130|NCT02569697|OTHER|Placebo Vaginal Film|
214339131|NCT02569697|OTHER|Placebo Vaginal Insert|
214486449|NCT06893796|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim Injection,0.25mg, s.c.,day 1 single dose .
214941943|NCT00115037|BEHAVIORAL|Medication Management (MM)|Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
214941944|NCT00115037|BEHAVIORAL|Combined Behavioral Intervention (CBI)|45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
214676500|NCT02005523|DRUG|RNS60|
214941945|NCT00115037|BEHAVIORAL|Telephone Counseling|Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
214676501|NCT02005523|DRUG|Saline|
214941946|NCT03241537|RADIATION|Intensity modulated radiotherapy|
214941947|NCT00396877|DRUG|Clopidogrel (SR25990)|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
215074337|NCT06051318|OTHER|Standardized breakfast A|Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
214486450|NCT06893796|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim Injection,0.5mg, s.c.,day 1 single dose .
214676502|NCT06085391|OTHER|REThink Game|REThink Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of seven levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change, positive bias, distinction between useful and useless thoughts, problem solving and compassion.
215074338|NCT06051318|OTHER|Standardized breakfast B|Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
215074339|NCT03426462|DRUG|Propofol|Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
214339132|NCT03455855|DEVICE|Jetstream System|including Atherectomy Console (Jetstream Console) and Atherectomy Catheter(Jetstream Catheter), intended for use in atherectomy of the peripheral vasculature and to break apart and remove atherosclerotic disease, debris, and thrombus from the SFA and/or PPA.
214941948|NCT00396877|DRUG|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
214941949|NCT05765253|DEVICE|Scorpion Portal Vein Access Kit|Portal Vein Access with Scorpion or Scorpion X set
214941950|NCT05765253|DEVICE|Cook Transjugular Liver Access Set|Portal Vein Access with Ring or Rosch-Uchida set
214941951|NCT05765253|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Transjugular Intrahepatic Portosystemic Shunt (TIPS)
214941952|NCT03219086|PROCEDURE|combined spinal epidural anaesthesia|To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group
214676503|NCT06085391|OTHER|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
214676504|NCT06085391|OTHER|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress."
214676505|NCT06673329|DRUG|Brodalumab|Brodalumab 210 mg subcutaneous injection
214676506|NCT06673329|RADIATION|CT scan|CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment
214941953|NCT03219086|DRUG|Prilocaine|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
214941954|NCT03219086|DRUG|Bupivacaine|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
214941955|NCT03161886|DEVICE|Pan-enteric Capsule Endoscopy (PCE)|Second generation of colon capsule endoscopy (Medtronic)
215074340|NCT05151445|BEHAVIORAL|mHealth dietary app + health coaching intervention|"The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart."
215074341|NCT04193085|OTHER|Observational|Observational
214339133|NCT02009618|DRUG|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
214339134|NCT02009618|DRUG|placebo|
214339135|NCT03111225|DIAGNOSTIC_TEST|massage|a 15 minutes thoracic massage will be added to the regular physical therapy treatment
214339136|NCT01511952|OTHER|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
214339137|NCT01511952|OTHER|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
214339138|NCT05507606|DRUG|Osimertinib|osimertinib 80mg/d
214339139|NCT05507606|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
214339140|NCT05507606|DRUG|Carboplatin|Carboplatin AUC5, d1; was stopped after 4 cycles
214339141|NCT05507606|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
214339142|NCT03196921|DRUG|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
214339143|NCT04193202|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
214941956|NCT05988710|DRUG|Buccal Buprenorphine 300 mcg|buprenorphine for 300mcg buccal administration
214941957|NCT05988710|DRUG|Buccal Buprenorphine 600 mcg|buprenorphine for 600mcg buccal administration
214941958|NCT05988710|DRUG|Buccal Buprenorphine 900 mcg|buprenorphine for 900mcg buccal administration. Note: This arm has been discontinued as of 06/25/2024 and has been replaced with the 450mcg buprenorphine buccal administration arm.
214941959|NCT05988710|DRUG|Buccal Placebo|Placebo for buccal administration
214941960|NCT05988710|DRUG|Oral Placebo|Placebo for oral administration
214941961|NCT05988710|DRUG|Oral immediate-release oxycodone 10mg|Immediate-release oxycodone for 10 mg oral administration
214941962|NCT05988710|DRUG|Buccal Buprenorphine 450mcg|buprenorphine for 450mcg buccal administration. Note: This arm has been added to replace the 900mcg buprenorphine buccal administration arm.
214941963|NCT03660124|DEVICE|Deep Brain Stimulation|DBS is a neurosurgical procedure that involves the administration of small amounts of electricity to disrupt abnormal activity of brain structures associated with disease symptoms. It involves inserting thin electrodes into deep brain structures and electrically stimulating them in a controllable and ultimately reversible manner. The electrodes are connected to an internal pulse generator that is implanted in the upper chest region, below the collarbone.
214941964|NCT00169624|DRUG|Metformin|
214941965|NCT00169624|DRUG|Gliclazide|
214941966|NCT00160134|DRUG|SLV320|
214941967|NCT06238713|PROCEDURE|Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
215074342|NCT04199091|PROCEDURE|Craniosacral Therapy (CST) self-help techniques|Manual self-help techniques based on Craniosacral Therapy (group setting).
214339144|NCT04193202|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
214339145|NCT03491735|OTHER|collection of data from patient files|recording of patient data and its input into an excel sheet from which statistics will be derived
214941968|NCT06238713|PROCEDURE|Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
214941969|NCT03827902|DEVICE|Telcare 2.0 BGM|Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.
214339146|NCT06155981|OTHER|Coke Zero|Coca-Cola Zero Sugar drink will be given.
214339147|NCT06155981|OTHER|Coke|Coca-Cola drink will be given.
214339148|NCT03971617|DRUG|Hydrogen|each hydrogen tablet contains 80mg magnesium
214339149|NCT03971617|DRUG|Placebo oral tablet|matching placebo tablet
214339150|NCT02453789|DRUG|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
214339151|NCT02453789|DRUG|Placebo|
214339152|NCT02998242|DRUG|Apatinib|
214339153|NCT02998242|RADIATION|SBRT to symptomatic bony metastatic bony site(s)|
214339154|NCT00581945|DRUG|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
214339155|NCT00581945|DRUG|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
214339156|NCT05020483|DRUG|FEIBA|Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.
214339157|NCT05020483|DRUG|Placebo|Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
214339158|NCT06388577|OTHER|Education|Participants in the intervention group (n = 36) will be administered the Epilepsy Education Programme based on Pender's Health Promotion Model by the researcher and will be given the education booklet developed by the researcher in line with the literature. The training topics of the intervention programme are: General information about epilepsy, seizure moment management, management of antiepileptic drug treatments, controlling the factors that may trigger seizures, and recommendations to parents about health promoting and protective behaviours. In the training, learning and teaching techniques such as presentation, video demonstration, question and answer sections, lecture and discussion will be applied. The training will last approximately one hour.
214941970|NCT02424864|OTHER|4d PET-CT|Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
214941971|NCT00073502|DRUG|OSI-7904L|
214676507|NCT05421377|DIAGNOSTIC_TEST|clinical assessment|screening of patients at risk for developing unilateral or bilateral lower limb lymphedema
214339159|NCT06182865|DRUG|Ga-68 Dolacga Injection|Ga-68 Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
214339160|NCT01868581|DRUG|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
214339161|NCT01868581|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
214339162|NCT05772793|DEVICE|Telerehabilitation|The home visual telerehabilitation path using the EyeFitness software consisted of performing one visual training session per day, 5 days a week (from Monday to Friday) for a total of 6 weeks.
214339163|NCT01169870|DRUG|Genexol-PM|Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
214339164|NCT01169870|DRUG|Paclitaxel|
214339165|NCT00788554|PROCEDURE|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
214339166|NCT00788554|PROCEDURE|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
214339167|NCT04269928|PROCEDURE|Endovascular chemical ablation of adrenal gland|Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
214339168|NCT06191705|DIAGNOSTIC_TEST|QuickDASH|Participants will be administered Urdu version of QuickDASH to collect data regarding Disabilities of Arm, Shoulder \& Hand twice with a time interval of 72 hours to determine validity and reliability.
214339169|NCT01413451|DRUG|Amatuximab (MORab-009)|
214486451|NCT06893796|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim Injection,1mg, s.c.,day 1 single dose .
214676508|NCT01481246|BEHAVIORAL|Categorization training|Behavioral intervention consisting of cognitive training exercises to improve categorization performance
214676509|NCT01481246|BEHAVIORAL|Psychosocial and Psychoeducational Group training|Group treatment with a focus on psychosocial and psychoeducational intervention in healthy adults and in adults with cognitive decline. Ten week cycle, 2 hours per week group intervention study.
214941972|NCT05344690|GENETIC|SLMAP and EPO genetic polymorphism|Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
214941973|NCT02274064|BEHAVIORAL|Motivational Interview and Implementation Intention|Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
214941974|NCT03422159|DRUG|Ascorbic Acid|Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
214941975|NCT03422159|DRUG|Thiamine|Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
214941976|NCT03422159|DRUG|Hydrocortisone|Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
214941977|NCT03422159|DRUG|Sodium Chloride 0.9%|"Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days)."
214941978|NCT00150306|DRUG|Zoloft (Sertraline)|
214941979|NCT02009059|DEVICE|Non-invasive temperature in hypothermia|accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
214339170|NCT03152747|DEVICE|ultrasound, b-scan|Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.
214339171|NCT03749551|DIAGNOSTIC_TEST|cardiac magnetic resonance (CMR) post haemodialysis|patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)
214339172|NCT01335243|PROCEDURE|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
214339173|NCT01348451|DEVICE|surgical implantation|human spinal cord stem cell implantation in ALS patients
214339174|NCT01813799|DRUG|DA-9801 300mg|300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
214941980|NCT02155075|DEVICE|MIRA device imaging|MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result
214941981|NCT04136275|BIOLOGICAL|CAR-37 T cells|CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells
214941982|NCT01971632|DRUG|Oxycodone & naloxone combination, prolonged release|
214941983|NCT01971632|DRUG|placebo oxycodone / naloxone|
214339175|NCT01813799|DRUG|DA-9801 600mg|600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
214339176|NCT01813799|DRUG|DA-9801 900mg|900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
214339177|NCT01813799|DRUG|Placebo|Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
214339178|NCT00121771|BIOLOGICAL|FP9 CS|
214339179|NCT00121771|BIOLOGICAL|MVA CS|
214339180|NCT04820673|DRUG|Sarecycline|Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
214339181|NCT05975541|OTHER|Observational|No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.
214339182|NCT04489095|DIAGNOSTIC_TEST|Electrophysiology Study|After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
214941984|NCT06731387|OTHER|Pharmaceutical technical assistants supported medication dispensation on the hospital ward|Pharmaceutical technical assistants (PTAs) visit the hospital ward for two hours in the morning or afternoon to dispense medications for admitted patients for the following day. Night nurses then complete any final additions or adjustments as needed.
214676510|NCT05821504|BEHAVIORAL|High-Intensity Interval Training|The training intervention is a popular exercise format that consist of alternating brief bouts of high-intensity efforts with bouts of light effort or complete rest.
214676511|NCT01589094|DRUG|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
214339183|NCT02123407|DRUG|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
214941985|NCT02631070|DRUG|Luspatercept|
214941986|NCT02631070|OTHER|Placebo|
214941987|NCT04826133|DRUG|Calcitriol|Subjects will receive an oral administration of calcitriol (1,25-dihydroxyvitamin D3) 1.5 μg (three capsules of 0.5 μg each) at 9 pm, night before each cocaine session, and at 8 am, morning of each cocaine session. This dose of calcitriol is lower than doses safely administered in other human studies and for a duration of time shorter than doses safely administered in other trials. In addition, this dose has been already tested by our group, subject of a different grant application, and should be effective at enhancing stimulant's induced dopamine release, in comparison to placebo.
215074343|NCT04199091|PROCEDURE|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation according to Jacobsen (group setting).
215074344|NCT05300568|OTHER|No Intervention|This is a non-product related survey.
215074345|NCT06690242|DRUG|MT1013|MT1013 is a novel calcimimetic agent
215074346|NCT06690242|DRUG|MT1013|MT1013 is a novel calcimimetic agent
214941988|NCT04826133|OTHER|Placebo|Subjects will receive an oral administration of three capsules of placebo at 9 pm the night before each cocaine session, and at 8 am, morning of each cocaine session.
214941989|NCT01417585|BEHAVIORAL|Client-centered ADL intervention|Client-centered ADL refers to rehabilitation of activities of daily living specifically guided by the needs as expressed by the client/patient and her/his significant others, a process that specifically aims to support the client by taking the client's goals and views as the guide for the rehabilitation process.
214941990|NCT01417585|BEHAVIORAL|Usual ADL intervention|The variation of strategies and ways to conduct usual ADL rehabilitation according to the routines and praxis of the participating rehabilitation units randomized to supply the control condition.
215074347|NCT06690242|DRUG|Etelcalcetide Hydrochloride|the already-marketed therapeutic agents
215074348|NCT06690242|DRUG|Placebo|The measure does not contain the active ingredients
214941991|NCT06731309|PROCEDURE|Punch Debridement|A punch biopsy tool is positioned over the inflamed follicular unit, and a small circle of skin (4 to 8 mm in diameter) is excised. A firm twisting motion is necessary to ensure adequately deep excision.
214941992|NCT06731309|PROCEDURE|Incision and Drainage|Incision and Drainage is a minimally invasive surgical procedure often employed for the treatment of intensely painful, tense, and fluctuant abscesses that are too deep to drain spontaneously. After administration of a broad circumferential local anesthetic, a small linear incision is made using a standard scalpel blade. Digital pressure is applied to expel the fluid collection. Saline rinses can be used to flush out the remaining contents. This method offers instant pain relief, commonly performed in acute settings by dermatologists, emergency department physicians and general practitioners
214941993|NCT06731153|DRUG|Ivarmacitinib|a selective Janus kinase 1 inhibitor
214941994|NCT06731153|DRUG|Camrelizumab (SHR-1210)|a humanised anti-programmed death-1 (anti PD-1) antibody
214941995|NCT06731153|DRUG|Eribulin|Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.
214941996|NCT05490134|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
214941997|NCT05490134|DRUG|Saline|0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
214941998|NCT04559035|OTHER|Nasal lavage|Twice daily nasal lavage.
214941999|NCT02077413|PROCEDURE|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
214942000|NCT02077413|PROCEDURE|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of \~5 minutes."
214942001|NCT02077413|PROCEDURE|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
214676512|NCT06698536|DEVICE|Aktiia G2C|Study subjects are asked to stay seated while 3 successive measurements are taken with the Aktiia G2C device under investigation (BP and PR) and two references (Aktiia Bracelet G2 and Aktiia Init I1 oscillometric cuff).
214676513|NCT03427775|COMBINATION_PRODUCT|multimodal perioperative pain protocol (MP3)|administration of gabapentionoid, acetaminophen, non steroidal anti-inflammatory drugs around the clock in addition to the peripheral nerve block offered before surgery
214676514|NCT06742294|BEHAVIORAL|Movement education|(1) providing preschool teachers professional development training in pedagogical knowledge and methods in the physical domain, (2) creating a set of teaching materials (in printed and digital formats) and methods that could be incorporated into the overall and preschool-based curricula, (3) creating a parental toolkit with contents mirroring the school materials, to enhance parents' knowledge and promote family-school collaboration, and (4) developing a smartphone-based artificial intelligence rating system to help preschool teachers conveniently and accurately assess children's motor skills, and provide appropriate instructional feedback.
214676515|NCT03575468|BEHAVIORAL|Enhanced E-cigarette Coaching|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
214676516|NCT03575468|BEHAVIORAL|Quitline treatment as usual|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
214676517|NCT03123939|BIOLOGICAL|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10\^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg)
214676518|NCT06864962|PROCEDURE|Renal sympathetic denervation|Under the guidance of the 3-dimensional navigation system, HFS was performed from the accessible branches to the proximal (the ostium of renal artery) segments of the bilateral renal arteries, and the target ablation sites were identified by HFS-induced SBP elevation \>5mmHg, and radiofrequency ablations were performed with a power setting of 8 to 12 Watts and a duration of 90 seconds. The endpoint of RSD was defined as the elimination or bluntness of HFS-induced SBP elevation response (≤5mmHg). If this was not achieved, ablation was repeated until the desired response was attained.
214676519|NCT06864962|PROCEDURE|Renal sympathetic denervation plus aorticorenal ganglion ablation|Following RSD, HFS was performed in the the junction area of abdominal aorta and renal arteries to recognize ARG. Radiofrequency ablations were performed with a power setting of 12 to 20 Watts and a duration of 90 seconds. The endpoint of ablation was defined as the elimination or bluntness of HFS-induced SBP elevation response (≤5mmHg). If this was not achieved, ablation was repeated until the desired response was attained.
214942002|NCT02077413|PROCEDURE|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
214942003|NCT02525536|DRUG|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 mg/kg, intravenous infusion.
214942004|NCT02525536|DRUG|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, intravenous infusion.
214339184|NCT02123407|PROCEDURE|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
214339185|NCT02621983|BEHAVIORAL|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
214339186|NCT02621983|BEHAVIORAL|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
214942005|NCT02525536|DRUG|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
214942006|NCT01759836|DRUG|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
214942007|NCT03848806|DRUG|HAT1|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
214942008|NCT03848806|DRUG|Calcipotriol|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
214942009|NCT00231309|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor
214942010|NCT05871671|BEHAVIORAL|Pulmonary Rehabilitation|A 16-week PR programme shall be delivered twice weekly to the active group. This shall be followed by a 36-week maintenance home exercise programme which shall be monitored every 4 weeks via a phone call from the researcher herself for 36 weeks. The subjects shall self-document their adherence to the home exercise programme on a diary which shall be returned to the researcher at week 52.
214942011|NCT05871671|OTHER|Control|The control group shall not receive the 16-week PR programme and the following 36-week maintenance home exercise programme until completion of the study.
214942012|NCT01752868|DIETARY_SUPPLEMENT|Supplement|Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
214942013|NCT05029804|OTHER|Education|This intervention will be applied to the patients in the experimental group. The education will be provided by the researcher and based on the transtheoritical model. Printed materials and PowerPoint presentations will be used for the education and the education will be conducted in a face-to-face session with each participant (10 weeks).
214942014|NCT05320068|DRUG|Oral Vancomycin|A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
214942015|NCT05320068|DRUG|Placebo|A blinded capsule that contains no vancomycin every 6 hours during 10 days.
214942016|NCT04982172|DRUG|Infliximab|Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered
214942017|NCT04982172|DRUG|Infliximab|Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
214942018|NCT05899647|DIAGNOSTIC_TEST|Ultraviolet Microscopic Analysis|"Data to be collected from subjects at the time of their clinical visit; or upon chart review by the research team; will include demographic information, whether the subject is presenting for a routine screen or for a follow-up, and the subject's most recent cervical cytology result. Data to be collected from the standard-of-care cytology will include the cytologic diagnosis and the presence or absence of human papilloma virus (HPV), if applicable based on the subject's age. The Pap results of each subject will be reviewed and classified as screen negative (NIL), screen positive (LSIL, HSIL), or indeterminate (ASCUS, ASC-H). Subjects with a positive screen, or an indeterminate result, who undergo colposcopy will have their colposcopy results recorded as well. The UV microscopy imaging features will be coded and collected."
214942019|NCT01962545|DRUG|OAC alone|Single APT with either aspirin or clopidogrel is discontinued in this arm.
214942020|NCT01413074|OTHER|Peritoneal Dialysis treatment|PD treatment
214942021|NCT01413074|OTHER|Hemodialysis treatment|HD treatment
214339187|NCT04576169|PROCEDURE|Arthroscopic Debridement|Wrist arthroscopy can be performed with or without irrigation. In the debridement arm, a central or radial TFCC tear found during arthroscopy is debrided with a shaver. Portals are closed either with sutures or with medical tape. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
214942022|NCT01153620|DRUG|Lavasept 0.04%|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes"
214942023|NCT01153620|OTHER|Ringer's Solution|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes"
214942024|NCT04698421|BIOLOGICAL|Blood collection on admission and longitudinally|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).
214942025|NCT06304740|DRUG|IMG-007|Subcutaneous injection of IMG-007
214942026|NCT06304740|DRUG|Placebo|Subcutaneous Injection of Placebo
214942027|NCT05489640|OTHER|No Intervention|No Intervention will be administered in this study.
214942028|NCT04902729|DRUG|Carbetocin|Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
214942029|NCT04902729|DRUG|Oxytocin|Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
214942030|NCT06404840|DRUG|nimotuzumab|nimotuzumab (400 mg, iv, d1, qw)
214942031|NCT06404840|DRUG|AG chemotherapy|(gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)
214942032|NCT04167930|OTHER|electronic medical record(EMR) Data and patient survey|"1. Retrospective Data Collection (1) Neck Disability Index (NDI), Oswestry Low Back Disability Index(ODI), euroqol-5 dimension(EQ-5D) scores during hospitalization (2) symptom onset date, symptom onset motive, past history, accident occurrence date, accident treatmen termination agreement date, etc.~2. Question items (consistent with the case record) according to the purpose of the investigation (1) General: Demographic sociological characteristics (gender, age, occupation, income, etc.) (2) Matters concerning the correlation between traffic accident agreements and symptoms"
214942033|NCT03769194|BIOLOGICAL|VLA15|a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate
214942034|NCT03769194|BIOLOGICAL|Placebo|Placebo: PBS (Phosphate Buffered Saline)
214942035|NCT05769920|DRUG|TTHX1114(NM141) Ophthalmic Solution|Eye drop twice daily
214942036|NCT01474031|OTHER|Biomechanics|"* Time interval: pre-op - 3m - 6m - 12m~* Assessment of all subjects:~  * XR~ * Gait analysis with surface EMG and trunk markers:~    * Unipodal standing: 3 trials Right and 3 trials Left on FP~   * Level walking: 3 trials Right and 3 trials Left on FP~   * Chair rise: 3 trials, both legs on FP~   * Stair ascent: 3 trials Right and 3 trials Left on first FP~   * Stair descent: 3 trials Right and 3 trials Left on first FP~   * Squat: 3 trials, both legs on FP~ * Bipodal squat: 3 trials Right and 3 trials Left on FP~* Functional scores (HHS, UCLA, HOOS, SF-36)"
214942037|NCT02758873|GENETIC|Personalised medicine (Salmeterol)|If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
214942038|NCT02758873|GENETIC|Personalised medicine (Montelukast)|If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
214942039|NCT02758873|OTHER|Standard care|If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
214942040|NCT05039320|DIETARY_SUPPLEMENT|Bactoblis|dissolve the tablets in the mouth once a day for 4 weeks
214942041|NCT05039320|DIETARY_SUPPLEMENT|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
214942042|NCT04262804|DRUG|Margetuximab|Margetuximab IV
214942043|NCT04262804|DRUG|Trastuzumab|Trastuzumab IV
214942044|NCT04262804|DRUG|Chosen Chemotherapy (Capecitabine)|Capecitabine tablet
214942045|NCT04262804|DRUG|Chosen Chemotherapy (Vinorelbine )|Vinorelbine IV
214942046|NCT04262804|DRUG|Chosen Chemotherapy (Gemcitabine )|Gemcitabine IV
214942047|NCT04694768|BEHAVIORAL|Rehabilitation|Rehabilitation program
214942048|NCT01821950|BEHAVIORAL|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
214942049|NCT01858623|DRUG|Losartan/hydrochlorothiazide|
214942050|NCT01858623|DRUG|Losartan|
214942051|NCT01858623|DRUG|Hydrochlorothiazide|
214942052|NCT00087126|DRUG|topotecan hydrochloride|
214676520|NCT06933485|OTHER|Exercise|These sessions of the postural exercise aim to increase student's knowledge and awarenes their benefits for trunk stabilization, posture correction and diaphragmatic breathing will be explained by the expert physiotherapist. In the exercise planning; the exercise session start with warm-up exercises; A transition to the flow of exercise is ensured with warm-ups that include arm, leg and trunk movements for approximately 10 minutes, and then all extremities are worked for approximately 40 minutes in the main exercise session to ensure trunk alignment. The last 10 minutes of the exercise session is completed with approximately 10 minutes of cool-down exercises to which light stretching is added, making the exercise session a total of 60 minutes.
214942053|NCT00699712|DRUG|CD-NP (Chimeric natriuretic peptide)|Infusion of CDNP at two of four doses
214942054|NCT05096572|DEVICE|VIM Stimulation|Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.
214942055|NCT05096572|DEVICE|PSA Stimulation|Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.
214942056|NCT05096572|DEVICE|VIM+PSA Stimulation|Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.
214942057|NCT01399970|OTHER|Mobile Teleconsultation Arm (MTA)|"In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines."
214942058|NCT01399970|OTHER|Outpatient Consultation Arm (OCA)|Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
214942059|NCT01839799|DRUG|Gemcitabine|1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
214942060|NCT01839799|DRUG|Abraxane|125 mg/m2 IV over 30 minutes, day 1, 8, 15
214942061|NCT01839799|DRUG|FOLFIRINOX|Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
214942062|NCT01839799|RADIATION|Chemoradiation|
214942063|NCT01836809|DRUG|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
214942064|NCT01836809|DRUG|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
214339188|NCT04576169|PROCEDURE|Placebo surgery|Diagnostic wrist arthroscopy can be performed with or without irrigation. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed either with sutures or with medical tape. The procedure is performed in general or regional anesthesia in operating room. Participants are not able to see to the operation area or monitor. They will listen to music with noise-cancelling headphones throughout the operation. The operative time will be matched, with the surgeon simulating a debridement procedure. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
214339189|NCT04576169|PROCEDURE|Arthroscopic or Open Repair|An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
214339190|NCT04576169|PROCEDURE|Physiotherapy|An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
214339191|NCT02387021|PROCEDURE|Continuous femoral nerve block|
214339192|NCT02387021|PROCEDURE|Continuous adductor canal block|
214942065|NCT00934856|DRUG|Docetaxel|Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).
214942066|NCT00934856|DRUG|Pertuzumab|Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
214942067|NCT00934856|DRUG|Trastuzumab emtansine|T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
214339193|NCT02387021|PROCEDURE|infragluteal Sciatic nerve block|
214339194|NCT02387021|DRUG|Ropivacaine 0.2%|
214339195|NCT02387021|DRUG|Saline|
214339196|NCT00587587|DEVICE|Apligraf|Application at Day 0, potential re-application at Week 4
214339197|NCT00587587|OTHER|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
214339198|NCT00453765|DRUG|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
214676521|NCT03237208|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
214942068|NCT01742715|OTHER|PEEP by Best oxygenation|"Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
214942069|NCT01742715|OTHER|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
214942070|NCT01742715|OTHER|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
214676522|NCT03237208|DEVICE|placebo group|Transcutaneous electrical nerve stimulation treatment will not be activated.
214676523|NCT02112448|DRUG|continuous infusion|Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
214676524|NCT02112448|DRUG|as needed dosing|morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
214676525|NCT02112448|DRUG|Acetaminophen|Acetaminophen will be given every 4 hours for a total of 24 hours.
214676526|NCT02112448|DRUG|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
214676527|NCT05910801|PROCEDURE|Biopsy|Undergo biopsy
214339199|NCT00453765|DRUG|placebo|placebo
214347381|NCT02389543|DRUG|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
214676528|NCT05910801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214347382|NCT05651477|DEVICE|Wearable Device (Smart Watch)|A smart watch refers to an embedded system portable watch equipped with improved functions than a general watch, and is almost always in the form of a wrist watch. The device we are using is the Samsung Galaxy 4 (SM-R860/870).
214676529|NCT05910801|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214676530|NCT05910801|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214676531|NCT05910801|PROCEDURE|Computed Tomography|Undergo CT scan
214676532|NCT05910801|DRUG|Lenalidomide|Given PO
214676533|NCT05910801|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214676534|NCT05910801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214676535|NCT05910801|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214676536|NCT05910801|BIOLOGICAL|Tafasitamab|Given IV
214676537|NCT05910801|DRUG|Venetoclax|Given PO
214676538|NCT03998735|DRUG|Herbal Snuff (Smokeless Tobacco)|4 levels of \[D4\]nornicotine in herbal snuff
214339200|NCT02385955|PROCEDURE|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
214676539|NCT05270694|BEHAVIORAL|Public Health Intervention Package|"The intervention package consists of two components:~1. At the time of study enrollment, participants will attend an in-person training on how to properly take an at-home COVID-19 test. Study staff will verbally walk through the steps of the test with the participant while the participant administers the test on themselves, with the opportunity to ask questions and receive corrective feedback, as needed.~2. To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits at the training and then every other month throughout the course of the year-long study for a total of 35 kits."
214942071|NCT03765112|DEVICE|Optical coherence tomography angiography|Multiple scans of the retina will be recorded to evaluate microvascular changes.
214942072|NCT02184910|DRUG|pepsinogen and gastrin|
214942073|NCT01273155|DRUG|Belinostat|Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
214942074|NCT06731634|DEVICE|Hand grip strength dynamometer, pinch strength dynamometer|Both devices will be used to assign the strength of grip and pinch for both dominant and non dominant hands by using jamar hydraulic hand grip strength dynamometer and Jamar hydraulic pinch strength dynamometer
214676540|NCT05613010|BEHAVIORAL|mHealth Messaging Intervention Group|Participants will receive an electronic pill box; the research team will instruct participants on how to use this device. Participants will be asked to use the electronic pill box for their prescribed medicines for the duration of the study (up to 16 months). During the 12-week micro-randomized trial, participants will be randomized within person to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. Dose timing will be determined based on participant report of when they typically take their tacrolimus or sirolimus medicine.
215074349|NCT06628284|DEVICE|Dexcom G7|The study will be conducted as a single-arm trial consisting of participants enrolled in the test group. Each participant will receive a G7 CGM and their blood glucose levels will be continuously transmitted to the Dexcom Clarity system for monitoring and data collection. As a observational study, the test group glucose levels will be monitored after receiving a steroid for pain management. The CGM profile of steroid-induced hyperglycemia in patients will be studied for the following corticosteroids: dexamethasone (10 mg), methylprednisolone (40 mg or 80 mg), triamcinolone (40 mg or 80 mg).
214339201|NCT06018740|DIETARY_SUPPLEMENT|Daily Balance Gummy|Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
214339202|NCT00797784|DRUG|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
214339203|NCT05433558|OTHER|Neuropsychological Rehabilitation|Neuropsychological Rehabilitation
214339204|NCT01138124|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
214676541|NCT05989477|OTHER|At-home Breast Oncology care Delivered with E-health solutions - ABODE|The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.
214676542|NCT03624101|DRUG|Symdeko|CFTR modulator
214676543|NCT03624101|DRUG|Ivacaftor and Symdeko|CFTR modulator
214676544|NCT01991977|PROCEDURE|Diffusion Weighted Imaging|Undergo DTI
214676545|NCT01991977|DRUG|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET
214676546|NCT01991977|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214339205|NCT03226067|DRUG|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
214339206|NCT03226067|DRUG|Placebo oral capsule|Matching capsules.
214339207|NCT00954213|BEHAVIORAL|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
214347383|NCT05651477|DEVICE|Edge-Box|Edge-Box collects data such as air. The device we are using is the TDS Mfepc-4C2R.
214676547|NCT01991977|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo pMRI
214676548|NCT01991977|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET
214676549|NCT01991977|OTHER|Quality-of-Life Assessment|Ancillary studies
214676550|NCT01991977|DRUG|Temozolomide|Receive temozolomide
214676551|NCT06272175|OTHER|Open Kinetic Chain Activity|PNF Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns will be actively performed on the hemiplegic upper extremity.
214676552|NCT06272175|OTHER|Closed Kinetic Chain Activity|Weight-bearing on the hemiplegic hand with extended elbow in standing position
214676553|NCT06583096|BEHAVIORAL|Surveys|Participants (in both arms) will complete surveys once per week and participants in the intervention arm will also complete additional 1-minute surveys daily. Study participation will be completed at the conclusion of the final follow-up survey administered 6-weeks after study enrollment.
215074350|NCT07017647|OTHER|Conservative treatment|Conventional physiotherapy treatments will be administered to patients in both groups three days a week for six weeks. This programme will include the following treatments: electrotherapy modalities for pain relief (TENS current application), moist heat application, flexibility and strengthening exercises to stretch and strengthen the back and spinal muscles, and massage and manual therapy applications to relax the back muscles and reduce pain. First, TENS current will be applied for 15 minutes using an electrical stimulation device due to its pain-relieving properties. Then, moist heat application will be performed for 15 minutes. Following this, flexibility and strengthening exercises aimed at stretching and strengthening the lower back and back muscles will be performed under the supervision of a physical therapist for approximately 20 minutes.
214339208|NCT04011059|BIOLOGICAL|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
214339209|NCT01075321|DRUG|everolimus|Given orally
214339210|NCT01075321|DRUG|lenalidomide|Given orally
214942075|NCT06731634|DIAGNOSTIC_TEST|Finkelstein test|Finkelstein test which is used to diagnose the de quervain tenosynovitis and it will be used to assist the people with smartphone addiction
214942076|NCT04423575|OTHER|Outpatient health care pathway|A surgical procedure performed as an outpatient procedure means that the patient leaves the hospital before 8pm the same day. The surgery is identical but the standard care pathway is reinforced to insure a safe return to home.
214942077|NCT04297475|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld 3D PA/US probe, and able to provide 3D volume data of dual-wavelength PA imaging of small joints, in addition to real-time 2D PA/US imaging.
214942078|NCT06511115|OTHER|Experimental Group|"Each session will be divided into three clearly differentiated parts:~i) A 5-minute warm-up consisting of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise. This portion will include flexibility and stretching movements, as well as joint mobility exercises; ii) 35 minutes dedicated to the main section of the intervention using the Nintendo Wii to promote physical, mental, and cognitive activity; iii) 5 minutes for relaxation techniques that incorporate flexibility exercises and stretches.~Each session will be led by a qualified and experienced professional. No incidents of injuries or negative effects were reported during the intervention period. Throughout the 12-week intervention, participants will be periodically followed up by phone to inquire about their physical activity habits."
214942079|NCT04255407|DEVICE|I-ONE® therapy|I-ONE® therapy will be used in patients with bone bruise on the knee after anterior cruciate ligament (ACL) injury 15 days before and 60 days after ACL reconstruction surgery for 4 hours a day compared to a control group (no-treatment).
214942080|NCT04255407|DRUG|Anti-inflammatory drug|Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
214942081|NCT01256385|BIOLOGICAL|Cetuximab|Given IV
214942082|NCT01256385|OTHER|Laboratory Biomarker Analysis|Correlative studies
214942083|NCT01256385|DRUG|Temsirolimus|Given IV
214942084|NCT06731712|OTHER|Physical Function Exercises|Physical function interventions included strength, balance, and mobility exercises. More specifically, the exercises include progressively increasing intensity strengthening exercises with a resistance band for the following muscle groups: hip abductor and extensor muscles, knee flexor and extensor muscles, and shoulder abductor and external rotator muscles. Other exercises consist of standing calf raises, squats, bridges, and push-ups. Additionally, functional exercises include heel-to-toe standing or walking, single-leg standing, stepping over obstacles, bending down, and lifting an object with feet together.
214942085|NCT05307718|DRUG|Oral Anticoagulant, Direct-Acting|Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.
214942086|NCT01711775|DRUG|aleglitazar|Single oral dose Day 1, repeated oral dose once daily Days 5-14
214942087|NCT05297110|DRUG|atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
215074351|NCT07017647|OTHER|Patient Education|Patient education will be provided immediately after conventional physiotherapy applications in each session. Patients will be asked to pay attention to and comply with the recommendations/issues covered in this education. Comprehensive patient education includes the following: the cause of chronic back pain, negative factors that may cause discomfort and exacerbate symptoms, how to cope with back pain, ways to prevent pain, exercises and proper postures to reduce pain, and harmful movements and positions to avoid in daily life.
215074352|NCT06352892|DRUG|Maridebart Cafraglutide|Solution for SC injection.
215074353|NCT07021157|DRUG|SK-08|Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given SK-08 once.
214339211|NCT01075321|OTHER|laboratory biomarker analysis|Correlative studies
214339212|NCT01075321|GENETIC|polymorphism analysis|Correlative studies
214339213|NCT01075321|OTHER|immunohistochemistry staining method|Optional correlative studies
214339214|NCT01075321|GENETIC|microarray analysis|Optional correlative studies
214339215|NCT01075321|GENETIC|fluorescence in situ hybridization|Optional correlative studies
214339216|NCT04362358|BEHAVIORAL|Online cognitive behavioral therapy (CBT)|7 sessions of Cognitive Behavioural Therapy (CBT) online + possibility to contact the psychological hotline
214339217|NCT04362358|BEHAVIORAL|Online bibliotherapy programme|online bibliotherapy programme on the Ma Santé website Also with explanatory sheets and tools to improve stress management and the possibility of contacting the Psychological Hotline
214339218|NCT00969891|OTHER|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
214339219|NCT00875394|DRUG|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
214942088|NCT01529294|DRUG|Iloperidone|
214942089|NCT05754255|DEVICE|Nasal Cannula|"A nasal cannula is a medical device to provide supplemental oxygen therapy to people who have lower oxygen levels. There are two types of nasal cannulas: low flow and high flow.~The device has two prongs and sits below the nose. The two prongs deliver oxygen directly into your nostrils."
214942090|NCT05754255|DEVICE|Nasal Positive Airway Pressure System|Positive airway pressure (PAP) treatment uses a machine to pump air under pressure into the airway of the lungs. This helps keep the windpipe open during sleep. The forced air delivered by CPAP (continuous positive airway pressure) prevents episodes of airway collapse that block the breathing in people with obstructive sleep apnea and other breathing problems.
214942096|NCT01060878|DRUG|PYM50028|IMP
214942097|NCT01060878|DRUG|Placebo|Matching placebo comprising identical vehicle to active doses
214942098|NCT00126269|DRUG|cisplatin|
214942099|NCT00126269|DRUG|gemcitabine|
214942100|NCT03477994|DRUG|Dexmedetomidine|an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
214942101|NCT03477994|DRUG|Clonidine|an infusion of 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4.
214942102|NCT00951834|DRUG|Epigallocatechin-Gallate|"Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~* Months 1-3: 200 mg EGCG/die (200-0-0 mg)~* Months 4-6: 400 mg EGCG/die (200-0-200 mg)~* Months 7-9: 600 mg EGCG/die (400-0-200 mg)~* Months 10-18: 800 mg EGCG/die (400-0-400 mg)"
214942103|NCT00951834|DRUG|Placebo|Placebo
214942104|NCT01860742|DRUG|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
214942105|NCT01860742|DRUG|177Lu-DOTATATE|177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
214942106|NCT01736605|PROCEDURE|Massage|Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.
214942107|NCT01736605|PROCEDURE|Massage combined with meditation|Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
214942108|NCT03050047|BIOLOGICAL|BCD-100|Anti-PD1 monoclonal antibody
214676554|NCT06583096|BEHAVIORAL|Supportive Text messages|Text messages will be sent Mondays-Sunday if participants are randomized to receive them in a given week, with a daily 50:50 send/no-send randomization. A bank of 25 text messages will be used for the study, providing tips/strategies across a range of topics, including managing time and academic stressors, recommendations for self-care and mood management, and messages geared towards fostering social connections and support. Some messages will contain links to videos, websites, or articles for more information on a topic.
214676555|NCT06583096|BEHAVIORAL|Personalized Feedback (PF) Report|For individuals that are randomized to receive a Personalized Feedback Report, the study team will send participants a text on a Monday with the feedback from the prior survey (baseline survey in the first week, weekly survey in the next five weeks). There will be graphs for depression, anxiety, stress, and flourishing.
214339220|NCT00875394|DRUG|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
214942109|NCT02433067|OTHER|Physical activity intervention|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
214942110|NCT02433067|OTHER|Control Group|standard oncologic care
214942111|NCT05309473|DEVICE|Philips SmartSleep Acoustic Stimulation Device|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive acoustic stimulation during the four hours of sleep.
214942112|NCT05309473|DEVICE|Sham (no Acoustic Stimulation)|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive Sham (no acoustic stimulation) during the four hours of sleep.
214942113|NCT05715047|BEHAVIORAL|CBT for Fatigue|10, individualized counseling sessions with a behavioral health counselor via Zoom platform.
214942114|NCT05715047|BEHAVIORAL|Usual Care|Standard transplant care.
214942115|NCT00725101|DRUG|Treatment for Fibromyalgia|FM participants starting any new pharmacologic FM agent.
214942116|NCT02079142|BEHAVIORAL|High Intensity Strategy: Train-the-trainer|"Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT. Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.~Trainers will then return to Washington University to be trained in how to train their other staff members in IPT."
214942117|NCT02079142|BEHAVIORAL|Low Intensity Strategy: Expert Consultation|Investigators will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depression.
214942118|NCT03564080|OTHER|Combined - PAD and CAD|12-week supervised exercise programme in a hospital setting
214942119|NCT01923844|DRUG|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached \> 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
214942120|NCT00556205|DRUG|Sunitinib|Sunitinib orally once daily
214942121|NCT00556205|DRUG|Bevacizumab|Intravenously every 14 days
214942122|NCT06621498|PROCEDURE|Ridge preservation technique|Tooth extraction, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
214942123|NCT06621498|PROCEDURE|ridge preservation|Tooth extraction, socket filling with PRP, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
214942124|NCT06621498|PROCEDURE|ridge preservation|Tooth extraction, full-thickness graft harversting and socket sealing with it.
214942125|NCT03528564|DRUG|Iron sucrose|Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)
214942126|NCT03528564|DRUG|Epoetin Alfa|Erythropoietin to be administered to half of study participants (40,000 IU x 1-2 subcutaneous injections)
214942127|NCT03528564|DRUG|Placebo|Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
214942128|NCT02501083|OTHER|no intervention|The study will not include any intervention.
214942129|NCT06604767|BIOLOGICAL|parainfluenza virus type 3 vaccine (PIV3)|Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular
214942130|NCT06604767|BIOLOGICAL|RSV/hMPV/PIV3 vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
214942131|NCT06604767|BIOLOGICAL|RSV/hMPV vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
214942132|NCT06604767|BIOLOGICAL|RSV vaccine 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214942133|NCT06604767|BIOLOGICAL|RSV vaccine 2|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
215074354|NCT07021157|DRUG|Placebo|Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given placebo once.
215074355|NCT07024901|BEHAVIORAL|Dance-walk|Dance-Walk is a 4-week somatic intervention combining movement, dance, and walking elements designed to enhance body awareness and emotional regulation. The program consists of 4 weekly group sessions, each lasting approximately 90-120 minutes. Sessions focus on helping participants connect with their body sensations through guided movement exercises that integrate dance movements with mindful walking practices. The intervention targets autonomic nervous system regulation and aims to improve interoceptive awareness, emotional expression, and stress management through embodied practices. Sessions are facilitated by trained practitioners and emphasize non-verbal emotional expression and somatic experiencing to promote mental health and vitality.
214339221|NCT00875394|DRUG|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
214942134|NCT03196037|BEHAVIORAL|Tai Chi|An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
214942135|NCT06122233|BEHAVIORAL|Pulmonary Fibrosis self-management package and smartphone application|"The pulmonary fibrosis package includes modules on understanding treatment options for pulmonary fibrosis, managing medication and side effects, understanding and accessing clinical trials, managing shortness of breath, managing fatigue and mood, managing co-existing conditions, the role and importance of pulmonary rehabilitation and regular physical activity, role of oxygen therapy, smoking cessation advice and support, accessing community support, and communicating with others when living with pulmonary fibrosis.~The RE-BUILD app is used as a tool for data collection and to help participants self-monitor their disease over time. Participants enter their health data, including baseline conditions, medications and diagnosis, pulmonary function results and supplementary oxygen use. It also tracks air quality data close to the participant as well as physical activity level (step count). The app also has links to ILD-related educational resources."
214942136|NCT06991166|BEHAVIORAL|Cognitive behavioral therapy (CBT) psychotherapy group/telehealth|Type of psychotherapy. CBT focuses on identifying and changing unhelpful beliefs and behavioral patterns that lead to negative emotions (e.g., depression, anxiety, grief, shame) in order to break the emotion-thought-behavior cycle
214942137|NCT06991166|BEHAVIORAL|Interpersonal therapy (IPT) psychotherapy group/telehealth|Type of psychotherapy. IPT focuses on improving interpersonal communication and deficits, processing grief, and role transitions
214942138|NCT00877955|DRUG|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
215074356|NCT07022392|OTHER|Technology-enhanced gender support platform|Technology-based platform to support parents
215074357|NCT05980104|BEHAVIORAL|Empowered Relief|The participants will attend an online pain relief skills intervention (Empowered Relief). The two-hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
215074358|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
214339222|NCT00875394|DRUG|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
214339223|NCT04684797|BEHAVIORAL|Virtual T-maze task|Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
214339224|NCT02278497|OTHER|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
214339225|NCT04494919|DEVICE|Ultrafine Endoscope|The reversal of the normal colonoscope (CV-260SL; Olympus, Tokyo, Japan) along the guidewire to replace the UFE (GIF-XP260NS; Olympus, Tokyo, Japan).
214942139|NCT00877955|DRUG|alprazolam sublingual tablet test|0.5 mg tablet, single dose
214942140|NCT04173728|OTHER|Standard mixed macronutrients tolerance test|Consumption a standard mixture containing 75g glucose, 60g fat and 20 protein.
214942141|NCT00189852|DEVICE|Chronic heart failure monitoring system|
214942142|NCT00189852|DEVICE|Lifestyle monitoring system|
214942143|NCT01890213|BIOLOGICAL|AVX701|
214942144|NCT01758198|BIOLOGICAL|Abatacept|
214942145|NCT01758198|DRUG|Placebo matching with Abatacept|
214942146|NCT01758198|DRUG|Methotrexate|
214942147|NCT01018381|PROCEDURE|PEIT|"For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease."
214942148|NCT01018381|PROCEDURE|TOCE|For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
214942149|NCT01018381|PROCEDURE|TOCE plus PEIT|A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
214942150|NCT01018381|PROCEDURE|TOCE plus RFA|For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
214339226|NCT01693224|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
214339227|NCT01693224|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
214339228|NCT01693224|DEVICE|Cepheid Xpert MTB/Rif assay|
214339229|NCT00699881|DRUG|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
214339230|NCT01933334|DRUG|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
214339231|NCT00927745|DEVICE|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
214339232|NCT00927745|DEVICE|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
214339233|NCT01264302|DRUG|Finasteride|Finasteride Tablets 5 mg
214339234|NCT02048761|DRUG|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
214339235|NCT02048761|DRUG|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
214339236|NCT05927402|OTHER|Laughter Therapy Based on Kolcaba Comfort Theory|The laughter yoga will be applied to experimanetal group. Every laughter yoga practice is 45 minutes long and is planned 3 times a week for a total of 6 sessions. Control group patients will take only routine nursing care.
214942151|NCT01018381|DIETARY_SUPPLEMENT|MGN-3|For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
214942152|NCT01018381|DRUG|Entecavir|For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
214942153|NCT06596577|BEHAVIORAL|Palliative care needs information|clinician-directed EHR alert providing information about serious illness diagnosis(-es) and unmet palliative care needs
214942154|NCT06596577|BEHAVIORAL|Default consult order|clinician-directed EHR alert providing information about serious illness diagnosis(-es) and unmet palliative care needs + a choice to cancel the default palliative care consult order
214942155|NCT05477212|DIETARY_SUPPLEMENT|Ketogenic Diet|all patients will receive a very low calorie ketogenic diet
214942156|NCT03164265|BIOLOGICAL|Regulatory Donor-Derived Dendritic Cell infusion|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to surgery
214942157|NCT06874335|DRUG|BHV-1530|BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle
214942158|NCT06704295|BEHAVIORAL|Control ad with dark gray product with tobacco flavor name|The e-cigarette ad with a dark gray product with a tobacco flavor name
214942159|NCT06704295|BEHAVIORAL|Dark gray product with strawberry flavor name|The e-cigarette ad with a dark gray product with a strawberry flavor name
214942160|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor name|The e-cigarette ad with a colorful (strawberry color) product with strawberry flavor name
214942161|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor name and image|The e-cigarette ad with colorful (strawberry color) product with strawberry flavor name and strawberry image
214942162|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor features|The e-cigarette advertisement with colorful (strawberry color) product with strawberry flavor name, strawberry image, and strawberry flavor sensation descriptor
215074359|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
215074360|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
214339237|NCT04358926|DEVICE|Hyperbaric oxygen therapy|8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
214339238|NCT01914432|DRUG|YH16410|
214339239|NCT01914432|DRUG|Rosuvastatin|
214339240|NCT01914432|DRUG|Telmisartan|
214339241|NCT01914432|DRUG|YH16410 placebo|
214339242|NCT01914432|DRUG|Rosuvastatin placebo|
214339243|NCT01914432|DRUG|Telmisartan placebo|
214339244|NCT05027191|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin (NGAL)|The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
214339245|NCT05027191|DRUG|Desflurane|Desflurane
214339246|NCT05027191|DRUG|Sevoflurane|Sevoflurane
214339247|NCT00767000|DRUG|MK-0941|MK-0941 tablets three times daily
214339248|NCT00767000|DRUG|Comparator: Placebo|Matching placebo to MK-0941 three times daily
214942163|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor features and choice claim|The e-cigarette ad with colorful (strawberry color) product with strawberry flavor name, strawberry image, strawberry flavor sensation descriptor, and flavor choice claim
214942164|NCT07138118|BEHAVIORAL|Blood Flow Restriction + Dual Task Training|Participants will undergo lower limb resistance and gait training while wearing blood flow restriction cuffs at 40% of their individualized arterial occlusion pressure. Tasks include walking, sit-to-stand, and obstacle crossing combined with verbal fluency or serial subtraction. Training is performed 3 times per week for 5 weeks.
214942165|NCT07138118|BEHAVIORAL|Dual Task Training Only|Participants will perform the same cognitive-motor dual task training without blood flow restriction. Tasks include forward walking, obstacle crossing, and sit-to-stand exercises with concurrent cognitive tasks such as verbal fluency or serial subtraction. Training is performed 3 times per week for 5 weeks.
214942166|NCT06709391|PROCEDURE|Fusion surgery|"After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to fusion (active treatment):~Pedicle screws are placed. Interbody cages may be used. Fluoroscopy or intraoperative computed tomography with or without intraoperative navigation is performed for correct implant positioning. Decortication is performed in the surgical area, and the cartilage in the facet joints is partially removed to allow fusion. Local bone graft is used and placed in the surgical area. Rods are placed in the screws and the fixation system is locked. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue, and skin is sutured."
214942167|NCT06709391|PROCEDURE|Non-fusion surgery|"After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to non-fusion surgery (control):~No implants are placed. No decortication is performed. The facet joints are left intact. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue and skin is sutured."
214942168|NCT07136272|DEVICE|SSAM|Embedded software featuring neural-network classifiers designed to detect and classify sleep stages (N1/N2, N3, REM, Wake), autonomic arousals, and an Arousal Index based on data (specifically instantaneous pulse rate and full-resolution flow waveforms) collected during PAP therapy.
214942169|NCT07136272|DIAGNOSTIC_TEST|Polysomnography|Polysomnography (PSG) is an overnight, in-laboratory diagnostic procedure that records multiple physiological parameters during sleep. It typically includes monitoring of brain activity (EEG), eye movements (EOG), muscle activity (EMG), heart rhythm (ECG), respiratory effort, airflow, oxygen saturation, and body position. PSG is used to evaluate sleep architecture, identify sleep stages, detect arousals, and diagnose sleep disorders such as sleep apnea. The collected data are analyzed manually by trained sleep technologists following standardized scoring criteria.
214942170|NCT07136272|DEVICE|EnsoSleep|EnsoSleep is software-only medical device intended for use by physicians to assess sleep quality and aid in the diagnosis of sleep disorders. The software analyzes physiological signals and automatically scores sleep study results, including respiratory, sleep staging, arousal and movement events. Automatically scored events and physiological signals are analyzed, displayed, and summarized for review by clinicians.
215074361|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
215074362|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
214676556|NCT02311712|DEVICE|Capsule sponge|Capsule sponge cytology examination coupled with H\&E staining analysed for the presence of atypia and p53 immunohistochemistry
214676557|NCT05155631|BEHAVIORAL|COGNITIVE BEHAVIORAL THERAPY|8-10 week self directed on line CBT program approved by FDA
214676558|NCT00260559|PROCEDURE|Questionnaires|Quality of life and heartburn assessment questionnaires are administered preoperatively and at set intervals postoperatively.
214676559|NCT05934799|DRUG|Clopidogrel film-coated tablet 75 mg|Clopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.
214676560|NCT05934799|DRUG|Plavix® film-coated tablet 75 mg|Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.
214339249|NCT00767000|BIOLOGICAL|Lantus|Lantus injection once daily
214676561|NCT00814073|DRUG|Masitinib|Masitinib 6 mg/kg/day
214676562|NCT00814073|DRUG|Placebo|Matching placebo
214676563|NCT00814073|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
214676564|NCT03260335|BEHAVIORAL|Anxiety management strategy|Anxiety management strategy as per standard care plan
214676565|NCT01053624|PROCEDURE|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
214676566|NCT00746577|OTHER|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
214676567|NCT04755400|OTHER|isotonic saline 9%|1 Liter of Isotonic saline administered I.V.
214676568|NCT04755400|DIETARY_SUPPLEMENT|Potassium nitrate|24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.
214676569|NCT04755400|DIETARY_SUPPLEMENT|Potassium chloride|24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
214339250|NCT00767000|DRUG|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
214676570|NCT05724667|OTHER|Flippin' Pain Seminar Series|A chronic pain education campaign
214676571|NCT00945750|DRUG|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
214676572|NCT00945750|DRUG|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
214676573|NCT00983450|OTHER|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
214942171|NCT06879418|OTHER|Low dose shock wave therapy plus strengthening and stretching exercise for upper trapezius|Patients will receive 2000 shocks, 1 bar (energy flux density 0.045 mj/mm2) at frequency 10 MHz on upper trapezius trigger points plus strengthening and stretching exercises for upper trapezius.
214486452|NCT06749860|DRUG|Disitamab Vedotin + tislelizumab + bevacizumab|"Disitamab Vedotin, dosing regimen: 2.0 mg/kg, intravenous infusion, infusion should be about 30-90 minutes (usually about 60 minutes), every 21 days a cycle, the first day of administration, continuous use.~Tislelizumab, dosing regimen: 200 mg administered by intravenous infusion every 21 days in a cycle on the first day, continuous.~Bevacizumab, dosing regimen; 7.5 mg/kg administered by intravenous infusion every 21 days in a cycle on the first day of continuous use."
214676574|NCT00983450|OTHER|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity \[Celnik et al., 2008\]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
214676575|NCT05553548|PROCEDURE|biologically oriented alveolar ridge preservation|xenogenic bone graft placed in coronal part of the non molar socket ,, collagen plug placed in appical part of socket and as socket seal
214676576|NCT05553548|PROCEDURE|xenogenic bone graft in entire (apico-coronal) extension|xenogenic bone graft placed in the entire apico coronal extension and sealed with collagen plug
214676577|NCT02531035|DRUG|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
215074363|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
214676578|NCT02531035|DRUG|Placebo|Placebo, once daily, before the first meal of the day
214676579|NCT02892461|PROCEDURE|Umbilical cord milking|As same as that in arm descriptions.
214676580|NCT02898207|DRUG|Olaparib|Given PO
214676581|NCT02898207|DRUG|Onalespib|Given IV
214676582|NCT00071201|DRUG|Adefovir Dipivoxil for oral suspension, 2 mg/mL|
214676583|NCT05768620|OTHER|CAVE|The training is designed to train spatial navigation and memory and in particular egocentric and allocentric processes
214676584|NCT05768620|OTHER|TAU|This is the usual care used to train visuospatial processes
214676585|NCT02069223|PROCEDURE|Gastrectomy|
214942172|NCT06879418|OTHER|Medium dose shock wave therapy plus strengthening and stretching exercise for upper trapezius|patients will receive 2000 shock with 4 bars (Energy flux density 0.18 mj/mm2) at frequency 10 MHz on upper trapezius trigger points plus strengthening and stretching for upper trapezius
214942173|NCT06879418|OTHER|sham shock wave therapy plus strengthening and stretching exercise for upper trapezius|patients will receive 2000 shock with energy flus density 0.00 on upper trapezius trigger points plus strengthening and stretching exercise for upper trapezius.
215074364|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
215074365|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
215074366|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
215074367|NCT02298179|DRUG|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
215074368|NCT07026305|PROCEDURE|Pressure-guided laminectomy (PGL)|Osseous resection of the lamina and ligamentum flavum until the epidural pressure reaches a normal value at the stenotic segment.
215074369|NCT07026305|PROCEDURE|Laminectomy without pressure guidance (LWPG)|Complete resection of both the lamina and the ligamentum flavum at the stenotic segment.
215074370|NCT07034014|DEVICE|Dressing|The dressing will be applied to intact skin on healthy volunteers participants to assess the self-adhesive properties of two investigational devices compared to a test specimen reference. The dressing will be worn for up to 14 days on a designated area on the health volunteers participants back.
215074371|NCT07033468|DEVICE|VR-WLC|First, conduct the Virtual Reality (VR) training activity. After the evaluation is completed, proceed to the Waitlist Control (WLC) session, approximately 5 to 10 weeks later.
215074372|NCT07033468|DEVICE|CTL-VR|First, conduct the Control (CTL) session for approximately 5 to 10 weeks. After the evaluation is completed, proceed to the Virtual Reality (VR) training activity.
215074373|NCT07033858|DRUG|Rapamune Pill|Rapamiune Tablet 1mg daily plus Advograf plus prednisolone
215074374|NCT07033871|DIAGNOSTIC_TEST|comprehensive geriatric assessment|The comprehensive geriatric assessment (CGA) is a multi dimensional diagnostic process used to determine the medi cal, psychological, and functional capabilities of a frail elderly person to develop a coordinated and integrated plan for treat ment and long-term follow-up.
214942174|NCT06718803|BEHAVIORAL|Hypnosis|"The Evia program includes three mayor components, 1. A hypnotherapy program for the reduction of hot flashes, 2. Educational readings on hot flashes and menopausal-related topics, 3. Daily hot flash tracker.~The hypnotherapy is delivered in short, daily 10-20 minute audio recordings that involve numerous suggestions for coolness and relaxation (i.e., cool breeze, snowy mountain, deep lake) for a period of five weeks. The hypnotherapy program is based on previous randomized controlled trials for the reduction of hot flashes (Elkins et al., 2008; Elkins et al., 2013)."
214942175|NCT06718803|OTHER|Structured Attention|Data collection of hot flash severity and frequency will mirror the hot flashes daily tracker offered by the intervention group (Evia app), and account for time and structured attention control while removing any potential therapeutic effects.
214942176|NCT06702436|OTHER|Observational Study|This study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians
214942177|NCT07031739|BEHAVIORAL|Resource information|Participants randomized to this arm will receive a tailored list of information about community resources.
214942178|NCT07031739|BEHAVIORAL|Community Health Worker (CHW) assistance|The CHW will meet with the participant at the baseline visit and will follow up with participants at least every other week. The CHW will also work directly with the patient's care team.
214942179|NCT07031739|BEHAVIORAL|Medically-tailored Meals (MTM)|MTM will consist of weekly home meal delivery. During the 3 months, participants will receive 10 medically tailored refrigerated or frozen meals (5 lunches and 5 dinners) delivered to their home weekly.
214942180|NCT06723015|DRUG|18F-AV-1451|"Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection.~Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment.."
214942181|NCT07039461|DEVICE|OptiLIGHT|three IPL or sham treatment in 1 week interval followed by 1 follow-up 4 weeks after the last treatment
214942182|NCT06890637|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
215074375|NCT06827327|DIETARY_SUPPLEMENT|LC-Plasma|1 tablet containing 50mg LC-Plasma is taken daily for 24 weeks
215074376|NCT06827327|OTHER|Placebo|1 tablet containing 50mg MCC is taken daily for 24 weeks
215074377|NCT00318279|DEVICE|Surgical simulator to practice vascular anastomosis|
215074378|NCT06889428|DIAGNOSTIC_TEST|CMR|No CMR
215074379|NCT04617912|DEVICE|Long AFOV PennPET Explorer|A long-axial field-of-view (LAFOV) time-of-flight PET scanner, developed at the University of Pennsylvania, being tested for real-world applications.
214676586|NCT02069223|PROCEDURE|BPD-DS|
214676587|NCT01009801|DRUG|doxorubicin-eluting beads|Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
214676588|NCT01009801|DRUG|everolimus|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
214676589|NCT01009801|OTHER|placebo|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
214676590|NCT02193269|DRUG|Sugar pill|you will receive 0.0 mg as a single daily dose for 4 days
214676591|NCT02193269|DRUG|Minocycline|you will receive 200 mg as a single daily dose for 4 days
214676592|NCT00912158|OTHER|standard therapy (ST)|standard medical therapy
214676593|NCT00912158|DEVICE|CPAP|Non-invasive mechanical ventilation (CPAP)
214942183|NCT06890637|OTHER|Crohns Disease Exclusion Diet|The modified diet plan will be given to each study participant
214942184|NCT06890637|OTHER|Sham transplantation|Sham transplantation will involve saline infusion via colonoscopy
214942185|NCT06890637|OTHER|Sham Diet|Dietary counselling alone
214942186|NCT06890637|OTHER|Advanced therapy|Advanced therapy as standard dose and schedule
214942187|NCT06740071|BEHAVIORAL|somatosensory interactive pelvic floor muscle training|synchronized PFMT guidance through a combination of audio and video
214942188|NCT06740071|PROCEDURE|pelvic floor magnetic stimulation therapy|stimulation frequency was set at 10 Hz, with stimulation administered in cycles of 5 seconds on followed by 5 seconds off. Each treatment session lasted 20 minutes, conducted twice a week, for a total of 10-12 sessions
215074380|NCT05503186|OTHER|Text Message|The intervention consists of a series of text messages aimed to facilitate secure storage and disposal of unused opioid medications.
215074381|NCT05503186|OTHER|Standard of Care|Information provided by the physician and/or pharmacist.
214676594|NCT00912158|DEVICE|BIPAP|Non-invasive mechanical ventilation (BIPAP)
214676595|NCT04885491|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
214676596|NCT04885491|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
214676597|NCT02252874|BEHAVIORAL|Slow-paced action video game|20 hours slow-paced action video games
214676598|NCT02252874|BEHAVIORAL|Fast-paced action video game|20 hours fast-paced action video games
214339251|NCT06635460|OTHER|Motivational interviewing|This programme has been developed from the literature and structured according to expert opinion. It will consist of a total of 8 online sessions. The duration of the motivational interviewing sessions will be limited to 30-45 minutes, in line with the literature.
214942189|NCT06740071|BEHAVIORAL|standard pelvic floor muscle training|"traditional verbal instructions and paper-based educational materials of PFMT are given to participants.~All patients would receive PFMT under the guidance of digital rectal examination by nurses, and their pelvic floor muscle function was graded according to the Oxford Grading System (grades 0-5), ensuring the correctness of subsequent PFMT."
214942190|NCT06828445|BEHAVIORAL|Veggie Vouchers|"Caregivers will receive brief education about a SNAP fruit and vegetable incentive program in South Carolina during their child's pediatrician visit. Following the visit, caregivers will receive a free trial of this SNAP program to encourage first-time use. After the free trial, caregivers can continue purchasing the same fruit and vegetable boxes at a steeply discounted price using their SNAP card. Free home delivery during the free trial and for all subsequent boxes purchased at a discounted rate will be offered during the full study duration."
214942191|NCT00139100|DRUG|antimicrobial agent in soap|
214942192|NCT06861062|DRUG|Vitamin D3|Vitamin D3(cholecalciferol),1600 IU per day.
214942193|NCT06861062|DIETARY_SUPPLEMENT|yeast β-glucan|yeast β-glucan, 600mg per day.
214942194|NCT06861062|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
214942195|NCT06861062|DIETARY_SUPPLEMENT|yeast β-glucan placebo|yeast β-glucan placebo
214339252|NCT06635460|OTHER|Social media-based patient monitoring|Blood glucose results, lowest and highest values, and reasons will be included in the content of the patient follow-up, which will be conducted at intervals on the WhatsApp platform. There will be a total of 10 follow-ups. Although the duration of the written dialog will vary among adolescents, it will be limited to an average of 2-10 minutes.
214339253|NCT00119444|PROCEDURE|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
214339254|NCT06634563|OTHER|mindfulness meditation|the patients will receive mindfulness meditation in the form of Attention-focusing technique (body scan, directing attention throughout the body in a relaxed, supine state) guided by audiotapes. Relaxing every part of the body by guided audiotape from head to toes and Sitting meditation (systematically directing attention to breath) guided by audiotapes. Relaxing deep rhythmic breathing with concentration on every breath.
214339255|NCT06634563|OTHER|cognitive behavioral training|Training sessions will include three cognitive training tasks each of them target a particular core cognitive capability and are grouped into three categories by target domain: memory (working memory), attention (selective attention), and problem solving (logical reasoning) through these games (organic order and fuse clues for logical reasoning training, lost in migration, trouble brewing, assist ants and train of thought for attention training and memory match and memory match one drive for working memory training).
214339256|NCT06635421|OTHER|Model of care delivery for long-acting injectable ART|This study is assessing a novel model of care delivery, i.e. pharmacist administered long-acting cabotegravir + rilpivirine (CAB+RPV LA). In phase 2 and 3, no medication will be provided by the study. The decision to initiate CAB+RPV LA will be at the discretion of the patient and their provider in accordance with both standard of care and local prescribing practices. This will occur independent of study participation. The study intervention is the model of care for CAB+RPV LA administration. The models of care being studied include (1) pharmacist administered CAB+RPV LA in MetroHealth satellite pharmacy setting (novel model of care); (2) nurse administered CAB+RPV LA in the Infectious Diseases clinic at MetroHealth main campus (current standard of care).
214347384|NCT02727101|DRUG|perampanel|Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated.
214347385|NCT02405455|PROCEDURE|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
214942196|NCT06864169|BIOLOGICAL|Raludotatug Deruxtecan (R-DXd)|Administered via intravenous (IV) infusion.
214942197|NCT06894914|BEHAVIORAL|24-hour Activity Counselling|"Physiotherapists will participate in the self-paced brief action planning (BAP) online training (2-4 hours long), followed by 2-3 hours of practice and feedback over the phone with an experienced BAP instructor. In addition, they will attend a 2-hour session with the research team on training around on prescribing physical activity while balancing with rest and sleep.~Once training is complete the PT can start implementing the counselling approach with the older adult patients."
214942198|NCT06894368|BEHAVIORAL|UP-A|The intervention is a group adaptation of the Spanish version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018, 2020, 2022). It consists of 16 weekly 90-minute sessions held in person at a public Mental Health Center. The intervention also includes three in-person group sessions for parents, each lasting one hour, held at the beginning, middle, and end of the program. These sessions cover content from the therapist's guide, including the Parent Module (Parenting the Emotional Adolescent), and provide a space for questions and emotional support.
214942199|NCT06741644|DRUG|CS2009|CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
214942200|NCT06741644|DRUG|CS2009|CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).
214942201|NCT06741644|DRUG|Pemetrexed|IV infusion
214942202|NCT06741644|DRUG|Carboplatin|IV infusion
214942203|NCT06741644|DRUG|Paclitaxel|IV infusion
214942204|NCT06741644|DRUG|Etoposide|IV infusion
214942205|NCT06741644|DRUG|Nab-paclitaxel|IV infusion
214942206|NCT06741644|DRUG|Oxaliplatin|IV infusion
214942207|NCT06741644|DRUG|Capecitabine|oral tablets
214942208|NCT04008940|DEVICE|Distal femur plates|By assessing the rate and mode of mechanical failures we aim to identify risk factors for mechanical failures among the analysed plate types. This, finally, is depending on the overall number of cases and number of failure cases.
214942209|NCT06778876|OTHER|lavender sachet group|The normal procedure applied in the sleep clinic (keeping a sleep diary, sleep hygiene education) will be followed and participants will be asked to sleep with lavender sachets inside their pillows for two weeks.
214942210|NCT06778876|OTHER|control group|Participants will follow the normal procedure applied (keeping a sleep diary, sleep hygiene training) in the sleep clinic and no additional intervention will be performed.
214942211|NCT07074977|DRUG|nemolizumab|Participants will receive either 30 mg or 60 mg dose of nemolizumab as SC injection.
214942212|NCT07074977|DRUG|Placebo|Participants will receive matching placebo as SC injection.
214942213|NCT06927804|PROCEDURE|Virtual reality intervention|A virtual reality device will be used in one study arm during the implantation of the subcutaneous port.
214339257|NCT06635239|OTHER|Co-creation and assessment|"1. MOOC co-creation: development of a MOOC initially structured into modules consisting of a variety of downloadable educational resources such as videos, audios, infographics, texts, etc., covering several units related to Person-Centered Care (Shared Decision-Making, strategies for managing the clinical encounter, Patient Decision Aids, etc.) and Digital Health Literacy (skills, tools, etc.). These resources will serve as the central focus of the educational intervention, and may undergo appropriate adjustments established during the co-creation sessions.~2. MOOC acceptability and effectiveness: evaluation of the MOOC in terms of effectiveness (level of Health Literacy, Digital Health Literacy, and knowledge acquired) and acceptability (usability, areas for improvement, etc.)"
214339258|NCT03103282|DEVICE|PuraStat®|Synthetic haemostatic material
214942214|NCT06927804|PROCEDURE|Standard Care (in control arm)|Patients in this study arm will receive standard care, without the use of VR.
214942215|NCT07132918|RADIATION|MRgART|Magnetic Resonance-guided Adaptive Radiation Therapy (MRgART) is a form of MRgRT that incorporates daily adaptive planning, or making a new treatment plan each treatment, and real-time imaging during treatment delivery.
214942216|NCT07132918|RADIATION|LINAC|Daily 3D x-ray scans will be obtained for radiation delivery to confirm tumor and organ at risk placement.
214486453|NCT06739395|DRUG|Olaparib tablet|Usage and dosage: The recommended dosage is 200mg, twice a day, equivalent to a total daily dose of 400mg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided(from the I-PREDICT study).
214942217|NCT04847453|PROCEDURE|Biospecimen Collection|Undergo blood and urine specimen collection
214676599|NCT02252874|BEHAVIORAL|Control|20 hours leisure activities
214676600|NCT00900380|OTHER|flow cytometry|
214676601|NCT00900380|OTHER|immunological diagnostic method|
214676602|NCT00900380|OTHER|laboratory biomarker analysis|
214942218|NCT04847453|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214339259|NCT00030550|DRUG|thalidomide|
214339260|NCT00335907|PROCEDURE|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
214942219|NCT04847453|PROCEDURE|Computed Tomography|Undergo CT scan
214942220|NCT04847453|DRUG|Dexamethasone|Given PO
214942221|NCT04847453|PROCEDURE|Echocardiography Test|Undergo ECHO
214942222|NCT04847453|DRUG|Ixazomib Citrate|Given PO
214942223|NCT04847453|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214942224|NCT04847453|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214942225|NCT04847453|PROCEDURE|Transabdominal Ultrasound|Undergo transabdominal ultrasound
214942226|NCT04847453|DRUG|Venetoclax|Given PO
214942227|NCT04847453|PROCEDURE|X-Ray Imaging|Undergo x-ray
214942228|NCT07076433|OTHER|Core Stability Exercises|Participants will engage in core stability exercises targeting the muscles of the trunk and pelvis, such as pelvic tilting, abdominal crunches, back extension, side bridges, and bird dog. These exercises will be performed twice a week for 6 weeks, with each session lasting 30 minutes. The intensity will be progressively increased based on individual tolerance.
214942229|NCT07076433|OTHER|Pilates:|Participants will undergo Pilates sessions that emphasize flexibility, posture, and core engagement. Pilates exercises will be performed twice a week for 6 weeks, with each session lasting 30 minutes. The focus will be on breathing, spinal alignment, and strengthening exercises that challenge flexibility and balance.
214942230|NCT07078877|OTHER|home based exercise|The conventional home based exercise program includes: hip and knee range of motion (ROM) exercises; stretching exercises for the hamstring, calf, and quadriceps muscles; isometric, concentric, and eccentric strengthening exercises for the quadriceps, hamstrings, and hip adductors/abductors; relaxation exercises; and walking as aerobic exercises. The program will begin with ROM, stretching, relaxation, aerobic, and isometric strengthening exercises. After one week, concentric and eccentric strengthening exercises will be added using elastic bands. The home exercise program will be performed 3 days a week, each exercise in 3 sets of 10 repetitions and 2 minutes of rest between sets. Aerobic walking at a moderate pace (as determined by the talk test: the patient can talk but not sing during exercise) for 30 minutes will be recommended. Program will continue for 12 weeks.
215074382|NCT01585779|DEVICE|Contour 3D® implant for tricuspid valve repair|Tricuspid annuloplasty ring
215074383|NCT01585779|DEVICE|Tri-Ad® implant for tricuspid valve repair|Tricuspid annuloplasty ring
215074384|NCT03559517|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
215074385|NCT03559517|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
215074386|NCT06459999|DIAGNOSTIC_TEST|Urine and circulating blood biomarkers|Urine and circulating blood biomarkers in all cohorts
214942231|NCT07078877|DEVICE|Low Level Laser Therapy|Patients will receive LLLT treatment, they will be treated in a supine position with the knee flexed to 30 degrees, 5 sessions per week for 2 weeks. A total of 6 points will be treated each for 60 seconds. The treatment will be applied using the BTL SMART 4000 laser device at a wavelength of 835 nm and a dose of 10 J/point.
214942232|NCT03233204|DRUG|Olaparib|Given PO
214942233|NCT06510777|DEVICE|PICO Treatment|"PICO 7 is a single-use Negative Pressure Wound Therapy System consisting of a small portable pump, 2 AA batteries, 1 or 2 dressings, and fixation strips. The dressing is changed when the dressing is saturated or after 7 days of treatment.~PICO Treatment will be given in addition to compression therapy.~If the wound is healed and until the wound healing confirmation visit, Venous Leg Ulcers (VLUs) allocated to the PICO group may be covered using a protective dressing.~If the wound meets the wound improvement criteria as assessed by the PI during the monthly visits, PICO treatment may be stopped."
214942234|NCT06510777|DEVICE|Standard of Care (SOC) Treatment|"Application of an appropriate wound primary dressing according to its intended purpose and chosen appropriately according to wound healing stage:~1. Dressing choice should take wound condition into consideration but may also consider subject's comfort (including pain) and HCP's preference.~2. Sequential treatment:~   * Debridement stage: alginate, hydrogel, absorbent, or hydro-detersive dressings~  * Granulation stage: wound contact layer, foam, petrolatum, or hydrofiber dressings~  * Epithelialization stage: wound contact layer, hydrocolloids~  * Other: dressings for specific clinical situations (e.g. fragile skin, infection; hemorrhagic wound, malodorous wound)~3. Application of appropriate venous compression therapy based on Ankle Brachial Pressure Index (ABPI) value."
215074387|NCT06422221|DRUG|Clindamycin|Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
215074388|NCT06422221|DRUG|Doxycycline|Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
215074389|NCT02860208|PROCEDURE|3 years follow-up|Examination 3 years after surgical treatment of peri-implantitis
214676603|NCT03254017|PROCEDURE|Bilateral surgical implantation of DBS system to Habeluna|The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.
214676604|NCT03254017|OTHER|Follow-up Period|The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
214676605|NCT04424433|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
214676606|NCT03490669|BIOLOGICAL|MSC-1|humanized monoclonal antibody for intravenous administration
214676607|NCT04962542|OTHER|ventilation|low volume positive pressure ventilation is better than continuous positive airway pressure and passive deflation on arterial oxygenation and PPD after CPB in pediatrics undergoing cardiac surgeries for non-cyanotic congenital heart defects.
214676608|NCT04817085|DEVICE|Visant Medical Canalicular Plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
214676609|NCT04817085|DEVICE|Commercially available canalicular plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
214676610|NCT03032068|OTHER|At-Home Monitoring|Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
214676611|NCT04747548|BEHAVIORAL|Kurbo Only|Kurbo is a structured behavioral weight management program for youth that focuses on diet, physical activity and mindset skills and is based on the traffic light diet developed at Stanford University. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories consumed. Foods are categorized into the colors of a traffic light signal based on their nutritional and caloric content, such that youth are encouraged to eat more of green and yellow foods, and less of red foods. Participants will log their daily food intake and self-monitor dietary and physical activity behaviors, incorporating behavior substitution and habit formation. Participants will also have 15 minute weekly individualized coaching sessions.
214676612|NCT04747548|BEHAVIORAL|Kurbo + PolyRules!|In addition to Kurbo, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
214676613|NCT03080220|DEVICE|Astym|therapeutic massage instrument
214676614|NCT03080220|DEVICE|Stick|massage instrument
214676615|NCT03080220|DEVICE|Massage|massage instruments
215074390|NCT01457014|DEVICE|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
215074391|NCT01457014|DEVICE|Continuous positive airway pressure|continuous positive airway pressure
215074392|NCT01457014|DEVICE|servo ventilation manual|servo ventilation titrated in manual mode
215074393|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
215074394|NCT00255918|DRUG|Placebo|Placebo dosed to match active medication
215074395|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
214942235|NCT06891911|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 4-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size."
214942236|NCT06891911|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a stipend during the 4-week intervention period. They are permitted to use the stipend however they choose and will not be asked about how they spent these funds."
214942237|NCT04173104|DIAGNOSTIC_TEST|PET/MR with [18F]PARPi|One PET/MR study (with up to 3 scan times) with \[18F\]PARPi
214942238|NCT04173104|DRUG|[18F]PARPi|Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
214942239|NCT06785051|BEHAVIORAL|AI-based physiotherapy|jaw, neck, shoulder ROM exercises, and scapular-focused exercises guided by AI technology, 30 minutes of intervention, once a week, and a total of 12 weeks
214942240|NCT06785051|BEHAVIORAL|Conventional physiotherapy|jaw, neck, shoulder ROM exercises, and scapular-focused exercises, 30 minutes of intervention, once a week, and a total of 12 weeks
214942241|NCT06785051|BEHAVIORAL|Scar management|scar massage and jaw-mobilizing exercises combined with devices or depressors
214942242|NCT06842173|BIOLOGICAL|Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg|Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg + IB160 adjuvant (0.5mL total)
214942243|NCT06842173|BIOLOGICAL|Monovalent influenza vaccine type A (H5N8) 15 mcg|Monovalent influenza vaccine type A (H5N8) 15 mcg + IB160 adjuvant (0.5mL total)
214676616|NCT00841503|OTHER|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
214339261|NCT03120104|OTHER|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just one month before the stoma closure
214339262|NCT03120104|OTHER|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just two weeks after the stoma closure
214339263|NCT03229551|DRUG|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
214942244|NCT06842173|OTHER|Placebo|Phosphate buffered saline (PBS) (0.5 mL/dose).
214942245|NCT06751563|BEHAVIORAL|Behavioral Text Messages and Produce Box Delivery|Participants will receive a produce box delivered weekly to the participants home customized based on the participants cooking preferences and household size. Participants will also receive a daily text message aimed to support a healthy diet and lifestyle. These texts will include information to build participants' knowledge and skills for healthy eating. The participants will also include weekly goals that focus on eating a healthy diet. Participants will receive automated, personalized feedback via text messages based on participant goal attainment and daily responses.
214676617|NCT04656964|DRUG|remimazolam tosilate group|Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).
214676618|NCT04656964|DRUG|Midazolam group|Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
214676619|NCT00146393|BEHAVIORAL|People with Arthritis Can Exercise program|
214676620|NCT01597622|DRUG|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
214676621|NCT04484779|DEVICE|IIM System|IIM System
214676622|NCT04484779|DRUG|Insulin Lispro and/or Insulin Glargine|Administered subcutaneously (SC)
214676623|NCT05238948|DRUG|Midazolam|Substrate of CYP3A4
214676624|NCT05238948|DRUG|CKD-506|Perpetrator of CYP3A4
214676625|NCT04126967|DIAGNOSTIC_TEST|NGS patients|The next generation sequencing technique (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation
214676626|NCT01358500|DRUG|Fentanyl|Intravenous infusion using STANPUMP
214676627|NCT04065022|DEVICE|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
214676628|NCT00673998|DEVICE|Isokinetic Dynamometer (Biodex system III)|Biodex system III Isokinetic Dynamometer (Biodex Medical, Inc., Shirley, NY).
214942246|NCT06751563|BEHAVIORAL|Behavioral Text Message Program and Produce Voucher|Participants will receive a weekly produce voucher redeemable at a local market vendor for fresh produce of the participant's choice. Participants will also receive a daily text message aimed to support a healthy diet and lifestyle. These texts will include information to build participants' knowledge and skills for healthy eating. The participants will also include weekly goals that focus on eating a healthy diet. Participants will receive automated, personalized feedback via text messages based on goal attainment and daily responses.
214942247|NCT04961398|DEVICE|OCT imaging|OCT imaging on Normal Eyes without any filter and with various ND filters as per protocol
214942248|NCT07081178|DRUG|Semaglutide|Semaglutide injection will be self-administered once weekly subcutaneously at any time of the day with or without meals.
215074396|NCT03698578|OTHER|combat fight|Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
215074397|NCT01663818|DEVICE|Tack-It Endovascular Stapler|
215074398|NCT02614170|OTHER|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
215074399|NCT04208386|DRUG|JNJ-73763989|JNJ-73763989 will be administered SC under fasted condition.
215074400|NCT01027234|DRUG|AZD8418|Single oral dose
215074401|NCT01027234|DRUG|Placebo|single oral dose
214942249|NCT07083765|DRUG|Dehydrated Alcohol Injection, USP|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
214942250|NCT07083765|PROCEDURE|Sham procedure|Endovascular, renal angiography
215074402|NCT04913168|OTHER|Front Line Worker Pilot Project|13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
214339264|NCT03229551|DRUG|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
214486454|NCT06739395|DRUG|Temozolomide capsule|Administration method and dosage: 75mg/m2, orally administered for 7 consecutive days, with a treatment cycle of every 21 days.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214942251|NCT05983198|DRUG|225Ac-PSMA-R2|PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide
214942252|NCT05983198|RADIATION|68Ga-PSMA-R2|Kit for radiopharmaceutical preparation
214942253|NCT05983198|RADIATION|68Ga-PSMA-11|Kit for radiopharmaceutical preparation
214942254|NCT06665620|BEHAVIORAL|ViraBrite nudges|Each day, participants will receive prompts via smartphone notifications that encourage them to access the ViraBrite app and utilize suicide safety planning skills.
214942255|NCT07081932|DRUG|Nerandomilast|Nerandomilast
214942256|NCT07081932|DRUG|Bosentan|Bosentan
214942257|NCT07082738|DRUG|AZD6793|Oral dosage
214942258|NCT07082738|OTHER|Placebo|Oral dosage
214942259|NCT07086339|DEVICE|Implantable pulmonary stent|Implantable polymer based pulmonary stent for severe COPD/emphysema
214942260|NCT06929273|DRUG|KarXT|Specified dose on specified days
214942261|NCT06430580|DRUG|Hydrocortisone Oral|20mg hydrocortisone, single oral dose
214942262|NCT06430580|DRUG|Yohimbine Hydrochloride|54mg yohimbine hcl, single oral dose
214942263|NCT06430580|DRUG|Cornstarch Placebo 20mg|20mg cornstarch placebo, single oral dose
214942264|NCT06430580|DRUG|Cornstarch Placebo 54mg|54mg cornstarch placebo, single oral dose
214339265|NCT03952247|DEVICE|Single Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
214339266|NCT03952247|DEVICE|Conventional Multi Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
214339267|NCT01076595|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
214942265|NCT06930976|DRUG|13C6-Glucose|Compounded as 5% 13C6-Glucose in sterile water given IV over 2-4 hours as a split bolus and infusion
214942266|NCT06929338|DIAGNOSTIC_TEST|Functional precision medicine|The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices. Treatment will not be given as part of the study.
214942267|NCT02888392|OTHER|Kiwifruit|2 green kiwifruit cultivar 'Hayward'
214942268|NCT02888392|DIETARY_SUPPLEMENT|Psyllium|Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
214942269|NCT06619678|DRUG|MK-8507|Oral administration
214942270|NCT06619678|DRUG|Islatravir|Oral administration
214942271|NCT03809377|PROCEDURE|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
214942272|NCT02222831|PROCEDURE|Day 0 denudation and time lapse culture on IVF-oocytes.|
214942273|NCT04056273|OTHER|Guide sheath group|After the lesion was found by rEBUS, insert the rEBUS into a guide sheath and re-locate the lesion. Fix the guide sheath at that position and perform transbronchial biopsy and brushing through the guide sheath.
214942274|NCT04056273|OTHER|Conventional group|After the lesion was found by rEBUS, mark the location and depth. Insert the biopsy forceps and cytology brush to the marked depth of that bronchiole to perform biopsy and brushing.
214942275|NCT03467763|DRUG|Metformin Extended Release Oral Tablet|Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.
214942276|NCT03467763|DRUG|Placebo oral capsule|Placebo capsule
214942277|NCT02180802|BEHAVIORAL|motivational interviewing|
214942278|NCT02180802|BEHAVIORAL|motivational interviewing with parental involvement|
214942279|NCT02180802|BEHAVIORAL|Control group|
214942280|NCT02889835|DEVICE|Supreme Universal Restorative|
214942281|NCT02889835|DEVICE|Supreme Flowable Restorative|
214942282|NCT02889835|DEVICE|Bulk Fill Flowable Restorative|
215074403|NCT02709551|BEHAVIORAL|HRV_Bfb|
215074404|NCT02709551|BEHAVIORAL|MBI|
215074405|NCT02709551|BEHAVIORAL|MBI_HRV_Bfb|
215074406|NCT02855021|OTHER|Explorations|"Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment."
215074407|NCT02617394|OTHER|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
214339268|NCT01444534|DEVICE|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
214339269|NCT01444534|DEVICE|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
214339270|NCT04789421|DEVICE|Clinical, dermoscopy and Reflective confocal microscopy evaluations|Adjunctive reflective confocal microscopy to dermoscopy and clinical dermatological evaluation.
214339271|NCT04789421|DEVICE|Clinical, dermoscopy evaluations|Dermoscopy and clinical dermatological evaluation only
214942283|NCT07111182|DEVICE|HIVEN Medical Device|A medical device (HIVEN®) detects 5-ALA-induced fluorescence from the surgical suction and gives sound feedback to the operating surgeon indicating tumor tissue and overcoming the challenges is the contemporary FGS methods. The device is used for detecting fluorescence of flowing tissues within a transparent tube and providing auditory feedback of tissue fluorescence for neurosurgeons. There is no patient contact intended with this device.
214942284|NCT06531499|DRUG|AAA617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.
214942285|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
214942286|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) antagonists|Degarelix, Relugolix
214942287|NCT06677151|DEVICE|nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device|The NPA-OSA is a flexible, medical-grade silicone, tube-like device that is self-inserted into the user's nasopharyngeal airway through one nostril prior to sleep and worn throughout the night to reduce or alleviate snoring and obstructive sleep apnea.
215074408|NCT02617394|OTHER|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
214942288|NCT07116200|OTHER|Early Literacy Intervention in Kindergarten|In the kindergarten intervention, children will receive early literacy instruction through the Early Literacy Program, adapted for those using augmentative and alternative communication. Based on Accessible Literacy Learning by Light and McNaughton, the program enables nonverbal responses such as signs, symbol pointing, or eye-gaze, removing the need for speech. Instruction follows evidence-based practices including direct and explicit teaching, scaffolding, immediate feedback, cumulative review, practice, and subvocal rehearsal. The program targets five foundational literacy skills: phonological awareness, letter-sound correspondence, sound blending, shared reading, and understanding concepts about print. Supplementary materials such as flashcards and lotto games will also be used to reinforce learning.
214942289|NCT07116200|OTHER|Literacy Intervention in First Grade|In the first-grade intervention, students will receive literacy instruction using the Reading for All program, which is adapted for children who use augmentative and alternative communication. Based on Accessible Literacy Learning by Light and McNaughton, the program allows responses through nonverbal methods like signs, symbol pointing, or eye-gaze, eliminating the need for oral replies. Instruction is grounded in evidence-based practices such as direct and explicit instruction, scaffolding, immediate corrective feedback, cumulative review, practice, and subvocal rehearsal. Reading for All addresses six key literacy skills: sound blending, letter-sound correspondence, phoneme segmentation, sight word recognition, shared reading, and decoding. Additional activities (flashcards and lotto games) will be a supplement to the material.
214339272|NCT06105489|PROCEDURE|Lateral Sinus Lift using tunnel flap technique|"The surgical procedure will involve the following steps:~* A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
214347386|NCT02405455|DEVICE|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
214942290|NCT05105828|DIAGNOSTIC_TEST|Share wave fibro scan|Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis
215074409|NCT04710550|DRUG|F18-3F4AP|PET Scan
215074410|NCT01357161|DRUG|adavosertib|Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
215074411|NCT01357161|DRUG|Placebo|placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
215074412|NCT01357161|DRUG|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
215074413|NCT01357161|DRUG|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
215074414|NCT00904462|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
215074415|NCT00904462|DRUG|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
215074416|NCT02321189|DRUG|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
215074417|NCT02321189|DRUG|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
214942291|NCT03816319|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
214942292|NCT03816319|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214942293|NCT03816319|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214942294|NCT03816319|PROCEDURE|Echocardiography Test|Undergo ECHO
214676629|NCT01655264|BEHAVIORAL|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
214676630|NCT01655264|BEHAVIORAL|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
214676631|NCT05121727|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
214676632|NCT05121727|PROCEDURE|Deep and Superficial Serratus Anterior Plane Block|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
214676633|NCT03225781|DEVICE|Electrochemotherapy with Bleomycin|Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin
214676634|NCT06255470|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation.
214676635|NCT01458444|DEVICE|Non invasive ventilation (VNI)|BIPAP® vision
214676636|NCT01458444|DEVICE|Non invasive ventilation|OPTIFLOW system
214676637|NCT06257498|PROCEDURE|MRI scan|MRI scan on open scanner and some questionnaires
214942295|NCT03816319|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214942296|NCT03816319|DRUG|UAE Inhibitor TAK-243|Given IV
214942297|NCT07119437|PROCEDURE|low pneumoperitoneum laparoscopy with microsurgery|Use of low pressure for pneumoperitoneum (8-10 mmHg) and mini surgical access for bariatric procedure (sleeve gastrectomy).
214942298|NCT07119437|PROCEDURE|standard laparoscopy|Standard laparoscopy (12-14 mmHg) and normal surgical access for bariatric procedures (sleeve gastrectomy).
214942299|NCT06917872|DRUG|BI 1291583|BI 1291583
214942300|NCT06917872|DRUG|erythromycin|erythromycin
214339273|NCT06105489|PROCEDURE|Lateral Sinus Lift using crestal incision flap|"The surgical procedure will involve the following steps:~* A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
214942301|NCT07102810|BEHAVIORAL|Standardized Hypnotic Susceptibility Testing|Participants will be guided through the Harvard Group Scale of Hypnotic Susceptibility: Form A (HGSHS:A), a validated group hypnosis protocol that includes standardized hypnotic inductions and suggestibility tasks.
214942302|NCT04918355|OTHER|Clinical Decision Support (CDS) alerts|CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
214942303|NCT06933329|DRUG|Zelenectide pevedotin (BT8009)|Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.
214942304|NCT07137624|BEHAVIORAL|Action Observation + Motor Imagery|Participants will watch videos showing walking actions and will be instructed to mentally simulate the movement.
214942305|NCT07137624|BEHAVIORAL|Nature Video|Participants will watch a video of nature scenes.
214942306|NCT07137598|DRUG|Afimkibart|Afimkibart will be administered as SC injection.
215074418|NCT02320812|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
215074419|NCT02760173|OTHER|perception of vertical after static roll-tilt over 5min|subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
215074420|NCT04788797|DRUG|Prolyl Endopeptidase|Two capsules three times a day.
215074421|NCT04788797|OTHER|Placebo|Two capsules three times a day
215074422|NCT03619928|DEVICE|Dry needling|20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
214942307|NCT07137598|DRUG|Placebo|Placebo will be administered as SC injection.
214942308|NCT06940037|OTHER|Progressive Resistance Training|3 times a week
214942309|NCT06940037|OTHER|Health Education|once a week
214942310|NCT07143734|DEVICE|transcranial pulse stimulation (TPS)|The TPS/Sham-TPS therapy is administered for the first two weeks, followed by additional sessions at some week intervals.
214942311|NCT07143734|DEVICE|transcranial pulse stimulation (TPS-Sham)|Participants will undergo an identical procedure using a device that mimics the sound and sensation of active TPS but delivers no therapeutic energy pulses to the brain.
214942312|NCT07140146|DEVICE|Trehalose Powder Air-Polishing|Air-polishing procedure using trehalose-based powder (particle size \<65 µm, low abrasiveness) applied supra- and subgingivally with a professional air-polishing device in patients diagnosed with peri-implant mucositis. The intervention is combined with non-surgical debridement using manual curettes and ultrasonic scalers. The procedure is performed at baseline (T0), and repeated at 1 month (T1), 3 months (T2), and 6 months (T3). Clinical outcomes assessed include Plaque Index (PI), Bleeding on Probing (BoP), Probing Pocket Depth (PPD), and Bleeding Score (BS). Implant surfaces are also evaluated in vitro using scanning electron microscopy (SEM) to assess any surface alterations after powder application.
214942313|NCT07140146|DEVICE|Glycine Powder Air-Polishing|Air-polishing procedure using glycine-based powder (particle size \~25 µm, amino acid composition) applied supra- and subgingivally with a professional air-polishing device in patients with peri-implant mucositis. This treatment is combined with standard non-surgical supportive peri-implant therapy involving manual and ultrasonic debridement. The procedure is performed at baseline (T0), and repeated at 1 month (T1), 3 months (T2), and 6 months (T3). The intervention aims to reduce plaque accumulation and inflammation. Clinical parameters recorded include PI, BoP, PPD, and BS. Implant surfaces are also assessed in vitro via SEM to compare the effects of glycine versus trehalose on implant surface integrity.
214942314|NCT07141732|BIOLOGICAL|Resection of newly diagnosed glioblastoma combined with intraoperative balloon electronic brachytherapy using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System|The Elekta Xoft® Axxent® Electronic Brachytherapy (eBx®) System is a device that delivers high-dose-rate radiation. It is designed for use with Axxent applicators to treat neoplastic tumors inside or on the body surface where radiation therapy is indicated. The Axxent System and its applicators were cleared by the FDA under 510(k) submissions K050843, K072683, K090914, and K122951. The Russian Federation medical device registration certificate (No. RZN 2015/2593) was obtained on April 17, 2015.
214942315|NCT07145918|DRUG|Emraclidine|Oral Tablets
214942316|NCT07145918|DRUG|Placebo|Oral Tablets
214942317|NCT06946680|BIOLOGICAL|Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells|Single dose of 8R-70CAR T cells administered IV
214942318|NCT06945952|DEVICE|diaphragmatic ultrasonography|using diaphragmatic ultrasonography to measure diaphragmatic thickening fraction and then calculate the ratio RR/DTF
214942319|NCT03200847|DRUG|Pembrolizumab with All-Trans Retinoic Acid|All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
214942320|NCT05194072|DRUG|Felmetatug Vedotin|Given into the vein (IV; intravenously)
214942321|NCT05194072|DRUG|Pembrolizumab|400 mg every 6 weeks, given by IV
214942322|NCT06953817|BEHAVIORAL|Kangaroo Care Intervention Group|The mother should wear a comfortable outfit that can be easily opened at the front, and attention should be given to the mother's privacy. The infant should be covered with a light blanket. While applying kangaroo care, the baby may be completely naked, or the baby may wear items such as a hat, diaper, and socks. The kangaroo care position involves placing the baby upright between the mother's breasts. The newborn's abdomen should be positioned at the level of the mother's epigastric region. While performing kangaroo care, the mother should ensure that the baby's face is visible and that the baby's head is not in extreme extension or excessive flexion. During the procedure, care should be taken to ensure that the baby can breathe comfortably while on the mother's chest. The pregnant women will be instructed to practice kangaroo care intermittently for 30 minutes.
214942323|NCT07153016|OTHER|Legal Services|Legal care services from Cancer Legal Care (CLC), a nonprofit organization located in the Twin Cities of Minnesota.
214942324|NCT07157566|BEHAVIORAL|Mindfulness|Structured over 8 weeks (twice weekly) with dual modules (dietary + movement), this group employs Mindfulness-Based Eating Awareness Training (MB-EAT) to improve mind-body awareness. Week 1 establishes foundational practices through mindful eating concepts and introductory yoga; Weeks 2-4 systematically train awareness of hunger/satiety cues using partner breathing techniques, postural alignment, and group-assisted stretching; Week 5 analyzes emotional eating triggers while integrating therapeutic yoga for emotional regulation; Weeks 6-7 foster body acceptance and autonomous food choices; the program concludes with closing rituals. Rooted in Mindfulness-Based Stress Reduction (MBSR), it strengthens interoceptive awareness, non-judgmental self-acceptance, and emotional management to transform dysfunctional eating patterns.
215074423|NCT03619928|DEVICE|Massotherapy|A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
215074424|NCT04565444|DIETARY_SUPPLEMENT|Ketone|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* Isocaloric carbohydrate control: dextrose + vanilla flavouring"
214676638|NCT03995238|BEHAVIORAL|Error-augmentation gait training|Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.
214676639|NCT03995238|BEHAVIORAL|Error-correction gait training|Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.
214676640|NCT03995238|BEHAVIORAL|Supervised walking|An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
214942325|NCT07157566|BEHAVIORAL|e-Health Literacy|This 8-week program (twice weekly) aims to enhance participants' ability to access, evaluate, and apply digital health information. It progresses through sequential modules: Week 1 introduces e-Health literacy fundamentals and physical activity principles; Weeks 2-3 focus on nutritional assessment and personalized planning; Week 4 addresses sleep health; Weeks 5-7 train health information retrieval skills, including database navigation and source reliability verification; the final week hones critical appraisal capabilities. The intervention is based on the e-Health Literacy 3.0 model and cultivates three core competencies: digital navigation, information discernment, and evidence-based decision-making, enabling participants to independently navigate the digital health ecosystem.
214942326|NCT07154225|BEHAVIORAL|Social Prescribing|SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and Link Workers (LWs), based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have a good knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
214942327|NCT07154225|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
214942328|NCT07161427|PROCEDURE|Fu's Subcutaneous Needling therapy|Participants first assume the supine position. After routine disinfection, the Fu's subcutaneous needle is inserted parallelly into the subcutaneous loose connective tissue around the pathologically taut muscles (such as the tibialis anterior, peroneus longus, gastrocnemius, soleus, peroneus brevis, and extensor digitorum longus, etc.). After the needle is fully inserted, fix the protruding part of the hose holder onto the card slot.To minimize the participants' perception of pain, the doctor uses the index finger and ring finger to perform a smooth, gentle, and fan-shaped swinging motion in an alternating front-to-back manner.The sector angle is approximately 60°. It makes a total of round - trips 45 times within 30 seconds. The rocking motion is accompanied by Reperfusion Approach: A set of procedures consists of 20 times of rocking followed by 10 seconds of reperfusion method. Each target lesioned tense muscle requires 2 - 3 sets of the above - mentioned procedures.
214942329|NCT07161427|BEHAVIORAL|Ankle joint aids combined with exercise therapy|Participants in the combination therapy group wore ankle orthoses during their daily activities from 9:00 to 20:00 every day for a total of 2 weeks. To ensure standardization, a unified specification is selected for the ankle joint orthosis: Product number: 100159548, the 195R Super Sports Ankle Brace for Inversion/Eversion Sprains and Ligament Fixation by McDavid from the United States. During the treatment with ankle joint orthosis, complete the resistance training every day.
215074425|NCT04565444|DIETARY_SUPPLEMENT|Ketone + Protein|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
214676641|NCT03546725|DEVICE|Compression stocking|Compression stocking with length below the knee and a class two compression level (corresponding to 23-32 mmHg compression).
214676642|NCT05380297|DEVICE|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
214676643|NCT04904653|DEVICE|Hemopatch|"HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~* HEMOPATCH 27 x 27 mm~* HEMOPATCH 45 x 45 mm~* HEMOPATCH 45 x 90 mm"
215074426|NCT04565444|DIETARY_SUPPLEMENT|Protein|"* Isocaloric carbohydrate control: dextrose + stevia~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
215074427|NCT02952963|DRUG|Chenodeoxycholic Acid|
214339274|NCT03263377|DIETARY_SUPPLEMENT|The school feeding intervention|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
214339275|NCT02039505|DRUG|Vedolizumab|Vedolizumab intravenous infusion
214339276|NCT02039505|DRUG|Vedolizumab placebo|Vedolizumab placebo
214339277|NCT02832895|OTHER|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
215074428|NCT02952963|DRUG|Colesevelam|
214339278|NCT02799433|BEHAVIORAL|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
214339279|NCT02799433|BEHAVIORAL|Usual services|Control condition
214339280|NCT01800877|DRUG|Vasopressors|
214339281|NCT03697291|DEVICE|PS wire|The wiring connection used to convey ECG signal from inside the body
214339282|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a phospholipid|A shake with 3000 mg choline added as a phospholipid
214339283|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a salt|A shake with 3000 mg choline added as a salt
215074429|NCT02825420|DRUG|trabectedin|
214942330|NCT07163026|PROCEDURE|Erector Spine Plane Block|Bilateral erector spinae plane block was performed under aseptic conditions at the T7 vertebral level using ultrasound guidance with a convex probe. An 80-mm peripheral nerve block needle was inserted 3-4 cm lateral to the midline with an in-plane approach to the fascial plane deep to the erector spinae muscle. After negative aspiration and hydrodissection with 1-3 ml of saline, 30 ml of 0.25% bupivacaine was injected on each side, with craniocaudal spread confirmed by ultrasound. Patients were then positioned for surgery.
214942331|NCT07163026|PROCEDURE|External Oblique - Intercostal Plane Block|Bilateral external oblique-intercostal plane block was performed under aseptic conditions by identifying the 6th and 7th ribs along the midclavicular line. Using ultrasound guidance with the probe placed parallel to the midclavicular line, the ribs, intercostal muscles, external oblique muscle, and pleura were visualized. A 50-mm block needle was advanced craniocaudally into the plane between the external oblique and intercostal muscles. After negative aspiration and hydrodissection with 1-3 ml saline, 30 ml of 0.25% bupivacaine was injected on each side, with craniocaudal spread confirmed by ultrasound. Patients were then positioned for surgery.
214942332|NCT07163481|DRUG|Sacituzumab Govitecan + Fulvestrant|Sacituzumab Govitecan 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles Combined with Fulvestrant 500 mg intramuscularly into the buttock on Day 1 of 28-day cycles and Cycle 1 Day 15
214942333|NCT07163481|DRUG|Sacituzumab Govitecan + Anastrozole / Exemestane|Sacituzumab Govitecan 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles Combined with One of the Two Investigator's choice of aromatase inhibitors (ICAI), orally, once daily: Anastrozole 1 mg Exemestane 25 mg
214942334|NCT07166042|BEHAVIORAL|10-15 minute, Audio-Recorded Guided Mediation Practices|"The 5 mindfulness practices, all of which have been validated in prior research.~Body Scan practice will consist of how to direct non-judgmental attention to different regions of the body~The Mindful Breathing practice will consist of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations.~The Mindfulness of Discomfort practice will consist of instruction in how to zoom in to deconstruct discomfort and precisely map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences.~The Savoring practice will consist of instruction in identifying and amplifying pleasant memories.~The Loving-Kindness practice will consist of instruction in cultivating feeling of warmth and compassion toward the self and others."
214942335|NCT07158528|PROCEDURE|coronally advanced flap with connective tissue graft|The gum at the recession site is elevated and repositioned higher, combined with a connective tissue graft.
214942336|NCT07158528|PROCEDURE|tunneled coronally advanced flap with a connective tissue graft|The gum at the recession site is undermined, only partially detached, and repositioned higher, combined with a connective tissue graft.
214942337|NCT07169890|OTHER|Dextrose Phonophoresis|To apply Dextrose Phonophoresis on a patient with acne vulgaris, begin by cleansing the affected skin area thoroughly with a gentle, non-comedogenic cleanser to remove any dirt or oils. Pat the skin dry with a clean towel. Prepare a dextrose gel, a 10% dextrose gel, which is then coupled with low-frequency ultrasound to facilitate deeper penetration of the dextrose
214942338|NCT07169890|OTHER|Ultrasound|the ultrasound probe is moved in a circular motion over the skin for a duration of 5 to 10 minutes per session
214942339|NCT07169890|OTHER|Dextrose Topical application|Apply a thin layer of the dextrose gel evenly across the acne-affected areas using a sterile applicator or cotton pad
214676644|NCT04904653|OTHER|Control group|No sealant (liquid, gel or patch) + suction drain
214676645|NCT04043507|OTHER|Sample Collection|Blood and urine samples will be collected for research purposes along with the routinely collected blood and urine samples that are collected as part of the standard of care.
214676646|NCT01101568|DRUG|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
214676647|NCT01101568|DRUG|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
214676648|NCT01101568|DRUG|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
214676649|NCT05835752|DRUG|RAY1225|Administered SC
214676650|NCT05835752|DRUG|Placebo|Administered SC
214676651|NCT05835752|DRUG|RAY1225|Administered SC
214676652|NCT05835752|DRUG|Placebo|Administered SC
214676653|NCT05835752|DRUG|RAY1225|Administered SC
214676654|NCT05835752|DRUG|Placebo|Administered SC
214676655|NCT00004895|DRUG|octreotide acetate|
214339284|NCT05228613|BIOLOGICAL|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
214339285|NCT05228613|BIOLOGICAL|SARS-CoV-2 inactivated vaccine|active control manufactured by Sinovac Life Sciences Co.Ltd
214339286|NCT03752281|OTHER|Investigation of health and activity|During a six months multidisciplinary investigation of health status, activity and working ability for individuals receiving long-term social assistance, the health and activity status as well as function will be described using established questionnaires and the International Classification of Functioning
214339287|NCT00935103|BEHAVIORAL|Psychoeducation|
214676656|NCT01213433|DRUG|Artesunate-Amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
214676657|NCT01976819|DEVICE|TW speaking valve/HME|The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
214339288|NCT04007952|PROCEDURE|Anterior Gastropexy|Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
214339289|NCT05078645|DEVICE|Maya|The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy
214676658|NCT03789682|DRUG|Adjuvant chemotherapy|adjuvant chemotherapy using Gemcitabine plus Cisplatin
214676659|NCT06513767|DEVICE|Zirconia Dental Ceramics|This investigation was conducted by enrolling subjects who met the enrolment criteria, using the investigational device (Zirconia Dental Ceramics) to perform dental prosthesess.
214676660|NCT05995522|DIETARY_SUPPLEMENT|Vitamin K2|100 µg per day for 90 days
214676661|NCT05995522|OTHER|Cornstarch|500 mg per day for 90 days
214942340|NCT07160361|DRUG|Lenvatinib + losartan|"Patients will receive a combination of lenvatinib and losartan at the same time after surgery for treatment cycles once daily (lenvatinib and losartan).~Adjuvant therapy will be started within 2-6 weeks after surgery for a period of time to evaluate the effect of different treatment regimens on reducing tumor recurrence and improving survival.~lenvatinib: orally once daily according to standard dosing guidelines, starting postoperatively.~losartan: 50mg losartan potassium tablets orally once daily starting postoperatively."
215074430|NCT04734418|DRUG|Remifentanil|Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
215074431|NCT04734418|DRUG|Dexmedetomidine|Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
214676662|NCT06352216|DIAGNOSTIC_TEST|Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS)|Each subject is examined for the presence of synovitis using the aforementioned diagnostics.
214339290|NCT05979792|DRUG|CAR-T Therapy|CAR-T cell infusion
214942341|NCT07166913|BEHAVIORAL|Toolkit|The toolkit contains information regarding enhanced stakeholder engagement strategies. The toolkit includes guidance materials, checklists, and templates/ sample materials, to increase stakeholder engagement in the research. This includes guidance on setting up a stakeholder advisory board (SAB) and ensuring literacy- and language- sensitivity of participant-/stakeholder-facing materials.
214942342|NCT07166211|BIOLOGICAL|CM512 injection|subcutaneous injection
214942343|NCT07166211|DRUG|placebo|subcutaneous injection
214942344|NCT07161882|OTHER|Observational Data Collection|Collection of clinical, pathological, molecular, and treatment-related data during routine care, with no additional procedures or interventions required by the study.
214676663|NCT04366271|BIOLOGICAL|Mesenchymal cells|1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
214942345|NCT07169136|DRUG|GLP-1 Receptor Agonists|Weekly subcutaneous Semaglutide.
214339291|NCT05259449|BEHAVIORAL|Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
214339292|NCT05259449|OTHER|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
214676664|NCT04366271|DRUG|Standard of care|Best treatment option for COVID-19 according to investigator criteria
214942346|NCT07175480|DRUG|Intermittent PD-1/PD-L1 ICI + VEGFR-TKI|Any PD-1/PD-L1 inhibitor or VEGFR-TKI that is commercially marketed, regulatory-approved and reimbursed under public health plans.Dose as recommended by the manufacturer.
214942347|NCT07176325|OTHER|Creatine Monohydrate|Creatine Monohydrate was dosed based on industry recommendations, with and without a loading dose
215074432|NCT04027049|DEVICE|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
215074433|NCT00798460|DRUG|adefovir|adefovir 10mg
214676665|NCT03569423|PROCEDURE|Transepithelial photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
214676666|NCT03569423|PROCEDURE|Alcohol assisted photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
214942348|NCT07175116|DEVICE|3M™ Tegaderm™ Antimicrobial Transparent Dressing (chlorhexidine gluconate-impregnated)|Individually applied transparent dressing containing chlorhexidine gluconate (0.5-1 mg/cm²) for antimicrobial protection at the central venous catheter insertion site. The dressing maintains site visibility, reduces catheter manipulation frequency, and provides sustained release of chlorhexidine to lower colonisation and bloodstream infection risk.
214942349|NCT07175116|DEVICE|Conventional transparent polyurethane dressing|Transparent polyurethane dressing without antimicrobial impregnation, applied at the central venous catheter insertion site. This dressing allows site inspection and is widely used in standard paediatric intensive care protocols but provides no antimicrobial activity.
214942350|NCT07177014|BEHAVIORAL|Stress First Aid for Harm Reduction Workers|Stress First Aid for Harm Reduction Workers is a 2-hour training and up to six virtual 30-minute monthly learning collaborative meetings.
214942351|NCT07175519|DEVICE|Endovascular treatment of aneurysms|Aneurysm can be treated by endovascular devices using catheters, Treatment modalities can include coils, stents, flow diverters as well as intrasaccular devices
215074434|NCT00798460|DRUG|clevudine|clevudine 30mg
214942352|NCT07175636|DRUG|Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)|"QL1706 is an investigational bifunctional MabPair antibody that simultaneously targets PD-1 (IgG4) and CTLA-4 (IgG1). It is administered intravenously according to the study protocol during the neoadjuvant chemotherapy cycles. The use of QL1706 aims to enhance antitumor immunity in the pMMR/MSS rectal cancer setting, a population typically unresponsive to immune checkpoint blockade alone.~mFOLFOX6 is a standard oxaliplatin-based chemotherapy regimen composed of oxaliplatin, leucovorin, and 5-fluorouracil. It is administered in combination with QL1706 during the neoadjuvant phase as part of total neoadjuvant therapy (TNT). The regimen is modified to optimize tolerability while maintaining efficacy in locally advanced rectal cancer.~Short-course radiotherapy consists of a total dose of 25 Gy delivered in 5 fractions over one week to the pelvis. This approach is designed to rapidly downstage tumors, release tumor antigens, and prime the immune microenvironment for subsequent immunotherapy"
214339293|NCT05259449|OTHER|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
214339294|NCT00633984|BEHAVIORAL|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
214339295|NCT00633984|DRUG|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
214942353|NCT07175662|BIOLOGICAL|NWRD08 administered by electroporation|NWRD08 delivered via IM injection + electroporation using TERESA device
214942354|NCT07175662|BIOLOGICAL|Placebo administered by electroporation|Placebo delivered via IM injection + electroporation using TERESA device
214942355|NCT07177105|PROCEDURE|Cytoreductive surgery|* Preoperative evaluation must confirm resectability. Thoracoscopic minimally invasive surgery will be performed, with the surgical approach selected according to disease conditions, such as lobectomy, segmentectomy, wedge resection, or sleeve resection; ② Systematic mediastinal lymph node dissection or lymph node sampling (based on preoperative imaging and intraoperative evaluation) must be performed; ③ Postoperative recovery must be adequate (postoperative complications ≤ Clavien-Dindo grade II).
214942356|NCT07177105|DRUG|Immunochemotherapy|"1. Treatment phase:~   ① Sintilimab Dose: 200 mg, administered intravenously over 30 minutes or less;~   ② Pemetrexed Dose: 500 mg/m², administered intravenously over 10 minutes or less;~   ③ Carboplatin Dose: administered according to the area under the curve (AUC) of 5 mg/mL/min, with infusion time controlled within 15-60 minutes.~   The above regimen will be administered every 3 weeks after surgery for a total of 4 cycles.~2. Maintenance phase:~   * Sintilimab Dose: 200 mg, administered intravenously over 30 minutes or less; ② Pemetrexed Dose: 500 mg/m², administered intravenously over 10 minutes or less; The above regimen will be administered every 3 weeks. Maintenance with sintilimab will continue for up to 31 cycles, or the total duration of systemic therapy from randomization will not exceed 2 years, or until disease progression or the occurrence of unacceptable toxicity"
214942357|NCT07175324|DEVICE|optical coherence tomography angiography|correlation between OctA and Visual field changes in Multiple Sclerosis
214942358|NCT07175324|DEVICE|Visual Field Perimetry|Correlation between OctA and Visual field changes in Multiple sclerosis
214942359|NCT07177274|RADIATION|Low Level Laser Therapy|Collecting wound stiffness data using the OCT-air-jet and Myoton Pro before and after the LLLT treatment using the device's indentation system. Then the intervention is applying LLLT to the wound for 3 min. The LLLT utilized the Red Dot Laser Diode Module Class IIIA.
214942360|NCT07176117|PROCEDURE|Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA)|A single dose of surfactant will be given via Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA). A supraglottic airway device will be used as a standardized procedure for surfactant administration via SALSA using an AirLife Air-Q.
214942361|NCT07176117|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Infants to receive continuation of non-invasive respiratory support will remain on continuous positive airway pressure (CPAP).
214942362|NCT07175740|DIETARY_SUPPLEMENT|Fasting|No meal
214942363|NCT07175740|DIETARY_SUPPLEMENT|Sucrose enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, 22g sucrose
214942364|NCT07175740|DIETARY_SUPPLEMENT|Fructose enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, 22g fructose
214339296|NCT00633984|DRUG|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
214942365|NCT07175740|DIETARY_SUPPLEMENT|Fat enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, 15g fat
214942366|NCT07175740|DIETARY_SUPPLEMENT|Aspartame enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, aspartame (matched for taste)
214942367|NCT07175740|OTHER|Exercise session|A 60-minutes exercise session on a cycle ergometer (Corival 400, Quinton Instruments, Seattle, WA, USA) at 60% of the VO2peak (determined at a baseline visit)
214942368|NCT07175259|RADIATION|Echocardiography|Simple, bedsides, non invasive
214942369|NCT07176611|OTHER|Guided imagery|Participants in this group will receive the guided imagery intervention. The guided imagery audio recording will be applied in a quiet room once during the initial session, and participants will be instructed to continue the practice at home before sleep for eight weeks.
214942370|NCT07175415|DRUG|Capivasertib|Oral
214942371|NCT07175415|DRUG|Venetoclax|Oral
214339297|NCT05368597|PROCEDURE|PCI in native vessel or in bypass graft|Native vessel PCI,which choose native coronary artery as the target vessel, while the bypass graft PCI choose graft vessel as the target vessel.
214339298|NCT00003545|DRUG|nelarabine|
214942372|NCT07175415|DEVICE|Dexamethasone|oral/intravenous
214339299|NCT00618020|DEVICE|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
214942373|NCT07175415|DRUG|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
214942374|NCT07175129|PROCEDURE|Transverse Tibial Bone Transport|Tibial tibial bone transport is a novel surgical procedure that involves the gradual movement of a bone segment in order to improve perfusion and tissue healing.
214676667|NCT04854265|OTHER|Mindfulness Meditation|Mindfulness meditation will include mindfulness based stress reduction program, Qigong, Tai Chi exercise, Yoga, and Pranayama breathing exercise.
214676668|NCT04930640|DIETARY_SUPPLEMENT|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week
214676669|NCT04930640|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
214339300|NCT03569644|OTHER|qualitative study|Interviews
214339301|NCT04692246|OTHER|Plant-based oral rinse|Oral rinse enriched with plant-based essential oils.
214339302|NCT04692246|OTHER|Placebo oral rinse|Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
214339303|NCT03006666|BEHAVIORAL|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
214339304|NCT03006666|BEHAVIORAL|Data Only|The teams randomly allocated will not have access to Community Health Workers.
214339305|NCT03980847|DRUG|Alendronate 20 mg|The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
214339306|NCT03980847|PROCEDURE|Nanocrystal hydroxyapatite|Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
214339307|NCT03893513|DEVICE|Transthoracic Electrical Bioimpedance|Non-invasive hemodynamic monitor
214676670|NCT03348657|OTHER|Music Session|Three to four times a week, volunteer musicians came to the geriatric assessment unit and would provide music sessions (duration of about 60 minutes) to the patients who volunteered to attend.
214339308|NCT03893513|DEVICE|Pulse Contour Analysis|Invasive hemodynamic monitor
214339309|NCT00097591|DRUG|Prasugrel|Administered orally
214339310|NCT00097591|DRUG|Clopidogrel|Administered orally
214339311|NCT02061462|PROCEDURE|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
214676671|NCT03566537|PROCEDURE|Thyroidectomy|Thyroidectomy
214942375|NCT07175129|DEVICE|TrueLok Elevate|This device is used to move the bone segment as a part of the tibial bone transport surgery.
214942376|NCT07175649|DRUG|Methylprednisolone sodium succinate|"Intravenous methylprednisolone sodium succinate will be administered at a dose of 2 mg/kg/day for 3 days, with a maximum daily dose of 160 mg (4 vials, 40 mg/vial).~It is recommended that the initial dose be administered as soon as possible after randomization."
214339312|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #1|Vitamin K supplement : 2mg, once a day, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
214676672|NCT02505555|DEVICE|four dimensional hysterosalpingo-contrast sonography|compare accuracy and tolerability of 4D-HyCoSy with that of laparoscopy and chromotubation
214676673|NCT01289392|DEVICE|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
214676674|NCT01289392|DEVICE|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
214676675|NCT01289392|BEHAVIORAL|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
214676676|NCT02016417|DRUG|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
214942377|NCT07175649|DRUG|Placebo|Matched intravenous placebo will be administered for 3 days, with a maximum daily dose of 4 vials.
214942378|NCT07174687|DRUG|Dapagliflozin|Dapagliflozin is an SGLT2 inhibitor used in diabetes, heart failure, and chronic kidney disease patients.
214942379|NCT07174687|OTHER|Matching Placebo|Matching oral placebo to dapagliflozin
215074435|NCT00798460|DRUG|lamivudine|lamivudine 100mg
215074436|NCT02748668|OTHER|Blood specimen collection|
215074437|NCT06910761|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
215074438|NCT06910761|RADIATION|Craniospinal Irradiation|Undergo photon-VMAT-CSI
214339313|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #2|Vitamin K supplement : 7mg, twice a week, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
214339314|NCT02798848|DEVICE|Tablet computer|iPad
214339315|NCT03722875|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
214339316|NCT03722875|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor
214339317|NCT01586442|DRUG|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
214339318|NCT01586442|DRUG|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
214339319|NCT04928742|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
214339320|NCT05928221|DEVICE|Thrombectomy|removal of fresh soft emboli and thrombi from the vessels of the venous system
214339321|NCT01409694|DRUG|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
214339322|NCT01409694|DRUG|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
214339323|NCT01409694|DRUG|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
214339324|NCT00898911|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
214339325|NCT04177524|DEVICE|Background Mode|The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.
214339326|NCT04177524|DEVICE|Manual Mode|"In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button."
214339327|NCT04177524|DEVICE|Auto-Detect Mode|"In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle."
214339328|NCT06573788|BEHAVIORAL|Internet + wearble device multimodal prehabilitation|Use the Prehabilitation Learning Platform to learn what to do and follow along with the videos for follow up exercises
214339329|NCT06573788|BEHAVIORAL|traditional multimodal prehabilitation|The researchers used a prehabilitation manual to explain to subjects what they needed to do, and the patients went home and practiced on their own, recording the exercises daily
214339330|NCT06068816|DIETARY_SUPPLEMENT|Nutrient-dense drink|a nutrient-dense drink developed by FrieslandCampina in line with the European Society for Clinical Nutrition and Metabolism guidelines for the dietary management of older malnourished patients
214339331|NCT00055328|BEHAVIORAL|Problem-Solving Treatment for Primary Care|
214339332|NCT03561779|DRUG|YYD302 2ml|YYD302 2ml
214942380|NCT07176793|OTHER|Implementation mapping to develop a multilevel health system implementation strategy for prevention of type 2 diabetes through targeted breastfeeding support for patients with gestational diabetes|Conduct implementation mapping to develop a multilevel health system breastfeeding support strategy for patients with GDM at UC Davis Health in Sacramento, California, a large academic medical center. The study design for this mapping process will include five steps in this 1-year proposal: (1) conduct a needs and assets assessment and identify implementers; (2) identify implementation outcomes and determinants; (3) choose mechanisms of change and design implementation strategies; (4) produce implementation protocols and materials; and prepare for the final step, (5) evaluate implementation outcomes, by selecting outcome measures for a future trial . This disciplined and systematic approach to intervention development will directly inform my future directions: a mixed methods feasibility trial to pilot the implementation strategy developed here, followed by a full-scale randomized trial to test the strategy's effectiveness in reducing diabetes risk.
214942381|NCT07175285|DRUG|Current standard of care treatment options|According to the product label
214942382|NCT07175818|PROCEDURE|Silk suture only|After third molar extraction, the surgical wound will be closed using silk sutures without plasma application.
214339333|NCT03561779|DRUG|Active comparator: Synovian Inj.|Active comparator: Synovian Inj.
214339334|NCT04134897|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
214339335|NCT04134897|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
214339336|NCT04134897|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
214339337|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
214942383|NCT07175818|PROCEDURE|PTFE suture only|After third molar extraction, the surgical wound will be closed using PTFE sutures without plasma application.
214942384|NCT07175818|PROCEDURE|Silk Suture + Cold athmospheric Plasma|After third molar extraction, silk sutures will be exposed to cold atmospheric plasma before being used for wound closure.
214942385|NCT07175818|PROCEDURE|PTFE Suture + Cold athmospheric Plasma|After third molar extraction, the surgical wound will be closed using PTFE sutures without plasma application.
214676677|NCT02016417|DRUG|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
215074439|NCT06910761|OTHER|Electronic Health Record Review|Ancillary studies
215074440|NCT06910761|PROCEDURE|Lumbar Puncture|Undergo LP
215074441|NCT06910761|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215074442|NCT06910761|PROCEDURE|Ommaya Reservoir Tap|Undergo Ommaya reservoir tap
215074443|NCT06910761|OTHER|Questionnaire Administration|Ancillary studies
215074444|NCT06910761|RADIATION|Volume Modulated Arc Therapy|Undergo photon-VMAT-CSI
215074445|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Premeal Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for daily water intake timing and volume.
215074446|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Total Daily Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for total daily water intake.
215074447|NCT05843318|BEHAVIORAL|Water Intake and weight control in older adults - hypocaloric diet alone|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive instructions in the hypocaloric diet, without specific fluid intake recommendations.
215074450|NCT04910074|DEVICE|Low-level laser therapy|The proposed LLLT protocol will use the Biolase Epic X, an InGaAsP diode laser (940nm) using the pain relief handpiece, a device which has received FDA approval (GUDID 00647529002537) for the treatment of pain, muscle relaxation and healing via increased local circulation. The LLLT will be administered to the experimental group at 30 j/cm2. The laser will be applied extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
215074451|NCT04910074|DEVICE|Dummy LLLT|The Biolase Epic X with pain relief handpiece will be applied with no power extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
215074452|NCT05176197|OTHER|Almond|Participants will consume almonds every day for 16 weeks.
215074453|NCT05176197|OTHER|Control|Participants will consume pretzels every day for 16 weeks.
215074454|NCT00349180|DRUG|Enoxaparin sodium|
214942386|NCT07175818|PROCEDURE|Silk Suture + Cold athmospheric argon Plasma|After third molar extraction, silk sutures will be exposed to cold atmospheric argon plasma before being used for wound closure.
214942387|NCT07175818|PROCEDURE|PTFE Suture + Cold athmospheric argon Plasma|After third molar extraction, PTFE sutures will be exposed to cold atmospheric argon plasma before being used for wound closure.
214942388|NCT07175779|OTHER|Face-to-Face Preanesthesia Consultation|Participants receive a standard preoperative anesthesia consultation in person at the hospital
214942389|NCT07175779|OTHER|Telemedicine Preanestehsia Consultation|Participants receive a preoperative anesthesia consultation remotely via video conferencing using a secure telemedicine platform.
214676678|NCT02787512|DEVICE|Stent|Endoscopic biliary stent insertion
214676679|NCT00000581|PROCEDURE|leukocyte transfusions|
214676680|NCT01579539|DRUG|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
214676681|NCT01579539|DRUG|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
214339338|NCT04134897|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision
214676682|NCT05002192|DRUG|Eucalyptol, Limonene and Pinene Enteric Soft Capsule|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
214942390|NCT07176000|BEHAVIORAL|Patient Navigation|Receive tailored PN activities
214942391|NCT07176000|OTHER|Educational Intervention|Receive LCS educational handout
214942392|NCT07176000|OTHER|Best Practice|Receive enhanced usual care
214942393|NCT07176000|OTHER|Interview|Ancillary studies
214942394|NCT07176000|OTHER|Survey Administration|Ancillary studies
214942395|NCT07176000|OTHER|Electronic Health Record Review|Ancillary studies
214942396|NCT07174479|DEVICE|Augmented reality|Augmented reality markers show the surgical trainee the expert's gaze location during the kidney exploration phase of surgery.
214942397|NCT07176663|DRUG|Tirzepatide|2.5 mg weekly first month and 5 mg weekly for two month
214942398|NCT07176780|DEVICE|Semiconductor embedded body sleeve|The active device contains semiconductors embedded into the body sleeve fabric
214942399|NCT07176780|DEVICE|Placebo Non-Compressive Body Sleeve|Identical body sleeve absent of semiconductors
214942400|NCT07175051|DRUG|Empagliflozin (oral)|10 mg
214942401|NCT07175753|OTHER|chiropractic applied clinical neuroscience care|Standard chiropractic care with physiotherapy and phototherapy over two sessions
214942402|NCT07174453|DRUG|Nivolumab|Immunotherapy
214676683|NCT05002192|DRUG|Ambroxol injection|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort
214676684|NCT05002192|DRUG|Other oral mucolytic drugs|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
214676685|NCT03251014|OTHER|YSS|Intervention providing steamed whole YSS (\~265 g/day, 3 days/week) for eight weeks
214942403|NCT07174453|DRUG|Pembrolizumab|Immunotherapy
214942404|NCT07176520|DEVICE|AI-assisted rehabilitation|Receives AI-assisted rehabilitation post-discharge at home in addition to usual care
214942405|NCT07176520|OTHER|usual care only|Verbal and written discharge summary, advice, and referral to outpatient physiotherapy (if applicable)
214942406|NCT07174544|BEHAVIORAL|Mobile Self-Management Program integrated with Positive Psychology and Behavioral Activation)|The mobile self-management program consisted of a 4-week guided intervention phase followed by a 4-week self-directed period to encourage continued use. The guided phase was organized around weekly objectives: (1) experiencing positive affect, (2) identifying personal strengths, (3) applying strengths in daily life, and (4) planning a positive future. Program activities included emotional check-ins, gratitude journaling, mindfulness practice, positive behavioral tasks, and goal setting. During the self-directed phase (Weeks 5-8), participants selected from 10 recommended activities tailored to their strengths, promoting sustained engagement and self-management. The program integrated Positive Psychology and Behavioral Activation strategies to reduce stress, enhance resilience, and foster positive behavioral change.
214676686|NCT03251014|OTHER|Salmon|Intervention providing steamed salmon fillet (\~246 g/day, 3 days/week) for eight weeks
214942407|NCT07172074|DIAGNOSTIC_TEST|General Psych Trait Measure|Respondents were randomized to answer whether psychological trait questions were general or about vaccines
214942408|NCT07172074|OTHER|Vaccine-Specific Psych Trait Measures|Respondents were randomized to answer whether psychological trait questions were general or about vaccines
214942409|NCT07176871|PROCEDURE|Archwires|All patients were treated with 0.022-inch MBT brackets and sequential NiTi/HANT archwires. A 0.014 NiTi wire was placed initially, followed by monthly archwire changes if no deflection remained. Digital scans were taken from baseline (T0) to 6 months (T6) to measure alignment using Little's irregularity index. Pain was recorded at 24 hours, 3 days, and 1 week with a visual analog scale. CBCT scans before and after alignment assessed root length and alveolar bone changes, with standardized 3D superimpositions ensuring accurate comparisons.
214942410|NCT06410248|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214676687|NCT02847936|PROCEDURE|vicryl plus suture|episiotomy with triclosan-coated sutures
215074455|NCT04120883|DRUG|Hydroxychloroquine lower dose|The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
214942411|NCT06410248|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214942412|NCT06410248|OTHER|Questionnaire Administration|Ancillary studies
214942413|NCT06410248|PROCEDURE|Resection|Undergo surgical resection
214942414|NCT06410248|DRUG|Temozolomide|Given PO
214942415|NCT06410248|DRUG|Triapine|Given PO
214942416|NCT07177235|DRUG|Ketamine|Timing of ketamine initiation will differ between groups (early versus late ketamine)
214942417|NCT07177235|DRUG|Midazolam|Midazolam infusion will be initiated at the same time in both groups
214942418|NCT07174609|DEVICE|Scrambler Therapy|"Adults with chronic pancreatitis and refractory abdominal pain will receive Scrambler Therapy, a non-invasive neuromodulation device. Electrodes are placed near the painful area to deliver non-pain signals aimed at reducing pain perception. Participants will complete 5-10 daily treatment sessions, each lasting 30-40 minutes, with pain ratings collected before and after sessions and follow-up assessments over 3 months."
214676688|NCT02847936|PROCEDURE|vicryl suture|episiotomy with non antibacterial coated suture
214676689|NCT00038545|DRUG|Filgrastim SD/01|
214676690|NCT00038545|DRUG|Paclitaxel|
214676691|NCT00038545|DRUG|Topotecan|
214676692|NCT02996539|OTHER|Clinical examination and laboratory measurements|Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
214942419|NCT03947775|DRUG|9-valent HPV vaccination|Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) \[38\]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
214942420|NCT04624542|DEVICE|Electromyographic device|the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS
214942421|NCT06288542|OTHER|group d|this group will receive 1 mL/kg/h 5% Dextrose infusion, applied preoperatively during fasting until induction of anesthesia
214942422|NCT06288542|OTHER|group R|this group will receive 1 mL/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia
214942423|NCT05365919|OTHER|Family Talk Intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
214942424|NCT00001646|DRUG|Voriconazole|
214942425|NCT00001646|DRUG|Amphotericin B|
214942426|NCT00183833|DRUG|capecitabine, imatinib mesylate|Capecitabine and imatinib mesylate will both be taken by mouth twice a day
214942427|NCT06291285|DRUG|Decitabine-THU|Orally administered immediate release tablets.
214942428|NCT06291285|DRUG|Decitabine-THU|Orally administered delayed release capsules.
214942429|NCT03321461|DRUG|TMTP1|Fluorescent sites will be removed
214942430|NCT03321461|DRUG|ICG|Fluorescent sites will be removed
214942431|NCT02211092|BEHAVIORAL|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
214942432|NCT02211092|OTHER|Usual care|Access to usual community resources but no active lifestyle coaching.
214676693|NCT05406297|PROCEDURE|pressure-temperature sensor guidewire-based measurement|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire was first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
214339339|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
214942433|NCT04688398|DIETARY_SUPPLEMENT|Seal oil|Consumption of seal oil once per day (at breakfast)
214942434|NCT04688398|DIETARY_SUPPLEMENT|Control|Consumption of vegetable oil once per day (at breakfast)
214942435|NCT00577005|DRUG|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
214942436|NCT00577005|DRUG|Placebo|
214942437|NCT04647994|DIAGNOSTIC_TEST|SARS-CoV-2 serology|Serology test of SARS-CoV-2 for pregnant women
214942438|NCT00507065|DRUG|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
214942439|NCT00507065|DRUG|Placebo|
214942440|NCT04715217|BIOLOGICAL|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
214942441|NCT06292858|DRUG|IMB071703 injection|Intratumoral injection
214942442|NCT03613883|PROCEDURE|Endovascular management|"Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure"
214942443|NCT06037525|DEVICE|PowerGlide™ Pro Midline Catheter|Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease
214942444|NCT03444051|PROCEDURE|EUS-FNB with 20-gauge Procore® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle
214942445|NCT03444051|PROCEDURE|EUS-FNB with 22-gauge Acquire® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
214942446|NCT04355429|DRUG|captopril 25mg|Drug administration
214942447|NCT01984489|DRUG|Placebo|
214942448|NCT01984489|DRUG|SHR117887|
214942449|NCT00002369|DRUG|Indinavir sulfate|
214942450|NCT00002369|DRUG|Lamivudine|
214942451|NCT00002369|DRUG|Stavudine|
214942452|NCT00002369|DRUG|Zidovudine|
214339340|NCT04468295|PROCEDURE|Bonding|Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch
214942453|NCT01253668|DRUG|Brivanib alaninate|Brivanib by mouth daily at a dose of 800mg.
214942454|NCT01253668|GENETIC|Polymerase chain reaction|Undergo 1241-cG250 PET/CT imaging (correlative studies)
214339341|NCT04468295|PROCEDURE|Leveling and alignment|Leveling and alignment till 0.016 x0.022 Ni Ti
214339342|NCT04468295|PROCEDURE|Extraction|Extraction of maxillary 1st premolars
214942455|NCT01253668|OTHER|Iodine I 124 chimeric monoclonal antibody G250|Undergo 124I-cG250 PET/CT imaging (correlative studies)
214942456|NCT01253668|PROCEDURE|Positron emission tomography/computed tomography|Undergo 1241-cG250 PET/CT imaging (correlative studies)
214942457|NCT01253668|GENETIC|Protein expression analysis|Correlative studies
214942458|NCT01253668|OTHER|Immunohistochemistry|correlative studies
214339343|NCT04468295|PROCEDURE|Retraction|En-masse retraction using 0.017x0.025 TMA T loop
214339344|NCT04468295|PROCEDURE|Digital models|impression taking and digital scanning
214339345|NCT04468295|PROCEDURE|measurement|Assessment the rate of retraction for 6 months
214339346|NCT06573736|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 combines protein markers tPSA, fPSA, KLK2, PSP94 and GDF15, genetic markers and clinical data to estimate risk for clinically significant prostate cancer.
214339347|NCT05009563|RADIATION|FDG-PET/CT|whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
214942459|NCT03289325|DRUG|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation."
214676694|NCT01386580|DRUG|2B3-101|IV every 21 days
215074456|NCT04120883|DRUG|Hydroxychloroquine higher dose|"The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily."
215074457|NCT00571207|DEVICE|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
215074458|NCT00571207|BEHAVIORAL|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
215074459|NCT00164385|BEHAVIORAL|Adolescent Impact|
215074460|NCT04827797|DEVICE|balls|Birth balls to exercise
214676695|NCT01386580|DRUG|Trastuzumab|IV every 21 days
214339348|NCT01538875|DRUG|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
214942460|NCT03289325|DRUG|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation."
214942461|NCT04108988|BEHAVIORAL|InvestiDate|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
214942462|NCT04108988|OTHER|Non-Health Related Video Game|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
214942463|NCT00034346|DRUG|ABX-EGF|
214676696|NCT01386580|DRUG|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
214676697|NCT01386580|DRUG|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
214676698|NCT04347811|BEHAVIORAL|Death Cafe|Death Cafés are a specific form of debriefing that focuses on discussing death, dying, loss, and illness. Nourishment in the form of cake is provided. These sessions may allow for reflection on distressing patient events while developing a sense of community and collaboration among hospital employees.
214676699|NCT05099757|BIOLOGICAL|20 µg dose hepatitis B vaccine|one-dose, two-dose or three-dose, 20 µg per dose
214676700|NCT02418403|BEHAVIORAL|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
214339349|NCT01538875|DRUG|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
214339350|NCT00847574|BEHAVIORAL|Moderate-fat|35% of calories from fat
214339351|NCT00847574|BEHAVIORAL|Lower-fat|20% of calories from fat
214339352|NCT03571061|PROCEDURE|whole colon water immersion and sigmoid water immersion|we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
214339353|NCT05109910|PROCEDURE|Pelvic lymph node dissection|Bilateral extended pelvic lymph node dissection
214942464|NCT00034346|DRUG|paclitaxel|
214942465|NCT00034346|DRUG|carboplatin|
214676701|NCT02418403|BEHAVIORAL|Educational website|"Research-verson of the Prepare for your care website (www.prepareforyourcare.org)"
214676702|NCT01795469|DEVICE|Zoex compression garment|5-strap compression of abdomen, thighs and legs
214339354|NCT03017508|DRUG|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
214339355|NCT03017508|DRUG|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
214339356|NCT05319314|DRUG|GCC19CART|Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
214339357|NCT01557946|DRUG|citalopram|citalopram 20-40 mg daily
214339358|NCT03296189|DRUG|Levobupivacaine|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
214339359|NCT03296189|DRUG|Dexamethasone Sodium Phosphate|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
214339360|NCT03296189|DRUG|Placebos|10 mls normal saline
214339361|NCT03297879|DRUG|Exenatide or metformin hydrochloride|Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
214339362|NCT04652193|PROCEDURE|Recovery profile from general anesthesia|It includes the phases during recovery from general anesthesia: Time to spontaneous ventilation, Laryngeal Mask Airway (LMA) removal time, open eyes, and Post-Anesthesia Care Unit (PACU) discharge.
214942466|NCT05190822|OTHER|College student|Our research will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students studying in departments other than Physiotherapy and Rehabilitation at Acibadem Mehmet Ali Aydinlar University.
214942467|NCT04980651|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
214942468|NCT04980651|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
214942469|NCT03738800|DRUG|CD5789 Cream 200 µg/g|A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA
214942470|NCT03738800|DRUG|CD5789 Cream 100 µg/g|A fixed dose (determined at Visit 1) of 100 µg/g applied topically twice weekly to up to 90% BSA
214942471|NCT03738800|DRUG|CD5789 Cream Vehicle|A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
214942472|NCT02466217|OTHER|1: AID groups|Clinical and Biological investigations
214942473|NCT02466217|OTHER|2: Control groups|Clinical and Biological investigations
214942474|NCT00104819|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
214942475|NCT00104819|BIOLOGICAL|sargramostim|
214942476|NCT06519409|PROCEDURE|Open flap debridement and photodynamic therapy|
214942477|NCT03014713|DRUG|Dezocine|Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
214942478|NCT03014713|DRUG|Flubiprofen|Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
214942479|NCT03014713|DRUG|Dexmedetomidine|Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
214942480|NCT01777295|BIOLOGICAL|Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214942481|NCT01777295|BIOLOGICAL|EngerixTM-B|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214942482|NCT01777295|BIOLOGICAL|Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
214942483|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Sucrosomial® B12
214942484|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|B-SUB® B12
214942485|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Mecogen SL® B12
214942486|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Evermin® B12
214942487|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Neuromax® B12
214339363|NCT01422759|DRUG|Spironolactone|50-100 mg PO BID (X 12 weeks)
214942488|NCT00156000|DEVICE|Fetal Fibronectin|fFN test done during pregnancy
214942489|NCT00156000|DEVICE|Salivary Estriol|Salivary Estriol done during pregnancy
214942490|NCT02554318|DRUG|Rifampicin|
214942491|NCT02554318|DRUG|Isoniazid|
214942492|NCT02554318|DRUG|Pyrazinamide|
214676703|NCT02590016|DRUG|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
214676704|NCT00000289|DRUG|Ondansetron|
214676705|NCT03567291|DRUG|TEV-50717|6, 9, and 12 mg oral tablets
214676706|NCT03567291|DRUG|Placebo|Placebo comparator
214942493|NCT02554318|DRUG|Ethambutol|
214942494|NCT02554318|DIETARY_SUPPLEMENT|Fermented soybean|
214942495|NCT00033657|DRUG|cisplatin|"Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
214942496|NCT00033657|DRUG|irinotecan hydrochloride|"Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
214942497|NCT00033657|DRUG|paclitaxel|"Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles"
214942498|NCT00033657|PROCEDURE|conventional surgery|The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
214339364|NCT02639884|DEVICE|SedLine EEG|
214339365|NCT02639884|DEVICE|RRa monitoring|
214942499|NCT00033657|RADIATION|radiation therapy|The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
214942500|NCT06126094|DIETARY_SUPPLEMENT|Myrkl|The subject of the test will be supplementation with precise probiotic for hangovers (Myrkl, De Fair) in the form of one pill of 800 mg
214676707|NCT05649124|BEHAVIORAL|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4, SP6 and ST36 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
214942501|NCT06126094|DIETARY_SUPPLEMENT|dextrin|The subject of the test will be supplementation with placebo (maltodextrin) in the form of two pills (each 400 mg)
214942502|NCT05189522|DEVICE|Innova Breeze®-based roadmap|An Innova Breeze® bolus chase acquisition is realized to assess the final result of the Revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm
214942503|NCT05189522|OTHER|Control Group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
214942504|NCT00374218|DRUG|High Fructose Corn Syrup|
214942505|NCT00374218|DRUG|Sucromalt|
214942506|NCT02271724|PROCEDURE|Lumbar puncture|Lumbar puncture for spinal fluid
214942507|NCT02271724|PROCEDURE|Blood sample|Blood sample
214942508|NCT02945254|DEVICE|NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)|
214339366|NCT00145431|DRUG|torcetrapib/atorvastatin|
214339367|NCT00145431|DRUG|atorvastatin|
214942509|NCT03168490|DIETARY_SUPPLEMENT|Gluten Friendly bread|parallel study
214942510|NCT04289090|DRUG|Sevoflurane Inhalant Product|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
214942511|NCT04289090|DRUG|Propofol 10 MG/ML|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
214942512|NCT02348359|DRUG|X-82|
214942513|NCT02348359|DRUG|Anti-VEGF|
214942514|NCT02348359|DRUG|Placebo|
214942515|NCT03186859|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) surgery|RYGB operation using surgeons' standard technique
214942516|NCT03186859|PROCEDURE|Sleeve Gastrectomy (SG) surgery|SG surgery using surgeons' standard technique
214942517|NCT04060459|DRUG|Paclitaxel-binding albumin|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
214676708|NCT01103349|DRUG|BI 671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma
214339368|NCT00145431|DRUG|fenofibrate|
214339369|NCT03522662|DRUG|GSK1070806|Single 10mg/kg infusion on Day 0
214339370|NCT02185352|DRUG|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
214942518|NCT03436199|DRUG|ADS-5102, 137 mg|Oral capsules
214942519|NCT03436199|DRUG|ADS-5102, 274 mg|Oral capsules
214942520|NCT03436199|OTHER|Placebo|Oral capsules
214942521|NCT04788875|PROCEDURE|Small bite suturing Technique|Small bite suturing technique with PDS 2.0
214942522|NCT04788875|PROCEDURE|Standardised Large Bites Technique|Standardised large bite suturing technique with PDS 2.0
214339371|NCT06266221|DRUG|Prednisone 20 Mg|Oral corticosteriods
214339372|NCT06266221|DRUG|Oral Placebo|Oral placebo
214339373|NCT06266221|DRUG|Methylprednisolone 120 Mg|IV corticosteriods
214339374|NCT06266221|DRUG|IV Placebo|IV placebo
214942523|NCT03146871|DRUG|Azacitidine|Given IV or SC
214942524|NCT03146871|DRUG|Decitabine|Given IV
214339375|NCT04499157|DRUG|MEMOPTIC|Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
214339376|NCT04499157|DRUG|usual treatment of glaucoma|Patients will receive only their usual treatment of glaucoma.
214942525|NCT03146871|OTHER|Laboratory Biomarker Analysis|Correlative studies
214942526|NCT03146871|OTHER|Pharmacological Study|Correlative studies
214942527|NCT03146871|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
214942528|NCT05180955|OTHER|Digital drainage system|In the intervention group; chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data, the tube will not be clamped.
214942529|NCT05180955|OTHER|Digital drainage system + clamping trial|In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
214942530|NCT01792323|DRUG|Insulin LISPRO|Administration of 15 IU of insulin lispro over a period of 30 seconds
214942531|NCT02898558|BEHAVIORAL|Magnification hand size|Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
214942532|NCT02898558|DEVICE|magnifying lenses|
214339377|NCT05410574|BEHAVIORAL|Family-based Behavioral Weight Loss Treatment|The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts
214339378|NCT01952912|PROCEDURE|PkEP|
214339379|NCT01952912|PROCEDURE|OP|
214339380|NCT01597687|PROCEDURE|Blood collection|1 blood sample will be collected from each subject.
214339381|NCT01597687|OTHER|Data collection|Quality of Life and HE questionnaires.
214339382|NCT03736525|BEHAVIORAL|Design For Wellness (DWELL)|Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
214942533|NCT02484638|DRUG|CSL689|Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
214339383|NCT03736525|BEHAVIORAL|Wait list control group|Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
214339384|NCT05779267|DRUG|NRX-101|D-cycloserine/lurasidone fixed dose combination
214339385|NCT00993720|DRUG|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
214339386|NCT00993720|DRUG|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
214339387|NCT00993720|OTHER|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
214676709|NCT01103349|DRUG|Placebo|Patients receive placebo capsules and/or encapsulated tablets
214339388|NCT01114646|DEVICE|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
214339389|NCT01114646|DEVICE|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
214339390|NCT01381172|DEVICE|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
214339391|NCT01381172|OTHER|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
214942534|NCT02484638|DRUG|Eptacog alfa (activated)|Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
214676710|NCT01103349|DRUG|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma
214676711|NCT05058131|DIETARY_SUPPLEMENT|Dietary fibre|Dietary fibre as a powder, 24 g per day for 6 weeks
214676712|NCT05058131|DIETARY_SUPPLEMENT|Placebo compound|Maltodextrin powder, 24 g per day for 6 weeks
214676713|NCT00090285|BIOLOGICAL|(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
214339392|NCT03346668|DRUG|Topical gabapentin|topical gabapentin 6% solution
214339393|NCT00486343|DRUG|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
214339394|NCT00486343|DRUG|Placebo|Placebo tablets 2x600mg BID for 24 weeks
214339395|NCT01857544|DRUG|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
214339396|NCT04078282|BEHAVIORAL|Intervention group|see above
214339397|NCT01243450|DRUG|Tretinoin|Treatment of acne
214339398|NCT01243450|DRUG|placebo|treatment of acne
214339399|NCT06101693|DIAGNOSTIC_TEST|Plasma biomarker levels|"This study will investigate the diagnostic utility and performance of:~1. Alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity, in whom~2. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity.~3. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L~4. The prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L).~The diagnosis of heart failure will be determined according to international guidelines, when there are symptoms and/or signs of HF in association with objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures. Non-invasive testing with rest and diastolic stress echocardiography will be used to evaluate for evidence of raised filling pressures, in order to make the study procedures applicable to usual clinical practice."
214676714|NCT00090285|BIOLOGICAL|Comparator: placebo (unspecified)|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
214942535|NCT04189133|DRUG|Lutropin alfa|daily increasing dosages of lutropin alfa
214942536|NCT04189133|DRUG|Human chorionic gonadotropin|human chorionic gonadotropin increasing administration
214942537|NCT03514706|DIAGNOSTIC_TEST|volume controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
214942538|NCT03514706|DIAGNOSTIC_TEST|pressure controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
214942539|NCT03027206|OTHER|Vibration technique|Comparison of different technique
214942540|NCT03027206|OTHER|Acceleration of expiratory flow|Comparison of different technique
214942541|NCT01329588|DRUG|Monthly antibiotic|Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
214942542|NCT01329588|DRUG|Monthly placebo|Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
214942543|NCT05499078|DEVICE|SULFEX 13081.22|Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day). Severity of the nasal symptoms will be compared before and 6 days after spray use on a 7-point nasal symptoms scale basis.
214942544|NCT00432315|DRUG|Docetaxel + CDDP|"* 3 cycles chemotherapy : docetaxel + CDDP~* Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~* 3 cycles adjuvant chemotherapy docetaxel"
214942545|NCT00432315|DRUG|docetaxel + CDDP|"* 3 cycles chemotherapy: docetaxel + CDDP~* Radiochemotherapy~* 3 cycles adjuvant chemotherapy docetaxel"
214942546|NCT06125340|DRUG|Placebo|5 days of placebo to be given after 3-5 days of antibiotics
214942547|NCT06125340|DRUG|Amoxicillin|Standard-dose amoxicillin (approved by Health Canada) to be given x 5 days.
214942548|NCT04499105|DRUG|Mesenchymal Stem Cell + NaCl 0,9% 2ml|Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.
214942549|NCT00085098|BIOLOGICAL|filgrastim|Given by infusion or injection
214942550|NCT00085098|DRUG|carboplatin|Given IV over 1 hour
214942551|NCT00085098|DRUG|cisplatin|Given IV over 6 hours
214942552|NCT00085098|DRUG|cyclophosphamide|Given IV over 1 hour
214942553|NCT00085098|DRUG|etoposide|Given IV over 2 hours
214339400|NCT02769091|DRUG|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
214942554|NCT00085098|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week
214942555|NCT05416645|PROCEDURE|patients with GERD after LSG|patients with GERD after LSG
214942556|NCT04222140|COMBINATION_PRODUCT|ERIPTO Protocol|combination biologic treatment
214942557|NCT04222140|BIOLOGICAL|BMAC Only|BMAC treatment only
214942558|NCT03725501|DRUG|ALS-L1023|ALS-L1023 is an active fraction extracted from Melissa officinalis L. (Labiatae; lemon balm) leaves.
214942559|NCT03725501|DRUG|Ranibizumab|LUCENTIS® (an anti-neovascular VEGF-A inhibitor) 0.5 mg, intravitreal injection
214942560|NCT03725501|OTHER|Placebo|Control group for comparison with oral administration of ALS-L1023
214942561|NCT03515629|DRUG|REGN2810/ipi|REGN2810 plus ipilimumab
214942562|NCT03515629|DRUG|REGN2810/chemo/ipi|REGN2810 plus chemotherapy plus Ipilimumab
214942563|NCT03515629|DRUG|Pembrolizumab|Reference drug administered IV infusion
214942564|NCT01303640|DEVICE|Biolimus-eluting stent|Biolimus-eluting stent
214942565|NCT01303640|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
214942566|NCT05005689|DRUG|Fluoride mouthwash (0.05%; 225ppm).|Mouthwash
214942567|NCT05005689|DRUG|Tooth Mousse Plus|Tooth Mousse
214339401|NCT02769091|DRUG|Placebo|
214339402|NCT03060941|BEHAVIORAL|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
214339403|NCT03060941|BEHAVIORAL|Facility access|Participants will receive at 6 month membership to a local fitness facility.
214339404|NCT03060941|BEHAVIORAL|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
214339405|NCT03060941|BEHAVIORAL|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
214942568|NCT04324866|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
214942569|NCT05993026|BEHAVIORAL|Mental health course|The student course involves classroom-based teaching of eight lessons over eight weeks. The aim is to strengthen students' faith in their own abilities (self-efficacy) and ability to understand themselves and others (mentalization). In this way, students become better at entering into positive relationships and communities as well as better at handling everyday challenges both academically and socially. The student course includes teaching, exercises and training in simple tools for mastery and mentalization. The student courses in the classes are handled by staff close to the students and are based on both physical and digital material as well as an app for the students. The employees initially participate in a competency development course.
214942570|NCT01201174|OTHER|fermented papaya preparation (FPP)|Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
214942571|NCT03595865|DRUG|tafluprostin|Both patients in PACG and POAG groups will dose 1 time daily in each eye for 6months. Each eye will be preformed tafluprostin 0.0015% at 9 PM.
214942572|NCT00000448|DRUG|naltrexone|Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
214942573|NCT00000448|DRUG|Placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
214942574|NCT00002048|DRUG|Zidovudine|
214942575|NCT05155722|DRUG|BAT1308|A 21 day treatment cycle was administered every 3 weeks (Q3W) on day 1 of each cycle. Six consecutive dosing cycles are recommended for the dose escalation phase. In the extended study phase, after the end of the 6th treatment cycle, after the risk and benefit are evaluated by the investigator in combination with the clinical practice, if the subjects are still in a state of clinical benefit (including CR, PR and SD), the investigator can decide to appropriately extend the treatment of BAT1308. Until disease progression, unacceptable toxicity, withdrawal of informed consent, loss of follow-up, death, acceptance of new antitumor therapy, termination of treatment by investigator evaluation, or 12 months after initial administration, whichever is the earliest.
214942576|NCT00688922|DRUG|Pravastatin|Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
214942577|NCT01819948|DIETARY_SUPPLEMENT|PhytoMed™|
214942578|NCT01886781|DRUG|Lactobacillus plantarum 299v|two capsules of 5 X 10 \^9 c.f.u each
214942579|NCT01886781|DRUG|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
214942580|NCT01886781|OTHER|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
214942581|NCT01886781|OTHER|Wash - out period|Wash - out period following treatment phase of eight weeks
214942582|NCT03493581|PROCEDURE|BIOPSY|re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)
214942583|NCT03493581|DIAGNOSTIC_TEST|blood-sampled|"* after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),~* after 6 weeks (V2),~* after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),~* \- after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).~* after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),~* after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses)."
214942584|NCT03493581|OTHER|feces samples|If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
214339406|NCT03060941|BEHAVIORAL|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
214942585|NCT06731595|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
214942586|NCT05495217|DEVICE|Conventional Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY using Induced pneumoperitoneum.
214339407|NCT00592995|DRUG|Creatine monohydrate|10 to 30 grams daily
214339408|NCT00592995|DRUG|Placebo|10 to 30 grams daily
214339409|NCT05916508|DRUG|0.454% stannous fluoride|Brush two times daily
214339410|NCT05916508|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
214339411|NCT05916508|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
214339412|NCT04992260|BIOLOGICAL|Inactivated COVID-19 Vaccine|The inactivated COVID-19 vaccine was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
214339413|NCT04992260|BIOLOGICAL|Controlled vaccine|The placebo was manufactured by Sinovac Research\& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
214339414|NCT02011438|BEHAVIORAL|UTalk|Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
214942587|NCT05495217|DEVICE|Gasless Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY without Induced pneumoperitoneum.It mechanically elevates the abdominal wall and allows laparoscopic visualization through a single incision, providing diagnostic and therapeutic procedures.
214942588|NCT03974841|PROCEDURE|laparoscopic cornual resection|patients undergoing laparoscopic cornual resection due to cornual ectopic pregnancy
214942589|NCT05725213|DRUG|Metvix® 160 mg/g Creme|Patients are treated with Metvix creme and exposed to artificial daylight
214942590|NCT04982016|OTHER|crystal therapy|Infusion of 250ml crystal solution before anesthesia induction
214339415|NCT01734668|DEVICE|In Vitro Diagnostic device to aid in diagnosis|
214339416|NCT04601155|DEVICE|AlloSure|AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8
214339417|NCT04834323|PROCEDURE|distal mesogastric fixation after sleeve gastrectomy|Investigators performed traditional laparoscopic sleeve gastrectomy then we fixed the greater omentum \& mesocolon that were cut during gastrectomy to the remaining gstric pouch along the new greater curvature as high as possible along the stable line then we plicated the remaining staple line till angle of His. (the greater omentum \& mesocolon not reach this part of staple line) , so the remaining gastric pouch remained tension free and was returned to original position and this may prevent the axial gastric rotation
214942591|NCT04982016|OTHER|colloid therapy|Infusion of 250ml colloid solution before anesthesia induction
214942592|NCT01522235|DRUG|Double blinded IVIg|Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
214339418|NCT06047769|OTHER|Board Games|Participants will receive cognitive training in board games including Ludo, Chutes \& Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
214942593|NCT01522235|OTHER|Double blinded Placebo|Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
214942594|NCT01522235|OTHER|Single Blinded IVIg|This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
214942595|NCT00980018|DRUG|Nilotinib|Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).
214339419|NCT06055088|OTHER|Hand and foot exercise|"The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week.~Patients in the massage ball group will be given a massage ball to be used in exercises. Patients in the stress ball group will be given a stress ball to be used in exercises."
214339420|NCT00826501|PROCEDURE|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
214339421|NCT00826501|PROCEDURE|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
214339422|NCT01598480|DRUG|Flamazine|Silver sulfadiazine cream
214339423|NCT01598480|DEVICE|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
214339424|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
214942596|NCT04570163|DEVICE|Interventional therapy mainly of tricuspid regurgitation (TriClip, Cardioband)|Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).
214942597|NCT03105921|DEVICE|NanoKnife|The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
214339425|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
214339426|NCT03197220|OTHER|fish|300 gr/week fish
214942598|NCT04853108|OTHER|Remote Monitoring of COVID-19|Remote monitoring of acute COVID-19 illness included use of a Medtronic pulse oximeter, photoplethysmography (PPG), patient-reported symptoms data, static vital signs captured during the course of the clinical evaluation and various physiomarkers.
214942599|NCT00123461|DRUG|Hectorol (doxercalciferol capsules), 0.5mcg|
214942600|NCT05886998|DRUG|Heparin|Heparin sodium (Generic, 5000 IU/ml ampoules)
214942601|NCT05886998|OTHER|Normal Saline|0.9% sodium chloride solution (normal saline)
214942602|NCT06730282|DRUG|Danggui Shaoyao San (DSS)|Danggui Shaoyao San is a traditional Chinese medicine (TCM) formula used to regulate blood flow, alleviate pain, and reduce inflammation. Participants in this arm will receive DSS starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
214942603|NCT06730282|DRUG|Cuscuta Chinensis (Tu Si Zi)|Cuscuta Chinensis is a TCM formula traditionally used to nourish kidney essence and improve menstrual health. Participants in this arm will receive Tu Si Zi starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
214676715|NCT06517849|BEHAVIORAL|Monetary Incentive for Take-Up of Cognitive Behavioral Therapy|Both treatment arms will be offered a monetary incentive (in form of a retail gift card) for undergoing a certain number of CBT sessions.
214942604|NCT06730282|DRUG|Combination Therapy (DSS + Tu Si Zi)|This intervention combines Danggui Shaoyao San and Cuscuta Chinensis. Participants will receive both formulas starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
214942605|NCT06730282|DRUG|Placebo|Participants in this arm will receive a placebo that matches the appearance of the study medications. The placebo will be administered on the same schedule as the active treatments for two menstrual cycles.
214942606|NCT01621971|DRUG|inhaled milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
214942607|NCT01621971|DRUG|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
214942608|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
214676716|NCT05874986|OTHER|Resistance training|12-week resistance training intervention
214676717|NCT06038474|DRUG|Descartes-08|Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
214676718|NCT04454996|DRUG|tong-jiang granules|This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
214942609|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
214339427|NCT03197220|OTHER|walnut|18 walnut per week
214339428|NCT03197220|OTHER|fish-walnut|150 gr fish and 9 walnut per week
214339429|NCT00575588|DRUG|Metformin|open-label metformin
214339430|NCT00575588|DRUG|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
214339431|NCT00575588|DRUG|Saxagliptin|Saxagliptin 5 mg tablets
214339432|NCT05212636|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|A total of 12 sessions of rTMS (5 sessions per week for 2 weeks, follow by 1 session per week for next 2 weeks) .
214339433|NCT05885347|OTHER|360 videos|Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.
214339434|NCT05885347|OTHER|VR|Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.
214339435|NCT05885347|OTHER|AR|Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
214942610|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
214942611|NCT03442374|OTHER|Exercise|The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
214942612|NCT02802644|DRUG|Sitagliptin|Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
214339436|NCT05885347|OTHER|Control group|Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
214942613|NCT02802644|DRUG|Non DPP-4 Inhibitor|This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
214942614|NCT01944826|OTHER|Registry of patients with Tako-Tsubo cardiomyopathy|
214942615|NCT06083701|DRUG|Linperlisib in combined with Chidamide|"* Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;~* Phase 2: dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;"
214676719|NCT04454996|DRUG|Chang 'an II Recipe|This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
214942616|NCT02791646|BEHAVIORAL|Pain Coping Skills Training Full|Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
214942617|NCT02791646|BEHAVIORAL|Pain Coping Skills Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
214942618|NCT01523704|DEVICE|BIOTRONIK Home Monitoring System|Home Monitoring system transfers implantable device's data to the main server via internet.
214339437|NCT00902616|DIETARY_SUPPLEMENT|L-arginine|3gm TDS for three months
214339438|NCT00902616|DIETARY_SUPPLEMENT|Placebo Lactose powder|3gm TDS for 3 months
214339439|NCT02664428|DIETARY_SUPPLEMENT|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
214339440|NCT02664428|DIETARY_SUPPLEMENT|Control|A daily dose of about 90 gram will be given for 8 weeks
214339441|NCT00141960|DRUG|Famotidine|
214339442|NCT05896592|DIAGNOSTIC_TEST|Invasive electrophysiological study|Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
214676720|NCT04454996|DRUG|The placebo of tong-jiang granules|This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
214676721|NCT04454996|DRUG|The placebo of Chang 'an II Recipe|This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
214942619|NCT01523704|DEVICE|BIOTRONIK Home Monitoring System with In-office Follow-up|
214942620|NCT06655467|BEHAVIORAL|Routine Care|This study involves no change in clinical care and no study specific interventions for participants.
214942621|NCT06247072|DEVICE|Tonometer|measures IOP
214942622|NCT05260216|COMBINATION_PRODUCT|Comprehensive prevention and treatment|Children with low risk of caries will receive routine prevention including fluoride foam application twice a year and oral hygiene guidance. Children with middle or high risk of caries will receive fluoride varnish application twice a year and caries restorative treatment in addition to routine prevention. The risk-graded intervention is one kind of comprehensive prevention and treatment.
214942623|NCT05260216|COMBINATION_PRODUCT|Routine prevention|Routine prevention includes fluoride foam application twice a year and oral hygiene guidance.
214942624|NCT00622596|OTHER|Mobile Access|Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
214942625|NCT01985958|DEVICE|Radiation therapy|
214942626|NCT02433899|PROCEDURE|MICROSURGERY|Semilunar coronally repositioned flap performed under magnification with a surgical microscope
214942627|NCT02433899|PROCEDURE|MACROSURGERY|Semilunar coronally repositioned flap performed without magnification
214942628|NCT02433899|DRUG|Dexamethasone|8mg Dexamethasone, single dose, 1 hour before surgery
214942629|NCT02433899|DRUG|Chlorhexidine gluconate|Oral rinses with chlorhexidine gluconate, BID, for 14 days
214942630|NCT02433899|DRUG|2.0% Mepivacaine + 1:100.000 epinephrine|Regional block
214942631|NCT01832818|DEVICE|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
214942632|NCT06536088|OTHER|Walking assesment|Spatiotemporal walking assessments are performed using the Gait Analyzer app (version 0.9.95.0) on a smartphone. Participants who can walk independently without assistance walk a 25-meter path at their normal speed, with the smartphone securely attached to their body above the third lumbar vertebra using a belt. The app records gait velocity, cadence, step time, step length, and vertical center of mass for all participants.
214942633|NCT05937607|BEHAVIORAL|Hand massage|It is reported in the literature that the application should last 5-10 minutes on average to reduce acute pain, state anxiety, and provide physiological positive changes and relaxation in individuals during the procedure
214942634|NCT01672294|OTHER|Preparation and life completion|Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
214942635|NCT01672294|OTHER|Attention Control|Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
214942636|NCT00360802|BEHAVIORAL|Cognitive Behavioral Treatment|Behavioral treatment to reduce pain in chronic back pain patients
214942637|NCT00360802|BEHAVIORAL|Mindfulness Based Stress Reduction|Behavioral treatment to reduce pain in chronic back pain patients
214942638|NCT02810171|BEHAVIORAL|Cognitive Behavioral Therapy|A therapy which teaches patients coping skills to manage anxiety and gradually yet repeatedly exposes patients to anxiety-provoking thoughts and situations until the anxiety habituates/diminishes.
214942639|NCT02810171|BEHAVIORAL|Relaxation Therapy|An active control therapy with minimal effects on anxiety symptoms. If randomized to this therapy, participants will have the option to cross-over to CBT once the relaxation therapy arms has been completed.
214942640|NCT00336323|PROCEDURE|Laser Photocoagulation|Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart
214942641|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
214942642|NCT00336323|DRUG|Bevacizumab|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
214942643|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
214942644|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
214942645|NCT02548923|DRUG|Dexmedetomidine|comparison to propofol
214942646|NCT01438814|DRUG|metformin placebo|metformin placebo tablets 500mg
214942647|NCT01438814|DRUG|linagliptin placebo|linagliptin placebo tablets 5mg
214942648|NCT01438814|DRUG|metformin|metformin tablets 500mg
214942649|NCT01438814|DRUG|metformin|metformin tablets 500 mg
214942650|NCT01438814|DRUG|linagliptin|linagliptin tablets 5mg
214942651|NCT03017521|DRUG|TAS-117|TAS-117 16mg, daily
214942652|NCT01488396|DRUG|0.05%cyclosporin eye drop|use twice daily for 6 months
214942653|NCT01448863|OTHER|Culture medium metabolomic analysis|"During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile."
214942654|NCT06419010|PROCEDURE|Surgery with the use of L-PRF|The study protocol is the same as the standard surgery one but with additional use of L-PRF membranes
214942655|NCT06419010|PROCEDURE|Standard surgery|The standard surgical treatment, taking place in the operating room under general anesthesia
214942656|NCT01666210|DRUG|OTX-DP (Dexamethasone punctum plug)|Sustained and tapered release of dexamethasone from hydrogel punctum plug
214942657|NCT01666210|DRUG|Placebo Vehicle Punctum Plug|Hydrogel punctum plug without dexamethasone
214942658|NCT01715519|DRUG|Treatment (Viibryd)|
214942659|NCT01935713|DRUG|Nicotine polacrilex|Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.
214942660|NCT01935713|DRUG|Electronic Cigarette|Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.
214942661|NCT01935713|DRUG|Dissolvable Tobacco Lozenge|Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, \>2 packs per day).
215074461|NCT00984607|PROCEDURE|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
214339443|NCT05896592|DIAGNOSTIC_TEST|Extracardiac vagal stimulation|"Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia."
214339444|NCT05896592|PROCEDURE|Cardioneuroablation|CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
214942662|NCT06224036|DRUG|JDB0131|"JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
214942663|NCT06224036|DRUG|Delamanid|Delamanid is a new drug developed by Otsuka Pharmaceutical Co., Ltd. in Japan to treat multidrug resistant tuberculosis. In 2014, Delamanid was conditionally approved for marketing by the European Medicines Agency and recommended for use in adult MDR-TB patients who cannot form an effective regimen due to drug resistance or tolerance reasons. In the same year, WHO recommended that Delamanid be conditionally used for long-term treatment of adult MDR-TB. In 2016, the WHO recommended widening the age range for Delamanid to 6-17 years old. In March 2018, Delamanid was listed in China.
214942664|NCT06224036|DRUG|Ethylpyrazine rifampicide (II)|Ethylpyrazine rifampicide (II) is suitable for the first two months of intensive treatment of pulmonary tuberculosis with short-term therapy. This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol hydrochloride (C10H24N2O2 · 2HCl) per tablet.
214942665|NCT02234336|PROCEDURE|Noncontrast echocardiography|
214942666|NCT02234336|PROCEDURE|Contrast Echocardiography|
214942667|NCT02234336|PROCEDURE|Cardiac magnetic resonance imaging|
214942668|NCT03322436|DIAGNOSTIC_TEST|HeartLinc kit|Samples are collected and analyzed afterwards
214942669|NCT03593187|DRUG|Cal-1 (LVsh5/C46) drug product|Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
214942670|NCT01440387|BIOLOGICAL|FLULAVAL® QUADRIVALENT|Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups
214942671|NCT00956605|BEHAVIORAL|Computer attention training systems for children with ADHD|Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
214942672|NCT01870297|DRUG|LY3025876|Administered SQ
214942673|NCT01870297|DRUG|Placebo|Administered SQ
214942674|NCT01870297|DRUG|Liraglutide|Administered SQ
214942675|NCT02690597|OTHER|Anxiety visual analog scale|Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling
214942676|NCT03268512|OTHER|L-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
214942677|NCT03268512|OTHER|A-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
214942678|NCT04760223|BEHAVIORAL|Video intervention|a 100-second video, presenting a personal story of a boy/girl dealing with depression
214942679|NCT04128124|OTHER|processing signals of airway pressure and airway flow to calculate entropy|processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
215074462|NCT00437450|DRUG|Epoetin/Atra|
215074463|NCT02601092|PROCEDURE|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
214339445|NCT05896592|PROCEDURE|Redo cardioneuroablation|It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
214339446|NCT05896592|PROCEDURE|Implantation of the implantable loop recorder|Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
214339447|NCT05896592|DIAGNOSTIC_TEST|Pacemaker check|It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
214942680|NCT05571423|BEHAVIORAL|Medical Play|Study subject will be engage in the medical play.
214942681|NCT05571423|BEHAVIORAL|Routine Play|Study subject will be engage in the routine play (coloring exercise).
214942682|NCT04328610|PROCEDURE|LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique|Patients will receive a lymphatic-venous anastomosis at time of their required Axillary Dissection
214942683|NCT00441155|DRUG|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
214942684|NCT05855408|BIOLOGICAL|Intramuscularly administered Ad5-nCoV vaccine|This vaccine is produced by CanSino Biologics Inc.
214942685|NCT05855408|BIOLOGICAL|Aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc.
214942686|NCT05855408|BIOLOGICAL|DelNS1-2019-nCoV-RBD-OPT1|This vaccine is produced by Wantai Biopharmaceutical Company.
214942687|NCT05855408|BIOLOGICAL|SYS6006|This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
214942688|NCT04341558|OTHER|Family supplemented patient monitoring|Intervention training sessions will last 30 minutes and will be held twice a day over a period of six months. Carers will be welcome to attend as often as they wish. Carers will be given practical training to assess the following vital signs: heart rate, respiratory rate, conscious level (AVPU scale) and arterial oxygen saturation (SpO2) in accordance with trial standard operating procedures. An important component of the training package will be ensuring carers know how to wash their hands before and after contact with their patients. The study team will ensure that handwashing facilities are available on the ward for use by carers. Carers will record vital signs on a basic observation chart every 4 hours after surgery. They will compare results with colour posters displayed throughout each ward, providing guidance on how and when to notify nursing staff of abnormal vital signs.
214942689|NCT01004458|BEHAVIORAL|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
214942690|NCT01004458|OTHER|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
214942691|NCT05133258|OTHER|Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension|Micro-aspirate of middle ear fluid will be taken from participants with a Juhn Tym-Tap specimen trap following standard-of-care delivery of ciprofloxacin 0.3% and dexamethasone 0.1% suspension. Samples will be analyzed to measure antibiotic concentration in the middle ear fluid.
214942692|NCT00464555|PROCEDURE|Islet transplant|Transplantation of pancreatic islet cells
214339448|NCT05896592|DIAGNOSTIC_TEST|Implantable loop recorder check|Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
214339449|NCT05896592|DIAGNOSTIC_TEST|Holter ECG|24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
214339450|NCT05896592|DIAGNOSTIC_TEST|Anamnesis|Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
214339451|NCT03937375|BEHAVIORAL|High PEEP|Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
214339452|NCT03937375|BEHAVIORAL|Low PEEP|Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
214347387|NCT02252055|BIOLOGICAL|ATDC_Nantes|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"
214347388|NCT03431168|DRUG|Azithromycin/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
214942693|NCT00464555|DRUG|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
214942694|NCT00464555|DRUG|Basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
214942695|NCT00464555|DRUG|Lisofylline|An anti-inflammatory that may reduce the rate at which islet cells die.
214942696|NCT00464555|DRUG|Sirolimus|Maintenance immunosuppressive therapy
214942697|NCT00464555|DRUG|Tacrolimus|Maintenance immunosuppressive therapy
214942698|NCT02926417|PROCEDURE|High Density-Electroencephalogram|
214339453|NCT05634265|BEHAVIORAL|Vijana-SMART|The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
214339454|NCT01946061|DRUG|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
214339455|NCT03701477|BEHAVIORAL|Trans-diagnostic cognitive-behavioral therapy|10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
214942699|NCT04298034|DRUG|Labetalol, Nifedipine|Antihypertensive treatment that is safe and well studied in peripartum women.
214942700|NCT00337779|DRUG|Glatiramer Acetate (GA) 40 mg|Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
214942701|NCT00337779|DRUG|glatiramer acetate 20 mg|Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
215074464|NCT02601092|PROCEDURE|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
214676722|NCT06539897|BEHAVIORAL|Sexual education|These sessions of the sexual education program aim to increase women's knowledge and awareness about their own bodies. Women are informed about their own bodies, their identities, and the stages of sexual response, aiming to make the process clearer and more understandable. They will be encouraged to discover what sexuality means to them, their knowledge about sexuality will be questioned, and sexual myths, if any, will be revealed, and correct information about sexual myths will be provided to normalize sexuality. In addition, discussions will be held on the meanings of being a woman and an older woman, and women's perspectives on themselves and their self-esteem will be emphasized. In the third session, participants will be taught effective communication techniques to improve their communication skills with their partners.
214339456|NCT03701477|BEHAVIORAL|General relaxation/stress management therapeutic session|Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
214339457|NCT01506245|BEHAVIORAL|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
214339458|NCT03176394|DEVICE|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
214339459|NCT03176394|DEVICE|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
214339460|NCT00614939|DRUG|Saxagliptin|2.5 mg once daily oral dose
214339461|NCT00614939|DRUG|Placebo|Placebo
214339462|NCT01369290|DRUG|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
214339463|NCT01369290|DRUG|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
214339464|NCT01369290|DRUG|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
214339465|NCT01369290|OTHER|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
214339466|NCT01369290|DRUG|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
214676723|NCT03077178|PROCEDURE|Geriatric assessment|Geriatric assessment, questionnaire assessment
214676724|NCT00775359|DRUG|Fenofibrate 160 mg tablets|
214942702|NCT04408508|DRUG|Amoxicillin 250 MG|Low dose oral amoxicillin will be administered to patients enrolled in the study meeting the inclusion and exclusion criteria.
214942703|NCT00542100|DEVICE|PCMRI|
214942704|NCT01512459|DRUG|Venlafaxine|Venlafaxine MR Capsules 150 mg
214942705|NCT05849506|DEVICE|Touch® Prosthesis|The Touch® prosthesis is a medical device approved in Switzerland, which is an effective surgical treatment for advanced CMC I osteoarthritis.
214942706|NCT03107975|BIOLOGICAL|human amniotic epithelial cells|intrathecal injection of human amniotic epithelial cells
214942707|NCT01544192|DRUG|Gingko Biloba|2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
214942708|NCT01544192|DRUG|α-tocopherol|2x300 mg α-tocopherol
214942709|NCT01544192|DRUG|Placebo|control group did not receive oral neuroprotective agent
214942710|NCT01544192|DRUG|Antioxidant formula|2x1 tablet AOF
214942711|NCT01807468|PROCEDURE|haploidentical stem cell transplantation and NK cell therapy|
214942712|NCT03637530|OTHER|inverse ratio ventilation|during general anaesthesia in laparoscopic surgeries, this group of patients will receive inverse ratio ventilation with proper observation of hemodynamics
214942713|NCT03932929|DEVICE|Scotchbond Universal Adhesive (3M ESPE)|Adhesive system
214942714|NCT00570180|DRUG|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
214942715|NCT04283526|DRUG|MBG453|Intravenous. 600mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
214942716|NCT04283526|DRUG|NIS793|Intravenous. 2100mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
214942717|NCT04283526|DRUG|Spartalizumab|Intravenous. 300mg. Every first day of a 21-day cycle
214942718|NCT04283526|DRUG|Decitabine|Intravenous. Starting dose: 5mg/m2 (dose cap at 20mg/m2). On days 1, 2 and 3 of a 42-day cycle
214942719|NCT05775926|OTHER|Education|Nursing Care and Challenges Training for Nurses Caring for Dying Cancer Patients and Their Families was given in 4 modules and 2 days.
214942720|NCT01126866|DRUG|intensified chemotherapy (FOLFOXIRI/Bevacizumab)|intensified chemotherapy (FOLFOXIRI/Bevacizumab)
214942721|NCT00819572|BIOLOGICAL|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
214942722|NCT00819572|DRUG|Placebo|
214942723|NCT02897167|GENETIC|Retrospective study of frozen samples|Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
214942724|NCT02897167|GENETIC|Prospective study of fresh samples|Samples of serum and cells will be drawn.
214942725|NCT03717168|DRUG|Recombinant human growth hormone|All the patients received subcutaneous rHGH (0.3 IU/kg/ twice daily) for 10 days in addition to intensive care standard management.
214942726|NCT03717168|OTHER|Control|All patients will not receive growth hormone.
214942727|NCT01162122|BIOLOGICAL|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
214942728|NCT01162122|BIOLOGICAL|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
214942729|NCT00088816|DRUG|cisplatin|
214942730|NCT00088816|DRUG|tegafur-gimeracil-oteracil potassium|
214942731|NCT00088816|PROCEDURE|adjuvant therapy|
214339467|NCT06262087|BEHAVIORAL|Change of direction training|The experimental group is implemented FIFA 11+ program combined with COD training
214339468|NCT06262087|BEHAVIORAL|FIFA 11+ program|The experimental group is implemented FIFA 11+ program.
214942732|NCT00088816|PROCEDURE|conventional surgery|
214942733|NCT00088816|PROCEDURE|neoadjuvant therapy|
214942734|NCT02262416|DRUG|leuprolide|normal saline
214942735|NCT02020512|DRUG|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
214339469|NCT00000463|DRUG|lovastatin|
214942736|NCT01001806|DRUG|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
214942737|NCT01001806|DRUG|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
214339470|NCT00000463|DRUG|cholestyramine|
214339471|NCT00000463|DRUG|warfarin|
214942738|NCT01001806|DRUG|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
214942739|NCT04460131|DIAGNOSTIC_TEST|soluble ST2|Serum sST2 was measured on a monoclonal electrochemiluminescence immunoassay. Samples were exposed to two freeze cycles before analysed. Samples were exposed to two thawfreeze cycles before analysed.
214339472|NCT03901248|OTHER|No Intervention|Observational study
214339473|NCT00840970|DEVICE|non-coated Intranasal Splint|placement of non-coated intranasal splint following FESS
214339474|NCT00840970|DEVICE|Sinexus Intranasal Splint|placement of Sinexus Intranasal Splint placed following FESS
214339475|NCT00003863|GENETIC|comparative genomic hybridization|
214339476|NCT00003863|GENETIC|cytogenetic analysis|
214339477|NCT00003863|GENETIC|fluorescence in situ hybridization|
214339478|NCT00003863|GENETIC|gene rearrangement analysis|
214339479|NCT00824109|DEVICE|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
214339480|NCT03663114|DRUG|Lenvatinib|Lenvatinib capsule
214339481|NCT04620317|DIETARY_SUPPLEMENT|Synbiotic|10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
214339482|NCT04620317|DIETARY_SUPPLEMENT|Placebo|Non-active ingredients - Maltodextrins
214339483|NCT05702957|DRUG|letrozole 2.5mg-7.5mg|Tab letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
214942740|NCT05282589|OTHER|lumbopelvic manipulation and conventional therapy|"Lumbopelvic manipulation was given along with conventional physical therapy~Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes."
214942741|NCT05282589|OTHER|conventional therapy|"Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes."
214942742|NCT06009289|BEHAVIORAL|Light therapy|One hour of exposure to bright light, either by being outdoors or with a phototherapy lamp if indoor
214942743|NCT00546494|DRUG|Effexor® (Venlafaxine)|
214339484|NCT05702957|DRUG|Clomiphene Citrate 50mg-150mg|Tab clomiphene citrate 50-150mg per day for 5 days started from 2nd day of menses.
214339485|NCT03650205|DRUG|Ivabradine|Ivabradine capsule
214339486|NCT03650205|DRUG|Placebo|Placebo oral capsule.
214339487|NCT00504829|DRUG|LCP-AtorFen|40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia
214339488|NCT00504829|DRUG|atorvastatin|dyslipidemia and mixed dyslipidemia
214339489|NCT00504829|DRUG|fenofibrate|dyslipidemia and mixed dyslipidemia
214339490|NCT04939259|DEVICE|New Music Program|A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
214339491|NCT04939259|DEVICE|Standard Listening Program|A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
214339492|NCT01771003|DEVICE|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
214339493|NCT03959501|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10mg daily for 24 weeks
214339494|NCT03959501|DRUG|Sitagliptin 100mg|Sitagliptin 100mg daily for 24 weeks
214339495|NCT01854827|DRUG|Intravenous immunoglobulin (IVIG)|All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
214339496|NCT00687258|DEVICE|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
214339497|NCT02688634|DRUG|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
214339498|NCT01850160|DRUG|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
214339499|NCT01850160|DRUG|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
214339500|NCT01850160|DRUG|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
214339501|NCT01991834|PROCEDURE|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
214339502|NCT01991834|DRUG|Cefazolin|Intravenous administration of 1 g of cefazolin
214339503|NCT01991834|DRUG|Placebo|Intravenous administration of saline sterile solution
214339504|NCT03038373|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
214339505|NCT05709730|DIAGNOSTIC_TEST|HPV genotyping|"HPV genotyping of samples classified that were positive for other HPV"
214339506|NCT03789539|BIOLOGICAL|LD Universal Influenza Vaccine Uniflu|low dose Universal Influenza Vaccine Uniflu
214339507|NCT03789539|BIOLOGICAL|HD Universal Influenza Vaccine Uniflu|High dose Universal Influenza Vaccine Uniflu
214339508|NCT03789539|BIOLOGICAL|Placebo|Placebo saline
214339509|NCT02571452|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
214942744|NCT00422422|DRUG|Brivaracetam|"Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~* \~0.4 mg/kg bid for Week 1~* \~0.8 mg/kg bid for Week 2~* \~1.6 mg/kg bid for Week 3~For subjects \<8 years:~* \~0.5 mg/kg bid for Week 1~* \~1.0 mg/kg bid for Week 2~* \~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~* \~0.8 mg/kg bid for Week 4~* \~0.4 mg/kg bid for Week 5~For subjects \<8 years:~* \~1.0 mg/kg bid for Week 4~* \~0.5 mg/kg bid for Week 5"
214942745|NCT04949763|OTHER|rehabilitation|Patients underwent ususal rehabilitation treatment
214942746|NCT01758718|PROCEDURE|Eyelash line resection|Eyelash resection surgery was performed for entropion with Down's syndrome
214339510|NCT02571452|BEHAVIORAL|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
214339511|NCT05581446|DIAGNOSTIC_TEST|Visual Analogue Scale|pain type severity determination and quality of life assessment
214339512|NCT05117606|DEVICE|LYNG by Ably Medical|Comparing LYNG to traditional, standard equipment for heart rate, respiration, movement, and blood pressure.
214339513|NCT06095414|DIAGNOSTIC_TEST|MRI|MRI based assessment of tumor microenvironment in breast cancer mass
214339514|NCT00908440|BEHAVIORAL|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
214339515|NCT02268773|DRUG|Asasantin®|
214339516|NCT02268773|DRUG|Acetylsalicylic acid low dose|
214339517|NCT02268773|DRUG|Acetylsalicylic acid high dose|
214339518|NCT00499187|PROCEDURE|Blood Draws|A single whole blood sample was collected for genomic analysis.
214339519|NCT03807362|DRUG|CC-11050|CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
214339520|NCT03888573|OTHER|Stretching protocol|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms. Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
214676725|NCT03585374|COMBINATION_PRODUCT|Methoxyflurane and Penthrox inhaler|3ml of methoxyflurane vaporized through an inhaler (Penthrox). Inhalation, by regular breathing, last about 25 minutes.
214676726|NCT03585374|DRUG|Morphine|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a dose of 0.10 mg/Kg body weight. The time of infusion should be not longer than 10 minutes.
215074465|NCT05497050|BEHAVIORAL|Family education|By calling the families in the experimental group by phone; Nursing interventions for family empowerment will last for 10 weeks, they will be invited to the Family Health Center (FHC) or child metabolism polyclinic twice in this process, they will be called once a week (with 2 phone calls) for two weeks after the face-to-face training initiative in the first stage, In the second stage, at the end of the face-to-face training, they will be informed that they will be called once a week for two weeks (4 phone calls in total). The families in the experimental group will be informed that 4 weeks after the completion of the training and phone calls (at the 10th week), they will call the FHC or the pediatric metabolism polyclinic again for the application of the post-tests and that the nursing training for family empowerment will be completed.
215074466|NCT04906967|PROCEDURE|flaps|coverage of soft tissue defect around ankle
214339521|NCT00749151|BEHAVIORAL|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
215074467|NCT04080986|PROCEDURE|Double Sequential Defibrillation|Defibrillation using pad placement in anterior-posterior position
215074468|NCT04080986|PROCEDURE|Vector Change Defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.
215074469|NCT05340634|DIETARY_SUPPLEMENT|Metionac|Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
215074470|NCT05340634|DRUG|Oral contraceptive|Drospirenone 4 mg once a day
214676727|NCT03585374|DRUG|Paracetamol|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 1 g dose The time of infusion should be not longer than 10 minutes.
214676728|NCT03585374|DRUG|Ketoprofen|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
214676729|NCT03640143|OTHER|venous blood lead|data about ve,nous blood lead
214676730|NCT03666260|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block with echography
215074471|NCT02094027|BEHAVIORAL|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
214942747|NCT01635309|OTHER|Coronary CT Angiogram|pre-operative coronary CTA
214942748|NCT06073756|RADIATION|Echocardiogram|Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
214942749|NCT02928601|DRUG|Ondansetron|After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.
214942750|NCT02928601|DRUG|Saline|After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
214942751|NCT04854083|DRUG|Semaglutide, 1.34 mg/mL|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to semaglutide 1.34mg/ml (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
214942752|NCT04854083|DRUG|Placebo|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to placebo (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
214339522|NCT02816671|DEVICE|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
214676731|NCT03666260|PROCEDURE|femoral block|femoral block with echography
214676732|NCT05907967|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
214676733|NCT06068725|BEHAVIORAL|Training videos|After determining the application and control groups in the research, the purpose of the research was explained to both groups. The mobile phone usage skills of the individuals who will be included in the application group were evaluated with the Digital Literacy Scale. Training videos for 15 people each (30 minutes in total) regarding symptom management were shared on the phones of the patients/relatives in the application groups, and the patients and their relatives were informed and watched the training video. Data collection forms would be filled out before the application (Z0), on the 30th day of the application (Z1), and on the 90th day of the application (Z2).
214676734|NCT05588895|OTHER|Notification|"For patients randomized to notification, the affiliated non-EP cardiologist, if present, or if patient does not have one, the PCP will be notified and will receive an electronic health record (EHR) message notifying them of the presence of CAC (with images) and the ACC/AHA guideline recommendation to consider starting statin therapy. Simultaneously, the patient will be notified via a MyHealth message describing the presence of CAC with personalized scan images, its significance, and the recommendation that statin therapy should be considered.~For the notification arm, we will check for either statin prescription or a documented discussion in the EHR at 2 months. For those not prescribed a statin and without a documented discussion in Epic at 2 months follow-up, we will send a repeat notification to their home address and to their affiliated clinician."
214676735|NCT00002445|DRUG|IM862|
214676736|NCT02420964|OTHER|video instruction|Patient Directed Video Instruction
214676737|NCT02420964|OTHER|Nurse instruction|Nurse directed instruction
214339523|NCT01828242|BEHAVIORAL|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
214339524|NCT01828242|OTHER|Control group following conventional approach|Control group following conventional approach
214339525|NCT03955484|DIAGNOSTIC_TEST|Urinary Glycosaminoglycan|Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
214339526|NCT01984398|DRUG|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
214339527|NCT01984398|DRUG|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
214339528|NCT01984398|DRUG|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
214339529|NCT01984398|DRUG|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
214339530|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
214339531|NCT03834194|BEHAVIORAL|Lottery + Overall Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
214942753|NCT05721183|BEHAVIORAL|NOST|"The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period."
214942754|NCT06311526|OTHER|Extracorporeal Shockwave Therapy|Extracorporeal Shockwave Therapy administered to the belly of spastic muscles of the upper limb.
214339532|NCT03834194|BEHAVIORAL|Lottery + Overall Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
214339533|NCT03834194|BEHAVIORAL|Loss + Overall Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
214339534|NCT03834194|BEHAVIORAL|Loss + Overall Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
214339535|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
214339536|NCT03834194|BEHAVIORAL|Loss + Monthly Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
214339537|NCT03834194|BEHAVIORAL|Loss + Monthly Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
214339538|NCT02515019|DEVICE|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
214339539|NCT02660944|DRUG|RSLV-132|RNase-Fc fusion protein
214339540|NCT02660944|DRUG|Placebo|Saline placebo
214942755|NCT00019630|DRUG|doxorubicin HCl liposome|
214942756|NCT02454868|DRUG|Remifentanil|Remifentanil for intubation without neuromuscular blockade
214942757|NCT03313310|BEHAVIORAL|Employment Intervention|Participants will complete 4 workshop sessions in groups of 6-12. The workshop curriculum was based on the pre-existing iFOUR program, and tailored based on feedback from a Community Advisory Board (CAB), Focus Groups, and In Depth Interviews.
214942758|NCT05187559|OTHER|Standard physiotherapy|Neuromuscular exercise program with standard physiotherapy with no visual feedback
214942759|NCT05187559|DEVICE|Biodex Balance SD and Biodex Gait Trainer|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
214339541|NCT06635993|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient\&#39;s weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
214339542|NCT05134805|PROCEDURE|Bipolar hemiarthroplasty , proximal femoral nail|"* Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~* Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail)."
214339543|NCT02395354|DEVICE|Placing a self-expanding metallic stent|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center~* Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~* Clips can be placed at the distal end of the prosthesis according to the endoscopist.~* Prosthesis removal time in 4 weeks."
214339544|NCT02395354|DEVICE|A balloon dilatation|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center.~* Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~* Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~* It shall be deemed failure to expansion if required\> 2 expansions."
214942760|NCT00912106|OTHER|Synovial fluid composition and lubrication analysis|Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
214942761|NCT04786171|DIAGNOSTIC_TEST|4D X-ray Velocimetry|X-ray velocimetry uses fluoroscopy to quantify local ventilation in the lung.
214942762|NCT01052623|DRUG|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
214942763|NCT01916421|PROCEDURE|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|
214942764|NCT00926536|DEVICE|C-arm CT + DSA as needed|C-arm CT images obtained and supplemented with DSA if needed
214942765|NCT00926536|DEVICE|DSA only|DSA imaging only
214942766|NCT01385956|DRUG|SOM 230 LAR|We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
214942767|NCT01385956|DRUG|Gemcitabine|Fixed dose: 1000mg/m\^2 weekly x3 then 1 week off
214942768|NCT03029845|DRUG|Propranolol 1|Participants will take 20 mg propranolol twice a day for 2 weeks
214942769|NCT03029845|DRUG|Propranolol 2|Participants will take 10 mg propranolol twice a day for 2 weeks
214942770|NCT03029845|DRUG|Placebo|Participants will take placebo twice a day for 2 weeks
214942771|NCT05330585|DEVICE|Hearing aids|Participants will listen to stimuli in the environment while wearing hearing aids which should make the stimuli more audible. Speech in noise performance is expected to improve and PFC oxygenation is expected to be reduced in this condition.
214942772|NCT05330585|OTHER|Unaided|Participants will listen to stimuli in the environment with their hearing loss. Speech in noise performance is expected to decline and PFC oxygenation is expected to be increased in this condition.
214942773|NCT02612545|DRUG|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
214942774|NCT02612545|DRUG|Mefloquine (MQ)|ACT partner drug
214942775|NCT05610579|OTHER|Remedial exercise|Remedial exercise program will be taught by qualified physiotherapist. Patients will be practiced to the exercise 3 sets of 15 repetitions without compression. Patients will be monitored telephonically in the washout period for remain the routine activities.
214942776|NCT05610579|OTHER|Compression bandage|Multi-layered short stretch bandaging will be applied for 23 hour. Patients will be practiced to the exercise 3 sets of 15 repetitions with compression bandage. The bandage will be removed at the same time the next day. Patients will be monitored telephonically in the washout period for remain the routine activities.
214942777|NCT06618612|OTHER|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
214942778|NCT06618612|DEVICE|PuraPly AM|PuraPly Antimicrobial Wound Matrix is a 2-layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
214942779|NCT06618612|DEVICE|PuraPly XT|PuraPly Antimicrobial XT Wound Matrix is a 5- layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
214676738|NCT03520023|OTHER|Palliative Care Consult|Consult of hospital palliative care service for those meeting study inclusion criteria
214942780|NCT00449228|PROCEDURE|-preoperative education and total hip replacement|-preoperative education and total hip replacement
214339545|NCT01231698|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
214339546|NCT01231698|OTHER|control|standard treatment without strict heart rate control
214942781|NCT01637766|DRUG|Melphalan (intra-arterial infusion)|"Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.~The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.~The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.~We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts."
214942782|NCT00990665|DEVICE|CRT-D and LV lead (Quartet™ lead and Promote Q® device system)|Promote Q CRT-D and Quartet LV lead
214942783|NCT02560324|DRUG|Ramelteon|
214942784|NCT02560324|DRUG|Placebo|
214942785|NCT02656134|PROCEDURE|Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.
214942786|NCT02656134|GENETIC|Molecular analysis.|DNA analysis
214942787|NCT01953835|DRUG|GSK2586184 standard formulation|GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
214942788|NCT01953835|DRUG|Simvastatin|Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
215074472|NCT02094027|OTHER|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
215074473|NCT00777530|DRUG|Bosutinib (SKI-606)|
215074474|NCT04234087|OTHER|Additional balance and resistance training|Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
214339547|NCT00088218|DRUG|Clofarabine|1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)
214347389|NCT03431168|DRUG|Placebo/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
214942789|NCT01953835|DRUG|Rosuvastatin|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
214942790|NCT01953835|DRUG|GSK2586184 new formulation|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
214339548|NCT00088218|DRUG|Ara-C|20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
214339549|NCT01546493|RADIATION|MRI|MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.
214942791|NCT05220566|BEHAVIORAL|Reserved Therapeutic Space|The main objective of the 'Reserved Therapeutic Space' intervention is to enhance the therapeutic bond of trust, to enable the agreement of objectives and interventions in a shared manner in relation to their recovery process in the unit. The intervention is carried out through individual meetings between the nurse and the patient in a comfortable and intimate space, where there are no interruptions and which is also chosen by the person who is hospitalized. The content of the spaces must be constructed individually according to the patients' concerns at each moment of the process.
214942792|NCT04568291|OTHER|model treatment|the treatment decisions were decided by Machine Learning （ML） model in model treatment group
214942793|NCT04568291|OTHER|routine treatment|the treatment decisions were decided by multi-disciplinary team （MDT）
214942794|NCT06648187|OTHER|Early motor-cognitive integrative training (e-MCIT)|Early motor-cognitive integrative training (e-MCIT) is an approach where motor and cognitive training are conducted simultaneously. The intervention consists of 30-minute sessions, conducted 4-5 times per week, until discharging from the hospital. Both motor and cognitive training have five stages each, and their progression is independent, meaning that during training, a participant might be in the fourth stage of motor training and the second stage of cognitive training. According to hospital's policy, occupational therapy and speech therapy will be provided in schedule if needed. Motor training is derived from a previous protocol of early mobilization intervention applied to a population with SAH, which based on the ICU Mobility Scale. The activities of cognitive training target areas such as attention, orientation, language ability, memory, calculation, judgment, working memory, executive function, and daily living functions.
214942795|NCT05294159|OTHER|The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)|The Feasibility and Acceptability of Intervention Measure (FIM and AIM) are used to evaluate the feasibilit and acceptability of our implementation strategies. The FIM and AIM is a validated implementation outcome measure where higher scores indicate greater feasibility and acceptability
214942796|NCT02660879|OTHER|Written Document Educational Resource|A 2 page document with pictures discussing how to use an inhaler properly.
214942797|NCT02660879|OTHER|Online Video Education|Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
214942798|NCT01323816|OTHER|Medically directed care|There is no research directed care. Patients are treated as medically indicated.
214942799|NCT01479192|DRUG|Fenretinide|100mg (2cps/day) for 5 years
214942800|NCT01479192|OTHER|Placebo|2 cpr/day of matched placebo for 5 years
214942801|NCT03838237|DIAGNOSTIC_TEST|Cardiological evaluation|"Baseline evaluation~* FAbry STabilization indEX (FASTEX)~* 12 leads ECG~* Blood samples for microRNA, TnT HS and NT-proBNP dosages~* 2D echocardiogram~* Cardio-pulmonary test~* Contrast-enhanced CMR including:~  * Cine images~ * T2 mapping sequences~ * T1 mapping sequences before and 15' after contrast medium administration~ * Late Gadolinium Enhancement (LGE) imaging~ * Phase contrast images (LVOT, aortic flow)~Follow up evaluation~•After 18 months, the same procedures will be repeated"
214942802|NCT06516874|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy for complex presentation (TF-CBT-CP)|This TF-CBT-CP is a short-term intervention to treat outpatients. This will be carried out via videoconference.
214942803|NCT06516874|OTHER|TAU|waiting list, access to pharmacological treatment, and/or non-specialized PTSD psychotherapy sessions.
215074475|NCT01730339|DRUG|PF-06473871|Single dose administered by injection four different times
215074476|NCT01730339|DRUG|PF-06473871|Single dose administered by injection three different times
215074477|NCT03193723|PROCEDURE|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):~* Subdermic infiltration. Approximately 8 milliliters~* Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~* Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~* Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~* Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
214676739|NCT05200949|PROCEDURE|Kidney transplant|Transplant surgery of Kidney
214676740|NCT00638066|DRUG|botulinum toxin|500 units of botulinum toxin for the second arm
214676741|NCT00638066|DRUG|botulinum toxin A|250 units of botulinum toxin A once
214676742|NCT03189225|OTHER|Capillary And Venous Accuracy|Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
214676743|NCT03670082|DRUG|Lu AF35700|20 mg Lu AF35700 single oral dose
214676744|NCT03670082|DRUG|Lu AF35700 iv|100 μg \[14C\]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
214339550|NCT01546493|RADIATION|qCT|Quantitative computed tomography(QCT) scans using a CT phantom
214339551|NCT01546493|OTHER|Motion Analysis|3D motion analysis to assess hip function.
214347390|NCT00290823|DRUG|Albendazole|400 mg tablet taken orally twice daily
214339552|NCT01546493|RADIATION|PET-MRI|Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.
214339553|NCT04725994|DRUG|IDX-1197+XELOX|The dose levels will be escalated following a 3+3 dose escalation scheme.
214339554|NCT04725994|DRUG|IDX-1197+Irinotecan|The dose levels will be escalated following a 3+3 dose escalation scheme.
214339555|NCT01701375|DRUG|PD 0332991|• PD 0332991 will be given orally days 1,2,3
214339556|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
214339557|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
214339558|NCT06494735|BEHAVIORAL|MyMCT|Using the french version of the metagognitive bibliotherapy MyMCT
214339559|NCT04889092|OTHER|Blood Flow Restriction exercise|Exercise training will consist of blood flow restriction exercise. Specifically blood pressure cuff will be wrapped around the most proximal portion of the thigh and inflated to a pressure that is 80% of the pressure required to completely occlude femoral blood flow. With the cuff inflated the subject will perform a series of knee extension/flexion exercise protocol. This consists of 30 reps, 15 reps, 15 reps and 15 reps all separated by 1 minute of recovery. All reps will be performed at 30% of the subjects 1 repetition max. This will be preformed 20 times over 8 weeks.
214339560|NCT04889092|OTHER|Traditional resistance exercise|Traditional knee extension/flexion exercise will be performed. This will consist of a series of 13 reps, 12 reps, 12 reps with 1 minute recovery between each set. The resistance will be set at 60% of their 1 repetition max. This will be performed 20 times across 8 weeks.
214942804|NCT02143167|DRUG|SR-fampridine|"One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks."
214942805|NCT02143167|DRUG|Placebo|
214942806|NCT04248504|OTHER|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
214942807|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
214942808|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
214339561|NCT02877706|OTHER|no specific intervention|
214339562|NCT06003855|BEHAVIORAL|Supervised exercise therapy|Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
214347391|NCT00290823|DRUG|Dexamethasone|6mg or 8mg taken daily
214347392|NCT00290823|DRUG|Omeprazole|20 mg tablet taken orally daily
214942809|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
214676745|NCT03855254|BEHAVIORAL|communication type|Positive and negative communication types are the way that the practitioner communicates to the participant about the potential effectiveness of the osteopathic treatment. The control is a neutral communication condition.
214942810|NCT00971035|DRUG|placebo|Subcutaneous repeating dose
214942811|NCT01080391|DRUG|Dexamethasone|40 mg orally or IV on days 1, 8, 15, 22
214676746|NCT04498910|DRUG|LY3451838|Administered IV
214676747|NCT04498910|DRUG|Placebo|Administered IV
214676748|NCT06077422|DRUG|bupivacaine liposome injectable suspension|Bupivacaine liposome injectable suspension (Exparel) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
214676749|NCT06077422|DRUG|Bupivacaine Hydrochloride|Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
214942812|NCT01080391|DRUG|Lenalidomide|25 mg orally on days 1-21
214942813|NCT01080391|DRUG|Carfilzomib|20 mg/m², 27 mg/m² intravenously
214942814|NCT02877719|OTHER|Questionnaires|Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
214942815|NCT04191941|BIOLOGICAL|Novel CAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells
214942816|NCT04197895|PROCEDURE|Socket preservation with APRF|Socket preservation with APRF , A-PRF membranes were implanted into the extraction socket following tooth extraction. One entire A-PRF membrane would be placed at the base of the extraction socket and another A-PRF membrane will cover the extraction site then suturing will be done .Venous blood will be collected via venipuncture of the forearm with a butterfly needle into at least 10 mL sterile glass vacuum tube. The blood sample will be immediately centrifuged at 1,300 rpm (200 x g) for 8 minutes
214942817|NCT04197895|PROCEDURE|natural healing|after atraumatic extraction , the socket will be left for natural healing after suturing
214942818|NCT04204928|DRUG|pralsetinib (BLU-667)|Pralsetinib will be administered orally (PO) at a dose of 400 mg once daily (QD) in continuous 28 day cycles
214942819|NCT04501783|DRUG|Favipiravir|TL-FVP-t will be administered orally
214676750|NCT01849848|DRUG|SyB L-0501|The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
214676751|NCT01549847|DRUG|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
214676752|NCT01549847|DRUG|Placebo|Placebo PO BID
214339563|NCT00833924|DEVICE|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
214942820|NCT04501783|DRUG|Standard of care (SOC)|SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19
214942821|NCT04501783|DRUG|standard concomitant therapy|Standard of care according to MoH of Russian Federation recomendation for COVID-19
214942822|NCT06505161|OTHER|Dry needling|It consists in application of dry needling on active and/or latent TPs in low back multifidus muscles
214942823|NCT06505161|OTHER|Percutaneous electrolysis|It consists in the application of intratissue percutaneous electrolysis with galvanic current as a cathodic flow electrode in the low back multifidus muscles. The intervention will be guided by ultrasound equipment medically certified.
214942824|NCT03058367|DIETARY_SUPPLEMENT|IQP-AE-103 (330mg)|High dose capsules
214942825|NCT03058367|DIETARY_SUPPLEMENT|IQP-AE-103 (165mg)|Low dose capsules
214942826|NCT03058367|DIETARY_SUPPLEMENT|Placebo|Placebo identical to verum capsules
214942827|NCT01904903|DRUG|Trastuzumab|HER2 therapy
214942828|NCT01904903|DRUG|Pertuzumab|HER2 therapy
214942829|NCT01904903|DRUG|Ado Trastuzumab Emtansine|HER2 therapy
214942830|NCT00672841|DRUG|Preemptive Therapy with Anidulafungin|Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.
214942831|NCT00672841|DRUG|Empiric antifungal therapy based on physician discretion.|Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
214942832|NCT01616849|DRUG|cisplatin and 5-Fu combined with nimotuzumab|"DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week"
214942833|NCT03578146|COMBINATION_PRODUCT|PRT064445/Rivaroxaban|
214942834|NCT03578146|COMBINATION_PRODUCT|Placebo/Rivaroxaban|
214676753|NCT01070303|BIOLOGICAL|Adalimumab 40 mg eow or ew|Adalimumab 40 mg by subcutaneous injection every other week or every week
214676754|NCT02584569|DRUG|TAK-915|TAK-915 oral suspension
214942835|NCT03578146|DRUG|Placebo|
214942836|NCT04164823|DEVICE|Medical taping|For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
214942837|NCT04164823|DRUG|Analgesic self-medication (OTC)|Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
214942838|NCT03138200|BIOLOGICAL|Blood transfusion|Blood transfusion is a safe, routine procedure in which blood is given to a patient through an intravenous cannula inserted into one of the patient's veins.
214942839|NCT02453854|BEHAVIORAL|Group motivational interviewing|Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
214942840|NCT06143254|BEHAVIORAL|Infant sign training|Training session 1: Information is given about what infant signs are, how they originated, how speech and (gestural) language develop in young children with CP ± L, the possible advantages of using infant signs and tips for success. Twelve signs are chosen to start with: six narrative signs (mostly object concepts) and six steering signs (mostly non-object concepts). Training session 2: Experiences with using infant signs at home are shared, repetition of the 12 infant signs and tips for success are discussed. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Reading aloud while using infant signs is shown and practiced.
215074478|NCT03193723|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
215074479|NCT05708781|OTHER|Core strengthening exercise|"1. Isolated lumbar stabilization muscle training:~2. Bridge track:~3. Dead bug track:~4. Quadruped Track:~5. Supine Track:~6. Side-support Track:~7. Prone Track:~8. Standing Track:"
214339564|NCT03208738|BEHAVIORAL|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
214339565|NCT03208738|BEHAVIORAL|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
214339566|NCT02176733|DRUG|cyclosporine|
214942841|NCT06143254|BEHAVIORAL|Verbal training|Training session 1: Information is given about how speech and language develop in young children with CP ± L and how caregivers can support their child during this development Tips for success and suggestions on how to use these supportive verbal techniques at home are discussed. Training session 2: Experiences with using supportive verbal techniques at home are shared and supportive verbal techniques repeated. Information is provided about how children learn new words and tips for success are expanded. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Additionally, advances of reading aloud are discussed and reading aloud is practiced.
214942842|NCT04148859|PROCEDURE|amnioreduction|The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate.
214942843|NCT04294251|DRUG|DWP450|Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
214339567|NCT01485861|DRUG|Abiraterone|Orally once daily
214339568|NCT01485861|DRUG|Apitolisib|Orally once daily
214339569|NCT01485861|DRUG|Ipatasertib|Orally once daily
214339570|NCT01485861|DRUG|Placebo|Orally once daily
214339571|NCT01485861|DRUG|Prednisone|Orally bid
214942844|NCT04294251|DRUG|Placebo|Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
214676755|NCT06012604|BIOLOGICAL|allogeneic mesenchymal stromal stem cells|mesenchymal stromal stem cells injection under ultrasound guidance into parotid and submandibular glands
214339572|NCT01485861|DRUG|Prednisolone|Orally bid
214339573|NCT04002674|DRUG|Placebo oral capsule|"Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
214339574|NCT04002674|DRUG|Nilotinib Oral Capsule|Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
214339575|NCT00434096|DRUG|rimonabant (SR141716)|oral administration once daily
214339576|NCT00434096|DRUG|placebo|oral administration once daily
214339577|NCT02354638|BEHAVIORAL|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
214339578|NCT02354638|DRUG|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
214339579|NCT04328493|DRUG|Chloroquine phosphate|"Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days"
214339580|NCT05337878|DRUG|Placebo|Pelacarsen-matching placebo administered by SC injection.
214339581|NCT05337878|DRUG|Pelacarsen|Pelacarsen administered by SC injection.
214339582|NCT01006811|DIETARY_SUPPLEMENT|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
214676756|NCT00259259|BEHAVIORAL|SALATRIM|
214676757|NCT03121352|DRUG|Carboplatin|AUC 4.5 IV day 1 of 21-day cycle
214339583|NCT01006811|OTHER|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
214339584|NCT01734226|DIETARY_SUPPLEMENT|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
214339585|NCT01734226|DIETARY_SUPPLEMENT|Placebo|Placebo (3.94g/day)
214339586|NCT05613439|PROCEDURE|Day-surgery|Standard surgical procedure but with planned discharge on day of surgery
214339587|NCT05613439|PROCEDURE|High-risk patient|Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.
214339588|NCT05613439|PROCEDURE|Main Group|Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
214339589|NCT02928341|OTHER|Improved water supply|
214347393|NCT00809757|DRUG|Levalbuterol|90 ug Levalbuterol (2 actuations)
214676758|NCT03121352|DRUG|Nab-paclitaxel|75mg/m2 IV days 1, 8 and 15 of 21-day cycle
214676759|NCT03121352|DRUG|Pembrolizumab|200 mg IV every 21 days
214676760|NCT06469658|OTHER|The standard practice dietary supplements intervention|Participants receive supplements prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
214339590|NCT05145920|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 5 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
214942845|NCT01909726|OTHER|ScreenPlay|Interactive technology
214942846|NCT01717391|DRUG|fluorothymidine F 18|A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
214942847|NCT04251962|DRUG|Bupivacaine|epidural solution containing bupivacaine 0.1% in normal saline
214942848|NCT04251962|DRUG|Fentanyl|Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
214942849|NCT02561741|DRUG|COV155|COV155 tablets
214942850|NCT01731769|PROCEDURE|vacuum assisted closure in experimental arm|
214942851|NCT01731769|PROCEDURE|Axillary dissection|
214942852|NCT05559424|DIAGNOSTIC_TEST|OCT|OCT will be used to assess results after intervention
214942853|NCT04172857|PROCEDURE|anterior vitrectomy combined with hyaloidotomy, zonulectomy and iridectomy|First, a 23-G incision was made at the peripheral inferior temporal sector of the cornea and connected with an anterior chamber infusion cannula. Another corneal incision was made at the superior temporal sector or superior nasal sector, and Viscoat® (Bausch \& Lomb, Shandong, China) was infused though the incision to fill the anterior chamber. Iridotomy was performed through the incision using Wescott scissors and toothed forceps. Hyaloidectomy and zonulectomy were performed through a peripheral iris defect using an anterior chamber approach to set up a pathway between the anterior chamber and the vitreous cavity. We repeatedly carried out vitrectomy around the pathway to reduce the risk of postoperative re-obstruction of the tunnel created.
214942854|NCT04338243|DRUG|Glumetinib|Phase Ib is a dose escalation study, the initial dose of Glumetinib is 300mg, then will be escalated to 400mg，according to the result of Phase Ib， will confirm the RP2D
214942855|NCT04201678|PROCEDURE|CLIA Group (conventional local anesthesia infiltration)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
214339591|NCT00466323|BEHAVIORAL|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
214339592|NCT00466323|BEHAVIORAL|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
214339593|NCT05349669|DRUG|Jafron use during CPB|Use of filter Jafron during CPB
214942856|NCT04201678|PROCEDURE|EPIAA Group (Extrapedicular infiltration anesthesia)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
214942857|NCT04201678|PROCEDURE|ESP Group (Erector Spina Block)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
214942858|NCT03677934|DRUG|PDS Implant filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
214942859|NCT03677934|DRUG|Intravitreal Injections of 10 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
214942860|NCT04192656|DEVICE|non-invasive positive airway pressure|non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea
214339594|NCT01603550|OTHER|Sleep Deprivation|Sleep Deprivation
214339595|NCT01603550|OTHER|Energy Restriction|Energy Restriction
214339596|NCT03269591|DEVICE|Pulsed electromagnetic field|EASY Qs portable (by ASA, Italy)
214339597|NCT03269591|DRUG|diclofenac tablets|drugs
214339598|NCT03269591|DIAGNOSTIC_TEST|Visual analogue scale|a graphic rating scale
214339599|NCT03269591|DIAGNOSTIC_TEST|Progesterone blood level|blood test
214339600|NCT03269591|DIAGNOSTIC_TEST|Menstrual symptom questionnaire|questionnaire
214339601|NCT01144338|DRUG|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
214339602|NCT01144338|DRUG|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
214339603|NCT06043414|DEVICE|triclosan-coated barbed suture|STRATAFIX™ Symmetric PDS™ (Johnson \& Johnson) triclosan-coated polydioxanone barbed suture caliber 0 or 1 will be the standardized suture used for abdominal fascial closure in patients randomized to the treatment group. STRATAFIX™ Symmetric PDS™ is an FDA approved sterile, synthetic, absorbable, barbed triclosan-coated polydioxanone suture. Its indications for use include soft tissue approximation where absorbable suture is appropriate.
214347394|NCT00809757|DRUG|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
214347395|NCT00809757|DRUG|Placebo|Placebo (2 actuations)
214942861|NCT04192656|DRUG|Methylprednisolone Hemisuccinate|Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
214339604|NCT06043414|DEVICE|triclosan-coated non-barbed suture|PDS™ Plus (Johnson \& Johnson) non-barbed triclosan-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ Plus is an FDA approved sterile, synthetic, absorbable, triclosan-coated surgical monofilament suture prepared from the polyester, poly(p-dioxanone). Its indications for use include soft tissue approximation where absorbable suture is appropriate.
214339605|NCT06043414|DEVICE|Non-coated non-barbed suture|PDS™ II (Johnson \& Johnson) non-barbed non-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ II is a FDA approved sterile, synthetic, absorbable, surgical monofilament suture prepared from the polyester, polyester, poly(p-dioxanone) indicated for use in soft tissue approximation where absorbable suture is appropriate.
214339606|NCT00079105|BIOLOGICAL|bleomycin sulfate|Treatment
214339607|NCT00079105|DRUG|cyclophosphamide|Treatment
214339608|NCT00079105|DRUG|etoposide|Treatment
214339609|NCT00079105|DRUG|mitoxantrone hydrochloride|Treatment
214339610|NCT00079105|DRUG|prednisolone|Treatment
214339611|NCT00079105|DRUG|procarbazine hydrochloride|Treatment
214339612|NCT00079105|DRUG|vinblastine sulfate|Treatment
214339613|NCT04819685|DRUG|KANG FU PEN|FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
214339614|NCT05622591|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
214339615|NCT04796610|BEHAVIORAL|Mopati|The intervention will provide training to health care providers on how to guide unsuppressed HIV patients in the selection of treatment partners. The Mopati program will provide education to patients and their treatment partners about HIV treatment and how treatment partners can support patients in treatment adherence.
214339616|NCT03036514|DEVICE|Sublingual sufentanil tablet system|Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
214942862|NCT04192656|DRUG|Ginaton|ginnaton is ginkgo biloba extract
214942863|NCT00003734|DRUG|flutamide|
214942864|NCT00003734|DRUG|triptorelin|
214942865|NCT00003734|RADIATION|radiation therapy|
214942866|NCT02461797|OTHER|healthy controls|biopsy of nasal mucosa for healthy controls
214942867|NCT02461797|OTHER|AR patients without medication|biopsy of nasal mucosa for allergic rhinitis patients without allergy medication
214942868|NCT02461797|OTHER|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
214942869|NCT03583905|DRUG|CKD-330|CKD-330 Tab.
214942870|NCT03583905|DRUG|Placebo of CKD-330|Placebo of CKD-330 Tab.
214942871|NCT03583905|DRUG|D086|D086 Tab.
214942872|NCT03583905|DRUG|Placebo of D086|Placebo of D086 Tab.
214942873|NCT03583905|DRUG|D723|D723 Tab.
214942874|NCT03583905|DRUG|Placebo of D723|Placebo of D723 Tab.
214942875|NCT04604405|RADIATION|photobiomodulation|650nm low energy red light eye irradiation
214942876|NCT06354205|DIAGNOSTIC_TEST|Sliva Procalcitonin|Sliva Procalcitonin vs Blood procalcitonin
214942877|NCT05509686|DEVICE|Intermittent theta burst stimulation (iTBS)|A single-session standard 600-pulse intermittent theta burst stimulation (iTBS) is applied to the ipsilesional primary motor cortex.
214942878|NCT05509686|DEVICE|Sham intermittent theta burst stimulation (iTBS)|The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp. Electrical field simulation shows that the setups for sham stimulation would not induce any valid cortical activation.
214942879|NCT06516185|DEVICE|direct-printed aligner|Patients will be treated with direct-printed aligners until dental alignment is achieved.
214942880|NCT06516185|DEVICE|thermoformed aligner|Patients will be treated with thermoformed aligners until dental alignment is achieved.
214942881|NCT00519792|DRUG|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
214942882|NCT06228833|DEVICE|monopolar radiofrequency|Each subject underwent monopolar radiofrequency treatment (Thermage FLX ™ ) on both sides of the face
214942883|NCT06228833|OTHER|SkinCeuticals A.G.E and Skinceuticals CE FERULIC|Test Side receives SkinCeuticals A.G.E and Skinceuticals CE FERULIC
214339617|NCT03036514|DRUG|Patient-controlled intravenous analgesia|Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
214339618|NCT04331080|DRUG|Granexin® gel 100 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
214339619|NCT04331080|DRUG|Granexin® gel 200 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
214339620|NCT04331080|DRUG|Vehicle gel|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
214339621|NCT02344186|DRUG|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
214339622|NCT00648869|DRUG|metformin tablet, metformin gum|500 mg, 250 mg
214942884|NCT06228833|OTHER|Standard Cream|Control Side applies Standard Cream
214942885|NCT04810559|DEVICE|OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test|OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in oral fluid and fingerstick blood conducted by untrained healthcare providers compared to laboratory 4th generation Ag/Ab EIA results performed on venous blood.
214942886|NCT01825239|OTHER|Collection of measurements during LV pacing during electrophysiology study|During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
214942887|NCT05213026|PROCEDURE|Regenerative endodontics|Regenerative endodontic procedure with 3 Mix-MP
214942888|NCT03825185|PROCEDURE|Transcervical Thymectomy|Transcervical Thymectomy. All transcervical thymectomies were performed with an 8 cm transversal cervicotomy was performed approximately 2 cm above the sternal notch. Musculocutaneous flaps were developed up to the thyroid cartilage and the suprasternal notch. Strap muscles were split in the middle and retracted laterally. The upper horns of the thymus were exposed and were freed up to the level of the innominate vein. All tributary veins were suture ligated. A sternal retractor was then placed to retract the sternum upward until the patient was nearly lifted off the table. The rest of the Thymus was dissected, from the pericardium and the pleura. Care was specially taken to remove as much fatty tissue adjacent to the thymus as possible preserving the phrenic nerves.
215074480|NCT05708781|OTHER|intensive dynamic back exercise|"1. Trunk lifting Prone on a couch, hips at the edge, upper part of the body free but supported by the hands against the floor. Strap fixation over the calves. With hands on the forehead, the trunk is lifted to the greatest possible extension in hips and spine. If necessary, starting with support from physical therapist. During pauses a chair in front of the couch supports the patient.~2. Leg lifting Standing by the end of the couch, leaning over to a prone position with the hips against the edge in 90 degree flexion, knees 45 degree and feet on the floor. Strap fixation over the chest. Straps around knees to keep legs together. Both legs are straightened and lifted to the greatest possible extension in hips and spine. Again support from physical therapist is necessary.~3. Pull to neck Sitting on a tool with the arms straight and abducted over the head and hands grasping a weight lever. Against sub-maximal resistance the lever is pulled behind neck and shoulders."
214676761|NCT06469658|OTHER|The AI-guided practice dietary supplements group|Participants receive DS prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
214676762|NCT00602862|DRUG|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
215074481|NCT05708781|OTHER|Control group|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.
214942889|NCT03825185|PROCEDURE|Transsternal Thymectomy|Transsternal Thymectomy. A standard formal median sternotomy was carried out. The sternum was retracted laterally using an automatic retractor. All thymic tissue with the adjacent adipose tissue was removed starting with the inferior horns of the thymus. Thymic vessels were ligated and dissection was continued until the upper horns could be separated from the thyroid. A mediastinal tube was placed before closing the sternum and was kept in close suction for 2 to 3 days.
214942890|NCT01260584|DRUG|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
214942891|NCT01260584|DRUG|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
214942892|NCT05489042|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|5 Sessions of rTMS - brief single pulse TMS or short TMS pulse bursts consisting of 2-5 pulses delivered per second at a standard intensity. If a brief single pulse TMS is applied, a standard single pulse TMS procedure will be used - This procedure consists of 10 trains of 180 seconds duration and each train will be separated by at least 30 seconds. If short TMS pulse bursts are applied, a standard theta-burst TMS procedure will be used - This procedure consists of TMS triplets (i.e., 3 pulses) that repeat for 10 trains of a total duration of 40-190 seconds and these bursts will be separated by at least 6 seconds and each train will be separated by at least 30 seconds
214942893|NCT05489042|DEVICE|sham rTMS|5 sessions of sham rTMS
215074482|NCT06489990|COMBINATION_PRODUCT|combination intervention strategy of [Comorbidity-Co-causes-Joint-prevention]|combination intervention strategy of \[Comorbidity-Co-causes-Joint-prevention\]
214339623|NCT00491790|DRUG|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
214339624|NCT00491790|OTHER|Sterile water|Sterile water
214339625|NCT03565406|DRUG|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
214339626|NCT03565406|DRUG|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
214339627|NCT02304237|DRUG|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
214347396|NCT01053858|PROCEDURE|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
214339628|NCT02304237|DRUG|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
214339629|NCT02648087|DEVICE|With and without SDB|Screening of sleep-disordered breathing (SDB)
214339630|NCT01950143|DIETARY_SUPPLEMENT|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
214942896|NCT06977269|DEVICE|High-frequency repetitive transcranial magnetic stimulation|High-frequency repetitive transcranial magnetic stimulation targeting the primary motor cortex (M1) of the limbs, delivered at a frequency above 5 Hz and an intensity of 90-100% of the resting motor threshold, across 10 sessions with up to 2400 stimuli per session, is a standard intervention used in various neurological disorders. However, its effects have not been studied in patients with spinal muscular atrophy (SMA).
214942897|NCT06977269|DIAGNOSTIC_TEST|lumbar puncture|Cerebrospinal fluid sampling to measure SMN protein and neurofilament concentrations before and after the TMS intervention.
214942898|NCT06601296|DRUG|IMSA101|"All enrolled patients to undergo the following treatment:~SOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: five intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C1D8, C1D15, C2D1, C3D1)"
214942899|NCT06660108|GENETIC|blood draw|Multiple blood draw for genomic and transcriptomic investigations
214942900|NCT02874885|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
214942901|NCT03295552|DRUG|Decitabine|decitabine 7mg/m2, d1-d5, q3w
214942902|NCT03295552|DRUG|Carboplatin|carboplatin AUC = 6, d6, q3w
214942903|NCT06648005|PROCEDURE|the spinal manipulative therapy combined brace|Besides bracing, the SMTB group was treated with spinal manipulative therapy. If discomfort occurs, we will stop the treatment immediately. Spinal manipulation is performed twice a week. Two doctors with 10 years of clinical experience will perform all examinations and manipulations. Intensive training was given to the physiotherapists in spinal manipulation. The doctors took the medical history of all participants and performed a clinical examination.
214942904|NCT06648005|OTHER|brace|Subjects were requested to wear orthosis 23 hrs/d and 1 hr for personal hygiene and exercise activities. The subjects were treated for 12 months. In addition, interview for compliance was launched when the subjects came to the scoliosis clinic for follow-up visits.
214339631|NCT01950143|DIETARY_SUPPLEMENT|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
215074483|NCT06489990|COMBINATION_PRODUCT|routine health education and mental health knowledge|routine health education and mental health knowledge
215074484|NCT04594265|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
214339632|NCT01950143|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
214339633|NCT06202885|DRUG|Immunotherapy|Immunotherapy
214339634|NCT02059148|DRUG|LY2835219|Administered orally.
214339635|NCT01320163|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
214339636|NCT01320163|DEVICE|Laryngeal Mask Airway|supra-glottic airway device
214339637|NCT02157558|DRUG|Fexofenadine|All subjects will receive 180 mg fexofenadine
214339638|NCT02157558|DRUG|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
214339639|NCT01714024|DEVICE|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
214339640|NCT01714024|DEVICE|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
214339641|NCT06460194|DRUG|Botuinum toxin|Injection of botulinum toxin in the palm of the hand
214339642|NCT01048138|DRUG|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
214339643|NCT01048138|DRUG|Placebo|5mg IV(in the vein)every 6 hours for 10 days
214339644|NCT00185029|PROCEDURE|Ferumoxtran-10 enhanced MRI (MRL)|
214339645|NCT00490425|DRUG|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
214339646|NCT00403546|DRUG|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
215074485|NCT04594265|DIETARY_SUPPLEMENT|Science in Sport Go Enegy|Dosis isocaloric to the KetoneAid Arm
215074486|NCT01888731|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
215074487|NCT01145352|DRUG|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
215074488|NCT02346331|OTHER|WHO algorithm of fluid boluses guided by physical examination|
214339647|NCT00403546|DRUG|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
214339648|NCT00403546|DRUG|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
214676763|NCT00602862|DRUG|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
215074489|NCT02346331|OTHER|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
214676764|NCT00602862|DRUG|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
214676765|NCT02926573|DRUG|Gabapentin|
214676766|NCT02926573|DRUG|Placebo|
214676767|NCT02875210|PROCEDURE|Laximeter measurement|
214676768|NCT04995744|PROCEDURE|Pectoralis Major Pedicle Bone Graft|It is aimed to restore the integrity of the medial cortex with the bone pedicle from the insertion region of the pectoralis major muscle in middle-aged patients with Neer type 4 proximal humerus fractures. Researchers aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method. The investigators aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method.
215074490|NCT02346331|OTHER|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
214339649|NCT05859347|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
214942905|NCT00787098|OTHER|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
214942906|NCT02784522|DEVICE|locking compression plate group|Closed reduction via shoulder lateral approach followed by locking compression plate fixation using minimally invasive technique
215074491|NCT02346331|OTHER|Oxygen delivery|
214339650|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
214339651|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
214339652|NCT02580526|PROCEDURE|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
214339653|NCT02580526|PROCEDURE|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
214676769|NCT03667677|DRUG|Tandospirone + Amlodipine|The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
214942907|NCT02784522|DEVICE|conventional locking plate group|Closed reduction via shoulder lateral approach followed by conventional locking plate fixation using minimally invasive technique
214942908|NCT02991417|BIOLOGICAL|CDVAX|
214942909|NCT00690300|DRUG|Docetaxel|75 mg/m2 IV on day 1 of each 22 day cycle
214942910|NCT00690300|DRUG|Oxaliplatin|80 mg/m2 IV on day 2 of each 22 day cycle
215074492|NCT02346331|OTHER|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
214676770|NCT03667677|DRUG|Tandospirone placebo + Amlodipine|The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
214676771|NCT03667677|DRUG|Tandospirone + Amlodipine placebo|The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
214676772|NCT03667677|DRUG|Tandospirone placebo + Amlodipine placebo|The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
214676773|NCT02221427|OTHER|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
214676774|NCT02221427|OTHER|Static labour progression curve (F)|
214676775|NCT03340441|DEVICE|Prizma|sensor unit with mobile application installed on smartphone
215074493|NCT02346331|OTHER|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
215074494|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-6 months|Modification of behaviours achieved with reframing thoughts and impulses
215074495|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-12 months|Modification of behaviours achieved with reframing thoughts and impulses
215074496|NCT04484896|OTHER|Gain-framed SMS message|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
214339654|NCT02388321|DRUG|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
214676776|NCT05196932|DEVICE|Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies|"A drop of blood obtained by both finger-prick and venipuncture will be placed on the test card, which has been activated by the addition of diluent. Visual clumping of red blood cells (RBCs) will be seen within minutes if SARS-CoV-2 antibodies are present. Additionally, the COVID card is semi-quantitative, meaning that the yielded hemagglutination pattern will correlate with the concentration of antibodies in the serum.~A research team member will be present at bedside to provide their interpretation based on an established visual agglutination scoring system."
214676777|NCT03340077|OTHER|Medicines Optimisation Review toolkit|The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.
214676778|NCT03340077|OTHER|Standard of Care|Pharmacist review of ART medications
214676779|NCT03081325|PROCEDURE|low-dose lymphocyte immunotherapy|Peripheral venous blood (PBMCs) was drawn from the husbands of uRM and RIF patients and then the PBMCs were resuspended and administered intradermally to uRM and RIF patients 3 times at 3-week intervals. Once conceived, the uRM and RIF patients undergo 2 rounds of treatment at 8-week intervals.
214942911|NCT06475885|OTHER|Infant Massage Program|The experimental group received the International Association of Infant Massage (IAIM) Infant Massage Program starting from day 14 postpartum for a duration of 5 weeks.
214942912|NCT02624388|DRUG|Genistein|Estrogen-like compound (isoflavone) derived from soybeans
214942913|NCT02624388|DRUG|Placebo|Pill that contains no medicine
214942914|NCT00618241|DRUG|lamotrigine|100 mg
214942915|NCT00618241|DRUG|Raltegravir|400 mg BD
214942916|NCT04101032|BEHAVIORAL|eBEfree|Contextual interventions based on promoting acceptance,mindfulness and self-compassion abilities
214942917|NCT00932451|DRUG|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
214942918|NCT01718145|DRUG|Daclatasvir|
214942919|NCT01718145|DRUG|Asunaprevir|
214942920|NCT01718145|DRUG|Ribavirin|
214942921|NCT01718145|BIOLOGICAL|pegIFNα-2b|
214942922|NCT01718145|DRUG|Telaprevir|
214942923|NCT03370523|OTHER|No intervention is planned in our study|No intervention is planned in our study
214339655|NCT02388321|DRUG|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
214339656|NCT03893448|BIOLOGICAL|V114|V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.
214676780|NCT05452161|OTHER|Control group|All patients follow only the standard care of the department, which includes a preoperative group session of 1h30, with 15 to 30 participants, 6 to 8 weeks before the operation The objectives of these sessions are to inform the patients in a general way about the operation, its preparation and the postoperative process in order to standardize the information received. The content includes general information from the surgeon, explanations related to the course and management of patients by the various professionals (nurse, surgeon, anesthesist, physiotherapist, ergotherapist and liaison-nurse).
214942924|NCT01933178|DEVICE|Cirrus AS-OCT|
214942925|NCT00757185|DRUG|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
214942926|NCT00757185|DRUG|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
214942927|NCT00425893|BEHAVIORAL|hand hygiene|alcohol-based hand wash
214942928|NCT00425893|OTHER|health education|Proper nutrition, etc.
214942929|NCT00425893|DEVICE|face masks|face masks
214942930|NCT03794505|DRUG|Methylprednisolone Acetate|depo-medrol 40 mg
214942931|NCT03794505|DRUG|Lidocaine 2% Injectable Solution|2ml of 2% lidocaine
214942932|NCT03794505|DRUG|Ropivacaine HCl Inj 7.5 MG/ML|25 mg
214942933|NCT04080518|DRUG|Dapagliflozin 10 MG [Forxiga]|24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
214942934|NCT04079257|OTHER|Blood collection for measurement of eculizumab peak concentrations|collection of blood
214942935|NCT04679636|BEHAVIORAL|heart rate variability biofeedback|receive biofeedback training for heart rate variability for eight weeks
214942936|NCT04977414|BEHAVIORAL|Making Data Count Training intervention|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
214942937|NCT05753891|DEVICE|Suture Tape Reconstruction|This intervention will utilize a suture tape to suspend the 1st and 2nd metacarpal post trapeziectomy compared to the standard procedure of a trapeziectomy followed by ligament reconstruction and tendon interposition.
214942938|NCT03545646|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
214942939|NCT03463707|DRUG|BP101|Investigational product BP101, nasal spray
214942940|NCT03463707|DRUG|Placebo|Placebo to Investigational product BP101, nasal spray
214942941|NCT03290547|DEVICE|Cutera enLighten laser|Subjects will receive laser treatments.
214942942|NCT03414996|OTHER|Exercise training|Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
214942943|NCT02285543|DRUG|TPF induction chemotherapy|"TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy"
214942944|NCT02285543|PROCEDURE|surgery|In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
214942945|NCT02285543|RADIATION|radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
214942946|NCT06649123|DIAGNOSTIC_TEST|Oricol Test|Assessment of diagnostic accuracy of Oricol Sampling device for triage in patients with suspected lower gastrointestinal cancer
214942947|NCT05700812|PROCEDURE|Sound sparing levonorgestrel 52 mg IUD placement|"In phase one, the IUD will be placed in a standard fashion with the use of a uterine sound to obtain baseline data.~In the experimental phases of the study (phase 2 and 3) the levonorgestrel 52 mg IUD will be placed without the use of a uterine sound. In phase 2 the IUD will be placed under abdominal ultrasound guidance. In phase 3 the IUD will be placed without abdominal ultrasound guidance."
214942948|NCT06260033|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214942949|NCT06260033|PROCEDURE|Bone Scan|Undergo bone scan
214942950|NCT06260033|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214942951|NCT06260033|DRUG|F-18 16 Alpha-Fluoroestradiol|Given IV
214942952|NCT06260033|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214942953|NCT06260033|OTHER|Questionnaire Administration|Ancillary studies
214942954|NCT06260033|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214942955|NCT01293513|OTHER|Gradual anti-HIV treatment interruption|Gradual interruption of anti-HIV treatment: the interruption initially for a week, up to six weeks' interruption, and continuing anti-HIV treatment for two weeks between successive interruptions
214942956|NCT04316039|DRUG|Temozolomide|Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.
214339657|NCT03893448|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
214339658|NCT03893448|BIOLOGICAL|RotaTeq™|A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.
214339659|NCT03893448|BIOLOGICAL|Pentacel™|A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
214942957|NCT04316039|RADIATION|intensity modulated radiation therapy|The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).
214942958|NCT04275726|DEVICE|Myval THV Series|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
214942959|NCT04275726|DEVICE|Contemporary Valves (Sapien THV Series and Evolut THV Series)|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
214942960|NCT02387528|BEHAVIORAL|1- Mindfulness Intervention|An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and illness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
214339660|NCT03893448|BIOLOGICAL|RECOMBIVAX HB™|A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
214339661|NCT03893448|BIOLOGICAL|VAQTA™|One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
214942961|NCT02387528|BEHAVIORAL|2- Relaxation Intervention|Eight meetings where the participants will practice relaxation techniques.
214942962|NCT02387528|OTHER|3- Wait List Control Group|No intervention
214339662|NCT03893448|BIOLOGICAL|MMR II™|One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
214339663|NCT03893448|BIOLOGICAL|VARIVAX™|One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
214339664|NCT03893448|BIOLOGICAL|HIBERIX™|One HIBERIX™ 0.5 mL IM dosing at Visit 5.
214339665|NCT02029924|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
214339666|NCT02029924|DRUG|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
214339667|NCT01369628|DRUG|Atacicept|"1. Regimen 1: Atacicept 25 mg weekly for 12 weeks~2. Regimen 2: Atacicept 75 mg weekly for 12 weeks~3. Regimen 3: Atacicept 150 mg weekly for 12 weeks"
214676781|NCT05452161|OTHER|Intervention group A|The day of the preparatory surgical consultation (CPC), the patient has a 30 minute patient-centered education session by a physiotherapist and a 30 minute patient-centered education session by a nurse. The physiotherapist's session addresses the technical skills to be mastered postoperatively (crutching, stairs, exercises), the course of postoperative rehabilitation, the patient's role in the rehabilitation process, the questions still remaining on this subject and the patient's perspective concerning the rehabilitation (degree and sources of anxiety, expectations of follow-up and results, degree of self-efficacy). The nursing intervention addresses the postoperative pain management, the patient's role in pain management, the care pathway, the organization of the return home and the postoperative follow-up.
214942963|NCT02169206|RADIATION|Bilateral shoulder anteroposterior radiography|"1. Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~2. In the same position, the patient only elevates the arm up to 90 degrees of abduction."
214942964|NCT03067675|DEVICE|Topcon DRI OCT Triton (plus)|OCT Machine used for diagnostic purposes
214942965|NCT00945204|OTHER|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
214942966|NCT01605032|DRUG|Busulfan|Given IV
214942967|NCT01605032|DRUG|Melphalan|Given IV
214942968|NCT01605032|DRUG|Bortezomib|Given IV
214942969|NCT01605032|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
214942970|NCT01605032|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
214942971|NCT01058759|DRUG|Enoxaparin|
214942972|NCT01058759|OTHER|No Enoxaparin|
214942973|NCT01044953|OTHER|shortened winter break|winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
214942974|NCT06244498|DRUG|Tranexamic acid injection|Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.
214942975|NCT04089345|DRUG|Ustekinumab|All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
214942976|NCT06400706|PROCEDURE|EEG guided general anesthesia|EEG guided general anesthesia: General anesthesia is guided by SedLine (EEG-guided care). The goal of EEG-guided care is to maintain spectral edge frequency (SEF) between 10 and 15 and patient state index (PSI) between 25 and 50.
214942977|NCT03434249|DIETARY_SUPPLEMENT|Bifidobacterium, BB-12® (Bifidolactis Infant)|
214942978|NCT03434249|DIETARY_SUPPLEMENT|Bifidolactis Infant Placebo|
214942979|NCT04650906|BEHAVIORAL|Mindhelper - a national youth mental health promotion website|Mindhelper is a fully digital youth mental health service reaching out to a large number of young people when and where they need it, with full anonymity. Mindhelper was developed in 2014-2017 by Centre for Telepsychiatry in the Region of Southern Denmark in a partnership with four Danish municipalities. The development of the site was funded by the Danish foundation TrygFonden. The original idea behind the site was inspired by the Australian youth mental health promotion service ReachOut.com. The Mindhelper service was launched in September 2016. From January 2019 Mindhelper received permanent funding through a joint agreement between the five Danish Regions. Mindhelper is Denmark's most comprehensive youth mental health promotion website where young people can seek mental health information, advice, and self-help tools to improve their mental health and well-being. Since it was launched, the site has been very successful in attracting large numbers of visitors.
214942980|NCT00561470|DRUG|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
214942981|NCT00561470|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
214942982|NCT00561470|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours"
214942983|NCT00561470|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours"
214942984|NCT00637806|DRUG|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
214942985|NCT00637806|DRUG|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
214942986|NCT00637806|DRUG|Placebo|Placebo oral suspension, 5 mL once daily
215074497|NCT04484896|OTHER|Loss-framed SMS message|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
215074498|NCT04484896|OTHER|Information SMS message|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
215074499|NCT05302206|DIETARY_SUPPLEMENT|colonic infusion|colonic glucose or colonic saline infusion
215074500|NCT02795507|DEVICE|Rehabit-Tec System|Device with visual and kinesthetic feedback
214942987|NCT06623877|DIAGNOSTIC_TEST|renal shear wave elastography|"Renal shear wave elastography is a non-invasive ultrasound elastography technique that allows measurements of tissue stiffness. It provides real-time measurements of shear wave velocity (SWV) generated with an acoustic impulse, thereby providing quantitative information about tissue elasticity. Harder tissues have been shown to have higher SWV .~Renal shear wave elastography will be done to both groups"
214942988|NCT00426777|DRUG|risedronate|risedronate 35mg tablet, weekly for 12 months
214942989|NCT00426777|DRUG|risedronate|35mg weekly
214942990|NCT00426777|DRUG|Control|risedronate-matched placebo weekly
214339668|NCT04408963|BIOLOGICAL|VRC-HIVMAB0102-00-AB|The VRC-HIVMAB0102-00-AB (CAP256V2LS) broadly neutralizing monoclonal antibody (bNAb) targets the V1V2 region of the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
214339669|NCT05205603|DRUG|Infliximab|Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks
214339670|NCT05205603|DRUG|Vedolizumab|Vedolizumab, 300mg at week 0,2,6 and schedule administration at every 8 weeks
214942991|NCT03705000|DEVICE|Slit Stent II|The Slit-Stent II device is created by modifying the BIKA for DCR lacrimal stent through the addition of a center slit, 12 ± 1.5 mm in length, and two lateral slits 32 ± 4.5 mm in length, each having identical depth measurements to facilitate the drainage of tears. The BIKA for DCR is a sterile, single-use device that is FDA cleared as part of the BIKA family of devices under K911109..There are no changes to the raw materials used in making the modifications to the BIKA for DCR during the manufacturing of the Slit Stent II.
215074501|NCT02795507|DEVICE|Rehabit-Tec System|Device without visual and kinesthetic feedback
214339671|NCT05205603|DRUG|Mesalazine|Mesalazine, 4-6g/d, systemic and/or topical administration
214339672|NCT00352729|DEVICE|ACell dressing|dressing
214339673|NCT00780091|OTHER|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
214676782|NCT05452161|OTHER|Intervention group B|"In addition to intervention A, patients receive a interdisciplinary intervention of three 10-15 minute phone or video conferences between the patient, a physiotherapist and a nurse.~The aim of these interviews is to identify the patient's difficulties in the living environment, to detect possible postoperative complications and to provide advice on practical aspects (e.g. ability to perform activities), therapeutic aspects (e.g. exercises to be performed, medication), pain management, interpretation of symptoms and subjective needs (e.g. need for support). Advice on rehabilitation and care is individualized according to the results of the questionnaires administered on the day of the pre-surgical consultation and those administered at discharge, as well as the needs of the moment discussed with the patient. Any suspected complication is reported to the operating physician for appropriate management."
214676783|NCT06344520|BEHAVIORAL|pektoralis minor shortnes|One factor that is effective in acceleration during swimming is the force of the arm pulling the water. While the pectoralis minor muscle pulls the crocoid process forward, it pulls its posterolateral corner down, which helps the latismus dorsi to make an extension movement and the lower trapezius to depress the scapula. When the pectoralis minor muscle is short, it prevents maximum reach in the arm because its full function cannot be revealed. It is thought that depression of the scapula will directly affect acceleration in swimming, as it increases the backward thrust of the arm.
215074502|NCT02795507|BEHAVIORAL|conventional exercises|
215074503|NCT04143217|DRUG|SPN-812|SPN-812 200 to 600 mg/day
215074504|NCT06456125|DEVICE|amber SEL-P Peripheral Liquid Embolic System|Transcatheter arterial or venous embolization with the liquid embolic agent amber SEL-P embolization across seven different indications for peripheral embolization.
214676784|NCT06344520|BEHAVIORAL|Group in which the Pectoralis Minor stretching exercise was performed in a sham manner|In most cases, exercise practices also affect the person psychologically. In order to ignore the psychological effects of the exercises, they were made to perform exercises that were similar to pectoralis minor stretching exercises but did not activate the muscle
214676785|NCT06344520|BEHAVIORAL|The group in which Pectoralis Minor stretching exercise was not applied|The Control Group was not given any exercise and they continued to do their own training.
214676786|NCT05367804|DIETARY_SUPPLEMENT|Isolated pea protein|The subjects eligible to take part in this study will consume an isolated plant protein for 4 weeks (week 4 to 8), in each week the amount of protein supplementation will increase (0.25 to 1.0 g of protein per kg of body weight). The protein will be provided as a powder in opaque bags and participants will be instructed to dissolve the contained powder in liquids (as water) or on their food (e.g., yogurt, oat porridge). The baseline will consist of 4 visits (1 to 4) to see how stable are the baseline results.
214676787|NCT05743023|BEHAVIORAL|Ayurvedic lifestyle protocol|"Based on each participant's current mind-body imbalance determination, a personalized 12-week intervention lifestyle protocol will be given.~Each protocol will mainly address diet and daily routine, quality of food, food combinations, and living in harmony with natural rhythm for balancing the predominant imbalance based on Ayurvedic principles. In addition, the lifestyle protocol will also include stress-reducing methods and more specifically, participants will be recommended to learn and practice the Transcendental Meditation technique."
214676788|NCT02487745|BEHAVIORAL|Abstinence-contingent wage supplements|Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
214339674|NCT00780091|OTHER|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
214339675|NCT04163276|DIAGNOSTIC_TEST|18F FDG PET exam|All patients have received 18F-FDG PET/CT in nuclear medicine
214339676|NCT02754167|BIOLOGICAL|PRS-080#022-DP|Hepcidin antagonism to mobilize iron and to treat anemia
214339677|NCT02754167|BIOLOGICAL|PRS-080-Placebo#001|Placebo comparator
214339678|NCT04498936|DRUG|Sofosbuvir and Ledipasvir|Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19
214676789|NCT02487745|BEHAVIORAL|Individual Placement and Support (IPS) supported employment|Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
214676790|NCT05436808|RADIATION|Partial Chest Wall Radiation Therapy|Patients will receive radiation therapy (30 Gray in 5 fractions) to the affected chest wall, delivered on consecutive days or every other day
214942992|NCT03705000|DEVICE|BIKA for DCR|The BIKA for DCR lacrimal stent is a bicanalicular intubation device used for intubation of the lacrimal drainage apparatus, especially in cases of dacryocystorhinostomy (conventional or laser). The silicone tube acts as a conformer during the healing process while facilitating drainage of tears through capillary action around the stent. In cases of canalicular lacerations, the silicone tube guides wound healing and prevents the onset of synechia. The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device
214942993|NCT01100892|DRUG|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
214676791|NCT03873350|OTHER|Consumption of kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of living kombucha daily for three weeks.
214676792|NCT03873350|OTHER|Consumption of heat-sterilized kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of heat-sterilized kombucha daily for three weeks.
214676793|NCT02844582|DRUG|Cabazitaxel|Given IV
214676794|NCT02844582|DRUG|Prednisone|Given PO
214676795|NCT00443404|PROCEDURE|perioperative epidural catheter|Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
214676796|NCT02974946|DEVICE|RenalGuard|
214676797|NCT02575313|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
214676798|NCT04039828|DRUG|Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)|Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for \> 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
214676799|NCT02179307|BEHAVIORAL|12-week progressive strength training protocol|Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
214676800|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement|For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
214676801|NCT02634164|DIETARY_SUPPLEMENT|Isoleucine Supplement|For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
215074505|NCT05397587|BIOLOGICAL|Experimental Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
215074506|NCT05397587|BIOLOGICAL|Control Vaccine|The EV71 vaccine was manufactured by Institute of Medical Biology,Chinese Academy of Medical Sciences ,and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
215074507|NCT01416103|OTHER|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
215074508|NCT01416103|OTHER|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
215074509|NCT02975414|PROCEDURE|rTARUP technique|obot-assisted rTARUP technique
215074510|NCT03429673|PROCEDURE|Surgeries|Lobectomy or segment/wedge dissection
215074511|NCT02264665|DRUG|sunitinib|sunitinib 37.5mg/d orally
215074512|NCT02264665|DRUG|everolimus|everolimus 10mg/d orally
215074513|NCT02264665|DRUG|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
215074514|NCT01962987|DRUG|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
215074515|NCT01962987|OTHER|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
215074516|NCT05516030|OTHER|HIFT for people with MRD|12-wk, 3x/week HIFT participation for individuals with MRD
215074517|NCT01214304|OTHER|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
215074518|NCT01214304|OTHER|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
215074519|NCT04165655|BEHAVIORAL|Keep Achieving (KA)|The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
214339679|NCT04498936|DRUG|Nitazoxanide|Evaluate the efficacy of Nitazoxanide in treatment of COVID-19
214339680|NCT02418546|BEHAVIORAL|In-Person Nutritional Counseling by a Registered Dietitian|
214339681|NCT02418546|BEHAVIORAL|Nutritional counseling using an e-Health Application|
214676802|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement combined with Isoleucine Supplement|For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
214942994|NCT02222441|DRUG|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
214942995|NCT02222441|DRUG|Palbociclib plus Modafinil|For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
214942996|NCT02222441|DRUG|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
214942997|NCT02222441|DRUG|Palbociclib plus pioglitazone|For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
214942998|NCT05582369|BEHAVIORAL|Affective Rewards Messages|Messages about the affective rewards of exercise
214942999|NCT03256292|DRUG|Testosterone replacement|Testosterone replacement therapy
214943000|NCT03256292|BEHAVIORAL|lifestyle|lifestyle intervention consisting of diet and increased physical activity
214943001|NCT02918552|DRUG|sodium nitrite|Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
214943002|NCT02918552|DRUG|Control|Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
214943003|NCT05583500|OTHER|Experimental: Single group: excentric exercise protocol|Excentric exercise protocol will be performed for all subjets, consisted of 10 sets of 20 repetitions of squats, jumping from a height of 50 cm
214943004|NCT00825526|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) Therapy|The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
214943005|NCT04003545|RADIATION|LED Photobiomodulation|A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.
214943006|NCT04003545|OTHER|Placebo LED Photobiomodulation|For the placebo group, the procedures will be the same, however the LED equipment will remain off.
214943007|NCT06448858|DIAGNOSTIC_TEST|serum Mn, Se, iron, Cu & Zn levels|Evaluate the concentration of serum Mn, Se, iron, Cu \& Zn levels in obese and overweight adolescents.
214339682|NCT01032967|PROCEDURE|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
214943008|NCT05572177|DEVICE|Asthma SMART|The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.
214676803|NCT05775692|DRUG|fluconazole|According to the models of population pharmacokinetics,the investigators and want to correlate use of fluconazole with treatment effectiveness and safety in newborns
214676804|NCT02448901|DRUG|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
214943009|NCT01686698|DIETARY_SUPPLEMENT|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
214676805|NCT03120403|PROCEDURE|intrathecal morphine|
214676806|NCT03561285|DIAGNOSTIC_TEST|antiphospholipid Abs|Laboratory test
214943010|NCT01686698|OTHER|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
214676807|NCT00956475|BEHAVIORAL|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
214676808|NCT00956475|OTHER|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
214676809|NCT00956475|PROCEDURE|assessment of therapy complications|questionnaire via telephone
214676810|NCT00956475|PROCEDURE|fatigue assessment and management|questionnaire via telephone
214676811|NCT00956475|PROCEDURE|psychosocial assessment and care|questionnaire via telephone
214676812|NCT00956475|PROCEDURE|quality-of-life assessment|questionnaire via telephone
214339683|NCT01032967|RADIATION|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
214339684|NCT05156723|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
214339685|NCT05156723|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
214339686|NCT05002101|DIETARY_SUPPLEMENT|zinc|The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
214339687|NCT05002101|DRUG|Placebo|Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
214339688|NCT04192097|OTHER|Professionalism curriculum|"One year training program including ten two-hours sessions about~* Knowing yourself~* Interaction with patients and their families~* Teamwork and organization with colleagues"
214339689|NCT02801045|BEHAVIORAL|art therapy|"Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~* humanistic phenomenological focus~* transpersonal therapeutic bound~* transdisciplinarity in the artistic approach~* integrative-relational specialized counseling of the grief, loss and trauma aspects."
214339690|NCT04304690|OTHER|blood sample|2 blood samples at T0 and 3 months
214943011|NCT03652116|DRUG|Wound infiltration by Bupivacaine|Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
214943012|NCT03652116|DRUG|Wound infiltration by Pethidine|Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
214943013|NCT04939753|DRUG|Sevoflurane|Sevoflurane administration to sedate the patient
214943014|NCT04403659|DEVICE|Telemedicine/telemonitoring (TM) suite|"The couples patient/caregiver will receive and trained to use a suite of TM instruments including: sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph. During the intervention phase (i.e. from allocation to exit from the study), the caregiver/patient will be asked to measure twice daily, at prespecified times, the following parameters using TM devices: arterial blood pressure, peripheral arterial haemoglobin saturation, tympanic temperature. Body weight will be evaluated once daily.~The TM glucometer and TM electrocardiograph will be used exclusively by healthcare staff in case of patients in need of capillary blood glucose testing and according to clinical needs, respectively. All data will be automatically sent to a central interface and made readily available to physicians and nurses, to enable a prompt clinical response. In case of malfunctioning, a technical support will be ensured."
214943015|NCT03866733|OTHER|continous erector spinea block|Ultrasound guided erector spinea block will be performed while the patient is in left lateral position ) the US probe will be placed in longitudinal parasagittal plane lateral to the T5 spinous process. An 18-gauge epidural needle will be inserted in-plane in a cranial-to-caudal direction until the tip is deep to erector spinae muscle. A 5 cm of epidural catheter will be threaded in cephalad direction. The same steps will be performed on the other side, after the negative aspiration for blood, bolus dose 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 0.1 ml/kg/h.
214339691|NCT05409417|DRUG|Experimental drug|Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
214339692|NCT00378417|BIOLOGICAL|7-valent pneumococcal-CRM197 conjugate vaccine|
214339693|NCT00378417|BIOLOGICAL|7-valent pneumococcal-OMPC conjugate vaccine|
214339694|NCT00285753|BEHAVIORAL|support groups|cognitive behavioral intervention with psychoeducation
214676813|NCT03479879|DRUG|Estradiol|Estradiol
215074520|NCT05297487|DEVICE|early use of intermittent positive pressure breathing|standard care associated with daily and early use of intermittent positive pressure breathing
215074521|NCT02937857|DRUG|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
215074522|NCT02937857|DRUG|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
214676814|NCT03479879|DRUG|Placebo Oral Tablet|Placebo
214676815|NCT03479879|DRUG|Misoprostol|Misoprostol
215074523|NCT03691818|DRUG|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
215074524|NCT03691818|DRUG|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
214339695|NCT01339650|DRUG|ABT-767|ABT-767 once or twice daily for a 28 day cycle
214339696|NCT03321981|DRUG|Zenocutuzumab|full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3
214339697|NCT03321981|DRUG|Trastuzumab|humanised IgG1 monoclonal antibody
214339698|NCT03321981|DRUG|Vinorelbine|antineoplastic drug of vinca alkaloid family
214943016|NCT03866733|DRUG|intravenous narcotics|intervention: injection of boluses of intra venous Narcotic drugs (fentanyl) in the dose of (1-2mcg/kg) during the surgery after induction of anesthesia then fentanyl infusion through the postoperative first 24 hours postoperative till extubation then intravenous pethidine till 48 hours after surgery.
214339699|NCT03321981|DRUG|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
214943017|NCT01731470|BIOLOGICAL|Liposomes|Intravesical instillation of liposomes.
214943018|NCT05359770|DEVICE|Active HD-tDCS|Experimental group: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
214943019|NCT05359770|DEVICE|Control group|Sham Control: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
214943020|NCT04486469|OTHER|Physical Therapy Group|"1. Performing direct physical treatment on the diaphragm, using stretching, followed by teaching exercises for re-education of the abdomen and diaphragm.~2. Transcutaneous retrograde electrostimulation: L1-L4 (2hz-10hz) rectangular asymmetric biphasic at the level of the dermatome. From the anterior inferior iliac spine to a pubic symphysis. Second canal from the greater trochanter to the saphenous veins. (30 min). Parameters of this program: 2 Hz and 180ms.~3. Connective Tissue Massage or Dicke~4. Massage with direct maneuvers on the abdomen: The direction of the maneuvers will be clockwise. We will perform 6 very slow strokes adding small pressures on the ascending, transverse and descending colon respectively and repeating this maneuver 3 times. (10 minutes)"
214943021|NCT04134520|DEVICE|ProLung System|Non-invasive bioconductance measurements
214943022|NCT03325894|DRUG|SHP465|SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.
214943023|NCT01541670|DRUG|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Intravenous injection
214943024|NCT01205074|DEVICE|13C Methacetin Breath Test|
214943025|NCT01205074|DIETARY_SUPPLEMENT|Grape fruit juice|
214339700|NCT00592449|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
214339701|NCT00592449|BEHAVIORAL|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
214339702|NCT03424876|DRUG|Imatinib 400mg|exposure 400 mg/day or 600mg/day,
214339703|NCT03424876|DRUG|Sunitinib 37.5Mg Oral Capsule|exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)
214339704|NCT05927129|DRUG|Antidepressant|Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
214339705|NCT05927129|OTHER|Psychotherapy IPT|The participants will receive standardized IPT treatment for 12 weeks. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
214339706|NCT05927129|OTHER|The combination of antidepressant and IPT|The participants will receive standardized IPT treatment for 12 weeks. Also，long-term antidepressant will be administered in accordance with clinical guidelines. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
214339707|NCT02628119|PROCEDURE|Intra-procedural access flow|"Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
214943026|NCT01205074|DRUG|Non selective beta blocker - Propranolol|
214943027|NCT01205074|DIETARY_SUPPLEMENT|Ethanol|
214943028|NCT05365269|BEHAVIORAL|Proactive Automatized Lifestyle intervention|Multi-behavioral; including individually-tailored, theory-based, repetitive, ipsative and normative feedback.
214943029|NCT02315872|DRUG|ACTH|ACTH injections twice weekly for 28 weeks.
214943030|NCT02315872|DRUG|Placebo|Placebo injections twice weekly for 28 weeks.
214943031|NCT01546597|DRUG|Metformin|"* Metformin 500 mg bid on Days 1-5~* Metformin 850 mg bid on Days 6-10~* Metformin 500 mg bid on Days 11-15~* Metformin 850 mg bid on Days 16-20"
214339708|NCT02628119|PROCEDURE|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
214339709|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
214943032|NCT01546597|DRUG|Ranolazine|"* Ranolazine 1000 mg bid on Days 11-15~* Ranolazine 1000 mg bid on Days 16-20"
214943033|NCT05103839|BEHAVIORAL|Gentle Yoga|Yoga classes are twice a week for up to 10 weeks with a trained yoga instructor at a location in the community. Classes will last up to 75 minutes.
214943034|NCT05842005|DEVICE|Mesh-reduced Sling|In this proposed study, the investigators aim to evaluate the role of using a ¾ x ⅜ inch cm polypropylene mesh suspended by sutures as a mesh-reduced solution for SUI.
214943035|NCT01920867|PROCEDURE|RB (Retrobulbar)|Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
214943036|NCT01920867|PROCEDURE|ST (Subtenon)|Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
214943037|NCT01920867|PROCEDURE|IV (Intravenous)|Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
214943038|NCT01920867|PROCEDURE|IVIT (Intravitreal)|Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
214943039|NCT01920867|PROCEDURE|IO (Intraocular)|Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
214943040|NCT01592292|DRUG|Rituximab|Rituximab as per physician's discretion.
215074525|NCT03691818|DRUG|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
214943041|NCT01592292|DRUG|Adalimumab|Adalimumab as per physician's discretion.
214339710|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
214339711|NCT05061446|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
214943042|NCT01592292|DRUG|Etanercept|Etanercept as per physician's discretion.
214943043|NCT01592292|DRUG|Infliximab|Infliximab as per physician's discretion.
214943044|NCT06619886|BIOLOGICAL|Autologous, engineered T Cells targeting TP53 R248Q|TP53-R248Q mutant TCR-T Cells Injection, 28 days as a treatment cycle (cycle number N≤3), each cycle was divided into three D0, D7, D14 infusion, a total of 3 dose groups were set up, the single infusion of cells within the range of ±20% all meet the requirements
214943045|NCT05961345|OTHER|late mobilization|Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.
214943046|NCT02690519|DRUG|GLPG1837 dose 1|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
214676816|NCT00931957|DRUG|Etanercept, Methotrexate, Prednisolone|"In: Arm A, Etanercept-MTX-Prednisolone:~Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.~In Arm B:~Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses."
214676817|NCT01364571|BIOLOGICAL|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
214676818|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
214676819|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
214676820|NCT01364571|BIOLOGICAL|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
214676821|NCT01364571|PROCEDURE|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
214676822|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
214676823|NCT01364571|BIOLOGICAL|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
214339712|NCT03880578|DRUG|Levothyroxine Sodium|thyroid hormone replacement
214339713|NCT04934670|DRUG|T-Guard|T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
214943047|NCT02690519|DRUG|GLPG1837 dose 2|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
214943048|NCT02598011|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
214943049|NCT02598011|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
215074526|NCT03691818|DRUG|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
215074527|NCT03711929|DRUG|DE-109 Intravitreal Injections|440 ug of DE-109 Injectable Solution
215074528|NCT03711929|OTHER|Sham Procedure|The sham procedure mimics an intravitreal injection without penetrating the eye.
215074529|NCT03711929|DRUG|DE-109 Intravitreal Injections|Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
215074530|NCT03711929|DRUG|DE-109 Intravitreal Injections (Open Label)|After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
215074531|NCT03883919|DRUG|5-FU|-Standard of care drug
215074532|NCT03883919|DRUG|Leucovorin|-Standard of care drug
215074533|NCT03883919|DRUG|Liposomal Irinotecan|-Standard of care drug
215074534|NCT03883919|DRUG|Paricalcitol|-Investigational drug
215074535|NCT03883919|PROCEDURE|Serum and plasma blood samples|-baseline, day 1 of each cycle beginning with cycle 2
214339714|NCT04934670|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
214943050|NCT00335959|DRUG|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
214943051|NCT00335959|DRUG|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
215074536|NCT03883919|PROCEDURE|Tumor biopsy|"* 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~* After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible."
214943052|NCT00335959|PROCEDURE|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
214339715|NCT04240821|DRUG|Theophylline ER|Oral theophylline
214943053|NCT00335959|RADIATION|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
214339716|NCT06435871|BEHAVIORAL|Expanded Prostate Cancer Index Composite and Decision Regret Scale|This comprehensive instrument measures urinary, sexual, and bowel symptoms in men treated for prostate cancer. It can provide a detailed view of the patient's quality of life post-treatment.
214339717|NCT01544712|PROCEDURE|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
214943054|NCT04738136|DRUG|S-1226|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8%, or 12% CO2
214943055|NCT00670605|OTHER|medical chart review|
214943056|NCT00670605|OTHER|study of socioeconomic and demographic variables|
214943057|NCT06413745|DRUG|SHR-A1811|SHR-A1811
214339718|NCT01544712|PROCEDURE|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
214339719|NCT00420680|DRUG|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
214339720|NCT00420680|DRUG|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
214676824|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
214676825|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
214676826|NCT01364571|BIOLOGICAL|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
214676827|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
214676828|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
214943058|NCT01521156|OTHER|1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
214676829|NCT05248958|OTHER|Turkish Validity and Reliability of The CRAVE Scale|The aim of this study is to adapt the Cravings for Rest and Volitional Energy Expenditure (CRAVE) scale to Turkish society and to make its validity and reliability in Turkish.
214676830|NCT00675285|DRUG|montelukast sodium|one tablet 5 mg once/day for 4 weeks
214676831|NCT00675285|DRUG|placebo|one tablet 5 mg once/day for 4 weeks
214943059|NCT01521156|OTHER|2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).|2 = Intervention 2 (1 test product/day)
214943060|NCT02624245|OTHER|Conventional Physical Therapy|
214943061|NCT02903524|DRUG|Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|
214943062|NCT02903524|DRUG|pirarubicin and cyclophosphamide|
214943063|NCT02450552|DRUG|Ezogabine|Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
214943064|NCT02450552|DRUG|Placebo|Matched placebo
214943065|NCT02722837|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
214943066|NCT04300452|DRUG|Carbetocin|Administration of Carbetocin after placental detachment
214943067|NCT04300452|DRUG|Ergometrine Maleate|Administration of ergometrin after placental detachment
214943068|NCT04582500|DRUG|Iohexol|Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
214339721|NCT00420680|DRUG|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
214339722|NCT03259035|DRUG|Folfox Protocol|6 cycles of q2weekly FOLFOX, or
214339723|NCT03259035|DRUG|Capox|4 cycles of q3weekly CAPOX
214676832|NCT01771302|DEVICE|Bio-Oss|It is a bone substitute of bovine origin
214676833|NCT01771302|DEVICE|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
214676834|NCT04982549|DRUG|Durvalumab|Durvalumab (intravenous infusion)
214676835|NCT04982549|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
214676836|NCT04982549|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
214676837|NCT04982549|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
214676838|NCT04982549|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
214943069|NCT03431662|PROCEDURE|Ellipse IM HTO Nail|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
214943070|NCT03431662|PROCEDURE|TomoFix|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
214943071|NCT06183203|PROCEDURE|Pulpotomy|Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.
214943072|NCT06183203|PROCEDURE|Pulpectomy|Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Endoflas)
214943073|NCT04321317|OTHER|Measure of body composition by Air Displacement Plethysmography (ADP)|Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.
214943074|NCT02490462|OTHER|Education + Conventional PhysicalTherapy|The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.
214943075|NCT02490462|OTHER|Conventional Physical Therapy|The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
215074537|NCT03086707|OTHER|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
215074538|NCT00408655|DRUG|paclitaxel|Given IV
215074539|NCT00408655|DRUG|carboplatin|Given IV
215074540|NCT00408655|DRUG|temsirolimus|Given IV
215074541|NCT02286934|DRUG|Carvedilol|"* Day 1 to 3 : Carvedilol 12.5 mg qd~* Day 4 to 8 : Carvedilol 25 mg qd~* Day 9 to 11 : Carvedilol 12.5 mg qd"
214339724|NCT05844878|BEHAVIORAL|Cognitive behavioral therapy (CBT) by using Distraction technique.|"Distraction: The distraction in this arm will be done by hearing of soft music; the name of music that will be used is relaxing piano music and water sounds 24/7 - ideal for stress relief. This music will be used in both the reception room and in the dental room treatment from the time-point that patient enters the reception room, and continues into the dental treatment room until the end of dental treatment when the patient exits the dental treatment room"
214339725|NCT05844878|BEHAVIORAL|Mindfulness technique by using of relaxation breathing with muscle relaxation|"The mindfulness technique consist of combination of 2 procedures:~1. Relaxation breathing: this will be done during the course of dental treatment by asking the patient to do the following Gently breathe in - hold - and let go. This procedure will be applied at the first moment when the patient sits on the dental chair before any dental treatment is done and the patient is asked to repeat this twice, each for a duration of 10 seconds. This procedure will be repeated twice; at zero time and after an interval of 16 minutes of dental treatment that extend for a 30-minute duration for each patient.~2. Muscle relaxation: this will be done by asking the patient during dental treatment to do the following Hands - gently clench - hold - and let go. This procedure will be applied after 8 minutes from starting dental treatment, and ask the patient to do it twice for about 10 seconds. This procedure will be repeated twice; at 8 minutes and at 24 minutes of dental treatment."
214339726|NCT04519229|BEHAVIORAL|Child-Parent Psychotherapy|Relationship-based trauma focused psychotherapy for Children 0-6 years old and their caregivers. The objective is to decrease symptoms of post-traumatic tress and re-establish a secure attachment for the child and good caregiving from the caregiver/s.
214676839|NCT06152263|OTHER|Compare color information and mucosal microvascular density|To investigate the association between the color and mucosal microvascular density of CAG and EGC using linked color imaging.
214676842|NCT04083144|DEVICE|Deep Repetitive Transcranial Magnetic Stimulation (Active)|Active deep rTMS (10 Hz) using the H-coil to target the bilateral insula
214676843|NCT04083144|DEVICE|Deep Repetitive Transcranial Magnetic Stimulation (Sham)|Sham deep rTMS using the H-coil. The sham coil is built into the same helmet as the active coil. It mimics the active coil with regards to acoustics and scalp sensations.
214676844|NCT04083144|DRUG|Varenicline|12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).
215074542|NCT02286934|OTHER|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
215074543|NCT01338480|OTHER|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
215074544|NCT04338633|DRUG|Conventional calcium hydroxide paste|Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
215074545|NCT04338633|DRUG|Calcium hydroxide nanoparticle|Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
215074546|NCT04338633|DRUG|Combined Calcium hydroxide with silver nanoparticle|Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
215074547|NCT06405737|DRUG|Intranasal oxytocin|Subject assigned to receive intranasal administration of oxytocin (24 IU).
214676845|NCT02949661|PROCEDURE|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block
214676846|NCT02949661|PROCEDURE|Local wound infiltration|Patients will receive local wound infiltration
214676847|NCT04343573|RADIATION|Involved-field Photon Radiation Therapy|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions)
214943076|NCT03751800|DRUG|Chronic hormonal treatment|Drugs used in this study are described by the physicians during routine gynecological visits
214943077|NCT00825656|DRUG|Sinol or Sinol-M nasal spray|"One spray in each nostril up to a maximum of 12 times / day on an as needed basis"
214339727|NCT06133582|BEHAVIORAL|Internet Based Psychodynamic Psychotherapy|"This is a 10-week intervention, delivered on a website called 'Iterapi' which was developed in Sweden. The programme involves creative and interactive web-based content- worksheets, audio, video, expressive writing exercises. Additionally, each participant is assigned a Therapeutic Support Worker (TSW). The TSW logs into the platform and views the questionnaires and other data provided by the participants that they are supporting. Each week, the TSW sends each of their participants a reflective message in response to the data they have provided when interacting with the programme over the last week. The participant can reply to this message.~The principal objective of the iPDT intervention is to reduce depressive symptoms through the promotion of emotional awareness and emotional experience. The intervention is an affect-focused therapy and draws on Malan's Triangle of Conflict (Malan, 1995)."
214943078|NCT02106416|PROCEDURE|PET/MRI|Simultaneous PET/MRI (3T system)
214943079|NCT02595281|OTHER|Experimental arm|"Serum samples are collected:~* at each neoadjuvant chemotherapy cycle~* before surgery~* at each adjuvant chemotherapy cycle~* at each injection of bevacizumab as maintenance therapy~* stop at the progression or after 24 months post chemotherapy"
214943080|NCT05439616|DRUG|Cariprazine|Oral Capsules or Oral Solution
214943081|NCT05439616|DRUG|Placebo|Oral capsules or Oral Solution
214943082|NCT07027735|OTHER|Rotator Cuff Repair with Allograft Patch|Rotator cuff repairs will be augmented with use of a decellularized human placental allograft patch
214943083|NCT07027735|OTHER|Rotator Cuff Repair with No Augmentation|Standard rotator cuff repair with no augmentation
214676848|NCT04343573|RADIATION|Proton Craniospinal Irradiation (CSI)|Proton CSI (30Gy \[RBE\] in 10 fractions)
214339728|NCT01961869|OTHER|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
214339729|NCT01961869|OTHER|Intermed release BRB confection|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
214339730|NCT01961869|OTHER|Prolong release BRB confection|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
214339731|NCT04534829|PROCEDURE|Fluoroscopic-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under fluoroscopic-guidance
214339732|NCT04534829|PROCEDURE|Ultrasound-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under ultrasound-guidance
214339733|NCT00899223|OTHER|biologic sample preservation procedure|
214339734|NCT00817089|DRUG|Placebo Oral Tablet|Placebo pill
214339735|NCT00817089|DRUG|Naltrexone|50 mg of naltrexone prior to challenge session
214339736|NCT03067441|DRUG|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
214339737|NCT04257370|DEVICE|Kerecis™ Omega3 Wound|Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.
214339738|NCT04257370|OTHER|Standard of care|Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
214339739|NCT01990053|BEHAVIORAL|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
214339740|NCT01785602|DRUG|QAW039|Capsules
214339741|NCT01785602|DRUG|Placebo|Capsules
214339742|NCT02950493|OTHER|perflutren lipid microsphere|Definity and Lumason are tools for diagnosis used in echocardiography. Compare activated Definity or Lumason with compressed Definity or Lumason.
214339743|NCT00900484|OTHER|biologic sample preservation procedure|
214339744|NCT00900484|OTHER|immunohistochemistry staining method|
214339745|NCT00900484|OTHER|laboratory biomarker analysis|
214339746|NCT04177108|DRUG|Atezolizumab|Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.
214339747|NCT04177108|DRUG|Ipatasertib|Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.
214943084|NCT03080766|DRUG|Decitabine|Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
214943085|NCT06182384|DRUG|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：1mL AI, injection two needles. Second period: 2mL AI, injection one needle).
214943086|NCT06182384|DRUG|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：2mL AI, injection one needle. Second period: 1mL AI, injection two needles).
214943087|NCT00507650|DIETARY_SUPPLEMENT|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
214943088|NCT00507650|DIETARY_SUPPLEMENT|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
214943089|NCT03715231|OTHER|NIDEK Gonioscope GS-1|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
214943090|NCT03715231|OTHER|Standard Digital Gonioscopic Images|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
214943091|NCT06631326|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
214943092|NCT06631326|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
214943093|NCT01451944|BEHAVIORAL|education|home asthma case management and education
214943094|NCT04888845|BEHAVIORAL|Safety Plan|The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
214943095|NCT04888845|BEHAVIORAL|Crisis Response Plan|Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
214943096|NCT04888845|BEHAVIORAL|Structured interview|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach.
214943097|NCT04888845|BEHAVIORAL|Narrative Assessment|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis."
214943098|NCT01876979|DEVICE|IMF Screws|stainless steel screws placed in bone
214943099|NCT01876979|DEVICE|Erich Arch Bars|Surgical braces wired around teeth
214943100|NCT06375616|DRUG|Nafamostat Mesylate|During RRT, a priming dose of 20 mg of nafamostat mesylate (NM) is administered before initiation of the procedure. Upon starting the machine, there is no loading dose, but a maintenance infusion rate of 25 mg/h of NM is maintained. NM is discontinued in the last half hour before the end of the RRT session.
214943101|NCT06375616|DRUG|Unfractionated Heparin|During RRT, a priming dose of 50 mg of unfractionated heparin (UFH) is administered before initiation of the procedure. Upon starting the machine, a loading dose of 0.2 mg/kg of UFH is given, followed by a maintenance infusion rate of 0.1 mg/kg/h of UFH. The anticoagulant is discontinued in the last half hour before the end of the RRT session.
214943102|NCT05308602|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
214943103|NCT05308602|BIOLOGICAL|SCTV01C|Day 28; intramuscular injection
214943104|NCT05308602|BIOLOGICAL|SCTV01C|Day 180; intramuscular injection
214943105|NCT05308602|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
214943106|NCT05308602|BIOLOGICAL|SCTV01E|Day 28; intramuscular injection
214339748|NCT04177108|DRUG|Paclitaxel|Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.
214339749|NCT04177108|DRUG|Placebo for Atezolizumab|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
214339750|NCT04177108|DRUG|Placebo for Ipatasertib|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
214339751|NCT02100072|DEVICE|Nd:YAG 1440 nm laser|
214339752|NCT03127228|OTHER|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
214339753|NCT03127228|DEVICE|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
214339754|NCT03380039|GENETIC|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
214943107|NCT05308602|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
214943108|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 0; intramuscular injection
214943109|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 28; intramuscular injection
214943110|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 180; intramuscular injection
214943111|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
214943112|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 28; intramuscular injection
214943113|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 180; intramuscular injection
214943114|NCT05171634|DEVICE|DiscoveryTM|Colonoscopy assisted by an artificial intelligence system (DiscoveryTM).
214943115|NCT05171634|DEVICE|iSCAN|Virtual colonoscopy assisted by iSCAN
214943116|NCT03366324|GENETIC|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.
214943117|NCT03366324|PROCEDURE|Hematological stem cell transplantation|Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
214943118|NCT01786824|DRUG|Hydration strategy using saline|For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
214943119|NCT01786824|DRUG|Hydration strategy using sodium bicarbonate|For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.
214339755|NCT03380039|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
214339756|NCT03380039|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
214339757|NCT00338026|DRUG|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
214339758|NCT01542866|OTHER|Health Management Tool (HMT)|Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
214339759|NCT04040972|OTHER|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
214339760|NCT06142201|DRUG|JT001|oral administration
214943120|NCT01786824|DRUG|L-carnitine|"Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed."
214943121|NCT01786824|PROCEDURE|Coronarography|All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
214943122|NCT00948506|DRUG|1% topical cidofovir|1% topical cidofovir
214943123|NCT00948506|DRUG|3% topical cidofovir|3% topical cidofovir
214943124|NCT00948506|DRUG|Placebo|topical placebo
214943125|NCT04445506|DRUG|Dexamethasone|4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.
214943126|NCT03660475|DRUG|Naltrexone|naltrexone formulated as ophthalmic solution
214676849|NCT04343573|OTHER|Neurocognitive Assessment|All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT. The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available. Patients will also complete self-report mood and fatigue scales at each of the same time points. This testing will only be done at MSKCC. Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments. Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
214943127|NCT03660475|DRUG|Placebos|Placebo ophthalmic solution
214943128|NCT06392854|DRUG|Insulin|2 dose insulin infusion 4 hours
214943129|NCT06766656|PROCEDURE|Incision|"The pocket for the vascular port is made through a small incision in the skin in the subclavicular area. The skin incision can be made transversely or longitudinally"
214943130|NCT05156554|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.
214943131|NCT05156554|DRUG|rhG-CSF|rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 5μg/kg once per day until the count of neutrophil\>0.5×10\^9 /L.
214943132|NCT01224652|DRUG|Paclitaxel|Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
214943133|NCT01224652|DRUG|Irinotecan|irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
214943134|NCT06901323|DRUG|L-carnitine|44 patients diagnosed as a case of phenylketonuria will receive l-carnitine at a dose of 100 mg/kg/day for 1 year and then blood sample will examined for level of brain-derived neurotrophic factor levels before and after therapy and another group composed of 44 patients diagnosed as a case of phenylketonuria will not receive l-carnitine and their blood sample will examined for level of brain-derived neurotrophic factor levels treated and untreated patients will compared with healthy children and infants has same age and sex .
214943135|NCT03846115|BEHAVIORAL|Peer-Led Seeking Safety app|This app offers participants sessions of Seeking Safety plus enhanced app features designed to engage and sustain participants in their recovery work.
214943136|NCT03846115|BEHAVIORAL|Control app|This app offers the Seeking Safety content but without the enhanced features
214943137|NCT01294007|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
214943138|NCT01294007|PROCEDURE|Autograft bone|Iliac Crest and Local Autograft Bone
214943139|NCT04245215|DRUG|Ustekinumab|re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
214943140|NCT03439215|DRUG|Lorlatinib|Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
214943141|NCT04026334|DEVICE|V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline|-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
214943142|NCT06863636|DRUG|Celecoxib + Acetaminohen|One tablet of 200 mg / 200 mg a day
214943143|NCT06863636|DRUG|Celecoxi + Acetaminophen|One tablet of 200 mg / 500 mg a day
214943144|NCT06863636|DRUG|Celecoxib|One capsule of 200 mg a day
214943145|NCT04149782|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
214943146|NCT02589327|OTHER|Exercise Intervention|The intervention will consist of 3 weeks of whole body circuit training (resistance training) where participants in the intervention group will perform 7 different exercises. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round. Intensity will be 6-7 of RPE at the first set, and 9-10 at the third set.
214943147|NCT03033316|DRUG|Dexamethasone|
214943148|NCT06277869|DEVICE|Thermal Jacket|In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention Thermal Jacket as well as Kangaroo Mother Care.
215074548|NCT06405737|DRUG|Intranasal placebo|Subjects assigned to receive intranasal administration of placebo (24 IU).
215074549|NCT01344681|DRUG|Micafungin sodium|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   \- Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
214943149|NCT06277869|PROCEDURE|Kangaroo Mother Care|Skin-to-Skin care, provided by primary caregiver.
214943150|NCT04132453|DEVICE|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
214943151|NCT04132453|DEVICE|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
214943152|NCT04132453|DEVICE|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
214943153|NCT05401448|BIOLOGICAL|Influenza|Influenza: 0.5 ml of reconstituted Influenza vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
214943154|NCT05401448|BIOLOGICAL|MMR vaccines|MMR: 0.5 ml of reconstituted MMR vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
215074550|NCT01344681|DRUG|Itraconazole|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   \- Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
215074551|NCT00951236|DRUG|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
214676850|NCT04343573|OTHER|MDASI-BT and MDASI-SP|Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).
214943155|NCT05401448|OTHER|Placebo|Placebo: 0.5 ml of 0.9% NaCl will be administered intradermally in the left upper arm.
214943156|NCT00824382|DRUG|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
214943157|NCT00824382|DRUG|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
214943158|NCT00824382|DRUG|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
214943159|NCT00824382|DRUG|Placebo|2 puffs delivered by the RespimatÂ® inhaler
214943160|NCT05126667|PROCEDURE|Breast-conserving surgery|Breast conserving surgery plus whole breast irradiation
214943161|NCT05126667|PROCEDURE|Mastectomy|Breast mastectomy
214943162|NCT00311064|BEHAVIORAL|physical activity|
214943163|NCT00721279|DRUG|Sifrol® (pramipexole dihydrochloride)|
214943164|NCT01482143|DRUG|AFQ056|
214943165|NCT03977753|DRUG|2LVERU® or 2LVERU® JUNIOR|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
214943166|NCT03977753|DRUG|Placebo|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
214943167|NCT02680834|DEVICE|Dual Action Pneumatic Compression Device|Dual action pneumatic compression device used to treat chronic VLUs.
214943168|NCT02680834|DEVICE|Multi-Layer Bandaging|Multi-layer bandaging used to treated chronic VLUs
214943169|NCT01958216|OTHER|Intravenous injection of deuterated cholesterol diluted in intralipid 20%|At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
214676851|NCT00946270|DRUG|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
214339761|NCT04813341|OTHER|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles. The participant will be instructed to perform 3-5 repetitions of these movements at the start, and to add two more repetitions for each movement every week until the end of the intervention.
214943170|NCT05744037|BIOLOGICAL|regimen with BTK inhibitor +Anti-CD19 CAR T cells|After FC regimen (fludarabine (25mg/m2/d) on days -5 to -3 and cyclophosphamide (750mg/m2) on days -5) were pretreated, Anti-CD19 CAR T cells were transfused on day 0. The dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. Intravenous drip/push at a constant rate for 30 minutes; Ibrutinib, a BTK inhibitor, was enrolled with a standard dose of 560mg qd.
214943171|NCT06647706|DEVICE|Transthoracic echocardiography|MPNs patients who have echocardiographic probability of PH
214943172|NCT00862342|DRUG|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
214943173|NCT05718427|BEHAVIORAL|Ayres Sensory Integration Therapy|Ayres sensory integration theory provides evidence from basic and applied science about the ability to receive, sort, process, and make use of the information originating from the body and the environment and perceived by our senses (touch, gravity, body position and movement, sight, smell, hearing, taste). This sensory information goes to the brain, where it is organized and interpreted. As a result, we form a plan of action that allows us to have an adaptive response appropriate for the demands of the environment. A thorough assessment guides the preparation of goals addressing the referring concerns and the recommendations for intervention. Ayres Sensory Integration intervention is provided within the context of professional practice. It is designed to improve sensory perceptual abilities, self-regulation, motor skills, and praxis. In doing so, it supports the client's ability to show improved behavior, learning, and social participation.
214676852|NCT00946270|DRUG|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
214676853|NCT00946270|DRUG|CC-4047|3.0 mg capsules daily by mouth day 1 through 21.
214339762|NCT04813341|OTHER|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
214339763|NCT00911365|BIOLOGICAL|autologous mesenchymal stem cells|"4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-\> Total four times"
214339764|NCT00911365|BIOLOGICAL|normal saline|saline
214339765|NCT01988818|DEVICE|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
214339766|NCT01988818|DEVICE|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
214339767|NCT06151249|COMBINATION_PRODUCT|Meritup oral solution|chemotherapy + Meritup
214339768|NCT04777682|PROCEDURE|ultrasound, double balloon enteroscopy|compare intestinal ultrasound versus double-balloon enteroscopy in diagnosis of malabsorption syndrome
214339769|NCT05090449|DRUG|Chlorthalidone (HIGROTON® 50)|Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
214943174|NCT06648876|DRUG|YG1699|10mg qd for 8 days
214943175|NCT06648876|DRUG|Placebo|10mg qd for 8 days
214339770|NCT05090449|DRUG|Losartan (COZZAR®)|Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
214943176|NCT06547424|DRUG|Chondroitin sulfate|Neonates with Bell's Stage 2 NEC will be given chondroitin sulfate (20mg/kg/day) mixed with 1-2 ml of milk or formula for 2 days
214943177|NCT05179018|DIAGNOSTIC_TEST|Ribosomal p2 Autoantibodies as a Serum marker|Using serum marker
214943178|NCT05918419|DRUG|Serplulimab|PD-1 antibody
214943179|NCT05554913|DRUG|QL0911|This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
214943180|NCT05554913|DRUG|Placebo|Placebo comparator
214943181|NCT01483482|PROCEDURE|Conservative Treatment|Simple Sling
214943182|NCT01483482|PROCEDURE|Surgical treatment|Superior Locking plate
214943183|NCT00033176|DRUG|Alpha Lipoic Acid|
214943184|NCT05222022|DEVICE|Retitrack|Retitrack device measures and analyzes eye movement
214943185|NCT01765244|DRUG|Anterior lamellar nanostructured artificial human cornea.|Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold
214943186|NCT01765244|OTHER|Amniotic membrane transplantation|Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.
214943187|NCT04000698|DRUG|Preparative regimen|"Preparative chemotherapy before allogeneic HSCT~* Fludarabin~* Cytarabine~* Venetoclax~* Daratumomab~* Vecanoid Condition~* treosulfan~* fludarabine~* thiophosphomide~* Venetoclax~* Plerixafor GVHD prophylaxis~* abatacept~* tocilizumab~* rituximab~* HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
214943188|NCT03471728|DRUG|linaclotide|Oral
214943189|NCT03535454|OTHER|working hours|weekly working hours
214943190|NCT01732471|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
214943191|NCT03668717|DEVICE|Robotic-arm assisted medical MCK implant|Robotic-arm assisted medical MCK implant system to replace the medial compartment of the knee.
214943192|NCT00232596|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
214676854|NCT04771715|DRUG|Regorafenib|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
214676855|NCT04771715|DRUG|Nivolumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
214339771|NCT05090449|DRUG|A1+ A2 Co-administration of Chlorthalidone and Losartan|50mg chlorthalidone + 100 mg losartan potassium
214943193|NCT00232596|DRUG|Placebo|Oral tablet.
214943194|NCT01253174|DRUG|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
214943195|NCT01253174|DRUG|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
214943196|NCT01253174|DRUG|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
214943197|NCT02244346|DRUG|Secotex®|
214943198|NCT01873300|PROCEDURE|Endoscopic Esophageal Myotomy|Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
214676856|NCT04771715|DRUG|Pembrolizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
214339772|NCT05090449|DRUG|Chlorthalidone + Losartan Fixed-Dose combination|Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
214943199|NCT04398654|DEVICE|CardioMEMSTM HF sensor - pulmonary artery pressure measurement|CardioMEMSTM HF sensor implantation to meassure pulmonary artery pressure. Evaluation of the pressure curves by telemetric transmission and coordination of necessary adjustments of the therapy.
214943200|NCT03627377|BEHAVIORAL|Multi-component Intervention for Diabetes in Adults with Serious Mental Illness|Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
214943201|NCT04590677|OTHER|Samples required from group 1 (procedure within observational study)|"* Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs~* Daily Heart rate monitoring (only applicable to a subset of women in group 1)"
214943202|NCT04590677|OTHER|Samples required from group 2 (procedure within observational study)|"* Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs"
214943203|NCT00475345|BEHAVIORAL|Bedtime snacks|
214943204|NCT01759316|OTHER|heliox|heliox or oxygen is used in the two groups respectively
215074552|NCT00951236|DRUG|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
215074553|NCT03015649|DEVICE|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
215074554|NCT04778163|BEHAVIORAL|Clinical use of humor|"Clinical study in psychiatry in young adult patients between 18 and 25 years old. The aim of the study is to evaluate the therapeutic impact of the clinical use of humor through 6 group sessions (group of 5 to 10 patients), at the rate of one hour session per week for 6 weeks.~The investigators will form 2 groups of 5 to 10 patients matched in terms of gender, education level and score on a scale measuring their sense of humor. The participants will be asked to complete a series of tests measuring their ability to use humor, psychiatric symptoms and well-being."
214339773|NCT03684798|OTHER|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
214943205|NCT05714046|BEHAVIORAL|Control|An informative presentation
214943206|NCT05714046|BEHAVIORAL|Yoga training|Yoga exercise training
214943207|NCT02039973|BEHAVIORAL|Task-sharing approach to group therapy|"Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.~Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions."
214943208|NCT02039973|BEHAVIORAL|Enhanced standard of care|
214943209|NCT06622122|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
214943210|NCT06622122|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-increase cognitive flexibility|Increase the intervention dose of cognitive flexibility in Mindfulness Intervention for Emotional Distress (MIED). For example, including more cognitive reappraisal practice, psychoeducational content and practice about regarding thoughts just as thoughts.
214943211|NCT05545020|DRUG|Trivalent chromium versus synthetic and/ or biological DMARDs|Supplement and immunesuppressants
214943212|NCT04533191|PROCEDURE|LAL IOL lens|Standard of care Cataract surgery with IOL placement
214943213|NCT02063048|BEHAVIORAL|Text Message Based Weight Loss Support|
215074555|NCT06457646|GENETIC|Genetic polymorphism|The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. This study aims to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism.
215074556|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
214676857|NCT04771715|DRUG|Camrelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
214676858|NCT04771715|DRUG|Sintilimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
214676859|NCT04771715|DRUG|Toripalimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
214676860|NCT04771715|DRUG|Tislelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
214676861|NCT01811030|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
214676862|NCT06513364|DRUG|WH002|"Group A（ddWH002-ddEC）： Regimen for Group A during Cycles 1-Cycles 4:WH002， 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles."
214676863|NCT06513364|DRUG|paclitaxel injection|"Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles."
214339774|NCT03684798|OTHER|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
215074557|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
215074558|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
215074559|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
214339775|NCT01827904|DEVICE|Transcranial ExAblate|
214339776|NCT01827904|DEVICE|Sham Transcranial ExAblate|
214339777|NCT05944263|BEHAVIORAL|weRISE; The gratitude, kindness and hope (GKH) program|weRISE is an arts based train the trainer intervention that promotes positive mental health through cultivating gratitude, kindness and hope among youth in schools and informal settlements in India and Kenya
214339778|NCT05944263|BEHAVIORAL|The [adapted] Stan Kutcher Teen Mental Health (TMH) program|The 'Teen Mental Health' curriculum developed by Dr. Stan Kutcher, aims to increase mental health literacy among young people ;will be used in the control group (active comparator group). The control intervention consists of eight sessions (45 minutes each) delivered by older groups of young people (ages 18-24) in schools and community settings through a didactic approach.
214339779|NCT03792685|OTHER|Normo-carbohydrate meal intake|Subjects are going to receive the normo-carbohydrate meal.
214943214|NCT06909292|DEVICE|Sacroiliac Joint transfixing and fusion system (Nevro1)|The Nevro1 is a titanium cage the is implanted in the sacroiliac join from a posterior direction, and then anchors are deployed that stabilize the joint. It has multiple openings to allow surgeons to fill them with autogenous bone graft to encourage bone bridging through the implant for SIJ fusion.
214943215|NCT00621465|BEHAVIORAL|Critical Time Intervention (CTI)|CTI is designed specifically to enhance the continuity and focus of care during the transition from psychiatric hospital to community care. CTI does not replace community treatment and support, but instead is meant to complement available services. CTI will provide training in community living skills and in team-managed transfer of caregiving from hospitals to services and supports in the community. Participants will receive CTI for 9 months after hospital discharge.
214943216|NCT00621465|BEHAVIORAL|Usual care|Usual care will include the standard aftercare and community care services.
214943217|NCT06908941|DIETARY_SUPPLEMENT|dark chocolate|Participants consumed 85% dark chocolate (1g/kg body weight) before high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles. Finger-toe pulse wave velocity (ftPWV), arterial stiffness, blood pressure, and plasma NO levels were measured at rest, 2 hours after chocolate consumption (baseline), immediately post-exercise (T0), and at 60 (T60) and 120 (T120) minutes post-exercise.
214943218|NCT06908941|DIETARY_SUPPLEMENT|milk chocolate|Participants consumed milk chocolate (1g/kg body weight) before high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles. Finger-toe pulse wave velocity (ftPWV), arterial stiffness, blood pressure, and plasma NO levels were measured at rest, 2 hours after chocolate consumption (baseline), immediately post-exercise (T0), and at 60 (T60) and 120 (T120) minutes post-exercise.
214943219|NCT06908941|BEHAVIORAL|high-intensity resistance exercise|Participants performed high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles.
214943220|NCT06182046|PROCEDURE|Complete decongestive treatment program|It consists of manual lymph drainage, multi-layer bandaging, skin/nail care and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks.
214943221|NCT06182046|PROCEDURE|Balance exercises|These exercises will be performed in 2 sets, 5 days a week for 3 weeks. Each set will last 15 minutes. It will take 15 sessions in total. These exercises include 10 balance exercise movements performed on a bosu ball.
214943222|NCT06618625|PROCEDURE|nasotracheal intubation|"For nasotracheal intubation, the nasal RAE tube will be inserted with it rotated by 90 degrees in counter-clockwise direction for patients in the 'Rotation' arm.~For nasotracheal intubation, the nasal RAE tube will be inserted without tube rotation for patients in the 'Neutral' arm."
214943223|NCT06911125|DEVICE|TENS|"TENS will be applied paravertebrally using four electrodes in the neck and back areas. Self-adhesive electrodes specific to each participant will be used for the application. TENS will run on symmetrical biphasic current at 100 Hz and 120 microseconds. The current intensity is determined by the level at which the person perceives the current. The participants are informed that they will get a current, which may induce a pins-and-needles sensation. It is essential for them to perceive the current distinctly; the intensity should be sufficient to be sensed without causing discomfort. The duration of the treatment is 20 minutes. Participants will receive exercises to strengthen the muscles around the neck.~All participants will receive treatment once a day, five days a week. A total of 15 sessions will be conducted over a duration of 3 weeks."
215074560|NCT04603781|DIETARY_SUPPLEMENT|CBD Isolate|300 mg. daily dose of CBD Isolate Oil
215074561|NCT04603781|DIETARY_SUPPLEMENT|Full Spectrum CBD Oil|300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
215074562|NCT04603781|DIETARY_SUPPLEMENT|Broad-Spectrum CBD Oil|300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
215074563|NCT04603781|DIETARY_SUPPLEMENT|Placebo Oil|MCT Oil with mint flavoring
214339780|NCT03792685|OTHER|High-carbohydrate meal intake|Subjects are going to receive the high-carbohydrate meal.
215074564|NCT02563535|DEVICE|DEB|angioplasty with Litos drug eluting balloon
215074565|NCT02563535|DEVICE|PTA|angioplasty with conventional balloon
215074566|NCT05418283|BEHAVIORAL|Exercise|1 hour of aerobic exercise will be applied 3 days a week for 12 weeks.
215074567|NCT03860012|DRUG|Folic Acid|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
215074568|NCT02200328|DRUG|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
215074569|NCT02200328|DRUG|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
214339781|NCT03792685|OTHER|High-fat meal intake|Subjects are going to receive the high-fat meal.
214339782|NCT03792685|OTHER|High-protein meal intake|Subjects are going to receive the high-protein meal.
214339783|NCT06531759|DRUG|Fentanyl|Fentanyl soaked nasal packs.
214339784|NCT01583972|DIETARY_SUPPLEMENT|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
214339785|NCT01583972|DIETARY_SUPPLEMENT|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
214339786|NCT00101101|DRUG|Cyclophosphamide|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
215074570|NCT02916888|OTHER|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
214943224|NCT06911125|DEVICE|Diadinamic Current|Diadynamic current will be performed paravertebrally using two electrodes on the neck and back areas. Participant-specific self-adhesive electrodes will be utilized for the application. In diadynamic current, two distinct current modules, namely diphase-fixed (2 minutes) and short period (8 minutes), will be utilized. The cumulative duration of the treatment is 10 minutes. The program will provide the current intensity at the threshold perceived by the individual. The participants will be informed about the application as follows: 'You will receive a current; you may have a pins-and-needles sensation; it is crucial to perceive the current distinctly and thoroughly; the intensity should neither be insufficient to be felt nor excessive to cause discomfort.' Participants will receive exercises to strengthen the muscles around the neck.All participants will receive treatment once a day, five days a week. A total of 15 sessions will be conducted over a duration of 3 weeks.
214943225|NCT06911463|OTHER|suprainguinal fascia iliaca block group (SIFIB)|The anterior superior iliac spine is identified by a high-frequency linear probe (SonoSite HFL50x, 15-6 MHz, 55-mm broadband linear array, USA) the inguinal ligament in the parasagittal plane, following appropriate disinfection and draping of the patient in the supine position. Then, the probe is moved medially, and the internal oblique muscle in the cranial direction, the sartorius muscle in the caudal direction, the bow-tie shape formed by these muscles, the underlying iliacus muscle, and the fascia iliaca surrounding it is visualized. (21) An 80-mm peripheral nerve block needle is inserted from the caudal side, and the iliac fascia is passed. After identification of the correct area following 2 to 3 mL of hydro-dissection, 40 mL of 0.25% bupivacaine is injected.
215074571|NCT02916888|OTHER|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
215074572|NCT05173948|OTHER|Kinesio taping|Kinesio taping: The tape is measured from the sacrum to the 12th thoracic vertebra with forwarding flexion of the trunk. The base is affixed to the insertion in the resting position. The muscle is elongated and the base anchored with skin displacement. The tape is then affixed with 10% stretch paravertebrally over the muscle bundles up to T12. The tape is rubbed with the muscle in the elongated state.
215074573|NCT05173948|DEVICE|Conventional physical therapy|Transcutaneous electrical nerve stimulation device settings, such as the frequency of 80 Hz, the pulse width of 100 µs, and symmetrical biphasic waveform. Four mediums sized (2 × 2 cm) carbon-impregnated rubber cutaneous electrodes were placed bilaterally in a standard dermatomal pattern over the most painful lumbar region. The current intensity was increased up to the patient's perception of paraesthesia. The supervised exercise therapy management consisted of stretching exercises for the back, iliopsoas, gluteal and hamstring muscles, and strengthening exercises for the abdominal and back muscles. Three sets of stretching exercises, each involving a 30-sec hold and 30-sec of rest repeated three times, were performed in three sessions per week over four weeks. One set of strengthening exercises, consisting of 10 repetitions with a 5-sec hold, was performed in three sessions per week over four weeks.
215074574|NCT01887015|DEVICE|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
214676864|NCT04368130|BEHAVIORAL|SIGNAL|"SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
214676865|NCT03591029|OTHER|blood samples|blood samples will be obtained from the superior vena cava (via centra venous catheter), from the pulmonary artery (via Swan Ganz catheter), and from a radial or femoral artery catheter
214676866|NCT03047460|OTHER|multimodal evoked potentials|
214676867|NCT06972043|OTHER|Intervention Group|The functions performed by the robot include guiding patients through unit-specific locations for environmental orientation and equipment usage instructions, playing educational videos related to care, reminding patients of important examination precautions, providing health education on specimen collection, and delivering responses through an expert-developed medical Q\&A system.
214676868|NCT00510692|DRUG|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
214676869|NCT00510692|PROCEDURE|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
214676870|NCT00510692|PROCEDURE|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
214676871|NCT00510692|DRUG|Placebo|2 x 500mg placebo capsules twice daily for 6 months
214676872|NCT04522752|OTHER|Size and pathological type of benign epithelial gastric polyp|All subjects will undergo gastroscopy and biopsy to determine the size and pathological type of benign epithelial gastric polyps.The correlation between polyp size and type and polyp development was observed at 6 months, 12 months and 18 months after inclusion.
214676873|NCT01180725|DIETARY_SUPPLEMENT|Dried Plum|
214676874|NCT01180725|DIETARY_SUPPLEMENT|Metamucil|
214676875|NCT02093975|DEVICE|iPad air with 4G/3G SIM card|"iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation"
214676876|NCT06180551|DIAGNOSTIC_TEST|DKK-3|DKK-3-Urine measurement
214676877|NCT01765712|PROCEDURE|Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft|
214676878|NCT01765712|BIOLOGICAL|Platelet Rich Plasma|
214676879|NCT02406872|DRUG|Remimazolam Tosilate|IV pumping for anesthesia
214676880|NCT02406872|DRUG|Propofol|IV bolus for anesthesia
214676881|NCT01341509|PROCEDURE|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
214676882|NCT01341509|PROCEDURE|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
214676883|NCT01341509|PROCEDURE|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
214676884|NCT00221845|DRUG|ACE Inhibition|ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
214676885|NCT00221845|DRUG|Intensified Blood Pressure Control|Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
214943226|NCT06911463|OTHER|iliohypogastric and ilioinguinal group (IL-IH)|Group II (I): iliohypogastric and ilioinguinal group (IL-IH) After preparation of the inguinal region sterile linear high frequency probe (SonoSite HFL50x, 15-6 MHz, 55-mm broadband linear array, USA) is placed between the iliac crest and costal margin (more cephalad than the usual location for ilioinguinal block). In this location, the ilioinguinal and iliohypogastric nerves in between the transverses abdominus and internal oblique are well defined (22) After visualization, a 22G 1.5-inch needle is used in out of-plane approach to reach the nerves. After identification of the correct area following 2 to 3 mL of hydro-dissection, 40 mL of 0.25% bupivacaine is injected (kayak sign).
214339787|NCT00101101|DRUG|Doxorubicin|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
214339788|NCT00101101|DRUG|Vincristine|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
214339789|NCT00101101|DRUG|Prednisone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
214339790|NCT00101101|DRUG|Dexamethasone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
214339791|NCT00101101|BIOLOGICAL|Autologous Tumor Cell-Based Vaccine|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
214943227|NCT06911463|OTHER|Local infiltration|patients receive infiltration of 0.5% 10ml bupivacaine and 1% 10 ml lidocaine in the groin at the site of puncture.
214943228|NCT06912399|DEVICE|Transauricular Vagus Nerve Stimulation|Participants enrolled will have a commercial transcutaneous electrical nerve stimulation unit (tVNS501,RISHENA,Changzhou,China) attached to their left outer ear after VATS. The stimulation pulses will target at the cymba concha which is 100% dominated by the auricular branch of the vagus nerve. Stimulation pulses will be 25Hz in frequency according to current clinical research, 500µs in pulse width which has been suggested to be most biologically active, with its amplitude increasing to the maximum amount that the patients can tolerate without pain.
215074575|NCT05290987|DEVICE|nasal spray|2 sprays in each nostril, 6 times a day
214676886|NCT00221845|DRUG|Add-on Angiotensin Receptor Blockade|In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
214339792|NCT00101101|DRUG|IL-2|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
214339793|NCT03876327|PROCEDURE|fecal microbial transplantation|Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.
214676887|NCT05441150|DRUG|Low dose ketamine infusion|Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
214339794|NCT01800903|DEVICE|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
214339795|NCT01800903|DEVICE|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
214339796|NCT01800903|DEVICE|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
214339797|NCT01513252|BEHAVIORAL|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
215074576|NCT02688088|DRUG|Drug Cocktail|Administered orally
215074577|NCT02688088|DRUG|Abemaciclib|Administered orally
215074578|NCT03758079|DRUG|Doxepin|10 mg Doxepin for 4 weeks
214943229|NCT06912399|DEVICE|Sham Transauricular Vagus Nerve stimulation|The only thing differs with the taVNS group is that the device will automatically shut down after running for 15 seconds.
214339798|NCT03061539|DRUG|Nivolumab & Ipilimumab|"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"
214339799|NCT02384603|OTHER|Global postural reeducation|
214339800|NCT02384603|OTHER|Segmental muscle stretching exercises|
214339801|NCT02384603|OTHER|Cognitive behavioral therapy|
214339802|NCT02317159|DRUG|Imatinib|400mg imatinib qd PO
214339803|NCT04150575|DRUG|HLX10+Albumin-Bound Paclitaxel|HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
214339804|NCT02541266|OTHER|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
214339805|NCT03218111|OTHER|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
215074579|NCT03758079|DRUG|Gabapentin|dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks
215074580|NCT03905317|DRUG|Bevacizumab Injection|Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
214943230|NCT06911047|BEHAVIORAL|Education Intervention|Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components: 1. One multimedia e-learning lesson on promoting brain health and preventing dementia; 2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson. 3. Curated resources related to dementia risk factors
214943231|NCT06911047|BEHAVIORAL|Education Control|Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components: 1. One multimedia e-learning lesson on mild cognitive impairment; 2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson. 3. Curated resources related to mild cognitive impairment
214943232|NCT06910852|PROCEDURE|Vascular stapler|the utilization of vascular staplers for the division of the right portal and hepatic veins in patients undergoing right lobe liver donation for living donor liver transplantation
214943233|NCT00059878|BIOLOGICAL|recombinant interferon gamma|
214943234|NCT00059878|DRUG|voriconazole|
214943235|NCT03618563|OTHER|functional individualized therapy for teenagers with executive deficits|Intervention to improve self-perceived performance and performance satisfaction in daily activity goals that adolescent selected,
214943236|NCT04318171|DEVICE|3D Imaging.|"When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:~* Plaque volume where detectable.~* Max area stenosis.~* Volumetric stenosis.~* Measured length.~* 3D GSM. The entire assessment should not take more than 45 minutes."
214943237|NCT04438499|DEVICE|eSense 7fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
214943238|NCT06251024|BIOLOGICAL|RSV vaccine candidate|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
214943239|NCT06251024|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
214943240|NCT06468163|DEVICE|Drug infusion into joint through catheter.|With or without using catheter after DAIR operation for drug infusion.
214676888|NCT05441150|DRUG|0.9% NaCl infusion|Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
214676889|NCT01182129|DRUG|Nicotine|Nicotine pouch, 2.2 mg, single dose, 30 minutes
214676890|NCT01182129|DRUG|Nicotine|Chewing Gum, 4 mg, single dose, 30 minutes
214676891|NCT02379910|DRUG|AM1030-CREAM or placebo|
214676892|NCT01499238|DEVICE|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
214943241|NCT00481013|DRUG|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
214943242|NCT00481013|DRUG|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
214943243|NCT00224406|DRUG|Repertaxin|An initial 'loading dose' of repertaxin was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The study medication was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
214943244|NCT00224406|OTHER|Placebo|An initial 'loading dose' of placebo was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The placebo was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
214943245|NCT00934232|DRUG|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
214943246|NCT03073356|BIOLOGICAL|Infusion of 3-OHB|Increase in 3-OHB levels
214943247|NCT03073356|BIOLOGICAL|Infusion of placebo|NaCl
214676893|NCT01499238|DEVICE|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
214943248|NCT06227715|OTHER|universal adhesive|
214943249|NCT04368832|OTHER|Remote consultation|One or more consultation is conducted by phone or teleconsultation during prenatal monitoring
214943250|NCT01618461|BEHAVIORAL|Drug indication icons|Icons illustrate the purpose of each medication
214943251|NCT01618461|BEHAVIORAL|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
214943252|NCT04964583|DRUG|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
214943253|NCT04009161|PROCEDURE|Tooth extraction|Tooth extraction before the beginning of radiotherapy in patients irradiated for Head and Neck cancer
214943254|NCT05033483|DIETARY_SUPPLEMENT|Ferrous Fumarate|Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose
214943255|NCT05033483|DIETARY_SUPPLEMENT|Placebo|Gelatin capsule containing microcrystalline cellulose
214943256|NCT01556997|DRUG|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
214943257|NCT01556997|DRUG|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
214943258|NCT01556997|DRUG|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
214943259|NCT02535377|OTHER|Sperm cryopreservation|Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
214943260|NCT03571776|PROCEDURE|Surgery|Laparoscopic ovarian cystectomy
214676894|NCT04337138|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination
214676895|NCT04135781|DRUG|nab paclitaxel|nab paclitaxel （120mg/m2；iv；d1，8）
214676896|NCT04135781|DRUG|Tegafur|S-1 （\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）
214676897|NCT04135781|DRUG|Oxaliplatin|Oxaliplatin（130mg/m2 , iv, d1）
214943261|NCT03571776|PROCEDURE|Sclerotherapy|US-aspiration and alcohol sclerosis
214943262|NCT06032026|DRUG|11C-HY-2-15 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-HY-2-15
214943263|NCT06032026|DIAGNOSTIC_TEST|brain MRI|brain MRI scan
214943264|NCT06032026|DIAGNOSTIC_TEST|Amyloid PET scan|PET scan with Florbetaben F18 or 11C-PiB
214943265|NCT06032026|BEHAVIORAL|Neurological assessments|Neurological assessments, including video interview
214943266|NCT01172808|DRUG|Placebo|Placebo that represents comparator
214943267|NCT01172808|DRUG|tiotropium Respimat® low dose|IMP
214943268|NCT01172808|DRUG|Placebo|Placebo that represents comparator
214943269|NCT01172808|DRUG|Placebo|Placebo that represents comparator
214943270|NCT01172808|DRUG|tiotropium Respimat® high dose|IMP
214943271|NCT01172808|DRUG|50 mcg salmeterol HFA MDI|Active comparator
214943272|NCT01172808|DRUG|Placebo|Placebo that represents BI drug
214943273|NCT01172808|DRUG|Placebo|Placebo that represents BI drug
214943274|NCT00507858|DRUG|Pemetrexed|Starting dose of 500 mg/m\^2 IV Once Over 10 Minutes Every 3 Weeks
214676898|NCT04135781|DRUG|Capecitabine|Capetabine（1000 mg/m2 po, d1-14 bid ）
214676899|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is made.
214676900|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve not preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is not made/ can be severed.
214943275|NCT00507858|DRUG|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
214943276|NCT03315598|PROCEDURE|Electroacupuncture|lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
214943277|NCT03529799|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
214943278|NCT03315962|BEHAVIORAL|SPIRIT Intervention|The intervention will include implementing a teaching collaborative among group of DHOs and TB Supervisors, enabling text messaging between DHOs and front line providers, and establishing a report collaborative where DHOs will receive feedback on the performance of their district in administering IPT compared to other districts.
214676901|NCT02909166|DRUG|aliskiren|
214676902|NCT00879268|DEVICE|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
214676903|NCT03151525|DRUG|Azathioprine|AZA treatment after IFX withdrawal for maintenance of remission
214676904|NCT03151525|DRUG|Infliximab|IFX treatment for maintenance of remission
214676905|NCT00389077|DRUG|Perifosine|Perifosine 50 mg tablets
214676906|NCT05104151|DIETARY_SUPPLEMENT|Nutritional bar|Protein-based nutritional bar, providing 155 calories per bar
214676907|NCT05104151|BEHAVIORAL|Healthy Habits Intervention|The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
214676908|NCT04792138|DIAGNOSTIC_TEST|VERDICT MRI|Advanced Diffusion Model
214676909|NCT04792138|DIAGNOSTIC_TEST|Luminal Index Imaging|Advanced T2 mapping
214676910|NCT05665985|DRUG|Moringa Oleifera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
214943279|NCT00450853|DRUG|granisetron|Granisetron SC followed by granisetron IV
214943280|NCT01010009|DIETARY_SUPPLEMENT|Trans- resveratrol|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
214943281|NCT01010009|OTHER|Placebo (silica)|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
214676911|NCT06656247|OTHER|Online consenting|The design and establishment of an innovative digital tool (a software application) to implement the dynamic consent and allowing interaction among healthcare professionals and patients
214676912|NCT06658951|BIOLOGICAL|Anti-HER2 CAR-T cells|All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.
214676913|NCT00787332|DRUG|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
214943282|NCT05313802|DRUG|LY3502970|Administered orally.
214943283|NCT00689624|DRUG|Irinotecan|Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
214943284|NCT00689624|DRUG|Leukovorin|Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
214943285|NCT00689624|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
214943286|NCT00689624|DRUG|5-FLUOROURACIL|5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
214943287|NCT00689624|DRUG|Cetuximab|Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
215074581|NCT03905317|RADIATION|chest radiation|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
215074582|NCT03905317|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
214339806|NCT03218111|OTHER|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
214943288|NCT00311103|PROCEDURE|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
214943289|NCT05264103|DEVICE|Exoskeleton for gait rehabilitation (Atalante)|Subjects will walk with different levels of assistance given by the robot.
214943290|NCT06133413|DEVICE|Body Comp Pro connected scale (Withings manufacturer)|Use once a week
214943291|NCT06133413|OTHER|Alert generation by remote plateform|Alert will be generated from weight regain \> 5% of baseline weight
214943292|NCT02175381|DRUG|Carboplatin|Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
214943293|NCT02175381|DRUG|Gemcitabine|Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
214943294|NCT03468452|OTHER|extubation|Time of extubation
214943295|NCT03458923|DRUG|Diclofenac Sodium 0.1 ml containing 500µg|15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
214943296|NCT03458923|DRUG|Ranibizumab 0.5 mg Solution for Injection|15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months
214943297|NCT02245113|OTHER|diets|Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.
214943298|NCT01631838|DIETARY_SUPPLEMENT|Tocotrienol-rich fraction 400mg|Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
214943299|NCT01631838|DIETARY_SUPPLEMENT|Placebo|Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
214943300|NCT04395313|OTHER|no intervention carried out|no intervention was done
214943301|NCT02513602|PROCEDURE|Dental implant insertion|Dental implant insertion will be carry out in the mandible of the patients enrolled, through a surgical template in order to repeat the same position of the simulating implant insertion. After a trephine bur passage, the final two or three twist-drills will be used to realize the implant socket. After implant positioning, a cover screw will be tightened and the mucosa sutured above.
214676914|NCT04286867|OTHER|Alcohol Moderation Mobile Application|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. Individuals in this group will define their drinking limits within the application. The application will provide time points to aid the individual in maintaining their predefined drinking limits throughout the course of the drinking occasion. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
214676915|NCT04286867|BEHAVIORAL|Alcohol Moderation Drink Tracker|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). Individuals in this group will define their drinking limits, and record their alcohol consumption on the drink tracking card. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
214676916|NCT01001494|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
214339807|NCT00907920|OTHER|laboratory biomarker analysis|Correlative studies
214943302|NCT05026580|BEHAVIORAL|Joint Academy exercise and education smart phone application|The Joint Academy® (www.jointacademy.com) program for people with hip or knee OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period.
214339808|NCT06354153|OTHER|Polarity Management Training Program|60 first-line nurse managers received a training program involving theoretical and practical sessions
214339809|NCT00228527|DRUG|Esomeprazole (Nexium)|
214943303|NCT05284929|GENETIC|A single blood sample for HLA typing|Extracting of DNA from the blood sample using PCR-reaction
214943304|NCT03605940|COMBINATION_PRODUCT|Methoxsalen + ECP device|2 sessions per week during 4 weeks and 1 session per week during 8 weeks
214943305|NCT03605940|DRUG|Corticosteroids|2 mg/kg/day
214943306|NCT02278367|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), up to two doses
214943307|NCT02278367|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
214943308|NCT01022775|PROCEDURE|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
214943309|NCT01022775|PROCEDURE|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
214943310|NCT06237816|OTHER|Patient Education Intervention|Multimedia Educational Videos
214943311|NCT06237816|OTHER|Provider Education Intervention|Provider workshops via zoom
214339810|NCT05896358|BEHAVIORAL|ketogenic diet|a low calorie ketogenic diet
214339811|NCT02466308|DEVICE|SAM Ultrasound Diathermy Device|
214339812|NCT05580731|DIAGNOSTIC_TEST|Diagnostic test: 5 different Rapid diagnostic test and Reference tests|Diagnostic test: 5 different Rapid diagnostic test and Reference tests
214339813|NCT03058406|DRUG|Eribulin mesylate|Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
214339814|NCT01245179|DRUG|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week"
214339815|NCT00000252|DRUG|0% N2O|
214676917|NCT01001494|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
214676918|NCT01001494|DRUG|Placebo|Placebo twice-daily by inhalation for 24 weeks
214339816|NCT00000252|DRUG|10% N2O|
214339817|NCT00000252|DRUG|20% N2O|
214943312|NCT00810017|DRUG|Etoposide|etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles
214943313|NCT00810017|DRUG|Trastuzumab|intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
214943314|NCT02340312|PROCEDURE|EGD|In this study patients are being scoped(EGD) as standard of care and being asked to allow .5 aggregate of tissue biopsy to be taken for research purposes.
214943315|NCT02340312|OTHER|Collection of Stool Specimens|We will be collecting stool samples from each participant for research purposes. Within two weeks after EGD tissue collection.
214943316|NCT05932225|OTHER|Propylene glycol solution/drops|Commercially available eye drops
214943317|NCT02633566|DEVICE|Plantar orthoses|
214943318|NCT02777281|BEHAVIORAL|Shoulder pain and SCI|Shoulder pain and SCI
214943319|NCT02777281|BEHAVIORAL|Shoulder pain and able bodies|
214943320|NCT00933582|DRUG|JNJ-39439335; Placebo; Naproxen|
214943321|NCT00334191|DRUG|Sodium Bicarbonate|
214943322|NCT00334191|DRUG|Placebo|
214943323|NCT02638129|DRUG|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
214943324|NCT02638129|DRUG|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
214943325|NCT02397291|DRUG|Mannose|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
214943326|NCT02397291|DRUG|Myoinositol|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
214943327|NCT02397291|DRUG|Placebo|placebo
214943328|NCT04236336|DEVICE|TSV dental implant|Qualified patient will be those patients who have been newly diagnosed with needing a dental implant (or more than one) in one or more edentulous areas in the maxilla and/or mandible.
214943329|NCT02949908|DRUG|Rebif|Participants diagnosed with RRMS who had discontinued their oral or injectable first-line multiple sclerosis (MS) medication, and have been receiving subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif) were observed during the study. Participants received Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information.
214676919|NCT01914718|DRUG|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
214676920|NCT00591383|DRUG|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
214676921|NCT00591383|DRUG|erlotinib|erlotinib taken at 150 mg every morning with food.
214339818|NCT00000252|DRUG|30% N2O|
214339819|NCT00000252|DRUG|40% N2O|
214339820|NCT02541240|OTHER|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
214339821|NCT05458349|DEVICE|acellular dermis|
214347397|NCT04982042|OTHER|Pulmonary Rehabilitation|The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
214347398|NCT04771169|OTHER|vestibular Training Group|this Group will receive vestibular Adaptation \& Balance exercises
214676922|NCT01011686|BIOLOGICAL|ANT-SM|autologous adipose-derived stem cell
214676923|NCT00163137|DRUG|lasofoxifene|lasofoxifene 0.25mg
214676924|NCT00163137|DRUG|raloxifene|raloxifene 60 mg/day
214676925|NCT00163137|DRUG|Placebo|0 mg/day
214943330|NCT03442166|RADIATION|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
214943331|NCT03442166|RADIATION|Sham group|Patients will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
214943332|NCT00000774|BIOLOGICAL|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
214943333|NCT00000774|BIOLOGICAL|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
214943334|NCT00000774|BIOLOGICAL|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
214943335|NCT00000774|BIOLOGICAL|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
214943336|NCT00664794|PROCEDURE|without acromioplasty|This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.
214943337|NCT00664794|PROCEDURE|with acromioplasty|This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
214943338|NCT01679912|OTHER|phone to the call center|recommendations to phone to the call center for all the patients who have an acute attack
214943339|NCT01131039|DRUG|Gemcitabine/Bevacizumab|"Gemcitabine: IV, days 1,8, and every 21 days~Bevacizumab: IV, day 1 and every 21 days until disease progression"
214943340|NCT00402610|DRUG|isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment|
214676926|NCT03896425|DEVICE|Transcranial direct current stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
214676927|NCT02519231|DRUG|Naproxen|Naproxen 440mg 1x pid
214339822|NCT01891734|OTHER|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
214339823|NCT01891734|OTHER|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
214339824|NCT02780349|DEVICE|WIRION|Embolic Protection System
214347399|NCT04771169|OTHER|Virtual Reality Group|This Group will receive Virtual Reality Training by using exergaming.
214347400|NCT00253864|PROCEDURE|Single row|Fixation type in arthroscopic rotator cuff repair.
214943341|NCT06146699|DEVICE|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross-sectional view of the retina.
214943342|NCT06146699|DEVICE|Fundus fluorescein angiography (FFA)|Fundus fluorescein angiography (FFA) is an invasive diagnostic procedure. It helps to assess the anatomy, physiology, and pathology of retinal and choroidal circulation. It aids in the diagnosis of various ocular pathologies.
214943343|NCT01137461|PROCEDURE|ultrasound-guided embryo transfer|Embryo transfer in oocyte recipients
214943344|NCT06212713|OTHER|Questionnaire administration|Questionnaire administration - version older adults and informal caregivers
214347401|NCT00253864|PROCEDURE|Double row|Fixation type in arthroscopic rotator cuff repair.
214676928|NCT02519231|DRUG|Placebo|Placebo tablet 440mg 1x pid
214943345|NCT04946552|DIAGNOSTIC_TEST|PET Scan|Participants will come to the PET Center to undergo the whole body \[11C\]MRB PET scan. An intravenous bolus dose of MRB (\~20mCi) will be injected by an infusion pump. PET data will be acquired dynamically for 120 min using the Siemens mCT-X whole-body PET/CT scanner using continuous bed motion to image multiple PET bed acquisitions from the top of the head to the lower abdominal region.
214676929|NCT02528695|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT
214676930|NCT02528695|DEVICE|euglycemic clamp|euglycemic clamp
214676931|NCT02528695|DEVICE|hypoglycemic clamp|hypoglycemic clamp
214676932|NCT00233779|DEVICE|SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT|
214676933|NCT00768378|DEVICE|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
214676934|NCT01554215|BEHAVIORAL|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
214676935|NCT01554215|BEHAVIORAL|Mom Power Attentional Control Group|at home control, weekly mailings
214676936|NCT05946330|BEHAVIORAL|NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).|The intervention group will receive educational actions in individual nutrition with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up
214676937|NCT00296439|BEHAVIORAL|Behavior|
214943346|NCT04946552|DIETARY_SUPPLEMENT|Mixed Meal Test|High Carbohydrate Mixed Meal Test (MMT): participants will be studied after a 10-hour overnight fast. A nurse will insert an intravenous (IV) catheter and subjects will ingest a liquid meal (65% carbohydrate, 20% fat, and 15% protein, corresponding to 40% of daily energy expenditure, in \~16 ounces) to be prepared by the Hospital Research Unit Metabolic Kitchen. Blood samples will be collected at -10, 0, 15, 30, 60, 90, and 120 min) for measurement of glucose, insulin and C-peptide concentrations. Plasma samples will be drawn at baseline and throughout the MMT for measurement of additional hormones (such as thyroid hormones, and catecholamines) and free fatty acids (FFA) levels.
214943347|NCT04946552|DIAGNOSTIC_TEST|Muscle sympathetic nerve activity (MSNA)|Recording of multiunit postganglionic muscle sympathetic nerve activity (MSNA) will be made from the common peroneal nerve as it winds around the fibular head with the subject in the supine position with the subject's thigh comfortably supported. This procedure requires to first trace the course of the nerve using small electrical stimuli applied to the surface of the skin over the nerve or use of ultrasound to visually assist.
214943348|NCT04946552|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Following a 10-hour overnight fast, a nurse will insert an intravenous (IV) catheter. Subsequently, subjects will ingest 7.5 oz of Glucola, which contains 75 g of dextrose in orange flavored water. Blood samples will be taken at -15, 0, 10, 20, 30, 60, 90 and 120 minutes (after glucola ingestion) for the measurement of plasma glucose, insulin, and C-peptide concentrations, and calculation of measurements of insulin sensitivity index (Matsuda Index). Approximately 40 mL of blood will be drawn at this visit.
214943349|NCT04946552|OTHER|Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)|will be assessed using bioelectrical impedance analysis Tanita® scale; which is a special multi frequency segmental body composition analyzer that delivers a very mild electrical current that allows measurement of fat mass, percent body fat, fat free mass, total body water, and percent body water. This test will be performed at screening visit.
214943350|NCT04946552|DIAGNOSTIC_TEST|CT Scan|A CT scan will be performed for attenuation correction and to help delineate the BAT and other regions of interest (ROIs). Images will be reconstructed with an ordered subset expectation maximization algorithm using point spread function correction and time-of-flight information. To delineate fat (WAT, BAT) and skeletal muscle regions of interests (ROIs), CT images are first resliced to match the resolution and location of PET images. As performed in previous studies 2, a supraclavicular ROI is first manually drawn on the CT images. Within that area, the fat ROI is segmented using the CT images and an intensity window from -200 to -50 HU. Subsequently the fat ROI is segmented into WAT and BAT ROIs by using the 11C-MRB PET images: Standardized Uptake Value (SUV) ≥ 1.25 for BAT, SUV \< 1.25 for WAT.
214943351|NCT04946552|OTHER|Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)|For better accuracy, measurement of percent fat and percent body water will be obtained with whole body Dual X-Ray Absorptiometry (DXA) scan (Hologic®) on screening-OGTT visit. The scanner arm will move over the participant's body from feet to head. The machine uses a small amount of radiation (one tenth of the amount of radiation from a chest x-ray) to measure body fat, muscle and bone density.
214943352|NCT02890849|OTHER|Liquid biopsy|
214943353|NCT03528057|DEVICE|Hemostat|Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
214943354|NCT00337324|DEVICE|Frequency-modulated electromagnetic neural stimulation|
214943355|NCT00092339|DRUG|MK0966, rofecoxib|
214943356|NCT00092339|DRUG|Comparator: valdecoxib, placebo|
214943357|NCT03102697|DEVICE|Air-filled Intragastric balloon|Weight loss system that consists of an air balloon that occupies space in the stomach, thus reducing the gastric capacity and leaving less volume for food.
214943358|NCT00004892|DRUG|O6-benzylguanine|
214943359|NCT00004892|DRUG|polifeprosan 20 with carmustine implant|
214943360|NCT00004892|PROCEDURE|conventional surgery|
214943361|NCT00729040|BEHAVIORAL|Stepping Up to Health|Internet-mediated walking program with pedometers, goal-setting and tailored messaging
214943362|NCT04260386|OTHER|Non-Interventional|"During the cardiac arrest scenario, the delegates observing will be asked to refer to the maternal cardiac arrest proforma and record those details of events that they are able to see/hear from the video link. In addition, the proforma will be provided to the team taking part in the simulation. One or more team members would routinely be given the role of 'scribe', recording events as they occur. The proforma is accompanied by explanatory notes on how to use it.~Delegates (observers plus scribes) will then be asked to complete a questionnaire, seeking their opinions on the usefulness of the proforma. Questionnaires will be linked to the written consent forms by a participant ID number."
214943363|NCT04129840|OTHER|dual combination|Participants will be started on a dual therapy with half dose of CCB and an ARB. If needed, a) the dose of the CCB will be increased at 4 weeks, and b) the dose of the ARB at 8 weeks, if blood pressure remains uncontrolled ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
214943364|NCT04129840|OTHER|triple combination|Participants will be started with low dose (1/4) triple combination treatment with CCB, TZD and ARB. If uncontrolled after 4 weeks, dosages of all drugs will be doubled. If after 8 weeks still uncontrolled dosage will be increased to full dose of all three drugs ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
214943365|NCT04129840|OTHER|Standard of care|Participants will be started on regular dose of CCB with a) addition of TZD at 4 weeks, if needed, b) increase of dose of TZD after 8 weeks, if needed (if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
214943366|NCT00763516|RADIATION|Proton radiation and chemotherapy|"Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only~Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks~Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation~Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses"
214943367|NCT05070468|DRUG|Dexamethasone 0.5mg|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
214943368|NCT05070468|DRUG|Placebo|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
214943369|NCT03220568|OTHER|Fatty acids present in adipose tissue samples|
214943370|NCT00741585|DRUG|Any antihypertensive medication alone or in combination|All drugs on awakening
214676938|NCT04631718|RADIATION|Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)|"MRI-based QSM methods estimate the susceptibility of tissues based on measuring the magnetic field distortion produced by the tissues themselves.~Upon successful validation, MRI-based abdominal QSM will provide accurate, repeatable, and reproducible quantification of Liver iron concentration (LIC) that is independent of the distribution of iron and does not require calibration."
214676939|NCT02408250|PROCEDURE|Exercise program|Exercise program in intensive care unit established from a decisional algorithm and applied to the critical care unit patients
214676940|NCT02167555|DIETARY_SUPPLEMENT|Active Comparator|Wild Blueberry Beverage
214676941|NCT02167555|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Beverage
214676942|NCT04698408|OTHER|high-protein, carbohydrate-reduced diet|the high-protein, carbohydrate-reduced diet will consist of 1.2-1.4 g/kg/d protein, 26-20en% carbohydrates and +/- 50en% fatty acids, with mainly unsaturated fatty acids. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
214339825|NCT05585333|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
214339826|NCT01181895|DRUG|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
214943371|NCT00741585|DRUG|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
214943372|NCT00741585|DEVICE|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
214943373|NCT02164032|DRUG|Intranasal insulin administration|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
214943374|NCT02164032|DRUG|Insulin Dilution Buffer (Novo Nordisk)|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
214943375|NCT02164032|OTHER|1H magnetic resonance spectroscopy|1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
214943376|NCT03535532|PROCEDURE|unilateral laparoscopic adrenalectomy|unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
214943377|NCT03535532|DRUG|standard medical treatment|standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
214676943|NCT04698408|OTHER|Dutch Nutritional Guidelines|the diet according to the Dutch Nutritional Guidelines will consist of a protein intake of 0.8-1.0 g/kg/d and 50-60en% carbohydrates, and +/-30en% fatty acids, with restriction of saturated fatty acids \<10en%. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
214676944|NCT02246270|DRUG|Intravesical Heparin|Heparin bladder instillation
214676945|NCT02246270|OTHER|Placebo|Intravesical saline
214676946|NCT03958201|COMBINATION_PRODUCT|Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
214339827|NCT01181895|DRUG|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
214943378|NCT02363985|DIETARY_SUPPLEMENT|Mega-dose of vitamin A supplement|vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
214676947|NCT01421368|DRUG|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
214943379|NCT06356818|OTHER|Conventional physiotherapy program|Physiotherapy and rehabilitation treatment program will be applied to the patients. In this program, a 30-40-minute exercise protocol covering proprioceptive, balance and strengthening exercises will be implemented. For a total of 12 sessions, 3 days a week, over a 4-week period
214339828|NCT01181895|DRUG|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
214676948|NCT01421368|DRUG|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
214676949|NCT01421368|DRUG|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
214339829|NCT01181895|DRUG|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
214339830|NCT00363987|DRUG|Ketosteril®|1 tablet Ketosteril/5kgBW/d
214339831|NCT00363987|OTHER|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
214339832|NCT01639079|BEHAVIORAL|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
214339833|NCT06294314|PROCEDURE|Fertilized ACL|Fertilized ACL is an acl reconstruction with Bone marrow aspirate, demineralized bone matrix, and an internal brace.
214339834|NCT05739500|OTHER||no intervention, just observation
214339835|NCT04002765|DIAGNOSTIC_TEST|pulmonary function tests|"1. Lung function tests (standard of care)~   1. Dynamic and static volumes (FVC, FEV1, TPC, RV)~  2. Lung diffusion capacity for CO (DLCO)~2. Chest Xrays~3. High resolution CT scanner (HRCT)"
214339836|NCT03362515|DRUG|Furosemide|furosemide
214339837|NCT03362515|DRUG|Placebo|placebo
214339838|NCT02747069|DEVICE|NICU electronic stethoscope|Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU
214339839|NCT02747069|DEVICE|Newborns <32 weeks and ECG|The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (\<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
214943380|NCT06356818|OTHER|Virtual reality (VR)|virtual reality (VR) program will be applied using balance and strengthening games by Nintendo Wii Fit Plus; warm-up exercise (5 minutes), workout (20 minutes) and cool-down exercise (5 minutes) for a total of 30 minutes. For a total of 12 sessions, 3 days a week, over a 4-week period
214676950|NCT02124798|DEVICE|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
214676951|NCT03851861|OTHER|Mediterranean Diet|"Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consumption of ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fresh fruits (including natural juices); d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish or seafood (at least one serving of fatty fish); f) ≥3 weekly serving of nuts or seeds; g) select white instead of red meats or processed meats (burgers, sausages); h) cook at least twice a week with a tomato herb sauce.~Participants will be instructed to eliminate or limit the consumption of the following foods: cream, butter, margarine, cold meat, paté, duck, carbonated and/or sugared beverages, pastries, industrial bakery products and desserts, French fries or potato chips, and out-of-home pre-cooked cakes and sweets. For usual drinkers, the main source of alcohol should be wine."
214943381|NCT06356818|OTHER|Motor imagery (MI)|Patients will be introduced to explicit Motor imagery program which the content of the imagery program will last 20 minutes in total, with 5 minutes of relaxation and 15 minutes of imagery training. For a total of 12 sessions, 3 days a week, over a 4-week period.
214943382|NCT05514743|PROCEDURE|6 minute walk test , Blood pressure monitoring|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day \&in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days."
214943383|NCT06096298|OTHER|Vitamin B12 bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour containing vitamin B12 produced by P. freudenreichii bacteria.
214943384|NCT06096298|OTHER|Control bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour.
214943385|NCT02607280|DRUG|DS-5565|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
214943386|NCT04480333|DRUG|Drug: NA-831 - 0.10 mg/kg|NA-831 in nanoparticle inhalation formulation
214943387|NCT04480333|DRUG|Placebo- 0.10 mg/kg|Placebo in nanoparticle inhalation formulation
214943388|NCT04480333|DRUG|Drug: NA-831 - 0.20 mg/kg|NA-831 in nanoparticle inhalation formulation
214943389|NCT04480333|DRUG|Placebo- 0.20 mg/kg|Placebo in nanoparticle inhalation formulation
214943390|NCT04480333|DRUG|Drug: GS-5734 - 1.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
214943391|NCT04480333|DRUG|Placebo- 1.00 mg/kg|Placebo in nanoparticle inhalation formulation
214943392|NCT04480333|DRUG|Drug: GS-5734 - 2.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
214943393|NCT04480333|DRUG|Placebo- 2.00 mg/kg|Placebo in nanoparticle inhaled formulation
214943394|NCT04480333|COMBINATION_PRODUCT|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
214943395|NCT04480333|COMBINATION_PRODUCT|Placebo 0.10 mg + 1.00 mg/kg|The combined placebo are in nanoparticle inhaled formulation
214943396|NCT04480333|COMBINATION_PRODUCT|Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
214943397|NCT04480333|COMBINATION_PRODUCT|Placebo 0.20 mg + 2.00 mg/kg|Placebo 0.10 mg + 1.00 mg/kg
214943398|NCT06401343|DRUG|Empagliflozin 10 MG|Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.
214943399|NCT03745105|DRUG|Dexamethasone sodium phosphate|prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.
214943400|NCT03745105|DRUG|Piroxicam Injectable Solution|prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
214943401|NCT03745105|DRUG|Mepivacaine HCL|prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml
214339840|NCT00996567|DRUG|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
214339841|NCT00766415|DRUG|AZD1981|Oral tablet, twice daily, 4 weeks treatment
214339842|NCT00766415|DRUG|Placebo|Placebo
214339843|NCT01312467|DRUG|metformin hydrochloride|
214339844|NCT02430077|DRUG|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
214339845|NCT02430077|DRUG|Placebo|Identical to Obeticholic Acid - placebo drug
214339846|NCT02752048|DRUG|TAS-205|2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
214339847|NCT02752048|DRUG|Placebo|1 group: Placebo group. Oral administration for 24 weeks, BID after meal
214339848|NCT03899870|PROCEDURE|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
214339849|NCT03899870|DRUG|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil \[5-FU\] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
214339850|NCT03899870|DRUG|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
214339851|NCT03030833|DEVICE|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
214339852|NCT03772405|DRUG|Nascum Plus|nasal application of nascum plus
214339853|NCT03772405|OTHER|ACC|4 hours challenge to grass pollen in the allergen challenge chamber (ACC)
214943402|NCT04148898|DRUG|Osimertinib|Treatment of LM With osimertinb
214943403|NCT04148898|DRUG|Bevacizumab|Treatment of LM With osimertinb combined with bevacizumab
214943404|NCT06428994|RADIATION|Radiotherapy|Post-operative radiotherapy for head and neck cancer
214943405|NCT02532452|BIOLOGICAL|Viral Specific VST Infusion|"VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \> 1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~* Evidence of PML or other CNS infection due to JC virus"
214943406|NCT01004432|DRUG|Golimumab 50 mg SC|Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
214943407|NCT01004432|DRUG|Golimumab 2 mg/kg IV|Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
214943408|NCT01004432|DRUG|Methotrexate (MTX)|Participants will continue taking their current Methotrexate (MTX) treatment regimen.
214943409|NCT01004432|DRUG|Placebo SC|Placebo matched to golimumab SC injection every 4 weeks.
214943410|NCT01004432|DRUG|Placebo IV|Placebo matched to golimumab intravenous infusion every 8 weeks.
214339854|NCT00969852|DRUG|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
214943411|NCT06386900|OTHER|Cyclist|Participating in the Grand Tour as cyclist
214339855|NCT05095584|DIAGNOSTIC_TEST|3 meter backward walk test|validity and reliability of 3-meter backward walk test in lower limb amputation group
214339856|NCT03213093|OTHER|Measure of cutaneous microcirculation|Measure of cutaneous microcirculation in response to a local application of pressure, to local heating and to the iontophoretic administration of acetylcholine
214339857|NCT04090944|PROCEDURE|the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position|-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
214339858|NCT06532045|DEVICE|Transcutaneous electrical nerve stimulation|TENS applied for 30 min for each time, five times a week, for 2 weeks and deep breathing relaxation exercise given to the intervention group twice a day (10min/exercise) for two weeks.
214339859|NCT01455649|DRUG|Everolimus|Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
214339860|NCT01455649|DRUG|calcineurin inhibitor|Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
214339861|NCT02376413|PROCEDURE|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
214339862|NCT02376413|DRUG|Chemotherapy or endocrine therapy or Trastuzumab therapy|
214339863|NCT02376413|RADIATION|Radiation therapy|
214339864|NCT00217906|BEHAVIORAL|A+ Asthma early intervention program|
214943412|NCT02862132|DRUG|Vedolizumab|
214943413|NCT02022475|DRUG|Vitamin D|100 000 units oral vitamin D as 2 capsules 50 000 units each
214339865|NCT02440152|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
214339866|NCT01287442|PROCEDURE|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
214943414|NCT02022475|OTHER|placebo|2 placebo capsules will be applied as a single dose
214943415|NCT06731842|OTHER|18F-RO948|Tau PET imaging using the tau PET tracer 18F-RO948 in famial and sporadic Alzheimer´s disease
214943416|NCT02667626|OTHER|Reproductive Health Survivorship Care Plan (SCPR)|The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
214943417|NCT02667626|OTHER|Control|Web-based resource lists and text-based study adherence reminders
214943418|NCT05167331|DRUG|Nitrous Oxide inhalation|use of Nitrous Oxide inhalation on children's anxiety during a dental treatment
214943419|NCT05167331|DEVICE|Dispositif de RV - HYPNO VR|use of Virtual Reality on children's anxiety during a dental treatment
214943420|NCT01134289|PROCEDURE|lumbar sympathetic block|unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
214943421|NCT02114294|OTHER|Isolated hip strengthening|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
214943422|NCT02114294|OTHER|Quadriceps based training|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.
214943423|NCT02114294|OTHER|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
214943424|NCT03933020|DEVICE|VR active video game intervention|The Microsoft VR active game program will consist of 3 weekly sessions of 45 minutes each combining 3 different types of exercise
214943425|NCT03933020|BEHAVIORAL|Educational session|This consists of two education discussion sessions on the benefits of exercise for people with MS. The investigator MS specialists will conduct these sessions either by phone or at the time of a clinic visit and will also discuss difficulties encountered by participants with adherence.
215074583|NCT02275390|BEHAVIORAL|Nurse-led Psycho-education (or SPBB: self-learning program)|"The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).~\[Note: SPBB consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5: Dealing with \[physical and mental health\] effects of the illness).\]"
214676952|NCT04756895|OTHER|Vancomycin dose adjustment using the Bayesian method|This intervention is the experimental method. The AUC/MIC target is 400-600 mg\*hour/L.
214676953|NCT04756895|OTHER|Vancomycin dose adjustment using the trough level method|This intervention is the standard method. Previous clinical guidelines recommended this method. The trough target is 10-15 mg/L for non-severe infections and 15-20 mg/L for severe infections.
214339867|NCT04702074|DRUG|Traditional Chinese medicine granules|"Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months."
214339868|NCT04702074|DRUG|Traditional Chinese medicine granules placebo|"Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules ."
214943426|NCT03933020|BEHAVIORAL|Standard Management of Physical Activity|Routine discussion of lifestyle factors including physical activity during clinic visits
214943427|NCT00201812|DRUG|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
214943428|NCT00201812|DRUG|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
214943429|NCT00201812|DRUG|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
214943430|NCT00568568|DRUG|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
214943431|NCT06304922|BEHAVIORAL|Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer|Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer
214943432|NCT02696434|DRUG|Naltrexone|daily dosing
214943433|NCT02696434|DRUG|Placebo|daily dosing
214943434|NCT02696434|DRUG|Buprenorphine|daily dosing
214943435|NCT00235781|DRUG|Thymoglobulin|
214676954|NCT06388369|RADIATION|[177Lu]Lu-PSMA-617|2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals
214676955|NCT06388369|DRUG|Ipilimumab|4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals
214676956|NCT00827203|DRUG|Elesclomol Sodium|Chemotherapy agent
214676957|NCT02862795|PROCEDURE|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
214676958|NCT01435512|BEHAVIORAL|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
214943436|NCT02411318|BEHAVIORAL|Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.
214339869|NCT04159831|DRUG|LTI-01|single-chain urokinase plasminogen activator, scuPA
214943437|NCT02411318|DRUG|ProLab 200mg caffeine capsule|Participants will swallow one ProLab caffeine 200mg tablet.
214943438|NCT02411318|OTHER|Ethanol ingestion|Participants will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.
214943439|NCT02411318|DRUG|Glucose Tolerance Drink|Participants will consume 100 grams of glucose
214339870|NCT04159831|DRUG|Placebo|normal saline
214339871|NCT02769143|OTHER|Whole-Body Vibration|Will be performed six months of WBV exercises
214943440|NCT00747253|DEVICE|AutoLITT system|laser treatment with the AutoLITT system
214943441|NCT02944435|DRUG|CB-839 Capsules|3 x 200 mg CB-839 Capsules (Reference Formulation)
214943442|NCT02944435|DRUG|CB-839 Tablets|3 x 200 mg CB-839 Tablets (Test Formulation)
214943443|NCT03990779|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic examination before and after cardiopulmonary bypass
214943444|NCT05480228|DRUG|NRD135SE.1|The double-blind treatment phase is up to 13 weeks.
215074584|NCT02275390|BEHAVIORAL|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
215074585|NCT00366028|BEHAVIORAL|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
214339872|NCT02769143|OTHER|Pilates|Will be performed six months of Pilates exercises
214339873|NCT05676411|DRUG|Benzoyl Peroxide Topical|Topical benzoyl peroxide cream will be applied to the shoulder skin twice a day for 2 days leading up to and in the morning of surgery.
214943445|NCT05480228|OTHER|Placebo|A matching placebo will be taken for up to 13 weeks.
214339874|NCT05676411|PROCEDURE|Electrocautery surgical skin incision|The skin incision will be made entirely using electrocautery at the beginning of shoulder replacement.
214943446|NCT06127654|DEVICE|Healthy lung sparing treatment plan|CT Ventilation imaging will be used to create a healthy lung sparing treatment plan for patients who will receive radiation therapy treatment for their lung cancer.
214943447|NCT06366620|BEHAVIORAL|FAST-B PEERS|FAST-B PEERS consists of trained Peer Support providing weekly check-in calls with families going through FAST-B behavioral parent training program. Peer Support are parents who have previously participated in a behavioral parent training program who have undergone 6-8 hours of additional dedicated training.
214943448|NCT06366620|BEHAVIORAL|FAST-B (First Approach Skills Training - Behavior)|5-week parent behavioral management training program
214943449|NCT02539134|DRUG|TAK-935|TAK-935 oral solution
214339875|NCT01003418|BIOLOGICAL|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
214339876|NCT01003418|BIOLOGICAL|Infanrix™-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
214339877|NCT01003418|BIOLOGICAL|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
214339878|NCT04141293|PROCEDURE|alveolar recruitment|Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
214339879|NCT02798198|OTHER|T2DM|T2DM without DKD
214339880|NCT02206529|BEHAVIORAL|Social Network Engagement+Std Treatment|
214339881|NCT02206529|BEHAVIORAL|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
214676959|NCT01797432|DRUG|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
214676960|NCT01797432|DEVICE|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
214676961|NCT05968950|DEVICE|Thoracic ultrasound|The use of ultrasound to count ribs in order to surface mark the corresponding spinal level
214676962|NCT00815308|DRUG|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)
214676963|NCT00815308|DRUG|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)
214676964|NCT00815308|DRUG|Cisplatin|Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)
214676965|NCT00815308|RADIATION|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
214943450|NCT02539134|DRUG|Placebo|TAK-935 placebo-matching oral solution
214943451|NCT01116713|DRUG|intravenous dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.
214943452|NCT01116713|DRUG|Homologated placebo.|Patients of the control group received homologated placebo 60 minutes before skin incision
214943453|NCT02436902|PROCEDURE|TACE|TACE is performed one month after resection.
214943454|NCT02436902|DRUG|Sorafenib|Sorafenib is submitted one month after resection.
215074586|NCT00366028|BEHAVIORAL|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
215074587|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
214943455|NCT02436902|DRUG|TACE plus sorafenib|TACE plus sorafenib will be submitted one month after resection.
214943456|NCT02436902|OTHER|empty control|This group will not receive adjuvant therapy.
214943457|NCT02911259|DEVICE|Suction is set to -2 cmH2O|Post-operative suction is set to -2 cmH2O (intervention).
214943458|NCT02911259|DEVICE|Suction is set to -10 cmH2O|Post-operative suction is set to -10 cmH2O (standard treatment).
214943459|NCT05969496|DRUG|Axitinib|Axitinib is a potent oral, vascular endothelial growth factor, c-kit and platelet derived growth factor inhibitor.
214943460|NCT05969496|DRUG|Pembrolizumab|Pembrolizumab is a type of immunotherapy. It stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
214943461|NCT06435351|PROCEDURE|Leukapheresis|"Removal of white blood cells (leukocytes) from the blood. The dendritic cells are harvested from the white blood cells that are collected and trained to recognize the specific abnormal proteins found in the tumor sample.~One needle is inserted in each arm. An apheresis machine removes blood from the vein in one arm, separates and retains the leukocytes from the blood, and then returns the rest of the blood to the other arm."
214943462|NCT06435351|BIOLOGICAL|Dendritic Cell (DC) Vaccine|"The vaccine will be given intranodally (inguinal or axillary) under ultrasound guidance using a dose of 40-50 million cells three times spaced 2 weeks apart for the initial priming sequence.~3 doses of the priming vaccines are given once every 2 weeks. 2 booster shots (if available) will be given 6 months and 12 months following completion of initial priming vaccines."
214943463|NCT01778738|PROCEDURE|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
214943464|NCT01778738|PROCEDURE|Sleeve gastrecomy|Vertical sleeve gastrectomy
214943465|NCT01778738|PROCEDURE|Bastric bypass|Gastric bypass surgery
215074588|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
215074589|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
215074590|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
214943466|NCT00034619|DRUG|ALIMTA|
214943467|NCT00034619|DRUG|Oxaliplatin|
214943468|NCT05350332|DEVICE|Negative Pressure Ventilator|The negative pressure ventilator is an off-the-shelf FDA-approved device designed to treat respiratory patients with hypoventilation syndromes. This ventilator places the torso within a fixed container that is connected to a vacuum source, which inflates the lungs by pulling a negative pressure around the chest and abdomen. After the clinically routine DISE, a negative pressure ventilator will be placed on the participant's chest to increase lung volumes and the DISE evaluation will be repeated to observe changes.
214943469|NCT05350332|DEVICE|Pulmonary Function Testing (PFT)|PFT is a routine standardized clinical test evaluating lung function, consisting of two parts: spirometry and body plethysmography. In spirometry, participants breathe through a mouthpiece that measures airflow and volume to determine normal and maximal volume of inspiration/expiration. Body plethysmography is performed to calculate residual lung volumes. Participants enter in an enclosed chamber where they breathe through a mouthpiece. Changes in pressure in the sealed chamber during breathing are used to calculate the volume of air that remains in the lung after expiration. A MiniBox+ device may be used. The MiniBox+ device derives total lung capacity (TLC) during tidal breathing by the analysis of gas pressures and airflows immediately preceding and immediately following airway occlusions to calculate the same measures as conventional PFT analysis.
214943470|NCT05350332|DEVICE|Transcutaneous Phrenic Nerve Stimulation|Phrenic nerve stimulation (PNS) will be performed transcutaneously using a commercially available and FDA approved peripheral neurostimulator. (Digitimer DS8R Bipolar Constant Current Stimulator). The neurostimulator consists of a stimulation generating box connected to electrodes that will be placed over the skin of the neck bilaterally over both phrenic nerves where an bipolar electric current will be used to stimulate the phrenic nerve leading to diaphragm contraction.
214943471|NCT03722745|BEHAVIORAL|TARGET|TARGET is manualized cognitive-behavioral treatment designed to help adolescents and adults with symptoms of posttraumatic stress
214943472|NCT03722745|BEHAVIORAL|TAU|It involves referral to an offsite community mental health provider with no attempt to control the treatment modality-type-quality (i.e., evidence-based-treatment or not).
214943473|NCT04605380|OTHER|Virtual reality online world|Virtual patient with open fracture inside a virtual world
214676966|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
214676967|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
214676968|NCT02171715|DRUG|BIBW 2992 MA2|powder for oral solution
214676969|NCT05783258|PROCEDURE|Periodontal surgery with CAF+tSCTG|Coronally advanced flap and subepithelial connective tissue graft harvested from the maxillary tuberosity area.
214676970|NCT05783258|PROCEDURE|Periodontal surgery with CAF+L-PRF|Coronally advanced flap and L-PRF membranes
215074591|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
215074592|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
215074593|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
215074594|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
215074595|NCT01768156|OTHER|Experimental arm|"Serum samples are collected:~* at time of diagnosis of recurrence (before 1st chemotherapy)~* during each cycle of chemotherapy~* after the end of chemotherapy~* every 3 month until treatment failure (3-6 samples)~* stop at the progression or after 18 months post chemotherapy"
215074596|NCT05996029|COMBINATION_PRODUCT|Digital Smoking Cessation|The core technology of the study is a smoking cessation assistance practice service driven by a machine learning algorithm. The small programs used by the intervention group in this study included smoking cessation service packages based on cognitive behavioral therapy and online guidance from medical staff on staff, and more digital smoking cessation tools.
215074597|NCT04207918|RADIATION|Radiotherapy|44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
215074598|NCT04207918|DRUG|Nimotuzumab|400mg, by intravenous infusion once a week in 4-6 weeks.
214676971|NCT01520792|DRUG|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
214676972|NCT06070610|DRUG|BI 1015550|BI 1015550
214339882|NCT06169917|BEHAVIORAL|Paced Resonance Frequency Breathing|Participants are required to pace their breathing to their pre-determined individual resonance frequency.
214339883|NCT06169917|BEHAVIORAL|Paced Breathing at Natural Frequency|Participants are required to pace their breathing to their pre-determined individual breathing frequency at rest.
214339884|NCT06169917|OTHER|Heat Stimulations|Participants will undergo a heat stimulation procedure on their left and right foot (the order of which is counterbalanced across participants). During this procedure, there are 10 blocks, with an inter-stimulus interval of 30 seconds between two blocks. During a block, six 6-second heat stimulations (48 degrees) are given. Between the stimulations, the temperature quickly returns to baseline (32 degrees).
214676973|NCT06070610|DRUG|Nintedanib|Soft capsules
214943474|NCT01811862|PROCEDURE|Acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
214943475|NCT01811862|PROCEDURE|Sham acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
214943476|NCT06100692|DRUG|Vitamin D|the patients will receive a 30 pts a combination of oral vit D and zinc
214943477|NCT06618430|OTHER|None (Observational Study)|None (Observational Study)
214943478|NCT01947426|DIETARY_SUPPLEMENT|DHA Supplementation|mothers consuming 400 mg of DHA/day and their neonates
214943479|NCT01947426|DIETARY_SUPPLEMENT|Control (milk without DHA)|mothers consuming placebo product and their neonates
214943480|NCT04336462|DEVICE|oxyhydrogen|Hydrogen-Oxygen Generator with Nebulizer Model: AMS-H-03 Gas production: 2.0 L/min, 2.5 L/min, and 3 L/min, three gears in total (in this study, the gas production of each machine is 3 L/min, two sets are connected and used together by three-way connection, and the total gas production is 6 L/min.) Manufacturer: Shanghai Asclepius Meditech Co., Ltd.
214943481|NCT04336462|DEVICE|Oxygen|oxygen inhaled,3 L/min . 6 hour a day.
214943482|NCT05528913|DRUG|Fasenra Prefilled Syringe|Fasenra 60mg s.c. administration at weeks 0,4 and 8
214943483|NCT05528913|OTHER|Matching Placebo Solution|Placebo s.c. administration at weeks 0,4 and 8
214943484|NCT06623565|PROCEDURE|Multimodal image-guided resection|Supramarginal resection using combination of ADC MRI and FET PET
214943485|NCT02193139|DRUG|WL8713, 6 mg|
214943486|NCT02193139|DRUG|WL8713, 12 mg|
214943487|NCT02193139|DRUG|WL8713, 18 mg|
214943488|NCT02193139|DRUG|WL8713, 24 mg|
214943489|NCT02193139|DRUG|Placebo|
214943490|NCT02823834|DEVICE|PROFEMUR® Gladiator Plasma Femoral Stems|THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
214943491|NCT01149421|DRUG|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
214943492|NCT01149421|DRUG|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
215074599|NCT04207918|DRUG|S-1|40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
215074600|NCT00099060|DRUG|lapatinib ditosylate|"For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):~* Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).~* Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.~For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):~• Phase II: 750 mg GW572016 po b.i.d.~For all patients:~• Dose reductions as required based on adverse events."
214943493|NCT03160001|DRUG|Placebo|Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
214943494|NCT03160001|DRUG|Niclosamide|Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks
214943495|NCT03160001|DRUG|Etanercept|Etanercept 50mg weekly
214347402|NCT03955653|PROCEDURE|Femoral artey access|We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention
215074601|NCT03790358|DRUG|Lysergic Acid Diethylamide|Drug will be administered in solution form.
215074602|NCT03679858|OTHER|Platelet function test|Ex vivo platelet aggregation analysis by Multiplate aggregometer
215074603|NCT05128474|OTHER|Neuromuscular Control-Based Exercise Training Group|Exercises for the neuromuscular control of the shoulder will be progressed by starting with the body weight, and in the following phases, a program that progresses to exercises that will improve the dynamic stabilization, coordination and proprioception of the shoulder will be applied to train the sensorimotor system. The exercise program will be performed twice a week for 8 weeks (16 sessions).
215074604|NCT05128474|OTHER|Conventional Exercise Training Group|In this group, which will mainly benefit from conventional open kinetic chain strength exercises, a strengthening exercise program will be applied by advancing from body weight to elastic bands and weights. The exercise program will be performed twice a week for 8 weeks (16 sessions).
214339885|NCT05436574|OTHER|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the elderly population housed in the establishments of UNIVI group.
214339886|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
214339887|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
214339888|NCT00898677|DRUG|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
214339889|NCT00898677|DRUG|Comparator: Placebo|placebo to rizatriptan
214339890|NCT05857046|DRUG|Melatonin 10 MG|Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
214339891|NCT05857046|OTHER|Placebo|Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
214339892|NCT02157740|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
214943496|NCT06643767|DEVICE|Bexa and focus ultrasound|The Bexa exam uses pressure elastography to produce a map of the breast tissue's elasticity to identify any masses. Focused ultrasound is then used to further classify the mass into a BIRADS category.
214943497|NCT00707902|DRUG|chlorhexidine/lidocaine|
214943498|NCT00707902|DRUG|echinacea/sage|
214943499|NCT00616603|DRUG|Ropivacaine|20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
214676974|NCT06070610|DRUG|Pirfenidone|Film-coated tablets
214339893|NCT00019682|BIOLOGICAL|Aldesleukin|Given IV
214339894|NCT00019682|BIOLOGICAL|gp100 Antigen|Given SC
214339895|NCT00019682|DRUG|Montanide ISA 51 VG|Given SC
214339896|NCT00019682|OTHER|Quality-of-Life Assessment|Ancillary studies
214339897|NCT00019682|OTHER|Questionnaire Administration|Ancillary studies
214339898|NCT00019682|OTHER|Laboratory Biomarker Analysis|Correlative studies
214943500|NCT00616603|DRUG|Dexamethasone|8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
214943501|NCT00616603|DRUG|Dexamethasone|2ml(8mg)Dexamethasone given once intravenously.
214943502|NCT00616603|DRUG|Normal Saline|2ml of normal saline given once intravenously.
214943503|NCT06514378|BIOLOGICAL|Mesenchymal stem cells|Endobronchial administration of 10⁶ MSCs/kg in each transplanted lung, 4 weeks apart.
214943504|NCT03964467|DEVICE|transcranial direct current stimulation|see arm/group descriptions
214943505|NCT06648525|DRUG|Adebrelimab|Adebrelimab, IV
214943506|NCT06648525|DRUG|Irinotecan liposomes|Irinotecan liposomes, IV
214943507|NCT06648525|DRUG|Lenvatinib|Lenvatinib, po
214943508|NCT06648525|DRUG|5-Fluorouracil (5-FU)|5-Fluorouracil (5-FU), IV
214676975|NCT06096194|DIETARY_SUPPLEMENT|vitamin D-enhanced egg|"In our study, the vitamin D3-enhanced eggs were produced by hens that received 23,500 IU of vitamin D3 per kg of feed. Which does not confer them any harm or danger of intoxication. This experiment was carried out at the Center for Teaching, Research and Extension in Poultry Production (CEIEPAv, FMVZ-UNAM) and lasted 40 weeks.~This ensured that the hens eggs were enhanced with vitamin D achieving a final concentration of approximately 400 IU of vitamin D"
214676976|NCT06096194|OTHER|Control|Unfortified eggs were used for the control group with a concentration of approximately 43 IU of vitamin D
214676977|NCT02086773|BIOLOGICAL|Red blood cell transfusion|
214676978|NCT02585804|DRUG|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
214339899|NCT02116322|PROCEDURE|EUS-FNA with Corkscrew technique|
214339900|NCT02116322|DEVICE|Expect 19 G Flex needle|
214339901|NCT00373243|DRUG|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
214339902|NCT03860896|DRUG|GB004|GB0004 high dose
214339903|NCT03860896|DRUG|Placebo|Placebo
214339904|NCT03860896|DRUG|GB004|GB004 low dose
214339905|NCT01142245|DRUG|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
214339906|NCT01142245|DRUG|Intravenous Esomeprazole|"Esomeprazole IV 80mg loading bolus~* Esomeprazole intravenous infusion 8mg/hr for 72 hours"
214339907|NCT02479984|PROCEDURE|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
214339908|NCT02479984|DEVICE|Laparoscopic ultrasound|
214339909|NCT05039905|DRUG|99mTc-MSA-ICG|Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
214339910|NCT00385970|DRUG|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
214943509|NCT06648525|DRUG|Calcium Folinate|Calcium folinate, IV
214943510|NCT05900817|OTHER|antivet|A material used for micro abrasion of teeth
214943511|NCT05900817|OTHER|Oplsture|A material used for micro abrasion of teeth
214943512|NCT05286359|DIAGNOSTIC_TEST|NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device|"NxTekTM Malaria Pf/Pv Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum(P.f.) on one test line and of pLDH of Plasmodium vivax (P.v.) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~NxTekTM Malaria Pf Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Plasmodium falciparum(P.f.) malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
214943513|NCT06623279|GENETIC|HG202|Method of Administration: Once unilateral subretinal injection; The duration of the study includes a 4-week screening period, enrollment visit, treatment visit and 52 weeks follow-up period, 4 more years long term follow up as an extension study.
214676979|NCT01916369|BIOLOGICAL|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
214676980|NCT02796989|DIETARY_SUPPLEMENT|Wheat bran|20 g each day
214676981|NCT02796989|DIETARY_SUPPLEMENT|Placebo|20 g each day
215074605|NCT04801459|PROCEDURE|Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction|In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
215074606|NCT04847752|PROCEDURE|carotid artery stenting|common treatments for carotid artery stenosis
214676982|NCT03927729|DRUG|Methoxyflurane|Pain will be treated with inhaled methoxyflurane (Penthrox®).
214676983|NCT03078491|OTHER|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
214676984|NCT02569489|DRUG|HBI-8000|
214676985|NCT02569489|DRUG|Trastuzumab|
214676986|NCT02569489|DRUG|Paclitaxel|
214676987|NCT02428140|DEVICE|Medtronic Reveal LINQ|
214943514|NCT04750733|OTHER|Assessment|Assessment of core strength and endurance, muscle strength, postural sway in different condition, physical capacity and fatigue
214943515|NCT03147300|BEHAVIORAL|Current routine practice|Current routine practice for the primary care management of LBP
214339911|NCT00385970|DRUG|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
214339912|NCT00385970|DRUG|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
214339913|NCT06662643|PROCEDURE|Delayed transanal pull-through anastomosis|Laparoscopic surgery is recommended. A standard 5-port method is used to create pneumoperitoneum after placing the trocar. The sigmoid colon and upper rectal mesentery are dissected along Toldt's fascia. Autonomic nerves should be preserved, and high ligation of the inferior mesenteric vessels with lymph node dissection is recommended. TME: Using a posterior-to-anterior approach, the mesorectal plane is dissected down to the pelvic floor, cutting the Waldeyer's fascia to enter the intersphincteric space, where sharp dissection is carried out toward the levator ani muscle hiatus. The dissection endpoint is the dentate line, where the proximal colon is exteriorized by at least 2 cm and sutured to the anal canal with 6-8 stitches, without a protective ileostomy.Two to four weeks after the first surgery, after the colon has adhered well to the surrounding tissue, the exteriorized colon is excised (under epidural or spinal anesthesia, trimming the exteriorized colon to form the anus).
214347403|NCT00659334|DRUG|Ferumoxtran-10 (Combidex)|2.6 mg/kg
214347404|NCT00659334|PROCEDURE|Neurosurgery|neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
214347405|NCT01538017|DRUG|Xiapex|Collagenase Clostridium Histolyticum
214676988|NCT02428140|DEVICE|Sorin Spiderflash-t|
214676989|NCT04055935|PROCEDURE|elevation of full thickness mucoperiosteal flap|A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
214676990|NCT04055935|DEVICE|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
214676991|NCT05315310|DEVICE|Soft Exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
215074607|NCT04847752|PROCEDURE|carotid endarterectomy|common treatments for carotid artery stenosis
215074608|NCT04847752|DRUG|Aspirin|the dosage and duration
215074609|NCT04847752|DRUG|Clopidogrel|the dosage and duration
215074610|NCT04847752|DRUG|Anticoagulant|the dosage and duration
215074611|NCT04847752|DRUG|Statin|the dosage and duration
215074612|NCT04847752|DRUG|PCSK9 inhibitor|the dosage and duration
215074613|NCT01309048|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
215074614|NCT00306657|PROCEDURE|Optic nerve sheath fenestration|
215074615|NCT05921682|OTHER|observation|This study is an observational study. Patients will receive conventional cooling measures and organ function support.
215074616|NCT05811520|OTHER|Scapular stabilization exercises with conventional therapy|The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec
214339914|NCT06662643|PROCEDURE|Direct Anastomosis Plus Prophylactic Ileostomy|ISR is categorized into partial ISR (PISR), subtotal ISR, and total ISR (TISR). Correspondingly, the anastomosis site after coloanal anastomosis is located below the levator ani hiatus (PISR, near the dentate line; subtotal-ISR and TISR, below the dentate line).The dissection steps are the same as in the first stage of the Staged Turnbull-Cutait Pull-through Anastomosis group (TME and intersphincteric space dissection).The bowel is transected at least 1 cm below the tumor, leaving a larger segment of healthy tissue on the non-tumor side while ensuring that no more than 1/3 of the dentate line is resected to avoid impairing fecal control.Anastomosis is performed using absorbable sutures under direct visualization. A protective ileostomy is created 25-30 cm from the ileocecal valve.3 to 6 months after surgery, the ileostomy is reversed. Prior to closure, digital rectal examination, defecography, MRI, colonoscopy, and other evaluation must perform.
214943516|NCT03147300|BEHAVIORAL|Multifaceted implementation of the BetterBack|"The multifaceted intervention is composed of the following:~1. Forming an implementation forum including head of departments/managers of the rehabilitation units and the clinical researchers.~2. Forming a support team comprised of experience clinicians as local supervisors and faculty researchers as knowledge facilitators.~3. Developing the Betterback model of care through a collaboration of the implementation forum, support team and international experts.~4. Forming and delivering a 2-day package of education and training that the support team can utilize to assist the use of the BetterBack model of care by clinicians."
214943517|NCT00317200|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
214943518|NCT00317200|DRUG|Bevacizumab|Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
214943519|NCT00385775|DRUG|AEG35156|weekly IV solution infused over 2 hrs
214943520|NCT00328159|DRUG|Oil special 107 and MYGLIOL 810|
214943521|NCT04428242|DEVICE|RHMS-RTM|Assessment of retinal thickness.
214943522|NCT04428242|DIAGNOSTIC_TEST|SD-OCT|Assessment of retinal structure.
214943523|NCT00390442|DEVICE|continuous positive airway pressure|
214943524|NCT04486170|OTHER|Education provided via a video format|The intervention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room and the investigator will step outside. At the conclusion of the video, the investigator will return into the patient room and provide a pamphlet with similar information that was discussed in the video for them to take home.
214943525|NCT03042871|DRUG|0.5mg intravitreal ranibizumab|Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
214943526|NCT02631278|DEVICE|Intraoperative radiofrequency ablation|Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
214943527|NCT00150397|DRUG|Tofimilast|
214943528|NCT00842998|DRUG|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
214943529|NCT03194711|DEVICE|BVS implantation|BVS implantation using conventional semicompliant or non-compliant balloon
214943530|NCT05100953|BEHAVIORAL|Physical Activity Counseling|Physical activity counseling will be provided under supervision by the researcher physiotherapist via video conference and an individual physical activity program will be organized weekly for two months.
214943531|NCT00901784|DRUG|Topiramate|25mg Tablets
214943532|NCT00130429|DRUG|PYM50028|
214943533|NCT02613429|BEHAVIORAL|identification of the airway by from the cranial end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally
214943534|NCT02613429|BEHAVIORAL|identification of the airway from the distal end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
214943535|NCT04395391|DIAGNOSTIC_TEST|SARS-CoV-2|Determine usability of study materials and kit
214943536|NCT02110940|OTHER|Neurodynamic mobilization exercise|"The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise."
214943537|NCT02110940|OTHER|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
214943538|NCT00766467|DRUG|Armodafinil|Taken orally once a day in the morning. Dose will change depending upon level of fatigue
214676992|NCT04653415|DRUG|Gabapentin 300mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
214943539|NCT00766467|OTHER|Placebo|Placebo taken once a day in the morning
214943540|NCT00676572|OTHER|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
214943541|NCT02893904|DEVICE|EEG monitoring|Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
214943542|NCT02893904|DEVICE|Target Controlled Infusion|Steady state effect site concentrations of remifentanil administrated to all patients.
215074617|NCT05811520|OTHER|Thoracic extension exercises with conventional therapy|Thoracic extension exercises consist of three exercise protocols
215074618|NCT01921218|DRUG|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
215074619|NCT01921218|DRUG|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
215074620|NCT01921218|DRUG|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
215074621|NCT01921218|DRUG|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
214339915|NCT06664229|BEHAVIORAL|Fall and dementia prevention exercise|"The fall and dementia prevention exercise is designed as a combination of balancing and cognitive exercise and games that is conducted as a group activity. The session will be provided three times per week for six weeks for a pilot test and three times per week for 12 weeks for a main comparison study.~The fall prevention exercise involves the pressure mat based balancing exercise such as side stepping, heel or toe standing, and quarter squat. The safety bar will be placed around the mat, so that older adults with instability can hold while they follow the movements.~The cognitive exercise will concise of multiple types of cognitive tasks to train memory, numeric processing, spatial perception, and logical thinking. For example, memory task such as memorizing the series of positions on the screen and use the mat to point the positions in the right order.~At the end, older adults play games in which they use balancing movements and cognitive tasks to gain scores for their team."
214339916|NCT06664476|BEHAVIORAL|PortCare Professional Training Program|The intervention is a targeted educational program to enhance oncology nurses' skills in managing Port-A-Catheters for chemotherapy patients. It includes a preparatory phase to assess baseline knowledge and practices, followed by an implementation phase with theoretical and practical training. Theoretical sessions cover device basics and care guidelines, while practical sessions provide hands-on training on procedures like catheter insertion, flushing, and removal. This program aims to improve patient safety, reduce complications, and boost nurses' confidence in Port-A-Catheter care.
214339917|NCT05747118|BEHAVIORAL|Physical training|A 12 week supervised training intervention with 1 hour physical training two times a week.
214339918|NCT05551364|DEVICE|ATLAS 2030 exoskeleton|"Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases:~1. Telephone contact phase (1 session)~2. Inclusion Phase (1 session)~3. Signing of informed consent (1 session)~4. Initial Evaluation Phase (1 session)~5. Treatment Phase (1st part) (7 sessions)~6. Monthly Evaluation Phase (1 session)~7. Treatment Phase (2nd part) (7 sessions)~8. Monthly Evaluation Phase (1 session)~9. Treatment Phase (3rd part) (7 sessions)~10. Final Evaluation Phase and results (2 sessions)"
214339919|NCT05654324|OTHER|pelvic floor muscle exercises|Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.
214339920|NCT00109564|DRUG|ispronicline (nicotinic acetylcholine receptor agonist)|
214339921|NCT05932290|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
214339922|NCT05932290|DRUG|Standard of care|Standard of care
214339923|NCT01850004|DRUG|Dasatinib|
214339924|NCT06261697|OTHER|A web based survey|An online based questionnaire includes three screens, the first includes the consent form, the second includes the demographic data , and the third page includes questionnaires
214339925|NCT03059108|PROCEDURE|Early Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 4 weeks earlier. The device (dental implant) is of the same type in both groups.
214339926|NCT03059108|PROCEDURE|Conventional Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 8 weeks earlier. The device (dental implant) is of the same type in both groups.
215074622|NCT04821102|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
214339927|NCT05382416|BEHAVIORAL|SHARE! Peer Toolkit Training|The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
214339928|NCT02023385|DEVICE|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
214339929|NCT02023385|DEVICE|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
214339930|NCT02459067|BIOLOGICAL|ImmuniCell®|Autologous γδ T Lymphocytes
214347406|NCT01538017|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
214347407|NCT03448146|DRUG|Para-Toluenesulfonamide|
214676993|NCT04653415|DRUG|Methylprednisolone 125 mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
215074623|NCT04821102|DRUG|Saline|saline, 1 time injection under ultrasonic guided
215074624|NCT05299996|PROCEDURE|flexible ureterorenoscopy|stone disintegration stricture dilation tumor resection access guidance
215074625|NCT02498886|DIETARY_SUPPLEMENT|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
214676994|NCT04653415|DRUG|Tablet|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
214676995|NCT04653415|DRUG|Normal Saline 10 mL Injection|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
215074626|NCT02498886|DIETARY_SUPPLEMENT|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
215074627|NCT00297895|PROCEDURE|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
215074628|NCT00297895|PROCEDURE|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
214339931|NCT06272916|DRUG|Aminophylline , magnesium sulphate and placebo|Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section
214339932|NCT05115162|OTHER|Exercise|The exercises consist of flexibility, strengthening exercises for the trunk and extremities, and walking indoors.The walking program was applied for at least 30 minutes. Eight different exercises were given for the trunk and extremities and these exercises were applied 3 times a week, 2 sets, each set with 10 repetitions.
214339933|NCT05177809|OTHER|Clinical rating scale to measure ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
214339934|NCT01639209|PROCEDURE|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
214339935|NCT01639209|PROCEDURE|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
214339936|NCT02184468|OTHER|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
214339937|NCT04577144|OTHER|Online survey only|There are no interventions planned for this study. This is an observational study only.
214943543|NCT04766255|PROCEDURE|Soft Tissue graft augmentation|"Donor site:~SCTG group: The SCTG will be harvested in the palat,In order to extract the same thickness in each grafts a double-bladed knife (separated by 1,5mm) will be used. The donor area will be sutured.~Recipient site:~SCTG group: the connective tissue graft will be trimmed to the correct dimensions (10mm height, 12mm length and 1,5mm thick) and placed and secured at the recipient site with a resorbable 5-0 suture CM group: The CM graft (Geistlich Fibro-gide) will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture PADM Group: the ADM (NovoMatrix, Biohorizons, Birmingham AL) graft will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture"
214339938|NCT03787368|DRUG|BAY1213790|Single intravenous infusion of BAY1213790 (Two different doses)
214339939|NCT03787368|DRUG|0.9% sodium chloride solution|Single intravenous infusion of Placebo (0.9% sodium chloride solution)
214943544|NCT04766255|PROCEDURE|Implant Placement|A crestal incision will be made in the implant reception area, extending from the distal of the most mesial tooth to the mesial of the most distal tooth. A mucoperiosteal flap will be elevated in the most crestal part of the ridge. The receptor bed will be prepared following the established drilling protocol for the placement of a BioHorizons Tapered Pro Implant (Biohorizons, Birmingham AL). The diameter and length of the implant will be previously established during the implant study. Later a healing abutment will be placed.
214943545|NCT03754855|BEHAVIORAL|Questionnaire|Questionnaire
214943546|NCT01966419|DRUG|ornithine phenylacetate|Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
215074629|NCT04793451|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
214339940|NCT02256501|BIOLOGICAL|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
214339941|NCT00434720|DEVICE|GlideScope Specific Stylet|
214339942|NCT00824681|BEHAVIORAL|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
214339943|NCT00824681|OTHER|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
214339944|NCT05507268|OTHER|no intervention|no intervention
214676996|NCT03534271|DEVICE|iPhone with Kenek Edge and Samsung S8|Smartphones with pulse oximetry and heart rate monitoring capabilities
214339945|NCT02447731|DEVICE|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
214339946|NCT00812292|DRUG|TMC278|
214339947|NCT02365051|BEHAVIORAL|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
214339948|NCT00738842|DRUG|AZD6140|Oral tablets taken bid for 5 days
214339949|NCT00738842|DRUG|Placebo to match AZD6140|Oral tablets taken bid for 5 days
214339950|NCT05422118|DIAGNOSTIC_TEST|ascitic fluid calprotectin|ascitic fluid calprotectin
214339951|NCT01698060|BIOLOGICAL|ND1.1|
214943547|NCT01966419|DRUG|placebo intravenous infusion|Placebo for continuous IV infusion that is visually identical to the experimental product
214943548|NCT00259285|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
214943549|NCT00259285|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 3 cycles
214943550|NCT00800956|DRUG|[14C]-esreboxetine|Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi \[14C\]-esreboxetine
214339952|NCT01946711|DRUG|Budesonide|Inhalation
214339953|NCT01946711|DRUG|Budesonide|Nasal spray
214339954|NCT02607579|DRUG|Exparel|
214339955|NCT02607579|DRUG|Ropivacaine|
214943551|NCT01484093|OTHER|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
214943552|NCT06618378|BEHAVIORAL|Biofeedback exercise combined with breathing exercise|Urotherapy training will be given at the beginning of the treatment process. Contraction and relaxation will be applied around the external sphincter in combination with diaphragmatic breathing by visual imagery with EMG biofeedback application. The second channel EMG will be placed on the transversus abdominus muscle and its activation will be checked. The treatment will be completed with 30-minute sessions twice a week for 12 weeks. Each session will consist of 40 cycles of 10 minutes of diaphragmatic breathing exercise followed by 20 minutes of 10 seconds of contraction followed by 20 seconds of relaxation.
214943553|NCT06618378|BEHAVIORAL|urotherapy educational group|"1. An important part of urotherapy is to provide parents and children with detailed explanations of etiology, prevalence and pathophysiology. This will reassure parents and help them understand the causes of the child's bedwetting accidents and the rationale for treatment. This will increase compliance with treatment.~2. Recommendations are given regarding appropriate fluid intake and regular voiding throughout the day. The child is encouraged to go to the toilet seven times a day and drink seven glasses of water.~3. The correct sitting position for the toilet is explained. If the feet do not touch the floor easily, it is recommended to use a step stool for foot support. Additionally, children are taught to relax their abdomen when peeing.~4. In addition to monitoring and motivation, a bladder diary should be kept to give the child and parents an idea about the progress of treatment, compliance with treatment and continuity."
214943554|NCT01492725|DEVICE|Intra-arterial Clot Retrieval with Solitaire device|Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
214676997|NCT05182515|DRUG|Therapeutic plasma exchange|"Plasma exchange techniques reported in COVID-19 vary from study to study. No consensus exists on the use of a specific technique.~The use of a central venous catheter will be left to the discretion of investigators. If so, central venous catheter will be inserted through the internal jugular or femoral route under ultrasound control by a trained operator. After radiographic control of the position of the catheter and the absence of complications in the placement of the catheter, plasma exchanges will be carried out.~Three plasma exchanges of 1.5 plasma volume will be carried out every 48 hours on D1, D3 and D5. Plasma volume will be assessed by this equation VP = (1-Hct)x70xweight Body(measured). The substitution volume will be 5% albumin as first intervention. The use of a hemofiltration or centrifugation technique will be left to the discretion of each center."
214676998|NCT05058378|DEVICE|perfusion index measurement|Clip will be attached to the patient's toe for perfusion index measurement
214339956|NCT01787604|PROCEDURE|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
214339957|NCT01787604|PROCEDURE|Aortic Valve Reimplantation Procedure|David I
214339958|NCT06300008|DRUG|cetylated fatty acid|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
214339959|NCT06300008|DRUG|Placebo|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
214339960|NCT02239718|PROCEDURE|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
214339961|NCT02239718|PROCEDURE|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
214339962|NCT01197222|DEVICE|EndoClear Lens Cleaning Device|EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
214339963|NCT05265468|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
214339964|NCT05265468|OTHER|Lewit Group|Isometric muscular exercise acompained with stretching technique
214339965|NCT05265468|OTHER|Chaitow Group|Isometric muscular exercise acompained with stretching technique and diaphragmatic breathing
214339966|NCT05265468|OTHER|Placebo Group|No pain positioning of participants
214339967|NCT04331366|DEVICE|GO2 PEEP MOUTHPIECE|The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.
214339968|NCT05827367|DEVICE|Ultrasound|"The high-power pain threshold ultrasound (HPPTUS) In this technique, which be applied in continuous mode with intensity from t0.5 to 2 watt/cm to elicit pain threshold the US probe was kept motionless, and the intensity progressively increased until the maximum level of pain patient can endure was selected, it was maintained on this level for 3 to 4 seconds and then decreased to half intensity for 15 seconds the treatment process was repeated three times."
214676999|NCT04668846|OTHER|non-invasive sample collection of skin tissue|Both lesional and non-lesional skin will be sampled with up to 24 adhesive patches.
214677000|NCT04176822|OTHER|Educational animated movie group|Watching educational animation movie which were designed by the researcher before operation for fear and pain.
214677001|NCT04176822|OTHER|Documentary movie group|Watching documentary movie about trees before operation for fear and pain.
214677002|NCT02896725|DEVICE|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
214677003|NCT02896725|DEVICE|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
214677004|NCT00823329|DEVICE|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
214677005|NCT00764894|DEVICE|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
214677006|NCT04512729|DIAGNOSTIC_TEST|Colonoscopy|"For all patients, either moderate sedation with intravenous midazolam or conscious sedation with intravenous propofol will be administered in a standard fashion prior to undergoing colonoscopy.~The colonoscope will be inserted and cecum will be intubated. Photo documentation of the cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of the colonoscope.~The time spent in inspecting the mucosa during withdrawal of the colonoscope will be documented as the withdrawal time. Meticulous technique will be employed during the withdrawal phase with special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral folds, flexures and valves.All polyps detected will be documented: size, location, and morphology. Photo documentation of the polyps will be performed."
214339969|NCT05827367|OTHER|Myofascial release technique|Plantar fascia myofascial release Soluse muscle myofascial release Gastrocnmias muscle myofascial release
214339970|NCT05827367|OTHER|Strength and stretching|Plantar fascia stretching Interstice foot muscles strengthing
214943555|NCT01492725|GENETIC|intravenous tissue plasminogen activator (tPA)|Standard care IV tPA therapy administered as per registered product information
214943556|NCT00985517|BIOLOGICAL|CERE-120: Adeno-Associated Virus Delivery of Neurturin|
214943557|NCT00985517|PROCEDURE|Sham Surgery|
214943558|NCT01152216|DRUG|Dimebon|20 mg orally three times daily
214943559|NCT04492917|OTHER|CV4|The osteopath was sitting at the head of the examination table, with the subject lying supine. The osteopath approximated with the hands the lateral angles of the occipital squama, taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
214943560|NCT04492917|OTHER|ST|The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point
214943561|NCT04492917|OTHER|Sham CV4|the sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
214943562|NCT04492917|OTHER|Sham ST|The sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
214339971|NCT05103761|OTHER|Study diet|A low carbohydrate diet (\<20g/day) is administered to achieve diet-induced ketosis.
214339972|NCT05103761|OTHER|Low glycemic index treatment diet|A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
214339973|NCT03019536|DRUG|LY3303560 - IV|Administered IV
214339974|NCT03019536|DRUG|Placebo - IV|Administered IV
214339975|NCT03019536|DRUG|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
214339976|NCT03019536|DRUG|Flortaucipir F18|Administered IV during the PET scan performed during the study.
214347408|NCT00875680|DEVICE|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
214347409|NCT04121728|DRUG|Ginkgo biloba extract|Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.
214677007|NCT03668548|DIETARY_SUPPLEMENT|Leucine|192 mg/kg body mass/day
214677008|NCT03668548|DIETARY_SUPPLEMENT|Placebo|A taste and calorie-matched placebo
214677009|NCT04135625|BEHAVIORAL|Integrated nutrition and agricultural (INA) trainings|Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.
214677010|NCT04135625|BEHAVIORAL|Ceremonial Gifting of Livestock|Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
214677011|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
214943563|NCT06718270|DRUG|CAR-T cells Infusion|chimeric antigen receptor T cells
214943564|NCT00943670|BIOLOGICAL|pertuzumab|Intravenous repeating dose
214943565|NCT00943670|BIOLOGICAL|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
214943566|NCT03956615|OTHER|Blood sampling and bone marrow analysis|Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)
214943567|NCT02149316|PROCEDURE|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
214943568|NCT02149316|PROCEDURE|control|a deflated cuff placed on the right upper arm
214943569|NCT03156907|DRUG|Buprenorphine|HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).
214943570|NCT00829088|DRUG|AZD2066|1 dose oral solution
214943571|NCT04374682|OTHER|exercises|stretching exercises - physiotherapy modalities - self care instructions
214339977|NCT01973127|OTHER|Verum rTMS|rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.
214943572|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.
214943573|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.
214943574|NCT00303212|OTHER|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
214943575|NCT04122664|DEVICE|RayOne® Hydrophobic lens 800C|Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C
214943576|NCT04122664|DEVICE|RayOne® Hydrophilic lens 600C|Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
214943577|NCT01685853|DRUG|Bisacodyl plus PEG-CS|"* the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~* the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam"
214943578|NCT01685853|DRUG|PEG 4 litres split|"* the day before colonoscopy: 2 litres of PEG~* the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination"
214943579|NCT00908076|DRUG|LUBIPROSTONE|Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
214943580|NCT02382796|DRUG|Dacomitinib|Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
214339978|NCT01973127|OTHER|Sham rTMS|TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
214339979|NCT05738395|DIAGNOSTIC_TEST|Questions|Questions
214677012|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
214677013|NCT03809546|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
214677014|NCT03809546|DRUG|dextrose|We are administering dextrose to health volunteers for our placebo group
214677015|NCT00125203|DRUG|Botulinum toxin type B (Myobloc)|
214943581|NCT02570321|PROCEDURE|Corneal Cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
214943582|NCT02570321|DRUG|Anti Fungal Drug|Topical Amphotericin B vs Topical Natamycin
214943583|NCT05729542|DEVICE|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
214943584|NCT05729542|DEVICE|Synthes Fibulink|High-tensile strength suture syndesmosis repair
214943585|NCT06016985|DIETARY_SUPPLEMENT|caffeine gum|This study investigated the effects of chewing 3 mg/kg of caffeinated gum on basketball free throw accuracy and basketball -specific performance.
214943586|NCT06391593|DRUG|ALTO-203 25 μg|Active, ALTO-203 25 μg
214943587|NCT06391593|DRUG|ALTO-203 75 μg|Active, ALTO-203 75 μg
214943588|NCT06391593|DRUG|Placebo|Comparator, Placebo-to-match
214677016|NCT00125203|PROCEDURE|Injection of salivary glands|
214943589|NCT05217511|BEHAVIORAL|Neuromuscular Electrical Stimulation|NMES was performed using a portable machine.The negative electrodes were placed in the motor points of the following muscles: chest muscles (pectoralis major muscle fibres) and rectus abdominis muscles bilaterally. A second (positive) electrode was positioned distally to the first, at a site close to the muscle that was being electrically stimulated, totalling 1 channel with 2 electrodes for each muscle . Each NMES session lasted 30 min. The following parameters were used: 50 Hz frequency, pulse duration 300 ms, rise time 1 s, stimulus time (ON) 3 s, decay time 1 s, and relaxation time (OFF) 10 s. Intensity was increased until muscle contraction was visible or could be identified through palpation. In conscious patients, intensity was adjusted according to their tolerance.
214943590|NCT03616561|DRUG|Apremilast|Target nail ultrasound will be performed in patients on apremilast by two expert dermatologists and each one will determine the ecographic parameters described in the protocol. These variables would be measured in one target nail in each patient, the greatest and most severely affected, at the investigator's criterion. The same nail will be assessed in all visits of the study (baseline, weeks 4, 16, 24, 38 and 52) . The ultrasound study will be performed with the same device in both hospitals: Esaote's MyLab ultrasound with a 20 MHz transducer. Prior to the start of the study the investigators evaluated the ultrasonographic inter-intraobserver concordance.
214943591|NCT05225571|OTHER|no intervention|there is no any intervention in this study. it is an observational and cross-sectional study.
214943592|NCT02618694|PROCEDURE|Posterior retroperitoneoscopic adrenalectomy|Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).
214943593|NCT02618694|PROCEDURE|Transperitoneal laparoscopic adrenalectomy|On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, \& Ihara, 2012; Linos, 2005; George \& Kavoussi, 2010).
214943594|NCT01286194|DRUG|Rabeprazole sodium|Rabeprazole sodium 10 mg orally every day for 14 days
214943595|NCT05863091|DEVICE|HiCardi+|A patch-type electrocardiogram device is attached to a patient undergoing pulmonary function tests.
214943596|NCT05863091|DEVICE|HiCardi+|A patch-type electrocardiogram device is attached to a patient on a ventilator in an intensive care unit.
214943597|NCT03212066|BEHAVIORAL|Master Mind|Master Mind is a 25-lesson elementary school mindfulness education substance abuse prevention program. Each lesson takes approximately 15 minutes and is designed to be taught by trained teachers every day for 5 weeks.
214943598|NCT05502991|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
214943599|NCT00334802|DRUG|gemcitabine|"Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)~Phase 2: dose determined by phase 1"
214943600|NCT00334802|DRUG|paclitaxel|"Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles~Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"
214943601|NCT00001300|DRUG|doxorubicin|
214943602|NCT00001300|DRUG|ifosfamide|
214943603|NCT00001300|DRUG|mesna|
214943604|NCT00672399|DRUG|exenatide|Subcutaneously injected, 10 mcg, single doses
214943605|NCT00672399|DRUG|Moxifloxacin|oral, 400 mg tablet, single doses
214943606|NCT00672399|DRUG|Placebo|Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
214943607|NCT05370508|COMBINATION_PRODUCT|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS
214943608|NCT06731543|OTHER|No interventions will be made|
214677017|NCT03830138|GENETIC|Oxidized-LDL gene polymorphism|Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA
214677018|NCT05574543|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
214943609|NCT00203463|DRUG|topiramate|
214943610|NCT03887117|OTHER|IQOS + Exercise Training Program|Switch to IQOS use + participation in a training program
214677019|NCT05574543|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
214677020|NCT02746679|OTHER|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
214677021|NCT00385086|DRUG|TNF blocker|Treatment with TNF-alpha blocker
214677022|NCT00385086|DRUG|Placebo|Treatment with placebo
214943611|NCT03887117|OTHER|IQOS without Exercise Training Program|Switch to IQOS use only, without participation in a training program
214943612|NCT03887117|OTHER|Cigarette Smoking + Exercise Training Program|Continue to smoke cigarettes + participation in a training program
214943613|NCT03887117|OTHER|Smoking Abstinence + Exercise Training Program|Switch to smoking abstinence + participation in a training program
214943614|NCT04879836|DEVICE|Teething Gel|Dosage: application of an even coat of 1mm thickness Frequency: 5 times/day (after main meals and before sleeping) Duration: 4 weeks
214943615|NCT04879836|DEVICE|Teething Ring|The teething ring was filled with a coolant Usage: 5/10 min per time Frequency: 5 times/day Duration: 4 weeks
214943616|NCT05626218|OTHER|stress ball|The woman is usually laid in the last side position during the procedure. A stress ball will be given to the right hand of the participants during the NST procedure (average 15-20 minutes). This stress ball will be squeezed for 2-3 seconds, and then the hand and arm will be told to relax. This process will be repeated throughout the NST. Hospital protocol will also be applied to these participants.
214943617|NCT01739764|DRUG|Vemurafenib|Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).
214943618|NCT06204120|DRUG|LPM3480392 Injection|PCA administration
214943619|NCT06204120|DRUG|Placebo|PCA administration
214943620|NCT06204120|DRUG|morphine hydrochloride injection|PCA administration
214943621|NCT05639504|DIAGNOSTIC_TEST|IMX-BVN-4 and IMX-SEV-4|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
214943622|NCT04260269|DRUG|Fluoropyrimidine|"This is the assessment of a specific evaluation of cardiac safety for patients with solid tumors who have experienced cardiotoxicity grade 1-4 during treatment with a fluoropyrimidine based treatment and are re-challenged with a different fluoropyrimidine.~This multicentre, retrospective database is built to assess the impact on the cardiac and global safety of two different fluoropyrimidine based treatment regimens, of which the first has caused cardiotoxicity grade 1-4.~Cardiac data will be collected by medical record review from initiation of first fluoropyrimidine-based treatment and switch to second fluoropyrimidine-based treatment until death or last follow-up. Basic demographics, cancer and treatment information from the whole course of cancer until death or last follow-up."
214943623|NCT03544125|BIOLOGICAL|Durvalumab|Given IV
214943624|NCT03544125|DRUG|Olaparib|Given PO
214943625|NCT01914965|DRUG|Bupropion|Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
214677023|NCT02436798|DRUG|Ondansetron|All patients will be receiving treatment with ondansetron as part of standard care.
214943626|NCT01914965|DRUG|Placebo|Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
214943627|NCT01389258|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
214943628|NCT02772146|DEVICE|CLS UF|One single ultrafiltration session of 10 hours.
214943629|NCT00511654|DRUG|GW823296 tablet|GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
214943630|NCT00511654|DRUG|GW823296 matching placebo|Matching placebo tablets will be identical in appearance to the GW823296 tablets.
214943631|NCT00511654|DRUG|Midazolam|Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
214943632|NCT01304303|DRUG|SPARC1023 I|IV administration
214943633|NCT01304303|DRUG|SPARC1023 II|IV administration
214943634|NCT00526565|BEHAVIORAL|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
214943635|NCT00526565|BEHAVIORAL|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
214943636|NCT02460523|PROCEDURE|conservative|1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
214677024|NCT01986205|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen (USP oxygen \>99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.
214677025|NCT01986205|COMBINATION_PRODUCT|Minimal pressure air|Room air delivered in a hyperbaric chamber with minimal pressurization.
214677026|NCT02262130|DRUG|Omalizumab|
214677027|NCT00000530|DRUG|nifedipine|
214677028|NCT00000530|BEHAVIORAL|biofeedback (psychology)|
214677029|NCT00000530|PROCEDURE|electromyography|
214677030|NCT04125823|BEHAVIORAL|Video game-based physical activity training|"Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with a motion sensor (Microsoft) and a 52'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades and types of games will be changed.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
214943637|NCT02460523|PROCEDURE|ERCP|2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.
214943638|NCT01361269|DRUG|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
214677031|NCT04125823|BEHAVIORAL|Conventional physiotherapy program|"A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
214339980|NCT05776485|OTHER|Progressive resistance training|Only the control group: 3 exercise bouts within the study period. Comparison between exercised and non-exercised leg.
214943639|NCT02027857|DEVICE|EIT monitoring|
214943640|NCT02027857|DEVICE|non-invasive ICP monitoring|
214677032|NCT00232570|DRUG|quetiapine|
214677033|NCT05153005|OTHER|examination methods|Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.
214677034|NCT04397055|DIETARY_SUPPLEMENT|Cottonseed Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil
214677035|NCT04397055|DIETARY_SUPPLEMENT|Olive Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil
214339981|NCT05776485|OTHER|Cross-sectional comparison between healthy and tendinopathic group|Comparison of primary and secondary outcomes.
214943641|NCT05541900|BEHAVIORAL|TEC-Sacredness|The participant is asked to identify and select the correct match on each trial as quickly as possible. Match pairs (i.e., a self-related word paired with a life-related stimulus, a sacredness of life-related stimulus paired with a pleasant stimulus, and a neutral stimulus paired with a neutral stimulus) are first presented to the participant. A grid is then shown containing one of the match pairs along with distraction stimuli.
214677036|NCT04963218|DIAGNOSTIC_TEST|AI Algorithm to detect LVEF in ECG|A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.
214677037|NCT00298662|DRUG|Interferon beta-1b and Tacrolimus|
214677038|NCT00004429|DRUG|growth hormone|
214677039|NCT05101421|DIETARY_SUPPLEMENT|Rice ceramide supplementation|At the dosage of 40mg daily for 3 months
214677040|NCT03604328|DRUG|PA5108|single ocular implant, administered on day 1
215074630|NCT04793451|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
215074631|NCT05465798|DRUG|MC 3x3|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
215074632|NCT05465798|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
214339982|NCT06532448|DIAGNOSTIC_TEST|Single dose low-risk penicillin challenge|Initial screening to establish low risk allergy status followed by a single dose challenge using a standard penicillin dose. All challenges will be oral, conducted in a hospital setting and will be followed by a 1 hour monitoring period.
215074633|NCT02449889|DRUG|highly purified human chorionic gonadotropin|
214943642|NCT05541900|BEHAVIORAL|TEC-Control|The participant is asked to identify and select the correct match on each trial as quickly as possible. Match pairs (i.e., a neutral stimulus paired with a neutral stimulus) are first presented to the participant. A grid is then shown containing one of the match pairs along with distraction stimuli.
214943643|NCT01534208|DRUG|Androxal|Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
214943644|NCT03551951|DIAGNOSTIC_TEST|Test for circulating tumor cells, DNA alterations|
214339983|NCT03223298|DRUG|Botulinum toxin type A|37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
214943645|NCT01048684|DRUG|Mannitol|Variation of mannitol dose
214339984|NCT03223298|DRUG|0.9% Sodium Chloride Injection|1cc syringe
214943646|NCT01048684|DRUG|Mannitol|Variation of mannitol dose
214943647|NCT04108221|PROCEDURE|laparoscopy or laparotomy withTransversusAbdominis Plane Block|"The US-TAP is performed by the anesthetist under ultrasound control after the end of the procedure of laparoscopy or laparotomy. Under sterile conditions, the anesthetist identifies the oblique abdominal muscles externally, obliquely internally and transversely by ultrasound. A 20 ml needle of 0.5% ropivacaine is injected.~The surgical TAP (c-TAP) block is performed by the surgeon at the end of the procedure of laparoscopy or laparotomy.The needle and the product used are identical to those of the us-TAP block. The positioning of the needle is in the plane of the fascia between the internal oblique muscle and the transverse muscle, identified by a significant loss of resistance."
215074634|NCT02449889|DRUG|recombinant human chorionic gonadotropin|
215074635|NCT03664791|PROCEDURE|Vanguard Rocc|Patient operated with the Vanguard Rocc knee prosthesis
214339985|NCT06074094|DRUG|Control Test|Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
214339986|NCT01979926|DRUG|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
214339987|NCT01134874|BEHAVIORAL|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
214339988|NCT01134874|BEHAVIORAL|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
214339989|NCT01134874|BEHAVIORAL|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
214339990|NCT00359112|DRUG|metformin|
214339991|NCT00359112|DRUG|sulphonylurea|
214339992|NCT00359112|DRUG|Avandamet|
214339993|NCT04514315|PROCEDURE|Minimally invasive cardiac valvular surgery|Minimally invasive valve surgery via right mini-thoracotomy.
214339994|NCT04514315|PROCEDURE|Conventional cardiac valvular surgery|Conventional valve surgery via full median sternotomy
214339995|NCT00264615|DRUG|lamotrigine extended-release|
214339996|NCT01782131|DRUG|Posaconazole|POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD
214339997|NCT01782131|DRUG|Voriconazole|VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID
214339998|NCT01782131|DRUG|Placebo|Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
214339999|NCT06025955|PROCEDURE|minimally invasive non- surgical therapy|hand and ultrasonic instrumentation will be done
214340000|NCT06025955|PROCEDURE|open flap debridement|flap surgery will be done
214943648|NCT06731361|COMBINATION_PRODUCT|Systematic multidisciplinary medication review + ACP (SMMR+)|"The intervention is a training in medication assessment. The goal is to align prescription with the treatment goals of nursing home patients which are set in advance care planning conversations. The training consists of 2 components:~1. Medication assessment with the use of the ReNeWAL criteria (adjusted STOPP/START criteria, tailored to nursing home patients with a limited life expectancy)~2. Advance care planning component. Discussing medication in line with the treatment goals set in advance care planning conversations.~Healthcare professionals receive the training in combination with supporting tools (pocket card) and educational material (the ReNeWAL criteria and PowerPoint slides of the training if requested). Also, intervision moments are planned."
214943649|NCT06731660|OTHER|Education with personalized performance feedback|Education about proper otitis media diagnosis following criteria from the American Academy of Pediatrics with personalized performance feedback on otitis media diagnosis and treatment rates delivered via email
214943650|NCT06731660|DEVICE|Use of digital otoscope|Use of the Wispr digital otoscope to diagnose otitis media in place of a traditional visual otoscope
214943651|NCT03438526|DRUG|Melatonin (Circadin ®)|4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
214943652|NCT03438526|DRUG|Placebo|Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
214943653|NCT05727306|OTHER|No intervention|Observational analysis of usual care only.
214943654|NCT06358729|BEHAVIORAL|Typical Nipple|Infants are fed their typical milk/formula by their caregiver when hungry, one feeding with their typical nipple.
214943655|NCT06358729|BEHAVIORAL|Challenging Nipple|Infants are fed with a smaller sized nipple (i.e. with a smaller aperture, slowing the rate of milk delivery).
214943656|NCT03482167|DRUG|Niagen®|250 mg capsules (4 capsules daily)
214943657|NCT03482167|OTHER|Placebo|placebo
214943658|NCT00885742|BIOLOGICAL|FXIII Concentrate (Human)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023\_2002 \[NCT00883090\]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion."
214340001|NCT01627249|DRUG|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
214340002|NCT01627249|DRUG|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
214340003|NCT01627249|DRUG|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
214340004|NCT01772433|DIETARY_SUPPLEMENT|Olive oil|Phonophoresis with Olive oil for 10 day, daily
214340005|NCT01772433|DRUG|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
214340006|NCT02794493|DRUG|Traditional Chinese Medicine Formula LC09|
214340007|NCT02794493|OTHER|Placebo|
214340008|NCT00919243|DRUG|prednisone|1 mg/kg/day with a maximum dose of 60 mg/day given orally
214340009|NCT00919243|DRUG|allopurinol|allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
214340010|NCT00796718|RADIATION|Standard radiotherapy|Administered as prescribed according to normal clinical practice.
214340011|NCT00796718|DRUG|Capecitabine [Xeloda]|825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.
214943659|NCT02643797|BEHAVIORAL|Medical Assistant Health Coaching|One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
214943660|NCT02200237|BIOLOGICAL|EV71 with adjuvant aluminium phosphate|Two arms, EV71 with aluminium phosphate
214943661|NCT02200237|BIOLOGICAL|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
214943662|NCT00737893|DRUG|Placebo|Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
214943663|NCT00737893|DRUG|Erythropoietin (EPO)|Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
214943664|NCT02014220|OTHER|dietary treatment|
214943665|NCT05958771|DRUG|ROTAVAC 5D|monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells. Each dose contains NLT 10 e 5.0 FFU
214943666|NCT05958771|DRUG|Placebo|Placebo contains all the excipients of ROTAVAC 5D but without the suspension of live attenuated rotavirus
214943667|NCT01319851|DRUG|Alefacept|0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
214340012|NCT03266588|DRUG|Rimegepant|75 mg oral tablet
214340013|NCT04367168|DRUG|Colchicine|Colchicine 1mg, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
214340014|NCT04367168|DRUG|Placebo oral tablet|Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
214340015|NCT03239379|DRUG|BNZ132-1-40|Injectable peptide antagonist of IL-2, IL-9 and IL-15
214340016|NCT03239379|DRUG|Placebo|Normal Saline
214340017|NCT00393926|DEVICE|TheraDrive Assistive Device|
214340018|NCT00393926|PROCEDURE|Rote Therapy versus Fun Therapy|
214943668|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
214943669|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
214943670|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
214943671|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of placebo in each eye.
214943672|NCT01001598|DRUG|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
214340019|NCT04785404|PROCEDURE|primary skin closure|skin will be stitched after stoma reversal to heal by primary intention
214340020|NCT00736242|BIOLOGICAL|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
214340021|NCT00736242|DRUG|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
214340022|NCT03711981|PROCEDURE|TAP Block|
214340023|NCT00814372|DRUG|MBX-102|capsule
214340024|NCT00814372|DRUG|Placebo|matching placebo
214340025|NCT00814372|DRUG|Actos|over-encapsulated to match MBX-102 and placebo
214340026|NCT00814372|DRUG|Metformin|greater than or equal to 1500 mg/kg day
214340027|NCT04981587|PROCEDURE|Strength exercise|Strength exercise protocol for upper and lower limbs, using weights and elastic bands
214340028|NCT04981587|OTHER|Usual treatment|The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
214340029|NCT00648232|BEHAVIORAL|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
214340030|NCT00648232|BEHAVIORAL|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
214340031|NCT00648232|BEHAVIORAL|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
214340032|NCT00648232|BEHAVIORAL|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
214340033|NCT05674695|DRUG|Ciclosporin|Any systemic drug used for atopic dermatitis in clinical practice
214340034|NCT01220011|PROCEDURE|Fetoscopic laser surgery|Fetoscopic laser surgery
214340035|NCT06373822|DIAGNOSTIC_TEST|Circulating-mirna|A single blood sample (1 tube of 10 ml) on the day of the patient's visit to the service de Gynécologie of the CUSL.
214340036|NCT04181554|OTHER|Measurement of postural stability|The postural stability will assess by using Biodex balance system.
214340037|NCT05385016|BEHAVIORAL|Cooking Skills|This session will consist of a hands-on cooking demonstration in a demo kitchen. Skills addressed in this portion of the session will include proper kitchen utensil and appliance use, measuring dry and wet ingredients, following/reading a recipe, preparing ingredients, cooking a meal, etc. The participant will follow a visual recipe that provides a breakdown of each skill needed to complete each step of the recipe. Additionally, during the cooking session investigators will address nutrition topics related to food/kitchen safety, basic nutrition education (i.e., portion sizes, food groups, reading food labels, meal planning etc.) in a discussion format.
214347410|NCT04121728|DRUG|Placebo|The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
214347411|NCT06260657|OTHER|Histological analysis on fetal ethmoids|Immunohistological analysis (immunohistochemical or immunofluorescent) on fetal ethmoids
214943673|NCT00002615|DRUG|cisplatin|
214943674|NCT00002615|DRUG|epirubicin hydrochloride|
214943675|NCT00002615|DRUG|fluorouracil|
214943676|NCT00002615|PROCEDURE|conventional surgery|
214943677|NCT05640297|BEHAVIORAL|KMC with Massage therapy|investigator will provide tactile and kinesthetic massage
214943678|NCT04746729|OTHER|No intervention|No intervention
214943679|NCT04568967|DIAGNOSTIC_TEST|Concentrated urine with Xpert Ultra|Molecular TB diagnostic test on urine
214943680|NCT04568967|DIAGNOSTIC_TEST|Stool with Xpert Ultra|Molecular TB diagnostic test on stool
214943681|NCT04827537|DRUG|20-hydroxyecdysone Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
214677041|NCT03996538|DRUG|Metformin Hydrochloride Extended-Release Tablets|Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
215074636|NCT05250635|DEVICE|electronic stethoscope|It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
214347412|NCT02967302|DRUG|Morphine Sulfate|active intervention
214347413|NCT02967302|DRUG|Triamcinolone|active control
214943682|NCT04827537|DRUG|Metronidazole Oral|500 mg (one pill) x two times a day orally, 10 consecutive days
214943683|NCT04827537|DRUG|Placebo Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
215074637|NCT01345513|OTHER|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
214340038|NCT05385016|BEHAVIORAL|Physical Activity|This session will consist of a group functional fitness class. Each session will include a warm-up (\~5 min) moderate-to-vigorous intensity aerobic and resistance exercise (\~20 min) and cool-down/stretching (\~5 min). Exercises may be accompanied by music and will include walking/jogging, dancing, imitating animal movements, vertical/horizontal jumps, squats, hurdles, walking on balance beam etc. Thera-Band, kettle bells, free weights, and medicine balls will be used during strength exercises for major muscle groups. These sessions will be led by certified personal trainers with experience in adaptive physical activity.
214340039|NCT05740462|BEHAVIORAL|Recipes consumption|Participants will eat two recipes a day for 17 weeks
214340040|NCT05740462|BEHAVIORAL|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
214340041|NCT01443962|OTHER|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
214943684|NCT04877535|DEVICE|ML-based report card|PACU and ward providers caring for participants will be notified by Anesthesia Control Tower clinicians before arrival if the patient's report card. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.The ML risk profile generated for each patient will include risk of 30 day mortality, risk of respiratory failure, risk of acute kidney injury, and risk of postoperative delirium
214943685|NCT00005876|DRUG|rubitecan|
214943686|NCT06647680|DRUG|Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles|Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four - six hours during pre-study, study and end of study visits.
214943687|NCT02167815|DEVICE|Mepilex XT|Experimental arm
214943688|NCT02167815|OTHER|standard care|
214943689|NCT03796338|DEVICE|Sleep Profiler|Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
214943690|NCT06084390|OTHER|Interdisciplinary care + booster session (intervention)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden + one extra booster-session 3 months after the standard care rehabilitation. At the booster-session, the participant´s individual rehabilitation plan is followed-up and adjusted. This extra period also includes extended access to the team, meaning that the participants have the possibility to contact the team and, if needed, have digital or telephone contact.
214943691|NCT06084390|OTHER|Interdisciplinary care (control)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden.
214943692|NCT04797156|DRUG|High Dose Tranexamic acid|50mg/kg IV TXA
214943693|NCT04797156|DRUG|Low Dose Tranexamic acid|20mg/kg IV TXA
214943694|NCT04797156|DRUG|Tranexamic acid Topical|2g topical TXA
214943695|NCT04797156|DRUG|Normal saline|Normal saline poured on wound
214943696|NCT02519634|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
214943697|NCT02519634|PROCEDURE|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
214943698|NCT01343667|DEVICE|Gore Flow Reversal System|Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting
214943699|NCT01343667|DEVICE|Gore Embolic Filter|Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting
214943700|NCT02852668|OTHER|Power Training|This experimental groups underwent an intervention period of power training
214943701|NCT02852668|OTHER|Strength Training|This experimental groups underwent an intervention period of strength training
214677042|NCT03996538|BIOLOGICAL|Influenza Vaccine|All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
214677043|NCT04441931|DRUG|LY3832479|Administered IV.
214677044|NCT04441931|DRUG|Placebo|Administered IV.
214677045|NCT06070038|BEHAVIORAL|Integrated Behaviour Change Based Intervention Materials|The intervention will be delivered over a three-month period as a series of four zoom hosted workshops, online content, and a moderated social support group. Zoom workshops will last 45 minutes and will target key constructs from the integrated behavior change model. Main topics of the workshops are autonomy Supportive parenting (Week 1), goal setting and outcome beliefs (Week 3), physical activity norms (Week 5), and encouraging self-efficacy and maintenance (Week 8). Following each workshop, participants will receive links to online content that builds on workshop themes, such as messages, worksheets, and reflection tasks. Throughout the trial, participants will be able to participate in social support chat groups to discuss their progress with other members of the intervention group and intervention facilitators.
214943702|NCT01046851|DRUG|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
214943703|NCT01046851|DRUG|Placebo|Placebo in a manner similar to the active comparator
214340042|NCT01443962|OTHER|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
214340043|NCT02627677|DRUG|Ponatinib 30 mg QD|Ponatinib 30 mg, taken orally once daily.
214943704|NCT01352247|PROCEDURE|Unicompartmental Knee Replacement|A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.
214943705|NCT01352247|PROCEDURE|Total Knee Replacement|A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
214943706|NCT04445844|BIOLOGICAL|Pelareorep|Given IV
214943707|NCT04445844|OTHER|Quality-of-Life Assessment|Ancillary studies
214677046|NCT03183921|OTHER|No intervention|No Interventions
214677047|NCT00542815|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
214677048|NCT00542815|DRUG|Another Phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
214677049|NCT04674137|DRUG|XC8 100 mg|1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
214677050|NCT04674137|DRUG|Placebo|1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
214677051|NCT04252807|BEHAVIORAL|Intervention arm|In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
214677052|NCT04252807|OTHER|Treatment as Usual|The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
214677053|NCT03211078|PROCEDURE|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
214677054|NCT00703807|DRUG|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
214340044|NCT02627677|DRUG|Ponatinib 15 mg QD|Ponatinib 15 mg, taken orally once daily.
214943708|NCT04445844|OTHER|Questionnaire Administration|Ancillary studies
214943709|NCT04445844|BIOLOGICAL|Retifanlimab|Given IV
214943710|NCT04817566|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
214677055|NCT00703807|DRUG|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
214340045|NCT02627677|DRUG|Nilotinib 400 mg BID|Nilotinib 400 mg, taken orally twice daily.
215074638|NCT06140498|BEHAVIORAL|Self-Efficacy Training and Ecological Momentary Assessment|Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week
215074639|NCT06140498|BEHAVIORAL|Control intervention: Ecological Momentary Assessment only|Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
214677056|NCT03384511|DRUG|Apatinib|Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.
214677057|NCT03070132|DRUG|BIIB074|Administered as specified in the treatment arm
214677058|NCT03070132|DRUG|Placebo|Matched placebo
214677059|NCT02499965|DRUG|Ethyl Chloride Topical Aerosol Anesthetic|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
215074640|NCT04700345|DEVICE|Onyx|Embolization of the Middle Meningeal Artery using the liquid embolic material
215074641|NCT04700345|PROCEDURE|Burr-hole|Burr-hole drainage of subdural hematoma
214677060|NCT02499965|DRUG|Nature's Tears Sterile Water|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
214677061|NCT04128592|DEVICE|diagnosing noisy breathing in infants and toddlers|breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
215074642|NCT04700345|OTHER|Medical Management|best medical management
215074643|NCT00634257|BEHAVIORAL|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
215074644|NCT00090142|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
214677062|NCT00734929|DRUG|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
214677063|NCT00734929|DRUG|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
214677064|NCT04151004|OTHER|Incremental cycling test (ICT)|Incremental cycling test to volitional exhaustion
214340046|NCT01346657|DRUG|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
214340047|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Commercially available Oral Nutritional Supplement alone consumed 90 minutes prior to an ad libitum breakfast
214340048|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement + Whey Protein Hydrolysate|Whey Protein Hydrolysate dissolved in an Oral Nutritional Supplement consumed 90 minutes prior to an ad libitum breakfast
214340049|NCT06478147|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate + still water|Whey Protein Hydrolysate dissolved in still water consumed 90 minutes prior to an ad libitum breakfast
214347414|NCT02967302|DRUG|placebo|placebo control
214347415|NCT00506961|DRUG|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
214347416|NCT00506961|DRUG|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
214347417|NCT04697758|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye
214347418|NCT04697758|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye
214677065|NCT04151004|OTHER|Constant load cycling test (CET)|Constant load cycling test to volitional exhaustion.
214677066|NCT04151004|OTHER|Incremental respiratory muscle test (IncRMET)|Incremental respiratory muscle test to volitional exhaustion.
214677067|NCT04151004|OTHER|Incremental quadriceps muscle test (IncQMT)|Incremental quadriceps muscle test to volitional exhaustion.
214943711|NCT04817566|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
214943712|NCT04817566|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
214340050|NCT05064969|BEHAVIORAL|Blended intervention based in acceptance and commitment therapy|"Blended intervention includes completing 9 e-modules consist of written material, videos, and assignments (one e-module per week) that can be completed over 9 to 12 weeks AND 9 (to 12 ) coaching sessions (telephone call). Weekly coaching will be offered by a motivational coach based in Maastricht University.~After the post-intervention assessments, individuals will receive monthly calls from the motivational coach as booster sessions. Booster sessions will be received on monthly basis for a period of 6 months (one session per month) and until the last follow-up assessment. Communication with participants will take place online or via telephone."
214340051|NCT01737112|DRUG|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
214943713|NCT03899532|DEVICE|Remote Ischemic Conditioning|Standard manual blood pressure cuff
214943714|NCT03899532|OTHER|No-Remote Ischemic Conditioning|No-Remote Ischemic Conditioning
214677068|NCT04151004|OTHER|Respiratory muscle training like interventions|Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
214677069|NCT02725385|OTHER|Laboratory Biomarker Analysis|Correlative studies
214677070|NCT02725385|OTHER|Physiologic Testing|Undergo Trier Social Stress Test
214677071|NCT02725385|OTHER|Questionnaire Administration|Complete questionnaire
214340052|NCT04247854|DIETARY_SUPPLEMENT|Bacillus subtilis probiotic|Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.
214340053|NCT04247854|OTHER|Placebo|Over 5 days of interventional period, the patient receives 1 placebo tablet per day
214677072|NCT01687231|OTHER|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
214677073|NCT03004014|OTHER|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
214347419|NCT04697758|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye
214677074|NCT03251976|BEHAVIORAL|video|informational video
214677075|NCT03251976|BEHAVIORAL|usual care|usual physician counseling on end of life care
214677076|NCT03067558|DIAGNOSTIC_TEST|Children's automated respiratory rate monitor|"The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities."
214677077|NCT03067558|DIAGNOSTIC_TEST|MK2 Acute Respiratory Infection (ARI) Timer|The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
214677078|NCT02955186|DRUG|Saracatinib|Saracatinib 125 mg once per day for 8 days
214677079|NCT02955186|DRUG|Placebos|Placebo once per day for 8 days
214677080|NCT01267435|PROCEDURE|Anterior cruciate ligament reconstruction|reconstruct the anterior cruciate ligament rupturing
215074645|NCT00090142|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
215074646|NCT00688324|DRUG|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
214677081|NCT00757523|DRUG|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
214347420|NCT05178628|DRUG|Innohep|Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
214347421|NCT05178628|DRUG|Chemotherapy: Gemcitabine + Nab-Paclitaxel|All patients will receive chemotherapy per clinical practice
214347422|NCT01410448|DRUG|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
214347423|NCT01410448|DRUG|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
214677082|NCT00757523|DRUG|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
214677083|NCT03424330|DEVICE|ReX-C intervention|Patients receive medication by the ReX-C device
214677084|NCT03424330|OTHER|Standard of Care|Patients receive medication as usual
214677085|NCT04187001|OTHER|Content Validity|Use Delphi technique for achieve consensus
214677086|NCT04187001|OTHER|Cultural adaptation|Adapt the content to the target population
214677087|NCT02961764|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
214677088|NCT02961764|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
214943715|NCT05498792|DRUG|CBL0137|Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
214943716|NCT05498792|DRUG|Ipilimumab|Patient will be on Ipilimumab (1 mg/kg)
214943717|NCT05498792|DRUG|Nivolumab|Patient will be on Nivolumab (3 mg/kg)
214943718|NCT01534780|PROCEDURE|laparoscopic ventral herniotomy|Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
214943719|NCT01534780|DEVICE|Protack|fixation of mesh with protack
214943720|NCT01534780|DEVICE|Securestrap|fixation of mesh with Securestrap
214943721|NCT01534780|DEVICE|Glubran|fixation of mesh with Glubran
214677089|NCT01422304|DRUG|Sugammadex|Sugammadex 4 mg/kg intravenously
215074647|NCT02904005|OTHER|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
214677090|NCT01422304|DRUG|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
214677091|NCT01422304|DRUG|Placebo to neostigmine|Normal saline (NaCl 0.9%)
215074648|NCT00003946|DRUG|danazol|
214677092|NCT01422304|DRUG|Placebo to sugammadex|Normal saline (NaCl 0.9%)
214340054|NCT01509573|BEHAVIORAL|Family Strengthening Intervention in Rwanda (FSI-R)|"Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.~8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material."
214340055|NCT06395350|DEVICE|Spire Health Monitor|Use of Health Monitor is Assessed
214340056|NCT00966940|DRUG|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
214340057|NCT00966940|DRUG|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
214340058|NCT06191926|DIAGNOSTIC_TEST|ultrasound|Shear-wave elastography and shear-wave dispersion ultrasound to evaluate the diagnostic performance of solid breast lesions for the diagnosis of breast cancer
214347424|NCT01410448|DRUG|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
214347425|NCT01410448|DRUG|Steroids|Steroids were administered according to local clinical practice.
214943722|NCT04612777|BEHAVIORAL|Opening Doors to Recovery|Opening Doors to Recovery (ODR) was created by a large, collaborative group in southeast Georgia as a recovery-oriented approach that navigates clients into services that may in some cases be fragmented and seemingly inaccessible. The team of three Community Navigation Specialists (CNSs) strives to help clients reduce institutional (e.g., hospital, jail) recidivism and embrace recovery. Their process of community navigation is a broader function than traditional case management as it includes mapping out and connecting clients to all available local resources, which requires being embedded in the community. The work of the CNSs benefits from commitments of diverse collaborative ODR partners, including local treatment providers, law enforcement, employers, and housing programs. Each CNS was expected to meet with the client at home or in community settings at least monthly, with the client having contact with at least one CNS weekly.
215074649|NCT00099242|DRUG|rivastigmine transdermal patch|
215074650|NCT05139381|DRUG|Mepolizumab|Treatment with Mepoluzimab
214677093|NCT01874704|BEHAVIORAL|Comparison of biomarkers of stress|
214677094|NCT01301612|DRUG|Nimotuzumab|Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
215074651|NCT00006046|BIOLOGICAL|monoclonal antibody hu3S193|
214677095|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
215074652|NCT00900679|BEHAVIORAL|telephone-based intervention|
215074653|NCT00900679|OTHER|counseling intervention|
215074654|NCT00900679|OTHER|educational intervention|
214677096|NCT01301612|RADIATION|Brachytherapy|"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."
215074655|NCT00900679|OTHER|medical chart review|
215074656|NCT00900679|OTHER|questionnaire administration|
214677097|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
214677098|NCT01301612|RADIATION|Radiation Therapy|"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"
215074657|NCT00900679|PROCEDURE|psychosocial assessment and care|
215074658|NCT00900679|PROCEDURE|quality-of-life assessment|
214677099|NCT01347684|BEHAVIORAL|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
214677100|NCT01347684|DRUG|Standard care using current drugs|Standard Drug therapy
214943723|NCT04612777|BEHAVIORAL|Case Management|Case Management (CM) services, as defined by the State mental health agency, consist of providing essential environmental support and care coordination to assist the individual with improving his/her functioning, gaining access to necessary services, and creating an environment that promotes recovery as identified in his/her Individual Recovery Plan (IRP). The focus of interventions include assisting the individual with: (1) developing natural supports to promote community integration, (2) identifying service needs, (3) referring and linking to services and resources identified through the service planning process, (4) coordinating services identified on the IRP to maximize service integration and minimize service gaps, and (5) ensuring continued adequacy of the IRP to meet his/her ongoing and changing needs. Contact must be made with the individual ≥2 times per month, at least one of which must be in-person, in a non-clinic setting.
214943724|NCT04612777|BEHAVIORAL|Intensive Case Management|Intensive Case Management (ICM) is very similar to CM, but four in-person visits are required monthly. Additional contacts may be either face-to-face or via telephone, depending on the individual's needs. At least 60% of total contacts must be face-to-face with the individual, and at least 50% must be delivered in non-clinic/community-based settings. An ICM team includes nine professionals: a licensed clinician, four masters-level clinicians, two bachelors-level clinicians, and two paraprofessionals. The team's maximum case load is 200 in rural settings and 300 in urban settings (22-33 per team member).
214943725|NCT00810446|DRUG|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.."
214943726|NCT02455609|PROCEDURE|intrathecal drug administration|pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
214943727|NCT02455609|DRUG|Dexmedetomidine|
214943728|NCT02455609|DRUG|ketamine|
214943729|NCT02455609|DRUG|Bupivacaine|
214943730|NCT05079230|DRUG|Magrolimab|Administered intravenously (IV)
214340059|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Notched Noise Therapy|Notched Noise Therapy involves presenting wide-band sound with the tinnitus frequency region notched out, referred to as notched noise, or notch therapy. This procedure may distribute lateral inhibition into the notched frequency region, suppressing tinnitus neural activity believed to be occurring there. This type of therapy is provided through a sound file that is streamed through hearing aids.
214340060|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Broadband Noise|"Broadband Noise, or white noise, is a common tinnitus sound therapy treatment option. It is also commonly used as a masker noise for individuals with tinnitus that like to enrich their environment with sound."
214340061|NCT04661995|DEVICE|Hearing Aid|A-O groups will use ear-level, self-contained devices (hearing aids) that (1) are capable of streaming shapeable broadband noise between 1-10 kHz; (2) allow for normal conversation; and (3) are comfortable, easy to use, and discrete. These criteria describe a behind-the-ear hearing aid with the capability of streaming custom sounds. Hearing aids are used to provide amplification to those with hearing loss and are fit by licensed audiologists. Sometimes, hearing aids can provide benefit to those with bothersome tinnitus.
214340062|NCT03708341|DRUG|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
214340063|NCT03708341|DRUG|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
214340064|NCT04167397|OTHER|Collaborative learning|Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
214340065|NCT05148000|BIOLOGICAL|QM1114-DP|QM1114-DP
214340066|NCT02092948|RADIATION|[124I] PSCA-Minibody PET/CT imaging of the whole body|Whole body Imaging
214340067|NCT00244244|DRUG|arimoclomol|
214340068|NCT03750396|PROCEDURE|Surgical resection|Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.
214943731|NCT05079230|DRUG|Venetoclax|Tablets administered orally
214943732|NCT05079230|DRUG|Azacitidine|Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
214340069|NCT03750396|RADIATION|Stereotactic body radiotherapy|Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57\~97.5Gy/6\~10 Fraction).
214677101|NCT06512311|DIAGNOSTIC_TEST|CBMed Drug Screening Plattform|The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics.
214677102|NCT05191329|DIAGNOSTIC_TEST|TPQue Greek version, NEI-VFQ-25 Greek version|Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
214347426|NCT01060215|PROCEDURE|Normal saline|20 cc normal saline injection into the knee joint
214677103|NCT03321929|COMBINATION_PRODUCT|LUM Imaging System|Drug: LUM015 Device: LUM 2.6 Imaging Device
214677104|NCT00866294|DRUG|paroxetine IR 10mg tablet|1 or 2 tablets once a day
214943733|NCT05079230|DRUG|Placebo|Administered intravenously (IV)
214943734|NCT00169728|BIOLOGICAL|DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa|
214943735|NCT00169728|BIOLOGICAL|heptavalent pneumococcal conjugate vaccine, Prevenar|
214943736|NCT05420857|OTHER|Overground Visual Biofeeback|Subjects participate in biofeedback training for 3 6-minute bouts in a single session.
214943737|NCT03817034|DRUG|Multimodal analgesia|Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
214677105|NCT00866294|DRUG|paroxetine IR 20mg tablet|1 tablet once a day
214677106|NCT00866294|DRUG|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
214943738|NCT04181437|DRUG|NVP-1203-R1|1 tablet, Single oral dosing
214677107|NCT00866294|DRUG|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
214677108|NCT00866294|DRUG|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
214677109|NCT00866294|DRUG|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
214677110|NCT05417529|OTHER|music therapy intervention|"Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation"
214677111|NCT05417529|DRUG|Standard Preparation|Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
215074659|NCT02850861|DEVICE|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
214677112|NCT01821248|DRUG|Gemcitabine, Cisplatin, S-1|"Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7"
214677113|NCT05333562|OTHER|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
214677114|NCT05333562|OTHER|Motor control exercise with mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
214340070|NCT03750396|PROCEDURE|Radiofrequency ablation|RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.
214340071|NCT01073618|DRUG|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
214340072|NCT02007486|OTHER|Cardiopulmonary Exercise Testing|Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
214943739|NCT04181437|DRUG|NVP-1203-R2|1 tablet, Single oral dosing
214943740|NCT04181437|DRUG|NVP-1203-R1 and NVP-1203-R2|NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
214943741|NCT05564026|OTHER|Questionnaire Administration|Questionnaire provide to participant's about their health and quality of life since treatment
214943742|NCT05564026|OTHER|Tumor Specimen Collection|Tumor DNA requested from the Biopathology Center
214943743|NCT05564026|OTHER|Germline DNA Samples|Germline DNA specimens requested from the Biopathology Center or newly collected saliva
214943744|NCT05564026|PROCEDURE|Blood Sample Collection|Collection and storing of serum/plasma
214340073|NCT06300645|PROCEDURE|SPLATT|split tibialis anterior tendon transfer to peroneus brevis total tibialis anterior tendon transfer to lateral cuneiform
214340074|NCT05147818|OTHER|CBC ,renal function tests , fundus Examination|Laboratory investigations
214340075|NCT00171587|DRUG|PTK787/ZK 222584 (vatalanib)|
214340076|NCT03041415|BEHAVIORAL|ALED Alone Physical Activity Program|• 12-week class focused on teaching self-regulatory skills to increase regular PA
214340077|NCT03041415|BEHAVIORAL|ALED + Our Voice PA Program|"* 12-week class focused on teaching self-regulatory skills to increase regular PA~* Neighborhood assessment, consensus-building, \& advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity"
214943745|NCT06696157|BEHAVIORAL|PRSS intervention for MOUD initiation|All participants of this expanded scope pilot study will be in a single-arm of an uncontrolled trial of PRSS intervention for MOUD initiation for a total of 8 weeks, starting in inpatient substance abuse treatment. This is distinguished from the R34 parent grant which targets MOUD retention and adherence rather than MOUD initiation.
214943746|NCT06465134|OTHER|No intervention|There is no intervention
214340078|NCT00137332|DRUG|GAP-486 (ZP-123)|
214943747|NCT02920177|DRUG|platelet-rich plasma injection|platelet-rich plasma injection
215074660|NCT00832247|GENETIC|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
215074661|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with the digital method
215074662|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with a speculum
214340079|NCT00137332|DRUG|0.9% Sodium Chloride, USP|
214340080|NCT02812810|DEVICE|active rTMS|
214340081|NCT02812810|DEVICE|sham rTMS|
214340082|NCT03818373|PROCEDURE|polysomnography|Sleep examination strictly non-invasive with skin sensors. This exploration would allow for the detection of respiratory sleep disorders and consider of appropriate management for patients.
214340083|NCT01144312|DRUG|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
214943748|NCT02920177|DRUG|Kenalog 10 MG/ML Injectable Suspension|4 mL corticosteroid injection
214943749|NCT07027176|BEHAVIORAL|walking exercise|Divided into low-intensity and moderate-intensity exercise intervention groups, participants exercised either during the day or at night. The intervention lasted for 12 weeks.
215074663|NCT03176472|DRUG|ricolinostat|120 mg per dose in 12 mL liquid formulation
215074664|NCT03176472|DRUG|Placebo|12 mL liquid formulation placebo
215074665|NCT05529979|DEVICE|EPIONE® CT-Guided Percutaneous procedures|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
215074666|NCT02568098|DRUG|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
214943750|NCT07024888|DRUG|SSS17|Single oral administration of SSS17
215074667|NCT02568098|DRUG|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
215074668|NCT02568098|DRUG|DHA-PQP|Regimen 6: DHA-PQP
214943751|NCT03229629|BEHAVIORAL|Behavior change communication|Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks
214677115|NCT05440955|DEVICE|left fronto-temporal transcranial Direct Current Stimulation (tDCS)|"The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session."
214677116|NCT05046210|BEHAVIORAL|LHA intervention|The participants in the EG received 4 lessons from a LHA over 4 weeks. Four lessons were taught one-on-one once a week by a certified LHA at the participants' homes. The lessons including understand oral structure, learn oral self-care skills and oral function promotion, understand the status of oral self-care and the relationship between oral diseases and systemic diseases, understand swallowing dysfunction and safe eating skills and review.
214677117|NCT05046210|BEHAVIORAL|Oral exercise intervention|Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.
214677118|NCT02890771|PROCEDURE|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
214677119|NCT02890771|PROCEDURE|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
214677120|NCT02890771|PROCEDURE|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
214677121|NCT04799782|DRUG|Mirtazapine|15 mg dose before bed-time
214677122|NCT04799782|DRUG|Placebo|One placebo pill before bed-time
214677123|NCT01466725|DRUG|CC-930|
214943752|NCT03229629|OTHER|Food Voucher (Monetary)|Monthly voucher worth 200 birr(\~$10) every month for the duration of 6 month
214943753|NCT06711146|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion
214677124|NCT01466725|DRUG|Placebo|Placebo
214943754|NCT06886269|DRUG|14C-VX-993|Solution for Oral Administration.
214943755|NCT00426140|DRUG|Patupilone|
214677125|NCT04272125|BIOLOGICAL|CD123 CAR-T cells|A single infusion of CD123-CAR-T cells will be administered intravenously
214340084|NCT00389714|DEVICE|dental restoration|
214340085|NCT00999479|DRUG|Norethindrone acetate and ethinyl estradiol tablets, USP|"Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc."
214943756|NCT02634372|BEHAVIORAL|EMDR therapy|EMDR: We designed a specific EMDR Bipolar Protocol which consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol, and five new specific bipolar adapted EMDR protocols focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and moodstabilization.
214943757|NCT02634372|BEHAVIORAL|Supportive Therapy|Supportive therapy: Therapists adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise. If no specific topic is mentioned by the patient, information about bipolar disorder and medication will be delivered by the therapist without referring to written or any other material.
214340086|NCT00999479|DRUG|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
214340087|NCT02842775|OTHER|balance perturbation training|perturbation training on the split-belt balance perturbance treadmill,
214943758|NCT00835627|DRUG|sertraline|flexible dose sertraline
214943759|NCT00835627|BEHAVIORAL|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions
214943760|NCT00835627|OTHER|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions
215074669|NCT00912080|GENETIC|genomic signature|genomic signature analysis
215074670|NCT05105750|DRUG|aspirin 100 mg/d|100mg aspirin for at least 3 days followed by aspirin 100 mg/d
215074671|NCT05105750|DRUG|indobufen 200 mg bid|100mg aspirin for at least 3 days followed by indobufen 200 mg bid
215074672|NCT04243018|BEHAVIORAL|Acceptance and Commitment Therapy Group Treatment|The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
214943761|NCT00835627|OTHER|Standard Care|community care, treatment as usual: routine follow up with existing providers
214943762|NCT04561102|DIAGNOSTIC_TEST|Diagnostic test for detection of SARS-CoV-2|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
215074673|NCT04243018|BEHAVIORAL|Peer Support Group|The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
215074674|NCT00596154|OTHER|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
215074675|NCT03784599|DRUG|Trastuzumab emtansine|Infusion
214677126|NCT04118361|DIAGNOSTIC_TEST|HINTS Test|"The HINTS test is a clinical test composed of 3 oculomotor examinations:~* Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~* Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~* Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging."
214677127|NCT04118361|DIAGNOSTIC_TEST|STANDING Algorithm|The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
214943763|NCT01870804|DRUG|Rosuvastatin|
214943764|NCT01870804|DRUG|Atorvastatin|
214943765|NCT03968224|DRUG|Dapagliflozin/Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
214943766|NCT03968224|DRUG|Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
214677128|NCT04798417|DIETARY_SUPPLEMENT|Probiotic supplement|Use of a probiotic sachet
214943767|NCT00992134|DRUG|Rituximab, Bendamustine, Cytarabine|"Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.~Four to six cycles. Recycle every 28 days."
214677129|NCT04798417|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic sachets
214943768|NCT02202044|DEVICE|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
214943769|NCT02763982|OTHER|Physical evaluation|
214943770|NCT02838836|PROCEDURE|Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
214943771|NCT02183259|DRUG|ESR 1150 CL, Capsule, oral|
214943772|NCT02183259|DRUG|ESR 1150 CL, solution, intravenous|
214943773|NCT02573831|DRUG|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
214943774|NCT02573831|DRUG|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
214943775|NCT05032274|OTHER|Home-based Exercise Program|The exercise program will include chink tuck and shoulder retraction exercises. The chin tuck exercise will be performed in standing position. The shoulder retraction exercise includes activation and strengthening components. The activation component will be performed in standing position and strengthening component will be performed in prone position.
214943776|NCT05330702|DEVICE|Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft No Intervention: No Soft Tissue Augmentation|Fibro-gide is the VCMX
214677130|NCT04798417|DIETARY_SUPPLEMENT|Maltodextrin|Placebo comparator
214677131|NCT04666961|DRUG|Tamoxifen 20 mg|Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
214677132|NCT04666961|DRUG|Anastrozole 1Mg Tab|Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
214943777|NCT05330702|PROCEDURE|Tuberosity Connective Tissue Graft (CTG)|CTG will be taken from the patient's own mouth
214943778|NCT05296902|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
214943779|NCT01362244|DRUG|Mepolizumab|750 mg of mepolizumab by IV infusion
215074676|NCT03784599|DRUG|Osimertinib|Tablet
214943780|NCT01362244|DRUG|Placebo|Placebo by IV infusion
215074677|NCT00037817|DRUG|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
215074678|NCT00037817|BIOLOGICAL|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
214340088|NCT03932565|BIOLOGICAL|CAR-T therapy for nectin4-positive malignant solid tumor|The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence.
214340089|NCT00547560|DRUG|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
214340090|NCT03434717|OTHER|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
214340091|NCT03434717|OTHER|Care as usual|Patients will get care as usual
214340092|NCT03796455|DIETARY_SUPPLEMENT|Capsule + Powder supplementation|For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).
214340093|NCT03796455|OTHER|stable tracer infusion|labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
214340094|NCT03421925|PROCEDURE|Laparoscopic totally extraperitoneal procedure for inguinal hernia|Laparoscopic totally extraperitoneal procedure for inguinal hernia is a technique that is done by not entering the peritoneal cavity
214943781|NCT01362244|DRUG|Run In Medication|subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
214943782|NCT05137847|DRUG|Remitoro|Intravenous infusion.
214943783|NCT03357133|DRUG|Tirofiban|Tirofiban Injection after the alteplase intravenous thrombolysis
214943784|NCT03357133|DRUG|Alteplase|Only alteplase intravenous thrombolysis
214943785|NCT05153148|DRUG|NDI-034858|NDI-034858 oral capsule
214943786|NCT05153148|OTHER|Placebo|NDI-034858-matching oral placebo capsule
214943787|NCT02974920|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10 mg once daily for 180 days
214943788|NCT02974920|DRUG|Aspirin|Aspirin 100 mg once daily for 180 days
214943789|NCT01712334|DRUG|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
214943790|NCT01712334|DRUG|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
215074679|NCT00037817|DRUG|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
214340095|NCT01834365|OTHER|Structured education|Formatted education about hypertension
214340096|NCT01834365|OTHER|Checklist|
214340097|NCT01834365|OTHER|Without structure education with checklist|
214943791|NCT01953432|DRUG|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
214943792|NCT01953432|DRUG|Placebo|Matched placebo daily dosing
214943793|NCT06439589|DRUG|HRS2398|HRS2398: Tablets, 40mg/tablet, oral
214943794|NCT06439589|DRUG|Adebrelimab|Adebrelimab (SHR-1316): injection, 600mg(12mL), intravenous infusion
214943795|NCT02106663|PROCEDURE|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.
214943796|NCT02106663|PROCEDURE|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.
214943797|NCT04535050|DEVICE|Renal denervation|Renal Denervation: DENEX system
215074680|NCT05554978|DRUG|Landiolol|patient receives landiolol in addition to standard-of-care
215074681|NCT05554978|DRUG|Sodium Chloride (NaCl) 0.9%|Placebo
215074682|NCT06188650|DRUG|Anlotinib|After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
215074683|NCT00906139|DRUG|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
214677133|NCT02109003|DEVICE|Pressure easy® device|Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
214677134|NCT02109003|DEVICE|Manual control of Pcuff followed by continuous control.|Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
214677135|NCT02584621|BEHAVIORAL|Check Yourself App with Feedback|
214677136|NCT03271255|DRUG|Apatinib Mesylate Tablets|Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
214677137|NCT03271255|DRUG|Bevacizumab Injection|Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
214677138|NCT06511609|PROCEDURE|double-flap technique（DFT）; double-tract reconstruction(DTR),|DFT (experiment group). Patients receive double flap technique after laparoscopic proximal gastrectomy. DTR (control group). Patients receive double-tract reconstruction after laparoscopic proximal gastrectomy.
214943798|NCT04535050|PROCEDURE|Renal angiography|Renal angiography
214943799|NCT02123836|BIOLOGICAL|NK cells|"7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.~Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.~NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.~The NK cells will then be infused into the vein, through a peripheral catheter."
214943800|NCT02892513|DEVICE|Percutaneous auricular neurostimulation|The Bridge device (manufactured by Key Electronics \[Jeffersonville, IN, USA\] and distributed by Innovative Health Solutions \[Versailles, IN, USA\]) provides continual neurostimulation for five days with alternating current.
214943801|NCT02892513|DEVICE|Sham percutaneous auricular neurostimulation|Identical in appearance to active, device, but no stimulation will be given.
214943802|NCT03426436|DIAGNOSTIC_TEST|Two consecutive 15-lead ECGs|The 15-lead ECG consists of a traditional 12-lead ECG and an additional three leads on the right side of the body. The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
214943803|NCT06486649|DIAGNOSTIC_TEST|Multimodal Large Language Model Diagnosis|Diagnosis for heart failure with preserved ejection fraction (HFpEF) using the multimodal large language model MedGuide-72B.
214943804|NCT06486649|DIAGNOSTIC_TEST|Routine diagnostic and therapeutic procedure|Routine diagnostic and therapeutic procedure
214943805|NCT04367493|DIETARY_SUPPLEMENT|Chocolate|25 g of chocolate by day for 4 weeks
214340098|NCT02044510|DRUG|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
214340099|NCT02044510|DRUG|Placebo|Matched placebo capsules to the intervention arm
214340100|NCT03185975|BEHAVIORAL|at-home test kit|Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
214347427|NCT01185574|DIETARY_SUPPLEMENT|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
214677139|NCT04258553|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
214677140|NCT04258553|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
214677141|NCT04258553|DIAGNOSTIC_TEST|Ischemia Modified Albumin(IU/mL)|The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).
214677142|NCT03687177|OTHER|With visual cue and nurses informed|Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
214677143|NCT03687177|OTHER|Without visual cue and nurses informed|Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
214677144|NCT01123447|PROCEDURE|Open reduction and internal fixation|Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.
214677145|NCT01123447|PROCEDURE|Closed reduction and short-arm cast|Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
214677146|NCT03727711|OTHER|TPTNS|We will be comparing hospital treatment to TPTNS at home
214677147|NCT02606877|DRUG|nintedanib|
214677148|NCT02606877|DRUG|pirfenidone|
214943806|NCT05519137|DEVICE|Active lighting intervention|Lighting intervention designed to impact the circadian system
214943807|NCT05519137|DEVICE|Control lighting intervention|Lighting intervention designed to have no impact on the circadian system
215074684|NCT00906139|DRUG|Midazolam|Midazolam dose: 0.1 mg/kg
215074685|NCT00906139|DRUG|Fentanyl|Fentanyl dose: 0.05 mg
214340101|NCT03185975|BEHAVIORAL|Motivational Interviewing and Certified Testing and Referral|Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
214340102|NCT04858737|BEHAVIORAL|e-predictD-Work intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.
214943808|NCT06107907|DEVICE|Non-invasive ventilation (NIV) or high-flow oxygen therapy (HFOT) using electrical impedance tomography (EIT)|Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase. NIV will be administered in continuous positive airway pressure (CPAP) mode. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities.
214943809|NCT04491747|DIAGNOSTIC_TEST|functional capacity|Six minute walk test used assessment of functional capacity.
214943810|NCT06624254|OTHER|lung mechanics, respiratory drive and effort|Patient lung mechanics and respiratory drive and effort will be measured
214943811|NCT00841347|BEHAVIORAL|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
214943812|NCT00841347|BEHAVIORAL|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
214943813|NCT05968027|OTHER|"Nouveal numeric application Onco'nect"|A remote monitoring application, Onco'nect® (smartphone /tablet /PC), in partnership with the company Nouveal facilitates communication between patients undergoing Intra Vascular (IV) chemotherapy and the care team. A questionnaire before and after each session can be used to alert the oncology department and adapt patient management.
214943814|NCT06128291|PROCEDURE|posterior colporrhaphy|posterior colporrhaphy for rectocele.
214943815|NCT02261662|DRUG|Ribavirin|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
214943816|NCT02261662|DRUG|Betamethasone|Topical Steroids alone will be used; Betamethasone
214943817|NCT04514744|PROCEDURE|Knee bracing|Participants will have one leg immobilized, by means of a removable Don Joy Knee Brace. Participants will be expected to keep the knee brace on for 14 days, completely prevent weight bearing on the immobilized leg, and use crutches.
214943818|NCT04514744|OTHER|Unilateral Resistance Exercise Training|Participants will perform resistance training on 4 occasions throughout an 8 day time period.
214340103|NCT04858737|OTHER|Brief psychoeducational messages|The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
214340104|NCT04139811|OTHER|Pars Plana Vitrectomy|vitrectomy with and without ILM peeling
214340105|NCT05058911|BEHAVIORAL|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
214340106|NCT05058911|BEHAVIORAL|Internet-delivered traditional cognitive behavior therapy|This treatment is based on components typical of T-CBT for FM, such as relaxation, activity planning or pacing, cognitive restructuring techniques and stress management strategies.
214340107|NCT05494398|DRUG|N-acetylcysteine|12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
214340108|NCT00382343|DRUG|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
214943819|NCT00718380|DRUG|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
214943820|NCT02919267|DEVICE|Double lumen tube|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.
214943821|NCT02919267|DEVICE|Bronchial blocker|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
214340109|NCT05242679|OTHER|Myofascial release technique along with conventional physiotherapy exercises|Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
214943822|NCT04546516|DEVICE|HYAcorp Lips and HYAcorp Face|Dermal filler injection to different facial areas
214943823|NCT00256321|DRUG|Oxaliplatin|Oxaliplatin 70mg/m2 IV on Days 1 and 8
214943824|NCT00256321|DRUG|Capecitabine|Capecitabine 1000mg/m2 PO BID from Days 1 through 14.
214943825|NCT00256321|DRUG|Celecoxib|Celecoxib 400mg PO BID from Days 1 through 21.
214943826|NCT00574210|DRUG|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
214943827|NCT00574210|DRUG|Placebo|Placebo Tablets administered twice per day
214943828|NCT04106050|DRUG|BIIB095|Administered as specified in the treatment arm.
214943829|NCT04106050|DRUG|BIIB074|Administered as specified in the treatment arm.
214943830|NCT04106050|DRUG|Placebo|Administered as specified in the treatment arm.
214340110|NCT05242679|OTHER|Conventional physiotherapy exercises|Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
214340111|NCT03269032|OTHER|American Diet|"According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, \>11% Saturated Fatty Acids, \<12% Monounsaturated Fatty Acids, and \>8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
214340112|NCT03269032|OTHER|Mediterranean-style Diet|"The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, \<7% Saturated Fatty Acids, \>18% Monounsaturated Fatty Acids and \<5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
214340113|NCT00326235|DRUG|Buspirone|
214340114|NCT01648777|DEVICE|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
214340115|NCT01648777|DRUG|placebo|"* Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
214340116|NCT02602574|OTHER|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
214340117|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Norway|
214340118|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
214340119|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
214340120|NCT03455075|DRUG|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
214340121|NCT03455075|DRUG|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
214340122|NCT03455075|DRUG|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
214340123|NCT02230657|PROCEDURE|Same day discharge|
214340124|NCT02230657|PROCEDURE|Next day discharge|
214340125|NCT00585897|BEHAVIORAL|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
214340126|NCT02081794|OTHER|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
214486455|NCT06739395|DRUG|Anlotinib|Usage, dosage, and administration method: Take orally once a day before breakfast. Take the medication continuously for 2 weeks and stop taking it for 1 week, that is, 3 weeks (21 days) is one course of treatment. Until disease progression or intolerable toxic side effects occur.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214943831|NCT04106050|DRUG|Lidocaine|Administered as specified in the treatment arm.
214943832|NCT05454046|OTHER|Food intake among women and men in fertility treatment|Filling in an FFQ
214943833|NCT06451796|DEVICE|Obtinu|Treatment of Female Stress Incontinence with a hydrophilic coated valved intraurethral catheter
214943834|NCT02231593|OTHER|SAGIT|SAGIT is a Clinician-Reported Outcomes (ClinROs) tool
214943835|NCT01615211|DRUG|Letrozole|Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
214943836|NCT01615211|DRUG|Trilostane|Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
214943837|NCT01366859|DIETARY_SUPPLEMENT|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
214943838|NCT01366859|DIETARY_SUPPLEMENT|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
214943839|NCT06128785|DEVICE|Electroacupuncture group|Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37). All acupoints will be taken by tonifying method after obtaining qi, and unilaterally connected to an electroacupuncture instrument for electrical stimulation with a continuous wave frequency of 5 Hz and a stimulation intensity as tolerated by the patient for 30 min each time. Acupuncture stimulation was given every 12 h. The duration of treatment was from postoperative to the fourth postoperative day (d0-d4) or until the patient's first postoperative anal exhaust or until the fourth day.
214943840|NCT06128785|OTHER|Sham EA group|Sham acupuncture needle will have the same appearance as the traditional needle, with a blunt tip (Suzhou Medical Supplies Factory, specification 0.25×40mm), lifting and inserting and twisting, but not piercing the adhesive pad. The output wire of the special sham electroacupuncture apparatus is cut in the middle, and the appearance is as usual; that is, the electroacupuncture apparatus shows an on state, but is not actually energized; the electroacupuncture points, acupuncture time points, frequency, retention time, and duration of treatment are the same as the intervention group, and the patients are informed that it is an effective light current input and may not feel stimulation, but the current is output.
214943841|NCT04109937|RADIATION|External beam radiation therapy|The post-operative radiation will cover entire prosthesis/surgical fixation device and will consist of the dose fractionation of: 20 Gy in 5 fractions or 30 Gy in 10 fractions.
214340127|NCT02081794|OTHER|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
214340128|NCT03454594|DEVICE|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
214677149|NCT01058577|DEVICE|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
214677150|NCT01058577|PROCEDURE|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
214943842|NCT00989456|BEHAVIORAL|Self management education programme|"The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.~After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh."
214677151|NCT00756977|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
214340129|NCT05237622|DEVICE|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data on lung volume changes will be measured using electrical impedance tomography.
214943843|NCT00989456|BEHAVIORAL|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
214340130|NCT02912533|DRUG|JR-131|
214340131|NCT05668182|PROCEDURE|TRUMATCH Graft Cage|TRUMATCH Graft Cage for surgical repair of segmental long bone defect
214340132|NCT01049555|OTHER|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
214340133|NCT04849234|BEHAVIORAL|newborn cries|"Their cries will be longitudinally registered from the age of birth until the first 15 minutes of birth using an automatic record device: Recorder ZOOM H4N.~The wav-sized files obtained from each recording will then be analyzed indiscriminately via an acoustic processing script created for the PRAAT software® by the post-doctoral fellows of the ENES laboratory (Sensory NeuroEthology Team) on the site of the Faculty of Sciences of Saint-Etienne."
214340134|NCT00907569|RADIATION|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
214340135|NCT03846843|DRUG|OCR-002 IR Oral Tablet|OCR-002 3 gram immediate release (IR) tablet for oral administration
214340136|NCT03846843|DRUG|OCR-002 Oral Solution|OCR-002 5 gram solution for oral administration
214340137|NCT03846843|DRUG|OCR-002 IV Solution|OCR-002 5 gram solution for intravenous (IV ) administration
214340138|NCT06043921|OTHER|No intervention|There is no intervention associated with this observational study.
214340139|NCT06532110|OTHER|Endoscopy/Colonoscopy|Esophagogastroduodenoscopy and colonoscopy with video recording and biopsy collection
214340140|NCT02577705|BEHAVIORAL|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
214340141|NCT02577705|BEHAVIORAL|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
214340142|NCT02577705|BEHAVIORAL|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
214340143|NCT04596163|PROCEDURE|Transversus thoracis muscle plane block|After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
214347428|NCT06486753|PROCEDURE|Chevron osteotomy bunion surgery with lateral soft tissue release|Lateral soft tissue release is often performed in hallux valgus correction, and there is preliminary evidence to suggest it may be useful in improving post-surgical outcomes for the Chevron osteotomy bunion surgery.
214677152|NCT00756977|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
215074686|NCT01665079|DRUG|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS\>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 \> 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS \> 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
215074687|NCT06060132|DRUG|Sodium arsenite chloride injection|Patient use of arsenite sodium chloride injection
214943844|NCT03376347|DEVICE|FlotracIQ with HPI algorithm|FlotracIQ with hypotension probability indicator (HPI) algorithm connected to arterial line. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and what. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
214340144|NCT04497441|OTHER|Electronic Survey questionnaire|"This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Survey Questionnaire contained following sections:~Section I: Minimum required personal details Section II: 10 Questions regarding the source of COVID-19 information Section III: 6 Questions regarding perception of the COVID-19 information~The very first part of the Questionnaires seeks responders' consent for giving responses to the survey questions. participation Section II \& III contained all closed ended questions. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms."
214943845|NCT03195647|DRUG|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
214943846|NCT02407054|DRUG|LY3023414|Administered orally
214943847|NCT02407054|DRUG|Enzalutamide|Administered orally
214943848|NCT02407054|DRUG|Placebo|Administered orally
214943849|NCT05097547|BEHAVIORAL|Contingency Management|Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.
214943850|NCT01091545|RADIATION|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
214943851|NCT04656197|OTHER|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
214943852|NCT00131365|DEVICE|ExAblate 2000|
214943853|NCT02826265|DEVICE|multiple breath washout test (MBW)|
214943854|NCT02826265|DEVICE|impulse oscillometry (IOS)|
214340145|NCT03788889|DRUG|Ketamine|Ketamine infusion
214340146|NCT03788889|DRUG|Phenobarbital|Phenobarbital intravenous injection
214943855|NCT02826265|DEVICE|body plethysmography (BP)|
214943856|NCT02826265|DEVICE|quantitative computed tomography (qCT)|ultra-low-dose qCT
214340147|NCT03788889|DRUG|Lorazepam|Standard of Care
214340148|NCT03788889|DRUG|Placebo A|Placebo injection
214943857|NCT04608344|DRUG|Atorvastatin|Administered as single dose tablet orally.
214943858|NCT04608344|DRUG|Pravastatin|Administered as single dose tablet orally.
214943859|NCT04608344|DRUG|Rosuvastatin|Administered as single dose tablet orally.
214943860|NCT04608344|DRUG|Filgotinib|Administered as tablet orally once daily for 11 days.
214943861|NCT00645281|DRUG|tolterodine extended release|Tolterodine ER capsule 4 mg daily for 12 weeks
214943862|NCT02781181|DEVICE|CAS with CPD|using a neuroprotection device
214943863|NCT02781181|OTHER|CAS without CPD|No Neuroprotection
214943864|NCT00058084|DRUG|ixabepilone|Given IV
214943865|NCT00058084|DRUG|mitoxantrone hydrochloride|Given IV
214340149|NCT03788889|DRUG|Placebo B|Placebo infusion
214340150|NCT04021680|OTHER|pre-eclampsia screening program|This screening program included the use of ultrasound, biomarkers and maternal factors in calculating the risk of developing preeclampsia.
214340151|NCT04558957|DEVICE|FLEBOGRIF|The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.
214340152|NCT02032901|DRUG|Daclatasvir|
214340153|NCT02032901|DRUG|Sofosbuvir|
214340154|NCT02677545|DRUG|Ticagrelor|
214340155|NCT02677545|DRUG|Clopidogrel|
214340156|NCT02677545|DRUG|Aspirin|
214943866|NCT00058084|DRUG|prednisone|Given orally
214943867|NCT04888403|DRUG|Toripalimab+Nedaplatin+Albumin Paclitaxel|"Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel"
214943868|NCT00846703|DRUG|6-mercaptopurine, Methotrexate|"6-mercaptopurine p.o. qd~Methotrexate p.o. qw"
214943869|NCT00846703|DRUG|6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone|"(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)"
214943870|NCT02549976|PROCEDURE|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
214943871|NCT02549976|PROCEDURE|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
214943872|NCT02549976|PROCEDURE|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
214943873|NCT02549976|PROCEDURE|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
214943874|NCT02044874|DRUG|APD356-lorcaserin hydrochloride|
214943875|NCT02044874|DRUG|Placebo|
214943876|NCT06512454|OTHER|No Intervention|This is a non-interventional study.
214943877|NCT04506398|PROCEDURE|liver transplant|Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.
214677153|NCT03991377|BEHAVIORAL|Eye movement desensitization and reprocessing therapy|"EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~1. Patient history.~2. Patient preparation.~3. Patient assessment.~4. Memory desensitization.~5. Installing the positive cognition.~6. Body scan.~7. Closure.~8. Reevaluation."
215074688|NCT02840643|BEHAVIORAL|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
214943878|NCT04506398|DIAGNOSTIC_TEST|ctDNA|Circulating Tumor DNA Correlates With Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma
214943879|NCT04506398|DIAGNOSTIC_TEST|whole exome sequencing|xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.
214943880|NCT05531305|DEVICE|Muscle ultrasound|Standardized ultrasonographic measurement of quadriceps muscle layer thickness.
214943881|NCT05531305|DEVICE|Indirect calorimetry|Non-invasive measurement of resting energy expenditure using the Q-NRG metabolic monitor with hood and canopy.
214943882|NCT05531305|DIAGNOSTIC_TEST|Hand dynamometry|Assessment of handgrip strength using hand dynamometry.
214943883|NCT05531305|DIAGNOSTIC_TEST|MRC Sum Score|Assessment of muscle function/limb strength using the Medical Research Council sum score (12-60 points).
214943884|NCT00389298|DRUG|VCH-759 (BCH-27759)|
214943885|NCT00415597|DRUG|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
214943886|NCT01447927|DRUG|metformin hydrochloride|Given PO QD and BID
214943887|NCT01447927|OTHER|placebo|Given PO QD and BID
214943888|NCT00222482|DRUG|Depakote ER|
214943889|NCT06730776|OTHER|Topical medication|It will be given to all participants in both groups (A\&B). The most commonly prescribed topical medication is lidocaine ointment 5% (Xylocaine jelly 2% or ointment 5%; AstraZeneca Pharmaceuticals LP, Wilmington, DE), applied as required for symptoms and for 30 minutes before sexual activity.
214943890|NCT06730776|OTHER|Transcutaneous electrical acupoint stimulation|This procedure will be applied for group B only. Before starting the first treatment session, each patient will be instructed briefly about the nature of the treatment to gain the patient's confidence and cooperation. This procedure will be performed by using TENS device on acupoints as the following: The participating woman will be placed in a relaxed comfortable supine position with her back well supported. The surface of the treated skin and the electrodes will be cleaned with alcohol wipe. The TENS protocol consists of a 30-minute weekly. session for 10 weeks of biphasic pulses with modulation 0/10-50 Hz of frequency and 300/100/3000 microseconds of pulse duration (s). The intensity parameter will be adapted individually according to each woman's perception, and modulated so that it is applied without discomfort, ranging between 10 and 100 mA (pulsing sensation) (Dionisi and Senatori ,2011)
214943891|NCT01043562|DIAGNOSTIC_TEST|Defibrillator threshold testing|Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.
214943892|NCT01043562|OTHER|Observation of post-shock intrinsic cardiac rhythm|Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole \>4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a \>10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
214943893|NCT04005144|DRUG|Binimetinib|Given PO
214943894|NCT04005144|DRUG|Brigatinib|Given PO
214943895|NCT04102865|DEVICE|Negative-Pressure Wound Therapy (NPWT)|Investigational single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 7 days.
214677154|NCT03991377|DRUG|Treatment as usual|Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
214340157|NCT00982020|DRUG|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
214340158|NCT00982020|BEHAVIORAL|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
214943896|NCT06648291|DEVICE|QOCA EKG Device|The investigators scheduled telephone interviews every three days to encourage and monitor the development of good self-health care behaviors by: (1) asking about daily blood pressure, weight, and lower extremity edema; (2) providing medication counseling, as well as exercise and dietary hygiene recommendations; (3) offering wound care guidance; (4) advising on the proper use of wounds; (5) advising on avoiding cardiac risk factors such as smoking and secondhand smoke; and (6) following up on physical status at outpatient clinics and assisting with referrals to relevant clinics, such as nutrition or rehabilitation, based on the patient's condition. A QOCA portable electrocardiogram (ECG) measurement device will be provided for patients to use at home. In the event of abnormal physiological values, the investigator will contact the patient to assess his or her medical status and provide 24-hour online counseling.
214943897|NCT06648291|OTHER|Usual Care|Provide post-operative education on the day of discharge and follow up with a phone call one week after discharge to check on the patient.
214943898|NCT05531448|OTHER|two way texting|"Automated 2WT-based adherence support messages combined with scheduled visit reminders focus on preventing visit default will be implemented. One-way blast motivational support messages will be sent to all new ART patients who opt-into 2WT. ART visit reminders 3- and 1- day before visits will ask clients to respond with 1=attend and 0=no, triggering 2wT responses to clients to reschedule visits, record transfers, etc. 2WT clerks proactively communicate with clients before a visit to prevent default or ascertain true outcomes for those who don't return. Those who miss visits receive additional 2wT reminders. On day 14 post visit, 2wT patients who missed visits, did not respond to text or did not have outcomes updated (transfer, stop, etc.), are identified by the 2WT system and referred to B2C for tracing, days or months earlier than routine B2C. The 2wT-generated tracing list is more timely and accurate, reducing workload and increasing B2C effectiveness"
214943899|NCT00147784|DRUG|Ribavirin|800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
214943900|NCT00147784|DRUG|Pegylated Interferon|180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
214677155|NCT02989727|DRUG|Lamotrigine|Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
214677156|NCT02989727|DRUG|Placebos|Placebo tablets
214943901|NCT03218319|BIOLOGICAL|Renin measurement|patients will have a blood sample for measuring renin activity
214340159|NCT00982020|BEHAVIORAL|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
214340160|NCT01384344|OTHER|observational|Observation during a physical exercise
214340161|NCT00444158|DRUG|MOA-728|
214943902|NCT00615979|DEVICE|Miniature echo machine|Images captured and real-time and store-and-forward file transfers performed
214943903|NCT00223964|DRUG|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
214943904|NCT05745207|DRUG|E2086|E2086 tablets.
214943905|NCT05745207|DRUG|Placebo|E2086 matched placebo tablets.
214943906|NCT00493233|DRUG|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."
214677157|NCT00797927|DRUG|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
214340162|NCT01229345|DRUG|Breakfast & exercise|1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
214943907|NCT00493233|DRUG|main antipsychotic medication and placebo|"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."
214677158|NCT00797927|OTHER|no intervention|keep the original conventional antipsychotic agent for 28 days
215074689|NCT02840643|BEHAVIORAL|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
215074690|NCT03829943|DIAGNOSTIC_TEST|Vitamin D|Blood will be drawn for Vitamin D level
215074691|NCT01944566|BIOLOGICAL|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
215074692|NCT01937793|OTHER|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
215074693|NCT01937793|OTHER|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
215074694|NCT02092051|DEVICE|Continuous glucose monitoring with DexCom G4 platina|
215074695|NCT04657380|BEHAVIORAL|PLAN-e-PSY mobile application|"The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops"
214340163|NCT02528201|DRUG|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
214340164|NCT02528201|DRUG|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
214340165|NCT02528201|DRUG|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
214340166|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence A|Starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.
214943908|NCT02910570|DRUG|Liraglutide 3 mg (Saxenda)|Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
214677159|NCT05299827|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
214677160|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group|"The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
214943909|NCT02910570|DRUG|Liraglutide 3 mg placebo|Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
214943910|NCT03966937|OTHER|Dry needling|"Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points."
214943911|NCT03966937|OTHER|Control|Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
214943912|NCT01764997|DRUG|Sarilumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
214943913|NCT01764997|DRUG|Etanercept|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
214943914|NCT01764997|DRUG|Methotrexate|Dispensed according to local practice.
214943915|NCT01764997|DRUG|Placebo (for sarilumab)|
214943916|NCT01764997|DRUG|Placebo (for etanercept)|
214943917|NCT01764997|DRUG|Adalimumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
214340167|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence B|Starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position and collect the last group of figures.
214943918|NCT02895646|OTHER|Collection of blood sample|
214943919|NCT04237129|DRUG|Gan & Lee Insulin Aspart|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
214943920|NCT03013296|OTHER|GIP-A|GIP-A
214943921|NCT03013296|OTHER|Placebo|Placebo
214943922|NCT03013296|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Exendin\[9-39\]
214943923|NCT03013296|OTHER|GIP-A + Exendin[9-39]|GIP-A + Exendin\[9-39\]
214943924|NCT02386930|BEHAVIORAL|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
214943925|NCT01893580|BEHAVIORAL|Experimental: 1. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
214340168|NCT01438632|DEVICE|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
214943926|NCT01893580|BEHAVIORAL|Experimental: 2. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
214943927|NCT01893580|BEHAVIORAL|Experimental: 3. Experimental|"Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
214677161|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
214943928|NCT01893580|BEHAVIORAL|Other: 4. Usual care|"Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.~The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
214943929|NCT00979524|BEHAVIORAL|Comprehensive Mental Health Services and Supports|"This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group."
214943930|NCT02921633|OTHER|Intervention letter|
214943931|NCT03383900|DEVICE|Inspiratory muscle training|"The inspiratory muscle training program will be of the strength and endurance type, using the POWERbreathe® device and composed of: daily sessions (3 sets of 15 repetitions -inspiration), 6 days a week for 8 weeks. Participants will begin training breathing with a resistance of 20% of their PImax during the first week. After the first week, the resistance will increase between 5% and 10% in each session until reaching 80% of the PImax, which will be maintained during the first month. Upon completion, the PImax value will be re-evaluated and the player will train 80% of this new value during the second month. At the end of the second month, the PImax is evaluated and the player will train the third month with a resistance of 80% of this new value."
214677162|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
214340169|NCT01335711|DRUG|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)"
215074696|NCT04657380|BEHAVIORAL|Control Group|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
215074697|NCT00642369|DRUG|quetiapine fumarate|600-750mg/day
214677163|NCT01319760|DEVICE|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
215074698|NCT00642369|DRUG|haloperidol|6-40mg/day
214677164|NCT01319760|OTHER|Standard of care (Control)|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
214677165|NCT03538392|DEVICE|Serranator® Alto|Serranator® Alto PTA Serration Balloon Catheter
214677166|NCT01245894|DRUG|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
214677167|NCT01245894|DRUG|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
214677168|NCT04534894|DIAGNOSTIC_TEST|fluorescence lifetime imaging microscopy|collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
214677169|NCT01236222|BEHAVIORAL|Cycling to school|Regular cycling to school
214677170|NCT02029430|DRUG|50 mg/m2 aldoxorubicin|
214677171|NCT02029430|DRUG|100 mg/m2 aldoxorubicin|
214340170|NCT01335711|DRUG|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
214340171|NCT05004623|DEVICE|Sentinel Lymph Node Biopsy|Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
214340172|NCT01320410|DRUG|ISM®|
214340173|NCT02376452|DRUG|Raltitrexed|2mg/m2 iv gtt, d1
214677172|NCT02029430|DRUG|150 mg/m2 aldoxorubicin|
214677173|NCT02616822|DIETARY_SUPPLEMENT|Trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
214677174|NCT02616822|OTHER|Placebo|Used for placebo substance single dose
214677175|NCT00649519|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
214340174|NCT02376452|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
214340175|NCT02376452|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
214340176|NCT02376452|DRUG|Leucovorin|400mg/m2 iv gtt,d1
214340177|NCT01722331|DRUG|Tildrakizumab 200 mg|Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
214677176|NCT00649519|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
214340178|NCT01722331|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg/mL PFS
214340179|NCT01722331|DRUG|Matching Placebo|Matching placebo to tildrakizumab PFS
214340180|NCT04485403|DRUG|Ibuprofen|800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing\> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
214340181|NCT04419636|DRUG|Lu AG06466|capsules, orally
214943932|NCT01650545|DRUG|Liposomal aerosol cyclosporine|inhaled form of immune suppression
214943933|NCT01650545|OTHER|standard immune suppression, oral|"conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin"
214943934|NCT01264354|DRUG|Clevudine 30mg|Clevudine 30mg
214943935|NCT01264354|DRUG|Clevudine 20mg+Adefovir dipivoxil 10mg|Clevudine 20mg+ Adefovir 10mg
214943936|NCT01264354|DRUG|Clevudine 20mg|Clevudine 20mg
214943937|NCT02505451|DRUG|dobutamine|In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
214340182|NCT03502343|DRUG|Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy|"All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -\> 80%; Level 2: 80% -\> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial."
214340183|NCT03112772|OTHER|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
214340184|NCT03112772|OTHER|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
214340185|NCT02423473|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
214340186|NCT02423473|PROCEDURE|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
214943938|NCT06649227|DRUG|CAR-T cell therapy|cyclophosphamide and fludarabin conditioning , followed by a target dose of 1 x 10exp6 of autologous, genetically modified, anti-CD19 CAR-T cells per kg of body weight.
214943939|NCT00001076|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
214943940|NCT00001076|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
214943941|NCT00001076|BIOLOGICAL|rgp120/HIV-1 SF-2|
214943942|NCT00834730|DRUG|N2O gas vs ketamine|Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
214943943|NCT01463267|DEVICE|iPhone or pillbox|People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
214943944|NCT01463267|BEHAVIORAL|Non-reminding|As a comparison, the devices will collect medication taking information without providing reminders.
214943945|NCT01013623|PROCEDURE|Surgery|surgical resection to remove all known disease
214943946|NCT01013623|PROCEDURE|Surgery plus 2 adjuvant doses of BCG|Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
214943947|NCT01013623|OTHER|best medical therapy|Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
214943948|NCT05297084|PROCEDURE|non surgical periodontal therapy|Scaling and root planing
214943949|NCT00737334|DEVICE|EEGo, BIS, FORE-SIGHT cerebral oximeter|"The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed."
214340187|NCT05570526|DIETARY_SUPPLEMENT|Melatonin|Puritan's Pride ® Melatonin 5mg tablets orally once daily.
214943950|NCT03211429|BEHAVIORAL|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity
214340188|NCT05570526|OTHER|Placebo|Placebo tablet once daily.
214340189|NCT00262834|DRUG|vorinostat|Given orally, conventional surgery to follow.
214340190|NCT00262834|OTHER|conventional surgery|Undergo conventional surgery
214340191|NCT02893215|OTHER|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
214340192|NCT00059683|PROCEDURE|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
214677177|NCT00193310|DRUG|Paclitaxel|
214340193|NCT05230329|PROCEDURE|right sided hemicolectomy, laparoscopy|Comparison of CME
214340194|NCT06535282|OTHER|surgery|Surgical treatment of conductive hearing loss with tinnitus
214677178|NCT00193310|DRUG|Carboplatin|
214677179|NCT01081210|OTHER|Ultrasound examination|Screening with bedside ultrasound examination
214677180|NCT04649710|BIOLOGICAL|BMS-986036|Specified dose on specified days
214677181|NCT04649710|OTHER|Placebo|Specified dose on specified days
214677182|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
214677183|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
214340195|NCT05801601|BEHAVIORAL|Many Ways of Being, an innovative sexual health promotion program focused on addressing rigid gender norms and promoting healthy relationships|The Many Ways of Being program is a gender-synchronous program informed by Equimundo's existing single-gender Manhood 2.0 and Sisterhood 2.0 programs. The curriculum is designed to shift unequal gender attitudes and behaviors and provide skill-building on maintaining healthy relationships, making healthy and informed decisions around sex, and avoiding risky sexual behaviors.
214340196|NCT05801601|BEHAVIORAL|A career readiness program|Youth enrolled in the control condition will receive a career readiness curriculum, either International Youth Foundation's Passport to Success, LAYC's Next Generation program or LAYC's Career Readiness Curriculum, depending on the site and implementation period. These programs equip young people with a range of professional, employment readiness, and practical skills that will help them stay in school and acquire the education, professional skills, employment
214340197|NCT04901611|BEHAVIORAL|Parental touch|Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
214340198|NCT05739747|OTHER|Questionnaire|"All patients should complete the following questionnaires:~On the day of surgery:~* Patient registration.~* Complete medical history.~* Gendolcat scale (including the Spanish version of the SF-12 scale).~* Spanish version of the catastrophizing scale."
214340199|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire during the surgical procedure specifying the anesthetic technique used, drugs and doses used and record any incident during the surgical procedure
214340200|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire 24 hours after surgery to assess the possible presence of postoperative pain as well as the intensity and need for rescue analgesia.
214340201|NCT05739747|OTHER|Questionnaire via telephone call|At 3 months, patients will be called and a structured questionnaire will be completed to assess the presence of chronic postoperative pain.
214340202|NCT05739747|OTHER|Physical examination|Those women who, after the telephone call, are considered to have chronic post-surgical pain will undergo a physical examination to confirm it. The type of pain and its intensity will also be evaluated. The impact on their daily physical activity and quality of life will be evaluated by means of a questionnaire.
214340203|NCT02779179|PROCEDURE|Periodontal treatment|"* Mechanical debridement (scaling, root planning, subgingival curettage)~* Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~* Antiseptic mouthrinses, gel or dentifrice~* Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
214340204|NCT06534801|DRUG|Oxycodone will be administered intravenously in the group 1|Oxycodone will be administered intravenously 30min before the end of surgery, and Dixon sequential method will be used for the study
214677184|NCT01177150|DRUG|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
214340205|NCT00003457|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
214340206|NCT03931577|DIAGNOSTIC_TEST|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.
214340207|NCT03931577|PROCEDURE|Communication skill enhancement|Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.
214340208|NCT00052065|DRUG|TLK286|
214677185|NCT01177150|DRUG|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
214677186|NCT03633643|DRUG|oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)|"five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital."
214943951|NCT03211429|OTHER|Tai chi|Tai Chi training in the Yang style of 24 movement
214943952|NCT03211429|OTHER|Postural control exercise|Individually adjusted progressive and specific postural control training,
214943953|NCT04659629|DRUG|NL-201|NL-201 is a de novo protein therapeutic.
214943954|NCT04659629|DRUG|Pembrolizumab Injection [Keytruda]|A programmed death receptor-1 (PD-1)-blocking antibody
214943955|NCT06909786|PROCEDURE|HPI guided hemodynamic management|"BP, ECG and SpO2 were monitored after entering the operating room, peripheral venous access was established, radial artery puncture catheterization under local anesthesia and connected to the HPI (Edwards Lifesciences).~The treating anesthetist is trained to understand Acumen IQ parameters and the meaning of HPI, MAP, CI, SVI, SVR, SVV, Eadyn, dP/dtmax. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and how to treat hypotension. The hemodynamic management is performed according to the HPI guided algorithm."
214943956|NCT06909786|OTHER|standard arterial line|BP, ECG and SpO2 were monitored after entering the operating room, peripheral venous access was established, radial artery puncture catheterization under local anesthesia and connected to TruWave DPT and run data via HemoSphere machine (Edwards Lifesciences). The target of intraoperative blood pressure was to maintain MAP \> 65mmHg. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
214943957|NCT06912139|DRUG|Nitroglycerin transdermal|Nitroglycerin cream is applied \~ 15 minutes before radial artery puncture for emergency or planned invasive cardiology procedure (example: coronary angiography), and radial artery spasm and diameter are determined by angiography, injecting contrast into the radial artery through the placed radial sheath.
214943958|NCT06912139|OTHER|Placebo|Placebo cream with no active compounds is applied by the designated nurse to the radial puncture site, similar to NTG cream, with both patient and invasive cardiologist blinded wo which arm the patient is included in.
214943959|NCT06911944|DRUG|Donanemab|Donanemab will be administered as an IV infusion every 4 weeks using an up-titration regimen that will allow participants to reach a target dose of 1400 mg within 24 weeks.
214943960|NCT06911944|DRUG|Placebo|The control product (placebo) will be supplied in vials containing 350 mg/20 mL of donanemab Placebo for donanemab is supplied to the clinical site to match the active study intervention and contains only inactive ingredients. Normal sterile saline solution (0.9% sodium chloride) will be used for dilution.
214943961|NCT06911489|DIAGNOSTIC_TEST|68Ga-NRT6020 Injection|Participants will receive a single intravenous injection of 68Ga-NRT6020 Injection (3 mCi or 5 mCi) and PET/CT scans at multiple time points.
214943962|NCT06911489|DRUG|177Lu-NRT6020 Injection (stage 2)|It is planned to evaluate 4 dose levels of 177Lu-NRT6020 Injection: 50mCi, 100mCi, 150mCi and one/more adaptive dose groups (ranged from 150 to 250 mCi, the specific doses and/or doses with other frequencies within the range of 150\~250mCi, need to be determined after the completion of the dose-limiting toxicity (DLT) assessment for the previous three dose groups, in combination with the safety, pharmacokinetics and radiation dosimetry results of the participants, following confirmation by the SRC) which will be administered every 6 weeks (Q6W), and/or other dosing intervals determined by the SRC, for up to 6 cycles.
214943963|NCT06911489|DRUG|177Lu-NRT6020 Injection (stage 3)|Participants will receive intravenous injection of 177Lu-NRT6020 Injection, administered Q6W and/or other dosing intervals determined by the SRC, for up to 6 cycles.
214943964|NCT06910189|DEVICE|Fish Skin Graft (FSG)|FSG will be applied to the wound bed, followed by a wound VAC at the time of surgical debridement
214943965|NCT06910189|DEVICE|Wound Vacuum-Assisted Closure (VAC)|Participants will have a wound VAC applied to their wound bed at the time of surgical debridement.
214943966|NCT06910995|BEHAVIORAL|AR location-based game|This study aims to utilize the AR location-based game Pikmin Bloom to gradually encourage middle-aged and older adults in the community to develop a habit of walking outdoors. A step goal will be set every two weeks to progressively increase daily walking activity. By integrating the AR game with a LINE chatbot for feedback and engagement, this approach aims to motivate older adults, enhance their willingness to go outside, and increase their daily step count.
214943967|NCT06911814|OTHER|kinesio taping|KT is an elastic, wave-textured, waterproof, breathable cotton tape applied directly to the skin.We are going to apply to patients in three times.
215074699|NCT04621214|DEVICE|Audio-Visual Triage System (AVT)|Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
215074700|NCT05596617|DRUG|Oral bedtime melatonin|Different doses of oral bedtime melatonin
214340209|NCT03669003|BIOLOGICAL|Gelfoam slurry|Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.
214340210|NCT03669003|PROCEDURE|CT-guided percutaneous lung biopsy|Biopsy of a lung nodule under CT guidance.
214340211|NCT02505932|PROCEDURE|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
214340212|NCT02505932|PROCEDURE|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
214340213|NCT02199847|DRUG|Pharmaton® Caplets|
214340214|NCT02199847|DRUG|Placebo|
214340215|NCT06110312|BEHAVIORAL|NavCare-EU|NavCare-EU is a person- and family-centered intervention in which navigators collaborate with older persons and their close family caregivers across the continuum of supportive, palliative, and end-of-life care,. NavCare-EU is based on the existing and successfully tested Nav-CARE intervention from Canada. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
214340216|NCT04564833|DRUG|Low Dose RBT-1|intravenous administration
214340217|NCT04564833|DRUG|High Dose RBT-1|intravenous administration
214340218|NCT04564833|DRUG|Placebo|intravenous administration
214340219|NCT02671487|BEHAVIORAL|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
214340220|NCT02246998|DRUG|STB|150/150/200/300 mg fixed dose combination (FDC) tablet administered orally once daily with food
214340221|NCT02246998|DRUG|TVD|200/300 mg FDC tablet administered orally once daily with food
214340222|NCT02246998|DRUG|ATR|600/200/300 mg FDC tablet administered orally once daily on an empty stomach at bedtime
214340223|NCT02246998|DRUG|RTV|100 mg tablet administered orally once daily with food
214340224|NCT02246998|DRUG|ATV|300 mg capsule administered orally once daily with food
214943968|NCT06911814|OTHER|THE EXERCİSE|KT is an elastic, wave-textured, waterproof, breathable cotton tape applied directly to the skin.We are going to apply to patients in three times.
214943969|NCT06909981|RADIATION|Low-Dose Computed Tomography Scan|Imaging of chest to screen for lung cancer.
214943970|NCT06911138|BEHAVIORAL|Behavorial|Behavioral intervention that focuses on improving syntactic knowledge.
215074701|NCT05877040|DRUG|Rituximab|Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
214677187|NCT03633643|DRUG|oral applications of Placebo|five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
215074702|NCT05362591|PROCEDURE|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
215074703|NCT05362591|PROCEDURE|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation of tooth enamel
214340225|NCT02246998|DRUG|ABC/3TC|600/300 mg FDC tablet administered orally once daily with food
214340226|NCT02246998|DRUG|Iohexol|1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
214347429|NCT02759900|DEVICE|Non-thermal, atmospheric plasma to treat skin lesions and acne|Non-thermal, atmospheric plasma treatment of affected area or lesions using a nanosecond dielectric barrier discharge plasma device
214340227|NCT02270346|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
214340228|NCT02270346|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
214340229|NCT05367453|DIETARY_SUPPLEMENT|Tropical juice with probiotics (B.coagulans)|Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
214943971|NCT06911307|OTHER|standard care group|The standard care (SC) group will also include 80 participants. Wounds will be cleansed with sterile normal saline and managed using conventional wound care techniques. Participants will undergo regular postoperative follow-ups to assess wound healing progression and secondary outcome measures.
214943972|NCT06911307|OTHER|NPWT|The NPWT group will also include 80 participants. Wounds will be cleansed with sterile normal saline and coverd the SIMO NPWT dressing. Participants will undergo regular postoperative follow-ups to assess wound healing progression and secondary outcome measures.
214943973|NCT06911554|BIOLOGICAL|Recombinant Human Albumin Injection|Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.
214943974|NCT06911554|BIOLOGICAL|Human Albumin|Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
214677188|NCT05045755|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
214340230|NCT05367453|OTHER|a Tropical juice with no probiotics|Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
214943975|NCT01715402|PROCEDURE|liver surgery|this intervention type includes hepatectomies; wedge; segmentectomies etc...
214677189|NCT04988607|DRUG|Osimertinib|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle
214677190|NCT04988607|DRUG|Bevacizumab|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a
214677191|NCT04988607|DRUG|Osimertinib|Osimertinib is dosed orally at 80 mg once per day
214340231|NCT05367453|OTHER|lactase tablet|lactase tablet
214340232|NCT05367453|OTHER|placebo tablet (cornstarch)|placebo tablet (cornstarch)
214340233|NCT01664845|DRUG|metformin|metformin 500mg tid
214340234|NCT01664845|DRUG|pegylated-IFN|pegasys 180 mcg qw
214340235|NCT01664845|DRUG|ribavirin|ribavirin 800-1200 mg qd according to BW
214943976|NCT02972333|DRUG|AZD9291 80mg oral each day|All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.
214943977|NCT02972333|RADIATION|Radiation therapy|Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
214677192|NCT05242588|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
214340236|NCT00836823|DRUG|Alfuzosin|Alfuzosin 10mg once daily for 12 months
214340237|NCT06063629|PROCEDURE|Subcutaneous drain|The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.
214340238|NCT06063629|PROCEDURE|No drain|No drain will be inserted into patients allocated to this group
214340239|NCT02855060|DEVICE|Pelvic Binder|
214340240|NCT01686711|DRUG|AD-4833 15 mg|
214340241|NCT01686711|DRUG|AD-4833 30 mg|
214340242|NCT01686711|DRUG|Placebo|
214677193|NCT05242588|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
214677194|NCT01411397|OTHER|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
214677195|NCT01411397|OTHER|mesh repair|mesh repair of strangulated hernia without resection
214677196|NCT06667440|OTHER|Cryotherapy|Women in the intervention group will apply cryotherapy on their hypogastrium with a coldpack
214943978|NCT00094549|DRUG|olanzapine|
214943979|NCT00094549|DRUG|divalproex sodium|
214943980|NCT00094549|DRUG|placebo|
214943981|NCT02920814|OTHER|Cognitive Behavioural Therapy|Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
214943982|NCT02713854|PROCEDURE|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
215074704|NCT06629896|DIAGNOSTIC_TEST|Contrast Enhancement Mammography|In the experimental arm women will receive two rounds of CEM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk non mutated women at each participating center.
215074705|NCT06629896|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI) and digital mammography (DM)|women will receive two rounds of MRI+DM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk nonmutated women at each participating center.
214943983|NCT06460337|OTHER|Modified Otago exercises|Participants will engage in modified Otago exercise sessions, either individually or in groups, for 45 minutes, thrice weekly over an 8-week period. The program entails moderate-intensity strengthening exercises targeting various muscle groups such as hip extensors, abductors, knee flexors and extensors, inner range quadriceps, ankle plantar flexors, and dorsiflexors, performed at 10 repetitions maximum (RM) with ankle cuff weights ranging from 0.5 to 1 kg. Additionally, balance exercises will be conducted, initially with support and gradually progressing to without support, including knee bends, backwards walking, sideways walking, tandem stance and walk, one leg stance, heel and toe walking, sit-to-stand, stair climbing, stepping over objects, and bending to pick up objects from the floor. Participants are also encouraged to walk outdoors at their usual pace for 30 minutes at least three times weekly.
214943984|NCT06460337|OTHER|Frenkel's exercises|Frenkel's exercise regimen comprises a series of movements performed in lying, sitting, stride standing, and standing positions aimed at improving coordination and motor control. In the lying position, exercises include alternating hip and knee flexion/extensions, hip abduction/adduction, pedaling the lower limbs, and simultaneous movements of hips and knees. These are executed slowly to enhance coordination. In sitting, exercises involve leg stretching, hip flexion with knees flexed or straightened, and transitions from sitting to standing and back. Stride standing exercises focus on weight transfer and sideways walking, while standing exercises encompass walking on marked paths, trunk rotations, 360-degree turns, smaller arcs of hip abduction/adduction and flexion/extension, straight-line walking, and directional changes to simulate real-life obstacles. 3 sets comprising 10 repetitions are performed for each exercise, aiming for motor skill improvement and balance enhancement
214943985|NCT06020209|DIAGNOSTIC_TEST|Cardiac Computed Tomography|A comprehensive CCT protocol will be performed in the post-acute phase of STEMI. Specifically, the CCT protocol will include a pre-contrast scan and an angiographic scan ( also set up to assess ventricular volume and function) followed by late contrast enhancement scan.
214943986|NCT06020209|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|A comprehensive CMR protocol will be performed in the post-acute phase of STEMI. Specifically, the CMR protocol is designed for morpho-functional analysis and tissue characterisation (including assessment of late gadolinium enhancement and mapping). CMR will be considered the gold standard.
214943987|NCT05315154|PROCEDURE|No axillary surgery|In the study arm will be omitted surgery in axilla
214943988|NCT05315154|PROCEDURE|SLNB|in the control arm will be realized SLNB
214943989|NCT02539654|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
214943990|NCT02539654|PROCEDURE|Tympanostomy Tube Insertion|
214943991|NCT00715845|PROCEDURE|Carbon dioxide insufflation|For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
214943992|NCT04066777|PROCEDURE|alcohol septal ablation|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
214943993|NCT06210373|DEVICE|Myrialen Gel|Myrialen Gel will be instilled as 1 drop per eye 3 times a day and one drop per eye before going to bed in the conjunctival sac for 30 days.In case of bilateral dry eye syndrome, both eyes will be treated. In case of monolateral dry eye syndrome, the decision to treat both eyes will be taken according to the Investigator's judgment.
214943994|NCT06210373|DEVICE|Recugel|"Recugel will be instilled as 1 drop per eye 3 times a day and one drop per eye before going to bed in the conjunctival sac for 30 days.~In case of bilateral dry eye syndrome, both eyes will be treated. In case of monolateral dry eye syndrome, the decision to treat both eyes will be taken according to the Investigator's judgment."
214943995|NCT04247568|OTHER|Listening to an audiotape|The participants listen to a audiofile that consists of hypnosis
214943996|NCT05331781|PROCEDURE|Ultrasound-Guided Transversus Abdominis Plane Block|patient in the supine position, ultrasound will be used to identify the plane between the internal oblique and transversus abdominis muscle to inject 20 ml of local anesthetic for each side
214943997|NCT05331781|DRUG|Morphine|intrathecal 150 microgram morphine in a 0.5 ml volume will be added to bupivacaine as an adjuvant to spinal anesthesia
214943998|NCT01709773|PROCEDURE|Focal treatment|Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
214943999|NCT04825496|GENETIC|ssCART-19 Cells|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
214944000|NCT04825496|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
214944001|NCT04825496|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
214944002|NCT03318081|BEHAVIORAL|cognitive function rehabilitation and bias modification|cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias
214944003|NCT01892800|PROCEDURE|Lung resection|
214677197|NCT06667804|OTHER|Laughter yoga|Laughter yoga was applied to the experimental group for 4 weeks, 2 days a week, for 8 sessions (each session duration is 30-45 minutes on average). - The researcher is certified as an International Leader of Laughter Yoga. As a nursing intervention, patients with T2DM were made to do laughter yoga by the researcher. The laughter yoga program was conducted online (Google meet online) due to the ongoing COVID-19 pandemic at the time of the study. - The sessions were organized as follows: Monday-Thursday 10:00-10:45, Tuesday-Friday 10:00-10:45, Wednesday-Saturday 10:00-10:45. Participants participated in two sessions that were suitable for them within a week. A participant in a group was not allowed to change days in the following weeks.
214677198|NCT02222129|DRUG|Bupivacaine|
214677199|NCT02222129|DRUG|liposomal bupivacaine|
214677200|NCT05078567|DEVICE|5% Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
214677201|NCT03863392|DRUG|Misoprostol|induction of labor
214677202|NCT01558089|DRUG|etanercept|according to SmPC and clinical practice
214340243|NCT03826277|OTHER|Melanostop peel|"Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol, 6% phytic acid, 3% tranexamic acid. (4 treatments, performed at 2-week intervals), in combination with home care products (twice daily):~* a facial tonic and cream containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid,~* sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR"
214340244|NCT00004179|BIOLOGICAL|rituximab|
214340245|NCT00004179|DRUG|CHOP regimen|
214944004|NCT01210352|DRUG|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
214944005|NCT06906835|OTHER|RET-He-Guided Iron Supplementation|"Participants in this arm will receive intravenous (IV) iron therapy guided by reticulocyte hemoglobin equivalent (RET-He) levels.~Iron dosing will follow a protocol based on RET-He values:~* RET-He \< 26 pg: IV iron 100 mg weekly~* RET-He ≥ 26 pg and \< 30 pg: IV iron 100 mg every 2 weeks~* RET-He ≥ 30 pg and ≤ 36 pg: IV iron 100 mg every 4 weeks~* RET-He \> 36 pg or ferritin ≥ 800 ng/mL: Discontinue iron supplementation to prevent iron overload"
214944006|NCT06906835|OTHER|TSAT-Guided Iron Supplementation|"Participants in this arm will receive IV iron therapy guided by transferrin saturation (TSAT) and serum ferritin, as per the Thai Clinical Practice Guidelines for Anemia in CKD (2021).~Iron dosing will follow this TSAT-based protocol:~* TSAT \< 30% and ferritin \< 200 ng/mL: IV iron 100 mg weekly~* TSAT \< 30% and ferritin 200-500 ng/mL: IV iron 100 mg every 2 weeks~* TSAT \< 30% and ferritin 500-800 ng/mL or TSAT 30-40%: IV iron 100 mg every 4 weeks~* TSAT ≥ 40% or ferritin ≥ 800 ng/mL: Discontinue iron supplementation"
214944007|NCT06906835|OTHER|Common|"All participants will receive erythropoiesis-stimulating agents (ESAs) according to a standardized dose adjustment protocol based on hemoglobin levels.~Oral iron supplements will be discontinued."
214944008|NCT06911762|BEHAVIORAL|Exercise|Participants will receive a 6-week structured hand exercise program. Participants will attend a face-to-face exercise session to learn all hand exercises. The exercise program will include: (1) Finger flexor stretching, (2) Tendon gliding exercise and (3) Isometric finger flexor exercise. A weekly tele follow-up will be done to participants in the experimental group
214944009|NCT06911671|DEVICE|Virtual Reality Interface + Cerebellar iTBS (c-iTBS)|Subjects will sit in a chair with their forearm inserted in a splint attached to a force transducer. The subjects' view of their hand will be occluded by a mirror displaying the virtual scene. EMGs from arm and shoulder muscles will be recorded by surface EMG electrodes. Subjects will displace a virtual handle according to either the forces recorded by the force transducer or forces estimated from the recorded EMGs (EMG control).
214944010|NCT06911671|DEVICE|Vitual Reality + Sham Cerebellar iTBS (sham c-iTBS)|c-iTBS will be carried out using Magstim Rapid magnetic biphasic stimulator. Twenty 2-s trains of three-pulse bursts at 50 Hz repeated every 200 ms with an inter-train interval of 10 s, for a total of 190 s will be applied over the contralesional lateral cerebellum. The coil will be positioned tangentially to the scalp for real and 90° angled for sham c-iTBS.
214944011|NCT06911671|OTHER|Physical Therapy|Passive mobilization and motor recruitment of impaired upper limb will be performed with the support of a physical therapist specialized in neurological rehabilitation.
214944012|NCT05835427|OTHER|Cervical Extensor Stretch|Fibromyalgia individual: Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
214944013|NCT05835427|OTHER|Cervical Extensor Stretch|Healthy volunteers : Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
214944014|NCT04582565|COMBINATION_PRODUCT|Decongestive lymphatic therapy (DLT)|Manual lymphatic drainage
214944015|NCT04582565|OTHER|Standard Care|
214677203|NCT01558089|DRUG|methotrexate|according to SmPC and clinical practice
214677204|NCT01571882|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
214677205|NCT01571882|OTHER|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
214677206|NCT01571882|OTHER|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
214677207|NCT04552236|DEVICE|Ultrasound ELastography|"A standardized liver Elastography is critical to obtain reliable and accurate results . The patient is imaged in supine or slight 30 degrees left lateral decubitus position, with the right arm elevated above the head to open the intercostal spaces and improve the acoustic window to the liver . it is recommended to sample measurements in the right lobe , which has shown the most reliable results. Transducer pressure on the skin should be similar to regular anatomical B-mode imaging.~When using SWE techniques, the acoustic radiation force push pulse should be applied perpendicular to the liver capsule, with measurements obtained 4-5 cm deep to the skin and within a minimum 1-2 cm of liver parenchyma to limit refraction of the pulse. The operator should verify that these areas are free of vascular and biliary structures and rib shadows."
214944016|NCT02187575|DRUG|UHAC 62 XX tablet|
214944017|NCT02187575|DRUG|UHAC 62 XX capsule|
214340246|NCT00004179|DRUG|cyclophosphamide|
214340247|NCT00004179|DRUG|doxorubicin hydrochloride|
214340248|NCT00004179|DRUG|prednisone|
214340249|NCT00004179|DRUG|vincristine sulfate|
215074706|NCT03582553|DIETARY_SUPPLEMENT|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
215074707|NCT03582553|OTHER|Placebo|Cellulose
214340250|NCT04563858|DIAGNOSTIC_TEST|Validation|Assessment of Polish version of the 4AT
214340251|NCT02525133|DRUG|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
214340252|NCT02525133|OTHER|Placebo|Plain collagen implant (vehicle)
214340253|NCT01343082|DRUG|DE-111 ophthalmic solution|
214340254|NCT01075074|PROCEDURE|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
214340255|NCT05978882|PROCEDURE|Laparoscopic sentinel navigation surgery using fluorescence|If the frozen biopsy of sentinel lymph nodes are all negative using fluorescence, stomach-preserving surgery is performed
214944018|NCT06250634|DRUG|esomeprazole + amoxicillin|esomeprazole enteric-coated tablets (AstraZeneca) 20mg four times daily and amoxicillin capsules (Hainan General Sanyang Pharmaceutical) 750mg four times daily
214944019|NCT06250634|DRUG|esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent|20mg twice daily of esomeprazole enteric-coated tablets, 1000 mg twice daily of amoxicillin capsules, 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical) and 165 mg three times daily of colloidal bismuth tartrate capsules (Shanxi Xinbaoyuan Pharmaceutical)
214944020|NCT06250634|DRUG|Vonoprazan + amoxicillin|20 mg twice daily of vonoprazan fumarate tablets (Takeda Pharmaceutical Company Limited) and 1000 mg three times daily of amoxicillin capsules (Hainan General Sanyang Pharmaceutical)
215074708|NCT00868088|PROCEDURE|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
214340256|NCT00873795|DRUG|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
214340257|NCT02199457|DEVICE|SVSS and reference devices|Blood pressure will be measured with standard mercury manometer
214340258|NCT02199457|DEVICE|SVSS and reference devices|Body temperature taken with infrared thermometer
214944021|NCT06250634|DRUG|Vonoprazan + amoxicillin + clarithromycin|20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)
215074709|NCT05430503|DIAGNOSTIC_TEST|Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise|DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
215074710|NCT05848544|DIETARY_SUPPLEMENT|Very low-calorie ketogenic diet for patients with symptomatic knee osteoarthritis|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
215074711|NCT05848544|DIETARY_SUPPLEMENT|Very low-calorie ketogenic diet for patients with fibromyalgia|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
214677208|NCT04099901|DRUG|Anakinra|Subjects will be treated with a daily dose of 300 mg anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
214677209|NCT04099901|DRUG|Placebos|Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
214944022|NCT03795025|OTHER|Strength training 3x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.
214944023|NCT03795025|OTHER|Strength training 6x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.
215074712|NCT00585546|DRUG|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
215074713|NCT05171309|DRUG|Apatinib|250 mg once daily (QD) oral dosing.
215074714|NCT05171309|DRUG|Camrelizumab|200 mg intravenously every 2 weeks.
214340259|NCT02199457|DEVICE|SVSS and reference devices|Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
214944024|NCT03795025|OTHER|3x10RM + 6x10RM|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.
214944025|NCT01298141|BIOLOGICAL|agalsidase alfa|"Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly"
215074715|NCT05171309|DRUG|NK cell|Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
214340260|NCT02199457|DEVICE|SVSS and reference devices|Measurement of respiration rate
214340261|NCT05331352|BEHAVIORAL|Semi-structured interviews|Interview
214340262|NCT05331352|BEHAVIORAL|Projective methode|Rorschach + thematic aperception test
214340263|NCT05331352|BEHAVIORAL|Selfreported|RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R
214340264|NCT04265755|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).
214340265|NCT04779801|BEHAVIORAL|Attachment-Based Family Therapy|16 weeks of Attachment-Based Family Therapy treatment.
214340266|NCT02624973|DRUG|Neoadjuvant tamoxifen + goserelin (premenopausal women)|
214340267|NCT02624973|DRUG|Neoadjuvant letrozole (postmenopausal women)|
214340268|NCT02624973|DRUG|Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|
214340269|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide|
215074716|NCT00956137|PROCEDURE|Ultrasound guidance|ultrasound imaging
215074717|NCT00956137|PROCEDURE|Manual palpation|Manual Palpation of vertebra
215074718|NCT01299220|DRUG|Acitretin|Acitretin 10 mg by mouth daily
215074719|NCT03453762|PROCEDURE|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
214340270|NCT02624973|DRUG|Neoadjuvant docetaxel|
214340271|NCT02624973|DRUG|Neoadjuvant docetaxel + trastuzumab + pertuzumab|
214340272|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|
214944026|NCT00005941|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214944027|NCT00005941|DRUG|cyclosporine|
214944028|NCT00005941|DRUG|fludarabine phosphate|
214944029|NCT00005941|DRUG|mycophenolate mofetil|
214944030|NCT00005941|PROCEDURE|peripheral blood stem cell transplantation|
214944031|NCT00005941|RADIATION|radiation therapy|
214944032|NCT03510221|DIETARY_SUPPLEMENT|Antioxidants capsules|1 capsule of cranberry, 1 capsule of blueberry, and 1 capsule of pomegranate extracts were offered during 4 weeks
214944033|NCT05345769|BIOLOGICAL|AM712(ASKG712)|AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
214944034|NCT06911606|DRUG|4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin|After 4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin then MDT determines surgery or radical radiotherapy
214944035|NCT06912191|OTHER|Left cerebellar TMS stimulation combined with the RECT task|The first group will receive left cerebellar single-pulse TMS stimulation combined with the RECT task. RECT refers to rostral anterior cingulate cortexr (rACC)-engaging cognitive task. The theoretical basis of this task is that when subjects are in a state of focused attention, the power of theta neural oscillations in the midline of their frontal lobe will increase. By considering the features of post-stroke depression, this study combines the emotional recognition task with the RECT task. During each trial, individuals will view 4 faces consecutively, each displaying a different expression, and they will be required to memorize the sequence of expressions. Emoticons consist of joy, sorrow, and rage. After displaying four facial expressions, a brief text flowchart will appear. Participants need to check if the sequence reflected in the flowchart matches the order in which the four facial expressions appeared. If they match, click the left mouse button; if they do not match, click the
214944036|NCT06912191|OTHER|Right cerebellar TMS stimulation combined with the RECT task|Right cerebellar single-pulse TMS stimulation combined with the RECT task
214340273|NCT02624973|DRUG|Neoadjuvant olaparib|
214340274|NCT02624973|DRUG|Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)|
214944037|NCT06912191|OTHER|Midline cerebellar TMS stimulation combined with the RECT task|Midline cerebellar single-pulse TMS stimulation combined with the RECT task
214340275|NCT02624973|PROCEDURE|Breast conserving surgery or mastectomy + SNB/axillary dissection|After response to neoadjuvant treatment
214340276|NCT02624973|RADIATION|Postoperative radiotherapy breast/chest wall + regional lymph nodes|
214340277|NCT02624973|DRUG|Adjuvant trastuzumab|
214944038|NCT06912191|OTHER|Sham cerebellar TMS stimulation combined with the RECT task|Sham cerebellar single-pulse TMS stimulation combined with the RECT task, The TMS coil was placed at the cerebellar site but tilted 90° to prevent effective magnetic field penetration.
214340278|NCT02624973|DRUG|Adjuvant letrozole (postmenopausal women)|
214340279|NCT02624973|DRUG|Adjuvant tamoxifen + goserelin (premenopausal women)|
214944039|NCT06912191|OTHER|The best stimulation protocol combined with left dorsolateral prefrontal cortex iTBS|The optimal stimulation protocol determined in Experiment 1 combined with stimulation of the left dorsolateral prefrontal cortex.
214944040|NCT06912191|OTHER|Left dorsolateral prefrontal cortex iTBS stimulation, as well as sham TMS stimulation and sham RECT task.|Subjects in the group underwent left dorsolateral prefrontal cortex iTBS stimulation, in addition to receiving sham TMS stimulation and participating in a sham RECT task. The sham RECT task involves having participants watch a continuous scroll of faces without needing to react.
214944041|NCT06912191|OTHER|Sham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.|The participants in this group received sham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.
214944042|NCT06911710|DRUG|CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）|"Phase I study: dose-escalation component.This part follows the 3+3 dose-escalation model, with 5 dose groups: 1×10\^6, 1.5×10\^6, 2×10\^6, 2.5×10\^6, 3×10\^6 CAR+ cells/kg (different target CAR-T can be adjusted by the investigator according to the dose used in the previous clinical trial). Each dose group enrolled 3\~6 patients with relapsed/refractory hematological diseases respectively, totaling 15\~30 subjects, in order to evaluate the safety of CAR-T cells for the treatment of relapsed/refractory malignant hematological neoplasms and to determine the MTD. Phase II study: dose-expansion portion. After the MTD was confirmed, in the dose-expansion portion of the study (Phase II), it was expected that 65\~60 subjects would receive the CAR-T cell injection infusion under RP2D to further evaluate the efficacy of CAR-T cell injection."
214944043|NCT06909812|DRUG|pirfenidone 8% gel|topic aplication
214944044|NCT06909812|DRUG|silicon gel|topic aplication
215074720|NCT03453762|PROCEDURE|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
214340280|NCT02624973|DRUG|Adjuvant palbociclib (if palbociclib given neoadjuvant)|
214340281|NCT02624973|DRUG|Adjuvant Epirubicin+ Cyclophosphamide|
214340282|NCT04659980|DEVICE|hilotherapy|continuous cooling of hands and feet at a constant temperature
214340283|NCT04659980|DEVICE|frozen gloves|cooling of hands and feet using frozen gloves
214340284|NCT05794269|OTHER|TQoR-15 questionnaire|The TQoR-15 questionnaire (Turkish version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
214340285|NCT06137547|DEVICE|Hypotension prediction index (HPI)|The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.
214340286|NCT00934999|PROCEDURE|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
214340287|NCT00934999|PROCEDURE|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
214944045|NCT06912412|OTHER|Community-based supervised remote cardiac rehabilitation|"Community-based supervised remote cardiac rehabilitation begins with a weekly session led by exercise specialists, who use remote-based materials to match each participant's target heart rate and rate of perceived exertion (RPE). During these sessions, participants perform aerobic, strength, and respiratory exercises using progressive overload principles, with devices such as the POWERbreathe Plus supporting individualized respiratory training.~Depending on the risk classification for each participant, they will be provided with different intensity of exercises (depending on their measured HR max, HRR, and/or RPE)."
214944046|NCT06912412|OTHER|Home-based cardiac rehabilitation program|"Beyond the single supervised session, participants undertake four weekly home-based sessions.~* Low-Risk Group: Aerobic and respiratory exercises are performed four times per week, plus strength training once or twice weekly. Each 60-minute session includes a 10-minute warm-up, 40-minute main exercise, and 10-minute cool-down. Indoor sessions use remote exercise content and respiratory training devices, while outdoor activities may involve walking, jogging, cycling, or swimming. Exercises progress in duration, intensity, and resistance.~* Moderate-Risk Group: Aerobic and respiratory exercises are done four times per week with an RPE of 8-13. Intensity and duration increase gradually, contingent on symptom stability and improved endurance.~* High-Risk Group: Aerobic and respiratory sessions occur four times a week at an RPE of 8-10, each lasting around 30 minutes (5-minute warm-up, 20-30-minute main exercise, 5-minute cool-down)."
214340288|NCT02563158|PROCEDURE|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
214944047|NCT06912516|PROCEDURE|Controlled desaturation|"A subject rests comfortably on a hospital bed, so that they do not have to move during the desaturation process.~The subject wears the altitude simulator head bivy and breathes freely without any oxygen regulation. During the measurement, the time in low O2 saturation plateaus is limited to ten minutes in each desaturation plateau.~They are monitored with ECG, clinical pulse oximeter, EtCO2 from non-invasive capnography with nasal cannulas and periodically non-invasive blood pressure. The monitoring is supervised by two medical doctors, present during the entire duration of the study."
214944048|NCT06910150|PROCEDURE|Non-invasive analgesic electrostimulation|Application of a single session of non-invasive analgesic electrostimulation to motor points of the vastus medialis and vastus lateralis of the quadriceps femoris muscle in patients who have undergone an anterior cruciate ligament reconstruction. A biphasic, symmetrical, square-wave current was applied at a frequency of 100 Hz, a pulse width of 200 μs, and an intensity adjusted to the patient's pain threshold for 30 minutes.
215074721|NCT03077438|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate|0.5 milliliter (mL), Intramuscular
215074722|NCT03077438|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, Intramuscular
215074723|NCT02689739|PROCEDURE|venous duplex ultrasound|Venous duplex ultrasound
215074724|NCT02578966|BEHAVIORAL|Motivational Interview|
215074725|NCT02578966|OTHER|Traditional health education|
214340289|NCT03311074|GENETIC|Strimvelis|Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
214340290|NCT03448367|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
214340291|NCT01575561|DRUG|Lurasidone|Lurasidone 20-80 mg taken orally once daily
214340292|NCT04014660|DIETARY_SUPPLEMENT|Probiotic|The probiotic product consists of two different bacterial strains, L.plantarum Heal 9 and L.paracasei 8700:2
214340293|NCT04014660|DIETARY_SUPPLEMENT|Placebo|The placebo supplement consists of corn starch only.
214340294|NCT04409756|OTHER|shoulder rating questionnaire|to investigate reliability of turkish version of shoulder rating questionnaire
214340295|NCT03524391|BEHAVIORAL|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
214340296|NCT03524391|DRUG|Chemotherapy|Usual Care group had standard chemotherapy regimens
214340297|NCT02496884|DRUG|DS-5565|DS-5565 7.5 mg tablet for oral use
214340298|NCT02496884|DRUG|Placebo|Placebo tablet for oral use to match DS-5565 7.5 mg tablet
214340299|NCT05434897|DRUG|AK3280 Cream|Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
214340300|NCT05434897|DRUG|Placebo cream|Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
215074726|NCT05148013|OTHER|Pilates exercise|All participants will be given a basic introduction to the Pilates-based exercises and will be taught how to activate the core muscles, which entails isometric contraction of the transverses abdominis, pelvic floor, and multifidus muscles while exhaling during diaphragmatic breathing, before beginning the exercise program. The Pilates exercise program will consist of floor exercises on a mat, including the following exercises: one-leg kick, single leg stretch, shoulder bridge, the hundred, one leg circle, and swimming. All exercises progressed at three degrees of difficulty: basic, intermediate, and advanced. Depending on the patient's tolerance, each exercise will be done for 8-10 repetitions. The treatment plan included a five-minute warm-up, twenty minutes of exercise, and a five-minute cool-down.
214340301|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
214944049|NCT06910150|PROCEDURE|Invasive analgesic electrostimulation|Application of a single session of invasive analgesic electrostimulation to a motor point of the vastus medialis of the quadriceps femoris muscle in patients who have undergone an anterior cruciate ligament reconstruction. A biphasic, symmetrical, square-wave current was applied at a frequency of 100 Hz, a pulse width of 250 μs, and an intensity defined as perceptible to the patient but never painful (200 μA above the detection threshold for each subject).
214944050|NCT06910982|BEHAVIORAL|Sphinx Pose Yoga Therapy|A structured yoga-based intervention focusing on the Sphinx Pose, aimed at improving spinal flexibility and reducing pain. Participants will perform three sessions per week for 12 weeks.
214944051|NCT06912178|OTHER|Acupuncture|Whether or not a patient has been treated with acupuncture will be one of the exposure factors of interest in the study
214944052|NCT06910683|BEHAVIORAL|TREE-Connect|TREE-Connect is a mental health app that aims to increase engagement in rewarding activities
214677210|NCT03663985|OTHER|Groupe FALCOn|The objective of the study is to determine what are the anthropo-sociological factors in the surgeon, the oncologists and radiotherapists influencing decision making in ENT carcinology.
214677211|NCT02571179|DRUG|intranasal fentanyl 50 microg dose up to 250 microg|When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
214340302|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
214340303|NCT01577134|BEHAVIORAL|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
214340304|NCT03318575|DEVICE|autoRIC|Automated Remote Ischemic Conditioning
214340305|NCT03318575|DEVICE|autoRIC Sham|Automated Remote Ischemic Conditioning Sham
214340306|NCT00633035|DRUG|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
214340307|NCT00633035|DRUG|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
214340308|NCT06372730|OTHER|Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT)|All patients will undergo a V/Q SPECT/CT scan at inclusion.
214340309|NCT02841423|PROCEDURE|neuropsychological test battery|
214340310|NCT05924828|OTHER|no intervention|no intervention
214340311|NCT02109055|OTHER|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
214340312|NCT02109055|OTHER|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
214340313|NCT02956629|DRUG|Uprifosbuvir|Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
214340314|NCT02956629|DRUG|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
214340315|NCT02956629|DRUG|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
214340316|NCT02879461|PROCEDURE|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
214340317|NCT04840745|DRUG|CKD-841 A-1 3.75mg|Single injection, subcutaneous injection
214340318|NCT04840745|DRUG|CKD-841 A-1 1.88mg|Single injection, subcutaneous injection
214340319|NCT04840745|DRUG|CKD-841 D 2.92mg|Single injection, subcutaneous injection
214340320|NCT04840745|DRUG|Leuplin Inj. 3.75 mg|Single injection, subcutaneous injection
214340321|NCT01764334|DEVICE|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
214340322|NCT00618657|DRUG|Carboplatin|Given IV
214340323|NCT00618657|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214340324|NCT00618657|DRUG|bevacizumab|Given IV
214340325|NCT00618657|DRUG|trastuzumab|Given IV
214340326|NCT00618657|PROCEDURE|magnetic resonance imaging|Optional correlative studies
214677212|NCT02255591|DRUG|Lidocaine-adrenaline added gadolinium.|
214677213|NCT04442620|OTHER|Physical activity and Mediterranean Diet (PA-MD)|Physical Activity plus caloric restricted Mediterranean diet
214677214|NCT04442620|OTHER|High meal frequency of Mediterranean Diet (HMF-MD)|High meal frequency of unaltered Mediterranean diet
214677215|NCT04442620|OTHER|Control diet (CD)|Control Diet
214677216|NCT01361529|DRUG|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
214677217|NCT02377934|RADIATION|Cardiac Magnetic Resonance Imaging (MRI)|
214677218|NCT01903434|DRUG|Evacetrapib|Administered orally
214944053|NCT06910683|BEHAVIORAL|Clinician-delivered psychotherapy|Clinician-delivered psychotherapy is delivered remotely and aimed to increase engagement in rewarding activities
214944054|NCT02622490|OTHER|two test meals with two different macronutrient compositions|Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
214944055|NCT04284930|DRUG|Depobupivacaine|surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.
214944056|NCT04284930|DRUG|OnQ pump|group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.
214944057|NCT04284930|DRUG|0.25% Bupivacaine|group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
214677219|NCT03465735|COMBINATION_PRODUCT|Vascular Boot|The Vascular Boot is one size fits all, insulated fleece padding, and cell foam to enhance and maintain lower limb warmth while maintaining no pressure points on the lower extremity.
214944058|NCT06910111|DEVICE|Polyglucosamine|The treatment will continue for 12 months administering a customized Polyglucosamine (formoline AtheroGuard) (twice/day) before the two main meals for a total of 4 tabs/day (each tab consists of 750 mg). Controls will be conducted at screening/baseline, and after 3/6/9 and 12 months
214677220|NCT03465735|DRUG|Standard of Care|Anticoagulant therapy will be decided by physician and patient.
214677221|NCT04946110|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
214677222|NCT00472342|BEHAVIORAL|exercise prescription|
214677223|NCT01884285|DRUG|Part A: AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
214677224|NCT01884285|DRUG|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
214944059|NCT06910111|DEVICE|Placebo|2x 2 Placebo tablets The treatment will continue for 12 months administering Placebo (twice/day) before the two main meals for a total of 4 tabs/day. Controls will be conducted at screening/baseline, and after 3/6/9 and 12 months
214944060|NCT05417308|DRUG|Minoxidil|Applied topically
214944061|NCT05417308|DRUG|Minoxidil|Given PO
214944062|NCT05417308|OTHER|Quality-of-Life Assessment|Ancillary studies
214944063|NCT05417308|OTHER|Questionnaire Administration|Ancillary studies
214944064|NCT01879033|OTHER|Reactive hyperemia peripheral artery tonometry (Rh-PAT)|Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
214944065|NCT01879033|OTHER|Blood levels for glucose, insulin, lipids and adipocytokines|A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
214944066|NCT02093390|DRUG|TAK-385|TAK-385 tablets
214944067|NCT02093390|DRUG|Fluconazole|Fluconazole tablets
214944068|NCT02093390|DRUG|Atorvastatin|Atorvastatin tablets
214944069|NCT03744845|OTHER|Virtual Reality Distraction|This RCT will utilize an Oculus Go VR headset that delivers VR images and sound. Users will wear the VR headset. A research coordinator will familiarize patients with hardware before use. The VR will be used preoperatively and intraoperatively to distracts patients, and aid with the treatment of pain and anxiety.
214944070|NCT01854879|DEVICE|Nucleus 6 sound processor|
214944071|NCT05125952|DEVICE|Viasys Avea Ventilator|Measuring dynamic airway driving pressure and static airway driving pressure during pressure support breath, and static airway driving pressure during a volume control breath. Measuring airway occlusion pressure during pressure support breath.
214944072|NCT05125952|DEVICE|Philips Respironics NM3 device|Measuring static airway driving pressure during pressure support breath
214340327|NCT00618657|PROCEDURE|therapeutic conventional surgery|Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
214677225|NCT01884285|DRUG|Part C1: Abiraterone acetate combination with AZD8186|Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
214677226|NCT01884285|DRUG|Part D1: AZD2014 combination with AZD8186|Dose \& schedule finding of AZD8186 in combination with AZD2014
214677227|NCT01884285|DRUG|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
214944073|NCT05125952|DEVICE|Servo U ventilator|Measuring static airway driving pressure and p0.1 during pressure support breath.
214944074|NCT05125952|DEVICE|Vyaire SmartCath adult nasogastric tube with Esophageal balloon|Measuring static and dynamic esophageal driving pressure during pressure support breath, and esophogeal pressure change during airway occlusion maneuver.
214944075|NCT04381507|DEVICE|endovascular repair|Endovascular repair of descending thoracic aneurysms or PAU using a stent graft.
214944076|NCT06382441|BEHAVIORAL|tele-exercise|It is a prospective and pilot study of RCT. It will be a pilot to test acceptability and feasibility of a two-armed tele-exercise RCT to mitigate symptoms and improve health for breast cancer survivors. In this study, outcome assessors and data analysts will be masked from the allocation results. The pilot will recruit 24 patients and randomly assign them to an intervention group (Group A) and an active control group (Group B). All participants in both groups will continue receiving usual care from the study hospital during the study period. Additionally, those in Group A (intervention) will receive the tele-exercise (12 home-based online training sessions + 4 psychological counselling sessions), while those in Group B (active control) will receive 4 essays on exercise and health. Outcome measurements will be repeatedly performed before and after the intervention.
214944077|NCT04723953|DIAGNOSTIC_TEST|68Ga-FAPI PET/MRI|PET and MRI in patients with acute myocardiac infarction are simultaneously analyzed using hybrid PET/MRI device for monitoring myocardial fibrosis and function.
214944078|NCT03632538|DIAGNOSTIC_TEST|"Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)"|Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).
214944079|NCT02301039|DRUG|Pembrolizumab|
214944080|NCT03811288|OTHER|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
214944081|NCT01210677|DRUG|Prednisone|Prednisone 0.5 mg/Kg orally per day for 3 months
214340328|NCT03890341|DRUG|Drospirenone/Ethinylestradiol|A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
214340329|NCT03890341|DRUG|Midazolam|Midazolam 2 mg will be administered orally on Days 1, 13 and 19.
214340330|NCT03890341|DRUG|JNJ-64530440|A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
214340331|NCT02250885|DRUG|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
214340332|NCT01762761|DRUG|eltrombopag|TPO-R agonist
214340333|NCT01762761|DRUG|placebo|placebo
214944082|NCT05176548|DIAGNOSTIC_TEST|Bone-cardiac scintigraphy|Patients with confirmed ATTR type CA will undergo a study of mutations in the TTR gene
214944083|NCT04683939|DRUG|BNT141|Intravenous (IV)
214944084|NCT04683939|DRUG|Nab-paclitaxel|IV
214340334|NCT04704414|DEVICE|Exophthalmos measurement|Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
214340335|NCT00995449|BIOLOGICAL|KB003|KB003 IV x5 doses
214340336|NCT00995449|OTHER|Placebo Comparator|Placebo IV x5 doses
214340337|NCT00120393|DRUG|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
214340338|NCT00120393|DRUG|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
214340339|NCT02421991|BEHAVIORAL|Telephone Delivered Intervention|
214944085|NCT04683939|DRUG|Gemcitabine|IV
214944086|NCT05875493|DRUG|JAB-21822|2 discrete single doses
214944087|NCT05875493|DRUG|JAB-21822|2 discrete single doses
214340340|NCT06425393|DIAGNOSTIC_TEST|Urea beath test (UBT)|H. pylori infection will be tested using a 13C-urea breath test Kit for all enrolled family members, following the manufacturer's instructions. The sensitivity and specificity of the assay are both over 95%, according to the manufacturer's introduction.
214340341|NCT04233814|DRUG|Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)|LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
214340342|NCT04233814|DRUG|Placebo|Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
214340343|NCT01793857|OTHER|Data collection|Paper questionnaire
214340344|NCT01219738|DRUG|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
214677228|NCT01884285|DRUG|Part C2: Abiraterone acetate combination with AZD8186|Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
214677229|NCT02267499|OTHER|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
214677230|NCT02442999|OTHER|Screening for obstructive sleep apnea|
214340345|NCT01219738|DRUG|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
214340346|NCT01219738|DRUG|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
214340347|NCT01219738|DRUG|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
214340348|NCT01219738|DRUG|Placebo|A single inhaled dose of placebo from a DPI.
214340349|NCT00058305|DRUG|bryostatin 1|Given IV
214340350|NCT00058305|DRUG|vincristine sulfate|Given IV
214340351|NCT00058305|OTHER|laboratory biomarker analysis|Correlative studies
214340352|NCT05590091|OTHER|Parenteral nutrition;Enteral nutrition|The intelligent nutrition management system was used to carry out standardized nutrition management of patients after hematopoietic stem cell transplantation
214340353|NCT04897048|PROCEDURE|Incremental exercise test (IET)|Incremental cardio pulmonary exercise test until exhaustion
214340354|NCT04897048|PROCEDURE|Constant work rate exercise test (CWRET)|constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
214340355|NCT06126562|DRUG|Lanifibranor|Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
214340356|NCT01799174|PROCEDURE|UVA-1 Phototherapy|
214340357|NCT01799174|PROCEDURE|Placebo|
214340358|NCT05761691|PROCEDURE|Dental treatment|Children treated for ECC under general (DGA) and local anesthesia (LA).
214340359|NCT00426478|DRUG|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
214944088|NCT05179759|BEHAVIORAL|Tealeaf|Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
214944089|NCT05179759|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment
214340360|NCT00426478|DRUG|Amlodipine (5mg)|
214340361|NCT06533709|DIAGNOSTIC_TEST|Radio-score|A score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.
214340362|NCT06270121|BEHAVIORAL|Living-lab digital intervention group|Older adults will receive individualized daily health feedback via the mobile applications, which will be shared with caregivers. They will also receive support for health emergency by the platform sending automatic emergency push alarm to community and family caregivers.
214340363|NCT04695691|DEVICE|Cutera Laser System|Subjects will receive laser treatments
214340364|NCT03136601|OTHER|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
214677231|NCT02442999|DEVICE|CPAP - continuous positive airway pressure|
214944090|NCT04455776|DRUG|Propofol|Sedation by propofol
214944091|NCT04648527|PROCEDURE|arthroscopic synovectomy and thermocoagulation|An diagnostic arthroscopy and an arthroscopic synovectomy and thermocoagulation of the dorsal hypertrophic synovial will be performed
214677232|NCT06511011|DRUG|Modified Suan ZaoRen Tang-TianWang BuXin Dan|Chinese medicine granules for 6 weeks
215074727|NCT05148013|OTHER|PNF exercise|The PNF techniques utilized in the PNF exercise group will include a combination of isotonics, rhythmic stabilization, and repeated stretch. The exercises which will be performed are; (1) Trunk rotation in sitting position (1a) Chopping to the left and right and (1b) Lifting to the left and right, (2) Rolling activity (2a) Resistance to pelvic anterior patterns 2(b) Resistance to posterior patterns, 2(c) Combination of scapula and pelvis, 2(d) Combination of scapula and pelvis (i.e. asymmetrical exercise for trunk extension: the scapula moves in posterior elevation, the pelvis in posterior depression) and (3) Bridging activity (3a) Stabilize the pelvis in its neutral position, 3(b) Bridging lower trunk rotation and, 3(c) Bridging on two legs in the supine position.
214340365|NCT00387218|BEHAVIORAL|Exercise, Physical therapy|
214340366|NCT03424746|DRUG|disodium EDTA|Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
214340367|NCT02250404|OTHER|cytology specimen collection procedure|Correlative studies
214340368|NCT02250404|OTHER|laboratory biomarker analysis|Correlative studies
214340369|NCT04815603|DRUG|BGE-117|Active Treatment
214340370|NCT04815603|OTHER|Placebo|Placebo
214340371|NCT04598282|DEVICE|Prokera Slim|Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.
214944092|NCT02839382|OTHER|Coaching|An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
214944093|NCT02839382|OTHER|Educational Outreach|Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting
214944094|NCT02839382|OTHER|Site Visits|"Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities."
214944095|NCT02000882|DRUG|BKM120|
215074728|NCT02172131|DRUG|BI 1744 CL|
214677233|NCT06511011|DRUG|Placebo|Placebo granules for 6 weeks
214677234|NCT03212547|BEHAVIORAL|Verbal Intervention|"Promotion of verbal interventions:~1. Detecting whether the infant has social withdrawal.~2. The physician will verbally intervene.~3. Positive response (+) from the infant, the evaluator will point out this to the parents.~4. Negative response (-) from the infant, the evaluator will include the parents in the interaction.~5. If he infant establishes positive contact (+) with the parents, he/she will point out this response to them.~6. If the infant does not establish positive contact (-)with the parents, repeat step 2.~7. If the infant offers a positive response (+) to the second attempt of verbal intervention, the evaluator will point out this response to the parents.~8. At the end of each medical check-up, give and explain the ADBB Intervention Sheet."
215074729|NCT02172131|DRUG|Placebo|
214340372|NCT04598282|OTHER|Standard of Care|Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
215074730|NCT04867512|DIETARY_SUPPLEMENT|Liquid Tincture|Biocidin Liquid Tincture: 1 drop by mouth twice daily, increased by one drop each day until 15 drops twice daily have been reached. 15 drops by mouth twice daily will be maintained through the duration of the study.
214677235|NCT04986293|DEVICE|CPAP|Different settings of CPAP and BiPAP will be tested using a home mechanical ventilator
214677236|NCT00116311|BEHAVIORAL|allergen inhalation|
214340373|NCT01081587|PROCEDURE|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
214340374|NCT01081587|BEHAVIORAL|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
214340375|NCT01081587|OTHER|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
214340376|NCT00649012|DRUG|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
214340377|NCT00649012|DRUG|Actos® Tablets 45 mg|45mg, single dose fed
214944096|NCT02000882|DRUG|capecitabine|
214944097|NCT02000882|DRUG|Trastuzumab|
214677237|NCT00116311|BEHAVIORAL|withdrawal of medication|
214677238|NCT00116311|PROCEDURE|sputum induction|
214944098|NCT01063894|OTHER|breakfast cereal|breakfast cereal and milk
214944099|NCT01063894|OTHER|water|water
214944100|NCT00946062|OTHER|orientation and mobility training|orientation and mobility training
214944101|NCT03964701|OTHER|no intervention|no interventional study
214944102|NCT00549601|DRUG|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
214944103|NCT00549601|DRUG|Rivastigmine patch (9.5 mg/day)|Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
214340378|NCT01319006|DRUG|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
214340379|NCT01319006|DRUG|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
214340380|NCT01319006|DRUG|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
214340381|NCT01168050|DRUG|Nilotinib|Nilotinib 400 mg twice per day
214340382|NCT00795600|DRUG|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
214340383|NCT00795600|DRUG|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
214340384|NCT04218019|DEVICE|TTFields|The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
214340385|NCT04425226|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
214340386|NCT04425226|DRUG|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
214944104|NCT00549601|DRUG|Rivastigmine capsules (6 mg to 12 mg/day)|Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
214944105|NCT01733992|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
214944106|NCT01733992|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
214944107|NCT01733992|DRUG|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
214944108|NCT01733992|DRUG|Placebo|Placebo, single and multiple ascending dose
214944109|NCT03457844|DRUG|Anlotinib|Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
214944110|NCT05816460|OTHER|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I)|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I) will be delivered through an online platform called Sleepio (BigHealth Ltd)
214944111|NCT05816460|OTHER|Sleep Hygiene Education (SHE)|Sleep Hygiene Education (SHE) will be provided electronically
214944112|NCT03690362|DRUG|VNRX-5133 and VNRX-5022|intravenous infusion
214944113|NCT00004176|DRUG|amifostine trihydrate|
214944114|NCT00004176|DRUG|cisplatin|
214944115|NCT00004176|DRUG|etoposide|
214944116|NCT00004176|RADIATION|radiation therapy|
214944117|NCT02102594|DRUG|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
214944118|NCT01145794|BEHAVIORAL|smoking hygiene intervention|The intervention, SHI, will address SHS and quitting. It will include behavioral counseling to address health hazards of SHS for children, brief advice to quit and to adopt a no smoking policy around children and self-help materials (related to second hand smoking).
214944119|NCT04719429|DIETARY_SUPPLEMENT|Cricket-derived Protein|Beverage containing 25 g cricket-derived protein
214944120|NCT04719429|DIETARY_SUPPLEMENT|Beef-derived Protein|Beverage containing 25 g beef-derived protein
214944121|NCT03081091|DEVICE|Acupuncture|"The needles used for the treatments will be single-use needles of two different gauge sizes. One size or the other will be used depending on the area to be treated and the physical condition of the patient. The needles and gauge sizes used in the study are as follows:~Dong Bang siliconized needle 0.25 mm x 40 mm Dong Bang siliconized needle 0.20 mm x 30 mm~The therapist will assess the patient's condition according to traditional Chinese medicine and will look at the relationship between the patient's most affected areas and the paths of the acupuncture meridians. Subsequently, the combination of Yuan and Luo points to be treated will be determined. This procedure will be followed before every acupuncture session, in such a way that the combination of the points used will depend on the evolution of the symptoms."
214340387|NCT00081588|DRUG|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
214944122|NCT03081091|DEVICE|Sham Acupuncture|"It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body.~The Park device for the performance of sham acupuncture consists of two plastic tubes, one sliding within the other, and inside which the needle created for the device slides. The longest tube is attached to a circular base, which has an adhesive surface that sticks to the skin so that the device and the needle cannot fall. Blunt ended needles will be used for this technique and thus the needle does not get to pass through the skin but produces a cutaneous stimulation similar to conventional acupuncture needles. These needles are supplied with the kit that contains the Park sham acupuncture device and are registered in the European Union as CE 0120."
214944123|NCT02215746|DRUG|BI 44370 powder for oral solution|
214944124|NCT02215746|DRUG|BI 44370 tablet|
214944125|NCT02215746|OTHER|high fat breakfast|
214944126|NCT00915265|OTHER|Multilobed catheter (group CPA)|\- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia
214944127|NCT00915265|OTHER|Multilobed catheter (group EA)|EA group : thoracic epidural infusion of 0.2 % ropivacaine
214944128|NCT05063526|DEVICE|ultrasound|ultrasound on diaphragm
214944129|NCT02724566|DRUG|apelin|Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).
214677239|NCT03766997|DRUG|Compound Betamethasone Injection|local injection
214340388|NCT04890002|DEVICE|Far-infrared emitting pyjamas|Clothing made in far infrared (FIR) - based textiles could be a sustainable way for alleviating sleep problems with many advantages. Firstly, the proposed far infrared textiles are made of man-made profiled fibers without the addition of chemicals such as ceramic additives or other related coatings.
214944130|NCT02724566|DRUG|placebo|2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
214340389|NCT04890002|DEVICE|Sham-pyjamas|The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function.
214944131|NCT04525326|DRUG|Cetuximab|mFOLFOX+Cetuximab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
214944132|NCT04525326|DRUG|Bevacizumab|mFOLFOX+Bevacizumab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
214340390|NCT03936244|DEVICE|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
214340391|NCT01973790|DRUG|Z-338|100mg TID
214340392|NCT01748435|DRUG|Qutenza|Single treatment with Qutenza
214340393|NCT03401970|BEHAVIORAL|Acellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
214340394|NCT03401970|BEHAVIORAL|Cellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
214340395|NCT03401970|BEHAVIORAL|Low-carbohydrate high-fat diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
214677240|NCT03766997|DRUG|Hydrocortisone Butyrate 0.1% Cream|topical use
214677241|NCT00259805|DRUG|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
214677242|NCT00075751|DRUG|gemcitabine hydrochloride|Given IV
214677243|NCT00075751|DRUG|carboplatin|Given IV
214677244|NCT00075751|DRUG|bortezomib|Given IV
214677245|NCT03640897|DEVICE|Liniderm|Cleaning of the diaper area with Liniderm at each diaper change during 28 days
214677246|NCT03640897|OTHER|Wipes|Cleaning of the diaper area with wipes at each diaper change during 28 days
214677247|NCT03640897|OTHER|Water|Cleaning of the diaper area with water and cotton pads at each diaper change during 28 days
214677248|NCT03074305|DEVICE|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~1. DEB strategy~2. DES strategy"
214677249|NCT06511505|OTHER|TEMPUS AI-enabled ECG-based Screening Tool|The AI-enabled ECG-based screening tool, Tempus Next software, analyzes 12-lead ECG recordings to identify patients at increased risk for undiagnosed cardiovascular diseases, specifically atrial fibrillation (AF) and structural heart disease (SHD). Clinicians in the intervention group will receive a risk assessment for AF and SHD each time they order an ECG for their patients.
214944133|NCT04525326|DRUG|mFOLFOX/FOLFIRI ( Standard Chemotherapy)|Standard Chemotherapy
214944134|NCT02389374|DRUG|chloroquine|standard dose
214944135|NCT02389374|DRUG|Artemether-lumefantrine combination|standard dose
214944136|NCT02389374|DRUG|Primaquine|single dose
214677250|NCT06110234|BEHAVIORAL|Episodic Specificity Induction|Recalling complex scenes using the Episodic Specificity Induction
214677251|NCT06110234|BEHAVIORAL|Associative Memory|Recalling word/picture pairs
214677252|NCT05694078|OTHER|Hand Therapy Splinting Protocol|Relative motion splinting protocol
214944137|NCT02389374|DRUG|Primaquine|14 days
215074731|NCT04867512|DIETARY_SUPPLEMENT|GI Detox|GI Detox: 2 capsules by mouth every evening and 1 hour away from all food maintained through the duration of the study.
214944138|NCT00937092|DRUG|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
214944139|NCT00937092|DRUG|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
214944140|NCT04959292|DIAGNOSTIC_TEST|arthroscopy|arthroscopy
214944141|NCT06028386|DEVICE|AC5® Advanced Wound System|This group will receive AC5® Advanced Wound system, a synthetic self-assembling peptide matrix to the wound and covered with non-adherent dressing followed with appropriate outer dressing to maintain moisture balance. AC5 is applied weekly and outer dressing will be redressed as necessary.
214944142|NCT06028386|DEVICE|Fibracol Plus Collagen Dressing|This group will receive Fibracol Plus collagen dressing to the wound and covered with appropriate out dressing. Treatment will be done 3x a week.
214944143|NCT00908596|DRUG|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
214944144|NCT00932386|DRUG|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
214944145|NCT00932386|DRUG|normal saline|0.9% normal saline infusing
214944146|NCT05365334|BEHAVIORAL|Low intensity exercise session|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
214944147|NCT05365334|BEHAVIORAL|Moderate intensity exercise session|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
214340396|NCT01197040|DRUG|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
214340397|NCT01197040|DRUG|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
214944148|NCT05365334|BEHAVIORAL|High intensity exercise session|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
214944149|NCT03812263|BIOLOGICAL|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
214944150|NCT05919524|RADIATION|Prostate SBRT (stereotactic body radiation therapy) with focal boost|"* Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT~* mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL.~* Additional urethra and bladder trigone sparing constrains~* Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking"
214677253|NCT05924360|OTHER|conventional exercise program|The conventional treatment program will be applied to all participants included in the study, consisting of wand, codman, active and passive stretching exercises. This program will be administered to all patients five days a week. Wand exercises will be applied in the directions of flexion, abduction, extension, internal and external rotation, and will consist of 10 repetitions. Codman exercises will be applied in the directions of flexion, abduction, and circular, and will also consist of 10 repetitions. Active and passive stretching exercises will be applied in the directions of flexion, abduction, and external rotation, and will consist of 10 repetitions.
214677254|NCT05924360|OTHER|Mulligan application|The mobilization with movement technique, a part of Mulligan applications, will be performed twice a week in the directions of flexion, abduction, and external rotation.
215074732|NCT04867512|DIETARY_SUPPLEMENT|Olivirex|Olivirex: 2 capsules by mouth twice daily taken with Biocidin liquid tincture starting at week 10 until week 14 of the study for non-responders determined by symptoms and lactulose breath test results.
215074733|NCT01190475|DRUG|Active treatment with a high dose of BGS649|
215074734|NCT01190475|DRUG|Active treatment with a low dose of BGS649|
214340398|NCT03891212|BEHAVIORAL|Placed in prone position for at least 16 consecutive hours a day.|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
214347430|NCT02759900|DEVICE|Indirect non-thermal, atmospheric plasma to treat hair loss and acne|A compound of non-thermal, atmospheric plasma and medium is delivered to or generated at the target area. Plasma is generated using either microsecond dielectric barrier discharge plasma device or PiezoBrush (a helium jet plasma). The medium is an aqueous alcohol solution
214347431|NCT03362255|OTHER|thoracic epidural catheterization|thoracic epidural catheterization with different speed of injection
214347432|NCT04985591|PROCEDURE|Liposuction|A small, inconspicuous incision was made in the liposuction group to dislodge fat out of the body.
214944151|NCT03010241|DRUG|Tangbi (prescription)|A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
214944152|NCT03010241|DRUG|Placebo|"Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
214944153|NCT02232555|DRUG|Duloxetine|
214944154|NCT02232555|DRUG|Placebo|
214944155|NCT05727150|PROCEDURE|Reconstruction of Soft tissue defects of head and neck by Supraclavicular artery flap|Supraclavicular artery flap will be used in the reconstruction of traumatic and non-traumatic defects of head and neck.Flap harvesting and reconstruction will be performed under general anesthesia. The defect dimensions are measured and the superficial landmarks for the supraclavicular artery are drawn .The flap will be used as island flap, transposed or interpolated flap depending on the arc of rotation needed to achieve flap inset without tension and flap elevation proceeds from lateral to medial.The flap is rotated and inset into the defect
214944156|NCT01943955|BEHAVIORAL|home-based computer gaming|A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
215074735|NCT01190475|DRUG|Placebo treatment to blind study|
215074736|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for pregnant and lactating women
215074737|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for infant and young children
215074738|NCT01129089|DIETARY_SUPPLEMENT|Micronutrient powder|Micronutrient powder for infant and young children
214677255|NCT05924360|OTHER|Maitland application|Maitland Group: The Maitland application will be applied in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be administered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
214677256|NCT05924360|DEVICE|TENS|TENS application will be administered for 20 minutes at 100Hz
214677257|NCT00865462|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
214677258|NCT00865462|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
215074739|NCT06462040|PROCEDURE|Fixation of osteochdral fragments with reabsorbable screws|Arthroscopic or mini-open fixation of free-intrarticular or unstable osteochondral fragments due to osteochondritis dissecans or osteochondral fractures with reabsorbable screws
215074740|NCT06571591|DRUG|CT-L03 Group 1|tablets, QD, oral administration
215074741|NCT06571591|DRUG|CT-L03 Group 2|tablets, QD, oral administration
215074742|NCT06571591|DRUG|Placebo|tablets, QD, oral administration
215074743|NCT06571591|DRUG|Empagliflozin|tablet, QD, oral administration
214944157|NCT03747913|DIETARY_SUPPLEMENT|Antioxidative supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
214944158|NCT03691506|OTHER|Classic CIMT group|Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.
214944159|NCT03691506|OTHER|Modified CIMT group|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
214944160|NCT05259618|OTHER|Tasso+ SST|alternative site blood sample collection.
214944161|NCT02219386|OTHER|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
214944162|NCT02219386|OTHER|group 2. Passive analitical stretch (performed in both groups)|
214944163|NCT05037890|DIETARY_SUPPLEMENT|Margarine|Intake of margarine
214944164|NCT00516490|DRUG|triptorelin acetate|Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
214944165|NCT00516490|DRUG|Na Cl %0.9|0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
214944166|NCT01075464|DRUG|MEGF0444A|Intravenous escalating dose
214944167|NCT01075464|DRUG|bevacizumab|Intravenous repeating dose
214944168|NCT01075464|DRUG|paclitaxel|Intravenous repeating dose
214944169|NCT01281943|DRUG|Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2|"Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle"
214944170|NCT03793959|DIETARY_SUPPLEMENT|Synbiotic Supplement|
214944171|NCT03793959|DIETARY_SUPPLEMENT|Placebo|
214944172|NCT03259906|OTHER|DASH score|Questionnaire asking about Disability of Arm, Shoulder and Hand
214944173|NCT03259906|PROCEDURE|X-ray|postoperative x-rays at 6 weeks, 3, 6 and 12 months
214944174|NCT03259906|PROCEDURE|posterior osteosynthesis|Osteosynthesis using a posterior plate
214944175|NCT03259906|PROCEDURE|Anterior osteosynthesis|Osteosynthesis using an anterior plate
214944176|NCT03354052|DEVICE|Real-rTMS + Gloreha device|The real rTMS will be delivered using a 8-shaped coil placed over the primary motor cortex (M1). The resting motor threshold (RMT) will be assessed at the place of the first dorsal interosseous (FDI) contralateral to the stimulated cortex. RMT of the FDI will be determined as the lowest strength of TMS needed to elicit 5 or more electromyographic responses ≥50 μV within 10 trials. Stimulation will be applied with frequency 10 Hz and intensity of 90% of RMT. Every session will last 15 minutes and includes 3000 pulses (30 trains of 10 seconds, following intertrain interval of 20 seconds). Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
214944177|NCT03354052|DEVICE|Sham-rTMS + Gloreha device|The sham rTMS will be delivered using a sham stimulator. All procedures will be performed as for the real treatment. Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
214944178|NCT04202536|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
214944179|NCT04202536|DRUG|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily Other Name: VIREAD®
214677259|NCT00048906|DRUG|DRX005B|
214677260|NCT04272905|OTHER|Non-interventional study|The participants will be asked to complete a questionnaire on their knowledge of, and attitudes towards the recording of patient care by patients or relatives/friends in the maternity unit. An investigator will be immediately available to facilitate completion of the survey and assist with understanding of the questions. The data recorded will be a mixture of nominal data (selections from a number of options using a tickbox) or ordinal (as above, but graded e.g. yes / yes with qualifiers / no). Free text will be coded and presented as nominal data or presented verbatim to illustrate points that arise.
214347433|NCT04985591|PROCEDURE|Other plastic surgery|Other plastic surgery like blepharoplasty or keloid excision.
214347434|NCT05262153|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
214677261|NCT01946048|BIOLOGICAL|mesenchymal stem cells|"Procedure: Selected patients were randomly divided into a cell therapy group and a control group.~Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million."
214677262|NCT04676139|DRUG|Fluoxetine|Fluoxetine 10 mg capsules once daily for 12 months
214677263|NCT04676139|DRUG|Placebo|placebo for 12 months
214677264|NCT02190435|DEVICE|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
214677265|NCT02190435|DEVICE|Conventional technique|Conventional Technique
214944180|NCT01842906|DEVICE|Theravent|nasal EPAP device
214944181|NCT01842906|DEVICE|Control|Sham device without EPAP
214944182|NCT00095459|DRUG|Bevacizumab|
214944183|NCT00095459|DRUG|BAY 43-9006|
214944184|NCT01335854|BEHAVIORAL|Web-based Access to CPAP Data|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.
215074744|NCT06571591|DRUG|Metformin|tablets, oral administration
215074745|NCT05966363|RADIATION|Nanodot|Radiation measurements using nanodots placed on the eyes, ears, neck and lower abdomen during an imaging examination.
215074746|NCT06474507|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
214944185|NCT01335854|BEHAVIORAL|Web-based Access to CPAP Data with Financial Incentive|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
215074747|NCT04662775|BEHAVIORAL|HERizon Project|"1\. Participants were asked to complete 3x30-minute physical activity sessions each week \& record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information."
214944186|NCT03695328|BEHAVIORAL|physical activity level|
214944187|NCT03695328|BEHAVIORAL|Dietary Intake|
214340399|NCT01625793|DRUG|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
214340400|NCT05515055|OTHER|Blood test|1 blood sample extra to standard of care is taken
214340401|NCT03251469|DRUG|Tranexamic Acid 15mg/kg , iv, Single Dose|Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
214944188|NCT00003328|DRUG|porfiromycin|
214944189|NCT00003328|RADIATION|radiation therapy|
214944190|NCT04852211|PROCEDURE|Open or laparoscopic surgery|"Patients, with their consent, will be recruited to participate by investigators after considering the inclusion and exclusion criteria. Treatment allocation to the eligible patients will follow a randomization schedule. A total of 212 subjects will be randomized 1:1 to one of the two treatment arms:~1. Laparoscopic group: LMH~2. Open group: OMH"
214944191|NCT00413309|PROCEDURE|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
214944192|NCT00935454|PROCEDURE|Hepatocyte matrix implantation|"First operation:~Removal of liver tissue and biopsy of pancreas~Second operation:~Implantation of hepatocyte matrix implant into small bowel mesentery"
214944193|NCT02437188|BEHAVIORAL|ACT (Acceptance and Commitment Therapy)|The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
214944194|NCT02517021|DRUG|Pro-netupitant/Palonosetron|
214944195|NCT02517021|DRUG|Netupitant/Palonosetron|
214944196|NCT02517021|DRUG|Dexamethasone|
214944197|NCT01619098|OTHER|Patient Navigator|In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
214944198|NCT01619098|OTHER|Usual care|Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
214944199|NCT02661061|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
214944200|NCT02661061|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
214944201|NCT02331784|BEHAVIORAL|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
215074748|NCT03834610|DRUG|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
215074749|NCT03834610|DRUG|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
215074750|NCT03834610|DIAGNOSTIC_TEST|serum testosterone level|measurement of serum testosterone level
215074751|NCT03834610|DIAGNOSTIC_TEST|HbA1C|measurement of HbA1C levels
214944202|NCT02331784|BEHAVIORAL|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
214944203|NCT02993965|OTHER|Vaccine Reminder/Recall|The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.
214944204|NCT00428012|BEHAVIORAL|Quality of Life Therapy|8 weekly individual counseling sessions
214944205|NCT00428012|BEHAVIORAL|Supportive Therapy|8 weekly individual counseling sessions
214944206|NCT04063995|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
215074752|NCT03834610|DEVICE|penile doppler|penile doppler to measure the degree of erection and penile vasculature
215074753|NCT02713984|BIOLOGICAL|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
214944207|NCT00719394|DRUG|GSI 136|
214944208|NCT00719394|DRUG|placebo|
215074754|NCT01877850|PROCEDURE|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
214677266|NCT05552586|DIETARY_SUPPLEMENT|Melatonin|patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
214944209|NCT01013389|PROCEDURE|Actifuse ABX|bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion
214944210|NCT01013389|PROCEDURE|INFUSE, plus master granules (MGG)|bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
214944211|NCT03917043|DRUG|APG-2449|Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle
214944212|NCT02376205|DRUG|bupivacaine hydrochloride 0.5% solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
214944213|NCT02376205|DRUG|0.9% NaCl solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
214944214|NCT06219018|DRUG|Medical grade honey formulation (MGH) (L-Mesitran®)|Daily application of 5 grams (with applicator) for the first 3 months, followed by weekly application of 5 grams for the following 3 months.
214944215|NCT03246061|DEVICE|Intracept System|BVN ablation using radiofrequency energy
214677267|NCT05552586|OTHER|placebo|patients will receive capsules of the same size and color
214677268|NCT00005029|DRUG|topotecan hydrochloride|
214944216|NCT03246061|OTHER|Standard Care|Non-surgical standard care
214944217|NCT00401401|DRUG|zalutumumab|Eight weekly infusions
214944218|NCT00401401|DRUG|cisplatin|Infusions
214944219|NCT00401401|PROCEDURE|Radiotherapy|Daily in the treatment period
214944220|NCT01937715|DRUG|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
214944221|NCT01937715|DRUG|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
214944222|NCT01937715|BIOLOGICAL|Bevacizumab|5 mg/m\^2 every 2 weeks or 7.5 mg/m\^2 every 3 weeks
214944223|NCT01937715|DRUG|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
214944224|NCT01922856|BIOLOGICAL|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
214944225|NCT01922856|OTHER|No Intervention|Controls only receive challenge
214944226|NCT03331731|DRUG|pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
215074755|NCT00000487|DRUG|antihypertensive agents|
215074756|NCT00000487|BEHAVIORAL|smoking cessation|
215074757|NCT00000487|BEHAVIORAL|diet, fat-restricted|
215074758|NCT00000487|DRUG|diuretics|
214340402|NCT03251469|DRUG|Normal Saline, 100mg, iv, Singe dose|Normal Saline, 100mg, administered intravenously, preoperatively in single dose
214944227|NCT05563935|DEVICE|Repetitive transcranial magnetic stimulation|The OCD group will receive rTMS treatment for 6 weeks. There are 5 rTMS treatments per week (Monday to Friday), and 30 rTMS treatments in total. Treatment is administered by Ma GPro X100 device (Maga Venture) with Cool-DB80 coil. Detailed parameters of rTMS: intensity of stimulus is 120% RMT; the frequency of trains is 1Hz and the number of pulses is 1; no intertrain intervals and the pulses number is 1000.
214944228|NCT05300659|OTHER|Action for Rehabilitation for Neurological Injury (ARNI)|If randomised to upper limb training, a patient will undertake 10 therapy sessions with an instructor from the Action for Rehabilitation for Neurological Injury (ARNI) program during their hospital stay. The last two ARNI-led sessions will be filmed by a nurse/carer on either their own tablet/phone or an i-pad. Participants in the ARNI group will be encouraged to continue doing their personalized exercises while in hospital and continued at home. They will also be given a task-training board to take home
214944229|NCT03286660|DIAGNOSTIC_TEST|Chair Rise Tests and short questionnaire|"Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.~This test is combined with a questionnaire to collect quantitative and qualitative information:~* dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise~* Saturation at rest, and at the end of the exercise~* the number of total a chair rise"
214944230|NCT01885663|PROCEDURE|Umbilical cord blood therapy|Intravascular umbilical cord blood therapy
214944231|NCT01760213|OTHER|CBT delivered via Internet|
214944232|NCT03341494|DRUG|Thalidomide|Gefitinib 250mg Thalidomide 200 MG
214944233|NCT05459558|DRUG|Experimental Dentifrice 1|5 percent (%) potassium nitrate (KNO3) dentifrice with 1% alumina and 5% sodium tripolyphosphate (STP).
214944234|NCT05459558|DRUG|Experimental Dentifrice 2|5% KNO3 dentifrice with 1% alumina, 5% STP and 2% high cleaning silica.
214944235|NCT05459558|DRUG|Reference Dentifrice|Regular Fluoride Dentifrice.
214944236|NCT02020837|PROCEDURE|Lymphaticovenous Micro-Anastomosis|
214944237|NCT04421157|OTHER|Schroth Exercises|The Schroth approach consists of 3D scoliosis-specific exercises based on kinesthetic and sensorimotor principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. The treatment program consists of scoliotic posture correction and a breathing pattern with the help of proprioceptive and exteroceptive stimulations and mirror control. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. Schroth group received Schroth exercises in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
215074759|NCT05073796|DEVICE|Cochlea Implant|"* examination and documentation of vital signs and concomitant medication~* application of an cochlea implant loan processor (external body surface) with varying stimulus pattern for vestibular stimulation by means of basal, medial and apical electrodes~* attraction of an special mask to determine the subjective visual vertical (SVV)~* assessment of the vertical spatial axis with all electrodes turned off~* assessment of the vertical spatial axis with all electrodes turned on~* assessment of the vertical spatial axis while using basal (12-16) and medial (6-11) electrodes~* assessment of the vertical spatial axis while using basal (12-16) and apical (1-5) electrodes~* assessment of the vertical spatial axis while using medial (6-11) and apical (1-5) electrodes"
214340403|NCT01329601|BEHAVIORAL|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
214340404|NCT01329601|BEHAVIORAL|booklet based training|Home based training of episodic memory using paper-pencil exercizes
214340405|NCT01046110|DRUG|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
214340406|NCT01046110|DRUG|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
214340407|NCT00620308|DRUG|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
214944238|NCT04421157|OTHER|Core stabilization Exercises|Each exercise session consisted of a warm-up exercise, core stabilization exercise, and a cool-down exercise. The core stabilization exercise was designed with consideration of local, global muscle stability training, global muscle mobility training,and strengthening training of these core structures was carried out progressively advancing more difficult. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. The Stabilization group received Core stabilization in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
215074760|NCT03085628|DRUG|Oxytocin|40IU
214340408|NCT00620308|DRUG|Placebo|Dextrose 5% in water (the vehicle)
214340409|NCT02897544|BEHAVIORAL|Individualized Manualized Health Education Intervention|
214340410|NCT02326402|DEVICE|TandemHeart or LifeSPARC System|Percutaneous insertion of TandemHeart or LifeSPARC System
214340411|NCT04421144|PROCEDURE|orthognathic surgery|patients with maxillofacial disharmony will undergo orthognathic surgery using CAD/CAM Cutting Guides and Customized Titanium Plates.
214340412|NCT05036629|DEVICE|MRI Protocol|"Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse,~* NIRS Oxymon artinis medical system~* tES (transcranial electrical stimulation, Neuroelectrics)"
214340413|NCT00905580|DRUG|Pregabalin|Pregabalin 150 mg orally
214340414|NCT00905580|DRUG|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
214347435|NCT01308580|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
214944239|NCT03758235|DRUG|IncobotulinumtoxinA 100 UNT Injection [Xeomin]|Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
214944240|NCT03758235|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
214944241|NCT05328388|DIETARY_SUPPLEMENT|Lycomato|Lycomato sof gels
214944242|NCT01765608|DRUG|Zonisamide|Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
214944243|NCT01765608|DRUG|Placebo|
214944244|NCT01765608|DEVICE|nCPAP|
214944245|NCT01361113|DRUG|Pazopanib|800 mg orally once daily for 8 weeks, prior to nephrectomy
214944246|NCT01807728|OTHER|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
214944247|NCT01807728|OTHER|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
214944248|NCT03030274|DEVICE|Occlutech AFR device|Catheter-guided placement of an AFR device following balloon atrial septostomy.
214944249|NCT02810015|DRUG|Botulinum Toxin Type A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
214677269|NCT03255525|OTHER|Deep friction massage P50|Deep friction massage as described by Dr. James Cyriax, applied with the mean pressure (P50)
214677270|NCT03255525|OTHER|Deep friction massage P25|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 25 of the mean pressure (P25)
214677271|NCT03255525|OTHER|Deep friction massage P75|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 75 of the mean pressure (P75)
214677272|NCT00202410|BIOLOGICAL|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
214677273|NCT00202410|OTHER|placebo|subcutaneous administration of physiologic solution
214677274|NCT05515549|OTHER|Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers|"The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group."
215074761|NCT03085628|DRUG|Placebo|40IU
215074762|NCT05647343|DRUG|Ciclopirox Olamine Oral|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
214677275|NCT03136211|BEHAVIORAL|EIRA intervention|Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
214677276|NCT02660697|PROCEDURE|Extraction site development|In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
214677277|NCT01781026|DRUG|Vemurafenib|Single arm trial
214677278|NCT06672393|DRUG|HS-10374 6mg tablets|Specified dose of HS-10374 tablets administered orally QD on specified days
214944250|NCT00919542|DRUG|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
214944251|NCT00919542|DRUG|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
214944252|NCT01301885|PROCEDURE|Laparoscopy/laparotomy|Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.
214944253|NCT06355856|DRUG|DNN.22.17.036|Apply twice daily to the affected area and around it.
214944254|NCT06355856|DRUG|10573048700|Apply twice daily to the affected area and around it.
214944255|NCT05509764|DIAGNOSTIC_TEST|lung ultrasound score|determination of atelectasis by lung ultrasound score
214944256|NCT04167163|DRUG|Abaloparatide|18 month ABL treatment
214944257|NCT03292458|DRUG|Sodium Oxybate|Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
214944258|NCT01378715|DRUG|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
214944259|NCT02461680|PROCEDURE|tangential resection|the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
214944260|NCT02461680|PROCEDURE|suture|
215074763|NCT05647343|OTHER|Placebo|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
215074764|NCT01018329|PROCEDURE|Magnetic Resonance Imaging|
215074765|NCT01018329|PROCEDURE|Diffusion Tensor Imaging|
215074766|NCT01018329|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|
215074767|NCT01018329|PROCEDURE|Dynamic Contract-Enhanced magnetic resonance imaging|
215074768|NCT01018329|PROCEDURE|Diffusion-weighted magnetic resonance imaging|
215074769|NCT05083013|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction (RT-PCR)|For SARS Corona Virus 2 (COV2) confirmation
214340415|NCT05307224|DEVICE|Mandala|Experimental group will paint mandala for 30 minutes/day in the evenings for six consecutive days. Six pre-selected mandalas were planned to be printed separately on A4 paper. Each patient will be given a new mandala each day. Additionally, At the beginning of the study, the experimental group will be given six colors (yellow, blue, green, red, purple, brown).
214944261|NCT06455397|BEHAVIORAL|The Building Emotional Awareness and Mental Health (BEAM) Program|"The BEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving maternal mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy, and the Unified Protocol.~Program delivery will be facilitated through a mobile application. The BEAM program uses a stepped care model to address the pressing need for accessible and effective mental health interventions. Stepped care is a framework that provides mental health services in a tiered manner, ensuring that participants receive appropriate levels of support based on the severity of needs. At the heart of this model are BEAM peer coaches, who will have the most direct contact with participants. Peer coaches are trained to escalate concerns to the program clinical team as required."
214944262|NCT03564132|DRUG|Yigansan|Yigansan granules
214944263|NCT03564132|DRUG|Placebo|One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
214944264|NCT05030207|DIAGNOSTIC_TEST|Real-time Gated 4DCT|Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.
214944265|NCT05030207|DIAGNOSTIC_TEST|Conventional 4DCT|Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
214944266|NCT06404684|BEHAVIORAL|Cognitive behavioral therapy (CBT)|se above
214944267|NCT06285136|PROCEDURE|DEC3-VEN|Venetoclax in combination with decitabine (+-sorafenib) Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 800mg/d, d8-14 (only for FLT3/ITD mutation positive patients)
214944268|NCT01326000|DRUG|FOLFIRI|standard iv chemotherapy
214944269|NCT01326000|DRUG|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
214944270|NCT01326000|DRUG|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
214677279|NCT06672393|DRUG|HS-10374-matched placebo tablets|Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days
214944271|NCT01197014|DRUG|Amlodipine plus Losartan|Amlodipine/Losartan high dose
214944272|NCT01197014|DRUG|Amlodipine, Losartan|Amlodipine, Losartan
214944273|NCT05850104|OTHER|the effects of classical Chopart prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of classical Chopart prosthesis and silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
214944274|NCT05850104|OTHER|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
214944275|NCT00593606|DRUG|Rotigotine|Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
214944276|NCT02481180|DRUG|T0001|injection (SC) T0001 15mg weekly for 12 weeks
214944277|NCT02481180|DRUG|T0001|injection (SC) T0001 30mg weekly for 12 weeks
214944278|NCT02481180|DRUG|T0001|injection (SC) T0001 30mg every two weeks for 12 weeks
214677280|NCT06671691|RADIATION|SBRT level I|20Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
214944279|NCT02481180|DRUG|T0001|injection (SC) T0001 50mg every two weeks for 12 weeks
214944280|NCT02481180|DRUG|Enbrel|injection (SC) enbrel 50mg twice a week for 12 weeks
214944281|NCT02897726|DRUG|NVP-1402|Oral
215074770|NCT05083013|DIAGNOSTIC_TEST|Glycated haemoglobin (HbA1C)|Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control
214944282|NCT02897726|DRUG|NVP-1402R|Oral
214944283|NCT01601457|DRUG|activated recombinant human factor VII|90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
214944284|NCT01601457|DRUG|placebo|Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
215074771|NCT05083013|RADIATION|High Resolution Computed Tomography (HRCT)|with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation
214340416|NCT02753751|OTHER|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
214340417|NCT01787526|DRUG|ferric carboxymaltose|1 g intravenously per infusion
214944285|NCT05948124|DRUG|L-carnitine|L-carnitine supplementation
214944286|NCT05948124|OTHER|isotonic saline|Intravenous 5 ml of isotonic saline
214944287|NCT06730503|DRUG|Immune checkpoint inhibitor|Observe a situation before and after immunotherapy
215074772|NCT05083013|DIAGNOSTIC_TEST|Routine Laboratory investigations|"* Arterial blood gases (ABGs)~* Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)"
214944288|NCT06622525|DRUG|Sodium bicarbonate|This group will receive 100 mEq of sodium bicarbonate diluted in one liter of saline solution, administered at a rate of 100 ml/h, with the goal of maintaining a urinary pH greater than 6.5.
214944289|NCT06622525|OTHER|No intervention|The usual management for heat stroke will be given to this group
214944290|NCT01420562|PROCEDURE|blood sampling|During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
214944291|NCT05940129|BEHAVIORAL|Women and Child, Safety, Health and Empowerment (WC-SHE)|The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons
214944292|NCT03145662|DEVICE|high pressure balloon|high pressure balloon will be used to treat stenosis
214944293|NCT03145662|DEVICE|cutting balloon|cutting balloon will be used to treat stenosis
214944294|NCT01897662|DIETARY_SUPPLEMENT|NUTRIOSE FB06|14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day
214677281|NCT06671691|RADIATION|SBRT level II|23Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
214677282|NCT06671691|RADIATION|SBRT level III|26Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
214677283|NCT06671691|RADIATION|SBRT level IV|28Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
215074773|NCT05083013|DIAGNOSTIC_TEST|Random Blood Sugar (RBS)|Blood Sugar will be measured before each meal and before bed time during hospitalization.
215074774|NCT01535599|DRUG|AL-60371, 0.3% Otic Suspension|
214677284|NCT06671691|RADIATION|SBRT level V|30Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
214677285|NCT06672276|DRUG|TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.
214677286|NCT06671444|DRUG|YZJ-1139|Single oral dose, 20 mg tablet
214677287|NCT06673186|OTHER|overdenture|Patient satisfaction (primary outcome) was measured by a visual analog scale (VAS). OHRQoL (secondary outcome) was measured by oral health impact profile (OHIP-14). Questions of VAS and OHIP-14 were evaluated after 3 months The patients were divided into two equal groups.
214944295|NCT01897662|DIETARY_SUPPLEMENT|GLUCIIDEX 21|7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
215074775|NCT01535599|OTHER|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
215074776|NCT04052763|DIAGNOSTIC_TEST|FFR-CT|FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
214944296|NCT03035734|DRUG|BMS-986141 Form A Tablet|tablet
214944297|NCT03035734|DRUG|BMS-986141 Form B tablet (low dose)|tablet
214944298|NCT03035734|DRUG|BMS-986141 Form B tablet (high dose)|tablet
214944299|NCT03416634|BEHAVIORAL|App|The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
215074777|NCT04052763|DIAGNOSTIC_TEST|FFRangio™|Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
215074778|NCT04987996|DRUG|GR-MD-02|Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
215074779|NCT04987996|DRUG|Placebo|Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
215074780|NCT04987996|DRUG|Pembrolizumab|Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
215074781|NCT05587062|BIOLOGICAL|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) by intravitreal injection
215074782|NCT05587062|BIOLOGICAL|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) by intravitreal injection
214340418|NCT01787526|DRUG|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
214944300|NCT03416634|BEHAVIORAL|Wearable Device|A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
214944301|NCT03416634|BEHAVIORAL|Automated Motivational Message|An automated behavioral intervention will be delivered once weekly via an in-app motivational message, over the 12-week intervention period.
214944302|NCT03416634|BEHAVIORAL|Personalized Motivational Message|A behavioral intervention will be delivered once weekly via an in-app motivational message adapted to each patient's personalized PA goal progression based on the previous week data from the smartphone activity app (Microsoft band) or the Garmin wearable device over a 12-week intervention period.
214944303|NCT05523141|DRUG|ASC10|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner"
214944304|NCT05523141|DRUG|Placebo|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner"
214944305|NCT04936698|DRUG|PTU 50 MG Oral Tablet|to treat if the patient has hyperthyroidism
214944306|NCT04936698|DRUG|Levothyroxin|to treat if the patient has hypothyroidism
214944307|NCT00018291|DRUG|Risperidone|
214944308|NCT00018291|DRUG|Gabapentin|
214944309|NCT02839564|PROCEDURE|Laparoscopic adhesiolysis|After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
214944310|NCT02839564|PROCEDURE|Diagnostic laparoscopy|After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
214340419|NCT04880551|RADIATION|Fluoroscopy|In this study the patient will be exposed to radiation during the fluoroscopy for lungs. There is a small chance of alopecia. There is a rare chance that the patients skin may turn red or be damaged.
214340420|NCT02176889|DIETARY_SUPPLEMENT|Lactospore|Bacillus coagulans MTCC 5856
214340421|NCT02176889|OTHER|Placebo|
214340422|NCT03149094|BEHAVIORAL|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
214340423|NCT03149094|BEHAVIORAL|CBSM-SMI control|this group will receive the LifeSum app.
214340424|NCT02013765|DRUG|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
214944311|NCT00405743|DRUG|CP-4055|CP-4055 Continuous IV infusion
214944312|NCT00405743|DRUG|CP-4055|CP4055 2 and 4 hour IV infusion
214677288|NCT06673420|OTHER|No Interventions|This is an observational study
214677289|NCT06672952|DIETARY_SUPPLEMENT|400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.
214677290|NCT06672952|DIETARY_SUPPLEMENT|Placebo|The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.
214677291|NCT06672952|DIETARY_SUPPLEMENT|200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.
214340425|NCT05394623|DIAGNOSTIC_TEST|HDV-Ab (IgG), HDV-RNA, RNA genotype|Anti-HDV was evaluated semiquantitatively by means of end-point dilutions. Quantitative HDV-RNA was performed by means of LightCycler 2.0. Genotyping of HDV was performed by direct sequencing of the delta antigen region.
214944313|NCT05792995|DRUG|Sindillimab|Any treatment regimen that includes immunotherapy.
214944314|NCT04977492|PROCEDURE|extracapsular release of lateral retinaculum|A new kind of surgery which releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
214944315|NCT04713436|DRUG|Differentiation Markers|Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
214944316|NCT04480567|DRUG|BMN 307|AAV Gene Therapy Infusion
214944317|NCT01493700|PROCEDURE|heated circuit|use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
214944318|NCT01493700|PROCEDURE|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
214340426|NCT01086657|BIOLOGICAL|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
214340427|NCT01086657|BIOLOGICAL|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
214340428|NCT06475157|OTHER|No intervention|No intervention is applied.
214340429|NCT00583726|BEHAVIORAL|motivational interviewing|telephone counseling
214340430|NCT00583726|BEHAVIORAL|written materials only|dietary guidance materials and pedometers
214340431|NCT04023695|DRUG|Corticosteroid with lidocaine with epinephrine|Trigger finger injection
214340432|NCT04023695|DRUG|Corticosteroid with normal saline|Trigger finger injection
214340433|NCT02216331|DRUG|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
214340434|NCT02216331|DRUG|rifapentine|
214340435|NCT02216331|DRUG|rifampicin|
214944319|NCT04739332|BEHAVIORAL|The Newborn behavioral observations system|The NBO system is a relationship building tool to enhance parental sensitivity in the newborn period. Mothers at risk for post-partum depression are supported by a clinician to respond with confidence to their newborn's individual needs.
215074783|NCT02376725|PROCEDURE|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
215074784|NCT02376725|PROCEDURE|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
215074785|NCT00322296|DRUG|Bexarotene 1% gel|
214340436|NCT05043337|BEHAVIORAL|Maternal voice|"The recordings were made in a quiet and separate consultation room. For infants in the maternal voice group, mothers were recorded what they wanted to say to their baby and read an independently published children's book, Xiao Qi's yellow persimmon which describes how mothers with premature babies care for their infants. After reviewing the quality of the recordings, the maternal voice recordings were edited for 13 minutes using a sound organizer. Respiration, heart rate, oxygen saturation, and Neonatal Infant Pain Scale (NIPS) were measured and recorded 3 minutes before, during, 1 minute, 3 minutes, and 10 minutes after the puncture."
214677292|NCT06672848|DIAGNOSTIC_TEST|Numeretic rating scale (NRS)|NRS is a pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
214944320|NCT03298256|RADIATION|EOS X-rays|Full length, orthogonal anteroposterior and lateral X-rays will be taken simultaneously in a standardised standing position, with arms folded anteriorly in 45 degrees . All radiographs will include C7 proximally and the femoral heads distally. 3D reconstruction of the spine can be performed. X-rays will be repeated after the brace is applied, and at intervals of no fewer than 6 months until the brace is weaned off, or if surgical intervention is required. Coronal, sagittal and axial parameters will be calculated from the reconstruction. 3D vertebral wedging will be calculated in the posterofrontal, sagittal and diagonal planes at the apex, 3 superior and 3 inferior vertebrae, as described by Scherrer et al. Changes in the pre- and post-bracing and follow-up parameters can be calculated.
214944321|NCT04643964|BEHAVIORAL|Entrée: Cognitive skills|In this condition, participants view a video-based intervention covering cognitive emotion regulation skills. This intervention asks participants to respond to questions and practice identifying and evaluating their own thoughts using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
214944322|NCT04643964|BEHAVIORAL|Entrée: Behavioral skills|In this condition, participants view a video-based intervention covering behavioral emotion regulation skills. This intervention asks participants to respond to questions and practice scheduling activities that might give them a sense of pleasure or accomplishment using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to schedule and engage in behaviors in line with the intervention skills.
214944323|NCT04643964|BEHAVIORAL|Entrée: Interpersonal skills|In this condition, participants view a video-based intervention covering interpersonal emotion regulation skills. This intervention asks participants to respond to questions and practice communicating effectively using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
214944324|NCT04643964|BEHAVIORAL|Sampler skills|In this condition, participants view a video-based intervention covering three emotion regulation skills: cognitive, behavioral, and interpersonal skills. This intervention asks participants to respond to questions and practice using skills using intervention worksheets. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
214944325|NCT03729414|PROCEDURE|mucopexy with Doppler artery ligation|Hemorrhoids will be treated by mucopexy with Doppler guided hemorrhoids arteries ligation performed in all quadrants
214944326|NCT03729414|PROCEDURE|mucopexy without Doppler artery ligation|Hemorrhoids will be treated by mucopexy alone performed in all quadrants
214944327|NCT04653623|PROCEDURE|High tibial osteotomy|Treatment option for medial compartment osteoarthritis of knee
215074786|NCT03046095|OTHER|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
215074787|NCT03046095|PROCEDURE|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
215074788|NCT04184414|DRUG|CD19-CART|1-10x106 / kg CD19 CART cells
215074789|NCT04892550|OTHER|Denneroll traction|The participants will be instructed to lie flat on their back on the ground with their knees slightly bent at 20-30° for comfort and arms gently folded across their stomach. The examiner will position the apex of the Denneroll in one of three regions: lower thoracic (T9-T12), mid-thoracic (T5-T8), and upper-thoracic (T1-T4) depending on the apex of each participant's thoracic kyphosis deformity. For lower thoracic kyphosis (T9-T12) the Denneroll is turned 180° so the peak contacts the lower thoracic spine (T10) while the tapered end supports the mid thoracic region
215074790|NCT04892550|OTHER|Multimodal Program|The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
215074791|NCT05056688|DIAGNOSTIC_TEST|Testicular Model BSE/TSE Training Set|The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
214677293|NCT06672848|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI)|BPI is a chronic pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
214944328|NCT04653623|DRUG|Tranexamic acid|Medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation
215074792|NCT04170530|DRUG|mFOLFOXIRI|irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
215074793|NCT04955483|DIAGNOSTIC_TEST|Virtual single energy combined with MAR reconstruction group|combined with MAR reconstruction group
215074794|NCT03051412|OTHER|No Intervention|No intervention
215074795|NCT04372654|DEVICE|Electroducer Sleeve|The device's safety will be assessed at the radial and femoral puncture site
215074796|NCT03751358|PROCEDURE|Unilateral Erector spinae plane block|Magnetic résonance imaging
215074797|NCT04079062|BIOLOGICAL|ONO-4685|Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
215074798|NCT04079062|BIOLOGICAL|Placebo|Placebo will be administered by intravenous continuous infusion at the designated speed.
214340437|NCT05043337|BEHAVIORAL|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.
214944329|NCT06201455|PROCEDURE|PEI+GT|After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
214944330|NCT06201455|PROCEDURE|PEI+MED|Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.
214944331|NCT01472939|DRUG|SSP-002358 (0.1 mg) + PPI|0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
214944332|NCT01472939|DRUG|SSP-002358 (0.5 mg) + PPI|0.5 mg tablet t.i.d. taken in addition to a PPI
214944333|NCT01472939|DRUG|SSP-002358 (2.0 mg) + PPI|2.0 mg tablet t.i.d. taken in addition to a PPI
214944334|NCT01472939|DRUG|Placebo + PPI|Placebo t.i.d. taken in addition to a PPI
214944335|NCT00461110|DRUG|BMS-663513|mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
214944336|NCT00114738|DRUG|Rituximab (R)|Rituximab is given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.
215074799|NCT04079062|BIOLOGICAL|KLH|KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
215074800|NCT04079062|BIOLOGICAL|KLH, ONO-4685|Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
214340438|NCT05043337|BEHAVIORAL|Maternal voice combined with lullaby|"The recordings were made in a quiet and separate consultation room. For infants in the  Maternal voice combined with lullaby group,  mothers were recorded what they wanted to say to their baby and read an independently published children's book-Xiao Qi's yellow persimmon , and giving mother listening to the Brahms Lullaby at the same time, the maternal voice recordings were edited for 13 minutes using a sound organizer. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture."
214340439|NCT00002026|DRUG|Acyclovir|
214340440|NCT02302729|DIETARY_SUPPLEMENT|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
214944337|NCT00114738|BIOLOGICAL|EPOCH|EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
214944338|NCT00114738|DRUG|Bortezomib (B)|Bortezomib is given alone for one cycle.
214944339|NCT00114738|DRUG|Bortezomib|Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.
214944340|NCT00114738|DRUG|Bortezomib or observation|At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
214944341|NCT01991899|BIOLOGICAL|MMR Bio-Manguinhos|1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline
214944342|NCT01991899|BIOLOGICAL|MMR GlaxoSmithKline|390 children will receive 0,5 ml MMR GlaxoSmithKline
214944343|NCT03453112|DRUG|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler
214944344|NCT03453112|DRUG|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA\_134a propellant
214677294|NCT06672848|DIAGNOSTIC_TEST|The S-LANSS Pain Score|The Leeds assessment of neuropathic symptoms and signs (LANSS) Pain Scale is based on analysis of sensory description and bedside examination of sensory dysfunction, and provides immediate information in clinical settings. It was developed in two populations of chronic pain patients.
214944345|NCT06449508|DRUG|Probiotic Formula|drops of probiotic supplement containing bacillus clausil spores (Enterogermania Amp 2 Billion/5Ml )
214944346|NCT00841308|OTHER|Decision to start and titrate drug treatment based only on home blood pressure monitoring|"Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm)."
214944347|NCT04484155|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
214944348|NCT05370404|OTHER|Prescription by surgical team|The surgical team prescribes medications to the patient
214944349|NCT05370404|OTHER|Recommendation by surgical team|The surgical team recommends the patient to take over-the-counter medications
214944350|NCT00308750|DRUG|enzastaurin|1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
214944351|NCT00308750|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease
214944352|NCT00308750|DRUG|docetaxel|75 mg/m\^2, IV, q 21 days, six 21 day cycles or progressive disease
214944353|NCT00308750|DRUG|carboplatin|Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease
214944354|NCT01358578|DRUG|Placebo|Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
214944355|NCT01358578|DRUG|secukinumab (AIN457)|secukinumab (AIN457) 150mg or 300mg subcutaneous
214340441|NCT02302729|BEHAVIORAL|Responsive feeding|"Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil"
214340442|NCT02302729|DIETARY_SUPPLEMENT|Placebo|Riboflavin Vitamin B2
214340443|NCT03649022|DEVICE|Catheter ablation|Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)
214944356|NCT01358578|DRUG|etanercept|etanercept 50mg subcutaneous
214340444|NCT02116465|DRUG|Levodopa Carbidopa immediate release tablets|oral administration
214340445|NCT04171700|DRUG|Rucaparib|Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
214340446|NCT02491320|OTHER|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
214340447|NCT02491320|DRUG|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
214340448|NCT01462994|OTHER|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
214340449|NCT03039673|DRUG|Riluzole|"All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS."
214340450|NCT03039673|DRUG|IL-2|"The dose of IL-2 to be used in this study will be 2.0 million IU/day.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.~In case of intolerance, a flexible dose-reduction schedule is available."
214340451|NCT03039673|DRUG|5% glucose water solution|"The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period."
214340452|NCT03408158|PROCEDURE|same type infusion of main HPA antigen|Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
214944357|NCT00388297|DRUG|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
214340453|NCT01134900|OTHER|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
214944358|NCT00388297|DRUG|Placebo for Levothyroxine|
214944359|NCT01822951|DRUG|Cerebrolysin|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
214944360|NCT01822951|DRUG|Donepezil|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20."
214944361|NCT01048905|DRUG|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children \< 15 years of age.
214944362|NCT00669851|DRUG|AI-700|
214944363|NCT03623659|PROCEDURE|Laser assisted hatching|After warming, blastocysts are subjected to laser assisted hatching (LAH) following the standard procedure.The LAH procedure lasts one minute per blastocyst.
214340454|NCT04098627|BEHAVIORAL|Laughter Therapy|Once weekly 30-minute long group laughter therapy session for 8 weeks
214340455|NCT04423965|DRUG|mFOLFOXIRI|irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day \*2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle
214340456|NCT04423965|COMBINATION_PRODUCT|Chemoradiotherapy|Capecitabine based chemoradiotherapy
214340457|NCT03497325|DRUG|autologus platelet rich plasma|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
214340458|NCT03497325|DRUG|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
214340459|NCT02334800|DRUG|Palbociclib 75 mg Capsule|Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
214340460|NCT03698682|DRUG|Levofloxacin 500mg|One tablet per day for 7 days.
214944364|NCT01185262|DRUG|Lenalidomida and Rituximab|"Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.~Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).~In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.~If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).~In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1."
214944365|NCT01492101|DRUG|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
214944366|NCT01492101|DRUG|Treatment of Physician's Choice (TPC)|"One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel"
214944367|NCT01378832|PROCEDURE|Intra-peritoneal antibiotic lavage|The lavage was performed immediately prior to closure of the abdominal wall. Prior to the lavage, a microbiological sample from the peritoneal surface (parietal and visceral) was obtained with a swab (sample 1), followed by a lavage with 500 ml normal saline, similar to the one performed in Group 1. After this lavage, a new microbiological sample was obtained from the peritoneal surface (sample 2), and a second lavage with an antibiotic solution, including gentamicin (240 mg) and clindamycin (600 mg) dissolved in 500 ml normal saline was performed. During this lavage, the solution was allowed to sit in the abdominal cavity for 3 minutes. After aspirating the lavage, a third microbiological sample was obtained in the same way as the two previous ones (sample 3).
214944368|NCT01055080|DIETARY_SUPPLEMENT|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
214944369|NCT00770666|DRUG|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
214944370|NCT00770666|DRUG|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
215074801|NCT04079062|BIOLOGICAL|KLH, placebo|Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
214677295|NCT06671223|DRUG|Infiltration|The intervention consists of the administration of infiltrations in the affected plantar fascia of participants with a diagnosis of plantar fasciopathy. A drug such as a corticosteroid, PRP or hyaluronic acid will be used, which will be injected under ultrasound guidance to ensure precision at the site of the injury. This intervention aims to reduce inflammation and pain, thus improving the functionality of the foot. Up to three infiltrations will be performed, depending on the patient\&amp;amp;#39;s response to treatment and medical evaluation. The infiltrations will be compared with a control group that will receive conservative treatment without infiltrations, to evaluate the relative effectiveness of this pharmacological intervention in the management of plantar fasciopathy.
215074802|NCT03941457|BIOLOGICAL|BiCAR-NK cells (ROBO1 CAR-NK cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
215074803|NCT05495841|DEVICE|Pre-oxygenation|Process of administrating oxygen prior to intubation
215074804|NCT02502669|DRUG|Finasteride 23.5 mg tablets|
215074805|NCT02502669|DRUG|Finasteride 33.5 mg tablets|
215074806|NCT02502669|DRUG|Placebo tablets|
215074807|NCT03090386|OTHER|Cognitive Surveys|Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment
215074808|NCT01710943|BEHAVIORAL|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
215074809|NCT01165320|DRUG|Caspofungin|
215074810|NCT01727115|OTHER|Infant Formula Feeding|"Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months"
215074811|NCT02938832|BEHAVIORAL|Advice on what food to choose and eat|Dietary advice
215074812|NCT01284478|DRUG|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
214340461|NCT03678012|DRUG|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
214340462|NCT03678012|DRUG|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
214340463|NCT03678012|DRUG|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
214340464|NCT01430130|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
214340465|NCT06026566|DRUG|Dos of Afentanil 20|the dosage of Afentanil is 20 ng/ml for TCI
214340466|NCT06026566|DRUG|Dos of Afentanil 30|the dosage of Afentanil is 30 ng/ml for TCI
214340467|NCT06026566|DRUG|Dos of Afentanil 40|the dosage of Afentanil is 40 ng/ml for TCI
214340468|NCT06026566|DRUG|Dos of Afentanil 50|the dosage of Afentanil is 50 ng/ml for TCI
214340469|NCT06026566|DRUG|Dos of Afentanil 60|the dosage of Afentanil is 60 ng/ml for TCI
214340470|NCT06026566|DRUG|Dos of Afentanil 70|the dosage of Afentanil is 70 ng/ml for TCI
214340471|NCT06026566|DRUG|Dos of Afentanil 80|the dosage of Afentanil is 80 ng/ml for TCI
214340472|NCT06026566|DRUG|Dos of Afentanil 90|the dosage of Afentanil is 90 ng/ml for TCI
214944371|NCT04909372|BEHAVIORAL|Labelling|"Food products in the virtual supermarket will display an environmental label on their packaging, from A (lowest impact) to E (highest impact). The label categories are based on the Product Environmental Footprint, a score recommended by the European Commission that evaluates the environmental impact of a food product based on 16 indicators calculated throughout the life cycle of the products (e.g., climate change in kg carbon dioxide eq, marine eutrophication in kg N eq, land and water use or acidification in mol H+ eq).~Instructions will introduce and explain the environmental label to the participants as In the virtual supermarket, each product will have an environmental label. This label describes whether a product had a negative impact on the environment (green house gaz emissions, water resources depletion, etc.) from A, lowest impact, to E, highest impact."
214944372|NCT04219839|BEHAVIORAL|SOC + Educational Videos Designed Especially for post-transplant patients|Patient focused videos (3-5 minutes each) with topics that will include: What to Expect After Transplant, What is the Kidney, Understanding your Labs, Transplant Medications, General Medical Care Post-Transplant, When to Call your Coordinator, and Self-Management/Sick Day protocols. Video curriculum will be offered in two ways. First, tablet computers with active links to each video will be available in kidney transplant clinic. At provider/coordinator discretion, study participants may also view videos while waiting for other appointments. In addition, for patients with smartphones who consent to this, a desktop link will be provided to the transplant video curriculum webpage (mobile friendly view).
214944373|NCT00805519|DRUG|Glucosamine and chondroitin sulfate|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
214944374|NCT00805519|DRUG|glucosamine and chondroitin sulfate plus Prednisolone|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
214944375|NCT00805519|DRUG|Glucosamine and Chondroitin sulfate plus Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
214944376|NCT00805519|DRUG|Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
214944377|NCT04035629|COMBINATION_PRODUCT|MagniXene, hyperpolarized 129Xe MRI|"All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results."
214944378|NCT01072578|DRUG|Dapagliflozin|Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
214944379|NCT01072578|DRUG|Dapagliflozin|Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
214944380|NCT03701698|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet （Jakafi）, 5\~10mg bid po for at least 28 days.
214944381|NCT03701698|DRUG|Methylprednisolone|Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.
214944382|NCT00541008|DRUG|sunitinib malate|
214944383|NCT01675154|DRUG|SLx-4090 placebo|Given for 4 weeks
214944384|NCT01675154|DRUG|Orlistat Placebo|Given for 4 weeks
214944385|NCT01675154|DRUG|Orlistat|Given for 4 weeks
214340473|NCT06026566|DRUG|Dos of Afentanil 100|the dosage of Afentanil is 100 ng/ml for TCI
214340474|NCT03608800|BEHAVIORAL|Intermittent fasting|The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
214944386|NCT01675154|DRUG|Slx-4090|Given for 4 weeks
214944387|NCT06490172|DEVICE|Shock wave therapy|Radial Extracorporeal Shock Wave Therapy and feasibility as treatment for adhesive capsulitis
214944388|NCT02210169|DRUG|Continuous infusion of vancomycin|Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
214340475|NCT03459417|PROCEDURE|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
214340476|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
214340477|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
214944389|NCT04268654|PROCEDURE|Preoperative Arterial Embolization|"PAE will be performed by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. Embolization by coils of the left gastric artery, splenic artery and the right gastric artery is realized."
214944390|NCT01810705|DRUG|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
214944391|NCT03193749|DRUG|Amiodarone Hydrochloride|Starting (loading) dose 400 mg PO once a day for 10 days. Maintainance dose 200 mg PO once a day for at least 6 months, up to 24 months
214944392|NCT03193749|DRUG|Placebo Oral Tablet|Matching placebo for tablets of 200 mg of Amiodarone
214944393|NCT02552498|PROCEDURE|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
214944394|NCT02971800|DRUG|sodium fluorescein injection 10%|
214944395|NCT00098462|DRUG|gefitinib|
214944396|NCT00098462|DRUG|sirolimus|
214944397|NCT04929860|BEHAVIORAL|social marketing campaign|social marketing campaign delivered over 4 weeks in 4 separate sessions
214944398|NCT02543320|OTHER|LORETA Neurofeedback Training|Undergo LORETA neurofeedback training
214944399|NCT02543320|OTHER|Questionnaire Administration|Ancillary studies
214944400|NCT05483101|OTHER|Alternative birth units|"Midwife-led alternative birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative birth units named Filière physiologique (FP) co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room."
214944401|NCT02056106|DRUG|antidepressant therapy|
214340478|NCT06332794|DEVICE|KOKU4PD|Exercise at home using the KOKU app for 4 weeks.
214944402|NCT02953587|PROCEDURE|Oral Glucose Tolerance Test (OGTT)|Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.
214944403|NCT02953587|DRUG|Human Ghrelin|Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.
214944404|NCT02953587|DRUG|Saline|Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
214944405|NCT04487483|BEHAVIORAL|Sleep App|A sleep app offering 6 evidence based techniques to improve sleep (such as Cognitive Behavioural Therapy for Insomnia, Progressive Muscle Relaxation and Mindfulness Meditation), allowing for a personally tailored journey of sleep aids within the app.
214944406|NCT04738422|DRUG|Alkaline glycine|Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
214944407|NCT05288296|DEVICE|dynamic taping|"1. The intervention of dynamic tape can improve the LESS, which also means that we may reduce the probability of ACL injury through the intervention of dynamic tape.~2. By establish a native model of single-leg and double-leg LESS can predict the occurrence of ACL injury early and further prevent it."
214944408|NCT02090621|PROCEDURE|Extracorporeal photopheresis|Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
214944409|NCT04443621|BEHAVIORAL|questionnaire|Questionnaire battery for assessment of dignity, cognition, self-sufficiency, and depression.
214944410|NCT04443621|BEHAVIORAL|in-depth interview|Individual in-depth interviews with OAwD on the topic of dignity (two interviews with each respondent at a 12-month interval) .
214944411|NCT02864927|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
214944412|NCT02864927|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
214944413|NCT06620289|BEHAVIORAL|Dental Desensitization Clinic|The goal of offering desensitization visits is to reduce the dental anxiety and distress of patients and enhance their cooperation during future appointments. The specifics of the desensitization are individualized to meet the unique needs of each patient based on information provided by the parent/caregiver. A standard desensitization visit involves providing the patient the opportunity to sit in the exam chair; touch the toothbrush and rubber prophy cup, mouth mirror, fluoride applicator brush, air-water syringe tip and saliva ejector tip; gain exposure to the dental lights and sounds commonly experienced in the dental visit; practice opening their mouth; and tolerate toothbrush and rubber prophy cup, mirror, explorer, fluoride applicator brush, air-water syringe, and salvia ejector in the mouth. If the child is unable or unwilling to participate, these activities are modeled on the parent or by the CCLS.
214944414|NCT00041665|DRUG|Recombinant Human Keratinocyte Growth Factor|
214944415|NCT00460265|DRUG|ARM 2|Subjects will receive Cisplatin plus 5FU
214944416|NCT00460265|DRUG|ARM 1|Subjects will receive Panitumumab plus cisplatin and 5FU
214944417|NCT02060266|DRUG|semaglutide|Subjects will receive a single dose subcutaneously (s.c., under the skin).
214340479|NCT02752412|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214340480|NCT02752412|DRUG|Insulin glargine U100 (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214340481|NCT02752412|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
214944418|NCT00067769|BEHAVIORAL|Internet-based intervention UCanPoopToo|Internet-based intervention to administer Enhanced Toilet Training (ETT).
214944419|NCT00067769|BEHAVIORAL|treatment as usual|Routine clinical care.
215074813|NCT03826173|BEHAVIORAL|PPPA|The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
215074814|NCT03826173|BEHAVIORAL|PA|The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
215074815|NCT00385944|DRUG|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
215074816|NCT00385944|DRUG|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
214944420|NCT02289846|DRUG|IW-9179|
214677296|NCT06671223|OTHER|Conservative treatment|The control group is used to compare the effectiveness of infiltrations with a non-invasive approach in the treatment of plantar fasciopathy. This group will not receive any infiltration and will focus on conservative interventions.
215074817|NCT02076308|OTHER|Electroacupuncture and physical therapy|real electroacupuncture
215074818|NCT02076308|OTHER|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
214340482|NCT00801684|DRUG|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
214340483|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
214340484|NCT00801684|DRUG|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
214340485|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
214340486|NCT00801684|DRUG|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
214944421|NCT02289846|DRUG|Matching Placebo|
214944422|NCT06119243|DEVICE|Vivior|The Vivior is a wearable clip-on sensor that objectively quantifies near viewing distance and duration, and ambient illumination. The Vivior will be attached to the spectacles frame of children undergoing myopia control treatment.
214340487|NCT05604729|DRUG|Botulinum toxin type A|Botulinum Neurotoxin type A
214340488|NCT05604729|DRUG|Placebo|Saline solution
214340489|NCT02139163|OTHER|Cohort Study|
214340490|NCT01795001|OTHER|No intervention|
214340491|NCT06535672|OTHER|kamishibai education|Patients in the intervention group will be given Kamishibai diabetes education.
214340492|NCT06535672|OTHER|routine education|Patients in the control group will be given routine diabetes education.
214340493|NCT05810922|OTHER|arbutus berry|consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
214340494|NCT01714219|PROCEDURE|Posterior reconstruction|
214340495|NCT01751568|DRUG|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
214340496|NCT03284268|GENETIC|VCN-01|VCN-01 intravitreal injection
214340497|NCT05824884|BEHAVIORAL|Visual Feedback|Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
214340498|NCT05824884|BEHAVIORAL|Self-efficacy enhancement:|specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).
214340499|NCT05824884|BEHAVIORAL|placebo intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
214677297|NCT06671132|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain|CBOT device with beta-caryophyllene
214944423|NCT04701918|DRUG|Pembrolizumab|Intravenous injection through a vein (IV) every 3 weeks
214677298|NCT06671132|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactoy stimuli with no BCP
214677299|NCT02269319|DRUG|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
214677300|NCT02269319|DRUG|Linezolid|Oral linezolid 600mg given twice a day for 10 days
214944424|NCT04701918|PROCEDURE|Cryoablation|Needle inserted through the skin and into the tumor using CT guidance
214944425|NCT04701918|DRUG|Avelumab|Intravenous injection through a vein (IV) every 2 weeks
214944426|NCT02581228|DEVICE|ML-PrediCare|
214944427|NCT02416050|PROCEDURE|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
214944428|NCT02680613|BEHAVIORAL|Motivational SMS|Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
214944429|NCT02680613|BEHAVIORAL|Travel Voucher|A code for return public transportation to closest cervical cancer screening clinic included in the research.
214944430|NCT03203759|OTHER|Home hospitalization|See above
215074819|NCT02186054|DEVICE|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
215074820|NCT02022215|DRUG|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
215074821|NCT02022215|DRUG|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
215074822|NCT02022215|DRUG|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
215074823|NCT02114125|BEHAVIORAL|Physical Activity|group-based physical activity
214944431|NCT03203759|OTHER|Traditional inpatient hospitalization|See above
214944432|NCT02454075|DRUG|YF476|Gastrin receptor antagonist
214944433|NCT05596500|DIETARY_SUPPLEMENT|Blueberry-protein gel|Sport gel with blueberry extract and plant protein.
214677301|NCT00792766|DRUG|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
214944434|NCT05596500|DIETARY_SUPPLEMENT|Blueberry gel|Sport gel with blueberry extract only.
214944435|NCT05596500|DIETARY_SUPPLEMENT|Placebo|Sport gel without the blueberry extract polyphenols and without protein.
214944436|NCT04658706|OTHER|A supervised exercise program|is a 12-week exercise program supervised by specially trained instructors combining moderate to high intensity aerobic and strength exercises (three 1 hour sessions a week).
214944437|NCT04658706|OTHER|exercise prescription|they will receive a prescription concerning healthy lifestyles and a personalized exercise plan
214944438|NCT02440542|OTHER|Survey of outcomes following popliteal nerve block|Patients will be instructed to complete journals of pain and narcotic use until postoperative day 10. On first follow-up visit, patients will complete a patient satisfaction survey. VAS Pain scores and pain medication use will be collected up to 12 weeks postoperatively.
214944439|NCT05520970|BIOLOGICAL|AdCLD-CoV19-1|All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region
214944440|NCT01992315|DEVICE|Adipose-derived ECM|Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
214944441|NCT05939115|DEVICE|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
214944442|NCT06437275|OTHER|Questionnaire for the degree of knowledge and attitude|Questionnaire for the degree of knowledge and attitude of Egyptian physicians regarding emergency treatment of traumatic dental injuries.
214944443|NCT06649071|OTHER|Naturalistic observation|Naturalistic observation
214944444|NCT04792671|BEHAVIORAL|Sociodemographic variables|age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.
214944445|NCT04792671|BEHAVIORAL|Family affluence scale (FAS)|a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.
214944446|NCT04792671|BEHAVIORAL|Edinburgh postnatal depression scale (EPDS)|s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed
214944447|NCT04792671|BEHAVIORAL|"Symptom Checklist 90 SCL 90:"|is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed
214340500|NCT05824884|BEHAVIORAL|No visual feedback|Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
214340501|NCT00042328|DRUG|Valacyclovir|
214347436|NCT01308580|DRUG|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
214347437|NCT00360529|DRUG|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
214347438|NCT03385876|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
214347439|NCT04695327|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
214944448|NCT00237471|DRUG|Insulin (tight blood glucose control)|
214944449|NCT02719353|DEVICE|comfilcon A Extended Range test lens|contact lens
214944450|NCT02719353|DEVICE|comfilcon A control lens|contact lens
214944451|NCT03921970|OTHER|ESP block (Group ESP)|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
215074824|NCT02114125|BEHAVIORAL|Cognitive Training|individual-based, multi-domains cognitive training
215074825|NCT00590824|DRUG|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
215074826|NCT00590824|DRUG|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
215074827|NCT01833260|BEHAVIORAL|Music|
215074828|NCT04277117|BEHAVIORAL|Waitlist|"Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes."
215074829|NCT04277117|BEHAVIORAL|Medically tailored meals - Daily delivery with human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 MTM a week: mix of hot and frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~* Delivery: 3 to 5x per week. Each delivery day, one meal is warm, the other is frozen. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off \& visual check) with the participant."
214340502|NCT06214585|PROCEDURE|Intermittent heat and cold versus heat-only therapy|for the experimental group, a cyclical method of alternating heat and cold application will be used on the lumbosacral and lower abdominal area of the laboring women. The process involves applying a hot pack with a temperature range of 38-40°C on their lower abdomen and low back for 30 minutes during contractions and a relaxing period using a 2-litre rubber hot water bag. Subsequently, reusable ice packs typically contain water, covered with a towel and with a temperature range of 0-5°C will be applied to the same areas for 10 minutes. After a 30-minute interval, the heat application will be reapplied, and this alternating heat and cold cycle will be repeated throughout the first stage of the laboring process.
214340503|NCT06214585|PROCEDURE|Heat- only Therapy|hot water bag will be used to provide heat to the lower back of primigravida women during the first stage of labor. The water in the bag will be maintained at a temperature of 40-42ºC. The application of heat will last for 20 minutes, and it will be repeated every hour until the cervix is fully dilated.
214340504|NCT03594448|PROCEDURE|Specimen Collection|Undergo collection of blood samples
214340505|NCT03594448|PROCEDURE|Serial Liquid Biopsy|Undergo serial liquid biopsy
214340506|NCT03698955|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
214340507|NCT03698955|OTHER|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
214340508|NCT00309998|BIOLOGICAL|bevacizumab|
214340509|NCT00309998|DRUG|vinorelbine tartrate|
214340510|NCT05905965|DRUG|Empagliflozin 20 mg|Patients receiving empagliflozin 20 mg daily - experimental arm
214340511|NCT05905965|DRUG|Empagliflozin 10 mg|Patients receiving empagliflozin 10 mg daily - control arm
214340512|NCT04079933|OTHER|Oral tobacco-derived nicotine product (OTDN)|
214340513|NCT05813743|DIAGNOSTIC_TEST|3 dimensional ultrasound|Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
214944452|NCT02651415|DRUG|Regorafenib|"Stivarga® will be used as per the marketed indication (on label), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.~Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is \<30% fat, \~300-550 calories."
214944453|NCT02651415|DRUG|Perindopril|COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
214944454|NCT01685957|BEHAVIORAL|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
214944455|NCT01685957|BEHAVIORAL|"Ned i vaegt (NIV)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation."
214944456|NCT01685957|BEHAVIORAL|"Verdens bedste kur (VBK)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals."
214944457|NCT05620992|DEVICE|Echocardiography|Echocardiography 3 and 6 months post operative
214677302|NCT02502877|DRUG|Midazolam|The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
214340514|NCT01717573|PROCEDURE|Deferred stenting|
214340515|NCT01717573|PROCEDURE|Conventional treatment|
214340516|NCT04151810|DRUG|CDP1|"Single dose part:~Cohort 1:400 mg/m2; Cohort 2: 500 mg/m2; Cohort 3: 750 mg/m2;~Multi-dose Part:~Starting dose: Cohort 1:400 mg/m2; Cohort 2/3: 500 mg/m2; Maintenance dose: Cohort 1:250 mg/m2, QW; Cohort 2/3: 500 mg/m2, Q2W;"
214340517|NCT04151810|DRUG|CDP1|Starting dose: 400 mg/m2; Maintenance dose: 250 mg/m2,QW;
214340518|NCT04151810|DRUG|TIP chemotherapy|Paclitaxel: 175 mg/m2 in day 1, Q3W; Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W; Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W; Participants received TIP chemotherapy up to 6 cycles (21 days per cycle).
214340519|NCT00618215|BEHAVIORAL|peer group educational implementation strategy|"Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice"
214340520|NCT06041477|DRUG|Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU|Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
214340521|NCT06041477|DRUG|Concurrent Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the first cycle
214677303|NCT02502877|DRUG|Propofol|The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
214677304|NCT02502877|DRUG|Standard|The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
214340522|NCT06041477|DRUG|Concurrent PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)
214944458|NCT02777944|BEHAVIORAL|Motivate: a web-based intervention|A web-based intervention focuses on managing expectations of assessment, addressing ambivalence and increasing users' motivation and confidence to attend their initial appointment. This is achieved through the use of information, motivational tools, interactive activities and stories from other individuals with EDs spread across four 15-20 minute modules.
214944459|NCT06355167|DIETARY_SUPPLEMENT|Bacopa monnieri|Daily oral intake of Bacopa monnieri during 6 weeks
214944460|NCT03284372|BEHAVIORAL|Text Message Only|The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
214944461|NCT03284372|BEHAVIORAL|Text message + Incentive 1|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
214944462|NCT00103922|DRUG|cilomilast|
214944463|NCT06016439|PROCEDURE|Arthroscopic rotator cuff partial repair with superior capsular augmentation with LHBBT|Residual rotator cuff defect will be reconstructed using LHBBT.
214944464|NCT06016439|PROCEDURE|Arthroscopic rotator cuff partial repair|Rotator cuff will be repaired with remaining residual defect.
214944465|NCT06016439|PROCEDURE|Arthroscopic complete rotator cuff repair|Arthroscopic complete repair as a standard procedure.
214944466|NCT06016439|DEVICE|Suture anchor(s)|Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
214944467|NCT01917344|OTHER|MRI|
214944468|NCT06621667|OTHER|diaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis|diaphragmatic myofascial release
214677305|NCT02502877|DEVICE|SpotOn|Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
214340523|NCT06041477|DRUG|Sequential Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
214340524|NCT06041477|DRUG|Sequential PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)
214944469|NCT06621667|OTHER|traditional physical therapy exercises for hyperkyphosis|traditional physical therapy exercises for hyperkyphosis
214340525|NCT00343187|DRUG|ACZONE (dapsone) Gel, 5%|
214340526|NCT00343187|DRUG|Vehicle Control|
214340527|NCT03174340|BEHAVIORAL|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
214347440|NCT00505739|DRUG|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
214677306|NCT06080347|OTHER|Anti-inflammatory Diet|Dietary intervention
214677307|NCT06080347|OTHER|Healthy Diet|Dietary intervention
214677308|NCT06672614|OTHER|Post-Exercise Hot Water Immersion|Participants will cycle for 60 minutes at 50% of maximal oxygen uptake (VO2 max) followed by 30 minutes post-exercise hot water immersion (40oC) for 5 consecutive days.
214677309|NCT06672614|OTHER|Control Group|Participants will cycle for 60 minutes at 50% maximal oxygen uptake (VO2 max) for 5 consecutive days. There is no water immersion following the exercise.
214677310|NCT06672302|DIAGNOSTIC_TEST|ExoPred|Performing in vitro diagnostics with devices developed by EXoPERT
214677311|NCT04294784|DRUG|Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;SHR-1210 200mg, ivdrip,d1,Q21d.
214677312|NCT04294784|DRUG|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;
214677313|NCT02214758|OTHER|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
214677314|NCT06697327|DRUG|(Daunorubicin, Cytarabine, Venetoclax)|"* Drugs：Daunorubicin~  * Dosage: 40 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 5~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U~* Drugs：Venetoclax~  * Dosage: 100 mg on day 1, 200 mg on day 2, and 400 mg from days 3 to 14~ * Other names: ABT-199, Venclexta, Venclyxto"
214944470|NCT01626625|DRUG|stem cells + hydroxy apatite|patient will be transplanted with stem cells and hydroxyapatite
214944471|NCT01626625|OTHER|autograft taken from iliac crest|patient will be transplanted with autograft
214944472|NCT01497886|BEHAVIORAL|Hip Hop Stroke educational program|Three one-hour sessions, conducted over three consecutive days
214340528|NCT04068675|BEHAVIORAL|Group pre-operative counseling|Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
214340529|NCT01229436|DRUG|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
214944473|NCT01497886|BEHAVIORAL|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
214944474|NCT00697034|DRUG|Capsaicin|natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
214944475|NCT03594019|PROCEDURE|Connective tissue graft|Connective tissue graft (CTG) is an oral and maxillofacial surgical procedure first described by Alan Edel in 1974. It includes the preparation the recipient site of tissue exhibiting recession by incising the gingival, obtaining the CTG from the donor site, securing the CTG at the recipient site and suturing the incised gingival tissue at both the donor and recipient sites.
214944476|NCT03594019|PROCEDURE|socket shield technique|The procedure is used to split the teeth and preserve the buccal part
214944477|NCT03594019|PROCEDURE|Immediate implant placement|The implant will be placed in the frest socket immediately after tooth extraction
214944478|NCT06071182|DEVICE|Task-oriented Fruit ninja game|The fruit ninja game were played from tablet PC 20 minutes in a day and 2 times in a week for 4 weeks
214944479|NCT06071182|OTHER|sham-controlled therapy|The fruit ninja game playing video (https://www.youtube.com/watch?v=cAb0cAviA1s) was watched on the same tablet for 3 minutes a day, twice a week, for 4 weeks, and the wrist and wrist exercises were repeated for 2 minutes on a flat and smooth table. movements were made.
214944480|NCT05388695|BIOLOGICAL|Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells|Single or sequential injection of CD19, CD20 and CD22 CAR T cells.
214944481|NCT00073892|DRUG|PI-88|250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
214944482|NCT01038414|BEHAVIORAL|Extended Duration Behavioral Smoking Cessation Counseling|Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
214347441|NCT06052501|PROCEDURE|Removable of the full arch implant-supported prostheses|The intervention planned will be the removal of full arch implant-supported prostheses and the acquisition of a digital image through a facial scanner before and after this moment.
214347442|NCT05155436|DRUG|Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg|Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
214677315|NCT06697327|DRUG|(Daunorubicin, Cytarabine)|"* Drugs：Daunorubicin~  * Dosage: 60 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 7~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U"
214677316|NCT05592938|RADIATION|rPBI|External beam partial breast reirradiation (rPBI) using 26Gy in 5 fractions delivered daily over 1-week
214677317|NCT06755671|DRUG|Danning Tablet|Danning Tablet is the only exposure in this observational study.
214677318|NCT04950985|OTHER|Observational Study|Observational study
214340530|NCT04242316|BEHAVIORAL|Mirror Therapy|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.
214944483|NCT05260424|OTHER|non-invasive ventilation|Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.
214944484|NCT05307796|BEHAVIORAL|Strategy training|The strategy training of focus in this study is metacognitive strategy training intended to build awareness of naming and methods to overcome instances of difficult naming. Strategy training involves (a) teaching the participant to identify instances in which they are unable to name objects, (b) learn a 6-feature framework (e.g. group, use, action) that has been identified to support semantic feature activation in aphasia, (c) learn and practice strategies to utilize the framework in instances of word finding difficulty
214944485|NCT00624559|DRUG|celecoxib (Celebrex)|Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
214944486|NCT00624559|OTHER|Placebo|Placebo pill taken twice per day on each day of the diet
214944487|NCT04453800|DRUG|sofadil【Neu2000KW】|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
214944488|NCT04453800|DRUG|Sofadil|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
214944489|NCT04453800|DRUG|Sofadil|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
214944490|NCT04453800|OTHER|placebo|Saline was administered intravenously
214944491|NCT04385875|BIOLOGICAL|Vaccine + extension of the ATI period|During the AELIX-002 trial participants received the following: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. After that, on ATI\_extension trial, ATI will be extended for 48 weeks.
214944492|NCT04385875|OTHER|Placebo + extension of the ATI period|During the AELIX-002 trial participants received the following: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. After that, on ATI\_extension trial, ATI will be extended for 48 weeks.
214944493|NCT06250907|PROCEDURE|The guidance of dynamic navigation|Osteotomy and implant placement with the guidance of dynamic navigation
214677319|NCT02211495|DEVICE|GEKO device|Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
214677320|NCT02211495|OTHER|Best Medical Therapy|Seen in outpatient clinic for wound care and ongoing advice
214677321|NCT06013956|DEVICE|Neurostimulation|Electrical stimulation delivered via deep brain stimulation electrodes based on measurements of brain activity.
214677322|NCT06013956|DRUG|Carbidopa 25/Levodopa 100Mg Tab|Anti-parkinsonian medication.
214677323|NCT06045572|DEVICE|VTM examination and breast biopsy|VTM examination performed by a radiologist, at the MART (Metabolic Activity in Real-Time) station, using the SaMD Mart 2.0, according to the inspection protocol to identify breast alterations and/or suspicious images to be biopsied for validation by genetic tests and histology / immunohistochemistry.
214677324|NCT00432133|BEHAVIORAL|Protection Motivation Theory-Based Intervention|Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
214677325|NCT00432133|BEHAVIORAL|Environmenta|Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
214677326|NCT02646436|OTHER|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
215074830|NCT04277117|BEHAVIORAL|Medically tailored meals - Weekly delivery with no human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~* Delivery: 1x per week shipment.~* Engagement: Meals are shipped to the participant's home. No human engagement."
214944494|NCT06250907|PROCEDURE|The guidance of static template|Osteotomy and implant placement with the guidance of static template
214944495|NCT03412188|DRUG|Eltrombopag|Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)
214944496|NCT03412188|DRUG|conventional|Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment
214944497|NCT05313282|COMBINATION_PRODUCT|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2\. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 8th day 30minutes after meals, once a day, for continuous medication.~3\. On the 22nd day of treatment, namely the second session of HAIC, intravenous infusion of Camrelizumab 200mg every 3 weeks.~4\. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
214944498|NCT05313282|COMBINATION_PRODUCT|Apatinib combined with Camrelizumab|Drug: Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally 30minutes after meals, once a day, for continuous medication 2. Intravenous infusion of Camrelizumab 200mg every 2 weeks.
214944499|NCT04526574|BIOLOGICAL|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
214944500|NCT04526574|OTHER|Saline|Normal saline for injection
214944501|NCT04526574|BIOLOGICAL|Influenza vaccine|Seasonal inactivated influenza vaccine (SIIV)
214944502|NCT04958902|BEHAVIORAL|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
214944503|NCT04448600|OTHER|MRI|"The patients included in the study will all have a cerebral MRI as part of the cholesteatoma follow-up or for the assessment of cerebral or inner ear pathology.~\- ENT evaluation"
214944504|NCT00970099|BEHAVIORAL|exercise|Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR
214944505|NCT00970099|BEHAVIORAL|Non exercise|subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist
214944506|NCT01678885|BEHAVIORAL|Digital Photography of Foods|The digital photography of foods method was developed to unobtrusively measure energy intake in naturalistic settings (e.g., cafeterias). Participants will be provided with cell-phones with digital cameras and cellular network capability. Participants were trained to take pictures of their food selection and plate waste and to send these pictures to the researchers over the cellular network. The participant will collect data in free-living conditions and these data will be collected in near real time.
214944507|NCT01678885|OTHER|doubly labeled water|Doubly labeled water, considered the gold standard for measuring energy intake in humans, was used to measure total daily energy expenditure during free-living conditions. DLW is used to obtain an accurate measure of total daily energy expenditure, which is equal to energy intake during energy balance.
214944508|NCT01678885|DEVICE|IDEEA|The Intelligent Device for Energy Expenditure and Activity (IDEEA) will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
214944509|NCT01678885|BEHAVIORAL|low-calorie diet|Participants will be instructed to consume five packets of Health One per day, which provides 800 kcal and 125% of Recommended Daily Intake of vitamins and minerals. Additionally participants will be instructed to consume a meal consisting of 200 kcal to 350 kcal daily, which could consist of a portion-controlled meal replacement or a home-cooked meal. Participants will meet with a Registered Dietitian at weeks 0, 2, 4, and 6 and receive instructions on adhering to the meal plan.
214944510|NCT01678885|DEVICE|Actical|The Actical will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
214944511|NCT01678885|DEVICE|Sensewear Armband|The Sensewear armband will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
214944512|NCT04717388|OTHER|acoustics tests, Questionaries,|"acoustics tests at V1 Questionaries at V1~* cognitive~* emotional~* auditory"
214944513|NCT04717388|RADIATION|MRI|Anatomical and functional MRI at V2
214944514|NCT05673161|OTHER|iron|iron treatment
214944515|NCT02340611|DRUG|Olaparib|Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
214944516|NCT02340611|DRUG|Cediranib|Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
214944517|NCT04076371|DRUG|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
214677327|NCT02646436|OTHER|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
214677328|NCT04811677|OTHER|radiology|image analysis
214677329|NCT03733678|BEHAVIORAL|Price discounts for SARCs|SARCs are offered free to the client
214677330|NCT03733678|BEHAVIORAL|Price discounts for LARCs|LARCs are offered at lower prices to the client
214677331|NCT03733678|BEHAVIORAL|Sequential vs. simultaneous recommendations|Top ranked methods are presented to the client sequentially or simultaneously
214944518|NCT04076371|DRUG|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
214944519|NCT04076371|DRUG|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
214944520|NCT04076371|DRUG|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
214944521|NCT04076371|DRUG|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
214944522|NCT04076371|DRUG|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
214944523|NCT04076371|DRUG|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
214944524|NCT04076371|DRUG|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
214944525|NCT01916161|OTHER|Questionnaire|
214944526|NCT03603977|DRUG|Lpv/r+3TC|It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.
214944527|NCT02889705|OTHER|Ultrasonographic examination|
214944528|NCT03859791|OTHER|THA|Study participants have received a total hip arthroplasty due to arthritis. We do not make further intervention.
214944529|NCT01099774|DRUG|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
214944530|NCT01099774|DRUG|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
214944531|NCT02939482|DRUG|Triamcinolone Acetonide and normal saline solution|80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
214944532|NCT02167048|DRUG|Psychostimulants|"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."
214944533|NCT06649448|DRUG|Efbemalenograstim alfa Injection|This product should be administered subcutaneously 48 hours after the completion of anti-tumor drug administration in each chemotherapy cycle. The recommended dose for adults is 20mg administered subcutaneously once per chemotherapy cycle. Please do not administer this product within 14 days before and 24 hours after the administration of cytotoxic chemotherapy drugs.
215074831|NCT04277117|BEHAVIORAL|Medically tailored meals - Standard MOWCTX delivery with human interaction|"Phase 2 (6 months)~* Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~* Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~* MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care)."
215074832|NCT04401618|OTHER|Retrospective evaluation of RMGI and GIC Class V Restorations|Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
215074833|NCT04403243|DRUG|Colchicine|0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight \> 85kg for seven days.
215074834|NCT04403243|DRUG|Ruxolitinib 5 MG|Ruxolitinib - 5mg twice a day per os for ten days
214944534|NCT06649448|DRUG|carboplatin/cisplatin-etoposide|one of the following chemotherapy regimens can be selected: EC, Q3W: Carboplatin AUC = 5\~6 on Day 1; Etoposide 80\~100 mg/m² on Days 1-3. EP, Q3W: Cisplatin 75\~80 mg/m² on Day 1; Etoposide 80\~100 mg/m² on Days 1-3.
214944535|NCT06649448|DRUG|Carboplatin plus Paclitaxel|"For non-small cell lung cancer (squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Carboplatin AUC = 5\~6 on Day 1 + Taxane: Paclitaxel 175-200 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, administered every 3 weeks (Q3W); Cisplatin/Carboplatin 75 mg/m²/AUC = 5\~6 on Day 1 + Gemcitabine 1000 mg/m² on Days 1 and 8, administered every 3 weeks (Q3W)."
214944536|NCT06649448|DRUG|Cisplatin/pemetrexed or Carboplatin/pemetrexed|"For non-small cell lung cancer (non-squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Cisplatin 75 mg/m² on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).~Carboplatin AUC = 5\~6 on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W)."
214944537|NCT06649448|DRUG|TP regimen|"The chemotherapy regimen options include:~TP regimen: Cisplatin 60-80 mg/m² administered via intravenous drip on Day 1 + Taxane: Paclitaxel 175 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, with a treatment cycle of every 3 weeks (Q3W)."
214944538|NCT04602572|BEHAVIORAL|Lifestyle course.|Pharmacotherapy
214944539|NCT04602572|PROCEDURE|Bariatric surgery.|Sleeve gastrectomy or gastric bypass.
214944540|NCT03025568|OTHER|PEEK|PEEK (poly-ether-ether-ketone) has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth. Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
214944541|NCT03025568|OTHER|Bre.flex|In the recent time thermoplastic materials (breflex) become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus.
214944542|NCT04734275|DRUG|AZD5718|Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.
214944543|NCT00673426|BIOLOGICAL|Enoxaparin sodic|
214340531|NCT04242316|BEHAVIORAL|Bilateral arm training|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
214944544|NCT02879708|OTHER|Information Only|Households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village (such as the VHSNC meetings and Village Health and Nutrition Days). Information will be disseminated through an initial visit to all households, and from then on either through (1) broadcast messages sent to households via mobile phone, (2) central individuals in the village social network who will be asked to spread that information, or (3) public officials charged with spreading the information throughout the village.
214944545|NCT02879708|OTHER|Information and Facilitation|In addition to the information interventions described above, this intervention will provide trained facilitators to help community members engage in a participatory process with VHSNCs and identify key deficiencies for improvement in health services that most concern community members. The facilitators are trained to help organize meetings and are provided a detailed checklist of activities to be undertaken prior to the the meetings. The three key health workers at the village level (ASHA, ANM, and AWW) report to the local (village level) elected representatives and block level authorities, who receive feedback from the community in the accountability interventions.
214944546|NCT03457805|DEVICE|Prostatic Artery Embolization|PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
214340532|NCT03515148|PROCEDURE|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
214944547|NCT02987569|BEHAVIORAL|mConnect plus mobile connections to multidisciplinary professionals & peers|mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.
215074835|NCT04403243|DRUG|Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Secukinumab - 300mg subcutaneously singly
215074836|NCT04403243|OTHER|standard therapy|standard therapy for COVID 19
215074837|NCT06110858|BEHAVIORAL|Tinkering Activities|Tinkering activities encompass elements of science, art and technology. They emphasize that learning is not simply about teachers imparting knowledge to students, but rather about students actively constructing knowledge themselves. Tinkering activities are characterized by three key elements: active engagement, open-ended exploration and problem-solving. In such activities, participants are provided with products without telling the steps. They are then encouraged to attempt creating it on their own. During this hands-on learning process, participants need to flexibly change their mindset, think outside the box and tackle emerging problems, which challenge their executive functions.
215074838|NCT04851210|OTHER|No intervention|No intervention
214340533|NCT03515148|PROCEDURE|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
214340534|NCT00710502|PROCEDURE|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
214340535|NCT00710502|PROCEDURE|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
214340536|NCT04424368|DEVICE|The remote monitoring system|Usage of remote monitoring system
214340537|NCT00024518|DRUG|30,000 units hrINF-alpha|
214340538|NCT00024518|DRUG|5,000 hrINF-alpha|
214340539|NCT00024518|OTHER|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
215074839|NCT00445107|DRUG|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
215074840|NCT01329276|DRUG|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
214340540|NCT06280300|OTHER|health services intervention|Health services intervention
215074841|NCT04429386|PROCEDURE|Bariatric surgery|Laparoscopic bariatric surgery including gastric bypass and sleeve gastrectomy
215074842|NCT06345950|DIETARY_SUPPLEMENT|Liposomal Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
215074843|NCT06345950|DIETARY_SUPPLEMENT|Standard Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
215074844|NCT06345950|DIETARY_SUPPLEMENT|New Micellar Glutathione (Lipomicel)|A maximum single dose of 600 mg glutathione (soft gel capsules)
215074845|NCT04251897|DEVICE|Novel support surface|This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
215074846|NCT04352088|PROCEDURE|Nasal provocation test|Allergen extract under controlled conditions will be applied into nasal mucous.
215074847|NCT00834990|DRUG|divalproex sodium|delayed-release 500 mg tablet
215074848|NCT00834990|DRUG|Depakote®|delayed-release 500 mg tablet
215074849|NCT00003914|DRUG|dolastatin 10|
215074850|NCT02195999|OTHER|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
214340541|NCT04590391|DEVICE|Visual and Auditory Breathing-swallowing Coordinated Training device|This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
214340542|NCT01141296|DRUG|fenofibrate|fenofibrate 200 mg PO daily for 1 year
214340543|NCT01141296|DRUG|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
214340544|NCT04010110|DIAGNOSTIC_TEST|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
214340545|NCT05035979|DRUG|BaidI Quzhi granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
214340546|NCT05035979|DRUG|Ju Yin cream|Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
214944548|NCT02987569|BEHAVIORAL|iPad use plus one mobile connections to multidisciplinary professionals & peers|iPad with a data plan and one professionally moderated iPad visual meeting with peers.
214944549|NCT00775554|OTHER|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
214944550|NCT00775554|OTHER|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
214944551|NCT03806023|DEVICE|hand movements (signals from thumb muscle) triggered PNS and TMS|"PNS, TMS or PNS+TMS will be delivered while the participant performs specific finger tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
214944552|NCT02762552|DEVICE|Transcranial-holter monitoring|Transcranial holter with an 4 hour-recording
214944553|NCT05007574|DEVICE|Microphone MI-305|Remote data collection
214944554|NCT06098417|DIAGNOSTIC_TEST|Plasma Test|IGF-2 (insulin-like growth factor 2)
214486456|NCT06739395|DRUG|Trametinib tablet|Usage, dosage, and administration method: The recommended dose is 2 mg, taken orally once a day with an interval of approximately 24 hours. The dose should be taken at least 1 hour before meals or 2 hours after meals. Do not take any missed doses of trametinib within 12 hours of taking the next dose.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214944555|NCT06098417|DIAGNOSTIC_TEST|Plasma test|SPARC (secreted protein acidic and rich in cysteine)
214944556|NCT06098417|DIAGNOSTIC_TEST|Plasma test|EPICAN (heparan sulfate proteoglycan)
214944557|NCT06098417|DIAGNOSTIC_TEST|Plasma test|EGFR (epidermal growth factor receptor)
215074851|NCT02195999|OTHER|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
214944558|NCT06098417|DIAGNOSTIC_TEST|Liver biopsy|Fibrosis and steatosis grade according to Brunt-Kleiner classification
214944559|NCT06098417|DIAGNOSTIC_TEST|Visceral adipose tissue biopsy|Presence of inflammation
214944560|NCT06098417|DIAGNOSTIC_TEST|Liver elastography|Grade of fibrosis according to Hamaguchi score
214944561|NCT06098417|DIAGNOSTIC_TEST|Blood test|Determination of surrogate based diagnostic tests/scores for liver fibrosis
214340547|NCT05035979|DRUG|Baidi Quzhi placebo granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
214340548|NCT05035979|DRUG|Ju Yin placebo cream|Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
214340549|NCT04734379|DRUG|Fasudil|Oral fasudil 180 mg/day
214340550|NCT05036187|BEHAVIORAL|Behavioral Weight Loss Intervention|Rx Weight Loss: PRIDE is a fully automated online behavioral obesity treatment that is tailored for sexual minority women and involves viewing 12 online video lessons delivered each week, self-monitoring body weight, calorie intake, and physical activity levels, and receiving personalized automated weekly feedback on progress toward goals.
214944562|NCT04377464|OTHER|SF12, EQ-5D-5L and work status standardized quantitative assessments|Quality of life assessments
214944563|NCT00045734|DRUG|imatinib mesylate|Given orally
214944564|NCT00045734|OTHER|laboratory biomarker analysis|Correlative studies
214944565|NCT00045734|OTHER|pharmacological study|Correlative studies
214944566|NCT05490602|PROCEDURE|Running subcutaneous sutures technique|The Running subcutaneous sutures consist of running sutures in the profound and superficial dermis without knotting the thread (suture).
214944567|NCT05490602|PROCEDURE|Classical closures|Classical closures
214944568|NCT04430023|OTHER|epidemiological and demographic characteristics|Patients' age, gender, BMI, medical history, symptoms at admission (e.g., cough, fever, myalgia, gastrointestinal symptoms, headache), concomitant diseases (e.g., diabetes mellitus, hypertension, chronic lung disease, cerebrovascular disease, kidney disease, heart disease, cancer, smoking
214944569|NCT06260046|DRUG|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
214944570|NCT06260046|DRUG|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
215074852|NCT02195999|OTHER|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
215074853|NCT02195999|OTHER|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
215074854|NCT03584841|DIAGNOSTIC_TEST|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
215074855|NCT01114971|DRUG|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
214340551|NCT05036187|BEHAVIORAL|Minority Stress Intervention|The Minority Stress Intervention is designed to help sexual minority women cope with stress and stigma (e.g., due to weight, sexual orientation, gender). In this program, participants watch online video lessons that teach cognitive and behavioral strategies for coping with minority stress so that it may have less of an influence on participants' weight and well-being.
214340552|NCT05036187|BEHAVIORAL|Negative Body Image Intervention|The Negative Body Image Intervention is designed to help participants improve their body image. In this program, participants will watch online video lessons that provide education on queer women's body image and teach cognitive and behavioral strategies for improving your body image (regardless of your weight) to reduce its influence on your health.
214340553|NCT05036187|BEHAVIORAL|Social Support Intervention|The Social Support Intervention provides online opportunities for participants to receive more social support as they work toward their weight loss goals. Participants receive education on the importance of social support for weight management, they can earn badges for completing program milestones, and they gain access to a private online forum to get support and advice from other participants.
214340554|NCT05101252|DEVICE|senofilcon A C3|TEST Lens
214944571|NCT01067261|DEVICE|Transcutaneous mechanical nerve stimulation (TMNS)|"Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)~A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes."
214944572|NCT01067261|OTHER|Pelvic floor muscle training|Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
214944573|NCT04836364|OTHER|No Intervention|There is no intervention; observation only.
214677332|NCT01118143|BEHAVIORAL|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
214677333|NCT06294847|DRUG|Ursolvan|single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.
215074856|NCT01114971|DRUG|Labetalol|"Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
215074857|NCT01114971|DRUG|Esmolol|"Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
215074858|NCT00791479|DRUG|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
215074859|NCT00791479|DRUG|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
215074860|NCT05525052|OTHER|Trans-Facet fixation|Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
214944574|NCT04668170|BIOLOGICAL|Blood collection on admission and longitudinally|Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
214944575|NCT04668170|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|Samples already collected on consultation (D0) and 14 days later
214944576|NCT06350604|BEHAVIORAL|Project WHADE: A Partner-Based Physical Activity Program for Women|Combination of behavioral, cognitive, social, and acceptance-based skills training to increase physical activity
214944577|NCT00925652|DRUG|Bevacizumab|
214944578|NCT00925652|DRUG|Cyclophosphamide|
214340555|NCT05101252|DEVICE|Dailies Total 1 Multifocal Contact Lenses|CONTROL Lens
214340556|NCT03028376|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
214340557|NCT02188823|BEHAVIORAL|Low carbohydrate diet|
214677334|NCT06294847|DRUG|Placebo|Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days
214677335|NCT05089864|OTHER|Stent Placement Timing - Early|Stent placement 5-7 weeks after STAR procedure
214944579|NCT00925652|DRUG|Methotrexate|
214944580|NCT00925652|BEHAVIORAL|Lifestyle: Diet|
214944581|NCT00925652|BEHAVIORAL|Lifestyle: Diet+Exercise|
214677336|NCT05089864|OTHER|Stent Placement Timing - Late|Stent placement 12-14 weeks after STAR procedure
214677337|NCT05482347|OTHER|Educational video|The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
214677338|NCT05471297|OTHER|There is no intervention|There is no any intervention
215074861|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for 120 days
215074862|NCT05308472|DRUG|DISC-1459|Oral dose level 2, once a day for 120 days
215074863|NCT05308472|DRUG|Placebo|Oral dose, once a day for 120 days
214944582|NCT05496283|OTHER|denture adhesive|After 1 month of using the complete denture with no denture adhesives, patients fill up satisfaction and quality of life forms and given 1 of 3 types of denture adhesive to use for month to compare satisfaction and quality of life forms
214944583|NCT05706038|DRUG|Adalimumab|"Adalimumab is a fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, etc.~Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa.\[4\] It inhibits the binding of TNF alpha (both soluble and membrane-bound) to its receptor. Specifically, it inhibits TNF alpha's interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. It is identical in structure and function to the naturally occurring human IgG1 and thus has high selectivity for TNF alpha and has low immunogenic potential."
214944584|NCT05519046|DEVICE|Cardiac Contractility Modulation (CCM)|Cardiac Contractility Modulation (CCM) implantation
214944585|NCT05519046|DEVICE|CRT|Cardiac Resynchronization Therapy
214944586|NCT05069311|DRUG|Multimodal analgesia|"Multimodal analgesia includes the combination of:~1. morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~2. bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~3. bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~4. bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~5. etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~6. paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery"
214944587|NCT05069311|DRUG|Conventional intravenous analgesia|Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
214944588|NCT06649565|OTHER|no intervention|no intervention
214944589|NCT03720145|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
215074864|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for up to 8 months
215074865|NCT05978960|OTHER|Nutrition and resistance training exercise intervention|"3 month 2-3 times/week, 60 min exercise regimen utilizes compound movements to focus on body composition, strength, and mobility. Classes are run by certified strength and conditioning specialists and adjusted for linear progression and safety, progressing from compound to isolated movements to maximize safety.~The nutrition intervention focuses on dietary quality by following a healthy low-carbohydrate diet, focusing on nutrient dense foods high and avoiding processed foods and simple carbohydrates to keep totals under 100g/day. Participants will be advised to eat vegetables, avoid snacking, cook all meals with family and friends, avoid eating on the run, and focus on whole foods that require preparation. Calculations and quantification of calories will be avoided, while protein consumption goals are 1.3-1.8 g/kg per. Dietary strategy will be continuously discussed during exercise sessions and the PI will have twice monthly meetings with participants."
215074866|NCT06298617|PROCEDURE|Diagnostic laparoscopy|All women will undergo exploratory laparoscopy under general anesthesia
215074867|NCT06298617|DIAGNOSTIC_TEST|Full Blood Count (FBC)|Blood samples withdrawn from patients on EDITA tubes and gone through full blood count and differential leucocytic count
214340558|NCT01459796|DRUG|Rilonacept|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
214340559|NCT01459796|DRUG|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
214340560|NCT01459796|DRUG|Allopurinol|Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
214340561|NCT03117335|DRUG|Placebos|"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
214340562|NCT03117335|DRUG|Sulijia|"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
214340563|NCT06391996|DRUG|After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.|During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
214340564|NCT00003326|DRUG|paclitaxel|
214340565|NCT04513600|DIAGNOSTIC_TEST|Cardiac MRI|Lab work: Hs- Troponin, Serum N-terminal-proBNP CMR: Native T1, Native T2, extracellular volume, strain and strain rate.
214340566|NCT00643955|OTHER|muscle strength|muscle strength
215074868|NCT01684709|BEHAVIORAL|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
215074869|NCT02624063|DRUG|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
215074870|NCT02624063|DRUG|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
215074871|NCT01778049|DRUG|BI 10773|Empagliflozin active
214340567|NCT04112849|DIAGNOSTIC_TEST|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
214340568|NCT01275924|DEVICE|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
214340569|NCT01275924|DEVICE|Syndesmotic screw|Quadricortical syndesmotic screw
214340570|NCT01151241|PROCEDURE|Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.|Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
214944590|NCT05650346|OTHER|Deep Cervical Training|The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.
214944591|NCT05650346|OTHER|Deep cervical training + Upper cervical mobilization group|"1. the patient in supine crook lying with the neck in a neutral position.The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg~2. The therapist will cover the rear of the cervical part of the participant with his right hand for stabilization, and will place his thumb and index fingers on the atlas of the participant. To conduct the atlanto-occipital mobilization, the therapist will place his left hand at the right side of the participant and at the same time will place his fifth finger under the occipital area and will pull the participant's head toward his trunk."
214944592|NCT05650346|OTHER|Deep cervical training + Upper thoracic mobilization group|"1. The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.~2. The participants will be placed in the prone position and the therapist will stand facing the joint where the mobilization will be applied to improve the extension of the upper thoracic spine (T1-2)."
214944593|NCT04492072|DRUG|Oxytocin|Intervention
214944594|NCT04492072|DRUG|Misoprostol|Control
214944595|NCT00154050|DRUG|candesartan (drug) or quinapril (drug)|
214944596|NCT05621005|DRUG|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months
214944597|NCT04407416|PROCEDURE|Breath sampling|The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography
214944598|NCT02521558|BEHAVIORAL|Intervention Group|The investigators are interested in how practicing memory tasks can improve memory in patients with MCI and with AD. Specifically, patients will perform a set of cognitive rehabilitation tasks designed to train memory in order to determine if these tasks are effective in improving memory or slowing the progression of Alzheimer's disease. Patients will practice memory tasks for about an hour daily, for a total duration of 6 months. A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the Intervention Group exhibit weekly improvements and to determine if patients are regularly adhering to the tasks.
214944599|NCT02521558|BEHAVIORAL|Control Group|"The Control Group will not receive any cognitive rehabilitation tasks for a six month period. Instead, they will simply be given booklets of puzzles (e.g., word search, number puzzles, etc.) to work on for the duration of 6 months.~A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the control group feel like they are benefiting from the puzzles.~Participants in the Control Group will be given a standard battery of neuropsychological tests prior to the the puzzles and after the puzzles to assess any changes in memory, language, attention, and executive functioning."
214944600|NCT04546321|OTHER|serum L carnitine level measuring|The serum level of total L carnitine was measured for both HIE and TTN cases
215074872|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
215074873|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
215074874|NCT01778049|DRUG|BI 10773|Empagliflozin active
215074875|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
214340571|NCT01151241|OTHER|Early Discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
214340572|NCT01151241|OTHER|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
214340573|NCT01340339|DEVICE|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
214340574|NCT01340339|DEVICE|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
215074876|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
215074877|NCT01778049|DRUG|BI 10773|Empagliflozin active
215074878|NCT01778049|DRUG|BI 10773|Empagliflozin active
215074879|NCT01778049|DRUG|BI 10773|Empagliflozin active
215074880|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
215074881|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
215074882|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
214340575|NCT00638547|DRUG|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
214944601|NCT05433909|DIAGNOSTIC_TEST|Blood, fecal, vaginal and endometrial liquid samples|"During the surgical pre-hospitalization, eligible patients who accept participation in the study will undergo a blood sample and collection of stool samples.~Before surgery, after anesthesia, they will undergo a vaginal swab and endometrial fluid sampling."
214944602|NCT03978013|OTHER|Pomegranate juice|Pomegranate juice
214944603|NCT03978013|OTHER|Apple juice|Apple juice
214944604|NCT03451916|DRUG|PLX-PAD|PLX-PAD (120 subjects): 150×10\^6 PLX-PAD cells (10×10\^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
214944605|NCT03451916|DRUG|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells).
214944606|NCT03788980|PROCEDURE|Carotid endarterectomy|Patients will undergo a surgery called carotid endarterectomy where a surgeon will remove material that causes carotid stenosis (i.e. plaque)
215074883|NCT01778049|DRUG|BI 10773|Empagliflozin active
214944607|NCT03788980|DIAGNOSTIC_TEST|Mini Mental Status Examination|Short questionnaire used to diagnose cognitive dysfunction
214944608|NCT01524783|DRUG|Everolimus|Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
215074884|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
214340576|NCT05663398|DRUG|Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
214340577|NCT05663398|DRUG|Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
214340578|NCT02073968|DRUG|Carboplatin|Given IV
214340579|NCT02073968|PROCEDURE|Computed Tomography|Undergo PET-adjusted IMRT
214340580|NCT02073968|RADIATION|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
214944609|NCT01524783|DRUG|Placebo|Participants were treated with two tablets of matching placebo once daily orally taken.
214340581|NCT02073968|DRUG|Paclitaxel|Given IV
214944610|NCT01524783|OTHER|Best suportive care (BSC)|Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
214340582|NCT02073968|PROCEDURE|Positron Emission Tomography|Undergo PET-adjusted IMRT
214340583|NCT02073968|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
215074885|NCT01814098|DRUG|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
215074886|NCT01711489|DRUG|isavuconazole|oral
214340584|NCT01722591|DEVICE|Cardiapex device|Cardiapex percutaneous transapical access and closure system
214340585|NCT01061294|PROCEDURE|Advanced CustomVue™ iLASIK procedure|
214340586|NCT01061294|DEVICE|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
214340587|NCT04989998|DEVICE|Hip7 Software on Kick/ CORI platforms|Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
214340588|NCT04989998|DEVICE|Conventional surgical procedures|THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.
214340589|NCT01384539|DRUG|Cholecalciferol|
214340590|NCT01384539|DRUG|Calcitriol|
214340591|NCT04856319|PROCEDURE|Dental implant placement|Insertion of not more than two dental implants at the same area
214340592|NCT04856319|DRUG|Antibiotic prophylaxis|Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
214340593|NCT04856319|OTHER|Placebo|Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
214340594|NCT05831852|OTHER|no intervention|no intervention
214944611|NCT01915654|PROCEDURE|study population|Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
214944612|NCT03482570|DEVICE|ActiGraph|Activity behaviours will be objectively assessed by 7-day triaxial accelerometer assessment (ActiGraph GT3X+ Pensacola, FL, USA). Participants will be asked to wear an accelerometer around their waist, 24 hours a day for 7 days.
214944613|NCT00733083|DRUG|0,1 mg/kg of oxycodone|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
214944614|NCT00733083|DRUG|Morphine 0,1 mg/kg|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
214944615|NCT00733083|DRUG|Dexamethasone 0,5 mg/kg|solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
214944616|NCT00733083|DRUG|NaCl 0,9%|solution for injection one injection in the beginning of anesthesia
214944617|NCT00100841|BIOLOGICAL|cetuximab|Given IV
214944618|NCT00100841|BIOLOGICAL|bevacizumab|Given IV
214944619|NCT00100841|DRUG|oxaliplatin|Given IV
214944620|NCT00100841|DRUG|leucovorin calcium|Given IV
214944621|NCT00100841|DRUG|fluorouracil|Given IV
214944622|NCT05470816|DRUG|Tranexamic Acid 100Mg/ml Inj Vial 10ml|Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
214944623|NCT05470816|DRUG|Placebo|Normal saline
214944624|NCT02054910|PROCEDURE|Celiac Plexus Block|Patients will receive celiac plexus block during endoscopy.
215074887|NCT01711489|DRUG|Mycophenolate mofetil|oral
215074888|NCT01480414|BIOLOGICAL|4times injection|bone marrow derived mono nuclear stem cell
214340595|NCT04574895|OTHER|Hematology Review|VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
214340596|NCT05797779|PROCEDURE|Skin biopsy|Punch biopsy of the skin
214340597|NCT00345579|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
214340598|NCT00345579|BIOLOGICAL|ActHIB|3-dose intramuscular injection
214340599|NCT00345579|BIOLOGICAL|Pediarix/Infanrix Penta|3-dose intramuscular injection
214340600|NCT01921972|DRUG|Galantamine CR|24 mg/day with dose-titration over twelve weeks
214340601|NCT01921972|DRUG|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
214340602|NCT01921972|DRUG|Placebo|Placebo will be similar in appearance to Memantine
214944625|NCT02054910|PROCEDURE|Sham|Patients will not receive celiac plexus block during endoscopy.
214944626|NCT00936130|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
214944627|NCT00936130|PROCEDURE|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
214944628|NCT00936130|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
214944629|NCT00936130|BEHAVIORAL|Low Calorie Diet|Low Calorie Diet Program
214944630|NCT06912542|OTHER|Whole flaxseed bread|French bread with the addition of 30g of whole flaxseed.
214944631|NCT06912542|OTHER|Ground flaxseed bread|French bread with the addition of 30g of ground flaxseed.
214944632|NCT06912542|OTHER|French bread|Plain French bread (control).
214944633|NCT05638802|DRUG|DS-7011a|20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
214340603|NCT05283291|BEHAVIORAL|Directed Imagery Technique|"The sound recording will include a soothing light background music for approximately 30 minutes.~Imagination will be practiced, starting with the patient's focusing his/her attention on his/her breath, relaxation, and relaxation with the suggestions given in the recording with the accompaniment of relaxing music."
215074889|NCT01480414|BIOLOGICAL|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
215074890|NCT01000922|DRUG|Regular Human Insulin|Individual dose of RHI administered subcutaneously
214340604|NCT01731171|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
214340605|NCT01731171|DIETARY_SUPPLEMENT|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
214340606|NCT05247944|PROCEDURE|Fenestrated and branched endovascular aortic repair (F-BEVAR)|Fenestrated and branched endovascular aortic repair (F-BEVAR)
214340607|NCT05247944|PROCEDURE|Open repair|Open surgery for complex abdominal aortic aneurysm
214340608|NCT04123639|PROCEDURE|PTA|Percutaneous transluminal angioplasty
214340609|NCT03758898|OTHER|Treatment|Chest physiotherapy and mobilization were applied twice a day, 8 times in total.
214340610|NCT03758898|OTHER|Group 2|Only mobilization was applied twice a day, 8 times in total.
214340611|NCT01446848|DIETARY_SUPPLEMENT|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
214340612|NCT01579344|DRUG|Radioiodine therapy|Radioiodine therapy with NaI131
214340613|NCT01415661|OTHER|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
214340614|NCT00413413|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
214340615|NCT00413413|DRUG|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
214340616|NCT00413413|DRUG|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
214340617|NCT01607034|DRUG|Dexpramipexole|150 mg single dose
214340618|NCT00541762|DIETARY_SUPPLEMENT|Fat perfusion to the small intestine|"1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~2. Orlistat perfused to the small intestine~3. DEXLOX as CCK-1 receptor antagonist"
214340619|NCT00826085|DRUG|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
214340620|NCT01884298|DRUG|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
214340621|NCT01884298|DRUG|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
214944634|NCT05638802|DRUG|Placebo|Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
215074891|NCT01000922|DRUG|Lispro|Individual dose of lispro administered subcutaneously
215074892|NCT01000922|DRUG|VIAject|Individual dose of VIAject administered subcutaneously
215074893|NCT01000922|DRUG|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
215074894|NCT01000922|DRUG|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
215074895|NCT01000922|DRUG|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
215074896|NCT02450448|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
215074897|NCT02450448|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
215074898|NCT05573750|BEHAVIORAL|Singing group|Intervention involves singing groups with person with dementia and carer. Please see earlier descriptions.
215074899|NCT03371134|BIOLOGICAL|Harvesting of muscular biopsies|Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
215074900|NCT02862483|DRUG|Tamsulosin 0.2mg|
214944635|NCT01370824|PROCEDURE|Punch biopsy|Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.
214944636|NCT01370824|PROCEDURE|Surgical excision|"Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.~After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds."
214944637|NCT00181129|BEHAVIORAL|home based self paced walking program|
214944638|NCT04489875|BEHAVIORAL|Chewing Gum|The intervention would be chewing gum. The patients in the intervention arm would be asked to chew gum for 15 minutes before meals thrice a day.
214944639|NCT01131065|DRUG|Hepatitis B immune globulin|Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
214944640|NCT05255250|BEHAVIORAL|PLAYshop|The intervention includes: 1. Educational Training - the 60 min virtual workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be sent physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
214944641|NCT05237804|OTHER|Patient component|Video, booklet, website
214944642|NCT05237804|OTHER|Organisational component|Coronarography, CT-scan, anesthesia...
214944643|NCT01587417|DRUG|Placebo to BI 187004 CL|1 single dose per subject as oral solution
214944644|NCT01587417|DRUG|BI 187004 CL|1 single dose per subject as oral solution
214944645|NCT01902212|OTHER|Oral Nutritional Supplement|
214944646|NCT03679169|PROCEDURE|pancreatosplenectomy|standard or radical anterograde modularpancreatosplenectomy
214944647|NCT02143830|DRUG|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
214944648|NCT02143830|DRUG|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
214944649|NCT02143830|DRUG|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
214944650|NCT02143830|DRUG|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
214944651|NCT02143830|DRUG|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
215074901|NCT02862483|DRUG|Tadalafil 5mg|
214677339|NCT06501872|DEVICE|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
214340622|NCT01736852|DEVICE|CRB|Labor induction using the CRB
214340623|NCT01736852|DRUG|Pitocin|Labor induction using Pitocin
214944652|NCT02143830|BIOLOGICAL|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
214340624|NCT03054844|DRUG|Lidocaine|Lidocaine will be administered before administration of midazolam.
214340625|NCT03054844|DRUG|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
214944653|NCT04963959|DEVICE|Peripheral blood mononuclear cell apheresis|mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
214944654|NCT01589107|BEHAVIORAL|video decision aid|video decision aid
214944655|NCT01782352|DRUG|Omega-3 fatty acids (fish oil)|
215074902|NCT02862483|DRUG|Placebo for Tamsulosin|
215074903|NCT01552785|DEVICE|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
215074904|NCT05497102|DRUG|Lenalidomide maintenance|Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
215074905|NCT00177567|DRUG|lithium carbonate|
215074906|NCT00177567|DRUG|Depakote-ER|
215074907|NCT00177567|DRUG|risperidone|
215074908|NCT00177567|DRUG|olanzapine|
215074909|NCT00177567|DRUG|paroxetine|
214340626|NCT03054844|DRUG|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
214677340|NCT06256380|BEHAVIORAL|Enhanced Cognitive-behavior therapy for adolescents with an eating disorder|Psychotherapy
214677341|NCT06256380|BEHAVIORAL|Family-based therapy for adolescents with an eating disorder|Psychotherapy
214340627|NCT04492046|OTHER|Manual Lymph Drainage|Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.
214340628|NCT04492046|OTHER|Bandaging|Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
214340629|NCT04136106|DRUG|IL-2|IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
214340630|NCT03009110|DEVICE|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
214340631|NCT03009110|DEVICE|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
214340632|NCT05447169|DIAGNOSTIC_TEST|EBV antibodies test|ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
214944656|NCT01782352|DIETARY_SUPPLEMENT|Vitamin D3|
214944657|NCT01782352|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
214944658|NCT01782352|DIETARY_SUPPLEMENT|Fish oil placebo|
214944659|NCT05299372|OTHER|Telemonitoring via Careportal®|The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
214944660|NCT05721300|DRUG|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combined with interferon treatments"|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
214944661|NCT05721300|DRUG|"NAs （EntecavirorTenofovirorTenofovir alafenamide） treatments"|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） treatment at least 48 weeks"
214944662|NCT06888778|OTHER|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive brain stimulation technique that stimulates specific brain areas through repeated magnetic pulses to treat depression, anxiety and other mental illnesses, and to study brain function.
215074910|NCT00177567|DRUG|bupropion|
215074911|NCT00177567|DRUG|lamotrigine|
215074912|NCT00177567|DRUG|venlafaxine|
214340633|NCT05447169|DIAGNOSTIC_TEST|EBV DNA test|quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
214340634|NCT05491733|DRUG|APX001|Low-load oral tablet
214944663|NCT06888778|OTHER|Non-stimulation|participants receive Non-stimulation:The side of the double cone coil is placed against the scalp, and the target of the coil is stimulated in the direction of air.
214944664|NCT05496608|PROCEDURE|L-PRF|a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.
214944665|NCT05496608|PROCEDURE|OFD|Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.
214944666|NCT05496608|PROCEDURE|CM|Xenogeneic collagen membranes that are used as barrier membranes in guided tissue regeneration of periodontal defects
214944667|NCT01428687|BEHAVIORAL|Sleep Duration|Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
214944668|NCT01428687|BEHAVIORAL|No change in sleep|This group is taught to maintain their current sleep habits.
214944669|NCT00671827|BEHAVIORAL|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
214944670|NCT04263636|PROCEDURE|Phacoemulsification with bilateral trifocal diffractive IOLs|Uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs
215074913|NCT00177567|DRUG|tranylcypromine|
214677342|NCT05378399|DRUG|Descovy or Truvada|Descovy or Truvada prescribed with digital pills for PrEP
214677343|NCT05378399|DEVICE|ID-Cap System|Digital pills overencapsulating Descovy or Truvada for PrEP
214677344|NCT05378399|DEVICE|Beiwe|Digital phenotyping app
214677345|NCT02934529|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
214677346|NCT02934529|DRUG|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
214677347|NCT02934529|DRUG|5-FU|5-FU 400 mg/m² bolus day 1, q d15
214340635|NCT05491733|DRUG|APX001A|High-load oral tablet
214340636|NCT02462395|DEVICE|tDCS|"Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software."
214340637|NCT01428323|DEVICE|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
214340638|NCT01650389|BIOLOGICAL|MVA85A|
214340639|NCT01650389|BIOLOGICAL|Candin|
214677348|NCT02934529|DRUG|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
214677349|NCT02934529|DRUG|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
214677350|NCT02934529|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
215074914|NCT00177567|DRUG|mirtazapine|
215074915|NCT04960930|DRUG|FMX101|topically once daily
214340640|NCT01650389|BIOLOGICAL|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."
214340641|NCT00948831|BIOLOGICAL|Osteocel Plus|biologic
214340642|NCT02893722|DRUG|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
214340643|NCT02893722|DRUG|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
214340644|NCT02233712|BIOLOGICAL|G17DT|
214944671|NCT06448195|DRUG|Polyethylene Glycol Somatropin (rDNA origin) Injection|Specification: 54IU/9.0mg/1.0ml/ bottle Dosage form: injection; Dose: 1mg/ week. Subcutaneous injection (upper arm, thigh or abdomen periumbilical) for a total course of 6 months, a total of 3 bottles per patient
214944672|NCT06738849|DEVICE|EkiYou V2|"Use of a Digital Therapy in the form of a mobile application that helps users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.~The device includes the following features to participants:~* Carbohydrate counting through an extensive food database with more than 200k items.~* Bolus calculation based on their meal, physical activity and blood glucose.~* Bolus correction advice.~* Long-acting insulin reminders and automatic periodic titration.~* Insulin-to-carb ratios and correction factor automatic adjustment."
214944673|NCT05814705|DIETARY_SUPPLEMENT|Protein supplement|Ready-to-drink protein beverage consumed once daily for 28 days
214944674|NCT05814705|DIETARY_SUPPLEMENT|Protein supplement with Urolithin A|Ready-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days
214944675|NCT05850897|OTHER|Masaj|Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
214944676|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
214944677|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
214677351|NCT02934529|DRUG|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
214944678|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
214944679|NCT01096589|DEVICE|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
214944680|NCT06781827|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times (January, March, June, and December).
214944681|NCT06781827|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study had last 8 weeks and each patient will make 4 visits (January, March, June, and December).
214944682|NCT04045899|DEVICE|Proseal LMA|The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.
214944683|NCT04045899|DEVICE|Air-Q LMA|Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.
214944684|NCT04045899|DEVICE|Ambu AuraGain LMA|The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
214944685|NCT04513444|OTHER|Relaxation with music listening and medical hypnosis during radiotherapy treatment:|"* Music listening (According to the patient's wishes),~* Hypnosis sessions with the hypnotherapist during the 1st, 2nd and 3rd radiotherapy session,~* Self-hypnosis during the 4th and 5th radiotherapy session,~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations."
214944686|NCT04513444|OTHER|Relaxation with music listening during radiotherapy treatment:|"* Music listening (According to the patient's wishes),~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations."
214944687|NCT03326284|OTHER|15 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein
214944688|NCT03326284|OTHER|35 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein
214944689|NCT03326284|OTHER|60 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein
214944690|NCT03326284|OTHER|35 g protein energy balance|Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
214944691|NCT02252900|OTHER|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
214677352|NCT02934529|DRUG|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
214677353|NCT02934529|DRUG|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
214677354|NCT02934529|DRUG|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
214677355|NCT06738797|DIAGNOSTIC_TEST|SPHERTEST test|The SPHERETEST is an in vitro model of heterotypic spheroids composed of commercial urothelial carcinoma tumor cells and leukocyte mononuclear cells from healthy donors.
214677356|NCT03656835|PROCEDURE|Molecular Nanotechnology|Undergo ILN biochip testing
214677357|NCT04868773|DRUG|Cabozantinib|Oral cabozantinib
214944692|NCT02713438|BEHAVIORAL|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
215074916|NCT05154617|DIAGNOSTIC_TEST|Standard surgical monitoring, along with the Flo Trac® system monitoring.|Under standard thoracic anesthesia protocol, extra monitoring will be done by FloTrac® System using a minimally invasive sensor in combination with an advanced monitoring device to derive cardiac output (CO) and cardiac index (CI) parameters through arterial pulse pressure waveform analysis. Intraoperative blood gases collection will be at different intraoperative times. From this data, calculations will be performed to obtain DO2, DO2i, O2ER, and O2ERi.
215074917|NCT04319029|BEHAVIORAL|Pharmaceutical care plan|"The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study."
215074918|NCT03893240|DIAGNOSTIC_TEST|Neutralizing Antibody to SPK-3006 capsid|Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
215074919|NCT00336167|DRUG|bezafibrate (drug)|
215074920|NCT04231058|DEVICE|TENS and pulmonary rehabilitation|Three treatments with TENS per week for 3 weeks each , lasting 45 minutes
214677358|NCT04868773|DRUG|TAS-102|Oral TAS-102 (trifluridine and tipiracil)
215074921|NCT04852705|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
215074922|NCT04852705|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
215074923|NCT04033887|DIAGNOSTIC_TEST|13 Rapid Diagnostic Tests and reference tests|"Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0"
214340645|NCT02358486|DEVICE|Acupuncture|"1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 \~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
214340646|NCT02358486|DEVICE|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
214340647|NCT01420796|OTHER|Swallowing exercise|"Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side."
214677359|NCT04841304|DEVICE|Loop recorder (Reveal LINQ, Medtronic)|Implantation of a loop-recorder
214677360|NCT04841304|DEVICE|Continuous Glucose Measurement (G6, Dexcom)|Monitoring with a continuous glucose monitor
214677361|NCT03559985|DRUG|paracetamol|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
214944693|NCT02713438|BEHAVIORAL|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads)."
215074924|NCT03770728|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
215074925|NCT03770728|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
215074926|NCT03770728|DRUG|Background therapy: Metformin alone or in combination with SU|Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
215074927|NCT01267331|PROCEDURE|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
215074928|NCT01267331|PROCEDURE|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
215074929|NCT00503776|BEHAVIORAL|exercise intervention|Patients undergo low weight resistance training.
215074930|NCT00503776|DRUG|amifostine trihydrate|Given subcutaneously
215074931|NCT00503776|PROCEDURE|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
215074932|NCT04095351|DIAGNOSTIC_TEST|Pulmonary function test|Spirometry or plethysmography, measurement of diffusion capacity
214340648|NCT01420796|OTHER|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
214340649|NCT01420796|OTHER|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
214340650|NCT04345146|COMBINATION_PRODUCT|FSRT combined with Bevacizumab|"Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases."
214340651|NCT00744536|DRUG|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
214340652|NCT01547650|OTHER|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
214340653|NCT02175446|DRUG|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
214340654|NCT03908684|DEVICE|Ultrasound Imaging|Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
214340655|NCT02604589|DRUG|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
214340656|NCT02604589|PROCEDURE|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
214340657|NCT02604589|DRUG|bupivicaine 0.25%|Low Dose analgesia
214340658|NCT02604589|DRUG|bupivicaine 0.5%|High dose analgesia
214340659|NCT04901559|PROCEDURE|Graft type at ACLR|The choice of graft at primary ACL Reconstruction
214340660|NCT04592367|PROCEDURE|Patient age at time of procedure of reconstruction of ACL|Primary reconstruction of ACL with no other concomitant ligament reconstructions. Treatment of cartilage og meniscal injury may be a part of the procedure
215074933|NCT04095351|DIAGNOSTIC_TEST|Imaging|Thoracic ultrasound, HRCT as scheduled within routine clinical examinations, echocardiography
215074934|NCT04095351|BIOLOGICAL|Blood sampling|Standard laboratory test for CTDs as part of routine clinical examination
215074935|NCT02168049|DEVICE|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
215074936|NCT02168049|DEVICE|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
215074937|NCT02168049|DEVICE|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
215074938|NCT01985711|DEVICE|web-based collaborative care|"Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months."
215074939|NCT01985711|OTHER|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
215074940|NCT01985711|BEHAVIORAL|usual diabetes outpatient care|
215074941|NCT00260767|DRUG|HEC placebo gel|
215074942|NCT02379988|RADIATION|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
215074943|NCT03135158|OTHER|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
214340661|NCT05013892|RADIATION|NTS-WBRT (normal tissue sparing whole brain radiation therapy)|Radiation
214340662|NCT05013892|DRUG|Memantine|Capsule, taken orally
214340663|NCT01063205|DRUG|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
214340664|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
214340665|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
214340666|NCT01286818|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
214340667|NCT01286818|DRUG|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
214340668|NCT01286818|DRUG|levofolinate|IV infusion, 200 mg/m² every 2 weeks
214944694|NCT02713438|BEHAVIORAL|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity."
214944695|NCT02713438|BEHAVIORAL|Education|"CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.~The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners."
214944696|NCT06815263|BEHAVIORAL|Listener Training|Partner participants are presented with individual audio phrases that make up passage reading speech stimuli and orthographic transcriptions of what the patient is saying. Partners are asked to listen carefully to the audio files and use the written subtitles to help them understand what is being said.
214944697|NCT06745674|BEHAVIORAL|a mobile app-delivered Acceptance Commitment Therapy (ACT)|The study utilized a specially tailored internet-based self-help ACT program for cancer patients. It consisted of an introductory module and six core intervention modules: (1) Refusing Avoidance; (2) Accepting Distress; (3) Living in the Present Moment; (4) Observing Yourself Psychologically; (5) Exploring Meaningful Values; and (6) Committing to Action. Each module, designed to take 30-60 minutes, was delivered over a two-week period.
214944698|NCT03073694|DRUG|Mitomycin c|Mitomycin-c will be given to participants in Treatment Arm 1 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes. 45 minutes into the perfusion, a maintenance dose will be administered.
214944699|NCT03073694|DRUG|Melphalan|Melphalan will be given to participants in Treatment Arm 2 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes.
214944700|NCT02086084|DEVICE|NIV|Standard care
214340669|NCT01286818|DRUG|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
214340670|NCT01168934|DRUG|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
214340671|NCT01168934|DRUG|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
214340672|NCT02087800|BEHAVIORAL|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
214944701|NCT02086084|DEVICE|ECCO2R|Application of ECCO2R in addition to NIV
214340673|NCT02087800|BEHAVIORAL|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
214340674|NCT01504438|DEVICE|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
214340675|NCT01504438|DEVICE|STAR Total Ankle Replacement|STAR Total Ankle Replacement
214340676|NCT00961974|BEHAVIORAL|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
214340677|NCT00961974|BEHAVIORAL|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
214340678|NCT03931434|DIETARY_SUPPLEMENT|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
214340679|NCT03931434|DIETARY_SUPPLEMENT|Placebo|Placebo
214340680|NCT04994626|DRUG|Ibrutinib Combined With Rituximab|"Drug: ibrutinib ibrutinib 560mg administered orally once daily. Other Name: Imbruvica~Drug: rituximab rituximab 375mg/m² administered intravenously (IV)"
214340681|NCT03753126|RADIATION|4-dimensional volume-rendered computed tomography|
215074944|NCT03309319|DRUG|Rosiglitazone|rosiglitazone is added to the primary treatment
215074945|NCT00639041|DIETARY_SUPPLEMENT|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
215074946|NCT00639041|DIETARY_SUPPLEMENT|Placebo|dairy products without special oils
215074947|NCT00531557|DRUG|Darunavir ritonavir|
215074948|NCT06178848|DRUG|propofol group|During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
215074949|NCT06178848|DRUG|remimazolam group|The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
215074950|NCT00004495|DRUG|cyanocobalamin|
214944702|NCT04998721|BEHAVIORAL|Promoting First Relationships-Brief|A brief version of the evidence based Promoting First Relationships (PFR) parenting intervention in which a parent is supported in appropriate interpretation of infant cues and in developing skills to effectively parent an infant. Sessions consist of reflective content (observing and reflecting back to the mother on patterns of dyadic interaction) and informational handouts. Reflective content will be delivered in person, and text messaging protocol will deliver informational content at developmentally appropriate times. PFR-B sessions are delivered in primary care settings beginning in the third trimester and continuing postpartum.
214944703|NCT04998721|BEHAVIORAL|Perinatal Collaborative Care|Collaborative Care (CC) is an integrated care model that is effective in the treatment of perinatal depression. CC provides team driven, population focused, measurement guided and evidence based care to improve access and outcomes, control costs, and increase patient satisfaction.
214944704|NCT05047731|DRUG|Antihypertensive medication|Antihypertensive medication will be continually reduced provided an upper systolic threshold of 145 mmHg is not exceeded
214944705|NCT05836974|PROCEDURE|Ex-utero cord blood collection|SCU units are collected after placental delivery (ex-utero) by trained obstetric personnel. The cord is clamped at one minute postpartum. Once the placenta is expelled, it is rapidly transported to the collection area, which contains supplies and a surgical table designed for ex-utero SCU collection. This table has a top tray supported by an armrest. The placenta is placed on this specially designed tray with a central hole that allows the umbilical cord to hang. Proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol. Subsequently, the umbilical vein is cannulated at the most distal point of the placenta, and placental blood is collected by gravity into a sterile bag. Gentle massage can be applied to the placenta to continue draining blood by gravity. If visible blood remains, a second puncture can be made by bringing the needle insertion point closer to the placenta.
214944706|NCT05836974|PROCEDURE|In-utero cord blood collection|The cord blood is clamped in a delayed modality, defined as after at least 1 minute after delivery. The cord is sterilized, and cord blood is collected using aseptic technique (proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol). Blood is allowed to flow by gravity and the needle is removed when blood flow ceases.
214944707|NCT02535130|DEVICE|Positive expiratory pressure|
214944708|NCT02535130|DRUG|amikacine nebulization|
214944709|NCT03673345|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).
214944710|NCT05893004|DIAGNOSTIC_TEST|Headache Screening Questionnaire|The Dutch Headache Screening Questionnaire (HSQ) is the only screening questionnaire based on ICHD-3 which has at least moderate confidence in its criterion validity according to GRADE. The HSQ has already been translated into Portuguese and validated5. The HSQ has only 8 items and requires little time to complete. Due to its good sensitivity, the HSQ screening questionnaire is particularly well suited to exclude migraine.
214944711|NCT01426464|DRUG|0.005% Latanoprost dosed once.|0.005% Latanoprost dosed once. Placebo lotion dosed once.
214944712|NCT02522013|DRUG|Aminophylline|
214944713|NCT02522013|DRUG|isotonic saline|
214944714|NCT02267135|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
215074951|NCT00004495|DRUG|folic acid|
215074952|NCT00004495|DRUG|pyridoxine|
215074953|NCT02497378|DRUG|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
214340682|NCT00761839|BEHAVIORAL|After-care summary|"The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals."
215074954|NCT02497378|DRUG|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m\^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
214340683|NCT00761839|BEHAVIORAL|Control group|Patients in the control group will receive usual counseling for self-management.
214340684|NCT01448759|OTHER|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
215074955|NCT02497378|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
215074956|NCT02479165|DRUG|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
215074957|NCT02479165|DRUG|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
215074958|NCT02231411|PROCEDURE|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
215074959|NCT02231411|PROCEDURE|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
214340685|NCT05983653|PROCEDURE|arthrocentesis without PRP|150 ml arthrocentesis without PRP
214340686|NCT05983653|PROCEDURE|arthrocentesis with PRP|150 ml arthrocentesis with PRP
215074960|NCT02231411|PROCEDURE|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
215074961|NCT03650101|PROCEDURE|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.
215074962|NCT02095665|DRUG|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
215074963|NCT02095665|DRUG|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
215074964|NCT02095665|DRUG|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
215074965|NCT00107315|BIOLOGICAL|bevacizumab|
215074966|NCT00107315|DRUG|capecitabine|
215074967|NCT03477851|DRUG|Tramadol Hydrochloride|Tramadol i.m. simultaneous with sciatic nerve block
215074968|NCT03477851|DRUG|Placebo|0,9%NaCl i.m. simultaneous with sciatic nerve block
215074969|NCT02696057|OTHER|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
214340687|NCT00487201|PROCEDURE|endoscopic balloon dilatation|
214340688|NCT00487201|PROCEDURE|plastic stent placement|
214340689|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 250 Mcg|
214340690|NCT00877448|BIOLOGICAL|Multimeric-001 250 Mcg|
215074970|NCT02696057|OTHER|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
214340691|NCT00877448|BIOLOGICAL|Phosphate Buffered saline|
214944715|NCT02267135|BIOLOGICAL|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
214340692|NCT00877448|BIOLOGICAL|Adjuvanted PBS|
214340693|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 500 Mcg|
214340694|NCT00877448|BIOLOGICAL|Multimeric-001 500 Mcg|
214944716|NCT03273400|OTHER|Lumbar Mobilisations|Please see arm (intervention) description
214944717|NCT06618209|DIAGNOSTIC_TEST|physical and chemical methods|Salivary flow rate, pH
214340695|NCT00877448|BIOLOGICAL|Multimeric-001 125 Mcg|
214340696|NCT03727204|PROCEDURE|On-pump cardiac surgery|All participants will undergo on-pump cardiac surgery
214944718|NCT06618209|DIAGNOSTIC_TEST|biochemical methods|Total oxidant and antioxidant capacities, Lactoperoxidase, Oxidative Stress Index, Glutathione, Superoxide Dismutase
214340698|NCT03673436|PROCEDURE|Lumbar spinal fusion|The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
214340699|NCT00907270|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
214340700|NCT06294509|DEVICE|in-house developed transcutaneous auricular Vagus Nerve Stimulation device|taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus. The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation. Before each session, taVNS is calibrated for each participant. Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached. Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train. Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation. Participants adapt their movements over up to six sessions across two weeks. The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
214340701|NCT04182425|OTHER|Infant formula|Healthy full-term infants fed on an infant formula marketed on the French market
214340702|NCT02094989|OTHER|posture dependence of VCG-ECG-transformation|
214340703|NCT05759598|OTHER|Rehabilitation protocol + guided spontaneous breathing exercises|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
214340704|NCT05759598|OTHER|Rehabilitation protocol + specific respiratory muscle training program|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects
215074971|NCT04589234|DRUG|Salmonella-IL2|Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
215074972|NCT04589234|DRUG|FOLFIRINOX Alone (Historical Controls)|We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
215074973|NCT04589234|DRUG|Gemcitabine/Abraxane Alone (Historical Controls)|We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
215074974|NCT00236990|DRUG|pentosan polysulfate sodium|
215074975|NCT00945061|RADIATION|intracavitary balloon brachytherapy|Patients undergo brachytherapy
215074976|NCT00945061|RADIATION|intraoperative radiation therapy|Patients undergo radiotherapy
215074977|NCT02509039|DRUG|CC-122|5 continuous days out of 7 days per week intermittent dosing
215074978|NCT04053946|DEVICE|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
215074979|NCT01794741|DRUG|Dymista Nasal Spray|
215074980|NCT01794741|DRUG|Fluticasone propionate nasal spray|
215074981|NCT00823433|DRUG|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
215074982|NCT04969965|DRUG|aumolertinib|EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
215074983|NCT02089464|DEVICE|NBS-guided rTMS|
215074984|NCT02089464|DEVICE|Sham rTMS|
215074985|NCT02089464|PROCEDURE|Task oriented rehabilitation|
215074986|NCT05427539|DEVICE|TEST LENS|AO1DfA manufactured with PG hydration
214944719|NCT06618209|DIAGNOSTIC_TEST|Oral Findings|DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries. DDE Index: Developmental Defects of Enamel index.GI (Gingival Index): Assesses the severity of gingivitis based on inflammation.PI (Plaque Index): Assesses the severity of plaque based on inflammation. basic erosive wear examination: measures dental erosion
214944720|NCT06618209|DIAGNOSTIC_TEST|Pediatric Oral Health Quality of Life|The Pediatric Oral Health Quality of Life (POQL) Scale is a tool used to assess the impact of oral health conditions on the overall quality of life in children.
214944721|NCT06003907|OTHER|conventional|hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises
214944722|NCT06003907|OTHER|traditional and complementary medicine methods|"The Graston Technique is a form of manual therapy known as instrument assisted soft tissue mobilization. Graston massage is performed using titanium-coated metal rods specially designed for different parts of the body.~Cupping therapy is a treatment method that creates a regional vacuum to increase the blood circulation of the person and provide healing."
214944723|NCT05418894|DEVICE|Device: Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
214944724|NCT02631460|DRUG|S1 80-120 mg/d|d1, every 3 weeks
214944725|NCT02631460|DRUG|pemetrexed 500 mg/m2|d1, every 3 weeks
214944726|NCT02631460|DRUG|carboplatin AUC=5|d1, every 3 weeks
214944727|NCT03129282|OTHER|Home-based Metacognitive Therapy (Home-MCT)|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
214944728|NCT04323267|DEVICE|Limber Digital Application|A mobile application was recently developed to address these needs. The application provides evidence-based, symptom specific home-exercise video programs for MSK conditions, as well as clinically-validated outcome measures for tracking progress.
215074987|NCT05427539|DEVICE|CONTROL LENS|AO1DfA manufactured with IPA hydration
215074988|NCT04440397|OTHER|xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined
215074989|NCT01935583|BEHAVIORAL|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
214340705|NCT01851057|BEHAVIORAL|STAR|Problem-solving and education intervention (8 total sessions)
214340706|NCT01851057|BEHAVIORAL|Education Only|Education around epilepsy (8 total sessions)
214340707|NCT00723177|DRUG|AV411|Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
214340708|NCT00723177|DRUG|Placebo (PCB)|Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
214340709|NCT05319327|OTHER|Nutritional intervention|"A nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.~Total intervention will last 6 months for both groups. During the intervention phase, a monthly interview with nutritionist/dietitian is scheduled. Face-to-face interviews will be carried out in months 2 and 4. Phone interviews will be carried out in months 1, 3 and 5. In the baseline and final visits (months 0 and 6) a sample and data collection will be performed."
214340710|NCT05319327|OTHER|Control|General counseling to adhere to a healthy Mediterranean diet
215074990|NCT01895543|DRUG|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
215074991|NCT04552639|BEHAVIORAL|Newbridge Eating disorders Activity Treatment group|A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
214340711|NCT04285606|BEHAVIORAL|Patient-led rehab with short immobilization|Short immobilization followed by patient-led shoulder rehab
214340712|NCT03969810|BEHAVIORAL|Rounding Summary|Written summary of rounds
214340713|NCT06535126|DRUG|CanProFem-AK|Dosage form - vaginal suppositories (100 mg). Dosage regimen - single intravaginal administration of suppository. Vaginal suppositories are inserted as deeply as possible while the participant is lying down; the participant must remain in a horizontal position for 45 minutes after the administration. The total duration of volunteer participation in the study is one day. Medical observation (including gynaecological monitoring with vaginal bacterial swab test) of the subject condition after the drug administration will be carried out after 3, 6, 9, 12 and 24 hours. Repeated laboratory blood and urine tests will be performed after 24 hours. Participants of the study will be closely monitored for 24 hours after the initial administration of the drug to detect any immediate adverse events. If the subject experiences an immediate adverse event, appropriate treatment will be provided.
214944729|NCT04323267|BEHAVIORAL|Physical therapy Therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
214944730|NCT03104426|DRUG|Darbepoetin Alfa|Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
214944731|NCT00900731|DRUG|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
214944732|NCT00900731|DRUG|Tiotropium 18 μg|Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
215074992|NCT04552639|BEHAVIORAL|Newbridge House treatment as usual|Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
214944733|NCT00900731|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
214944734|NCT00900731|DRUG|Placebo to tiotropium|Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
214944735|NCT03806231|DRUG|Outpatient Dinoprostone 10mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.
214944736|NCT03806231|DRUG|Inpatient Dinoprostone 10 mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.
214944737|NCT03379844|DEVICE|Holmium-166 radioembolization|An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.
214944738|NCT01000350|DRUG|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
214944739|NCT01000350|OTHER|Placebo|Placebo x1 lactose tablet
214944740|NCT05546723|BIOLOGICAL|Autologous CAR-T cell therapy expressing the BAFF-ligand.|LMY-920
214944741|NCT06157112|OTHER|Lifestyle behaviour (exposure in a observational study)|Lifestyle behaviour, including physical activity, sleep duration, alcohol consumption, smoking, cannabis and other illegal drugs
214944742|NCT01228110|DRUG|Hydrocortison|
215074993|NCT02501317|BEHAVIORAL|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
215074994|NCT02501317|BEHAVIORAL|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
214944743|NCT01228110|DRUG|Saline Solution|
214944744|NCT00526903|BEHAVIORAL|Elimination Diet|Daily diet change for 8 days.
214944745|NCT04505384|PROCEDURE|left bundle branch pacing|left bundle branch pacing
214944746|NCT04505384|PROCEDURE|biventricular pacing|biventricular pacing
215074995|NCT02398422|BEHAVIORAL|Listening Project Protocol|"The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention."
215074996|NCT01572363|DRUG|Sildenafil|50 mg once
214944747|NCT02521532|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
215074997|NCT00283270|BEHAVIORAL|Brief counselling|
215074998|NCT00283270|BEHAVIORAL|Behavior|
215074999|NCT03797118|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
215075000|NCT04446130|DRUG|Decitabine combined with HAAG Regimen|Decitabine :20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine :1mg/d,d3\~16,intravenous infusion; Aclarubicin :10mg/d, d3\~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection
214944748|NCT02521532|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
214944749|NCT06394856|PROCEDURE|Rotator Cuff Repair With a Modified Versus Classic Double-Row Suture -Bridge Techniques|rotator cuff tears with modified versus classic double row suture bridge
214944750|NCT04613193|OTHER|Blood presssure reduction|Patients will be uptitrated in antihypertensive treatment until the treatment target is achieved.
214944751|NCT05541978|OTHER|Multiple myeloma|We will explore the multiple myeloma associated thrombosis risk.
214944752|NCT00692107|RADIATION|Gray|68 Gy vs. 78 Gy
214944753|NCT00692107|RADIATION|Gray|68 Gy vs. 78 Gy
214944754|NCT02599597|BEHAVIORAL|Therapist-assisted iCBT|13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
214944755|NCT02599597|BEHAVIORAL|Monthly screening with feedback|Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
214944756|NCT00932698|DRUG|Ixazomib|Ixazomib capsules
214944757|NCT04299139|OTHER|chiropractic treatment|There is no intervention. Data that has been collected during the time a patient was attending a chiropractor. This data will be evaluated
215075001|NCT01371240|DRUG|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
215075002|NCT01986387|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
215075003|NCT00543296|DRUG|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
215075004|NCT01715350|DRUG|PM012|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
214340714|NCT01592708|OTHER|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
214340715|NCT02066935|OTHER|kidney transplant patient|kidney transplanted patients for at least one year
214340716|NCT02921412|DEVICE|fanfilcon A|contact lens
214340717|NCT02806739|DIETARY_SUPPLEMENT|Soy Group (Soy Protein + Isoflavones)|Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
214944758|NCT00655681|DRUG|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children \< 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
214944759|NCT00655681|OTHER|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
214944760|NCT00086112|DRUG|risperidone oral tablets|
214944761|NCT02594774|OTHER|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
214944762|NCT03493750|OTHER|Oral and dental evaluation|Mouth inspection done by a nurse, in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface.
215075005|NCT01715350|DRUG|Placebo|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
215075006|NCT06425809|OTHER|Observation|The data collection will be carried out by the two researchers, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the athletes whose data are collected. The members of the research group will not have access to personal data that could facilitate the identity of any person on the basis of the data collected. The data collected in this study, anonymised from the outset, will be exported to an Excel file. Access to the Excel file will require password access and will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialities).
215075007|NCT00934947|DRUG|Propranolol|40 mg
215075008|NCT00934947|DRUG|Placebo|sugar pill
215075009|NCT00934947|DRUG|Propanolol|120 mg twice per day
215075010|NCT01907321|BEHAVIORAL|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
214340718|NCT02806739|DIETARY_SUPPLEMENT|Control Group (Minimize Soy Intake)|Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
214340719|NCT06336070|BEHAVIORAL|HIIT program (8 weeks)|Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
214340720|NCT06336070|BEHAVIORAL|MPI program (8 weeks)|Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
214340721|NCT02579993|PROCEDURE|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
214340722|NCT02579993|PROCEDURE|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
214340723|NCT02073045|OTHER|educational intervention|Receive educational handouts
214340724|NCT02073045|OTHER|lymphedema survey|Ancillary studies
214340725|NCT01284400|OTHER|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
214944763|NCT03604770|OTHER|Survey & Food Diary|Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
214944764|NCT01519297|DRUG|Irbesartan|150mg orally for one dose
215075011|NCT01907321|BEHAVIORAL|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
215075012|NCT01907321|DRUG|Measures performed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
215075013|NCT01907321|BEHAVIORAL|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
215075014|NCT01907321|RADIATION|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
215075015|NCT00735826|DRUG|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
214944765|NCT03034473|OTHER|Translational Research and multimodal treatment|"Blood/biopsy samples (tumor \& mucosa) are taken pretherapeutically. Blood samples (serum \& plasma) are drawn at 11 time points during RCTx (e.g. for analysis of 5-FU metabolism, genomic DNA extraction). After pathohistological workup of the TME specimen, the formalin-fixed material will be transferred to the central biobank of KFO179. Blood samples (plasma \& serum) will be drawn during 5y-follow-up. Treatment (based on CAO/ARO/AIO-94- and CAO/ARO/AIO-04-phase-III trials of the GRCSG):~Preoperative RCT: 28x1.8 Gy (total: 50.4 Gy, 5 fractions per week on d1-d38) combined with 5-FU (1000 mg/m2/d) as 120 h civ during 1st and 5th week.~TME-surgery is performed 6 weeks after RCTx. 4 to 8 weeks after surgery, patients receive either 4 cycles 5-FU (500 mg 5-FU/m2 iv, d1-5, repeat d 29-33) or 3 cycles (6 single appl.) of FOLFOX regimen \[(400 mg FA/m2, 2-h civ, d 1; 100 mg oxaliplatin/m2, 2-h civ in 500 ml Glucose 5%, d 1; 2400 mg 5-FU/m2 as 46-h civ) on d1+d15, d30+d45 and d60+d75\]."
214944766|NCT06620874|BIOLOGICAL|STABHA Injection|Participants will receive two ultrasound-guided STABHA injections into the medial collateral ligament of the knee at a 2-week interval
214944767|NCT06620874|OTHER|High-Concentration Glucose Water Injection|Participants will receive two ultrasound-guided high-concentration glucose water injections into the medial collateral ligament of the knee at a 2-week interval
214944768|NCT06620874|OTHER|Saline Injection|Participants will receive two ultrasound-guided saline injections into the medial collateral ligament of the knee at a 2-week interval
214944769|NCT00560586|DRUG|Budesonide|1 puff each nostril (32 micrograms) at bedtime
214944770|NCT00560586|DRUG|placebo|1 puff each nostril at bedtime
214944771|NCT03486002|DEVICE|Cleansweep|The Cleansweep closed suction system
214340726|NCT05102890|OTHER|ESOGER|For patients in the intervention group, ESOGER will be administered by phone by a member of the clinic team prior to their virtual or in-persons consultation with their primary care provider. ESOGER is already available on an online platform for data entry. Based on feedback our team obtained from interviews with current users of ESOGER, administration of the tool is expected to take between 5 and 10 minutes. A report summarizing the health and social status of the patient along with flagged potential vulnerabilities will be generated automatically by the online ESOGER platform. This report will then be uploaded to the patient's electronic chart by a member of the clinic and made available for the primary care provider at the time of the consultation.
214340727|NCT01918995|DRUG|Regadenoson|Intravenous (IV)
214340728|NCT01918995|DRUG|Placebo|Intravenous (IV)
214340729|NCT02177344|DRUG|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
214340730|NCT02177344|DRUG|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
214340731|NCT02177344|DRUG|Atrovent|Two puffs, 4 times daily by oral inhalation
214944772|NCT03486002|DEVICE|Halyard|Halyard Closed Suction System
214944773|NCT02429310|DEVICE|Revitive IX|This is a neuromuscular electrical stimulation device
214944774|NCT05561946|DEVICE|Owlet OSS 3.0|The Owlet OSS 3.0 is worn continuously for a minimum of 48 hours and the skin where the device is worn is monitored for any skin injury/irritation
214944775|NCT03240523|DRUG|Vilaprisan (BAY1002670)|Orally, 2 mg, once daily
215075016|NCT06249698|DIETARY_SUPPLEMENT|meal replacements and supplements|Consumed daily: 2 Nutrimeal Active meal replacement shake, 1 electrolyte replacement drink, 3 metabolism + supplements, 1 whole food meal, and whole food snacks consisting of fruits and vegetables. 1200-1600 calories per day
215075017|NCT02970630|DRUG|Tacrolimus|once a day
215075018|NCT02970630|DRUG|Everolimus|twice daily
214340732|NCT02177344|DRUG|Placebo|
214340733|NCT05710523|BEHAVIORAL|I-ACE training|"The I-ACE training encompasses a training on the non-pharmacological therapies' methodology and a training on awareness of body language which favors a passage from implicit to explicit knowledge. It allows the reading of the subjective relational experience of the care situation by the professional caregiver and a comparison of shared readings of the situation itself by the group of colleagues, and with the residents. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia.~Ten monthly supervisions, each lasting two hours, on theatrical exercises guided by an expert actor, with the help of a psychologist-psychotherapist who promotes understanding and awareness of self-reading in the relationship with the other."
214944776|NCT02132975|DEVICE|Biopsies using Apollo and UroStation®|Apollo : Motorised probe handler for prostate biopsies
214944777|NCT02132975|PROCEDURE|Biopsies using UroStation® (image fusion)|
214944778|NCT05992961|DIAGNOSTIC_TEST|Troponin I|"Troponin I were measured 6-12 hours postoperatively and on each of the succeeding four postoperative days for patients operated March 1, 2019, to February 28, 2021.~Patients with increased troponin I levels were assessed regarding symptoms of myocardial ischaemia including electrocardiography. Each patient was individually assessed, and relevant treatment and follow-up were planned in collaboration between surgeons, cardiologists, and anaesthesiologists."
214340734|NCT05710523|OTHER|Standard non-pharmacological therapies (NPT) training|"The standard NPT training encompasses a training on the non-pharmacological therapies' methodology. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia."
214340735|NCT02283528|DEVICE|Stryker Hybrid|Place Hybrid arch bars
214340736|NCT02283528|DEVICE|Erich|Control group is Erich arch bars
214340737|NCT03136068|DRUG|Digoxin|Trans-abdominal injection
214340738|NCT03136068|DRUG|Placebo|Trans-abdominal injection
214340739|NCT03189914|DRUG|RX-3117|RX-3117 will be administered orally in combination with Abraxane.
214944779|NCT01502137|DRUG|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
214944780|NCT01502137|DRUG|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
214340740|NCT03505658|BEHAVIORAL|Education and Behavior|Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
214340741|NCT01429545|DRUG|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
214944781|NCT02707588|DRUG|Pembrolizumab|"200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
214944782|NCT02707588|DRUG|Cetuximab|"Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
214944783|NCT02707588|RADIATION|Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
214944784|NCT00394433|DRUG|Bevacizumab|
214944785|NCT00394433|DRUG|Docetaxel|
214944786|NCT00394433|DRUG|Cisplatin|
214944787|NCT00394433|DRUG|Irinotecan|
214944788|NCT06620328|PROCEDURE|endoscopic ultrasonography-guided biliary drainage|"Skilled endosonographers performed EUS-BD with patients under conscious sedation by intravenous medication. All patients were given intravenous antibiotics prophylactically. A therapeutic curved linear array echoendoscope is positioned in the stomach with carbon dioxide insufflation. Standard 19G fine needles are used to puncture the dilated left intrahepatic bile duct or commo bile duct. Bile juice aspiration with 20ml syringe was performed to confirm intraductal puncture. After contrast medium injection, an insulated guidewire (0.025 inch VisiGlide2; Olympus Medical Systems, Tokyo, Japan) is advanced antegradely.~Dilation of the needle tract is initially performed with a diathermic sheath (6Fr Cyst-Gastro set; Endoflex, Voerde, Germany) or an ultra-tapered mechanical dilator (7Fr ES Dilator; Zeon Medical Co., Tokyo, Japan) according to randomization result. If needed, additional dilation can be attempted with dilating balloon. Finally, the dedicated plastic stent or partially cover"
214944789|NCT02651805|DEVICE|Mechanical Insufflation-Exsufflation|Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
214944790|NCT02651805|OTHER|Usual Care|The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
214944791|NCT05640284|DIAGNOSTIC_TEST|Nuclear Factor-Kappa B Ligand (RANKL) analysis|samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
214944792|NCT05640284|DIAGNOSTIC_TEST|Osteoprotegerin (OPG) analysis|samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
214944793|NCT05640284|DIAGNOSTIC_TEST|Tumor Necrosis Factor Alpha (TNF-α) analysis|samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
214944794|NCT05640284|DIAGNOSTIC_TEST|MicroRNA-223 analysis|samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
214944795|NCT05640284|DIAGNOSTIC_TEST|Microrna-27a analysis|samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
214944796|NCT05766904|BIOLOGICAL|4CMenB vaccine|Four-component MenB vaccine
214944797|NCT05766904|OTHER|Placebo|0.9% Sodium Chloride Inj. B.P.
214944798|NCT00411073|DRUG|Darapladib|
214944799|NCT06278727|DRUG|angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor|Guideline-directed Medical Therapy (GDMT) includes those 4 drugs, and only taking at least 3 drugs could be recognized as GDMT.
215075019|NCT01639573|DRUG|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
215075020|NCT04850391|OTHER|Mobile app|To compare changes induced by the movile app intervention among the three study groups
215075021|NCT03350958|DIETARY_SUPPLEMENT|Alginate Bread|100g Alginate Bread, toasted with 20g of butter.
214340742|NCT01429545|DRUG|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (\<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
214340743|NCT03047447|BEHAVIORAL|Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome|30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
214340744|NCT00432380|BIOLOGICAL|Rotarix™|oral doses
214340745|NCT00432380|BIOLOGICAL|Placebo|oral dose
215075022|NCT03350958|OTHER|Control Bread|100g standard White Bread (control), toasted with 20g of butter.
215075023|NCT05031091|OTHER|standardised exposure questionnaire|A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
215075024|NCT00812409|DIETARY_SUPPLEMENT|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
214944800|NCT06278727|OTHER|The development of the prediction model|The prediction model of FMR regression would be developed to recognize patients whose FMR would regress due to GDMT, and consequently help determine the treatment.
214944801|NCT01554176|DRUG|Filorexant|Filorexant, one 10 mg tablet, orally, once daily at bedtime
214944802|NCT01554176|DRUG|Placebo|Placebo, one tablet, orally, once daily at bedtime
214944803|NCT05330273|DRUG|Ganaplacide|Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
214944804|NCT05330273|COMBINATION_PRODUCT|Lumefantrine|Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration
214944805|NCT05330273|DRUG|Efavirenz|Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
214944806|NCT06903299|DRUG|Intra-articular Tranexamic acid application|Intra-articular Tranexamic acid application during THA and evaluation of postoperative blood losses, hemoglobin decline and associated blood transfusion, heterotopic ossification and other parameters.
214944807|NCT05520021|DRUG|Nifedipine|A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
214944808|NCT05520021|DRUG|Magnesium sulfate|A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
214944809|NCT06906315|DRUG|Dexamethasone 4 mg|Participants in this group received a single 4 mg oral dose of dexamethasone 1 hour before undergoing endodontic treatment. No additional preoperative analgesics were administered. Standard endodontic procedures, including local anesthesia, were performed. Post-treatment, no routine analgesic medication was provided unless additional pain relief was required. Pain intensity was assessed at 4, 6, 8, 12, and 24 hours using the Visual Analog Scale (VAS) to evaluate the efficacy of preoperative dexamethasone in controlling postoperative pain and inflammation.
214944810|NCT06906315|DRUG|Ibuprofen group|Participants in this group received no preoperative medication but were prescribed 400 mg of ibuprofen every 4 hours postoperatively for pain management. The same standard endodontic procedures were performed. Pain levels were recorded at 4, 6, 8, 12, and 24 hours using the VAS scale to compare the effectiveness of postoperative ibuprofen with preoperative dexamethasone.
214944811|NCT04777669|OTHER|Noise Reduction|In within subject design, listeners will have background noise removed by a noise reduction algorithm
214944812|NCT03589118|OTHER|Qi Gong sessions|13 sessions of Qi Gong in a 9 weeks period
215075025|NCT00812409|OTHER|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
215075026|NCT06343350|DEVICE|OPTDR01 software application|Retinal images will be sent to the OPTDR01 software application for mtmDR and vtDR detection
215075027|NCT03501004|DEVICE|Sterile acupuncture needles for single use|Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.
215075028|NCT03276026|DRUG|Sugammadex|Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
215075029|NCT03276026|DRUG|Neostigmine|Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
214340746|NCT00483522|BEHAVIORAL|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
214944813|NCT01085136|DRUG|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
214944814|NCT01085136|DRUG|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
214944815|NCT01079754|DRUG|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
214944816|NCT01079754|DRUG|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
214944817|NCT00503451|DRUG|LBH589|
214944818|NCT01090154|DRUG|Cimzia|Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
214944819|NCT03094676|OTHER|Massage|Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)
214944820|NCT03094676|OTHER|Exercise|A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.
214944821|NCT03328494|DRUG|BOS172722|Oral capsules
214944822|NCT03328494|DRUG|Paclitaxel|IV infusion
214944823|NCT00083720|BIOLOGICAL|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
214944824|NCT06223321|DIAGNOSTIC_TEST|Computed Tomography in congenital heart diseases|"● CT examination will be done by~* 160 MDCT Toshiba Machine or 128 MDCT GE machine or 160 MDCT Philips Machine:~* We used the following parameters during cardiac CT scanning:~  * Pitch of 1.3, helical thickness of 0.5 mm and coverage of 32 cm.~ * The radiation dose set to 80-100 kvp.~ * Tube current from 10 to 40 mA/kg.~ * The gantry rotation speed at 0.35-.4 sec.~ * ECG gated Retrospective With MA modulation.~ * Wide FOV.~* A scout will be taken and dual-phase injection conducted using non ionized contrast material. The total contrast volume is 1.5-3 ml/kg.~* Scanning begins when contrast filled the LV by bolus tracking.~* All images were transferred to workstation multiplanar reformation (MPR), maximum (MIP) and minimum (MinIP) intensity projections and volume rendering images will be performed for reporting."
214944825|NCT05497336|DRUG|IBI351|IBI351 is administered orally
214944826|NCT05497336|DRUG|Cetuximab|Cetuximab is administered intravenously
214944827|NCT02678000|DRUG|LHW090|LHW090 is orally administered
214944828|NCT02678000|DRUG|Placebo|Matching placebo of LHW090
214944829|NCT02535351|DRUG|sunitinib or pazopanib|First-line treatment
214944830|NCT02535351|PROCEDURE|Cytoreductive nephrectomy|Cytoreductive nephrectomy and first-line treatment
214340747|NCT00726531|BEHAVIORAL|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
214944831|NCT04038177|BEHAVIORAL|Superset strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.
214944832|NCT04038177|BEHAVIORAL|Traditional strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
214944833|NCT04447677|OTHER||
214944834|NCT04303754|OTHER|Diabetes-Specific Formula|Other: Diabetes Specific Formula
214944835|NCT04303754|OTHER|Bread with Spread|Other: White Bread with Spread
214944836|NCT04303754|OTHER|Rice Porridge|Other: Rice Porridge
214944837|NCT01498705|OTHER|Procalcitonin level|PCT level upon admission and on days 1, 3, and 5 following baseline level
214944838|NCT02334176|PROCEDURE|Ultrasound guided axillary plexus block with 1 injection|The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
214944839|NCT02334176|PROCEDURE|Ultrasound guided axillary plexus block with 2 injections|The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
214944840|NCT02334176|DRUG|lidocaine 1.5% with epinephrine 5µg/ml|35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
214944841|NCT02811497|DRUG|Azacitidine|
214944842|NCT02811497|DRUG|Durvalumab|
214944843|NCT00930631|DRUG|[3H] BMS747158|Single bolus intravenous injection of \[3H\] BMS747158
214944844|NCT00441818|DRUG|TNX-650|
215075030|NCT03215303|DEVICE|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
214944845|NCT06911918|OTHER|time restricted eating with caloric restriction|will be asked to reduce their energy intake by 550 each day. Total energy expenditure will be calculated using the Bioelectrical impedance (BIA); Inbody 120 and multiplied by the physical activity factor and reduced by 550 kilo calories for each participant. The acceptable macronutrient distribution range (AMDR) will be 45-60% carbohydrates, 15-25% protein, and 20-30% fat of the total caloric value and fasted from 18:00 to 8:00 daily (a 14-h fast) in the 12-weeks intervention
214944846|NCT06911918|OTHER|time restricted eating without caloric restriction|will be asked to maintain their normal diet to the acceptable normal distribution ranges and fast from 8:00 to 18:00. They do not need to restrict caloric intake during the feeding window
214944847|NCT06911918|OTHER|Caloric restriction without Time restricted eating|will be asked to reduce their energy intake by 550 each day. Total energy expenditure will be calculated using the Bioelectrical impedance (BIA); Inbody 120 and multiplied by the physical activity factor and reduced by 550 kilo calories for each participant. The acceptable macronutrient distribution range (AMDR) will be 45-60% carbohydrates, 15-25% protein, and 20-30% fat of the total caloric value
214944848|NCT06911918|OTHER|No time restricted eating - Normal diet|will be asked to maintain their normal diet as the second intervention arm without time restricted eating throughout the trial
214944849|NCT06912113|BEHAVIORAL|Motivational interviewing|What distinguishes this intervention from other clinical applications is that in this study, the clinical effectiveness of motivational interviewing was examined by using a smoking cessation intention scale before and after the intervention.
214944850|NCT05602129|DRUG|HSK36273|HSK36273
214944851|NCT05602129|DRUG|Heparin sodium|Heparin sodium
214944852|NCT06912425|BEHAVIORAL|Health prevention.|Unlike other projects, this study focuses on an underexplored area in exercise and kidney disease research. Typically, exercise recommendations are directed toward individuals undergoing hemodialysis or peritoneal dialysis. However, in the early stages of the disease, when the kidneys begin to show alterations, there is no established safe training protocol as a preventive measure. This clinical trial will fill that gap by providing references for an exercise program specifically designed for individuals in the early stages of kidney disease. The main objective will be to compare two different exercise strategies to determine potential benefits for renal health.
214944853|NCT06912230|OTHER|Normoxia|Participants will undergo a 6-hour passive exposure to normoxia in a climate-controlled environmental chamber maintained at 22°C with 30% relative humidity. They will remain in a fasted state throughout the exposure period.
214944854|NCT06912230|OTHER|Hypoxia (simulated altitude of 5000 meters above sea-level)|Participants will undergo a 6-hour passive exposure to a simulated altitude of 5000 meters above sea-level in a climate-controlled environmental chamber maintained at 22°C with 30% relative humidity. They will remain in a fasted state throughout the exposure period.
214944855|NCT06910163|DIAGNOSTIC_TEST|Diagnostic standard of care|Participants will receive the diagnostic standard of care: standard laboratory workup, non-contrast brain CT, brain CTA, brain CTP, or brain MRI.
214944856|NCT06910163|DIAGNOSTIC_TEST|LVOne Test|Participants will receive the LVOne test, which will measure D-dimer and Glial Fibrillary Acidic Protein (GFAP) levels to diagnose acute stroke.
214944857|NCT06910072|DRUG|paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab|paclitaxel polymeric micelles 300mg/m2, d1 carboplatin AUC=5, d1 iparomilimab and tuvonralimab 5mg/kg, d1 Every 3 weeks (Q3W) is a cycle, a total of 6 cycles.
214944858|NCT06911281|COMBINATION_PRODUCT|Mesenchymal Stem Cells；755nm picosecond laser treatment|Stem Cell Treatment Group 1 received intravenous infusion of MSCs followed by multi-point injection into the melasma area, combined with 755nm picosecond laser treatment. Stem Cell Treatment Group 2 received multi-point injection of MSCs into the melasma area, combined with 755nm picosecond laser treatment. The Control Group only received 755nm picosecond laser treatment.
214944859|NCT06911411|OTHER|Prospective observational cohort study.|"No systematic approach exists for symptom assessment, management, and reporting in delivered basic palliative care within the Danish healthcare system, implying considerable variation in hospital-based palliative care. The PALMA study consists of two superior phases divided in a development and an implementation stage that anchors basic palliative assessment and management within existing geriatric workflows and cross-sectoral collaborative care.~The PALMA cohort will test the applicability of the EORTC-C15-PAL questionnaire along with measures of clinical frailty and sociodemographic risk factors.~The development phase will enable the development of a clinical algorithm for elderly patients' need for cross-sectoral palliation care planning."
215075031|NCT05093595|DEVICE|SFC|The lubricated SFC passed nasally into the oropharynx under the visual guidance of visual laryngoscope to ensure that the cuff had passed through the posterior choanae and reached the oropharynx. The guide wire is removed and the balloon inflated with 5 ml normal saline. The catheter is then pulled slightly until the balloon is fixed and concealed by the soft palate . The ETT is anchored to the SFC with a cable tie .
214340748|NCT00726531|BEHAVIORAL|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
214340749|NCT00726531|OTHER|Treatment As Usual|Treatment as usual by the general practitioner
214340750|NCT06197139|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.
214944860|NCT06911411|OTHER|A prospective observational cohort study|Observational design
214944861|NCT04470284|OTHER|Mobile Application|SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.
214944862|NCT04470284|OTHER|Standard SMBP|Standard treatment (SMBP-alone)
214944863|NCT04104113|OTHER|Modified Xiang Bei Yang Rong Tang|Modified Xiang Bei Yang Rong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
214944864|NCT04104113|OTHER|Placebo|Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
214340751|NCT00734305|DRUG|MM-121|Dose escalation Frequency - once weekly
214340752|NCT00512759|DRUG|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
214944865|NCT00107354|BIOLOGICAL|aldesleukin|
215075032|NCT01542697|DRUG|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
215075033|NCT01595230|PROCEDURE|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
214340753|NCT04790253|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer.
214340754|NCT06127420|OTHER|coronary physiological indices|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance
214340755|NCT01071395|DRUG|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
214340756|NCT01071395|DRUG|Placebo|Sugar pill given 3 times daily
214944866|NCT00107354|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214944867|NCT00107354|BIOLOGICAL|therapeutic autologous lymphocytes|
214944868|NCT00107354|DRUG|cytarabine|
214944869|NCT00107354|DRUG|etoposide|
214944870|NCT00107354|DRUG|mitoxantrone hydrochloride|
214944871|NCT00107354|PROCEDURE|allogeneic bone marrow transplantation|
214944872|NCT00107354|PROCEDURE|peripheral blood stem cell transplantation|
214944873|NCT05865847|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
214944874|NCT02696954|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
214944875|NCT02696954|DRUG|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
214944876|NCT02696954|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
214944877|NCT02696954|DRUG|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
214944878|NCT02696954|DRUG|Primaquine|Primaquine on Day 0 Washout period: more than 1 week
214944879|NCT02696954|DRUG|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
214944880|NCT02696954|DRUG|Artemether-lumefantrine + Amodiaquine + Primaquine|Artemether-lumefantrine Day 0, 1 and 2 + Amodiaquine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
214944881|NCT02696954|DRUG|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0
214944882|NCT02652598|DRUG|Tolcapone|
214944883|NCT05075044|BIOLOGICAL|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
214944884|NCT01725360|DRUG|montelukast|Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
214944885|NCT00004982|DRUG|Combination Iron Chelation Therapy|
214340757|NCT03019952|BEHAVIORAL|Care Coordination Visit|This is a longitudinal study. Adolescents or young adults with autism will participate in this study. Participants will be required to complete a baseline of assessment measures at enrollment and then monthly assessments (described in the study procedures below) during the first (approximately) 10-15 minutes of each visit with the t-CARE coordinator. The remainder of the visit will focus on care coordination and clinical treatment goals.
214340758|NCT01539291|DRUG|Idelalisib|Idelalisib tablet(s) administered orally twice daily
214340759|NCT02239510|DRUG|Senna|1 capsule (50 mg) Senna daily for 12 weeks
214340760|NCT02239510|DRUG|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
214340761|NCT04987918|DIAGNOSTIC_TEST|Applied Biosystems TaqPath COVID- 19 Combo Kit|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
214340762|NCT02398097|BIOLOGICAL|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
214340763|NCT02398097|BIOLOGICAL|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
214340764|NCT02398097|BIOLOGICAL|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
214340765|NCT06398353|OTHER|Real acupuncture|Real acupuncture twice a week for two weeks
214340766|NCT06398353|OTHER|Sham acupuncture|Sham acupuncture twice a week for two weeks
214340767|NCT03773744|DRUG|Ad-MAGEA3|Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
214340768|NCT03773744|DRUG|MG1-MAGEA3|MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
214340769|NCT03773744|DRUG|Pembrolizumab|monoclonal antibody; checkpoint inhibitor of PD1
214340770|NCT03773744|DRUG|Cyclophosphamide|low-dose chemotherapy
214340771|NCT06326801|OTHER|Resistive Diaphragmatic breathing exercise|"1. Resistive Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
214340772|NCT06326801|OTHER|Diaphragmatic breathing exercise|"1. Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
214340773|NCT06326801|OTHER|Conventional stroke physiotherapy|Conventional stroke physiotherapy
214340774|NCT03778736|OTHER|Cumulase denudation|Testing the effect of cumulase for women with poor oocyte yield due to poor ovarian reserve
214944886|NCT02178527|OTHER|Foot and ankle exercises, foot orthoses, footwear provision|Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.
214944887|NCT02178527|OTHER|Usual Care|Usual general podiatry care provded by UK National Health Service
214944888|NCT03903367|DRUG|Fentanyl Citrate|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
214944889|NCT02978885|RADIATION|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT CT
214944890|NCT02978885|DRUG|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
214944891|NCT02978885|PROCEDURE|Whipple procedure|"A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care."
214944892|NCT02978885|PROCEDURE|Major surgery|Additional surgical procedure(s) that is clinically indicated. Standard of care.
214944893|NCT03121573|DRUG|Duloxetine|duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
214944894|NCT06474650|DRUG|LPM3770164 sustained release tablet|Single-dose of 30 mg of LPM3770164 sustained release tablet
214944895|NCT05807438|OTHER|Self myofascial Release|Myofascial release participants on their own will roll the foam roller in each area for two minutes.
214944896|NCT05807438|OTHER|myofascial release|Myofascial release will be applied to the participants by the physiotherapist.
214944897|NCT03286231|DIAGNOSTIC_TEST|CT imaging|Contrast-enhanced CT imaging of the pelvis in prone and jackknife positions
214944898|NCT00465543|OTHER|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
214944899|NCT00465543|OTHER|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
214944900|NCT05286164|DRUG|Eltrombopag|Eltrombopag 150 mg QD for 8 weeks
214944901|NCT01764659|OTHER|Contrast-enhanced 4D computed tomography|All enrolled patients each underwent three CT scans: a 4DCT immediately following a contrast-enhanced 3DCT and an individually optimized contrast-enhanced 4DCT.
214944902|NCT03279354|BEHAVIORAL|Family Move app intervention|All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
214944903|NCT03279354|BEHAVIORAL|"HK FitNuts app intervention"|"The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics \& Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week."
214944904|NCT05079776|OTHER|Physical length measurement|Physical length will be measured and images will be collected for AI to estimate the length
214944905|NCT01524068|DRUG|Standard Steroid Treatment|One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
214944906|NCT01524068|DRUG|The Standard Steroid Treatment, Plasma Exchange and rituximab|The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
214944907|NCT02440854|DRUG|afatinib|Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib.
214944908|NCT00699231|BIOLOGICAL|HBV-MPL vaccine 208129|IM injection
214944909|NCT00699231|BIOLOGICAL|Engerix™-B|IM injection
214944910|NCT02897180|BIOLOGICAL|Nyaditum resae(R)|Capsules containing Nyaditum resae(R)
214944911|NCT02897180|BIOLOGICAL|Placebo|Capsules containin Placebo
214944912|NCT05415371|BEHAVIORAL|Standard Care + Financial Incentives|Financial incentive participants will receive standard care and receive incentives for completing counseling calls and for abstinence.
214944913|NCT05415371|OTHER|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
214944914|NCT03919591|OTHER|Challenge virus RSV-A Memphis 37b|Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.
214944915|NCT03958942|OTHER|Ultrasound quadratus lumborum block with bupivacaine 25%|echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle
214944916|NCT03958942|OTHER|lumbar epideural block with bupivacaine 25%|lumbar epidural will be performed for patients in group II using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces will be chosen for the injection. The epidural space identified by the loss of resistance technique.
214944917|NCT06912334|DEVICE|tVNS|tVNS L is a battery-driven electrical stimulator connected to an ear electrode which is positioned over the skin of the cymba conchae. Thus, auricular vagal stimulation will be applied using the typical ear electrodes of the tVNS® L device. tVNS will be applied over the left branch for safety reasons. For sham auricular tVNS, the anodal electrode will be placed over the center of the left ear lobe. The cathode will be placed over the antitragus. This method and these stimulation parameters have been previously used for reliable blinding in other clinical studies. Series of electrical pulses with 250 μs pulse width, 25 Hz frequency, and 28 s inter-burst interval (32 sec on/28 sec off duty cycle) will be applied in each intervention session. Auricular tVNS will be applied at 1mA - 5mA intensity for 30 min per session (1 session per day, 7 consecutive days a week, 14 sessions in total)
214944918|NCT05758272|BEHAVIORAL|mobile phone-based simple physical exercise reminder to help quit smoking|Regular messages supporting participants in practicing simple physical exercises and assist in managing cravings will be sent to participants via IM apps and scheduled in a tapering manner for 3 months (twice per week in the first month to once per week in the third month). Images and videos explaining and demonstrating the simple physical exercises will be sent to the participants via IM apps, which serves as a reminder and supporting materials for participants. The benefits of exercise in SC will be explained. The investigator will also encourage the practice of moderate/ vigorous exercises to further improve the physical activity and well-being of the participants. Various delivery formats of messages will be considered to attract participants' interest such as text, emojis, voice, image, animation, and video. The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises and c) resistance exercises.
214340775|NCT03850119|PROCEDURE|Nanofat injection|Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.
214340776|NCT00206648|DRUG|Betaferon/Betaseron|Betaseron 250 µg SC every other day
214340777|NCT00206648|DRUG|Betaferon/Betaseron|Avonex 30 µg IM once per week
214340778|NCT04777565|OTHER|Robotic surgery|Cochlear implant surgery with HEARO procedure
214340779|NCT01895504|DEVICE|ColoAssist|Screening colonoscopy with the test instrument
214340780|NCT01895504|DEVICE|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
214340781|NCT02959060|DRUG|BMS-986177|Single dose of BMS-986177 and multiple doses of Rifampin
214340782|NCT02959060|DRUG|Rifampin|Single dose of BMS-986177 and multiple doses of Rifampin
214340783|NCT03257982|PROCEDURE|BCI-FES hand therapy|BCI-FES rehabilitation therapy of the upper limb
214340784|NCT01244048|DIETARY_SUPPLEMENT|n3 long chain polyunsaturated fatty acids|Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
214340785|NCT06373094|DRUG|Donepezil Dihydroxynaphthalate for Injection|HHT201 will be injected into the muscle of gluteus.
214677362|NCT03559985|OTHER|Placebo comparator|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
214944919|NCT05758272|BEHAVIORAL|regular text-based intervention|The control group will receive 6 regular messages via IM at twice per month within 3 months. These messages cover simple cessation advice and reminders for telephone follow-ups.
214340786|NCT04372966|DEVICE|Total hip arthroplasty|Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
214340787|NCT01194115|DRUG|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
214340788|NCT01194115|DRUG|placebo|placebo representing standard of care
214340789|NCT00949247|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
214340790|NCT00949247|BIOLOGICAL|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
214340791|NCT00949247|DRUG|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
214340792|NCT00949247|DRUG|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
214340793|NCT00949247|OTHER|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
214340794|NCT06257147|BEHAVIORAL|multifaceted antibiotic stewardship intervention|Group 3 wards will receive a multifaceted antibiotic stewardship intervention. Physician education will be provided as in Group 1. All consecutive patients fulfilling inclusion and exclusion criteria for study eligibility will be assessed by an Antibiotic Stewardship team. A trained nurse will first assess the patients for clinical and host criteria to determine eligibility for short-course antibiotic therapy. The antibiotic susceptibility test results and the prescribed antibiotics treatment will be reviewed. An Infectious Diseases physician will subsequently make written recommendations for the duration and choice of antibiotic therapy, and provide an appointment within 2 weeks after hospital discharge to review patients' clinical condition when indicated.
214340795|NCT00466193|DRUG|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
214340796|NCT00466193|DRUG|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
214340797|NCT02672904|DEVICE|CO2 laser|surgical removal of carcinoma from the vocal cords with CO2 laser
214340798|NCT02672904|DEVICE|KTP laser|surgical removal of carcinoma from the vocal cords with KTP laser
214677363|NCT01772342|OTHER|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
214677364|NCT01772342|OTHER|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
214677365|NCT03083158|DRUG|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
214944920|NCT01652625|DRUG|Yunnan Baiyao toothpaste|The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
214944921|NCT01652625|DRUG|Placebo toothpaste|One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
214944922|NCT01463358|DEVICE|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
214944923|NCT01463358|DEVICE|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
214340799|NCT05881044|OTHER|Psychiatric interview|"1. Psychiatric interview which include personal identification, present history, past history and family history~2. Complete physical and Neurological Examination.~3. Mini Neuropsychiatric Interview scale. (MINI): to diagnosis psychiatric disorders~4. Symptom checklist 90(SCL 90)~5. Quality of life questionnaire.~6. Hamilton Depression scale.~7. Hamilton Anxiety scale.~8. Socioeconomic scale (A.El.Gilany,A.El.Wehady,and M.EL.Wasify)"
214944924|NCT06731751|OTHER|Management of spontaneous intracranial haemorrhage|Admission to hospital for spontaneous intracranial haemorrhage management. This includes admission for observation, conservative or interventional (surgical or endovascular) management to both ward-based and critical care settings.
214944925|NCT01200277|PROCEDURE|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
214944926|NCT01200277|PROCEDURE|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
214944927|NCT05080361|DRUG|BRAF inhibitor|Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
214944928|NCT04655534|OTHER|Inspiratory Muscle Warm-up (IMW)|The IMW protocol applied before each inspiratory muscle training (IMT) session by using a threshold inspiratory muscle trainer. The IMW protocol consists of 2 sets of 30 breaths in 40% of the maximal inspiratory pressure (MIP), with 1 min rest between sets. The intensity of MIP adjusted by two weekly MIP measurements.
214944929|NCT04655534|OTHER|Inspiratory Muscle Training (IMT)|The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.
214944930|NCT04655534|OTHER|Respiratory exercises and aerobic exercise program|Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.
214944931|NCT04103034|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
214944932|NCT04103034|DRUG|Desmopressin|Sterile solution for injection
214944933|NCT04103034|DRUG|Placebo|Sterile saline for injection
214944934|NCT00316914|DRUG|calcium gluconate|Given IV
214944935|NCT00316914|DRUG|magnesium sulfate|Given IV
214944936|NCT00316914|OTHER|placebo|Given IV
214340800|NCT01998373|BEHAVIORAL|training leaflet and oral training|The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
214340801|NCT00709163|DRUG|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
214340802|NCT00709163|DRUG|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
214340803|NCT00856401|DRUG|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
214340804|NCT04997174|DRUG|Celecoxib|Patients in ERAS group received celecoxib
214677366|NCT04742257|DEVICE|MyoRegulator® device|Trans-spinal DCS paired with peripheral DCS
214340805|NCT04073043|BEHAVIORAL|Telephone Coaching|Access to Telephone Coaching for a period of 12 weeks
214340806|NCT01054729|DRUG|Sofosbuvir|Sofosbuvir tablet(s) administered orally once daily
214340807|NCT01054729|DRUG|Placebo|Placebo to match sofosbuvir administered orally once daily
214677367|NCT01029288|OTHER|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
214677368|NCT01029288|OTHER|Statin Choice Decision Aid|Statin Choice Cards
214944937|NCT01589679|OTHER|standard of care|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
214944938|NCT01589679|DEVICE|Metarsal Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
214944939|NCT02687295|DIETARY_SUPPLEMENT|Thylakoids|
214944940|NCT02687295|OTHER|Control|
215075034|NCT03828903|DEVICE|Cryoprobe|"* The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~* The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~* The frozen tissue is going to be extracted by gently pulling of the probe.~* Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~* The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~* The biopsy sample will be released from the probe by thawing in the saline.~* The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding."
215075035|NCT04049266|DRUG|KSI-301|Intravitreal Injection
215075036|NCT04049266|DRUG|Aflibercept|Intravitreal Injection
215075037|NCT04049266|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
214677369|NCT01029288|OTHER|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
214677370|NCT01029288|OTHER|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
214340808|NCT01054729|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
214944941|NCT04780633|BEHAVIORAL|Precede-Proceed based Training Program on Genital Hygiene Behaviors|A Training Program for Genital Hygiene Behaviors prepared in line with the Precede-Proceed model was presented to the women in the experimental group. The trainings started one week after the pre-test data were collected and were conducted in a total of 5 sessions, each lasting an average of 40 minutes, once a week. At the end of the five-week training, a post-test was applied. In order to determine the behavior changes of the women in the experimental group, a follow-up test was applied 4 weeks after the training ended. At the end of the training, women were given a training booklet prepared by the researcher.
214944942|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in NSCLC|Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
214944943|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in HNSCC|Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
214944944|NCT04105010|DRUG|golidocitinib|golidocitinib will be administered orally as capsules. golidocitinib treatment will be continued until disease progression or intolerant adverse reactions
214944945|NCT04735471|GENETIC|ADI-001|Anti-CD20 CAR-T
214340809|NCT01054729|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
214340810|NCT03876067|DRUG|Ozone|"Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:~50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).~At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution"
214677371|NCT05732155|DRUG|methylenedioxymethamphetamine|The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of MDMA HCl, in participants with PTSD and moral injury, in individual and group treatment settings
214677372|NCT03919890|DRUG|ONO-7684|Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
214677373|NCT03919890|DRUG|ONO-7684 Placebo|Placebo comparator
214944946|NCT04735471|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
214944947|NCT04735471|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
214944948|NCT05900089|DRUG|SHR0302|SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
215075038|NCT03315897|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
215075039|NCT03315897|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
215075040|NCT01703208|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
215075041|NCT01703208|DRUG|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
215075042|NCT00948233|BEHAVIORAL|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
215075043|NCT00948233|BEHAVIORAL|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
214340811|NCT03876067|DRUG|Cardioplegic Solutions|in which in which only cold blood cardioplegia
214944949|NCT04643418|DRUG|MPB-1734|Administered once daily in a 21-day cycle
214944950|NCT04692766|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
214944951|NCT04692766|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL in a polypropylene ampoule, 10 ampoules per labeled package
214340812|NCT01258114|OTHER|SPA treatment (ST)|"Drug: spa treatment soon after randomization :~Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;~* nutritional counseling (french nutritional recommendations booklet) ;~* caloric restriction and physical training on demand (non mandatory)."
214944952|NCT05878821|DEVICE|Shockwave|Shockwave therapy session once a week for month 1000shock per session
214340813|NCT01258114|OTHER|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
214340814|NCT03358225|PROCEDURE|anterior cervical discectomy and fusion|The patients undergoing anterior cervical discectomy and fusion sugery
214340815|NCT03358225|PROCEDURE|cervical artificial disc replacement|The patients undergoing cervical artificial disc replacement surgery
214340816|NCT03358225|PROCEDURE|hybrid surgery|The patients undergoing 1-level C-ADR plus 1-level ACDF surgery
214677374|NCT04160156|DEVICE|Long term sensor|Observational study including subjects using long term sensor according to local guidelines and patients preferences
214944953|NCT03616444|DRUG|Shenbai Granules|In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.
214944954|NCT00880386|DRUG|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
214340817|NCT03464227|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
214340818|NCT03464227|OTHER|Placebo|"* Pharmaceutical form: intravenous infusion~* Route of administration: intravenous use"
214677375|NCT03005847|DIETARY_SUPPLEMENT|fermented papaya preparation|dietary supplementation with fermented papaya preparation
214944955|NCT01534364|OTHER|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
214944956|NCT05167175|DRUG|Olaparib tablet|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily.
214944957|NCT05167175|DRUG|Abiraterone acetate|Qingkeshu (Abiraterone acetate tablets) 1000 mg should be taken orally once daily.
214944958|NCT05167175|DRUG|Prednisone tablet|Prednisone Tablets should be taken 5 mg once daily.
214944959|NCT00641875|PROCEDURE|Nocturnal Hemodialysis|
214340819|NCT03753438|PROCEDURE|Intragstric Ballooning|Intragstric Ballooning will be put.
214340820|NCT05785780|BEHAVIORAL|Targeted CRC Screening Toolkit|Strategies in the toolkit include but are not limited to: identification of patient and practice-level barriers, routine tailored patient reminders, provider reminders, \& clinic staff feedback.
214340821|NCT01725646|DRUG|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
214340822|NCT01725646|DRUG|Placebo|Subjects in placebo group will take this drug
214340823|NCT04074642|PROCEDURE|Neurosurgery|adenoma removal
214340824|NCT01347190|BIOLOGICAL|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
214340825|NCT01347190|BIOLOGICAL|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
214340826|NCT05873114|DIAGNOSTIC_TEST|Mobilization|Effects of Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
214340827|NCT05873114|DIAGNOSTIC_TEST|Muscle Energy Technique (MET)|Effects of Muscle Energy Technique (MET) in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
214340828|NCT02738567|PROCEDURE|patients undergoing surgery or medical procedure|
214677376|NCT04922892|PROCEDURE|Parathyroidectomy|Total Parathyroidectomy With Autotransplantation or Total Parathyroidectomy Alone
214677377|NCT01937130|DRUG|IDN-6556|
214677378|NCT01937130|OTHER|Placebo|
214944960|NCT01741506|DRUG|Dalteparin (Fragmin®)|
214944961|NCT02737228|DRUG|CG200745 PPA|CG200745 PPA IV every week three times per cycle (4 weeks)
214944962|NCT02737228|DRUG|Gemcitabine|1000 mg/m\^2 intravenously every week three times per cycle (4 weeks)
214944963|NCT02737228|DRUG|Erlotinib|100 mg per oral daily per cycle (4 weeks)
214944964|NCT03386617|DRUG|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
214944965|NCT06025253|DEVICE|Negative Pressure Wound Therapy|Application of negative-pressure wound therapy (NPWT) post major lower extremity amputation
214944966|NCT06025253|DEVICE|Standard Wound Dressing|Application of standard wound dressing post major lower extremity amputation
215075044|NCT00948233|BEHAVIORAL|Surveys|Computer surveys taken at 4 points throughout the study.
215075045|NCT04676841|DEVICE|Conventional ventilation + instrumental tables with integrated laminar airflow|Surgical instruments protected from contamination by local laminar airflow
215075046|NCT04676841|DEVICE|Conventional ventilation + standard instrumental tables|Control
215075047|NCT04676841|DEVICE|Laminar airflow ventilation + standard instrumental tables|Control
215075048|NCT00441428|DRUG|solifenacin|
215075049|NCT03752190|DRUG|Cosyntropin|intramuscular and intravenous administration
214944967|NCT04234269|OTHER|Assessment|Evaluation forms will be applied to the patients who meet the inclusion criteria by face to face interview method.The sociodemographic information of the patients and the time taken to answer the questions in the questionnaires will vary according to each patient, but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1 week intervals.
214677379|NCT01823627|PROCEDURE|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
214677380|NCT05017285|PROCEDURE|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum
214340829|NCT03866616|BEHAVIORAL|Brain Builders Parenting Class|Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting
214944968|NCT04258969|BEHAVIORAL|Pedaling|Participants will pedaling at a low-moderate intensity using a stationary pedal ergometer concurrent to their chemotherapy (FOLFOX or FOLFIRI) infusion. Participants will cycle for 30 min within the first 2 hours of their infusion.
215075050|NCT05215223|DEVICE|whole body vibration|the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session
214677381|NCT05017285|PROCEDURE|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
214340830|NCT03866616|BEHAVIORAL|Control (Usual care)|"This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
214340831|NCT01375049|DRUG|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
214340832|NCT02066857|DEVICE|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
214340833|NCT02066857|DEVICE|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
214340834|NCT00130767|DRUG|finasteride|
214340835|NCT04840758|RADIATION|Stereotactic Ablation Radiotherapy|Stereotactic ablation radiotherapy was performed sequentially on the primary and secondary lesions. 50Gy/4F or 70Gy/10F were used according to the specific location of the tumor。
214340836|NCT04840758|DRUG|Sintilimab|Sintilimab was started 2 weeks after the end of radiotherapy. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles
214944969|NCT06731114|PROCEDURE|Suboccipital muscle release|"Suboccipital muscle release.6 consecutive sessions for 2 weeks~• Frequency:( 3mins 3 reps) 9 mins .12 sessions in total"
214944970|NCT06731114|PROCEDURE|Conventional physical therapy|TENS and hot pack for 10 mins 6 days a week for consecutive 2 weeks
214340837|NCT01175382|BEHAVIORAL|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
214340838|NCT01175382|DRUG|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
214677382|NCT06126705|DRUG|Radiation: 18F-AlF-FAPi-04|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
214677383|NCT06126705|DRUG|Radiation: 18F-FDG|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
214677384|NCT05807022|PROCEDURE|Percutaneous or transbronchial argon-helium cryoablation|The participants would undergo Percutaneous or transbronchial argon-helium cryoablation.
214677385|NCT00409422|BEHAVIORAL|weight management program|
214677386|NCT03766334|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet(20g, thrice-daily)
214944971|NCT06731114|PROCEDURE|Sternocleidomastoid release|Frequency: 5 mins of SCM release and 9 mins (3 mins 3 reps )of suboccipital release. 12 sessions in total.
214944972|NCT01103947|DEVICE|EcoAnaesthesia facemask first|The trial facemask will be used before the standard one.
214944973|NCT01103947|DEVICE|Portex Adult (Standard) facemask first|The standard facemask will be applied before the trial device.
215075051|NCT05215223|DEVICE|Treadmill|Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
215075052|NCT04614870|DIAGNOSTIC_TEST|DETEC® Esterase|DETEC® Esterase is a disposable diagnostic device that is used to indicate the presence or absence of infection based on the presence or absence of the evaluated level of leukocyte esterase by testing the freshly recovered wound dressing which are soaked with wound exudate.
215075053|NCT02131103|OTHER|Percutaneous coronary intervention|"All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
214677387|NCT05184296|PROCEDURE|Extracorporeal Membrane Oxygenation (ECMO)|All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
214677388|NCT02563288|DRUG|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
214677389|NCT02563288|DRUG|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
214677390|NCT02030561|DRUG|Trastuzumab + NK cells|
214944974|NCT01103947|DEVICE|Portex Adult (Standard) facemask second|The standard facemask will be applied after the trial device
214944975|NCT01103947|DEVICE|EcoAnesthesia facemask second|The trial facemask will be used after the standard one.
214340839|NCT01175382|OTHER|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
214340840|NCT03616418|DRUG|antiplatelet drugs;statins;antihypertensive drugs|
214340841|NCT02481687|OTHER|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
214340842|NCT02869217|DRUG|Cyclophosphamide|
214944976|NCT00237250|DRUG|vildagliptin|
214340843|NCT02869217|BIOLOGICAL|TBI-1301|
214340844|NCT02869217|DRUG|Fludarabine|
214340845|NCT00774787|DRUG|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
214944977|NCT05873335|COMBINATION_PRODUCT|Mixtures of nitrogen, air, and carbon dioxide|Hypoxia was induced to different and stable levels of oxyhemoglobin saturation (between 70-100%) by having subjects breathe mixtures of nitrogen, air, and carbon dioxide controlled by the study physician by adjusting gas flows with valves according to breath-by-breath estimates of oxygen saturation calculated from end-tidal PO2 and PCO2 displayed on a screen using LabVIEW 2015
214944978|NCT04603794|DRUG|0.5% Povidone Iodine|Commercially Available Mouth Rinses and Over the Counter Standard Formulations
214944979|NCT04603794|DRUG|0.12% Chlorhexidine Gluconate Mouth Rinse|Commercially Available Mouth Rinses
214944980|NCT04603794|DRUG|1% Hydrogen Peroxide|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
214340846|NCT05403047|DRUG|Fumarate, Tenofovir Disoproxil|all participants receive the intervention
214944981|NCT04603794|DRUG|0.9% Normal Saline|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
214944982|NCT00947024|DRUG|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
214944983|NCT00947024|DRUG|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
214944984|NCT00947024|DRUG|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
214944985|NCT03541109|DRUG|Polypill|fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)
215075054|NCT02725814|OTHER|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
215075055|NCT01263678|BEHAVIORAL|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
215075056|NCT01263678|OTHER|Usual Care|Patient views DA and completes post DA survey.
215075057|NCT01077999|DRUG|Carboplatin|Carboplatin AUC = 2 , weekly.
215075058|NCT01077999|DRUG|Paclitaxel|Paclitaxel 50 mg/m2, weekly
215075059|NCT01077999|DRUG|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
215075060|NCT01077999|RADIATION|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
215075061|NCT00555763|DEVICE|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
215075062|NCT00990431|PROCEDURE|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
215075063|NCT00990431|PROCEDURE|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
215075064|NCT05638269|OTHER|no intervention|Observational studies, no intervention
214944986|NCT03905356|BEHAVIORAL|Exercise Therapy|Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.
214944987|NCT04505605|OTHER|Blood samples|A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.
214944988|NCT03526198|DEVICE|Force plate|Device: force plate An equipment model with the approach of providing the evaluated person with the movement that is closest to the biomechanical and functional reality of the ankle and foot joint and which could equalize the possible changes of the center of mass would contribute to the clinical evaluation and would provide a more efficient therapeutic reasoning rehabilitation.
214944989|NCT06620250|COMBINATION_PRODUCT|Digital Prevention and control of myopia|The Digital Intervention Programme for parents/primary caregivers is primarily a digital intervention to address the attitudes, knowledge and actions of parents or primary caregivers of pre-school children regarding the prevention and control of myopia.
214944990|NCT03042416|DRUG|18F-DOPA|18F-DOPA intravenous injection single dose
214944991|NCT06304558|DEVICE|Non-Invasive Neuromodulation (NESA)|Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus,. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs are covered through the sympathetic paravertebral ganglia and the sacral plexus.
214944992|NCT01075399|DRUG|[F 18]HX4|Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with \[F 18\]HX4
214944993|NCT01179737|DRUG|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
214944994|NCT01179737|DRUG|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
214944995|NCT01326507|BIOLOGICAL|Dosage de l'h-FABP|Dosage de l'h-FABP
214944996|NCT00971061|DEVICE|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
214944997|NCT00971061|DEVICE|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
214944998|NCT04769505|BEHAVIORAL|digital mindfulness-based intervention (MBI)|The digital MBI consists of four auditory guided mindfulness exercises lasting between 10 and 15 minutes. The four exercises are a body scan and three sitting meditations (awareness of the heartbeat, awareness of the body, awareness of sounds). The exercises can be conducted via a software (https://www.movisens.com/de/produkte/movisensxs/) on participants' smartphones. Participants will be familiarized with the concept of mindfulness and the intervention in a single face-to-face introductory session. Additionally, participants will receive a manual, containing all relevant information. Participants will be instructed to practice at least once daily over the course of eight weeks. We recommended to come up with a fixed time point for the mindfulness practice to facilitate a routine. They can choose individually between the exercises. After the intervention period, participants received the exercises as audio files and could continue practicing.
214944999|NCT06507631|BEHAVIORAL|Blended care pirate group|During the blended care pirate group, children will receive training while their less affected arm is in a sling. They will perform play-like activities with their affected arm both on-site and at home.
214945000|NCT02570334|OTHER|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
214945001|NCT02253121|DRUG|Dapagliflozin|Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
214945002|NCT02253121|DRUG|Sliding scale insulin|Sliding scale insulin with short acting insulin based on current glucose levels
214945003|NCT04240964|OTHER||
214945004|NCT02818621|DRUG|Group Dex (dexmedetomidine)|1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
214340847|NCT02554773|DRUG|Fitusiran (SAR439774)|Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
214340848|NCT02403310|DRUG|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~* Dose Level 2: 80 mg twice weekly.~* Dose Level 1 (starting dose): 60 mg twice weekly.~* Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
214945005|NCT06013202|OTHER|Nigella Sativa Oil Mouth Rinse|Nigella Sativa Oil Mouth Rinse
214945006|NCT06013202|OTHER|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)
214340849|NCT02403310|DRUG|Daunorubicin|"Induction: Daunorubicin 60 mg/m\^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m\^2/day (days 1-2)."
214945007|NCT00696202|DRUG|Mirena (BAY86-5028)|Intrauterine levonorgestrel containing device (market product)
214945008|NCT04295343|DIAGNOSTIC_TEST|Three-dimensional (3D) rectal water contrast transvaginal ultrasonography|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
214340850|NCT02403310|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m\^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m\^2/day (continuous infusion on days 1-5)."
214340851|NCT01170780|DRUG|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
214945009|NCT04295343|DIAGNOSTIC_TEST|Computed colonography|Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.
214340852|NCT01170780|DRUG|Saline|2 ml IV
214945010|NCT03146975|PROCEDURE|Non-surgical periodontal treatment|Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.
214945011|NCT05570370|OTHER|This is an observational study|This is an observational study
214945012|NCT00717275|DRUG|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
214945013|NCT01881087|DRUG|Hyperbaric Levobupivacaine 0.75%|Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
214945014|NCT04205149|OTHER|ERAS post-operative pathway|ERAS Pathway
214945015|NCT00711607|DRUG|nomegestrol acetate and estradiol|Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
214945016|NCT02193711|OTHER|Topical Arthritis Cream|
214945017|NCT06535633|OTHER|Intervention arm: Exercise class|The exercise trainers, who are educated in chronic pain, will lead a set of classes, adapted to the needs of people with chronic pain. The investigators have conducted PPI activities with the members of Chronic Pain Ireland, to understand the barriers and facilitators for community-based exercise and their needs in relation to same. A forthcoming publication reports the results of a survey of a survey of (n=130) members of CPI highlightinged that key barriers to community-based exercise included fear of pain exacerbation, and not having skilled exercise instruction. The exercise modalities of choice have been informed by the survey results as well as alignment with the LSP class offerings and trainer competency. Classes on offer are focused on aquatic exercise, Activator pole walking, yoga or Pilates, and circuit-style fitness, for participants to choose their own preferred option. Classes will run weekly for 8 weeks, duration 1 hour.
214945018|NCT00263055|DRUG|oxaliplatin|
214945019|NCT04146623|BIOLOGICAL|CodaVax-H1N1 influenza vaccine|CodaVax-H1N1, a live attenuated vaccine (LAIV) strain based on the A/California/07/2009 (H1N1) influenza virus, administered once intranasally via a sprayer at a dose of 8 x10\^5 plaque forming units (PFU).
214945020|NCT04146623|BIOLOGICAL|Normal Saline Placebo|Saline (0.9%) administered intranasally via sprayer
214340853|NCT03663413|DEVICE|non-invasive monitor|cutaneous EEG monitor
214945021|NCT03794934|BEHAVIORAL|Structured Education for new glucose management devices|Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus
214945022|NCT03662113|DRUG|Domperidone|5ml Domperidone prior to VCE
214945023|NCT03662113|DIETARY_SUPPLEMENT|water|5ml water prior to VCE
214945024|NCT03447652|OTHER|Resistance Band Ankle Rehabilitation|Resistance Band - uses a tension band to provide resistance during ankle motion
214945025|NCT03447652|OTHER|Biomechanical Ankle Platform System Rehabilitation|Biomechanical Ankle Platform System Board Group - uses different levels of half spheres to increase the amount of motion allowed at the ankle.
214340854|NCT00865527|OTHER|Fecal occult blood test|FOBT
214340855|NCT00865527|PROCEDURE|Virtual colonoscopy|computed tomographic colonography
214340856|NCT00865527|PROCEDURE|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
214340857|NCT02203019|DRUG|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
214340858|NCT02203019|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
214340859|NCT02203019|DRUG|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
214945026|NCT03447652|OTHER|Combination Rehabilitation|Combination Group - includes both the resistance band and Biomechanical Ankle Platform System programs.
214945027|NCT02564406|DEVICE|LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR|
214945028|NCT02636556|RADIATION|concurrent chemoradiation|The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w\*4.
214945029|NCT04507893|OTHER|Clinical, laboratory and imaging characteristics of pneumonia|"Evaluation of the clinical, laboratory and imaging characteristics in patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as COVID-19 patients and negative COVID-19 patients."
214945030|NCT02634905|OTHER|Individual session therapeutic education|within 2 weeks after inclusion (week 0)
214945031|NCT02634905|OTHER|Phone Call|
214340860|NCT04842240|PROCEDURE|Pre- or sub-pectoral implant based immediate breast reconstruction|All study participants will undergo skin sparing mastectomy (with or without nipple preservation) for breast cancer or for risk reduction. Patients will undergo immediate breast reconstruction using an implant or a tissue expander. The device will be placed in pre- or sub-pectoral plane which will be supported by mesh (Tiloop/Surgimend Acellular Dermal Matrix) and/or a dermal flap.
214340861|NCT02588040|BIOLOGICAL|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
214945032|NCT06221098|PROCEDURE|bilateral medial rectus recession|release muuscle from its original insertion and backword inserted in sclera
214340862|NCT02031276|DRUG|risankizumab IV|risankizumab administered by IV infusion
214340863|NCT02031276|DRUG|risankizumab SC|risankizumab administered by SC injection
214340864|NCT02031276|DRUG|Placebo|Placebo for risankizumab administered by IV infusion
214340865|NCT06402500|DRUG|Icon Infiltrant|White spot lesions are treated with the resin ICON (DMG, NJ, US) for masking their color. The mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
214340866|NCT06402500|DRUG|Bioactive infiltrant|White spot lesions are treated with HI-Bond universal bioactive resin (MEDICLUS, south Korea) for masking their color. Mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
214340867|NCT01148810|DRUG|BAF312|
214340868|NCT01148810|DRUG|Placebo|
214340869|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.
214340870|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.
214340871|NCT04400552|DIETARY_SUPPLEMENT|Usual intake Pre-op + ONS Post-op|Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital
214340872|NCT06419127|DIAGNOSTIC_TEST|Timelapse incubation and PGT|Patients will have their embryos cultured in a timelapse incubator and their PGT results will be compared to the data collected during timelapse incubation.
214340873|NCT02974361|DRUG|Ibuprofen|
214677391|NCT00384540|PROCEDURE|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
214945033|NCT05693545|DRUG|phenoxymethyl penicillin|Prophylaxis
214945034|NCT05693545|DRUG|intramuscular benzathine penicillin G (BPG) prophylaxis|Prophylaxis
214340874|NCT02974361|DRUG|Ibuprofen Lysine|
214340875|NCT02974361|DRUG|Ibuprofen-LDH|
214340876|NCT03981003|DIAGNOSTIC_TEST|Blood sample|2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
214945035|NCT06291740|DEVICE|continuous nebulization|continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min
214340877|NCT05148494|DRUG|Fleet Enema|standard pre-op application, see arm description
214340878|NCT05148494|DRUG|Pico-Salax|standard pre-op application, see arm description
214340879|NCT03769441|DRUG|Ferric carboxymaltose|Four intravenous dosages of ferric(III) carboxymaltose
214340880|NCT03769441|DRUG|Sodium chloride|Four intravenous dosages of sodiumchloride
214340881|NCT05480605|BEHAVIORAL|Occupational Therapy|Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
214340882|NCT01166932|DRUG|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
214340883|NCT01166932|DRUG|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
214340884|NCT00005619|GENETIC|polymerase chain reaction|
214340885|NCT00005619|OTHER|flow cytometry|
214945036|NCT06291740|DEVICE|Intermittent nebulization|intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour
214945037|NCT00047229|BIOLOGICAL|oblimersen sodium|
214340886|NCT00005619|OTHER|immunohistochemistry staining method|
214340887|NCT02182284|DRUG|low dose BI 201335 NA soft gelatine capsule (SGC)|
214340888|NCT02182284|DRUG|high dose BI 201335 NA soft gelatine capsule (SGC)|
214340889|NCT02182284|DRUG|low dose BI 201335 NA powder in bottle (PIB)|
214945038|NCT00047229|DRUG|doxorubicin hydrochloride|
215075065|NCT00924430|DRUG|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
215075066|NCT00924430|DRUG|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
215075067|NCT03479294|DRUG|Shenlingcao Oral Liquid|Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
215075068|NCT02099344|DEVICE|Artegraft|Surgical placement of graft for hemodialysis access
215075069|NCT02099344|DEVICE|Propaten|Surgical placement of graft for hemodialysis access
215075070|NCT05055388|OTHER|Multidrug-resistant bacteria|Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
215075071|NCT01798173|BIOLOGICAL|Serum, plasma and DNA samples|
214340890|NCT02182284|DRUG|high dose BI 201335 NA powder in bottle (PIB)|
214486457|NCT06739395|DRUG|Dabrafenib|Usage and dosage: Take 150mg orally twice a day, with an interval of about 12 hours.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided. When this product is used in combination with trametinib, it should be taken once a day at the same time, along with this product administered in the morning or evening.The dosage for combined use will be adaptively adjusted by the researcher.
214945039|NCT01433744|PROCEDURE|Non-surgical periodontal treatment|Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
214945040|NCT03129789|OTHER|Volumetric Bladder Ultrasound Training|teaching residents to perform bladder volumetric ultrasound
214945041|NCT05808790|PROCEDURE|Minimally invasive pulmonary metastasectomy|Surgical margin is equal to tumor size, if possible The goal is a parenchymal-sparing resection
214945042|NCT05808790|RADIATION|Stereotactic ablative radiotherapy|Depending on tumor location, 54 Gy in 3 fractions, 55 Gy in 5 fractions, 60 Gy in 8 fractions.
214945043|NCT00849134|DRUG|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
214945044|NCT01510535|DRUG|Placebo|First 2 weeks Placebo(2ml) once weekly in experimental group
214945045|NCT01510535|DRUG|Hyruan Plus|Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
214340891|NCT05665218|DIAGNOSTIC_TEST|right heart catheterization|Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.
214340892|NCT03354000|BEHAVIORAL|Take-home online training|We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.
214945046|NCT01510535|DRUG|LBSA0103|at third week LBSA0103(60mg) once in experimental group
214945047|NCT03853902|BEHAVIORAL|Mindfulness Program|Mindfulness Program
214945048|NCT00424021|DRUG|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
214945049|NCT01805973|BEHAVIORAL|Exercise Training|Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
214945050|NCT03724240|BIOLOGICAL|Placebo solution|4 x 2 injection over 21 days the dosage is100 µg/ml
214945051|NCT03724240|BIOLOGICAL|gpASIT+TM|4 x 2 injection over 21 days the dosage is100 µg/ml
214945052|NCT04240860|BIOLOGICAL|platlet rich plasma|"Drug: PRP PRP subendometrial infusion~Device: ovum oickup needle PRP subendometrial infusion by hysteroscopic guided ovum pickup needle day 9 of the cycle"
214945053|NCT04240860|PROCEDURE|endometrial scratch|Three Snip Hysteroscopic Endometrial Scratching in luteal phase of preceeding cycle
214945054|NCT03000530|DRUG|SAGE-217|
214945055|NCT03000530|DRUG|Placebo|
214945056|NCT01996657|DRUG|Warfarin|
214945057|NCT05414266|DRUG|Placebo|Placebo is acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
214945058|NCT05414266|DRUG|SADBE 5%|SADBE 5% is a solution of 5% Squaric Acid Dibutyl Ester (SADBE) in acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
214945059|NCT04662294|BIOLOGICAL|CD70 CAR T-cells|Each subject receive CD70 CAR T-cells by intravenous infusion
214945060|NCT06725667|OTHER|Transversalis fascia plane block|Patients will receive transversalis fascia plane block after the induction of general anesthesia.
214945061|NCT06725667|OTHER|Caudal block|Patients will receive caudal block after the induction of general anesthesia.
215075072|NCT01798173|PROCEDURE|Radiological exploration by CT scan or MRI|
215075073|NCT00123370|DRUG|Modafinil|
215075074|NCT00835198|DRUG|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
215075075|NCT00835198|DRUG|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
214945062|NCT02219776|DRUG|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
214945063|NCT02219776|OTHER|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
214945064|NCT01018160|DRUG|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12 weeks
214677392|NCT02617732|DRUG|Tianqi capsule|"The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day"
214677393|NCT02617732|DRUG|placebo|"The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day"
215075076|NCT02523157|OTHER|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
214677394|NCT03990766|DRUG|Theophylline|Theophylline delivered via high-volume, low-pressure nasal saline irrigation
214677395|NCT03990766|DRUG|Saline Nasal|Lactose delivered via high-volume, low-pressure nasal saline irrigation
214677396|NCT02060201|DRUG|Saxagliptin|
214677397|NCT02060201|DRUG|Dapagliflozin|
214677398|NCT02060201|DRUG|Saxagliptin/Dapagliflozin FDC|
214677399|NCT05521685|PROCEDURE|Endoscopic Ultrasound (EUS) administration of cyanoacrylate tissue adhesive to control bleeding gastric varices|Subjects will have undergone treatment and been enrolled into the existing registry.
214677400|NCT02272621|PROCEDURE|Minimally invasive aortic valve replacement|
215075077|NCT02523157|OTHER|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
214340893|NCT03354000|BEHAVIORAL|In-person online training|For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
214677401|NCT02272621|PROCEDURE|Full sternotomy aortic valve replacement|
214945065|NCT05123391|RADIATION|External beam image guided radiotherapy|Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)
214945066|NCT03138746|PROCEDURE|HBO|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
215075078|NCT06523218|DIETARY_SUPPLEMENT|MindMD Supplement|Participants will take two capsules of the MindMD supplement once daily with their morning meal for a duration of 3 months. The supplement is designed to improve and maintain cognitive function and memory.
215075079|NCT06523218|OTHER|Placebo|Participants will take two capsules of the placebo once daily with their morning meal for a duration of 3 months. The placebo is designed to be indistinguishable in appearance and administration from the MindMD supplement to ensure blinding.
214677402|NCT01550718|BEHAVIORAL|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
214677403|NCT01550718|BEHAVIORAL|ESML-Social (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session."
214677404|NCT02674997|BIOLOGICAL|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
214677405|NCT05072769|DIETARY_SUPPLEMENT|Date Fruit|Within the first hour after birth, 100gr (5-6 pieces) dates will be eaten.
214677406|NCT04437017|DRUG|Olanzapine+NK-1 RA+5-HT3 RA|On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
214677407|NCT04437017|DRUG|Dexamethasone+NK-1 RA+5-HT3 RA|On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
214677408|NCT02575794|DRUG|Terameprocol|Given PO
214945067|NCT03138746|PROCEDURE|Hyperbaric air|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
214945068|NCT05343104|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
214945069|NCT01281267|PROCEDURE|Facial Allograft Transplantation|Facial allograft transplantation surgery is the transfer of face tissue from a deceased human donor to a patient with a severe facial deformity.
214945070|NCT03597022|DRUG|Befovacimab (BAY1093884)|Once weekly doses until premature termination of the study, subcutaneous injection
214945071|NCT00312572|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
214945072|NCT03195972|OTHER|Drug diary filling|patient will fill every day a drug diary
214945073|NCT00601822|BEHAVIORAL|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
215075080|NCT01862471|DEVICE|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
215075081|NCT01862471|DEVICE|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
215075082|NCT00394602|BEHAVIORAL|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
215075083|NCT00394602|OTHER|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
215075084|NCT02049190|DRUG|onapristone|
215075085|NCT02049190|DRUG|abiraterone|
215075086|NCT00856089|DRUG|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
214340894|NCT05942508|DRUG|TQB2450 Injection + Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody
214945074|NCT00601822|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
214945075|NCT02014922|DRUG|TheraTears® Lubricant Eye Drop|
214945076|NCT02014922|DRUG|TheraTears® preservative-free single-use containers|
214945077|NCT02014922|DIETARY_SUPPLEMENT|TheraTears® Nutrition|
214945078|NCT02014922|OTHER|TheraTears® TheraLid® Eyelid Cleanser|
214945079|NCT03012763|DRUG|Paracetamol|Oral administration of 250 mg paracetamol
214945080|NCT03012763|DRUG|Sulfasalazine|Oral administration of 50 mg sulfasalazine
214677409|NCT02575794|OTHER|Pharmacological Study|Correlative studies
215075087|NCT06095882|OTHER|acupuncture|"Study group: Acupuncture treatment was performed from day 3 to day 14 after surgery. Points include: Zhongwan, Tianshu, Watercourse, Taichong, Sanyinjiao, Zusanli, Yin Lingquan.~Control group: No intervention, the urinary tube was removed until the 14th day after surgery. Patients with urinary retention may receive further acupuncture treatment."
215075088|NCT01168791|DRUG|doxorubicin in combination with palifosfamide-tris|"palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles."
214677410|NCT00403117|DRUG|Placebo + Inactive Marijuana (0% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
214677411|NCT00403117|DRUG|Placebo + Active Marijuana (3.27% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
215075089|NCT01168791|DRUG|doxorubicin in combination with placebo|"doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles."
215075090|NCT00996294|PROCEDURE|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
215075091|NCT04243902|DEVICE|Fill and Flush Valve|"The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O"
214340895|NCT01854554|RADIATION|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
214945081|NCT03012763|DRUG|Fexofenadine|Oral administration of 120 mg fexofenadine
214945082|NCT03012763|DRUG|Valsartan|Oral administration of 40 mg valsartan
214945083|NCT03012763|DEVICE|non-caloric water|Oral administration of 240 ml non-caloric water
214945084|NCT03012763|DEVICE|caloric drink|Oral administration of 240 ml caloric drink
214340896|NCT01854554|RADIATION|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
214340897|NCT01854554|BEHAVIORAL|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
214340898|NCT01854554|BEHAVIORAL|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
214340899|NCT02509624|DRUG|Selonsertib|6 mg tablets administered orally in fed state
214340900|NCT06033989|DRUG|Hyaluronic acid|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
214677412|NCT00403117|DRUG|Naltrexone 12 Mg+ Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
214945085|NCT03012763|DEVICE|grapefruit juice|Oral administration of 240 ml grapefruit juice
214945086|NCT02716766|DRUG|Sorafenib|PO
214945087|NCT02716766|DRUG|Capecitabine|PO
214945088|NCT02716766|DRUG|Oxaliplatin|IV
214945089|NCT00997022|DRUG|Sorafenib|"Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)"
214945090|NCT04825886|DEVICE|Zotarolimus-Eluting Stent|Percutaneous coronary intervention using zotarolimus-eluting stent
214945091|NCT03398863|PROCEDURE|Cleaning of uterine cavity|Procedure: Cleaning the uterine cavity These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
214945092|NCT02561663|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
214945093|NCT02561663|OTHER|Placebo|
214945094|NCT06206122|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
215075092|NCT04416529|BEHAVIORAL|Tele-MBCT|Please see arm/group description.
215075093|NCT03494517|DRUG|Magnesium Sulfate|Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
214340901|NCT06033989|DRUG|sandblasted, and acid-etched|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
214340902|NCT06033989|PROCEDURE|Delayed dental implant|Surgical procedure of delayed dental implant in posterior maxilla after application of surface treatment to enhance Osseointegration and healing .
214340903|NCT02124590|OTHER|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
214340904|NCT02124590|OTHER|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
214945095|NCT06206122|DEVICE|Intermittent Oro-esophageal Tube|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214945096|NCT06206122|BEHAVIORAL|Comprehensive rehabilitation training|"1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214945097|NCT05476666|PROCEDURE|Peripherial and central venous access|Passing a peripherial and a central venous catheter/cannula
214945098|NCT05200117|DEVICE|Pregnolia System|The cervical stiffness is measured with the Pregnolia System three times over a two-day period.
214945099|NCT00295516|PROCEDURE|Fetal Middle Cerebral Artery Doppler measurement|
214945100|NCT05104424|DRUG|Insulin aspart|intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
214340905|NCT01902017|DRUG|Ketotifen|5 mg PO bid
214340906|NCT01902017|DRUG|Placebo|5 mg placebo PO bid
214340907|NCT02700646|BEHAVIORAL|Developmental recommendations|
214340908|NCT02700646|BEHAVIORAL|Standard care|standard care
214340909|NCT01518205|DEVICE|LDL-apheresis|"The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
214945101|NCT06255717|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214677413|NCT00403117|DRUG|Naltrexone 25 Mg + Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
214340910|NCT02546245|BEHAVIORAL|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
214340911|NCT02546245|BEHAVIORAL|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
214340912|NCT05516199|BEHAVIORAL|Antenatal breastmilk expression|Stimulation of the breast by hand/handexpression of breastmilk during pregnancy from week 34
214340913|NCT05516199|BEHAVIORAL|Breastfeeding consultation|60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills
214340914|NCT02613481|DRUG|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
214340915|NCT01033747|DRUG|Deferasirox|10 mg/kg or 30 mg/kg orally daily
214340916|NCT01033747|DRUG|Deferasirox|5 mg/kg or 30 mg/kg orally daily
214340917|NCT02805192|DEVICE|Size Measurement by a Smart phone App|
214340918|NCT00058890|DRUG|Gabapentin|Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
214340919|NCT00058890|DRUG|Placebo|
214340920|NCT03270761|OTHER||
214340921|NCT02306915|DRUG|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
214340922|NCT01100463|DRUG|Cream|Twice daily lotion to prevent HFS
214340923|NCT01100463|DRUG|0.1% Uracil Cream|Twice daily lotion to prevent HFS
214340924|NCT00221936|BEHAVIORAL|Self-administration or nurse administered medication|
214677414|NCT00403117|DRUG|Naltrexone 50 Mg+ Active Marijuana (3.27% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
214340925|NCT05170698|PROCEDURE|Coaltion excision and arthroereisis|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
214340926|NCT05170698|PROCEDURE|Coalition excision and corrective osteotomies|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
214340927|NCT01754558|PROCEDURE|Ajust system|The use of Ajust system for stress incontinence
214340928|NCT01754558|PROCEDURE|TVT/TVT-O|sling surgery
214340929|NCT02773979|DRUG|Chloroquine|Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
214340930|NCT02773979|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
214340931|NCT02773979|OTHER|Placebo|Placebo
214340932|NCT03272191|PROCEDURE|Liposuction and stem cell implantation|The adipose tissue specimen will be collected mainly from the patient's abdomen using a liposuction cannula. The adipose tissue may be collected from other areas if necessary The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred to an injection/infusion catheter for delivery into the akinetic myocardial scar in the region of a previous infarct
214340933|NCT02881281|OTHER|educational program for Development of problem-solving skills|
214340934|NCT02881281|OTHER|no education program|no education program
214340935|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
214340936|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
214340937|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
214340938|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
214945102|NCT06255717|BEHAVIORAL|Rise-bed Training|"gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue."
214945103|NCT05140616|DRUG|Chidamide|After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
214340939|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
214340940|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
214340941|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
214340942|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
214340943|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
214340944|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
214340945|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
214340946|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
214340947|NCT01057212|DRUG|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
214340948|NCT01057212|DRUG|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
214340949|NCT01410838|OTHER|Broth|200 mL of sodium chloride containing broth, consumed three times per day
214340950|NCT01410838|OTHER|Broth|200 mL of MSG containing broth consumed three times per day
214340951|NCT02647658|BEHAVIORAL|Guideline Based Care plus Psychologically Informed Physical Therapy|PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement
214340952|NCT02647658|BEHAVIORAL|Guideline Based Care (GBC)|Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
214340953|NCT00803023|DRUG|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
214340954|NCT00803023|DRUG|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
214340955|NCT00803023|DRUG|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
214340956|NCT00803023|DRUG|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
214340957|NCT00701389|DRUG|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
214340958|NCT00701389|DRUG|sumatriptan|single oral dose of 100 mg sumatriptan
214340959|NCT00701389|DRUG|sumatriptan placebo|single oral dose
214340960|NCT00701389|DRUG|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
214340961|NCT01542528|BEHAVIORAL|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
214945104|NCT04916314|BEHAVIORAL|Low Carbohydrate diet|Second Nature is a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), encouraging adoption of a low energy, low-carbohydrate diet, peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application; each participant additionally receives an instructional handbook, and recipe book (+/-wireless weighing and activity tracking technology).
214945105|NCT03493022|OTHER|Test Granola|50.5 Test Granola
214945106|NCT03493022|OTHER|Control Granola|54.3 Control Granola
214677415|NCT00403117|DRUG|Naltrexone 100 Mg+ Active Marijuana (3.27% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
214677416|NCT00403117|DRUG|Naltrexone 12 Mg + Inactive Marijuana (0% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
214677417|NCT00403117|DRUG|Naltrexone 25 Mg + Inactive Marijuana (0% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
214677418|NCT00403117|DRUG|Naltrexone 50 Mg + Inactive Marijuana (0% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
214340962|NCT01267071|DRUG|A|GSK962040 (50 mg, SD, oral)
214340963|NCT01267071|DRUG|B|14C GSK962040 (100 μg, SD, iv)
214340964|NCT03073616|DEVICE|Lung ultrasound|Lung ultrasound and chest RX
214945107|NCT06400407|DEVICE|Continuous Theta-burst Stimulation|Based on the map, an 8-shaped coil was used to stimulate the motor function-related targets. The stimulation intensity was RMT80%, 600 pulses, 50Hz, 40s per target, and the stimulation interval was more than 2 hours. The total course of treatment lasted 7 days.
214945108|NCT06400407|DEVICE|Sham stimulation|A Sham stimulation coil was used to stimulate based on the map. The sound and duration were the same as the cTBS group, ensuring no effective stimulation. The total course of treatment lasted 7 days.
214945109|NCT04753268|BEHAVIORAL|Noom Healthy Weight Program|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight, physical activity, and meals daily."
215075094|NCT05250076|DEVICE|Kinesio Tape|"The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination."
214677419|NCT00403117|DRUG|Naltrexone 100 Mg + Inactive Marijuana (0% THC)|One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
214340965|NCT03663075|BEHAVIORAL|Group information (GI)|The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
214340966|NCT03663075|BEHAVIORAL|Structured person-centered support (PCS)|The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
214340967|NCT01597206|DEVICE|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
214340968|NCT01597206|OTHER|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
214340969|NCT00659165|DRUG|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
214340970|NCT00659165|DRUG|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
214340971|NCT01910844|DRUG|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
214340972|NCT01910844|DRUG|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
214677420|NCT05445622|OTHER|learning spinal mobilization with a force sensor|Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
214677421|NCT05392127|DRUG|SHR0302 Tablets|SHR0302 Tablets once daily
214677422|NCT05392127|DRUG|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
214677423|NCT05392127|DRUG|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
214677424|NCT05392127|DRUG|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
214945110|NCT01577719|BEHAVIORAL|Multimedia Lifestyle Improvement|"* Online Goal setting to improve diet, physical activity or smoking behaviours~* regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.~* Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks."
214945111|NCT01577719|BEHAVIORAL|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
214340973|NCT02591394|BEHAVIORAL|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
214340974|NCT02591394|BEHAVIORAL|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
214340975|NCT06175494|BIOLOGICAL|Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
214340976|NCT06175494|BIOLOGICAL|Recombinant COVID-19 Variant Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
214340977|NCT06175494|BIOLOGICAL|Placebo|boost with saline
214340978|NCT04077008|PROCEDURE|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
214340979|NCT04077008|PROCEDURE|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
214340980|NCT02239458|DRUG|Saxagliptin|
214340981|NCT04478097|DRUG|CKD-330 Tab. and D086 Tab.|1T
214340982|NCT04478097|DRUG|CKD-333 Tab.|1T
214340983|NCT01931839|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
214340984|NCT01931839|DRUG|Ivacaftor|Film-coated tablet, oral use
214945112|NCT05786638|DRUG|Allergen Immunotherapy Extract|Sublingual subcutaneous allergen immunotherapy
214945113|NCT02764203|OTHER|Dark Chocolate|50g dark chocolate consumed for a period of 2 weeks
214340985|NCT06460623|OTHER|external mobilization|two 5-minute sessions of external manipulation per week over a 5-week period.
214340986|NCT06460623|OTHER|rectal coccygeal mobilization|consisted of two 5-minute sessions of external manipulation per week over a 5-week period.
214340987|NCT03736200|OTHER|Exergaming group|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (1/day)
214340988|NCT03736200|OTHER|Physiotherapy|Physiotherapy 4-week-long.
214340989|NCT03736200|OTHER|Exergaming group 2/day|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/day)
214340990|NCT05036148|OTHER|Data analysis|MH registry data will be screened for MH positive diagnosis
214340991|NCT01190241|DRUG|desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib|The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
214340992|NCT01316627|BEHAVIORAL|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
214340993|NCT01316627|BEHAVIORAL|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
214945114|NCT02764203|DEVICE|Wearable devices|Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
214677425|NCT05392127|DRUG|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
214677426|NCT05392127|DRUG|Repaglinide Tablets|Repaglinide Tablets single dose
214677427|NCT03026504|DRUG|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
214340994|NCT05140278|DRUG|Argesun 60mg (1 step parenteral artesunate)|Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.
214340995|NCT05140278|DRUG|Artesun 60mg (2-step parenteral artesunate)|Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
214340996|NCT03984266|DIAGNOSTIC_TEST|NGS panel|A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.
214340997|NCT03956303|DRUG|Chirocaine %0.5|Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
214340998|NCT03956303|DRUG|Chirocaine Heavy 40|Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl
214340999|NCT03956303|DRUG|Chirocaine Heavy 60|Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl
214945115|NCT05462275|DEVICE|Intubation using 3-cuffed double lumen endotracheal tube|After patient's position, 3-cuffed double lumen endotracheal tube is intubated without fiberoptic bronchoscopy guidance
214945116|NCT03878875|DIAGNOSTIC_TEST|Session One Test Battery|"Prior to noise exposure:~Test battery - High-frequency audiometry, Distortion Product Otoacoustic Emissions, Middle Ear Muscle Reflex, Speech-in-Noise test (Around 35 minutes with breaks if required)~* Extended Frequency Audiometry (\~ 8 min), 0.25-16 kHz: Participants will be asked to press the button when they hear a sound through the headphones in a soundproof booth.~* DPOAE (\~ 5 min), 0.5-10 kHz: A small tip will be placed in participants' ear and they will hear a sound. The tip measures a response from hair cells in the cochlea and they will not need to do anything.~* MEMR (\~ 8 min), 4 kHz: A small tip placed in both ears and again a sound heard, however, this sound will gradually get louder until an involuntary muscle reflex is noted.~* Speech-in-Noise Test (\~ 5 min): Participants asked to repeat back a list of words as best as they can.~* Tinnitus: Participants were also asked if they experience any tinnitus i.e. bilateral, lasting \> 5 minutes. This was reported as Y/N."
214945117|NCT03878875|DIAGNOSTIC_TEST|Session Two Test Battery|"Exposure at single loud music event (Important that this is part of participants' normal recreational routine, and specifically require that attendance is not prompted by participation in this study): Participants to use sound level meter provided from the Audiology Department at Charing Cross Hospital or sound level meter applications to measure sound levels inside the loud event.~Morning after exposure: Repeat test battery from session one - Ideally as soon as event is over."
214945118|NCT03878875|DIAGNOSTIC_TEST|Session Three Test Battery|1 week later (recovery): Repeat test battery.
214677428|NCT05326399|BEHAVIORAL|renal biospy|Standard percutaneous biopsy has been performed in all participants. Modification of treatment will be jointly decided by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks.
214677429|NCT00479804|DEVICE|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
214677430|NCT00479804|DEVICE|spirometry|spirometry for testing the ventilatory function
214341000|NCT03956303|DRUG|Chirocaine Heavy 80|Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
214341001|NCT01790750|DEVICE|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
214341002|NCT02378142|DRUG|Pazopanib|
214341003|NCT01992536|BIOLOGICAL|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
214341004|NCT01992536|BIOLOGICAL|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
214341005|NCT01992536|BIOLOGICAL|Placebo|Saline solution for injection (0.5mL)
214341006|NCT03907501|DIETARY_SUPPLEMENT|Synbiotic|an herbal prebiotic plus probiotic
214341007|NCT03907501|DIETARY_SUPPLEMENT|Probiotic|Triphala alone
214677431|NCT00479804|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
214677432|NCT06348420|PROCEDURE|anti-reflux mucosal valvuloplasty (ARMV)|During the ARMV procedure, a segment of the mucosa at the esophagogastric junction (EGJ) is released and reconstructed to form a mucosal flap. Cautery markings are made on 3/4-4/5 of the mucosa along the lesser curvature, approximately 2 cm below the dentate line. After submucosal injection of saline with indigocarmine, the premarked mucosa is dissected from the caudal to cranial side using an endoscopic submucosal dissection technique. The cranial edge of the released mucosa is left in place, and the semi-free mucosa naturally curls to form a double-layer flap. Metal clips are then used to anchor the free edge of the mucosa to the exposed submucosa/smooth muscle to prevent flattening of the mucosal flap. Any visible bleeding on the exposed submucosa is coagulated using electric forceps.
214341008|NCT03907501|DIETARY_SUPPLEMENT|Placebo|Inert capsule
214677433|NCT04655950|OTHER|protocols and practices for the immobilization of vertebral osteomyelitis in different French hospitals and bone and joint infections Centers|"Evaluation of the frequency of neurological complications in a large prospective cohort, and to identify clinical and imaging risk factors for neurological complications.~We search for association between type and duration of spine immobilization and neurological status at the end of follow-up"
214677434|NCT04297670|OTHER|Measurement of HPV types prevalence|Self collected genital samples to be tested for the presence of different HPV types.
214945119|NCT06083688|DRUG|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).
214945120|NCT06083688|DRUG|Chloroquine|Treatment will be with CQ alone if female and 13 years old or older in both intervention arms.
214341009|NCT00229008|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
214341010|NCT00229008|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
214341011|NCT04861649|BIOLOGICAL|fecal microbiota transplantation|"The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
214341012|NCT00879294|DEVICE|Motion sickness wristband|No drugs are involved.
214341013|NCT00879294|DIETARY_SUPPLEMENT|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
214341014|NCT03862118|OTHER|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
214677435|NCT06036433|DEVICE|Infrared laser photobiomodulation device|904 super pulsed Infrared laser PBM therapy for the treatment of the signs and symptoms associated with Parkinson's, such as improved motor, non-motor and Quality of Life.
214677436|NCT06036433|DEVICE|Infrared & Red LED photobiomodulation device|Infrared \& red LED therapy for the treatment of the signs and symptoms associated with Parkinson's, such as motor, non-motor and Quality of Life.
214677437|NCT00246038|DEVICE|Boston Scientific ENOVUS AAA Endograft|
214677438|NCT02380352|DRUG|Amoxicillin|
214677439|NCT02380352|DRUG|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
214341015|NCT01709227|DRUG|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
214341016|NCT01709227|PROCEDURE|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
214341017|NCT03669081|DRUG|Ketorolac|Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
214677440|NCT04168645|BEHAVIORAL|Cognitive Behavioral Therapy|Up to 4 sessions of BCBT (depending on length of stay) will be provided. The first session lasts 1.5 hours and subsequent sessions are 1 hour.
214945121|NCT06083688|DRUG|Sulfadoxine-pyrimethamine-amodiaquine|Treatment in Arm 2 (females less than 13 years old and all males).
214945122|NCT02614131|DRUG|LY2599666|Administered SC
214945123|NCT02614131|DRUG|Solanezumab|Administered IV
214945124|NCT02614131|DRUG|Placebo SC|Administered SC
214945125|NCT02614131|DRUG|Placebo IV|Administered IV
214677441|NCT01840176|PROCEDURE|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
214677442|NCT01452776|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
214677443|NCT01452776|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
214341018|NCT03669081|DRUG|Pregabalin|Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
214341019|NCT03669081|DRUG|Placebo oral capsule|Placebo oral capsule was administered orally 30 minutes prior to operation.
214341020|NCT03669081|DRUG|Saline|Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
214341021|NCT05748639|OTHER|Mobile health application|Participants randomized to receive the QG-A (Experimental) intervention will receive monthly appointments with a medical provider, access to naltrexone, and weekly and bi-weekly appointments with a licensed clinical counselor through an integrated digital health application.
214677444|NCT02343536|DRUG|Oral Azacitidine|
214677445|NCT02343536|DRUG|Rituximab|
214677446|NCT02343536|DRUG|cyclophosphamide|
214677447|NCT02343536|DRUG|Vincristine|
214945126|NCT06400004|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|Bolus administration of 2 mL undiluted Lumason®, to be administered in 20 seconds
214945127|NCT06400004|DRUG|Lumason|Continuous infusion of 8 mL of diluted Lumason® (4 mL of Lumason® diluted in 4 mL of saline) at a rate of 1.0 mL/min
214945128|NCT00655512|DRUG|pimecrolimus 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
214945129|NCT00655512|DRUG|hydrocortisonacetat 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
214945130|NCT00655512|DRUG|betamethasonvalerat 0,1% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
214945131|NCT00655512|DRUG|clobetasol-17-propionat 0,05% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
214677448|NCT02343536|DRUG|Prednisone|
214677449|NCT01797276|DRUG|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
214945132|NCT00655512|DRUG|Placebo|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
214945133|NCT03080584|OTHER|acupuncture|12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
214945134|NCT01562249|OTHER|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
214945135|NCT01562249|OTHER|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
214945136|NCT01562249|OTHER|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
214945137|NCT05901584|DRUG|Cadonilimab|Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle.
214945138|NCT00853879|DIETARY_SUPPLEMENT|Folic Acid, Vitamin B6, Vitamin B12|"Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate."
214945139|NCT00853879|DIETARY_SUPPLEMENT|B6, B12, L-methylfolate|Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
214341022|NCT05748639|OTHER|Medical Management|Participants randomized to receive the MM (Control) intervention will receive monthly appointments with a medical provider and access to naltrexone.
214945140|NCT00853879|DIETARY_SUPPLEMENT|B6, B12, Placebo|"Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo"
214945141|NCT04665518|OTHER|Acupressure|Acupressure will be applied to the patients in the acupressure group for 10 min before the venipuncture procedure. Venipuncuture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
214945142|NCT00798018|DRUG|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
214945143|NCT00798018|DRUG|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
214945144|NCT00798018|DRUG|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
214945145|NCT00798018|DRUG|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
214945146|NCT04240275|DEVICE|Reliability of the G-Walk device in children with Cerebral Palsy|"The purpose of this study was to confirm the test-retest reliability of a commercially available body-worn sensor-G-Walk® sensor system-for spatiotemporal gait parameters in children with CP.~The children will be assessed with the G-Walk on two separate occasions.For the reliability analysis, the second measurement tests will be repeated 3 days after the first assessment.~The device is placed on an elastic belt and worn on the waist of the person being evaluated, with the center of the device at the fifth lumbar vertebrae. To ensure correct placement of the device, the L4-L5 intervertebral space will be palpated via the posterior superior iliac spines (SIPS).~After the accelerometer is placed, the children are asked to walk calmly at normal speed, on a 10 m track, whose boundaries will be determined with colored lines and to return to the starting position."
214945147|NCT00354042|DRUG|GW597901X|
214945148|NCT05721638|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin|Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 KDa, neutrophil-derived molecule from the lipocalin family. It is also secreted in small amounts from kidney, prostate, and respiratory tract epithelial cells. After ischemic and nephrotoxic acute tubular necrosis, NGAL levels peak at the 3rd hour and remain elevated for approximately 24 hours. In patients who do not progress to AKI, NGAL levels begin to decrease as of the 1st hour after injury.
214945149|NCT04126642|BEHAVIORAL|Assessment only group|Individuals randomized to this group will receive radiation therapy as usual plus baseline, follow-up, and EMA assessments.
214945150|NCT04126642|BEHAVIORAL|Intervention group|Individuals randomized to the intervention group will complete the same measures (in person and daily EMAs) as the assessment only group, but will additionally receive messaging that is tailored to patient responses on EMAs.
214341023|NCT00559897|OTHER|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
214341024|NCT00559897|PROCEDURE|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
214341025|NCT04455919|OTHER|Wait-list group|The wait-list group benefit from a 8-week yoga program after the interventional group
214341026|NCT04455919|OTHER|Yoga group|During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home
214341027|NCT00389324|BIOLOGICAL|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
214341028|NCT02779218|PROCEDURE|Paired Associative Stimulation|Patient with Paired Associative Stimulation only
214341029|NCT02779218|PROCEDURE|Paired Associative Stimulation + Motor Imagery exercises|Patient with Paired Associative Stimulation + Motor Imagery exercises
214341030|NCT02779218|PROCEDURE|Placebo Paired Associative Stimulation + Motor Imagery exercises|Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
214341031|NCT06071039|COMBINATION_PRODUCT|3D spacer Fabric Based Mattress|For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
214341032|NCT03749226|DRUG|Aztreonam lysine|nebulization
214945151|NCT00840242|DRUG|Nicotine gum|8-12 pieces per day, maximum 24 daily
214945152|NCT00840242|DRUG|Placebo gum|8-12 pieces per day, maximum 24 daily
214945153|NCT00840242|DRUG|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
214945154|NCT00840242|DRUG|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
214945155|NCT06240988|DEVICE|Modified Constraint Induced Movement Therapy|Modified Constraint Induced Movement Therapy
214945156|NCT06240988|OTHER|Motor Imagery Technique|Motor Imagery Technique
214945157|NCT03888183|DRUG|salt solution without 0.15% HA|received AIM Artificial Tears (4 to 8 times per day) with 12 weeks
214945158|NCT03888183|DRUG|preservative-free 0.15% HA|received Per-Young Eye Drops (4 to 8 times per day) with 12 weeks
214341033|NCT03749226|DEVICE|Aerogen Solo|Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.
214945159|NCT04523870|DIETARY_SUPPLEMENT|Botanical extract|One capsule
214341034|NCT03749226|DEVICE|CombiHaler|The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
214341035|NCT00477711|DRUG|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
214341036|NCT03751904|DEVICE|AcoustiCare|Electronic stethoscope
214341037|NCT03089424|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
214341038|NCT03089424|DEVICE|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
214341039|NCT06535178|BEHAVIORAL|Sleep Regularity Group|Maintained consistent sleep onset time (±30 min self-selected sleep time) for 12-weeks.
214341040|NCT04353297|OTHER|EEG-based BCI system for (hand) Motor Imagery training|The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
214341041|NCT04353297|OTHER|Motor Imagery training|Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
214341042|NCT04020510|DRUG|onaBoNT-A|Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
214945160|NCT04523870|DIETARY_SUPPLEMENT|Main compound of the botanical extract|one capsule
214945161|NCT04523870|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, one capsule
214945162|NCT01285492|DRUG|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
214945163|NCT01285492|DRUG|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
214945164|NCT06112678|DRUG|CKD-348(6)|QD, PO
214945165|NCT06112678|DRUG|CKD-828, D097, D337|QD, PO
214945166|NCT05000853|DRUG|Iron Carboxymaltose|Iron supplementation when is needed according to usual care
214945167|NCT03213925|RADIATION|Radiation therapy|"Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region.~Techniques: 3D conformal radiation therapy or intensity modulated radiation therapy (IMRT).~Standard systemic treatment for patients with hormonal positive receptor (hormone therapy for at least 5 years) and HER2 positive (trastuzumab for 1 year)"
214945168|NCT03777111|OTHER|Exercise|Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.
214945169|NCT03365453|OTHER|frailty evaluation|frailty and comorbidity scores
214945170|NCT00211315|DRUG|anecortave acetate|
215075095|NCT02526823|DRUG|R-CHOP/CHOPE or ABVD chemotherapy regimen|"R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
214945171|NCT05172791|BEHAVIORAL|Antibiotic stewardship messaging|Counseling regarding antibiotics for patients prescribed antibiotics for possible pneumonia despite respiratory rates and oxygenation levels within normal ranges
214341043|NCT05759091|BEHAVIORAL|cognitive defusion techniques|"Defusing from your delusions helps to lessen their negative impact on your behaviour. So defusion is a vital step towards being able to act flexibly, in accordance with core values, instead of being dictated to by inflexible rules, reasons, judgments etc. There are numerous exercises in ACT Companion with a focus on identifying unhelpful thoughts which would benefit from defusion, or building defusion skills, most of which are found in the open up section of the app. Some of these are reading and writing exercises, and some are guided meditation audio recordings.~ACT Companion defusion exercises~1. Letting go~2. Not good enough~3. Thought defusion~4. Observing your thoughts~5. Labelling thoughts and feelings~6. I am having the thought that.....~7. milk.milk.milk exercise~8. silly voice exercise, passenger on the bus, tug of war with a monster"
214945172|NCT03299894|PROCEDURE|systematic calculation of qSOFA|calculation of qSOFA for each patient
214341044|NCT02317575|BIOLOGICAL|LY900014|Administered SC
214341045|NCT02317575|BIOLOGICAL|Insulin Lispro|Administered SC
214945173|NCT01797094|BIOLOGICAL|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
214945174|NCT01797094|BIOLOGICAL|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
214945175|NCT03881891|BEHAVIORAL|Follow-app intervention arm|The intervention includes implementation and evaluation of the effectiveness of a mobile phone-based text messaging system (FollowApp.Care) to collect patients' assessments of their post-op symptoms (pain intensity) and to use that data to improve their quality of care (pain experience) in the dental office setting
214945176|NCT03798392|DEVICE|Self-pressurizing Air Q blocker mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
214945177|NCT03798392|DEVICE|Baska mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
214945178|NCT00899613|OTHER|laboratory biomarker analysis|
214341046|NCT03957122|DEVICE|repetitive transcranial magnetic stimulation|"Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6"
214945179|NCT00899613|PROCEDURE|study of high risk factors|
214945180|NCT04373564|PROCEDURE|Motor Tests|To assess motor function annually
214945181|NCT04373564|PROCEDURE|Cognitive Tests|To assess cognitive function annually
214945182|NCT04373564|PROCEDURE|Unenhanced-MRI of the brain|The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
214945183|NCT04373564|PROCEDURE|Gadolinium Measurements|Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
214945184|NCT04373564|DRUG|Gadoxetate disodium|Administered as defined by the treating physician as part of routine clinical practice
214945185|NCT04373564|DRUG|Gadobenate dimeglumine|Administered as defined by the treating physician as part of routine clinical practice
214945186|NCT04373564|DRUG|Gadodiamide|Administered as defined by the treating physician as part of routine clinical practice
214945187|NCT04373564|DRUG|Gadoterate meglumine|Administered as defined by the treating physician as part of routine clinical practice
214945188|NCT04373564|DRUG|Gadobutrol|Administered as defined by the treating physician as part of routine clinical practice
214945189|NCT04373564|DRUG|Gadoteridol|Administered as defined by the treating physician as part of routine clinical practice
214945190|NCT01550107|DRUG|Allopurinol|300mg b.d for 24 weeks
214677450|NCT02155296|BEHAVIORAL|Restorative Practices Intervention|"RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension."
214341047|NCT00130884|DRUG|levosimendan|
214341048|NCT01921348|DEVICE|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
214341049|NCT01921348|DEVICE|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
214341050|NCT01129310|DRUG|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
214677451|NCT05128435|DIAGNOSTIC_TEST|Blood sample|Blood sample taken 3 to 5 months after the infection
214677452|NCT02004054|OTHER|measure of pupil diameter|The measure will use infra-red cameras
214945191|NCT01550107|DRUG|Lactose tablets|matched placebo tablets b.d
214945192|NCT05640388|OTHER|RV3278A - ET0943 cosmetic product|RV3278A - ET0943 study product is applied twice a day on the face during the whole study.
214945193|NCT05640388|OTHER|RV4632A - RY1845 cosmetic product|RV4632A - RY1845 study product must be applied only in case of sensation of skin discomfort
214341051|NCT04273958|DEVICE|Virtual reality helmet|During a painful procedure, the patient will watch a virtual world in a virtual reality helmet, while wearing a noise-canceling headset with soothing music.
214341052|NCT04273958|DEVICE|Computer screen|During a painful procedure, the patient will watch the same virtual world, while wearing a noise-canceling headset with the same soothing music.
214341053|NCT04462796|DIETARY_SUPPLEMENT|Magnesium Citrate|Magnesium Citrate 200 mg daily
214341054|NCT00452634|DRUG|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
214341055|NCT00452634|DRUG|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
214341056|NCT00452634|DRUG|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
214341057|NCT06149260|DRUG|Semaglutide Pen Injector|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
214945194|NCT02914431|DEVICE|3D Printing Personalized Titanium Plate|The cutting guides were placed onto the planned position. The cutting guides also worked as the drilling guide. Several screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The screw holes on the bones prepared by the cutting guides were used as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding screw holes on the plate to the bone. Afterwards, the position of the osteotomized Le Fort I segment was adjusted till all the remaining corresponding screw holes on bone and plate were aligned.
214945195|NCT06368882|DRUG|Peg-Interferon α|Peg IFN-α injection was subcutaneously injected 180 μg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNα is not more than 96 weeks. If Peg IFNα combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.
214945196|NCT00310076|DRUG|thalidomide|Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
214945197|NCT00310076|PROCEDURE|surgery|Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
214945198|NCT05262166|DRUG|INTRATHECAL dexmedetomidine INJECTION|intrathecal bolus of 3ml bupivacaine 0.5% (15mg) plus 10 micrograms dexmedetomidine at 2-3 or 3-4 spinal level.
214677453|NCT01608789|DEVICE|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
214677454|NCT04676464|DIAGNOSTIC_TEST|Ultra- sound|Ultrasound assessment of quadricep muscle layer thickness QMLT within 72hrs of initial CT scan
214677455|NCT03896399|PROCEDURE|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
214341058|NCT00816634|DRUG|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
214341059|NCT05286918|PROCEDURE|The intervention (CRP-guided) group|"The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to \<5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
214341060|NCT03326999|DRUG|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
214945199|NCT00630591|BEHAVIORAL|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
214677456|NCT03950245|OTHER|Placebo|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.
214677457|NCT03950245|OTHER|GLP-1 antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.
214677458|NCT03950245|OTHER|GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.
214677459|NCT03950245|OTHER|GLP-1 and GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
214945200|NCT00630591|BEHAVIORAL|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
215075096|NCT02526823|DRUG|R-CDOP/CDOPE or DBVD chemotherapy regimen|"R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
214341061|NCT03326999|DRUG|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
214341062|NCT03326999|DRUG|Saline|Saline as placebo comparator
214341063|NCT02063646|DIETARY_SUPPLEMENT|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
214341064|NCT02063646|DIETARY_SUPPLEMENT|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
214341065|NCT05718765|BEHAVIORAL|PACES intervention|"The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE."
214341066|NCT05718765|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
214347443|NCT05044572|OTHER|Open chain kinetic exercises|Group A will perform open chain kinetic exercises Before the intervention all the participants will perform 20 minutes of warm up and 10 minutes of cool down. The Open kinematic chain exercises(Three sets of each exercise while one set of each exercise will be performed at the setup and remaining two sets will be guided to the patient as a home plan)-:Blackburn exercises ( 20 repetitions ) , Dynamic hug( 10 repetitions), W exercise(10 repetitions), lunges with dumbbells-forward(10 repetitions with half kg dumbbell), upward and diagonal, and Pectoralis minor stretching(3 to 5 stretches)will be performed
214945201|NCT00630591|BEHAVIORAL|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
214945202|NCT04591457|DRUG|Insulin Glargine Sansulin|Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose
214945203|NCT04591457|DRUG|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
214945204|NCT03942926|DRUG|Sirolimus|Patients will receive sirolimus for 6 months.
214945205|NCT02203162|DEVICE|electronic cigarette exposure|30 puffs of a disposable electronic cigarette, 30 seconds apart.
214945206|NCT03217968|DEVICE|Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
214945207|NCT00625404|DRUG|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
214945208|NCT00625404|OTHER|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
214945209|NCT05020704|DRUG|Empagliflozin 10 MG|SGLT2inhibitor
214945210|NCT05020704|DRUG|Placebo|Matched placebo
214945211|NCT00886925|DRUG|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
214945212|NCT00886925|DRUG|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
214945213|NCT05590117|DRUG|Pentoxifylline|Pentoxifylline is a potent anti inflammatory may prevent chemotherapy induced neuropathy and mucositis and will be administered 400mg twice daily
214945214|NCT05590117|DRUG|Placebo|placebo tablets
214945215|NCT05590117|DRUG|FOLFOX-6 regimen|12 cycles of FOLFOX-6 regimen
214945216|NCT01655134|OTHER|Blood simples|
214945217|NCT01655134|OTHER|Capillary punction|
214945218|NCT01655134|OTHER|Urine simples|
214945219|NCT06011096|OTHER|skin-to-skin contact and delayed cord clamping|Placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated with skin-to-skin contact and late cord clamping after delivery.
214945220|NCT06011096|OTHER|avoiding skin-to-skin contact and early cord clamping|After delivery, placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated without skin-to-skin contact and late cord clamping.
214945221|NCT02168452|PROCEDURE|sentinel lymph node biopsy(SLNB)|"* incision will be made over the skin site that had fluorescence lymphatic flow which visualized using fluorescence imaging camera and gamma probe.~* double check after removal of the sentinel lymph node~* sending frozen biopsy"
214945222|NCT06415396|OTHER|Complete Decongestive Therapy|conventional CDT program consisting of MLD, compression bandage, skin care and lymphedema exercises, for a total of 15 sessions, five days a week for three weeks.
214945223|NCT06415396|DEVICE|ESWT|ESWT was applied to the second group for a total of 5 sessions, 2 sessions in the first two weeks and 1 session in the last week. .
214945224|NCT06415396|DEVICE|LLLT|In the third group, LLLT was applied for a total of 9 sessions, 3 sessions per week, in addition to conventional CDT.
214945225|NCT01528137|BIOLOGICAL|talactoferrin|Given PO
214945226|NCT01528137|OTHER|laboratory biomarker analysis|Correlative studies
214945227|NCT01600599|DRUG|Tranexamic Acid|intravenous 1g and topical 1g
214945228|NCT01600599|DRUG|saline|100mls of topical saline
214945229|NCT03326752|DRUG|DV281|\- Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
214945230|NCT03326752|DEVICE|Breath Actuated Nebulizer|Breath-actuated, electronic system designed to aerosolize liquid medication.
214945231|NCT03326752|DRUG|DV281 (RP2D)|\- Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
214341067|NCT05205135|BEHAVIORAL|SHARE Programme|"SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting."
214341068|NCT00871481|BIOLOGICAL|ipilimumab|Given IV
214341069|NCT00871481|DRUG|cyclophosphamide|Given IV
214341070|NCT00871481|PROCEDURE|biopsy|Optional correlative studies
214341071|NCT00871481|BIOLOGICAL|aldesleukin|Given SC
214341072|NCT00871481|OTHER|immunohistochemistry staining method|Correlative studies
214341073|NCT00871481|GENETIC|polymerase chain reaction|Correlative studies
214341074|NCT00871481|OTHER|immunoenzyme technique|Correlative studies
214341075|NCT00871481|BIOLOGICAL|therapeutic cytotoxic T lymphocytes|Given IV
214341076|NCT01775891|DRUG|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
214341077|NCT01775891|DRUG|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
214945232|NCT03326752|DRUG|Approved Anti-PD-1 Inhibitor|FDA approved Anti-PD-1 Inhibitor
214945233|NCT02447575|OTHER|Education on Use of MDI|After the subject demonstrated the use of MDI with the electronic flowmeter in place, the intervention was provided- a short verbal education to demonstrate the correct use of MDI.
214945234|NCT04387799|DIAGNOSTIC_TEST|Serology for Covid-19|Antibody tests designed to provide results to individuals or healthcare providers can show whether someone was previously infected with SARS-CoV-2 being the RT-PCR negative for the population of patients
214945235|NCT02089087|BIOLOGICAL|CFZ533|Single dose at varying dosage levels depending on treatment assignment
214945236|NCT02089087|DRUG|Placebo|
214945237|NCT00306787|DRUG|Famciclovir|Famciclovir 500 mg tablet
214945238|NCT00306787|DRUG|Valacyclovir|Valacyclovir 500 mg capsule
214945239|NCT00306787|DRUG|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
214945240|NCT00306787|DRUG|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
214341078|NCT00389662|DEVICE|"Wearing the Nike Free shoe"|
214341079|NCT03139656|BEHAVIORAL|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
214945241|NCT04924023|BEHAVIORAL|kaleidoscope application|The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished.
214945242|NCT01064635|DRUG|Letrozole|letrozole for 2-3 years after Tam
214945243|NCT01064635|DRUG|Letrozole|Letrozole for 5 years after Tam
214945244|NCT03370458|DIETARY_SUPPLEMENT|Lactobacillus plantarum DR7|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
214945245|NCT03370458|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
214945246|NCT02254057|DRUG|BIBT 986 BS - single rising dose|
214945247|NCT02254057|DRUG|Placebo|
214945248|NCT05045404|DRUG|Poziotinib Hydrochloride|"1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO"
214945249|NCT05045404|BIOLOGICAL|1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE|"Biological/Vaccine Ramucirumab 947687-13-0, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, ramucirumab, RAMUCIRUMAB~Given IV"
214945250|NCT04622072|DRUG|XZP-5809-TT1 Tablet|Single tartrate of XZP-5809
214945251|NCT02407587|DEVICE|cochlear implants|"PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
214945252|NCT00895570|DRUG|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
214945253|NCT00895570|DRUG|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
214945254|NCT00580749|PROCEDURE|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
214945255|NCT00580749|PROCEDURE|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
214945256|NCT00220948|PROCEDURE|CERSR Myoelectric monitoring during standardized tasks|
214945257|NCT04183569|OTHER|Sequencing RNA.|RNA-seq, central pivot between genomics and proteomics allows to make the connection between the observed mutations and alteration of protein expression with the identification and quantification of RNA. Thus, we can attest to the expression of mutations identified on DNA, protein and understand whether deregulation is linked to dysregulation of transcription or post-translational modification
214945258|NCT02488967|DRUG|Carboplatin|Given IV
214945259|NCT02488967|DRUG|Cyclophosphamide|Given IV
214945260|NCT02488967|DRUG|Doxorubicin Hydrochloride|Given IV
214945261|NCT02488967|OTHER|Laboratory Biomarker Analysis|Correlative studies
214945262|NCT02488967|DRUG|Paclitaxel|Given IV
214945263|NCT04686812|BEHAVIORAL|Worksite health promotion program|Physical activity, nutrition, and stress management programs
214945264|NCT01538394|DRUG|Varenicline|
214945265|NCT01538394|DRUG|Nicotine patches|
214945266|NCT01538394|DRUG|Placebo (nicotine patches)|
214945267|NCT05664451|BEHAVIORAL|UI-Assist|"To support primary care in implementing guideline-based care, it is helpful to distill interventions to their key components, such as the five major intervention steps for tobacco use and dependence (the 5 A's). The 5 A's (Ask, Advise, Assess, Assist, Arrange) has been shown to help primary care providers implement clinical practice guidelines with minimal additional burden. The 5 A's can be similarly simplified for urinary incontinence (UI) screening and treatment to Ask (screen for UI); Advise (inform that effective nonsurgical treatments exist); and Assist (help patient get treatment with pharmacotherapy, referral to community classes, physiotherapy or urology / urogynecology)."
214945268|NCT05664451|OTHER|Partnership Building|In addition to the strategies described above, those practices allocated to streamlined practice facilitation and partnership building will have facilitation and configurable solutions that engage community resources and enable coalition building. In addition to a practice facilitator, a partnership facilitator from the Wisconsin Institute for Healthy Aging (WIHA) will identify existing local community resources with which the practice may choose to partner. After initiating academic detailing, these practices will have further access to Drs. Brown and Neuner for ongoing consultation. An online learning community will also be created where information can be shared and exchanged throughout the duration of the project and beyond the maintenance phase.
214945269|NCT02094950|PROCEDURE|Acupuncture|
214945270|NCT00191802|DRUG|teriparatide|
214945271|NCT03489902|PROCEDURE|Transobturator Paravaginal Repair|Transobturator application of sutures to the white line in cases needing paravaginal repair
214945272|NCT03489902|PROCEDURE|traditional transvaginal Paravaginal Repair|traditional transvaginal application of sutures to the white line
214945273|NCT03486964|DRUG|DPP-4 inhibitors|Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
214945274|NCT02366403|BEHAVIORAL|SKY meditation|SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.
214945275|NCT02366403|BEHAVIORAL|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
214945276|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
215075097|NCT03858335|OTHER|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
214945277|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group
214945278|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
214945279|NCT02408952|BEHAVIORAL|Primary Care Physician|The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
214945280|NCT02408952|BEHAVIORAL|Behavioral Medicine Specialist|The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
214945281|NCT00520052|DRUG|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
214945282|NCT02830932|BIOLOGICAL|VXA-RSV-f Tablets (high dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.
214945283|NCT02830932|OTHER|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
214945284|NCT02830932|BIOLOGICAL|VXA-RSV-f Tablets (low dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose
214945285|NCT01438385|PROCEDURE|Interventional Endoscopy|Advanced imaging endoscopic or therapeutic endoscopy
214945286|NCT01887678|DRUG|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
214945287|NCT01887678|DRUG|Placebo|Placebo is an injection of Saline
214945288|NCT02702232|OTHER|Ultrasonography|Ultrasonography is applied for normal subjects and patients with Parkinson's disease
214945289|NCT03013985|DRUG|Glargine U300|Glargine U300 is a new generation long-acting insulin.
214945290|NCT03013985|DRUG|Glargine U100|Glargine U100 is a long-acting insulin.
214945291|NCT03013985|DRUG|Glulisine Insulin|Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
214945292|NCT02456961|PROCEDURE|iontophoresis of riboflavin|
214945293|NCT02456961|PROCEDURE|epithelium-off|
214341080|NCT03139656|BEHAVIORAL|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer \& Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
214341081|NCT03139656|BEHAVIORAL|Combined|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When \[I encounter the specified obstacle\], I will do \[X\] and remember \[values-based statement or image identified during values clarification exercise\]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
214341082|NCT03239041|BEHAVIORAL|Social navigation team|Social navigation team
214341083|NCT06635265|DEVICE|Target Stimulation (HGN, AC, GG, Strap muscles)|Simulation of a combination of: HGN, AC, GG or strap muscles
214341084|NCT01720095|DRUG|Niaspan|
214341085|NCT02187016|DEVICE|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
214341086|NCT02187016|DEVICE|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
214341087|NCT02187016|DEVICE|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
214341088|NCT02187016|DEVICE|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
214341089|NCT06087939|DEVICE|Mechanical ventilation|Mechanical ventilation (MV) is a life support technique that is routinely used in the intensive care units (ICUs) for patients with life-threatening conditions.
214945294|NCT02456961|PROCEDURE|Corneal collagen crosslinking|Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
214945295|NCT02456961|DEVICE|galvanizator, Potok-1|Device for providing iontophoresis procedure
214945296|NCT02456961|DRUG|Dextralink|Riboflavin 0,1% + Dextran T-500
215075098|NCT05564884|OTHER|no intervantion|no intervention
215075099|NCT05446792|OTHER|PFMT|The PFMT will consist of 10 maximum voluntary contractions that must be maintained for at least 6 seconds. Participants will be encouraged to sustain the maximum contraction for a longer time each week. The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: lying in lateral decubitus; seated; on all fours and standing.
214945297|NCT02456961|DRUG|Riboflavin 0,1%|
215075100|NCT05446792|OTHER|PE|"The PE group will be instructed and reminded to voluntarily contract the PFMs during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction.~The stretching and strengthening exercises will be performed in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups."
215075101|NCT05436587|GENETIC|The whole-exome sequencing|Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.
214341090|NCT00027430|DRUG|TheraDerm|
214341091|NCT02618993|PROCEDURE|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
214341092|NCT02091999|DRUG|enfortumab vedotin|intravenous (IV) infusion
214341093|NCT00188526|DEVICE|lung biopsy|
214341094|NCT05279261|PROCEDURE|The axillary approach|The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
214341095|NCT04788147|DEVICE|RMRS IDE Device|Participants will be injected with FDG at the studied dose and will undergo imaging sessions using the RMRS IDE device and a third-party Positron Emission Tomography (PET)/CT imaging device.
214341096|NCT00781326|DRUG|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
214341097|NCT00781326|DRUG|Placebo|Placebo will be given in doses matching those of nimodipine.
214341098|NCT02266381|PROCEDURE|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
214945298|NCT02456961|DEVICE|UFalink|device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
214945299|NCT00099177|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3, and 50mg po from day 22 to week 24
214945300|NCT00099177|DRUG|zoledronic acid|4mg iv on day 1, and every 3-4 weeks
214945301|NCT05288933|DEVICE|Instrument assisted soft tissue mobilization ( IASTM ) and Ultrasound|"Instrument-assisted soft tissue mobilization (IASTM) is a popular treatment for the myofascial limitation that is based on James Cyriax's rationale.~High-power pain threshold ultrasound is a noninvasive approach used in myofascial pain syndrome ( MPS) treatment, and it has no serious adverse effects."
214945302|NCT01941251|DEVICE|navigated Transcranial Magnetic Stimulation|"* individualized α frequency~* left DLPFC 110% motor threshold (MT)~* 13-15 sessions for 3 weeks"
214945303|NCT01941251|DEVICE|navigated Transcranial Magnetic Stimulation|\- placebo treatment: sham coil
214945304|NCT01714856|DRUG|Ropinirole hydrochloride CR 2mg Tablets|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
214341099|NCT02266381|PROCEDURE|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
214341100|NCT02266381|PROCEDURE|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
214341101|NCT05187455|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).
214341102|NCT02067013|DRUG|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
214341103|NCT02067013|OTHER|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
214341104|NCT00813930|BEHAVIORAL|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
214341105|NCT02401672|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
214341106|NCT02443038|OTHER|Yoga|"16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups."
214945305|NCT04509817|DEVICE|Acupuncture+Usual care|"Acupuncture intervention Disposable, sterilized needles (0.25×40 mm and 0.30×50 mm) will be used and selected acupoints will include GV20, CV4, and bilateral BL32, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9. Subject will be prone position first and BL32 will be inserted with an angle of 30-45° in an inferomedial direction and a depth of 30-50 mm. Once the subject has a needle sensation ('De-qi'), the needle will be removed immediately. Then the subject will be supine position, and GV20, CV4, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9 will be needled with a depth of 10-40mm. After subject feel 'De-qi', the needles will be placed for 20 min to maintain the stimulation.~Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.~Behavioral: Usual care Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise."
214945306|NCT04509817|BEHAVIORAL|Usual care|Usual care intervention The subjects will receive the health advice
214341107|NCT00701051|BEHAVIORAL|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
214945307|NCT06526325|DEVICE|Enhanced golgi tendon organ stimulation|Enhanced Golgi Tendon Organ Stimulation is a method that can be used by physiotherapists and doctors. The Golgi tendon organ is the proprioceptors located in the tendon adjacent to the myotendinous junction. It is applied using two separate heads, the stimulator and the algometer. The sternocleidomastoideus, platysma, colli longus, capitis longus, scalene, rhomboid major and minor, levator scapulae and trapezius muscles and their tendons will be vibrated with a stimulator for 30 seconds, then 0.5 kilograms of pressure will be applied with an algometer from the origin to the insertion of the muscle in the region at 0.5 centimetre intervals at an angle of 90 degrees.
214945308|NCT01041677|DRUG|R256918|10 mg capsule twice daily
214945309|NCT01041677|DRUG|placebo|placebo capsule twice daily
214945310|NCT01041677|DRUG|R256918|15 mg capsule twice daily
214945311|NCT03556397|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Sentinel lymph node biopsy will be performed in the patients
214945312|NCT03556397|PROCEDURE|Axillary dissection|Axillary dissection procedure will be performed in the patients
214945313|NCT01044589|DEVICE|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft reinforcement
214945314|NCT01044589|OTHER|Overlapping Sphincter Repair|Overlapping Sphincter Repair Alone
214945315|NCT00791492|DRUG|Fx-1006A|Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
214341108|NCT00701051|BEHAVIORAL|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
214341109|NCT04777461|OTHER|Survey on patient's perspectives on the development of an structured education programme for PCOS|The outcome of this survey will help with developing curriculum for the structured education programme.
214341110|NCT04777461|OTHER|Pre-pilot questionnaire|The questionnaire is aimed to capture the knowledge and expectations of the participants from taking part in the educational sessions.
214341111|NCT04777461|OTHER|Piloting the structured education programme for PCOS|Piloting the education program through 2 educational group sessions
214341112|NCT04777461|OTHER|Post-pilot questionnaire|The questionnaire aimed to capture participant's satisfactions and knowledge gained by taking part in the pilot study
214945316|NCT00927225|DRUG|ropivacaine 0.2%, 50 mL|
214945317|NCT00927225|DRUG|normal saline|
214945318|NCT04716036|OTHER|Alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
214945319|NCT04716036|OTHER|Placebo beverage|placebo beverage condition.
214945320|NCT05635500|PROCEDURE|Different Approach to endotracheal intubation.|Different insertion way.
214341113|NCT04777461|OTHER|cognitive outcomes outcome evaluation form|This aimed to capture skills developed, knowledge gained and changes in participants behaviour and perceptions by taking part in the pilot study.
214341114|NCT02113020|DRUG|TAK-233|Oral administration of TAK-233
214341115|NCT02113020|DRUG|Placebo|Oral admininstration of Placebo
214341116|NCT02983955|DEVICE|UPnRIDE Powered Wheelchair|The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
214945321|NCT02322333|DRUG|MLD10|
214945322|NCT02322333|DRUG|Placebo|
214945323|NCT01465256|DRUG|Aspirin|Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
214945324|NCT05872659|OTHER|normal saline|iv at D0, D30, D60
214945325|NCT05872659|BIOLOGICAL|Mesenchymal stem cells|iv at D0, D30, D60
214945326|NCT02410213|DRUG|Ferric Carboxymaltose (FCM)|
214945327|NCT01017757|PROCEDURE|High-resolution CT scanning|High-resolution CT scanning
214945328|NCT04296851|DRUG|Niclosamide|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
214945329|NCT04296851|DRUG|placebo|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
214945330|NCT06620419|DEVICE|Perineal-applied electrical stimulation|Small controller that outputs stimulation for stress incontinence and OAB, attached to a male-anatomy thin GelPad placed in the perineal area.
214945331|NCT04844905|DRUG|Ivermectin|Ivermectin will be given as tablets of 3 or 6mg. It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken on an empty stomach with water.
214945332|NCT04844905|DRUG|Placebo|Placebo will be given as tablets of 3 or 6mg (identical to Ivermectin in colour, size, shape and packaging). It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken by mouth with water and without food.
214945333|NCT04844905|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine will be given as tablets of 320/40mg (adult) and 160/20mg (child) piperaquine/dihydroartemisinin per tablet. Administration of a full course of dihydroartemisinin-piperaquine will be given in accordance with the manufacturer's guidelines once daily for 3 days each month for 3 months according to body weight. Dihydroartemisinin-piperaquine will be taken by mouth with water and without food.
214945334|NCT06618677|OTHER|LOW FODMAPs Diet|patients will be randomized to low or standard FODMAP diet for 14 days; then, children from both arms started the wash-out period of two weeks and subsequently started the final 2-week period on standard or low FODMAP diet. The LFD will have a FODMAP content expressed in grams 0.15 g/kg/d FODMAPs (maximum 10 g/day) while the SFD will contain 0.7 g/kg/d FODMAPs (maximum 60 g/day).
214945335|NCT02137109|DRUG|natalizumab|Administered as specified in the treatment arm.
214945336|NCT02648477|DRUG|Anastrozole|Given PO
214945337|NCT02648477|DRUG|Doxorubicin Hydrochloride|Given IV
214945338|NCT02648477|DRUG|Exemestane|Given PO
214945339|NCT02648477|OTHER|Laboratory Biomarker Analysis|Correlative studies
214945340|NCT02648477|DRUG|Letrozole|Given PO
214945341|NCT02648477|BIOLOGICAL|Pembrolizumab|Given IV
214945342|NCT01115556|DRUG|Ranibizumab|2.0 mg
214945343|NCT01115556|DRUG|Ranibizumab|0.5 mg
214945344|NCT00713661|DRUG|TachoSil®|"Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.~Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy."
214945345|NCT02119221|DRUG|Copanlisib (BAY80-6946)|Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of \[14C\]
214945346|NCT00739505|BIOLOGICAL|Asfotase Alfa|"The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC."
214945347|NCT00739505|BIOLOGICAL|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
214341117|NCT05051241|DRUG|GFH018|Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
214341118|NCT04641468|PROCEDURE|DCB|OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
214945348|NCT00463294|PROCEDURE|Coronary Artery Bypass Graft with the use of CPB|Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures
214945349|NCT00463294|PROCEDURE|Coronary Artery Bypass Graft without the use of CPB|Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
214945350|NCT06619431|DEVICE|Mobile Application|"Rumbo is an easily shared bi-lingual application that helps Hispanic individuals with unhealthy substance use find and access treatment services and related resources. The application stands out from other eHealth tools by leveraging the collective efficacy of the Hispanic community to overcome barriers and support individuals' self-efficacy for engaging the treatment system. Rumbo's simple, user-centered design provides less-acculturated Hispanic individuals with a culturally appropriate tool to understand their needs within the complex US treatment system. Rumbo is comprised of four innovations: (1) a sharing function that facilitates its own implementation among the target population; (2) culturally responsive content and design; (3) problem identification and treatment navigation enhanced to include related resources; (4) an API that is designed for interoperability across extant technologies."
214945351|NCT02983435|OTHER|G1 - Thrust manipulation|Osteopathic manipulation with Thrust technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
214945352|NCT02983435|OTHER|G2 - Muscle Energy|Osteopathic manipulation with Muscle Energy technique. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
214341119|NCT00889122|BEHAVIORAL|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
214341120|NCT00004926|DIETARY_SUPPLEMENT|vitamin D3 analogue ILX23-7553|
214341121|NCT05372198|DRUG|Chohort 1: Surufatinib|Surufatinib 300mg, qd, every 3 weeks as a cycle
214341122|NCT05372198|DRUG|Chohort 2: Immunotherapy|Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
214341123|NCT05372198|DRUG|Chohort 2: Surufatinib|Surufatinib 250mg, qd, every 3 weeks as a cycle
214341124|NCT04972500|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
214341125|NCT01002599|DEVICE|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
214341126|NCT01002599|DEVICE|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
214341127|NCT00614211|PROCEDURE|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
214341128|NCT00614211|PROCEDURE|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
214341129|NCT02399267|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
214945353|NCT03161626|DRUG|Coagadex|Plasma-driven blood coagulation factor X concentration
214945354|NCT04182568|DRUG|nab-paclitaxel followed by anthracycline and cyclophosphamide|nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
214945355|NCT04182568|DRUG|Docetaxel followed by anthracycline and cyclophosphamide|Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
214945356|NCT03799406|DRUG|Cholecalciferol|Therapeutic trial of vitamin D supplementation during acute episode of bronchiolitis
214945357|NCT03799406|OTHER|Placebo|Placebo supplementation during acute episode of bronchiolitis
214945358|NCT03490396|DEVICE|Gelclair|Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel
214945359|NCT03490396|COMBINATION_PRODUCT|First® Mouthwash BLM|Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash
214945360|NCT06451328|DRUG|Lignosus rhinoceros TM02®|Lignosus rhinoceros TM02®
214945361|NCT04986943|DEVICE|Using ABTHERA Advance without a Wittmann Patch|In this group, patients will be receiving only the ABTHERA Advance product, without the use of the Wittmann Patch
214945362|NCT01097070|DRUG|Bevirimat|
214341130|NCT02399267|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
214341131|NCT02399267|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =\< 8 cm H2O with PEEP =\< 5 cm H2O.
214341132|NCT02399267|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
214341133|NCT05393310|OTHER|post isometric relaxation|The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks
214341134|NCT05393310|OTHER|MWM group|MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
214341135|NCT06065696|PROCEDURE|Early mobilization|Patients who received early mobilization in postoperative period
214341136|NCT06065696|PROCEDURE|No early mobilization|Patients who did not receive early mobilization in postoperative period
214341137|NCT06097052|DEVICE|Hypotension Predictive Index|Introduction of Hypotension Predictive index and transition from a reactive to a proactive approach of intraoperative hypotension treatment.
214341138|NCT03789526|PROCEDURE|ultrasound guidance|ultrasound guidance of tendon injection
214341139|NCT02235766|OTHER|Echocardiographic assessment|
214341140|NCT01018849|DIETARY_SUPPLEMENT|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
214341141|NCT01018849|DIETARY_SUPPLEMENT|Placebo|placebo by mouth every 2 months for 1 year
214341142|NCT04265079|OTHER|Additional weight at hand|Added weight of an inactive hand orthosis (300 gram)
214341143|NCT03207750|BIOLOGICAL|Rotarix|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
214341144|NCT03207750|BIOLOGICAL|Pediarix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
214341145|NCT03207750|BIOLOGICAL|Hiberix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
214341146|NCT03207750|BIOLOGICAL|Prevenar 13|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
214341147|NCT06534736|PROCEDURE|Electrotherapy and physical agents|It will comprise of hot pack for 10 minutes, Tens for 10 minutes.
214341148|NCT06534736|PROCEDURE|Post Facilitation Stretch|Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles
214341149|NCT06534736|PROCEDURE|Scapular Stabilization Exercise|Scapular Stabilization exercises protocol will consist of scapular wall slide exercise, scapular retraction, wall Ball Circle exercises, scapula squeeze, wall press ups. Exercise program 3 sets of 5 - 10 repetition for 10 seconds hold a 20 second break between each sets. The intervention will be applied 2 weeks 3 times a week and 30 min per session. Post Facilitation stretch of the targeted muscles also will be carried out during the sessions
214341150|NCT06364566|RADIATION|Neoadjuvant chemradiotherapy|Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage
214341151|NCT06364566|PROCEDURE|Minimally invasive esophagectomy|The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes
214341152|NCT02449824|OTHER|magnetic resonance imaging|early MRI
214945363|NCT02550704|PROCEDURE|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
214945364|NCT02046772|DRUG|Bupivacaine low dose|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
214945365|NCT02046772|DRUG|Bupivacaine standard dose|Single intradural standard dose of bupivacaine
214945366|NCT02046772|DRUG|Morphine Chloride|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
214945367|NCT00719914|DRUG|eptifibatide|Intra-coronary injection, weight based, of eptifibatide.
214945368|NCT00719914|DRUG|eptifibatide|Intra-coronary injection, based on weight, of eptifibatide
214945369|NCT00719914|DRUG|normal saline|Intra-coronary injection, weight based, of normal saline.
214945370|NCT03533881|DIETARY_SUPPLEMENT|Arom Digest Slim|"Arom Digest Slim is a dietary supplement approved in Romania by SNPMAPS, with notification number AA 10802/2017.~It contains: hydrolyzed fish collagen (94,8 %) and volatile oils (5,2 %): Citrus paradisi (2,40 %), Citrus aurantifolia (1,24 %), Menta avensis (0,92 %), Cinamomum zeylanicum (0,56%) Patients take 4 grams of supplement per day; the supplement is dissolved in 750 ml water and drunk throughout the day"
214945371|NCT03533881|BEHAVIORAL|Nutritional changes|Education to increase the fruits and vegetables, decrease refined carbohydrates, decrease high fat animal products, regulation of meal programme, increase water intake to at least 1,5 liters per day
214341153|NCT04170127|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
214945372|NCT06045442|BEHAVIORAL|Intradialytic exercise training|The patients in the intervention group will receive 3 months of endurance training, 2x/week for 30 min. 5 min of this should be a warm-up, 20 min of exertion and 5 min of cool down. The warm-up and cool-down should be equivalent to a very light load (Borg scale 9), whereas the exertion phase should be exhausting for the patients (Borg scale 14-15).
214945373|NCT06045442|BEHAVIORAL|Control|Usual care
214341154|NCT04498650|DRUG|PQ912|PQ912 50 mg tablets and 150 mg tablets
214341155|NCT04498650|DRUG|Placebo|Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
214341156|NCT00793910|DRUG|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
214341157|NCT00793910|DRUG|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
214341158|NCT01700946|DRUG|dexamethasone|given intravenously or orally
214945374|NCT01367600|DRUG|SC Methylnaltrexone (MNTX)|
214945375|NCT01162148|BEHAVIORAL|Conventional or regular pulmonary rehabilitation program alone|Conventional or regular pulmonary rehabilitation program alone
214945376|NCT01162148|DEVICE|very low load IMT (sham IMT) alone|very low load IMT (sham IMT) alone
214945377|NCT01162148|DEVICE|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
214945378|NCT01162148|DEVICE|Targeted inspiratory resistive or threshold IMT alone|Targeted inspiratory resistive or threshold IMT alone
214945379|NCT03333408|DRUG|Postoperative Oral Antibiotics (Clindamycin or Augmentin)|Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
214945380|NCT03600012|OTHER|Cycling Functional Electrical Stimulation|
214341159|NCT01700946|DRUG|vincristine sulfate|given intravenously
214945381|NCT03600012|OTHER|Physiotherapy|
214945382|NCT05656703|DEVICE|BIS guidance of anesthesia|Anesthesia is to be directed to a specific (light) level by the dosage of administered hypnotics and analgesics
214341160|NCT01700946|BIOLOGICAL|rituximab|given intravenously
214341161|NCT01700946|DRUG|clofarabine|given intravenously
214341162|NCT01700946|DRUG|cyclophosphamide|given intravenously
214341163|NCT01700946|DRUG|etoposide|given intravenously
214945383|NCT05656703|OTHER|Standard of Care|Anesthesia is administered as usual
214341164|NCT01700946|BIOLOGICAL|aldesleukin|given subcutaneously
214341165|NCT01700946|DRUG|pegaspargase|given intravenously
214341166|NCT01700946|DRUG|methotrexate|given intrathecally or intravenously
214341167|NCT01700946|DRUG|mercaptopurine|given orally
214341168|NCT01700946|DRUG|cytarabine|given intrathecally or intravenously
214341169|NCT01700946|DRUG|mitoxantrone|given intravenously
214341170|NCT01700946|DRUG|teniposide|given intravenously
214341171|NCT01700946|DRUG|vinblastine|given intravenously
214341172|NCT01700946|BIOLOGICAL|natural killer cell infusion|undergo allogeneic natural killer cell infusion
214341173|NCT01700946|OTHER|laboratory biomarker analysis|correlative studies
214341174|NCT01700946|DRUG|therapeutic hydrocortisone|given intrathecally
214341175|NCT01700946|PROCEDURE|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
214945384|NCT01889121|BEHAVIORAL|Structured psychosocial intervention|This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
214945385|NCT00634049|DRUG|isavuconazole|Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
214945386|NCT00004809|PROCEDURE|gene therapy|
214945387|NCT02150070|DRUG|ASP2408|Intravenous (IV) infusion and subcutaneous (SC) injection
214945388|NCT02150070|DRUG|Placebo|Intravenous (IV) infusion and Subcutaneous (SC) injection
214341176|NCT01700946|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
214341177|NCT00001402|DEVICE|PET scan|
214341178|NCT03129893|DEVICE|Cuffed tracheal tubes|Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
214341179|NCT05996887|OTHER|standard care protcol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to standard care protocol.
214341180|NCT05996887|OTHER|enhanced recovery protocol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to following the recommendation of ERAS society guidelines.
214341181|NCT02308202|DRUG|doxazosin|
214341182|NCT02308202|DRUG|Perindopril|
214341183|NCT02308202|DRUG|Placebo|
214341184|NCT03509935|OTHER|Intervention Ultrasound Group|"Protocol:~* US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~* US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~* Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced."
214341185|NCT05284994|DRUG|TQ-B3525 Tablets, Osimertinib Mesylate Tablets|TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
214341186|NCT02520635|DRUG|supra-early TEMODAL® chemotherapy|
214341187|NCT02520635|DRUG|standard TEMODAL® chemotherapy|
214341188|NCT02520635|RADIATION|Radiotherapy 60Gy|
214341189|NCT00583492|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
214677460|NCT05055115|PROCEDURE|Balloon Eustachian Tuboplasty|Balloon Eustachian Tuboplasty of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
214341190|NCT00583492|RADIATION|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
214341191|NCT00811083|DRUG|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
214341192|NCT02958644|DIETARY_SUPPLEMENT|Synbiotics|12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
214341193|NCT02958644|DIETARY_SUPPLEMENT|Placebo|12g / day placebo (polydextrose) supplemented orally for 90 days
214341194|NCT03503942|BEHAVIORAL|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
214341195|NCT03503942|DRUG|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
214341196|NCT03503942|OTHER|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
214341197|NCT03178734|DEVICE|Foley Catheter vs Self-Contained Valved Catheter|This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
214341198|NCT05658692|DEVICE|protective ventilation|Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.
214341199|NCT05658692|BEHAVIORAL|prone position ventilation|patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.
214341200|NCT05658692|DRUG|glucocorticoid therapy|"Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours)."
214341201|NCT05658692|OTHER|restrictive fluid resuscitation|"1. without other organ dysfunction patients: Minimize fluid was given;~2. other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance."
214341202|NCT05658692|BIOLOGICAL|Thymosin Alpha|People received thymosin Alpha subcutaneous injections, twice a week.
214341203|NCT05658692|DRUG|Muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
214341204|NCT05658692|OTHER|Integrated Chinese and Western Medicine Treatment|"1. ventilation;~2. conventional western medicine treatment；~3. Chinese herbal medicine（Determining medication based on syndrome differentiation）"
214677461|NCT04349995|DEVICE|Amplatzer PFO Occluder|Percutaneous PFO closure using Amplatzer PFO Occluder
214677462|NCT06491823|BEHAVIORAL|Adaptation|Auditory adaptation in speech
214677463|NCT06491823|BEHAVIORAL|Adaptation baseline|Auditory baseline in speech
214677464|NCT06491823|DEVICE|Motor evoked potentials|motor evoked potentials will be obtained in each recording block
214677465|NCT06491823|DEVICE|Auditory evoked potentials|auditory evoked potentials will be obtained in each recording block
214341205|NCT05658692|DRUG|statin therapy|"1. Simvastatin: 80mg qd po for not more than 28days;~2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died."
214341206|NCT05658692|COMBINATION_PRODUCT|anti-infective treatment|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
214341207|NCT05658692|DEVICE|Extracorporeal Membrane Oxygenation（ECMO）|"1. For severe ARDS patients with refractory hypoxemia within 7 days of onset;~2. (Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O;~3. V-V Model."
214341208|NCT05658692|GENETIC|stem cell therapy|A single injection of bone marrow stem cells, doses of 1, 5, 10\*106 cells/kg was taken according to the previous clinical studies.
214341209|NCT05658692|DRUG|Sedative analgesia/muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
214341210|NCT05658692|DRUG|inotropes therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
214341211|NCT05658692|DRUG|Vasoactive drug therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
214341212|NCT02534974|DEVICE|NOSTEN|
214341213|NCT00418171|DRUG|Ziprasidone|
214341214|NCT00418171|DRUG|Olanzapine|
214341215|NCT01784705|DEVICE|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
214341216|NCT01784705|DEVICE|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
214341217|NCT04260581|DRUG|Determination of drug effects through amantadine cessation|Patients will discontinue amantadine, which has been taken since beginning of diagnosis.
214341218|NCT04287933|DEVICE|Drain insertion|insertion of a drain
214341219|NCT01902849|OTHER|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~* T0- before the induction of anesthesia (venous cannula insertion time)~* T1- after induction but before starting surgery~  * In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~ * In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~* T2, T3- at 2 and 24 hours after surgery"
214341220|NCT03789422|DRUG|association of levocetirizine and tranexamic acid|levocetirizine 10 mg/day + tranexamic acid 2 g/day
214341221|NCT03789422|DRUG|Levocetirizine only|levocetirizine 20 mg/day
214341222|NCT00893490|DEVICE|Ahmed Glaucoma Valve (AGV)|AGV implantation
214945389|NCT02018354|PROCEDURE|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
214945390|NCT02018354|PROCEDURE|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
214945391|NCT04962828|OTHER|Vocabulary based intervention- Non Collaborative|List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks Only with SLP
214341223|NCT00893490|DRUG|Mitomycin C (MMC)|3 minute MMC application
214341224|NCT00893490|PROCEDURE|amniotic membrane coverage|single layer coverage of amniotic membrane
214341225|NCT04674059|OTHER|patient survey|A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.
214341226|NCT03299595|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
214341227|NCT04616651|BEHAVIORAL|Online Survey|Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
214341228|NCT04616651|BEHAVIORAL|Chatbot prototype|An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
214341229|NCT04616651|BEHAVIORAL|Open to Options (O2O) Program|Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
214341230|NCT05005546|BEHAVIORAL|Yoga|Yoga will be applied to mothers in the yoga group
214341231|NCT05005546|BEHAVIORAL|Laughter Yoga|Laughter Yoga will be applied to mothers in the yoga group
214341232|NCT04880941|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
214347444|NCT05044572|OTHER|Forward head posture correction exercises|PatienGroup B participants will perform forward head correction exercise(22) Chin tuck Patient will Stand with upper back against a wall, feet shoulder-width apart. • Face forward, tuck your chin down, and pull head back until it meets the wall. • t
214347445|NCT02588391|BEHAVIORAL|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
214347446|NCT02588391|BEHAVIORAL|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
214341233|NCT03634579|DEVICE|MRI Guided Focal Laser Interstitial Thermal Ablation|"The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps."
214341234|NCT05378711|DRUG|Fluoxetine|Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.
214341235|NCT02905526|BEHAVIORAL|Contraceptive instant messages|Contraceptive Instant messages
214341236|NCT02905526|OTHER|Mobile phone app|Mobile phone app
214341237|NCT02817789|DRUG|Ticagrelor alone|180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
214341238|NCT02817789|DRUG|Combination lysine acetylsalicylate - clopidogrel|75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
214341239|NCT00187798|DRUG|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
214341240|NCT01789944|BEHAVIORAL|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
214341241|NCT03604250|DIETARY_SUPPLEMENT|Lifestyle plus prebiotic supplement|Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
214945392|NCT04962828|OTHER|Vocabulary based intervention - Collaborative|List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks With SLP and to be reinforced by teachers in class over the week
214945393|NCT06055998|DEVICE|MRI|MRI SPINE
214945394|NCT02733198|OTHER|Prognosis-guided therapy|
214945395|NCT05032456|DEVICE|Oculus Quest All-in-one VR Gaming Headset (128 GB) VR system|The laboring women who enrolled in the VR group were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the screenshots of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance.
214945396|NCT01180556|DIETARY_SUPPLEMENT|Probiotics|Daily oral supplementation for four weeks
214945397|NCT01180556|DIETARY_SUPPLEMENT|Placebo|Placebo administration
214945398|NCT04477733|DRUG|Butorphanol Injection|Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy
214945399|NCT04477733|DRUG|Saline|Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
214945400|NCT00206089|DRUG|EXANTA|
214945401|NCT06081959|DRUG|SKB264|IV infusion on day 1 and Day 15 of each 28 day cycle
214945402|NCT06081959|DRUG|Eribulin|1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
214945403|NCT06081959|DRUG|Capecitabine|1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
214945404|NCT06081959|DRUG|Gemcitabine|1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
214945405|NCT06081959|DRUG|Vinorelbine|25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
214945406|NCT01564641|DEVICE|iDuo G2|single comparator
214945407|NCT03383952|BIOLOGICAL|ICAR19 CAR-T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
214945408|NCT00314132|BIOLOGICAL|ChimeriVax-JE, Japanese Encephalitis vaccine|0.5 mL, Subcutaneous
214945409|NCT00314132|BIOLOGICAL|0.9% Saline|0.5 mL, Subcutaneous
214945410|NCT00678470|DRUG|Intralesional Alefacept|Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
214945411|NCT03108937|DRUG|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
214341242|NCT04986657|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
214341243|NCT01927445|OTHER|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
214341244|NCT02297152|DEVICE|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
214945412|NCT03108937|DRUG|saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
214945413|NCT00968097|DRUG|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
214341245|NCT01897584|OTHER|inverse IE|in only one group changes of I:E ratio would be applied
214341246|NCT00984841|OTHER|Tailored letter|
214341247|NCT02323724|GENETIC|BRAF V600E mutation by pyrosequencing technique|
214341248|NCT01494285|DRUG|ARK-E021 5%|Topically applied once daily at bedtime
214945414|NCT00428922|DRUG|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
214945415|NCT00428922|DRUG|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
214945416|NCT00428922|DRUG|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
214945417|NCT03131934|BIOLOGICAL|Autologous EBV-CTL transduced with vector SFG-CNA12|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
215075102|NCT06380439|PROCEDURE|wrist ankle acupuncture|wrist ankle acupuncture: wrist ankle acupuncture using 0.25 x 25mm filiform needle on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, then covered with 5cm long micropore, retention for 4 hours
215075103|NCT04699032|DRUG|Apraglutide|Single dose of apraglutide 5 mg.
214677466|NCT06491823|DEVICE|Somatosensory evoked potentials|Somatosensry evoked potentials will be obtained in each recording block
214677467|NCT03478124|BEHAVIORAL|Cognitive evaluation|An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
214677468|NCT03825042|DIETARY_SUPPLEMENT|A mix of bioactive natural compounds|A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets
214677469|NCT03825042|DIETARY_SUPPLEMENT|Placebo|Inactive compound in oral tablets
214677470|NCT02385032|DRUG|Ursodiol|
214341249|NCT01494285|DRUG|ARK-E021 10%|Topically applied once daily at bedtime
214341250|NCT01494285|DRUG|Placebo|Topically applied once daily at bedtime
214341251|NCT04111497|DRUG|Glasdegib|Given PO
214341252|NCT06141642|DEVICE|Self-adaptive serious game|A self-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
214341253|NCT06141642|DEVICE|Non-adaptive serious game|A non-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
214341254|NCT03321019|DRUG|Capsaicin|Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
214341255|NCT03321019|DEVICE|Resistive respiratory loads|Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
214341256|NCT03321019|OTHER|Event-related evoked potential using electroencephalography (EEG).|The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
214341257|NCT03321019|PROCEDURE|Fluoroscopic swallow evaluation|Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
214341258|NCT02323464|PROCEDURE|Surgery for colorectal cancer|Includes open and minimally invasive surgery for colon- and rectal cancer
214341259|NCT02323464|OTHER|No Interventions|This is a control group from the population. They are not scheduled for surgery
214945418|NCT03131934|BIOLOGICAL|Autologous EBV-CTL transduced with control vector SFG-CNA8|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
214945419|NCT03131934|PROCEDURE|Leucapheresis|Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
214945420|NCT01380691|DRUG|LY2216684|Administered orally
214341260|NCT04090307|BEHAVIORAL|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for \~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
214347447|NCT02588391|BEHAVIORAL|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
214677471|NCT02385032|DRUG|URSO Forte|
214945421|NCT01380691|DRUG|Placebo-matching LY2216684|Administered orally
215075104|NCT02839577|DRUG|High Volume injection without corticosteroid|"Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon."
215075105|NCT02839577|DRUG|High Volume injection with corticosteroid|Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
215075106|NCT00775112|DEVICE|pillow|use of pillow for lumbar punctures
215075107|NCT00051220|BEHAVIORAL|One-Session Treatment for Specific Phobias|
215075108|NCT05076214|BEHAVIORAL|Aerobic exercise in group|"The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions~Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
214677472|NCT00805883|PROCEDURE|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
214677473|NCT05801523|PROCEDURE|laparoscopic ethanol sclerotherapy|ethanol (96%) sclerapy of endometrioma - endometrioma is filled with ethanol via foley catether, left for 10 min and than aspirated, endometrioma is washed with saline
214677474|NCT05801523|PROCEDURE|laparoscopic cystectomy of endometrioma|cystectomy of endometrioma - removal of endometrioma from ovary surgically
214677475|NCT05453370|DEVICE|CALMA m-health app|CALMA is an app for smartphones that provides evidence-based tools to prevent suicide. Out of Crisis modality consists of 4 sections: Moments, Agenda, Profile and Tips. The I need help modality uses DBT skills presented in a card format. The Problem-solving Card is the first one showed and helps the user to know if the problem that triggered the crisis can be addressed through a problem-solving strategy. If not, the next step is to use the CALMA thermometer (to identify the intensity of the emotion) and the DBT Skills Cards. They are based fundamentally in two groups of DBT skills, emotional regulation and distress tolerance. If distress worsens or does not diminish the Emergency Card is activated, offering the user the option to make one or several calls to emergency contacts and providing the option to use the geolocation function to show all emergency services near the user's location so that he/she can consult personally. All participants will also receive mental health treatment.
214677476|NCT05453370|OTHER|Treatment As Usual (TAU)|Participants who do not receive the application will continue the usual mental health treatment (psychotherapeutic and/or psychopharmacological) by their usual treating professionals throughout the duration of the study.
214677477|NCT01654562|DRUG|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
214341261|NCT04184076|BEHAVIORAL|Time-restricted feeding (TRF) with dietary counseling|"1. Subjects will be instructed to administer time-restricted feeding.~2. Subjects have to compete a 3-d food record, including 2 regular day and 1 holiday. At baseline, a dietitian will provide 15 min of instruction to each participant on how to complete the food records. Subjects will be asked to measure the volume of foods consumed with household measures. The timing of food intake will be also recorded. Food records will be collected each week during the experiment and will be reviewed by the dietitian for accuracy and completeness. A database for food content will be used to calculate the total daily intake of energy, fat, protein, carbohydrate, cholesterol, and fiber. All subjects will be asked to maintain their level of physical activity throughout the entire trial.~3. Blood withdraw will be performed prior to the first consumption of food and analyze some biochemistry data."
214341262|NCT04543929|BEHAVIORAL|exercise|partially supervised and home-based exercise activity
214341263|NCT01304836|DRUG|Advagraf|oral
214341264|NCT01304836|DRUG|Mycophenolate Mofetil|oral
214341265|NCT01304836|DRUG|Simulect|IV
214341266|NCT01304836|DRUG|Corticosteroids|IV \& oral
214341267|NCT05872139|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
214341268|NCT05872139|DIETARY_SUPPLEMENT|Mitoquinone Mesylate|MitoQ was given once (single dose, 80 mg)
214945422|NCT01380691|DRUG|Placebo-matching alcoholic beverage|Administered orally
214341269|NCT04481347|DEVICE|Sleep EEG recording using a DREEM® headband|Sleep EEG recording using a Dreem® headband (Rythm, Paris, France), an EEG recording device adapted to sleep conditions and completely non-invasive
214341270|NCT04481347|OTHER|Montreal Cognitive Assessment (MoCA)|Neuropsychological assessment using the The Montreal Cognitive Assessment (MoCA) questionnaire to detect postoperative cognitive dysfunction
214341271|NCT04481347|DEVICE|Intraoperative EEG recording using a Sedline® monitoring|Intraoperative brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
214945423|NCT01380691|DRUG|Alcoholic beverage|Administered orally
214945424|NCT05475626|PROCEDURE|Arthroereisis-|Surgical options include soft tissue procedures, realignment osteotomies and non-fusion motion-limiting techniques.
214945425|NCT03996226|DRUG|E7386|E7386 oral tablets.
214945426|NCT03930784|OTHER|Nil intervention|
214945427|NCT00815334|PROCEDURE|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
214945428|NCT02247232|DRUG|Z-100|
214945429|NCT02247232|DRUG|Placebo|
215075109|NCT05076214|BEHAVIORAL|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together
214677478|NCT01959555|OTHER|No treatment given|Patients will not be treated with any specific product. Data collection only.
214677479|NCT03080922|BIOLOGICAL|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
214677480|NCT06169865|OTHER|cross sectional study|cross sectional study to explore magnitude of peripheral vascular diseases and presentations in patients with autoimmune diseases in sohag society.
214677481|NCT03723265|DEVICE|Cardiac Resynchronization Therapy|
214341272|NCT04413604|OTHER|Young children's milk (1-<3)|young children's milk containing protein, energy and fat and micronutrients, in accordance with global and local nutritional recommendations for ages 1-3.
214341273|NCT03895060|DEVICE|autogenous ring blockls with GBR covered by collagen membrane|"* A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~* Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~* Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~* The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
214945430|NCT05360914|OTHER|Hospital at Home (HaH) treatment|The intervention is a new pathway of providing acut treatment for elderly acute ill patients in their own home. If the patient is randomized to the intervention group, the municipalities acute teams start the treatment. The acute team can take venous blood tests, ECG and bladder scan at home. The acute team handles the treatment at home and follows the patient closely. During the treatment course, the acute team and the ED specialist discuss the treatment process either over the phone or virtually on an iPad, where the patient is also involved. If the specialist would like to see the patient for assessment or send the patient for an X-ray, the specialist informs the acute team that the patient must go to a short check-up in the ED. Here, the specialist examines the patient himself and assesses whether the patient can continue to be treated at home, or whether the patient must be admitted to the hospital due to deterioration of the condition.
214945431|NCT05360914|OTHER|Standard hospital admission|The active comparator is the standard hospital admission for elderly acute ill patients.
214945432|NCT03151213|DRUG|Pregabalin 150mg|Pregabalin 150mg before RFA of liver cancer
214945433|NCT03151213|OTHER|Placebo|Placebo before RFA of liver cancer
214945434|NCT05269589|OTHER|Thermoneutral water|Participants will immerse their feet in a foot bath that contains thermoneutral water
214945435|NCT05269589|OTHER|Hot water|Participants will immerse their feet in a foot bath that contains hot water
214945436|NCT02811575|OTHER|Biopsy|Ileon and colon biopsy
214945437|NCT00571025|BEHAVIORAL|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
214945438|NCT05972941|BEHAVIORAL|Health communications|Participants will view eight culturally targeted or non-targeted health communications about the health risks of nicotine and tobacco use.
214945439|NCT05636787|DRUG|Treosulfan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
214945440|NCT05636787|DRUG|Melphalan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
214945441|NCT01060605|DRUG|rapamycin|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
214945442|NCT06204406|OTHER|Observational|This is a prospective observational study with observation only and no intervention
214945443|NCT01987232|DRUG|Carfilzomib|Administered by intravenous infusion.
214677482|NCT04483362|BEHAVIORAL|Complex physical activity intervention|"Structured weekly sessions with a Physiotherapist over an 8 week period, including:~* Evaluation of current levels of physical activity and physical function - including discussion of results~* Education regarding the importance of physical activity~* Supervised physical activity session with a physiotherapist~* Structured weekly sessions applying behavioural change techniques which aim to increase participation in physical activity. Sessions include: provision of activity monitor (Fitbit Inspire), goal setting, monitoring, collaborative problem solving and action plan implementation. Intervention includes additional time allowance of 1 hour per week to assist in implementing action plan items"
214677483|NCT01225393|DRUG|MLTA3698A|Subcutaneous repeating dose
214677484|NCT01225393|DRUG|adalimumab|Subcutaneous repeating dose
214677485|NCT01225393|DRUG|leflunomide|Stable dose if not on methotrexate
214945444|NCT01987232|DRUG|Carboplatin|Administered by intravenous infusion.
214945445|NCT01987232|DRUG|Etoposide|Administered by intravenous infusion.
214945446|NCT00586508|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).
214677486|NCT01225393|DRUG|methotrexate|Stable dose if not on leflunomide
214677487|NCT01225393|DRUG|placebo|Subcutaneous repeating dose
214677488|NCT03591705|DRUG|TACE-HAIC|transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
214677489|NCT03591705|DRUG|HAIC|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
214677490|NCT04270851|DIAGNOSTIC_TEST|LiMAx test|The LiMAx test is a fully licenced liver function test, testing liver maximum capacity via a breath test.
214677491|NCT04270851|DIAGNOSTIC_TEST|HepaT1ca magnetic resonance scan|The HepaT1ca scan is a pre-operative magnetic resonance scan providing a detailed report permitting interactive virtual pre-operative planning prior to liver surgery.
214677492|NCT02992470|DIETARY_SUPPLEMENT|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
214341274|NCT05758662|DIAGNOSTIC_TEST|18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)|Patients undergo a hybrid 18F-NaF-PET CT scan and TTE at five years after TAVI
214341275|NCT03814447|DRUG|anti- MESO CAR-T cells|Autologous genetically modified anti- MESO CAR transduced T cells
214945447|NCT00586508|DRUG|bevacizumab|10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).
214945448|NCT00586508|DRUG|Enzyme-inducing antiepileptic drugs (EIAED)|Administered orally
214945449|NCT00586508|DRUG|Non-enzyme inducing antiepileptic drugs (NEIAED)|Administered orally
214945450|NCT06465914|BIOLOGICAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
214945451|NCT06465914|BIOLOGICAL|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
214945452|NCT00051181|DRUG|Travoprost (0.004%)|
214945453|NCT00051181|DRUG|Latanoprost (0.005%)|
214945454|NCT04904783|RADIATION|Low dose radiotherapy|Patients in study group will receive LDRT to both lungs by two parallel opposed fields, antero-posterior (AP) and postero-anterior (PA) to deliver a midplane dose of 0.5 Gy in a single fraction. As this dose is very less, doses to the critical structures including heart and lungs would be very low. All the patients will be treated on Telecobalt unit (Theratronics Phoenix, Canada) and not on the linear accelerator to avoid risks to cancer patients on treatment with linear accelerator. CT based plan will not be undertaken for logistic issues and is also not felt to be mandatory for this LDRT. Dose computation would be carried out by manual dose calculation for the Telecobalt unit.
214341276|NCT03814447|DRUG|Fludarabine|Dose: 30mg/m2/d
214341277|NCT03814447|DRUG|Cyclophosphamide|Dose: 300mg/m2/d
214945455|NCT04311281|BIOLOGICAL|[F-18]FDDNP-PET|\[F-18\]FDDNP, or 2-(1-{6-\[(2-\[F-18\]fluoroethyl)(methyl)amino\]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.
214945456|NCT00367419|DRUG|Erythromycin|
214945457|NCT02928146|PROCEDURE|Hernia Repair|
214945458|NCT00758147|DEVICE|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
214945459|NCT00235066|DEVICE|PCI|PCI with Cypher Sirolimus-Eluting Stent
214945460|NCT06671587|DRUG|iGlarLixi (insulin glargine/lixisenatide)|"iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector.~There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day:~\- iGlarLixi must not be mixed with other insulins nor diluted."
214945461|NCT06671587|DRUG|Gla-100 (insulin glargine)|Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
214945462|NCT02959515|PROCEDURE|Capnothorax|Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
214945463|NCT02959515|PROCEDURE|Capnothorax and CPAP|"Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.~Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager."
214945464|NCT06353646|BIOLOGICAL|XH001|XH001 will be administered 12 weeks post-tumor resection (+/- 2 weeks)
214945465|NCT06353646|DRUG|Ipilimumab Injection|Ipilimumab will be administered 12 weeks post-tumor resection (+/- 2 weeks)
214945466|NCT06353646|DRUG|Sintilimab injection|Sintilimab will be administered 12 weeks post-tumor resection (+/- 2 weeks)
214945467|NCT06353646|DRUG|Chemotherapy|gemcitabine + capecitabine
214341278|NCT05269264|DIAGNOSTIC_TEST|Assessor A (first measurement): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
214677493|NCT02992470|DIETARY_SUPPLEMENT|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
214347448|NCT00845572|BEHAVIORAL|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
214945468|NCT06011460|DRUG|Clozapine|"Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5).~Age from 18 to 65 years old."
214945469|NCT03599856|OTHER|TraceBook|TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
214945470|NCT06173739|PROCEDURE|Non-surgical mechanical treatment|"Nonsurgical mechanical therapy (NSMT) aims to control infection and minimize bacterial burden through debridement of the implant surface. It is the gold standard treatment method for both peri-implantitis and peri-implant mucositis.~Non-surgical mechanical treatment will be applied to patients with the purpose of surface debridement and reducing bacterial flora in implants with peri-implant disease for which clinical examination has been completed and the diagnosis has been confirmed. All intraoral implants of the patients will be evaluated and all implants that do not meet the clinical definition of health will be intervened. Each implant surface will be treated with a titanium curette. In all groups, mechanical debridement was performed on the surfaces by the same clinician.~The procedure will continue gently until it is felt that it has been adequately debrided. Subgingival irrigation will be performed with physiological saline. Post NSMT No medication will be administered."
214677494|NCT02467452|DRUG|BDP/FF/GB|
214677495|NCT02467452|DRUG|FlF/VI + Tiotropium|
214677496|NCT02316470|BIOLOGICAL|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
214347449|NCT06284811|BEHAVIORAL|Exercise program focusing on quadriceps|Participants will be asked to perform the exercise program that focusing on quadriceps muscle
214945471|NCT03259828|RADIATION|Adjuvant image-guided radiotherapy|Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
214945472|NCT02183805|DRUG|Abraxane,Cyclophosphamide,Carboplatin|High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
215075110|NCT06102122|DIETARY_SUPPLEMENT|Compleat|Patients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch
215075111|NCT05996055|DEVICE|improved version_support device|designed the NTUH version\_support device based on the clinical suggestion.
215075112|NCT05996055|DEVICE|the NTUH version_support device|original designed by NTUH
214347450|NCT05457946|BIOLOGICAL|LBVD (Hexavalent vaccine)|Injection within the muscle into the front area of the thigh
214677497|NCT02316470|BIOLOGICAL|Placebo|phosphate buffered saline (PBS) solution
214677498|NCT03475407|DRUG|Ozurdex intravitreal injection|"1. Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~2. AC paracentesis at 6 wk~3. intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk"
214677499|NCT00404404|BIOLOGICAL|bevacizumab|
214677500|NCT00404404|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
214677501|NCT03070457|OTHER|Early discharge|Patients randomised to early discharge or not
214945473|NCT03176667|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process. The trapezius, rhomboid major, and erector spinae muscles will then be identified superficial to the tip of the T5 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.5% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg), followed by insertion of a 19-gauge catheter under direct vision 5 cm beyond the needle tip. The catheter will then be secured in place.
214341279|NCT05269264|DIAGNOSTIC_TEST|Assessor B: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
214347451|NCT05457946|BIOLOGICAL|Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)|Injection within the muscle into the front area of the thigh
214945474|NCT03176667|PROCEDURE|Intercostal block|The surgeons will identify the desired rib, and advance the needle at an approximately 20-degree angle until contact with rib is made, the needle is then walked of the inferior border of the rib and advanced slightly to plaice the tip of the needle in the neurovascular bundle. The intercostal nerve blocks will be performed at T4-T11 using 0.25% Marcaine with epinephrine and a volume of 5 ml per block (maximum of 2.5mg/kg) after negative aspiration has been confirmed.
214945475|NCT05556850|BEHAVIORAL|STABL Virtual Rehabilitation|"STABL is a digital health platform that uses computer-vision technology to facilitate at-home post-op recovery for patients while enabling remote monitoring by their surgeon. The platform is fully HIPAA compliant.~STABL analyzes a patient's biomechanics in real time while they perform their recovery exercises to provide them with cues to ensure the exercises are done correctly and track adherence. They then relay all the data to the patient's clinician to allow them to monitor their recovery remotely, address any adherence barriers, and mitigate readmission risks that arise in a more timely manner."
214945476|NCT00083668|DRUG|Paliperidone ER|
214945477|NCT06600191|DEVICE|Capstan System transcatheter mitral valve replacement|This is a first human use trial exploring a novel transcatheter mitral valve replacement implant and electro-mechanical delivery system. The device offers a minimally invasive repair for patients who have at symptomatic regurgitation who are otherwise ineligable for surgical intervention, or who have no other prospects for treatment and in whom medical therapy has already been optimised.
214945478|NCT06624436|DRUG|Dexamethasone|Dexamethasone 6mg in 10mL NaCl 0.9% i.v. bolus + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
214945479|NCT06624436|DRUG|Tocilizumab|Tocilizumab 600mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
214945480|NCT06624436|DRUG|Anakinra|Anakinra 200mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
214945481|NCT06624436|DRUG|Placebo|Bolus of 10mL NaCl 0.9% placebo + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
214945482|NCT06624436|BIOLOGICAL|LPS|This is a non-investigational product. It is used as challenge agent to achieve a controlled inflammatory state.
214945483|NCT06625983|OTHER|CRC decision tool|CRC decision tool included in the primary care bundle questionnaire
214945484|NCT07014631|DRUG|SSS17|The SSS17 treatment arm comprises three dose levels: the first two dose levels will have an 8-week treatment duration, while the third dose level will extend to 24 weeks. At each dose level, participants will be allocated in a 4:1 ratio (SSS17:placebo) for enrollment.
214945485|NCT07014631|DRUG|Placebo|At each dose level, participants will be allocated in a 4:1 ratio (SSS17:placebo) for enrollment.Placebo recipients will undergo weekly dosing identical to the active treatment group within their assigned dose cohort.
214677502|NCT03070457|OTHER|Conventional protocol|Discharge as usually done 48-72 hours after surgery
214347452|NCT03712917|PROCEDURE|Greater Occipital Nerve Block|An enjection to paralyze the occipital nerve.
214347453|NCT03712917|DRUG|Topiramate|An antiepileptic agent used for migraine prophylaxis.
214347454|NCT03712917|DRUG|Flunarizine|A calcium overload blocker agent used for migraine prophylaxis.
214347455|NCT00119509|PROCEDURE|HPV DNA testing|
214677503|NCT01856491|DEVICE|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
214341280|NCT05269264|DIAGNOSTIC_TEST|Assessor A (second measurement: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
214341281|NCT05269264|DIAGNOSTIC_TEST|Assessor A (2 weeks later): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
214341282|NCT04842695|DEVICE|electroacupuncture group|compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
214341283|NCT01465893|DRUG|Vitamin D|vitamin D ,50000 unit /week
214341284|NCT01465893|DRUG|Vitamin D withheld|do not receive anything
214341285|NCT04109989|DEVICE|HominisTM Surgical System|Trans-vaginal gynecological procedures
214341286|NCT00931177|OTHER|weight|weight and dehydration scores
214341287|NCT00931177|OTHER|weight and dehydration score|weight and dehydration score
214341288|NCT04125693|DRUG|Rogaratinib (BAY1163877)|Participants will be treated with investigational drug following the treatment schedule and dosing instructions from the feeder-study protocol.
214341289|NCT04125693|DRUG|Combination drug|Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
214341290|NCT00043446|DRUG|intravenous T900607-sodium|
214341291|NCT06341218|OTHER|Pediatric Cardiopulmonary Resuscitation Training Based On Team Resource Management|"The sociodemographic information form, Pediatric CPR knowledge level and teamwork attitudes pretest were administered to the healthcare teams just before the training intervention.~The intervention group received a 3-hour training intervention on technical/non-technical skills for CRM-Based Pediatric CPR Training To measure pediatric CPR team performance, 5 different scenarios were prepared by the researcher by INACLS standards. One day after the training intervention, simulation application including pediatric cardiac arrest scenarios was applied to all CPR teams in the intervention(5 groups) and control(5 groups) groups. The scenario content was based on a 5-year-old male patient diagnosed with Pneumonia+Septic Shock.~Pediatric CPR skill levels of the healthcare teams were evaluated during the simulation practice. Immediately after the simulation, the post-intervention post-test of Pediatric CPR knowledge level and team attitudes of the healthcare teams was performed."
214347456|NCT00119509|PROCEDURE|Conventional management (repeat Pap smear at 6 months)|
214347457|NCT00119509|PROCEDURE|Decision aid with choice of management|
214347458|NCT02098200|DEVICE|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
214677504|NCT02823262|OTHER|Breast Cancer Treatment Decision Aid for women 70+|We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
214677505|NCT02823262|OTHER|Usual Care|
214945486|NCT05537610|BEHAVIORAL|CDT|In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.
214945487|NCT05537610|BEHAVIORAL|Control|This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
214945488|NCT05215912|DRUG|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
214945489|NCT05215912|DRUG|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
214945490|NCT06207240|DEVICE|NeuroLife FES Sleeve / NeuroLife EMG-FES Sleeve|Electrical stimulation will be delivered via the NeuroLife FES Sleeve and NeuroLife EMG-FES Sleeve devices to assist with movement during functional task practice.
214945491|NCT05125913|DIAGNOSTIC_TEST|FMD|Measurements will be made by using ultrasound system with a 12-Mhz probe. All vasoactive medications will be withheld for 24 h before the procedure. The participants will remain at rest in the supine position for at least 15 minutes before the examination. Each subject's right arm will be comfortably immobilized in the extended position to allow consistent recording of the brachial artery 2-4 cm above the antecubital fossa. If an arteriovenous fistula is present, the contralateral arm will be used for assessment. Three adjacent measurements of end-diastolic brachial artery diameter will be made from single 2D frames. The maximum FMD diameters will be calculated as the average of the three consecutive maximum diameter measurements after hyperemia and nitroglycerin, respectively.
215075113|NCT00741195|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
214945492|NCT05125913|DIAGNOSTIC_TEST|Arterial stiffness|Arterial stiffness assessment will be performed by applanation tonometry with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference-acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
214341292|NCT02332486|DRUG|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
214945493|NCT05125913|DIAGNOSTIC_TEST|Assessment of IMT|A high-resolution B-mode ultrasound of the common carotid arteries with scanning of the longitudinal axis until the bifurcation and of the transversal axis will be performed using ultrasonic pulse with a middle frequency of 12 MHz. For each carotid artery, two longitudinal measurements will be obtained by rotating the vessels at 180o increments along their axis. IMT will be measured at 1 cm proximal to the bifurcation on each side.
214945494|NCT05125913|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed on each patient at baseline; the measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
214945495|NCT05125913|DIAGNOSTIC_TEST|LUS|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
214945496|NCT05125913|DIAGNOSTIC_TEST|BIS analysis|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device using specific electrodes. Based on a fluid model using 50 discrete frequencies (5-1000kHz), the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
214945497|NCT05125913|OTHER|Biomarkers determination|Biomarkers by ELISA: IL-1, IL-6, VCAM1, Endoglin, NO and ADMA
214945498|NCT02909829|DEVICE|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm.
214945499|NCT02909829|DEVICE|Closed Loop Delivery with Meal Detection Module|Closed Loop Delivery with Meal Detection Module Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm
214945500|NCT02909829|DEVICE|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate
214945501|NCT06618521|DRUG|Anti-hypertensive drug (Methyldopa 250 mg)|Each women in the three groups will receive Medical treatment Anti-hypertensive drug (Methyldopa 250 mg) according to physician instructions.
214945502|NCT06618521|OTHER|Pilates exercise|Each women in the second group will receive Mat Pilates training exercise for 40 minutes/ day, 3 days/week, for 12 weeks beginning 20 weeks' gestation. The Pilates exercise includes pelvic floor exercise, deep tummy strengthening, pelvic tilt, upper back stretch, the cat stretch, thigh stretch, the sword, sword arm, and wagging the tail.
214677506|NCT04695730|OTHER|Active physical therapy (including both pain education and home exercises)|"One session (60 minutes). In this session, a physical therapist will explain and demonstrate the exercises to perform individually at home. Exercises will be performed daily. In addition, an education session will be provided, concerning pain mechanisms and management. To support patients during the treatment, a booklet will be created.~One booster session (30minutes) will be planned after 4 weeks. Patients will follow the active treatment for 8 weeks."
214341293|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-5 minutes|
214341294|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-1 minute|
214677507|NCT04695730|OTHER|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
214347459|NCT04160780|PROCEDURE|L-PRF|sinus augmentation using L-PRf as sole graft material
214677508|NCT04056130|DRUG|KBL697|"Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral"
214677509|NCT04056130|DRUG|KBL697|"Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral"
214677510|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral"
214677511|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral"
214677512|NCT05031325|DEVICE|Endoscopic submucosal dissection with Purastat|Purastat (peptidic gel) application
214341295|NCT02255110|DRUG|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m\^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
214341296|NCT02255110|DRUG|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
214341297|NCT05235880|OTHER|Virtual reality based games|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes virtual reality based games aiming improvement on upper extremities, trunk and cognitive functions.
214341298|NCT05235880|OTHER|Conventional exercises|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes conventional physiotherapy approaches aiming improvement on upper extremities, trunk and cognitive functions.
214341299|NCT03877367|OTHER|Upper extremity manipulation|An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
214341300|NCT04289753|BEHAVIORAL|EHR clinical decision support nudges|Clinical decision support nudges delivered within the EHR when conditions meet alert triggering criteria.
214341301|NCT04289753|BEHAVIORAL|Brief clinician education|Clinicians will be invited to view brief education material.
214341302|NCT01646476|DEVICE|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
214341303|NCT01646476|DEVICE|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
214341304|NCT00034762|DRUG|risperidone|
214341305|NCT06057051|DEVICE|iStent Infinite|iStent Infinite Trabecular Micro-Bypass System
214341306|NCT03433456|BEHAVIORAL|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
214945503|NCT06618521|OTHER|Circuit exercise training|Each women in group C will receive circuit training exercises in form of single leg curl up and press, sumo squat and row to reverse fly stand for 40 minutes/ day, 3 days/ week, for 12 weeks beginning 20 weeks' gestation. The Circuit exercise training includes sumo squat, quadruped extension, row to reverse fly stand, and single leg curls up.
214945504|NCT03564795|DEVICE|KeraStat Gel|Wound dressing for partial thickness burns
214677513|NCT00184639|DRUG|insulin detemir|
214677514|NCT00079612|DRUG|Sorafenib (Nexavar, BAY43-9006)|800mg daily (2x 400mg tabs)
214341307|NCT03433456|BEHAVIORAL|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
214341308|NCT02038738|DRUG|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
214341309|NCT05548790|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S)|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
214677515|NCT00079612|DRUG|Placebo|2x 400mg tabs daily
214945505|NCT03564795|DEVICE|Silver Sulfadiazine|Wound dressing for partial thickness burns
214945506|NCT04984759|DRUG|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
214945507|NCT04984759|DRUG|Tafenoquine|Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
214945508|NCT04877158|BEHAVIORAL|Self-Blame and Perspective-Taking Intervention|The intervention is a group therapy that consists of experiential art tasks followed by psychoeducation about social behaviors with weekly homework. There are four sessions, each one week apart.
214945509|NCT02647489|BIOLOGICAL|PAMVAC|
214945510|NCT02647489|BIOLOGICAL|Alhydrogel|
214945511|NCT02647489|BIOLOGICAL|GLA-SE|
214945512|NCT02647489|BIOLOGICAL|GLA-LSQ|
214945513|NCT02647489|OTHER|Placebo|
215075114|NCT00741195|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
215075115|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule|Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks
214341310|NCT05548790|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
214945514|NCT06875882|BEHAVIORAL|Occupational Stress in Surgeons and Musicians|Participants will complete 5 questionnaires about participants demographics, burnout rates, and anxiety levels after participants consent to this study. These questionnaires will be sent to participants via email and should take about 15-20 minutes to complete.
214945515|NCT07019857|DIAGNOSTIC_TEST|Blood sample collection at surgery time and 12 months later|"each participant undergoes a blood test 1) at surgery time and 2) 12 months after surgery. These 5mL samples include:~* Blood cell count~* TREC dosage~* Complete Lymphocytes immunophenotyping~* Immunoglobulin dosage"
214945516|NCT00770133|DRUG|Ketotifen/naphazoline|One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.
214945517|NCT00770133|DRUG|Naphazoline|One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
214945518|NCT00770133|DRUG|Ketotifen|One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
214945519|NCT00770133|DRUG|Vehicle|One drop of vehicle ophthalmic solution at visit 3 and visit 4.
214945520|NCT02580474|DRUG|Daclatasvir plus Asunaprevir|
214945521|NCT02906033|OTHER|New perioperative practice model|The one and same anesthesia nurse takes care of the patient during the entire perioperative process and even pays the patient a visit to the ward the day after surgery.
214945522|NCT06113341|DRUG|IDegLira|Pre-filled pen injection.
214945523|NCT04650126|BIOLOGICAL|ATM001|monovalent anti-TNF-receptor 1 antibody format
214945524|NCT04650126|BIOLOGICAL|ATM001 Placebo|ATM001 Placebo
214945525|NCT01921738|DRUG|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
214945526|NCT01921738|DRUG|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
214945527|NCT01921738|DRUG|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
214945528|NCT01921738|DRUG|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
214945529|NCT00006341|OTHER|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
214945530|NCT06006273|DRUG|Eribulin|Given by vein (IV)
214945531|NCT06006273|DRUG|Irinotecan|Given by vein (IV)
214945532|NCT06006273|DRUG|Temozolomide|Given by PO
214945533|NCT07027514|DRUG|tolododekin alfa|Participants will receive tolododekin alfa as an intratumoral injection every 3 weeks (Q3W).
214945534|NCT07027514|DRUG|Cetrelimab|Participants will receive cetrelimab Q3W.
214677516|NCT02299908|DRUG|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
214677517|NCT02299908|DRUG|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
214677518|NCT00667758|DRUG|Cetrorelix|3-5 mg s.c. on days 1-5
214677519|NCT00667758|DRUG|Placebo|3-5 ml NaCl s.c. on days 1-5
214677520|NCT01207739|DRUG|Doxycycline|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
214341311|NCT05548790|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
214347460|NCT04160780|PROCEDURE|L-PRF mixed with xenograft|sinus augmentation using L-PRF mixed with xenograft as sole graft material
214347461|NCT04160780|PROCEDURE|xenograft|sinus augmentation using xenograft as sole graft material
214677521|NCT01207739|DRUG|Clarithromycin and hydroxychloroquine|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
214945535|NCT04402281|DIAGNOSTIC_TEST|suPAR algoritm|All medical patients attending to the ED and who will have blood drawn for routine examination will be part of the study. In patients with low suPAR (green group, suPAR below 3 ng/ml) and in patients with high suPAR (red group, suPAR \> 6 ng/mL) the Intervention will be carried out
214945536|NCT06493656|PROCEDURE|Ultrasound-guided glenohumeral space isolated corticosteroid injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
214945537|NCT06493656|PROCEDURE|Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection|Using a 21-gauge spinal needle, the predefined steroid solution with additional 15 mL of normal saline was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
214945538|NCT06493656|DRUG|1mL of Triamcinolone (40mg/1mL) Injectable Solution|1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen.
215075116|NCT04170504|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
214677522|NCT01207739|DRUG|Placebo|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
214677523|NCT03092258|OTHER|Questionnaire|Questionnaire to be completed by staff
214341312|NCT05548790|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
214341313|NCT03694548|BEHAVIORAL|Part A Survey|Survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
214341314|NCT03694548|BEHAVIORAL|Part B Yoga Program|Eight in-person instructor-led group yoga sessions.
214945539|NCT06493656|DRUG|4mL of Lidocaine 1% Solution Injectable Solution|4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen.
214945540|NCT06493656|DRUG|15mL of Normal Saline|15mL of 1% Lidocaine solution was included in the hydrodilatation regimen.
214341315|NCT02256475|DRUG|NBI-98854|
214341316|NCT03193294|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
214945541|NCT00889187|RADIATION|Neoadjuvant Short-Course Photon Radiation|
214945542|NCT00889187|DRUG|Capecitabine|
214945543|NCT02127736|DRUG|Amitriptyline|
214945544|NCT02127736|DRUG|Placebo|
214945545|NCT01468753|PROCEDURE|Vaginal Insemination|Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
214945546|NCT02237924|DRUG|endostar|Endostar 7.5mg / m2, 2 cycles of continuous intravenous pumping for ten days,and 2 cycles of maintenance therapy after radiotherapy
214341317|NCT02046434|DRUG|Glycerol Phenylbutyrate|
214341318|NCT05528094|DIETARY_SUPPLEMENT|GeniusDrops|"The active ingredients listed below are safe and the study sponsor has noted there are no known side effects of the supplement. The main ingredients are:~Hibiscus flower- Has been shown to boost oxygenation to the brain and vital organs. Has also demonstrated efficacy for boosting the immune system.~Gingko leaf- Has been shown to stimulate memory by increasing mental sharpness and clarity.~Rhodiola- Helps regulate energy and stress level. Gotu kola- Has been shown to have impacts on reducing anxiety. Licorice Root- Helps boost the key brain neurotransmitter called Brain Derived Neurotrophic factor which can help with cognitive development Peppermint Leaf- Reduces fatigue while helping improve cognitive abilities. Has also been shown to promote immune system function."
214341319|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by lavage)|
214945547|NCT02237924|DRUG|DDP|DDP:100mg/m2 for 2-3 cycles
214945548|NCT02237924|RADIATION|IMRT|IMRT:70-74Gy for 2-3 cycles
214945549|NCT01333956|DRUG|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
214945550|NCT01333956|DRUG|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
214677524|NCT05085392|BEHAVIORAL|Trauma-Informed Yoga|6 weeks of twice weekly trauma-informed yoga for 45 minutes per session
214341320|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by bolus)|
214341321|NCT02438566|DRUG|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
214341322|NCT02438566|DRUG|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
214341323|NCT06468488|PROCEDURE|DIEP flap surgery without drain|Patients will undergo a breast reconstruction with a DIEP flap without the placement of drains.
214341324|NCT06468488|PROCEDURE|DIEP flap surgery with drains|Patients will undergo a breast reconstruction with a DIEP flap with the placement of drains.
214945551|NCT01333956|DRUG|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
214945552|NCT01333956|DRUG|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
214945553|NCT02773745|BEHAVIORAL|Aquatic Prehab|Pool therapy
214945554|NCT05616117|OTHER|Intrauterine 90µg D-vitamin|Children of mothers who received 90 µg vitamin D3 daily during pregnancy:10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3
214945555|NCT05616117|OTHER|Intrauterine 10µg D-vitamin|Children of mothers who received 10 µg vitamin D3 daily during pregnancy, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
215075117|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule placebo|Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks
214677525|NCT02588846|DEVICE|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
214677526|NCT01988012|BIOLOGICAL|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
215075118|NCT00426400|DRUG|The cessation of anti-aggregative treatment for 10 days|
214945556|NCT04496505|DEVICE|Device|is a mask that uses sequences of flashing lights and analogous sounds to trigger a relaxed state in those with intense pain. Pilot studies have so far shown a statistically significantly decrease in pain, anxiety and opiate withdrawal, as well as an increase in heart rate variability. Preliminary data shows a statistically significant decrease in depression symptoms as measured by Patient Health Questionnaire 9 (PHQ-9) scale .
214945557|NCT04496505|DEVICE|Sham Device|The sham treatment device was designed to copy the look and feel of thetherapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
214945558|NCT01863498|OTHER|Epidural|Patients will have an epidural for pain control
214945559|NCT01863498|OTHER|PCA|Patients will have PCA for pain control
214945560|NCT00432276|DRUG|Alogliptin|Alogliptin tablets.
214945561|NCT00432276|DRUG|Pioglitazone|Pioglitazone tablets.
214945562|NCT00432276|DRUG|Metformin|Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
214945563|NCT00432276|DRUG|Placebo|Matching placebo tablets.
214945564|NCT02829827|DRUG|Radiprodil|Radiprodil at individualized doses.
214945565|NCT02330757|DRUG|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
214945566|NCT02330757|DRUG|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
214677527|NCT04842721|DRUG|Hypertonic Saturated Saline Mouth Rinse Active Arm|Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
214341325|NCT04496258|BEHAVIORAL|Positive Emotion Induction|Participants are expected to have a positive emotional response to the more positive beach scene.
214341326|NCT04496258|BEHAVIORAL|Neutral Emotion Induction|Participants are expected to have a neutral emotional response to the neutral office scene.
214341327|NCT00180739|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
214341328|NCT05343611|BEHAVIORAL|Combination of High Protein Diet and Physical Exercise protocol|"A high Protein Diet (HPro) will be provided to maintain individual caloric endpoint and to adjust protein intake to 0.9-1.0 g/Kg ideal body weight. Each participant will receive a tailored diet (taking into account personal preference) which will follow common general guidelines. Servings of food high in polyphenols will be limited to one per day.~Physical exercise will be undertaken three times each week for about 50 minutes per session. The intervention will consist of both aerobic and strength training exercises. Aerobic exercise will consist of walking on a treadmill with 4 x 4 minutes at (85-95% of HRmax), interrupted by 3-minute active recovery periods (60-70% of HRmax). Strength exercise consists of maximal strength training, using a seated leg press with 4 sets of 4 repetitions at \~90% of maximal strength (1RM). Rest periods between the sets will be 3-4 min."
214945567|NCT03948035|DRUG|Elotuzumab|i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.
214945568|NCT03948035|DRUG|Carfilzomib|i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
214945569|NCT03948035|DRUG|Lenalidomide|hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
214945570|NCT03948035|DRUG|Dexamethasone|orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
214945571|NCT03948035|OTHER|autologous stem cell transplant|autologous stem cell transplant
214677528|NCT04842721|OTHER|Placebo Plain Water Mouth Rinse Arm|Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
214945572|NCT01454843|PROCEDURE|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser for myopia.
214945573|NCT01454843|PROCEDURE|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
214945574|NCT01101659|DRUG|JNJ-40411813|500 mg as 20 mL of oral suspension
214945575|NCT01101659|DRUG|normal saline|single dose
214677529|NCT00426049|DRUG|Everolimus|
214341329|NCT05343611|DIETARY_SUPPLEMENT|HPP Choko|Participants add to their diet with 30 g/day of 85% dark chocolate high in polyphenols
214341330|NCT05343611|DIETARY_SUPPLEMENT|HPP/VE Choko|Participants add to their diet 30 grams of 85% dark chocolate high in polyphenols, functionalized with 100 mg of Vitamin E per day.
214945576|NCT01101659|DRUG|ketamine|20 mL of oral suspension
214945577|NCT01101659|DRUG|Placebo|single dose
214945578|NCT05249127|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
214945579|NCT05822362|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.
214945580|NCT05822362|OTHER|Placebo|Placebo arm.
214945581|NCT01528943|DRUG|Prostacycline|Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
214945582|NCT01528943|DRUG|Isotonic saline|same volume as the group that are allocated to prostacycline
214341331|NCT01711086|DEVICE|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
214945583|NCT04805697|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
214945584|NCT04805697|DIETARY_SUPPLEMENT|fermented grape drinks|subjects drank 50 ml , 1 bottle a day for 8 week
214945585|NCT05210153|DRUG|Sertraline|"Drug: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is commercially known as Sidata® or Zoloft® in Serbia. The recommended dose for Major depressive disorder is 100 mg/day. It is recommended to start therapy with 50 mg/day, and in the case of lack of therapeutic effect dose should be increased in 50 mg increments every 2 weeks until intended pharmacological effect is reached. Dose can be increased up to the maximum dose is 200 mg/day. Sertraline is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia), Panic disorder (with or without agoraphobia) and Post-traumatic Stress Disorder by Medicines and Medical Devices Agency of Serbia.~Drug levels are expected to be 50% higher in CYP2C19 poor metabolizers as compared to normal metabolizers, but no specific dosing recommendations are given by the Medicines and Medical Devices Agency of Serbia."
214341332|NCT01711086|DEVICE|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
214945586|NCT05400395|DRUG|GNX80|GNX80 oral intake(BID) for 24 weeks
214945587|NCT05400395|DRUG|Placebo|Placebo oral intake(BID) for 24 weeks
214341333|NCT04339335|PROCEDURE|Pulsed radiofrequency of the occipital nerves|pulsed radiofrequency of the greater and lesser occipital nerves bilaterally
214341334|NCT02133326|DRUG|Caldolor|Subject will be given Caldolor by IV prior to surgery.
214945588|NCT06619665|DRUG|MK-6552|MK-6552 gelatin coated capsules taken orally two times 8 hours apart
214945589|NCT06619665|DRUG|MK-6552 placebo|MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
214945590|NCT06619665|DRUG|Modafinil|Modafinil tablet taken once orally
214945591|NCT06619665|DRUG|Modafinil placebo|Modafinil placebo tablet taken once orally
214341335|NCT02133326|DRUG|Ofirmev|Subject will be given Ofirmev prior to surgery.
214341336|NCT03660956|BEHAVIORAL|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
214341337|NCT03660956|BEHAVIORAL|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
214341338|NCT06133491|BIOLOGICAL|Daxibotulinumtonix A|SQ injections of 10u per site will be given over standard landmarks (18 sites) to patients who consent and are found eligible.
214341339|NCT06574022|DRUG|Bupivacain|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
214341340|NCT06574022|DRUG|Exparel|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
214341341|NCT06574022|PROCEDURE|Intraoperative Pecs II block (IOB) & superior AT (EX or BP)|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle with superior anesthetic as determined by stage I, after mastectomy completion and prior to reconstruction, if performed, or wound closure.
214347462|NCT01218438|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
214347463|NCT01218438|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
214945592|NCT02073565|DEVICE|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
214347464|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|Pneumococcal vaccine 3+1 and 2+1 schedule comparison
214945593|NCT02073565|DEVICE|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
214945594|NCT06648330|PROCEDURE|Paraaortic retroperitoneal lymph node dissection|The relationship between lactate level and mesenteric ischaemia in gynaecological cancer surgeries with paraaortic retroperitoneal lymph node dissection will be evaluated.
215075119|NCT01498393|DEVICE|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
215075120|NCT01415479|BEHAVIORAL|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
215075121|NCT01415479|BEHAVIORAL|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
215075122|NCT01415479|BEHAVIORAL|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
215075123|NCT04117490|OTHER|Epiitalis|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
215075124|NCT04117490|OTHER|Placebo|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
214341342|NCT06574022|PROCEDURE|Preoperative Pecs II block (POB) & superior AT (EX or BP)|Preoperative Pecs II block to be administered by 1 of 6 acute pain specialized anesthesiologists in same day surgery. Patient will be lightly sedated with midazolam, at the discretion of the anesthesiologist. The pecs II block will be performed under ultrasound guidance using a 21-gauge, 80 mm length needle to administer the superior anesthetic as determined in stage I.
214945595|NCT06657170|PROCEDURE|Pulmunary veins reconnection plus hidden slow conduction ablation|"Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium.~HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm.~After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed.~The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms)."
214945596|NCT06657170|PROCEDURE|Pulmunary veins (PV) reconnection ablation only|Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).
214945597|NCT03646305|BEHAVIORAL|Cognitive Defusion|Cognitive defusion aims to change one's relationship to their thoughts - as opposed to changing the content, form, or frequency - by reframing internal experiences as less threatening (Hayes, Luoma, Bond, Masuda, \& Lillis, 2006). It is the process of detaching the link between one's thoughts and perceptions of reality and acknowledging the role one's thoughts play in their internal events. A number of techniques have been developed to remove the literal quality of such thoughts, including repeating the thought, and, more recently, singing the thought.
214945598|NCT02795520|DRUG|OTS167IV|
214945599|NCT01382316|BEHAVIORAL|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
214945600|NCT01382316|BEHAVIORAL|Usual care|Group format, six weekly education sessions about alcohol and drugs
214677530|NCT00089843|DRUG|Testosterone|Testosterone patch 150mcg daily
214677531|NCT00089843|DRUG|Actonel (risedronate)|Actonel (risedronate) 35mg PO one time weekly
214677532|NCT00089843|DRUG|Placebo Actonel (risedronate)|Placebo tablet identical in appearance to active Actonel (risedronate) tablet
214677533|NCT00089843|DRUG|Placebo testosterone|Placebo patch identical in appearance to testosterone patch
214677534|NCT04712578|DIETARY_SUPPLEMENT|Caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse caffeinated pre-workout supplement (Legion Athletics, Inc.).
215075125|NCT03066700|DEVICE|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
214341343|NCT03132116|DRUG|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
214341344|NCT03132116|DRUG|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
214341345|NCT02559986|OTHER|telephone interview|telephone interview about their care received during the first year of life and associated events
214347465|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|3+1 doses vs 2+1 doses
214945601|NCT06455124|RADIATION|Radiation|Shor-course radiotherapy: 25Gy/5Fx
214945602|NCT06455124|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
215075126|NCT03365258|DIETARY_SUPPLEMENT|Trophic feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
215075127|NCT03365258|DIETARY_SUPPLEMENT|volume-based feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
214347466|NCT00690703|DEVICE|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
214677535|NCT04712578|DIETARY_SUPPLEMENT|Non-caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse non-caffeinated pre-workout supplement (Legion Athletics, Inc.).
214677536|NCT04712578|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of consuming a standardized meal followed by a placebo beverage.
214677537|NCT02664285|OTHER|closure of subcutaneous tissue|the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
214677538|NCT02664285|OTHER|No closure of subcutaneous tissue|the subcutaneous fat will not sutured after cesarean section in diabetic patients.
214677539|NCT03234868|DEVICE|Impression procedure|Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
214677540|NCT03234868|DEVICE|Crown manufacturing procedures|Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
214945603|NCT06455124|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
214945604|NCT06455124|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
214945605|NCT04954716|OTHER|Deep Neck Flexor Massage|Deep friction massage is a specific connective tissue massage that was given across the affected fibers.The therapist's fingers and patient's skin must move as one, otherwise moving subcutaneous fascia against muscle or ligament could lead to blister formation or subcutaneous bruising.The friction massage must have sufficient sweep and be deep enough.
214945606|NCT04954716|OTHER|Post-Isometric Relaxation Technique|The PIR technique is performed as follows.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted.A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction . The patient should inhale during this effort.After the isometric contraction the patient is asked to relax and exhale while doing so.Following this a gentle stretch is applied to take up the slack till the new barrier.Starting from this new barrier, the procedure is repeated two or three times.
214945607|NCT02103335|DRUG|pomalidomide|Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
214945608|NCT02103335|DRUG|marizomib|IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
214945609|NCT02103335|DRUG|low-dose dexamethasone|Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
214341346|NCT05977595|OTHER|Quick DASH Score Visual Analog Scale Scar quality Healing Number of surgeries|Functional and aesthetic criteria : Quick DASH Score at 3 month and 6 months, Visual Analog Scale at 3 month and 6 months, scar quality (assessment by surgeon), healing (discontinuation of dressings), need for a second surgical procedure.
214341347|NCT03553745|BEHAVIORAL|Gentle Yoga Intervention|10-week exercise program structured around gentle yoga practice.
214341348|NCT03553745|BEHAVIORAL|Rigorous Yoga Intervention|10-week exercise program structured around rigorous yoga practice.
214341349|NCT03553745|BEHAVIORAL|Physical Exercise Intervention|10-week exercise program structured around cardiovascular exercise.
214945610|NCT05278338|DRUG|JMT103|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
214945611|NCT05278338|DRUG|Denosumab|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
214945612|NCT05278338|DRUG|Placebo|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
214945613|NCT01072513|OTHER|Semen analysis|Semen analysis before and after proton radiation therapy.
214945614|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.
214945615|NCT04015518|DRUG|Placebo|Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
214945616|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
214945617|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
214945618|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
214945619|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
214945620|NCT06619470|OTHER|binaural beats|binaural beats
214945621|NCT06505551|BIOLOGICAL|SCG142|Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy
214945622|NCT06505551|DRUG|Cyclophosphamide|for 3 consecutive days
214341350|NCT04072965|OTHER|balance training|Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
214341351|NCT04102501|DRUG|RT001|RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
214341352|NCT04102501|DRUG|Placebo|The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
214945623|NCT06505551|DRUG|Fludarabine|for 3 consecutive days
214945624|NCT05581433|OTHER|Topical Cooling Spray|The process of cooling the area to be injected with a cooling spray before the application in order to reduce the pain.
214945625|NCT05581433|OTHER|Saline spray as Placebo|Application of saline spray without cooling effect to the area to be injected for placebo purposes
214945626|NCT04469673|BIOLOGICAL|Biological：JS002|Administered by subcutaneous injection
214945627|NCT04469673|BIOLOGICAL|Placebo|Administered by subcutaneous injection
214945628|NCT00386425|DRUG|Drotrecogin alfa (activated)|intravenous
214945629|NCT05432050|DEVICE|Bispectral index and Patient state index monitoring|The depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
214945630|NCT06354790|OTHER|Motor evaluations|Evaluation of patients motor function using motor scales (MFM32, RULM), Timed functioned tests (6MWT, Rise from floor, 4SCT, 10mWT), dynamometric strength evaluation (grip, pinch, flexion/extension)
214945631|NCT06354790|OTHER|Cognitive assessment|Patients cognitive evaluation (WPPSI-IV, WISC-V)
214945632|NCT06354790|OTHER|Pulmonary function test|Evaluation of patients' respiratory function (FVC, PCF, MIP, MEP, SNIP)
214945633|NCT06354790|OTHER|Cardiac evaluation|Evaluation of patients' cardiac function (ECG, Echo-cardiography)
214945634|NCT06354790|OTHER|Quality of life|Evaluation of patients quality of life with questionnaires and PROM
214945635|NCT06354790|OTHER|Spine X Ray|Evaluation of spinal deformities by X-ray
214945636|NCT06354790|OTHER|Muscular MRI|Evaluation of a qualitative whole-body muscle part and a quantitative lower limb muscle part by MRI
214945637|NCT06354790|OTHER|Biomarkers collection and analysis|Collection of blood and urinary sample for biomarkers research.
215075128|NCT04570605|DEVICE|parasacral transcutaneous electrical nerve stimulation (PTENS)|electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.
214341353|NCT01427712|DRUG|Pancrelipase|
214341354|NCT01361087|OTHER|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
214945638|NCT06245447|OTHER|Retrospective evaluation of specific brain MRI features|"* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
214945639|NCT03897933|PROCEDURE|Erector Spinae Plane block ( Group I)|ESP Block was performed preoperative to all patients in ESP block group. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
214945640|NCT03897933|PROCEDURE|non- blocked Group (GROUP II)|This group was received no intervetion. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
214945641|NCT02268747|DRUG|Dacomitinib|"The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade \<2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade \>2, then the patient will interrupt the treatment following the criteria for dose reduction."
214945642|NCT05037487|DRUG|Placebo Cannabis|Smoked placebo cannabis
214945643|NCT05037487|DRUG|20 mg CBD Cannabis|Smoked cannabis with CBD
214945644|NCT05037487|DRUG|20 mg CBD + 20 mg THC Cannabis|Smoked cannabis with CBD and THC
214945645|NCT05037487|DRUG|20 mg THC Cannabis|Smoked cannabis with THC
214945646|NCT00407927|DRUG|Epinastine Nasal Spray|
214945647|NCT00431873|DRUG|MGCD0103|MGCD0103 Administered orally three times per week.
214945648|NCT03984227|GENETIC|Taking peripheral blood samples|quantitative real-time polymerase chain reaction
214945649|NCT05530980|BEHAVIORAL|GameDay Ready Program|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. Each weekly session will be led by a trained facilitator and will include a brief educational component, participant updates on progress, group discussions about overcoming barriers, supervised competitive physical activities, and goal setting for the upcoming week. Educational content will be reinforced and social support will be provided during warmup and cool down walks. Participants will be asked to set behavioral goals toward increasing physical activity and improving dietary habits and will be provided resources to self-monitor their activity, dietary intake, and weight.
214945650|NCT01803776|BEHAVIORAL|lifestyle counseling|The physical activity and dietary intervention is based on the Finnish physical activity and dietary recommendations. The children and their parents in the intervention group undergo individualized and family-based physical activity and dietary intervention between the baseline and 2-year follow-up examinations. The children and their parents meet a physical activity specialist and a nutritionist who give detailed and individualized instructions on health promoting physical activity and diet at months 0, 1.5, 3, 6, 12, and 18 with a specific topic at each visit. Between the 2-year follow-up and 8-year follow-up examinations, the intervention continues with yearly physical activity and dietary counseling sessions. The children in the intervention group, particularly those who do not attend organized sports or exercise, will also be encouraged to participate in after-school exercise clubs organized by trained exercise instructors of the study.
214945651|NCT00759057|DEVICE|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
214945652|NCT02764567|OTHER|Essential Oil|Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
214341355|NCT04736784|OTHER|Food-based - beetroot juice|Beetroot juice containing approximately 340 mg nitrate daily
214341356|NCT04736784|OTHER|Food-based - leafy green vegetable juice|Leafy green vegetable juice containing approximately 340 mg nitrate daily
214341357|NCT03329352|DEVICE|F&P Full-Face Mask|The F\&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
214341358|NCT00968617|DRUG|MK2578|MK2578 1.0 mcg/kg/month
215075129|NCT04570605|OTHER|Standard Urotherapy|standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
215075130|NCT02165293|DRUG|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
215075131|NCT02979093|DRUG|Oxytocin|All women will receive a nasal spray containing oxytocin.
215075132|NCT02979093|DRUG|Placebos|All women will receive a nasal spray containing a placebo solution.
215075133|NCT02979093|PROCEDURE|Functional MRI scanning|Study participants undergo two functional MRI scans.
215075134|NCT05083091|BEHAVIORAL|Mindfulness and Attention Training|Guided mindfulness meditation with attention monitoring and acceptance skills training
214341359|NCT00968617|DRUG|MK2578|MK2578 2.0 mcg/kg/month
214341360|NCT00968617|DRUG|MK2578|MK2578 3.6 mcg/kg/month
214341361|NCT00968617|DRUG|Comparator: darbepoetin alfa|darbepoetin alfa
214341362|NCT05207696|OTHER|retrospective data analysis|The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)
214945653|NCT06061172|OTHER|gp-multitool.de|"The intervention is based on a digital tool, which implements recommendations of the S3 guideline multimorbidity of the German College of General Practitioners and Family Physicians. The tool includes nine questionnaires addressing four dimensions of care:~1. preferences (including a. treatment goals, and b. involvement of other persons in decision making);~2. activities (including a. activities and participation, and b. social support);~3. treatment (including a. problems with medication, and b. treatment burden);~4. complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~The GPs can send the questionnaires by email to the patients and the patients can fill out the questionnaires at their home or in the waiting room of the GP's practice using their own smartphones, tablets or computers. The digital tool also includes instructions for conducting a medication review. Results from talks between GPs and patients can be documented in the tool."
214945654|NCT00365001|DRUG|tocilizumab [RoActemra/Actemra]|10mg/kg iv on day 8
214945655|NCT00365001|DRUG|Methotrexate|10-25mg po/week
214945656|NCT00365001|DRUG|Simvastatin|40mg po on days 1, 15 and 43
214945657|NCT06287710|PROCEDURE|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Study of diagnostic accuracy (non-interventional, prospective, monocentric). Fluid expansion will be delayed for a few minutes while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard test). This will allow to test the diagnostic performance of the index test for the prediction of fluid responsiveness.~The index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline (stroke volume, cardiac output, left ventricular ejection fraction), During a standardized abdominal compression (stroke volume),After the 10 to 20ml/kg fluid expansion prescribed by the physician in charge (cardiac output)."
214945658|NCT03903003|DEVICE|high flow nasal oxygen device (POİNT)|With POINT device (peri-operative insufflatory nasal therapy); patients are heated at higher flow and applied to humidified oxygen.
214945659|NCT03903003|DEVICE|Face mask|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
214945660|NCT05215379|DRUG|xintilimab injection|neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle
214945661|NCT05215379|OTHER|Control|neoadjuvant chemoradiation therapy
214945662|NCT01801241|DEVICE|Anatomic TSA using IRI Instrumentation|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Intelligent Reusable Instrument (IRI) to transfer the pre-operative plan for glenoid implant positioning to the patient's anatomy.
214945663|NCT01801241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same in the two arms, with the exception of the tools used to place the guide pin for placement of the glenoid implant.
214945664|NCT03240406|OTHER|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
214945665|NCT03240406|OTHER|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
214945666|NCT00756600|DRUG|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
214945667|NCT00756600|DRUG|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
214945668|NCT01324570|DRUG|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
214945669|NCT06336278|DIAGNOSTIC_TEST|Pressure Algometer|Pressure algometer is used to detect pain pressure treshold.
214945670|NCT03407547|DIAGNOSTIC_TEST|Electroencephalography|EEG is a device to measure brain activity via surface electrodes
214945671|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
214945672|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
214945673|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
214341363|NCT02323594|DRUG|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
214341364|NCT02323594|DRUG|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
214945674|NCT02360475|BIOLOGICAL|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
214945675|NCT03101722|DRUG|BTHE and Huperzine A|huperzine A intervention
214945676|NCT03101722|OTHER|BETH|basic treatment and health education
214945677|NCT01918150|DEVICE|Titan 2 stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
214945678|NCT01918150|DEVICE|Cobalt-Chromium Bare Metal Stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
214945679|NCT06035861|DRUG|XBD173|Participants will be treated with XBD173 90mg twice daily for 6 weeks
214945680|NCT00180427|DEVICE|ICD|
214945681|NCT00207727|DRUG|CNTO 1275|
214945682|NCT03017027|BEHAVIORAL|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
214945683|NCT03017027|BEHAVIORAL|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
214945684|NCT00316862|DRUG|cisplatin|Given IV
214341365|NCT02323594|DRUG|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
214945685|NCT00316862|DRUG|irinotecan hydrochloride|Given IV
214945686|NCT00316862|PROCEDURE|therapeutic conventional surgery|Undergo Surgery
214945687|NCT00316862|RADIATION|radiation therapy|Undergo radiation
214945688|NCT04268940|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography (TEG 6s, global hemostasis cartridge) will be performed before ECMO insertion and at different time-points during the course of ECMO. In parallel a full coagulation work-up (aPTT, prothrombin time \[PT\], anti-Xa, activated clotting time\[ACT\], platelets count, d-dimers, von Willebrand panel and fibrinogen) will be measured simultaneously with each TEG.
214945689|NCT04861116|BEHAVIORAL|Intervention program for test anxiety|12-week ICT-based manualized, targeted and facilitated individual intervention for adolescent students, that aims to promote compassion, acceptance and mindfulness, in order to help improve test anxiety's regulation (and consequently symptom reduction), as well as increase general and school-related well-being, while promoting valued life action.
214945690|NCT00071968|DRUG|temsirolimus|
214945691|NCT00071968|PROCEDURE|conventional surgery|
214945692|NCT00071968|PROCEDURE|neoadjuvant therapy|
214945693|NCT05362695|DRUG|IW-3300|A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).
214945694|NCT05362695|DRUG|Placebo|A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).
214945695|NCT02596217|DRUG|ABBV-066|SC injection
214945696|NCT02596217|DRUG|ABBV-066|IV infusion
214945697|NCT02596217|DRUG|Placebo|SC injection (stage 1)
214945698|NCT02596217|DRUG|Placebo|IV infusion (stage 2)
214945699|NCT05995249|DRUG|TAK-279|TAK-279 capsules
214945700|NCT05995249|DRUG|Erythromycin|Erythromycin tablets
214945701|NCT05995249|DRUG|Phenytoin|Phenytoin capsules
214945702|NCT05995249|DRUG|Efavirenz|Efavirenz tablets
214945703|NCT00539032|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214945704|NCT00539032|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214945705|NCT06910462|BEHAVIORAL|Integrated pest management (IPM) practices|Provide IPM resources to family child care home directors along with information about their exposure to pesticides and use of pesticides to lower their health risks.
214341366|NCT02323594|DRUG|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
214341367|NCT04536896|OTHER|Smartphone breastfeeding application|This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.
214341368|NCT04536896|OTHER|Traditional face-to-face breastfeeding lecture|This intervention consists of the impartition of a face-to-face breastfeeding course
214341369|NCT03699306|PROCEDURE|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
214341370|NCT03702829|DRUG|Inotersen|Open Label Study
214945706|NCT06910891|DIAGNOSTIC_TEST|measurement of the peripheral perfusion index and marbling assessment|in addition to the classic hemodynamic parameters measured in all patients, a measurement of the peripheral perfusion index (from 1 sec to 10 sec) and marbling assessment (scale from 0 to 5) will be performed
214945707|NCT06909994|OTHER|individual assessments|Participants in the CP group underwent individual assessments using seven standardized instruments to evaluate sensory and motor function, as well as independence in daily activities. Data collection was conducted in person at the participating institutions by trained professionals following a structured protocol. All procedures were performed after verifying cognitive eligibility (score ≥ 19) and obtaining informed consent. The same protocol was applied across both centers to ensure consistency. The control group followed the same assessment process. Each evaluation session lasted approximately two hours per participant.
214945708|NCT00435019|DRUG|insulin detemir|s.c. injection, once or twice daily.
214945709|NCT00435019|DRUG|insulin NPH|s.c. injection, once or twice daily.
214677541|NCT01124058|DRUG|warfarin|"Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose)."
214945710|NCT00435019|DRUG|insulin aspart|s.c. injection, at main meals.
214945711|NCT03499275|DEVICE|Active NMES|Neuromuscular electrical stimulation to the quadriceps muscle
214945712|NCT03499275|DEVICE|Sham NMES|Sham neuromuscular electrical stimulation to the quadriceps muscle
214945713|NCT03499275|OTHER|Home exercise programme|Home exercise programme. Both arms of the trial receive this intervention.
214945714|NCT03499275|OTHER|Breathlessness advice|Breathlessness advice. Both arms of the trial receive this intervention.
214945715|NCT03660150|OTHER|Evaluation of health-related quality of life|Short Form-36 Medical Outcomes Survey (SF-36), and Brief Version of Burn Speciﬁc Health Scale (BSHS-B) are used for the present evaluation.
214945716|NCT04364464|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
214945717|NCT06018545|OTHER|Ground truthing|Two Consultant neuroradiologists will independently review the images to establish the 'ground truth' findings on the CT scans which will be used as the reference standard. In the case of disagreement, a third senior neuroradiologist's opinion will be sought for arbitration.
214945718|NCT06018545|OTHER|Reading|All 30 readers will review all 150 cases, in each of two study phases. The readers will provide their opinion on the presence or absence of some acute abnormalities, including intracranial haemorrhage, infarct, midline shift and fracture. They will provide a confidence in their diagnosis (10-point visual analogue scale), and a single click point to mark the location of each abnormality that they consider as being present. The time taken for each scan will be automatically recorded.
214945719|NCT03601273|PROCEDURE|Left gastric artery embolization|"450-micron Embozene microparticles will be used intraarterially to occlude the left gastric artery and its branches.~30-day post-embolization endoscopic biopsy"
214945720|NCT03257241|DRUG|A arm (DA-90)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
214945721|NCT03257241|DRUG|B arm (DAC)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
214945722|NCT03257241|DRUG|A arm (CLAG-M)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
214945723|NCT03257241|DRUG|B arm (FLAG-IDA)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
214945724|NCT02101749|BIOLOGICAL|trivalent inactivated influenza|intradermal or intramuscular injection in the deltoid area.
214945725|NCT01074151|DRUG|duloxetine|any exposure to duloxetine that occurred during pregnancy
214945726|NCT01669785|DEVICE|Group C|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
214945727|NCT01669785|DEVICE|Group A|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
214945728|NCT01669785|DEVICE|Group B|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
214677542|NCT01124058|DRUG|Warfarin|"Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR."
214945729|NCT03858283|BEHAVIORAL|Mindfulness Based Health Care (MBHC) Program|Mindfulness Based Health Care (MBHC) Program for Caregivers of Alzheimer's Disease Patients. The duration of this group was 8 weeks. The program included one session per week, with each session lasting 1 hour and 30 minutes
214945730|NCT00372047|DEVICE|multiphoton laser imaging|
214677543|NCT05158309|OTHER|8% Capsaicin patch|Cutaneous pain was induced using a (5x10 cm) 8% topical capsaicin patch (transdermal patch, 'Qutenza', Astellas) on the volar part of the dominant right forearm (5 cm from the wrist) of each participant.
214677544|NCT05158309|OTHER|placebo patch|A transparent patch with no formulation or effect but the same size of the capsaicin patch was applied to the same location.
214677545|NCT02560688|DRUG|DS-1040b|20 mg single 12-hour intravenous infusion
214945731|NCT01381991|DEVICE|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
215075135|NCT05083091|BEHAVIORAL|Mindfulness training|Guided mindfulness meditation, no attention monitoring or acceptance skills training
215075136|NCT05083091|BEHAVIORAL|Coping Condition|Guided training focused on coping effectiveness strategies, no monitoring or acceptance instruction
215075137|NCT06356259|DRUG|IRX-010|Administered IV
214677546|NCT02560688|DRUG|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
215075138|NCT06356259|DRUG|Placebo|Administered IV
215075139|NCT06345313|PROCEDURE|Day Group|Patient group that will be operated on between 08.00-12.00
215075140|NCT06345313|PROCEDURE|Night Group|Patient group that will be operated on between 18.00-22.00
214945732|NCT05247021|PROCEDURE|erector spinae block for group E|. The patient will be placed in the prone position. A high-frequency linear probe or a curved array probe, depending on the BMI of the patient, will be placed in longitudinal alignment, 2-3cm lateral to the vertebral column. The transverse processes of the vertebrae at the level of surgery, the erector spinae muscle, and the psoas muscle will be identified. A 5- or 8-cm 22-G ultrasound needle will be inserted with an in-plane technique in a cephalad-to-caudal direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20ml of bupivacaine 0.25% will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
214945733|NCT04239443|DRUG|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/2weeks or 200mg/3weeks)
214945734|NCT04239443|DRUG|Apatinib|NSCLC and Uterine cancer will be given oral of Apatinib (250mg/d), soft tissue sarcoma will be given oral of Apatinib (500mg/d).
214945735|NCT06169956|DRUG|Neoadjuvant nivolumab in combination with platinum-based chemotherapy|Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
214945736|NCT02669082|DRUG|Ramelteon|Ramelteon tablets
214945737|NCT06910007|PROCEDURE|dental implant will be inserted using surgical guide|dental implant will be inserted using blue sky plan computer software
214945738|NCT06910007|PROCEDURE|dental implant|surgical guide will be fabricated using exoplan computer software
214341371|NCT05359042|OTHER|Electronic Patient Reported Outcomes platform|The ePRO tool is developed by a third-party vendor, Conversa, and engages the patient in a chat-based interaction to assess patient symptoms and provide educational material.
214945739|NCT06910007|PROCEDURE|dental implant will be inserted using surgical guide|surgical guide will be fabricated using real guide computer software
214945740|NCT05883774|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is applied using a transcranial magnetic stimulator with a figure-of-8 coil once per day for 10 consecutive days. rTMS is delivered to the right dorsolateral prefrontal cortex (DLPFC) at a frequency of 1 Hz for 20 minutes (1200 total pulses).
214341372|NCT05359042|OTHER|Health Related Quality of Life Surveys|Surveys will be administered to participants
214341373|NCT03498534|DRUG|Isoniazid 300Mg Tab|-TST tests will receive isoniazid 300Mg Tab for 6 months
214341374|NCT03498534|DRUG|Isoniazid 300 MG|\+ TST test will receive isoniazid 300MG Tab for 6 months
214341375|NCT03498534|DRUG|Isoniazid 300 MG|HIV positive patient will receive isoniazid 300MGTab for 6 months
214341376|NCT04976920|DIAGNOSTIC_TEST|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
214341377|NCT00819182|BEHAVIORAL|Paced respiration|Breathing exercise
214341378|NCT00819182|BEHAVIORAL|Sham comparator: fast shallow breathing|sham breathing exercise
214945741|NCT05883774|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham-rTMS is performed in the same way as the treatment group except that the coil is rotated 90° away from the scalp.
214945742|NCT02249689|OTHER|Definitive 65|
214945743|NCT02249689|OTHER|Definitive 74|
214945744|NCT04081857|DRUG|HGP1810|HGP1810: Vildagliptin/Metformin
214945745|NCT04081857|DRUG|HCP1704|HCP1704: Vildagliptin/Metformin
214945746|NCT02259686|DRUG|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
214945747|NCT02259686|DRUG|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
214945748|NCT02259686|DRUG|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
214945749|NCT02259686|DRUG|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
214341379|NCT00977041|BEHAVIORAL|Neurofeedback|"Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly."
214945750|NCT02259686|DRUG|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
215075141|NCT04315792|DRUG|Endoxifen|Administration of Endoxifen for 3 weeks
215075142|NCT04315792|DRUG|Placebo oral tablet|Administration of Placebo for 3 weeks
215075143|NCT03822598|BEHAVIORAL|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
214341380|NCT03598504|DEVICE|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
214341381|NCT05427669|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
214341382|NCT05427669|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
214341383|NCT03191344|BEHAVIORAL|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
214341384|NCT01390246|DRUG|Bupropion SR|Bupropion SR 150 mg tablet
214341385|NCT01390246|BEHAVIORAL|Smoking Cessation Counseling|35-min counseling by trained research nurse
214341386|NCT01390246|DRUG|Placebo|Matching Bupropion SR placebo tablet
214341387|NCT00782613|DRUG|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
214341388|NCT00782613|DRUG|Placebo|Placebo in a cream formulation
214341389|NCT02687334|DRUG|100% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
214341390|NCT01024387|DRUG|AMG 479|
214945751|NCT02148016|PROCEDURE|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
214945752|NCT02148016|PROCEDURE|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
214945753|NCT02148016|PROCEDURE|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
214945754|NCT02148016|PROCEDURE|PRK only (Traditional Technique)|PRK alone will be performed.
214341391|NCT02408614|OTHER|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
214341392|NCT02408614|OTHER|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
214677547|NCT00206999|DRUG|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
214945755|NCT02148016|DRUG|Levofloxacin|
214945756|NCT02148016|DRUG|Betamethasone|
214945757|NCT02148016|DRUG|Limbal stem cells (LSCs)|
214945758|NCT00638261|RADIATION|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body-half
214945759|NCT03287011|OTHER|Shoplaq toothpaste|"ACTIVE INGREDIENT Sodium Monofluorophosphate 1000 PPM INGREDIENTS Precipitated Calcium Carbonate, Sorbitol, Glycerin, Precipitated Silica, Sodium Carboxy Methyl Cellulose, Sodium Benzoate, DM Water, Colour CI-45410, Holy Basil Oil, Neem Oil, Citrus Oil, Thymol Oi, Clove Oil, Piper Betel Leaf Oil, Tea Tree Oil, Eucalyptus Oil, Peppermint Oil, Spearmint Oil.~Dye containing tooth paste for disclosing plaque and efficient brushing for better oral health."
214341393|NCT02408614|OTHER|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
214341394|NCT02408614|DEVICE|Treadmill|
214341395|NCT06432127|DRUG|Placebo|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using normal saline 3 mL
214341396|NCT06432127|DRUG|Bupivacaine|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using 0.5% Bupivacaine 3 mL
214341397|NCT04972435|DIAGNOSTIC_TEST|Contrast sensitivity|All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
214677548|NCT03487380|PROCEDURE|Fecal sample collection|Fecal sample collection
214945760|NCT03287011|OTHER|Colgate toothpaste|fluoridated
214341398|NCT00359450|DRUG|BMS-275183 (oral taxane)|
214341399|NCT02515162|PROCEDURE|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
214341400|NCT02515162|PROCEDURE|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
214677549|NCT04497662|DRUG|KPL-404|humanized IgG4 monoclonal antibody
214677550|NCT04497662|OTHER|Matching Placebo|Placebo
214677551|NCT05795218|DEVICE|Deep Brain Stimulation|implant and DBS therapy with the directSTIM™ DBS system
214945761|NCT03510078|DRUG|Insulin|Insulin for glycemic control according to the allocation
214945762|NCT03290183|DEVICE|Confocal laser endomicroscopy|Real-time microscopic imaging technique
214945763|NCT06174545|DRUG|Pigment Solution Program|adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.
214945764|NCT05743647|DEVICE|Observation (OBS)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject only observe the movement on the screen during the recordings. The subject does not produce any movement."
214945765|NCT05743647|DEVICE|Observation and imagination (OBS-IM)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement but also imagine to realized it."
214945766|NCT05743647|DEVICE|Observation and realization (OBS-REAL)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement on the screen and realized it"
214945767|NCT02084433|PROCEDURE|intraosseous anaesthesia using a computerized system|"1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
214677552|NCT05864014|DRUG|Hetrombopag|Hetrombopag
214677553|NCT05864014|DRUG|Hetrombopag plus Placebo|Hetrombopag plus Placebo
214677554|NCT05864014|DRUG|Placebo|Placebo
214677555|NCT05519579|DRUG|Methotrexate|Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
214677556|NCT05519579|DRUG|Blinatumomab|Blinatumomab 28ug/day continuous infusion for 4 weeks
214341401|NCT00358267|PROCEDURE|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
214341402|NCT00358267|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
214945768|NCT02084433|PROCEDURE|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
214945769|NCT02121353|DRUG|Lucentis|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
214341403|NCT05419206|DIAGNOSTIC_TEST|CMV DNA analysis|CMV DNA quantitative viral load levels were studied
214341404|NCT02423382|PROCEDURE|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
214341405|NCT05166252|BEHAVIORAL|Time out from smartphone use during meal time|"One parent will be instructed to install a study app. Further, he/she press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and the parent needs to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the parent is instructed to take a picture with their smartphone from the smartphone-free family meal table . The time-out is over as soon as the parent presses the stop button."
214341406|NCT05166252|BEHAVIORAL|Control condition|The same as the experimental condition but without a timeout from smartphone use.
214341407|NCT00861419|DRUG|Sorafenib|Sorafenib 400 mg PO (BID)
214341408|NCT00861419|DRUG|AMG 706|AMG 706 125 mg PO (QD)
214341409|NCT00861419|DRUG|AMG 706|AMG 706 75 mg PO (QD)
214341410|NCT00861419|DRUG|AMG 386|AMG 386 10 mg/kg IV (QW)
214341411|NCT00861419|DRUG|Sunitinib|Sunitinib 50 mg PO (QD)
214341412|NCT00861419|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
214341413|NCT00861419|DRUG|AMG 386|AMG 386 3 mg/kg IV (QW)
214341414|NCT05944900|PROCEDURE|Cyanoacrylate glue application|"The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.~Cyanoacrylate glue should be applied in accordance with the instructions for use.~Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly."
214945770|NCT02121353|DRUG|PF582|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
214945771|NCT02552953|DRUG|CYC065|
214945772|NCT03331705|DEVICE|Uro-C (Use of new cystoscope)|Diagnostic cystoscopic procedure of the urethra and bladder
214945773|NCT03545620|DEVICE|rescue technique|which rescue technique will be preferred while established/predicted difficult airway/intubation occurs in the operation room after failed direct laryngoscopy
214945774|NCT00550576|DRUG|Digibind (Fab)|Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
214945775|NCT01709864|DRUG|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
214945776|NCT01709864|DRUG|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
214945777|NCT02510703|OTHER|Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)|
214945778|NCT00597064|DRUG|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
214341415|NCT02682654|DEVICE|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
214341416|NCT02682654|DEVICE|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
214341417|NCT04707235|DRUG|Hydroxycarbamide|Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
214945779|NCT02657824|OTHER|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
214341418|NCT03344991|OTHER|Cardboard Cot Care|When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
214347467|NCT01932164|PROCEDURE|maxillary alveolar graft by tissue engineering|Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;
214945780|NCT04616040|DRUG|Camrelizumab|The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.
214945781|NCT03986229|OTHER|"Evaluate the variation in the travel speed of the center of pressure with and without compression garments."|"Each evaluation will be done according to the following protocol:~* Evaluation of the pain~* Berg test~* One test per condition starting with open eyes~* Standardized instructions:~* Break about 15 minutes (wash-out) between each test.~* Both conditions will be tested on the same day.~* Evaluation in an environment free from visual and audible interference."
214945782|NCT00493987|DRUG|Testosterone Enanthate|testosterone ester
214945783|NCT00493987|DRUG|Dutasteride|5 alpha-reductase inhibitor
214945784|NCT03790605|DRUG|1 % curcumin chip|CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle
214945785|NCT03790605|OTHER|Placebo chip|PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle
214677557|NCT06359236|OTHER|BI'KILO Intervention|"The study consists of three stages: preparation phase, implementation phase and follow-up phase. During the preparation phase, participants' weight and body fat ratio will be calculated using a body analysis scale, and their height, waist and hip circumference will be measured.~The implementation phase will last six weeks and consists of six modules, each lasting one week. The skills and practices aimed to be acquired in each module will be required to be applied in the following practice modules.~At the end of the implementation phase, participants' weight, waist and hip circumferences will be measured again.~The final phase, called the follow-up phase, will last four weeks. During this phase, participants will continue to keep a self-monitoring record of their eating and physical exercise, complete a hunger scale, and application card notifications will continue to be displayed."
214677558|NCT05347914|BEHAVIORAL|Mindfulness|Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
214677559|NCT02517112|OTHER|Parabolic flight|
214677560|NCT02517112|OTHER|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
214677561|NCT02517112|DEVICE|3D-BCG sensor|
214677562|NCT02074215|OTHER|Aerobic exercises|Aerobic exercises + dual task
214677563|NCT02074215|OTHER|Stretch exercise|Stretch exercise
214341419|NCT03344991|OTHER|Open Crib|When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
214341420|NCT06460701|OTHER|m-CIMT without Kinesio taping|Baseline treatment m-CIMT will be applied includeing ROM with a sling, e.g shoulder flexion, extension, abduction, and rotation. The elbow's flexion and extension, Forearm supination is the extension of the wrist and fingers. Functional Training Using a tiny toy ball, practice tossing and catching it from various angles. Play with modeling clay, constructing towers of the toy bricks using LEGOs,Using crayons, ripping a piece of paper towel,Grasping biscuits, Using a spoon, utilizing a glass to drink, comb hair, brush teeth,Using a bubble blower,With a toy in hand, putting cap, putting lotion.stretching to shoulder's extensors, adductor, and internal rotators ,wrist and elbow flexors. strengthening exercises e.g a ball above head position in various directions,Using paper adhered to the window or wall at varying heights for drawing. The session will go for one hour.
214341421|NCT06460701|OTHER|m-CIMT along with kinesiotaping|"Modified constraint-induced movement therapy along with kinesiotaping will be applied. m-CIMT protocol is baseline treatment and it is is same as in the other group.~This group also participated additionally in a kinesio taping program, which utilize KT with the goal of enhancing middle and lower trapezius function to increase stability in the scapula on the afflicted side. During the application of the tape, the shoulders were kept in a low and backward posture, and the scapular alignment was manually maintained. KT was administered at the acromion and positioned medially at the spinous processes (T2-T3 for the middle trapezius and T12 for the lower trapezius). For eight weeks in a row, there will be three sessions every week"
214341422|NCT00861497|DRUG|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
214341423|NCT02621905|DRUG|Sporanox|At least 2 capsules twice a day for 3 weeks
214341424|NCT02621905|DRUG|Lozanoc|At least 2 capsules twice a day for 3 weeks
214945786|NCT03790605|PROCEDURE|Scaling and root planing|Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
214945787|NCT02106702|BEHAVIORAL|Navigator enhanced case-management|Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
214945788|NCT02106702|BEHAVIORAL|Forensic AIDS Project|The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
214677564|NCT03952208|OTHER|Neurocognitive Testing|A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
214677565|NCT00312351|DRUG|Pegaptanib sodium|
214677566|NCT03042611|DRUG|Rivoceranib|Oral tablet
214347468|NCT01932164|PROCEDURE|Bone tissue engineering using mesenchymal stem cells|Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
214347469|NCT00052468|DRUG|TCG|
214347470|NCT00052468|DRUG|TC|
214347471|NCT02409173|DEVICE|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
214677567|NCT03042611|DRUG|Placebo|Oral tablet
214677568|NCT01741272|PROCEDURE|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
214677569|NCT01741272|PROCEDURE|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
214677570|NCT01809990|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
214677571|NCT01099410|PROCEDURE|Fiberoptic bronchoscopy|"which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours."
214677572|NCT01099410|PROCEDURE|blood draw|Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
214945789|NCT03527862|OTHER|Treatment according to lung ultrasonography|Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
214945790|NCT02503644|DRUG|IVA337|Capsules of 200mg IVA337
214945791|NCT02503644|DRUG|Placebo|Identical capsules without active substance
214945792|NCT05369689|OTHER|No interventions|As this is a prognosis evaluation study, there are no interventions.
214945793|NCT00941824|DRUG|mycophénolate acid|"* Day 0 to Day 7, 720 mg twice daily~* Day 8 to Day 30, 540 mg twice daily~* Day 30 to Day 90, 360 mg twice daily"
214945794|NCT04888858|DRUG|Epidural analgesia (0.125% bupivacaine/2mcg fentanyl solution)|As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
214341425|NCT01478945|DEVICE|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
214341426|NCT06047197|BIOLOGICAL|RC19D2 cell injection|The functional component of RC19D2 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
214341427|NCT03864900|BEHAVIORAL|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
214945795|NCT04501016|BEHAVIORAL|Tailored behavioral counseling|Participants will initially receive a six-session telephone intervention. Standard cognitive behavioral treatment strategies will be included. Participants will be screened for elevated depressive symptoms, risky alcohol use, and concerns about weight and and offered supplemental behavioral counseling related to these issues as appropriate. Those that are unable to quit tobacco initially will receive an enhanced, four-session counseling module focused on reduced scheduled smoking. Those who do quit tobacco use initially will receive four sessions of extended counseling based on positive psychology intervention strategies.
214945796|NCT04501016|DRUG|Tobacco cessation pharmacotherapy|Pharmacotherapy will be selected based on medical and psychiatric history and potential interactions with other current medications combined with shared decision making. Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily). Monotherapy and combination therapy options will be provided.
214945797|NCT00034918|DRUG|ZD6474|
214341428|NCT02546752|OTHER|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
214945798|NCT01955317|BEHAVIORAL|Hand cleansing with chlorhexidine|Pregnant women in the intervention arm will receive an intensive hand cleansing promotion delivered at 3 in-home visits between one month prenatal and 1 week post natal. The intervention will promote and discuss with mothers the benefits of hand cleansing with chlorhexidine before breastfeeding, before umbilical cord care, after contact with respiratory secretions, and the convenience of using a waterless hand sanitizer especially during the neonatal period. Each mother will receive a half-liter pump bottle with chlorhexidine lotion. The program will also educate mothers about infectious causes of morbidity and mortality in neonates and promote understanding of the risk to the neonate from these diseases.
214945799|NCT01955317|BEHAVIORAL|Mother and neonatal health counselling|This arms will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
214945800|NCT04895488|DRUG|Vortioxetine|"First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks"
214945801|NCT04895488|DRUG|Usual Antipsychotic Treatment|Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
214341429|NCT06567639|PROCEDURE|Catheter ablation|"Hybrid epicardial right ventricular (RVOT-EPI) mapping and Brugada syndrome substrate ablation technique.~The procedure is performed in the hybrid operating room. The Advisor™ HD-Grid Mapping Catheter is delivered inside the chest through a working port and positioned under thoracoscopic view over the pulmonary artery that is consequently labeled on EAM. As a standard protocol the mapping catheter is positioned over the pulmonary artery and moved down progressively over the RVOT-EPI under continuous thoracoscopic view and at least three consecutive beats are required for each recording location point with a stable catheter position."
214347472|NCT02409173|PROCEDURE|Bariatric Surgery|Standard Roux-en-Y gastric bypass
214347473|NCT01218646|BIOLOGICAL|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
214347474|NCT01218646|BIOLOGICAL|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
214341430|NCT06441513|OTHER|Chinese traditional medicine nursing combined with case tracking management|First, we set up a team for the prevention of hand foot syndrome, including 1 head nurse of the tumor chemotherapy department, 2 doctors, 16 nurses (16 nurses were divided into 4 groups, each group designated a team leader) and the researchers of this experiment. Doctors are responsible for the diagnosis of HFS and the determination of traditional Chinese medicine prescriptions, head nurses and team leaders are responsible for quality control, and nurses are responsible for the assessment, intervention and evaluation of patients.
214341431|NCT06441513|OTHER|Health Education|elaborating the symptoms, mechanism and corresponding treatment measures of HFS for patients, reducing the fear of patients, helping them relax and adjust their mentality, and cooperating with observation.
214945802|NCT02435056|OTHER|IEPR Approach|"Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~* Minimum Data Set for supporting the diagnosis~* Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~* Second opinion system for improving the management"
214945803|NCT04657575|PROCEDURE|Narcotrend|ECT stimulation within an anaesthesia depth range of 41-64
214945804|NCT04277767|DIAGNOSTIC_TEST|observational|No intervention
214945805|NCT02455973|BEHAVIORAL|Lifestyle modification and cardiovascular risk|Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.
214945806|NCT02455973|BEHAVIORAL|Health Education|The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
214945807|NCT04347655|PROCEDURE|handgrip test|The patient will be supine for at least 5 minutes to collect baseline data before being handed a dynamometer device. The subject will then be asked to squeeze the dynamometer with maximum force for a minimum of 2 minutes while only engaging their forearm and remaining relaxed in the rest of their body. The subject will then release the dynamometer and remain supine, in recovery, for a minimum of 5 minutes.
214945808|NCT05457114|DEVICE|Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA)|PAC was inserted and connected to a continuous cardiac output monitor (Vigilance I from 2006 to 2012; Vigilance II from 2012 to 2022, Edward Lifesciences, Irvine, USA)
214341432|NCT01752140|PROCEDURE|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
214945809|NCT05457114|DEVICE|FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)|Without PAC, monitoring with FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA) was performed for continuous cardiac output monitoring.
214945810|NCT03038776|BIOLOGICAL|Recombinant influenza hemagglutinin|Avian H7N9 influenza vaccine
214945811|NCT06944860|DEVICE|Conventional TBA|Conventional TBA fabricated with polymethylmethacrylate
214945812|NCT06944860|DEVICE|3D TBA|3D TBA made out of a 3D printing resin (Graphy TR07)
214341433|NCT01752140|PROCEDURE|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
214341434|NCT03461627|DRUG|Salmeterol Xinafoate and Fluticasone Propinate Powder|50ug/250ug 1 puff twice a day for 4 weeks
214341435|NCT03461627|DRUG|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
214341436|NCT03191903|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
214341437|NCT03191903|DEVICE|Monovisc|Hyaluronic acid
214341438|NCT03191903|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
214341439|NCT01443442|DRUG|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
214341440|NCT01443442|DRUG|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
214341441|NCT05976334|DRUG|[14C] Subasumstat|\[14C\] Subasumstat IV infusion.
214341442|NCT05976334|DRUG|Subasumstat|Subasumstat IV infusion.
214341443|NCT01578551|DRUG|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
214347475|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
214945813|NCT05279937|DRUG|Dextrose 50% Intravenous Solution|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
214945814|NCT05279937|DRUG|Lidocaine 1% Injectable Solution|10mL of 1% Lidocaine (Control)
214945815|NCT04202289|DEVICE|Nile Tilapia Fish Skin|In the search of new therapies for burns, the skin of Brazil's most cultivated fish, the Nile tilapia, which was mostly a waste product (although sometimes used as a resistant material for artisanal handicraft), was suggested as a possibility for the development of a low-cost xenograft. Apart from non-infectious microbiota, Nile Tilapia Fish Skin presented histomorphological similarities with human skin in pre-clinical studies. It was shown to have a deep dermis formed by thick collagen fibers organized on parallel/horizontal and transversal/vertical arrangement and composed, in comparison, by larger amounts of type I collagen. Nile Tilapia Fish Skin did not present variations in its microscopic structure and tensile strength after glycerolization, irradiation and posterior rehydration, recovering its natural consistency after glycerol removal.
214945816|NCT04202289|DRUG|Silver Sulfadiazine Cream 1%|Topical antibiotic commonly used for the treatment of superficial and deep partial-thickness burns.
214945817|NCT00556738|PROCEDURE|Nasal Continuous Positive Airway Pressure ventilation|Nasal Continuous Positive Airway Pressure ventilation
214945818|NCT00556738|PROCEDURE|Intrapulmonary Percussive Ventilation|Intrapulmonary Percussive Ventilation
214945819|NCT00427999|DRUG|imatinib mesylate|
214341444|NCT01578551|DRUG|Carboplatin|"Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy"
214341445|NCT01578551|DRUG|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
214341446|NCT01578551|DRUG|Metformin|1000 mg twice daily with food.
214341447|NCT04577092|OTHER|Warm-up exercise|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.
214341448|NCT04577092|OTHER|Motor-Cognitive exercise|After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
214341449|NCT04577092|OTHER|Motor-Motor exercise|participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
214945820|NCT00427999|DRUG|Treosulfane|
214945821|NCT00427999|DRUG|etoricoxib|
214945822|NCT00427999|DRUG|pioglitazone|
214945823|NCT00427999|DRUG|dexamethasone|
214945824|NCT02380859|BEHAVIORAL|Prism adaptation|Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
214945825|NCT03889938|DIAGNOSTIC_TEST|Serum and urinary assessment|Assess bioactive lipid mediators in blood and biopyrins in urine
214945826|NCT03767777|DEVICE|Artery Stent Graft System|The Artery Stent Graft System consists of Ankura pro Aorta Stent Graft System along with Longuette Aortic Branch Stent Graft System for chimney technique in the aim of revascularization of aorta branches.The Ankura pro aorta stent graft and Longuette Aortic Branch Stent Graft System are pre-assembled within delivery system. During the operation, the stent graft was delivered to the target lesion location of the vascular real cavity through a delivery system, which was accurately positioned and released to isolate the ruptured opening of aortic dissection, block the continuous flow of blood into the false cavity of the dissection, and avoid further tearing or even rupture of the dissection.
214945827|NCT06543719|OTHER|Simulated work in the heat|Participants perform a continuous heavy-intensity work bout (metabolic rate of \~260 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 1:1 work-rest allocation, starting with a 30 min rest break followed by a 30 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
214945828|NCT02284568|DRUG|Placebo|Placebo
214945829|NCT02284568|DRUG|Laquinimod|Laquinimod capsules in 0.5 mg and 0.6 mg strengths
214945830|NCT02284568|DRUG|Placebo|Placebo capsules
214945831|NCT03776071|DRUG|Enzastaurin Hydrochloride|mg
214945832|NCT03776071|OTHER|Placebo|mg
214945833|NCT03776071|DRUG|Temozolomide|mg/m\^2
214945834|NCT03776071|RADIATION|Radiotherapy|Gy
214341450|NCT04577092|OTHER|Cool-down exercise|In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
214341451|NCT00002495|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15
214341452|NCT00002495|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15
214341453|NCT00002495|RADIATION|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
214341454|NCT00001100|DRUG|ganciclovir|
214341455|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight \< 60 kg and Age \< 65 years and ASAI and II)
214341456|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight \<60 kg and Age \<65 years and ASAI and II)
214341457|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight \< 60 kg and Age \>/=65 years and ASA 3 or 4
214341458|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight \<60 kg and Age \>/=65 years and ASA 3 or 4
214341459|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
214341460|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
214341461|NCT04369469|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.
214341462|NCT04369469|OTHER|BSC|Participants received medications, therapies, and interventions per standard hospital treatment protocols.
214945835|NCT00412217|DRUG|Placebo|Participants will receive placebo tablets (matched to erlotinib) once daily.
214945836|NCT00412217|DRUG|Erlotinib|Erlotinib will be given as 150 mg PO once daily.
214945837|NCT00412217|OTHER|Standard of care|Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.
214341463|NCT02536859|DRUG|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
214341464|NCT02536859|DRUG|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
214341465|NCT02841644|PROCEDURE|Operatively treated traumatic arthrotomy|operatively treated traumatic arthrotomy.
214341466|NCT02841644|OTHER|Non-operatively treated traumatic arthrotomy|non-operatively treated traumatic arthrotomy.
214945838|NCT04600063|PROCEDURE|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
214341467|NCT03568916|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
214341468|NCT03568916|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
214341469|NCT03568916|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
214341470|NCT01164046|DRUG|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
214341471|NCT01164046|DRUG|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
214341472|NCT03112317|OTHER|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
214341473|NCT04261816|PROCEDURE|extubation in the operating room|Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
214341474|NCT04261816|PROCEDURE|extubation in the ICU|Patients who underwent liver transplantation extubation in the ICU following liver transplantation
214341475|NCT05634616|DEVICE|Motor imagery and motor execution based BCI|We designed a motor imagery and motor execution-based BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed
214341476|NCT05634616|DEVICE|Sham BCI|The training equipment was the same, but the program was changed to record only the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set training performance data of the previous pretest patients, i.e., sham neurofeedback.
214341477|NCT02733497|PROCEDURE|Sympathectomy|Resection of ganglia at T3 level
214341478|NCT02733497|PROCEDURE|Sympathicotomy|Cutting of symptahetic chain at T3 level without ganglia excision
214341479|NCT01919385|DEVICE|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
214945839|NCT04600063|PROCEDURE|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
214945840|NCT04676685|DRUG|E2730|E2730 capsules.
214945841|NCT04676685|DRUG|E2730-matched placebo|E2730-matched placebo capsules.
214341480|NCT06572514|DRUG|immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin|The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
214341481|NCT05549674|OTHER|The COPAIN study is observational. There is no intervention.|The COPAIN study is observational. There is no intervention.
214341482|NCT02592733|DEVICE|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
214341483|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
214341484|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
214945842|NCT00162175|DRUG|Muraglitazar|
214945843|NCT00299559|DRUG|smart textiles containing menthol, camphor, cineol|application to skin
214945844|NCT04291495|DIAGNOSTIC_TEST|ANDROSITOL®TEST|Sperm incubation with ANDROSITOL®DGN and evaluation of sperm motility and mithocondrial membrane potential
214341485|NCT04368598|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
214341486|NCT04368598|DRUG|Acetylcysteine|Acetylcysteine, po, 400mg tid, for 4 weeks
214341487|NCT06420635|BEHAVIORAL|Interdisciplinary intervention program on maternal self-efficacy and the motor development of premature children|The experimental group will receive an intervention about maternal self-efficacy and motor stimulation strategies for premature children applied by mothers. There will be two face-to-face meetings: the first with a theoretical session on motor development, a practical workshop on stimulation skills using a baby simulator and strengthening of maternal self-efficacy. The second meeting seeks for mothers to reflect on self-efficacy and carry out practical simulation of strategies with their children. At home (for four weeks), self-efficacy will be strengthened through 4 strategies twice a week, for 8 sessions. Mothers will put into practice with the baby the 10 stimulation strategies explained in the face-to-face sessions, must complete 14 sessions per week, 2 times a day, for a total of 56 sessions. The initial measurement will be carried out before the intervention, the second at 4 weeks and the third at 8 weeks after the intervention began.
214341488|NCT06420635|BEHAVIORAL|Traditional kangaroo program|The control group will receive the conventional family-centered care plan, including kangaroo position, exclusive breastfeeding, and outpatient follow-up. The traditional intervention for the control group is based on the Kangaroo Mother Method (KMC) program, proposed according to technical guidelines, which promotes skin-to-skin contact between mother and premature baby. In periodic outpatient consultations, clinical assessments are carried out focused on optimal growth (goal 15-20g/kg/day), neurological and psychomotor development, and timely detection of pathologies that require specialized care according to findings. Compliance with the vaccination schedule and medical indications, and assurance of breastfeeding, are monitored. The frequency of check-ups is daily initially, then weekly until 40 weeks and then monthly. The approach includes early stimulation and follow-up until 12 months of corrected age.
214341489|NCT05820022|OTHER|Research Barriers Scale|This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
214341490|NCT06341244|DEVICE|Air Stacking Technique|To perform the air stacking technique, an air manual breathing unit (AMBU) was used, attached to a unidirectional valve and nasal/oral mask. For each AMBU manual compression (three in the total), the patient was instructed to breathe in deeply and hold the air inside the lungs.
214341491|NCT01344460|DRUG|Gadobutrol (Gadovist, BAY86-4875)|a single bolus injection of approx. 0.1mmol/kg
214341492|NCT05252559|PROCEDURE|ultrafiltration|In cardiac surgery patients, ultrafiltration is usually applied to reduce free water and concentrate all blood components before weaning from cardiopulmonary bypass
214341493|NCT05252559|DIAGNOSTIC_TEST|maximal clot firmness in EXTEM assay of ROTEM test|before and after applying ultrafiltration, arterial blood sample underwent EXTEM and FIBTEM assays of rotational thromboelastometry
214341494|NCT00755586|PROCEDURE|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 \* 10e8 cells in the m. biceps brachii.
214341495|NCT00755586|PROCEDURE|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 \* 10e8 cells in the m. biceps brachii.
214341496|NCT00755586|PROCEDURE|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
214341497|NCT05690958|OTHER|Survey|Filling in a survey
214341498|NCT01702129|DRUG|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
214341499|NCT03041610|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
214341500|NCT03600285|DEVICE|TB1-K|Use of TB1-K for preservation and transport of donated kidneys
214347476|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
214945845|NCT02783456|PROCEDURE|Noise|The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.
214945846|NCT02783456|PROCEDURE|Silence|The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.
214945847|NCT03011983|DEVICE|MEG|MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.
214945848|NCT03011983|DEVICE|MRI|MRI is a non-invasive imaging modality that provides measures of brain structure.
214945849|NCT03011983|BEHAVIORAL|Neuropsychology assessment|A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
214945850|NCT03114657|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
214945851|NCT03114657|DRUG|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
214945852|NCT04840524|PROCEDURE|Laminate veneers preparation|facial laminate veneers teeth preparation
214945853|NCT01135875|OTHER|GBM Patients|2 teaspoons of blood will be collected during select clinic visits.
214945854|NCT01135875|OTHER|Normal Controls|2 teaspoons of blood will be collected once.
214341501|NCT06275100|OTHER|Prehabilitation|"Participants will be exposed to exercise and psychoeducation. Aerobic exercise will be on a cycle ergometer tailored to their capability and will aim for a low to moderate intensity.The patients will be exercised using the intermittent protocol of alternating 1 minute moderate and 1 minute low intensity aerobic exercise. This duration can be gradually increased during subsequent sessions depending on the patient's ability. Aerobic exercise will be conducted 2- 3 times per week depending on patient's ability.~In addition, participants are expected to do strength and inspiratory muscle training in their own time.~The psychoeducation booklet and audio are designed with input from in-house clinical psychologist. The aim of the booklet is to explain the emotions they may feel whilst being in hospital, symptoms of anxiety, suggest how to manage anxiety, behavioural strategies that may help and signposting if they require further support."
214341502|NCT00987298|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
214341503|NCT03283670|DRUG|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
214341504|NCT03283670|DRUG|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
214341505|NCT03283670|DRUG|Placebo Gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
214341506|NCT04596566|OTHER|Therapeutic diet Intervention|The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
214341507|NCT01085318|DRUG|Rebif|44 mcg tiw
214341508|NCT05987267|OTHER|multidisciplinary precision care|The experimental group received precision nursing based on a multidisciplinary collaborative team in addition to standard treatment and care
214945855|NCT03349905|PROCEDURE|fresh transfer|"Women randomized in the non experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~* All of their embryo kept in prolonged culture~* A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~* Supernumerary blastocysts cryopreserved"
214945856|NCT03349905|PROCEDURE|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~* All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~* A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
214945857|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
214945858|NCT01546038|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
214945859|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
214341509|NCT06536010|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；|VAG in the induction phase of the ND-AML treatment protocol
214341510|NCT00411021|PROCEDURE|Pipelle (Endometrial Sampling)|
214341511|NCT05052970|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
214341512|NCT05052970|DRUG|Bortezomib for Injection|Bortezomib (1.3 mg/m\^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
214341513|NCT05052970|DRUG|Dexamethasone Acetate Tablets|Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
214677573|NCT01099410|PROCEDURE|intravenous catheter|An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
214945860|NCT01546038|DRUG|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
214945861|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days
214945862|NCT01546038|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
214945863|NCT01546038|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
214945864|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days
214945865|NCT01546038|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
214945866|NCT01546038|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
214945867|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
214945868|NCT01546038|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
214945869|NCT03410810|DIAGNOSTIC_TEST|MRI|MRI analysis
214945870|NCT03410810|DIAGNOSTIC_TEST|Neurodevelopmental/Neuropsychological Assessment|Standardized Cognitive and Developmental Tests
214945871|NCT01980810|DRUG|albumin-bounded paclitaxel|200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
214945872|NCT01980810|DRUG|S-1|40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
214945873|NCT04339010|OTHER|Hypopressive exercise|The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.
214945874|NCT04339010|OTHER|Pelvic floor muscle contraction|Pelvic floor muscle contraction (PFMC) is performed through a sequence of contraction and relax the PFM. It will improve PFM strength and is effective for treating urinary incontinence.
214945875|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single infusion over 60 minutes
214945876|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single infusion over 120 minutes
214945877|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single sc injection
214945878|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single infusion over 60 minutes
214341514|NCT03626181|DEVICE|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
214945879|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single infusion over 120 minutes
214945880|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single sc injection
214945881|NCT01923337|DRUG|irinotecan hydrochloride|Given IV
214945882|NCT01923337|DRUG|alisertib|Given PO
214945883|NCT03329248|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214945884|NCT03329248|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
214945885|NCT03329248|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
214945886|NCT03329248|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
214945887|NCT03329248|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
214945888|NCT03329248|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
214945889|NCT03329248|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
214945890|NCT03329248|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
214945891|NCT03329248|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
214945892|NCT03329248|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
214945893|NCT03329248|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
214341515|NCT01751022|DEVICE|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
214945894|NCT03329248|DRUG|lovaza|Omega-3-acid ethyl esters
214945895|NCT03329248|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
214945896|NCT03329248|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
214945897|NCT03628248|PROCEDURE|embolization of the inferior mesenteric artery|proximal occlusion of the inferior mesenteric artery, before its divisional branches, by coils or plug 3-4 weeks prior to surgery.
214945898|NCT03628248|PROCEDURE|Inferior mesenteric artery ligation|Endovascular ligation of Inferior mesenteric artery
214945899|NCT00421317|DRUG|Imatinib|800 mg/day until disease progression or toxicity
214945900|NCT00987402|OTHER|Plain soap and water (PSW)|Presence or absence of infection
214945901|NCT00987402|OTHER|Alcohol-based hand rub (ABHR)|Presence or absence of infection
214945902|NCT01254721|DRUG|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
214945903|NCT01254721|DRUG|lithium|300mg tablet, oral
214945904|NCT03181243|PROCEDURE|Madajet|The spermatic cord is firmly trapped between the middle finger, index finger and thumb of the left hand. The injector's sheath is placed over the spermatic cord with gentle pressure adjacent to the external inguinal ring. Depending upon the thickness of spermatic cord, three or four injections are consecutively administered around it, beginning from proximal to distal points.
214945905|NCT03181243|PROCEDURE|Needle injection|The pubic tubercle is palpated on the side that is going to be blocked. The spermatic cord is then immobilised with the non-dominant hand between the thumb and index finger. Right after needle puncture with attached syringe and local anaesthetic solution is conducted at a point that is 1 cm inferior to and 1 cm medial to the pubic tubercle, pass the needle directly downward in a vertical fashion, which leads it into the spermatic cord. After a check-up (negative aspiration) for bleeding, approximately 3 mL of solution (Lidocaine 2%) is injected into the cord.
214945906|NCT02827643|DRUG|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
214945907|NCT02827643|OTHER|TDF/3TC or FTC/EFV|arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
214945908|NCT04633902|DRUG|Olaparib|Olaparib 300 mg BID daily
214945909|NCT04633902|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV eveyr 3 weeks (for up to 2 years)
214341516|NCT06165705|DEVICE|CureSight|dichoptic therapy with anaglyph goggles and eye tracking
214341517|NCT06663514|OTHER|SupporTive Care At Home|"Home-based medical care is based on a specialized home-based medical team approach, including following:~Specialized Home-Based Medical Team Approach Initial Assessment and Education Initial Home Visits and Education Multidisciplinary Team Meeting Regular Assessment After the Initial Visit"
214341518|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
214341519|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
214341520|NCT06663826|DIAGNOSTIC_TEST|oculomotor and pupillary function assessment|This is an exploratory open-label single-centre research project intended to collect data of PD patients in order to develop machine learning models for helping in the diagnosis and monitoring of PD. Each patient will have an initial visit and then a second visit after two weeks. The estimated duration of the study visit 1 is 3 hours, not taking into account the time for patient information and informed consent. The estimated duration of the study visit 2 is 2 hours. During these two visits, patients will undergo an MDS-UPDRS assessment, a neos examination, a standard manual ocular motor and pupil function examination, and gait assessment simultaneously with GaitQ senti and an IMU sensor placed on their back. In the two weeks separating the two visits, patient's gait will be monitored daily at home with GaitQ senti, where they will perform a daily TUG test comprising of 15 m walk, 5 sit to stand, and 5-minute walk. Healthy individuals data will be included from a previous study.
214341521|NCT04286594|DRUG|CBD|Participants will receive CBD solution during the open-label phase of the trial.
214341522|NCT06444789|DEVICE|connected smartwatch|The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
214341523|NCT06664372|PROCEDURE|Trans fontanelle US Guided VP Shunt|Insertion of proximal VP shunt catheter by trans fontanelle US
214341524|NCT06662877|DRUG|Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib|Albumin-bound Paclitaxel, 125mg/m2,iv.drip,d1,d8,Q3W +Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W+Anlotinib 10mg,p.o,d1-d14,Q3W
214341525|NCT06662877|DRUG|Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)|Oxaliplatin 85 mg/m2,d1,iv.drip,Q2W + Leucovorin 400mg/m2,d1,iv.drip,Q2W+ Fluorouracil 2400 mg/m2 civ46h, Q2W
214341526|NCT06325098|DIAGNOSTIC_TEST|Anti-nephrin antibodies|Assessment of anti-nephrin antibodies on serum samples and in vitro study of permeabilizing effect on 3D organ-on-a-chip models and STED microscopy on healthy human kidneys.
214341527|NCT06325098|DIAGNOSTIC_TEST|u-RPC cultures|Urine sample collection for u-RPC cultures
214341528|NCT06587347|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy, or use a loading dose, 25 μg/kg, administrated within 3 minutes, then 0.15μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy.
214341529|NCT06587347|DRUG|Standard medical treatment (SMT)|Patients will receive standard antiplatelet therapy.
214945910|NCT04685278|BIOLOGICAL|Blood samples|Blood samples were collected in dry tubes on days 1, 3, 5, 8 and 10 of hospitalization
214945911|NCT05640661|DEVICE|Oculus Quest II|"active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~During the realization of the exposure with VRi they will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
214945912|NCT05640661|DEVICE|Oculus Quest II|active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.
215075144|NCT00579241|PROCEDURE|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
215075146|NCT03666897|OTHER|DTI Images and Plasma Biomarkers|Additional Images added from standard of care MRI, Bio-markers identified
214341530|NCT03360500|OTHER|EXERCISE PROTOCOL + CRYOTHERAPY|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field."
214677574|NCT03218852|DRUG|prednisone and cyclophosphamide|Prednisone and cyclophosphamide are both administered to participants in this group.
214677575|NCT03218852|DRUG|prednisone alone|Prednisone is administered to participants in this group.
214341531|NCT03360500|OTHER|EXERCISE PROTOCOL|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises."
214341532|NCT03360500|OTHER|EXERCISE PROTOCOL + PLACEBO|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field."
214341533|NCT02932397|DRUG|Intravenous dose of 0.5 mg/kg of propofol|
214341534|NCT02932397|DRUG|Intravenous dose of 0.05 mL/kg of saline solution|
214341535|NCT04274738|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
214341536|NCT04274738|DRUG|Ibrutinib|Ibrutinib capsules will be administered per dose and schedule specified in the arm.
214341537|NCT03823651|BEHAVIORAL|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
214341538|NCT03823651|BEHAVIORAL|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
214341539|NCT03823651|BEHAVIORAL|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
214341540|NCT03823651|BEHAVIORAL|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
214341541|NCT06618599|PROCEDURE|Mid-transverse process to pleura block combined with erector spinae block|The probe will be placed vertically 3 cm lateral to the T5 spinous process and the transverse process will be identified. The needle will be introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. One milliliter of normal saline will be injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. 20 mL of 0.25% bupivacaine will be injected .The needle will be directed aiming for the midpoint between the transverse process and pleura from cephalad to caudad. One milliliter of normal saline will be given to confirm the position of the needle tip, then a total of 20 ml of 0.25% ropivacaine will be injected
214347477|NCT04198662|DEVICE|Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas)|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
214945913|NCT06234111|COMBINATION_PRODUCT|Semaglutide 2.4 mg, total diet replacement, behavioural intervention|Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
214945914|NCT04621162|BEHAVIORAL|Positive Expectations (initial)|"A positive expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will generate hypoalgesia"
214677576|NCT03527056|BIOLOGICAL|Fecal Microbiota Transplantation|This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.
214677577|NCT04076722|BEHAVIORAL|Stress reactivity stimuli|An evaluated speech task delivered to participants after baseline testing.
214677578|NCT00216359|DRUG|Fuzeon (Enfuvirtide)|
214677579|NCT00216359|PROCEDURE|Laboratory diagnostic (CD4-cells)|
214347478|NCT04198662|DRUG|Intercostal nerve block ropivacaine with epinephrine|3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
214677580|NCT00216359|PROCEDURE|Laboratory diagnostics (HIV-1 viral load)|
214677581|NCT00216359|DRUG|antiretroviral co-medication beside Fuzeon|
214677582|NCT02897973|OTHER|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
214677583|NCT05014698|GENETIC|WGS|Whole Genome sequencing
214677584|NCT04151563|BIOLOGICAL|nivolumab|Specified dose on Specified days
214677585|NCT04151563|BIOLOGICAL|ipilimumab|Specified dose on Specified days
214677586|NCT04151563|DRUG|cabozantinib|Specified dose on Specified days
214677587|NCT04151563|BIOLOGICAL|docetaxel|Specified dose on Specified days
214677588|NCT04151563|BIOLOGICAL|ramucirumab|Specified dose on Specified days
214677589|NCT04151563|DRUG|lucitanib|Specified dose on Specified days
214677590|NCT00392002|DRUG|Esomeprazole|
214677591|NCT02470013|DIETARY_SUPPLEMENT|Balanced, energy dense, moderate protein sip feed|2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
214677592|NCT04919993|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|Group presentation
214945915|NCT04621162|BEHAVIORAL|Negative Expectations (initial)|"A negative expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will not generate hypoalgesia"
214341542|NCT06618599|PROCEDURE|paravertebral block|the transducer will be positioned laterally 3 cm to the midline at T5 spinous process, defining the spinous process, pleura, transverse process, the paravertebral (PV) space, and superior costotransverse ligament. The trapezius, rhomboid major, and erector spinae muscles will be recognized as superficial to the hyperechoic transverse process shadow. However, when the rhomboid major muscle disappeared, this indicated that we will be at the 7th thoracic vertebra's level. Local infiltration using 2-3 mL of 2.0% lignocaine will be done. A spinal 22-gauge needle will be injected at the cephalic side of the transducer using an in-plane technique, and the needle directed towards the costotransverse ligament (CTL). The passage of the needle through the CTL will be associated with a pop, informing that the superior costotransverse ligament will be passed. Following a 3 mL testing dose of normal saline containing epinephrine (1:200,000), 30 mL bupivacaine 0.25% injected.
214341543|NCT03556046|DIAGNOSTIC_TEST|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
214341544|NCT01464918|DEVICE|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
214341545|NCT06620926|OTHER|IDH mutant-type|The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
214945916|NCT04621162|BEHAVIORAL|Neutral Expectations (initial)|This group will act as a control. No expectations will be given that will influence the participant.
214945917|NCT04621162|BEHAVIORAL|Positive Expectations (during intervention)|"A positive expectation will be given during the performance of the mental practice. This is working very well"
214945918|NCT04621162|BEHAVIORAL|Experimental: Negative Expectations (during intervention)|"A negative expectation will be given during the performance of the mental practice. This is working very bad"
214341546|NCT06620926|OTHER|IDH wild-type|The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
214341547|NCT02404363|DRUG|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --\> clopidogrel 150 mg/d x 7days then 75mg/d"
214341548|NCT02404363|DRUG|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --\> placebo 150 mg/d x 7days then 75mg/d"
214341549|NCT04465175|DRUG|Magnesium Sulfate|Second dose magnesium sulphate infusion over one hour
214341550|NCT04465175|DRUG|Placebo|Normal saline (2.5 ml/kg) infusion over one hour
214341551|NCT04581499|COMBINATION_PRODUCT|DynamiCare Motivation Support Program|DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.
214341552|NCT04581499|OTHER|Untreated or Routine Care Control Group|No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.
214341553|NCT00452101|DRUG|Aquamin F|
214341554|NCT00016094|BIOLOGICAL|bevacizumab|Given IV
214341555|NCT00016094|OTHER|laboratory biomarker analysis|Correlative studies
214341556|NCT03864614|DRUG|SAGE-217|SAGE-217
214341557|NCT03590977|OTHER|licorice extract mouthwash|mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.
214341558|NCT03590977|OTHER|chlorohexidine mouthwash|mouth wash that contains chlorohexidine as an active component
214945919|NCT04621162|BEHAVIORAL|Neutral Expectations (during intervention)|This group will act as a control. No expectations will be given that will influence the participant.
214945920|NCT00757029|GENETIC|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
214945921|NCT02538692|DRUG|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
214945922|NCT02538692|DRUG|Placebo|The placebo is the same as Tong-Xie-Yao-Fang in appearance.
214341559|NCT05309382|DIAGNOSTIC_TEST|Prospera|Monthly testing and results provided
214341560|NCT06369740|OTHER|Case scenarios - questionnaire|Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.
214341561|NCT06369740|OTHER|Case scenarios - Focus groups|Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.
214341562|NCT06369740|OTHER|Use scenarios - Usability test|Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).
214341563|NCT06369740|OTHER|Use scenarios - interview|The participants will be interviewed and asked for their opinions and experiences with the mock-ups.
214945923|NCT02736591|DRUG|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.
214341564|NCT05413187|DRUG|Medical Grade Cannabis oil|MGC, 30% CBD and 1.5% Δ9-THC
214341565|NCT05413187|DRUG|Placebos|Olive oil and Chlorophyl
214341566|NCT00206674|DRUG|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
214945924|NCT02736591|DRUG|Growth Hormone-Releasing Hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
214945925|NCT02736591|DRUG|Placebo 1|Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
214945926|NCT02736591|DRUG|Placebo 2|Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
214945927|NCT02176460|DRUG|Colchicine|0.5mg twice daily for 16 weeks
214945928|NCT02176460|DRUG|Placebo|1 tablet twice daily
214945929|NCT02647255|PROCEDURE|Plasma Exchange (PE)|PE treatment\>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
214341567|NCT00206674|DRUG|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
214677593|NCT01096771|DRUG|ClinOleic 20%|96 hour continuous infusion.
214677594|NCT01096771|DRUG|Intralipid 20%|96 hour continuous infusion.
214677595|NCT01858883|DRUG|itacitinib|
214341568|NCT06111092|OTHER|Design Thinking|Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.
214341569|NCT06111092|OTHER|Focus Groups|Participants attend the FG that includes the introduction. discussion, and reflection.
214341570|NCT06321718|PROCEDURE|PENG + LFCN block versus S-FICB|1\. Group (A) will receive PENG + LFCN block:
214341571|NCT03859323|DRUG|SHP681|Participants will receive SC injection of SHP681 in the abdomen.
214341572|NCT03859323|OTHER|Placebo|Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
214341573|NCT04286035|DRUG|Bupivacaine Injection|Femoral nerve block with 20 ml %0.375 bupivacaine
214677596|NCT01858883|DRUG|Gemcitabine|
214677597|NCT01858883|DRUG|nab-paclitaxel|
214677598|NCT01858883|DRUG|filgrastim|
214677599|NCT03391518|PROCEDURE|Water drinking test|Ingestion of 800 ml water in less than 5 minutes.
214677600|NCT03799315|DRUG|Nicotine Replacement Therapy|All participants randomized to the JUST group will receive training on proper use of nicotine lozenges to aid in smoking cessation. Upon release from jail, participants will receive 2mg nicotine lozenges.
214677601|NCT03799315|BEHAVIORAL|Counseling|All participants randomized to the JUST group will receive one hour of in-person, individual, guideline-based smoking cessation counseling during their jail stay. Upon release from jail, they will receive four 30-minute counseling phone calls over 3 weeks. These phone calls will take place at 24 hours, day 7, day 14, and day 20.
214677602|NCT00000348|DRUG|Dihydrexidine|
214341574|NCT04286035|DRUG|Bupivacaine Injection|Adductor canal block with 20 ml %0.375 bupivacaine
214341575|NCT02343341|BEHAVIORAL|Preschool Health Promotion Education Program|
214341576|NCT00822510|BEHAVIORAL|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
214341577|NCT00822510|BEHAVIORAL|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
214341578|NCT06081660|BEHAVIORAL|ACP-I Plan|ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
214341579|NCT04624698|DEVICE|iStent Inject Implantation|Subjects will be implanted with the iStent Injection Micro-Bypass device
214677603|NCT00158652|PROCEDURE|Conventional radiotherapy 70 Gy in 7 weeks|2 gy per fraction, 1 fraction per day, 5 fractions per week
214677604|NCT00158652|PROCEDURE|middle accelerated radiotherapy 70 Gy in 6 weeks|5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
214677605|NCT00158652|PROCEDURE|very accelerated radiotherapy 64.8 Gy in 3.5 weeks|2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
214677606|NCT00158652|DRUG|5FU, Paraplatin|5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
214677607|NCT03069339|DRUG|Carvedilol|Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
214677608|NCT03069339|PROCEDURE|Endoscopic Variceal Ligation|EVL will be done every 3 weeks till eradication
214677609|NCT00480753|DRUG|Nitroglycerin|
214677610|NCT00907478|BIOLOGICAL|romiplostim|Romiplostim administered by subcutaneous injection
214677611|NCT03053089|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
214677612|NCT00002410|DRUG|Indinavir sulfate|
214677613|NCT00002410|DRUG|Lamivudine|
214677614|NCT00002410|DRUG|Zidovudine|
214677615|NCT01362712|RADIATION|[F18]CP-18 Injection|Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.
214677616|NCT03285217|DIETARY_SUPPLEMENT|Ensure Plus Advance|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
214945930|NCT02647255|DRUG|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
214341580|NCT05424419|PROCEDURE|Brace therapy|A Chêneau-type brace was made to be worn as a full-time brace or during daytime only (double-brace group), whereas the nighttime brace was produced according to the Charleston approach.
214341581|NCT05577429|OTHER|Low-moderate intensity exercise under normoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 20.9%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
214341582|NCT05577429|OTHER|Low-moderate intensity exercise under moderate hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 16.5%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
214341583|NCT05577429|OTHER|Low-moderate intensity exercise under high hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 14.8%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
214341584|NCT01404312|DRUG|Rifapentine (RPT)|"RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets)."
214677617|NCT03285217|DIETARY_SUPPLEMENT|Ensure High Protein|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
214677618|NCT06424366|BEHAVIORAL|Ballet for All Kids|The intervention consists of 12 weeks of ballet classes that follow the structure and curriculum of Ballet for All Kids (BFAK). BFAK is a non-profit organization that has been tailoring ballet classes for children with autism spectrum disorder for over one decade. Ballet classes will be held once a week for 45 minute sessions and led by trained medical and graduate students who have successfully completed BFAK's training and certification. BFAK instruction is based on the Schlachte Method, which combines auditory, visual, vestibular, and emotional learning to individualize instruction to match each child's skill level. In classroom accommodations include, but are not limited to a visual schedule, personal dance areas demarcated by tape on the floor, and one-on-one volunteer assistance.
214677619|NCT05427851|PROCEDURE|pulpotomy|coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
214677620|NCT05427851|DEVICE|Diode laser - fonalaser|diode laser beam application
214677621|NCT02639182|DRUG|AGS-16C3F|Intravenous (IV) infusion
214945931|NCT02984514|RADIATION|Positron emission tomography with tracer 18F-deoxy glucose|Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
214945932|NCT04012424|DRUG|curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf|"effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric"
214677622|NCT02639182|DRUG|Axitinib|Oral
214945933|NCT04012424|DIETARY_SUPPLEMENT|400mg starch|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
214945934|NCT03385616|DEVICE|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
214945935|NCT05199896|BEHAVIORAL|Behavioral protocol|A touch sensitive computer screen either displaying a downscaled (45cm long) image of the rod (for the sighted), or supporting a same sized wooden rod (for the blind), will be placed on the table in front of the participant to record their localization performance. They will be instructed to use their left index fingertip to indicate on the image of the screen (for sighted) or on the wooden rod (for the blind) the position where they have felt the touch provided to the 90 cm long they held in their right dominant hand. Participants will wear a headset playing white noise to prevent any auditory localization cues when the long rod will be touched. The rod will be touched by a computer controlled solenoid. Thus, participants will respond with a hand gesture on the image or rod and will be asked to validate the position by pressing a foot-pedal with their left foot.
214945936|NCT05199896|DEVICE|EEG protocol|"The EEG protocol will be similar as the behavioral one described above, with the distinction of taking place in two separate sessions: one where the rod are touched, and one where their hand is touched. The participant will hold a rod in each hand and he will have to indicate on which rod he felt the touch.~Additionally electrophysiological responses will be continuously recorded using a 65 channel ActiCap system (Brain Products)."
215075147|NCT05015855|OTHER|NP-PC PrEP|All participating providers will be provided standard education around PrEP and HIV prevention, but half of the providers will be randomized to also partner with a nurse practitioner who will provide additional consultation to patients.
214677623|NCT06018831|OTHER|Urine and Ultrasound Screening|When an infant was born, he/she will receive the first urine and ultrasound screening in 3 months in Kunshan/Qidong City Maternal and Child Health Hospital.In Kunqi Cohort, 9,000 will complete 3 years follow-up(urine screening once every year, another ultrasound screening in 24-30 months). Urine sample (50ml) will be stored only once within one year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study.1,000 children will complete 6 year follow-up(receive urine and ultrasound screening once every year). Urine sample (50ml) will be stored once a year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study. The 14 urine test items include: leukocytes, urobilinogen, microalbumin, protein, bilirubin, glucose, ascorbic acid, specific gravity, ketone bodies, nitrite, creatinine, pH, occult blood, and urinary calcium. Ultrasound test will screen for kidneys, ureters and the bladder.
214677624|NCT06120478|OTHER|observe|observational study
214341585|NCT01404312|DRUG|Isoniazid (INH)|Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
214945937|NCT05199896|DEVICE|fMRI protocol|"The same behavioral task and procedures of the behavioral protocol described above will be applied, adapted to take into account the constraints posed by the magnetic environment of the MR scanner. The participant will be placed on the scanner bed and provided with earphones that will both protect against the noise of the machine (80dB) and ensure a continuous communication with the participant.~During the fMRI sessions, the participant will solve the same rod localization behavioral task while we will record brain activations by measuring the brain oxygen level dependent signal via Echo Planar Imaging sequences. We will use an MRI compatible tactile stimulator to touch the hand-held rod and participants location judgement will be recorded by using an MRI-compatible tablet, positioned on their abdomen, where the participant will have to indicate the judged position."
214945938|NCT04929158|PROCEDURE|Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)|Preoperative criminal vascular assessment； The criminal vascular assessment after surgery
214945939|NCT03872258|BEHAVIORAL|Control|Counseling on physical activity
214945940|NCT03872258|BEHAVIORAL|Intervention group|Program of combined exercise and a Smartband for 6 months.
214945941|NCT05426824|DRUG|Pegaspargase（P-GOD）|stage I/II) ENKTL patients receiving P-GOD for the first time, gemcitabine 1000 mg/m2 intravenously on day 1 and day 5, oxaliplatin 75 mg/m2 intravenously on day 1, dexamethason 40 mg intravenously on day 1-4, and pegaspargase 3750 IU intramuscularly on day 2. The cycle was repeated every 21 days.The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
214945942|NCT05426824|DRUG|Pegaspargase（PEMD）|stage III/IV ENKTL patients receiving PEMD for the first time,methotrexate 3.0 g/m2 intravenously over 6 h on day 1, etoposide 100 mg/m2 intravenously on days 2-4, dexamethasone 40 mg intravenously on days 1-4, pegaspargase 3750 IU intramuscularly on day 2. The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
214945943|NCT00853515|OTHER|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
214945944|NCT01069315|PROCEDURE|Type of fluid lavage solution|Comparison of castile soap solution vs. normal saline solution.
214945945|NCT01069315|PROCEDURE|Type of fluid lavage pressure|Comparison of low pressure vs. high pressure.
214945946|NCT01789671|BEHAVIORAL|Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
214945947|NCT04578093|BEHAVIORAL|LARC peer-based curriculum|Peer-based educational videos and supplemental activities
214945948|NCT05608278|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|Novel CBT treatment
215075148|NCT05015855|OTHER|OBGYN-PrEP|"OBGYN-PrEP is based on PC4PrEP (R01MH107297) that has four steps: announce the policy that PrEP counseling is the responsibility of OBGYN providers to address the purview paradox; train providers to manage patients on PrEP; use a screening tool to identify women appropriate for PrEP; and implementation coaching to monitor and encourage PrEP counseling"
215075149|NCT05899595|OTHER|Exercise protocol|"Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises."
214945949|NCT05608278|BEHAVIORAL|Gold standard cognitive behavioral therapy (gold standard CBT)|Gold standard CBT treatment
214341586|NCT01404312|DIETARY_SUPPLEMENT|Pyridoxine (Vitamin B6)|"Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH."
214341587|NCT00584688|DRUG|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
214945950|NCT03197194|DRUG|Alteplase|alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.
214945951|NCT03197194|DRUG|acetylsalicylic acid|one tablet of aspirin 300 mg
214945952|NCT03197194|DRUG|Placebo Oral Tablet|One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
214945953|NCT03197194|DRUG|placebo IV|IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
214945954|NCT02358772|OTHER|thrombolysis in a pre-hospital setting (STEMO concept)|
214945955|NCT02778386|DRUG|N-Methanocarbathymidine|Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.
214945956|NCT02778386|OTHER|Placebo Capsule|Two patients in Cohort 3 \& 4 will receive placebo capsules which is mannitol filled into size 0 capsules.
214945957|NCT06323317|BEHAVIORAL|Multi-component exercise programme|Each exercise session will start with a warm-up, followed by core exercise training and ending with a cool-down period. A series of flexibility training and stretching exercises will be performed during the warm-up and cool-down phases (10 minutes in total). The core exercise session will comprise aerobic (10 minutes), resistance (20 minutes), and balance (20 minutes) training, where resistance and balance exercises constitute the major components, as they are particularly effective in strengthening functional capacity, muscle strength, and balance function for mobility in frail patients.
214945958|NCT06323317|OTHER|Attention Placebo|The control group will receive routine preoperative care provided by the clinical team, which includes unstructured patient education on the surgeries/procedures, and a brief session on the use of an incentive spirometer, breathing, and coughing exercise. Other perioperative care procedures will be implemented according to the existing clinical protocols.
214945959|NCT06323317|BEHAVIORAL|Structured preoperative education|The prehabilitation programme will begin with a 60-minute (group- or individual-based) structured education session at the centre. The content will cover frailty, its impacts on postoperative recovery, cardiovascular and overall health, and functional well-being. The importance of nutrition and exercise on their recovery potential and postoperative functional capacity will be elaborated. Their commitment to intervention engagement will be highlighted as the key to success. This session will also cover the principles of exercise, its progression, and exercise safety.
214945960|NCT06323317|BEHAVIORAL|Nutritional optimization|The Malnutrition Universal Screening Tool (MUST) will be used for a nutritional screening to determine the risk of malnutrition (low, medium, or high). The nurse will evaluate the dietary patterns of each participant, and provide tailored nutritional advice on daily protein intake according to a protein supplementation protocol. The participants and their caregivers will be provided with plenty of suggestions for high-quality protein foods according to patients' preferences. The nurse will follow-up with the participants to identify any barriers they encountered in real-world settings when they attend the exercise sessions. She will reinforce the advice and provide suggestions to overcome barriers according to the preference and lifestyle of the participants.
214945961|NCT06323317|BEHAVIORAL|Stress management|Relaxation techniques to reduce tense arousal, including guide imagery and breathing techniques, will be taught. Guided imagery makes use of attention-focus to target mental arousal, whereas deep and diaphragmatic breathing is a fundamental relaxation method for various stress relieving techniques. Both techniques are designed to reduce sympathetic arousal, which is particularly beneficial to cardiac patients. Participants will be encouraged to self-practice on a daily basis, and a sound track will be provided to guide their practice.
214341588|NCT05704959|DIAGNOSTIC_TEST|povidone iodine|Reference measurements were made simultaneously with two separate calibrated pulse oximeter devices from the index, middle and ring fingers of both hands of the participants. One layer of 10% povidone iodine was applied to the index finger, two layers to the middle finger, and three layers to the ring finger of one hand of the participant's choice. Two pulse oximetry measurements were made with the fingers of the other hand, immediately after the application of povidone-iodine and three minutes later, and it was noted on the data collection form.
214347479|NCT04198662|DEVICE|Sham cryoneurolysis with a Painblocker|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
214677625|NCT03864237|BEHAVIORAL|Alcohol texts|A text message each day for 10 weeks, containing factual information about campus drinking norms.
214945962|NCT00201617|DEVICE|Bone-anchored hearing aid|
214945963|NCT01362517|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age"
214945964|NCT06084624|DRUG|Rebamipide mouthwash|Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinone-4-yl\]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome
214945965|NCT06084624|DRUG|Betamethasone mouthwash|Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers
214945966|NCT00822224|DRUG|MEOPA|inhalation of MEOPA during the painful care
214945967|NCT01122784|BIOLOGICAL|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
214945968|NCT01122784|BIOLOGICAL|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
214945969|NCT01122784|BIOLOGICAL|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
214945970|NCT01122784|BIOLOGICAL|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
214945971|NCT00296127|DRUG|Celecoxib|
214945972|NCT04176081|DRUG|Darolutamide|Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
214945973|NCT04176081|DRUG|Degarelix|Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
214945974|NCT04176081|RADIATION|Radiation Therapy|The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
214945975|NCT03209518|DRUG|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
214677626|NCT03864237|BEHAVIORAL|Attention control|"A text message each day for 10 weeks, containing this day in history facts."
214945976|NCT00718796|OTHER|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
214945977|NCT00718796|OTHER|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
214945978|NCT06182618|OTHER|dietary, semaglutide or/and metformin|patients were prescribed dietary and pharmaceuticals for weight loss
214945979|NCT01507402|DRUG|REGN1033(SAR391786)|Administration method A
214341589|NCT06349902|BEHAVIORAL|Re-Link|The HCV nurse will attempt to contact the PWDU HCV via phone call and text. If unable to connect with a client via phone, an alert is added to the client's chart in the electronic medical record. When the client presents to the CBSUTP for their regular substance use follow up appointment, the chart alert is flagged by the administrative team and the client is connected with the HCV nurse via telemedicine. Clients who are connected to the HCV team are considered re-linked. The HCV nurse will provide an HCV intake as per program guidelines. Clients who would prefer to pursue treatment elsewhere will be supported with a referral to their family doctor or an alternative HCV program in the community. Clients who choose to be treated at the CBSUTP will receive a HCV consultation, DAA treatment and follow-up from the HCV clinical team onsite as per existing program guidelines.
214341590|NCT00354705|BEHAVIORAL|Questionnaire|Two questionnaires taking 30 minutes to complete.
214341591|NCT00880932|BEHAVIORAL|Electronic Alert|
214341592|NCT05684016|OTHER|NeuroQuant|Reliably defines the volume of those parts of the brain that are important for memory and thinking.
214341593|NCT05684016|OTHER|Automated Neuropsychological Assessment Matrices|This is like an IQ test.
214341594|NCT05684016|OTHER|EDSS|Extended Disability Status Score
214341595|NCT05684016|OTHER|Physical Examination|Physical Examination
214341596|NCT00711685|PROCEDURE|coronary artery bypass grafting via midline sternotomy|
214341597|NCT04419493|DRUG|Alteplase (from modified manufacturing process)|Alteplase, TPA-05
214341598|NCT04419493|DRUG|Alteplase (from current manufacturing process)|Alteplase, TPA-02
214341599|NCT04419493|DRUG|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
214341600|NCT00524134|DRUG|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
214945980|NCT01507402|DRUG|REGN1033(SAR391786)|Administration method B
214945981|NCT01507402|DRUG|Placebo|(inactive substance)
214945982|NCT00780624|DEVICE|NIPPV|Ventilator is Bird VIP.
214945983|NCT00780624|DEVICE|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
214945984|NCT00780624|DEVICE|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
214945985|NCT00390624|DRUG|URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)|
214341601|NCT01283789|DRUG|Lapatinib and RAD-001|"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
214945986|NCT00390624|DRUG|MANNITOL|
214945987|NCT00236899|DRUG|Gemcitabine|"Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).~Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
214945988|NCT00236899|DRUG|Docetaxel|"Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
214341602|NCT02279758|DRUG|Metformin|
214341603|NCT02357212|PROCEDURE|coronary angiography|invasive procedure performed to determine coronary anatomy
214341604|NCT02357212|PROCEDURE|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
214341605|NCT03574168|BIOLOGICAL|CD19-CAR-T Cells|T cells purified from the PBMC of subjects or subjects' relatives which depends on their conditions, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
214945989|NCT00236899|DRUG|Paclitaxel|"Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
214945990|NCT05687838|OTHER|Music|Music medicine
214945991|NCT06301009|DIAGNOSTIC_TEST|AI-CAC score|Deep-learning based prediction of the coronary artery calcium score with a plain chest x-ray
214945992|NCT01469975|DRUG|OTSA101-DTPA-90Y level 1|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
215075150|NCT05671718|OTHER|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
214945993|NCT01469975|DRUG|OTSA101-DTPA-90Y level 2|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
214945994|NCT01469975|DRUG|OTSA101-DTPA-90Y level 3|"Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data."
214945995|NCT06018506|DRUG|BR108 injection|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
214945996|NCT05840328|DRUG|Dexmedetomidine Injection [Precedex]|interventional drug will be administred either intravenously or epidurally
214945997|NCT05840328|DRUG|Bupivacaine Injection|intervention drug will be administred epidurally
214945998|NCT02388711|OTHER|C-TraC Intervention|C-TraC utilizes a nurse case manager to coordinate the patient's transitional care through active participation in inpatient multidisciplinary discharge rounds, a single brief protocol-driven inpatient encounter, and 1-4 protocol-driven post-hospital telephone calls with the patient/caregiver using spaced retrieval techniques.
214945999|NCT03009383|DEVICE|A bedside portable endoscopy|
214946000|NCT00416793|DRUG|bortezomib|Given IV
214946001|NCT00416793|DRUG|carboplatin|Given IV
214946002|NCT00416793|OTHER|laboratory biomarker analysis|Correlative studies
214946003|NCT06504888|DRUG|Penicillin|Compare whether there is a higher incidence of sinus elevation in patients allergic to penicillin compared to non-allergic patients, evaluating clinical histories.
214946004|NCT06307509|OTHER|Diagnosis of sepsis|Patients will be recruited on the basis of a diagnosis of sepsis, as this is the exposure of interest
214946005|NCT03946228|BEHAVIORAL|Behavioral Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
214946006|NCT00423397|BIOLOGICAL|PEG-interferon alfa-2a|
214946007|NCT00423397|DRUG|gefitinib|
214946008|NCT04413383|OTHER|Traditional Curved Iris Scissors|Aesculap Curved Iris Scissors
214946009|NCT04413383|OTHER|Wuennenberg Modified Curved Iris Scissors|Modified Silent Curved Iris Scissors
214946010|NCT04413383|OTHER|Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors|Patients experience both types of scissors
214946011|NCT05619380|PROCEDURE|physiotherapy treatment|Three different physiotherapy treatments will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 5th and 10th day of therapy, it will be measured ROM and sEMG.
214946012|NCT00237276|PROCEDURE|colonoscopy|
214946013|NCT03696485|BIOLOGICAL|SCM-010|SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.
214946014|NCT01429974|OTHER|amniometer model po1|"The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.~The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform."
214946015|NCT05977465|DRUG|Empagliflozin 25 MG|treatment
214946016|NCT02929966|OTHER|palliative care program|The program includes psychological support, spiritual care and respiratory therapist support
214946017|NCT02929966|OTHER|standard respiratory care|the usual standard pharmacological care plus oxygen therapy
214946018|NCT03317457|BIOLOGICAL|Durvalumab and Tremelimumab|immun checkpoint inhibitor
214946019|NCT03317457|DRUG|Doxorubicin|Anthracycline
214946020|NCT01325194|DRUG|liposomal cytarabine|50 mg intrathecally three times
214946021|NCT05035849|DRUG|sitagliptin and acarbose|One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
214946022|NCT02703818|DEVICE|Senza|Spinal Cord Stimulation
214946023|NCT01121536|DRUG|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
214946024|NCT05674318|DIETARY_SUPPLEMENT|Alpha-lactalbumin|Oral assumption of two tabs/day containing Alpha-lactalbumin for 30 days
214946025|NCT00070213|DRUG|FOLFOX regimen|
214946026|NCT00070213|DRUG|capecitabine|
214946027|NCT00070213|DRUG|fluorouracil|
214946028|NCT00070213|DRUG|leucovorin calcium|
214946029|NCT00070213|DRUG|oxaliplatin|
214946030|NCT00070213|PROCEDURE|quality-of-life assessment|
214946031|NCT01840137|OTHER|Baseline Strength Test|A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
214946032|NCT01840137|OTHER|Exercise|Treadmill and muscle exercises.
214946033|NCT01487213|OTHER|Home self assessment of complete medical abortion|Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
214946034|NCT00495599|PROCEDURE|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
214946035|NCT00387049|BEHAVIORAL|Anxiety Sensitivity Program for Smoking Cessation|
214946036|NCT05805007|DRUG|ZVS203e|ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.
214341606|NCT01184066|BEHAVIORAL|ACTS Intervention|ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.
214946037|NCT01589809|DRUG|nicotinamide|dose-escalation, 2-8 grams, oral
215075151|NCT06146946|PROCEDURE|Dissection of the No.253 lymph node|The range of the No.253 lymph node is as follows: medially, it extends from the root of the inferior mesenteric artery to the starting section of the left colonic artery; caudally, from the starting point of the left colonic artery to the intersection with the inferior mesenteric vein; laterally, it is bordered by the outer margin of the inferior mesenteric vein; and cranially, from the horizontal section of the duodenum to the beginning of the jejunum. In the controlled group, the surgery is performed with dissection of the No.253 lymph node.
215075152|NCT06146946|PROCEDURE|Omitting the dissection of the No.253 lymph node|In the experimental group, the surgery is performed without dissection of the No.253 lymph node.
215075153|NCT06002854|DRUG|PRP( platelet rich plasma) and Insulin human|Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
214677627|NCT04286191|COMBINATION_PRODUCT|Operant Conditioning|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
214677628|NCT04286191|COMBINATION_PRODUCT|Control Group|This is the control intervention, or the non-conditioning group. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
214677629|NCT02972723|DRUG|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
215075154|NCT00603070|OTHER|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
214341607|NCT01184066|BEHAVIORAL|Usual Care|Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
214677630|NCT04756635|OTHER|Experimental Group|This 3-year project will include two groups of participants: 1) young men accustomed to resistance training (study #1) and 2) young men accustomed to endurance training (study #2). Inclusion will be limited to healthy participants (i.e. nonsmokers, normotensive with systolic and diastolic values \<135/85 mmHg, non-obese, non-medicated, and free of any known disease as assessed by medical history) (Pickering, Hall et al. 2005). Month 1-3 will focus on literature review and month 4 to 8 will address experimental settings preparation and selection of participants to include in each study. Testing and data collection will be scheduled for months 9-14 and 13-18 (study # 1 and 2 related testing, respectively). Data processing, analysis and presentation will occur from month 21 to 33. All participants will read and sign an informed consent document with the description of the testing procedures. The Faculty's ethical committee will be asked to approve this document before testing.
214946038|NCT05763056|PROCEDURE|McGrath videolaryngoscopy|The McGrath video laryngoscope has a thin, disposable, clear, regularly shaped blade similar to a Macintosh blade and a large LCD display attached to the arm. It is lighter in weight and the Mc VL has a small camera at the tip, with a more compact screen and handle that can make tracheal intubation easier and faster in normal or difficult airway. The smaller volume, thinner and portrait screen helps reduce blind spots
214946039|NCT05763056|PROCEDURE|C-MAC videolaryngoscopy|The Macintosh blade is attached to the handle and the light beam is passed through the blade tip into a small metal guide tube indented 40 mm. The camera cable is connected to the control unit and the optical cable is connected to the light source. The video macintosh system is installed in a small trolley for easy portability of the device. The trolley supports an 8-inch monitor mounted on a rotating arm on the patient's left side. C-MAC VL devices can create continuous video recordings or static images on a secure removable digital card. The electronic module includes 2 buttons for photo and video shooting. In addition, the image of the C-MAC VL device can be viewed on other devices or recorded via a standard video output port. 3 C-MAC VL reusable metal macintosh blades (sizes 2 to 4) can be used for adult patients. These non-disposable knives have a closed design without gaps in terms of hygiene and have beveled edges to prevent tissue damage.
214946040|NCT05763056|DEVICE|Direct laryngoscopy|During intubation with a direct laryngoscope (DL), the laryngoscope is inserted into the oral cavity from the right side of the mouth, the tongue is pushed to the left, and after advancing up to the vallecula, it hangs up and forward. In this way, the floor of the mouth and the epiglottis structure are removed from the field of view. If a straight blade laryngoscope is to be used, it is advanced so that the epiglottis remains under the blade after viewing the epiglottis (1). In DL, manipulations such as head extension, sniffing position, and compression of the cricoid cartilage may be required to facilitate visualization of the vocal folds. In 10-15% of the complications experienced during intubation with DL, there are problems related to the angle of view.
214946041|NCT05135793|DRUG|Topoprazan|1 tablet contains 20 mg vonoprazan
214946042|NCT05135793|DRUG|Takecab|1 tablet contains 20 mg vonoprazan
214946043|NCT02696928|DRUG|Artemeter-Lumefantrine and MB (combination therapy)|AL first 3 days MB next 14 days
214946044|NCT02696928|DRUG|Artemeter-Lumefantrine (combination therapy)|AL first 3 days
214946045|NCT02696928|DRUG|Artemeter-Lumefantrine and Primaquine (combination therapy)|AL first 3 days PQ next 14 days
214946046|NCT03146728|OTHER|exercise|energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
214946047|NCT05580328|DRUG|Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy|Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
214946048|NCT03896178|OTHER|None, observational study|None, observational study
214677631|NCT02950662|OTHER|Overdenture|Active comparator will be metal housing and peek housing
214341608|NCT00129987|BEHAVIORAL|Self management education|
214341609|NCT02684422|OTHER|Intervention N/A. Observational study|There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
214341610|NCT03721380|BEHAVIORAL|Treatment as usual|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
214341611|NCT01017406|DEVICE|PSU heel cushion and plantar fascia specific stretching exercise|"* Wear heel cushion during daily activity~* Plantar fascia stretching exercise 3 times per day"
214677632|NCT03627455|OTHER|Percutaneous coronary intervention|Percutaneous coronary intervention
215075155|NCT00603070|OTHER|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
215075156|NCT01096368|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
214946049|NCT04436705|OTHER|Progressive Muscle Relaxation (PMR) technique|The PMR technique utilized in this study was based on the original technique designed by Jacobson (1938) and subsequently modified by Bernstein and Borkovec (1973). The PMR technique involves tensing the individual muscle groups for about 5 seconds for each muscle. Then, allowing them to relax for about 10 seconds, and notice how the muscle feels when it is relaxed in contrast to how it felt when it was tensed. The technique is accompanied by breathing exercises in order to feel the sense of relaxation. In this study, the PMR technique refers to tensing and relaxing the muscles from the forehead to the feet one by one, including the eleven muscle groups (right arm, left arm, forehead, jaw and neck, back and shoulders, stomach, thighs, right calf, left calf, right foot and left foot). The total procedure takes around 20 minutes.
215075157|NCT01096368|DRUG|Carboplatin|Given IV
215075158|NCT01096368|DRUG|Cisplatin|Given IV
215075159|NCT01096368|OTHER|Clinical Observation|Patients undergo observation
215075160|NCT01096368|DRUG|Cyclophosphamide|Given IV
215075161|NCT01096368|DRUG|Etoposide|Given IV
215075162|NCT01096368|BIOLOGICAL|Filgrastim|Given SC or IV
215075163|NCT01096368|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214946050|NCT02860871|OTHER|infrared spectroscopy|
214946051|NCT02977728|OTHER|Olfactory Evaluation|The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
214946052|NCT00257205|DRUG|dacarbazine|decarbazine 1000 mg/m2 IV Q 21 days x 12
214946053|NCT00257205|DRUG|CP-675,206|CP-675,206 15 mg/kg IV Q 90 days x 4
214946054|NCT00257205|DRUG|temozolomide|temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
214946055|NCT03345628|DRUG|Sedatives|sedated group received sedative drugs to tolerated intubation and ventilation
214946056|NCT05022628|DRUG|Donafenib|"Donafenib treatment regimen.~1. Donafenib started on the day of the first radiation treatment.~2. starting dose 0.2 g bid twice daily orally on an empty stomach (1 hour before or 2 hours after a meal).~3. Surgery after at least 1 week off Donafinil; resume Donafinil dosing as soon as possible after postoperative wound healing until any of the following occurs, whichever occurs first: (i) the subject develops an intolerable toxic reaction that does not resolve after dose adjustment (see 5.3 for details); (ii) 12 months of postoperative dosing; (iii) the subject has the first imaging-confirmed recurrence of disease or withdraws from the study (whichever occurs first).~4. Dose adjustment/withdrawal: Subjects are allowed up to 2 dose adjustments if they experience an adverse event related to the trial drug during treatment."
215075164|NCT01096368|DRUG|Mesna|Given IV
215075165|NCT01096368|DRUG|Vincristine|Given IV
215075166|NCT05867836|DIETARY_SUPPLEMENT|IFA vs. MMS during pregnancy|Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
215075167|NCT05473156|DRUG|AP203|"Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D\[s\]).~Participants will be administered by intravenous (IV) infusion, every week (Q1W \[± 1days\]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W \[± 3 days\]) for all the following doses."
215075168|NCT05473156|DRUG|AP203|The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
215075169|NCT03070223|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
215075170|NCT03070223|DRUG|Placebos|One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
215075171|NCT03496792|OTHER|Tilt + external pressure|In Visit 1, the anti-shock trousers will be inflated to 20, 40, or 60 mmHg. BP will be measured 3 times from the brachial artery. Then the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals. The tilt table is returned to 0o and the resting supine baseline BP will be collected. Then, the anti-shock trousers will be inflated to a different pressure (20, 40, or 60 mmHg) and the head up tilt will be repeated. Repetitions at the various pressures will be performed in a random order with suitable resting intervals in between the tilting bouts.
215075172|NCT03496792|OTHER|Tilt + no external pressure.|In Visit 1, the anti-shock trousers will NOT be inflated. Auscultatory BP will be measured 3 times from the brachial artery. Thereafter, the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals.
214341612|NCT01735539|DIETARY_SUPPLEMENT|15g EAA bolus|Oral; in aqueous solution
214341613|NCT01735539|DIETARY_SUPPLEMENT|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
214677633|NCT02976493|OTHER|No Intervention|No Intervention
214946057|NCT05708183|DIETARY_SUPPLEMENT|Multiple micronutrient supplementation (MMS)|Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
214341614|NCT01735539|DIETARY_SUPPLEMENT|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
214341615|NCT05234294|OTHER|Survey|We will investigate symptoms through monthly surveys.
214946058|NCT05708183|DIETARY_SUPPLEMENT|Iron folate supplementation (IFA)|IFA delivered as part of routine antenatal care, according to current policy
214946059|NCT05197205|PROCEDURE|nasopharyngeal swabbing|A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study
214946060|NCT02854605|DRUG|GS-9674|Tablet administered orally once daily
214946061|NCT02854605|DRUG|Placebo to match GS-9674|Tablet(s) administered orally once daily
214946062|NCT02925377|BEHAVIORAL|Neuromuscular warm-up|The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
214946063|NCT02925377|BEHAVIORAL|Standard warm-up|Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
214946064|NCT03924505|OTHER|Organize and Mobilize for Implementation Effectiveness|Our trial is trying to understand how a multi-faceted, facilitation-based implementation strategy advances effective implementation of naloxone within syringe services programs
214946065|NCT03924505|OTHER|Dissemination|Our comparison group receives dissemination of best practice recommendations for naloxone implementation.
214946066|NCT01290198|DRUG|Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)|At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
214946067|NCT00213577|DRUG|type A botulinum toxin|
215075173|NCT03496792|OTHER|Limb occlusion + negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. After the cuff is inflated to 250 mmHg, the pressure in the tank will be reduced to -100mmHg for 2 minutes. The application of negative pressure creates a suction effect on the leg, and leads to an overall increase in pressure gradient across the blood vessel wall and induces vascular distension.
215075174|NCT03496792|OTHER|Limb occlusion + no negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. The cuff is inflated to 250 mmHg for 2 minutes, but the pressure in the tank is not changed.
214341616|NCT00033254|RADIATION|radiation therapy|Undergo conventional radiation therapy
214341617|NCT00033254|DRUG|thalidomide|Given orally
214341618|NCT00033254|PROCEDURE|quality-of-life assessment|Ancillary studies
214341619|NCT06467045|OTHER|Pediatric patients who received sedation for magnetic resonance imaging|Pediatric patients who underwent MRI under sedation will be prospectively observed. All non-intubated patients under the age of 16 will be included in the study. The demographic data, comorbidities, and medications of the patients, the procedures performed, the anesthetic drugs used, the expertise duration of the anesthesiologist, and the adverse effects encountered will be recorded.
214341620|NCT03114254|DRUG|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days."
214341621|NCT02609243|BEHAVIORAL|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
214341622|NCT03137511|OTHER|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
214341623|NCT01577706|DRUG|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
214341624|NCT01577706|DRUG|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
214946068|NCT03205098|BIOLOGICAL|Blood analysis|Blood test of biological markers of mesenteric ischemia
214946069|NCT04191122|OTHER|COPESS|The intervention includes brief psychotherapy to be delivered within primary care settings
214946070|NCT03014622|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
214946071|NCT03014622|BIOLOGICAL|Placebos|Intramuscular injection
214946072|NCT02560857|OTHER|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
214946073|NCT02644330|PROCEDURE|transthoracic device closure|minimally invasive transthoracic device closure
214946074|NCT02644330|PROCEDURE|surgical repair|surgical repair with cardiopulmonary bypass
214946075|NCT00153010|DRUG|NS 2330 (Tesofensine)|
214946076|NCT05869110|OTHER|Effects of odours on calorie intake, food choice and metabolic parameters|"Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.~Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week."
214946077|NCT00568334|BIOLOGICAL|Varilrix (inactivated varicella vaccine)|subcutaneously injection
214946078|NCT05415241|DRUG|FB2001|"Stage 1 (Exploring the dose): Twenty participants will be enrolled for aerosol inhalation of FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, another twenty participants will be enrolled for aerosol inhalation of FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): Another twenty participants will be enrolled for aerosol inhalation of FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1."
214946079|NCT06137534|OTHER|Proprioceptive Neuromuscular Facilitation Upper Extremity Pattern|"Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.~PNF upper extremity patterns to be applied to the participants:~1. Bilateral symmetrical flexion-adduction-external rotation.~2. Bilateral symmetrical flexion-abduction-external rotation.~3. Bilateral asymmetric right: flexion-abduction-external rotation, left: flexion-adduction-external rotation.~4. Bilateral reciprocal (same diagonal) right: extension-adduction-internal rotation, left: flexion-abduction-external rotation.~5. Bilateral reciprocal (same diagonal) right: flexion-adduction-external rotation, left: extension-abduction-internal rotation.~6. Bilateral reciprocal (opposite diagonal) right: extension-adduction-internal rotation, left: flexion, adduction, external rotation."
214946080|NCT02869841|DRUG|Levobupivacaine continuous infusion|Levobupivacaine continuous infusion to rectus sheath catheters
214677634|NCT03069690|BEHAVIORAL|HABITpreg|"Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
214946081|NCT02869841|DRUG|levobupivacaine bolus dosing|Levobupivacaine bolus dosing to rectus sheath catheters
214946082|NCT02869841|DRUG|single bolus of levobupivacaine|Levobupivacaine single dose to rectus sheath catheters
214946083|NCT02869841|OTHER|Placebo|No rectus sheath analgesia
214946084|NCT05070143|BEHAVIORAL|RISE-UP Routine|The participants in this condition will be instructed to substitute their current sleep habits with the RISE-UP routine that has been developed by our team (Kaplan, Talavera, \& Harvey, 2018). This involves instructing participants to devise an individually tailored routine that will help them get up each morning (e.g., open blinds, make the bed, head for the shower).
214341625|NCT01577706|OTHER|Placebo|Placebo, gel-capsule, single-dose, 1-day
214341626|NCT03405987|DIAGNOSTIC_TEST|Strain analysis by CMR|Strain analysis by CMR will be performed
214341627|NCT06082180|PROCEDURE|prophylactic central neck dissection|prophylactic central neck dissection was performed for the ipsilateral lesion
214341628|NCT01156753|DRUG|CDX-011|CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
214341629|NCT01156753|DRUG|"Investigator's Choice chemotherapy"|Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
214341630|NCT01952340|DIETARY_SUPPLEMENT|Flaxseed|Milled flaxseed
214341631|NCT01952340|DIETARY_SUPPLEMENT|Placebo|Wheat germ/wheat bran and mixed dietary oils
214341632|NCT02732535|PROCEDURE|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
214341633|NCT02516618|DRUG|Fasinumab|
214946085|NCT05070143|BEHAVIORAL|Awareness Training|The participants in this condition will be instructed in dismantling/disrupting the association between the cue and the habit via awareness training from habit reversal approaches (Azrin \& Nunn, 1973; Ladouceur, 1979). This condition involves instructing the participant to develop an awareness of their decisions to stay in bed and snooze.
214946086|NCT05070143|BEHAVIORAL|Vigilant Monitoring|"The participants in this condition will be instructed in vigilant monitoring which involves internal repetition of get up! and don't do it and watching carefully for slipups (Quinn, Pascoe, Wood, \& Neal, 2010)."
214341634|NCT02516618|DRUG|Placebo|
214341635|NCT03525353|OTHER|Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care|No intervention has been used and this is an observational study
214341636|NCT04489446|DRUG|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
214946087|NCT05070143|BEHAVIORAL|Implementation Intentions|"The participants in this condition will be instructed in counter habitual implementation intentions. This involves instructing the participant to engage in implementation intentions in which they imagine replacing snoozing with getting up out of bed (Adriaanse, Gollwitzer, De Ridder, De Wit, \& Kroese, 2011). The structure of this implementation intention is: If I wake up in the morning and I want a sleep-in then I will get up and start my day."
214341637|NCT04489446|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
214341638|NCT00857324|DRUG|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~* Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~* In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
214341639|NCT02980367|OTHER|Non-Surgical Management (Rehabilitation)|Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
214341640|NCT02980367|PROCEDURE|Surgical Management (Reconstruction)|All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
214341641|NCT06471101|DIAGNOSTIC_TEST|clusters|clustering
214341642|NCT04256551|OTHER|Heali mobile application + Registered Dietitian|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. RDs employed by Heali provide real-time messaging to users. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
214677635|NCT03069690|BEHAVIORAL|HABITpost|"Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
214946088|NCT05070143|BEHAVIORAL|Values-based Approach|The participants in this condition will be instructed in a values-based approach (Anshel, Brinthaupt, \& Kang, 2010; Anshel \& Kang, 2007). This involves asking the participants to reflect on how getting up consistently at the same time each day does or does not align with their values. They are asked to compare the costs and long-term consequences of continuing to engage in the unwanted habit and clearly articulating the disconnect between the habit and their values.
214946089|NCT05070143|BEHAVIORAL|Brief Education|"In this condition, participants only receive the learning module. This condition is included as a minimal intervention comparison condition that controls for the passage of time.~First, education about the importance of regular wake times and sleep inertia that is a normal transitional stage between sleep and wake. The education will be delivered in this video format: https://www.youtube.com/watch?v=P6zcSFA7ymo. Second, after viewing the video, the key points will be summarized. Lastly, participants will be asked to summarize the four key takeaways for good sleep habits."
214946090|NCT05721690|DEVICE|UED-A Videolaryngoscopy|Tracheal Intubation with UED-A videolaryngoscope
214946091|NCT05721690|DEVICE|Glidescope Videolaryngoscopy|Tracheal Intubation with Glidescope Titanium videolaryngoscope
214946092|NCT01540084|DRUG|propofol|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
214946093|NCT05528484|PROCEDURE|ERAS nursing|Patients were given education before surgery, fluid and anesthetic drug management during surgery, early ambulation, fluid management and early feeding after surgery, etc
215075175|NCT05242224|OTHER|Evolutionary Nutrition Package|The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
215075176|NCT06209593|DIETARY_SUPPLEMENT|Compleat plant protein tube feed|Patients on a tube feed will act as their own control and switch to new tube feed.
215075177|NCT04405128|DIAGNOSTIC_TEST|Transcranial Tissue Doppler (TCTD)|"Doppler ultrasound technique called Brain Tissue Velocimetry (Brain TV), to investigate brain tissue motion over the cardiac cycle."
215075178|NCT04405128|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging|Brain MRI for investigation of brain tissue motion in the presence of suspected stroke.
214341643|NCT04256551|OTHER|Heali mobile application|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
214341644|NCT04256551|OTHER|Standard Dietary Education|An educational guide to the implementation of the elimination and reintroduction phases of the diet, a suitable/unsuitable food guide, 19 substitutes for unsuitable foods, a guide of example meals (i.e., breakfast-6 recipes, lunch-8 recipes, dinner-12 recipes, and snacks/beverages-13 recipes), and tips for reading labels and eating a balanced diet while following the LFD. The website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System.
214341645|NCT04444154|BEHAVIORAL|Control group|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.
214341646|NCT04444154|BEHAVIORAL|Group with active participation|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
214677636|NCT02445378|PROCEDURE|Aromatherapy and Essential Oils|Undergo aromatherapy and essential oils
214341647|NCT04444154|BEHAVIORAL|Group with video and quizz|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
214946094|NCT05528484|PROCEDURE|non eras nursing|Patients were under the routine management without eras protocol
214946095|NCT05456854|DIAGNOSTIC_TEST|Hyperglycemic Clamp|Administration of a hyperglycemic clamp
214946096|NCT05456854|DRUG|Kisspeptin-10|Administration of kisspeptin-10 \* 16 hr
214946097|NCT05456854|DRUG|Placebo|Administration of placebo \*16 hr
214946098|NCT01287975|OTHER|Occupational Therapy|"Use of conventional manual facilitation and function-based training used in conventional occupational therapy training for post-stroke upper limb weakness.~Training is modelled along the neurodevelopmental techniques and will include stretching, tone management, weight bearing exercises, movement facilitation, selfcare training, arm ergometry by arm bicycles and grip strength training.~Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively."
214946099|NCT01287975|DEVICE|BCI Haptic Knob|BCI based robotic rehabilitation works by detecting the motor intent of the user from electroencephalogram signals to drive the robotic rehabilitation via Haptic Knob. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
214946100|NCT01287975|DEVICE|Haptic Knob|Haptic Knob is an upper limb robot designed for use in robotic-assisted rehabilitation of the stroke wrist and hand. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
214946101|NCT00004770|DRUG|thioctic acid|
214946102|NCT01897571|DRUG|Tazemetostat|Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
215075179|NCT05770934|OTHER|Blood flow restricted low-load resistance exercise|Blood flow restricted low-load resistance exercise
214341648|NCT04431323|BEHAVIORAL|ESPRIMO|"Participants will receive the intervention during Phase 2.~The intervention is based on the cognitive behavioral, the third-wave (mindfulness and acceptance and commitment therapy), and the positive psychology approach.~The frequency of the intervention and the specific content and aims of the psychological and physical intervention will be based on the results of the surveys and the focus group discussion (Pre-phase and Phase 1). In order to maximize the benefit of the integrated intervention, all the three components of the interventions (i.e., psychological, motor exercise and social components) will be administered in the same time period.~A preliminary theoretical framework of the intervention will be created prior to the survey phase according to the literature in the field. Specific aspects of this preliminary framework will be discussed during the co-creation phase and adapted after the analysis of the qualitative results."
214946103|NCT01897571|DRUG|Prednisolone|Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.
214946104|NCT01897571|DRUG|Tazemetostat|Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.
214946105|NCT01421745|OTHER|Cultural Competence Education module|A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
214946106|NCT00939471|DEVICE|Relieva™ Balloon Sinuplasty™ System|Balloon dilation will be performed using endoscopic equipment with video documentation capability.
214946107|NCT02357615|DRUG|nifedipine CR tablets (Xin Ran)|
214946108|NCT02357615|DRUG|Adalat|
215075180|NCT04200755|DRUG|Dupilumab 300Mg Solution for Injection|First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
215075181|NCT04200755|OTHER|Placebo|First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
214341649|NCT01760954|DRUG|Elagolix|Elagolix tablets administered orally
214341650|NCT03320070|DRUG|Acthar Gel|Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)
214341651|NCT03320070|DRUG|Placebo|Placebo gel for SC injection
214347480|NCT04198662|DRUG|Placebo intercostal nerve block with normal saline|3 mL of normal saline will be injected perineurally to provide placebo intercostal nerve blocks
214946109|NCT00178269|DRUG|docetaxel|
214946110|NCT00178269|PROCEDURE|Radiation Therapy|
214946111|NCT01612507|DRUG|600 mg Ceftaroline fosamil|1 h infusion
214946112|NCT01612507|DRUG|Placebo|1 h infusion
214946113|NCT01612507|DRUG|600 mg Ceftaroline fosamil|2 h infusion
214946114|NCT01612507|DRUG|Placebo|2 h infusion
214946115|NCT05061485|OTHER|Sucrose|The participants consume A) water with 75 g sucrose
214946116|NCT05061485|OTHER|Sucrose + protein|The participants consume B) water with 75 g sucrose + approx. 100 kcal protein
214946117|NCT05061485|OTHER|Sucrose + fat|The participants C) water with 75 g sucrose + approx. 100 kcal fat
214946118|NCT01329666|DIETARY_SUPPLEMENT|Placebo|Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.
214946119|NCT01329666|DIETARY_SUPPLEMENT|Vitamin D3|"Baseline:~50,000 IU/week for 8 weeks~Week 8:~Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.~Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks."
214946120|NCT04720950|OTHER|Exercise|1 hour of exercise on a motorised treadmill at 70% maximal heart rate
214946121|NCT00208234|DRUG|Omalizumab|0.016 mg/kg IgE
214946122|NCT00208234|DRUG|Placebo for Omalizumab|Placebo
214946123|NCT00208234|DRUG|omalizumab|Monoclonal antibody against IgE. 0.016 mg/kg IgE
215075182|NCT05365568|PROCEDURE|Left Bundle Branch Area Pacing (LBBAP)|Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy
215075183|NCT05365568|PROCEDURE|Biventricular pacing (BiV)|Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)
215075184|NCT04997109|OTHER|APPLES-tele|The APPLES-tele intervention is 5 weekly telehealth sessions of therapist-demonstrated tasks, delivered over a 6 week period. Infant participants wear a soft-constraint harness (C-Mitt) on their less affected arm for 6 hours per day, while their parent encourages them to use their more affected arm to complete play-based activities as instructed by the study therapist. As the infant experiences success, heavier objects are provided. During times when the C-Mitt is not worn, parents engage therapist-demonstrated bimanual play of increasing difficulty.
214341652|NCT06170008|DEVICE|Physical microstructure-modified transparent silicone film sheet|The main component of the physical microstructure-modified transparent silicone film sheet is transparent silicone rubber, which has a three-dimensional microstructure on its trauma contact surface through physical mechanics treatment, which can provide effective mechanical stimulation for trauma healing. And after testing, the silicone film sheet is breathable, light-permeable, non-toxic and non-allergenic. It is expected to significantly reduce the number of dressing changes, reduce the damage to the wound and the painful stimulation to the patient during dressing changes, and promote the healing of the wound to a certain extent, thus improving the quality of wound repair and saving medical costs.
214341653|NCT06170008|DEVICE|Decellularized pig skin|Decellularized pig skin is an allogeneic trauma covering from pigs and is a commonly used trauma covering for second-degree burn wounds. It adheres to clean superficial wounds, creates a temporary barrier to the wound, reduces wound exudation, limits loss of body components, improves microcirculatory stasis, provides a microenvironment suitable for wound healing, protects inter-ecological tissue, promotes repair and regeneration, and reduces pain. Its disadvantages are: soft structure, difficult to fix the trauma; opaque, unable to observe the trauma; pigskin needs to be stored under suitable temperature and humidity, and has a limited time. When used, decellularized pig skin is directly covered on conventionally treated second-degree burn wounds.
214341654|NCT06170008|DEVICE|Vaseline gauze|Vaseline gauze is the most commonly used conventional dressing for the implant area, which is mainly made of skimmed cotton gauze impregnated with petroleum jelly and paraffin oil, which has a lubricating effect and can promote the growth of granulation and wound healing. However, its moisturizing time is relatively short and requires frequent dressing changes; moreover, petroleum jelly gauze often adheres to the wound surface severely, which may cause bleeding and new epidermal damage during dressing changes and affect the wound healing; the wound surface is constantly oozing blood and fluid, and the dressing cannot be effectively isolated from the outside world after wetting, which increases the chance of infection. Vaseline gauze is applied directly to the post-operative skin grafting wound.
214677637|NCT02445378|OTHER|Placebo|Undergo placebo intervention using rose water
214946124|NCT01010399|DIETARY_SUPPLEMENT|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
214946125|NCT01010399|DRUG|fosamprenavir/ritonavir|Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
214946126|NCT04129775|DRUG|OTO-413|Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)
214946127|NCT04129775|DRUG|Placebo|Single intratympanic injection of placebo
214946128|NCT02900261|OTHER|No intervention|This study is observational and does not entail any intervention. Different methods to assess sodium and caffeine consumption will be compared.
214946129|NCT04422314|DIAGNOSTIC_TEST|T-Detect Lyme|T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.
214946130|NCT01126008|DRUG|CCRT with weekly docetaxel & cisplatin|radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
214946131|NCT01448603|BIOLOGICAL|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
214946132|NCT01448603|BIOLOGICAL|ToleroMune Ragweed|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
214946133|NCT05538923|OTHER|No intervention was given to the patients|This study was an observational epidemiological study.
214946134|NCT05922813|BIOLOGICAL|BMI2004|hyaluronidase, recombinant
214946135|NCT05922813|OTHER|0.9% NaCl|Normal Saline
214946136|NCT05106920|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, to cause a tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
214946137|NCT00347321|PROCEDURE|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
214946138|NCT01436864|BIOLOGICAL|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
214946139|NCT05268016|DRUG|ME3183|ME3183 capsule
214946140|NCT05268016|DRUG|Placebo|Placebo capsule
214946141|NCT04122755|DRUG|ALA-1000|Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.
214946142|NCT04122755|DRUG|buprenorphine sublingual film|ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1
214946143|NCT02742714|DEVICE|PillCam SBC system|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
214946144|NCT00469495|DRUG|Anti-helminthic|
214677638|NCT02445378|OTHER|Questionnaire Administration|Ancillary studies
214946145|NCT00469495|DRUG|meglumine antimony|
214946146|NCT02273908|OTHER|No intervention|The study is observational
214946147|NCT04352738|DIAGNOSTIC_TEST|Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)|Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon
214946148|NCT01375634|DRUG|Midazolam|2 mg intravenous over 2 minutes For patients \>60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
214946149|NCT03727295|DRUG|Idebenone/placebo|The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
214946150|NCT03472313|DRUG|[18F]MNI-958|Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-958 injection and PET scan.
214946151|NCT01733823|RADIATION|76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole|
214341655|NCT02496013|DRUG|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
214946152|NCT01691703|DEVICE|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
214946153|NCT03371056|BIOLOGICAL|Bacteriological analyses on clinical samples performed with swabs|Bacteriological analyses will be performed to assess the InSPIRe kit
214677639|NCT01372878|DEVICE|PillCam® COLON 2 procedure|Subjects will undergo a PillCam® COLON 2 procedure which includes ingestion of the PillCam® COLON 2 capsule. PillCam® COLON 2 is a disposable, ingestible capsule that takes video images throughout the digestive system.
214677640|NCT01372878|PROCEDURE|Colonoscopy|"Subjects will undergo standard Colonoscopy procedure 4-6 weeks after PillCam® COLON 2 procedure.~Standard colonoscopy involves placement of a standard endoscope (a thin, flexible plastic tube) into the anus and into the colon, a tiny camera in the endoscope allows the study doctor to see the surface of the colon."
214677641|NCT05911958|DRUG|SHR-A1811 for injection|SHR-A1811 for injection
214677642|NCT03283215|DIAGNOSTIC_TEST|complete blood count , electrolytes|it is a labarotory test to assess hemoglobin white blood count plate let
214341656|NCT03676062|OTHER|exercise|All exercises programs applied three sessions per week, totally six week.
214946154|NCT02106143|DEVICE|RejuvenAir™ Radial Spray Cryotherapy|Metered dose radial spray cryotherapy treatment
214946155|NCT05917808|OTHER|Ready-to-eat wholegrain porridge|A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated
214946156|NCT04908475|DRUG|Risankizumab|Subcutaneous injection
214946157|NCT04908475|DRUG|Apremilast|Oral Tablets
214946158|NCT03163459|DRUG|selective brain cooling by cold saline perfusion|During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
214946159|NCT03163459|DEVICE|mechanical thrombectomy|conventional mechanical thrombectomy using Solitaire
214946160|NCT03579823|DRUG|Adalimumab 100 MG/ML [Humira]|prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1
214946161|NCT03579823|DRUG|AVT02 100MG/ML|prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
214946162|NCT02962206|DEVICE|Point-of-care ultrasound|After the fracture reduction maneouver, the physician will assess residual dorsal angulation using point-of-care ultrasound. If deemed adequate, the physician will progress to immobilization. If the reduction is not adequate, the physician will attempt further reduction at their discretion.
214946163|NCT02962206|PROCEDURE|Closed fracture reduction|The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician
214946164|NCT03900156|OTHER|goal-setting|The interviewer will have access to key information from the initial assessment such as details of identified risks. Areas where the participant would like to make changes or improvements will be identified and prioritized, and up to five specific, realistic and achievable goals will be identified.
214946165|NCT06533267|PROCEDURE|Endoscopic nasopharyngectomy followed close follow-up|"Radical resection of primary lesion using nasal endoscopy.~After the treatment, the electronic nasal endoscopy was reviewed every two weeks to determine the healing of the wound, whether there was tumor recurrence, until the surgical wound was completely healed. The patients were followed up at least once every three months from the first year to the third year, at least once every six months from the fourth year to the fifth year, and at least once every year after five years."
214677643|NCT01412242|OTHER|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
214341657|NCT04741568|BEHAVIORAL|Parental psychoeducational Intervention|"The psychoeducation intervention for parents will focus on providing skills, knowledge and support motivation for caregivers of children with diabetes.~A brief (one-day or two half days) workshop, and a website with downloadable content will be made available to review and refresh any skills and techniques."
214341658|NCT05615467|DRUG|LY3556050|Administered orally.
214677644|NCT02240628|DEVICE|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
214677645|NCT02240628|DRUG|Saline|Patients in arm 2 will receive Saline with the Propofol.
214677646|NCT02240628|DRUG|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
214677647|NCT03408080|DRUG|BHV-4157|BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
214946166|NCT06533267|RADIATION|Intensity-modulated Radiotherapy|"GTVnx (nasopharyngeal lesions): 69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82Gy CTV2: 54.12Gy/33Fr/1.64Gy.~After treatment, patients were followed up every 3-6 months from the first year to the third year, every 6-12 months from the fourth year to the fifth year, and at least once a year after five years."
214946167|NCT06135116|DIAGNOSTIC_TEST|Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA|"Gingival crevicular fluid samples collection After removing supragingival plaque, sampling sites were isolated by cotton rolls and dried using air syringe, GCF samples were collected by inserting standardized paper point in the sulcus/ pocket at the proximal-facial line angle of six preselected sites in each patient teeth . Fluid was sucked by paper points for 30 seconds. The samples were immediately placed inside graduated eppendorf vials containing 250µl phosphate-buffered saline (PBS), and transported to the laboratory for subsequent assays .~Blood Samples Collection From control and patient groups and under standard aseptic conditions, the peripheral blood was collected in Ethelene Diamine Tetra Acetic Acid (EDTA) coated vacutainer tubes (K2 EDTA) 5.4mg (BD vacutainer) and transferred immediately to flow cytometric analysis lab."
214946168|NCT05127655|PROCEDURE|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
214946169|NCT00000923|DRUG|Indinavir sulfate|
214946170|NCT00000923|DRUG|Lamivudine|
214946171|NCT00000923|DRUG|Stavudine|
214946172|NCT00000923|DRUG|Zidovudine|
214946173|NCT00000923|DRUG|Didanosine|
214946174|NCT00000923|DRUG|Aldesleukin|
214946175|NCT04579614|BEHAVIORAL|The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers|"A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period."
214341659|NCT05615467|DRUG|Metformin|Administered orally.
214341660|NCT05615467|DRUG|Iohexol|Administered IV.
214341661|NCT00164801|DRUG|Baclofen, Diltiazem|
214341662|NCT00996996|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
214341663|NCT00534196|RADIATION|Permanent iodine-125 (Brachytherapy)|Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
214946176|NCT05555602|DEVICE|Cold-air cooling|Cryo 6 works with a compressor system like those in refrigerators and uses ambient air to generate a permanent stream of cold air with a maximum flow to 1000 L/min and a temperature as low as -30°C, depending on the cooling delivery system and the desired cooling level (range 1-9).
214341664|NCT06529679|BEHAVIORAL|Split-belt Training|Walking on a split-belt treadmill in which the speed of one belt will be different (move faster or slower) than the speed of the other belt.
214341665|NCT06529679|BEHAVIORAL|Tied-Belt Training|Walking on a split-belt treadmill in which the speed of both belts is the same.
214946177|NCT05482906|OTHER|eGait|IMU sensor (as part of eGait device) worn at the hip during T25FW
214341666|NCT00335244|DRUG|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
214946178|NCT00394316|DRUG|Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells|
214946179|NCT02215785|OTHER|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
214341667|NCT00335244|DRUG|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
214946180|NCT00404924|DRUG|ZD6474 (vandetanib)|once daily oral tablet
214946181|NCT00404924|OTHER|Best Supportive Care|standard of care
214946182|NCT01980498|DRUG|Fentanyl pectin nasal spray (FPNS)|The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.
214677648|NCT03805295|OTHER|BOKS Program|12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
214946183|NCT01980498|DRUG|Physician choice-Usual care (PC-UC)|"The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.~If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice."
214946184|NCT01644760|PROCEDURE|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
214946185|NCT05175820|OTHER|No intervention|Survey questions were sent through the mailing list of the Turkish Dental Association, where all dentists in Turkey are registered
214946186|NCT03303391|OTHER|Intradialytic Blood Pressure Slope Based Ultrafiltration|Algorithmic Determination of ultrafiltration based on intradialytic blood pressure slopes calculated at the beginning of each month from the prior two weeks of dialysis treatments
214946187|NCT02103257|DRUG|Sequential Icotinib Plus Chemotherapy|Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
214946188|NCT02103257|DRUG|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
214946189|NCT01216046|DRUG|VX-809|capsule, taken once daily
214946190|NCT01216046|DRUG|VX-770|tablet, taken once every 12 hours
214946191|NCT01216046|DRUG|VX-809 placebo|capsule, taken once daily
214946192|NCT01216046|DRUG|VX-770 placebo|tablet, taken once every 12 hours
214341668|NCT01459276|BIOLOGICAL|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
214341669|NCT01459276|BIOLOGICAL|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
214341670|NCT03272100|PROCEDURE|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
214341671|NCT02819726|BIOLOGICAL|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
214341672|NCT02819726|BIOLOGICAL|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
214341673|NCT02819726|BIOLOGICAL|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
214946193|NCT03913104|DRUG|Mifepristone|Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
214946194|NCT06150469|COMBINATION_PRODUCT|"Blend of ginger and lemon essential oils, Neutral oil"|Patients will be given aromasticks to inhale the blend of essential oils.
214946195|NCT02084914|PROCEDURE|Endometrial scratching|Group A: pipelle Group B: sound
214946196|NCT02797418|BEHAVIORAL|Cognitive remediation program|"Comparison between a cognitive remediation program (Cognitus and Me) (groupe 1) and a training group of fine motor skills (group 2)"
214946197|NCT06215794|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
214946198|NCT06215794|PROCEDURE|Glossopharyngeal Nerve Block|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
214946199|NCT00179894|BEHAVIORAL|Physician training|Physicians are trained in guidelines for medication management.
214946200|NCT05338866|RADIATION|Magnetic resonance guided radiotherapy|Radical radiotherapy boosting for low rectal cancer through magnetic resonance guided radiotherapy linear accelerator.
214946201|NCT05338866|DRUG|Chemotherapy|"For patients with AJCC stage II and III and age \< 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses."
214946202|NCT02734225|OTHER|Functional Recovery|Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
214946203|NCT02734225|OTHER|Balance Training|Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
214946204|NCT02734225|OTHER|Dynamometric Platform Training|Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
214946205|NCT01239524|PROCEDURE|denervation of thoracodorsal nerve or saving the nerve|
214946206|NCT00827658|PROCEDURE|Volar Wrist Block|"Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
214341674|NCT03499158|OTHER|nerve conduction study|nerve conduction study
214341675|NCT01982916|DRUG|AGR tablet|
214341676|NCT01982916|DRUG|Placebo (for AGR tablet and/or Active Comparator)|
214341677|NCT01982916|DRUG|Active Comparator|
214341678|NCT05490667|DRUG|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
214341679|NCT00125216|BEHAVIORAL|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
214341680|NCT02125058|PROCEDURE|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
214341681|NCT02125058|PROCEDURE|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
214341682|NCT02545712|OTHER|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
214341683|NCT02545712|OTHER|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
214341684|NCT02545712|OTHER|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
214341685|NCT02545712|OTHER|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
214946207|NCT00827658|PROCEDURE|Hypothenar Palm block|"Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
214946208|NCT00089635|DRUG|Panitumumab|Administered by intravenous infusion
214341686|NCT02545712|OTHER|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
214341687|NCT02545712|OTHER|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
214946209|NCT02477709|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only
214946210|NCT01353573|RADIATION|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
214341688|NCT02545712|OTHER|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
214341689|NCT02545712|OTHER|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
214341690|NCT02545712|OTHER|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
214341691|NCT02545712|OTHER|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
214341692|NCT00406029|DRUG|Preladenant|1 mg BID capsules
214341693|NCT00406029|DRUG|Preladenant|2 mg BID capsules
214341694|NCT00406029|DRUG|Preladenant|5 mg BID capsules
214341695|NCT00406029|DRUG|Preladenant|10 mg BID capsules
214341696|NCT00406029|DRUG|Placebo|BID capsules
214341697|NCT00406029|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
214341698|NCT00406029|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
214341699|NCT02162810|DRUG|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
214341700|NCT02162810|DRUG|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
214341701|NCT00674310|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
214486458|NCT06739395|DRUG|Vebreltinib Enteric Capsules|Usage and dosage: The recommended starting dose is 200 mg/time, taken orally twice a day (once in the morning and once in the evening), until disease progression or intolerable toxicity occurs.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214946211|NCT01353573|RADIATION|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
214946212|NCT01870167|DRUG|co-amoxiclav|a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.
214486459|NCT06739395|DRUG|Alpelisib Pill|Usage and dosage: The recommended dosage is 300mg (two 150mg film tablets), taken once a day with food; Continue treatment until the disease worsens or unacceptable toxicity occurs.Administration method: Patients should take aspirin at approximately the same time every day and swallow the entire aspirin tablet (the tablet should not be chewed, crushed, or separated before swallowing).The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214677649|NCT04476771|BEHAVIORAL|Feliz-Mente (third generation psychotherapy)|The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
214677650|NCT02107391|BIOLOGICAL|Dendritic Cells DCVAC/PCa|Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
214677651|NCT02107391|DRUG|Leuprolide acetate|Standard of Care Hormone Therapy as an Active Comparator
214677652|NCT02107391|DRUG|Goserelin Acetate|Standard of Care Hormone Therapy as an Active Comparator
214946213|NCT01870167|DIETARY_SUPPLEMENT|Placebo|Placebo
214341702|NCT06108063|DRUG|Losartan|12.5 mg oral Losartan taken for 28 days total (4 week postoperative).
214341703|NCT06108063|DRUG|Placebo - Losartan|Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
214341704|NCT05046938|BEHAVIORAL|Motivational İnterviewing|Students with food addiction will be provided with motivational interviews about food addiction in 5 sessions, each of which varies between 6-8 groups.
214341705|NCT06535074|OTHER|Detecting changes in lung volume with hypoxemia episodes|"Electrical impedance tomography (EIT) will be used to assess changes in lung aeration prior and during hypoxemia episodes to classify them into four different subtypes.~FE subtype: Defined as HEs preceded by reduction in EELI below the baseline.~Apnea subtype: Defined as HEs not meeting the criteria for FE subtype and preceded by cessation of breathing.~Mixed subtype: Defined as HEs meeting the criteria for both FE and apnea subtypes.~Unclassified: Defined as HEs not categorized into any of the above parameters."
214341706|NCT02233660|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
214341707|NCT02233660|PROCEDURE|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
214946214|NCT00825981|OTHER|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
214946215|NCT02751164|OTHER|Day/time of admission to the critical care unit|
214946216|NCT02026869|DRUG|Metformin|Metformin is taken either orally or vaginally every 12 hours
214946217|NCT00821015|DEVICE|Pulmonary vein isolation with cryoballoon catheter|For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
214341708|NCT02281006|DRUG|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
214341709|NCT02223390|BEHAVIORAL|Improving AIDS Care after Trauma (ImpACT)|
214946218|NCT05619770|DRUG|101-PGC-005|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
214946219|NCT06000553|OTHER|blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.|If the patient agrees to take part in the study, he or she will have a blood sample taken from 8 x 4 ml EDTA tubes at the time of inclusion in the trial.Then, at 6 months (+/- 1 month), 1 year and 2 years, the patient will have the same blood sample as at inclusion.If a biopsy is performed as part of routine care, a tumor sample will be taken and sent to the IPC pathology department for FFPE block. If a biopsy is performed and the patient consents, a cystic fluid sample will be taken.
214946220|NCT01361867|DEVICE|Robot-induced perturbations|A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
214946221|NCT02550080|DRUG|Dapsone|For the HLA-B\*1301 positive subjects, dapsone will not be administrated.
214946222|NCT02550080|GENETIC|HLA-B*1301|The prospective genetic screening group will be tested before administrating dapsone
215075185|NCT04997109|BEHAVIORAL|Parent-centered Approach (PCA) Support Intervention|The PCA support intervention is 5 weekly telehealth sessions delivered over a 6 week period. The PCA curriculum includes 5 basic principles of positive parenting from Triple P: ensuring a safe engaging environment, creating a positive learning environment, using assertive discipline, having reasonable expectations, and looking after yourself as a parent. All of these elements, when taught to parents in an individualized manner, can help promote responsivity, structure and expectations that are tailored to their child's condition and developmental stage. In addition, a curriculum of CP-specific knowledge will address the challenges unique to parents of children with CP, such as understanding principles of infant learning of new movements, challenges and solutions for self-directed activity in infants with CP.
215075186|NCT04997109|BEHAVIORAL|Standard of Care|Participants will receive the usual care from being followed in high-risk infant follow-up (HRIF) programs in the Early Detection and Intervention (EDI) Network.
214341710|NCT06364046|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres are loaded with irinotecan. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is irinotecan 80mg/ m2. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
214341711|NCT06364046|DRUG|Serplulimab|Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
214341712|NCT06364046|PROCEDURE|Intravenous chemotherapy|Intravenous chemotherapy with irinotecan 65mg/m2 on day 1 and day 8, given once every 21 days
214341713|NCT01994486|DRUG|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
214341714|NCT01911364|DRUG|BDP/FF/GB|Superiority over Tiotropium
214341715|NCT01911364|DRUG|Tiotropium|Superiority of CHF5993 over Tiotropium
214341716|NCT01911364|DRUG|BDP/FF + Tiotropium|non inferiority vs CHF5993
214946223|NCT01897792|DIETARY_SUPPLEMENT|Vitamin C|
214946224|NCT01897792|DIETARY_SUPPLEMENT|Vitamin E|
214946225|NCT01897792|DIETARY_SUPPLEMENT|Saline (for Vitamin C)|0.9% saline administered to mimic Vitamin C
214946226|NCT01897792|DRUG|Placebo (for Vitamin E)|Sugar pill administered to mimic Vitamin E
214946227|NCT03057067|PROCEDURE|Embolization of pelvic vein varicosities|Embolization of pelvic vein varicosities
214946228|NCT06500650|BEHAVIORAL|Person-centred Occupational Therapy Intervention|Person-centred Occupational Therapy Intervention
214946229|NCT00265408|DRUG|aspirin|
214946230|NCT00265408|DRUG|warfarin|
214946231|NCT03681041|OTHER|Standard treatment|Treatment according to guidelines for pancreatic trauma according to the Chinese Trauma Association and the American Association for the Surgery of Trauma
214946232|NCT00939237|DRUG|Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
214946233|NCT00939237|DRUG|Placebo|
214946234|NCT05656885|DEVICE|Lens A|Soft spherical hydrogel contact lens for 15 minutes
214946235|NCT05656885|DEVICE|Lens B|Soft spherical silicone hydrogel contact lens for 15 minutes
214946236|NCT05698537|DIAGNOSTIC_TEST|EEG|EEG registration performed in PwE to confirm epilepsy diagnosis
214946237|NCT05698537|DIAGNOSTIC_TEST|Neuroimaging|Neuroimaging performed in PwE to diagnose epilepsy etiology
214341717|NCT02838602|RADIATION|Carbon ions therapy|External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
214341718|NCT02838602|RADIATION|Advanced external radiotherapy by Xrays or protons|Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
214341719|NCT01177111|OTHER|Sunflower seed oil|Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
214341720|NCT01177111|OTHER|Mustard seed oil|Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
214946238|NCT05698537|DIAGNOSTIC_TEST|Blood sample|Blood samples from both PwE and controls will be collected to measure full blood count, IgM and IgG antibodies to parasitic antigens including Taenia solium, Toxoplasma gondii and Plasmodium falciparum, to perform ELISA for HIV1 and HIV2, to measure HIV viral load and to conduct an emmel test.
214341721|NCT00793416|DEVICE|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
214341722|NCT04561570|DEVICE|Vivity ACRYSOF IQ IOL Group|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
214486460|NCT06739395|DRUG|Sacituzumab Govitecan-Hziy 180 MG|Usage and dosage: The recommended dosage is 10 mg/kg, administered intravenously every 21 days as a treatment cycle on the 1st and 8th days, and continued until disease progression or unacceptable toxicity occurs. The dosage of this product should not exceed 10 mg/kg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214341723|NCT04561570|DEVICE|ACRYSOF IQ IOL Control Group|Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
214677653|NCT04080115|BEHAVIORAL|Attention Training Technique|ATT will be administered through a customized Expiwell smartphone application that will be downloaded onto participants' cell phones at the first laboratory session (T2). For the purposes of the proposed study, participants need to complete the intervention once a day, for the six days between their lab sessions; signals will begin the day after their T2 session and they will be notified up to a maximum of five times per day to complete their daily session. The ATT sessions are comprised of three phases. The first is a 5-minute phase during which the participant is instructed to attend to specific sounds in the recording and disregard other sounds. The subsequent 5-minute phase includes instructions to rapidly switch their attention between sounds in the recording. The final phase is a dual attention task lasting 2 minutes wherein the participant is instructed to pay attention to multiple sounds in the recording at once. In total, each session of ATT lasts 12 minutes.
214946239|NCT05698537|OTHER|Risk factor questionnaire|Both PwE and control subjects will complete a structured questionnaire on a wide range of potential risk factors present before the onset of the epilepsy.
214946240|NCT01593254|DRUG|Imatinib|
214946241|NCT01593254|DRUG|Dasatinib|
214946242|NCT02242370|DRUG|Low dose of telmisartan|
214946243|NCT02242370|DRUG|High dose of telmisartan|
214946244|NCT01134861|DRUG|cisplatin|100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29
214946245|NCT01134861|DRUG|Etoposide|Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area \< 1.7 m2
214946246|NCT01134861|DRUG|Vinblastine|5 mg/m2 i.v. bolus weekly first 5 weeks of RT
214946247|NCT01134861|RADIATION|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment
214946248|NCT01134861|DRUG|Cisplatin|50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36
214341724|NCT00681317|DRUG|AZD6280|oral
214341725|NCT03032120|DIETARY_SUPPLEMENT|Orange juice|Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
214341726|NCT03032120|DIETARY_SUPPLEMENT|Control|Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
214946249|NCT01134861|RADIATION|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment
214946250|NCT01134861|RADIATION|Radiation therapy|69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy
214946251|NCT02748733|OTHER|Adapted double mini PET|The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
214946252|NCT02748733|OTHER|Standard double mini PET|The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
214946253|NCT05501067|OTHER|tai chi exercise|specific tai chi exercise
214946254|NCT05501067|OTHER|no intervention|no intervention
214946255|NCT05345756|DEVICE|Intraoral protraction device|Use of modified lingual arch with indirect anchorage from screws between lower lateral incisor and lower canine to protract maxilla after ALT-RAMEC protocol
214946256|NCT05345756|DEVICE|Extraoral protraction device|Facemask which is an extraoral appliance used for maxillary protraction
214946257|NCT00076869|DRUG|MK0991, caspofungin acetate|
214946258|NCT00076869|DRUG|Comparator: amphotericin B|
215075187|NCT06574126|DRUG|Group 1: Dara-VRD followed by apheresis and cilta-cel infusion|In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
214341727|NCT01053923|OTHER|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
214341728|NCT04295941|DRUG|TraZODone Hydrochloride 300 MG|Oral administration of Trazodone once-a-day.
214341729|NCT05662501|DEVICE|Pleioflow-RF|Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
214341730|NCT03963895|DRUG|AB002 Dose 1|AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
214341731|NCT03963895|DRUG|AB002 Dose 2|AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
214341732|NCT03963895|DRUG|placebo|placebo administered on Day 1 as a single intravenous infusion
214341733|NCT00114374|DRUG|Escitalopram|
214341734|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Demineralized Bone Fibers|Posterolateral Lumbar Fusion with Demimeralized Bone Fibers
214341735|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Bone Morphogenic Protein|Posterolateral Lumbar Fusion with Bone Morphogenic Protein
214341736|NCT06113042|BEHAVIORAL|Health talks, learning packs|All participants can join the health talks and receive the learning packs.
214341737|NCT06113042|BEHAVIORAL|Lifestyle modification programme|"In Group 1: The programme includes both knowledge and activity/practicum sessions for children and parents. It will be carried out in district community hubs.~Group 2: The programme focuses on the knowledge sessions for parents. It will be carried out in schools.~Group 3: The programme focuses on the activity/practicum sessions for children and parents. It will be carried out in district community hubs."
214341738|NCT06113042|BEHAVIORAL|School healthy environment evaluation|Evaluation on school healthy environment will be carried out in Group 1 and Group 2 to enhance the schools to provide a healthy school environment to children.
214341739|NCT03826420|BEHAVIORAL|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
214341740|NCT03826420|BEHAVIORAL|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
214341741|NCT03826420|BEHAVIORAL|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
214341742|NCT01049880|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
214341743|NCT03905057|DEVICE|Dornier Aries 2 (with active applicator)|Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
214341744|NCT03905057|DEVICE|Dornier Aries 2 (with sham applicator)|Sham ESWT - No shockwave administered
214341745|NCT05409924|DRUG|ATR-258|Single Ascending Dose
214341746|NCT05409924|DRUG|ATR-258|Multiple Ascending Dose
214341747|NCT05409924|DRUG|ATR-258|Repeat Dose
214341748|NCT03125668|BEHAVIORAL|Educational Program|At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
214946259|NCT00076869|DRUG|Comparator: lipid formulation of amphotericin B and/or azole|
214946260|NCT04166058|DRUG|Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)|Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
214341749|NCT03125668|BEHAVIORAL|Telephone follow-up|"After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment."
214341750|NCT03125668|BEHAVIORAL|Face to face counseling|They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
214946261|NCT04166058|DRUG|Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)|Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Randomized doses (72 μg or 145 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
214946262|NCT06165913|PROCEDURE|Early implant placement(type II)|in group 1, Tooth extraction will be performed with care to preserve alveolar bone walls. After 4-8 weeks from tooth extraction, dental implant will be placed
214341751|NCT03327480|OTHER|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
214341752|NCT01428960|DIETARY_SUPPLEMENT|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
214946263|NCT06165913|PROCEDURE|Early implant placement (type III)|in group 2, Tooth extraction will be performed with care to preserve alveolar bone walls. After 12-16 weeks from tooth extraction, dental implant will be placed.
214946264|NCT00103298|DRUG|FOLFOX regimen|
214946265|NCT00103298|DRUG|fluorouracil|
214946266|NCT00103298|DRUG|isolated perfusion|
214946267|NCT00103298|DRUG|leucovorin calcium|
214677654|NCT04080115|BEHAVIORAL|Sham intervention control condition|The sham control condition consists of the same 12 minutes of simultaneous sounds as the ATT technique, but will not include any verbal instruction, thus isolating the effects of intentional orientation of attention.
214677655|NCT03749642|DRUG|trazodone/gabapentin 2.5/25 mg|The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
214677656|NCT03749642|DRUG|trazodone/gabapentin 5/50 mg|The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
214677657|NCT03749642|DRUG|trazodone/gabapentin 10/100|The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
214677658|NCT03749642|DRUG|Gabapentin|"The total daily doses administered will be:~* 600 mg from day 0 to day 6 (±1)~* 900 mg from day 7 (±1) to day 13 (±1)~* 1200 mg from day 14 (±1) to day 20 (±1)~* 1800 mg from day 21 (±1) to day 56 (±2)"
214946268|NCT00103298|DRUG|melphalan|
214946269|NCT00103298|DRUG|oxaliplatin|
214341753|NCT03251846|DEVICE|Pops! One personalized mobile platform|Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
214341754|NCT05491473|DEVICE|Closed incisional negative pressure wound therapy (iNPWT) system|The closed incisional negative pressure wound therapy (iNPWT) system (PREVENA Incision Management System, KCI, an Acelity company, San Antonio, Texas, USA)
214341755|NCT02736084|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
214341756|NCT01354821|PROCEDURE|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
214341757|NCT01354821|PROCEDURE|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
214946270|NCT00456261|DRUG|Pemetrexed|pemetrexed 500 mg/m2
214341758|NCT05917730|BEHAVIORAL|Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)|"Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell."
214341759|NCT01248650|DRUG|nalfurafine hydrochloride|
214677659|NCT03749642|DRUG|Placebo oral capsule|Two capsules, three times a day, for 8 weeks.
214677660|NCT02385123|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
214677661|NCT00856427|RADIATION|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
214946271|NCT00456261|DRUG|Gemcitabine|gemcitabine 1500 mg/m2
214946272|NCT00456261|DRUG|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
214946273|NCT00456261|DRUG|Carboplatin|carboplatin AUC=5
214946274|NCT06137911|DRUG|JYP0061|JYP0061 orally administered
214946275|NCT06137911|DRUG|placebo|Placebo orally administered
215075188|NCT06574126|DRUG|Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion|In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
214946276|NCT04965428|BEHAVIORAL|Fear-focused Self-Compassion Therapy|The Fear-focused Self-Compassion Therapy will be delivered as a group format. The intervention consists of eight group face-to-face sessions (60-90 minute for each session) and will be delivered by three trained therapists for eight weeks (sessions are weekly). Each intervention group involves 10 patients.
214946277|NCT05559372|DIETARY_SUPPLEMENT|Acute energy drink or placebo consumption|Participants consumed either 16 oz of Nutrabolt C4 Energy Carbonated, Monster Energy Original, or Placebo in randomized order in three separate visits separated by 7±3 days.
214946278|NCT05624736|DIAGNOSTIC_TEST|multi-parametric magnetic resonance imaging scan|Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.
214946279|NCT05624736|DIAGNOSTIC_TEST|Pathology examination|The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
214946280|NCT05891106|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
214341760|NCT00000123|DEVICE|Polymethyl Methacrylate-Silicone Contact Lenses|
214341761|NCT00000123|DEVICE|Polymethyl Methacrylate Contact Lenses|
214341762|NCT03249623|DEVICE|Beacon Caresystem|The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
214341763|NCT05590702|DRUG|First line therapy|"Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).~Patients will be treated and managed according to the decision of their physicians and the related MDM. No treatment plan is recommended in the setting of this non-interventional study."
214341764|NCT02169687|DEVICE|HIFU|High Intensity focalized Ultrasounds
214341765|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
214946281|NCT04482036|OTHER|Mobile Phone Application Assessments|"The BrainCare Notes app was designed to be installed on the caregiver's phone. It has the capacity to send Neuropsychiatric Inventory Questionnaire (NPI-Q) assessments to the caregiver. If the answers to the behavioral and psychological symptoms rise above the threshold, the clinicians will be notified, and a care plan will be enacted, in order to keep the patient and caregiver safe.~The application also has the ability to send and receive private messages between caregiver and the patient's clinical care team."
214946282|NCT04482036|OTHER|Standard Assessments|The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.
214946283|NCT03699813|OTHER|Comparison of two approaches to bleeding management|
214946284|NCT00149370|PROCEDURE|Breast reduction surgery|
214946285|NCT00240656|DRUG|spironolactone captopril carvedilol|
214946286|NCT00076999|DRUG|TPV oral solution|Tipranavir oral solution
214946287|NCT00076999|DRUG|TPV oral solution|Tipranavir oral solution
214946288|NCT00076999|DRUG|RTV oral solution|Ritonavir oral solution
214946289|NCT00076999|DRUG|RTV oral solution|Ritonavir oral solution
214946290|NCT04964986|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
214946291|NCT06320158|OTHER|clinical evaluation of sarcopenic obesity|completion of scales and questionnaires, venous blood sampling, muscle ultrasound scan
214946292|NCT06538285|DRUG|Ketamine|Ketamine 0.50 mg/kg IM will be administered during the first dosing visit, and either 0.50 mg/kg IM or 0.75 mg/kg IM will be administered at the two subsequent dosing visits, depending on the participant's toleration of prior ketamine dose(s). All ketamine dosing visits will be facilitated by a licensed study therapist and clinician (i.e., NP or MD).
215075189|NCT01325454|DEVICE|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
214341766|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
214341767|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
214946293|NCT06538285|BEHAVIORAL|Psychotherapy|Psychotherapy will consist of three 1-hour preparatory talk therapy sessions over the 14 days preceding the first ketamine dosing visit, a 1-hour integration talk therapy session within 1-3 days following each ketamine dosing visit, and a final 1-hour integration talk therapy session about 1 week following the last ketamine visit. All talk therapy visits will be conducted by a licensed study therapist.
214341768|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
214341769|NCT01709019|BIOLOGICAL|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
214341770|NCT06384677|OTHER|M-Tapa Block|M-TAPA block was performed bilaterally with 20 mL of 0.2% bupivacaine under ultrasound guidance at the end of surgery
214341771|NCT02843568|OTHER|Laboratory Biomarker Analysis|Correlative studies
214341772|NCT02843568|RADIATION|Standard fractionation|60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
214946294|NCT01857102|DEVICE|etafilcon A|Soft contact lens to be worn in a daily wear, daily disposable modality for one week
214946295|NCT01857102|DEVICE|etafilcon A for Astigmatism|Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
214341773|NCT02843568|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
214341774|NCT02843568|PROCEDURE|Four Dimensional Computed Tomographic Imaging (4DCT)|Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
214946296|NCT05821296|DEVICE|Crystal Peel|3 applications performed by a dermatologist.
215075190|NCT04261972|GENETIC|Next generation sequencing (NGS)|NGS
215075191|NCT02783040|DRUG|Midazolam|
215075192|NCT02783040|DRUG|Warfarin|
215075193|NCT02783040|DRUG|Omeprazole|
215075194|NCT02783040|DRUG|Midazolam|
215075195|NCT02783040|DRUG|Digoxin|
215075196|NCT02783040|DRUG|BI 425809|
214946297|NCT03485937|BEHAVIORAL|Pre-Operative Videos|Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions. The videos will be split into two modules: 1) preparing for Mohs Surgery 2) Mohs Surgery Walk through. The intervention, in the form of a video walk through, will be provided to the patient via email prior to their surgical procedure once they schedule an appointment with the Mohs clinic for their surgery day.
214946298|NCT03485937|BEHAVIORAL|verbal instructions|As part of the standard of care for patients receiving Mohs surgery, patients are told about the day of their surgery and what to expect
214946299|NCT03485937|BEHAVIORAL|written instructions|As part of the standard of care for patients receiving Mohs surgery, patients receive written material about the day of their surgery and what to expect
214946300|NCT03772977|BEHAVIORAL|Brain Health Champion|A health coach embedded within an existing clinical care team
214946301|NCT06079762|BEHAVIORAL|AGE SELF CARE group visit program|"AGE SELF CARE: Adaptation, Growth, and Engagement; Socialization, Empowerment, Learning, and Function; and Community Activation for Resilience in Elderhood, is a virtual group visit program. It includes education and behavioral change elements in the broad areas of self/health, home environment, and community. There are 8 weekly 90-minute virtual sessions facilitated by an aging expert (e.g., geriatrician). Examples of topics include Aging Well: The Power of Movement, People Can Change, Homes Can Too, and Social World."
214946302|NCT04885894|DRUG|Zeposia|Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
214946303|NCT04093791|BEHAVIORAL|"Collective Intervention G"|"The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mothers. The operator maintains a nonjudgmental approach encouraging the women to describe the need for behavioral change.~2. Analysis. The situation must be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way and they will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mothers to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
214946304|NCT04093791|BEHAVIORAL|"Individual Intervention I"|"The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mother. The operator maintains a nonjudgmental approach encouraging the woman to describe the need for behavioral change.~2. Analysis. The situation have be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way, and she will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mother to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
214946305|NCT01939626|DEVICE|Single-step medium|This medium will allow in vitro culture of human embryos for 5/6 days
214946306|NCT01939626|DEVICE|Standard culture medium|This culture system needs media change on day 3 of culture.
214946307|NCT04536961|DRUG|Reference Treatment- BMS-986165-01|Specified dose on specified days
214946308|NCT04536961|DRUG|Prototype BMS-986165|Specified dose on specified days
214946309|NCT04536961|DRUG|Famotidine|Specified dose on specified days
214946310|NCT04536961|OTHER|Alcohol|Specified quantity on specified days
214946311|NCT04935008|DIAGNOSTIC_TEST|The recruitment maneuver|In patients with ARDS, 30 cm H2O positive pressure support and 30 seconds recruitment maneuver will be applied. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver. Optic nerve diameter will be evaluated with a linear probe on the eyeball before and after the collection maneuver, taking a value of 3 mm from the eyeball.
214946312|NCT05604794|COMBINATION_PRODUCT|Ketamine-Assisted Psychotherapy (KAP)|KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.
214946313|NCT04291482|BEHAVIORAL|Choosing Health Intervention|The intervention consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention, basic information on healthy eating and behaviour change and tables allowing self-monitoring of weight, physical activity and eating (i.e., brief food diary). The book is non-tailored and it has weekly tasks for the participants to complete during 26 weeks (initial 6 months) to support their weight loss. The intervention group will also receive a series of daily text messages and weekly email messages supporting their weight loss and promoting weight loss maintenance. In phase I (month 0-3), the messages and emails will be generic and factual; in the phase II of the intervention, participants will receive text messages and emails tailored to the strongest predictors of outcomes identified in phase I.
215075197|NCT03609385|DIAGNOSTIC_TEST|Coronary angiography|In patients eligible for participation in the study coronary angiography, echocardiography and EKG will be performed systematically.
214341775|NCT02313142|BEHAVIORAL|Leg exercises|
215075198|NCT03103698|DEVICE|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
214341776|NCT01255358|DRUG|Dexamethasone|"Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient).~The treatment has to be repeated at intervals of 30 days (±10 days)"
214677662|NCT00856427|PROCEDURE|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
214946314|NCT04291482|BEHAVIORAL|Choosing Health Control|The control consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention and basic information on healthy eating and physical activity. The control group will also receive monthly email messages with generic and factual information.
214341777|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 and 29 for vaccine naive cohorts.
214341778|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study.
214341779|NCT04847050|DIAGNOSTIC_TEST|ECG|Baseline (-28 days/Day 1); and Day 29 (+/- 3 days).
214341780|NCT04847050|OTHER|Antibiotics|Use of prophylactic antibiotics is recommended according to institutional standards.
214341781|NCT04847050|OTHER|Anti-viral agents|Use of prophylactic antiviral agents is recommended according to institutional standards.
214341782|NCT04847050|OTHER|Anti-fungal agent|Use of prophylactic antifungal agents is recommended according to institutional standards.
214341783|NCT04847050|OTHER|Anti-emetics|Use of prophylactic anti-emetics is recommended according to institutional standards.
214341784|NCT06247176|BEHAVIORAL|Sensory Habituation Protocol|"The first session continues with the Mock MRI, which lasts 10 minutes. Participant's comfort level in VR will be evaluated.~At the pre-exposure visit, participants complete an MRI scan on a 3 Tesla MRI, which takes approximately 1 hour \& 15 minutes. It consists of structural \& functional MRI scans. Structural scans require the participant to stay still with eyes closed. Functional scans will require the participant to lie with eyes closed or watch and listen to sensory stimulation.~VR exposure will occur across 3 1-hour sessions at most. Participants will be asked to complete a sensory habituation protocol, in which they will watch and listen to sensory stimuli in VR for an increasing amount of time. Between the sensory stimuli, the participant will watch a self-selected video.~Finally, the subject will be asked to do a post-exposure MRI visit, which is the same as the pre-exposure visit."
214946315|NCT06060106|PROCEDURE|Endoscopic submucosal dissection|The patient was positioned in the left lateral decubitus position.Marking dots were made with a dual knife/hybrid knife around the lesion, and a solution of glycerin fructose with indigo carmine was injected into the submucosal layer to lift the lesion. Finally, after pre-cutting of the mucosal and submucosal layers around the lesion and dissection of the submucosa, the lesion was removed en bloc.
214946316|NCT06060106|PROCEDURE|Esophagectomy|The main surgical methods of esophagectomy include the McKeown operation, Lvor-lewis, Sweet and minimally invasive radical resection of esophageal cancer (MIE)
214946317|NCT05726942|OTHER|Healthi|Healthi refers to the Healthi app, which is a mobile application for weight loss
214946318|NCT01022164|PROCEDURE|fibrin glue|
214946319|NCT06034379|DEVICE|eSpectacle Clinical prototype (CP1) device|The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
214946320|NCT06034379|DRUG|0.01% atropine|Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
214946321|NCT01436331|OTHER|Treatment As Usual (TAU)|Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
214946322|NCT01436331|BEHAVIORAL|TAU+CBT for pts+Family Intervention+CM.|The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
214946323|NCT02603562|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
214341785|NCT04011150|DEVICE|Epidural infusion pump|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
214341786|NCT04011150|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
214341787|NCT04011150|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
214341788|NCT05961202|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg qd
214341789|NCT05961202|DRUG|Prednisolone|Prednisolone 20mg qd
214341790|NCT04452461|DRUG|mFOLFIRINOX|mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
214341791|NCT04452461|DRUG|Gemcitabine / Nab-paclitaxel|Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
214677663|NCT02944747|BEHAVIORAL|Education & paper based calendar|The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.
214341792|NCT06299202|DIAGNOSTIC_TEST|Diagnostic test|"* Inclusion visit (V1) Initial baseline CESM (V2) 15 days after inclusion~* First chemotherapy treatment (V3) 28 days after V2.~* Unilateral follow-up CESM (V4) 4 to 6 weeks after the first course of chemotherapy.~* Surgery (V5):~  3 to 6 weeks later at the end of the complete treatment with primary chemotherapy~* End of research visit (V6) It corresponds to the histological analysis on the surgical specimen after the complete treatment with neoadjuvant or primary chemotherapy."
214341793|NCT06538532|OTHER|Zamzam water|Zamzam water
214341794|NCT05960682|OTHER|Questionnaire|Patients will complete the French version of the Brief Index of Sexual Functioning for Men (BISFM) paper questionnaire. The BISFM is a self-administered questionnaire. It has 22 questions, grouped into 7 domains allowing a qualitative and quantitative evaluation of the sexual experience: D1 (desire), D2 (excitement), D3 (frequency of activity), D4 (receptivity), D5 (pleasure, orgasm ), D6 (relationship satisfaction), D7 (problems affecting sexuality).
214946324|NCT04097197|BEHAVIORAL|Brief educational intervention|same as before
214946325|NCT02608255|OTHER|blood samples|
214946326|NCT04805359|BEHAVIORAL|Normoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
214946327|NCT04805359|BEHAVIORAL|Hypoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
214677664|NCT02944747|BEHAVIORAL|Education & SMS system|The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
214677665|NCT02944747|BEHAVIORAL|Education & smart-phone application|The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
214677666|NCT01897415|BIOLOGICAL|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1|
214677667|NCT04718987|RADIATION|Low dose rate (LDR) brachytherapy|Low dose rate (LDR) brachytherapy is a type of radiation treatment where doctor places the radioactive implants (seeds) inside patient's prostate gland and these seeds emits low dose radiation over a certain period of time. During low-dose-rate brachytherapy, a continuous low dose of radiation is released over time -from several hours to several days.
214677668|NCT02522962|BEHAVIORAL|GroupCoreSIT|"Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training."
214677669|NCT02522962|BEHAVIORAL|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
214677670|NCT02728934|BIOLOGICAL|Golimumab Intravenous (IV)|This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
215075199|NCT03103698|OTHER|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
214946328|NCT06622096|DIAGNOSTIC_TEST|Evaluation of laboratory exams prescription|Evaluation of laboratory exams prescription
215075200|NCT03656848|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
215075201|NCT03656848|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
215075202|NCT06416358|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
214341795|NCT05875584|DIAGNOSTIC_TEST|rbcDNA test|fecal immunochemical test
214677671|NCT02728934|BIOLOGICAL|Infliximab|This is an observational study. Patients who will receive infliximab will be observed for 3 years.
214341796|NCT06636617|DRUG|3.70 GBq (100 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
214341797|NCT06636617|DRUG|5.55 GBq (150 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04
214341798|NCT06636617|DRUG|7.40 GBq (200 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
214946329|NCT04491305|PROCEDURE|Surgically treated women with endometriosis and confirmed diagnosis|Women with indication for surgery or diagnostic laparoscopy will be enrolled in study.
214341799|NCT06636097|DEVICE|Full arch|design
214341800|NCT06635512|OTHER|The Effect of Stress Ball Application After Transurethral Resection of the Prostate on Patients' Recovery Quality and Hospital Discharge Time|The effect of the stress ball applied after surgery on patients' recovery quality will be evaluated.
214341801|NCT06635174|OTHER|Dextrose|we are using 2ml of 50% dextrose
214341802|NCT06635174|OTHER|normal water|patient will receive 2ml of normal water
214946330|NCT02013661|PROCEDURE|Periodontal resective surgery|surgical periodontal debridement is performed after periodontal phase I
214946331|NCT01572311|BEHAVIORAL|Exercise Intervention|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
214946332|NCT01572311|BEHAVIORAL|Exercise Control|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
214341803|NCT00851214|DEVICE|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
214341804|NCT00023829|DRUG|bicalutamide|
214341805|NCT00023829|DRUG|flutamide|
214341806|NCT00023829|DRUG|releasing hormone agonist therapy|
214341807|NCT00023829|PROCEDURE|adjuvant therapy|
214341808|NCT00023829|RADIATION|radiation therapy|
214341809|NCT04504045|DRUG|Metformin|500 mg tablet
214946333|NCT05604872|PROCEDURE|Small Incision Lenticule Extraction|A 500 kHzVisumax (Carl Zeiss Meditec AG) femtosecond laser was used with cap thickness ranging from 100 to 130μm, cap diameter from 7.3 to 7.9 mm. The lenticule was dissected with a blunt spatula through a 30 to 60-degree incision at the 10 o'clock position and removed using forceps afterward. Treatment targets of both eyes were set to emmetropia, the refraction corrections were based on manifest refractions
214677672|NCT02728934|BIOLOGICAL|Biosimilar Infliximab|This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
214677673|NCT01615003|DRUG|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
214677674|NCT01615003|DRUG|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
214677675|NCT01089777|DEVICE|ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test
215075203|NCT04990505|DIAGNOSTIC_TEST|lung ventilation/perfusion scintigraphy|"Chest CT-scan will be performed with blocked inspiration.~Lung ventilation/perfusion scintigraphy imaging will be performed within 24hrs after CT pulmonary angiography, 410MBq of Technegas will be inhaled by patients and ventilation tomography performed thereafter. Then, 185MBq 99mTc-macroaggegates will be injected intravenously followed by the perfusion tomography.~A combined CT acquisition will be performed.~The day following lung ventilation/perfusion scintigraphy, 740MBq of Tc99m labeled albumin will be intravenously administered.~Cardiac gated-blood-pool scintigraphy will be then performed in best septal left anterior oblique and left profile according to specific parameters.~45-60 min after injection, a non-gated tomographic acquisition over the lungs will be done, with the same parameters than for PS SPECT, resulting in a late albumin acquisition."
214341810|NCT04504045|DRUG|Caffeine|As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
214341811|NCT04504045|DRUG|Efavirenz|As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
214341812|NCT04504045|DRUG|Losartan|As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
214341813|NCT04504045|DRUG|Omeprazol|As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
214341814|NCT04504045|DRUG|Metoprolol|As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
214341815|NCT04504045|DRUG|Midazolam|As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
214341816|NCT05811104|DEVICE|Sequential bilateral theta burst stimulation|Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
214341817|NCT03858075|DRUG|BLU-782|oral capsules
214341818|NCT03858075|DRUG|Placebo|oral capsules
214946334|NCT06290804|OTHER|education|Training program on Health Impacts of Sustainable Behaviors and Climate Change
214341819|NCT03858075|DRUG|BLU-782 taken with food|oral capsules
214341820|NCT02468843|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes~3. Biphasic pulse stimulation mode (immediate assessment)~4. Biphasic pulse stimulation mode (assessment at 1h)~5. Biphasic pulse stimulation mode (assessment at 2h)"
214341821|NCT02468843|OTHER|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
214341822|NCT02468843|OTHER|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
214677676|NCT02734550|OTHER|Standard of care|Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
214946335|NCT04108663|BEHAVIORAL|Effect of tDCS on cognitive control task performance|Added verum or sham tDCS while working on a cognitive control task.
214946336|NCT00497770|DRUG|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
214946337|NCT01724801|RADIATION|whole brain radiation(WBI)|WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
214946338|NCT01724801|DRUG|Icotinib|administered orally at a dose of 125 mg 3 times daily
214946339|NCT02403349|DRUG|Fimasartan|
214946340|NCT02403349|DRUG|Valsartan|
214946341|NCT02403349|DRUG|Atenolol|
214946342|NCT00438802|DRUG|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
214946343|NCT01481272|DRUG|Ofatumumab|1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles
214946344|NCT01481272|DRUG|Etoposide|60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles
214946345|NCT01481272|DRUG|Ifosfamid|1500mg/m2 or 1000mg/m2 (patients \>/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles
214946346|NCT01481272|DRUG|Mesna|300mg/m2 or 200mg/m2 (patients \>/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients \>/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles
214946347|NCT01481272|DRUG|Cytarabine|2g/m2 or 0,5-1g/m2 (patients \>/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles
214946348|NCT01481272|DRUG|Methotrexate|12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
214946349|NCT01481272|DRUG|Leukovorin|15mg, po 24 hours after methotrexate it
214946350|NCT01481272|DRUG|Granulocyte-Colony Stimulating Factor|5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC\>1.0x109/l
214946351|NCT04339309|PROCEDURE|Non-surgical periodontal treatment with interdental hygiene devices|
214946352|NCT04339309|PROCEDURE|Non-surgical periodontal treatment without interdental hygiene devices|
214946353|NCT04937907|DRUG|Hydroxychloroquine Sulfate 100 milligram (mg) Tab|Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
214946354|NCT04937907|DRUG|Benazepril hydrochloride 10 milligram (mg) Tab|Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
214946355|NCT03750409|DEVICE|Helmet|The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.
214946356|NCT02472626|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
214946357|NCT02472626|DRUG|Cytarabine|Given IV
214946358|NCT02472626|DRUG|Daunorubicin Hydrochloride|Given IV
214946359|NCT06135025|OTHER|Telemonitoring|the patients included receive a weekly phone call from the participating physician to to support self-management improvement, use of inhalation devices, rehabilitation, monitoring of signs/symptoms by treatment management, counseling, motivation, and prevention of exacerbations, early recognition of exacerbation signs and planify access to health care facility. at 1 month a Face to Face visit is planned to collect data.
214946360|NCT00833118|PROCEDURE|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
214946361|NCT06333405|DRUG|Fecal Microbiota Transplantation|"Procedure: Fecal Microbiota Transplantation~Fecal Microbiota as a suspension obtained from healthy unrelated donor (woman in 3rd trimester of pregnancy) introduced two times per treatment:~* as a deep rectal infusion, via Foley's catheter inserted under ultrasound control, twice 6 hours apart, between 3 and 6 days after birth and/or up to 14 days~* Other Names: MBiotix HBI"
214946362|NCT05180370|OTHER|Questionnaies|Data entry staff who will be assigned to the centers for 2 weeks will apply a questionnaire consisting of different questions to the patients referred to them by clinicians with the diagnosis of HF (presented in the appendix to this protocol). In addition, Pittsburg Sleep Quality Index will be applied to all cases.
214946363|NCT05614778|OTHER|Zoledronic Acid injection, 5mg/100mL|Zoledronic Acid injection, 5mg/100mL
214946364|NCT00540904|DRUG|sodium bicarbonate|IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
214946365|NCT00540904|DRUG|NaCl|IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
214946366|NCT00796744|DRUG|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
214946367|NCT03698968|DEVICE|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
214946368|NCT03409120|DEVICE|Boston Scientific Vercise PC IPG with directional DBS lead|We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
214946369|NCT01904318|DRUG|IDP-73152 mesylate 40 mg|IDP-73152 mesylate 40 mg single dose administration
214946370|NCT01904318|DRUG|IDP-73152 mesylate 80 mg|IDP-73152 mesylate 80 mg single dose administration
214946371|NCT01904318|DRUG|IDP-73152 mesylate 160 mg|IDP-73152 mesylate 160 mg single dose administration
214946372|NCT01904318|DRUG|IDP-73152 mesylate 320 mg|IDP-73152 mesylate 320 mg single dose administration
214946373|NCT01904318|DRUG|IDP-73152 mesylate 640 mg|IDP-73152 mesylate 640 mg single dose administration
214946374|NCT01904318|DRUG|IDP-73152 mesylate 1280 mg|IDP-73152 mesylate 1280 mg single dose administration
214946375|NCT01904318|DRUG|Placebo|Placebo single dose administration
214946376|NCT04442438|OTHER|Monthly moral case deliberation|Once per month, ICU professionals will take part in moral case deliberation. As part of the intervention, two or three ICU professionals (physicians and nurses) are tasked with selecting a case for moral discussion. Moral case deliberation is attended by around thirty individuals per month per unit. A feedback system will be developed used to spread the knowledge/insights from the case deliberation to all professionals in the unit.
214946377|NCT01147003|DRUG|Investigational new drug, company code: BGG492|
214946378|NCT01147003|DRUG|Placebo|
214946379|NCT01147003|DRUG|Investigational new drug, company code: BGG492|
214946380|NCT05521841|PROCEDURE|Erector Spinae Plane Block(Bilateral Ultrasound Guided Erector Spinae Plane Block)|"Bilateral USG guided Erector Spinae Plane Block:~Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg Ultrasound transducer will be placed in a cephalocaudal orientation over the back at 10th thoracic vertebral level.~The probe will then slowly be moved laterally until the transverse process is visible The trapezius muscle and erector spinae muscle will be identified as superficial to the transverse process.~A 25-gauge Quincke spinal needle (Romsons spinal needle, Quincke type)will be inserted using an in-plane approach in the cephalad to the caudal direction and towards the transverse process.~A 5ml bolus of local anesthetic will be given. Erector spinae muscle plane is then visualized separating from the transverse process.~The local anesthetic is then injected in 5 ml increments, with aspiration after every 5 ml to avoid intravascular injection Same procedure will be repeated on the other side"
214946381|NCT05521841|PROCEDURE|Transversus abdominis plane block(Bilateral Ultrasound-guided bilateral Transversus abdominis plane block)|"Bilateral Ultrasound-guided bilateral Transversus abdominis plane block Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg The linear transducer will be placed in the transverse plane at the lateral abdominal wall in the mid-axillary line, between the lower costal margin and the iliac crest.~Abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized.~Bowel movement and visualization of hypoechoic peritoneum would further guide the block.~The needle will be inserted in-plane and advanced until the tip is between the internal oblique and the transversus abdominis muscle.~After negative aspiration, 20 mL of 0.25% bupivacaine is injected in a 5ml increment ,aspirating after every 5ml injection.~Same procedure will be repeated on the other side."
215075204|NCT05186701|OTHER|Kinesio Tape|"Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis."
215075205|NCT05186701|OTHER|Conventional Physical Therapy|Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
215075206|NCT01686659|DEVICE|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin \[SpHb\] and Pleth Variability Index \[PVI\]) to the clinicians in the operating room
215075207|NCT05102097|BEHAVIORAL|Warm-up|Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
215075208|NCT05102097|BEHAVIORAL|Main exercise|Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
215075209|NCT05102097|BEHAVIORAL|Cool down|Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
214677677|NCT02734550|OTHER|(1,3)-β-D-glucan guided therapy|Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
214677678|NCT03418246|DEVICE|GIC|tooth colored filling
214341823|NCT04394728|DRUG|Trabectedin|1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
214677679|NCT03418246|DEVICE|Biodentine|White filling -Biodentine
214677680|NCT00006246|DRUG|busulfan|
214677681|NCT01933984|DRUG|Bronchodilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
214677682|NCT04385030|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY|The study will consist of 12 sessions, carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
214677683|NCT04693247|DEVICE|EQ103|Refraction device
214341824|NCT05595291|OTHER|investigation of the factors affecting walking characteristics|In order to investigate the factors affecting walking characteristics, 2-minute walking test, 10-point VAS (overall prosthesis satisfaction level, socket comfort and satisfaction level, knee joint satisfaction level, prosthetic foot satisfaction level, pain level in amputated extremity) and locomotor capacity index will be applied.
214341825|NCT01061749|BIOLOGICAL|Cixutumumab|Given IV
214341826|NCT01061749|OTHER|Laboratory Biomarker Analysis|Correlative studies
214341827|NCT01061749|OTHER|Pharmacological Study|Correlative studies
214341828|NCT01061749|DRUG|Selumetinib|Given PO
214677684|NCT05652192|RADIATION|SBRT|SBRT was added to systematic treatment (chemo+ PD-1 antibody)
214677685|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's polyp detection function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.
214677686|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's quality monitoring function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.
214677687|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy without the assistance of EndoAngel's any function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's both functions.
214677688|NCT00163722|OTHER|Culture and histology|
214677689|NCT00163722|OTHER|Aspergillus galactomannan and PCR|
214341829|NCT02341248|OTHER|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
214946382|NCT01451138|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
214946383|NCT06618183|DIAGNOSTIC_TEST|Fingerprint sweat drug screen|Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen
214946384|NCT06618183|DIAGNOSTIC_TEST|Fingerprint sweat laboratory analysis|Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
214946385|NCT00966901|DRUG|Nicotine Patch|25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
214946386|NCT00966901|DRUG|Placebo Patch|As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
214946387|NCT00966901|DRUG|No Patch Control|As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
214946388|NCT00966901|RADIATION|UVA and UVB irradiation|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
214341830|NCT04426058|DRUG|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
214341831|NCT04426058|DRUG|Fascia Illica|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
214341832|NCT05592210|OTHER|Questionnaires|Participants will be asked to fill out the the Demographic Information Sheet, Karitane parenting confidence scale, Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU) and Dyadic Coping Inventory.
214341833|NCT03259711|DRUG|Hormonal therapies L02 in the ATC classification|Hormonal therapies L02 in the ATC classification
214341834|NCT01131481|DEVICE|Intraocular lens|
214341835|NCT05266326|OTHER|Western medicine conventional treatment +Bloodletting puncture|All acupoints are positioned according to the WHO standard acupuncture point locations in the Western Pacific Region. Operation: The patient is placed in a reasonable position, the acupuncture site is exposed, and the operator uses pushing, rubbing, squeezing and butterfly on or around the acupuncture site to collect blood at the acupuncture site before pricking, and then disinfects the acupuncture site with 75% ethanol. If more bleeding occurs, press with sterile dry cotton balls to stop the bleeding. The treatment was performed once daily for 7 days.
214341836|NCT05266326|OTHER|Western medicine conventional treatment|The patients in both groups were given conventional comprehensive treatment such as improving cerebral circulation, neuroprotection, antiplatelet aggregation, lipid regulation and symptomatic management after admission. Patients with hypertension, hyperglycaemia, hyperlipidaemia and coronary atherosclerotic heart disease were given individualised symptomatic treatment and advised to stop smoking, drinking alcohol and other adverse lifestyles as far as possible.
214341837|NCT05505708|DRUG|hydroxyethyl starch in sodium chloride injection Brand Name: Voluven|"(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5."
214341838|NCT05505708|DRUG|saline solution|Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
214341839|NCT05086458|DIETARY_SUPPLEMENT|probiotics|probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis
214341840|NCT04331327|DRUG|allogenic lyophilized growth factors|Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
214341841|NCT00096941|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
214341842|NCT05286905|DEVICE|Osteosynthesis cephalomedullary nail|Osteosynthesis of reverse oblique peritrochanteric fractures with cephalomedullary nail
214341843|NCT05286905|DEVICE|Osteosynthesis proximal femur locking plate|Osteosynthesis of reverse oblique peritrochanteric fractures with proximal femur locking plate
214341844|NCT05319418|BEHAVIORAL|Daily Blood Pressure Monitoring|Patients are provided standard off-the-shelf blood pressure monitors and take their BP vitals daily. Patients report their daily BP through phone or online. BP data is viewed online by physicians who use their independent medical judgement for any changes in medical management.
214946389|NCT01917604|PROCEDURE|open exposure|the open surgical methods of exposing the canine is compared with control
214946390|NCT01917604|PROCEDURE|closed exposure|closed exposure is compared with control
214946391|NCT05749068|DEVICE|CapScan intestinal sampling device|CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.
214946392|NCT04493151|DRUG|Imipenem, Cilastatin and Relebactam|After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
214946393|NCT04208321|OTHER|Placebo|Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.
214341845|NCT01040611|BEHAVIORAL|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
214341846|NCT00931021|DRUG|Varenicline (Chantix)|2 mg
214341847|NCT00931021|DRUG|Nicotine Patch|21 mg
214341848|NCT03827629|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
214341849|NCT03827629|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
214341850|NCT03827629|DRUG|Treatment C: Naloxone HCL Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
214946394|NCT04208321|DRUG|VT-1598|VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.
214341851|NCT03000894|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
214341852|NCT04884126|PROCEDURE|dental implant placement|The time of dental implant surgery
214341853|NCT03835377|OTHER|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
214341854|NCT03835377|OTHER|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
214946395|NCT00781170|PROCEDURE|allogeneic hematopoietic SCT|
214946396|NCT03925584|OTHER|Music Therapy|Standardized music playlist will be played centrally at the subjects head or feet for a period of 20 minutes once during a 12-hour shift for 14 days or until mechanical ventilation has been discontinued, whichever is first
214946397|NCT01058902|DRUG|Aspirin 75 mg|Aspirin 75 mg
214946398|NCT01058902|OTHER|no aspirin|nothing
214946399|NCT02166749|PROCEDURE|Subtotal abdominal hysterectomy|Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
214677690|NCT02439762|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
214341855|NCT01517451|RADIATION|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
214946400|NCT02934087|PROCEDURE|Endovascular Aneurysm Repair|Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
214946401|NCT02268370|DRUG|Dasatinib|
214946402|NCT06645912|DIETARY_SUPPLEMENT|oral nutritional supplement|The ONS group received a high-protein ONS providing 18.8 g of protein, 7 g of fat, 28 g of carbohydrates, and 250 calories of energy per 200 mL and medical nutrition therapy. The product is gluten-free and contains lactose, minerals, trace elements, and vitamins . The Control group received only standard nutrition therapy without ONS supplementation.
214946403|NCT02117713|DRUG|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
214946404|NCT05290480|OTHER|expiratory muscle training|participants performed expiratory muscle training according to their maximum expiratory pressure that measured earlier in addition to conventional chest physiotherapy
214946405|NCT05290480|DEVICE|Insentive spirometry|participants performed deep breating exercise with insentive spirometry in additional to convantional chest physiotherapy
214946406|NCT01800019|DRUG|Nicotine Replacement Therapy (NRT)|
214677691|NCT02439762|BEHAVIORAL|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
214341856|NCT01517451|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
214341857|NCT02961140|OTHER|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
214341858|NCT02961140|OTHER|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
214341859|NCT00022516|DRUG|Cyclophosphamide|50 mg/day orally continuously for 1 year
214341860|NCT00022516|DRUG|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
214341861|NCT06395597|DIAGNOSTIC_TEST|Nine Hole Peg Test|3 attempts of each subtest of the Nine Hole Peg Test performed according to the Czech Extended Version of Manual for the Nine Hole Peg Test; questionnaire
214341862|NCT03237689|DRUG|Hydrocortisone|Low dose hydrocortisone (10mg)
214341863|NCT03237689|DRUG|Placebo Oral Tablet|capsules of starch 1500 powder
214341864|NCT00983229|PROCEDURE|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
214946407|NCT01800019|DRUG|Varenicline|
215075210|NCT05102097|BEHAVIORAL|Standard of care|Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
215075211|NCT05544942|DIETARY_SUPPLEMENT|Lactobacillus plantarum|1 capsule once a day
215075212|NCT05544942|OTHER|maltodextrin|1 capsule once a day
214341865|NCT03535818|PROCEDURE|Radiofrequency ablation|RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
214341866|NCT06074926|BEHAVIORAL|Associative Conditioning|There will be 3 planned activities per week (9 total) within play kits provided to families. Children will first taste their assigned target vegetable and then complete an activity with their parent following provided instructions. Activity instructions will include positive parenting skills adapted from evidence-based parenting programs (i.e., Parent-Child Interaction Therapy (PCIT) and Triple-P) designed to promote positive parent-child interactions.
214341867|NCT06074926|BEHAVIORAL|Repeated Exposure|There will be 3 planned exposures per week (9 total). Exposures will include only individual tastes of the child's assigned target vegetable.
214946408|NCT01800019|BEHAVIORAL|HIV Tailored Quit Smoking Counseling|"A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24."
214946409|NCT00574795|BIOLOGICAL|13vPnC|"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
214946410|NCT06230666|RADIATION|SBRT|Stereotactic Body Radiation Therapy
214946411|NCT00162994|PROCEDURE|adenoidectomy and tymapanostomy|
214946412|NCT06651892|DRUG|Enema Phosphates Sodium|oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
214946413|NCT06651892|DRUG|Glycophos Injectable Product|intravenous sodium glycerophosphate as the standard of care or active control
214946414|NCT04306250|PROCEDURE|Apical prolapse fixation - anterior access|The surgery is done in anterior access
214946415|NCT04306250|PROCEDURE|Apical prolapse fixation - posterior access|The surgery is done in posterior access
214946416|NCT01884012|PROCEDURE|long term oxygen therapy|
214946417|NCT01889355|DEVICE|AgaMatrix Blood Glucose Monitor|
214946418|NCT05822648|BEHAVIORAL|Project Health|Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
214946419|NCT05822648|OTHER|Educational Video Control|We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
214946420|NCT06618326|DEVICE|Acupuncture|Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received acupuncture regardless of the number of acupuncture points, frequency, and courses of treatment in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary fiber consumption to a recommended daily intake of 30 g
214341868|NCT00700687|DRUG|PA32540|aspirin/omeprazole
214341869|NCT00700687|DRUG|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
214341870|NCT00700687|DRUG|aspirin and [NSAID]|aspirin and \[NSAID\]
214946421|NCT06618326|DEVICE|biofeedback|Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received biofeedback training in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary
214946422|NCT04777448|PROCEDURE|telerehabilitation|24 sessions (less Thant 1h hour each) of tele rehabilitation. Patients can choose among several activities (gym, dance, cardio training, ...)
214946423|NCT07015723|PROCEDURE|Living liver donors|Adults who are screened for living liver donation.
214946424|NCT05056792|OTHER|Isometric strength training for 8 week|Plyometric training for 8 week
214946425|NCT05056792|OTHER|Conventional training|Conventional training for 8 week
214946426|NCT00467961|COMBINATION_PRODUCT|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
214946427|NCT00643461|DEVICE|Adhesive A|Applied per manufacturer's instructions.
214341871|NCT03748498|DEVICE|laser|Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
214341872|NCT04504877|DRUG|Cannabidiol|Cannabidiol 300 mg daily for 4 weeks
214341873|NCT03513029|DEVICE|VytronUS Ablation System|Catheter Ablation for Paroxysmal Atrial Fibrillation
214341874|NCT06535217|PROCEDURE|Liver transplantation|Liver transplantation
214341875|NCT05253703|OTHER|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
214341876|NCT02266238|DEVICE|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
214341877|NCT02266238|DEVICE|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
214341878|NCT02266238|PROCEDURE|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
214341879|NCT00534729|DRUG|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
214341880|NCT06522451|OTHER|conventional physical therapy|Only conventional physical therapy (CPT) will be administered to this group. These regular workouts will include dynamic and static stretching, walking-specific functional exercises, passive mobilizations for pain-free mobility, balance modulation, and gait training. At baseline, the functional state of both groups will be evaluated. Treatment sessions will run for a total of 12 weeks, five days a week, for 45 minutes each. They will consist of four to six repeated exercises, six times on average, and use BSID-4 once the trial is over.
214341881|NCT06522451|OTHER|Conventional physical therapy along with cuevas medek exercises|In addition to regular physical therapy, this group will get Cuevas Medak exercises including head and trunk control (by stabilizing limb) and standing to sitting transition. For a duration of 12 weeks, five days a week, and 45 minutes, each session will be held. At the baseline, the functional state of both groups will be evaluated.
214946428|NCT00643461|DEVICE|Adhesive B|Applied per manufacturer's instructions.
214946429|NCT00643461|DEVICE|Adhesive C|Applied per manufacturer's instructions.
214946430|NCT02720900|DIETARY_SUPPLEMENT|B-GOS|1.8 g/day for 6 weeks
214946431|NCT02720900|DIETARY_SUPPLEMENT|Maltodextrin|1.8 g/day for 6 weeks
214946432|NCT03359798|BEHAVIORAL|Narcotic counseling script|Script regarding post-cesarean section narcotic use
214946433|NCT03359798|BEHAVIORAL|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
214946434|NCT02250066|OTHER|Diet|Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid
214946435|NCT05964114|DRUG|Vancomycin|Initial dosing based on (a combinations of) pharmacokinetic models tailored to the individual patient. Dose adjustment starting dose (within registered dosing range).
214946436|NCT05493813|BEHAVIORAL|Cognitive function and delirium evaluation|Cognitive functions (including delirium) will be assessed pre-procedure (baseline) and emergency department (before EVT), on day 1 and 7 and 3 months after EVT procedure
214946437|NCT05493813|BEHAVIORAL|Neurological functional assessment|National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) will be assessed before (baseline but after stroke) and after EVT on days 1 and 7 after procedure up to 3 months follow-up.
214946438|NCT02494375|OTHER|Sleep and glucose assessments|Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
214946439|NCT06617988|OTHER|Not applicable- observational study|Not applicable- observational study
214946440|NCT04397471|PROCEDURE|Bone Marrow Harvest|Healthy volunteer bone marrow harvest
214946441|NCT06293105|OTHER|Qualitative interview, participant observation|Qualitative in-depth interviews to explore experiences of and perspectives on stigma and discrimination, linked to being present in settings where there is participant observation
214946442|NCT05766345|BIOLOGICAL|BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331|Nothing to add
214946443|NCT05766345|BIOLOGICAL|Placebo|Nothing to add
214946444|NCT05864573|BIOLOGICAL|ZGGS15|ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
214341882|NCT01528228|DEVICE|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
214946445|NCT04624776|DRUG|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
214946446|NCT04624776|DRUG|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
214946447|NCT02971540|DRUG|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.
214946448|NCT02971540|DRUG|Tramadol|in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.
214946449|NCT02971540|DRUG|Bupivacaine|patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.
214946450|NCT02971540|DRUG|Ropivacaine|patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.
214946451|NCT02971540|OTHER|control group|patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.
214946452|NCT03417024|DEVICE|Automated Breast Ultrasound|The ABUS system is designed to methodically scan a breast and capture multiple ultrasound images that can be rendered and reviewed in three dimensions.
214946453|NCT03417024|DEVICE|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) systems are designed to collect 3-dimensional x-ray images of breast tissues.
214341883|NCT00377195|RADIATION|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
214946454|NCT03168919|RADIATION|Fractionated Radiation|Standard of care fractionated radiation therapy will be given to the tumor.
214946455|NCT03168919|DRUG|Temozolomide|Standard of care temozolomide will be given along with radiation therapy
214946456|NCT03168919|DEVICE|MRI|Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
214946457|NCT03641534|PROCEDURE|Lung Ultrasound examination|Use of lung ultrasound to detect pulmonary complications
214341884|NCT02056301|DRUG|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
214341885|NCT02056301|DRUG|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
214946458|NCT03641534|PROCEDURE|Compression ultrasonography (CUS)|CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
214946459|NCT03641534|PROCEDURE|Echocardiography|Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
214946460|NCT03641534|PROCEDURE|Inferior Vena Cava ultrasound|Measurement of the inferior vena cava diameter
214946461|NCT03641534|PROCEDURE|Passive leg raising test (PLR)|Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
214946462|NCT03641534|PROCEDURE|Orthogonal polarization spectral imaging (OPS)|Measurement of capillary flow in the rectal microcirculation
214946463|NCT03641534|PROCEDURE|Urine collection (Foley catheter)|For urinalysis, biochemistry, urine microscopy, pH, and culture.
214946464|NCT03641534|PROCEDURE|Venous blood samplings|for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
214946465|NCT03641534|PROCEDURE|Electrocardiogram|all patients will have an ECG performed on enrolment as a non-invasive investigation
214946466|NCT03641534|PROCEDURE|GlycoCheck|GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
214946467|NCT06009016|DIAGNOSTIC_TEST|Inflammatory factors and coagulation factors level in cerebrospinal fluid after subarachnoid hemorrhage|Inflammatory factors and coagulation factors level in cerebrospinal fluid will be tested by ELISA kits.
214946468|NCT04605393|DRUG|Cannabidiol|CBD
214946469|NCT04605393|DRUG|Placebo|Placebo
214946470|NCT04605393|DRUG|Delta-9-THC|THC
214341886|NCT05198232|BEHAVIORAL|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
214677692|NCT02235285|PROCEDURE|primary breast augmentation|With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.
214677693|NCT01842464|PROCEDURE|Anterior Sacro-Spinous|Anterior Sacro-Spinous
214946471|NCT03525028|DRUG|Metformin|The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.
214946472|NCT03525028|DRUG|Placebo|The investigators use placebo in the control group.
214946473|NCT02195427|DEVICE|TEOSYAL® RHA Global Action|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles."
214946474|NCT02195427|DEVICE|TEOSYAL® RHA Deep Lines|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles."
214946475|NCT04969380|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
214946476|NCT00379431|DRUG|Administration of rituximab and methylprednisolone|"Rituximab:~Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use."
214946477|NCT03650725|OTHER|Mandatory Split bowel preparation|Intervention describes the standard of care patient split bowel preparation instructions as mandatory, instead of giving patient instructions with option of choice between split or day before bowel prep.
214946478|NCT03330067|DEVICE|Cold and dry CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of cold (19-21°C) and nonhumidified (0%) CO2.
214946479|NCT03330067|DEVICE|Warm and humidified CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of warmed (95° F) and humidified (95% relative humidity) CO2, using a Lexion Insuflow device.
214946480|NCT01582659|OTHER|Telephone counseling|2 planned telephone counseling sessions are conducted.
214946481|NCT01582659|OTHER|Web access|Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
214946482|NCT06440733|OTHER|Multicomponent exercise program focused in elderly.|"Each of these sessions will be carried out taking into account the main physiotherapy objectives, such as gaining strength in both upper and lower limbs, as well as proprioception, balance, and promoting a pleasant and safe social environment where these older people feel valid.~All sessions will begin with a 5-minutes. It will begin with a general warm-up based on general joint mobility of the head and neck, shoulders, trunk, elbows, hands, wrists, hips, knees and ankles to begin to accustom the body to the physical work environment. And at the end of the sessions, a stretching program will be carried out, and it will end with a return to calm with a respiratory training program, in which you will be instructed to take in air through the nose and release it through the mouth, while the room is silent, and thus promote self-awareness."
214946483|NCT00857597|PROCEDURE|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
214946484|NCT00857597|DRUG|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
214946485|NCT02604173|DRUG|Budesonide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
214946486|NCT02604173|DRUG|Acetazolamide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
214946487|NCT02604173|DRUG|Placebo|Placebo pill and sham inhaler
214946488|NCT00756197|DEVICE|Cryo Spray Ablation Group 1|Cryo Spray Ablation
214946489|NCT00756197|DEVICE|Cryo Spray Ablation Group 2|cryo spray ablation
214946490|NCT02904551|PROCEDURE|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
214946491|NCT02904551|PROCEDURE|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
214946492|NCT06622954|OTHER|Protein- and Calorie restriction|The intervention consists of 30% calorie and 70% protein restriction, based on their daily nutritional intake. The protein and calorie restriction will be given in the form of Scandishake from Nutricia. These are ready available and easy to tailor to the caloric and protein need of each individual study subject.
214946493|NCT02484300|DIETARY_SUPPLEMENT|Melatonin|
214946494|NCT02484300|OTHER|Placebo|
214946495|NCT00038623|DRUG|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
215075213|NCT04127799|OTHER|Hospital-Community-Family-Care Management Platform Online|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
215075214|NCT04127799|OTHER|Subjects with AF conventional treatment|Subjects with standardized treatment according to latest guidelines via conventional visit.
215075215|NCT06540703|DIETARY_SUPPLEMENT|Therapeutic Ketogenic Diet (TKD)|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
215075216|NCT00053677|DRUG|Naltrexone|For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
214946496|NCT00038623|DRUG|Rituximab|250 mg/m\^2 in the vein over 6 to 8 hours on Day 1.
215075217|NCT00053677|DRUG|Placebo|For subjects who were randomly assigned to placebo.
215075218|NCT00425997|DRUG|Valsartan/HCTZ|
215075219|NCT00425997|DRUG|amlodipine|
215075220|NCT00425997|DRUG|HCTZ|
215075221|NCT01424748|DIETARY_SUPPLEMENT|Tahitian Noni Juice|noni fruit juice
215075222|NCT01424748|DIETARY_SUPPLEMENT|Placebo|Placebo juice
214946497|NCT02381769|DIETARY_SUPPLEMENT|Soybean based lipid emulsion|
214946498|NCT00174226|DRUG|Atomoxetine|
214946499|NCT00174226|DRUG|Buspirone|
214347481|NCT03013647|DRUG|Methyl Aminolevulinate|"Patients will be treated with Daylight Photodynamic therapy, following these steps:~1. mild curettage of the AK lesions~2. application of a chemical sunscreen SPF 30~3. application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)~4. exposition to daylight, for 120 minutes~5. cleaning of the face"
214946500|NCT04279782|OTHER|Comprehensive treatment|Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.
214946501|NCT00622804|PROCEDURE|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
215075223|NCT00353808|DRUG|[S,S]-Reboxetine|
215075224|NCT04199975|DEVICE|Orthoses|Power-Driven or Mechanical Orthoses
215075225|NCT05129904|OTHER|Double plasma molecular absorption system|DPMAS is an extracorporeal procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then returned to patients. It does not require large volumes of plasma and nor does it bear the risk of plasma-associated allergic reaction or disease transmissions. DPMAS can attenuate the jaundice in a short term and decrease the bilirubin concentration, which then reduces the toxicities of bile acid and high levels of bilirubin on the hepatocytes
214946502|NCT00622804|PROCEDURE|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
214946503|NCT00622804|PROCEDURE|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
214946504|NCT02983916|PROCEDURE|Adhesiolysis|Diagnostic laparoscopy or laparotomy with lysis of adhesions.
214946505|NCT01466517|DRUG|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
214946506|NCT01466517|DRUG|Ibuprofen|400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
214946507|NCT06302088|OTHER|SAINTS program|A brief descriptive name used to refer to the intervention(s) studied in each arm of the clinical study. A non-proprietary name of the intervention must be used, if available. If a non-proprietary name is not available, a brief descriptive name or identifier must be used.
214946508|NCT06082882|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include a \~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).
214946509|NCT06082882|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
214946510|NCT06909929|DIETARY_SUPPLEMENT|Lipid IV 2 g|This group will get 2 g of lipid IV in the early 24 hours of life
214946511|NCT06909929|DIETARY_SUPPLEMENT|lipid IV 1 gram|This group will get 1 g of lipid IV in the early 24 hours of life
214946512|NCT06911580|PROCEDURE|Graston Massage|The participant was positioned prone on the treatment table with the knee slightly flexed. A small amount of lubricating gel was applied to the entire gastrosoleus complex and the calcaneal tendon. For one minute, sweeping strokes were performed downwards on the gastrocnemius heads using the GT-5 tool. From the second to the fourth minute, the GT-5 was used in an upward direction to ensure that both the gastrocnemius and soleus were treated. Afterward, with the GT-2 tool, one minute of downward sweeping and one minute of upward sweeping were performed on the calcaneal tendon. Following the two minutes of sweeping, GT-3 was used to apply short, perpendicular strokes to the medial and lateral sides of the calcaneal tendon, with 30 seconds for each side. The total application lasted approximately 7 minutes (Palmer et al., 2017).
214946513|NCT05510219|DRUG|intravenous rapid infusion of obinutuzumab|This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
214946514|NCT06912035|DRUG|Diacerein 50 mg Capsule|The patients received diacerein capsules
214677694|NCT06313905|DIETARY_SUPPLEMENT|EVADRY|"The EVADRY oral spray and the placebo are produced by Wellnet laboratory.~• EVADRY spray: It is a phytotherapy-based medication in the form of an oral spray. It is a 100 ml bottle containing ALEO BARBADENSIS LEAF WATER (1 ml), Chamomilla Recutita Flower extract (30 mg), TOCOPHEROL (10 mg), hyaluronic acid (2 mg), mentha spicata herb oil (10 mg), and eugenol (40 µg)."
214946515|NCT06912035|DRUG|Placebo|Patients received placebo capsules
215075226|NCT06090981|DRUG|Bovine surfactant|Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
214946516|NCT03403621|DRUG|Pentamidine Isethionate|Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.
214946517|NCT03403621|DRUG|Placebo|No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
214946518|NCT03557684|DIETARY_SUPPLEMENT|leucine|amino acid leucine in powder
214946519|NCT03557684|OTHER|PO placebo|maltodextrin
214946520|NCT03557684|BIOLOGICAL|lipopolysaccharide (LPS)|purified bacterial wall component as an inflammatory challenge
214946521|NCT03557684|OTHER|IV placebo|0.9% saline
214946522|NCT02795845|DIETARY_SUPPLEMENT|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
214946523|NCT02795845|OTHER|Placebo|capsule without active ingredient
215075227|NCT02684058|DRUG|Dabrafenib|Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients \< 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients \< 12 years old and \< 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and \<19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
214946524|NCT05391919|OTHER|Multimodal technology (MT)|"Patients will receive a course of rehabilitation with multimodal correction using BOS-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, in moderate paresis of the upper limb, the neurointerface Exokist-3 with EEG registration will be used. The program for IS patients includes 15 sessions with the MT: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
214946525|NCT05391919|OTHER|Conventional rehabilitation (CR)|The patients will recieve Conventional rehabilitation technology (physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients includes 15 sessions with the CR: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
214946526|NCT03252197|DEVICE|UGIJVC with needle guide device|Study subjects assigned to each group were trained in ultrasound guided internal jugular venous cannulation (UGIJVC) in separate spaces. On each session, subjects were educated about UGIJVC for 30 minutes, and the instructor who was in charge of session, consisted of experienced physicians who had 50 or more UGIJVC success experiences without a supervisor in clinical field. The instructors explained the anatomical structure and the principles of UGIJVC and then demonstrated the procedures directly to the subjects using phantom. After that, all subjects were instructed to perform hands on practice for 30 minutes. In case group, the instructor trained subjects using device. On the other hand in control group, UGIVJC was demonstrated as a conventional method of approaching the target vessel while confirming the needle tip on the ultrasound screen in real time without a device.
214946527|NCT03252197|DEVICE|UGIJVC without needle guide device|participants who are tested performance for ultrasound guided cannulation using conventional method.
214946528|NCT03129711|OTHER|glazed Celtra Duo|zirconia reinforced lithium silicate
214946529|NCT03129711|OTHER|IPS Empress CAD|Standard etchable glass ceramic for laminate veneers
214946530|NCT01689233|DRUG|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
214946531|NCT01689233|DRUG|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
214946532|NCT01635907|DRUG|Dovitinib|
214946533|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, intramuscular (IM)
214946534|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, IM
214946535|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 Ml dose, IM
214946536|NCT00422292|BIOLOGICAL|Measles, Mumps, Rubella and Varicella|0.5 mL dose, SC
214946537|NCT05517733|BIOLOGICAL|Platelet Rich Fibrin|"for the preparation of PRF, A well-trained professional nurse drew 10ml of patient blood from the antecubital vein and transferred it to a test tube without anticoagulant. The blood sample was immediately centrifuged for 10-12 minutes at 3000 rpm. L-PRF was ready to use after centrifugation.~PRF membrane was put over the implant and slightly tucked under the soft tissue periphery, then held in place with a figure-of-8 suture by 0.5 proline suture"
214946538|NCT05517733|DEVICE|Diode laser|"* A 980 nm diode laser device (BIOLASE) was applied in a circular motion to the blood formed at the socket orifice at a power of 1W for 1 minute with a continuous wave mode, the application was done without touching the pooling blood and with a non-activated tip of the fiber optic.~* The laser application cycle was repeated 3-5 times to yield a stable fixed blood clot covering the dental implant with no oozing blood from its periphery."
214677695|NCT06313905|OTHER|Placebo|"The placebo corresponds to flavored water (mint extract) with the same taste as EVADRY. It is placed in a bottle with the same appearance as EVADRY.~Both products are administered at a rate of 5 intra-oral sprays per day."
214677696|NCT05331365|OTHER|Construction and evaluation of a composite score evaluating post ankle surgery residual instability by completing questionnaires and undergoing physical tests|"Four tests and two questionnaires, each evaluating specific physical or psychological dimensions will be used to construct the composite score Ankle Go Test composite score:~* Foot and Ankle Ability Measure Questionnaire (FAAM)~* Ankle ligament reconstruction-return to sport after injury Questionnaire(ALR-RSI)~* Single Leg Stance Test (SLST)~* Side Hop Test (SHT)~* Star Excursion Balance Test (SEBT)~* Figure-of-8"
214677697|NCT04565561|DEVICE|Neovas BRS or DCB|"All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis \< 30%; B. no flow limiting dissection or TIMI grade 2-3."
214677698|NCT02544984|DRUG|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
214677699|NCT02544984|DRUG|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
214677700|NCT01347697|PROCEDURE|Reconstruction with an acellular porcine dermal collagen implant (biological mesh)|Reconstruction of floor of lesser pelvis with an acellular porcine dermal collagen implant (biological mesh) after extended excision of rectum including levator muscles in advanced low rectal cancer.
214946539|NCT04607980|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
214946540|NCT04607980|DRUG|Ustekinumab|Participants will receive SC injection of ustekinumab.
214946541|NCT05628298|DEVICE|Soovu Pain Relief System|The Soovu Pain Relief system uses pulses of heat to block the TRPV-1 calcium channel on peripheral pain nerves. The study will determine if the FDA cleared device significantly reduces the subject's pregnancy related pain.
214946542|NCT00560911|BEHAVIORAL|educational program for the self-management of OAC|"Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.~After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly."
214946543|NCT00560911|BEHAVIORAL|1 hour education - afterwards physician leaded OAC control|"Patients in the routine control group participated a single 90-minute session~During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic."
214946544|NCT06910475|OTHER|Resistance training|"The training program will follow a periodized approach, starting with a low total volume (loads x sets x repetitions), ensuring gradual adaptation, patient safety, and performance progression. Strength training will begin 48 hours after muscle strength tests.Sessions will occur 2 to 4 times per week on non-consecutive days. Each session will include 6-12 exercises, with 1-3 seconds for concentric and eccentric actions, 6-20 repetitions, 1-6 sets, and 1-3 minutes of rest. Intensity will be gauged by perceived exertion, ranging from easy to hard, with load adjustments every 2 months based on progress.Patients undergoing hemodialysis may perform the sessions during or between treatments. Portable equipment like free weights, ankle weights, and resistance bands will be used."
214946545|NCT06910475|OTHER|Endurance training|Training sessions will be conducted 2 to 4 times per week on non-consecutive days. Patients will perform aerobic training on different ergometers, namely: bicycle, treadmill, and stair climber. The choice will depend on the patient's needs/abilities and/or equipment availability. The load will be adjusted between 50% and 100% of the ventilatory threshold, according to the patient's cardiorespiratory capacity. The duration of the training will vary between 10 and 60 minutes, always starting with low load and volume, with gradual progression to ensure patient comfort and safety.
214946546|NCT06910475|OTHER|Concurrent training|Training sessions will be conducted 2 to 6 times per week, alternating between strength training one day and aerobic training the next, as described above. As patients improve their physical fitness, strength and aerobic training may be performed on the same day.
214946547|NCT06910904|COMBINATION_PRODUCT|Constraint-Induced Movement Therapy (CIMT)|CIMT is a intensive training sessions of 6 hours/day for 5 weeks, focusing on functional tasks with the paretic arm while constraining the unaffected arm using a mitt or sling. Implement a constraint on the non-paretic arm to encourage increased use of the affected arm in daily activities. Use shaping techniques to gradually increase the complexity and difficulty of tasks performed with the affected arm (Rahman, 2016). Most commonly, the protocol continues to be 2 weeks in duration but the intensity is adjusted such that the restraint is worn for approximately 6 h per day and therapy is administered for 2 to 3 h per day (MacKenzie \& Viana, 2024). But this study implementing a 2 hour CIMT protocol with 6h restrain for 8 weeks in sub-acute stroke rehabilitation balances therapeutic intensity with practical considerations, potentially enhancing patient engagement and rehabilitation outcomes within clinical settings (Chen et al., 2014; Udoeyop, 2017).
214946548|NCT06910904|COMBINATION_PRODUCT|Mirror Therapy (MT)|A specific intervention that uses a mirror to create a visual illusion of the affected limb, with the goal of improving motor function and quality of life in chronic stroke patients. In mirror therapy, the patient is asked to move the unaffected limb while watching the moving limb being reflected in the mirror. The congruent visual feedback through the mirror affects brain lesions and motor-related areas on the affected side, facilitating motor recovery. Patients with chronic stroke who can benefit from visual feedback to enhance motor recovery (Gandhi et al., 2020; Rothgangel \& Braun, 2013). Mirror therapy sessions should last at least 10 minutes daily, with the option to increase up to 30 minutes for optimal benefits. Practice mirror therapy exercises at least once a day. Perform gentle movements with the intact limb while observing its reflection in the mirror(Crosby et al., 2016).
214946549|NCT01318746|PROCEDURE|Blood withdrawal|blood withdrawal every 2 hours during 24 hours
214946550|NCT06911086|DEVICE|3D printed models|A three-dimensional digital model is constructed based on the patient's preoperative CT/MRI images, and a personalized physical model is created using 3D printing. This model has the ability to self-heal after being cut. Surgeons can perform multiple simulated surgeries on the model to plan the optimal surgical path before the authetic surgery
215075228|NCT02684058|DRUG|trametinib|"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients \<6 years old and \<26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients \<6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg \< 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"
214677701|NCT01347697|PROCEDURE|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
214347482|NCT04458350|BEHAVIORAL|Digital Promotions Group|Digital promotions on the Fresh EBT app and Facebook will run for 13 weeks, advertising a SNAP fruit and vegetable incentive at farmers' markets in New England. The intervention will be applied to zip codes randomized to the intervention arm.
214347483|NCT04102358|PROCEDURE|Medial approach infraclavicular block with single injection|infraclavicular blocks performed with single injection
214347484|NCT04102358|PROCEDURE|Medial approach infraclavicular block with triple injection|infraclavicular blocks performed with triple injection
214677702|NCT01198444|DRUG|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
214946551|NCT06911086|OTHER|CT or MRI image|Obtain the patient's CT/MRI images and determine the definitive surgical path based on the two-dimensional images.
214946552|NCT06912282|DEVICE|deep brain stimulation|bilateral single-electrode VO combined with STN target implantation
214946553|NCT00727090|DRUG|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
214946554|NCT04651946|DIAGNOSTIC_TEST|DNA methylation testing|Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum
214946555|NCT06911697|DIAGNOSTIC_TEST|18F-TSPF PET/CT|Each subject receives interval imaging of 18F-TSPF PET/CT and 18F-FDG PET/CT, and further follow-up.
214946556|NCT05052606|OTHER|No intervention|This study is an observational study without treatment intervention.
214946557|NCT05988905|OTHER|robot assited gati training|SUBAR® (CRETEM, Korea) is a exoskeletal-robot with a footplate that assists gait movements. The patient's thigh length and lower leg length were measured before training, so that the SUBAR® can be adjusted to patient's size to ensure accurate training. During training, the therapist facilitated the treatment and stood by the patients' side to adjust the direction and speed. RAGT is programmed automatically, and it can be performed regularly over a long period. The patients received 30 min of robot-assisted training using SUBAR® once a day for 5 days a week for 8 weeks. Each training session lasted up to 40 min.
214946558|NCT05988905|OTHER|conventional traiing|Patients also received conventional exercise rehabilitation with the same duration and frequency. Conventional rehabilitation therapy, which consisted of active assistive knee exercises, knee stretching, patellar mobilization exercises, and quadriceps setting exercises, was performed every day throughout the rehabilitation period.
214946559|NCT04747990|PROCEDURE|Early Definitive Treatment|defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)
214946560|NCT01833936|DEVICE|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
214946561|NCT01833936|DEVICE|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
214341887|NCT05198232|BEHAVIORAL|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
214946562|NCT02163616|DRUG|Misoprostol|800 mcg of sublingual misoprostol
214946563|NCT04742660|DRUG|Ammonium Glycyrrhizinate|In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.
214946564|NCT04861194|RADIATION|Neurovascular-sparing|Dose reduction of the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb during 5x7.25 Gy MRgRT
214946565|NCT03728361|BIOLOGICAL|Nivolumab|Given IV
214946566|NCT03728361|DRUG|Temozolomide|Given PO
214946567|NCT04579445|OTHER|Education on tailored Quality Improvement measures|Centers will undergo an education on defined Quality of Care measures, with the aim to implement a standardized pathway which is reproducible, scalable and which will allow increased access. The implementation of these measures will help to reduce resource requirements, intensive care bed occupancy and overall length of hospital stay with uncompromised patient safety.
214946568|NCT05988892|BEHAVIORAL|Physical Activity|Use Exercise to increase physical activity (PA), as measured by cardiovascular endurance, muscular strength, and balance in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address and to increase quality of life (QOL), as measured by physical functioning and fatigue, in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address.
214946569|NCT05721677|DEVICE|2-octyl cyanoacrylate based topical skin adhesive|Tissue adhesive on CVL exit-site
214946570|NCT06209762|OTHER|Exercise|The core stabilization exercise program, which is individually prescribed and structured, will be applied for 8 weeks. The level of exercises will be increased over time according to the patient's condition. Exercises will be taught to patients. It will be carried out under the supervision of a physiotherapist three days a week for 8 weeks. On the remaining days, the patient will be asked to do it himself.
214946571|NCT05682729|BEHAVIORAL|Book Reading Intervention|Children read books containing relevant stimuli.
214946572|NCT02824562|BEHAVIORAL|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
214341888|NCT04483453|OTHER|EXPL feeding regimen|EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)
214946573|NCT02824562|BEHAVIORAL|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
214946574|NCT04562857|BEHAVIORAL|Moderate intensity interval training (MITT)|interval exercises (intervention) on bicycle for patients with AF and OSA or AF with CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
214341889|NCT04483453|OTHER|CTRL feeding regimen|CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
214341890|NCT01987713|BEHAVIORAL|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
214946575|NCT00161967|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.
214946576|NCT03627650|PROCEDURE|lipofilling/ fat grafting|liposuction, processing/ cleaning of fat tissue; reinjection with sharp needle transcutaneous
214341891|NCT02747342|DRUG|SHR3680; SHR3162|"SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase."
214341892|NCT02532218|DRUG|ARI-3037MO|Lipid lowering treatment Statins
214341893|NCT01999504|OTHER|PAL-2|meal
214341894|NCT01999504|OTHER|TFH-1|Meal
214946577|NCT03627650|PROCEDURE|placebo injection|
214946578|NCT00678964|DRUG|Erlotinib|Erlotinib 150 mg, p.o., once daily
214946579|NCT00678964|DRUG|Vinorelbine and Carboplatin|Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
214946580|NCT06376305|DEVICE|EndoBarrier|"During screening visit, a brief history, examination, blood tests and 2 sleep studies within a gap of 1 week will be performed. Then, there will be an assessment by gastroenterologist for EndoBarrier insertion. EndoBarrier will be inserted endoscopically as a day case procedure after the midnight fast, under general anaesthesia. Following the EndoBarrier insertion, there will be 3 monthly trial visits until one year where the following assessments will be performed - brief interview, observations, blood tests, urine test, dietitian review, compliance check with CPAP and quality of life questionnaire.~At the end of one year, EndoBarrier will be removed endoscopically again as a day case procedure under general anaesthesia. Then, there will be follow up trial visits every 3 months up to one year where there will be clinical assessments, sleep studies, blood tests, urine test, dietitian, compliance check and quality of life questionnaires."
214946581|NCT06509347|OTHER|Preassure release|Preassure release in Flexor digitorum brevis trigger point muscle.
214946582|NCT06509347|OTHER|Non-emision laser|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
214341895|NCT01999504|OTHER|Reference|Meal
214341896|NCT02209324|DRUG|ASP2151|
214946583|NCT02427243|DRUG|Crenezumab|
214946584|NCT02427243|DRUG|Crenezumab|
214946585|NCT02168777|DRUG|Refametinib (BAY86-9766)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
214946586|NCT02168777|DRUG|Regorafenib (Stivarga, BAY73-4506)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
214946587|NCT05243563|DEVICE|MonaLisa Touch|3 laser treatments at 6 week intervals for 6 months by a single trained operator
214946588|NCT05243563|DRUG|Topical steroid|self-applied topical steroid therapy using clobetasol propionate 0.05%
214946589|NCT06728709|DIAGNOSTIC_TEST|ultrasound detection of any abnormal ultrasonographical findings.|"ultrasound assessment within 24 hours. Then reassessment every 48 hours or when the patient develops respiratory distress.~While the patient is in a supine or semi-recumbent position, and the probe is in a short axis. The 8-region technique will be used. The areas are four on each side of the chest. The examiner will assess 8 regions -Anterior chest wall ( ACW), Anterior axillary line (AAXL), costo-phrenic angle (COSTO), Postero-lateral alveolar \&/ or pleural syndrome (PLAPS) right and left . Each region will be scored using the LUS aeration score. as follows: 0, A-pattern with 0-2 B-lines; 1, more than 2 separated B-lines; 2, multiple coalescent B-lines; or 3, lung consolidation, . A global LUS score will be calculated at each time point and range from 0 to 24.~posterior region will be assessed if needed and if feasible. The venous status will be assessed through a subcostal view for inferior vena cava diameter."
214341897|NCT04679467|DIETARY_SUPPLEMENT|PKU sphere|"TYR sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); Docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
214341898|NCT05988216|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
214341899|NCT06477445|DEVICE|Visual feedback balance training system|Using an visual feedback balance training system to provide a dynamic balance training platform for patients to perform balance training based on visual feedback.
214347485|NCT00507039|PROCEDURE|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
214946592|NCT02329782|BEHAVIORAL|Adherence Readiness Program|The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
214946593|NCT05229627|DRUG|MPH|the drug would be prescribed to patients without any contraindication
214946594|NCT05229627|DRUG|ATX|the drug would be prescribed to patients without any contraindication
214341900|NCT06477445|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
214341901|NCT06477445|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
214946595|NCT05240703|DEVICE|Stabilization splint treatment|The stabilization splints were made of heat-cured acrylic by the same dental technician. The occlusion of the splint was defined in the centric relation occlusion using wax (Astynax, Associated Dental Products Ltd, UK). The patients were instructed to use the splint every night during the course of the study. The patients were instructed to perform a standardized program for masticatory muscle exercises. At the beginning of the training program, active mouth openings, laterotrusive movements and protrusive movements were performed. The mandible was held in the maximal positions for a few seconds on each movement. Thereafter, these movements were made towards resistance (using the patient's own fingers). After jaw exercises, the patients were suggested to open the jaw wide, stretching it with fingers a few times for 10 to 20 seconds. These movements were repeated 7 to 10 times per training session, and the sessions were performed 2-3 times per day.
214946596|NCT03153345|DEVICE|bedside respiratory muscle training|The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
214946597|NCT03153345|BEHAVIORAL|conventional stroke rehabilitation program|The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
214946598|NCT03115593|PROCEDURE|Blind biopsy with a pipette|Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.
214946599|NCT03115593|PROCEDURE|Targeted biopsy using hysteroscopy|During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.
214946600|NCT03992378|DEVICE|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.
214946601|NCT03992378|DEVICE|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the ear lobe delivered by Parasym device.
214946602|NCT01473017|BEHAVIORAL|CBT-based Guided Self-Help|CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
214946603|NCT00963846|DRUG|placebo|matching pill placebo
214946604|NCT00963846|DRUG|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
214946605|NCT00963846|DRUG|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
214946606|NCT00963846|DRUG|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
214946607|NCT01304290|OTHER|Hyperinsulinemic/normoglycemic clamp|"Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours."
214946608|NCT04047823|DEVICE|a digital Infrared thermography (FLIR E5 Serial No.63985976）|Measurements were taken during radiation and additionally two weeks after radiotherapy weekly. Temperature change was measured by thermal infrared imager (FLIR) for 4 test areas within the supraclavicular radiation field and on an opposite non-irradiated area, which was outlined using a specific software package (FLIR Systems 6.3.17227.1001).
214946609|NCT01229319|DRUG|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
214946610|NCT01229319|DRUG|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
214946611|NCT02117219|BIOLOGICAL|MEDI4736 Evaluate MEDI4736 in MDS|MEDI4736 will be administered by IV infusion
214341902|NCT01198600|DEVICE|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
214341903|NCT01198600|DEVICE|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
214341904|NCT01198600|DEVICE|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
214341905|NCT02526992|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
214341906|NCT02350959|DRUG|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
214341907|NCT02350959|DRUG|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
214341908|NCT00206063|DRUG|EXANTA|
214946612|NCT02117219|DRUG|VIDAZA|VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
214946613|NCT02117219|BIOLOGICAL|tremelimumab|tremelimumab will be administered by IV infusion
214946614|NCT02153125|DRUG|Eplerenone|
214946615|NCT03584230|BEHAVIORAL|Assigned to positive group|See arm description
214946616|NCT03584230|BEHAVIORAL|Assigned to negative group|See arm description
214946617|NCT01540747|DIETARY_SUPPLEMENT|Myo-inositol + folic acid + melatonin|Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
214946618|NCT01540747|DIETARY_SUPPLEMENT|Myo-inositol + folic acid|Myo-inositol (2000mg) + folic acid (200 mcg)
214946619|NCT06138717|OTHER|yoga based exercises|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.In group 2, in addition to aerobic exercises, spinal stretching, relaxation, respiration and meditation will be performed. A yoga-based exercise programme consisting of exercises will be applied for 40 minutes and 12 session
214946620|NCT03870750|OTHER|Supportive Palliative Care|focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects
214946621|NCT03870750|OTHER|Clinical Management|physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education
214677703|NCT03341468|DEVICE|Urethral catheter immobilization|"Subjects assigned to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial.~Subjects will be asked to fill out a symptom-based questionnaire prior to leaving the office. This will conclude their participation in the study."
214677704|NCT01450930|DRUG|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
215075229|NCT02684058|DRUG|Carboplatin|"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m\^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m\^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."
215075230|NCT02684058|DRUG|Vincristine|"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."
214341909|NCT02439086|DEVICE|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
214341910|NCT05852444|DEVICE|Passive Ultrasonic Activation|Agitation of root canal irrigation solution with an ultrasonic activation device (Ultra X).
214677705|NCT01450930|DRUG|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
214341911|NCT05852444|DEVICE|Manual Dynamic Agitation|Agitation of root canal irrigation solution with master gutta percha cone
214946622|NCT03870750|OTHER|Best Practice|Given standard of care
214341912|NCT02635438|DRUG|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
214341913|NCT02635438|DRUG|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
214341914|NCT03397446|DRUG|Lisdexamfetamine dimesylate|50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
214341915|NCT00148057|BEHAVIORAL|Low-fat diet|
214677706|NCT00729118|DRUG|lenalidomide|combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
214677707|NCT00729118|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
214677708|NCT05279469|OTHER|no intervention, just observational for D-Dimer level in blood|observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients
214677709|NCT00114114|DRUG|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day
214677710|NCT00114114|DRUG|Goserelin acetate|3.6 gms sc every 4 weeks
214677711|NCT03340493|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
214677712|NCT00087204|DRUG|becatecarin|Given IV
214677713|NCT00087204|OTHER|laboratory biomarker analysis|Correlative studies
214946623|NCT03870750|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
214946624|NCT03870750|OTHER|Questionnaire Administration|Ancillary studies
214946625|NCT03870750|OTHER|Quality-of-Life Assessment|Ancillary studies
214946626|NCT03870750|OTHER|Survey Administration|Complete surveys
214946627|NCT05572892|OTHER|FAC scale|"Measurement of walking dependency according to the FAC scale :~* in the first week after stroke (in neurology by physiotherapists),~* then at 6 weeks, 12 weeks and 6 months (by telephone).~Trunk Control Test score (in the first week after stroke, by physiotherapists).~MRC score of hip extension and hip flexion, knee flexion/extension, ankle plantar and dorsal flexion (in the first week after stroke, by physiotherapists).~PHQ-9 depression scale (at 6 weeks by phone).~Denutrition (weight loss between neurology weight and 6-week weight, BMI +/- albumin).~Other intercurrent medical problems (at each telephone interview)."
214946628|NCT00259428|DRUG|Dronedarone (SR33589)|oral administration
214946629|NCT00259428|DRUG|placebo|oral administration
214946630|NCT00020202|DRUG|FR901228|
214946631|NCT01482299|DRUG|RAD001|"RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability."
214341916|NCT01541657|OTHER|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
214341917|NCT01541657|OTHER|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
214341918|NCT01541657|OTHER|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
214341919|NCT04726865|OTHER|Naser Al-Husban|voluntary completion of an online questionnaire
214341920|NCT01224496|DRUG|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
214341921|NCT04798586|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
214946632|NCT06033170|DEVICE|CELOX™ PPH|Celox™ PPH is intended to be a physical haemostatic treatment for control and treatment of uterine postpartum hemorrhage (PPH) when conservative management is warranted.
214946633|NCT02249507|OTHER|aerobic exercise|aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
214677714|NCT00957346|DRUG|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
214677715|NCT00957346|DRUG|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
214341922|NCT01669343|DRUG|Letrozole|Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
214341923|NCT05868798|DRUG|Ammonia Inhalant|For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
214341924|NCT03293342|BEHAVIORAL|D CBT|"Intervention:~a 3-5 session treatment of dental fear.~* Psychoeducation about anxiety~* Exploration of the individual anxiety~* Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
214341925|NCT03293342|COMBINATION_PRODUCT|Control|"Intervention:~Traditional treatment of dental fear common sense/ benzodiazepine"
214341926|NCT00000153|PROCEDURE|Blue-Green Argon Laser Treatment|
214341927|NCT00000153|PROCEDURE|Red Krypton Laser Treatment|
214341928|NCT02574923|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
214341929|NCT01099319|DIETARY_SUPPLEMENT|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
214341930|NCT01099319|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
214946634|NCT03872817|OTHER|Intervention ProLiSMentAl|"Using different methods and pedagogical techniques, mental health literacy psychoeducational intervention called ProLiSMentAl consist of 4 sessions of 90 minutes: 1) improvement social anxiety recognition; 2) prevention strategies; 3) self-help strategies; 4) knowledge of first aid strategies and 5) knowledge of professionals and treatments available."
214946635|NCT04557436|DRUG|PBLTT52CAR19|gene therapy
214946636|NCT05420493|BIOLOGICAL|CAR-T cells|Drug: CAR-T cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214946637|NCT05545085|DEVICE|Laser Speckle Contrast Imaging using the PerfusiX-Imaging Device|Patient will undergo the standard of care lobectomy for pulmonary cancer. In addition, peroperative imaging using the Laser Speckle Contrast Imaging device will be performed.
214946638|NCT03298308|DEVICE|Cranial Electric Stimulation|Micro amperage TCDS
214946639|NCT04747665|OTHER|Patient and endoscopist reported experience|Exploration of patient and endoscopists experiences of colonoscopy.
215075231|NCT03926533|OTHER|Telehealth|Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
215075232|NCT03042650|BEHAVIORAL|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
215075233|NCT03042650|BEHAVIORAL|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
214341931|NCT04433767|DRUG|Transdermal Nicotine patch|"Participants will begin a 12- week open label trial of transdermal nicotine patch during the day and remove it at night (16 hours). Dose titration starting at 3.5 mg patch/daily to maximum of 21mg patch/daily.~After week 12 , dose will be slowly tapered over 3 weeks."
214946640|NCT04247451|DIAGNOSTIC_TEST|Metabolic profile and nutritional goals in diabetic foot surgery patients|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using Bio electrical Impedance Analysis BIA (Nutrilab Akern) and Resting Energy Expenditure REE using indirect calorimetry (Cosmed Q NRG) will be analysed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
214946641|NCT05290077|DIAGNOSTIC_TEST|NGAL|Serum NGAL in blood for early detection of CVR
214946642|NCT04535557|DRUG|Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once daily in 28-day treatment cycles for up to approximately 4 months.
214946643|NCT00004464|DRUG|cyclophosphamide|
214946644|NCT00004464|DRUG|filgrastim|
214946645|NCT05118048|DIAGNOSTIC_TEST|Lactate, Hemoglobin, Hematocrit|Compare diagnostic tests to reference methods
214946646|NCT03102671|OTHER|Use of HeartHab application followed by usual care|use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
214946647|NCT03102671|OTHER|Usual care followed by the use of HeartHab application|Usual care (2 months) followed by the use of HeartHab application (two months)
214946648|NCT05033977|OTHER|Exercise (center-based)|Exercise therapy with a physical therapist in a clinic.
214946649|NCT05033977|OTHER|Exercise (home-based)|Patients did exercises at home every day and 3 times per day.
214946650|NCT02171832|DRUG|BI 1744 CL, low dose|
214946651|NCT02171832|DRUG|BI 1744 CL, high dose|
214946652|NCT01520519|DRUG|Rituximab|375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
214946653|NCT01520519|DRUG|PCI-32765|420 mg (3 \* 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
214946654|NCT01090297|DEVICE|S8 Spirit 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
214677716|NCT01205490|OTHER|head positions and spinal manipulation|Each subject will then undergo a baseline MRI in a head neutral position (0 degrees rotation). They will then be placed in head rotation (45 degrees) to the non-dominant and undergo a MRI. Maximum rotation to the side with MRI will follow. Finally, each subject will receive an upper cervical rotary manipulation to the non-dominant side with MRI immediately after. A total of 4 test conditions will be evaluated (rest, 45 degree, maximal, post-manipulation). The manipulation will be performed by an experience practitioner on a bed just outside the MRI room in supine position. A controlled impulse load will be applied and the head/neck returned to neutral position. Prior to each maneuver, the subject will be queried on their comfort, condition and willingness to continue
214677717|NCT05286398|PROCEDURE|Palatoplasty|Surgical closure of palatal defect
214946655|NCT01090297|DEVICE|Somnosmart 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
214946656|NCT01090297|DEVICE|Remstar Auto|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
214946657|NCT03774394|DRUG|Clopidogrel|Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.
214341932|NCT01682291|BEHAVIORAL|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
214946658|NCT03774394|DRUG|Clopidogrel active metabolite|In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
214946659|NCT02697916|DRUG|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
214341933|NCT01682291|DIETARY_SUPPLEMENT|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
214341934|NCT05209113|OTHER|Education|A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
214946660|NCT03334422|DRUG|Baricitinib|Administered orally
214677718|NCT05286398|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch
214347486|NCT00704145|DEVICE|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
214677719|NCT01660841|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
214946661|NCT03334422|DRUG|Placebo|Administered orally
214946662|NCT06956625|OTHER|Topical cosmetic cleanser|After applying the model pollutant, the test area will be topically cleaned with the active cosmetic cleanser with Mitopure.
214946663|NCT06956625|OTHER|Topical tap water|After applying the model pollutant, the test area will be topically cleaned with tap water (control).
214946664|NCT05574829|DEVICE|Esophageal manometry and monitoring of electrical activity of the diaphragm|Esophageal manometry and monitoring of electrical activity of the diaphragm
214946665|NCT06327360|OTHER|Psychological questionnaires|The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.
215075234|NCT04694755|DRUG|Placebo|On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
215075235|NCT04694755|DRUG|Traditional Chinese medicine prescription|Tianjiang brand formula granules, in line with GMP standards
214677720|NCT01883245|DEVICE|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
214677721|NCT01883245|DEVICE|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
214677722|NCT00114205|DRUG|docetaxel|
214677723|NCT00114205|PROCEDURE|therapeutic thoracoscopy|
214946666|NCT05668572|BIOLOGICAL|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30mcg, 40mcg, 60mcg, 40mcg, 20mcg, 20mcg, 20mcg, 20mcg and 20mcg, respectively, totaling 270mcg of antigens. A 3-dose regimen administered at months 0, 2 and 6.
214677724|NCT03988114|DRUG|Abemaciclib|Administered orally
214677725|NCT03988114|DRUG|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole administered orally or anastrozole administered orally (physician choice)
214677726|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
214341935|NCT00298233|DRUG|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
214341936|NCT04258696|DEVICE|diode laser|using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
214341937|NCT04258696|DEVICE|ultrapak Knitted retraction cord|using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
214341938|NCT04806815|OTHER|A survey of 60 questions was created through the internet-based 'Google Forms surveys' site.|"The following tests will be used together with the survey;~* Menstrual Symptom Questionnaire~* Fatigue Severity Scale~* Short Form Of Coronavirus Anxiety Scale"
214341939|NCT06516757|DIETARY_SUPPLEMENT|Boric Acid Suppository|Participants will complete a baseline questionnaire and a vaginal pH test before using the product, and additional questionnaires and a pH test after 3 and 7 days of product use.
214341940|NCT01621750|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
214341941|NCT06019104|OTHER|Task-oriented training|"Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition."
214341942|NCT06019104|OTHER|Control group|Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
214341943|NCT04772716|PROCEDURE|operation|The intervention was not decided by the investigator but studied following emergency or elective surgeries undergoing in the system
214341944|NCT06223945|DIAGNOSTIC_TEST|Prevention algorithm|Development of an algorithm for the prevention of thrombohemorrhagic complications
214341945|NCT03080519|PROCEDURE|Endovascular Therapy|Balloon angioplasty and stenting for renal artery stenosis
214946667|NCT05668572|BIOLOGICAL|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）|0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens
214341946|NCT01450358|OTHER|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
214341947|NCT03806829|OTHER|Water|250 ml
214677727|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
214677728|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
214677729|NCT02461732|BEHAVIORAL|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings"
214677730|NCT02461732|BEHAVIORAL|Cognitive-Behavioral Therapy for Substance Dependence|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities"
214677731|NCT00142103|DRUG|CPG10101|CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
214677732|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
214677733|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks
214677734|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
214946668|NCT00824707|DRUG|Entecavir|Entecavir 0.5mg per day
214946669|NCT00824707|DRUG|conventional therapy|conventional therapy including protecting the liver function, anti-tumor and so on
214677735|NCT00142103|DRUG|Control|Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
214341948|NCT03806829|OTHER|Red Wine|250 ml
214341949|NCT03806829|OTHER|Green Tea|250 ml
214341950|NCT03806829|OTHER|Orange Juice|250 ml
214341951|NCT02859194|PROCEDURE|Veno-veno-arterial ECMO|
214341952|NCT00439777|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
214341953|NCT00439777|DRUG|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
214946670|NCT00525876|DRUG|Cyclophosphamide|"Matched Donors:~750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
214946671|NCT00525876|DRUG|Fludarabine|"30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
214946672|NCT00525876|DRUG|Rituximab|"Matched Donors:~375 mg/m\^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m\^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m\^2 given intravenously, then 1000 mg/m\^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m\^2 then 1000 mg/m\^2 weekly x 3 if immunomanipulation is undertaken for persistent disease."
214946673|NCT00525876|DRUG|Alemtuzumab|"Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
214946674|NCT00525876|PROCEDURE|Allogeneic Stem Cell Infusion|Infusion of stem cells.
214946675|NCT03436069|OTHER|Conventional treatment protocols of breast cancer|
214946676|NCT01313221|BIOLOGICAL|etanercept|Administered by subcutaneous injection
214946677|NCT01313221|DRUG|Topical agents|"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~* hydrocortisone 2.5%~* betamethasone valerate 0.1%~* betamethasone dipropionate 0.05%~* clobetasol 0.05%~* calcitriol~* calcipotriol plus betamethsone dipropionate 0.05%"
214341954|NCT03209908|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
214341955|NCT02405286|OTHER|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
214341956|NCT02258633|OTHER|Interactive interview and tailored family centered seatbelt safety intervention|
214341957|NCT01746823|DRUG|Cyclosporins|
214341958|NCT02745379|PROCEDURE|BFPSCs+ DFDBA+ PRF|
214341959|NCT02745379|PROCEDURE|DFDBA + PRF|
214341960|NCT06350019|PROCEDURE|Penile revascularızation|The importance of resistive index in the preoperative evaluation of vascular-induced erectile dysfunction, predicting the success of penile revascularization surgery, and postoperative patient management was investigated.
214946678|NCT01516294|RADIATION|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
214946679|NCT05942781|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period.
214946680|NCT05942781|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
214946681|NCT01265004|PROCEDURE|Stitches|Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching
214341961|NCT00661492|DRUG|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
214341962|NCT00661492|DRUG|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
214341963|NCT03734224|PROCEDURE|Adhesix mesh|Adhesix mesh
214341964|NCT03734224|PROCEDURE|Progrip mesh|Progrip mesh
214341965|NCT04689984|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
214341966|NCT04689984|DRUG|Astaxanthin|Astaxanthin 6 mg tablet once daily
214341967|NCT03567226|BEHAVIORAL|WeChat Group|"Consenting participants will be randomized to either the intervention or the control arm after successfully wearing an accelerometer for one week. The WeChat Group will be a community forum to share information, encourage each other, and receive communications from the study team. In addition, the study team will disseminate the following information through the group:~1. Daily/Weekly Reminders to exercise~2. Health education materials regarding glaucoma and general health and exercise~3. Motivational content~4. Surveys to gauge what information participants found most interesting and useful to help them exercise"
214341968|NCT03567226|BEHAVIORAL|Counselling|Study participants in the control group will receive a handout telling them to increase walking and will be counseled that walking may be helpful for the eye at the return visit
214946682|NCT01265004|PROCEDURE|Fibrin-glue|Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
214946683|NCT01265004|PROCEDURE|Stitches and Fibrin-glue|Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
214946684|NCT04468815|DRUG|BMS-986278 Tablet|Specified dose on specified days
214946685|NCT04468815|DRUG|Esomeprazole|Specified dose on specified days
214946686|NCT04468815|DRUG|BMS-986278 suspension|Specified dose on specified days
214946687|NCT01537991|RADIATION|Radiotherapy|All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
214946688|NCT00003781|DRUG|docetaxel|
214341969|NCT02106026|OTHER|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
214677736|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
214946689|NCT00003781|PROCEDURE|pain therapy|
214946690|NCT00003781|PROCEDURE|quality-of-life assessment|
214946691|NCT00333632|DRUG|Dexmedetomidine|
214946692|NCT00333632|DRUG|Propofol|
214946693|NCT00333632|DRUG|Midazolam|
214946694|NCT00333632|DRUG|Fentanyl|
214946695|NCT00333632|DRUG|Isoflurane|
214946696|NCT00533559|DRUG|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
214946697|NCT00533559|DRUG|Placebo|Placebo comparator
214946698|NCT05947435|DRUG|Tranexamic acid|Tranexamic acid was administered in intravenous or locally within irrigation fluid
214946699|NCT01504191|BEHAVIORAL|Internet-based CBT|"The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.~A psychologist will communicate with the participants through internal text-messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc."
214946700|NCT02708030|OTHER|Ketogenic Diet|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
214946701|NCT02708030|OTHER|MAD|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
214946702|NCT02708030|OTHER|LGIT|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
214946703|NCT00994214|DRUG|BIM 23A760|Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
214946704|NCT01716611|DRUG|Tolvaptan|15 - 60 mg/day for 28 days
214946705|NCT01716611|DRUG|placebo|
214946706|NCT06532058|DRUG|QHRD107 capsule，Venclexta and Azacitidine|QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）
214946707|NCT05639686|DRUG|Tranexamic acid injection|Within 10 minutes of general anesthetic induction, 15mg/kg TXA suspended in 100mL of normal saline will be administered intravenously.
214946708|NCT05639686|DRUG|Total Intravenous Anesthesia|Within 10 minutes of induction, patients in the control (TIVA) group will be administered a 100mL bolus of normal saline as placebo.
214946709|NCT05639686|DRUG|Inhalational isoflurane|Inhalational isoflurane or sevoflurane will be administered as a general anesthetic at the induction of the surgical procedure.
214341970|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
214341971|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
214341972|NCT00748436|DRUG|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
214341973|NCT00845910|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
214341974|NCT00845910|DRUG|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
214341975|NCT00845910|DRUG|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
214347487|NCT04897893|OTHER|Eicosapentaenoic acid monoglycerid (MAG-EPA)|MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
214347488|NCT01911052|OTHER|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
214946710|NCT03917979|BEHAVIORAL|Individual GIM|Participants are provided with a series of 10 individual GIM sessions, scheduled once every two weeks. Frequency may change if clinically indicated. Individual GIM sessions begin with a discussion of important issues related to the client's life and symptoms, forming a focus for the session. Then, the therapist provides suggestions to help the client become highly relaxed and focused in preparation for the music-listening portion of the session. The therapist plays specially-selected music from the Western classical tradition to match the client and the focus for the session, and engages in verbal dialogue with the client to help them explore their own internal imagery while listening to the music. After the music ends, the therapist and client engage in discussion about their imagery in metaphoric connection to their therapeutic process. This may include arts-based approaches to process the session. Sessions last approximately 90-120 minutes.
214347489|NCT01911052|OTHER|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
214347490|NCT05145231|OTHER|observational|The scales will be filled by asking the family.
215075236|NCT02825706|OTHER|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
214677737|NCT04376346|BEHAVIORAL|Native WYSE CHOICES|Native WYSE (Women, Young, Strong, and Empowered) CHOICES (Changing High-risk alcohOl use and Increasing Contraception Effectiveness Study) is an alcohol-exposed pregnancy prevention program that translates CHOICES, an evidence-based targeted intervention, into an mHealth universal intervention for young urban American Indian/Alaska Native (AI/AN) women ages 16-20.
214677738|NCT00002089|DRUG|Azithromycin|
214677739|NCT02157831|BIOLOGICAL|CP-870,893|
214677740|NCT02909296|PROCEDURE|Endoscopic drainage|
214677741|NCT01830452|PROCEDURE|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
214341976|NCT01056744|DEVICE|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:~\- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~\- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
215075237|NCT06244407|DRUG|Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets|Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets
214677742|NCT00615940|DRUG|WX-671|capsules taken per os once daily until progression or toxicity
215075238|NCT00726037|DRUG|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
215075239|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214677743|NCT00615940|DRUG|placebo|capsule taken per os once daily until progression or toxicity
214677744|NCT05979090|BEHAVIORAL|Mastery learning in communication skills|Participants will undergo simulation-based mastery learning curriculum in difficult conversations.
215075240|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
215075241|NCT01394692|PROCEDURE|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
214677745|NCT04481100|DRUG|itraconazole|Oral administration of itraconazole twice daily concurrent with chemoradiation
214677746|NCT00744367|DRUG|metformin|\>1500 mg/day or maximum tolerated dose (MTD)
214677747|NCT00744367|DRUG|pioglitazone|\>= 30 mg/day
214677748|NCT00744367|DRUG|placebo|sc once weekly
214677749|NCT00744367|DRUG|taspoglutide|10 mg sc once weekly;
214677750|NCT00744367|DRUG|taspoglutide|20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
214341977|NCT03855189|DRUG|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
214341978|NCT03855189|DRUG|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
214341979|NCT03855189|DRUG|Placebo|Placebo nasal spray administered for 4 weeks.
214677751|NCT00379730|DRUG|Prednisolone|
215075242|NCT01394692|PROCEDURE|standard microsurgery|microsurgical tumor resection
215075243|NCT04338139|PROCEDURE|bone regeneration|bone regeneration using bio-oss collagen
215075244|NCT00443053|DRUG|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
215075245|NCT04823702|BIOLOGICAL|Aldafermin|Biological: Aldafermin (NGM282) Subcutaneous Injection
214341980|NCT01687517|DRUG|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
214341981|NCT02455986|BEHAVIORAL|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
214341982|NCT01681693|DRUG|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
214341983|NCT01601301|DEVICE|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
214341984|NCT02384148|OTHER|Circadian rhythm measurement|
214677752|NCT03072511|BEHAVIORAL|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
214677753|NCT03072511|DRUG|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
214677754|NCT05609422|OTHER|Physical therapy program|"* Stretching exercises~* Strength Training Kneeling exercises~* Standing exercises~* Gait Training"
214677755|NCT05609422|OTHER|scooter board activities|"1. Scooter board bear walk.~2. Scooter board crab walk.~3. Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~4. Cross sitting on scooter board, pulls along the rope using his/her hands~5. Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~6. Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items~7. Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~8. Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~9. Supine flexion on scooter board, Clip clothespins to a rope hanging above."
215075246|NCT04926610|OTHER|proactive clinical ethics consultation|When the patients meet the initiation criteria of this study, the patients were randomly assigned to the intervention group (providing proactive clinical ethics consultation) and the routine care group (no proactive clinical ethics consultation) after obtaining the consent of the subjects.
215075247|NCT02485249|DRUG|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
215075248|NCT05629208|DRUG|Edecesertib|Tablets administered orally
215075249|NCT05629208|DRUG|Edecesertib Placebo|Tablets administered orally
214341985|NCT02384148|PROCEDURE|Skin biopsy|A 2mm diameter skin biopsy is performed by a physician using standard procedure.
214341986|NCT04251468|DEVICE|GEPII|Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)
214341987|NCT04251468|DEVICE|Ion-selective electrodes|Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.
214946711|NCT03917979|BEHAVIORAL|Waitlist Control|Participants complete an initial wait list period of 26 weeks, equivalent to the treatment and 6-week follow-up period for the experimental arm. They are then provided with four Group GIM sessions scheduled once per week. Group GIM sessions start with a group discussion about events or feelings from the week and issues related to depression and wellbeing. Then the therapist provides suggests to help the clients relax and focus in preparation for the music-listening period. Group members will explore a theme or issue related to therapy while focusing on whatever comes to them as the music is played. After the music, there will be a time to work with the imagery experienced during the music. This may be in the form of discussion or other art forms. The session ends with a discussion about gains and insights from the music and imagery. Sessions last 90-120 minutes.
214341988|NCT01143259|DRUG|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
214341989|NCT01143259|DRUG|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
214341990|NCT02552836|BEHAVIORAL|Interpersonal Psychotherapy|A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
214341991|NCT02552836|BEHAVIORAL|Supportive Psychotherapy|A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
214341992|NCT06331221|OTHER|Muscle fatigue Protocol|Four experimental conditions consisting of different local muscle fatigue protocols performed in the isokinetic dynamometer in random order, with at least one week of interval between them.
214341993|NCT00099983|DRUG|Risperidone|Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
214341994|NCT00099983|DRUG|Placebo|Placebo
214341995|NCT03464682|DRUG|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
214341996|NCT03464682|DRUG|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
214946712|NCT02217800|DRUG|saline|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
214946713|NCT02217800|DRUG|DG3173|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
215075250|NCT05326932|PROCEDURE|Mechanical thrombectomy|Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
214677756|NCT05196698|OTHER|High Flow Oxygen Therapy|"HFOT will be delivered validated medical devices and established as follow:~* Patient will be acclimatized to HFOT which will aim to achieve a flow of air of 30L/min at a temperature of 34°C using dedicated nasal canula.~* Once patient acclimatized, oxygen will be entrained in the HFOT device at a flow that will aim to achieve a saturation \> 90%. An arterial blood gas will be performed with such oxygen delivery, flowrate and temperature to ensure a PaO2 ≥ 8kPa"
214677757|NCT05196698|OTHER|Long-term oxygen therapy|LTOT delivery will be performed according to French guidelines
214677758|NCT01302769|DEVICE|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
214677759|NCT04097717|BEHAVIORAL|"My Decision tubal sterilization decision aid"|"The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization."
214341997|NCT03464682|DRUG|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
214341998|NCT03464682|DRUG|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
214341999|NCT03464682|DRUG|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
214342000|NCT03464682|DRUG|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
214342001|NCT02641080|DRUG|Aspirin|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
214342002|NCT02641080|DEVICE|Portable Compression Device|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
214677760|NCT04097717|OTHER|Usual Care|Usual medical care will vary among participants.
214677761|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Atezolizumab + Bevacizumab|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.
214342003|NCT02288429|DRUG|colistimethate sodium|
214946714|NCT02217800|DRUG|octreotide|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
214946715|NCT05195099|OTHER|respiratory treatment|Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects.
214946716|NCT01958398|BEHAVIORAL|Promillekoll|Smartphone app monitoring alcohol use with feedback.
214677762|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Placebo (IV)|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.
214677763|NCT05326893|OTHER|Femoral nerve neurodynamic mobilization|The mobilization was carried out with the patient lying on the non-dominant side in a total flexion position, and the therapist performed the hip extension movement with the knee joint kept in flexion till the patient felt soreness or pain. This position was held for three seconds and then released. This tensioning maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
214677764|NCT05326893|OTHER|Femoral nerve placebo neurodynamic mobilization|The individual was asked to lie on his non-dominant side and keep his head in the midline. In this position, while the pelvis was stabilized, the upper leg, which was in full knee extension, was grasped and the hip was abducted for 3 seconds. This maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
215075251|NCT06658262|OTHER|Tai Chi Exercises With Cycling Exercises|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. Participants will be assisted to safely mount the ergometer bicycle. The height of the seat will be adjusted to ensure postural balance, upright seating and firm contact of the feet with the pedals. Treatment for the cycling will last for 30 minutes per session.
214677765|NCT04663867|DEVICE|AngioSafe Peripheral CTO Crossing System|The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.
214946717|NCT01958398|BEHAVIORAL|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
214342004|NCT03841786|OTHER|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.
214342005|NCT03841786|OTHER|Control Diet|Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week
214342006|NCT03171233|OTHER|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
214342007|NCT03171233|OTHER|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
214342008|NCT04837638|BEHAVIORAL|Diet|No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
214342009|NCT06243653|DIAGNOSTIC_TEST|CMD test|Measured CFR and IMR
214946718|NCT03488602|BEHAVIORAL|F-SPS+UC|"Manualized individual and family program. Weekly individual and family sessions with a therapist for 6 weeks.~Participants will continue to receive usual care."
214946719|NCT03488602|BEHAVIORAL|EUC|"Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed.~Participants will continue to receive usual care."
214946720|NCT02306421|PROCEDURE|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
214946721|NCT02306421|PROCEDURE|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
214946722|NCT02306421|PROCEDURE|RPH|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
214946723|NCT02306421|PROCEDURE|PPH|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
214946724|NCT02306421|PROCEDURE|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
214946725|NCT04843358|BEHAVIORAL|Emotional Disclosure|"The trial member will deliver instructions For the next three days, I want you to write about your experience with cancer. In your writing, I want you to really let go and explore your very deepest emotions and thoughts. It is critical that you delve deeply. Ideally, I would like you to write about those parts of the experience you found hard to share with others. Perhaps this will provide an opportunity to really examine those thoughts and emotions. You might tie your personal experiences to other parts of your life. How is it related to your family life, relationship with your spouse, your children, your sexuality, daily activities, hobbies, your past, your childhood, your work? These are just some examples."
214946726|NCT04843358|BEHAVIORAL|Non-Emotional Writing|"The trial member will deliver instructions were as follows. For the next three days, I want you to write about how you use your time. We are interested in everything you do during the course of a day. In your writing I want you to be completely objective. We are not interested in your emotions or opinions. Feel free to be as detailed as possible"
214946727|NCT03309345|OTHER|No intervention|No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake
214946728|NCT01967979|DRUG|RO5285119|Single dose, alone and after repeated administration of itraconazole or fluoxetine
214946729|NCT01967979|DRUG|fluoxetine|Multiple doses
214946730|NCT01967979|DRUG|itraconazole|Multiple doses
214946731|NCT04441749|DEVICE|Images acquired by needle-based Confocal Laser Endomicroscopy (nCLE)|Patients who are scheduled to undergo Robotic Navigational Bronchoscopy for a peripheral lung lesion will be enrolled. During bronchoscopy, confocal images will be captured using Cellvizio 100 Series Confocal Laser Imaging systems and their Confocal Miniprobes (Mauna Kea Technologies Paris, France). The Cellvizio system and miniprobes are FDA approved by 510(k) for use in through the respiratory tracts by endoscopy or endoscopic accessories. Only images and needle aspiration/ biopsy results from the expansion phase (20 patients) will be analyzed
214946732|NCT00632632|DRUG|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
214946733|NCT00632632|OTHER|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
214946734|NCT01698268|PROCEDURE|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
214946735|NCT01698268|PROCEDURE|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
214946736|NCT02864316|DRUG|Nivolumab|
214946737|NCT05989971|OTHER|continuous renal replacement therapy|continuous veno-venous hemofiltration or continuous veno-venous hemodialysis set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion
214946738|NCT00298363|DRUG|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
214946739|NCT00298363|DRUG|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
214946740|NCT00298363|DRUG|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
214946741|NCT00298363|DRUG|TDF placebo|Placebo to match TDF QD
214946742|NCT00298363|DRUG|FTC/TDF placebo|Placebo to match FTC/TDF QD
214946743|NCT00298363|DRUG|ETV placebo|Placebo to match ETV QD
214946744|NCT04793373|DEVICE|Syringe|A syringe will be used to detect the loss of resistance and needle's entry of epidural space.
214946745|NCT04721366|OTHER|Standard of Care|Neonatal and pediatric participants who has been on ERT (VPRIV) will be assessed as per SOC.
214946746|NCT03105856|BIOLOGICAL|CERVARIX|\- HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
214342010|NCT00803634|DRUG|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
214342011|NCT00803634|DRUG|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
214946747|NCT03105856|BIOLOGICAL|GARDASIL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp \& Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
214946748|NCT01793350|DRUG|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
214946749|NCT04710368|DRUG|Evolocumab Injections|Administered on day 1 (the day of the first treatment) and through week 26 with a personal injector or prefilled auto injector/pens.
214946750|NCT04393376|DIAGNOSTIC_TEST|PSA Glycomics Assay|PSA Glycomics Assay will be performed on urine and blood samples
214946751|NCT05885776|DRUG|Pyrrolidine、trastuzumab、AI|Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pirotinib+trastuzumab+AI, and their postoperative pathological remission was evaluated.
214946752|NCT00914082|BEHAVIORAL|Self hypnosis|3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
214946753|NCT00135356|DRUG|Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)|Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
214946754|NCT00135356|DRUG|continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)|Protease inhibitor \[PI\] combination + 2 NRTIs
214946755|NCT00153816|DRUG|Calcium Carbonate|3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
214946756|NCT00153816|DRUG|Vitamin D3|1000 IU/daily; two tablets per day; 500 IU per tablet
214946757|NCT00153816|DRUG|placebo|placebo; two tablets per day
214946758|NCT04638556|DIAGNOSTIC_TEST|lncRNA detection|The lncRNAs in the plasma of three groups of patients will be tested.
214946759|NCT06180083|DRUG|Azelastine Hydrochloride/ Fluticasone propionate nasal spray|A single dose \[four sprays (two sprays in each nostril)\] of Azelastine HCL/ Fluticasone Propionate 137 mcg/50 mcg Nasal Spray
214946760|NCT06180083|DRUG|'DYMISTA' NASAL SPRAY|A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
214946761|NCT05327088|DRUG|Dexmedetomidine|Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.
214946762|NCT05327088|DRUG|Nalbuphine|Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
214946763|NCT05274087|DRUG|Risankizumab|Subcutaneous autoinjector
214946764|NCT00846690|DRUG|benzocaine|20% benzocaine., topical placement onto site, minimal amount, for 1 minute
214946765|NCT00846690|DRUG|TAC alternate gel|use 1 pump, place topically onto site, leave for 1-3 minutes
214946766|NCT02102672|DRUG|Trimetazidine|
214946767|NCT03278847|DIETARY_SUPPLEMENT|Received enteral (milk) feeds during therapeutic hypothermia|"In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~* Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~* This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~* This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)"
214946768|NCT03278847|DIETARY_SUPPLEMENT|Enteral (milk) feeds withheld during therapeutic hypothermia|Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
214946769|NCT03278847|DIETARY_SUPPLEMENT|Received parenteral nutrition during therapeutic hypothermia|"In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~* Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~* This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~* This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater)."
214946770|NCT03278847|DIETARY_SUPPLEMENT|Did not receive parenteral nutrition during therapeutic hypothermia|Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
214946771|NCT01408082|DRUG|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
214946772|NCT01408082|DRUG|Azasite|Azasite twice daily for 2 weeks
214946773|NCT01408082|DRUG|Dexamethasone|Dexamethasone twice daily for 2 weeks
214946774|NCT01408082|OTHER|Vehicle|Vehicle twice daily for 2 weeks
214946775|NCT01887288|DRUG|Capecitabine|650 mg/m\^2 PO b.i.d.
214946776|NCT01887288|DRUG|Digoxin|0.25 mg once daily
214342012|NCT05090501|BEHAVIORAL|High Intensity Circuit Training|The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.
214946777|NCT02883621|PROCEDURE|cap assisted upper endoscopy|A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.
214946778|NCT02883621|PROCEDURE|standard upper endoscopy|standard examination without using a cap
214946779|NCT01692002|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate capsule or tablet
214946780|NCT01692002|DIETARY_SUPPLEMENT|Sodium Chloride|Placebo capsule or tablet
214946781|NCT01692002|PROCEDURE|Oral glucose tolerance test|
214946782|NCT01692002|PROCEDURE|Intravenous glucose tolerance test.|
214946783|NCT05064553|DEVICE|Study CT/MRI Imaging|Subjects with negative ultrasound will be sent for a study CT/MRI.
214946784|NCT05064553|DEVICE|Standard of Care CT/MRI Imaging|Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.
214342013|NCT03424681|DRUG|Modafinil|Modafinil 300 mg by mouth daily
214946785|NCT05064553|DIAGNOSTIC_TEST|Oncoguard™ Liver Test|Subjects will have a blood sample collected for the Oncoguard™ Liver Test.
214946786|NCT05481918|PROCEDURE|Home-based therapy after ACL reconstruction|Five physiotherapeutic supervisions (individual) take place within the first 12-13 weeks after ACL reconstruction with focus on home exercises
214946787|NCT05481918|PROCEDURE|Standardized ambulant therapy after ACL reconstruction|16 physiotherapeutic supervisions (groups+ individual) take place within the first 12-13 weeks after ACL reconstruction.
214946788|NCT04002778|DIAGNOSTIC_TEST|Fine needle aspiration|
214342014|NCT03424681|OTHER|Placebo|Placebo
214342015|NCT04307186|DRUG|Gadoquatrane (BAY1747846)|Solution for IV injection, single dose
214342016|NCT04307186|DRUG|Gadobutrol (Gadovist/Gadavist)|Solution for IV injection, single dose
214342017|NCT05760066|OTHER|Resistance Training Preconditioning|Resistance training prior to disuse-induced atrophy followed by another period of resistance training
214342018|NCT05760066|OTHER|Control|Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
214342019|NCT04326491|DIAGNOSTIC_TEST|Breath Biopsy|Analysis of breath samples to identify volatile molecules specific to HCC
214342020|NCT01175226|DRUG|BTA798|BTA798 twice daily
214342021|NCT01175226|DRUG|Placebo|Placebo twice daily
214946789|NCT04002778|DIAGNOSTIC_TEST|Rapid on-site evaluation|
214946790|NCT01166854|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy
214946791|NCT06517797|DRUG|S1B-509 low dose|S1B-509 has multiple neurotransmitter activities
214946792|NCT06517797|DRUG|Placebo|matched pills to S1B-509
214946793|NCT06517797|DRUG|S1B-509 High Dose|S1B-509 has multiple neurotransmitter activities
214946794|NCT00799799|BIOLOGICAL|NK cells|NK cells infusion after immunosuppressive chemotherapy
214946795|NCT05485233|DEVICE|REDSCAR App|"Patients will be discharged after surgery at the time it is considered by the responsible physician. Prior to discharge, patients taking part in the study will follow the same protocol as any other patient treated in our institution. Written consent will be signed after complete explanation of the study protocol by the researcher at this moment. The patient will download the RedScar© application and the researcher will explain how it works and how to answer all the questions about the wound (redness, pain).~At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge."
214946796|NCT00253370|DRUG|BAY 43-9006|Given orally
214342022|NCT02953626|BEHAVIORAL|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
214342023|NCT00150631|DRUG|Candesartan|placebo controlled double blind
214342024|NCT06157931|BEHAVIORAL|Resilient Student Training intervention (ReST)|ReST consists of one individual 60-minute session and two 90-minute group-based sessions.
214342025|NCT00087074|DRUG|temsirolimus|Given IV
214342026|NCT00087074|OTHER|laboratory biomarker analysis|Optional correlative studies
214342027|NCT02854540|DEVICE|Hydrogel electrode-based iontophoresis|Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
214342028|NCT00438516|BEHAVIORAL|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
214946797|NCT00253370|DRUG|docetaxel|Given IV
214946798|NCT00253370|DRUG|cisplatin|Given IV
214946799|NCT06187649|PROCEDURE|breast reconstruction|breast expander/implant insertion for breast reconstruction following mastectomy
214946800|NCT06511271|OTHER|relaxation exercises|"The first 10-minute part of the CD audio recordings prepared by the Turkish Psychologists Association is about deep relaxation.~purpose; The second 30-minute part includes instructions for relaxation exercises; The last 30 minutes are just consists of relaxation music"
214946801|NCT06279494|DRUG|Sirolimus|Orally (concentration 5-10ng/ml) from -1 to +100d post haplo-HSCT
214946802|NCT06279494|DRUG|Abatacept|5mg/kg subcutaneous, -1/+5/+14/+28/+42/+56d post haplo-HSCT
214342029|NCT04997642|BEHAVIORAL|neuropsychiatric and cognitive testing questionnaires|"Demographic data such as race, sex, age Family History Risk Factor Questionnaire Hoehn and Yahr Stage UPDRS Parkinson's symptom checklist Medication list Neuropsychological Test Battery Behavioral Exams~* Geriatric Depression Scale Quality of Life Questionnaire~* PDQ-39, SF-12"
214946803|NCT06279494|DRUG|MMF|0.5g bid orally, from -3d to +60d post haplo-HSCT
214342030|NCT03702465|OTHER|DNA-based dietary intervention|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
214946804|NCT06279494|DRUG|ATG|2.5 mg/kg, from -5d to -2d
214342031|NCT03702465|OTHER|DNA-based dietary intervention using an app|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
214342032|NCT03702465|OTHER|Control arm|Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
214342033|NCT03634761|BEHAVIORAL|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
214342034|NCT03634761|BEHAVIORAL|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
214946805|NCT03872141|DIAGNOSTIC_TEST|Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer|Quantitative measures that include additional aspects of peripheral neuropathy, such as pain, thermal allodynia, numbness and tingling are needed. We propose to evaluate several pharmacodynamics biomarkers in patients before and during chemotherapy: changes in nerve conduction velocity and amplitude, quantitative sensory testing (QST), computer based cognitive assessment, and rate of drop-out from treatment. The tests from this list that best correlate with decreased CIPN would be added to EORTC QLQ-CIPN20 scores and will provide an early indication of CIPN and/or CICI.
214946806|NCT03637309|BEHAVIORAL|BeReady2Smile Video and App|BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
214946807|NCT03576209|BEHAVIORAL|healthy lifestyle program|Participants (intervention group) are following a 12 week health promotion program. They will count daily steps by pedometers and participate in weekly organised walks (within socio-cultural organisation)
214946808|NCT00565227|DRUG|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
214946809|NCT00565227|DRUG|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
214946810|NCT03832673|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
214946811|NCT03832673|DRUG|Epacadostat|Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
214946812|NCT02847910|PROCEDURE|the disposable tissue suction set|Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
214342035|NCT01266759|DRUG|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
214946813|NCT02847910|PROCEDURE|traditional metal instruments of abortion|Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
214946814|NCT05916131|BEHAVIORAL|Basic Education|2-week text message intervention for providing knowledge about hypoglycemia management and prevention.
214342036|NCT01266759|DRUG|Norethisterone Acetate tablets - 5mg|Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
214342037|NCT01617291|OTHER|Induced therapeutic hypothermia|induced therapeutic hypothermia
214946815|NCT05916131|BEHAVIORAL|Hypoglycemia Symptom Detection Training|10-week text message intervention for providing training on skills of detecting hypoglycemia symptoms.
214946816|NCT05916131|BEHAVIORAL|Education Plus|10-week text message intervention for helping people consider how they think of hypoglycemia.
214946817|NCT06271486|DRUG|Pregabalin 75mg|Group A (pregabalin group) received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.
214946818|NCT06271486|BIOLOGICAL|An epidural blood patch (EBP)|Group B (EBP group) received active therapy in the form of an EBP
214946819|NCT06271486|COMBINATION_PRODUCT|conservative treatment.|Group C (control group) received conservative treatment providing recommendations to the patients, including 24 hours of bed rest, stool softener, and consuming a minimum of 2.0 liters of fluid daily. Analgesics were permitted for pain relief depending on the patient's disease status.
214342038|NCT05769673|PROCEDURE|Placement of dental implant|Placement of a dental implant on the edentulous ridge
214342039|NCT05769673|PROCEDURE|Placement of stock healing abutment|Placement of stock healing abutment after implant has been placed on the edentulous ridge
214342040|NCT05769673|PROCEDURE|Placement of customized CAD/CAM healing abutment|Placement of customized CAD/CAM healing abutment after implant has been placed on the edentulous ridge
214342041|NCT00906308|DRUG|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
214342042|NCT00906308|DRUG|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
214946820|NCT02272153|OTHER|Egg refined grain|
214946821|NCT02272153|OTHER|Egg Whole Grain|
214946822|NCT02272153|OTHER|Cereal Refined grain|
214946823|NCT04404829|OTHER|Manual Therapy|"The first level of IMT was treated in this study: the objective is to harmonize the cranio-sacral and sacro-pelvic systems, as this is fundamental for maintaining good posture. The first therapeutic maneuvers should be focused on releasing of the sacrum and the pelvis. The first is considered a key area for the correct transmission of forces and loads from the lower limbs to the upper limbs and vice versa and shares the role of rigid elements for this purpose (bones) and tensile elements (muscles, ligaments, fascia) in the whole body. In this level. Compensatory injuries that the body has started after a primary injury are treated on this level, through the Fluidic Chains. The diagnosis of this level is performed by cranial somotopias. Practically all the treatment is carried out on the sacrum. The first step are the fuses, which are vibration zones which act as a protection system for the body. These points sometimes stop working, which interrupts the correct movement of the PRM."
214946824|NCT02289105|BEHAVIORAL|Mandatory active choice|the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
214946825|NCT04343053|OTHER|SARS-Cov-2 infection|blood sample withdrawal
214946826|NCT02299505|DRUG|ceritinib|The investigational drug ceritinib was supplied to the Investigators as 150 mg capsules, for oral administration.
214946827|NCT05128045|BEHAVIORAL|NEW-R|Eight session class on nutrition, physical activity, diet, and weight management
214946828|NCT05601297|OTHER|questationair|acceptability of women to partner violance
214946829|NCT03706001|OTHER|Psychotherapy|Psychotherapy has gained increasing acceptance as a major treatment option for mood disorders.
214946830|NCT05921422|OTHER|Cognitive assessment|"All participants will receive cognitive assessment with a core battery (CPCog) and a supplemental battery.~The core battery includes standardized tests of general cognitive functioning (intelligence) and visual-spatial abilities, as well as a questionnaire on executive functioning in daily life. The supplemental battery assesses attention, executive functioning, memory, fatigue, and symptoms of mental health issues (including symptoms of anxiety, depression, and attention deficit hyperactivity disorder/ADHD)."
214946831|NCT06537050|DRUG|JX2105|Oral capsule
214946832|NCT06537050|DRUG|Placebo|Oral capsule
214677766|NCT06443879|OTHER|Axillary brachial plexus nerve block: loss and return of sensation|Evaluating loss and return of sensation after axillary brachial plexus nerve block
214677767|NCT05571150|BEHAVIORAL|Dyad-focused strategy training intervention|"The program consists of five critical ingredients: shared decision making, self-selected goals, self-evaluation of performance, strategy development and implementation, and therapeutic guided discovery.~Trained research therapists will deliver the intervention to the survivor-caregiver dyads on a one-to-two base at the participants' home or in a quiet room at our collaborative hospitals. The therapist will ask the dyad to identify 3 to 5 shared participation goals and provide them the global strategy (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
214946833|NCT01906281|OTHER|Blood analyse, arthrocentesis, ultrasound examination|
214946834|NCT04656678|DEVICE|Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance|Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.
214677768|NCT05571150|BEHAVIORAL|Attention-control intervention|The topics of the education will cover: (1) secondary stroke prevention; (2) prevention and management of comorbidities; (3) managing emotions and behaviors; (3) medications and personal care; (4) finances and transportation; and (5) home and community-based participation.
214342043|NCT00906308|DRUG|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
214946835|NCT01308632|DRUG|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
214342044|NCT03087266|PROCEDURE|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
214946836|NCT04111861|OTHER|Singing|To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
214342045|NCT03087266|PROCEDURE|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
214342046|NCT03632356|BEHAVIORAL|Stepped Care Intervention (STEP)|A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
214342047|NCT03632356|DIAGNOSTIC_TEST|Screening only|Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
214342048|NCT03238001|DEVICE|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
214342049|NCT03165045|DRUG|Spiolto® Respimat®|6 weeks
214342050|NCT00759109|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
214946837|NCT05775861|DRUG|single shot interscalene brachial plexus block group with dexmedetomidine added to ropivacaine group|"For the single shot group with dexmedetomidine added to ropivacaine group (Group D), after local analgesia with 3 mL of 1% lidocaine, the block will be performed under ultrasound guidance using an in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany).~The perineural solution will be pre-mixed in a 30 mL syringe before the realization of the block.~A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block."
215075252|NCT06658262|OTHER|Tai Chi Exercises Alone|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. 5.Part the Wild Horse's Mane
214677769|NCT01104818|BEHAVIORAL|Siblings in foster care curriculum, Parent Management Training|Each year, approximately 800,000 youth are cared for in foster homes across the nation. About 70% of these youth are known to suffer from mental health and educational disabilities and frequently transition to adulthood with lifelong deficits. The majority of youth in foster care have siblings in care. It is anticipated that the proposed intervention will significantly improve key outcomes for youth in the study and will provide much needed information on best practices to help youth in foster care.
214677770|NCT04977999|OTHER|Exercise|Both arms/conditions use varying forms of exercise as the intervention.
214677771|NCT05760456|DRUG|DIDALA hard capsules|DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
214677772|NCT05760456|DRUG|Metformin|Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
214677773|NCT06511414|DEVICE|duramesh|Duramesh™ non-absorbable polypropylene suture is a hollow core, microporous, cylindrical suture made off in polypropylene filaments that are loosely braided and bonded to each other with heat and pressure
214342051|NCT00759109|OTHER|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
214342052|NCT01398605|OTHER|Exercise training|Different dose of exercise training
214486461|NCT06739395|DRUG|Lenvatinib Capsules|Usage and dosage: For patients weighing less than 60kg, the recommended daily dose of lenvatinib is 8mg once a day; For patients weighing ≥ 60kg, the recommended daily dose of lenvatinib is 12mg once daily. Lunvatinib should be taken at a fixed time every day, on an empty stomach or with food.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214677774|NCT06511414|DEVICE|Control|standard closure of fascia
214677775|NCT04086134|OTHER|Fruit Products|Fruit Products with the potential to improve constipation-related outcomes
214677776|NCT05134298|DRUG|Piperacillin/tazobactam, Meropenem|This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
214677777|NCT04705298|DIETARY_SUPPLEMENT|Prebiotic|Oligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
214677778|NCT04705298|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
214342053|NCT00931151|DIETARY_SUPPLEMENT|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
214342054|NCT00538161|OTHER|Ventilation strategy|
214342055|NCT05874258|OTHER|Real-PL training + Real-tES(tDCS)|PLtraining : around 40mins, tDCS: 20mins
214342056|NCT05874258|OTHER|Real-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
214342057|NCT05874258|OTHER|Placebo-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
214342058|NCT06497257|OTHER|Evaluating wrist flexor and extensor peak torque|Evaluation of wrist flexor and extensor peak torque
214342059|NCT06497257|OTHER|Evaluating functional disability|Evaluation of functional disability
214342060|NCT06497257|OTHER|Evaluating hand grip strength|Evaluation of hand grip strength
214342061|NCT06452615|DEVICE|Extracorporeal shockwave|The patients will receive 3000 to 6000 pulses every session by a radius of 15 mm probe (R15) at a frequency of 10 Hz, with energy gradually increasing from 1.4 to 1.5 bar
214342062|NCT02582905|DRUG|Placebo|Inactive ingredient matching the active comparators in appearance.
214342063|NCT02582905|DIETARY_SUPPLEMENT|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
214342064|NCT02582905|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
214342065|NCT05071261|DIAGNOSTIC_TEST|Hepatitis C Virus Screening|1-2 Blood Screenings for Hepatitis C Virus
214677779|NCT01845077|DRUG|2x500 mg Metformin (Glumetza)|2 tablets
214677780|NCT01845077|DRUG|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
214677781|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
214677782|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
214677783|NCT01845077|DRUG|3x500 mg Metformin (Glumetza)|3 tablets
214677784|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
214342066|NCT02690545|BIOLOGICAL|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10\^8 cells/m\^2 and 2x10\^8 cells/m\^2. Phase II patients will receive the dose level decided upon in Phase I.
214342067|NCT01449916|OTHER|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
214342068|NCT01866709|DRUG|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
214342069|NCT01866709|DRUG|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
214342070|NCT02138318|OTHER|High definition (HD) endoscopy|
214342071|NCT02138318|OTHER|chromoendoscopy|
214342072|NCT03158558|BEHAVIORAL|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson \& Fredman, 2012)
214342073|NCT00472914|DEVICE|portable surface electromyography|
214342074|NCT05771519|BEHAVIORAL|HIV disclosure intervention|This will be a biobehavioral intervention focused on helping men with HIV to disclose their HIV status to a personal confidant inclusive with specific focus on sexual partners.
214342075|NCT03791398|DRUG|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
214342076|NCT03791398|DRUG|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
214342077|NCT03791398|DRUG|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
214946838|NCT05775861|DRUG|continuous interscalene brachial plexus block|The block will be performed under ultrasound guidance using an in-plane approach with a 17G Tuohy needle (Arrow FlexBlock). A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
214946839|NCT00935064|DRUG|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
214946840|NCT00935064|OTHER|Placebo|Placebo orally one tablet once a day for 6 weeks.
214946841|NCT06201468|OTHER|Group A SCAPULAR MOBILIZATION|"Two treatment groups will receive interventions as follows:~Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks."
214342078|NCT01223664|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
214342079|NCT01223664|DRUG|Conserved therapy|Oral or intravenous administration
214342080|NCT00289796|BIOLOGICAL|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
214946842|NCT03943823|DRUG|Estrogen vaginal cream|Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
214946843|NCT03943823|DRUG|Trimo-San vaginal gel|Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
214946844|NCT01723020|DRUG|AMG 232|Given an an oral tablet in escalating doses.
214946845|NCT06253000|PROCEDURE|Cryoablation|Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium.
214946846|NCT06253000|PROCEDURE|Radiofrequency ablation|"Radiofrequency ablation of pulmonary veins according to the box isolation type using a non-fluoroscopic navigation system."
214342081|NCT00853450|DRUG|AZD6482|Single intravenous infusion during a maximum of 5 hours
214677785|NCT01845077|DRUG|2 x 500 mg Metformin (Glumetza)|2 tablets
214946847|NCT01211483|DRUG|U3-1287|Liquid 70 mg/mL for IV infusion at high dose or low dose
214946848|NCT01211483|DRUG|Erlotinib|Tablet 150 mg for oral administration
214946849|NCT01211483|DRUG|Placebo|Placebo liquid matching U3-1287 for IV infusion
214342082|NCT00853450|DRUG|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
214342083|NCT00853450|DRUG|ASA|75 mg orally once daily during 7 days in each treatment arm
214342084|NCT02803710|OTHER|Microbiological study|
214342085|NCT02137629|DRUG|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
214342086|NCT06381908|OTHER|Calorie-restriction with low carbohydrate|Calorie-restriction and low carbohydrate availability
214677786|NCT01845077|DRUG|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
214342087|NCT06381908|OTHER|Calorie-restriction with moderate carbohydrate|Calorie-restriction and moderate carbohydrate availability
214342088|NCT02207829|DRUG|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
214342089|NCT02207829|DRUG|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
214342090|NCT02207829|DRUG|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
214342091|NCT02207829|DRUG|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
214677787|NCT01845077|DRUG|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
214677788|NCT03032887|BEHAVIORAL|voice prompts|voice prompts on disinfectant dispenser
214677789|NCT03032887|BEHAVIORAL|agitation|Education, reminders and optimising materials
214677790|NCT00002466|DRUG|cyclophosphamide|
214677791|NCT00002466|DRUG|doxorubicin hydrochloride|
214677792|NCT00002466|DRUG|etoposide|
214677793|NCT00002466|DRUG|ifosfamide|
214946850|NCT01700543|PROCEDURE|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
214946851|NCT05748158|BEHAVIORAL|Weight loss|"A behavioral lifestyle program, up to 20 weeks in duration, based on interventions shown to be successful for weight loss such as the Diabetes Prevention Program (DPP), Action for Health in Diabetes (Look AHEAD), and Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy Study (CALERIE). Weekly sessions, led by experienced interventionists, will provide education and behavioral strategies for weight loss focused an energy-reduced diet and physical activity.~Participants must meet the following milestones to continue in the study:~* ≥ 2% weight loss anytime between 28 and 34 days after the start of the intervention~* ≥ 5% weight loss anytime between 140 and 146 days after the start of the intervention~* ≥ 7% weight loss by the end of 35 weeks~After achieving ≥7% weight loss followed by weight stability, participants are observed, without further intervention, for 52 weeks."
214946852|NCT03420807|DEVICE|MHRC|Evaluate the feasibility of detection of beta-amyloid plaques by using their spectral signature in autofluorescence or reflectance.
214946853|NCT02590874|DRUG|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
214946854|NCT02590874|DRUG|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
214946855|NCT05730153|BIOLOGICAL|advanced PRF|advanced PRF+ surgery
214946856|NCT04072991|OTHER|dietary therapy|participants will undertake a four week diet as part of their IBS treatment
214946857|NCT01007760|OTHER|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
214946858|NCT00805077|PROCEDURE|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
214946859|NCT00805077|OTHER|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
214946860|NCT06637436|BEHAVIORAL|Motivational Interviewing (MI)|This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting pre-exposure prophylaxis (PrEP) in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.
214946861|NCT06637436|BEHAVIORAL|Contingency Management (CM)|Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.
214946862|NCT02615392|BEHAVIORAL|Park Prescription|Please refer to the information included in the arm description.
214946863|NCT04351126|DRUG|Fludrocortisone 0.1 Milligrams (mg)|0.2-0.6 mg/day of fludrocortisone is prescribed
214946864|NCT04351126|DRUG|Bromocriptine|2.5 mg prescribed Vaginally twice daily
214946865|NCT02332564|OTHER|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
214946866|NCT00365209|OTHER|laboratory biomarker analysis|Correlative studies
214946867|NCT00365209|OTHER|pharmacological study|Correlative studies
214946868|NCT00365209|DRUG|curcumin|Given orally
214946869|NCT01236950|DRUG|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indication
214677794|NCT00002466|DRUG|vincristine sulfate|
214946870|NCT01236950|DRUG|Delmopinol mouthrinse|Commercial mouthrinse with manufacturer's use indication
214946871|NCT03631719|BIOLOGICAL|Wolbachia-carrying Ae.aegypti mosquitoes|Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).
214946872|NCT05467670|DRUG|Pembrolizumab|A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
214946873|NCT05467670|DRUG|ALX148|A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
214342092|NCT00766376|DEVICE|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
214677795|NCT00002466|PROCEDURE|conventional surgery|
214677796|NCT00002466|RADIATION|radiation therapy|
214677797|NCT00077233|DRUG|cetuximab|IV
214677798|NCT00077233|DRUG|5-FU|IV
214677799|NCT00077233|DRUG|irinotecan|IV
214946874|NCT05467670|DRUG|Doxorubicin|An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
214946875|NCT03453281|DRUG|Aflibercept Injection [Eylea]|Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
214946876|NCT01618110|DEVICE|Transcranial Magnetic Stimulation (Magstim, Rapid)|Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
214946877|NCT01618110|OTHER|Placebo Treatment|Sham coil (minimal magnetic field, same noise and feeling)
214946878|NCT01398410|DRUG|Rabeprazole|Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
214946879|NCT01398410|DRUG|Rabeprazole|Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
215075253|NCT06659107|PROCEDURE|Closed reduction and fixation by K- wires|Fixation by k-wires with mutual linking technique
215075254|NCT06608576|OTHER|Face-to-face standard treatment|Individualized early intervention treatment on physical therapy area as usual in the early intervention facilities once a month for two months. Instructions will be given to the parents for follow-up at home to stimulate the baby's motor development until next face-to-face session.
214342093|NCT06057415|PROCEDURE|HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation|Tactile-kinaesthetic and Oral sensorimotor Stimulation
214342094|NCT06223646|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
214677800|NCT00077233|DRUG|leucovorin|IV
214677801|NCT00077233|DRUG|oxaliplatin|IV
214677802|NCT00394914|DRUG|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
214677803|NCT00394914|DRUG|Placebo to Pleconaril|Placebo nasal suspension
214342095|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
214946880|NCT02235441|OTHER|Cardiopulmonary Exercise Test (CPET)|All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
214946881|NCT05861102|DRUG|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
214946882|NCT05861102|DRUG|Placebo|Participants will receive matching placebo orally twice daily for 16 weeks
214677804|NCT05916638|OTHER|blood sample|blood sample collection
214677805|NCT02092415|DEVICE|Application of a Junctional Tourniquet|All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
214946883|NCT04245202|DEVICE|HFNCOT|The patient will receive a high flow nasal of humidified oxygen, set between 2 to 25 l/min. The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.
214946884|NCT04245202|OTHER|St-FMOT|The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.
214677806|NCT03095183|DEVICE|Grape flavored Puritan Junior tongue depressor|
214677807|NCT03095183|DEVICE|Traditional unflavored Puritan Regular Tongue Depressor|
214677808|NCT04706182|PROCEDURE|Platelet-rich fibrin (PRF)|Platelet rich fibrin (PRF) serves as a structural reservoir of cytokines such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), platelet factor 4 (PF4) and vascular endothelial growth factor (VEGF) which aids in healing and preventing infection. PRF will be prepared as recommended by the manufacturer (Intra-Lock International) by centrifuging 20 mL of the subject's venous blood for 12 minutes at 2700 rpm, followed by compression. The fibrin clot will then be applied to the SSO site prior to fixation. The blood draw for the PRF will be performed approximately 15 minutes prior to fixation of the mandible. 20 mL will be drawn for each PRF side treated. The blood venous draw will be from the subject's arm or from an existing intra-venous line.
214677809|NCT04706182|PROCEDURE|Proximal segment grooving (PSG)|Proximal segment grooving is a mechanical method to create additional space within the inferior alveolar canal to allow the IAN to rest without compression or trauma. The surgeon uses a round or acrylic bur to cautiously remove any bony spicules, and remove cancellous bone in the proximal mandibular segment. PSG will be done by using an acrylic round bur on a surgical handpiece to remove 3 to 4 mm of cancellous bone where the IAN will passively rest into prior to fixation.
214677810|NCT06039254|DRUG|HRS-1780|Single dose in each arm
214946885|NCT02470403|DRUG|LIK066|LIK066 25 mg tablets
214342096|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
214342097|NCT00876317|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
214342098|NCT00876317|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
214342099|NCT03943810|OTHER|No intervention|There is no intervention
214946886|NCT02470403|DRUG|Placebo|Matching placebo tablets
214946887|NCT04241393|DRUG|Tavapadon tablet|Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily \[QD\] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)
214946888|NCT04241393|DRUG|Tavapadon [14C] suspension|Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of \[14C\] Tavapadon on Day 16
214946889|NCT04742309|DRUG|Pecs-2 block (single injection)|For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
214342100|NCT00222937|BEHAVIORAL|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
214946890|NCT04742309|DRUG|Paravertebral block (single injection)|For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
214946891|NCT04812795|OTHER|Culturally tailored anti-smoking messages|Anti-smoking messages that are culturally tailored for sexual minority women.
214946892|NCT04812795|OTHER|Non-culturally tailored interventions|Anti-smoking messages that are not culturally tailored for sexual minority women.
215075255|NCT06608576|OTHER|Telematic Support|The physiotherapist in charge of the telematic sessions will review and guide in real time through WhatsApp platform, the performance and active participation of the parents in the therapeutic activities being asked to follow-up at home in the face-to-face appointment, correcting, as necessary.
215075256|NCT06608784|DIAGNOSTIC_TEST|Electrocardiography|12-lead electrocardiography
215075257|NCT06607107|DRUG|mFOLFOX7 combined with Camrelizumab and apatinib|mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.
215075258|NCT06606535|DIAGNOSTIC_TEST|validated questionnaires|Validated questionnaires for climacteric symptoms
215075259|NCT06606535|DIAGNOSTIC_TEST|functional MRI|functional MRI
214342101|NCT00222937|BEHAVIORAL|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
214342102|NCT00365118|DEVICE|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
214342103|NCT01252459|RADIATION|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
214946893|NCT00948415|BEHAVIORAL|Evaluation of the Shape Up RI Campaign|The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
214946894|NCT01772680|DIETARY_SUPPLEMENT|Zinc Supplementation|25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
214946895|NCT04587401|PROCEDURE|normotensive patients|patients who do not have high blood pressure diagnosis and actual blood pressure is within the normal range
214946896|NCT04587401|PROCEDURE|patients with hypertension diagnosis|Patients who have high blood pressure diagnosis
214946897|NCT04587401|PROCEDURE|patients who do not know they are hypertensive but actual blood pressure is high|patients with preoperative high blood pressure, who do not know they are hypertensive
214946898|NCT03845101|BEHAVIORAL|CBT with virtual reality exposure therapy|The patients receiving the in virtuo exposure will be immersed using an Oculus Go head-mounted display, enabling viewing of 360° spherically camera recorded VR environments. The VR scenarios will thus be high-resolution 360° stereoscopic films, that are played around the viewer. For ease of use, the individual videos will be administered from an app that has been designed to be as intuitive to operate as possible. The patient will only have to put on the headset, adjust the focus and choose the desired environment by looking at it in the app. 360° video was chosen because it gives the most photorealistic visuals, while also being the cheapest to produce. The downside is that it does not allow direct user-interaction (e.g. the viewer cannot affect the environment in any way). To circumvent this, there are multiple junctions throughout the films where the actors will talk directly and unsolicited to the viewer while also allowing time for the viewer to respond.
214946899|NCT03845101|BEHAVIORAL|CBT in vivo|The therapeutic intervention is manual-based cognitive-behavioral CBT group therapy adapted from the approach of Turk, Heimberg \& Magee and Graske \& Barlow with worksheets from Arendt \& Rosenberg and inspiration from Bouchard et al. The treatment will consist of 14 weekly two-hour group sessions following the manual to ensure equal and uniform treatment for every patient throughout the study. Concurrent psychopharmacological treatment is allowed in both intervention arms.
214946900|NCT00899704|GENETIC|microarray analysis|
214946901|NCT00899704|GENETIC|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
214677811|NCT00392444|DRUG|sunitinib malate|Given orally
215075260|NCT06606535|DIAGNOSTIC_TEST|Optical Coherent Tomography Angiography|OCT angiography, macular and peripapillary scans
214342104|NCT01252459|RADIATION|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
215075261|NCT06607042|BEHAVIORAL|Psychotherapy|Psychotherapy according to the Berlin Dissexuality Therapy (BEDIT)
214677812|NCT00387660|DRUG|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
214342105|NCT01438190|DRUG|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
214342106|NCT01438190|DRUG|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
214342107|NCT01094275|DRUG|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
214677813|NCT00387660|DRUG|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
214677814|NCT01786616|DRUG|Formoterol|
214677815|NCT05323552|PROCEDURE|Laparoscopic TEP hernia repair without curare and without orotracheal intubation.|"All the techniques and protocols used for this monocentric study are standardized:~* The anesthesia is general, the anesthetic products administered are identical,~* ventilation is ensured by the use of a laryngeal mask airway, without curare administered~* the surgery is an extraperitoneal laparoscopy with an optical trocar under the umbilical and two operators with the placement of a preformed type 3G polypropylene prosthesis~* the analgesic protocol is free of opioids (Opioid Free Anesthesia - OFA)"
214677816|NCT03689725|OTHER|Music|Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
214946902|NCT00899704|OTHER|diagnostic laboratory biomarker analysis|
214946903|NCT00190372|BEHAVIORAL|Controlled diet|Controlled diet
214946904|NCT00190372|BEHAVIORAL|Self-hypnotic relaxation|Self-hypnotic relaxation
214946905|NCT02258269|OTHER|SQ|
214946906|NCT02258269|OTHER|Control|
214946907|NCT05381922|OTHER|blood laboratory investigation(coagulation profile- platelet function test)|blood laboratory investigation including ( complete blood count, coagulation profile, platelet function test, level of factor decrease
214946908|NCT00004866|DRUG|exatecan mesylate|
214946909|NCT03098017|OTHER|Short pasta (dry)|50g available carbohydrate portion of penne (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
214946910|NCT03098017|OTHER|Long pasta (dry)|50g available carbohydrate portion of spaghetti (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
214946911|NCT03098017|OTHER|Couscous|50g available carbohydrate portion of couscous (\~70g uncooked) will be cooked according to package instructions and served with 500mL water
214946912|NCT03098017|OTHER|Glucose|50g available carbohydrate portion of glucose monohydrate (\~55g) will be dissolved in 500mL water
214946913|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a subepithelial connective tissue graft
215075262|NCT03576404|OTHER|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
215075263|NCT00350272|DRUG|Elvucitabine|Elvucitabine 10 mg orally daily
215075264|NCT00350272|DRUG|Lamivudine|Lamivudine 300 mg orally daily
215075265|NCT00350272|DRUG|Tenofovir|Tenofovir open-label 300 mg orally daily
215075266|NCT00350272|DRUG|Efavirenz|Efavirenze open-label 600 mg orally daily
214342108|NCT01296958|DRUG|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
214342109|NCT01296958|BEHAVIORAL|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
214946914|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
214946915|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a collagen membrane
214342110|NCT06222255|PROCEDURE|Transanal Irrigation (TAI)|The combination of transanal irrigation (TAI) and Loperamide (Lopmin®) involves administering Loperamide orally, with a daily dosage of 2 mg for males (2 tablets once daily) and 1 tablet for females (1 tablet once daily). This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate symptoms associated with LARS (Low Anterior Resection Syndrome).
214342111|NCT00624117|BEHAVIORAL|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
214342112|NCT05435599|DIAGNOSTIC_TEST|Serum regucalcin level|During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
214946916|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a Cytoplast
214946917|NCT02917824|DEVICE|High-intensity IMT|30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
214946918|NCT02917824|DEVICE|Low-intensity IMT|30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
214946919|NCT03398239|DEVICE|Noninvasive mechanical ventilation|
214946920|NCT00265525|BEHAVIORAL|CardioFit|CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
214946921|NCT00904839|DRUG|BIBF 1120|BIBF 1120 100 and 150 mg capsules
214946922|NCT00904839|DRUG|BIBF 1120|BIBF 1120 100 and 150 mg capsules
214946923|NCT00904839|DRUG|mFolfox|standard i.v chemotherapy
215075267|NCT00534508|DRUG|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
214677817|NCT05260931|DIAGNOSTIC_TEST|Fetal echocardiography|Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function. Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas at maximum distension at end of systole. Atria and ventricle to-heart ratios calculated. Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV. MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated. Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
215075268|NCT02226198|DRUG|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
215075269|NCT02226198|DRUG|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
214342113|NCT05089539|DRUG|Angiotensin Receptor-Neprilysin Inhibition|Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.
214342114|NCT05089539|DRUG|Placebo|Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
214342115|NCT00993213|PROCEDURE|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
214342116|NCT00993213|OTHER|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
214342117|NCT04548882|DEVICE|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
214946924|NCT00904839|DRUG|Bevacizumab|100 mg/Kg solution , IV infusion
214946925|NCT00904839|DRUG|mFolfox 6|IV standard chemotherapy
214946926|NCT00904839|DRUG|bevacizumab|100 mg/4 ml solution
214946927|NCT01430624|BEHAVIORAL|PPRS|Video including information psychoeducation and modeling of adaptive behavioral coping strategies for use post-assault. Shown at time of post assault medical exam.
214946928|NCT01430624|BEHAVIORAL|PIRI|Video containing pleasant imagery and relaxation instruction information. Shown at time of post assault medical exam.
214946929|NCT04344535|BIOLOGICAL|Convalescent Plasma|450-550 mL of plasma containing anti-SARS-CoV-2 antibody titer ideally \> 1:320, but meeting minimum titer per FDA Guidelines for convalescent plasma.
214946930|NCT04344535|BIOLOGICAL|Standard Donor Plasma|450-550 mL of plasma with low titer to anti-SARS-CoV-2 antibodies
214946931|NCT02927041|DEVICE|transesophageal echocardiography (hTEE)|Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
214946932|NCT06254235|DRUG|The test octreotide microsphere|A single intramuscular dose of the test octreotide microsphere 30mg,
214946933|NCT06254235|DRUG|The reference octreotide microsphere|A single intramuscular dose of the reference octreotide microsphere 30mg
214946934|NCT01306435|OTHER|Laser|3-week treatment with three Laser sessions per week
214946935|NCT01306435|OTHER|Placebo Laser|3-week treatment with three Placebo Laser sessions per week
214946936|NCT01010958|DRUG|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
214946937|NCT03598582|DRUG|Epoetin Zeta|"Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol."
214946938|NCT06330220|DRUG|Aflibercept Injection [Eylea]|intravitreal injection
214946939|NCT01688141|OTHER|Enhanced management|Specialist nurses providing enhanced CKD management using NICE guidelines and enhanced access to secondary care.
214677818|NCT04444700|DRUG|Therapeutic anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
214677819|NCT04855721|DRUG|AUR101|Oral ROR-gamma inverse agonist
214677820|NCT04855721|DRUG|Placebo|Placebo
215075270|NCT00859339|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
214677821|NCT04914637|PROCEDURE|Cervical interlaminar epidural steroid injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 cc 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the rest room after the procedure and followed up for any complications.
214677822|NCT04914637|PROCEDURE|Dry needling|Dry needling will be applied to the active trigger points for the patients in this group. After cleaning the area of interest with an antiseptic solution, dry needling will be applied with the fast-in/fast-out technique for the active trigger point. During needle maneuvers, local contractions (local twitch response-LTR) are obtained and rapid needle movements are continued until the contractions end. Afterwards, the needle is removed and compression is applied to ensure hemostasis in the relevant area.
214677823|NCT04914637|PROCEDURE|Sham dry needling|Although the method of intervention is like dry needling, the only difference is that the blunt end of the needle is used and it does not penetrate the skin.
214677824|NCT00312377|DRUG|Docetaxel|infusion
215075271|NCT00859339|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
214342118|NCT00909259|DEVICE|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
214342119|NCT01823393|DRUG|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
214342120|NCT01823393|DRUG|NaCl|valvuloplasty is performed without heparin (placebo injection)
214342121|NCT02358889|BIOLOGICAL|hI-con1|Intravitreal injection of hI-con1 0.3 mg
214342122|NCT02358889|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
214342123|NCT02358889|OTHER|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
214342124|NCT03643523|DIAGNOSTIC_TEST|Albumine detection|Control of serum albumine levels in postoperatori of colorectal surgery
214342125|NCT00377663|BEHAVIORAL|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
214342126|NCT00435123|DIETARY_SUPPLEMENT|Nutritional Supplement ProStat 64 twice a day|
214342127|NCT00435123|DIETARY_SUPPLEMENT|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
214677825|NCT00312377|DRUG|Vandetanib|oral
214677826|NCT00872898|DRUG|Memantine - Extended Release (ER)|Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
214677827|NCT00872898|DRUG|Placebo|Placebo capsules, once daily, oral administration.
214677828|NCT01378754|DRUG|Fospropofol (Lusedra®) 6.5|Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
214677829|NCT01378754|DRUG|Fospropofol (Lusedra®) 10|Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
214677830|NCT01378754|DRUG|Fospropofol (Lusedra®) 12|Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
214677831|NCT01583192|PROCEDURE|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
214946940|NCT04110717|DEVICE|Vestal Device|Vestibular nerve stimulator
214946941|NCT04110717|DEVICE|Control Device|Control Device
214946942|NCT04110717|BEHAVIORAL|Hypocaloric Diet|Hypocaloric diet
214946943|NCT02129634|DEVICE|CB-PTA|
214946944|NCT02129634|DEVICE|DEB-PTA|
214946945|NCT01167634|BEHAVIORAL|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
215075272|NCT00859339|DRUG|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
215075273|NCT00859339|PROCEDURE|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
215075274|NCT01288612|DEVICE|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
214342128|NCT02566551|PROCEDURE|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
214342129|NCT02566551|DEVICE|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
214342130|NCT02566551|PROCEDURE|TURP|Bipolar transurethral resection of the prostate
214342131|NCT02566551|DEVICE|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
214342132|NCT01027793|DRUG|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
214342133|NCT01027793|DEVICE|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
214342134|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
214342135|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
214946946|NCT01167634|BEHAVIORAL|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
214946947|NCT01167634|BEHAVIORAL|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
214946948|NCT00553358|DRUG|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
214342136|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
214342137|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
214342138|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
214342139|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
214342140|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
214946949|NCT00553358|BIOLOGICAL|Trastuzumab|Therapeutic Monoclonal Antibody
214946950|NCT00553358|DRUG|Paclitaxel|antimicrotubule agent
214946951|NCT05292482|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
215075275|NCT01288612|DEVICE|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
214342141|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
214946952|NCT05292482|PROCEDURE|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
214946953|NCT03887156|DIAGNOSTIC_TEST|Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test|Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.
214946954|NCT06308536|PROCEDURE|bone powder + collagen membrane|Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane.
215075276|NCT00138047|DRUG|zinc supplementation|
215075277|NCT00871923|DRUG|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
214342142|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
214342143|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
214342144|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
214342145|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
214342146|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
214342147|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
214342148|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
214342149|NCT06360549|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation (TEAS) is a treatment that combines acupoint theory of traditional Chinese medicine with modern electrical stimulation techniques. It achieves the purpose of acupoint stimulation by applying a weak current to a specific part. TEAS operate just like ordinary electrodes with non-invasive, safe, portable, adjustable and other advantages.
214342150|NCT02379585|DRUG|Doxorubicin|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
214342151|NCT02379585|DRUG|cyclophosphamide|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
214342152|NCT02379585|DRUG|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
214677832|NCT00447213|DRUG|Insulin glargine|Patient specific, injected, daily, 24 weeks
215075278|NCT00871923|RADIATION|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
215075279|NCT05599451|OTHER|THS Blade device|Tobacco Heating System (THS) device with Blade technology for Blade tobacco stick use
214342153|NCT02379585|DRUG|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
214946955|NCT06308536|PROCEDURE|bone powder + collagen membrane + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
214946956|NCT06308536|PROCEDURE|bone powder mixed wih CGF gel + collagen membrane + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder mixed with CGF gel (CGF gel is cutted into granules ), and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
214946957|NCT06308536|PROCEDURE|bone powder + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder and cover the extraction wound with CGF membrane(CGF gel is pressed into a film)
214946958|NCT06184906|DIETARY_SUPPLEMENT|Weaning by Mediterranean Diet|Introduce solid foods typical of the Mediterranean Diet at weaning of infants
215075280|NCT05599451|OTHER|THS Induction Mono device|Tobacco Heating System (THS) device with Induction technology (combined Charger-Holder device for Induction tobacco stick use).
215075281|NCT05599451|OTHER|THS Induction Mid device|Tobacco Heating System (THS) device with Induction technology (device with Induction stick Holder for Induction tobacco stick use and separate Charger).
215075282|NCT05599451|OTHER|CIG|Subject's preferred brand of commercially available regular (non-mentholated) cigarettes. (Cigarettes are not provided by the study sponsor.)
214677833|NCT00447213|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
214677834|NCT00447213|DRUG|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
214677835|NCT05661565|OTHER|No intervention|We try to find an association between insulin resistance with ovarian hormonal and morphological characteristics in patients with polycystic ovarian syndrome
214677836|NCT02868502|DEVICE|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
214342154|NCT02379585|DRUG|Trastuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
214342155|NCT02379585|DRUG|Pertuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
214677837|NCT02868502|DEVICE|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
214677838|NCT02868502|DEVICE|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
214342156|NCT03387800|BEHAVIORAL|Basic health education messages|Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.
214677839|NCT02868502|DEVICE|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
214677840|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
214677841|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
214946959|NCT03887429|DRUG|SXC-2023|SXC-2023 oral capsules
214946960|NCT03887429|DRUG|Placebos|Matching Placebo oral capsules
214946961|NCT00776620|DRUG|Glimepiride 1mg Tablets|
214946962|NCT01197209|BIOLOGICAL|Ad-REIC/Dkk-3|REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
214946963|NCT03737266|PROCEDURE|Sonographically assisted breast surgery|Sonography
215075283|NCT01371149|OTHER|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
215075284|NCT03795207|COMBINATION_PRODUCT|SBRT + Durvalumab|"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"
215075285|NCT03795207|RADIATION|SBRT|SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
215075286|NCT01204229|BEHAVIORAL|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
215075287|NCT01204229|BEHAVIORAL|Brief Motivational Intervention (BMI)|Integrate drinking intervention
215075288|NCT01452139|GENETIC|Point-of-Care Genetic Testing|Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)
214677842|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
214677843|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
214946964|NCT03737266|PROCEDURE|Conventional breast surgery|Conventional
214677844|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
214677845|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
214677846|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
214677847|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
214677848|NCT01343719|DRUG|BI 661051|low dose tablet
215075289|NCT01452139|DRUG|Prasugrel|Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
214342157|NCT03387800|BEHAVIORAL|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
214342158|NCT05882539|DEVICE|endotracheal tube material,Bite block Material|Exposure factors associated with tracheal intubation in patients that may influence the occurrence of oral mucosa pressure injurie, such as the material and fixation of the tracheal tube, the patient's own nutrition, the level of tissue perfusion and relevant treatment factors.
214342159|NCT01976416|DRUG|Hydroxyurea|
214342160|NCT01976416|DRUG|Placebo|
214342161|NCT00906646|DIETARY_SUPPLEMENT|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
214677849|NCT01343719|DRUG|Placebo|solution for administration
214677850|NCT01343719|DRUG|BI 661051|medium dose tablet
214677851|NCT03578354|DRUG|4-aminopyridine|an oral drug to be swallowed
214677852|NCT03578354|DRUG|Atenolol|an oral drug to be swallowed
214677853|NCT03578354|OTHER|Placebo|a masked placebo to be swallowed
214677854|NCT00044044|DRUG|Lurasidone 20 mg|Lurasidone 20mg/day tablets
214677855|NCT00044044|DRUG|Lurasidone 40mg|Lurasidone 40mg/day tablets
214677856|NCT00044044|DRUG|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
214677857|NCT00044044|DRUG|Haloperidol 10mg|Haloperidol 10mg/day tablets
214342162|NCT00906646|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
214342163|NCT04483804|COMBINATION_PRODUCT|Endocrine therapy|Endocrine therapy
214342164|NCT01870700|DRUG|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
214486462|NCT06739395|DRUG|Pazopanib Pill|"Usage and dosage: In the safety introduction section, the initial dose of pazopanib is 400mg, and in the dose escalation queue, the dose of pazopanib is 600mg.The dosage for combined use will be adaptively adjusted by the researcher.~Administration method: Oral treatment once a day, with a cycle of 28 days.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided."
214677858|NCT00044044|DRUG|Placebo|Matching Placebo to Lurasdione and Haloperidol
214677859|NCT06664515|PROCEDURE|Ciro Costagliola|invert flap tecnique
214677860|NCT04472104|BEHAVIORAL|MBCT-S|Group mindfulness treatment for sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
214677861|NCT04472104|BEHAVIORAL|SexEd|Group sex education on sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
214677862|NCT02179398|BIOLOGICAL|Allocation to the Lab-score group|
214677863|NCT02179398|BIOLOGICAL|Allocation to the control group|
214677864|NCT02905773|OTHER|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
214677865|NCT02905773|OTHER|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
214677866|NCT03714841|OTHER|CRP|Knowledge of CRP value
214677867|NCT01383122|DEVICE|Pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
214677868|NCT01383122|DEVICE|Inactive pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
214677869|NCT02764619|DRUG|Spironolactone|
214677870|NCT02764619|DRUG|Placebo|
214677871|NCT01296386|BIOLOGICAL|IC84|IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
214946965|NCT05692804|DIAGNOSTIC_TEST|Mini Mental State Examination(MMSE),Montreal Cognitive Assessment ( MoCA),S100B ( protein S100 subunit beta) ,GFAP ( glial fibrillary acidic protein ),NSE ( neuron-specific enolase )|MMSE and MoCA will be applied preoperative,postoperative first day and fourth day S100B,GFAP and NSE will be measured in blood tests preoperative,postoperative second hour,postoperative 24. hour and postoperative 96. hour
214946966|NCT05956522|DRUG|Test Empagliflozin And Linagliptin Tablets|specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd
214946967|NCT05956522|DRUG|Reference Empagliflozin And Linagliptin tablets|specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH \& Co. KG
214946968|NCT01074255|DRUG|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
214342165|NCT01870700|DRUG|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
214342166|NCT01623219|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
214946969|NCT03246919|DRUG|Oxytocin|Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta
214946970|NCT03246919|DRUG|Placebo|Placebo will be administered after delivery of the placenta
214946971|NCT05239117|DEVICE|Plenhyage|"Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter."
214946972|NCT03233789|BEHAVIORAL|neurologic rehabilitation|in-patient rehabilitation of neurologic disorders
214946973|NCT06154174|DIETARY_SUPPLEMENT|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
214946974|NCT06154174|DIETARY_SUPPLEMENT|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
214946975|NCT06154174|DRUG|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
214946976|NCT03953625|OTHER|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
214946977|NCT00513266|BIOLOGICAL|bevacizumab|
214946978|NCT00513266|BIOLOGICAL|cetuximab|
214946979|NCT00513266|DRUG|fluorouracil|
214946980|NCT00513266|DRUG|irinotecan hydrochloride|
214946981|NCT00513266|DRUG|leucovorin calcium|
214342167|NCT01110239|PROCEDURE|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
214342168|NCT00821691|DRUG|Amantadin|Amantadin caps
214342169|NCT00821691|DRUG|Placebo|Placebo caps
214946982|NCT00513266|DRUG|oxaliplatin|
214946983|NCT00513266|OTHER|laboratory biomarker analysis|
214946984|NCT00513266|PROCEDURE|adjuvant therapy|
214946985|NCT00513266|PROCEDURE|biopsy|
214946986|NCT00513266|PROCEDURE|conventional surgery|
214946987|NCT00513266|PROCEDURE|neoadjuvant therapy|
214946988|NCT00166049|BEHAVIORAL|Family Partnership Intervention (FPI)|HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.
214946989|NCT00166049|BEHAVIORAL|Patient and Family Education|HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
214946990|NCT00166049|BEHAVIORAL|Usual care with educational material|Usual care with provision of printed educational material, provided once at baseline
214946991|NCT02620358|OTHER|T Tube for 120 minuts|Spontaneous Breathing Trial using T Tube for 120 minutes.
214946992|NCT02620358|OTHER|Pressure Support Ventilation of 8 cmH2O for 30 minutes|Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
214946993|NCT02585687|DEVICE|liver Perfusion MRI|
214946994|NCT02943785|DRUG|Edoxaban-based Regimen|15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)
214946995|NCT02943785|DRUG|VKA-based Regimen|Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
214946996|NCT05243667|OTHER|Wearable wrist Smart Device of Huami|"All enrolled patients underwent continuous monitoring by wearing huami blood oxygen testing equipment, and signed the informed consent for the clinical trial.Smart wrist wristbands will be issued, and patient information will be bound to the Migang Health platform, and clinical trial doctors will improve relevant personal information and clinical data.After binding to the APP Migu Health, you can start collecting and recording dynamic data such as peripheral blood oxygen saturation, heart rate, exercise steps, sleep data, etc., and upload the data once a day."
214946997|NCT01000181|OTHER|PET-CT with CuATSM|PET-CT with CuATSM
214946998|NCT01956864|DRUG|Vitamin D|Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
214946999|NCT00033306|DRUG|ixabepilone|
214947000|NCT00033306|DRUG|Fluoropyrimidine|
214947001|NCT00033306|DRUG|Irinotecan|
214947002|NCT04103515|DEVICE|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
214947003|NCT04103515|DEVICE|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
214947004|NCT01325571|DRUG|Tacrolimus capsule|oral
214947005|NCT01325571|DRUG|Placebo|oral
214947006|NCT02679456|DRUG|SCY-078|
214947007|NCT02679456|DRUG|Fluconazole|
214947008|NCT01281956|DRUG|PRX-00023|PRX-00023 (Selective 5HT1A agonist)
214947009|NCT01281956|DRUG|Placebo|Placebo
214947010|NCT03170609|BIOLOGICAL|Multivalent group B streptococcus vaccine|Various formulations at three dose levels
214947011|NCT03170609|BIOLOGICAL|Placebo|Saline Control
214947012|NCT05606770|BEHAVIORAL|Structured Exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity. Classes will gradually progress in intensity throughout the program. Classes will include a full body warm up followed by a circuit of eight strengthening exercises. This will be repeated for increasing sets and adding resistance through the use of resistance bands . Exercises will involve simple full body exercises and movements for each major muscle group. This will ensure that exercises that can be completed regardless of possible unilateral weakness or physical impairment. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
214947013|NCT05606770|BEHAVIORAL|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
214947014|NCT02929615|OTHER|Hematopoietic stem cell transplantation|
214947015|NCT00359177|DRUG|GW679769|GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
214947016|NCT03191123|PROCEDURE|hepatic resection|The aim of this intervention is to reach curative resection.
214947017|NCT03191123|PROCEDURE|TACE|The aim of this intervention is one of the palliative treatment.
214947018|NCT01033708|BEHAVIORAL|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
214947019|NCT02452255|DRUG|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
214947020|NCT02452255|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months
214947021|NCT02452255|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
214947022|NCT06229899|DIAGNOSTIC_TEST|Serum follistatin levels|blood samples are taken
214947023|NCT02572856|DEVICE|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
214947024|NCT00460356|OTHER|Laboratory Biomarker Analysis|Correlative studies
214947025|NCT00460356|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
214947026|NCT02156063|DRUG|NT100|
214947027|NCT02156063|DRUG|Placebo|
214947028|NCT05911672|DEVICE|PRICE|Working closely with 51 cancer patients, medical and paramedical personnel, we co-designed an intelligent personalized mobile application to first collect ecologically momentary assessment data on symptoms like pain and fatigue and Health-Related Quality of Life and subsequently enhance symptom management of cancer patients at home. The full description is available here: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa\_token=tC5fSN8-k5EAAAAA:56\_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
214947029|NCT00072748|DRUG|EKB-569|
214947030|NCT01903759|OTHER|Blood samples|
214947031|NCT00802958|DRUG|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
214947032|NCT00802958|DRUG|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
214947033|NCT04283110|DRUG|intrthecl midazolam|midazolm as as adjuvant in spinal anesthesia
214342170|NCT06295133|BEHAVIORAL|Stress|The stress management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators of stress will be recorded to assess the progress of each student.
214342171|NCT02897141|DEVICE|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
214342172|NCT02897141|DEVICE|Control App|The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
214342173|NCT02369133|DRUG|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
214342174|NCT02369133|DRUG|Placebo|
214947034|NCT02463006|DRUG|Porous variant of Bioactive Glass.|Flap surgery with Porous variant of Bioactive Glass.
214947035|NCT02463006|DRUG|Non porous variant of Bioactive Glass.|Flap surgery with non-Porous variant of Bioactive Glass.
214947036|NCT05634642|DEVICE|Ultrasound|Using ultrasound to measure the diameter of distal radial artery
214947037|NCT00264030|DEVICE|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
214947038|NCT00264030|OTHER|PTCA|PTCA
214947039|NCT00146900|PROCEDURE|Cognitive Behavioral Therapy|12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)
214947040|NCT00146900|PROCEDURE|Cognitive Therapy|12 weekly 1.5 hours weekly session of cognitive therapy without exposure
214947041|NCT00146900|DRUG|Escitalopram|Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg
214947042|NCT00146900|OTHER|Placebo|Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
214947043|NCT01490697|DRUG|Mifepristone|1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.
214947044|NCT01490697|DRUG|d-Cycloserine|100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.
215075290|NCT06109051|DEVICE|EndeavorOTC|EndeavorOTC™ is an over-the-counter digital therapeutic designed to improve attention function, ADHD symptoms, and quality of life in users 18 years of age and older with primarily inattentive or combined-type ADHD, who have been identified as having a significant attentional impairment. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is not intended to be a replacement for any form of ongoing treatment. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
214947045|NCT01490697|DRUG|Placebo-matching Mifepristone|Placebo-matching mifepristone tablets
214947046|NCT01490697|DRUG|Placebo-matching d-Cycloserine (DCS)|Placebo-matching DCS capsules
214342175|NCT00080223|DRUG|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
214342176|NCT00400413|PROCEDURE|fMRI|
214342177|NCT02936076|OTHER|Exercise intervention|
214342178|NCT02936076|OTHER|Delayed exercise intervention|
214342179|NCT03798808|OTHER|Consumption of fruits, vegetables and dairy products|Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
214342180|NCT01879397|DEVICE|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam~* ARFI based images of the carotid artery and plaque~* Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
214947047|NCT01585610|BEHAVIORAL|DVD Intervention|Four theory-based intervention DVDs will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. DVDs focus on motivating smoking cessation among people with mobility impairments using Behavioral Activation as the primary theoretical construct. Short (\< 5 min.) phone calls will also be placed to each participant in between DVD deliveries and after receipt of DVD 4.
214947048|NCT01585610|BEHAVIORAL|Standard Care Printed Materials|Four sets of standard smoking cessation printed materials will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. Short (\< 5 min.) phone calls will also be placed to each participant in between materials deliveries and after the 4th and final set is sent by mail.
214947049|NCT06230029|OTHER|Music listening|Music will be played through individual headphones (BOSE AE2®). The headphones give the impression of personalized music that only the patient can hear. Patients will have a mask over their eyes to limit visual aggression. The songs will be pre-recorded on a digital tablet (Samsung Galaxy®) allowing the broadcasting of music programs. Patients will have the choice to listen to a song according to their musical preferences among 16 different musical styles. The volume will be adapted to the level that suits the patient.
214947050|NCT00090584|DRUG|Tolterodine|4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
214947051|NCT00090584|BEHAVIORAL|Behavioral training|Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
214342181|NCT05223543|DIAGNOSTIC_TEST|Blood sample|extraction of blood samples from women undergoing ovarian cystectomy or oophorectomy due to suspected Dermoid cyst and analysing plasma for antibodies
214342182|NCT00917059|DRUG|Escitalopram|Fixed dose of 10 mg per day
214947052|NCT05248724|COMBINATION_PRODUCT|periarticular infiltration (50ml) with Ropivacaine Hydrochloride 10 MG/ML (200 mg) + ketorolac tromethamine 30 mg/ml (30 mg) + adrenaline 1mg/ml (300 microgram) + morphine hydrochloride 10mg/ml (5 mg)|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride ,150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride , 30 mg of ketorolac tromethamine, 300 micrograms of adrenaline and saline 0.9% till reaching 50 ml of volume. Half of the solution was injected into the proximal hamstring stump. The surgical team closed the wounds and injected the other half of the intervention into the subcutaneous tissue in the distal wound and portals. There was not any medication introduced inside the articulation. Patients of the placebo group were treated in the same way, but the solution injected was 50 ml of saline 0.9%.
214947053|NCT05248724|DRUG|placebo|50 ml of 0.9 saline
214947054|NCT00270231|DRUG|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
214947055|NCT00270231|DRUG|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
214947056|NCT01388504|DRUG|sodium nitrite|sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
214947057|NCT01388504|OTHER|Placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
214947058|NCT04456166|DIETARY_SUPPLEMENT|noNPO|"Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting will be asked to be enrolled into the study.~Before induction of general anesthesia, all patients were evaluated the gastric volume under ultrasonography."
214947059|NCT01461252|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
214947060|NCT01461252|PROCEDURE|Radiation|Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
214947061|NCT00129181|DRUG|cabergoline|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
214947062|NCT00129181|DRUG|carbidopa/levodopa|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
215075291|NCT02120495|PROCEDURE|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
214342183|NCT00917059|DRUG|Bupropion XL|Fixed dose of 150 mg per day
214342184|NCT05567640|BEHAVIORAL|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
214342185|NCT05567640|BEHAVIORAL|Space for depression|Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
214342186|NCT05567640|BEHAVIORAL|Space for resilience|This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
214342187|NCT03864497|PROCEDURE|Myocardial perfusion imaging|
214677872|NCT06487884|OTHER|escape games|A suitable day and time will be determined in the curriculum of the students in the intervention group and escape games consisting of various games involving intravenous drug administration will be played. Games will be played within the determined game guidelines. Each group will play the games at the stations respectively and get a clue at the end of each game. After completing the last game, the time it takes to find the password and complete the game will be recorded. After all groups complete the game, the group that completes the games in the shortest time will win the game and receive the prize in the chest.
214677873|NCT06037655|DRUG|Total Neoadjuvant Treatment|Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
214342188|NCT05204134|DEVICE|Automated Insulin Delivery Settings Initialization and Adaptation Algorithm|All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
214342189|NCT01871948|OTHER|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
214342190|NCT03135522|DRUG|Zinc Acetate 50 Mg Oral Capsule|"* Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
214342191|NCT03135522|DRUG|Placebo oral capsule|"* Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
214342192|NCT05999409|OTHER|practice on birth simulator|making attempts at labor
214342193|NCT06573580|OTHER|The essential public health service（EPHS）for COPD|"Each group plans to recruit 3,000 participants. For the intervention group, the community-based management includes adding COPD management-related content to the primary public health service. This includes: Providing at least four follow-ups during the project at the 3rd, 6th, 9th, and 12th months. During each follow-up, patients must complete the COPD Patient Follow-up Questionnaire and receive oral health education and targeted clinical advice from the general practitioner (GP). In addition, the GPs must also distribute educational booklets and materials, record symptom assessment results and acute exacerbation situations, and provide targeted clinical advice and clinical decisions to the COPD patients according to the checklist of Chinese guideline for management of COPD in primary care. At the baseline and the last follow-up, patients need to undergo a routine physical examination, pulmonary function test, and bronchodilator test at their community health centers"
214947063|NCT00129181|PROCEDURE|DATscan and SPECT imaging|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
214947064|NCT00638209|DRUG|Human insulin|
214947065|NCT00638209|DRUG|Saline|
214947066|NCT02409381|DRUG|Motore|250 mg
214947067|NCT02409381|DRUG|Alivium|600 mg
214947068|NCT04764786|OTHER|EVOO+POLY|a test meal seasoned with extra virgin olive oil rich in polyphenols
214947069|NCT04764786|OTHER|OO-POLY|a test meal seasoned with olive oil poor in polyphenols
214342194|NCT06574308|DIAGNOSTIC_TEST|Blood cells classification|Comparison of the classification of peripheral blood and bone marrow cells with optical microscope reading with pre-classification using Scopio technology (AI based)
214947070|NCT06991686|DIAGNOSTIC_TEST|Blood samples|blood sample for CBC and procalcitonin
214947071|NCT06991686|DIAGNOSTIC_TEST|blood sample|blood sample for procalcitonin and CBC
214947072|NCT05307185|DIETARY_SUPPLEMENT|Tritordeum-based food|Diets will last 12 weeks with intermediate nutritional checks every four weeks before returning to the final study visit.
214947073|NCT01969084|DRUG|Linagliptin|
214947074|NCT01969084|DRUG|Placebo|
214947075|NCT01969084|OTHER|Microcirculation testing|The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
215075292|NCT04734522|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
214342195|NCT03281811|DRUG|Aminolevulinic Acid Hydrochloride|Given topically
214947076|NCT01969084|OTHER|Macrocirculation testing|Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
214947077|NCT01969084|OTHER|MRI Scans|Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
214947078|NCT06020339|OTHER|The midwife-led continuous care model (MLCC)|"Continuity of midwife-led care has been defined as care in which the midwife is the leading professional in the planning, organization and delivery of care given to a woman from the initial assessment of the pregnant woman to the postpartum period.~ELSBM; It is the same midwife or midwife group providing the care and counseling needed by the woman during pregnancy, childbirth and postpartum period. In this care model, the midwife is the leading health care specialist who is responsible for planning and arranging the care given to women in the antenatal, natal and postnatal period. MLCC is woman-centered and is based on the idea that pregnancy and childbirth are normal life events.~This care model includes education, counseling and care according to the needs of the woman. It promotes vaginal delivery as a normal process and advocates minimal interventions. Continuity of midwifery-led care is associated with superior outcomes for women and infants than other models of care."
214947079|NCT01037036|DRUG|Latanoprost Punctal Plug Delivery System|To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
214947080|NCT01037036|DRUG|Xalatan|Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
214947081|NCT06869551|DRUG|Deucravacitinib|Specified dose on specified days
214947082|NCT06869551|OTHER|Placebo|Specified dose on specified days
215075293|NCT04900337|DRUG|AMOR 18 Powder & Inhalation|AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
215075294|NCT04900337|DRUG|Placebo|Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
214342196|NCT03281811|DRUG|Photodynamic Therapy|Undergo PDT
214342197|NCT03281811|OTHER|Quality-of-Life Assessment|Ancillary studies
214342198|NCT03281811|RADIATION|Radiation Therapy|Undergo RT
214342199|NCT02605590|DRUG|AIR DNase|
214342200|NCT02605590|DRUG|Placebo|
214947083|NCT07014046|OTHER|Simple bed exercises|The participants will be asked to perform exercise by lying flat on bed in supine position with their eyes look towards to the ceiling of the ward and start focusing on deep breathing exercises with slow inhalations and exhalations. These exercises aim to achieve regular pattern of abdominal muscles and improve the coordination between breathing, abdominal muscle contractions and colonic propulsions. After one-minute deep-breathing exercises, intervention group participants will be asked to pull both knees towards chest in return and turning body from one side to another while lying on bed.
214947084|NCT06681896|OTHER|MICROFIT - personalised high intensity interval training exercise rehabilitation and dietary advice|"MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet.~Phase 1 - Induction (8 weeks) Exercise: Twice-weekly 1-hour personal trainer (PT) supervised exercise sessions. 45 minute homework exercise session once a week.~Diet: 1-hour educational session with a dietician, followed by two 30-minute follow up sessions.~Phase 2 - Consolidation (10 weeks) Exercise: Once weekly 1 hour PT sessions, two 45 minute homework sessions once a week.~Diet: 30-minute sessions every 5 weeks.~Phase 3 - Maintenance (6 weeks) Exercise: Supervised 1 hour PT sessions once every 3 weeks, 45-minute homework sessions three times a week.~Diet: one final 30 minute session after week 3."
214947085|NCT07015866|OTHER|Guided therapy group|Participants will engage in guided group discussions over five sessions. Each session will include a guided discussion focusing on self-care topics such as sleep hygiene, dental hygiene, nutrition, and personal interests and hobbies. The first individual session, 'Sleep hygiene, will be used to educate the participants of the importance of sleep and strategies to improve sleep quality. The four other sessions will be group-based (with four participants per group), focusing on dental hygiene, nutrition, personal interests and hobbies and general well-being and reflection. A session will be conducted each week over five weeks, with each session lasting 60 minutes. All sessions will be conducted in a room in the Urology Centre.
214947086|NCT07015866|OTHER|Creative arts therapy|"The intervention will be offered throughout five sessions. Session themes are as follows: 'bridge drawing', 'analogue drawing', 'life-sized body outline', a 'free session' to allow patients to express their feelings, and a final review with the art therapist in which all sessions will be brought to a conclusion.~The first individual session, 'bridge drawing', will be used to introduce the creative arts therapy approach and to elaborate on this project. The four other sessions will be group-based (with four participants per group), providing a supportive and communal environment where participants can engage in creative expression alongside others who may have had similar experiences or challenges. A session will be conducted each week over five weeks, with each session lasting 60 minutes. All sessions will be conducted in a room in the Urology Centre that has been equipped and prepared for the intervention."
214947087|NCT01288092|DRUG|BEZ235|
214947088|NCT06624865|OTHER|Blood and stool sampling|Blood and stool sampling
214947089|NCT07026110|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
214947090|NCT07026110|DRUG|[68Ga]Ga-NOTA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RT4 injection.
214947091|NCT07026110|DRUG|[18F]F-RESCA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
214677874|NCT04018287|OTHER|HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)|"HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation."
214342201|NCT03099382|BIOLOGICAL|camrelizumab|Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks
214342202|NCT03099382|DRUG|Docetaxel|Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks
214342203|NCT03099382|DRUG|Irinotecan|Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks
214342204|NCT05227079|DEVICE|MultCROC multibite forcep|Alligator style 2.4 mm diameter jaws that can hold up to six samples in one pass through endoscope.
214342205|NCT05227079|DEVICE|Conventional double bite forcep|Use of conventional double bite forceps that can store up to two specimens in one pass through endoscope
214342206|NCT00499369|DRUG|irinotecan hydrochloride|Given IV
214342207|NCT00499369|DRUG|leucovorin calcium|Given IV
214342208|NCT00499369|DRUG|fluorouracil|Given IV
214342209|NCT00499369|BIOLOGICAL|cetuximab|Given IV
214342210|NCT00499369|BIOLOGICAL|bevacizumab|Given IV
214342211|NCT00296101|BEHAVIORAL|Physical Activity|
214342212|NCT02825394|OTHER|anti-Xa activity point-of-care testing (aXa-POCT)|
214342213|NCT02825394|OTHER|ecarin clotting time point-of-care testing (ECT-POCT)|
214342214|NCT05181605|DRUG|Folfirinox and Stereotactic Body Radiotherapy|Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
214342215|NCT02528292|PROCEDURE|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
214342216|NCT02528292|DRUG|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
214342217|NCT01383941|DRUG|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
214342218|NCT01802411|DRUG|EXPAREL 266 mg|
214342219|NCT01802411|DRUG|Placebo|
214486463|NCT06739395|DRUG|Palbociclib Pill|Usage, dosage, and administration method: 100mg, orally administered once daily for 21 consecutive days, followed by a 7-day discontinuation; Every 28 days is a treatment cycle.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214947092|NCT07026110|DRUG|[18F]F-RESCA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RT4 injection.
214947093|NCT07026110|DRUG|[18F]F-RESCA-EPCD6|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-EPCD6 injection.
214947094|NCT07026110|DRUG|[68Ga]Ga-NOTA-EPCD6|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-EPCD6 injection.
214947095|NCT07026955|OTHER|colorectal cancer in patients over 50 years of age|description
214947096|NCT07027709|DEVICE|BeautiBond Xtreme pretreatment with BeautiLink SA cementation|Laminate veneers fabricated from HC hard blocks were pretreated on the internal surface with BeautiBond Xtreme, then bonded to tooth structure using BeautiLink SA self-adhesive resin cement. The tooth surfaces were also treated with BeautiBond Xtreme. Veneers were digitally designed and milled, then cemented following a standardized clinical protocol.
214947097|NCT07027709|PROCEDURE|HC Primer pretreatment with BeautiLink SA cementation|Laminate veneers fabricated from HC hard blocks were pretreated on the internal surface with HC Primer, then bonded to tooth structure using BeautiLink SA self-adhesive resin cement. The tooth surfaces were treated with BeautiBond Xtreme. Veneers were digitally designed and milled, then cemented following the same clinical protocol used in the experimental grou
214947098|NCT07027397|OTHER|Exercise|All participants will conduct a 2-day-a-week resistance training (RT) routine using the velocity-based method in the leg press exercise for one year. A tailored and constant intensity will be performed at 60% of the theoretical maximal isometric strength (F0) during the training intervention. Participants will conduct 3-4 sets, individualizing the repetitions numbers until they reach a velocity loss of 10-20%. A rest of 2 minutes was imposed between sets. A standardized warm-up will preced all RT session as follows: 4 minutes walking at usual gait speed and 6 minutes performing dynamic balance exercises.
214947099|NCT05020405|PROCEDURE|Immediate implant placement and ARS with GBR and SMV|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with SMV
214947100|NCT05020405|PROCEDURE|Immediate implant placement and ARS with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
214947101|NCT07027124|DRUG|Darolutamide|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg for 16 weeks prior to RP.
214947102|NCT07027124|DRUG|Pembrolizumab|Administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 5 cycles prior to RP (Neoadjuvant phase, study weeks 1, 4, 7, 10, 13 \& 16), and every 3 weeks, for a total of 12 cycles post-RP (Adjuvant phase, study weeks, 19, 22, 25, 28, 31, 34, 37, 40 43, 46, 49, \& 52). Total Pembrolizumab cycles=17
214947103|NCT07027124|DRUG|Lupron|Androgen deprivation, GnRH agonist Leuprolide will be administered at a dose of 22.5 mg SQ (Eligard)/IM Lupron every 12 weeks prior to RP (Study weeks, 1 and 13).
214947104|NCT07027774|DRUG|Henagliflozin 5 mg Group|Henagliflozin 5 mg once daily plus KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）
214947105|NCT07027774|DRUG|Henagliflozin 10 mg Group|Henagliflozin 10 mg once daily plus KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）
214947106|NCT07027774|DRUG|Conventional therapy group|KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）
214947107|NCT07027618|BEHAVIORAL|AI-based Software for Personalized End-of-Life Care|This intervention involves the use of an AI-powered software system designed to personalize end-of-life care for elderly patients. The software continuously monitors vital signs and behavior through wearable sensors, sends smart medication reminders, issues preventive alerts to care providers, delivers customized care plans, and provides psychological and social support through communication features.
214947108|NCT00416689|PROCEDURE|assessment of therapy complications|
214342220|NCT04902105|DRUG|ecopipam HCL|oral tablets
214342221|NCT04902105|DRUG|Mefenamic acid|oral capsules
214342222|NCT04902105|DRUG|Divalproex Sodium ER|oral tablets
214342223|NCT00389935|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
214677875|NCT01137435|BIOLOGICAL|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
214947109|NCT00416689|PROCEDURE|quality-of-life assessment|
214342224|NCT04471181|DEVICE|Endovascular repair of ruptured abdominal aortic aneurysm (EVAR) with Medtronic Endurant|Endovascular repair (EVAR) of ruptured abdominal aortic aneurysms with Medtronic Endurant II, and IIs device
214342225|NCT05522036|COMBINATION_PRODUCT|Metvix + Dermaris|Photodynamic Therapy
214342226|NCT03570736|PROCEDURE|Minimal invasive surgical technique|Minimal Invasive Surgical technique using either Modified Papilla Preservation or Simplified Papilla Preservation Technique.
214342227|NCT03570736|PROCEDURE|Open Flap Debridement|Buccal and lingual intrasulcular incisions will be done extending at least one tooth mesial and distal to the tooth associated with the intrabony defect. Full thickness mucoperiosteal flaps will be reflected to allow access for debridement of the defect.
214342228|NCT00249145|DRUG|risperidone|
214947110|NCT05998317|DRUG|At-night Dexamethasone|Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
214947111|NCT05998317|DRUG|At-induction Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
214947112|NCT03438734|DEVICE|Regional cerebral oxygen saturation|Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
214947113|NCT03438734|DEVICE|Bispectral Index (BIS)|The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.
214342229|NCT01577394|OTHER|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades"
214342230|NCT05042622|DEVICE|Cytokine adsorber filter|• Intervention group #1 a cytokine adsorber will be used (30 patients): patients on ECMO - subgroup A; septic patients - subgroup B.
214342231|NCT05042622|DEVICE|Extracorporeal hemoperfusion cartridge|• Intervention group #2 an extracorporeal hemoperfusion cartridge will be used (30 patients): patients on ECMO - subgroup C, septic patients - subgroup D.
214342232|NCT03407352|BEHAVIORAL|Active Video Game Play|60 minutes of active video game play at a moderate intensity
214342233|NCT03407352|BEHAVIORAL|Passive Video Game Play|60 minutes of passive video game play
214947114|NCT01236326|PROCEDURE|Laparoendoscopic single site donor nephrectomy|Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy
214947115|NCT01236326|PROCEDURE|Conventional laparoscopic donor nephrectomy|Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
214947116|NCT03916731|DEVICE|STARgraft AV|Implant of STARgraft AV shunt in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
214947117|NCT03916731|DEVICE|ePTFE AV graft (control)|Implant of standard ePTFE AV shunt as a control in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
214947118|NCT00437827|OTHER|Star*D algorithm|Standard of care based upon the therapies selected in the Star\*D study.
214947119|NCT00437827|OTHER|rEEG-guided therapy|An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.
214947120|NCT02985073|DEVICE|Veritas®|Biologic mesh
214947121|NCT02985073|DEVICE|TIGR®|Non biologic mesh
214947122|NCT04761081|BEHAVIORAL|Habitual physical activity assessment|7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
214947123|NCT05135884|BEHAVIORAL|Standard inpatient stroke rehabilitation|According to Swiss national guidelines and local protocols
214947124|NCT01481584|DIETARY_SUPPLEMENT|Protein drink - protein isolate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
214947125|NCT01481584|DIETARY_SUPPLEMENT|Protein drink - protein hydrolyzate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
214947126|NCT06618443|OTHER|Scapular mobilization with movement|The treatment consisted of scapular mobilization with arm movement in all directions for 15 min/session for 3 sessions/week for 4 weeks. Scapular mobilization included scapular upward glide and downward glid. Scapular upward glide was performed with shoulder adduction and extension, while scapular downward glide was performed with shoulder abduction and flexion.
214342234|NCT06533306|PROCEDURE|Surgery for cryptorchidism.|Patients previously operated on for cryptorchidism.
214342235|NCT02670629|PROCEDURE|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
214342236|NCT02670629|PROCEDURE|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
214342237|NCT00165438|PROCEDURE|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
214342238|NCT00165438|PROCEDURE|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
214342239|NCT05360238|BIOLOGICAL|MB-106|T-cells derived from autologous leukapheresis that are genetically modified.
214947127|NCT06225154|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
214947128|NCT05654428|OTHER|Mckenzie Extension Exercises|The exercises used to create space between under lying structures of lumber spine which help centralization of pain and can be performed in prone lying such as prone press ups, prone on elbow, and head lift in prone.
214947129|NCT05654428|OTHER|William Flexion Exercises|Exercises for strengthening of gluteal and abdominal muscles which help to reduce pressure on the nerve root by promoting flexion at lumber spine such as knee to chest, double knee to chest, bridging(Gluets bridge), and straight leg raise (SLR).
214947130|NCT05716854|DRUG|Clarithromycin|"Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD)."
214947131|NCT05716854|DRUG|Pimozide|"Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day."
214947132|NCT05716854|DRUG|Placebo (Part 1)|Subjects receive matching placebo for treatments.
214947133|NCT05716854|DRUG|Moxifloxacin|Subjects receive Moxifloxacin 800 mg orally once on day 1.
214947134|NCT05716854|DRUG|Cobicistat|Subjects receive Cobicistat 450 mg orally once on day 1.
214947135|NCT05716854|DRUG|Moxifloxacin and Cobicistat|Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.
214947136|NCT05716854|DRUG|Placebo (Part 2)|Subjects receive matching placebo for treatments.
214677876|NCT04630015|OTHER|Survey Administration|Participants will complete study specific survey
214486464|NCT06739395|DRUG|Chidamide|Usage and dosage: It is recommended to take 30mg (6 tablets) each time, twice a week, with an interval of no less than 3 days between each dose (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.). It should be taken 30 minutes after breakfast.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214677877|NCT02334969|DRUG|Naoxintong Capsule|This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
214677878|NCT02334969|DRUG|Placebo|placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
214947137|NCT02250261|BEHAVIORAL|KÄPY|
214947138|NCT04776018|DRUG|TAK-981|TAK-981 IV infusion.
214947139|NCT04776018|DRUG|Mezagitamab|Mezagitamab SC injection.
214947140|NCT04776018|DRUG|Daratumumab and Hyaluronidase-fihj|Daratumumab and Hyaluronidase-fihj SC injection.
214677879|NCT03945331|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
214677880|NCT03945331|DEVICE|Epidural spinal cord stimulation system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
214677881|NCT04663035|DRUG|Tislelizumab|200mg, iv. drip, Q3W. Tislelizumab will start within 3-7 days after ablation treatment. The longest course of treatment is 12 months.
214947141|NCT03005431|BEHAVIORAL|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
214947142|NCT01619020|DIETARY_SUPPLEMENT|Flaxseed Lignans|We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
214947143|NCT00326170|DRUG|5-Azacytidine (5-aza)|Start at 75 mg/m\^2 subcutaneously daily for 7 days.
214947144|NCT00326170|DRUG|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
214947145|NCT00326170|DRUG|All-Trans Retinoic Acid (ATRA)|45 mg/m\^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
214947146|NCT05583643|DRUG|Atorvastatin Calcium|Atorvastatin loaded into nano particles in-situ gel adjunctive to scaling and debridement
214947147|NCT05583643|DRUG|Atorvastatin Calcium|Atorvastatin loaded into in-situ gel adjunctive to scaling and debridement
214947148|NCT05583643|OTHER|Scaling and debridement only|Scaling and debridement only
214947149|NCT02344797|PROCEDURE|Remote ischemic preconditioning|The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures \>185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
214947150|NCT00322127|DRUG|AMD3100|a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
214677882|NCT04663035|PROCEDURE|Ablation|After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).
214342240|NCT04917679|DRUG|Eltrombopag plus diacerein|In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10\^9/L as follows: (1) if platelet count is less than 150 × 10\^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10\^9/L to 250 × 10\^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10\^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10\^9/L.
214947151|NCT02978391|DEVICE|UI-EWD Hemostatic system|Adhesive endoscopic hemostats, powder type
214947152|NCT02978391|DRUG|epinephrine endoscopic injection (conventional therapy)|endoscopic submucosal injection of epinephrine (1: 10,000)
214947153|NCT03870776|DRUG|MAP4343|Daily oral administration of MAP4343
214947154|NCT03870776|DRUG|Placebo|Daily oral administration of Placebo
214947155|NCT02908074|DRUG|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
214947156|NCT00698074|DEVICE|Cardiac Resynchronisation Therapy|Biventricular Pacemaker Implant
214947157|NCT06612463|DIETARY_SUPPLEMENT|Caffeine 6mg/kg|In the caffeine trial, participants ingested a capsule containing 3 mg/kg caffeine 60 min prior to each rugby sevens match. There was 2 matches per day. So the total dosage is 6 mg/kg/ day
214947158|NCT06612463|DIETARY_SUPPLEMENT|Placebo|In the placebo trial, participants ingested a capsule containing starch 60 min before each rugby sevens match. There were 2 matches per day
214947159|NCT02602613|DEVICE|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
214947160|NCT05455359|DRUG|Prucalopride|Prucalopride 0.04 mg/kg/day
214947161|NCT05455359|DRUG|Famotidine|Famotidine 0.4 mg/kg/day
214947162|NCT00898599|DIETARY_SUPPLEMENT|Prebiotic|Inulin type fructooligosaccharides
214947163|NCT00898599|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
214677883|NCT01363895|PROCEDURE|Percutaneous closure of LAA|Percutaneous closure of LAA
214677884|NCT01363895|PROCEDURE|Catheter ablation of AF|Catheter ablation of AF
214677885|NCT01048515|DRUG|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
214677886|NCT05616390|DRUG|Sintilimab|200mg IV d1,Q3W
214677887|NCT05616390|DRUG|Bevacizumab|7.5mg/kg IV d1,Q3W
214677888|NCT05616390|COMBINATION_PRODUCT|Liver Protective Support Therapy|Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy
214677889|NCT03531957|DRUG|ASN002|Daily dose of ASN002 for 12 weeks
214677890|NCT03531957|DRUG|Placebo Oral Tablet|Placebo of ASN002 for 12 weeks
214677891|NCT02095730|DRUG|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
214677892|NCT02095730|DRUG|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
214677893|NCT02095730|DEVICE|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
214677894|NCT02095730|DEVICE|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
214677895|NCT02467764|OTHER|Retrospective study|
214677896|NCT06085365|DRUG|Immunonutrition （Su yusu)|Immunonutrition （Su yusu） 250ml oral twice a day d1-d21
214677897|NCT06085365|DRUG|fluorouracil based chemotherapy regimens|fluorouracil based chemotherapy regimens
214947164|NCT00093847|DRUG|S-adenosyl methione (SAMe)|Oral SAMe tosylate, up to 1600 mg per day for 6 weeks
214947165|NCT00093847|DRUG|Placebo|Placebo to be taken daily for 6 weeks
214947166|NCT01827215|BEHAVIORAL|Virtual Patient Advocate (VPA)|Intervention participants will have access to the Virtual Patient Advocate (VPA) system for a period of 12 months. They will be encouraged to log on every two weeks or twice a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
214947167|NCT06618846|PROCEDURE|laparoscopic sleeve gastric bypass|This is the observational study that investigate the impact of laparoscopic Sleeve Gastrectomy (LSG) or laparoscopic Roux-en-Y Gastric Bypass on premature aging by the assesment of biological age markers (telomere lenght, IL-6, TNFalpha, total oxidative status, DNA damage, cognitive function)
214947168|NCT02436031|DRUG|Desipramine|200 mg administered 2 hours before normal sleep time
214947169|NCT02436031|DRUG|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
214947170|NCT05236972|DRUG|Sintilimab|Sintilimab 200mg iv drip Q3W
214947171|NCT05236972|DRUG|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
214947172|NCT05236972|DRUG|capecitabine|1000 mg/m² po twice daily on days 1- 14 repeated every 21 days
214947173|NCT01658592|OTHER|Deep brain stimulation|Stimulator setting is ON
214947174|NCT01658592|OTHER|Placebo|Stimulator setting is OFF
214947175|NCT01458717|DRUG|Neoadjuvant chemoradiation|"* Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* 4 weeks rest, re-evaluation for resectability~* operation~* start maintenance chemotherapy within 4\~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
214342241|NCT04917679|DRUG|Eltrombopag|In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10\^9/L to 150 × 10\^9/L.
214342242|NCT03421613|DRUG|3VM1001|Self treatment 3 times daily for 10 days
214947176|NCT01458717|PROCEDURE|Upfront surgery|"* Operation at time of diagnosis~* Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* start maintenance chemotherapy within 4\~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
214947177|NCT06090617|PROCEDURE|Skin Biopsy|Skin biopsies were obtained in all recruited patients.
214342243|NCT03421613|OTHER|Placebo|Cream without investigational drug. Self treatment 3 times daily for 10 days
214677898|NCT04859803|PROCEDURE|Patients will be received rhomboid intercostal block under ultrasound guidance.|Following endotracheal intubation, patients allotted to the RIB group were positioned in the lateral decubitus position with the chest on the operating side lying superiorly. The ipsilateral arm was abducted from the chest to move the scapula laterally. The RIB was performed as described previously \[8\]. A high-frequency (6-12 MHz) linear ultrasound probe (LOGIQ e ultrasonic system, Deutschland GmbH \& Co. KG, Solingen, Germany) was placed medial to the medial border of the scapula in the oblique sagittal plane. The landmarks, i.e., the trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung, were identified in the ultrasound. Under aseptic conditions, an 80-mm 21-gauge needle was inserted at the level of T6-7 in the ultrasound view. A single dose of 30 ml 0.25% bupivacaine will be injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography.
214677899|NCT04859803|DRUG|conventional intravenous analgesia|Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
214677900|NCT00487279|DEVICE|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
214677901|NCT00487279|OTHER|Control|No Intervention
214342244|NCT02455908|DRUG|Proleukin®|
214342245|NCT03113539|OTHER|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :~1. Modified low-dose, EKG-gated CT without contrast~2. Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols."
214342246|NCT03285477|DRUG|Placebo|Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
214947178|NCT06090617|PROCEDURE|Video-laparoscopic adrenalectomy|Video-laparoscopic adrenalectomy in those with unilateral PA. (PA group 1)
214677902|NCT04845776|DIETARY_SUPPLEMENT|ANRC Essentials Plus|a vitamin/mineral supplement designed for children and adults with autism
214677903|NCT00997412|DRUG|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
214677904|NCT00997412|DRUG|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
215075295|NCT00962169|OTHER|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
215075296|NCT00962169|OTHER|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
215075297|NCT03800342|OTHER|Aerobic Exercise Training|see arm/group description
215075298|NCT06343038|DRUG|Injection, 161Tb-SibuDAB,1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline
215075299|NCT06343038|DRUG|Injection, 177Lu-PSMA-I&T, 1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline
215075300|NCT06343038|DRUG|Injection, 161Tb-SibuDAB, Dose Escalation|"Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed."
214342247|NCT03285477|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
214342248|NCT01590641|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
214677905|NCT00501852|DRUG|NVA237|single-dose dry-powder inhaler (SDDPI)
214677906|NCT00501852|DRUG|Placebo|single-dose dry-powder inhaler (SDDPI)
214677907|NCT00501852|DRUG|Tiotropium|Handihaler inhaler
214677908|NCT00006452|DRUG|motexafin gadolinium|
214677909|NCT00006452|RADIATION|radiation therapy|
214677910|NCT02275572|PROCEDURE|Pharmacist Intervention|
214677911|NCT02602431|DEVICE|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
214947179|NCT01189734|PROCEDURE|laparoscopic common bile duct exploration|
214947180|NCT01189734|PROCEDURE|laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy|
214342249|NCT01590641|DRUG|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
214342250|NCT03453333|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
214947181|NCT01851187|BEHAVIORAL|antenatal psychological intervention|"emotion management included:~(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms."
214947182|NCT01851187|BEHAVIORAL|routine prenatal care|Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
214947183|NCT05296200|DEVICE|Hyperbuoyancy Floatation|Subjects are laid supine upon a HBF waterbed encased within a wooden frame partially (50%) filled with water (at 36ºC to maintain thermal comfort) super-saturated with magnesium sulphate. Thus, subjects are buoyant, sinking passively into the bed in proportion to their segmental mass.
214947184|NCT02742454|PROCEDURE|Standard 30-60 Seconds Cord Clamping|The infant is stimulated to breathe after birth. If the infant is not breathing well, the cord is clamped at 30 seconds. If the baby is breathing well, the cord is clamped at 60 seconds. Ventilatory assistance is given after cord clamping.
214947185|NCT02742454|PROCEDURE|VentFirst 120 Seconds Cord Clamping|The infant is stimulated to breathe after birth. If the infant is not breathing well, PPV by face mask is given starting at 30 seconds. If the baby is breathing well, CPAP is given starting at 30 seconds. The cord is clamped at 120 seconds.
214947186|NCT03572361|BIOLOGICAL|V3-MOMMO|Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months
214947187|NCT02655419|DRUG|ATM-AVI|"Cohort 1:~(Creatinine clearance \> 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance \> 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI"
214947188|NCT02655419|DRUG|Metronidazole|Metronidazole 500mg infused over 1 hour every 8 hours
214947189|NCT03838406|GENETIC|BRCA 1|The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.
214947190|NCT03838406|DRUG|Chemotherapy|"FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
214947191|NCT03305900|OTHER|No Intervention|Cross-sectional study requiring a single serum sample
214947192|NCT00657306|DRUG|hydrocortisone|50 mg/6 h per day
214947193|NCT00657306|DRUG|dextrose solution 5%|dextrose solution 5% 100 ml/6 h per day
214947194|NCT00441532|DRUG|Lidocaine|
214677912|NCT02602431|DEVICE|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
215075301|NCT03183323|BEHAVIORAL|Telerehabilitation|Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
215075302|NCT00395291|DRUG|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
214677913|NCT02602431|DEVICE|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
214342251|NCT03453333|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
214947195|NCT04412837|DRUG|Topical CBD Patch|35 mg CBD patch
214947196|NCT04412837|OTHER|Placebo Patch|Identical patch without active ingredient.
214947197|NCT04220333|BEHAVIORAL|Mandalas of Emotions|Application of mandalas during 15 minutes
214947198|NCT04220333|BEHAVIORAL|Control|"Participants were requested to lie down, relax and pay attention to your breath."
214947199|NCT01465633|DRUG|levothyroxine|
214947200|NCT01465633|DRUG|levothyroxine|
214947201|NCT03053427|DRUG|Placebo|Oral administration
214947202|NCT03053427|DRUG|Gabapentin enacarbil|Oral administration
214947203|NCT04407429|DIAGNOSTIC_TEST|Laboratory Analyses|Storage of serum for SARS-CoV-2-antibodies and biomarkers
214947204|NCT04205344|DRUG|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
215075303|NCT00395291|DRUG|Placebo|Placebo
215075304|NCT02390674|DRUG|Ciclosporin|Comparison between ciclosporin and placebo
215075305|NCT02390674|DRUG|Saline|
214677914|NCT02602431|DEVICE|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
214677915|NCT01631357|BIOLOGICAL|CIK cell|CIK cell injection
214677916|NCT01631357|DRUG|Gemcitabine Injection|Gemcitabine injection
214677917|NCT01631357|DRUG|Cisplatin injection|Cisplatin injection
214677918|NCT05965206|BEHAVIORAL|Follow-up phone interview|Follow-up phone interview within 7 business days after receiving intravenous chemotherapy
214677919|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
214677920|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
214677921|NCT03176212|DIETARY_SUPPLEMENT|Milk fat globule membrane|
214677922|NCT00059761|DRUG|cisplatin|
214677923|NCT00059761|DRUG|irinotecan hydrochloride|
214677924|NCT00059761|RADIATION|radiation therapy|
214677925|NCT01221298|DRUG|ABT-450|tablets
214677926|NCT01221298|DRUG|ABT-072|tablets
214342252|NCT04497701|DRUG|PEG-rhG-CSF group|Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
214342253|NCT04497701|DRUG|rhG-CSF group|Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
214947205|NCT04205344|DRUG|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
214947206|NCT03112668|BEHAVIORAL|Cognitive Behavior Therapy|Undergo ACT
214947207|NCT03112668|OTHER|Quality-of-Life Assessment|Ancillary studies
214947208|NCT03112668|OTHER|Questionnaire Administration|Ancillary studies
214947209|NCT03112668|OTHER|Survey Administration|Ancillary studies
214947210|NCT02172040|DRUG|Over-encapsulated 10 mg amlodipine besylate tablet|Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
214947211|NCT02172040|DRUG|Matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
214947212|NCT02172040|DRUG|Over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
214677927|NCT01221298|DRUG|Ribavirin|tablets
214677928|NCT01221298|DRUG|Ritonavir|capsules
214677929|NCT06316089|BEHAVIORAL|PrEPared for Release|A multilevel, behavioral and navigation intervention administered over two sessions to promote PrEP initiation, adherence and linkage to PrEP care in the community for incarcerated men with a history of injection drug use.
214677930|NCT01511146|DRUG|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
214677931|NCT01511146|DRUG|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
214677932|NCT02891746|OTHER|non invasive sampling|
214342254|NCT01081977|PROCEDURE|Early Cord Clamping|Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
214342255|NCT01081977|PROCEDURE|Delayed Cord Clamping|Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
214342256|NCT02756624|DRUG|AC-170 0.24%|
214342257|NCT02756624|DRUG|AC-170 Vehicle|
214342258|NCT00771680|DRUG|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
214342259|NCT00771680|DRUG|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
214342260|NCT00771680|DRUG|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
214342261|NCT01224041|DRUG|Tacrolimus|oral
214342262|NCT00175136|DEVICE|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
214342263|NCT01381055|DRUG|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
214947213|NCT02172040|DRUG|Matched placebo capsule for over-encapsulated amlodipine besylate tablet|Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
214677933|NCT01927562|DEVICE|Fractyl Duodenal Remodeling System|
214677934|NCT05452746|DEVICE|Acupuncture|"Unilateral and bilateral acupuncture points:~Du 20 and GV 29,39 MS1, MS2, MS3 and MS4,40~Location of points:~Number of needles: 9~Depth of insertion:~MS1, MS2, MS3: insert the needle obliquely in the frontal direction for 1 cm Du 20: insert the needle obliquely in the frontal direction for 0.5 cm GV 29: insert the needle obliquely and downward for 0.5 cm Needles retained for 20 min Needle type: Han Yi 0.25x25 mm Treatment regimen: once per day for 2 weeks"
214677935|NCT05452746|OTHER|Treatment as usual|Inpatient psychiatric care for depression
214677936|NCT00149929|DRUG|Mycophenolate sodium (enteric coated)|
214677937|NCT00642616|DRUG|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
214947214|NCT03816644|OTHER|5-Cog|The 5-Cog is a 5 minute cognitive screen which will identify patients with 'cognitive impairment' from those with 'no cognitive impairment'.
214947215|NCT03816644|OTHER|Health Literacy & Grip Assessment|The health literacy and grip assessment will take approximately 5 minutes, and will test the patient's comprehension and pronunciation of health-related terms as well as strength in their dominant hand. The screen will sort out patients with 'low health literacy' and 'frail (low grip strength)' from those with normal health literacy and normal grip strength.
215075306|NCT03788018|DRUG|lidocaine and dexmedetomidine IV|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
215075307|NCT03788018|DRUG|saline IV|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
215075308|NCT02870075|BEHAVIORAL|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
215075309|NCT02870075|BEHAVIORAL|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
214677938|NCT00642616|DRUG|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
215075310|NCT05802082|OTHER|The Modified Yale Preoperative Anxiety Scale (m-YPAS) of children|Postoperative 0,5,10,15,30,45,60.and 120 minutes , PAED and WBYAS values
215075311|NCT00746265|BEHAVIORAL|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
215075312|NCT02562209|DIETARY_SUPPLEMENT|PACER Diet|Pacer diet to be followed for 8 weeks
215075313|NCT02562209|OTHER|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
214677939|NCT05484063|OTHER|Multicomponent, mobility-focused intervention|The intervention group will receive early therapist review (within one working day of admission to HOME unit), to be mobilised at least three times a day. They will also receive additional group exercise therapy sessions, as well as nurse screening for geriatric syndromes. Besides that, they will be screened for 4Ms (Mobility, Mentation, Medication, What Matters) by doctor on admission.
214947216|NCT04733716|PROCEDURE|Using Tourniquet|The purpose of this prospective randomized double blinded study was to compare the effect of using a tourniquet on early-stage pain and 1-year postoperative functional outcomes when patients were divided into two groups according to the pain threshold.
214947217|NCT03248414|DIETARY_SUPPLEMENT|Lactobacillus sakei|1 pack contained 5 x 109 cfu
214342264|NCT01381055|DRUG|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
214342265|NCT05783180|DRUG|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™|Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)
214342266|NCT05783180|DRUG|Placebo|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)
214342267|NCT00125632|PROCEDURE|Eccentric Viewing Training for Reading|
214342268|NCT04064281|OTHER|the healthy Cantonese diet|After a 1-week run-in period, the intervention group will eat the healthy Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
214947218|NCT00001502|DRUG|RMP-7 and carboplatin|
214677940|NCT00399802|DRUG|ZA|Single ZA 4 mg IV infusion at the start of treatment
214677941|NCT00399802|DRUG|Odanacatib|Once-daily odanacatib 5 mg tablet for 4 weeks
214342269|NCT04064281|OTHER|the typical Cantonese diet|After a 1-week run-in period, the control group will still eat the typical Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
214677942|NCT00399802|DRUG|Odanacatib matching placebo|Once-daily odanacatib matching placebo for 4 weeks
214677943|NCT00399802|DRUG|ZA matching placebo|Single IV infusion of ZA matching placebo given at the start of treatment
214677944|NCT00350064|BEHAVIORAL|Exercise Training|16 weeks of aerobic exercise training at two different intensities
214947219|NCT00792506|DRUG|ITF2357|Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
214947220|NCT02607306|DRUG|insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
214947221|NCT02607306|DRUG|insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
214677945|NCT05743543|OTHER|Sphenopalatine ganglion block|The block is performed with a nasoscope and the administration of a local anesthetic.
214947222|NCT02607306|DRUG|liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
214947223|NCT02061449|DRUG|Romidepsin|
214677946|NCT00492921|DRUG|Cyclophosphamide|
214677947|NCT00652093|DRUG|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
215075314|NCT02093988|DRUG|Topical TXA|
215075315|NCT02093988|DRUG|Intravenous TXA|
215075316|NCT00002114|DRUG|Procysteine|
215075317|NCT00789581|DRUG|Doxorubicin|Doxorubicin 60 mg/m2
215075318|NCT00789581|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2
215075319|NCT00789581|DRUG|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
215075320|NCT00789581|DRUG|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
215075321|NCT04538235|PROCEDURE|Thoracic Regional Analgesia|In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
214342270|NCT05024812|DRUG|fruquintinib＋toripalimab + SOX|phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W.
214342271|NCT01267123|PROCEDURE|Trendelenburg position|The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
214677948|NCT00652093|DRUG|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
214677949|NCT00652093|DRUG|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
215075322|NCT00081315|DRUG|Amifostine|
215075323|NCT01468207|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
215075324|NCT01468207|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
215075325|NCT00571246|DRUG|Topiramate|Participants are randomized to take Topiramate (250mg/day) 2 times a day
215075326|NCT00571246|DRUG|lamotrigine|Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
215075327|NCT00571246|OTHER|Placebo|Participants are randomized to take placebo
214342272|NCT01267123|PROCEDURE|Standard care|The patient will be placed in the standard horizontal position
214947224|NCT02061449|DRUG|Poly ICLC|
214342273|NCT01475526|OTHER|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
214947225|NCT02061449|RADIATION|Focal lesional radiation|
214947226|NCT00142259|DEVICE|Deep brain stimulation of the internal globus pallidus|
214947227|NCT03026933|DRUG|KI1107 4 Capsules, QD|KI1107 4 Capsules
214947228|NCT03026933|DRUG|Rosuvastatin Calcium 20 MG, QD|Rosuvastatin Calcium 20mg, QD
214947229|NCT03909854|PROCEDURE|mode of mechanical ventilation|Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.
214947230|NCT06088251|BEHAVIORAL|Nutri Training|Nutri Training will begin with 1) a presentation of diet counseling evidence and best practices for advising patients, along with information about nutrition recommendations for patients with chronic illness and 2) tools supporting the patient for follow-up. This content will be delivered via a live demonstration of the Nutri interactive software and case demonstration, a novel approach to delivering the learning objectives of standard nutrition education for residents.
214947231|NCT06088251|BEHAVIORAL|Standard Nutrition Education|Standard Nutrition Education Standard Nutrition Training will present an overview of 1) nutrition recommendations for patients with chronic disease and 2) cover the role of a registered dietitian and referrals.
214677950|NCT00652093|DRUG|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
214677951|NCT00652093|DRUG|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
214677952|NCT00652093|DRUG|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
214677953|NCT04591288|OTHER|Functional Electrical Stimulation protocol|FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
214677954|NCT04591288|OTHER|Treadmill only protocol|We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
214677955|NCT06048016|DIAGNOSTIC_TEST|Scaling and Root Planning|Scaling and Root Planning by using ultrasonic scaler ,and Gracy currettes.
214677956|NCT05342831|OTHER|Biological Nutrition Technique|Biological nutrition technique woman trying Biological feeding technique was applied after each breastfeeding. Breastfeeding self-efficacy and breastfeeding success were assessed at regular intervals.
214677957|NCT01410591|DEVICE|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
214947232|NCT02528890|OTHER|vaginal/anal swab for GBS from all participants|All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
214342274|NCT03890302|DRUG|FB704A|Administered by IV infusion
214947233|NCT06617351|DIETARY_SUPPLEMENT|Melatonin|Gummy - 7.5 kilocalories (kCal), 2 g Carbohydrate, 1.5 g total sugars, 7.5 mg sodium, 5 mg melatonin.
214947234|NCT06617351|DIETARY_SUPPLEMENT|Placebo|Gummy - 12.5 kilocalories (kCal), 3g Carbohydrate, 1.875 g total sugars, 1.25 mg sodium.
214947235|NCT03204487|DRUG|Tafluprost 15µg/ml|Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp \& Dohme, Wien)
214947236|NCT04554992|BIOLOGICAL|COVID 19 Convalescent Plasma|COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
214947237|NCT02195726|PROCEDURE|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
214947238|NCT02195726|PROCEDURE|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
214947239|NCT03759366|DRUG|Eculizumab|Eculizumab will be administered by IV infusion.
214342275|NCT03890302|DRUG|Placebo|Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
214342276|NCT00852397|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
214342277|NCT00852397|DRUG|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
214342278|NCT00852397|OTHER|Placebo|Placebo tablet for 24 weeks
214947240|NCT05616429|DIETARY_SUPPLEMENT|Alcat based personal diet|Alcat based personalized diet with dietician supervision and follow-up + usual care
214947241|NCT05616429|DIETARY_SUPPLEMENT|Standard balanced diet|"Sham standard balanced diet with dietician supervision and follow up + usual care."
214947242|NCT05616429|OTHER|usual care|usual care
215075328|NCT04449939|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
214342279|NCT06446635|DEVICE|Semiflex Dome Catheter System|"Abces: In patients that present with a perianal abscess/sinus the semiflex dome catheter is inserted under general anesthesia. A small cut is made to drain and irrigate the septic sinus.~Fistula: Under general anesthesia the seton is removed, the internal opening is excised and the internal opening is closed with a 2-0 Vicryl cross stitch.~Both: Before surgery, the length of the tract is measured on MRI or CT. A Semiflex Catheter with the appropriate length and a diameter is selected. If during surgery appears that this is not the appropriate size, a different size catheter can be used. The catheter is fixed on a Renasys Adhesive gel patch (Smith and Nephew). The catheter is connected with a tubing system to a vacuum pomp with an average vacuum pressure of 80 cm H2O. The tube will be taped on the patient. After every 2-3 days the catheter will be exchanged by a 3-6 mm shorter catheter."
214342280|NCT00299234|DRUG|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
214342281|NCT06222996|BEHAVIORAL|vaccine hesitation training|Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
214677958|NCT01410591|DEVICE|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
214342282|NCT00114686|DRUG|Quetiapine fumarate|
214677959|NCT05673135|DRUG|Anti-Hypertensive|For control of the blood pressure
214677960|NCT05673135|RADIATION|Ultrasound|For assessment of gestational age and fetal weight
214677961|NCT05673135|RADIATION|Doppler ultrasound|Umbilical artery Doppler assessment
214677962|NCT05673135|DIAGNOSTIC_TEST|complete blood count|For assessment of platelet count
214677963|NCT05673135|DIAGNOSTIC_TEST|Body mass index|for assessment of maternal weight during pregnancy
215075329|NCT02090049|DIETARY_SUPPLEMENT|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
214677964|NCT05101291|DRUG|Bupivacain|Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
214677965|NCT00330629|BEHAVIORAL|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
214677966|NCT00330629|BEHAVIORAL|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
214677967|NCT03516799|OTHER|Acupuncture|Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
214677968|NCT02714946|DEVICE|Percutaneous Laser Ablation|Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
214342283|NCT00114686|DRUG|lithium|
214342284|NCT00114686|DRUG|divalproex|
214342285|NCT02345512|DEVICE|Lycra Splinting Garment|Wearing of lycra splinting garment for 6 weeks
214342286|NCT06205524|BIOLOGICAL|TI-0010|Sterile liquid for injection
214342287|NCT06205524|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214342288|NCT04020120|OTHER|questionnaires|answer questionnaires
214342289|NCT00725894|DEVICE|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
214342290|NCT02663817|DEVICE|CT Scan|
214342291|NCT02332031|DRUG|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
214342292|NCT02332031|DRUG|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
214342293|NCT03574220|DRUG|Pembrolizumab|200mg IV every 21 days over 6 months
214342294|NCT03574220|RADIATION|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
214342295|NCT00003801|PROCEDURE|management of therapy complications|
214342296|NCT00003801|PROCEDURE|quality-of-life assessment|
214342297|NCT02018055|DRUG|Aspirin+Ticagrelor|Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)
214342298|NCT02018055|DRUG|Aspirin+Clopidogrel|Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)
214342299|NCT04620473|DRUG|Anlotinib+Capeox|to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
214677969|NCT02714946|DEVICE|Percutaneous Radiofrequency Ablation|Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
214677970|NCT00782080|DRUG|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
214677971|NCT00782080|DRUG|Placebo|Placebo
214677972|NCT05599217|OTHER|Dietary and nutritional questionnaire|Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.
214677973|NCT05599217|OTHER|Neurological function, cognitive function, and life quality assessment|Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.
214677974|NCT05599217|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
214677975|NCT05599217|OTHER|Metabonomic test|Collect urine and stool samples from patients.
214677976|NCT05599217|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
214677977|NCT04251312|OTHER|Oral Hygiene Education and Oral Hygiene Packets|Patients will be educated on oral hygiene and will be given packets containing toothpaste, mouth rinse, floss and a toothbrush
214677978|NCT06468410|OTHER|long duration Hatha Yoga|60 min of Hatha yoga for 4 weeks. Week One:Participants begin with foundational breathing and yoga practicesOn the second day, Square Breathwork is introduced to foster calm and concentration. After a warm-up, the yoga flow focuses on heart openers to increase chest and shoulder flexibility, ending with a soothing cool-down. Week Two:Advanced breathing techniques and targeted yoga flows are introduced. The second session includes Nadi Shodhana to balance the nervous system. Week Three:The focus remains on heart openers with varied breathing exercises. The second day revisits Full Yogic Breath, followed by a warm-up and another heart opener sequence, concluding with a cool-down. Week Four:The final week integrates additional breathing techniques. The last session features Kapalabhati and Suddhi Pranayama to purify and energize the body. After a warm-up, participants engage in a well-rounded yoga flow combining various poses to enhance overall fitness, concluding with a final cool-down.
214677979|NCT06468410|OTHER|short duration Hatha Yoga|30 min of Hatha yoga for 4 weeks .
214677980|NCT06468410|OTHER|Control group|participants will receive information about physical activity guidelines but will not engage in any structured yoga exercise during the study period.
214677981|NCT01883310|DEVICE|sham tDCS + TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
214677982|NCT01883310|DEVICE|real tDCS +TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
214677983|NCT04599816|DRUG|levosimendan at a dose of 3 mcg/kg|levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction
214677984|NCT04599816|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
214677985|NCT04599816|DRUG|levosimendan at a dose of 12 mcg/kg|levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
214677986|NCT02263339|BEHAVIORAL|Aerobic Exercise|Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
214677987|NCT02263339|BEHAVIORAL|Stretching|Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
214947243|NCT00597012|PROCEDURE|Arthroscopic partial menisectomy|Arthroscopic partial meniscectomy is a surgical procedure that is performed to remove a piece of torn cartilage in the knee joint. Incisions for arthroscopy are quite small, usually about 1 centimeter each. The torn meniscus can be removed using a number of different instruments, including small shavers and scissors.
214947244|NCT00597012|OTHER|Standard physical therapy|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks. This physical therapy regimen will have similar elements and goals as the postoperative intervention offered to Group 1 participants.
214947245|NCT00597012|OTHER|Postoperative rehabilitative physical therapy|This physical therapy is geared specifically toward rehabilitation after APM surgery.
214947246|NCT04226495|DRUG|Sufentanil Infusion|Intra-operative sufentanil infusion
214947247|NCT04226495|DRUG|Sufentanil Bolus|Intra-operative sufentanil bolus
214947248|NCT06910501|OTHER|Traditional oral hygiene instruction|Individualized demonstration of proper toothbrushing techniques using a toothbrush and a dental model. Conducted by a trained dental professional.
214947249|NCT06910501|OTHER|Digital slide-based education|Educational session using a PowerPoint presentation on a tablet or projector. The session includes visual aids to explain proper brushing techniques, the importance of oral hygiene, and the effects of poor dental care.
214342300|NCT04620473|DRUG|Capeox|to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
214342301|NCT04829838|DRUG|intravenous levetireacetam|phenytoin is considered as control drug in the study
214342302|NCT05898542|PROCEDURE|Nature-based therapy|Therapy sessions conducted outdoors
214342303|NCT02171468|DRUG|Dabigatran high dose|
214342304|NCT02171468|DRUG|Dabigatran low dose|
214342305|NCT01438541|DEVICE|Window|Dressing
214342306|NCT05790434|DIAGNOSTIC_TEST|Laboratory test|including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin
214342307|NCT05790434|DIAGNOSTIC_TEST|History taking and physical examination|including fever, joint pain, local swelling and redness, sinus
214342308|NCT05790434|DIAGNOSTIC_TEST|biopsy|including arthrocentesis culture，and frozen section
214342309|NCT03861000|DRUG|[C-11]T-1650|radio-labeled drug
214342310|NCT03861000|DRUG|BPN14770|selective compound
214342311|NCT01968434|DEVICE|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
214677988|NCT02263339|BEHAVIORAL|Aerobic Exercise- Healthy Subjects|Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
214677989|NCT03852212|OTHER|Manipulation|Thrust technique application
214342312|NCT01968434|DRUG|carbocisteine cough syrup|Mucolytic
214342313|NCT01688336|DRUG|FOLFIRINOX|"FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~* Oxaliplatin (85 mg/m2)~* Leucovorin (400mg/ m2)~* Irinotecan (180 mg/m2)~* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours"
214342314|NCT01771406|DRUG|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
214342315|NCT01771406|DEVICE|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
214342316|NCT02091167|DEVICE|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
214342317|NCT03208972|DRUG|low dose hCG|
214947250|NCT06910501|OTHER|Brush DJ mobile appliaction|Children use the Brush DJ app, which includes gamified elements such as music, timers, and oral hygiene tips to encourage proper brushing habits. The app provides reminders and engaging content to maintain motivation.
214947251|NCT05760742|DIETARY_SUPPLEMENT|MicAlgae|2 months of supplementation with an innovative microalgae based ingredient
214947252|NCT05760742|DIETARY_SUPPLEMENT|Placebo|2 months of supplementation with a placebo (Maltodextrin)
214947253|NCT06907056|DRUG|dual therapy|Intervention arm will be dual therapy oh DRV/C 800/150 mg + 3TC 300 mg, this will be compared to standar therapy of 3 drugs with: DRV/c 800/150 mg + TDF/FTC 300/200 mg
214947254|NCT06907056|DRUG|Standard Medical Therapy|DRV/c+TDF/FTC
214677990|NCT04838912|BEHAVIORAL|Cool Kids (Chilled) Anxiety program adapted to children and youths with autism and anxiety disorders.|CBT program for anxiety in teenagers with autism
214677991|NCT02777463|OTHER|diffusion-weighted MRI|Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
214947255|NCT06281626|OTHER|Data collection|Data collection
214947256|NCT06648694|PROCEDURE|Abdominoplasty surgery|Correlation between IAP and Diaphragmatic Mobility
214947257|NCT06648694|PROCEDURE|Abdominoplasty|For the practice of the surgical procedure, the region to be operated on was marked using a surgical marking pen (Textel®). With the patient in the orthostatic position, a median line was drawn from the xiphoid appendix to the pubic symphysis, reaching the anterior vulvar commissure. Then, with the patient in the dorsal position, a transverse line was drawn 6 cm above the vulvar commissure and elongated to the iliac spine on each side. From there, the lateral skin surplus was estimated by means of bidigital clamping. The excess tissue was marked in a triangular shape, with a slight arching up to the xiphoid appendix. To determine the horizontal skin surplus, marking was performed, similar to that performed in classic abdominoplasty described in the literature(AMORIM FILHO; AMORIM, 2012). In this study, an anchor incision was recommended for all volunteers. All patients underwent intravenous sedation followed by spinal anesthesia.
215075330|NCT02090049|DIETARY_SUPPLEMENT|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
214342318|NCT03208972|DRUG|hp-FSH|
214342319|NCT03208972|DRUG|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG"
214342320|NCT01855009|DIETARY_SUPPLEMENT|MannaBears|Subjects will be administered 4 MannaBears daily
214342321|NCT01855009|DIETARY_SUPPLEMENT|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
214342322|NCT01855009|DIETARY_SUPPLEMENT|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
214342323|NCT01855009|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be administered 800 IU vitamin D3
214677992|NCT05376202|DRUG|Cetuximab-IRDye800CW|Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
214677993|NCT02351037|DRUG|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
214677994|NCT02351037|DRUG|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
214677995|NCT02351037|DRUG|Ibrutinib+Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
214947258|NCT03403946|DEVICE|Macintosh blade|Laryngoscopy with C-MAC PM in combination with Macintosh blade
214947259|NCT03403946|DEVICE|D-Blade|Laryngoscopy with C-MAC PM in combination with D-Blade
214947260|NCT03403946|DEVICE|Intubation|Intubation with C-MAC PM in combination with D-Blade
214947261|NCT03410901|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IV, intratumoral
214947262|NCT03410901|OTHER|Laboratory Biomarker Analysis|Correlative studies
214947263|NCT03410901|RADIATION|Radiation Therapy|Undergo radiation therapy
214947264|NCT03410901|DRUG|TLR9 Agonist SD-101|Given intratumorally
215075331|NCT01223885|DIETARY_SUPPLEMENT|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
214342324|NCT06393361|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
214947265|NCT05668104|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet|The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
214947266|NCT05668104|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet Placebo|Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
214947267|NCT06912022|DEVICE|FebriDx Device|Patients suspected of an acute respiratory infection were tested using the FebriDx POC assay.
214947268|NCT00583102|DRUG|Cytarabine|Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7.
214947269|NCT00583102|DRUG|Lovastatin|Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
214947270|NCT05584800|BIOLOGICAL|ZGGS18 for Injection|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18，intravenous infusion, once every 2 weeks.
214947271|NCT05584800|BIOLOGICAL|ZGGS18 for Injection|Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18，intravenous infusion, once every 2 weeks.
214947272|NCT00089700|DRUG|TNX-355|
214677996|NCT03002493|DRUG|Eribulin mesylate|"Treatment phase: During Cycle 1, eribulin mesylate was administered as a 2 to 5 minute (min) intravenous (IV) infusion at 1.4 mg/m2 on Day 1 and Day 15 of 21-day cycle. During subsequent cycles, eribulin mesylate administration as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of a 21-day cycle.~Extension phase: Eribulin mesylate was administered continuously as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of 21-day cycles, as long as the Investigator considered eribulin mesylate therapy to be clinically appropriate."
214677997|NCT03002493|DRUG|Eribulin mesylate|
214677998|NCT03002493|DRUG|Rifampicin|Treatment phase: Rifampicin 600 mg was administered orally once a day, from Day 9 to Day 20 of 28-day cycle of Cycle 1.
214677999|NCT05066893|OTHER|telehealth visits|intensive visits with doctor
214342325|NCT06393361|DRUG|Brentuximab Vedotin, anti-PD-1 antibody.|Brentuximab Vedotin 1.8mg/kg d1, anti-PD-1 antibody d1. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
214678000|NCT03176966|DRUG|Vitamin E|Patients will take 400 IU vitamin E nightly for 3 months.
214678001|NCT03176966|DRUG|Ropinirole|Patients will take 0.5mg ropinirole nightly for 3 months.
214678002|NCT03176966|OTHER|Muscle cramp survey|Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
214342326|NCT01679899|DRUG|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
214486465|NCT06739395|DRUG|PD-1/PD-L1/PD-1&CTLA4 inhibitor|Refer to the respective instructions for use, and the dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214947273|NCT06533852|DRUG|Fecal Microbiome Transplantation (FMT)|"Two doses:~First dose: 24 capsules of FMT at baseline. Second dose: 24 capsules of FMT at 3 months."
214947274|NCT06533852|OTHER|FMT Placebo|"Two doses:~First dose: 24 capsules of FMT placebo at baseline. Second dose: 24 capsules of FMT placebo at 3 months."
214678003|NCT04740866|RADIATION|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. (\[50Gy in 25 fractions conventional fractionation including tumor bed \& pelvic lymph nodes\]
214342327|NCT01679899|DRUG|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
214342328|NCT02090907|DRUG|Levothyroxine|
214342329|NCT02090907|DRUG|Placebo|
214342330|NCT02555410|DEVICE|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
214678004|NCT02182037|DRUG|Single rising doses of BIBT 1011 BS|
214678005|NCT02182037|DRUG|BIBT 1011 BS placebo|
214678006|NCT01520922|BIOLOGICAL|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
214678007|NCT01520922|DRUG|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
214678008|NCT04792996|OTHER|No intervention|No intervention. case - control design.
214678009|NCT06508996|DIAGNOSTIC_TEST|Xpert HCV|Detection of HCV RNA by Xpert HCV test
214678010|NCT05476549|DIETARY_SUPPLEMENT|Lemon verbena|Lemon verbena supplement administered at an estimated daily dose of 15mg/kg
214947275|NCT06910332|OTHER|Joint mobilization|Participants receive passive shoulder joint mobilization on the dominant-side glenohumeral joint. The mobilization includes inferior, anterior, and posterior glide techniques, each performed for 1 minute at a frequency of 0.5 Hz, with a 30-second rest between each mobilization. The participant is positioned comfortably to support the joint's range of motion.
214947276|NCT06910332|OTHER|Sham|In the sham intervention, the practitioner mimics the technique of shoulder mobilization but does not apply any actual movement or glide effect on the joint. The procedure is designed to closely resemble the real intervention in terms of duration, rhythm, and the practitioner's handling of the participant's shoulder. The practitioner will use superficial touch on the glenohumeral joint without applying any of the mobilizing forces necessary to move the joint.
214947277|NCT06911021|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT|A single-dose intravenous injection of the radiotracer 68Ga-FAPI-46 will be administered to participants. Approximately 60 minutes after injection, a whole-body PET/CT scan will be performed. The scan is designed to detect areas of high fibroblast activation protein (FAP) expression in and around pancreatic tumors, providing high-resolution images of tumor margins and potential spread. The goal is to evaluate whether this imaging method offers more accurate and useful information than standard imaging (MRI and CT) for preoperative staging and surgical planning.
214947278|NCT01093651|DRUG|Sitagliptin|100 mg sitagliptin daily for 4-6 months
214947279|NCT01093651|DRUG|Placebo|Daily placebo for 4-6 months
214947280|NCT06909903|PROCEDURE|Autogenous drainage of sputum caused by hypertonic saline in adolescents with cystic fibrosis.|"The procedure will be performed at the same session as follows :~* 30 minutes of autogenous drainage, followed by collection of secretions.~* 10 minutes of HSS followed by 30 minutes of autogenous drainage before secretions are collected.~The intervention first step involves verifying patient tolerance to Hypertonic saline solution nebulization (Auscultation, peak flow, saturtion levels), followed by the inhalation of 2 puffs of Ventolin® to prevent bronchospasm. Ten minutes later, the patient undergoes a 10-minute nebulization of 4 mL SSH 6% carried out according to the HAS recommendations.~The patient tolerance to SSH is reassessed. If there are no adverse reactions, the patient continues the protocol. If issues like wheezing, a ≥5% drop in SpO2, or a ≥20% drop in Peak Flow occur, 4 more puffs of Ventolin® are given, and the patient is reassessed.If still intolerant, the patient exits the study.~The session ends with physiotherapy (autogenous drainage) to aid mucus clearance."
214947281|NCT00505661|DRUG|Letrozole|2.5 mg PO Once Daily
214947282|NCT06911333|DRUG|AD1208|Up to 6 of cohorts will be applied sequentially in phase Ia part.
214947283|NCT06912503|DEVICE|Device to deliver trial restoration matrix|"Auto-polymerization bisacrylic material (Luxatemp Star, DMG) was used to perform the trial restoration for condensation silicone matrix, addition PVS-silicone matrix with external resin-based shell and CAD/CAM combination matrix. Light-cured flowable composite-resin (Filtek Flow, 3M Dental Products) was used to perform the trial restoration for transparent addition PVS-silicone matrix. The rationale behind using different material stands on the material selection usually chosen by clinicians for each matrix.~In the same appointment 4 trial restorations were performed to each patient using the four different matrixes."
214947284|NCT06912347|OTHER|Intervention Group|Starting 24 hours before pre-treatment, you will receive herbal fumigation of the perianal area twice daily (morning and afternoon), with each session lasting 5 minutes. Additionally, starting 30 minutes after each meal, acupoint application will be performed on five acupoints: Shenque (CV8), Tianshu (ST25), and bilateral Zusanli (ST36). The application will last 4 hours per day.
214947285|NCT06912347|OTHER|control group|Starting 24 hours before pre-treatment, you will receive povidone-iodine warm water fumigation of the perianal area twice daily (morning and afternoon), with each session lasting 15 minutes.
214947286|NCT06911853|OTHER|Virtual Reality Videos|Based on the Phase of Engagement Framework, two online orthopaedic modules focusing on interprofessional and intercultural educations on low back pain (LBP) and adolescent idiopathic scoliosis (AIS) were developed. The students (n=104) were randomized into two groups. In the first module, the Virtual Reality Group as the intervention group received a virtual reality (VR)-enhanced LBP education, while the Case-based Learning Group as the control group engaged with a case study on LBP. After a 3-week washout period, the groups crossed over: the the Virtual Reality Group as the intervention group received the VR-enhanced education on AIS, and the Case-based Learning Group as the control group focused on an AIS case study.
214947287|NCT06910098|DRUG|Rosuvastatin|a dose of 5mg were given and were compared for the cpk, ast and ldl levels
214947288|NCT06910098|DRUG|Rosuvastatin|a dose of 10 mg were given and were compared for the cpk, ast and ldl levels
214947289|NCT06910098|DRUG|Rosuvastatin|a dose of 20 mg were given and were compared for the cpk, ast and ldl levels
214947290|NCT06911528|PROCEDURE|EndoScell Scaner (ES) novel intraoperative cellular probing technology|In this project, we utilize the miniature wide-angle focusing microscope for intraoperative cell-level observation and detection, a technology in which our hospital has conducted extensive research and accumulated rich experience.
214947291|NCT06109376|PROCEDURE|hypothermia|In this trial, intra-arterial select cooling infusion is used to reduce brain tissue temperature to 33-35°C.
214342331|NCT05707234|DEVICE|VRH|The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).
214947292|NCT06109376|PROCEDURE|thrombectomy|Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.
215075332|NCT05192499|PROCEDURE|Stool test|At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.
215075333|NCT05192499|PROCEDURE|Blood test|Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.
214486466|NCT06739395|DRUG|Target Gene|Granting CFDA or FDA approved drugs(off-label approved drugs) based on specific molecular characteristics.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
214678011|NCT05476549|DIETARY_SUPPLEMENT|Placebo|Placebo supplement containing carrier material only
214678012|NCT04570449|DRUG|Fluoxetine|20 mg capsule
214947293|NCT03376191|DRUG|apatinib|Clinicians chose the initial dose of apatinib according to the patient's physical condition. Besides the clinicians adjusted the dose according to the patient's tolerance during the medication.The dosage was demanded not higher than 750 milligram (mg) per day. The patients received apatinib continuously, 28 days for a period, until intolerance, no longer getting benefits or patient wanted stop.
214678013|NCT04570449|DRUG|Placebo|fluoxetine placebo capsule
214678014|NCT00615706|OTHER|No intervention|no intervention
214678015|NCT04036136|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
214678016|NCT04036136|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
214678017|NCT05632250|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
214678018|NCT03713723|DEVICE|NICaS bioimpedance system|NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
214678019|NCT03245788|OTHER|Lay Navigation|Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
214947294|NCT03611582|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
214342332|NCT05707234|DRUG|Midazolam sedation|During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
214947295|NCT03611582|DRUG|Placebo (semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
214947296|NCT03127813|OTHER|Application of continuous positive airway pressure (CPAP)|CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
214678020|NCT01696877|DRUG|degarelix acetate|Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
214678021|NCT01696877|DRUG|Cyclophosphamide|Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
214678022|NCT01696877|DRUG|GVAX|GVAX is granulocytemacrophage -colony stimulating factor -secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
214678023|NCT02457052|DEVICE|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
214678024|NCT06396481|BIOLOGICAL|Vγ9Vδ2 T cell|The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
214678025|NCT01618656|DRUG|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
214678026|NCT01618656|DRUG|Placebo|Sugar pill
214678027|NCT02172222|DRUG|BI 10773|
214342333|NCT05872035|DEVICE|Apple Software|Amplification settings established by algorithm and further adjusted by participants per their preference
214678028|NCT02172222|DRUG|Linagliptin|
214678029|NCT01032785|DEVICE|no interventions|no interventions
214678030|NCT02658162|DRUG|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
214678031|NCT02658162|DRUG|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
214678032|NCT00477529|DRUG|ABI-008|nab-docetaxel
214947297|NCT00000298|DRUG|Buprenorphine/naloxone|
214678033|NCT03049540|DRUG|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
214678034|NCT03049540|DRUG|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
214678035|NCT04076072|DEVICE|Utravit High-Speed 10000 cpm Beveled Probe|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
214678036|NCT04076072|DEVICE|standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
214678037|NCT00205972|DEVICE|Humerus Nail or LC Plate|
214678038|NCT04910412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training
214947298|NCT04459598|DRUG|Efavirenz|Single oral dose, 600-mg tablet
214678039|NCT04770155|DIETARY_SUPPLEMENT|Dietary Nitrates 400 mg|The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.
214678040|NCT04770155|DIETARY_SUPPLEMENT|L-citrulline 3 g|Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.
214678041|NCT04770155|DRUG|Sildenafil 100 mg|Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
214678042|NCT04770155|DRUG|Bosentan 125 mg|Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
214678043|NCT05028023|BIOLOGICAL|Apneic oxygenation - supplemental high flow oxygen administration by an apneic way|In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
214678044|NCT01566838|DRUG|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
214678045|NCT01566838|DRUG|Standard acute pain management|"A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.~Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
214678046|NCT00469014|DRUG|Clofarabine|Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily
214678047|NCT00469014|DRUG|Busulfan|"Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7."
214678048|NCT00469014|DRUG|Fludarabine|Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily
214342334|NCT05872035|DEVICE|by Audiologist|Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice
214342335|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
214947299|NCT04459598|DRUG|Quizartinib|Single oral dose, 60 mg (2 x 30 mg) tablets
214947300|NCT05995405|DRUG|GTX-104|Nimodipine IV infusion
214947301|NCT05995405|DRUG|Nimotop 30 MG Oral Capsule|Oral nimodipine capsules
214947302|NCT03630913|PROCEDURE|Tagged axillary metastatic node|"First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy."
214947303|NCT05627752|DRUG|Enzalutamide 40 MG|Adding Enzalutamide to Docetaxel chemotherapy
214947304|NCT05627752|DRUG|Docetaxel injection|Docetaxel chemotherapy
214947305|NCT05658952|OTHER|Microcatheter-derived FFR|FFR pullback trace is obtained through the manual retrieval performed after the positioning of the microcatheter FFR in the distal portion of the vessel. The pullback speed should be steady and the overall duration would be between 20 and 40 seconds. Then, the Interventional Cardiologist has to decide the procedural plan according to the pullback trace aiming to obtain an optimal post-PCI result in terms of physiology. FFR with pullback can be repeated after stenting to check and correct the result if needed.
214947306|NCT05658952|OTHER|Angiography-derived FFR|FFR pullback trace is automatically obtained after the 3-Dimensional reconstruction of the vessel through angiography derived FFR. Then, Interventional Cardiologist has to decide the procedural plan according to the pullback result aiming to obtain an optimal post-PCI result in terms of physiology. Angiography-derived FFR can be repeated after stenting to check and correct the result if needed.
214947307|NCT05658952|OTHER|Angiography-guided PCI|Interventional Cardiologist will perform PCI plan according to his/her the evaluation of angiography.
214947308|NCT05768009|PROCEDURE|Interscalene brachial plexus block (ISB)|• Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided ISB using 10 ml bupivacaine 0.25%.
214947309|NCT01078298|DRUG|varenicline|varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
214947310|NCT01078298|DRUG|placebo|placebo tablets matched in appearance and dosage to varenicline tablets
214947311|NCT04908202|DRUG|Deucravacitinib|Specified dose on specified days
214947312|NCT04908202|OTHER|Placebo|Specified dose on specified days
214678049|NCT00469014|OTHER|Stem Cell Infusion|Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
214678050|NCT00469014|DRUG|Thymoglobulin (ATG)|Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
214947313|NCT01861873|OTHER|measuring liver function by 18-FDGal PET/CT|
214947314|NCT00463840|DRUG|Oxaliplatin|
214342336|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
214947315|NCT00463840|DRUG|5FU|
214947316|NCT00463840|RADIATION|Radiation|
214342337|NCT02394743|RADIATION|18FDG-PET|
214342338|NCT02791633|OTHER|Questionnaire|Quality of recovery and quality of recovery follow up questionnaires
214342339|NCT02070159|DRUG|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
214342340|NCT02070159|DRUG|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
214947317|NCT00463840|PROCEDURE|Surgery|
214947318|NCT00463840|DRUG|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
214947319|NCT00866333|DRUG|Entinostat|Entinostat tablets
214947320|NCT04812405|DIAGNOSTIC_TEST|Trios4|Examination of occlusal surfaces with 3D scanner and optical criteria
214947321|NCT02095405|DRUG|Caffeine|"SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring."
214947322|NCT02095405|OTHER|Placebo|"SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.~AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring."
214947323|NCT01653327|DRUG|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
214342341|NCT02070159|DRUG|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
214342342|NCT04280211|OTHER|Respiratory Assessment|Spirometric measurement
214342343|NCT04280211|OTHER|Vestibular Assessment|Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction
214947324|NCT01653327|DRUG|Placebo|
214947325|NCT00002131|DRUG|Vesnarinone|
214947326|NCT05735912|PROCEDURE|Endoscopic ultrasound-guided radio frequency ablation|Radiofrequency ablation performed under endoscopic ultrasound guidance of pancreatic insulinoma
214947327|NCT05735912|PROCEDURE|Surgery|Surgical resection of pancreatic insulinoma
214947328|NCT05015543|OTHER|Personal Training Program|One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.
214678051|NCT00469014|DRUG|Filgrastim|Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
214678052|NCT04044547|DRUG|Rotigotine, extended-release microspheres|"Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
214947329|NCT06442449|BIOLOGICAL|sIPV|vaccination with sIPV
214342344|NCT04280211|OTHER|Balance Assessment|Postural stability
214342345|NCT06664281|BEHAVIORAL|SIT|sprint interval training
214947330|NCT06442449|BIOLOGICAL|MMR|vaccination with MMR
214947331|NCT06442449|BIOLOGICAL|HepA-I|vaccination with HepA-I
214947332|NCT04291742|DIAGNOSTIC_TEST|cognitive vs software|cognitive vs software
214342346|NCT06664281|BEHAVIORAL|SIT combined RIPC|sprint interval training combined with remote ischemic preconditioning
214947333|NCT05935033|DRUG|Emraclidine|Tablet
214342347|NCT03065465|DEVICE|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
214947334|NCT03856333|OTHER|Assigned Interventions|exercises, physical agents
214947335|NCT03194347|DIAGNOSTIC_TEST|molecular genetic analyses|molecular genetic analyses
214947336|NCT04353154|DIAGNOSTIC_TEST|Spartan Cube Point-of Care Covid-19 test|Throat and nasal swab for COVID-19 point-of-care test.
214947337|NCT04886362|DRUG|Ivermectin|Treatment with Ivermectin in the first 7 days from symptoms onset.
214947338|NCT04886362|DRUG|Placebo|Treatment with Placebo in the first 7 days from symptoms onset.
214947339|NCT01738191|DRUG|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
214947340|NCT01738191|DRUG|Placebo|
214947341|NCT05343091|DEVICE|cardiac ultrasound|Cardiac ultrasound with Pocket ultrasound by expert and non expert physician
214947342|NCT04562220|OTHER|Routine conventional physical therapy plus Vibration session|Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
214947343|NCT04562220|OTHER|Routine conventional physical therapy|Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions
214678053|NCT04044547|DRUG|Placebo, extended-release microspheres|"Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
214678054|NCT05359627|DRUG|Polymyxin B|Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.
214342348|NCT03065465|OTHER|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
214342349|NCT05667298|DRUG|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
214947344|NCT05993091|OTHER|mirror therapy (MT)|Each participant will practice two different MT protocols: UMT and BMT. During UMT, the affected hand is static, whereas during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements (i.e., shoulder flexion, elbow flexion/extension, forearm pronation/supination, and wrist flexion/extension and circumduction), fine motor movements (i.e., opposition, grasp, and release), and object manipulation (i.e., reaching out to grasp a cup, flipping coins).
214342350|NCT05667298|DRUG|Adjuvant chemoradiotherapy|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
214342351|NCT06508554|OTHER|Haptonomy|5\. With the energy work, we will move on to the stage of harmonizing the intuitive and heart energy fields. It will be ensured that the mother's communication with her baby has a spiritual dimension as well as a physical one. 6. Then the stage of touching and communicating with the baby will begin. The hands of the researcher and the pregnant woman will be placed on the pregnant woman's uterus. Then, the pregnant woman will be the first to call her baby. This call to the baby will be repeated 2-3 times. 7. The pregnant woman and her uterus will be touched and exercises will be performed to adapt to the fetus. The aim is to increase the emotional awareness of the pregnant woman and to enable her to play intrauterine games with her baby (such as calling the baby, shaking her belly, moving the baby to the touched area with the mother's voice). Haptonomy will be completed with a deep relaxation exercise that will support the heart-uterus connection accompanied by breathing exercises.
214342352|NCT05556681|DEVICE|BD™ Sirolimus Drug Coated Balloon Catheter percutaneous transluminal angioplasty|The study will enroll patients presenting with clinical evidence of an angiographically significant lesion (Lesion ≥ 70% stenosis by visual estimate) in the femoropopliteal arteries. Eligible patients will undergo percutaneous transluminal angioplasty with the investigational BD™ Sirolimus Drug Coated Balloon Catheter.
214342353|NCT01198080|BIOLOGICAL|CD133+ cells|bone marrow derived CD133+ cells injection with core compression
214342354|NCT04477980|OTHER|Disease outcome (mortality)|Mortality rate between the two groups
214342355|NCT02965560|DIAGNOSTIC_TEST|plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.|
214342356|NCT02754635|OTHER|Induction of labour|Induction of labour
214342357|NCT02754635|OTHER|Expectant management|Expectant management
214342358|NCT00489970|PROCEDURE|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
214486467|NCT06737679|BEHAVIORAL|Body Scan|"Body scan is a guided meditation technique that allows people to detect signs and signals from their body (for instance, heart rate).~The intervention will last 20 minutes and will be performed 21 consecutives days. The first and last days it will be performed in presence, while the other ones online."
214678055|NCT00472927|DRUG|Premarin/MPA 0.45 mg/1.5 mg|
215075334|NCT05192499|PROCEDURE|Induced sputum|At inclusion (day 0), bronchial aspiration after inhalation induction of 4 mL of 6% salt serum administered (after 200 μg of salbutamol via an inhalation chamber during a bronchial drainage session).
215075335|NCT05192499|PROCEDURE|nasale virology|At inclusion (Day 0), patients will be taken nasal swab for virology with swab adapted for nasal swab or with suction trap when blowing the child's nose (depending on center practice)and multiplex PCR.
214342359|NCT00489970|BIOLOGICAL|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
214342360|NCT00489970|BIOLOGICAL|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
214342361|NCT00737087|DEVICE|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
214947345|NCT05993091|OTHER|augmented reality (AR)|The training program with different levels of difficulty provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg, etc.), activities of daily living training (i.e., reaching to grasp functionally relevant objects), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
214947346|NCT05993091|OTHER|Control intervention|Participants will perform 90 minutes of therapist-mediated conventional therapy. The treatment protocols will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. Specifically, the affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques will be used to alleviate functional deficits. In addition, the therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
214947347|NCT03988673|OTHER|Decision aid with implicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a grid where statements about the subject will be presented (decision aid with implicit VCM).
214947348|NCT03988673|OTHER|Decision aid with explicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a a grid where statements about the subject will be presented and men should indicate what statements they identify with (decision aid with explicit VCM).
214947349|NCT04616001|DRUG|IVIG|Patients will receive IVIG daily for four days.
214947350|NCT05105399|PROCEDURE|Serratus plane block (continuous or single-shot)|Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block
214947351|NCT05905133|DRUG|CBP-201|subcutaneous injection
214947352|NCT00520754|DRUG|levocetirizine dihydrochloride|
214947353|NCT01758978|DRUG|a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
214342362|NCT03859843|COMBINATION_PRODUCT|PRP|Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.
214342363|NCT03859843|OTHER|Chemical peeling (Salycilic acid)|SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.
214342364|NCT03859843|OTHER|Chemical peeling (Jessener's solution)|is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.
214342365|NCT06457542|OTHER|Active Release Technique|Active Release Therapy, which involves instructing the patient to sit and then positioning their shoulder in 90-degree abduction. The therapist will provide assistance to the patient's arm and then examine the supraspinous fossa by applying pressure with a finger. The patient will be instructed to gradually bring the arm towards the body as the therapist manipulates the muscle plane. This procedure should be repeated for a duration of 10 minutes, 3 times per week, over a duration of four weeks.
214342366|NCT06457542|OTHER|Soft Tissue Mobilization|Soft Tissue Mobilization (STM) targeting the subscapularis muscle. The participants will be placed in a position where their upper arm bone (humerus) is raised at a 45° angle, with the elbow bent at a 90° angle. Additionally, the humerus will be rotated outward to a position that is normally around 20° to 25° of external rotation. The subscapularis muscle remained examined by touch in the armpit area to locate regions of limited mobility due to myofascial limitations, trigger points or tense bands. The identified limitations remained addressed with STM, which included applying prolonged manual pressure and slow deep stroke to the subscapularis myofascial. This treatment was performed for a period of 7 minutes, three times a week, over a period of four weeks.
214678056|NCT03515980|DRUG|BMS-986231|Intravenous (IV) administration
214678057|NCT03453463|OTHER|exercise|3x week predominately resistance exercise for 18 months
214678058|NCT04806581|DRUG|Allogeneic Hepatocyte|Allogeneic hepatocyte with cell numbers L,M,H respectively.
214678059|NCT04083742|DEVICE|ANTERION|3 repeat angle measurements performed on each of the 3 Anterion devices and the 3 reference devices
214947354|NCT02174705|DRUG|Sucrose|Sucrose 24% orally prior to vaccine injections
214947355|NCT02174705|DRUG|Rotavirus|Rotavirus vaccine orally prior to vaccine injections
214947356|NCT03329105|OTHER|Sea Salt Mouth Rinse|Rinsing mouth with a tablespoon of sea salt mouth rinse without any dilution, for 30 seconds, once in the morning and once before bed, in addition to Standardized Oral Health Practices.
214947357|NCT03329105|OTHER|Standardized Oral Health Practices|Brushing teeth for two minutes using the modified Bass technique, twice per day with the provided dentifrice, and flossing once daily using the spool method
214342367|NCT01893242|DRUG|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
214947358|NCT02243046|DRUG|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
214947359|NCT02243046|DRUG|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
214947360|NCT02243046|DRUG|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
214947361|NCT03338569|DRUG|Vitamin C|Continuous infusion of vitamin C
214947362|NCT03338569|DRUG|Placebo|Placebo designed to mimic intervention
214947363|NCT04865991|PROCEDURE|TCI Propofol|Peripheral venous catheters were placed in all subjects. Subjects in the TCI propofol group had one specific intravenous catheter for propofol infusion apart from medication or intravenous fluid line. Subjects in the TCI Propofol group received TCI propofol (Schneider) with targeted Ce 4 -5 mcg/ml for anesthesia induction and maintenance. Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
214947364|NCT04865991|PROCEDURE|Sevoflurane|subjects in the sevoflurane group were cannulated only with one venous catheter. Midazolam 0.05 mg/kg BW and fentanyl 1 mcg/kg BW were given as premedication. Subjects in the sevoflurane group received intravenous propofol 1 - 2 mg/kg BW.
214947365|NCT01051440|DRUG|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
214947366|NCT01051440|DRUG|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
214947367|NCT05093985|OTHER|Neuromuscular electrical stimulation with blood flow restriction|Neuromuscular electrical stimulation with blood flow restriction
214947368|NCT04291456|DRUG|Minocycline 100mg|Single-arm trial of minocycline 100 mg twice daily
214947369|NCT02109445|DRUG|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
214947370|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
214947371|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
214342368|NCT01893242|DRUG|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
214342369|NCT00116805|DRUG|TDF|300 mg tablet administered orally once daily
214342370|NCT00116805|DRUG|ADV|10 mg tablet administered orally once daily
214342371|NCT00116805|DRUG|TDF placebo|Tablet administered orally once daily
214342372|NCT00116805|DRUG|ADV placebo|Tablet administered orally once daily
214486468|NCT06770153|PROCEDURE|Tensor|balancing will be carried out using the TEMIS DePuy tensioner and carrying out any releases according to the gap-balancing technique
214486469|NCT06770153|PROCEDURE|standard|primary TKA implantation with ligament balancing without use of the tensioner
214486470|NCT06775717|OTHER|Motor Imagery with conventional Treatment|This treatment will be given 5 sessions a week in 4 consecutive weeks.
214486471|NCT06775717|OTHER|Mirror therapy with conventional Treatment.|This treatment will be given 5 sessions a week in 4 consecutive weeks.
214342373|NCT00116805|DRUG|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
214342374|NCT03506516|DIETARY_SUPPLEMENT|Mixing alcohol|Alcoholic beverages, different types
214947372|NCT02109445|DRUG|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
214947373|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
214947374|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
214947375|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
214947376|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
214947377|NCT01636648|DEVICE|Aortic Valve Replacement|Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000
214947378|NCT05380986|DRUG|Camrelizumab combined with apatinib mesylate|Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
214947379|NCT04304261|DRUG|Canagliflozin|12 weeks of Canagliflozin(100mg/day) treatment
214947380|NCT04304261|DRUG|Sitagliptin|12 weeks of Sitagliptin (100mg/day) treatment
214342375|NCT03506516|DIETARY_SUPPLEMENT|Single type alcohol|Alcoholic beverages, different types
214342376|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
214342377|NCT01093794|DRUG|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
214678060|NCT02805699|DRUG|Baofeikang Granule|To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
214947381|NCT03446118|DIAGNOSTIC_TEST|MRI to detect inflammation and fibrosis in subjects with EoE|MRI will be performed on a 1.5T magnet. Patients will be scanned in an oblique prone position similar to how esophageal distention is assessed at barium fluoroscopy
214947382|NCT03257761|BIOLOGICAL|Durvalumab|Given IV
214947383|NCT03257761|DRUG|Guadecitabine|Given SC
214947384|NCT00441363|DRUG|Bromocriptine Mesylate|0.8 mg tablet
214947385|NCT01043094|DRUG|Pitavastatin 4mg|Pitavastatin 4mg single dose
214342378|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
214342379|NCT01093794|DRUG|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
214342380|NCT02740127|PROCEDURE|Caudal Nerve Block (CNB)|General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
214947386|NCT04818723|DRUG|Montelukast|We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)
214947387|NCT02849210|BIOLOGICAL|Allergovac depot with Olea europaea pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
214947388|NCT04755738|COMBINATION_PRODUCT|Almonertinib plus microwave ablation|Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.
214947389|NCT05964920|DRUG|Saline|Two placebo injections one at baseline and one week 3.
214947390|NCT05964920|DRUG|Testosterone Undecanoate|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.
214947391|NCT05964920|DRUG|Saline + Resistance exercise training|Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
214947392|NCT05964920|DRUG|Testosterone Undecanoate + Resistance exercise training|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
214947393|NCT00546312|DEVICE|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
214947394|NCT02889614|OTHER|Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)|LDL-C dosage.
214947395|NCT04826835|BEHAVIORAL|Prehabilitation intervention|"Participants will:~* Receive four supervised exercise classes (twice per week for two weeks) one-to-one by an exercise specialist;~* Practice six sessions of home-based exercise (three times per week for two weeks);~* Practice unsupervised respiratory muscle training at home (twice daily for two weeks);~* Receive usual care."
214947396|NCT04826835|BEHAVIORAL|Health education control|"Participants will:~* Receive four recorded health education talks (twice per week for two weeks)~* Receive a brief health education booklet on dietary education for chronic lung conditions, preoperative preparation, and postoperative recovery~* Receive usual care."
214947397|NCT05992259|DEVICE|TENS|TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.
214947398|NCT04542876|DRUG|Guduchi Ghan Vati|Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
214947399|NCT00851188|BEHAVIORAL|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
214947400|NCT00851188|BEHAVIORAL|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
214947401|NCT00851188|OTHER|Waiting list|Waiting list
214342381|NCT02740127|DRUG|Ropivacaine|Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
214342382|NCT02740127|DRUG|Epinephrine|Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
214342383|NCT02740127|DRUG|Decadron|Decadron 10 mg by bolus injection given by anesthesiologist in OR.
214342384|NCT02740127|DRUG|Clonidine|Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
214947402|NCT00000613|BEHAVIORAL|dietary supplements|
214947403|NCT00000613|DRUG|genistein|
214947404|NCT00000613|BEHAVIORAL|diet, soy proteins|
214947405|NCT05492747|OTHER|Kangaroo Care an Effect|Researchers evaluated vital signs and oxygen saturation of preterm infants in the kangaroo care group 15 minutes before kangaroo care. After the baby's mother was admitted to the NICU, she was assisted by the researcher for hand hygiene and they went to the incubator together. The mother was seated in a comfortable chair next to the incubator. After the researcher covered the head and back of the preterm baby with a baby blanket, she took it from the incubator and placed it between the mother's breasts, with the head up and upright. The baby was supported not only by the neck and shoulders, but also by the whole body. Skin contact between mother and baby was ensured at the highest level. The baby was positioned so that its lips were touching the mother's nipple. The researcher waited until the baby opened its mouth.
214947406|NCT02626650|OTHER|Symptom elicitiation|Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
214342385|NCT02740127|DRUG|Propofol|General anesthesia given in the OR using Propofol titrated for induction.
214342386|NCT02740127|BEHAVIORAL|Phone Call|Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
214947407|NCT06443515|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound examinations will be performed within 6 hours before and after blood transfusion to assess interstitial-alveolar fluid retention and calculate a LUS score
214947408|NCT04524767|BEHAVIORAL|SBIRT|Screening Brief Intervention and Referral to Treatment (SBIRT) is an evidence-based approach designed to provide screening, brief intervention, and referral to more intensive treatment for people at risk of developing mental disorders, including depression. SBIRT is composed of three core components: screening with a validated instrument, brief intervention, referral to treatment. Motivational Interviewing (MI) is the brief intervention most commonly used in SBIRT. MI is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. Subjects enrolled in the experimental SBIRT arm will receive up to a maximum of six sessions of MI.
214947409|NCT04524767|BEHAVIORAL|Referral as Usual|We will utilize depression educational brochures describing the nine hallmark symptoms of depression symptoms and the importance of seeking treatment from pamphlets from the National Institute of Mental Health (NIMH). Subjects will also receive a list of referral sites in the study's catchment area of Upper Manhattan
214947410|NCT04024878|DRUG|Nivolumab|Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
214947411|NCT04024878|BIOLOGICAL|NeoVax|"The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity"
214947412|NCT04024878|PROCEDURE|Core Needle Biopsy|Surgical procedure
214947413|NCT02474355|PROCEDURE|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
214947414|NCT02474355|PROCEDURE|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
214947415|NCT02474355|PROCEDURE|Baseline ECG|ECG to ensure absence of any cardiac abnormality
214947416|NCT02474355|PROCEDURE|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
214947417|NCT02474355|DRUG|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
214947418|NCT05753540|OTHER|Laser therapy|Multiwave locked system laser therapy
214947419|NCT05753540|OTHER|Sham laser therapy|Sham laser therapy
214947420|NCT01082796|DRUG|Glipizide|Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
214947421|NCT03484624|DEVICE|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
214947422|NCT04653155|BEHAVIORAL|Cognitive behavioural therapy for insomnia|Cognitive behavioural therapy for insomnia
214947423|NCT00943501|DRUG|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
214947424|NCT00943501|DRUG|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
214947425|NCT00943501|DRUG|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
214947426|NCT00943501|DRUG|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
214947427|NCT04605926|BIOLOGICAL|EQ001|itolizumab \[Bmab600\]
214342387|NCT04759820|DRUG|injecting Carbon Nanoparticles Suspension|injecting Carbon Nanoparticles Suspension for lymph node detection
214342388|NCT04759820|DRUG|Injecting indocyanine green|Injecting indocyanine green for lymph node detection
214342389|NCT01479660|OTHER|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
214342390|NCT01479660|DRUG|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
214947428|NCT04605926|BIOLOGICAL|EQ001 Placebo|EQ001 Placebo
214947429|NCT04209907|OTHER|retrolaminar block tecnique|By using ultrasound probe, the needle with in-plane , after seeing vertebral lamina, the local anesthetic will injectate
214947430|NCT04688606|DIAGNOSTIC_TEST|Circulating tumor cell capture technology|CTCBIOPSY® automatic testing platform
214947431|NCT01859871|BEHAVIORAL|Website Intervention|Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
214947432|NCT01066793|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
214947433|NCT01066793|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
214947434|NCT02844036|PROCEDURE|Percutaneous angioplasty|
214947435|NCT02844036|PROCEDURE|Balloon angioplasty|
214947436|NCT02844036|PROCEDURE|Right heart catheterization|
214947437|NCT02844036|PROCEDURE|Echocardiography|
214947438|NCT02844036|OTHER|A six-minute walking test|
214947439|NCT02844036|PROCEDURE|Functional respiratory investigations|
214947440|NCT02844036|PROCEDURE|Pulmonary tomography or pulmonary angiography|
214947441|NCT02844036|OTHER|Biological parameters|
214342391|NCT04898335|DEVICE|Tendyne Mitral Valve System|Tendyne Mitral Valve System for mitral valve disease in a commercial setting
214342392|NCT04000906|DRUG|Nab paclitaxel|Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
214342393|NCT04000906|DRUG|Cisplatin|10.5 mg/m2
214947442|NCT00315484|DRUG|Epoetin alfa and Darbepoetin alfa|
214947443|NCT05992688|OTHER|Sucrose sweetened beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
214947444|NCT05992688|OTHER|Stevia sweetened beverages|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
214947445|NCT05992688|OTHER|Calorie free flavored water beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
214947446|NCT01911793|DEVICE|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
214342394|NCT02707055|DRUG|PF-05190457|Ghrelin Receptor Inverse Agonist
214342395|NCT02707055|OTHER|Placebo|Placebo
214342396|NCT06158750|DEVICE|p64/p48 MW HPC Flow Modulation Device|Endovascular intervention with p64/p48 MW HPC Flow Modulation Device was performed in patients diagnosed with intracranial aneurysms
214947447|NCT00293800|DRUG|Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
214947448|NCT00293800|DRUG|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
214947449|NCT00293800|DRUG|Timolol 0.5% Ophthalmic Solution|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
214947450|NCT00293800|OTHER|Timolol Vehicle|Placebo
214947451|NCT05880667|RADIATION|Adaptive Stereotactic Body Radiation|"Radiation therapy is given following generation of planning imaging at the time of simulation. A recent development has been diagnostic quality onboard imaging incorporated within radiation treatment machines. The incorporation of onboard imaging into standard practice has allowed the use Stereotactic Body Radiation (SBRT), which is a precise radiation technique that allows safe delivery of ablative radiation doses.~More recently, the development of improved technologies and software have allowed radiation plans to be generated and delivered that are specific to the anatomy of the very moment the patient is being treated. This novel ability to adjust the radiation treatment plan based upon real time imaging is termed adaptive radiation therapy. This study will utilize the novel adaptive radiation therapy technology in a patient population with technically challenging disease to deliver ablative radiation with an appropriately low toxicity rate."
214947452|NCT06337747|DEVICE|Traditional technique|Subjects randomized to the traditional technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region.
214947453|NCT06337747|DEVICE|Experimental technique|Subjects randomized to the extended technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region, as well as 2cc (per side, per treatment) in the posterior (i.e., behind the hairline) temporal region.
214947454|NCT02981732|OTHER|Liuwei Dihuang Pill|
214947455|NCT01599481|BEHAVIORAL|Individual Career Management (ICM)|The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.
214947456|NCT01599481|BEHAVIORAL|Standard Care|A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
214947457|NCT04802083|BIOLOGICAL|Eculizumab|Eculizumab 900-1200 mg will be administered intravenously.
214947458|NCT06323395|DRUG|Vizol S LIPID BALANCE eye drops|1 drop 4 times a day
214947459|NCT06323395|DRUG|ophthalmic saline eye drops|1 drop 4 times a day
214947460|NCT04024566|DEVICE|Vivio System|Optical/sensor tonometer applied to the neck over the carotid pulse (bilateral)
214947461|NCT04112550|DRUG|Methadone Hydrochloride|FDA approved medication to treat pain
214947462|NCT04112550|DRUG|Oxycodone-Acetaminophen|FDA approved medication to treat pain
214947463|NCT02982148|DEVICE|methylene blue intradermal injection|Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
214947464|NCT02982148|DEVICE|methylene blue subcutaneous injection|Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
214947465|NCT01575002|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
214342397|NCT03564496|DEVICE|tDCS Administration during MRI|All participants including healthy controls and MS patients will be given approximately 15 minutes of active tDCS during MRI. The simultaneous tDCS will be performed up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on to when the tDCS is off. The stimulation consists of 15-min up to 2 mA tDCS using 5x5 cm electrode sponges with \~30s ramp-up and ramp-down periods.
214678061|NCT02805699|DRUG|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
214678062|NCT00897559|GENETIC|gene expression analysis|
214678063|NCT00897559|GENETIC|mutation analysis|
214678064|NCT00897559|GENETIC|polymorphism analysis|
214947466|NCT05891717|OTHER|Resistance training|Twice per week for 8 weeks. Total 16 sessions will given.
214947467|NCT05891717|OTHER|Flexibility training|Twice per week for 8 weeks. Total 16 sessions will given.
214947468|NCT01873157|DRUG|Bortezomib|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
214947469|NCT01873157|DRUG|Placebo|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
214947470|NCT04321941|DIAGNOSTIC_TEST|Lumentin|Contrast agent used in combination with CTE
214947471|NCT04321941|DIAGNOSTIC_TEST|Movprep|Contrast agent used in combination with MRE
214947472|NCT06397209|OTHER|Propioceptive Neuromascular facilitation|Propioceptive Neuromascular Facilitation techniques will be given for 5 days/week,10 repetitions,30 minutes/day for 8 weeks
214947473|NCT06397209|OTHER|Neural Flossing|Neural Flossing exercises will be given for 5 days/week, 3 sets of 10 repetitions in 2 minutes for 30 minutes for 8 weeks
214947474|NCT06199544|DRUG|Metformin|Comparing the effect of drugs on symptoms of PCOS
214947475|NCT00394394|DRUG|Amiloride 2,5/d or Enalapril/d 10 mg|
214947476|NCT04957199|OTHER||
215075336|NCT05630222|DRUG|Ibuprofen 800 mg|Ibuprofen from Caspian Taamin Company
215075337|NCT05630222|DRUG|Morphine Sulfate|Morphine Sulfate from Darupakhsh Company
215075338|NCT05630222|DRUG|Ibuprofen 400 mg plus Acetaminophen 1000 mg|Both from Caspian Taamin Company
214678065|NCT00897559|GENETIC|protein analysis|
214678066|NCT00897559|OTHER|flow cytometry|
214678067|NCT00897559|OTHER|laboratory biomarker analysis|
214678068|NCT03540368|DRUG|Tranexamic acid injection|Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
214947477|NCT05693025|BEHAVIORAL|Group Exercise|The study evaluates two different approaches for group exercise. Participants in the Standard Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. Participants are guided to learn and perform a series of stretching and strengthening exercises recommended in the base WWE program. Primary BCTs include instruction on how to perform behavior (#4.1) and Graded tasks (#8.7). Participants in the Enhanced Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. They may perform some of the same exercises as those in the SI group but they are also guided to learn and perform specific exercises prescribed by a physical therapist to improve balance and reduce risks of falling. The primary BCTs include instruction on how to perform behavior (#4.1), Graded tasks (#8.7) from the base program as well as Information on health consequences (#5.1) and Credible source (#9.1).
214947478|NCT05693025|BEHAVIORAL|Behavioral Training|The study evaluates two different approaches for promoting behavior change. Participants in the Standard Training (ST) model follow the standardized Walk with Ease training to support behavior change. Participants are provided with goal setting tools and an online tracker to monitor their progress. Weekly video-based lessons, resource links and eBook content support behavior change. Primary BCTs include Goal Setting (BCT #1.1) and self-monitoring (BCT#2.3). Participants in the Enhanced Training (ET) model access the same basic content as the ST model, but the weekly education-based videos are replaced with lessons focus on habit-formation training. Student coaches are also assigned to individual participants to support behavior change efforts using motivational interviewing strategies. Thus, participants in the ET model also receive two additional theory- and evidence-based BCTs: (1) habit formation training (BCT#1.2, #1.4, #8.3) and (2 health coaching (BCT# 3.3).
214947479|NCT01375452|DRUG|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
214947480|NCT03531476|BEHAVIORAL|Online Chronic Pain Management Program|With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program. The study therapist is a registered health professional. The program will consist of 5 weeks of mindfulness training. The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
214947481|NCT00851864|DRUG|Tinzaparin|"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy."
214947482|NCT02436499|DRUG|Botulinum Toxin-A|
214947483|NCT02812225|DEVICE|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
214947484|NCT02614404|DRUG|Imatinib combination therapy|Imatinib plus dihydroartemisinin plus piperaquine
214678069|NCT03540368|OTHER|Placebo|Administering placebo or sodium chloride 0,9% intravenously
214678070|NCT02575482|DRUG|SUVN-D4010|
214678071|NCT02575482|DRUG|Placebo|
214678072|NCT02963077|DRUG|A4250|
214678073|NCT02963077|DRUG|CRC (A3384)|
214678074|NCT02963077|DRUG|Questran|
214678075|NCT02963077|DRUG|Placebo|
214678076|NCT04526977|DIAGNOSTIC_TEST|Immune response study|"* ACE2 and CD26 receptor study~* Cytokine profile: Quantification of plasma cytokine levels~* SARS-CoV-2 CD4/CD8 T cell response~* TLR7/8 activation~* KIR characterization"
214678077|NCT04373980|DEVICE|phototherapy|estimate CD4 and CD8 subsets in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
214678078|NCT05044169|DRUG|Broncho-Vaxom|administration for 6 months after remmission
214678079|NCT04876664|DEVICE|measuring blood pressure with noninvasive blood pressure device|To measure blood pressure in different circumstances with noninvasive blood pressure device
214678080|NCT00547937|DEVICE|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
214678081|NCT04331730|DRUG|AKST4290|Oral AKST4290
214678082|NCT04331730|DRUG|Placebo|Oral placebo
214678083|NCT04331730|DRUG|Aflibercept|Aflibercept intravitreal injection
214347491|NCT02575599|BEHAVIORAL|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
214947485|NCT02614404|DRUG|Dihydroartemisinin-piperaquine|Standard of care
214947486|NCT01533688|DRUG|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
214947487|NCT01533688|DRUG|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
214947488|NCT01533688|DRUG|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
214947489|NCT01493115|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214947490|NCT01493115|DRUG|Insulin glargine - New formulation HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
214947491|NCT03748368|OTHER|Cataract presentation|Presentation about cataract surgery
214947492|NCT03748368|OTHER|Placebo presentation|Presentation about the history of the hospital
214947493|NCT03126123|PROCEDURE|acetic acid test|Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
214947494|NCT05205629|DRUG|Donafenib combined with TACE|Donafenib(200mg bid po) combined with TACE
214947495|NCT04591015|BEHAVIORAL|Hospital: DD-CA|In the DD-CA group, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with educational, motivational and medication adherence messaging that is currently an arm of our parent DD-ME grant with added COVID support messages that provide information addressing identified barriers in Hispanic underserved communities (e.g. obtaining testing supplies and medications, accessing routine medical care, and completing other important diabetes self-management behaviors such as healthful eating, exercise, social distancing, quarantine, and stay-at-home/lockdown guidelines).
214947496|NCT04591015|BEHAVIORAL|Hospital: Usual Care (UC)|In the UC group, participants will not receive the added COVID support messages, both groups will have a referral placed to the Diabetes Transitions Service (DTS) at the time of discharge as part of usual care. Participants will be contacted by a peer health coach following protocol to coordinate care with outpatient health and other community resources.
214947497|NCT02509078|DRUG|Cisatracurium Besylate|Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
214947498|NCT02686814|DEVICE|17mm MDT-2215 aortic valve bioprosthesis|
214947499|NCT03165084|BEHAVIORAL|Intervention arm: Person-centred interactive self-management support|"Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.~Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources."
214947500|NCT03165084|OTHER|Control arm|Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
214947501|NCT03165084|OTHER|External comparison group|External comparison groups in order to analyse possible Hawthorne effects.
214947502|NCT04051814|OTHER|Micra Transcatheter Pacemaker System|A miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart
214947503|NCT00452153|PROCEDURE|Characterization Legionnella|"* Characterisation Legionnella by polymerase chain reaction (PCR)~* Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region"
214947504|NCT02401698|OTHER|Functional clinical and TMS diagnostic|Functional clinical and TMS diagnostic examination to evaluate corticospinal motor tract activity and corticocerebellar tract activity and its relation with stroke recovery
214947505|NCT04844983|DRUG|STP705|The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
214947506|NCT04844983|OTHER|Placebo Saline|Normal Saline
214947507|NCT05124483|BIOLOGICAL|AKS-452X|subcutaneous injection of 90 µg AKS-452X
214678084|NCT05552599|PROCEDURE|woolen blanket|Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
214678085|NCT03845998|PROCEDURE|use the three-finger method|The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.
214678086|NCT03845998|PROCEDURE|use the weight-related method|The size of the laryngeal mask airway was determined by the patient's weight.
215075339|NCT04139577|BIOLOGICAL|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
215075340|NCT03239782|BEHAVIORAL|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
214678087|NCT04390815|DRUG|Insulin|Adding insulin to conventional wound treatment
214678088|NCT04372693|OTHER|impliminting Online Distance Learning|as a result of (COVID-19) social distancing measures, the Online Distance Learning will be implemented without prior planning for undergraduate nursing students
214947508|NCT02110628|PROCEDURE|Roux-en-Y anastomosis|Roux-en-Y anastomosis
214947509|NCT02110628|PROCEDURE|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
214947510|NCT02097771|DEVICE|LMA SupremeTM|
214947511|NCT02097771|DEVICE|AuraOnceTM|
214947512|NCT02799888|DRUG|Maraviroc|Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.
214947513|NCT02799888|DRUG|Cyclosporine (in HLA-Unrelated Donor Transplantation)|Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.
214947514|NCT02799888|DRUG|Tacrolimus (in HLA-Mismatched Related Donor Transplantation)|Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
214947515|NCT02799888|DRUG|Methotrexate|Methotrexate will be administered intravenously at a dose of 15 mg/m\^2 on day +1, and 10 mg/m\^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10\^9/L.
214947516|NCT01913522|PROCEDURE|Pulmonary Vein Isolation|
214947517|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE +200mg ALA|200mg green coffee extract + 200mg alpha-lipoic acid
214947518|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE +400mg ALA|200mg green coffee extract + 400mg alpha-lipoic acid
214947519|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE + 200mg DHB|200mg green coffee extract + 200mg dihydroberberine
214947520|NCT06137066|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose with 5 mg magnesium stearate and 5 mg silicon dioxide
214947521|NCT01609088|DIETARY_SUPPLEMENT|Erythritol-containing beverage|Orange flavored beverage containing erythritol
214678089|NCT05786261|DEVICE|experimental group MIRT|Task 1a: Assessing the effect of MIRT on cortical plasticity tested with rPAS Task 1b: Assessing the effect of MIRT on structural cortical plasticity and brain connectivity tested with MRI Task 1c: Assessing the effect of MIRT on movement-related beta modulation Task 1d: Assessing the effects of MIRT on motor skills formation with reaching tasks Task 1e: Assessing the effects of MIRT on EEG correlates of motor skills formation Task 2a: Assessing the effect of MIRT on muscle synergies during gait Task 2b: Assessing the effect of MIRT on muscle synergies during reaching movements Task 3a: Assessing the effect of MIRT on sleep microstructure
214947522|NCT02253381|PROCEDURE|Right|Right lateral decubitus position during spinal anesthesia
214947523|NCT02253381|PROCEDURE|Left|Left lateral decubitus position during spinal anesthesia
214947524|NCT04665973|BEHAVIORAL|Therapeutic patient education : oral semi-structured interview|The physiotherapist discusses and goes through each page of the booklet and involves the patient as much as possible. He demonstrates the exercises proposed in the booklet and then ask the patient to perform them in front of him. The physiotherapist tries to identify the patient's needs and suggests different ways to ensure that the patient has different opportunities to maintain the best possible level of PA
214947525|NCT04665973|BEHAVIORAL|Therapeutic patient education : booklet (passive)|The booklet (11 pages): explains why it is important to maintain a good level of PA as part of cancer treatment and reviews the most common side effects of cancer therapy and the relative importance of PA in combating these effects (pages 2-3) ; defines PA, its modalities and possible security precautions (pages 4-5), suggests exercises to be performed oneself and a target intensity to be reached (pages 6-8), provides a roadmap to be completed oneself (pages 9-10), and outlines procedures for joining an exercise medicine group (page 11).
214947526|NCT00290693|DRUG|Capecitabine|Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
214678090|NCT05786261|DEVICE|EEG task rTMS, fMRI|EEG task rTMS, fMRI
214678091|NCT03595215|DEVICE|TENS|Transcutaneous electrical nerve stimulation
214678092|NCT01627756|OTHER|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
214678093|NCT01627756|OTHER|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
214678094|NCT01359826|DRUG|Milnacipran|After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
214678095|NCT01753752|DRUG|Chitosan- N- Acetylcysteine eye drops|
214678096|NCT01753752|DRUG|Placebo|
214678097|NCT04064684|DRUG|Budesonide|Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
214678098|NCT04064684|DRUG|Placebo|Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
214678099|NCT04064684|DEVICE|Nebulizer|The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
214947527|NCT00290693|DRUG|Docetaxel|30 mg/m2, IV, days 1 and 8 every 3 weeks
214947528|NCT05212779|DIAGNOSTIC_TEST|Signatera testing|26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.
214947529|NCT05212779|DIAGNOSTIC_TEST|Altera Testing|6ml blood and tissue sample.
214947530|NCT05089812|PROCEDURE|Third-molar extraction using platelet-rich fibrin as a filling of the alveolus|see above
214947531|NCT03797131|OTHER|KB195 (a novel mixture of oligosaccharides)|KB195 (a novel mixture of oligosaccharides) for oral intake for 21 days.
214947532|NCT02907619|BIOLOGICAL|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
214947533|NCT00404716|DRUG|Cilostazol|
214342398|NCT03564496|DEVICE|Remotely-supervised Daily tDCS Administration|"While the first tDCS session will be performed at clinic under the full supervision, remaining sessions 2-20 (\~ 1 month) will be completed at home with remote monitoring by the study technician. Participants in the HC subgroup who opt-in to the additional 15 minutes of imaging +tDCS may complete the first session remotely.~For at-home tDCS administration, participants will be given the specially-designed tDCS device and headset, study laptop computer for secure video monitoring with study technician (must have internet access) and access to the cognitive training program, a detailed reference manual, and a training video. The device will produce up to 2.0 mA stimulation for around 20 minutes, and will not operate without the correct headset placement. The device will also automatically abort the session if optimal conditions are not maintained. It reports and records a completion code for each session."
214347492|NCT05437510|BIOLOGICAL|Nirsevimab|Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular
214678100|NCT04014504|DIAGNOSTIC_TEST|Neonatal Hearing Screening Test|neonatal hearing screening test results will be evaluated.
214678101|NCT01347918|DEVICE|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
214678102|NCT01347918|DIETARY_SUPPLEMENT|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
214678103|NCT00256828|DRUG|didanosine + lamivudine + efavirenz|
214947534|NCT05440721|DEVICE|Treatment A with device Clickotine® (Active intervention)|The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.
214678104|NCT03028025|DEVICE|StatSeal|Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
214947535|NCT05440721|DEVICE|Treatment B with smoking education (control)|The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.
214947536|NCT05509101|OTHER|commercially available control algorithm|Control of the prosthesis/orthosis is based on clinical standard of care using commercially available control algorithms.
214678105|NCT03028025|DEVICE|TR Band|Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
214678106|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 200mg PO is given
214678107|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 400mg PO is given
214347493|NCT01956526|DEVICE|CORolla™ TAA device|
214678108|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 600mg PO is given
214678109|NCT02644525|DRUG|Placebo|A single dose of placebo pill is given
214947537|NCT05509101|OTHER|experimental control algorithm|Control of the orthosis is based on residual muscle activity mapped to intended movement using high density electromyography and artificial intelligence control algorithms.
214947538|NCT02484768|DRUG|Iron isomaltoside 1000|Intravenous treatment
214947539|NCT02484768|DRUG|Sodium Chloride 0.9%|Intravenous treatment
214947540|NCT01327092|OTHER|Injury Intervention Group|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
214947541|NCT05161572|DRUG|Oxaliplatin|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1.
214947542|NCT05161572|DRUG|Tegafur-Gimeracil-Oteracil|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. S-1 is administered orally at 40-60 mg twice a day for 14 consecutive days. Then, the patients will have a one-week rest period. The dose of S-1 is according to the body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily.
214947543|NCT05161572|DRUG|Sintilimab|The immunotherapy includes perioperative treatment and postoperative maintenance treatment. The PD-1 mAb used will be sintilimab, and the dose is 200 mg intravenously every three weeks. Regardless of which arm, the courses of immunotherapy that will be received by the enrolled patients are the same: 3 times preoperatively, 3 times postoperatively, and then maintained until one year after surgery.
214947544|NCT05161572|RADIATION|Concurrent chemoradiation|The radiotherapy (RT) consists of 45 Gy delivered in 25 fractions every five days per week for five weeks. The dose of concurrent ChT is 60 mg/m2 S-1 orally, oral tablets twice daily, days 1-5 of each week.
214947545|NCT05161572|PROCEDURE|D2/R0 gastrectomy|Gastrectomy with standard D2 lymphadenectomy is recommended. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle third tumors, the gastric margin is recommended to be more than 5 cm, and a total gastrectomy is performed. For lower third tumors, a 2 cm duodenal margin is recommended, and a subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
214342399|NCT03564496|DEVICE|Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA|Participants in the healthy control subgroup who are willing may have an additional 15 minutes of imaging combined with 10 minutes of simultaneous tDCS of up to 4.0mA added at the end of their baseline scan. In this case, after the initial imaging and tDCS portion is complete, the participant will remain on the scanner for an additional 15 minutes during which brain imaging will continue and will be combined with 10 minutes of simultaneous tDCS up to 4.0mA. This will be a one-time add-on and will not be required at follow-up.
214342400|NCT04989348|PROCEDURE|Gonadotrophin releasing hormone antagonist protocol|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger or
214947546|NCT02527317|DRUG|Lipegfilgrastim|Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).
214947547|NCT00000589|PROCEDURE|platelet transfusion|
214947548|NCT05870670|DRUG|NNC0519-0130|Administered subcutaneously.
214947549|NCT05870670|DRUG|Placebo|Administered subcutaneously.
214947550|NCT06557421|DRUG|Venetoclax|complete discontinuation of Venetoclax
214947551|NCT06557421|DRUG|Azacitidine|complete discontinuation of Azacitidine
214947552|NCT06339827|BEHAVIORAL|Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List|Participants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.
214947553|NCT04349046|DEVICE|Total hip arthoplasty (THA)|Total hip arthroplasty (THA) is a common operative treatment where an arthritic, degenerative or fractured hip joint is replaced with a prosthetic device if conservative options are unable to relieve pain and debilitating symptoms. THA was traditionally performed on patients over 60 years old, but now includes young and active patients, as well as very old ones thanks to the continuous improvement in implant design. Major indications of THA include osteoarthritis, rheumatoid arthritis, avascular necrosis and hip fractures. The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.
214342401|NCT04989348|PROCEDURE|Progestin-primed ovarian stimulation protocol|Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
214342402|NCT02977624|BEHAVIORAL|The Cognitive Orientation to daily Occupational Performance|
214342403|NCT00709969|DRUG|Artemether-lumefantrine|20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - \< 10kg (BWG 1) = 6 doses of 1 tablet / 10 - \< 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
214342404|NCT02559674|BIOLOGICAL|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
214342405|NCT02559674|BIOLOGICAL|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
214342406|NCT02559674|BIOLOGICAL|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
214342407|NCT04433169|DRUG|All-trans Retinoic Acid|ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles
214342408|NCT04433169|DRUG|VEGFR inhibitor|VEGFR inhibitor
214342409|NCT04433169|DRUG|Chemotherapy|chemotherapy
214342410|NCT01159938|DRUG|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
214342411|NCT00457262|PROCEDURE|soy consumption|
214947554|NCT05035082|DRUG|semaglutide|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
214947555|NCT05035082|DRUG|oral glucose-lowering medications (commercially available)|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
214342412|NCT00122018|DRUG|N-acetylcysteine|
214342413|NCT00122018|DRUG|fenoldopam|
214347494|NCT05706506|DRUG|Tirzepatide|Administered SC
214947556|NCT05567406|DRUG|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
214947557|NCT05684796|DRUG|Anticoagulation|Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)
214947558|NCT05684796|DEVICE|mechanical aspiration thrombectomy|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
214947559|NCT05783466|OTHER|Low-fat dairy products|3-month intervention
214947560|NCT05783466|OTHER|Whole-fat dairy products|3-month intervention
214947561|NCT05783466|OTHER|Milk polar lipid enriched whole-fat dairy products|3-month intervention
214947562|NCT05210803|OTHER|No intervention.|All subjects that previously received RGX-314 in a parent study
214947563|NCT03196375|DRUG|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
214947564|NCT03196375|DRUG|Placebo ODT|Placebo ODT taken three times daily for 28 days
214947565|NCT01450072|DEVICE|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
214342414|NCT03914157|DEVICE|Low-energy extracorporeal ultrasound shockwave therapy (SWT)|SWT delivers 10% energy of the traditional SWT used for clinically indicated lithotripsy, evokes neovascularization, and improves regional blood flow and function in various ischemic tissues.
214342415|NCT02638662|OTHER|Observational|Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
214342416|NCT02126293|DRUG|Zinc Supplement|
214342417|NCT02126293|PROCEDURE|Repeat blood and urine tests|
214342418|NCT05864794|DIAGNOSTIC_TEST|MRI|MRI scan of the brain
214342419|NCT04608474|DRUG|Evolocumab|Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.
214342420|NCT04608474|DRUG|Statins (Cardiovascular Agents)|Previously prescribed statin therapy.
214342421|NCT00169169|DRUG|ACVBP|
214342422|NCT00169169|DRUG|ACE|
214342423|NCT00169169|DRUG|rituximab|
214342424|NCT00169169|PROCEDURE|Autologous stem cell transplant|
214342425|NCT01625429|DRUG|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
214342426|NCT03214497|DEVICE|Protector|All patients which are assigned to the Protector are studied with this laryngeal mask
214342427|NCT03214497|DEVICE|Supreme|All patients which are assigned to the Supreme are studied with this laryngeal mask
214342428|NCT05073016|OTHER|neuromodulation|neuromodulation: Neuromodulation is technology that acts directly upon nerves. It is the alteration-or modulation-of nerve activity by delivering electrical or magnetic stimulus/current.
214947566|NCT01450072|OTHER|Control arm|Venography and sham angioplasty
214947567|NCT04500678|DRUG|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
214947568|NCT02711943|DRUG|Levofloxacin 500|Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
214342429|NCT05073016|OTHER|motor learning training|motor learning training requires performing a sequential training called finger taping task
214342430|NCT00392561|DIETARY_SUPPLEMENT|Selenium|200 ug Selenium daily
214342431|NCT00392561|DIETARY_SUPPLEMENT|vitamin E|100 mg Vitamin E daily
214342432|NCT02001480|DEVICE|12 lead Holter|12 lead Holter measurements will be performed for 7 days
214342433|NCT02001480|DEVICE|CGM Continuous Glucose Monitoring|CGM will be performed continously for 7 days
214342434|NCT02942199|OTHER|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
214342435|NCT05709834|OTHER|Autogenic training|"Relaxation procedures will be performed in the following steps: First step - preparation: Each pre-eclamptic woman will be instructed about this method of treatment and its importance for reducing blood pressure to gain her confidence and cooperation during treatment. Second step - AT: The session began with a few minutes of mental relaxation as the patient will be asked to imagine herself in a lovely place that makes her relaxed. Each session include 18 exercises combining both relaxation and auto-suggestion (limb heaviness exercise, limb warmth exercise, cardiac exercise, respiration exercise, solar plexus warmth exercise, and forehead cooling exercise).~About 30 sec will be allowed for each exercise and a further 30-40 sec will allowed for continuing attention focusing by the patient. Third step - termination"
214342436|NCT05709834|OTHER|Conventional treatment|Patients will receive conventional treatment
214342437|NCT06065072|DEVICE|Optical measurement|Optical measurements by optical biometers and an OCT
214947569|NCT03749499|OTHER|HTN Educational Video|The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.
214947570|NCT03749499|OTHER|Visual Echocardiogram Image Clips|Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.
214947571|NCT03749499|OTHER|Mobile Health and Remote BP monitoring|All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
214342438|NCT03895424|DIETARY_SUPPLEMENT|IFAC|This intervention will contain the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope 58Fe
214342439|NCT03895424|DIETARY_SUPPLEMENT|MIFAC|This intervention will contain the micellarized form of the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope with 57Fe
214342440|NCT03895424|DIETARY_SUPPLEMENT|Control Ferrous Sulfate|This intervention will contain ferrous sulfate in the form of a solution labelled with the iron isotope 54Fe. A capsule with the same amount of fat as in the other arms will be administered to the participants
214947572|NCT03749499|OTHER|Post-Acute Care HTN Transition consultation (PACHT-c)|All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
214947573|NCT03208413|DRUG|Thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
214342441|NCT05659290|DRUG|Fruquintinib alternating with Bevacizumab plus Capecitabine|Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
214947574|NCT05199935|BEHAVIORAL|Video|Information on violence and safety behaviors. Women are encouraged to share their experience of domestic violence with others.
214947575|NCT05199935|OTHER|Control|Control video on healthy pregnancy
214342442|NCT05659290|DRUG|Bevacizumab plus Capecitabine|Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
214342443|NCT05851404|PROCEDURE|Thyroidectomy|Total thyroidectomy or lobectomy
214947576|NCT02958410|BIOLOGICAL|Anti-CD30-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
214947577|NCT03701685|PROCEDURE|nerve flap|sensory reconstruction via a nerve graft included in the flap
214947578|NCT04250428|BEHAVIORAL|Demand intervention|"Women in the demand intervention arm will receive a home visit by a study nurse who will highlight the importance of supplementation and prophyllaxis to women. During this session, women will also be informed regarding side effects and the ideal timing of supplementation (after meals)."
214947579|NCT04250428|BEHAVIORAL|Supply intervention|In order to directly test the importance of access barriers, we will deliver supplements as well as malaria chemo- prophyllaxis directly to women through home visits by study nurses.
214947580|NCT05119686|DRUG|AR882 Dose 1|Solid Oral Capsule
214947581|NCT05119686|DRUG|AR882 Dose 2|Solid Oral Capsule
214947582|NCT05119686|DRUG|Placebo|Matching Solid Oral Capsule Placebo
214947583|NCT03495115|DEVICE|MRI|A MRI uses a strong magnet to produce detailed pictures of the inside of your body.
214947584|NCT03495115|DEVICE|RSI|RSI is a technique that aims to improve the pictures produced during a MRI exam.
214947585|NCT05745753|OTHER|sample blood|At the time of enrolment, peripheral blood sampling is expected at the outpatient clinic of the experimental center and the study of the patient's clinical history.
214947586|NCT04402450|PROCEDURE|Ultrasound-guided suprainguinal fascia iliaca nerve block|After an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.
214947587|NCT04402450|PROCEDURE|Ultrasound-guided pericapsular nerves group of the hip block|After an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.
214947588|NCT00682994|BEHAVIORAL|Interview|Interview lasting about 5-10 minutes.
214947589|NCT00682994|BEHAVIORAL|Questionnaire|Questionnaires taking 20-30 minutes to complete.
214947590|NCT00072488|PROCEDURE|computed tomography|
214947591|NCT00072488|PROCEDURE|magnetic resonance imaging|
214342444|NCT02487563|DRUG|Decitabine|Decitabine
214342445|NCT02487563|DRUG|rhTPO|rhTPO
214947592|NCT00072488|PROCEDURE|positron emission tomography|
214947593|NCT04242485|OTHER|Osteopathic manipulative treatment|Each osteopathic manipulative treatment consisted of a structured evaluation to diagnose somatic dysfunction of the pelvis, abdomen, vertebral spine, and upper and lower limbs (10 min), followed by the therapeutic application of manually guided forces to improve physiological function and homeostasis that has been altered by somatic dysfunction for 20 min, using techniques that were left at the discretion of the osteopath, including the myofascial release and cranial sacrum techniques
214947594|NCT04242485|OTHER|Sham treatment|"The sham treatment consisted only in soft touch of the same body areas involved in the osteopathic manipulative treatment protocol without applying any pressure"
214947595|NCT05812430|DRUG|anlotinib+TQB2450+nab-paclitaxel+cisplatin|"Anlotinib: 10mg, po, d1\~14, q3w, until disease progression or unacceptable toxicity.~TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity.~nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles."
214947596|NCT00564291|OTHER|Examination with an OCT device|
214947597|NCT00675337|PROCEDURE|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
214947598|NCT00675337|PROCEDURE|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
214342446|NCT02487563|OTHER|Conventional Treatment|immunoglobulin, glucocorticoid etc
214947599|NCT02635009|RADIATION|Three-Dimensional Conformal Radiation Therapy|daily fractions
214947600|NCT02635009|RADIATION|Intensity-Modulated Radiation Therapy|daily fractions
214947601|NCT01249586|OTHER|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
214947602|NCT02838472|DRUG|Ascorbic Acid|Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
214947603|NCT02636699|BIOLOGICAL|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
214947604|NCT02636699|BIOLOGICAL|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
214678110|NCT03412422|DIAGNOSTIC_TEST|fluid responsiveness assessment|During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
214947605|NCT02763917|DEVICE|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight.
214947606|NCT02763917|DEVICE|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
214678111|NCT04631471|DRUG|Ibudilast|Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
214678112|NCT04631471|PROCEDURE|Cervical decompressive surgery|Surgical decompression of degenerate cervical myelopathy
214342447|NCT00317772|DRUG|Topotecan|"Phase I Starting Dose: 2 mg/m\^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."
214342448|NCT00317772|DRUG|Gefitinib|"Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days."
214342449|NCT03102398|DRUG|TR-399 (5% Vardenafil HCl·3H2O, topical gel)|5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
214342450|NCT02359669|BEHAVIORAL|StimuLearn Intervention|"* StimuLearn apps~* Cognitive questionnaires"
214342451|NCT02359669|BEHAVIORAL|Without StimuLearn intervention|Cognitive Questionnaires
214342452|NCT01886547|OTHER|Prostate health screening|
214342453|NCT05924919|PROCEDURE|Whole-body Passive Heat Therapy (HT)|The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.
214947607|NCT06378866|DRUG|Abiraterone|Given abiraterone
214342454|NCT05924919|PROCEDURE|Thermoneutral Control (CON)|Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
214342455|NCT03717532|PROCEDURE|Placebo|Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.
214342456|NCT03717532|PROCEDURE|Personalized Tourniquet System for Blood Flow Restriction|Patients will be receiving blood flow restriction therapy with a pressure cuff
214347495|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
214678113|NCT04631471|DRUG|Matching placebo|Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
214678114|NCT03686254|COMBINATION_PRODUCT|RFA, bevacizumab and second-line chemotherapy|Navigated by CT-ultrasound merged images, RFA is taken in the experimental arm at the first day of the first cycle during the second-line therapy. Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
214947608|NCT06378866|DRUG|Apalutamide|Given apalutamide
214947609|NCT06378866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214947610|NCT06378866|PROCEDURE|Bone Scan|Undergo bone scan
214947611|NCT06378866|PROCEDURE|Computed Tomography|Undergo CT
214947612|NCT06378866|DRUG|Darolutamide|Given darolutamide
214947613|NCT06378866|DRUG|Degarelix|Given degarelix
214947614|NCT06378866|DRUG|Enzalutamide|Given enzalutamide
214947615|NCT06378866|DRUG|Goserelin|Given goserelin
214342457|NCT06137391|PROCEDURE|Vital Pulp Therapy|The pulp is accessed after caries removal then the inflamed part of the pulp is excavated. After haemostasis is achieved, a pulpootmy medicament is used to coronally seal the remaining pulp tissue. In partial pulpotomy only part of the pulp chamber is excavated while in full pulpotomy the whole pulp chamber is excavated.
214342458|NCT02233829|DRUG|Brain Dopamine Reactivity|IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.
214342459|NCT02233829|RADIATION|Brain Dopamine Receptor|The radiotracer \[11C\] raclopride is used for imaging dopamine receptors and dopamine release.
214342460|NCT02048943|DRUG|dovitinib lactate|Given PO
214947616|NCT06378866|DRUG|Histrelin|Given histrelin
214947617|NCT06378866|DRUG|Leuprolide|Given leuprolide
214947618|NCT06378866|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214947619|NCT06378866|OTHER|Patient Observation|Undergo watchful waiting
214947620|NCT06378866|PROCEDURE|Positron Emission Tomography|Undergo PET
214947621|NCT06378866|DRUG|Prednisone|Given prednisone
214947622|NCT06378866|OTHER|Questionnaire Administration|Ancillary studies
214947623|NCT06378866|DRUG|Relugolix|Given relugolix
214947624|NCT06378866|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214947625|NCT06378866|DRUG|Triptorelin|Given triptorelin
214947626|NCT05578131|PROCEDURE|high flow nasal oxygen|In the intervention group, pre-oxygenation was provided using HFNO via Optiflow THRIVE™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) until SpO2 on pulse oximetry was \> 95% and for at least 3 min. A flow of 0.5 l/kg/min-1 was used until induction agents had been administered, and then increased to 2 l/kg/min-1. Nasal oxygenation was continued without ventilation of the lungs while waiting for neuromuscular blockade, and during placing, replacing or repositioning the airway. Anaesthetists were free to carry out bag-mask ventilation of the lungs if they considered this necessary to maintain safe oxygen saturations. After securing the airway, the patient was connected to a circle circuit primed with 100% oxygen and the FIO2 was continued at 100% for a period of at least five more minutes. Relevant times were recorded, including start of pre-oxygenation and start of induction of anaesthesia.
214947627|NCT05578131|PROCEDURE|face mask|In the control group, pre-oxygenation was provided using 100% oxygen via a sealed facemask and a circle-absorber anaesthetic circuit primed with 100% oxygen by installing a ventilation bag to the mouthpiece filter and ventilating the circuit with 100% oxygen. Anaesthetists were free to carry out bag-mask ventilation of the lungs once induction medications had been administered.
214947628|NCT03477513|RADIATION|Radation Therapy|Personalized Radiation Therapy
214342461|NCT02048943|DRUG|gemcitabine hydrochloride|Given IV
214947629|NCT06189794|OTHER|Rosa damascena oil|Essential oils will used by inhalation
214947630|NCT06660368|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.
214342462|NCT02048943|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214342463|NCT02048943|OTHER|pharmacological study|Correlative studies
214342464|NCT02048943|OTHER|laboratory biomarker analysis|Correlative studies
214342465|NCT04376996|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design - only a diagnostic testing|Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
214947631|NCT06660368|DRUG|Venetoclax|Venetoclax will be administered orally, once daily, with food.
214947632|NCT04687644|BEHAVIORAL|Online education|Education group
214947633|NCT05880342|DRUG|Reboxetine Pill|8 mg
214947634|NCT05880342|DRUG|Methylphenidate Oral Product|20 mg
214947635|NCT04032951|OTHER|Fine Needle Tissue Acquisition|diagnostic
214947636|NCT01973335|DRUG|Combination therapy with acetazolamide and low-dose loop diuretics|"* Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
214342466|NCT00774735|DRUG|GSK1349572|30 mg given in combination with lopinavir/ritonavir
214342467|NCT00774735|DRUG|GSK1349572|30 mg in combination with darunavir/ritonavir
214947637|NCT01973335|DRUG|High-dose loop diuretics|"* Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~* Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
214947638|NCT01973335|DRUG|Upfront therapy with oral spironolactone|"Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is \>5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not."
214947639|NCT04856631|DRUG|Toripalimab Injection|240mg once per 3 weeks
214947640|NCT04856631|DRUG|Cetuximab Solution for infusion|First infusion 400mg/m2，Subsequent infusions 250mg/m2。once per week
214947641|NCT01084395|BEHAVIORAL|Adolescent Safer Sex Intervention|Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
214678115|NCT03686254|DRUG|Bevacizumab and second-line chemotherapy|Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
214678116|NCT03040583|OTHER|No intervention|Patients data will be collected during their disease follow-up
214678117|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
214678118|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
214678119|NCT00336492|BIOLOGICAL|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
214678120|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
214678121|NCT04295304|DEVICE|Retinal surgery with implantation of epi-retinal device|Retinal surgery and implantation of epi-retinal prosthesis
214678122|NCT00001056|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
214678123|NCT03285009|OTHER|Training intervention|"Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.~Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school."
214678124|NCT00227877|BEHAVIORAL|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
214678125|NCT00227877|BEHAVIORAL|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
214678126|NCT03720080|DEVICE|OpenAPS|A self-constructed OpenAPS system will be worn contemporaneously to a Medtronic Minimed 670G hybrid closed loop system. Both systems will calculate recommended basal rate insulin adjustments but only the Minimed 670G system will inject insulin. The maximum treatment period will be 2 weeks per patient
214678127|NCT05208983|BIOLOGICAL|mRNA Vaccines or Viral vector-based vaccines for COVID|Participants receiving an approved COVID vaccine
214678128|NCT02517047|DEVICE|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
214678129|NCT04778761|BEHAVIORAL|Home ACP Video|A video focused on Advance Care Planning and Hospice for patients with serious illness
214678130|NCT01452425|DEVICE|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
214678131|NCT01452425|DEVICE|INVOS assessment|Near Infraread spectroscopy, non invasive
214947642|NCT01084395|BEHAVIORAL|Parent Safer Sex Communication Intervention|Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
214342468|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3 + K2-MK7|Combined supplementation
214342469|NCT05689632|DIETARY_SUPPLEMENT|Placebo|MCT
214342470|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 - 7000 IU
214347496|NCT00838110|DRUG|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
214347497|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
214947643|NCT01084395|OTHER|Adolescent Health Promotion Control Condition|Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
214947644|NCT01084395|OTHER|Parent Health Promotion Control Condition|Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
214947645|NCT04607681|BEHAVIORAL|EDUCATION|WEB BASED EDUCATION
214947646|NCT01636947|DRUG|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
214678132|NCT01452425|DEVICE|EMG assessment|Electromyography, non invasive
214678133|NCT06671509|DRUG|YZJ-1139|Single oral dose, 20 mg tablet
214678134|NCT06302322|PROCEDURE|Thin Tissues|Patients with thin tissues received implants 10 years ago and are now followed up after 10 years.
214678135|NCT06302322|PROCEDURE|Thick Tissues|Patients with thick tissues received implants 10 years ago and are now followed up after 10 years.
214678136|NCT06302322|PROCEDURE|Surgically augmented thin tissues|Patients with thin tissues received soft tissue augmentation and implants 10 years ago and are now followed up after 10 years.
214678137|NCT00004697|DRUG|choline chloride|
214678138|NCT06671808|OTHER|Examination of HIV Infection in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB)|This meta-analysis examines the impact of HIV infection on the prevalence and outcomes of multi-drug resistant tuberculosis (MDR-TB) among affected populations. The analysis synthesizes data from multiple studies conducted across various countries, focusing on the correlation between HIV co-infection and MDR-TB rates, treatment outcomes, and demographic factors. The findings aim to enhance understanding of the complex interactions between HIV and MDR-TB, ultimately informing clinical practices and public health strategies.
214678139|NCT06671769|DIETARY_SUPPLEMENT|Heart Health Supplement|This is a natural heart health supplement in powdered format, chocolate flavor where participants will take a daily dose.
214678140|NCT04445077|OTHER|Dementia Competence Education for care home setting|The intervention is a competency-based education program for care home staff who provide dementia care in Mainland China.
214678141|NCT04445077|OTHER|Printed educational materials|The educational materials will be delivered to the participants in the control group for their self-study.
214678142|NCT03531372|DEVICE|Mipolixin®|1.55g chewable tablet 5 times a day for 2 weeks
214678143|NCT03531372|DEVICE|Poliprotect®|1.55 g chewable tablet 5 times a day for 2 weeks
214678144|NCT02325999|PROCEDURE|ESD AND LRLD|A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
214678145|NCT03932136|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
214678146|NCT03932136|COMBINATION_PRODUCT|Placebo|The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.
214347498|NCT00838110|DRUG|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
214347499|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
214347500|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 61 mg of tafamidis orally once daily.
214678147|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T4 dental implants in posterior mandible|Nucleoss T4 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
214678148|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T5 dental implants in posterior mandible|Nucleoss T5 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
214678149|NCT05712031|PROCEDURE|Insertion of 2 Nucleoss T4 dental implants posterior mandible|2 freestanding Nucleoss T4 dental implants is used to support 3 unit fixed partial dentures
214678150|NCT00677144|DRUG|OS (oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
214678151|NCT00677144|DRUG|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
214678152|NCT06296264|DEVICE|Standard ultrasound|Placement of IV line using standard ultrasound.
214678153|NCT06296264|DEVICE|Ultra-portable ultrasound|Placement of IV line using ultra-portable ultrasound.
214678154|NCT06003816|BEHAVIORAL|Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI|The CHoBI7 program is during group sessions by a health promoter to those residing in a ring around a cholera patient reinforced through weekly voice and text messages from the CHoBI7 mHealth program over 12 months on the recommended water, sanitation, and hygiene behaviors.
214947647|NCT01636947|DRUG|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
214947648|NCT01636947|DRUG|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
214947649|NCT01636947|DRUG|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
214947650|NCT01636947|DRUG|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
214947651|NCT01636947|DRUG|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
214947652|NCT02696447|BIOLOGICAL|Biomarkers assays|D-Dimer assays, C-reactive protein, blood platelets assays
214947653|NCT00146913|DRUG|Imatinib mesylate 600mg/day|
214947654|NCT00146913|DRUG|Peg-Interféron at 90 microg/week|
214947655|NCT01840800|DRUG|Ropivacaine|
214947656|NCT01840800|DRUG|placebo|
214947657|NCT01713894|OTHER|Decision Aid|
214678155|NCT06003816|BEHAVIORAL|Standard message|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
214678156|NCT04267237|DRUG|Atezolizumab|Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
214947658|NCT01713894|OTHER|Standard|
214947659|NCT01851980|OTHER|CWS|Chest wall strapping to reduced vital capacity by 20% of its baseline value
214947660|NCT01851980|DRUG|Furosemide|40 mg and 120 mg
214947661|NCT01851980|DRUG|Placebo|0.9% saline
214947662|NCT00192348|BIOLOGICAL|CAIV-T|
214947663|NCT03582319|OTHER|Biodentine|Biodentine is mainly composed of tricalcium silicate, calcium carbonate and zirconium oxides while the liquid contains calcium chloride as the setting accelerator and water reducing agent
214947664|NCT03582319|OTHER|Formocresol|Formocresol is a devitalizing and fixing agent which was introduced to dentistry since 1904 with full concentration of Buckley's formula (19% formaldehyde, 35 % cresol, and 15 % glycerin in distilled water). A five times diluted formula of Buckley's formocresol was used in this study.
214678157|NCT04267237|DRUG|RO7198457|RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
214678158|NCT05061225|BEHAVIORAL|Physical activity counselling|Educational content on several topics regarding physical activity and its implementation in daily living
214678159|NCT02524080|PROCEDURE|Triage to optimal healthcare level|Triage to optimal healthcare level
214678160|NCT03291782|DRUG|D-0120|oral, single dose
214678161|NCT06055894|DIETARY_SUPPLEMENT|Omega-3|For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily
214947665|NCT05964010|BEHAVIORAL|Standard Screening|All consented youth age 12-17 years complete a patient-facing, well-validated digital screening tool, the CRAFFT (Knight et al., 2003), which assesses number of days during the past year, and then the past 3 months, during which various formulations of AOD were used. If youth report 0 days of AOD use, the tool asks whether they have ridden in a car whose driver was intoxicated; if this response is negative, they are categorized Low Risk. If youth report \> 0 days of AOD use, the tool asks five additional questions assessing use risk and consequences; also, youth who report nicotine use in the past 30 days complete a nicotine dependence checklist (DiFranza et al., 2002). Screen data are then combined to sort youth into three risk categories: Riding Risk Only (no reported AOD use but indicated rode in car driven by intoxicated person), Distant Use (reported AOD use in past year but not past 3 months), or Recent Use (reported AOD use in past 3 months).
214342471|NCT06535191|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|ASSET program is a manualized, theory-driven, 10-week soft skills intervention for autistic individuals, who seek employment or who wish to maintain employment by improving work-related social skills. Throughout a 10-week curriculum offered in a school-based group setting, ASSET addresses the following competencies for workplace success: Communication, Networking, Enthusiasm and Attitude, Teamwork, Problem-Solving and Critical Thinking, Professionalism, Mental Health and Stress Management, and Awareness of Self and Others.
214342472|NCT00803894|DRUG|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
214342473|NCT00803894|DRUG|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
214342474|NCT00803894|DRUG|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
214342475|NCT01786356|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
214342476|NCT01786356|OTHER|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B\&L MI60 in one eye
214342477|NCT01732393|DRUG|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
214947666|NCT05964010|BEHAVIORAL|Standard Psychoeducation|In the wait area, youth receive a tablet-delivered brief digital AOD education tutorial that includes advice to abstain from or reduce AOD use. The tutorial focuses on adolescent AOD prevalence rates and related behavioral symptoms; AOD use neurobiology and its relation to adolescent health; and common AOD impacts on developmental milestones (see Meredith et al., 2021). Psychoeducation for AOD has shown positive effects as both a universal and selective prevention strategy (Bröning et al., 2021; Das et al., 2016).
214947667|NCT05964010|BEHAVIORAL|Standard Brief Negotiated Interview (BNI)|In primary care (PC) office, youth and providers together complete a tablet-supported brief negotiated interview (BNI; see Beaton et al., 2016). The BNI is informed by AOD use data gathered during youth screening (O'Grady et al., 2015). The BNI focuses on (a) education about AOD disorders, including youth and family factors that impact AOD use; (b) user-tailored feedback comparing the given youth's AOD use and related problems to national norms, along with information on neurobiological effects and developmental impacts of frequent use (Harris et al., 2012); (c) motivational tools (e.g., reduction readiness rulers) and decisional balance exercises (weighing positive versus negative personal impacts of AOD use) tailored to the youth's use levels (Slavet et al., 2006; King et al., 2009); and (d) AOD reduction goal-setting interventions tailored to the youth's readiness to change AOD use (Walton et al., 2013).
214342478|NCT01732393|DRUG|Placebo|
214342479|NCT01772992|BEHAVIORAL|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
214342480|NCT02800707|OTHER|Sucralose|Sweetner
214342481|NCT02800707|OTHER|Stevia|Sweetner
214342482|NCT01836692|RADIATION|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
214342483|NCT01492881|DRUG|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
214342484|NCT01492881|DRUG|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
214342485|NCT01492881|DRUG|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
214342486|NCT05934344|OTHER|Action observation training|The activities proposed will be based on items from the FMA scale (Voluntary movement within synergies, voluntary movement mixing synergies, voluntary movement with little or no synergy, grip, coordination/speed, passive joint movement), and the exercises for the lower limbs will be designed by the authors of the study, based on Vivifrail (32), a multicomponent physical training program for the prevention of deconditioning and falls in older adults. These exercises will be progressive each week, focusing on strengthening, balance, and functional exercises to improve gait. The sessions will last between 20 and 30 minutes, with a frequency of three days per week. The intervention will last for 5 weeks.
214342487|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video and brochure
214342488|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video
214342489|NCT01801059|OTHER|questionnaire administration|Ancillary studies
214678162|NCT06055894|DIETARY_SUPPLEMENT|Curcumin|For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily
214342490|NCT06469320|OTHER|Online questionnaire|Pelvic floor dysfunction assessment questionnaire adapted from PFD-Sentinel
214347501|NCT05356221|DEVICE|Ponto Sound processor|Bone Anchored Hearing solution fitted to compensate for the subjects hearing loss
214347502|NCT05027217|OTHER|No intervention|No intervention. Arms are subdivided based on patients' diagnostic status on admission to ICU.
214347503|NCT03240588|DEVICE|Neurostimulation System|Spinal cord stimulation
214347504|NCT03421054|DIETARY_SUPPLEMENT|patients assuming nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
214342491|NCT02240082|BEHAVIORAL|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
214947668|NCT05964010|BEHAVIORAL|Standard Referral to Treatment (RT)|In primary care (PC) offices providers and youth discuss the value of attending counseling services to address AOD-related problems (Cucciare et al., 2015); counseling referral links that the PC site curates with local services; and the value of youth talking directly with caregivers about their AOD involvement as a first step toward support-seeking and behavior change (Gayes \& Steele, 2014). Providers directly recommend AOD counseling and facilitate a first appointment for youth who agree.
214947669|NCT05964010|BEHAVIORAL|Family Screening|Screening procedures incorporate procedures for youth described for Standard Screening. They also incorporate two sources of caregiver-report data. First is an estimate of youth AOD use based on the Screening 2 Brief Intervention tool (Levy et al., 2016). Second is a 9-item checklist of youth mental health (MH) problems (Achenbach \& Rescorla, 2001). If both youth and caregiver report no AOD use or clinical-level MH problem, the family is categorized Low Risk. Otherwise, screen data are combined to sort families into three risk categories: Hidden SU Risk (youth reports AOD use in past year; caregiver reports no youth AOD use in past year), Named MH Risk (caregiver reports no youth AOD use in past year; caregiver reports clinical-level score for at least one youth MH domain), Named SU Risk (caregiver reports youth AOD use in past year).
214947670|NCT05964010|BEHAVIORAL|Family Psychoeducation|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In the wait area, caregivers receive a tablet-delivered parenting tutorial that covers two AOD risk domains: education about adolescent AOD including prevalence rates, related behavior problems, neurobiological and health effects, and impacts on developmental milestones; and education and video modeling about parenting strategies that reduce or moderate AOD risk, including positive communication, fair and consistent discipline, and non-judgmental conversations about AOD use (Bo et al., 2018). Positive parenting education has been shown effective as a universal and selective prevention strategy in parent-focused AOD prevention trials (Kuntsche \& Kuntshce, 2016; Ladis et al., 2019; Van Ryzin et al., 2017). Tutorials are tailored for each risk category.
214947671|NCT05964010|BEHAVIORAL|Family Brief Negotiated Interview (BNI)|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In primary care (PC) offices, caregivers and providers together complete a tablet-supported parenting BNI informed by data from the caregiver screen only that parallels the youth BNI (e.g., AOD education, developmental risks) and also includes motivation, modeling, and goal-setting on positive parenting (e.g., non-judgmental conversations; see above) and effective parent-youth communication about AOD use (Carver et al., 2017).
214678163|NCT06055894|DIETARY_SUPPLEMENT|Probiotic|For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily
214342492|NCT03145116|DEVICE|CT ASPHINA 509|Intraocular lens
214342493|NCT01477034|DIETARY_SUPPLEMENT|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
214342494|NCT03399110|DRUG|Oxaliplatin|oxaliplatin 130 mg/m2
214342495|NCT03399110|DRUG|Capecitabine|Capecitabine 1000mg/m2
214342496|NCT04333277|OTHER|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10\^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
214342497|NCT04333277|OTHER|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
214678164|NCT06055894|OTHER|Whole food, plant-based diet (WFPBD)|Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2).
214342498|NCT06114823|PROCEDURE|carpal tunnel release mini-incision|Patients were subjected to a longitudinal mini-incision started just above the proximal flexor wrist crease and then extended for 1.5 - 2 cm in a proximal direction
214342499|NCT06114823|PROCEDURE|carpal tunnel release conventional incision|Patients were subjected a longitudinal incision which was created between the thenar and hypothenar eminences along the longitudinal axis of the ring finger. Then, it was extended to the proximal flexor wrist crease.
214342500|NCT01126593|DRUG|0.5% bupivacaine|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
214342501|NCT01126593|DRUG|Normal Saline|The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
214342502|NCT01407185|OTHER|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
214678165|NCT06519435|DEVICE|Mayo Dopplex ABIlity|Device used to measure lower extremity venous hemodynamic pressure
214678166|NCT06519435|DEVICE|Intermittent Pneumatic Compression (IPC)|Device used to measure lower extremity venous hemodynamic pressure
214678167|NCT03101891|PROCEDURE|Serial amnioinfusions with isotonic fluid|Amnioinfusions will be performed by an expert in fetal procedures with a 20 or 22 gauge needle using sterile technique and ultrasound guidance. Local anesthetic will be employed. The fluid will consist of warmed isotonic fluid. Infusions may take up to 1 hour.
214678168|NCT03101891|DEVICE|Spinal needle|A 20 or 22 gauge spinal needle will be used with sterile technique to access the uterus under ultrasound guidance and to infuse isotonic fluid.
214947672|NCT05964010|BEHAVIORAL|Family Facilitated Conversation (FC) & Referral to Treatment (RT)|In PC offices, providers meet separately with youth and caregivers to discuss the value of talking directly with the other family member about AOD risk while practicing positive communication strategies. Whenever both youth and caregiver agree to talk together, providers convene a brief facilitated conversation about AOD risk. In this conversation providers (a) emphasize that a positive youth-caregiver relationship is the strongest protective factor for youth development and (b) follow guidelines for brief triadic risk-reduction interventions focused on positive family communication about AOD risk (Guilamo-Ramos et al., 2020). When indicated, providers directly recommend AOD counseling and facilitate a first appointment for families who agree.
214947673|NCT01303614|DRUG|Lidocaine-Prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
214947674|NCT01303614|DRUG|placebo|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
214947675|NCT00396916|DEVICE|PET/CT imaging|
214947676|NCT03905538|DRUG|[18F]FLT-PET/CT|Dose of 0.07 mCi/Kg \[18F\]FLT to max of 5 mCi (± 20%) will be given intravenously.
214947677|NCT04935840|DIETARY_SUPPLEMENT|FertyBiotic Pregnancy|DHA, folic acid, Iodine, iron, Lactobacillus rhamnosus, Lactobacillus reuterii, magnesium, zinc, vitamin D3, Vitamin C, Vitamin E, Group B vitamins and Biotin
214947678|NCT04935840|OTHER|Control|400 mcg of folic acid
214947679|NCT00002266|DRUG|AS-101|
214947680|NCT05587426|DIETARY_SUPPLEMENT|SFF|Ingestion of 20g of SFF after 10-14 hours of fasting
214678169|NCT03101891|DRUG|Isotonic fluid|Isotonic fluids, including normal saline or lactated ringers solution, will be infused into the uterus through a spinal needle under ultrasound guidance using sterile technique. This fluid will act as replacement amniotic fluid.
214678170|NCT05180487|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
214678171|NCT06278987|DRUG|PENG block and cryoablation|will receive an ultrasound guided PENG block with 20 mL of 0.5% bupivacaine followed by cryoablation of the PENG nerves.
214678172|NCT06278987|DRUG|fascia iliaca compartment block|will receive an ultrasound guided fascia iliaca compartment catheter with initial bolus of 20 mL of 0.5% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour
214947681|NCT05587426|DIETARY_SUPPLEMENT|Glucose|Ingestion of 20g of glucose after 10-14 hours of fasting
214342503|NCT04725331|BIOLOGICAL|BT-001|Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose \[Phase I, Part A\]; one dose lower and at Recommended Dose for Part B \[Phase I, Part B\] by intra-tumoral (IT) route.
214342504|NCT04725331|DRUG|Pembrolizumab [KEYTRUDA®]|Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
214342505|NCT05093517|DRUG|REMD-477|A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1
214342506|NCT05093517|DRUG|Placebo Subcutaneous injection|Placebo for REMD-477 to which subjects will be randomized 1:2.
214342507|NCT04088097|BEHAVIORAL|Cognitive-Behavioral Therapy for Adolescent Binge/Loss-of-Control Eating|Cognitive-behavioral therapy (CBT) developed for adolescents with binge eating or loss-of-control eating.
214342508|NCT04088097|OTHER|Control Condition|Educational and informational materials on adolescent health and nutrition.
214342509|NCT00354354|DRUG|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
214342510|NCT01834820|DRUG|Epinephrine and Dexamethasone|
214342511|NCT01834820|DRUG|Hypertonic Saline|
214342512|NCT01834820|DRUG|Normal Saline|
214342513|NCT02067247|DEVICE|BeamMed Speed-of-Sound bone strength test at forearm|BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
214342514|NCT00373789|DRUG|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
214947682|NCT05587426|DIETARY_SUPPLEMENT|SFF chocolate chips|Ingestion of 50g of chocolate chips made with SFF after 10-14 hours of fasting
214947683|NCT05587426|DIETARY_SUPPLEMENT|Regular chocolate chips|Ingestion of 50g of regular chocolate chips after 10-14 hours of fasting
214947684|NCT00369161|DRUG|Everolimus (RAD001)|
214947685|NCT00369161|DRUG|Tacrolimus|
214342515|NCT00373789|DRUG|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
214342516|NCT03556761|DRUG|Oral furosemide|Furosemide (Lasix), 20 milligram, PO, PO, daily
214947686|NCT00369161|DRUG|Basiliximab|
214947687|NCT00369161|DRUG|Corticosteroids|
214947688|NCT04402359|DRUG|meropenem|meropenem one gram slowly IV infusion every 8 hours for 14 days
214947689|NCT04402359|DRUG|ceftazidime 2 grams and avibactam 500|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).
214947690|NCT04402359|DEVICE|ventilator|all patients selected to be ventilated for 14 days
214947691|NCT03039608|DRUG|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）|local steroid injection and oral steroid
214947692|NCT03039608|DRUG|oral steroid administration（prednisone）|oral steroid
214947693|NCT00256620|PROCEDURE|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
214342517|NCT03556761|DRUG|Placebo Oral Tablet|Placebo, PO, daily
214342518|NCT04897295|DEVICE|Active transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
214342519|NCT04897295|DEVICE|Sham transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
214342520|NCT03057119|BEHAVIORAL|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
214947694|NCT03793374|OTHER|Subcutaneous apocrine glands shaving|A 0.5-cm long incision was made in the identified elliptical surgical area at each axilla for the access of arthroscopy to remove the apocrine glands. A suction-assisted cartilage shaver (E9005 System, Linvatec Corporation, Largo, Florida, USA) was introduced through the incisions to remove of the subcutaneous apocrine glands radially. After defatting, the incisions were closed primarily with 4-0 polyglactin. We anchored the defatting skin to the axillary fascia by 4-0 nylon sutures instead of the tie-over dressing or tissue glues, and we also made several drainage holes by inserting an 18G needle obliquely into the defatting skin. Therefore, draining tubes were no longer needed. We will remove the stiches at the 8th day after the operation.
214947695|NCT01232374|DRUG|Nimotuzumab|200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
214947696|NCT01232374|DRUG|Placebo|4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
214947697|NCT01232374|DRUG|cisplatin|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
214947698|NCT01232374|RADIATION|Radiotherapy|"A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)"
214947699|NCT00255320|DRUG|VIP|
214947700|NCT01869569|DRUG|Pregabalin|At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
214947701|NCT01869569|DRUG|Placebo|At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
214678173|NCT04484220|DEVICE|Ellipsys Vascular Access System|The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients with a minimum vessel diameter of 2.0mm and less than 1.5mm of separation between the artery and vein at the fistula creation site who have chronic kidney disease requiring dialysis.
214678174|NCT02026908|DEVICE|Prostate Artery Embolization|Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
214678175|NCT06512363|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
214678176|NCT06512363|DRUG|Ramelteon placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
214678177|NCT02166840|PROCEDURE|Plastic stent (7-10Fr)|
214678178|NCT02166840|PROCEDURE|Self Expanding Metal Stent|
214678179|NCT04005209|DRUG|Ketamine|The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
214678180|NCT04005209|OTHER|Pain management|Pain management
214678181|NCT01818622|DEVICE|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
214678182|NCT01818622|DEVICE|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
214678183|NCT05922423|BEHAVIORAL|MBSR|Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
214678184|NCT05922423|BEHAVIORAL|health education|For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
214678185|NCT01074411|DRUG|Bortezomib|Given IP
214678186|NCT01074411|DRUG|Carboplatin|Given IP
214678187|NCT01074411|OTHER|Laboratory Biomarker Analysis|Correlative studies
214678188|NCT01074411|OTHER|Pharmacological Study|Correlative studies
214947702|NCT03737630|DEVICE|Inspiratory muscle training|This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training
214947703|NCT02147067|DRUG|Ranolazine|Ranolazine 1,000 mg twice daily
214678189|NCT05279794|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
214678190|NCT05279794|OTHER|Myofascial Induction Group|Myofascial Induction technique on the lumbar fascia
214678191|NCT05279794|OTHER|Placebo Group|No pain positioning of participants
214678192|NCT05776186|DRUG|Spinal anesthesia with heavy bupivacaine|Spinal anesthesia
214947704|NCT02147067|DRUG|Placebo|Placebo
214947705|NCT00146666|DEVICE|Intermittent compression|
214947706|NCT05484596|PROCEDURE|Measuring VA Coupling|Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
214947707|NCT01768221|BEHAVIORAL|Caregiver Intervention|"Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.~The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.~In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist."
214947708|NCT05397340|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
214678193|NCT02963727|BIOLOGICAL|Wharton Jelly derived mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
214678194|NCT05094154|DRUG|anti-pseudomonal cephalosporin|Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
214678195|NCT05094154|DRUG|anti-pseudomonal penicillin|Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
214678196|NCT00878540|DRUG|mirtazapine|30 mg mirtazapine once daily for 7 days
214678197|NCT04066556|OTHER|Brain CT imaging|"The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~* Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~* Cut-off values in areas of irreversible changes according to non-contrast CT images~* Cut-off values in occlusion sites and collateral scores according to CT angiographies~* Cut-off values of consolidated CT imaging index including clot, core, and collateral score~* Cut-off values of comorbidity index~* Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments."
214947709|NCT01179789|BEHAVIORAL|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform
214947710|NCT01179789|DIETARY_SUPPLEMENT|VSL#3®|probiotic blend Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
214947711|NCT01179789|DIETARY_SUPPLEMENT|AISA-5203-L|fruit extracted terpene Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
214342521|NCT03057119|BEHAVIORAL|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
214342522|NCT03057119|BEHAVIORAL|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
214678198|NCT06555692|BIOLOGICAL|Transplant acellular dermal matrix(ADM)|The principle of surgery is the pectoral muscle preservation (prepectoral) method and the subpectoral method (Breast Reconstruction using implants). After wrapping the implant with acellular dermal matrix(ADM), it is inserted into the breast and fixed to the underlying muscle or surrounding tissue depending on the situation.
214678199|NCT02426983|DEVICE|Direct Current Stimulation|"Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks."
214947712|NCT01179789|DIETARY_SUPPLEMENT|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
214947713|NCT05476640|GENETIC|NGS|In the Nation multicenter screening cohort, NGS testing was performed on the basis of conventional NBS to study the relationship between gene variation and disease occurrence;
214947714|NCT00346567|DRUG|Zidovudine and Lamivudine (Combivir)|
214947715|NCT00346567|DRUG|Emtricitabine and Tenofovir (Truvada)|
214947716|NCT03462992|DIAGNOSTIC_TEST|MonoMark|MonoMark (also known under the registered trademark ColonoKit), is a monocyte-based test using a transcriptomic signature and a mathematical predictive model aimed at discriminating between healthy individuals and CRC patients.
215075341|NCT00785421|DRUG|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS \< 80 % and increased creatinin plasma levels (\>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
215075342|NCT00785421|DRUG|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
215075343|NCT00785421|DRUG|only chemotherapy|observation, no treatment with LMWH
214947717|NCT06014125|OTHER|psychoeducative program|"The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.~The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment.~The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.~A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.~The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent."
214947718|NCT02603107|DRUG|RTV|100 mg capsule coadministered orally with ATV or DRV once daily with food
214947719|NCT02603107|DRUG|ATV|300 mg capsule administered orally once daily with food
214947720|NCT02603107|DRUG|DRV|800 mg tablet administered orally once daily with food
214947721|NCT02603107|DRUG|COBI|150 mg tablet coadministered orally with ATV or DRV once daily with food
214947722|NCT02603107|DRUG|ATV/co|300/150 mg FDC tablet administered orally once daily with food
214947723|NCT02603107|DRUG|DRV/co|800/150 mg FDC tablet administered orally once daily with food
214947724|NCT02603107|DRUG|FTC/TDF|200/300 mg FDC tablet administered orally once daily without regard to food
214947725|NCT02603107|DRUG|ABC/3TC|600/300 mg tablet administered orally once daily with or without regard to food
214947726|NCT02603107|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
214947727|NCT02001272|DRUG|Paclitaxel + Carboplatin every 3 weeks|Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.
214947728|NCT02001272|DRUG|Carboplatin monotherapy every 3 weeks|A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.
214947729|NCT02001272|DRUG|Weekly Paclitaxel and Carboplatin|A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.
214947730|NCT04170101|PROCEDURE|deep NMB|0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC \< 3
214342523|NCT03057119|BEHAVIORAL|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
214947731|NCT04170101|PROCEDURE|moderate NMB|0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.
214947732|NCT00951106|DRUG|Pyrimethamine/sulfdoxine (Fansidar)|
214678200|NCT02426983|DRUG|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
214678201|NCT04383977|DRUG|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
214342524|NCT03057119|BEHAVIORAL|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
214947733|NCT02565199|DEVICE|rTMS over Premotor Cortex (Contralateral Hemisphere)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator"
214947734|NCT02565199|DEVICE|rTMS over Premotor Cortex (Ipsilateral Hemisphere)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
214947735|NCT02565199|DEVICE|rTMS (Control 1)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 400 milliseconds after the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
214947736|NCT02565199|DEVICE|rTMS (Control 2)|"* Location of rTMS: somatosensory cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
214947737|NCT02565199|DEVICE|rTMS (Control 3)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil"
214947738|NCT02565199|OTHER|Motor Training|During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
214947739|NCT02826252|DRUG|Iloprost,(Ventavis, BAYQ6256)|Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
214947740|NCT02826252|DEVICE|I-Neb AAD system|Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
214947741|NCT02503371|OTHER|Blood coagulation anyalsis by Thromboelastogram|Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
214678202|NCT04383977|DRUG|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
215075344|NCT00004206|DRUG|FOLFOX regimen|
214342525|NCT03425149|BIOLOGICAL|VLA1601|purified inactivated ZIKV vaccine candidate adsorbed on alum
214342526|NCT03425149|BIOLOGICAL|Placebo|Phosphate buffered saline (PBS)
214947742|NCT05332717|DIETARY_SUPPLEMENT|Melatonin 5 mg|Participants will be taking one 5 mg tablet of Melatonin 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
214947743|NCT05332717|DIETARY_SUPPLEMENT|Placebo (Vitamin C)|Participants will be taking one placebo tablet 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
214947744|NCT04862832|OTHER|Music intervention|"The cold pressor test will consist in the immersion of the participants' arm in 10 degrees circulating water for two minutes.~The music sequences will be all 20 minutes, instrumental, professionally recorded in the studio and composed specifically for the Music Care application and are thus unfamiliar to participants. There will be two music conditions: the most-liked-music (MLM) and least-liked-music (LLM) conditions."
214947745|NCT06041906|PROCEDURE|Shunt Closure|Consist in spontaneous, surgical or interventional closure of the shunt. Depending on context, surgical intervention may also be transplantation.
214342527|NCT05222919|DIETARY_SUPPLEMENT|Bare performance supplement|dietary supplement
214342528|NCT05222919|DIETARY_SUPPLEMENT|Placebo|Placebo
214342529|NCT04344067|DEVICE|Far Infrared Therapy|The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.
214342530|NCT05966441|DIETARY_SUPPLEMENT|Curcumin|"The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders.~Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress.~Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily"
214342531|NCT05966441|DRUG|Paclitaxel|"Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV..~Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV."
214342532|NCT01888315|DEVICE|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
214342533|NCT01888315|DEVICE|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
214342534|NCT01888315|DEVICE|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
214342535|NCT01888315|DEVICE|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
214342536|NCT03876041|DRUG|solumedrol|intravenous solution for injection
214342537|NCT03876041|DRUG|Dexamethasone phosphate|intravenous solution for injection
214342538|NCT00693992|OTHER|Laboratory Biomarker Analysis|Correlative studies
214947746|NCT00004794|DRUG|cidofovir|
214947747|NCT01841801|DEVICE|Thermal Adhesive Patch|
214947748|NCT01841801|DEVICE|Marketed Thermal Adhesive Patch|
214947749|NCT01841801|DEVICE|Placebo Patch|
214947750|NCT00714155|OTHER|Questionnaires, Physical Examination|Questionnaires, Physical Examination
214342539|NCT00693992|OTHER|Placebo|Given PO
214342540|NCT00693992|OTHER|Quality-of-Life Assessment|Ancillary studies
214342541|NCT00693992|DRUG|Sunitinib Malate|Given PO
214342542|NCT01151670|DRUG|pioglitazone|Pioglitazone 22.5 mg daily before, during and after radiation therapy.
214678203|NCT02618850|PROCEDURE|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
214947751|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
214947752|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
214947753|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
214947754|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
214947755|NCT00814541|DRUG|Bortezomib|
214947756|NCT00814541|DRUG|Doxorubicin|
214947757|NCT00814541|DRUG|Dexamethasone|
214678204|NCT02618850|DRUG|first-line chemotherapy|as prescribed by oncologist
214947758|NCT03439410|OTHER|Clinical Complexity Index|Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.
215075345|NCT00004206|DRUG|fluorouracil|
215075346|NCT00004206|DRUG|leucovorin calcium|
215075347|NCT00004206|DRUG|oxaliplatin|
215075348|NCT06456229|DIETARY_SUPPLEMENT|Nestle Isocal|Nestle Isocal
215075349|NCT06456229|DIETARY_SUPPLEMENT|Nestle Boost Optimum|Nestle Boost Optimum
215075350|NCT01225965|DEVICE|Ectoin Inhalation Solution|Once daily inhalation of Ectoin Inhalation Solution
215075351|NCT01225965|DEVICE|Placebo|Once daily inhalation of Placebo Inhalation Solution
215075352|NCT01977443|DRUG|APD-209 Eye drops|
215075353|NCT01977443|DRUG|APD-209 Placebo Eye drops|
215075354|NCT00871039|DRUG|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
214947759|NCT04933864|DRUG|Methylene Blue and Photodynamic Therapy|"Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm\^2 energy dose.~For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm\^2 energy dose were performed."
214947760|NCT04677452|BIOLOGICAL|JWCAR129|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
214947761|NCT01621828|OTHER|video|a video, showing the patient pathway to and from the Operating Theatre, about the operating room experience and environment.
214947762|NCT01621828|OTHER|leaflet|a written leaflet, about the operating room experience and environment.
214947763|NCT00869583|BEHAVIORAL|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents \[METS\]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
214342543|NCT01151670|DRUG|Pioglitazone|Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
214342544|NCT03786601|OTHER|Observation|The participants were assigned to different groups according to the results of HPV detection.
214342545|NCT02614976|DEVICE|Padding|"Padding webrill (Covidian) TM 6"
214342546|NCT04634487|OTHER|No intervention|No intervention
214342547|NCT04199247|BEHAVIORAL|Sub symptom aerobic exercise|Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
214342548|NCT01637012|PROCEDURE|Implantation|index angioplasty with ALEX stent implatation
214342549|NCT01713218|DRUG|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
214342550|NCT01713218|DRUG|Vismodegib|150 mg capsule, oral, once daily
214342551|NCT01713218|PROCEDURE|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
214342552|NCT01017172|OTHER|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
214342553|NCT05152979|BEHAVIORAL|Verb Network Strengthening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
214947764|NCT05196477|DRUG|Olokizumab|The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
214947765|NCT05196477|DRUG|Standard therapy|Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
214947766|NCT04819477|BEHAVIORAL|Fact box|"All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot."
214947767|NCT04819477|BEHAVIORAL|Cates plot|In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
214947768|NCT03411902|DRUG|Risedronate Sodium 150 MG|Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
214947769|NCT03411902|OTHER|Placebo|Participants randomized to the placebo group will receive 150 mg placebo capsule once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
214947770|NCT00839787|DRUG|Morphine Sulfate|Morphine Sulfate group: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
215075355|NCT00871039|DRUG|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
214678205|NCT03158649|OTHER|"Embarazo y Bienestar"|"The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page."
214342554|NCT05519839|DRUG|qNIV Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV vaccine given on Day 0 and Day 70 .
214342555|NCT05519839|DRUG|Influenza Vaccine|Intramuscular (deltoid) injections of Comparator influenza vaccine given on Day 0 and Day 70 (if applicable).
215075356|NCT01559922|DRUG|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
214678206|NCT01311206|OTHER|partial blood flow restriction|Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus
214342556|NCT05519839|DRUG|CIC Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70
214947771|NCT01322698|BIOLOGICAL|Tests for candidiasis|Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
214947772|NCT05777083|DIAGNOSTIC_TEST|KardiaMobile 6L|Before coronary angiography, all participants will contact both fingers on the two probes at the front side of portable 6-leads electrocardiogram recorder (KardiaMobile 6L), and be recorded all six leads by contacting the other side of probe at lower extremities (left hip bone ridge, thigh, knee, lower abdomen, etc.).
214947773|NCT00624039|OTHER|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
214947774|NCT02195596|OTHER|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse."
214947775|NCT02195596|OTHER|Low intensity aerobic exercise+strength|"Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.~\--------------------------------------------------------------------------------"
214947776|NCT04217824|PROCEDURE|pilonidal sinus excision|Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.
214947777|NCT00190658|DRUG|Somatropin (rDNA origin) for injection|
214947778|NCT02917655|BEHAVIORAL|Womac|Answer WOMAC at baseline, 6, 12 and 24 months.
214947779|NCT02917655|BEHAVIORAL|Lequesne|Answer Lequesne at baseline, 6, 12 and 24 months.
214947780|NCT02917655|BEHAVIORAL|Numerical Rating Scales (NRS)|Answer NRS at baseline, 6, 12 and 24 months.
214947781|NCT02917655|BEHAVIORAL|IPAQ|Answer IPAQ at baseline, 6, 12 and 24 months.
214947782|NCT02917655|BEHAVIORAL|STS30|Perform the STS30 at baseline, 6, 12 and 24 months.
214678207|NCT01311206|OTHER|Low intensity exercise without partial blood flow restriction|Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
214947783|NCT02917655|BEHAVIORAL|TUG|Perform the TUG at baseline, 6, 12 and 24 months.
214947784|NCT02917655|BEHAVIORAL|Six-minute Test|Perform the six-minute test at baseline, 6, 12 and 24 months.
214947785|NCT02917655|BEHAVIORAL|Two days of lectures|Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
214342557|NCT05519839|OTHER|Placebo Comparator|Intramuscular (deltoid) injection of placebo given on Day 70.
214342558|NCT05519839|DRUG|SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS vaccine given on Day 0 and Day 70 .
214342559|NCT01176539|DEVICE|Non-Contact Respiratory Rate Monitor|"The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults."
214342560|NCT00353704|DRUG|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
214342561|NCT00353704|DRUG|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
214342562|NCT00353704|DRUG|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
214342563|NCT01277965|OTHER|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
214342564|NCT01277965|OTHER|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
214947786|NCT02917655|BEHAVIORAL|Session with the psychologists|Participate in a extra session group with the psychology team about their experiences with the program
214947787|NCT02917655|BEHAVIORAL|Sessions with the physical therapy team|Participate in a extra session group with the physical therapists
214947788|NCT02917655|BEHAVIORAL|Sessions with the physical educators team|Participate in a extra session group with the physical educators
214947789|NCT02917655|BEHAVIORAL|Nutritional habits to be improved|Attend 3 extra meetings about nutrition.
214947790|NCT02917655|BEHAVIORAL|Tampa Scale for Kinesiophobia (TSK)|Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
214947791|NCT02205294|OTHER|Osteopathic Treatment|The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
214947792|NCT03485703|DRUG|Azithromycin|the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
214947793|NCT03485703|DRUG|Placebo|the group of newborns will receive 0.9% saline once daily for 5 days
215075357|NCT01559922|DEVICE|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
214678208|NCT06196476|BEHAVIORAL|Interactive digital-based educational program|"The Interactive digital-based educational program Sessions:~Session 1: The road start to green planet: Introductory to climate change concept Session 2: Towards Climate Change Literacy Modifications: remove the cover on illiteracy.~Session 3: Green scrubs and green environment: raising climate activities and environment self-efficacy Session 4: Strengthen resilience to overcome climate related anxiety Session 5: Sustaining phase: closing session"
214947794|NCT06070675|DEVICE|Minze Diary Pod|The automated bladder diary utilized in this study consists of the Minze Diary Pod and Minze Flow app. The Diary Pod is a capacitance-based measuring device, that automatically registers voided volumes and time of void. The Diary Pod connects via Bluetooth to the Minze Flow app to request additional information from the patient, such as urge, drinks and leakages.
214678209|NCT02133235|PROCEDURE|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
214678210|NCT02133235|PROCEDURE|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
214678211|NCT01002859|DRUG|Sandimmum|Intravenous injection of cyclosporine
214678212|NCT01002859|DRUG|Placebo|Intravenous Injection of NaCl solution
214678213|NCT04018963|PROCEDURE|Single nostril approach endoscopic transsphenoidal pituitary surgery|Single nostril approach endoscopic transsphenoidal pituitary surgery
214678214|NCT04018963|PROCEDURE|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
214678215|NCT00824499|OTHER|Complex regional intervention|"Components of the complex intervention:~* Introduction of a program coordinator~* Introduction of a self-management education program~* Bottom up development of a interdisciplinary care protocol~* Support program for the intiation of insulin therapy in primary care~* Regional audit"
214678216|NCT02232672|DEVICE|Choline PET/CT and MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
214678217|NCT01543490|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 2 weeks
214678218|NCT01543490|OTHER|Vehicle|Vehicle twice daily for 2 weeks
214678219|NCT02829177|DRUG|Allopurinol|
214678220|NCT02829177|DRUG|Placebo|
214678221|NCT04435262|OTHER|Remote Monitoring|Remote Monitoring Follow-up
214678222|NCT05005559|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
214678223|NCT05005559|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
214678224|NCT04723524|COMBINATION_PRODUCT|Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
214678225|NCT04723524|OTHER|Placebo Comparator|Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
214678226|NCT05216211|DRUG|Bupivacaine Hydrochloride|1 ml / kg, % 0.25 bupivacaine
214947795|NCT06070675|OTHER|Paper bladder diary|The paper bladder diary utilized in this study is a paper timetable that has the patient enter (in the columns of the timetable) drinks in ml, urinations in ml (using a measuring cup) and leakage episodes for the nearest hours (rows of the timetable).
214947796|NCT00618852|DRUG|Furosemide|The dose of furosemide will be 1 mg/kg by intravenous bolus injection
214947797|NCT00618852|DRUG|Saline|1 mg/kg by intravenous bolus injection
214947798|NCT01422707|DRUG|Hydrocortisone|10 mg/m2/per day PO at bedtime (X4 weeks)
215075358|NCT01055665|OTHER|cognitive behavior therapy|6 cognitive behavior therapy groups
214678227|NCT04868461|DIETARY_SUPPLEMENT|Unheated Whey Protein (UWP) beverage|The preload is made from whey protein powder. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
214678228|NCT04868461|DIETARY_SUPPLEMENT|Heated Whey Protein (HWP) beverage|The preload is made from whey protein powder of 95% and it is heated for a certain amount of time. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
214678229|NCT04868461|DIETARY_SUPPLEMENT|Casein (Cas) beverage|The preload is made from casein powder. The energy load of the preload is 105 kcal and has banana flavor and sweetener.
215075359|NCT06167005|PROCEDURE|Primary bariatric-metabolic surgery|Primary bariatric-metabolic surgery
215075360|NCT05296460|DRUG|Dapsone gel|The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
215075361|NCT06351319|DIAGNOSTIC_TEST|SVM model|Bronchoscopic ultrasound images were analyzed according to SVM mode
215075362|NCT06487312|DEVICE|Test equipment: Name: Remote automatic ultrasound diagnostic system (Wuhan Cooper Technology Co., Ltd.) Model: CORUS-A30|A clinical trial to evaluate the effectiveness and safety of a remote automated ultrasound diagnostic system for automated ultrasound examination using a remote automated ultrasound diagnostic system (model: CORUS-A30, Wuhan Cooper Technology Co., Ltd., China).
215075363|NCT01328041|DRUG|dolutegravir|50 mg twice daily
215075364|NCT03079401|BIOLOGICAL|MPC; rexlemestrocel-L|MPCs will be injected into the patient's myocardium during planned surgical procedures.
215075365|NCT05685563|DIAGNOSTIC_TEST|DIERS formetic 4D|Assessment of mentioned tests and their comparison.
215075366|NCT00418431|DRUG|Intravitreal injection of Bevacizumab|
215075367|NCT02144987|BIOLOGICAL|Bone Marrow CD133+ Stem Cell Transplantation|"1. Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.~2. BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.~   The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.~3. CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization~4. Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients~5. Hysteroscopy will be performed 2-3 months after stem cell transplantation~6. Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"
215075368|NCT06300125|PROCEDURE|Cryoablation|Percutaneous Cryoablation of Breast Cancer
215075369|NCT05134662|DRUG|ALT-801|Injected subcutaneously (SC)
215075370|NCT05134662|OTHER|Placebo|Injected subcutaneously (SC)
214947799|NCT03147807|DEVICE|betaLACTA® rapid diagnostic test|Since ≥1 bacteriological sample(s) from ICU patients empirically treated with carbapenems (i.e. respiratory sample such as quantitative tracheobronchial aspirate with available volume ≥1 mL; urinary sample such as single catheter urine specimen; or blood culture) is positive for ≥2 GNB/field on direct examination, empirical carbapenem will be adapted: 1) early, since the second dose, according to the results of the betaLACTA® rapid diagnostic test (BLT) in the intervention arm (i.e. de-escalation to cefepim or to ceftazidim+amikacin in case of negativity, and carbapenem continuation in case of positivity); or 2) after 48-72h according to the results of the antibiotic susceptibility test in the control arm.
214947800|NCT03613688|DIETARY_SUPPLEMENT|Deepure|Pu'erh Tea extract
214947801|NCT05008471|DIETARY_SUPPLEMENT|Formula nutrition|The target energy of radiotherapy patients is recommended to be 25-30kcal/(kg·d), and the target energy of the intervention group should be increased by an additional 50% daily from the beginning of radiotherapy. Specifically, under the condition of ensuring the daily target energy 14kcal/(kg·d), formula nutrition should be added daily.
214947802|NCT06139705|OTHER|Walking outdoor|The individuals will walk in park along a pre-designated route 20 min.
214947803|NCT06139705|OTHER|Walking indoor|The individuals will walk in a gym on a treadmill 20 min.
214947804|NCT02945111|BEHAVIORAL|Real-time view|
214947805|NCT02945111|BEHAVIORAL|No visual support|
214947806|NCT05326256|OTHER|Exercise training- PSSE|Barcelona Scoliosis Physical Therapy School (BSPTS) method exercises
214947807|NCT05326256|OTHER|Exercise training- PSSE with vestibular exercises|Vestibular exercises added to Barcelona Scoliosis Physical Therapy School (BSPTS) exercises
214678230|NCT04868461|DIETARY_SUPPLEMENT|Water|The preload is water acting as a control and contain the same banana flavor and sweetener to match the other three intervention - protein beverages.
214678231|NCT06369675|DRUG|MOB015B|Topical formulation
214678232|NCT06369675|DRUG|0.2% SLS|Positive control
214678233|NCT06369675|DRUG|0.9% Saline|Negative control
214678234|NCT06369675|DRUG|MOB015B vehicle|Topical formulation
214678235|NCT06512415|DRUG|10 mcg Norepinephrine|The assigned dose (10 mcg) will be diluted with normal saline in a 10-cc syringe
214678236|NCT06512415|DRUG|15 mcg Norepinephrine|The assigned dose (15 mcg) will be diluted with normal saline in a 10-cc syringe.
214678237|NCT04592380|DRUG|Stage 1: Clevidipine (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
214947808|NCT00003703|DRUG|SarCNU|
214342565|NCT01277965|OTHER|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
214947809|NCT01634568|DRUG|V81444|"Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo"
214947810|NCT04723836|DIETARY_SUPPLEMENT|Riboflavin (5mg)|From 16th week gestation until end of pregnancy
214947811|NCT04723836|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate (400µg)|From 16th week gestation until end of pregnancy
214947812|NCT04723836|DIETARY_SUPPLEMENT|Placebo|From 16th week gestation until end of pregnancy
214947813|NCT01981070|BEHAVIORAL|Mindfulness Intervention for Parents|See Study Arms
214678238|NCT04592380|DRUG|Stage 1: Placebo (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
214678239|NCT04592380|DRUG|Stage 2: Clevidipine (open-label)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
214678240|NCT04592380|DRUG|Stage 2: Standard of Care (open-label)|Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
214947814|NCT01981070|BEHAVIORAL|Support and Information for Parents|See Study Arms
214947815|NCT00419159|DRUG|Everolimus (RAD001)|Everolimus was supplied in 5 mg tablets in blister packs.
214947816|NCT02206737|DEVICE|No nicotine e-cigarette|
214947817|NCT02206737|DEVICE|Low dose nicotine e-cigarette|
214678241|NCT02049255|DRUG|Chloroprocaine|"The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia"
214678242|NCT02049255|DRUG|Marcaine|"The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia"
214678243|NCT01445743|BIOLOGICAL|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
214678244|NCT06843889|DRUG|Toripalimab (240mg day1, Q3W*3cycle)|Phase 1: Toripalimab (240mg day1, Q3W\*2cycle) + investigator's choice of clinical conventional chemotherapy; Phase 2: Toripalimab (240mg day1, Q3W\*1cycle) + radiotherapy (intensity modulated radiotherapy, 40Gy/20F, 2Gy/F); Surgery was performed 4-6 weeks after completion, and subsequent treatment options were considered after surgery according to MDT discussion.
214678245|NCT03918642|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
214947818|NCT02206737|DEVICE|High dose nicotine e-cigarette|
215075371|NCT00764543|DEVICE|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
215075372|NCT05858632|DRUG|Guselkumab|Guselkumab treatment for \~ 9 months
215075373|NCT00202709|BEHAVIORAL|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
214947819|NCT00093977|DRUG|darbepoetin alfa SF|"Frequency of dosing depends on frequency at randomization:~rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL"
214947820|NCT01017601|BIOLOGICAL|Seneca Valley virus-001|Given IV
214947821|NCT01017601|OTHER|placebo|Given IV
214947822|NCT05005767|PROCEDURE|scaling and root planing|will receive scaling and root planing only
214947823|NCT05005767|PROCEDURE|Frankincense extract gel natural herbal product|will receive Scaling and root planing then. Subgingival application of Frankincense extract gel
214947824|NCT05919355|OTHER|Offer to try Komp|The participants are offered services using the communication solution Komp. If they accept, they will receive one unit at home.
214947825|NCT02051335|DRUG|Roflumilast|Roflumilast tablets
214947826|NCT02051335|DRUG|Roflumilast placebo|Roflumilast placebo-matching tablets
214947827|NCT02051335|DRUG|Donepezil|Donepezil overencapsulated tablets
214947828|NCT02051335|DRUG|Donepezil placebo|Donepezil placebo-matching overencapsulated tablets
214947829|NCT02051335|DRUG|Scopolamine|Scopolamine subcutaneous injection
214947830|NCT00274378|DEVICE|ALLOMATRIX injectable putty in distal radius fractures|
214947831|NCT06081491|DIAGNOSTIC_TEST|diagnosis|Pediatric patients within the inclusion criteria will be diagnosed for MIH by the primary investigator and the questionnaire will be filled with face to face interviews with their parents
214342566|NCT01277965|OTHER|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
214342567|NCT01277965|OTHER|Rest|Patient will be in rest, basal insulin flow rate will not be change
214342568|NCT04495374|DRUG|Pregabalin 300mg|Group P1 will receive a 300 mg tablet of pregabalin, 02h before the surgical procedure
214342569|NCT04495374|OTHER|Placebo|Group P0 will receive a placebo tablet, 02h before the surgical procedure
214947832|NCT04859309|BEHAVIORAL|ActiveHip+ mobile application|The mobile application with the educational and multidisciplinary tele-rehabilitation program.
214947833|NCT04859309|PROCEDURE|Standard care in a hip fracture|The participants of this group will receive the standard treatment for a hip fracture in the Andalusian healthcare system.
214342570|NCT02052349|DRUG|ABT-333|Dose of ABT-333
214342571|NCT03155750|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
214342572|NCT03155750|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
214342573|NCT02042482|DIETARY_SUPPLEMENT|Coenzyme Q10U, L-carnitine|
214342574|NCT03116919|OTHER|Potato|Participants will be given an extra serving of potato a day
214342575|NCT03116919|OTHER|Non-starchy vegetable|Participants will be given an extra serving of a non-starchy vegetable
214342576|NCT02907333|BEHAVIORAL|Advice to use condoms|
214342577|NCT06046313|DRUG|Decitabine for Injection|6mg/m2, ivgtt qd d1-10
214342578|NCT06046313|DRUG|VENCLYXTO|100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration
214342579|NCT02473614|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.
214678246|NCT03918642|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
214678247|NCT05382676|DEVICE|Eyeswift Pro|assessment of visual function parameters
214947834|NCT00187278|DEVICE|Biventricular Pacing|Biventricular Pacemaker implant
214947835|NCT00187278|DEVICE|RV Pacing|Standard Pacemaker implant
214947836|NCT04949204|PROCEDURE|Wearable sensor detection|Empatica E4 wearable wrist sensor
214947837|NCT00803205|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
214947838|NCT00803205|DRUG|Placebo|Placebo matching to ataluren will be provided.
214947839|NCT03362801|DIAGNOSTIC_TEST|sarcopenia and mobility measurement|"walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment"
214947840|NCT02126124|DEVICE|Sham Treatment|In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
214947841|NCT02126124|DEVICE|Active dTMS Treatment|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
214947842|NCT01292343|OTHER|Colgate Total Toothpaste|Toothbrushing with Colgate Total Toothpaste
214947843|NCT01292343|OTHER|Colgate Regular Toothpaste|Toothbrushing with Colgate regular toothpaste
214947844|NCT06730620|DRUG|Test preparation：Methylcholine chloroacetate for inhalation|Cholinergic agonists
214947845|NCT06730620|DRUG|Reference preparation：Methylcholine chloroacetate for inhalation（(Provocholin）|Cholinergic agonists
214947846|NCT05571176|DRUG|S-ketamine|S-ketamine infusion 0.29 mg/kg/h for 4 hours
214947847|NCT04612972|BIOLOGICAL|Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo|This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.
214947848|NCT03276468|DRUG|Atezolizumab|1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)
214947849|NCT03276468|DRUG|Obinutuzumab|1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8
214947850|NCT03276468|DRUG|Venetoclax|800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes\>5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5
214678248|NCT01943630|DRUG|15% AS101 gel|Administration of Topical 15% AS101 once a day (overnight)
214678249|NCT01943630|DRUG|Vehicle|Administration of Vehicle once a day (overnight)
214678250|NCT03710785|BEHAVIORAL|cervical spine extension exercise|cervical spine extension exercise for 4 weeks
214342580|NCT02473614|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
214342581|NCT04696068|OTHER|Porcelain plates|The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
214342582|NCT06358482|BEHAVIORAL|oscillating toothbrush|oscillating toothbrush
214342583|NCT06358482|BEHAVIORAL|standard manual toothbrush|standard manual toothbrush
214342584|NCT05263531|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to design pressure for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
214947851|NCT04116723|DEVICE|Flexible brace|Participants will be invited to undergo a fitting session of a flexible brace. After the fitting session, participants will join a two-hours wear trial of the flexible brace. Participants are required to wear the brace for two-hours and undergo assessments before and after the wear trial. The measurement outcomes of the assessment include 1) X-ray scan, 2) 3D body scan, 3) garment pressure, and 4) questionnaire.
214947852|NCT03099772|BEHAVIORAL|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
214947853|NCT02735096|DEVICE|EquiCue (Intraoral Electronic Balance Aid)|When the device is worn, a subject will receive small electrical pulses on roof of the mouth as alternative feedback of head tilting or movement.
214678251|NCT02601001|DRUG|Omecamtiv mecarbil|Omecamtiv mecarbil tablets for oral administration
214678252|NCT02601001|DRUG|Placebo|Matching placebo tablets
214678253|NCT05644210|DRUG|Telitacicept|160mg once a week for 24 weeks
214678254|NCT05644210|DRUG|Rituximab|Patients received 200mg of rituximab intravenously at week 0 and week 2.
214678255|NCT05644210|DRUG|Aspirin|50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
214342585|NCT01473654|BEHAVIORAL|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
214342586|NCT05934045|BIOLOGICAL|RNAseq|there is no intervention done.
214342587|NCT01303627|DRUG|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
214947854|NCT00379808|DRUG|montelukast|10 mg tablet (masked by capsule) daily for 1 month
214947855|NCT00379808|DRUG|Placebo|1 lactose-containing capsule daily for 1 month
214342588|NCT00022568|BIOLOGICAL|recombinant vaccinia-TRICOM vaccine|
214342589|NCT04180826|OTHER|Observational|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed, according to the usual care.~In a second step, the patient will be verticalized (from 0° to 90°). Intracranial hemodynamics parameters in supine position and during verticalization will be continuously recorded by attaching the ATYS TCD-X® transcranial Doppler helmet attached with glasses.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the ATYS TCD-X® helmet."
214678256|NCT05644210|DRUG|Warfarin|Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it
214678257|NCT05644210|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period
214678258|NCT05644210|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
214678259|NCT05573594|OTHER|Muscle Energy Technique|"The Janda method (Post isometric relaxation PIR Technique), one of the Muscle Energy Techniques, was used on m.piriformis, m.quadratus lumborum, m.hamstring, m.psoas major muscles in the study group. First, the dysfunctional muscle was stretched passively by the physiotherapist up to the movement barrier, and 5-7 seconds of isometric muscle contraction in the opposite direction was requested from the patient at the barrier. This practice was continued until muscle tension or joint dysfunction disappeared.~All participants performed standard home exercises consisting of stretching and strengthening. These exercises were taught to the participants by the physiotherapist in the first treatment session, and when they came to each treatment session, it was questioned whether they did it or not, and a control chart was created for exercise follow-up."
214678260|NCT05573594|OTHER|conventional physical therapy and rehabilitation|In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes.
214678261|NCT04488692|OTHER|Early intervention (Mobility functional training)|functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)
214678262|NCT04488692|OTHER|Sham intervention|friendly visit and education
214678263|NCT04451434|DRUG|Danicopan|Oral tablet
214678264|NCT03475888|DEVICE|Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Implantation of Medtronic Reveal LINQ™ ICM
214678265|NCT04788303|OTHER|School meal, garden, education, and community workshops|"School meal: midday meal provided at intervention schools~School garden: garden used to grow crops (which will be used to supplement the school meal in the full intervention schools)~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
214947856|NCT03689101|PROCEDURE|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
214947857|NCT01432561|DRUG|Cysteamine bitartrate|500 mg total, single dose taken orally on visits 2, 3 \& 4 which must occur within a 14 day period.
214947858|NCT02930746|DRUG|BAY987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-092)
214947859|NCT02503072|BEHAVIORAL|Small lottery prizes based on adherence|Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
214947860|NCT02503072|BEHAVIORAL|Small lottery prizes based on timely clinic visits|Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
214947861|NCT03174691|DIAGNOSTIC_TEST|Blood collection|"A total of ten (10) blood samples (2ml/each) will be collected during the study.~Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone."
214947862|NCT01587625|DRUG|Oxytocin|
214947863|NCT02638376|RADIATION|0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)|"KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.~PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off."
214947864|NCT02638376|PROCEDURE|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)|"The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.~This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.~The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.~A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution."
214947865|NCT01240395|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|"MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course."
214947866|NCT00944307|DRUG|raltegravir|raltegravir 400mg orally once
214947867|NCT00944307|DRUG|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
214947868|NCT03827551|BEHAVIORAL|Delivery of oral hygiene advices|Patients will benefit from hygiene advice and maintenance of good oral health. No treatment will be administered as part of this study. Patients will continue their usual treatment according to the contraindications. Patients will benefit from salivary sampling and a collection of oral bacteria contained in the dental plaque using paper tips. These reviews will be conducted during the Inclusion Visit and the 6 month Follow-Up Visit.
214947869|NCT04336813|OTHER|Audience Response system|In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
215075374|NCT04966728|DIAGNOSTIC_TEST|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI
214678266|NCT04788303|OTHER|Garden, education, and community workshops|"School garden: garden used to grow crops~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
214678267|NCT04450355|DRUG|Nefopam 80mg/day|continuous nefopam infusion
214678268|NCT04450355|DRUG|Normal saline|continuous normal saline infusion
214678269|NCT01210950|BIOLOGICAL|cell and RPR injection|mesenchymal cells and Plasma reach Protein are injected to the callus center
215075375|NCT00256815|DRUG|chemotherapy|
215075376|NCT00256815|PROCEDURE|Radiation|
215075377|NCT00262678|DRUG|EN3267|
214678270|NCT05318625|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
214678271|NCT06513325|OTHER|Canadian Occupational Performance Measure|It is a semi-structured scale that helps to identify problematic areas of performance experienced by individuals and to measure their perceived occupational performance and satisfaction. This scale assesses the level of performance of self-care, productivity and leisureoccupations and satisfaction with these performances as perceived by the individual.
214678272|NCT02601885|DRUG|ABT-555|Intravenous Infusion
214678273|NCT02601885|OTHER|Placebo|Intravenous Infusion
214678274|NCT03716063|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, every month for a course of treatment, a total of three courses
214678275|NCT01609959|DRUG|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
214678276|NCT01609959|DRUG|Valsartan|Valsartan 160 mg per day
215075378|NCT04496375|OTHER|Survey|Self-completed questionnaires
215075379|NCT01377948|BEHAVIORAL|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
215075380|NCT00908115|BIOLOGICAL|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
214947870|NCT05999838|DIAGNOSTIC_TEST|HRCT chest visual scoring|"CT-based semi-quantitative scoring will be calculated according to number of lung segments affected on both sides.~The finding on each segment will be given a score from 1 to 4 as follows:~1. for ground glass opacities.~2. for reticulations and fibrotic changes.~3. for bronchiectatic changes.~4. for honeycombing and sub-pleural cysts."
214947871|NCT06621199|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 24 mg/m\^2 on day 1, every 4 weeks
214947872|NCT06621199|DRUG|Cytarabine|Cytarabine 100 mg/m\^2 on day 1-5, every 4 weeks
214947873|NCT06621199|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
214947874|NCT06250179|PROCEDURE|free gingiva graft surgery|For insufficient gingival height in patients, the free gingival graft taken from the palate will be sutured to the relevant area.
214947875|NCT04787328|DRUG|HA121-28 tablets|HA121-28 450 mg, po, QD×21 days, every 4 weeks (28 days)
214947876|NCT03310892|BEHAVIORAL|Generic message|Generic message
214947877|NCT03310892|BEHAVIORAL|Tailored message|Tailored message
214947878|NCT05391945|DIAGNOSTIC_TEST|polysomnography|Patient will be assessed by home Polysomnography(PSG), one night, Pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function.
214947879|NCT01707251|DRUG|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
214947880|NCT01707251|DRUG|Saline|Placebo control
214947881|NCT03901053|DEVICE|Reaktiv AFO|This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.
214947882|NCT03901053|DEVICE|PhatBrace AFO|Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
214947883|NCT04789928|DRUG|Gentamicins-EDTA|Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.
214947884|NCT00703287|OTHER|Physiotherapy|Specialized physiotherapy programme developed by Jean-Pierre Bleton
214947885|NCT00703287|OTHER|Physiotherapy|Generic physiotherapy
214947886|NCT01186380|DEVICE|PET-512MC|Transesophageal Transducer
214947887|NCT00629876|DRUG|Peginesatide|"Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.~Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen."
214947888|NCT03661216|DIETARY_SUPPLEMENT|Nephure Oxalate-reducing Enzyme|3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
214947889|NCT03661216|OTHER|Placebo|3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
214947890|NCT04063605|OTHER|Clinical Pilates|This exercise model focus on the awareness of the neutral position of the spine and strengthen the deep postural muscles of the spine. Training of trunk muscles is emphasized and trunk stabilization is achieved and more difficult activities are initiated and thus, body awareness is improved. There are general principles to be followed during exercises. These; The principle of concentration is respiration, central focus, control, stability and isolation. These principles are achieved by simultaneous muscle activation of muscles responsible for trunk stabilization (multifidus, diaphragm, transversus abdominis and pelvic floor muscles). In order for an exercise to become a clinical pilates exercise, trunk stabilization must be ensured and breath control should be established in each exercise.
214947891|NCT04063605|OTHER|Classic Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
214947892|NCT00207792|DRUG|filgrastim|
214947893|NCT02568618|GENETIC|Pain Medication DNA Insight (TM) test|The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
214947894|NCT05648240|OTHER|Blood test|Venous blood samples taken at the moment of colonoscopy to test for biomarkers
215075381|NCT06255067|DRUG|Minocycline hydrochloride with noisome carrier|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
214947895|NCT04779606|DRUG|Ocular gel|3 drops instilled in the right eye
214947896|NCT01561599|DRUG|BB3|Daily intravenous administration of 2mg/kg for 4 days
214947897|NCT01561599|DRUG|Normal Saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
214947898|NCT02638259|DRUG|GP2015|Enbrel comparator
214947899|NCT02870842|DEVICE|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
214947900|NCT02870842|OTHER|Respiratory management|Appropriate respiratory managements depending on the lung ultrasound findings
214947901|NCT02569086|OTHER|Blood draw|
214947902|NCT00087425|BIOLOGICAL|rituximab|
214947903|NCT00087425|DRUG|bryostatin 1|
214947904|NCT03910530|DRUG|Retifanlimab|Part 1: INCMGA00012 500 mg every 4 weeks administered intravenously over 60 minutes.
214947905|NCT03910530|DRUG|INCB001158|Part 1: INCB001158 75 or 100 mg twice daily administered orally.
214947906|NCT03910530|DRUG|Retifanlimab + INCB001158|Part 2: INCB001158 at the recommended Phase 2 dose selected from Part 1 in combination with INCMGA00012 .
215075382|NCT06255067|DRUG|Minocycline Hydrochloride only|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
215075383|NCT04128397|DEVICE|traditional stimulation site continuous theta burst stimulation (cTBS)|before cTBS treatment, MRI was used to confirm the stimulation site
215075384|NCT04128397|DEVICE|precise stimulation site cTBS|before cTBS treatment, rs-fMRI was used to confirm the stimulation site
214342590|NCT00111657|BIOLOGICAL|Pegloticase|8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
214342591|NCT02416791|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
214342592|NCT02416791|DEVICE|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
214342593|NCT02416791|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
214947907|NCT06718673|OTHER|virtual delivery room visit|The real-time labour room demonstration video aims to increase participants' awareness of the labour process, reduce unfamiliarity, and facilitate participation for pregnant women with access restrictions. Produced with a 360-degree camera, it shows detailed sections of the labour room, starting from the entrance. Key areas like birthing beds, toilets, bathrooms, and labour materials (mats, pilates balls, TVs) are highlighted. The video also covers baby cots and rest areas for attendants. Narrated by an experienced midwife, the video ensures patient privacy, no interventions, and excludes images or sounds of other pregnant women. Converted to 360-degree format, the video is available on YouTube for repeated viewing. (https://www.youtube.com/watch?v=EyCt-jTDCVs)
214947908|NCT06718673|OTHER|standart of care|Pregnant women in the control group did not receive any intervention other than routine care and counselling.
214342594|NCT02416791|OTHER|Physical Therapy|Physical therapy will be administered for 40 minutes.
214678277|NCT06482645|PROCEDURE|Perilesional/regional systematic biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra). The location of these nine cores depended on the shape and location of the suspicious lesion.
214947909|NCT03914027|BEHAVIORAL|Telerehabilitation|"Each patient will have the opportunity to have minimum one VC per week the first month, one Video Consultation each second week the second month one VC a month the rest of the trial. Here the physiotherapist, via history will extract the information needed to calibrate the daily TR program according to the patient's physical status and needs.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home."
214947910|NCT04299048|DRUG|PF-06946860|subcutaneous injection
214947911|NCT01593280|DEVICE|TAP catheter|dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.
214947912|NCT01593280|DRUG|intrathecal morphine|0.3 mg
214947913|NCT05114057|OTHER|Renal Angina Index (RAI)|Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury
214947914|NCT05160194|BEHAVIORAL|Positive Parenting Intervention|"The highly interactive GROW Program consists of 5 core modules and 1 optional, supplemental session. Each session is expected to take 15-20 minutes to complete, and at the end of each module, parents record a 5 minute special play time video interacting with their child to demonstrate the skills they learned in the session. Each online module is followed by a meeting with a trained therapist who will discuss their special play time video and the skills they are learning. Parents make their way through the 5 core modules sequentially before accessing the supplemental session that may be relevant to them."
214947915|NCT06653101|DIETARY_SUPPLEMENT|Probiotic|The trial phase of this study lasted 8 weeks, and each patient will make 3 visits (week 0, week 4, week 8)
214947916|NCT06653101|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 8 weeks, and each patient will make 3 visits (week 0, week 4, week 8)
214947917|NCT00231439|DRUG|IvIg|
214947918|NCT05347134|DRUG|SKB264|"SKB264 ：5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
214947919|NCT01706575|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
214947920|NCT01706575|DRUG|Nucleos(t)ide Analogues (NA)|Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
214947921|NCT01550016|OTHER|Observation|Clinical follow-up and laboratory investigations.
214947922|NCT05260775|OTHER|Evaluation test: cataract surgery steps|The development datasets were used to train the deep learning model. The validation and test group were used to optimize hyperparameters
214947923|NCT03784859|DEVICE|Insertion of Tissue Expander with Fluid Reservoir|Use of unique expander type in first stage of a two-stage breast reconstruction, without prolonged drain placement.
214947924|NCT00001047|DRUG|Ethambutol hydrochloride|
214947925|NCT00001047|DRUG|Clarithromycin|
214947926|NCT00001047|DRUG|Clofazimine|
214342595|NCT02416791|OTHER|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
214342596|NCT01054820|DRUG|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
214947927|NCT00001047|DRUG|Rifabutin|
214947928|NCT01813513|DRUG|IDX719|50 mg tablet for oral administration
214947929|NCT01813513|DRUG|Simeprevir|150 mg capsule for oral administration
214947930|NCT06176313|OTHER|Mandala Group|"The Mandala activity lasts approximately 60 minutes.~• A calm environment is provided during the Mandala activity, and participants are ensured not to be disturbed by external stimuli or individuals unless they request assistance.~Each student's last menstrual date is recorded in an Excel table.~* Two days before the intervention day, students will be contacted and invited to participate in the study.~* Monitoring each student's menstrual cycle, the Mandala activity intervention is scheduled during the late luteal phase of each student's menstrual cycle. The intervention is planned within the 5 days before the expected start of menstrual bleeding on days and hours convenient for the student's class schedule.~* After each session, on the 4th day of the expected menstrual bleeding, students are subjected to PMSÖ.~* On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
214947931|NCT06176313|OTHER|Coping with Premenstrual Symptoms Education Group|"The education will be conducted through face-to-face interviews in the master's course classroom at the Faculty of Health Sciences at Bilecik Şeyh Edebali University. The education was conducted using PowerPoint presentations projected onto a white smartboard.~* One month after the completion of the education, a 1st Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~* One month after the 1st Reminder training, a 2nd Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~* On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
214947932|NCT06176313|OTHER|Control Group|"No intervention will be applied to the control group throughout the research. However, students in this group who cope with premenstrual syndrome using medication or non-medication methods will be monitored during the three-month menstrual cycle.~Each student's menstrual cycle in the control group has been recorded in the Excel table. The estimated end of menstruation for each student has been noted.~* At the estimated end of menstruation, the researcher contacts the students in the control group to inquire whether they have used any medication or non-medication methods to cope with premenstrual syndrome.~* Those who use medication or non-medication methods to reduce premenstrual symptoms are excluded from the study.~* On the 4th day of the 4th menstrual period bleeding, the post-test with PMSÖ will be applied to the students."
214947933|NCT06499012|DIETARY_SUPPLEMENT|All-plant Protein Booster Product Group|Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
214947934|NCT06499012|DIETARY_SUPPLEMENT|Placebo Group|Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
214947935|NCT04220086|PROCEDURE|Pediatric massage therapy|Children with ASD will receive pediatric massage therapy twice a week for 12 consecutive weeks by professional pediatric massage doctor. In addition, they will receive parent provided pediatric massage therapy at home after their parents received the professional pediatric massage therapy training. The frequency of pediatric massage will not be more than once every day and each session last about 30 minutes.
214947936|NCT04220086|PROCEDURE|Usual care|Including Applied Behavior Analysis (ABA), Educational intervention, Interpersonal development intervention.
214947937|NCT04220086|OTHER|No intervention|No intervention for healthy controls
214947938|NCT05716217|OTHER|Arm training|Daily arm training program
214947939|NCT03180424|DRUG|L Carnitine|L Carnitine liquid, single daily dose of 2g orally.
215075385|NCT01728077|DRUG|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
215075386|NCT02948907|OTHER|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
215075387|NCT01366612|DRUG|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1"
215075388|NCT01366612|DRUG|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
215075389|NCT02498990|BEHAVIORAL|Low calorie diet followed by life style intervention|"1. Low calorie diet of 800 kcal/day for 7 weeks.~2. Life style intervention for the remaining study period"
215075390|NCT03813004|DIAGNOSTIC_TEST|Reaction for gait perturbation|"Participants were subjected to four different perturbation types while walking on the treadmill:~1. left treadmill belt deceleration for right leg toe off~2. right treadmill belt deceleration for left leg toe off~3. left treadmill belt acceleration for right leg heel strike~4. right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait."
215075391|NCT01095354|DRUG|Sodium Chloride Inhalation|"Spirometry: all subjects Plethysmography and exhaled nitric oxide: \>6 years Multiple Breath Washout: Tidal breathing using a facemask \<9 years or mouthpiece \>9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches \<0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects \>10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum."
215075392|NCT03879044|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
215075393|NCT06089460|OTHER|Beef|Fresh, locally-sourced, grass-fed, grass-finished ground beef sufficient to meet protein needs based on body weight for 8 weeks
215075394|NCT06089460|OTHER|Meat analogue|Commercially-available and purchased meat analogue sufficient to meet protein needs based on body weight for 8 weeks
215075395|NCT06089460|OTHER|Beans/legumes|Canned beans/legumes sufficient to meet protein needs based on body weight for 8 weeks
214947940|NCT03180424|BEHAVIORAL|Supervised exercise|Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
214947941|NCT03180424|DRUG|Placebos|Liquid substance, similar to the one containing L carnitine, in the same presentation
214947942|NCT03180424|BEHAVIORAL|Exercise at home|A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
214947943|NCT01968902|BIOLOGICAL|incabotulinumtoxinA|A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
214947944|NCT01968902|BIOLOGICAL|Placebo|Saline injection on the day of injection visit
214947945|NCT05576441|PROCEDURE|volume stable collagen matrix|Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.
214947946|NCT05576441|PROCEDURE|subepithelial connective tissue graft|SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
214947947|NCT06446349|OTHER|Brief motivational intervention|identification followed by a brief motivational intervention in pharmacies (BMI) based on the mobilisation of patients' psychosocial skills and the integration of tools to help reduce consumption of BZD/Z prescribed over the long term (≥ 6 months).
214947948|NCT03738449|DRUG|CKD-387|Test drug
214947949|NCT03738449|DRUG|D484|reference drug
214947950|NCT01190111|BIOLOGICAL|Interleukin-7|20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
214947951|NCT06390761|PROCEDURE|Acupuncture|All acupoints were selected based on traditional Chinese medicine theory and previous articles on PD and constipation.
214947952|NCT06619028|DEVICE|Weighted vest|During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.
214947953|NCT02140983|DRUG|Liraglutide|90 days of liraglutide up to 1.8mg/day.
215075396|NCT03443479|DEVICE|Non-Invasive Ventilation|Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
215075397|NCT03443479|DEVICE|High-Flow Nasal Cannula|Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher\&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
215075398|NCT06112288|OTHER|Compressive Myofascial Release|Compressive myofascial release is manual therapy technics.
215075399|NCT06112288|OTHER|Ankle mobilisation|ankle mobilization is manual therapy technics.
215075400|NCT03100981|BEHAVIORAL|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
214947954|NCT02140983|DRUG|Placebo|Placebo medication
214947955|NCT02262156|OTHER|Cognitive behavioral therapy|"The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.~The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention"
214947956|NCT02262156|DRUG|SSRI|"Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned."
214947957|NCT03559803|DRUG|Cisplatin|"Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion)."
214947958|NCT02710344|BEHAVIORAL|Telehealth Program|Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
214947959|NCT04454710|DEVICE|Pulsed Radiofrequency|Pulsed radiofrequency is a novel therapeutic modality with many potential applications in pain management.
214947960|NCT04237558|PROCEDURE|Vaginal hysterectomy|Vaginal hysterectomy by removal of uterus through vagina in absence of prolapse
214947961|NCT04237558|PROCEDURE|Laparoscopic hysterectomy|Laparoscopic hysterectomy through key hole surgery through small incisions of the abdomen
214947962|NCT05489419|BEHAVIORAL|Multimodal Prehabilitation|Physical and cardiopulmonary training, personalized nutrition and treatment of anxiety and depression.
214342597|NCT05412862|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in physical activity.
214342598|NCT04040127|BIOLOGICAL|Cord blood stem cells|Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
214342599|NCT04040127|OTHER|Saline solution|saline solution used to rinse the canal.
214342600|NCT01154166|DRUG|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
214342601|NCT01154166|DRUG|Placebo|Placebo
214342602|NCT00311272|BIOLOGICAL|MelCancerVac|
214342603|NCT05477355|BEHAVIORAL|Group Problem Management Plus (PM+)|Group PM+ is a low-intensity, trans-diagnostic, brief psychological intervention developed by the WHO. Group PM+ consists of five sessions delivered in five consecutive weeks and includes strategies that are aimed towards decreasing symptoms of depression, anxiety, general distress, and other related conditions. Group PM+ is designed to be delivered by non-specialists, persons without a formal education and licensure in psychology or mental health.
214342604|NCT05440526|PROCEDURE|Herbst Group|"Herbst Group:~1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint."
214947963|NCT06509672|OTHER|Combined Plyometric and Endurance Training|this include Combined Plyometric and Endurance Training for 12 weeks
214947964|NCT06509672|OTHER|Plyometric Training|this include Plyometric Training for 12 weeks
214947965|NCT06509672|OTHER|Endurance training|this include Endurance Training for 12 weeks
214947966|NCT06059157|DEVICE|Advanced MRI|resting-state functional MRI, diffusion with advanced post-processing (microstructure analysis), myelin mapping
214947967|NCT05854043|OTHER|Modified ERAS protocol|"Modified ERAS protocol for OLIF mainly include perioperative analgesic drug management, operation optimization in the anesthetic management, management of gastrointestinal function, and early mobilization management.~Perioperative analgesic usage:~Nonsteroidal anti-inflammatory drugs (NSAIDs) given when Visual Analogue Scale (VAS)\>3. Prehabilitation: Respiratory function exercise; walk at least 200 meters daily. Gastrointestinal function management: Oral lactulose use routinely. Sedation and analgesia: patient status index (PSI) 25-50; analgesia nociception index (ANI) 50-70. Local anesthetic: local infiltration around the psoas muscle. Postop off-bed activity: start mobilization within 24h."
214947968|NCT05854043|OTHER|routine protocol|Perioperative analgesic usage: NSAIDs given follow the patients requirement. Prehabilitation: None. Gastrointestinal function management: None. Sedation and analgesia: bispectral index (BIS) 40-60. Local anesthetic: None. Postop off-bed activity: mobilization follow the patients wish.
214947969|NCT05932849|DRUG|Benralizumab|Patients were initiated on benralizumab as part of routine clinical practice
214947970|NCT02918643|OTHER|Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients|
214947971|NCT03466749|DEVICE|Paclitaxel Eluting Balloon Catheter|Paclitaxel Eluting Balloon Catheter
214947972|NCT04229199|BEHAVIORAL|simulation|Dyads allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
214947973|NCT04609241|DRUG|CD79b CAR-T Cells|Each subject receive CD79b CAR-Tcells by intravenous infusion
214947974|NCT03558841|OTHER|Gait training with the THERA-Trainer Lyra|Gait training with the THERA-Trainer Lyra end-effector gait trainer 3x/week during the inpatient and the outpatient periods.
214947975|NCT03558841|OTHER|Physical therapy|Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.
214947976|NCT03871959|DRUG|Pembrolizumab|200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
214947977|NCT03871959|DRUG|DEBIO1143|3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
215075401|NCT03100981|BEHAVIORAL|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
214342605|NCT05440526|DEVICE|TFBC Group|"TFBC Group:~1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months."
214678278|NCT06482645|PROCEDURE|Combination of systematic biopsy and targeted biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
214947978|NCT06230952|OTHER|BASDAI and BASFI reliability|The study will be carried out on volunteer patients who are diagnosed with axial spondyloarthritis and are followed up in the outpatient clinic of Dokuz Eylül University, Department of Internal Medicine, Rheumatology and Immunology Department, and who meet the inclusion criteria. Patients who volunteer to participate in the study will be contacted by phone and BASDAI and BASFI questionaires will be administered.
214947979|NCT05040100|OTHER|3D Mediastinum Model|The 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
214947980|NCT02722161|DRUG|[14C]BI 1482694|
214947981|NCT03973333|DRUG|IMC-C103C|Weekly IV infusions
214678279|NCT00788658|BEHAVIORAL|Diet modifications|Diet consultation
214678280|NCT00788658|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
214678281|NCT02857907|OTHER|Blood sample|A blood sample is performed one year after kidney transplantation.
214947982|NCT03973333|DRUG|Atezolizumab|IV infusions every 3 weeks
214947983|NCT03973333|DRUG|IMC-C103C|Weekly subcutaneous Injection
214947984|NCT02622087|BEHAVIORAL|One-Session-Treatment|There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
214947985|NCT02668159|DIETARY_SUPPLEMENT|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
214947986|NCT02668159|DIETARY_SUPPLEMENT|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
214947987|NCT02668159|DIETARY_SUPPLEMENT|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
214947988|NCT02668159|DIETARY_SUPPLEMENT|Placebo|7 tablets of placebos administered prior to one the OGTT
214947989|NCT02272933|DEVICE|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
214947990|NCT02272933|DEVICE|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
214947991|NCT02952872|BEHAVIORAL|Brief Tablet-based Intervention to Address Heavy Alcohol Use|The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
214947992|NCT04047849|DRUG|Antibiotics, oral Azithromycin and oral Amoxicillin|Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
214947993|NCT04384770|RADIATION|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT
214947994|NCT04384770|RADIATION|MRI-guided Stereotactic Body Radiation Therapy|Undergo MRI-guided SBRT
214947995|NCT04384770|OTHER|Questionnaire Administration|Ancillary studies
214947996|NCT01835028|OTHER|Echocardiography|Observational Study using Imaging and Biomarkers
214947997|NCT01835028|OTHER|Computed tomography|Observational Study using Imaging and Biomarkers
214947998|NCT01835028|OTHER|Magnetic resonance imaging|Observational Study using Imaging and Biomarkers
214947999|NCT01835028|OTHER|Blood biomarkers|Observational Study using Imaging and Biomarkers
214948000|NCT01835028|OTHER|Stress echocardiography|Observational Study using Imaging and Biomarkers
214948001|NCT00523523|BEHAVIORAL|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
214948002|NCT00523523|BEHAVIORAL|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
214948003|NCT03216655|OTHER|phone call|Investigators give a regular follow-up to participants: phone call monthly
214948004|NCT03216655|OTHER|wechat group|Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
214948005|NCT03066583|BIOLOGICAL|trephination with placebo|trephination under US guidance and placebo injection
214948006|NCT03066583|BIOLOGICAL|trephination with platelet rich plasma|trephination under US guidance and platelet rich plasma injection
215075402|NCT05897970|DIAGNOSTIC_TEST|Return-to-sport (RTS) follow-up|All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
214342606|NCT05360979|DRUG|envafolimab|Envafolimab: 300 mg, D1, Q3W, subcutaneously administered
214948007|NCT05830669|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.
214948008|NCT05830669|PROCEDURE|Sham RIPC|3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
214948009|NCT05641662|OTHER|Heart Farming|Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
214948010|NCT05412966|DEVICE|PEAR-002B|PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder
214948011|NCT05412966|DEVICE|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
214948012|NCT00221039|DRUG|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
214948013|NCT02942043|DRUG|Bevacizumab|"Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard."
214948014|NCT03942003|PROCEDURE|rhomboid blocks|Rhomboid nerve block was performed
215075403|NCT05638334|DRUG|89Zr-S095012 tracer and S095012 will be administered via an IV infusion|"Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C."
215075404|NCT05981001|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
215075405|NCT05981001|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
215075406|NCT05981001|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
215075407|NCT05981001|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
215075408|NCT05981001|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
215075409|NCT05981001|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
215075410|NCT05981001|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
214342607|NCT00954369|DRUG|[F-18]W372|"The individual doses of \[F-18\]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
214342608|NCT00446316|DRUG|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
214342609|NCT00446316|DRUG|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
214342610|NCT05382780|OTHER|The breather respiratory muscle trainer|The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.
214948015|NCT03942003|PROCEDURE|PEC blocks|PEC I-II blocks was performed
214342611|NCT05382780|OTHER|Diaphragmatic and localized breathing exercises|"A. Diaphragmatic breathing exercises:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~B. Localized Breathing:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~C. Mild Interval training exercise"
214342612|NCT05382780|OTHER|interval aerobic training and respiratory training|mild intensity interval aerobic training and respiratory training on treadmill
214948016|NCT03942003|PROCEDURE|Control groups|Infiltration analgesia was performed
214948017|NCT02536781|DRUG|Anthocyanin|Anti-inflammation gel
214948018|NCT02536781|DRUG|Placebo|Blank gel
214948019|NCT03834714|DEVICE|Near Infrared Light|NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
214948020|NCT03834714|OTHER|Noise Stimulus|Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.
215075411|NCT05981001|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
215075412|NCT05981001|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
215075413|NCT00619424|DRUG|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
215075414|NCT00619424|DRUG|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
214342613|NCT04020770|OTHER|Vibrating ball|Parameters: 5 30-sec bouts of 68Hz vibration followed by a 1-minute rest.
214342614|NCT03774186|DEVICE|Hybrid closed-loop therapy|Hybrid closed-loop therapy with a proportional integral derivative (PID) algorithm
214342615|NCT03774186|DEVICE|Sensor-augmented pump therapy|Insulin pump + non-communicating CGM
214342616|NCT02327026|PROCEDURE|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
214342617|NCT02327026|PROCEDURE|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
214342618|NCT04121962|BEHAVIORAL|Peer Mentor|Participants will be trained to be Peer Mentors and promote home-based testing to their social network
214342619|NCT04121962|BEHAVIORAL|Website only|Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
214342620|NCT02978144|RADIATION|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT-CT
214342621|NCT02978144|DRUG|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
214948021|NCT03834714|DEVICE|Sham Near Infrared Light|Sham NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
214948022|NCT03423147|DRUG|2% chlorhexidine gluconate cloth|applied to their abdomen
214948023|NCT03423147|DRUG|4% Chlorhexidine gluconate vaginal scrub|applied as a vaginal cleanse in the operating room prior to cesarean section
214948024|NCT03406624|PROCEDURE|Biopsy|Biopsies will be taken from disc and / or endplates during elective lumbar fusion surgery or disc herniation surgery (endplate biopsy is omitted in disc herniation surgery)
214948025|NCT05913596|DRUG|Daratumumab|After successful enrollment, the patient will receive daratumumab of 16mg/kg once every two weeks (0-22 weeks) for a total of 12 times. Peripheral blood samples were collected from 0 to 24 weeks (weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24) for routine blood tests, liver and kidney function electrolytes, tacrolimus or cyclosporine trough concentrations, HLA antibody quantification (weeks 0, 4, 8, 12, 16, 20, and 24), infection indicators (weeks 0, 8, and 24), immune status assessments (weeks 0, 4, 8, 12, 16, 20, and 24), and biopsy of transplanted kidneys was performed at 24 weeks to assess pathological changes.
214948026|NCT02069093|DRUG|Dexamethasone based mouthwash|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
214948027|NCT02069093|DRUG|Everolimus|Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
214948028|NCT02069093|DRUG|Exemestane|Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
215075415|NCT00619424|DRUG|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
215075416|NCT00574730|DRUG|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
214342622|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
214342623|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
214342624|NCT05980312|OTHER|Splint Immobilization|Patients will be randomized to receive a splint following their surgical procedure.
214342625|NCT05980312|OTHER|Early Motion|Patients will be randomized to receive no splint following their surgical procedure.
214342626|NCT02019719|DRUG|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
214342627|NCT02019719|DRUG|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
214342628|NCT01271881|OTHER|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
214342629|NCT01271881|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
214948029|NCT03905746|OTHER|blood sample at Day 0|"40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)"
214948030|NCT03905746|OTHER|blood sample at Day 2 and Day 7|20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.
215075417|NCT00574730|DRUG|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
215075418|NCT00347438|DRUG|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
214948031|NCT03905746|OTHER|stool sample at Day 0|stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.
214948032|NCT03123029|DRUG|Venetoclax|Venetoclax will be administered orally.
214948033|NCT02739308|OTHER|Proprioceptive Training|In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes , three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes , and preferably one of each category.
215075419|NCT04330391|BEHAVIORAL|Remote dietitian supervised weight loss intervention and mobile app|Please see intervention arm description for more details.
215075420|NCT02388035|DRUG|Cefotaxime|
214948034|NCT02739308|OTHER|Control Group|The control group will not make the intervention and will continue with usual training fencing.
214948035|NCT05284734|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and erector spinae blocks were administered
214948036|NCT05167279|BIOLOGICAL|JS026/placebo|Five dose groups (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg) will be set to receive an intravenous infusion of JS026/placebo on Day1, and two dose groups (300 mg JS026 + 1200 mg JS016, and 600 mg JS026+ 1200 mg JS016) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
214948037|NCT05167279|BIOLOGICAL|JS016/placebo|Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
214948038|NCT04748172|BIOLOGICAL|SARS-CoV-2 virus vaccines|mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)
214948039|NCT04748172|DIAGNOSTIC_TEST|AMH sampling|Blood sample for AMH on recruitment and after three months
214948040|NCT04748172|DIAGNOSTIC_TEST|anti Covid-19 antibody levels (Serology)|Blood sample for IgG against S1 protein after three months
214948041|NCT04045080|DEVICE|AMADEO|"AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.~Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient.~In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia."
214948042|NCT04045080|OTHER|Training|training
214948043|NCT04045080|OTHER|OT Training|training
214948044|NCT04554758|PROCEDURE|Sleeve gastrectomy|Bariatric operation will be done by laparoscopic sleeve gastrectomy procedure.
214948045|NCT04554758|PROCEDURE|Roux-en-Y gastric bypass|Bariatric operation will be done by laparoscopic Roux-en-Y gastric bypass procedure.
214948046|NCT04819412|BIOLOGICAL|ROTAVAC®|ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
214948047|NCT04819412|BIOLOGICAL|ROTAVAC 5C -F1|ROTAVAC 5C formulation BBIL-R2014-1
214948048|NCT04819412|BIOLOGICAL|ROTAVAC 5C -F2|ROTAVAC 5C formulation BBIL-R2014-2
214948049|NCT06730035|OTHER|Blood analysis|This is an experimental analysis on tissues (peripheral blood) and exploratory, which is why the enrollment of a limited number of patients has been planned. The results obtained from the study should not be considered conclusive but rather as generators of research hypotheses for potential subsequent studies to be conducted on larger populations. The qualitative and quantitative characteristics of the vesicles and their miRNA content will be analyzed descriptively.
214948050|NCT03232164|DRUG|18F-DCFPyL PET|18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
214948051|NCT05423366|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
214948052|NCT01368887|DRUG|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
214948053|NCT01368887|OTHER|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
215075421|NCT06164496|DEVICE|standart manual toothbrush|Device on plaque removal efficacy
215075422|NCT06164496|DEVICE|360 degree toothbrush|Device on plaque removal efficacy
214948054|NCT01368887|DRUG|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
214948055|NCT01368887|DRUG|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
214948056|NCT03130283|OTHER|Home Hospitalization|Visit every 24 hours
214948057|NCT03130283|OTHER|Conventional Hospitalization|No intervention
214948058|NCT03854604|OTHER|postoperative pain assessment|evaluation of the efficacy of PI as an objective measure for postoperative pain assessment in pediatric population undergoing adenotonsillectomy.
215075423|NCT00949754|DRUG|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
215075424|NCT00605098|DRUG|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
215075425|NCT00605098|DRUG|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
214948059|NCT06648720|DRUG|DAPT de-escalation|Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.
214948060|NCT01222377|PROCEDURE|endoscopic surgery|Undergo endoscopic breast surgery
214948061|NCT01222377|PROCEDURE|quality-of-life assessment|Ancillary studies
214948062|NCT03532815|BEHAVIORAL|Lifestyle Modification|
214948063|NCT02352987|DRUG|Neem plus propylene glycol plus salicylic acid|Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
214948064|NCT02352987|DRUG|Salicylic acid|salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
214948065|NCT05051800|BEHAVIORAL|Online Program to Support Coping and Communication in Families|Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.
214948066|NCT02258334|BIOLOGICAL|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
215075426|NCT05230108|PROCEDURE|Advanced Triage|Advanced triage is an intervention that allows the emergency nurse to resolve health problems of low clinical complexity. All actions are aimed at resolving a health problem based on a protocol previously agreed upon by a multidisciplinary team.
215075427|NCT00322023|DRUG|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
215075428|NCT00322023|DRUG|D-serine|
215075429|NCT00322023|DRUG|D-serine|
215075430|NCT00322023|DRUG|D-serine|
215075431|NCT02937077|DEVICE|Medtronic Reveal LINQ|
214948067|NCT02258334|BIOLOGICAL|Fluzone I®ntradermal vaccine, 2014-2015 formulation|0.1 mL, Intradermal
214948068|NCT02258334|BIOLOGICAL|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
214948069|NCT02258334|BIOLOGICAL|Fluzone High Dose vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
214948070|NCT06603220|DRUG|Oral EVO756|Oral EVO756, once daily
214948071|NCT05958069|DRUG|minocycline|Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;
214948072|NCT00473785|BEHAVIORAL|Group-based motivational interviewing|
214948073|NCT00473785|BEHAVIORAL|Individual CVD-risk factor feedback|
214948074|NCT00473785|BEHAVIORAL|Education for protective health behavior change|
214948075|NCT01688778|BEHAVIORAL|Telemedicine|"Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.~Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks."
214948076|NCT04610502|BIOLOGICAL|Administration of Equine immunoglobulin anti SARS-CoV-2|The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.
215075432|NCT01415648|OTHER|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
215075433|NCT01415648|OTHER|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
215075434|NCT05480189|OTHER|Non-intervention|Non-intervention,with real world study
215075435|NCT00693017|DRUG|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
215075436|NCT00693017|DRUG|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
214948077|NCT06613698|DRUG|GSK4532990|GSK4532990 will be administered
214948078|NCT06613698|DRUG|Placebo|Placebo will be administered
214948079|NCT07004881|PROCEDURE|Group A (Active Comparator) Mulligan's Mobilization With Movement (MWM)|"This group will receive two techniques of mulligan i.e. Medial Patellar Glide relative to femoral trochlea and other is tibial internal rotation relative to femoral condyles.In Medial Patellar Glide; patient is positioned supine with 40 degree knee flexion. Stabilizing hand of therapist stabilizes the posterior aspect of tibia and fibula and with mobilizing hand, the therapist gently glides the patella medially. With that, the patient is asked to actively flex and then extend the knee.~In the tibial internal rotation technique; similarly the patient is positioned supine with 40 degree knee flexion. Stabilizing hand of therapist stabilizes t~After mobilization; following exercises are to be performed all in 3 sets of 7 repetitions:~1. Side-lying hip abduction~2. Clamshell exercises~3. Quadriceps setting exercise~4. Vastus Medialis Oblique strengthening~5. Mini squats~6. Hamstring stretch~7. Iliotibial band stretch"
214948080|NCT07004881|PROCEDURE|Group B(Experimental) Maitland's Patellar Mobilizations|"For all the mobilizations the patient is positioned either in supine or sitting with 30-0 degree knee flexion or full knee extension. The therapist holds patella between his/her thumb and index finger and glides it cranially (Superior Patellar glide), caudally (Inferior Patellar Glide) and medially (Medial Patellar Glide). The fourth one i.e. Patellofemoral Distraction is given by grasping the patella between two fingers and lifting it above/away from underlying femoral trochlea. All 4 of these techniques are repeated 10 times with total 3 sets. 3 sessions are performed in a week on alternate days. Total duration of interventions is 2 weeks.~Both groups receive similar exercises therapy following mobilizations."
214948081|NCT04874532|OTHER|Community Paramedic Program|Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.
214948082|NCT04874532|OTHER|Education Material|Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
214948083|NCT03139864|PROCEDURE|controlled physical activity|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
214948084|NCT00862459|DRUG|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
214948085|NCT00862459|DRUG|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
214948086|NCT00862459|DRUG|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
214948087|NCT00862459|DRUG|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
214948088|NCT05188404|BEHAVIORAL|Choice of cannabis product|Participants choose and purchase their own cannabis product
214948089|NCT07012408|OTHER|Return to play program with progressive design|This design has more open objectives than the regressive design. In the progressive design, the duration of the return-to-play program is not determined by a future date, but rather by the player's daily progress. This design is less commonly used for scheduling tasks and planning work. It is intended to be compared with the regressive design to determine which is more appropriate.
214948090|NCT07012408|OTHER|Return to play program with regressive design|Control Group: Subjects with muscle injuries assigned to this group will follow a Return to Play program with a regressive design. This design has fixed times and objectives from the beginning of the program to predict the athlete's exact discharge time. This design is commonly used for scheduling tasks and planning work. It is intended to evaluate the benefits and drawbacks of the design and compare them with those of the progressive design to determine which is more appropriate.
214948091|NCT04246502|DRUG|Capecitabine and Pyrotinib|Pyrotinib 400mg orally daily until progressive disease
214948092|NCT04246502|DRUG|Capecitabine,Trastuzumab, and Pertuzumab|as instruction
214948093|NCT04296786|DRUG|Sintilimab|200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment
214948094|NCT04296786|DRUG|Chidamide|20mg po per week continuously
214948095|NCT00546741|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
214948096|NCT00546741|DRUG|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
214948097|NCT00546741|DRUG|Dapagliflozin + Metformin|"Tablets, Oral, once daily, single dose~Dapagliflozin: 20 mg~Metformin: 1000 mg"
214948098|NCT07026474|OTHER|radiotherapy|single doses of 1.8Gy up to a total dose of 55.8Gy to 63.0Gy
215075437|NCT02873065|DRUG|Ilaprazole|
215075438|NCT02873065|DRUG|Esoprazole|
215075439|NCT01082874|DRUG|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
214342630|NCT04943926|OTHER|Energy restricted diet|Nutritional complete formula diet followed by an energy restricted diet
214342631|NCT04943926|OTHER|Low carbohydrate high fat diet|Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
214342632|NCT04535037|BIOLOGICAL|DTPa-HBV-IPV/Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh
214342633|NCT04535037|BIOLOGICAL|DTaP5-HBV-IPV-Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh
214342634|NCT04535037|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
214342635|NCT06434532|OTHER|v-Care Online Game|A regular 2 hours traditional learning mode session - case study session and 2-hour online game session with peer-led discussion and interprofessional project submission. This spreads in 3 weeks interval
214342636|NCT06434532|OTHER|Case-based online discussion|A 2-hour traditional learning mode session with online peer-led discussion and submission of an interprofessional worksheet as an assignment
214948099|NCT07026474|DRUG|Cisplatin|40mg/m² BSA weekly concomitant to re-irradiation
214948100|NCT07026474|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w
214678282|NCT02115815|BIOLOGICAL|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
214948101|NCT07026474|DRUG|cisplatin + 5-fluorouracil (5FU)|Cisplatin: 100mg/m² BSA d1, q3w / 5-FU: 1000mg/m² BSA d1-4, q3w
214948102|NCT07026474|DRUG|Alternative medications: carboplatin + 5-fluorouracil (5FU)|Carboplatin: AUC5 d1, q3w / 5-FU: 1000mg/m² BSA d1-4, q3w
214948103|NCT07026474|DRUG|Alternative medications: carboplatin|AUC2 weekly
214948104|NCT07026474|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 8-14 days after completion of RCT
214948105|NCT07026604|DRUG|Daratumumab|Participants receive intravenous daratumumab (16 mg/kg weekly for 8 weeks), diluted in 1000 mL (first dose) or 500 mL (subsequent doses) of saline, with infusion rates escalated stepwise from 50 to 200 mL/h under vital sign monitoring. Premedication (antihistamines/analgesics) is administered 30 minutes prior to each infusion to mitigate reactions.
215075440|NCT01082874|DRUG|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
215075441|NCT01082874|DRUG|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
214948106|NCT07027033|OTHER|acid-rich sunflower oil oleic acid|Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of sunflower oil rich in oleic acid
214948107|NCT07027033|OTHER|conventional sunflower oil|Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of conventional sunflower oil
214948108|NCT07027189|DIAGNOSTIC_TEST|Artificial intelligence in diagnosis|AI-based diagnostic programs have proved to enhance diagnostic performance, however research on its effects on treatment decisions is scarce. In contrast to other studies focusing on AI's accuracy or the resulting increase in dentists' accuracy, this study aims to investigate the differences in dentists' treatment recommendations when supported by AI versus when they are not during caries detection.
214948109|NCT07026851|BIOLOGICAL|Blood and bone marrow sampling|"This intervention involves the collection of peripheral blood before and 3 days after coronary artery bypass grafting (CABG), as well as a one-time collection of bone marrow sample during sternotomy.~Samples are analyzed using spectral flow cytometry to characterize the phenotype and maturation stages of circulating and medullary megakaryocytes using a panel of specific surface antibodies."
214948110|NCT03626324|DEVICE|C2P|The C2P is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The C2P is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
214948111|NCT03092934|DRUG|LY3295668|Oral capsules
214678283|NCT02115815|BIOLOGICAL|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
214948112|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
214948113|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
214948114|NCT03654638|OTHER|Questionnaire Administration|Ancillary studies
214948115|NCT06877572|BEHAVIORAL|Weight loss with pharmacotherapy|Patients will meet with a weight management specialist and discuss their options for weight loss including medications (GLP-1 agonist, naltrexone/bupropion, orlistat, or phentermine/topiramate) or bariatric surgery.
214948116|NCT06877572|BEHAVIORAL|Weight loss without pharmacotherapy|Participants not on medications will have their weight recorded at subsequent cancer surveillance or other routine medical visits
214948117|NCT06717412|DRUG|Conbercept|Administered as an intravitreal injection
214948118|NCT02535169|BEHAVIORAL|Health Education and Coaching Strategy|Utilizing health education and health coaching to intervene with adolescents who are at high risk for type 2 diabetes or prediabetes regarding nutrition and physical activity. A 16-week curriculum will be utilized and phone-based coaching visits will be performed.
214948119|NCT02535169|BEHAVIORAL|Dietary consult|A routine clinic-based dietary consult will be performed (approximately 1-hour).
214948120|NCT06724666|BEHAVIORAL|Transdiagnostic Internet-delivered intervention|The intervention consists of 8 modules based on Rational emotive therapy, delivered via 8 weeks.
214948121|NCT00065767|DRUG|Raloxifene|
214948122|NCT03693469|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
214948123|NCT03449992|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|Nitrate-rich beetroot juice supplementation was administered for 15 consecutive days to participants in this arm
214948124|NCT03449992|DIETARY_SUPPLEMENT|Placebo|Placebo drink
214948125|NCT07027202|PROCEDURE|Early Left Ventricle unloading|"An Intraortic balloon pump will be systematically inserted as soon as possible, within 12 hours post-randomization.~* A pulmonary artery catheter (PAC) will enable hemodynamic monitoring of cardiac filling pressures, cardiac output and pulmonary artery pressures.~* Doppler Echocardiography will be performed at least daily to monitor LV ejection, LV dimension, appearance of LV blood stagnation, aortic time-velocity integral (VTI) and aortic valve opening.~* Escalation to a microaxial LV venting pump, central ECMO or atrial septostomy will be possible and discussed by the Shock team (as suggested by international recommendations) in case of~* Overt cardiogenic pulmonary edema requiring invasive mechanical ventilation~* Persisting more than 6 hours despite IABP support and optimization of patient's management (titration of ECMO blood flow, inotropes, non-invasive mechanical ventilation with PEEP, diuretics or hemofiltration)."
214948126|NCT06728657|RADIATION|HFRT targeted to the primary lesion and positive lymph nodes|Hypofractionated radiotherapy (HFRT) targeted to the primary lesion and positive lymph nodes (4Gy × 6 fractions)
214948127|NCT06728657|RADIATION|PULSAR targeted to the primary lesion and positive lymph nodes|Irradiation targeted to the primary lesion and positive lymph nodes (6 Gy/1 fraction)
214948128|NCT06728657|DRUG|Anti-PD-1 monoclonal antibody|The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status. The commonly used anti-PD-1 mAb usages are as follows: Nivolumab, 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Sintilimab, 200mg solution intravenously once daily, Q3W.
214948129|NCT06728657|DRUG|Chemotherapy|CAPOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks
214948130|NCT06728657|PROCEDURE|R0 total/subtotal gastrectomy with D2 lymphadenectomy|For resectable participants, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion.
215075442|NCT01082874|DRUG|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
214678284|NCT02115815|BIOLOGICAL|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
214342637|NCT05900024|OTHER|Funk It Cycle Bites|The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
214948131|NCT04441476|OTHER|Questionnaires|"An online questionnaire (Limesurvey platform) will be made available at 4 different times (M0, M1, M2 and M6).~* The first questionnaires (M0 and M1) will include a component for professional characterization. Generic and specific stress factors related to ICU and the current pandemic and collective and individual defensive strategies will also be collected in M0 and M1.~* At M2 and M6, the traumatic impact of the crisis, burnout, signs of depression and recourse to internal or external support in the department (occupational medicine, support unit) will be collected."
214948132|NCT04441476|OTHER|psychological and sociological interviews|"conducting semi-directive psychological interviews (40 interviews in M2, 40 interviews in M6).~sociological interviews: 40 (20 in M1-M2 then 20 in M6) in order to understand the consequences of the epidemic on daily life, both intra-family and micro-social."
214948133|NCT03816852|BIOLOGICAL|hucMSCs|Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
214948134|NCT00691639|OTHER|Blood Collection Only|Blood Collection Only
214948135|NCT04907227|BIOLOGICAL|Pembrolizumab|IV infusion
214948136|NCT04907227|DRUG|Docetaxel|IV infusion
214948137|NCT04907227|DRUG|Prednisone|Oral tablets
214948138|NCT04907227|DRUG|Placebo|IV infusion
214948139|NCT04907227|DRUG|Dexamethasone|Oral tablets
214948140|NCT00461760|PROCEDURE|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
214948141|NCT00461760|PROCEDURE|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
214948142|NCT02240069|BEHAVIORAL|Education (Tx1)|Education on best burn practices
214948143|NCT02240069|DEVICE|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove"
214948144|NCT02240069|DEVICE|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
214948145|NCT00576810|DRUG|sodium picosulphate|
214948146|NCT00410462|DRUG|brostallicin|
214948147|NCT00410462|DRUG|doxorubicin hydrochloride|
214948148|NCT06740019|DRUG|JMKX000197|for pleural perfusion
214948149|NCT06740019|PROCEDURE|Tube thoracostomy drainage|Tube thoracostomy drainage
214948150|NCT06655701|DIAGNOSTIC_TEST|No intervention|No intervention
214948151|NCT05073354|DEVICE|Full SWOT Model|Bundle of care that includes devices such as X Series monitor/defibrillator, AutoPusle automated compression device, Z Vent ventilator, and IPR therapies as well as bedside monitoring and diagnostics and training on a standardized care process.
214948152|NCT05545345|PROCEDURE|tympanostomy tube placement|An incision will be made in the the tympanic membrane, through which a ventilation tube will be inserted.
214948153|NCT05545345|PROCEDURE|adenoidectomy|The adenoid is resected transorally under a 70° endoscope with microdebrider or coblator until torus tubarius and choanae are completely revealed.
214342638|NCT01672125|OTHER|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
214948154|NCT04527211|DRUG|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
214948155|NCT03647605|BEHAVIORAL|VR Mind|"Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes."
214342639|NCT06202261|DRUG|TQB2930 for injection|TQB2930 for injection is a HER2 bispecific antibody.
214342640|NCT06202261|DRUG|Paclitaxel for injection (albumin-bound)|It is an anti-microtubule chemotherapy drug
214948156|NCT02990351|PROCEDURE|loco regional therapies for HCC|29 HCC patients received locoregonal therapy as a bridging therapy for those who were within milan and as downstaging for those were initially beyond milan. The main LRT types used for our patients were TACE and or RFA and microwave ablation
214948157|NCT00236275|DRUG|Fluoro-L-thymidine-(18F)|Fluoro-L-thymidine-(18F)
214948158|NCT02679833|DIETARY_SUPPLEMENT|Placebo|Toothpaste not containing the vitamin.
214948159|NCT02679833|DIETARY_SUPPLEMENT|Cyanocobalamin|Toothpaste containing100 µg cyanocobalamin/g.
214948160|NCT06614842|BEHAVIORAL|Common Factors Group Psychotherapy|This intervention will not contain active ingredients from established specific forms of psychotherapy (e.g., cognitive-behavioral therapy, dialectical behavioral therapy)
214342641|NCT06202261|DRUG|TQB3616 capsule|TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
214342642|NCT06202261|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
214342643|NCT06202261|DRUG|Capecitabine tablets|Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.
214342644|NCT06202261|DRUG|Vinorelbine tartrate injection|Vinorelbine is an anti-tumor drug of vinca alkaloids.
214948161|NCT03035006|DRUG|Lipotecan|Lipotecan based concurrent chemoradiotherapy
214948162|NCT03723070|DEVICE|The Cryterion Cardiac Cryoablation System|Cryoablation System that includes a Balloon Catheter, Circular Mapping Catheter, Steerable Sheath and Cryoablation Console. In combination, components of the System will be inserted into the left atrium and a thermal injury at the PV ostium will be created to electrically isolate the veins
214948163|NCT06767423|BEHAVIORAL|Text Message + Automated Caller (Intervention)|Standard text message appointment reminders to English and Spanish-speaking patients. Text reminders will go out 3-weeks, 3 days, and 24 hours before the appointment. If patient has not confirmed their appointment after the 3-week and 3-day reminders they will receive an automated caller.
214948164|NCT06890650|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
214342645|NCT06202261|DRUG|Eribulin mesylate injection|Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
214948165|NCT06890650|OTHER|Sham transplantation|Sham FMT will involve saline infusion via colonoscopy
214948166|NCT06890650|OTHER|Crohns disease exclusion diet|The modified diet plan will be given to each study participant
214948167|NCT06890650|OTHER|Sham diet|Dietary counselling alone
214342646|NCT06202261|DRUG|gemcitabine hydrochloride for injection|Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
214342647|NCT05075252|PROCEDURE|laparoscopic lavage|This study aims to investigate the impact of laparoscopic lavage on the incidence of postoperative abscesses stratifying patients on the grade of appendicitis and peritoneal contamination.
214342648|NCT02880852|DRUG|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
214347505|NCT03339050|BEHAVIORAL|Health for Hearts United|The intervention was framed around three conceptual components (awareness building, clinical learning, and efficacy development), and four types of programming (church-initiated, joint programming, standard programming (culturally tailored post cards and newsletters), and data collection health promotion (generic materials, clinical sessions with an Registered Dietitian). Key messages were identified for the intervention including eating better, moving around more, reducing stress, and taking charge of your health.
214347506|NCT01914926|DRUG|Metoprolol|
214948168|NCT02149095|DRUG|TransCon PEG treprostinil|
214948169|NCT00970424|DRUG|Placebo|placebo, oral tablet administered once daily on background of pioglitazone
214948170|NCT00970424|DRUG|Dutogliptin|dutogliptin, oral tablet administered once daily on background of pioglitazone
214948171|NCT04457934|DRUG|Plenvu|All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines
214948172|NCT01649310|OTHER|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
214948173|NCT04925284|DRUG|XB002|IV administration of XB002
214948174|NCT04925284|DRUG|Nivolumab|IV administration of Nivolumab
214948175|NCT04925284|DRUG|Bevacizumab|IV administration of bevacizumab
214948176|NCT06850857|OTHER|IMPACT-G Module|Administration of the general IMPACT survey module.
214948177|NCT06850857|OTHER|IMPACT-N Module|Administration of the IMPACT-N survey module.
214948178|NCT06850857|OTHER|IMPACT-O Module|Administration of the IMPACT-O survey module.
215075443|NCT01620164|OTHER|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
215075444|NCT02764528|BEHAVIORAL|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
215075445|NCT02764528|BEHAVIORAL|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
214347507|NCT01914926|DRUG|Diltiazem|
214948179|NCT06850857|OTHER|IMPACT-J Module|Administration of the IMPACT-J survey module.
214948180|NCT06850857|OTHER|15D Control Survey|Administration of the 15D QOL control survey.
214948181|NCT05029609|DRUG|Intranasal Foralumab Solution|The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
214948182|NCT05029609|DRUG|Placebo|The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
214948183|NCT06006143|DRUG|Varenicline|All participants will receive a prescription for varenicline and will meet with a clinical pharmacist and addiction psychiatrist for further support
214948184|NCT02208050|DRUG|Fampridine|
214948185|NCT02208050|DRUG|Placebo|
214948186|NCT03383094|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
214948187|NCT03383094|RADIATION|Radiation therapy|70 Gy in 33-35 fractions
214948188|NCT03383094|DRUG|Cisplatin|100 mg/m2 Weeks 1, 4, and 7.
214948189|NCT02770768|DRUG|Flibanserin|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
214948190|NCT02770768|DRUG|Placebo|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
214342649|NCT02165722|BEHAVIORAL|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit \[chronic and acute\] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
214948191|NCT01810783|DRUG|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
214342650|NCT01235910|DRUG|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
214948192|NCT06749392|BEHAVIORAL|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
214948193|NCT03283059|DRUG|Octohydroaminoacridine Succinate|Octohydroaminoacridine Succinate Tablet:4mg P.O. tid
214948194|NCT03283059|DRUG|Aricept|Aricept 5mg/day, P.O.
214948195|NCT03283059|DRUG|Placebos|Placebo Tablet: P.O. tid
214342651|NCT02762591|DRUG|Pimavanserin tartrate|Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
214948196|NCT00824434|DEVICE|PROMUS Element™|Drug eluting coronary stent system
214948197|NCT02134353|DRUG|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
214948198|NCT02134353|DRUG|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
214948199|NCT06905210|DRUG|Placebo of the experimental drug|Subjects randomized to this group will receive one (01) placebo of the experimental drug everyday for 28 weeks.
214948200|NCT06905210|DRUG|Experimental drug|Subjects randomized to this group will receive one (01) experimental drug everyday for 28 weeks.
214948201|NCT06831916|DIETARY_SUPPLEMENT|Active Cannabinoid Product|Participants will be administered a product with minor cannabinoids and terpenes.
214948202|NCT06831916|OTHER|Placebo|Participants will be administered a placebo.
214342652|NCT01421875|GENETIC|DNA methylation analysis|
214342653|NCT01421875|GENETIC|RNA analysis|
214948203|NCT04735770|PROCEDURE|Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine|Postoperative pain management
214948204|NCT00477607|DRUG|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
214948205|NCT00477607|BEHAVIORAL|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
214948206|NCT00477607|BIOLOGICAL|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
214948207|NCT00477607|DRUG|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
214948208|NCT03542331|DRUG|Lipiodol|Endometrial flushing with Lipiodol between day 6 and 8 of the cycle
214948209|NCT03542331|DEVICE|Mock catheter|Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle
214948210|NCT03784794|DIAGNOSTIC_TEST|Thromboelastometry|devices generate output by transducing changes in the viscoelastic strength of a small sample of clotting blood (300 µl) to which a constant rotational force is applied. These point of care devices allow visual assessment of blood coagulation from clot formation, through propagation, and stabilization, until clot dissolution. Computer analysis of the output allows sophisticated clot formation/dissolution kinetics and clot strength data to be generated
214948211|NCT03784794|DIAGNOSTIC_TEST|Standard Coagulation Test|coagulation tests, such as the prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT), to assess blood clotting function in patients. Clauss Fibrinogen.
214948212|NCT03784794|DRUG|Fibrinogen Concentrate Human|To treat acquired fribinogen deficiency investigators will treat with the following doses FIBTEM A5 = 9-11 MM a 2 G FIBRINOGEN CONC. (25 MG/KG); FIBTEM A5 = 4-8 MM a 4 G FIBRINOGEN CONC. (50 MG/KG); FIBTEM A5 \< 4 MM a 6 G FIBRINOGEN CONC. (75 MG/KG)
215075446|NCT02764528|BEHAVIORAL|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
214342654|NCT01421875|GENETIC|gene expression analysis|
214342655|NCT01421875|GENETIC|microarray analysis|
214342656|NCT01421875|GENETIC|nucleic acid sequencing|
214948213|NCT03784794|DRUG|Prothrombin Complex Concentrates|to treat acquired factor deficiency investigators will treat as follows PROTROMBIN COMPLEX CONCENTRATE EXTEM CT \> 80 SEC AND FIBTEM A5 ≥ 8 MM 4F-PCC 20 IU/KG (F II, VII, IX and X) GOAL: EXTEM CT ≤ 80 SEC
214948214|NCT03784794|OTHER|Platelets|PLATELETS EXTEM A5 \< 40 MM AND FIBTEM A5 ≥ 12 MM EXTEM A5 \< 40 MM → 1 PLATELET POOL OR APHERESIS; EXTEM A5 \< 30 MM → 2 PLATELET POOL OR APHERESIS GOAL: EXTEM A5: 40-50 MM or PLATELET COUNT \< 100/µL PLT \< 100/µL → 1 PLATELET POOL OR APHERESIS; PLT \> 50/µL → 2 PLATELET POOL OR APHERESIS GOAL: PLT COUNT \> 100/µL
214948215|NCT03784794|OTHER|Red Blood Cells|"Transfuce Red Blood Cells if Hemoglobine levels \< 7 G/DL;~1 unit of FFP for every unit of RBC Transfused GOAL: Hb \> 7.5 G/DL"
214948216|NCT03784794|OTHER|Fresh Frozen Plasma|FRESH FROZEN PLASMA TP AND/OR TTP PATHOLOGICAL INR, 2.0-4.0 → FFP 20 ML/KG GOAL: TP AND TTP NORMAL AND INR \< 2.0
214948217|NCT03784794|OTHER|cryoprecipitates|FIBRINOGEN (CLAUSS) \< 250 MG/DL FIB 200-250 MG/DL → CRYOS, PACK OF 10 (25 MG/KG); FIB 100-200 MG/DL → CRYOS, PACK OF 20 (50 MG/KG); FIB \< 100 MG/DL → CRYOS, PACK OF 30 (75 MG/KG) GOAL: FIB \> 250 MG/DL
214948218|NCT00474786|DRUG|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
214948219|NCT00474786|DRUG|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
214948220|NCT03164655|DRUG|Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil|Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h
214948221|NCT00358956|DRUG|ZD6474 (vandetanib)|100 mg once daily oral tablet
214948222|NCT05387681|DRUG|Envafolimab|short course radiotherapy ：5\*5Gy (25Gy/5F) ； Envafolimab：300 mg, subcutaneously, D1, Q3W; Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W; chemotherapy：SOX regimen
214948223|NCT06266156|BEHAVIORAL|Score of anxiety questionnaire|All participants were answered the dental anxiety questionnaire.
214948224|NCT06266156|DIAGNOSTIC_TEST|Heart rate|All participants heart rate were measured with finger type pulse oxymeter.
214948225|NCT06266156|DIAGNOSTIC_TEST|Oxygen saturation|All participants oxygen saturation were measured with finger type pulse oxymeter.
214948226|NCT05432947|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with a dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
214948227|NCT05432947|DRUG|18F-FDG|Intravenous injection of 18F-FDG with a dosage of 5.55 MBq (0.15 mCi)/kg.
214948228|NCT03852927|PROCEDURE|Computer guided contouring|Using virtual planing and rapid prototyping a surgical guide will be fabricated, and will be used for bone contouring of the bone lesion.
214948229|NCT00284427|DRUG|vitamin C|IV Vitamin C given 2-3 times a week
214948230|NCT04077710|RADIATION|Radioactive Iodine-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing template includes information on the path of the implantation needle, characteristics of the surface of the therapy area of the patient, and positioning and orientation effects which can make the operation more accurate.
214948231|NCT04760106|DIAGNOSTIC_TEST|gastric ultrasound|"For the qualitative assessment, every participant was scanned once by both examiners. Each scan session lasted no longer than 5 minutes to mitigate the confounding effect of gastric emptying time.~For the quantitative assessment, the participants were put in a right lateral decubitus position and the antral cross-sectional area (CSA) is measured in the sagittal plane."
214948232|NCT03519100|OTHER|quality of life evaluation|quality of life evaluation post surgery
214948233|NCT01506687|BEHAVIORAL|Health counselling by nurse navigator|Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
215075447|NCT03742999|PROCEDURE|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.
215075448|NCT03742999|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months
214342657|NCT01421875|OTHER|laboratory biomarker analysis|
214342658|NCT00900991|BIOLOGICAL|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
215075449|NCT03742999|COMBINATION_PRODUCT|physical therapy program and ELink Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months
214342659|NCT04895241|DRUG|Litifilimab|Administered as specified in the treatment arm.
214342660|NCT04895241|DRUG|Placebo|Administered as specified in the treatment arm.
214342661|NCT02172209|DRUG|BI 10773|
214347508|NCT03877523|DIETARY_SUPPLEMENT|Cocarnit|a metabolic complex
214347509|NCT05461872|OTHER|No intervention|No intervention
214347510|NCT06089161|OTHER|Standard of Care|Participants in this group will receive standard of care treatment for sleep apnea.
214948234|NCT01506687|BEHAVIORAL|Usual primary care counselling|Usual care health counselling on colorectal cancer and screening options
214948235|NCT02061644|OTHER|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
214948236|NCT02542137|RADIATION|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
214948237|NCT02542137|DRUG|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
214948238|NCT06515964|OTHER|observational study|observational study, no intervention
214948239|NCT03260114|OTHER|Personal Activity Intelligence|Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.
214948240|NCT01238341|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
214948241|NCT03300414|OTHER|One time blood draw|Same as part 1
214948242|NCT00499343|DRUG|Etoposide|150 mg/m\^2 given intravenously over 2 hours every 12 hours x 6 doses.
214948243|NCT00499343|DRUG|G-CSF|Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.
214347511|NCT06089161|BEHAVIORAL|Personalized OSA Treatment|Participants in this group will receive standard of care treatment plus the personalized treatment that consists of videos approximately three minutes long, virtual, accessed through web based application, that the participant watches weekly. The purpose of the video is tailored educational content for sleep apnea.
214948244|NCT00499343|DRUG|GM-CSF|250 mcg/m\^2 injection given every evening till the completion of apheresis.
214948245|NCT00499343|DRUG|Isophosphamide|10 g/m\^2 given intravenously continuous infusion over 72 hours.
214948246|NCT00499343|DRUG|Rituximab|Days +1 (375 mg/m\^2) and +8 (1000 mg/m\^2) given intravenously.
214948247|NCT00499343|PROCEDURE|Apheresis|Peripheral blood stem cell collection.
214948248|NCT05772507|DEVICE|URGO AWC_008 dressing or URGO AWC_022 dressing|local management of acute or chronic wounds
214948249|NCT05731752|DRUG|HX009|The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
214948250|NCT01156883|DRUG|asparaginase|
215075450|NCT04108845|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
215075451|NCT02128815|OTHER|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
215075452|NCT05181774|DIAGNOSTIC_TEST|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
215075453|NCT05181774|DIAGNOSTIC_TEST|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
215075454|NCT01952444|BIOLOGICAL|ETI-204|A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
214948251|NCT01156883|DRUG|cyclophosphamide|
214948252|NCT01156883|DRUG|cytarabine|
214948253|NCT01156883|DRUG|daunorubicin hydrochloride|
214948254|NCT01156883|DRUG|dexamethasone|
214948255|NCT01156883|DRUG|doxorubicin hydrochloride|
214948256|NCT01156883|DRUG|ifosfamide|
214948257|NCT01156883|DRUG|mercaptopurine|
214948258|NCT01156883|DRUG|methotrexate|
214948259|NCT01156883|DRUG|methylprednisolone|
214948260|NCT01156883|DRUG|prednisone|
214948261|NCT01156883|DRUG|thioguanine|
214347512|NCT03816904|OTHER|Blood samples|Blood samples before the introduction of chemotherapy
214948262|NCT01156883|DRUG|vincristine sulfate|
214948263|NCT01156883|DRUG|vindesine|
214948264|NCT06094543|BEHAVIORAL|Patient Engagement Tool|8 week daily patient education and engagement tool
215075455|NCT01952444|DRUG|Ciprofloxacin|A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
215075456|NCT01477463|DRUG|Vitamin D3|4,000 IU oral vitamin D3
215075457|NCT01477463|DRUG|placebo and vitamin D|
215075458|NCT04378465|OTHER|Enhanced Recovery Program (ERP)|An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
215075459|NCT00003044|DRUG|cisplatin-e therapeutic implant|
215075460|NCT03262766|OTHER|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
214948265|NCT03236129|PROCEDURE|T-reg depleted DLI|The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
214948266|NCT03236129|PROCEDURE|Standard DLI|The patients in this arm benefit of a standard DLI.
214948267|NCT00102154|DRUG|MK0928, gaboxadol / Duration of Treatment: 10 months|
214948268|NCT04730752|DIAGNOSTIC_TEST|Appendicitis Inflammatory Response|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
214948269|NCT04730752|DIAGNOSTIC_TEST|Adult Appendicitis Score|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
214948270|NCT02578940|DRUG|18F-Fluciclovine PET CT|Radioligand for PET CT scanning
214948271|NCT05373030|BIOLOGICAL|Recombinant adenovirus type-5-vectored COVID-19 vaccine|One dose COVID-19 vaccine
214948272|NCT04586465|DRUG|pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin|"Patients will receive 3 cycles pembrolizumab 200mg, fix dose, 60 minute IV infusion combination with chemotherapy.~Chemotherapy regimen: ① Eligible patients with non-squamous cell lung cancer, Pemetrexed 500mg/m2, IV infusion on day 1 and cisplatin 75mg/m2 or carboplatin area under the curve (AUC=5), on day 1 of a 3-week schedule for 3 cycles. ② Eligible patients with squamous cell lung cancer. Patients will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC=5 on day 1 of a 3-week schedule for 3 cycles"
214948273|NCT02915822|PROCEDURE|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique for hallux valgus correction
214948274|NCT02915822|PROCEDURE|Open Scarf/Akin osteotomy|Open technique for Hallux Valgus correction
214948275|NCT05682274|PROCEDURE|Partial restoration approach combined with CAF+CTG|The location of the CEJ prior to the restorative treatment was identified using the method developed by Zuchelli et al. 2006. The placement of the apical margin of the restoration was performed either at the level of estimated cementoenamel junction (CEJ) or within 1 mm apical to the CEJ. Two weeks after the restorative treatment, all recession defects were treated with CAF combined with CTG.
214948276|NCT03447106|PROCEDURE|laparotomy|This is a kind of traditional surgical method.
214948277|NCT03447106|PROCEDURE|Laparoscopic|laparoscopic surgery
214948278|NCT03447106|PROCEDURE|Robotic|the Da Vinci robot assisted gastric resection
214948279|NCT03127761|OTHER|Allogeneic Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
214948280|NCT02301845|DRUG|Diatoms Shells|Instillation of suspended diatom shells - 10 mg q12h
214948281|NCT03175315|BEHAVIORAL|Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)|Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
214948282|NCT04303234|OTHER|Artinibsa|local anaesthetic solution with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.
214342662|NCT06573125|BEHAVIORAL|MoodMover|MoodMover is a 9-week app-based program aimed at increasing physical activity (PA) among individuals with depression, delivered via Pathverse. The current version of MoodMover includes one introductory module for baseline self-monitoring, eight primary modules, and eight optional supplementary modules. The program uses a variety of formats to deliver educational content, including videos, podcasts, and illustrated articles. In addition to its structured psychoeducational content, the app provides a range of behavioral features.
214342663|NCT04243824|DRUG|Gallium 68 Macro-aggregated albumin|The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
214342664|NCT05423509|OTHER|Dynamic myofascial manipulation|Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
214948283|NCT04303234|OTHER|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
214948284|NCT03664921|DRUG|Omnitram Oral Tablet|Administered three times daily for 28 consecutive days.
214948285|NCT03664921|DRUG|Placebo Oral Tablet|Administered three times daily for 28 consecutive days.
214948286|NCT06069895|DRUG|NNC0113-6856|NNC0113-6856 will be administered as oral tablets.
215075461|NCT03262766|BEHAVIORAL|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
214948287|NCT06069895|DRUG|Placebo|NNC0113-6856 matching placebo will be administered as oral tablets.
215075462|NCT03262766|OTHER|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
215075463|NCT04881500|OTHER|Motivational interview|Patients will follow motivational interview (2 individual sessions by phone)
215075464|NCT04881500|OTHER|Routine Care|Patients will follow routine care
215075465|NCT01748136|DEVICE|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
215075466|NCT02383745|OTHER|Acute EEG with fast EEG electrode|
215075467|NCT04526873|BEHAVIORAL|Postcard|Mailed
214342665|NCT05423509|OTHER|Standard AIS treatment with observation or bracing|Observation with radiographs and bracing of curves greater than 20 degrees
214342666|NCT01542775|BEHAVIORAL|Aerobic Exercise Group|12 weeks Aerobic exercise
214948288|NCT03304275|BEHAVIORAL|Tdap|Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine
214342667|NCT01542775|BEHAVIORAL|Control Group|maintaining usual activities
214342668|NCT05507411|RADIATION|Neoadjuvant Radiotherapy|41.4Gy/23F
214342669|NCT05507411|DRUG|Neoadjuvant Chemotherapy|Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW
214342670|NCT05507411|DRUG|Immunotherapy|Camrelizumab 200mg Q3W
214342671|NCT04828759|BEHAVIORAL|VR-treatment|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
214342672|NCT04828759|BEHAVIORAL|Treatment as usual|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
214342673|NCT04120896|BEHAVIORAL|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
214678285|NCT02115815|BIOLOGICAL|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
214948289|NCT04104997|DRUG|5% GLH8NDE|5% GLH8NDE as eye drops
214948290|NCT04104997|DRUG|Placebos|Placebo as eye drops
215075468|NCT04526873|BEHAVIORAL|Phone call|May be automated or by human
215075469|NCT04526873|BEHAVIORAL|Humor/Salience|Funny cartoon + health risk examples
215075470|NCT04526873|BEHAVIORAL|Telehealth|Information about video visit
215075471|NCT04563728|BEHAVIORAL|Surveillance camera(s)|the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
215075472|NCT04265729|DIETARY_SUPPLEMENT|Neocate Infant and Junior marketed products|use of Neocate Infant and Junior marketed products
215075473|NCT01175486|DRUG|Actos (Pioglitazone)|Actos 30 mg for 6 months
215075474|NCT01175486|DRUG|Acarbose|Acarbose 50 mg tid for 6 months
215075475|NCT02106624|OTHER|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
214948291|NCT04513899|BEHAVIORAL|Community health worker (CHW)/ registered nurse (RN) [CHW/RN]|A team of 2-3 CHWs and a research RN will deliver all components of the program including daily DOT delivery of Direct Acting Antiviral (DAA) and assess HCV side effects all under the guidance of their RN. Recruitment will be continuous: each CHW may be assigned up to 7-8 participants every 2-3 months until the target sample size (n=54 for the intervention group) is achieved. After the first dose of the DAA, the CHW will run a brief weekly 1:1 education and case management session over the 8 or 12 weeks (total 20 minutes). The CHW/RN team will assist the participant in picking up the monthly medication and storing the medication in a secure, locked cabinet at the research office. The CHW will rigorously track participants who have missed a dose, and will also be involved in facilitating medical, mental health, substance use, social service, legal appointments for participants, housing referrals, and accompany the participants to the appointments.
214948292|NCT04513899|BEHAVIORAL|Clinic-based Standard of Care (cbSOC) Program (control group)|This program will be delivered by a clinic-based MD or clinic-based NP at the clinic site. Evaluation Staff (ES) will be hired and trained to do the interviewing/survey administration and follow-ups at the clinic-based site. The clinic NP will conduct, per usual care at the study clinics, the education and monitoring of these participants who will interact with the clinic-based-MD and/or NP monthly over the 8 or 12-week program. Usual care will include: 1) HCV pre-treatment education; 2) two month supply of DAA; 3) monitoring adverse events; and 4) responding to questions on HCV. Referral to drug/alcohol and housing programs will be provided over the standard of care. The cbSOC participants will not receive the community delivery of the DAA, or case management, or accompaniment to needed services. The cbSOC Program will receive the medication on a monthly basis from the clinic MD or NP.
215075476|NCT05664295|DIAGNOSTIC_TEST|Jenkins Sleep Disorders scale and Epworth Sleepiness scale|Jenkins Sleep Disorders scale and Epworth Sleepiness scale
215075477|NCT04185649|BIOLOGICAL|BAT8001 for injection|3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
215075478|NCT04185649|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
215075479|NCT04185649|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
215075480|NCT00986401|DRUG|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
215075481|NCT00986401|DRUG|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
215075482|NCT02581462|DRUG|FLOT alone|"Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43"
215075483|NCT02581462|BIOLOGICAL|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43."
215075484|NCT00746239|DRUG|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
215075485|NCT00746239|DRUG|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
215075486|NCT06404372|DEVICE|Demetech Barbed PDO Suture|The Demetech Barbed PDO Suture will be used for the correction of midface wrinkles in all patients enrolled in this study.
215075487|NCT02868450|BIOLOGICAL|Blood Sample|
215075488|NCT02818374|DEVICE|oral accessibility spatula (SAB)|
215075489|NCT00622947|PROCEDURE|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
215075490|NCT00622947|PROCEDURE|Sham-rTMS|The coil is angled 90 degrees away from the scalp
215075491|NCT00960037|DIETARY_SUPPLEMENT|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
215075492|NCT00960037|DIETARY_SUPPLEMENT|Placebo equivalent|One capsule daily for 8 weeks
215075493|NCT04699292|PROCEDURE|Surgery|Surgery
215075494|NCT04699292|RADIATION|Preoperative RT 36Gy|Preoperative radiotherapy to 36Gy (equivalent)
215075495|NCT04699292|RADIATION|Preoperative RT 50Gy|Preoperative radiotherapy to 50Gy (equivalent)
215075496|NCT04699292|RADIATION|Postoperative RT 50-66Gy|Postoperative radiotherapy to 50-66Gy (equivalent)
215075497|NCT04699292|RADIATION|RT 36Gy|Definitive radiotherapy to 36Gy (equivalent)
215075498|NCT02671539|GENETIC|rAAV2.REP1|single subretinal injection
215075499|NCT03279523|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
215075500|NCT02267304|DRUG|50 mL of sodium chloride (0,9%)|
215075501|NCT02267304|DRUG|Morphine 0,05mg/kg|
215075502|NCT02267304|DRUG|Naloxone 10mg|
215075503|NCT01678352|BIOLOGICAL|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
215075504|NCT01678352|DRUG|Imiquimod|Cohort 1 Cohort 2 Cohort 3
215075505|NCT01612650|DEVICE|tomosynthesis|2 incidences 3D numeric mammography
215075506|NCT01612650|DEVICE|2D mammography|2 incidences 2D analogic mammography
215075507|NCT00369226|DRUG|Bortezomib (Velcade)|Infusion for a total of 3 doses
215075508|NCT00369226|DRUG|Tacrolimus|Taken until Doctor determines it is not necessary any more
215075509|NCT00369226|DRUG|Methotrexate|Infusion for a total of 4 doses
215075510|NCT00369226|PROCEDURE|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
214948293|NCT05666479|DEVICE|Dexcom G6 Pro Continuous Glucose Monitor (CGM)|"A DexCom G6 CGM will be implanted on the subject's abdomen contralateral to the surgical site (i.e. left abdomen for right knee or right hip replacements) no less than 30 cm from the surgical site. This CGM shall be termed primary for study purposes. Subjects will wear the primary DexCom G6 CGM for the entirety of the following 10-day timeline: 3/4-days pre-operative, day of hip or knee replacement surgery, and 5/6-day postoperative recovery.~A second CGM will be implanted in subjects postoperatively while in the Post Anesthesia Care Unit (PACU). This CGM, termed secondary for study purposes, will be implanted immediately adjacent to the primary CGM. Subjects will wear the secondary DexCom CGM for the 7 days: day of hip or knee replacement surgery (postoperatively) and 5/6-day postoperative recovery."
214948294|NCT03267602|DEVICE|CPAP|"If following patients are suffering from sleep apnea and agree to receive treatment,~1. older than 18 years, AHI\> 15 and present obvious symptoms or~2. less than 18 years, AHI still\> 5 after tonsillectomy and present obvious symptoms.~Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months."
214948295|NCT06251518|BEHAVIORAL|vimida|Participants will receive access to the digital health intervention vimida in addition to TAU.
214948296|NCT03674437|BEHAVIORAL|Traditional Neurocognitive Assessments|Traditional Neurocognitive Assessments given with pen and paper
214948297|NCT03674437|BEHAVIORAL|Online Cognitive Battery (Cogsuite)|Cognition (Cogsuite) for a battery that consists of seven measurements.
214948298|NCT04060771|DRUG|Palonosetron|prophylaxis of postoperative nausea and vomiting
214948299|NCT04060771|DRUG|Dexamethasone|prophylaxis of postoperative nausea and vomiting
214948300|NCT06640946|DRUG|Topical lidocaine|Topical lidocaine cream prior to laser follicle ablation
214948301|NCT06640946|DRUG|Sham cream|Placebo cream without lidocaine will be placed and removed before laser.
214948302|NCT06538636|OTHER|PCP-Facing Tools|PCP-facing tools will be turned on as a package: a) enhanced LCS clinical reminder including DP+ generated smart message; b) Integrated one-click DP+ full decision tool for automating personalized information about the net benefit of LCS based on patient characteristics; c) the TurboHM tool: automated Health maintenance app for tracking all preventive care, including a dedicated LCS section with personalized information
214948303|NCT06538636|OTHER|LCS team population management tools|site-specific dashboard and proactive outreach toolkit
214948304|NCT00487097|DIETARY_SUPPLEMENT|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
214948305|NCT02290145|DRUG|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
214948306|NCT02290145|PROCEDURE|surgery group|The patients in the control group received the radical surgery and post-operative radiotherapy.
214948307|NCT02290145|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
214948308|NCT04040647|BEHAVIORAL|mobilization and ambulation|6-min walk test (6-MWT)
214948309|NCT04886388|DEVICE|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
214948310|NCT04886388|OTHER|Physician-guided Standard of Care for type 2 diabetes|Current ADA Standard of Care Guidelines for type 2 diabetes
214948311|NCT02128334|DRUG|Eligard 45 mg Exposure|Subcutaneous injections
214948312|NCT00021645|DRUG|Vitamin E|
214948313|NCT01014481|DRUG|tenofovir, lamivudine, efavirenz|initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
214948314|NCT05048615|DRUG|Venetoclax 100 MG|Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.
214948315|NCT05048615|DRUG|Itraconazole capsule|Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.
214948316|NCT05048615|DRUG|Azacitidine Injection|Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.
214948317|NCT05885061|DEVICE|Spinal cord stimulation turned on (suggestions: off)|Spinal cord stimulation turned on with verbal suggestions of treatment off
214948318|NCT05885061|DEVICE|Spinal cord stimulation turned off (suggestions: on)|Spinal cord stimulation turned off with verbal suggestions of treatment on
214948319|NCT05885061|DEVICE|Spinal cord stimulation turned on with suggestions (suggestions on)|Spinal cord stimulation turned on with verbal suggestions of treatment on
214948320|NCT04350879|OTHER|Data record|Data record
214948321|NCT00146549|DRUG|Trastuzumab|
214948322|NCT00146549|DRUG|Vinorelbine|
214948323|NCT00146549|DRUG|Paclitaxel|
215075511|NCT01407835|BIOLOGICAL|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
214678286|NCT02115815|BIOLOGICAL|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
215075512|NCT01539733|DRUG|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
214948324|NCT00146549|DRUG|Docetaxel|
214948325|NCT02370056|DIAGNOSTIC_TEST|3-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
214948326|NCT02370056|DIAGNOSTIC_TEST|2-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
214948327|NCT02072070|BIOLOGICAL|TissueGene-C|TissueGene-C at 1.8 x 10\^7 cells
214948328|NCT02072070|DRUG|Placebo|Placebo control(Normal Saline)
214948329|NCT04942210|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection Subcutaneous injection
214948330|NCT04942210|BIOLOGICAL|Yellow fever vaccine|Powder and diluent for suspension for injection Subcutaneous injection
214342674|NCT04120896|BEHAVIORAL|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
214948331|NCT03688802|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
214948332|NCT03688802|DRUG|Placebo (vehicle control) nasal spray|Placebo
214342675|NCT04465994|PROCEDURE|gastrocnemius turn-down flaps|We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
214948333|NCT03421275|DRUG|Esketamine|anesthetic used as analgetic in subanesthetic doses given intranasally
214948334|NCT03421275|DRUG|Fentanyl Citrate|intravenous fentanyl given intranasally
214948335|NCT03421275|DRUG|Saline Nasal|intravenous saline given intranasally as placebo
214948336|NCT05697627|DEVICE|Computerized cognitive training (CCT) using EndeavorRx|"The EndeavorRx video game is a digital therapeutic designed to improve attention and related cognitive control processes by training interference management.~\~25 minutes of EndeavorRx video game play per day, for 5 days/week, for up to 4 weeks"
214948337|NCT02570750|BEHAVIORAL|QUESTIONNAIRE ON SMOKING HABITS|"Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).~Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points."
214948338|NCT03549065|DEVICE|Brain Stimulation|"Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008)."
214948339|NCT01256580|DRUG|Bevacizumab (Avastin; Genentech, Inc.)|1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
214948340|NCT01256580|DRUG|Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy|Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
214948341|NCT01962246|DRUG|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
214948342|NCT01962246|OTHER|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
214948343|NCT00369772|DRUG|darbepoetin alfa|
214948344|NCT01410240|PROCEDURE|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
215075513|NCT01539733|DRUG|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
215075514|NCT01180036|DRUG|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
214342676|NCT01319318|PROCEDURE|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
214342677|NCT01914848|OTHER|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
214342678|NCT01914848|OTHER|Control Group|A routine care discharge planning with the social service
214342679|NCT01594905|DRUG|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
214342680|NCT02731131|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
214342681|NCT02731131|DRUG|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
214342682|NCT05515159|OTHER|electroconvulsive therapy|electrical stimulation of the brain while the patient is under anesthesia.
214342683|NCT05881941|DEVICE|using a soundproof nebulizer with a music and a funny mask added|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
214342684|NCT05881941|DEVICE|using a silent nebulizer with no extra attachments|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
214948345|NCT01410240|DRUG|FLOSEAL Hemostatic Matrix + Standard of care|"FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~\+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used"
214948346|NCT03425994|DRUG|Elvitegravir/Cobicistat/Emtricitabine|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya) film coated tablet
214948347|NCT00910546|DEVICE|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
214948348|NCT00791037|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
214948349|NCT00791037|PROCEDURE|leukapheresis|Undergo leukapheresis
214948350|NCT00791037|BIOLOGICAL|ex vivo-expanded HER2-specific T cells|Given IV
214948351|NCT00791037|DRUG|cyclophosphamide|Given IV
214948352|NCT00791037|BIOLOGICAL|sargramostim|Given ID
214948353|NCT00791037|OTHER|laboratory biomarker analysis|Correlative study
214948354|NCT05626075|DIAGNOSTIC_TEST|Using Oculus Pentacam® which is s a rotating Scheimpflug camera. The rotational measuring procedure generates Scheimpflug images in three dimensions.|Scheimpflug imaging attains a wide and high depth-of-focus , providing sharp images that include information from an anterior corneal surface through to the posterior crystalline capsule
214948355|NCT05647720|PROCEDURE|Distalization combined with upper third molars extraction|After surgical extraction of unerupted upper third molars, the maxillary first molars were distalized using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
214948356|NCT05647720|PROCEDURE|Distalization without upper third molars extraction|The maxillary first molars were distalized , without extracting upper third molars, using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
215075515|NCT01180036|DRUG|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine \>30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
214342685|NCT05881941|DEVICE|using a routinely employed nebulizer|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
214678287|NCT02115815|BIOLOGICAL|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
214948357|NCT04480996|DRUG|Drugs Responsible for Cognitive Side Effects|identification of road traffic accidents associated with drugs responsible for psychomotor side effects
214948358|NCT03610321|DRUG|Gefarnate|Gefarnate (100 mg, three times daily, oral) treatment for 1 month.
214948359|NCT03610321|DRUG|Statin|Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.
214948360|NCT00998205|DRUG|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micro-grams/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micro-grams/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate.
214948361|NCT00998205|DRUG|Atropine bolus|If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
214948362|NCT02743065|DEVICE|HepaSphere with 50-75mg Doxorubicin|HepaSphere with 50-75mg Doxorubicin
214948363|NCT06543420|PROCEDURE|lateral reconstruction|In lateral reconstruction group, lateral reconstruction is performed by suturing the levator ani muscle to the prostatic collateral ligament and fascia to strengthen the lateral posterior support structure.
214948364|NCT06543420|PROCEDURE|posterior reconstruction|In posterior group, prior to completion of the operation, the posterior fibrous tissues of the sphincter are joined to the residual Denonvilliers fascia on the posterior bladder wall 1-2 cm cephalad and dorsally to the new bladder neck.
214948365|NCT06228495|BEHAVIORAL|Daily Intervention for Active Recovery|"Daily Intervention for Active Recovery - DIARY - is a 28-day intervention during which participants are prompted once daily to engage with intervention content. Each daily intervention interaction includes a short questionnaire with questions regarding sleep quality, current mood (e.g., tense, relaxed), and energy levels. Participants were prompted to open the application through a notification at 18:00 each evening. In case they did not fill out the questionnaire, an additional reminder notification was sent out at 20:00. The questionnaire closed each night at 03:00 am, at which point it was no longer possible to access the questionnaire for that day. The questionnaire took at most 5 minutes to complete. Upon completing the daily questionnaire participants received a prompt - a bit-size amount of information regarding stress and recovery as well as suggestions for a specific recovery strategy."
214948366|NCT02026596|PROCEDURE|Magnetic resonance imaging|
214948367|NCT02026596|PROCEDURE|Cerebral microdialysis catheter insertion|Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
214948368|NCT05906654|BEHAVIORAL|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Behavioral intervention to increase physical and social activity. In triads, participants walk 1-mile neighborhood routes three times per week and engage in image-based conversational reminiscence.
214948369|NCT02553798|DRUG|Glycopyrronium Topical Wipes|Glycopyrronium Topical Wipes
214948370|NCT05411601|OTHER|Methodology of attachment of external foot prothesis|establishing the methodology of specific measurements of attachment of external foot prothesis
214948371|NCT03099226|DRUG|Placebo|Placebo blue hard gelatine capsules
214948372|NCT03099226|DRUG|BIA 5-453|Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
214948373|NCT00983541|DRUG|Fluorouracil (5-FU)|5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy
214948374|NCT00983541|RADIATION|Brachytherapy or SBRT (Stereotactic body radiation therapy)|Patients receive 45 Gy (gray) external beam radiation therapy including the primary tumor and regular lymph nodes (25 fractions over 5 weeks). Within 1 month of external beam radiation therapy, patients will have boost treatment of 20 Gy in 4 fractions, via Ir-192 brachytherapy or SBRT (Stereotactic Body Radiation Therapy).
214948375|NCT00983541|DRUG|Gemcitabine|"Pancreatic:Indicated as first line treatment for patients with locally advanced (nonresectable Stage II or III) or metastatic(Stage IV) pancreatic adenocarcinoma.~Ovarian:Gemzar with carboplatin is indicated for treatment of patients with advanced ovarian cancer relapsed 6 months after plat-based therapy.~Breast:Gemzar with paclitaxel is indicated for first line treatment of patients with metastatic breast cancer after failed anthracycline-containing adjuvant chemotherapy, unless anthracyclines.~Non-small cell lung cancer(NSCLC):Gemzar is indicated with cisplatin for first line treatment of patients with inoperable, local advanced (Stage IIIA/IIIB), metastatic (Stage IV) NSCLC."
214948376|NCT00401492|DRUG|gemcitabine prolonged continuous infusion|
214948377|NCT00401492|DRUG|cisplatin|
214948378|NCT00401492|DRUG|vinorelbine|
214948379|NCT02211664|DEVICE|Passeo-18 balloon|
214948380|NCT02211664|DEVICE|Passeo-18 Lux drug releasing balloon|
214948381|NCT02211664|DEVICE|Pulsar-18 stent|
214948382|NCT04889170|OTHER|Intervention|"Intervention: After recording the patient characteristics and the baseline dysphagia characteristics, the intervention begins. The intervention lasts 3 weeks, by extended stay it lasts 5 or 7 weeks.~The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and an SLT watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training or a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.~Allocation to the Groups will be done by a randomization software"
214948383|NCT02722746|DRUG|Ropivacaine|Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
214948384|NCT02722746|DRUG|Epinephrine|Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
215075516|NCT04243577|DEVICE|Tele-EaT Sensors|Two iterations of a wearable surface EMG (sEMG) sensors patch we developed will be tested against commercially available wired devices. The first iteration of the wearable sensor patch is an ultrathin patch with a honeycomb-inspired design that included sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The second iteration is a more durable slightly thicker flexible, non-stretchable, and double-sided thin sEMG patch. Participants will perform standardized swallow tasks while wearing the device.
215075517|NCT04243577|DEVICE|Conventional Sensors|Conventional sensors will include snap-on wired electrodes as the control condition. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
215075518|NCT02275715|BEHAVIORAL|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
215075519|NCT06446063|OTHER|Test product|Twice daily applications The product is applied to the entire face.
215075520|NCT06446063|OTHER|Control Product|Twice daily applications The product is applied to the entire face.
215075521|NCT02820246|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
215075522|NCT02059889|DEVICE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
215075523|NCT02059889|DEVICE|4-dimensional computed tomography|Undergo 4D CT
215075524|NCT02059889|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET
215075525|NCT02059889|DEVICE|FDG-PET|Undergo FDG-PET
215075526|NCT00162747|DRUG|Aquaphor|
215075527|NCT00162747|DRUG|Sunflower Seed Oil|
215075528|NCT04095663|PROCEDURE|Partial Colectomy|Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
214342686|NCT01785589|PROCEDURE|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
215075529|NCT04095663|OTHER|Medical Management|"Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
215075530|NCT05749666|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 24 weeks
214342687|NCT05234099|DIAGNOSTIC_TEST|18F-FDG Positron emission tomography - MRI|All the examinations will be performed in the supine position on the same integrated 3T PET-MRI scanner
215075531|NCT05749666|DRUG|Prednisolone|Prednisolone taken daily according to preset tapering protocol
215075532|NCT05749666|OTHER|Placebo of tofacitinib 5mg|Placebo of tofacitinib 5mg BID taken orally for 24 weeks
215075533|NCT05749666|OTHER|Placebo of prednisolone|Placebo of prednisolone taken daily according to preset tapering protocol for 24 weeks
215075534|NCT00206128|DRUG|Seroquel SR|
215075535|NCT05058196|RADIATION|Whole breast radiotherapy|Whole breast radiotherapy after surgery
214342688|NCT05234099|DIAGNOSTIC_TEST|Multiparametric ultrasound imaging|Acquisitions of respiratory muscles (diaphragm, intercostal muscles) will be performed using two 6 MHz central frequency linear transducer (SL 10-2) driven by two identical ultrafast ultrasound devices.
214342689|NCT05234099|DIAGNOSTIC_TEST|Surface electromyography|sEMG recordings will be performed in the left side on the sternocleidomastoid muscle, the intercostal parasternal muscle, and the external oblique muscle using pairs of 20-mm-diameter silver chloride surface electrodes.
214342690|NCT05234099|DIAGNOSTIC_TEST|Transdiaphragmatic preasure measurmement|Esophageal and gastric pressures will be measured using 8-cm balloon-catheters.
214948385|NCT05804253|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus grafting with 2 different xenogenic materials
214948386|NCT03923452|BEHAVIORAL|Mindfulness-based Stress Reduction|"Mindfulness-based stress reduction is a manualized mindfulness training protocol that has been researched for over 20 years. The original protocol will be used, with the exception of the prescribed home practice duration (i.e. 30 mins of practice). Rather, the program will be modified to set up participants for success by providing them with instruction to build on their meditation practice, beginning with 8 minutes a day."
214948387|NCT05689008|BIOLOGICAL|UC-MSCs treatment|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
215075536|NCT05058196|RADIATION|Intra Operative Radiotherapy|Intra Operative Radiotherapy
215075537|NCT03449940|PROCEDURE|Immediate repair|
215075538|NCT03449940|PROCEDURE|Delayed repair|
215075539|NCT03449940|DRUG|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
215075540|NCT03449940|DRUG|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
215075541|NCT03449940|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
215075542|NCT04247009|OTHER|Meal based on red meat, fish products or vegan products|Three meals will be served
214342691|NCT05234099|DIAGNOSTIC_TEST|Magnetic stimulation of the phrenic nerves|In order to quantify the contractile fatigue in diaphragm induced by the ventilatory task (described below), we will use bilateral anterior magnetic stimulation of the phrenic nerves using two Magstim 200 stimulator.
214342692|NCT05234099|DIAGNOSTIC_TEST|Ventilation against inspiratory loading|A POWERbreathe KH2 device (POWERbreathe International Ltd) will be connected on the inspiratory side of the two-way valve. Level of inspiratory loading will be randomized in order to produce different amounts of muscle work in each subject.
214948388|NCT01615159|BEHAVIORAL|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
214948389|NCT02806830|DRUG|Optive|Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
214948390|NCT03807622|DEVICE|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System
214948391|NCT05979207|DRUG|MMV367|Single dose
215075543|NCT04247009|OTHER|Meal based on red meat|Matched Controls will be served only one meal of meat to compare response between (non-RA) matched controls and patients with RA
215075544|NCT04071015|DEVICE|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line.
215075545|NCT03389724|DRUG|Capoten®|ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
215075546|NCT05377658|DRUG|AK104|10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
215075547|NCT05377658|DRUG|Albumin-Bound Paclitaxel|260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
215075548|NCT05377658|DRUG|Carboplatin|AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
215075549|NCT03895580|OTHER|In-store POP education|Six in-store nutrition counseling sessions with a registered dietitian nutritionist.
215075550|NCT03895580|OTHER|Online POP education|Education on the use of an online grocery shopping, an online recipe tool, a grocery pickup service, a home grocery delivery service, and a phone application that promotes healthy food selection.
215075551|NCT03892057|BEHAVIORAL|Internet-based Positive Psychological Intervention|"The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and home practice with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities."
214948392|NCT05979207|OTHER|P. falciparum IBSM infection|Induced Blood Stage Malaria
214948393|NCT03706469|DRUG|TAK-831 T2|TAK-831 T2 Tablets.
214948394|NCT03706469|DRUG|TAK-831 T3|TAK-831 T3 Tablets.
214948395|NCT05952791|OTHER|Surgery|Laparoscopic transabdominal preperitoneal (TAPP) groin hernia repair
214948396|NCT02838875|PROCEDURE|Blood samples|After birth - taking blood sample from the umbilical cord (arterial and venous) + blood sample from the patient.
214948397|NCT04325867|OTHER|Tele-medicine platform|Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).
214948398|NCT00000290|DRUG|Cocaine|
214948399|NCT01543737|DEVICE|3ml hyaluronic acid (DUROLANE)|DUROLANE Hyaluronic acid 20mg/ml
214948400|NCT01543737|DEVICE|2ml hyaluronic acid, (HYALGAN)|HYALGAN Hyaluronic acid 10mg/ml
214948401|NCT03728621|BEHAVIORAL|Normocaloric and balanced diet, physical activity|Promotion of normocaloric \& balanced diet and physical activity
214948402|NCT04754087|DEVICE|Vivacit-E and Longevity (HXLPE) Liners|This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.
214948403|NCT05869864|BEHAVIORAL|Schools Championing Safe South Africa|The intervention consists of 2 parts - a poster campaign with social norms messages on violence and HIV risk, and 2 lessons in life orientation (a health curriculum delivered during school).
214948404|NCT03846557|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the Acurate Neo Transcatheter Heart Valve
214948405|NCT05294302|BEHAVIORAL|eSCCIP/eSCCIP-SP|eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.
214948406|NCT05294302|BEHAVIORAL|Coping Space|Coping Space is a psychosocial informational website for PCCC.
214948407|NCT06386185|DIAGNOSTIC_TEST|Electrocardiogram|Non-invasive multi-vector voltage/time graph visualising the electrical conduction of the heart
214342693|NCT01431066|DEVICE|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
214342694|NCT01431066|DEVICE|ActiPatch PRFE Device|Actipatch PRFE device
214342695|NCT02940470|OTHER|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
214948408|NCT06386185|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Non-invasive 2 \& 3 dimensional imaging of the heart using ultrasound
214948409|NCT06386185|DIAGNOSTIC_TEST|Right heart catheter|Minimally invasive cardiac chamber pressure measurement using balloon catheterisation
214948410|NCT05841524|DIAGNOSTIC_TEST|Vector flow imaging measurement|Ultrasound measurement, using high framerate measurement techniques.
214948411|NCT05952817|DEVICE|virtual reality|Virtual reality (VR) technology is a new medical intervention technique founded on the principle of distraction, providing real perceptual stimuli such as visual images, spatial sounds, tactile, and sensory feedback stimuli.(Zhang et al., 2022)
214948412|NCT05665504|DIAGNOSTIC_TEST|DetermaRX|A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.
214948413|NCT00851019|BEHAVIORAL|DDR|"Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period"
214948414|NCT00851019|BEHAVIORAL|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
214948415|NCT00047736|DRUG|Tarceva (erlotinib HCl)|
214948416|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
214948417|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
214948418|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
215075552|NCT01679600|DEVICE|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
215075553|NCT01679600|DEVICE|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
214342696|NCT02940470|OTHER|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
214342697|NCT04026100|BIOLOGICAL|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10\^6), medium dose (2×10\^6), and high dose (3×10\^6).
214342698|NCT03575130|DRUG|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
214948419|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
214948420|NCT01134263|BIOLOGICAL|Placebo: NaCl 0.9%|0.5 ml, SC
214342699|NCT03575130|DRUG|Optive eye drops|Artificial tears (placebo)
214342700|NCT03575130|PROCEDURE|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
214342701|NCT05404529|DRUG|Tavapadon|Oral tablets
214342702|NCT04975568|OTHER|App and face-to-face physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites. During the app used they will have 6 face-to-face sessions in 6 people groups with a physical Therapist in a 3 months period
214948421|NCT04698174|PROCEDURE|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.
214948422|NCT04698174|PROCEDURE|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.
214948423|NCT04698174|PROCEDURE|Standard Photorefractive keratectomy (PRK)|Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.
214948424|NCT00506714|DEVICE|single point cane|Adjustable single point cane with SureGrip handle
214948425|NCT06365450|OTHER|Educational Intervention|Participants will receive hybrid educational intervention on breast and cervical cancer
214948426|NCT05884294|DEVICE|PowerGlide Pro Midline catheter.|The Intervention Group will be represented by hospitalized adult clinical patients who have been identified with difficult intravenous access. These patients will receive an ultrasound-guided insertion of the PowerGlide ProTM Midline 20G (10 cm).
214948427|NCT00290381|PROCEDURE|Oxagen OC000459|
214948428|NCT01164917|DRUG|AMG811|Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
214948429|NCT01164917|DRUG|AMG811 Placebo|8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
214948430|NCT02305446|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
214948431|NCT06158009|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214948432|NCT06158009|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
215075554|NCT05489172|BEHAVIORAL|Hola Bebe|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
215075555|NCT03300271|OTHER|Mobile application for self monitoring|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
215075556|NCT03300271|OTHER|Education|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
214948433|NCT00409032|DRUG|Strontium malonate|
214948434|NCT03919344|OTHER|Critical airway closure pressure (Pcrit) measurment|Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
214948435|NCT03919344|OTHER|Acoustic pharyngometry|Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.
214948436|NCT03919344|OTHER|High density surface electroencephalogram neural mapping|Mapping of the respiratory neural network will allow us to study the areas of the brain activated during breathing
214948437|NCT00957424|BEHAVIORAL|telephone-based intervention|10-15 minute web-based survey on a computer
214948438|NCT00957424|DRUG|nicotine replacement therapy|One week supply
214948439|NCT00957424|OTHER|informational intervention|
214948440|NCT00957424|OTHER|internet-based intervention|
214948441|NCT00957424|OTHER|questionnaire administration|Given out week 2, 3 and 4.
214948442|NCT02097459|DRUG|Anastrozole|
214948443|NCT02097459|DRUG|Tamoxifen|
214948444|NCT02097459|DRUG|Toremifene|
214948445|NCT02332161|OTHER|surveys, evaluative tests for leg function|See outcome measures
214948446|NCT06192498|OTHER|Virtual Reality Glasses|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the Blood Draw procedure.
214948447|NCT06192498|OTHER|Kaleidoscope|Kaleidoscope were introduced to the children pre-procedure. The children were made to watch Kaleidoscope before starting the application and it continued until the end of the Blood Draw procedure.
215075557|NCT03300271|OTHER|Mobile application for personal coaching|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
215075558|NCT04236024|OTHER|Board game|The students in the experimental group will play board game to learn medication about 30-60 minutes.
215075559|NCT04236024|OTHER|Traditional lecture|The students in the comparison group will receive medication lecture using PPT slides about 30-60 minutes.
215075560|NCT01685801|DRUG|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
215075561|NCT01685801|DRUG|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
215075562|NCT00274859|DRUG|gemcitabine hydrochloride|
215075563|NCT00274859|DRUG|oxaliplatin|
214948448|NCT06192498|OTHER|Distraction Cards|Distraction Cards were introduced to the children pre-procedure. The children were made to apply Distraction Cards before starting the application and it continued until the end of the Blood Draw procedure.
214948449|NCT05542394|DIETARY_SUPPLEMENT|Curcumin|"water soluble version of turmeric extract standardized to 10% curcuminoids~."
214948450|NCT02370069|BIOLOGICAL|Prevnar 13|One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
214948451|NCT06731465|DEVICE|Clear aligner therapy|Participants in this group will receive clear aligners (EON Aligner, Minneapolis), designed and customized based on a digital model of each patient's dental structure. Aligners will be worn for at least 22 hours daily, and patients will change to a new aligner depending on treatment progress.
214948452|NCT06731465|DEVICE|Fixed pre-adjusted edgewise orthodontic appliance|Participants in this group will be treated with pre-adjusted fixed orthodontic appliances (Master Series®, American Orthodontics™, WI, USA). This system includes fixed brackets bonded on the labial surface of teeth and a sequence of progressively larger arch wires aimed at achieving alignment over time.
214948453|NCT04856397|DRUG|Intravitreal Implant in Applicator|Dexamethasone intravitreal implant
214342703|NCT04975568|OTHER|App physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites.
214948454|NCT04856397|DRUG|Eylea|anti-VEGF medication
214948455|NCT04485494|DIAGNOSTIC_TEST|Biochemical Analysis of Blood Biomarkers|Using established biochemical techniques, the bloods will be probed for specific biomarkers s100B, UCH-L1, GFAP, and BDNF. The techniques include individual ELISA kits for each biomarker mentioned and Luminex multiplate assay which will probe for all biomarkers in one plate. Ultimately, these techniques will be able to measure the level of these biomarkers in the blood relative to the participants baseline reading.
214948456|NCT02041052|PROCEDURE|Subtotal gastrectomy as an adjunct to traditional whipple procedure.|Subtotal gastrectomy as an adjunct to traditional whipple procedure.
214948457|NCT02041052|PROCEDURE|Conventional whipple procedure|All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
214948458|NCT00318175|DRUG|Bosentan (Tracleer)|
214948459|NCT03899207|OTHER|training +acupressure|".Training+acupressure group; received training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. In addition to the training, acupressure was applied by the researcher twice a week and 24 times in total. Acupressure application was continued with the same frequency until the end of the study (24 times in total for 3 months). One month after the first home visit, reminder training for coping with premenstrual symptoms was given to the women"
214948460|NCT03899207|OTHER|training|"Training Group; received the training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. One month after the first home visit, reminder training was given to the women."
214948461|NCT02508415|OTHER|Non Surgical Periodontal Therapy|OHE, scaling root planing, mouth wash
214948462|NCT02401061|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
214948463|NCT00445744|DRUG|cyclophosphamide|Given IV
214948464|NCT00445744|DRUG|busulfan|Given IV
214948465|NCT00445744|DRUG|tacrolimus|Given IV or PO
214948466|NCT00445744|DRUG|methotrexate|Given IV
214678288|NCT02115815|BIOLOGICAL|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
214678289|NCT00112099|PROCEDURE|Surgery: Splenectomy|Procedure/Surgery: Surgery: Splenectomy
214678290|NCT00112099|PROCEDURE|Surgery: Spleen-preservation|Procedure/Surgery: Surgery: Spleen-preservation
214948467|NCT00445744|GENETIC|cytogenetic analysis|Correlative studies
214948468|NCT00445744|OTHER|flow cytometry|Correlative studies
214948469|NCT00445744|OTHER|pharmacological study|Correlative studies
214948470|NCT00445744|OTHER|pharmacogenomic studies|Correlative studies
214948471|NCT00445744|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBPC transplantation
214948472|NCT00445744|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
214948473|NCT02245919|OTHER|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
214948474|NCT02343380|OTHER|calorimetric exam after a standard meal|The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
214948475|NCT01004718|RADIATION|Fludeoxyglucose F18|Undergo FDG PET/CT scans
214948476|NCT01004718|PROCEDURE|Computed Tomography|Undergo FDG PET/CT scans
214948477|NCT01004718|PROCEDURE|Positron emission tomography|Undergo FDG PET/CT scans
214948478|NCT03394417|DEVICE|StrataXRT|randomized patient allocated to this group will receive StrataXRT for application during the treatment and 4 weeks further after the treatment ends.
214948479|NCT01544764|OTHER|Assessment , Feedback, Incentives, and eXchange Program|The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
214948480|NCT02882464|DEVICE|PC-02 Centrifuge device,2PRF+CAF|In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
214342704|NCT05401123|DEVICE|milking pump|"n the study, all mothers who come to the Lactation/Relactation outpatient clinic will be informed about the study, and mothers who accept the study will have to fill out the Conformity to Criteria Form created by the researcher. Between the ages of 20-35, postpartum 1-5. Participants who gave birth after the 37th week of pregnancy, did not have literacy problems, mental disabilities and communication problems, did not have chronic diseases, did not use any medication, and volunteered to participate in the study will be included in the study. by milking, 2 ml of first milk will be taken from the participants in the control group (via the milking pump). The collected milk will be taken to the laboratory for analysis by the researcher."
214486472|NCT06901167|OTHER|Residential In-Reach Program|All enrolled residential aged care homes will be able to access the residential-in-reach (RIR) program intervention. The RIR program provides a consultation service from a central hospital to an aged care facility in the Grampians region in the state of Victoria, Australia. Aged care staff will make a telehealth referral to central hub, where a nurse practitioner will triage the patient and make recommendations (for example, monitor resident condition, more examples: comprehensive assessment for unwell residents, liaison with the General Practitioners for diagnosis and treatment plan, provide education and support to staff) or further referrals (for example, refer to geriatrician or call an ambulance).
214486473|NCT06742151|PROCEDURE|implant can be placed or not|the possibility of receiving dental implants
214678291|NCT00678509|BIOLOGICAL|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
214948481|NCT02882464|DEVICE|PC-02 Centrifuge device, 4 PRF+CAF|Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
214948482|NCT02882464|PROCEDURE|CTG+CAF|The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
214948483|NCT01189708|DEVICE|Ultrapro® Mesh implantation|After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.
214948484|NCT01189708|OTHER|Standard wound closure|Abdominal closure will be performed with standard sutures without a mesh.
214948485|NCT02483325|DRUG|Allogeneic transplant conditioning|Allogeneic transplant
214948486|NCT00830635|OTHER|educational intervention|
214948487|NCT00830635|OTHER|informational intervention|
214948488|NCT00830635|OTHER|internet-based intervention|
214948489|NCT00830635|OTHER|questionnaire administration|
214948490|NCT00830635|OTHER|study of socioeconomic and demographic variables|
214948491|NCT00830635|OTHER|survey administration|
214948492|NCT00830635|PROCEDURE|psychosocial assessment and care|
214948493|NCT00830635|PROCEDURE|quality-of-life assessment|
214948494|NCT02143934|DRUG|Primaquine|
214678292|NCT01228071|DRUG|testosterone gel 2%|40 mg testosterone gel 2%
214678293|NCT05994794|DIETARY_SUPPLEMENT|Alpha-GPC, Creatine and Ashwagandha (Sensoril®)|Other Ingredients: Microcrystalline Cellulose, Rice Fiber, Maltodextrin, Silica, Vegetable Stearate
214948495|NCT02143934|DRUG|Placebo|Sugar pills, appearance identical to Primaquine tablets
214948496|NCT02143934|DRUG|Chloroquine|
214948497|NCT02143934|DRUG|Artemether Lumefantrine|
214948498|NCT05047614|DEVICE|including sham|Repositiong feedback training and biofeedback pressure training unit
214948499|NCT04422964|DEVICE|3D Obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
214948500|NCT02741466|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number - SR16-01.
214948501|NCT05899712|OTHER|Removable Partial Denture Construction|Construction of class I Removable partial denture by digital workflow
214948502|NCT05203965|DRUG|Mavoglurant (AFQ056)|Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.
214948503|NCT05203965|DRUG|Placebo|Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.
214948504|NCT06057831|RADIATION|Total Neo-adjuvant Therapy|"* TNT incorporates chemotherapy with concurrent chemoradiotherapy (CRT) in any order.~* Radiotherapy includes 5000 cGy/25 fractions over 5 weeks.~* Chemotherapy regimen for Concurrent CRT: Capecitabine~* Chemotherapy regimens used with TNT are: FOLFIRINOX x 6 cycles, 8-9 courses FOLFOX or 5-6 courses of CAPEOX delivered over 4-6 months.~* The chemotherapy regimen or the order of treatment will be decided at the discretion of the patient's medical oncologist"
214948505|NCT06057831|OTHER|18FDG-PET/MRI scan|18FDG-PET/MRI scan within 4 weeks of commencing chemo-radiation and within 1 - 2 weeks before radical rectal cancer surgery.
214948506|NCT04624178|DRUG|Rucaparib|Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
214948507|NCT04624178|DRUG|Nivolumab|Nivolumab 480mg intravenously on day 1 of every four-week cycle.
214948508|NCT04422730|BEHAVIORAL|Psychological evaluation|Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
214948509|NCT04033211|DEVICE|Novosyn® CHD for fascia and skin closure|Experimental
214948510|NCT04033211|DEVICE|Novosyn® for fascia and skin closure|Comparator
214948511|NCT02736695|DRUG|F-18 AV 1451|Tau binding agent
214948512|NCT06029374|PROCEDURE|Functional Treatment|Patients receiving buddy taping for fingers IV and V and an elastic bandage in terms of a functional treatment. Duration of bandage treatment is determined with 4 weeks.
214948513|NCT06029374|PROCEDURE|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
214948514|NCT05723913|DIETARY_SUPPLEMENT|Dietary Supplement: A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
214948515|NCT03724084|DRUG|Cytarabine|Given IV
214948516|NCT03724084|DRUG|Daunorubicin|Given IV
214948517|NCT03724084|DRUG|Daunorubicin Hydrochloride|Given IV
214948518|NCT03724084|DRUG|Pinometostat|Given IV
214948519|NCT02537652|OTHER|Blood pressure assessment|Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
214948520|NCT05048589|DRUG|Standard-Dose Quadrivalent Influenza Vaccine|For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.
214948521|NCT05048589|DRUG|High-Dose Quadrivalent Influenza Vaccine|For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
214948522|NCT04799106|BEHAVIORAL|Community Based Strategies for Early Detection of Melanoma|"The main procedures of this study include educational sessions about melanoma and how to detect it at its earliest stages with the help of a community health worker, conducting a self-skin examination every three months, helping to perform a skin examination every three months for a family member or friend who would be selected as a partner, and completing short questionnaires at the beginning of the study, at month three during the study, and at completion of the study."
214948523|NCT02773277|OTHER|head-impulse testing|all patients will receive quantitative head impulse testing using video goggles for all six semicircular canals.
214948524|NCT05688254|BEHAVIORAL|FOREST-A|The internet-based psychosocial intervention will be delivered. The intervention comprises six modules: introduction, relaxation, psychological detachment, mastery, control, and summary, within psychoeducation and exercises in each module. The interactions with psychologists will be on demand. The whole intervention duration will be 4 weeks.
214948525|NCT04856059|DIAGNOSTIC_TEST|Cardiac MRI, ECG/Holter and Blood Biomarkers|Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
214948526|NCT02623608|OTHER|Reference breakfast|A high fat, high calorie breakfast
214948527|NCT02623608|OTHER|Active Ingredient 1|A high fat, high calorie breakfast including the Active Ingredient 1
215075564|NCT06088394|DEVICE|Acupuncture|"Participants will be asked to assume supine lying position on the plinth and the following points will be located then needles will be inserted:~* CV3,4 \&5-40 mm needles at a depth of 1 cun perpendicular insertion.~* ST 25 bilaterally-40 mm needles at a depth of 1 cun oblique insertion.~* SP6 \& 9, K13\&7 bilaterally-25 mm needles at a depth of 0.5 cun perpendicular insertion. A total of 13 needles will be inserted at each session."
214678294|NCT05994794|OTHER|Placebo|Microcrystalline Cellulose
214948528|NCT02623608|OTHER|Active Ingredient 2|A high fat, high calorie breakfast including the Active Ingredient 2
214948529|NCT02623608|OTHER|Active Ingredient 3|A high fat, high calorie breakfast including the Active Ingredient 3
214948530|NCT02623608|OTHER|Active Ingredient 4|A high fat, high calorie breakfast including the Active Ingredient 4
214948531|NCT04735159|DEVICE|SCS implanted with Precision SpectraTM|Analyze the relationship between neuroimaging biomarkers and the different clinical scales and variables captured from each patient
214678295|NCT03314519|DIAGNOSTIC_TEST|Lung ultrasonography by experienced anaesthesiologist|Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
214948532|NCT03319810|BIOLOGICAL|Octagam 10%|FDA approved human normal immunoglobulin solution ready for intravenous administration
214948533|NCT03395847|BIOLOGICAL|Pembrolizumab|Given IV
214948534|NCT05182606|BEHAVIORAL|Pilot study of algorithms implementation package|The algorithm implementation package includes a link to the algorithms in the Electronic Health Record, Smartphrases, audited feedback, and instructions.
214948535|NCT05988333|OTHER|Psychoeducational Family Intervention|Supportive intervention administered to families with a member affected by MDD
214948536|NCT05988333|OTHER|Informative intervention|Informative intervention administered to families with a member affected by MDD
214948537|NCT03473613|DRUG|Oral Cabergoline|Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days
214948538|NCT03473613|DRUG|Calcium Gluconate|Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days
214948539|NCT06976138|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|This program will focus on changing the participant's sleep patterns, activities, and habits.
215075565|NCT06088394|OTHER|pelvic floor exercises|pelvic floor muscle exercises can help strengthen pelvic floor muscle, which provides better control of urinary urgency by interfering with urethral-detrusor reflexes and inhibiting detrusor contractions
214948540|NCT06976138|DEVICE|Bright Light therapy via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer® The participant will be asked to wear the device every morning for about four weeks before surgery, four weeks after surgery and again for 1-week, 3-months after surgery
214948541|NCT06976138|DEVICE|Negative Ion exposure via IonMi Device|This procedure involves wearing a light weight negative ionizer (IonMi Device) around neck for one hour in the morning. An ionizer gives off special negatively charged ions into the air. The participant will be asked to wear the device every morning for about four weeks before surgery, four weeks after surgery and again for 1-week, 3-months after surgery
214948542|NCT06976138|BEHAVIORAL|Sleep / Knee Osteoarthritis Education|This program will focus on increasing The participant's knowledge about sleep, sleep disorders and knee osteoarthritis.
215075566|NCT01281254|DRUG|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
215075567|NCT01281254|DRUG|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
215075568|NCT04286841|DRUG|Immunotherapy|Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
215075569|NCT00742365|DEVICE|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
215075570|NCT00742365|DEVICE|Red light placebo|One hour of exposure to red light.
215075571|NCT00113399|BIOLOGICAL|filgrastim|
215075572|NCT00113399|DRUG|cisplatin|
215075573|NCT00113399|DRUG|docetaxel|
214342705|NCT03966404|DIAGNOSTIC_TEST|EyeBOX device|The EyeBOX medical device tracks a patient's eye movement and calculates a BOX Score ranging from 0-20. The BOX score is interpreted as a binary classification for eye movement abnormalities, where anything equal to or greater than 10 is a positive result for the initial evaluation of concussion and everything below 10 is negative.
214342706|NCT02348216|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
214342707|NCT02348216|DRUG|Fludarabine|Administered according to package insert
214342708|NCT02348216|DRUG|Cyclophosphamide|Administered according to package insert
214342709|NCT02348216|DRUG|Levetiracetam|Administered according to package insert
215075574|NCT00113399|DRUG|fluorouracil|
215075575|NCT00113399|DRUG|paclitaxel|
215075576|NCT00113399|RADIATION|radiation therapy|
215075577|NCT00065039|BEHAVIORAL|Promotion of a healthy diet and physical activity|
215075578|NCT00065039|BEHAVIORAL|Avoidance of Alcohol, Drugs, and Tobacco|
214342710|NCT02348216|DRUG|Tocilizumab|Administered according to package insert
214342711|NCT02348216|DRUG|Dexamethasone|Administered according to package insert
214342712|NCT02348216|DRUG|High-dose methylprednisolone|Administered according to package insert
214342713|NCT02348216|DRUG|Bendamustine|Administered according to package insert
214948543|NCT00191659|DRUG|Atomoxetine Hydrochloride|
214948544|NCT03839875|DRUG|Gynomax® XL Vaginal Ovule|tioconazole, tinidazole, lidocaine
214948545|NCT06406634|DRUG|Cadonilimab|Injectable solution
214948546|NCT06406634|DRUG|Lenvatinib|capsule
214948547|NCT01425567|DRUG|Intravenous Lipid Emulsion Comprised of Fish Oil|IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
214948548|NCT05405894|DRUG|Zoledronic acid|Once-yearly infusion of zoledronic acid following denosumab discontinuation
214948549|NCT01087840|DRUG|Raltegravir|"Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.~Arms: Raltegravir/Truvada Other Names: Isentress/Truvada"
214342714|NCT02348216|DRUG|Rituximab|Administered according to package insert
214342715|NCT02348216|DRUG|Doxorubicin|Administered according to package insert
214342716|NCT02348216|DRUG|Prednisone|Administered according to package insert
214342717|NCT02348216|DRUG|Vincristine|Administered according to package insert
214342718|NCT02348216|DRUG|Ifosfamide|Administered according to package insert
214342719|NCT02348216|DRUG|Carboplatin|Administered according to package insert
214342720|NCT02348216|DRUG|Etoposide|Administered according to package insert
214948550|NCT01464801|DIETARY_SUPPLEMENT|Resveratrol|Tablet Resveratrol 500 mg 3 times daily for 6 months
214948551|NCT01464801|DIETARY_SUPPLEMENT|Placebo|Tablet Placebo 3 times daily for 6 months
214948552|NCT05760222|OTHER|Acupuncture|Acupuncture for prevention/early treatment of vasomotor symptoms and sleep impairment in LHRHa induced amenorrhea in Breast Cancer patients
215075579|NCT05482477|OTHER|Transcutaneous acupoint electrical stimulation|Transcutaneous electrical acupoint stimulation (TEAS) is a new type of acupoint stimulation therapy that inputs low-frequency pulse current into human acupoints through electrodes pasted on the skin surface to achieve therapeutic purposes, which combined the preponderances of both acupuncture and transcutaneous electrical nerve stimulation (TENS). TEAS is non-invasive, easy to operate and acceptable to patients. Study showed that TEAS treatment can reduce the consumption of intraoperative anesthetic and improve postoperative nausea and vomiting (PONV) and postoperative recovery.
215075580|NCT03226379|OTHER|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~1. Health system strengthening~2. Delivery of a co-designed education program tailored to frontline healthcare workers~3. Implementation of an algorithm for HIV-related meningoencephalitis~4. Infectious diseases/AHD mentorship and laboratory capacity building"
214342721|NCT02348216|DRUG|Gemcitabine|Administered according to package insert
214342722|NCT02348216|DRUG|Oxaliplatin|Administered according to package insert
214342723|NCT02348216|DRUG|Cisplatin|Administered according to package insert
214342724|NCT02348216|DRUG|Methylprednisolone|Administered according to package insert
214342725|NCT04103229|PROCEDURE|The use of different types and volumes of solutions to inflate the catheter balloon|In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
214948553|NCT05753059|DRUG|Placebo|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
214948554|NCT05753059|DRUG|Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
214948555|NCT05753059|DRUG|Bendroflumethiazide|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
214948556|NCT03318679|OTHER|No intervention is planned.|None is planned
214948557|NCT05990959|OTHER|No intervention for research purpose|No any intervention will be applied under research purpose. All procedure or drugs would be given to the patient under best clinical judgment, not for research purpose.
214948558|NCT06622863|BEHAVIORAL|Standard oral hygiene instructions will be given verbally by the periodontics resident|Standard oral hygiene instructions will be given verbally by the periodontics resident
214948559|NCT06622863|BEHAVIORAL|Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice|Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice
214948560|NCT03981965|OTHER|Physical activity|Physical activity as described previously.
214948561|NCT06138002|DEVICE|LumbaCure®|LumbaCure®is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
215075581|NCT00396136|DEVICE|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
215075582|NCT03729037|OTHER|CPR self-training|
214948562|NCT06138002|PROCEDURE|Physical Exercises supervised by the physiotherapist|A set of core stability/active qualitative mobilization exercises have been defined, corresponding to standard exercises proposed in center rehabilitation program
214948563|NCT02174575|DRUG|Sevoflurane|Sevoflurane is administered during anesthesia in Sevoflurane group.
214948564|NCT02174575|DRUG|Desflurane|Desflurane is administered during anesthesia in Desflurane group.
214948565|NCT06286475|DRUG|VRG50635|Specified dose on specified days
214948566|NCT06286475|DRUG|Placebo|Specified dose on specified days
214948567|NCT04697212|BEHAVIORAL|Healthcare team- + patient-directed intervention|"Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities, and will also complete a patient prompt list that elicits strategies that they prefer the healthcare team to use during their visit."
214948568|NCT04697212|BEHAVIORAL|Healthcare team-directed intervention|Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
214948569|NCT06270017|DRUG|Chemotherapy drug|rsponse evaluation in zebrafish embryo model
214948570|NCT04140240|BEHAVIORAL|intervention group|Parallel Assignment a experimental design with pre test and post test
214948571|NCT06125067|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
215075583|NCT06482697|PROCEDURE|total colpocleisis|Total colpocleisis refers to the process where, during the dissection of the anterior and posterior vaginal walls to remove the vaginal mucosa, no holes are left. When suturing, the anterior and posterior vaginal walls are completely interrupted with mattress sutures, and no holes are left on either side or at the top of the vagina.
215075584|NCT06482697|PROCEDURE|partial colpocleisis (LeFort)|LeFort involves the removal of a rectangular piece of mucosa from the anterior and posterior walls of the vagina, leaving a strip of mucosa 2 to 3 cm wide on each side of the vagina. The dissection is carried out close to the vaginal mucosa while preserving the vaginal bladder fascia as much as possible, creating channels on both sides of the vagina.
214342726|NCT01294839|DEVICE|Right ventricular lead location|RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
214342727|NCT00525317|DRUG|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
214342728|NCT00610051|DRUG|Alprostadil|central venous access continuous delivery with 500mcg/48 hours in active arm
214342729|NCT01513850|DRUG|Hepabulin IV|I.V.
214342730|NCT04741425|OTHER|REST intervention|"The breastfeeding talk will be conducted by Zoom at the third trimester about breastfeeding benefits and other practical advices. There is also a sharing session by a successful breastfeeding mother and a group discussion with different breastfeeding scenarios.~Once the mothers return home after delivery, individualized breastfeeding coaching will be provided by PI through a daily Zoom videoconference within 24 hours upon hospital discharge till Day 7 after delivery.~During the last breastfeeding videoconference, mothers will be reminded to have weekly telephone follow-ups by PI from week 2 to 2 months postpartum.~Women who are randomised into the intervention group will receive REST in addition to the standard antenatal and postnatal care (described at below) by the Obstetrics Department of their delivery hospitals."
214342731|NCT03871387|DRUG|Deep Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
214948572|NCT06125067|PROCEDURE|Fascia Iliaca Compartment Block|Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.
214948573|NCT06125067|PROCEDURE|iPACK Block|During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
214948574|NCT03212391|BEHAVIORAL|Diet|52 weeks of Diet supervised by a dietician
214948575|NCT03212391|BEHAVIORAL|Walking|26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
214948576|NCT03212391|BEHAVIORAL|Nordic Walking|26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
214948577|NCT01294748|DEVICE|MiStent DES|The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
214948578|NCT01294748|DEVICE|Endeavor DES|The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
214948579|NCT02954822|DRUG|Evogliptin→Evogliptin+Glimepiride→Glimepiride|"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"
214948580|NCT02954822|DRUG|Glimepiride→Evogliptin→Evogliptin+Glimepiride|After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
214948581|NCT06355843|DRUG|68Ga-PSMA|"PSMA is located in prostate epithelial cells and is converted to a membrane-bound protein in prostate cancer, and PSMA expression is approximately 100 to 1000 times higher in prostate cancer tissue compared to normal prostate tissue. PSMA is expressed at high levels in 95% of prostate cancer patients and is upregulated in castration-resistant prostate cancer (CRPC) and metastatic prostate cancer. PSMA expression was also increased after androgen deprivation therapy (ADT). The use of positronuclide 68Ga-labelled PSMA small molecule inhibitors can be specifically combined with prostate cancer cells, and it is important for the diagnosis of prostate cancer and its metastatic foci through PET/CT and PET/MR visualisation.~With the popularity of integrated PET/MR imaging, combining the higher resolution and morphological performance of MR imaging with the N-staging and M-staging of PET, the specificity of primary prostate cancer diagnosis can be greatly improved."
214948582|NCT00300443|DRUG|bimatoprost|
214948583|NCT04520334|OTHER|Zhineng Qigong intervention|"The intervention consisted of group activities which were performed in one group, as lectures, demonstrations, and Zhineng Qigong training, all planned and led by European Zhineng Qigong.~The group activities were performed during four weekends (12 hours each) and weekly training two times per week (each for two hours). Introductory lecture (two hours) was given at the evening before the first weekend. The respondents were recommended daily Zhineng Qigong training with help of an instructional training CD."
214948584|NCT01262924|BIOLOGICAL|GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine|Intramuscular, single dose
214948585|NCT01262924|BIOLOGICAL|GSK Biologicals' reduced-antigen-content acellular pertussis vaccine|Intramuscular, single dose
214948586|NCT01262924|BIOLOGICAL|Tedivax-Adult™/ Td-Rix™|Intramuscular, single dose or 2 doses (in the annex phase)
214948587|NCT04813913|DRUG|Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV|Enrollement of major patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, naive in antineoplastic treatment and eligible to start a systemic carcinological treatment comprising bevacizumab in combination with chemotherapy based on fluoropyrimidine IV. The main objective is to show that there is an increase in the stiffness of the carotid artery at 4 months in patients with stage IV colorectal cancer exposed to bevacizumab.
214948588|NCT01955109|BIOLOGICAL|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
214948589|NCT04820231|OTHER|intra-articular PRP injection|
214948590|NCT02214862|DRUG|[F18]-FDDNP|radiopharmaceutical tracer
214948591|NCT06044272|OTHER|Factors associated|Factors associated with the type of resistance by microorganisms.
214948592|NCT02600767|DRUG|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
214948593|NCT01323504|OTHER|Music|Patient are listen music during their local care
214948594|NCT01323504|OTHER|no music|There are no music during the local care
215075585|NCT03368053|PROCEDURE|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
215075586|NCT00318747|DRUG|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
215075587|NCT03028844|OTHER|Music therapy|The musical intervention will be played for ten minutes prior to venepuncture
215075588|NCT04686084|DEVICE|Dual-energy computed tomography scan|Diagnostic CT scan
215075589|NCT00321958|DEVICE|CSA System (CryoSpray AblationTM System)|10 second spray times
215075590|NCT00321958|DEVICE|CryoSpray Ablation|10 second spray times
215075591|NCT01779856|DEVICE|REVEAL Insertable Cardiac Monitor (ICM)|
215075592|NCT02576041|DRUG|Bilastine|Bilastine tablets once a day for 7+3 days
215075593|NCT02576041|DRUG|Placebo|Placebo tablets once a day during 7+3 days run in period
214342732|NCT03871387|DRUG|Control Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
214342733|NCT01620463|DRUG|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
214342734|NCT01620463|DRUG|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
215075594|NCT04817137|DEVICE|CareTaker PDA Device|Non-invasive blood pressure monitoring
214342735|NCT00765245|DRUG|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
214342736|NCT00765245|DRUG|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
214342737|NCT00765245|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
214342738|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
214948595|NCT05935995|OTHER|microscopy confocal (Histolog Scanner)|"Surgical margins of tumor samples will be examined by conventional histopathology (H\&E) and confocal microscopy (Histolog® scanner, SamanTree Medical, Switzerland).~Depending on the histopathological result obtained between the two methods, the patient may benefit directly from early surgery if the experimental result confirms the presence of positive margins (excluding the learning curve).~A learning curve will be established over the first fifteen surgeries, enabling surgical teams to gain experience and systematize specimen flattening. This learning curve will also enable reference images to be produced. The procedure will be carried out by the surgeon and the pathologist in the operating room during this phase."
214948596|NCT03884816|OTHER|Determine the Incidence and Retention Rate|Determine the incidence of HIV and the retention rate of MSM/TGW/TGM/Intersex at risk for HIV infection
214948597|NCT05957224|OTHER|Shake 1 then Shake 2|Oral administration of Caribbean low-calorie meal-replacement shake then commercial low-calorie meal-replacement shake
214948598|NCT05957224|OTHER|Shake 2 then Shake 1|Oral administration of commercial low-calorie meal-replacement shake then Caribbean low-calorie meal-replacement shake
214948599|NCT03174678|DRUG|Dexmedetomidine|1µg/kg dexmedetomidine oral
214948600|NCT03174678|OTHER|apple juice|apple juice
214948601|NCT03896672|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be applied three times daily during 7 consecutive days, if the physiotherapist follow the previous training. Each application should during 30 minutes. Pressure should be adjusted in 15 centimeters of water.
215075595|NCT00460486|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
215075596|NCT04574414|DIAGNOSTIC_TEST|Psychological testing and MRI imaging|"Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI."
215075597|NCT01478685|DRUG|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
214342739|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
214342740|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
214342741|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
214342742|NCT02010385|DRUG|Octreotide|
214342743|NCT02010385|DRUG|Saline|
214342744|NCT05874934|DEVICE|Intrahepatic biliary stent with retrieval string|Plastic biliary stent with 3-0 nylon (ethilon) thread tied to the distal end of the stent through the existing sidehole.
214342745|NCT06531525|DRUG|Enoxaparin|Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
214342746|NCT06531525|DRUG|Aspirin|Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
214948602|NCT01618916|DRUG|LY3015014|Administered SC
214948603|NCT01618916|OTHER|Placebo|Administered SC
214948604|NCT05157698|DRUG|Naltrexone and Bupropion Combination|Participants in this intervention will take active naltrexone and bupropion pills.
215075598|NCT01478685|DRUG|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
215075599|NCT01478685|DRUG|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2
215075600|NCT03350256|DEVICE|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.|BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
215075601|NCT04660292|OTHER|Maitland's mobilization|Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
215075602|NCT04660292|OTHER|Traditional Physical therapy|BASELINE TREATMENT INCLUDES TENS and Hot PACKS
214342747|NCT06531525|DRUG|Enoxaparin|Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
214948605|NCT05157698|BEHAVIORAL|Behavioral Weight Loss|Participants in this intervention will receive behavioral weight loss treatment.
214948606|NCT05157698|OTHER|Placebo|Participants in this intervention will take inactive (placebo) pills.
214948607|NCT04521114|DRUG|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
214948608|NCT04521114|DRUG|leronlimab 700 mg|700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
214948609|NCT04521114|DRUG|leronlimab 350 mg|350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
214948610|NCT05040334|DRUG|Group 1: Antibiotic receiving group|Group 1; receiving antibiotic prophylaxis; single dose of oral doxycycline (200 mg) tablet and metronidazole (500 mg) tablet 2 hours before the surgical evacuation Group B ;receiving placebo 2 hours before the surgical evacuation
214948611|NCT03774134|PROCEDURE|Complete mesocolic excision|Based on the principles of CME. The inferior mesenteric artery (IMA) was divided at its origin from the aorta to perform central lymph nodes dissection along the IMA between the aorta and the branching of the left colic artery. Sigmoid resection included the complete sigmoid colon and resection of the upper part of the rectum to ensure sufficient perfusion of the colo-rectal anastomosis. To achieve sufficient distance at the proximal bowel resection margin, parts of the descending colon or even left hemicolectomy were performed at the surgeon's discretion.
214948612|NCT03774134|PROCEDURE|Conventional colon resection|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
214948613|NCT04674735|DRUG|APSLXR|Oral coated tablets once a day for 60 days.
214948614|NCT04369235|DEVICE|tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. tCES will be applied for 20 minutes at an intensity of 1.0 -1.5 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 6 weeks.
214948615|NCT04369235|DEVICE|Sham tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham tCES will consist of a 5-second ramp up to 1.0-1.5 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
215075603|NCT01467050|OTHER|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
215075604|NCT01467050|OTHER|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
215075605|NCT03971240|PROCEDURE|evacuation of traumatic acute subdural hematoma|craniotomy will be done with evacuation of the hematoma
215075606|NCT03603587|PROCEDURE|biopsy|Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.
215075607|NCT03603587|DIAGNOSTIC_TEST|blood sample|Blood sample will be collected for performed for HIV serology, B and C hepatitis.
215075608|NCT03603587|DIAGNOSTIC_TEST|questionnaire on sun exposure|Questionnaire on sun exposure will be completed by patients.
215075609|NCT03603587|DIAGNOSTIC_TEST|examination of the scalp|A complete examination of the scalp will be completed by dermatologist.
215075610|NCT03603587|DIAGNOSTIC_TEST|Norwood scale|Norwood scale measure the evolution of baldness. It will be completed by dermatologist.
215075611|NCT03603587|DIAGNOSTIC_TEST|questionnaire of clinicals signs|Questionnaire of clinicals signs will be completed by dermatologist and patient.
215075612|NCT03603587|DIAGNOSTIC_TEST|scinexa score|It's a assessment score of skin aging. It will be completed by dermatologist.
215075613|NCT03603587|DIAGNOSTIC_TEST|questionnaire of the history of the hair loss|Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
215075614|NCT03354312|DRUG|Lidocaine Hydrochloride 1% Gel|Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
214342748|NCT00883571|PROCEDURE|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
214342749|NCT00883571|PROCEDURE|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
214948616|NCT00394134|BEHAVIORAL|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
214948617|NCT03486119|OTHER|nivolumab|Subjects will be treated with 3mg/kg in nivolumab IV every 2 weeks for a maximum of 12 months.
214948618|NCT00865241|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
214948619|NCT00865241|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
214342750|NCT00883571|PROCEDURE|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
214342751|NCT01658683|BEHAVIORAL|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
214342752|NCT03286491|DIAGNOSTIC_TEST|Further cardiac imaging|Study patients will be reviewed whether they will have coronary interventions in 30 days
214342753|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
214342754|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
214342755|NCT05114681|OTHER|Assessment of Oral care as per patient personal choice|We just inquire from patients or attendants about products used, the timing for oral care.
214342756|NCT02740348|BEHAVIORAL|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
214342757|NCT02740348|BEHAVIORAL|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
214342758|NCT02731092|DIETARY_SUPPLEMENT|Lactoferrin|Bovine Lactoferrin 100 mg/ml dissolved in sterile water
214342759|NCT00504244|DRUG|switch to Myfortic|Myfortic 2 dd 720 mg
214342760|NCT00504244|DRUG|continuation of azathioprine|Azathioprine 2 mg/kg
214342761|NCT02377986|BEHAVIORAL|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
214342762|NCT02377986|BEHAVIORAL|In-Home Decluttering|In-home decluttering practice
214342763|NCT04450823|OTHER|no intervention|no intervention study, survey amongst health workers
214948620|NCT04847102|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine|"The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection.~Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2.~The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:~15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000)."
214342764|NCT05745077|BEHAVIORAL|Telemedicine Consultation|Patients will be contacted by their surgeon over the phone to discuss surgical treatment.
214342765|NCT05745077|BEHAVIORAL|Traditional Care|Patients will proceed with their surgical consultation as per standard practice.
214678296|NCT03314519|DIAGNOSTIC_TEST|Fiberoptic bronchoscopy for double lumen tube's position|Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
215075615|NCT03354312|DRUG|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride|Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
215075616|NCT02724917|DRUG|APN1125|Oral solid dose form of APN1125
215075617|NCT02724917|DRUG|Placebo|Placebo to match
215075618|NCT00899197|DRUG|tamoxifen citrate|
215075619|NCT00899197|GENETIC|gene expression analysis|
215075620|NCT00899197|GENETIC|protein expression analysis|
215075621|NCT00899197|OTHER|immunoenzyme technique|
215075622|NCT00899197|OTHER|laboratory biomarker analysis|
214342766|NCT00053131|BIOLOGICAL|filgrastim|
214342767|NCT00053131|BIOLOGICAL|sargramostim|
214342768|NCT00053131|DRUG|cytarabine|
214342769|NCT00053131|DRUG|mitoxantrone hydrochloride|
214342770|NCT01614210|DRUG|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
214342771|NCT01614210|PROCEDURE|Breast cancer surgery|Breast cancer surgery
214342772|NCT02665000|PROCEDURE|Structured training programme|Participants will undergo 5-days training sessions
214342773|NCT03565718|BEHAVIORAL|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
215075623|NCT01835574|BEHAVIORAL|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete \>=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
214948621|NCT04847102|BIOLOGICAL|Placebo|0.9% sodium chloride solution, 0.5 mL/vial
214342774|NCT03565718|BEHAVIORAL|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
214948622|NCT03684421|DIAGNOSTIC_TEST|Pregnancy Rate|The clinical pregnancy and live birth rate according to the protocol of COS
214948623|NCT02867202|DEVICE|Intrauterine balloon|After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.
214948624|NCT02867202|DEVICE|Intrauterine Contraceptive Device Plus Foley Catheter|After the completion of hysteroscopic adhesiolysis, Intrauterine Contraceptive Device Plus Foley Catheter were inserted into the uterine cavity. Foley Catheter was removed after three days and Intrauterine Device was removed at the second time of hysteroscopy.
214948625|NCT02631902|BEHAVIORAL|Exercise|Community-based exercise program with 3 weekly exercise sessions
214948626|NCT02631902|BEHAVIORAL|Dietary intervention|Community-based dietary intervention program
214342775|NCT00723775|DRUG|GSK706769 & KALETRA|GSK706769 alone and GSK706769 + Kaletra
214948627|NCT05375084|DRUG|BBP-398 with nivolumab|BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)
214948628|NCT06260475|PROCEDURE|Aortobifemoral bypass|Open surgery with aortic and iliac reconstruction
214948629|NCT06260475|PROCEDURE|aortoiliac stenting|"Endovascular reconstruction of aortic and iliac arterial obstruction:~Balloon angioplasty may be performed initially to dilate the narrowed segment of the iliac artery.~Subsequently, a stent delivery system is advanced over the wire and positioned across the lesion.~The stent is deployed under fluoroscopic guidance to expand and scaffold the diseased artery, restoring blood flow.~Vascular - iliac dedicated Stent - any brand"
215075624|NCT05067023|DIAGNOSTIC_TEST|MRI scan|All participants will undergo 1 DCE-MRI scan.
215075625|NCT01825486|BEHAVIORAL|accidental falls|
215075626|NCT00571870|DRUG|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
215075627|NCT02901002|OTHER|Sensory testing in the two hand|spontaneous sensations while watching a hand
215075628|NCT02901002|OTHER|Neuropsychological evaluation|Score to anxiety-depression scale
215075629|NCT04452435|DRUG|C21|C21
215075630|NCT04452435|DRUG|Placebo|Placebo
215075631|NCT04009694|OTHER|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
214342776|NCT02911402|OTHER|sea sickness questionnaires|
214948630|NCT05961475|DIETARY_SUPPLEMENT|Fruit snack 1|Fruit snacks with original level of sugar
214948631|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 2|Fruit snacks with original level of sugar and mulberry leaf extract
214948632|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 3|Fruit snacks with reduced level of sugar
214948633|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 4|Fruit snacks with zero added sugar
214948634|NCT05961475|DIETARY_SUPPLEMENT|White Bread|White bread with matched carbohydrate as control
214948635|NCT00968188|BEHAVIORAL|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
214948636|NCT00968188|BEHAVIORAL|Information only|Medically fact based HIV information delivered online.
214948637|NCT01133288|DEVICE|Yulex gloves|Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (\~30 minutes per day) over a 3 month period.
214948638|NCT00438256|PROCEDURE|Proton Beam Radiation|Given over different schedules and duration
214948639|NCT00438256|DRUG|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
215075632|NCT04043234|DEVICE|RESCU|Retrospectively Supervised Classification Updating (RESCU) is founded on two innovations that promise significant improvement in performance and outcome. The first is a highly robust machine intelligence algorithm, an Extreme Learning Machine with Adaptive Sparse Representation (EASRC), and the second is a novel adaptive learning algorithm and communication interface we call Nessa. We contend that these two technologies allow the prosthetic device to adapt to its user from the initial fitting through continuing, long-term use in the activities of daily living, shifting the paradigm of training from the current prospective data gathering methods to a more dynamic retrospective application.
215075633|NCT04043234|DEVICE|Pattern Recognition|Pattern recognition prostheses associate the patterns of activity of multiple EMG sites to the action of a prosthesis. Such strategies have historically required prospective calibration of the EMG activation patterns.
215075634|NCT05709717|PROCEDURE|Regenerative therapy with SVF-PRP to supplement perianal surgery|Regenerative therapy with autologous stromal vascular fraction derived mesenchymal stem cells and platelet-rich plasma to supplement perianal surgery
215075635|NCT01234805|PROCEDURE|yoga therapy|Participates in yoga classes and yoga at home
215075636|NCT01234805|OTHER|questionnaire administration|Ancillary studies
215075637|NCT01234805|PROCEDURE|quality-of-life assessment|Ancillary studies
214342777|NCT01181921|DRUG|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
214342778|NCT02021435|DIETARY_SUPPLEMENT|salt substitute|Free salt substitute provided
214948640|NCT04548388|OTHER|rehabilitation|"A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
214948641|NCT06417866|OTHER|informed consent|standard verbal and written informed consent
214948642|NCT06417866|OTHER|spine model|standard verbal and written informed consent + visual spine model
214948643|NCT00167401|DRUG|docetaxel|
214948644|NCT00167401|DRUG|cisplatin|
214948645|NCT00167401|PROCEDURE|radiation treatment|
214948646|NCT01918072|OTHER|Clinical innovation|Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
214948647|NCT04151238|BEHAVIORAL|Exercise intervention for cancer patients to increase physical activity during chemotherapy|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.
214948648|NCT01861418|OTHER|Lumbopelvic Manipulation|Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
214948649|NCT01861418|OTHER|Sham manipulation|Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
214948650|NCT00458575|DRUG|CNTO 2476|Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
214948651|NCT06155513|COMBINATION_PRODUCT|Omega-3 monoglyceride based topical Serum and cream of formulation A (light)|Omega-3 monoglyceride based serum and cream of lighter formulation
214948652|NCT06155513|COMBINATION_PRODUCT|Omega-3 monoglyceride based topical Serum and cream of formulation B (rich)|Omega-3 monoglyceride based serum and cream with a richer formulation
214948653|NCT00744406|BEHAVIORAL|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
214948654|NCT00744406|BEHAVIORAL|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
214948655|NCT00744406|DRUG|Antidepressant medication (sertraline ,paroxetineor or venlafaxine)|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
214948656|NCT03292471|DEVICE|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
215075638|NCT04860895|DIAGNOSTIC_TEST|AP-23|AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
214342779|NCT04718246|OTHER|Dental Implants Placed In hyperlipidemia patients|"A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~* Penetration of cortical bone will be achieved with no. 6 round burs.~* The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~* Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks"
214342780|NCT02973958|DRUG|Bupivacaine|See active comparator description
214342781|NCT02973958|DRUG|Sevoflurane|See active comparator description
214342782|NCT02973958|DRUG|Acetaminophen|See active comparator description
214948657|NCT03324828|DRUG|Hydroxyzine|Hydroxyzine solution
214948658|NCT03324828|OTHER|Clowns intervention|Clowns intervention
214948659|NCT02865811|DRUG|Pembrolizumab|"Please see Arms for description."
214948660|NCT02865811|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Please see Arms for description."
214948661|NCT02771925|DRUG|Gabapentin 2g/day divided in two doses for 24 weeks|"Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.~All patients will receive standard of care treatment."
214948662|NCT02771925|DRUG|Placebo 2g/day divided in two doses for 24 weeks|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
214948663|NCT00911586|DRUG|Testosterone undecanoate|
214948664|NCT00676416|DRUG|2,6-Diisopropylphenol|Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)
214948665|NCT02397824|OTHER|Salivary and blood samples|
215075639|NCT02614807|DIETARY_SUPPLEMENT|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
214342783|NCT02973958|DRUG|Ibuprofen|See active comparator description
214342784|NCT02973958|DRUG|Ketorolac|See experimental arm description
214342785|NCT00131794|BIOLOGICAL|BCG|
214342786|NCT05792553|DEVICE|bonded tongue tamers|Enamel surface will be treated initially with 37% phosphoric acid for 30 seconds then tongue tamers will be bonded to the palatal/lingual surface of upper and lower central incisors
214342787|NCT05792553|DEVICE|customized bonded spurs|Composite restoration will be used to fabricate the customized bonded spurs with sharp ends and 3 mm in length.
214342788|NCT05792553|DEVICE|conventional fixed palatal spurs|conventional fixed palatal spurs will be fabricated by taking impression after band selection, then the spurs appliance will be fabricated from 0.9 mm stainless steel wire and soldered to the bands bilaterally.
214342789|NCT01523691|BEHAVIORAL|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
214342790|NCT01523691|BEHAVIORAL|Control sleep|Regular amounts of sleep across study protocol
214342791|NCT01317953|DIETARY_SUPPLEMENT|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
214342792|NCT04091399|DRUG|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
214342793|NCT03574454|OTHER|Machine Learning (ML)|Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma
214342794|NCT05778214|DEVICE|Interventional Robotic System|Cerebral angiography was performed by using the interventional robotic system
214342795|NCT02139501|DRUG|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
214948666|NCT00279006|PROCEDURE|Percutaneous coronary intervention|
214948667|NCT04346771|BEHAVIORAL|Working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
214342796|NCT04408469|BEHAVIORAL|Online EQuIP|This online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
214342797|NCT04408469|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
214342798|NCT00910481|DEVICE|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
214342799|NCT02065466|DRUG|nab-paclitaxel|
214342800|NCT02065466|DRUG|Temozolomide|
214342801|NCT02065466|DRUG|Bevacizumab|
214948668|NCT04346771|BEHAVIORAL|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
214948669|NCT03271671|OTHER|NAVA during Non invasive ventilation|NIV during respiratory failure
214948670|NCT03271671|OTHER|PSV during Non invasive ventilation|PSV during respiratory failure
214948671|NCT03423966|DEVICE|Smartphone Pedometer App|Installation of the free pedometer app and explanation to participants to target 10000 steps per day. The intent is not the accuracy of the pedometer but the motivation especially to a community yet to harness the full potentials of the mobile phone technology
214948672|NCT02555930|OTHER|No Intervention|No intervention - observational only
214948673|NCT04625933|OTHER|No intervention|No intervention
214948674|NCT01555918|DRUG|Isavuconazole|oral
214948675|NCT01555918|DRUG|Isavuconazole (IV)|intravenous (IV)
214948676|NCT04766099|OTHER|Childbirth Educational Video|Educational video describing techniques for pushing
214948677|NCT01250353|PROCEDURE|pterygium surgery|pterygium was removed surgically
214948678|NCT04606667|OTHER|Exercise Program|Exercise program
214948679|NCT04110496|DRUG|RTX-134|RTX-134 is a cellular therapy containing AvPAL
214948680|NCT04725123|DIAGNOSTIC_TEST|Microbiome analysis|Stool microbiome analysis of 16S rRNA sequencing to an anticipated number of 8,000,000 reads
214948681|NCT04727255|BEHAVIORAL|Engaged and Resilient intervention|"Engaged and Resilient is a 3-phase program addressing the promotion of psychological resilience strategies for leaders.~To implement resilience training as a strategic and ethical intervention in the organization, stakeholders from Management/HR will be involved in the final design of the training program based on local institutional data, and the baseline measure result. Local training sessions will be selected from a bag-log of resilience skills structured by three general resilience factors.~To support ownership and internal sustainability, internal trainers will be educated on how to train the resilience skills in the program.~The Engaged and Resilient program consists of 20 short-term sessions for leaders based on cognitive and positive psychology."
214948682|NCT05958108|BEHAVIORAL|SinergiAPS intervention|Audit and feedback intervention, with the audit being based on patient-reported experiences and outcomes of patient safety.
214948683|NCT00750919|DRUG|esmirtazapine|
214948684|NCT06174818|PROCEDURE|PRF|Pulsed Radiofrequency Current of the Gasserian Ganglion
214948685|NCT05249621|DRUG|MZE001|Small molecule inhibitor of muscle glycogen synthase
214948686|NCT05249621|DRUG|Placebo|Product containing excipients with no active ingredients
215075640|NCT05664347|BEHAVIORAL|Verbal teach to goal education|Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.
214342802|NCT03274700|DRUG|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
214948687|NCT05507502|BIOLOGICAL|Influenza vaccination administration|There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.
214948688|NCT02290379|DRUG|TNX-201 35 mg|Drug: TNX-201 35 mg
214948689|NCT02290379|DRUG|TNX-201 70 mg|Drug: TNX-201 70 mg
214948690|NCT02290379|DRUG|TNX-201 140 mg|Drug: TNX-201 140 mg
214948691|NCT02290379|DRUG|Racemic isometheptene 70 mg|Active Comparator: Racemic isometheptene 70 mg
214948692|NCT02290379|DRUG|Placebo|Drug: Placebo
214948693|NCT04848259|DRUG|Normal saline|Saline will be applied after surgery
214948694|NCT04848259|DRUG|Dexamethasone|Dexamethason will be given IV before surgery
214342803|NCT03274700|DRUG|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
214342804|NCT01263743|BEHAVIORAL|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
214342805|NCT01263743|BEHAVIORAL|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
214342806|NCT04587089|PROCEDURE|Irrigation|Irrigation and aspiration in the root canals with 1% sodium hypochlorite (Milton's solution).
214342807|NCT04587089|PROCEDURE|Filling with Guedes-Pinto Paste|The root canals will be filled with Guedes-Pinto Paste, which is a composite of 3 medications: Rifocort® (dermatologic ointment), camphorated paramonochlorophenol (PMCC) and iodoform. It will be prepared at the moment of use with the same proportion in volume of 3 visually identical parts, one for each of its components.
214342808|NCT04587089|PROCEDURE|Filling with CTZ Paste|The powder that composes the CTZ paste will be previously manipulated in a 1:1:2 ratio (500mg of Chloramphenicol, 500mg of Tetracycline and 1,000mg of Zinc Oxide) by Formula \& Ação (F\&A) and incorporated into the eugenol liquid at the time of use, with the aid of a flexible spatula nº 24 and on a sterile glass plate. The cleaning of the coronary chamber must be carried out with saline solution and drying with sterile cotton balls and the CTZ paste must be inserted into the cavity.
214342809|NCT03361813|OTHER|trans-cutaneous ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a transcutaneous route
214342810|NCT03361813|OTHER|trans-oral ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a trans-oral route
214342811|NCT04274517|OTHER|Sterile Water|1L of sterile water used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
214948695|NCT04848259|DRUG|Honey|Honey will be applied locally after surgery
214948696|NCT04848259|DRUG|Dexamethasone and honey|Dexamethason will be given IV before surgery and then Honey will be applied locally after surgery
214948697|NCT00506207|DRUG|S-1, Irinotecan, Oxaliplatin|
214948698|NCT06038006|DIAGNOSTIC_TEST|Sleep Respiratory Monitoring System|Millimeter-Wave radar-based Sleep Respiratory Monitoring System to be used on each participant undergoing PSG
214948699|NCT02612688|BEHAVIORAL|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
214948700|NCT03538067|PROCEDURE|Percutaneous coronary intervention (PCI)|Patients will undergo PCI with intravascular ultrasound (IVUS) as part of standard clinical care in accordance with operator discretion. The research protocol will be observational - using IVUS to determine the effects of balloon inflation time, balloon inflation pressure, balloon type, atherosclerotic plaque morphology on stent expansion (minimal luminal area, MLA)
214948701|NCT01273662|DRUG|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
214342812|NCT04274517|OTHER|3.5% Betadine|1L of 3.5% betadine used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
214342813|NCT04274517|OTHER|0.05% Chlorhexidine Gluconate|1L of clorhexidine gluconate used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
214342814|NCT02061631|DRUG|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
214342815|NCT02061631|DRUG|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
214342816|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
214342817|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
214342818|NCT04944823|OTHER|Clinical follow-up for 24 months|Sampling and clinical follow-up for 24 months
214342819|NCT01886976|BIOLOGICAL|CART-138 cells|
214342820|NCT04321460|DRUG|LRG-002|Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
214342821|NCT04321460|DRUG|Placebo|Capsules containing placebo
214342822|NCT03788486|DEVICE|2-3 Joule LED blue light device|application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
214342823|NCT01871298|OTHER|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
214342824|NCT05620758|OTHER|Nd YAG laser|patients from those diagnosed with TMD will receive Nd YAG laser 1064 nm
214342825|NCT05620758|OTHER|diode laser (980 nm)|patients from those diagnosed with TMD will receive a diode laser (980 nm)
214342826|NCT05620758|OTHER|diode laser (940 nm)|patients from those diagnosed with TMD will receive a diode laser (940 nm)
214342827|NCT05620758|OTHER|diode laser (660 nm)|patients from those diagnosed with TMD will receive a diode laser (660 nm)
214342828|NCT05620758|OTHER|diode laser (635 nm)|patients from those diagnosed with TMD will receive a diode laser (635 nm)
214342829|NCT04495712|DRUG|spironolactone|aldosterone blocker
214342830|NCT04495712|DRUG|placebo|identical in appearance to spironolactone study drug
214342831|NCT06533774|DEVICE|Phonak Audéo Lumity 90-R|This study will be using the Audeo L90-R devices, which are programmed by the hearing care professional (HCP) using Target fitting software version 8.1.
214342832|NCT05906693|OTHER|Quality of life|Parkinson's Disease Quality of Life Questionnaire (PDQ-39)
214342833|NCT05906693|OTHER|Upper limb functionality|Nine-Hole Peg Test
214678297|NCT06221605|DIETARY_SUPPLEMENT|Probiotic|The intervention lasted for 3 months and 3 visits (at 0 month, 3rd and 6th month respectively).
214678298|NCT05811364|DEVICE|Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
214678299|NCT05811364|DEVICE|Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent|Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.
214678300|NCT04388657|DIAGNOSTIC_TEST|Echo-Doppler|Utrasound Doppler of the lower limbs
214342834|NCT05906693|OTHER|Grip and pinch strength|Dynamometer
214342835|NCT05906693|OTHER|Tremor amplitude|Electromyography
214342836|NCT05906693|OTHER|Depression and anxiety levels|Hospital Anxiety and Depression Scale
214342837|NCT05906693|OTHER|Clinical manifestations|The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale
214342838|NCT02889549|DRUG|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
214342839|NCT02889549|DRUG|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
214342840|NCT02349958|DEVICE|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
214342841|NCT02349958|DEVICE|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
214342842|NCT02349958|DEVICE|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
214342843|NCT02349958|DEVICE|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
214342844|NCT00706121|DRUG|Vitamin E|400 IU daily by mouth for 7 - 12 years
214342845|NCT00706121|DRUG|Selenium|200 mcg daily for 7 - 12 years
214342846|NCT00706121|DRUG|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
214342847|NCT00706121|DRUG|selenium placebo|1 pill by mouth daily for 7 - 12 years
214342848|NCT02835534|DRUG|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
214342849|NCT02835534|DRUG|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
214342850|NCT02824068|DRUG|glucosidase alfa|Long-term use in an observational study of licenced drug
214342851|NCT01308749|DRUG|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
214342852|NCT01308749|DRUG|Placebo|Placebo Nasal Spray
214342853|NCT05447546|DRUG|HT-6184|Oral capsule
214342854|NCT05447546|DRUG|HT-6184 Placebo|Oral capsule
214342855|NCT04726709|BEHAVIORAL|Poised for Parkinson's|Lecture, demonstration, activities, and supplemental materials designed to improve self-awareness, situational awareness, and ability to make good choices for physical and emotional self-care, moment-to-moment.
214948702|NCT01583205|BEHAVIORAL|Coping Effectiveness Training - ALS|Eight coping effectiveness training counseling sessions.
214948703|NCT03246191|OTHER|blood sample collection|blood sample collection
214948704|NCT04374292|BEHAVIORAL|Family intervention|"Topics covered in each session with intervention group mothers.~1. Dietary and physical activity habits and their link to obesity and cardio-metabolic diseases. Children learn about healthy eating habits and health risks at home.~2. Food-preparation processes. Selecting and purchasing food and beverages; importance of food groups and their impact on health; importance of fruit and vegetables. Balance between food groups, source of foods, organic or industrialized. Family menu preparation.~3. Habits and behaviors surrounding eating processes identified as health or risk factors, such as energy density, portion-size control, controlling emotional eating.~4. Beverages. Water versus sugar-sweetened drinks prepared at home or purchased at the store.~5. Preventing the risk of cardiovascular diseases by learning healthy eating habits and practicing these habits at home.~6. Integration. Practicing the skills learned during the intervention in each stage of preparing food and eating"
214948705|NCT04374292|OTHER|Usual nutritional consultation|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
214948706|NCT00576004|PROCEDURE|Pelvic organ prolapse repair and Burch colposuspension|Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
214948707|NCT06730724|OTHER|No intervention|No intervention
214948708|NCT03994406|DRUG|CLM2 topical gel|Active topical gel for forehead dermal application
214948709|NCT03994406|DRUG|Placebo topical gel|Placebo topical gel for forehead dermal application
214948710|NCT02794506|DRUG|Propolis|Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
214948711|NCT02794506|DRUG|Placebo|Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
214948712|NCT04234594|DRUG|QL1203|6 mg/kg intravenous (IV) infusion only once，on the first day.
214948713|NCT04234594|DRUG|Vectibix®|6 mg/kg intravenous (IV) infusion only once，on the first day.
214948714|NCT03478189|PROCEDURE|use of O-arm surgical imaging|during acetabular fracture surgery , use of O-arm surgical imaging with
214948715|NCT04731077|DEVICE|Avenir Complete Femoral Stem|All enrolled subjects will receive the Avenir Complete Femoral Stem
214948716|NCT06033677|PROCEDURE|Distal radial artery cannulation|Interventional application for invasive blood pressure monitoring
214948717|NCT06033677|PROCEDURE|Forearm radial artery cannulation|Interventional application for invasive blood pressure monitoring
214948718|NCT06171568|OTHER|Tests and questionnaires|"1 year after discharge from neurosurgery department, included patients will answer to the:~* Modified Rankin Scale;~* Instrumental Activities of Daily Living (IADL) questionnaire;~* Montreal Cognitive Assessment (MoCA);~* Frontal assessment battery (BREF);~* Rivermead questionnaire;~* Short Form (36) Health Survey (SF-36)~* Community Integration Questionnaire - Revised (CIQ-R)~* Posttraumatic stress disorder CheckList (PCL-5)"
214948719|NCT03394625|PROCEDURE|Socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
214948720|NCT03394625|PROCEDURE|using Xenograft material|placing xenograft material in gap between the implant and the buccal plate of bone
214342856|NCT03950193|OTHER|Questionnaires to evaluate psychic development of the child|Child Behaviour Checklist. This test, completed by parents and with 52 questions, is designed to screen children at high risk for emotional problems, mood disorders, anxiety, pervasive developmental problems, attention deficit and hyperactivity, antonymic reactions (oppostion, provocation) and sleep problems.
214948721|NCT00925197|OTHER|INR self-testing program|
214948722|NCT03922282|PROCEDURE|Gasless BABA|BABA robotic-thyroidectomy that is using elevation of flap instead of using carbon dioxide.
214948723|NCT03922282|PROCEDURE|Classic BABA|BABA robotic-thyroidectomy that is using carbon dioxide.
214948724|NCT06525974|DRUG|Febuxostat|40mg of Febuxostat once daily
214948725|NCT06525974|DRUG|Mesalamine|1 g mesalamine three times daily for 3 months.
214948726|NCT00812500|OTHER|Lower Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
214948727|NCT00812500|OTHER|Medium Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
214342857|NCT01116817|DRUG|Lumbar puncture (Lopinavir/ritonavir monotherapy)|Lumbar puncture at week 0
214342858|NCT01116817|DRUG|Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)|Lumbar puncture at week 0
214342859|NCT03793881|BEHAVIORAL|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
214342860|NCT03793881|BEHAVIORAL|Dietary Prescription|Dietary prescription according to guidelines.
214678301|NCT04003155|DRUG|fezolinetant|Oral Tablet
214948728|NCT00812500|OTHER|Higher Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
214948729|NCT05180981|DEVICE|Transcutaneous vagal nerve stimulation|Noninvasive stimulation vs sham stimulation will be delivered via an auricular device.
214948730|NCT05180981|BEHAVIORAL|Breathing task|Participants will be asked to breathe in specific patterns.
214948731|NCT00013923|DRUG|Nutritional Supplement|
214948732|NCT00537355|BIOLOGICAL|Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate|6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
214948733|NCT00537355|DRUG|Histamine|6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
214342861|NCT04544826|DRUG|JNJ-77474462|JNJ-77474462 will be administered as SC injection.
214342862|NCT04544826|DRUG|Placebo|Matching placebo to JNJ-77474462 will be administered as SC injection.
214342863|NCT02546544|DRUG|Linsitinib|
214948734|NCT02150681|BEHAVIORAL|Mindfulness-based cognitive therapy|This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
214948735|NCT01129271|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
214948736|NCT01129271|DRUG|Matching placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214948737|NCT03763058|OTHER|Music Therapy|"The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month."
214948738|NCT00005821|DRUG|patent blue V dye|
214948739|NCT00005821|PROCEDURE|conventional surgery|
214948740|NCT00005821|PROCEDURE|lymphangiography|
214948741|NCT00005821|PROCEDURE|radionuclide imaging|
214948742|NCT00005821|PROCEDURE|sentinel lymph node biopsy|
214948743|NCT00005821|RADIATION|Technetium Tc 99m human serum albumin colloid|
214948744|NCT06730659|BIOLOGICAL|CHT101|CHT101: CD 70 UCAR T
214948745|NCT02445859|DRUG|Cefuroxime 4 hourly bolus|Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
214948746|NCT04967859|DRUG|0.1% gentamicin|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
214948747|NCT04967859|DRUG|Placebo|Patients using placebo ointment at the exit site of the hemodialysis catheter
214948748|NCT02475759|DIETARY_SUPPLEMENT|Nutritional perioperative prehabilitation program for two weeks|nutritional intervention received two weeks before surgical intervention
214948749|NCT02475759|DIETARY_SUPPLEMENT|Nutritional perioperative prehabilitation program for one week|nutritional intervention received one weeks before surgical intervention
214948750|NCT05816759|DRUG|CKD-383|QD, PO
214948751|NCT05816759|DRUG|CKD-501, D744, D150|QD, PO
214948752|NCT05456633|DEVICE|Capri Cervical Static|When used in the cervical spine (C2-T1), CAPRI Static cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
214948753|NCT05456633|OTHER|CAPRI Static Expandable|When used in the cervical spine (C2-T1), CAPRI Static Expandable cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
214948754|NCT05456633|DEVICE|Capri Thoracolumbar|Intended for use to replace a collapsed, damaged, or unstable vertebral body due to tumor and trauma (i.e. fracture).
214948755|NCT01455285|DEVICE|transcutaneous electrical nerve stimulation|
214948756|NCT01404949|DRUG|Tretinoin and Arsenic Trioxide|See Detailed Description
214948757|NCT02637388|DIETARY_SUPPLEMENT|Oatwell28 Oatwell Original Powder|
214948758|NCT02637388|DIETARY_SUPPLEMENT|Control Breakfast|Isocaloric breakfast without added beta-glucans
214948759|NCT03279601|DRUG|Capecitabine, Dacarbazine|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
214948760|NCT03279601|DRUG|Capecitabine, Temozolomide|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
214948761|NCT00397592|DRUG|Growth Hormone|
214342864|NCT02810535|OTHER|Observation|"Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE"
214342865|NCT04351152|BIOLOGICAL|Lenzilumab|Administered as an intravenous (IV) infusion
214342866|NCT04351152|DRUG|Standard of Care|Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
214342867|NCT06534307|BEHAVIORAL|Questionnaire Child Behaviour Checklist|The Child Behavior Checklist comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of problems.
214678302|NCT04003155|DRUG|placebo|Oral Tablet
214948762|NCT00032630|PROCEDURE|Coronary artery bypass - on-pump|CABG procedure performed on heart lung machine
214948763|NCT00032630|PROCEDURE|Coronary artery bypass - off-pump|CABG procedure performed without the use of the heart lung machine
214948764|NCT01180023|PROCEDURE|Sweeping|Sweeping of membranes during digital exam
214948765|NCT05718141|OTHER|COMET-GB|"Online self-guided single session intervention - comprised of 4 modules based on the core principles of CBT, combined with principles from positive psychology. Each module includes short reading exercises, informational videos, and writing exercises.~* Cognitive Restructuring (labelled Flexible Thinking)~* Behavioural Activation (labelled Positive Activities)~* Gratitude~* Self-Compassion~The initial intervention modules and assessment will take participants approximately 60-75 minutes to complete (15-20 minutes for the assessment measures only)."
214948766|NCT02865200|OTHER|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique.
214948767|NCT02865200|OTHER|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
214948768|NCT05614583|DEVICE|MORT-PFPS app|The MORT-PFPS, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
214948769|NCT05614583|OTHER|treatment as usual (TAU)|In the control group, psychoeducation is delivered and self-exercise is recommended.
214948770|NCT02227719|DEVICE|CTI|CTI is the titanium mesh
214948771|NCT02227719|DEVICE|Collagen membrane|
214948772|NCT01608191|BEHAVIORAL|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
214948773|NCT03668522|OTHER|Genetic testing|To determine whether H3F3AK27M exist in spinal glioma
214948774|NCT01687855|DEVICE|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
214948775|NCT05749406|OTHER|Focus group|Small virtual focus group discussion about experiences/attitudes towards post-operative anal dilatation.
214948776|NCT05749406|OTHER|Semi-structured interview|Individual virtual interview to ascertain participant's experiences of performing anal dilatation post-operatively for their child with an anorectal malformation.
214948777|NCT06274710|BEHAVIORAL|ODYSSEE-KH|Automated digital counselling program
214948778|NCT00380718|DRUG|pemetrexed|"500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity\* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.~\*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets \<50 x 10\^9/L; absolute neutrophil count \<1.0 x 10\^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade \>2; Skin Grade \>2; Serum bilirubin \>3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase \>10 x ULN; Other non-hematologic toxicities Grade \>2 (except nausea, vomiting)."
214948779|NCT00926640|DRUG|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
214948780|NCT00926640|DRUG|Cisplatin|6 cycles at 60mg/m2 IV on day 2
214342868|NCT06534307|BEHAVIORAL|Questionnaire Young Self Report|The Questionnaire Young Self Report comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score.
214342869|NCT06534307|DIAGNOSTIC_TEST|physical examination|physical development examination including height (in cm), weight (in g) and tanner states
214342870|NCT06534307|DIAGNOSTIC_TEST|metabolic examination|metabolic development using blood analysis including blood components, metabolic parameters (Glucose, HbA1c, cholestrol)
214342871|NCT06534307|BEHAVIORAL|Questionnaire Reynolds Intellectual Assessment Scales and Screening|"The RIAS is standardized intelligence test. The RIAS provides an Total Intelligence Index (GIX, estimate of the general intelligence/g-factor), Verbal Intelligence Index (VIX) and the Nonverbal Intelligence Index (NIX). Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better cognitive performance."
214342872|NCT06534307|DIAGNOSTIC_TEST|electroencephalogram|neurocognitive development
214342873|NCT06534307|OTHER|Questionnaire Movement Assessment Battery for Children|"The M-ABC-2 is an standardized test to assess the motoric development. Adding up subscores addressing manual dexterity, aiming and catching, and balance delivers a total score of the motoric performance.~Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better performance."
214948781|NCT00926640|DRUG|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
214948782|NCT00032721|PROCEDURE|Reiki; Subtle energy therapy|
214948783|NCT02656563|RADIATION|Radium 223 Dichloride (Xofigo®)|Radium 223 Dichloride (Xofigo®) monthly for six months
214948784|NCT02393326|PROCEDURE|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
214948785|NCT02393326|PROCEDURE|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
214678303|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus (ST) tendon only|ACL reconstruction with a ST tendon graft received a reconstruction according to the Tape Locking Screw technique (FH Industrie, Quimper, France) with a dedicated interference screw
214948786|NCT03118791|DIETARY_SUPPLEMENT|anthocyanins|Acute intake of capsules
214948787|NCT01520194|OTHER|women attending reproductive health clinics|women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al
214948788|NCT01520194|OTHER|medical records|medical chart review of patients assisted January 2009 to December 2010
214948789|NCT01925157|BIOLOGICAL|LY3090106 - SQ|Administered SQ.
214948790|NCT01925157|BIOLOGICAL|LY3090106 - IV|Administered IV.
214948791|NCT01925157|BIOLOGICAL|Placebo - SQ|Administered SQ.
214948792|NCT02860117|DEVICE|Ketamine continuous infusion|Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
214948793|NCT02860117|DRUG|Placebo|Placebo continuous infusion (0,2 ml/kg/h)
214948794|NCT01902875|DRUG|Paclitaxel + Cisplatin|Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
214948795|NCT01902875|BIOLOGICAL|CIK cell therapy|Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
214948796|NCT01094782|OTHER|Acupuncture|Subjects receive 6 acupuncture treatments for neck or back pain.
214948797|NCT01094782|OTHER|Sham Acupuncture|Subjects receive 6 sham acupuncture treatments for neck or back pain.
214948798|NCT05330468|DEVICE|Abbott Mechanical Heart Valve (MHV) Regent™|SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
214948799|NCT06289686|PROCEDURE|Rotator cuff repairs with BioEnthesis augmentation|Rotator cuff repair using BioEnthesis allograft patch
214948800|NCT06289686|PROCEDURE|Rotator cuff repairs without BioEnthesis augmentation|Rotator cuff repair using standard of care sutures and anchors
214948801|NCT01712308|BIOLOGICAL|Sotatercept|Given SC
214948802|NCT01712308|DRUG|Ruxolitinib|
214948803|NCT04322786|DRUG|ACE inhibitor|Any prescription of ACE inhibitor
214948804|NCT02912455|DRUG|canagliflozin|encapsulated (gelatin capsule).
214948805|NCT02912455|DRUG|Placebo (for canagliflozin)|encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
215075641|NCT05664347|BEHAVIORAL|Video based teach to goal education|Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
214948806|NCT04169438|OTHER|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Topical vehicle white (bone) color, oil/water emulsion moisturizer.
214948807|NCT04169438|OTHER|FS2 Emulsion Moisturizer + Petrolatum|Topical FS2 white (bone) color, oil/water emulsion moisturizer.
214948808|NCT03070041|OTHER|Baby-friendly Hospital Initiative|The intervention is Baby-friendly Hospital Initiative as described by WHO and UNICEF. The ten steps to successful breastfeeding will be implemented in the hospital.
215075642|NCT02562508|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
215075643|NCT02562508|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
215075644|NCT01155466|DRUG|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
214948809|NCT04505202|DRUG|0.12% chlorhexidine gluconate|The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care
214948810|NCT04505202|DRUG|Placebo|The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
214948811|NCT00004759|DRUG|methylprednisolone|
214948812|NCT00004759|DRUG|tirilazad|
214948813|NCT03725033|DRUG|Subetta|Oral administration.
214948814|NCT03725033|DRUG|Placebo|Oral administration.
214948815|NCT06614777|PROCEDURE|skin biopsies and blood extraction|"Two 5 mm skin biopsies: lesional area and non-lesional area, on the trunk.~* One blood sample (20 ml) to extract the plasma.~* 15 successive tape-strippings in a lesional area.~* Scans with two swabs: lesional area (preferably the trunk, 5 cm x 5 cm area) and non-lesional area."
214948816|NCT05270915|BEHAVIORAL|Family supportive care in EOLC|The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
214948817|NCT03534115|DIETARY_SUPPLEMENT|NAC|solution containing NAC
214948818|NCT03534115|DIETARY_SUPPLEMENT|Placebo|Placebo
214948819|NCT02613715|DIETARY_SUPPLEMENT|Blackberry juice with 12% ethanol|
214948820|NCT02613715|DIETARY_SUPPLEMENT|Blackberry juice|
215075645|NCT01155466|DRUG|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
215075646|NCT01155466|DRUG|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
214342874|NCT06534307|OTHER|Questionnaire Continuous Performance Test|The CPT measures selective attention, sustained attention as well as impulsive behavior. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean worse performance.
214342875|NCT06534307|OTHER|Questionnaire Diagnostic System for Mental Disorders|The FBB-ADHS assesses a total score for ADHD-like behavior and subscores for the symptom trias of ADHD (attention deficit, motoric hyperactivity as well as impulsive behavior, Questionnaire scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of symptoms.
214948821|NCT06979089|BEHAVIORAL|Doing What Matters in Times of Stress|"DWM is the illustrated guide of the original stress management intervention - Self-Help Plus and can be offered online through a web-based application.~DWM is a low-intensity and transdiagnostic intervention that has been designed to be widely applicable to a variety of mental health problems (depression, anxiety and PTSD). DWM is based on acceptance and commitment therapy (ACT), a modern form (third wave) of cognitive-behavioural therapy with a strong focus on mindfulness practices and identification of values, with exercises which aim to reduce distress and build social support, adaptive coping and resilience.~DWM includes five modules, each of which focuses on a specific skill. The online version of DWM has been designed to release a module every week, so the program is finalized in 5 weeks. In this trial, participants will receive the guided version of DWM: participants will have a short (15 minutes) weekly support call with a helper (6 calls in total)."
214948822|NCT04092829|PROCEDURE|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
214948823|NCT04505449|DIAGNOSTIC_TEST|Left heart catheterization|Patients who underwent left heart catheterization
214342876|NCT06534307|DIAGNOSTIC_TEST|kidney function tests|urine examination (proteomics, cytokines, lipidomics)
214342877|NCT06534307|OTHER|Questionnaire Five to Fifteen|The FTF 5-15R is a questionnaire to evaluate the child's developmental outcome in different areas of everyday life (cognition, language, and motor impairment as well as social, emotional, and behavioral problems). Individual item scores are added up per area and divided by the number of items. This results in a common scale value. Range of Percentile scores from 0 to 100 (0-90: no developmental problem; 90 and higher: hint for developmental problem). Higher scores mean worse developmental outcome.
214342878|NCT06534307|DIAGNOSTIC_TEST|cardiovacular examination|measurement of pulse wave velocity
214948824|NCT00004036|BIOLOGICAL|sargramostim|
214342879|NCT01025713|DRUG|GS-9411|Inhaled GS-9411
214342880|NCT01025713|DRUG|Placebo|Inhaled Placebo
214342881|NCT01476046|DRUG|GSK1995057 single dose|Single intravenous dose
214342882|NCT01476046|DRUG|Placebo|Single intravenous dose
214342883|NCT00844623|GENETIC|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
215075647|NCT01155466|DRUG|Placebo to Preladenant Tablet|one tablet orally twice daily
214342884|NCT00600600|DRUG|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
214342885|NCT00930111|OTHER|2-week rotation|Attending physician is assigned to a 2-week rotation.
214342886|NCT00930111|OTHER|4-week rotation|Attending physician is assigned to a 4-week rotation.
214342887|NCT02251535|DEVICE|ATTUNE® Knee System|
214342888|NCT02251535|DEVICE|PFC® SIGMA® Knee System|
214342889|NCT05209893|OTHER|Telerehabilitation|Application based video home exercise for the knee osteoarthritis
214342890|NCT05209893|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the knee osteoarthritis
214948825|NCT00004036|DRUG|amifostine trihydrate|
214948826|NCT00004036|DRUG|carboplatin|
214948827|NCT00004036|DRUG|cyclophosphamide|
214948828|NCT01499641|DRUG|Methylprednisolone|Epidural methylprednisolone 40 mg or none
214948829|NCT02230540|DEVICE|SelfCath (comparator)|Commercially available CE-marked catheter for urinary drainage.
214948830|NCT02230540|DEVICE|Product A SelfCath and urine bag, Conveen Security+|SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
214948831|NCT02230540|DEVICE|Product B SelfCath and urine bag, Conveen Contour|SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
214948832|NCT05920668|DRUG|Orelabrutinib|Orelabrutinib monotherapy for CLL/SLL 12 cycles
215075648|NCT01155466|DRUG|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
215075649|NCT01155466|DRUG|Placebo to Rasagiline capsule|one capsule orally in AM
215075650|NCT01382004|DRUG|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
214342891|NCT05164510|GENETIC|ct-DNA guided therapy|treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
214342892|NCT05343871|BIOLOGICAL|Sinovac|"Sinovac inactivated COVID-19 vaccine:~● Full dose (0.5 ml)"
214342893|NCT05343871|BIOLOGICAL|AZD1222|"AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:~* Full dose (0.5 ml)~* Half dose (0.25 ml)"
214342894|NCT05343871|BIOLOGICAL|BNT162b2|"Pfizer/BioNTech BNT162b2 mRNA vaccine:~* Full dose (30 micrograms)~* Half dose (15 micrograms)~* One-third dose (10 micrograms)"
214948833|NCT05299619|DEVICE|Tixel|a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
214948834|NCT05353634|DIAGNOSTIC_TEST|Effects of mNGS on infected patients|The impact of mNGS on infected patients, including diagnostic value, drug selection, treatment prognosis, economic burden, etc.
214948835|NCT02671019|BEHAVIORAL|Guide to better alcohol habits|A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
214948836|NCT05800496|DIETARY_SUPPLEMENT|SesZen-Bio™|mode of usage: 1 capsule in the morning and 1 capsule at night. administration: Oral Administration
214948837|NCT05800496|OTHER|Placebo|Mode of Usage: 1 capsule in the morning and 1 capsule at night. Route of Administration: Oral Administration
214948838|NCT01743118|DRUG|SPS4251 Ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
214948839|NCT01743118|DRUG|Placebo|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
214948840|NCT01743118|DRUG|Daivonex® ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
214948841|NCT00898326|OTHER|biopsy|Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
215075651|NCT01382004|DRUG|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
215075652|NCT02210689|DRUG|clindamycin phosphate vaginal cream 2%|
215075653|NCT02210689|OTHER|placebo|vehicle used as placebo
214342895|NCT02548962|DRUG|Ibrutinib|
214342896|NCT02548962|DRUG|Pomalidomide|
214948842|NCT01007292|DRUG|YM155|intravenous infusion
214948843|NCT01007292|BIOLOGICAL|Rituximab|intravenous infusion
214948844|NCT02710916|DEVICE|SD-OCT Spectralis|All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
214948845|NCT04760379|OTHER|Conventional therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
214948846|NCT04760379|OTHER|vibration therapy|Focal muscle vibrator (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
214948847|NCT05935423|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell transplantation|50 million UC MSC will be transplanted 10-15 days after primary PCI
214948848|NCT01511003|DRUG|Tacrolimus|oral
214342897|NCT02548962|DRUG|Dexamethasone|
214342898|NCT02548962|DRUG|Placebo|
214342899|NCT01197950|DEVICE|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
214342900|NCT01197950|DEVICE|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
214678304|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon|ACL reconstruction with a ST/G tendon graft received a reconstruction with the anteromedial portal technique with endobutton fixation (Smith \& Nephew, London, UK).
214678305|NCT04664660|OTHER|Retrospective analysis of obstetrics outcomes|Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
214948849|NCT02673242|DEVICE|Threshold IMT Philips Respironics|Inspiratory muscle training
214948850|NCT05556642|OTHER|Biospecimen collection|Clinical information and biospecimens will be collected
214948851|NCT05281900|DIAGNOSTIC_TEST|Clinical Tests|Shoulder impingement and instability tests and shoulder normal range of motion measurement.
214948852|NCT05281900|OTHER|MVIC measurements|For the normalization of muscle activation during exercises, muscle activation levels during maximum voluntary isometric contraction (MVIC) of the dominant side Upper Trapezius, Middle Trapezius, Lower Trapezius, Serratus Anterior, Biceps Brachii, Triceps Brachii and Infraspinatus muscles will be recorded. Participants will be asked to stop for 10 seconds at the point where they show resistance. A total of three measurements will be taken and the highest value recorded. The areas where the electrodes will be placed will be prepared by shaving and cleaning with alcohol. The electrode placement will be made parallel to the muscle fibers. A rest period of at least 2 minutes will be allowed between measurements.
215075654|NCT03645694|DEVICE|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
214342901|NCT06536114|OTHER|CRISP: Criteria-Based Approach for the Rehabilitation for Non-Operative Shoulder Injuries|The CRISP group will undergo physical therapy treatment, directed by a research physical therapist, including both supervised physical therapy and a guided home exercise program. This approach has three phases: stabilization, to facilitate joint protection; strength and endurance, to optimize functional capacity; and power, to prepare the Service member for returning to previous level of duty.
214342902|NCT06536114|OTHER|Standard of Care|The Standard of Care group will serve as the control arm and complete a period of physical rehabilitation under the supervision of a Military Health System physical therapist without study-specific guidance or interventions.
214342903|NCT00006172|DEVICE|Bright light box|60-min light therapy shortly after awakening
214948853|NCT05281900|OTHER|Exercises|"Activation of the scapula and shoulder girdle muscles will be measured during variations of the plank exercise.~* In the tests, participants will be asked to stay in this position for 10 seconds after providing the standardized stance in the plank position. During the test, a video will be taken and incorrect attempts will be repeated.~* Determined plank variations will be done in mixed order. Each exercise will be repeated 3 times and the average of the repetitions will be recorded as the result. A 2 minute rest period will be given between exercises.~* After each exercise, the perceived effort level will be questioned with the BORG scale.~  4 assisted exercises:~ 1. Low plank~ 2. Low plank w/ isometric shoulder external rotation~ 3. High plank~ 4. High plank plus~ 5. Bear plank~  3 assisted exercises:~ 1. Low plank w/ front reach~ 2. High plank w/ shoulder taps~ 3. High plank w/ toe touch~  2 assisted exercises:~ 1. Low plank bird dog~ 2. High side plank"
214948854|NCT04310475|OTHER|Virtual reality assisted CBT|This study uses virtual reality technology to assist cognitive behavioural therapy for social difficulties in people with first episode psychosis.
214948855|NCT01848509|DEVICE|With teletransmission|Teletransmission of alerts
214948856|NCT01299415|DRUG|Vadimezan™|
215075655|NCT05424978|OTHER|Standardized green channel treatment methods for stroke|The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.
215075656|NCT05434871|OTHER|Yoga training|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
215075657|NCT05434871|OTHER|Physiotherapy|The standard physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
215075658|NCT02643563|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
215075659|NCT02643563|DRUG|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
215075660|NCT02643563|DRUG|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
215075661|NCT03119181|DRUG|Tymbion Lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution
215075662|NCT03119181|COMBINATION_PRODUCT|Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM
215075663|NCT04998539|OTHER|Wheelchair forward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
215075664|NCT04998539|OTHER|Wheelchair backward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
215075665|NCT04998539|OTHER|Upright technique|Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
215075666|NCT04998539|OTHER|Wheelie technique|Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
215075667|NCT04998539|OTHER|Wheelchair occupant upright body position|The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
214948857|NCT00797407|DIETARY_SUPPLEMENT|Creatine|Creatine 5 gm orally twice a day for 5 days, followed by 5 gm once a day
214948858|NCT00957905|DRUG|Alvocidib Hydrochloride|Given IV
214342904|NCT00006172|DEVICE|High-output negative ion generator|60-min high-density ion exposure shortly after awakening
214342905|NCT00006172|DEVICE|Low-output negative ion generator|60-min low-density ion exposure shortly after awakening
214342906|NCT05983601|DEVICE|Transcranial Direct Current Stimulation|The anode electrode will be placed at the midline of the Cz according to international 10-20 EEG system, and the cathode electrode will be placed at the midline of forehead. In this way, both hemisphere of motor cortex can be stimulated which is used as protocol in various balance studies (Siedel-Marzi and Ragert, 2020b; Saruco et al., 2017). Participants will continue their training with tDCS (2mA) for 20 minutes. This application will continue three times a week for four weeks. In the end of the study, participants will be asked to guess which group they were in (active or sham).
214342907|NCT01745861|DIETARY_SUPPLEMENT|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
214342908|NCT01745861|DIETARY_SUPPLEMENT|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
214342909|NCT04831736|DRUG|Ketamine|Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
214948859|NCT00957905|DRUG|Fluorouracil|Given IV
214486474|NCT06855849|DRUG|Amivantamab + FOLFIRI|"The dosage of amivantamab will be based on the participant's body weight during screening. Participants will receive 1,050 mg if BW is \<80 kg or 1,400 mg if BW is ≥80 kg.~* Cycle 1: once weekly (with the first dose split over Day -2 \[350 mg, IVF for 4-6hrs\] and Day -1 \[remainder of the dose, IVF for 6-8hrs\]; subsequent dose \[planned dose IVF over 2 hrs\]).~* Cycles 2+: Days 1 and 15 of each cycle (planned dose IVF over 2 hrs) On days when both amivantamab and chemotherapy are administered, amivantamab should be administered before chemotherapy. In general, leucovorin 400 mg/m2 IV over 2 hours and irinotecan 180 mg/m2 IV over 90 min, then 5-FU 400 mg/m2 IV bolus followed by 5-FU continuous infusion 2,400 mg/m2 over approximately 46-48 hours or 1,200 mg/m2/day for two days. Irinotecan and leucovorin may be administered concurrently (via separate infusion lines) or sequentially according to the institutional standard."
214948860|NCT00957905|DRUG|Leucovorin Calcium|Given IV
214948861|NCT00957905|DRUG|Oxaliplatin|Given IV
214948862|NCT03278405|DRUG|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
214948863|NCT05469022|DRUG|Neoadjuvant lazertinib|Lazertinib 240mg p.o once daily.
214948864|NCT00667797|DRUG|levalbuterol HCl|Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.
214948865|NCT00667797|DRUG|albuterol Sulfate|Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
214948866|NCT02073656|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214948867|NCT02073656|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214948868|NCT00755885|DRUG|abiraterone acetate|
214948869|NCT00755885|OTHER|laboratory biomarker analysis|
214948870|NCT00755885|OTHER|pharmacogenomic studies|
214948871|NCT01938989|DEVICE|Clear clip-on glasses|Clip-on glasses with no light filtering properties
214948872|NCT01938989|DEVICE|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
214948873|NCT03059251|BIOLOGICAL|Obinutuzumab|Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
215075668|NCT01025076|DEVICE|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
214342910|NCT04831736|DRUG|Placebo|Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
214342911|NCT06534866|OTHER|Traditional Physical Therapy|"1. TENS+cold pack (For 10 mins on plantar ascpect of foot)~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch"
214678306|NCT04897412|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
214948874|NCT05245045|PROCEDURE|Shengtaibufen Photodynamic Therapy(STBF-PDT)|Shengtaibufen Photodynamic Therapy(STBF-PDT)
214948875|NCT05245045|PROCEDURE|Red light|Red light
214948876|NCT03592498|DRUG|Sulfadiazine, Silver|Application of silver sulfadiazine ointment, bandage covered with gauze and bandage.
214948877|NCT03592498|DEVICE|Skin of Nile tilapia|Application of skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
214948878|NCT02638051|DEVICE|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
214948879|NCT02638051|DIETARY_SUPPLEMENT|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
214948880|NCT02638051|DRUG|IPCI (CDDP+5FU)|Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
214948881|NCT06444828|PROCEDURE|Non-operative|Non-operative treatment versus operative treatment (surgery)
214948882|NCT03953157|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary intervention
214948883|NCT03953157|BEHAVIORAL|Exercise Intervention|Receive exercise intervention
214948884|NCT03953157|OTHER|Questionnaire Administration|Ancillary studies
214948885|NCT05226234|DEVICE|MRI|Late gadolinium enhancement cardiac magnetic resonance (LGE-MRI)
214948886|NCT06731517|PROCEDURE|intubation|Double-Lumen Tube Intubation
214948887|NCT01207115|DRUG|ABT-652|ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
214948888|NCT01207115|DRUG|Placebo|Placebo capsules - twice daily for 8 weeks
214948889|NCT01207115|DRUG|Naproxen|Naproxen capsules - twice daily for 8 weeks
214948890|NCT04172428|DIAGNOSTIC_TEST|Functional MRI (fMRI)|fMRI will be done on 3 separate MRI scanners to compare.
214948891|NCT03218228|PROCEDURE|implants in periodontitis|it targets immediate implant placement in patients suffering from aggressive periodontitis
214678307|NCT04897412|OTHER|Placebo|Sodium Chloride (0.9% NaCl) placebo for injection
215075669|NCT01364558|DRUG|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
215075670|NCT01364558|DRUG|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
215075671|NCT00266214|DRUG|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
215075672|NCT02789943|PROCEDURE|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
215075673|NCT04876066|DRUG|Ketamine|Weight-based ketamine dose will be prepared and delivered personally to study physician or study personnel by pharmacy personnel as is done during standard protocol for use of ketamine not part of a clinical study.
214948892|NCT03926468|DIAGNOSTIC_TEST|Liquid biopsy|Before onset of treatment, cell-free DNA (cfDNA) is extracted from venous blood sample for next-generation DNA sequencing (NGS) using a commercially available platform (Roche Foundation ACT) For this purpose, 4 x 10 ml of venous blood will be collected from each patient. Two tubes (Streck) will be sent to service provider (Roche), one tube will be used for droplet digital polymerase chain reaction (ddPCR, QX200 Droplet Digital PCR System, BioRad) and ddPRC/NGS analyses and one is collected and stored in Auria Biobank (www.auria.fi) for possible future analyses.
214948893|NCT04875689|OTHER|Group A (Experimental|"Laser therapy is performed on patients in supine lying position. Treatments will be delivered with a diode laser (wavelength 830 nm, continuous wave, power 50 mW) in skin contact at a dose of 6 J/point. Treatment times per point are in the range of 30 seconds to 1 minute. eight points were irradiated per session.~Conventional therapy will include:~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching. Strengthening exercises ,straight leg raising exercise in crook lying position~* Joint mobilizations"
214342912|NCT06534866|OTHER|Kinesiotaping|In the first step, after the metatarsophalangeal joints is dorsiflexed, the first strap will be adhered firmly to the posterior heel at its proximal end. The other end of the strap is cut into four slices of equal width. Each slice is applied with a 50% stretch (50% tensile strain) and attached to the plantar forefoot. In the second step, another strap is applied with gentle compression across the bases of the four slices beneath the foot and wrapped around the rearfoot
214342913|NCT05298085|DRUG|Oxytocin nasal spray|Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study
214342914|NCT05298085|DRUG|Placebo|Study treatment will be administered intranasally daily for 12 weeks.
214948894|NCT04875689|DIAGNOSTIC_TEST|Group B (Control)|"1\. Participants of this group will receive only conventional therapy which will include;~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching.Each stretch was sustained for 30 seconds, with 10-second rest intervals.~* Strengthening exercises include quadricep drills(full knee extension maintained for 5 seconds, followed by a 5-second rest) 20 repetitions per session,straight leg raising exercise in crook lying position(the patients were asked to tense the quadriceps muscle, elevate the limb to 45° and maintain it for 6 seconds, and lower the limb slowly and then relax for 6 seconds; the exercise was performed for three sets of 10 repetitions per session).~* Joint mobilizations (tibiofemoral extension and flexion; patellofemoral medial-lateral and inferior glide)."
214948895|NCT02801526|DRUG|CKD-330 16/5mg - A|
214948896|NCT02801526|DRUG|Candesartan 16mg and Amlodipine 5mg|
214948897|NCT04292639|DEVICE|The Vital Detect Pulse Oximeter|The Vital Detect is a noninvasive device designed for spot-checking physiological parameters, such as Noninvasive Blood Pressure, Oxygen Saturation, Pulse Rate, Body Temperature, and Respiratory Rate. This device is a finger-cuff technology which is applicable for use at-home or in healthcare facilities in/on individuals 18 years of age and older. It may be used by the individual themselves or an operator. The Vital Detect is not intended for continuous monitoring or for use with high frequency surgical equipment. It is non transit-operable. The Vital USA Vital Detect is composed of a sensor head mounted on a base connected to a phone or computer via Vital Detect App which is free to download.
214948898|NCT00082459|BIOLOGICAL|autologous human tumor-derived HSPPC-96|
214948899|NCT04736732|OTHER|Medical follow-up|Patients will be followed for medical evaluation and for biobanking of data and biological samples.
215075674|NCT03144193|OTHER|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
215075675|NCT05046990|DIAGNOSTIC_TEST|Regular Arrangement of Collecting Venules|This is a prospective, multicentre, international study without a control group.
215075676|NCT05809544|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
215075677|NCT05809544|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
214342915|NCT04475601|DRUG|Enzalutamide Pill|The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
214342916|NCT01690650|DRUG|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
214342917|NCT03043183|PROCEDURE|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
214342918|NCT00005633|BIOLOGICAL|OVA BiP peptide|
214342919|NCT00005633|BIOLOGICAL|gp209-2M antigen|
214678308|NCT05927246|DIAGNOSTIC_TEST|ECG|12 lead ecg for each participant
214678309|NCT01912872|DRUG|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
214678310|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
214342920|NCT00005633|BIOLOGICAL|recombinant 70-kD heat-shock protein|
214342921|NCT00005633|BIOLOGICAL|tyrosinase peptide|
214342922|NCT05260710|BEHAVIORAL|Telemedicine Intervention|"Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~\+~Continuing education activities: video classes and discussions of complex cases."
214948900|NCT05892549|DEVICE|COVOICE application use - initial|Recording (only once) of sound related to respiratory movements, coughing and voice using a mobile phone application
214948901|NCT05892549|DEVICE|COVOICE application use - follow-up|Daily recording of sound related to respiratory movements, coughing and voice using a mobile phone application. Duration: up to 30 days
214948902|NCT06366698|DRUG|Venofer 200 MG Per 10 ML Injection|200 mg IV every 2 days until the targeted dose
214948903|NCT06366698|DRUG|Ferrous sulfate|Take 1 tablet every other day with lemon/orange juice
214948904|NCT05508945|DEVICE|Dermabond Prineo Skin Closure System|synthetic mesh patch is positioned and lightly pressed over 50% of the surgical incision. 2-octyl cyanoacrylate liquid adhesive is evenly applied over the mesh and allowed to dry
214948905|NCT05508945|DEVICE|silk|SERI surgical scaffold with dermaFLEX backing is positioned over the remaining 50% of the surgical incision
214948906|NCT05508945|DEVICE|3M Steri-Strip|non-woven rayon with adhesive backing is applied to 50% of the surgical incision.
214948907|NCT01048099|PROCEDURE|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
214948908|NCT01048099|DRUG|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
215075678|NCT04557514|PROCEDURE|platelet rich plasma injection in post burn facial scar|"2 spins\>\>\>~1. st spin (separate plasma from blood) 2500 for 10 minutes~2. nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy"
215075679|NCT04557514|PROCEDURE|fat injection in post burn facial scar|Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
214342923|NCT03450031|OTHER|NAC (no drug/no device)|Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
214342924|NCT00000218|DRUG|Carbamazepine|
214948909|NCT01048099|DRUG|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
214948910|NCT00508157|DRUG|Aripiprazole|Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
214948911|NCT00508157|DRUG|Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)|Tablets, Oral, According to summary of product characteristics (SmPC)
214948912|NCT04606875|DIAGNOSTIC_TEST|Campbell Score|The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.
214342925|NCT00406575|DRUG|Placebo|Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
214342926|NCT00406575|DRUG|Recombinant human relaxin (rhRlx)|Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
214342927|NCT06534476|OTHER|Education|"Patients who agreed to participate in the study and met the inclusion criteria were interviewed face to face before the HD session and their verbal and written permissions were obtained by reading the voluntary consent form. The researcher interviewed the patients one-on-one and provided information about the purpose of the study and the training program. Then, scale forms were applied to the patients. In order not to interrupt the training and not to distract the patients in this group, a separate room in the Dialysis Unit was used during the training. The education booklet Living with Hemodialysis on hemodialysis management prepared in line with the literature was given to the patients by the researcher. The training of a patient lasted an average of 40-50 minutes. During and at the end of the training, the patients' questions were answered in the training room."
214342928|NCT05575947|DEVICE|da Vinci Surgical System|da Vinci Surgical System
214342929|NCT05575947|PROCEDURE|laparoscopic bariatric surgery|laparoscopic bariatric surgery
214342930|NCT03398538|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
214342931|NCT03398538|OTHER|Additional (outer) Dressing Application|Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
214342932|NCT03398538|OTHER|Mirragen Wound Matrix Dressing|Application of Mirragen to wound site along with standard of care treatment
214678311|NCT01912872|DRUG|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
214948913|NCT02300142|BIOLOGICAL|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
215075680|NCT01841125|DRUG|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
215075681|NCT01841125|DRUG|Placebo|placebo 15mg, QD(once a day), Oral medication
214948914|NCT02300142|BIOLOGICAL|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
214948915|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
214948916|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
214948917|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
214948918|NCT06266520|PROCEDURE|MNK therapy to release the superficial fascia|The patient, positioned supine and wearing shorts for full lower limb exposure, undergoes layered palpation by the practitioner at the procedure points, identifying tender nodules and swelling in superficial fascia and muscles, followed by disinfection with an iodophor cotton swab. The practitioner, donning sterile latex gloves, holds the micro-needle-knife between the thumb and index finger of the right hand, inserting it parallel to the body's longitudinal axis, while the left thumb presses and holds the cord-like nodules for parallel incisions, with a maximum insertion depth of 5mm, performing lifting and cutting motions. Depending on the nodule size, 1-3 incisions are made. Post-procedure, any bruising or tissue fluid is expelled by massaging from distal to proximal around the incision. The area is then compressed with dry sterile gauze until bleeding ceases. Treatments are administered every other day, totaling six sessions.
214948919|NCT06266520|PROCEDURE|acupuncture|Acupuncture treatment employing needles produced by Suzhou Medical Supplies Factory Co., Ltd., with specifications of 0.30mm\*40mm and conforming to standard GB2024-1994. Patients, positioned prone or laterally with exposed lower limbs below the knee, are disinfected with an iodophor cotton swab. Acupuncture points selected include GB34, GB39, BL60, BL40, ST41, KI9, and KI6. The practitioner applies pressure to the points with the left hand and swiftly inserts the needle with the right, using a 0.30mm\*40mm disposable sterile acupuncture needle, penetrating the skin about 0.5-0.8 inches. After achieving deqi, the needle is twisted and thrust several times, left in place for 30 minutes. Upon removal, the needle site is compressed with a dry cotton swab until bleeding stops. Treatments occur every other day, totaling six sessions
215075682|NCT01727648|BEHAVIORAL|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
214948920|NCT06811389|BEHAVIORAL|Re-imagining Interventions for Support and Education in Hypersensitivity Pneumonitis (RISE-HP)|"The RISE-HP intervention consists of three components: peer support (peer coach), cognitive restructuring, and patient education. It consists of 10 weekly one-on-one meetings with a peer coach (a person with lived experience with HP who has been trained to deliver the content of the RISE-HP intervention to another person with HP).~The RISE-HP intervention delivered by peer coaches using the principles of cognitive behavioral therapy combined with theory driven patient education targets the health-related quality of life of patients living with hypersensitivity pneumonitis."
214948921|NCT06811389|BEHAVIORAL|Staying Well|The Staying Well intervention consists of 12 weeks of educational sessions. The participants can choose the 10 education sessions out of the 12 they want to cover with the research assistant. Participants will meet weekly with the research coordinator for an estimated 30-45 minutes per session.
214342933|NCT03398538|OTHER|Fibracol Wound Dressing|Application of Fibracol Alginate along with standard of care treatment
215075683|NCT01727648|BEHAVIORAL|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
215075684|NCT01727648|BEHAVIORAL|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
215075685|NCT01727648|BEHAVIORAL|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
215075686|NCT02604654|DRUG|Yiqitongluo granule|administered after dissolved
215075687|NCT06205355|DEVICE|Analgesia/Nociception Index (ANI) monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to ANI monitor.
215075688|NCT06205355|DEVICE|Standard monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to the clinician's decision
214342934|NCT02167633|PROCEDURE|Decompression surgery|Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
214342935|NCT02167633|RADIATION|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
214948922|NCT06977230|PROCEDURE|Remote Ischemic Preconditioning|Remote ischemic preconditioning (RIPC) will be performed after anesthesia induction and before surgical incision. A standard blood pressure cuff will be placed on the upper limb (without arterial cannulation), inflated to 200 mmHg for 5 minutes, and then deflated for 5 minutes. This cycle will be repeated five times prior to sternotomy. The procedure will be carried out under general anesthesia, ensuring patient blinding. No pharmacological agents are involved in this intervention
214948923|NCT05345444|DEVICE|IRE & MRgRT|Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
214948924|NCT05981755|OTHER|Breathing tasks|Breathing tasks include normal breathing through nose or mouth, breathing while resting wakefully, increase and decrease in breathing rate, and breath counting.
214948925|NCT05981755|DEVICE|Brain mapping with stimulation|Electrical stimulation will be used to find specific areas of the brain involved in breathing function. Stimulation will be applied using a Nihon Kohden MEE-1000A neural function measuring system with the MS-120BK extension unit for brain stimulation.
214948926|NCT05538091|DRUG|Vismodegib|A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
214948927|NCT05538091|DRUG|Atezolizumab|Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
214948928|NCT01982838|PROCEDURE|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
214948929|NCT01982838|PROCEDURE|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
214948930|NCT03452241|OTHER|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
214948931|NCT03452241|OTHER|Control Group|The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
214948932|NCT03274362|BEHAVIORAL|Headspace Mindfulness App|Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
214948933|NCT02295761|BEHAVIORAL|Lifestyle counseling (Fb)|Facebook-delivered lifestyle counseling
214948934|NCT02295761|BEHAVIORAL|Lifestyle counseling + activity monitor (Fb+Act)|Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
214948935|NCT03148717|DRUG|Misoprostol|Cytotec
214948936|NCT03148717|OTHER|Placebo|Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
214948937|NCT06731790|OTHER|Blood sampling for inflammatory phenotype analysis|Blood sampling for basal and post-stimulation inflammatory phenotype analysis
214948938|NCT06731790|GENETIC|Blood sampling for genetic analysis|Collection of a blood tube for whole exome sequencing of the RANBP2 gene and analysis of the presence of the mutation by RTqPCR.
214948939|NCT02567864|OTHER|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
214948940|NCT02567864|OTHER|control|participants maintain their daily activities.
214948941|NCT01786538|DRUG|Regorafenib/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
214948942|NCT01786538|DRUG|Placebo/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
214948943|NCT05191368|OTHER|No intervention|No intervention
214948944|NCT05324280|PROCEDURE|Acupuncture|Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture.
214948945|NCT03704116|BEHAVIORAL|Expedition|On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.
214948946|NCT00004358|DRUG|calcitonin|
214948947|NCT04656366|DIAGNOSTIC_TEST|Coronary Angiography|Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)
215075689|NCT04002284|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
215075690|NCT03087942|DRUG|QAW039|450 mg
215075691|NCT03087942|DRUG|QAW39A|450 mg
215075692|NCT03087942|DRUG|QAW39A2107|450 mg
214948948|NCT04719195|OTHER|Meniscus extrusion ultrasonogrphic evaluation|This study will enroll the patients with knee medial compartment osteoarthritis of the knee joint who undergo open proximal tibial osteotomy. The degree of medial and lateral meniscus extrusion will be measured through ultrasound measurements before and after surgery. Also, demographic factors and radiographic measurements will be also investigated before and after surgery. In addition, preoperative, postoperative 3, 6, and 1 year clinical results including meniscus extrusion will be compared and judged, and the evaluation will be evaluated by an orthopedic surgeon who has not participated in the operation among registered researchers.
214948949|NCT00553293|DRUG|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
214948950|NCT00553293|DRUG|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
214948951|NCT05073861|BEHAVIORAL|STEM learning|"Classes will be randomly assigned to the experimental group and to the control group. As treatment, the experimental group will be assigned to an intervention that uses a STEM blended learning app with gamified videos for content knowledge along with hands-on experiments. The videos are fictitious educational narratives related to the content knowledge and students were asked to step into the shoes of the cartoon scientist (a chipmunk) to solve various problems during the stories. The science experiments will be completed with step-by-step video guidance on the app. The control group will be assigned to read the same content on an e-book and receive an arts-and-craft kit for each lesson that is unrelated to the content knowledge."
214948952|NCT04175431|PROCEDURE|Positron Emission Tomography|Undergo fluciclovine PET/CT
214948953|NCT04175431|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
214948954|NCT04175431|RADIATION|Radiation Therapy|Undergo radiation therapy
214948955|NCT04175431|DRUG|Abiraterone Acetate|Given PO
214948956|NCT04175431|DRUG|Prednisone|Given PO
214948957|NCT04175431|PROCEDURE|Computed Tomography|Undergo fluciclovine PET/CT
214948958|NCT04175431|DRUG|Abiraterone|Given PO
214342936|NCT02167633|RADIATION|Fractionated Radiotherapy|"Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.~Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume."
214342937|NCT02167633|DRUG|Glucocorticoids|All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
214342938|NCT02167633|DRUG|Pantoprazole|All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
214342939|NCT05734846|DEVICE|Control Lenses (control fitting approach)|Daily wear multifocal lenses for 1 week
214342940|NCT05734846|DEVICE|Test Lenses (test fitting approach)|Daily wear multifocal lenses for 1 week
214678312|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
214948959|NCT04175431|PROCEDURE|PSMA PET Scan|Undergo PSMA PET scan
214948960|NCT05825651|OTHER|no interventions|This is an observational study without any intervention.
214948961|NCT06365840|DRUG|IMC-001|All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.
214342941|NCT00668460|DRUG|Lactic acid (Dermacid)|
214342942|NCT03811067|PROCEDURE|Transversus abdominis plane block|Transversus abdominis plane block will be performed bilaterally after the surgery.
214342943|NCT03811067|PROCEDURE|Rectus sheath block|Rectus sheath block will be performed bilaterally after the surgery.
214342944|NCT01666002|DEVICE|Laser Treatment (Pulsed Nd:YAG 1064 nm Laser)|0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
214342945|NCT06178666|BIOLOGICAL|BCG|Three dose levels of intradermal BCG
214678313|NCT01912872|DRUG|Formoterol|Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
214678314|NCT00635531|OTHER|placebo|Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
214948962|NCT06135896|DRUG|Tripegfilgrastim|Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers
214342946|NCT03178357|OTHER|Cardiac rehabilitation + standard therapy|Patients with HCM subjected to cardiological rehabilitation
214342947|NCT03178357|OTHER|Standard therapy|Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
214342948|NCT00001112|DRUG|Zidovudine|
214342949|NCT00001112|DRUG|Interferon gamma-1b|
214342950|NCT00925158|PROCEDURE|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
214342951|NCT02706158|DIETARY_SUPPLEMENT|1500 mg Calcium and 1200 IU Vitamin D for 2 months|1500 mg Calcium and 1200 IU Vitamin D for 2 months
214342952|NCT02706158|BEHAVIORAL|balanced diet|participants will get a balanced diet according to pregnancy stage
214342953|NCT04121104|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
214342954|NCT04121104|OTHER|SCS is switched on|Spinal cord stimulator is on
214948963|NCT03871725|COMBINATION_PRODUCT|Sonodynamic therapy (SDT)|Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
214948964|NCT04164004|OTHER|Kansas City Cardiomyopathy Questionnaire-12|Health status assessment will be completed using the well-validated Kansas City Cardiomyopathy Questionnaire-12 prior to or at the time of heart failure clinic visits.
214948965|NCT02974205|PROCEDURE|Jack brace|Rehabilitation after acute isolated PCL rupture with orthosis
214948966|NCT02974205|DEVICE|Rehabilitation|Rehabilitation after acute isolated PCL rupture without orthosis
215075693|NCT03087942|DRUG|QAW39A2107|450 mg
214948967|NCT02974205|DEVICE|össur brace|Rehabilitation after acute isolated PCL rupture
214948968|NCT03053648|OTHER|Self-acupressure|The subjects will be told to perform self-acupressure 30 min before sleep for 20 min every night for 4 weeks. Telephone follow-up will be made twice a week by the trained student research assistant during the 4-week treatment period to remind subjects to practice self-acupressure.
214948969|NCT03053648|OTHER|Sleep hygiene education|A training hand-out will be provided to each subject. The hand-outs included manualized sleep hygiene instructions. A registered nurse who has been trained by a clinical psychologist will be the instructor on sleep hygiene and activity scheduling. To enhance interaction and ensure the quality of teaching, each course will be conducted in a group of 5 participants.
214948970|NCT00380666|PROCEDURE|PET/CT scan|
214948971|NCT01878734|DIETARY_SUPPLEMENT|Micronutrient Powders|Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
214948972|NCT01990872|DIETARY_SUPPLEMENT|Vitamin D3 (20 micrograms/day)|Vitamin D3 (20 micrograms/day)
214948973|NCT01990872|DIETARY_SUPPLEMENT|Placebo|Placebo (0 micrograms vitamin D3/day)
214948974|NCT03851978|BEHAVIORAL|Pharmacist Vaccine Education|When an eligible patient presents to the pharmacy for prescription pick up or drop off, the pop-up note will notify the technician to get a pharmacist for education. The pharmacist will educate the patient on the vaccine and then recommend that the patient receives the vaccine.
214948975|NCT06995690|DRUG|Ketamine|Patients receive crystalloid preloading of 15ml/kg (Ringer's lactate) +the sub-anesthetic dose of ketamine of 0.5 mg/kg IV added to the first bottle of ringer for blinding over 20 min before the spinal injection.
214948976|NCT06995690|DRUG|Normal Saline|Patients receive a crystalloid preloading of 15 ml/kg (Ringer's lactate)+ 0.5 mg/kg IV of Normal Saline added to the first bottle of ringer for blinding, over 20 min before the spinal injection.
214948977|NCT06995053|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214948978|NCT06995053|PROCEDURE|Computed Tomography|Undergo CT
214948979|NCT06995053|RADIATION|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT with intrafraction motion monitoring
214948980|NCT06995053|OTHER|Intrafraction Motion Monitoring|Undergo CT-guided SBRT with intrafraction motion monitoring
214948981|NCT06995053|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214948982|NCT06995053|OTHER|Questionnaire Administration|Ancillary studies
214342955|NCT02159482|DRUG|Interferon Alfa-2a|
214948983|NCT05724485|DRUG|Branched-chain Amino Acid|12.45 grams of BCAA orally per day before bedtime
214948984|NCT05724485|DRUG|Placebo|12.45 grams of Maltodextrin orally per day before bedtime
214948985|NCT00486707|BEHAVIORAL|Questionnaire|A questionnaire will be completed.
215075694|NCT04606589|DEVICE|neoGuard vital signs monitor|The neoGuardTM device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate, respiratory rate and blood oxygen saturation in newborns.
214342956|NCT00135954|DRUG|Cyclophosphamide and steroids|comparison of difference in time of start of therapy
214342957|NCT05639738|OTHER|Clinical and instrumental measurements|"* Clinical evaluations~* Non-invasive instrumental measurements~* Subject's evaluations"
214342958|NCT04485962|BIOLOGICAL|Fibroblasts and keratinocytes|"Autologous cultured fibroblasts and keratinocytes~For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
214342959|NCT01513304|PROCEDURE|Manual therapy|
214948986|NCT02905643|OTHER|Study subjects|This study does not include an intervention it is only observational.
214948987|NCT06228872|DEVICE|Cognitive Computerized Training (CCT) plus Anodic transcranial Direct Current Stimulation (tDCS)|Computerized Cognitive Training (15 min) + Anodal tDCS over DLPFC (20 min) daily for 1 month
214948988|NCT06228872|DEVICE|Cognitive Computerized Training (CCT) plus sham transcranial Direct Current Stimulation (tDCS)|Computerized Cognitive Training (15 min) + Sham tDCS over DLPFC (20 min) daily for 1 month
214948989|NCT05573529|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
214948990|NCT05573529|DEVICE|intraocular lens implantation|intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
214948991|NCT01565798|OTHER|Copper-alloy surfaced patient care objects|Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
214948992|NCT04744259|BEHAVIORAL|Behavioural Activation|A psychological intervention which aims to increase activity and reduce depressive symptoms.
214948993|NCT05158686|DEVICE|Paclitaxel-coated Balloon dilation angioplasty|Paclitaxel-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
214948994|NCT05158686|DEVICE|Non-coated Balloon dilation angioplasty|Non-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
214948995|NCT05519072|DRUG|Nitrofurantoin|For those randomized to the treatment arm, antibiotics will be prescribed at the discretion of the ordering physician. They will be prescribed only in oral form and in accordance with the patient's allergy profile.
214948996|NCT07019350|OTHER|Upfront DCB-based hybrid strategy|In upfront DCB-based hybrid strategy group, stepwise provisional strategy with side branch DCB angioplasty will be performed according to the follow standardized procedural steps. In this group, provisional stenting strategy will be performed in accordance with the European Bifurcation Club (EBC) consensus. Bail-out stenting will be performed using operator's preferred technique (e.g. T, TAP, culotte) when there will be one of the following after hybrid strategy: \<TIMI 3 flow in the side branch, severe (\>90%) ostial pinching, or flow-limiting dissection.
215075695|NCT03600766|DRUG|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks.
215075696|NCT03600766|DRUG|placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
215075697|NCT02100020|OTHER|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
215075698|NCT00412347|DRUG|Insulin Drip Therapy|
215075699|NCT04193345|OTHER|Documentation of Maternal blood loss and neonatal outcome|Comparing and monitoring the maternal blood loss and neonatal effect of delayed umbilical cord clamping and early umbilical cord clamping after delivery of the baby durin cesarean delivery in severe preeclampsia
214948997|NCT07019350|OTHER|Upfront 2-stenting strategy|In upfront 2-stenting strategy group, systematic planned 2-stenting will be performed according to EBC recommendations. The stent technique will be at the discretion of the operator but could be one of culotte, DK-culotte, mini-crush, DK-crush, T or TAP.
214948998|NCT07026006|OTHER|Active Release Technique|Patients will receive Active Release Technique (ART) protocol will be applied to 4 muscles Including; trapezius, levator scapulae, sternocleidomastoid (SCM), and suboccipital muscles (for 15 minutes)
214948999|NCT07026006|OTHER|Strain-counterstrain|Patients will receive Strain-counterstrain (SCS) protocol will be applied to 4 muscles Including the trapezius, levator scapulae, sternocleidomastoid (SCM), and suboccipital muscles for 15 minutes.
214949000|NCT07025941|OTHER|Standard Critical Care Nursing Protocol|"The Standard Critical Care Nursing Protocol encompasses evidence-based, routine nursing practices for critically ill patients in the intensive care unit (ICU). This protocol serves as the control intervention in comparative studies evaluating novel nursing strategies.~Key Components:~Basic Physiological Monitoring:~Continuous assessment of vital signs (heart rate, blood pressure, respiratory rate, SpO₂).~Strict intake/output monitoring and electrolyte balance management.~Airway Management:~Standard oxygen therapy (nasal cannula, face mask) or mechanical ventilation as prescribed.~Scheduled suctioning, positional changes, and oral care (every 4-6 hours).~Infection Prevention:~Aseptic techniques for invasive procedures (e.g., central line care, urinary catheter management).~Ventilator-associated pneumonia (VAP) bundle compliance (e.g., head-of-bed elevation, sedation vacations).~Mobility \& Skin Integrity:~Passive range-of-motion exercises for immobilized patients (2×/day).~Pr"
214949001|NCT07025941|BEHAVIORAL|ICU-PRO Nursing Protocol (Integrated Critical Care Protocol for Rehabilitation Outcomes)|"The intervention group received a standardized 14-day nursing protocol combining three evidence-based components:~Comprehensive Rehabilitation Nursing:~Early mobilization protocol with passive/active exercises (3-4 sessions/day)~Respiratory training using incentive spirometry (Triflo II® devices)~Swallowing rehabilitation with VitalStim® electrical stimulation~Refined Airway Management:~Humidification via Fisher \& Paykel® MR850 systems (33-44 mg/L)~Closed suction systems (Ballard® Trach Care) with strict aseptic technique~Oral care with 0.12% chlorhexidine solution (Peridex®) 4×/day~Nutritional Support:~Enteral feeding using Abbott Nutrition® formulas~Parenteral nutrition via Baxter®/Fresenius Kabi® solutions~Gastric residual monitoring with Kangaroo™ feeding pumps~Key Features:~Implemented by specialized ICU nurses, respiratory therapists, and dietitians~Daily monitoring using Philips® IntelliVue patient monitors~Protocol adjustments based on weekly APACHE II scoring"
214949002|NCT07025928|BEHAVIORAL|Decreased Salt High Potassium Tool (DSHP Tool)|Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) .
214949003|NCT07026019|OTHER|Bruegger's relief exercise|Participant will be in a high sitting position. An elastic resistance band will be wrapped on each hand of the participant leaving the palm open and will be told to abduct and extend of thumb along with fingers, followed by wrist extension and forearm supination, the participant will be instructed to perform scapular retraction with shoulder external rotation, elbow extension, shoulder abduction, and extension and chin tuck. The treatment protocol will be for 4 weeks, having 3 sessions in a week and 4 sets of 12 repetitions in each session. Intervention was started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time was 30 seconds.
214949004|NCT07026019|OTHER|Multimodal exercise program|Multimodal exercise program including chin tucks, bilateral pectoral stretching, scapular region strengthening exercises and Wand exercises. The training program applied 3 times a week, 50 minutes each time, for 4 weeks
214949005|NCT07026877|DEVICE|Fenestrated TREO Stent Graft System|"The Fenestrated TREO Stent-Graft System is a modular, endoluminal, over-the-wire system intended for the endovascular treatment of juxtarenal and pararenal to paravisceral aneurysms requiring a fenestrated stent-graft and having suitable morphology. The system is composed of the following components:~Fenestrated TREO Bifurcate Stent-Graft - The main body fenestrated bifurcate provides the following; proximal seal, fenestrations and gates for connection to the leg extensions.~Bridging Stents - The bridging stent connects the main body bifurcated device to the target visceral artery allowing the target anatomy to maintain perfusion while keeping the pathology sealed~TREO Leg and Straight Extension Stent-Grafts: The Leg Extension and Straight Extension stent-grafts are used to complete coverage of the pathology from the main body bifurcated device to the distal landing zones (usually the common iliac artery just proximal to the iliac bifurcation)."
215075700|NCT03103204|COMBINATION_PRODUCT|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants."
215075701|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
215075702|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|250 mg weekly x 4
215075703|NCT00223977|DRUG|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
215075704|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
215075705|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
215075706|NCT05859373|COMBINATION_PRODUCT|TQB2450 injection, sequential or concurrent chemoradiation|TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
214342960|NCT05524194|DRUG|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
214949006|NCT07026188|OTHER|Ultrasound with SMI|The use of ultrasound allows observation of new bone formation in the distraction gap, also visualize the formation of blood vessels in the distraction gap with SMI, including the velocity and resistance of blood vessels, and can also indicate the environment of new bone formation. All US examination were performed by one US doctor.
214949007|NCT07025876|BIOLOGICAL|low dose PCV24|"The 24-valent pneumococcal polysaccharide conjugate vaccine (low-dose) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~* 3 serotypes (3, 6B, 12F): 4.0 μg per vial each~* 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 2.0 μg per vial each After conjugation with carrier proteins, the polysaccharides of each serotype are adsorbed onto an aluminum phosphate adjuvant (aluminum content: 0.25 mg per dose)."
214949008|NCT07025876|BIOLOGICAL|high dose PCV24|"The 24-valent pneumococcal polysaccharide conjugate vaccine (high-dose) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~3 serotypes (3, 6B, 12F): 8.0 μg per vial each 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 4.0 μg per vial each After conjugation with carrier proteins, the polysaccharides of each serotype are adsorbed onto an aluminum phosphate adjuvant (aluminum content: 0.25 mg per dose)."
214949009|NCT07025876|BIOLOGICAL|PPV23|"The 23-valent pneumococcal polysaccharide vaccine (PPV23) produced by Chengdu Institute of Biological Products is available in vials of 0.5 ml, with a dosage of 0.5 ml per person per administration. It contains the following pneumococcal polysaccharides for each serotype:~Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F: 25 μg per vial for each serotype.~Additionally, it contains sodium chloride and water for injection."
214949010|NCT07025876|BIOLOGICAL|Placebo|"In addition to the antigen components, the 24-valent pneumococcal polysaccharide conjugate vaccine developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. contains the following excipients:~Aluminum phosphate adjuvant (aluminum content: 0.25 mg per dose) Sodium chloride Succinic acid Polysorbate 80 Water for injection It is a liquid formulation, available in vials of 0.5 ml, with a dosage of 0.5 ml per person per administration."
214949011|NCT01625689|BIOLOGICAL|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
214949012|NCT01625689|BIOLOGICAL|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
214949013|NCT01162720|PROCEDURE|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
215075707|NCT00764257|DEVICE|PREVELLE Shape|
215075708|NCT00764257|DEVICE|Restylane|
214342961|NCT03221582|DRUG|EBR/GZR|Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
214342962|NCT01140035|OTHER|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
214342963|NCT05354050|DRUG|DARE-BV1|2% Clindamycin 100 MG
214342964|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
214342965|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound only|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
214486475|NCT06627790|DRUG|Mouthwash preparation|Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval
215075709|NCT03136497|DRUG|400mg ABT-199|Oral dose daily until disease progression
215075710|NCT03136497|DRUG|Ibrutinib|Oral dose daily until disease progression
215075711|NCT03136497|DRUG|Rituximab|Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
214486476|NCT06868979|OTHER|Clinical assessment|Clinical examination including Medical history, developmental trajectory, epilepsy history, ASD symptoms, clinical examination at the inclusion visit by a neuropediatrist
214486477|NCT06868979|OTHER|Parental questionnaires|Parental questionnaires including Vineland-2, ABC, CBCL, PPD-MRS, SRS-2 and BRIEF completed at the inclusion visit
215075712|NCT03136497|DRUG|800mg ABT-199|Oral dose daily until disease progression
214486478|NCT06868979|OTHER|Cognitive assessment|Cognitive assessment including Leiter-3, PPVT 5, EVT 3 completed at the inclusion visit
215075713|NCT00410826|DRUG|erlotinib hydrochloride|Given orally
215075714|NCT00410826|DRUG|cisplatin|Given IV
215075715|NCT00410826|RADIATION|3-dimensional conformal radiation therapy|35 fractions
215075716|NCT00410826|RADIATION|intensity-modulated radiation therapy|35 fractions
214949014|NCT01162720|PROCEDURE|Short duration tourniquet|Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
214949015|NCT02927496|DRUG|Doxycycline|"Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)"
214949016|NCT02927496|DRUG|Placebo|Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
214949017|NCT03218267|OTHER|Static Posturography|The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.
214949018|NCT03218267|OTHER|One-leg standing test (OLS)|During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).
214949019|NCT01807416|PROCEDURE|implant insertion and abutment connection|After implant insertion (standard platform or switching platform) the titanium abutment (standard or flat) will be connected
214949020|NCT03657940|BEHAVIORAL|VIVIFRAIL multicomponent exercise training program|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using dumbbells aiming for 2-3 sets of 10-15 repetitions at an intensity of 30-50% of 1Repetition Maximum ( combined with balance-training, flexibility and gait exercises that progressed in difficulty.
214949021|NCT00106834|DRUG|Infliximab|
214949022|NCT00157716|DRUG|(MC-1) Pyridoxal-5'-phosphate|
214486479|NCT06868979|OTHER|Reasoning assessment|Simple reasoning tasks on tablets performed at the inclusion visit.
215075717|NCT00410826|PROCEDURE|quality-of-life assessment|Ancillary studies
215075718|NCT01299857|DRUG|Rituximab|375mg/m2
215075719|NCT00839462|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
215075720|NCT00839462|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
215075721|NCT04314999|DIAGNOSTIC_TEST|Examination of stool samples|Tests for diagnosis of parasitic diseases
215075722|NCT05459649|DRUG|Cyclosporine Oral Product|A combination of cyclosporin with standard steroid in newly diagnosed ITP patients: cyclosporin was started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. The therapeutic serum level of cyclosporin was 75 to 150 ug/L. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count; standard steroid regimen included orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
215075723|NCT05459649|DRUG|Prednisone|Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
215075724|NCT00557310|DRUG|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
215075725|NCT06334081|PROCEDURE|undersized drilling technique|In group A The implant site preparation was made according to the protocol of the manufacturer except that the final drill was omitted. The drilling was done using a low speed reduction, high torque with coolant contra-angle hand piece with surgical motor unit. Speed of drilling was 800-1200 rpm.
214486480|NCT06868979|DEVICE|fNIRS assessement|Imaging session using fNIRS (NIRSport 8x8, NIRx Medical Technologies LLC, Berlin, Germany) performed at the inclusion visit.
214486481|NCT06787976|DRUG|Dolutegravir (DTG)|Dolutegravir + Tenofovir Disoproxil Fumarate / Emtricitabine
214949023|NCT02192853|DRUG|sitagliptin|"In randomized order:~Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion"
215075726|NCT06334081|PROCEDURE|single drilling technique|In group B The implant bed was prepared using the new specially designed drills. First, the use of the guide drill of length 3.5mm with speed of 800 rpm and torque of 35 nm, then the use of the one drill of the same diameter of the selected implant size to the full length of the osteotomy site.
214486482|NCT06787976|DRUG|Darunavir/Cobicistat (FDC)|Darunavir Cobicistat + TDF/FTC
214949024|NCT02192853|DRUG|Placebo|Day 4: placebo tablet
214949025|NCT03089853|DEVICE|Neuromuscular electrical stimulation (NMES)|Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
214949026|NCT04857853|OTHER|Exercise Without Rest Break|"Participants in the exercise group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Exercises include shoulder shrugs, neck tilts, wrist and forearm stretch, back and hip stretch, upper body stretch, hamstring stretch, upper back stretch, hand/finger stretch. Side stretch and neck stretch.~Follow up 3 times a week for 5 weeks."
214949027|NCT04857853|OTHER|Exercise With Rest Break|"Participants in the exercise with rest break group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Participants will also receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation Follow up 3 times a week for 5 weeks."
214949028|NCT04857853|OTHER|Rest Break|"Participants in the rest breaks group will receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours.~Follow up 3 times a week for 5 weeks. During the rest breaks, participants will not perform any exercises."
214949029|NCT01742754|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
214949030|NCT00025753|DRUG|rosiglitazone (Avandia)|
214949031|NCT00025753|BEHAVIORAL|Aerobic and weight lifting exercise training|
214949032|NCT05436353|OTHER|Turkish validity and reliability|Contact with developers and formation of steering committee Translation from English to Turkish Back translation from Turkish to English Comparison of translation Review of translated versions. Reaching consensus and development of pilot version Testing in clinical setting Revision of pilot version Testing of final version
214949033|NCT02419651|DRUG|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
214949034|NCT02419651|DRUG|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
214949035|NCT02419651|DRUG|Placebo|Women will receive a placebo 1 hour before the procedure
214949036|NCT02142205|BIOLOGICAL|BG00002|IV Infusion
214949037|NCT01957839|DRUG|cabergoline treatment|cabergoline treatment for hyperprolactinemia group
214949038|NCT01307384|DEVICE|Continuum Metal on Polyethylene Acetabular System|Used in primary hip arthroplasty
214949039|NCT00006087|PROCEDURE|annual screening|
214949040|NCT00006087|PROCEDURE|bronchoscopic and lung imaging studies|
214949041|NCT00006087|PROCEDURE|comparison of screening methods|
214949042|NCT00006087|PROCEDURE|computed tomography|
214949043|NCT00006087|PROCEDURE|radiography|
214949044|NCT00006087|PROCEDURE|study of high risk factors|
214949045|NCT05513755|PROCEDURE|cardioneuroablation|Endocardical radiofrequency ablation of vagal ganglia located close to pulmonary veins antra and interatrial septum.
214949046|NCT00031772|PROCEDURE|psychosocial assessment and care|Questionnaire and telephone intervention
214949047|NCT04974606|DIETARY_SUPPLEMENT|Cherry-flavored still beverage|10 oz bottle
214949048|NCT04974606|OTHER|Placebo cherry-flavored still beverage|10 oz bottle
214949049|NCT00153725|DRUG|Aspirin and Pantoloc|
214949050|NCT04114656|DRUG|Placebo|Placebo will be available as intravenous (IV) infusion of normal saline (0.9 percent \[%\] sodium chloride solution).
214949051|NCT04114656|DRUG|GSK3858279|GSK3858279 will be available as IV infusion and the dose level to be administered is 3 milligrams (mg) per kilogram (kg).
215075727|NCT03429985|BEHAVIORAL|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
214949052|NCT05118217|OTHER|This is a non-interventional study|This is a non-interventional study
214949053|NCT02720159|DEVICE|Percutaneous Osseintegrated Prosthesis|
214949054|NCT03370185|DRUG|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
214949055|NCT03282591|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
214949056|NCT03282591|DRUG|Matching Placebo Tablets|Placebo Tablets
214949057|NCT03627715|DRUG|Propagermanium|Immediate release capsule
214949058|NCT03627715|DRUG|Placebo|Placebo capsule
214949059|NCT03955588|DIAGNOSTIC_TEST|aCGH|
214949060|NCT01254084|DIETARY_SUPPLEMENT|Gynostemma Pentaphyllum tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
214949061|NCT01254084|DIETARY_SUPPLEMENT|Placebo tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
214949062|NCT00086398|BEHAVIORAL|Behavior Therapy|
214949063|NCT01198535|BIOLOGICAL|Cetuximab|Given IV
214949064|NCT01198535|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214949065|NCT01198535|OTHER|Laboratory Biomarker Analysis|Correlative studies
214949066|NCT01198535|OTHER|Pharmacological Study|Correlative studies
214949067|NCT00442819|PROCEDURE|Hemodialysis with Polymethylmethacrylate Artificial Kidney|
214949068|NCT03937674|BEHAVIORAL|HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
214949069|NCT04425811|OTHER|kinesiological taping|The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
214949070|NCT00312767|DRUG|Fabrazyme (agalsidase beta)|
214949071|NCT00214656|DRUG|Recombinant Activated Factor VII|
214949072|NCT01241331|DRUG|BLI1100|BLI110 topical cream
214949073|NCT01241331|DRUG|Vehicle cream|Vehicle topical cream
214949074|NCT03110081|PROCEDURE|Quadratus lumborum block|Quadratus lumborum (QL) block for open partial nephrectomy.
214342966|NCT05191576|OTHER|Children's sleep habits questionnaire (CSHQ)|"1. Children's Sleep Habits Questionnaire is a validated tool to screen sleep behavior in young children's assessment of pediatric sleep problems.~2. DSM-V Level II Sleep Disturbance- Child Report. is retrospective, 8-item self-report used to assess the pure domain of sleep disturbances in children and adolescents age of 11-17 years in the past seven days.Higher scores indicate more severe sleep disorders. High scores on a particular domain might indicate significant and problematic areas for the child that may warrant further assessment.~3. DSM -V Sleep Disturbance -Adult Report. is used to assess the pure domain of sleep disturbances in adults for the past seven days.~   SDQ).is used to screen emotional and behavioral problems in children.~4. SDQ is used to screen emotional and behavioral problems in children."
214342967|NCT00001180|DRUG|Ovine Corticotropin-Releasing Hormone (oCRH)|
214342968|NCT00968110|DRUG|omalizumab|Dosing table established for omalizumab
214342969|NCT05002322|OTHER|Systems Analysis and Improvement Approach|"Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel."
214342970|NCT02772068|DRUG|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
214342971|NCT02772068|OTHER|Exercise|
214342972|NCT02703844|DEVICE|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
214342973|NCT02703844|DEVICE|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
214342974|NCT01820130|DEVICE|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
214342975|NCT03704818|DRUG|Dapagliflozin 5mg|Dapagliflozin treatment taken daily for 4-weeks.
214342976|NCT03704818|DRUG|Placebo Oral Tablet|Placebo treatment taken daily for 4-weeks.
214342977|NCT05481112|DRUG|Extended-Release Buprenorphine Injection|Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
214342978|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^6 TCID50/mL.
214342979|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^7 TCID50/mL.
214342980|NCT02828111|DRUG|Patidegib|
214342981|NCT02828111|DRUG|Vehicle gel|
214342982|NCT00965224|BIOLOGICAL|dendritic cell vaccination (active specific immunotherapy)|
214342983|NCT02289131|PROCEDURE|Tooth Brushing Protocol|A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
214949075|NCT03110081|PROCEDURE|Epidural analgesia|Epidural analgesia for open partial nephrectomy.
214949076|NCT00633490|DRUG|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
214949077|NCT05162430|DRUG|Propofol|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg, kg, 0.5mg/kg Propofol was injected to five groups of P1, P2, P3, P4 and P5, respectively, and 5mg dexamethasone sodium phosphate was given to groups P1, P2, P3, P4, P5 and D1 after 30s
214949078|NCT03941028|DEVICE|3D printed titanium implant|The 3D printed titanium implant is fabricated by related companies. And some implants have been used in spinal disease in our hospital.
214949079|NCT02674126|BEHAVIORAL|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
214949080|NCT02674126|BEHAVIORAL|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
214342984|NCT03173196|DEVICE|Non-invasive Multispectral Sonography|We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
214342985|NCT01184014|DRUG|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
214342986|NCT01184014|DRUG|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
214342987|NCT01111500|DEVICE|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
214342988|NCT01111500|DEVICE|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
214342989|NCT01686087|BEHAVIORAL|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
214342990|NCT01686087|PROCEDURE|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
214342991|NCT00016289|BIOLOGICAL|recombinant interleukin-12|Given intraperitoneally
214342992|NCT02379598|DIETARY_SUPPLEMENT|Aminoacid based formula|Formula based on aminoacid
214342993|NCT02379598|DIETARY_SUPPLEMENT|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
214342994|NCT05110885|OTHER|Questionnaire|A questionnaire prepared by the researchers will be presented to the group.
214949081|NCT00940576|DIETARY_SUPPLEMENT|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
214949082|NCT00940576|OTHER|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
215075728|NCT04887584|OTHER|Control diet|The control Typical American Diet (TAD) diet pattern will mimic the level of intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium in the general U.S. population. This diet will feature no servings of pulses per day.
214949083|NCT04987931|DRUG|Talazoparib|This retrospective chart review study focuses on patients with HER2- ABC with gBRCA1/2m initiating talazoparib on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
214949084|NCT02824211|DEVICE|Right Dose System|Automated titration of oxygen system during exertion
214949085|NCT02435563|DRUG|ticagrelor 180 mg administrated alone|
214949086|NCT02435563|DRUG|Ticagrelor adjusted dose + ritonavir 100mg|
214949087|NCT02624154|PROCEDURE|pancreatectomy|Remove the pancreatic neuroendocrine tumor by surgery
214949088|NCT03090503|DRUG|Aripiprazole|Initial dose: 10 mg.
214949089|NCT03090503|DRUG|Risperidone|Initial dose: 2 mg.
215075729|NCT04887584|OTHER|Low Pulse diet|The Low Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 0.2 cups of pulses per day at 2,000 kilocalories (kcals).
215075730|NCT04887584|OTHER|High Pulse diet|The High Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 1.5 cups of pulses per day at 2,000 kilocalories (kcals).
215075731|NCT05725486|DIETARY_SUPPLEMENT|N-3 PUFAs Chicken Meet|Intake of n-3 PUFAs enriched chicken meet for three weeks.
215075732|NCT05725486|DIETARY_SUPPLEMENT|Regular Chicken Meet|Intake of regular chicken meet for three weeks.
215075733|NCT05456568|DEVICE|LymphAssistTM Professional|An intermittent pneumatic compression (IPC) device that mimics manual lymphatic drainage. Participants use the device daily for 12 weeks alongside their usual and standard lymphoedema care
214342995|NCT04574622|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
214342996|NCT03465540|DRUG|AMG 397|AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
214342997|NCT03465540|DRUG|Dexamethasone|Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
214342998|NCT03465540|DRUG|Azacitidine|Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
214342999|NCT02030691|DEVICE|Nasal continuous airway positive pressure (nCPAP)|
214949090|NCT03038711|DRUG|BMS-986166|Specified dose on specified days
214949091|NCT03038711|OTHER|Placebo matching BMS-986166|Specified dose on specified days
214949092|NCT06397053|PROCEDURE|robotic surgery|robotic surgery
214343000|NCT02030691|DEVICE|Nasal high frequency percussive ventilation (nHFPV)|
214949093|NCT05382429|PROCEDURE|OWHTO|OWHTO Surgical procedure For the OWHTO Surgical procedure, only medial split biplanar osteotomy performed.
214949094|NCT05382429|PROCEDURE|CWHTO|CWHTO Surgical procedure For the OWHTO Surgical procedure, only lateral closure osteotomy was performed.
215075734|NCT01833728|DRUG|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
214343001|NCT00916877|RADIATION|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
214343002|NCT04177511|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked.~The electrode is positioned in the cymba concha of the left ear."
214343003|NCT03815071|DRUG|Ips-nsc cells|Total dose of ips-nsc cells will be administered at day0.
214949095|NCT01130324|DRUG|VIBATIV|Observational
214949096|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (active)|The tDCS montage is developed to modulate the functional connectivity between the dorsal attention network and the default network.
214949097|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (Sham)|"The tDCS Acti- Sham montage is developed to recreate the cutaneous sensations associated with tDCS, yet essentially a null electrical field over the networks of interest."
214949098|NCT04512352|OTHER|Online curriculum|"The psychologist and our advisory team had successfully developed a total of 100 hours of parenting curriculum.~The adopted curriculum had focused on using play to facilitate parents in promoting their children's development in cognitive, motor, emotional and social aspects. Play-based activities are instrumental in improving children's development. Given that parents in poverty had difficulties spending time and money travelling back-and-forth to the training site and their homes, the research team decided to use e-learning as the medium of learning for our parenting programme. Web-based learning has the advantage of cutting time and travelling costs, which are luxuries to many parents in poverty."
214949099|NCT03928275|BIOLOGICAL|Interleukin-2|IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion.
214949100|NCT03928275|BIOLOGICAL|Combination therapy Interleukin-2 and Bacillus Calmette Guerin|"BCG (OncoTICE solutions 1-8 x 10-8 Colony Forming Units (CFU)) will be administered at a maximum dose of 3.2 million CFU per treatment at a maximum of 1.6 million CFU per lesion (max 2 lesions).~IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion (in remaining lesions)."
214949101|NCT02290119|DEVICE|Sensor-assisted TKR (Verasense)|Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofemoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.
214949102|NCT02290119|PROCEDURE|Control - Without the use of Verasense|Patients in this cohort will undergo manual total knee replacement without the use of Verasense
214949103|NCT04404049|BIOLOGICAL|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
215075735|NCT01833728|DRUG|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
215075736|NCT01259648|DRUG|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
214343004|NCT02844946|BEHAVIORAL|Acceptance and Commitment Therapy|Contextually focused form of cognitive behavioral psychotherapy that uses MINDFULNESS and behavioral activation to increase patients' psychological flexibility in areas such as ability to engage in values-based, positive behaviors while experiencing difficult thoughts, emotions, or sensations.
214343005|NCT03813329|DIETARY_SUPPLEMENT|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
214343006|NCT03813329|DIETARY_SUPPLEMENT|Acute Sodium Bicarbonate|3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
214343007|NCT03813329|DIETARY_SUPPLEMENT|Calcium carbonate (placebo)|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
214343008|NCT00736996|DRUG|Pioglitazone|30 - 45mg tablet daily for 6 months
214949104|NCT04404049|BIOLOGICAL|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
214949105|NCT03670511|OTHER|sit-to-stand test|to sit and stand from a chair
214949106|NCT03670511|OTHER|six minute walking test|to walk for six minutes
214949107|NCT04511000|DRUG|Lipilou®(generic atorvastatin drug) 20 mg|Patients assigned to experimental group are treated with Lipilou® 20 mg
214949108|NCT04511000|DRUG|Lipilou®(generic atorvastatin drug) 10 mg|Patients assigned to comparator group are treated with Lipilou® 10 mg
214949109|NCT03309228|OTHER|individual interviews|Semi-structured individual interviews with patients, relatives and general practitioners.
214949110|NCT01717157|DRUG|Treatment A: DUROGESIC (8.4 mg fentanyl)|One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
214949111|NCT01717157|DRUG|Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)|One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
214949112|NCT01717157|DRUG|Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)|One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
214949113|NCT01717157|DRUG|Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)|One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
214949114|NCT01717157|DRUG|Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)|One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
214343009|NCT00736996|DRUG|Placebo|Matching tablet daily for 6 months
214343010|NCT00736996|BEHAVIORAL|Endurance Exercise Training|Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
214343011|NCT01060761|BEHAVIORAL|Rehabilitation program|"Patient and their relative receive three supportive, structured conversation with a trained nurse.~Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities"
214343012|NCT02806986|BIOLOGICAL|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
214343013|NCT00462384|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
214343014|NCT02873611|DEVICE|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
214343015|NCT02873611|PROCEDURE|genicular ablation procedure|
214343016|NCT04487977|OTHER|Survey|Answering a survey on airway management in COVID-19 patients
214949115|NCT05445388|DEVICE|Aurisvue|OCT imaging of the middle ear
214949116|NCT05211908|PROCEDURE|Composite resin restoration with Self Etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
214949117|NCT05211908|PROCEDURE|Composite resin restoration with Seletive enamel etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
215075737|NCT01259648|DRUG|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
215075738|NCT01259648|DRUG|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
215075739|NCT01180894|DRUG|Iron sucrose|100 mg IV TIW
215075740|NCT01180894|DRUG|Placebo|
215075741|NCT02894164|OTHER|No intervention|
215075742|NCT02135328|BEHAVIORAL|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
215075743|NCT02135328|BEHAVIORAL|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
214949118|NCT05211908|PROCEDURE|Composite resin restoration with Self Etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
214949119|NCT05211908|PROCEDURE|Composite resin restoration with Seletive enamel etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
214949120|NCT01722032|OTHER|Childhood Obesity|
214949121|NCT03326518|DIAGNOSTIC_TEST|Lumentin® 44|Contrast agent
214949122|NCT03326518|DIAGNOSTIC_TEST|Diluted Omnipaque®|Contrast agent
214949123|NCT03326518|DIAGNOSTIC_TEST|Movprep®|Contrast agent
214949124|NCT02400892|OTHER|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
214949125|NCT06124651|PROCEDURE|Total knee replacement with cruciate retaining femoral component|To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate a metallic implants. Implants are fixed to patients' bone with bone cements. Many designs for femoral component designs are available. In the present study, two types of implants, one CR(cruciate retaining), where the posterior cruciate ligaments are retained, and one PS(Posterior cruciate substituting), where the posterior cruciate ligaments are resected, will be compared. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component design remains the same and the tibial component remains the same. Only the cruciate ligament parts are different. For this arm of intervention, CR knee will be used, so posterior cruciate will remain intact after the surgery and still function to aid in the knee stability.
214949126|NCT06124651|PROCEDURE|Total knee replacement with cruciate substituting femoral component|"To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate metallic implants that has similar contours of a native knee. Implants are fixed to patients' bone with bone cements. This procedure will use the femoral component that sacrifice the posterior cruciate ligament and having a box area with a post, so that cam-post mechanism of implants can mimic the function of the posterior cruciate ligament. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component remains the same. The tibial component will remain the same design. Therefore, only the cruciate ligament parts will be different."
214949127|NCT06252467|DEVICE|Photobiomodulation Therapy|"Phototherapy treatment (Photobiomodulation therapy or placebo) was performed using a Photobiomodulation therapy device (Vectra Genisys Systems, Chattanooga Group, Dallas, TX, USA). The cluster probe consisted of five low-level laser therapy diodes (850 nm) and 28 light emitting diodes therapy (670 nm, 880 nm, and 950 nm). Photobiomodulation therapy was applied in nine sites of each quadriceps femoris muscle~. A dosage of 15 J per site led to a total energy of 135 J per thigh, effectively increasing cycling performance in a previous study. We chose to apply Photobiomodulation therapy specifically to the quadriceps femoris because this muscle group is of utmost significance in generating torque and propelling the pedaling cycle. Its pivotal role in cycling performance made this muscle a prime target for the Photobiomodulation therapy intervention in our study."
214949128|NCT06252467|DEVICE|Placebo Photobiomodulation|The placebo treatment was performed in exactly the same manner as the Photobiomodulation therapy treatment, but with the device switched off, and the cluster was held stationary in contact with the skin at a 90° angle, with light pressure on the skin. The total application time of Photobiomodulation therapy or placebo was \~5 min for both limbs (9 points per thigh = 18 points × 16 s per point) before each time-to-exhaustion test.
214949129|NCT02653898|DRUG|DHA-PIP|Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
214949130|NCT02653898|DRUG|Primaquine|22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
214343017|NCT02897843|DEVICE|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
214343018|NCT02897843|DEVICE|sham tDCS|sham tDCS
214343019|NCT00742703|OTHER|Mineralized water|
214343020|NCT00742703|OTHER|Low mineralized water|
214343021|NCT01323439|DEVICE|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
214343022|NCT02765932|PROCEDURE|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
214343023|NCT02765932|PROCEDURE|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
214678315|NCT00635531|DRUG|alprazolam XR|Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
214678316|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 14 days
214678317|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 56 days
214678318|NCT00834002|BIOLOGICAL|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
214678319|NCT00161824|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
214678320|NCT02967848|OTHER|99mTc-mebrofenin hepatobiliary scintigraphy (HBS)|99mTc-mebrofenin HBS is a SPECT imaging procedure that allows evaluation of global and local liver function. Mebrofenin, bound to albumin, is taken up by hepatocytes in a similar manner to organic anions such as bilirubin. After hepatic uptake, the mebrofenin is excreted into the bile canaliculi. Dynamic imaging tools allow measurement of clearance rates for global function, and 3D SPECT imaging with corresponding CT allows visualisation of the local liver function with respect to anatomy. HBS allows direct visualisation of hepatocyte function.
214949131|NCT02653898|DRUG|Artesunate + Mefloquine|Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
214949132|NCT02653898|DRUG|Permethrin (Insecticide treated uniform)|40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
214949133|NCT02030886|DEVICE|Sensimed Triggersfish® (TF)|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
214949134|NCT04786366|OTHER|The study does not have an intervention, but observe the AF incidence of the UK disease-free population|The study does not have an intervention, but observe the AF incidence of the UK disease-free population.
214949135|NCT02303834|DEVICE|Continuous Positive Airway Pressure Ventilation (CPAP)|A mask worn over the nose that delivers air under slight pressure.
214949136|NCT01375374|DRUG|Lacosamide|4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
214949137|NCT01375374|DRUG|Levetiracetam|Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
215075744|NCT02539173|OTHER|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
215075745|NCT04495556|DIAGNOSTIC_TEST|MRI|The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
214678321|NCT02967848|OTHER|Indocyanine Green|ICG is a fluorescent dye injected into the patient. The dye is exclusively excreted by the liver. The ICG clearance rate is measured in the finger of the subject.
214678322|NCT02967848|OTHER|Liver Elasticity|This is an Ultrasound measurement of the elasticity of the liver.
214678323|NCT06532019|OTHER|Targeted intervention based on risk factors|Correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower NT-proBNP, CRP, NYHA Classification, to add diuretics for patients with higher RADs, multidiscipline intervention for patients complicating COPD, and actively reperfusion for ischemic HFpEF patients.
214678324|NCT00598533|DEVICE|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
214678325|NCT00598533|DEVICE|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
214678326|NCT00260741|DRUG|Smoked Cannabis|
214678327|NCT03428191|DRUG|Remifentanyl+Dexmedetomidine|In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.
214678328|NCT03252639|PROCEDURE|EVT for RAS & PBV acquisition protocol for target kidneys|
214678329|NCT04030481|OTHER|inhalation anesthesia|sevoflurane was used to maintain anesthesia
214678330|NCT04030481|OTHER|Total intravenous anesthesia|propofol was used to maintain anesthesia
214678331|NCT03198169|DEVICE|Atteris Antimicrobial Skin and Wound Cleanser|Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
214678332|NCT03198169|DEVICE|Atteris Antimicrobial Barrier Film Dressing|Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
214949138|NCT01908582|DRUG|Evacetrapib|Administered orally
214949139|NCT01908582|DRUG|Rifampin|Administered orally
214949140|NCT00163033|DRUG|estetrol|
214949141|NCT05831306|OTHER|Diet A|Modified Diet A
214949142|NCT05831306|OTHER|Diet B|Modified Diet B
214949143|NCT05948332|BEHAVIORAL|Delphi Rounds to generate consensus opinions among Experts|The Investigators (Steering Committee) will select the experts from across the globe based on pre-specified qualification criteria and will conduct iterative Delphi rounds to generate consensus on the definition and management of acute RVI in patients with receiving V-V ECMO, among the Experts. The selection criteria will be self-assessed through a survey among the potential Experts.
214949144|NCT02550925|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|A 7-session Acceptance and Commitment Therapy (ACT) group intervention
215075746|NCT04585269|BEHAVIORAL|Bright IDEAS-YA|Bright IDEAS-YA is a manualized problem-solving skills training intervention conducted by a trainer who teaches the participant the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach.
214949145|NCT02550925|BEHAVIORAL|Usual Care|Check in with clinical social worker at oncology care site and obtain list of supportive resources
215075747|NCT03263130|OTHER|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
215075748|NCT02478697|BEHAVIORAL|ProChange ExpertSystem|The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
215075749|NCT04717648|DIAGNOSTIC_TEST|Biochemical test|C Reactive protein and sodium
215075750|NCT04138914|DEVICE|Focal Cryotherapy|Ablation of the cancer focus within the prostate using cryotherapy
215075751|NCT02276352|DRUG|Treatment 1|
215075752|NCT02276352|DRUG|Treatment 2|
214949146|NCT00431899|BEHAVIORAL|fish oil supplementation|
214949147|NCT05254470|DEVICE|Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device
214949148|NCT00004197|BIOLOGICAL|keyhole limpet hemocyanin|
214949149|NCT00004197|BIOLOGICAL|sargramostim|
214949150|NCT00004197|BIOLOGICAL|tumor cell-based vaccine therapy|
214949151|NCT00004197|DRUG|cyclophosphamide|
214949152|NCT00004197|DRUG|doxorubicin hydrochloride|
214949153|NCT00004197|DRUG|mitoxantrone hydrochloride|
214949154|NCT00004197|DRUG|prednisone|
214949155|NCT00004197|DRUG|vincristine sulfate|
214949156|NCT01734083|DEVICE|Whole body vibration exercise|The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
214949157|NCT01734083|BEHAVIORAL|Conventional exercise|The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
214949158|NCT00888290|DRUG|Sodium bicarbonate|Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
214949159|NCT00888290|DRUG|Placebos|Placebo at 3 different doses to match Sodium bicarbonate dosing
214949160|NCT00073645|BEHAVIORAL|Peer/Group CBT|Children will be trained to be more helpful and positive toward other children through role-playing activities.
214949161|NCT00073645|BEHAVIORAL|Family/Parents CBT|Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
214949162|NCT04886752|DIETARY_SUPPLEMENT|vitamin C without liposome|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
214949163|NCT04886752|DIETARY_SUPPLEMENT|liposomal process A vitamin C|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
214949164|NCT04886752|DIETARY_SUPPLEMENT|liposomal process B vitamin C (Double Nutri™)|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
214949165|NCT06075043|DRUG|AND017|Oral administration of AND017 capsules three times per week
214949166|NCT00621998|DRUG|risperidone|0.5-6 mg/day
214949167|NCT00621998|DRUG|olanzapine|2.5-20 mg/day
214949168|NCT03135574|DIAGNOSTIC_TEST|MRI T2 sequence of the oculomotor tract|Patients with ophthalmoplegia will benefit from an MRI T2 sequence of the oculomotor tract (additional time of 4 minutes).
214949169|NCT04019262|RADIATION|Radiation Therapy|Radiation
214949170|NCT04019262|DRUG|Temozolomide Oral Product|Oral Temozolomide (150mg/m\^2 or 75 mg/m\^2)
214949171|NCT01108237|OTHER|TruMatch™ Personalized Solutions|TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.
214949172|NCT01108237|DEVICE|Total Knee Arthroplasty with Conventional Instrumentation.|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
214949173|NCT00039481|BIOLOGICAL|oblimersen sodium|Given IV
214949174|NCT00039481|DRUG|dexrazoxane hydrochloride|Given IV
214949175|NCT00039481|DRUG|doxorubicin hydrochloride|Given IV
214949176|NCT00039481|DRUG|cyclophosphamide|Given IV
214949177|NCT00039481|BIOLOGICAL|filgrastim|Given SC
214949178|NCT00039481|OTHER|laboratory biomarker analysis|Correlative studies
214949179|NCT00039481|OTHER|pharmacological study|Correlative studies
214949180|NCT00003902|DRUG|capecitabine|
214949181|NCT00003902|DRUG|vinorelbine tartrate|
214949182|NCT01829997|DEVICE|nanOss Bioactive 3D BVF|nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
214949183|NCT02851316|OTHER|Whole Body Vibration|Participants will stand in a squatted position on a platform that provides a brief vibratory stimuli.
215075753|NCT02276352|DRUG|Treatment 3|
215075754|NCT03618732|OTHER|Bilateral movement-based computer training|
215075755|NCT03618732|OTHER|Video-directed conventional training|
215075756|NCT05088083|DEVICE|Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon|After predilation, using drug-coated balloon catheter to cover the whole treated segment
215075757|NCT00851981|OTHER|Placebo|TID
215075758|NCT00851981|DIETARY_SUPPLEMENT|SAMe|300 mg TID
215075759|NCT05449379|OTHER|Respiratory training with the use of resistance set on respiratory muscle trainer|Performing respiratory training with resistance set on respiratory trainer.
215075760|NCT05449379|OTHER|Respiratory training without resistance set on respiratory muscle trainer|Performing respiratory training with no resistance set on respiratory trainer
215075761|NCT00036855|BIOLOGICAL|rituximab|Given IV
215075762|NCT00036855|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
215075763|NCT00036855|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
215075764|NCT00036855|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
214678333|NCT00905879|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
214949184|NCT05003830|DEVICE|PET/MR|18F-FDG, 11C-PIB and 18F-PM-PBB3 injection are radiopharmaceuticals used for positron emission tomography (PET) imaging. 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), and used in the assessment of brain glucose metabolism. 11C-PIB dose is about 5-10mCi, and used in the assessment of amyloid deposition. 18F-PM-PBB3 dose is about 5-10mCi, and used in the assessment of tau deposition. Use PET/MR equipment for simultaneous PET and MR collection.
214949185|NCT05029245|BIOLOGICAL|Comirnaty®|intradermal injection or intramuscular injection
215075765|NCT00036855|BIOLOGICAL|filgrastim|Given subcutaneously
215075766|NCT00036855|OTHER|laboratory biomarker analysis|Correlative studies
215075767|NCT02585024|DRUG|Cytisine|
215075768|NCT01730365|PROCEDURE|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
214949186|NCT06040671|OTHER|Vectra M3 imaging|Study subjects from both arms will undergo Vectra M3 imaging to evaluate the result of the surgery.
214949187|NCT00109941|BIOLOGICAL|opioid growth factor|OGF was administered in saline at 250 ug/kg intravenously over 45 minutes
214949188|NCT00109941|BIOLOGICAL|metenkephalin, OGF-opioid growth factor|OGF given in saline iv 250 ug/kg weekly
214949189|NCT02776540|DRUG|Clopidogrel|there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
214949190|NCT02776540|DRUG|Aspirin|there's another group will receive 400 mg Aspirin
214949191|NCT00370435|DRUG|GW274150|
214949192|NCT02065518|DEVICE|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 21-30% of MVC during weeks 3-6 and 31-40% of MVC during weeks 6-9, 41-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
214949193|NCT02065518|BEHAVIORAL|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved. At week 7, participants will be given a weighted vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
214949194|NCT02065518|BEHAVIORAL|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
214949195|NCT05223803|RADIATION|Prostate radiation (XRT)|Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.
214949196|NCT05223803|DRUG|Systemic Therapy|All systemic therapy is provided as best prescribed for patient per their medical oncologist.
214949197|NCT05223803|RADIATION|Stereotactic ablative radiation therapy (SABR)|SABR is delivered to those randomized to Arm 2.
214949198|NCT05621707|DRUG|chemotherapy combined with PD-1 inhibitors|Induction chemotherapy combined with PD-1 inhibitors followed with standard concurrent chemoradiotherapy
214949199|NCT02446535|OTHER|achievement of the DW by means of the BIA DW (RE.S.T.)|
214949200|NCT01100190|DEVICE|NUVANCE Facial Rejuvenation System|The NUVANCE™ Facial Rejuvenation System is a partially absorbable porous mesh device implant with applicator.
215075769|NCT03404531|BEHAVIORAL|Social Media Messages Intervention Group|The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
215075770|NCT03404531|BEHAVIORAL|Website Only Group|The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
215075771|NCT02042586|OTHER|Analysis of movement before total hip replacement|
215075772|NCT02042586|OTHER|Analysis of movement after total hip replacement|
214949201|NCT06321497|DEVICE|Extracorporeal carbon dioxide removal|Low flow extracorporeal carbon dioxide removal with PrismaLung+
214949202|NCT05712837|DRUG|25% TRICHLOROACETIC ACID|Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
214949203|NCT05712837|DRUG|30% salicylic acid|Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
214949204|NCT01071434|PROCEDURE|MR Imaging|
214949205|NCT04185584|OTHER|Not Applicable (Observational Study)|Not Applicable (Observational Study)
214949206|NCT05742074|OTHER|Faecal microbiota transplantation|25-30 capsules of faecal material
214949207|NCT05742074|OTHER|Placebo|25-30 placebo capsules
215075773|NCT04491019|OTHER|Balance exercise group|Balance exercises will be carried out with a physiotherapist
215075774|NCT05300230|DEVICE|Neuro Zti cochlear implant and Neuro 2 sound processor|"The study will consist in 3 visits:~* Visit 1: it will be carried out the first contact and learning the measurement procedure.~* Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~* Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters."
215075775|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
215075776|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
214949208|NCT02008032|DEVICE|Stationary Breast Tomosynthesis|The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.
214949209|NCT05573438|OTHER|Group fructose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
214949210|NCT05573438|OTHER|Group Sucrose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
214949211|NCT05573438|OTHER|Group Glucose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
214949212|NCT05962788|DRUG|voclosporin|Subjects will receive 2 capsules (15.8 mg) BID (twice daily), 3 capsules (23.7 mg) BID of voclosporin in addition to standard of care with mycophenolate mofetil (MMF) and steroids.
214949213|NCT05087446|BEHAVIORAL|Early assessment team|Early assessment team (EAT):The patients receive their first assessment by an early clarification team within a few weeks after the team receiving the referral. The team then decides whether further assessment and/or treatment should be given in the general outpatient clinic, and/or whether any other follow-up may be appropriate. In the first meeting the patient preferably meets two therapists, who conduct a semi-structured interview with focus on health and level of functioning. If considered appropriate, the team may offer a short-term intervention.
214949214|NCT05087446|BEHAVIORAL|Admission to General psychiatric outpatient clinic|Ordinary procedures for admission to an outpatient clinic are followed in accordance with the Norwegian Directorate of Health's national prioritization guide. Referrals are assessed on the basis of severity and placed on a regular waiting list (usually a waiting period of 1-3 months). The patients receive their first personal assessment from a therapist in a general outpatient clinic who takes a position on what is to be initiated and, if necessary, offers further assessment / treatment in accordance with procedures in the outpatient clinics. This is not standardized beyond current practice.
214949215|NCT04055649|DRUG|Akt/ERK Inhibitor ONC201|Given orally (PO)
214949216|NCT04055649|DRUG|Paclitaxel|Given IV
214949217|NCT04055649|OTHER|Questionnaire Administration|Ancillary studies
214949218|NCT05230199|BEHAVIORAL|SENSE multisensory program|In order to support parent's ability to implement the daily SENSE program they will be provided with an educational manual reviewing the program, weekly meetings with a therapist, and logs to report their visitation schedule and activities. Parents are able to choose different types of each sensory exposure. All options address the same key principles for that behavior and only include those that have evidence to support their use and are appropriate at each PMA.
214949219|NCT05230199|BEHAVIORAL|Monitored standard of care|Infants who receive sensory exposures only as standard of care but do not recieve the SENSE program
215075777|NCT01381276|OTHER|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
215075778|NCT03495310|BEHAVIORAL|Mindfulness|Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
215075779|NCT03627559|PROCEDURE|Pancreaticoduodenectomy microdialysis catheter analyses|A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
215075780|NCT04728477|DEVICE|OPti BP measurements|measurement of blood pressure with the new smartphone App ( OPTIBP)
215075781|NCT00367744|DRUG|Rosiglitazone|Rosiglitazone 4mg BID
214343024|NCT06580808|OTHER|Fontan Training Group|The Fonta training group consisted of 14 children in the late postoperative period of Fontan surgery. These children underwent cardiopulmonary testing, spirometry, chest ultrasound to assess the diaphragm, 6-minute walk test, respiratory muscle strength and quality of life. These tests were performed at the initial stage and after two months of inspiratory muscle training to assess the results of these in postoperative patients and what changes the training could bring. The training was performed with the Power Breath device, the carda was quantified at 40% of the force exerted at maximum inspiratory pressure by manovacuometry. The patient was asked to perform 3 sets of 20 repetitions twice over the course of 7 days of the week. Monitoring was done in person and virtually, and the carda was increased according to the evaluator's perception of the ease of the exercise or if the patient reported it to be easy. The training lasted 2 months.
215075782|NCT00367744|DRUG|Placebo|Placebo for rosiglitazone
215075783|NCT05100940|PROCEDURE|Cardiac Catheterization|Cardiac Catheterization
215075784|NCT00793572|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
215075785|NCT00793572|DRUG|Bortezomib|Given SC
215075786|NCT00793572|DRUG|Cyclosporine|Given IV
214949220|NCT06118450|OTHER|Non-intervention|non-intervention
214949221|NCT00858468|BIOLOGICAL|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
214949222|NCT00858468|BIOLOGICAL|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
214949223|NCT02119806|DRUG|Benzodiazepine|Receive as premedication in the Benzodiazepine group.
214949224|NCT02119806|DRUG|Fentanyl|Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
214949225|NCT02119806|DRUG|Propofol|Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
214949226|NCT05090306|DIAGNOSTIC_TEST|Routine ultrasound examination|ULTRASOUND EXAMINATION Women recruited to take part in the study will undergo the routine ultrasound examinations and monitoring, including a fetal echocardiogram between 12-13+6 weeks of gestation (for the first trimester cases) and between 18-24 weeks of gestation (for the second trimester cases). Two-dimensional evaluation of each fetal heart will include a cine loop sweep obtained from the from the four-chamber view plane by moving the transducer cranially towards the upper mediastinum, allowing the visualization of the following planes: four-chamber view, left and right ventricular outflow tracts, three vessels and trachea view. The examination will be stored for further analysis.
214949227|NCT03484403|OTHER|Lumbar back brace|A brace that supports the lumbar region of the spine.
214949228|NCT03484403|BEHAVIORAL|Back school|Back school consists of patient education physical therapy exercise instruction.
214949229|NCT02060864|DIETARY_SUPPLEMENT|AN-PEP|Two pills are consumed in the morning with a breakfast
214949230|NCT02060864|DIETARY_SUPPLEMENT|Placebo|
214949231|NCT04187716|DRUG|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
214949232|NCT01114295|DEVICE|Capsule Endoscopy|Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
215075787|NCT00793572|DRUG|Cyclosporine|Given PO
215075788|NCT00793572|DRUG|Fludarabine Phosphate|Given IV
215075789|NCT00793572|OTHER|Laboratory Biomarker Analysis|Correlative studies
215075790|NCT00793572|DRUG|Melphalan|Given IV
215075791|NCT00793572|DRUG|Mycophenolate Mofetil|Given PO
215075792|NCT00793572|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
215075793|NCT00793572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
215075794|NCT00793572|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo transplantation
214343025|NCT05391282|OTHER|ultrasound assessment|Transfontanel ultrasound assessment before and after prone positioning
215075795|NCT00793572|RADIATION|Total-Body Irradiation|Undergo radiotherapy
215075796|NCT03649529|BIOLOGICAL|GPA-TriMAR-T|Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
215075797|NCT00309699|DRUG|Placebo|Daily for 3 weeks
215075798|NCT00309699|DRUG|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
214343026|NCT05695859|DRUG|99mTc-DARPinG3 SPECT/CT|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection
214343027|NCT01168817|DRUG|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
214343028|NCT01168817|DRUG|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
214343029|NCT01168817|DRUG|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
214343030|NCT03647514|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
215075799|NCT00309699|DRUG|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
215075800|NCT05133622|OTHER|Physical Activity Level|IPAQ-SF assesses the physical activity levels of the individuals. The short form of the questionnaire consists of seven questions and provides information about the time spent sitting, walking, moderately vigorous, and vigorous activities. In scoring, below 600 MET-min/week indicates individuals who are not physically active, 600-3000 MET-min/week values indicate low physical activity levels, and 3000 MET-min/week and above values indicate individuals with high physical activity levels. In our study, sedentary individuals who receive 600-3000 MET-min/week from the questionnaire will be included
215075801|NCT05133622|OTHER|Evaluation of knee extension and elbow flexion muscle strength|"To measure the knee extension strength, the individual brings the knee from 90 degrees flexion to full extension in sitting. To standardize the test, the lower extremities will be fixed of the chair with a belt, allowing full extension of the knee. Three measurements will be performed from the distal tibia with a dynamometer, and the score will be recorded in Newtons.~Elbow flexion will also be measured in a sitting position in a chair. To standardize the given resistance, the upper extremity of the individual will be fixed to the arm support of the chair, allowing elbow flexion with a belt. During the measurement, the individual will try to flex the forearm in supination. Meanwhile, three measurements will be taken from the distal forearm with a dynamometer. The average score will be recorded in Newtons."
214949233|NCT01114295|RADIATION|CT Enterography|CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
214949234|NCT02173379|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
214949235|NCT02173379|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
214949236|NCT03699371|PROCEDURE|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU. Central venous catheter placement would not be assessed as a part of intervention due to the fact that it is a part of routine medical activities performed during admission to ICU.
214949237|NCT02263014|BEHAVIORAL|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
214949238|NCT05946668|PROCEDURE|Biospecimen Collection|Undergo vaginal specimen self-collection via vaginal swab collection kit
214949239|NCT05946668|OTHER|Electronic Health Record Review|Medical records reviewed
214949240|NCT05946668|OTHER|Questionnaire Administration|Complete questionnaires
214949241|NCT05993234|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC."
214949242|NCT05960357|OTHER|To inform|It includes providing all necessary information about the fetus to the pregnant woman by using the ultrasound monitor during the detailed ultrasound.
214949243|NCT00674479|DRUG|INCB018424|Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
214949244|NCT06617546|DRUG|FTX-101|Lyophilized powder for subcutaneous injection
214949245|NCT06617546|DRUG|Placebo|Lyophilized powder for subcutaneous injection
214949246|NCT04624295|DRUG|Early aspirin Therapy|Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
214949247|NCT04624295|DRUG|Non-Early aspirin Therapy|Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
214949248|NCT06226649|BEHAVIORAL|Digital Dyadic Empowerment|"The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~1. Access to CKD Health Education Information;~2. Supportive Information for Significant Others;~3. Physiological Values Logging for Self-Monitoring;~4. Reminders for Clinical Appointments and Daily Self-Management Tasks;~5. Kidney Health Diary for Lifestyle Modification Progress Tracking;~6. Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers."
214949249|NCT02632448|DRUG|LY2880070|Capsules
214949250|NCT02632448|DRUG|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
214949251|NCT01000883|OTHER|biologic sample preservation procedure|approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
214949252|NCT01000883|OTHER|laboratory biomarker analysis|Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
215075802|NCT05133622|OTHER|Evaluation of functional strength of trunk muscles|"Sit-ups test: The sit-ups test is a measure the endurance of the abdominal and hip-flexor muscles. The physiotherapist will fix the feet and ask the individuals to do trunk flexion in the knee flexion position. The number of movements performed for 30 seconds will be recorded.~Push-ups test: The test will be in the prone position, with the hands at shoulder level and the elbows flexed, positioned near to the body. Individuals will raise the head, shoulders, and trunk from the ground with their elbows in full extension. The test is performed with the knees in full extension for men and modified knees in flexion for women. The number of movements performed for 30 seconds will be recorded."
214949253|NCT01000883|PROCEDURE|biopsy|cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.
214949254|NCT05118724|DRUG|Atezolizumab|Atezolizumab 840mg i.v., on Day 1 and Day 15 (q2w) of every 28-day treatment cycle for a total of 12 cycles (24 doses)
215075803|NCT05133622|OTHER|Muscle Endurance|"Lateral bridge test: Lateral bridge test involves static, isometric contractions of the lateral muscles on each side of the trunk that stabilizes the spine.~Modified Biering-Sorensen test: The test measuring how many seconds the individual can keep the unsupported upper body horizontal, while placed prone with the buttocks and legs fixed to the couch by three wide canvas straps and the arms folded across the chest.~Trunk flexors endurance test: Trunk flexion test involving a static, isometric contraction of the anterior muscles, stabilizing the spine until the individual exhibits fatigue. The researcher stops the test when the individual cannot hold the assumed position.~Prone bridge test: The prone bridge test measures the muscular endurance of the abdominal muscles."
215075804|NCT05133622|OTHER|Flexibility|"Back scratch test The back-scratch test evaluates upper extremity flexibility. The individual will externally rotate one arm over her/his shoulder to reach the lowest point on the back with the palm facing the back. The other extremity reaches the highest point on the back with the palm facing forward by internal rotation of the other arm. The distance between the middle fingers of both hands will be measured with a tape measure.~Sit and reach test Sit and reach test evaluates lower extremity flexibility. In the test, a sit and reach board is used. The 0 reference point is taken as the 25 cm inner part where the feet are placed on the sit and reach the board. The part closer to the individual from the reference point shows negative values, and the part towards the far side shows positive values. Individuals will reach as far as with their fingertips by placing their feet on a sit-and-reach board."
214343031|NCT03647514|DRUG|Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
214343032|NCT01705457|DRUG|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
214343033|NCT01705457|DRUG|placebo|
214343034|NCT01056224|DRUG|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
214949255|NCT05118724|DRUG|IMM-101|Suspension of Heat-Killed Whole Cell Mycobacterium obuense (NCTC 13365) in Borate Buffered Saline for Intradermal Injection
214949256|NCT04767529|DRUG|Efruxifermin|subcutaneous injection
214949257|NCT04767529|DRUG|Placebo|subcutaneous injection
214949258|NCT04991116|DRUG|TILD sub-cutaneous (SC) injection|1 mL injection of study medication
214949259|NCT06464302|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
214949260|NCT06464302|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation
214949261|NCT04354649|DRUG|Hydroxychloroquine|Hydroxychloroquine 5mg/kg PO daily
214949262|NCT04354649|OTHER|Placebo|Hydroxychloroquine-matching placebo
214949263|NCT06038149|DIAGNOSTIC_TEST|Transthoracic echocardiogram|A painless ultrasound scan of the heart.
214949264|NCT04716153|OTHER|Multifactorial sensory rehabilitation workshops|A multifactorial sensory rehabilitation Workshops : a multifactorial program in order to optimize the recovery of flavors, focused on smell and taste which integrates several non-drug interventions, which are part of the current recommendations: hydration of the mucous membranes with daily (3 times a day) liposomal sprays (nose and mouth), presentation of visual dishes.
214949265|NCT04716153|OTHER|Usual care|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified."
214949266|NCT04716153|OTHER|Tests and Questionnaire|fulfillment of Taste Strips Test, Sniffin'sticks test and QGO, FACT-G, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients
214343035|NCT02501304|DEVICE|ReVENT Sleep Apnea System|The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
214343036|NCT02667912|PROCEDURE|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
214343037|NCT02667912|PROCEDURE|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
214949267|NCT06114056|BIOLOGICAL|JWK007 Single intravenous infusion administration|"Six male children aged 5-10 years were enrolled in the study. The patients were divided into two different dose groups, and a 3+3 dose escalation design was used, the low dose was 1.0×1014vg/kg, and the high dose was 2.0×1014vg/kg. Only one intravenous infusion of JWK007 was administered to each patient."
215075805|NCT05133622|OTHER|Balance|"Single leg stance test Individuals bend one knee and place the sole on the other thigh and maintain their balance in this position. The test will be performed separately for the right and left extremities with eyes open and closed. The single-leg stance balance time was recorded as seconds (Linda,2013).~Functional reach test The functional reach test evaluates dynamic balance and limit of stability. This test measures the distance between the length of an outstretched arm in a maximal forward reach from standing while maintaining a fixed base of support. The scoring record is centimeter. Higher scores indicate a good level of balance (Lin,2012)."
215075806|NCT05133622|OTHER|Fatigue|"Individuals will score perceived fatigue during walking and running activities with the Modified Borg Scale. According to the scale, 0 indicates no fatigue, and a score of 10 indicates unbearable fatigue (Borg,1987)."
215075807|NCT04535713|DRUG|Gemcitabine|600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
214949268|NCT05807256|OTHER|collection and analysis of treatments and procedures already performed by normal clinical practice|The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
214949269|NCT03128034|DRUG|Cyclosporine|Given PO or IV
215075808|NCT04535713|DRUG|Doxorubicin|18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
214949270|NCT03128034|DRUG|Fludarabine Phosphate|Given IV
214949271|NCT03128034|DRUG|Mycophenolate Mofetil|Given PO or IV
214949272|NCT03128034|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
214949273|NCT03128034|RADIATION|Pretargeted Radioimmunotherapy|Given 211\^At-BC8-B10 IV
214949274|NCT03128034|RADIATION|Total-Body Irradiation|Undergo TBI
214949275|NCT03128034|RADIATION|Pretargeted Radioimmunotherapy|Given 131\^I-BC8-B10 IV
214949276|NCT03128034|PROCEDURE|Biospecimen Collection|Undergo blood and bone marrow aspirate sample collection
214949277|NCT03128034|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
214949278|NCT04542434|DRUG|Niclosamide Oral Tablet|Niclosamide tablets 400 mg 3 times daily for 14 days
214949279|NCT04542434|DRUG|Placebo|Matching placebo tablets 3 times daily for 14 days
214949280|NCT04404985|PROCEDURE|Surgical AVF|"Surgical fistula creation is standard surgical procedures, where a small cut through the skin is made to create a channel directly between a vein and artery .~The study procedures are standard clinical practice, and not considered an experimental procedure."
214949281|NCT04404985|PROCEDURE|Endo-vascular AVF|Endovascular fistula creation is a minimally invasive procedure used to create a canal between close artery and vein at the forearm. A magnet attached to a catheter is passed over a guidewire into the artery while another magnet passed over the guidewire into the vein. The two magnets are aligned close to each other, then the radiofrequency electrode is released from the venous catheter and energized for 2 seconds, creating a channel between the vein and the artery.
214949282|NCT05467813|OTHER|mirror therapy|The mirror therapy (MT) will be done with participants seated at a table. The affected upper-extremity (UE) will be placed behind the mirror and the unaffected UE in front of the mirror. Participants will be asked to do the same movements using both the unaffected and affected UE as possible. Each participant will practice two different MT protocols: unilateral mirror therapy (UMT) and bilateral mirror therapy (BMT). During UMT, the affected hand is static, while during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements, fine motor movements, and object manipulation.
214949283|NCT05467813|OTHER|augmented reality (AR)|The training program provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. To ensure safety, the investigators will place a handrail in front of the participant for support. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg), activities of daily living training (i.e., reaching), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
214949284|NCT05467813|OTHER|control therapy|The control intervention will include practice of upper limb activities, balance activities, activities of daily living, and cognitive enhancement tasks. The protocols of the conventional therapy will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their prioritized goals. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
214949285|NCT06172790|OTHER|Training|A protocol has been established for the progression of the strengthening and balance training components of the Otago Exercise Program, increasing every two weeks in a four-stage manner. The exercise intensity will be gradually increased based on patient tolerance, ensuring that the perceived difficulty level remains in the range of 4-6 on the Borg dyspnea scale throughout the 8-week period. Supervised walking training is planned to be conducted on a treadmill to ensure standardization. The initial treadmill walking speed for patients will be determined based on the submaximal walking speed in the 6-minute walking test. The progression of the walking program will be carried out every two weeks, similar to the other exercise components of the program, with a 10% increase in walking speed each time.
215075809|NCT04535713|DRUG|Docetaxel|25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
215075810|NCT04535713|DRUG|Nivolumab|240 mg i.v. on Day 1 beginnning Cycle 2+
214949286|NCT02374437|DRUG|Aramchol|PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
214343038|NCT06089304|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
214343039|NCT06104735|PROCEDURE|Synaptic Pairing Interval|Optimize interstimulus pairing between brain and spinal cord stimulation.
214343040|NCT06104735|PROCEDURE|Frequency|Compare 2 Hz continuous to intermittent theta burst frequency
214343041|NCT06104735|PROCEDURE|Bouts|Compare effects of 1, 2, or 4 bouts of SCAP
214343042|NCT06104735|PROCEDURE|Spacing|Compare 6 versus 12 minutes of rest in between bouts of SCAP
214343043|NCT06104735|PROCEDURE|Exercise|Task-oriented hand exercises
214343044|NCT06104735|PROCEDURE|SCAP plus Exercise|Compare interleaved versus serial bouts of SCAP and exercise.
214343045|NCT04036916|OTHER|Virtual Reality Sensorimotor Training|Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
214343046|NCT04443218|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient mitral valve.
214343047|NCT04836260|DRUG|SARS-CoV-2 convalescent plasma|Included patients will receive at least one unit of convalescent plasma with NTAB titer ≥1:160 at maximum 3-7 days after diagnosis by RT-PCR or symptom onset. A second unit of plasma from a different donor can be proposed 24h after the first unit if immunocompromised and/or the patient received less than 3-5ml/kg of plasma volume. Additional units can be exceptionnally infused, at the investigator discretion.
214949287|NCT02374437|DRUG|Placebo|PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
214949288|NCT02598778|DRUG|Chlorhexidine gluconate (0.12%)|30 second oral rinse of 10mL of solution
214949289|NCT02598778|DRUG|Sodium Fluoride (0.05%)|30 second oral rinse of 10mL of solution
214949290|NCT02598778|OTHER|Paraffin wax chewing gum (sugar-free)|Approximately two minutes of chew time
214949291|NCT02598778|OTHER|Deionized water|30 second oral rinse of 10mL of solution
214949292|NCT04875572|DEVICE|Analgesia Nociception Index (ANI) Monitor|The ANI monitor produces an objective measure of parasympathetic tone through non-invasive electrodes placed on the patient's chest. The patient's standard of care is not affected, and the anesthetist is blinded to the monitor, so as not to affect their anesthetic practice.
214949293|NCT02342145|DRUG|Basiliximab,|Basiliximab was used on 0d (after transplantation) and +4d (10mg for weight under 35kg, 20mg for over 35kg) .
214949294|NCT02342145|DRUG|Tacrolimus|Specifically Tacrolimus was used by intravenous drip infusion on 0.03mg/kg dosage from -1d and change to 0.1mg/kg oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 5-10 ng/ml.
214949295|NCT02342145|DRUG|Methotrexate|Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3d,+6d,+11d by intravenous for prevention of graft-versus-host-disease.
214949296|NCT02342145|DRUG|Mycophenolate mofetil|Mycophenolate mofetil was used 0.25g per day from -1d to 90d for prevention of graft-versus-host-disease.
214949297|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation A
214949298|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation B
214949299|NCT06631430|DRUG|Placebo|Placebo
214949300|NCT01874418|OTHER|Biomarker|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
214949301|NCT02373007|PROCEDURE|Scopinaro Surgery|Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
214949302|NCT04998383|DEVICE|HVNI|High velocity nasal insufflation (Fisher \&Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort.
214949303|NCT04122625|DRUG|Debio 1143|Administered as capsules.
214949304|NCT04122625|DRUG|Nivolumab|Administered as IV infusion.
214949305|NCT04348500|DRUG|Clazakizumab|IV Infusion
215075811|NCT04617886|OTHER|Sadness induction|"Sadness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
214949306|NCT02776670|OTHER|Propylene glycol, 0.6% eye drops|
214949307|NCT02776670|OTHER|Lubricant eye drops|
214949308|NCT03402425|DIAGNOSTIC_TEST|18F-FET PET|Patient are investigated with an 18F-FET PET
214949309|NCT06006637|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.
214949310|NCT04063722|PROCEDURE|modified Benelli procedure|use of modified Benelli procedure for surgical treatment of gynecomastia
214343048|NCT02053233|DEVICE|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
214949311|NCT06307171|DIAGNOSTIC_TEST|In-house Western blot, specific for Leishmania|"Sample will be collected at the collaborating centres and at the DITM, if not already stored at -80°C. The samples will be delivered to the DITM. For the CONTROL groups, two serological tests for Leishmaniasis, based on different antigenic fraction, will be performed on serum samples.~Different strains of Leishmania infantum and Leishmania donovani will be cultivated axenically at the DITM.~Whole soluble fraction of promastigote (WSF), the whole membrane protein fraction (WMF) and the whole soluble fraction secreted by promastigotes (WSFe) of Leishmania spp. will be obtained and the ARPs from WSF, WMF and WSFe, of each Leishmania will be checked trough Western-blot analysis testing at a final dilution of 1/100 each serum sample. The predominant bands detected by Western-blot analysis will be identified by SDS-PAGE separation. Selected bands, corresponding to the immunogenic bands, will be excised, digested and identified with Mass Spectrometry analysis."
214949312|NCT01937884|DRUG|Parenteral Nutrition|
214949313|NCT04740996|DRUG|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
214949314|NCT00004088|BIOLOGICAL|filgrastim|
214949315|NCT00004088|BIOLOGICAL|recombinant interferon alfa|
214949316|NCT00004088|DRUG|busulfan|
214949317|NCT00004088|DRUG|cyclophosphamide|
215075812|NCT04617886|OTHER|Happiness induction|"Happiness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
215075813|NCT04782050|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
215075814|NCT00123578|DRUG|Lorazepam|Lorazepam
215075815|NCT00123578|DRUG|Pentobarbital|Pentobarbital
215075816|NCT00269503|PROCEDURE|Prone Distraction|
215075817|NCT00269503|PROCEDURE|Side-Posture Manipulation|
215075818|NCT00269503|PROCEDURE|Side-Posture Manipulation & Prone Distraction|
215075819|NCT00269503|PROCEDURE|Usual Care (Control Group)|
215075820|NCT02511483|DRUG|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
215075821|NCT02511483|DRUG|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
215075822|NCT02511483|DRUG|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
215075823|NCT02511483|PROCEDURE|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
215075824|NCT02511483|OTHER|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
215075825|NCT02511483|GENETIC|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
215075826|NCT00221806|DEVICE|endothelialised prosthesis|
215075827|NCT05680480|BIOLOGICAL|Telitacicept 240 mg|Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
215075828|NCT05680480|BIOLOGICAL|Telitacicept 160 mg|Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
215075829|NCT05680480|DRUG|Placebo|Participants will receive placebo weekly in addition to SOC for 48 weeks.
215075830|NCT06264219|BIOLOGICAL|Microbiome restoration - FMT|Pathogen-free microbiota from maternal stool sample is transferred from mother to infant.
215075831|NCT06264219|BIOLOGICAL|Microbiome restoration - FVT|Sterile-filtered and ultracentrifuged FMT, containing only viruses, is transferred from mother to infant.
214343049|NCT02053233|DEVICE|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
214343050|NCT00346034|DRUG|Pregabalin|150 to 600mg/day
214343051|NCT04000165|DRUG|AG-348|This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
214343052|NCT06535360|BIOLOGICAL|Platelet transfusion|platelet administration through intravenous access
215075832|NCT06264219|BIOLOGICAL|Placebo|Inactive solution buffer
215075833|NCT06264219|OTHER|Vaginal birth, untreated control|No intervention. This group is for secondary outcomes comparisons.
215075834|NCT06230016|OTHER|questionnaires|"human and social science questionnaire (specifically designed by the expert lab of Grenoble) on motivation and restraint perceived by patient and parents, elaborated especially for this study.~Questionnaire administred before the start of current care APA programm and after 4 to 6 months."
214949318|NCT00004088|DRUG|melphalan|
214949319|NCT00004088|DRUG|pamidronate disodium|
214949320|NCT00004088|DRUG|thalidomide|
214949321|NCT00004088|PROCEDURE|peripheral blood stem cell transplantation|
214949322|NCT04617964|OTHER|Ultrasound|Assessment the intra and interoperator reproducibility of the measurement of the right portal vein diameter at the routine third trimester ultrasound
214949323|NCT02445742|DRUG|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
215075835|NCT06230016|OTHER|PedsQL quality of life questionnaires|validated PedsQL (The Pediatric Quality of Life Inventory) questionnaires administred to children (if adequate) and parents before the start of current care APA programm and after 4 to 6 months
215075836|NCT01271712|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
214949324|NCT05437016|BEHAVIORAL|HUBER exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises. HUBER exercises require the synergistic activation of various muscle groups of the lower limbs, trunk and upper limbs to develop low-high force levels against the handles.
214343053|NCT01201525|PROCEDURE|Pulsed dye laser treatment|Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
214949325|NCT05437016|BEHAVIORAL|Standard exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises.
214949326|NCT05164198|BIOLOGICAL|Adalimumab and its biosimilars|"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
214949327|NCT05164198|BIOLOGICAL|Biological: Etanercept and its biosimilars|"1. Active substance: Etanercept~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 50mg/mL~4. Route of administration: Subcutaneous injection"
214678334|NCT03089177|BEHAVIORAL|Community Garden Intervention|"The investigators will recruit prospective adult gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. Individuals randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The Wait List Control group will remain on the community gardening wait lists and will not receive these resources.~Duration of the intervention is 1 year."
214678335|NCT02629081|OTHER|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
214949328|NCT05164198|BIOLOGICAL|Golimumab|"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
214949329|NCT05164198|BIOLOGICAL|Infliximab biosimilar|"1. Active substance: Infliximab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 120mg/mL~4. Route of administration: Subcutaneous injection"
214949330|NCT05301582|DIAGNOSTIC_TEST|Tidal volume challenge test|The purpose of our study is to verify the predictability of TVC test during laparoscopic abdominal surgery for early postoperative AKI and intra-operative hypotension.
214949331|NCT00981058|BIOLOGICAL|Necitumumab|"Administered intravenously.~Continues until progressive disease, toxicity, noncompliance, or withdrawal."
214949332|NCT00981058|DRUG|Gemcitabine|"Administered intravenously.~Continues for a maximum of six cycles."
214949333|NCT00981058|DRUG|Cisplatin|"Administered intravenously.~Continues for a maximum of six cycles."
215075837|NCT01271712|DRUG|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
215075838|NCT01271712|DRUG|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
215075839|NCT03465397|DIAGNOSTIC_TEST|biomarkers driven immunosuppressive therapy|the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
215075840|NCT06493097|BEHAVIORAL|Gut-directed hypnotherapy via audio files|5 audio files 10-15 min each, min 5 times a week for 12 weeks
215075841|NCT00145184|DIETARY_SUPPLEMENT|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
215075842|NCT00145184|DRUG|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
214343054|NCT01201525|PROCEDURE|Control|Part 2 of the surgical scar will serve as a within patient control.
214343055|NCT02024334|DRUG|Leflunomide|
214343056|NCT00750789|DIETARY_SUPPLEMENT|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
214343057|NCT03549689|DRUG|Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)|Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
214949334|NCT06560008|DIETARY_SUPPLEMENT|EnXtra® (300 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
214949335|NCT06560008|DIETARY_SUPPLEMENT|Caffeine (200 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
214949336|NCT06560008|DIETARY_SUPPLEMENT|EnXtra® (300 mg) + Caffeine (200 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
214949337|NCT06560008|DIETARY_SUPPLEMENT|Placebo (MCC 300 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
214949338|NCT02667587|DRUG|Nivolumab|
214949339|NCT02667587|DRUG|Temozolomide|
214949340|NCT02667587|RADIATION|Radiotherapy|
214949341|NCT02667587|OTHER|Nivolumab Placebo|
214343058|NCT03549689|DRUG|Current tenofovir alafenamide (TAF)-containing ART regimen|Continuation of current TAF-containing ART for 96 weeks.
214949342|NCT03919435|DRUG|Trimethoprim Sulfamethoxazole|Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks
214949343|NCT04708275|PROCEDURE|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
214949344|NCT01541761|BEHAVIORAL|Family groups|The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
214949345|NCT04451525|DEVICE|MicroVention Mechanical Thrombectomy Devices as first-line treatment|Patient will be treated with mechanical thrombectomy at the direction of the treating physician
214949346|NCT05739617|OTHER|Comprehensive Respiratory Training Exercise Program|This comprehensive respiratory training exercise program consists of four main components, including oropharyngeal muscle training, respiratory muscle training, aerobic exercise, and sleep hygiene education.
214949347|NCT05739617|OTHER|Sleep hygiene education|Sleep hygiene education
214949348|NCT05155449|DIETARY_SUPPLEMENT|Probiotics|Capsule
214949349|NCT05155449|DIETARY_SUPPLEMENT|Placebo|Capsule
214949350|NCT03418194|PROCEDURE|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation(TAES) is a kind of noninvasive therapy similar to acupuncture and moxibustion. Its physiological effect is similar to that of electroacupuncture and hand acupuncture which is a Chinese traditonal therapy using acupuncture.
214949351|NCT03418194|PROCEDURE|sham transcutaneous acupoint electrical stimulation|Sham transcutaneous acupoint electrical stimulation is the same procedure as transcutaneous acupoint electrical stimulation at points without electronic stimulation.
214949352|NCT04108780|DEVICE|T-tube|T shaped tube used as stent after CBD exploration
215075843|NCT00607269|BEHAVIORAL|Voucher-Based Reinforcement Therapy|"Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol \<0.05) urine sample."
215075844|NCT06435364|OTHER|Vagus nerve stimilation|This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear. Somatosensory innervation is provided by the auricular branch.
215075845|NCT06435364|OTHER|Manual therapy|Manual therapy is mostly defined by the tissue targeted by the practitioner; it can be joint biased, muscle and connective tissue biased and/or neurovascular system biased techniques.
215075846|NCT00096226|DRUG|Induction Carboplatin|
214343059|NCT00841867|PROCEDURE|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
214949353|NCT01140412|DRUG|Maraviroc|maraviroc 300 mg BID x 5 days
215075847|NCT00096226|DRUG|Induction Paclitaxel|
215075848|NCT00096226|PROCEDURE|Resection|
214343060|NCT04071002|OTHER|12 weeks physical therapy programme|The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
214343061|NCT04289649|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
214343062|NCT04289649|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
214949354|NCT01140412|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
214949355|NCT01140412|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
214949356|NCT01140412|DRUG|Maraviroc|maraviroc 300 mg QD x 5 days
214949357|NCT01140412|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
214949358|NCT01140412|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
214949359|NCT06654297|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.
214949360|NCT06654297|DRUG|Palbociclib(100mg)|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
214343063|NCT04289649|DRUG|K-924 LD Placebo|Pitavastain 2 mg
214343064|NCT04289649|DRUG|K-924 HD Placebo|Pitavastain 4 mg
214949361|NCT06654297|DRUG|Palbociclib(125mg)|Palbociclib will be given at a dose of 125 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
214949362|NCT02562092|BEHAVIORAL|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
214949363|NCT02562092|BEHAVIORAL|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
214949364|NCT04785040|OTHER|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale
214949365|NCT03945994|OTHER|Connecting People Intervention|Improve the resourcefulness of social networks of people with mental health problems
215075849|NCT00096226|DRUG|Consolidation Carboplatin|
215075850|NCT00096226|RADIATION|Radiation Therapy|
215075851|NCT00096226|DRUG|Consolidation Paclitaxel|
215075852|NCT05923931|DEVICE|cooling blanket|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
215075853|NCT05923931|DEVICE|non-cooling blanket|Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, convection,etc.
215075854|NCT01069159|DRUG|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
215075855|NCT01069159|DRUG|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
215075856|NCT05752942|BEHAVIORAL|Student Intervention Matching System (SIMS)|"The Student Intervention Matching System (SIMS) is a pre-intervention matching assessment following the behavioral consultation model. The SIMS entails three steps to sequentially assess and then match students' individual characteristics to precise acquisition- or performance-based interventions. The 1st step corresponds to the problem identification stage in behavioral consultation. The 2nd step corresponds to the problem analysis stage of behavioral consultation.The 3rd step of SIMS corresponds to the implementation planning and evaluation stages of behavioral consultation."
215075857|NCT05752942|BEHAVIORAL|group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based intervention (group-based social skills training). We selected group-based social skills training for four reasons: (a) participating schools had already been delivering it as their treatment-as-usual, (b) it is a common intervention in US schools, (c) it is only effective for students with acquisition needs, and (d) it represents a counterfactual contrast to the treatment condition because externalizing behaviors driven by performance needs will be reduced more by performance-based interventions than acquisition-based ones.
215075858|NCT05807087|PROCEDURE|Conventional osteotomy|The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.
215075859|NCT05807087|PROCEDURE|Piezosurgery osteotomy|full exposure of the nasal bony pyramid is needed.
215075860|NCT05872997|DIAGNOSTIC_TEST|Sensory Motor Training|Mobilization With Movement Along With Sensory Motor Training
214343065|NCT01234506|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
214343066|NCT02543359|BEHAVIORAL|Training Models of PCIT|Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
214343067|NCT02543359|BEHAVIORAL|Training Models of PCIT|One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
214343068|NCT02543359|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT) Treatment|Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
214343069|NCT02063503|OTHER|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
214343070|NCT00650468|DRUG|tacrolimus|Oral
215075861|NCT02451683|OTHER|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
215075862|NCT02451683|OTHER|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
215075863|NCT02451683|OTHER|Training with some stimulation|motor task combined with real or sham stimulation
215075864|NCT00112411|DRUG|Bronchodilator|
215075865|NCT01666119|DRUG|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
215075866|NCT03186508|BEHAVIORAL|Optimize Sleep (OS)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
215075867|NCT03186508|BEHAVIORAL|Optimize Sleep-Plus (OS-Plus)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
214343071|NCT00650468|DRUG|CellCept|IV or Oral
214343072|NCT00650468|DRUG|steroids (methylprednisone or prednisone)|IV or Oral
214343073|NCT05951322|DEVICE|Shockwave therapy|Radial extracorporeal shock wave device, it is serial number (1107394), medispec and connected to electrical supply 115/220 A C frequency.
214343074|NCT05951322|DEVICE|Phonophoresis|Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
214343075|NCT03584594|DIAGNOSTIC_TEST|Presepsin measurement|Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
214343076|NCT05719974|OTHER|rehabilitation protocol|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.
214949366|NCT04790097|RADIATION|Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost|"78Gy in 30 fractions on FET-PET based target volumes;~60Gy in 30 fractions on 2cm margin from MRI based target volumes;~all patients will be treated with concomitant and adjuvant temozolomide"
214949367|NCT00061750|DRUG|ICL670|
214343077|NCT03912857|DRUG|Camrelizumab|"Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
214343078|NCT03220191|DRUG|Palbociclib|palbociclib tablet formulation
214486483|NCT06769243|DEVICE|TMS|"Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It is primarily used to treat OCD, particularly in patients who have not responded well to traditional treatments such as medications or psychotherapy. The most common target is the supplementary motor area (SMA), which has an indirect connection with the Cortico-Striato-Thalamo-Cortical (CSTC) pathway, known to be hyperactive in OCD.~Another option to target the CSTC pathway is deep TMS, although it is not available in most advanced centers. The magnetic pulses from TMS stimulate or inhibit brain activity in the targeted area, which is believed to help reset or correct neural activity patterns associated with OCD and other psychiatric disorders.~TMS represents an alternative treatment for those struggling with OCD, offering a non-invasive approach with relatively few side effects and significant potential benefits."
214949368|NCT00061750|DRUG|deferoxamine|
214949369|NCT04165135|DRUG|Standard of Care for Haemophilia A|There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
214949370|NCT03503734|BEHAVIORAL|Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
214949371|NCT04034316|OTHER|Cord-blood mesenchymal stromal cells|The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.
214949372|NCT01022216|DEVICE|Procellera™ Wound Dressing with V.A.C.® Therapy|Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
215075868|NCT04444492|DRUG|Ranibizumab Injection|initial three injections of Ranibizumab - afterwards pro re nata monthly
215075869|NCT04444492|DEVICE|Laser photocoagulation|Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times
214486484|NCT06523556|BIOLOGICAL|Axatilimab|Given IV
214949373|NCT01022216|DEVICE|V.A.C.® Therapy|Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
214949374|NCT04549623|DEVICE|Novel end-tidal CO2 monitoring device|Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.
214949375|NCT04549623|DEVICE|SpO2 and respiratory motion monitoring|Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.
215075870|NCT06052826|OTHER|Best Practice|Undergo standard of care
214949376|NCT00404833|DRUG|prednisolone and mycophenolate mofetil|
215075871|NCT06052826|OTHER|Cognitive Intervention|Receive delirium prevention education
215075872|NCT06052826|OTHER|Comprehensive Geriatric Assessment|Undergo geriatric assessment
215075873|NCT06052826|OTHER|Nutritional Intervention|Undergo nutritional optimization
214486485|NCT06523556|DRUG|Azacitidine|Given IV or SC
214949377|NCT00404833|DRUG|prednisolone and chlorambucil|
214949378|NCT05890274|OTHER|AF and EKG Interpretation Project ECHO|The AF and EKG Interpretation Project ECHO program is delivered via Zoom videoconferencing technology and includes 12, 1-hour long sessions that involve education on best practice management of AF for primary care providers. Each session includes an EKG challenge, case presentation by a participant, didactic presentation, and time for open Q\&A. Supplementary materials are made available to all participants.
214949379|NCT06613542|DIETARY_SUPPLEMENT|4g of taurine daily|Intervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months
214949380|NCT06613542|DIETARY_SUPPLEMENT|Placebo|Controll group (4g of placebo/day): 2g of placebo (4 capsules, 500mg each) in the morning and 2g of placebo (4 capsules, 500mg each) in the evening for 6 months
215075874|NCT06052826|PROCEDURE|Physical Therapy|Undergo physical function optimization
215075875|NCT06052826|OTHER|Questionnaire Administration|Ancillary studies
215075876|NCT04773782|DRUG|avapritinib|oral administration
215075877|NCT05082051|DRUG|Part A|"Randomized, double-blind, placebo-controlled dose escalation part to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single oral dose administration in healthy adult subjects.~Single-dose administration of CDX-7108 at the following anticipated dose levels. 10 000, 50 000, 150 000, 250 000, and 500 000 lipase units will be evaluated in 5 sequential cohorts of 6 subjects each."
214343079|NCT03220191|DRUG|Rabeprazole|rabeprazole as PPI
214343080|NCT05712291|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
214343081|NCT05712291|DEVICE|TSolution One TCAT, and system for planning TPlan|the active robotic surgical system TSolution One TCAT, and system for planning TPlan
214343082|NCT05712291|PROCEDURE|total knee arthroplasty using the standard manual technic|total knee arthroplasty using the standard manual technic
214343083|NCT04612361|OTHER|insommnia severity index questionnaire|insomnia severity index questionnaire and scoring system
214343084|NCT02602301|DRUG|Oxytocin|different oxytocin diluents and effect on fetal bilirubin\&sodium levels.
214949381|NCT03729323|BEHAVIORAL|Motivational interviewing|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be addressed based on the principles and techniques of the Motivational Interviewing.
214949382|NCT03729323|BEHAVIORAL|Nursing Consultation|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be approached in a conventional manner, as routine of the services, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in DM2 and SAH and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
214949383|NCT02466607|DEVICE|RETeval color flicker ERG|Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.
214949384|NCT02466607|DEVICE|RETeval dilated versus un-dilated flicker ERG|Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.
214949385|NCT02466607|OTHER|pupil dilation|Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
214949386|NCT02735707|DRUG|Ceftriaxone|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
214949387|NCT02735707|DRUG|Moxifloxacin or Levofloxacin|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
214949388|NCT02735707|DRUG|Piperacillin-tazobactam|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
214949389|NCT02735707|DRUG|Ceftaroline|"The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.~Note: this intervention is now closed."
214949390|NCT02735707|DRUG|Amoxicillin-clavulanate|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
214949391|NCT02735707|DRUG|Standard course macrolide|"Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
214949392|NCT02735707|DRUG|Extended course macrolide|"Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
214949393|NCT02735707|OTHER|No systemic corticosteroid|Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
214949394|NCT02735707|DRUG|Fixed-duration Hydrocortisone|"50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention is now closed."
214343085|NCT02026700|DEVICE|bariederm cream|patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
214949395|NCT02735707|DRUG|Shock-dependent hydrocortisone|50mg IV hydrocortisone every 6 hours while the patient is in septic shock
214949396|NCT02735707|DRUG|Fixed-duration higher dose Hydrocortisone|"100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed."
214343086|NCT00089440|DRUG|Aripiprazole|
214343087|NCT02667158|OTHER|Survey to Eval Relation between Shopping and Misuse, Abuse|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
214343088|NCT04378075|DRUG|Vatiquinone|Vatiquinone will be administered per the treatment arm description.
214343089|NCT04378075|OTHER|Placebo|Vatiquinone-matching placebo will be administered per the treatment arm description
214343090|NCT06573957|DRUG|Dexmedetomidine|Patient in experimental arms will received intravenous dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before general anesthesia induction
214343091|NCT06573957|DRUG|Lidocain|Patient in experimental arms will receive intravenous lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation
214343092|NCT06634667|DRUG|third-generation EGFR-TKI combined with anlotinib|third-generation EGFR-TKI combined with anlotinib as maintenance therapy following 4 to 6 cycles of chemotherapy and immunotherapy until progressive disease.
214343093|NCT01218724|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
214486486|NCT06523556|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214486487|NCT06523556|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
214486488|NCT06523556|OTHER|Survey Administration|Ancillary study
214343094|NCT05841745|DEVICE|Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console. A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI.
214343095|NCT05799495|DRUG|PF-07817883|Arm 1: low dose Arm 2: medium dose Arm 3: high dose
214343096|NCT05799495|DRUG|Placebo|Placebo
214343097|NCT06299501|PROCEDURE|Routine questions|The routine group of nurses receive training and supervision and will ask questions about family violence to everyone, disregarding if they suspect family violence or not.
214343098|NCT06299501|PROCEDURE|Questions on evidence based indication|The group of nurses will receive training and supervision and will ask questions on evidence based indication
214343099|NCT06299501|PROCEDURE|Treatment as usual|The group of nurses will ask questions when suspecting ongoing violence in the family
214343100|NCT03105362|DIETARY_SUPPLEMENT|Enterade® oral rehydration solution|Commercially available amino acid based oral rehydration solution
214949397|NCT02735707|OTHER|No antiviral agent for influenza|No antiviral agent intended to be active against influenza infection is to be administered
214949398|NCT02735707|DRUG|Five-days oseltamivir|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
214949399|NCT02735707|DRUG|Ten-days oseltamivir|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
214949400|NCT02735707|OTHER|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
214949401|NCT02735707|DRUG|Lopinavir / Ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Note: this intervention is now closed."
214949402|NCT02735707|DRUG|Hydroxychloroquine|"Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
214949403|NCT02735707|DRUG|Hydroxychloroquine + lopinavir/ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
214949404|NCT02735707|DRUG|Ivermectin|"Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.~Note: this intervention is now closed."
214949405|NCT02735707|OTHER|No immune modulation for COVID-19|"No immune modulating agent intended to be active against COVID-19 is to be administered.~Note: this intervention is now closed."
214949406|NCT02735707|DRUG|Interferon beta-1a|"IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
214949407|NCT02735707|DRUG|Anakinra|"A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.~In patients with renal impairment, anakinra will be administered on alternate days.~Note: this intervention is now closed."
214949408|NCT02735707|DRUG|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.~Note: this intervention is now closed."
214949409|NCT02735707|DRUG|Sarilumab|"Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.~Note: this intervention is now closed."
214949410|NCT02735707|DRUG|Local standard venous thromboprophylaxis|"Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
215075878|NCT05082051|DRUG|Part B|"Randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after multiple oral dose administration in healthy adult subjects.~It will evaluate multiple dose administration of CDX-7108 at an appropriate low (50 000 lipase units), mid (150 000 lipase units), and high dose (250 000 lipase units) 4 times a day (QID) for 6 consecutive days in 3 sequential cohorts of 6 subjects each."
214343101|NCT06530953|BEHAVIORAL|Patient Navigator Model|The patient navigator model is an evidence-based intervention to improve access to healthcare services.
214343102|NCT01075659|DRUG|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
214343103|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
214486489|NCT06373653|DRUG|Manzanilla Sophia®|Matricaria recutita 0.025%, Ophthalmic solution.
214343104|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
214949411|NCT02735707|DRUG|Therapeutic dose anticoagulation|"Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.~Note: this intervention is now closed."
214949412|NCT02735707|DRUG|Conventional low dose thromboprophylaxis|Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
214949413|NCT02735707|DRUG|Intermediate dose thromboprophylaxis|Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
214949414|NCT02735707|DRUG|Continuation of therapeutic dose anticoagulation|"Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
214949415|NCT02735707|OTHER|No immunoglobulin|No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
215075879|NCT05082051|DRUG|Part C|"Randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI.~Approximately 10 subjects with severe EPI from partial/total pancreatectomy or chronic pancreatitis will be enrolled. It is anticipated that Part C (POC study) will commence after completion of the third single-dose cohort from Part A (SAD study) and following SRC review of the data from this cohort."
215075880|NCT05487040|DRUG|PF-07321332 (nirmatrelvir)/ritonavir|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
215075881|NCT04270682|DRUG|Blinded CDCA 250 mg TID|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
215075882|NCT04270682|DRUG|Placebo|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
215075883|NCT04270682|DRUG|Open-Label CDCA 250 mg TID|Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
215075884|NCT04270682|DRUG|Rescue Medication CDCA 250 mg TID|CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
215075885|NCT04270682|DRUG|CDCA Weight-Based Dose TID|Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
214343105|NCT01723891|DRUG|Surfolase capsule|
214343106|NCT01723891|DRUG|HT-002-01|
214343107|NCT02139852|DIETARY_SUPPLEMENT|Capsaicin|
214343108|NCT03074006|DRUG|TEW-7197|50mg tablets (doses will be determined through dose-escalation part)
214949416|NCT02735707|BIOLOGICAL|Convalescent plasma|Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
214949417|NCT02735707|BIOLOGICAL|Delayed administration of convalescent plasma|Note: this intervention is now closed.
214949418|NCT02735707|OTHER|No vitamin C|"No high dose intravenous vitamin C is to be administered~Note: this intervention is now closed."
214949419|NCT02735707|DRUG|Vitamin C|"Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses~Note: this intervention is now closed."
214949420|NCT02735707|OTHER|No antiplatelet|"No antiplatelet agent or NSAID to be administered.~Note: this intervention is now closed."
214949421|NCT02735707|DRUG|Aspirin|"Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
214949422|NCT02735707|DRUG|P2Y12 inhibitor|"Site-selected P2Y12 inhibitor:~* Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.~* Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.~* Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
214949423|NCT02735707|OTHER|No simvastatin|"No simvastatin intended to be active against COVID-19 is to be administered~Note: this intervention is now closed."
214949424|NCT02735707|DRUG|Simvastatin|"Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation~Note: this intervention is now closed."
214949425|NCT02735707|DRUG|Eritoran|"Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital~Note: this intervention is now closed."
214486490|NCT06373653|DRUG|Meticel Ofteno®|Hypromellose 0.5%, Ophthalmic solution.
214486491|NCT05756660|DRUG|Sodium Thiosulfate|This goal of this study is to evaluate the efficacy of the proposed regimens in patients with relapsed/refractory platinum pre-treated patients with Hepatoblastoma, Wilms tumor, Germ Cell Tumor (GCT), and Neuroblastoma. The patients' initial cisplatin response (hepatoblastoma) and diagnosis will determine their treatment regimen on this study.
215075886|NCT05479097|DRUG|Anti-Hypertensive|Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
214343109|NCT03330834|BIOLOGICAL|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
214949426|NCT02735707|DRUG|Apremilast|"Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
214949427|NCT02735707|PROCEDURE|Clinician-preferred mechanical ventilation strategy|Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
214949428|NCT02735707|PROCEDURE|Protocolised mechanical ventilation strategy|Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
214949429|NCT02735707|OTHER|No renin-angiotensin system inhibitor|"No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.~Note: this intervention is now closed."
214949430|NCT02735707|DRUG|Angiotensin converting enzyme inhibitor|"Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
214949431|NCT02735707|DRUG|Angiotensin Receptor Blockers|"Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
214949432|NCT02735707|DRUG|ARB + DMX-200|"Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.~ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.~Note: this intervention is now closed."
214949433|NCT02735707|OTHER|No cysteamine|"No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.~Note: this intervention is now closed."
214949434|NCT02735707|DRUG|Cysteamine|"Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
214949435|NCT02735707|DRUG|Fixed-duration dexamethasone|6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
214949436|NCT02735707|DRUG|Baloxavir Marboxil|Baloxavir marboxil administered on days 1 and 4 post-randomisation.
214949437|NCT02735707|DRUG|Five-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
215075887|NCT02589652|DRUG|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
215075888|NCT02589652|DRUG|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
215075889|NCT02589652|DRUG|Entecavir|ETV 0.5mg oral daily for 48 weeks
215075890|NCT01377610|DRUG|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
215075891|NCT01377610|DRUG|Buprenorphine|Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
215075892|NCT01377610|DRUG|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
215075893|NCT02110680|DEVICE|Sports TENS 2|transcutaneous electric stimulation
215075894|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
215075895|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
215075896|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
215075897|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
215075898|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
215075899|NCT00822419|DRUG|lidocaine|lidocaine cream 5%
215075900|NCT00822419|DRUG|ketamine|ketamine 5%
215075901|NCT00822419|DRUG|non-drug cream|will be put on the skin
215075902|NCT03269968|DEVICE|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
214486492|NCT03215706|BIOLOGICAL|Ipilimumab|Specified dose on specified day
215075903|NCT03269968|DEVICE|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
215075904|NCT03325868|DRUG|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
214343110|NCT01110291|DRUG|docetaxel + CEF|"Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.~Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times."
214343111|NCT01672151|DRUG|rapamycin|4mg oral administration on the first day, 2 mg/d oral administration for 3 months
214949438|NCT02735707|DRUG|Ten-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
214949439|NCT02735707|OTHER|No endothelial modulator|No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
214949440|NCT02735707|DRUG|Imatinib|Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
214949441|NCT02735707|OTHER|No Immune Modulator for Influenza|No immune modulating agent intended to be active against influenza is to be administered.
214949442|NCT02735707|DRUG|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period."
214949443|NCT02735707|DRUG|Baricitinib|Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
214949444|NCT02735707|OTHER|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
214949445|NCT02735707|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
214949446|NCT02735707|DRUG|Remdesivir|Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
214949447|NCT02735707|DRUG|Nirmatrelvir/ritonavir + remdesivir|Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
214343112|NCT05146791|PROCEDURE|Inlay Bristow|A modified Bristow procedure
214343113|NCT05146791|PROCEDURE|Bristow|Traditional Bristow procedure
214343114|NCT01389219|OTHER|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~1. Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron \& vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~2. Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~3. Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5\. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
214343115|NCT02977546|DEVICE|Noninvasive pulse contour analysis|For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
214343116|NCT02977546|DEVICE|Pulmonary artery catheterization|As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
214343117|NCT06458361|PROCEDURE|Type of bowel resection, surgical complexity score, intraoperative blood loss, perioperative erythrocyte transfusion, type of anastomosis|Basic information about ovarian cancer patients and factors associated with preoperative, intraoperative and postoperative periods
214343118|NCT02371369|DRUG|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
214343119|NCT02371369|DRUG|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
214343120|NCT05316038|DIAGNOSTIC_TEST|Oral glucose tolerance test|The test is performed on an empty stomach for at least 10 hours. The first blood sugar level is taken on an empty stomach. Then ingestion of 75g of sugar. A second blood test takes place 1 hour after the sugar intake and the third blood sugar test takes place 2 hours after the sugar intake.
214343121|NCT03607383|DRUG|Red Rice Yeast Extract|adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
214343122|NCT03607383|DRUG|Statin|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
214343123|NCT00256789|PROCEDURE|Radiation|
214343124|NCT00256789|DRUG|Chemotherapy|
214343125|NCT03352115|DRUG|Prednisolone|5 day course of oral prednisolone
214949448|NCT02893423|DRUG|Ropivacaine|Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
214949449|NCT00315042|DRUG|Telithromycin (HMR3647)|
214949450|NCT00315042|DRUG|Penicillin|
214949451|NCT05857670|BEHAVIORAL|Genetic predisposition to breast cancer|Guilt feelings about procreating
214949452|NCT03555942|DRUG|Follicular phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the follicular phase (day 2 or 3 of the menstrual cycle)
214343126|NCT03352115|DRUG|Placebos|Placebo syrup
214949453|NCT03555942|DRUG|Luteal phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the luteal phase (5 days after an LH peak)
214949454|NCT06241066|OTHER|no-Intervention|no-Intervention
214949455|NCT03602794|PROCEDURE|PECs Block|Regional Anaesthesia Technique ie Pectoralis Nerve Block under ultrasound guidance
214949456|NCT03602794|PROCEDURE|Local infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
214949457|NCT00232466|PROCEDURE|Vertebroplasty|"Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay."
214949458|NCT03092336|OTHER|Electrical Stimulation|electrical stimulation training
214949459|NCT03092336|OTHER|Strength training|strength training group
214949460|NCT02412254|OTHER|Best practices hearing rehabilitative treatment|Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
214949461|NCT02412254|OTHER|Successful aging intervention|One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
214949462|NCT01051258|DEVICE|AeriSeal System|AeriSeal System for Lung Volume Reduction
214949463|NCT05525780|DRUG|GB-5001|Depending on the cohort, volume will be varied to administer.
214949464|NCT05525780|DRUG|Placebo|A matched volume of placebo product will be administered to each subject in each cohort.
215075905|NCT02632669|RADIATION|Hemigland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre-treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine-125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks, 3, 6, 9, 12,18, 24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
215075906|NCT00142805|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
214343127|NCT06123767|PROCEDURE|CAS + Intravascular measuring the pressure gradient|"Measurements taken during the procedure during CAS~* placement of a FFR- micro catheter on the neuroprotection wire and taking a measurement before the stenosis and in the internal carotid artery above the stenosis~* reading the pressure gradient after obtaining a stable value (a minimum of 5 cardiac cycles)~  * the study of intravascular pressure measurements will be performed using a special micro catheter"
214343128|NCT06123767|PROCEDURE|CAS (standard)|"Animation of blood pressure measurements on the FFR console without actual measurement in carotid artery (blinding of the study to the patient) during CAS procedure."
214343129|NCT06123767|DIAGNOSTIC_TEST|Doppler ultrasonound of cephalic arteries|non-invasive assessment of carotid stenosis before surgery and assessment of results after CAS (3 and 12 months after CAS)
214949465|NCT05525780|DRUG|Oral cohort|Single dose of Aricept tablet
214949466|NCT02415062|DRUG|Donepezil|23mg/day for 24 weeks versus 10mg/day for 24 weeks
214949467|NCT00006220|DRUG|arsenic trioxide|
214949468|NCT00006220|DRUG|tretinoin|
214949469|NCT01249326|OTHER|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
214949470|NCT03245190|DRUG|Chiauranib|50mg, orally once daily
214949471|NCT04650334|BEHAVIORAL|Collaborative Care|Health services intervention to implement a team based model of care for perinatal depression.
214949472|NCT04065581|DRUG|Acarbose/Metformin FDC(BAY81-9783)|Single dose: 50 mg acarbose/500 mg metformin tablet, oral
214343130|NCT06123767|RADIATION|Angio-CT of the neck and head|Non-invasive pre-operative assessment and post-CAS result (3 months after)
214486493|NCT03215706|BIOLOGICAL|Nivolumab|Specified dose on specified day
214949473|NCT04065581|DRUG|Glucobay|Single dose: 50 mg tablet, oral
214949474|NCT04065581|DRUG|Glucophage|Single dose: 500 mg tablet, oral
214949475|NCT02074319|DRUG|Methotrexate|Treatment as usual or standard treatment for psychosis will be common in all arms
214949476|NCT02454634|DRUG|IDH1 peptide vaccine|
214949477|NCT05266924|DRUG|Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen|fixed-dose of 225 IU/day, subcutaneous (SC), daily, for 5 days. further dosage will be adjusted till adequate follicular development.
214486494|NCT03215706|DRUG|Carboplatin|Specified dose on specified day
214486495|NCT03215706|DRUG|Paclitaxel|Specified dose on specified day
214486496|NCT03215706|DRUG|Pemetrexed|Specified dose on specified day
214949478|NCT00001037|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
215075907|NCT00142805|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
215075908|NCT02242136|BEHAVIORAL|FORNET|
214343131|NCT06123767|OTHER|Otolaryngological examination|Hearing and balance tests (before and after CAS) - prospective follow-up
214343132|NCT06123767|OTHER|Psychological examination|psychological examination with questionnaires (before and after CAS) - prospective follow-up
214949479|NCT04104087|PROCEDURE|tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.|enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
214949480|NCT05537285|DEVICE|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|active side magnetic coil stimulation applied to individualized target in the left dorsal lateral prefrontal cortex.
214949481|NCT05537285|DEVICE|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|active side magnetic coil stimulation applied to standardized target in the left dorsal lateral prefrontal cortex.
214949482|NCT05537285|DEVICE|Sham Accelerated Intermittent Theta Burst Stimulation (Sham)|sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
214949483|NCT03316066|PROCEDURE|stellate ganglion block with ropivacaine 0.2% 5 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
214949484|NCT03316066|PROCEDURE|stellate ganglion block wit ropivacaine 0.2% 2 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
214949485|NCT01243294|DEVICE|SS|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
214949486|NCT01243294|DEVICE|SenSura|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
214949487|NCT06730789|DEVICE|Epicondylitis bandage|A conservative treatment method of lateral epicondylitis.
214949488|NCT06730789|DEVICE|Wrist dorsiflexion splint|A conservative treatment method of lateral epicondylitis.
215075909|NCT04627324|DEVICE|The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)|"The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
215075910|NCT04627324|DEVICE|Conventional toothbrush|"toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
215075911|NCT00570011|DRUG|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
215075912|NCT00570011|DRUG|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
215075913|NCT04003207|DRUG|Recombinant human Growth hormone|Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
214343133|NCT06123767|OTHER|Neurological examination|neurological examination with questionnaires (before and after CAS) - prospective follow-up
214949489|NCT06730789|DEVICE|Kinesio tape|A conservative treatment method of lateral epicondylitis
214949490|NCT01487239|DRUG|[14C]-GDC-0980|100 uCi of \[14C\]-GDC-0980 in total dose of 10 mg GDC-0980
214949491|NCT05072587|BEHAVIORAL|Plant-based diet with no oxysterols|This group will be given 3 prepared plant-based meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
214949492|NCT05072587|BEHAVIORAL|Standard ADA Diet (SADA)|This group will be given 3 prepared meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
215075914|NCT01790178|PROCEDURE|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
215075915|NCT04104815|OTHER|Experimental Thickener|Use to thicken liquids
215075916|NCT01098604|DEVICE|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
215075917|NCT01098604|DEVICE|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
214343134|NCT06123767|DIAGNOSTIC_TEST|MR cerebral perfusion|"Assessment of the cerebral perfusion alterations using DSC (dynamic susceptibility contrast) MR perfusion, before and after CAS (after 3 months):~Parametric maps of cerebral blood flow (CBF), cerebral blood volume (CBV), time to peak (TTP), and mean transit time (MTT) will be generated and used for the qualitative and quantitative analyses of the following perfusion parameters:~* cerebral blood volume (CBV) value in ml/100ml;~* cerebral blood flow (CBF) value in ml/100ml/min;~* mean transit time (MTT) value in seconds~* time to peak (TTP) value in seconds"
214486497|NCT03215706|DRUG|Cisplatin|Specified dose on specified day
214486498|NCT06737016|DRUG|Tamsulosin|Children will be maintained on an oral dose of Tamsulosin 0.1 mg once daily (in children aged less than 2 years old) and 0.2 mg once daily (≥2 years old).
215075918|NCT01730664|DRUG|ertapenem|single dose of 2000mg ertapenem IV
215075919|NCT04403152|OTHER|Post-operative rehabilitation|Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
215075920|NCT04403152|OTHER|Post-operative mobilization|Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
214949493|NCT06239805|DEVICE|QMR|"A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off."
214949494|NCT01827709|OTHER|A polymerase chain reaction -based hypoxia classifier|"Recently, a polymerase chain reaction (PCR) -based hypoxia classifier gene signature was published that can be easily applied. Using this classifier, patients will be divided in hypoxic or non-hypoxic subgroups.~These subgroups will be correlated to locoregional control. The hypoxic signature will also be related to parameters on DCE-MRI, DWI and FDG-PET."
214949495|NCT01827709|OTHER|Functional imaging before treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with pathology.
214949496|NCT01827709|OTHER|Immunohistochemical staining|At 3 levels of the tumour, chosen by the radiologist on the functional imaging modalities, 4µm thick slices will me taken. On each level an immunohistochemical staining will be carried out (GLUT-1, CA-IX, HIF-1alpha, VEGF, KI 67). The result of this staining will be correlated with parameters derived from the functional imaging modalities.
214949497|NCT01827709|OTHER|MRI of the resection specimen|To account for the shrinkage of the tumour due to fixation, the resection specimen will be placed in a box and scanned with an MRI. From this a shrinkage factor will be calculated using the original pre-treatment MRI.
214949498|NCT01827709|OTHER|Tumour volume delineation and comparison|On the imaging modalities the tumor volume will be delineated. This will also be done on the resection specimen. Later on the different tumour volumes will be correlated.
215075921|NCT06289127|BEHAVIORAL|Lower Quarter Y Balance Test|The LQYBT is a widely used test for assessing lower extremity dynamic balance and neuromuscular control. Participants' lower limb balance was performed using The Y Balance Test Kit™ (Move2Perform, Evansville, IN).
215075922|NCT02342457|DEVICE|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
215075923|NCT05045742|OTHER|Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2|We will retrospectively compare the alarms produced from traditional vital sign alarms (thresholds set by clinicians) versus the BioVitals Index vs the National Early Warning Score 2
215075924|NCT03894969|BIOLOGICAL|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
215075925|NCT03894969|BIOLOGICAL|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh\_NTHi-Mcat\_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
215075926|NCT01757223|BIOLOGICAL|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
215075927|NCT01757223|BIOLOGICAL|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
215075928|NCT00003406|DRUG|carboplatin|
215075929|NCT00003406|DRUG|docetaxel|
214949499|NCT05067894|BIOLOGICAL|SARS-CoV-2 Protein Subunit Recombinant Vaccine|intramuscular injection
214949500|NCT05067894|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|intramuscular injection
215075930|NCT00003406|DRUG|ifosfamide|
215075931|NCT00003406|PROCEDURE|autologous bone marrow transplantation|
215075932|NCT00003406|PROCEDURE|bone marrow ablation with stem cell support|
215075933|NCT00003406|PROCEDURE|peripheral blood stem cell transplantation|
215075934|NCT06489821|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy in 5 fractions (body) or 2 or 4 fractions (spine) plus continuation of first line systemic therapy
215075935|NCT06287593|OTHER|ctDNA monitoring|Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.
214949501|NCT01063231|DEVICE|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
214949502|NCT00004901|DRUG|ethynyluracil|
214949503|NCT00004901|DRUG|fluorouracil|
214949504|NCT00004901|DRUG|hydroxyurea|
214949505|NCT00004901|RADIATION|radiation therapy|
214949506|NCT03129295|DRUG|MPC-SHRC|Oral tablet four times a day for 3 days
214949507|NCT03129295|DRUG|Placebo Oral Tablet|Oral tablet four times a day for 3 days
214949508|NCT02886884|DRUG|20 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
214949509|NCT02886884|DRUG|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
215075936|NCT04732858|OTHER|Cross sectional e-Survey on surgeons exposed to any educational intervention|"Educational intervention was considered as any procedure or program to facilitate the acquisition of basic skills about the disease, its ramifications and treatment2,6,7:~* Education in infectious disease, including~  * pandemic training for health personnel~ * Personal protective equipment (PPE) and protection.~ * Specific speed-training focusing on environmental control (decontamination area, dressing...), personal protection, hand hygiene, sample management, risky gestures, control measures.~* Intensive care education:~  * mechanical ventilation~ * airways management~ * emergencies and cardiovascular drugs~ * Intensive care monitoring systems~* Basic nurse skills~* COVID-specific clinical management"
215075937|NCT00589056|DRUG|cisplatin|
215075938|NCT00589056|DRUG|etoposide|
215075939|NCT00589056|DRUG|nelfinavir mesylate|
215075940|NCT00589056|GENETIC|protein expression analysis|
215075941|NCT00589056|OTHER|immunohistochemistry staining method|
214343135|NCT06119659|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
214343136|NCT06119659|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
214949510|NCT03756818|DRUG|Mivavotinib|Given PO
214949511|NCT03756818|DRUG|Paclitaxel|Given IV
214343137|NCT06119659|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
214949512|NCT03756818|OTHER|Pharmacokinetic Study|Correlative studies
215075942|NCT00589056|OTHER|laboratory biomarker analysis|
214343138|NCT04295889|DIAGNOSTIC_TEST|Approach A (PeeSpot urine collection device).|The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
214343139|NCT04295889|DIAGNOSTIC_TEST|"Approach B (ACR | EU Test kit)."|"The participant will receive the ACR \| EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app."
214343140|NCT00761059|DRUG|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
214343141|NCT00761059|DRUG|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
214343142|NCT01573702|PROCEDURE|Stereotactic Radiosurgery|21 Gy daily for 5 days
214343143|NCT01573702|DRUG|Erlotinib|150mg once daily
214343144|NCT03925636|DIETARY_SUPPLEMENT|Specific Carbohydrate Diet|The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
214343145|NCT03115424|DRUG|Saxenda|Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
214343146|NCT03115424|DRUG|Placebos|Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
214343147|NCT03115424|PROCEDURE|RYGB|Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
214343148|NCT02278601|DEVICE|epidural delivery system|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
214343149|NCT02278601|DRUG|Ropivacaine|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
214343150|NCT02278601|DRUG|Fentanyl|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
214949513|NCT03497767|DRUG|Osimertinib|All participants will receive a dose of Osimertinib 80mg once daily
214949514|NCT03497767|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation depend on lesion size. All SRS must be completed within 21 days of randomisation and all lesions are to be treated within 7 days.
214949515|NCT00497055|DRUG|Aripiprazole|
214949516|NCT00497055|DRUG|Placebo|Sugar pill manufactured to mimic Aripiprazole gel caps.
214949517|NCT00575510|BEHAVIORAL|Intervention|Multiple component intervention based in the unified theory of behavior
214949518|NCT00575510|BEHAVIORAL|Active control|Partial intervention (full intervention minus cultural-specific component)
214949519|NCT01170819|DEVICE|Double balloon catheter|The balloons either side of the cervix are inflated with 50 ml of water. The catheter is removed after 12 hours if spontaneous expulsion has not occurred.
214949520|NCT01170819|DRUG|Dinoprostone 10 mg controlled-release vaginal insert|Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
215075943|NCT00589056|PROCEDURE|biopsy|
215075944|NCT00589056|RADIATION|radiation therapy|
214343151|NCT00240422|DRUG|Telmisartan|
214343152|NCT00240422|DRUG|Ramipril|
214949521|NCT00999700|DRUG|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
214949522|NCT00999700|RADIATION|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
214949523|NCT00999700|DRUG|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
214949524|NCT00999700|DRUG|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
214949525|NCT00999700|RADIATION|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
214949526|NCT03489200|OTHER|EH301|1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene
214949527|NCT03489200|OTHER|Placebo|No intervention- placebo
214949528|NCT01745107|RADIATION|Prophylactic postoperative radiation therapy|Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
214949529|NCT05410704|OTHER|exercises|Pelvic floor muscle exercises and diaphragmatic breathing exercise
214949530|NCT02540967|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Gadovist dosage following summary of product characteristics
214949531|NCT06414876|BEHAVIORAL|Hospital dog|The hospital dog always has a well educated dog instructor beside.
214949532|NCT02634944|DIAGNOSTIC_TEST|Vestibular Ocular Motor Screening Tool (VOMS)|Vestibular Ocular Motor Screening Tool (VOMS)
214949533|NCT04046822|DRUG|Liraglutide 6 MG/ML [Saxenda]|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
214949534|NCT04046822|DRUG|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
214949535|NCT01267422|DRUG|rAAV2-ND4|injection
214949536|NCT03002532|RADIATION|whole brain radiotherapy|
214949537|NCT03738761|DRUG|Amlessa®|Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
214949538|NCT03738761|DRUG|Co-Amlessa®|Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
214949539|NCT03173261|DIAGNOSTIC_TEST|Genexpert|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
214949540|NCT04118777|DRUG|Ropivacaine|0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
214949541|NCT03904316|BIOLOGICAL|Biodesign Otologic graft|Acellular matrix derived from porcine small intestine submucosa
214949542|NCT03904316|OTHER|Autologous temporalis fascia|An autologous graft for tympanic membrane repair
214949543|NCT01872650|DEVICE|C-Qur|In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
214949544|NCT05041660|OTHER|Virtual-reality-based training|Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
214949545|NCT05041660|OTHER|Inhibitory Control Training|"Uses an active inhibitory control training which includes a stop signal."
215075945|NCT04613765|BEHAVIORAL|Measure adherence behaviors|"Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings."
215075946|NCT02198482|DRUG|Volasertib|
215075947|NCT02198482|DRUG|Cytarabine|
215075948|NCT02198482|DRUG|Daunorubicin|
215075949|NCT02198482|DRUG|Mitoxantrone|
214343153|NCT04638608|OTHER|EMBRACE (relatives)|Online support program for both relatives
214343154|NCT04638608|OTHER|EMBRACE (Health care providers)|Online support program for health care providers
214343155|NCT06398704|OTHER|Standart of care|No additional intervention was made. An evaluation was made.
214949546|NCT05041660|OTHER|Sham Inhibitory Control Training|"Uses an inhibitory control training which does not include a stop signal."
214949547|NCT05041660|OTHER|Computerized training|Uses a relatively simplistic computerized training.
214949548|NCT02256306|OTHER|Plasma|1 unit of Plasma From Young Donors (Male, aged 30 or younger)
214949549|NCT03048071|OTHER|Data collection within medical files|Data collection within medical files
214343156|NCT05584501|OTHER|Care Navigator|The Dental Team will have a Care Navigator as an added resource to assist with offering, implementing, and counseling for HIV testing; providing PrEP education and linkage; and providing linkage and re-linkage to HIV care.
214343157|NCT05584501|OTHER|Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting|Dental Teams will receive a Best Practice Alert (BPA) when they have a patient who should be offered HIV testing. Dental Teams will also be notified when they have a patient known to be HIV positive but out of HIV care.
214343158|NCT02422030|DRUG|Lipitor Tab. 40mg|
214343159|NCT02422030|DRUG|Trilipix 135mg|
214949550|NCT01464853|OTHER|Enteral nutrition with fatty acids|Enteral Feeding to provide 25 kcal/Kg/day
214949551|NCT01464853|OTHER|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
214949552|NCT02104167|DEVICE|ROIC interbody cage with VerteBRIDGE plating|
214949553|NCT00426972|DRUG|estradiol (Zesteem)|
214949554|NCT00004896|DRUG|busulfan|
214949555|NCT00004896|DRUG|cyclophosphamide|
214949556|NCT00004896|PROCEDURE|allogeneic bone marrow transplantation|
214949557|NCT00004896|PROCEDURE|bone marrow ablation with stem cell support|
214949558|NCT00004896|RADIATION|radiation therapy|
214949559|NCT01699308|DRUG|Genotropin|
214949560|NCT04043208|BEHAVIORAL|Biofeedback|Three sessions of biofeedback will be performed during the first 3 weeks of the intervention period. Biofeedback sessions will be performed 30 min after ingestion of the offending meal: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; specifically, they will be instructed to reduce the abdominal perimeter (girth). Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
214949561|NCT04043208|DIETARY_SUPPLEMENT|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. Each session will be performed 30 min after ingestion of the offending meal: abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
214949562|NCT02599337|DRUG|Nexavar|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
214949563|NCT02599337|DRUG|Sorafenib|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
214949564|NCT02548715|DRUG|Levothyroxine|
214949565|NCT02548715|DRUG|Placebo|
214949566|NCT06265571|OTHER|perineural injection|perineural injection of local anesthestetic for postoperative pain management
214949567|NCT03103685|DRUG|Clopidogrel|The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
214343160|NCT05897216|DRUG|CKD-383|QD, PO
214343161|NCT05897216|DRUG|CKD-501, D745, D150, D029|QD, PO
214343162|NCT03231384|DEVICE|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906"
214343163|NCT00452881|DRUG|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
214343164|NCT00452881|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
214343165|NCT00452881|DRUG|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
214343166|NCT02869971|DEVICE|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
214949568|NCT02774187|DRUG|Sorafenib|administration of Sorafenib
214949569|NCT02774187|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214343167|NCT02869971|DRUG|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
214343168|NCT00732121|DRUG|Sitagliptin|100 mg daily for 4 weeks
214343169|NCT00732121|DRUG|Placebo|Placebo
214949570|NCT02774187|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
214949571|NCT01773356|DIETARY_SUPPLEMENT|Dihydrocapsiate|Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
214949572|NCT03949738|DIAGNOSTIC_TEST|Near-infrared spectroscopy-based assessement of cerebral autoregulation.|"Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation."
214949573|NCT05981014|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
214949574|NCT05981014|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
214343170|NCT03339518|BEHAVIORAL|BRIM3 educational intervention|Breast Cancer risk education and counseling
214343171|NCT03339518|BEHAVIORAL|Wait List|Booklet at the end of study
214343172|NCT00503685|BIOLOGICAL|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
214343173|NCT00503685|BIOLOGICAL|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
214343174|NCT00917813|DRUG|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
214949575|NCT05981014|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
214949576|NCT05981014|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
214949577|NCT05981014|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
214343175|NCT00917813|DRUG|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
214949578|NCT05981014|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
214949579|NCT05981014|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
214949580|NCT05981014|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
214949581|NCT05981014|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
214949582|NCT00164164|DRUG|HalfLytely|
214949583|NCT00164164|DRUG|NuLytely|
214949584|NCT05298436|OTHER|Follow-up interview|All participants will be followed up at defined time points post-stroke by face-to-face or telephone interview or postal questionnaire.
214949585|NCT07027384|DEVICE|Web-Based Apps PRIMA|Apps PRIMA (posyandu monitoring tools) is delivered using a web-based app accessible through web browsers with basic core functionalities
214949586|NCT07027384|DEVICE|Apps PRIMA Mobile|Enhancement of Apps PRIMA delivered using a standalone mobile app. Enhanced core functionalities include the looping system of children measurements, automatic charts, and GEDSI-sensitive features
214949587|NCT07027384|BEHAVIORAL|Advance GEDSI Training|Additional training to address vulnerabilities in communities and empathetic service from CHWs to caregivers. The training is a follow-up training from a basic GEDSI materials already delivered to CHWs
215075950|NCT00468676|BEHAVIORAL|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
215075951|NCT00468676|BEHAVIORAL|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
215075952|NCT03569748|DEVICE|IQOS|IQOS USE FOR 12 WEEKS
214343176|NCT00485108|DRUG|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
214343177|NCT00485108|DRUG|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
214343178|NCT00485108|DRUG|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
214343179|NCT00389818|BIOLOGICAL|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
214343180|NCT00389818|BIOLOGICAL|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
214343181|NCT00389818|BIOLOGICAL|rituximab|375 mg/m2 IV Day 1 of each cycle
214343182|NCT00389818|BIOLOGICAL|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
214343183|NCT00389818|DRUG|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
214343184|NCT00389818|DRUG|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
214343185|NCT00389818|DRUG|prednisone|100 mg PO Days 1-5 of each cycle
214343186|NCT00389818|DRUG|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
214343187|NCT00389818|OTHER|immunohistochemistry staining method|tissue specimen collected at baseline
214343188|NCT00389818|OTHER|laboratory biomarker analysis|tissue specimen collected at baseline
214343189|NCT04530175|OTHER|blood sampling|2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.
214949588|NCT06885580|BEHAVIORAL|Education|Students will be provided with digital privacy literacy training designed using the puzzle method, which will consist of 8 sessions over a 12-week period.
214949589|NCT06884397|PROCEDURE|Abdominal aortic endoprosthesis|An endoprosthesis consisting of a metal spring covered with an impermeable fabric is inserted through an artery and deployed inside the aorta.
214949590|NCT06728722|DIAGNOSTIC_TEST|ultrasound detection of body composition|"Muscle mass and fat thickness The examiner will use a five-site protocol. The protocol includes the examination of quadriceps on four sides and one bicep will be used The technique is reported by USVALID (Arabella, 2020) GRADING OF QUALITY OF ULTRASOUND SCANS - Muscle quality (fat and fibrotic infiltration) grading for each scan~1. = Muscle fascia and bone surface visible~2. = muscle fascia and bone surface still possible to spot~3. = muscle fascia and bone surface not distinguishable; no evaluation possible~The FLUID protocol for edema will be done as follows: MEASURING POINTS 36 points, GRADING OF QUALITY: The examiner will use a 5-point scale of ultrasonic subcutaneous edema grade (USEG) to evaluate subcutaneous edema at each site based on echo intensity, tissue transparency, and fluid properties.~Day zero, day 2 then Every 2 days if extended length."
214949591|NCT00106639|DRUG|CP-690,550|15 mg twice daily
214949592|NCT00106639|DRUG|CP-690,550|30 mg twice daily
214949593|NCT00106639|DRUG|tacrolimus|dose adjusted according to level
215075953|NCT03569748|DEVICE|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
215075954|NCT01893372|DRUG|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
215075955|NCT01893372|DRUG|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
214949594|NCT03904368|PROCEDURE|Open myomectomy|laparotomy then enucleation of the myoma followed by closure of the myometrial cavity
214949595|NCT03904368|DRUG|Gonadotropins|Gonadotropin stimulation of follicular growth
214343190|NCT06572280|DEVICE|PNS group|non-invasive phrenic nerve stimulation
214343191|NCT03110159|DRUG|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
214343192|NCT03110159|DRUG|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
214343193|NCT06574867|DEVICE|viQtor Wearable Monitoring Device|The viQtor device is a wearable medical device designed for continuous monitoring of vital signs, including heart rate (PR), respiratory rate (RR), and blood oxygen saturation (SpO2). It is worn on the upper arm and transmits data wirelessly to a cloud-based platform. This device is being evaluated as part of the standard monitoring protocol for post-operative patients in a surgical ward setting.
214343194|NCT05404022|OTHER|Tailored nutrition and physical activity programme|"Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~1. Information on side-effects that may affect eating and their mitigation~2. Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~3. Feedback on assessment of food intake and how to improve~4. a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~5. a recipe book Making the most of every bite~6. tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required"
214343195|NCT06440668|BEHAVIORAL|Chronic Pain Management Workshop with Non-Pharmacological Therapies|"1st Session: Welcome. Expectations. Pathophysiological mechanism of pain. Influence of emotions on pain intensity. Activities: My limiting beliefs; Affirmations in front of the mirror; Mental analgesia. / 2nd: Pain and its impact on the patient's life. Forgiveness and self-forgiveness. Ho'oponopono technique. Self-esteem. Activities: Labels that limit us; Reading When I Loved Myself for Real; Self-healing meditation; Life purpose. / 3rd: Tips to slow down aging. Promotion of healthy habits; Metta meditation; Motivation for change. / 4th: Active participation in my own healing. How to face illness. Creative visualization. Activity:Energy wheel. / 5th: Review of the tools. Resolving doubts. Workshop evaluation and scales. Guide with the tools presented. Activities: Final farewell. / At the end of each session, the homework assignments are explained, and at the beginning of the next, they are reviewed. Sessions 2, 3, 4 5: Experience of a previous workshop patient."
214343196|NCT03762226|DRUG|Anti-VEGF|Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
214343197|NCT04170192|PROCEDURE|Cord Blood Stem Cell Transplantation|Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
214343198|NCT02838017|DEVICE|Tissue Adhesive|
214343199|NCT02838017|DEVICE|Sterile strips|
214343200|NCT02120924|DRUG|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
214343201|NCT02120924|DRUG|Vehicle|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
214343202|NCT02120924|DRUG|Finacea|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
214343203|NCT02212223|DIETARY_SUPPLEMENT|Vitamin D3|
214343204|NCT01884350|DRUG|Apixaban|
214949596|NCT03904368|DRUG|Human chorionic gonadotropin|HCG triggering of ovulation
214949597|NCT03904368|PROCEDURE|Ovum pick up|34 to 36 hours after HCG triggering
214949598|NCT03904368|PROCEDURE|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
214949599|NCT02105389|BEHAVIORAL|Individualized Yoga Intervention|
214949600|NCT06750445|DRUG|Fluoxetine|Patients in the fluoxetine group received oral fluoxetine starting at 40 mg/day for six months. Treatment was discontinued if serious adverse reactions developed or if no improvement was observed after dose escalation. Compliance and treatment progress were monitored via telephone follow-ups. For patients unable to have a bowel movement for three consecutive days or experiencing intolerable symptoms, polyethylene glycol (PEG, 10 g) was provided as rescue medication. Bowel movements within 24 hours of rescue medication use were excluded from the count of complete spontaneous bowel movements (CSBM).
214949601|NCT06750445|DRUG|Polyethylene Glycol 400 0.4%|The control group (PEG) used polyethylene glycol as a rescue medication under the same conditions, following similar monitoring and follow-up procedures.
214949602|NCT06759415|OTHER|Exercise|Exercise therapy was applied to individuals in both groups.
214949603|NCT06770933|DRUG|VX-01|There is no physical difference in VX-01 and the placebo. The only difference lies in active ingredient found in VX-01, which is the compound that will be evaluated in the course of this study.
214949604|NCT06770933|DRUG|Placebo|Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.
214949605|NCT06417307|BEHAVIORAL|Supervised exercise training|Participants perform Intradialytic cycling exercise training in the hospital for 6 months (24 weeks) and 3 months (12 weeks) at home. Exercise prescription: 50-60% maximal workload for 20-30 minutes, including low intensity warm-up and cool down (30% of maximal workload).
214949606|NCT06417307|BEHAVIORAL|Control group|Maintain daily lifestyle until the end of the study. Receive no intervention/supplements.
214949607|NCT04636671|DRUG|Methylprednisolone|Per-protocol methylprednisolone administration and tapering (see arm description)
214949608|NCT04636671|DRUG|Dexamethasone|Per-protocol dexamethasone administration (see arm description)
214343205|NCT03062826|DRUG|dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)|Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).
214343206|NCT01059617|BIOLOGICAL|GSK Biologicals' FluLaval®|Intramuscular injection
214343207|NCT01059617|BIOLOGICAL|Placebo (saline)|Intramuscular injection
214343208|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
214343209|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
214343210|NCT06535087|DRUG|Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis|"1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation."
214949609|NCT06899451|OTHER|systematic desensitization and balance|"1. Systematic desensitization: 2 techniques~   1. Jacobson's technique (progressive muscle relaxation):~  2. Guided imagery training is a relaxation technique~2. Goal-directed paradigm (selected program)"
214949610|NCT04958291|DRUG|CC-99677|CC-99677
214949611|NCT04958291|OTHER|Placebo|Placebo
214949612|NCT02360202|PROCEDURE|Impedance analysis|"Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.~impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle"
214949613|NCT02360202|DRUG|Clobetasol Propionate cream treatment|clobetasol propionate treatment initiated following French recommendations
214949614|NCT04328415|RADIATION|Cerebral scintigraphy|Radioactive tracer 99mTc-DTPA
214949615|NCT06879145|DRUG|SHR-A2102；Adebrelimab|Treatment with SHR-A2102 in combination with fixed dose Adebrelimab
214949616|NCT06762457|DRUG|MT-501|MT-501 Tablets
214949617|NCT03193034|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
214949618|NCT06746402|DRUG|BMS-986278|Specified dose on specified days
214949619|NCT06746402|DRUG|Placebo|Specified dose on specified days
214949620|NCT06746402|DRUG|Moxifloxacin|Specified dose on specified days
214949621|NCT01490606|OTHER|knee OA project|"physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy."
214949622|NCT01490606|OTHER|conventional PT|12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
214949623|NCT06438445|DIETARY_SUPPLEMENT|Real Jelly|Participants will receive 500mg of royal jelly capsules per day for two months.
214949624|NCT06438445|DIETARY_SUPPLEMENT|Placebo|Participants will receive 500mg of placebo capsules per day for two months.
215075956|NCT01048307|DEVICE|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
215075957|NCT02254785|DRUG|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
215075958|NCT02254785|DRUG|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
214343211|NCT00319423|PROCEDURE|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
214949625|NCT06369519|PROCEDURE|Surgery treatment or local tumor destruction.|Surgery treatments mainly include partial nephrectomy and radical nephrectomy. Local tumor destruction mainly includes renal mass ablation.
214949626|NCT02973334|OTHER|Ingestion of artificially-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
214949627|NCT02973334|OTHER|Ingestion of sugar-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
214949628|NCT02973334|OTHER|Ingestion of water|From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
214949629|NCT06906107|PROCEDURE|Cervical Manipulation|High velocity low amplitude thrust joint manipulation to the cervical spine facet joints
214949630|NCT06906107|PROCEDURE|Exercise|Therapeutic exercises to the cervical, thoracic, and scapular musculature
214949631|NCT06906107|PROCEDURE|Mobilization|Low velocity, low amplitude movements applied to the cervical spine facet joints (Grade I or II)
214949632|NCT00005817|DRUG|becatecarin|Given IV
214949633|NCT00005817|OTHER|laboratory biomarker analysis|Correlative studies
214949634|NCT05011890|DEVICE|Moovcare® use|Moovcare® performs symptom monitoring by automatically delivering ePRO surveys on common symptoms experienced by lung cancer patients. Results are stored in a secure web-based portal for provider review. Providers will manage ePRO responses through a combination of reports graphically displaying responses over time and e-mail alerts about concerning levels or combinations of symptoms.
214949635|NCT06649279|DEVICE|Oxygen reserve index|Measuring oxygen reserve index during preoxygenation and under general anesthesia
215075959|NCT02254785|DRUG|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
215075960|NCT04566393|DRUG|Ulixertinib (BVD-523)|Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
215075961|NCT02388490|DRUG|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
215075962|NCT06067048|DRUG|Zanubrutinib Oral Capsule|36 cycles (1 cycle is 28 days)
214343212|NCT05520957|PROCEDURE|Tracheostomy|We collected data from all tracheotomised patients including age, sex, existing comorbidities, duration indicators (length of endotracheal intubation, day of tracheotomy, length of stay in the intensive care unit (ICU), and total length of hospital stay), respirator weaning marked with YES / NO. From the laboratory parameters, we analyzed: lactate, urea, creatinine, potassium and D-dimer. They were collected at two time intervals, before tracheotomy and after tracheotomy.
214343213|NCT06664632|BEHAVIORAL|Exp|"Participants in this group will receive treatment using the Knee Sync Partner, a novel portable device designed to provide electrical traction and stimulation specifically for the knee joint.~controlled mechanical traction to the knee joint to reduce joint contact pressure, enhance synovial fluid flow, and increase joint space. This is expected to alleviate pain and improve mobility."
214343214|NCT06664632|DIAGNOSTIC_TEST|control|This will include a combination of isometric and isotonic exercises aimed at strengthening the knee musculature, enhancing joint stability, and reducing pain. The exercise regimen will focus on major muscle groups supporting the knee, such as the quadriceps, hamstrings, and calf muscles.
214343215|NCT02352038|DEVICE|low-level laser therapy|The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.
214343216|NCT02352038|OTHER|orthodontic treatment|Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
214949636|NCT00594386|DRUG|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
214949637|NCT04192058|DEVICE|Sham transcranial direct current stimulation (tDCS)|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
214949638|NCT04192058|DEVICE|Active transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) it is a therapeutic method that modulates membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively. The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min.
214949639|NCT04040634|DRUG|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine
214949640|NCT04040634|DRUG|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
214949641|NCT02098616|DRUG|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
214949642|NCT02098616|DRUG|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
215075963|NCT06034951|DIETARY_SUPPLEMENT|Compleat 1.5 HP|Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
215075964|NCT06562660|DEVICE|apnoeic|In group S, High-Flow Nasal Oxygen was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 95 %.
215075965|NCT03554941|DEVICE|noise stimulation|noise stimulation
215075966|NCT00700544|DRUG|chemotherapy treatment (see arm) + norethandrolone|"oral form~Dosage:~10 mg in patients with a weight \< 60 kgs 20 mg in patients with a weight \> 60 kgs frequency: every day Duration: 2 years"
215075967|NCT00700544|DRUG|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
215075968|NCT00099944|DRUG|vildagliptin|
215075969|NCT00099944|DRUG|Glimepiride|Glimepiride 4 mg qd
215075970|NCT00099944|DRUG|LAF237 placebo|
215075971|NCT02144506|OTHER|T&E|
215075972|NCT02144506|OTHER|OTAGO|
215075973|NCT01360749|DRUG|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
215075974|NCT01360749|DRUG|Placebo|Placebo dose: 2 g for 10 cm2.
215075975|NCT06554054|DRUG|GZR18|Oral administered the GZR18 tablet
214343217|NCT03358563|DRUG|Docetaxel|Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
214343218|NCT03358563|DRUG|Degarelix|Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
214343219|NCT03358563|DRUG|Bicalutamide|The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
214486499|NCT06737016|DRUG|Oxybutynin|Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.
214486500|NCT06737016|DRUG|Trimethoprim/sulfamethoxazole (TMP/SMZ)|Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.
215075976|NCT00118846|DIETARY_SUPPLEMENT|25 gm soy protein supplement|25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)
214343220|NCT03358563|RADIATION|Ferumoxytol-enhanced MRI imaging|Ferumoxytol-enhanced MRI imaging will evaluate immune micro-environment in the prostate. Three subjects enrolled to the study will undergo the first ferumoxytol-enhanced MRI imaging within 21 days prior to start of hormonal therapy followed by second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
214343221|NCT06495671|DEVICE|Magnetically enhanced diffusion|Iron nanoparticle (intra-arterial) + External magnet workstation
214343222|NCT02426671|DEVICE|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
214343223|NCT02671669|BEHAVIORAL|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
215075977|NCT00118846|OTHER|Placebo|Milk protein administered twice daily
215075978|NCT02392390|PROCEDURE|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
215075979|NCT02392390|DRUG|Metvixia cream|
215075980|NCT06225375|DEVICE|Restorelle® Flat Mesh|Pelvic organ prolapse repair using Restorelle® Flat Mesh
215075981|NCT02471118|DRUG|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
215075982|NCT02471118|DRUG|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
215075983|NCT03638531|DEVICE|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
215075984|NCT03638531|DEVICE|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
215075985|NCT01574157|DRUG|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
215075986|NCT01574157|DRUG|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
215075987|NCT03811925|PROCEDURE|Angioplasty and drug coated balloon of the superficial femoral artery (SFA)|In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
215075988|NCT03811925|PROCEDURE|Angioplasty and stenting of the superficial femoral artery (SFA)|In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
214343224|NCT02671669|BEHAVIORAL|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~* Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~* Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
214949643|NCT03679286|DEVICE|PCM and ROTEM|Test of blood sample by both PCM and ROTEM
214949644|NCT04791605|OTHER|Gait analysis|Kinematic and kinetic analysis
214949645|NCT05068492|DIAGNOSTIC_TEST|CT|enhanced CT with standard procedure
214949646|NCT05068492|DIAGNOSTIC_TEST|MRI|enhanced MRI with standard procedure
214949647|NCT05068492|DIAGNOSTIC_TEST|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
215075989|NCT00052091|BEHAVIORAL|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
215075990|NCT00052091|BEHAVIORAL|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
215075991|NCT00721578|DRUG|voriconazole|Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
214949648|NCT05068492|DIAGNOSTIC_TEST|Ultrasound|Digestive ultrasound with standard procedure
214949649|NCT01210144|DRUG|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
214949650|NCT01210144|DRUG|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (\>) 16 millimeter (mm), and with estradiol (E2) \> 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
214949651|NCT01210144|DRUG|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
214949652|NCT01210144|DRUG|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
214949653|NCT03260426|DIETARY_SUPPLEMENT|Clear Liquids|Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
214343225|NCT00390052|DRUG|triapine|Given IV and orally
214343226|NCT00390052|OTHER|pharmacological study|correlative study
214343227|NCT00390052|PROCEDURE|laboratory biomarker analysis|Correlative study
214343228|NCT06533202|BEHAVIORAL|Psychoeducational Programme|The objective of this type of programme is to equip individuals with the knowledge and skills required to navigate the challenges and capitalise on the opportunities presented by retirement. In particular, the programme strives to enhance the quality of life and attitudes towards retirement, elevate levels of life satisfaction, psychological flexibility, perceived social support and general health, self-efficacy and self-regulation, and mitigate stereotypes associated with ageing.
214949654|NCT03260426|DIETARY_SUPPLEMENT|Regular Solid|Regular diet from postoperative day zero immediately upon return to floor and onwards
214949655|NCT03260426|DEVICE|Abstats|Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
214949656|NCT00924391|DIETARY_SUPPLEMENT|phytosterol enhanced soy based beverage|
214949657|NCT00924391|DIETARY_SUPPLEMENT|1% milk|
214949658|NCT00771329|DRUG|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
214949659|NCT00771329|OTHER|Placebo (sterile normal saline)|Single IV dose of Placebo
214949660|NCT04747444|OTHER|Anti-Gravity Treadmill|Treadmill in which the body weight percent placed on the lower extremities can be controlled
214949661|NCT06083480|DRUG|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
214949662|NCT06083480|DRUG|Placebo|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
214949663|NCT02664922|DRUG|Propofol|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
214949664|NCT02664922|DRUG|Ketamine|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
214949665|NCT02664922|DRUG|Remifentanil|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
214949666|NCT02664922|DRUG|Sevoflurane|1 general anesthesia group for VT ablations and afib procedures.
215075992|NCT01828606|DEVICE|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
214343229|NCT06533202|BEHAVIORAL|Education Programme|At the end of the baseline assessment, participants will receive instructions and recommendations to facilitate a positive and healthy transition to retirement, as part of an education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow.
215075993|NCT01828606|DEVICE|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
215075994|NCT04246775|DEVICE|Peristeen|rectal irrigation
214343230|NCT01383070|BEHAVIORAL|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
214343231|NCT01834417|DEVICE|TexiMat|
214343232|NCT06548555|OTHER|systematic educational intervention|This is a non-interventional study and does not impose a therapy protocol, or a diagnostic/therapeutic procedure. Patients are treated according to the local prescribing information, and routine medical practice in terms of visit frequency and types of assessments performed and only these data is collected as part of the study.
214949667|NCT02035774|PROCEDURE|LSIB + SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
214949668|NCT04687748|DEVICE|Electromographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength. Electromyographic biofeedback is a specific form of biofeedback. The device records muscle activity through application of vaginal probe will be inserted in vagina and the reference surface electrode would be placed over the right anterior superior iliac spine.
214949669|NCT04687748|OTHER|PFM exercises|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds. Three attempts would be made with 40 seconds rest in between each contraction. The exercises would be performed with the patient initially in supine position, with hip and knee flexed at 30 and 90 degrees.
214949670|NCT03736330|BIOLOGICAL|Combinations treatment|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with low dose anti-PD-1 antibody（pembrolizumab, Merck \& Co., Inc.） and were transferred to participants via intravenous infusion .
214949671|NCT06454422|OTHER|wu qinxi|"Wuqinxi, also known as the Hundred-step Sweating Exercise, is one of the most emblematic Health qigong exercises. Huatuo, guided by the principle, formulated the 'Wuqinxi':  Running water is never stale and a door-hinge is never gets worm-eaten, and sums up the experiences of the fitness activities of Huatuo's predecessors that imitate the movements of tigers, deer, bears, apes, birds, and other animals, and are associated with human organs, meridians, and 'qi'"
215075995|NCT06357780|OTHER|close-loop synchronization controller with spontaneous mode|30 minutes period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during NIV mode.
214343233|NCT06189976|DIAGNOSTIC_TEST|Rapid atrial pacing|Rapid atrial pacing after TAVI
214343234|NCT02265042|DEVICE|Stimulette|electrical stimulation device by Dr. Schuhfried Medizintechnik GmbH, Vienna, Austria
214343235|NCT05427799|DIETARY_SUPPLEMENT|Honey|A mixed flora honey that will be obtained from local producers. and will be consumed by a daily dose of 0.5 g/kg body weight of honey by each participant and will be divided into two doses.
214343236|NCT05427799|DIETARY_SUPPLEMENT|Other carbohydrate alternatives such as jell-o|A daily dose of 0.5 g/kg body weight of Jell-O will be consumed by each participant and will be divided into two doses. Jell-O was selected as a source of sucrose with negligible phenolic capacity.
214343237|NCT02669329|DEVICE|CoolSculpting device with vacuum applicator.|The CoolSculpting device with a vacuum applicator will be used to perform the treatments.
214343238|NCT00244504|DRUG|moxonidine|moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
214343239|NCT01873794|DEVICE|Bright white light|
214343240|NCT01873794|DEVICE|Dim red light|
214343241|NCT03070522|DRUG|Prednisone|oral prednisone for 7 days during pulmonary exacerbation
214343242|NCT03070522|DRUG|Placebos|Placebo
214949672|NCT00094536|DEVICE|Extended treatment regimen using Her Option Cryotherapy|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
214949673|NCT02865603|BEHAVIORAL|PAX Good Behavior Game|PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
214949674|NCT02153658|PROCEDURE|Subjects cleaned the foreskin with soapy water using a syringe once a day.|
214949675|NCT02153658|PROCEDURE|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.|
214949676|NCT05883059|DEVICE|Lower limb robot assisted walking training|The participants in the robot group received lower limb robot assisted walking training combined with routine rehabilitation therapy. Lower limb robot assisted walking training for 30 minutes each time, once a day, 5 times a week, for 4 consecutive weeks; Routine rehabilitation treatment includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabilitation treatment once a day, five times a week, for four consecutive weeks.
215075996|NCT06357780|OTHER|Conventional|30 minutes period where the synchronization of pressure support of patient effort during NIV mode will be manually set.
215075997|NCT03374800|DRUG|Placebo (0.9% saline)|normal saline
214949677|NCT05883059|OTHER|routine rehabilitation|The control group participants received routine rehabilitation, including lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabil
214949678|NCT00684632|DRUG|Placebo|Placebo
214949679|NCT00684632|DRUG|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
214949680|NCT02913027|OTHER|External Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam."
214949681|NCT02913027|OTHER|Bimanual Exam|
214949682|NCT02913027|OTHER|Speculum Exam|
214949683|NCT05501327|DRUG|SLI-F06|Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
214949684|NCT01855282|BEHAVIORAL|Behavioral Intervention|Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
215075998|NCT03374800|DRUG|Pantoprazole|40 mg powder for injection reconstituted with 0.9% saline
215075999|NCT04224714|COMBINATION_PRODUCT|FFR|FFR measurement: Pressure guid wire(radianalyzer Xpress 12711) is produced in Switzerland. After the pressure of the aorta and the pressure guide wire is balanced, Send the pressure guide wire to the distal part of the lesion(more than 20 mm away from the lesion) . Adenosine is injected into the vein,then,record the FFR index 3 times and take the average value as the final measurement index.
215076000|NCT05852158|DRUG|Cefazolin 2 GM Injection|Single pre-op dose of 2g IV cefazolin
214343243|NCT03357601|BEHAVIORAL|HIIT|The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
214343244|NCT03357601|BEHAVIORAL|MCEET|The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
214343245|NCT01543256|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|"Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)"
214343246|NCT01543256|DEVICE|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
214343247|NCT01318226|DRUG|ATx08-001|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
214343248|NCT01318226|DRUG|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
214343249|NCT03823118|DRUG|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
214949685|NCT06205173|OTHER|Hot compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
214343250|NCT03704376|DRUG|30 ml of 0.2% ropivacaine|
214949686|NCT06205173|OTHER|Cold compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
214949687|NCT04898972|BEHAVIORAL|Mindfulness-based stress reduction intervention|The 8-group sessions of MBSR will be conducted once a week, lasting two and a half hours, with two additional sessions in the following two months. Between sessions, participants will have to practice at home for 45 minutes a day, 6 days a week. For the practice, patients and caregivers will be provided with audio files containing the meditations proposed in the classroom, readings, and the diary of the practice. During the sessions, the following mindfulness-based techniques will be introduced: body scan; sitting meditation; awareness movement exercises; and walking meditation.The sessions will be held face to face or online using common videoconferencing platforms, such as Skype or Zoom, based on the preferences of the participants. This will facilitate the participation of patients and caregivers, overcoming the obstacles related to travel. The course will be taught by certified mindfulness teachers with experience in MBSR interventions on patients with respiratory diseases.
214949688|NCT04898972|BEHAVIORAL|Information on stress reduction|"COPD patient-caregiver dyads will be delivered by hand, sent by email or by post an information booklet Coping with your chronic disease, targeting COPD patients, to teach them how to manage stress. This booklet, available in Italian, provides simple information on the meaning of stress and anxiety, and suggests some actions that people can implement at home to reduce stress."
214949689|NCT05542667|COMBINATION_PRODUCT|Giomer varnish|* After dryness and isolation are accomplished, Giomer varnish ( PRG coat barrier, by Shofu) will be applied once at the first treatment visit, one drop of PRG Coat Barrier ACTIVE will be added to the container provided in the package containing PRG Coat Barrier BASE the materials will be mixed together with a disposable tip provided by the kit a thin layer is to be applied and left untouched for 3 seconds according to manufacturer instructions and finally varnish is to be light-cured.
214949690|NCT05542667|COMBINATION_PRODUCT|Fluoride varnish|After dryness and isolation are accomplished, fluoride varnish (Biflourid 10, by Voco ) single-use type, the foil in the single-use Bifluorid 10 will be pierced using Micro-Tim brush, then a thin layer of the varnish is to be applied using a micro brush for four sessions at a frequency of one session each week, the varnish will be left undisturbed for 10-20 seconds then air-dried according to manufacturer instructions.
214949691|NCT03969264|OTHER|High Carbohydrate or Tree Nut Food Snacks|Snack consumption
214949692|NCT04840459|BIOLOGICAL|BAMLANIVIMAB|n. Bamlanivimab is a recombinant neutralizing human mIgG1? monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region.
214949693|NCT04840459|BIOLOGICAL|CASIRIVIMAB|CASIRIVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
214949694|NCT04840459|BIOLOGICAL|IMDEVIMAB|IMDEVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
214949695|NCT06215300|GENETIC|coronary artery bypass grafting|coronary artery bypass grafting
214949696|NCT02660606|OTHER|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
214949697|NCT00494221|DRUG|AZD2171|oral tablet
214949698|NCT00494221|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
215076001|NCT05852158|DRUG|Cefazolin Injection|Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
214343251|NCT03704376|DRUG|15 ml of 0.2% ropivacaine|
214343252|NCT03704376|DRUG|100 mcg clonidine|
214343253|NCT03704376|DEVICE|High-frequency linear ultrasound transducer|
214343254|NCT04020991|DIAGNOSTIC_TEST|Sleep Study|Participants who noted to have Oxygen Desaturation Index more than 10 (moderate to severe OSA) will be referred to do formal sleep study and referral to Sleep Medicine Clinic
214949699|NCT00494221|DRUG|Placebo Cediranib|oral tablet
215076002|NCT06356935|OTHER|RT|Resistance training
215076003|NCT06356935|OTHER|CON|Control group
214343255|NCT01865370|DIETARY_SUPPLEMENT|Kochujang Pills|Kochujang Pills (34.5g/day)
214343256|NCT01865370|DIETARY_SUPPLEMENT|Placebo|Placebo (34.5g/day)
214343257|NCT01108848|BIOLOGICAL|Berinert® (C1 Esterase Inhibitor)|Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
214343258|NCT02053948|PROCEDURE|Pursestring Wound Closure|
214343259|NCT02053948|PROCEDURE|Gunsight Skin Incision and Closure Technique|
214343260|NCT02201927|DEVICE|galvanic vestibular stimulation|
214949700|NCT00874562|DRUG|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
214949701|NCT00874562|DRUG|Rapamycin|Taken orally mixed with water or orange juice
214949702|NCT05922527|PROCEDURE|Combined regenerative technique|Periodontal regenerative technique using amnion chorion membrane combined with DFDBA in a putty form
214949703|NCT05922527|PROCEDURE|Open flap debridement|Open flap debridement
214949704|NCT03040427|DRUG|F-18 florbetapir|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
214949705|NCT06729931|DIAGNOSTIC_TEST|Pleural Fluid Quantitative C-Reactive Protein (Q-CRP) Measurement|The intervention involves the measurement of Quantitative C-Reactive Protein (Q-CRP) levels in pleural fluid obtained from patients presenting with lymphocytic exudative pleural effusion. The Q-CRP test is performed using standardized laboratory methods to quantitatively analyze CRP levels, which are then compared between patients with confirmed tuberculous pleural effusion and those with malignant pleural effusion. This diagnostic approach aims to evaluate the efficacy of pleural fluid Q-CRP as a biomarker to differentiate between these two conditions. No therapeutic or invasive interventions are introduced as part of this study beyond routine diagnostic procedures.
214949706|NCT04477694|PROCEDURE|colonoscopy under sedoanalgesia|Colonoscopy is a widely used method for diagnosing and treating colonic diseasea with a thin, flexible camera.
214949707|NCT03526926|DRUG|CPX-351|VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
214949708|NCT00732680|DRUG|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
214949709|NCT01900431|DRUG|Sarilumab|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
214949710|NCT01900431|DRUG|Prednisone|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
214949711|NCT01900431|DRUG|Methotrexate|Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
214949712|NCT01900431|DRUG|Folic/folinic acid|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
214949713|NCT01900431|OTHER|Placebo (for Sarilumab)|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
214949714|NCT05655468|DRUG|Dronedarone|oral administration fed conditions
214949715|NCT05655468|DRUG|Placebo|strictly identical in appearance with dronedarone,oral administration fed conditions
214949716|NCT03765424|DIAGNOSTIC_TEST|Ultrasound|Ultraosund of temporal, carotid and axillary arteries
214949717|NCT02452840|OTHER|No Intervention|No Intervention
214949718|NCT00475514|DRUG|Frovatriptan 2.5mg QD|
214949719|NCT00475514|DRUG|Frovatriptan 2.5 mg BID|
214949720|NCT00475514|DRUG|placebo|
214949721|NCT04527913|BEHAVIORAL|Interdental Oral Hygiene Instruction (Int-OHI)|"Int-OHI will be given focusing on the interdental device of the allocated group for each patient and will be given only once at timepoint T-7. No further formal Int-OH instructions will be given, unless specifically asked by the patient.~Int-OHI will be delivered by trained dental hygienist/periodontist."
214949722|NCT04527913|PROCEDURE|One session of professional supragingival scaling and polishing|A session of professional supragingival scaling and polishing: instrumentation will be performed by a trained dental hygienist/periodontist with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed.
214949723|NCT04527913|PROCEDURE|Oral Hygiene Instruction (OHI)|"OHI will be given focusing on manual toothbrushing and will be given only once at timepoint T-7. No further formal OH instructions will be given, unless specifically asked by the patient.~OHI will be delivered by trained dental hygienist/periodontist."
214949724|NCT03005613|PROCEDURE|ischial spine fascia fixation|The participants will receive ischial spine fascia fixation.
214949725|NCT03005613|PROCEDURE|sacrospinous ligament fixation|The participants will receive sacrospinous ligament fixation.
214949726|NCT01902355|PROCEDURE|modified Seldinger technique|modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
214949727|NCT01902355|PROCEDURE|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
214949728|NCT03172364|OTHER|Micellar cleanser|Participants will apply the micellar cleanser topically twice a day (morning and evening). Micellar cleanser will be applied on cotton pad and wiped over the entire face and closed eye to gently cleanse. No need to rub or rinse the micellar cleanser.
214949729|NCT03172364|OTHER|Micellar foaming cleanser|Participants will use the micellar foaming cleanser topically twice a day (morning and evening). Micellar foaming cleanser will be massaged gently onto wet skin on the face using fingertips. After which participants will rinse thoroughly and pat the skin dry.
214949730|NCT01348113|OTHER|Brief Alcohol intervention|Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
214949731|NCT03755518|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
214949732|NCT04936659|OTHER|neuromodulation|Palpatory neuromodulation of the V1 and V2 branches of the trigeminal nerve where they exit onto the face.
214949733|NCT04722952|DRUG|Visilizumab|Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle. Anti-PD-1 mAb 200mg by IV on day 8 of every cycle. Homoharringtonine(HHT) 2mg/(m2.d) by IV on days 1-6 of every cycle Cytarabine 10mg/(m2.d) by SC on days 1-7 of every cycle Granulocyte colony-stimulating factor(G-CSF) 300ug/d by SC on days 1-7 of every cycle，until absolute neutrophil count(ANC) \> 5X109／L or white blood cell（WBC）\> 20X109／L.
214949734|NCT05449938|PROCEDURE|Scaling and root planing|Scaling and root planing involves removal of plaque and calculus on tooth surface.
215076004|NCT05091281|DEVICE|Intubation of the double lumen tube by Macintoch laryngoscope|After induction of anesthesia insertion of the double lumen tube was done by Macintosh laryngoscope
214343261|NCT04525391|DRUG|Durvalumab+AZD2811 to SCLC patients|AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
214949735|NCT04463732|OTHER|Loaded inspiratory muscle test and cardiopulmonary exercise test|This is an observational study. Loaded inspiratory muscle test is setting at 30% of maximal inspiratory pressure. Subjects will perform only 15 breaths under this intensity to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training. Cardiopulmonary exercise test is performed by using bicycle ergometer. These two tests will be performed at least 1 week separately.
214343262|NCT06269770|DRUG|Tapentadol|Add tapentadol, for effective pain management in a multimodal setting during TKR.
214949736|NCT06510387|DEVICE|Ultrasound using suprasternal method|"The research resident will perform suprasternal ultrasound (US) with a curvilinear probe) C6-2) of US machine (Philips Affiniti 50) which will be placed transversely on the suprasternal area just above to the suprasternal notch immediately after intubation, The position of the trachea will be determined by a hyperechoic air-mucosa (A-M) interface with reverberation artifact posteriorly (comet-tail artifact).~The position of endotracheal tube (ETT), when it is placed in trachea, will be defined as observable contour between A-M and comet-tail artifact. If the second contour appears, it will be similar to the second airway which is called double-tract sign which means that the ETT will be in the esophagus. (7) If the position of the esophagus is suspected of being exactly behind the trachea, operator of ultrasound can specify the location of the esophagus by moving the probe to the left and right sides during scan."
214343263|NCT06269770|DRUG|Tramadol|Add tramadol, for effective pain management in a multimodal setting during TKR.
214343264|NCT04712942|DRUG|Pevonedistat|Patients receive pevonedistat at 20 mg/m2 i.v. (d1,3,5, q4w) up to 12 cycles
214949737|NCT06510387|DEVICE|Ultrasound using subxiphoid method|Immediately after suprasternal sonography, the research resident will perform subxiphoid sonography to detect diaphragmatic motion, and information will be recorded.
214949738|NCT01714609|DRUG|Placebo|Placebo Comparator: Placebo
214949739|NCT01714609|DRUG|Sorafenib|Sorafenib, 400 mg twice daily
214949740|NCT00630747|BIOLOGICAL|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
214949741|NCT04803591|DRUG|Tranexamic Acid|Tranexamic Acid will be administered as an injectable solution (500mg/5ml or 1000mg/10ml).
214949742|NCT03858894|DRUG|DE-117 Ophthalmic Solution QD|DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye
214949743|NCT03858894|DRUG|DE-117 Ophthalmic Solution BID|DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye
214949744|NCT02306694|DRUG|Advate|Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
214949745|NCT04775576|OTHER|Pleth Variability Index|Conventional fluid management is widely used in clinical practice. In this method, the fluid need of the patient is decided according to pulse, arterial blood pressure, central venous pressure, urine output and clinical condition. In the targeted fluid therapy method, besides static parameters such as pulse, arterial blood pressure, central venous pressure; Dynamic parameters such as Stroke volume variability (SVV), pulse pressure variability (PPV), pleth variability index (PVI), continuous hemoglobin (SpHb) are also used noninvasively.
214343265|NCT04712942|DRUG|Azacitidine|azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles
214343266|NCT02733900|PROCEDURE|femoral head removal|
214343267|NCT04058769|DEVICE|Premedication Guide|Software with guidelines recommendations for preoperative assessment
214949746|NCT04775576|OTHER|Conventional fluid theraphy|8-10 ml / kg / hour iv fluid maintenance will be started for the control group. If the mean arterial pressure (MAP) is \<65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
214949747|NCT04775576|OTHER|Anesthesia method|All patients included in the study will be premedicated with 1mg of midazolam after monitoring with pulse, non-invasive blood pressure, oxygen saturation. Then, invasive arterial cannulation will be applied and continuous blood pressure monitoring will be done. In the PVI group, non-invasive PVI and SpHb monitoring will also be performed from the other upper extremity without arterial cannulation. After two minutes of preoxygenation, anesthesia induction will be started. Anesthesia induction doses used routinely in our clinic include iv 2 mg / kg propofol, 0.6 mg / kg rocuronium and 2 μg / kg fentanyl. Sevoflurane will be administered by inhalation during anesthesia maintenance after tracheal intubation.
214949748|NCT00902980|OTHER|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
214949749|NCT00603382|DRUG|GW685698X|GW685698X
214949750|NCT00603382|DRUG|Placebo|placebo comparator
215076005|NCT05091281|DEVICE|Intubation of the double lumen tube by Glidescope videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by GlideScope® videolaryngoscope
215076006|NCT05091281|DEVICE|Intubation of the double lumen tube by C-MAC®(D) videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by C-MAC®(D) videolaryngoscope
215076007|NCT06606093|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
215076008|NCT06606093|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
214343268|NCT05500469|DEVICE|Paul glaucoma drainage device (GDD)|Implantation of the GDD
214343269|NCT03330379|DEVICE|Tracoe Smart CuffmanagerTM|In patients randomly assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff. Within the 2 days following the inclusion, all the intermittent Pcuff measurements will be collected as well as the incidence of Pcuff manual adjustments
214343270|NCT06462326|DRUG|Moxifloxacin Oral Tablet|400mg per tablet
214343271|NCT06462326|DRUG|Omadacycline Oral Tablet|150 mg per tablet
214343272|NCT00074282|BIOLOGICAL|rituximab|
214343273|NCT00074282|DRUG|cyclophosphamide|
214343274|NCT00074282|DRUG|pentostatin|
214343275|NCT00074282|DRUG|Alemtuzumab|
214343276|NCT05973071|BEHAVIORAL|Tuune Supplemented Contraceptive Visit|Participants complete the Tuune contraceptive decision aid health questionnaire (Tuune for clinics) as part of their standard OBGYN clinic appointment.
214343277|NCT05973071|BEHAVIORAL|Traditional Contraceptive Visit|Participants will complete a standard OBGYN clinic appointment without using the Tuune contraceptive decision aid health questionnaire (Tuune for Clinics).
214343278|NCT00464542|DRUG|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
214343279|NCT00740545|DRUG|enoxaparine 40 mg daily|Women inject ourselves every days with 40 mg of enoxaparine
214343280|NCT00740545|DRUG|placebo|Women inject ourselves every days with placebo
214343281|NCT00605241|DRUG|GSK598809|Drug
214343282|NCT02290665|OTHER|Thermosensitive gel rectal formulation|
214343283|NCT02290665|OTHER|Saline enema|
214343284|NCT01882634|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
214343285|NCT00275093|DRUG|temsirolimus|Given IV
214949751|NCT05869279|BIOLOGICAL|CARCIK-CD19|allogeneic cytokine induced killer cells transduced with a transposon CD19-chimeric antigen receptor (CARCIK-CD19) gene
214949752|NCT04504149|BEHAVIORAL|Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD|A primary care-based shared decision making intervention
214949753|NCT01569256|DRUG|Cabergoline|Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
214949754|NCT00395642|DEVICE|Kronos LV-T, Lumax HF-T|Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
214949755|NCT02012959|DRUG|Tolvaptan|
214949756|NCT02993354|DEVICE|The EUM300 (electrical uterine myography)|This study involves monitoring one group of pregnant women for contractions simultaneously using two different devices to determine if one is superior: the usual tocodynamometer commonly used. Women are simultaneously monitored with both devices.
214949757|NCT05539261|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
214949758|NCT05539261|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
214949759|NCT00714753|RADIATION|brachytherapy|
214949760|NCT00714753|RADIATION|hypofractionated radiation therapy|
214949761|NCT00714753|RADIATION|image-guided radiation therapy|
214949762|NCT00714753|RADIATION|intensity-modulated radiation therapy|
214949763|NCT05690165|BEHAVIORAL|Walking Exercise|Heart rate controlled walking exercise
214343286|NCT00275093|OTHER|laboratory biomarker analysis|Correlative studies
214343287|NCT00275093|OTHER|pharmacological study|Correlative studies
214343288|NCT02861690|DRUG|Liposomal Paclitaxel|Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
214343289|NCT02861690|DRUG|Nedaplatin|Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
214343290|NCT01474603|DIETARY_SUPPLEMENT|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
214343291|NCT01773226|DEVICE|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
214343292|NCT01429259|DRUG|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
214343293|NCT03440632|DEVICE|FES|Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
214343294|NCT04040803|DEVICE|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
214949764|NCT02804867|PROCEDURE|Online questionnaire and self-administered blood spot|
214343295|NCT04000451|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
214343296|NCT04000451|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
214949765|NCT04910672|OTHER|Control Group|"Bilateral global pelvic manipulation. Lower right limb in extension. The left lower limb in flexion, until the tension on the SPIS was felt. Introduce very little rotation of the spine. ASI anterior slide until crease forms at waist.~We bring the elbow towards our hips. We rotate the patient posteriorly to open the lumbo sacral facet. The thrust is performed by simultaneously increasing these three parameters, with kick and joint compression."
214949766|NCT04910672|OTHER|Experimental Group|"Bilateral Global Pelvic Manipulation and Internal Correction Technique for Laterflexion of the Uterus The technique consists of making contact with the vaginal fingers on the upper and anterior part of the cervix, while the abdominal hand, dragging the skin towards the pubis, tries to make contact as posterior as possible on the fundus of the uterus. The technique consists, while the patient breathes widely, in progressively raising the uterine fundus forward and upward and lowering the cervix until the normal anteversion position is achieved.~At the end of the technique, fixing the correction position of the uterus, we can ask the patient to perform a pelvic anteversion, while the correction is maintained. At the end of the technique, all abnormal tension should have disappeared and the uterus should have recovered a physiological position of anteversion."
214949767|NCT02951572|DEVICE|NIV|
214949768|NCT04236167|DEVICE|Fractional CO2 laser treatment -|UltraPulse CO2 Laser (Lumenis, Israel). Patients will receive laser treatments at 4 to 8-week intervals for a total of 3 sessions. A combination of the SCAAR FX and Deep FX treatment modes, with or without Active FX treatment mode, will be used according to individual patient and scar characteristics. For SCAAR FX, the settings include energy (70-150mJ), density (1-5%), and frequency (150-250Hz).For Deep FX, the settings include energy (12.5-22.5mJ), density (5-15%) and frequency (300-600Hz). For Active FX, the settings include energy (80-125mJ), density (2-3%) and frequency (100-150Hz)
215076009|NCT06654505|BEHAVIORAL|Paired Community Health Workers|Community Health Workers will promote maternal and child health services as paired female and male
214949769|NCT01676818|DRUG|eribulin mesylate|Given IV
214949770|NCT02418741|OTHER|Neck flexion|Patient's neck was flexed using a 4 cm or 8 cm height of pillow
214949771|NCT06731439|OTHER|Starting feeds within 6 hours of life|Starting feeds within 6 hours of life
214949772|NCT06731439|OTHER|Standard feeding protocol|Starting feeds based on standard protocol as per primary team
214949773|NCT05233384|BIOLOGICAL|Blood test|"For each patient included, this study will involve the collection of 20 ml of blood during a blood test carried out as part of routine care. One EDTA tube (4,5 ml) will be withdrawn and frozen for genetic testing. 15 ml of citrated blood sample (3 to 5 tubes, depending on the used tubes) are necessary for the study of fibrin clot structure. Citrated tubes will be double centrifugated and frozen (-80°C) according to Groupe Français d'Études sur l'Hémostase et la thrombose guidelines (centrifugation protocol: 1500 to 2000g at least 15min, or 2000 to 2500g at least 10min with an intermediate decantation)."
214949774|NCT03349281|DRUG|Pevonedistat|Administered each cycle on days 1, 3 and 5.
214949775|NCT03349281|DRUG|Vincristine|Administered each cycle on days 2, 9, 16 and 23.
214949776|NCT03349281|DRUG|Dexamethasone|Taken orally each cycle on days 2 through 15.
214949777|NCT03349281|DRUG|PEG-asparaginase|Administered via intramuscular injection (IM) each cycle on days 9 and 23.
214949778|NCT03349281|DRUG|Doxorubicin|Administered via IV each cycle on day 2.
214949779|NCT03349281|DRUG|Cytarabine|Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.
214949780|NCT03349281|DRUG|Methotrexate|Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
214949781|NCT03349281|DRUG|Hydrocortisone|Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
215076010|NCT06658964|DRUG|Cohort 1: JMKX003142 and itraconazole|"JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD"
215076011|NCT06658964|DRUG|Cohort 2: JMKX003142 and rifampicin|"JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD"
215076012|NCT06606717|DIETARY_SUPPLEMENT|Creatine Whey Protein|3 grams creatine + 30 grams whey protein
215076013|NCT06606717|DIETARY_SUPPLEMENT|Whey Protein|30 grams Whey Protein
215076014|NCT06660511|DRUG|Disitamab Vedotin in Combination With Anlotinib Hydrochloride|"The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)"
215076015|NCT06660134|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
215076016|NCT05893771|DRUG|Methylprednisolone Injection|Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.
215076017|NCT05893771|DRUG|Bupivacaine Hcl 0.5% Inj_#2|Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline
215076018|NCT05893771|DRUG|normal saline|Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
215076019|NCT04465435|OTHER|Web-based self-report questionnaires|Web-based self-report questionnaires based on well established instruments.
214343297|NCT04000451|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
215076020|NCT04465435|OTHER|Focus Group Interviews|Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
215076021|NCT04644471|DIAGNOSTIC_TEST|CT scanner|1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition
214343298|NCT02699177|DEVICE|CBF measurements|CBF measurements
214343299|NCT04269772|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
214343300|NCT04269772|OTHER|Treatment As Usual|Treatment as usual, unrestricted, as provided by prison and community providers.
214343301|NCT03593083|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
214343302|NCT03593083|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
214343303|NCT01097135|DRUG|Duraprep Surgical Solution|
214949782|NCT05598710|PROCEDURE|Pigtail Insertion|Pigtail is inserted for any reason of ureteral obstruction except for malignant
214949783|NCT06075810|DRUG|MBQ-167|MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
214949784|NCT06460610|OTHER|Blow Bottle technique|Patients sit at a table with comfortable position Hold the bottle with one hand and the tube with the other Put the tube in mouth by holding lips firmly Breath in through nose and out through mouth Blowing enough water is bubbled Short Breaks for 2 to 3 mints When mucus rises up get out of it by coughing or huffing
214343304|NCT02295111|DEVICE|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
214949785|NCT06460610|OTHER|Acapella along with Diaphragmatic Breathing|Device which uses a counter weighted plug and magnet to create airway oscillations Acapella combines the effects of PEP therapy and airway vibrations and mobilize to clear pulmonary secretions Facilitates opening of airways in patients with lung disease. Patients instructions to close the mouth piece making surety to no leakage of air. Take a long breath in nose and blow out through the Acapella ,feel vibrations on chest. Duration of performing this technique 3 days a week for 20 mints per day, 4 weeks regular
214949786|NCT01507714|PROCEDURE|Preventive transobturator tension free vaginal tape|during the vaginal wall repair surgery, a TVT-O procedure will be done
214949787|NCT06730581|DRUG|Utidelone Capsule 60mg/m2/d|60mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
214949788|NCT06730581|DRUG|Utidelone capsule 75mg/m2|75mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
214949789|NCT06730581|DRUG|Utidelone Capsule|Dosing regimens were determined based on the results of gastric and ovarian cancer dosing regimens.D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
214949790|NCT01523210|OTHER|physiotherapy|thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
214949791|NCT01029613|DRUG|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
214949792|NCT03723421|OTHER|Rapid Injection Group Without Aspiration|After filling in the personal information form, the tetanus vaccine was administered by using rapid injection without aspiration technique (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
214949793|NCT03723421|OTHER|Control|After filling in the personal information form, the tetanus vaccine was made in accordance with the standard injection technique included in the application (the injector was held at 90 degrees, it was pricked into tissue, and the drug was given in 5-10 seconds after performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
214949794|NCT02510313|OTHER|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
214949795|NCT01432964|PROCEDURE|Orbital revision surgery|Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
214949796|NCT03669484|DRUG|Remimazolam|Lyophilisate for preparation of solution for intravenous administration, 50 mg. Required to prepare a 50 ml syringe with the infusion solution at a concentration of 1 mg/ml (in accordance with guidance given in protocol)
214949797|NCT03669484|DRUG|Propofol|Emulsion for infusion, 10 mg/mL in 20-mL glass vials
214949798|NCT03669484|DRUG|Fentanyl|Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
214949799|NCT03669484|DRUG|Rocuronium bromide|Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
214949800|NCT02769936|DRUG|D-cycloserine|100 mg D-cycloserine administered orally as encapsulated pill
214949801|NCT02769936|OTHER|Placebo|Placebo administered orally as encapsulated pill
214949802|NCT02101333|DRUG|Tocilizumab|intravenous injection 8 mg/kg, monthly during 6 months
214949803|NCT05342428|DRUG|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
215076022|NCT04644471|DIAGNOSTIC_TEST|Lung MRI|3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence
215076023|NCT07033975|OTHER|Flavonoid-enriched Mediterranean Diet|A set of dietary guidelines describing an adjusted Mediterranean diet focusing on the intake of flavonoid-rich products.
214343305|NCT02295111|BEHAVIORAL|TCM health consult|Traditional Chinese Medicine Health Consult without needling
214343306|NCT02295111|OTHER|Usual Care|Standard NHS care
214949804|NCT02333383|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
214949805|NCT01665677|DRUG|Atorvastatin calcium|40 mg PO daily
214949806|NCT05633277|PROCEDURE|Polidocanol|Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.
214949807|NCT04294797|DIAGNOSTIC_TEST|Blood draw|One additional blood sample for study purpose from the day before surgery, postoperative 1, 3 and 8.
214949808|NCT03213197|OTHER|CPR video|Patient watches a short CPR video
214949809|NCT04270227|OTHER|Survey study|The questionnaire including Exercise Benefits / Barriers Scale, IPAQ (International Physical Activity Survey), The Bady Awareness questionnaire and demographic information will be filled in one time by face-to-face interview method.
215076024|NCT06888180|OTHER|Non interventional study|"Documentation of Non-Invasive Ventilation Settings at Different Stages of Patient Management"
215076025|NCT04657367|OTHER|Observational study - registry|Observational study - registry
215076026|NCT06896019|DIAGNOSTIC_TEST|Community Pneumonia|The BALF of CAP patients
215076027|NCT06895512|DRUG|HLX15-IV|recombinant anti-CD38 human monoclonal antibody injection
215076028|NCT06895512|DRUG|Darzalex|recombinant anti-CD38 human monoclonal antibody injection
215076029|NCT06897306|PROCEDURE|surgery|The patient underwent surgery.
214343307|NCT01806480|BEHAVIORAL|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
214949810|NCT00001863|DRUG|Leflunomide|
214949811|NCT03027323|DEVICE|AxoTrack System|The AxoTrack system is a novel ultrasound guidance system intended to facilitate central venous cannulation (CVC) by a single operator as well as to reduce complications and time associated with CVC. The AxoTrack has a small ultrasound scan head which facilitates imaging of the subclavian vein.
214949812|NCT06318819|DEVICE|Dental Floss Holders|Dental Floss Holders for flossing purposes
215076030|NCT06896500|BEHAVIORAL|Kegel Exercises|Kegel exercises performed three times daily in different positions (supine, sitting, and standing) for three weeks, followed by a six-week home program
215076031|NCT06572982|DRUG|Azacitidine|300 mg Film coated tablets
215076032|NCT03922594|DIAGNOSTIC_TEST|Differential diagnosis for infectious causes of microcephaly|Zika virus, cytomegalovirus, rubella, toxoplasmosis
215076033|NCT06379958|DRUG|leramistat 40mg|Oral capsule
215076034|NCT06379958|DRUG|Itraconazole 200 mg|Oral capsule
215076035|NCT06379958|DRUG|Phenytoin 100 Mg Oral Capsule|Oral capsule
214343308|NCT06391112|OTHER|Painting Based Art intervention|Painting Based Art Effect of Intervention on Maternal Anxiety and Fetal Parameters
214343309|NCT02081300|DRUG|Oral testosterone undecanoate, LPCN 1021|
214949813|NCT00001043|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
214949814|NCT03652584|OTHER|High Protein Diet|
214949815|NCT03652584|OTHER|Control Diet|
214949816|NCT00618709|DRUG|ATX-101|ATX-101 single dose
215076036|NCT06379958|DRUG|Simvastatin 40mg|Oral capsule
215076037|NCT06379958|DRUG|Upadacitinib 15 MG|Oral Capsule
214949817|NCT04580537|DRUG|Enstilar|Daily application on affected fingers (nail plates, nail folds, and surrounding skin)
214949818|NCT04580537|DEVICE|Ablative fractional laser|Pre-treatment of affected fingers (nail plates, nail folds)
215076038|NCT01352442|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
215076039|NCT03265002|DIETARY_SUPPLEMENT|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
215076040|NCT03265002|DIETARY_SUPPLEMENT|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
215076041|NCT03265002|DIETARY_SUPPLEMENT|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
215076042|NCT03265002|DIETARY_SUPPLEMENT|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
215076043|NCT06227676|DIETARY_SUPPLEMENT|Cramp Bites by Aunt Flo's Kitchen|Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
214949819|NCT06514456|OTHER|no intervention|no intervention
214949820|NCT00774007|DRUG|mesalazine|
214949821|NCT00774007|DRUG|placebo|
214949822|NCT00986947|DRUG|IVIg and rituximab|"A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA)."
214949823|NCT03402347|RADIATION|Non-ionising radiation|Laser regimes will be applied to ex vivo skin samples.
214949824|NCT05106751|DEVICE|Hyaluronic acid dermal filler|Hyaluronic acid dermal filler used for facial volume or wrinkle correction
215076044|NCT03755674|PROCEDURE|CHRONOTYPE-ADJUSTED DIET|Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
215076045|NCT03013101|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
215076046|NCT05953597|BEHAVIORAL|Nutrition Education|The intervention will consist of 12 monthly nutrition education sessions catered to people with spinal cord injuries. The curriculum is based on the 2020-2025 Dietary Guidelines for Americans such as consuming recommended amounts of fruits/vegetables, whole grains, etc. The sessions will be approximately 30-60 minutes and will be available in-person.
214343310|NCT02081300|DRUG|Topical testosterone gel 1.62 %|
214343311|NCT03129334|BEHAVIORAL|LST Middle School Online|The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
214343312|NCT02094703|DRUG|Levofloxacin|
214343313|NCT02094703|DRUG|Solifenacin succinate|
214343314|NCT02094703|DRUG|Placebo (for Solifenacin succinate)|
214343315|NCT02337647|OTHER|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
214343316|NCT01203189|DRUG|ketoconazole 2% foam|Subjects in the Foam (F) group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
214949825|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Boost motivation and self-efficacy|"In the boost motivation and self-efficacy dialog, the conversational agent will tell the participant that they can successfully resist smoking, try to take away their self-doubts and assert that the participant can and will succeed. For example, the conversational agent will send text messages such as: Even though the temptation can be high, I have no doubts that you can resist smoking in this situation. If you want something, you can do it. Believe in yourself!."
214343317|NCT01203189|DRUG|ketoconazole 2% shampoo|Subjects in the Shampoo (S) group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
214343318|NCT05403489|PROCEDURE|Bronchoalveolar lavage|In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
214486501|NCT06922669|DRUG|Methylprednisolone|Initially, an intravenous dose of 1 mg/kg/day of methylprednisolone will be administered for one week, with the possibility of extending treatment to two weeks if necessary. Following this, participants will receive oral methylprednisolone tablets, starting at a dose of 40 mg/day. The oral dosage will be gradually tapered based on the participants' condition over a period of 1 to 3 months.
214949826|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Future-selves and implementation intentions|"In the future-selves and implementation intentions dialog, the conversational agent will first tell the participant to imagine themselves in a future in which they successfully quit smoking (i.e., desired future self). The conversational agent can send text messages such as: Please think about yourself in the future. Imagine that you have quit smoking successfully. Think about the person you will be. What do you look like? What does your life look like? Consider this future image as well as you can.. This procedure will be repeated for a future in which the participant continued smoking (i.e., the undesired future self). Finally, the conversational agent will explain to the participant that it is important to think about how to resist smoking in HRSs (i.e., implementation intentions) to ensure that the participant comes closer to becoming their desired future self as non-smoker and to avoid their undesired future self as a smoker."
214949827|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Identity-related positive self-talk|"In the identity-related positive self-talk dialog, the conversational agent will tell the participant to use positive self-talk focused on their identity to motivate themselves to successfully resist smoking. For example, the conversational agent will send text messages such as: When you feel tempted to smoke, it can help to say positive things to yourself and motivate yourself to resist the temptation. What positive things can you say about yourself to motivate yourself to resist smoking? For instance, 'I am a strong person who can resist smoking' or 'I am a person who is persistent and has control over the urge to smoke'. Now say the sentence(s) you find motivating or your own motivating words to yourself, by thinking it, and repeating it in your head or out loud.."
214949828|NCT05654545|BEHAVIORAL|Attention control dialog: neutral topic|"The neutral dialog will act as an attention control condition. In this dialog, the conversational agent will not provide support using relapse prevention strategies. Instead, the conversational agent will start with a short introduction (e.g., Hi, how are you doing?), ask questions to show interest (e.g., How are you feeling today?) and will talk about a neutral topic (e.g., animals; What is your favorite animal?), and then closes the conversation (e.g., It was nice speaking with you. I hope you have a good rest of the day!)."
214949829|NCT02342977|DRUG|Placebo|Patients will randomly receive placebo
214949830|NCT02342977|DRUG|Lacosamide|Patients will randomly receive lacosamide
214343319|NCT05403489|PROCEDURE|endotracheal aspirate culture|In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
214343320|NCT00765115|DRUG|LY450139|
214949831|NCT00030680|RADIATION|radiation therapy|
214949832|NCT00701480|OTHER|skin cleanser contained Hibiscus sabdariffa extract|face washing 2-3 times/day
214949833|NCT00701480|OTHER|marketed skin cleanser|face washing 2-3 times/day
214343321|NCT00765115|DRUG|placebo|
214949834|NCT05083676|BEHAVIORAL|Acceset Intervention|". The intervention comprises of: i) Digital peer support training for youth befrienders to equip them with the knowledge and application of the four active ingredients-Mattering, selfhood, compassion, and mindfulness-to provide effective peer support as they respond to youth seekers' emotional experiences.~ii) Acceset Intervention with features or digital markers of psychological well-being, peer emotional disclosure process and community engagement."
214949835|NCT03667027|DEVICE|Respiratory support|Mechanical ventilation or extracorporeal life support
214949836|NCT01580176|DEVICE|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
214949837|NCT06925854|DRUG|AZD4144|Oral tablet of AZD4144 will be administered.
214949838|NCT06925854|DRUG|Rosuvastatin|Oral tablet of rosuvastatin will be administered.
214949839|NCT03832504|OTHER|No intervention|The participant will rest in a seated position.
214949840|NCT03832504|OTHER|Fan|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure.
214949841|NCT03832504|OTHER|Skin Wetting|Tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
215076047|NCT00146809|DRUG|Minocyline|
215076048|NCT02885480|BEHAVIORAL|questionnaires|
214486502|NCT06922669|DRUG|Magnesium isoglycyrrhizinate|It is suitable for patients with hepatocellular or mixed DILI. A daily dose of 0.15g to 0.2g
214343322|NCT03380442|DRUG|Psilocybin|Psilocybin ingested orally
214343323|NCT03380442|DRUG|Ketamine (Ketalar)|Ketamine administered intranasally
214343324|NCT05476224|BIOLOGICAL|Blood sample of 30 ml|The parameters analyzed on this blood sample: Fasting blood glucose, HbA1C, creatinine, creatinine clearance (MDRD), fasting lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
214343325|NCT05812573|OTHER|no intervention|No intervention, only observation
214343326|NCT02055352|DRUG|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
214343327|NCT02055352|DRUG|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
214486503|NCT06922669|DRUG|Glutathione|It is suitable for patients with hepatocellular or mixed DILI. A daily dose of 1.2g to 1.8g
214486504|NCT06922669|DRUG|Silymarin|It is suitable for patients with hepatocellular or mixed DILI. The dosage is 140 mg, taken 2 to 3 times per day.
214486505|NCT06922669|DRUG|Polyene Phosphatidylcholine|It is suitable for patients with hepatocellular or mixed DILI. The dosage is 228mg-456mg, taken 3 times per day.
214486506|NCT06922669|DRUG|Ursodeoxycholic acid capsules|It is suitable for patients with cholestatic or mixed DILI. A daily dose of 10mg-15mg/kg/day.
214486507|NCT06922669|DRUG|Ademetionine 1,4-Butanedisulfonate|It is suitable for patients with cholestatic or mixed DILI. A daily dose of 0.5g to 1g.
215076049|NCT03643315|BEHAVIORAL|Exercise and Meal (EX)|30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
214949842|NCT03832504|OTHER|Fan + Skin wetting|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure. In addition, tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
214343328|NCT02055352|DRUG|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
214343329|NCT02055352|DRUG|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
214343330|NCT02136173|DEVICE|Heliosphere bag (air filled balloon)|sequential balloons . Heliosphere bag (air filled balloon)
214343331|NCT04589819|DRUG|Teriparatide|Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.
214343332|NCT04589819|DRUG|Placebos|Placebo will be a sugar solution of the manufacturer's design.
214343333|NCT03956017|DRUG|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
214343334|NCT03956017|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
214343335|NCT04120506|DRUG|VPRIV|Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
214949843|NCT03704948|BEHAVIORAL|RCT Treatment -Listening Visits delivered by NICU nurse in person|6 sessions, approximately one hour in length, delivered by a nurse who uses empathic listening and problem solving.
214949844|NCT03704948|BEHAVIORAL|RCT Control Usual mental health care delivered by NICU social workers|RCT Control Usual mental health care delivered by NICU social workers
214949845|NCT03704948|BEHAVIORAL|Open trial: Listening Visits delivered by a NICU nurse via zoom|Open trial: Listening Visits delivered by a NICU nurse via zoom
214949846|NCT01726621|DEVICE|Medtronic MiniMed 620G or 640G Insulin Pump|Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
214949847|NCT04361214|DRUG|Leflunomide|Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.
214949848|NCT03489941|DRUG|EM-100|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
214949849|NCT03489941|DRUG|Zaditor®|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
214949850|NCT03489941|DRUG|Vehicle|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
214949851|NCT00198913|BEHAVIORAL|lower fat food supplied and education|
214949852|NCT00198913|BEHAVIORAL|gift cards for grocery foods and written education|
214949853|NCT05329727|DRUG|Angiotensin receptor neprilysin inhibitor (ARNI)|The group with ARNI was defined as patients with HFrEF took ARNI more than 3 months
215076050|NCT03643315|BEHAVIORAL|No-Exercise and Meal (NEX)|30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
215076051|NCT01543399|DRUG|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
215076052|NCT01543399|DRUG|Placebo|patients of the placebo group will use placebo one a day for 30 days
215076053|NCT01330628|DEVICE|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
215076054|NCT01330628|PROCEDURE|Balloon angioplasty|standard balloon catheters for PTA
215076055|NCT02358200|DRUG|BMN-673|
215076056|NCT02358200|DRUG|Carboplatin|
214343336|NCT02180646|OTHER|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
214343337|NCT02180646|OTHER|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
214343338|NCT03347500|OTHER|use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
214343339|NCT04576208|DRUG|TAK-788|TAK-788 capsules
214343340|NCT04576208|DRUG|Antidiarrheal prophylaxis|Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
214343341|NCT03809182|DRUG|Dexmedetomidine|A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.
214343342|NCT03809182|DRUG|0.9% Sodium-chloride|The same infusion rate used in the dexmedetomidine group.
214949854|NCT05329727|DRUG|Renin-Angiotensin System Inhibitor (RAS inhibitor)|The group with RAS inhibitor was defined as patients with HFrEF took RAS inhibitor more than 3 months
214949855|NCT04332731|DEVICE|Symplicity Spyral™ multi electrode renal denervation system|Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity Spyral catheter, Medtronic) and associated Symplicity G3™ renal denervation radiofrequency generator (Symplicity G3 generator, Medtronic) will be used in this study. The Symplicity Spyral™ multi-electrode renal denervation catheter is intended to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.
214949856|NCT04332731|DIAGNOSTIC_TEST|Renal angiogram|Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
215076057|NCT02358200|DRUG|Paclitaxel|
215076058|NCT05308017|DEVICE|Richard Wolf 24F Laser scope|24F Laser with HoLEP
215076059|NCT05308017|DEVICE|Karl Storz 28F Laser Scope|28 F Laser with HoLEP
215076060|NCT03977025|DIAGNOSTIC_TEST|Lumbar punction|Patients will be evaluated prior to surgery with the Montreal Cognitive Assessment (MoCA) to determine the presence of cognitive impairment, and CSF samples, obtained by lumbar punction, will be analyzed by immunodetection of Aβ40, Aβ42, tau and ptau with multiplex technology
215076061|NCT02070419|PROCEDURE|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
215076062|NCT02070419|RADIATION|stereotactic radiosurgery|Undergo SBRT
215076063|NCT04854525|RADIATION|Pre reconstruction Radiotherapy|Previous PMRT
214343343|NCT03809182|DRUG|Fentanyl|Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
214343344|NCT03809182|DRUG|Morphine Sulfate|Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
214949857|NCT00182000|DRUG|seromycin|100mg tablet administered 1 hour prior to each therapy session
214949858|NCT00182000|BEHAVIORAL|Behavior Therapy|10 weekly hour-long behavior therapy sessions
214949859|NCT00750256|DRUG|GSK1278863A|GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
214949860|NCT04177888|DEVICE|Hot Pack|It is a single-use pack filled with magnesium sulfate and water, which was squeezed between the hands to activate their warming effect. The temperature ranges between 40°C to 50°C, which is safe to use. Thus, it provided a consistent heat therapy for up to 30 minutes. They can be used directly on the skin or covered with gauze to avoid direct skin contact. Applied to the lower back area for 30 minutes, followed by 10 minutes rest between each hot pack application, then it was reapplied for another 30 minutes. This procedure was repeated till delivery.
214949861|NCT04792372|PROCEDURE|Initial periodontal treatment|Conventional periodontal treatment (scaling and root debridement) will be conducted
214949862|NCT04691167|DEVICE|repetitive trans magnetic stimulation|Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.
214949863|NCT06184139|DRUG|Misoprostol|Oral misoprostol for induction of labor in late term pregnancies
214949864|NCT00427427|DRUG|Trastuzumab|
214949865|NCT01995864|BEHAVIORAL|CTI-TS|"The following briefly describes the three phases of CTI-TS:~Phase 1: Initiation: The client and CTI-TS team formulate a treatment plan that focuses on selected areas identified as crucial for strengthening stability and facilitating the assimilation of the individual into community living.~Phase 2: The Try-Out phase is devoted to testing and adjusting the support systems that have been established in the community.~Phase 3: The final phase, Transfer of Care, is devoted to making any necessary improvements in the network of supports of the individual."
214949866|NCT00482599|DRUG|Sugammadex|2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
214949867|NCT01905592|DRUG|niraparib|300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops
215076064|NCT04300517|DRUG|Three sachet of protein supplement to be mixed in with water used daily|Three sachet of protein supplement to be mixed in with water used daily
215076065|NCT03401567|OTHER|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
215076066|NCT02511093|BEHAVIORAL|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~* BP measurements;~* an educational and counselling intervention on patient adherence;~* an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
215076067|NCT04265157|PROCEDURE|Surgical technique surgical occlusion|Occlusion of hepatoduodenal ligament by clamp or occlusive bands
215076068|NCT02910401|BIOLOGICAL|Rhinovirus (GMP RV16 HRV-16)|300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
215076069|NCT05687773|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
214343345|NCT02062502|BIOLOGICAL|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
214343346|NCT02062502|BIOLOGICAL|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
214343347|NCT02062502|BIOLOGICAL|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
214343348|NCT04411108|OTHER|Kaia Back Pain App|The Kaia Back Pain App provides instructions on exercise execution to participants for one week
214486508|NCT06922669|PROCEDURE|Plaslna exchange|It is suitable for patients whose condition continues to worsen or even develop to liver failure.
214949868|NCT01905592|DRUG|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
214949869|NCT04137341|DRUG|GLPG1972 - A|Film-coated tablet, formulation A
214949870|NCT04137341|DRUG|GLPG1972 - B|Film-coated tablet, formulation B
214949871|NCT04137341|DRUG|GLPG1972 - C|Film-coated tablet, formulation C
214949872|NCT05050500|DRUG|Dapagliflozin 10mg/Tab|patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months
214949873|NCT05050500|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
214949874|NCT01484860|DRUG|AUY922|AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
214949875|NCT01500044|PROCEDURE|Program targeting the opening of foramen|Rehabilitation intervention that specifically targets the opening of the intervertebral foramen
214949876|NCT01500044|PROCEDURE|Conventional Rehabilitation Program|Program used in previous randomized clinical trials in this population
214343349|NCT04411108|OTHER|Physiotherapist Exercise Instructions and written handouts|Participants will be instructed by physiotherapists in exercise execution and receive handouts and exercise for one week
214343350|NCT04554862|DRUG|Magnesium sulfate|magnesium sulfate will be added to the block
214343351|NCT04554862|DRUG|Ketorolac Tromethamine|ketorolac will be added to the block
214343352|NCT04554862|PROCEDURE|supraclavicular block|it is done by ultrasound- guided
214343353|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
214949877|NCT04622761|DRUG|Cabazitaxel|"Patients will receive Cabazitaxel 25 mg/m2 \* intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~\*Cabazitaxel dose should be capped at 50mg (BSA=2)"
214949878|NCT02824588|BEHAVIORAL|Working Memory Training|Training mental flexibility
214949879|NCT02824588|BEHAVIORAL|Internet use|Used as control for time spent on computer
214949880|NCT02135705|DRUG|Lomitapide|As prescribed by Physician.
214949881|NCT04413942|BIOLOGICAL|FB825|Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
214949882|NCT04413942|OTHER|Placebo|Formulation buffer
214949883|NCT06954246|DRUG|MHB088C for Injection|2 mg/kg intravenous dose on Day 1 and Day 15 of each 28-day cycle
214949884|NCT06954246|DRUG|Topotecan|1.25 mg/m\^2 intravenous dose on Day 1 to Day 5 of each 21-day cycle
214949885|NCT06954246|DRUG|Irinotecan|65 mg/m\^2 intravenous dose on Day 1 and Day 8 of each 21-day cycle
214343354|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
214949886|NCT06954246|DRUG|Paclitaxel|135 mg/m\^2 intravenous dose on Day 1 of each 21-day cycle
214949887|NCT06042244|OTHER|Multimodal Exercise Group|Listed in arm/ group descriptions
214949888|NCT06042244|OTHER|Waitlist|listed in arm/group description
214949889|NCT01865604|DEVICE|Anodal tDCS|
214949890|NCT01865604|DEVICE|Cathodal tDCS|
214949891|NCT01865604|DEVICE|sham tDCS|
214949892|NCT06052644|OTHER|Exercise Dose-Response|"The intervention will last for 12 weeks. Depending on the group, participants will engage in the intervention either four times a week or only two times, with the duration ranging from 30 to 60 minutes per session. Each session will consist of three phases: an initial warm-up phase, a central phase, and a cool-down phase.~The warm-up phase will focus on joint mobility, beginning with flexion-extension, rotation, and lateral neck flexion while maintaining eye contact with a fixed point. This will be followed by trunk mobility exercises, including rotations.~The central phase will consist of aerobic and strength training performed at an intensity of 80-85% of the maximum heart rate. Each exercise will be performed intensely for 20 to 30 seconds, followed by a rest period of 10 to 15 seconds before repeating the exercise."
214949893|NCT00726258|DRUG|ketamine|ketamine with various concentrations
214949894|NCT00726258|DRUG|placebo|physiological serum
215076070|NCT05687773|DEVICE|Leap Motion Controller in Head-Mounted Display|For the immersive group, the same equipment mentioned above Leap Motion Controller will be projected on the Head-Mounted Display model Oculus Quest 2 (Meta Platforms Inc.). The device has binocular displays with Fresnel lenses with a resolution of 1832 by 1920 pixels per eye. It is equipped with a Qualcomm Snapdragon XR2 processor with the refresh rate of 72hz - 120hz and 6GB of RAM. The equipment has a 90º field of view and approximately 500 grams of total weight. The treatment protocol and patient positioning will be the same as previously mentioned, except for the type of projection used. At the 2-minute rest interval between games, the HMD will be removed from the user to change the game in question, returning at the end of this period.
215076071|NCT01660672|DRUG|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
214343355|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
214949895|NCT01687283|DRUG|fluticasone propionate inhalation solution|1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID
214949896|NCT01687283|DRUG|budesonide suspension|2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID
214949897|NCT03351153|RADIATION|X-ray|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week
214343356|NCT00587873|DRUG|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
214343357|NCT00587873|DRUG|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
214343358|NCT00587873|DRUG|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
214343359|NCT00326508|DRUG|Daclizumab|
214343360|NCT04824313|DIAGNOSTIC_TEST|Chest CT|Chest CT without intravenous contrast material
214343361|NCT04824313|DIAGNOSTIC_TEST|Chest CTA|Chest CT with intravenous contrast material
214343362|NCT00053833|DRUG|irinotecan|
214343363|NCT05081414|BEHAVIORAL|Program for Teaching Self-Care in HF (PEAC-IC)|As described previously
214343364|NCT05556408|DRUG|Succinylcholine|1.5mg/kg was given intravenously
214343365|NCT06201182|DRUG|FMT via rectal enema|50 grams of FMT via rectal enema
214343366|NCT06201182|DRUG|FMT capsules|FMT capsules given twice daily for 2 consecutive days
214343367|NCT06201182|DRUG|Placebo via rectal enema|Placebo via rectal enema
214343368|NCT06201182|DRUG|Placebo capsules|Placebo capsules given twice daily for 2 consecutive days
214949898|NCT03351153|RADIATION|CT|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week
214949899|NCT03351153|OTHER|specimen|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
214949900|NCT00642954|DRUG|Vorinostat|Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
214949901|NCT00642954|DRUG|Lenalidomide|Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
214949902|NCT00642954|DRUG|Dexamethasone|Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
214949903|NCT02863653|OTHER|observational study|application of several standard instruments in patients with rheumatoid arthritis
214949904|NCT01663857|DRUG|LY2228820|Administered Orally
214949905|NCT01663857|DRUG|Carboplatin|Administered IV
214949906|NCT01663857|DRUG|Placebo|Administered Orally
214949907|NCT01663857|DRUG|Gemcitabine|Administered IV
214949908|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
214949909|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
214949910|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
214949911|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
214949912|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE
214949913|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
214949914|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.45 EE
214949915|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.60 MT
214343369|NCT00270543|DRUG|Taxotere, Fluorouracil, Leucovorin|
214949916|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, Placebo
214949917|NCT00806858|DEVICE|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
214949918|NCT00797940|DRUG|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
214949919|NCT03041467|DEVICE|IN.PACT AV DCB|IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
214949920|NCT03041467|DEVICE|Standard Balloon Angioplasty|Standard PTA Balloon
214343370|NCT03399734|DRUG|Perampanel|Single oral dose of 1 x 4-mg perampanel tablet
214949921|NCT05777564|OTHER|High intensity exercise|High intensity exercise on a indoor aerobic exercise device.
214949922|NCT04505254|DRUG|Acalabrutinib|Given PO
214343371|NCT03399734|DRUG|Perampanel|Single 4-mg dose of perampanel fine granules
214343372|NCT05820724|DIAGNOSTIC_TEST|PSMA PET scan|Subjects will undergo DCFPyL PET/CT imaging and mpMRI imaging prior to the prostate biopsy. The decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. The intervention includes a mpMRI, a PSMA PET scan, and a prostate biopsy.
214343373|NCT05820724|OTHER|No PSMA PET|Subjects will undergo mpMRI imaging prior to the prostate biopsy. These subjects do not undergo a PSMA PET scan prior to the prostate biopsy. The decision for biopsy targets will be made based on the findings of mpMRI. The intervention includes a mpMRI and a prostate biopsy.
214343374|NCT05820724|DRUG|18F- DCFPyl Injection|DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
214949923|NCT04505254|BIOLOGICAL|Obinutuzumab|Given IV
214343375|NCT00005854|DRUG|cyclophosphamide|
214343376|NCT00005854|DRUG|cyclosporine|
214343377|NCT00005854|DRUG|methotrexate|
214343378|NCT00005854|PROCEDURE|allogeneic bone marrow transplantation|
214343379|NCT00005854|PROCEDURE|in vitro-treated bone marrow transplantation|
214949924|NCT00274547|DRUG|Tiotropium|
214949925|NCT05319262|RADIATION|Pink noise exposure|Continuous pink noise sound exposure at 45 dBA, throughout the whole night
214949926|NCT05319262|RADIATION|Traffic noise|120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.
214949927|NCT01569698|PROCEDURE|acute extra renal replacement therapy|usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
214949928|NCT05599386|DIAGNOSTIC_TEST|Preoperative test|Patients are subject to quantitative sensory testing, questionnaires, and biomarker analysis prior to surgery.
215076072|NCT00771043|DRUG|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
215076073|NCT02975479|DRUG|ALK Diluent|
215076074|NCT02975479|DRUG|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
214343380|NCT00005854|RADIATION|radiation therapy|
214949929|NCT02528617|DRUG|Velaglucerase alfa|Enzyme replacement therapy
214949930|NCT05614401|OTHER|functional and medical information|1\) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.
214949931|NCT05968430|DRUG|lorundrostat|Tablet, administered orally
214949932|NCT05968430|DRUG|Placebo|Tablet, administered orally
214949933|NCT06549881|PROCEDURE|emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence|emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence
214949934|NCT02732015|DRUG|Dexamethasone|Given IV
214949935|NCT02732015|DRUG|Doxorubicin|Given IV
214949936|NCT02732015|DRUG|Fosaprepitant Dimeglumine|Given IV
214949937|NCT02732015|DRUG|Ifosfamide|Given IV
214949938|NCT02732015|OTHER|Laboratory Biomarker Analysis|Correlative studies
214949939|NCT02732015|DRUG|Mesna|Given IV
214949940|NCT02732015|DRUG|Ondansetron|Given IV
215076075|NCT06106724|PROCEDURE|sphincterotomy|cutting the papilla and cannulation with sweeping of common bile duct by ballon and stent insertion
215076076|NCT06106724|PROCEDURE|precutting of the papilla by knife needle|precutting of the papilla by knife needle
214949941|NCT02732015|OTHER|Questionnaire Administration|Ancillary studies
214949942|NCT02732015|DRUG|Rolapitant Hydrochloride|Given PO
214949943|NCT02732015|DRUG|Vincristine Sulfate|Given IV
214949944|NCT03052920|DEVICE|Cochlear implant|Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.
214949945|NCT00488137|DRUG|Prucalopride|2 mg o.d.
214949946|NCT00488137|OTHER|Placebo|o.d.
214949947|NCT00488137|DRUG|Prucalopride|4 mg o.d.
214949948|NCT01980628|DRUG|ibrutinib|
214949949|NCT04465656|DIAGNOSTIC_TEST|Serology test for COVID-19|"In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed in two parts:~1. ELISA test~2. Rapid Diagnostic tests (only if ELISA test is positive)"
214949950|NCT03952026|PROCEDURE|osteosynthesis of the pelvis|Osteosynthetic Fixation of the pelvic fracture
214949951|NCT06458777|DIAGNOSTIC_TEST|poligraphy|OSA diagnosis
214949952|NCT02686788|DRUG|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
214949953|NCT00335010|DRUG|Nitroglycerin|
214949954|NCT00495690|DRUG|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
215076077|NCT03955250|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
215076078|NCT03955250|BEHAVIORAL|Mobile app attention control|The control app provides ecological momentary assessment and psychoeducation about illness.
215076079|NCT01261442|PROCEDURE|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
215076080|NCT03010891|BEHAVIORAL|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC \> 45 minutes
215076081|NCT03010891|BEHAVIORAL|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC \< 20 minutes
215076082|NCT02777606|DRUG|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
214343381|NCT05637463|OTHER|No intervention|no intervention was made
214486509|NCT06922669|PROCEDURE|Liver transplantation|It is suitable for patients whose condition continues to worsen or even develop to liver failure.
215076083|NCT03802344|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
215076084|NCT03802344|DRUG|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
214949955|NCT04990765|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 3 weekly treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations (6 different scenes from a restaurant) in virtual reality. From scene 1 to scene 6, alchol-related cues increase in intensity in order to perform gradual exposure therapy as a part of CBT. Furthermore, VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
214949956|NCT04990765|BEHAVIORAL|CBT|The active comparator receives 3 conventional cognitive behavioral therapy sessions with 1 week intervals.
214949957|NCT00930527|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|4g per day for 3 weeks
214949958|NCT02644447|BIOLOGICAL|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
214949959|NCT02644447|BIOLOGICAL|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
214949960|NCT04457401|DIETARY_SUPPLEMENT|Probiotic|This probiotic is commercially available and contains Bifidobacterium (3 x 10\^9 colony forming units/capsule) as the active ingredient and potato starch, magnesium stearate and ascorbic acid as excipients.
214949961|NCT04457401|DIETARY_SUPPLEMENT|Placebo|The placebo contains potato starch, magnesium stearate and ascorbic acid.
214949962|NCT05273905|DIAGNOSTIC_TEST|Ultrasound derived Avi|Assess the Avi of carotid arteries, hepatic arteries, renal arteries and central retinal arteries.
214949963|NCT00564278|DRUG|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
214949964|NCT00564278|BEHAVIORAL|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
215076085|NCT03802344|DRUG|Vehicle|Vehicle cream
215076086|NCT01670786|PROCEDURE|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
215076087|NCT03865745|DIETARY_SUPPLEMENT|Korean Red Ginseng|Take one pack of the product (3g) once a day for 24 weeks
215076088|NCT02793817|DRUG|KPI-121 1% Ophthalmic Suspension dosed BID|
215076089|NCT02793817|DRUG|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
215076090|NCT04899258|PROCEDURE|Femtosecond laser assisted LASIK|Refractive surgery
215076091|NCT01728506|BEHAVIORAL|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
215076092|NCT02153424|DRUG|Apixaban|
215076093|NCT00733200|PROCEDURE|Minor or Major Liver Resection|
215076094|NCT05648864|DEVICE|Viamigo|Mobile application with the aim to enhance the independent outdoor mobility of the user while a coach (informal caregiver) can monitor the route from a distance.
215076095|NCT03222973|DRUG|BIIB033 (opicinumab)|Administered as specified in the treatment arm
214486510|NCT06922812|DEVICE|Intermittent White Light Stimulation (IWLS)|A wearable device developed by SyntropicMedical (Austria) delivers intermittent white light at 60 Hz using LED strips embedded in safety goggles. The light is diffused (approximately 700 lux) and projected tangentially to the participant's eyes. Participants will undergo 10 daily sessions (30 minutes each) over a two-week period. The intervention aims to evaluate the safety, tolerability, and potential antidepressant effects of 60 Hz visual stimulation in individuals with moderate to severe Major Depressive Disorder.
214949965|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Rind|watermelon rind
214949966|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Flesh|watermelon flesh
214949967|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Seeds|watermelon seeds
214949968|NCT03365960|DIETARY_SUPPLEMENT|Placebo|Control Comparator
214949969|NCT02333500|OTHER|olfactory workshop|olfactory workshop
214949970|NCT02333500|OTHER|other workshop|other workshop: discussion group, dance and body Expression
214949971|NCT02333500|OTHER|No intervention|control group
214949972|NCT06473766|DIAGNOSTIC_TEST|RF data extraction|"To will be acquired:~10 S-Harmonic images (5 in longitudinal plane, 5 in orthogonal plane), 10 B-mode fundamental images (without Harmonic), 1 gray-scale video clip, 1 gray-scale 3D vol will be stored in Harmonic settings and RF-preset.~The Region of interest (ROI) of each image will be manually segmented by a trained gynecologist using the software Aliza version 1.48. The ROI will include only the solid component of the mass. Additional analysis will be performed by using a predefined ROI (area 2x2 cm2). Radiomic features will be extracted using the MODDICOM, an open-source in-house software solution developed by the Knowledge Based Oncology Labs (Rome, Italy) for quantitative imaging analysis fully compliant with the Image Biomarker Standardization Initiative recommendations. The features will be considered: intensity-based statistical and textural."
214949973|NCT05810896|OTHER|AF at Home|The AF at Home education program will be delivered via Zoom videoconferencing technology and will include 6, 1-hour long sessions that involve education on AF self-monitoring and self-management. Each session will include a didactic presentation and open Q\&A. Supplementary educations materials will be made available to participants.
214949974|NCT03714711|PROCEDURE|total hip arthroplasty|Total hip replacement
214949975|NCT03714711|PROCEDURE|total knee arthroplasty|Total knee replacement
214949976|NCT05245422|OTHER|Infant Formula - Partially hydrolyzed protein|Partially hydrolyzed cow's milk protein
214949977|NCT05245422|OTHER|Infant Formula - Intact protein|Intact cow's milk protein
214949978|NCT05603923|BEHAVIORAL|Lumen Coached PST Intervention.|Lumen Intervention Orientation. Participants in the Lumen intervention arm attend a Lumen orientation visit (60 minutes) during which they will be given a Lumen intervention tutorial and receive a study iPad, configured to limit access to only the Lumen intervention enabled on the device. Before leaving, participants are scheduled for the first PST session with Coach Lumen. At the end of each PST session, participants are prompted to schedule their next session with Coach Lumen. They receive automated reminder notifications 1 day prior to their next session, on the session day, and have the opportunity to make up missed sessions. As needed, Lumen intervention orientations can be done remotely.
214949979|NCT05603923|BEHAVIORAL|Human Coached PST Intervention.|Participants in the human coached PST arm will serve as active treatment controls given the demonstrated efficacy of human coached PST in depression and anxiety. They will complete 8 PST sessions with a human coach; first session in-person and remaining sessions via videoconferencing (i.e., Zoom preferred; with phone calls allowed) on the same 4 weekly and then 4 biweekly schedule as that for Lumen participants. Participants will receive a study iPad to use for their PST sessions via zoom. Participants also complete the PHQ-9 and GAD-7 during each session. Participants will receive a certificate of completion.
214949980|NCT05603923|BEHAVIORAL|Optional (delayed) Lumen Coached PST (Waitlist control).|Waitlist control participants will only complete assessments during the 18-week trial period. At the end of their 18-week assessment, they will have the option to complete 8 PST sessions on their assigned iPads.
214949981|NCT06125535|DIAGNOSTIC_TEST|Sub-phenotyping by biomarkers concentration|Plasma will be collected at ICU admission (i.e., \< 6 hours from graft reperfusion), centrifuged (1500G for 15 min), frozen at -80°c, and then centralized at the Institutional laboratory. The following biomarkers will be assessed: Interleukin-1β, Interleukin-2, Interleukin-6, Interferon-γ, Tumor Necrosis Factor-alpha (TNF-α), chemokine (C-C motif) ligand-2 (CCL-2), Interleukin-15 (IL-15), Ferritin, and D-dimer, by a point-of-care biochip-array device (RANDOX, Multistat)
214949982|NCT06439095|GENETIC|Salivary Collection|Expression levels of IL-2, IL-5 and IL-17 in the saliva of individuals aged 3-9 years who underwent stainless steel crown will be recorded before and after the procedure. Before the saliva sample collection procedure, the patient will be asked to rinse their mouth with sterile water and then spit into sterile plastic cups. After collecting approximately 3 ml of saliva, the saliva will be transferred to appropriate eppendorfs and stored at -40 degrees Celsius. For the second post-procedure, the same algorithms will be applied for saliva collection seven days after the crown procedure.
214949983|NCT06439095|DIAGNOSTIC_TEST|Ph and ion level measurement of saliva|Salivary concentration of nickel, chrome ions will be measured using an atomic absorption spectrophotometer.
214949984|NCT06445647|OTHER|core Stability exercise|core stability exercise training
215076096|NCT03222973|DRUG|Placebo|Administered as specified in the treatment arm
215076097|NCT05122260|DRUG|Q-Griffithsin|intranasal spray administered as a single dose
215076098|NCT05122260|OTHER|Placebo|intranasal spray administered as a single dose
215076099|NCT04135560|DRUG|PF-07038124 and Vehicle|PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
215076100|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
214949985|NCT06445647|OTHER|Breathing exercises|Deep breathing and diaphragmatic breathing exercises
214949986|NCT04544189|DRUG|Alpelisib|300mg (oral) once daily, in a 28-day cycle
215076101|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
214343382|NCT05117645|DIAGNOSTIC_TEST|Computed tomography|All patients will be examined by multislice CT scanner,Light speed 5X GE 8 detector elements scanner or GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) or Toshibe Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Axial scanns will be done commences at 1 cm above the diaphragm and ending at lesser trochanters then coronal and sagittal reconstruction images will be exposed.
214949987|NCT04544189|DRUG|Fulvestrant|Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
214949988|NCT04544189|DRUG|Placebo|300 mg by mouth once daily, in a 28-day cycle
214949989|NCT04095299|RADIATION|50.4 Gy to the tumor and elective volume|Standard radiotherapy
214949990|NCT04095299|RADIATION|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume|Experimental radiotherapy
214949991|NCT04095299|DRUG|Capecitabine 825 mg/m2 twice daily on weekdays|Standard chemotherapy
214949992|NCT03789591|DRUG|Hydroxyurea|The alternative arm will use PK data to choose a starting hydroxyurea dose to achieve an AUC of 115 mg\*h/L to approximate maximum tolerated dose. On the standard arm, participants will start at the traditional, weight-based dose of 20 mg/kg/day. Following selection of the starting dose, all participants will follow the same dose escalation and laboratory monitoring procedures.
214949993|NCT05564689|PROCEDURE|Intracoronary flow and pressure|Measurement of absolute coronary flow and resistance
214949994|NCT05978232|BEHAVIORAL|NAVAH|Patient navigator program that aims to inform African-American prostate and breast cancer patients about their treatment options, specifically radiotherapy
214949995|NCT06216093|BIOLOGICAL|EuRSV|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
214949996|NCT06216093|OTHER|Placebo Comparator|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
215076102|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
214343383|NCT03794089|BEHAVIORAL|Brief anxiety intervention|Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills
214343384|NCT03794089|BEHAVIORAL|Usual PC-MHI care|Anxiety treatment with mental health provider in local primary care clinic
214949997|NCT05642572|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214949998|NCT05642572|DRUG|Capmatinib|Given PO
214949999|NCT05642572|PROCEDURE|Computed Tomography|Undergo CT scan
214950000|NCT05642572|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214950001|NCT05642572|DRUG|Osimertinib|Given PO
214950002|NCT05642572|BIOLOGICAL|Ramucirumab|Given IV
214343385|NCT00404339|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
214343386|NCT00404339|BIOLOGICAL|tetanus toxoid helper peptide|
214343387|NCT00404339|PROCEDURE|adjuvant therapy|
214486511|NCT06759116|PROCEDURE|Control group|The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ml saline)
214486512|NCT06759116|PROCEDURE|Fentanyl group|The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 50 mcg fentanyl)
214950003|NCT05429619|OTHER|PeerOnCall|A mobile health peer-to-peer support platform that consists of two inter-connected apps: PeerOnCall and PeerOnCall Support. The apps were co-designed by and for the public safety community in Canada, with customized content for correctional workers, emergency communicators, firefighters, paramedics and police.
214950004|NCT03341936|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
214950005|NCT03341936|DRUG|Lirilumab|Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
214950006|NCT02368886|DRUG|Clobetasol Propionate|Given topically
214950007|NCT02368886|OTHER|Pharmacological Study|Correlative studies
214950008|NCT02368886|OTHER|Quality-of-Life Assessment|Ancillary studies
214950009|NCT02368886|DRUG|Regorafenib|Given PO
214950010|NCT02339974|DEVICE|Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava|
214950011|NCT05680337|DEVICE|TENS|TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.
214950012|NCT06564428|GENETIC|Suspective gene mutations and family history|To observe if the patients with suspective gene mutations or family history take higher risk of suffering from ovarian cancer.
214950013|NCT04849416|DRUG|LOXO-305|Administered orally.
214950014|NCT01744171|BIOLOGICAL|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Given ID
214950015|NCT01744171|OTHER|Laboratory Biomarker Analysis|Correlative studies
214950016|NCT04460534|DIAGNOSTIC_TEST|diagnostic|The principle of this study is to propose to patients in whom a COVID-19 infection is suspected and who are screened for the disease, the joint search for the virus in the semen.
215076103|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
215076104|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
215076105|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle BID applied to 10% BSA
214343388|NCT04553952|OTHER|Measurement of gingival display|"All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all."
214343389|NCT03985423|DRUG|Emapalumab-Lzsg|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day \[SD\] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
214343390|NCT01954706|OTHER|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
214343391|NCT01954706|OTHER|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
214343392|NCT03119766|DRUG|Kolofort|Oral administration
214343393|NCT03119766|DRUG|Placebo|Oral administration
214343394|NCT02562755|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
214343395|NCT02562755|DRUG|Sorafenib|"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
214343396|NCT02034578|DRUG|Apixaban|
214343397|NCT06264440|DRUG|BIIB122|Administered as specified in the treatment arm.
214343398|NCT06264440|DRUG|Rabeprazole|Administered as specified in the treatment arm.
214950017|NCT02485418|DRUG|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
214950018|NCT04555499|OTHER|Standardized neurological examination|
215076106|NCT03935724|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
214950019|NCT05056571|BEHAVIORAL|Progressive muscle relaxation|Progressive muscle relaxation exercise is a type of exercise in which tense muscles in your body gradually relax and relax. It is an application that allows you to forcefully stretch every muscle group in your body, hold it tight for 5 seconds, and then relax it. Visualize your tense muscles throughout this exercise and imagine that the feeling of relaxation spreads to all your muscles in the form of a wave and the tension is relieved. Keep breathing throughout the entire exercise.
214950020|NCT02960477|OTHER|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain.
214343399|NCT05377398|BEHAVIORAL|Digital individual-level intervention (Bit Habit)|"All participants in the intervention group receive access to the BitHabit app for the 1-year intervention period. The BitHabit app was designed in the StopDia project, and it aims to help its users to adopt healthier lifestyles and habits.The content and approach of the app is based on habit formation theories and the Self-Determination Theory. The app provides an extensive library of suggested lifestyle habits that was created according to lifestyle guidelines and recommendations. The habits are related to diet, physical activity, sleep, positive mood, stress management, smoking, and alcohol consumption. Users of the app select these habits from the library to their shopping basket to complete in their everyday life. The app also allows the users to report and monitor their performance and progress."
214486513|NCT06759116|PROCEDURE|Dexmedetomidine group|The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ug/kg dexmedetomidine not exceeding 100 ug (to be completed to 1mL with normal saline if needed). )
214950021|NCT02960477|OTHER|Biomedical Education|A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
214950022|NCT06046209|DEVICE|Control Lens|Daily disposable contact lens for 90 minutes
214950023|NCT06046209|DEVICE|Test Lens|Monthly replacement contact lens for 90 minutes
214950024|NCT05461365|DRUG|Insulin|Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
214950025|NCT04525131|DRUG|CPX-POM|CPX-POM
214950026|NCT03944993|DEVICE|Pulsed Electromagnetic Fields Therapy (Dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
215076107|NCT02080481|DEVICE|Infiniti Plus needle guidance system|The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
215076108|NCT02080481|DEVICE|Conventional block needle|conventional block needle used for insertion of femoral nerve catheters.
214343400|NCT05377398|BEHAVIORAL|Group-based healthy lifestyle and green power intervention|The group-based healthy lifestyle intervention is based on the Supportive Environment Theory (SET). The intervention is implemented in accordance with DiClemente and Prochaska's Stages-of-Change Model which is often used as framework for lifestyle change as well as Shazer and Berg's Solution Focused Brief Therapy. We expect participants to increase knowledge about healthy lifestyle choices and notice the beneficial effect of exercise, healthy diet and staying in nature. The intervention includes 12 to 16 hours of group activities during a period of 8 weeks. Interventions comprehend guided activities in nature, related to healthy relationship to food and exercise, as well as reflecting on shared experiences. In addition to group meetings, participants have access to material for mental well-being on an electronic learning environment.
214950027|NCT03944993|DEVICE|Pulsed Electromagnetic Fields Therapy (Non-dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their non-dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
214343401|NCT05377398|BEHAVIORAL|Individual-level healthy lifestyle intervention|The individual-level healthy lifestyle intervention follows the principles and theoretical background of the group-based intervention, but the intervention is carried out entirely on the electronic learning environment. The participants complete activities and exercises independently or with a friend in their own time.
214950028|NCT03944993|DEVICE|Sham Therapy (Control)|Participants of this arm will be not be exposed to the fields. Sham treatment will utilise the same PEMF apparatus for 10 minutes, but in non-operational mode, which is indistinguishable from when the apparatus is in operation. Duration of intervention is 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
214950029|NCT00111306|DRUG|epratuzumab|
214950030|NCT02131636|DRUG|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
215076109|NCT04148196|OTHER|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
215076110|NCT04809818|DRUG|LT3001 drug product|Multiple doses of LT3001 drug product administered by intravenous infusion
215076111|NCT04809818|DRUG|Placebo|Multiple doses of Placebo administered by intravenous infusion
215076112|NCT04809818|DRUG|Aspirin|Loading and maintenance doses of Aspirin administered by oral
215076113|NCT04809818|DRUG|Clopidogrel|Loading and maintenance doses of Clopidogrel administered by oral
215076114|NCT04809818|DRUG|Apixaban|Multiple doses of Apixaban administered by oral
214343402|NCT05377398|BEHAVIORAL|Mini-intervention for substance use|The mini-intervention for substance use follows the principle of the ASSIST-linked brief intervention created by WHO. This brief intervention is a phone-call lasting 3 to 15 minutes and given to the participant according to their risk score calculated with the ASSIST questionnaire which is included in the baseline survey. The intervention includes presenting the participant with their test score and associated health problems related to their level of risk. Especially in primary health care context, brief intervention according to the ASSIST score has been found to be successful in moderating risk for substance use. The intervention is not intended as a stand-alone treatment and in cases where high risk substance use is detected, the professional should encourage the participant to seek specialized drug and alcohol assessment and treatment.
214343403|NCT01822860|DRUG|Chlorthalidone 12.5 mg|
214343404|NCT01822860|DRUG|Hydrochlorothiazide 25 mg|
214950031|NCT02131636|DRUG|Vehicle to AGN-199201|Vehicle to AGN-199201 applied to the face once daily for 29 days.
214950032|NCT01824121|BIOLOGICAL|stem cell therapy|Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
214950033|NCT03887624|DRUG|Ethosuximide|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
214950034|NCT03887624|DRUG|Placebo|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
214950035|NCT03887624|DRUG|Escitalopram|1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
214950036|NCT00235248|DRUG|Warfarin|Warfarin
215076115|NCT04809818|DRUG|Dabigatran|Multiple doses of Dabigatran administered by oral
214343405|NCT01822860|DRUG|Placebo|
214343406|NCT04711564|OTHER|Olive oil-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
214343407|NCT04711564|OTHER|Soybean-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
214343408|NCT03419169|DEVICE|Light load BFR resistance training|A novel training light load resistance training modality.
214950037|NCT00235248|DRUG|Clopidogrel-aspirin|Clopidogrel-aspirin
214343409|NCT03419169|PROCEDURE|Heavy load resistance training|A common form of resistance training used for rehabilitation within the National Health Service.
214343410|NCT02405715|DRUG|Oxytocin nasal spray or placebo|
214343411|NCT03873649|OTHER|Bronchoscopy with lavage|"Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response."
214343412|NCT03049124|BEHAVIORAL|Exercise|Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than \< 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than \< 60% of heart rate reserve) component.
214343413|NCT01045447|DRUG|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
214343414|NCT01045447|DRUG|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
214343415|NCT03157986|OTHER|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
214343416|NCT03157986|OTHER|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
214343417|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using digene HC2 DNA Collection Device|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
214343418|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using Evalyn Brush|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
214343419|NCT05372445|BEHAVIORAL|Non-intensive intervention|"After an evaluation of 7 day initial food-recall, subjects will receive counseling in order to improve their dietary habits, according to the American Diabetes Association 2019 Guidelines. The goals of this intervention are (i) achieve a caloric restriction of 500 kcal from their habitual energy intake, (ii) prioritize natural, minimally processed foods with a low glycemic index and glycemic load, (iii) eat lean protein sources, both from plant and animal origin and (iv) gradual increments of fiber intake, to achieve at least the minimum recommendations for the general population.~The frequency of the follow-up appointments will be every 4 weeks, alternating between a clinical control and nutritional one. Therefore, the planned nutritional follow-up frequency will be every 2 months. In these appointments, the objective will be to achieve the mentioned energy intake reduction of 500 kcal, aiming to the nutritional goals previously mentioned, with the aid of the food-recalls."
214343420|NCT05372445|BEHAVIORAL|Intensive intervention|"People will have virtual education with food and nutrition coaching workshops, as well as weekly meetings in small groups as a support and follow-up groups. The frequency of the face-to-face follow-up appointments will be every 3 weeks.~The nutritional intervention will emphasize the consumption of mainly minimally processed food from plant origin. A vitamin b12 supplement per week will be provided. This intervention group will have 2 stages. First stage will have a duration of 3 months setting the nutritional bases going to a plant-based diet with basic considerations regarding fiber intake reducing meat consumption, and incorporating protein from vegetable sources, among other considerations. Second stage will progress to higher levels of fiber and others nutritional requeriments in order to intensify the nutritional plant-based intervention."
214343421|NCT01659918|DRUG|Montelukast|
214343422|NCT01659918|DRUG|Singulair|
214343423|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing|Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration
214343424|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)|Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
214343425|NCT06535685|DRUG|Romiplostim|Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.
214950038|NCT02493530|DRUG|TGR-1202|"Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established."
214343426|NCT02181530|OTHER|No Intervention|No treatment (intervention) is being administered as part of this study.
214950039|NCT02493530|DRUG|ruxolitinib|
214950040|NCT04414163|DRUG|IMC-001|Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)
214950041|NCT05989386|PROCEDURE|0.9% saline solution|During emergency laparotomy, after the primary surgical procedure. the sheath will be sutured and the incision site will then be irrigated with three rounds of 1 liter of 0.9% saline solution, which will be completely aspirated before the closure of the incisional wound in experimental group.
214950042|NCT05989386|PROCEDURE|Povidone-iodine Swab|No intra-operative wound lavage done, and wound would be cleaned with povidone doused swab.
214950043|NCT05280197|PROCEDURE|TAP block|Transversus abdominis plane (TAP) nerve block with liposomal bupivacaine plus free bupivacaine
214343427|NCT00826891|DRUG|Cisplatin Combined With Topotecan|"Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).~Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.~Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2~Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2"
214343428|NCT00374530|DRUG|PGE2|
214950044|NCT05280197|PROCEDURE|TAP block|Transversus abdominis plane (TAP) nerve block with normal saline
214343429|NCT03845257|DIAGNOSTIC_TEST|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as \>300/µl (or \>150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
214343430|NCT05006170|DRUG|DTG DT 20 mg|Give 2 tabs of MYLTEGA DT (10mg) PO once daily
214343431|NCT05006170|DRUG|DTG DT 25 mg|Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
214343432|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
214343433|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
214343434|NCT00332748|DRUG|Oral Taxane|
214950045|NCT05280197|DRUG|liposomal bupivacaine plus free bupivacaine|TAP block using liposomal bupivacaine plus free bupivacaine
214950046|NCT05280197|DRUG|normal saline|TAP block using normal saline
214950047|NCT06347575|DEVICE|Implantation of the caverStim device|Implantation of caverStim in SCI patients.
214950048|NCT04220190|BIOLOGICAL|RAPA-501 Autologous T stem cells|Experimental: Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T stem cells 80 x 10EE6 cells per infusion (no host conditioning)
214950049|NCT05208905|DEVICE|Esprit BTK Device|Participants will receive Esprit BTK Device
214950050|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Maintenance Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Maintenance in Immunosuppression medication.
214950051|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Withdrawal Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Withdrawal of MMF immunosuppression medication.
214950052|NCT06319222|OTHER|DALC Digital Clinic|Providers randomized to the intervention arm will be able to refer their patients with ALD, to the DALC in addition to standard of care. Patients with providers randomized to the intervention arm will be consented by the study team. After appropriate consent, the referred patients will be instructed by our study team to download the RTP application in their smart devices (smartphones or tablets).
214343435|NCT01141894|OTHER|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
214343436|NCT01141894|OTHER|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
214950053|NCT04997265|OTHER|Low intensity anticoagulation|Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.
214950054|NCT04997265|OTHER|Moderate Intensity Anticoagulation|"Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers."
214950055|NCT04847232|DRUG|Sodium Zirconium Cyclosilicate (SZC)|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the long interdialytic interval (LIDI).
214950056|NCT04847232|DRUG|SZC Placebo|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the LIDI.
214950057|NCT05429008|DRUG|HMPL-A83 injection|Day 1,8,15,22 dose; 28 day treatment cycles.
214950058|NCT03798327|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
214950059|NCT06101095|DRUG|Dupilumab|Subcutaneous injection (SC) as per protocol
214950060|NCT06101095|DRUG|Placebo|SC injection as per protocol
214343437|NCT03285282|PROCEDURE|Thoracolumber interfascial plane block|Thoracolumber interfascial plane block versus placebo
214343438|NCT03844763|DRUG|Avelumab|Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity
214343439|NCT03844763|DRUG|CTX|CTX: 50 mg Daily untill PD or major toxicity
214343440|NCT03844763|RADIATION|RT|RT: 8 Gy single shot day 8
214343441|NCT02848508|DRUG|Metformin|
214950061|NCT05682352|DRUG|LEO 158968|IV infusion or SC injection
214950062|NCT05682352|DRUG|Placebo|IV infusion or SC injection
214950063|NCT05682352|DRUG|LEO 158968|SC injection
214950064|NCT05682352|DRUG|Placebo|SC injection
214950065|NCT06444139|DIETARY_SUPPLEMENT|Probiotics|Probiotics
214950066|NCT06444139|DIETARY_SUPPLEMENT|Placebo|Placebo
214950067|NCT01354522|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
214343442|NCT00846664|PROCEDURE|Logan Short Arc Banding|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
214343443|NCT05402267|PROCEDURE|Adenoidectomy|Adenoidectomy will be conducted in OA and CA groups
214343444|NCT04931511|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|Gluteal muscle injection(Compound betamethasone 1ml + Sodium Chloride Injection 4ml) + Subacromial Ultrasound Guided injection(Sodium Chloride Injection 5ml)
214343445|NCT04931511|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|Gluteal muscle injection (Sodium Chloride Injection 5ml)+ Subacromial Ultrasound Guided injection (corticosteroid 1ml+Sodium Chloride Injection 4ml)
214343446|NCT04931511|BEHAVIORAL|Physical therapy|paticipant will be teached by the Physicaltherapist to reduce the shoulder pain at home
214343447|NCT01417312|DIETARY_SUPPLEMENT|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
214343448|NCT01417312|DIETARY_SUPPLEMENT|Placebo|Daily intake of placebo capsules for 3 months
214343449|NCT00122512|DRUG|Tenofovir Disoproxil Fumarate|
214950068|NCT01354522|DRUG|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
214950069|NCT01560715|BIOLOGICAL|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
214950070|NCT01300156|DRUG|Oxaliplatin-based chemotherapy (ESHAOx)|"* Etoposide 40 mg/m2, D1-4~* Methylprednisolone 500mg, D1-5~* Cytarabine 2 g/m2, D5~* Oxaliplatin 130 mg/m2, D1"
214950071|NCT01690195|DRUG|ABT-126|See arm description
214950072|NCT05560698|OTHER|Motivation-enhancing intervention|The web app is designed as an efficient and easy-to-use app configurable to personal preferences. Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. The questionnaire addresses the same questions as the questionnaire in the standard intervention, but the format is different, and some shortcuts makes it easier to answer. When the questionnaire is answered, the web app gives access to different features. The following features distinct the motivation-enhancing intervention from the standard intervention (1) only complete the entire questionnaire on days with symptoms, (2) integration of grass pollen counts and forecasts, (3) showing personal response rate, (4) access to own data via a graph, (5) advice against grass pollen allergy, (6) status of the study, (7) individually choosing the time of response, (8) option to download an icon for the home screen and (9) contact information. The development is an ongoing iterative process
214950073|NCT05560698|OTHER|Standard intervention|Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. When the questionnaire is answered, the tab needs to be closed.
214950074|NCT04196335|DEVICE|intra-procedural intracardiac echocardiography|use of intra-procedural intracardiac echocardiography during Watchman FLX devices
214343450|NCT05496504|OTHER|Holter ECG|
214950075|NCT02145143|DRUG|Vemurafenib|
214950076|NCT02145143|DEVICE|serial 124I PET/CT|
214950077|NCT02145143|DRUG|thyrotropin alpha|
214950078|NCT03307187|BEHAVIORAL|GLB Adapted for Individuals with Impaired Mobility|The 12-month Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility (GLB-AIM) promotes 5% - 7% weight loss by reducing calories and increasing energy expenditure to 150 minutes of weekly activity. The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls. Participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
214950079|NCT02500771|BEHAVIORAL|ABA therapy enhanced with V-Motive software|Tutors will use the V-Motive software to enhance their delivery of Applied Behavioral Analysis therapy.
214950080|NCT02250950|BEHAVIORAL|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
214950081|NCT02250950|BEHAVIORAL|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
215076116|NCT03104972|DEVICE|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
214343451|NCT00299650|DRUG|cisatracurium|
214343452|NCT00299650|DRUG|Placebo|physiological serum infusion
214343453|NCT00299650|DRUG|Cisatracurium besilate|Cisatracurium besilate infusion (900mg/day)
214343454|NCT00989651|BIOLOGICAL|Bevacizumab|Given IV
214343455|NCT00989651|DRUG|Carboplatin|Given IV
214343456|NCT00989651|DRUG|Cisplatin|Given IP
214343457|NCT00989651|OTHER|Laboratory Biomarker Analysis|Correlative studies
214343458|NCT00989651|DRUG|Paclitaxel|Given IV or IP
214343459|NCT00989651|DRUG|Veliparib|Given PO
214343460|NCT03249922|DEVICE|Spinal Cord Stimulation|Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
214343461|NCT03821376|DRUG|Contrast enhanced ultrasound with Lumason|Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
214486514|NCT00945724|DRUG|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate|"Weeks 1-15:~* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days~* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle~* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\&5 of R-CHOP~Weeks 18-22:~• Methotrexate 1.5 g/m2 q14 Days x 2~From Week 24:~• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)"
214950082|NCT04912414|BEHAVIORAL|Brief Family Therapy (BFT)|Patients transferred to the hospital for the treatment of psychosomatic symptoms was randomized (1:1) to receive either Brief Family Therapy (BFT) or a control treatment. Some participants randomized to the BFT arm receive a combination of chemotherapy and BFT and others receive only BFT. BFT comprises 10 sessions using a generic model of problem formation and resolution. This psychotherapy is useful for treating individual, couple, and family problems. Its broad applicability is based on its view that the client's complaint is the problem, not a symptom of something else BFT views behavior, especially a client's problematic behavior, as a function of interaction with other people. After randomization, all participants were asked to complete questionnaires about their psychosomatic symptoms and health at baseline, at the end of the intervention (at 4 months).
214950083|NCT01056913|DEVICE|Compression Anastomosis Device|Restoring intestinal continuity using the NITI CAR27 device
214950084|NCT01056913|OTHER|follow-up colonoscopy|endoscopic exploration of anastomosis after complete healing
214950085|NCT02139774|BEHAVIORAL|Walk with Ease|A six week walking program by the Arthritis Foundation
214950086|NCT03761004|DRUG|carbidopa-levodopa|single dose of WD-1603, BID dose of WD-1603 and Sinemet IR
214950087|NCT05352880|DIAGNOSTIC_TEST|serum magnesium level, FEMg|"Blood (serum) for: Magnesium (Mg).Urea, creatinine. Calcium (ca), phosphorus (ph).Sodium (Na), potassium (k), chloride (CL).Fasting blood glucose, cholesterol, triglycerides. Intact PTH, 25OH vitamin D.uric acid, albumin. CBC.~Trough level of cyclosporine or tacrolimus. ii. Urine for:24 hour urinary: Mg, Ca, Ph, Cl and protein. Spot urine sample to calculate fractional excretion of Mg (FEmg)~. Detailed history taking, Thorough Systemic physical examination."
214950088|NCT02530697|DRUG|Meglumine antimoniate|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
214950089|NCT02530697|DRUG|Miltefosine|Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.
214950090|NCT02530697|DRUG|Pentoxifylline|Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
214950091|NCT00119483|DRUG|Nebido (Testosterone Undecanoate)|
214950092|NCT03700918|DEVICE|DaVingiTR System|DaVingiTR Tricuspid valve annuloplasty repair device
214950093|NCT03894475|DEVICE|AioCare|AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).
214950094|NCT03894475|DEVICE|Spirometer USB CPFS/D (MGC Diagnostics)|Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.
214950095|NCT03900572|BIOLOGICAL|HPV Vaccine|Intramuscular injection, 3 doses
214950096|NCT03900572|DRUG|Placebo|Intramuscular injection, 3 doses
214950097|NCT00463034|GENETIC|microarray analysis|
214950098|NCT00463034|GENETIC|polymerase chain reaction|
214950099|NCT00463034|GENETIC|polymorphism analysis|
214950100|NCT00463034|OTHER|high performance liquid chromatography|
214950101|NCT00463034|OTHER|immunohistochemistry staining method|
214950102|NCT00463034|OTHER|laboratory biomarker analysis|
214950103|NCT00463034|OTHER|questionnaire administration|
214950104|NCT02290925|DRUG|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
214950105|NCT02290925|DIETARY_SUPPLEMENT|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
214950106|NCT01716520|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
214950107|NCT01716520|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
215076117|NCT03104972|DEVICE|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
214950108|NCT01716520|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
214950109|NCT04186897|PROCEDURE|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
214950110|NCT04186897|PROCEDURE|Sham occlusal reduction|The occlusal surface left intact. No actual occlusal reduction.
214950111|NCT00170352|PROCEDURE|Hyperbaric Oxygen Treatment (HBOT)|
214950112|NCT00170352|PROCEDURE|Enhanced Oxygen Treatment (Enhanced FiO2)|
214950113|NCT00702026|DIETARY_SUPPLEMENT|multispecies probiotic (Ecologic 801)|once daily, 5 gram \[10e9 cfu/gram\]
214950114|NCT00702026|DIETARY_SUPPLEMENT|Placebo|once daily, 5 gram \[10e9 cfu/gram\]
214950115|NCT04218617|DEVICE|Diagnostic MRI|Diagnostic MRI
214343462|NCT03153332|OTHER|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
214343463|NCT02391402|BEHAVIORAL|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
214486515|NCT06952673|BEHAVIORAL|Multiple speed increments from 3km/h to 8km/h on a treadmill|Healthy participants will undergo a fixed experimental protocol of multi-stage treadmill speed walking/running wearing microsensors and a respiratory/metabolic testing mask.
214486516|NCT06480994|DIAGNOSTIC_TEST|Routine Assays on fresh plasma|"Routine coagulation tests using STA-R Max analyzer :~Prothrombin Time (PT) activated Partial Thromboplastin Time (aPTT Thrombin Time (TT) Fibrinogen Anti-Xa activity"
214486517|NCT06480994|DIAGNOSTIC_TEST|New Clinical Decision Support on fresh plasma|D-Dimer and fibrin formation assays on STA-R Max analyzer. Calculation of the exclusion score using an algorithm (manual or based on Machine Learning) compared to a Clinical Decision Support cut-off.
214486518|NCT06480994|DIAGNOSTIC_TEST|New Clinical Decision Support on frozen plasma|D-Dimer and fibrin formation assays on STA-R Max analyzer. Calculation of the exclusion score using an algorithm (manual or based on Machine Learning) compared to a Clinical Decision Support cut-off.
214950116|NCT04218617|DEVICE|Planning MRI|Planning MRI: high definition (HD) MRI of the region of interest (1 vertebral level above and below the level(s) being treated)
214950117|NCT04218617|OTHER|Simulation CT|Simulation CT is obtained (1.5 mm slice thickness)
214950118|NCT04218617|OTHER|QOL assessment|QOL assessment
214950119|NCT04218617|OTHER|Brief pain inventory (BPI)|Brief pain inventory (BPI), including narcotic assessment
214950120|NCT04218617|RADIATION|sSRS in 1 fraction|sSRS 18 Gy in 1 fraction
214950121|NCT04218617|RADIATION|sSRS in 2 fraction|sSRS 24 Gy in 2 fractions to be delivered either on consecutive days or one day apart.
214950122|NCT05296447|OTHER|No Intervention|All subjects that previously received RGX-314 in a parent study
214950123|NCT03547232|DRUG|Indomethacin SR|Indomethacin SR 50mg given q12h from admission day 1 to day 7
214950124|NCT03547232|DRUG|Placebos|Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
214950125|NCT06434727|OTHER|observational study|Observational Study
214950126|NCT02283320|DRUG|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
214950127|NCT02066077|DRUG|Etomidate|
214950128|NCT02066077|DRUG|Propofol|
214950129|NCT02066077|DEVICE|Bilateral temporal MECT|
214950130|NCT02066077|DEVICE|The right temporal MECT|
214486519|NCT00994643|BIOLOGICAL|Rituximab|Given IV
214950131|NCT02066077|DEVICE|Bilateral frontal MECT|
214950132|NCT02390713|DEVICE|MID-AVR|"Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.~Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography."
214950133|NCT05394454|PROCEDURE|Bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins.
214950134|NCT05176925|DRUG|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
214950135|NCT05176925|DRUG|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 2 cycles of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
215076118|NCT03104972|DEVICE|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
214950136|NCT05251636|RADIATION|Episcleral Brachytherapy|Minimally invasive, single fraction brachytherapy
214950137|NCT05251636|DRUG|Aflibercept Injection|Standard of Care intravitreal aflibercept injection
214950138|NCT00002478|DRUG|etoposide|
214950139|NCT02061423|BIOLOGICAL|HER-2 pulsed Dendritic Cell Vaccine|Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
214950140|NCT02542592|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
214950141|NCT02542592|DRUG|Isotonic Sodium Chloride|Placebo
215076119|NCT02345772|DRUG|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
214950142|NCT00323076|DRUG|18F-FAZA PET Imaging|"Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient."
214950143|NCT03699540|DRUG|Marijuana|Experimental, non-therapeutic administration of active marijuana dose(s)
214950144|NCT03699540|DRUG|Alcohol|Experimental, non-therapeutic administration of active alcohol dose(s)
214950145|NCT03699540|DRUG|placebo alcohol|Experimental, non-therapeutic administration of inactive alcohol dose(s)
214950146|NCT03699540|DRUG|Inactive marijuana|Experimental, non-therapeutic administration of inactive marijuana dose(s)
214950147|NCT01309750|RADIATION|Small Bowel Transit Study|Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
214950148|NCT06012526|DIAGNOSTIC_TEST|Polysomnography|Polysomnography is done for patients to find any sleep disordered breathing
214486520|NCT00994643|BIOLOGICAL|Interleukin-2|Given SC
214486521|NCT05443555|DRUG|Gabapentin|Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.
214486522|NCT05443555|DRUG|Placebo|Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
214950149|NCT02066727|DRUG|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
214950150|NCT02066727|DRUG|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
214950151|NCT01902511|DRUG|G-CSF+Erythropoetin|
214950152|NCT01902511|DRUG|G-CSF|
214950153|NCT05460078|BEHAVIORAL|Virtual Psychiatric Transition of Care Program|"Behavioral Health facility or units that have discharged patients meeting inclusion criteria will be randomly assigned as either an intervention or standard care site. Intervention sites will be those using the VPTC program. This evaluation design will integrate into current workflows for the measurement of outcomes. Prior to discharge, patients may be referred to the VPTC program if they report residency or shelter in North Carolina, are 18 years of age or older on the day of discharge and can access virtual care (phone/video).~The VPTC program is defined by:~* Psychiatric consultation~* Medication management services with pharmacological consultation~* following of Health Coaching participation and provide treatment recommendations~* Tracking of behavioral health symptoms and provide treatment recommendations~* Health coaching; Psychoeducational support~* Treatment and safety planning~* Assistance connecting with an outpatient care provider"
214950154|NCT01489852|DRUG|17beta-estradiol|Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
214950155|NCT02697591|DRUG|INCAGN01876|Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
214950156|NCT00968357|DRUG|SCV-07|"SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy."
214950157|NCT02032771|DEVICE|M22 IPL and ResurFX|The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
214950158|NCT01917695|DRUG|Chemotherapy|cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
214950159|NCT01917695|RADIATION|External Beam Radiotherapy|50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
214950160|NCT01917695|RADIATION|Brachytherapy|Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
214950161|NCT01917695|PROCEDURE|Radical Hysterectomy|Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
214950162|NCT00460863|PROCEDURE|using cool versus warm dialysate during hemodialysis|
214950163|NCT05478551|DRUG|Botulinum Toxin|We will be comparing botulinum toxin following the biopsies to placebo injection. We will then compare photos of each biopsy site at set intervals following the procedure.
214950164|NCT05478551|DRUG|Normal saline|Normal saline will serve as the placebo control on the contralateral side of the back.
214950165|NCT03877588|DIETARY_SUPPLEMENT|Oral Nutritional Support|Preoperative oral nutritional support is provided according to malnutrition grade
214950166|NCT04848246|DRUG|Bupropion|This group received Bupropion 150 mg twice daily for 10 weeks
214950167|NCT04848246|BEHAVIORAL|Behavioural Change Communication|This group will receive Behavioural Change Communication
214950168|NCT03998371|DIAGNOSTIC_TEST|Low-coverage whole-genome sequencing of urine exfoliated cells|The level of CIN The extracted DNA from morning urine will be analyzed by UCAD to determine the level of CIN.
214950169|NCT03630029|DRUG|FeS and SnPP|Escalating doses of drug will be compared for biomarker changes
214950170|NCT05732077|DRUG|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
214950171|NCT05732077|DIAGNOSTIC_TEST|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
215076120|NCT02345772|DRUG|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
214343464|NCT02391402|BEHAVIORAL|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
214678336|NCT01713036|DRUG|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) \[14C\] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries \[mcgCi\]) of \[14C\] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
214950172|NCT05732077|DEVICE|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
214950173|NCT06080425|BEHAVIORAL|Medical Nutrition Therapy|Counselling
214950174|NCT05387512|DRUG|Camrelizumab|Patients with EGFR-mutation-negative and ALK-negative advanced non-squamous non-small cell lung cancer were treated with first-line chemotherapy in combination with camrelizumab.
214950175|NCT00495859|DIETARY_SUPPLEMENT|Immunonutrition|food for special medical purpose (FSMP)
214950176|NCT00495859|DIETARY_SUPPLEMENT|food for special medical purposes (FSMP)|an isocaloric isonitrogenous non-specific nutritional support
214950177|NCT05061381|BEHAVIORAL|A Lust for Life Schools Programme|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in children. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the childrens' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
214950178|NCT00005796|PROCEDURE|filgrastim|GCSF is given after chemo administration
214950179|NCT00005796|BIOLOGICAL|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
214950180|NCT00005796|DRUG|lomustine|chemotherapy is administered every 21 days
214950181|NCT00005796|DRUG|procarbazine hydrochloride|chemotherapy is administered every 21 days.
214950182|NCT00005796|DRUG|vincristine sulfate|chemotherapy is administered every 21 days
214950183|NCT00005796|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
214950184|NCT04177966|BEHAVIORAL|pre-prepared video describing the cesarean surgery|a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation - from the woman's perspective - from the time they were admitted to the department, preparation for surgery, entrance to the operating r
214950185|NCT04177966|BEHAVIORAL|general information|In the control group - women will receive general information about the surgery as part of informed consent, without watching a pre-prepared film.
214950186|NCT00596063|BIOLOGICAL|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
214950187|NCT00596063|BIOLOGICAL|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
214950188|NCT04102488|PROCEDURE|Six-step hand hygiene technique with an application time of 30 seconds|Six-step hand hygiene technique with an application time of 30 seconds
214950189|NCT04102488|PROCEDURE|Six-step hand hygiene technique with an application time of 15 seconds|Six-step hand hygiene technique with an application time of 15 seconds
214950190|NCT04102488|PROCEDURE|Three-step hand hygiene technique with an application time of 30 seconds|Three-step hand hygiene technique with an application time of 30 seconds
214950191|NCT04102488|PROCEDURE|Three-step hand hygiene technique with an application time of 15 seconds|Three-step hand hygiene technique with an application time of 15 seconds
214950192|NCT03642444|DEVICE|Cane|Assistive walking device
214950193|NCT03642444|DEVICE|Elasticated worn orthotic-garment|Assistive walking device -elasticated worn orthotic garment
214343465|NCT02318329|DRUG|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
214678337|NCT02778867|OTHER|1 Food Elimination Diet Therapy|
214678338|NCT02778867|OTHER|6 Food Elimination Diet Therapy|
214950194|NCT05180890|DRUG|Danavorexton|Danavorexton intravenous infusion.
214950195|NCT05180890|DRUG|Placebo|Placebo intravenous infusion.
214678339|NCT02778867|OTHER|6 Food Elimination Diet (after 1FED failure)|
214950196|NCT00624832|DRUG|Xolair|Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
214950197|NCT00624832|DRUG|Placebo|Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
214950198|NCT00299403|PROCEDURE|Right prefrontal lowfrequency ( 1 hz) rTMS.|"Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2"
214950199|NCT00299403|PROCEDURE|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
214950200|NCT04379700|PROCEDURE|Transcatheter arterial embolization|Transcatheter arterial embolization of one or more genicular artery(ies) using Embozene™ Color-Advanced Microspheres. Embozene™ Color-Advanced Microspheres are spherical, tightly calibrated, biocompatible, non-resorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer used for embolization.
215076121|NCT02345772|DRUG|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
214950201|NCT04379700|DEVICE|Embozene™ Microspheres|Embozene™ Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer (Polyzene™-F). The microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue. They are available in prefilled syringes in a range of sizes suitable for embolic therapy. The microspheres are compressible to enable smooth delivery through the indicated delivery catheter and color-coded by size to allow for easy identification. 250 μm microsphere will be used and are supplied in prefilled yellow syringes.
214343466|NCT02328664|PROCEDURE|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
214950202|NCT05439057|DRUG|Remimazolam|Remimazolam is infused at a rate of 0.3 mg/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
214950203|NCT05439057|DRUG|Control|Normal saline is infused at a rate of 0.3 ml/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
214950204|NCT04920097|OTHER|In-person training for seed placement and APA|In-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points.
214950205|NCT04920097|OTHER|Virtual training for seed placement and APA|Self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement.
214950206|NCT04920097|OTHER|Usual Care|Participants will continue with usual care from oncologist.
214950207|NCT04920097|OTHER|Post-training zoom session for seed placement and APA coaching|Zoom session for seed placement and APA coaching, to occur after initial APA and seed placement training (initial training is either in person or guided by the smartphone app videos).
214950208|NCT06012253|OTHER|Home Based Walking Program|"The intervention group will be applied to Home Based Walking Program. It was aimed that the patients should do at least 150 minutes of moderate-intensity physical exercise per week for up to 8 weeks. The content of the program includes a walking information booklet (information notes, activity chart and obstacle avoidance form), exercise diary, face-to-face-telephone counseling, sending text messages, prepared in line with international guides. It was planned to give weekly counseling to the patients included in the intervention group for an 8-week period."
214950209|NCT05988671|DRUG|normal Saline|Intraperitoneal route
214950210|NCT05988671|DRUG|Dexamethasone|Intraperitoneal route
214950211|NCT05988671|DRUG|Dexmedetomidine|Intraperitoneal route
214950212|NCT05988671|DRUG|Combination of dexamethasone + dexmedetomidine|Intraperitoneal route
214950213|NCT04519645|DRUG|Lacosamide intravenous|Study participants will receive lacosamide (LCM) as an intravenous (iv) infusion during the Treatment Period.
214950214|NCT04519645|DRUG|Lacosamide oral|Study participants may receive lacosamide (LCM) as an oral solution during the Extension Period.
214950215|NCT04519645|OTHER|Active Comparator|Active Comparator treatment will be chosen and dosed based on StOC (per local practice and treatment guidelines).
214950216|NCT05859061|DEVICE|cryoICE® system (AtriCure, Inc) with CryoSphere (CryoS) probe|Per manufacturer instructions, the cryoprobe will be positioned under direct visualization and ablation of the intercostal nerve will be performed 2-4 cm lateral to the internal mammary artery near the mid-clavicular line. The study team plans to perform each cryoablation (-50°C to -70°C) for 120 seconds to sustain an ablation length of 2-3 cm at each intercostal nerve (bilateral T2 - T6). The probe will be removed after defrosting to avoid mechanical damage to the intercostal nerve. Cryoablation will be performed once hemostasis is achieved and prior to sternal wire placement and chest closure by a provider from the cardiac surgery team.
214343467|NCT04283929|OTHER|Experimental: Intervention 1 (Int1)|This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
214343468|NCT04283929|OTHER|Experimental: Intervention 2 (Int2)|The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.
214486523|NCT05038150|DRUG|SGN1|The study drug, SGN1, will be administered as an IV infusion through a dedicated line catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.
214950217|NCT05108987|BEHAVIORAL|Morning Exercise|Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the morning.
214950218|NCT05108987|BEHAVIORAL|Afternoon Exercise|Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the afternoon.
214950219|NCT00991094|OTHER|Quality-of-Life Assessment|Complete questionnaires
214950220|NCT00991094|OTHER|Questionnaire Administration|Complete questionnaires
214950221|NCT06205134|DRUG|A: Epinephrine injection|Autoinjector for intramuscular, single-use, 0.3mg
214950222|NCT06205134|DRUG|B: FMXIN002 3.6mg|Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
214950223|NCT06205134|DRUG|C: FMXIN002 4.0mg|Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
215076122|NCT02345772|DRUG|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
215076123|NCT01828619|PROCEDURE|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
214343469|NCT04283929|OTHER|Experimental: Intervention 3 (Int3)|The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows \> 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
214343470|NCT05006625|OTHER|Collaborative Care Model|Use of the collaborative care model to screen and deliver care for depression in adolescents and young adults aged 15-24 years seeking HIV prevention and treatment services
214343471|NCT00244608|DRUG|Budesonide/Formoterol Turbuhaler|
214343472|NCT00244608|DRUG|Budesonide Turbuhaler (Pulmicort)|
214343473|NCT00244608|DRUG|Terbutaline Turbuhaler|
214343474|NCT02580149|DRUG|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
214950224|NCT06313502|DRUG|75gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
214678340|NCT02778867|DRUG|Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)|
214678341|NCT04492956|DRUG|Ecopipam|Oral tablet
214950225|NCT06313502|DRUG|100gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
214950226|NCT06313502|DRUG|125gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
214950227|NCT00592592|RADIATION|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
214950228|NCT01030471|BEHAVIORAL|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
214950229|NCT01028495|DRUG|RX-0201 plus Gemcitabine|RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
214950230|NCT01583270|DIETARY_SUPPLEMENT|Arabinoxylan|Porridge rich in arabinoxylan
214950231|NCT01583270|DIETARY_SUPPLEMENT|Rye kernel|Porridge made of rye kernels
214950232|NCT01583270|DIETARY_SUPPLEMENT|Arabinoxylan and rye kernels|Porridgde made of rye kernels and arabinoxylan
214950233|NCT01583270|DIETARY_SUPPLEMENT|Semolina|Semoline porridge. control meal.
214950234|NCT00285792|BEHAVIORAL|Physical Activity|
214950235|NCT05032820|DRUG|Lenalidomide and bb2121|Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m\^2 and fludarabine 30mg/m\^2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x10\^6 cells. Maintenance lenalidomide, starting at 5mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.
214950236|NCT06959381|OTHER|Fascial release with instrument assisted soft tissue mobilization|The fascial release group will be treated with the Graston device to the superficial and deep fascia of the hamstrings and the gastro-soleus muscle complex in both extremities for a total of 16 minutes.
214343475|NCT02580149|DRUG|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
214343476|NCT04081207|BEHAVIORAL|AAC for Language Recovery (AAC-LaRc)|iPads will be programmed with a personalized communication application (app) and a structured 4-step intervention will be employed to instruct patients how to cue themselves during anomic events via pictures, text, or speak buttons.
214343477|NCT00151801|DRUG|estroprogestins|
214343478|NCT00151801|DRUG|interferon-beta 1a|
214343479|NCT00179088|BEHAVIORAL|Patient may be able to put weight on the operated leg|
214343480|NCT00746837|DRUG|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
214343481|NCT00746837|DRUG|AZD5672|50 mg od, 12 days
214343482|NCT00746837|DRUG|AZD5672|150mg od, 12 days
214343483|NCT02653521|RADIATION|Dose adaptation|Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
214343484|NCT00086346|DRUG|Sirolimus (Rapamune)|
214343485|NCT00086346|DRUG|Cyclosporine or Tacrolimus|
214678342|NCT04492956|DRUG|Placebo|Oral tablet
214678343|NCT01278680|BEHAVIORAL|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
214950237|NCT06959381|OTHER|Fascial release with foam roller|Fascial release with a foam roller will be applied to the fascia of the hamstring and gastro-soleus muscle complex with a self-foam roller for a total of 16 minutes.
214950238|NCT01366794|OTHER|Macronutrients|Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
214343486|NCT05544994|OTHER|Aerobic Exercise Training|Aerobic training will be performed 3 days a week for 12 weeks at 60%-%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.
214343487|NCT05544994|OTHER|Home exercise program|Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.
214343488|NCT00035438|DRUG|St. John's Wort|
214343489|NCT05197959|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
214343490|NCT05197959|OTHER|Sensorimotor training|Sensorimotor training is a non-invasive, non-painful procedure using nerve stimulation to cue motor action. Nerve stimulation is applied the second through the fifth digit and the median nerve at the wrist. This stimulation is used to cue a motor action. The number of stimulations will indicate the amount of movements. For example, two pulses of stimulations to the index finger would require two flexion and extension actions with the index finger. Once the stimulation occurs, the participant will flex and extend the corresponding area where the nerve stimulation was felt. This will take \~ 30 minutes to complete.
214950239|NCT00894244|DEVICE|Radiofrequency device|One treatment pass on one arm. 2-5 treatment passes on the other
214950240|NCT03836456|BEHAVIORAL|Mindfulness-based Stress Resilience Training|Mindfulness is a form of cognitive training that cultivates self-regulative ability and enhances resilience
214950241|NCT03836456|BEHAVIORAL|Health Enhancement Program|This is a validated active control developed to serve as a control for mindfulness-based studies.
214950242|NCT02325245|DRUG|Metformin|Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
214950243|NCT02325245|DRUG|Placebo|Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
214950244|NCT00429845|BEHAVIORAL|Nutritional|
214950245|NCT04634032|GENETIC|mRNA expression and SNP analysis|mRNA expression and SNP analysis from samples
214950246|NCT04634032|DIAGNOSTIC_TEST|Blood sampling|Peripheral blood sampling for SNP analysis
214950247|NCT02287259|DRUG|olanzapine|
214950248|NCT02287259|DRUG|lithium|
214950249|NCT04764383|DRUG|L-Histidine|1000 mg capsules taken by mouth (PO) twice daily (BID).
214950250|NCT04764383|DRUG|Placebo|Microcrystalline cellulose (placebo) 1000 mg capsules taken by mouth (PO) twice daily (BID).
214950251|NCT04764383|DRUG|Lodosyn|50 mg capsules taken PO BID.
214950252|NCT05290428|DIAGNOSTIC_TEST|DNA methylation testing|All cervical cytology samples will be tested for PAX1 and JAM3 methylation
214950253|NCT01935245|DEVICE|Mini extracorporeal circulation|"Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.~The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products."
214950254|NCT01935245|DEVICE|Conventional extracorporeal circulation|
214950255|NCT03159845|DRUG|Zinc Sulfate Oral Product|
214950256|NCT03159845|DRUG|Levofloxacin 500Mg Oral Tablet|once daily from day +10 until day +30 after stem cell transplantation
214950257|NCT03159845|DRUG|Fluconazole 200mg tab|twice daily from day +10 until day +30 after stem cell transplantation
214950258|NCT03159845|DRUG|Acyclovir 400 MG|twice daily from day +10 until day +30 after stem cell transplantation
214950259|NCT02981563|OTHER|Time Together|For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
214950260|NCT06283680|PROCEDURE|Lung transplantation|Three different groups will be investigated with respect to the effect of NRI, BMI and body fat, muscle ratio on functional capacity, lung capacity, exercise capacity index, all-cause mortality, post-transplant intensive care unit stay and survival time in end-stage lung patients on the lung transplant list.
214950261|NCT03901508|DEVICE|TDCS|20 minutes, 2 electrodes (C3/FP2)
214950262|NCT04953286|OTHER|Measure of visual acuity|ETDRS and Parinaud scale
214950263|NCT04953286|OTHER|Interferometry|Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus
214950264|NCT04953286|OTHER|Samples of basal tears|Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary
214950265|NCT04953286|OTHER|Central corneal sensitivity|Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)
214950266|NCT04953286|OTHER|Slit lamp examination and undilated fundus|Slit lamp examination and undilated fundus
214950267|NCT04953286|OTHER|Conjunctival impression|Conjunctival impression with anesthetic instillation
214343491|NCT04192994|DRUG|Intravitreal Antibiotic Injection|Intravitreal Antibiotic Injection
214343492|NCT04192994|PROCEDURE|Pars Plana Vitrectomy|Pars Plana Vitrectomy
214950268|NCT04953286|OTHER|Evaluation of the corneal innervation|Contact corneal confocal microscopy
214950269|NCT05765448|OTHER|Soy control|Soy isolate control meal
214950270|NCT05765448|OTHER|Intervention (Laver/nori (Porphyra umbillicus) macroalgae whole biomass)|Laver/nori (Porphyra umbillicus) macroalgae whole biomass treatment meal
214950271|NCT05765448|OTHER|Intervention (Laver/nori macroalgae (Porphyra umbillicus) protein isolates)|Laver/nori macroalgae (Porphyra umbillicus) protein isolates treatment meal
214950272|NCT05765448|OTHER|Intervention (Chlorella microalgae (Chlorella vulgaris) whole biomass)|Chlorella microalgae (Chlorella vulgaris) whole biomass treatment meal
214343493|NCT04016168|BIOLOGICAL|Blood sample collection|Three additional blood tubes (3 x 8mL) will be collected for this study. They will be added to the traditional diagnostic assessment carried out for their IPF, during their consultation at the competence centre for rare lung diseases. These samples will be taken by a registered nurse in the presence and under the responsibility of the investigator.
214343494|NCT03905759|DRUG|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
214343495|NCT03905759|DRUG|Amiodarone|Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
214343496|NCT03905759|DRUG|Colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
214343497|NCT03268811|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
214343498|NCT02270580|BEHAVIORAL|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
214343499|NCT02270580|BEHAVIORAL|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
214343500|NCT01210768|DRUG|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
214343501|NCT01210768|DRUG|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
214343502|NCT02995668|OTHER|Strength-Function|Preoperative functional and strength capabilities training.
214343503|NCT02995668|OTHER|Balance-Proprioception|Preoperative proprioceptive and balance capabilities training
214343504|NCT04704245|DRUG|epidermal growth factor (EGF)-containing ointment|The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
214950273|NCT05765448|OTHER|Intervention (Chlorella microalgae (Chlorella vulgaris) protein isolates)|Chlorella microalgae (Chlorella vulgaris) protein isolates treatment meal
215076124|NCT04847895|DRUG|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.
215076125|NCT05270291|PROCEDURE|rectal swab|rectal swab
214343505|NCT04704245|DRUG|Vehicle ointment|To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
214343506|NCT04704245|PROCEDURE|Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening."
214343507|NCT00519805|DRUG|dalteparin|
214343508|NCT00519805|PROCEDURE|quality-of-life assessment|
214950274|NCT01038752|DRUG|Suramin Drug:Docetaxel Drug: Carboplatin|Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
215076126|NCT04664530|DRUG|esketamine|The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
214678344|NCT05868642|PROCEDURE|subarachnoid block|subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
214678345|NCT03245671|DRUG|Kenalog Injectable Product|80 mg of Kenalog will be used.
214343509|NCT01055639|BEHAVIORAL|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
214678346|NCT03245671|DRUG|Decadron Phosphate, Injectable|15 mg of Decadron will be used.
214678347|NCT03245671|PROCEDURE|Epidural Steroid Injection|Patient will receive epidural steroid injections of either Kenalog or Decadron.
214678348|NCT02394444|OTHER|Triadic parent-infant Relationship Therapy (TRT)|22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
215076127|NCT04664530|DRUG|Saline|The titration process in the control group with saline are the same as those in the treatment group with esketamine.
214343510|NCT01055639|BEHAVIORAL|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
214343511|NCT00562159|DRUG|Placebo|Placebo sublingual tablet
214343512|NCT00562159|BIOLOGICAL|SCH 697243|SCH 697243 (2800 Bioequivalent Allergen Units \[BAU\] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
214678349|NCT04141345|DIAGNOSTIC_TEST|cardiopulmonary exercise test|Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
215076128|NCT04126720|DIETARY_SUPPLEMENT|topical corticosteroids and vitamin E suplements|
214343513|NCT00562159|DRUG|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
214343514|NCT00562159|DRUG|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
214950275|NCT01038752|DRUG|Placebo Drug: Docetaxel Drug: Carboplatin|Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
214950276|NCT00653978|PROCEDURE|ERCP plus one biliary stent|ERCP ＋ one biliary stent insertion
214343515|NCT00562159|DRUG|Mometasone 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
214343516|NCT00562159|DRUG|Prednisone 5 mg Rescue Treatment|"Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day~(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray."
214950277|NCT00653978|PROCEDURE|ERCP plus two biliary stents|ERCP ＋ two biliary stents insertion
214343517|NCT00562159|DRUG|Albuterol sulfate 108 mcg|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
214343518|NCT00562159|DRUG|Fluticasone propionate 44 mcg|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
214950278|NCT00819949|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
214950279|NCT02109406|DRUG|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
214950280|NCT02109406|DRUG|AZD 2115, Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
214950281|NCT02109406|DRUG|Placebo MDI|Placebo MDI administered as two inhalations BID
215076129|NCT04126720|DRUG|Topical corticosteroid and placebo capsules|
215076130|NCT01457677|DRUG|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
215076131|NCT01457677|DRUG|RO4995819|5 mg oral once daily for 6 weeks
215076132|NCT01457677|DRUG|RO4995819|15 mg oral once daily for 6 weeks
215076133|NCT01457677|DRUG|RO4995819|30 mg oral once daily for 6 weeks
215076134|NCT04909892|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
214343519|NCT00562159|DRUG|Prednisone 5 mg|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
214343520|NCT00918294|DEVICE|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
214343521|NCT01391377|DRUG|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
214343522|NCT01391377|DRUG|Sugar pill|Placebo
214486524|NCT05994508|OTHER|Pickleball program|The intervention will be a 6-week pickleball program, at a frequency of two times a week. Each session will be one hour which will consist of dynamic warm-up drills, pickleball-related skill practice and game play, and a cool-down period.
214486525|NCT06048978|OTHER|Commercial native starch without processing|A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.
214486526|NCT06048978|OTHER|Modified starch with extrusion processing|A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.
214950282|NCT04780243|OTHER|counseling|Mothers presented to infant immunization units are going to be counseled for family planning services and if decide to take any method, they will be linked to family planning services
215076135|NCT04536948|OTHER|Cooling Gel|Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
215076136|NCT04536948|OTHER|Cold Pack|Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
215076137|NCT06463353|OTHER|trilinolein cream group|Apply trilinolein cream evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
215076138|NCT06463353|OTHER|cream base group|Apply cream base evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
215076139|NCT01440517|DRUG|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
215076140|NCT03753100|OTHER|Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint|The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
214950283|NCT06281158|DRUG|[14C]-DNL343|Single dose
215076141|NCT03065842|BEHAVIORAL|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
214950284|NCT02703896|DRUG|Drug either PPIS or H2RA and prokinetics|"Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)"
214950285|NCT02703896|PROCEDURE|orogastric intubation|OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
214950286|NCT00530790|DRUG|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
214950287|NCT02499510|DEVICE|GoldenFlow Stent|The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
214950288|NCT00423358|DIETARY_SUPPLEMENT|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
215076142|NCT03065842|BEHAVIORAL|Usual Standards|Usual standards according to the school curriculum in Kenya.
215076143|NCT04141189|PROCEDURE|weekly|fetal surveillance frequency
215076144|NCT04141189|PROCEDURE|bi-weekly|fetal surveillance frequency
215076145|NCT05920473|DEVICE|rTMS with Magstim Rapid 2 magnetic stimulation device|The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.
215076146|NCT05920473|DEVICE|sham control with Magstim Rapid 2 magnetic stimulation device|In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
215076147|NCT04701580|DIAGNOSTIC_TEST|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
215076148|NCT04701580|DIAGNOSTIC_TEST|18F-FDG PET-MR|Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
215076149|NCT00733057|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
215076150|NCT00733057|DRUG|Placebo (200 mg/day)|
215076151|NCT05686096|DRUG|MYK-224|Specified dose on specified days
215076152|NCT03889210|OTHER|HVMN Ketone|Water-based, flavoured sport beverage
215076153|NCT03889210|OTHER|Placebo|Water, stevia, malic acid, and thickening agent
214678350|NCT02884791|DIETARY_SUPPLEMENT|oral carbohydrate challenge|Participants will fast for 8 hours and then drink a beverage containing fructose.
214678351|NCT00426985|DRUG|Ketoprofen Topical Patch 20%|
215076154|NCT06386341|PROCEDURE|Maxillomandibular Advancement Surgery|Surgery where the upper and lower jaw are repositioned.
215076155|NCT02714361|DIETARY_SUPPLEMENT|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
215076156|NCT02714361|OTHER|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
215076157|NCT03535285|PROCEDURE|Periodontal ligament distraction|decrease the bony resistant during canine retration
215076158|NCT02263911|DRUG|Baricitinib|Administered orally
215076159|NCT02723006|DRUG|TAK-580|TAK-580 tablets
215076160|NCT02723006|DRUG|TAK-202|TAK-202 infusion
214678352|NCT06041529|DRUG|Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
214950289|NCT00423358|DIETARY_SUPPLEMENT|placebo|matching placebo
214950290|NCT05874063|DRUG|Thromboprophylaxis|Thromboprophylaxis in addition of the standard chemotherapy
214950291|NCT00901979|DRUG|LCQ908A|
214950292|NCT00901979|DRUG|LCQ908A|
214950293|NCT00901979|DRUG|LCQ908A|
214950294|NCT00901979|DRUG|LCQ908A|
214950295|NCT00901979|DRUG|LCQ908A|
214678353|NCT06041529|DRUG|Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
214950296|NCT00901979|DRUG|Placebo|
214343523|NCT04824846|BEHAVIORAL|Integrated back pain module (IBPM)|All Ambulance drivers will be screening with the Proforma to determine their low back pain symptoms. Those workers who are diagnosed with mechanical back pain during the 12 months fulfill a self-report quality of life questionnaire (SF-36). Then Integrated back pain module (IBPM) will be delivered to them after the introduction course conducted for 1 day and then the intervention will last for 6 months. Research staff will explain how to operate and use the module. Subjects must comply with all the care and prevention guidelines of the research module so that it achieves the expected results. They also need to complete the checklist provided in the Edmodo software via their respective smartphones.
214343524|NCT04824846|OTHER|Health Educational Pamphlet.|In Health Educational Pamphlet (HEP) sessions, Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
214343525|NCT04703881|DIETARY_SUPPLEMENT|AYMES ActaGain|AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.
214343526|NCT03161834|OTHER|Observational|
214343527|NCT04602520|BEHAVIORAL|3 Wishes Project|Behavioral: Focused conversations at end-of-life to promote the connections between patients, family members, and clinicians.
214343528|NCT02417246|DRUG|brand name metoprolol ER|This medication will be taken for 7 to 28 days
214343529|NCT02417246|DRUG|Generic A|This medication will be taken for 7 days
214343530|NCT02417246|DRUG|Generic B|This medication will be taken for 7 days
214343531|NCT00291382|DRUG|Salmeterol/fluticasone propionate combination|
214950297|NCT00901979|DRUG|Sitagliptin|
214950298|NCT00901979|DRUG|metformin|
214950299|NCT02779660|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
214950300|NCT02779660|PROCEDURE|sham-intervention|In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
214950301|NCT05277350|DRUG|SNIPR001|SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli
214950302|NCT05277350|DRUG|Placebo|Matching placebo
214950303|NCT03007134|OTHER|Retrospective Chart Review|No intervention.
214950304|NCT04851418|DEVICE|Possible NSTE-ACS|As mentioned in the group description
214950305|NCT00528632|OTHER|Specimen biopsy and serum laboratory tests|"Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides"
214950306|NCT06628388|BEHAVIORAL|Nurse-Led Risk-Based 5As Primary Healthcare Model|The intervention is developed based on the 5As model (ask, advice, assess, assist, arrange). In this model, nurse will play the central role in delivering the service as a case manager. In Ask, all participants will be assessed on the demographics, health related status, and health risk stratification (i.e. 3-tier risk stratification). In Advice, all participants will be given the education booklet. Those assessed to be at low risks will receive general advice, while those at medium risk will receive condition-specific advice instead. High risk participants will be provided with referral suggestions. The assessment of medium or high risk participants willingness and any barriers in seeking changes will be conducted in Assess. In Assist, active referrals will be provided to high risk participants, with weekly advice messages provided to medium and high risk participants. In Arrange, all participants will receive their follow-ups.
214950307|NCT06628388|BEHAVIORAL|Minimal Intervention|Consisting general advice on women health with the education booklet. No risk-based services nor active referral will be offered during the waitlist control exposure. Participants will be switched to receive intervention from 6-month.
214950308|NCT02005627|DRUG|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
214950309|NCT02005627|DRUG|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
214950310|NCT04224220|OTHER|Adult Medical Care Coordination|Nurse-based support that includes a home visit and follow-up coaching telephone calls to monitor patient status and ability to self-manage symptoms.
214950311|NCT04224220|OTHER|Remote Patient Monitoring|Nurse-based support and coaching that incorporates the use of technology to monitor patient status and ability to self-manage symptoms.
214950312|NCT04000360|OTHER|High-Intensity Aerobic Exercise (AE)|The home-based exercise group will have a Peloton indoor cycle, heart rate monitor strap, and Garmin activity monitor to track daily activity levels delivered to the home. Participants will be asked to cycle 3x/week for 12 months on this bike with heart rate monitor at aerobic intensity 60-80% of heart rate reserve and target cadence 80-90 revolutions per minute. Study team members will telephone all participants biweekly for similar contact times between treatment groups. During these calls, a study team member reviews fall diary information, inquires about possible adverse events, and reviews participants' activity monitor wear times on the Garmin Connect website (https://connect.garmin.com). For those in the AE group, exercise recommendations, e.g., increase duration, cadence or heart rate, are given based on review of exercise session data on the Peloton portal (onepeloton.com). Compliance barriers or technical challenges with the activity monitor or exercise cycle are addressed.
214950313|NCT04000360|OTHER|Usual and Customary Care (UCC)|Participants in this group will continue to receive their usual care. They will also receive activity monitors to monitor their daily activity levels, and telephone monitoring throughout the study. Study team members telephone all participants every 2 weeks for similar amounts of contact time between treatment groups. During the calls, a study team member of the reviews fall diary information, inquires about possible adverse events, and reviews participants' activity monitor wear times via the Garmin Connect website (https://connect.garmin.com).
214950314|NCT03865394|BIOLOGICAL|Application of allogeneic ADSC stem cells in fibrin gel|Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control.
215076161|NCT02723006|DRUG|vedolizumab|vedolizumab infusion
215076162|NCT02723006|DRUG|nivolumab|nivolumab infusion
215076163|NCT02723006|DRUG|ipilimumab|ipilimumab infusion
215076164|NCT00227318|DRUG|ATACAND|
214343532|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
214343533|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
214343534|NCT05827224|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
214343535|NCT05827224|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
214343536|NCT05827224|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
214343537|NCT00001101|DRUG|ceftriaxone|
214343538|NCT00001101|DRUG|doxycycline|
214343539|NCT04729803|BEHAVIORAL|Experimental: Attention Guidance + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention guidance condition: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given target audience members to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target audience member for the whole response."
214343540|NCT04729803|BEHAVIORAL|Active Comparator: Exposure Alone|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial."
214343541|NCT04729803|BEHAVIORAL|Experimental: Attention Control + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~   F~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention control condition: (1) the intervention rationale will include information about the importance of attention control; (2) participants will be given target at the center of the screen to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target for the whole response."
214343542|NCT04050592|DRUG|Estradiol|Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
214343543|NCT04050592|OTHER|Placebo|Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.
214343544|NCT06534281|PROCEDURE|BAO-G|Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
214343545|NCT00975234|PROCEDURE|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
214343546|NCT00975234|PROCEDURE|Revascularisation|Revascularisation surgery
214343547|NCT05881668|BIOLOGICAL|MSC-EV|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
214950315|NCT03865394|PROCEDURE|Standard care in diabetic foot ulcer|Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.
214950316|NCT02587754|DEVICE|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
214950317|NCT01693185|DRUG|Remifentanil|continuous infusion 0.4 mcg/kg/min
214950318|NCT01693185|DRUG|Midazolam|bolus injection
214950319|NCT01693185|DRUG|Meperidine|bolus injection for 30 sec 1.0 mg/kg
214950320|NCT01693185|DRUG|placebo (for remifentanil)|normal saline mimic diluted remifentanil
214950321|NCT01693185|DRUG|placebo (for midazolam)|normal saline mimic to midazolam injection
214950322|NCT01693185|DRUG|placebo (for meperidine)|normal saline mimic meperidine injection
214950323|NCT05061901|DRUG|Lisinopril tablet 20 mg|Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.
214950324|NCT05061901|DRUG|Zestril® tablet 20 mg|Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.
214950325|NCT04331093|DRUG|SHR-1210+Apatinib|"Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg~Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression"
214950326|NCT01084538|DRUG|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
214950327|NCT05848596|OTHER|hand hygiene theoretical training|"Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,"
214950328|NCT05848596|OTHER|hand hygiene theoretical + simulation training|"Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,~Hand hygiene simulation training will be carried out by the researcher in an environment with a sink.~* Simulation-based training on standard patients,~* Hand hygiene application and important points to be considered during the application will be emphasized."
214343548|NCT03391648|OTHER|Observation|Observation only
214486527|NCT06953648|BEHAVIORAL|High Intensity Interval Training|The intervention will consist of three 30-minute training sessions/week, each starting with a five-minute warm-up, followed by 20 minutes of interval training, and ending with a five-minute cool-down. The interval training will consist of 10 alternating high- and low-intensity intervals, with a 1:1 work-to-rest ratio (one minute of high intensity followed by one minute of low-moderate intensity). As participants' fitness improves, the interval intensity will increase accordingly.
214343549|NCT05184413|OTHER|Multimodal treatment|A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
214486528|NCT06104670|DIETARY_SUPPLEMENT|Synaquell(TM)|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
214950329|NCT05982808|PROCEDURE|CLIF correction|CLIF correction was a novel surgical techqiue of correction of spinal deformtiy with minimal invasive approach
214950330|NCT05982808|PROCEDURE|conventional correction strategy|conventional correction was the classic surgical techqiue of correction of spinal deformtiy with open posterior approach
214950331|NCT02279745|DRUG|Ralinepag|Active
214950332|NCT04893356|GENETIC|O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine treated sarcoma patients|"Tumor samples of Leiomyosarcoma and Solitary Fibrous Tumours patients, dacarbazine (as single agents or in combination with anthracyclines) treated, will be obtained from and characterized by the Pathology Unit of the Istituto Nazionale Tumori Fondazione Pascale in Naples, Campus Biomedico of Rome, Istituto Oncologico of Bari and University of Palermo.~Glioblastomas control samples will be obtained from CEINGE-Biotecnologie Avanzate, in Naples and characterized by the Pathology Unit of the University of Naples Federico II.~After biopsy or surgical resection, the tissues were fixed in 10% formalin and included in paraffin blocks. All patients partecipating in this study provided informed consent."
214950333|NCT06314451|OTHER|Cognitive Interview|"The study involves a single cognitive interview with a researcher, either online, by telephone, or face-to-face. People who want to take part will be given information about the study and asked to give written consent. Then they will be asked to talk about the wording of the questionnaire and how relevant it is to them.~Cognitive interviewing is recognized as a significant part of developing questionnaires for patient reported outcome measures (PROMs). The cognitive interviewing process used in PROM development will be adapted in this study to test the Steroid PRO in new disease populations. Cognitive interviewing will be carried out using pragmatic, light-touch interviews, underpinned by think aloud techniques and clean language principles."
214950334|NCT00003045|DEVICE|Hyperthermia|Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session
214950335|NCT00003045|RADIATION|XRT|external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
214950336|NCT01708720|DRUG|IPV|
214950337|NCT01708720|DRUG|Sabin-IPV|
214950338|NCT01708720|DRUG|Adjuvanted Sabin-IPV|
214950339|NCT06436391|OTHER|Kinesio taping|Kinesio taping will be applied to the lateral part of the baby's heel to increase blood flow. Blood collection will always be performed by the same nurse
215076165|NCT02845947|BEHAVIORAL|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
215076166|NCT05945771|DIETARY_SUPPLEMENT|Grape seed extract|Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.
215076167|NCT02958202|DRUG|BMN 044 IV 6 mg/kg|
214950340|NCT06436391|OTHER|ShotBlocker|Shotblocker will be applied to the baby's heel average 10-15 seconds with minimal pressure.
215076168|NCT02958202|DRUG|BMN 044 IV 9 mg/kg|
214950341|NCT01108419|OTHER|Fermented dairy product|
214950342|NCT01108419|OTHER|milk-based non-fermented dairy product|
214950343|NCT00987597|BEHAVIORAL|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
214950344|NCT00987597|BEHAVIORAL|conventional follow-up|nicotinic substitutes
214950345|NCT06075550|OTHER|single cone technique using TotalFill BC Sealer|Gutta percha cone size X5 (Dentsply, Maillefer) TotalFill BC Sealer (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
214950346|NCT06075550|OTHER|warm vertical compaction technique using TotalFill BC Sealer HiFlow|TotalFill BC Sealer HiFlow (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
214950347|NCT01300208|DRUG|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
214950348|NCT01300208|OTHER|Placebo|
214950349|NCT00595101|DRUG|PF-03187207|
214950350|NCT00595101|DRUG|Latanoprost 0.005%|
214950351|NCT00595101|DRUG|PF-03187207 Vehicle|One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
214950352|NCT00595101|DRUG|Latanoprost Vehicle|
214950353|NCT03387501|DRUG|Plasma rich in growth factors (PRGF-Endoret)|Intrauterine administration of PRGF
214950354|NCT00890240|DRUG|JNJ-31001074|
214950355|NCT04764084|DRUG|Niraparib|Niraparib 100mg or 200mg, PO, qd，d1-d21
215076169|NCT02958202|DRUG|BMN 044 SC 6 mg/kg|
215076170|NCT05492799|DRUG|AX 250|biweekly infusion by intracerebroventricular (ICV) infusion
215076171|NCT03698045|DRUG|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
214486529|NCT06104670|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
214950356|NCT04764084|DRUG|Anlotinib|Anlotinib 12mg, PO, qd，d1-d14
214950357|NCT01993641|DRUG|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
214950358|NCT01993641|DRUG|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
214950359|NCT01993641|DRUG|Decitabine|"All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks."
214950360|NCT00272870|DRUG|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
214950361|NCT00272870|GENETIC|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
214950362|NCT00272870|DEVICE|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
214950363|NCT01549262|DEVICE|"Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)"|Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
214950364|NCT01549262|DEVICE|Observe embryo development|Observe embryo development in the traditional manner
214950365|NCT05207722|BIOLOGICAL|CYNK-101|CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to express a variant of CD16, Fc gamma receptor III (FcγRIII).
214950366|NCT05207722|DRUG|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
214950367|NCT05207722|DRUG|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
214950368|NCT05207722|DRUG|Recombinant Human Interleukin-2|6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.
214950369|NCT05207722|DRUG|Cyclophosphamide|Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
214950370|NCT05207722|DRUG|Fludarabine|Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
214950371|NCT05207722|DRUG|Mesna|MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.
214950372|NCT04447495|DIAGNOSTIC_TEST|iAMP test|The low-cost Atila BioSystems iAMP® COVID-19 Detection kit consists of a reaction buffer mix, primer mix, three sample buffer components, a positive and negative control, nasopharyngeal swabs, and sample collection vials. Each kit is suitable for 100 tests.
214950373|NCT00842400|DRUG|Metformin, VI-0521, Sitagliptan, Probenecid|"This trial is an open-label, non-randomized, one-sequence crossover study.~* metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34~* sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39~* VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)~* 2 g (four 500 mg) probenecid tablets on Day 29."
214950374|NCT05724459|OTHER|Peer education|Training on stem cell transplantation for a total of 12 hours, two days a week for three weeks, two lesson hours a day (60 min. + 60 min.)
214950375|NCT00389051|DRUG|bendamustine hydrochloride|1 cycle; 120 mg/m2/day,2 days concecutively, followed by 19days of oveservation period. (3 to 6 cycles)
214950376|NCT01606748|BIOLOGICAL|Necitumumab|"PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product"
214950377|NCT01606748|DRUG|Gemcitabine|"PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2"
214950378|NCT01606748|DRUG|Cisplatin|"PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2"
215076172|NCT03310008|BIOLOGICAL|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
215076173|NCT02100163|BEHAVIORAL|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
214486530|NCT06952933|BEHAVIORAL|Other|Surveys will be distributed for data collection. A subset of patients will participate in diagnostic clinician interviews. No interventions will be tested.
214950379|NCT02590757|DEVICE|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
214950380|NCT02590757|DEVICE|N-CPAP|Nasal-continuous positive airway pressure
214950381|NCT03150394|DIETARY_SUPPLEMENT|GASTRUS|Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment
214950382|NCT03150394|OTHER|PLACEBO|Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment
215076174|NCT02100163|BEHAVIORAL|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
215076175|NCT02100163|OTHER|Standard treatment|
215076176|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
214950383|NCT02603926|DRUG|Allopregnanolone|Allopregnanolone is an endogenous inhibitory pregnane neurosteroid. It is synthesized from progesterone, and is a potent positive allosteric modulator of the action of γ-aminobutyric acid at GABAA receptor. Subjects will receive up to 12 infusions in the study. Subjects will all begin with 2.0 mg dosage. If tolerated, the next infusion will be 4.0 mg, and if that is tolerated, the next infusion will be 6.0 mg. Subject infusions will remain stable at the highest dosage tolerated for the remainder of the study. Each infusion will consist of 2.0 mg, 4.0 mg, or 6.0 mg aliquots of the 0.5 mg/ml allopregnanolone in 6% sulfobutylether-β-cyclodextrin with 0.9% sodium chloride injection solution.
214950384|NCT03066219|DRUG|BRM421|A topical solution of BRIM421 ophthalmic drops
214950385|NCT03066219|DRUG|Placebo|vehicle ophthalmic drops
214950386|NCT04936113|BIOLOGICAL|FB-401|Topical
214950387|NCT02557373|DIETARY_SUPPLEMENT|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
214950388|NCT02557373|DIETARY_SUPPLEMENT|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
214950389|NCT05896800|OTHER|Inhaled nitric oxide (NO)|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
214950390|NCT05896800|OTHER|air|use air（21%O2）as the placebo of inhaled treatment
214950391|NCT00095589|GENETIC|loss of heterozygosity analysis|
214950392|NCT00095589|GENETIC|microarray analysis|
214950393|NCT00095589|GENETIC|microsatellite instability analysis|
214950394|NCT00095589|OTHER|cytology specimen collection procedure|
214950395|NCT00095589|OTHER|laboratory biomarker analysis|
214950396|NCT00095589|PROCEDURE|computed tomography|
214950397|NCT00095589|PROCEDURE|cystoscopy|
214950398|NCT06602167|COMBINATION_PRODUCT|True electroacupuncture + True self-administered acupressure|"True electroacupuncture: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2Hz for 30 minutes. True self-administered acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi for three minutes."
214950399|NCT06602167|DRUG|Doctor-prescribed treatment|Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants.
214950400|NCT06602167|COMBINATION_PRODUCT|Sham electroacupuncture + Sham self-administered acupressure|"Sham electroacupuncture: The sham electroacupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi sensation. Sham self-administered acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
214950401|NCT04761159|DRUG|Ketamine|Different mixture of ketamin-propofol will apply for anesthesia induction.
214950402|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar medial branch nerve radiofrequency denervation.|"While in prone position, lumbar facet joints are identified by fluoroscopy. 18 gauge needles are then advanced aiming to the medial branch of lumbar facet joints. Correct positioning is confirmed by anteroposterior and lateral fluoroscopy. Then, the needles are attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz (hertz), 1ms, 0,6V (volts). In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms (millisecond) and twice the voltage that produced sensitive response. After correct positioning and repositioning the needles if needed, conventional radiofrequency ablation of medial branch nerves is performed using the following settings: 90 seconds, 80º Celsius degrees.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation."
214950403|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar medial branch nerve injection.|"While in prone position, lumbar facet joints are identified by fluoroscopy. An anteroposterior image of the lumbar vertebrae is obtained. Then, the fluoroscope is tilted between 10 to 20 degrees to the side to inject. 22 gauge needles are then advanced aiming to the medial branch of lumbar facet joints.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation. Correct positioning is confirmed with anteroposterior and lateral fluoroscopy. A mixture of 3 ml of ropivacaine 0,2% + 1 ml (40 mg) of triamcinolone (trigon depot) is prepared. 1 ml of the mixture is injected in each lumbar facet joint through the needles. Four facet joints are selected for therapy. Some patients receive bilateral and other unilateral but contiguous medial branch nerve injection."
215076177|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
215076178|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
215076179|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
215076180|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
215076181|NCT00979368|DRUG|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
215076182|NCT05093543|BEHAVIORAL|physical rehabilitation/physiotherapy and psychosocial group sessions|physical rehabilitation/physiotherapy and psychosocial group sessions
215076183|NCT06516263|PROCEDURE|Leukocyte and platelet rich fibrin|Formation of an Leukocyte and platelet rich fibrin clot and placement into the osteotomy site prior to implant placement
215076184|NCT06516263|PROCEDURE|Standard implant placement|Standard implant placement without Leukocyte and platelet rich fibrin
215076185|NCT00393341|PROCEDURE|Blood Draw|Blood sample will be drawn from a vein in the arm.
214950404|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the interlaminar approach using a loss of resistance technique for the identification of the lumbar epidural space. When loss of resistance is encountered, 1 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 4 ml of ropivacaine 0,1%, 2 ml (12 mg) of betamethasone and 2 ml of saline serum is injected in the epidural space. The lumbar level to which it infiltrates depends on each patient.
214950405|NCT04451252|PROCEDURE|Fluoroscopically guided caudal epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the sacral hiatus using a loss of resistance technique for the identification of the epidural space. When loss of resistance is encountered, 2 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 7 ml of ropivacaine 0,2%, 2 ml (12 mg) of betamethasone and 7 ml of saline serum is injected in the epidural space.
214950406|NCT04451252|PROCEDURE|Fluoroscopically guided pulsed radiofrequency of the lumbar dorsal root ganglion.|With the patient in prone position and guided by fluoroscopy, a 18 gauge needle is advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root. Then, the needle is attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz, 1ms, 0,6V. In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms and twice the voltage that produced sensitive response. After correct positioning is confirmed, pulsed radiofrequency ablation of lumbar dorsal root ganglion is performed using the following settings: 4 minutes, 42ºC (degrees Celsius).
214950407|NCT04451252|PROCEDURE|Fluoroscopically guided transforaminal epidural corticosteroid injection or lumbar selective root block.|With the patient in prone position and guided by fluoroscopy, a 22 french needle is then advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt along the course of the lumbar root when the needle touches the nerve. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root.
214950408|NCT03742856|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
214950409|NCT03906851|BEHAVIORAL|Activity and diet|Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
214950410|NCT03409445|OTHER|no intervention|no intervention (observational study)
214343550|NCT05184413|OTHER|Unimodal treatment|An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
214343551|NCT04376541|DRUG|Fentanyl|amount of fentanyl used in both groups
214343552|NCT03317704|BEHAVIORAL|Speed endurance training|Speed endurance training
214343553|NCT04346758|PROCEDURE|lumbar plexus block|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
214343554|NCT05883306|DRUG|[14C]LXI-15028|\[14C\]LXI-15028
214343555|NCT04155931|OTHER|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
214343556|NCT05219240|OTHER|20Lighter Program|Visceral Adiposity-Focused Anti-Obesity Telehealth Program
214343557|NCT01233817|OTHER|Progressive strength training|the systematic increase in resistance weights
214343558|NCT05224791|PROCEDURE|Roux-en-Y Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
214486531|NCT06670404|DEVICE|Vertebroplasty|Vertebral compression fractures treated with CONFIDENCE High Viscosity Cement
214486532|NCT04224246|DRUG|Gamma Hydroxybutyrate|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
215076186|NCT04810936|DIETARY_SUPPLEMENT|oral nutritional supplements|Oral nutritional supplements is usually administrated to improve nutritional status in cancer patients.
215076187|NCT06519383|PROCEDURE|guided implant surgery|Surgical guide is fabricated and fitted onto the patient's arch and implant is placed with guide in place.
215076188|NCT05792592|DIAGNOSTIC_TEST|IOS (Impulse Oscillometry)|Small Airways Disease Assessment
215076189|NCT00750529|DRUG|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
215076190|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
214486533|NCT06281795|DEVICE|tVNS|tVNS will be performed daily after workouts for 60 minutes over a period of 8 weeks.
214486534|NCT06390059|DEVICE|Tumor Treating Fields|"The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the patient by means of insulated transducer arrays. The NovoTTF-200T produces TTFields that exert electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz application will be continuous for at least 18 hours a day on average. TTFields will be continued until disease progression according to RECISTv1.1 or loss of clinical benefit."
214950411|NCT04371211|BEHAVIORAL|Telemedicine Brain Injury Coping Skills|"BICS is a 12 session (one session per week), manualized, cognitive-behavioral treatment group designed to provide support, coping skills, and psychoeducation aimed to improve perceived self-efficacy (PSE) and emotional functioning. PSE has been found to be strongly linked to social participation, increased positive regard toward the caregiving role, and was found to be the greatest contributing factor to predicting life satisfaction.~For this study, the Brain Injury Coping Skills (BICS) group intervention will be administered electronically in a web-based group telemedicine platform, BICS-T. The purpose of this phase is to test the feasibility, participant training protocol, and ease of use of equipment and technology."
214950412|NCT00858715|DRUG|aspirin|100 mg aspirin
214950413|NCT00858715|DRUG|clopidogrel|75 mg (Arm 1) and 150 mg (Arm 2)
214950414|NCT05631782|DRUG|Shenkang decoction|Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
214950415|NCT03796715|DIAGNOSTIC_TEST|Red Cell Distribution Width (RDW)|A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.
214950416|NCT03796715|DIAGNOSTIC_TEST|Presepsin (sCD14-ST)|: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
214950417|NCT01663194|PROCEDURE|primary percutaneous coronary intervention, each groups|All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
214950418|NCT00940641|DRUG|AZD7325|IV Dose
214950419|NCT00940641|DRUG|AZD7325|oral dose
214343559|NCT05224791|PROCEDURE|Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption"
214950420|NCT03230136|OTHER|multimodal cardioprotection strategy|Multimodal cardioprotection therapeutic strategy will include (1) remote ischemic preconditioning, (2) volatile anesthetic sevoflurane-induced preconditioning, (3) blood glucose control every 30 minutes during cardiac surgery, (4) temporary respiratory acidosis prior to the aortic cross-unclamping and (5) gradual restoration of blood flow after aortic cross-unclamping (gentle reperfusion).
214950421|NCT03230136|OTHER|standard anesthetic procedure|standard anesthetic procedure will include: anesthesia under propofol throughout the cardiac surgery, blood glucose control every 60 minutes, arterial pH maintained at 7.40, theoric blood flow restored at the earliest after aortic cross-unclamping.
214343560|NCT02999555|PROCEDURE|Ovum pickup|Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
214343561|NCT00370162|DRUG|lactoserum|
214343562|NCT00005776|DRUG|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
214950422|NCT03289299|DRUG|Carfilzomib|56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.
214950423|NCT03289299|DRUG|Lenalidomide|"25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase."
214950424|NCT03289299|DRUG|Daratumumab|16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.
214678354|NCT04280601|DIETARY_SUPPLEMENT|vitamin D|Patients with insufficient and/or deficient vitamin D status (\<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months
214343563|NCT00005776|DRUG|Placebo|100% Oxygen
214486535|NCT06390059|DRUG|Atezolizumab|"Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution.~Atezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit."
214950425|NCT03289299|DRUG|Dexamethasone|40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
214950426|NCT02468713|DRUG|Combiflex® lipid peri|total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
214950427|NCT02468713|DRUG|Winuf® peri|total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
214950428|NCT03084315|DEVICE|E-Cig Zero Nicotine|E-Cig Zero Nicotine
214950429|NCT03084315|DEVICE|E-Cig 24mg Nicotine|E-Cig 24mg Nicotine
214950430|NCT02260349|DRUG|indocyanine green infusion|intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
214950431|NCT02536274|DEVICE|Lumbo Sensa® bandage|Patients have to wear it over 21-28 days for at least 8 hours a day
214950432|NCT02536274|DEVICE|Dynaflex® flexion orthosis|Patients have to wear it over 21-28 days for at least 8 hours a day
214486536|NCT06390059|DRUG|Gemcitabine|"Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion.~Gemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit."
214678355|NCT03357276|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
214343564|NCT01858662|PROCEDURE|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
214486537|NCT06390059|DRUG|nab-paclitaxel|"Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion.~Nab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit."
214950433|NCT00110799|DRUG|SB497115|Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
214950434|NCT00110799|OTHER|Placebo|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
214950435|NCT04286334|DEVICE|Bone augmentation with cad-cam laser-sintered mesh|Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.
214950436|NCT04475770|OTHER|Real Sustained Natural Apophyseal Glides (SNAGS)|"Manual therapists use treatment modalities that include passive techniques such as mobilization and manipulation. Mobilization with movement (MWM) developed by Mulligan involves applying a sustained transverse glide to the spinous process of a vertebra while actively or passively performing. These techniques have gained the name Sustained Natural Apophyseal Glides (SNAGS) as it is maintained at the pain-free range and follows the plane of the apophyseal joints under treatment."
214950437|NCT04475770|OTHER|Sham Sustained Natural Apophyseal Glides (SNAGS)|The participants in the Sham SNAGs group will be positioned same as the SNAG group. Mulligan belt will be used, which included the patient's waist and physiotherapist's hip. The physiotherapist will place the hypothenar region of his hand on the spinous processes of the symptomatic lumbar spine levels and waited a few seconds without no glide will be performed. Sham SNAGs practice consisted of 3 sets of 6 repetitions and a 60-second rest period was given between the sets.
214950438|NCT04787614|OTHER|No intervention|No intervention
214950439|NCT01057797|BEHAVIORAL|Exercise-specific self-efficacy|Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
214950440|NCT01057797|BEHAVIORAL|Gentle chair exercise|Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
214950441|NCT01057797|BEHAVIORAL|upper body strength training|16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
214950442|NCT03963180|OTHER|coffee|All patients were asked to drink the entire 150-mL amounts within 20 minutes under the supervision of a nurse or doctor. Patients were free to drink any amount of water but no more coffee, black tea, or other forms of caffeine, such as soda. Coffee and hot water were prepared with a conventional coffee machine (Nescafe Alegria; 100 g caffeine; Nestlé. Gatwick, United Kingdom).
214950443|NCT03634683|BIOLOGICAL|LioCyx|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
214950444|NCT01952080|DRUG|teduglutide|Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
215076191|NCT00983515|DRUG|Ritonavir|One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
215076192|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
215076193|NCT05179668|DRUG|Dapagliflozin 10 MG|administered orally once daily
215076194|NCT05179668|DRUG|Placebo|administered orally once daily
215076195|NCT05704907|OTHER|gallbladder ultrasound|gallbladder ultrasound
214343565|NCT01858662|DRUG|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
214486538|NCT06136741|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
214486539|NCT06136741|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
215076196|NCT02720640|DEVICE|Implant 'on' vs implant 'off'|Single group assignment
215076197|NCT06135636|BEHAVIORAL|Education|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
214343566|NCT01858662|DRUG|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
214343567|NCT01858662|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
214486540|NCT05025774|OTHER|Physical activity|Participant Reported Physical Activity and Outcomes (completed via REDCap or on paper)
214486541|NCT06784843|DRUG|Dexmedetomidine as an adjuvant to local anesthesia for peribulbar block|Dexmedetomidine as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
214950445|NCT05244434|OTHER|Best Practice|Given standard of care ribociclib + AI or palbociclib + AI
214950446|NCT05244434|PROCEDURE|Biopsy|Undergo biopsy of tumor tissue
214950447|NCT05244434|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214950448|NCT05244434|OTHER|Laboratory Biomarker Analysis|Undergo analysis of previously collected tumor tissue
214343568|NCT01858662|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
214343569|NCT01858662|DRUG|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
214343570|NCT06360835|PROCEDURE|total hip arthroplasty|
214343571|NCT02484794|BEHAVIORAL|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
214343572|NCT02484794|BEHAVIORAL|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
214486542|NCT06784843|DRUG|Midazolam as an adjuvant to local anesthesia for peribulbar block|Midazolam as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
214950449|NCT02414802|DEVICE|a manual spiral thrombus broken suction device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis
214950450|NCT02414802|PROCEDURE|catheter-directed thrombolysis|catheter-directed thrombolysis will be used in both arms
214343573|NCT04223453|DIAGNOSTIC_TEST|BIA and DXA|Patients with acute pneumonia measured simultaneously with DXA-scan and BIA-impedance
214343574|NCT00475059|DRUG|cimetidine arrow|patients who received cimétidine
214486543|NCT03512405|BIOLOGICAL|Blinatumomab|Given IV
214486544|NCT03512405|OTHER|Laboratory Biomarker Analysis|Correlative studies
214950451|NCT02414802|DRUG|low-molecular-weight heparin calcium|anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
214950452|NCT02414802|DRUG|urokinase|A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
214950453|NCT06730178|BEHAVIORAL|relaxation training|The training tapes used were meditation relaxation training tapes translated form Jacobson progressive relaxation technique with copyrights. The tapes were recorded by a male therapist. Participants were instructed to perform the treatment in the evening, preferably just before bedtime, total time was 15 minutes.
214950454|NCT01841034|DRUG|Conceptio EA|The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
214950455|NCT06614933|DEVICE|Biphasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a biphasic current, continuous at 25 Hz, for 1 hour, in-person.
214950456|NCT06614933|DEVICE|Monophasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a monophasic current, with a 50% duty cycle at 25 Hz, for 1-hour, in-person.
214343575|NCT01248884|BIOLOGICAL|Infanrix hexa™|3 doses, intramuscular into left thigh
214343576|NCT01248884|BIOLOGICAL|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
214343577|NCT01248884|BIOLOGICAL|GSK217744|3 doses, intramuscular into left thigh
214343578|NCT06507267|OTHER|Pain and Clinical Reflections in Pelvic Congestion Syndrome|Pain and Clinical Reflections in Pelvic Congestion Syndrome
214343579|NCT03110289|OTHER|superdonor FMT|"Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient."
214343580|NCT03110289|OTHER|autologous FMT|Fecal microbiota transplantation (FMT) with feces from the patient him/herself
214343581|NCT02511431|DRUG|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
214343582|NCT02511431|DRUG|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
214950457|NCT05669469|PROCEDURE|Bariatric surgery|1\) gastric pouch creation, 2) creation of biliopancreatic limb, 3) jejunojejunostomy creation, and 4) creation of gastrojejunostomy.
214950458|NCT06731400|DIETARY_SUPPLEMENT|EPA supplementation|Six healthy individuals will be supplemented with fish oil contains omega 3 (EPA) for eight weeks, with blood samples collected before and after the intervention.
214950459|NCT06183125|BEHAVIORAL|Traditional Chinese Medicine-based program|"Week1-2: one health talk session(60 mins); three workshops (each workshop will last for 60-90mins) to provide hands-on training in Baduanjin, acupressure techniques, mindful stretching, and effective strategies to combat sedentary behavior in the workplace.~Week 3-4: group practice sessions will take place for one hour every other day throughout the workweek; website support."
214950460|NCT07026630|DEVICE|Cooking In the Kitchen|"The virtual reality (VR) training tool simulates cooking, an activity of daily living (ADL). The layout of VR environments intentionally place ingredients, tools, and the recipe book far away from the user to require gross upper-limb physical movements. Successful step completion requires reaching to obtain ingredients or turn book pages, grabbing to hold or release objects, and chopping, scooping, stirring, and pouring motions to prepare food items. The VR tool includes three versions of varying graphical complexity: Simple, Standard, and Complex.~Complexity is controlled by stimuli count and detail level. For example, Simple features an empty room with monotone colors, basic shapes, and no extra features. In contrast, Complex resembles a fully-fledged kitchen with color patterns, textures, background details, and sounds."
214950461|NCT07026357|DEVICE|3D-planimetric measurement|Esophageal stenosis is evaluated by 3D-planimetric measurement
214950462|NCT07026357|RADIATION|Fluoroscopic control|Fluoroscopic control of dilatation therapy
214343583|NCT02511431|OTHER|Placebo|Placebo
214343584|NCT03074422|PROCEDURE|Hypnosis|Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
214343585|NCT05996354|DEVICE|Concave Supra-arch Branched stent-graft system|To evaluate the efficacy and safety of the Concave Supra-arch Branched stent-graft system for endovascular treatment of aortic arch diseases.
214678356|NCT05425238|OTHER|Blood flow restriction|"strengthening protocol but with Blood flow restriction technique~.Standard BFR Application: a standard pressure (used for all patients) for e.g. 180~mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.40% cuff pressure as percentage of LOP.(4) And performing BFR-RE with low load exercises. So 30% of 1 RPM would be enough 4 times a week for 6 week"
214950463|NCT07026357|DIAGNOSTIC_TEST|Endoscopic control|Macroscopic endoscopic control of dilatation therapy
214950464|NCT07026565|BEHAVIORAL|Psychotherapy group for parents|The psychotherapy group will consist of 10 virtual sessions, each lasting 1 hour and 15 minutes. Each session will begin with a mindfulness exercise to bring the participants into the present moment, followed by a pre-determined topic for discussion. At the end of each session, there will be a closing segment to summarize the reflections and teachings of the day, and a homework assignment will be provided. The topics covered will be: Opening, Psychoeducation, Diagnosis Report, Acceptance, Psychological Flexibility, Cognitive Defusion, Self as Context, Values, Committed Action, and Closure.
214950465|NCT07026565|BEHAVIORAL|Control Group|For the parents who will participate in the control group, the steps undertaken will include the administration of the Self-Reporting Questionnaire, Parental Stress Scale, Acceptance and Action Questionnaire, Cognitive Fusion Questionnaire, and Freiburg Mindfulness Inventory, before the intervention, after the intervention, and after 3 months.
214343586|NCT04479618|DEVICE|Usual Practice|A saline soaked piece of gauze, conformed to the size of the open ulcer area, will be placed over the ulcer and held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
214343587|NCT04479618|DEVICE|Improvised dressing|A piece of a new food-grade plastic bag, cut slightly larger than the ulcer, will be placed over the ulcer, sealed at the edges with an emollient to create an occlusive dressing. The dressing will be gently conformed to the ulcer contours to eliminate dead space, and a slit will be cut in the center to allow excess fluid to escape into a clean absorbent material placed over the slit. The device will be held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
214343588|NCT04479618|DEVICE|Advanced dressing|A piece of polymeric membrane dressing, cut to extend at least 0.5cm beyond the open ulcer edges, will be placed over the ulcer and held in place with a wrap of stretch gauze. The approximate wound edges will be marked on the back of the dressing. Dressing changes will consist only of removing the dressing when the saturation level, visible through the wound backing, reaches the mark indicating the dressing edges and applying a new cut dressing. Changes will be conducted by the patient after they master the procedure.
214678357|NCT05425238|OTHER|Conventional physical therapy|Resistance exercise 75 repetitions across four sets of exercises, with30 repetitions in the first set and 15 repetitions in each subsequent set. 4 times a week for 6
214950466|NCT07027579|OTHER|Nutrineal|"The Education for Thyroid Patients' Nutrition power point presentation prepared by the researcher will also be done using a computer."
215076198|NCT06135636|BIOLOGICAL|Vaccine administration|Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
215076199|NCT04350021|DRUG|Capecitabine, Cyclophosphamide|Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily
214950467|NCT07026643|DEVICE|active aVNT vs. Sham|Patients in both groups will receive daily stimulation with the Parasym device, temporarily connected to the tragus of the right ear (Fig 2).54 The stimulation parameters will be frequency of 20 Hz, pulse width of 200 µs, and the stimulation amplitude will be titrated to 1 mA below the discomfort threshold, consistent with parameters used in published clinical studies.54-56 With this stimulation at just below the discomfort threshold, people will often feel the stimulation for less than 60 seconds before they lose awareness of the ongoing stimulation. The stimulation will continue for 1 hour daily for 3 months, and we will track its use with a patient diary. Participants can continue their regular activities while wearing the aVNT device, as long as it is not soaked in water. Parasym will obtain Health Canada approval for use of their device in the study.
214950468|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (90% MT + 1 Hz)|Low frequency stimulation (1 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
214950469|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (100% MT + 1 Hz)|Low frequency stimulation (1 Hz) at 100% of resting motor threshold intensity, delivering a total of 2400 pulses.
214950470|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (110% MT + 1 Hz)|Low frequency stimulation (1 Hz) at 110% of resting motor threshold intensity, delivering a total of 2400 pulses.
214950471|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (90% + 10 Hz)|High frequency stimulation (10 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
214950472|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (100% MT + 10 Hz)|High frequency stimulation (10 Hz) at 100% of resting motor threshold intensity, delivering a total of 2400 pulses.
214950473|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (110% MT + 10 Hz)|High frequency stimulation (10 Hz) at 110% of resting motor threshold intensity, delivering a total of 2400 pulses.
214950474|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (90% MT + 25 Hz)|High frequency stimulation (25 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
214950475|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (100% MT + 25 Hz)|High frequency stimulation (25 Hz) at 100% of resting motor threshold intensity, delivering a total of 2400 pulses.
214950476|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (110% MT + 25 Hz)|High frequency stimulation (25 Hz) at 110% of resting motor threshold intensity, delivering a total of 2400 pulses.
214950477|NCT07026721|PROCEDURE|Retrograde intrarenal surgery (RIRS)|"The intervention involves Retrograde Intrarenal Surgery (RIRS) performed using a flexible ureteroscope to access the renal collecting system via a retrograde (urethra → bladder → ureter → kidney) approach. Stones are fragmented using a holmium:YAG laser, with or without the use of a ureteral access sheath, depending on the case.~What distinguishes this intervention from others is the integration of preoperative scoring systems-specifically the RIRS Scoring System and the Resorlu Unsal Stone Score (RUSS)-to predict stone-free outcomes and guide case selection and surgical planning. Additionally, all procedures are performed by experienced endourologists following a standardized protocol, including consistent patient positioning, anesthesia, access technique, and post-operative imaging at defined intervals to assess outcomes."
214950478|NCT07025980|DIETARY_SUPPLEMENT|The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS|The test product is a ready-to-use preparation PROBalansHepatocare, manufactured by PharmaS d.o.o., which contains 8 strains of live cultures of microorganisms (Bifidobacteriumbreve BBR8, Bifidobacteriuminfantis SP37, Bifidobacteriumlongum SP54, Lactobacillus acidophilus LA1, Lactobacillus bulgaricus LB2, Lactobacillus paracasei IMC502®, Lactobacillus plantarum BG 112, Streptococcusthermophilus SP4) with about 100 billion bacteria (50x109 CFU/capsule) in two capsules per day. In addition, the test product contains 100 mg of fructooligosaccharides, 210 mg of Ca-butyrate, and 10 ug (400 IU) of vitamin D in each capsule.
214950479|NCT07025980|DIETARY_SUPPLEMENT|Placebo Drug|Contains only excipients (cellulose; hydroxypropyl-methyl cellulose) and 10 ug (400 IU) of vitamin D. They do not contain dyes, flavors or preservatives, and contain traces of soy and milk, the levels of which do not affect people who are lactose intolerant.
214950480|NCT07027410|DEVICE|Intermittent normobaric hypoxia|Participants in the experimental group undergo a single session of intermittent normobaric hypoxia simulated by the iAltitude device. The session consists of breathing air with 12% oxygen concentration (equivalent to 4400 meters altitude) for a specified duration. Cognitive tests are administered before and after the hypoxia exposure to assess executive functions.
214950481|NCT07027410|OTHER|Normoxia|Participants undergo the same cognitive tests without exposure to hypoxia, serving as the control condition.
214950482|NCT07027423|DRUG|BOLD-100|BOLD-100 in combination with Doxorubicin (Escalation)
214950483|NCT07027423|DRUG|Doxorubicin 75 mg/m^2|BOLD-100 in combination with Doxorubicin (Escalation)
214950484|NCT07027423|DRUG|BOLD-100|BOLD-100 in combination with Doxorubicin (Expansion)
214950485|NCT07027423|DRUG|Doxorubicin 75 mg/m^2|BOLD-100 in combination with Doxorubicin (Expansion)
214950486|NCT07026214|BEHAVIORAL|Vitalis Cancer|Participants receive five free health coaching sessions with a trained student health coach, access to three health education videos, and a free wrist worn activity monitor to keep track of their physical activity and sleep behaviors.
214950487|NCT07025798|DIETARY_SUPPLEMENT|Probiotic|Probiotic strips with different strain formulas, Specification: 2g/bag. Storage method: Keep away from light, seal tightly, and store in a cool, dry place.
214950488|NCT07026396|OTHER|Creative drama group|In the intervention phase of the study, creative drama training was given to adolescents one day a week for 4 weeks. Before the training, permission was obtained from the families of the individuals, and only voluntary adolescents were allowed to participate. The empty classroom in the school was made suitable for creative drama activities. Adolescents gathered in the empty classroom one day a week, and the models and activity materials prepared by the researcher were taken to the classroom during the implementation week.
215076200|NCT03396679|OTHER|Ultrasound examination|Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
215076201|NCT03727087|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
215076202|NCT03994250|OTHER|Kinematic Alignment for total knee replacement surgery|Using Kinematic Alignment for total knee replacement surgery
215076203|NCT03994250|OTHER|Mechanical Alignment for total knee replacement surgery|Using mechanical alignment for total knee replacement surgery
215076204|NCT04385238|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
214343589|NCT03713762|DRUG|peribulbar block 1 lidocaine/bupivacaine|Peribulbar block: 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml.
214343590|NCT03713762|DRUG|peribulbar block 2 lidocaine/bupivacaine/fentanyl|Peribulbar block: 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
214950489|NCT07026045|OTHER|Post isometric relaxation (Lewit,s)|Post-isometric relaxation technique for the erector spinae, Iliopsoas, Quadratus Lumborum
215076205|NCT05132998|OTHER|Cardiac Rehabilitation Program|In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team
215076206|NCT05132998|OTHER|Community exercise intervention|In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
215076207|NCT00002440|DRUG|Indinavir sulfate|
215076208|NCT00002440|DRUG|Ritonavir|
215076209|NCT00002440|DRUG|Abacavir sulfate|
215076210|NCT00002440|DRUG|Amprenavir|
215076211|NCT00002440|DRUG|Nelfinavir mesylate|
214343591|NCT04984044|DIETARY_SUPPLEMENT|Vitamin D3|"Dietary supplement:Vitamin D3~1 capsule of Vitamin D3 (40,000IU) weekly for 8 weeks with antidiabetic drug"
214343592|NCT04984044|DIETARY_SUPPLEMENT|Placebo|1 capsule weekly for 8 weeks with antidiabetic drug
214486545|NCT03512405|BIOLOGICAL|Pembrolizumab|Given IV
214950490|NCT07026045|OTHER|Post-Facilitation Stretch Technique (Janda's technique)|Post-Facilitation Stretch Technique for the erector spinae, Iliopsoas, Quadratus Lumborum
215076212|NCT00002440|DRUG|Saquinavir|
214343593|NCT05843942|OTHER|Questionnaire|A food frequency questionnaire that was designed to assess folate, iron, and vitamin B12 intake will be administered. Furthermore a 24-hour recall food record will be administered and a complete blood count will be collected. Food frequency questionnaire data will be compared to recall food records and blood count data.
214343594|NCT01202773|DRUG|LY2127399|Administered Subcutaneously (SC)
214343595|NCT01202773|DRUG|Placebo Q4W|Administered SC
214343596|NCT01202773|DRUG|Placebo Q2W|Administered SC
214343597|NCT00146952|DEVICE|Vibrotactile feedback|
214486546|NCT05550571|DEVICE|Nautilus Intrasaccular Bridging System|Patients will be treated with the Nautilus, then followed-up for 12 months
214486547|NCT04875754|GENETIC|ICM-203|Intra-articular injection
214950491|NCT07025863|BEHAVIORAL|Alarm Fatigue Intervention Program|Train nurses in terms of alarm fatigue stressors, coping resources, and cognition. The training content for stress management includes forming a multidisciplinary team, selecting appropriate equipment, replacing accessories and dressings in a timely manner, and comforting the children promptly. The training content for dealing with resources includes standardizing alarm response procedures, increasing manpower allocation, enhancing knowledge, skills, and psychological adjustment, etc. The training content of cognition includes fostering a positive attitude and strengthening responsibility, etc.
214950492|NCT07027215|COMBINATION_PRODUCT|Gradual Intermittent pneumatic compression therapy (IPC),Balance excercises.PNF technique|PNF technique
215076213|NCT02830347|DRUG|Amoxicillin|Extraction
215076214|NCT02830347|PROCEDURE|Extraction|Extraction of third molars
215076215|NCT03693963|DEVICE|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
215076216|NCT05916625|OTHER|neuropsychological assessment|a consultation to assess cognitive and psycho-behavioral functions with questionnaires
215076217|NCT05916625|OTHER|biological sample|10 mL intravenous whole blood collection in EDTA tube
215076218|NCT05916625|PROCEDURE|medical imagery|Pet scan with the specific radioligand \[11C\]SB207145 and MRI
215076219|NCT05448404|DRUG|18F-PSMA-1007|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
215076220|NCT05448404|DRUG|18F-FDG|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
215076221|NCT01024582|PROCEDURE|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
215076222|NCT01024582|PROCEDURE|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
214343598|NCT05053087|DRUG|Ropivacaine Continuous Infusion|0.2% continuous infusion 6mL/hr
214486548|NCT04875754|DRUG|Placebo|Intra-articular injection
214678358|NCT03888300|OTHER|Physiotherapy|Chest Physiotherapy, physical exercises
214678359|NCT02288767|DEVICE|Conventional arterial blood pressure monitoring|
214678360|NCT02288767|DEVICE|Stroke volume variation monitoring with arterial blood pressure monitoring|
214678361|NCT03393052|PROCEDURE|Coronary Angiography|Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery
214678362|NCT00046319|DRUG|BSF 208075|
214678363|NCT06480305|DIETARY_SUPPLEMENT|Post dinner snack|one walnut, 2 cashews, 2 almonds, and 2 pistachios.
215076223|NCT01024582|RADIATION|accelerated partial breast irradiation|
215076224|NCT01024582|RADIATION|image-guided radiation therapy|
215076225|NCT05227599|OTHER|Online survey questionnaire|Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
215076226|NCT05254275|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
215076227|NCT05254275|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
215076228|NCT01967823|BIOLOGICAL|Anti-NY ESO-1 mTCR PBL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
215076229|NCT01967823|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenously (IV) in 250 mL dextrose 5% in water (D5W) infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
215076230|NCT01967823|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
215076231|NCT01967823|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenously (IV) (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
215076232|NCT00316693|BIOLOGICAL|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
214950493|NCT07027215|COMBINATION_PRODUCT|selected physical therapy program as arm excercises|selected physical therapy program only. The program consisted of (core exercises, AROM exercises, and stretching exercises for LL for 18 sessions every other day, over 6 weeks
215076233|NCT00316693|BIOLOGICAL|Aimmugen™|Intramuscular injection, 3 doses
215076234|NCT00539513|DRUG|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
215076235|NCT00539513|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
215076236|NCT04607941|OTHER|Questionnaires|Self-administered questionnaires
215076237|NCT04607941|OTHER|Phone interviews|A small amount of subjects will be selected at random for phone interviews.
215076238|NCT00074529|DRUG|MK0677|
215076239|NCT06536205|BEHAVIORAL|psychoeducation|Psychoeducation, psychological difficulties or physical diseases; These are structured educational interventions aimed at teaching people about their illness and their emotional responses to the illness, developing coping skills, ensuring compliance with the illness and cooperation with treatment.
215076240|NCT04679922|PROCEDURE|Soft Tissue Enhancement around dental implant|Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
215076241|NCT04086797|DIETARY_SUPPLEMENT|IQP-AE-103|1980 mg
215076242|NCT04086797|DIETARY_SUPPLEMENT|Placebo|Placebo
215076243|NCT05608525|DEVICE|transcranial current stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
214678364|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-1|Prepackaged dose of 25 peanuts.
214678365|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-2|Prepackaged dose of 25 raisins
214950494|NCT07026799|OTHER|Exercise|Orthopedic consultation and home-based, individualized, structured resistance training during induction therapy.
214950495|NCT07026799|OTHER|Control group|Orthopedic consultation and stretching exercises/walking. No resistance training.
214950496|NCT07026175|OTHER|Diet-induced low energy availability|6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing restricted energy intake on the control trial.
214950497|NCT07026175|OTHER|Exercise-induced low energy availability|6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing increased exercise energy expenditure on the control trial.
214950498|NCT07027566|DRUG|Potassium nitrate and sodium fluoride|Gel with 5% potassium nitrate and 2% sodium fluoride gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
214950499|NCT07027566|DRUG|Cannabidiol (CBD) Gel|Cannabidiol gel for teeth ( 2% cannabidiol oil) before bleaching with hydrogen peroxide
214678366|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-3|Prepackaged dose of 25 peanuts on one day and 25 raisins as a pre-breakfast.
214950500|NCT07027566|DRUG|Natrosol 4% Gel|placebo gel (natrosol-based gel 4%) for topical application to teeth before bleaching with hydrogen peroxide.
214343599|NCT05053087|DRUG|Ropivacaine Intermittent Bolus|0.2% intermittent bolus infusion 8mL every 2 hours
214678367|NCT03504774|DRUG|Cashew or Shrimp Oral Immunotherapy|All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
214678368|NCT02344628|DRUG|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
214950501|NCT07027241|BEHAVIORAL|Exercise Intervention|"This arm will include and exercise and nutritional intervention in addition to usual postoperative hip fracture care.~The exercise program will be delivered 3-5 times per week, each session lasting between 20-30 minutes depending on patient tolerance. The program will be progressed gradually between sessions and be guided by patient tolerance. The program will involve bed/ chair-based aerobic and resistance training (using an arm crank ergometer, resistance bands and ankle weights). The program will be delivered over the entire length of a patient's hospital stay up to a duration of 6 weeks for prolonged stays.~All patients will undergo baseline assessments including assessment of level of frailty, pre-fracture level of mobility \& function, postoperative mobility, nutritional status/ screening, grip strength and level of pain."
214950502|NCT07027241|OTHER|Usual Care|"This arm will assess all aspects of usual postoperative hip fracture care which will include multidisciplinary team assessment which include physiotherapists, occupational therapists, dieticians as well as specialist nurses and doctors working as part of the orthogeriatric team (falls and bone health assessment). They will receive daily physiotherapy training starting on the first postoperative day which will include mobility, balance, strength and gait training. This group will also receive additional protein supplementation in the form of a nutritional supplement twice daily as part of usual postoperative hip fracture care.~All patients will undergo baseline assessments including assessment of level of frailty, pre-fracture level of mobility \& function, postoperative mobility, nutritional status/ screening, grip strength and level of pain.~All patients will be asked to maintain a three-day food diary to monitor their protein intake."
214950503|NCT07027241|DIETARY_SUPPLEMENT|Nutritional Intervention|The nutritional intervention will take the form of a protein fortified evening snack administered by nursing staff (additional 20g of protein).
214343600|NCT05053087|DRUG|Placebo|Saline filled catheter
214343601|NCT03607448|DEVICE|Freestyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
214343602|NCT06387251|OTHER|30 day wellness program|30 days and will evaluate the effects of sponsor-designed 30-day wellness program consisting of 3 supplement and functional food products, recommended diet, physical activity, hydration and mindfulness activities.
214343603|NCT04388293|OTHER|Exposure of interest|Very Low Birth Weight infants admitted to tertiary NICUs in Canada.
214343604|NCT00235794|DRUG|temsirolimus|
214343605|NCT04885829|DRUG|Tocilizumab Prefilled Syringe|0.9ml Subcutaneous pre-filled syringes containing 162mg of Tocilizumab.
214343606|NCT05870098|DIAGNOSTIC_TEST|All participants|"1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine."
214950504|NCT07026578|PROCEDURE|Blood draw for the laboratory assessment|This is an observational study . The procedures will be carried out in according to clinical practice
214950505|NCT07027371|BEHAVIORAL|Health education|Health education was given in the form of a printed colored brochure designed in easy-to-understand Arabic language. Participants were encouraged to read the brochure thoroughly and as many times as needed and to ask questions to the researchers if they had any.
214950506|NCT07021352|PROCEDURE|Ear acupuncture|Ear Acupuncture: Participants will receive bilateral NADA ear acupuncture protocol treatment for a one-time insertion in addition to the weekly mindfulness therapy received by participants. The NADA consists of 5 ear acupuncture points inserted bilaterally: shen men, sympathetic, kidney, liver, and lung. Sterile, semi-permanent acupuncture needles (2mm) will be inserted into the participant's ear and left in place until they naturally fall out, typically within 3-7 days.
214950507|NCT07021352|BEHAVIORAL|Mindfulness therapy|Mindfulness: Participants will receive virtual mindfulness therapy weekly for 30 minutes each session via the MS Teams platform.
214950508|NCT07027254|DIAGNOSTIC_TEST|68Ga-pentixafor PET/CT|Diagnostic PET/CT imaging using gallium-68 labeled pentixafor to assess adrenal CXCR4 expression in patients with primary aldosteronism. The imaging is performed prior to treatment allocation and used to assist lateralization of aldosterone production when combined with adrenal venous sampling (AVS).
214950509|NCT07027150|DEVICE|Chest Worn Pulse Oximeter|"The Perin Health Patch is a non-invasive, chest-worn wearable device designed to continuously monitor physiological signals, including photoplethysmography (PPG), oxygen saturation (SpO₂), electrocardiography (ECG), and other health metrics. In this study, the device will be evaluated for its ability to accurately measure SpO₂ during controlled hypoxemia in healthy adult volunteers. The SpO₂ values recorded by the Perin Health Patch will be compared against arterial oxygen saturation values (SaO₂) obtained via co-oximetry, following the UCSF Hypoxia Lab protocol aligned with ISO 80601-2-61 standards.~This device integrates PPG and ECG sensors into a single chest-applied unit, distinguishing it from conventional finger or earlobe pulse oximeters. The intervention in this study is limited to the application and use of the device for data collection under clinically controlled oxygen saturation conditions."
214950510|NCT07026123|DRUG|Nal-IRI (Onivyde®)-based treatment|Nal-IRI (Onivyde®) combined with 5-FU/LV is used for metastatic pancreatic ductal adenocarcinoma patients who have progressed after treatment with gemcitabine. The recommended dose of Nal-IRI (Onivyde®) is 70 mg/m\^2, administered intravenously for 90 minutes, once every 2 weeks. In patients known to be homozygous for the UGT1A1 \* 28 allele, the recommended starting dose of Nal-IRI (Onivyde®) is 50 mg/m\^2, administered intravenously within 90 minutes. Based on tolerance, increase the dose of Nal-IRI (Onivyde®) to 70 mg/m\^2 in subsequent cycles.
214950511|NCT07026123|DRUG|Other second-line treatment|Other second-line treatment
214950512|NCT07026500|BIOLOGICAL|EV71 Vaccine|EV71 vaccine of commercial production batch
214950513|NCT07026097|OTHER|Pilates Exercise - Online|Will receive Pilates exercise protocol online under supervision as patient will instructed to join online meeting and do their exercise 02 times a week along with standard physical therapy protocol for 4 weeks. The Pilates exercise protocol will be of 30 minutes. Repetitions: Exercises started with 6 to 10 reps. and hold time for 30 sec for each exercise. Rest period of 2 mins will be given
214950514|NCT07026097|OTHER|Pilates Exercise - Supervised|Will receive Pilates exercise protocol clinically supervised as patient will instructed to do their exercise 0 times a week along with standard physical therapy protocol for 4 weeks. The Pilates and common standard physical therapy protocol will be the same which is mention in detail in group A description
214950515|NCT07027761|BEHAVIORAL|Online self-help|Online Self-Help refers to a 24/7 accessible, internet-based platform that offers digital modules grounded in evidence-based approaches, including infant mental health, cognitive-behavioral therapy (CBT), and psychodynamic interventions, aimed at addressing perinatal depression (https://perinatalehulp.be/). Upon logging in, participants receive an overview of the available modules and can select from three distinct treatment trajectories, ideally to be completed over the course of 10 weeks: (a) a self-directed option allowing free choice among all modules; (b) a structured CBT trajectory incorporating both second-wave and third-wave cognitive-behavioral strategies; or (c) a psychodynamic trajectory primarily focused on relational and attachment-related factors contributing to the onset and maintenance of perinatal depression.
214950516|NCT07027761|BEHAVIORAL|Maternal Mental Health Intervention (MaMHI)|A brief, eight-session face-to-face intervention designed for (expectant) mothers and their infants across the perinatal period, consisting of four prenatal sessions (during the second and third trimesters of pregnancy) and four postnatal sessions conducted within the first three months postpartum. The intervention is grounded in psychodynamic principles and informed by mentalization-based approaches
214950517|NCT07027761|OTHER|Usual Care|Prenatal care is provided through follow-up by a general practitioner and a gynecologist and/or a midwife, while postnatal follow-up is conducted by Child and Family Care Services.
214950518|NCT07026461|DEVICE|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique that uses pulsed magnetic fields to activate or suppress specific brain regions. It is used to treat various conditions, including major depressive disorder, by inducing small electrical currents that stimulate nerve cells.
214343607|NCT00620477|DRUG|injection in the knee joint with 20 ml of chirocaine 0.125%|injection in the knee joint with 20 ml of chirocaine 0.125%
214950519|NCT07026461|DEVICE|intermittent theta burst stimulation|Intermittent theta-burst stimulation (iTBS) is a form of transcranial magnetic stimulation (TMS) used to modulate brain activity. It involves delivering brief bursts of magnetic pulses to specific brain regions, typically the left dorsolateral prefrontal cortex (DLPFC)
215076244|NCT05608525|BEHAVIORAL|GRASP|A standardized occupational therapy- GRASP will be performed daily together with tDCS over the period between the Pre Assessment and the Post Assessment. GRASP exercise will be administered concurrently with or immediately after tDCS stimulation. GRASP is a self-directed arm and hand exercise program for which is supervised by a therapist, but done independently by the participant (and with their family if possible). GRASP has been shown to improve arm and hand function and strength in stroke patients in community \[22-27\]. The versions of the program- Home GRASP will be used. All occupational tasks will be selected from the GRASP task pool and be progressed according to the GRASP protocol (https://neurorehab.med.ubc.ca/grasp). Each GRASP session will take about 1 hour. A total of 20 GRASP sessions will be administered.
215076245|NCT03809091|DIAGNOSTIC_TEST|Whole genome sequencing|Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
215076246|NCT02858531|OTHER|data retrieval|data retrieval with the Hospital Information System
215076247|NCT01925911|DRUG|IPI-145|25 mg BID Oral Capsule
215076248|NCT01925911|DRUG|Midazolam|2 mg midazolam syrup
214343608|NCT00620477|DRUG|injection in the knee joint with 20 ml of physiological fluid|injection in the knee joint with 20 ml of physiological fluid
214343609|NCT01895166|PROCEDURE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
214343610|NCT01895166|PROCEDURE|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
214343611|NCT01279226|DEVICE|Auralevée device|Single treatment with Auralevée device.
214678369|NCT06381674|OTHER|Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback|During physical therapy sessions participants will wear sensors on their head, chest, waist, and feet for real-time instrumented audio and visual biofeedback on quality of therapeutic exercise.
214678370|NCT06381674|OTHER|Vestibular therapy for mTBI|During physical therapy sessions participants will go through vestibular therapeutic exercise WITHOUT audio and visual real-time biofeedback.
214678371|NCT06483555|DRUG|Gemcitabine|1000 mg/m2, intravenously on day 1 and day 15, for subjects with basal-like cell type pancreatic carcinoma.
214678372|NCT06483555|DRUG|Nab paclitaxel|125 mg/m2 intravenously on day 1 and day 15 for subjects with basal-like cell type pancreatic carcinoma.
214678373|NCT06483555|DRUG|Erlotinib|50 mg per oral daily. for subjects with basal-like cell type pancreatic carcinoma.
214343612|NCT03356912|DRUG|Cabazitaxel|"Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route"
214343613|NCT03356912|DRUG|Prednisone|Prednisone should be administred by oral route
214343614|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
214343615|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
214343616|NCT03238937|DEVICE|Phrenic nerve stimulator|Implantation of phrenic nerve stimulator
214950520|NCT06702137|DEVICE|EXOPULSE MOLLII SUIT (active)|"This study aims to evaluate the effects of the EXOPULSE Mollii suit, a non-invasive assistive device that delivers transcutaneous electrostimulation. The suit includes a CE-labeled class IIa control unit and class I body garments. Equipped with 58 electrodes, the full-body suit stimulates various muscle groups to reduce spasticity by activating antagonistic muscles through reciprocal inhibition, rather than causing muscle contractions. Designed to relax spastic muscles, improve range of motion, prevent atrophy, enhance circulation, and provide pain relief, the device is easy to use, requiring only one hour of daily wear, with effects lasting over 24 hours.~Current treatments for spasticity, such as botulinum toxin and oral medications, have limitations like side effects and minimal mobility improvement. The EXOPULSE Mollii suit offers an innovative alternative, with early studies indicating positive impacts on mobility and motor function."
214950521|NCT06702137|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
214950522|NCT01507532|OTHER|pharmacokinetic monitoring|pharmacokinetic monitoring
214950523|NCT04554342|OTHER|V01 candy|candy with sweetener (Isomalt) and apple flavour
214950524|NCT04554342|OTHER|V02 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)
214950525|NCT04554342|OTHER|V03 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C
214950526|NCT04554342|OTHER|V04 candy|candy with sweetener (Isomalt) (control group 1)
214950527|NCT04554342|OTHER|V05 candy|candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)
214950528|NCT07027540|DRUG|Bupivacaine 0.25% 20ml|Adult patients will take a total 20 ml of Bupivacaine 0.25%
214950529|NCT07027540|DRUG|2mg of dexamethasone|2mg of dexamethasone in the right T7
214950530|NCT07027540|DRUG|35 ml of Bupivacaine 0.25%|Adult patients will take a total 35 ml of Bupivacaine 0.25%
215076249|NCT03859518|OTHER|blood and skin samples|To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
215076250|NCT01797848|DRUG|Peginterferon alfa 2a|
215076251|NCT01797848|DRUG|Ribavirin|
214950531|NCT07025889|DRUG|IBI343|"Subjects in the phase 1b stage will receive IBI343 3/4.5/6mg/kg intravenous infusion (IV) D1 Q3W in 3-week cycles.~Subjects in the phase 2 stage will receive IBI343 RP2D intravenous IV D1 Q3W in 3-week cycles."
214950532|NCT07025889|DRUG|Sintilimab|Subjects will receive sintilimab 200mg IV D1 Q3W in 3-week cycles.
214950533|NCT07025889|DRUG|Oxaliplatin|Subjects will receive oxaliplatin 130mg/m2 IV D1 Q3W in 3-week cycles.
214678374|NCT06483555|DRUG|NALIRIFOX|Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.
214678375|NCT06483555|DRUG|Folfirinox|Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.
214950534|NCT07025889|DRUG|S-1|Subjects will receive S-1 40-60mg BID PO D1-14 Q3W in 3-week cycles.
214950535|NCT07026292|PROCEDURE|Immediate Distal Lymphaticovenous Anastomosis (ID-LVA)|ID-LVA (Immediate Distal Lymphaticovenous Anastomosis) is an supermicrosurgical technique performed during axillary lymph node dissection (ALND) to prevent breast cancer-related lymphedema, offering the dual advantages of immediate intervention and radiation-field avoidance. Compared to LYMPHA (Lymphatic Microsurgical Preventive Healing Approach), which utilizes proximal axillary anastomoses within the radiation field with larger vessels and higher venous pressure, ID-LVA creates precise anastomoses between 0.3-0.8mm distal superficial lymphatic vessels and low-pressure venules in the upper arm. In contrast to DD-LVA (Delayed Distal Lymphaticovenous Anastomosis) performed postoperatively (typically 4-12 weeks after ALND) for subclinical lymphedema, ID-LVA provides earlier prevention by utilizing undamaged lymphatics and avoids the need for a second procedure.
214950536|NCT03953105|DEVICE|ePER|usind the ePER for weight estimation and suggestion of the defined parameter
214950537|NCT03953105|DEVICE|BT|usind the BT for weight estimation and suggestion of the defined parameter
215076252|NCT01797848|DRUG|Placebo matching Daclatasvir|
215076253|NCT01797848|DRUG|Daclatasvir|
215076254|NCT04008992|DRUG|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
215076255|NCT04008992|OTHER|Placebo|Placebo matching BMS-986259
215076256|NCT04008992|DIAGNOSTIC_TEST|P-Aminohippurate|Diagnostic Agent
215076257|NCT04008992|DIAGNOSTIC_TEST|Iohexol|Diagnostic Agent
215076258|NCT03346551|BEHAVIORAL|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"
215076259|NCT03346551|BEHAVIORAL|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"
214343617|NCT01452269|BEHAVIORAL|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
214950538|NCT04592627|OTHER|Simulated home environment visit|During the simulated home environment visit participants will 1) participate in a simulated University of Texas (UT) Physicians Stroke Outpatient Clinic telemedicine visit using an iPAD during which participants will be audio- and visually-recorded in order for the research team to collect raw facial expression data; 2) be instructed to complete a series of activities of daily living (e.g., sitting down and brushing hair) during which participants will be audio- and visually-recorded in order for the research team to collect raw body motion tracking data; and 3) complete a participant satisfaction survey via a REDCap link and participate in an audio-recorded, semi-structured interview (e.g., asking the participants thoughts on privacy considerations related to future use of the facial expression and body motion technology in a home environment) with members of the research team.
214343618|NCT03021226|BEHAVIORAL|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
214950539|NCT02732327|DRUG|CAZ-AVI|Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)
214343619|NCT03021226|BEHAVIORAL|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
214950540|NCT02732327|DRUG|Vancomycin|15 mg/kg
214950541|NCT02732327|DRUG|Linezolid|600 mg
214950542|NCT02732327|DRUG|Cefepime|2 g
214950543|NCT02732327|DRUG|Meropenem|1 g
214950544|NCT02732327|DRUG|Piperacillin/tazobactam|4.5 g
214950545|NCT04585620|DRUG|Onabotulinum Toxin A|Series of subcutaneous injections
214950546|NCT04585620|DRUG|Normal saline|Series of subcutaneous injections
214950547|NCT06910722|PROCEDURE|Liver transplant|follow-up of liver transplant patients after selective internal radiotherapy (SIRT) with Yttrium-90 and chemotherapy
214950548|NCT04503668|DRUG|Ondansetron|8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
214950549|NCT04503668|DRUG|Dexamethasone|20 mg IV on day 1 pre-chemotherapy
214950550|NCT04503668|DRUG|Neurokinin-1 Receptor Antagonist (NK1-RA)|150 mg IV on day 1 pre-chemotherapy
214950551|NCT04503668|DRUG|Olanzapine|5 mg by mouth on days 1-4 of chemotherapy (taken at night)
214950552|NCT04503668|DRUG|Compazine|5-10 mg by mouth, available as needed, every 6 hours, days 1-5
214950553|NCT00034944|DRUG|MK0869, aprepitant|
214950554|NCT00034944|DRUG|Comparator: placebo|
214950555|NCT03788668|PROCEDURE|Hyoid suspension|Hyoid suspension will be done with barbed reposition pharyngoplasty
214950556|NCT02237560|BEHAVIORAL|Cybercycle-Game|Exercising on a virtual-reality enhanced stationary recumbent bicycle while playing interactive 3D video-game for 6 months, 3-5x/week.
214950557|NCT02237560|BEHAVIORAL|Cybercyle-Tour|Exercising on virtual-reality enhanced stationary recumbent bicycle and pedaling through interactive 3D scenic bike tours for 6 months, 3-5x/week.
214950558|NCT02237560|BEHAVIORAL|Game Only|While seated on a stationary recumbent seat play interactive 3D video-game for 6 months, 3-5x/week (no pedaling).
214950559|NCT04728373|PROCEDURE|surgery|the need for surgery after aircraft accidents
214950560|NCT03782974|DIETARY_SUPPLEMENT|beta glucan|Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
214950561|NCT04437472|OTHER|CareSignal|The CareSignal software will be programmed to automatically ask a subset of the NCI-PRO-CTCAE questions using SMS depending on patient group as designated by the treating physician: (1) thoracic radiation with chemotherapy, (2) thoracic radiation alone, (3) extremity/body wall sarcoma, and (4) other.
214950562|NCT03802435|PROCEDURE|two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval)
214950563|NCT03802435|PROCEDURE|One-sessions of ultrasound-guided PIT|One-session of ultrasound-guided PIT with 10cc D5W and 10cc normal saline separately (3 months interval)
214950564|NCT03802435|PROCEDURE|Placebo ultrasound-guided injection with nerve hydrodissection|Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
214950565|NCT01500967|OTHER|Shi-style cervical manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
214950566|NCT01500967|OTHER|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
214950567|NCT04684875|DEVICE|Radiofrequency Stylus|Low power radiofrequency energy delivered to the posterior nasal nerve area
214950568|NCT05273775|DRUG|HRS5091 Tablets|HRS5091 Tablets once daily
214950569|NCT05273775|DRUG|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
214950570|NCT05273775|DRUG|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
214950571|NCT05273775|DRUG|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
214950572|NCT05273775|DRUG|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
214950573|NCT05273775|DRUG|Digoxin Tablets|Digoxin Tablets single dose
214950574|NCT05273775|DRUG|Rosuvastatin Calcium Tablets|Rosuvastatin Calcium Tablets single dose
214950575|NCT02119975|BEHAVIORAL|Working memory training|
214950576|NCT02119975|BEHAVIORAL|Placebo training|
214678376|NCT03697278|DEVICE|Smith medical CADDsolis|This group will be monitoring from a network.
214950577|NCT05202275|DRUG|Olanzapine|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx, 69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5 at every chemotherapy cycle.
214950578|NCT01366300|DRUG|Intravenous lidocaine infusion|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
214950579|NCT01366300|OTHER|Placebo (0.9% saline infusion)|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
214950580|NCT01366300|DRUG|Propofol 1% (intravenous infusion)|Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
214950581|NCT01366300|PROCEDURE|Placement of arterial line|An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
214950582|NCT04747951|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy|"50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
214950583|NCT04747951|PROCEDURE|TME|Total mesorectal excision
214950584|NCT04747951|DRUG|consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course
214950585|NCT04747951|DRUG|adjuvant chemotherapy|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
214950586|NCT01578954|DRUG|Lenalidomide|"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"
214950587|NCT02930161|DRUG|Runihol|"Composition of Runihol®:~One tablet contains:~Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate."
214950588|NCT02930161|OTHER|Placebo|"The composition of the drug in one tablet:~Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.~Tablet weight enteric coated - 0.695 g"
214950589|NCT06233877|DRUG|G-GLIP plus Mitomycin C|G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin plus Mitomycin C
214950590|NCT06911879|OTHER|Ketogenic diet with caloric restriction|Participants in this group will follow a ketogenic diet with caloric restriction (-550 kcal/day), consisting of approximately 5-10% carbohydrates, 15-25% protein, 70-80% fat. The daily carbohydrate intake will be limited to less than 50g per day. The intervention will last for 12 weeks, with regular dietary monitoring and adherence checks every two weeks.
214950591|NCT06911879|OTHER|Normal diet with caloric restriction|Participants in this group will follow a normal diet with caloric restriction (-550 kcal/day), consisting of approximately 45-60% carbohydrates, 15-25% protein, 20-30% fat. The intervention will last for 12 weeks, with regular dietary monitoring and adherence checks every two weeks.
214950592|NCT06911879|OTHER|Normal diet without caloric restriction|Participants in this group will follow a normal diet without caloric restriction, consisting of approximately 45-60% carbohydrates, 15-25% protein, 20-30% fat. The intervention will last for 12 weeks, with regular dietary monitoring and adherence checks every two weeks.
214950593|NCT03090633|DEVICE|Fetoscopy|Minimally invasive in-utero surgery
214950594|NCT06618053|OTHER|cost-effectiveness and audiometry outcomes|Evaluate cost-effectiveness of stapes surgery performed under local anesthesia as well as evaluate audiometry outcomes
214950595|NCT06469697|BEHAVIORAL|School music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at both school and community levels.
214950596|NCT06469697|BEHAVIORAL|Community music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at community levels.
214950597|NCT00409851|DRUG|valsartan+amlodipine|
214950598|NCT06002776|OTHER|a retrospective study|a retrospective study
215076260|NCT02627287|DEVICE|FlexPen®|For subcutaneously (s.c. under the skin) injection.
215076261|NCT02627287|DEVICE|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
214343620|NCT03021226|BEHAVIORAL|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
214678377|NCT03955848|BIOLOGICAL|Alloreactive NK cell infusion|Alloreactive NK cell infusion
214678378|NCT05226585|BEHAVIORAL|In-Person Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi). CBTi contains the following well-validated components of cognitive behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
215076262|NCT02627287|DRUG|placebo|For subcutaneously (s.c. under the skin) injection
214343621|NCT02685254|BEHAVIORAL|Structural skills training group|Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.
214950599|NCT03943927|OTHER|Guided Metoprolol Management|"CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient."
214343622|NCT02685254|OTHER|Treatment as usual|Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
214343623|NCT01243333|RADIATION|[F-18]fluorodeoxyglucose|Undergo PET scans with \[F-18\]fluorodeoxyglucose
214343624|NCT01243333|RADIATION|[F-18]fluorothymidine|Undergo PET scans with fluorine \[F-18\]fluorothymidine
214343625|NCT01243333|PROCEDURE|Positron Emission Tomography|Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
214950600|NCT05947227|OTHER|Buteyko breathing technique|Group A : will be treated with manual chest physiotherapy \& Buteyko Breathing exercise
214950601|NCT05947227|OTHER|Diaphragmatic breathing technique.|Group B : will be treated with manual chest physiotherapy \& Diaphragmatic Breathing Treatment evaluation will be done after 8 weeks through 6MWT \& St George respiratory Questionnaire. Patients will perform technique 5 times a weeks for 8 weeks
214950602|NCT04312282|DRUG|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
214950603|NCT04312282|DRUG|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
214343626|NCT01243333|RADIATION|Water O-15|Undergo PET scans with water O-15 tracers
214343627|NCT03791125|DRUG|Salvianolic Acid A|4 anticipated doses are 30 mg, 90 mg, 180 mg and 270 mg, respectively. All of these are single-dose study.
214343628|NCT03791125|DRUG|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
214343629|NCT03524404|BEHAVIORAL|6 Week Intervention|Weekly interactive webinars based on the DPP curriculum at senior center.
214343630|NCT00243373|DEVICE|Barcode technology/eMAR|
214343631|NCT01060228|DRUG|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
214343632|NCT01060228|DRUG|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
214343633|NCT03181360|DRUG|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
214343634|NCT03181360|OTHER|Control|Best standard treatment
214343635|NCT00749138|DRUG|tamoxifen|giving drug tamoxifen
214343636|NCT02811029|BEHAVIORAL|measurement of phonology|measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
214343637|NCT04827212|BEHAVIORAL|Companion|"Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time."
214950604|NCT04312282|DRUG|Itraconazole|Itraconazole orally once daily from Day -3 to Day 14 of a 21-day cycle
214950605|NCT04312282|DRUG|Rifampin|Rifampin orally once daily from Day -6 to Day 14 of a 21-day cycle
214950606|NCT03296020|OTHER|HONEY|100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
214950607|NCT06517173|DRUG|Y-3 for injection|Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
214950608|NCT06517173|DRUG|Placebo control group|Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
214950609|NCT04064580|OTHER|diagnostic test|performing a capnography examination
214950610|NCT04724031|DRUG|PARP inhibitor|use at any line of treatment in patients with advanced ovarian cancer
215076263|NCT02502058|DEVICE|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
215076264|NCT03690739|DRUG|Carboplatin|Administration according to investigator's discretion
215076265|NCT03690739|DRUG|Gemcitabine|Administration according to investigator's discretion
215076266|NCT03690739|DRUG|Bevacizumab|Administration according to investigator's discretion
214343638|NCT06308939|DRUG|Eribulin|1.4mg/m\^2 day1、8，repeated every 3 week.
214950611|NCT04747873|BEHAVIORAL|e-CBT|The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.
214343639|NCT06308939|DRUG|Sintilimab|500mg once every three weeks.
214343640|NCT01865591|DEVICE|Ultrasound-based Renal Denervation|
214950612|NCT04747873|BEHAVIORAL|Stepped Care|Stepped care procedure (see arm/group descriptions).
214343641|NCT04898608|OTHER|Intradialytic Exercise|"Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions.~To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 1RM for resistance protocols.~Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
214950613|NCT04666844|OTHER|no intervention|Observational Study
214950614|NCT01174810|DRUG|Exenatide|Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
214950615|NCT01783821|DRUG|Budesonide|Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
214950616|NCT01783821|DRUG|Placebo|Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
214950617|NCT01783821|DRUG|Formoterol|Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
214950618|NCT06446336|OTHER|HASS Score|Creation of a pre-operative score
214950619|NCT05306236|OTHER|LLL therapy , postural correction ex|"study group: will receive low level laser therapy 2 sessions per week for 6 weeks in addition to posture correction exercises.~control group: will be treated by posture correction ex only."
215076267|NCT03690739|DRUG|PLD|Administration according to investigator's discretion
214678379|NCT05226585|BEHAVIORAL|Telehealth Cognitive Behavioral Therapy for Insomnia|Telehealth cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi) conducted via audio-video communication. tCBTi contains the following well-validated components of cognitive-behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
214950620|NCT04849533|DRUG|Belatacept|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
214950621|NCT04849533|DRUG|Everolimus|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
214950622|NCT04849533|DRUG|mycophenolate mofetil|belatacept with mycophenolate is approved regimen for prevention of rejection
214950623|NCT04849533|DRUG|corticosteroids|belatacept with chronic steroids is approved regimen for prevention of rejection
214950624|NCT04849533|DRUG|rabbit antithymocyte globulin|rabbit antithymocyte globulin induction for prevention of rejection
214950625|NCT02425033|PROCEDURE|POEM|Under general anesthesia, patient undergoes upper endoscopy and a small longitudinal submucosal incision is created and a dilating balloon is inserted submucosally via the created incision. The balloon is slightly inflated to allow entrance of the endoscope. The gastroscope is advanced into the submucosal space and the tunnel is created via endoscopic or blunt dissection as appropriate. The tunnel is created distally and is stopped several centimeters beyond the lower esophageal sphincter (LES), which can easily be identified using endoscopic landmarks. Using a dissection knife, the clearly visible circular muscles are divided. The longitudinal layer is left intact and the mucosal entry is closed.
214950626|NCT04956627|DRUG|BMS-986166|Specified dose on specified days
214950627|NCT04956627|DRUG|Itraconazole|Specified dose on specified days
214950628|NCT04956627|DRUG|Extended Phenytoin Sodium|Specified dose on specified days
214950629|NCT04956627|DRUG|Gemfibrozil|Specified dose on specified days
215076268|NCT03690739|DRUG|Paclitaxel|Administration according to investigator's discretion
215076269|NCT03690739|DRUG|PLD|Administration 30 mg/m² q21
215076270|NCT03690739|DRUG|Trabectedin|Administration 1.1 mg/m² q21
215076271|NCT03690739|DRUG|Cisplatin|Administration according to investigator's discretion
215076272|NCT01242306|DRUG|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
214343642|NCT04691765|DRUG|Kineret|escalating doses of drug will be administered to 3 groups of 4 patients for 7 months
214343643|NCT02806180|PROCEDURE|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
214343644|NCT02806180|PROCEDURE|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
214343645|NCT00077025|DRUG|Gefitinib|ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
214343646|NCT00077025|DRUG|Anastrozole|1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
214343647|NCT03898817|OTHER|taking of cutaneous cells|Taking of cutaneous cells by biopsy Sample of blood
214343648|NCT03874364|DEVICE|Lidocaine gel|10 ml 2% lidocaine gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
214950630|NCT03337035|DRUG|intranasal oxytocin|4-24 IU per day, dosage gradually increases
214950631|NCT03337035|DIETARY_SUPPLEMENT|oral probiotics|200 million cfu per day
214950632|NCT03337035|DIETARY_SUPPLEMENT|oral placebo|2 pills per day
214950633|NCT00722163|OTHER|Cognitive Behavioural Therapy|
214950634|NCT00722163|OTHER|befriending|
215076273|NCT00712218|PROCEDURE|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
214950635|NCT01907217|DEVICE|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
214343649|NCT03874364|OTHER|Counselling|Patients receive a brochure in the waiting room explaining the procedure in details.
214343650|NCT03874364|OTHER|Monitor|Patients are allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
214343651|NCT03874364|DEVICE|Lubricating gel|10 ml plain lubrificant gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
214950636|NCT01907217|DRUG|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
214343652|NCT03874364|OTHER|No counselling|Patients won't receive a brochure in the waiting room explaining the procedure in details.
214678380|NCT05226585|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia|Sleep Healthy Using The Internet (SHUTi; aka iCBTi) is a self-guided, fully automated, online CBTi program that includes interactive features: personalized goal setting, graphical feedback based on inputted data, animations/illustrations to enhance comprehension, patient vignettes, and video-based expert explanations.
214950637|NCT01907217|DRUG|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
214950638|NCT03409939|DIETARY_SUPPLEMENT|Aromatic Amino Acid Intake|Intakes will be randomly chosen from a list of 8 doses of aromatic amino acids. Each intake will will be repeated approximately 4 times.
214950639|NCT04038554|DIAGNOSTIC_TEST|Feces and saliva analysis|Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
214950640|NCT03362580|DEVICE|Slit lamp examination|The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.
214950641|NCT03362580|DEVICE|Undilated 7-field color fundus photography|Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.
214950642|NCT03362580|DEVICE|Color scan|Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.
214950643|NCT03362580|DEVICE|Spectral domain optical coherence tomography|Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.
214950644|NCT01226680|DRUG|Tasocitinib|0.005% QD for 12 weeks
214950645|NCT01226680|DRUG|Tasocitinib|0.003% QD for 12 weeks
214950646|NCT01226680|DRUG|vehicle for Tasocitinib|vehicle QD for 12 weeks
214950647|NCT06531629|PROCEDURE|Surgery, radiation therapy and chemotherapy|Surgery, radiation therapy and chemotherapy
214950648|NCT06147960|DIAGNOSTIC_TEST|Immunohistochemistry|Blocks containing formalin-fixed, paraffin-embedded (FFPE) biopsies will be used to analyse the expression of XIAP, cIAP1 and cIAP2 proteins by immunohistochemistry. The antibodies will be selected on the basis of the literature and their validation for this technology (Schnoell et al. 2020). The immunohistochemical techniques will be performed on an automated immunolabelling machine (DakoLink®) after antigen demasking. The specific binding of primary antibodies will be revealed by the application of Flex reagent (Dako Agilent), a dextran polymer coupled on the one hand to anti-mouse and anti-rabbit immunoglobulins, and on the other hand to a large number of horseradish peroxidase (HRP) molecules. 3,3'-Diaminobenzidine (DAB) will be used as a substrate for this enzyme to highlight the specific expression of the biomarker. The use of an automated system will ensure the reproducibility of inter-sample labelling.
214950649|NCT06379568|OTHER|No intervention|No intervention
214950650|NCT04621838|OTHER|Assigned interventions.|"Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing.~The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited."
214950651|NCT03001479|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid|HMF with additional hydrolyzed protein
214343653|NCT03874364|OTHER|No monitor|Patients are not allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
214343654|NCT00189371|DRUG|paclitaxel, carboplatin, epoetin alpha|
214343655|NCT04888000|OTHER|Educational Intervention|Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
214343656|NCT03507166|DRUG|RC48-ADC|2 mg/kg IV every 2 weeks
214950652|NCT03715387|DRUG|Tacrolimus Topical 0.1% Topical Ointment|Topical tacrolimus ointment
214343657|NCT01173848|DRUG|Ergocalciferol|1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
214950653|NCT03715387|DRUG|Polysporin Ointment|Polysporin ointment
214950654|NCT02314754|DRUG|Mifepristone followed by misoprostol 24-48 hours later|200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
214950655|NCT03718754|DEVICE|En-Bloc TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. Laser resection, hydrodissection with HybridKnife® or electric resection are allowed. All procedures, including cTURB, must be performed with an imaging enhancing technique (PDD / NBI at surgeon's discretion). After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
214950656|NCT03718754|DEVICE|Conventional TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
214950657|NCT03632577|DEVICE|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
214950658|NCT03632577|DEVICE|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.
214950659|NCT00659776|DRUG|Ferumoxytol|Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2\* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
214950660|NCT02055274|DRUG|LY03003|
214950661|NCT02055274|DRUG|Neupro|
215076274|NCT00712218|PROCEDURE|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions \[24, \].
215076275|NCT04643639|DEVICE|CytoSorb hemoperfusion|Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
215076276|NCT04421859|OTHER|EyeCU Mobile Application|Augmented reality glaucoma education mobile phone application
214343658|NCT01173848|DRUG|Cholecalciferol|1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
214343659|NCT04360824|DRUG|Intermediate dose thromboprophylaxis|2\) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
214950662|NCT03972020|BEHAVIORAL|Mindfulness Based Intervention|"The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on:~(1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a window of tolerance in order to maximize the clinical utility of the intervention and tailor it to breast cancer patients."
214950663|NCT03972020|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavior therapies will include cognitive restructuring, relaxation, skills training, and visual imagery, among other modalities.
214950664|NCT01196663|DEVICE|Intraoperative temperature measurement by TMS thermometer|Measurements will be taken from the patient's body using a biocompatible patch that will transfer data to the receiving unit. The patch will be sterilized before each surgery.
214950665|NCT01196663|DEVICE|Esophageal or urinary bladder temperature measurement|Standard temperature measurement as is being measured from patients during surgery today
214950666|NCT00005624|DRUG|CI-994|CI-994 as outlined in treatment arm.
214950667|NCT01180049|DRUG|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
214950668|NCT01180049|DRUG|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
214950669|NCT03050112|OTHER|MacNew questionnaire|Patients will be asked to fill in the MacNew questionnaire on quality of life (phone contact).
214950670|NCT00659542|PROCEDURE|cyanoacrylate glue|1 ml glue
214950671|NCT04504175|DRUG|Ketamine|ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight over 40 minutes
214950672|NCT02585388|DRUG|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
214950673|NCT02585388|DRUG|Letrozole|Lestrozole at 2,5 mg every day , per oral
214950674|NCT02585388|DRUG|Anastrozole|Anastrozole at 1 mg every day, per oral
215076277|NCT03217370|OTHER|education of guidelines|"* Guidelines will be updated and education will be given to haematologists in several ways.~* ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
215076278|NCT04266509|DRUG|PF-06651600|50 milligram (mg) tablet
215076279|NCT04266509|DRUG|Rifampin|600 mg provided as two 300 mg capsules.
215076280|NCT03688698|RADIATION|PET/MRI|PET/MRI scans
214950675|NCT05920785|DIAGNOSTIC_TEST|Determination of the level of interleukins in the blood, stool analysis for the intestinal microbiome, general clinical tests, glucose tolerance test, hormonal profile|"comprehensive laboratory and instrumental diagnostics in accordance with federal clinical guidelines on obesity (Peterkova V. A., 2021), including:~* general blood test, general urine test,~* biochemical blood analysis (total protein, urea, creatinine, total bilirubin, AST, ALT, total cholesterol, high and low density lipoproteins, triglycerides, uric acid, alkaline phosphatase, C-reactive protein),~* hormonal profile (T4 free, TSH, cortisol, C-peptide, fasting insulin, stimulated insulin),~* glycated hemoglobin,~* \- glucose tolerance test,~* ultrasound examination of abdominal organs, kidneys (in the presence of arterial hypertension),~* blood pressure monitoring.~Special laboratory methods:~* Blood test to determine the level of HCRP, pro-inflammatory cytokines (leptin, IL-1b, IL-6, IL-8, tumor necrosis factor-α).~* analysis of feces for microbiota by MALDI-TOF mass spectrometry,~* bioimpedance measurement."
214343660|NCT04360824|DRUG|Standard of Care thromboprophylaxis|Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
214950676|NCT01559688|BEHAVIORAL|Accelerated Resolution Therapy (ART)|ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.
214343661|NCT05107362|DIAGNOSTIC_TEST|untrained lay user performs investigational diagnostic test|Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
214950677|NCT01559688|BEHAVIORAL|Waitlist|Fitness assessment or career counseling
214950678|NCT04409015|DEVICE|ROTEM - rotation thromboelastometry testing|The ROTEM® is a simple blood test that provides information about specific components involved in blood clotting and stopping hemorrhage.
214950679|NCT00696228|DIETARY_SUPPLEMENT|Placebo|Placebo
214950680|NCT00696228|DIETARY_SUPPLEMENT|MUFA|MUFA
214950681|NCT00696228|DIETARY_SUPPLEMENT|PUFA|PUFA
214343662|NCT03353428|BIOLOGICAL|LC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time
214678381|NCT01479088|DRUG|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value \<180 pg/mL as tolerated by the patient
214950682|NCT00696228|DIETARY_SUPPLEMENT|SFA|SFA
214343663|NCT04894474|DRUG|BI 767551 intravenous|BI 767551 intravenous
214950683|NCT02004327|DRUG|DW1029M300mg|DW1029M300mg PO Once
214950684|NCT02004327|DRUG|DW1029M600mg|DW1029M300mg 2 tablets Once
214950685|NCT02004327|DRUG|DW1029M1200mg|DW1029M300mg 4 tablets PO Once
214950686|NCT03875976|PROCEDURE|Fast Track Protocol|Fast Track Care consists in educational preoperative preparation for patients, particular strategies for controlling pain and intensive early rehabilitation protocol
214950687|NCT03875976|PROCEDURE|Standard Care Protocol|Standard Care Protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol
214950688|NCT06731231|DRUG|SGLT2 inhibitor|Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents used in the treatment of type 2 DM by improving glycemic control, weight reduction, blood pressure control and albuminuria. the use of SGLT2i as a cardiorenal protective tool may be of particular value in renal transplant patients due to the risk of multiple comorbidities such as diabetes and hypertension. Recently, sodium-glucose transport protein 2 inhibitors (SGLT2i) emerged as a new class of therapeutics with beneficial effects on both cardiovascular (CV) and kidney outcomes in patients with diabetic kidney disease, nondiabetic proteinuric chronic kidney disease (CKD), and heart failure with and without diabetes in patients with native kidneys
214950689|NCT05731167|BEHAVIORAL|Multidomain frailty prevention method|We use the nutrition, physical training, medication consultation, cognition training to prevent the occurrence of frailty or other adverse outcome.
214950690|NCT05731167|OTHER|Regular follow up|Subjects will receive regular follow up and suggestion in outpatient department.
214950691|NCT04008264|DRUG|Scopolamine Patch (Transderm V)|During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
214950692|NCT00300833|DRUG|Tirofiban|pci
214950693|NCT01036633|DEVICE|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
214950694|NCT03986554|PROCEDURE|Videofluoroscopic swallow study|The Swallowing Systems Core laboratory is fully equipped to perform VFSS with a C-arm (OEC 9900) that is dedicated solely for research purposes. VFSS recordings will be kept to a minimum and only turned on during the execution of each swallow in all sequences. Video recording and images captured during the VFSS will be synced and saved to a secure server for data analysis. VFSS allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the hyolaryngeal complex during swallowing) cannot be visualized with any other technique. Patients will swallow only water. Aspiration (bolus into trachea) is not expected to occur during this study given that the individuals recruited will have no prior history of disease or disorder, and aspiration is uncommon in healthy individuals.
214950695|NCT03986554|PROCEDURE|pharyngeal High Resolution Manometry|This procedure will only take place once during sequence 2 of the randomization B session. If desired, a small amount (\< 0.5 mL) of topical 2% viscous lidocaine hydrochloride will be applied to the participant's nostril of choice prior to catheter insertion. The catheter will be placed through the nasal passage, oropharynx, and hypopharynx to the esophagus. Correct catheter placement will be verified with VFSS. With the catheter in place, the subject will perform 10 swallows of 10ml and is expected to take approximately 2.5 minutes. The catheter will then be removed and the subject will move on to sequence 3. Individuals have the option to decline this procedure if it is uncomfortable or difficult to tolerate.
214950696|NCT00350779|DRUG|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
214950697|NCT00350779|DRUG|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
214950698|NCT00350779|DRUG|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
214950699|NCT00350779|DRUG|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
214950700|NCT00350779|DRUG|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
214950701|NCT00005762|DRUG|Indinavir sulfate|
214950702|NCT00005762|DRUG|Ritonavir|
214950703|NCT00005762|DRUG|Amprenavir|
214950704|NCT00005762|DRUG|Nelfinavir mesylate|
214950705|NCT00005762|DRUG|Efavirenz|
214950706|NCT00005762|DRUG|Saquinavir|
214950707|NCT00760812|BEHAVIORAL|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
214950708|NCT00760812|BEHAVIORAL|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
214950709|NCT02968680|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLNB
214950710|NCT02968680|DEVICE|Ultrasonography|Undergo sonazoid-enhanced ultrasonography
214950711|NCT02968680|DRUG|Sonazoid|Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging.
214950712|NCT01053338|DRUG|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
214950713|NCT03482895|BIOLOGICAL|Blood sampling|Quantitative analysis of enterohormones, citrulline and ApoB48
214950714|NCT03482895|BIOLOGICAL|Feces sampling|Intestinal absorption assessment
214950715|NCT03337906|OTHER|Observation|
214950716|NCT04318262|BIOLOGICAL|Determination of the clinical and biological characteristics|"* clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis…), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications…~* biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP…"
214950717|NCT04318262|BIOLOGICAL|Description of the antibiotic resistance profile|Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique
214950718|NCT04318262|BIOLOGICAL|Molecular epidemiology of S. lugdunensis infections|Genome sequencing (Illumina technique)
214950719|NCT03464474|DEVICE|digital holographic microscopy|Colonic biopsies from all patients will be assessed using digital holographic microscopy in comparison to the existing Goldstandard (histopathological analysis).
214950720|NCT02972450|BIOLOGICAL|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection."
214950721|NCT02972450|BIOLOGICAL|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection. Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline."
214950722|NCT02972450|DRUG|Vedolizumab 300 MG [Entyvio]|Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
214343664|NCT04894474|DRUG|BI 767551 inhalation|BI 767551 inhalation
214343665|NCT04894474|DRUG|Placebo intravenous|Placebo intravenous
214343666|NCT04894474|DRUG|Placebo inhalation|Placebo inhalation
214343667|NCT00320216|DRUG|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
214343668|NCT00320216|DRUG|Placebo|Patients in the placebo group will receive placebo medication.
214343669|NCT02265705|DRUG|Baricitinib|Administered orally
214343670|NCT02265705|DRUG|Placebo|Administered orally
214343671|NCT05580900|OTHER|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment.
214950723|NCT02972450|OTHER|Placebo|"Placebo for MVA it is a solution composed of S08 buffer (as for the MVA vaccine) that will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.~Placebo for GTU-MultiHIV B-clade vaccine: Sodium Chloride (NaCl) for infusion, 0.9%.~Placebo for Vedolizumab: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
214950724|NCT05206786|OTHER|Conventional preventive work out|Female players in the control group will carry out a conventional preventive work that is organised in 3 training days per week. First training session includes preventive strength and proprioception exercises. Junior and senior teams (above 16 years old) will also do plyometrics exercises. In the second training session, players will do preventive strength exercises with an increased load compared to the previous session and proprioception exercises. Junior and senior players will also do anaerobic work. In the third session, players will perform reaction speed exercises.
214950725|NCT05206786|OTHER|Gluteus maximus strengthening specific program|"Female players will carry out a gluteus maximus strengthening work out in addition to the control group programme. Of the following four exercises, the first and the third ones will be done on the first training session and the second and the fourth exercises will be done on the second one. Dosage will be 2 sets of 10 repetitions for each leg.~1. Clam Shell: Lateral decubitus with the knees and hips bend, the working leg placed on top of the other. Separate this knee while feet stay in contact.~2. Unilateral gluteal bridge: Supine decubitus with one foot flat on the floor and bent knee. This leg pushes the ground with the foot until the pelvis is lifted while the other leg remains straight.~3. Quadruped hip extension with knee extension : Quadruped on forearms. Straighten the hip by bringing the whole leg up and back with knee extension.~4. Quadruped hip extension with bent knee: Performed as the previous one, but during this one, the knee of the working leg is bent at 90º."
214950726|NCT04159324|OTHER|optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation|the optimized treatment pathway includes coordinated transitions between rehabilitation phases and institutes using individual case management and portal solutions
214950727|NCT03571022|BEHAVIORAL|USE-MI System|"Pilot Phase: 10 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for 1 month and receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s).~Second Phase: Up to 50 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for up to 6 months. During their first month, subjects will receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s). Subjects will then have monthly follow-up visits to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s)."
214950728|NCT05059925|OTHER|Structured gym activities|"Planned and structured activities such as Strength training~* Dumbbell Exercises (1kg with 2 sets of 10 repetitions)~* Sit-ups (2 sets of 10 repetitions)~* Stair climbing, (2 sets of 10 stairs up and down)~* Squat (2 sets of 10 repetitions) Flexibility training • Tai chi (Peng. Lu, chi, an Tsai, lieh, chou, Kao (Hold each posture for 20 seconds)) • Pilates (Breathing., Shoulder bridge, Leg lifts (Hold each pose for 20 seconds)) • Stretching techniques (Neck stretch, Shoulder stretch, Side stretch Hold each stretch for 20 seconds))."
214950729|NCT05059925|OTHER|Traditional aerobic activities|"Activities performed such as~* Treadmill Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Cycle ergometer Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Elliptical exercises Time: 10 minutes Intensity: 60 to 80% of target heart rate"
214950730|NCT02094248|DRUG|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000U/ml, s.c injection
214950731|NCT02094248|DRUG|control|Normal saline，1ml/day, s.c injection
214950732|NCT00588939|DEVICE|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
214950733|NCT06040216|OTHER|optical coherence tomography|We observed the postoperative improvement in EIFL severity with optical coherence tomography
214950734|NCT01864252|OTHER|Remote ischaemic preconditioning|3 cycles of 5 minutes to arm and legs
214950735|NCT01864252|DRUG|IV Normal saline|Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.
214950736|NCT01864252|DRUG|IV Glyceryl trinitrate 2-5ml/h|IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
214950737|NCT00989859|DEVICE|Plethysmographic monitoring|Plethysmographic monitoring
214950738|NCT06101537|DEVICE|Brain temperature-pressure monitoring|An intracranial pressure monitoring device that continuously records brain temperature-pressure data was used during treatment.
214950739|NCT01979237|PROCEDURE|SPASO method and FARES method|SPASO method and FARES method as shoulder dislocation reduction methods
214950740|NCT02087137|BEHAVIORAL|Memory and Aging Program|
214950741|NCT01832909|OTHER|Walnut Diet|Controlled diet with 1.5 oz/d of walnuts.
214950742|NCT01832909|OTHER|Control Diet|Controlled diet without walnuts.
214950743|NCT06910280|PROCEDURE|conservative surgery for breast cancer with local anesthesia|conservative surgery for breast cancer with local anesthesia
214950744|NCT06910280|PROCEDURE|conservative surgery for breast cancer with general anesthesia|conservative surgery for breast cancer with general anesthesia
214950745|NCT02360748|DIETARY_SUPPLEMENT|Plant based high protein food items|Patients will add high protein plant based food items to their diet
214950746|NCT02946489|DRUG|CI-581a|CI-581a will be administered in wk2 and potentially in wk 3 or 4.
214950747|NCT01356329|DRUG|Enoxaparin, Heparin|"Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician."
214950748|NCT01358240|DRUG|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
214950749|NCT01358240|DRUG|Vehicle Foam|Vehicle Foam applied once a day for 4 week
214950750|NCT01358240|DRUG|Econazole Nitrate Cream 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
214950751|NCT01358240|OTHER|Placebo Cream|Placebo cream applied once a day for 4 weeks
214950752|NCT03996564|DEVICE|Battlefield Acupuncture|1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.
214950753|NCT03996564|DRUG|Acetaminophen|Acetaminophen 500mg-1000mg,
214950754|NCT03996564|DRUG|Diclofenac|Diclofenac 50mg-75 mg orally
214950755|NCT03996564|DRUG|Diazepam|Diazepam 5mg-10 mg intravenous or oral
214950756|NCT03996564|DRUG|Hydrocodone|Hydrocodone 5mg/325mg-10mg/650mg mg
214950757|NCT03996564|DRUG|Ketorolac|oral, or intramuscular Ketorolac 30mg-60 mg
214950758|NCT00105287|DRUG|OraVescent fentanyl (OVF)|
214343672|NCT05580900|OTHER|Live Modality (control)|For this evaluation, the live or in-person modality is considered the control group.
214343673|NCT01375296|DEVICE|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
214343674|NCT01375296|OTHER|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
214343675|NCT05846009|DRUG|SAR442501|Subcutaneous injection
214343676|NCT05846009|DRUG|Placebo|Subcutaneous injection
214950759|NCT00724802|DIETARY_SUPPLEMENT|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
214343677|NCT00377676|DRUG|Cycloset|Usual diabetes therapy plus Cycloset
214950760|NCT00724802|DRUG|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
214950761|NCT01158014|PROCEDURE|Fibrin Glue, Quixil|quixil 0.1 ml
214950762|NCT01158014|PROCEDURE|Suture|vicryl 10/0
214343678|NCT00377676|DRUG|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
214343679|NCT01060293|DRUG|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
214343680|NCT01060293|DRUG|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
214950763|NCT02919007|DEVICE|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
214950764|NCT00884845|DRUG|PM02734 and erlotinib|PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion
214950765|NCT00884845|DRUG|Erlotinib|Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
214950766|NCT00028522|DRUG|R(+)XK469|Given IV
214950767|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
214950768|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
214950769|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
214950770|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
214950771|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
214950772|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
214950773|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
214950774|NCT04564105|BEHAVIORAL|simulation education|Intubation protocol will be trained by simulation exercise.
214950775|NCT04361097|BIOLOGICAL|Faecal microbiota transplant|Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
214950776|NCT04361097|BIOLOGICAL|Placebo|Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
214950777|NCT06262022|OTHER|cold therapy|A cold ice pack will be applied to the patient's knee for 20 minutes every hour for three days, starting after total knee arthroplasty.
214950778|NCT01399398|PROCEDURE|Brain Scan-PET|
214950779|NCT01399398|PROCEDURE|Brain Scan-MRI|
214950780|NCT01399398|PROCEDURE|Arterial Line|
214950781|NCT01399398|PROCEDURE|Venous Line|
214950782|NCT01399398|PROCEDURE|Blood Sampling|
214950783|NCT06067581|BIOLOGICAL|SENL103|Patients will be treated with BCMA CAR-T cells
214950784|NCT00761371|DRUG|Imiquimod 5% cream|Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
214950785|NCT04521842|PROCEDURE|Total hip replacement|Total hip replacement in treatment of end-stage osteoarthritis
214950786|NCT03548350|BEHAVIORAL|HealthyKidz physical activity programme|A 24 week physical activity intervention to promote fitness and wellbeing in primary schools
214343681|NCT01060293|DRUG|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
214343682|NCT02853968|PROCEDURE|Blood draw/buccal swab|The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
214343683|NCT03421197|DRUG|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg tablet once per day
214343684|NCT03421197|DRUG|PPC-06 400 mg BID|Tepilamide Fumarate tablets 400 mg twice per day
214343685|NCT03421197|DRUG|PPC-06 600 mg|Tepilamide Fumarate tablets 600 mg twice per day
214343686|NCT03421197|DRUG|Placebo|white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
214950787|NCT03550547|OTHER|Educational workshops|1 workshop : Knowledge of the pathology ; 2a workshop: Educational physical activity; 2b workshop : Educational physical activity; 4 workshop : Dietary; 5 workshop : Management of pain, fatigue and the medical treatments; 6 workshop : Articular hygiene and ergonomics; 7 workshop : Technical assistance, an adaptation of the living condition
214950788|NCT03550547|OTHER|Spa Therapy|Approved Spa therapy of knee osteoarthritis patients
214950789|NCT06955689|OTHER|Non invasive focal vibration with heads|3 sessions over 3 consecutive weeks, with one intervention day per week. Non invasive focal vibration at 120 Hz for 10 minutes while pedaling at 90-100 rpm
214343687|NCT01821781|DRUG|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
214343688|NCT02505646|OTHER|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
214343689|NCT00779246|OTHER|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
214343690|NCT00779246|DRUG|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
214343691|NCT00779246|OTHER|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
214950790|NCT06955689|OTHER|Non invasive focal vibration without heads|3 sessions over 3 consecutive weeks, with one intervention day per week. Non invasive focal vibration at 0 Hz for 10 minutes while pedaling at 90-100 rpm
214950791|NCT03015194|DEVICE|Edwards SAPIEN 3 transcatheter heart valve|"Used to relieve aortic stenosis in patients with symptomatic heart disease~In this study it is not used for aortic stenosis-----the device is used in the mitral valve position."
214950792|NCT03015194|DEVICE|ASHI INTECC Astato XS 20|"The Astato 0.014 guidewire is used for transcatheter electrosurgery in two steps in this procedure. First it is used for leaflet traversal during electrification. This procedure is similar to the use of the Astato XS20 and an amputated Asahi Confienza Pro 12 in the transcaval IDE investigation recently published. Second, the midshaft is focally denuded and electrified for the leaflet traversal step."
214950793|NCT02707172|BEHAVIORAL|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
214950794|NCT02707172|BEHAVIORAL|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
214950795|NCT02844894|DRUG|Dexmedetomidine|
214343692|NCT05237765|OTHER|controlled (automatic) massage|Massage methods that are performed with mechanical methods are called automated massage. Automated massage is also individual-controlled massage. This is because in automated massage, to relax, solve or reduce their pain, the individual applies the massage under their own control or under the control of someone else through a controller in a way where the duration and intensity of the massage in the body part of application vary. Individual-controlled massage devices may be in the form of chairs, cushions, beds and mattresses. These massage devices have functions such as vibrating, applying vacuum, imitating manual massage motions and applying heat.
214343693|NCT02523534|PROCEDURE|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
214343694|NCT02523534|PROCEDURE|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
214343695|NCT04715594|DEVICE|1st-generation drug-eluting stent|Implantation of 1st-generation drug-eluting stent
214343696|NCT04715594|DEVICE|2nd-generation drug-eluting stents|Implantation of 2nd-generation drug-eluting stent
214343697|NCT05042219|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter
214343698|NCT05204524|DRUG|Temozolomide for injection combined with epirubicin|Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months.
214343699|NCT06216626|DIETARY_SUPPLEMENT|myota's prebiotic fibre blend|"Each 10g daily serve of supplement contains the following fibres:~* Fructooligosaccharides~* Inulin~* Resistant dextrin~* Resistant maltodextrin~* Partially hydrolysed guar gum~* Guar gum"
214343700|NCT02446808|DEVICE|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
214950796|NCT02844894|DRUG|Esmolol|
214950797|NCT02844894|DRUG|Placebo|normal saline
214950798|NCT03866629|DRUG|Lifitegrast|Lifitegrast ophthalmic solution 5%
214950799|NCT05633589|BIOLOGICAL|Sc610 cell injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell product preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and amplification factor, and cell quantity are amplified. The obtained Sc610 is used for one-time intravenous infusion."
214950800|NCT04611282|PROCEDURE|surgical techniques in the treatment of localized gingival recession defects.|Micro or macrosurgical echniques were performed using a coronally positioned flap with a subepithelial connective tissue graft.
214343701|NCT05319691|BEHAVIORAL|Yoga|The trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment Phase during which, yoga participants will receive a reproducible standardized weekly yoga intervention delivered virtually with additional resources for home practice, followed by a 12-week Follow-up Phase.
214950801|NCT05989919|OTHER|CT scan for nose and paranasal sinuses|CT scan for nose and paranasal sinuses
214950802|NCT06304402|DEVICE|The Percussive Massage Treatment|In the group where regional vibration is applied, the Hypervolt™ vibrating massage device (HYPERICE Inc, US) will be used. This device is a vibration device with five different speed settings, vibrating at 3,200 percussions per minute (HYPERICE Inc. 'Hypervolt' device. Retrieved from https://hyperice.com/hypervolt-bluetooth, Accessed on: 08.12.2021). The device offers five different head attachment options. For this study, the ball attachment option will be selected as it is the least aggressive option, and the vibration from the device will be applied to the relevant muscle body (Kayoda, 2019). For facilitatory effect, the application will be performed on the posterior deltoid for 5 minutes at a low frequency.
214950803|NCT06304402|BEHAVIORAL|The Proprioceptive Neuromuscular Facilitation Stretching|Among the PNF stretching techniques, the muscle-relaxation technique will be applied. The athlete will be positioned in a side-lying posture on the treatment table with the dominant shoulder in the modified sleeper position, ensuring stabilization of the scapula on the table. The other arm will be positioned in extension along the body with the palm facing upwards. The participant will be instructed to actively bring the arm of the lower limb to the physiological barrier of internal rotation. At this point, they will be asked to perform maximum isometric contraction in external rotation for 7 seconds. After the isometric contraction, the muscle will be relaxed, and active-assisted stretching will be applied in internal rotation for 15 seconds. A 5-second rest will be provided between repetitions, and the exercise will consist of 5 repetitions.
214950804|NCT04757805|DIAGNOSTIC_TEST|Ultrasound|Ultrasound to locate the appropriate lumbar interspace to perform spinal anesthesia.
214950805|NCT02469168|DEVICE|Recell|ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix
214950806|NCT02469168|PROCEDURE|Control|Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
214950807|NCT04191343|DRUG|Toripalimab injection combined with GEMOX|Toripalimab Injection (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w)
214950808|NCT00433017|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of the infusion.
214950809|NCT00433017|DRUG|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
214950810|NCT00433017|DRUG|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
214950811|NCT03323970|OTHER|semi-structured interviews|individual semi-structured interviews
214950812|NCT03955900|OTHER|No intervention|Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
214950813|NCT05498064|DRUG|Ensartinib|Ensartinib 225 mg administered once daily orally
214950814|NCT02222116|DEVICE|MGuard Prime|
214950815|NCT02222116|DEVICE|Control BMS DES|
214950816|NCT03180931|DEVICE|Bioresorbable vascular scaffold|"No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.~Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants."
214950817|NCT04823806|DIETARY_SUPPLEMENT|Spermidine (spermidineLIFE ®) OR Placebo|21 day of 6mg spermidine OR Placebo supplementation per day
214950818|NCT01872806|RADIATION|a dialing smartphone will be placed on the chest and the ear|
214950819|NCT01277432|OTHER|Psychiatrist Interview|"Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~* MINI~* SSI-28 (somatization)"
214950820|NCT01277432|OTHER|Depression screening - control|"All study participants will undergo;~1. a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal~2. a detailed psychological and behavioral assessments using validated questionnaires~3. several specialist questionnaires on depression, self care and quality of life"
214950821|NCT04563637|DIAGNOSTIC_TEST|Computer based vision application by video|patients will be tested by computer based analysis of a video as well as by dexa scan.
214950822|NCT04563637|RADIATION|whole body dual energy x-ray absorptiometry scan|subjects will receive a whole body dual energy x-ray absorptiometry scan to measure their body fat percentage
214950823|NCT04193553|DRUG|Lenvatinib|"Lenvatinib will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for dose reductions will be respected according to BI Lenvatinib.~If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met."
214950824|NCT04193553|DRUG|Placebo|"Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.~In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm."
214343702|NCT04153409|DRUG|LAT8881|Two 30 mg capsules of LAT8881
214343703|NCT04153409|DRUG|Placebo|Two capsules of placebo
214343704|NCT04844281|DEVICE|Precision1® Daily Disposable Toric Contact Lens|Soft, toric contact lens used to correct distance vision and astigmatism.
214678382|NCT06077058|OTHER|Nicotine Replace Therapy (NRT) sampling|The intervention involves a Zoom/WhatsApp meeting or face-to-face session with a trained counselor who introduces NRT use, possible side effects, and patch dosage based on a previous RCT guide. An online intervention pack with a pamphlet and 1-week free NRT sample (14mg or 21mg patch) is mailed to participants. After 1 week, the counselor follows up. If participants need more patches, an additional pack is mailed, and they are advised to obtain further patches from smoking cessation services or pharmacies. NRT patch users may experience skin reactions, insomnia, or vivid dreams; if severe side effects occur, they are asked to stop using NRT.
214678383|NCT06077058|BEHAVIORAL|Simple exercise education (SEE)|All participants will be given a handgrip at study enrolment. The SEE includes a Zoom/WhatsApp meeting or face-to-face session including 1) watching a 5-minute video (www.youtube.com/watch?v=mZex2Wwy3fU) showing a chair professor of public health demonstrating the 10s-E, including the simple exercises with and without handgrip. The video also encourages participants to 1) follow the exercise instructions during the video demonstration; 2) perform the exercises whenever they experience craving or an urge to smoke during the quitting process; and 3) increase their exercise frequency and intensity as much as possible, which may also increase their grip strength. Participants will also receive a leaflet with exercise instructions and motivational messages.
214950825|NCT04193553|OTHER|Best supportive care|At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy…
214950826|NCT00562731|DRUG|ARD-0403|Daily transdermal ARD-0403
214343705|NCT03988179|DIAGNOSTIC_TEST|The Cholinesterase Inhibitor Prognosticator (ChIP) application for iPad|The first part of this application will be used, consisting of a visual vigilance test based on the Continuous Performance Test (CPT). Stimuli consist of a one digit number presented in the middle of the screen. For each trial the application randomly selects a specific number as the target stimulus. Patients are instructed to keep their dominant trigger finger close to the screen and press a button which is located at the bottom of the screen, whenever the target appears. In case another stimulus appears the patient is instructed to do nothing. Each stimulus is presented until the patient presses the button (maximum 3 sec.). Stimuli are presented in a random fashion with a 1, 2, 3, 4, or 5 second inter-stimuli-interval blank, which randomly varies. After an 8 stimuli practice trial, the test starts and a total of 50 stimuli are presented with a 50% target rate. Full-trial duration is approximately 5 minutes. During the trial, reaction time and accuracy of response are registered.
214343706|NCT06112210|OTHER|HBOT group|The HBOT will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The HBOT group will be exposed to 100% oxygen at 2.2 ATA (atmospheres absolute). Session will last 70 minutes.
214343707|NCT06112210|OTHER|CON group|The placebo protocols will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The CON group will be exposed to normobaric ambient pressure (1 ATA). The session will last 70 minutes.
214343708|NCT04442217|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
214343709|NCT00233935|OTHER|placebo|Given PO
214343710|NCT00233935|DRUG|defined green tea catechin extract|Given PO
214343711|NCT04592757|DEVICE|Virtual mirror therapy via VR headset|Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
214343712|NCT03660683|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg PO QD
214950827|NCT01741350|BEHAVIORAL|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
214950828|NCT01741350|BEHAVIORAL|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
214950829|NCT00255840|BEHAVIORAL|Monitoring by an HIV-trained medical doctor|Participants will receive care from an HIV-trained medical doctor
214950830|NCT00255840|BEHAVIORAL|Monitoring by an HIV-trained primary care nurse|Participants will receive care from an HIV-trained primary care nurse
214950831|NCT00255840|DRUG|Efavirenz|600 mg tablet taken orally daily
214950832|NCT00255840|DRUG|Lamivudine|150 mg tablet taken orally daily
214950833|NCT00255840|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
214950834|NCT00255840|DRUG|Nevirapine|200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
214950835|NCT00255840|DRUG|Stavudine|Tablet taken orally daily. Dosage depends on weight.
214950836|NCT04680832|DIAGNOSTIC_TEST|Electronic nose|First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow \<0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.
214950837|NCT04415021|OTHER|Experimental: Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
214950838|NCT04415021|OTHER|Sham Comparator: Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
214343713|NCT03660683|DRUG|Saxagliptin 5mg|Saxagliptin 5 mg PO QD
214343714|NCT03660683|DRUG|Placebo Oral Tablet|Matching Placebo Tablets
214950839|NCT00715520|OTHER|Transcranial Magnetic Stimulation (TMS)|Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single-pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post-training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
214950840|NCT00715520|DRUG|Carbidopa-Levodopa|"Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant."
214950841|NCT00715520|DRUG|Methylphenidate|"Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant."
214950842|NCT00715520|DRUG|Amphetamine Sulfate|"Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant."
214950843|NCT00715520|DRUG|Placebo|"Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant."
214950844|NCT00715520|OTHER|Sham Transcranial Magnetic Stimulation (TMS)|Sham TMS pulses will be randomly administered during TMS sessions.
214950845|NCT00715520|OTHER|Transcranial Magnetic Stimulation (TMS) Training|TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
214950846|NCT03332095|DRUG|Doravirine (DOR)|100 mg of DOR administered orally
214950847|NCT03332095|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)|DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg) once daily
214950848|NCT03332095|DRUG|Antiretroviral (ARV) medications|Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
214950849|NCT06035211|OTHER|3D model pré-operative education|Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group
214950850|NCT04617483|BIOLOGICAL|Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the commercial scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 26-45.
214343715|NCT06114797|OTHER|Chamomile|"* Chamomile was topically applied to the oral mucosa as oral rinse.~* Based on this protocol, patients had oral rinses 3 times per day.~* Patients were instructed to perform chamomile rinses in the oral mucosa.~* Patients were instructed not to swallow the chamomile oral rinse."
214343716|NCT06114797|OTHER|Saline mouthwash|Saline mouthwash was used by elderly patients in the control arm.
214950851|NCT04617483|BIOLOGICAL|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 18-59.
214950852|NCT04617483|BIOLOGICAL|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group above 60.
214950853|NCT00895934|DRUG|vorinostat|Given orally
214950854|NCT00895934|DRUG|gemtuzumab ozogamicin|Given intravenously (IV)
214950855|NCT00895934|DRUG|azacitidine|Given IV or subcutaneously (SC)
214950856|NCT00560898|DRUG|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
214950857|NCT00560898|DRUG|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
214950858|NCT00560898|DRUG|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
214950859|NCT00560898|DRUG|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
214950860|NCT01331135|DRUG|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
214343717|NCT00941603|DRUG|SCH 900271 15mg|oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
214343718|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
214343719|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
214343720|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
214343721|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
214343722|NCT00941603|DRUG|Placebo|oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
214343723|NCT03862404|DRUG|Bupivacaine-epinephrine|See previous description
214343724|NCT03862404|DRUG|Normal saline|See previous descreption
214343725|NCT06148129|DIAGNOSTIC_TEST|Tissue Biopsy|The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM
214343726|NCT04631822|PROCEDURE|Spinal anaesthesia|spinal anesthesia shall be conducted with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position.
214950861|NCT05447026|DEVICE|Control group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, the sites in the control group received only saline irrigation for 1 min.
214950862|NCT05447026|DEVICE|Antimicrobial photodynamic therapy (aPDT) group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, aPDT group received additional application of a diode laser with a wavelength of 810 nm and a power rating of 200 mW (continuous mode). Indocyanine-green (ICG) as a photosensitizer at a concentration of 1 mg/ml was applied at the surgical site on both the buccal and the lingual sides of the flaps. Irradiation was performed in non-contact mode in a constant distance of 1 mm during 30 s per site
214950863|NCT05447026|DEVICE|LED photobiomodulation group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, irradiation was carried out with a LED device with a wavelength of 626 nm in the near-infrared region at a dose of 20 mw/cm2 for 20 min with a total energy of 222 J
214950864|NCT05447026|DEVICE|Topical ozone group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, topical ozone group received ozone application with an ozone generator at 80% concentration using probe #3 for 30 s per site
214950865|NCT05356650|OTHER|Mulligan Mobilization|The patient will be in a prone position. With one hand, the physiotherapist will fix the sacrum and place the fingers of her other hand under the anterior superior iliac spine. The therapist then pull the ilium on the sacrum and will instruct the patient to do press-ups. Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
214950866|NCT05356650|OTHER|PNF|"PNF stretching will be performed using contract-relax techniques of agonists in supine, prone and side-lying. Contract-relax will be applied with a 6-second contraction with 80% force of the maximal isometric contraction on the muscles (iliopsoas, hamstrings and gluteal muscles) and will be followed by a 15-second passive static stretching in the opposite direction of that muscles. Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.~Patient will be in supine, prone, side lying. Both groups will receive a baseline treatment (Moist Heat Pack for 10 minutes and 10 minutes of Ultrasound (0.75 MHz, continuous wave)"
214950867|NCT03280316|PROCEDURE|surgery|patients with SVMs receive surgery
215076281|NCT04376957|BEHAVIORAL|Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool|"This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise."
214950868|NCT03280316|PROCEDURE|sacral neuromodulation|sacral neuromodulation (SNM) with InterStimTM
214950869|NCT03280316|PROCEDURE|botulinum toxin A injection|BOTOX
214950870|NCT03280316|DRUG|M receptor antagonist|Tolterodine
214950871|NCT00366652|DRUG|desvenlafaxine SR|
214950872|NCT00366652|DRUG|desipramine|
214950873|NCT00366652|DRUG|duloxetine|
214950874|NCT00407407|DRUG|ABI-007|80mg/m\^2 to 150mg/m\^2 IV every 3 weeks
214950875|NCT00407407|DRUG|Carboplatin|6 AUC IV every 3 weeks on the same day as ABI-007
215076282|NCT04376957|BEHAVIORAL|Standard of care consisting of standard counselling|Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
214343727|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexamethasone|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery. then, a 20-ml mixture of 0.25% bupivacaine, and 4 mg dexamethasone will be injected."
214343728|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexmedetomedine|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine, and 0.5 Mg/kg dexmedetomidine will be injected."
214343729|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine"
214343730|NCT02513654|DRUG|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
214343731|NCT02014116|DRUG|LY3009120 capsule|Administered orally.
214950876|NCT01054313|DRUG|Docetaxel (Taxotere)|Starting dose 30 mg/m\^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
214950877|NCT01054313|DRUG|Sirolimus (Rapamycin)|Starting dose 1 mg daily by mouth 1 time a day.
214950878|NCT01054313|DRUG|Prednisone|5 mg by mouth twice a day with prostate cancer.
214950879|NCT03013790|DRUG|Melatonin|Patients will receive Melatonin at 2 different doses or a placebo
214950880|NCT05491395|RADIATION|Hypofractionation|Hypofractionation scheme will comprise 40 Gy in 15 fractions
214950881|NCT04595084|BEHAVIORAL|Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|MBCT-R is designed to foster resilience and prevent new-onset anxiety and depression disorders or exacerbation of existing conditions. MBCT-R follows the MBCT structure of eight classes and one half-day retreat, with home practice and specific daily meditation, but is live-online and focuses on specific stressors (COVID-19, its economic and social consequences). Classes of 40-50 participants are led by 2 co-leaders. Participants have CHA MindWell Monitoring and telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
214950882|NCT04595084|BEHAVIORAL|Internet Cognitive Behavioral Therapy plus CHAMindWell|MoodGYM is based on CBT and interpersonal therapy targeting depression, anxiety, stress, and general psychological distress. MoodGYM has 6 sessions with five curriculum modules and a review session that can be completed within an 8-week period. iCBT participants will also be enrolled in CHA MindWell Monitoring and Support (CHA-MW). Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If there are difficulties with accessing iCBT technology or if monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
214950883|NCT04595084|BEHAVIORAL|CHAMindWell|Participants across arms will have CHA MindWell Monitoring and Technician support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
214950884|NCT04691687|DRUG|Furosemide|IV loop diuretic therapy
214950885|NCT04691687|DRUG|IV Solution|IV Placebo comparator
214950886|NCT04728984|DRUG|Nalfurafine Hydrochloride|"Nalfurafine Hydrochloride 2.5μg\*2~; Oral administration after dinner, once daily for 14 consecutive days"
214950887|NCT04728984|DRUG|Nalfurafine Hydrochloride+Placebo|Nalfurafine Hydrochloride 2.5μg+ A placebo pill; Oral administration after dinner, once daily for 14 consecutive days
214950888|NCT04728984|DRUG|Placebo|two placebo pills; Oral administration after dinner, once daily for 14 consecutive days
214950889|NCT02419794|PROCEDURE|endovascular treatment|endovascular treatment for acute ischemic stroke patients with large vessel occlusion
214950890|NCT04423562|OTHER|No intervention|No intervention
214950891|NCT03693001|DEVICE|Intermittent Exposure to Oxygen via Oro-Nasal Mask|Patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ATA) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask for 40 treatments over a 2 month period.
214950892|NCT01905774|DRUG|Deferasirox|
214950893|NCT04265300|DIETARY_SUPPLEMENT|Creative Roots|The Creative Roots beverage is a coconut water-based drink with three flavors Mixed Berry, Watermelon Lemonade, and Peach Mango. The ingredients are as follows and are the same for all three flavors: water, coconut water concentrate, citric acid, stevia leaf extract, natural flavor, rosemary extract (to preserve flavor). Contains: coconut
214950894|NCT03280706|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 50g in water 500ml
214950895|NCT03280706|DIETARY_SUPPLEMENT|Orange Juice|Orange juice 480ml + 20ml of water
214950896|NCT03280706|DIETARY_SUPPLEMENT|Coffee with milk|Coffee with milk (330 ml of milk + 220 of water)
214950897|NCT04801043|DRUG|XNW4107|XNW4107 250mg IV over 60 minutes as a single dose
214950898|NCT04801043|DRUG|Imipenem/Cilastatin|500mg/500mg IV over 60 minutes as a single dose
214950899|NCT04801043|DRUG|placebo|"Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose"
214343732|NCT05818735|OTHER|electroacupuncture (EA) treatment|The regular acupuncture treatment will be applied at the acupoints including Baihui (GV20), Yintang (GV29), Guanyuan (RN4), Qihai (RN6), bilateral ZuSanli (ST36) and bilateral SanYinjiao (SP6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for 'De qi' sensation. Three pairs of electrodes of the electroacupuncture apparatus will be connected to the needles of GV20 and GV29, and bilateral ST36 and SP6 for 25 minutes, delivering a continuous wave with a frequency of 2-8Hz which is based on the tolerance of each patient. The selection of matching acupuncture points will be determined by the acupuncturist according to the patients' different syndrome patterns.
214343733|NCT05818735|OTHER|sham acupuncture (SA) treatment|The sham acpunture treatment will be applied at the same acupoints as the EA treatment with the Streitberger placebo needles. When the blunt needle tip of the placebo needles touches the skin, the patient will get a pricking sensation, but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set on the table beside the patients and two pairs of electrodes will be connected to the needles at bilateral ST36 and SP6. Acupuncturists will turn on the apparatus but all indicators will be set to '0'. Participants will be informed when needles are removed after 25 minutes. Acupuncturists will use dry cotton balls to press the skin around the acupoints when withdrawing the needles so that patients can feel the withdrawal of the 'needles'.
214486549|NCT06182423|BEHAVIORAL|STEPS-CI (Support, Training, and Education for Pain Self-management- Cognitively Inclusive version)|This intervention is a community health worker (CHW)-led chronic pain self-management program designed for older adults with chronic pain and mild to moderate cognitive impairment. It is a 7-week intervention that includes two primary components: a website that includes brief instructional videos on pain management skills as well as testimonials from individuals living with the two target health conditions; and weekly telephone sessions with a CHW to support and motivate participants in setting goals related to pain management. Reminder strategies and content addressing pain management challenges related to cognitive impairment are incorporated throughout. Participants may choose to work with a care partner during intervention activities.
214950900|NCT06356324|OTHER|Music Intervention|Participants assigned to 20 minutes of music listening
214950901|NCT06356324|OTHER|Television Intervention|Participants assigned to 20 minutes of television viewing
214950902|NCT04279990|OTHER|No intervention: assessment of GI function|"Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria."
214950903|NCT06195176|OTHER|Shoulder exercises|"Operational Definition:~* Lift the shoulders as high as possible toward the ears.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night."
214950904|NCT06195176|OTHER|Hand exercises|"Operational Definition:~* Open and close the hands, making a fist and applying force.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night."
214950905|NCT00456781|DEVICE|Augmentation|Rotator Cuff Repair plus Graft Jacket
214950906|NCT00456781|PROCEDURE|Rotator Cuff Repair without augmentation|Rotator Cuff Repair without augmentation
214950907|NCT03636048|DRUG|Bupivacaine Hcl 0.5% Inj|The patients undergo surgery under spinal anesthesia and a catheter would be inserted into epidural space during the procedure. 0.5% bupivacaine is injected into intrathecal space for spinal anesthesia. For pain control, 0.2% ropivacaine is continuously infused into epidural space postoperatively.
214950908|NCT03636048|DRUG|Propofol 10 milligram/ML|The patients undergo surgery under general anesthesia and a catheter would be inserted to abdominal incision site at the end of the operation. Propofol is used for induction of general anesthesia, and sevoflurane is used for maintenance of anesthesia. At the end of the operation, the surgeon inserts wound catheter in the surgical site and connects wound patient-controlled analgesia device filled with 0.5% ropivacaine.
214486550|NCT06020261|BEHAVIORAL|Parent Management Training|developing parenting skills and competencies dealing with oppositional and irritable behaviors in the child.
214950909|NCT06965504|DEVICE|Impella 5.5 SmartAssist|The intervention is Impella 5.5 with SmartAssist® support combined with heart failure guideline directed medical therapy (GDMT).
214950910|NCT05053035|DRUG|AL001|Administered via intravenous (IV) infusion
214950911|NCT05053035|DRUG|Placebo|Administered via intravenous (IV) infusion
214950912|NCT05258318|PROCEDURE|DK crush|Double Kissing Crush (DK-Crush) technique in patients with Unprotected Left Main Bifurcation lesions (ULMb).
214950913|NCT05258318|PROCEDURE|DR crush|Double Rewire crush technique (DR-Crush) in patients with Unprotected Left Main Bifurcation lesions (ULMb).
214950914|NCT05835063|BEHAVIORAL|We Chatt communication tool|This arm involves the collaborative completion of a 2-page communication preferences document between a primary physician and an adolescent/young adult patient. Physicians will participate in a 1-hour training led by study principal investigator featuring didactic, multimedia, and experiential-based learning to support the facilitation of the WE CHATT intervention with patients.
214950915|NCT05835063|BEHAVIORAL|Usual/standard care|Usual/standard care will be provided. Physicians randomized to the control arm will not receive training in the WE CHATT communication intervention.
214950916|NCT06361498|DEVICE|Ultrasound Imaging|Participant will receive ultrasound imaging to evaluate the replaced G-tube placement.
214950917|NCT05008445|BIOLOGICAL|LM-102 Injection|LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.
214950918|NCT05008445|COMBINATION_PRODUCT|LM-102 Injection combined with SOC|LM-102 Injection with appropriate dose level(s), combined with SOC.
215076283|NCT00841048|DRUG|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
215076284|NCT00841048|DRUG|Placebo|
215076285|NCT00966849|OTHER|Conditional Cash Transfer|"Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:~* An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.~* All children under 5 years in the household must be up-to-date with vaccinations.~* All children under 5 years must attend a growth monitoring clinic twice per year.~* All children 6-17 years in the household attended school at least 90% of days in the last month.~* At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes."
215076286|NCT00966849|OTHER|Unconditional Cash Transfers|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
214343734|NCT05818735|DRUG|Escitalopram 10mg|Escitalopram will be used as the antidepressants for relieving patients' depressive mood. The dose of the drug will be the minimum clinical starting dose of 10 mg once daily, taken orally in the morning, for a period of 3 months. During the intervention period, patients will be allowed to increase the drug dose (up to 20 mg) according to their mental status. Patients will record the details of the drug dose, duration of dosing,responses and possible side effects on a drug dairy. Pateints will receive 7 tablets of escitalopram from an independent dispencer at a set time each week. They may receive additional dose of escitalopram once again during the week if necessary and it will be recorded by the dispenser.
215076287|NCT00966849|OTHER|Standard Agricultural Package|A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
215076288|NCT00966849|OTHER|Parenting Skills Classes|2-3 parenting skills classes will be held annually in each study cluster.
215076289|NCT03211026|OTHER|No intervention|No intervention
215076290|NCT00711113|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
215076291|NCT05220319|DRUG|Methylprednisolone|250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
214486551|NCT04300127|DRUG|Pioglitazone 30 mg|Patients will received 30 mg of Pioglitazone once a day for 8 weeks
214950919|NCT06966765|PROCEDURE|Continuous Veno-Venous Hemodiafiltration|CVVHDF will be delivered following hemoperfusion with a dialysate-to-replacement fluid ratio maintained at 1:1, a blood flow rate of 150-200 mL/min, and a target dialysis dose of 30 mL/kg/h (excluding additional fluid removal). Regional anticoagulation (e.g., heparin or other agent per device requirements) will be used to prevent clotting within the circuit. Once CVVHDF is initiated in either arm, it will not be discontinued until one of the following encountered: (i) death; or (ii) a change in goals of care with withdrawal of life-sustaining interventions; or (3) recovery of kidney function, as determined by treating clinician(s), such that CVVHDF will be no longer required. However, CVVHDF will be reinitiated at the discretion of treating clinician(s), if kidney function comes suboptimal after a period of discontinuation.
214950920|NCT05503875|BIOLOGICAL|adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate|Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
214950921|NCT00864136|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
214950922|NCT00864136|DRUG|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
215076292|NCT05220319|DRUG|NaCl 0.9%|100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
215076293|NCT00503334|DIETARY_SUPPLEMENT|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
215076294|NCT00001812|DRUG|Nystatin|
215076295|NCT03963089|PROCEDURE|Tidal volume_6mL/kg|Set tidal volume to 6mL/kg for 1 minute
215076296|NCT03963089|PROCEDURE|Tidal volume_10mL/kg|Set tidal volume to 10mL/kg for 1 minute
215076297|NCT03963089|PROCEDURE|Tidal volume_14mL/kg|Set tidal volume to 10mL/kg for 1 minute
215076298|NCT03963089|PROCEDURE|Fluid loading|Administer 10mL/kg of crystalloid for 5 minutes
215076299|NCT02057094|DIETARY_SUPPLEMENT|Protein, High-Protein, and Control|
215076300|NCT00100230|DRUG|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
215076301|NCT00458042|DRUG|treprostinil sodium|
215076302|NCT01332188|DRUG|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
214343735|NCT05818735|DRUG|Placebo|Placebo drugs are tablets of the same color and size as escitalopram tablets, consisting mainly of starch, and will be tested for safety before being used in the trial. The way the medication is dispensed, the details of how the medication is administered, the dosage, and the record of the drug diary are consistent with the application of the real drugs.
215076303|NCT01332188|DRUG|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
215076304|NCT01332188|DRUG|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
215076305|NCT01332188|DRUG|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
215076306|NCT01046604|DRUG|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
215076307|NCT06508645|DRUG|DWP14012 injection|"1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)"
214486552|NCT05412004|DRUG|Tirzepatide|Administered SC
214486553|NCT05412004|DRUG|Placebo|Administered SC
214486554|NCT05448833|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
214950923|NCT00864136|DRUG|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
214950924|NCT05587413|PROCEDURE|periodontal care|periodontal treatment
214950925|NCT04965103|PROCEDURE|SCR|Superior Capsule reconstruction
214950926|NCT04965103|PROCEDURE|Bridging|Tendon repair with graft interposition
214950927|NCT00772187|DRUG|morphine|Single dose: 0.1-0.5 mg
214950928|NCT00772187|DRUG|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
214950929|NCT00772187|DRUG|general anesthesia (fentanyl)|general anesthesia alone
214950930|NCT03266575|BEHAVIORAL|Pulmonary Rehabilitation Exercise|Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session
214950931|NCT03266575|BEHAVIORAL|Home Based Exercise|Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
214950932|NCT01069770|DRUG|Sunitinib|50mg daily(4 weeks on \& 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops
214950933|NCT03811054|DRUG|Apatinib（250mg/d） combined with EGFR-TKI|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
214950934|NCT00543920|DRUG|MK0777|
214950935|NCT03813134|PROCEDURE|Percutaneous coronary intervention (PCI)|Primary PCI or early/immediate PCI for NSTEMI will be undertaken according to recommended Guideline standards of care. This will include appropriate pre-loading with dual anti-platelet therapy, a preferred radial approach, intra-procedural anti-coagulation (with measure of ACT if considered appropriate every 30 minutes) and the use of drug eluting stents. Treatment will be delivered essentially to the culprit vessel only. A successful procedure will be one considered to have achieved TIMI 2-3 flow and residual stenosis \< 50%. PCI failure will not be an exclusion itself from the trial.
214486555|NCT06797050|DEVICE|Training in reordering figurative stories with a social robot through the Learning by Teaching approach|A test session of the 'picture sequencing' task with the social robot is planned. The selected children will undergo an initial neuropsychological, motor and school learning assessment and will be divided into Group 1 and Group 2: Group 1 (Experimental) will be offered training with the social robot, while Group 2 (Control) will continue standard care. Both groups will be re-evaluated after approximately about 4 months. After which Group 2 will be able to start treatment. After about 4 months, the children in both groups will again undergo the planned assessments. During the training, the child will be asked to help the social robot to reorder sequences of pictures from figurative stories in order to create a story that respects temporal or causal links, or motor actions of increasing complexity, according to the Learning by Teaching paradigm.
214486556|NCT05774704|DRUG|Low curcumin group|One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
214486557|NCT05774704|DRUG|High curcumin group|One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
214950936|NCT03813134|OTHER|Pharmacological Support|Use of pharmacological agents (Norepinephrine, Dobutamine, Levosimendan) according to ESC Guidelines to maintain mean arterial pressure \>75 mmHg in accordance with recognised standards of care. Changes in pharmacotherapy will NOT be regarded as escalation therapy. However the number of and dose of inotropes will be documented in the CRF.
214950937|NCT03813134|DEVICE|VA-ECMO|"Following PCI of the culprit lesion, patients will have ECMO initiated as soon as echocardiography (to exclude mechanical causes) has been completed, once they have been assessed as having failed to improve (with the aim to start ECMO as early as possible from 30 mins after completed P-PCI procedure ad fully established within 6 hours after randomisation).~Peripheral Veno-arterial ECMO will be employed with a flow rate according to individual patient needs. Other methods of LV unloading, distal limb perfusion, maintenance of ejection/aortic valve opening and anti-coagulation will be instituted as per sites' usual care.~A minimum 24 hours be allocated to the randomised therapy in order that strategy failure is demonstrated but this will be at the physicians' discretion."
214950938|NCT05328284|DEVICE|PASCAL leaflet repair system|transcatheter Implantation of one or more PASCAL devices in the tricuspid valve
214950939|NCT06020196|PROCEDURE|surgical rectus sheath block|Local anaesthetic will be administered into the rectus sheath space by the surgeon, towards the end of the operation, at the time of closure of the anterior abdominal wall (before the closure of peritoneum)
214950940|NCT06020196|PROCEDURE|subdermal local anaesthetic infiltration|After closure of the subcutaneous fat, the edges of the skin become more stable; subdermal Infiltration with moving needle technique was done to optimize distribution of the local anesthetic solution
214950941|NCT05952713|DRUG|Antidepressant|Treatment with an antidepressant according to Danish register data.
214950942|NCT04412642|DRUG|Methoxyflurane, MEOF|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
214950943|NCT03580499|DIETARY_SUPPLEMENT|Vitamin B6|Given PO
214950944|NCT03580499|OTHER|Questionnaire Administration|Ancillary studies
214950945|NCT05590533|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the F-2-MS
215076308|NCT04837989|BEHAVIORAL|Diabetes Body Project|Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators
215076309|NCT04837989|BEHAVIORAL|Psychoeducation|Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.
214950946|NCT01656187|DRUG|Memantine 10 mg capsule|"Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
214950947|NCT01656187|DRUG|Memantine-matched Placebo capsule|"Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
214950948|NCT03525782|BIOLOGICAL|CAR-T Cells|Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
214950949|NCT03525782|COMBINATION_PRODUCT|CAR-T combining PD-1 Knockout|Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
214950950|NCT03525782|BIOLOGICAL|PD-1 knockout|Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients
214950951|NCT03525782|DRUG|PD-1 mAb|Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1
214950952|NCT03525782|OTHER|Sham control|Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.
214950953|NCT04846816|COMBINATION_PRODUCT|SQIN-01|The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
214950954|NCT01054391|DEVICE|NEC - Neurovascular Embolization Cover|Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
214950955|NCT00946894|PROCEDURE|Total thyroidectomy|Total thyroidectomy
214950956|NCT00946894|PROCEDURE|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
215076310|NCT03411564|OTHER|Filming Together to See Ourselves in a New 'Present'|"PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process."
215076311|NCT01606787|DRUG|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
215076312|NCT01606787|OTHER|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
214343736|NCT04866264|DEVICE|eNutrition Optimizer|The eNutrition optimizer is based on the electronic food frequency questionnaire (FFQ) used in the multicentre randomized controlled trail DO-HEALTH \[56\] developed by the CAM. The FFQ is split up in sections of 33 food groups and contains 216 items. It asks the user on the relative frequency of consumption of the different foods showing a picture of the food in the portion size of interest. Within the eNutrition Optimizer, the FFQ will be extended to create an output of the user's adherence to the Mediterranean diet, the MIND diet and the adherence with the current dietary recommendations for micro- and macronutrients provided by the Swiss Society for Nutrition and the DACH-references, compare it to the DO-HEALTH population and give recommendations on how to improve the score.
214950957|NCT00946894|PROCEDURE|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
214950958|NCT05948839|DEVICE|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
214950959|NCT05948839|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
214950960|NCT01291134|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
214950961|NCT04757324|OTHER|breastfeeding education|
214950962|NCT01192724|DRUG|Cilostazol|100 mg BID, for 3 months
214950963|NCT01192724|DRUG|Aspirin|Aspirin 100 mg QD, for 1 year
214950964|NCT01192724|DRUG|Clopidogrel|Clopidogrel 75 mg QD, for 1 year
214950965|NCT03438058|OTHER|Graft survival and/or Rejection appearance|
214950966|NCT00507832|DRUG|Pimecrolimus|twice daily topical
214950967|NCT00507832|DRUG|Hydrocortisone|twice daily topical
214950968|NCT00507832|DRUG|Pimecrolimus|topical application as a cream twice daily
214950969|NCT02958332|OTHER|video game program|Participants will use the Wii console and the Wii balance board, to play different video games which imply shoulder movements. They will receive 5 individual sessions of 30 minutes.
215076313|NCT03888677|DRUG|5-FU, epirubicin and cyclophosphamide|Tailored dose escalation of epirubicin and cyclophosphamide.
214950970|NCT03274752|DRUG|Paroxetine|Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.
214343737|NCT04099069|PROCEDURE|anesthesia|patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
214950971|NCT03274752|DRUG|Placebo oral capsule|Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
214950972|NCT03003000|DRUG|ibuprofen|
214950973|NCT03003000|DRUG|caffeine|
214950974|NCT03003000|DRUG|placebo|
214950975|NCT01678599|DRUG|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients \> 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
214950976|NCT01912352|DRUG|Methylphenidate|
214950977|NCT03464942|RADIATION|SABR|Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.
214950978|NCT03464942|DRUG|Atezolizumab|All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months
214950979|NCT03998137|DEVICE|AUGMENT® Injectable Bone Graft|AUGMENT® Injectable Bone Graft
214950980|NCT03998137|PROCEDURE|Standard of Care|Autologous Bone Graft
214950981|NCT02527915|OTHER|Mental Health eConsults|Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.
214950982|NCT02527915|OTHER|Care as usual|Providers in primary care clinics will deliver care as usual to their patients.
215076314|NCT06286826|PROCEDURE|Postero-lateral thoracotomy|this incision extends from the anterior axillary line, goes posteriorly behind the scapula and includes the division of the fibres of the latissimus dorsi muscle and the serratus anterior muscle. The latter approach presents the risk of numerous long-term musculoskeletal complications such as costal abnormalities (costal hypoplasia, costal fusion), winged scapula, scoliotic spine posture
215076315|NCT06286826|PROCEDURE|Minithoracotomy|Minithoracotomy aims to preserve the muscles of the rib cage by retracting or disconnecting them rather than sectioning them (muscle sparing technique)
215076316|NCT05614908|OTHER|11 week restrictive regime|"As part of standard care at AUH (until May 2024), patients are immobilized in scotch cast with the foot in plantarflexion during week 0-4. Next, the scotch cast is replaced by a ROM-WALKER in plantarflexion for the next 7 weeks (week 5-11 after injury). The ROM-WALKER is gradually corrected from 30 degrees plantarflexion to 0 degrees. No weight bearing or exercises is allowed and they are not allowed to remove the ROM-WALKER during week 0-10. At week 11, the patients are allowed weight bearing up to 30 kg, after which there is no longer weight bearing restrictions.~From week 12 they are allowed full weight bearing with a 1 cm heel lift i their shoes."
214950983|NCT03085771|DRUG|desferal|It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
214343738|NCT06152536|OTHER|Vegetarian Meal|"meal with vegetarian protein and meal with animal protein"
214343739|NCT04821596|OTHER|biological collection|"Six 5 mL heparinized tubes, approximately 24 mL of blood will be collected as per standard practice. The 5 tubes collected from a given individual will be transported directly to the laboratory. In the laboratory, peripheral blood mononuclear cells (PBMC) will be prepared for the various analyses.~However, in order to minimize the effect of agents other than CoA in MS patients, it is necessary that peripheral blood mononuclear cells are collected before treatment is given: for RR MS patients treated with first-line drugs (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...), RR MS patients treated with second-line drugs (natalizumab and fingolimod, ...) and RR MS patients treated with third-line drugs (alemtuzumab, ...)."
214950984|NCT03085771|DRUG|Isotonic saline|It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
214950985|NCT01178814|DRUG|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
214950986|NCT04933617|BIOLOGICAL|Rituximab|Rituximab 375 mg/m\^2 intravenous (IV) per protocol on Day 1 of each cycle up to 6 cycles
214950987|NCT04933617|DRUG|Etoposide|Etoposide 50 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
214950988|NCT04933617|BIOLOGICAL|Copanlisib|Copanlisib intravenous (IV) is administered at a fixed dose (30 mg, 45 mg, or 60 mg) on days 1 and 5 of each 21-day cycle for up to 6 cycles
214950989|NCT04933617|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 intravenous (IV) on Day 5 of each cycle up to 6 cycles
214950990|NCT04933617|DRUG|Doxorubicin|Doxorubicin 10 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
214950991|NCT04933617|DRUG|Vincristine|Vincristine 0.4 mg/m\^2/day (no cap) continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
214950992|NCT04933617|DRUG|Prednisone|Prednisone 60 mg/m\^2 by mouth (PO) twice a day (BID) Days 1-5 (total 120mg/m\^2/day)
214950993|NCT04933617|DIAGNOSTIC_TEST|ECHO|At screening.
214950994|NCT04933617|DIAGNOSTIC_TEST|EKG|At screening.
214950995|NCT04933617|DIAGNOSTIC_TEST|MRI Brain|At screening.
214950996|NCT04933617|DIAGNOSTIC_TEST|18F-FDG - PET|At screening, baseline, after cycle 1, 3, and 6, and end of treatment.
214950997|NCT04933617|DIAGNOSTIC_TEST|CT Scan|At screening, baseline, after cycle 1, 3, and 6, end of treatment and follow-up.
214343740|NCT01230476|DRUG|Cetuximab|Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
214343741|NCT04169841|DRUG|olaparib, durvalumab, tremelimumab|"STEP 1:~Olaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food~STEP 2:~Olaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing."
214343742|NCT06121713|DIETARY_SUPPLEMENT|GCE + Low ALA|Participants will consume a pill containing 200mg green coffee extract and 200mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
214343743|NCT06121713|DIETARY_SUPPLEMENT|GCE + High ALA|Participants will consume a pill containing 200mg green coffee extract and 400mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
214343744|NCT06121713|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo pill (500mg insoluble microcrystalline cellulose, 5mg magnesium stearate, 5mg silicon dioxide) prior to a 75g oral glucose tolerance test
214343745|NCT01753193|BIOLOGICAL|Anifrolumab|Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
214343746|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
214950998|NCT04933617|PROCEDURE|Bone Marrow Aspiration|At screening and end of treatment.
214950999|NCT04933617|PROCEDURE|Bone Marrow Biopsy|At screening and end of treatment.
214951000|NCT04933617|DIAGNOSTIC_TEST|Lumbar Puncture (LP)|Baseline and end of treatment.
214343747|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
214951001|NCT03743402|BEHAVIORAL|Pain self-management training|"This intervention will have 4 components:~1. telephone-delivered evidence-based pain self-management training,~2. web-based video of successfully tapered patients with motivational interviewing debriefing,~3. a voluntary, self-paced opioid taper~4. opioid and non-opioid prescribing guidance for the patient's primary care provider."
214343748|NCT00383435|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
214343749|NCT00383435|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
214951002|NCT03743402|BEHAVIORAL|video education, motivational interviewing|web-based video of successfully tapered patients with motivational interviewing debriefing
214951003|NCT03743402|BEHAVIORAL|voluntary self-paced opioid taper|Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they will negotiate details with their primary care provider.
214951004|NCT03743402|BEHAVIORAL|prescribing guidance for primary care provider|Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper. All prescriptions will be written by the primary care provider.
214951005|NCT03743402|OTHER|usual care|Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses
214951006|NCT02065414|OTHER|Listerine Advance Gum Defense|
214951007|NCT02065414|OTHER|Mouth rinse containing Chlorhexidine|
214951008|NCT02065414|OTHER|Mouth rinse containing 5% Hydroalcohol|
214343750|NCT00383435|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
214343751|NCT03111927|OTHER|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
214951009|NCT02658708|OTHER|Bright blue-green light using light visor cap|
214951010|NCT02658708|OTHER|Dim red light using light visor cap|
214951011|NCT02658708|OTHER|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire|-Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
214951012|NCT02658708|OTHER|Epworth Sleepiness Scale|-Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
214951013|NCT02658708|OTHER|Pittsburgh Sleep Quality Index|-Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
214951014|NCT02658708|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|-Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
214951015|NCT02658708|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|-Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
214343752|NCT03111927|OTHER|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
214343753|NCT00583557|DRUG|belimumab|IV 10mg/kg Q28 days
214343754|NCT03273439|DEVICE|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
214343755|NCT03273439|DEVICE|Sham rTMS|Sham rTMS, without stimulation
214343756|NCT05995912|DRUG|etoricoxib-tramadol|Oral administration (with or without food)
214343757|NCT05995912|DRUG|Naproxen|Oral administration (with or without food)
214951016|NCT02658708|DIAGNOSTIC_TEST|Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)|-The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
214951017|NCT02658708|DIAGNOSTIC_TEST|Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)|-A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
214951018|NCT02658708|OTHER|Horne-Ostberg Morningness-Eveningness Questionnaire|
214951019|NCT02658708|OTHER|Daily Fatigue and Sleep Log|"* Two visual analog scales (VAS) for diurnal fatigue and daytime sleepiness~* Two 0-10 point rating scales (average and worst fatigue levels in 24 hours)"
214951020|NCT03726736|DRUG|Anlotinib combined Docetaxel|Anlotinib ( dose base on phase I study, QD PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
214951021|NCT03726736|DRUG|Docetaxel|Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
214951022|NCT02616718|RADIATION|Repeated computed tomography scan of abdomen|Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
214951023|NCT00974038|BEHAVIORAL|psychotherapy|1\) cognitive-behavioral therapy or 2) supportive psychotherapy
214951024|NCT01403506|DRUG|N-acetyl Cysteine|600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
214951025|NCT02191046|DEVICE|squeezable bottle|nasal irrigation twice daily for 2 weeks period
214951026|NCT02191046|DEVICE|syringe 20 ml|nasal irrigation twice daily for 2 weeks
214951027|NCT01025375|DIETARY_SUPPLEMENT|inulin|10gram/day inulin for 13-day treatment
214951028|NCT01025375|DIETARY_SUPPLEMENT|inulin|16gram/day inulin for 13-day treatment
214951029|NCT01025375|DIETARY_SUPPLEMENT|placebo|16gram/day maltodextrin (placebo) for 13-day treatment
214951030|NCT02286375|BEHAVIORAL|Intervention group|A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
214951031|NCT01592604|DEVICE|Compressive bandage|Compressive below knee bandage for 4 weeks in group A
214951032|NCT01592604|DEVICE|Below knee walking cast|Below knee walking cast for 4 weeks
214951033|NCT03061799|DIETARY_SUPPLEMENT|HPC-03|HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
214951034|NCT03061799|DIETARY_SUPPLEMENT|Placebo|Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
214951035|NCT05480553|DRUG|NPC-06|"1. Initial dose (Day 1) \<Dose\> An 18 mg/kg of NPC-06 will be injected by intravenous drip infusion once daily. The maximum dose of the test drug should not exceed 1,200 mg as fosphenytoin sodium.~   \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A 7.5 mg/kg of NPC-06 will be injected as needed by intravenous drip infusion once daily. The maximum dose of NPC-06 should not exceed 500 mg as fosphenytoin sodium.~\<Administration method\> Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
214951036|NCT05480553|DRUG|Placebo|"1. Initial dose (Day 1) \<Dose\> A placebo will be injected by intravenous drip infusion once daily. \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A placebo will be injected as needed by intravenous drip infusion once daily. Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
214951037|NCT02451397|OTHER||This is a cross-sectional study, and we do not assign specific interventions to the subjects of the study.
214343758|NCT05995912|DRUG|Tramadol|Oral administration (with or without food)
214951038|NCT04049305|DEVICE|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
214343759|NCT06291272|DIETARY_SUPPLEMENT|Psyllium|15 g psyllium + 15 g inulin
214343760|NCT06291272|DIETARY_SUPPLEMENT|Methylcellulose|15 g methylcellulose + 15 g inulin
214343761|NCT06291272|DIETARY_SUPPLEMENT|Inulin|15 inulin
214343762|NCT06291272|DIETARY_SUPPLEMENT|Maltodextrin|15 maltodextrin
214343763|NCT04792346|RADIATION|breast/chest wall radiotherapy|34 Gy/10 fxs/2 wks to the whole breast/chest wall and locoregional lymph nodes; an optional single fraction 8 Gy boost was administered with electrons to the tumor bed in patients undergoing conservative surgery
214343764|NCT01040104|OTHER|Skin sample|Taken from regularly discarded tissue during routine operation
214343765|NCT01040104|OTHER|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
214343766|NCT01040104|OTHER|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
214343767|NCT01040104|OTHER|Blood taking|Blood taking on day 0
214343768|NCT01040104|OTHER|Blood taking|Blood taking on day 90
214343769|NCT05094323|DRUG|Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine|Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
214343770|NCT05094323|DRUG|Local wound infiltration with isobaric bupivacaine|Patients will receive local wound infiltration with isobaric bupivacaine.
214343771|NCT05094323|DRUG|Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine|Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
214343772|NCT02431039|DEVICE|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
214343773|NCT02431039|DEVICE|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
214951039|NCT04049305|PROCEDURE|conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
214951040|NCT04049305|PROCEDURE|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
214951041|NCT03760458|DRUG|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets|Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
214951042|NCT03760458|DRUG|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)|Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
214343774|NCT01131312|DEVICE|Thinprep|Pap test
214343775|NCT01131312|DEVICE|Hybrid capture 2|Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
214343776|NCT01131312|PROCEDURE|Colposcopy|Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
214343777|NCT02682264|DRUG|CB-03-01 cream, 1%|Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
214343778|NCT01691300|OTHER|ACT PET/CT|Old tracer but new indication
214343779|NCT02934373|DEVICE|A New Sound Processor|
214343780|NCT02657278|PROCEDURE|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
214343781|NCT00059813|BIOLOGICAL|recombinant interferon alfa|Given SC
214343782|NCT00059813|BIOLOGICAL|oblimersen sodium|Given IV
214343783|NCT00059813|OTHER|pharmacological study|Correlative studies
214343784|NCT01155544|BEHAVIORAL|Behavioral Intervention|Preventing recurrence of substance use.
214951043|NCT03104218|OTHER|tDCS group|Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
214343785|NCT01601574|BEHAVIORAL|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
214343786|NCT01601574|OTHER|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
214951044|NCT03104218|OTHER|Placebo group|"Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition."
214951045|NCT02515084|DEVICE|PET|A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma
214343787|NCT00604981|BEHAVIORAL|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
214343788|NCT00604981|BEHAVIORAL|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
214343789|NCT00698568|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
214343790|NCT00698568|BIOLOGICAL|Placebo|Intramuscular injection, 3 doses
214343791|NCT05403541|DRUG|Batoclimab 680 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
214343792|NCT05403541|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
214343793|NCT05403541|DRUG|Matching Placebo SC|Placebo
214343794|NCT05403541|DRUG|Batoclimab 340 mg SC bi-weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
214343795|NCT04939480|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenous solution
214951046|NCT02515084|DEVICE|MRI imaging|
214343796|NCT06572722|DRUG|Atezolizumab|atezolizumab adjuvant therapy
214951047|NCT06405659|OTHER|correction for pedicle fixation|The patient was diagnosed with idiopathic scoliosis and underwent a posterior idiopathic scoliosis procedure and correction for pedicle fixation.
214951048|NCT03921359|BEHAVIORAL|SMARTfit training|For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session. There is an additional cognition component that can be manipulated using features provided by SMARTfit.
214951049|NCT03921359|BEHAVIORAL|Conventional physical training|For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session.
214951050|NCT04006509|BEHAVIORAL|Prenatally Delivered Lactation Educational Program|The support person (SP) of mothers at risk for preterm birth will be educated on how to use a breast pump and instructions regarding breast milk expression and have a pump in their hospital room
214951051|NCT05571215|DEVICE|Transcranial Direct Current Stimulation|Five sessions of tDCS will be performed following completions of baseline data collection. This will include 3 sessions during week one and 2 sessions in week 2. A tDCS unit (neuroConn Ilmenau, Germany) will be applied to the left DLPFC with participants in the sitting position for a 20 minutes of tDCS. An anodal 2.0 mA current will be applied to each participant, including a 30-second ramp up at the beginning of stimulation and a 30 second ramp down period and the end of stimulation. The left DLPFC (F3 from EEG 10/20 system) will be located using the Beam F3 measurement system. These parameters are consistent with those used in current literature on tDCS for pain. tDCS procedures will be performed by the PI (CA).
214343797|NCT06572722|DRUG|Nivolumab|nivolumab neoadjuvant therapy
214343798|NCT06572722|DRUG|Pembrolizumab|pembrolizumab neoadjuvant+adjuvant therapy
214343799|NCT02942160|BIOLOGICAL|Collagenase Clostridium Histolyticum|
214343800|NCT03566719|OTHER|Exercise program|Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
214486558|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling|The slow-pull capillary technique was performed as follows: after identification and measurement of the target lymph node, a needle was used to puncture the lymph node with the stylet in place.At the same time, the stylet was slowly and continuously pulled to create weak negative pressure.
214486559|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration|The operation steps are the same as above, but the negative pressure device of 10ml syringe is connected behind the puncture needle.
214343801|NCT02882802|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
214951052|NCT05571215|BEHAVIORAL|Pain Neuroscience Education|Immediately following completion of each tDCS intervention, participants will be given a one-on-one PNE session provided also by the PT (CA), who is a licensed healthcare provider with expertise in delivery of the content. This educational session will last about 30 minutes. Initial sessions will involve discussion and questioning of participants about their own understanding of their pain and this information will be used to subsequently individualize the forthcoming educational sessions. The educational sessions will follow the content of Explain Pain, a patient booklet, and will include information on the neurophysiology of pain, pain as typical process, the transition from acute to chronic pain, neuroplasticity, central sensitization, factors that promote pain chronicity. Information will be presented verbally along with visuals on paper.
214951053|NCT04373850|BEHAVIORAL|Home Visit|Physical exam, medication dose titration
214951054|NCT02781376|OTHER|CHICA OSA|Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
214951055|NCT02781376|OTHER|Snoring Identification Only|Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
214951056|NCT04707560|PROCEDURE|EUS fine needle biopsy with heparin wet suction|"EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion."
214951057|NCT04282720|DEVICE|SurgiMend Mesh|Following placement of SurgiMend mesh during laparoscopic hiatal hernia repair, patient will be scheduled for follow up using an upper GI series to check for recurrence of the hiatal hernia. Follow up upper GIs will be performed at 6 months post-surgery. Subjects will also complete a QOL survey to assess other GI associated symptoms before and after surgical repair. The QOL survey can be administered by phone by study team members
214951058|NCT04497974|OTHER|Dietary intervention|Varying the exposure to sweetness via diet manipulation.
214951059|NCT01660802|DRUG|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
214951060|NCT01660802|OTHER|Sham|Sham administered in the study eye on Day 1.
214951061|NCT06333782|DEVICE|Experimental- Genefill Contour®|Genefill Contour® Hyaluronic Acid Injection
214951062|NCT06333782|DEVICE|Marketed comparator - Desirial®Plus|DESIRIAL®PLUS Hyaluronic Acid Injection
214951063|NCT05981404|DIETARY_SUPPLEMENT|β-glucan|Consuming 3g β-glucan with each meal.
214951064|NCT05981404|DIETARY_SUPPLEMENT|Placebo|Consuming 3g Cellulose with each meal.
214951065|NCT02295267|OTHER|walnut allergy provocation|double blind placebo controlled food challenge
214951066|NCT05250986|DEVICE|GoCheck Kids (iOS)|"Visual Acuity method is used to measure of the sharpness or clearness of vision.~Device: GoCheck Visual Acuity in Office (Windows) Photorefraction method is used to screen amblyopia risk factors."
214951067|NCT05250986|DEVICE|GoCheck Kids (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
214951068|NCT05250986|DEVICE|GoCheck at Home (iOS)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
214951069|NCT05250986|DEVICE|GoCheck at Home (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
214951070|NCT05943431|DEVICE|paired taVNS|The stimulator will be placed on the left ear of the patient. While the patient performs the action training, the EMG signal feature evoked by the action will trigger an electrical stimulation of the transcutaneous auricular vagus nerve. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
214951071|NCT05943431|DEVICE|Unpaired taVNS|The stimulator will be placed on the patient's left ear. Patients will receive taVNS with pulses every 5-7 seconds. Following the stimulation, motor training will be performed. The motor training will be identical to that of the paired group. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
214951072|NCT05943431|DEVICE|Sham taVNS|The stimulator will be placed on the patient's left ear. The amplitude of the electrical stimulation will be adjusted at 0 mA. The intervention will be performed daily for 14 days.
214951073|NCT04309487|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
214951074|NCT02281240|DRUG|thrombopoietin, interleukin-11, heparin,|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
214951075|NCT04089878|PROCEDURE|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration
214951076|NCT04089878|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
214951077|NCT02648464|DRUG|Hydroxychloroquine|
214951078|NCT02648464|DRUG|Placebo|
214951079|NCT05247346|DEVICE|SENSITIVE system|probe-based integrated Raman spectroscopy and scattering measurements of Barrett's and colorectal tissue during GI endoscopy
214951080|NCT00374257|PROCEDURE|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
214951081|NCT04187274|DEVICE|IKORUS technology|Ikorus technology is a new micro perfusion device measuring via urethral photoplethysmography, the urethral perfusion index (uPI) in patients equipped with an urinary catheter.
214951082|NCT05659303|PROCEDURE|Laparoscopic hysterectomy|Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
214343802|NCT02882802|BEHAVIORAL|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
214343803|NCT06636032|DRUG|AdMSC (CellReady®)|At day 0, patients will have AdMSC injections. Patients will be followed-up for 6 months
214951083|NCT04876313|DRUG|Nivolumab + Nab-paclitaxel|4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8
214951084|NCT04876313|DRUG|Nivolumab|360 mg IV Q3W x 13 cycles
214951085|NCT00048997|RADIATION|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
214951086|NCT00048997|OTHER|Observation|
214951087|NCT01490307|BEHAVIORAL|Family Check-Up|The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
214951088|NCT02819440|DRUG|Tadalafil|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
214951089|NCT02819440|DRUG|Placebo|100 patients will be randomized to receive a placebo pill. Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
214951090|NCT03585946|DRUG|Site specific standard of care comparison|Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
214951091|NCT03758105|OTHER|tDCS associated with usual care|"A tDCS cure will be given to the group tDCS, one week after their randomization.~This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.~Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks."
215076317|NCT05614908|OTHER|8 week liberal regime|"The patients are treated with a walker orthosis with 3 wedges in plantarflexion, during week 1-2 with no weight bearing and no exercises. After 2 weeks, the tendon will be examined, and if no defect in the tendon is detected by palpation, the patients will start partially weight bearing in week 3-5, and full weight-bearing week 6-8. They are instructed in unloaded exercises for the calf and anklejoint after 2 weeks, and loaded exercises (elastic) after 5 weeks, with a maximum position til 0 degrees in the anklejoint. Balancetraining and stationary bike training after 7 weeks. The wedges are removed one by one after 3, 5 and 7 weeks, respectively.~If there is a palpable defect in the tendon after 2 weeks, the patient must wait 1 week with partially weight bearing and exercises, and remove the wedges at 4, 5 and 7 weeks after the initiation of treatment.~From week 9, walking i their shoes with a 1 cm heel lift."
214343804|NCT06635343|OTHER|CPRP|In the CPRP group, a chest physiotherapy program was given by the physiotherapist 5 days a week, for 8 weeks, including respiratory control, diaphragmatic breathing, thoracic expansion exercises, and physical activity recommendations, to be applied once a day.
214343805|NCT06635343|OTHER|Experimental Inspiratuar Muscle Training|In the experimental group inspiratory muscle training was applied. Children in the experimental group started inspiratory muscle training at 30% of the measured intra-oral maximum inspiratory pressure (MIP) value with 30x2 breaths (1 minute rest between repetitions) for 5 days a week for 8 weeks. The training was carried out with MIP every week. The training was continued for a total of 8 weeks with 30% of the new value by re-measuring the MIP value every week The value was measured again and continued at 30% of the new value for a total of 8 weeks. During each inspiratory muscle training session, oxygen saturation data from the index finger were monitored with a pulse oximeter to prevent individuals from experiencing hypoxia
214951092|NCT03758105|OTHER|Usual care|Medication and psychotherapy as prescribed in usual care
214951093|NCT01701505|DRUG|400uL of Kovacaine Mist|2 unilateral intranasal sprays of 200uL each.
214951094|NCT01701505|DRUG|200uL of Kovacaine Mist|2 unilateral intranasal sprays of 100uL each.
214951095|NCT01701505|DRUG|120uL of Kovacaine Mist|2 unilateral intranasal sprays of 60uL each.
214951096|NCT06524167|RADIATION|adjuvant radiotherapy|The patients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. 6MV-X-ray irradiation. Conventional segmented irradiation is used, once a day, five times a week, with a segmented dose of 2Gy per dose.
214951097|NCT05086666|DRUG|AZD4547|"In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor."
214951098|NCT02252926|DRUG|Bupivacaine|25 mg bupivacaine lozenge
214951099|NCT02252926|DRUG|Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)|Standard treatment includes lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin
214951100|NCT00960167|RADIATION|3DCRT or IMRT|"All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)"
215076318|NCT04652375|OTHER|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
214343806|NCT06635278|BEHAVIORAL|Mindfulness meditation|"The experimental group received eight 60-minute weekly sessions of mindfulness meditation over eight weeks in a private and quiet room at the hospital, according to Smith's (2005) recommendation. The study intervention was an audio based MBI sent to them by the WhatsApp application. It is a free, self-paced program developed by a study researcher based on the Smith's (2005) protocol.~The theory-based program (Smith, 2005) includes the ABC standardized versions of MBI (Smith, 2005), described as follows:~* Meditation of the body (Body sense meditation)~* Meditation of the body (Rocking meditation)~* Meditation of the body (Breathing meditation)~* Meditation of mind (Mentra meditation)~* Meditation of mind (visual Image)~* Meditation of sense (External image)~* Meditation of the senses (A sound)~* Open monitoring (Mindfulness)"
214343807|NCT03539562|DRUG|Morphine Sulfate and Promethazine|Morphine sulfate and promethazine
214343808|NCT02078323|DRUG|Linaclotide|
214343809|NCT02078323|DRUG|Placebo|
214343810|NCT01314651|BEHAVIORAL|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
214343811|NCT01314651|BEHAVIORAL|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
214343812|NCT00849342|DRUG|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
214343813|NCT01063010|DRUG|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
214343814|NCT01063010|DRUG|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
214343815|NCT06184698|DRUG|liposomal irinotecan|liposomal irinotecan 70 mg/m²
214343816|NCT06184698|DRUG|5-FU|5-FU 2400 mg/m²
214343817|NCT06184698|DRUG|LV|5-FU 2400 mg/m²
214343818|NCT06184698|DRUG|Bevacizumab|bevacizumab 5 mg/kg
214343819|NCT05724186|DEVICE|Test myopia control lenses (CSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
214343820|NCT05778305|DRUG|Dexmedetomidine|a central sympatholytic drug
214951101|NCT06553079|OTHER|Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy|"The intervention in this study involves the administration of the Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy, a newly developed tool designed to measure various aspects of surgeon satisfaction related to shoulder arthroscopy procedures."
214951102|NCT01924104|DRUG|Low molecular weight heparin|2500 mIU/day, subcutaneously
214951103|NCT01924104|DRUG|Low dose aspirin|75 mg/day, orally
214951104|NCT01924104|DRUG|Heparin & aspirin|Aspirin (70 mg/day, orally) \& heparin (40 mg/day, subcutaneously)
215076319|NCT04652375|OTHER|Lactated Ringer's Solution|Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
215076320|NCT06581731|DRUG|remimazolam combined with remifentanil|Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.
215076321|NCT06581731|DRUG|dexmedetomidine combined with remifentanil|Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
215076322|NCT06446856|DEVICE|VR application|"The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min."
214343821|NCT05778305|OTHER|normal saline|saline is given to control group
214343822|NCT04040985|PROCEDURE|Total Knee Arthroplasty using LEGION™ Total Knee System|Primary Total Knee Arthroscopy using LEGION™ Total Knee System
214343823|NCT04071951|BEHAVIORAL|Pharmacist-led Hospital Discharge Care Intervention|"Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions. Some or all of the pharmacist activities may take place over the phone."
214343824|NCT06962774|DRUG|ESK-001|Single oral dose of ESK-001 in participants from all cohorts
214951105|NCT01924104|OTHER|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
214951106|NCT02443272|PROCEDURE|Vessel Loop Drainage|Minimally invasive approach will utilize a vesi-loop device for the vessel loop drainage technique by placing 2 peripheral stab incisions into the abscess with a tunnel through the abscess cavity, and loop passed through the tunnel and tied atop the skin.
214951107|NCT02443272|PROCEDURE|Incision and Drainage|Standard of care treatment will utilize incision and drainage over the center of the abscess cavity with or without packing at physicians discretion.
214951108|NCT03012295|OTHER||
214951109|NCT01584700|PROCEDURE|Renal Artery Denervation|Radiofrequency ablation of the renal artery sympathetic outflow tract.
214951110|NCT00072059|BIOLOGICAL|methoxy polyethylene glycol epoetin beta|
214951111|NCT04996836|BIOLOGICAL|Next Generation Sequencing and Network Analysis|Next Generation Sequencing and Network Analysis will profile genetic and epigenetic abnormalities in blood from patients with BC.
214343825|NCT03264989|DRUG|crizanlizumab|Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days
214343826|NCT06357728|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring sensor: All study participants wear the sensor on the back of either right or left upper arm for up to 10 days. Glucose levels will be recorded from the interstitial fluid every 5 minutes using intermittent/ flash glucose scanning. Data will be captured using a receiver.
214343827|NCT06635187|DIAGNOSTIC_TEST|Speech and swallowing assessment|This is an observational study in which post-stroke patients will undergo a series of assessments tapping oral-motor and speech functions. Both behavioral and instrumental examinations will be used. Their performance will be captured via an artificial intelligence(AI)-powered mobile health application. The relation between the oral/speech-motor movements captured by the app and their performance as measured via instruments/behavioral means will be investigated.
214343828|NCT06636305|BEHAVIORAL|physical activity intervention|Women in the intervention group were instructed to obtain 10,000 steps per day and 150 minutes of MVPA (defined as physical activity that resulted in a heart rate in the range of 120-170 bmp) per week and were given a physical activity tracker (FitBit Charge HR 2, Fitbit, San Francisco, USA) to self-monitor progress.
214343829|NCT01559402|PROCEDURE|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
214343830|NCT01559402|PROCEDURE|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
214343831|NCT01559402|PROCEDURE|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
214343832|NCT06634550|OTHER|Mulligan technique|The participants will receive Mulligan technique (modified SNAGs) (10 rep. / 3 sets with 5 min rest in between) for 30 minutes, 3 sessions / week in addition to lifestyle modification advice for 4 weeks.
214343833|NCT06634550|OTHER|Core stability exercise|The participants will perform core stability exercises (spinus multifiduse ex, diaphragmatic strengthening ex, frontal plank, pelvic floor ex,) 3 sessions / week for 30 min each session in addition to lifestyle modification advice for 4 weeks
214343834|NCT06634550|OTHER|Lifestyle modification advice|The participants will receive lifestyle modification advice only for 4 weeks
214343835|NCT00797667|DRUG|Telcagepant 140 mg|
214343836|NCT00797667|DRUG|Telcagepant 280 mg|
214343837|NCT00797667|DRUG|140 mg telcagepant placebo|
214343838|NCT00797667|DRUG|280 mg telcagepant placebo|
214343839|NCT03249038|OTHER|Measurement of external blood loss|
214343840|NCT03249038|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|
214343841|NCT01981434|OTHER|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
214343842|NCT01986829|DEVICE|Microwave ablation|"* Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~* Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
214951112|NCT04644159|OTHER|Human biological samples|Blood , saliva, nasopharyngeal mucosa
214951113|NCT00198432|DRUG|Paclitaxel, vinorelbine, cisplatin|
214951114|NCT02759835|DRUG|osimertinib|Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.
214951115|NCT02759835|OTHER|Local Ablative Therapy (LAT)|local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
214951116|NCT05411380|DRUG|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
214951117|NCT05411380|DRUG|Capecitabine|500mg orally three times a day (continuously)
214951118|NCT05411380|DRUG|Endocrine Therapy|Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily or fulvestrant 500 mg each time, intramuscularly, injected on the 1st day and 15th day of the 1st cycle, and on the 1st day for subsequent cycle( 4 weeks for one cycle)
215076323|NCT06099418|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
214343843|NCT01986829|DEVICE|Cryoablation|"* Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~* Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
214951119|NCT02007278|DRUG|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
214951120|NCT02007278|DRUG|glimepiride|
214951121|NCT02007278|DRUG|Metformin|
215076324|NCT06099418|DRUG|Atezolizumab Injection [Tecentriq]|Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
215076325|NCT06099418|DRUG|Placebo|Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
214343844|NCT01986829|DEVICE|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
214343845|NCT01986829|OTHER|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
214343846|NCT01986829|OTHER|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
214343847|NCT04950335|PROCEDURE|AOPT|The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
214343848|NCT04950335|PROCEDURE|AOCT|Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
214343849|NCT01775137|DRUG|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
214343850|NCT04606953|BEHAVIORAL|Attention Process Training (APT-II)|The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
214343851|NCT02424916|BIOLOGICAL|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
214343852|NCT04363905|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
214343853|NCT04363905|DIETARY_SUPPLEMENT|Ferrous sulfate|20 mg per day of elemental iron for 6 weeks
214343854|NCT03532789|DRUG|herbal patch|One patch with medicine should be applied to the skin every other day within two weeks
214343855|NCT03532789|DRUG|placebo patch|One patch without medicine should be applied to the skin every other day within two weeks
214343856|NCT02192268|OTHER|PEP|
214343857|NCT02192268|OTHER|HFOO|
214343858|NCT02192268|OTHER|Assisted Coughing|
214343859|NCT04255095|PROCEDURE|experiment|Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。
214343860|NCT04255095|PROCEDURE|control|Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
214343861|NCT05102994|DIAGNOSTIC_TEST|mutation test|detect the tumor-related mutation in introcular fluid
214343862|NCT04236349|GENETIC|immunogenetics|blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
214343863|NCT03795844|PROCEDURE|liver retraction Nathanson retractor|liver retractor will be used for the retraction of left lobe of liver
214343864|NCT03795844|PROCEDURE|liver retraction snake retractor|liver retractor will be used for the retraction of left lobe of liver
214343865|NCT03795844|PROCEDURE|liver retraction fan retractor|liver retractor will be used for the retraction of left lobe of liver
214343866|NCT03795844|PROCEDURE|liver retraction laparoscopic grasper|laparoscopic grasper without any special tools
214343867|NCT01030224|DRUG|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
214343868|NCT01030224|DRUG|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
214343869|NCT01961830|DRUG|ME1100 inhalation solution|
214343870|NCT00720616|DRUG|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
214343871|NCT01070004|OTHER|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
214343872|NCT01070004|OTHER|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
214343873|NCT05166018|DIAGNOSTIC_TEST|SuMO Patient|"The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves."
214343874|NCT03029208|DRUG|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
214343875|NCT03029208|DRUG|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
214343876|NCT03029208|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
214951122|NCT01530711|DRUG|Terlipressin and albumin|"Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase \< 10 mmHg and the creatinine values decrease \<25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.~Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day."
214951123|NCT02080338|DEVICE|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
214951124|NCT04539756|BEHAVIORAL|positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
215076326|NCT06141538|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
215076327|NCT02258971|DRUG|BEA 2180 BR oral|Oral solution
214951125|NCT04539756|BEHAVIORAL|Active control condition|Participants will be asked to complete the same writing activity each day, which will ask them to list their daily activities. Participants will be encouraged to process their daily activities superficially by the receiving the following instructions: (1) list each activity in brief, incomplete sentences, (2) document only facts about performing the activities, and (3) to not provide any information about emotional responses to performing the activities. By following these instructions, participants are presumably deriving less meaning from their activities, which may minimize gains in positive affect in the active control condition
214343877|NCT01316744|DRUG|ketamine hydrochloride|
214951126|NCT05999656|BIOLOGICAL|human cord blood-derived mononuclear cells (HCB-MNCs)|All patients received cell therapy for the first time. HCB-MNCs were injected subcutaneously or intramuscularly into the ulcers of the patients' feet, with an interval of about a centimeter between every two points and an injection volume of 0.2ml at each puncture point. The total injection volume required by the patients was the injection needles multiply 0.2ml (about 2ml of suspended cell in total). The remaining suspension was injected on both sides of the center of the main ischemic site. All patients received three injections of umbilical cord blood mononuclear cells at a week interval, with the latter two injections located around the site of the first injection. The adjuvant therapy remained unchanged within two weeks after cell injection. The follow-up period is 12 weeks after treatment to observe safety and efficacy. If the patient does not recover after 12 weeks, the follow-up period can be extended to 24 weeks.
214951127|NCT00371709|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent System
214951128|NCT00371709|DEVICE|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
214951129|NCT01593449|BEHAVIORAL|Community-based social networking intervention|Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
214951130|NCT05951920|PROCEDURE|Lymph node aspiration / Blood sampling|Lymph node aspiration / Blood sampling
214951131|NCT03366961|PROCEDURE|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
214951132|NCT06199271|DRUG|Adebrelimab and dalpiciclib|Before surgery, the eligible patients received 3 cycles of adebrelimab (1200 mg intravenously every 3 weeks, Day 1, 22 and 43) and 2 cycles of dalpiciclib (150 mg, po, every 4 weeks, day 1-21 and 29-49). Administration dose adjustments were permitted according to the haematological or non-haematological toxicity.
214951133|NCT00038311|DRUG|PN-152,243)/PN-196,444|
214951134|NCT02028962|BEHAVIORAL|Lifestyle counseling|
214951135|NCT00677573|DRUG|Fostimon|450 IU for 4 days then adjusted
214343878|NCT01316744|OTHER|pharmacogenomic studies|
214951136|NCT04687566|DRUG|Dextromethorphan|The participants will take dextromethorphan 60 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
214951137|NCT04687566|DRUG|Memantine|The participants will take memantine 5 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
214951138|NCT04687566|DRUG|Dextromethorphan and memantine|The participants will take dextromethorphan (60 mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
214951139|NCT04687566|DRUG|Placebo|The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
214951140|NCT04475718|BEHAVIORAL|Fourth Trimester Mobile Tool|A mobile web-based tool for underserved women in the fourth trimester. The mobile platform teaches self-efficacy, care management, and coping skills to help reduce major health risks and provide tools and resources to maintain mental health.
214951141|NCT04622202|DRUG|Pregabalin 150mg|oral capsule pregabalin 150 mg.
214343879|NCT01316744|OTHER|questionnaire administration|
214343880|NCT01316744|PROCEDURE|assessment of therapy complications|
214951142|NCT04622202|DRUG|multivitamin|oral placebo in the form of oral multivitamin capsule.
214951143|NCT01315288|OTHER|One of 6 video presentation by one of 4 presenters|
214951144|NCT05279118|DIETARY_SUPPLEMENT|Ketogenic diet|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
214951145|NCT05279118|DRUG|ACTH|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
214343881|NCT01316744|PROCEDURE|quality-of-life assessment|
214343882|NCT01732835|DEVICE|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
214343883|NCT02334748|DRUG|canakinumab|canakinumab
214343884|NCT02243787|DRUG|COVA322|
214343885|NCT02243787|OTHER|Placebo|
214951146|NCT05409755|OTHER|Vivacy|Vivacy and minoxidil
214951147|NCT02372435|PROCEDURE|Shortening of the interval of two-stage prosthesis exchange|The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
214951148|NCT03604575|DRUG|Insulin Lispro|
214951149|NCT03604575|DRUG|Humalog®|
215076328|NCT02258971|DRUG|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
214343886|NCT01408589|DRUG|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
214343887|NCT00216151|DRUG|Zoledronic Acid|Zoledronic Acid 4mg, every three months
214343888|NCT03112616|OTHER|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
214343889|NCT06097039|DEVICE|abdominal U/S|A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.
214951150|NCT00886964|BIOLOGICAL|Intradermal HBV 1 course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
214951151|NCT00886964|BIOLOGICAL|Intramuscular HBV I course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
214951152|NCT05262790|OTHER|This is not an intervention study|
214951153|NCT05262790|OTHER|This is not an intervention study|
214951154|NCT05262790|OTHER|This is not an intervention study|
214951155|NCT00675870|DRUG|NRX 195183 Soft Gelatin Capsule|Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.
215076329|NCT03526393|DEVICE|Survey training equipment|The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
214951156|NCT00435188|BEHAVIORAL|Multi-component physical activity counseling program|A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
214951157|NCT00521885|DRUG|Arixtra (Fondaparinox) 2.5 mg SC Daily|Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
214951158|NCT00521885|DRUG|Lovenox 40mg SC Daily|Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
214343890|NCT06097039|DEVICE|Fibroscan with Controlled Attenuated Parameter (CAP scan):|"Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m)."
214951159|NCT01040715|BIOLOGICAL|TNFa Kinoid|TNFa kinoid
214951160|NCT01040715|BIOLOGICAL|TNF kinoid|IM administration 2 or 3 injections within 28 days
214951161|NCT00478907|DRUG|KETAMINE, PROPOFOL, THIOPENTAL|
214951162|NCT00033878|DRUG|Noni Extract|
215076330|NCT03526393|DEVICE|Attack and serve training equipment|The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.
215076331|NCT03526393|DEVICE|Pass training equipment|The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
214951163|NCT02236078|DRUG|High dose isoniazid|See arm description
214951164|NCT04106271|OTHER|dyadic pain management program|a dyadic pain management program for older adults and their informal caregivers is developed as intervention. The program will be conducted at community activity center face-to-face combined with digital-based activities and the program will include 4 sessions, weekly 1 hours. Each session will be classified into three stages, including 10 minutes for watching videos and group discussion, 20 minutes for theoretical knowledge and coping skills and 20 minutes for exercising together. Last 10 minutes of each session is to wrap up and Q \& A. There will be a brief introduction of program and self-introduction of participants at the beginning of the first session. One exercise book is given to each pair and researchers have a 4-week follow-up.
214951165|NCT00335855|DEVICE|Auto-injector for IM/SC vaccine administration|
214951166|NCT02907775|DEVICE|ShefStim|Electrode arrays will be worn over the affected arm with stimulation applied over the extensor aspect of the upper arm
214951167|NCT02907775|DEVICE|Electrodes|electrodes placed over the radial nerve in radial grove
214951168|NCT02756598|DRUG|Sufentanil I|bolus dose of sufentanil 1 microgram/kg
214951169|NCT02756598|DRUG|Sufentanil II|bolus dose of sufentanil 0.5 microgram/kg
214951170|NCT02756598|DRUG|Propofol I|Continued dose of propofol 0.03 mg/kg/min
214951171|NCT02756598|DRUG|Propofol II|Continued dose of propofol 0.06 mg/kg/min
214951172|NCT00657995|DEVICE|Artificial Pancreas (STG-22)|safe tool
214951173|NCT00459368|BEHAVIORAL|Feedback of patient adherence information|Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
214951174|NCT00459368|BEHAVIORAL|Active control group|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
214951175|NCT04066322|PROCEDURE|system treatment and surgery|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
214951176|NCT04066322|OTHER|system treatment|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.
214951177|NCT04081116|OTHER|Symmetric settings (high pressures/fast rate)|Describes settings on the MI-E device
214951178|NCT04081116|OTHER|Asymmetric settings (Pi<Pe/Ti>Te)|Lower insufflation pressures at longer times
214951179|NCT04081116|OTHER|Preinclusion settings|Settings in use at start of study
214951180|NCT01500655|PROCEDURE|Regional nerve block|a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
214951181|NCT01500655|PROCEDURE|Catheter|After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
214951182|NCT03704506|DRUG|Reyanning mixture|Reyanning mixture , 20ml by mouth , 3 times per day for 7 days
214951183|NCT03704506|DRUG|amoxil capsule|amoxil capsule , 0.5g by mouth , 3 times per day for 7 days
214951184|NCT03704506|DRUG|Reyanning mixture simulator|Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
214951185|NCT03704506|DRUG|amoxil capsule simulator|amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
214343891|NCT04257318|OTHER|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregnancy
214951186|NCT01077102|OTHER|Eccentric exercise training|The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
214951187|NCT00441987|DRUG|GSI-953|
214951188|NCT05127928|DIETARY_SUPPLEMENT|Dietary Supplement: Vitamin C and vitamin E|Antioxidant supplementation
214343892|NCT00324623|BIOLOGICAL|Melan-A VLP vaccine, IMP321 adjuvant|
214343893|NCT00324623|BIOLOGICAL|adoptive immunotherapy|
214343894|NCT00324623|BIOLOGICAL|therapeutic autologous lymphocytes|
214951189|NCT05127928|DIETARY_SUPPLEMENT|Placebo|Placebo administration
214951190|NCT04971083|BEHAVIORAL|Intervention Group|This study is designed to provide patients a tool with which they can record the nutrition related symptom burden (NRSB) they are experiencing in real time. A pre-defined algorithm then provides them with tailored nutrition information and behavioural tipps based on the severity grade of the symptom recorded. The aim is to increase the chances that such symptoms, when clinically relevant, are addressed in a timely matter and thus the nutrition status is stabilized.
214951191|NCT05576428|BEHAVIORAL|Diet and exercise|diet and exercise in patients of NAFLD
214951192|NCT05576428|DRUG|NAC with diet and exercise|NAC with diet and exercise in patients of NAFLD
214951193|NCT00055497|BIOLOGICAL|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
214951194|NCT00055497|BIOLOGICAL|DB adalimumab 40 mg eow|Double-blind adalimumab 40 mg every other week by subcutaneous injection
214951195|NCT00055497|BIOLOGICAL|DB adalimumab 40 mg ew|Double-blind adalimumab 40 mg every week by subcutaneous injection
214951196|NCT00055497|BIOLOGICAL|OL adalimumab 40 mg|Open-label adalimumab every other week or every week by subcutaneous injection
214951197|NCT01648192|DRUG|Losmapimod for single dose|Film coated white tablet
214951198|NCT01648192|DRUG|Losmapimod for repeat dose|Film coated white tablet
214951199|NCT04477967|OTHER|No intervention|There are no interventions because it is a protocol study
214343895|NCT00324623|DRUG|cyclophosphamide|
214343896|NCT00324623|DRUG|fludarabine phosphate|
214343897|NCT05742373|OTHER|Exercise training in the fasted state|Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal
214343898|NCT05742373|OTHER|Exercise training in the fed state|Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal
214343899|NCT02093299|DRUG|Clopidogrel|a blood sample is drawn on all patients to determine responder status
214343900|NCT02529020|DEVICE|Mouthguard|Condition of wearing mouthguard
214343901|NCT02529020|DEVICE|No mouthguard|Condition without mouthguard
214343902|NCT00305058|DRUG|Morphine|0.05 mg/kg Intravenous
214343903|NCT00305058|DRUG|Hydromorphone|0.0075 mg/kg intravenous
214343904|NCT02987413|BIOLOGICAL|Autologous Mesenchymal stem cells (MSCs)|2 intrathecal autologous MSCs infusions (1x10\^8 cells) will be performed, escalated from 30 days apart
214343905|NCT04879472|PROCEDURE|Osteosynthesis|The elderly are mainly treated by arthroplasty (total hip replacement or hemiarthroplasty) while the younger age groups, by osteosynthesis either using pins, screws or nails
214951200|NCT05383833|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening.
214951201|NCT03910140|PROCEDURE|TILA-TACE treatment|TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China ) that was advanced from celiac artery to common hepatic artery, proper hepatic artery, hepatic artery and ultimately to tumor feeding arteries which are defined by angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate was infused alternatively with doxorubicin-lipiodol emulsion. Finally, the artery was embolized with PVA (Embosphere®, BioSphere Medical, Paris, France) and microcoil ( Tornado ®, COOK Medical, USA).
214951202|NCT00048165|DRUG|Daclizumab|Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.
214951203|NCT00048165|DRUG|Methylprednisolone|Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).
214951204|NCT00048165|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.
214951205|NCT00048165|DRUG|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
214951206|NCT00048165|DRUG|cyclosporine|Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
214951207|NCT06352125|DIAGNOSTIC_TEST|TEG 6s Citrated K, KH, RTH, FFH Cartridge|The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.
214951208|NCT06352125|DIAGNOSTIC_TEST|Clauss Fibrinogen|"Diagnostic Test: Clauss Fibrinogen Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days."
214951209|NCT03584425|DIAGNOSTIC_TEST|Rasch modified version of the Fugl-Meyer Motor assessment|All participants will receive a comprehensive clinical assessment of motor function including the Rasch modified version of the Fugl-Meyer Motor assessment and a kinematic assessment of unimanual and bimanual movements using a 45 sensor 3D active marker based motion capture system. The three primary measures investigated in the kinematics include: 1) movement efficiency, 2) movement smoothness, and 3) motor compensation.
214951210|NCT03584425|DIAGNOSTIC_TEST|Anatomical image acquisition|High-resolution structural scans will be obtained using an inversion recovery 3D spoiled gradient echo (3DSPGR) sequence using a matrix size of 256 x 256, field of view of 24 cm, section thickness of 1.5 mm with no gap between sections, and 128 slices, giving an in-plane resolution of 0.94 mm. This sequence will be used for anatomic overlays of the functional data and for spatial normalization to a standard atlas.
214951211|NCT03584425|DIAGNOSTIC_TEST|Functional MRI task and acquisition|Briefly, patients will be given two pressure-sensitive bulbs (one to be held in each hand and fastened lightly to their wrists with Velcro such that they do not drop it during the scan. During two 2½ minute runs they will be prompted to squeeze the bulb in either their affected or unaffected hand in blocks of 15 seconds. These blocks will be interspersed with blocks of rest. The pressure from the bulbs will be digitally recorded and quantified offline in order to: 1) verify that the patient was squeezing the ball, and 2) assess the presence of 'mirror movements' from the opposing hand that may inform the imaging results regarding loss of laterality).
214951212|NCT04303468|DIETARY_SUPPLEMENT|GABA|The dietary supplement GABA will be taken orally 3 times daily, before each main meal
214951213|NCT04303468|OTHER|Placebo|Gelatin capsule containing powdered cellulose
214951214|NCT00279604|BEHAVIORAL|'Problem Profile Intervention' vs. WHO-Brief Intervention|
214951215|NCT03899012|PROCEDURE|Incisional Hernia Surgery|Verification of the accuracy in the collection of 21 selected variables in the Spanish EVEREG Incisional Hernia Surgery Registry
214343906|NCT01744236|DRUG|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
214951216|NCT02387424|BEHAVIORAL|MBCT-PD|The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.
215076332|NCT05223348|OTHER|Meditation practice|Our intervention will involve two meditation exercises. 1) the experimental condition (body scan meditation). 2) the active comparator condition (listening task)
214343907|NCT01744236|DRUG|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
214343908|NCT01744236|DRUG|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
214486560|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle capillary sampling|The operation steps are the same as above, but there is no negative pressure device behind the puncture needle
214486561|NCT00968149|DRUG|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
214486562|NCT00968149|DRUG|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
214951217|NCT02387424|BEHAVIORAL|OAR|Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
214951218|NCT01812616|DRUG|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
215076333|NCT00413894|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
215076334|NCT05264987|OTHER|intensive care follow-up|The need for the mechanical ventilator, the length of stay in the intensive care unit, and outcomes of mothers were recorded. Deceased patients were evaluated in detail.
215076335|NCT02491242|OTHER|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
215076336|NCT04149158|DIETARY_SUPPLEMENT|Placebo|
215076337|NCT04149158|DIETARY_SUPPLEMENT|Sinetrol® Xpur|
214343909|NCT01744236|DRUG|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
214343910|NCT01744236|DRUG|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
214951219|NCT01812616|DRUG|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs \& Cosmetics (FD\&C)certified color additives; FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
214951220|NCT05715424|OTHER|Six interventions for children and adolescents|"* Vision Health Record Establishment and Myopia Risk Assessment.~* Evaluation of vision care behavior and development of reasonable eye use behavior.~* Health education for teachers and parents.~* Action to improve the reading and writing environment at home and school.~* One hour of outdoor activities in and out of school during the day.~* Myopia grading management and medical correction action."
214951221|NCT05216640|DEVICE|High Flow Oxygen Therapy|• The patient will be allocated into 2 groups, patients who will require ventilatory support via HFNC and those who will require HVNI
214951222|NCT01575730|PROCEDURE|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
214951223|NCT01575730|PROCEDURE|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
214951224|NCT01575730|DRUG|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
214951225|NCT00731731|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
214951226|NCT00731731|PROCEDURE|Cognitive Assessment|Ancillary studies
214951227|NCT00731731|OTHER|Laboratory Biomarker Analysis|Correlative studies
214951228|NCT00731731|DRUG|Temozolomide|Given PO
214343911|NCT01744236|DRUG|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
214343912|NCT01744236|DRUG|L-NMMA|
214343913|NCT00804947|DRUG|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
214343914|NCT00969033|DRUG|CS-1008|CS-1008
214343915|NCT00969033|DRUG|irinotecan|irinotecan
214343916|NCT05637021|OTHER|Carbon dioxide insufflated during colonoscopy|Carbon dioxide is insufflated to dilate the bowel lumen during colonoscopy.Record the amount of gas insufflated during colonoscopy.
214951229|NCT00731731|DRUG|Vorinostat|Given PO
214951230|NCT05396352|DEVICE|Transcranial direct current stimulation|TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.
214951231|NCT05232799|OTHER|Care Anywhere with Community Paramedics program|Outpatient management with supportive services provided by the community paramedic team.
214951232|NCT05790642|DEVICE|Pulse wave measurement and analysis|Different contact-less and cuff-less pulse wave measurements will be used and compared to cuff-based reference method.
214951233|NCT03471806|BEHAVIORAL|Food reward at baseline|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.
214343917|NCT02106468|DRUG|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
214343918|NCT02106468|DRUG|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
214343919|NCT05499923|DEVICE|Debonding|Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
214343920|NCT02465229|PROCEDURE|Multimodal tissue-sampling methods before and after stricture dilation|Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
214951234|NCT03471806|BEHAVIORAL|Food reward after treatment|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
214951235|NCT03970200|DRUG|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
214951236|NCT03970200|DRUG|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
214951237|NCT03970200|DRUG|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
214951238|NCT03970200|DRUG|Antibiotics|Standard of care antibiotics
214951239|NCT03521752|OTHER|Specific Exercise Program|4 weeks of exercise classes, 2 to 3 times a week for a total of 10 sessions. Classes last approximately 40 minutes. The sessions included balance training, motor strength, endurance and flexibility. The training sessions were divided into warm-up, main activity and finally relaxation.
214951240|NCT04102332|DEVICE|Safe Infusion Device|Safe infusion device is a different method than usual infusion practices (neutral solvent-purged infusers)
214951241|NCT01211132|DEVICE|Cap - Transparent retractable extension device.|Attaching a Cap - Transparent retractable extension device.
214951242|NCT01211132|DEVICE|Standard|Without attaching a transparent cap to the tip of colonoscope.
214343921|NCT02410395|PROCEDURE|Conventional|Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
214343922|NCT02410395|PROCEDURE|Modified|The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
214343923|NCT04957602|OTHER|Blood collection|Blood collection (4\*10ml) before treatment initiation and after the first evaluation (usually 3-4 months after treatment initiation).
214951243|NCT01139671|DRUG|Remifentanil|"Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.~The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses."
214951244|NCT04213833|DRUG|Propofol Injection [Diprivan]|patients will be sedated with 50 mg propofol(10 mg/ml) given slowly intravenously over 1 min
214951245|NCT04213833|DRUG|Dexmedetomidine [Precedex]|patients will received 0.5 mcg/ kg dexmedetomidine intravenously followed by syringe containing 50 mg propofol(10 mg/ml).
214951246|NCT04213833|DRUG|Palatable Lidocaine Topical Gel|15 g of palatable lidocaine gel will be gradually applied 3-5 min before the endoscopy at three consecutive 30-s intervals to the base of the tongue, the palate and the peritonsillar areas and the patients will be informed to spread it within their mouth with their tongue and swallow it later to cover the oropharynx and esophagus. Patients will be asked to register the onset of numbness, then patient will receive syringe containing 50 mg propofol (10 mg/ml) intravenously as a sedation.
214951247|NCT02112877|DEVICE|Veniti Vici™ Venous Stent System|
214951248|NCT06485011|PROCEDURE|Paltysma suturing|platysma muscle was sutured in this group with vicryl
214951249|NCT06485011|PROCEDURE|Without Platysma suturing|platysma muscle was not sutured in this group
214951250|NCT04006678|PROCEDURE|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
214951251|NCT03183479|DRUG|Fibrinogen Concentrate Human|After start of surgery when all pedicle screws are placed, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.
214951252|NCT03183479|DRUG|Normal saline|100mL normal saline will be administered to patients in control group as placebo
214951253|NCT00151164|PROCEDURE|donor bone marrow cell injection into thymus gland|
214951254|NCT04375098|BIOLOGICAL|COVID-19 convalescent plasma|COVID-19 convalescent plasma
214951255|NCT03876496|DEVICE|SensableCare System|"The Sensable®Care Mattress has sensors embedded in it. Sensable®Care System is able to identify if the subject is stirring in bed, sitting up from the bed, attempting to leave the bed, or being out of the bed. If the subject is found to be in any of these four scenarios, four different types of alerts/notifications will warn clinicians: Stirring Notification, Sitting Up Notification, Bed Leaving Alert, Out of Bed Alert, will be generated by Sensable®Care System respectively.~Once these four alerts/notifications are generated, designated attending nurses or caregivers equipped with a mobile app will receive audible, vibratory, and/or visual alerts from the Dashboard with subject's room number and type of alert displayed mobile app. Thus, interventions/assistance can be carried out presumably early. Harm to patient safety may be prevented."
214951256|NCT03817099|OTHER|Nutrition Intervention based on My Dia-RNP|Subjects in this group will be advised to follow My Dia-RNP and to incorporate diabetes-specific formula (Nutren®Untuk Diabetik)
214951257|NCT03817099|OTHER|Usual Care|Subjects in the group continue with the usual care
214951258|NCT01242501|BEHAVIORAL|60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling.|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
214951259|NCT01242501|BEHAVIORAL|20-Min education session|Patients receive a single 20 min education session for STI/HIV informationSingle brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
214951260|NCT03285659|OTHER|Intervention: INDI Implementation|Implementation of a collaborative care model in the context of primary care to manage depression
214951261|NCT06648954|DEVICE|multisite HD-tDCS|5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.
214951262|NCT06648954|DEVICE|Conventional tDCS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
214951263|NCT06648954|DEVICE|Sham stimulation|5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.
214951264|NCT06368323|BEHAVIORAL|Choir singing|The 12-week intervention will consist of 12 in-person choir-singing sessions (1 session/week, 1,5 h/session, total 18h) conducted by a choir master in addition to home training (3 x 30-minutes-sessions/week, total 18h). In total, participants will undergo the intervention for 3 hours/week for 12 weeks (i.e., 36 hours).
214343924|NCT05928598|BEHAVIORAL|Survey questionnaires|Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
214343925|NCT05928598|BEHAVIORAL|Epilepsy Visit Planner|"Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner.~Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record."
214343926|NCT05928598|BEHAVIORAL|Questionnaires for Providers|Providers will be asked to complete a survey after the clinic visit for the intervention group.
214343927|NCT04575428|DRUG|Splanchnic nerve block|Percutaneous splanchnic nerve block
214343928|NCT02944877|BEHAVIORAL|social media intervention|social media intervention
214343929|NCT02837341|DEVICE|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
214343930|NCT02940990|RADIATION|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
214343931|NCT02940990|DRUG|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
214951265|NCT06368323|OTHER|Usual care|Rehabilitation services received by patients and social activities will be monitored and documented.
214951266|NCT03742258|DRUG|Cyclophosphamide|Given IV
214951267|NCT03742258|DRUG|Doxorubicin Hydrochloride|Given IV
214951268|NCT03742258|DRUG|Prednisone|Given PO
214951269|NCT03742258|BIOLOGICAL|Rituximab|Given IV
214343932|NCT04711304|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
214343933|NCT04711304|DEVICE|Hyaluronic acid|Intraarticular injection
214951270|NCT03742258|DRUG|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
214951271|NCT03742258|DRUG|Vincristine Sulfate|Given IV
214951272|NCT05980143|OTHER|Metacognitive Therapy|The transdiagnostic Metacognitive model suggests that psychological difficulties arise from the activation of a thinking style called the CAS (Cognitive Attentional Syndrome). Metacognitive Therapy (MCT) aims to bring the CAS under control. The therapist helps the patient to learn new ways of relating to stressful thoughts.
214951273|NCT02503254|OTHER|CHTP 1.0|CHTP 1.0 ad libitum for 5 days in confinement
214951274|NCT02503254|OTHER|Conventional Cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
214343934|NCT04711304|OTHER|Saline|Intraarticular injection
214343935|NCT03779386|OTHER|music|music during labor and delivery
214343936|NCT03965052|DRUG|PRO 179|"* Generic name: Travoprost~* Distinctive denomination: Bristrio® (PRO-179)~* Active principles: Travoprost 0.004%.~* Pharmaceutical form: Ophthalmic solution~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Sophia Laboratories, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
214951275|NCT00964015|DRUG|6% Hydroxyethyl Starch 130/0.4|
214951276|NCT00964015|DRUG|0.9% Normal Saline|
214951277|NCT00196430|DEVICE|silver-contained textiles|
214951278|NCT00196430|DRUG|corticosteroid|
214951279|NCT02083653|DRUG|Sym004 (12 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
214951280|NCT02083653|DRUG|Sym004 (9/6 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
214951281|NCT02083653|OTHER|Best Supportive Care (BSC)|BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
214951282|NCT02083653|DRUG|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
214951283|NCT02083653|DRUG|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
214951284|NCT06536322|OTHER|OHS-interRAI|An oral health screening tool is being tested. Former name was the optimized oral health-related section of the interRAI (ohr-interRAI). This was further optimized into the OHS-interRAI. The OHS-interRAI comprises of 3 oral health-related items that are assessed through questioning the resident, and 6 items that require visual inspection of the mouth.
214951285|NCT03327961|DEVICE|scaffold|implantation of scaffold (eg Magmaris, Desolve, Others)
214951286|NCT05846217|DEVICE|Multiwave Locked System|Multiwave Locked System laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
214951287|NCT04558489|BEHAVIORAL|IPR + GMI|The IPR + GMI intervention aims to impact reported hopelessness, attitudes to treatment, and view of self as changeable as well as targets treatment attendance and utilization.
214951288|NCT03142373|OTHER|CV4 technique|
214951289|NCT03142373|OTHER|RR technique|
214343937|NCT03965052|DRUG|Travatan 0.004 % Ophthalmic Solution|"* Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe."
214343938|NCT06262035|OTHER|Periodontitis and Peri-implantitis|Defined periodontitis at ≤ 2 non-adjacent teeth AND Defined peri-implantitis at ≤ 1 implant, in function of at least 1 year.
214343939|NCT02545907|DRUG|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
214951290|NCT03142373|OTHER|Placebo treatment|
214951291|NCT04693156|PROCEDURE|unilateral ultrasound-guided oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. The rectus abdominis and underlying transversus abdominis muscles will be identified. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
214951292|NCT04693156|PROCEDURE|unilateral ultrasound-guided oblique subcostal TAP block with %0.9 NaCl 30ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. %0.9 NaCl 30ml will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
214951293|NCT04693156|PROCEDURE|unilateral ultrasound-guided posterior TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound (Esaote MyLab5) probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration.
214951294|NCT04693156|PROCEDURE|unilateral ultrasound-guided posterior TAP block with %0.9 NaCl 30ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. %0.9 NaCl 30ml will be injected after negative aspiration.
214951295|NCT00623051|PROCEDURE|Male Circumcision|
214951296|NCT05322356|OTHER|Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D|Target dose supplement with the TRINITY® PERINE 3D system
214951297|NCT02671656|DEVICE|Uricemia|serum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods
214951298|NCT05350345|OTHER|Root-cause analysis|The first part of this study involves a report with a root-cause analysis done by the students. The second part is a gamification in which they have to evaluate each other and give feedback.
214951299|NCT05076747|BEHAVIORAL|Cardiovascular training|8 weeks of cardiovascular training
214951300|NCT05076747|BEHAVIORAL|Standard Therapy|8 weeks of Standard Therapy
214951301|NCT01980745|DRUG|Chloroquine diphosphate 250mg|Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
214951302|NCT01980745|DRUG|Placebo|
214343940|NCT02545907|DRUG|Thalidomide|50mg capsule.
214343941|NCT02545907|DRUG|Dexamethasone|2mg tablet.
214343942|NCT04895397|DEVICE|ultrasound guided Nerve Block procedure|"In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane."
214343943|NCT02416323|OTHER|AIM HI Training|
214343944|NCT00325299|DRUG|Magnesium|
214343945|NCT01233297|DRUG|Azithromycin|10 mg/kg peroral for 3 consecutive days
214343946|NCT01233297|OTHER|Placebo mixture|Placebo mixture containing no active substance.
214343947|NCT02578524|OTHER|Survey|
214343948|NCT02985658|DRUG|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit"
214343949|NCT02985658|DRUG|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
214343950|NCT02985658|DRUG|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
214343951|NCT00399152|DRUG|Perifosine|Perifosine Oral Dose
214343952|NCT00399152|DRUG|Sunitinib Malate|Sunitinib oral dose
214343953|NCT01910519|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."
214343954|NCT01910519|BIOLOGICAL|H5N1 vaccine without adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."
214343955|NCT04266028|BIOLOGICAL|DM-101|DM-101 administered by subcutaneous (SC) injection
214951303|NCT04517045|DRUG|Dachengqi decoction|Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
214951304|NCT04517045|DRUG|probiotic L9|L92 2 tablets/time, tid, oral or nasal feeding
214951305|NCT04517045|OTHER|Conventional treatment|Conventional treatment
214951306|NCT01272375|DRUG|Treatment A|PF-04764793 250/50 using inhaler A
214951307|NCT01272375|DRUG|Treatment B|PF-04764793 250/50 using inhaler A
214343956|NCT04266028|BIOLOGICAL|Placebo to match DM-101|Placebo to match DM-101 administered by SC injection
214343957|NCT01563861|GENETIC|RNA analysis|
214343958|NCT01563861|GENETIC|gene expression analysis|
214343959|NCT01563861|OTHER|immunohistochemistry staining method|
214343960|NCT01563861|OTHER|laboratory biomarker analysis|
214343961|NCT04018872|DRUG|Itraconazole|Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
214343962|NCT02444650|DEVICE|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
214343963|NCT02444650|DEVICE|tonometer|
214343964|NCT03917693|DIETARY_SUPPLEMENT|Phytin, rice extract|Consumption of a rice extract, called phytin for a period of 2 weeks
214343965|NCT03917693|OTHER|MCC, placebo|Consumption of MCC, a placebo, for a period of 2 week
214343966|NCT02291627|DEVICE|MAC|direct laryngoscopy
214343967|NCT02291627|DEVICE|Coopdech|Video laryngoscopy
214343968|NCT02291627|DEVICE|AirTraq|optical laryngoscopy
214343969|NCT05257889|DIAGNOSTIC_TEST|blood and CSF studies + neuroimaging studies|blood and CSF studies + neuroimaging studies
214343970|NCT00000838|DRUG|Lamivudine|
214343971|NCT00000838|DRUG|Stavudine|
214343972|NCT00000838|DRUG|Zidovudine|
214343973|NCT00000838|DRUG|Didanosine|
214343974|NCT03917290|BEHAVIORAL|Neuromuscular training|Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
214343975|NCT04511689|DEVICE|gene-activated bone substitute mixed with autobone|gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
214951308|NCT01272375|DRUG|Treatment C|PF-04764793 250/50 using inhaler A
214951309|NCT01272375|DRUG|Treatment D|PF-04764793 250/50 using inhaler A
214951310|NCT01272375|DRUG|Treatment E|PF-04764793 250/50 using inhaler B
214951311|NCT01272375|DRUG|Treatment F|PF-04764793 250/50 using inhaler B
214951312|NCT01272375|DRUG|Treatment G|PF-04764793 250/50 using inhaler B
214951313|NCT06264037|OTHER|semi structured interview|semistructured interview on patient\&#39;s experience of hospitalization.
214951314|NCT05437237|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. For this purpose the Waveguard touch dry electrode EEG cap and compatible eego mini amplifier (ANT Neuro B.V., Hengelo, Netherlands) are used to record and amplify the EEG signal, respectively. Both products are CE marked as medical devices in the European Union and will be used within the intended use as described in the user manuals.
214951315|NCT03988972|DEVICE|diathermy|In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?
214951316|NCT03988972|DEVICE|scalpel|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
214343976|NCT04045457|PROCEDURE|dry needling|insertion of needle into active myofascial trigger point
214343977|NCT04619641|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
214343978|NCT04619641|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
214343979|NCT02863991|DRUG|ONC201|375 mg or 625 mg ONC201
214343980|NCT02863991|DRUG|Dexamethasone|20 mg dexamethasone
214343981|NCT02008383|BIOLOGICAL|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
214343982|NCT02008383|DRUG|Cabozantinib|"There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily."
214343983|NCT03177993|DRUG|3 drug dose - IDA|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
214486563|NCT06490783|OTHER|Noninvasive wearable devices (smartwatch and heart rate monitor band)|"Each enrolled subject will be equipped with noninvasive wearable devices (smartwatch and heart rate monitor band) to monitor physiological parameters and emotional states related to anxiety and stress. Each subject will be required to wear the smartwatch on his or her wrist for the duration of the study, about 3-6 months; while the heart rate monitor band will be worn for about 10 minutes a day. At the same time, a mobile application, RESILIENT, will be developed and implemented to serve as the main interface for self-assessment data entry and for feedback and recommendations.~The psycho-physical condition of each subject will be monitored by the app through customized and contextualized mental exercises based on daily activities. This approach will test the effectiveness of the proposed architecture in reducing unhealthy habits and promoting health and wellness recommendations"
214486564|NCT06224439|PROCEDURE|hypobaric spinal anaesthesia|0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
214486565|NCT06224439|PROCEDURE|lumbar plexus block|ultrasound and nerve stimulator will be used for lumbar plexus block
214951317|NCT04365049|RADIATION|Radiotherapy|Radiotherapy started after two cycles of chemotherapy. External beam radiation therapy was performed using an intensity modulated radiation therapy technique. The gross target volume included the gross primary tumor and positive regional lymph nodes as defined by the multiphasic imaging. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
214951318|NCT04365049|DRUG|Nab-paclitaxel|Eight 21-day cycles of nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins on days 1 and 8.
214951319|NCT04365049|DRUG|Gemcitabine|Eight 21-day cycles of gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8.
214951320|NCT04365049|DRUG|Camrelizumab|Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy.
214951321|NCT00286065|DRUG|AeroLEF|
214951322|NCT04757233|BEHAVIORAL|GlucoType|GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.
214951323|NCT00621517|DRUG|Bupropion|Partipants will receive 150 mg bupropion per night
214951324|NCT00621517|DRUG|Placebo|1 capsule nightly for six weeks
214951325|NCT01758159|DIETARY_SUPPLEMENT|Iron supplementation|
214951326|NCT01758159|OTHER|CFR|Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
215076338|NCT02281110|DEVICE|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
214951327|NCT05376020|DEVICE|Densah Burs|Densah Burs will be used in the intervention group
215076339|NCT02174367|DEVICE|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
215076340|NCT01304069|DRUG|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
214951328|NCT05376020|DEVICE|Conventional Burs|Conventional Burs will be used in the control group
215076341|NCT01304069|DRUG|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
215076342|NCT01304069|DRUG|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
214486566|NCT06224439|PROCEDURE|hyperbaric spinal anesthesia|0.5% hyperbaric Bupivacain hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
214951329|NCT04466605|OTHER|Tele-yoga therapy|Each session included combinations of different yoga exercises, postures, yoga breathing, yoga relaxation techniques, yoga counselling and meditative practices based on individualisation.
214951330|NCT04466605|OTHER|Primary care|Patients will follow standard care provided by primary care physicians including analgesics and self care management.
214951331|NCT02949141|DEVICE|Lung Ultrasound|All patients will receive lung ultrasound, chest x-ray and computed tomography
214951332|NCT02949141|DEVICE|Chest X-ray|All patients will receive chest x-ray as per usual care for evaluation for pneumonia
214951333|NCT02949141|DEVICE|Chest Computed Tomography (CT)|All enrolled patients will receive a CT scan as the gold standard for diagnosing pneumonia
214951334|NCT03213418|BEHAVIORAL|Contingency management|Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
214951335|NCT03429283|OTHER|descriptive retrospective epidemiological study|descriptive retrospective epidemiological study
214951336|NCT06295497|DEVICE|Lung-SIGHT|"* The LDCT images will be interpreted by an artificial intelligence-based programme (Lung-SIGHT) for lung nodules.~* LDCT with lung nodules ≥5mm detected by AI programme (AI+) will be sent for reporting by board-certified radiologists.~* Participants with abnormal LDCT reported by radiologists (Rad+) will be followed up at designated clinic. Management of lung nodules will follow the guidelines below for two years.~* Participants with negative LDCT determined by AI programme (AI-) will undergo LDCT thorax and blood taking two years later (T1). Patients with lung nodules detected by AI programme (AI+) will be sent for radiologist reporting and those with abnormal CT reported by radiologists (Rad+) will be followed up in lung nodule clinic as per standard of care. Patients with normal second-round LDCT as determined by AI (AI-) or radiologists (AI+ Rad-) do not require follow up."
214951337|NCT02249013|PROCEDURE|Cytoreductive Surgery (CRS)|CRS was performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.
214951338|NCT02249013|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC was performed according to the closed-abdomen technique using CDDP (25 mg/L of perfusate/m2, total limit of 240mg) for the first 10 patients and thus, using CDDP plus Doxorubicin (15mg/L) thereafter, both for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 4L to 6L) was circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.
214951339|NCT02249013|DRUG|Neoadjuvant Chemotherapy (NACT)|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
214951340|NCT02249013|DRUG|Adjuvant Chemotherapy|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
214951341|NCT02249013|PROCEDURE|Fast-track recovery strategy|A comprehensive fast-track program was applied to accelerate recovery, reduce morbidity, and shorten convalescence for patients enrolled in our trial.
214951342|NCT03063099|OTHER|ReNu™ Injection|Injection into the hip for the treatment of Osteoarthritis.
214951343|NCT02155322|BIOLOGICAL|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
215076343|NCT04225676|BIOLOGICAL|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight."
215076344|NCT03245736|DRUG|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
214486567|NCT05266417|DRUG|INS-GSH|Intranasal INS-GSH Twice Daily
214486568|NCT05266417|DRUG|Matched Placebos|Intranasal Matched Placebos Twice Daily
214951344|NCT02155322|BIOLOGICAL|Pegylated Interferon Alfa-2b|3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
214486569|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
214951345|NCT03353181|DEVICE|Endoscopic scissors|Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.
214951346|NCT03353181|DEVICE|Biliary stent|Standard placement of biliary stent
215076345|NCT01942161|DRUG|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
215076346|NCT01942161|DRUG|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
215076347|NCT01942161|DRUG|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
215076348|NCT01853579|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
214951347|NCT02800395|PROCEDURE|Malnutrition screening and perioperative nutritional support|"* Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines"
214951348|NCT00073008|DRUG|GW572016 (lapatinib)|tyrosine kinase inhibitor
214951349|NCT06364202|DIETARY_SUPPLEMENT|Peanut Butter|2 tablespoons of peanut butter
214951350|NCT02130700|DRUG|VT-464: given orally twice daily in 28-day cycles|Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
214951351|NCT02130700|DRUG|VT-464: given orally once daily in 28-day cycles|Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
214951352|NCT04491526|DRUG|TAMSULOSIN Mepha Ret Depocaps 0.4 mg|"0.4mg/day Tamsulosin hydrochloride (TAMSULOSIN Mepha Ret Depocaps 0.4 mg) from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)"
214951353|NCT04491526|DRUG|Control Intervention|One placebo capsule matching the active study drug per day from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)
214951354|NCT04540731|OTHER|This is an observational study without intervention|This is an observational study without intervention
214951355|NCT00623857|DIETARY_SUPPLEMENT|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
214951356|NCT00623857|DIETARY_SUPPLEMENT|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
214951357|NCT00623857|DIETARY_SUPPLEMENT|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
214951358|NCT00623857|DIETARY_SUPPLEMENT|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
214951359|NCT04842552|DRUG|Hydralazine hydrochloride 25mg tablets|Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
214951360|NCT04842552|DRUG|Placebo|Placebo
214951361|NCT05569993|DRUG|Glutamine|.3 mg/kg of glutamine
214951362|NCT05569993|OTHER|Placcebo|Patients will recieve placcebo
214951363|NCT02392702|DRUG|C-10355|
214951364|NCT02392702|DRUG|C-10358|
214951365|NCT02392702|DRUG|Kalydeco|
214951366|NCT02676635|BEHAVIORAL|Ergonomics training and/or Safety Voice training|"Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a safety voice about safety in general, and ergonomics specifically."
214951367|NCT00913770|BEHAVIORAL|Brief Negotiation Interview (BNI)|Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
214951368|NCT00913770|DRUG|Buprenorphine Initiation|
214951369|NCT00555776|DRUG|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
214951370|NCT00555776|DRUG|placebo|placebo is given with the same definition as Gabapentin
214951371|NCT03846128|BIOLOGICAL|blood sample|blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1
214951372|NCT03337048|DEVICE|SpeediCath|SpeediCath is a standard intermittent catheter that is on the market.
214951373|NCT00320697|DRUG|bupropion + nicotine patch + nicotine gum or lozenges|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
214951374|NCT00320697|DRUG|Placebo pill + placebo patch|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
214951375|NCT03260790|BIOLOGICAL|PCV13|Single 0.5 ml dose of PCV13 administered via intramuscular injection
214951376|NCT03260790|BIOLOGICAL|PPSV23|Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
214951377|NCT06854809|BEHAVIORAL|Cognitive functional therapy|"The intervention consists of a Cognitive-Functional Therapy (CFT) program for individuals with shoulder pain, conducted by trained physiotherapists (106 hours of training) under the supervision of an expert with over 8 years of experience. CFT adopts a biopsychosocial approach and is structured into three main components:~Making Sense of Pain - A cognitive component aimed at reinterpreting dysfunctional beliefs about pain through a reflective process based on the patient's life history, promoting understanding and self-efficacy.~Graded Exposure with Control - Gradual exposure to functional activities, aiming to modify maladaptive associations between movement and pain, fostering the development of movement confidence.~Lifestyle Change - Discussion and implementation of strategies to promote a healthy lifestyle, including physical activity, sleep habits, and stress management.~All three components are integrated from the first session, with initial focus on building the therapeutic all."
214951378|NCT06854809|OTHER|Therapeutic exercise|Participants in the Therapeutic Exercises Group will engage in individualized exercises targeting the scapulothoracic musculature and rotator cuff. The exercises, performed bilaterally, include lateral arm rotation, T, W, wall hand slide, and diagonal arm movement upwards. Each participant will be guided by one of two physiotherapists, randomly assigned. The exercises will follow a protocol consisting of 3 sets of 12 repetitions, with 1-minute rest between sets, using progressively resistant Thera-Bands®. Resistance will increase when pain is ≤2 on the Numerical Rating Scale and perceived exertion is \<3 on the Borg Scale. The protocol was designed based on scientific literature and shoulder pain treatment guidelines to address muscle activation deficits and rotator cuff and scapulothoracic imbalances.
214951379|NCT05278494|DRUG|Dextromethorphan Hydrobromide|PO
214951380|NCT05278494|DRUG|Placebo|PO
214951381|NCT03286933|BEHAVIORAL|yoga|75 minute weekly group yoga classes for 8 weeks. Home program online.
214343984|NCT03177993|DRUG|3 drug dose - IDA with second dose of ivermectin|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
214343985|NCT03177993|DRUG|2 drug dose - DA|"Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
214343986|NCT02746692|OTHER|Fit15|"Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).~Total duration 15 minutes circle training: 20s workout, 10 rest"
214343987|NCT02746692|OTHER|Endurance|Moderate intensity ergometer training. Total duration 50 minutes
214343988|NCT05368805|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5
214343989|NCT05368805|DRUG|Dabigatran Etexilate|Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5
214343990|NCT05368805|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
214343991|NCT04887870|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
214343992|NCT04887870|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
214343993|NCT04887870|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
214343994|NCT04887870|DRUG|Enfortumab Vedotin-Ejfv|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
214951382|NCT05687682|BIOLOGICAL|AM-928|AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.
214951383|NCT02838589|DRUG|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
214951384|NCT02838589|DRUG|Isotonic saline|Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
214951385|NCT01531595|DRUG|Bevacizumab plus alternating XELOX/XELIRI|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
214343995|NCT04887870|DRUG|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
214343996|NCT01853150|DEVICE|rTMS Motor cortex|
214343997|NCT01853150|DEVICE|rTMS Supplementary motor area|
214951386|NCT04938414|DIAGNOSTIC_TEST|Lumbar puncture|Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test
214951387|NCT02507024|OTHER|Online questionnaire|
214951388|NCT02862925|PROCEDURE|Fetal Scalp Stimulation|"During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention."
214951389|NCT02791438|DRUG|Azilsartan|Azilsartan granules and tablets
214951390|NCT02791438|DRUG|Placebo|Placebo-matching azilsartan granules and tablets
214951391|NCT02298413|DEVICE|PCI with Absorb scaffold|Implantation of biovascular scaffold during PCI
214951392|NCT02910726|PROCEDURE|Sentinel Lymph Node Biopsy|
214951393|NCT02910726|DRUG|indocyanine green (ICG)|
214951394|NCT05310526|OTHER|Training Group|Training for prescribing the Brazilian cardioprotective diet
214951395|NCT06670833|OTHER|Lung ultrasound|Portable lung ultrasound
214951396|NCT06670833|OTHER|Standard of Care (SOC)|SOC antibiotic treatment
214951397|NCT07010952|DIAGNOSTIC_TEST|AI-based image analysis|AI-based imaging analysis
214951398|NCT07010952|OTHER|AI-based imaging analysis|AI-based imaging analysis
214951399|NCT07005518|OTHER|No Intervention: Observational Cohort|This is a non-interventional observational study. It will simply look at the data and compare them between the monitors provided.
214343998|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on Planned Behavior Theory|On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
214343999|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on standart|Standard training for gestational diabetes will be given once at 28 weeks of gestation.
214344000|NCT05294757|OTHER|Physical exercise|1\. Hospital exercise cohort: Participants will be consecutively recruited from the scheduled patient list of the falls unit and the outpatient clinics of Hospital 1. After informed consent acquisition, patients will receive a baseline clinical evaluation. Ultrasound measurements and DXA scan will be conducted, and blood samples will be collected, processed, and stored. Patients will be included in the 16-week multicomponent physical exercise program described below. After the completion of the exercise program, at 16-week follow-up, clinical evaluation, ultrasound, DXA, and blood-sample testing will be repeated.
214344001|NCT05239026|BEHAVIORAL|Advanced treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
214344002|NCT05239026|BEHAVIORAL|Traditional treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
214344003|NCT01651429|BEHAVIORAL|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
214486570|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase)
214486571|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase)
214486572|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
214486573|NCT05383352|DRUG|Folinic Acid|LV 400 mg/m2 intravenously over 30 minutes, on Day 1 and Day 15 of every 28-day cycle
214486574|NCT05383352|DRUG|5-Fluorouracil|5-FU 2,400 mg/m2 intravenously over 46 hours, on Day 1 and Day 15 every 28-day cycle
214486575|NCT05901727|OTHER|No intervention|Observational data collection only.
214951400|NCT02393430|DRUG|Rebamipide|Rebamipide is a
214951401|NCT02393430|BEHAVIORAL|optimization of life style|
214951402|NCT07019831|PROCEDURE|Body positioning|Each subject will breathe in both the supine and prone positions, randomly applied for 15 minutes each. The procedure will be performed twice: once for the assessment of respiratory physiology, and once for computed tomography acquisition.
214951403|NCT07015996|BIOLOGICAL|Tezepelumab|"Monotherapy Period: Participants randomized to tezepelumab will receive two subcutaneous (SQ) injections of tezepelumab 210 mg during the monotherapy period.~Combination Therapy Period: Participants randomized to Tezepelumab will continue to receive Tezepelumab 210 mg every 4 weeks.~Withdrawal Period: Participants will stop receiving Tezepelumab injections."
214951404|NCT07015996|DRUG|Peanut Oral Immunotherapy (OIT)|"Monotherapy Period: Not Applicable. Combination Therapy Period: During combination therapy period, each participant will start peanut OIT. Participants will start on a minimum of 0.1 mg peanut OIT, with starting dose depending on last tolerated dose from screening double-blind placebo-controlled food challenge (DBPCFC) and build to a maximum of 6 mg peanut OIT on the initial dose escalation (IDE) day. Participants will return every 2 weeks for dose escalation to a goal maintenance dose of 2000 mg peanut protein.~Withdrawal Period: Participants will stop peanut OIT."
214951405|NCT07015996|BIOLOGICAL|Placebo for Tezepelumab|"Monotherapy Period: Participants randomized to placebo for tezepelumab will receive two subcutaneous (SQ) injections of placebo 210 mg during the monotherapy period.~Combination Therapy Period: Participants randomized to placebo will continue to receive placebo for Tezepelumab every 4 weeks.~Withdrawal Period: Participants will stop receiving placebo injections."
214951406|NCT03443258|OTHER|Needs assesment tool integrated in nursing consultation.|Needs assessment tool consisting of 57 items related to functional, emotional, social and existential areas guide follow-up care and referral to multidisciplinary team rehabilitation e.g. dietician; speech-pathologist; psychologist, etc
214951407|NCT07022821|DRUG|Dexmedetomidine|"Dexmedetomidine infusion at one of the following doses:~Group A: 0.2 µg/kg/hr Group B: 0.3 µg/kg/hr Group C: 0.4 µg/kg/hr Route of Administration: Intravenous Frequency: Continuous infusion during postoperative period"
214951408|NCT07022821|DRUG|ketamine|"Ketamine infusion at a fixed dose of 0.25 mg/kg/hr administered in all three groups.~Route of Administration: Intravenous Frequency: Continuous infusion during postoperative period"
214951409|NCT07022951|OTHER|Preoperative fasting|This cohort study assesses the duration of preoperative fasting and its clinical effects
214951410|NCT07023198|OTHER|Clinical breast examination and Navigation|trained nurses on clinical breast examination and navigation will provide screening for all eligible women and they will follow those women who will have suspicious breast lesions until they have completed their final diagnosis of breast cancer and initiation of breast cancer treatment
214951411|NCT00564395|DRUG|Insulin Detemir mixed with RAI injection|Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection
214951412|NCT00564395|DRUG|Insulin Detemir and RAI injection|Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection
214951413|NCT07026058|OTHER|Sound Wave Treatment|"Sound wave treatment with 6 sessions initially, 3 times a week, followed by the next 6 sessions with a frequency of 2 times a week. Patient's position was analysed through digital X-ray of cervical spine, 80 pulses are typically administered in a session. These pulses are applied generally, targeting the 1st cervical vertebra of the spine. This method aims to achieve spinal alignment through the vibrations generated by the treatment. Before and after the treatment, a patient assessment is conducted to observe visible improvements. A mixed waveform of 8Hz-202 Hz resonated throughout the spine, with intensities ranging from 0.3 to 1. In order to affect the lumbar region, where they are also applied, sound waves are employed to activate C1.~After First 3 sessions vibrations on pain focal points also given to the patient the 40 pulses are typically administrated at pain point."
214951414|NCT07026058|OTHER|Standard physiotherapy|Flexibility Training: Stretching exercises are crucial to improve the flexibility of the spine and surrounding muscles. This includes stretches for the hamstrings, hip flexors, and lower back Strengthening Exercises: Focus on strengthening the core muscles, including the abdominal and back muscles. Common exercises include pelvic tilts, bridging, and lumbar stabilization exercises Postural Training: Education and exercises to correct posture are vital. Proper posture reduces strain on the spine and helps prevent further injury.(31). Techniques such as ergonomic adjustments at work and home, along with exercises like seated squats and calf stretches Manual Therapy: Techniques such as myofascial release (32) and spinal mobilization. Spinal mobilization as one of the most preferable approaches for the management of LBP
214951415|NCT07026487|OTHER|Music intervention|This group will receive music therapy while performing Needle EMG
214344004|NCT02693873|BEHAVIORAL|GLA:D Canada (education and neuromuscular exercise program)|"EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.~EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions)."
214344005|NCT01471002|DEVICE|Galil Medical patented 17G Cryoablation Needles|
214344006|NCT00901290|DRUG|monophasic oral contraceptive|mg, oral dose
214344007|NCT00901290|DRUG|AZD7325|mg, oral dose
214486576|NCT05180838|DEVICE|BioSticker|The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring
214951416|NCT07027085|DEVICE|virtual reality|The intervention group will be applied 14 sessions of virtual reality application, each session lasting 30 minutes and 2 sessions per week. The sessions will be held in a room allocated for this study in the community mental health center. The device on which the application will be made was determined as Meta Quest 3. The contents to be used in the device were determined to be in line with the areas to be examined.
214344008|NCT00724347|BEHAVIORAL|Consonant Identification Training|Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
214344009|NCT00147186|DEVICE|Hylan G-F 20|
214486577|NCT03217461|PROCEDURE|Limbal autograft|Simple dermoid excision will be performed, followed by closure of the bare sclera and cornea by sutured femtosecond laser-assisted limbal autograft.
214486578|NCT03217461|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
214951417|NCT00687882|OTHER|Shortened duration (6 weeks) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
214951418|NCT00687882|OTHER|Conventional duration (3 months) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
214951419|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
214951420|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
214951421|NCT07025902|DIAGNOSTIC_TEST|Standardized Psychological Screening Using EPDS and HAM-D|Participants will undergo a standardized psychological screening protocol for postpartum depression within 72 hours after delivery. The protocol includes: (1) completion of the Edinburgh Postnatal Depression Scale (EPDS), a 10-item self-administered questionnaire assessing depressive symptoms; and (2) administration of the Hamilton Depression Rating Scale (HAM-D), a 17-item clinician-administered tool for evaluating the severity of depressive symptoms. The combined use of these tools allows early detection and stratification of postpartum depressive symptoms in a clinical population.
214344010|NCT04420299|DRUG|Bemiparin|Bemiparin at therapeutic dose for 10 days
214344011|NCT04420299|DRUG|Bemiparin|Bemiparin at prophylactic dose for 10 days
214344012|NCT01629329|DRUG|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
214344013|NCT01629329|DRUG|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
214344014|NCT04391582|OTHER|Tilapia skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
214344015|NCT04391582|DRUG|silver sulfadiazine cream 1%|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
214344016|NCT01164059|DRUG|Olanzapine|Olanzapine 10, 15, or 20 mg / day
214344017|NCT01164059|DRUG|Flupentixol|Flupentixol 6, 9, or 12 mg / day
214344018|NCT01164059|DRUG|Quetiapine|Quetiapine 400, 600, or 800 mg / day
214486579|NCT02719574|DRUG|FT-2102 (olutasidenib)|FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
214344019|NCT01164059|DRUG|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
214951422|NCT07026838|BEHAVIORAL|The Light Building Emotional Awareness and Mental Health (BEAM) Program|"The LightBEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving parental mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy.~Program delivery will be facilitated through a mobile application. The LightBEAM program consists of four different components; weekly parenting and mental health videos, weekly progress tracking, a group forum, and exercises designed to reinforce skills learned through the video content."
214344020|NCT01164059|DRUG|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
214344021|NCT03096782|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214344022|NCT03096782|DRUG|Busulfan|Given IV
214344023|NCT03096782|DRUG|Clofarabine|Given IV
214344024|NCT03096782|DRUG|Cyclophosphamide|Given IV
214344025|NCT03096782|BIOLOGICAL|Filgrastim-sndz|Given SC
214344026|NCT03096782|DRUG|Fludarabine|Given IV
214344027|NCT03096782|DRUG|Melphalan|Given IV
214344028|NCT03096782|DRUG|Mycophenolate Mofetil|Given IV or PO
214344029|NCT03096782|BIOLOGICAL|Rituximab|Given IV
214486580|NCT02719574|DRUG|Azacitidine|azacitidine will be administered per site's standard of care
214486581|NCT02719574|DRUG|Cytarabine|low-dose cytarabine will be administered per site's standard of care
214486582|NCT06336967|BEHAVIORAL|GUIDE|The GUIDE App is a wellbeing app designed for first responders and veterans that uses small group support, a learning management system, drivers of behavior change, and an anonymous member experience safeguarded by a leader in identity and login privacy, Okta (okta.com). It includes three main features: 1) Community, 2) Wisdom, and 3) Daily Practice. The Community feature connects app users with an online community of like folks, allowing for human support, encouragement, accountability and coaching. Online communities are moderated by GUIDE employees. The Wisdom feature includes tools and interactive media for personal growth. The Daily Practice feature includes simple, daily routines to maintain mental and emotional wellness.
214486583|NCT02720068|BIOLOGICAL|Favezelimab|IV infusion
214951423|NCT07027592|OTHER|Survey Study|The injury risk in veteran football players will be assessed based on FIFA 11+.
214951424|NCT07025837|DEVICE|iRESTORE Illumina LED Face Mask and Neck & Chest Mask|A pair of light-emitting diode (LED) therapy devices designed for at-home use. The facial and neck/chest masks deliver low-level red light therapy through embedded LEDs to improve visible signs of skin aging.
214344030|NCT03096782|DRUG|Tacrolimus|Given IV
214344031|NCT03096782|RADIATION|Total-Body Irradiation|Undergo total body irradiation
214486584|NCT02720068|BIOLOGICAL|Pembrolizumab|IV infusion
214951425|NCT07026149|DRUG|Apatinib+Camrelizumab+SOX|Apatinib 250mg+Camrelizumab 200mg +S-1, Oxaliplatin, q3w
214951426|NCT07026149|RADIATION|Preoperative Radiotherapy|Radiotherapy was administered using IMPT or IMRT. The target volume includes the gastric lesion, and regional lymph nodes. A regimen of 41.4 Gy in 23 fractions is preferred.
214951427|NCT07026201|OTHER|colectomy with primary anastomosis|left hemicolectomy or sigmoidectomy, formal resection was carried out following conventional steps of radical resection.with primary anastomosis
214951428|NCT07027267|DEVICE|Implantation of Spirair device into the middle turbinates|The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery.
214951429|NCT07027267|DEVICE|TurbAlign|The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery
214344032|NCT03096782|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
214344033|NCT00558675|BIOLOGICAL|AlloStim|single intravenous infusion of 1 x 10\^9 AlloStim cells
214344034|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7
214344035|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7 and day 14
214344036|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7, day 14 and day 21
214344037|NCT06592313|PROCEDURE|Intubation|Aiway management procedure involving the Insertion of an orotracheal cannula through the oropharynx.
214344038|NCT06664346|BEHAVIORAL|Immersive virtual reality mindfulness|Immersive virtual reality mindfulness
214344039|NCT06662669|DRUG|YL-13027|YL-13027 is a small molecule inhibitor of the TGF-βRI target.
214344040|NCT06662669|DRUG|HY-0102|HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.
214344041|NCT06662669|DRUG|Gemcitabine|Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.
214344042|NCT06662669|DRUG|Nab-paclitaxel|Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis
214344043|NCT06663878|GENETIC|MWAV201|Nonreplicating, recombinant gene transfer vector
214344044|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to sit on a chair with their back facing the examiner, placing their arms in a relaxed position with their head supported on a surface in front of them. The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
214486585|NCT02720068|DRUG|Oxaliplatin|IV infusion
214486586|NCT02720068|DRUG|Irinotecan|IV infusion
214951430|NCT07025967|BEHAVIORAL|Mölkky|The Mölkky group participants receive two-hour weekly or bi-weekly Mölkky training sessions at their elderly community centers. In the sessions, participants are divided into two teams, taking turns throwing a wooden pin called the Mölkky to hit 12 smaller skittles. The fallen skittles are placed upright where they landed after each turn. The first team that reaches exactly 50 points wins.
214951431|NCT07025967|BEHAVIORAL|Home activity|The participants in the home program receive weekly visits by social workers, physiotherapists, or occupational therapists at their homes for an activity regime including closed-skilled exercises and cognitive training. The closed-skilled exercises included stretching, elastic band exercises and functional exercises like tandem standing and bridging. Cognitive training included reality orientation, memory exercises, calculation, and mind-body exercises like Baduanjin.
214951432|NCT07027501|OTHER|The video based education group|The parents in the intervention group were provided with a video-based educational material on febrile seizures, which they accessed via a QR code.
214344045|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to lay prone position.The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
214344046|NCT02760238|OTHER|Observational|
214344047|NCT04823598|PROCEDURE|Coached pushing and Finnish manual perineal protection|"Pushing technique: Rest will be encouraged between uterine contractions. With the onset of uterine contraction, women will be instructed to breathe normally. They will then be instructed to take a deep breath and hold (closed-glottis), and push down strongly for as long as possible (up to 10 seconds). After pushing effort, normal breathing will be encouraged, then the same pushing instruction will be repeated again.~Fetal expulsion: The expulsion rate of the fetal head will be controlled by light pressure applied on the fetal occiput. Simultaneously, the thumb and index finger of the dominant hand will be used to support the perineum, while the bent middle finger will grasp the baby's chin. Once a good grip is achieved, the investigator slowly assists in the expulsion of the fetal head from the vaginal introitus. When most of the fetal head is out, the perineal ring will be pushed under the baby's chin."
214344048|NCT04823598|PROCEDURE|Uncoached pushing and Hands-poised perineal protection|Women will not be given any instructions regarding straining and breathing, and will be allowed to follow their own pushing impulses. During the expulsion of the fetal head, the hands of the researcher will be kept in the air and ready for the intervention, but pressure will not be applied to the fetal head or perineum unless necessary (fetal hypoxic appearance, strain detection with a risk of spontaneous laceration towards the anus in the midline).
214344049|NCT03843788|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (\>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
215076349|NCT01853579|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
214344050|NCT02899897|DEVICE|echocardiography in IV fluid therapy|
214486587|NCT02720068|DRUG|Leucovorin (Calcium Folinate)|IV infusion
214486588|NCT02720068|DRUG|Fluorouracil [5-FU]|IV infusion
214951433|NCT07026240|DIAGNOSTIC_TEST|DNA test|a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood
214951434|NCT07026682|DRUG|Low Osmolar ORS|"Composition: Na⁺ 75 mmol/L, K⁺ 20 mmol/L, Cl- 65 mmol/L, citrate 10 mmol/L, glucose 75 mmol/L; osmolarity 245 mmol/L.~Administered orally in rehydration regimen over 24 hours."
214951435|NCT07026682|DRUG|ReSoMal|"Composition: Na⁺ 45 mmol/L, K⁺ 40 mmol/L, Cl- 76 mmol/L, citrate 7 mmol/L, glucose 125 mmol/L, Mg 6 mmol/L, Zn 300 µmol/L, Cu 45 µmol/L; osmolarity 300 mmol/L.~Administered orally over 24 hours according to rehydration protocol."
214951436|NCT07027137|DRUG|SRP+ANB+SURG|SRP (scaling and root planing) with ANB (local antibiotic application- 10%doxycycline) and SURG (regeneration procedure according to MIST/M-MIST)
215076350|NCT01783574|DRUG|Testosterone|
215076351|NCT01783574|DRUG|Placebo|
215076352|NCT02422836|OTHER|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
215076353|NCT02213185|OTHER|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
214486589|NCT02720068|BIOLOGICAL|Favezelimab/Pembrolizumab|IV infusion
215076354|NCT02762240|OTHER|DHQP 2016|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
215076355|NCT02762240|OTHER|DHQP 2018|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
215076356|NCT02608775|DEVICE|Metrodoloris Medical System|Application of a skin electrode
214344051|NCT00607841|DRUG|Ispinesib|10 mg/m2 dose as a 1-hour intravenous infusion.
214951437|NCT07027137|PROCEDURE|SRP+SURG|SRP (scaling and root planing) and SURG (regeneration procedure according to MIST/M-MIST)
214951438|NCT07026227|DRUG|Xuebijing Injection|Xuebijing injection (Tianjin Hongri Pharmaceutical Co., Ltd., National Drug Standard Z20040033).
214951439|NCT07026227|PROCEDURE|Conventional Treatment for High-Voltage Electrical Burns and AKI|Standard multidisciplinary care including general burn assessment, wound management (cleaning, debridement, dressings), fluid resuscitation as per burn protocols, management of electrolyte imbalances
214951440|NCT07027436|DRUG|Chemotherapy/Radiation|Combination of radiation and chemotherapy
214344052|NCT00607841|DRUG|Ispinesib|12 mg/m2 dose as a 1-hour intravenous infusion.
214344053|NCT00607841|DRUG|Ispinesib|14 mg/m2 dose as a 1-hour intravenous infusion.
214486590|NCT02720068|DRUG|Lenvatinib|Oral
214486591|NCT06284876|DRUG|Ilaprazole|Ilaprazole 10 mg
214951441|NCT07026136|OTHER|Hybrid Digital Learning with AI Chatbot for Geriatric Communication|A web-based, self-directed learning program integrated with a conversational AI chatbot. The chatbot reinforces learning and allows for flexible post-training practice.
214951442|NCT07026136|OTHER|Traditional Learning: Printed Educational Materials|Traditional teaching materials, printed document including structured readings on aging knowledge, empathy, communication barriers, and case-based communication strategies with older adults.
214951443|NCT07027020|DRUG|Oxybutynin Hydrochloride|Pharmaceutical form: solution. Route of administration: Intravesical. Medicinal product unique ID: PRD8074745. EU active substance code: SUB03581MIG.
214951444|NCT07027020|DRUG|Placebo|Pharmaceutical form: solution. Route of administration: Intravesical.
214951445|NCT07026422|COMBINATION_PRODUCT|Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy|"1. Radiotherapy:~   Radiotherapy location: primary site and the corresponding draining lymph node. Radiotherapy techniques: IMRT/VMRT.~   Radiotherapy dose and fractionation pattern: conventional external irradiation, 50Gy/25 fx/5 weeks or 25Gy/5fx/1 week.~2. Chemotherapy:~Long-course radiotherapy concurrent with chemotherapy: capecitabine 825mg/m2, bid, d1-5/week.~Short-course radiotherapy without concurrent chemotherapy. Consolidation chemotherapy and immunotherapy: QL1706 (iparomlimab and tuvonralimab 5mg/kg, d1) and CAPOX (Oxaliplatin 130mg/m2, d1 + capecitabine 1000mg/m2, bid, d1-14), repeated on a 21-day cycle, for 6 cycles. 3. Surgery or watch-and-wait Total mesorectal excision (TME), or watch-and-wait (for patients with clinical complete response)."
214951446|NCT07026747|BEHAVIORAL|Standard Hand Rehabilitation Only|Standard Hand Rehabilitation Program will be delivered over a total duration of six weeks. During the first three weeks, the program will be administered five days per week, and during the following three weeks, it will be performed three days per week. The rehabilitation program will include scar tissue massage, passive and active range of motion exercises for the fingers and wrist, sensory re-education, and edema control using retrograde massage and Coban wrapping. Joint mobilization techniques will be applied to the finger and wrist joints, along with tendon gliding and tendon blocking exercises. Strengthening and stretching exercises targeting the hand and wrist muscles will be progressively introduced throughout the program. Functional training and moderate-level activities will be included as tolerated, particularly in the later stages of the program. The intervention will be structured to gradually increase in intensity and complexity across three phases, each lasting two weeks.
215076357|NCT02608775|DEVICE|Aisys® care station, Acertys|Standard photoplethysmography
215076358|NCT05289271|BIOLOGICAL|Vaxelis™|Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
215076359|NCT06344052|DRUG|SP-002|SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
215076360|NCT06344052|DRUG|Vismodegib|The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
215076361|NCT06017921|DRUG|Eszopiclone 3 mg|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
215076362|NCT06017921|DRUG|Placebo|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
214344054|NCT06311994|DEVICE|Virtual reality|"Factors that may affect patient compliance with the VR-based intervention method to be applied to patients undergoing knee surgery and the factors that may affect the measurements to be performed were evaluated through a literature review and inclusion and exclusion criteria were created."
214344055|NCT05471973|OTHER|Multidisciplinary Team|Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
214344056|NCT05471973|OTHER|Outreach Visits|An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
214486592|NCT06284876|DRUG|Lansoprazole|Lansoprazole 15 mg
214486593|NCT06284876|DRUG|Ilaprazole Placebo|Placebo of Ilaprazole 10 mg
214486594|NCT06284876|DRUG|Lansoprazole Placebo|Placebo of Lansoprazole 15 mg
214486595|NCT05567068|DRUG|Atorvastatin 80mg|Atrovastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement and immunomodulation independent of its basic lipid-lowering properties
214486596|NCT05567068|DRUG|Mesalamine|Mesalamine
214486597|NCT04864652|DEVICE|CHILLS Procedure|CHILLS Cryotherapy procedure
214486598|NCT05768139|DRUG|STX-478|STX-478 is a mutant-selective PI3Kα inhibitor
214486599|NCT05768139|DRUG|Fulvestrant|Fulvestrant
214486600|NCT05768139|DRUG|Ribociclib|Ribociclib
214486601|NCT05768139|DRUG|Palbociclib|Palbociclib
214486602|NCT05768139|DRUG|Letrozole|Letrozole
214486603|NCT05768139|DRUG|Anastrozole|Anastrozole
214486604|NCT05768139|DRUG|Exemestane|Exemestane
215076363|NCT05223907|DRUG|Etomidate|Etomidate will be used for general anesthesia
215076364|NCT05223907|DRUG|Propofol|Propofol will be used for general anesthesia
215076365|NCT02567370|DRUG|AMG 581|Active drug
214951447|NCT07026747|BEHAVIORAL|Supervised Core Stabilization + Standard Hand Rehabilitation|"The second group will receive the same six-week Standard Hand Rehabilitation Program as the control group (5 days per week for the first 3 weeks, and 3 days per week for the last 3 weeks). In addition, participants will perform a Supervised Core Stabilization Exercise Program three times per week for six weeks under a physiotherapist's supervision.The exercises will focus on activating the transversus abdominis and coordinating breathing to improve core stability.Each session will include a warm-up, main core exercises, and a cool-down.In weeks 0-2, the program will include diaphragmatic breathing, transversus abdominis activation, curl-ups, and bridging. In weeks 2-4, it will progress to cross arm-leg extensions, side planks, the hundred exercise, and single-leg bridging. In weeks 4-6, Swiss ball exercises will be introduced, including weight shifting forward and backward, hip flexion, bridging, and contralateral arm.The program will advance in intensity across three phases."
214951448|NCT07026747|BEHAVIORAL|Unsupervised Core Stabilization + Standard Hand Rehabilitation|"he third group will receive the same six-week Standard Hand Rehabilitation Program as the control group (5 days/week for 3 weeks, then 3 days/week for 3 weeks). They will also do an Unsupervised Core Stabilization Exercise Program three times a week for six weeks in the same clinic. Exercises will be the same as the supervised group but done alone using videos without a physiotherapist. The exercises will focus on activating the transversus abdominis and coordinating breathing to improve core stability. Each session includes warm-up, main exercises, and cool-down. In weeks 0-2, exercises include diaphragmatic breathing, transversus activation, curl-ups, and bridging. Weeks 2-4 add cross arm-leg extensions, side planks, the hundred, and single-leg bridging.Weeks 4-6 introduce Swiss ball exercises, including weight shifting forward and backward, hip flexion, bridging, and contralateral arm lifts. The program will advance in intensity across three phases."
214951449|NCT07027683|DIAGNOSTIC_TEST|Cardiac MRI|Post-MI cardiac MRI
214951450|NCT02901301|DRUG|Pembrolizumab|200mg, IV, q3weeks, Day 1
214951451|NCT02901301|DRUG|Trastuzumab|6mg/kg (8mg loading dose), IV, q3weeks, Day 1
214951452|NCT02901301|DRUG|Capecitabine|1000mg/m2, PO, BID, Day 1-14
214951453|NCT02901301|DRUG|Cisplatin|80mg/m2 (level 1), IV, q3weeks, Day 1
214951454|NCT00777322|PROCEDURE|Excimer laser ablation, and collagen cross-linking|Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15-30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross-linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
214951455|NCT00653302|DRUG|Lantus (insulin glargine) + Glucophage (Metformin)|
214951456|NCT05159102|OTHER|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) and Sports (during intervention)
214951457|NCT05159102|BEHAVIORAL|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, parent workshops provide them with resources to engage in Physical activity
214951458|NCT00366119|DRUG|Ramipril|
214951459|NCT02620384|DRUG|Experimental: Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
214951460|NCT02620384|DRUG|Experimental: Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
214951461|NCT00259974|DRUG|Rituximab|Rituximab
214951462|NCT02071082|DRUG|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
214951463|NCT05447676|DRUG|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose.
214951464|NCT05447676|OTHER|Placebo drug|The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.
214951465|NCT05447676|OTHER|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
214951466|NCT05447676|BEHAVIORAL|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
214951467|NCT00691873|DRUG|Placebo|placebo
214951468|NCT00691873|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
214951469|NCT06150768|DEVICE|Cobalt Chromium Removable Partial Denture|The patient will receive Removable Partial Denture to restore missing teeth in Kennedy Class II cases.
214951470|NCT06150768|DEVICE|Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture|The patient will receive Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
214951471|NCT06150768|DEVICE|Implant-Supported Zirconia Fixed Partial Denture.|The patient will receive Implant-Supported Zirconia Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
214951472|NCT02101359|DRUG|T2380|200 microlitres of T2380 will be administrated intracamerally
215076366|NCT02567370|DRUG|Placebo|Placebo
215076367|NCT02823054|DEVICE|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
214344057|NCT05471973|OTHER|Multifaceted Intervention|These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
214344058|NCT05471973|OTHER|Measurement and Feedback|The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
214951473|NCT02101359|DRUG|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
214344059|NCT01177098|DRUG|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
214344060|NCT01177098|DRUG|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
214344061|NCT04365946|PROCEDURE|Gastroscopy|Upper GI endoscopy and biopsy
214344062|NCT05032703|DEVICE|Arm ergometer|"The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises."
214344063|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²) The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
214344064|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Escalating dosage of drugs for PIPAC: Cisplatin + Doxorubicin (from 15 mg/m² + 3 mg/m² to 100 mg/m² + 30 mg/m²) or Oxaliplatin (from 92 mg/m² to 300mg/m²).The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters.
214344065|NCT03203213|PROCEDURE|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
214344066|NCT04381026|DIETARY_SUPPLEMENT|Botanical dry extracts combination|Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)
214344067|NCT04381026|DIETARY_SUPPLEMENT|Placebo|Filler agent
214344068|NCT05869305|DIETARY_SUPPLEMENT|whey protein isolate|Take 1 sachet/day for 12 weeks.
214344069|NCT05869305|DIETARY_SUPPLEMENT|isolated soy protein|Take 1 sachet/day for 12 weeks.
214344070|NCT05869305|DIETARY_SUPPLEMENT|placebo|Take 1 sachet/day for 12 weeks.
214951474|NCT02101359|DRUG|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
214951475|NCT06061211|OTHER|TREADMILL(SIDEA-Germany treadmill ) with TENS|"TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: SIDEA-Germany treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min."
214951476|NCT04620954|DRUG|Oregovomab|2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.
215076368|NCT02555813|DRUG|Abraxane|Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
215076369|NCT02555813|DRUG|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
214344071|NCT00993447|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
214344072|NCT00993447|BIOLOGICAL|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
214951477|NCT04620954|DRUG|Nivolumab|480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).
214951478|NCT04620954|DRUG|Chemotherapy|Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m\^2 and 5 AUC (Area Under the Curve) respectively.
215076370|NCT01257568|DEVICE|Rejuvenate Modular Hip|Rejuvenate Modular Hip
215076371|NCT01116024|DEVICE|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
215076372|NCT01801748|DIETARY_SUPPLEMENT|oral wheat challenge|
215076373|NCT02074345|BIOLOGICAL|TAK-816|TAK-816 intramuscular injection
215076374|NCT05662774|DIAGNOSTIC_TEST|Ultrasound contrast agent (Sonovue)|Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments
215076375|NCT00604643|DEVICE|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
215076376|NCT00801034|DRUG|Calcium|tablets, 1 tablet 2 times per day in 28 days
215076377|NCT00801034|DRUG|Potassium|Tablets, 5 tablets 2 times per day for 28 days
214344073|NCT05409014|OTHER|PFMT|The phase 1 of the protocol was awareness-raising, the athlete receives guidance from a physical therapist and learns the location of the PFM and the ability to contract them in isolation. The phase 2 is stabilization, consisting of 15 stabilization exercises, which are performed through pelvic floor contractions for 10 seconds and with the same relaxation time, repeating each group 10 times. The phase 3 is strength, the same exercises as the second phase are performed using 2 kg weights at the end of each leg and/or arm. There are eight groups of exercises and with changes in the time of slow contraction and relaxation. The phase 4 is power, in power exercises the training loads are increased and the sequence of movements is also increased. The phase 5 is to complement the power, this phase was the continuation of the previous one in the sense of potentiation of the results where ballistic movements, speed and impact fundamentally predominate.
214344074|NCT05131295|DRUG|Dapsone|Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.
214951479|NCT04094831|OTHER|Health education|The intervention group will receive health education through CKD campaign and mHealth technology. During the half day CKD campaign, health education materials (leaflet and short textbook and recording notebook) will be provided to the study participants. A nephrologist will facilitate the campaign and contents (Annex-3) of the text book and leaflet (Annex-4) will be discussed. Important message from the text book (such as stage, risk factor, preventive measures) will be used to develop the leaflet. In addition,Basic health education information about CKD is included in the contents to help patients gain knowledge, awareness, and improve their behaviors. Discussion on basic kidney diseases, risk factors, and preventive measures of CKD is performing by CHWs over a mobile phone call to the study patients. The patients have the liberty to discuss their health-related issues with the CHWs over a period of 10 minutes
214951480|NCT02727426|OTHER|Low Salt (LS) diet|Intake of less than 2.3 g of salt per day for 7 days.
214951481|NCT02727426|OTHER|High Salt (HS) diet|Intake of 11.2 g of salt per day for 7 days.
214951482|NCT04148963|DRUG|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
214951483|NCT04148963|DRUG|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
214951484|NCT00785902|DEVICE|AtriCure Bipolar System|
214951485|NCT00624650|DRUG|Diuresis (furosemide) part I|"Goal: Overall I/O net negative 50ml/hour~Initiation:~1. Continuous IV furosemide at 3mg/hour or last known protocol specified dose~2. Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~3. Do not exceed 30mg/hour~Furosemide Bolus:~1. If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~2. By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~3. Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period"
214951486|NCT00624650|OTHER|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP\<8 or measured PaOP \<12mmHg in addition to concurrent urine output of \<0.5 ml/kg/hr
214951487|NCT00624650|OTHER|Fluid Bolus (crystalloid or albumin)|"10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.~Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases \> 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map \< 60 or who are on vasopressors that also have a measured GEDI less than goal"
214951488|NCT00624650|DRUG|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use any alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg."
214951489|NCT00624650|DRUG|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of \< 60"
214344075|NCT05131295|DRUG|Aluminum Hydroxide Gel|Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
214344076|NCT00970502|DRUG|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
214344077|NCT00870805|PROCEDURE|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
214344078|NCT00870805|PROCEDURE|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
214344079|NCT00870805|PROCEDURE|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
214344080|NCT00870805|PROCEDURE|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
214344081|NCT03811912|DRUG|CTP-543|CTP-543 administered as 8 mg tablet.
214344082|NCT03811912|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
214344083|NCT06478927|DRUG|Palbociclib capsules|Palbociclib capsules, oral, 125 mg/dose, qd, take 3 weeks and then stop for 1 week, 28d for one treatment cycle until disease progression or intolerable toxicity.
214344084|NCT00566228|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
214951490|NCT00624650|DRUG|Dobutamine|"1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index \< 2.5"
214951491|NCT00624650|DRUG|Dobutamine|"1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol."
214344085|NCT00566228|PROCEDURE|leukapheresis|Stem cells collected
214344086|NCT03521635|DRUG|Pramipexole SR|Tablets
214344087|NCT03521635|DRUG|Pramipexole IR|Tablets
214344088|NCT02244944|DRUG|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
214344089|NCT00414700|DRUG|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
214344090|NCT00414700|PROCEDURE|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
214344091|NCT00373776|DRUG|miltefosine 2.5 mg/kg/day for 28 days|
214344092|NCT01214772|DRUG|heparin|5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
214344093|NCT03466333|DRUG|Enalapril Maleate|Enalapril maleate will be encapsulated; participants will take the drug once a day for 6 months following delivery.
214951492|NCT00624650|OTHER|Concentrate all drips and nutrition|"Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.~EVLW arm: Patients with a MAP \> 60 and off vasopressors for \>12 hours, as well as patients with a measured cardiac index \>2.5 that also have a measured GEDI \> goal."
214951493|NCT00624650|DRUG|Diuresis (furosemide) part II|"Withhold furosemide if:~1. Significant hypokalemia (K+ \<= 2.5 meq/L), or hypernatremia (Na+ \>= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~2. Dialysis dependence~3. Oliguria (less than 0.5ml/kg/hour) with either creatinine \> 3, or clinical suspicion of rapidly evolving ARF~4. More than 800mg has been given in less then 24 hours~5. Creatinine increases \> 1.5 mg/dl in any 24 hour period"
214951494|NCT00624650|PROCEDURE|Dialysis|"1. Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~2. CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~3. EVLW arm: Fluid balance as per algorithm~4. When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm."
214951495|NCT04181268|DEVICE|Percutaneous coronary Intervention|Calcified plaque modification during percutaneous coronary intervention
214951496|NCT01704001|DRUG|ART-123|380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
214951497|NCT05612802|DIAGNOSTIC_TEST|IGF-1|We need to diagnose acute kidney injury in the early postoperative period. The markers examined so far do not provide enough information to diagnose acute kidney injury early. For this reason, many different biomarkers are used in the early diagnosis of acute kidney injury in many parts of the world. Thanks to our research, we can recognise the development of acute kidney injury at an early stage and determine whether a previously unused biomarker (IGF-1) is effective in the early diagnosis of acute kidney injury.
214951498|NCT02183909|OTHER|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
214951499|NCT02183909|BEHAVIORAL|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
214951500|NCT02183909|OTHER|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
214951501|NCT02183909|DRUG|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
214951502|NCT02320227|DEVICE|Miami w/o frag Personal lubricant|
214951503|NCT01240928|DRUG|MSK-2206|Level 1: MK-2206 135mg weekly
214951504|NCT01240928|DRUG|Exemestane|Level 1: Exemestane - 25mg daily
214951505|NCT01240928|DRUG|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
214951506|NCT04268628|OTHER|Serum and plasma samples analysis|This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.
214951507|NCT02811380|DEVICE|BIP CVC|BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery
214951508|NCT02811380|DEVICE|Uncoated Standard CVC|Standard CVC catheterization for venous access during and after elective large surgery
214951509|NCT00416429|BIOLOGICAL|aldesleukin|
214951510|NCT00416429|BIOLOGICAL|recombinant interferon alpha-2a|
214951511|NCT00416429|DRUG|medroxyprogesterone|
214951512|NCT00002575|PROCEDURE|conventional surgery|
214344094|NCT03466333|DRUG|Placebo oral capsule|The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
214951513|NCT00002575|PROCEDURE|laparoscopic surgery|
214951514|NCT06271759|OTHER|Fragrance inhalation|Inhalation of fragranced essential oils
214951515|NCT06339359|OTHER|Exmainations including clinical measurement, kinetic and kinematic measurmetns. Behavioral assessments|Collection of clinical data including K-Bayley Scales of Infant and Toddler Development Third Edition (K-BSID-Ⅲ), , Beery-Buktenica Visual-Motor Integration, Sixth Edition (VMI-6) and clinical measurement. motor analysis and eye tracking
214951516|NCT05998460|BEHAVIORAL|Glucose-Guided Eating with CGM|The GGE intervention consist of up to four weeks of training to learn to eat when glucose levels are at or below their usual fasting level. Specifically, participants following GGE will self-monitor their glucose levels with an unblinded CGM while using a mobile app (GGE app) that will provide feedback on whether or not to eat. At desired mealtimes participants will enter their current glucose level, rate their perceived hunger, and label the type of hunger they are experiencing (physical, emotional, sensory and practical). Participants following GGE will be instructed by the app to eat when two conditions are met: (a) the desire to eat arises and (b) their glucose levels are at or below a personalized threshold. During the training period, participants are meant to associate feelings of perceived hunger with fasting glucose levels (i.e., physical hunger). After the training period, participants continue to follow GGE without CGM or use of the app.
214951517|NCT05998460|OTHER|CGM only|Comparator participants will use unblinded CGM for up to 4 weeks without the use of the GGE app or any other dietary recommendations.
214951518|NCT00369148|DRUG|nateglinide(drug) mitiglinide(drug)|
214951519|NCT02518841|DEVICE|ThermaWedge TM|ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
214951520|NCT02518841|OTHER|Achilles Tendon Stretching|Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
214951521|NCT00723463|PROCEDURE|3T MRI scan|Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.
214951522|NCT06178562|BEHAVIORAL|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
215076378|NCT04288453|BEHAVIORAL|Engagement in a 8-week community-based activity program|"Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.~Other Names:~• Pathways and Resources for Engagement and Participation"
215076379|NCT04159987|OTHER|Spinraza intrathecal injection|The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
215076380|NCT00657839|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
215076381|NCT00657839|DRUG|Placebo|Matching placebo
215076382|NCT01689012|BEHAVIORAL|Facial Exercise|
215076383|NCT00194584|BEHAVIORAL|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
214951523|NCT06178562|DEVICE|PNG|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214951524|NCT06178562|DEVICE|IOE|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214951525|NCT01741155|DRUG|SPI-1620|SPI-1620 11 μg/m2 administered intravenously over one minute.
214951526|NCT01741155|DRUG|Docetaxel|Docetaxel: 75 mg/m2 administered as IV infusion.
215076384|NCT02446704|DRUG|Olaparib|
215076385|NCT02446704|DRUG|Temozolomide|
215076386|NCT00303771|DRUG|fluorouracil|
215076387|NCT00303771|DRUG|irinotecan hydrochloride|
215076388|NCT00303771|DRUG|leucovorin calcium|
214344095|NCT03932643|DRUG|ONC-201|"ONC-201 Capsules, 125 mg~Oral ONC-201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle."
214344096|NCT03365765|DRUG|Apatinib|Apatinib tablet
214344097|NCT03365765|DRUG|Oxaliplatin|Oxaliplatin Intravenous
214344098|NCT03365765|DRUG|5-fluorouracil|5-fluorouracil Intravenous
215076389|NCT03666507|PROCEDURE|Intraoperative Monitoring during resection of brain tumor|Intraoperative Monitoring during resection of brain tumor
214951527|NCT00038870|BIOLOGICAL|Dendritic Cell Activated Lymphocyte|
215076390|NCT02241057|DEVICE|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|
215076391|NCT02241057|OTHER|Temperature Probe|
215076392|NCT00996515|DRUG|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
214951528|NCT02836951|OTHER|Withdrawal of blood|Withdrawal of blood
214951529|NCT05096598|DRUG|ZP8396|Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
214951530|NCT05096598|DRUG|Placebo (ZP8396)|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
214951531|NCT00003178|BIOLOGICAL|filgrastim|
214951532|NCT00003178|DRUG|cladribine|
214951533|NCT00003178|DRUG|idarubicin|
214951534|NCT03267459|DEVICE|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.
214951535|NCT06648889|DRUG|Isatuximab|Cohort 1: All patients will receive two cycles of induction therapy with standard chemotherapy, Bortezomib and Isatuximab. Isatuximab maintenance may be administered in patients with CR until SCT, progression/relapse, unacceptable toxicity, physicians' decision to change treatment or withdrawal of consent.
214951536|NCT06648889|DRUG|Isatuximab|Cohort 2: All patients will receive at least one cycle with Isatuximab. Each cycle will be 4 weeks in duration. Isatuximab will be administered until SCT, hematologic relapse including extramedullary, unacceptable toxicity, physicians' decision, or withdrawal of consent.
214951537|NCT05809596|DEVICE|WATCHMAN FLX Pro LAAC Device|Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device
214951538|NCT03975725|DEVICE|the use of the WitCard|electrocardiogram (ECG)
214951539|NCT03975725|OTHER|the use of WitDisplayer|a software to visualize, measure, annotate, comment, archive, and share the different ECGs acquired with the WitCard (ECGW) of different patients.
214951540|NCT00840697|BEHAVIORAL|Exercises and work related rehabilitation|Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
214951541|NCT00840697|BEHAVIORAL|Brief intervention|1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
214951542|NCT00840697|BEHAVIORAL|multidisciplinary exercise group|10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
214951543|NCT04561297|DIAGNOSTIC_TEST|TDC differential value|TDC measurements in all patients agreeing to participate who are scheduled for a biopsy of a breast tumor or mass
214951544|NCT03070405|DRUG|Tenofovir disoproxil fumarate 300mg|Single oral dose on the first day of each period
214951545|NCT03070405|DRUG|Para-aminosalicylic acid Ca granule 5.28 g|Twice daily oral administration from the first day of each period to the seventh dose
214951546|NCT05368909|DIETARY_SUPPLEMENT|Sleep Supplement|Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.
214951547|NCT05368909|DIETARY_SUPPLEMENT|Placebo|Placebo product
214951548|NCT01630356|BEHAVIORAL|in-person counseling|The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
214951549|NCT01630356|DEVICE|Demonstration of PM2.5 Pollution|The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
214951550|NCT01630356|BEHAVIORAL|Follow-up Counseling Calls|Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
214951551|NCT01630356|BEHAVIORAL|Printed material|"The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency."
214951552|NCT06216405|PROCEDURE|Colonoscopy|Colonoscopy
214951553|NCT06916312|BEHAVIORAL|High ventilation breathwork|Single guided conscious connected breathing session.
214951554|NCT06916312|BEHAVIORAL|Meditation|Single guided body scan meditation session.
215076393|NCT00996515|DRUG|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
215076394|NCT03392883|BEHAVIORAL|Laddr|Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
215076395|NCT00929188|DRUG|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
215076396|NCT00929188|DRUG|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
214344099|NCT02537912|DIETARY_SUPPLEMENT|Sugarlock®|Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
214344100|NCT02537912|DIETARY_SUPPLEMENT|Placebo|Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
214344101|NCT02239887|DEVICE|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
214344102|NCT03335553|DRUG|BMS-986235|Specified dose on specified days
214951555|NCT06915883|DEVICE|Relaxation virtual reality (VR)|A newly developed self-guided app BreezeTrerraVR that helps patients practice relaxation breathing in an immersive virtual environment, using voice prompts, visual cues, and respiratory biofeedback for guidance. The app was developed in the VR center at the National Institute of Mental Health, Czech Republic (supported by THE JOHANNES AMOS COMENIUS PROGRAMME (OP JAC) EXCELLENCE IN RESEARCH, Title: Research of Excellence on Digital Technologies and Wellbeing, Project Registration Number: CZ. 02.01.01/00/22\_008/0004583).
214951556|NCT06915883|DEVICE|Experiential virtual reality (VR)|"The experiential VR intervention will use the VR program Ocean Rift (an experience of the underwater world and its animals). It is a calm experiential and distraction game program that does not require much mobility and interaction and is therefore suitable for pediatric patients and hospital environments. This VR application is also used in available published research."
214951557|NCT05347290|DEVICE|Rampart IC, M1128|Rampart IC, M1128 aims to address the challenge of radiation protection in the cardiac catheterization laboratory without the burden of wearing a heavy lead apron. Rampart M1128 is a compactly designed, portable, fully adjustable system that provides radiation protection for interventionalists and their technicians. It has independently adjustable flexible panels, allowing interventionalists multiple vascular access points, including right radial, bi-lateral femoral, and bi-lateral pedal. Participants in this arm will conduct catherization procedures using only the Rampart System, and radiation exposure will be measured using real-time dosimeters.
214951558|NCT05347290|DEVICE|Lead Apron and Ancillary Shield|Participating providers in this arm will use conventional skirt and vest, thyroid collar, and 100% use of 2 types of ancillary shields. Most wrap-around skirts and vests were (0.25-0.5 mm) Pb. Thyroid shields were 0.5 mm Pb equivalent. Under the table lead x 2. Radiation exposure will be measured using real-time dosimeters.
214344103|NCT03335553|OTHER|Placebo|Specified dose on specified days
214344104|NCT05905952|DIAGNOSTIC_TEST|balance and ROM assessment|assessment of postural stability and ankle range of motion
214344105|NCT06573632|DIETARY_SUPPLEMENT|TPN-N7 Baxter|providing TPN to all malnutrition patients preoperatively as well as postoperatively.
214344106|NCT04440111|OTHER|One year training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015.~After that, they will make a practical workshop on BLS. Finally they will repeat the initial test. The second year, this group will only make the test, they won't receive any theory or practice."
214951559|NCT05347290|DEVICE|Rampart IC, M1128 and Lead Apron|Participating providers will use both the lead apron and the Rampart Shield. Radiation exposure will be measured using real-time dosimeters.
214951560|NCT02494401|OTHER|Internet-based self-management program|
214951561|NCT02494401|OTHER|Scleroderma book|
214951562|NCT00003215|BIOLOGICAL|filgrastim|
214951563|NCT00003215|DRUG|CHOP regimen|
214951564|NCT00003215|DRUG|cyclophosphamide|
214951565|NCT00003215|DRUG|cytarabine|
214951566|NCT00003215|DRUG|doxorubicin hydrochloride|
214951567|NCT00003215|DRUG|etoposide|
214951568|NCT00003215|DRUG|leucovorin calcium|
214344107|NCT04440111|OTHER|Two years training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015. After that they will make a practical workshop on BLS.~Finally they will repeat the initial test. The second year, this group will repeat the same process."
214951569|NCT00003215|DRUG|melphalan|
214951570|NCT00003215|DRUG|methotrexate|
214951571|NCT00003215|DRUG|methylprednisolone|
214951572|NCT00003215|DRUG|mitoxantrone hydrochloride|
214951573|NCT00003215|DRUG|prednisone|
214951574|NCT00003215|DRUG|therapeutic hydrocortisone|
214951575|NCT00003215|DRUG|vincristine sulfate|
214951576|NCT00003215|PROCEDURE|bone marrow ablation with stem cell support|
214951577|NCT00003215|PROCEDURE|peripheral blood stem cell transplantation|
214951578|NCT00003215|RADIATION|radiation therapy|
214951579|NCT00966355|DRUG|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
214344108|NCT03793101|PROCEDURE|BiMICS|Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.
214344109|NCT01100177|DRUG|Sunitinib|Sunitinib 37.5mg/m2/d
214344110|NCT01100177|RADIATION|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
214951580|NCT00966355|DRUG|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
214951581|NCT00966355|DRUG|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
214951582|NCT00958412|DRUG|Proellex®|one (1) 25 mg capsule daily
214951583|NCT05288855|DRUG|Voclosporin|calcineurin inhibitor
214951584|NCT05288855|DRUG|Placebo Oral Capsule|matching placebo capsule
214951585|NCT03934359|DRUG|DN1508052-01|DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.
214951586|NCT05077813|COMBINATION_PRODUCT|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
214951587|NCT05077813|COMBINATION_PRODUCT|9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
214951588|NCT05077813|COMBINATION_PRODUCT|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|Active Comparator: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D 50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
214951589|NCT05077813|COMBINATION_PRODUCT|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
214951590|NCT05077813|COMBINATION_PRODUCT|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
214951591|NCT05077813|OTHER|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days
214951592|NCT03339336|DRUG|BIIB074|Administered as specified in the treatment arm.
214951593|NCT03339336|DRUG|Placebo|Administered as specified in the treatment arm.
214951594|NCT03646487|DIETARY_SUPPLEMENT|Probiotic LP299v 10x10 colony forming units in capsule form|Daily lactobacillus plantarum (LP299v) 10x10 colony forming units in capsule form
214951595|NCT03646487|OTHER|Placebo in capsule form|Daily placebo in capsule form
214951596|NCT06066723|COMBINATION_PRODUCT|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.
214951597|NCT06940674|DRUG|Cannabidiol|1 capsule CBD 200mg
214951598|NCT06940674|DRUG|Placebo|Bovine Gel Placebo capsule
214951599|NCT00777192|BEHAVIORAL|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
214344111|NCT00512135|DRUG|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
214344112|NCT00761501|DRUG|PN400|Oral
214344113|NCT00761501|DRUG|Naproxen (Proxen S)|Oral
214344114|NCT00761501|DRUG|Naproxen (Naprosyn E)|Oral
214951600|NCT06938477|OTHER|THERA-TRAINER BASED EXERCISES|The interventions will carried out two days a week and 40 minutes for eight weeks
214344115|NCT01853449|DRUG|Fentanyl Citrate|
214344116|NCT01853449|OTHER|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
214344117|NCT01853449|DRUG|Placebo|0.9% saline
214344118|NCT04507191|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining of programmed death-ligand 1 (PDL1) marker
214344119|NCT04154280|DIAGNOSTIC_TEST|PET/MR scan|"* The PET will be performed with 68Ga-PSMA tracer.~* The 3 tesla magnet of the MRI will be used with sequence allowing MRS acquisition, additional sequences will include T2-weighted contrast and diffusion weighted contrast.~* Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV) or Ki (in case dynamic PET protocol will be applied). In addition, content relationship between metabolic entities detected will be extracted.~Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity."
214344120|NCT02783404|DRUG|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
214951601|NCT06938477|OTHER|FUNCTIONAL STROKE TRAİNİNG|he interventions will carried out two days a week and 40 minutes for eight weeks
214951602|NCT05037084|OTHER|no intervention|no intervention
214951603|NCT06286020|DEVICE|Virtual Reality Therapy|The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.
214951604|NCT06286020|BEHAVIORAL|Conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
214951605|NCT06950762|PROCEDURE|Giomer based injectable composite|Giomers utilize surface pre-reacted glass (SPRG) technology, which involves an acid-base reaction between fluorine-containing glass particles and polymer-containing acid when exposed to water. This reaction results in the formation of a glass ionomer phase, which is then dispersed throughout the resin. Furthermore, the S-PRG fillers present in giomer materials enable the continuous release and replenishment of fluoride, offering long-lasting protection against the recurrence of caries
214951606|NCT06950762|PROCEDURE|Universal injectable resin composite|Conventional injectable resin composite
214951607|NCT05940025|DEVICE|MORT-LBP|The MORT-LBP, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioral therapy for patients with chronic lower back pain.
214951608|NCT05940025|OTHER|treatment as usual (TAU)|In the control group, education and physiotherapy is delivered and self-exercise is recommended.
214951609|NCT04267185|BEHAVIORAL|Physical Activity Together for PwMS and their CGs (PAT-MS)|A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
214951610|NCT06326411|DRUG|NST-628|NST-628 is a small molecule non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway.
214951611|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction
214951612|NCT05124132|BEHAVIORAL|Exercise|Exercise
214951613|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction + Exercise|Mindfulness-Based Stress Reduction + Exercise
214951614|NCT05124132|BEHAVIORAL|Health Education|Health Education
214951615|NCT05651828|DRUG|Vismodegib 150 MG Oral Capsule|Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
214344121|NCT02783404|DRUG|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
214955408|NCT01724944|PROCEDURE|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
214955409|NCT03363893|DRUG|CT7001|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
214955410|NCT03363893|DRUG|Fulvestrant|Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
214955411|NCT00005049|DRUG|carboplatin|
214955412|NCT00005049|DRUG|cisplatin|
214955413|NCT00005049|DRUG|floxuridine|
214955414|NCT04954417|DIAGNOSTIC_TEST|Radiological scanning|The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.
214955415|NCT04954417|OTHER|Deep learning|We will use a conditional generation adversarial network-based image mapping technique to train the mapping model between MSCT images and Micro-CT images, find the correspondence between the image information contained in each of MSCT and Micro-CT, and finally obtain high-resolution micro-CT-like images.
214955416|NCT04954417|PROCEDURE|Bio-mechanical testing|we will cut a standardized cubic sample from the vertebral cancellous bone , obtain the bio-mechanical performance index of this cancellous bone sample by mechanical experiments, and analyze the correlation between bone structure of Micro-CT-like images and bio-mechanical index.
214955417|NCT02099383|OTHER|normal saline|intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
214955418|NCT04235322|DRUG|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
214951616|NCT03850691|DRUG|Aldesleukin: All Patients|"Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)"
214951617|NCT03850691|DRUG|Nivolumab: Cohort 1 (Cutaneous)|"Cycle 1: 6 Week Duration Nivolumab 240 mg IV~Cycle 2: 6 Week Duration Nivolumab 240 mg IV on Day 1, 15 and 29~Cycle 3: 4 Week Duration Nivolumab 240 mg IV on Day 1 and 15~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
214951618|NCT03850691|DRUG|Nivolumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
214951619|NCT03850691|DRUG|Ipilimumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Ipilimumab 1 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Ipilimumab 3 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Ipilimumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Ipilimumab on Day 8 using the same dose regimen as used Cycle 1 Day 29"
214951620|NCT03862872|DIETARY_SUPPLEMENT|Anti-Aging Formula|Anti-Aging Formula contains 1050 mg of EPA and 350 mg of DHA from anchovies, sardines, and/or mackerel whole body oil, 120 mg of GLA from Borage (Borago officianalis) seeds, 2.5 mg of zeaxanthin from Capsicum annuum L. fruit, 5 mg of lutein from Tagetes erecta flower, and 25 μg (1000 IU) of vitamin D3 (cholecalciferol) from lanolin per 4 capsule daily dose. This dosage form is the same as is commercially marketed in Canada under license Natural Product Number (NPN) 80077254.
214951621|NCT03862872|DIETARY_SUPPLEMENT|Control Fish Oil|The control fish oil is a soft gelatin capsule containing 1,106 mg of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil. A four capsule per day dose provides 816 mg EPA and 572 mg DHA, which is only slightly less EPA+DHA than is provided within a four capsule per day dose of Anti-Aging Formula. This minor difference would not be expected to alter clinical outcomes.
214951622|NCT03862872|OTHER|Inert Placebo|The inert placebo is a soft gelatin capsule containing 1040 mg of corn oil.
214951623|NCT04121767|DRUG|Edoxaban|oral edoxaban 60mg once daily for 3 months
214951624|NCT04121767|DRUG|Warfarin|oral warfarin once daily for 3 months according to prothrombin time
214951625|NCT02227368|DRUG|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
214951626|NCT02227368|DRUG|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
214951627|NCT02411344|DRUG|Pertuzumab|"* Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~* Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~* Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."
214344122|NCT02358577|DEVICE|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
214344123|NCT02358577|OTHER|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
214344124|NCT05481762|DEVICE|Aided read with contextflow DETECT Lung CT|Radiologists read chest CT scabs with and without the aid of contextflow DETECT Lung CT as a second reader
214344125|NCT04157244|BEHAVIORAL|Tailored music listening intervention|The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.
214344126|NCT00364481|DRUG|omeprazole|
214344127|NCT00364481|BEHAVIORAL|Tongue exercises|
214344128|NCT01659021|DRUG|Idelalisib|150 mg tablets administered orally twice daily
214344129|NCT01659021|DRUG|Ofatumumab|Administered intravenously
214951628|NCT06045494|DIETARY_SUPPLEMENT|Meiji Yogurt Group|Participants in this arm need to eat assigned product for 12 weeks, one bottle each day.
214951629|NCT03765229|DRUG|Entinostat|Oral drug 5 mg taken once weekly for up to nine 3-week (21 day) cycles. Take on an empty stomach i.e., at least 2 hours after a meal and at least 1 hour before the next meal. On days when entinostat is administered on the same day as pembrolizumab, entinostat should be taken before the pembrolizumab infusion.
214951630|NCT03765229|DRUG|Pembrolizumab|200 mg IV starting on Day 22 (cycle 2, Day 1) given every 3 weeks for up to 8 cycles.
214951631|NCT00479830|BEHAVIORAL|Focus Groups|Eight Focus Groups Consisting of 8-10 Members Each
214951632|NCT00479830|BEHAVIORAL|Questionnaire|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
214951633|NCT00479830|BEHAVIORAL|Interview|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
214951634|NCT05050422|DIAGNOSTIC_TEST|Trunk Impairment Scale (TIS), PedsQLTM Multidimensional Fatigue Scale (PedsQL-MFS), Pediatric Balance Scale (PBS)|control/study group
214951635|NCT00719940|BEHAVIORAL|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
214951636|NCT00719940|OTHER|Waiting group|No intervention
214344130|NCT03883672|BEHAVIORAL|Personality and transactional factors|"1. Pre-admission transplant questionnaire: given and collected by the transplant physician during the pre-graft consultation before entering hospitalization (approximatively 15 days before). To be completed by the patient on site (approximately 45 minutes to complete the questionnaire)~2. Transplant admission questionnaire: given during the first days of hospitalization. To be completed within 6 days and returned to the transplant physician (approximately 30 minutes to complete the questionnaire)~3. Post-transplant follow-up questionnaire: given in consultation at 6 months by the transplant physician (between 30 and 45 minutes to complete the questionnaire in consultation)"
214951637|NCT06122467|OTHER|EQ Exfoliating Cleanser|Product contains: Purified water, disodium laureth sulfosuccinate, coco betaine, decyl glucoside, Juglans regia (walnut) shells, PEG-40 hydrogenated castor oil, sodium cocoyl isethionate disodium cocoyl glutamate, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), Aloe barbadensis (aloe vera) leaf juice concentrate (Aloe barbadensis leaf juice, potassium sorbate, sodium benzoate, citric acid).
214951638|NCT06122467|OTHER|EQ Gel|Product contains: Purified water, witch hazel (containing 14% grain alcohol), PEG-40 hydrogenated castor oil, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), xanthan gum.
214951639|NCT06122467|OTHER|EQ Moisturizer|Product contains: Purified water, glycerin, dicaprylyl carbonate, cetyl alcohol, glyceryl stearate citrate, squalane, PEG-40 hydrogenated castor oil, caprylic/capric triglycerides, stearic acid, jojoba oil, phenoxyethanol SA (phenoxyethanol, caprylyl glycol, sorbic acid), ethoxydiglycol, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), allantoin, sodium carbomer.
214951640|NCT04118179|OTHER|Blood sample collection|A blood sample (1 tube) will be collected for the analysis of the CR signature.
214951641|NCT02379455|OTHER|Comprehensive drug review|1\) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
214951642|NCT02642783|BEHAVIORAL|Descriptive analysis|subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
214951643|NCT02642783|BEHAVIORAL|acceptability test|subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
214951644|NCT00038805|DRUG|Mylotarg|
214951645|NCT05581368|OTHER|Chronic Cannabis use|The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
214951646|NCT05400486|OTHER|Therapeutic exercise|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
214955419|NCT04235322|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
214955420|NCT04680247|PROCEDURE|VA-LCP|Surgery using the VA-LCP implant
214344131|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - coronal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
214955421|NCT04680247|PROCEDURE|NCB-PT|Surgery using the NCB-PT implant
214955422|NCT04324528|DEVICE|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
214955423|NCT04324528|DEVICE|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
214955424|NCT05644288|OTHER|Help eNursing|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation.~Over the 36 weeks of the HELPeN Program, each volunteer is expected to provide intervention to 2 seniors, making 1 call per week to each subject lasting approximately 30 minutes. Students will perform physical and psychosocial assessments of the elders and create individualized care plans based on each subject's needs."
214955425|NCT02047994|DRUG|Triple therapy|"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~* Esomeprazole 40 mg bid for 10 days~* Clarithromycin 500 mg bid for 10 days~* Amoxicillin 1000 mg bid for 10 days"
214955426|NCT05259917|DRUG|Placebo|Placebo to KVD900 Tablet
214955427|NCT05259917|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
214344132|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - caudal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~T1-T4 posteriorly, anode over \~C5-T1 anteriorly
214344133|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - rostral|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~C3-C5 posteriorly, anode over \~C5-T1 anteriorly
214344134|NCT04727866|DEVICE|intermittent theta burst stimulation (iTBS)|3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS
214344135|NCT01205685|DRUG|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~* Dose level 2 = 150 mg twice a day~* Dose level 1 = 100 mg twice a day~* Dose level -1 = 100 mg twice a day~* Dose level -2 = 100 mg twice a day"
214344136|NCT01205685|DRUG|Erlotinib|"During the safety run phase of the study:~* Dose Level 2 = 100 mg/d~* Dose Level 1 = 100 mg/d~* Dose Level -1= 75 mg/d~* Dose Level -2 = 50 mg/d"
214344137|NCT01205685|DRUG|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
214344138|NCT01205685|DRUG|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
214951647|NCT05400486|OTHER|Therapeutic exercise group + high frequency TENS|TENS (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda) will be applied to the cervical region through 4 silicon-carbon electrodes measuring 4 x 4 cm, with a water-based gel to reduce the impedance at the interface electrode skin. Thus, TENS will be applied with a rectangular, biphasic, and symmetrical pulse, with a pulse width of 100 µm, and a frequency of 100 Hz, at the maximum tolerated sensitive threshold, for 30 minutes (VANCE et al., 2012).
214951648|NCT05400486|OTHER|Therapeutic exercise group + Interferential|In sequence, the interferential current will be applied. Through the Endophasys® device - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square) will be positioned around the center of the neck. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (Sweep Mode), 60 Hz Amplitude of frequency modulation (AMF), 30 Hz (Delta AMF), automatic vector mode, with intensity at the motor threshold of sensation, lasting 30 minutes (Albornoz-Cabello et al., 2019).
214951649|NCT04136262|DRUG|Tripterygium wilfordii Hook F (TwHF)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
214951650|NCT04136262|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
214951651|NCT04136262|OTHER|Dummy Tripterygium wilfordii Hook F (TwHF)|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
214951652|NCT04122209|OTHER|HIIE-First|Multiple exercise bout during the same day; HIIE first followed by continuous exercise
214951653|NCT04122209|OTHER|Continuous-First|Multiple exercise bout during the same day; Continuous exercise first followed by HIIE
214951654|NCT00088309|PROCEDURE|Eye exam|
214951655|NCT00088309|PROCEDURE|Oral exam|
214951656|NCT00088309|PROCEDURE|CT scan|
214951657|NCT00088309|PROCEDURE|Neuropsychological testing|
214951658|NCT00088309|PROCEDURE|Electrocardiogram|
214951659|NCT00088309|PROCEDURE|Echocardiogram|
214951660|NCT05363956|DRUG|salvadora|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
214951661|NCT05363956|DRUG|Eucalyptus Oil|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
214951662|NCT04494425|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
214951663|NCT04494425|DRUG|Capecitabine|Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
214951664|NCT04494425|DRUG|Paclitaxel|Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
214344139|NCT03659552|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
214951665|NCT04494425|DRUG|Nab-Paclitaxel|Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
214951666|NCT00399711|DRUG|repaglinide and metformin combination tablet|
214344140|NCT05525624|DEVICE|TRAMPRE|discharge interventions Transition Model is discharge interventions in parents of preterm infants.
214344141|NCT05525624|OTHER|Control Group|routine neonatal clinic discharge training of the hospital
214344142|NCT02599168|DRUG|Propofol|
214344143|NCT02599168|DRUG|Dexmedetomidine|
214344144|NCT02599168|DRUG|Placebo (normal saline)|
214951667|NCT00399711|DRUG|rosiglitazone and metformin combination tablet|
214951668|NCT02822833|PROCEDURE|Sentinel lymph node mapping|Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
214951669|NCT03840408|OTHER|Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation|Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
214951670|NCT03840408|PROCEDURE|Surgery|Patients will be treated with surgery
214951671|NCT02209818|RADIATION|Laser Irradiation One dose|
214951672|NCT02209818|RADIATION|Laser Irradiation Two doses|
214955428|NCT05259917|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
214955429|NCT05133336|DRUG|Saroglitazar Magnesium 1 mg|Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment for the entire treatment period up to Week 52.
214955430|NCT05133336|DRUG|Saroglitazar Magnesium 2 mg|Subjects randomized to Saroglitazar Magnesium 2 mg arm are switched to Saroglitazar Magnesium 1 mg treatment up to Week 52
214955431|NCT05133336|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
214344145|NCT01718769|OTHER|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
214344146|NCT00354523|DRUG|Capecitabine (Xeloda)|Starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle.
214344147|NCT00354523|DRUG|DTIC-Dome (Dacarbazine)|Starting Dose 250 mg/m\^2 a day on Days 1-3 of 21 Day Cycle.
214344148|NCT00354523|DRUG|Gleevec (Imatinib Mesylate)|Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
214344149|NCT01193803|PROCEDURE|Microbiological cultures and Molecular biology|"Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.~Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol."
214951673|NCT05176613|DEVICE|HF-rTMS|HF-rTMS stimulated a 70-mm, 8-shaped coil stimulator (The Magstim Company, UK, 2012) on the damaged cerebral cortex. Prior to the application of HF-rTMS, the motor point was identified that stimulates maximum thresholds on the primary motor cortex, causing flexion of the opposite index finger. If the cerebral hemisphere does not show a kinetic response even at the maximum stimulus, the motor point of the opposite hemisphere was found to be symmetrically changed. The intensity of the stimulus was 80% of the resting motor threshold, which means the motor eveked potential above which the first dorsal interosseous muscle can produce 50 μV more than five times out of 10 stimuli. The subject sat on a chair made to hold the head. The stimulation was stimulated at high frequency (10 Hz) for 2 seconds, and the rest was performed for 58 seconds for a total of 200 times for 10 minutes.
215076397|NCT00991328|PROCEDURE|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
214344150|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 30mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
214344151|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 60mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
214344152|NCT03790982|DRUG|AD-35 30 mg + Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
214344153|NCT03790982|DRUG|AD-35 60 mg|AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
214344154|NCT05321524|DRUG|OCA 0.1mg|Tablets administered orally once daily.
214344155|NCT05321524|DRUG|OCA 1.5mg|Tablets administered orally once daily.
214344156|NCT05321524|DRUG|OCA 5mg|Tablets administered orally once daily.
214951674|NCT05176613|BEHAVIORAL|ML|Motor learning was conducted for two minutes each in five sessions, and the first is the external rotation training to maximum range of the shoulder joint in sitting position. The second method is to stack cups by transferring them from the non-affected side to the affected side by transferring 25 plastic cups of five colors in sitting position with both hands inserted. Third, by pushing and pulling the ball forward and backward with the hands folded, the subject puts a 55 cm healing ball on the table in a sitting position, and pushes and pulls it forward with the upper limb. The fourth method is to insert and remove pegs from the peg board, and the target uses the affected side hand in sitting position. The fifth method is to tear a newspaper, in which the subject overlaps a newspaper on the table in a sitting position, holds it with the non-affected hand, and tears it with the hands of the damage. A total of 10 minutes of motor learning.
214951675|NCT05176613|DEVICE|Sham-rTMS|Sham rTMS gives a small intensity of 2% of the resting motor threshold that cannot cause excitement in the motor cortex, and is set to listen to the same frequency of noise as HF-rTMS, and motor learning is applied equally. A total of 20 minutes were applied three times a week for four weeks by applying 10 minutes of Sham rTMS and 10 minutes of motor learning.
214951676|NCT00892814|RADIATION|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
214951677|NCT00892814|RADIATION|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
214951678|NCT00063336|BEHAVIORAL|Cognitive Remediation|A computerized cognitive rehabilitation treatment with day-program activities
215076398|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
214951679|NCT00063336|BEHAVIORAL|Computer-skills training|A computerized cognitive rehabilitation treatment with day-program activities
214951680|NCT01673087|DRUG|Metyrapone|750 mcg, oral, administered twice, 3.5 hours apart
214951681|NCT01673087|DRUG|Dexamethasone|"Administered twice:~1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration."
214951682|NCT01673087|DRUG|Cortrosyn|250 mcg, IV, bolus, in the afternoon.
214951683|NCT01673087|DRUG|Corticorelin ovine triflutate|100 mcg, IV, over 30 seconds, in the afternoon.
215076399|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
215076400|NCT03344107|OTHER|USSQ questionnaire administration after RIRS.|USSQ symptoms questionnaire administration after RIRS
215076401|NCT03676543|PROCEDURE|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
215076402|NCT00132691|DRUG|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
215076403|NCT00132691|DRUG|oral corticosteroid with immunosuppressive agents as needed|Prednisone
214344157|NCT05734508|BIOLOGICAL|MVA-BN vaccine|A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
215076404|NCT01792817|DEVICE|GammaCore|Treatment with active gammacore vagus nerve stimulator
215076405|NCT01792817|DEVICE|Sham GammaCore device|Treatment with sham stimulator
214344158|NCT02620553|DRUG|Human Insulin|There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
214951684|NCT04100655|DRUG|GM-CSF|3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice
214344159|NCT02620553|OTHER|Oral Placebo|Oral Placebo is given orally daily
214951685|NCT04100655|DRUG|17-ß estradiol|A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
214951686|NCT04473534|BEHAVIORAL|web based cognitive-behavioral therapy|one web session of psycho-education about sleep
214951687|NCT02330224|OTHER|Hypertension Management Intervention|"The multifaceted intervention consists of three main components:~1. Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~2. Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~3. Telephone based follow-up for all patients by nurses"
214951688|NCT01744483|DEVICE|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
214951689|NCT01744483|DEVICE|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
214951690|NCT01744483|DEVICE|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
214951691|NCT01754766|DRUG|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
214951692|NCT01754766|OTHER|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
214951693|NCT04626700|DEVICE|iNAP|iNAP for the treatment of OSA
214951694|NCT04626700|DEVICE|CPAP|CPAP for the treatment of OSA
214951695|NCT05926466|DRUG|BTZ-043|BTZ-043 belongs to the chemical class of benzothiazinones, and is a promising antibiotic for the treatment of Tuberculosis. Its mechanism of action is based on the covalent inhibition of the enzyme decaprenylphosphoryl-ß-D-ribose-2'-epimerase (DprE1), which is essential for the cell wall assembly of mycobacteria. . Formation of the covalent adduct between BTZ-043 and DprE1 results in inhibition of cell wall biosynthesis and loss of viability of Mycobacteria Tuberculosis. BTZ-043 has been evaluated in three clinical studies: a phase Ia, First Time in Human study (FTIH), a two-stage phase Ib multiple ascending dose (MAD) and phase IIa monotherapy early bactericidal activity (EBA) study, and a human ADME (Absorption/Distribution/Metabolism/Excretion) study.
214951696|NCT05926466|DRUG|Bedaquiline|Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.
214951697|NCT05926466|DRUG|Delamanid|Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.
214951698|NCT05926466|DRUG|Moxifloxacin|Moxifloxacin belongs to the group of fluoroquinolones (FQ). FQs are a mainstay of MDR-TB treatment, and Moxifloxacin is considered the most potent drug in second line MDR-TB therapy, recently reviewed by WHO, with only moderate pre-existing resistance in the community.
214951699|NCT05742113|DEVICE|Masimo Radical-7|perfusion index measuring device
214951700|NCT04379765|BEHAVIORAL|Exercise and physical therapy|Decompression operation
214951701|NCT01709409|DRUG|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
214951702|NCT01709409|DRUG|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
214951703|NCT02412878|DRUG|Carfilzomib|Carfilzomib was administered as an IV infusion
214951704|NCT02412878|DRUG|Dexamethasone|Commercially available dexamethasone was obtained by the investigational site.
214951705|NCT02190721|DRUG|tbo-filgrastim|5 μg/kg
214951706|NCT01142505|DRUG|Mannitol|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack.
214951707|NCT01142505|DRUG|Montelukast|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack
214951708|NCT02562599|DRUG|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
214951709|NCT02562599|RADIATION|Intensity-modulated radiotherapy (IMRT)|Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
214951710|NCT05025332|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
214951711|NCT04163926|PROCEDURE|Intervention Group cataract follow up|Intervention group will have cataract follow up conducted by the referring optometrist 4-6 weeks after surgery
214951712|NCT04163926|PROCEDURE|Usual Care consultant follow up|Usual care group - Consultant led post op follow up
214951713|NCT06133959|BEHAVIORAL|The-Optimal-Lymph-Flow (TOLF) Program|TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.
214951714|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 low dose
214951715|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 low dose
214951716|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 high dose
214951717|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 high dose
214344160|NCT04200066|DRUG|Temozolomide, Tamoxifen, Maprotiline|Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
214344161|NCT00530361|DRUG|Nesiritide|
214951718|NCT01306214|DRUG|BI 10773|BI 10773 low dose once daily
214951719|NCT01306214|DRUG|BI 10773|BI 10773 high dose once daily
214951720|NCT04116775|BIOLOGICAL|Fecal microbiota transplant|A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.
214951721|NCT04116775|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.
214951722|NCT04116775|DRUG|Enzalutamide|Daily oral dose.
214951723|NCT01888653|BEHAVIORAL|Attention Bias Modification (ABM)|The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.
214951724|NCT01888653|BEHAVIORAL|Attention control training (ACT)|In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
214951725|NCT02956707|OTHER|No pre-operative steroids|Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
214951726|NCT01928199|DRUG|Sitagliptin|
214951727|NCT01928199|DRUG|Placebo|
214951728|NCT05000736|DRUG|palbociclib + aromatase inhibitor|palbociclib + aromatase inhibitor therapy
214951729|NCT05000736|DRUG|fulvestrant|fulvestrant monotherapy
214951730|NCT06311071|DIAGNOSTIC_TEST|calcium score|Calcium score of coronaries obtained fro coronary CT angiography
214951731|NCT06311071|DIAGNOSTIC_TEST|Invasive coronary angiography|Invasive coronary angiography from radial artery with contrast injection
214951732|NCT00002255|DRUG|Filgrastim|
214951733|NCT00002255|DRUG|Epoetin alfa|
214951734|NCT00002255|DRUG|Zidovudine|
214951735|NCT06435078|DEVICE|mPETS(modified-PETS system)|The pressing evaluation and training system (PETS) consists of five force transducers, a pad position-adjustable frame, and biofeedback system. Five force transducers are used to collect the applied normal force from five digits.
214951736|NCT00046540|DRUG|Liposome-encapsulated SN38|
214951737|NCT02799121|DEVICE|ReGenerCell™ Autologous Cell Harvesting Device|
214951738|NCT01089452|DRUG|Perindopril|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
214951739|NCT01089452|DRUG|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
214951740|NCT01089452|DRUG|Olmesartan/amlodipine|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
214951741|NCT03671785|DRUG|PRIM-DJ2727|Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks
214951742|NCT03671785|DRUG|Placebo oral capsule|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks
214951743|NCT03405571|OTHER|No intervention|No intervention
214951744|NCT02874716|OTHER|Tuberculosis Program (PPIA)|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.
214951745|NCT05126173|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
214951746|NCT05869396|DIAGNOSTIC_TEST|echocardiography|Bedside echocardiography
214951747|NCT05242536|OTHER|Nurse- led program|A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
214951748|NCT02878096|DRUG|[14C]-SK-1404|In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of \[14C\]-SK-1404.
214951749|NCT01317498|OTHER|Standard Care|CD4, liver function and CBC every 6 months
214951750|NCT01317498|OTHER|Virological Monitoring|Viral Load test every 6 months
214951751|NCT03909698|OTHER|Blood and urine sampling|During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.
214951752|NCT00639106|PROCEDURE|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
214951753|NCT00639106|PROCEDURE|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
215076406|NCT02994953|DRUG|Avelumab|Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
214951754|NCT04099537|BEHAVIORAL|Computerized cognitive training|Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.
214951755|NCT06543082|DRUG|Colchicine 0.6 mg|Participants will take low-dose colchicine (0.6 mg once daily) in addition to ticagrelor maintenance therapy (90 mg twice daily), and discontinue aspirin the day after PCI. They will have an hs-CRP test 1 month after PCI. If the hs-CRP level is below 2 mg/L, colchicine will be discontinued 1 month after PCI. If it is 2 mg/L or higher, colchicine will be continued for 12 months after PCI.
214951756|NCT00190398|DEVICE|Carotid angioplasty and stenting with cerebral protection|Carotid angioplasty and stenting with cerebral protection
214951757|NCT00280696|DRUG|Levetiracetam 250 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg~* Route of Administration: Oral Use"
214951758|NCT00280696|DRUG|Levetiracetam 500 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 500 mg~* Route of Administration: Oral Use"
214951759|NCT00280696|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg and 500 mg~* Route of Administration: Oral Use"
214951760|NCT03959488|DRUG|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
214951761|NCT03959488|DRUG|Palivizumab|Approved anti-RSV monoclonal antibody
214951762|NCT02502695|OTHER|VATS-associated best practices|
214951763|NCT02834832|DEVICE|PECVD coating|SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
214951764|NCT01059019|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
214951765|NCT02393131|RADIATION|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
214951766|NCT02393131|RADIATION|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
214951767|NCT01760447|DRUG|Sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.
214951768|NCT01760447|DRUG|Placebo to metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.
214951769|NCT01760447|DRUG|Metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.
214951770|NCT01760447|DRUG|Placebo to sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.
214951771|NCT01760447|DRUG|Sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.
214951772|NCT01760447|DRUG|Placebo to metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.
214951773|NCT01760447|DRUG|Insulin|"Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the Sitagliptin/Metformin and Metformin arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the Sitagliptin/Metformin XR and Metformin XR arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine."
215076407|NCT02994953|DRUG|M9241|Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
215076408|NCT02994953|DRUG|Avelumab (Once weekly)|Participants received avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
215076409|NCT02994953|DRUG|M9241 (MTD)|Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
215076410|NCT02994953|DRUG|Avelumab (Expansion cohort)|Participants in the expansion cohorts received Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
215076411|NCT02417116|OTHER|Tear supplement|Application as required to improve comfort
215076412|NCT02417116|OTHER|Tear supplement 2|Application as required to improve comfort
215076413|NCT02417116|DIETARY_SUPPLEMENT|Omega 3 nutrition supplement|Taken each day
215076414|NCT02417116|DEVICE|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
215076415|NCT02417116|OTHER|Saline|Application as required to improve comfort
215076416|NCT01739933|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
215076417|NCT01739933|DRUG|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
215076418|NCT04284735|OTHER|Quantitative ATX and LPA determination in plasma and sputum|"Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (cases) and in plasma and sputum from RA patients without ILD (controls) after sputum induction using hypertonic saline inhalation"
214344162|NCT04517721|OTHER|Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)|The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
214344163|NCT01053026|DRUG|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
214344164|NCT02345057|DRUG|CS-3150|
214344165|NCT02345057|DRUG|placebo|
214344166|NCT02855099|OTHER|Rehabilitation|The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
214344167|NCT00957502|DEVICE|ENTact™ Septal Stapler|1 year aged septal staples
214951774|NCT01760447|DRUG|Placebo to sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.
214951775|NCT01760447|DRUG|Metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
215076419|NCT01022515|OTHER|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
215076420|NCT01022515|OTHER|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
214344168|NCT00957502|DEVICE|ENTact™ Septal Stapler|18 Month Aged Staples
214344169|NCT02206503|DRUG|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
214951776|NCT05208268|DRUG|Pariet|Pariet Tablets.
214951777|NCT04779281|DIETARY_SUPPLEMENT|Oral Rehydration Salts supplemented with L. Rhamnosus GG|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides
215076421|NCT04098367|DEVICE|VIVITY|Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction
215076422|NCT04098367|DEVICE|SYMFONY|Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed
214344170|NCT02206503|DRUG|Lenalidomide|
214951778|NCT04779281|DIETARY_SUPPLEMENT|Oral Rehydration Salts only|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
214344171|NCT02206503|DRUG|Dexamethasone|
214951779|NCT02875873|DRUG|Plasma-Lyte|Plasma-Lyte will be used for fluid expansion and maintenance
214951780|NCT02875873|DRUG|Saline 0.9%|Saline 0.9% will be used for fluid expansion and maintenance
214951781|NCT02875873|OTHER|Slow infusion speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.
214951782|NCT02875873|OTHER|Fast Infusion Speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
214951783|NCT04295369|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep, stress management, and Chinese dietary recommendations.
214951784|NCT00311870|DRUG|nisoldipine|
214951785|NCT00311870|DRUG|lisinopril|
214951786|NCT02740790|BIOLOGICAL|HPV vaccine|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
214344172|NCT04863066|BIOLOGICAL|CAR-T cells|The presence of latent infected cells remains a key barrier to HIV-1 functional cure. Current approach to reducing the latent HIV reservoir is to reactivate virus-containing cells to make them be detected and eliminated by host defense. Endogenous cytotoxic T-lymphocytes (CTL) may not be adequate because of cellular exhaustion and immune escape of virus. We have designed a kind of CAR-T cell based on CTL engineered to express a scFv of a broadly neutralizing anti-HIV antibody. According to our preclinical studies, CAR-T cells strongly eradicated HIV-1-infected target cells making them a particularly suitable candidate to reach a functional HIV cure. In this clinical trial, we mainly intend to evaluate the safety of CAR-T-Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after antiviral therapy.
214344173|NCT04735133|DEVICE|pNBYT|pNPWT device (80mm Hg) was placed in the pNPWT group for seven days The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
214344174|NCT06033261|BIOLOGICAL|mRNA-1608|Sterile liquid for injection
214344175|NCT06033261|BIOLOGICAL|BEXSERO|A vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B.
214951787|NCT02740790|BIOLOGICAL|Placebo|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
214344176|NCT01733004|DRUG|MM-141|
214344177|NCT05562440|OTHER|Focus Group Discussion|Each focus group will consist up to five participants in every session, two sessions each for both low and high risk group. Every FGD sessions will last for 1 to 2 hours and be conducted in Indonesian, and will be recorded. Both groups will be asked the following questions: 1) What is your opinion regarding the clarity of information in the dummy breast cancer risk prediction report?; 2) What is your opinion regarding the completeness of information in the dummy breast cancer risk prediction report?; and 3) What is your impression regarding the results presented in the dummy breast cancer risk prediction report?.
214344178|NCT03190382|OTHER|Decision Support Tool|Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
214344179|NCT04320069|DEVICE|Omnipod Horizon™ Automated Glucose Control System|Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
214344180|NCT06042348|DIAGNOSTIC_TEST|Trans abdominal ultrasound|Ultra sound of the uterus and uterine blood vessels
214344181|NCT01844323|OTHER|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
214344182|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
214344183|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
214344184|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
214344185|NCT06342362|DRUG|Magnesium sulfate|Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
214951788|NCT00176514|DRUG|Administration of the antineoplastic|
214951789|NCT01641471|DEVICE|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current.
214951790|NCT01641471|DEVICE|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
214951791|NCT05393687|OTHER|Eccentric exercise|progressive eccentric exercise with elastic band
214951792|NCT00571116|DRUG|Disulfiram|Given PO
214951793|NCT00571116|DRUG|Arsenic trioxide|Given IV
214344186|NCT06342362|OTHER|placebo or standard treatment)|placebo or standard treatment)
214344187|NCT01169467|DRUG|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
214951794|NCT00441038|BEHAVIORAL|The Back Guide|Education on postural hygiene and handout of The Back Guide
214951795|NCT00441038|BEHAVIORAL|The Back Book|Education on active management and Handout of The Back Book
214951796|NCT00441038|BEHAVIORAL|Cardiovascular and general health|Education on cardiovascular and general health
214951797|NCT03996122|OTHER|fMRI|3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)
214951798|NCT00068029|DRUG|Pegvisomant/ Sandostatin LAR|
214951799|NCT00068029|DRUG|Sandostatin LAR|
214344188|NCT01169467|OTHER|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
214344189|NCT01990235|BEHAVIORAL|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
214344190|NCT01741753|DRUG|BKM120|Orally, every morning
214344191|NCT01741753|DRUG|Abiraterone|Orally, 1000 mg, every morning
214951800|NCT00068029|DRUG|Pegvisomant|
214951801|NCT03993977|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
214951802|NCT03993977|OTHER|Conventional treatment|Clinical judgement and conventional coagulation tests
214951803|NCT02004314|DRUG|Chloroquine|
214951804|NCT04575584|DRUG|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
214951805|NCT04575584|DRUG|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
214951806|NCT06148155|RADIATION|[68Ga]Ga-NOTA-RG2 PET Imaging|Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RG2 in a single dose.
214951807|NCT01653340|DEVICE|Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine|http://nevro.com/corporate/system-us
214951808|NCT00077155|DRUG|cilengitide|
214951809|NCT05768997|DRUG|Ferric Derisomaltose Injection|Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes
214951810|NCT05768997|DRUG|Darbepoetin Alfa Injection|Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
214951811|NCT03782129|BIOLOGICAL|blood samples|Blood samples drawn during hospitalisations when needed
214344192|NCT01741753|DRUG|Prednisone|Orally, 5 mg, every morning
214344193|NCT00329277|PROCEDURE|perimetry|
214951812|NCT03782129|OTHER|Clinical exam and DFU medical cares|Clinical exam and DFU's medical cares at each visit (planned evry 1 to 3 months), during all the 5 years follow up, or until death.
214951813|NCT03488563|BIOLOGICAL|B244|B244 Suspension
214344194|NCT01008033|DRUG|IDP-108|Topical application once a day for 48 weeks
214344195|NCT01008033|DRUG|Vehicle|Topical application once a day for 48 weeks
214344196|NCT04250272|PROCEDURE|Thoracoscopic lobectomy|Thoracoscopic lobectomy was performed for lung cancer
214344197|NCT04749420|OTHER|Survey study|Cervical Radiculopathy Impact Scale (CRIS) will be applied
214344198|NCT03058679|OTHER|Diet|food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
214344199|NCT01796574|DIETARY_SUPPLEMENT|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
214344200|NCT02187757|DIETARY_SUPPLEMENT|Study Dietary Supplement (Prelipid 500 mg capsules)|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
214344201|NCT02187757|DIETARY_SUPPLEMENT|Placebo|
214951814|NCT03488563|BIOLOGICAL|Vehicle|Vehicle Suspension
214951815|NCT03033160|DRUG|Estradiol Ring|
214951816|NCT02462109|DRUG|Lorazepam|Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with \>30 kg body weight.
215076423|NCT04098367|DEVICE|AT LARA|Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction
215076424|NCT04098367|PROCEDURE|Cataract surgery|Cataract removal by routine small incision surgery
215076425|NCT06390696|BIOLOGICAL|Microbial intervention|Children in microbial intervention arm receive an indoor sandbox containing play sand enriched with organic leaf compost, moss and humus substances. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and microbe rich growing medium containing organic leaf compost, moss, biochar and humus substances.
215076426|NCT06390696|OTHER|Placebo|Children in placebo arm receive an indoor sandbox containing visually similar play sand modified with peat with low microbial diversity. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and growing medium containing peat, inorganic fertilizers, and potting gravel with low microbial diversity.
215076427|NCT01510015|DRUG|Risperidone|variable dose
215076428|NCT04829305|DRUG|SHR2285|SHR2285 is a selective inhibition of human FXIa small molecule compound.
215076429|NCT00031655|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
215076430|NCT00031655|BIOLOGICAL|donor lymphocytes|Given IV
215076431|NCT00031655|DRUG|cyclosporine|Given PO
215076432|NCT00031655|RADIATION|total-body irradiation|Undergo TBI
214344202|NCT03108924|DRUG|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
214344203|NCT00695331|DRUG|Misoprostol|Titrated Misoprostol Solution
214344204|NCT00695331|DRUG|Oxytocin|Titrated Intravenous Oxytocin
214344205|NCT02264067|DRUG|Talsaclidine|
214344206|NCT02264067|DRUG|Placebo|
214344207|NCT03302962|BEHAVIORAL|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
214344208|NCT05997043|DRUG|oral anti-Parkinson drugs and injection of botulinum toxin|The experimental group was treated with oral anti-Parkinson drugs and injection of botulinum toxin
214344209|NCT05997043|DRUG|oral anti-Parkinson's drugs|The control group only took oral anti-Parkinson's drugs.
214951817|NCT02788188|BIOLOGICAL|SAB-301|SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
214344210|NCT03939286|OTHER|Clinical-neurological and neuropsychological tests|The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
214344211|NCT03939286|DIAGNOSTIC_TEST|Blood sampling|Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.
214951818|NCT02788188|OTHER|Normal (9%) Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
215076433|NCT00031655|DRUG|fludarabine phosphate|Given IV
215076434|NCT00031655|DRUG|mycophenolate mofetil|Given PO
215076435|NCT00031655|OTHER|laboratory biomarker analysis|Correlative studies
215076436|NCT00031655|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
215076437|NCT03285087|DRUG|DEX 0.2 μg/kg/h.|DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
214344212|NCT03939286|OTHER|Assessment of physical activity via fitness tracker/diary|All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.
215076438|NCT00309712|DRUG|fenofibrate 160 mg and placebo|
215076439|NCT00309712|DRUG|simvastatin 20 mg and placebo|
215076440|NCT00309712|DRUG|fenofibrate 160 mg and simvastatin 20 mg|
214951819|NCT05979896|DRUG|Standard age based SPAQ administration for SMC|"Sulfadoxine-pyrimethamine and amodiaquine (SPAQ) is administered in standard WHO approved age based regimens as used in Seasonal Malaria Chemoprevention Programmes.~Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug. AQ Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine."
214951820|NCT02588729|OTHER|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
214951821|NCT02860962|DRUG|Dextromethorphan Hydrobromide|Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
214951822|NCT04108741|DEVICE|C-Mill augmented reality treadmill training|PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.
214951823|NCT06329986|DEVICE|TAMER Lens Spectacle|Regular daily wear of TAMER lens spectacle
214951824|NCT06329986|DEVICE|SV lenses|SV lenses
214951825|NCT05844085|OTHER|Non-polar lipids|The shame comparator lipid intervention product contains no polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of lipids are15g, and the total amounts of available carbohydrates are 50 g.
214951826|NCT05844085|OTHER|No lipids|The placebo comparator contains no added lipids. The product contains a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
214951827|NCT05844085|DIETARY_SUPPLEMENT|Polar lipids low|The experimental intervention product contains 7,5 g plant based lipids polar lipids and 7.5 g plant based lipids non polarlipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. TThe total amounts of available carbohydrates are 50 g.
215076441|NCT03833271|BIOLOGICAL|Influenza vaccine, Immune function|Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
215076442|NCT04809558|BEHAVIORAL|Tongue resistance exercise|Participant will complete tongue resistance exercises.
214344213|NCT03939286|OTHER|MRI-examinations|Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
214344214|NCT06086730|DEVICE|blow bottle positive expiratory pressure|Water was poured into a 1 L plastic container until it reached a 10 cm height. A 30 cm long tube was put into the water in the bottle, 8 cm deep. The participants were instructed to close their mouths around the tubing in the apparatus for three seconds to produce bubbles, do this for a total of 10 breaths, perform two huffs, then cough. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized,Because it is a homemade device and can be used with less equipment and with more ease at home . patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes.
214344215|NCT06086730|DEVICE|acapella|"Make sure the frequency adjustment dial has been rotated counterclockwise to the lowest frequency-resistance setting before using the Acapella for the first time.On a chair, adopt a straight stance. maintaining a straight back and relaxing your elbows on a table. Now gradually tilt your head upward to maintain the opening of your upper airways.Inhale more deeply than you frequently do. Make sure your lips are encircling the mouthpiece, then blow into the device with a strong expiration.You should ideally blow out roughly twice as quickly as usual.For around ten breaths, keep going like this.Make careful to expel to clear the secretions from the airways after the final try. You can even conduct 2 to 3 huffs to improve secretion elimination when necessary.It should be noted that while using the device, you must be capable of exhale for a minimum of three to four seconds. patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes"
214344216|NCT00003011|DRUG|marimastat|10 mg PO BID
214344217|NCT00003011|DRUG|Placebo|10 mg PO BID
214344218|NCT03517644|OTHER|DP|Participants are informed that they are about to receive an effective analgesic cream. They are instructed to apply the cream using a cotton pad.
214344219|NCT03517644|OTHER|OLP Hope|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. Therefore, participants are supposed to evaluate the subjective probability for a positive effect of the cream as rather low. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect for them because this placebo cream did have a positive among some former participants who were similar to the current participant. The emphasis of this similarity (regarding age and sex) aims to induce a feeling of connectedness to previous participants who reported positive effects of the placebo cream.
214951828|NCT05844085|DIETARY_SUPPLEMENT|Polar lipids high|The experimental intervention product contains15 g plant based polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
214951829|NCT00857467|DRUG|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
215076443|NCT01842932|DRUG|Phloroglucin|Premedication of colonoscopy
215076444|NCT01842932|DRUG|Cimetropium bromide|Premedication of colonoscopy
215076445|NCT01842932|PROCEDURE|Colonoscopy|Diagnostic examination of colon
215076446|NCT01842932|DRUG|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
214951830|NCT00857467|DRUG|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
214951831|NCT02815267|DRUG|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
214951832|NCT02815267|DRUG|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
214951833|NCT04330222|DIAGNOSTIC_TEST|7 Tesla Magnetic Resonance Imaging|Diagnostic Imaging
214344220|NCT03517644|OTHER|OLP Expectation|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, participants are told that placebos have been shown to contribute substantially to clinical outcomes such as pain intensity/unpleasantness. This positive effect of placebos is reasoned by explaining learning mechanisms such as classical conditioning. We anticipated that after hearing this instruction, participants would consider it to be likely that the placebo has a positive effect for them.
214344221|NCT03517644|OTHER|Placebo cream|The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).
214344222|NCT03517644|OTHER|Heat pain|Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
214344223|NCT06486259|OTHER|Controlled mechanical ventilation|Patients were ventilated under similar tidal volume, respiratory rate, and plateau pressure. PEEP was the adjustment variable to reach a similar plateau pressure
214951834|NCT04330222|OTHER|Brief Memory and Executive Test|Cognitive Assessment
214344224|NCT03243526|OTHER|fluid therapy|fluid resuscitation guided by CVP or PPV
214344225|NCT01098006|OTHER|Blood withdrawal|A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
214344226|NCT00599326|DRUG|Deferasirox|250 mg of deferasirox once daily for 6 months
214951835|NCT06025201|BEHAVIORAL|Resting State EEG|During this intervention, participants will be asked to not think about anything in particular while EEG is recorded. Resting state will be conducted with either the participants having their eyes open, or eyes closed.
214951836|NCT06025201|BEHAVIORAL|Picture Viewing EEG|During this intervention, participants will view emotionally charged pictures for a short period of time. Afterwards, participants will be asked to rate their emotional reactions to the pictures. EEG will be recorded during this intervention.
214344227|NCT02544243|DRUG|Vinorelbine|
214344228|NCT02544243|DRUG|Gemcitabine|
214344229|NCT02544243|DRUG|Cisplatin|
214344230|NCT06143618|BEHAVIORAL|escape room games|The escape room game will include a patient scenario of four female patients who are victims of violence and apply to different clinics. Necessary equipment and materials will be provided and stations will be established where four female patients who are victims of violence will be evaluated. In the game, each student will contact the patient at only one station and evaluate signs and symptoms of violence. The activities at the stations will be carried out together as a group. The group, which completes the tasks and activities and collects the puzzle pieces that will lead to the code of the lock, will complete the puzzle and enter the number codes on it into the key of the locked box on the table (4 numerical codes received), open the box and get the message 'you can escape'. The group with the most time left at the end of the game will come first and will be rewarded.
214951837|NCT06025201|BEHAVIORAL|Stop Signal EEG|During this intervention, participants will be asked to respond quickly to a visual stimulus with a button press. At times, participants will be asked to inhibit their responses. EEG will be recorded during this intervention.
214951838|NCT03221179|BIOLOGICAL|RO7049665|A single ascending dose (starting dose 1.5 micrograms \[mcg\])of RO7049665 will be administered SC.
214951839|NCT03221179|BIOLOGICAL|Placebo|Matching placebo will be administered SC once.
214951840|NCT01955577|DRUG|Placebo orally everyday|
214951841|NCT01955577|DRUG|Vitamin D3 cholecalciferol|
214344231|NCT06143618|BEHAVIORAL|role playing|In the role play application, there will be scenarios of four female patients who are victims of violence and apply to different clinics. Before the role play activities, students will be asked to form groups of 4-5 people, and each week, a group will be asked to choose one of the four scenarios given by lot and improvise the case-based role play activity within 40 minutes. Before the role play application, the materials that may be required for the students (clothes, materials, etc.) and the preparation of the environment (hospital, polyclinic, etc.) will be provided by the researchers in accordance with the activity to be enacted. At the end of the role play activities, students will be able to express, evaluate and discuss their feelings and thoughts within and between groups.
214951842|NCT03594955|DRUG|SAR440234|Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
214951843|NCT01681095|DRUG|Custodiol HTK|After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.
214951844|NCT01681095|DRUG|Cold Blood Cardioplegia|After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional \> 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
214951845|NCT01584505|DRUG|CHF1535 + CHF5992 dose 1 BID|CHF1535 + CHF5992 dose 1 BID for 14 days
214951846|NCT01584505|DRUG|CHF1535 + CHF5992 dose2 BID|CHF1535 + CHF5992 dose 2 BID for 14 days
214951847|NCT01584505|DRUG|CHF1535 daily dose|CHF1535 daily dose for 14 days
214951848|NCT04925778|DRUG|monomethyl fumarate|Patients will be prescribed 190 mg (two 95 mg capsules) self-administered twice/day,
214951849|NCT00000888|DRUG|Ritonavir|
214951850|NCT00000888|DRUG|Lamivudine|
214951851|NCT00000888|DRUG|Zidovudine|
214951852|NCT03152487|OTHER|Celiac Plexus Neurolysis|This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.
215076447|NCT04441164|OTHER|Observation of Virtual Actions|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
214344232|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Reduced Single Lumen|Thin tip to penetrate the tissue
214344233|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Single Lumen (1.4 mm)|Standard (1.4 mm) needle to penetrate the tissue
214344234|NCT01876173|BEHAVIORAL|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
214344235|NCT04302857|OTHER|routine MRI|MRI with routine DTI sequence
214344236|NCT01257295|DIETARY_SUPPLEMENT|control: no fiber addition|liquid breakfast without addition of fiber
214951853|NCT03152487|OTHER|Radiofrequency Ablation|Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
214951854|NCT03271099|OTHER|Navigator|Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance
214951855|NCT01602679|DRUG|oral micronized progesterone suspension|oral micronized progesterone (100 mg p.o.) suspension
214951856|NCT01602679|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
214951857|NCT00504543|DRUG|AEB071|oral, twice daily
214951858|NCT00504543|DRUG|Certican|twice daily
214951859|NCT00504543|DRUG|Neoral|twice daily
214951860|NCT00270621|BEHAVIORAL|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
214951861|NCT04159441|OTHER|None intervetion|None intervetion
214951862|NCT01010802|DRUG|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
215076448|NCT04441164|OTHER|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
214951863|NCT03984955|DEVICE|Sodium hyaluronate with mannitol (Ostenil Tendon)|1ml isotonic solution contains 20.0mg sodium hyaluronate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol and water for injections.
214951864|NCT03984955|DEVICE|Platelet-Rich Plasma Injection|Platelet-rich plasma (PRP) describes an autologous blood plasma fraction enriched with platelets which is then injected at the site of tendon injury.
214951865|NCT03984955|OTHER|Subcutaneous sham injection|Sham injection will penetrate the skin, but no therapeutic substance will be injected
214951866|NCT06844617|DEVICE|BathMat|Repositioning patients using the BathMat
214951867|NCT05777720|DEVICE|Filtration Fan|Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
215076449|NCT04441164|OTHER|Acceptability questionnaire|It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
215076450|NCT04441164|OTHER|Observation of Virtual Actions (step 4)|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
215076451|NCT04441164|OTHER|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
214344237|NCT01257295|DIETARY_SUPPLEMENT|breakfast with low viscous, low gelling pectin|10g of low viscous, low gelling pectin dissolved in a liquid breakfast
214344238|NCT01257295|DIETARY_SUPPLEMENT|high viscous, low gelling pectin|10g of high viscous, low gelling pectin dissolved in a liquid breakfast
214344239|NCT01257295|DIETARY_SUPPLEMENT|low viscous, high gelling pectin|10g of low viscous, high gelling pectin dissolved in a liquid breakfast
214344240|NCT01257295|DIETARY_SUPPLEMENT|high viscous, high gelling pectin|10g of high viscous, high gelling pectin dissolved in a liquid breakfast
214344241|NCT01257295|DIETARY_SUPPLEMENT|pectin supplement|10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
214344242|NCT00120172|DRUG|oxaliplatin, capecitabine, bevacizumab|
214951868|NCT05777720|BEHAVIORAL|Safe-home pamphlet|The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
214951869|NCT05777720|BEHAVIORAL|Mid-week phone call|On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
214951870|NCT06239350|BEHAVIORAL|Counseling|Research staff will provide skills-based counseling at remote weekly visits, starting at Day 0. Counseling sessions will be brief (\~5-10 minutes) and will focus on strategies for preparing for the quit attempt, dealing with triggers, refusal skills, and enhancing motivation.
214951871|NCT06239350|BEHAVIORAL|Contingency management|Contingency management (CM): CM will be provided to all study participants to promote abstinence from all nicotine products. Incentives for abstinence (based on submission of a negative cotinine sample) will be provided on an escalating schedule during treatment (Days 8-84).
215076452|NCT04441164|OTHER|Haptic stimulation|According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
214344243|NCT02630667|OTHER|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
214344244|NCT02630667|OTHER|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
214344245|NCT02630667|OTHER|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
214344246|NCT00784810|DRUG|Oxycodone/Naloxone|5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
214344247|NCT00784810|DRUG|Codeine/Paracetamol|15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
214344248|NCT04825457|PROCEDURE|Anchoring-tip vs. Conventional|"Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection."
214344249|NCT00208793|DIETARY_SUPPLEMENT|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
214344250|NCT00208793|DRUG|Placebo|Placebo
214344251|NCT00208793|DIETARY_SUPPLEMENT|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
214344252|NCT00208793|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
214344253|NCT01101737|OTHER|Nurse-led blood pressure clinic|Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
214344254|NCT02862106|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
214951872|NCT06239350|BEHAVIORAL|Text-based support|All participants will be provided with evidence-based nicotine cessation resources. For those who are vaping nicotine, participants will be provided information for This is Quitting (SMS text-based program). For those who are primarily smoking cigarettes, NCI's QuitSTART (mobile app, web content), as well SmokefreeTXT (SMS-text based program), will be recommended, potentially in addition to This is Quitting for those using multiple products. These resources provide real time monitoring of nicotine use, mood, triggers and lapses.
214951873|NCT05613179|PROCEDURE|Group1 (lever positioning manipulation)|The specific lever positioning manipulation is as follows: the patient lies prone at the mouth-open position with muscles relaxed, waist exposed, knees and hips bent, and ankle joints crossed. The practitioner uses the right elbow olecranon to point at the lumbar vertebrae, then hold the patient's two ankle joints in both hands to cause the lumbar vertebra to make hyperextension and flexion movements through the arms and pull the patient backward and upwards hard. When pulling upwards to the trigger point, the practitioner pulls wit lever quickly with a technique and then senses a clatter or looseness at the positioning point. When the practitioner pulls with lever manipulation, the patient is asked to exhale and then inhale at the end of the manipulation.
214951874|NCT05613179|PROCEDURE|Group2 (placebo group)|The specific sham lever positioning manipulation is as follows: the patient lies prone with his mouth open, muscles relaxed, waist exposed, knees bent at the hip and ankles crossed. The practitioner points to the lumbar spine with the right elbow olecranon, and then holds the patient's two ankles in both hands, so that the lumbar spine through the arm for overextension and flexion, and forcefully pulls the patient back and up. When pulling up to the trigger point, maintain this movement for a short period of time, depending on the patient's endurance, about 1-5 minutes. After finishing, ask the patient to rest in prone position.
214951875|NCT05908487|BEHAVIORAL|AA Communities Speak to Healthcare Professionals|The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.
214951876|NCT05786547|DRUG|Varenicline|Per package dosing, tablet taken orally
214951877|NCT05786547|BEHAVIORAL|Positively Smoke Free Mobile (PSF-M)|Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
214344255|NCT02508480|BEHAVIORAL|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
214951878|NCT05786547|BEHAVIORAL|Standard Care|Brief cessation advice plus referral to local tobacco quitline
214951879|NCT03602196|OTHER|Perineal ultrasound assessment|"women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study."
214344256|NCT02508480|BEHAVIORAL|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
214344257|NCT01088451|DRUG|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
214344258|NCT04981665|DRUG|Tislelizumab|Tislelizumab 200mg IV Q3W
214344259|NCT04981665|DRUG|TACE|TACE will be performed after curative resection (4±1w)
214951880|NCT03602196|OTHER|Peripheral muscles assessment|"The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study."
214344260|NCT02618473|OTHER|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
214951881|NCT03602196|OTHER|Clinical pelvic floor assessment|"Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination"
214951882|NCT00766623|DIETARY_SUPPLEMENT|high fat meal|milkshake containing 95g fat
214951883|NCT00766623|DIETARY_SUPPLEMENT|control meal|milkshake comparable with a normal breakfast
214951884|NCT00162084|DRUG|apadenoson|
215076453|NCT04441164|OTHER|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
215076454|NCT00002839|DRUG|cisplatin|
215076455|NCT00002839|DRUG|fluorouracil|
215076456|NCT00002839|PROCEDURE|conventional surgery|
215076457|NCT00002839|PROCEDURE|neoadjuvant therapy|
215076458|NCT00002839|RADIATION|radiation therapy|
215076459|NCT06353399|PROCEDURE|Intra-marrow penetrations|Intra-marrow penetrations
215076460|NCT06353399|PROCEDURE|No Intra-marrow penetrations|No Intra-marrow penetrations
215076461|NCT04837729|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
215076462|NCT00998855|BEHAVIORAL|Exercise|12 wk aerobic or/ resistance exercise program
215076463|NCT01839019|DRUG|ODM-102|Single dose escalation
215076464|NCT01839019|DRUG|Placebo for ODM-102|Single dose escalation
215076465|NCT05143723|DRUG|Gonadotropin-releasing hormone agonist|luteal phase support with gonadotropin-releasing hormone agonist
215076466|NCT03824405|DRUG|BTX 1204|BTX 1204 liquid formulation
215076467|NCT03824405|DRUG|Vehicle|Vehicle liquid formulation
215076468|NCT05010941|DEVICE|Hypotension Prediction Index|Hypotension Prediction Index monitored via radial arterial line
215076469|NCT03201042|DIAGNOSTIC_TEST|PCR based assay|"Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.~In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen)."
215076470|NCT03201042|DIAGNOSTIC_TEST|Serology based assay|"1. The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.~2. The Immunetics C6 Lyme ELISA assay.~3. A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines~4. A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.~Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared."
215076471|NCT03201042|DIAGNOSTIC_TEST|Tcell based assay|A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
214344261|NCT04017026|DEVICE|Implantation|Implantation of 6 mm short implants
215076472|NCT02927704|OTHER|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
215076473|NCT02262442|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
215076474|NCT02262442|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
215076475|NCT05358431|OTHER|Neuroimaging and electrophysiology|Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
215076476|NCT03946982|PROCEDURE|low thoracic epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces
214344262|NCT01840423|DRUG|ODM-104|ODM-104
214951885|NCT06235606|DRUG|Bupivacaine Liposome 13.3 Milligrams/Milliliter [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
214951886|NCT06235606|DRUG|Dexmedetomidine 0.5milligram (50micrograms)|Dexmedetomidine is a full α₂ adrenergic receptor agonist roughly eight times more selective for the α₂ receptor than clonidine.
214951887|NCT06147752|BEHAVIORAL|"mobile internet healthcare and co-management of three disciplines"|"co-management of three disciplines:~Endocrinologist:~Assess disease status and rule out secondary obesity; Identify the causes of overweight/obesity and the status and extent of associated diseases; receive patients for return visits. Timely reply to patients' questions on the mobile medical platform, and timely adjust medication plans according to changes in patients' conditions.~Dietitians:~Conduct diet assessment, develop personalized medicine nutrition treatment plan and provide daily real-time guidance and follow up patients' daily diet outside the hospital.~Weight managers:~Establish weight loss record for patients, guide the installation and use of mobile medical Application , including weight monitoring, real-time uploading of daily diet and online interactive consultation; Follow up patients' weight changes; Assist patients in making appointments for follow-up visits."
214951888|NCT06476431|OTHER|dual task|The intervention program will be a program created by the researcher based on the iPad application Brainilis The tasks (logic, memory, math, and concentration) will be performed using a Type-C cable connected to the smartglasses, and the difficulty level will be adjusted according to the individual's cognitive ability. The experimental group will perform cognitive tasks with the smartglasses while simultaneously performing a walking task on a treadmill. This will be done three times a week for 30 minutes for four weeks. The subjects will not be able to touch the answers, so they will tell the therapist what they think is the correct answer and the therapist will touch the iPad to move on to the next step. The investigators will start with 10 minutes on the treadmill without incline, followed by a 5 minute break, then 10 minutes on the treadmill with incline, followed by a 5 minute break. It will run for 30 minutes, 3 times a week for 4 weeks.
214951889|NCT06476431|OTHER|non dual task|No cognitive task, just treadmill walking. Same as the experimental group 1: 10 minutes without treadmill incline, followed by a 5 minute rest period, followed by 10 minutes on the treadmill with incline, followed by a 5 minute rest period. It will run for 30 minutes, 3 times a week for 4 weeks.
214951890|NCT04278924|DRUG|Placebo|TAK-079 placebo-matching SC injection.
214951891|NCT04278924|DRUG|TAK-079|TAK-079 SC injection.
214951892|NCT06463301|OTHER|Treadmill Training In CP child|"Treadmill training for children should be carefully tailored to their developmental level, physical ability, and specific therapeutic goals. Initial Sessions start with shorter sessions, around 5-10 minutes, especially for children with disabilities.~Progression will be made when the child becomes more accustomed to the treadmill. Aim for a total of 20-30 minutes per session, including breaks if necessary then then Start at a slow walking pace, approximately 0.5 to 1.0 miles per hour (mph) or 0.8 to 1.6 kilometers per hour (kph). Adjust the speed based on the child's comfort and ability to maintain a safe and effective walking pattern.~Older Children (8-12 years Begin with a walking pace of 1.0 to 1.5 mph (1.6 to 2.4 kph). Gradually increase the speed to a brisk walk or light jog, up to 2.0 to 3.0 mph (3.2 to 4.8 kph), depending on the child's progress and comfort level along with conventional physical therapy."
214951893|NCT06463301|OTHER|Conventional Physical Therapy|conventional physical therapy session would typically include gentle stretching, joint mobilization, range of motion exercises for both the upper and lower body, gait training, and standing frame activities. Each component is designed to improve various aspects of physical function, ensuring a comprehensive approach to rehabilitation
214951894|NCT06087185|BEHAVIORAL|Mindful Eating|Mindful Eating practices will be taught during a weekly meeting lasting 150 minutes and individuals will be encouraged to integrate the practices learned into their daily lives, for at least 15 minutes a day, being progressively integrated into the other practices that will be taught in subsequent weeks. There will be a WhatsApp group with reminders during the week and audio for guided practice.
215076477|NCT03946982|PROCEDURE|lumbar epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces (conventional)
215076478|NCT01846195|DEVICE|CM 1500|
215076479|NCT02362945|DRUG|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
214344263|NCT01840423|DRUG|Placebo|Placebo
214344264|NCT01840423|DRUG|Entacapone|entacapone + levodopa/carbidopa
214344265|NCT01840423|DRUG|levodopa/carbidopa|entacapone + levodopa/carbidopa
214344266|NCT02995967|PROCEDURE|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
214344267|NCT02995967|DRUG|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
214344268|NCT04137380|DRUG|Mirikizumab - IV|Administered IV
214344269|NCT04137380|DRUG|Mirikizumab - SC|Administered SC
214344270|NCT04137380|DRUG|Placebo - IV|Administered IV
214344271|NCT04137380|DRUG|Placebo - SC|Administered SC
214344272|NCT05250596|DRUG|Colchicine|Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge.
214344273|NCT05250596|DRUG|Atorvastatin|Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
214344274|NCT05061264|PROCEDURE|Abdominal wall reconstruction|The repair of abdominal wall defects with polyvinylidene (PVDF) mesh
214344275|NCT00563784|DRUG|Erlotinib|150 mg by mouth daily for 7 Weeks
214344276|NCT00563784|DRUG|Carboplatin|2 AUC by vein weekly for 7 Weeks
214344277|NCT00563784|DRUG|Paclitaxel|45 mg/m\^2 by vein weekly for 7 Weeks
214344278|NCT00563784|RADIATION|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
214344279|NCT00281541|DRUG|YM155|
214344280|NCT04499794|DRUG|ALK inhibitor|ALK inhibitor treatment on ALK fusion positive NSCLC patients
214344281|NCT02161744|BIOLOGICAL|ADSCs administration|100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
214344282|NCT03652311|DEVICE|ThermoNeuroModulation TNM Device|Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
214344283|NCT03966976|DEVICE|ECG monitoring & record|This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
214344284|NCT03966976|OTHER|Conventional follow-up|Conventional follow-up
214344285|NCT04461977|OTHER|True acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen, 2011) and on previous studies (Jeong,2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment. The needles will be inserted at a depth of 10 - 15 mm, being gently manipulated to obtain de qi sensation. The needles will be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
214344286|NCT04461977|OTHER|Sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet. The needles will also be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
214344287|NCT01479920|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
214344288|NCT01479920|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|"Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable."
214344289|NCT01479920|PROCEDURE|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
214951895|NCT06087185|BEHAVIORAL|Video Group|"Composed of 5 videos sent weekly produced by trained professionals. The topics discussed will be relevant to the management of anxiety in general and lifestyle changes.~Video 1: Psychoeducation of anxiety. Video 2: Healthy eating. Video 3: Sleep hygiene. Video 4: Physical activity. Video 5: Substance use. This protocol used as a control was effective as a Psychoeducation Group in improving anxiety symptoms in patients with generalized anxiety disorder."
214951896|NCT06056635|DEVICE|Karl Storz Curved Scope|The curved fetoscope (11508AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the front of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
214951897|NCT06056635|DEVICE|Karl Storz Straight Scope|The straight fetoscope (11506AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the back of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
214951898|NCT05600036|DRUG|ESK-001|Oral tablet
214951899|NCT05600036|DRUG|Placebo|Oral tablet
214951900|NCT05923359|OTHER|Apple Watch|Apple Watch
214951901|NCT00201318|DRUG|Cyclophosphamide Doxorubicin Vincristine Lamivudine|
215076480|NCT05160519|RADIATION|Class IV Laser|"30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the efficacy of class IV laser on ejection fraction, Cardiac Biomarker and functional outcomes.~Device: Litecure LCT-1000C Class IV laser will be used in contact method over the left parasternal area in 2nd, 3rd intercostal space and apex. Dosage and Parameters for the irradiation will be calculated. Parameters: 1. Wavelength: 980nm, 2. Power/ Energy density: 6W/6J/cm2 3. Frequency: CW 4. Energy delivered at each spot: 360J 5. irradiation spots: 3 6. Irradiation time: 60 sec at each spot.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
215076481|NCT05160519|RADIATION|Sham Class IV Laser|"30 participants in sham control group will be suppose to irradiate with Class IV laser therapy over the left parasternal area, but the radiation will not be delivered.~Device: Litecure LCT-1000C Class IV laser will be placed over the left parasternal area in 2nd, 3rd intercostal space and apex without switching on the instrument.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
215076482|NCT02166645|OTHER|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
214344290|NCT04634604|DRUG|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
214344291|NCT04634604|PROCEDURE|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.
214344292|NCT02127164|DEVICE|"Veraflo device, Dakin's solution"|Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
214344293|NCT03434119|DRUG|Insulin glargine/Lixisenatide|Insulin glargine (100 units per milliliter \[U/mL\]) and lixisenatide (33 micrograms per milliliter \[mcg/mL\]) self administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
214344294|NCT03434119|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL self-administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting SMPG of 80 to 100 mg/dL (4.4 to 5.6 mmol/L) while avoiding hypoglycemia.
214344295|NCT03434119|DRUG|Background therapy|Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
214344296|NCT04942080|BIOLOGICAL|CALR allele burden quantification|"* DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~* at diagnosis and follow-up (inclusion period: 3 years)~* max 1 sample/year~* secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"
214951902|NCT05386576|DRUG|Venetoclax|"During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42."
214951903|NCT06556069|OTHER|Peer-Support Enhanced Agitation Code Team (PACT)|"PACT will address systems challenges experienced by staff, safety threats to ED patients with mental illness and substance use disorders, and known structural biases against marginalized individuals during decisions in use of restraints for behavioral crises in the ED.~The PACT intervention includes a peer support service component to deliver patient-centered, trauma-informed, culturally sensitive care to patients presenting with behavioral complaints in the ED and experiencing distress."
214951904|NCT05160298|DRUG|Ropivacaine 0,2% Injectable Solution|Echo-guided bilateral erector spinae block
215076483|NCT02166645|OTHER|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
214951905|NCT05160298|OTHER|Control group|Sham block
214951906|NCT00561535|DIETARY_SUPPLEMENT|Lactobacillus FARCIMINIS|10.10 UFC of lactobacillus FARCIMINIS
214951907|NCT00561535|DIETARY_SUPPLEMENT|placebo (starch)|Once daily
214951908|NCT06187233|OTHER|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied during the procedure.
214951909|NCT06551298|OTHER|Menggongzi Tibetan Tea Special Drink|Menggongzi Tibetan Tea Special Drink (50ml/time, taken after breakfast and lunch)+Low fat diet
214951910|NCT06551298|DRUG|Atorvastatin Calcium 20Mg Tab|Atorvastatin Calcium Tablets (20mg, qn)+Low Fat Diet
215076484|NCT01231321|DRUG|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
214951911|NCT06551298|OTHER|Low fat diet|Low fat diet
214951912|NCT02489617|OTHER|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
214951913|NCT04003272|DEVICE|Comprehensive Reverse Versa-Dial Titanium Glenosphere|Implant used for patients with allergy to typical device material metals to repair shoulder malfunction/disease.
214951914|NCT00408187|DRUG|voclosporin|voclosporin 0.4 mg/kg po BID
214951915|NCT00408187|DRUG|Ciclosporin|ciclosporin 1.5 mg/kg po BID
214951916|NCT00408187|DRUG|Placebo|Placebo
214951917|NCT06377332|DIAGNOSTIC_TEST|High density electroencephalogram (HdEEG)|High-density electroencephalography (HdEEG) will be utilised in the investigation of sleep-mediated neuronal functions in controls, OSA, COPD and overlap syndrome and the association with accelerated brain ageing and cognitive impairment.
214951918|NCT06377332|DIAGNOSTIC_TEST|Functional near infrared spectroscopy (fNIRS)|Functional near infrared spectroscopy (fNIRS) is one of the most advanced techniques in measuring brain oxygen content and hemodynamic activity. This information indirectly displays neuronal activity and provides a novel opportunity understand brain oxygenation, neurodegenerative diseases, and cognitive function.
215076485|NCT01247363|DRUG|LY2608204|Administered orally.
215076486|NCT04185974|RADIATION|C12 re-irradiation|51 Gy(RBE) or 54 Gy
215076487|NCT04185974|RADIATION|Photon re-irradiation|54 Gy(RBE) or 60 Gy
215076488|NCT06268327|DRUG|Cisplatin injection and gemcitabine|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with gemcitabine plus cisplatin Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
214344297|NCT02700282|BEHAVIORAL|Backpack Carrying|A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
214344298|NCT00304070|DRUG|Cisplatin|Given IV
214344299|NCT00304070|PROCEDURE|Conventional Surgery|Patients undergo surgery
214344300|NCT00304070|DRUG|Doxorubicin Hydrochloride|Given IV
214344301|NCT00304070|DRUG|Etoposide|Given IV
214344302|NCT00304070|BIOLOGICAL|Filgrastim|Given subcutaneously
214344303|NCT00304070|DRUG|Mitotane|Given orally
214344304|NCT00304070|BIOLOGICAL|Pegfilgrastim|Given subcutaneously
214344305|NCT04528563|DRUG|Ketorolac Tromethamine 10 MG/ML|Non-Steroidal-Anti-Inflammatory given intravenously.
214344306|NCT04528563|DRUG|Morphine Sulfate 10Mg/1mL Injection|Opioid commonly used for acute abdominal pain given intravenously.
214344307|NCT04044677|DEVICE|tDSC-active|10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation
214951919|NCT06377332|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be utilised to assess potential structural neuronal changes associated with neurodegenerative disease in those with COPD, OSA and overlap syndrome. MRI has the capacity to provide vital information regarding neuroimaging standards in cerebral vascular damage such as white matter hyperintensities (WMH), lacunes, cerebral microbleeds, brain atrophy and subcortical infarct. Through the utility of MRI sequences such as T1 and T2 weighted imaging, diffusion weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) and resting-state fMRI (rs-fMRI), the investigators will assess neurodegenerative-related structural brain changes in individuals with COPD, OSA and overlap syndrome and examine the differences between these target groups.
214951920|NCT06377332|BIOLOGICAL|Blood collection|"A fasting 50mL blood sample will be collected at the experimental visit in the morning following the overnight sleep study. Blood samples will be processed after collection and stored at -80 degrees for future batch analyses. Analyses will include markers for inflammation and dementia including but not limited to ptau217 and beta amyloid. Routine blood analyses will be conducted on 17.5mL of the sample collected for baseline measures. Routine blood analyses includes lipid profile, glucose studies, insulin, high-sensitivity C-reactive protein (hs-CRP), iron studies, thyroid function, b12/folate, homocysteine, prolactin, calcium, full blood count and biochemistry panel for the OSA, COPD and overlap syndrome groups.~Routine blood analyses for controls include glucose studies, lipid profile, hs-CRP and biochemistry panel."
215076489|NCT06268327|DRUG|Capecitabine tablets|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with capecitabine Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
215076490|NCT02860624|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
215076491|NCT02860624|DRUG|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
215076492|NCT02071186|DEVICE|Virtual Reality training|"Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis."
215076493|NCT02071186|OTHER|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
214344308|NCT04044677|DEVICE|tDCS-sham|10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
214344309|NCT00238927|DRUG|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
214344310|NCT05465226|DRUG|Oliceridine|see arm description
214344311|NCT05465226|DRUG|Historical opioid use|Historical matched, control group in 2:1 ratio
214344312|NCT04998240|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration:~Intramuscular~Storage Conditions: 2°C to 8°C"
214344313|NCT04998240|BIOLOGICAL|Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|"Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein), manufactured by Johnson and Johnson in the United States of America.~Dose formulation: One dose (0.5 ml) contains contains 5 x 10 10 virus particles~Mode of administration: Intramuscular~Storage Conditions: 2°C to 8°C"
214344314|NCT04998240|BIOLOGICAL|Placebo - Normal saline (0.9% sodium chloride solution)|"Placebo - Normal saline (0.9% sodium chloride solution)~Dose formulation: Not Applicable~Mode of administration: Intramuscular~Storage conditions: 15°C to 30°C"
214344315|NCT03579459|BIOLOGICAL|Clostridium difficile vaccine|Toxoid based Clostridium difficile vaccine
214344316|NCT03579459|BIOLOGICAL|placebo|Normal saline solution
214344317|NCT00148343|DEVICE|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation \& use for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
214344318|NCT00148343|OTHER|Conventional Standard of Care|Conventional standard of care (which may include implementation \& use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
214344319|NCT00148343|PROCEDURE|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
214344320|NCT02866890|DEVICE|Laryngeal Tube Suction|Laryngeal Tube Suction Measurement of leak pressure
214344321|NCT03448549|DRUG|Oxaliplatin|adjuvant chemotherapy
214344322|NCT03448549|DRUG|Tegafur，gimeracil and oteracil potassium|adjuvant chemotherapy
214344323|NCT03448549|DRUG|Xeloda|adjuvant chemotherapy
215076494|NCT02071186|OTHER|Standard of care|
214344324|NCT02612012|RADIATION|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
214344325|NCT02317458|BIOLOGICAL|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
214951921|NCT06377332|DIAGNOSTIC_TEST|Neuropsychological battery|"A. Montreal Cognitive Assessment (MoCA):~B. Test of Premorbid Functioning (TOPF):~C. Rey Auditory Verbal Learning Test (RAVLT):~D. D-KEFS Colour Word Interference Test (D-CWIT):~E. Trail Making Test (TMT):~F. Symbol Digit Modalities Test (SDMT) - Oral Version:~G. RAVLT 20-minute recall~H. Controlled Oral Word Association Test (COWAT):"
214951922|NCT06377332|OTHER|Questionnaires|"1. Epworth Sleepiness Scale (ESS)~2. PROMIS sleep questionnaire 8a,~3. PROMIS sleep questionnaire 8b~4. EQ-5D-5L~5. Insomnia Severity Index (ISI)~6. Pittsburgh Sleep Quality Index (PSQ-I)~7. St George's Respiratory Questionnaire (SGRQ)~8. COPD Assessment Test (CAT)"
214951923|NCT06377332|DIAGNOSTIC_TEST|Pulmonary Function Test (PFT)|Full pulmonary function testing will be conducted in control, COPD, OSA and overlap syndrome groups. Full lung function testing will include spirometry with pre and post bronchodilator, oscillometry, lung diffusion testing (DLCO) and lung volumes.
214951924|NCT06377332|OTHER|Cognitive Assessment|"The following cognitive assessments will be administered using a digital format on CANTAB:~1. Motor Screening Task (MOT) Used to assess sensorimotor function and comprehension and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease. This task acts as a practice trial for the subsequent tasks.~2. Reaction Time (RTI) Used to assess processing and psychomotor speed and is applicable in the assessment of general cognitive function and Alzheimer's disease.~3. Paired Associate Learning (PAL) Used to assess visual episodic memory and is applicable in the assessment of general cognitive function, Alzheimer's disease, Parkinson's disease and cerebrovascular disease.~4. Spatial Working Memory (SWM) Used to assess working memory and strategy and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease."
214951925|NCT06377332|DIAGNOSTIC_TEST|Polysomnogram (PSG)|During the sleep study, physiological signals are recorded to capture eye movements (electrooculogram, EOG) and chin muscle movements (electromyogram, EMG). A nasal airflow piece, two respiratory inductance plethysmography (RIP) bands and an oximeter probe on the finger will monitor breathing and oxygen levels in the blood. Electrocardiogram (ECG), leg movements, sleeping position and snoring are also recorded.
214951926|NCT00671047|OTHER|non-interventional|SLE nature history observational
214344326|NCT02317458|BIOLOGICAL|Sham comparator|One arm with standard of care undergoing a sham procedure
214344327|NCT06580886|DEVICE|Ultrasound|All patients having ultrasound with Clarius L15/L20 and GE logic E9/E10 in same visit.
214344328|NCT05130112|DEVICE|high flow nasal cannula and nasal cannula|"HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min."
214344329|NCT01754714|DRUG|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
214951927|NCT03141034|DRUG|Irinotecan|-Irinotecan is commercially available and will be billed to insurance.
214951928|NCT03141034|DRUG|Ramucirumab|-Ramucirumab will be provided free of charge by Eli Lilly and Company.
214951929|NCT03141034|GENETIC|Blood for angiome profiling|-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment
214951930|NCT03141034|GENETIC|Blood for cfDNA|-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
214951931|NCT04640155|BEHAVIORAL|Low FODMAP Diet|Patients in the low FODMAP group will schedule a telephone visit with a registered dietician. During this approximately hour-long session, patients in the low FODMAP cohort will be counselled regarding FODMAP containing foods and how to effectively remove them while maintaining a nutrition-rich diet.
214951932|NCT04640155|BEHAVIORAL|Regular Diet|Patients in the regular diet group will receive an educational handout discussing low fiber diet, which is standard of care for those with pouchitis symptoms.
215076495|NCT02827383|BEHAVIORAL|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
215076496|NCT03675425|OTHER|Group 1: non chest shielding|non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
215076497|NCT03675425|OTHER|Group 2: chest shielding|chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
215076498|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
214344330|NCT01754714|DRUG|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
214344331|NCT01754714|DRUG|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
214344332|NCT01610323|OTHER|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
214344333|NCT01610323|OTHER|Standard Care|
214344334|NCT02528214|DRUG|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
214344335|NCT02528214|DRUG|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
214344336|NCT02528214|DRUG|Oral corticosteroid therapy (prednisone/prednisolone)|Oral administration.
214344337|NCT02528214|DRUG|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
214344338|NCT02528214|DRUG|Albuterol/Salbutamol|Oral inhalation as needed.
214344339|NCT02528214|DRUG|Levalbuterol/Levosalbutamol|Oral inhalation as needed.
215076499|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
215076500|NCT04046315|DIAGNOSTIC_TEST|CMR|GLS measurement with CMR
215076501|NCT02146703|DRUG|Gemcitabine, and S-1|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14"
215076502|NCT02978547|DRUG|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
215076503|NCT01106859|DRUG|zopiclone|7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
215076504|NCT01106859|DRUG|zolpidem tartrate sublingual tablet|3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
215076505|NCT01106859|DRUG|Placebo (sublingual tablet)|Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
215076506|NCT01106859|DRUG|Placebo|Placebo matching zopiclone
215076507|NCT03213743|DRUG|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
215076508|NCT00354107|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
215076509|NCT00354107|DRUG|therapeutic hydrocortisone|Given IT
215076510|NCT00354107|DRUG|ifosfamide|Given IV
215076511|NCT00354107|DRUG|carboplatin|Given IV
215076512|NCT00354107|DRUG|etoposide|Given IV
215076513|NCT00354107|DRUG|methotrexate|Given IT
214951933|NCT05068011|DEVICE|Spinal Cord Stimulation|differential target multiplexed stimulation
214951934|NCT03534999|DEVICE|Experimental. This was the group that received TENS|Patients that were on TENS . They were treated twice daily for 5 days. VAS and Hip Score scale were used to assess the pain intensity and disability level
215076514|NCT00354107|DRUG|cytarabine|Given IT
215076515|NCT00354107|OTHER|pharmacological study|Correlative studies
215076516|NCT00354107|OTHER|laboratory biomarker analysis|Correlative studies
215076517|NCT01311128|DEVICE|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
215076518|NCT00415428|BEHAVIORAL|Patient adherence to national educational guidelines.|
215076519|NCT03979456|DRUG|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
215076520|NCT05202574|DRUG|Intravenous drug|intravenous drug injection
215076521|NCT04070716|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
215076522|NCT04070716|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
215076523|NCT00307840|DRUG|paricalcitol|
215076524|NCT02780635|BEHAVIORAL|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
215076525|NCT02780635|BEHAVIORAL|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
215076526|NCT02574650|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
215076527|NCT06105736|BEHAVIORAL|Behavioral Intervention in a small group platform|RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.
215076528|NCT01813552|DRUG|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
215076529|NCT01813552|DRUG|Omeprazole|40 mg delayed-release oral capsules, once daily
215076530|NCT01813552|DRUG|Ritonavir|100 mg oral tablets, once daily
215076531|NCT05162001|DRUG|Disulfiram 250 mg|Disulfiram used qd during nine weeks to observe effects on body weight
214951935|NCT03534999|OTHER|No intervention|Patients in this group were on their drugs only. There was no physiotherapy intervention for the patient. VAS and Hip Score scale were used to ascertain the pain intensity and hip disability at the before the treatment and after the treatment
214951936|NCT00498810|PROCEDURE|complete repair|
214951937|NCT00498810|PROCEDURE|partial repair of the abdominal wall|
214951938|NCT01979601|DRUG|LGT209|150 mg lyophilized powder in glass vial
214951939|NCT01979601|DRUG|Placebo|Placebo comparator
214951940|NCT01006590|DRUG|Saxagliptin|5 mg, oral tablet, once daily
214951941|NCT01006590|DRUG|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
214951942|NCT00057005|DRUG|CAMPATH-1H|Day-8 through Day-6 according to institutional SOPs
214951943|NCT00057005|DRUG|Anti-CD45|Day-5 400 μg/kg
214951944|NCT00057005|DRUG|Ara-C|day-7 through day-5 3000 mg/m2 q 12h
214951945|NCT00057005|DRUG|Cyclophosphamide|Day-7 through Day-6 45 mg/kg
214344340|NCT06276855|OTHER|Sleep hygiene education|The sleep hygiene education booklet was prepared by the researchers by in line with the literature. The booklet contains information on the definition and benefits of sleep, sleep problems during insomnia, arrangements for regular sleep, and the principles of sleep hygiene. The principles of sleep hygiene include individual habits that facilitate sleep, proper arrangement of the physical environment, exercises before going to bed, and dietary habits. This educational content was applied to those in the experimental group. The education took an average of 30 minutes.
214344341|NCT00513669|BIOLOGICAL|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
214344342|NCT00513669|BIOLOGICAL|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
214344343|NCT00347308|BEHAVIORAL|Eyebrow Position|Photography of brow positions
214344344|NCT01970033|DRUG|Placebo|"* Run in period ：oral tablets of Placebo twice daily for 2 weeks~* Phase A : oral tablets of Placebo twice daily for 24 weeks~* Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks"
214951946|NCT00057005|DRUG|Mesna|Days -7 and -6 45 mg/kg divided into 5 doses
214951947|NCT00057005|RADIATION|Total Body Irradiation|150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
214951948|NCT02957487|DEVICE|Denture supported by 3 dental implants|Metal-reinforced denture without palatal coverage incorporating nylon rings retained by friction to Locator abutments fitted on top of dental implants
214951949|NCT00329745|BIOLOGICAL|Rotarix™|Oral administration, 2 doses
214344345|NCT01970033|DRUG|SP2086 50 mg b.i.d.|"* Run-in period: placebo twice daily for 2 weeks~* Phase A:SP2086 50 mg b.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d for 28 weeks"
214951950|NCT00329745|BIOLOGICAL|Placebo|Oral administration, 2 doses
214951951|NCT02649517|PROCEDURE|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
214951952|NCT02486172|BEHAVIORAL|Peer support program|Peer support program as an additional service to the routine clinical service
214951953|NCT00647595|BEHAVIORAL|Experimental group|Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
214344346|NCT01970033|DRUG|SP2086 100 mg q.d.|"* Run-in period:placebo twice daily for 2 weeks~* Phase A: SP2086 100 mg q.d. for 24 weeks~* Phase B: SP2086 100 mg q.d. for 28 weeks"
214486605|NCT06752109|OTHER|Antipronation Taping|Before applying the tape, its length was measured by passing it over the areas on the foot where it would be applied. The tape was first attached to the medial side of the big toe, with tension in the direction of flexion and abduction of the toe. The ankle was then positioned in full plantar flexion. The tape was applied from the medial side of the foot towards the heel, wrapping around it, and then directed towards the sole. While the foot was in an inversion position at the navicular level, the tape was applied with maximum tension from medial to lateral and brought back to the sole. The remainder of the tape, with maximum tension, was applied from the sole to the dorsal side of the ankle, ending without tension at the proximal and lateral side of the leg. A second strip of tape, with maximum tension, was applied to support the medial longitudinal arch. The ends of the tape were placed over the malleoli without tension, aiming to reduce excessive pronation.
214486606|NCT06752109|OTHER|Sham|In the sham taping application, the length of the tape was measured by passing it over the areas where it would be applied. The tape was applied to the medial side of the big toe, but without tension, simply placed. Then, the tape was directed towards the sole of the foot, passing over the heel. At the navicular level, the tape was applied from medial to lateral, returning to the sole without tension. A second strip of tape was applied to the sole without tension. The ends of the tape were placed over the malleoli without stretching. Since no tension was applied, this application was only placed and has a limited effect on reducing excessive pronation.
214951954|NCT00178646|DRUG|Botox|Botox 75-150 units, single treatment only
214951955|NCT05627947|DRUG|Mitomycin c|Comparing the effect of Mitomycin C versus Cyclosporine after primary pterygium surgery
214951956|NCT05443503|OTHER|Mobile health applications (mHealth apps) based intervention|Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH). Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track.
215076532|NCT02051153|DRUG|Modafinil|Modafinil (2-\[(Diphenylmethyl) sulfinyl\]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg \& Carter, 2008).
215076533|NCT02051153|DRUG|Placebo|
215076534|NCT01173549|DRUG|Canagliflozin/Placebo Placebo/Canagliflozin|Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
215076535|NCT01173549|OTHER|no intervention|Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
214344347|NCT00511576|DRUG|MGCD0103 & Docetaxel|"In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks."
214344348|NCT01278329|OTHER|"Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)"|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
214486607|NCT06441487|BEHAVIORAL|Mobile Health Decision Support|Subjects randomized to this arm receive a link to a mobile health decision support tool (mPATH™- Cloud). Within mPATH™-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who select FIT, as well as subjects who do not click on the link or select a screening test receive a FIT mailed to their home address.
214951957|NCT06276023|BEHAVIORAL|Mindful and Self-Compassionate Care Program (MASC)|"The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
214951958|NCT06276023|BEHAVIORAL|Health Education Program (HEP)|"The control arm will be comprised of:~Six Virtual Group Sessions. The sessions will discuss caregiver stress, sleep hygiene, nutrition, and ways to stay physically active as a caregiver.~At Home Practice. After each group session, participants will have the opportunity to complete journal exercises that encourage them to integrate the health information that they learn into their daily lives."
214951959|NCT03675893|DRUG|Letrozole|Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.
214951960|NCT03675893|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.
215076536|NCT00830713|PROCEDURE|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
215076537|NCT03777709|BEHAVIORAL|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
215076538|NCT04774536|DRUG|CRISPR_SCD001|CRISPR\_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
215076539|NCT00033046|DRUG|Modafinil|
214951961|NCT03675893|DRUG|LY3023414|LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.
214951962|NCT03675893|DRUG|Metformin|Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.
214951963|NCT03675893|DRUG|Zotatifin|Zotatifin is a selective eukaryotic initiation factor 4A (eIF4A) inhibitor.
214951964|NCT03675893|DRUG|Gedatolisib|Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor.
214951965|NCT03970226|DRUG|Tocilizumab|"Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year)."
214951966|NCT01660347|BIOLOGICAL|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
214951967|NCT01660347|BIOLOGICAL|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
214951968|NCT01660347|PROCEDURE|Management of therapy complications|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
214951969|NCT02742675|DRUG|Bicalutamide|Given orally
214951970|NCT02742675|DRUG|goserelin acetate|Given subcutaneously or as an injection
214951971|NCT02742675|DRUG|flutamide|Given orally
215076540|NCT05959577|PROCEDURE|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.
215076541|NCT05959577|PROCEDURE|Ferguson hemorrhoidectomy|Ferguson hemorrhoidectomy
215076542|NCT03575065|DRUG|BGB-290|Administered orally
215076543|NCT00206050|DRUG|Esomeprazole|
215076544|NCT00206050|DRUG|pantoprazole|
215076545|NCT04697537|DRUG|Ultrasound guided regional anesthesia|Applied perineurally preoperatively ultrasound guided regional anesthesia
215076546|NCT04697537|DRUG|Local infiltration analgesia|Applied in the wound intraoperatively from the orthopedics
215076547|NCT01405352|DIETARY_SUPPLEMENT|Vitamin A|"25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month"
215076548|NCT01775579|DRUG|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
214951972|NCT02742675|DRUG|leuprolide acetate|Given subcutaneously or as an injection
214951973|NCT02742675|DRUG|triptorelin|Given subcutaneously or as an injection
214951974|NCT02742675|PROCEDURE|Definitive Treatment|surgery to remove prostate or radiation therapy to the prostate.
214951975|NCT04169997|DRUG|IMP4927|IMP4297 tablet.The starting dose from 100mg QD
214344349|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~* The number of trocars is 6 or less~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Combined organ resection only in cholecystectomy and splenectomy~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
214344350|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
214344351|NCT01985594|DRUG|utrogestan|Oral Tablet Utrogestan 400 mg daily for 2 days
214344352|NCT01985594|DRUG|Nifedipine|Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
214344353|NCT04950699|GENETIC|Single-nucleotide Polymorphism of genes related with Dyslipidemia|This study is an observational study to study the effect of different genotypes on the incidence of myocardial infarction
214344354|NCT06636552|DRUG|Daratumumab (Subcutaneously)|"D-PAD (21-Day Cycles 1, 3 and 5):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycles 1 and 3) 1,800 mg (Q3W) SC on day 1 (for Cycle 5)~D-CVD (21-Day Cycles 2, 4, 6, 7 and 8):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycle 2) 1,800 mg (Q3W) SC on day 1 (for Cycles 4, 6, 7 and 8)~Daratumumab monotherapy (28-Day Cycles 9 to 32):~1,800 mg (Q4W) SC on day 1"
214344355|NCT03343262|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
214344356|NCT03343262|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
214344357|NCT02610062|DRUG|AGS67E|Intravenous (IV) infusion
214344358|NCT05787418|DRUG|HH-120 Nasal Spray|HH-120 nasal spray 8 times per day for 7 consecutive days
214344359|NCT05787418|DRUG|Placebo|Placebo 8 times per day for 7 consecutive days
214344360|NCT06161363|OTHER|The Morisky Medication Adherence Scale|The Morisky Medication Adherence Scale will be completed bu the patients
214344361|NCT05659602|BIOLOGICAL|HH-120 Nasal Spray|HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
214344362|NCT03447769|DRUG|Canakinumab|200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
214344363|NCT03447769|DRUG|Placebo|Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
214344364|NCT01123759|OTHER|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
214344365|NCT03518177|OTHER|Hospital-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, treadmill walking, cycle ergometer, arm ergometer training and strengthening trainning with free weights at hospital.
214344366|NCT03518177|OTHER|Home-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, free-walking, and strengthening training with free weights at home
214344367|NCT05462626|BEHAVIORAL|Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program|The intervention is comprised of the following sessions and themes; Session 1: Informed Consent and Pre-Testing; Session 2: Occupation and Healthy Aging; Session 3: Longevity and Thriving; Session 4: Movement Matters; Session 5: Thoughtful Eating; Session 6: Stress and Sleep; Session 7: Navigating Health Care; Session 8: Post-Testing and Discharge.
214344368|NCT04429490|OTHER|Adipose tissue sampling during surgery and urine sampling|Adipose tissue sampling during surgery and urine sampling
214951976|NCT04169997|DRUG|Placebos|Placebos tablet.The starting dose from 100mg QD
214951977|NCT03848624|DEVICE|Cycling Group|Electrical pulses from a stimulator can stimulate the target muscles to generate muscle contraction to support a continuous cycling motion
214951978|NCT01124799|DRUG|TMC435|one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
214951979|NCT01124799|DRUG|Placebo|placebo dose in the morning, at noon and in the evening, for 9 days
214951980|NCT01124799|DRUG|Ciprofloxacin|one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
214951981|NCT04897035|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
214344369|NCT03913273|PROCEDURE|AMI transtibial amputation|Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.
214344370|NCT03913273|PROCEDURE|Standard transtibial amputation|A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
214344371|NCT01343407|DRUG|MK-1029 10 mg|Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
214344372|NCT01343407|DRUG|MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
214344373|NCT01343407|DRUG|Placebo for MK-1029 10 mg|"Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design."
214344374|NCT01343407|DRUG|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
214344375|NCT03950739|DRUG|Treprostinil Inhalation Powder|Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
214344376|NCT04639414|DRUG|Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
214344377|NCT04639414|DRUG|Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide|Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
214344378|NCT04639414|DRUG|Placebo matching empagliflozin and placebo pen injector matching semaglutide|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
214344379|NCT02758431|DRUG|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
214951982|NCT05987059|BEHAVIORAL|SBIRT Intervention|"Project IMPACT intervention will follow a Screening, Brief Intervention, and Referral to Treatment (SBIRT) Model. In the proposed study, staff at community sites will deliver a tailored SBIRT model for people seeking to get pregnant as our Project IMPACT intervention. SBIRT was originally developed as a public health model designed to provide universal screening, secondary prevention (detecting risky or hazardous substance use before the onset of abuse or dependence), early intervention, and treatment for people who have problematic or hazardous alcohol problems within primary care and other health care settings. Morehouse School of Medicine (MSM) has adapted this SBIRT model for people who are seeking to get pregnant to assess their risks and provide early intervention to at-risk people of reproductive age who want to get pregnant. Brief preconception counseling interventions addressing multiple behavioral risk factors have been found to be effective in prior studies."
214951983|NCT03728998|OTHER|Passive leg raise (PLR)|"A PLR will simulate an autotransfusion of 250-300 cc.~* 1\. Starting in semi-succumbed position (45 degree head-up)~* 2\. PLR is performed by lowering head-end and putting a for this purpose designed device of 45 degrees under the patients legs. The PLR is non-invasive."
214951984|NCT03728998|OTHER|Clearsight non-invasive hemodynamic monitoring system|3 baseline readings will be done for CO, CI, SV and SVR, separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CO, CI, SV and SVR will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CO, CI, SV and SVR is done. Then all patients will receive a fluid challenge of 500cc natriumchloride 0.9% IV, considered as normal treatment/ common practice in our ED. 120 seconds after finishing the fluid challenge the final reading of CO, CI, SV and SVR is done.
215076549|NCT00762138|DEVICE|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
215076550|NCT02178254|DRUG|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
214344380|NCT02758431|DRUG|Placebo Gel|Placebo gel packet applied daily for 28 days.
214344381|NCT02758431|DRUG|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
214344382|NCT02758431|DRUG|Testosterone Gel|Testosterone Gel applied daily for 28 days
214344383|NCT02758431|DRUG|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
214344384|NCT03526900|DRUG|Atezolizumab|"* Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."
214344385|NCT05685485|PROCEDURE|Standard Implantation|Traditional Ahmed plantation without vicryl ligature
214344386|NCT05685485|PROCEDURE|Tied off Tube|Ahmed implantation with vicryl ligature
214344387|NCT06962241|OTHER|Warming group|When the pregnant women in the experimental group were laid on the operating table, they were heated from the back with a heating pad. The heating pad remained on the pregnant woman's back throughout the cesarean section. The cesarean section took an average of 35 minutes from the first surgical incision to the completion of the incision after spinal/epidural anesthesia.
214344388|NCT06961487|PROCEDURE|EndovascularThrombectomy|Endovascular thrombectomy is a minimally invasive procedure that uses catheters and devices to remove blood clots, restoring blood flow to the brain. The procedure involves inserting a catheter (a long, thin tube) into an artery, usually in the groin, and guiding it through the blood vessels to the site of the blocked artery/blood clot in the brain. After the catheter reaches the affected area, a specialized device is guided through the catheter to capture and remove the clot.
214344389|NCT06961487|DEVICE|Endovascular thrombectomy with any FDA-approved device|"The following FDA approved thrombectomy devices will be included:~Stryker Neurovascular Products:~* AXS Vecta 74 Aspiration System~* AXS Vecta Aspiration System (AXS Vecta 71 Aspiration Catheter and AXS Vecta 74 Aspiration Catheter)~* AXS Vecta Intermediate Catheters (AXS Vecta 71 Intermediate Catheter \& AXS Vecta 74 Intermediate Catheter)~* Trevo XP ProVue Retriever, 3x20 and 4x20~* Trevo XP ProVue Retriever, 4x30~* Trevo XP ProVue Retriever, 6x25~Medtronic Products:~Solitaire X Revascularization Devices:~* Solitaire X 4x20, 4x40, 6x40~* Solitaire X 3x20, 3x40~Aspiration catheters:~* React 68~* React 71~* REACT-71-115 \& REACT-71-125~MicroVention Inc. Products:~* SOFIA, Aspiration pump and tubing kit~  * SOFIA Plus Aspiration catheter~* BOBBY balloon guide catheter~* ERIC retrieval device"
214344390|NCT06962059|OTHER|Self-Administered Sample Collection|Participants will collect vaginal swabs and a stool sample.
214344391|NCT06634914|DIETARY_SUPPLEMENT|Moonbrew|A blend of adaptogens with Chamomile, Rose, and Magnesium in a powdered form, designed to be mixed in liquid and consumed 2-3 hours before bed.
214344392|NCT06635018|OTHER|Resting conditions|The volunteer's hands are at rest and PI readings are taken for six minutes. After two minutes, there is always a randomized rotation of the sensors between the fingers.
214344393|NCT06635018|OTHER|Movement artifacts|The volunteer periodically spreads his/her fingers and clenches them into a fist, and PI readings are taken for six minutes. After two minutes there is always a randomized rotation of sensors between the fingers.
214344394|NCT06635018|OTHER|Circulation constriction|The volunteer's arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize, the sensors are randomly rotated, and the measurement is repeated.
214344395|NCT06635005|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214344396|NCT06635005|OTHER|Dietary Intervention|Receive the Low-EDIH dietary pattern intervention
214344397|NCT06635005|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
214344398|NCT06635005|BEHAVIORAL|Motivational Interviewing|Undergo motivational interviews
214486608|NCT06441487|BEHAVIORAL|Usual care|The study team will send subjects a prompt to visit the mobile health decision support tool (mPATH™-Cloud). Subjects with a mobile phone (as determined by their electronic health record) will receive a link to mPATH-Cloud by text. Subjects with a mailing address, but no mobile phone number in the EHR, will receive a letter inviting them to access mPATH-Cloud via URL code. Within mPATH-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who do not click on the link or select a screening test receive a FIT.
214951985|NCT04104594|DIAGNOSTIC_TEST|Sniffin Stick Test|"The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic."
214344399|NCT06635005|OTHER|Nutritional Assessment|Participate in nutrition counseling
214344400|NCT06635005|OTHER|Questionnaire Administration|Ancillary studies
214486609|NCT00495677|DRUG|PF-00232798|Solution, 20 mg. once daily, 10 days
214486610|NCT00495677|DRUG|PF-00232798|Solution, 150 mg. once daily, 10 days
214951986|NCT04104594|OTHER|numerical evaluation scale for olfaction|numerical rating scale from 0 (no smell) to 10 (perfect smell)
215076551|NCT02178254|DRUG|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
215076552|NCT00950391|DRUG|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
215076553|NCT02312999|DRUG|Plasmalyte|
215076554|NCT02312999|DRUG|Volulyte|
215076555|NCT01377155|DRUG|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
215076556|NCT04345861|DRUG|Hydroxychloroquine + placebo|hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
215076557|NCT04345861|DRUG|hydroxychloroquine + azithromycin|Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
215076558|NCT04050696|DEVICE|BQ 1.2|BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
215076559|NCT03960580|DRUG|OPN-375|OPN-375, BID
215076560|NCT01331343|DEVICE|Guardian RT Telemetered Glucose Monitoring System|
214344401|NCT06635369|DIAGNOSTIC_TEST|Periodontal Indices|Saliva, serum and periodontal indexes were obtained from patients
214344402|NCT06635798|BIOLOGICAL|GR2001|The packaging for GR2001 injection uses a borosilicate glass vial, a brominated halobutyl rubber stopper for injectable solutions and an aluminum-plastic combination cap for antibiotic vials as its primary packaging materials. The specification is 5mg/1ml per vial.
214344403|NCT06635798|BIOLOGICAL|HTIG|The HTIG is a Chinese licensed Human Tetanus Immunoglobulin produced by Tonglu-Bio, which are derived from human plasma, and then purified and filled in the injectable vial form.
214344404|NCT06635083|OTHER|Telerehabilitation|A video conference software system will be installed on the subjects' laptops or tablets. Then, via video conference, strengthening/stretching exercises and breathing exercises will be performed for the areas affected by the deformity with the physiotherapist three times a week.
214344405|NCT04848025|DEVICE|Custom-designed tracheobronchial prostheses|Computer-assisted segmentation of airways and stent from CT data (AnatomikModeling) Fabrication of a mold and then a silicon stent by mold injection and sterilization (NOVATECH) Insertion of the stent under rigid bronchoscopy and general anesthesia
214344406|NCT05085600|OTHER|Exercise|"Patients will begin performing the cervical stabilization exercise, and will taught to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine.~In addition, progress will continued in the exercise of the contraction of deep neck flexor muscles in other positions.~The progression of the exercises will be adapted to each patient, depending on their evolution. Firstly, exercises will undertaken in the supine and standing positions; once these positions will mastered, the exercises progressed to asymmetric positions with cervical bending and/or rotation toward each patient's most symptomatic side."
214344407|NCT05085600|OTHER|Manual Therapy + Exercise|20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
214344408|NCT01023100|DRUG|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
214344409|NCT00061490|BEHAVIORAL|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
214344410|NCT02504866|OTHER|Vigorous exercise|Exercise training of vigorous intensity
214344411|NCT02504866|OTHER|Light to moderate exercise|Exercise training of light to moderate intensity
214344412|NCT04368923|DEVICE|Oxygen Therapy|Patients receive oxygen therapy
214344413|NCT04368923|PROCEDURE|Physical Therapy|Patients receive physical therapy
214344414|NCT00293540|PROCEDURE|oophorectomy|Excision of an ovary
214344415|NCT00293540|DRUG|Tamoxifen|20 mg orally every day
214344416|NCT00397423|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd\*5 days,3 months interval for 4 times
214344417|NCT00397423|DRUG|NS|NS 1ml iH Qd\*5 days, 3 months interval for 4 times
214951987|NCT04104594|OTHER|numerical evaluation scale for nasal obstruction|numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
214951988|NCT04104594|OTHER|nasal outcome test|"list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days"
214951989|NCT04104594|BIOLOGICAL|dosage of 17 cytokines|dosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α
214951990|NCT04701489|DEVICE|Splenic ultrasound|GE LOGIQ E10 device with C1-6 ultrasound probe
214951991|NCT04153968|DIETARY_SUPPLEMENT|β-cryptoxanthin|"Phase 1:~2.0mg of \[13C14\]β-cryptoxanthin, 1.0mg of \[13C10\]β-carotene and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil at Time 0.~Phase 2:~1.5mg of \[13C14\]β-cryptoxanthin, 0.75mg of \[13C10\]β-carotene, 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.25mg β-carotene and 0.5mg β-cryptoxanthin from maize are given at Time 0.~Then, 0.75mg of \[13C14\]β-cryptoxanthin, 1.5mg of \[13C10\]β-carotene, and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.5mg β-carotene and 0.25mg β-cryptoxanthin from maize are given on day 21."
214951992|NCT05741814|DRUG|Propofol|Gynecologist guided individualised propofol only sedation
214951993|NCT05409508|OTHER|mindfulness meditation care|mindfulness meditation care
214951994|NCT05409508|OTHER|no mindfulness meditation care|no mindfulness meditation care
214951995|NCT01118572|DRUG|YM177|oral
214951996|NCT01118572|DRUG|etodolac|oral
214951997|NCT01118572|DRUG|Placebo|oral
214951998|NCT03850405|DIETARY_SUPPLEMENT|Dark Chocolate|20 patients (10 male, 10 female) will undergo a diet containing 25g of dark chocolate (70%), corresponding to ca. 145 kcal which will be detracted from the total caloric intake.
214951999|NCT01081405|OTHER|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
214344418|NCT03526913|PROCEDURE|PRP|PRP: autologous platelet-rich plasma
214344419|NCT03526913|PROCEDURE|STSG|skin graft: Split Thickness Skin Grafting (STSG)
214344420|NCT04802733|BIOLOGICAL|MSK-DA01|MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.
214344421|NCT04802733|DEVICE|MSK-DA01 Cell Delivery Device|A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.
214486611|NCT00495677|DRUG|PF-00232798|Solution, 5 mg. once daily, 10 days
214952000|NCT03470623|DEVICE|bioabsorbable screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the bioabsorbable screw
214344422|NCT01343056|BEHAVIORAL|Office Staff Support|The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
214344423|NCT01343056|BEHAVIORAL|Peer Support|Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
214952001|NCT03470623|DEVICE|steel screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the steel screw
214952002|NCT03867968|BEHAVIORAL|TIPS Intervention|Web-based training for family member.
214952003|NCT03867968|BEHAVIORAL|Control|Traumatic Brain Injury website for family members.
214952004|NCT05553535|DIAGNOSTIC_TEST|MRI|retrospective review of shoulder MRI
214486612|NCT00495677|DRUG|PF-00232798|Solution, 40 mg. once daily, 10 days
214952005|NCT04438798|OTHER|F Group|In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
214952006|NCT04438798|OTHER|H Group|In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
214486613|NCT00495677|DRUG|PF-00232798|Solution, 300 mg. once daily, 10 days
214952007|NCT02994641|PROCEDURE|COMA Score Assessment|
214952008|NCT04505306|PROCEDURE|Macular Laser|All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.
214952009|NCT06498726|DEVICE|transcranial doppler|Demographic and procedural variables will be extracted from medical record assistants , and analysis of recorded images TCD, MRA ,interpretation reports will be assessed , Completeness of protocol components will be assessed Data accuracy and protocol fidelity will be ensured through site monitoring
214952010|NCT01016574|DEVICE|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
214952011|NCT03299725|DRUG|colloidal bismuth sub-citrate|colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
214952012|NCT01343966|DRUG|MABT5102A|Repeating subcutaneous injection
214952013|NCT01343966|DRUG|MABT5102A|Repeating intravenous infusion
214952014|NCT01343966|DRUG|placebo|Repeating subcutaneous injection
214952015|NCT01343966|DRUG|placebo|Repeating intravenous infusion
214486614|NCT00495677|DRUG|PF-00232798|Solution, 400 mg. once daily, 10 days
214952016|NCT00703118|DRUG|Telaprevir|Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
214952017|NCT00703118|DRUG|Peg-IFN-alfa-2a|Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
214952018|NCT00703118|DRUG|Ribavirin|Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
215076561|NCT01528891|DRUG|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
215076562|NCT01528891|OTHER|Placebo|
215076563|NCT00914446|PROCEDURE|hepatic biopsies|hepatic biopsies
215076564|NCT02249299|DRUG|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
215076565|NCT02249299|DRUG|Placebo|
214344424|NCT01343056|BEHAVIORAL|Usual Care Support|Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
214344425|NCT01343056|BEHAVIORAL|Educator Support|Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
214486615|NCT04319549|OTHER|Ketorolac Tromethamine irrigant|Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.
214952019|NCT00703118|DRUG|Placebo|Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
214952020|NCT00591019|DRUG|Modafinil|200 mg/day, morning dose
214952021|NCT00591019|OTHER|Placebo|Sugar pill once per day in the morning.
214952022|NCT00441948|DEVICE|Peterio|
214952023|NCT04290325|DRUG|HMPL-453|HMPL-453 tablet
214952024|NCT02400203|OTHER|Control|
214952025|NCT02400203|OTHER|Hemp foods|
215076566|NCT05113121|DIAGNOSTIC_TEST|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)
215076567|NCT02408003|DRUG|Levosimendan|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
215076568|NCT02408003|DRUG|Milrinone|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
215076569|NCT05433051|BIOLOGICAL|buccal miniscrew and TPA|intrusion of molars
215076570|NCT05433051|BIOLOGICAL|vertical holding appliance|intrusion of molars
215076571|NCT02399540|DEVICE|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
215076572|NCT02399540|DEVICE|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
214952026|NCT06201208|BEHAVIORAL|The ST-Facilitation Psychoeducation Program|"One of the important roles of the psychiatric nurse, who helps healthy/sick individuals and their families to improve their mental health, prevent and cope with diseases, is their educational role. The psychiatric nurse determines the psychosocial care needs of the patient and his family and plans, implements and evaluates psychoeducational interventions, which are an evidence-based practice, to meet these needs.~Psychiatric nurses can benefit from existing programs when developing a psychoeducation program, or they can be advised to create programs that include educational and psychosocial goals based on theory specific to the problems of the relevant population. The theoretical basis is of great importance when planning a psychoeducation program. In this study, the psychoeducation program was based on the Self-Transcendence Theory of Pamela G. Reed, a psychiatric nurse."
214952027|NCT02593955|BEHAVIORAL|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
214952028|NCT02593955|BEHAVIORAL|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
214952029|NCT06142734|PROCEDURE|pyeloplasty|"* For laparoscopic pyeloplasty:~* Anaesthesia: general~* Position: a 45-degree lateral decubitus position with the concerned side up. Patient is secured to the operating table. Pneumoperitoneum is adopted through a camera port lateral to the umbilicus~* extra operating ports are created at subcostal and at spinoumbilial line.~* the UPJ is transperitoneally accessed by incising the white line of Toldt and the ipsilateral colon is reflected and the proximal ureter and the pelvis are identified an mobilized~* then Anderson- Hynes pyeloplasty is carried out with insertion of nephroureterostomy or pyeloureterostomy tube."
214952030|NCT01454219|OTHER|Bakery and confectionary products|Control product: Glucose solution, Test products: 11 bakery and confectionary products
214952031|NCT03922841|OTHER|Pleural disease management|History, physical examination, pleural drainage, lab/radiographic investigations
214952032|NCT03301935|PROCEDURE|Electrophysiology testing and exercise stress testing|Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice.
214952033|NCT00005896|DRUG|filgrastim|
215076573|NCT02399540|DEVICE|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
215076574|NCT02399540|DEVICE|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
215076575|NCT06411886|DIAGNOSTIC_TEST|Allergen challenge|Inhaled allergen
215076576|NCT06411886|DIAGNOSTIC_TEST|Saline challenge|Inhaled saline
214952034|NCT00005896|GENETIC|Autologous stem cells transduced with FACC retroviral vector|
214952035|NCT00005896|PROCEDURE|Autologous Stem Cell Transplantation|
214952036|NCT02963519|DEVICE|VistaCare®|
214952037|NCT02963519|DEVICE|Dressings|
214952038|NCT04708496|DRUG|Artemether-lumefantrine|"A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria."
215076577|NCT00096525|DRUG|lenalidomide|
215076578|NCT00189332|DRUG|852A|
215076579|NCT04088240|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
215076580|NCT04088240|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
215076581|NCT04088240|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
215076582|NCT05894720|OTHER|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs."
215076583|NCT04155086|BIOLOGICAL|the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis|The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
215076584|NCT06307522|DRUG|MRG-001|Patients will receive subcutaneous administration of MRG-001 at designated visits.
215076585|NCT02916641|DRUG|Fuzhenghuayu|
215076586|NCT02916641|DRUG|UDCA|
215076587|NCT05577312|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
215076588|NCT00453700|PROCEDURE|Trypanosoma cruzi serology|
214952039|NCT03102008|BEHAVIORAL|Unified Protocol for Emotional Disorders in Adolescents (UP-A)|The Unified Protocol for Emotional Disorders in Adolescents (UP-A), is a transdiagnostic therapeutic intervention employing core dysfunction approaches, defined as such due to their attendance to features of various (emotional) disorders. The treatment may work to ameliorate symptoms more broadly by targeting cross-cutting features common to the range of disorders targeted. Specifically, the UP-A might lead to the successful treatment of an array of emotional disorders in youth by targeting processes common across these frequently co-occurring problems including poor distress tolerance, limited cognitive flexibility, and heightened avoidance.
214344426|NCT01747980|DRUG|PRX-112|Single dose level, four doses per cohort
214344427|NCT01285375|DEVICE|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
214952040|NCT05975918|BEHAVIORAL|Motivational İnterview|Participants in the experimental group will be informed about the study through pre-interviews and data (Caregiver Descriptive Characteristics Form, Patient Descriptive Characteristics Form, Depression Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale) will be collected through pre-tests. A motivational interview intervention consisting of a total of 6 interviews will be conducted.
214952041|NCT05975918|OTHER|Psychoeducation|2 hours of training on coping with stress and problem solving skills will be provided.
214952042|NCT04448639|DIAGNOSTIC_TEST|Echocardigraphy (ECHO)|Standar 12 lead electrocardiogram
214952043|NCT04448639|DIAGNOSTIC_TEST|Bloodtest|cardiac biomarkers
214952044|NCT05881122|BEHAVIORAL|Mad Dog Dietary Consultation|The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
214952045|NCT03409484|OTHER|Concord Grape Juice|Concord Grape Juice
214952046|NCT03409484|OTHER|Low flavoniod low essence beverage|Low flavoniod low essence beverage
214344428|NCT01285375|DEVICE|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
214952047|NCT03409484|OTHER|Low flavonoid beverage|Low flavonoid beverage
214952048|NCT03132974|DRUG|Sogyeonghwalhyeol-tang granule|Sogyeonghwalhyeol-tang herbal extract granule
214952049|NCT03132974|OTHER|Sogyeonghwalhyeol-tang granule with manipulation procedure|Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
214952050|NCT03132974|OTHER|Placebo with manipulation procedure|Placebo granule with manipulation procedure
214952051|NCT00670657|DRUG|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
215076589|NCT02010333|DRUG|Ha44 Gel 0.74% w/w|HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
215076590|NCT02359045|DRUG|D1400147|Treatment A
215076591|NCT02359045|DRUG|D14000136|Treatment B
214344429|NCT02923037|PROCEDURE|Yoga|Complete guided and home yoga sessions
214344430|NCT02923037|OTHER|tape measurement of arm|Ancillary studies
214344431|NCT02923037|OTHER|Quality-of-Life Assessment|Ancillary studies
214344432|NCT02923037|OTHER|ldex measurement of arms|
214952052|NCT01522131|PROCEDURE|bioresorbable membrane alonewill be used for regeneration of the periodontium(control)|bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
214952053|NCT01111682|DRUG|Mannitol|0.9% normal saline infusion and boluses of mannitol
214952054|NCT01111682|DRUG|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
214952055|NCT03339557|DEVICE|NexGen|Comparing two conventional designs and one novel design
214952056|NCT03339557|DEVICE|Persona|Comparing two conventional designs and one novel design
215076592|NCT02359045|DRUG|D14000137|Treatment C
215076593|NCT02359045|DRUG|Epanova®|Treatment D
215076594|NCT02731677|OTHER|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
215076595|NCT06542601|DEVICE|Motor cognitive intervention|Older adults were given cognitive training and motor training for 12 weeks using a tablet computer
214344433|NCT03293940|PROCEDURE|Cryoablation|The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.
214344434|NCT03293940|PROCEDURE|Therapeutic Peripheral Nerve Block (tPNB) Injection|"During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.~The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone."
214952057|NCT03339557|DEVICE|PFC|Comparing two conventional designs and one novel design
214344435|NCT03400397|OTHER|Cool Kids programme|A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
214344436|NCT03892941|DEVICE|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
214344437|NCT00777517|DRUG|Lipitor|A single dose of 10 mg Lipitor tablet
214952058|NCT01684124|OTHER|conservative O2 therapy|target lower O2 saturation
214952059|NCT01684124|OTHER|standard care|
214344438|NCT00777517|DRUG|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
214344439|NCT03231371|DRUG|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
214952060|NCT05357885|DIAGNOSTIC_TEST|SARS-CoV-2 Antibody test|SARS-CoV-2 antibody test at Jefferson is Roche Elecsys Anti-SARS-CoV-2 immunoassays performed under FDA's Emergency Use Authorization.
214952061|NCT03514056|DIAGNOSTIC_TEST|group 1:Patients diagnosed with Behcet disease|Frequency and severity of fibromyalgia will be investigated in patient diagnosed with Behcet disease
214952062|NCT03514056|DIAGNOSTIC_TEST|group 2: Patient diagnosed with fibromyalgia without Behcet disease|Severity of fibromyalgia will be investigated in patient diagnosed with fibromyalgia
215076596|NCT04889768|DRUG|HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"1. HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~2. Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~3. Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~4. After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
215076597|NCT00944736|DIETARY_SUPPLEMENT|VSL#3|1 packet BID
215076598|NCT00944736|DIETARY_SUPPLEMENT|Placebo|1 inactive packet BID
215076599|NCT05984407|PROCEDURE|cytokine hemadsorption therapy|Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
215076600|NCT06121609|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy
215076601|NCT02327390|PROCEDURE|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
215076602|NCT02327390|BIOLOGICAL|X-ACT|Administered as an IV infusion
215076603|NCT01745744|OTHER|Mesenchymal stem cells from adipose tissue|\- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
215076604|NCT01372072|DEVICE|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
215076605|NCT01714206|DRUG|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
214344440|NCT02717091|DRUG|FOLFIRINOX|
214344441|NCT02717091|DRUG|gemcitabine + nab-paclitaxel|
214344442|NCT06060405|DRUG|Durvalumab|Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.
214344443|NCT06060405|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.
214344444|NCT02201602|DRUG|Gliclazide|
214344445|NCT02201602|DRUG|Glibenclamide|
214344446|NCT04842955|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
214344447|NCT04842955|DEVICE|Sham tACS over the superior parietal cortex|Single session of sham tACS over the superior parietal cortex
214344448|NCT02938416|DEVICE|Isokinetic strengthening exercise|Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.
214344449|NCT02938416|DEVICE|Isotonic strengthening exercise|Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.
214344450|NCT02938416|BEHAVIORAL|isometric strengthening exercise|home exercise education on isometric quadriceps strengthening on the day of out-patient appointment
214344451|NCT02745626|DEVICE|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
214344452|NCT03916003|DRUG|primaquine|Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
215076606|NCT01714206|DRUG|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
215076607|NCT01714206|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
215076608|NCT01391572|RADIATION|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
214344453|NCT02970344|BEHAVIORAL|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
214344454|NCT03149640|DRUG|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
214344455|NCT03149640|DRUG|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
214344456|NCT03697785|DEVICE|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
214344457|NCT01298297|DRUG|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
214344458|NCT01298297|DRUG|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
214952063|NCT06217445|DEVICE|high intensity focused ultrasound|High-intensity focused ultrasound (HIFU) therapy is becoming more familiar in medical field because it is non-invasive technique with fewer side effects and provides promising therapeutic results. Several HIFU therapy applications have approved by many approval authorities of deferent countries since last decade
214952064|NCT06217445|OTHER|Doubled chin exercises|1\. Straight jaw jut. 2-ball exercise. 3-Pucker up 4. Tongue stretch 5. Neck stretch 6-bottom jaw jut.
214952065|NCT01204918|DRUG|Riluzole|Riluzole 100mg PO
214952066|NCT01204918|DRUG|placebo|placebo
214952067|NCT03714776|DRUG|Placebo|Placebo matching solution administered as SC injection.
214952068|NCT03714776|DRUG|ISIS 757456|Administered as SC injection.
214952069|NCT01269099|DRUG|IV-PCA|IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
214952070|NCT01269099|DRUG|Control|control group (No-PCA group)
214952071|NCT01122069|OTHER|Perflutren Lipid Microsphere ultrasound contrast|Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus
214952072|NCT01245816|DRUG|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
214952073|NCT01245816|DRUG|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
214952074|NCT01245816|DRUG|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
214952075|NCT05804227|DRUG|Ulixertinib|Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
214952076|NCT01859962|DRUG|PPI-668|
214952077|NCT01859962|DRUG|BI 207127 Dose 1|
214952078|NCT01859962|DRUG|BI 207127 Dose 2|
214952079|NCT01859962|DRUG|Faldaprevir|
214952080|NCT01859962|DRUG|Ribavirin|
214952081|NCT01859962|DRUG|BI 207127 Placebo|
214952082|NCT01420042|DRUG|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
214952083|NCT01420042|DRUG|Placebo|Lemon flavoured cordial and Water for Injection
214952084|NCT02109016|DRUG|Lucitanib|"Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability."
214952085|NCT01853696|DRUG|loteprednol etabonate|
214952086|NCT01853696|DRUG|prednisolone acetate 1%|
214952087|NCT00913224|DRUG|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)|
214952088|NCT00913224|DRUG|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)|
214952089|NCT02671734|BEHAVIORAL|video|Short (2 minute 43 second), animated videos were designed addressing nature of the procedure, risks, benefits, and alternatives for upper and lower endoscopy respectively using PowToon (www.powtoon.com). Sixth grade language was used throughout the video. Videos were shown to youth and their parents on an iPad.
214952090|NCT04645134|BEHAVIORAL|Brain Health Assessments|The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.
215076609|NCT01391572|RADIATION|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
214952091|NCT05442541|BEHAVIORAL|not included any interventions(Evaluation of menstrual well-being in women of reproductive age, field survey study)|This is a prospective cross-sectional analytical study conducted through a questionnaire.
214952092|NCT01238094|DRUG|Simvastatin|simvastatin 40 mg qd daily until disease progression
214952093|NCT02798120|DRUG|SB204 4%|Open label, topical SB204 4%
214952094|NCT06572943|OTHER|Moderate intensity physical activity|Moderate intensity exercise of 30 minutes for at least 4-5 times per week (if not daily).
214952095|NCT04365075|DEVICE|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
214952096|NCT04365075|DEVICE|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
214952097|NCT05672589|DIAGNOSTIC_TEST|Relaxed Rotational Thromboelastometry|Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
214952098|NCT05672589|DIAGNOSTIC_TEST|Standard Coagulation Tests|Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
215076610|NCT01391572|DRUG|cisplatin|
215076611|NCT01391572|DRUG|fluorouracil|
215076612|NCT03142724|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
215076613|NCT00416156|BEHAVIORAL|Lifestyle modification|
215076614|NCT01063491|PROCEDURE|bypass graft angiography|
214344459|NCT04008134|BEHAVIORAL|CHoBI7 health facility program|The CHoBI7 health facility program focuses on promoting handwashing with soap and water treatment to diarrhea patients and their household members during the one-week period after the patient is admitted to the health facility, when their household is at highest risk for diarrheal diseases. The CHoBI7 program includes: (1) a WASH pictorial module delivered by a health worker bedside to diarrhea patient and their household members in a health facility on handwashing with soap, water treatment, and safe water storage; and (2) a diarrhea prevention package containing chlorine tablets for water treatment, a soapy water bottle (water and detergent powder), a handwashing station, and a water vessel with a lid and tap for safe drinking water storage. Households are instructed to boil their water once their supply of chlorine tablets is completed.
214486616|NCT04319549|OTHER|sodium hypochlorite irrigant|NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
214952099|NCT01981148|DEVICE|Fluorescence lifetime ophthalmoscope|All patients and healthy subjects will be imaged with the fluorescence lifetime ophthalmoscope
214952100|NCT00431067|DRUG|BIBW 2992|
214952101|NCT03761225|DRUG|Masitinib|
214952102|NCT03761225|DRUG|Docetaxel|
214952103|NCT03761225|DRUG|Prednisone|
214952104|NCT03761225|DRUG|Placebo|
214952105|NCT03062995|OTHER|Infant Formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
214952106|NCT03062995|OTHER|Standard Infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
214952107|NCT00849290|BIOLOGICAL|APC8015F|APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
214952108|NCT00548249|DEVICE|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
214952109|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
214952110|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
214952111|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
214952112|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
214952113|NCT00938587|DRUG|PF-04171327 10 mg|PF-04171327 10 mg tablet every day for 14 days
215076615|NCT05655507|DRUG|Zuranolone|Administered as capsules
215076616|NCT02922764|DRUG|RGX-104|
215076617|NCT02922764|DRUG|Ipilimumab|
215076618|NCT02922764|DRUG|Docetaxel|
215076619|NCT02922764|DRUG|Pembrolizumab|
215076620|NCT02922764|DRUG|Carboplatin|
215076621|NCT02922764|DRUG|Pemetrexed|
215076622|NCT02668900|BEHAVIORAL|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
215076623|NCT02239835|DRUG|Tipranavir (TPV) low dose|
214952114|NCT00938587|OTHER|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
214952115|NCT00938587|DRUG|PF-04171327 25 mg|PF-04171327 25 mg tablet every day for 14 days
214952116|NCT00938587|OTHER|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
214952117|NCT00938587|DRUG|Prednisone 5 mg|Prednisone 5 mg tablet every day for 14 days
214952118|NCT00938587|OTHER|Placebo for PF-04171327|Placebo for PF-04171327 every day for 14 days
214952119|NCT00938587|OTHER|Placebo|Placebo tablet every day for 14 days
214952120|NCT00938587|OTHER|Placebo for PF-04171327|Placebo tablet every day for 14 days
214952121|NCT03437161|RADIATION|Radiation Therapy (RT)|Undergo RT either in the supine position with DIBH or in the prone position.
214952122|NCT01715142|DRUG|Gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
214952123|NCT01715142|DRUG|Abraxane|Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
214952124|NCT01687387|DRUG|IPH2102 at 0.1 mg/kg|every 3 months
215076624|NCT02239835|DRUG|Tipranavir (TPV) high dose|
215076625|NCT02239835|DRUG|Ritonavir low dose|
215076626|NCT02239835|DRUG|Ritonavir high dose|
215076627|NCT02239835|DRUG|Saquinavir|
214344460|NCT04008134|BEHAVIORAL|CHoBI7 mHealth program|The CHoBI7 mHealth (mobile health) program targets five key behaviors: (1) preparing soapy water using water and detergent powder; (2) handwashing with soap at food and stool related events; (3) treating household drinking water using chlorine tablets during the one week high risk period after the diarrhea patient in the household was admitted to the health facility; (4) safe drinking water storage in a water vessel with a lid and tap; and (5) heating of household drinking water until it reaches a rolling boil after the one week high risk period. Participant households receive bi-weekly voice and text messages from the CHoBI7 mHealth program over a 12-month period. These mobile messages are sent using the VIAMO platform (www.viamo.io).
214952125|NCT01687387|DRUG|IPH2102 at 1 mg/kg|every 4 weeks
214952126|NCT01687387|DRUG|Placebo (normal saline solution)|every 4 weeks
214952127|NCT00490672|BEHAVIORAL|No Active Intervention.|Conventional Chronic Disease Management in Malaysia Primary Care
214952128|NCT00490672|BEHAVIORAL|Community Based Multiple Risk Factor Intervention Strategies|Multi-faceted Intervention in Chronic Diseases Management i.e. Hypertension, Diabetes Mellitus, Hyperlipidaemia involving Primary Health Care Physicians, Nurse Educators, Dieticians and Pharmacists.
214952129|NCT04344522|PROCEDURE|Descemet membrane endothelial keratoplasty DMEK|DMEK : it involves separating the Descemet membrane from a corneal donor graft , doing a descematorhexis in the recepient cornea , loading and injection of the graft into the anterior chamber , unfolding and fixing the graft to the recepient cornea by intracameral air bubble.
214952130|NCT04344522|PROCEDURE|IOL exchange|IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.
214952131|NCT04344522|PROCEDURE|iridoplasty|iridoplasty : repairing any iris defect by using 10/0 prolene.
214952132|NCT04344522|PROCEDURE|Inferior peripheral iridectomy|Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .
214952133|NCT03992898|OTHER|No special intervention was suitable for this observational study|Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.
214952134|NCT00466206|DEVICE|Magnetic Mini-Mover Procedure (3MP)|"A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.~A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.~In another outpatient procedure, the Magnimplant is explanted 18 months after implantation."
215076628|NCT06497062|DRUG|sonrotoclax|"Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase."
215076629|NCT06497062|DRUG|idarubicin/daunorubicin|idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years
215076630|NCT06497062|DRUG|Cytarabine|In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).
215076631|NCT06497062|DRUG|Azacitidine|75 mg/m\^2, subcutaneously, once daily, on D1-7
215076632|NCT06497062|PROCEDURE|allo-HSCT|Per standard of procedure
215076633|NCT00918320|DRUG|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
214344461|NCT04008134|BEHAVIORAL|CHoBI7 home visit program|The CHoBI7 home visit program involves two, 30-minute home visits conducted during the week after the index diarrhea patient was recruited at the health facility. A health worker reinforces the content of the CHoBI7 health facility program in the participant's home.
214344462|NCT05211219|DIETARY_SUPPLEMENT|Probiotics|According to the groups, they were involved simultaneously with the treatment, kefir group was advised to consume kefir as a liquid once a day in 14 days; the probiotics group was advised to consume as a chewable tablet once a day in 14 days; the control group was advised without additional food supplements.
214952135|NCT00466206|DEVICE|Magnatract (external magnet in a removable external brace)|"An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed."
214952136|NCT00466206|PROCEDURE|3MP (Magnetic Mini-Mover Procedure)|"* Subject has EKG performed to measure baseline cardiac activity.~* Magnimplant is implanted.~* After one week, Magnatract is fitted.~* Chest x-ray and 2nd EKG performed 30 days post-implantation.~* Patient and parents complete QoL questionnaire 30d post-implantation.~* Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.~* At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.~* At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.~* Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.~* CT scan and third EKG performed after explanation.~* Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation."
215076634|NCT00541866|DRUG|Voreloxin injection and cytarabine|"Dose-escalation Phase~* Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~* Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous \[IV\] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~* Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~* Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
214344463|NCT05211219|DIETARY_SUPPLEMENT|AOÇ Kefir|AOÇ Kefir
214344464|NCT05211219|OTHER|Food without additional food supplements|Food without additional food supplements
214344465|NCT03701659|PROCEDURE|Surgery combinate with Endocrine therapy|TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.
214344466|NCT03701659|DRUG|Endocrine therapy|MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
214344467|NCT01584063|BEHAVIORAL|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
214344468|NCT02083523|BEHAVIORAL|Motivational Interview with Normative Feedback|NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
214952137|NCT04712513|DIAGNOSTIC_TEST|Dynamic cardiac CT perfusion imaging|Multiple images of the heart are acquired with a clinical CT scanner after an intravenous bolus injection of contrast solution. The images are then analyzed to provide fractional flow reserve and myocardial perfusion values.
214344469|NCT02083523|BEHAVIORAL|Motivational Interview|The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
214678384|NCT06077058|OTHER|Chat-based instant messaging|Participants will receive individualized chat-based encouragement and support messages about motivation and preparation for quit attempts using WhatsApp for 8 weeks. A trained smoking cessation counsellor will have real-time (synchronous), one-to-one interaction with the participants and provide personalized motivational, behavioural support according to the participants' needs. The conversation intensity will be flexible and depends on the participant. The conversation will also be integrated with brief advice using the Behaviour Change Techniques (BCTs) (18) and the AWARD (Ask, Warn, Advise, Refer, Do-it-again) intervention model (11). The intervention protocol will be similar as that in our previous RCT on CBIM (19). For participants who receive the SEE and NRTS, the trained counsellor shall follow-up on their compliance and provide adequate advice in adhering to these interventions.
214678385|NCT06077058|OTHER|Chatbot for smoking cessation|The information and access to the chatbot will be introduced to participants. Through the chatbot service, participants shall access to practical information on smoking cessation 24 hours at any time, such as details on cessation services and skills for tackling cravings. By using the second-generation chatbot, participants could receive personalized risk information and recommendations for smoking cessation, as well as reach to a counsellor through WhatsApp live chat for urgently needed advice.
214678386|NCT00916604|DRUG|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
214678387|NCT00916604|DRUG|Placebo|Placebo oral suspension, 8 days treatment
214678388|NCT04845698|DEVICE|i-Dashboard|i-Dashboard is a team-designed, patient-centered electronic medical record viewer, which retrieves data from multiple databases and provides a quick representation of essential metrics for each patient.
214952138|NCT01179438|DRUG|Dexmedetomidine|The loading does of 0.5 mcg/kg dexmedetomidine is infused over 10 minutes. The following maintenance does of dexmedetomidine is 0.5 mcg/kg/hour.
214952139|NCT03603288|DRUG|idebenone 150 mg film-coated tablets|900 mg idebenone/day
214952140|NCT05432219|PROCEDURE|endoscopic surgery|endoscopic resection of recurrent nasopharyngeal carcinoma via the transoral retropterygoid nasopharyngectomy approach
214344470|NCT03591692|PROCEDURE|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
214344471|NCT03591692|PROCEDURE|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
214344472|NCT01863017|DEVICE|tDCS|
214678389|NCT03634215|DIAGNOSTIC_TEST|fibrinogen plasma concentration, coagulation factor XIII activity|blood sampling for a routine coagulation test
215076635|NCT05066581|DEVICE|Live Chat|Subjects from the intervention group will be able to ask for a medical intervention if needed with the phisycians from the sleep unit. After the following period, we expect to see better sleep habits in this group when compared to the no intervention one
214344473|NCT02804958|PROCEDURE|STEMI treated with primary PCI|Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
214344474|NCT06548451|DEVICE|Augmented reality guided localization|In this study, AR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
214344475|NCT02493361|DRUG|Pembrolizumab|
214952141|NCT05739305|OTHER|Risk factor|No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
214952142|NCT04384198|PROCEDURE|Sonolysis|Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy
214952143|NCT00316329|DRUG|Artesunate + Amodiaquine|
214952144|NCT00001031|BIOLOGICAL|rgp120/HIV-1MN|
214952145|NCT00001031|BIOLOGICAL|rgp120/HIV-1 SF-2|
214952146|NCT03647072|DRUG|CHOP|CHOP only
214952147|NCT03647072|DRUG|CHOP Plus Lanzoprazole|CHOP plus Lanzoprazole 60 mg
215076636|NCT02856243|DRUG|new antiviral therapy|
215076637|NCT03718572|PROCEDURE|Laparoscopic cholecystectomy|Surgical removal of Gall bladder using laparoscopy
214344476|NCT02493361|DRUG|pIL-12|
214344477|NCT01327534|DRUG|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
214678390|NCT04797013|DRUG|rt-PA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
215076638|NCT03172884|DRUG|Copanlisib (ALIQOPA, BAY80-6946)|12mg single dose, intravenous on Day 0
215076639|NCT04041466|DIAGNOSTIC_TEST|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
215076640|NCT00977275|RADIATION|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
215076641|NCT01327053|DRUG|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
215076642|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
215076643|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
214952148|NCT03647072|DRUG|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
214952149|NCT00002525|DRUG|fluorouracil|"Perioperative 5-FU: 600 mg/m\^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m\^2 IV push on days 1-5"
214952150|NCT00002525|DRUG|leucovorin calcium|given after surgery at dose of 20mg/m\^2 IV push on days 1-5
214952151|NCT02745483|DEVICE|Separable clustered electrodes|patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
215076644|NCT00448851|BIOLOGICAL|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
215076645|NCT04915989|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
214344478|NCT01327534|DRUG|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
214952152|NCT01111422|DRUG|N-acetylcysteine|N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
214952153|NCT04221022|OTHER|Light physical activity|Each session started with leisure walk, duration of which was set to 35 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
214952154|NCT04221022|OTHER|Moderate physical activity|Each session started with brisk walk, duration of which was set to 30 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
214952155|NCT04221022|OTHER|Vigorous physical activity|Each session started with jogging, duration of which was set to 15 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
214952156|NCT00768339|DRUG|AEG35156 antisense IV infusion|"AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~* Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~* Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion"
214952157|NCT03450616|DEVICE|PICO Negative Pressure Wound Therapy|Negative Pressure Wound Therapy Device
214344479|NCT01046643|DRUG|Estradiol (E2)|One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
214678391|NCT04797013|DRUG|rhTNK-tPA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
214678392|NCT03984760|DRUG|Ferric Citrate|Take the capsules with meals or immediately after meals.
214678393|NCT03984760|DRUG|Sevelamer Carbonate|Take the tablets with meals.
214678394|NCT00308542|DRUG|dexamethasone|
214952158|NCT03450616|PROCEDURE|Compression Dressing|Standard of Care Compression Dressing
214952159|NCT00002379|DRUG|Indinavir sulfate|
214952160|NCT00002379|DRUG|Levocarnitine|
214952161|NCT00002379|DRUG|Adefovir dipivoxil|
214952162|NCT00002379|DRUG|Lamivudine|
214952163|NCT00002379|DRUG|Stavudine|
214952164|NCT00002379|DRUG|Zidovudine|
214344480|NCT01046643|DRUG|Progesterone (P10) x90|One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
214344481|NCT01046643|DRUG|Progesterone (P10) x10|One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
214344482|NCT01169389|PROCEDURE|Intraarticular injection|Durolane, one vial
214952165|NCT03304184|DEVICE|Photac-fil|Application of a tooth colored filling in a non-cavitated dental lesion.
214952166|NCT03304184|DEVICE|Biodentine|Application of a white colored filling in a non-cavitated dental lesion.
214952167|NCT03230838|DRUG|Ceftolozane/Tazobactam|12 to \<18 years of age: Ceftolozane 1 g/dose; Tazobactam 0.5 g/dose via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days. \<12 years of age: Ceftolozane 20 mg/kg with Tazobactam 10 mg/kg (not to exceed Ceftolozane 1 g and Tazobactam 0.5 g) via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days.
214952168|NCT03230838|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.
215076646|NCT00957944|DRUG|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
215076647|NCT03325348|DRUG|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
214952169|NCT02636803|DRUG|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
214952170|NCT02636803|DRUG|albendazole|group receives one 400 mg dose of albendazole
215076648|NCT03325348|DRUG|Labetalol|IV labetalol 20 mg \& mint tablet will be given to patients every 15 min until one hour
215076649|NCT00522418|DEVICE|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
215076650|NCT00522418|DRUG|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
215076651|NCT01996696|DRUG|Metformin|Metformin 500 mg PO TID x 30-36 months
214344483|NCT01169389|PROCEDURE|Intra-articular injection of 0.5% Bupivacaine|
214952171|NCT04045990|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
214952172|NCT05145608|DRUG|Lamotrigine ER tablet 50mg|In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
214344484|NCT04181034|BEHAVIORAL|Adolescent Family Life Program Positive Youth Development (PYD) program|Home visiting program for pregnant and parenting teens with PYD component
214344485|NCT04181034|BEHAVIORAL|Adolescent Family Life Program (AFLP)|Home visiting program for pregnant and parenting teens
214344486|NCT00289341|BIOLOGICAL|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
214344487|NCT00289341|BIOLOGICAL|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
214344488|NCT02680600|DRUG|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
214344489|NCT02680600|OTHER|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
214952173|NCT00893906|BIOLOGICAL|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
214952174|NCT00893906|BIOLOGICAL|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
214952175|NCT05610475|DIAGNOSTIC_TEST|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
214952176|NCT01505179|DRUG|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
214952177|NCT01505179|DRUG|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
214952178|NCT03236571|DEVICE|Rehabilitation program|The rehabilitation program will consist of a Personalized Training Program and a muscle building program.
214952179|NCT00978393|DRUG|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
214952180|NCT00978393|DRUG|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
215076652|NCT01996696|DRUG|Placebo|Identical placebo TID x 30-36 months
215076653|NCT00874640|BIOLOGICAL|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
215076654|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
215076655|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
215076656|NCT03315273|OTHER|Test battery to measure the motor imagery ability|Participants will perform 3 different tests to measure the motor imagery ability
214952181|NCT00978393|DRUG|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
214952182|NCT00978393|DRUG|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
214952183|NCT00978393|DRUG|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
214952184|NCT00978393|DRUG|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
214952185|NCT01915771|DRUG|lomitapide|20 mg dose
214952186|NCT05869877|DEVICE|Bundled|An peripheral intravenous catheter will be inserted by an RN specially trained in PIVC placement, with or without ultrasound. Using best of class medical products, will evaluate dwell time and complications of the PIVC inserted using a bundled approach versus one inserted with the bundle
214952187|NCT01683877|PROCEDURE|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
214952188|NCT01683877|PROCEDURE|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
214952189|NCT02700880|DEVICE|LifeVest|LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
214952190|NCT01210014|DRUG|zinc sulphate 220mg/day in one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
214952191|NCT01210014|DRUG|placebo: one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
214952192|NCT03582514|RADIATION|Preoperative brain irradiation (single fraction)|Dose and volume escalation of preoperative single-fraction radiotherapy.
214952193|NCT00001119|BIOLOGICAL|Tetanus Toxoid Vaccine|
214952194|NCT00001119|DRUG|Indinavir sulfate|
214952195|NCT00001119|DRUG|Lamivudine/Zidovudine|
214952196|NCT00001119|DRUG|Ritonavir|
214952197|NCT00001119|DRUG|Abacavir sulfate|
214952198|NCT00001119|DRUG|Amprenavir|
214952199|NCT00001119|DRUG|Efavirenz|
214952200|NCT00001119|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
214952201|NCT00001119|DRUG|Lamivudine|
214952202|NCT00001119|DRUG|Zidovudine|
214952203|NCT03947502|BEHAVIORAL|Educational intervention in neurobiology of pain|The educational intervention will intend to make the individual aware that in the processes of learning, sensitization, habituation and acquisition of beliefs about pain there are automatic unconscious mechanisms, which can be modulated through conscious behaviors. Based on this the investigators propose the active participation of patients in the process of desensitization of their central nervous system. The investigators will try to encourage attention and weaken the neuronal connections that make up the pain neuromatrix to establish new connections thanks to neuroplasticity.
214952204|NCT05987943|PROCEDURE|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
215076657|NCT04074694|PROCEDURE|Sialoendoscopy|Sialoendoscopy
215076658|NCT00385281|BIOLOGICAL|FluMist|
215076659|NCT00003675|DRUG|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
215076660|NCT01482169|DRUG|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
214952205|NCT03202732|OTHER|DiabetesFlex|"DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk."
214678395|NCT00758914|DIETARY_SUPPLEMENT|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
214344490|NCT02680600|OTHER|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
214344491|NCT02680600|OTHER|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R\&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
214344492|NCT02680600|OTHER|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
214344493|NCT02680600|OTHER|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
214344494|NCT02680600|OTHER|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
214344495|NCT02270320|BEHAVIORAL|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
214344496|NCT02785406|DRUG|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
214678396|NCT04727112|DRUG|Usual care versus primary care|RCT study
214952206|NCT05529732|OTHER|e-Mobile Application Patient Education for Patients with Thyroidectomy|"Its mobile application is prepared according to the Android Operating System and can be downloaded free of charge from the Google Play Store, it is an application that provides training and consultancy services for patients who have had thyroidectomy surgery."
214952207|NCT06721637|COMBINATION_PRODUCT|Group A (n = 20): received core stability exercise trained three times a week for 8 weeks.|Woman was in crook lying position with feet flat on the treatment table. The therapist put his two thumbs on the anterior superior iliac spines then, asked the woman to contract the abdominal muscle, hold the contraction for 10 seconds, then, asked her to relax for 10 seconds
214952208|NCT06721637|DEVICE|Group B (n = 20): received whole body vibration trained three times a week for 8 weeks|The woman assumed a full squat position on a vibration platform. The apparatus was set at a frequency of 30 Hz, amplitude of 2 mm, and duration of 5 min. The women were instructed to remain in the squatting position with holding hand rail after turning on the vibration and to report any discomfort that might arise. At the end of 5 min, the vibration turned off automatically. Thereafter, the women took a 1-min rest. They were then asked to stand on the vibration platform for 5 min, with the same parameters as those used in the squatting position. Thus, the total time for the application of WBV in each session was 10 min
214952209|NCT02362152|DRUG|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
214952210|NCT02362152|DRUG|5-fluorouracil|Topical field treatment as prescribed by dermatologist
214952211|NCT02362152|DRUG|Imiquimod|Topical field treatment as prescribed by dermatologist
214952212|NCT02362152|DRUG|Diclofenac|Topical field treatment as prescribed by dermatologist
214952213|NCT02226848|DRUG|Erythropoeitin|
214952214|NCT02547701|DRUG|P-3058|
214952215|NCT01096680|DRUG|SPD489 20 mg|Single oral dose of 20 mg
214952216|NCT01096680|DRUG|SPD489 50 mg|Single oral dose of 50 mg
214952217|NCT01096680|DRUG|SPD489 70 mg|Single oral dose of 70 mg
214952218|NCT01096680|DRUG|Armodafinil|Single oral dose of 250 mg
214952219|NCT01096680|DRUG|Placebo|Single oral dose
214952220|NCT03420222|DRUG|AVP-786|oral capsules
214952221|NCT03420222|DRUG|Placebo|oral capsules
214952222|NCT02697734|DRUG|osilodrostat|In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
214952223|NCT02697734|DRUG|osilodrostat Placebo|Matching Placebo in the form of filmcoated tablets for oral administration
214952224|NCT00001341|DRUG|ZD1694 (TOMUDEX)|
214952225|NCT05087121|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F)|The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) 6-week training course has been derived from existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group therapy protocols. Participants in this intervention will receive psychoeducation on sleep and practice skills standard of CBT-I including, stimulus control techniques, sleep restriction, counter-arousal skills, cognitive restructuring, sleep hygiene, goal setting, and relapse prevention skills. Weekly sessions will include discussions regarding difficulties specific to occupational barriers and how to mitigate the impact of occupational requirements on sleep quality.
214952226|NCT05087121|DEVICE|Fitbit Inspire HR Wrist Worn Device (NCT04176926)|"The Fitbit Inspire HR wrist worn device will be worn by eligible participants throughout the duration of the intervention and for two weeks following completion of the 6-week intervention to collect objective data on enduring sleep changes. This device is an FDA-registered medical device that is not the object of investigation and is being used on label only to gather data.~501(K) Number: K200948 Device Name: Fitbit ECG App Regulation Number: 870.2345 Classification Product Code: QDA Clinical Trials: NCT04176926"
214952227|NCT01608516|DRUG|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
214952228|NCT02483494|OTHER|APN-led Telemedicine|"Allocation to experimental or Usual care is 1:1.~The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention."
214952229|NCT05808816|DRUG|Lactobacillus Crispatus M247|Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related
214952230|NCT04785560|DEVICE|Initial shunt setting post-operatively of the Certas Plus shunt valve.|The setting/resistance of the Certas Plus Shunt valve implanted is set according to randomisation and is not changed until the first post-operative MRI is performed 36-48 hours after surgery.
214952231|NCT05808270|BEHAVIORAL|Nutrition care process|"According to the randomization and simple blinding, there will be 2 study groups in which group 1 will be operated on Nutrition care process and group 2 with Conventional nutritional intervention.~* The Nutrition Care Process is a standardized model intended to guide RDNs in providing high quality nutrition care. The NCP consists of four distinct, interrelated steps: Nutrition Assessment, Diagnosis, Intervention, and Monitoring/Evaluation (AND, 2023).~* In the case of Conventional nutritional intervention, we will base ourselves on the application of a habitual nutritional clinical history, where information will be obtained on the reasons for consultation and the specific needs of the patient to carry out an intervention based on their priorities."
215076661|NCT04015284|PROCEDURE|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
214344497|NCT02785406|DRUG|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
215076662|NCT04015284|PROCEDURE|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
214344498|NCT01776645|BEHAVIORAL|Compassion Cultivation Training Course|
214344499|NCT06534606|PROCEDURE|Electrotherapy and physical agents|"Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~• TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks."
214344500|NCT06534606|PROCEDURE|Headache SNAGs|"Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~• Frequency: 3 times a week for 2 weeks. 6 sessions in total."
214344501|NCT06534606|PROCEDURE|Sternocleidomastoid Release|Sternocleidomastoid Release: Group B will also receive Sternocleidomastoid release in addition with headache SNAGs. Release to the sternocleidomastoid muscle will be given once per session for 5-8 minutes.Frequency: 3 times a week for 2 weeks. 6 sessions in total.
214344502|NCT04579263|OTHER|Fecal microbiota|Transplantation of fecal microbiota of healthy donor with normal body mass index
214344503|NCT04947111|DIAGNOSTIC_TEST|Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue|"Indirect IgG ELISA to estimate seroprevalence: The seropositivity will be evaluated with the Indirect IgG ELISA following the instructions of the Panbio E-DEN 01 G manufacturer, which has a specificity of 98% and a sensitivity of 100%. In brief, 10 microliters of participant serum will be used for each assay. Each kit provides a positive and negative control, as well as three calibrators, with the respective values for quality control. Samples will be classified as positive, negative or indeterminate according to the cut-off point for each ELISA kit.~Neutralizing antibody titers serotype-specific: To establish the type of humoral immunity that the selected city presents, the measurement of the neutralizing antibody titers will be carried out by means of the neutralization test by reducing the number of lytic plaques to 50% (PRNT50%) , using Vero cells and the following reference strains for each serotype: DENV-1 (HAWAI), DENV-2 (NEW GUINEA), DENV-3 (H-887) and DENV-4 (H-24)"
215076663|NCT00653848|DRUG|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
215076664|NCT05257460|DEVICE|Hybrid closed-loop using ultra-rapid insulin lispro|Hybrid closed-loop using ultra-rapid insulin lispro
214678397|NCT04410783|BEHAVIORAL|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of ED-based sedation, and the objectives of the research. Education will include in-services and lectures focused on the importance of sedation protocols on patient outcome. The use of sedation will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based sedation protocols.
215076665|NCT05257460|DEVICE|Hybrid closed-loop using standard insulin lispro|Hybrid closed-loop using standard insulin lispro
215076666|NCT04894305|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection.
215076667|NCT02193386|OTHER|No intervention, no follow-up, only registration|Usual Care
215076668|NCT02193386|OTHER|Intervention period|Predefined intervention program
214678398|NCT04410783|OTHER|Standard post intubation sedation practices|Usual care sedation provide in the ED
214952232|NCT00284154|DRUG|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
214344504|NCT00991250|BIOLOGICAL|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
214344505|NCT00991250|DRUG|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-\[3,3-Dimethyl-1-triazenyl\]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
214952233|NCT02334384|BIOLOGICAL|Antimicrobial TheraGauze|"In the intervention arm: Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.~In the comparator arm: Standard wound packing, plain cotton wick or iodoform gauze - at the discretion of the provider will be used to pack the wound cavity after incision and drainage of the skin abscess."
215076669|NCT01666535|BIOLOGICAL|Influenza vaccination|
215076670|NCT00524953|DEVICE|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last \~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
215076671|NCT00857831|DIETARY_SUPPLEMENT|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
214486617|NCT05980559|DRUG|Xeomin|50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally (15 Units per muscle applied with 2 injections in each masseter muscle) (10 Units per muscle applied with 2 injections in each temporalis muscle)
214952234|NCT02651688|DRUG|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
214952235|NCT02651688|DRUG|Enclomiphene|Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
214952236|NCT04389307|OTHER|Electrical stimulation (IVES)|IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24 session treatment program of IVES.
214952237|NCT04389307|OTHER|Bladder Training|Bladder Training
214952238|NCT01194193|DRUG|AZD8055|Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
214952239|NCT04527978|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
214952240|NCT04527978|DEVICE|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
214952241|NCT03174288|OTHER|Exercise|24 weeks of exercise treatment
215076672|NCT03756155|PROCEDURE|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
215076673|NCT03760887|OTHER|Home exercise program only|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only
214344506|NCT02011880|DIETARY_SUPPLEMENT|Chinese Herbs|"Dietary Supplement:Experiment group:~Fructus Cnidii,Psoralea Corylifolin L.，monkshood~-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Dietary Supplement:Contrast Group:~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity"
214344507|NCT01351740|DRUG|atazanavir|switch to unboosted atazanavir 400 mg daily
214344508|NCT01351740|DRUG|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
214344509|NCT04096092|OTHER|No intervention|No intervention
214344510|NCT04160819|OTHER|Assigned Interventions|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
214344511|NCT05956431|DRUG|Levosimendan Injection|The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
214344512|NCT05956431|DRUG|physiological saline|The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
214344513|NCT00153049|DRUG|Telmisartan|
214344514|NCT00153049|DRUG|Hydrochlorothiazide|
214344515|NCT00153049|DRUG|Telmisartan + Hydrochlorothiazide|
214344516|NCT01491243|DRUG|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
214344517|NCT01491243|DRUG|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
214344518|NCT03579745|PROCEDURE|Lingual orthodontics|A coil spring will be attached from the lever arm to the first molar tube
214952242|NCT03174288|DRUG|Spironolactone|24 weeks of spironolactone
214952243|NCT00006378|DRUG|carboplatin|
214952244|NCT00006378|DRUG|paclitaxel|
214952245|NCT00006378|RADIATION|radiation therapy|
214952246|NCT04553003|DRUG|Glucocorticoids+hepatoprotectant|Participants received glucocorticoids (0.4mg/kg/d po.) and hepatoprotectant for 7 days.
214952247|NCT04553003|DRUG|hepatoprotectant|Participants received hepatoprotectants (i.v.gtt.) for 7 days.
215076674|NCT03760887|OTHER|Home exercise program and home program of sensory discrimination|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
215076675|NCT05410171|DEVICE|early warning platform|High risk inpatients will be evaluated by early warning platform
215076676|NCT01944098|DRUG|Lidocaine|
214344519|NCT03296995|DEVICE|Flash glucose monitoring system|Flash glucose monitoring systems in critically ill patients may improve glycemic control and reduce glucose variability.
214344520|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 2 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
214344521|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 10 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
214344522|NCT04473404|OTHER|Placebo|The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
214344523|NCT00412087|DRUG|cholecalciferol (vitamin D3)|randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
214344524|NCT00412087|DRUG|cholecalciferol|randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
214344525|NCT00412087|DRUG|cholecalciferol|cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
214344526|NCT00319215|DRUG|Ramelteon 8 mg|
214344527|NCT00319215|DRUG|Zopiclone 7.5 mg|
214344528|NCT05916742|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions
214952248|NCT03344146|BEHAVIORAL|Medication intake reminders|Acoustic and visual alarm at predefined DOAC-intake timepoints.
214952249|NCT03344146|BEHAVIORAL|Pillbox use and counselling|All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
214952250|NCT00600158|DRUG|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
214952251|NCT00600158|DRUG|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients \> 70 kg)
214952252|NCT00018421|PROCEDURE|Treadmill Exercise|
215076677|NCT01944098|DRUG|Placebo|
215076678|NCT06659198|PROCEDURE|total hip replacement|minimally-invasive hip replacement
215076679|NCT06608238|DRUG|D-MNA 200 mcg|D-MNA , (doxorubicin) patch, 200 mcg
215076680|NCT06608238|DRUG|D-MNA 100 mcg|D-MNA (doxorubicin) patch, 100 mcg
215076681|NCT06608238|OTHER|Placebo|P-MNA patch, placebo
215076682|NCT06607380|BIOLOGICAL|TNM002|A single intramuscular (IM) gluteal injection
215076683|NCT06607380|BIOLOGICAL|Adsorbed tetanus vaccine|A single IM deltoid injection
215076684|NCT06607380|BIOLOGICAL|TNM002 + adsorbed tetanus vaccine|A single IM gluteal injection+ a single IM deltoid injection
215076685|NCT06607536|OTHER|calcium chloride surface treatment in mini implant|0.1M of Calcium Chloride were used to immersed the orthodontic mini implant
215076686|NCT06607536|OTHER|Acid Etched|Mini implant etched in Hydrochloric acid
214344529|NCT05916742|PROCEDURE|i-PRF|Blood-derived biomaterial. Two sterile plastic tubes (Process for PRF, Nice, France) with a volume of 10 ml will be used to generate fluid blood concentrate. After blood collection, the tubes will be centrifuged using a Duo centrifuge (Process for PRF, Nice, France) (fixed angle rotor with a radius of 110 mm) following the protocol proposed by Choukroun et al. (2018) (600 rpm; 8 min).
214952253|NCT05614635|DEVICE|Plastalgin and Plastalgin Fast|Plastalgin and Plastalgin Fast are potassium alginate-based powders designed for dental impression. The powder is mixed with water to obtain an impression material paste, used to imprint the teeth and mouth of the patient. The product is available under two presentations: Plastalgin and Plastalgin Fast. Plastalgin Fast has a shorter mixing time.
214952254|NCT01429441|DRUG|Ocriplasmin|0.125 mg single intravitreal injection
214952255|NCT01429441|OTHER|Sham injection|Sham injection
214952256|NCT00715871|DRUG|Nicotine|"Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study."
214952257|NCT00715871|DEVICE|Smoke-Break nicotine delivery device|"The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive."
214952258|NCT00042653|DRUG|Placebo|30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
214952259|NCT00042653|DRUG|AMG 073|30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
214952260|NCT06055621|DRUG|Dasatinib|Daily orally administration of DASATINIB
214952261|NCT03780972|DRUG|ONL1204|Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection
214344530|NCT05916742|DEVICE|VCMX|Porcine derived collagen matrix.
214344531|NCT05916742|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
214344532|NCT05916742|DRUG|Chlorhexidine rinse|All participants will be instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
214344533|NCT05916742|DRUG|Amoxicillin 500mg|Participants enrolled in the CAF+VCMX and CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
214344537|NCT01467323|DRUG|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
214344538|NCT01467323|DRUG|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
214952262|NCT03780972|PROCEDURE|Intravitreal Injection|Injection of study drug into the eye
214952263|NCT03780972|PROCEDURE|Collection of ocular fluids|vitreous and aqueous fluid collection by a tap and during vitrectomy
214952264|NCT04159168|BEHAVIORAL|Facial Affect Sensitivity Training (FAST)|The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.
214344539|NCT02669823|OTHER|None, treatment as actual best practice|
214344540|NCT04183322|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
214344541|NCT00634413|DRUG|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
214344542|NCT00634413|DRUG|Placebo|Inhaled matching placebo administered twice daily for 28 days
214344543|NCT00634413|DRUG|Budesonide|Inhaled budesonide twice daily for 28 days
214344544|NCT05221164|DRUG|Aspirin 162 mg|Daily aspirin 162 mg during pregnancy to prevent preeclampsia
214344545|NCT03772080|OTHER|Early counseling of prematurity in high-risk pregnancies.|Standardized information regarding prematurity, including associated complications and ways to decrease chances of preterm birth using web-based educational platform.
214344546|NCT04236557|BEHAVIORAL|Music listening|Other than usual care, subjects will listen to a 30-min individualized playlists with preferred music genres sequenced by a registered music therapist according to the ISO-Principle when agitated.
214344547|NCT04236557|BEHAVIORAL|Audio Book Listening|Other than usual care, subjects will listen to to a 30-min audio-script of book reading in Cantonese (a common dialect in Hong Kong being spoken by most people) when agitated.
215076687|NCT06660771|PROCEDURE|Functional orthodontic treatment|"The patients were treated with Twin block and Herbst functional appliances. Alginate impressions and a protrusive wax bite were taken for the construction of each appliance. Each device was fitted and then reviewed 4-6 weeks later. First group was treated with Twin block which was manufactured basically according to the original design described by Clark. The overjet was measured from the patients in centric relationship and maximum protrusion position, and construction bite was recorded with 70% of the total advancement capacity of the mandible and 2-4 mm above the freeway space vertically. Overjet measurements were made at each session and active treatment was terminated when a normal overjet in the retracted position was recorded.~Second group was treated with the stainless-steel crown Herbst appliance, included crowned maxillary first molars and mandibular first premolars. The construction bite was recorded with the mandible forward by edge-to-edge incisor position."
215076688|NCT03474848|OTHER|HABIT|Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
214344548|NCT00298428|PROCEDURE|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
214344549|NCT02316236|DRUG|dexmedetomidine|an alpha-2 receptor agonist
214952265|NCT04159168|BEHAVIORAL|Implicit Gaze Training task (Active control condition)|"This computerized task was developed to target implicit training of eye gaze but not facial emotion recognition per se via real-time feedback and incentives. On each trial, a fixation cross is followed by an emotional face with eyes directed either left, straight ahead, or right (balanced across expressions), followed by a response key. The child's task is to say which direction the eyes are looking (e.g., 1 or left). Stimuli are black and white standardized photographs of men and women models from the Ekman Pictures of Facial Affect each displaying the 3 gaze directions for 6 emotion expressions."
214952266|NCT00655603|OTHER|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
214952267|NCT00464295|DRUG|Capecitabine in HCC|
214952268|NCT05827588|DEVICE|AWAK PD|Daily 7- or 9-hour therapy (with or without a last fill) that is a form of automated peritoneal dialysis being done by subjects who are already on daily PD therapy
214952269|NCT01349933|DRUG|Akt inhibitor MK2206|Given PO
214952270|NCT01578499|DRUG|Brentuximab Vedotin|Brentuximab vedotin intravenous injection.
214952271|NCT01578499|DRUG|Methotrexate|Methotrexate tablets.
214952272|NCT01578499|DRUG|Bexarotene|Bexarotene tablets.
214952273|NCT03142256|BEHAVIORAL|Incentivised - Conditional Cash Transfer|Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer
214952274|NCT03142256|DRUG|Truvada 200Mg-300Mg Tablet|Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
214952275|NCT02957604|DRUG|evolocumab|Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
214952276|NCT00830518|DRUG|Alisertib|Alisertib capsules
215076689|NCT03474848|OTHER|Conventional Occupational Therapy (OT)|Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
214344550|NCT02316236|OTHER|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
214344551|NCT02316236|OTHER|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
214344552|NCT05809570|DIAGNOSTIC_TEST|Clinical examination|"A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient."
214344553|NCT02262845|DEVICE|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
214344554|NCT02438449|PROCEDURE|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
214344555|NCT02192437|OTHER|Sulfur amino acid restricted diet|Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
214344556|NCT06186648|DRUG|Glofitamab + Obinutuzumab|Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
214344557|NCT00553267|DRUG|fixed dose combination of telmisartan+amlodipine|
214344558|NCT00553267|DRUG|amlodipine|
214344559|NCT01310036|DRUG|Erlotinib|Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
214952277|NCT05971472|PROCEDURE|Arthroscopic Repair|Arthroscopic Repair for medial meniscus posterior Root tears
214952278|NCT05971472|PROCEDURE|High tibial osteotomy|Open Wedge High tibial osteotomy for medial meniscus posterior Root tears
214952279|NCT01624402|BEHAVIORAL|Education on Stroke and Depression (ESD)|"* Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.~* Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.~* Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.~* ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy)."
214344560|NCT04046874|DRUG|Usual Care|Pain Medication, imaging, referrals to other health services, other health care appointments
214344561|NCT04046874|OTHER|SPLIT Stratified Model of Care|Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
214952280|NCT01624402|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|"1. EFT offers an action-oriented, new perspective about the subject's recovery;~2. It provides an adherence enhancement structure;~3. It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;~4. It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;~5. It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities."
214344562|NCT05383248|BEHAVIORAL|High Reward - High Variance|Computerized reward learning task designed to increase reward responsiveness
214344563|NCT05383248|BEHAVIORAL|High Reward - Low Variance|Computerized reward learning task designed to have minimal effect on reward responsiveness
214344564|NCT06416215|OTHER|Psychological intervention based on WBT and cognitive restructuring|Participants will engage in 6 weekly group session of two hours. One part will be held by a trained dietician and will focus on nutritional education, particularly emphasizing the adoption of healthy and sustainable eating behaviors. The remaining part will be dedicated to a group psychological intervention inspired by the principles of Well-Being Therapy and will be held by a trained psychologist. During these sessions, participants will be introduced to the six dimensions of psychological well-being and will be gradually provided with cognitive-behavioral strategies to enhance psychological well-being and seek a balance between the presented dimensions. Participants will be given cognitive-behavioral tools to recognize justification cognitive mechanisms and replace them with more functional cognitions. These objectives will also be achieved through the use of a food diary to highlight emotions and thoughts experienced during food intake.
214952281|NCT02779270|DRUG|BAY987518|"Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104"
214952282|NCT02779270|DRUG|Sunscreen Lotion (U77-030 Control)|Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
215076692|NCT02591758|DEVICE|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
215076693|NCT02591758|BEHAVIORAL|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
214344565|NCT06416215|OTHER|Basic Nutritional Intervention|Participants will receive treatment as usual (TAU) by participating in 6 weekly group sessions of two hours of a Basic Nutritional Intervention (BNI) held by a trained dietician. This course focuses on promoting healthier lifestyles through nutritional education, diet monitoring using a dedicated food diary, and recommendations for proper physical activity.
214952283|NCT01425606|OTHER|blood test|blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
214952284|NCT04498039|DEVICE|Portable Neuromodulation Stimulator|Examining the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibit a dysfunctional gait. Adopting a rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain.
215076694|NCT02591758|OTHER|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
215076695|NCT02591758|OTHER|Angina assessment with the angina diary, the SAQ and the SF-36|
215076696|NCT02591758|OTHER|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
215076697|NCT02591758|OTHER|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
215076698|NCT06606548|BEHAVIORAL|comprehensive oral care|including cleaning, facial massage, oral muscle massage and stretching, and oral moisturizing.
215076699|NCT05422534|DIETARY_SUPPLEMENT|CoQ10|Participants will receive 1800 mg/day for 12 weeks
215076700|NCT05422534|DRUG|Placebo|Participants will receive placebo or CoQ10/day for 12 weeks
214344566|NCT03124641|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
214344567|NCT03124641|PROCEDURE|Conventional cold storage (CCS)|Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
214344568|NCT03332862|PROCEDURE|catheter ablation|catheter ablation for atrial fibrillation treatment
214344569|NCT01562574|DRUG|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
214344570|NCT01562574|DRUG|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
214952285|NCT05194852|PROCEDURE|ultrasound-guided posterior hydrodilatation|Group I was treated through posterior approach; The injection needle is introduced at the skin surface just lateral to the transducer and in an oblique lateral to medial direction. Group II was treated through anterior rotator interval approach. A 21-gauge needle is introduced into the rotator interval using an oblique path within the imaging plane of the transducer; from lateral to medial, the needle tip is imaged in real time throughout its passage from superficial to deep and is positioned in the biceps tendon sheath between the coracohumeral ligament above and biceps tendon below. Both groups were given the same guided stretching and strengthening exercise program
214952286|NCT05194852|DRUG|corticosteroid, saline, and local anesthetic|corticosteroid, saline, and local anesthetic
214952287|NCT05194852|OTHER|guided stretching and strengthening exercise program|guided stretching and strengthening exercise program
214952288|NCT04091815|OTHER|Type of anaesthesia|Two different types of anesthesia general vs combined (spinal and general)
214952289|NCT00523809|DRUG|Bevacizumab|10 mg/kg IV Daily Over 30 Minutes for 1 Day
214952290|NCT00523809|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Stem Cell Transplantation on Day 8.
214952291|NCT00523809|DRUG|Fludarabine|25 mg/m\^2 IV Daily Over 30 Minutes for 5 Days
214952292|NCT00523809|DRUG|Melphalan|70 mg/m\^2 IV Daily Over 30 Minutes for 2 Days
214952293|NCT00523809|DRUG|Thymoglobulin|0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
214952294|NCT00808470|DRUG|beta-carotene, vitamins C and E, magnesium|"6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene."
214952295|NCT00808470|OTHER|Placebo|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
214952296|NCT03955809|DRUG|Ketamine 0.5|İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml
214344571|NCT03194802|BEHAVIORAL|Sleeping Without Pills Program|Participants receive this program online and are asked to log in daily for 6 weeks.
214344572|NCT03194802|BEHAVIORAL|Self-monitoring|Participants enter sleep diary data online daily for 6 weeks
214344573|NCT03939468|DEVICE|DES+DCB|A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease
214344574|NCT04045392|BEHAVIORAL|Mediterranean diet|Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
214344575|NCT02775526|PROCEDURE|TOT|70 patients
214344576|NCT02775526|PROCEDURE|TVT|70 patients
214344577|NCT02775526|PROCEDURE|Burch Colposuspension|70 patients
214344578|NCT00346060|DEVICE|Retinal transplantation instrument|
214344579|NCT00346060|DEVICE|Fetal tissue.|
214344580|NCT05834504|OTHER|Short distributed training (1-2 days)|"The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved."
214952297|NCT03955809|DRUG|Ketamine 1|İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml
214952298|NCT03955809|DRUG|% 0.9 NaCl|Intraarticular %0.9 NaCl
214952299|NCT00649233|DRUG|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fed
214952300|NCT00649233|DRUG|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fed
214952301|NCT02669667|DRUG|MEDI9314|single dose of MEDI9314
214952302|NCT02669667|DRUG|placebo|single dose of placebo
214952303|NCT04892992|BEHAVIORAL|DFG|
214952304|NCT04714762|DEVICE|eMOM GDM application|"Participants in the intervention group will use the eMOM GDM -application one week/month.~eMOM GDM application includes:~* continuous glucose monitor (CGM, Medtronic)~* diet (digital food tracker) (min 3 days during one application week)~* heartrate, stress and physical activity with the wrist-worn activity tracker (Vivosmart 3)~* weight measured once a week~The sensors can be worn and the application used during the whole pregnancy (if a mother is interested in)"
214952305|NCT03713996|BEHAVIORAL|Cognitive behavioral therapy for insomnia|CBT-I is designed to change sleep habits as well as direct misconceptions about sleep and insomnia. Participants will receive several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components. The intervention will be provided in 6-session (one session/week).
214952306|NCT03713996|OTHER|Health Education|Participants in this arm will receive education in sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity. The education will be provided in 6-session (1 session/week).
214952307|NCT00553852|DRUG|Recombinant GH Saizen (Merck-Serono)|Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
214344581|NCT01782989|DRUG|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
214344582|NCT01782989|DRUG|Placebo|Placebo capsule daily for 24 months
214952308|NCT00600405|DRUG|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
214952309|NCT00600405|DRUG|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
214952310|NCT00003028|DRUG|sabarubicin|
214952311|NCT06263517|DRUG|Clodronate|For Arm 1, patients will be treated with intra articular clodronate 2 mg/2 ml from Baseline to Week 3
214952312|NCT06263517|DRUG|Clodronate|For Arm 2, patients will be treated with intra articular clodronate 5 mg/2 ml from Baseline to Week 3
214952313|NCT06263517|DRUG|Clodronate|For Arm 3, patients will be treated with intra articular clodronate 10 mg/2 ml from Baseline to Week 3
214952314|NCT06263517|DRUG|Placebo|For Arm 4, patients will be treated with Placebo 2 ml from Baseline to Week 3
214952315|NCT00055679|DRUG|cyclophosphamide|
214952316|NCT00055679|DRUG|epirubicin hydrochloride|
214952317|NCT00055679|DRUG|fluorouracil|
215076701|NCT05422534|BEHAVIORAL|HB-HIIT|Participants will be performed on non dialysis days. It will be video supervised exercise sessions with self directed exercises using pre-recorded bodyweight and strength exercise videos.
214344583|NCT06530017|DEVICE|Ingested, Space Occupying hydrogel capsules|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
214344584|NCT06530017|DEVICE|placebo|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
214344585|NCT00153738|DRUG|phytosterol|
214344586|NCT04464304|DEVICE|Smartphone|Patients will participate in a similar game to the VR cohort, but will use a smartphone device.
214952318|NCT00811993|DRUG|RG1507|Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
214952319|NCT00811993|DRUG|RO1507|27mg/kg iv, monotherapy
214952320|NCT00811993|DRUG|bevacizumab [Avastin]|as prescribed
214952321|NCT00811993|DRUG|capecitabine [Xeloda]|as prescribed
214344587|NCT04464304|DEVICE|Virtual Reality (Oculus Quest)|Patients will participate in a game using VR.
214952322|NCT00811993|DRUG|carboplatin|as prescribed
214952323|NCT00811993|DRUG|cetuximab|as prescribed
214344588|NCT03456908|COMBINATION_PRODUCT|18F-TFB-PET|Infusion of F-18 TFB and PET / CT imaging
214344589|NCT00834457|DRUG|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
214344590|NCT00834457|DRUG|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
214344591|NCT01952535|DRUG|HMS5552|
214344592|NCT01952535|DRUG|Placebo|
214344593|NCT01269892|DIETARY_SUPPLEMENT|lactose-free milk|a milk without lactose
214344594|NCT01269892|DIETARY_SUPPLEMENT|conventional milk|a milk with lactose
214952324|NCT00811993|DRUG|docetaxel|as prescribed
214952325|NCT00811993|DRUG|erlotinib [Tarceva]|as prescribed
214952326|NCT00811993|DRUG|etoposide|as prescribed
214952327|NCT00811993|DRUG|gemcitabine|as prescribed
214952328|NCT00811993|DRUG|irinotecan|as prescribed
214952329|NCT00811993|DRUG|mFOLFOX6|as prescribed
214952330|NCT00811993|DRUG|paclitaxel|as prescribed
214952331|NCT00811993|DRUG|pemetrexel|as prescribed
214952332|NCT00811993|DRUG|sorafenib|as prescribed
214952333|NCT00811993|DRUG|temozolomide|as prescribed
214952334|NCT00811993|DRUG|trastuzumab [Herceptin]|as prescribed
214952335|NCT01916902|DRUG|Ticagrelor- Delayed Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
214952336|NCT01916902|DRUG|Ticagrelor- Immediate Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
214952337|NCT01916902|PROCEDURE|Optical Coherence Tomography|
214952338|NCT02093403|DRUG|decitabine|Given IV
214952339|NCT02093403|DRUG|selinexor|Given PO
214952340|NCT02093403|OTHER|pharmacological study|Correlative studies
215076702|NCT05422534|BEHAVIORAL|Observational|Participant regular activities
215076703|NCT04137653|DRUG|nab-Paclitaxel+carboplatin|Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
215076704|NCT04137653|DRUG|Paclitaxel+carboplatin|Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
214344595|NCT03867877|OTHER|Periodized training with motor practice|Exercises at 75-80% of the subject's maximum for strength exercise using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
214344596|NCT03867877|OTHER|Simple Periodized Training|Exercises at 75-80% of the subject's maximum for strength using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and for hypertrophy day at 60-75% of subjects' maximum strength. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes exercise using contractions warm-up, 50 minutes of training and five minutes of cool-down.
214678399|NCT03626051|DEVICE|Rigid tape|This taping method used an anchor, two stirrups, three figure-six's (two preventing inversion and one preventing eversion), heel lock and a lock off. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
214952341|NCT02093403|OTHER|laboratory biomarker analysis|Correlative studies
214952342|NCT01945294|DRUG|Boceprevir|800 mg three times daily orally
214952343|NCT01945294|BIOLOGICAL|Peg-interferon alfa-2b|1.5 mcg/kg weekly subcutaneously
214952344|NCT01945294|DRUG|Ribavirin|800-1400 mg twice-daily divided orally based on body weight
214952345|NCT01239836|BEHAVIORAL|Constructivist interactive workshop on urinary incontinence|A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.
214952346|NCT01239836|BEHAVIORAL|Evidence-based self-management tool|Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.
214952347|NCT01239836|BEHAVIORAL|General health lecture|Participants will attend a lecture on general women's health issues that does not address urinary incontinence.
214952348|NCT02839876|DRUG|Intravenous acetaminophen|Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
214952349|NCT02839876|DRUG|Oral acetaminophen|Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
215076705|NCT06542978|DEVICE|40Hz stimulation|Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
215076706|NCT05625789|BEHAVIORAL|Postural control (weight shift) training|Visual cues to improve amplitude of weight shift prior to initiating gait.
215076707|NCT05625789|BEHAVIORAL|Steady state gait training|Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.
215076708|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
215076709|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
214952350|NCT03385369|DRUG|MEDI0382|Single dose of MEDI0382
215076710|NCT02030717|DRUG|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
214952351|NCT03385369|DRUG|Placebo|Single dose of placebo
214952352|NCT00000997|DRUG|Zalcitabine|
214952353|NCT05392088|OTHER|DATA EXTRACTION|"For all patients enrolled Data Mart COVID-19 developed within Generator Real World will be used to automatically extract both structured and unstructured data from hospital databases of patients infected from SARS-CoV-2.The specific data that which will be exploited are:~* Demographics data;~* Patient comorbidities, vital signs and symptoms at the time of admission;~* Laboratory analysis;~* In-hospital complications (e.g.: need for non-invasive or invasive ventilation, access to intensive care unit, length of hospitalization, use of glucocorticoids or antibiotics, death);~* Blood gas exchange information;~* Radiological reports;~* Medications at the time of admission, during hospitalization and at the time of discharge;~* Vaccination status."
214952354|NCT05392088|OTHER|FOLLOW-UP|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 12 months from hospital discharge, during which the incidence of MACE, dysrhythmias, inflammatory heart disease and/or thrombotic disorders (both as incidence of the composite and as incidence of each individual components) in the past months will be investigated.
214952355|NCT03985488|RADIATION|Radiation exposure|Radiation exposure via Eview Fluoroscopy machine.
214952356|NCT05735678|DEVICE|Single-Use Duodenoscopes|Single-Use Duodenoscopes
214952357|NCT04261010|PROCEDURE|Global/single cell gene expression profiles obtained from Synovial biopsies|Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.
214952358|NCT03406988|PROCEDURE|Autologous fat grafting|Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU
215076711|NCT02030717|DRUG|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
215076712|NCT04360239|DIETARY_SUPPLEMENT|Fish Oil|Fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
215076713|NCT05396222|DEVICE|3D-printed custom-made non-rigid biomimetic implant|We developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.
215076714|NCT05890170|OTHER|Patient Reported Outcomes Measures|Questionnaires and information extracted from the medical records would be collected.
215076715|NCT05967741|OTHER|Erythritol|Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)
214952359|NCT03406988|PROCEDURE|Sham procedure|Local injection of 0.5ml saline solution after a simulated liposuction procedure.
214344597|NCT01175668|DRUG|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores \<8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
214344598|NCT01175668|DRUG|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
214344599|NCT06371885|DEVICE|shock wave therapy|shock wave therapy will be applied one session per week, each ESWT session will involve 2,000 pulses of the focus probe at 4-bar pressure and 5 Hz frequency for twelve weeks
214486618|NCT06403995|BEHAVIORAL|Self-referred, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
214952360|NCT02455713|DEVICE|PEEP and PIP|Changing ventilator settings and measuring oxygen delivery and cardiac output
214952361|NCT02721017|DEVICE|Cryoanalgesia|
214952362|NCT02721017|DRUG|Thoracic epidural (ropivicaine, fentanyl)|Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
214952363|NCT00413933|PROCEDURE|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
214952364|NCT00571753|DRUG|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
214952365|NCT00571753|DRUG|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
215076716|NCT05967741|OTHER|Aspartame|Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
215076717|NCT01903551|DEVICE|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
215076718|NCT05475665|DRUG|Irbesartan/Amlodipine|Irbesartan/Amlodipine once daily for 8 weeks
214344600|NCT06371885|OTHER|traditional physical therapy|the traditional physical therapy will be in form of (10 minutes hot pack around wrist and forearm and 10 minutes of gentle stretching exercises for wrist joint, three sessions per week for twelve weeks
214344601|NCT05732168|DIAGNOSTIC_TEST|A test battery for evaluation of muscle strength, balance and functional performance|Subjects with chronic ankle instability (CAI) were evaluated with five tests of strength, balance and functional performance.
214344602|NCT02443181|DEVICE|Activa PC+S|Implementation of closed loop DBS for essential tremor
214952366|NCT05513768|DIAGNOSTIC_TEST|level of myosin binding protein c in serum|Serum samples will be taken from the participants in the first trimester, transferred to eppendorf tubes after appropriate procedures, and stored at -80 degrees until the time of deliveryParticipants will be divided into two groups according to the timing of birthThe first group is those who gave birth earlier than 37 weeks those who gave birth on time in the other group The mbpc levels will be looked at and compared.
214952367|NCT05739656|PROCEDURE|CATARACT SURGERY|Approximately up to 100 subjects (100 eyes) will be successfully implanted with an enVista Toric IOL (Model MX60ET) in one or both eyes.
214952368|NCT00430456|PROCEDURE|Exercise|Treadmill Training
214952369|NCT03872765|DEVICE|Laser surgery|Use of CO2 laser to perform surgeries to treat chronic anal fissure
214952370|NCT04973241|RADIATION|OPG & CBCT|panoramic images , cone beam computed tomography
214344603|NCT05209282|OTHER|Video Based Action Observation|Individuals in this group will receive video-based action observation training in addition to the conventional physiotherapy program.
214952371|NCT01700738|PROCEDURE|gastric ring surgery|
214952372|NCT01700738|OTHER|nutritional help|
214952373|NCT01313351|DEVICE|RPS InflammaDry Detector™|A noninvasive immunoassay for detecting MMP-9 levels in tears
214952374|NCT06505278|DRUG|Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening|Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 10:00 pm and 12:00 pm in the evening.
214952375|NCT02721303|DIETARY_SUPPLEMENT|3-day diet Run-in|Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.
215076719|NCT05475665|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
214344604|NCT05209282|OTHER|Live Action Observation|Individuals in this group will receive live action observation training in addition to the conventional physiotherapy program.
214952376|NCT02721303|PROCEDURE|fMRI|After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
214952377|NCT02721303|PROCEDURE|Intravenous catheter placed for blood draws|On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
214952378|NCT00610233|PROCEDURE|deep brain stimulation ON|deep brain stimulation in the ON state
214952379|NCT00610233|PROCEDURE|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
214952380|NCT05386732|DEVICE|Micro needling|All patients were treated with a 16 needle, 3mm, 33-gauge surgical grade stainless steel needle cartridge. The operator began treatment using a depth of (1mm) and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occured, the minimum and maximum depth used to create pinpoint bleeding was recorded. The operator began treatment using a minimum depth of 1mm and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occurred.
214952381|NCT01156051|DRUG|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
214952382|NCT01156051|DRUG|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
214952383|NCT00133653|BEHAVIORAL|Observational|
214952384|NCT01892878|PROCEDURE|VerteLoc|Single Arm
214952385|NCT05574907|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Patients with suspected breast cancer underwent 68Ga-FAPI PET/CT after an injection of 74-148 MBq (2-4 mCi) 68Ga-FAPI to image lesions of breast cancer.
214952386|NCT03963778|BEHAVIORAL|Improving nutritional care|The interventions will be co-designed with the action research team
214952387|NCT00041041|DRUG|imatinib mesylate|Given PO
214952388|NCT00041041|OTHER|laboratory biomarker analysis|Correlative studies
214952389|NCT00478088|DEVICE|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
215076720|NCT01915121|BEHAVIORAL|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
214344605|NCT05209282|OTHER|Conventional physiotherapy program|Individuals in this group will only receive a conventional physiotherapy program.
214344606|NCT03236103|OTHER|Clinical Recommendations|"The clinical recommendations will regard the following:~1. Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Optimizing hemodynamics (Mean arterial BP\>65mmHg)~5. Assessment of kidney function with serum creatinine and/or cystatin C~None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice."
214344607|NCT02078284|BIOLOGICAL|CPP|One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
214344608|NCT02078284|BIOLOGICAL|LSP|
214952390|NCT00478088|DEVICE|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
214952391|NCT01218971|DRUG|Medisorb naltrexone 190 mg|naltrexone for extended-release injectable suspension
214952392|NCT01218971|DRUG|Medisorb naltrexone 380 mg|naltrexone for extended-release injectable suspension
214952393|NCT06862375|BEHAVIORAL|Mayo Clinic Diet|"Subjects will utilize their choice of the following resources for 12 weeks:~* Mayo Clinic Diet book, 3rd Edition~* Digital Wellness app subscription~* Both the Mayo Clinic Diet book and Digital Wellness app"
214952394|NCT06862375|BEHAVIORAL|Usual Care|Subjects will be given the 'Eat Well Use the Plate' informational hand-out, as well as a list of food, physical activity and weight tracking apps to be utilized as resources for self-monitoring .
214952395|NCT06863298|OTHER|Podcast|A podcast is content that can be listened to on any digital audio listening device, including a computer, that supports audio file playback.
214952396|NCT03406000|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection"
214952397|NCT01846806|OTHER|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
214952398|NCT00572975|OTHER|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|"Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1"
214952399|NCT00268684|DRUG|Erlotinib, Temozolomide|
214952400|NCT03813641|DRUG|Raltitrexed|Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
214952401|NCT03813641|DRUG|Capecitabine|Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
214486619|NCT06403995|BEHAVIORAL|Recommended, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
214952402|NCT03581617|DIAGNOSTIC_TEST|NK cell analysis|"We selected to perform the study during the proliferative phase (day 9-11), where only resident eNK cells are present in the endometrium. The samples will be analyzed with the following methods, that are routinely used in the OUs of the proposal:~\- pNK cell analysis: PBMCs will be purified with Ficoll solution and NK cells will be analyzed by flow cytometry (FacsVantage, BD) with anti-CD56, CD16, CD9, CD49a, KIRs, LILRB1, LILRB2, CD94, CD107a eNK cell analysis: eNK cells will be obtained from endometrial biopsies during proliferative phase, determined by ultrasound scan and analyzed for NK cell subtypes and KIRs, LILRB1, LILRB2, CD94, CD107a expression by flow cytometry"
214952403|NCT03581617|DIAGNOSTIC_TEST|Herpesvirus detection|Herpesvirus detection: DNA will be analyzed by specific primers for HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-7, VZV, and HHV-8, with PCR and nested PCR
214952404|NCT03581617|DIAGNOSTIC_TEST|sHLA-G analysis|sHLA-G analysis: sHLA-G quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-G (G233) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
214952405|NCT03581617|DIAGNOSTIC_TEST|HLA-G 14bp INS/DEL typing|Genomic DNA will be genotyped by RealTime PCR
214952406|NCT03581617|DIAGNOSTIC_TEST|sHLA-E analysis|sHLA-E analysis: sHLA-E quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-E (3D12, eBioscience) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
214952407|NCT06616246|BEHAVIORAL|HealthyLifetime|HealthyLifetimeTM \[HL\] seeks to intervene early in the aging process when individuals have the best chance for longer-term benefits of changing their health behavior, staving off functional decline, and minimizing the onset or exacerbation of chronic conditions.
214952408|NCT04660773|DEVICE|NB UVB phototherapy|ultraviolet phototherapy sessions
214952409|NCT04660773|DRUG|Pregabalin|oral medication
214952410|NCT00347594|DEVICE|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
214952411|NCT00347594|DEVICE|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
214952412|NCT03979183|BEHAVIORAL|Lumbopelvic, stretching, aerobic and relaxation exercises|Intervention program will comprises brisk walks and small choreographies, global and analytical stretching exercises, as well as lumbopelvic stabilization exercises (with intensity and volume progression)
214952413|NCT05006846|OTHER|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
214952414|NCT03289806|PROCEDURE|Samples of fibroblasts from Tenon's capsule|
214952415|NCT01926197|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
214952416|NCT01926197|DRUG|Irinotecan|Irinotecan 180 mg/m² IV over 90 minutes on Day 1 of a 14-day cycle.
214952417|NCT01926197|DRUG|Leucovorin|Leucovorin 400 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
215076721|NCT01915121|BEHAVIORAL|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
215076722|NCT06411977|DIETARY_SUPPLEMENT|Vegetable juice|Vegetable juice (Fa. Fitrabbit, Voglsam)
214952418|NCT01926197|DRUG|5FU|5FU 2,400 mg/m² IV over 46 to 48 hours starting on Day 1 of a 14-day cycle.
214952419|NCT01926197|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Radiotherapy treatment starting about 8 weeks after modified FOLFIRINOX induction chemotherapy, administered as 5 fractions of 8 Grey (Gy) each, on 5 separate days.
214952420|NCT02570035|DRUG|Mirabegron|oral
214952421|NCT07007598|DEVICE|Hemostatic clip|The hemostatic clip is endoscopically applied after a colorectal polypectomy to close the mucosal defect.
214952422|NCT07006558|DIETARY_SUPPLEMENT|Diamino Oxidase|The investigational product is a dehydrated power of DAO enzyme from green pea (Pisum sativum L.) sprouts (adiDAO®Veg, DR Healthcare, S.L.U., Barcelona, Spain), with an enzymatic activity \> 298 mU/g (\> 14,500 kHDU/g).
214952423|NCT05776914|BIOLOGICAL|Donor Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
215076723|NCT05350228|DIAGNOSTIC_TEST|CNN based model|It is an automatic detector model based on convolution neural network created by computer science expert
214344609|NCT05409443|PROCEDURE|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"* Electrodes are positioned along the lateral sacral crest lateral to the inflection points of the S1, S2 and S3 lateral foraminal walls along first to third transverse sacral tubercles maintaining a craniocaudal line with an interelectrode distance of no more than 15mm.~* The appropriate locations are confirmed in both AP and lateral views and the tines are deployed. Following injection of lidocaine, lesions are performed at 85 degrees Celsius for 180 seconds at each site for bipolar sites and 80 degrees Celsius for 90 seconds for the monopolar site. Following ablation, the tines are retracted for all electrodes prior to removal."
214344610|NCT05409443|PROCEDURE|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|"* To target the L4 medial branch and L5 dorsal ramus, an electrode will be placed in parallel between the junction of the L5 transverse process and superior articular process and the sacral ala and S1 superior articular process.~* A periforaminal electrode position will be used to target the lateral branches from S1 to S3. An 22-G cannula with a 5-mm exposed tip will be directed to a location approximately 3-5mm lateral to the PSFA of S1, S2, and S3. The analog clock positions for the probes at S1 and S2 levels will be 1:00, 3:00, and 5:30 on the right, and 6:30, 9:00, and 11:00 on the left. For the S3 level the positions at 1:30 and 4:30 on the right, and 7:30 and 10:30 on the left will be used (6,18).~* The appropriate locations are confirmed in both AP and lateral views. Following injection of lidocaine, monopolar RFA is performed for 90 seconds at 80 degrees Celsius at each location."
214344611|NCT05201157|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch
214344612|NCT05201157|OTHER|Control Group|No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
214344613|NCT02565641|DRUG|Capecitabine|Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).
214344614|NCT02565641|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m\^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
214344615|NCT01260246|DRUG|sitagliptin|pill, 100mg/daily for 6 months
214344616|NCT01260246|DRUG|placebo|placebo match for 6 months
214344617|NCT00096135|BIOLOGICAL|filgrastim|given subcutaneously (SC)
214952424|NCT05776914|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
214952425|NCT07009184|DRUG|[111In]In-DOTA-TCO-trastuzumab|\[111In\]In-DOTA-TCO-trastuzumab is a chemically cleavable \[111In\]In-labeled trastuzumab conjugate that is administered first to the patient, it accumulates in HER2-positive tumors and internalizes in HER2-expressing tumor cells.
214952426|NCT07009184|DRUG|Small molecule tetrazine trigger component|TRG001 is a small molecule tetrazine trigger that reacts with \[111In\]In-TGW211-DC in blood and extracellular space thus releasing a fast clearing \[111In\]In-DOTA containing fragment which is rapidly eliminated via the kidney. Because of its non-cell permeable nature, TRG001 does not reach \[111In\]In-TGW211-DC inside tumor cells and therefore the radioactivity inside tumor cells is retained by the tumor.
215076724|NCT07034911|DRUG|Ketalar|women receiving sub-anesthetic dose of ketamine of 0.5 mg/kg IV bolus in 3 ml of normal saline.
215076725|NCT07034911|DRUG|Ephedrine|women receiving bolus of 15mg of ephedrine
214344618|NCT00096135|DRUG|cyclophosphamide|IV over 15-30 minutes
214344619|NCT00096135|DRUG|cytarabine|IV over 3 hours twice daily
214344620|NCT00096135|DRUG|daunorubicin hydrochloride|IV over 15 minutes
214344621|NCT00096135|DRUG|dexamethasone|oral twice daily
214952427|NCT07007104|BEHAVIORAL|Mindful Eating Intervention|The mindful eating intervention consisted of six structured group sessions delivered over a six-week period, each lasting approximately 60-90 minutes. The sessions were led by a registered dietitian certified in both Mindful Eating (The Center of Mindful Eating, EatRight Certified, 2023) and Mindfulness-Based Eating Awareness Training (MB-EAT, 2019). The curriculum was designed to improve participants' awareness of hunger and satiety cues, reduce emotional eating, enhance eating satisfaction, and foster non-judgmental eating practices. Each session incorporated guided mindfulness practices, cognitive-behavioral techniques, and experiential activities such as sensory-focused eating. The intervention was provided in addition to standard post-treatment care, which included nutritional counseling by an oncology dietitian.
215076726|NCT07032428|DEVICE|A new non-invasive brain stimulation tool|kTMP is a magnetic induction method that delivers continuous kHz-frequency cortical electric fields (E-fields) which may be amplitude-modulated to potentially mimic electrical activity at endogenous frequencies which will be tested on anhedonia patients in this study.
215076727|NCT07032428|DEVICE|A new non-invasive brain stimulation tool with sham setting selected|This device will counterbalance the active kTMP conditions
215076728|NCT05708638|OTHER|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
215076729|NCT05708638|OTHER|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
214344622|NCT00096135|DRUG|etoposide|IV over 1 hour
214344623|NCT00096135|DRUG|leucovorin calcium|rescue IV over 24 hours
214344624|NCT00096135|DRUG|mercaptopurine|oral
214344625|NCT00096135|DRUG|methotrexate|intramuscularly (IM)
214344626|NCT00096135|DRUG|pegaspargase|intramuscularly (IM)
214344627|NCT00096135|DRUG|therapeutic hydrocortisone|
214344628|NCT00096135|DRUG|vincristine sulfate|given IV
214952428|NCT07007104|BEHAVIORAL|Oncology Nutrition Counseling|Participants in this group received individualized nutrition counseling and education from a registered oncology dietitian as part of standard post-treatment care for breast cancer survivors. The counseling focused on balanced eating, long-term weight management, and general lifestyle guidance based on survivorship needs. No additional behavioral or mindful eating interventions were delivered.
214344629|NCT00096135|RADIATION|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
214344630|NCT00107419|DRUG|pemetrexed disodium|pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
214344631|NCT03867331|BIOLOGICAL|5 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
214344632|NCT03867331|BIOLOGICAL|15 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
214344633|NCT03867331|BIOLOGICAL|30 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
214952429|NCT03884985|OTHER|Visual stimulation|In the experiments, participants will sit in front of a computer monitor located a less than a meter of distance and will analyze the content of images extracted from collections of natural and computer-generated scenes. Subjects will be asked to report verbally or by pressing keys on a keyboard on image characteristics such as the locations of the objects present in the scenes, their number and/or their identities. Some experiments will involve a search paradigm in which subjects will have to report on the location and/or fine characteristics of a target element among a field of distracting similar elements, and/or visual discrimination tasks. The duration of the interval of time in which the image is maintained on the screen may be varied between few tens of milliseconds to several seconds. In a set of experiments, the eye movements performed by the subjects during the execution of the visual tasks will be recorded as explained below.
214952430|NCT06645821|DRUG|EVO101|EVO101 topical cream 0.1%
214952431|NCT05960149|DRUG|using Indocyanine Green|Nerve-sparing robot-assisted laparoscopic radical prostatectomy using Indocyanine Green
214952432|NCT05960149|PROCEDURE|Nerve-sparing robot-assisted laparoscopic radical prostatectomy|Nerve-sparing robot-assisted laparoscopic radical prostatectomy without the use of Indocyanine Green
214952433|NCT01781052|DRUG|Ventavis (Iloprost, BAYQ6256)|Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
214952434|NCT03609957|OTHER|Aerobic Exercise Training|Traditional, continuous aerobic exercise (cycling) at a moderate intensity
214952435|NCT03609957|OTHER|Interval Training|High-intensity interval exercise consisting of short bursts of exercise interspersed with rest periods
214344634|NCT03867331|OTHER|Plasmodium falciparum challenge|Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
214344635|NCT00004181|DRUG|busulfan|
214344636|NCT00004181|DRUG|cyclophosphamide|
214344637|NCT00004181|PROCEDURE|allogeneic bone marrow transplantation|
214344638|NCT00004181|RADIATION|radiation therapy|
214344639|NCT04725721|BEHAVIORAL|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
214952436|NCT04320953|DEVICE|Non-contact MCE system|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.
215076730|NCT03628144|DIETARY_SUPPLEMENT|Impact® Advanced Recovery|The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
215076731|NCT03628144|DIETARY_SUPPLEMENT|Boost® High Protein|The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
214344640|NCT04725721|BEHAVIORAL|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
214344641|NCT06059196|BEHAVIORAL|ARCHES (Addressing Reproductive Coercion in Health Settings)|ARCHES (Addressing Reproductive Coercion in Health Settings) includes training existing contraceptive providers to (1) provide contraceptive clients with education on reproductive coercion and methods/ways to use contraceptive methods covertly if desired, (2) provide screening for reproductive coercion and intimate partner violence, (3) provide a referral to specialized services for those disclosing intimate partner violence, (4) and offer a palm-sized mini-booklet with educational information on reproductive coercion and intimate partner violence. A mobile application was developed to guide contraceptive providers through the counselling protocol.
214344642|NCT06059196|BEHAVIORAL|BCS+ (Balanced Counseling Strategy Plus)|BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
214344643|NCT05706727|DRUG|Intravenous bolus dose of Mephentermine and mephentermine|intravenous bolus dose of mephenteramine 6mg
214344644|NCT05706727|DRUG|intravenous bolus dose of phenylephrine 50 mcg|intravenous bolus dose of phenylephrine 50 mcg
214344645|NCT03473886|BEHAVIORAL|Intervention arm: PP-MI|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
214344646|NCT00595244|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
214952437|NCT06338215|BEHAVIORAL|Moderate Alcohol Drinking Pattern|"Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~1. moderate consumption (7 or less drinks/wk for women, 14 or less drinks/wk for men) of red wine (a drink=150 ml).~2. always during meals~3. spread out throughout the whole week, and~4. avoidance of binge-drinking episodes. No participant will be invited to start or increase his/her alcohol intake."
214952438|NCT06338215|BEHAVIORAL|Abstention|"Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~Abstention. Message of 0 alcohol."
214952439|NCT04006522|DRUG|89Zr-DFO-Atezolizumab|89Zr-DFO-Atezolizumab infusion
214952440|NCT04006522|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.
214952441|NCT07012577|OTHER|GPT-4 Assessment|Diagnostic/Prognostic evaluation of any single case provided by AI (GPT-4). GPT-4 provides diagnosis/treatment recommendations via standardized prompts
214952442|NCT07012577|OTHER|Arthroplasty Fellow Assessment|Diagnostic/Prognostic evaluation of any single case provided by an human expert
214952443|NCT07012577|OTHER|Specializing Resident (4th year) Assessment|Diagnostic/Prognostic evaluation of any single case provided by an human expert
214952444|NCT07012577|OTHER|Junior Resident (3rd year) Assessment|Diagnostic/Prognostic evaluation of any single case provided by an human expert
214952445|NCT07016594|BEHAVIORAL|Aerobic exercise|Aerobic exercise was done with and without neuromuscular electrical stimulation
214952446|NCT02470663|DIETARY_SUPPLEMENT|DENSITYTM caplets (marketed as Amorphical)|supplementation
214952447|NCT02470663|DIETARY_SUPPLEMENT|Calcium carbonate 600 mg once daily|supplementation
214952448|NCT02425202|DRUG|Ketamine|Post-operative continuous infusion until 0600 the next day
214952449|NCT02425202|OTHER|Saline infusion|Post-operative continuous infusion until 0600 the next day
214952450|NCT07020637|DEVICE|Cheetah NICOM|Bioreactance-based noninvasive cardiac output monitoring device used to measure stroke volume before and after passive leg raising. Used solely for observational measurement. No therapeutic intervention is performed.
214952451|NCT07018232|BEHAVIORAL|Unplanned healthcare encounter|Patient needing to connect with healthcare to fill a medication gap
214952452|NCT07023146|DEVICE|Moderate to high intensity (PTMH; 65-80% of 1-repetition maximum [1RM]) )|Power training performed at maximum velocity in the concentric phase with moderate to high intensity
214952453|NCT07023146|DEVICE|low to moderate intensity (PTLM; 40-60% of 1-repetition maximum [1RM])|Power training performed at maximum velocity in the concentric phase with lower to moderate intensity
214952454|NCT07027358|DEVICE|NETSmart software|Use of NETSmart software by healthcare professionals
214952455|NCT06632678|OTHER|behavior, procedure, diet, exercise, device, education, and any other|Any type of intervention except pharmacological interventions (drugs, biologicals, genetics)
214344647|NCT05436782|OTHER|core strengthening exercises|•Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval
214344648|NCT05436782|OTHER|Routine physical therapy|•Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
215076732|NCT03628144|RADIATION|Radiation Therapy|Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
214344649|NCT02621762|DEVICE|Magnesium|Magnesium in dialysate increased
214344650|NCT02621762|DEVICE|Bicarbonate|Bicarbonate in dialysate increased
214952456|NCT03576352|OTHER|a rapid sequence tracheostomy (RST) on rabbit cadaver|"The Rapid Sequence Tracheostomy (RST) consists of the following steps:~1. Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~2. Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~3. Perform a vertical puncture with a tip scissors between the Cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~4. An age adapted tracheal tube is inserted into the trachea and the lungs are ventilated."
214952457|NCT01483599|DRUG|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
214952458|NCT01483599|DRUG|CNTO 1959 (15 mg)|SC injections
215076733|NCT03628144|DRUG|Chemotherapy|Standard of Care: Chemotherapy as already planned for each participant.
214952459|NCT01483599|DRUG|CNTO 1959 (50 mg)|SC injections
214952460|NCT01483599|DRUG|CNTO 1959 (100 mg)|SC injections
214952461|NCT01483599|DRUG|CNTO 1959 (200 mg)|SC injections
214344651|NCT03524222|OTHER|Home Hospitalization|See above
214344652|NCT01568047|DRUG|Placebo|once-daily
214344653|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
214344654|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
214344655|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
214344656|NCT01568047|DRUG|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
214344657|NCT01568047|DRUG|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
214952462|NCT01483599|DRUG|Adalimumab|SC injections
214952463|NCT01483599|DRUG|Placebo|SC injections
214952464|NCT01072747|BIOLOGICAL|bovine heparin|5.000UI/mL bottle with 5mL
214952465|NCT01072747|BIOLOGICAL|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
214952466|NCT02254798|OTHER|no intervention|this is a non interventional study
214952467|NCT04337476|DEVICE|The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention|Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.
214952468|NCT00495989|PROCEDURE|saliva sampling + dental calculus collection|
214952469|NCT02175329|DEVICE|CAD/CAM Veneering|CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer
214952470|NCT02175329|DEVICE|Manually layered veneering|
214952471|NCT01160380|DRUG|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
214952472|NCT01160380|DRUG|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
214952473|NCT02851212|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
214952474|NCT02851212|DRUG|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
214952475|NCT02851212|DRUG|Canagliflozin|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
214952476|NCT02851212|DRUG|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
214344658|NCT02961972|DIETARY_SUPPLEMENT|monohydrate and micronized creatine|oral supplementation with creatine
214344659|NCT02961972|OTHER|placebo|oral supplementation with maltodextrin (control group)
214344660|NCT02124642|DIETARY_SUPPLEMENT|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
214344661|NCT02124642|DIETARY_SUPPLEMENT|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
214344662|NCT01663493|PROCEDURE|FNB|
214344663|NCT00561223|DRUG|iloprost Inhalation|inhale 2.5 mg, repeat times one
214344664|NCT00561223|DRUG|iloprost|inhaled 2.5 mg, repeat times one
214344665|NCT03874676|OTHER|PEACE Rounds|PEACE Rounds are a routine process for providing self help to clinicians who care for difficult patients from the perspective of ethics and the need for cross-disciplinary communication. PEACE Rounds participants will be interviewed about how they experience the rounds and for their perspective on the effects on their own wellness and resilience.
214952477|NCT04798326|DRUG|MW032|Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.
214952478|NCT04798326|DRUG|Xgeva®|Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.
214952479|NCT02524626|PROCEDURE|Sham stimulation|Sham stimulation
214952480|NCT02524626|PROCEDURE|Vagus stimulation|Vagus stimulation
214952481|NCT02510820|DEVICE|comfilcon A|soft contact lens
214344666|NCT03779529|DIETARY_SUPPLEMENT|Olive oil|Intervention includes dosage and amount of biophenols administered daily
214952482|NCT02510820|DEVICE|Synergi|Multipurpose solution
214952483|NCT02510820|DEVICE|Biotrue|Multipurpose solution
214952484|NCT02510820|OTHER|stenfilcon A|daily disposable contact lenses for washout period
214952485|NCT01512433|PROCEDURE|Ture acupuncture|Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
214952486|NCT01512433|PROCEDURE|Sham acupuncture|"The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling."
214952487|NCT03046056|DRUG|Filgotinib|Tablet(s) administered orally once daily
214952488|NCT03046056|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
214952489|NCT03001245|BEHAVIORAL|Interpersonal Counseling|Interpersonal Counseling 1+6 sessions
214952490|NCT03001245|BEHAVIORAL|Standard treatment|Psychosocial treatment 1+6 sessions guided by the professional's standard professional principles and routinely available methods
214952491|NCT01282333|DRUG|gemcitabine hydrochloride|Given IV
214952492|NCT01282333|DRUG|veliparib|Given orally
214952493|NCT01282333|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214952494|NCT01282333|OTHER|pharmacological study|Correlative studies
214952495|NCT01282333|DRUG|cisplatin|Given IV
214952496|NCT05683951|DRUG|DWKH|Administration of DWKH three times daily
214952497|NCT05683951|DRUG|DWKH-R|Administration of DWKH-R three times daily
214952498|NCT05683951|DRUG|Placebo|Administration of Placebo three times daily
214952499|NCT02874833|OTHER|Exercise|After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
214952500|NCT00500253|DEVICE|exhaled nitric oxide measurement|exhaled nitric oxide measurement
214952501|NCT00500253|PROCEDURE|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
214952502|NCT00500253|PROCEDURE|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
215076734|NCT03628144|OTHER|Quality of life (EORTC-QLQ-30)|Participants will undergo pre- and post-treatment assessments.
215076735|NCT03628144|OTHER|Evaluation of Cognitive Function (FACT-Cog, v. 3.0)|Participants will undergo pre- and post-treatment assessments.
215076736|NCT03628144|OTHER|Mindfulness Questionnaire (FFMQ)|Participants will undergo pre- and post-treatment assessments.
215076737|NCT02445677|DEVICE|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
215076738|NCT02445677|DEVICE|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
215076739|NCT03180437|PROCEDURE|IRE surgery|IRE surgery will be used in local tumor
215076740|NCT03180437|BIOLOGICAL|IRE plus γδ T cells|Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer
215076741|NCT06805396|BEHAVIORAL|Palliative Care Consult|Patients receive a regular consult (30-45 min) with the hospital palliative care consult team (PCCT) that is tailored to the preferences and needs of the individual patient. The following topics can be discussed: 1) physical symptoms, and, where appropriate, followed by recommendations for symptom management and transfer of handovers to the treating care team, 2) psychological, social and spiritual distress, followed by provision of counseling or referral to another specialist if needed, 3) goals of care to explore participants' values, preferences and needs (advance care planning), and 4) discussion about the needed follow-up of palliative care, and 5) care for caregivers. At baseline, patients receive a validated symptom questionnaire (Utrecht Symptom Diary (USD)-4D), which can be used as input for discussion during the consultation. If necessary, patients may have a follow up.
215076742|NCT06891469|DIETARY_SUPPLEMENT|Caffeine administration according to body mass (moderate intake- 7 mg/kg)|This randomized, double-blind, crossover study aimed to investigate the acute effects of caffeine consumption on physiological responses and performance during a strength-focused CrossFit workout. Participants will consume either anhydrous caffeine (7.1 ± 0.7 mg/kg of body mass) or placebo, 60 minutes before a CrossFit workout aiming to perform as many repetitions as possible.
214344667|NCT01465490|BEHAVIORAL|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
214344668|NCT03640910|DEVICE|OT Equators® (Rhein83)|Attachment systems to retain an implant overdenture
214344669|NCT03640910|DEVICE|Locator® (Zest)|Attachment systems to retain an implant overdenture
214952503|NCT06320353|DRUG|RPH-075|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
214952504|NCT06320353|DRUG|Keytruda®|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
214952505|NCT03492905|BEHAVIORAL|Internet-based Cognitive Behaviour Therapy (iCBT)|Guided self-help for 7 weeks. Contact with therapist 2 times per week.
214952506|NCT02913105|DRUG|LMB763|Hard Gelatin Capsules
214952507|NCT02913105|DRUG|Placebo|Hard Gelatin Capsule
214952508|NCT00543998|DEVICE|Optical Measurement transillumination|Optical Measurement of sinus
214952509|NCT02924805|OTHER|Telemedical care|Telemedically guided care based on a standard operating procedure
214952510|NCT00202891|DRUG|sisomicin|
214952511|NCT01317004|DRUG|Fingolimod|0.5 mg/day oral capsule
214952512|NCT01317004|DRUG|Standard MS DMT|Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
214952513|NCT03370692|OTHER|Cognitive assesment, Frailty assessment|Asking relatives (using a structured questionaire) about cognitive function at admission , likewise about frailty using the Clinical Frailty Score
215076743|NCT06891469|DIETARY_SUPPLEMENT|Placebo (Biotin Capsules)|Consumption of biotin (BIOTIN tablets by Myprotein) at the same time as caffeine.
214952514|NCT00818740|DRUG|ORM-12741|i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
214952515|NCT02727309|DRUG|Apatinib|Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
214952516|NCT00768573|DRUG|sildenafil|Oral suspension of sildenafil.
214952517|NCT04645329|DEVICE|shoulder immovilization sling|immobilization of the arm after surgery
214952518|NCT04409977|DIAGNOSTIC_TEST|MRI examination|Patient will be scanned in the MRI twice, once at noon (+/- 1 hour), once at 1 a.m. (+/- 1 hour). The investigators will search for any changes in functional connectivity, particular regarding the connection between the hypothalamus and pain-processing networks.
214952519|NCT02092649|DIETARY_SUPPLEMENT|Omega-3 Complete|
214952520|NCT02092649|DIETARY_SUPPLEMENT|Placebo Pill|
214952521|NCT01526278|DRUG|Maxmarvil®|Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
214952522|NCT00300846|DRUG|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
214952523|NCT00300846|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
214952524|NCT04067596|PROCEDURE|epiphysiodesis|"The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase."
214952525|NCT04835883|BIOLOGICAL|CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)|Two intravenous infusions of CS20AT04 (2.0×10\^6cell/kg), on 0 day and on 12 weeks The target population of this study is subjects in South Korea with a diagnosis of either lupus nephritis or lupus cytopenia.
215076744|NCT06896396|DRUG|Lenvatinib, Pembrolizumab|Pabilizumab: intravenously every three weeks Lenvatinib, with a dosage based on body weight: 8 mg (≤60 kg) or 12 mg (\>60 kg), once daily
215076745|NCT06896396|DRUG|Icaritin soft capsules|Starting 3-5 days after the first TACE treatment, take 6 capsules orally, twice a day, and swallow them with warm water within 30 minutes after breakfast and dinner
214344670|NCT06066112|DRUG|Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.|Randomly assign to TR or RT sequence groups based on a predetermined random table and receive the corresponding study drug according to the corresponding administration sequence.
214344671|NCT02962830|DRUG|Sufentanil|intra-amniotic injection of 10 micrograms of Sufentanil
214344672|NCT00874029|DEVICE|Halt Procedure|The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
214344673|NCT02992639|BEHAVIORAL|Control group|The participants who included in control group did not receive any treatment.
214344674|NCT02992639|BEHAVIORAL|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
214952526|NCT04664907|OTHER|Videomusic listening|Patients will attend a 8 min videomusic session and questionnaires will be performed before and after this session.
214952527|NCT03092947|OTHER|No intervention|
214952528|NCT00264251|BEHAVIORAL|Weight loss through diet and exercise|
214952529|NCT00264251|DRUG|Rosiglitazone insulin sensitizing agent|
214952530|NCT00640731|DEVICE|OmniWave Endovascular System|Treatment with mechanical thrombolysis/thrombectomy
214952531|NCT01533948|DRUG|axitinib|Given PO
214952532|NCT01533948|OTHER|laboratory biomarker analysis|Correlative studies
214952533|NCT01156909|DRUG|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
214952534|NCT06478082|DEVICE|Home-based virtual reality training|8-week training with an advised frequency of 30 minutes per day, for 5 days per week.
214952535|NCT03726801|OTHER|HEALTH EDUCATION|"The nursing intervention prior to surgery: (breast and colon cancer):~1. First phase: At first these subjects suffered a great emotional impact after knowing the diagnosis, which could generate intense anxiety reactions.~2. Second phase or phase of coping, in which they begin to be aware of their illness and the future changes they will suffer in their body. In this phase they react with fear, anger, anger, denial, ...~3. Third phase or phase of adaptation to the new situation, where there is a decrease in previous emotional reactions, the patient being able to start up the resources learned to reduce their psychological discomfort."
214952536|NCT01212146|DIETARY_SUPPLEMENT|Lactobacillus paracasei IMPC 2.1 LMGP22043|participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10\^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10\^10 CFU.
215076746|NCT06896396|PROCEDURE|TACE|TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2023 Edition).
214344675|NCT03359096|DEVICE|Therapeutic HGNS|Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
214952537|NCT01212146|DIETARY_SUPPLEMENT|Ordinary artichokes|Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
214952538|NCT01221558|DIETARY_SUPPLEMENT|lycopene|
214952539|NCT02664064|BEHAVIORAL|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
214344676|NCT03359096|DEVICE|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds"
214952540|NCT01344759|DRUG|Dexmedetomidine|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
214344677|NCT06312839|OTHER|Collecting data from the medical record|"Collecting data from the medical record:~* Gastroepiploic artery diameter before and after ischaemic preconditioning~* Postoperative mortality~* Complications related to embolisation and surgery~* Length of stay in intensive care unit and total length of hospital stay"
214952541|NCT01344759|DRUG|Propofol|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
214952542|NCT01153009|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
214952543|NCT01153009|DRUG|Duloxetine|Overencapsulated duloxetine delayed-release capsules
214952544|NCT01153009|DRUG|Placebo|Placebo-matching capsules
214952545|NCT00347230|DEVICE|Intacs intracorneal ring insertion for the treatment of keratoconus|
214952546|NCT05331105|DRUG|HL-085|"IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen."
214952547|NCT01856998|DRUG|Propofol|
214952548|NCT01856998|DRUG|Diprivan|
214344678|NCT04937374|OTHER|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast.
214678400|NCT03626051|DEVICE|Fibular tape|This taping method used a rigid strapping tape to reinforce a posterior-superior mobilisation of the distal fibula. Tension was applied on the tape in a posterior and superior direction. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
214952549|NCT05488951|OTHER|Otago Exercise Program|The Otago Exercise Program will be led by a physical therapist in a group setting (5-7 participants/exercise class). The exercise will be 20 min of walking and 30 min of strength and balance exercises (i.e., 50 min exercise class) 3x/week for 6 months. The physical therapist will select suitable exercises for each participant, such that the exercise is individualized and progressive.
214952550|NCT05788484|DRUG|CDX-585|CDX-585 is administered by infusion every 2 weeks
214952551|NCT00034047|PROCEDURE|Acupuncture|
214952552|NCT00034047|DRUG|Chinese Products|
214952553|NCT00034047|DRUG|Nafarelin|
214952554|NCT04723589|BIOLOGICAL|Thawed plasma|"Plasma not labeled convalescent plasma is presumed to be free of COVID antibodies, but is not tested for antibodies. To ensure that we are using antibody-free plasma, we will test each unit of plasma with a quick COVID test before it is utilized in this study."
214952555|NCT04444336|BEHAVIORAL|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms
214952556|NCT00910117|DRUG|nimotuzumab|nimotuzumab 400 mg d1
214952557|NCT00910117|DRUG|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
214952558|NCT01342783|GENETIC|DNA analysis|
214344679|NCT04937374|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast.
214344680|NCT05893108|DRUG|Ethosomal gel bearing losartan 5%|A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%
214344681|NCT05893108|DRUG|triamcinolone acetonide 10 mg/ml|intralesional injection
214678401|NCT02870452|BEHAVIORAL|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
214952559|NCT01342783|GENETIC|RNA analysis|
214952560|NCT01342783|GENETIC|mutation analysis|
214952561|NCT01342783|GENETIC|nucleic acid sequencing|
214952562|NCT01342783|OTHER|laboratory biomarker analysis|
214952563|NCT03454386|BEHAVIORAL|Stress Management and Resilience Training Program|"This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives."
214952564|NCT03454386|BEHAVIORAL|Self-Management Stress Reduction Program|Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
214344682|NCT00856583|DRUG|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
214952565|NCT03151083|BEHAVIORAL|Internet-based Self-help Insomnia Intervention|The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
214952566|NCT04003623|DRUG|Pemigatinib|Pemigatinib administered orally once daily.
214344683|NCT00856583|DRUG|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
214952567|NCT01469598|DRUG|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
214952568|NCT00623298|BEHAVIORAL|Narrative Exposure Therapy|
214952569|NCT00623298|BEHAVIORAL|group IPT|
214952570|NCT00623298|OTHER|6 months-baseline|
214952571|NCT02918097|DRUG|Lithium Carbonate|
214952572|NCT02918097|DRUG|Sertraline|
214952573|NCT02918097|DRUG|Nortriptyline|
214952574|NCT02918097|DRUG|Risperidone|
214952575|NCT02116725|OTHER|Shower gel with zinc|Standard shower gel (Sanex) supplemented with zinc sulfate.
214952576|NCT02116725|OTHER|Plain shower gel|Standard shower gel (Sanex).
215076747|NCT06641713|PROCEDURE|TACE|TACE was carried out under the guidance of digital subtraction angiography, and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The emulsion of the selected drug and the embolization agents was therefore injected infused into tumor-feeding arteries via the selective microcatheter. A final arteriography confirmed the success of the procedure. The endpoint of the TACE procedure was reached when there was no flow in the tumor-feeding vessels.
214344684|NCT04327414|BEHAVIORAL|Intervention group|Standing desks
214344685|NCT01084044|DRUG|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
214344686|NCT02287103|OTHER|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
214952577|NCT02116725|OTHER|Distilled water|Sterile distilled Water.
214952578|NCT04854941|OTHER|Probiotics|Probiotics (10\^9 CFU of each strain: Lactobacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301) 3 times per day in addition to standard treatment regimen for 2 weeks
214952579|NCT00703326|BIOLOGICAL|ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
214952580|NCT00703326|DRUG|docetaxel|Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
214952581|NCT00703326|OTHER|Placebo|Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
214952582|NCT02076347|BEHAVIORAL|Office visit intervention|Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit
214952583|NCT02076347|BEHAVIORAL|Electronic Message Intervention|Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
214952584|NCT02961387|DEVICE|Hydrogen generator treatment|The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
214952585|NCT02961387|DEVICE|Oxygen-making machine treatment|The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
214344687|NCT02287103|OTHER|Eating Breakfast|YesB: will eat all three meals
214952586|NCT05964439|DEVICE|HoloUS app for ultrasound visualization|Study participants will wear HoloLens see-through glasses and use the HoloUS app for ultrasound visualization in the conduct of a vascular access procedure in a phantom.
214344688|NCT06529497|DRUG|Racecadotril|The intervention group will receive racecadotril+ORS+Zinc
214952587|NCT00063297|DRUG|R209130|
214952588|NCT02242019|DEVICE|Erchonia LUNULA|The Erchonia LUNULA is administered to the infected toes for 12 minutes per treatment for 4 treatments, each treatment one week apart.
214952589|NCT02425462|DRUG|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
214952590|NCT04316260|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
214952591|NCT04316260|BEHAVIORAL|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
215076748|NCT06641713|PROCEDURE|HAIC|HAIC was carried out under the guidance of digital subtraction angiography, 990and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
215076749|NCT06180629|BEHAVIORAL|Music conset|The music modes to be used (Rast and Hüseyni), classical music, nature music, and listening time of 20-30 minutes were determined by taking expert opinion from a faculty member from the Conservatory department and by reviewing the literature. The researcher asked the patients to choose the music genres. After each patient decided on the music they wanted to listen to, the researcher recorded the selected music genres on their smartphones. The music playback application was played to the patients in the experimental group for 20-25 minutes in each session for 4 sessions, i.e. 4 times in total, once a week for a month, until the end of one course. During each session, the patients listened to the music genre they had chosen each week.
215076750|NCT06180629|OTHER|normal treatment routine|normal treatment routine
215076751|NCT03532854|DRUG|Valsartan|Valsartan P.O
215076752|NCT03532854|DRUG|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin P.O
215076753|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
215076754|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
215076755|NCT05694312|DRUG|Ibrutinib 420 mg|Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
215076756|NCT03757650|DRUG|Bismuth Subsalicylate|omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
214344689|NCT00439959|DRUG|GSK625433/placebo|
214344690|NCT05520905|OTHER|TelePrEP|HIV pre-exposure prophylaxis delivered via telemedicine.
214344691|NCT04880759|OTHER|bike desks in the classroom|Children will use bike desks for 13 weeks during school time
214344692|NCT03020420|OTHER|Cicatricell Cream|Cream to be applied 2 times a day for 8weeks to 6 months
214344693|NCT02291718|DRUG|Isovue|iodine contrast
214678402|NCT02870452|BEHAVIORAL|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
214952592|NCT06427629|DEVICE|Imaging of conjunctival goblet cell|After instillation of moxifloxacin and illuminating with a 405nm light source using confocal fluorescence microscopy, conjunctival goblet cell imaging will be performed in patients with ocular surface disease and patients scheduled for ocular surgery without ocular surface disease
214952593|NCT01190189|BIOLOGICAL|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
214952594|NCT00708474|DEVICE|OsseoFit™ Porous Tissue Matrix™|Bone void filler
214952595|NCT05727748|OTHER|Multimodal exercise with augmented reality|The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group with augmented reality was divided into 4 sub-groups. The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.
215076757|NCT03900858|DRUG|Isoniazid；Rifapentine|1 months (12 doses) of three-weekly rifapentine at a dose of 450mg plus isoniazid at a dose of 400mg given under direct observation
215076758|NCT04407026|BIOLOGICAL|biofluids|Gingival crevicular fluid, saliva and serum samples were obtained.
215076759|NCT04348149|DIETARY_SUPPLEMENT|Lindera obtusiloba extract|One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
215076760|NCT03020134|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
215076761|NCT03020134|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
215076762|NCT03020134|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
215076763|NCT03020134|DRUG|Placebo|Placebo
215076764|NCT04309877|DRUG|Theophylline ER|Capsules of theophylline ER
215076765|NCT04309877|OTHER|PO placebo|Capsules of methylcellulose
215076766|NCT04309877|BIOLOGICAL|Lipopolysaccharide (LPS)|Purified bacterial wall component as an inflammatory challenge
215076767|NCT04309877|OTHER|IV placebo|Normal (0.9%) saline
214952596|NCT05727748|OTHER|Multimodal exercise|"The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group was divided into 2 sub-groups. The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).~The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed)."
214344694|NCT03958903|DEVICE|Amygdala recording and stimulation using Neuropace RNS|Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
214952597|NCT05727748|OTHER|Control group|The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
214952598|NCT02942121|OTHER|LifeScience Technologies application|Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
214952599|NCT02375425|OTHER|no intervention|no intervention-specimen collection study only
214952600|NCT03166839|OTHER|Experiencing PPH|No intervention given
214952601|NCT01589588|DEVICE|Open Hudson Mask|Mask type 1 oxygen
214952602|NCT01589588|DEVICE|Cluster headache mask with 3 L reservoir|Mask type 2 with oxygen
214952603|NCT01589588|DEVICE|Mask 3|Mask type 3 oxygen
214952604|NCT01589588|DEVICE|Carnét oxygen demand valve|mask type 3 oxygen
214952605|NCT01589588|DEVICE|Carnét oxygen demand valve|mask type 3 placebo
214952606|NCT04690335|BIOLOGICAL|MV-012-968|MV-012-968 is a recombinant, live attenuated RSV vaccine.
214952607|NCT04690335|OTHER|Placebo|Saline solution
214952608|NCT05201443|DEVICE|Diode laser|Diode Laser is applied to one group as an adjunctive therapy.
214952609|NCT05201443|DEVICE|Titanium curettes|Non-surgical treatment with titanium curettes were administrated to both groups.
214952610|NCT04064515|DIAGNOSTIC_TEST|Blood Assayed for CTCs|All study participants will have 15 mL of blood drawn for the purpose of the study.
214952611|NCT02287688|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This study is strictly observational. Decisions of vaccination are made by health care providers.
214952612|NCT04895852|DEVICE|TEAS|The self-adhesive gel electrode pad will be placed at the center of DU20 (Baihui), EX-HN3 (Yintang) and both sides of LI4 (Hegu), LR3 (Taichong) in strict accordance with the World Health Organization Standardized Acupuncture Location. Electric stimulation will be used with a TEAS apparatus (HANS200A Beijing Huawei Co., LTD.) . The frequency of the electrical stimulation will be set as alternating 2/100Hz to relieve anxiety. The current intensity will be adjusted individually, starting at 1 mA and increasing gradually until the patient can perceive and tolerate it (preferably slight twitching of local muscles without pain).
214952613|NCT04895852|DEVICE|Sham TEAS|The STEAS group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA. The acupuncturist responsible for the operation will tell patients in STEAS group that this is a type of stimulus without perception.
214952614|NCT01115387|OTHER|Observational-1|"Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.~Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing."
214952615|NCT01115387|OTHER|Observational-2|"A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.~No prospective retina photographs but ongoing follow-up for reported changes in ARM status.~A saliva or blood sample for genetic testing."
214952616|NCT02888561|DRUG|Dobutamine|Dobutamine will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
214344695|NCT03958903|BEHAVIORAL|Behavioral tasks|Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
214344696|NCT00133289|DEVICE|Pacemaker with Automatic Capture|
214344697|NCT04357028|DRUG|Measles-Mumps-Rubella Vaccine|Measles mumps Rubella vaccine is a weak attenuated life vaccine
214678403|NCT01198418|BEHAVIORAL|Experimental|Internet-based intervention that assesses transmission risk and provides prevention messages
214952617|NCT02888561|DRUG|Nitrite|Nitrite will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
214952618|NCT00161668|DRUG|Mylotarg|
214952619|NCT02603510|DRUG|SAR342434|"Pharmaceutical form:solution~Route of administration: subcutaneous"
214952620|NCT02603510|DRUG|insulin lispro|"Pharmaceutical form:solution~Route of administration: subcutaneous"
214952621|NCT03214679|OTHER|Accessible Care|Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.
214952622|NCT03214679|OTHER|Usual Care|Usual care entails referral to an on site HCV care coordinator (not provided by study)
214952623|NCT05372185|BEHAVIORAL|VA Coordinated Anxiety Learning and Management- Substance Use Version|VA Coordinated Anxiety Learning and Management- Substance Use Version (VA CALM-S) is a cognitive behavior therapy (CBT) program that employs computer assistance to empower providers to deliver CBT with high fidelity. The computer program guides both providers and patients in a course of CBT, and in this study the content will focus on using transdiagnostic treatment elements to address co-occurring anxiety and substance use disorders.
214952624|NCT05372185|BEHAVIORAL|Usual care|Veterans will engage in VA care using the standard procedures of their facility.
214952625|NCT02827175|OTHER|blood sample|
214952626|NCT03992677|OTHER|No intervention|No intervention
214952627|NCT01227525|DEVICE|Vibraject|The VibraJect clips onto the barrel of a conventional and intraligamentary dental syringe (and some disposable syringes) and vibrates the needle at a high frequency while injections are administered.
215076768|NCT00951080|DEVICE|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
214344698|NCT04357028|DRUG|Placebos|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
214952628|NCT05212584|BIOLOGICAL|CD7CAR T cells|CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
214952629|NCT02889146|OTHER|Conventional Physical Therapy|Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.
214952630|NCT02889146|OTHER|Early and progressive mobilization program|Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.
214952631|NCT02889146|OTHER|Respiratory therapy|Respiratory therapy according to the service routine.
214952632|NCT03147976|DRUG|AMG 337|6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
214952633|NCT00645372|DRUG|Risperidone|Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
214952634|NCT00645372|DRUG|Ziprasidone|Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
214952635|NCT05155956|OTHER|transcranial Doppler ultrasonography (TCD)|"Transcranial Doppler (TCD) is a non-invasive ultrasound-based technique that facilitates insonation of the cerebral arteries. TCD probe design enables continuous monitoring of cerebral blood flow velocity (CBFv). TCD has a variety of clinical applications, including intraoperative monitoring for detection of microemboli. The TCD probe can be comfortably secured to the patient's head by a headframe in order to maintain continuous vessel insonation. Microembolic signals (MES) can be reliably detected based on standard criteria:~1. Brief in duration (\<300msec)~2. High intensity (amplitude \>3 dB above background)~3. Unidirectional~4. Audible chirp or snap~Further, CBFv monitoring during may inform flow perturbations that occur during cardiac or vascular manipulations."
214952636|NCT04013685|BIOLOGICAL|Orca-T|an allogeneic stem cell and T-cell immunotherapy biologic
214952637|NCT01601067|BEHAVIORAL|Integrated Prolonged Exposure Therapy|Prolonged exposure (PE) therapy is an evidence based practice for the treatment of PTSD. Components of PE included education about PTSD and exposure to avoided reminders of trauma.
214952638|NCT01601067|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) teaching coping skills in behavioral, cognitive, and interpersonal domains so that people are able to make safe choices rather than drinking or PTSD-related behaviors such as avoidance.
214952639|NCT03231137|COMBINATION_PRODUCT|PRGF/ATV|Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold
214952640|NCT03231137|DRUG|ATV gel|Atorvastatin gel
214952641|NCT03231137|BIOLOGICAL|PRF|Platelet rich fibrin
214952642|NCT03231137|BIOLOGICAL|PRGF|plasma rich in growth factor
214952643|NCT05922137|BEHAVIORAL|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and limiting alcohol consumption
214952644|NCT05922137|BEHAVIORAL|Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) diet|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
214952645|NCT04722536|PROCEDURE|Cervico-isthmic cerclage|There is no intervention in this study. It's an observational retrospective study, before/after.
214952646|NCT00693485|DRUG|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
214952647|NCT00693485|DRUG|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
215076769|NCT00951080|DEVICE|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
215076770|NCT05496452|DIETARY_SUPPLEMENT|Beta-lactoglobulin|Beta-lactoglobulin (BLG) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
214344699|NCT04671862|DEVICE|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~* 1 Treatment 4J continuous prior to RT. (Within 14 days of RT start)~* 3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)"
214344700|NCT05222230|OTHER|FFP3 Mask|Participans will wear FFP3 respirators during the study.
214344701|NCT03520634|OTHER|PD-L1 PET imaging|PD-L1 PET imaging
214952648|NCT00693485|DRUG|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
215076771|NCT05496452|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate (dextrose monohydrate) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
214344702|NCT00184860|PROCEDURE|PET-scan, MRI-scan|
214344703|NCT03832127|DRUG|18F-Fludarabine|Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
214344704|NCT03981458|DEVICE|Hyalofemme|Gel made with hyaluronic acid to be applied vaginally to treat atrophic vaginitis.
214344705|NCT03981458|DEVICE|Ialuril|Bladder instillation of hyaluronic acid to treat recurrent UTI.
214344706|NCT02997358|DRUG|Doxorubicin|75 mg/m² Day 1 of each 3-weeks cycle
214344707|NCT02997358|DRUG|Trabectedin|150 μg/m²/day s.c From day 3 to day 9
214344708|NCT00882674|DRUG|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
214952649|NCT01142492|DRUG|Interferon beta-1a|Subjects first received Interferon beta-1a at a dose of 22 µg x3 over a period of 4 weeks. An attempt was then made to increase the dose of interferon beta-1a to 44 µg x3 as a self-administered subcutaneous (s.c.) injection. If intolerable interferon-specific side effects or problems of acceptance occured, the treatment with Rebif 22 µg three times weekly was continued.
214952650|NCT05612269|DIAGNOSTIC_TEST|interleukin 6|follow up of type 2 diabetes with SGLT2 inhibitors like empagliflozin, canagliflozin, and dapagliflozin for measurement of inflammatory factors like interleukin-6, CRP
214952651|NCT03156569|DIAGNOSTIC_TEST|Analysis of the saliva|IFN-, IL-10, IL-1b, IL-4 and IL-6
214952652|NCT01712048|PROCEDURE|Submucosal Injection EMR|"Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare."
214952653|NCT01712048|PROCEDURE|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
215076772|NCT05757154|OTHER|Diet|All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
215076773|NCT05947565|DIAGNOSTIC_TEST|Invasive Urodynamic Study|"Invasive Urodynamic Study (Filling cystometry and pressure-flow study) Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped.~While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded."
214952654|NCT04901234|RADIATION|Standard radiotherapy +/- chemotherapy|No radiotherapy adaptation unless major dosimetric deviation
214952655|NCT04901234|RADIATION|Experimental radiotherapy +/- chemotherapy|Systemic MRI-based radiotherapy adaptation mid-treatment
214952656|NCT00313287|DRUG|clevudine|
214952657|NCT06380933|OTHER|experimental group|first received a foot bath with lavender essential oil at 41-42C warm water for 20 minutes for 3 days, then rested for 3 days, and then received routine care for 3 days
214952658|NCT03923049|DIAGNOSTIC_TEST|hybrid PET/MRI|On the day of the procedure, subjects will undergo a PET scan followed by MRI scan.
215076774|NCT06457230|DEVICE|10Hz rTMS based on cerebellum and FPC|We compare the efficacy of paired-pulse stimulation relative to single-pulse stimulation. Subjects will be randomly assigned to a cerebellar + frontal pole paired-pulse experimental group.
215076775|NCT06457230|DEVICE|10Hz rTMS based on cerebellum or FPC|Subjects will be randomly assigned to a cerebellar or frontal pole randomised control group.
215076776|NCT02899234|OTHER|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
215076777|NCT04709016|BEHAVIORAL|self-questionnaire|self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
214344709|NCT06389812|OTHER|Dual-task exercise traning|To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function
214344710|NCT04790981|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
214344711|NCT04790981|OTHER|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern including.
214952659|NCT03083353|DRUG|Isradipine|Isradipine will be administered 90 minutes prior to the initiation of cue exposure.
214952660|NCT03083353|BEHAVIORAL|Cue Exposure|Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.
214952661|NCT05251064|DEVICE|Suture|Standard suture wound closure device.
214952662|NCT05251064|DEVICE|Clozex|Interlaced adhesive wound closure device.
214952663|NCT05251064|DEVICE|Zipline|Adhesive wound closure device using zip-tie like strips.
214952664|NCT02771860|DRUG|denosumab|60mg sc
214952665|NCT02771860|DRUG|Placebo|identical syringe
214952666|NCT02771860|DIETARY_SUPPLEMENT|Calcium/Vit D supplementation|Daily dosage Calcium 1000mg / Vit D 880 IU
214344712|NCT01944046|DRUG|Double blind phase Placebo Nasal Spray|This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
214486620|NCT06403995|BEHAVIORAL|Recommended, directed Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
214952667|NCT05671159|OTHER|Blood sample|A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube
214952668|NCT06174194|DIETARY_SUPPLEMENT|Tulsi Gum|"The intervention involves participants chewing a specially formulated gum known as Tulsi Gum for 5 minutes. Tulsi Gum contains Tulsi extract, a natural substance derived from the Tulsi plant. This extract is recognized for its potential antimicrobial properties. Participants are then required to discard the gum. The study aims to assess the effect of Tulsi Gum on salivary Streptococcus mutans count in children aged 4 to 11 years. This assessment contributes to understanding the potential of Tulsi Gum in preventing dental caries in children."
214952669|NCT03435159|DIAGNOSTIC_TEST|Doppler Ultrasonography|GE LOGIQ S8 ultrasound machine was used to measure blood flow parameters in right and left a. carotis communis, a. carotis interna and a. vertebralis. All vessels were examined in the axial plane through their traces in the B-mode with a C6-15 MHz curvilinear matrix probe. Flow patterns and directions of vessels were then examined with Colour Doppler and it was determined whether there was any stenosis. Intimal thickness of a. carotis communis was measured by spectral doppler method. Measurements were recorded by visualizing the CCA at the supraclavicular level, the ICA carotid sinus (C4 level), and the VA at the V2 segment (C3-4 level), with less angle at 60 degrees. All measurements before and after the application were made at the same level. Immediately after manipulation, blood flow parameters were recorded as numerical data by the same physician again with Doppler USG of the relevant arteries.
214952670|NCT03435159|PROCEDURE|Manual Chiropractic Spinal Manipulation|"Manipulation procedures were applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Manual chiropractic manipulation for C1 vertebra was applied in sitting position, using the digit / atlas pull technique. This technique is applied with the contact of practitioner's middle finger to the posterior part of transverse process of atlas, and generate a rotation force between C1 and C2 vertebrae.~The procedure was applied to C2 vertebra using the index / facet push technique in the supine position. This technique places pushing force in the direction of rotation between the C2-C3 vertebrae, placing the practitioner's index finger in contact with the posterior surface of the C2 facet joint."
214952671|NCT03435159|DEVICE|Instrumental Chiropractic Spinal Manipulation|"Activator technique was applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Instrumental spinal manipulation was applied with Activator V chiropractic instrument. For C1 vertebra, the procedure was applied in supine position, by placing the Activator device horizontally on the participant's atlas transverse process of the affected side and applying a pushing force in the medial direction.~For C2 vertebra, the procedure was applied in prone position, by placing the Activator device in the relevant C2 pedicle-lamina junction of the participant's affected side and applying a pushing force in the anterior, superior and mild medial direction of movement of the facet joint."
214952672|NCT06020248|OTHER|Wear clothing that has been exposed to cigarette smoke for 3 hours.|Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.
214952673|NCT00559169|DRUG|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
214952674|NCT02163317|RADIATION|stereotactic radiosurgery|Undergo MRI-guided focal SRS
214952675|NCT02163317|DEVICE|magnetic resonance imaging|Undergo staging MRI with contrast
214952676|NCT02163317|OTHER|quality-of-life assessment|Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
214952677|NCT02163317|PROCEDURE|Serum Prostate Antigen Test|Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
214952678|NCT02163317|PROCEDURE|Digital Rectal Exam|Exam of rectal health. Performed every three months for up to two years throughout the study.
214952679|NCT02163317|BEHAVIORAL|Expanded Prostate Cancer Index Composite|This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
214952680|NCT00855699|DRUG|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
214952681|NCT02309450|DRUG|.Asunaprevir, Daclatasvir and BMS - 791325|All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
214952682|NCT02752711|PROCEDURE|the PECARN clinical decision rule|the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma
214952683|NCT02006433|DEVICE|Deep Brain Stimulation|Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
214344713|NCT01944046|DRUG|double Blind Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.
214344714|NCT01944046|DRUG|Open Label intranasal oxytocin|All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin
214952684|NCT03972501|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is an ophthalmic ointment
214952685|NCT03972501|DRUG|AZR-MD-001 Active Dose|AZR-MD-001 is an ophthalmic ointment
214952686|NCT04482738|OTHER|High-calorie meal|Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.
214952687|NCT02377128|PROCEDURE|Bilateral salpingectomy|Surgical bilateral removal of fallopian tubes (not involving ovaries)
214952688|NCT02377128|PROCEDURE|Tubal ligation|Bilateral ligation of fallopian tubes (not involving ovaries)
214952689|NCT04571385|DRUG|AP30663|Administer by intravenous infusion.
214952690|NCT04571385|DRUG|Placebo|Placebo matched to AP30663.
214952691|NCT03703674|DRUG|GCSF|Granulocyte-colony stimulating factors (G-CSF)
214952692|NCT04831996|DRUG|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
214952693|NCT04046263|DRUG|Sucroferric Oxyhydroxide Chewable Tablet|Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal
214952694|NCT01383252|PROCEDURE|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
214952695|NCT01383252|PROCEDURE|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
214952696|NCT03815435|PROCEDURE|Controlled hypotension|Controlled hypotension will be administered according to the clarity of the surgical field.
214952697|NCT02263729|DRUG|Losartan|Cozaar
214952698|NCT02263729|DRUG|Placebo|
214952699|NCT01212159|DEVICE|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
214952700|NCT02301819|DEVICE|Veno-arterial extracorporeal membrane oxygenation (ECMO)|Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
214952701|NCT02301819|OTHER|Early conservative therapy according to standard practice|Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
214952702|NCT05475834|DRUG|SIM0417|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
215076778|NCT02124018|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
215076779|NCT02124018|DEVICE|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
214344715|NCT01707602|BIOLOGICAL|INTANZA® 15|intradermal vaccination
214952703|NCT00779753|DIETARY_SUPPLEMENT|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
214952704|NCT04663854|DRUG|Trehalose|Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
214952705|NCT00755261|DRUG|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
214952706|NCT00755261|DRUG|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
215076780|NCT00903136|OTHER|questionnaire administration|
215076781|NCT00903136|PROCEDURE|comparison of screening methods|
215076782|NCT00903136|PROCEDURE|diagnostic endoscopic procedure|
215076783|NCT00903136|PROCEDURE|esophagogastroduodenoscopy|
215076784|NCT00903136|PROCEDURE|tethered capsule endoscopy|
215076785|NCT00017654|DRUG|anti-thymocyte globulin|
215076786|NCT00017654|DRUG|cyclophosphamide|
215076787|NCT00017654|DRUG|cyclosporine|
215076788|NCT00017654|DRUG|methylprednisolone|
215076789|NCT00017654|PROCEDURE|Allogeneic Bone Marrow Transplantation|
215076790|NCT04077866|DRUG|Temozolomide|Temozolomide is an FDA-approved drug that is given to patients
215076791|NCT04077866|BIOLOGICAL|B7-H3 CAR-T|B7-H3-targeting CAR-T cells derived from patient own peripheral blood mononuclear cells will be given to patients via intracerebral injection though an Ommaya catheter
214952707|NCT03879551|DEVICE|repetitive Transcranial Magnetic Stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor digiti minimi (ADM), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
214952708|NCT03321409|DIAGNOSTIC_TEST|The general population|After recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out. Then validating the reliability, validity of the SSS-CN will be compared with the PHQ-15.
214952709|NCT03321409|DIAGNOSTIC_TEST|Patients with suspected CAD|In patients with suspected CAD, after recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out before undergo coronary angiography. Then the prevalence of somatic symptoms will be investigated.
214952710|NCT06186596|DEVICE|Triamcinolone delivered via injection assistance device|0.1mL of 1% to 2% triamcinolone solution will be delivered to up to 3 facial inflammatory acne lesions
214952711|NCT03963921|DRUG|HepaStem|Heterologous human adult liver-derived progenitor cells
214952712|NCT02081014|DRUG|G-Pen Mini™ (glucagon injection)|stable, pre-mixed, liquid glucagon for subcutaneous injection
214952713|NCT01502956|DEVICE|InterStim® device|Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
214952714|NCT01502956|DRUG|Botox® injection|Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
214952715|NCT04162405|BEHAVIORAL|Tinnitus Handicap Inventory Test|A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
214952716|NCT02748759|DEVICE|CPM|15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)
214952717|NCT02748759|OTHER|Manual mobilization|Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
214952718|NCT04056312|BEHAVIORAL|Group Memory retraining exercises|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
214952719|NCT04056312|BEHAVIORAL|Placebo controlled group memory exercise training|Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
214952720|NCT06218342|DRUG|Henagliflozin|Besides lifestyle intervention and background medication, participants will be prescribed Henagliflozin at standard clinical doses.
215076792|NCT02507180|OTHER|LEFt clinical decision rule|"The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: \> 1 point"
215076793|NCT01783314|PROCEDURE|MRI of liver|MRI of liver with intravenous gadoxetate disodium
215076794|NCT01165788|PROCEDURE|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
215076795|NCT03786302|DRUG|TAMP bioglass|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
215076796|NCT03786302|DRUG|Biodentine|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
214344716|NCT01707602|BIOLOGICAL|Vaxigrip®|Intramuscular vaccination
215076797|NCT00075114|BEHAVIORAL|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
214344717|NCT01707602|BIOLOGICAL|INTANZA® 15 T|transcutaneous vaccination
214952721|NCT06218342|OTHER|Background medication|Participants will only receive lifestyle intervention and background medication.
214952722|NCT00104377|BIOLOGICAL|Grass MATA MPL|
214952723|NCT00084877|DRUG|triapine|Given IV
214952724|NCT00084877|DRUG|irinotecan hydrochloride|Given IV
214952725|NCT00084877|OTHER|laboratory biomarker analysis|Correlative studies
214952726|NCT00084877|OTHER|pharmacological study|Correlative studies
214952727|NCT03574688|DIETARY_SUPPLEMENT|Water|Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
214952728|NCT02365038|OTHER|Driving pressure limited ventilation|We will use volume controlled ventilation or pressure support in the weaning phase. We will adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). We will not limit plateau pressure in this arm.
214344718|NCT03023891|DRUG|Prednisone|Prednisone 60 mg tablet once
214344719|NCT04724655|OTHER|gastric lavage with paraffin oil and bicarbonate|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube
214344720|NCT04724655|OTHER|gastric lavage with coconut oil and bicarbonate|Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube
214344721|NCT04724655|DRUG|standard treatment|inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
214952729|NCT02365038|OTHER|Conventional ventilation|ARDSNet Strategy: conventional mechanical ventilation strategy with tidal volume between 4 and 6 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.
214952730|NCT03999528|DIAGNOSTIC_TEST|14-3-3η Protein assay|blood sampling for assessment of serum 14-3-3η Protein
214952731|NCT02926261|OTHER|Bioelectrical impedance vector analysis|Evaluation of nutritional status with Bioelectrical impedance vector analysis, hand-grip strength and computed-tomography scan
214952732|NCT01026818|DRUG|Tadalafil|Administered by mouth for 9 months
214952733|NCT01026818|DRUG|Placebo|Administered by mouth, daily or on demand for 9 months
214952734|NCT00003190|DRUG|cytarabine|Given IV
214952735|NCT00003190|DRUG|daunorubicin hydrochloride|Given IV
214952736|NCT00003190|DRUG|etoposide|Given IV
214952737|NCT00003190|DRUG|valspodar|Given IV
214952738|NCT02830074|BEHAVIORAL|Best practices PAP + patient Education +ongoing Support and Training|"This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training"
214952739|NCT02830074|BEHAVIORAL|Sleep Education|This program includes non-directive sleep education plus standard treatment of SDB.
214952740|NCT05695118|DIAGNOSTIC_TEST|Non-contrast low-dose abdomen CT|target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.
214952741|NCT05695118|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.
214952742|NCT05695118|DIAGNOSTIC_TEST|bioelectrical impedance analysis (BIA)|BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.
214952743|NCT02963129|DRUG|Mupirocin|Mupirocin ointment in the nose for 5 days
214344722|NCT04724655|OTHER|gastric lavage with saline and bicarbonate|Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube
214952744|NCT02963129|OTHER|Placebo|Placebo ointment in the nose for 5 days
214344723|NCT00823082|DRUG|Antithrombin III|Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
214344724|NCT04223102|PROCEDURE|Tissue collection|A flexible sigmoidoscopy is a procedure in which a flexible tubularized camera approximately 1 cm in diameter is inserted into the anus and advanced proximally to the sigmoid colon (approximately 20 cm). At that time a rectal biopsy of the tumor will be obtained as well as a sample from \>5cm proximal to the tumor, with a separate biopsy forcep. Tattoo injection, as standard of care, will be performed within 1 cm distal to the tumor to identify the location in the future or for surgical intervention. If there is inability to get proximal to the tumor then a location at least 5 cm adjacent in any direction will be sufficient so long as it is grossly normal appearing.
214344725|NCT02328326|OTHER|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
214486621|NCT06274775|OTHER|Educational Video|Educational video about the nail biopsy procedure
214486622|NCT05934383|DEVICE|Paradise® ultrasound renal denervation system.|Bilateral renal sympathetic denervation of the native kidneys using the Paradise® ultrasound renal denervation system.
214486623|NCT04304768|BIOLOGICAL|Fluzone Quadrivalent|0.5 ml prefilled syringe administrated intramuscularly
214952745|NCT02975531|OTHER|Simulator's construction|Model to build the mold for the simulator
214952746|NCT02975531|OTHER|Model Features|Volunteers to determine the elasticity of the skin and cirtometry neck to compare with the simulator.
214952747|NCT02975531|OTHER|Parameterization technique|Evaluation of the simulator features and parameterization of the Pompage technique in the simulator.
214952748|NCT02975531|OTHER|Simulator training|Training of pompage technique using the simulator.
214952749|NCT02975531|OTHER|Training Evaluation|Evaluation of volunteers from GE group before and after training with the simulator.
214952750|NCT03479138|DIAGNOSTIC_TEST|Induced sputum|Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome
214952751|NCT05274529|BEHAVIORAL|Psychological health and flexibility|A remote coaching programme concentrating on psychological health and flexibility
214952752|NCT05274529|BEHAVIORAL|Work ability|A remote coaching programme concentrating on work ability
214952753|NCT05274529|BEHAVIORAL|Sleep and recovery|A remote coaching programme concentrating on sleep and recovery
214952754|NCT05274529|BEHAVIORAL|Healthy lifestyle|A remote coaching programme concentrating on healthy lifestyle
214952755|NCT05274529|OTHER|No coaching|Participants also have the option to choose no coaching for the coming 3 month period.
214952756|NCT04150536|DRUG|Lidocaine topical system 1.8%|
214952757|NCT01439490|OTHER|FES-PET|Patients undergo FES-PET prior to obtaining histology
214952758|NCT00823485|PROCEDURE|fibrinolysis in situ|intraventricular injection of actilyse
214952759|NCT00823485|PROCEDURE|drainage|drainage
214952760|NCT03157596|OTHER|Oral Health Educational Program for Caregivers of Children with developmental disabilities|Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD \& methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
214952761|NCT04794673|OTHER|brain damage|Have or not have the brain damage and the location of the damage
214952762|NCT03027245|DRUG|Eribulin|
214952763|NCT02135016|DRUG|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
214952764|NCT02135016|DRUG|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
214344726|NCT02328326|OTHER|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
214344727|NCT05392634|DRUG|Meropenem 1000 mg|Group B: prolonged antibiotic prophylaxis \>72 hours (5 days) from the moment of the skin incision in accordance with the selected clinic drug + correction of the appointment based on clinical events after 5 days.
214344728|NCT05392634|DRUG|Amoxicillin+clavulanic acid 1200 mg or Cefuroksim 1500mg|Group A: antibiotic prophylaxis within 24 hours from the moment of skin incision according to local clinical practice;
214952765|NCT02135016|DRUG|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
214952766|NCT06699381|DEVICE|use of spinal mouse|Spinal Mouse (SM) is an external non-invasive measurement device that evaluates the spinal angle and shape in the frontal and sagittal planes
214952767|NCT06699381|DIAGNOSTIC_TEST|Brunnstrom's Hemiplegia Recovery Staging|According to Brunnstrom's stages of recovery, the individual will be identified at which stage
214952768|NCT06699381|DIAGNOSTIC_TEST|The six minute walking test (6MWT)|It evaluates the functional capacity of the individual and it provides valuable information regarding all the systems during physical activity, including pulmonary and cardiovascular systems, blood circulation, neuromuscular units, body metabolism, and peripheral circulation
214952769|NCT06699381|DIAGNOSTIC_TEST|Functional Reach Test (FRT)|"Functional Reach Test (FRT) is a clinical outcome measure and assessment tool for ascertaining dynamic balance in in simple task.~In standing, measures the distance between the length of an outstretched arm in a maximal forward reach, while maintaining a fixed base of support.~This information is correlated with risk of falling A number of factors exert a major influence on this evaluation: Research revealed that movement strategy and reduced spinal flexibility both affect reach distance."
214952770|NCT06699381|DIAGNOSTIC_TEST|Mini Balance Evaluation Systems Test (Mini-BESTest)|"This test measures dynamic balance, functional mobility, and gait. It is commonly used in populations who have or have had multiple sclerosis (MS), Parkinson disease (PD), strokes, spinal cord injury (SCI), or cancer.~The Mini-BESTest was developed in 2010 from the Balance Evaluation Systems Test (BESTest), then revised in 2013 to clarify inconsistencies in scoring. The scoring instructions were different in the published and online versions. The revision clarified that the Mini-BESTest should be scored out of 28 points. Explanations for how to score items 3, 6, and 14 were also given.~The Mini-BESTest consists of 14 items, including 4 of the 6 sections (anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait) from the BESTest."
214952771|NCT06699381|DIAGNOSTIC_TEST|The five Times Sit to Stand Test (5x Sit-To-Stand Test)|It's used to asses functional lower limbs strength, transitional movements, balance, and fall risk in older adults.
214952772|NCT06699381|DIAGNOSTIC_TEST|The Postural Assessment Scale for Stroke (PASS)|The Postural Assessment Scale for Stroke (PASS) is an outcome measure specifically designed to assess and monitor postural control after stroke. It was developed in 1999 as an adaptation of the Fugl-Meyer Assessment balance subscale\[1\]. It contains 12 four-level items of varying difficulty for assessing ability to maintain or change a given lying, sitting or standing posture
214952773|NCT06699381|DIAGNOSTIC_TEST|Postural Symmetry Index and Weight Transfer Symmetry|It is a form of measurement in which two scales are used to calculate the weight transferred to the intact and stroke limb. The values obtained as a result of the test are calculated with formulas.
215076798|NCT02690428|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
215076799|NCT03663127|DIETARY_SUPPLEMENT|Beauty Drink|"Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks."
214344729|NCT00246636|DRUG|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
214344730|NCT00246636|DRUG|Antara (fenofibrate)|Antara (fenofibrate) + placebo
214344731|NCT02264795|DRUG|Lidocaine|Lidocaine 2% with epinephrine 5mcg/ml
214344732|NCT02264795|DRUG|Placebo|0.9% Sodium Chloride Solution
214344733|NCT01060865|DRUG|Aliskiren|150 mg during the first two weeks , 300 mg for another 10 weeks
214344734|NCT01637753|DRUG|Carmustine(BCNU)|Carmustine Sustained Release Implant
214344735|NCT01637753|PROCEDURE|Surgery|Routine tumor resection surgery
214344736|NCT01213758|OTHER|Measuring liver function by PET/CT|Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
214344737|NCT04618354|OTHER|No interventions|This clinical study is a retrospective study, and no interventions have been implemented for patients.
214952774|NCT06699381|DIAGNOSTIC_TEST|Measurement of the craniovertebral angle|Measurement of the craniovertebral angle; the patient is asked to find the most natural position by flexion and extension of the head in the standing position and a photograph is taken with a digital camera from a distance of 1.5 m to the shoulder level of the patient and this process is repeated 3 times. The images obtained are then digitally calculated with the help of an appropriate program.
214952775|NCT00285376|DRUG|vilazodone|titration to 40mg tablets qd for 8 weeks
214952776|NCT06490250|OTHER|Inspiratory Muscle Training|The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other day
214952777|NCT06490250|OTHER|Baduanjin Exercise|The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.
214952778|NCT00575471|DRUG|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
214952779|NCT00575471|DRUG|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
214952780|NCT00575471|DRUG|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
214952781|NCT00575471|DRUG|Placebo|Matching placebo tablets once daily for 12 weeks
214952782|NCT03451955|OTHER|Gluten-free diet|Participants in the intervention group abstain from gluten for 6 months.
214952783|NCT02625246|BIOLOGICAL|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
214952784|NCT01889732|DEVICE|ROTEM|
214952785|NCT03921632|BEHAVIORAL|Smiles Matter Oral Health Education Series|Three sessions scheduled 2 weeks apart consisting of 15-20 minutes of didactic learning, 10 minutes of a group/personal exercise, and 10 minutes of questions that the patients have on the topic discussed that day
214952786|NCT02295332|DRUG|Placebo|Matching oral placebo capsules to RG7625, according to treatment schedule
214952787|NCT02295332|DRUG|RG7625|oral administration, capsules, single ascending dose according to treatment schedule
214952788|NCT03541447|DRUG|Tolvaptan|Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.
214952789|NCT03541447|DRUG|Octreotide LAR|A single dose of two 20 mg i.m. injections.
214952790|NCT03541447|OTHER|Placebo|A single dose of two 20 mg i.m. injections.
215076800|NCT03663127|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
215076801|NCT02584530|PROCEDURE|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
215076802|NCT03993990|BEHAVIORAL|individual empowerment-based intervention|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
214952791|NCT05481827|GENETIC|GT005|GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study.
214952792|NCT00528918|DRUG|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
214952793|NCT01711008|DIETARY_SUPPLEMENT|Cereal|
214952794|NCT01711008|DIETARY_SUPPLEMENT|No breakfast|
215076803|NCT03465462|DIETARY_SUPPLEMENT|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
215076804|NCT03465462|DIETARY_SUPPLEMENT|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
215076805|NCT03465462|DIETARY_SUPPLEMENT|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
215076806|NCT00274898|DRUG|celecoxib|
215076807|NCT00274898|DRUG|docetaxel|
215076808|NCT00274898|PROCEDURE|adjuvant therapy|
215076809|NCT00274898|RADIATION|radiation therapy|
214344738|NCT05400096|OTHER|Psychological therapy|The protocol for the group will be developed collaboratively between the chief researcher and the supervisor based in the weight management service. The protocol will contain Compassion Focused Therapy (CFT) based therapeutic approaches, but the group will integrate some Acceptance and Commitment Therapy (ACT) concepts.
214344739|NCT03452917|DRUG|Placebo|500 patients will 2 ml of normal saline
214344740|NCT03452917|DRUG|sodium nitrite 45 mg|500 patients will receive 45 mg IV sodium nitrite
214344741|NCT03452917|DRUG|sodium nitrite 60 mg|500 patients will receive a dose of 60 mg IV sodium nitrite
214344742|NCT03198000|DRUG|F# 13418-148 Eye Drops|ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day
214344743|NCT03198000|DRUG|F#13418-158 Eye Drops|ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day
214344744|NCT03198000|DRUG|F# PF-004390 Eye Drops|Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day
214344745|NCT02958436|DRUG|REGN3500|
214344746|NCT02958436|DRUG|Placebo|
214344747|NCT04016597|DEVICE|Jaeger Masterscreen TM|Single-breath nitric oxide lung diffusing capacity
214952795|NCT03243123|DEVICE|Robotic passive mobilization|The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.
215076810|NCT05697289|OTHER|satisfaction survey|Non-comparative longitudinal observational study over 12 months conducted during usual follow-up of patients living with HIV-1 and having changed treatment for an injectable dual therapy with prolonged release cabotegravir-rilpivirine. Decision to change treatment and follow-up of patients are part of routine care. Study is proposed after the doctor has taken the decision to modify treatment, the patient has accepted and injectable dual therapy is prescribed. It is based on self-questionnaires to collect patient perceptions (Patient-Reported Outcomes) and clinical and biological data collected routinely at inclusion and during follow-up visits.
214344748|NCT04016597|DEVICE|HypAir Medisoft|Single-breath nitric oxide lung diffusing capacity
214344749|NCT05309161|DIETARY_SUPPLEMENT|Crassocephalum rabens extract|dosage: a capsule (180 mg)/day; duration: 1 month
214344750|NCT03592212|DRUG|Salbutamol|Measurement of bronchodilator response (BDR)
214952796|NCT02482545|DIETARY_SUPPLEMENT|Meal replacement|
214952797|NCT03195322|PROCEDURE|Pre-pectoral Tissue Expander|All participants in the study will undergo bilateral mastectomy followed by Immediate, bilateral pre-pectoral tissue expander breast reconstruction with complete AlloDerm® coverage.
214952798|NCT06237608|BEHAVIORAL|Dialectical behavioural therapy (DBT)-informed skills group|16 week 1.5hr DBT-informed skills group facilitated by the lead researcher and two charity facilitators
214952799|NCT04356599|OTHER|Early dynamic 18F-FDG PET/CT assessment of cerebral glucose uptake|The intervention will consist in a dynamic cerebral 18F-FDG PET study performed at D2+/-1. Kinetic modeling will be performed using in-house software at the global, regional, and voxel level. In addition, cerebral perfusion and blood-brain-barrier permeability will be assessed at D4+/- 1 using perfusion MRI and permeability MRI.
215076811|NCT02378012|OTHER|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
214344751|NCT02976766|DRUG|Gypenosides|Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.
214344752|NCT02976766|DRUG|Placebo|Participants will receive placebo three times a day for 10 days.
214344753|NCT06100497|DRUG|Pembrolizumab|Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment
214344754|NCT06100497|DRUG|Cisplatin|Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy
214344755|NCT06100497|DRUG|Paclitaxel-albumin|Mainly used for neoadjuvant treatment
214344756|NCT05062928|OTHER|Virtual coach|This group will be trained and assessed by the virtual coach.
214344757|NCT05212974|OTHER|Questionnaires|The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
214344758|NCT01788683|PROCEDURE|Regenexx SD|stem cell treatment
214344759|NCT01788683|OTHER|Exercise Therapy|exercise therapy control
214344760|NCT00827034|DRUG|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
214344761|NCT00827034|DRUG|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
214344762|NCT00827034|DRUG|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
214344763|NCT06528119|OTHER|COVID 19 pandemic|Physiological indicators such as blood pressure, heart rate, respiratory rate, and consciousness status of COVID-19 patients are used to apply the START, MEWS, and qSOFA in COVID-19 patients.(COVID 19 病患).
214344764|NCT00174993|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
214344765|NCT00174993|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
214344766|NCT03631979|OTHER|Intestinal lavage with normal saline|Specially trained pediatric surgeon will administer 10ml/kg pre-warmed (37oC) normal saline via a single-use rectal tube of size 6FR twice per day, aiming at a depth of maximum 10 cm/kg, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. However, the intervention will be applied at a maximum of 2 weeks from birth.
214344767|NCT00276445|DRUG|beta-1,3-glucan|
214344768|NCT01082666|DEVICE|Continuous control of cuff pressure|Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
214344769|NCT01082666|DEVICE|Manual control of cuff pressure|Manual control of cuff pressure is a routine practice in ICU patients
214344770|NCT05441930|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
214952800|NCT00198523|DRUG|Prednisolone and Tobramycin|
214952801|NCT00198523|DRUG|Prednisolone|
214952802|NCT05080738|OTHER|Upper Extremity Home Exercises|"The exercises will be performed as follows:~1. Stretching exercises: It will be applied in the form of 10 seconds\*10 repetitions for fingers, wrists, elbows and shoulders.~2. Strengthening exercises: It will be applied as 2 sets\*10 repetitions for fingers, wrists, elbows and shoulders."
214344771|NCT05441930|DRUG|Control|Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
214344772|NCT03191084|DRUG|Low Dose THC Marijuana|Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
214344773|NCT03191084|DRUG|High Dose THC Marijuana|Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
214344774|NCT03191084|DRUG|Placebo Marijuana|Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
214344775|NCT03668145|PROCEDURE|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
214344776|NCT00399477|DRUG|rasagiline mesylate|Azilect®
214344777|NCT00399477|DRUG|Rasagiline mesylate plus Mirapex|Mirapex, Azilect®
214344778|NCT00399477|DRUG|Rasagiline mesylate with Levodopa|Azilect®, Levodopa
214952803|NCT02025933|OTHER|Salmon Group|The children are advised to eat at least 75g of salmon per serving, but no more than 150g
214952804|NCT02025933|OTHER|Cod Group|The children are advised to eat at least 75g of cod per serving, but no more than 150g
214952805|NCT02025933|OTHER|Meat Group|The children are advised to eat at least 75g of meat per serving, but no more than 150g
214952806|NCT00501709|DRUG|Belatacept and Raptiva|immunosuppressant agent to prevent rejection in transplant recipients
214952807|NCT03739801|DRUG|Liposomal Irinotecan|Given IV
214952808|NCT03739801|OTHER|Quality-of-Life Assessment|Ancillary studies
214952809|NCT03739801|OTHER|Questionnaire Administration|Ancillary studies
214952810|NCT03739801|BIOLOGICAL|Ramucirumab|Given IV
214952811|NCT03543176|OTHER|UMEC/VI|UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .
214952812|NCT03543176|OTHER|FLUT/SAL|FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.
214952813|NCT03543176|OTHER|CAT|Questionnaire used to asses Condition-related well-being, for COPD subjects.
214952814|NCT03543176|OTHER|mMRC|Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.
214952815|NCT03543176|DEVICE|Ellipta|It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.
214344779|NCT00399477|DRUG|Rasagiline mesylate with Requip|Azilect®, Requip
214344780|NCT03906058|DRUG|Anlotinib|All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
214344781|NCT01194674|DRUG|Microplasmin|Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
214344782|NCT02096055|DRUG|Cladribine|Given IV
214344783|NCT02096055|DRUG|Guadecitabine|Given SC
214344784|NCT02096055|DRUG|Idarubicin|Given IV
214344785|NCT04327466|DEVICE|Osciflow|Osciflow is a non-invasive high frequency oscillatory ventilation support delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
214344786|NCT04327466|DEVICE|Highflow|Standard highflow therapy without oscillations delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
214344787|NCT00002872|BIOLOGICAL|bleomycin sulfate|
214344788|NCT00002872|DRUG|doxycycline|
214344789|NCT00002872|OTHER|talc|
214344790|NCT03719066|BIOLOGICAL|killed whole cell oral cholera vaccine|two week interval
214344791|NCT04906018|DEVICE|Ultrasound scans|Each subject will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
214344792|NCT02080026|BIOLOGICAL|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
214344793|NCT02080026|BIOLOGICAL|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
214344794|NCT02080026|DRUG|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
214344795|NCT02080026|DRUG|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
214952816|NCT03543176|DEVICE|Diskus|It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
214952817|NCT01293747|DRUG|Estradiol + Progesterone|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
214952818|NCT01293747|DRUG|Estradiol + Progesterone|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
214952819|NCT00758329|DEVICE|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
214952820|NCT01515566|DRUG|Fentanyl|Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
214952821|NCT01515566|OTHER|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test.
214952822|NCT01515566|OTHER|Walking Tests|6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
214952823|NCT01515566|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
215076812|NCT02378012|OTHER|Computer-Assisted Intervention|Receive iPad and instruction manuals.
215076813|NCT02378012|OTHER|Questionnaire Administration|Ancillary studies
214952824|NCT03300050|BIOLOGICAL|cH8/1N1 LAIV|"Live-attenuated influenza virus vaccine (LAIV) expressing chimeric hemagglutinin (HA) with the H8 head and H1 stalk and neuraminidase (NA) subtype 1 (N1) (cH8/1N1):~HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1) containing the backbone of the cold-adapted/temperature sensitive of the Russian LAIV A/Leningrad/134/17/1957 (Len17 IDCDCRG46D).~Administered intranasally as drops at a dose of 10⁷·⁵ (plus or minus ⁰·⁵) 50% egg infectious dose (EID50), formulated in a total volume of 0.5 mL sterile saline (0.25 mL per nostril)."
214344796|NCT05647447|DRUG|Osanetant|Osanetant 200 mg orally, twice per day
214344797|NCT06347419|OTHER|Physiotherapy evaluation|In the physiotherapy evaluation, patients' spinal stability, rotary stability, and body awareness will be assessed.
214344798|NCT01713595|DRUG|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
214344799|NCT03671603|DRUG|Iodixanol|Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
214344800|NCT03146169|BEHAVIORAL|Training group|"The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months"
214952825|NCT03300050|BIOLOGICAL|AS03-adjuvanted cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV) plus AS03 adjuvant: HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
214952826|NCT03300050|BIOLOGICAL|cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV):~HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
214952827|NCT03300050|BIOLOGICAL|AS03-adjuvanted cH8/1N1 IIV|"Chimeric H8 head with H1 stalk plus N1 (cH8/1N1) inactivated influenza vaccine plus AS03 adjuvant: HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
214952828|NCT03300050|BIOLOGICAL|Normal saline|Administered intranasally as 0.25 mL nasal drops per nostril
214952829|NCT03300050|BIOLOGICAL|Phosphate buffered saline (PBS)|Administered intramuscularly as 0.5 mL injection
214952830|NCT05768529|DRUG|U16|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
214952831|NCT01898052|DRUG|single anaesthetic drug|inject periarticular tissue of the knee after implantation
214952832|NCT01898052|DRUG|multimodal drug injection|inject periarticular tissue of the knee
214952833|NCT00985933|DRUG|AZD8529|6 capsules by mouth 1 time 12 to 24 prior to assessments
214952834|NCT00985933|DRUG|Placebo to match AZD8529|6 capsules by mouth 1 time 12 to 24 hours prior to assessments
214952835|NCT02104882|RADIATION|Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)|
214952836|NCT00469248|DEVICE|Intra-aortic balloon pump counterpulsation|
214952837|NCT00812175|DRUG|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
214952838|NCT01810744|OTHER|capillaroscopy|
214344801|NCT00647712|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fasting
214344802|NCT00647712|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fasting
214952839|NCT01810744|OTHER|blood pressure measurement|
214952840|NCT02634619|PROCEDURE|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
214952841|NCT02634619|PROCEDURE|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
214952842|NCT06548633|OTHER|Lumbar Vertebral Mobilisation|The participants received Vertebral Lumbar Mobilisations, these were posterior-anterior central vertebral pressures (PACVPs) for four sets of 30 seconds, with up to 30s between each, at a grade III amplitude.
214952843|NCT04146857|OTHER|Normoxia|Nap in hypoxia chamber at 20.9% oxygen (36 m asl)
214952844|NCT04146857|OTHER|Hypoxia 1|Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)
214952845|NCT04146857|OTHER|Hypoxia 2|Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)
214344803|NCT04483869|OTHER|Thermography|thermographic image a 1, 3, 5 et 10 minutes of life
214344804|NCT06534203|OTHER|Investigation - Observational Study|In this study, there will be no intervention, instead, it will be an observational study aimed at identifying the specific physical demands of caregivers working in long-term care facilities. This information will inform future interventions that can help reduce the occurrence of work-related musculoskeletal injuries.
214952846|NCT04099342|DEVICE|FEAST|FEAST with standard electrode configuration and current flow
214952847|NCT04099342|DEVICE|FEAST RP|FEAST with standard electrode configuration and reversed current flow
214952848|NCT05732285|BEHAVIORAL|CRT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
214344805|NCT06281548|BEHAVIORAL|RESTART|Project RESTART (Resisting STigma And Revaluating your Thoughts) is a theory-informed, 4-week automated text message intervention to address self-stigma in people who use drugs. The intervention delivers two daily messages to participants for four weeks (56 messages total). Messages address the four components of the personal level of Stigma Resistance Theory: Not believing stigma/catching and challenging stigmatizing thoughts; empowering oneself through learning about substance use and one's own recovery; maintaining one's recovery and proving stigma wrong; and developing a meaningful identity and purpose apart from one's substance use. Content is informed by evidence-based psychotherapeutic approaches (e.g., Acceptance and Commitment Therapy) and health communication theory (e.g., Elaboration Likelihood Model). Messages include psychoeducation about substance use and stigma, coping advice, and suggestions for how to set personal goals, identify values, and build self-esteem.
214952849|NCT05732285|BEHAVIORAL|CBT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
214952850|NCT05732285|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
214344806|NCT01618838|RADIATION|CyberKnife radiosurgery|"Treatment Planning:~Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the Planning Treatment Volume (PTV) and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively."
214344807|NCT00288587|DRUG|IV loop diuretic|Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
214678404|NCT02707094|DEVICE|Biomodulator|The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
214678405|NCT02707094|OTHER|Usual Care (Medication + Exercise)|The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
214344808|NCT00288587|DEVICE|NxStage System One|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
214952851|NCT05732285|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
214952852|NCT05617963|DRUG|Durvalumab|Patients showing a disease control (defined as stable disease \[SD\], partial response \[PR\], or complete response \[CR\] according to RECIST v1.1) at the radiological evaluation performed after the end of thoracic CRT will receive durvalumab intravenously 1500 mg every 4 weeks until disease progression, unacceptable toxicity, death or patient's decision for a maximum of 24 months.
214952853|NCT03957590|DRUG|Tislelizumab|Administrated at dose of 200 mg intravenously (IV)
214344809|NCT03689322|OTHER|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
214344810|NCT03689322|OTHER|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
214344811|NCT03689322|OTHER|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
214344812|NCT00022464|DRUG|temsirolimus|
214344813|NCT00778466|DRUG|metformin hydrochloride 1000 mg tablets|
214344814|NCT05903560|PROCEDURE|endovascular recanalization via radial approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach
214344815|NCT05903560|PROCEDURE|endovascular recanalization via femoral approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach
214344816|NCT03910127|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214952854|NCT03957590|DRUG|Placebo|Placebo to match tislelizumab
214952855|NCT03957590|DRUG|Paclitaxel|Administered as 135 mg/m² IV injection
214344817|NCT03910127|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
214344818|NCT03910127|DRUG|Anlotinib|matching placebo
214344819|NCT00949351|DRUG|Aliskiren 300mg/d|Aliskiren 300mg/d v.s. placebo for 12wk
214344820|NCT00754845|DRUG|letrozole|Given orally
214344821|NCT00754845|OTHER|placebo|Given orally
214344822|NCT03030300|DRUG|Novolin 30R;Pioglitazone;Metformin|"* Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~* Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~* Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
214344823|NCT00210834|DRUG|epoetin alfa|
214344824|NCT01678326|PROCEDURE|EUS-Rendezvous or direct intervention|
214952856|NCT03957590|DRUG|Cisplatin|Administered as 25 mg/m² IV injection
214952857|NCT03957590|RADIATION|Radiotherapy|Administered at a total dose of 50.4 Gy in 28 fractions
214952858|NCT04697719|DRUG|Aspirin 81mg|81mg oral capsule
214952859|NCT04697719|DRUG|Aspirin 325mg|325mg oral capsule
214952860|NCT04721353|DRUG|Prazosin Hydrochloride|prazosin hydrochloride oral 1-25 mg/day
214952861|NCT04264897|DRUG|Metformin|"Metformin (Hunter Pharmacy) following a ramp up dosing protocol with a targeted dose of 1500 mg/day for 12 weeks."
214952862|NCT04264897|DRUG|Placebo oral tablet|Silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate
215076814|NCT05734001|DIAGNOSTIC_TEST|ROTEM Tests|"This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~1. EXTEM CT \> 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg~2. FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
215076815|NCT05734001|DIAGNOSTIC_TEST|Conventional Haemostatic Tests|"To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~1. If INR: \> 2.5 FFP will be transfused at 15 ml/kg~2. If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~3. If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
215076816|NCT05115240|BEHAVIORAL|Body Scan|The body scan intervention aims to raise one's awareness of one's own body. It is considered a relaxation, meditation or mindfulness intervention. During the body scan participants will walk through his or her body by focusing their mind on specific body parts without analyzing, judging or reacting.
215076817|NCT05115240|OTHER|Audio-book|Participants listen to an audio book for the same amount of time as the body scan groups
215076818|NCT03968575|DEVICE|laser treatment|sub-threshold micro-pulse laser treatment
215076819|NCT05305833|BIOLOGICAL|Stem Cells|ATMP
215076820|NCT06112821|OTHER|Data collection in medical records|Data collection in medical records
215076821|NCT06112821|OTHER|Blood sampling|Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.
214344825|NCT01678326|PROCEDURE|Advanced ERCP Biliary Access Techniques|
214344826|NCT00141440|PROCEDURE|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
215076822|NCT01607333|DRUG|Lamotrigine use|Lamotrigine prescription during the study period
214344827|NCT03443466|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
214344828|NCT03443466|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
214344829|NCT02268591|DEVICE|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
214344830|NCT00661063|DRUG|ketamine|ketamine 150 mcg/g bid
214344831|NCT00661063|DRUG|vehicle gel|bid - 12 weeks
214344832|NCT00661063|DRUG|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
214952863|NCT06390995|DRUG|TAK-853|TAK-853 intravenous injection
214952864|NCT05351749|BEHAVIORAL|New-prescription Alert|An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
214952865|NCT05351749|BEHAVIORAL|New-prescription Alert with referral option|An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
214952866|NCT05351749|BEHAVIORAL|Existing-prescription notification to prescriber|Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
214344833|NCT00661063|DRUG|clonidine gel 1%|bid 12 weeks
214952867|NCT05351749|BEHAVIORAL|Existing-prescription notification to pharmacist|Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
214952868|NCT06343714|DRUG|FB1003|Subcutaneous (SC) injection
214952869|NCT06343714|DRUG|Placebo|Subcutaneous (SC) injection
214952870|NCT05355311|DRUG|L-carnitine|L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
214952871|NCT05367024|OTHER|Broccoli soup|Participants will consume one broccoli soup three times a week for one 12-week intervention period as part of their normal diet.
214344834|NCT00127673|DRUG|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
214678406|NCT02940054|OTHER|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
214952872|NCT05367024|OTHER|Courgette soup|Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
214952873|NCT04752306|OTHER|Interviews|Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.
214952874|NCT05187091|RADIATION|Swallowing and submandibular sparing IMRT|Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures \& submandibular gland sparing by SWOAR-IMRT
214952875|NCT02088398|DRUG|ACY-1215|
214952876|NCT00631163|DRUG|Deferasirox (ICL670)|The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
214952877|NCT02233621|OTHER|[18F]FES (16α-[18F]Fluoro-17β-estradiol)|PET with \[18F\]FES before coelioscopy
214952878|NCT02750696|DRUG|Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
214952879|NCT02750696|DRUG|Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
214952880|NCT01482234|BEHAVIORAL|TXT Me|text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
214952881|NCT06636812|DRUG|Losartan potassium|Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo
214952882|NCT06636812|OTHER|Placebo|Single tablet encapsulated identically to placebo
214952883|NCT05362370|DEVICE|Stryker's PEEK Customized Implant|The PEEK Customized Implants will be used in this patient cohort for augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton (orbital rim, zygoma, and adjacent bone); including but not limited to, the correction and prevention of persistent temporal hollowing (PTH).
214952884|NCT02714036|DRUG|ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
214952885|NCT02714036|DRUG|Ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
214952886|NCT05180799|BIOLOGICAL|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
214952887|NCT05180799|BIOLOGICAL|Nivolumab|Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1
214952888|NCT05180799|BIOLOGICAL|Pembrolizumab|Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor
214952889|NCT05180799|DRUG|Pemetrexed (Alimta)|pemetrexed with either cisplatin or carboplatin
214952890|NCT05353660|OTHER|No intervention|No intervention
214952891|NCT00913302|BEHAVIORAL|Cardiovascular Training|cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
214952892|NCT01080859|DEVICE|OCT|Optical coherence tomography
214952893|NCT01080859|DEVICE|OCT|Optical coherence tomography
214952894|NCT03590223|PROCEDURE|Coronary Bypass Revascularization|analysis of perioperative major cardiovascular events in diabetic patients
214952895|NCT03294200|DEVICE|TriCinch Coil System implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
214952896|NCT02146820|DEVICE|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
214952897|NCT01597492|BIOLOGICAL|Belimumab plus Early Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
214952898|NCT01597492|BIOLOGICAL|Belimumab plus Late Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
215076823|NCT03496350|BEHAVIORAL|Internet-delivered CBT|Culturally adapted transdiagnostic internet-delivered CBT in Arabic
214344835|NCT00127673|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
214344836|NCT03348254|DRUG|Single shot antibiotic prophylaxis|single shot preoperative antibiotic prophylaxis
214344837|NCT03348254|DRUG|Multiple shot antibiotic prophylaxis|Multiple shot perioperative antibiotic prophylaxis
214678407|NCT01148056|RADIATION|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
214344838|NCT04740515|OTHER|pharmacists involved PPMTM|This was an open labelled randomised study. Preterm Infants With iron supplementation were recruited and arbitrarily divided into the intervention group (usual care plus PPMTM) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
214344839|NCT00358735|DEVICE|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
214344840|NCT00358735|DRUG|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
214344841|NCT01334697|DRUG|recombinant human cardiotrophin-1|Single dose intravenous administration
214344842|NCT01334697|OTHER|Placebo|Single dose intravenous administration
214344843|NCT03985319|DRUG|YYD601 20mg|Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
214344844|NCT03985319|DRUG|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori
214952899|NCT03961516|DEVICE|Frequently Sampled Oral Glucose Tolerance Test and CGM|Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.
214952900|NCT03961516|RADIATION|MRI Pancreas and Liver|Patients will undergo an MRI of the pancreas and liver
214952901|NCT03518502|PROCEDURE|transarterial chemoembolization (TACE)|Standard therapy for intermediate HCC, but nor for advanced HCC
214952902|NCT03518502|DRUG|Sorafenib|Standard therapy for advanced HCC
214952903|NCT04269720|BEHAVIORAL|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques, guided imagery, and/ or self-talk.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to use this device daily for 10 mins for the duration of the 8-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the 8-week biofeedback intervention.
214952904|NCT01633970|DRUG|5-FU|Participants will receive 5-FU 400 mg/m\^2 IV q2w.
214952905|NCT01633970|DRUG|Atezolizumab|Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
214344845|NCT05509972|DEVICE|total knee prosthesis implantation|Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living
214344846|NCT05274945|RADIATION|Radiotherapy|radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil
214344847|NCT05274945|DRUG|consolidation chemotherapy|6 cycles of FOLFOX or CAPOX
214344848|NCT05274945|PROCEDURE|TME or APR|total mesorectal excision or abdominoperineal resection
214344849|NCT03947645|DEVICE|Ipsilesional stimulation|Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle
214678408|NCT03955107|DEVICE|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) every 4 weeks since diagnosed with GDM，and the control grouponly once receive CGMS during the last month and have management adjusted based on the CGMS readings Other Name: iPro, Medtronic
214678409|NCT01902797|OTHER|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
214678410|NCT03293095|PROCEDURE|Standard Care|The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
214952906|NCT01633970|DRUG|Bevacizumab|Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.
214678411|NCT00915005|RADIATION|Photon Therapy|Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
214952907|NCT01633970|DRUG|Carboplatin|Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
214952908|NCT01633970|DRUG|Leucovorin|Participants will receive leucovorin 400 mg/m\^2 IV q2w.
215076824|NCT03496233|DRUG|Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]|Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
215076825|NCT01728558|OTHER|Early goal Directed Sedation|
214344850|NCT03947645|DEVICE|Contralesional stimulation|Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
214344851|NCT03176693|DRUG|Phenoxybenzamine|Non-selective alpha blocker
214344852|NCT03176693|DRUG|Doxazosin|Selective alpha blocker
214678412|NCT00915005|RADIATION|Proton Therapy|"Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete."
214678413|NCT00915005|DRUG|Paclitaxel|50 mg/m2 by vein 1 time each week for 7 weeks.
214678414|NCT00915005|DRUG|Carboplatin|AUC 2 by vein 1 time each week for 7 weeks.
214952909|NCT01633970|DRUG|Nab-paclitaxel|Participants will receive nab-paclitaxel 100 mg/m\^2 IV qw.
214952910|NCT01633970|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV q2w.
214952911|NCT01633970|DRUG|Paclitaxel|Participants will receive paclitaxel 200 mg/m\^2 IV q3w.
214952912|NCT01633970|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV q3w.
215076826|NCT01728558|OTHER|Standard care sedation|
215076827|NCT01939002|DRUG|BIIB017|
215076828|NCT01939002|DRUG|naproxen|
214344853|NCT04450589|DIETARY_SUPPLEMENT|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
214344854|NCT04450589|OTHER|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
214344855|NCT04450589|OTHER|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
214344856|NCT04450589|OTHER|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
214344857|NCT04450589|DIETARY_SUPPLEMENT|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
214344858|NCT04450589|OTHER|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
214344859|NCT04450589|OTHER|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
214344860|NCT04450589|OTHER|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
214344861|NCT03846700|DEVICE|aquablation|"minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet"
214344862|NCT03846700|DEVICE|holep|holmium laser enucleation of prostate
214952913|NCT02148315|BEHAVIORAL|garden|
214952914|NCT02288481|DRUG|TBA-354|TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
215076829|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
214344863|NCT03846700|DEVICE|pvp|photoselectivevaporization of prostate
214952915|NCT02288481|OTHER|Placebo|Placebo Suspension
214952916|NCT03404934|DEVICE|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
214952917|NCT03232268|BIOLOGICAL|HLA-mismatched microtransplantation|3 administrations of hematopoietic stem cells without immunosupression
214952918|NCT01729858|DEVICE|Ceramic-Ceramic|"Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.~Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline."
215076830|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
215076831|NCT01568450|DRUG|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
215076832|NCT05049213|DRUG|Carrageenan nasal spray and 1% PVP- mouthwash and gargle|"Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time"
215076833|NCT01182805|DEVICE|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
215076834|NCT01182805|DEVICE|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
215076835|NCT01182805|DEVICE|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
214344864|NCT06558318|OTHER|Assessment of temporomandibular dysfunction|TMJ dysfunction will be measured using the Fonseca Amnestic Index. The Fonseca Amnestic Index is used to assess the severity of temporomandibular joint (TMJ) dysfunction. The index consists of 10 questions, with each question scored as 0, 5, or 10 points, depending on the severity of symptoms. The maximum total score is 100, where a higher score indicates a more severe level of TMJ dysfunction. Therefore, patients with higher scores on the Fonseca Amnestic Index are considered to have more significant TMJ issues. Based on Fonseca scores, two groups will be formed: those with scores over 20 will be labeled 'with TMJ dysfunction,' and the others 'without TMJ dysfunction.
214952919|NCT01729858|DEVICE|Metal-Ceramic|"Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.~Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline."
214952920|NCT06349811|DRUG|BL-M05D1|Administration by intravenous infusion for a cycle of 3 weeks.
214952921|NCT05977881|OTHER|CHECKIT!|"Participants will not be assigned to the intervention as it will be available to everyone.~Check it will be a van-based HIV- and overdose-prevention program offered in the four areas of Baltimore city from which study participants are recruited. Intervention services will include point-of-care drug checking and PrEP assessment, prescription, and management, and they will be available to everyone, regardless of whether they are part of the SCOPE study cohort or not.~Individual-level service usage data collected by intervention staff will not be considered in analysis of outcomes. However, study participants will self-report Check it utilization on the internally-developed surveys at 6, 12, and 18 months."
214344865|NCT05923281|DRUG|K-877 0.2 mg/day (once daily)|K-877 0.2mg tablet
214952922|NCT06634108|DRUG|Genistein|The genistein capsules are manufactured and obtained from MCS Formulas, and each capsule contains 250 mg genistein and 50 mg inulin. The genistein is certified to be 98% pure genistein by HPLC and is certified by Good Laboratory Practice (GLP). They will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood and stool samples are collected. Then, participants will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before collecting fasting blood and stool samples. Afterward, participants will take 750 mg of genistein BID (1500 mg total) for 4 weeks before collecting fasting blood and stool samples. Afterward, participants will have a washout for 6 weeks before returning for fasting blood and stool sample collection.
214952923|NCT06484699|PROCEDURE|open repair of perforated peptic ulcer|group (A) includes patients with perforated peptic ulcer that will be operated by open repair approach
214952924|NCT06484699|PROCEDURE|laparoscopic repair of perforated peptic ulcer|group (B) includes patients with perforated peptic ulcer that will be operated by laparoscopic repair approach
214952925|NCT03624569|OTHER|Bagel|A bagel will be consumed daily for 2 weeks.
214952926|NCT03624569|OTHER|Potato|A potato will be consumed daily for 2 weeks.
214952927|NCT04577859|DEVICE|ensoETM. Esophageal cooling during AF ablation|Esophageal cooling during AF ablation: The ensoETM probe is inserted via the orogastric route when the patient is under general anesthesia. The device is set to cool during ablation of the posterior aspect of the left atrium, to protect against transmitted thermal energy and so reduce or prevent esophageal thermal injury.
214952928|NCT04577859|DEVICE|Esophageal temperature monitoring probe|An esophageal temperature monitoring probe is a typical monitoring device used in standard of care AF ablations. This allows any temperature rise in the esophagus to be detected during ablation. If the temperature reaches \>38 degrees then it is widely recognized that ablation should be halted until the temperatures fall back to below 38 degrees. It therefore has the ability to detect esophageal temperature rise only.
214952929|NCT03911947|DEVICE|Vibrolung|Device for vibroacoustic respiratory therapy
214952930|NCT02247297|PROCEDURE|Blood collection|Diagnostic blood collection
214344866|NCT05923281|DRUG|K-877 0.4 mg/day (once daily)|K-877 0.2mg tablet
214344867|NCT05923281|DRUG|Placebo (once daily)|Placebo tablet
214344868|NCT01694537|DRUG|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
214952931|NCT05286060|DRUG|GX-188E, GX-I7, Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 1200㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
214952932|NCT05286060|DRUG|GX-188E, Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
214952933|NCT05286060|DRUG|GX-188E, GX-I7, Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
215076836|NCT04715204|OTHER|High Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. Formula with caloric density of \>1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
214344869|NCT01694537|DRUG|placebo|Placebo is made with same size and shape with study drug.
214344870|NCT00053430|DRUG|Thalidomide|Tablet taken orally daily
214344871|NCT00053430|DRUG|Thalidomide placebo|Placebo tablet taken orally daily
214344872|NCT02279641|DRUG|RDEA3170 10 mg|
214344873|NCT02279641|DRUG|allopurinol 300 mg|
214344874|NCT03809845|DEVICE|High-density surface electromyography|High-density surface electromyography
214344875|NCT04012398|DIAGNOSTIC_TEST|Amsterdam IADL Questionnaire short, German version|Questionnaire to assess impairments in instrumental activities of daily living
214952934|NCT05286060|DRUG|GX-188E, GX-I7|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa
214952935|NCT02826577|DRUG|Pregnenolone 175mg|Single Dose 175mg
214952936|NCT02826577|DRUG|Pregnenolone 400mg|Single Dose 400mg
214952937|NCT02826577|DRUG|Placebo|Single Dose
214952938|NCT04072731|OTHER|pathologic|All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
214952939|NCT04081831|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Follow clinical administration
214952940|NCT03561545|OTHER|weightlessness (parabolic flight)|weightlessness (parabolic flight)
214952941|NCT06187272|BEHAVIORAL|Listening to music|Students listened to background music during a practical examination of 60 bpm.
214952942|NCT04273867|OTHER|Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument|This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.
214952943|NCT04733222|OTHER|Perturbation training|"The treadmill perturbation training will be performed on a computer-controlled treadmill. The perturbation will be induced by fast forward (slip) or backward (trip) accelerations of the treadmill at specific gait cycle timings. The perturbations will be delivered randomly to enhance the unpredictability. A ceiling-mounted body-harness ensures the safety of the participants.~Participants will be assigned to three initial sessions of treadmill slip- and trip-perturbation training on two days separated by a week and a booster-session after six months. On day 1, participants will first undergo a session 1 with 40 slip perturbations and then a session 2 with 40 trip perturbations. On day 2, participants will undergo a session 3 with 20 slip and 20 trip perturbations in random order. The booster-session after six months will be similar to session 3 (20 of each perturbation in random order)."
214952944|NCT04733222|OTHER|Treadmill walking|Participants allocated to the walking group will walk at a self-selected pace on a computer-controlled treadmill for the same amount of time as the treadmill perturbation training participants.
214952945|NCT04358211|BIOLOGICAL|Biological: COVID-19 convalescent plasma|One unit of ABO compatible COVID-19 convalescent plasma
214952946|NCT02053259|BEHAVIORAL|Adaptive Goals|
214952947|NCT02053259|BEHAVIORAL|Reinforcement|
214952948|NCT02053259|BEHAVIORAL|Static Goals|
214344876|NCT05928338|BEHAVIORAL|Peer-supported, WhatsApp-assisted lifestyle modification intervention|The lifestyle modification intervention, supported by peers and WhatsApp voice calls aimed to assist participants in making dietary modifications, increasing physical activity, and achieve a weight loss of 5% of their initial body weight as well as avoid weight gain. A trained nutritionist delivered the intervention after the baseline assessment individually or in groups that covered six sessions related to dietary modifications, physical activity, set-up goals and action plans, and peer assignments and then once monthly for a year using WhatsApp voice calls to the participants and peers.
214952949|NCT01785758|DRUG|Sugammadex (4 mg/Kg)|Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
215076837|NCT04715204|OTHER|Standard Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
214344877|NCT03873051|BEHAVIORAL|Challenge-Focused Program|Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.
214952950|NCT06482619|DIETARY_SUPPLEMENT|Creatine supplementation|The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained creatine monohidrate (Creapure, Crown Sport Nutrition, Arnedo, Spain)
214952951|NCT06482619|DIETARY_SUPPLEMENT|Placebo|The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained placebo (i.e., sucrose)
214952952|NCT05388084|BEHAVIORAL|Male peer engagement|Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.
214952953|NCT05388084|BEHAVIORAL|SOC and delayed intervention|Females receive standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
214952954|NCT00489294|DRUG|Syntropin|
214952955|NCT06257160|PROCEDURE|Surgical infiltration|"During surgery, local anesthetics are injected as follow: in the deep plane and in the subcutaneous territory.~Infiltration of the deep plane corresponds to pericotyloid injection, with particular attention to the posterior subcapsular area, the obturator foramen and the psoas muscle. Infiltration of the muscular planes is added, with infiltration of the gluteal and pelvitrochanteric muscles."
214344878|NCT03873051|BEHAVIORAL|Rewards-Focused Program|Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
214678415|NCT01109706|OTHER|biological parameters dosage|"200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up."
214678416|NCT04761497|OTHER|Actice music therapy|active music therapy sessions for three months
214952956|NCT06257160|PROCEDURE|PENG Block ultrasound-guided|"We perform the femoral block under ultrasound after anesthesia (general or rachianesthesia). The PENG block is a peripheral diffusion nerve block that specifically targets the articular divisions of the femoral, obturator and accessory obturator nerves.~The femoral nerve innervates the four parts of the joint capsule, with inconsistency in the anterior inferomedial part of the capsule.~The obturator nerve innervates the inferior part of the anterior face of the capsule.~The accessory obturator nerve innervates the medial half of the hip joint capsule in over 50% of cases."
214952957|NCT04671355|DRUG|Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg|Pressurized metered dose inhaler
214952958|NCT04671355|DRUG|Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg|Dry powder inhaler
214952959|NCT01259674|DEVICE|AboMeg-B-09|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
214952960|NCT01259674|OTHER|Placebo|Placebo syrup: 5ml to be taken 4 times a day during the entire study period
214952961|NCT00528073|DRUG|Rifaximin-EIR|Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
214952962|NCT04885790|OTHER|"Respiratory assessment using Spiropalm 6MWT portable spirometry"|"Spiropalm 6MWT portable spirometry will be used during six-minute walk test for evaluation of dynamic hyperinflation and other related ventilatory parameters. The device will also be used as regular spirometry."
214952963|NCT04885790|OTHER|Evaluation of functional exercise capacity|Functional exercise capacity of patients will be evaluated using six-minute walk test.
214952964|NCT04885790|OTHER|Evaluation of peripheral muscle strength|Handgrip strength and M. Quadriceps strength will be evaluated using hand-held dynamometer.
214952965|NCT04885790|OTHER|Evaluation of chronic cough|The Leicester Cough Questionnaire will be used for evaluating cough.
214952966|NCT04350931|BIOLOGICAL|intradermal injection of BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds
214952967|NCT04350931|OTHER|placebo|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus
214952968|NCT04365673|OTHER|Pharmacist transition of care consultation|Pharmacist-delivered comprehensive medication review
214952969|NCT04627558|OTHER|stroke patients, balance assessment|validity relability dubousset functional test
214952970|NCT00650728|PROCEDURE|placing gastric tube|
214952971|NCT01404897|OTHER|Dietary Intervention|3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
214952972|NCT01404897|OTHER|Dietary Intervention|3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
214952973|NCT01404897|OTHER|Dietary Intervention|3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
214952974|NCT05057858|DRUG|co-formulated 300 mg TDF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
214952975|NCT01096498|DRUG|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of one 0.75 mg coated tablet
215076838|NCT04715204|OTHER|Formula-75/Formula-100|"Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml"
214678417|NCT04761497|OTHER|Watching nature videos|nature videos sessions for three months
214678418|NCT04761497|OTHER|Passive music therapy|passive music therapy for three months
214952976|NCT01096498|DRUG|Levonorgestrel (Postday)|Single dose of one 0.75 mg tablet
214952977|NCT00497341|DRUG|cefuroxime|cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm
214952978|NCT00497341|DRUG|placebo|cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
214952979|NCT02683408|OTHER|placebo|inactive placebo
214952980|NCT02683408|DIETARY_SUPPLEMENT|diosmiplex|diosmiplex is an FDA regulated medical food product
214952981|NCT04140084|DEVICE|Real-life clinical meetings|Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
214344879|NCT05415098|DRUG|APG-5918|"The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.~The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study."
214344880|NCT04662307|DEVICE|Intelligent cardiopulmonary rehabilitation system (ICRS)|Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%\~80% HRR determined in the pretest of cardiopulmonary exercise test.
214344881|NCT02762526|PROCEDURE|Lipoabdominoplasty|
214344882|NCT00333593|DEVICE|Large pore dialyser|
214344883|NCT00333593|DEVICE|Standard dialyser|
214344884|NCT06535815|OTHER|Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.
214344885|NCT01501318|BEHAVIORAL|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
214952982|NCT00004500|DRUG|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
215076839|NCT01165112|DRUG|Bendamustine Hydrochloride|Given IV
215076840|NCT01165112|DRUG|Carboplatin|Given IV
215076841|NCT01165112|BIOLOGICAL|Rituximab|Given IV
215076842|NCT01165112|DRUG|Etoposide|Given IV
215076843|NCT01165112|OTHER|Laboratory Biomarker Analysis|Correlative studies
215076844|NCT04269577|BEHAVIORAL|SSP training|Participants will practice the Swipe Slide Pattern (SSP) task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
215076845|NCT04376047|OTHER|Reverse Trendelenburg position|The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.
214344886|NCT01501318|BEHAVIORAL|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
214344887|NCT05800522|BEHAVIORAL|Behavioral parent or child directed intervention|Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.
214344888|NCT05800522|BEHAVIORAL|Supportive Parents - Coping Kids|Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.
215076846|NCT04376047|OTHER|Semi-recumbent position|The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
215076847|NCT02629848|DRUG|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
214678419|NCT03070418|PROCEDURE|Mini Incision Dynamic Hip Screw Technique|This technique is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision over the guide wire that is inserted parallel to the anteversion wire by using the 135° guide fixed on the T-handle; (step 2-2), and continuing AO technique steps, until step 3-4, for the plate assembling we remove the guide wire, and insert the plate sliding it through the skin cut over the femur shaft under the muscles using the plate for dissection the soft tissue above the bone surface non using any tool as periosteal elevator but the plate itself by holding it from its DHS screw canal and in 180 degree rotation position in axial aspect (transvers aspect) using the plate end for soft tissue gentle dissection over the bone, then turning the plate 180 degree over the bone shaft to the right position and sliding the DHS screw plat canal over the DHS screw using the measuring bar. Two skin stitches are enough.
214952983|NCT00004500|OTHER|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
215076848|NCT02629848|DRUG|Placebo|Motesanib placebo-matching tablets
215076849|NCT02629848|DRUG|Paclitaxel|Paclitaxel IV
215076850|NCT02629848|DRUG|Carboplatin|Carboplatin IV
214344889|NCT03857438|DRUG|Ongoing treatment for bipolar mania|Prescribed by the following doctor during hospitalization and after discharge
214344890|NCT03857438|DIAGNOSTIC_TEST|Audiovisual recording during guided presentation|Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
214952984|NCT02976402|RADIATION|SBRT|"Postoperative RT consisting in:~* 31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~* 32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
214952985|NCT03517449|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
215076851|NCT03300024|DEVICE|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
215076852|NCT03300024|DEVICE|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
215076853|NCT01518998|DRUG|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
214952986|NCT03517449|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
214952987|NCT03517449|DRUG|Paclitaxel|80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
215076854|NCT01926171|DRUG|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
215076855|NCT00845039|BIOLOGICAL|Cetuximab|Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
215076856|NCT00845039|DRUG|Irinotecan|180 mg/m² every 14 days until disease progression or participant intolerance
215076857|NCT00845039|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
215076858|NCT00570037|BIOLOGICAL|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
215076859|NCT00433160|DRUG|Teriparatide|daily, subcutaneous
214344891|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose1|Tablet,dose1,QD
214344892|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose2|Tablet,dose1, dose2 QD
214344893|NCT04180982|DRUG|SHR4640 dose2 plus Febuxostat dose3|Tablet,dose2, dose3 QD
214344894|NCT01924325|DRUG|Apixaban|orally active direct factor Xa inhibitor
214344895|NCT01924325|DRUG|Clopidogrel|an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
214344896|NCT01924325|DRUG|Aspirin|a non-steroidal anti-inflammatory drug
214952988|NCT03517449|DRUG|Doxorubicin|60 mg/m\^2 administered by IV on Day 1 of each 21-day cycle.
214952989|NCT05463939|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
214952990|NCT06822075|BEHAVIORAL|SANTE program|"The intervention will consist of distinct period. Fisrt, 3 complete assessment periods will be realized : pre-intervention (week 1-2) ; mid-intervention (week 8-9) ; post-intervention (week 15 - 16) for evaluate the evolution of the health-related behavior, mental and physical health. Second, the SANTE program intervention will be implemented. Intervention 1 (week 3 and 7) for INT-1 group receive the SANTE program and INT-2 group do noting ; Intervention 2 (week 10-14) for INT-2 group receive the SANTE program and INT-1 do noting.~The SANTE intervention will consist of (at a minimum):~* 1 to 2 group physical activity sessions per week~* 1 outdoor outing (full-day or half-day) per month~* 1 individual meeting with a physical activity and sports expert"
214952991|NCT05903313|DRUG|Chang Gung ECG Abnormality Detection Software|This device is expected to be used for the static 12-lead ECG to detect whether there are abnormal ECG signals related to diseases and outputs the results.
214952992|NCT01230216|DRUG|control systolic blood pressure less than 120 mmHg|use losartan to control blood pressure
215076860|NCT00433160|DRUG|Placebo|daily, subcutaneous
215076861|NCT05417269|DRUG|IMCY-0141|"The investigational medicinal product (IMP) consists in a small synthetic peptide (23 amino acids - IMCY-0141) combining a known human epitope of MOG flanked with a thioredox motif, presented in the form of a freeze-dried sterile powder and diluent for subcutaneous (SC) administration. The diluent includes the adjuvant aluminium hydroxide (alum) at a concentration of 900 μg/mL. Treatment will be injected within 4h of resuspension of the powder with the diluent.~Treatment will consist of 6 immunizations (separated by 14 days) of the IMP by SC injection in the upper arm, in the region of the triceps (lateral part of the arm, midway between the elbow and the shoulder). Half of the dose to be administered will be injected concomitantly in both arms."
215076862|NCT05417269|DRUG|Placebo|"The placebo will be administered by subcutaneous route, once every two weeks for 6 times. Placebo will be administered to patients randomized in the placebo group during Phase II only."
215076863|NCT05417269|DRUG|Dimethyl Fumarate|"Dimethyl Fumarate (DMF) will be given orally, according to its SmPC for the whole duration of the study.~Dimethyl Fumarate (DMF) will be administered to patients randomized in the active control group during Phase II only."
215076864|NCT03197428|OTHER|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
215076865|NCT03197428|OTHER|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
214344897|NCT01924325|DRUG|placebo|
214344898|NCT03882125|BEHAVIORAL|Mindfulness-based relapse prevention|Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
214952993|NCT01230216|DRUG|control systolic blood pressure less than 140 mmHg|use losartan to control blood pressure
214952994|NCT05742191|OTHER|Daylight Savings time transitions|Daylight Savings time transitions.
214344899|NCT02194049|DRUG|BKM120|Given PO
214344900|NCT02194049|DRUG|cisplatin|Given IV
214344901|NCT02194049|DRUG|etoposide|Given IV
214344902|NCT04425083|OTHER|no intervention|no intervention
214344903|NCT06127069|DEVICE|chitosan brush|debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
214344904|NCT06127069|DEVICE|ultrasonic scaler|debridement of periodontal pockets only with ultrasonic scaler
214344905|NCT02370212|DIETARY_SUPPLEMENT|Creatine|
215076866|NCT05565573|DRUG|Medroxyprogesterone Acetate 500 MG Oral Tablet|500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate At a dosage of 500 mg/day
214952995|NCT06972875|DRUG|Fezolinetant|Participants will receive fezolinetant for 28 days at FDA approved dosing and schedule of 45 mg po (per os/by mouth) once daily for treatment of hot flashes in menopausal women.
214952996|NCT04384757|PROCEDURE|Distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
214952997|NCT06416969|DRUG|Somatostatin|Intravenous infusion 200 ug/hr for 2 hours, 100 ug/hr for 30 minutes
214952998|NCT06416969|DRUG|Epinephrine|Intravenous infusion
214952999|NCT06383091|BEHAVIORAL|Anterior Neck Manual Therapy|Manual massage applied to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
214953000|NCT06383091|BEHAVIORAL|Pain Neuroscience Education|Description of how the pain system works from a neurobiological level, discussing the biopsychosocial model that influences pain.
214953001|NCT06383091|BEHAVIORAL|Neck Stretches|Bilateral cervical side bending, cervical extension and bilateral rotational neck stretches held for 20 seconds x3.
214953002|NCT06383091|BEHAVIORAL|Scar massage|Digital manipulation of the scar itself in circles.
214953003|NCT06383091|BEHAVIORAL|Voice Exercises|Stemple Voice Exercises
214953004|NCT06383091|BEHAVIORAL|Placebo Anterior Neck Manual Therapy|Will apply extremely light manual contact to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
214344906|NCT02370212|DIETARY_SUPPLEMENT|Placebo|
214953005|NCT06383091|BEHAVIORAL|Placebo Pain Neuroscience Education|Will discuss how pain will as a result of the surgical intervention.
215076867|NCT05565573|DEVICE|Levonorgestrel-Releasing Intrauterine System|Uterine cavity insertion
215076868|NCT04294615|OTHER|FMT through a naso-jejunal tube|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
215076869|NCT04294615|OTHER|FMT through TET|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
215076870|NCT05332743|DIETARY_SUPPLEMENT|Nutrafol Vegan Women's Hair Supplement|Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
215076871|NCT02218073|DRUG|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
215076872|NCT02218073|DRUG|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
215076873|NCT02218073|DRUG|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
215076874|NCT05950061|DRUG|Sertraline|Sertraline (200 mg/day) capsule
214344907|NCT02370212|OTHER|High intensity interval training|
215076875|NCT05950061|DRUG|Escitalopram|Escitalopram (10 mg/day) capsule
215076876|NCT01010568|DRUG|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
215076877|NCT06389331|OTHER|closed the defect with barbed suture|In direct hernia, content was reduced, and the fascia transversalis (pseudo sac) was pulled and incorporated into closure with a non-absorbable polypropylene barbed monofilament size-0 suture
214953006|NCT06383091|BEHAVIORAL|Placebo Neck Stretches|Will ask patient to look down as a neck stretch held for 20 seconds x3.
214953007|NCT04296669|DEVICE|Ergotron LearnFit Sit-Stand desk|An adjustable sit-stand desk design for children
214953008|NCT01532206|OTHER|Blood pressure cuff insufflation|Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
214953009|NCT02782754|DRUG|Carboplatin|
214953010|NCT02782754|DRUG|Etoposide|
214953011|NCT02782754|DRUG|Cyclophosphamide|
214953012|NCT02782754|DRUG|Bleomycin|
214953013|NCT02782754|RADIATION|Reduced dose of radiotherapy|
214953014|NCT02468999|DRUG|human insulin|
214953015|NCT02124070|DRUG|rh Growth Hormone|
214953016|NCT05788107|DRUG|HLX51|anti-OX40 tetravalent agonistic humanized monoclonal antibody
214953017|NCT02131116|BEHAVIORAL|Integrated Metacognitive Therapy|Integrated Metacognitive Therapy
214953018|NCT02131116|BEHAVIORAL|Treatment as Usual|Treatment as Usual
214953019|NCT00629538|PROCEDURE|Therapeutic thoracentesis|Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.
214953020|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and no tampons|Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
214953021|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 with tampons|followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
214953022|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 with no menses|Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
214953023|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and same ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
214953024|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and new ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
214344908|NCT04006977|DIETARY_SUPPLEMENT|a multistrain probiotic product (DSF)|In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.
214344909|NCT04006977|DIETARY_SUPPLEMENT|Placebo|In Arm 1, participants will receive standard medical therapy plus the placebo.
214344910|NCT00746954|DRUG|Acetazolamide|Cabonic Anhydrase inhibitor
214344911|NCT00746954|DRUG|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
214486624|NCT05441449|DEVICE|Cooling Vest|"A self-regulating cooling vest for persons with SCI that can utilize both conductive and evaporative methods to dissipate body heat as a proof-of-concept to prevent an excessive rise in Tcore and thermal discomfort during a controlled exposure to a warm environment. The vest is an article of clothing, is made of commercially-available wicking material, which once saturated with water, uses evaporation to dissipate heat. Channels embedded in the vest supply cooled water to keep the wet vest cool. The cooling capacity of the vest is regulated by a microprocessor which continuously receives feedback from the user's skin and core temperature. The vest is non-invasive and supplies no energy to the user."
214486625|NCT05791708|DRUG|Sutimlimab|CAD patients in Sutimlimab cohort must be treated according to routine clinical practice
215076878|NCT03372460|DEVICE|Active stimulation|For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinates AF7/Fp1/AF3 (using the 10-20 EEG convention) and the cathode between EEG coordinate OZ and the contralateral mastoid (covering approximately PO8/P8). The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.
215076879|NCT03372460|DEVICE|Sham stimulation|For sham tDCS, the investigators will use the same electrode and sponge configuration as active tDCS, but using the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current).
215076880|NCT03372460|OTHER|Virtual Reality (VR)|Participants will undergo VR exposure to trauma-related context.
215076881|NCT05023473|PROCEDURE|Pericapsular nerve group block|patients will receive pericapsular nerve group block
215076882|NCT05023473|DRUG|Morphine Sulfate|morphine will be given to both groups as patient-controlled analgesia PCA
215076883|NCT02499900|DRUG|Copaxone®|Subcutaneous Injections
215076884|NCT01863173|DRUG|metoprolol|using B blocker in patient group
214486626|NCT06418217|PROCEDURE|Exercise and Patient Education|"Patients will undergo a 12-week physiotherapist-led exercise program consisting of 8 supervised sessions and home-based training in between.~Patients will keep training diaries, where each session is tracked in regards of completed repetitions and pain before and after the sessions. Each session will consist of four exercises."
215076885|NCT01863173|DRUG|placebo|placebo to control group
215076886|NCT02489708|BEHAVIORAL|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
215076887|NCT04532593|PROCEDURE|autologous adipose stem cell injection|Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
215076888|NCT04532593|PROCEDURE|saline injection|saline will be injected underneath skin graft (0.05 ml/cm2).
215076889|NCT01608217|DRUG|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
215076890|NCT01608217|DRUG|Placebo|placebo (tablet) three times daily for a period of three weeks.
215076891|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
215076892|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
215076893|NCT01895231|DRUG|Iron isomaltoside 1000 (Monofer®)|
215076894|NCT01895231|DRUG|Placebo|
214344912|NCT00536133|DRUG|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
214344913|NCT00536133|OTHER|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
214344914|NCT01759589|DRUG|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
214344915|NCT01759589|DRUG|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
214344916|NCT01759589|DRUG|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
214344917|NCT01797146|PROCEDURE|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~1. Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~   * Type and duration of urinary catheter use.~  * Indication of urinary catheter \_\_\_\_\_\_\_\_\_~  * Type and duration of central venous catheter use~  * Indication of urinary catheter \_\_\_\_\_\_\_\_\_~2. Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
214344918|NCT04218929|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
214344919|NCT04218929|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
214486627|NCT05442489|DEVICE|GORE Excluder Thoracoabdominal Branch Endoprosthesis|TEVAR
215076895|NCT04590313|PROCEDURE|Arthrodesis|MTPJ I arthrodesis
215076896|NCT01796119|PROCEDURE|Ridge Splitting|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
214953025|NCT03633916|BEHAVIORAL|Classroom sensitization session|"A one-off classroom information and engagement session will be delivered in addition to school-level sensitization activities. Individual classroom sessions will be conducted by a 'lay' counsellor with support from a researcher.~The classroom session will start with a short animated video which provides age-appropriate information about types, causes, impacts and ways of coping with common mental health problems. The video will be followed by a guided group discussion, structured around a standardized script that builds on the topics covered in the video. In case of technical difficulties that may prevent the video from being shown, a flipchart based on still illustrations from the video will be used.~At the end of the session, students will be handed a self-referral form which includes normalizing information and question-based prompts to assist with self-identification of mental health problems."
214953026|NCT03633916|BEHAVIORAL|School-level sensitization activities|"The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~1. Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~2. A drop-box for student self-referral slips will be set up in a prominent location at each school.~3. Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial."
214953027|NCT01008813|BIOLOGICAL|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (3,8 microgram) adjuvanted with AS 03A
214953028|NCT01008813|BIOLOGICAL|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (15 microgram)
214953029|NCT01119846|DRUG|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
214953030|NCT01119846|DRUG|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
214953031|NCT01119846|DRUG|Sitagliptin|"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."
214953032|NCT03130270|DRUG|Apatinib mesylate tablet|"Patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC) after second-line treatment are assigned to receive apatinib mesylate tablet. A treatment cycle was defined as 28 days (4 weeks). The starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd). All patients continuous treatment until progression disease or non-tolerated toxicity.~Note: good tolerance was defined that no grade 3/4 hematology or/and non hematologic side effects occurred within 4 weeks after initiation treatment; poor tolerance was defined that grade 3/4 hematology or/and non hematologic side effects appeared within 4 weeks after initiation treatment."
215076897|NCT01796119|PROCEDURE|Implants placed using drilling technique|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
215076898|NCT01708265|OTHER|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
215076899|NCT01708265|PROCEDURE|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
215076900|NCT01771848|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
215076901|NCT03540537|OTHER|Patient-controlled intravenous analgesia|PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
215076902|NCT03540537|OTHER|Quadratus Lumborum Block|Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
214344920|NCT06535594|OTHER|Laser acupuncture|Laser acupuncture therapy will be performed five times a week for 4 weeks using laser beam. The acupoints on the ear that will be treated with laser acupuncture therapy are Zhouliao (LI12), Chize (LU5), Quchi (LI11), Shousanli (LI10) and Ashi.
214344921|NCT06535594|OTHER|Physical therapy|Physical therapy method involved six elbow joint exercises. Patients performed the six exercises sequentially under guidance, each exercise performed five times, three times a day, gradually increasing weight until the movement was effective but below the pain threshold.
214344922|NCT03641482|DRUG|NBF|Once the molar is extracted, the socket is cleaned with water, NBF gel is introduced, and the flap is closed. Then, the patients are instructed to apply NBF Gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
214486628|NCT05526664|OTHER|Genetic testing and Omics analysis|Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
214486629|NCT01606488|DRUG|Florbetapir F 18 (18F-AV-45)|Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
214486630|NCT01606488|OTHER|no intervention|
214486631|NCT06289504|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously once weekly.
214486632|NCT06289504|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
214344923|NCT03641482|DEVICE|Placebo|Once the molar is extracted, the socket is cleaned with water, placebo gel is introduced, and the flap is closed. Then, the patients are instructed to apply placebo gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
214344924|NCT03082963|DEVICE|Electrogram Morphology Mapping (EMR)|Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium \& then the left atrium.
214344925|NCT00142974|DRUG|Tegaserod|
214344926|NCT03551015|OTHER|Change in the timing of components of usual care|Bringing forward outpatient review, and cardiac rehabilitation after CABG by 3 and 4 weeks respectively.
214344927|NCT00000831|DRUG|Lamivudine|
214344928|NCT00000831|DRUG|Stavudine|
214344929|NCT00000831|DRUG|Zidovudine|
214953033|NCT03992833|OTHER|lung cancer screening|"In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume \< 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume \> 300 mm3 (positive)."
214344930|NCT00000831|DRUG|Didanosine|
214953034|NCT05940766|OTHER|Automated fever alerts|Fever alerts are automated sent to participants if fever is detected
214953035|NCT04592679|DEVICE|FES-C|The participants were submitted to 20 sessions of FES-C three/five times per week. Each session lasted about 30'.
215076903|NCT03540537|OTHER|Thoracic Paravertebral Block|Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
215076904|NCT03982264|PROCEDURE|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
214953036|NCT04592679|OTHER|Standard Treatment|The participants were submitted to 20 sessions of standard rehabilitation for lower limbs with manual mobilization, three/five times per week. Each session lasted about 30'.
214344931|NCT00655187|OTHER|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
214344932|NCT00655187|PROCEDURE|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
214953037|NCT02651649|DEVICE|Continuous Positive Airway Pressure (CPAP)|FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
214344933|NCT06116773|OTHER|Training|"Training group is supervised exercise group and will be included in a supervised cardiac rehabilitation program for 3 days a week. The program will start 2 weeks after CABG surgery and continue for 8 weeks, totaling 24 sessions. Aerobic, resistance, balance and stretching exercises will be applied within the program. Total exercise time is aimed to be ≥150 min/week for 8 weeks. A home-based exercise program will be recommended.~Moderate-intensity continuous aerobic training will be implemented using an upright exercise bike (5 minutes warm-up, 20 minutes load, 5 minutes cool down, 5 minutes recovery). Rhythmic unloaded aerobic exercises or low-load (0.5-1 kg) resistance exercises (starting from the 6th week post-op) will be performed for an average of 15-20 minutes. Balance exercises will progress from easy to difficult depending on the person's performance. Stretching exercise for the gastrocnemius muscle will be performed for 4 repetitions in a short stretching period of 15 seconds."
214344934|NCT06116773|OTHER|Control|"Patients will be informed about secondary prevention approaches which is routinely performed after discharge after CABG operation and will be recommended a home-based exercise program. Patients will be called by phone once a week and exercise monitoring will be provided. Recommended home exercise program includes:~* Breathing exercises~* Moderate intensity (RPE 4-6) walking (150 min/week).~* Posture exercises (shoulder elevation-depression, 90 degree shoulder flex-extend, 90 degree shoulder abd-add, neck joint range of motion exercises)~* They will be advised to continue range of motion exercises in the early post-operative period. (Twice a day, 10 repetitions).These exercises include ankle dorsi-plantar flexion, hip abduction-adduction, hip internal-external rotation, hip flexion-extension, arm elevation-depression in the supine position; flexion-extension in the sitting position; hip abduction-adduction, hip hyperextension and counting movements in the standing position."
214486633|NCT06289504|DRUG|Atorvastatin|Atorvastatin will be administered as a single dose orally 2 times during the study.
214486634|NCT06289504|DRUG|Warfarin|Warfarin will be administered as a single dose orally 2 times during the study.
214486635|NCT02632305|DRUG|nab-paclitaxel in combination with gemcitabine + cisplatin|Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
214953038|NCT03646071|DRUG|RX108|RX108
214344935|NCT06104215|BIOLOGICAL|BGT007H Injection|BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10\^8 cells,5.0 ×10\^8 cells, 1.0× 10\^9 cells,3.0 × 10\^9 cells,6.0 ×10\^9 cells.
214344936|NCT05234892|DEVICE|ALTO endograft implantation|Implantantion of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
214344937|NCT06334770|DEVICE|Roxolid implants|four Straumann BLX® roxolid implant 15% zirconium and 85% titanium), 3.7 mm in diameter, and 10 mm in length.implants were selected with the following criteria: tapered, self-tapping, aggressively threaded,were inserted with novalock attachments.
214953039|NCT01557192|DEVICE|Low Field Magnetic Stimulation Device|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
214953040|NCT01557868|DEVICE|hylan G-F 20|Three 2 cc injections at weekly intervals
214953041|NCT01557868|DEVICE|1% sodium hyaluronate|Three 2 cc injections at weekly intervals
214344938|NCT06334770|DEVICE|Titanium implants|four conventional acid etched pure implants tapered, self-tapping, threaded, two-piece, with the 10 mm length and 3.7 mm diameter were inserted with Sphero flex attachments.
214344939|NCT00547391|PROCEDURE|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
214953042|NCT05401461|OTHER|Evening mobilisation|Evening mobilisation delivered between (19.00 and 21.00) according to standardised procedures and established safety criteria. The intervention will begin on day 1 of admission or the first evening following recruitment. Mobilisation will be defined as a score of ≥ 2 on the Manchester mobility score (sit on the edge of the bed or higher), with actual mobilisation level achieved and duration of intervention based on clinical decision of the mobilisation therapists. Patients will also be offered the opportunity to engage in activities which may be part of their normal evening routines (e.g. brushing teeth, reading or watching television). The intervention will be carried out for up to seven consecutive evenings. The evening mobilisation will be delivered in addition to any input from the MDT during normal daily working hours and will not replace any standard therapy.
214344940|NCT00547391|OTHER|no intervention|No intervention (controls). Follow up started from the day of randomization.
214344941|NCT04401579|OTHER|Placebo|The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.
214344942|NCT04401579|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
214344943|NCT04401579|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
214344944|NCT00002334|DRUG|Saquinavir|
214344945|NCT00002334|DRUG|Zidovudine|
214344946|NCT00002334|DRUG|Zalcitabine|
214344947|NCT04993924|DRUG|Cetrorelix Acetate, Ganerelix Acetate|3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle
214344948|NCT04390438|PROCEDURE|Percutaneous Electrolysis|Needle emplacement with a galvanic electrical current
214344949|NCT04390438|PROCEDURE|Dry needling|Needle emplacement without electrical current nor substance
214953043|NCT03739580|DEVICE|DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
214344950|NCT01349634|OTHER|Iodized salt|salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
214344951|NCT04337099|DRUG|MBM-02 (Tempol)|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
214344952|NCT00967850|DRUG|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
214344953|NCT00967850|DRUG|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
214344954|NCT01828502|BEHAVIORAL|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
214344955|NCT01828502|BEHAVIORAL|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
214953044|NCT03739580|DEVICE|Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
214953045|NCT00795769|DRUG|ondansetron|Given IV
214953046|NCT00795769|OTHER|survey administration|Correlative studies
214953047|NCT00795769|PROCEDURE|management of therapy complications|Ondansetron IV
214953048|NCT00602446|DRUG|deferasirox|20 mg/kg once daily orally for 6 months
214953049|NCT03001466|DRUG|urea-loaded nanoparticles eye drops|one drop five times a day for 8 weeks
214344956|NCT05528081|OTHER|Phone interview|Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
214344957|NCT01438411|DRUG|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
214344958|NCT01863680|DRUG|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent \[%\] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
214953050|NCT03001466|DRUG|Balance Salt Solution eye drops|one drop five times a day for 8 weeks
214953051|NCT05309239|OTHER|ROX index|observation of ROX index to evaluate the efficacy of non invasive ventilation
214953052|NCT01370616|DRUG|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
214953053|NCT01370616|DRUG|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
214953054|NCT01370616|DRUG|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
214953055|NCT01370616|DRUG|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
214953056|NCT00031044|DRUG|Enfuvirtide|
214953057|NCT00031044|DRUG|Amdoxovir|
215076905|NCT03982264|PROCEDURE|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
215076906|NCT04913987|DEVICE|Stryker Triathlon total knee replacement|Knee arthroplasty using a standard care total knee.
215076907|NCT04913987|DEVICE|Zimmer Biomet Persona Partial Knee unicondylar knee replacement|Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
215076908|NCT00563069|DRUG|Midazolam|
215076909|NCT00436423|DRUG|gemcitabine, TS-1|
215076910|NCT03568253|OTHER|Caries treatment|Treatment by Bulk fil composite after randomization of the tooth
215076911|NCT03568253|OTHER|Caries treatment|Treatment by High viscosity glass ionomer after randomization of the tooth
215076912|NCT03998670|DEVICE|Prism Glasses|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
214953058|NCT00386230|DRUG|ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
214953059|NCT00386230|DRUG|ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
214953060|NCT00386230|DRUG|ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
215076913|NCT03998670|DEVICE|Non-Prism Glasses|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
214344959|NCT01863680|DRUG|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
214344960|NCT01863680|DRUG|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
214344961|NCT01863680|DRUG|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
214953061|NCT00386230|DRUG|ZDV Long (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
214953062|NCT02940873|BEHAVIORAL|HARPdoc courses|A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
215076914|NCT03200275|DIAGNOSTIC_TEST|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
214953063|NCT02940873|BEHAVIORAL|BGAT courses|A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
214953064|NCT02888275|DRUG|Dexmedetomidine|
214953065|NCT02888275|DRUG|normal saline|
214953066|NCT01614106|BEHAVIORAL|Retention Clinic|The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
214953067|NCT02324699|DRUG|Prednisone|
214953068|NCT02324699|DRUG|Placebo|
215076915|NCT04959617|DEVICE|Quantitative Fecal Immunochemical Test (qFIT)|The study only included quantitative FIT examination in the general physical examination population over 30 years old.
215076916|NCT01745523|PROCEDURE|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
215076917|NCT01745523|PROCEDURE|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
215076918|NCT06343870|DRUG|testosterone pellet (100 mg)|Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)
214344962|NCT00618514|DEVICE|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
214344963|NCT00618514|DEVICE|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
214344964|NCT06536127|DIAGNOSTIC_TEST|Blood samples|Nk cells and ImmunoScore
214344965|NCT06322472|OTHER|The Turkish Early Language Development Test (TEDIL)|The Turkish Early Language Development Test (TEDIL) is a test that measures the receptive and expressive language skills of children between the ages of 2 and 7 years and 11 months.
214344966|NCT06322472|OTHER|The Family Literacy Scale|The Family Literacy Scale, which is a reliable and valid measurement scale, was developed by Kılıç, Doğan, and Özden (Kılıç, Doğan, and Özden 2017). The items of the scale consist of questions about parental literacy, child literacy, and early literacy. Parental Literacy Scale to identify and analyse situations such as the use of literacy skills, role modelling for children, performing simple literacy activities at home, on the street, etc. and generally helping children to learn to read and write.
214344967|NCT06322472|OTHER|The Early Childhood Phonological Sensitivity Scale (PASECP)|The Early Childhood Phonological Sensitivity Scale (PASECP), developed by Sarı and Aktan Acar (2013), measures the phonological awareness of children aged 60-72 months (Sari and Aktan Acar 2013).
214344968|NCT06322472|OTHER|The Early Literacy Home Environment Scale (ELHES)|The Early Literacy Home Environment Scale (ELHES) developed by Karaahmetoğlu and Turan is a reliable and valid questionnaire for assessing the early literacy home environment of families with children aged 0-6 years (Karaahmetoğlu and Turan 2020)
214953069|NCT02324699|DRUG|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
214953070|NCT03782532|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
214953071|NCT03782532|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
214953072|NCT03782532|DRUG|Asthma Controller Therapies (include prednisone/prednisolone)|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral"
214953073|NCT03782532|DRUG|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
214953074|NCT05436171|OTHER|No intervention|No intervention
214953075|NCT02651493|DEVICE|photographs|computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
214953076|NCT02693899|OTHER|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
214953077|NCT06074627|DIETARY_SUPPLEMENT|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
214953078|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
214953079|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
214953080|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.3 Usage|Participants will use their Radicle Energy Active Study Product 1.3 as directed for a period of 6 weeks.
214953081|NCT06488872|PROCEDURE|comparison of CT scan with routinely assessed methods of muscle mass and strength|comparison of CT scan with routinely assessed methods of muscle mass and strength
214953082|NCT06222814|PROCEDURE|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft
214953083|NCT06222814|PROCEDURE|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)
215076919|NCT06343870|DRUG|Placebo|Pellet of cholesterol (placebo)
215076920|NCT00132756|DRUG|Doxil and Estramustine|
215076921|NCT00581269|BEHAVIORAL|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
215076922|NCT00581269|DIETARY_SUPPLEMENT|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
215076923|NCT01170065|DRUG|BIBF 1120|Intermediate dose BIBF 1120 twice daily
215076924|NCT01170065|DRUG|BIBF 1120|High dose BIBF 1120 twice daily
215076925|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 twice daily
215076926|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 once daily
215076927|NCT03762889|DEVICE|Eyeprotx™ General Anesthesia Protective Goggles|Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.
214953084|NCT04779710|OTHER|Staff Survey|A mixed mode survey design comprising of a self-administered electronic survey with a secondary option of a postal survey. The survey population was Speech and Language Therapy (SLT) Clinical Leads for Acute Stroke in Hyper/Acute Hospital Stroke Units in England and Wales. The sample frame was Routinely Admitting, and Non-Routinely Admitting Acute Stroke Hospital Teams registered on the Sentinel Stroke National Audit Programme (SSNAP) register. One hundred and sixty-six hospital teams were included after exclusions. Survey participants were asked to respond about assessment and management of dysphagia and other clinical processes during the first seven days of a person's admission to hospital following a stroke. Respondents were asked to respond about practice on behalf of the Stroke Unit rather than as an individual practitioner.
214953085|NCT03292614|DIAGNOSTIC_TEST|Measurements of the postoperative refraction|"The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)"
214953086|NCT00212264|BEHAVIORAL|Behavioral Therapy|Pelvic Floor Muscle Exercises and Bladder control strategies
214953087|NCT00212264|DEVICE|Pelvic Floor Electrical Stimulation|Pelvic Floor Electrical Stimulation daily for 8 weeks
214953088|NCT00212264|BEHAVIORAL|Biofeedback|Pelvic Floor Muscle training via biofeedback
214953089|NCT00212264|OTHER|No Treatment|No treatment
214953090|NCT01605825|DRUG|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
214953091|NCT01605825|DRUG|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
214953092|NCT03476902|BEHAVIORAL|Therapist assisted mobile intervention|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
214953093|NCT05152199|PROCEDURE|Cystoscopy - with use of obturator sheath|The intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
214953094|NCT05152199|PROCEDURE|Cystoscopy - without use of obturator sheath|The intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
214953095|NCT04723407|OTHER|questionnaires|Questionnaire completion
214953096|NCT00691561|BEHAVIORAL|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
214953097|NCT03418142|BEHAVIORAL|Priovi|Priovi is an Internet intervention for people with BPD. Content is continuously adapted to patients' concerns and needs. Priovi is a comprehensive program, which is conceptually and substantially based on the schema therapeutic approach used in BPD patients. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audios and motivating text messages. Techniques to cope with borderline symptoms (e.g., psychoeducation about modes, schemas and basic emotional needs in addition to relevant strategies to weaken, reduce and/or heal maladaptive schemas and modes) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
214953098|NCT03418142|OTHER|CAU|Care as Usual: In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Priovi after 12 months post-baseline (i.e., wait list with respect to Priovi access).
214344969|NCT06322472|OTHER|Demographic Questionaries|The demographic survey was prepared by the researchers. The demographic survey includes questions about educational status and family's socio-economic status.
214344970|NCT05294068|OTHER|standard of care for patients with cognitive impairments|clinical examination, radiological, biological and physiological examinations.
214344971|NCT05294068|OTHER|standard of care for patients with neuromotor impairments|clinical examination, radiological, biological and physiological examinations.
214344972|NCT05294068|OTHER|standard of care for patients with sensory impairments|clinical examination, radiological, biological and physiological examinations.
214953099|NCT03237052|OTHER|model|a model that has been established in advance.
214953100|NCT03237052|OTHER|non-model|real-world psychiatrist decision
214953101|NCT02740335|DRUG|Octaplex|OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
214344973|NCT00694317|DRUG|Zaleplon|Short term treatment of insomnia
214344974|NCT00956865|OTHER|Voucher|Vouchers given to reimburse transportation
214344975|NCT00956865|OTHER|Telephone Call|Telephone reminder calls
214344976|NCT00956865|OTHER|Contact|Contact at senior center to encourage follow up
214344977|NCT03806153|OTHER|Morphokinetic|The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).
214344978|NCT03418454|DIAGNOSTIC_TEST|Buccal mucosa samples for Extraction of BACTERIAL DNA|"Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome)."
214953102|NCT02740335|DRUG|Beriplex P/N (Kcentra)|Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
214953103|NCT02415231|BEHAVIORAL|humor|
215076928|NCT03762889|DEVICE|Eyelid Tape|Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.
215076929|NCT03762889|DEVICE|Eye Ointment|Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
215076930|NCT00770042|DRUG|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
214953104|NCT03973697|DRUG|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
214953105|NCT03973697|DRUG|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
214953106|NCT03973697|DRUG|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
214953107|NCT05687409|DRUG|Entecavir 0.5 mg|Orally administered Entecavir 0.5 mg, once a day. For six months
214953108|NCT05687409|DRUG|A 10-g packet of lactulose oral solution and three capsules of probiotics|"A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis).~Participants orally administered the contents three times daily after meals. For six months."
214953109|NCT05687409|DIETARY_SUPPLEMENT|A 10-g packet of glucose oral solution and three capsules of starch|A 10-g packet of glucose oral solution and three capsules of starch. Participants orally administered the contents three times daily after meals. For six months.
214953110|NCT06146634|BEHAVIORAL|Hazard Perception Training|The hazard perception training is comprised of three modules. Each module is comprised of four scenarios. Each hazard perception scenario has two activities. The entire training is expected to take approximately an hour to complete.
215076931|NCT00770042|DRUG|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
215076932|NCT00770042|DRUG|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
215076933|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 8
214344979|NCT02267395|OTHER|(1) cranio-cervical flexion test;|Test to determine level of strength for Deep Neck Flexor muscles
214344980|NCT02267395|OTHER|(2) scapular dyskinesis test|Test to determine scapular control
214953111|NCT06146634|BEHAVIORAL|Vehicle Maintenance Training|For participants randomized into the placebo group, they will receive a brief training on vehicle maintenance using a series of short videos. These videos describe regular checks that drivers should do, such as checking windshield wiper fluid levels, and how to change engine oil. Altogether the videos will last approximately 1 hour.
214953112|NCT06146634|BEHAVIORAL|Attention Maintenance Training|The attention maintenance training is comprised of three modules. Each module is comprised of four scenarios, with each scenario corresponding to one activity. The entire training is expected to take approximately an hour to complete.
214953113|NCT02039323|DRUG|Tenofovir|
214953114|NCT02039323|DRUG|Maraviroc|
214953115|NCT00639392|DRUG|Placebo|Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
214344981|NCT02267395|OTHER|(3) deep neck flexor endurance test.|Test do determine endurance for the deep neck flexor muscle group.
214344982|NCT02053350|DRUG|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
214344983|NCT05938634|BEHAVIORAL|Stage-matched interventions|Precontemplation-based intervention Contemplation-based intervention Preparation-based intervention Action-based intervention Maintenance-based intervention
214953116|NCT00639392|DRUG|Zoledronic Acid|Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
214953117|NCT04288817|BIOLOGICAL|Tuberculin purified protein derivative|Intralesional injection of tuberculin PPD in treatment of multiple common warts
214953118|NCT03362138|DEVICE|dermoscopy|Solely after the dermatologist has decided to biopsy a lesion and sent the patient to biopsy, a dermoscopic image is captured by a camera attached to a dermoscope.
214953119|NCT00214734|DRUG|rAHF-PFM|
214953120|NCT03086109|OTHER|Risk factors|Risk factors associated bone degenerative diseases
214953121|NCT04080089|COMBINATION_PRODUCT|Surgical treatment, drug therapy, remote cognitive training|"Surgical treatment：Children with OSAHS who had surgical indications and informed consent from the parents underwent tonsillectomy and adenoidectomy.~drug therapy：For children whose parents only agree to receive medical treatment, montelukast sodium tablets are given for 6 months to reduce the inflammatory response of adenoids, tonsils, etc.~remote cognitive training:For children whose parents did not agree to undergo surgery or medication, the cognitive function was evaluated at the time of enrollment, and cognitive training was performed. Individualized training programs were developed according to the cognitive assessment system, and cognitive function was evaluated again after one course of treatment."
214953122|NCT05268354|OTHER|6-week neuromuscular training program|Training program consisting of three neuromuscular training sessions per week
215076934|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 6
215076935|NCT00770042|DRUG|Avanafil|Avanafil 200mg Days 1 and 6
215076936|NCT02486991|PROCEDURE|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
215076937|NCT02486991|PROCEDURE|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
215076938|NCT03602313|DEVICE|Body Weight Support Gait Training|
215076939|NCT03602313|OTHER|Traditional Gait Training|
215076940|NCT03256903|DRUG|Methoxyflurane|Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
215076941|NCT03256903|DRUG|Standard of care|Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
215076942|NCT03568552|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
215076943|NCT00463463|DRUG|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
215076944|NCT04676308|OTHER|Artificial Intelligence|Artificial intelligence
214344984|NCT00492349|DRUG|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
214953123|NCT02574416|OTHER|There is no intervention|The study is observational and there is no intervention
214344985|NCT00492349|DRUG|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
214953124|NCT00513890|DEVICE|Infantflow [EME, Brighton, England]|
214953125|NCT04350814|BEHAVIORAL|Self-Compassion Step by Step|This is a 6-lesson self-guided audio program by Dr. Kristen Neff (2013)
215076945|NCT00686322|DRUG|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
215076946|NCT00255138|DRUG|Atomoxetine|
215076947|NCT00000293|DRUG|Nefazodone|
215076948|NCT06437886|OTHER|opioid-sparing protocol|Patients in the OSA group was administrated with 0.5 to 1 mcg·kg-1 sufentanil and received PIFB combined with RSB after anesthetic induction. Patients in the control group were recommended to receive 2 to 3 mcg·kg-1 opioid-based sufentanil. PIFB was conducted at the T2 to T5 levels under ultrasound guidance. Each side received 20 ml 0.3% ropivacaine containing 2.5 mg dexamethasone. Bilateral RSB was conducted after the PIFB and the needle was inserted into the plane between the rectus abdominal muscle and its posterior sheath using an in-plane approach. After verifying needle placement, 15 ml 0.3% ropivacaine containing 2.5 mg dexamethasone was delivered to each side. In the control group, patients received no procedure and were administrated with traditional anesthetic protocol. Patients received continuous intravenous sufentanil (50 to 100 mg) and tropisetron (5 to 10 mg) at 2 ml·h-1 for the first 48 hours after surgery.
215076949|NCT04258995|BIOLOGICAL|Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)|2 formulations at 1 dose level
215076950|NCT04580277|DRUG|Tofacitinib 10 mg|Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
215076951|NCT03415698|DRUG|G-CSF|G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
215076952|NCT03415698|DRUG|Standard Medical Therapy|Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
215076953|NCT02978105|OTHER|self-conditioning techniques|Self-hypnosis to increase self-control before meals and every food compulsion episode
214344986|NCT00272168|BEHAVIORAL|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
214486636|NCT06418178|DRUG|Midomafetamine|One to five MDMA-assisted therapy sessions, each followed by three non-drug psychotherapy sessions (see behavioral intervention below)
214486637|NCT06418178|BEHAVIORAL|Psychotherapy|Standardized psychotherapy performed by therapy team
214953126|NCT04350814|BEHAVIORAL|Self-Reflection Active Control|Participants randomized to this active control condition will be asked to complete study measures at the same intervals as those assigned to the intervention condition. In addition to completing study questionnaires, participants in this arm will also be invited to reflect on their weekly reported symptoms, whether they experienced changed, what they believe these changes are attributed to, etc.
215076954|NCT02978105|OTHER|standard care (diet, exercise and behavioral therapy)|dietary recommendations, exercise recommendations, and behavioral recommendations
215076955|NCT06198101|OTHER|Myofascial Release Technique|The treatment will be applied by the therapist standing at the side of the patient with different levels according to subject's tolerance for duration of 3 minutes in each sitting. Level one will be performed by longitudinal movements without causing any tension to the tissues. The level two will be performed by longitudinal movements with light pressure to the tensed muscle. The level three will be performed by compressing the treatment area then passively fullest possible range of motion will be performed and then longitudinal movement will be done with same compression. In level four, the patient will actively move the tissue through the fullest possible range of motion. The taut band will palpate and then firm pressure will be maintained and then longitudinal movements will be performed. Treatment will be applied for two intervention sessions per week and a total of 12 sessions over 6 weeks.
215076956|NCT06198101|OTHER|Myofascial Release Technique along with segmental vibrator|this group will receive vibratory stimulations through segmental vibrator along the muscle fibers of upper limb flexors, extensors, and wrist flexors for 10-minutes each session with low amplitude (0.3-0.5 mm peak to peak) at fixed frequency of 150 Hz(23). Along with segmental vibrator group B will also receive myofascial release technique through the same method to the upper limb flexors, extensors, and wrist flexors. Group B will receive both treatments for two intervention sessions per week and a total of 12 sessions over 6 weeks.
215076957|NCT04377802|DIAGNOSTIC_TEST|molecular testing for virus RNA using RT-PCR|Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
215076958|NCT04326036|PROCEDURE|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
215076959|NCT04326036|DEVICE|Centricyte 1000|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
214486638|NCT06953128|PROCEDURE|Spinal Anesthesia|Participants will receive subarachnoid (spinal) anesthesia with 15-20 mg of isobaric bupivacaine 0.5% and 100 μg of intrathecal morphine. Clonidine (1 μg/kg) may be added at the discretion of the anesthesiologist. Sedation will be achieved with intravenous midazolam (up to 5 mg), fentanyl (up to 100 μg), and/or target-controlled infusion of propofol. Patients will remain spontaneously breathing throughout the procedure and receive supplemental oxygen via nasal cannula.
214953127|NCT00006110|BIOLOGICAL|trastuzumab|infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
214953128|NCT00006110|DRUG|cyclophosphamide|600 mg/m2, intravenous infusion every 3 weeks for four cycles
214953129|NCT00006110|DRUG|doxorubicin hydrochloride|60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
215076960|NCT04326036|PROCEDURE|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
215076961|NCT04326036|DRUG|Liberase Enzyme (Roche)|Sterile Collagenase Blend to separate cSVF from the AD-SVF
215076962|NCT04326036|DRUG|Sterile Normal Saline for Intravenous Use|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
215076963|NCT06153433|DRUG|Rosuvastatin Immediate-Release Tablet (IRT) 10mg|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
215076964|NCT06153433|DRUG|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
215076965|NCT04736953|DRUG|Sirolimus|Sirolimus
215076966|NCT04736953|OTHER|Placebo|Placebo
214344987|NCT00272168|OTHER|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
214344988|NCT02367911|DRUG|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
214344989|NCT02367911|DRUG|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
214344990|NCT04011553|OTHER|Virtual Reality based Rehabilitation Program|"Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles."
215076967|NCT01336751|DRUG|Insulin glargine|solution for subcutaneous injection
215076968|NCT01336751|DRUG|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
214344991|NCT04584112|DRUG|Tiragolumab|Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.
214344992|NCT04584112|DRUG|Atezolizumab|Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.
214344993|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 milligrams per square meter (mg/m\^2) administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
215076969|NCT05782114|OTHER|Extracorporeal Shockwave therapy|The shockwave will be applied for the experimental group (Group A). The patients will be positioned on a chair, and the hand with the disorder will be placed on a surface with the radio ulnar joint will be in mid position and the thumb will be directed up. will be 1000 impulses with 2 bar pressure at a frequency of 15 Hz on the radial head and focused on the tissue surrounding the maximal pain point.
215076970|NCT05782114|OTHER|Traditional physical therapy program|"1. Instruction to wear Thumb Spica splint:~   The Thumb Spica splint will be used for 4 weeks for both groups of patients.~2. Ultrasound Therapy:~   Therapeutic Ultrasound parameters will be mode: continuous, duration: 5 minutes, intensity: 1.2watt/cm2 and frequency: 1MHZ.~3. Stretching exercise:~1\. Self-stretch of the thenar eminence: 2. Opposition stretches: 3. Wrist stretch:~4\) Strengthening exercise:~1. Resisted exercise for thumb extension:~2. Resisted exercise for thumb abduction:~3. Resisted exercise for thumb opposition:~4. Wrist radial deviation strengthening:~5. Grip strengthening:~6. Finger spring:"
215076971|NCT04883840|DRUG|Rosuvastatin 10mg|Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).
215076972|NCT01863251|DRUG|Atomoxetine|
215076973|NCT03224065|DIAGNOSTIC_TEST|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
215076974|NCT04159584|OTHER|Medical Music|Enrolled subjects will undergo 30 minutes of medical music listening
215076975|NCT03879304|OTHER|multimodal physiotherapy program with RV|Physiotherapy Programm includes: respiratory physiotherapy, stretching, resistance training, aerobic training and adaptation and training with virtual reality glasses and relaxation.
214344994|NCT04584112|DRUG|Tiragolumab|Tiragolumab 420 mg administered by IV infusion Q2W.
214344995|NCT04584112|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion Q2W.
214344996|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 administered by IV infusion QW.
214344997|NCT04584112|DRUG|Carboplatin|Carboplatin (area under the concentration-time curve \[AUC\]: 5 milligrams per milliliter per minute \[mg/mL/min\]) administered by IV infusion Q3W.
214344998|NCT04584112|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.
214344999|NCT04584112|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.
214345000|NCT04584112|DRUG|Granulocyte colony-stimulating factor (G-CSF)|G-CSF support for four doses.
214345001|NCT04584112|DRUG|Granulocyte-macrophage colony-stimulating factor (GM-CSF)|GM-CSF support for four doses.
214345002|NCT00342316|PROCEDURE|Reduced Intensity Conditioning Stem Cell Transplantation|"One of the following conditioning regimens:~1. Busulphan (orally or IV), fludarabine~2. Fludarabine, carmustine, melfalan~3. Cyclophosphamide, fludarabine"
214345003|NCT03412669|OTHER|Supporting Addiction Affected Families Effectively|Counselling
214345004|NCT03412669|OTHER|Enhanced Usual Care|Information sheet
214345005|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via prepared syringe
214345006|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via syringe pump
214345007|NCT00902304|DRUG|Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
214953130|NCT00006110|DRUG|paclitaxel|90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
214953131|NCT00006110|PROCEDURE|conventional surgery|Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
214953132|NCT01122017|PROCEDURE|Retro-Tubercle Opening-Wedge High Tibial Osteotomy|Retro-Tubercle Opening-Wedge High Tibial Osteotomy (ROWHTO) is among the latest approaches for the treatment of varus deformity of knee.
214953133|NCT01826045|DRUG|Poly-gamma Glutamic Acid|
214953134|NCT01826045|DRUG|Placebo|
214953135|NCT03469999|DRUG|Dysport Injectable Product|Selected dose of medication will be determined by affected muscle(s), severity of spasticity, and the patient's body weight. We will follow the recommended total Dysport dose of 10-15 units/kg per limb, not to exceed 15 units/kg for unilateral lower limb, 30 units/kg for bilateral lower limb, or a total of 1000 units, whichever is lower in a given session.
214953136|NCT05699785|OTHER|plasma inflammatory markers|Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)
214953137|NCT05699785|OTHER|CD4/CD8 ratio|Evolution of CD4/CD8 ratio
214953138|NCT02998359|DEVICE|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
214345008|NCT00902304|DRUG|Valsartan and amlodipine|From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
214953139|NCT02998359|DEVICE|Total hip arthroplasty|A cemented polished double taper stem arthroplasty stem inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
214953140|NCT03439462|DRUG|nab-sirolimus|nab-sirolimus combined with mFOLFOX6 + bevacizumab
214345009|NCT00902304|DRUG|Usual care|As directed by investigator
214953141|NCT03920423|PROCEDURE|improvement of arterial depth|deepen radial arterial depth by injection of saline to more than deep cutoff point relative to result.
214953142|NCT06345014|DRUG|OM-89 [Uro-Vaxom® Capsule]|Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day
214953143|NCT06345014|DRUG|OM-89 Placebo [Uro-Vaxom® Capsule Placebo]|Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)
214345010|NCT00902304|DRUG|Valsartan|Valsartan 160mg per day to 320mg per day orally
214345011|NCT00902304|DRUG|Valsartan and hydrochlorothiazide (HCTZ) - combination arm|Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
214486639|NCT06953128|PROCEDURE|General Anesthesia|Participants will undergo general anesthesia induced with intravenous propofol (1.5-2.5 mg/kg) or etomidate (0.2-0.3 mg/kg), remifentanil (0.2-0.4 μg/kg/min), and rocuronium (0.6 mg/kg), followed by endotracheal intubation and controlled mechanical ventilation. Maintenance will include continuous remifentanil infusion and inhaled sevoflurane. Ventilation parameters will follow a protective strategy (tidal volume 6-8 mL/kg predicted body weight and PEEP of 5 cmH₂O).
214953144|NCT02336009|DEVICE|total wrist arthroplasty, Trimed|A new total wrist arthroplasty design. A pilot study.
214953145|NCT03828682|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Tacrolimus Extended Release Oral Tablet \[Envarsus\]
214953146|NCT03828682|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil capsules or tablets
214953147|NCT03828682|DRUG|Mycophenolic Acid Oral Product|mycophenolic acid tablets
214953148|NCT03828682|DRUG|Tacrolimus|Twice daily tacrolimus
214953149|NCT03828682|DRUG|Methylprednisolone|Methylprednisolone taper
215076976|NCT03879304|OTHER|traditional physiotherapy program|Multimodal physiotherapy Programm includes: traditional physiotherapy, stretching, massage.
215076977|NCT05858450|BIOLOGICAL|Comirnaty|COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
215076978|NCT05858450|BIOLOGICAL|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines
214953150|NCT03828682|DRUG|Prednisone|Prednisone taper
214953151|NCT03828682|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]|Rabbit Anti-Human T-Lymphocyte Globulin
214953152|NCT03080480|DRUG|Pioglitazone|"Pioglitazone is PPARγ agonist that may be enhance ROS production and partially restore host phagocytes in CGD.~pioglitazone is administered at a starting dose of 1 mg/kg and given the absence of adverse effects is progressively increased up to 3 mg/kg or 30 mg/daily."
214953153|NCT00394771|DRUG|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
214953154|NCT00394771|DRUG|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
214953155|NCT00394771|DRUG|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
214953156|NCT01195181|DRUG|peginterferon plus ribavirin|peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
215076979|NCT04088981|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet and a portion-controlled diet
215076980|NCT02683070|PROCEDURE|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
215076981|NCT02683070|DRUG|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
214953157|NCT04586335|DRUG|CYH33|Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
214953158|NCT04832750|DEVICE|intermittent theta burst stimulation (iTBS) or sham stimulation|30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
214953159|NCT07011641|BEHAVIORAL|Structured Online CBT Program|The interventions consisted of eight weekly group sessions (1.5-2 hours each), with each session addressing a specific theme identified through literature as closely related to parental burnout. The sequential themes were the social pressure on parenting, the dynamic balance of parental stressors and resources, parental perfectionism, personal emotional competencies, parent-child relationship quality, co-parenting quality, help seeking, with a last session focused on relapse prevention.
214953160|NCT07021937|DRUG|Semaglutide 1.7mg subcutaneous|Semaglutide subcutaneous max dose of 1.7mg over 24 or 32 weeks of active treatment
214953161|NCT07021937|DRUG|Placebo|Placebo saline solution subcutaneous
214953162|NCT02314312|DRUG|Everolimus + low dose cyclosporin A + prednisolone|
214953163|NCT02314312|DRUG|Standard immunosupressive regimen|
214953164|NCT06088368|PROCEDURE|in-plane needle guidance|Ultrasound -guided lumbar plexus block with in-plane needle guidance using the Shamrock method
214953165|NCT06088368|PROCEDURE|out-of-plane needle guidance|Ultrasound -guided lumbar plexus block with out-of-plane needle guidance using Shamrock method
214953166|NCT07021560|DEVICE|ZEISS MyoCare spectacle lenses|Spectacle lenses with conventional power profile including myopia control design.
214953167|NCT07021560|DEVICE|ZEISS SV RX SPH 1.5|Commercially available single vision
214953168|NCT07021560|DEVICE|ZEISS Clearview|Commercially available single vision
214953169|NCT07027098|PROCEDURE|Perflurocarbon liquid|Used to facilitate surgery of retinal detachment to stabilise macular during surgery.
214953170|NCT07027098|PROCEDURE|Without Perflurocarbon liquid|Standard retinal detachment surgery (vitrectomy) without the use of Perflurocarbon liquid (PFCL).
214953171|NCT07026916|DRUG|GFH375|GFH375 will be administered at the 600mg QD, orally, until disease progression or intolerable toxicity.
214953172|NCT05443750|BEHAVIORAL|Motivational Behavioral Economic Alcohol Intervention|The intervention combines an alcohol brief motivational intervention (US-THRIVE \[Tertiary Health Research Intervention via Email\]) with the Substance-Free Activity Session (SFAS), shown to reduce drinking and related negative consequences by increasing future orientation and engagement in pro-social alternatives to drinking. The intervention will be delivered using a web-based platform appropriate for the young adult target population whose social networks operate through such communications.
214953173|NCT05443750|BEHAVIORAL|Health Education|Participants view web-based health educational material about alcohol, sleep, and nutrition of a similar length and style to the experimental intervention materials.
214953174|NCT00815477|BEHAVIORAL|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
214953175|NCT00815477|BEHAVIORAL|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
214953176|NCT02855177|DRUG|Placebo|Placebo as suspension administered every 8 hours, with food
214953177|NCT02855177|DRUG|PF-06427878|500 mg suspension administered every 8 hours, with food
214953178|NCT06757634|DRUG|Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant|"Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off~Other Names:~• PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle.~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks~Other Names:~• Faslodex"
214953179|NCT06757634|DRUG|Arm B: Palbociclib or Ribociclib + Fulvestrant|"Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI®~Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4~Other Names:~• Faslodex"
214953180|NCT05175950|BIOLOGICAL|SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03|SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose
214953181|NCT05175950|OTHER|Normal saline|Normal saline
214953182|NCT05674877|DRUG|Opioid-based group (OB) (placebo/saline)|Patients in the opioid-based group will receive placebo boluses and infusions of saline.
214953183|NCT05674877|DRUG|"Opioid sparing group (OS) (dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine)"|"Patients in the Opioid Sparing group will receive a dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine."
214953184|NCT00524004|BIOLOGICAL|Anti-CsbD Bovine IgG|Three times a day for seven days
214953185|NCT00524004|OTHER|Placebo|Three times a day for seven days
214953186|NCT00524004|BIOLOGICAL|Anti-CS17 Bovin IgG|Three times a day for seven days
214953187|NCT02870127|OTHER|blood sample|
214953188|NCT03093051|DEVICE|Unpinning Termination therapy|Electrotherapy comprised of standard biphasic and monophasic pacing pulses
214953189|NCT05247892|PROCEDURE|Ultrasound-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under ultrasound-guidance
215076982|NCT03297073|DRUG|paracetamol|"Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form"
215076983|NCT03297073|PROCEDURE|hepatic surgery|
215076984|NCT01713504|BIOLOGICAL|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
215076985|NCT01746511|PROCEDURE|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
214345012|NCT01153633|DEVICE|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
214345013|NCT01153633|DEVICE|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
214345014|NCT03108534|DRUG|CHF1535 NEXThaler|Rescue treatment
214345015|NCT03108534|DRUG|CHF1535 pMDI|Rescue treatment
214345016|NCT03108534|DRUG|Placebo|Rescue treatment
214345017|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
214345018|NCT00384085|DRUG|Insulin Glargine|Subcutaneous injection once-a-day
215076986|NCT01746511|DRUG|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
215076987|NCT00646321|DRUG|budesonide/formoterol (Symbicort)|
215076988|NCT00646321|DRUG|budesonide|
215076989|NCT01118104|OTHER|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
215076990|NCT02125903|DRUG|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
215076991|NCT00642174|DRUG|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
214345019|NCT00384085|DRUG|Premixed Insulin|Subcutaneous injection twice-a-day.
214345020|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
214345021|NCT02626559|DRUG|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
214953190|NCT05247892|PROCEDURE|Fluoroscopic-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under fluoroscopy-guidance
214953191|NCT02003261|BEHAVIORAL|Unified Protocol with Treatment As Usual|"Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.~UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure."
214953192|NCT02003261|OTHER|Treatment As Usual|Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
214953193|NCT03387345|OTHER|100% steel cut barley|25 g of available carbohydrate was delivered to participants via steel cut Sustagrain barley (Ardent Mills, LLC).
214953194|NCT03387345|OTHER|100% barley flakes|25 g of available carbohydrate was delivered to participants via Sustagrain barley flakes (Ardent Mills, LLC).
214953195|NCT03387345|OTHER|50/50 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 50/50 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
215076992|NCT00642174|DRUG|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
215076993|NCT00896363|DRUG|GSK163090 1 mg|Developed for the treatment of Major Depressive Disorder
214953196|NCT03387345|OTHER|80/20 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 80/20 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
214953197|NCT03387345|OTHER|100% rice|25 g of available carbohydrate was delivered to participants via Goya medium grain white rice
214953198|NCT03387345|OTHER|white bread|25 g of available carbohydrate was delivered to participants via Sara Lee Classic White Bread (Bimbo Bakeries USA, Inc.)
215076994|NCT00896363|DRUG|GSK163090 Placebo|Developed for the treatment of Major Depressive Disorder
215076995|NCT00896363|DRUG|GSK163090 3 mg|Developed for the treatment of Major Depressive Disorder
215076996|NCT02409004|DRUG|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
215076997|NCT02409004|DRUG|Rifampin|Capsule 2x3oo mg Oral
215076998|NCT04644978|OTHER|anonymous online survey|An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.
214953199|NCT00931827|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
214953200|NCT00931827|DRUG|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
214953201|NCT06131216|DRUG|SHR-2022 Injection|SHR-2022 Injection is administered by intravenous (IV) infusion
214953202|NCT03077386|BEHAVIORAL|ENCOMPASS Intervention|Patients will be matched to a CHN who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (i.e., social, financial, insurance), helping patients set health related goals, liaising with a patient's employer, facilitating health care referrals and appointments, monitoring appointments, and facilitating transportation to appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in person or over the telephone using motivational interviewing principles
214953203|NCT01968512|DEVICE|Transcranial Direct Current Stimulation|This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.
215076999|NCT01478802|DEVICE|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
215077000|NCT01478802|DEVICE|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
214345022|NCT03846024|DEVICE|RibFx Orthosis Belt|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
214345023|NCT03152305|OTHER|Intracranial pressure variations|Self-measure of ICP will be performed outside and during menstrual migraine attacks.
214345024|NCT02673658|BEHAVIORAL|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
214345025|NCT02673658|BEHAVIORAL|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
214345026|NCT04450615|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions, with a total duration of 5 weeks and a frequency of 3 sessions per week.~Dynamic exercises: 2 sets of 10 to 15 repetitions (each side) Isometric exercises: 2 sets of 5 to 15 seconds (each side) Week 1- As mentioned above Week 2- Add 1 set Week 3 - Add 5 seconds and 5 repetitions Week 4 - Add 1 set Week 5- Add 5 seconds and 5 repetitions"
214345027|NCT05227508|DIETARY_SUPPLEMENT|BRIZO|A capsule containing 400 mg. SC012 (unique soy extract)
214345028|NCT05227508|OTHER|placebo|Comprecel microcrystalline cellulose
214953204|NCT01968512|DEVICE|Sham|Same character of Transcranial Direct Current Stimulation but without current
214953205|NCT02086409|DIETARY_SUPPLEMENT|Yogurt supplemented with vitamin D and calcium|The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
214953206|NCT02086409|DIETARY_SUPPLEMENT|Yogurt not supplemented with vitamin D and calcium|The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
214953207|NCT02628509|DEVICE|cardiac devices|patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
214953208|NCT03631654|DRUG|Ivabradine|Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
214953209|NCT03631654|DRUG|Placebos|Placebo
214345029|NCT03432624|DIAGNOSTIC_TEST|Serum MicroRNA-25 detection|The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.
214345030|NCT00991926|DRUG|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
214953210|NCT02927002|DEVICE|Noninvasive brain stimulation|
214953211|NCT05616091|DEVICE|painful stimulation by using a laser device (DEKA Stimul 1340, Calenzano, Italy)|In each of the two sessions, 80 experimental painful stimuli of different intensities (2.5 J, 3 J, 3.5 J, 4 J) will be applied using the laser device listed above.
214953212|NCT00520767|DRUG|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
214953213|NCT00520767|DRUG|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
214953214|NCT00520767|DRUG|melphalan|Melphalan 9 mg/m2/day days 1-4
214953215|NCT00520767|GENETIC|microarray analysis|≤28 days prior to enrollment
214953216|NCT00520767|OTHER|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
214953217|NCT00520767|OTHER|laboratory biomarker analysis|≤28 days prior to enrollment
214345031|NCT00991926|OTHER|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
214345032|NCT01742767|DRUG|Cisplatinum|
214345033|NCT01742767|DRUG|Pemetrexed|
214345034|NCT00352365|DRUG|lenalidomide|Given orally
214345035|NCT03790176|DRUG|Intravenous Infusion|see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
214345036|NCT04941755|DRUG|BMS-986256|Specified dose on specified days
214953218|NCT00520767|PROCEDURE|quality-of-life assessment|Start of each cycle
214953219|NCT03597139|DRUG|Voclosporin Ophthalmic Solution|Investigational Drug
214953220|NCT03597139|DRUG|Restasis®|Comparator
214953221|NCT01342172|DRUG|Lenalidomide|"Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least stable disease will proceed with maintenance lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression."
214953222|NCT00312104|DRUG|insulin detemir|
215077001|NCT03633630|DRUG|Amla|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
215077002|NCT03633630|DRUG|Placebo|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
215077003|NCT02273076|DEVICE|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
215077004|NCT02465749|DRUG|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
215077005|NCT02465749|DEVICE|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
215077006|NCT02465749|DRUG|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
215077007|NCT02465749|DRUG|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
215077008|NCT02465749|DRUG|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
215077009|NCT02465749|DRUG|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
215077010|NCT03790774|BEHAVIORAL|Neurofeedback|Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
215077011|NCT06326619|PROCEDURE|Primary tumor resection|In addition to systemic therapy a primary tumor resection was performed.
215077012|NCT06326619|PROCEDURE|Systemic Therapy|chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis
215077013|NCT04989205|BEHAVIORAL|Cannabis cessation Program|Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising \~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
215077014|NCT04926207|BEHAVIORAL|Physical Activity Breaks Intervention|Participants will be asked to walk on a treadmill for 3 min at a moderate intensity (55% of heart rate reserve) at an increasing speed and incline to reach and maintain their target heart rate.
214345037|NCT04941755|DRUG|Famotidine|Specified dose on specified days
214345038|NCT01088932|DRUG|SRX246|capsules
214345039|NCT06633263|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Introduce self-recording with the sleep diary; Introduce basic notions of insomnia; Introduce basic notions of sleep hygiene; Introduce basic notions of sleep; Recreate a time and place dedicated to sleep; Limit time spent in bed to time slept; Promote attitudes and beliefs that favor sleep and manage worries; Relapse prevention. This intervention is empirically validated (Morin, 2022).
214953223|NCT00312104|DRUG|insulin glargine|
214953224|NCT00312104|DRUG|insulin aspart|
215077015|NCT04926207|BEHAVIORAL|Talking Breaks Control|Every 30 min a researcher will start a brief conversation with a participant based on a pre-selected topic, which will change with each break. Topics are standardized across participants and include, for example, pollution, smart clothes, and hydration. A presentation will be followed by questions and answers. The break will last 3 min.
215077016|NCT01909882|OTHER|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
214953225|NCT03307122|OTHER|Routine Infant Formula 1|Routine infant formula with probiotic
214953226|NCT03307122|OTHER|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
214953227|NCT01770067|DRUG|CITA-RNPT|
214953228|NCT01770067|PROCEDURE|Extraction of infected CIED|
214953229|NCT01310244|DRUG|Belinostat, Carboplatin, Paclitaxel|Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
215077017|NCT01791881|DRUG|Hugeltox|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
215077018|NCT01791881|DRUG|Botulinum Toxin Type A(Botox®)|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
214345040|NCT06633263|BEHAVIORAL|Behavioral Activation Treatment for Depression|Introduce self-recording with daily activities; Introduce the basic concept of depression; Identify and increase activities associated with positive reinforcement; Reflect on life domains and values to identify reinforcing activities; Identify and decrease activities associated with negative reinforcement; Identify and decrease activities associated with negative reinforcement; Relapse prevention. This intervention is empirically validated (Ciharova et al., 2021)
214345041|NCT04410432|BIOLOGICAL|Blood sample collection|"Additional blood volumes taken during a routine care blood test:~* 1 dry tube 5 mL for isolation and freezing of serum~* 1 x 5 mL EDTA tube to isolate and freeze plasma~* 8 heparinized 6 mL tubes for flow cytometry study"
214953230|NCT04902079|DEVICE|Device for Cardiac Contractility Modulation Therapy (CCM)|Evaluate the effect from CCM Therapy in HF population
214953231|NCT00382109|DRUG|thiotepa|Given IV
214953232|NCT00382109|DRUG|cyclophosphamide|Given IV
214953233|NCT00382109|DRUG|tacrolimus|Given IV or orally
214953234|NCT00382109|DRUG|methotrexate|Given IV
214953235|NCT00382109|DRUG|sirolimus|Given orally
214953236|NCT00382109|RADIATION|total body irradiation|Part of the transplant preparatory regimen
214953237|NCT03131700|BIOLOGICAL|RPH001|Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
214953238|NCT03131700|BIOLOGICAL|Avastin®|R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
214953239|NCT04441385|DRUG|Maraviroc 300 mg|Patients will receive maraviroc 300 mg twice daily for 14 days
214953240|NCT04441385|OTHER|Standard care therapy|Subjects randomized to control group will be on standard care treatment according to the Ministry of Health and Local Guidelines and Protocols.
214953241|NCT01120132|DRUG|CsA high dose|Solution of Cyclosporine (high dose) administered during 28 days
214953242|NCT01120132|DRUG|CsA low dose|Solution of Cyclosporine (low dose) administered during 28 days
214953243|NCT01120132|DRUG|PA|Suspension of Prednisolone Acetate administered during 28 days
214953244|NCT01120132|DRUG|Placebo|Placebo solution administered during 28 days
214345042|NCT04097132|DEVICE|echocardiography|echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
214345043|NCT06186388|DIAGNOSTIC_TEST|TEMPO iMOvifa|Screening test with 28 testing points
214345044|NCT05489926|DRUG|Pamiparib|Pamiparib, 60mg PO BID
215077019|NCT03698786|BEHAVIORAL|Exercise|Participants will be required to complete two, 8-hours trials (exercise \& control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
215077020|NCT01344044|DEVICE|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
214345045|NCT01230593|DRUG|Hot Compress plus Tobramycin Drops and Ointment|In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
214345046|NCT01230593|DRUG|Hot compress plus Tobramycin/Dexamethasone Drops and Ointment|In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
214345047|NCT01230593|OTHER|Hot Compresses|Hot compresses 3x/day to eyelids
214953245|NCT02941354|DRUG|turoctocog alfa|Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
214953246|NCT04061733|DEVICE|Hydrogel injection|Hydrogel injection
214953247|NCT05068479|DEVICE|Bilateral Laser Scleral Microporation procedure|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
214953248|NCT06725680|OTHER|Retrolaminar block|Patients will receive retrolaminar block after the induction of general anesthesia.
214953249|NCT06725680|OTHER|Erector spinae plane block|Patients will receive erector spinae plane block after the induction of general anesthesia.
214953250|NCT06147323|OTHER|Normal Healthy Diet|Participants aged 18-65 years in general good health will be following the Eatwell booklet advice\*and NICE/NHS guidelines (https://www.nice.org.uk/).
214953251|NCT06147323|DIETARY_SUPPLEMENT|Seaweed Group|Participants aged 18-65 prediabetics will take 2 seaweeds brown extract capsules/day (information detailed in the safety product sheet, total dose of 700 mg before each of the two main meals. All participants will be advised on product storage and use conditions prior to use to ensure product consistency throughout the period of the study.
214953252|NCT06147323|OTHER|Placebo Diet Group|Participants aged 18-65 prediabetics will take 2 capsules/day (750mg Maltodextrin placebo comparator) before each of the two main meals without any advice on the diet to follow.
214953253|NCT02724410|DRUG|home intravenous ertapenem|see arm description
214953254|NCT02724410|DRUG|home oral amoxicillin-clavulanate|see arm description
214953255|NCT02724410|DEVICE|peripheral inserted central Catheter|All patients undergoing home intravenous ertapenem will require placement of peripheral inserted central Catheter (PICC) for home delivery of antibiotics.
215077021|NCT05942378|DRUG|HRXG-K-1939|HRXG-K-1939
215077022|NCT05942378|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody
215077023|NCT02982018|DEVICE|senofilcon A with new UV blocker|Investigational Contact Lens
215077024|NCT02982018|DEVICE|senofilcon A|J\&J Marketed Contact Lens
215077025|NCT00563095|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|
215077026|NCT00563095|PROCEDURE|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
214953256|NCT04256213|DRUG|Nivolumab and Ipilimumab|"Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)"
214345048|NCT00987467|DRUG|Cyclosporin 0.05% ophthalmic|Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
215077027|NCT03638908|DRUG|Fluoxetine|
215077028|NCT03404908|PROCEDURE|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
214953257|NCT01163006|OTHER|Polydextrose and soluble gluco fibre|Polydextrose and soluble gluco fibre
215077029|NCT03404908|PROCEDURE|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
215077030|NCT03404908|DRUG|Ropivacaine|In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
215077031|NCT03404908|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
215077032|NCT03404908|DRUG|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
215077033|NCT03404908|DRUG|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
215077034|NCT03404908|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
215077035|NCT03404908|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
215077036|NCT04173195|OTHER|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
215077037|NCT02369666|DIETARY_SUPPLEMENT|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
214953258|NCT00248833|BIOLOGICAL|25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
214953259|NCT00248833|BIOLOGICAL|50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
215077038|NCT02369666|DIETARY_SUPPLEMENT|Placebo|Contains MCT oil.
215077039|NCT03259048|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
215077040|NCT03212417|OTHER|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
215077041|NCT02253056|OTHER|Fasting / Caloric Restriction|
215077042|NCT02253056|OTHER|Healthy Diet|
215077043|NCT02282800|GENETIC|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
214953260|NCT01900899|PROCEDURE|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
214953261|NCT01329432|PROCEDURE|Take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.
215077044|NCT00780481|DRUG|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
215077045|NCT01211353|BEHAVIORAL|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
215077046|NCT01211353|BEHAVIORAL|Education-Only|Educational information about alcohol use
215077047|NCT05379114|OTHER|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
215077048|NCT05379114|OTHER|Comparator device|well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
215077049|NCT00495924|PROCEDURE|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
215077050|NCT01833234|OTHER|Interviews and questionnaires|
215077051|NCT02832024|DEVICE|plaque excision system|
215077052|NCT02832024|DEVICE|stent|
215077053|NCT02832024|DEVICE|Balloon|
214953262|NCT01329432|PROCEDURE|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
215077054|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval recess group,we injected 20 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into into the Rotator cuff interval/anterior capsule.
215077055|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval and posterior glenohumeral recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval and posterior glenohumeral recess group,we injected 10 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the Rotator cuff interval/anterior capsule and 10 mL mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the posterior glenohumeral.
215077056|NCT06024837|OTHER|CT Images|Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
215077057|NCT00045149|BIOLOGICAL|aldesleukin|
215077058|NCT00045149|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
215077059|NCT01803178|DIETARY_SUPPLEMENT|Plant Sterols|
215077060|NCT01803178|DIETARY_SUPPLEMENT|Placebo Product|
215077061|NCT01926899|DRUG|Bortezomib administration|
215077062|NCT04482530|OTHER|fruit paste matrice|Evaluation of the kinetics of the appearance of nutrients and the metabolic response induced by the consumption of fruit pastes (5 different matrices will be tested: 1 Original recipe, 1 maltodextrine recipe, 1 fructose recipe, 1 isomaltulose recipe and 1 mixed recipe comprising fructose and isomaltulose) in elderly healthy volunteers.
215077063|NCT00092872|DRUG|MK0557|
214953263|NCT02006056|DRUG|Ondansetron|Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
214345049|NCT05190081|OTHER|TASK TRAINING|A special program including motor and cognitive tasks was prepared. Both lower and upper extremity motor tasks and verbal, arithmetic, auditory, and visual cognitive tasks were planned based on evidence. The dual-task and single-task training were held 2 days a week, 40 minutes, for a total of 10 sessions for 5 weeks. A patient-appropriate task was selected for each cognitive task each week.
214953264|NCT00723697|DRUG|buprenorphine|0.4, 2, or 8 mg sublingual tablets
214953265|NCT03414905|DEVICE|Aspira Catheter|"* 15.5Fr catheter~* Standard of care"
214953266|NCT03414905|PROCEDURE|Ultrasound|Standard of care
214953267|NCT05049473|DRUG|Rituximab|Rituximab 375 mg/m² IV. Day 1. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*. Two additional doses after 6 cycles in case of localized stage patients without CR after four cycles or advanced stage patients.
214953268|NCT05049473|DRUG|Methotrexate|Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
214953269|NCT05049473|DRUG|Dexamethasone|Dexamethasone 10 mg/m² PO or IV bolus. Days: 2 to 6. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*.
214953270|NCT05049473|DRUG|Iphosphamid|"Iphosphamid 800 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1, A2 (500 mg/m² if patient in CR).~Iphosphamid 400 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1\*."
214953271|NCT05049473|DRUG|Vincristine|Vincristine 2 mg IV bolus. Day 2. Cycles: A1, B1, A2, B2 Vincristine 1 mg IV bolus. Day 2. Cycles: B1\*, B2\*, B3\*
214953272|NCT05049473|DRUG|Etoposide|Etoposide (VP16) 100 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1, A2. Etoposide (VP16) 250 mg/m² IV in 1 hour. Days: 5, 6. Cycle: C1, C2. Etoposide (VP16) 60 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1\*, A2\*, A3\*.
214953273|NCT05049473|DRUG|Cytarabine|Cytarabine 150 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1, A2 Cytarabine 2 g/m² IV in 3 hours every 12 hours. Day: 6. Cycle: C1 (1.5 g/m² if patient in CR), C2 (1.5 g/m² if patient in CR) Cytarabine 60 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1\*, A2\*, A3\*
214953274|NCT05049473|DRUG|Cyclophosphamide|Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1\*, B2\*, B3\*
214953275|NCT05049473|DRUG|Doxorubicin|Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1\*, B2, B2\*, B3\*
214953276|NCT05049473|DRUG|Vindesine|Vindesine 3 mg/m2 (max 5 mg) IV bolus. Day 2. Cycles: C1, C2
214953277|NCT05049473|DRUG|Cytarabine|Cytarabine 30 mg IT. Days 2 and 6. Cycles A1, B1, A2, B2
214953278|NCT05049473|DRUG|Methotrexate|Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
214953279|NCT05049473|DRUG|Hydrocortisone|Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2
214953280|NCT05049473|DRUG|Prednisone|Prednisone 60 mg/m2 PO or IV bolus. Days 1 to 5. Pre-phase.
214953281|NCT02546076|DEVICE|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
214953282|NCT02546076|DEVICE|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
214953283|NCT05292976|OTHER|Methacholine Chloride|Serial Methacholine dilutions
214953284|NCT05292976|DRUG|Albuterol Sulfate HFA 0.09 mg (Reference)|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols.
214953285|NCT05292976|DRUG|Albuterol Sulfate HFA 0.18 mg (Reference)|One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
214953286|NCT05292976|DRUG|Albuterol Sulfate HFA 0.09 mg (Test)|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols.
214953287|NCT05292976|DRUG|Albuterol Sulfate HFA 0.18 mg (Test)|One actuation each from two different Test inhalation aerosols and one actuation each from two different placebo Reference inhalation aerosols.
214953288|NCT05292976|DRUG|Placebo|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
214953289|NCT05058092|DEVICE|Immediate Remedee Solution|"* D0 to M3: Remedee Solution + medical care~* M3 to M6: Remedee Solution without personalized support + medical care~* M6 to M9: medical care only"
214953290|NCT05058092|DEVICE|Delayed Remedee Solution|"* D0 to M3: medical care only~* M3 to M6: Remedee Solution + medical care~* M6 to M9: Remedee Solution without personalized support + medical care"
214953291|NCT02770846|PROCEDURE|Immediate loading|
214953292|NCT02770846|PROCEDURE|Delayed loading|
214953293|NCT06371066|OTHER|experimental group|the experimental group was educated by video
214953294|NCT06371066|OTHER|Control group|the control group was educated by traditional formal training
214953295|NCT04291365|DIAGNOSTIC_TEST|Blood pressure measurement|Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)
214953296|NCT06731725|DEVICE|DayDrop®|The patient will administer 1 to 2 instillations each time it is necessary (at least 2 times a day) and will record it in their data collection notebook.
214953297|NCT00069563|BEHAVIORAL|Reaching Educators, Children, and Parents (RECAP)|
214953298|NCT05337384|DIAGNOSTIC_TEST|Sonography|Sonographic Venous Doppler Imaging
214953299|NCT00607542|DRUG|baclofen|2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
214953300|NCT02068859|DRUG|Diclofenac Cream 8%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
214953301|NCT02068859|DRUG|Diclofenac Gel 1%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
214953302|NCT01417858|PROCEDURE|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
214953303|NCT01417858|PROCEDURE|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
214953304|NCT03374163|DRUG|intralipid 20%|milky soulation for energey supplement.
215077064|NCT02706275|OTHER|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
215077065|NCT00006042|BIOLOGICAL|filgrastim|
215077066|NCT00006042|DRUG|cyclophosphamide|
215077067|NCT00006042|DRUG|fludarabine phosphate|
215077068|NCT00006042|DRUG|mycophenolate mofetil|
215077069|NCT00006042|DRUG|tacrolimus|
214953305|NCT03077100|OTHER|Laboratory identification of positive cultures|Laboratory identification of positive cultures
214953306|NCT04436653|DEVICE|Tricuspid Valve Replacement System|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.
214953307|NCT00072904|DRUG|Insulin Asparte|Insulin asparte given 0.5 units per carb per meal
214953308|NCT00072904|DRUG|Repaglinide|0.5mg tab with meals tid
214953309|NCT06730841|DEVICE|Dose-Optimized and Spaced Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of up to 4 milliamp (mA).~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
214953310|NCT06730841|DEVICE|Spaced Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of 2 mA.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
215077070|NCT00006042|PROCEDURE|allogeneic bone marrow transplantation|
215077071|NCT00006042|RADIATION|radiation therapy|
215077072|NCT04899375|DEVICE|Floss band|Tissue-flossing, is the use of an elastic band to provide compression on soft-tissue and joints whilst performing active and, or passive range of motion.
215077073|NCT04899375|DEVICE|ACE bandage|An ACE bandage is a cloth wrap used to provide compression
215077074|NCT04675658|BEHAVIORAL|CBPA + family support|Classroom Based Physical Activity + family support as described in the Arm
215077075|NCT04675658|BEHAVIORAL|CBPA|Classroom Based Physical Activity
215077076|NCT03334851|DRUG|PF-06835375|Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.
215077077|NCT03334851|DRUG|Placebo|Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
215077078|NCT06163495|BEHAVIORAL|Screen Free Time with Friends intervention|School-based extracurricular intervention focusing on time spent with friends and screen media use
215077079|NCT05791409|DRUG|Epcoritamab|Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
215077080|NCT05791409|DRUG|Venetoclax|All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
215077081|NCT05467761|DRUG|Oral Psilocybin|25mg orally
215077082|NCT05467761|DRUG|IV Psilocybin|5mg intravenously
215077083|NCT01967017|DRUG|Lidocaine|
215077084|NCT01967017|DRUG|Placebo|
215077085|NCT01229072|BIOLOGICAL|Heparin sodic|Heparin sodic 150UI/kg
215077086|NCT01229072|BIOLOGICAL|heparin liquemine|Heparin sodic 150UI/kg
215077087|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine|Combination therapy
215077088|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule|Single agent
215077089|NCT05081349|DRUG|L-Carnitine, 250 Mg Oral Capsule|single agent
215077090|NCT03091985|DEVICE|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
215077091|NCT03091985|DEVICE|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
214953311|NCT06730841|DEVICE|Sham Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. This group will be treated using sham stimulation.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
214953312|NCT05275634|OTHER|Stander treatment|Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).
215077092|NCT04385641|OTHER|Cell infusion for Dose-finding (Group A)|Group A：HLA-I and HLA-II molecular typing were performed at the serological and molecular levels, and the HLA-I and HLA-II molecular antigens of donor and subjects match on 3, 4, 5 or 6 / 6. After the successful matching, the non myeloablative immunosuppressive pretreatment with cyclophosphamide (900 mg / m＾2 / day) and fludarabine (30 mg / m＾2 / day) will be performed 6, 5, 4 and 3 days before the infusion of UCB-NK cells. After the pretreatment, the cell infusion was started on day 0, and the cell infusion could be divided into 50% and 50% for two consecutive days or every other day. To ensure clinical safety, if treatment-related adverse events reach DLT after the first infusion, the cell infusion will stop.
214345050|NCT03999606|BEHAVIORAL|Music Training - Choir participation|"Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform."
214953313|NCT05275634|DEVICE|Interferential current with carrier frequency 2 KHz|Interferential current treatment parameters will be as following; carrier frequency 2 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
214345051|NCT05330663|DIETARY_SUPPLEMENT|Low protein diet with Fresubin® renal|Low protein diet with Fresubin® renal Dosage: 1 bottle per day as a replacement for one regular meal. All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight.
214345052|NCT05330663|OTHER|Low protein diet with normal food|All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight/day.
214345053|NCT06417281|DRUG|5 Aminolevulinic Acid|3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
214953314|NCT05275634|DEVICE|Interferential current with carrier frequency 4 KHz|Interferential current treatment parameters will be as following; carrier frequency 4 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
214953315|NCT05275634|DEVICE|Interferential current with carrier frequency 8 KHz|Interferential current treatment parameters will be as following; carrier frequency 8 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
214953316|NCT05275634|DEVICE|placebo interferential current|Interferential current intensity will not be raised.
214953317|NCT02995629|PROCEDURE|laser indirect ophthalmoscopy pan retinal photocoagulation|"* Prior to procedure, eligible patient is dilated and a topical anesthesia is administered 3 to 5 minutes prior to treatment initiation~* Treatment duration is fixed at 50 minutes and power is titrated until moderate gray-white burns are achieved, avoiding long ciliary nerves~* Target treatment of 250 spots~* Only one eye per eligible patient randomized with regard to whether green or yellow laser utilized first~* After treatment,pain assessment conducted:spot count, laser parameters and treatment duration recorded for each respective laser wavelength"
214953318|NCT02482753|DRUG|Chidamide|30 mg, administered orally twice per week (BIW)
214953319|NCT02482753|DRUG|exemestane|25 mg, PO daily
214953320|NCT02482753|DRUG|placebo|Administered orally twice per week (BIW)
214953321|NCT00743847|DRUG|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
214953322|NCT00743847|DRUG|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
214953323|NCT00743847|DRUG|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
214953324|NCT03816618|DRUG|Medihoney Gel in A Tube|TREATMENT1
214953325|NCT03816618|DRUG|Hydrogel|PURLOIN GEL
214953326|NCT03816618|DRUG|Fucidin Ointment|FUCIDIN ANTIBIOTIC OINTMENT 10%
214953327|NCT00532727|DRUG|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
214953328|NCT00532727|DRUG|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
215077093|NCT04385641|OTHER|Cell infusion for Extended research (Group B)|Group B：Non myeloablative immunosuppressive pretreatment and cell transfusion were the same as group A.
215077094|NCT00539383|DRUG|ANG1005|IV infusion once every 21 days
214953329|NCT02132728|OTHER|Flaxseed or rice raw powder ingestion|The experimental groups received isocaloric diets and different proportions of carbohydrates, and the introduction of 60g of brown flaxseed or rice raw powder. Flaxseed and raw rice were crushed weekly by minimal particle type mill and appropriate sieves for fine grinding grain with a degree to 250 mm/micrometers. After crushing flaxseed and raw rice, they were weighed in semi-analytical balance. The addition of flaxseed or raw rice powder was made in the collation (40 g added to milk) and lunch (20 g added to baked beans). The volunteers received flaxseed or rice raw powder, portioned to be used for 42 days, including the weekends.
214953330|NCT04322084|OTHER|Wearable Sensors|To develop predictive algorithms that identify early onset of sepsis in children being treated for ALL. This study will use a two-stage design. The initial stage (the feasibility phase) will evaluate the feasibility of data collection, and the second stage (the completion phase) will provide data for the design of predictive models.
214953331|NCT01015105|OTHER|observation|observation
214953332|NCT00385827|DRUG|Mitoxantrone|Mitoxantrone 12 mg/m\^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2)
215077095|NCT05362227|DRUG|Low volume macrogol|Clensia 2 lt
215077096|NCT05362227|DRUG|High volume macrogol|Selg 4 lt
215077097|NCT01691885|DRUG|Fluticasone Furoate|100mcg Once daily
215077098|NCT01691885|DRUG|Vilanterol|25mcg Once daily
214953333|NCT00385827|DRUG|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
214953334|NCT00385827|DRUG|Prednisone|Prednisone 5 mg orally twice daily
214953335|NCT01909960|OTHER|Flow imaging|"Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in Larson's score and MMSE"
214953336|NCT06544746|RADIATION|Periapical radiographs|oral radiographs taken with the paralleling technique and film holders at 1- and 3-years post-prosthesis insertion with an X-ray apparatus equipped with a long cone and a Rinn Universal Collimator (Dentsply RINN, York, PA, USA). All radiographs were stored on a PC and analyzed with the software program DBSWIN software. Each radiograph was calibrated using the implant diameter and length as reference measures to correct any distortion before measurement. An image processing program was employed to quantify peri-implant MBL, the EA, EP.
214953337|NCT02927678|OTHER|white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging|
214953338|NCT01273909|PROCEDURE|Perforator Flap Breast Reconstruction|perforator flap breast reconstruction with or without vascularized lymph node transfer
215077099|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
215077100|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
215077101|NCT02180880|DRUG|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
215077102|NCT02373436|OTHER|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
215077103|NCT02373436|OTHER|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
215077104|NCT03555981|OTHER|Early Kangaroo Mother Care|Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
215077105|NCT03555981|OTHER|Standard care|Incubator or radiant heater care until stable, off oxygen and \>24h of admission, at which point will start intermittent or continuous kangaroo mother care
215077106|NCT02442791|DRUG|Byetta (Lilly, Exenatide)|See description of Arms
215077107|NCT02442791|OTHER|20% Human Albumin|See description of Arms
215077108|NCT00234481|DRUG|XL844|
215077109|NCT04384445|BIOLOGICAL|Zofin|Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10\^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
214953339|NCT01273909|PROCEDURE|Vascularized Lymph Node Transfer|perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
214953340|NCT02527174|DRUG|Volasertib|Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
214953341|NCT02527174|DRUG|Idarubicin|Given IV daily on Days 1-3 of treatment protocol.
214953342|NCT02527174|DRUG|Cytarabine|Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
214953343|NCT02182986|PROCEDURE|transplant|All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).
214953344|NCT02182986|DRUG|Immunosuppressive Drugs|Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
214953345|NCT01380652|PROCEDURE|whole body vibration training|pulmonary rehabilitation with strength and endurance training and additionally vibration training
214953346|NCT00008125|BIOLOGICAL|filgrastim|
214953347|NCT00008125|DRUG|carboplatin|
214953348|NCT00008125|DRUG|docetaxel|
214953349|NCT00008125|DRUG|gemcitabine hydrochloride|
214953350|NCT03218371|PROCEDURE|chandelier-assisted peripheral vitrectomy under air|chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
214953351|NCT01857180|OTHER|Curriculum|
214953352|NCT06476405|OTHER|Study Product A: Ploom® Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product A: Ploom Non-menthol) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
214953353|NCT06476405|OTHER|Study Product B: Usual Brand Combustible Cigarette (UBCC) Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product B: Non-menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
214953354|NCT06476405|OTHER|Study Product C: Ploom® Menthol Heated Tobacco Product (HTP)|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product C: Ploom® Menthol HTP) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
214953355|NCT06476405|OTHER|Study Product D: Usual Brand Combustible Cigarette (UBCC) Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product D: Menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
214953356|NCT02374424|DRUG|GA101_DHAP|"Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~* GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~* Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~* Dexamethasone 40 mg day 1-4 of every cycles~* Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~* GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy"
214953357|NCT02872233|DRUG|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
214953358|NCT02872233|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
214953359|NCT00410072|DRUG|Entecavir|Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
214953360|NCT00410072|DRUG|Entecavir + Tenofovir|Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
214953361|NCT05339919|DIAGNOSTIC_TEST|gait speed; ct scan;grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
214953362|NCT03692637|BIOLOGICAL|anti-Mesothelin Car NK Cells|anti-Mesothelin Car NK Cells injection
214953363|NCT02414100|OTHER|Laboratory Biomarker Analysis|Correlative studies
214953364|NCT02414100|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214953365|NCT05741242|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Personalized Synthetic Long Peptide Vaccine
214953366|NCT05780749|DIETARY_SUPPLEMENT|DDI-IBS-001|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.
214953367|NCT05780749|OTHER|DDDI-IBS-001 placebo|The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.
214953368|NCT02106598|DRUG|fluorescent cRGDY-PEG-Cy5.5-C dots|
215077110|NCT04384445|OTHER|Placebo|Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
215077111|NCT05835232|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
215077112|NCT03989427|OTHER|Brushing first and Flossing later (BF)|Participants will follow Brushing first and flossing later (BF) sequence for 2 weeks, and after 1 week wash out period, Flossing first and Brushing later (FB) sequence for another 2 weeks.
215077113|NCT03989427|OTHER|Flossing first and Brushing later (FB)|Participants will follow Flossing first and Brushing later (FB) sequence for 2 weeks, and after 1 week wash out period, Brushing first and flossing later (BF) sequence for another 2 weeks.
215077114|NCT06233864|DRUG|Disitamab Vedotin|Disitamab Vedotin
214953369|NCT05123482|DRUG|AZD8205|AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.
214953370|NCT05123482|DRUG|AZD8205 and AZD2936 (Rilvegostomig)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
215077115|NCT06233864|DRUG|Gemcitabine|Gemcitabine
215077116|NCT03545711|DRUG|Anlotinib Hydrochloride with Irinotecan|Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
215077117|NCT03497546|OTHER|Exercise|Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
215077118|NCT06151951|OTHER|Cervical Stabilization|Isometric stretching and strengthening exercises of Neck flexor muscle including suboccipitalis, levator scapulae,scalnae anterior and upper trapezius. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.
215077119|NCT06151951|DEVICE|Pressure Biofeedback|"In this method patients in supine position. Sphygmomanometer is used and 100 mmHg pressure will be maintained before the treatment start then cuff will be placed under the occiopit of spine and patient will be asked to press the cuff against the occiopit until gauze show target pressure then hold this position for 6 second and release. Repeated this pressure to 10 times, 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
214345054|NCT06532266|DEVICE|TechTrade Ready Heat Half Body Temperature Management Blankets|"The thermal blanket will be placed on top of the cotton blanket. Newborn will be first covered with conventional warm blanket then adding the thermal blanket on top. The thermal blanket will be placed inside a pillowcase like cotton blanket to avoid direct contact with mother or newborn."
214345055|NCT06532266|OTHER|Control|3 layers of 100% cotton woven blankets
214345056|NCT06297538|DEVICE|gamma transcranial alternating current stimulation (tACS)|Transcranial alternating current stimulation (tACS) will be delivered using a BrainSTIM (EMS, Italy) connected to two electrodes (5x5cm) enclosed in sponges soaked with saline solution. One electrode will be centred over the first dorsal interosseus (FDI) hotspot and the other over P3. tACS will be delivered at peak-to-peak amplitude of 1 milliampere (mA), and with 3-seconds ramp-up and down periods. The stimulation frequency will be 70 Hz, as representative of the endogenous motor network-related gamma frequency.
214953371|NCT05123482|DRUG|AZD8205 and AZD5305 (saruparib)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
214953372|NCT05123482|DRUG|AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
214953373|NCT05295459|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
214345057|NCT06297538|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham-tACS will consist of ramp-up and down periods and only 1-second stimulation at 1 mA amplitude.
214345058|NCT01621360|PROCEDURE|Arthroscopic hip surgery|Hip arthroscopy
214345059|NCT01621360|OTHER|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
214345060|NCT00004010|BIOLOGICAL|bleomycin sulfate|
214345061|NCT00004010|BIOLOGICAL|filgrastim|
214345062|NCT00004010|DRUG|ABVD regimen|
214345063|NCT00004010|DRUG|cyclophosphamide|
214345064|NCT00004010|DRUG|dacarbazine|
214345065|NCT00004010|DRUG|doxorubicin hydrochloride|
214345066|NCT00004010|DRUG|etoposide|
214345067|NCT00004010|DRUG|prednisone|
214345068|NCT00004010|DRUG|procarbazine hydrochloride|
214345069|NCT00004010|DRUG|vinblastine sulfate|
214345070|NCT00004010|DRUG|vincristine sulfate|
214678420|NCT04405804|DRUG|Ivabradine 5Mg Tab|"Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 2.5 mg/day in patients between 3-18 years with weight \> 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 15 mg/day in patients between 3-18 years, weight \> 40 kg"
214953374|NCT05295459|DRUG|Sham procedure control|Sham procedure control
214345071|NCT00004010|RADIATION|radiation therapy|
214953375|NCT05295459|OTHER|Background therapy|Daily Saline Irrigation
214953376|NCT00116636|DRUG|Kaletra|
214953377|NCT06695910|DIETARY_SUPPLEMENT|Monoglyceride Eicosapentaenoic acid (omega-3)|515 mg MAG-EPA + 33 mg MAG-DHA per capsule x 3 capsules daily: 1.5g/day (MAG-EPA). Subjects will be treated over a period of 56 days (or 112 days in phase 2) followed by a wash-out period of 28 days.
214953378|NCT06695910|OTHER|Sunflower Oil|698 mg sunflower oil per capsule x 3 capsules: 2.0g/d sunflower oil (Placebo) Subjects will be treated over a period of 112 days followed by a wash-out period of 28 days.
214345072|NCT02646423|BEHAVIORAL|Prior CD Decision App|The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
214345073|NCT02566395|RADIATION|Radiation|1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days
214345074|NCT02566395|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
214345075|NCT02566395|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI containing 1 x 10E8/kg donor T-cells
214345076|NCT02566395|BIOLOGICAL|Haploidentical Stem Cell Transplantation|2-10 x 10E6/kg donor CD34+ selected cells
214345077|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
214345078|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
214345079|NCT00533390|DRUG|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
214345080|NCT03517774|DEVICE|3D Printed Socket|Twenty participants will be fitted with a 3D Printed socket created using 3DPrintAbility hardware and software. To do this, a 3D model of the participants residual limb will be generated which will be used to create the 3D printed sockets. These 20 participants will also receive standard care for prosthetic fitting at SJR. The fittings will be done by one prosthetist. Our team will compare the feasibility, function, quality and stability of the prosthetics through quantitative, economic and qualitative analyses. All fittings will be done under the supervision of a qualified Sunnybrook prosthetist who has previous experience with using 3D printed technologies for creation of prosthetics.
214345081|NCT02807948|DEVICE|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
214345082|NCT00898716|DRUG|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
214345083|NCT02286544|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi®)|A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
214953379|NCT05636137|OTHER|Survey application|Researchers will go to the designated high schools and meet face-to-face with the responsible/guidance teachers at the school. The research will be explained to the students by going to the classrooms with the teachers, and they will be asked to fill in the consent forms of the parents and themselves. Students will be given 5 days to explain the work to their families and bring their signed consent forms. Students who bring consent forms, meet the criteria for participation in the study, and volunteer will be included in the study. Evaluation forms and questionnaires will be explained to the students included in the study by a designated researcher and they will be asked to fill them in under the supervision of the researcher. The completed evaluation form and questionnaires will be collected by a researcher in a sealed envelope.
215077120|NCT06151951|DEVICE|Visual Biofeedback|"In this method Led Head Band light will be used as a visual feedback. Patients in sitting or standing position with neck straight with the alignment of front wall marking followed by control movement training. Patient will be asked to follow the marking through head band light while performing motion control training. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
214345084|NCT02286544|DRUG|Oxygen (Oxymask®)|"As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.~Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended."
214953380|NCT04156451|PROCEDURE|Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg|Crystalloid loading or furosemide administration with the CVP target 8-10 mmHg is reached in septic shock patients
214345085|NCT02286544|DRUG|Atorvastatin|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
214345086|NCT02138591|PROCEDURE|Blood draw pre-operatively|Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
214345087|NCT02138591|PROCEDURE|Blood draw post-operative Day 1|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
214345088|NCT02138591|PROCEDURE|Blood draw post-operative Day 2|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
214345089|NCT04412395|DIETARY_SUPPLEMENT|Lactoferrin (Apolactoferrin)|Apolactoferrin is an iron-free Lactoferrin (with very low iron saturation). Lactoferrin (Lf) is a natural glycoprotein that is found predominantly in milk. Lf represents a known component of the innate immune system present in neutrophil-specific granules and broadly distributed within the body fluids and exocrine secretions.
214345090|NCT04412395|DRUG|Placebo of excipient(s) will be administered|Placebo of the equivalent excipient will be administered to placebo group
214345091|NCT04471818|DRUG|Ketamine|Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
214953381|NCT04156451|PROCEDURE|Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg|active fluid removal with furosemide bolus and continuous or crystalloid loading until the CVP target 0-4 mmHg is reached in septic shock patients
214953382|NCT06240312|DEVICE|Images of eye at 2 eye pressures|subject images of the eye's optic nerve head are studied
214953383|NCT03900247|DEVICE|REMAP EEG based BCI and SEM-Glove BioServo|EEG-based brain computer interface (BCI) will be adapted to individual ALS patients and modified to control external robotic devices
214953384|NCT03276845|DIAGNOSTIC_TEST|Ultrasound of the breast|Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
215077121|NCT00293904|BIOLOGICAL|CYT005-AllQbG10|
214345092|NCT04471818|OTHER|Placebo|Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
214345093|NCT01504594|PROCEDURE|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
214345094|NCT04242927|DRUG|Nicotinic acid +Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
214345095|NCT04242927|DRUG|Routine care|Routinely apply urea ointment and provide best supportive care.
214345096|NCT06167668|OTHER|the routine chronic disease management mode|indoor temperature and humidity adjustment, regular ventilation and hygiene of ward and clinic environment, promotion of patients' health awareness by distributing disease brochures, regular inspection of wards, and home nursing and health guidance based on disease knowledge when discharged
214953385|NCT06653400|PROCEDURE|paracervical block|paracervical block with office hysteroscopy
214953386|NCT06653400|DRUG|Lidocaine|Dosage: 20 mL of 1% lidocaine
214953387|NCT06653400|DRUG|ketorolac|Dosage: 2 mL (30 mg) of ketorolac
214953388|NCT01501032|DEVICE|MD-logic artificial pancreas system|The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
214953389|NCT03767426|BEHAVIORAL|Sleep Deprivation|Subjects are sleep deprived for an entire night
215077122|NCT05043792|DRUG|TT-00920|TT-00920 Tablets
215077123|NCT05043792|DRUG|TT-00920 Placebo|TT-00920 Placebo Tablets
215077124|NCT02563860|DRUG|Lovastatin|dose escallating
214345097|NCT06167668|OTHER|the family-centered family enabling health management mode|The specific measures were as follows :(1) intervention group construction. (2) Online knowledge promotion. (3) Disease assessment.(4) Medication guidance reminder.(5) Enabling psychological counseling.
214345098|NCT05080569|DRUG|Progesterone Vaginal Product|3dd200mg
214345099|NCT05080569|DRUG|Placebo|3dd1 vaginal capsule
214953390|NCT03767426|BEHAVIORAL|Daytime nap|After a night of sleep deprivation, participants will be given a 2 hour nap opportunity
214953391|NCT01504139|DRUG|hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase|when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
214953392|NCT01504139|DRUG|hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase|hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
214953393|NCT01504139|DRUG|LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase|LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
214953394|NCT01504139|DRUG|vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase|The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
215077125|NCT04730778|DIAGNOSTIC_TEST|serum creatinine and estimated glomerular filtration rate, on daily basis|Assess establishing criteria of CIN through a week after primary PCI
214345100|NCT00974168|RADIATION|Cumulative BED ≤ 100|Radiation
214345101|NCT00974168|RADIATION|Cumulative BED ≤ 130 Gy2|Radiation
214345102|NCT05355974|DRUG|Norepinephrine|Norepinephrine continuous infusion at 0.10 mcg/kg/min
214678421|NCT06034704|OTHER|Plantar fascia self massage with a magnetic fascia ball|Participants were asked to roll the magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
214345103|NCT05355974|DRUG|Lactated Ringers, Intravenous|500mL infusion run at 999mL/hr
214678422|NCT06034704|OTHER|Plantar fascia self massage with a non-magnetic fascia ball|Participants were asked to roll the non-magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
214678423|NCT00373971|BEHAVIORAL|Involving the patients in their own nutritional care|
214678424|NCT02653378|BEHAVIORAL|DIET|25% Energy Depletion by Diet only for 3 Days
214678425|NCT02653378|BEHAVIORAL|EX|25% Energy Depletion by Exercise only for 3 Days
214678426|NCT00719576|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation via mini-arthrotomy
214678427|NCT00719576|PROCEDURE|Microfracture|Microfracture performed by arthroscopic surgery
214953395|NCT01362023|BEHAVIORAL|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~1. Classroom practice by HPA to highlight healthy lifestyle habits~2. Teaching practice by HPA using books designed to include the nutritional objectives~3. Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~1. Experimental development of activities regarding each healthy lifestyle habit~2. Assessment of activity performed in classroom~3. An activity developed for use at home"
214953396|NCT06034132|OTHER|Stock healing abutments|2ND stage surgery will be performed and stock healing abutment were placed
214953397|NCT06034132|OTHER|Compoiste healing abutments|2ND stage surgery will be performed and composite healing abutment were placed
214953398|NCT00810498|DEVICE|Trilogy|Exposure for one hour on the Trilogy ventilator
214953399|NCT00810498|DEVICE|Standard of Care|Exposure to participants current ventilator
214953400|NCT05708352|BEHAVIORAL|Keto Diet|The experimental intervention includes a strict and controlled diet that manages daily macronutrient breakdown and increases the ratio of dietary fat relative to protein and carbohydrate consumption.
214345104|NCT05355974|DRUG|normal saline|500mL infusion run at 999mL/hr
214345105|NCT05355974|DRUG|Plasma-lyte|500mL infusion run at 999mL/hr
214678428|NCT06148233|RADIATION|[18F]CSF-23|Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[18F\]CSF-23 in a single dose.
214678429|NCT02196142|DRUG|Cortisol 20mg|Drug: Cortisol 20mg
214678430|NCT02196142|DRUG|Placebo Mannitol|Drug: Placebo Mannitol
214678431|NCT03090620|DRUG|Physostigmine|Administration of physostigmine bolus followed by an infusion
214678432|NCT03090620|DRUG|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
215077126|NCT01117740|BEHAVIORAL|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
215077127|NCT04939181|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents:~pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
214678433|NCT00109317|DRUG|Raptiva (efalizumab)|
214678434|NCT00003750|BIOLOGICAL|hu14.18-IL2 fusion protein|
214953401|NCT05708352|BEHAVIORAL|Standard Anti-Cancer Diet|Dietitian sessions will utilize the American Institute for Cancer Research Food resources and will reference foods low in fats such as fruits, vegetables and whole grains, providing key micronutrients and phytonutrients. Sessions will also focus on dietary support to help decrease any treatment related symptoms.
214953402|NCT01971515|DRUG|MSC2363318A|"Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.~Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle)."
215077128|NCT04939181|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
215077129|NCT03760159|DEVICE|Kinocardiography unintrusive recording|"The Kinocardiography (Kino) is a device which records the electric and mechanic function of the heart. The device comprises a combination of ECG recording, (6 degrees of freedom), accelerometer and gyroscope sensors. The Kino device consists of a back and a chest housing in contact with the patient. The back housing is placed in the middle of the lower back of the patient, and the chest housing is placed on the chest (either on the sternum or on the costal grill at the apex of the heart). The housings are connected by two cables. Data obtained from the device are visualized on a digital application via a Bluetooth connection.~For the group A, the KCG records the cardiac signals while the patient performs specific respiratory manoevres, as describe above.~For group B, C, D, the KCG records the cardiac contraction during sleep along with the PSG recording."
215077130|NCT01067599|OTHER|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
215077131|NCT01067599|OTHER|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
215077132|NCT01067599|OTHER|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
215077133|NCT04580758|COMBINATION_PRODUCT|Fractional laser with PRP fluid or PRP gel|20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
215077134|NCT02754141|BIOLOGICAL|BMS-986179|Specified dose on specified days
215077135|NCT02754141|BIOLOGICAL|Nivolumab|Specified dose on specified days
215077136|NCT02754141|BIOLOGICAL|rHuPH20|Specified dose on specified days
215077137|NCT03361189|DEVICE|Closed loop stimulation|Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.
215077138|NCT03361189|DEVICE|Standard rate response|Standard rate response is an algorithm to increase heartrate based on movement
214678435|NCT00305006|PROCEDURE|Constraint-Induced Movement Therapy (CIMT)|90 hours
214678436|NCT00305006|PROCEDURE|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
215077139|NCT01003756|OTHER|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
215077140|NCT03617536|DRUG|CR845 0.25 mg Oral Tablet|CR845 0.25 mg medication taken orally 1 time/day
215077141|NCT03617536|DRUG|CR845 0.5 mg Oral Tablet|CR845 0.5 mg medication taken orally 1 time/day
215077142|NCT03617536|DRUG|CR845 1 mg Oral Tablet|CR845 1 mg medication taken orally 1 time/day
215077143|NCT03617536|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
215077144|NCT04787783|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application
215077145|NCT00196027|DEVICE|PFX Closure System|
215077146|NCT04500392|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min
215077147|NCT04500392|DEVICE|Regular nasal cannula|Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
215077148|NCT03344549|BEHAVIORAL|Renal nutrition teleconsultation|Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.
215077149|NCT03344549|BEHAVIORAL|Face-to-face consultation of renal nutrition|Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
215077150|NCT05709561|PROCEDURE|Acupresur|acupressure application was applied 2 times a week for a total of 12 weeks and 24 times.
215077151|NCT05709561|PROCEDURE|Mindfulness|Mindfulness practice was applied with the students once a week for 8 weeks, accompanied by a researcher. Then, students were asked to apply for 3 cycles.
215077152|NCT05709561|PROCEDURE|Plasebo|No intervention was applied to the control group.
214678437|NCT00631488|DRUG|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
214678438|NCT00631488|DRUG|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
214678439|NCT00631488|DRUG|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
214345106|NCT02982252|BEHAVIORAL|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
214345107|NCT02624804|BIOLOGICAL|Stem Cell Educator Therapy|"Patients will receive apheresis and then have their own blood returned to them with the educated lymphocytes"
214345108|NCT01206738|BEHAVIORAL|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
214345109|NCT01206738|BEHAVIORAL|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
214345110|NCT01206738|BEHAVIORAL|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
214345111|NCT01309620|DIETARY_SUPPLEMENT|Zinc gluconate|Zinc gluconate (GNC, USA), 100 mg twice daily
214345112|NCT01309620|DIETARY_SUPPLEMENT|Placebo|Placebo, Twice Daily
214345113|NCT01227889|DRUG|GSK2118436|150 mg twice daily
214953403|NCT01971515|DRUG|MSC2363318A plus Trastuzumab|"Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion."
214953404|NCT01971515|DRUG|MSC2363318A plus Tamoxifen|"Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration."
214345114|NCT01227889|DRUG|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
214345115|NCT06250686|BEHAVIORAL|combined exercise and nutrition intervention|Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.
214345116|NCT05325086|OTHER|Adapted information arm|A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits
214953405|NCT05163730|DEVICE|COVID-19/ Flu A&B Rapid Panel|Rapid Diagnostic Device
214953406|NCT02548884|PROCEDURE|Biliary cannulation|
214345117|NCT05325086|OTHER|Neutral information arm|A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
214345118|NCT05560867|DEVICE|robot-assisted training|These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
214345119|NCT03752164|BEHAVIORAL|Yoga and Mindfulness Skills|Single brief session in which children are taught yoga and skills in mindfulness
214345120|NCT05969353|OTHER|accupunture|BFA
214345121|NCT00591812|DEVICE|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
214678440|NCT00631488|DRUG|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
214678441|NCT00631488|DRUG|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
214953407|NCT03185494|BIOLOGICAL|anti-CD19/22-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
214953408|NCT02557685|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
214953409|NCT05627648|DRUG|KP-100LI|Intracordal injection, 20 mcg once per week, 3 weeks
214953410|NCT05627648|DRUG|Placebo|Intracordal injection, once per week, 3 weeks
214953411|NCT03234920|DIETARY_SUPPLEMENT|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily
214953412|NCT03234920|OTHER|Placebo|The placebo will be 200 ml of fruit juice given twice daily
214953413|NCT06079632|BEHAVIORAL|parent coaching via telehealth|Participants receive 12 weeks of parent-child interaction strategy coaching and sensory processing strategy coaching intervention.
214953414|NCT06079632|BEHAVIORAL|weekly self-learning materials and group discussion session|Participants receive 1-hour self-learning materials, including parent-child interaction and sensory processing strategies, and 1-hour remote group discussion session weekly.
214953415|NCT03250338|DRUG|Crenolanib|Crenolanib will be administered orally
214953416|NCT03250338|DRUG|Cytarabine|"HAM regimen~FLAG-Ida"
214953417|NCT03250338|DRUG|Mitoxantrone|HAM regimen
214953418|NCT03250338|DRUG|Placebo Oral Tablet|Placebo will be administered orally
214953419|NCT03250338|DRUG|Fludarabine|FLAG-Ida regimen
214953420|NCT03250338|DRUG|Idarubicin|FLAG-Ida regimen
215077153|NCT05661864|BEHAVIORAL|Multi-Tiered Systems of Support for Teacher Training|In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
215077154|NCT02323126|DRUG|EGF816|EGF816 150 mg once daily (QD) administered orally as a capsule
215077155|NCT02323126|DRUG|INC280|INC280 400 mg twice daily (BID) administered orally as a tablet
215077156|NCT02323126|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
215077157|NCT04607304|DEVICE|ABCA2 GIRMS|Two systems (ABCA-C and ABCA-D) with run order randomized
215077158|NCT02639169|OTHER|Music Therapy|apply live music through the techniques of music therapy
215077159|NCT02121769|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
215077160|NCT02454439|OTHER|CRT implantation|
215077161|NCT01887561|DRUG|dasatinib|
215077162|NCT02441491|DRUG|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster."
215077163|NCT00397852|PROCEDURE|Kirschner-wires or not|
215077164|NCT03333252|BEHAVIORAL|Intervention Condition|Caregivers will access caregiving related information. Care Recipients will access cognitive training program
215077165|NCT03333252|BEHAVIORAL|Control Condition|Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games
215077166|NCT00003434|BIOLOGICAL|carcinoembryonic antigen peptide 1|
215077167|NCT00003434|BIOLOGICAL|hepatitis B antigen peptide|
215077168|NCT05977309|DEVICE|Topical ozone therapy|the topical ozone therapy group received a concentration of 30 mg/L at a frequency of 30 minutes per day for 30 days. Participants received ozone therapy topically every three days for eight treatments.
215077169|NCT02615938|DRUG|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
215077170|NCT02615938|OTHER|Placebo|Apply Placebo not to modify lysosomal pH
215077171|NCT05158335|DRUG|MBX 2109 (Part A)|Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
215077172|NCT05158335|DRUG|MBX 2109 (Part B)|Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
215077173|NCT05158335|DRUG|Placebo|Single SC dose or repeated SC doses of placebo.
215077174|NCT03065621|DRUG|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
215077175|NCT00108303|OTHER|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
215077176|NCT01425450|DRUG|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
214953421|NCT03250338|DRUG|G-CSF|FLAG-Ida regimen
214953422|NCT01832883|DEVICE|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
214953423|NCT01962623|OTHER|IPT-MBD|IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
214953424|NCT04930705|DEVICE|Treatment with TempSure Applicator|Subjects will receive up to 5 treatments on the abdomen.
214953425|NCT01421147|DRUG|LY2963016|Administered subcutaneously
214953426|NCT01421147|DRUG|Lantus|Administered subcutaneously
214953427|NCT01421147|DRUG|Insulin Lispro|Administered subcutaneously
215077177|NCT01425450|DRUG|HF1020 placebo|Single dose: HF1020 placebo capsule
215077178|NCT04046016|DRUG|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
215077179|NCT05427448|DIAGNOSTIC_TEST|Measurement of amyloid and pTau blood biomarkers|Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
215077180|NCT04714203|OTHER|sarcopenia assessment|evaluation of sarcopenia status
215077181|NCT01672463|DRUG|OKN-007|"Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter."
215077182|NCT02185573|PROCEDURE|Bulk fill|This is one of the composite restoration application techniques
215077183|NCT02185573|PROCEDURE|SonicFill|This is the recent intervention under evaluation
215077184|NCT00666588|DRUG|idarubicin|Given IV
215077185|NCT00666588|DRUG|cytarabine|Given IV or IT
215077186|NCT00666588|DRUG|bortezomib|Given IV
215077187|NCT00666588|DRUG|etoposide|Given IV
215077188|NCT00666588|OTHER|laboratory biomarker analysis|Correlative studies
215077189|NCT04549805|DIAGNOSTIC_TEST|Computed Tomography Coronary Angiography|In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
215077190|NCT02130830|DRUG|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
215077191|NCT02130830|DRUG|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
215077192|NCT06241638|DRUG|Vitamin B12 0.5 MG/ACTUAT|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
214345122|NCT00798798|DEVICE|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
214953428|NCT01559610|OTHER|Intervention Group|The patients were instructed by a nurse
214953429|NCT02660684|DRUG|Prograf|Injection or oral
214953430|NCT02660684|DRUG|Methotrexate|Injection
214953431|NCT02660684|DRUG|Cyclosporine|Injection or oral
214953432|NCT02721914|PROCEDURE|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive an amount of eight sessions that will be applied within five weeks; four massotherapy sessions and another 4 of H.A.G. The three first weeks one session of each methodology will be applied, starting always with massotherapy (with sessions on Mondays and Thursdays or on Tuesdays and Fridays). On the fourth week a session of massotherapy will be applied on the same day as usual. And, finally, on the fifth week a session of H.A.G will be applied on the same day as massotherapy is applied.
214953433|NCT02721914|PROCEDURE|GROUP RECEIVING MASSOTHERAPY|"The sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~Massotherapy technics will be applied all over the back, covering the thoracolumbar area as well as upper areas reaching the cervix and occiput.~In particular, posterosuperior iliac spines, iliac crests, ribs, shoulder girdle and the entire spine (sacral bone- lumbar area-backbones-cervical vertebrae) and its attached tissues will be worked down.~Massotherapy protocol will be applied by the physical therapist, always respecting the postural ergonomics. This enables the verticality of the body (avoiding the slopes) which makes work much easier thanks to the inertia triggered by the load transfer in the lower extremities in both sagittal and horizontal plane."
214953434|NCT02721914|PROCEDURE|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|"The subjects of this group will receive a total of 8 sessions of 30 minutes each; sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~The techniques applied are an assembly of rhythm, postural and breathing exercises that have to be done in a systematically. The physical therapist will check that all of the group subjects have assimilated properly the H.A.G and the breathing patterns from the exercises protocol. If they have, then the practical session which comprises 6 hypopressive exercises, can be started.~The subjects must remain in each position between 10 and 30 seconds and repeat the exercise three times, with a rest period among each that will last at least 20 seconds."
214953435|NCT01270321|DRUG|Everolimus|Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
214953436|NCT01270321|DRUG|Pasireotide|Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
214953437|NCT01270321|DRUG|Everolimus and Pasireotide|Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
214953438|NCT03581955|OTHER|Banana Cavendish|240g of fruit plus 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)
214953439|NCT03581955|OTHER|Tomato|"300g of raw tomato (coeur de boeuf) with refined sunflower oil (12g) and 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)."
214953440|NCT03581955|OTHER|Fresubin ® 2kcal fiber neutral flavor|250 ml Fresubin ® 2kcal fiber neutral flavor
214345123|NCT01301963|DRUG|plerixafor|Given SC
214345124|NCT01301963|BIOLOGICAL|filgrastim|Given SC
214345125|NCT03073603|DRUG|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
214345126|NCT03073603|DRUG|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
214953441|NCT01875263|DRUG|Cloxacilin|2g/4 hours i.v., 5 days
214953442|NCT01875263|DRUG|Cloxacillin|2g/4h 14 days Standard therapy
214953443|NCT01875263|DRUG|Levofloxacin|500 mg v.o./24h, 9 days
214953444|NCT02751619|DRUG|Lidocaine patch 5%|Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
215077193|NCT06241638|DRUG|Dapagliflozin 10mg Tab|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
214345127|NCT06531720|DRUG|Chlorhexidine Gluconate|topical preparation applied on oral mucosa lesion containing 0,2% CHX
214345128|NCT06531720|DRUG|Choline Salicylate 8.7 % Oral Gel|topical preparation applied on oral mucosa lesion containing, ethanol-based
214345129|NCT06531720|OTHER|control group|no medication has been prescribed
214345130|NCT04712526|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
214345131|NCT04965844|DEVICE|Oxygen close-loop|The Automatic FiO2 option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the Oxygen setting to keep the patient's SpO2 in the target range.
214345132|NCT04965844|DEVICE|No intervention|Manual FiO2 adjustment according to SpO2 values
214345133|NCT00220194|DRUG|leuprolide acetate|
214345134|NCT02090738|DRUG|Acetazolamide group|
214345135|NCT02090738|DRUG|Standard regimen group|
214345136|NCT00215852|DRUG|Alferon LDO|500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
214345137|NCT03900260|DEVICE|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
214345138|NCT02600130|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
214345139|NCT02600130|BIOLOGICAL|Placebo|via peripheral intravenous infusion
214345140|NCT04892654|DRUG|Doravirine|Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
214345141|NCT04892654|DRUG|Dolutegravir|Antiretroviral, Integrase strand transfer inhibitors
214345142|NCT04892654|OTHER|Triple cART regimen|Participant standard triple cART regimen
214345143|NCT06535412|DRUG|IMC-002 + SOC|intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg
214345144|NCT06535412|DRUG|Placebo + SOC|intravenous injection of Placebo
214345145|NCT00731315|OTHER|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
214345146|NCT00731315|OTHER|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
214345147|NCT00559559|DEVICE|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
214345148|NCT00559559|PROCEDURE|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
214345149|NCT00941239|DRUG|metformin ER|850mg daily for 30 days
214345150|NCT00941239|DRUG|metformin|850 mg daily for 30 days
214345151|NCT01636310|OTHER|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
214345152|NCT02312739|PROCEDURE|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
214953445|NCT02751619|DRUG|Placebo patch|A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
214953446|NCT01613079|DRUG|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
215077194|NCT04820634|OTHER|Virtual Reality Job Interview Training|The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills \& concepts of job interviews. Sessions are approximately 90 minutes long.
215077195|NCT04820634|OTHER|Wonderworks|The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
214345153|NCT02312739|DRUG|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
214345154|NCT02312739|DRUG|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
214345155|NCT02312739|DRUG|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
214345156|NCT02312739|OTHER|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
215077196|NCT00134654|DRUG|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
214345157|NCT02312739|OTHER|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
214345158|NCT04511715|DRUG|Intravitreal Bevacizumab IVB|Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment
214953447|NCT01613079|DRUG|Methotrexate|Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
215077197|NCT01194843|DRUG|Ropivacaine|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
214953448|NCT04565483|DRUG|Benralizumab Prefilled Syringe|Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
214953449|NCT05624216|DEVICE|BTL-084|Radiofrequency and targeted pressure energy devices for the treatment of cellulite
214953450|NCT03518398|DEVICE|Intense Pulsed Light|E\> Eye (E-SWIN, Paris, France) IPL machine
214953451|NCT03518398|COMBINATION_PRODUCT|Standard treatment|warm compression, lid scrub and non-preservative ocular lubricants
215077198|NCT01194843|DRUG|Physiological serum|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
215077199|NCT00384423|DRUG|PRX-03140|
215077200|NCT05498233|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
215077201|NCT03887065|DRUG|JM-4|Novel small human peptide derived from erythropoietin
214953452|NCT06402877|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
214953453|NCT04640038|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
214953454|NCT04927923|OTHER|hope-focused motivational interview|The eight-week hope-focused motivational interview will be applied to each individual individually during dialysis treatment. Within the scope of the study, a hope tree will be created for each individual together with the patients to be used in the evaluation process of the interview sessions. Through the hope tree, it is aimed for the individual to set goals, to discover the obstacles and solutions in achieving these goals.
214953455|NCT05418959|DIAGNOSTIC_TEST|DermTech PLA noninvasive adhesive biopsy|The clinician will firmly press the DermTech noninvasive adhesive on the lesion and use their thumb to make five circular motions on the lesion. The adhesive patch will then be pulled off of the area. This will be repeated for an additional three patches.
214953456|NCT03364036|DRUG|Mavenclad®|Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
215077202|NCT02075047|DRUG|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
215077203|NCT02075047|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
214953457|NCT04198142|BEHAVIORAL|Imagery Rehearsal Therapy|"The Imagery Rehearsal Therapy (IRT) intervention used in this study is a short version of the treatment, consisting of 1-2 sessions.~The protocol starts with a very brief explanation of the treatment. Then the patient will be guided through an imagery exercise. The next step is to choose a nightmare. This nightmare is then rescripted to a new narrative, which is in no way distressing to the patient anymore. Subsequently, the therapist will guide the patient through an imagery exercise with the new narrative. The new narrative is then either written down or recorded. Lastly, the therapist will explain to the patient, that he or she should rehearse the new narrative daily with imagery exercises."
215077204|NCT05424263|DRUG|Calcium Acetate Oral Solution|Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
215077205|NCT05424263|DRUG|Calcium Carbonate Oral Suspension|Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
215077206|NCT03552536|DRUG|MK-8583|A single oral dose of MK-8583 in capsule form
214345159|NCT04511715|OTHER|Follow-up with regular examination for determination of DR progression|regular examination for determination of DR progression
214345160|NCT04393545|DEVICE|hallux valgus night splint|The HV night splint holds the hallux in abduction in order to provide a correct position. The SP group was given splints consisting of a rigid polyethylene bar along the medial of the hallux, and soft polyform and Velcro fastener parts.
214345161|NCT04393545|OTHER|exercise|The exercises involved strengthening the AbdH (abductor hallucis) and plantar fascia muscles, and stretching the hallux
214345162|NCT04393545|OTHER|Electrotherapy|Two self-adhesive electrodes were used. One was placed over the medial distal end of the first metatarsal and the other was attached to the motor point of the AbdH (inferior and posterior to the navicular tuberosity).21 The stimulation intensity was increased until a contraction was observed without causing discomfort and pain. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks.
214345163|NCT02179112|PROCEDURE|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
214345164|NCT06386484|DEVICE|PolarCap System|The PolarCap Coolant flows through a silicone-based head cap. An insulating neoprene cover is put on top of the cap to isolate the cold. Using PolarCap system to selective head and neck cooling for 45 minutes post fight in boxing.
214345165|NCT00606424|DRUG|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
214345166|NCT05675345|DEVICE|HFNC only|HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
214678442|NCT00631488|DRUG|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
214678443|NCT03648476|BEHAVIORAL|ICAN|A 6-week group therapy sessions once a week for 90-120 minutes.
214345167|NCT05675345|DEVICE|HFNC + CNEP10|HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
214345168|NCT05675345|DEVICE|HFNC + CNEP20|HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
214678444|NCT03793816|DEVICE|BiZactTM Open Sealer/Divider|The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
214678445|NCT04081883|OTHER|Biosensor algorithm|The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
214678446|NCT02662777|DEVICE|Eso-SPONGE® vacuum treatment|
214678447|NCT05634031|RADIATION|PET imaging|PET imaging visit, which will take approximately 1-2 hours.
214678448|NCT05634031|RADIATION|Coronary CT angiogram|A coronary CT angiogram if the participant has not had one recently.
215077207|NCT03295383|DRUG|Rituximab 1g IV|Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
215077208|NCT03295383|DRUG|Cyclophosphamide 50Mg Oral Tablet|"cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally."
215077209|NCT03295383|DRUG|Placebo of Rituximab|Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
214345169|NCT05675345|DEVICE|HFNC + CNEP30|HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
214345170|NCT00444548|DRUG|[S,S]-Reboxetine|
214345171|NCT05045521|OTHER|plyometric warm up group|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 \* 8 squat jumps, 2 \* 8 scissor jumps, and 2 \* 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos."
214345172|NCT05045521|OTHER|resistance warm up|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6\*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest"
214678449|NCT05634031|PROCEDURE|Functional Angiography|"A subset of patients with abnormal results on cardiac PET myocardial perfusion imaging study (estimated number of patients = 12) will be invited to participate in an invasive sub-study wherein they would undergo detailed invasive coronary physiology evaluation.~Functional Angiography (coronary reactivity test- CRT): is an angiography procedure done in the catheterization laboratory. It evaluates the coronary artery microcirculation and how the blood vessels respond to different medications."
214678450|NCT05634031|PROCEDURE|Treadmill exercise stress study|A treadmill exercise stress study
214678451|NCT03293199|PROCEDURE|Chest tube drainage|In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.
215077210|NCT03295383|DRUG|Placebo Oral Tablet|cyclophosphamide placebo will be administered orally once daily
215077211|NCT02557958|DRUG|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
215077212|NCT02557958|DRUG|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
214345173|NCT05045521|OTHER|control warm up group|"participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6\*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests."
214345174|NCT06526572|DIAGNOSTIC_TEST|Brain wave analysis using electroencephalography (EEG).|Asessment of pain with objective neurophysiological assessment through brain wave analysis using electroencephalography (EEG).
214345175|NCT06526572|DIAGNOSTIC_TEST|Numerical rate Scale (NRS)|Asessment of pain with the subjective numercal rate scale method (NRS
214345176|NCT03360461|DRUG|EMI-137|EMI-137 - a fluorescent c-Met receptor targeted peptide
214953458|NCT04198142|BEHAVIORAL|Treatment as Usual with dream diaries|Treatment as Usual means that patients in this arm will receive usual inpatient care. Additionally, they will keep a dream diary. It has been shown in previous studies that keeping a dream diary has a positive effect on nightmares.
214953459|NCT03172377|OTHER|Lengthening adalimumab dosing interval|Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
214953460|NCT01865656|OTHER|Skills training|Refresher training on Basic Emergency Obstetric and Newborn care
214953461|NCT01865656|OTHER|Emergency obstetric drills|Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
214953462|NCT01865656|OTHER|Revised Case Sheets|Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
214953463|NCT01865656|OTHER|Supportive supervision|Quarterly supportive supervision visits each of the intervention first referral units.
214953464|NCT01865656|OTHER|Referral strengthening|To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
214953465|NCT01905332|OTHER|Literacy promoting home based program|The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
215077213|NCT01929720|BEHAVIORAL|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
215077214|NCT05882864|DRUG|6-Gingerol|6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
215077215|NCT05882864|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
215077216|NCT03098251|PROCEDURE|3D typing|typing the patient with 3D typing system and give specific treatment
215077217|NCT03098251|PROCEDURE|routine typing|typing the patient with routine typing system and give specific treatment
214345177|NCT02553330|DRUG|Placebo Cream|
214345178|NCT02553330|DRUG|Ruxolitinib Phosphate Cream|
214345179|NCT03750487|BEHAVIORAL|e-screening & brief intervention (e-SBI)|Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement
214345180|NCT03750487|BEHAVIORAL|Control e-SBI|Computer-delivered screening and brief motivational intervention targeting healthy eating and exercise
214345181|NCT02390804|DEVICE|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
214345182|NCT02390804|DEVICE|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
215077218|NCT05192018|PROCEDURE|Early reversal of a defunctiong ileostomy|Early reversal of a defunctiong ileostomy after 3 weeks of its creation
215077219|NCT05868928|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
215077220|NCT05868928|DIAGNOSTIC_TEST|Diffusion-weighted MRI|Diffusion-weighted MRI
215077221|NCT05868928|DIAGNOSTIC_TEST|Arterial spin labeling (ASL)|Cerebral blood flow imaging parameter
215077222|NCT05868928|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-MRI (DSC-MRI)|Cerebral blood volume and vessel architectural imaging parameters
215077223|NCT04591548|DIAGNOSTIC_TEST|proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample|All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
215077224|NCT05480215|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
215077225|NCT06306651|OTHER|High flow nasal cannula therapy group|Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC
215077226|NCT06306651|OTHER|Conventional oxygen therapy group|Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
215077227|NCT02681796|DRUG|Bupivacaine|
215077228|NCT03867786|BEHAVIORAL|Exercise|Participants will complete an acute exercise visit.
215077229|NCT03867786|BEHAVIORAL|Video Control|Participants will complete a video control visit.
215077230|NCT02101801|OTHER|vegetables from fresh or recycled water|
215077231|NCT02101801|OTHER|receives vegetables from fresh water or recycled waste water farms|
214678452|NCT03293199|PROCEDURE|Repetitive needle aspiration|In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
214953466|NCT01905332|OTHER|Literacy Toolkit|Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
214953467|NCT04554381|BIOLOGICAL|JL1 antigen|we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
214953468|NCT02394119|DRUG|Ofatumumab|1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
214953469|NCT02394119|DRUG|Rituximab|375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
214953470|NCT01393106|DRUG|Idelalisib|Idelalisib tablets administered orally
214953471|NCT03307837|DRUG|CA-008|Local administration during surgery
214953472|NCT03307837|DRUG|Placebo|Local administration during surgery
214953473|NCT02157571|DRUG|Prulifloxacin|600 mg/tablet, oral administration of a single tablet.
214345183|NCT03555669|OTHER|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
214345184|NCT05879744|DRUG|CLN-978|CD19xCD3 T cell engager
214953474|NCT02157571|DRUG|Levofloxacin|500 mg/tablet, oral administration of a tablet daily.
214953475|NCT02157571|DRUG|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet, without active components.
214345185|NCT03197792|OTHER|All patients|"TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death."
214345186|NCT03551938|BEHAVIORAL|Relationship skills session for YMSM partnered-individuals and couples|Relationship skills session as an addition to the current CTR and CHTC intervention for 15-24 year old YMSM and their partners.
214345187|NCT06270823|PROCEDURE|Knee-to-chest-flexion manoeuvre|The obstetrician will place one hand at the neck and shoulder of the baby and gently bend the infant into dorsiflexion while with the other hand bending the hips and knees against the abdomen and chest (squatting into fetal position). This holding position will be continued for 30 seconds, while compression of the umbilical cord is avoided to maintain an undisturbed umbilical circulation to and from the infant during KCF.
214345188|NCT05150730|OTHER|Multi professional care|Participants were instructed to respect their pain threshold during body practice and the evolution of the participants happened gradually and individually. Associated with the practice of exercise, workers received information about their disease, chronic pain, guidelines for daily activities, and the importance of physical exercise. In the second hour, the responsible psychologist addressed issues such as the repercussions of illnesses on the individual's social and affective life, self-esteem, self-image, conformism, and self-indulgence after the illness and prospects for the future. Throughout the program, participants also received informative lectures from other professionals, such as social workers, nurses, and dentists.
214678453|NCT01391312|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
214678454|NCT01391312|DRUG|normal saline (placebo)|Normal saline (placebo) injected into the glabellar region on Day 0.
214678455|NCT03952078|DRUG|CPI-818|Interleukin-2 inducible T-cell Kinase Inhibitor
214953476|NCT02157571|DRUG|Prulifloxacin placebo|Placebo of prulifloxacin film-coated tablet without active components.
214953477|NCT04569929|OTHER|(DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture|The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
214953478|NCT05805111|DEVICE|endovascular intervention|Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) is a new, minimally invasive technique, for treating extensive and/or recurrent aorto-iliac occlusive disease. The technique rebuilds the diseased aortic bifurcation and iliac arteries through the use of stent-grafts introduced through the groin or arm arteries.
214953479|NCT00458861|BIOLOGICAL|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
214953480|NCT00458861|OTHER|Placebo Comparator|Subcutaneous administration of placebo given every other week for 12 weeks
214953481|NCT02951793|OTHER|AUDIT-C|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C\>4 versus AUDIT-C of 4 or below.
215077232|NCT02123238|OTHER|bed positioning|
214953482|NCT02951793|OTHER|Smoking history|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
214953483|NCT02951793|OTHER|Prior psychotropic medication use|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
214953484|NCT02666820|PROCEDURE|Large balloon dilatation|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
214345189|NCT06430567|DEVICE|Blood flow restriction (50% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 1) BFR Group with 50% AOP compression~Group 1 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 30-15-15-15 at 40% 1RM (repetition maximum)~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
214345190|NCT06430567|DEVICE|Blood flow restriction (10% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 2) BFR Group with 10% AOP compression~Group 2 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 15-15-15-15 at 70% 1RM~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
214345191|NCT00353275|DRUG|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
214345192|NCT00353275|DRUG|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
214345193|NCT06031246|PROCEDURE|Selective Lymph Node Dissection|For patients with NSCLC with CTR\>0.5 located in the apical segment, the inferior mediastinal lymph node was not need to dissected
214345194|NCT01090804|DEVICE|BreatheMAX breathing device|secretion clearance, breathing exercise
214345195|NCT02079805|DRUG|Azilsartan|Azilsartan tablets
214953485|NCT02666820|PROCEDURE|Mechanical lithotripsy|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
214345196|NCT02079805|DRUG|Telmisartan|Telmisartan tablets
214953486|NCT03971916|DRUG|HBM9161(HL161BKN)|Subcutaneous injection; Single dose on Day 1
214953487|NCT03971916|DRUG|Placebo|Subcutaneous injection; Single dose on Day 1
214953488|NCT00334165|PROCEDURE|Auricular acupuncture (procedure)|
214953489|NCT04310293|OTHER|Femara,Grotwth hormone,HMG|NOVEL THERAPY
214953490|NCT02032615|DIETARY_SUPPLEMENT|Education plus Gudness Nutritional Bar|
214953491|NCT02032615|OTHER|Education|
214953492|NCT00823602|DRUG|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
214953493|NCT00823602|DRUG|suprefact|GnRH agonist, standard protocol
214953494|NCT04177992|OTHER|Servo control|FiO2 adjustments will be made by one of two respiratory devices depending on the clinical requirements and current ventilatory therapy of the infant
214345197|NCT01891123|DEVICE|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
214345198|NCT01891123|DRUG|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
214345199|NCT04272281|PROCEDURE|medical shared decision|The experimental group will use the share decision making tool during consultation to adapt antibiotherapy
214345200|NCT04272281|PROCEDURE|Standard medical care|control group will act as usual in their practice.
214345201|NCT01764984|DEVICE|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
214345202|NCT01300130|DIETARY_SUPPLEMENT|low docosahexaenoic acid formula|
214345203|NCT01300130|DIETARY_SUPPLEMENT|medium docosahexaenoic acid formula|
214345204|NCT01300130|DIETARY_SUPPLEMENT|high docosahexaenoic acid formula|
214345205|NCT01300130|DIETARY_SUPPLEMENT|breast milk|a non randomized group of breast milk fed infants was included
214345206|NCT04546087|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
214953495|NCT01550523|DRUG|IGF-1R/AS ODN|Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
214953496|NCT01550523|DEVICE|biodiffusion chamber|The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
214953497|NCT01542086|PROCEDURE|Myocardial SPECT|
215077233|NCT06364813|OTHER|COMPANION eHealth Program|COMPANION consists of online, self-paced educational modules with information on a range of topics such as providing medical care, applying for financial aid and home aid, working on the relationship with the care recipient, dealing with mental health issues, and learning life skills.
215077234|NCT00457977|BIOLOGICAL|Pneumovax (PPSV23)|Injection
215077235|NCT00457977|BIOLOGICAL|Prevnar (PCV7)|Injection
215077236|NCT00773786|DRUG|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
215077237|NCT00773786|DRUG|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
215077238|NCT02382029|DRUG|Clonazepam|Active medical treatment for burning mouth syndrome
215077239|NCT02382029|OTHER|acupuncture|Traditional chinese acupuncture
215077240|NCT04195438|PROCEDURE|CO Testing Pre/Post Hepatic Resection|Monitor CO in exhaled air of patients before liver resection, at 4 hours and 24 hours after PH
215077241|NCT04195438|DIAGNOSTIC_TEST|ABG Testing Pre/Post Hepatic Resection|Monitor carboxyhemoglobin(COHb) in the arterial blood gas of patients before liver resection at 4 hours and 24 hours after PH
215077242|NCT04195438|DIAGNOSTIC_TEST|CT Evaluations|Analyze the relationship between CO production and the extent of hepatic resection assessed by computed scans liver volumetric study at one and three months after PH, size and weight of the resected specimen and operative report
214345207|NCT05225818|BEHAVIORAL|PLAN - Home|home-based intervention program for dementia evaluation, education, and care planning
214345208|NCT02522533|OTHER|Physical Therapy|6 weeks of an exercise program.
214345209|NCT00428454|DEVICE|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
214345210|NCT04082065|OTHER|conventional physical therapy|hot pack for 15 minutes Myofacial release (10 minutes) and Stretching of hamstrings and Piriformis (5 reps each with 2 second hold)
214345211|NCT04082065|OTHER|cyriax lumber manipulation group|Hot Pack, Myofacial Release, stretching of hamstrings and Piriformis (five reps each with 2 seconds hold) and Cyriax Lumbar Manipulation Techniques
214345212|NCT02347761|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
214345213|NCT02347761|DRUG|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
214345214|NCT02347761|DRUG|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
214345215|NCT06162520|OTHER|Contrast-enhanced computed tomography (CECT) and 3D morphological analysis|Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.
214345216|NCT00769366|BEHAVIORAL|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
214345217|NCT00769366|DRUG|Medical therapy|Optimal medical therapy after Acute myocardial infarction
214345218|NCT06582615|PROCEDURE|Biospecimen Collection|Undergo dried blood spot collection
214345219|NCT06582615|PROCEDURE|Cognitive Assessment|Ancillary studies
214345220|NCT06582615|OTHER|Dietary Intervention|Receive MIND counseling sessions
214345221|NCT06582615|OTHER|Dietary Intervention|Follow a personalized diet
214345222|NCT06582615|OTHER|Dietary Intervention|Receive general health recommendations counseling sessions
214953498|NCT01542086|PROCEDURE|64-channel coronary CT angiography (CCTA)|
215077243|NCT01453751|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)|ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
215077244|NCT06116539|DRUG|Cyanoacrylate|In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
215077245|NCT06116539|PROCEDURE|Suture|After harvesting the full-thickness connective tissue graft, the edges of the control group will be approximated with 4/0 non-absorbable monofilament nylon suture (Aragó, Barcelona, Spain).
214953499|NCT03312465|DEVICE|AS Domelock System|Hemi or Total Shoulder Arthroplasty
215077246|NCT04331184|PROCEDURE|RFA using combined bipolar and monopolar energy deliver|RFA technique combining bipolar mode and switching monopolar mode using dual / Twin Cooled-wet electrodes is performed on residual tumors after transarterial chemo-embolization.
214345223|NCT06582615|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit
214345224|NCT06582615|OTHER|Questionnaire Administration|Ancillary studies
214345225|NCT03879798|DRUG|DS-3201b|100 mg daily
214345226|NCT03879798|DRUG|irinotecan|Irinotecan 125 mg/m\^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
214678456|NCT02546856|OTHER|Heart Failure (HF) nurse up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support."
214678457|NCT02546856|OTHER|Heart Failure (HF) cardiologist up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist."
214953500|NCT05437640|BEHAVIORAL|Protein Redistribution Diet|PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.
214953501|NCT05437640|BEHAVIORAL|Protein Consistent Diet|PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
214345227|NCT04723875|DRUG|Paclitaxel or docetaxel + Cisplatin or carboplatin|Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
214345228|NCT03625570|BEHAVIORAL|Power training combined with interval treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors according to resistance training guidelines for muscle power training. The interval treadmill training portion will include short-bursts (30 seconds) of high speed walking intervals alternating with 30 seconds of low to moderate speed walking for a total of 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
214345229|NCT03625570|BEHAVIORAL|Strength training combined with traditional treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors following the dosing and resistance training guidelines for muscle strength. Traditional treadmill training will consist of walking at steady-state speeds for 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
214678458|NCT00003386|BIOLOGICAL|BCG vaccine|
214678459|NCT00003386|BIOLOGICAL|autologous tumor cell vaccine|
214678460|NCT00003386|DRUG|carboplatin|
214678461|NCT00003386|DRUG|cisplatin|
214953502|NCT04945174|BEHAVIORAL|Cardiorespiratory exercise combined with patient education and individual follow-up sessions|6 weeks of cardiorespiratory exercise combined with patient education at the hospital, followed by 6 weeks of cardiorespiratory exercise in the local municipality. Subsequently individual follow-up sessions with the aim to facilitate the patients to stay physically active in their everyday life
215077247|NCT02112682|PROCEDURE|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
215077248|NCT03117608|BIOLOGICAL|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
215077249|NCT03117608|BIOLOGICAL|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
215077250|NCT01524432|DRUG|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
215077251|NCT01524432|DRUG|Placebo|No drug loaded microcapsules socks
214345230|NCT05681559|BEHAVIORAL|Medi for All|Please see description of Medi for All arm
214678462|NCT00003386|DRUG|cyclophosphamide|
214678463|NCT00003386|DRUG|paclitaxel|
214678464|NCT00003386|OTHER|dinitrophenyl|
214953503|NCT00904917|BEHAVIORAL|Prevention Intervention Project|Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
214953504|NCT00904917|BEHAVIORAL|Psychoeducation|Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
215077252|NCT05229211|DEVICE|Cardiac monitoring|Continuous ECG monitoring via VitalConnect patch worn on the chest.
214345231|NCT05681559|DIETARY_SUPPLEMENT|Standard Fiber Supplementation|Please see description of Fiber Supplementation arm
214678465|NCT00003386|PROCEDURE|surgical procedure|
214345232|NCT05748405|DRUG|Placebo|Matching Tablets
214345233|NCT05748405|DRUG|AEF0217|Tablets of 100 mcg AEF0217
214345234|NCT03750318|DEVICE|Vital sign monitoring|Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.
214345235|NCT06962657|DIETARY_SUPPLEMENT|Ubiquinone 100 mg Oral Soft Gel|Active comparator arm receives three ubiquinone 100mg soft gels per day. Supplement is taken orally in divided doses, with the last soft gel not close to bedtime.
214345236|NCT06962657|DIETARY_SUPPLEMENT|Placebo|Placebo comparator arm receives three placebo soft gels per day. Supplement is taken orally in divided doses, with the last soft gel not close to bedtime.
214345237|NCT06961474|PROCEDURE|Endoscopic treatment|The endoscopic treatment methods for patients with esophageal variceal rupture bleeding usually include variceal ligation and injection of tissue adhesive.
215077253|NCT02308527|DRUG|Bevacizumab|10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
214345238|NCT06962540|DEVICE|Hearing aid with settings customized to match their individual listening strategy|Behind-the-ear hearing aids that have been programmed based on the participant's individual listening strategy and hearing loss.
215077254|NCT02308527|DRUG|Temozolomide|200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
215077255|NCT02308527|DRUG|Temozolomide|100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
214345239|NCT06962540|DEVICE|Hearing Aid with settings based on audiogram alone|Behind-the-ear hearing aids that have been programmed based on their hearing loss and typical clinical settings.
214345240|NCT06962501|DIETARY_SUPPLEMENT|Oral ketone monoester (KME)|The oral ketone monoester supplement should increase the global CBF and improve resting-state connectivity in the DMN in adults with SCD or MCI. The participants will take one dose of the supplement followed by measurement, to figure out if there are any noticeable changes.
214345241|NCT06963255|PROCEDURE|arterial revascularization|arterial revascularization
214345242|NCT05678348|DRUG|Pyrimethamine|Patients will be instructed to take their dose at approximately the same time each day.
214678466|NCT01097616|DRUG|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
214678467|NCT01097616|DRUG|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
214953505|NCT05206734|OTHER|No specific intervention|Observational analysis of usual care only.
214953506|NCT04250415|PROCEDURE|Surgery|
214953507|NCT04228965|DRUG|Varenicline|Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
215077256|NCT02308527|DRUG|Irinotecan|50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
215077257|NCT02308527|DRUG|Bevacizumab|15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
215077258|NCT02308527|DRUG|Topotecan|0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
215077259|NCT02308527|DRUG|Temozolomide|150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
215077260|NCT02308527|DRUG|Dinutuximab Beta|10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression
215077261|NCT02308527|DRUG|Cyclophosphamide|250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
214953508|NCT04228965|BEHAVIORAL|Contingency Management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
214953509|NCT04228965|BEHAVIORAL|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
214953510|NCT02330172|OTHER|Injection of neostigmine or sugammadex|"At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected."
214953511|NCT00329589|DRUG|Velcade (bortezomib)|
215077262|NCT03584997|PROCEDURE|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
215077263|NCT03584997|PROCEDURE|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
215077264|NCT05981079|DRUG|Piperacillin/tazobactam|Piperacillin Sodium and Tazobactam Sodium for Injection
215077265|NCT05220280|DRUG|Imatinib|Oral imatinib 400 mg tablet once a day for 14 days.
215077266|NCT05220280|DRUG|Infliximab|Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
215077267|NCT04136327|DRUG|GLPG1972 film-coated tablets|single oral dose of GLPG1972
215077268|NCT04136327|DRUG|[14C]-GLPG1972 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1972
215077269|NCT04136327|DRUG|[14C]-GLPG1972 oral solution|single oral dose of \[14C\]-GLPG1972
215077270|NCT00098046|DRUG|famciclovir|
215077271|NCT00002858|DRUG|cisplatin|
215077272|NCT00002858|DRUG|cyclophosphamide|
215077273|NCT00002858|DRUG|doxorubicin hydrochloride|
215077274|NCT00002858|DRUG|etoposide|
215077275|NCT00002858|RADIATION|radiation therapy|
214953512|NCT04544163|DRUG|Magnesium sulfate- Fentanyl|drug administration before intubation
214953513|NCT04544163|DRUG|Fentanyl 4Mcg/kg|drug administration with induction of anesthesia
214953514|NCT04544163|DRUG|Fentanyl 2Mcg/kg|drug administration with induction of anesthesia
214953515|NCT04544163|DRUG|Lidocaine 1.5 mg/kg|drug administaration 90 sec before intubation
214953516|NCT00734656|DRUG|dutasteride + ethanol|4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
214953517|NCT00734656|DRUG|placebo medication + ethanol|placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
214953518|NCT00734656|DRUG|dutasteride + placebo alcohol|4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
215077276|NCT05311449|OTHER|Acupressure|The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
215077277|NCT05311449|OTHER|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
214953519|NCT00734656|DRUG|placebo medication + placebo alcohol|placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
214953520|NCT04647513|DEVICE|Intradermal injection (superficial dermis for Art Filler Fine Lines / moderately deep to deep dermis for Art Filler Universal and Art Filler Lips)|The function of injectable fillers for the treatment of dermal contour deformities is to smooth dermal depressions formed by the loss of volume and the aging process. These fillers (also known as soft tissue augmentation medical devices) can correct the skin depressions/wrinkles, balance the disproportions or correct topographical anomalies.
214953521|NCT06062095|PROCEDURE|AI-powered computer-aided diagnosis (CADx)|Real time AI will be used to diagnosis polyps found during colonoscopy.
214953522|NCT04469634|DIAGNOSTIC_TEST|Assessing antibody responses, neutralizing capacity and memory B-cell function|Assessing antibody responses, neutralizing capacity and memory B-cell function and their contribution to protection against re-infection
214953523|NCT02100735|OTHER|Sedation protocol|Nursing driven sedation protocol
215077278|NCT02997436|DEVICE|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
215077279|NCT05311995|PROCEDURE|Only different trocar sites|Only different trocar sites in literature
214953524|NCT04298879|DRUG|IBI376|IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily
214953525|NCT01127594|DRUG|Temozolomide|Dose level selection will proceed according to the modified Accelerated Titration Design. The starting dose will be TMZ 200mg/m2 x 0.09 BSA for the upper extremity and 200mg/m2 x 0.18 BSA for the lower extremity. We will enroll one-patient cohorts with dose doubling between cohorts until 1st occurrence of a ≥ CTC (Common Terminology Criteria) grade 2 adverse event. At that time, the present cohort and all future cohorts will be extended to enroll 3 to 6 patients.
214953526|NCT03915626|DRUG|Rivastigmine (RLD) transdermal patch|brand name patch
214953527|NCT03915626|DRUG|Rivastigmine (generic) transdermal patch|generic patch
214953528|NCT03628833|DEVICE|Incontinence Management System|Incontinence detection device
214953529|NCT06954805|DRUG|Rituximab|Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B cell lysis. 375 mg/m2 Rituximab will be administered to participants by IV.
214345243|NCT03370887|DRUG|AZD8601|AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
214678468|NCT01097616|DRUG|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
214678469|NCT04446936|PROCEDURE|Flap covering for pressure ulcer|Flap covering for pressure ulcer
214953530|NCT06954805|DRUG|Etoposide|Etoposide is a topoisomerase II inhibitor and appears to cause DNA strand breaks. It has been shown to delay transit of cells through S phase and arrest cells in late S or early G2 phase. 50 mg/m2 Etoposide will be administered to participants by IV.
214953531|NCT06954805|DRUG|Prednisone|Prednisone can prevent or suppress inflammation and immune responses. Prednisone's action may include the inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, and suppression of humoral immune responses. 60 mg/m2 Prednisone will be administered to participants by PO.
214953532|NCT06954805|DRUG|Vincristine|Vincristine is a vinca alkaloid. The mechanism of action of vincristine is thought to be due to inhibition of microtubule formation in the mitotic spindle. This leads to arrest of dividing cells during the metaphase stage. 0.4 mg/m2 Vincristine will be administered to participants by IV.
214345244|NCT03370887|DRUG|Placebo|Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
214345245|NCT02807597|DRUG|LS301|-LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.
214345246|NCT02807597|DEVICE|Cancer Vision Goggles and standard fluorescence imaging systems|-Member of the operating team will wear the CVG during surgery
214678470|NCT04430972|PROCEDURE|Aortic valve replacement|Open surgical replacement of aortic valve
214953533|NCT06954805|DRUG|Cyclophosphamide|The mechanism of action is thought to involve cross-linking of tumor cell DNA. Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites which are thought to cross-link to tumor cell DNA. These metabolites interfere with the growth of rapidly proliferating susceptible malignant cells. 375 mg/m2 Cyclophosphamide will be administered to participants by IV.
214953534|NCT06954805|DRUG|Doxorubicin|Doxorubicin is an anthracycline, topoisomerase II inhibitor. It is isolated from cultures of Streptomyces peucetius var. caesius. The cytotoxic effect of doxorubicin is related to nucleotide base intercalation and cell membrane lipid binding activities. It blocks nucleotide replication and the action of DNA and RNA polymerases. The interaction between doxorubicin and topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of its cytocidal activity. 10 mg/m2 Doxorubicin will be administered to participants by IV.
214953535|NCT06954805|DEVICE|CAPP-seq|Next generation sequencing (NGS) tool used to detect tiny amounts of cancer DNA in the blood, allowing for early diagnosis and monitoring of cancer in a non-invasive way.
214953536|NCT06955637|DEVICE|dental movement|Possibility to reduce the protrusion of upper incisors
215077280|NCT03061721|DRUG|Saroglitazar magnesium 1 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
215077281|NCT03061721|DRUG|Saroglitazar magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
215077282|NCT03061721|DRUG|Saroglitazar magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
215077283|NCT03061721|DRUG|Placebos|Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
215077284|NCT03447314|DRUG|GSK1795091|GSK1795091 will be available as solution for injection
215077285|NCT03447314|DRUG|GSK3174998|GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
215077286|NCT03447314|DRUG|GSK3359609|GSK3359609 will be available as solution for infusion.
214345247|NCT02807597|PROCEDURE|Surgery|-Standard of care
214345248|NCT05084196|DRUG|Melatonin|Melatonin 5 mg capsule by mouth at bedtime
214345249|NCT05084196|OTHER|Placebo Capsule|Placebo capsule by mouth at bedtime
214345250|NCT06635746|DRUG|Vinpocetine|Increasing doses of vinpocetine to assess tolerability.
214345251|NCT01136837|OTHER|primary pcı|
214345252|NCT04034433|PROCEDURE|Handgrip exercise program|Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
214345253|NCT02842398|BEHAVIORAL|Balance Master|
214345254|NCT02842398|BEHAVIORAL|Customary Care|
214345255|NCT04118218|OTHER|Rhizolysis pain analysis|"Definition of the subgroup of good clinical outcome after rhizolysis (called effective rhizolysis) by lumbar VAS or lower extremity pain VAS or Oswestry index decreased at 6 weeks after rhizolysis.~The efficiency criterion based on the decrease in the dolorimeter or the Oswestry index corresponds to a decrease of at least 50% \[1, 2, 3, 4\]."
214678471|NCT05348850|DEVICE|Tensiomayography (TMG)|Quadriceps muscle contractile properties will be assessed using tensiomayography
214678472|NCT01820689|OTHER|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
214678473|NCT04787809|BEHAVIORAL|Living Well|Living Well is a single session digital intervention that aims to decrease experiential avoidance and increase engagement in values-consistent behavior.
214678474|NCT01052168|OTHER|skills training|participants will train using different performance goals (based on different metrics)
214953537|NCT03166488|DEVICE|MRI|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE).
214953538|NCT05933694|OTHER|Artificial Intelligence-powered Spirometry Interpretation Report|A report generated by artificial intelligence powered software that assessed technical quality of spirometry and estimates the diagnostic probability of six categories: COPD/Asthma/ILD/ Normal/Other obstructive/Other Unidentified
214953539|NCT02603965|RADIATION|Copper Cu 64 TP3805|Given IV
214953540|NCT02603965|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
214953541|NCT02603965|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
214953542|NCT02603965|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
214953543|NCT02603965|OTHER|Laboratory Biomarker Analysis|Correlative studies
214345256|NCT04145752|PROCEDURE|Nurse-led femoral nerve block|The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
214953544|NCT01051726|OTHER|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
214953545|NCT01051726|OTHER|None essential oil|Baby oil
214953546|NCT06321341|DRUG|Vespireit|Buspirone
214953547|NCT06321341|DRUG|Arlevert|Dimenhydrinate + Cinnarizine
214953548|NCT03585517|DRUG|IM23|T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
214953549|NCT03102749|OTHER|metacholine provocation test and CT-scan low dose|Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
214953550|NCT03039465|DEVICE|Modified Trans-Esophageal Prosthesis|This device is a biomedical grade silicon voice prosthesis with an inner esophageal flange, a stem and an outer tracheal flange. Insertion would be done through a modified 'romovac' inserter set / curved metal inserter (provided with the TEP) and an oesophagoscope in case of secondary insertion would be used. in patients with existing TEP puncture / who require a TEP change, on out-patient basis, the insertion would be done with a novel two-part inserter device (front loading)
214953551|NCT01881698|OTHER|Platelet function during pregnancy Multiple Electrode Aggregometry (Multiplate@) device|Observation of platelet function in pregnancy
214953552|NCT03589157|DEVICE|drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES) for treating diffuse coronary artery lesions
214953553|NCT03589157|DEVICE|drug-coated balloon (DCB) combined with second-generation of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with second-generation DES for treating diffuse coronary artery lesions
214953554|NCT00618124|DRUG|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
214953555|NCT02829502|DRUG|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
214953556|NCT02829502|DRUG|Normosaline|Single dose of subcutaneous injection of 20 μL normosaline (placebo).
214953557|NCT05366296|BIOLOGICAL|A Lyophilized COVID-19 mRNA Vaccine|Active substance: NTD-RBD derived from S protein of Omicron variant Excipient: ALC-0315 (4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2- hexyldecanoate), ALC-0159 (2-\[(polyethylene glycol)-2000\]-N, N-ditetradecylacetamide), DSPC \[1,2- distearoyl-sn-glycero-3-phosphocholine\], Cholesterol, Trometamol and Sucrose
215077287|NCT03447314|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
215077288|NCT05974475|RADIATION|SBRT|State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).
215077289|NCT05974475|PROCEDURE|Surgery|State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.
215077290|NCT01169415|DRUG|Dexamethasone acetate|Participants will receive a protracted (30 days) course of dexamethasone after surgery.
215077291|NCT01169415|DRUG|Dexamethasone|Participants will receive a protracted (14 days) course of dexamethasone after surgery.
215077292|NCT04275271|BEHAVIORAL|Educational intervention|Skill centered Protocol Training based on IMB model
214953558|NCT05366296|BIOLOGICAL|Placebo|Normal saline (0.9% sodium chloride solution
214953559|NCT04938596|COMBINATION_PRODUCT|Respiratory bundle|"* Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks~* Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks~* Promotion of strategies to improve house ventilation during 2 weeks~* Provision of a TB leaflet and nurse education about TB transmission."
214953560|NCT01797588|PROCEDURE|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
215077293|NCT04308460|PROCEDURE|arthrocentesis|lavage of the temporomandibular joint was done
215077294|NCT04308460|PROCEDURE|operative arthroscopy|operative intervention inside the temporomandibular joint was done using arthroscope
215077295|NCT00882596|DEVICE|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
214678475|NCT02205970|DEVICE|TENS|In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
215077296|NCT01926418|BEHAVIORAL|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
215077297|NCT05254132|PROCEDURE|Liquid biopsy|Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
214345257|NCT05902195|BEHAVIORAL|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
214953561|NCT01797588|PROCEDURE|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.
214953562|NCT04010084|RADIATION|Low level laser therapy|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
214953563|NCT04010084|PROCEDURE|Placebo group|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
214953564|NCT00001070|DRUG|Oral Vitamin C|
214953565|NCT02965508|OTHER|Home-based Primary Care|Care in the programs is inter-professional and team-based. Each physician leads a team charged with the care of a panel of patients and directs the team's activities. New patients are assigned a Mount Sinai Visiting Doctors (MSVD) primary care physician or the Chelsea Village House Calls Program (CVHCP) who makes an initial visit within 2 weeks of the patient's enrollment in the program. The primary care physician completes a comprehensive medical history and physical exam during the initial visit including standardized assessments of physical functioning and cognition. The primary care physician then provides ongoing management of the patients' acute and chronic health problems, including palliative and home hospice care when needed, every 2 to 12 weeks as determined on a case-by-case basis.
214953566|NCT02965508|OTHER|Usual Care|Office based care
214953567|NCT01830907|DIETARY_SUPPLEMENT|carbohydrates|
214953568|NCT01830907|DIETARY_SUPPLEMENT|vitamins|
214953569|NCT00692497|BEHAVIORAL|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
214953570|NCT04578509|DIAGNOSTIC_TEST|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test
214953571|NCT04578509|DIAGNOSTIC_TEST|Saliva sample|Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach
214953572|NCT04578509|DIAGNOSTIC_TEST|axillary sweat sample|Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.
214345258|NCT05902195|OTHER|Usual care|Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
214345259|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
214345260|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
214345261|NCT01040130|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
214953573|NCT04578509|OTHER|Data collection|Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected
214953574|NCT04676152|DEVICE|Masimo Noninvasive Blood Pressure Device|Non-invasive blood pressure device
214953575|NCT01532258|BEHAVIORAL|Go! Foods for You without Weekly MA Support.|"* Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule activities on a built in calendar and practice the activity throughout the week."
214345262|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose
214345263|NCT01040130|DRUG|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
214345264|NCT03050476|DRUG|RESCAP®|intravenous application before, during, and for 24 or 96 hours after heart surgery
214345265|NCT03050476|DRUG|placebo|intravenous application before, during, and for 24 or 96 hours after heart surgery
214953576|NCT01532258|BEHAVIORAL|Go! Foods for You with Weekly MA Support.|"* Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals."
214953577|NCT00370422|DRUG|Triamcinolone, Bevacizumab|
214953578|NCT00662987|DRUG|7 days of amoxicillin|Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
214953579|NCT00662987|DRUG|3 days of amoxcillin followed by 4 days of placebo|3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
214953580|NCT03894761|OTHER|Night Pain in Patients with Rotator Cuff Syndrome|The pain severity was evaluated using a 10 cm visual analogue scale , where 0 represented no pain, while 10 represented unbearable pain.At evaluation, the average of the pain during night for the last one week were inquired.
214953581|NCT01319487|DRUG|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
214953582|NCT01319487|DRUG|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
214953583|NCT01319487|DRUG|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
214953584|NCT04652947|DIAGNOSTIC_TEST|MRI diagnostic|no intervention, patient only have MRI
214953585|NCT00675077|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
214953586|NCT01713296|DRUG|Pazopanib|
214953587|NCT00624364|DRUG|biphasic insulin aspart|
214953588|NCT00624364|DRUG|metformin|
214953589|NCT02954588|DIETARY_SUPPLEMENT|Pyridoxamine|
214345266|NCT01977118|DRUG|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
214345267|NCT01977118|OTHER|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
214345268|NCT01595919|OTHER|Nutritional Intervention|Ad libitum amounts of beverage at a meal
214345269|NCT01098448|OTHER|scaling and root planing|scaling and root planing as a single therapy
214345270|NCT01098448|DRUG|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm
214345271|NCT01098448|DRUG|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
214345272|NCT01098448|OTHER|surgery|periodontal surgery in residual pockets of \>4mm
214953590|NCT02954588|DIETARY_SUPPLEMENT|Placebo|
214953591|NCT00315718|DRUG|Extract from Hintonia latiflora bark|
214953592|NCT06196697|BIOLOGICAL|Cadonilimab|Subjects will receive AK104 by intravenous administration
214953593|NCT06196697|BIOLOGICAL|Ivonescimab|Subjects will receive AK112 by intravenous administration
214953594|NCT06196697|DRUG|XELOX|Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)
214953595|NCT06196697|DRUG|SOX|Subjects will receive AK104 and AK112 in combination withSOX(oxaliplatin and Tegafur)
214953596|NCT06257953|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be applied to the patients under real-time ultrasound guidance.
215077298|NCT03798730|BEHAVIORAL|Solid Model|"Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)"
215077299|NCT03798730|BEHAVIORAL|Liquid Model|"Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages."
215077300|NCT01485900|DRUG|SAR407899A|"Pharmaceutical form:capsule~Route of administration: oral"
215077301|NCT01004731|DRUG|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
215077302|NCT04172415|OTHER|Retrospective cohort|Chart Review
215077303|NCT06490068|DRUG|LTC004+Toripalimab|"LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W."
214953597|NCT02501941|DRUG|ketamine|Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
214345273|NCT01098448|DRUG|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
214345274|NCT01098448|OTHER|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm and periodontal surgery in residual pockets of \>4mm
214953598|NCT02190123|DRUG|ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
214953599|NCT05190965|DEVICE|OCTAngiography .FFangiography|octa.ffa findings in pts with diapetic retinopathy
214345275|NCT01098448|OTHER|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets \>4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
214345276|NCT01098448|OTHER|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets \>4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets \>5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
214345277|NCT05768308|BEHAVIORAL|Internet CBT-UP intervention iCBT-UP|The self-helped internet intervention for students experiencing emotional difficulties, especially adjustment disorder. This intervention is based on transdiagnostic cbt principles - unified protocol (Barlow et al., 2018). It is a modular intervention consisting of six modules teaching different skills of dealing with emotions. Intervention is interactive and contains of video materials, quizes, texts and audio materials.
214345278|NCT05768308|BEHAVIORAL|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR) (Bernstein, Borkovec, Hazlett-Stevens, 2000). It is also a modular intervention and, similar to the i-cbt condition, consists of 5 modules. During the intervention, participants learn how to progressively tighten and relax different muscle groups.The first module is planned for two weeks and the rest of them for one week each. Intervention consists of video materials and audio guided relaxations. Participants are encouraged to train these relaxations once a day.
214345279|NCT04001465|PROCEDURE|Volumetric methacholine challenge unmodified|Bronchoprovocation challenge performed per volumetric method
214345280|NCT04001465|PROCEDURE|Modified volumetric methacholine challenge|Bronchoprovocation challenge performed per volumetric method modified to include use of ultrasonic spirometer fitted with vibrating mesh nebulizer
214345281|NCT03453606|OTHER|Home respiratory rehabilitation|Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.
214345282|NCT03453606|OTHER|Center respiratory rehabilitation|"In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician"
214345283|NCT00775749|DRUG|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
214345284|NCT00775749|DRUG|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
214345285|NCT01049425|DRUG|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
214345286|NCT01049425|DRUG|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
214345287|NCT01049425|DRUG|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
214345288|NCT01049425|DRUG|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
214345289|NCT01049425|DRUG|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
214345290|NCT01829412|OTHER|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
214345291|NCT04968938|DRUG|midomafetamine|80 mg or 120 mg midomafetamine HCl followed by a 40 mg supplement dose
214345292|NCT04968938|BEHAVIORAL|Therapy|Manualized therapy
214345293|NCT01384617|PROCEDURE|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
214345294|NCT01384617|PROCEDURE|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
214345295|NCT00283504|DRUG|ANTI-IGE THERAPY (XOLAIR)|Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
214345296|NCT04276545|DRUG|IV administration of DEX to investigate the effects for functional nasal endoscopic surgery|IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
214345297|NCT04276545|DRUG|IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery|IV administration of midazolam (0.05mg/kg) after induction.
214953600|NCT03453957|OTHER|Professional development program|Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
214953601|NCT01420341|DRUG|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
214345298|NCT00737841|DRUG|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
214345299|NCT00737841|DRUG|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
214345300|NCT01485510|BEHAVIORAL|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
214345301|NCT01485510|BEHAVIORAL|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
214345302|NCT00633321|BIOLOGICAL|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
214345303|NCT00633321|BIOLOGICAL|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
214345304|NCT00152295|DRUG|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
214345305|NCT00093769|DRUG|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~* Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
214345306|NCT01761747|DRUG|ponatinib|
214345307|NCT02937545|OTHER|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
214345308|NCT02937545|OTHER|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
214345309|NCT01228162|PROCEDURE|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
214345310|NCT02095262|OTHER|reactive auditory training|
214345311|NCT02095262|OTHER|Interactive auditory training|
214345312|NCT00273117|PROCEDURE|transnasal gastroscopy|
214345313|NCT01914796|DRUG|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
214345314|NCT01914796|DRUG|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
214345315|NCT02845908|DRUG|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
214345316|NCT02845908|DRUG|FOLFOX|Oxaliplatin plus Leucovorin plus 5-FU
214345317|NCT02845908|DRUG|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally PAC
214345318|NCT05457335|PROCEDURE|undergoing PGT|Preimplantation genetic testing for aneuploidy
214345319|NCT02007577|DRUG|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
214678476|NCT02205970|DEVICE|TENS (sham)|In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
214678477|NCT00302237|DEVICE|RX ACCULINK, RX ACCUNET Embolic Protection System|1\) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
214953602|NCT01420341|DRUG|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
215077304|NCT03904953|OTHER|Pilates Training|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
215077305|NCT03904953|OTHER|Conventional exercise programme|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
215077306|NCT02694068|OTHER|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
214345320|NCT02007577|DRUG|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
214345321|NCT02429128|OTHER|14 weeks exercise training|
214345322|NCT03176680|PROCEDURE|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
214345323|NCT02635477|BEHAVIORAL|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
214345324|NCT02635477|BEHAVIORAL|Control|Behavioral: actigraphy device, step count measurement only
214345325|NCT02280603|DRUG|DA-4001C|1ml by topical application twice a day
214345326|NCT02280603|DRUG|5% minoxidil|1ml by topical application twice a day
214345327|NCT03797534|OTHER|dose regime|The initial dose of the experimental group will be calculated by the Bayesian model.
214678478|NCT01586663|DEVICE|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
214678479|NCT01586663|DRUG|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
214678480|NCT02829346|DRUG|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
214953603|NCT01166711|DEVICE|Coroflex Blue (BMS) followed by SeQuent Please (DEB)|"* standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type~* BMS needs to be fully embedded in vessel wall~* post-dilation with high pressure is required before treatment with DEB~* DEB will be inflated with nominal pressure (balloon equates to vessel diameter)~* length of DEB should exceed the BMS by 2-3 mm on each side~* if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)"
214345328|NCT03466580|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
214345329|NCT03437499|PROCEDURE|Sustained Inflation|Application of positive pressure by face mask with T-piece resuscitator for a prolonged period of 15 seconds at a peak pressure of 25 cmH20 followed by PEEP set at 5 cmH2O
214345330|NCT03437499|PROCEDURE|Positive Pressure Ventilation|Application of positive pressure by face mask with T-piece resuscitator at a peak pressure of 25 cmH20, PEEP set at 5 cmH2, for 40 inflations/minute
214345331|NCT04595708|BEHAVIORAL|Phone Call|Calls were made by volunteers trained to engage with participants. Call structure was unscripted and call length was recommended to be between 5-10 min.
214345332|NCT02504294|BIOLOGICAL|Epoetin Hospira Arm|Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
214345333|NCT02504294|OTHER|Standard of Care Arm|Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
214345334|NCT02504294|DRUG|IV Iron|Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
214345335|NCT05255640|PROCEDURE|operation of ischemia of the lower limbs|The intervention technique is left to the judgment of the investigator to treat the ischemia
214345336|NCT02504632|OTHER|test|"Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates."
214345337|NCT02504632|OTHER|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
214345338|NCT01412723|OTHER|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
214345339|NCT01412723|OTHER|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
214953604|NCT01166711|DEVICE|Coroflex Please (DES)|"* standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type"
215077307|NCT02694068|OTHER|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
215077308|NCT04600076|BEHAVIORAL|BabyCenter site and the community group|Participants will be asked to sign on to the BabyCenter community group for people with pregnancy or infant loss at least 3 times weekly for 6 weeks. Participants may choose to post or comment on the site but are not required to do so.
215077309|NCT02043912|DRUG|Haloperidol|
214345340|NCT04614389|OTHER|Contrast-enhanced ultrasound|Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio
214678481|NCT02829346|DRUG|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
214953605|NCT00547417|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
214953606|NCT04123249|DRUG|Propofol|Group Propofol was given propofol 4mg/kg/h intravenous pumping to assist sedation
214953607|NCT04123249|DRUG|Sevoflurane|Group Sevoflurane was given sevoflurane inhalation maintenance (concentration of 2% to 3% and mixed with 50% oxygen and air) to assist sedation；
215077310|NCT00150111|DRUG|Methimazole|
215077311|NCT00150111|DRUG|Rituximab|
215077312|NCT00150111|BIOLOGICAL|Immunization with various vaccines|
215077313|NCT00926419|BIOLOGICAL|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
214345341|NCT04614389|OTHER|Shear Wave Elastography|Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.
214345342|NCT04614389|DEVICE|Sequoia System|UltraSound System Cleared by FDA 510 (k) K180067
214345343|NCT01103206|DRUG|cinacalcet|Intake of a single tablet of cinacalcet
214345344|NCT01103206|DRUG|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
214345345|NCT01103206|DRUG|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
214345346|NCT05255016|COMBINATION_PRODUCT|PXL Platinum 330 system + Riboflavin 0.25% TE Solution|"Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution \[0.25%\], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min)."
214345347|NCT05255016|OTHER|Sham CXL + Artificial Tears|Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
214345348|NCT05898867|OTHER|Saline|Open label intra-articular injection of isotonic saline.
214345349|NCT03806985|DRUG|Placebo oral capsule|microcrystalline cellulose capsule
214345350|NCT03806985|DRUG|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
214345351|NCT03806985|DRUG|High Dose Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
214953608|NCT01982799|DRUG|Oral placebo|placebo
214953609|NCT01982799|DRUG|Oral ibuprofen|Ibuprofen
214953610|NCT01982799|DRUG|oral naproxen|naproxen
214953611|NCT01982799|DRUG|oral acetaminophen/hydrocodone + ibuprofen|vicodin/ibuprofen
214953612|NCT02932605|DRUG|Placebo|Placebo
214953613|NCT02932605|DRUG|Cannabidiol|Cannabidiol
214953614|NCT04592796|DEVICE|Xiaomi MiBand2|Recording of sleep and activity data to study their association with age.
214953615|NCT04592796|OTHER|Socio-demographic questionnaire|Self-made questionnaire to be administered at the beginning of the study with the following personal data: age, gender, marital status, residential environment, mobility aids, educational level, occupation, retirement type, socioeconomic status, medical records, treatment.
214953616|NCT04592796|OTHER|EuroQol-5D-5L|Quality of life questionnaire to be administered at the beginning and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
214953617|NCT04592796|OTHER|Mini mental State Examination|Questionnaire to be administered at the beginning and completion of the study that measures cognitive impairment.
214953618|NCT04592796|OTHER|Tinetti Scale|Physical test to be administered at the beginning and completion of the study that measures gait and balance of the participants.
214953619|NCT04592796|OTHER|Barthel Index|Questionnaire to be administered at the beginning and completion that evaluates the level of independence in basic activities of life.
214953620|NCT04592796|OTHER|Pittsburgh Sleep Quality Assessment (PSQI)|Questionnaire to be administered whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning and completion of the study.
214953621|NCT05403840|PROCEDURE|Mitral valve surgery|Surgical mitral valve repair or replacement
214953622|NCT05403840|PROCEDURE|Transcatheter mitral valve intervention|Transcatheter mitral valve repair or replacement
214953623|NCT01366183|PROCEDURE|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
214953624|NCT01366183|DRUG|Carboplatin|Undergo chemotherapy
215077314|NCT00926419|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
215077315|NCT03732326|PROCEDURE|bariatric surgery|Bariatric surgery for enrolled patients who fulfill the including criteria
214345352|NCT01659723|DRUG|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
214345353|NCT05499429|DEVICE|Transcranial low intensity focused ultrasound stimulation|Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.
214345354|NCT02252211|DRUG|DS-8895a 1 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
214953625|NCT01366183|BIOLOGICAL|Filgrastim|Undergo chemotherapy
214953626|NCT01366183|DRUG|Paclitaxel|Undergo chemotherapy
214953627|NCT01366183|OTHER|Pharmacological Study|Correlative studies
214953628|NCT01366183|OTHER|Quality-of-Life Assessment|Ancillary studies
214953629|NCT01366183|OTHER|Questionnaire Administration|Ancillary studies
214953630|NCT00106158|BIOLOGICAL|protein vaccination|
214953631|NCT06472687|OTHER|FIFA 11+ warm-up exercise training|FIFA 11+ warm-up training program was applied to the experimentel group. control group (CG) did their usual warm-up program.
214345355|NCT02252211|DRUG|DS-8895a 3 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
214345356|NCT02252211|DRUG|DS-8895a 10 mg/kg|Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
214345357|NCT03116594|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
214345358|NCT03116594|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
214345359|NCT03727191|OTHER|Control Group (education, guidelines, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
214345360|NCT03727191|OTHER|Experimental Group (education, guidelines, 2 pckts diet, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
214345361|NCT04481048|DRUG|N-Acetyl cysteine|Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).
214345362|NCT04481048|OTHER|Placebo|Eight (8) weeks of treatment with placebo.
214345363|NCT00003289|DRUG|7-hydroxystaurosporine|
214345364|NCT01985126|DRUG|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
214345365|NCT01985126|DRUG|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
214345366|NCT01985126|DRUG|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
214953632|NCT06472687|OTHER|warm-up exercise training|exercise training
214345367|NCT01985126|DRUG|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
214345368|NCT01985126|DRUG|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
214345369|NCT01985126|DRUG|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
214345370|NCT02352064|PROCEDURE|PET (18-FDG)|Every patient will have a PET
214345371|NCT00968669|BIOLOGICAL|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
214345372|NCT00968669|BIOLOGICAL|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
214345373|NCT00968669|BIOLOGICAL|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
214345374|NCT00968669|OTHER|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
214345375|NCT02255175|DRUG|Estradiol|Participants will receive transdermal estradiol (100μg/day) for 3 weeks
214345376|NCT02255175|DRUG|Progesterone|Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
214953633|NCT01756339|DRUG|Solithromycin|
214953634|NCT01756339|DRUG|Moxifloxacin|
214953635|NCT01756339|OTHER|Placebo to match solithromycin|
214345377|NCT01602848|OTHER|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
214953636|NCT02662335|OTHER|Computer-Assisted Cognitive Training|Participate in Cogmed computerized working memory training
214953637|NCT02662335|OTHER|Questionnaire Administration|Ancillary studies
214953638|NCT02662335|PROCEDURE|Standard Follow-Up Care|Undergo standard follow-up care
214953639|NCT00292916|BEHAVIORAL|whole body vibration|
214953640|NCT00292916|BEHAVIORAL|resistance exercise|
214953641|NCT00292916|BEHAVIORAL|"wellness"|
214953642|NCT01088711|DRUG|Omarigliptin|Once-weekly 50 mg capsule
214953643|NCT01088711|DRUG|Placebo|Once-weekly placebo capsule
214953644|NCT04406116|DEVICE|Microwave coagulation using HS1 Instrument|Microwave therapy at 5.8 GHz
214953645|NCT05050305|DRUG|Marizomib|Intravenous Infusion
214953646|NCT05050305|DRUG|Pomalidomide|Taken orally
214953647|NCT05050305|DRUG|Dexamethasone|Taken orally
214953648|NCT03020277|OTHER|Ecological Momentary Assessment with Smartphone© Application|Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
214953649|NCT01240902|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
214345378|NCT00941187|OTHER|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
214953650|NCT01240902|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
214953651|NCT03678675|DRUG|Ketorolac|The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
214953652|NCT04394156|BEHAVIORAL|Brief cognitive intervention|See the information provided in the experimental arm description.
214953653|NCT00027287|DRUG|Vitamin E|
214953654|NCT05524727|OTHER|Concept-guided, personalized, motor-cognitive training by means of an exergame|12 weeks, two times per week for 30-40min
214953655|NCT04762563|OTHER|IASTM application|IASTM application .
214953656|NCT04762563|OTHER|Kinesio Tape® Tex Gold)|Kinesio Tape® Tex Gold)
214953657|NCT01441245|DRUG|furosemide infusion|Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours
214953658|NCT03300362|DRUG|Seasonal influenza vaccine|Seasonal influenza vaccine
214953659|NCT03300362|DRUG|MVA-NP+M1|Trial vaccine
214953660|NCT03300362|DRUG|Sodium chloride|Saline placebo
214953661|NCT03961750|OTHER|OTAGO|12 Week exercise class programme
214953662|NCT04241822|BEHAVIORAL|Vestibular exercises combined with body awareness exercises and cognitive therapy|The intervention is group based and is a combination of information/education, vestibular exercises (head movements and gaze stability exercises) body awareness exercises and cognitive therapy
214953663|NCT04241822|BEHAVIORAL|Exergaming|The intervention consists of different balance exercises using non-immersive virtual reality
214953664|NCT00284011|DIETARY_SUPPLEMENT|SAMe|800 mg dose daily for 4 weeks.
214953665|NCT00284011|OTHER|Placebo|2 placebo pills daily for 4 weeks.
214953666|NCT02626000|DRUG|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.
214953667|NCT02626000|BIOLOGICAL|Pembrolizumab|Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W
214345379|NCT01142557|DRUG|Interferon beta-1a (Rebif)|A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
214345380|NCT00987207|DRUG|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
214345381|NCT00987207|OTHER|No injection|No cyclosporine A is administered before aortic cross-declamping.
214953668|NCT02164318|OTHER|Handgrip training|
214953669|NCT02164318|DRUG|Nitroglycerin ointment|
214953670|NCT02508103|DRUG|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
214953671|NCT02508103|DRUG|Placebo|Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
214953672|NCT05745233|DRUG|Nivolumab|Intraperitoneal administration of nivolumab Nivolumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
214953673|NCT05745233|DRUG|Pembrolizumab|Intraperitoneal administration of pembrolizumab Pembrolizumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
214953674|NCT06239025|OTHER|ultrasound-guided Transversus Thoracis Muscle Plane Block|block with ropivacaine 0.5 %, 30 mL
214953675|NCT04321083|DIAGNOSTIC_TEST|INVOS|INVOS monitoring brain o2 saturation
214953676|NCT04392219|DRUG|EIDD-2801|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 2:~Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
214953677|NCT04392219|DRUG|Placebo|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
214345382|NCT06533982|OTHER|High intensity interval exercise session|Physical activity session supervised and adapted on ergometer
214345383|NCT06533982|OTHER|Isometric neuromuscular exercise session|Physical activity session supervised and adapted with a handgrip
214345384|NCT00358046|DRUG|ILY101|
214345385|NCT01560520|BEHAVIORAL|Physical activity|Observation only
214345386|NCT04669704|OTHER|Experimental: Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
214345387|NCT04669704|OTHER|Comparator: Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
214345388|NCT05282381|BEHAVIORAL|DRS : Decision Regret Scale|"The DRS is a self-administered questionnaire including 5 items assessing decisional regret in a score graduated between 0 and 100 (0 = no regret).This scale is associated with the ReTransQoL, a specific quality of life questionnaire.~Questionnaires are administrated at 1, 3, 6 and 12 months post-transplantation."
214345389|NCT05542368|DIAGNOSTIC_TEST|Thyroid tests|Thyroid function test TSH ,T3,T4 Thyroid antibody test anti TPO,antithyroglobulin
214345390|NCT05487508|DRUG|Dexamethasone|Administration of intraoperative 1 mg/kg body weight dexamethasone
214345391|NCT05487508|DRUG|Normal saline|Placebo (NaCl 0.9%)
214345392|NCT03926507|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214345393|NCT03926507|OTHER|Fluciclovine F18|Given IV
214345394|NCT03926507|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214345395|NCT00061295|PROCEDURE|Body weight support treadmill training|
214345396|NCT00144339|DRUG|tiotropium|
214345397|NCT00144339|DRUG|placebo|
214953678|NCT06054763|COMBINATION_PRODUCT|Buyang Huanwu Decoction|Buyang Huanwu Decoction is a common prescription for treating stroke. The possible mechanism is to replenish qi, activate blood circulation, and remove blood stasis.
214953679|NCT06054763|OTHER|Placebo|90% starch and 10% Buyang Huanwu Decoction
214953680|NCT05233215|BEHAVIORAL|GROW (Glioma Specialists Reaching Out With Support) Support Program|Follow-up survivorship care plan for patients and caregivers
214953681|NCT02335346|DRUG|Duloxetine|Administered orally
214953682|NCT04034511|OTHER|Medically-tailored meal delivery and medical nutrition therapy|Home-delivered, medically-tailored meals for 3 months combined with monthly individual medical nutrition therapy sessions for 6 months
214953683|NCT03738163|DEVICE|Epaderm Cream|The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
214953684|NCT03671512|DEVICE|Periodontal Structure Repair (PSR)|Following local anesthesia, initial pocket preparation will be done by bur abrasion utilizing specially designed burs to plane the root surface and remove the inner lining of the pocket. Following bur abrasion, thin strips of gauze sponge are placed into the created space. After removing the gauze strips, PSR is inserted to fill the spaces beginning at the pocket bottom. The final step is placing a layer of cyanoacrylate on both the gingival margin and tooth supragingivally.
214953685|NCT03671512|DEVICE|Standard Root Planing|Ultrasonics and hand instruments are used to remove any subgingival deposits on the roots. Standard instruments and standard application are used. Visual or instrument tactile inspection is used to verify the roots are hard-smooth and have been adequately cleaned.
214953686|NCT00195195|DRUG|Sirolimus|Transplantation patients treated with sirolimus who consent to participate in the study (register)
214953687|NCT02085070|DRUG|MK-3475|IV MK-3475
214953688|NCT03287648|DIAGNOSTIC_TEST|optical coherence tomography and blue-fundus autofluorescence|Simultaneous infra-red and optical coherence tomography (cube and radial pattern) centered on the fovea Simultaneous fundus autofluorescence and optical coherence tomography (radial pattern) centered on the fovea
214953689|NCT04584840|PROCEDURE|Surgical treatment|"Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment~* Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~* Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~* Secure a two layered waterproof closure without tension (simple or with local flaps).~* Samples will be sent for Pathological and microbiological analysis.~* Stitches removal after two weeks~* Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
214345398|NCT06196723|PROCEDURE|transjugular intrahepatic portal shunt|TIPS was performed by experienced clinicians in the Gastroenterology/Hepatology Department according to standard operating procedures, utilizing 8 mm or 10 mm expanded polytetrafluoroethylene-covered stents at the discretion of the local physician.
214345399|NCT02268838|DRUG|E6007|
214345400|NCT02268838|DRUG|E6007 matching placebo|
214345401|NCT02529319|PROCEDURE|MRI-Guided Ablation|Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.
214345402|NCT02529319|PROCEDURE|Conventional Ablation|Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
214345403|NCT01273727|DRUG|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
214345404|NCT01273727|DRUG|dexamethasone|intravitreal implant 0.7 mg duration 6 months
214345405|NCT01109992|DRUG|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
214345406|NCT01109992|DRUG|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
214345407|NCT00232804|DEVICE|Bx Cypher stent|
214345408|NCT03799575|BEHAVIORAL|Transmission Electron Microscopy analysis|Morphology of two vitreal side of Internal Limiting Membrane in contact
214953690|NCT06135571|PROCEDURE|Laparoscopic colorectal surgery|Patients underwent laparoscopic left colectomy, sigmoid resection or rectal surgery according to the location of tumor.
214953691|NCT00791427|DRUG|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
214953692|NCT04808258|DEVICE|C3+ Holter Monitor|Long-Term ECG monitoring (up to 7 days)
214953693|NCT02769312|DEVICE|Theta burst stimulation|Theta burst transcranial magnetic stimulation
214345409|NCT06270901|OTHER|High Protein Planetary Health Diet|Planetary Health Diet Meal with 62 g of protein primarily from plant origin
214345410|NCT06270901|OTHER|Low Protein Planetary Health Diet|Planetary Health Diet Meal with 36 g of protein primarily from plant origin
214345411|NCT06270901|OTHER|High Protein Western Diet|Western Diet Meal with 62 g of protein primarily from animal origin
214345412|NCT06270901|OTHER|Low Protein Western Diet|Western Diet Meal with 36 g of protein primarily from animal origin
214345413|NCT06381479|DIETARY_SUPPLEMENT|probiotics|each capsule contains Lactiplantibacillus plantarum and Lacticaseibacillus paracasei, 2 caps daily use
214345414|NCT06381479|DIETARY_SUPPLEMENT|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
214345415|NCT05383677|DRUG|Anifrolumab|Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
214345416|NCT05383677|DRUG|Placebo|Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
214345417|NCT06532838|PROCEDURE|Optimized treatment strategies|The optimized strategies based on 6-hour threshold from symptom onset. For malperfused patients with symptom onset within 6 hours, central repair will be performed immediately. Additional stenting will be used in patients with persistent malperfusion. For malperfused patients with symptom onset beyond 6 hours, individualized delayed central repair according to the different types of MPS will be performed after organ function improved and the patient could tolerate central repair.
214345418|NCT06532838|PROCEDURE|Traditional treatment strategies|Immediate central repair will be performed for patients with coronary and cerebral malperfusion syndrome. However, for patients with mesenteric and lower extremity malperfusion syndrome, interventional therapy will be administered through fenestration and/or stenting to ﬁrst alleviate organ ischemia. Once the patients had a resolution of organ failure, corrective open aortic repair will be performed.
214345419|NCT05850533|BEHAVIORAL|Virtual Tai Chi Easy|Unique to other mind-body therapies, Tai Chi Easy (TCE) is multi-component mind-body therapy including: 1) Gentle movement, 2) Breath practice, 3) Self-massage, and 4) Meditation.
214345420|NCT05668195|PROCEDURE|systematic aerobic exercise and intelligent monitoring system in executive skill training|This is a closed-loop training initially developed by the research team in conjunction with other teams, adding a systematic aerobic exercise and intelligent monitoring system to the typical executive skill training, and is being further explored in training.
214953694|NCT02769312|DEVICE|Sham stimulation|Sham Theta burst transcranial magnetic stimulation
214953695|NCT05172401|DEVICE|Oxulumis® suprachoroidal microcatheterization administration of Triesence®|Suprachoroidally administered Triamcinolone acetonide (Triesence) 2.4mg/60µl
214953696|NCT01680952|DRUG|A) TEST|"1. Extended Release Tacrolimus (Advagraf®)~   ① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~   ② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~2. Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level."
214953697|NCT01680952|DRUG|B) CONTROL|"1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid"
214345421|NCT05668195|PROCEDURE|executive skill training|The training program, based on Dawson and Guare's (2010) training of executive skills for children, aimed to improve the everyday performance of executive skills among children with ADHD. Qian Y and her team added some culturally adapted information, following the theory of cognitive behavioral therapy, to ensure that the concepts were acceptable to Chinese children.
214953698|NCT03580395|DRUG|Apatinib|500mg, day1-21,neoadjuvant therapy
214953699|NCT03580395|DRUG|paclitaxel|paclitaxel 165mg/m2 day 1
214345422|NCT02081651|DIETARY_SUPPLEMENT|Parmigiano Reggiano cheese|
214345423|NCT00022776|PROCEDURE|Surgical decompression|Simple decompression not requiring fusion.
214345424|NCT00022776|PROCEDURE|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
214345425|NCT02338362|DRUG|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
214345426|NCT02338362|DRUG|Saline placebo inhaler|saline metered dose inhaler
214345427|NCT02466945|DEVICE|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
214345428|NCT04277598|BIOLOGICAL|APO-2|APO-2: dose adjusted gel for topical administration.
214345429|NCT04277598|OTHER|Placebo|Placebo gel for topical administration.
214953700|NCT03580395|DRUG|cisplatin|cisplatin 40mg, day 1-3
214953701|NCT05369390|DRUG|NNC0487-0111 A|Participants will receive NNC0487-0111 A tablet once daily.
214953702|NCT05369390|DRUG|NNC0487-0111 B|Participants will receive NNC0487-0111 B tablet once daily.
214953703|NCT05369390|OTHER|Placebo B (NNC0487-0111 B)|Participants will receive placebo matched to NNC0487-0111 B tablet once daily.
214345430|NCT06015776|OTHER|Gender|Differences between men and women will be observed
214345431|NCT02426632|DRUG|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
214953704|NCT05369390|OTHER|Placebo A (NNC0487-0111 A)|Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
214345432|NCT02426632|DRUG|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
214345433|NCT02426632|DRUG|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
214345434|NCT02426632|DRUG|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
214345435|NCT02426632|DRUG|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
214345436|NCT02426632|DRUG|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
214345437|NCT02426632|DRUG|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
214345438|NCT02426632|DRUG|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
214345439|NCT02426632|DRUG|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
214345440|NCT02426632|DRUG|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
214345441|NCT02426632|DRUG|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
214345442|NCT02426632|DRUG|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
214345443|NCT06034600|OTHER|taping|Taping will be applied to the exercise and taping group after the exercises with theraband. Other exercises that are not performed will be performed with the tape on the skin.The application will be repeated three days a week for eight weeks.
214345444|NCT06034600|OTHER|exercise|"Stretching and strengthening exercises will be applied to both groups three days a week for 8 weeks.The exercises performed with theraband will be performed in the same way in both groups. While the other exercises will be done after taping in the taping and exercise group, the exercise group will be done without taping."
214953705|NCT04652518|DRUG|LYT-100|oral administration
214953706|NCT04652518|OTHER|Placebo|oral administration
214953707|NCT04767971|DEVICE|Standard Colonoscopy|Colonoscopy with a standard colonoscope
214345445|NCT00013312|PROCEDURE|Determine colonic tone|
214953708|NCT04767971|DEVICE|G-EYE Colonoscopy|Colonoscopy with a G-EYE Colonoscope
214953709|NCT00429975|DRUG|levofloxacin|
214953710|NCT00429975|DRUG|ceftriaxone|
214953711|NCT02178358|DRUG|LY2157299|Administered orally
214953712|NCT02178358|DRUG|Sorafenib|Administered orally
214953713|NCT02178358|DRUG|Placebo|Administered orally
214953714|NCT02018770|RADIATION|Phototherapy|Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.
214953715|NCT02018770|RADIATION|Placebo phototherapy|The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
214953716|NCT05060107|BIOLOGICAL|Exosomes (sEVs)|Exosomes 3-5x10e11 particles/dose
215077316|NCT03526809|DIAGNOSTIC_TEST|MRI scan and FDG-PET scan|Scanning with MRI and FDG-PET
214345446|NCT06403592|OTHER|optic nerve sheath diamater|Measurement of optic nerve sheath diameter
214345447|NCT04448184|DRUG|Tranexamic Acid|"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
214345448|NCT03356002|DEVICE|C-Scan System|"Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
214345449|NCT03111498|OTHER|practice-based training programme (one-to-one teaching)|practice-based training programme (one-to-one teaching) for conducting VAD
214345450|NCT03111498|OTHER|theory-based training programme|theory-based training programme for conducting VAD
214345451|NCT01924936|BEHAVIORAL|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
214953717|NCT00621725|DRUG|AZD2171|Oral dose
214953718|NCT01066663|DRUG|pyrimethamine|Taken orally once a day
214953719|NCT02985021|DRUG|Carboplatin|Chemotherapy
214953720|NCT02985021|DRUG|Docetaxel|Chemotherapy
214953721|NCT02756819|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil tablets
214953722|NCT04184011|DEVICE|SRT-100™|SRT delivers a precise, calibrated dose of radiotherapy following surgical excision for large and more difficult-to-treat keloids that cannot otherwise be treated by or have failed more conservative measures.
215077317|NCT04920630|BEHAVIORAL|Cognitive Behavioral Therapy - Insomnia (CBT-I)|CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.
215077318|NCT03006458|DEVICE|comfilcon A|toric contact lens
214345452|NCT04757012|DEVICE|calinange|calinange
214345453|NCT03007927|DRUG|Bupivacaine-Dexamethasone|Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
214345454|NCT03007927|DRUG|Bupivacaine- physiological solution|Bupivacaine 1,5 mg/kg- physiological solution
214345455|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
214345456|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
214953723|NCT01090050|DRUG|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
214953724|NCT01090050|DRUG|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
214345457|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
214345458|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
214345459|NCT02057055|OTHER|Soap 300000027003|
214953725|NCT02871284|BEHAVIORAL|Exercise|
214953726|NCT03539484|DRUG|RO7172508|RO7172508 was administered at a dose and as per the schedule specified in the respective arms.
214953727|NCT03539484|DRUG|Obinutuzumab|In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.
214953728|NCT03539484|DRUG|Tocilizumab|Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)
214953729|NCT06955455|DRUG|Triamcinolone and Bupivacaine Injection|A single injection consisting of 1 cc of 0.25% bupivacaine mixed with 2 cc (20 mg) of triamcinolone (40 mg/mL) is administered under ultrasound guidance. The injection targets the extratemporal portion of the facial nerve approximately 1.5-2 cm distal to the stylomastoid foramen in an inferior and anterior direction. The intervention is designed to reduce inflammation and pain, potentially accelerating facial nerve recovery in acute Bell's palsy.
214953730|NCT05597449|BEHAVIORAL|YouTube videos on care after urologic surgery|Supplemental educational videos regarding care following pediatric urologic surgery
214953731|NCT06336811|DEVICE|passive virtual reality distraction|watching the application by wearing virtual glasses to the child during the phlebotomy
214953732|NCT06336811|DEVICE|active virtual reality distraction|The remote control of the virtual glasses will be given to the hand, and the child will start, slow down or stop the application herself.
214953733|NCT02232061|DRUG|Fingolimod|Fingolimod 0.5 mg tablet
215077319|NCT03006458|DEVICE|omafilcon B|toric contact lens
214345460|NCT02057055|OTHER|Soap 300000029240|
214345461|NCT01012882|BIOLOGICAL|sublingual immunotherapy with allergen extract|sublingual application
214345462|NCT01012882|BIOLOGICAL|sublingual immunotherapy with placebo|sublingual application
214345463|NCT02341300|DEVICE|Cast Iron Pot|Cast iron pot
214345464|NCT02341300|DEVICE|Alumnium Pot|Aluminum Skillet
214345465|NCT00784043|DEVICE|Cochlear Implant|Bilateral Implantation in children
214345466|NCT00375089|OTHER|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
214345467|NCT00375089|OTHER|Group 2|Individuals with Early-onset Morbid Obesity.
214345468|NCT01028209|DRUG|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
214953734|NCT02256735|DRUG|Treatment A|Ritobegron Cl (KUC 7483 CL) tablets low dose
214953735|NCT02256735|DRUG|Treatment B|
214953736|NCT02256735|DRUG|Treatment C|
214953737|NCT02256735|DRUG|Treatment D|
214953738|NCT02256735|DRUG|Placebo|
214953739|NCT02256735|DRUG|Moxifloxacin|
214953740|NCT04378595|OTHER|During COVID-19 Pandemic|Assessing status of food insecurity during the COVID-19 pandemic
214953741|NCT04378595|OTHER|After COVID-19 Pandemic|Assessing status of food insecurity after the COVID-19 pandemic
214953742|NCT02878200|BIOLOGICAL|dihydroartemisinin-piperaquine|A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
215077320|NCT04256668|DIAGNOSTIC_TEST|Obtaining one or semen samples|Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
215077321|NCT03581695|OTHER|Blood test|Blood test
215077322|NCT03117374|BEHAVIORAL|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
215077323|NCT00457821|DRUG|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
215077324|NCT00457821|DRUG|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
215077325|NCT00457821|DRUG|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
215077326|NCT00457821|DRUG|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
214345469|NCT02541253|BIOLOGICAL|GC3110A|A single 0.5mL dose intramuscular injection
214345470|NCT02541253|BIOLOGICAL|GCFLU Pre-filled Syringe inj.|A single 0.5mL dose intramuscular injection
214345471|NCT01069783|DRUG|A3309|A3309 in two different dosage levels
214345472|NCT01069783|DRUG|A3309|A3309 in two different dosage levels for the duration of the study
214345473|NCT01069783|DRUG|Placebo|Placebo comparator once daily for the duration of the trial
214345474|NCT05883852|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
214345475|NCT05883852|DRUG|carboplatin|Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
214345476|NCT05883852|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
214345477|NCT05883852|DRUG|Pertuzumab|Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
214345478|NCT05883852|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
214345479|NCT05883852|DRUG|cyclophosphamide|An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
214345480|NCT04191772|OTHER|Periodized, home-based running program|All participants will perform a home-based supervised exercise training program. Participants will receive weekly training instructions using a smartphone-based heart rate monitor application (Polar® app). Training sessions will involve running and the design of the training program will be based on linear periodization, where aerobic capacity is built firstly through a period of high-volume/low-intensity training before the proportion of high-intensity training is increased. The total duration of the exercise program will be 12 months with three weekly training sessions. Training progression will be dependent on initial VO2max values and running experience. VO2max classification is based on reference values described in V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics.
214345481|NCT05553691|DRUG|SPL026|Intravenous
214345482|NCT05162820|DIETARY_SUPPLEMENT|100 mg Solarplast|100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days
214345483|NCT05162820|DIETARY_SUPPLEMENT|Placebo|rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days
214345484|NCT03305679|PROCEDURE|Direct provisional technique|The method of implantation will be accomplished directly.
214953743|NCT04605718|DRUG|RO7223280|For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.
214953744|NCT03108066|DRUG|MK-3795|800 mg twice daily (four 200 mg oral tablets twice daily)
214345485|NCT03305679|PROCEDURE|Indirect Provisional technique|The method of implantation will be accomplished indirectly.
214345486|NCT00921492|DEVICE|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
214953745|NCT00144950|DRUG|insertion of a chest drain with urokinase instillation|
214953746|NCT00144950|PROCEDURE|primary video-assisted thorascopic surgery|
214953747|NCT04726111|OTHER|Specimens specific for the study|Specimens (blood, umbilical cord, umbilical cord blood, placenta)
215077327|NCT05143307|BIOLOGICAL|EBT-101|Long term follow up of participants who received EBT-101
214345487|NCT00921492|OTHER|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
214953748|NCT04161521|PROCEDURE|Novel Technique of Placenta Accreta in Menoufia University Hospital|"* Classical CS to decrease haemorrhage from placental bed.~* Delievery of the fetus.~* At the delivery 10 UI of oxytocin IV will be injected.~* The placenta is not attempted to be delievered.~* Opening of the broad ligament via round ligament division and ligation.~* Gentle dissection of the urinary bladder from lateral to medial.~* Bilateral uterine artery clamping at low level below the placental bed .~* Gentle attempt to deliver The placenta.~* If the placenta is delievered we will do bilateral uterine artery ligation at multiple levels and multiple square compression sutures(if needed) for proper hemeostasis at the placental bed. Then closure of uterine incision.~* If the placenta is not delievered we will do segmental ressection of lower uterine segment including the placenta .~* Intraperitoneal drain insertion."
214953749|NCT00931112|OTHER|individualized exercise training|Lower extremities resistance exercise and bicycle training
214345488|NCT05847777|RADIATION|CBCT|cone beam computer tomography
214345489|NCT04827004|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
214345490|NCT02461121|GENETIC|HLA mismatched stem cell|HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
214345491|NCT02461121|GENETIC|HLA matched stem cell|HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
214345492|NCT02461121|DRUG|cyclosporine A|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
214345493|NCT02461121|DRUG|Mycophenolate mofetil|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
214345494|NCT02461121|DRUG|Ara-C|2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
214345495|NCT02461121|DRUG|fludarabine|30 mg/m2/d for 5days
214953750|NCT00560703|DRUG|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
214953751|NCT00560703|DRUG|placebo|sugar capsule
215077328|NCT04333186|OTHER|Data from ultrasound measurements|Data from ultrasound measurements and from the electronic patient record will be obtained / analyzed. One additional blood sample will be obtained within 24 hours after inclusion, during planned blood collection (from arterial line or venous puncture).
215077329|NCT01287390|PROCEDURE|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
215077330|NCT01287390|PROCEDURE|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
214345496|NCT02461121|DRUG|anti-lymphocyte globulin|1.5-2 mg/kg/d for 4 days
214345497|NCT02461121|DRUG|cyclophosphamide|40 mg/kg/d for 2 days
214345498|NCT04300738|DEVICE|CCS wit CT Scann measurement|Measurement with 2 devices
214345499|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients on Hydroxyurea
214345500|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients on Hydroxyurea
214345501|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients not on Hydroxyurea
214345502|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients not on Hydroxyurea
214345503|NCT05493553|DIETARY_SUPPLEMENT|Dietary supplement regimen|"The powdered, soluble fiber-based supplement contains soluble fibers, phytosterols, plant-derived polysaccharides, flavor, maltodextrin, orange juice powder, citric acid, vitamin and mineral blend, and sweetener. This is prepared in water and consumed twice per day, prior to a meal.~The yerba mate-based supplement (containing green yerba mate leaf extract, sweeteners, and flavor) is a powdered supplement prepared in water and consumed in the morning."
214345504|NCT05493553|OTHER|Dietary supplement and intermittent fasting regimen|The dietary supplement regimen is the same as in Phase 1. The intermittent fasting protocol consists of a 16-hour fasting period and an 8-hour eating window.
214953752|NCT05723952|OTHER|Barcelona scoliosis physical therapy school|procedure for treating Adolescent Idiopathic scoliosis
214345505|NCT01958151|OTHER|State-Trait Anxiety Inventory Scores|Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
214953753|NCT05723952|OTHER|International scoliosis schroth therapy|procedure for treating Adolescent Idiopathic scoliosis
214953754|NCT03244267|BEHAVIORAL|Standard Education|Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
214953755|NCT03244267|BEHAVIORAL|Medication Reminder App|Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle. The app will alert participants when it is time (selected by the participant) to take their medication.
214953756|NCT02693717|OTHER|Laboratory Biomarker Analysis|Correlative studies
214953757|NCT02693717|DRUG|Pemetrexed Disodium|Given IV
214953758|NCT00156091|DRUG|Olanzapine|5- 20 mg QD
214953759|NCT00156091|DRUG|Asenapine|5 or 10 mg BID
214953760|NCT00156091|OTHER|Placebo|
214953761|NCT05912075|DRUG|mFOLFIRINOX|prior to tolinapant (ASTX660) for 6 cycles over 12 weeks
214953762|NCT05912075|RADIATION|Pelvic radiotherapy LCRT|50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks
214953763|NCT05912075|DRUG|Capecitabine|800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
214953764|NCT05912075|DRUG|TOLINAPANT (ASTX660)|starting from 14 days before the first dose of radiotherapy, for 10 weeks.
215077331|NCT01287390|OTHER|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
214953765|NCT05912075|RADIATION|Pelvic radiotherapy SCRT|total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)
215077332|NCT01287390|OTHER|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
214345506|NCT00733265|DRUG|AZD6140|single oral dose
214345507|NCT01476215|DRUG|Paracetamol fast dissolution suspension|
214345508|NCT01476215|DRUG|Paracetamol medium dissolution suspension|
214953766|NCT05912075|DRUG|FOLFOX4|given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
214953767|NCT05912075|DRUG|CAPOX|every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
214953768|NCT01315522|DEVICE|ComVi stent|Endoscopic insertion of ComVi stent
214953769|NCT01315522|DEVICE|Uncovered SEMS|Endoscopic insertion of uncovered SEMS
214953770|NCT03675529|BEHAVIORAL|High Intensity Interval Training bout|Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
214953771|NCT00383370|DRUG|VEGF Trap|VEGF Trap formulation 1, ITV-1
214953772|NCT00383370|BIOLOGICAL|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
214345509|NCT01476215|DRUG|Paracetamol slow dissolution suspension|
214345510|NCT01476215|DRUG|Paracetamol|
214345511|NCT02167828|BEHAVIORAL|Social Support|
214345512|NCT00652665|DRUG|Leflunomide|Tablets, 20mg, single-dose
214345513|NCT00652665|DRUG|ARAVA|Tablets, 20mg,single-dose
214345514|NCT03538626|BIOLOGICAL|VRC-HIVMAB091-00-AB|N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.
215077333|NCT01287390|OTHER|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).
215077334|NCT01441908|DRUG|Pravastatin|40mg or 80mg dose 28 days for 6 month period
215077335|NCT03548506|DEVICE|Omnidirectional Deep Brain Stimulation of STN|Deep Brain Stimulation
215077336|NCT03548506|DEVICE|Directional Deep Brain Stimulation of STN|Deep Brain Stimulation
215077337|NCT03479177|BEHAVIORAL|High Intensity Interval Training|The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
215077338|NCT05611229|DRUG|Nivolumab|Nivolumab
215077339|NCT05611229|DRUG|Pembrolizumab|Pembrolizumab
215077340|NCT05611229|COMBINATION_PRODUCT|Dabrafenib+Trametinib|Dabrafenib+Trametinib
215077341|NCT05611229|COMBINATION_PRODUCT|Ipilimumab+Nivolumab|Ipilimumab+Nivolumab
215077342|NCT05611229|COMBINATION_PRODUCT|Vemurafenib+Cobimetinib|Vemurafenib+Cobimetinib
215077343|NCT05611229|COMBINATION_PRODUCT|Encorafenib+Binimetinib|Encorafenib+Binimetinib
214953773|NCT01679028|DRUG|T89 Group A|150mg single dose on day 1
214345515|NCT03538626|BIOLOGICAL|rHuPH20|Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP). EDP is a purified preparation of rHuPH20.
214345516|NCT05408494|BEHAVIORAL|Gamified behavioral weight loss treatment|12-month mHealth fully-gamified version of the same program, comprised of a behavior change program with digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game
215077344|NCT01434394|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
215077345|NCT00842946|BEHAVIORAL|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
214953774|NCT01679028|DRUG|Placebo Group A|150mg single dose
214953775|NCT01679028|DRUG|Placebo Group B|300mg single dose
214953776|NCT01679028|DRUG|T89 Group B|300mg single dose
214953777|NCT01679028|DRUG|Placebo Group C|225mg bid
214953778|NCT01679028|DRUG|T89 Group C|225mg bid
215077346|NCT00842946|BEHAVIORAL|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
215077347|NCT00578877|DEVICE|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
215077348|NCT00578877|COMBINATION_PRODUCT|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
214345517|NCT05408494|BEHAVIORAL|mHealth behavioral weight loss treatment|a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining
214953779|NCT04410471|DIAGNOSTIC_TEST|CLIA of IgG and IgM against SARS-Cov-2|Report of clinical data
214953780|NCT04678609|OTHER|Exercise|CKC: exercise with joints fixed on the ground OKC: exercise with joints not fixed on the ground
214953781|NCT02943187|BEHAVIORAL|Cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
214345518|NCT01156701|DRUG|Receiving a prescription of Relenza for prophylaxis|Receiving a prescription of Relenza for prophylaxis
214953782|NCT02943187|DIETARY_SUPPLEMENT|Nutrition|Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
214953783|NCT05446051|DEVICE|the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV)|Phase I Interventions：eRAPID-MV(TRAEs survey)
214953784|NCT05446051|DEVICE|the telephone triage decision support system (TTDSS)|Phase I Interventions：TTDSS
214953785|NCT02186899|OTHER|Ultrasound Guided Femoral Sciatic Obturator nerve blocks|
214953786|NCT02186899|OTHER|General Anesthesia femoral bolus|
214953787|NCT02186899|OTHER|General anesthesia femoral continuous|
215077349|NCT00578877|COMBINATION_PRODUCT|Buffer Gel|Buffer Gel
215077350|NCT02139878|OTHER|Wild blueberry juice|
214953788|NCT04923880|OTHER|Implementation of Primary Palliative Care Intervention in CF Centers|"Individuals with CF ages 12 years and above will complete an annual palliative care needs assessment with the CF care team using the IPOS (Integrated Palliative Care Outcome Scale).~Individuals with CF under 12 years of age will complete an annual palliative care needs assessment with the CF care team using IPOS as a conversation guide.~Caregivers of Individuals with CF of all ages will be offered the BASC (Brief Assessment Scale for Caregivers).~In addition to annual needs assessment, palliative care needs assessment will take place when triggered by changes in disease status, such as hospitalization, new diagnosis of CF related Diabetes or referral to transplant."
214345519|NCT01156701|OTHER|No prophylaxis with Relenza|No prophylaxis with Relenza
214345520|NCT01434602|DRUG|everolimus|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation: 5mg to 10mg daily.
214345521|NCT01434602|DRUG|sorafenib|Patients will be treated with sorafenib in combination with everolimus (days 1-28); There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation 400mg-600mg twice a day (bid) or 400mg-800mg twice a day, 7 days on and 7 days off.
214953789|NCT01185002|OTHER|PillCam® COLON 2 procedure using MgC boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.
214953790|NCT01185002|OTHER|PillCam® COLON 2 procedure using Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts
214953791|NCT01185002|OTHER|PillCam® COLON 2 procedure using reduced dose of Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
214953792|NCT03247322|OTHER|Pharmacist-led medication therapy using mHealth application|This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
214953793|NCT00914498|DRUG|Local, pre-incisional injection of 20 ml 1% xylocaine|Local, pre-incisional injection of 20 ml 1% xylocaine
214953794|NCT03730376|OTHER|Cost Information|participants will be given information on the personal and societal costs
214953795|NCT00339833|DRUG|Salsalate|The intervention was salsalate (3g/day) for 7 days.
214953796|NCT00339833|DRUG|Placebo|Identical placebo for 7 days.
214953797|NCT00911417|DEVICE|Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.
215077351|NCT02139878|OTHER|Placebo wild blueberry juice|
215077352|NCT06601517|DRUG|Repaglinide|Single dose; Administered orally
215077353|NCT06601517|DRUG|Atorvastatin|Single dose; Administered orally
215077354|NCT06601517|DRUG|Digoxin|Single dose; Administered orally
215077355|NCT06601517|DRUG|Rosuvastatin|Single dose; Administered orally
215077356|NCT06601517|DRUG|HDM1002|Administered orally
215077357|NCT06599710|DIETARY_SUPPLEMENT|AndoSanTM|Fermented water-based exctract of Agaricus subrufesence, Hericum erinacus, and Grifola frondosa
214345522|NCT05960500|PROCEDURE|implant|All on six versus parallel implant distribution
214345523|NCT01835626|DRUG|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
214345524|NCT01835626|RADIATION|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
214345525|NCT05035719|DEVICE|non-invasive cardiac output monitor|Equivalence of Caretaker cardiac output reading to reference standard
214345526|NCT00288158|DRUG|Allopurinol|
214345527|NCT00288158|DRUG|Probenecid|
214345528|NCT00288158|DRUG|Placebo|
214345529|NCT05413876|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
214345530|NCT05413876|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
214345531|NCT05472428|COMBINATION_PRODUCT|Autologous bone marrow mononuclear cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
215077358|NCT06657352|DIETARY_SUPPLEMENT|ACS Topical Treatment Group|The topical group applied the ACS cream to the face twice daily (morning and night) for 4 weeks.
215077359|NCT06657352|DIETARY_SUPPLEMENT|Topical Placebo Group|The topical group applied the cream (without ACS) to the face twice daily (morning and night) for 4 weeks.
214345532|NCT01108081|BEHAVIORAL|Physical activity|Moderate-intensity physical activity
214345533|NCT01108081|BEHAVIORAL|Diet|Dietary weight loss
214345534|NCT01108081|BEHAVIORAL|Health education|Attention control intervention
215077360|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Treatment Group|The combination group used both the topical and oral ACS products for 12 weeks.
214345535|NCT00793208|BIOLOGICAL|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
214345536|NCT05629026|PROCEDURE|Micro-biopsies|Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
214345537|NCT03397511|BEHAVIORAL|Financial Incentives|Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month
214345538|NCT00648908|DRUG|Fampridine-SR|Tablets, 10 mg, BID
214345539|NCT04545268|DEVICE|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days)."
214345540|NCT04545268|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
214345541|NCT05106231|BEHAVIORAL|PICC Program|Participants will attend the PICC program which consists of 4 sessions that involve Visualization in Participatory Programmes (VIPP) and quizzes to evaluate retention in diabetes knowledge.
214953798|NCT05761119|OTHER|Physical activity|The focus of the intervention is on exercises that can improve venous return, and consists of progressive walking training at moderate and high intensity as well as guidance on physical activity. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to hit 30 min. times/day at moderate intensity. After 14 days, the patient receives physiotherapeutic guidance in physical activity and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achieve 2 x 20 min./week of high-intensity physical activity. After one month of training, the patient will be guided on maintaining and possibly progressing physical activity.
214953799|NCT03891355|DRUG|Carfilzomib|Carfilzomib
214953800|NCT03891355|DRUG|Lenalidomide|Lenalidomide
214953801|NCT03891355|DRUG|Dexamethasone|Dexamethasone
214953802|NCT04441632|BEHAVIORAL|Positive feedback|Participants will submit positive feedback comments to their colleagues (anonymously or signed, participant-dependent) through an anonymous survey link, a minimum of twice weekly to 6 uniquely different individuals over a 4 week period (total minimum 24 unique individuals over the study period).
214953803|NCT06185439|BEHAVIORAL|Prenatal Pilates Assisted Childbirth Preparation Training|Training was given twice a week for two hours a day (one hour of theory, one An hour of exercise = 45 minutes of pregnant plates and 15 minutes of breathing exercises) total eight weeks.
214953804|NCT00806208|DRUG|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
214953805|NCT00806208|DRUG|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
214953806|NCT00806208|DRUG|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
214953807|NCT00806208|DRUG|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
214953808|NCT00806208|OTHER|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
214345542|NCT05106231|BEHAVIORAL|Control|The control arm received four sessions one-on-one education program by a pharmacist. It is a Malaysian national education pharmacy-led program to instil knowledge and inculcate medication adherence.
214345543|NCT00197977|BEHAVIORAL|Educational program to address patients' expectations|
214953809|NCT05718440|OTHER|Individualisation of uronephrological complications risk factors|description of pelvic disorders in terms of clinical presentation, electrophysiology/urodynamics/anorectal manometry patterns, urethrocystography/urinary ultrasound/defecography results and urinary complications (infections, vesicoureteral reflux), depending on the dysraphim's type and level of injury and to correlate these parameters to the uronephrological risk factors and complications recorded.
214953810|NCT06101888|DEVICE|TaurusTrio™ Heart Valve System|The TaurusTrio™ Heart Valve System contains the following sub-components: a prosthetic transcatheter porcine pericardial aortic valve, 20Fr Introducer Sheath System, transfemoral Delivery Catheter, and Loading Tool.
214953811|NCT03777280|DEVICE|peek framework RPD|it is a polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base made by injecting technique and have several advantages regarding strength and esthetics
214953812|NCT03777280|DEVICE|cobalt chromium framework RPD|standard framework device
214953813|NCT01745614|DRUG|Nimesulide 100 mg tablets|Reference product
214345544|NCT01253434|DRUG|E2022|E2022 Type A patch
214345545|NCT01253434|DRUG|E2022|E2022 Type B patch
214345546|NCT01253434|DRUG|E2022|E2022 Type C patch
214345547|NCT01253434|DRUG|E2022|E2022 Type D patch
214345548|NCT01253434|DRUG|E2022|E2022 Type E patch
214953814|NCT01745614|DRUG|Nimesulide 100 mg tablets|Test product
214953815|NCT03077607|DRUG|Talazoparib|Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
214953816|NCT03077607|DRUG|Itraconazole|100 mg oral dose
214953817|NCT03077607|DRUG|Rifampin|600 mg oral dose
214953818|NCT03306095|OTHER|Early refeeding group|Food Intake by patient with in 4 hours i.e \<4 hours after the EVL procedure
214953819|NCT03306095|OTHER|Delayed refeeding group|Food Intake by patient after 4 hours i.e \> 4 hours after the EVL procedure
214953820|NCT03621436|DEVICE|TRVD Therapy|A catheter-mounted expandable flow pump is to be deployed in a transfemoral venous catheterization procedure. Once in place, renal venous pressure is reduced to a pre-selected physiologic target pressure and kept there for up to 24 hours. After termination of TRVD therapy, the device is removed.
214345549|NCT03449602|DEVICE|Mini-thoracoscopy|Thoracoscopic pleural biopsy with the mini-thoracoscope
214345550|NCT03449602|DEVICE|Conventional rigid thoraoscopy|Thoracoscopic pleural biopsy with the conventional rigid thoraoscope
214345551|NCT00690521|DRUG|Treatment of Furosemide + Hydrochlorothiazide|A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.
214345552|NCT00690521|DRUG|Treatment of Furosemide + Metolazone|A randomized, double-blind, crossover study designed to compare the efficacy of metolazone in combination with stable doses of furosemide in congestive heart failure patients.
214345553|NCT01926106|DEVICE|nIPPV|one of the twins was randomly allocated to nIPPV
214953821|NCT04035525|DIETARY_SUPPLEMENT|MaxSimil® fish oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
214345554|NCT01926106|DEVICE|nCPAP|another of the twins was allocated to nCPAP
214345555|NCT03819660|DRUG|Amifampridine Phosphate 10 MG Oral Tablet|Oral tablets
214345556|NCT05218967|OTHER|Virtual Reality Headset|A head-worn apparatus that completely covers the eyes for an immersive 3D experience. The VR headset will be worn during the procedure.
214953822|NCT04035525|DIETARY_SUPPLEMENT|Rice bran oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
214953823|NCT04035525|DIETARY_SUPPLEMENT|CoQ10 as powder form|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
214953824|NCT00576862|DRUG|INSULIN GLARGINE|The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
214345557|NCT05203419|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
214345558|NCT05203419|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
214678482|NCT02149654|DEVICE|Engager Transcatheter Aortic Valve Implantation System|The Engager Transcatheter Aortic Valve Implantation System is indicated for use in patients with symptomatic severe aortic valve stenosis requiring aortic valve replacement and are at high or extreme risk for operative mortality or comorbidity judged by the heart team to pose an absolute or relative contraindication for conventional aortic valve replacement. The system is intended for use in patients with a life expectancy of at least one year following TAVI. The intended performance of the system is to provide relief of aortic valve obstruction without inducing significant regurgitation, thereby restoring effective hemodynamic function of the diseased aortic valve. The intended purpose of the system in this clinical study is in line with the intended purpose in the Instructions for Use.
214953825|NCT01873118|OTHER|RN-RHDS protocol|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
215077361|NCT06657352|DIETARY_SUPPLEMENT|ACS Oral Treatment Group|The oral group ingested one ACS capsule twice daily after breakfast and dinner for 12 weeks.
214345559|NCT02824276|DRUG|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
214345560|NCT02824276|DRUG|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
215077362|NCT06657352|DIETARY_SUPPLEMENT|Oral Placebo Group|The oral group ingested one capsule (without ACS) twice daily after breakfast and dinner for 12 weeks.
215077363|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Placebo Group|The combination group used both the topical and oral products without ACS for 12 weeks.
215077364|NCT06656117|OTHER|Elliptical training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
215077365|NCT06656117|OTHER|Resistance training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
214345561|NCT05354700|DRUG|HLX07|HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
214345562|NCT05354700|DRUG|HLX10|HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
214345563|NCT05354700|DRUG|carboplatin and etoposide|chemotherapeutics
214345564|NCT03421691|DEVICE|excel V Laser|excel V Laser Genesis procedure utilizing 1064 nm laser
214345565|NCT01286259|DRUG|Disulfiram|Open label 500mg disulfiram per day by mouth for 14 days
214345566|NCT03607305|PROCEDURE|BP limb 70cm|Performance of RYGB with a BP limb of 70cm
214345567|NCT03607305|PROCEDURE|BP limb 120cm|Performance of RYGB with a BP limb of 120cm
214345568|NCT06446804|OTHER|None, pure observationnal study|Pure observatonnal study
214345569|NCT00780962|DRUG|N-Acetylcysteine (NAC)|"Experimental:~* Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~* After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."
214345570|NCT00780962|DRUG|0.9% Sodium-chloride|"Placebo:~* Before CT: 500 cc 0.9% Sodium-chloride~* After CT: NS at 67 cc/hour for up to 24 hours."
214678483|NCT03761953|DRUG|Oritavancin Injection|single 1200mg infusion of IV oritavancin.
214345571|NCT06567509|OTHER|Core stability exercises and Short foot exercises|Core stabilty exercises are the exercises where subjects will be trained to perform exercises like: Curl ups, bridging, side bridges, Planks, and Quadripedal stance exercises in a phased manner, each phase lasting 2 weeks. Complexities and duration of exercises will be increased in each phase. Short foot exercises for control group will include traditional treatment of stretching and strengthening of foot musculature.
214953826|NCT01873118|OTHER|RN-RHDS+PT-RHDS protocol|The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
214953827|NCT01873118|OTHER|RN-RHDS + PT-RHDS + NIAF|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
214345572|NCT06567509|OTHER|Conventional foot exercises and short foot exercises|Ankle dorsiflexion, Plantar flexion, Inversion and Eversion range of motion exercises
214345573|NCT02909322|PROCEDURE|Bupivacaine and Hydromorphone|Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
214345574|NCT02909322|PROCEDURE|Ropivacaine and Hydromorphone|Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
214345575|NCT00499889|DRUG|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
214345576|NCT00499889|DRUG|Fludarabine (Fludara)|40 mg/m\^2 by vein daily for 4 Days
214345577|NCT00499889|DRUG|Busulfan|130 mg/m\^2 by vein daily for 2 Days
214345578|NCT00499889|DRUG|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
214345579|NCT00499889|DRUG|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
214345580|NCT00499889|DRUG|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
214345581|NCT00499889|PROCEDURE|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after \>4 weeks of imatinib.
214345582|NCT00499889|PROCEDURE|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
214345583|NCT00688805|DRUG|Propranolol|40 mg given as a single oral administration in an opaque capsule
214345584|NCT00688805|DRUG|Placebo|matching capsule containing no active medication
214345585|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
214345586|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
214953828|NCT00925808|BEHAVIORAL|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
214953829|NCT03001908|OTHER|glenohumeral mobilization-oscillation|posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds
214345587|NCT02908269|BIOLOGICAL|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
214345588|NCT03839238|BIOLOGICAL|hESC derived MSC like cell|Different dosage of hESC derived MSC like cell for the meniscus injured patients
214345589|NCT05861115|DEVICE|"Chang Gung Ventricular Systolic Dysfunction Screening Software"|This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
214345590|NCT02319239|RADIATION|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
214345591|NCT02319239|RADIATION|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
214345592|NCT02319239|RADIATION|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
214345593|NCT04724811|PROCEDURE|Open reduction and internal fixation (ORIF)|"Approaches used:~* Intrapelvic approach +/- iliac window~* Kocher-Langenbeck approach"
214345594|NCT02221115|DEVICE|Google Glass|The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
214345595|NCT03339986|BEHAVIORAL|Reduction or Replacement|
214678484|NCT05141526|OTHER|Non-restrictive satiating intervention|Diet group containing satiating foods
214953830|NCT03001908|OTHER|glenohumeral mobilization-sustained|posterior glide mobilization, sustained 4 x 30 seconds
214953831|NCT03634943|OTHER|Patients with Nutritional Support|Evaluation of Enteral Nutrition or Parenteral Nutrition or both administered to the patients needing artificial Nutritional Support
214953832|NCT05936853|OTHER|Intravenous approach to anaesthetic maintenance|Anaesthetic agents given directly into the bloodstream via a cannula.
214953833|NCT05936853|OTHER|Inhalational approach to anaesthetic maintenance|Volatile-based anaesthetic drugs are breathed in and then absorbed into the bloodstream through the lungs.
214953834|NCT04865679|DEVICE|Axoguard Nerve Cap®|Entubulation of the nerve stump into the Axoguard Nerve Cap® following surgical excision of symptomatic neuroma
214953835|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and placebo probiotic|the randomized patients will be receive active chlorhexidine rinse and placebo probiotic
214953836|NCT05548361|COMBINATION_PRODUCT|placebo chlorhexidine and active probiotic|the randomized patients will receive placebo chlorhexidine rinse and active probiotic
215077366|NCT02305017|DRUG|BIA 9-1067|BIA 9-1067 50 mg
215077367|NCT02305017|DRUG|Paracetamol|Paracetamol 1g
215077368|NCT05120765|BEHAVIORAL|The CONNECT Program|The CONNECT Program is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT). The group sessions take place once a week and they last 90 minutes each.
215077369|NCT02534558|BIOLOGICAL|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
214345596|NCT03059173|DIETARY_SUPPLEMENT|Myo-Inositol + Levomefolic acid|Dietary supplement Gynositol® MTHF containing myo-inositol (4 g) and Levomefolic acid on glucosamine salts(0.736 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
214345597|NCT03059173|DRUG|Clomiphene Citrate|Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
214953837|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and active probiotic|the randomized patients will receive active chlorhexidine rinse and active probiotic
214953838|NCT05789069|DRUG|HFB200603|Participants will be administered HFB200603 as described in the experimental arm.
214953839|NCT05789069|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
214953840|NCT03591224|OTHER|Pharmacogenomic Testing|pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism
214953841|NCT03591224|OTHER|Pharmacist Standard of Care|Pharmacist providing standard of care as per usual practice
214953842|NCT05876429|OTHER|New Standardized Accept Note|A standardized accept note for transfer patients will be implemented, after stakeholder engagement and subsequent finalization.
214953843|NCT05876429|OTHER|Existing Transfer Patient Admission Process|Maintain existing transfer patient admission processes, across GMS, Cardiology, and Oncology services.
214953844|NCT02723994|DRUG|Ruxolitinib|In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
215077370|NCT03233334|BEHAVIORAL|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
214345598|NCT03059173|DIETARY_SUPPLEMENT|placebo|a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
214345599|NCT02449538|DRUG|everolimus|everolimus 10 mg qd daily one cycle is 28days.
214345600|NCT00345397|DEVICE|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
215077371|NCT01696617|DRUG|Aripiprazole 6-week group|
215077372|NCT01696617|DRUG|Aripiprazole 8-week group|
215077373|NCT00169234|BIOLOGICAL|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
215077374|NCT00169234|BIOLOGICAL|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
215077375|NCT06490653|DRUG|Blood Stopper (Ankaferd)|5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
215077376|NCT02437409|DEVICE|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
214345601|NCT00968604|GENETIC|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
214345602|NCT04093934|BEHAVIORAL|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
214953845|NCT02723994|DRUG|Asparaginase Erwinia Chrysanthemi|
214345603|NCT00920192|DRUG|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
214345604|NCT06563089|OTHER|blood sampling|Albumin level in blood
214345605|NCT05762666|DEVICE|nociception level index monitor|The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
214953846|NCT02723994|DRUG|Cyclophosphamide|
214953847|NCT02723994|DRUG|Cytarabine|
214953848|NCT02723994|DRUG|Dexamethasone|
214953849|NCT02723994|DRUG|Doxorubicin|
214953850|NCT02723994|DRUG|Leucovorin Calcium|
214953851|NCT02723994|DRUG|Mercaptopurine|
214953852|NCT02723994|DRUG|Methotrexate|
214953853|NCT02723994|DRUG|Pegaspargase|
214953854|NCT02723994|DRUG|Prednisone|
215077377|NCT06605274|OTHER|Web-Based Education Program|"Before being discharged from the clinic, the women who experienced perinatal loss filled out the Personal Information Form, Perinatal Grief Scale, Edinburgh Postnatal Depression Scale, Beck Hopelessness Scale, and Stress Coping Styles Scale individually. The women were informed about the use of the website. The discharged women were contacted by phone, given the passwords of the birliktegücleniyoruz.com website, and invited to use the website for the five-week education program. Each week, only one session determined for that week was uploaded to the site. Participants who wished to do so were able to watch the uploaded sessions more than once. Retrospective sessions also remained accessible on the site. Each session lasted an average of 20-30 minutes. Women who completed five sessions were contacted by phone in the sixth week. Women filled out the PGS, EPDS, BHS, and SCSS online a second time"
214953855|NCT02723994|DRUG|Thioguanine|
214953856|NCT02723994|DRUG|Vincristine Sulfate|
214953857|NCT06536296|OTHER|Music|Arm 1: Music only
214953858|NCT06536296|OTHER|Music and parent voice|Arm 2: Music and parent voice
214953859|NCT06536296|OTHER|Standard Care|Standard Care
214953860|NCT05013242|DRUG|Zoladex|evaluate efficacy of Zoladex in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
214953861|NCT05013242|DRUG|Visanne|valuate efficacy of Dienogest in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
214345606|NCT06308159|DRUG|Vebeglogene autotemcel|Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
214345607|NCT05093452|BEHAVIORAL|Motivational Interviewing|Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a midwife. The midwife will have first received a standardized 3 days training session on the content and techniques of MI. The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
214345608|NCT05093452|OTHER|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the midwife.
214345609|NCT03351049|DEVICE|LAL|Reactive support surface with a low air loss feature
214345610|NCT03351049|DEVICE|Non-LAL|Reactive support surface without a low air loss feature
214345611|NCT03646344|DRUG|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
214953862|NCT04465526|DIAGNOSTIC_TEST|computed tomography perfusion imaging|The new-generation dual-source computed tomography scanner Somatom® Force will be used for all CTP studies. Myocardial perfusion will be evaluated in a stress dynamic CT protocol. The scan range will be determined based on a low-dose non-contrast scan. Subsequently, regadenoson will be administered intravenously at a single dose of 0.4 mg, and followed after 50 seconds delay by 35 mL of the iodinated contrast agent (iohexol, concentration 350 mg I/mL) injected at the flow rate of 5 mL/s. Finally, low-dose non-contrast dual-energy CT scan will be performed 5-6 min after the dynamic scan to assess late enhancement of the myocardium.
214345612|NCT03646344|DRUG|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
214345613|NCT04327284|DEVICE|Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
214345614|NCT04327284|DEVICE|Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
214345615|NCT05841017|BEHAVIORAL|Psychotherapy with Immersive Virtual Reality support.|Psychoeducational group intervention and cognitive behavioural therapy individual intervention.
214345616|NCT00820339|PROCEDURE|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
214345617|NCT00820339|PROCEDURE|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
214345618|NCT00461526|DRUG|crofelemer|125 mg crofelemer vs. placebo
214345619|NCT05437679|OTHER|Blood collection|Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.
214953863|NCT04008797|DRUG|E7386|E7386 dosing.
214953864|NCT04008797|DRUG|Lenvatinib|Lenvatinib, capsules, orally.
214953865|NCT04008797|DRUG|Doxorubicin|Doxorubicin dosing.
214953866|NCT04008797|DRUG|Paclitaxel|Paclitaxel dosing.
214953867|NCT02476916|DRUG|AG-348|Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
214953868|NCT05090384|DRUG|Prednisone|Prednisone starting dose of 0.5 mg/kg; for patients who respond clinically and continue to have low biomarkers will be tapered rapidly; those that are not clinically responding or whose biomarkers increase will be treated per their treating physicians plan or by standard of care
215077378|NCT06605274|OTHER|Control|Before being discharged from the perinatology clinic, the women filled out the Personal Information Form, PGS, EPDS, BHS, and SCSS individually. Six weeks after discharge, the participants filled out the same measurement tools online again. During this process, the hospital's routine monitoring continued for the control group. The website was opened to the use of participants who wanted to use the site after the completion of the final tests.
214953869|NCT06016517|DRUG|Etanercept|50 mg subcutaneously weekly
214953870|NCT06016517|DRUG|Adalimumab|40 mg subcutaneously every 2 weeks
214953871|NCT06016517|DRUG|Upadacitinib|15 mg orally once daily with subcutaneous placebo injection every 2 weeks
214953872|NCT06016517|DRUG|Tocilizumab|162 mg administered SQ every 2 weeks
214953873|NCT05288946|OTHER|local segmental control and closed kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then closed kinetic chain exercise in the form of Stand-up position on unstable surface, Closed chain lunge exercises, with the addition of hand weights, Bridge in prone position, Bridge in supine position, Lateral Bridge
214953874|NCT05288946|OTHER|local segmental control and open kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then open kinetic chain in the form of Lower limb abduction, Knee extension in a supine position on a roller, Open chain exercise of the upper limb after co-contraction of transversus abdominis and multifidus.
214953875|NCT05288946|OTHER|traditional therapy|the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
214953876|NCT06961643|DRUG|HRS-7535 Tables|Oral HRS-7535 tables.
214953877|NCT05542277|DEVICE|ClearPlasma|ClearPlasma ClearPlasma™ is an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma™ is a non-pyrogenic, sterile, single-use medical device
214953878|NCT06010732|DRUG|0 ppm F (placebo, negative control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
214953879|NCT06010732|DRUG|1100 ppm F as sodium fluoride (positive control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
214953880|NCT06010732|DRUG|1100 ppm F as sodium fluoride Test Product|• Each subject will use this product during one of the three treatment periods in the crossover study design.
214953881|NCT04401202|DIETARY_SUPPLEMENT|Nigella sativa oil|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
214953882|NCT02671617|OTHER|High intensity interval training (HIIT)|Preoperative HIIT protocol.
214953883|NCT03491397|DEVICE|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
214953884|NCT05223166|DRUG|Pitolisant|Wakix tablet
214953885|NCT05223166|DRUG|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
214953886|NCT04124328|PROCEDURE|ALINE + VoM infusion|In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.
214345620|NCT00677339|DRUG|L-arginine|L-arginine 6g orally daily
214953887|NCT04124328|PROCEDURE|ALINE only|In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
214953888|NCT03369626|BEHAVIORAL|FareWell Program|The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
214345621|NCT00677339|DRUG|Vitamin D|Cholecalciferol 50000 IU once monthly orally
214345622|NCT00677339|DRUG|Placebo L-arginine|placebo L-arginine once daily
214345623|NCT00677339|DRUG|Placebo Vitamin D|placebo vitamin D orally once monthly
214345624|NCT02877485|DRUG|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
214345625|NCT02877485|DRUG|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
214345626|NCT06333444|BEHAVIORAL|four weekly psychological counselling intervention|four weekly psychological counselling intervention delivered by university students asking help to university counselling service in Southern Italy
214345627|NCT06302764|DIAGNOSTIC_TEST|Qualitative & Quantitative Research|"1. Focused interviews - conducted by members of the appointed research team to recognize the issues faced by emergency medical staff in Poland, Ukraine, Portugal, and Spain with the aim of preparing the measurement framework.~2. Online questionnaire surveys - conducted using the Qualtrics platform (available in different, language versions - Polish, Ukrainian, Portuguese, and Spanish)."
214345628|NCT02261116|DRUG|Telmisartan|
214345629|NCT02261116|DRUG|Candesartan|
214953889|NCT01263717|DRUG|tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
214953890|NCT01263717|DRUG|placebo|Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
214953891|NCT05396859|DRUG|Decitabine and Cedazuridine|Given PO
214953892|NCT05396859|DRUG|Entrectinib|Given PO
214953893|NCT05396859|OTHER|Laboratory Biomarker Analysis|Correlative studies
214953894|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Nab-Paclitaxel|Given by IV, Given by PO
214345630|NCT02261116|DRUG|Placebo|
214345631|NCT00054899|BIOLOGICAL|EP2101|
214345632|NCT02835014|BEHAVIORAL|Mental Health Symptoms|Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
214953895|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
214953896|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|Given by IV, Given by PO
214953897|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
214953898|NCT05669339|DRUG|Irinotecan|All subjects will be given either 25 mg/m2 (dose level -1), 50 mg/m2 (dose level 0), or 75 mg/m2 (dose level +1) irinotecan intravenously every 7 days.
214953899|NCT05669339|DRUG|Sonidegib|All subjects will take 200 mg sonidegib orally either every 96 hours (dose level -1), every 48 hours (dose level 0), or every 24 hours (dose level +1).
214345633|NCT02835014|BEHAVIORAL|Self-efficacy regarding self-care and diabetes management|Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
214345634|NCT02835014|BEHAVIORAL|Parenting Styles|Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
214345635|NCT02787616|GENETIC|buccal swab|cheek swab for DNA sampling
214345636|NCT03765281|OTHER|Navigation|Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
214345637|NCT03765281|OTHER|Resource List|Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
214345638|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
214345639|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
214345640|NCT01700816|DEVICE|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
214345641|NCT01700816|DEVICE|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
214345642|NCT05211024|DRUG|Penicillin G Benzathine|Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
214345643|NCT03832192|BEHAVIORAL|care.coach Avatar (HELP-Protocolized)|care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
214345644|NCT00005787|BIOLOGICAL|epoetin alfa|
214345645|NCT00005787|BIOLOGICAL|filgrastim|
214953900|NCT05669339|DRUG|Sorafenib|All subjects will take 200 mg sorafenib orally either every 48 hours (dose level -1), every 24 hours (dose level 0), or every 12 hours (dose level +1).
214953901|NCT06564649|DIAGNOSTIC_TEST|CXCL10 Monitoring at clinical frequency|The intervention is the implementation of real-time, serial urinary CXCL10 monitoring, with protocolized further clinical responses in the setting of elevated urinary CXCL10 levels.
214345646|NCT00005787|BIOLOGICAL|recombinant flt3 ligand|
214345647|NCT00005787|BIOLOGICAL|recombinant interleukin-3|
214345648|NCT00005787|BIOLOGICAL|sargramostim|
214953902|NCT06022419|PROCEDURE|Lucerne Cast|Patients receiving reduction of fractured finger and subsequent customization of a lucerne cast. Duration of cast treatment is determined with 4 weeks.
214345649|NCT00005787|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214345650|NCT06572904|DRUG|Tenoxicam Injectable Product|(EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)
214345651|NCT06572904|DRUG|Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly|\* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)
214345652|NCT05511714|DRUG|L-(11C) methionine|Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).
214345653|NCT05336240|BEHAVIORAL|Physician Communication 2 Virtual (PCOM2-virtual)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
214345654|NCT05336240|BEHAVIORAL|Physician Communication Standard (PCOM-standard)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
214345655|NCT06161376|OTHER|S1P level|Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.
214953903|NCT06022419|PROCEDURE|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
214345656|NCT06487039|DRUG|EB-203|Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.
214345657|NCT06004817|OTHER|evaluation of clinical severity|evaluation of clinical severity
214953904|NCT03696199|DRUG|Long-Acting Local Anesthesia|"The cocktail consists of:~* 0.5% Ropivicaine, 24.6 mL~* Clonidine 100 mcg/mL, 0.4mL~* Epinephrine 1mg/mL, 0.5mL~* Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded."
214953905|NCT03696199|DRUG|Regional Anesthesia|0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
214345658|NCT06575218|DEVICE|Virtual reality training|Virtual reality training
214345659|NCT06575218|OTHER|Conventional exercise and cognitive exercise|Conventional exercise and cognitive exercise
214345660|NCT06575218|OTHER|control|no intervention
214345661|NCT03738150|BIOLOGICAL|Sotatercept|Sotatercept injection
214953906|NCT02650700|RADIATION|spleen radiotherapy|Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
214953907|NCT06300411|DRUG|SRG-514|SRG-514 monotherapy
214345662|NCT03738150|OTHER|SOC|SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
214345663|NCT03762135|OTHER|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
214345664|NCT03762135|OTHER|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
214345665|NCT06572670|OTHER|Progressive relaxation exercise before coronary angiography|Patients in the intervention group will undergo progressive relaxation before undergoing angiography.
214345666|NCT05268796|BEHAVIORAL|Behavior therapy|Caregivers will be coached either in-person or via telehealth to implement function-based behavioral treatment in 1-hour sessions each week with their child over 12 weeks.
214345667|NCT05268796|OTHER|Psychoeducation|Caregivers will complete online education modules in 1-hour sessions each week over 12 weeks.
214345668|NCT04712318|PROCEDURE|Relex Smile|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
214345669|NCT04712318|PROCEDURE|Relex smile with fresh corneal lenticule implantation|"VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule.~The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.~In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values."
214345670|NCT06574256|OTHER|Chemotherapy symptom Management Online Education|"Randomization was achieved and data collection began. Patients were given the Chemotherapy Symptom Management Education Booklet and were informed that they would be contacted by phone.~In the second and third stages of data collection, they were called by phone on the 7th day after receiving chemotherapy treatment. The symptoms experienced by the patient were evaluated with the N-SDS and the quality of life was evaluated with the EORTC QLQ-C30. Online nursing education videos were sent to the women in the intervention group regarding the symptoms they experienced. The practices they performed from the suggestions in the education videos and education booklets sent were recorded on the nurse follow-up form.~In the fourth stage, the practices specified in the third stage were repeated on the 7th day after the third chemotherapy course, and at this stage, the satisfaction of the women in the intervention group with the online education was evaluated."
214345671|NCT02198547|DRUG|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
214345672|NCT02198547|DRUG|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
214345673|NCT06572254|OTHER|Early Childhood Development Newborn Parenting Education Program|Investigators will be adapting the model used here at the tertiary care of newborn parenting which investogators have developed based on the nurturing care framework and keys to the caregiving framework. Both models have shown reliable evidence of their effectiveness.
214345674|NCT04642105|DEVICE|Sensor-Dot and Plug 'n Patch system|We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
214345675|NCT01915563|PROCEDURE|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
214345676|NCT02040597|DRUG|Beclometasone/Formoterol/Glycopyrrolate|
214678485|NCT05141526|OTHER|Conventional restrictive intervention + non-restrictive satiating intervention|Diet group with a calorie deficit during the first phase followed by a diet containing satiating foods in the second phase
214953908|NCT01387945|BEHAVIORAL|HBPM+website+patient navigator|In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
214953909|NCT01234701|OTHER|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
214953910|NCT01234701|PROCEDURE|Liver resection|Hepatectomy with an intention to cure
214953911|NCT01234701|OTHER|Histopathology diagnosis of resected liver specimen|Histopathology diagnosis by expert pathologist.
214953912|NCT05637190|OTHER|Expressive Arts Therapy group intervention|Art is helpful to reduce negative emotions and boost self-worth during the creative process. During the Expressive Arts Therapy workshops, participants experience different art forms, including visual art, body movement, writing, music, and guided imagery to identify the inner self and get in touch with the self to release suppressed emotions and stress.
214953913|NCT02546596|DEVICE|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
214953914|NCT02710552|DRUG|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
214953915|NCT02710552|DRUG|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
215077379|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + deep sea water|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a supplementation composed by deep sea water
215077380|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + Placebo|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
214345677|NCT06259344|BEHAVIORAL|Fractioned Pain Science Education (FPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 2 sessions of 45 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
214345678|NCT06259344|BEHAVIORAL|Full Dosage Mode Pain Science Education (FDPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 6 sessions of 15 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
214345679|NCT06259344|OTHER|Manual Therapy|Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
214345680|NCT06259344|OTHER|Orofacial and Neck Exercises (ONE)|"Orofacial Exercises: Mandibular body-condylar cross-pressure chewing technique; Post-isometric relaxation stretches-laterotrusion and opening (10 times/session; 10 seconds).~Neck Motor Control Exercises: Bracing exercises (6 hierarchical levels - HL). Extreme range of motion exercises (stable spine). Cervical isometric exercises (5 HL) directly forward, obliquely, toward right and left, and directly backward (stable spine - elastic resistive bands). Functional training with elastic resistance and exercise balls on unstable surfaces (8 HJ). The progress in each exercise domain will happen when sustaining the contraction for 10 seconds, 10 times."
214953916|NCT06046131|OTHER|Standard care|"Extra blood collection for dosages Urine collection for the dosage of non-persistent pollutants, isolation of extracellular vesicles released in urine, analysis of the microbiome, metagenomics to obtain a complete description of the bacterial functions represented as well as other microorganisms present, metabolome profiling and identification and/or assays of any other biological compound of interest strictly related to the specific objectives of the research.~Saliva collection for the extraction of the constitutional DNA. An interview using a structured questionnaire A quality of live auto-questionnaire"
214345681|NCT01524640|BIOLOGICAL|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
214345682|NCT01524640|BIOLOGICAL|Placebo|1.5 ml oral administration on day 0 and day 14
214953917|NCT02582697|DRUG|Bleomycin (active name: Bleomycin Sulfate)|"Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.~Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses."
214953918|NCT02582697|DRUG|Etoposide|"Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
214953919|NCT02582697|DRUG|Cisplatin|"Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
214345683|NCT02874547|BEHAVIORAL|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
214345684|NCT01903447|DRUG|SSRI|
214345685|NCT01903447|BEHAVIORAL|CBT|
214345686|NCT05901129|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
214345687|NCT04407663|OTHER|Telemedicine to remote outpatient visit in bariatric patient|Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
214345688|NCT05640934|DRUG|Melatonin|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
214953920|NCT02582697|DRUG|Pegylated G-CSF (Pegfilgrastim)|Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
214953921|NCT02582697|DRUG|Filgrastim|"Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 21-day cycle for 4 cycles.~Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 14-day cycle for 4 cycles."
214953922|NCT03564093|DRUG|Intranasal Drug|1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
214953923|NCT03564093|DRUG|Intranasal Drug|Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
215077381|NCT06600243|DIETARY_SUPPLEMENT|Control + deep sea water|A group that will maintain their usual live and at the same time will receive a supplementation composed by deep sea water
214345689|NCT05640934|DRUG|Placebo|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
214345690|NCT01451294|DRUG|Administration of phenylephrine|Phenylephrine: 50-100µg
214345691|NCT01451294|DRUG|Administration of ephedrine|Ephedrine: 5- 10 mg
214345692|NCT05626192|OTHER|Anatomical dissection and Immunohistochemical techniques|Anatomical dissection and description
214345693|NCT01898195|DRUG|Varenicline|Varenicline will be provided for three months.
214345694|NCT01898195|BEHAVIORAL|Text Message|Text messages will be developed twice daily for three months
214345695|NCT01898195|BEHAVIORAL|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
214345696|NCT02259608|BIOLOGICAL|BCG vaccine SSI|BCG vaccination
214345697|NCT06208618|OTHER|Education and Motivational Interviews|"The diabetes education aimed at supporting diabetes self-management in adolescents will include the following topics:~* What is Diabetes?~* Treatment in Diabetes~* Insulin Therapy~* Nutritional Therapy~* Physical Activity/Exercise~* Acute Complications of Diabetes~  * Hypoglycemia~ * Hyperglycemia~ * Diabetic Ketoacidosis~* Diabetes Management in Illness~Motivational interviews will consist of the following stages:~* First Meeting - Pre-awareness (Pre-contemplation)~* Second Meeting - Awareness (Contemplation)~* Third Meeting - Preparation~* Fourth Meeting - Taking Action (Action)~* Fifth Meeting - Maintenance~* Sixth Meeting - Termination or Review"
214345698|NCT02720484|OTHER|Laboratory Biomarker Analysis|Correlative studies
214345699|NCT02720484|DRUG|Nivolumab|Given IV
214345700|NCT02278276|DRUG|sodium polysulthionate|Bioavailable composition of α-sulfur
214345701|NCT02278276|DRUG|Placebo|400 mg capsules containing placebo
214345702|NCT01503905|DRUG|Docetaxel|75mg/m2, iv injection, day1, every 21 days
214345703|NCT01503905|DRUG|epirubicin|80mg/ m2, iv injection, day1, every 21 days
214345704|NCT01503905|DRUG|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
214345705|NCT01503905|PROCEDURE|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
214345706|NCT01503905|DRUG|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
214345707|NCT01503905|DRUG|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
214345708|NCT01503905|DRUG|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
214345709|NCT01503905|RADIATION|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
214345710|NCT01503905|DRUG|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
214953924|NCT05013281|PROCEDURE|Suprachoroidal hemorrhage associated with pars plana vitrectomy|SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.
214953925|NCT00212316|DRUG|sodium phenylbutyrate|
214953926|NCT03004924|DRUG|SHP640|Instill 1 drop of SHP640 (povidone-iodine \[PVPI\] 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
214345711|NCT01503905|DRUG|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
214345712|NCT01642797|DEVICE|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
214345713|NCT01642797|DEVICE|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
214345714|NCT01812044|DRUG|subtenons anesthetic - preservative-free bupivacaine 0.75%|
214345715|NCT01812044|DRUG|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
214345716|NCT01812044|DRUG|topical control - 0.5 cc of Hypromellose 0.3% gel|
214345717|NCT01812044|DRUG|subtenons control - 0.5 cc of Normal Saline|
214345718|NCT02755389|DRUG|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
214345719|NCT02755389|DRUG|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
214345720|NCT02755389|DRUG|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
214345721|NCT03286023|RADIATION|stereotactic radiotherapy|stereotactic radiotherapy for brain metastases
214345722|NCT05070897|OTHER|Questionnaires|"* Approved French version of the FCCHL scale~* Questionnaire on the use of digital tools adapted from the questionnaire on digital tools"
214345723|NCT05039268|DRUG|3K3A-APC Protein|3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
214345724|NCT05599594|OTHER|Aromatherapy|6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.
214678486|NCT05141526|OTHER|Control group|This group will receive minimal healthy guidelines
214678487|NCT05314348|DEVICE|High-density surface EMG|High-density surface EMG for fasciculation detection
214953927|NCT03004924|DRUG|PVP-I 0.6%|Instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
214953928|NCT03004924|DRUG|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
214345725|NCT01617629|BIOLOGICAL|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
214345726|NCT02500225|DRUG|Etomidate|0.2 mg/kg etomidate
214345727|NCT02500225|DRUG|Sevoflurane|8% Sevoflurane
214345728|NCT05861544|DIETARY_SUPPLEMENT|Pomegranate juice|The pomegranate juice that will be used in the experiment is a 100% natural product without conservatives. It will kindly be donated from the company Rodi Hellas SA, Pella, Greece. The product is in line with the quality assurance certificates by the International Organization for Standardization (ISO 22000:2005), Global Gap, Grasp and Kosher.
214953929|NCT01173419|DEVICE|VNUS RF ClosureFAST|VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.
215077382|NCT06600243|DIETARY_SUPPLEMENT|Control + Placebo|A group that will maintain their usual live and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
215077383|NCT06606236|OTHER|H2O2 at 35% for 8 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
214345729|NCT03325413|BEHAVIORAL|Systematic inclusion of family members|Systematic inclusion of family members/ reference person in the perioperative process
214345730|NCT03325413|BEHAVIORAL|Preoperative information|Detailed preoperative information about delirium prevention and procedures
214953930|NCT01173419|DEVICE|VenaCure EVLT NeverTouch|Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
214953931|NCT00309790|DRUG|sildenafil|
214953932|NCT03570008|BEHAVIORAL|9 days spa residential program|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
214953933|NCT03570008|BEHAVIORAL|3 sessions of 10 minutes per day of physical exercise|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
215077384|NCT06606236|OTHER|H2O2 at 40% for 20 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
215077385|NCT06606236|OTHER|H2O2 at 25% plus cold blue light for 15 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
215077386|NCT06605521|PROCEDURE|Subclavian lymph node dissection+radiotherapy|The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.
215077387|NCT06605521|PROCEDURE|Simple clavicular region radiotherapy|If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.
215077388|NCT06605716|PROCEDURE|Enucleation of cysts|Surgical removal of cystic structures larger than 1 cm in patients included in the study arms. Patients were monitored for TCR during the procedure.
214345731|NCT03325413|BEHAVIORAL|Physical and breathing exercises|Preoperative execution of physical and breathing exercises if necessary
214345732|NCT03325413|DIETARY_SUPPLEMENT|Dietary supplements|Dietary supplements if necessary
214345733|NCT03325413|OTHER|Evaluation of long-term medication|Avoidance of unsuitable drugs for elderly if possible
214345734|NCT03325413|PROCEDURE|Regional anesthesia|Regional anesthesia whenever possible
214345735|NCT03325413|OTHER|Personal aids|Personal orientation aids until anesthesia induction
214345736|NCT03325413|DEVICE|Temperature management|Perioperative warming
214345737|NCT03325413|DEVICE|Neurmonitoring|Using Bispectral index (BIS) to measure the depth of anesthesia
214345738|NCT03325413|PROCEDURE|Pain catheter|A pain catheter will be used as postoperative pain therapy if possible
214345739|NCT01337245|DRUG|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
214345740|NCT03223558|BEHAVIORAL|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
214345741|NCT01663636|BEHAVIORAL|SMS message reminding mothers to come for their scheduled vaccines|Reminder
214345742|NCT05267301|DIETARY_SUPPLEMENT|AlmegaPL (FDA NDIN # 826)|The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.
214345743|NCT06531746|OTHER|Extracorporeal shock wave|"participants will receive 2000 ESWT impulses, with 1500 targeting the taut band and 500 surrounding the taut band, with an energy flux density of 0.10 mJ/mm and frequency of 8 Hz, by using an~EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number:~EM12681015\], Italy, shock wave generator."
214345744|NCT06531746|OTHER|Selected physical therapy program|Stretching and strengthening of Iliopoas muscle and Stretching and strengthening of Lower back muscles
214953934|NCT06426160|DRUG|Tocilizumab 20 MG/ML [Actemra]|Tocilizumab 8 mg/kg every four weeks for 24 weeks.
214345745|NCT05427331|DRUG|FMT capsule|Patients with insomnia need to take FMT capsules orally in an empty stomach in the morning, 16 capsules once a week, for 4 consecutive weeks
214345746|NCT01273272|BEHAVIORAL|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
214953935|NCT06426160|DRUG|Sodium Chloride 0.9% Inj|Placebo (Sodium chloride) every four weeks for 24 weeks.
214953936|NCT03152994|OTHER|Checking fasting blood glucose(FBG)|This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
214953937|NCT02816541|OTHER|Pelvis Retroverted|Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
214345747|NCT01273272|BEHAVIORAL|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
214345748|NCT02091804|BEHAVIORAL|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
214345749|NCT02091804|BEHAVIORAL|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
214345750|NCT06146322|OTHER|WR|Unsweetened preload condition: 240 mL white glutinous rice, 250 kcal, 0 g β-glucan
214345751|NCT06146322|OTHER|LB|Unsweetened preload condition: 240 mL low β-glucan barley, 250 kcal, \~4 g β-glucan
214345752|NCT06146322|OTHER|MB|Unsweetened preload condition: 240 mL medium β-glucan barley, 250 kcal, \~5 g β-glucan
214345753|NCT06146322|OTHER|HB|Unsweetened preload condition: 240 mL high β-glucan barley, 250 kcal, \~6 g β-glucan
214345754|NCT06146322|OTHER|WR+50g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL white glutinous rice + 50g HFCS, 391 kcal, 0 g β-glucan
214345755|NCT06146322|OTHER|LB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL low β-glucan barley + 50 g HFCS, 391 kcal, \~4 g β-glucan
214345756|NCT06146322|OTHER|MB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL medium β-glucan barley + 50 g HFCS, 391 kcal, \~5 g β-glucan
214345757|NCT06146322|OTHER|HB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL high β-glucan barley + 50 g HFCS, 391 kcal, \~6 g β-glucan
214345758|NCT06057246|OTHER|Test meal with postprandial samples|The mixed-nutrient test meal consists of a sandwich made with bread, spread cheese, air-cured beef, and one apple. Nutritional composition of the meal will be: total energy (TE) content 532 kcal, carbohydrates 68,4 g (49.3% TE), total fat 17.1 g (29.5% TE), protein 27.8 g (21.4% TE), and fibre 6 g. Before and over 4 hours after the meal, venous blood samples will be taken for biochemical evaluations at the time points -15'; 0'; 15'; 30'; 60'; 120'; 180'; 240'.
214953938|NCT02816541|OTHER|Pelvis in Neutral Position|Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
214953939|NCT02816541|OTHER|Aerobic exercise|Aerobic exercises (walking) performed on a treadmill.
214953940|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214953941|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214953942|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214953943|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
215077389|NCT06661330|OTHER|Behavioral Treatment|Participants followed a 6-month hypocaloric Mediterranean-style diet, reducing energy intake by approximately 600 kcal/day. The diet emphasized fruits, vegetables, whole grains, and fish, while limiting red meat and processed foods. Additionally, participants were required to perform moderate physical activity, including 50 minutes of aerobic exercise, 3 times a wee
215077390|NCT06658288|OTHER|Rebound Training|12 participants will be in experimental group A giving them rebound training.
215077391|NCT06658288|OTHER|Theraband resistance exercise|12 participants will be in experimental group A giving them theraband resistance exercise with different band resistnce.
214345759|NCT02973451|DRUG|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
214345760|NCT02973451|DRUG|local Bupivacaine|Bupivacaine Trocar Site Infiltration
214345761|NCT03832946|DRUG|GB0139|GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
214345762|NCT03832946|DRUG|Placebo|Placebo is administered as inhalation once a day
214345763|NCT01079520|PROCEDURE|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
214678488|NCT05314348|DEVICE|Ultrasound|Ultrasound for fasciculation detection
214345764|NCT01079520|PROCEDURE|Mediastinoscopy|Traditional surgical method to stage lung cancers
214953944|NCT04519762|DRUG|Glycophos (Sodium Glycerophosphate)|Management of hypophosphatemia via Glycophos Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
214345765|NCT06112236|OTHER|no intervention|no intervention
214345766|NCT02972099|DEVICE|TcPRF|Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.
214953945|NCT04519762|DRUG|Antibiotics|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
214953946|NCT04519762|DRUG|Inotropes|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
214953947|NCT05041777|DEVICE|Optical Coherence Tomography|OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. \[2\] In such ways, microscopic details of lesions and tissues can be visualized. This information could be used to identify a lesion as BCC, and further specify the subtype. Therefore, the use of the OCT can reduce the number of biopsies and the accompanying morbidity.
214953948|NCT03300713|OTHER|MOCITRAINING program|The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.
214953949|NCT03300713|OTHER|usual follow-up|usual follow-up
214953950|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 90 mcg/actuation|E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period
214345767|NCT02972099|DEVICE|Placebo|In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
214345768|NCT05430529|BEHAVIORAL|Standard Smoke Cessation Service|Both of the intervention group and control group will receive standard smoke cessation service, which is same as usual practice.
214345769|NCT05430529|BEHAVIORAL|Short Advice for Control Group|If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.
214678489|NCT02061007|DRUG|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
214678490|NCT02061007|DRUG|Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
214678491|NCT02061007|PROCEDURE|Surgical Resection of Melanoma Metastases|Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
214678492|NCT02383719|DEVICE|Oro-nasal Mask|
214678493|NCT01351519|DRUG|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
214953951|NCT01025648|DRUG|E004 Placebo|E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period
214953952|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 125 mcg|E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
214953953|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 220 mcg|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
214953954|NCT01025648|DRUG|epinephrine inhalation aerosol, CFC propelled|epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
214345770|NCT05430529|BEHAVIORAL|Brief Alcohol Intervention for Intervention Group|"During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to the intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~In addition, HCPs can choose to discuss with participants the reasons for consuming alcohol.~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants."
214345771|NCT04617028|DRUG|Jaktinib|Jaktinib Hydrochloride Tablets administered orally twice daily
214345772|NCT04617028|DRUG|Placebo to match Hydroxycarbamide|Placebo to match Hydroxycarbamide Tablets administered orally twice daily
214345773|NCT04617028|DRUG|Hydroxycarbamide Tablets|Hydroxycarbamide Tablets administered orally twice daily
214345774|NCT04617028|DRUG|Placebo to match Jaktinib|Placebo to match Jaktinib Tablets administered orally twice daily
214345775|NCT04848766|DRUG|De-escalation Treatment Strategy of dual antiplatelet therapy|Patients receive de-escalation treatment of dual antiplatelet therapy after percutaneous coronary intervention
214345776|NCT01153594|BEHAVIORAL|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
214345777|NCT06626087|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
214345778|NCT06626087|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LIRADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
214345779|NCT00346008|GENETIC|mutation analysis|
214345780|NCT00346008|OTHER|high performance liquid chromatography|
214345781|NCT00346008|OTHER|laboratory biomarker analysis|
214345782|NCT00346008|OTHER|questionnaire administration|
214345783|NCT01314040|OTHER|Run in diet|Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other
214345784|NCT01314040|OTHER|High meat protein diet|Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.
214953955|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 160 mcg|E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
214953956|NCT05843032|DIAGNOSTIC_TEST|3D ultrasound, MRI, resected specimen examination by surgeon|3D ultrasound and MR scanning of the resected tongue tumor will be performed. The resected surgical specimen will also be examined by the surgeon to assess the margins. The accuracy of the margin assessment by 3D ultrasound, MRI, and surgeon examination will be evaluated by correlating the results to the final histopathology findings.
214953957|NCT06145113|DEVICE|Continuous positive airway pressure (CPAP), ResMed AirMini|Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.
214953958|NCT05266859|OTHER|Calcium hydroxide|Calcium hydroxide in the power/liquid form will be used and placed on the exposed pulp
214345785|NCT01314040|OTHER|High dairy protein diet|Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy
214953959|NCT05266859|OTHER|MTA|Mineral trioxide aggregate will be used as a powder / liquid form and placed over the exposed pulp
214345786|NCT01314040|OTHER|High grain protein diet|Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
214345787|NCT06348784|DIAGNOSTIC_TEST|Assesment of Different NEoplasias in the adenexa model|The ADNEX model includes nine parameters; Age, CA-125 level, Oncology center (yes/no), and 6 ultrasound features which are maximal diameter of the lesion, maximal diameter of the largest solid part, more than 10 locules (yes/no), number of papillary projections (0/1/2/3/more than 3), acoustic shadow, and ascites
214345788|NCT06348784|DIAGNOSTIC_TEST|Risk of malignancy index|The RMI was measured as follows; Menopausal status (score is 3 as all patients were postmenopausal X Ultrasound score is based on assessment of 5 features and with the presence of one feature, the score is 1 while if more than one feature is present, the score is 3; the five ultrasound features are the presence of solid components, multilocularity, bilaterality, ascites, and metastases X CA - 125 level
214345789|NCT06348784|DIAGNOSTIC_TEST|Histopathologic examination|Histopathologic examination of all excised specimens was done as this is the gold standard test for detecting ovarian malignancy
214345790|NCT04202380|DRUG|Azithromycin|Patients will receive Azithromycin orally 1000 mg
214345791|NCT04202380|DRUG|Ampicillin|All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
214345792|NCT04202380|DRUG|Azithromycin|Azithromycin 500 mg orally once
214345793|NCT04202380|DRUG|Azithromycin|Azithromycin 250 mg orally daily for 4 days
214953960|NCT05266859|OTHER|PRF|PRF will be placed directly over the exposed pulp
214953961|NCT02608814|PROCEDURE|Pleural biopsy sampling|6 - 8 pleural biopsy samples will be taken before the insertion of the chest drain. These samples will be sent to microbiology for examination.
214953962|NCT02608814|OTHER|Ultrasound|
214953963|NCT04396522|DEVICE|noninvasively Bio-electrical Impedance Analysis (BIA)|By means of noninvasively Bio-electrical Impedance Analysis (BIA) to measure body composition, which divides body weight into different components such as lean body mass and fat mass.
214953964|NCT00921713|OTHER|Oncology Nurse Care Management|
215077392|NCT06662370|OTHER|Replacement of the esophagus with a decellularized human esophagus graft|The Decellularized Human Esophagus (DHE) will be surgically implanted under general anesthesia via right or left thoracotomy or cervicotomy, depending on the location of the stenosis, to replace the esophageal defect created by resection of the stenosis. An omentoplasty is performed laparoscopically beforehand to provide secondary coverage of the graft area. A temporary esophageal stent is placed endoscopically to cover the DHE and the two anastomoses for a period of 3 months, to prevent the development of an anastomotic fistula and stenosis of the graft area.
214345794|NCT04437251|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
214953965|NCT00921713|OTHER|Patient-centered materials|
214345795|NCT01881139|BEHAVIORAL|exercise training|
214345796|NCT00136955|DRUG|Irinotecan|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
214345797|NCT06223412|BEHAVIORAL|video-based climate change program|The participants in this group received a series of short videos, ranging between 30- 45 minutes/ each video revolved around five core themes including The road start to green planet, The ripple effect climate change on Health, Climate Change Literacy, Strengthen resilience to overcome climate related- psychological impacts, and Sustaining phase: closing session.
214345798|NCT05462366|OTHER|Sample collection|Collect breast-milk and feces from mother-infant-pairs.
214345799|NCT00672048|OTHER|Computer Tablet|A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
214345800|NCT00672048|OTHER|Continuing Education Course|Annual standard continuing education
214345801|NCT00672048|OTHER|Continuing education|Annual standard continuing education materials
214345802|NCT06241404|PROCEDURE|trigger point therapy|patients who have been treated for shoulder tendinopathy by trigger point therapy
214953966|NCT06093971|DRUG|remimazolam|Remimazolam is administered for anesthesia induction.
214345803|NCT06241404|PROCEDURE|Exercise therapy|patients who have been treated for shoulder tendinopathy by exercise therapy
214345804|NCT04797338|DRUG|Synarel, 0.2 Mg/Inh Nasal Spray|Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.
214345805|NCT04797338|DRUG|Estrofem|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
214345806|NCT04797338|DRUG|Utrogestan|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
214953967|NCT06093971|DRUG|Propofol|Propofol is administered for anesthesia induction.
214953968|NCT02062775|PROCEDURE|Use of self-fixating mesh for inguinal hernia repair|Parietex ProGrip will be used to repair inguinal hernia
214953969|NCT02062775|PROCEDURE|Use of non-fixating mesh for inguinal hernia repair|Parietex Anatomic mesh will be used to repair inguinal hernias.
214953970|NCT02062775|PROCEDURE|Absorbable tacks may be used in hernias >2cm|Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures \>2cm
214953971|NCT05854849|DRUG|Camrelizumab|200mg, D1, Q3W, iv drip.
214953972|NCT05854849|DRUG|Gemcitabine|1000mg/m2, Day 1 and Day 8, Q3W, iv drip, maximum 6 cycles.
214953973|NCT05854849|DRUG|Cisplatin|80 mg/m2, D1, Q3W, iv drip, maximum 6 cycles.
214953974|NCT05854849|DRUG|Apatinib|250mg, PO, QD
214953975|NCT04538287|DEVICE|AtaCor StealthTrac Lead|Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
214345807|NCT04797338|DRUG|Hydroxyprogesterone Caproate|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
214345808|NCT00071669|PROCEDURE|Acupuncture|
214345809|NCT01852539|DRUG|dexmedetomidine|The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
214345810|NCT01852539|DRUG|propofol|Propofol 2.0 mg/kg was administrated
214345811|NCT01852539|DEVICE|laryngeal mask airway (LMA)|The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
214345812|NCT04966468|DEVICE|Virtual Reality|The Lenovo Mirage Solo Headset will be kept at home by the patient for the duration of the study (4 days). The VR headset will be equipped with 10 non-interactive videos and a short interactive game. The videos and the game are characterized by relaxing scenarios. The game will require the active interaction of the patient. At the end of the observational period, the investigator will download the usage data to detect information about the patient's use. Before and after each use of the VR headset, the patient will be asked to fulfil the Edmonton Symptom Assessment Scale (ESAS). On T0, the patient will be asked to wear a wearable device, the Empatica E4 wristband measuring physiological parameters. On day T1, the patient will return the VR headset and the wristband to the investigator and will fulfil again the HADS and BPI questionnaires.
214345813|NCT04966468|OTHER|Control|"The investigator will illustrate to the patient how to use the tablet for watching videos, suggesting using it especially in moments of psycho-physical discomfort. The tablet will be given to the patient for the duration of the study (four days). The tablet will be equipped with 10 non-interactive 2D videos characterized by relaxing settings with natural or artistic scenarios, giving a passive use to the patient. Before and after each use of the tablet, patient has to fullfil the ESAS digitally inserted into the tablet. Patient can answer by selecting the answer on the touchscreen. Without filling the scale, the patient will not be able to access the videos inserted in the tablet. On day T1, patient will return the tablet to the investigator and fill out the HADS and BPI questionnaires."
214345814|NCT02744534|DRUG|FACBC PET-CT Scan|"One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist."
214953976|NCT03474146|OTHER|Ocimum sanctum|Ocimum sanctum (known as Tulsi, Holy basil) is natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is one of the best examples of Ayurveda's holistic lifestyle approach to health. It is also been well practiced in traditional medicine in India and south Asian region. Literature showed that Ocimum sanctum extract have significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
214345815|NCT02744534|PROCEDURE|Three-dimensional ultrasound-guided biopsy|"A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.~The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.~This biopsy process is estimated to take about 10 minutes."
214345816|NCT02744534|PROCEDURE|Standard transrectal ultrasound (TRUS) guided biopsy|A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
214345817|NCT06530940|DIAGNOSTIC_TEST|Buccal Schirmer Test|"For each group, we will perform:~* SF measurement~* Buccal Schirmer test (BST) ."
214345818|NCT03321331|COMBINATION_PRODUCT|Lark (JITAI)|Lark works as a just-in-time adaptive intervention (JITAI), providing interactive counseling through a chat-style interface. The app prompts users to self-monitor, set goals, review them, provides feedback, and social support.
214345819|NCT03321331|COMBINATION_PRODUCT|MyFitnessPal (no JITAI)|MyFitnessPal (MFP) is a calorie counting app, which relies on user input for food tracking, but automatically tracks activity through the phone or through integrations with wearable devices. This app provides allows to set weight and caloric goals, review them and to receive feedback, but it has limited social support, a feature that is generally lacking in calorie-counting apps.
214345820|NCT05544799|OTHER|No intervention|No intervension
214345821|NCT03119454|DRUG|Diprospan|Intramuscular
214953977|NCT03474146|OTHER|Chlorhexidine Gluconate|Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. Chlorhexidine over a period of over 40 years has been thoroughly investigated and successfully used as plaque control agent in dental practice. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in variety of oral disorders in various formulations.
214345822|NCT00773968|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
214345823|NCT02263651|PROCEDURE|Quilting suture without drainage|"In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (\<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.~Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.~The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area."
214345824|NCT02263651|PROCEDURE|Conventional closure with drainage|"The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.~The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent."
214953978|NCT03474146|OTHER|Propylene Glycol|Propylene glycol or 1,2-dihydroxypropane or 1,2-propanediol, is a clear, colourless, viscous, practically odourless liquid with a density of 1.038 g/cm³ at 20 °C and a molecular weight of 76.095. It is miscible with water, acetone and chloroform. It is miscible in water. Propylene glycol is commonly used as an excipient in a variety of drugs and it is also authorised in food products and cosmetics.
214953979|NCT00813436|DRUG|Oxytocin (also: syntocinon, pitocin)|24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
214345825|NCT02100982|OTHER|Customized Care|Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
214345826|NCT02100982|OTHER|Care As Usual|Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
214953980|NCT00813436|DRUG|Placebo|saline liquid, intranasally administered
214953981|NCT00550264|OTHER|Automatic notification of readmissions|The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
214953982|NCT01756248|DRUG|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
214953983|NCT02033200|DRUG|Stendra 200 mg|
214953984|NCT02033200|DRUG|Placebo|
214953985|NCT01622725|PROCEDURE|Placing the resorbable mesh|Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
214953986|NCT01622725|PROCEDURE|Non-resorbable synthetic mesh.|Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
214953987|NCT05267223|OTHER|Semi-structured interviews|Semi-structured interviews with individuals with paraplegia
214953988|NCT05454254|OTHER|Individualised muscle strengthening exercise training protocol.|Based on the results of muscle function tests at baseline an individualised exercise protocol will be designed.
214953989|NCT05403528|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and retention/generalization as 2D
214953990|NCT05403528|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 3D
214953991|NCT05403528|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
214953992|NCT02670382|DIETARY_SUPPLEMENT|EPA|10 week supplementation
214953993|NCT02670382|DIETARY_SUPPLEMENT|DHA|10 week supplementation
214953994|NCT02670382|DIETARY_SUPPLEMENT|sunflower oil|4-week lead-in
214953995|NCT03244618|DEVICE|CSSP Toothpaste|Toothpaste containing calcium silicate, sodium phosphate and sodium monofluorophosphate
214953996|NCT03244618|DEVICE|Fluoride Toothpaste|Toothpaste containing sodium monofluorphosphate
214953997|NCT02771600|DEVICE|Buzzy|See arm description
214953998|NCT02771600|DRUG|Topical anaesthetic cream|See arm description
214953999|NCT02003456|DRUG|Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82|Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
214954000|NCT01354548|DEVICE|TheraBite® Jaw Motion Rehabilitation System™|A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
214954001|NCT02209025|DIETARY_SUPPLEMENT|Theobromine|Theobromine a compound for cocoa
214345827|NCT03562000|DEVICE|Cough Assistance and Systematic Non-Invasive Ventilation|"A standardised bundle of intervention will be tested using the combination of two medical devices previously used in daily clinical practice but without guideline and objective selection criteria, namely:~1. A mechanical cough assistance technic using the Cough Assist device (Model E70® by Philips Respironics, Carlsbad, CA, USA) before extubation then after extubation then 3 times a day (with possible additional treatment on demand) during 7 days maximum (with a possible cessation if the patient has strictly no bronchial overload during three consecutive physiotherapy sessions)~2. A systematic Non-Invasive ventilation during 24h minimum to indirectly improve the clearance of bronchial overload and to reduce the overall risk of re-intubation related a relative hypoventilation associated to the weak cough."
214954002|NCT02209025|DIETARY_SUPPLEMENT|Placebo drink|
214345828|NCT03562000|PROCEDURE|control group using the current gold standard of care after extubation, namely the manual drainage by a physiotherapist and the consensual use of Non-invasive ventilation|"1. After extubation, the physiotherapy will be managed according to standard care and cough assistance will be only manual. The use of a dedicated cough assistance device will be allowed if the bronchial overload clearance is repeatedly insufficient according to the physiotherapist in charge.~2. Non-invasive ventilation will not be systematic and only used in case of pre-defined condition, such as: age \> 65 years-old, BMI \> 30, Chronic cardiac failure, COPD, hypercapnia at the end of the weaning trial, post-operative admissions after abdominal and thoracic surgery."
214954003|NCT02200991|DRUG|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
214954004|NCT02200991|DRUG|Sitagliptin|Pharmaceutical form:tablet Route of administration: oral
214954005|NCT02200991|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
214678494|NCT06390618|OTHER|Aerobic Exercise (AE) Group|"A total of 24 sessions of aerobic exercise will be performed in 8 weeks, 3 days a week.~For aerobic exercise, a moderate intensity (50-60%) aerobic exercise program will be applied using the karvonen method. According to the aerobic exercise intensity karvonen method, the formula (Maximal Heart Rate (220-years) - Resting Heart Rate) x 50-60% + Resting Heart Rate) will be used. 1-4. week 50%, 5-8. Exercise intensity will be increased by 60% per week."
214678495|NCT06390618|OTHER|Combined Exercise (CE) Group|"In the combined exercise group, biopsychosocial exercise will be performed in addition to aerobic exercise.~In the combined exercise group, in addition to aerobic exercise (3, 8 weeks, 24 sessions of aerobic exercise per week), 16 sessions of biopsychosocial-based group exercise treatment will be performed 2 days a week for a total of 8 weeks.~BETY approach will be used in group exercise treatment."
214954006|NCT02397434|RADIATION|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
214954007|NCT01611428|DRUG|Ipragliflozin|Oral and Intravenous (i.v.)
214954008|NCT01762449|OTHER|Followup survey|
214954009|NCT06730165|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation of the vagus nerve through the tragus and concha in the ear
214954010|NCT06730165|DEVICE|Transcutaneous Auricular Trigeminal Nerve Stimulation|Stimulation of the trigeminal nerve via the auriculotemporal nerve with a clip electrode from the upper auricle
214954011|NCT05459194|DEVICE|RP - TA|randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
214954012|NCT05186259|DIAGNOSTIC_TEST|Self-reported signs of central sensitization|Self-reported signs of central sensitization by means of the Central Sensitization Inventory (questionnaire)
214954013|NCT05186259|DIAGNOSTIC_TEST|Objective signs of central sensitization|Objective signs of central sensitization by means of Quantitative Sensory Testing (mechanical and heat detection and pain thresholds, endogenous pain facilitation and inhibition)
214954014|NCT05186259|DIAGNOSTIC_TEST|Audiological outcome measures (audiometry, tinnitus analysis, uncomfortable loudness) in tinnitus patients with and without pain|"* Audiometry Performance of pure tone audiometry according to the modified Hughson-Westlake method~* Tinnitus analysis Measurement of psychoacoustic features of tinnitus, including (1) tinnitus pitch, (2) loudness, (3) masking ability, and (4) residual inhibition.~* Uncomfortable Loudness measures Performance of Uncomfortable Loudness measurements to evaluate the presence of hyperacusis. ."
214345829|NCT02763527|BEHAVIORAL|Smoking reduction|A brief intervention on smoking reduction plus a smoking reduction leaflet
214345830|NCT02763527|BEHAVIORAL|Smoking Cessation|A brief advice on quitting plus a leaflet on smoking cessation
214345831|NCT02460718|BEHAVIORAL|ENCOURAGE Study|This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
214345832|NCT00629187|DRUG|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
214678496|NCT02768909|DEVICE|E-Nose|1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
214954015|NCT05186259|DIAGNOSTIC_TEST|Cognitive functioning|"Evaluation of cognitive functioning by means of:~* Auditory Stroop test~* Detecting letters task~* Letter-number sequencing task"
214954016|NCT05186259|DIAGNOSTIC_TEST|Listening effort|Evaluation of listening effort by means of the modified version of the behavioral listening effort test based on a dual-task paradigm by Degeest, Keppler \& Corthals (2018) .
214345833|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 1|Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose
214954017|NCT05186259|DIAGNOSTIC_TEST|Self-reported psychological factors|"Evaluation of psychological factors by means of:~* Depression, Anxiety and Stress Scale (DASS-21)~* Beck Depression Inventory (BDI)~* Big Five Inventory (BFI)~* Connor-Davidson Resilience Scale"
214954018|NCT05186259|DIAGNOSTIC_TEST|Self-reported lifestyle factors|"Evaluation of lifestyle factors by means of:~Baecke Questionnaire Pittsburg Sleep Quality Index Insomnia Severity Index Stress subscale of the DASS 21"
214345834|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 2|Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose
214954019|NCT05186259|DIAGNOSTIC_TEST|Self-reported measure of pain processing|Evaluation of self-reported pain processing by means of the Pain Catastrophizing Scale
214345835|NCT05976282|OTHER|Fecal Immunochemical Test|The Fecal Immunochemical Test (FIT) is self-administered one-time for participants, per standard of care. This allows participants to obtain their own stool specimens from bowel movements without having a regular colorectal screening procedure in the doctor's office. Participants will use the FIT at the time of their next bowel movement and return their specimens to the laboratory by mail on the same or next day.
214345836|NCT05976282|OTHER|Septin9 Test|Septin9 (SEPT9) is a blood-based test that will be offered to eligible participants one-time who refused the FIT. Participants will undergo a blood draw collected by a nurse or certified phlebotomist, 90 days after their refusal of the initial offer of FIT.
214345837|NCT03640351|DRUG|1. Use of preservative free diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
214954020|NCT05186259|DIAGNOSTIC_TEST|Self-reported quality of life|Self-reported quality of life by means of the SF-36 questionnaire
214954021|NCT05186259|DIAGNOSTIC_TEST|Self-reported tinnitus severity and impact on daily life|Evaluation of self-reported tinnitus severity and impact on daily life by means of the Tinnitus Functional Index
214954022|NCT05186259|DIAGNOSTIC_TEST|Self-reported hyperacusis|Evaluation of self-reported characteristics of hyperacusis by means of the Hyperacusis Questionnaire
214954023|NCT05186259|DIAGNOSTIC_TEST|Self-reported tinnitus characteristics|Evaluation of self-reported tinnitus characteristics by means of the Tinnitus Sample Case History Questionnaire
214345838|NCT03640351|DRUG|2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
214345839|NCT03640351|DRUG|3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
214345840|NCT06961825|DIETARY_SUPPLEMENT|Dietary Supplement|complete, semi-elemental formula for tube feeding and orla intake based on peptides, in powder form, low in fat (32% of energy), high in MCTs (\>90% of total fat) free of fiber and gluten
214678497|NCT02768909|OTHER|Survey & Physical Exam|2\. Perform a oriented survey for risk factors and a complete physical exam.
214678498|NCT02768909|OTHER|Chest X-ray|Perform anteroposterior chest X-ray
214678499|NCT02768909|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear and Culture in L-J.
214678500|NCT02768909|DEVICE|Follow Up 5 days after beginning of Tx.|"Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
214954024|NCT05186259|DIAGNOSTIC_TEST|Self reported neck pain related disability|Evaluation of self-reported neck pain related disability using the Neck Disability Index
214954025|NCT05912985|OTHER|different oxygenation methods|Different oxygenation methods are used in bronchoscopy procedures under sedation.
214954026|NCT05292612|BEHAVIORAL|iCBT(C&W) for SAD|iCBT(C\&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.
214954027|NCT01724684|OTHER|Telehealth program|
214954028|NCT01724684|OTHER|Usual care|
214954029|NCT01863732|BIOLOGICAL|Secukinumab|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
214954030|NCT01863732|OTHER|Placebo (Pbo)|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
214954031|NCT02342600|DRUG|Pazopanib|A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
214954032|NCT02342600|DRUG|Trametinib|A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
214954033|NCT03567161|PROCEDURE|Cavitron ultrasonic surgical aspirator|"Cavitron Ultrasonic Surgical Aspirator (CUSA) has proven to be effective in biofilm disruption and cell stimulation . The hypothesis is that the employment of CUSA for non-surgical treatment of infrabony defects thanks to its abilities to disrupt, fragment and aspirate granulation tissue, will allow the formation of larger and more stable blood clot.~According to the anatomy of the osseous sites, the sonotrode (Sonocare 300 by Söring GmbH, Justus-von-Liebig-Ring 2 -25451 Quickborn Germany) will be inserted both intrasulcularly and trans gingivally (smallest tip is 0,8 mm); intrasulcularly in the cases of three wall defects, and trans gingivally in cases of one to two wall defects ."
214954034|NCT05921240|OTHER|observational study, no intervention|no intervention
214345841|NCT06962618|BEHAVIORAL|Music Motion Group|"Participants will engage in personalized, home-based motor training programs tailored to their individual goals. Each will wear a wireless Inertial Measurement Unit (IMU) on the targeted body part, which transmits movement data via Bluetooth to a tablet app. The training emphasizes task specificity and intensity, with five virtual check-ins to review progress and adjust training parameters.~The intervention studied is extrinsic feedback; the app analyzes movement data and provides feedback through music. Before each training session, the app guides participants to set personalized intensity thresholds based on current capacity. When participants meet the intensity threshold, musical elements (e.g., drumbeats, vocals) play. If they fall short, elements drop out, providing knowledge of erroneous performance."
214345842|NCT06962618|BEHAVIORAL|Control|Participants will follow personalized, home-based motor training programs designed like the Music motion group. They will wear a wireless Inertial Measurement Unit (IMU) on the targeted body part, transmitting movement data via Bluetooth to a tablet app. However, unlike the Music Motion Feedback group, participants in the Control group will not receive any extrinsic feedback during their training.
214345843|NCT06128616|DEVICE|ESWT|Extracorporeal Shock Wave Therapy
214345844|NCT06128616|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
214486640|NCT04947475|BEHAVIORAL|SBIRT|First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded.
214678501|NCT02768909|DEVICE|Follow Up 15 days after beginning of Tx.|"Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
214678502|NCT02768909|DEVICE|Follow Up 30 days after beginning of Tx.|"Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
214678503|NCT02768909|DEVICE|Follow Up 60 days after beginning of Tx.|"Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
214954035|NCT02795936|PROCEDURE|Cardiac rehabilitation|Perform exercise prescription for 12 weeks
214678504|NCT05170191|BEHAVIORAL|Sleep Deprivation|The participants will stay awake for 24 hours.
214678505|NCT03920605|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
214954036|NCT03972241|DEVICE|foot insole|arch support and toe extension
214954037|NCT02350088|DRUG|probiotics|probiotics
214954038|NCT02350088|DRUG|placebo|placebo
214954039|NCT06330571|DEVICE|Molar distalization by aligners with attachment|"1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner.~4. Aligners will be fabricated on 3d printed models.~5. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~6. Patient will receive the following aligner after 2 weeks.~7. Follow up visits every 4weeks until 6 months."
214954040|NCT01836185|DRUG|Evacetrapib|
214954041|NCT01473225|OTHER|Calorie information|Nutrition label featuring calorie information will be provided.
214954042|NCT01473225|OTHER|No calorie information|No nutrition label will be provided in this condition.
214345845|NCT06128616|OTHER|Serial Casting|Serial Casting
214345846|NCT06128616|BEHAVIORAL|Physical Therapy|Physical Therapy
214345847|NCT06128616|BEHAVIORAL|Occupational Therapy|Occupational Therapy
214345848|NCT03783169|OTHER|Cardiovascular Sonographic Assessment|Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, \& radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
214486641|NCT05895552|DRUG|RTA 901|Administered as specified in the treatment arm.
214345849|NCT05622981|BEHAVIORAL|Age-specific educational materials and monitoring|Subjects will receive age-specific behavioral modification and educational materials plus every 2-week monitoring for goals and progress at reducing BMI for 24 weeks in the pediatric primary care clinic.
214345850|NCT00071487|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
214345851|NCT00071487|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
214345852|NCT00071487|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
214345853|NCT00071487|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
214345854|NCT06092996|OTHER|Time of Sling Use|Standard sling worn for only three days post operatively
214954043|NCT01209247|OTHER|Nasal, rectal and pharyngeal swabs|Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.
214954044|NCT02982044|OTHER|Suprasystolic (300 mmHg) cuff compressions|10 minutes of ECG-gated repeated suprasystolic (300 mmHg) cuff compressions, with inflation occurring every other heart cycle. These cuff compressions may be triggered 0 seconds, 0.2 seconds, or 0.4 seconds from the R spike (systole) on the ECG signal.
214954045|NCT02982044|OTHER|Handgrip exercise|10 minutes of ECG-gated rhythmic handgrip exercise at 30% maximal voluntary contraction, with contraction occurring every other heart cycle
214954046|NCT02982044|OTHER|Passive heat stress|10 minutes of passive heat stress at 42 degrees Celsius with a commercially available heating blanket
214954047|NCT01603394|DRUG|pregabalin|Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
214954048|NCT04168840|DIAGNOSTIC_TEST|Compare clinical test with ultrasound parameters|Compare various clinical test with four ultrasound parameters to predict difficult intubation.
214954049|NCT01819844|DEVICE|Closed-loop blood glucose control|The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose \> 2 u/kg).
214954050|NCT05704179|OTHER|Obstetric Quality of recovery score|Patients' quality of recovery will be evaluated with Obstetric Quality of recovery score (ObsQoR-11) on postpartum day 1 and day 2.
214954051|NCT00840034|DRUG|LY2216684|Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
214954052|NCT00840034|DRUG|Placebo|3 tablets PO QD for up to 12 weeks
214678506|NCT03920605|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
214678507|NCT03920605|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
214678508|NCT00865501|DRUG|spironolactone|25mg per oral once daily
214345855|NCT06038877|OTHER|Interviews|Individual semi-structured interviews
214345856|NCT06038877|OTHER|Qualitative analysis|Thematic analysis of the content of responses
214345857|NCT04296617|OTHER|Medical Chart Review|Review of medical chart
214345858|NCT06057389|DIETARY_SUPPLEMENT|aronia melanocarpa extract|aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst；twice a day，one at a time) combined with an energy-restricted diet
214345859|NCT00686400|OTHER|TAU = treatment as usual|medication and psychosocial interventions to be chosen by treating psychiatrist
214345860|NCT03806738|OTHER|Intervention-specific Carevive questionnaire|includes standard of care questions with additional decision-making questions
214678509|NCT00865501|DRUG|placebo|placebo
214678510|NCT03333369|DRUG|200 mg levodopa/50 mg benserazide|
214678511|NCT03333369|DRUG|Dextrose|
214678512|NCT01541605|DRUG|methylphenidate|tablets for oral use
214678513|NCT01541605|DRUG|Placebo|tablets for oral use
214954053|NCT01215435|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
214954054|NCT01215435|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
214954055|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed"
214954056|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed"
214345861|NCT03806738|OTHER|Standard of Care questionnaire|includes the standard of care questions that are already in place for Carevive questionnaires
214345862|NCT03021382|OTHER|data collection, non-intervention|
214345863|NCT03725982|DEVICE|Laevo ®|A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).
214345864|NCT03725982|DEVICE|No Laevo ®|The subjects will not wear any supporting device to perform the experiment, which serves as the control condition.
214345865|NCT03904472|BEHAVIORAL|Web-based CBTI|Sessions comprise a range of cognitive and behavioral techniques and psychoeducation including sleep hygiene. During the intervention period the participant will complete daily online sleep diaries. Additionally, participants will be asked to complete multiple questionnaires.
214345866|NCT01703455|DRUG|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
214954057|NCT05866549|OTHER|Mindfulness-based Childbirth and Parenting Program|Mindfulness-based childbirth and parenting program will be applied to individuals in this group. The program consists of nine sessions, eight of which will take place during pregnancy. Sessions planned during pregnancy will be held once a week, lasting 8 weeks.
214345867|NCT02808962|PROCEDURE|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
214954058|NCT02870205|DRUG|GSP 301 NS|2 spray in each nostril twice daily for 14 days
214954059|NCT02870205|DRUG|GOM-NS|2 spray in each nostril twice daily for 14 days
214954060|NCT02870205|DRUG|GMM-2 NS|2 spray in each nostril twice daily for 14 days
214954061|NCT02870205|DRUG|GSP 301 placebo NS|2 spray in each nostril twice daily for 14 days
214954062|NCT00325624|DEVICE|Bluetooth-enabled Glucometer|blood glucose information provided to health care providers
214954063|NCT03557476|DIETARY_SUPPLEMENT|Octacosanol|One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
214954064|NCT03557476|DIETARY_SUPPLEMENT|Placebo|A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
214954065|NCT02423668|PROCEDURE|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
214345868|NCT04035941|BEHAVIORAL|Cycle Nation Multicomponent Intervention|"This intervention group will receive 4 elements:~1. Practical skills programme: a workplace-based programme covering basic cycling skills, delivered by trained 'cycle champions' - HSBC staff members.~2. Cycle provision scheme: participants will have the opportunity to have their own bicycles serviced or obtain a loaned bike or e-bike from local bike shops before the start of the programme.~3. Cycle-friendly workplace culture: all offices taking part will have a minimum of secure bike parking facilities as part of an ongoing roll-out of cycle infrastructure across HSBC UK offices.~4. Our Cycle Hub app: an adapted version of an existing HSBC app including route planning, goal setting and practical skills videos, as well as supportive social interaction among participants."
214345869|NCT03755505|DIAGNOSTIC_TEST|obtain samples from sputum, feces and urine|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
214954066|NCT02423668|PROCEDURE|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
214954067|NCT02423668|PROCEDURE|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
214954068|NCT05572372|BEHAVIORAL|Acceptance and Commitment Therapy|The aim of the intervention was to increase psychological flexibility. Therapeutic methods focused on values clarification, cognitive defusion, self-as-context, acceptance, commited action and flexible attention to present moment.
214954069|NCT03071510|DEVICE|Atlas Genetics io® system|Specimen Collection
214954070|NCT03602833|DRUG|Compound 451238|Each patient will receive compound 451238 until disease progression unacceptable toxicities.
214345870|NCT00000457|DRUG|bupropion (Wellbutrin)|"1 pill in the am of 150 mg of Bupropion~1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks."
214678514|NCT03450889|PROCEDURE|Colonoscopy|"Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'."
214678515|NCT05431465|OTHER|Vita Ambria|onlay restoration will be fabricated from Zirconia reinforced lithium disilicate glass ceramic(vita ambria)
214345871|NCT00000457|DRUG|Placebo|placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
214345872|NCT05826392|OTHER|Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention|Web-Based, 30-minute self-administered intervention for adolescents
214486642|NCT05895552|DRUG|RTA 901-Matching Placebo|Administered as specified in the treatment arm.
214345873|NCT05388253|BEHAVIORAL|Static Stretching|Using Static Stretching exercises
214345874|NCT05388253|BEHAVIORAL|Deep Kneading Massage|Using Deep Kneading Massage technique
214345875|NCT04806880|DEVICE|Web-application|support for olfactory coaching consisting of the inhalation of fragrant essential oils.
214345876|NCT05240105|OTHER|no intervention, purely observational|There will be no interventions. The study is purely observational and investigates differences in naturally occuring treatments at these four types of departments for Psychosomatic Medicine.
214486643|NCT05869149|BEHAVIORAL|Multilevel restaurant intervention to improve the food environment|FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
214678516|NCT05431465|OTHER|IPs emax onaly|onlay restoration will be fabricated from lithium disilicate glass ceramic(IPS emax)
214678517|NCT01383044|PROCEDURE|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
214678518|NCT01383044|DRUG|carvedilol|carvedilol 6.25mg-12.5 mg per day
214678519|NCT02876224|DRUG|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
214678520|NCT02876224|DRUG|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
214678521|NCT02876224|DRUG|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
214678522|NCT01461031|DRUG|nefopam|nefopam infusion for postoperative 24 hours
214678523|NCT01461031|DRUG|normal saline (control)|normal saline infusion for postoperative 24 hours
214678524|NCT01618981|PROCEDURE|pace make active/inactive cross over|
214345877|NCT06177964|DRUG|Lerapolturev|"Lerapolturev (intratumoral) will be dosed at 2x108 TCID50 in 3.0 mL x 2 doses (total dose 4x108 TCID50) by Convection Enhanced Delivery.~For the patients randomized to the lerapolturev Arm 1 of Stage 2, seven days (±2 days) following completion of the 2nd intratumoral infusion of lerapolturev, patients will begin cervical perilymphatic subcutaneous injection of lerapolturev at a dose of 2 x 108 TCID50 (in 0.5 ml diluent) around the cervical lymph node chain ipsilateral to the intracranial tumor."
214345878|NCT06177964|DRUG|Lomustine Pill|Lomustine will be given as a single oral dose of 110 mg/m2 every six weeks for up to 9 cycles.
214345879|NCT06175819|OTHER|Manuka honey( MgO 850, UMF+20) loaded nano-formulation|Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris
214345880|NCT04332705|DIAGNOSTIC_TEST|Detection of Cryptosporidium infection|A biopsy or a surgical sample will be collected from every participant
214345881|NCT04913857|BEHAVIORAL|24-week SUDOKU Training Programme|12-week face-to-face training session and a 12-week facilitated self-practice
214345882|NCT04913857|OTHER|Control Arm (wait-list)|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
214345883|NCT04897958|DRUG|Degarelix|Degarelix dispensing claim is used as the reference group.
214345884|NCT04897958|DRUG|Leuprolide|Leuprolide dispensing claim is used as the exposure group.
214345885|NCT05495854|DIAGNOSTIC_TEST|PCR test in the stool|"Patients randomized to the new strategy arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment."
214345886|NCT03553589|OTHER|Blood sampling|Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)
214954072|NCT05621967|BEHAVIORAL|Tonation Breathing Techniques|Tonation and Breathing Techniques (TBT): consist of a combination of organic inhalation and controlled exhalation with tonation. This will be guided by a trained facilitator, and the entire exercise will take 20 minutes. This will include guided relaxed breathing, mindful breathing, patterned tonation, nasal tonation, and pursed lip tonation.
214954073|NCT05621967|BEHAVIORAL|Music Driven Vocal Exercises|Music Driven Vocal Exercises (MDVE): A Music Therapy procedure will be implemented by a trained facilitator, utilizing an accompanying instrument (ie, guitar or Autoharp) and moving stepwise up and down within a scale of 8 whole steps. The total length of the procedure is 20-25 minutes. This will include vocal exercises, and melodic exercises alternating with speaking,
214954074|NCT05621967|BEHAVIORAL|Silent Breathing|Patient will sit in a quiet room and focus on silent breathing x 20 min.
214954075|NCT04765670|OTHER|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
214954076|NCT04765670|OTHER|Kinesiotape Application|Bilateral Kinesiotape application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
214954077|NCT03201393|DRUG|Low-dose naltrexone and acetaminophen combination|Twice a day
214954078|NCT03201393|DRUG|Placebo|Twice a day
214954079|NCT00384371|DRUG|Botulinum Toxin A|Botulinum Toxin A
214954080|NCT00384371|DRUG|Placebo|Placebo
214345887|NCT05926401|OTHER|ECG monitoring prior and after cardioversion|Continuous ECG monitoring at home 3-5 days prior to and 5-7 days after planned cardioversion
214345888|NCT02057822|PROCEDURE|Cytokins assay in tears|
214345889|NCT04014608|OTHER|Standard Practice to Prevent Hospital Onset CDI|Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
214345890|NCT03906227|DEVICE|ENUMERATION OF CD5+ B Cells|A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
214345891|NCT06532175|DEVICE|Su-Jok|Su-jok seed therapy
214345892|NCT00170118|BEHAVIORAL|motivational interviewing|
214345893|NCT01262651|DRUG|Nabiximols|
214345894|NCT01262651|DRUG|Placebo (GA-0034)|
214345895|NCT06333483|BIOLOGICAL|Obecabtagene autoleucel (obe-cel)|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a single dose of obe-cel
214345896|NCT03165526|DEVICE|AMPLATZER™ Post-infarct Muscular VSD Occluder|The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
214345897|NCT03132454|DRUG|Decitabine|Given IV
214345898|NCT03132454|DRUG|Dexamethasone|Given IV or PO
214345899|NCT03132454|DRUG|Palbociclib|Given PO
214345900|NCT03132454|DRUG|Sorafenib|Given PO
214345901|NCT04050189|BIOLOGICAL|Natural products: Probiotics|Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
214345902|NCT04050189|OTHER|Placebo|Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
214345903|NCT04743908|OTHER|Social Network Strategy + COVID-19 messaging|Contextually adapted and theory-driven messages - misinformation correction and self-affirmation - to increase awareness, self-efficacy and community engagement in our adapted Social Network testing Strategy (SNS). SNS is an evidence-based testing intervention that has been widely used in multiple settings with marginalized individuals (ie substance-users) who facilitate the recruitment of their social contacts into testing services.
214345904|NCT04969783|OTHER|Ventilated Cigarette Filter|Ventilated Cigarette Filter
214345905|NCT04969783|OTHER|Unventilated Cigarette Filter|Unventilated Cigarette Filter
214345906|NCT04837482|DRUG|AGN-190584|Topical eyedrop
214345907|NCT04837482|DRUG|Vehicle|Topical eyedrop
214345908|NCT06006520|OTHER|control|No exercises will be given.
214345909|NCT06006520|OTHER|oro-granary exercises.|soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises
214345910|NCT06006520|OTHER|aerobic exercises|We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; It includes activities such as walking, cycling, jogging, aerobic dancing, swimming.
214345911|NCT00328510|DEVICE|GTC frame|
214345912|NCT00328510|DEVICE|Thermoplastic facemask|
214345913|NCT00328510|RADIATION|Stereotactic radiation therapy|
214345914|NCT01248832|BEHAVIORAL|Telephone Counseling|"Counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by counselors at the Helpline. The protocol used is similar to that proved efficacious. However, to make the counseling culturally appropriate for Asian language speakers, we: capitalizing on first contact, present the Helpline as a credible quit smoking program staffed by experts, avoid the term counseling since it is associated with mental illness, and assume a more authoritative role and directive counseling style. Counseling is proactive (1st call is made by smoker, then subsequent calls are made by the counselor) to help reduce attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) scheduled according to the probability of relapse."
214345915|NCT01248832|BEHAVIORAL|Self-Help Materials|All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
214954081|NCT00586898|DRUG|GnRH|leuprolide and goserelin are gonadotropin-releasing hormone analogues
214954082|NCT00586898|DRUG|Ketoconazole|An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
214954083|NCT00586898|DRUG|Bicalutamide|A pure nonsteroidal antiandrogen
214954084|NCT00586898|DRUG|Testosterone transdermal gel|an androgenic anabolic steroid
214954085|NCT00586898|DRUG|Estrogen transdermal patch|Estradiol is the primary and most potent estrogen
214954086|NCT04938713|DRUG|Ketamine 50 MG/ML|Intravenous Ketalar® 0,30 mg/kg in 1 hour.
214954087|NCT04938713|DRUG|Esketamine 25 MG/ML|Intravenous Vesierra® 0,15mg/kg in 1 hour.
214345916|NCT02507895|DEVICE|MI-BCI|Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
214345917|NCT02298218|DRUG|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
214345918|NCT03227770|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
214345919|NCT03227770|DEVICE|hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
214345920|NCT06241326|OTHER|Immunotherapy-based Combination Therapies|immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
214345921|NCT03510572|DRUG|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
214345922|NCT06070714|DEVICE|Holmium laser with pulse modulation|The holmium laser with pulse modulation emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed.
214345923|NCT06070714|DEVICE|Thulium fiber laser|The thulium fiber laser has a different wavelength then the holmium laser with pulse modulation and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns.
214345924|NCT05192525|DEVICE|mChemotherapy|"The intervention is composed of one core intervention mChemotherapy, one pre-chemotherapy consultation, and two app follow-up visits. mChemotherapy will be specifically utilized to facilitate symptom self-management for intervention group covering chemotherapy for six weeks. The mChemotherapy includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. Intervention group participants will be given an individual username and password to log in to the mChemotherapy platform. The intervention nurses will deliver the intervention and contact patients through this platform."
214678525|NCT02242149|DRUG|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
214954088|NCT06396013|DRUG|Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment|"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."
214954089|NCT06396013|DRUG|placebo|"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."
214954090|NCT00379171|BEHAVIORAL|Cow's milk with fish oil|
214954091|NCT00379171|BEHAVIORAL|Cow's milk without fish oil|
214954092|NCT00379171|BEHAVIORAL|Formula with fish oil|
214954093|NCT00379171|BEHAVIORAL|Formula without fish oil|
214954094|NCT03983785|OTHER|Pilates|In pilates group: Pilates training twice a week for 6 weeks.
214954095|NCT03983785|OTHER|Elastic taping|Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List
214954096|NCT04641533|PROCEDURE|L-PRF + DPSC|After surgical removal of impacted mandibular third molars, extraction sockets were filled with L-PRF membranes + DPSCs.
214345925|NCT03582306|BEHAVIORAL|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
214345926|NCT03582306|BEHAVIORAL|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
214345927|NCT02061384|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
214345928|NCT02061384|DRUG|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
214345929|NCT06516588|DEVICE|Transcranial Dirrect Current Stimulation|tDCS will deliver direct current through rubber electrodes in saline-soaked sponges. Device sends a low-level current from the positive electrode, the anode, to the negative electrode, the cathode. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10mA. The anode will be placed over the LDLPFC and the cathode over the contralateral supra-orbital area.
214345930|NCT06634992|OTHER|Oral immunotherapy|Clinical Follow up
214345931|NCT00765167|DRUG|Fluoride|Brush half mouth twice daily for four days
214345932|NCT00765167|DRUG|Triclosan|Brush half mouth daily for four days
214345933|NCT00765167|DRUG|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
214345934|NCT00765167|DRUG|Fluoride|Brush half mouth daily for four days
214345935|NCT05853848|BEHAVIORAL|Postcard|Postcard with phone number to call for help scheduling a mammogram.
214954097|NCT04641533|PROCEDURE|L-PRF|After surgical removal of impacted contralateral mandibular third molars, each extraction sockets were only filled with L-PRF membranes.
214345936|NCT05853848|BEHAVIORAL|Letter|Letter with phone number to call for help scheduling a mammogram.
214345937|NCT05853848|BEHAVIORAL|Auto-dialer|Auto-dialer with option to press button for help scheduling a mammogram.
214678526|NCT02242149|DRUG|Placebo|Sugar pill manufactured to mimic Diacerein
214954098|NCT00540488|OTHER|Adult enteral formula|
215077393|NCT06659328|PROCEDURE|Structured Walking Intervention for Children with Autism Spectrum Disorder|"Participants: Thirty children with ASD will participate in the walking sessions.~Conditions: Each child will walk under three different speed conditions:~Normal Speed: 120 beats per minute (bpm) Slow Speed: 100 bpm Fast Speed: 140 bpm~Social Interaction: Each child will walk with two different types of adult companions:~Familiar Adult: A caregiver or individual known to the child. Unfamiliar Adult: An adult not known to the child. Procedure: The walking distance will be 10 meters. The adult will wear a metronome in an earbud to ensure that they maintain the prescribed walking speed, which the child will be instructed to follow. Each child will experience all combinations of walking speeds and social interactions, allowing for a comprehensive assessment of how these factors influence gait parameters.~Gait Parameters: The following parameters will be recorded during each walking session using video analysis software (Kinovea©):~Stride length Step time Cadence Velocity Joint amplitudes"
215077394|NCT06608979|BEHAVIORAL|Screening/Referral and Prevention|Session 1: One hour PTSD Screening/referral and Psychoeducation on interpersonal violence (consent, drug-and-alcohol-facilitated assault, intimate partner violence); Session 2: One hour sessions on Protective Behavioral Strategies for interpersonal violence (skills training)
214954099|NCT03530319|DRUG|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
214954100|NCT03530319|DRUG|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
215077395|NCT06587334|PROCEDURE|SRP|SRP alone
214345938|NCT05853848|BEHAVIORAL|Live call|Live call offering help scheduling a mammogram.
214345939|NCT06635031|PROCEDURE|Oral surgery|The patients were undergone routine oral surgeries. Surgical procedures included an incision on the oral mucosa and full-thickness flap reflection, and the primary wound closure was achieved by polyglactin absorbable sutures.
214345940|NCT04409964|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
214345941|NCT04409964|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
214678527|NCT01140542|DRUG|Roflumilast|500µg, once daily
214954101|NCT03816007|BEHAVIORAL|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
214954102|NCT03816007|BEHAVIORAL|Veteran Calm|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
214954103|NCT06614673|OTHER|text in non-narrative form|Participants will be asked to read a text and complete questionnaires
214345942|NCT04409964|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
214954104|NCT06614673|OTHER|text in narrative form|Participants will be asked to read a text and complete questionnaires
214954105|NCT06614673|OTHER|animated video in non-narrative form|Participants will be asked to watch a video and complete questionnaires
214954106|NCT06614673|OTHER|animated video in narrative form|Participants will be asked to watch a video and complete questionnaires
214345943|NCT06502314|BEHAVIORAL|Stress management training|"It is a psychoeducational program that includes seven modules (1. Stress and its components, 2. Stress Management, 3. Crisis and its components, 4. Crisis Management, 5. Anger and its components, 6. Anger Management, 7. Psychological resilience)~."
214345944|NCT00311077|DRUG|Insulin Glulisine|
214345945|NCT02937246|DEVICE|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
214345946|NCT02937246|DEVICE|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
214345947|NCT03830034|DRUG|Amino Acid chelated iron tab 15 mg|"Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
214954107|NCT06993740|DRUG|NaCl 0,9%|NaCl 0.9% continuous intravenous infusion during microsurgical reconstruction surgery in cancer patients, started after anesthesia induction and maintained intraoperatively and up to 48 hours postoperatively.
214954108|NCT06993740|DRUG|Dexmedetomidine|Dexmedetomidine continuous intravenous infusion during microsurgical reconstruction surgery in cancer patients, started after anesthesia induction and maintained intraoperatively and up to 48 hours postoperatively, titrated to maintain target sedation and hemodynamic stability.
214345948|NCT03830034|DRUG|Ferrous Fumarate tab 350 mg( 115 mg elemental iron)|"75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb\<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
214345949|NCT04810598|DRUG|Venetoclax|Oral Tablet
214345950|NCT05741736|BEHAVIORAL|five-days small group-based lifestyle modification program|healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
214345951|NCT04962464|DIETARY_SUPPLEMENT|Peak Human Labs calorie mimetic supplement|Supplement
214345952|NCT04962464|BEHAVIORAL|Fasting Mimicking Diet|Diet
214345953|NCT01483001|DRUG|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
214345954|NCT00855517|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
214345955|NCT04372771|OTHER|Curves Circuit|The Curves Circuit consists performing 13 hydraulic resistance exercise machines that utilize bidirectional resistance that work all major muscle groups. These are interspersed with floor-based calisthenic exercises designed to maintain an elevated heart rate.
214345956|NCT04372771|OTHER|Weight Watchers|The Weight Watchers program encourages one to increase physical activity.
214345957|NCT03877042|DEVICE|Cruciate-retaining (CR) prostheses|One leg is conducted TKA with Cruciate-retaining (CR) prostheses.
214678528|NCT02518178|DEVICE|NFC Necklace|
214954109|NCT00001237|DRUG|granulocyte-macrophage colony stimulating factor (GM-CSF)|
214954110|NCT06143787|DRUG|Tranexamic acid|7 days Oral rinsing following tooth extraction
214954111|NCT01249833|DRUG|Oseltamivir|Oseltamivir 75mg BID for 5 days
214954112|NCT01039805|DRUG|GSK962040 (50 mg)|Cohort 1 = 50 mg
214954113|NCT01039805|DRUG|Placebo|matching placebo
214954114|NCT01039805|DRUG|GSK962040 (75 mg)|Cohort 2 = 75 mg
214954115|NCT01900860|DIETARY_SUPPLEMENT|Vitamin D|Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
214954116|NCT03796676|DRUG|Placebo|Placebo
214954117|NCT03796676|DRUG|PF-04965842|100 mg QD
214954118|NCT03796676|DRUG|PF04965842|200 mg QD
214954119|NCT00535392|DRUG|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.~Dosage for subjects not on levetiracetam at study entry was based on weight: if \<50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily)."
214954120|NCT04588844|DRUG|Polyethylene Glycol Recombinant Human Somatropin|Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
214954121|NCT03130140|PROCEDURE|Macroscopic on-site evaluation|Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
214954122|NCT03130140|OTHER|Control|Conventional EUS-FNA
214954123|NCT03461302|DRUG|Topical coal tar|Solution carbonis detergens 10% in cremor vaselini lanette FNA and pix lihantracis 3% in zinc oxide paste
214954124|NCT03461302|DRUG|Topical corticosteroids|Clobetasone butyrate 0.05% ointment
214954125|NCT04267159|OTHER|Acute cardioversion|Acute restoration of sinus rhythm by medical or electrical cardioversion in the emergency department
214954126|NCT04267159|OTHER|Delayed cardioversion|Delayed restoration of sinus rhythm by medical or electrical cardioversion in the out-patient clinic
214345958|NCT03877042|DEVICE|Posterior-stabilized (PS) prostheses|One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
214345959|NCT02359526|DRUG|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
214345960|NCT03735329|DEVICE|Diagnostic test of SPO2|The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
214345961|NCT00382057|DRUG|Testosterone|
214345962|NCT00382057|DRUG|Anastrozole|
214345963|NCT00382057|DRUG|Goserelin|
214345964|NCT01331473|PROCEDURE|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
214345965|NCT01331473|PROCEDURE|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
214954127|NCT05144048|OTHER|Inpatient setting|These women stay at the maternity unit
214954128|NCT05144048|OTHER|Outpatient setting|These women leave the maternity unit
214954129|NCT06731257|OTHER|virtual ward early discharge|Patients who are randomised to the study group will receive a blood pressure monitor and instructions on how to use the device and transfer data to the study team. The study nurses will contact the patient every day for 3 days following their discharge and perform an virtual ward round assessment by telephone (see table). This will determine whether the patient continues to be monitored via the virtual ward, or whether they need to be referred to the clinical team. They will be issued with an emergency contact number out of hours (coronary care unit LGI) and the nursing hub will operate from 8am to 5pm 7 days a week. They will be referred to the community cardiac rehabilitation service whilst on the pathway.
214954130|NCT04559425|DRUG|Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
214954131|NCT04559425|OTHER|No Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
214954132|NCT02432144|DRUG|UX003|solution for intravenous (IV) infusion
214954133|NCT04788186|DRUG|De-prescribe beta blocker therapy|"Participants will be de-prescribed for beta-blocker therapy.~De-prescription will be performed as follows:~* Half of pre-randomization dose for the first 3 days, then~* Half of the above dose for the next 3 days, then discontinue"
214954134|NCT04861441|DEVICE|Aircast Cryo Cuff (Shoulder) and Aircast Cryo Cuff I/C Motorized Cooler|Patient will wear the continuous cryo cuff for a designated period of time and will record their pain and narcotic use post operatively.
214954135|NCT04861441|DEVICE|Icepacks|Standard of care icepacks will be used postoperatively for designated amount of times and patients will record pain and narcotic use post operatively.
214954136|NCT05983510|PROCEDURE|Aortic endarteriectomy|Thoraco-phreno-lumbotomy with thoracic aortic cross clamping Longitudinal aortotomy Endarteriectomy of the aorta Direct closure more or less bypass to the visceral arteries and downstream aorta reconstruction.
214954137|NCT00448812|DEVICE|Bronchial Thermoplasty with the Alair System|Treatment of airways with the Alair System (Bronchial Thermoplasty) in the PREDECESSOR STUDY (NCT00214526).
214954138|NCT02194764|DRUG|Naltrexone and 2-butanol|50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
215077396|NCT06587334|PROCEDURE|Nd: YAG Laser Assisted SRP|the patients receive SRP combined with Nd: YAG laser
215077397|NCT06606392|DEVICE|Biodex balance system|The Biodex Balance System has a wide range of clinical applications and provides objective measures from testing that can be used to establish progressions and discharge criteria, as well as be part of a comprehensive Fall Risk Assessment or Fall Screening Program. Balance ability can be assessed either statically or dynamically, as well as bilaterally and unilaterally. It also allows for bilateral comparisons between involved and uninvolved limbs.
215077398|NCT06606392|OTHER|Short Foot Exercise|Short foot exercise is used as a therapeutic exercise to strengthen intrinsic foot muscles and used as training to create an MLA. It helps improve the balance in functional movement of FF subjects, decreases navicular drop (ND) through intrinsic muscle activation, supports navicular stability, and improves balance
215077399|NCT06606964|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI examinations were conducted using a 1.5 Tesla closed MRI system with a body coil and spine coil. The participants\&#39; knees were positioned in full extension and their feet were in a neutral position during imaging. The scan was performed from the anterior superior iliac spine to the tip of the toes, and both legs were included in the field of view
214345966|NCT06580626|PROCEDURE|decompression technique|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by decompression technique.
214345967|NCT06580626|PROCEDURE|guided bone regenaration using Ethoss|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by guided bone regeneration using β-TCP/CS synthetic bone substitute.
214345968|NCT06580626|PROCEDURE|ridge splitting technqiue|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by ridge splitting technique using piezosurgery.
214345969|NCT02282449|DEVICE|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
214954139|NCT02194764|DRUG|2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)|a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
214954140|NCT06255600|OTHER|High Definition-transcranial Direct Current Stimulation|High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a neuromodulation technique, is non-invasive, targeted, safety.
214954141|NCT06255600|DIETARY_SUPPLEMENT|Chlorella Pyrenoidosa|functional food, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000)
214954142|NCT02346994|DIETARY_SUPPLEMENT|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
214954143|NCT02346994|DIETARY_SUPPLEMENT|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
214954144|NCT04516863|DIAGNOSTIC_TEST|German Autobiographical Memory Interview short-form|Diagnostic Test
214954145|NCT03634813|DEVICE|High Blood Pressure Monitor|High Blood Pressure Monitoring device (Omron MX3 model BP742, Omron, Shaumberg, IL)
214954146|NCT03634813|PROCEDURE|Usual Care|Usual Care
214954147|NCT03890978|OTHER|promotional Exclusive breastfeeding text messages|promotional Exclusive breastfeeding text messages will be send to women via mobile phone
214954148|NCT06168747|OTHER|Passive Joint Mobilization|Wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals. Applications were made 6 times with 3 repetitions
214954149|NCT05427747|DRUG|cefotaxime|"One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~* Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~* Decrease of peritoneal fluid PMN count to \< 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture."
214954150|NCT00005711|BEHAVIORAL|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
214954151|NCT06920797|DIAGNOSTIC_TEST|Reproductive tract microbiome analysis|Assessment of the endometrial and vaginal microbiome in three different samples: endometrial biopsy (EB), endometrial fluid (EF) and vaginal swab (VS).
214954152|NCT05293873|BIOLOGICAL|autologous bone marrow-derived mononuclear cell transplantation|Bm-MNC will be transplanted at baseline, and the second transplantation will be performed 6 months after the first transplantation
214954153|NCT05293873|OTHER|Rehabilitation therapy|Rehabilitation therapy
215077400|NCT06606964|OTHER|Isokinetic Strength|The strength of the concentric knee extensor-flexor and concentric hip abductor-adductor muscles was measured using an isokinetic dynamometer at two different angular velocities: 60˚/sec and 180˚/sec. Three repetitions were performed at 60˚/sec, and five repetitions were performed at 180˚/sec. To calculate the H/Q ratio, we divided the peak concentric torque of the hamstrings by that of the quadriceps during the same contraction velocity. Similarly, to determine the Add/Abd ratio, we divided the peak concentric torque of the adductors by that of the abductors during the same contraction velocity
215077401|NCT06608680|BEHAVIORAL|iTBS|Excitatory stimulation of supramarginal gyrus
215077402|NCT06608680|BEHAVIORAL|cTBS|Inhibitory stimulation to supramarginal gyrus
214954154|NCT04544943|DRUG|BioLexa- Cohort 1|Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects
214954155|NCT04544943|DRUG|BioLexa- Cohort 2|Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult mild to moderate AD patients
214954156|NCT04544943|DRUG|Placebo|Twice daily (BID) application of placebo for 14 days
214954157|NCT04544943|DRUG|Gentamicin|Twice daily (BID) application of Gentamicin for 14 days
215077403|NCT06608680|BEHAVIORAL|Sham Stimulation|Sham stimulation of supramarginal gyrus
215077404|NCT06608329|DRUG|HDM1002|Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.
214345970|NCT02282449|DEVICE|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
214345971|NCT00317239|DRUG|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
214345972|NCT00317239|DRUG|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
214345973|NCT05233826|BIOLOGICAL|COVI-VAC|Intranasal, live attenuated vaccine against SARS-CoV-2
214345974|NCT00803647|BIOLOGICAL|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
214678529|NCT02518178|DEVICE|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
214678530|NCT02518178|DEVICE|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
214954158|NCT06931431|BEHAVIORAL|Transition of Care Model (TCM)|Key components of the TCM include discharge assessment, care planning, provider communication with outpatient follow-up teams, and community-based follow-up
214954159|NCT05273489|PROCEDURE|Hepatectomy|Neoadjuvant treatment
214954160|NCT02014051|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.~The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle."
214954161|NCT00248976|BEHAVIORAL|Net-present value of individual health behaviors in years|
214345975|NCT00803647|DRUG|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
214954162|NCT01116076|BEHAVIORAL|Decision+ program (to improve optimal drug prescription for ARI)|DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
214954163|NCT01732445|DRUG|ruxolitinib phosphate|Given PO
214954164|NCT01732445|DRUG|danazol|Given PO
214954165|NCT01732445|OTHER|quality-of-life assessment|Ancillary studies
215077405|NCT06606977|OTHER|Training|"During the detraining period, the athletes did not follow any external (personal) trainer-supported training program and their diet was not altered. Athletes have reported that they have stayed at home as a necessity of the Covid-19 pandemic process, and have done simple home exercises, walking and jogging exercises in a limited way during this time.~The training period included the standard wrestling trainings, which were determined by the national team coaches and realized at different intensities, during the 8 weeks when the training started. Following the period of detraining the level of training intensity was progressively increased throughout the initial 5 weeks. In the 6th and 7th week, training intensity peaked . In the 8th week prior to the competition, the training intensity was reduced in order to prepare and recover for the following competition. After the training period, the wrestlers participated in an international competition."
215077406|NCT06607861|DRUG|saline group|nebulization of 4 mL 0.9% saline twice daily
215077407|NCT06607861|DRUG|dexmedetomidine group|nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily
214954166|NCT01732445|OTHER|questionnaire administration|Ancillary studies
214345976|NCT00803647|DRUG|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
214345977|NCT00803647|DRUG|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
214678531|NCT01020292|DRUG|Nelfinavir|
214678532|NCT01084499|DRUG|Femara (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
214954167|NCT03340298|DIETARY_SUPPLEMENT|fiber|the intervention of different sources of dietary fibers
214954168|NCT02041780|PROCEDURE|Shearwave electrography|
214954169|NCT04542278|DRUG|Prednisone|used to reduce inflammation
214345978|NCT00280332|PROCEDURE|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
214678533|NCT01084499|DRUG|Peratra (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
214954170|NCT03438942|DIETARY_SUPPLEMENT|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
214345979|NCT00010517|PROCEDURE|Acupuncture|
214345980|NCT06326372|PROCEDURE|control|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation
214345981|NCT06326372|PROCEDURE|ORi+SpO2|"Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
214345982|NCT00396604|DRUG|indacaterol maleate|
214345983|NCT00044382|DRUG|CC-5013|
214345984|NCT02649686|DRUG|Durvalumab|
214345985|NCT02649686|DRUG|Trastuzumab|
214678534|NCT01084499|DRUG|Femara (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
214678535|NCT01084499|DRUG|Peratra (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
214954171|NCT03438942|DIETARY_SUPPLEMENT|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
214954172|NCT01859949|DRUG|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
214954173|NCT01890759|BIOLOGICAL|Meningococcal Diphtheria Toxoid Vaccine|0.5 mL, Intramuscular
214345986|NCT02340039|DIETARY_SUPPLEMENT|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
214345987|NCT05305144|PROCEDURE|Vascular and ophthalmological examinations|"Part. 1 - Vascular checkup examinations:~After collecting classic clinical parameters (weight, height, waist circumference), the in-depth vascular workup of each participant will include the following measurements:~* Measurement of central arterial pressure,~* Measurement of arterial stiffness,~* Continuous blood pressure measurement (beat-to-beat),~* Heart rate measurement,~* 24-hour blood pressure measurement with QKD (holter).~Part. 2 - Ophthalmological examinations:~After dilating the pupil, a series of examinations will be conducted on the participant:~* Auto-refractometry~* Measurement of the axial length of the globe~* Color retinophotography of the retina,~* Adaptive Optics Exam~* SS-OCT-A exam"
214345988|NCT00235703|DEVICE|Antimicrobial Prescribing Decision Support|
214345989|NCT06535529|DRUG|Acetazolamide|Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
214345990|NCT06535529|DRUG|Dapagliflozin 10mg|patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
214345991|NCT04744363|DRUG|Stelara PFS|Pre filled syringes filled with AVT04 and Stelara
214678536|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Diabetic patients.
214954174|NCT04037800|PROCEDURE|SFUR-RARP|Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)
214954175|NCT04037800|PROCEDURE|Standard RARP|Robotic-assisted radical prostatectomy with conventional RARP procedures.
214954176|NCT05309694|COMBINATION_PRODUCT|Paragard® T380A Intrauterine Copper Contraceptive with New Inserter|"Paragard® IUS with Investigational Inserter combines the current insertion tube and white rod to form a new pre-assembled inserter device that supports a single hand operation.~The device is used to pass the IUS through the cervical canal and into the uterine cavity and facilitates insertion of the T shaped Paragard® IUS implant into the uterus."
214954177|NCT05525000|DEVICE|Validation|"The validation protocol consists of the following activities:~Activities of daily living, Exercise test on the treadmill, Exercise test on the cycle ergometer, Free-living session"
215077408|NCT06607861|DRUG|lidocaine group|bilateral nebulization (60 mg) using a mucosal atomization device twice daily
215077409|NCT06602388|OTHER|Biological sampling|Collection of biological samples from healthy volunteers: Stool, urine, saliva, buccal swab, nasal swab, superficial skin swab, hair
215077410|NCT06607328|OTHER|Assessment of participants in terms of different aspects.|This group was composed of individuals who have the prehypertensive stage.
215077411|NCT06608628|OTHER|Experimental Group|The experimental group students will play a patient safety escape room game. Control group students will be given traditional education. The knowledge level and team cooperation of the two groups will be compared.
215077412|NCT01793337|OTHER|Exposure to cold environmental temperature (-20°C)|
215077413|NCT06730698|OTHER|No intervention|No intervention
215077414|NCT04611425|DRUG|Remimazolam|Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
214345992|NCT02824913|DRUG|P-321 Ophthalmic Solution|
214345993|NCT02824913|DRUG|P-321 Ophthalmic Solution placebo|
214345994|NCT03430154|OTHER|No treatment given|No treatment given
214345995|NCT02563912|OTHER|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
214345996|NCT02563912|OTHER|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
214345997|NCT02063789|DRUG|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
214345998|NCT03701555|OTHER|PvP001 placebo|placebo
214345999|NCT03701555|DRUG|PvP001 100 mg|PvP001 100 mg
214346000|NCT03701555|DRUG|PvP001 300 mg|PvP001 300 mg
214346001|NCT03701555|DRUG|PvP001 900 mg|PvP001 900 mg
214346002|NCT03701555|DRUG|Maximum Feasible Dose (MFD) of PvP002|MFD of PvP002
214346003|NCT03701555|DRUG|Maximum Tolerated Dose (MTD) of PvP001|Maximum Tolerated Dose (MTD) of PvP001
214678537|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Nondiabetic patients.
214678538|NCT06207175|BIOLOGICAL|Nonavalent HPV study vaccine|A 3-dose regimen administered at months 0, 2 and 6.
214954178|NCT04462328|DRUG|Durvalumab|Durvalumab will be administered over 60 minutes
214954179|NCT04462328|DRUG|Acalabrutinib|Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
214346004|NCT03701555|DRUG|MTD of PvP001 following 7 days of PPI treatment|Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
214346005|NCT03701555|OTHER|PvP002 placebo|Placebo
214346006|NCT03701555|DRUG|PvP001 600 mg|PvP001 600 mg
214346007|NCT03701555|DRUG|PvP003 placebo|Placebo tablet orally.
214346008|NCT03701555|DRUG|PvP003|PvP003 tablet orally.
214346009|NCT03701555|DRUG|PvP003 150 mg|PvP003 150 mg
214346010|NCT06349161|PROCEDURE|One-trocar-assisted pyeloplasty|Positioned in a full lateral decubitus posture. A 12mm incision was made below the 12th rib, followed by a muscle-sparing technique to access and open the Gerota's fascia. A 10mm balloon trocar was inserted, and CO2 was insufflated to a pressure of 12 mmHg at a flow rate of 3L. An operative scope with dual channels was introduced for retroperitoneal dissection, utilizing a peanut to expand the working space. The proximal ureter, UPJ, and renal pelvis were visualized, and the UPJ was mobilized and exteriorized under direct visualization to prevent torsion. Anderson-Hynes dismembered pyeloplasty was performed using a 6/0 PDS suture, with possible enlargement of the incision if necessary. A 4 French double J ureteral stent was inserted antegradely before completing the anastomosis, verified by methylene blue presence at the anastomotic site. A final retroperitoneoscopic assessment ensured proper alignment of the anastomosis, with closure of the incision site without drain placement.
214346011|NCT00752375|DRUG|Trimethoprim Sulfamethoxazole|"* Children \>3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~* Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~* Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
214346012|NCT00752375|DRUG|placebo|"* Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~* Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~* Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
214346013|NCT03397212|OTHER|NADA acupuncture|Ear acupuncture protocol described by National Acupuncture Detoxification Association
214346014|NCT03397212|OTHER|Sham acupuncture|Ear acupuncture using inactive sham points
214346015|NCT04757649|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
214346016|NCT04066218|OTHER|Interviews|"* Participation will serve as verbal consent.~* Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~* REDCap link will be sent for PROMIS SexFS Brief.~* PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~* Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
214346017|NCT02211300|DEVICE|The OptiScanner|treatment of blood glucose per standard of care
214346018|NCT02211300|DEVICE|YSI 2300 STAT Plus™|
214678539|NCT06207175|BIOLOGICAL|GARDASIL® 9|A 3-dose regimen administered at months 0, 2 and 6.
214678540|NCT05312905|OTHER|Mirror Therapy|Mirror Therapy applied alone
214954180|NCT03523312|RADIATION|Hypofractionated ablative IMRT (HFA-IMRT)|total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions
214954181|NCT03523312|DRUG|capecitabine|Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
214954182|NCT06495801|BEHAVIORAL|Frendie PRO mobile application|Frendie PRO mobile application offers employees an environment to manage their social relationships, organize leisure activities, and discuss personal or work-related matters.
214954183|NCT02584374|OTHER|Venography with balloon occlusion test|First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
215077415|NCT06592014|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
214954184|NCT03887208|PROCEDURE|Laser therapy|non-ablative fractional laser therapy of skin
214954185|NCT03887208|BIOLOGICAL|Autologous ADSC injection|Subcutaneous injection of autologous ADSC
214954186|NCT03887208|PROCEDURE|Normal saline injection|Subcutaneous Normal saline injection
214954187|NCT02802696|DRUG|Furosemide|A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
215077416|NCT00160017|BEHAVIORAL|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
215077417|NCT03985410|DRUG|ETX2514|intravenous infusion
215077418|NCT03985410|DRUG|Placebo|intravenous infusion
215077419|NCT03985410|DRUG|moxifloxacin|oral tablet
215077420|NCT06606379|DEVICE|I1 (Intervention)|Resin ring (DR- Resin ring, Egypt)
215077421|NCT06606379|DEVICE|I2 (Intervention)|Elliot separator (Pfingst \& Co, South Plainfield, NJ, USA)
215077422|NCT06606379|DEVICE|I3 (Intervention)|Stainless Steel Metal ring (TOR VM ring, Moscow, Russia)
214954188|NCT02802696|DRUG|Normal Saline|A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
214954189|NCT03802734|DEVICE|Mindful meditation phone app|Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
214954190|NCT03510975|DRUG|desmopressin melt form 120 μg|desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
214346019|NCT05498259|DRUG|Orelabrutinib|Orelabrutinib 150mg qd PO
214346020|NCT05498259|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle
214346021|NCT05498259|DRUG|CHOP-like Regimen|cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
214346022|NCT01286779|BIOLOGICAL|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
214954191|NCT03510975|BEHAVIORAL|Verbal behavioral therapy|Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary
214346023|NCT06114420|PROCEDURE|salvage surgery|Some patients who cannot undergo surgery
214346024|NCT02896855|DRUG|Docetaxel|Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
214346025|NCT02896855|DRUG|Pertuzumab|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
214346026|NCT02896855|DRUG|Placebo|Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
214346027|NCT02896855|DRUG|Trastuzumab|Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
214346028|NCT02332070|PROCEDURE|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
214346029|NCT04106999|DRUG|Dexmedetomidine|Drug infusion will be delivered intra-operatively
214346030|NCT04106999|DRUG|Placebos|Normal Saline will be infused as a control drug
214954192|NCT03510975|BEHAVIORAL|Behavioral therapy with written check-list|Behavioral therapy with written check-list includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary, ensuring optimal posture to facilitate good bladder function and bowel movements, avoding holding urine, encouring healthy diet
214346031|NCT02239523|PROCEDURE|Letter Group|At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
214346032|NCT02239523|PROCEDURE|Intervention Group|The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
214346033|NCT00646802|DRUG|Progesterone|1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
214954193|NCT00171158|DRUG|imatinib mesylate|
214954194|NCT01305772|DRUG|Panitumumab|Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 \& 4 of RT alone or weeks 1 \& 4 of cisplatin/RT if they tolerated first dose of panitumumab.
214954195|NCT01305772|PROCEDURE|Surgery|Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).
214954196|NCT01305772|PROCEDURE|Radiation Therapy|Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
214954197|NCT06019026|DEVICE|Tri-Lock|Implant Stem
214346034|NCT00646802|DRUG|Placebo|1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
214346035|NCT01792089|OTHER|fat+protein meal|cream+ whey protein
214346036|NCT01792089|OTHER|Fat + protein + 13C fructose meal|cream+ whey protein +13C fructose
214346037|NCT01792089|OTHER|Fat+protein+13C fructose+glucose meal|Cream + whey protein + glucose:13C fructose mixture
214346038|NCT01792089|OTHER|13C Fat + whey protein|cream labelled with 13C palmitate + whey protein
214346039|NCT01792089|OTHER|13C Fat + whey protein + glucose+ glucose meal|cream labelled with 13C palmitate + whey protein + glucose:fructose mixture
214346040|NCT04842357|OTHER|standardised video concerning clinical skill|watching a video concerning clinical skills.
214346041|NCT03601832|PROCEDURE|4-D navigated stereotactic radiosurgical ablation|4-D Navigated Non-invasive radiosurgical ablation of ventricular tachycardia in patients with sustained monomorphic ventricular tachycardia/tachycardias after myocardial infarction.
214346042|NCT05091034|BEHAVIORAL|Controlling Asthma Program for Adolescents (CAMP Air)|Controlling Asthma Program for Adolescents (CAMP Air) is an e-health intervention grounded in social cognitive theory and motivational interviewing to guide teens through asthma self-care and how to navigate the health care system. It makes use of various interactive and personalized approaches.
214346043|NCT05091034|BEHAVIORAL|Attention Control Asthma Education Intervention|Using Asthma Plus, an asthma education program, teens learn about asthma and other conditions relevant to asthma and adolescents.
214954198|NCT06019026|DEVICE|Summit|Implant Stem
214954199|NCT01084148|DRUG|V0034CR01B|
214954200|NCT01084148|DRUG|V0034CR01B vehicle|
214954201|NCT03075332|OTHER|combined training|Combined training consisting of aerobic and resisted training in the same training session for 15 weeks followed by 5 weeks of detraining
214346044|NCT02370602|DRUG|TAK-063|TAK-063 tablets
214346045|NCT02370602|DRUG|[^11C]T-773|\[\^11C\]T-773 IV solution
214954202|NCT04230343|BEHAVIORAL|Self-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
214954203|NCT04230343|BEHAVIORAL|Other-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.
214954204|NCT01904747|DRUG|Palbociclib administered Fasted|palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
214346046|NCT03769623|DEVICE|Biolimus|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Biolimus
214954205|NCT01904747|DRUG|Palbociclib administered Fed high calorie|palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
214954206|NCT01904747|DRUG|Palbociclib administered Fed low calorie|palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
214346047|NCT03769623|DEVICE|Powerline|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Powerline
214346048|NCT01015742|DRUG|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
214346049|NCT01326364|PROCEDURE|Stereotactic body radiotherapy|Standard of Care
214346050|NCT01326364|DRUG|Iodixanol|IV, calculated per patient
214346051|NCT01326364|DRUG|Iohexol|IV, Calculated per patient
214346052|NCT01981135|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
214346053|NCT01981135|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
214346054|NCT00648076|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
214346055|NCT00648076|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fed
214346056|NCT01296568|DRUG|LY2603618|Administered intravenously
214346057|NCT01296568|DRUG|Pemetrexed|Administered intravenously
214346058|NCT01296568|DRUG|Gemcitabine|Administered intravenously
214346059|NCT02545673|BEHAVIORAL|Enhanced linkage to care|
214346060|NCT02545673|BEHAVIORAL|Standard-of-care plus|
214346061|NCT00237744|DEVICE|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
214954207|NCT01904747|DRUG|Palbociclib administered Fed moderate calorie|palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
214954208|NCT05394701|DIETARY_SUPPLEMENT|Omega-3 LipoMicel® soft gels|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
214954209|NCT05394701|DIETARY_SUPPLEMENT|RxOmega-3 soft gels (Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
214954210|NCT05394701|DIETARY_SUPPLEMENT|Omega-3 Complete soft gels (Non-Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
214954211|NCT03074604|PROCEDURE|aortic no-touch OPCABG|(Study arm 1) In this intervention only the internal mammary artery grafts will be used (i.e. left internal mammary artery graft, right internal mammary artery graft, or a Y-graft that uses right internal mammary artery graft anastomosed onto left internal mammary artery graft to allow for a wide territory of myocardial revascularization). However, in the rare event that the aforementioned approach is insufficient to reach all target vessels, a reversed (great) saphenous vein graft may be used to extend the left internal mammary artery graft or the right internal mammary artery graft.
214954212|NCT03074604|PROCEDURE|OPCABG with partial clamp applying carbon dioxide|(Study arm 2) In this intervention chest cavity will be insufflated with carbon dioxide at a flow above 5 l/min during the entire surgical procedure.
214954213|NCT03074604|PROCEDURE|OPCABG with partial clamp|"(Study arm 3) This is the control arm undergoing traditional OPCABG with partial clamp."
214346062|NCT00237744|DEVICE|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
214346063|NCT00237744|OTHER|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
214346064|NCT03821311|RADIATION|Computed tomography|End-inspiratory/end-expiratory CT is repeated 3 times corresponding to the 3 studied conditions: At baseline, through expiratory resistive loading using an adjustable PEP mask, and after 5 min of nasal high flow therapy at 25 L/min.
214346065|NCT02544906|DRUG|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
214678541|NCT05312905|OTHER|Mirror Therapy + Cognitive Therapy|Mirror Therapy supported with Cognitive Exercises
214346066|NCT02544906|DRUG|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
214346067|NCT06035133|DRUG|CapeOX + cetuximab|CapeOX + cetuximab for RAS wild-type patients and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
214954214|NCT03714477|PROCEDURE|Extracorporeal shock wave lithotripsy|A minimally invasive treatment for renal stone which was first introduced in early 1980's. It tries to fragment the renal stones by high-energy shockwave at the kidney from the outside.
214954215|NCT03536663|DEVICE|Optiflux and Dialyzer with Endexo|Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.
214954216|NCT01268189|DEVICE|Oxygen diffusing dressing|Oxygen diffusing dressing applied to study wound
214954217|NCT01268189|DEVICE|Standard of care dressing|Xeroform control dressing applied to control wound
214954218|NCT05757362|OTHER|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation (cq-HEPT)|An online application of the developed questionnaire form
214346068|NCT06035133|DRUG|CapeOX + bevacizumab|CapeOX + bevacizumab for RAS mutant patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
214346069|NCT06035133|RADIATION|radiotherapy|radiotherapy
214346070|NCT01373086|DRUG|LFF269|
214954219|NCT01141166|BEHAVIORAL|nutritional and a rehabilitation plan.|The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
214954220|NCT03525808|DEVICE|AXIOS|Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.
214954221|NCT06406166|DRUG|Lifei Xiaoji Wan|The Lifei Xiaoji Wan consists of ginseng, blackhead, rhubarb, aster, forehu, and thin on
214954222|NCT06406166|OTHER|Conventional treatment with Western medicine|Conventional treatment with Western medicine
214954223|NCT06955247|OTHER|sensory motor integration|Study group (1) sensory motor integration for 45 minutes/time ,3 days per week for 3 months Treatment program included two parts; tactile sensation and proprioception stimulation programs. Each of them accounted half of the session and in terms of the type of activity it was divided into three categories: active, passive
214954224|NCT06955247|OTHER|bobath technique|"\*study group ( 2) bobath techniquefor 45 minutes/time 3 days per week for 3 months in the form of:~1. Preparation phase~2. Intervention program (Movement facilitation \&Functional training)"
214346071|NCT01373086|DRUG|Eplerenone|
214954225|NCT03308929|DEVICE|G7 Dual Mobility hip|Total hip arthroplasty and implantation of the G7 device
214954226|NCT03685500|DRUG|Symtuza® (TAF/FTC/DRV/c)|Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
214954227|NCT03685500|DRUG|ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
214954228|NCT01883739|OTHER|Parental Presence at Handover Rounds|
214954229|NCT02449421|BEHAVIORAL|Quality Improvement Learning Community|Consultation with CPT experts to effectively use evidence-based psychotherapy.
214954230|NCT02449421|BEHAVIORAL|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
214954231|NCT06405802|OTHER|Tele-evaluation|Evaluations will be carried out in two different environments: face-to-face in the clinic and remotely using technology. Face-to-face applications and remote evaluations using technology will be repeated once. Face-to-face applications will be made to individuals with low back pain who come to Bozyaka Training and Research Hospital and volunteer to participate in the study. Then, patients will be video-called at home, asked to perform the tests twice as taught, and recorded as a video.
214346072|NCT01373086|DRUG|Placebo|
214954232|NCT03016468|DRUG|Parenteral Remodulin (treprostinil) injection|Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
214954233|NCT03016468|DRUG|Oral Treprostinil|Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
214954234|NCT01471444|DRUG|Fludarabine|"Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3."
214954235|NCT01471444|DRUG|Clofarabine|30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
214346073|NCT05170373|PROCEDURE|ESP block|Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture
214346074|NCT05014594|DRUG|Dapagliflozin (10Mg Tab) along with standard medical therapy|Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
214346075|NCT05014594|DRUG|Placebo of dapaglifozin along with standard medical therapy|Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
214346076|NCT02509533|DEVICE|V.A.C.®|Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
214346077|NCT02509533|DEVICE|dressing|Patients received usual dressing method (compresses) after a transplants of leg ulcers
214346078|NCT00574080|DRUG|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
214346079|NCT00574080|DRUG|Induction/Consolidation Dexamethasone|40 mg Days 1-4
214346080|NCT00574080|DRUG|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
214346081|NCT00574080|DRUG|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
214346082|NCT00574080|DRUG|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
214346083|NCT00574080|DRUG|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
214346084|NCT00574080|DRUG|Induction Pegfilgrastim|6 mg Days 6 and 13
214346085|NCT00574080|DRUG|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
214346086|NCT00574080|DRUG|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
214346087|NCT00574080|DRUG|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
214346088|NCT00574080|DRUG|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
214346089|NCT00574080|DRUG|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
214346090|NCT00574080|DRUG|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
214346091|NCT00574080|DRUG|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
214346092|NCT00574080|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
214346093|NCT00574080|DRUG|Transplant 2 Carmustine|300 mg/m2 Day -5
214346094|NCT00574080|DRUG|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
214346095|NCT00574080|DRUG|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
214346096|NCT00574080|DRUG|Transplant 2 Melphalan|140 mg/m2 Day -1
214346097|NCT00574080|DRUG|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
214346098|NCT00574080|DRUG|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
214346099|NCT00574080|DRUG|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
214346100|NCT01930773|DEVICE|Genotyping|Patients harboring CYP2C19 \*2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
214346101|NCT01930773|DEVICE|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
214346102|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 1|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.
214346103|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 2|Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.
214346104|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 3|Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.
214346105|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 4|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.
214346106|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 5|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.
214346107|NCT06183801|DIETARY_SUPPLEMENT|Placebo 1|Subjects take capsule three times a day before meal.
214346108|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 6|After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
214346109|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 7|After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
214346110|NCT06183801|DIETARY_SUPPLEMENT|Placebo 2|After 1 month wash out, subjects take capsule three times a day before meal.
214346111|NCT05605119|DRUG|AUR105|Once daily
214346112|NCT04071938|OTHER|Teaching to GPs|Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
214346113|NCT04071938|OTHER|Site visits to GP practices|Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
214678542|NCT05670119|OTHER|Structured Training|Structured catheter-related infection control training was prepared by using evidence-based information and receiving 10 expert opinions. This training will be given to the participants with a face-to-face PowerPoint presentation by the infection control nurse (researcher) and will also be presented as written material.
214346114|NCT01141192|DIETARY_SUPPLEMENT|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
214346115|NCT01141192|DIETARY_SUPPLEMENT|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
214346116|NCT03455283|DRUG|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
214346117|NCT03455283|OTHER|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
214678543|NCT00330824|DRUG|antibiotic/steroid combination|1gtt, 4x/d, 15 days
215077423|NCT06606379|DEVICE|C (comparator)|Nickel titanium 3D-fusion ring (Garrison, USA)
214346118|NCT00418535|DRUG|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
214346119|NCT05745857|DRUG|Avastin|Orally administered
214346120|NCT05745857|DRUG|Erbitux|Orally administered
214346121|NCT05745857|DEVICE|Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy|Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
214346122|NCT00745017|BEHAVIORAL|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
214346123|NCT00745017|BEHAVIORAL|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
214678544|NCT00330824|DRUG|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
214678545|NCT06513637|DIAGNOSTIC_TEST|12-Lead ECG and home sleep study (HST) diagnostics|"* 12-lead ECG hookup will be performed following standard placement procedures.~* The Home Sleep Study diagnostic device placement will be performed by study personnel following the manufacturer's instructions."
214678546|NCT01690949|DRUG|PUR118|inhaled PUR118, BID
215077424|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
214346124|NCT00745017|DRUG|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
214346125|NCT01817205|PROCEDURE|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
214346126|NCT05135910|DRUG|Hallux Terbinafine Subungual Gel|Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.
214346127|NCT01842139|BIOLOGICAL|basiliximab|Given IV
214346128|NCT01842139|BIOLOGICAL|WT1 126-134 peptide vaccine|Given SC
214346129|NCT01842139|DRUG|Montanide ISA 51 VG|Given SC
214346130|NCT01842139|DRUG|poly ICLC|Given SC
214346131|NCT01842139|OTHER|laboratory biomarker analysis|Correlative studies
214346132|NCT01387568|DRUG|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg-1.h-1. and were continued up to 6 hours postoperatively
214346133|NCT01387568|DRUG|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
215077425|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
214346134|NCT04833023|DRUG|Haldol 2mg/ml oral solution|"Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
214346135|NCT04833023|DRUG|Olanzapine Actavis 5mg orodispersible tablet|"Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
214346136|NCT04399629|BEHAVIORAL|PCIT-ED|12 sessions of PCIT-ED therapy
214346137|NCT04399629|BEHAVIORAL|Parenting Wisely|Teaches parents how to set more effective limits
214346138|NCT06529588|RADIATION|Radiation|HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months
214346139|NCT01299493|OTHER|Systems-level intervention to promote colon cancer screening|Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
214346140|NCT04272450|DIAGNOSTIC_TEST|respiratory muscle strenght measurement|Maximum inspiratory pressure-maximum expiratory pressure. The mouth pressure measurement was performed with the Micro-RPM® instrument from SensorMEDIC. Patient placed a rubber mouthpiece with flanges, on the device, sealed their lips firmly around the mouthpiece, exhaled/inhaled slowly and completely and then tried to breath in as hard as possible. The patient was allowed to rest for about a minute and the maneuver was repeated.
214346141|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
214346142|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
215077426|NCT01386242|OTHER|Saline Injection|Saline Injection, 1mL, im,three times per week
215077427|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
215077428|NCT06594042|DIAGNOSTIC_TEST|serum preptin|serum preptin level in chronic kidney disease
215077429|NCT04103541|BEHAVIORAL|IP-Colombia|The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, \[and\] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
215077430|NCT01632241|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
215077431|NCT01632241|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
215077432|NCT01632241|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
215077433|NCT06183372|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
215077434|NCT06183372|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
214954236|NCT01471444|DRUG|Busulfan|Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
214346143|NCT04018027|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg administered twice daily
214346144|NCT04018027|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg administered twice daily
214346145|NCT04018027|DRUG|difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg administered twice daily
214346146|NCT04018027|DRUG|Placebo|Oral Placebo administered twice daily
214954237|NCT01471444|DRUG|Thymoglobulin|"Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete."
214954238|NCT01471444|PROCEDURE|Stem Cell Infusion|Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.
214954239|NCT01471444|DRUG|Tacrolimus|Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
214954240|NCT01471444|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
214954241|NCT04140812|DIAGNOSTIC_TEST|mass spectrometry (LC-MS/MS)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.
214954242|NCT03373747|DIAGNOSTIC_TEST|Reliability of IET|The participants will be do three sessions: familiarization, test and retest to assess the reliability inter and intra rater of the test.
214954243|NCT03373747|DIAGNOSTIC_TEST|Physiological analysis of IET|The participants will be submitted two sessions, familiarization session and test session. In the test session there will be the physiological analysis by means of gas analysis, blood lactate concentrate and activation muscular percentage.
214954244|NCT05851638|DEVICE|Lung Oxygen measurement with GASMAS system|A specially designed light source probe (2x2cm size) with 2x incorporated laser sources and a detector probe (2x2cm size) will be attached to the torso of the infant in a total of 10 locations to measure lung oxygen.
214346147|NCT01134029|BEHAVIORAL|Stepped Care|This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
214954245|NCT04712409|PROCEDURE|Single anastomosis duodeno-ileal bypass|Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion
214954246|NCT04712409|PROCEDURE|Biliopancreatic diversion with duodenal switch|Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.
214954247|NCT04712409|PROCEDURE|SADI-S as a revisional procedure|In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery
214954248|NCT04712409|PROCEDURE|BPD-DS as a revisional procedure|In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery
214954249|NCT06956053|DIAGNOSTIC_TEST|Rapid ID/AST method|"1. BioFire® Film Array® Blood Culture Identification 2 BCID2 panel, bioMérieux/BioFire Diagnostics, CE marked (FDA cleared)~2. BioFire® FilmArray® Pneumonia Panels, CE marked (FDA cleared)~3. SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility test (AST) System, bioMérieux/Specific Diagnostics, CE-IVD and -IVDR marked"
214954250|NCT06956053|DIAGNOSTIC_TEST|Conventional biological methods|Usual care
214954251|NCT00833014|DEVICE|Dynamic Annuloplasty Ring (with option to adjust off-pump)|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
214954252|NCT01269619|DEVICE|Dynamic back support|A dynamic back support which provides pressure on the lumbar without pressure on the abdomen
214346148|NCT06380231|OTHER|kangaroo mother care (KMC)|"Kangaroo mother care is a simple care that aims to protect the health and well-being of premature babies, where skin-to-skin contact is achieved by placing the premature baby in an upright position, face down, between the parent's breasts, wearing only a diaper and a cap.~Before the experimental group infant was given to the mother, his/her hat was put on, and clothes were removed. The infant was placed in an upright position (approximately 60°) between the mother's two breasts. To enable the infant to breathe, his/her head was positioned to the right or left with ear touching the mother's chest, arms and legs were flexed, and hip was abducted. The mother supported the infant's neck and back with one hand and the hips with the other. The infant's back was covered with a cotton blanket. An noninvasive pulse Co-oximetry was attached to the right wrist of the infant to evaluate heart rate, oxygen saturation, and perfusion index."
214346149|NCT03787394|OTHER|adding taste enhancer|Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
214346150|NCT00407537|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
214346151|NCT03094689|OTHER|Cold water immersion|
214346152|NCT03094689|OTHER|Water immersion|
214346153|NCT01519206|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
214346154|NCT00102895|DRUG|CP-724,714|
214346155|NCT02009176|PROCEDURE|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
214346156|NCT02009176|PROCEDURE|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
214346157|NCT02356380|OTHER|Mobilization Type|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
214346158|NCT06486740|DEVICE|mesofiller aox|The investigated product M-AOX-2021 was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. The both sessions was conducted within 14 days interval.
214346159|NCT05369650|DRUG|Lidocaine Hydrochloride, Injectable|The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
214346160|NCT03892772|DRUG|SAS0421a|treatment will be given for 3 days
214346161|NCT03892772|DRUG|SAS0421b|treatment will be given for 3 days
214346162|NCT03892772|DRUG|SAS0421c|treatment will be given for 3 days
214346163|NCT03892772|DRUG|placebo|placebo will be given for 3 days
214346164|NCT05152693|OTHER|Low variety|Meal components are mixed together on the plate
214346165|NCT05152693|OTHER|High Variety|Meal components are served separately on the plate
214346166|NCT05152693|OTHER|Small Portion Size|Small meal portion size
214346167|NCT05152693|OTHER|Large Portion Size|Large meal portion size
214346168|NCT05152693|OTHER|With Beverage|Meal served with water
214346169|NCT05152693|OTHER|Without Beverage|Meal served without water
214346170|NCT00712842|OTHER|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
214346171|NCT01223313|DEVICE|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
214346172|NCT00781300|DRUG|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
214346173|NCT00781300|DRUG|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
214346174|NCT03861598|DRUG|Carvedilol|Carvedilol orally starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
214346175|NCT03899883|DRUG|Pegloticase 8 MG/ML [Krystexxa]|One time dosing of pegloticase will be administered. Participants will receive an infusion of pegloticase over two hours in the outpatient clinical and translational research center (CTRC) at Children's Hospital Colorado, and will be monitored after infusion.
214346176|NCT03295188|DIETARY_SUPPLEMENT|Plasmalogen|Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
214346177|NCT03295188|DIETARY_SUPPLEMENT|Placebo|Placebo Group takes two placebo capsules per day for 12 weeks.
214346178|NCT05230238|DEVICE|Pituitary gland stimulation|Pituitary gland stimulation via an surface electrode connected to an external neurostimulator
214346179|NCT05945875|DRUG|Panitumumab-IRDye800|Given by IV
214346180|NCT05945875|OTHER|Indium In 111 Panitumumab|Given by IV
214346181|NCT05945875|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Single Photon Emission Computed Tomography
214346182|NCT05945875|PROCEDURE|Computed Tomography|Undergo Computed Tomography
214346183|NCT05945875|PROCEDURE|Resection|Undergo standard of care surgical resection
214346184|NCT05945875|PROCEDURE|Fluorescence Imaging|Undergo standard of care fluorescence imaging
214346185|NCT05841784|BEHAVIORAL|MBCT-T|MBCT-T is an 8-week group-based program that combines training in mindfulness and cognitive-behavioral therapy to reduce psychological distress and negative emotions. Each weekly 1-hour session will consist of a check-in, discussion, teaching, mindfulness or cognitive behavioral practice or exercise, inquiry by the facilitator, and summary of the at-home practice.
214346186|NCT05841784|BEHAVIORAL|Booster Mindfulness Sessions|Following the standard 8-week MBCT-T program, participants in certain arms will receive monthly MBCT-T booster sessions for 4 months of follow up. Each booster session will be 1 hour long. The sessions will include a concise review and summary of the main MBCT-T sessions.
214346187|NCT05841784|BEHAVIORAL|Website Support|Participants in certain arms will receive continuous intervention support via the use of an online study website. The website will provide quick access to intervention materials and support to encourage participants to complete the at-home practice and apply the content of the MBCT-T program to real life situations.
214954253|NCT01269619|DEVICE|Static back support|A standard wrap-around sacro lumbar support
214954254|NCT05337995|OTHER|Quantified analysis of walking during a task of passage through a horizontal opening|Functional test that reproduce a task of daily living, similar to a doorway
214954255|NCT00864305|DRUG|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
214346188|NCT05288543|DRUG|IPG7236- Single ascending dose|Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state
214346189|NCT05288543|DRUG|IPG7236- Multiple ascending dose|Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state
214954256|NCT00864305|DRUG|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
214954257|NCT00864305|DRUG|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
214346190|NCT05288543|OTHER|Placebo (Part A)|Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state
214346191|NCT05308836|COMBINATION_PRODUCT|adipose-derived messenchymal stem cell|Collaborative research program between Vinmec Research Institute of Stem Cell and Gene Technology with the National Yang-Ming University in Taiwan The adipose mesenchymal stem cell line (GXIPC1) was collected from healthy donors who have screened for infectious diseases and then multiplied in large numbers. These products were produced following the GMP laboratory system and approved by Taiwan FDA for preclinical and clinical trials with completed certificates
214346192|NCT02964936|DRUG|roxadustat|Oral administration
214346193|NCT05026736|OTHER|Quality-of-Life Assessment|Ancillary studies
214346194|NCT05026736|BIOLOGICAL|Sintilimab|Given IV
214346195|NCT05794191|BIOLOGICAL|Vaccine Administration|PCV13 administration
214346196|NCT04081259|DRUG|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
214346197|NCT04139317|DRUG|Capmatinib|INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.
214346198|NCT04139317|BIOLOGICAL|Pembrolizumab|Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).
214346199|NCT05857163|DRUG|Rifasutenizol capsules|400 mg, BID, taken orally within half an hour after breakfast and dinner.
214346200|NCT05857163|DRUG|Rabeprazole sodium enteric-coated tablets|20 mg, BID, taken orally within half an hour before breakfast and dinner.
214346201|NCT05857163|DRUG|Amoxicillin Capsules|1 g, BID, taken orally within half an hour after breakfast and dinner.
214346202|NCT05857163|DRUG|Clarithromycin placebo tablets|BID, taken orally within half an hour after breakfast and dinner.
214346203|NCT05857163|DRUG|Bismuth potassium citrate placebo capsules|BID, taken orally within half an hour before breakfast and dinner.
214346204|NCT05857163|DRUG|Clarithromycin tablets|500 mg, BID, taken orally within half an hour after breakfast and dinner.
214954258|NCT02875717|DRUG|Acetylsalicylic acid|
214954259|NCT02875717|DRUG|low molecular weight heparin|
214954260|NCT00170391|BEHAVIORAL|Quarter of an Hour rule|
214954261|NCT01031004|DEVICE|narafilcon B|contact lens
214954262|NCT01031004|DEVICE|etafilcon A|contact lens
214954263|NCT04027179|DRUG|0.12% chlorhexidine digluconate mouthwash|0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
214954264|NCT04027179|PROCEDURE|Periodontal instrumentation|Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
214954265|NCT04027179|DRUG|Placebo mouthwash|placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
214954266|NCT04474977|OTHER|Microvascular Decompressive Surgery|Microvascular decompression for hemifacial spasm
214954267|NCT00263419|BEHAVIORAL|Mindfulness Based Stress Reduction|8 weeks mindfulness based stress reduction (MBSR) based on body and meditation practices that aims at cultivation of openness, awareness of the present moment and acceptance of all internal and external experiences. It is assumed that this allows to act more reflectively rather than impulsively.
214346205|NCT05857163|DRUG|Bismuth potassium citrate capsules|240 mg, BID, taken orally within half an hour before breakfast and dinner.
214346206|NCT05857163|DRUG|Rifasutenizol placebo capsules|BID, taken orally within half an hour before breakfast and dinner.
214346207|NCT05865106|DEVICE|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
214346208|NCT05865106|OTHER|Traditional speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
214346209|NCT06963268|PROCEDURE|Sentinel Node Technique|A 0.2 ml (27 mBq) dose of 99mTc and 0.5 ml (1.25 mg/ml) of ICG is injected subperitoneally in the dorsal or ventral side of the pelvic infundibulum stump, and 0.2 ml (27 mBq) of 99mTc and 1 ml (1.25 mg/ml) of ICG intracervically. Sentinel nodes are located using the auditory signal from the gamma probe and visually via ICG staining with an infrared light system. After 30 minutes, all identified nodes are removed. Deferred histology applies ultra-staging for negative or micrometastatic nodes.
214346210|NCT06962982|BEHAVIORAL|Therapeutic Exercises|Therapeutic exercises including stretching and active exercises for neck and shoulder.
214346211|NCT06962982|BEHAVIORAL|Ergonomic Training|Recommendations for adjustments to the chair, desk, and equipment to optimize comfort and efficiency and reduce unnecessary stress and loading on neck muscles.
214346212|NCT06962982|DEVICE|Human XR device - Oculus Quest 3|Meta Quest 3 is a standalone virtual reality headset by Meta Platforms featuring a slimmer design, higher-resolution dual LCD displays, improved performance with the Snapdragon XR2 Gen 2 chip, and advanced mixed reality capabilities through color passthrough cameras and a depth sensor.
214678547|NCT02238405|OTHER|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
214678548|NCT05000580|PROCEDURE|Surgical|Conservative vs surgical management
214954268|NCT00211432|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
214954269|NCT05861895|DRUG|HF158K1 /Arm 2 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
214954270|NCT05861895|DRUG|HF158K1 /Arm 6 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
214954271|NCT05861895|DRUG|HF158K1 /Arm 15 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
214954272|NCT05861895|DRUG|HF158K1 /Arm 30 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
214954273|NCT05861895|DRUG|HF158K1 /Arm 45 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
214954274|NCT05861895|DRUG|HF158K1 /Arm 60 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
214954275|NCT02799914|DEVICE|Sinus-Venous stent (Optimed GmbH)|Stent implantation
215077435|NCT06660992|DRUG|HSK31858, tablet|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis
215077436|NCT06660992|DRUG|Placebo|the placebo comparator of study
215077437|NCT06659068|DIETARY_SUPPLEMENT|Seluang fish oil (Rasbora argyrotaenia) and synbiotic|The patients received seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
214346213|NCT06961448|DEVICE|Hyaluronate Gel for Injection|Apply a maximum of 1.5 mL per side of the nasolabial fold using the test device (Lafullen) or the control device, with an optional touch-up of up to 0.5 mL per side at 4 weeks based on investigator assessment.
214346214|NCT06961448|DEVICE|Polycaprolactone microsphere filler|Apply a maximum of 1.0 mL per side of the nasolabial fold using the test device (Lafullen) or the control device, with an optional touch-up of up to 0.5 mL per side at 4 weeks based on investigator assessment.
214346215|NCT06962150|PROCEDURE|Surgeon-placed transversus abdominis plane block|Participants will receive a transversus abdominis plane (TAP) block intraoperatively, administered by the operating plastic surgeon. The drug components of the TAP block are 20 ml liposomal bupivacaine (Exparel) mixed with 20 ml 0.5% bupivacaine.
214678549|NCT06099054|DEVICE|Pigtail catheter|Pigtail catheter will be inserted using Seldinger technique under US guidance to drainage exudative pleural effusion by a trained radiologist
214678550|NCT06099054|DEVICE|Intercostal tube|Chest tube will be inserted according to BTS guideline for insertion of ICT by a trained thoracic surgeon
214678551|NCT00816218|DRUG|Pioglitazone|pioglitazone, 45 mg daily
215077438|NCT06659068|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
214346216|NCT06962150|PROCEDURE|Ultrasound-guided quadratus lumborum block|Participants will receive a quadratus lumborum (QL) block preoperatively, administered by the anesthesiologist under ultrasound guidance. The drug components of the QL block are 10 mg dexamethasone, 80 mg methylprednisolone acetate, plus either 0.25% or 0.5% bupivacaine at the dose of 0.25 mg/kg bupivacaine.
214346217|NCT02175433|DRUG|AGS67E|intravenous (IV) infusion
214346218|NCT03348670|DRUG|Abiraterone - Usual|"* Oral~* Abiraterone Combined Chemotherapy"
214346219|NCT03348670|DRUG|Abiraterone - Study|"* Oral~* Abiraterone Combined Chemotherapy"
214346220|NCT05935540|OTHER|ACP-Family|"It consists of two sessions (45-60 mins) to be delivered within one month in a face-to-face format as long as the patient is still in the hospital. The treatment will be continued in the patient's home if he/she is discharged before the two sessions are completed.~The treatment will cover five elements in ACP, namely (1) patients' understanding of their illness, (2) patients' values and beliefs underpinning care preferences, (3) possible health conditions in the future, (4) introducing the idea of AD and its arrangement, and (5) construction of the role of substituted decision maker. A 3-min video on end-of-life treatment options will be shown to help patients and family members to clearly understand the related topic. However, there will be no restriction on the order of the five topics to be discussed during the intervention."
214346221|NCT06636604|OTHER|DSA(Decision Support Algorithm)|Intramuscular injection will be given to 30 volunteer patients using the decision support algorithm.
214346222|NCT06635772|DRUG|HS-10390|HS-10390 will be administered daily
214346223|NCT06635772|DRUG|Irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg
214346224|NCT06634966|PROCEDURE|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
214346225|NCT06635096|DEVICE|Multimodal Tumor Thermal Therapy System (Shanghai MAaGI Medical Technology Co., Ltd.)|These patients will receive multimodal thermal therapy using Multimodal Tumor Thermal Therapy System.
214346226|NCT06636409|OTHER|Collection of medical data|A randomised selection of files to be analyzed will be conducted in each center to constitute a representative sample of liver transplanted patients. This represents 20% of the number of transplanted patients over the period 2008-2013 in the center, allowing a more in-depth analysis of the patients' medical records.
214346227|NCT06634511|OTHER|core stability exercises|"Group A: core stability exercise group:15 Patients assigned to this group will undergo a core stability exercises ts.2times per week /8weeksin addition to conventional therapy (Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes~Group B:(aerobic exercise group) 15 patients will receive aerobic exercise in the form of treadmill for 30 minutes2 session per week/8 weeks~Group C(conventional group): 15 patients will receive Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes, Participants were treated twice weekly"
214346228|NCT05395494|DRUG|D-Cycloserine|"Daily oral D-cycloserine 100mg during TMS treatments (20 days).~Other Names:~Seromycin"
214346229|NCT05395494|DRUG|Placebo oral tablet|Daily oral placebo during the TMS treatments (20 days).
214346230|NCT05395494|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
214346231|NCT06634446|DEVICE|a mobile application for cognitive training|"Personalized cognitive training (PCT) HappyNeuronwill be delivered via a tablet or mobile application for 24 hours within 12 weeks, with a weekly supervision-call to reinforce their motivation.~HappyNeuron Pro is a digital therapy tool designed for clinicians to provide engaging cognitive therapy via a web-based platform. It is compatible with PC, Mac, iPad, and Android devices and is available in multiple languages. The tool features exercises from established cognitive remediation programs.~Functionality: The program offers 22 cognitive exercises targeting seven key functions outlined in the MATRICS framework: Processing Speed, Selective Attention, Reasoning and Working Memory, Verbal Memory, Visual Memory, and Auditory Memory. Exercises are customizable to meet individual patient needs, facilitating personalized cognitive training.~User Experience: Each session comprises brief, self-administered exercises, with the order and difficulty adjusted by clinicians."
214346232|NCT06634446|DEVICE|video games|Patients in the control group will use video games with no prominent cognitive involvement no prominent cognitive involvement
214346233|NCT06635330|BIOLOGICAL|anti-CD19 CAR T cell therapy|Anti-CD19 CAR-T cell therapy for R/R B-ALL pediatric patients. For patients 50 kg and less: 0.2 to 5 in ten to the power of six live CAR+ T cells per kilogram of body weight/ For patients over 50 kg: 0.1 to 2.5 in ten to the power of eight live CAR+ T cells (without considering weight).
214346234|NCT05059678|OTHER|Best Practice|Receive standard of care
214346235|NCT05059678|OTHER|Educational Intervention|Receive educational materials and attend videoconference sessions
214346236|NCT05059678|OTHER|Questionnaire Administration|Ancillary studies
214346237|NCT06634628|RADIATION|Radioligand [11C]CHDI-00491009|Intravenous injection of radioligand in the arm with PET imaging of the brain.
214678552|NCT02458651|OTHER|No intervention|No intervention administered in this study
214678553|NCT01611077|DRUG|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
214954276|NCT06127758|OTHER|virtual reality glasses application|The experimental group will be given classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower). After 15 minutes video containing nature images and sounds will be shown through virtual glasses.
214954277|NCT06127758|OTHER|classical training|Information about classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower) will be given.
214954278|NCT04886297|DRUG|Mega Resveratrol® capsules|Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.
214954279|NCT04886297|DRUG|Mega Resveratrol® Placebo capsules|Mega Resveratrol® Placebo capsules
214954280|NCT04357938|DEVICE|CT-imaging|Chest CT to rule out pneumonia in PCR negative, nonspecific symptomatic patients to prevent the spread of SARS-CoV-2 within the hospital.
214954281|NCT00568893|DRUG|drotrecogin alfa (activated)|
214954282|NCT02865629|DRUG|N-acetyl cysteine|N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
214954283|NCT00420953|DRUG|Cordarone|
214954284|NCT02634801|DRUG|Fumaric Acid Esters|Administered orally
215077439|NCT06661512|OTHER|Neurorehabilitation program|"Participants will participate in a neurorehabilitation program, consisting in a structured, interdisciplinary approach designed to help individuals improve their functional abilities following acquired brain injury. The goal is to optimize the individual's physical, cognitive, emotional, and social functioning to enhance their quality of life~The neurorehabilitation program includes, physical rehabilitation, occupational therapy, speech therapy and neuropsychological rehabilitation (cognitive, emotional and behavioral)."
214346238|NCT06635733|BEHAVIORAL|Rhapsode Capable™ Platform (Intervention Group)|Participants in the intervention group will use the Rhapsode Capable™ platform to facilitate In-Person Skills Practice (ISP) sessions. The platform allows for scheduling ISP sessions, providing real-time performance feedback, and tracking progress. The platform integrates with the PACE adaptive learning modules, which cover pediatric acute care topics. The goal is to improve skills retention and performance in pediatric care through a blended learning approach.
214346239|NCT06635733|BEHAVIORAL|Paper-based ISP (Control Group)|Participants in the control group will also receive In-Person Skills Practice (ISP) sessions facilitated by clinical champions, but without the use of the digital platform. The ISP sessions will be tracked and scheduled using paper-based assessments. Feedback will be provided verbally or manually, and progress will be documented using paper forms. Both groups will receive the same PACE adaptive learning modules, but the method of ISP implementation differs between the groups.
214346240|NCT06027216|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
214346241|NCT05997693|DRUG|Ticagrelor 90 MG|Ticagrelor 90 mg twice daily taken orally for one month
214346242|NCT05997693|DRUG|Low-dose aspirin|75-150 mg once daily taken orally
214346243|NCT01316133|DRUG|tacrolimus|oral
214346244|NCT04049526|BEHAVIORAL|The influence of different music genres on Heart Rate Variability (HRV) in preterm infants|Neonates undergo a daily randomized music listening program (25 minutes, every day, for 3 days) based on different music genres listening (soft pop-rap, pop-rock and classical music). Music programs is followed by 1 day of no music monitoring (25 minutes). An electrocardiogram is performed to evaluate HRV parameters in each neonate with and without music exposure
214678554|NCT01611077|DRUG|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
214678555|NCT01611077|DRUG|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
214678556|NCT04003506|DRUG|Liposomal bupivacaine|LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine
214678557|NCT04003506|DRUG|Bupivacaine Injection|LIA with ACB will be given using 20ml 0.5% standard bupivacaine
214954285|NCT02634801|DRUG|Methotrexate|Administered orally
214954286|NCT02634801|DRUG|Ixekizumab|Administered SC
214954287|NCT04705532|DEVICE|tDCS|Multi-channel tDCS will be applied over the executive network for 20 minutes at 4mA
214954288|NCT04705532|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
214954289|NCT04705532|OTHER|Music|Subjects will listen to their preferred music for 20 minutes
214954290|NCT04705532|OTHER|White noise|Subjects will listen to a white noise for 20 minutes
214954291|NCT00888498|OTHER|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
214954292|NCT00888498|OTHER|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
215077440|NCT06657885|DRUG|his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi|"cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48"
214954293|NCT00888498|OTHER|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
214954294|NCT00280514|DRUG|cefpirome and moxifloxacin administration|
215077441|NCT06659471|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
214678558|NCT03626415|DRUG|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
214678559|NCT00359814|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
214678560|NCT00359814|DRUG|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
214678561|NCT02022423|BEHAVIORAL|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
214954295|NCT02228018|DEVICE|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
214954296|NCT04158505|OTHER|non-interventional|This prospective, observational study will be conducted according to each site's routine clinical practice
214954297|NCT00003974|BIOLOGICAL|lung tumor associated antigen|
214954298|NCT00003974|DRUG|DetoxPC|
215077442|NCT06659471|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
215077443|NCT06110715|OTHER|theta tACS stimulation|The low intensity transcranial electrical stimulation will be administered with a battery-powered, current-controlled, multi-channel stimulator from Neuroelectrics® Starstim 8. This device comes with a neoprene headcap to hold the electrodes in place. TACS will be delivered concurrently with the task. The multichannel, current-driven stimulator (Neuroelectrics StarStim 8) will be used to control independent stimulation electrodes on the scalp of the volunteer. The stimulation intensity will be up to 2 mA.
215077444|NCT06110715|OTHER|sham tACS stimulation|A placebo control stimulation will use an identical montage to the stimulation montage. However, polarities of the electrodes will be such that only a minimal amount of current reaches the brain, which is achieved through controlled current shunting between neighboring electrodes. This so-called ActiSham protocol is a verified method to imitate the sensations of actual tACS, with minimal stimulation of the brain .
215077445|NCT04942015|DRUG|Honghuaruyi Wan|Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
215077446|NCT04942015|DRUG|Placebo of Honghuaruyi Wan|Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
215077447|NCT05131971|DRUG|GSK3888130B|GSK3888130B will be administered.
215077448|NCT05131971|DRUG|Placebo|Placebo will be administered.
215077449|NCT06608342|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19-CART|Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation
214954299|NCT00003974|DRUG|chemotherapy|
214954300|NCT00003974|DRUG|cyclophosphamide|
214346245|NCT03246360|DRUG|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms"
214954301|NCT04129112|DRUG|We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening|Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening
214346246|NCT04994366|OTHER|Thank you card|A card thanking the patient for choosing NYU and entrusting us with their care. The card notifies the patient that they may receive a patient satisfaction survey after discharge.
214346247|NCT00003878|DRUG|polifeprosan 20 with carmustine implant|
214346248|NCT00003878|PROCEDURE|conventional surgery|
214346249|NCT04445584|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI
214346250|NCT02736539|DRUG|CBS 2004 (galacto-oligosaccharides)|CBS 2004 active treatment
214954302|NCT04078854|BEHAVIORAL|Diabetes education|Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.
214346251|NCT02736539|DRUG|Placebo|Placebo treatment
214346252|NCT05348681|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
214346253|NCT05348681|DRUG|Placebo|Matching placebo
214346254|NCT03850392|DEVICE|cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)|cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval
214346255|NCT01470027|DRUG|N-acetylcysteine|900mg NAC effervescent tablets
214346256|NCT01470027|DRUG|Placebo|effervescent tablets
214346257|NCT00716261|DEVICE|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
214346258|NCT03646513|DEVICE|SMF Short Modular Femoral Hip System|Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
214346259|NCT01993524|DIETARY_SUPPLEMENT|probiotic|antibiotic plus probiotic
214954303|NCT01141920|BEHAVIORAL|low threshold care|Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.
214346260|NCT01993524|OTHER|placebo|antibiotic plus placebo
214346261|NCT00782340|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
214346262|NCT00782340|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
214346263|NCT05668494|OTHER|immediate loading of implants|This is a randomized control clinical trial including 24 implants, immediately loaded with definitive abutment protocol and 24 implants immediately loaded with with temporary abutment protocol
214346264|NCT06059703|PROCEDURE|Blood punction|Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
215077450|NCT06608719|BIOLOGICAL|The study drug is SHED-CM manufactured by U-Factor|Patients diagnosed with ALS were administered SHED-CM
215077451|NCT06604936|OTHER|Fibromyalgia group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Functional status of the patients will be evaluated with the Fibromyalgia Impact Questionnaire. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
214346265|NCT06059703|PROCEDURE|Central blood sampling|Central blood sampling (2 ml) at inclusion and 3 months after treatment
214346266|NCT06059703|PROCEDURE|Intracranial pressure measurement|Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
214346267|NCT04952766|BIOLOGICAL|Biological samples|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
214346268|NCT05442411|DRUG|Ropivacaine 0.75% Injectable Solution|comparison of scalp block vs conventional post operative parecoxib
214678562|NCT02022423|BEHAVIORAL|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals
214678563|NCT05159232|PROCEDURE|hospital stay|hospital stay in in inguinal hernia repair
214954304|NCT01141920|BEHAVIORAL|stepped-based care|Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
214954305|NCT06229041|DRUG|Camrelizumab ＋Immunotherapy|Camrelizumab was used in preoperative treatment.
214346269|NCT03727893|BEHAVIORAL|Roller-based Intervention Group (IG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
214346270|NCT03727893|BEHAVIORAL|Control Group (CG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
214346271|NCT03471689|BEHAVIORAL|Mindfulness meditation|Participants will be trained to use mindfulness meditation to reduce pain perception.
214346272|NCT03471689|BEHAVIORAL|Positive reappraisal|Participants will be trained to use positive reappraisal to reduce pain perception.
214346273|NCT03116139|DIAGNOSTIC_TEST|V/Q imaging|Standard of care
214346274|NCT03116139|DIAGNOSTIC_TEST|Computed tomography scan|Standard of care
214346275|NCT03869229|BIOLOGICAL|Intra-articular injection of ADMSC|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
214346276|NCT02863016|DEVICE|SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
214346277|NCT03797027|DEVICE|Percutaneous Nephrolithotomy without an abdominal cushion|patients undergo prone PNCL without an abdominal cushion
214346278|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 5 cm abdominal cushion
214346279|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 10 cm abdominal cushion
214346280|NCT00743353|DRUG|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
214954306|NCT00582426|DRUG|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
214954307|NCT00582426|OTHER|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
214954308|NCT00143169|DRUG|Parecoxib and placebo|
214954309|NCT00373126|DRUG|transdermal nicotine patch|
214346281|NCT00001059|DRUG|Doxorubicin hydrochloride (liposomal)|
214346282|NCT00001059|DRUG|Filgrastim|
214346283|NCT00001059|DRUG|Bleomycin sulfate|
214954310|NCT06786832|BEHAVIORAL|Cognitive behavioral therapy for persistent fatigue|"The treatment is based on a treatment manual that has previously been evaluated in several randomized controlled trials for persistently fatigued patients with various types of chronic somatic disorders (primarily in specialized healthcare settings).~In this trial we have translated the treatment manual to Swedish and adopted it for implementation in a Swedish primary care setting. The treatment format is blended, meaning that the treatment is administered both via an online platform (where the participant can communicate with the therapist through asynchronous text-messages) and via face-to-face therapy sessions with the therapist."
214954311|NCT06786832|OTHER|Care as usual|Since there are no standardized, structured care programs and guidelines for the patient group, CAU may include a broad variety of psychosocial support, psychological treatment, physiotherapy, occupational therapy, pharmacological treatment, follow-up within specialist healthcare, and/or follow-up by general practitioners. An important aim of the project is to carefully map the content and scope of the care offered to patients in the study within the framework of CAU.
214954312|NCT05009134|BIOLOGICAL|There is no intervention in this study.|There is no intervention in this study.
214954313|NCT03475290|BEHAVIORAL|Personal resources' enhancement: self-efficacy and perceived social support|The condition reflects cultivation hypothesis and consists of 2 sequential modules with self-efficacy enhancement module (SE) preceding perceived social support enhancement module (SS). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SE: mastery experience, vicarious experience, and action planning, 2) SS: received support \& cognitive distortions, social skills \& peer support, action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
214346284|NCT00001059|DRUG|Vincristine sulfate|
214346285|NCT06397404|DIAGNOSTIC_TEST|Venous excess ultrasound score (VExUS) protocol|All patients upon admission undergo ultrasound assessment of diameter and collapsibility of the inferior vena cava, hepatic vein Doppler, portal vein Doppler, intra-renal venous Doppler.
214346286|NCT01972061|DEVICE|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
214346287|NCT02219932|DRUG|fampridine|
214346288|NCT02219932|DRUG|Placebo|Matched placebo
214346289|NCT01866410|DRUG|Cabozantinib S-malate|Given PO
214346290|NCT01866410|DRUG|Erlotinib Hydrochloride|Given PO
214346291|NCT01866410|OTHER|Laboratory Biomarker Analysis|Correlative studies
214346292|NCT02742727|BIOLOGICAL|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
214346293|NCT01271335|BIOLOGICAL|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
214346294|NCT00489450|DRUG|SK3530|
214346295|NCT06529653|PROCEDURE|autogenous bone wedge|autogenous bone block harvested from chin and adjusted to be wedged intercortical in split ridge
214346296|NCT01490346|DRUG|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
214346297|NCT03497923|DRUG|Magnesium Sulfate|After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.
214954314|NCT03475290|BEHAVIORAL|Personal resources' enhancement: perceived social support and self-efficacy|The condition reflects enabling hypothesis and consists of 2 sequential modules with perceived social support enhancement module (SS) preceding self-efficacy enhancement module (SE). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SS: received support \& cognitive distortions, social skills \& peer support, and action planning, 2) SE: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
214954315|NCT03475290|BEHAVIORAL|Personal resources' enhancement: self-efficacy|The condition consists of self-efficacy enhancement module (SE) and is comprised of 3 evidence-based, CBT-framed exercises: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
214954316|NCT03475290|BEHAVIORAL|Personal resources' enhancement: perceived social support|The condition consists of perceived social support enhancement module (SS) and is comprised of 3 evidence-based, CBT-framed exercises: received support \& cognitive distortions, social skills \& peer support, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
214954317|NCT03097926|PROCEDURE|Long alimentary limb BPD-DS|BPD-DS with a long strict alimentary limb and a 100-cm common channel.
214954318|NCT05110365|OTHER|Proprioceptive Neuromuscular Facilitation|"The patient will be provided with mild to moderate resistance PNF pattern which is a type of Endurance training which decreases BP through a reduction in systemic vascular resistance(15).In a regimen as follow with the frequency of 3 days a week, a repetition of 3 sets for one hour and a total duration of 3 months(16). The PNF patterns will be diagonal 1 (D1) and diagonal 2 (D2) patterns. Both patterns are subdivided into: A) Moving into Flexion: the toes start flexed and ends extended. Ankle and foot start plantar flexed; everted and ends dorsiflexed inverted. Tibia starts externally rotated and ends internally rotated. Knee starts extended, and ends flexed. The hip starts extended, abducted, internally rotated and ends flexed, adducted, externally rotated.B) Moving into Extension: The start and end are reversed to D1 Moving into Flexion"
215077452|NCT06604936|OTHER|Healthy group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
214954319|NCT06451666|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days
214954320|NCT06451666|DRUG|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
214954321|NCT05588934|DIETARY_SUPPLEMENT|Caffeine Gum|Commercially available caffeinated gum that contains 100mg of caffeine per piece of gum.
214954322|NCT05588934|OTHER|Placebo Gum|Commercially available non-caffeinated gum.
214954323|NCT04877899|DEVICE|EchoGo|"EchoGo Core is a stand-alone software application. Echocardiograms should be acquired under the supervision of a physician and standard clinical protocols which includes focused apical 2, 3 and 4 chamber views. The results contain calculated measurements that will be returned to the interpreting physician. These results are intended as an additional input to standard diagnostic pathways and should only be used by a board-certified cardiologist/physician.~EchoGo Core is intended to be used for the quantification and reporting of results of cardiovascular function to support physician diagnosis. EchoGo Core is indicated for use in adult populations."
214954324|NCT00872612|PROCEDURE|EUS-FNA/EBUS-TBNA + BAL|"EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.~EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.~BAL = bronchoalveolar lavage"
214954325|NCT00872612|PROCEDURE|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
214954326|NCT01442649|DRUG|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
214954327|NCT01442649|DRUG|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
214954328|NCT01442649|DRUG|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
214954329|NCT01442649|DRUG|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
214346298|NCT00112073|DRUG|bapineuzumab|IV, Q13w
214346299|NCT00112073|OTHER|placebo|IV Q13w
214346300|NCT01989650|OTHER|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
214346301|NCT01989650|OTHER|No break|No break will be provided
214346302|NCT00093145|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
214346303|NCT00093145|DRUG|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
214346304|NCT00093145|DRUG|Herceptin®|Administered by IV infusion
214346305|NCT05808725|DRUG|Amlodipine Freeze-Dried Powder for Oral Solution 5 mg|Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed
214954330|NCT01442649|DRUG|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
214954331|NCT01442649|DRUG|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
214954332|NCT01285778|DRUG|panitumumab, mytomicin C, 5-FU, radiation|"Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:~* First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks~* Then Mitomycin C, 10mg/m2 on days 1 and 29~* Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32~* Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy."
214954333|NCT00662311|DRUG|vorinostat|Given PO
214954334|NCT00662311|DRUG|paclitaxel|Given IV
215077453|NCT06586138|OTHER|STAI (State-Trait Anxiety Inventory) Scale : Psychological inventory of 20 self-report items on a 4-point scale|Patient completed STAI Scale in the 24 hours before Maintenance of Wakefulness Test during the hospitalization
214954335|NCT00662311|RADIATION|radiation therapy|Undergo radiation therapy
214954336|NCT06503289|DEVICE|Cytosorb therapy|Extracorporeal treatment with cytosorb filter to patients diagnosed with rhabdomyolysis
214954337|NCT01649362|OTHER|prefeeding oral stimulation program|"The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.~The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day."
214954338|NCT03699072|DEVICE|DermaRep™ Wound Contact Device|Treatment of venous leg ulcers once weekly for 8 weeks along with standard of care dressings
214954339|NCT03615820|DRUG|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film
214954340|NCT03615820|DRUG|Oromucoadhesive film|Oromucoadhesive film without PPE control testing which represents Placebo group
214954341|NCT00617747|DRUG|Zolmitriptan|5mg Nasal Spray
214954342|NCT00617747|DRUG|Placebo|
214954343|NCT01548768|DRUG|TNF inhibitors|"TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi."
214954344|NCT01548768|DRUG|DMARDs|Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
214954345|NCT02806271|BEHAVIORAL|Worry Postponement|"In worry postponement, participants are instructed to learn to notice naturally occurring episodes of worry. When they notice they are worrying they are instructed to disengage from their worry and postpone it to a designated 30 minute worry period to be carried out at the same time and place daily during the two week intervention. Participants are to use their worry time to worry about problems that have come up during the day and to problem solve where appropriate."
214954346|NCT02806271|BEHAVIORAL|Worry Monitoring|For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
215077454|NCT05032690|DRUG|Bosutinib capsule|Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast
215077455|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast
215077456|NCT05032690|DRUG|Bosutinib|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours
215077457|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast
215077458|NCT06661928|PROCEDURE|Papilla preservation flap|"Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used.~Suturing will be performed with external vertical mattress sutures to achieve primary intention closure."
214346306|NCT05808725|DRUG|Norvasc 5 mg tablets of Pfizer Labs|Norvasc 5 mg is given to R Fasting
214678564|NCT06212895|OTHER|Survey|"A survey is handled out at the patient registration. Patients can fill it out during waiting for their appointment. The physician, who treats the patients is not aware aout the filling status or content. The Survy will not influence the treatment.~The Survey consists of 3 parts: patients attidude and expectations, and questionnaire about their usual physical activity and the validated Expectation Treatment Score."
214346307|NCT00003269|BIOLOGICAL|sargramostim|
214346308|NCT00003269|DRUG|amifostine trihydrate|
214346309|NCT00003269|DRUG|cisplatin|
214346310|NCT00003269|DRUG|cyclophosphamide|
214346311|NCT00003269|DRUG|etoposide|
214346312|NCT03330665|BEHAVIORAL|Meditation|Meditate 3 times a week using headspace app
214954347|NCT04391777|OTHER|Fourth ventricle compression technique (CV-4)|The participant is in the supine position and the principal investigator is seated at the patient's head, with elbows resting on the table. The main investigator overlaps his hands with the thenar eminences, contacting the occipital bone squamous part, between the external occipital protuberance and the participant's occipito-mastoid suture. The technique begins with a maintained compression on the occipital squamous part during a deep thorax exhalation. Throughout the compression of the occipital bone and the participant's voluntary inspirations, the principal investigator feels a gradual pressure increase at the thenar eminences. The technique will be performed until reaching the still point, in which the mobility of the occipital bone, respiratory rate and muscle tone decrease, or until 5 minutes elapsed.
215077459|NCT06661928|PROCEDURE|Widman flap procedure|"Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures."
214346313|NCT00216684|DRUG|fentanyl|
214346314|NCT04389840|DRUG|Dociparstat sodium|Dociparstat is a glycosaminoglycan derived from porcine heparin.
214346315|NCT04389840|DRUG|Placebo|0.9% Normal Saline
214346316|NCT03057548|PROCEDURE|Cryo or RF Ablation only of Pulmonary Veins|"Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins~OR~FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.~Ablation of the Pulmonary Veins alone"
214346317|NCT03057548|PROCEDURE|Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW|"Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW~OR~RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW~Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)"
214346318|NCT03577002|OTHER|Serious Illness Care Program (SICP)|SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
214346319|NCT04279249|OTHER|HEPA Air Filtration|2 HEPA air filters placed in home (one in bedroom, one in living room) for 30 days
214346320|NCT04279249|OTHER|Sham HEPA Air Filtration|2 HEPA air filter devices with filter removed placed in home (one in bedroom, one in living room) for 30 days
214346321|NCT04733560|PROCEDURE|Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml 0.25% Bupivacaine prior to making any surgical incisions.
214346322|NCT04733560|PROCEDURE|Sham Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml Normal Saline prior to making any surgical incisions.
214346323|NCT04733560|DRUG|Bupivacaine Injectable Product|Used for pudendal nerve block in the intervention arm
214346324|NCT02633384|OTHER|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
214346325|NCT02633384|OTHER|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
214346326|NCT05970393|PROCEDURE|pressure support level tatrition|Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Upward and downward PS level adjustments were performed from the baseline PS level at a 1cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. PMI mean value was measured and calculated at every PS level. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O, and titrating PS was stopped until PMI was less than -1cmH2O and more than 3cmH2O.The inspiratory effort is measured as the pressure generated by inspiratory muscles using esophageal pressure monitoring.
214346327|NCT01283269|BEHAVIORAL|Memory Support System|Training in use of a memory notebook system
214346328|NCT01283269|BEHAVIORAL|Computer Training|Computer brain fitness training
214346329|NCT00518947|DRUG|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
214346330|NCT00518947|DRUG|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
214346331|NCT00518947|DRUG|verapamil plus lithium|
214346332|NCT01176253|PROCEDURE|Blood draw|Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
214346333|NCT00177229|BEHAVIORAL|Family-based treatment|20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
214346334|NCT02107521|OTHER|Intracytoplasmic morphologically selected sperm injection|Sperm selection for injection will be performed at 6600x magnification
214346335|NCT02107521|OTHER|Intracytoplasmic sperm injection|sperm selection for injection will be performed under 400x magnification
214346336|NCT02605980|BEHAVIORAL|Sedentary time|
214346337|NCT03776981|OTHER|Core Activation|Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.
214346338|NCT03776981|OTHER|Core Stabilization|Six-week core stabilization program for the group of participants with knee osteoarthritis.
214954348|NCT04391777|OTHER|Sham|The main investigator uses the technique contact but does not perform any type of tissue traction or compression, maintaining this contact for 5 minutes. At the end of the stipulated time, the contact is removed in a subtle way.
214346339|NCT02540200|DEVICE|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
214346340|NCT02540200|PROCEDURE|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
214346341|NCT03569280|COMBINATION_PRODUCT|Enzalutamide or Abiraterone or Apalutamid|Antitumor treatment
214678565|NCT06035380|OTHER|placebo group|aromatherapy
214678566|NCT06035380|OTHER|mint oil group|aromatherapy
214678567|NCT06035380|OTHER|rose oil group|aromatherapy
214954349|NCT01176123|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia
214954350|NCT05865158|OTHER|Home-based exercises|Home-based exercises proposed through the CardioSafe+ platform, guided by therapists specialized in cardiovascular disorders, who will try to adapt the sessions to each participant.
214954351|NCT00572871|OTHER|plyometric exercise|single bout of plyometric exercise
214954352|NCT00572871|OTHER|resistance exercise|single bout of resistance exercise
214954353|NCT00572871|OTHER|No exercise|Will not do any exercise
215077460|NCT06008418|BEHAVIORAL|The LINE Chatbot|The chatbot approach is selected as it uses artificial intelligence to simulate conversations with users. The information can be collected or distributed and even through these conversations trigger human actions. LINE is one of the most widely used freeware applications in Taiwan and its chatbot function is well-organized and relatively easy to modify, adapt, and use. The design of the chatbot aims at the two elements above, ensuring goal alignment and enhancing power sharing, by guiding participants to complete three activities: specifying their goals for today's discussions, providing patient-reported outcomes by self-rating their health-related quality of life, and learning question prompt list based on their needs.
215077461|NCT06264817|DEVICE|MOBIDERM Autofit Armsleeve|"In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks"
215077462|NCT06264817|DEVICE|Compressive bandaging|"In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks"
215077463|NCT06605898|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
215077464|NCT06605898|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
215077465|NCT03483805|DIETARY_SUPPLEMENT|Protalsafe|mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water
215077466|NCT03483805|DIETARY_SUPPLEMENT|Placebo|maize maltodextrin in powder form, to be diluted in water
215077467|NCT06605781|BEHAVIORAL|AR/VR technology-based training|Students will receive AR/VR Technology and OSCE in a Virtual Clinical Environment to learn how to assess and manage patients with auditory hallucination. The course was designed as a diverse and interactive learning experience, integrating a virtual clinical environment for auditory hallucinations with the application of Objective Structured Clinical Examination (OSCE). The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum. Additionally, students will have access to the AR/VR materials for self-practice during the practicum.
214954354|NCT04624048|DIAGNOSTIC_TEST|COVID-19 survey|Participants should complete a survey to analyze the impact of COVID-19 on University population.
214954355|NCT04145206|BEHAVIORAL|Flamenco dance|evaluation of ankle injuries in the flamenco dancers
214954356|NCT06259149|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
214346342|NCT05467644|PROCEDURE|Treatment of Fracture Related Infection|Observational Retrospective Study. Only one group. Patients diagnosed with fracture-related infection and submitted to surgical treatment
214346343|NCT00366626|DRUG|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
214346344|NCT00366626|DRUG|Placebo|Placebo for 7 days matched to Naltrexone
214346345|NCT04423068|BEHAVIORAL|SexHealth II|SexHealth II is an intervention that will focus exclusively on provision of hormonal contraception counseling and provision for hospitalized female adolescents
214346346|NCT04423068|DRUG|Contraceptive|"The investigators will offer initiation of the following contraceptives:~Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring) Etonogestrel 68mg subcutaneous implant (Nexplanon) Medroxyprogesterone 150mg/ml 150 mg IM injection Ethinyl Estradiol and Norgestimate (Sprintec) 35mcg-0.25mg tablet Norelgestromin/Ethinyl estradiol transdermal patch (Ortho Evra) Norethindrone 0.35mg tablet~Emergency Contraception:~Ulipristal 30 mg tablet Levonorgestrel 1.5mg tablet"
214346347|NCT01953926|DRUG|Neratinib|240 mg administered orally, once daily with food, continuously in 28 day cycles
214346348|NCT01953926|DRUG|Fulvestrant|500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
214346349|NCT01953926|DRUG|Trastuzumab|Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
214954357|NCT04868578|DIETARY_SUPPLEMENT|study treatment PPI|patient take PPI every day during 12 months
214954358|NCT04868578|DIETARY_SUPPLEMENT|Placebo comparator|patient take PPI placebo every day during 12 months
214954359|NCT00005872|DRUG|rubitecan|
214954360|NCT04039425|PROCEDURE|Hair cut|Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
214346350|NCT01953926|DRUG|Paclitaxel|80mg/m\^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
214346351|NCT01276587|DRUG|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
214346352|NCT04302792|BEHAVIORAL|Texture-modified foods for cancer patients (Stage 2)|Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.
214346353|NCT04302792|BEHAVIORAL|Taste-optimised foods for cancer patients (Stage 3)|Participants (cancer patients with taste \& smell alterations) will be expected to evaluate three foods at home over a period of one month.
214954361|NCT03528382|BEHAVIORAL|Cardiac rehabilitation quality improvement system|Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises
214954362|NCT01344473|DEVICE|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
214954363|NCT00556257|DRUG|Cyclosporine|Standard of care
214954364|NCT00556257|DRUG|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
214954365|NCT00603603|OTHER|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
214954366|NCT00603603|OTHER|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
214954367|NCT01280071|DRUG|aminophylline|
215077468|NCT06605781|BEHAVIORAL|traditional vedio and discussion group|Students will receive a traditional course on auditory hallucination assessment, which includes watching educational videos and participating in a general discussion group on auditory hallucinations. The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the traditional course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum.
215077469|NCT06614647|DIAGNOSTIC_TEST|Recurrence monitoring with circulating tumor DNA (ctDNA) as a high risk biomarker|"IG patients will receive the following intervention at 3, 12, 24, and 36 months post-surgery:~1\) Recurrence risk stratification by ctDNA analysis of blood samples:~a) Only if ctDNA becomes positive, will imaging be performed. b) If ctDNA is positive, but recurrent disease is not detected by imaging or clinical and endoscopic evaluation, the patient will be referred back to intensified ctDNA measurements repeated every 4 months until either ctDNA becomes negative or recurrence is confirmed by subsequent imaging."
215077470|NCT06614647|BEHAVIORAL|Monitoring for late adverse effects with electronic patient reported outcome measures (ePROMs)|2\) Collection and analyses of ePROMs to identify whether patients suffer from organ-specific late effects or biopsychosocial late effects and monitor of health related quality of life and the impact of late adverse effects hereon.
215077471|NCT06614647|BEHAVIORAL|Systematic treatment of organ-specific late effects and/or biopsychosocial late effects|3\) When needed, standardized treatment for organ-specific late effects according to newly published national guidelines at specialized centers. Further, online cognitive behavioral therapy is offered to patients suffering from severe biopsychosocial late effects.
214346354|NCT01153646|GENETIC|pHIV7-shI-TAR-CCR5RZ treated CD4 cells|Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
214346355|NCT04686448|DRUG|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
214346356|NCT04686448|DRUG|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
214346357|NCT03675386|OTHER|Interventional Group|The Transitional Pain Service Program enables targeted, mechanism-based, treatment innovations aimed at reducing the incidence and severity of chronic post-surgical pain, disability and enabling safe opioid prescribing/ weaning after major surgery. The investigator's TPSP intervention uses a variety of methods to support patients to manage pain and wean off opioids. This includes physician-guided opioid and non-opioid pharmacotherapy and tapering, and clinical psychology services specializing in pain education, Acceptance \& Commitment Therapy (ACT) and e-mobile self-management tools.
214346358|NCT03675386|OTHER|Control Intervention|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
214954368|NCT05640063|OTHER|Enhanced Delivery and Newborn kit|Under this study enhanced delivery and newborn kits will be provided to the identified pregnant women to utilize at home or at health facility and avoid delays at facility. After the training of community and health care providers, the intervention package will be delivered in the intervention clusters primarily through the LHWs and CMWs.
214954369|NCT01308034|DRUG|sunitinib|"All patients will be treated with sunitinib (2 dose levels) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.~Dose level 1 : 25 mg once daily Dose level 2 : 37.5 mg once daily Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring."
214954370|NCT00874913|DEVICE|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
214954371|NCT03441685|BEHAVIORAL|Semantic cues (perform action), syntactic cues (sentence frame), or combined semantic and syntactic cues|"Verb Learning Session Teaching phase. The examiner labels each target word and performs the action 6 times in each condition. She elicits the target word from the participant 2 times per word per condition and provides feedback on accuracy.~Testing phase. Receptive probes are administered after every 2 words are taught. Expressive probes are at the end of the condition. For receptive probes, the examiner asks the participant to identify novel verbs and for expressive probes, the examiner asks the child to label the novel action. Testing after 2 items is designed to decrease memory load. Participants have a brief break between conditions.~Data are collected on: a) child responses on standardized assessments, (b) responses to verb learning probes, (c) parent responses to intake form, and (d) relevant medical history from electronic medical record.~None of the above procedures present more than minimal risk to participants or research staff. Vanderbilt IRB approved all procedures."
214954372|NCT04948827|DRUG|SBP-9330|SBP-9330 oral capsules
214954373|NCT04948827|DRUG|Placebo|Placebo oral capsules
214954374|NCT01024361|DEVICE|CPAP|CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
214954375|NCT06679855|DRUG|Milrinone infusion|An intravenous (iv) infusion of milrinone will be administered at an initial dose of 0.33 mcg/kg/min and accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes).
214954376|NCT06679855|DRUG|Placebo infusion|An iv infusion of placebo (0.9% saline) of equivalent volume will be administered. The infusion will be accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes) to ensure blinding is maintained.
215077472|NCT06614647|BEHAVIORAL|Digital care-guide for long-term follow-up after cancer treatment|Use of a digital care-guide from study inclusion to guide the patient trough the follow-up program, in the form of a personalized smart phone app.
215077473|NCT06615817|DIETARY_SUPPLEMENT|Intermittent Fasting|In this group, a diet based on intermittent fasting will be administered - with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.
215077474|NCT06608043|BEHAVIORAL|Reborn lifestyle adjustment program|"The sessions are based on the 'Do Live Well' model, Kolb's Experiential Learning Theory, and CBT-based problem-solving skills.~Introduction to the Reborn Lifestyle: Core principles of the Reborn Program for building a healthy lifestyle during and after breast cancer.~Physical Activity: The role of physical activity during treatment and exercises to boost energy levels.~Fatigue Management: Scientific methods for managing fatigue during and after treatment.~Pain Management: Effective techniques to reduce pain and improve quality of life.~Mental Health Burden: Strategies to alleviate mental health burdens and cope with stress.~Quality Sleep: Practical methods to improve sleep patterns and achieve quality rest.~Preventive Rehabilitation Approaches: Essential rehabilitation strategies to protect health and reduce recurrence risk.~The study will be conducted online, with evaluations and sessions via Zoom before and after the 12-week modules."
214954377|NCT04126317|DRUG|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
214954378|NCT04126317|DRUG|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
214954379|NCT04377971|BEHAVIORAL|SOC education|Standard participant education from researcher
214346359|NCT03818139|OTHER|radiography thorax|The ultrasound of the thorax will be performed while waiting for the X-ray thorax
214346360|NCT04644328|BEHAVIORAL|Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday|Facebook ads to show a 15 second video clip recorded by MGH, Harvard and Lynn Community health center and other health care professionals. The ads will be shown before the Thanksgiving/Christmas holiday and will focus on staying safe - limiting travel and mask-wearing. The investigators will randomize exposure to the ad campaign at the ZIP code or county level.
214346361|NCT02149589|PROCEDURE|Mechanical ventilation|
214346362|NCT05805397|BEHAVIORAL|Motivation Skills Training|Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
214346363|NCT05805397|BEHAVIORAL|Healthy Behaviors Control Group|Participants will complete a baseline assessment, receive weekly HBC sessions in a group format for a duration of 12 weeks, and will repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
214346364|NCT01661660|OTHER|observationnal|Observation during a physical exercise
214346365|NCT04996784|OTHER|Capillary blood sampling|The capillary blood sample will be obtained by pricking the fingertip using contact-activated lancet (BD Microtainer). A total of five blood drops (10 μL each) will be collected by a micropipette and will be dropped off on the blotting paper 903 S\&S (Whatman).
214346366|NCT05588089|OTHER|Training group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers."
214954380|NCT04377971|BEHAVIORAL|Ask-tell-ask education|Participant education using the ask-tell-ask method. First the researcher will ask a question about participant understanding of wound care and after hearing the participant's answer, the researcher will then proceed to tell the patient how to best take care of their wound using a standardized script. After the educational portion, the researcher will then ask the patient to repeat the information that was shared. If the participant's answer is wrong or incomplete, the researcher will then explain the instructions again to ensure that the participant understands the steps needed.
214954381|NCT04377971|OTHER|Participant satisfaction survey|Participant satisfaction survey using components of the 16 item Skindex questionnaire and the 18 item version Patient Satisfaction Survey, adapted for treatment of skin cancer to characterize patient experience administered at two weeks post-operatively in person
214954382|NCT04377971|OTHER|Wound care adherence survey|Wound care adherence survey administered at one week over the phone and at two weeks in person
214954383|NCT00104806|DIETARY_SUPPLEMENT|cholecalciferol|100 milligrams orally once a day for 28 days
214954384|NCT00104806|DRUG|arsenic trioxide|0.3 milligram/kilogram weight intravenously for 5 days (loading) then 0.25/kg weight intravenously biweekly
214954385|NCT01796301|DRUG|Romozosumab|Administered by subcutaneous injection once a month.
214954386|NCT01796301|DRUG|Teriparatide|Administered by subcutaneous injection once a day.
215077475|NCT06608043|PROCEDURE|Conventional Physiotherapy and Occupational Therapy|Patients in the control group will continue conventional medical treatments, occupational therapy and physiotherapy sessions.
214346367|NCT02596724|OTHER|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
214346368|NCT01455441|OTHER|Training and liraglutide|
214954387|NCT00667563|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
214346369|NCT01455441|OTHER|Training and placebo|
214346370|NCT05010759|DEVICE|NanoTherm Ablation|Iron nanoparticles are instilled into the prostate cancer lesion and then the particles are heated using a magnetic field and this heating ablates the prostate cancer lesion.
214346371|NCT01469689|OTHER|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
214954388|NCT00667563|GENETIC|DNA analysis|Weeks 0, 2, 10, 26, and 52.
214954389|NCT00667563|GENETIC|polymerase chain reaction|Screening, week 36, and week 52.
214346372|NCT01469689|OTHER|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
214954390|NCT00667563|OTHER|cytology specimen collection procedure|Screening, week 36, and week 52.
214954391|NCT00667563|PROCEDURE|colposcopic biopsy|Screening, week 36, and week 52.
214954392|NCT00029783|PROCEDURE|Distant Healing|
215077476|NCT05403593|OTHER|No Intervention|No intervention, prospective data collection
214954393|NCT02696174|OTHER|HMI|A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
214954394|NCT03701152|DEVICE|Negative pressure therapy|Negative pressure therapy at sub atmospheric level
215077477|NCT06869798|DRUG|zinc sulphate|"Group A (intervention) and Group B (non-intervention). The patients in Group A will receive standard therapy along with oral zinc 20mg/day OD for 2 months. While the patients in Group B will receive only Standard therapy.~Then, all the patients of both groups will be trained to maintain diary regarding questionnaire asked in asthma control test, followed up 4 weekly for 8 weeks"
214346373|NCT02124967|OTHER|Exercise|A one hour exercise class including both aerobic activity and resistance training
214346374|NCT01272934|DRUG|Diclofenac Sodium|Topical gel 1%-4 times daily
214954395|NCT03302507|PROCEDURE|BESS|Biportal endoscopic surgery
214954396|NCT03302507|PROCEDURE|ULBD|Unilateral laminotomy bilateral decompression
214954397|NCT04403295|BEHAVIORAL|Collaborative Specialty Care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
214954398|NCT04403295|BEHAVIORAL|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
214346375|NCT01272934|OTHER|Placebo|Topical gel-4 times daily
214346376|NCT00214136|RADIATION|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
214346377|NCT01318187|DRUG|paracetamol|1 gr
214346378|NCT01318187|DRUG|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
214346379|NCT01318187|DRUG|Paracetamol|1 gr intravenous
214954399|NCT00548483|DRUG|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
214346380|NCT01318187|DRUG|Paracetamol|intravenous 1 gr
214346381|NCT01318187|DRUG|Morphine|0.1 mg/kg intravenous
214346382|NCT03650881|DRUG|Neutrogena ® Light Therapy Acne Mask (MASK)|Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
214346383|NCT03650881|DRUG|Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene|Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
214954400|NCT02855710|OTHER|Rhythm workers training Perceptive timing|Perceptive timing training
215077478|NCT01054040|OTHER|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
214346384|NCT04331600|DRUG|Chloroquine phosphate|Oral chloroquine phosphate for 14 days
214346385|NCT04331600|OTHER|Telemedicine|Telemedical supervision for 42 days
214346386|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
214346387|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
214346388|NCT02427529|DRUG|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
214346389|NCT02427529|DRUG|Placebo|
214346390|NCT02427529|OTHER|Low calorie diet|
214346391|NCT04287920|DRUG|Acomprosate|Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
214346392|NCT00357305|DRUG|vorinostat|Given orally
214346393|NCT00357305|DRUG|cytarabine|Given IV
214346394|NCT00357305|DRUG|etoposide|Given IV
214346395|NCT00357305|OTHER|pharmacological study|Correlative studies
214346396|NCT00357305|OTHER|laboratory biomarker analysis|Correlative studies
214346397|NCT04313634|DRUG|Dasatinib|Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
214346398|NCT04313634|DRUG|Quercetin|Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg
214346399|NCT04313634|DRUG|Fisetin|Fisetin will be supplied in 100 mg capsules to be administered orally
214346400|NCT05219877|DRUG|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
214346401|NCT05219877|DRUG|Post-urodynamic Levofloxacin|Administering once daily Levofloxacin 500 mg for 3 days after urodynamic study
214346402|NCT04254900|OTHER|evaluating energy availability|energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass
214346403|NCT00097812|DRUG|zoledronic acid|
214346404|NCT00002934|PROCEDURE|long-term screening|
214346405|NCT01693432|DRUG|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14"
214346406|NCT03144557|OTHER|Education|Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD
214346407|NCT06532955|DEVICE|Lymphaticovenous anastomosis using Microsure Motion Stabilizer|"The robot-assisted LVA is performed using the Microsure Motion Stabilizer, a telemanipulation tool that stabilizes a surgeon's movement during open microsurgical operations on extremities, specifically on veins and nerves that are close to the skin.~The surgeon controls a joystick, which directly copies the surgeon's movements in real-time to an instrument held by the device. The device's software scales down the motions and filters out tremor. Surgical technique and method of treatment are identical to conventional microsurgery. The device is equipped with genuine microsurgical instruments and is compatible with existing surgical microscopes. Instead of holding the instrument directly in hand, which is limited in precision and dexterity, the surgeon operates while the instrument's movements are stabilized. The modular design allows the surgeon to decide what level of manipulation assistance is required during a certain procedure."
214346408|NCT06532955|PROCEDURE|Lymphaticovenous anastomosis (manual)|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to an adjacent vein of similar size, thereby facilitating the outflow of lymphatic fluid in patients suffering from secondary lymphedema
214346409|NCT00810134|PROCEDURE|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
214346410|NCT00810134|PROCEDURE|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
214346411|NCT05907369|OTHER|Active EC training|The active EC includes pairing contamination-related pictures (CSs) with pleasant pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels.
214346412|NCT05907369|OTHER|Sham EC training|The active EC includes pairing contamination-related pictures (CSs) with neutral pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels, the same as active EC training.
214954401|NCT02855710|OTHER|Rhythm workers training sensorimotor timing|Sensorimotor timing training
214954402|NCT02855710|OTHER|No Rhythm workers training|No training
214954403|NCT03229850|DRUG|Insulin lispro|Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy
214954404|NCT01155349|BEHAVIORAL|InSight|A cognitive intervention designed to enhance speed of visual processing.
214954405|NCT01155349|OTHER|No contact-control group|No contact-control group.
214954406|NCT04293172|DRUG|Brilinta|"Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
214954407|NCT04293172|DRUG|Placebo|"Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
214346413|NCT05907369|OTHER|Active tDCS|For the active tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum. The brain stimulation is delivered with a 2mA current intensity for 20 minutes in 10 sessions (5 days a week).
214346414|NCT05907369|OTHER|Sham tDCS|For the sham tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum, the same as active tDCS. The device is on for 20 minutes, but the current intensity is under the threshold of affecting cortical activity modulation. The participants receive the sham tDCS in 10 sessions (5 days a week).
214346415|NCT02981394|PROCEDURE|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
214346416|NCT05415228|DRUG|68Ga-PSMA-11|68Ga-PSMA-11 is a radiopharmaceutical for the detection of prostate cancer using PET/CT imaging
214346417|NCT01736813|DRUG|Maraviroc|Twelve patients with 300 mg/bid
214346418|NCT05059691|OTHER|Electronic Health Record Review|Review of medical records
214954408|NCT00615147|PROCEDURE|CT pulmonary angiogram and d-dimer draw|A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
214346419|NCT05059691|PROCEDURE|Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy|Undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy
214346420|NCT02564575|BIOLOGICAL|HPIV3-EbovZ GP Vaccine|Administered intranasally by a VaxINator device
214346421|NCT00320658|BIOLOGICAL|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
214954409|NCT04150653|DEVICE|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
214954410|NCT03568383|DRUG|Delamanid (DLM)|"Adults and children ≥30 kg: delamanid 200 mg orally once daily.~Children ≥2.5 kg to \<30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits."
214954411|NCT03568383|DRUG|Isoniazid (INH)|"Adults and children ≥24 kg: INH 300 mg orally once daily.~Children ≥2.5 kg to \<24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted."
214954412|NCT03568383|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
214954413|NCT02164071|OTHER|Geriatric Assessment of Health Status Scale administration|Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
214346422|NCT00320658|BIOLOGICAL|CPG 7909|Adjuvant
214346423|NCT00066092|DRUG|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
214346424|NCT00066092|DRUG|filgrastim|Filgrastim given daily for PBPC mobilization
214346425|NCT00066092|DRUG|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
214346426|NCT06042647|DRUG|0.01% Halobetasol|Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.
214346427|NCT06042647|DRUG|0.045% Tazarotene|Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.
214346428|NCT06042647|DRUG|0.05% Clobetasol Propionate|Drug to be applied to designated psoriatic plaque at bedtime.
214346429|NCT02197923|PROCEDURE|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
214346430|NCT02197923|PROCEDURE|endometrial biopsy|transcervical endometrial biopsy
214954414|NCT00151086|DRUG|Estramustine|
214954415|NCT00151086|DRUG|Vinorelbine|
215077479|NCT06625099|OTHER|Mechanical Ventilation (MV) with Low PEEP|Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and 5cmH2o PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.
214346433|NCT03818217|DEVICE|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
214346434|NCT03818217|DEVICE|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
214678568|NCT05920850|OTHER|Educational Video about LDCT lung cancer screening|A culturally tailored video that provides education about the process LDCT lung cancer screening
214954416|NCT01138527|OTHER|MRI examination|45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging
214954417|NCT00985660|DRUG|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
214954418|NCT00985660|DRUG|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
215077480|NCT06625099|OTHER|Mechanical Ventilation (MV) with Optimum PEEP|"Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and optimum PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.~The optimum PEEP will be adjusted by titrating to the highest compliance with the open lung strategy."
215077481|NCT01713361|DRUG|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
215077482|NCT01713361|DRUG|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
215077483|NCT01713361|DRUG|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). \[Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.\]
215077484|NCT07033091|DIAGNOSTIC_TEST|Self-sampling by gargling kit at dental clinic|Participants will perform a self-sampling at the dental clinic using gargling kit
215077485|NCT07033091|OTHER|Questionnaire|Participants will answer questionnaire online/paper at their home or at the dental clinic
215077486|NCT07033091|DIAGNOSTIC_TEST|Self-sampling by gargling kit at home|Participants will perform a self-sampling at home using gargling kit
215077487|NCT07033091|DIAGNOSTIC_TEST|Blood sampling|Venous blood will be collected from study participants with oral hrHPV positivity, in which the presence of circulating hrHPV DNA will be determined.
215077488|NCT07033091|DIAGNOSTIC_TEST|Self-sampling of the urogenital area|In case of a positive examination in the oropharynx, the tested individuals will be offered a self-collection HPV examination in the urogenital area (cervicovaginal swab in women or external genital swab in men).
215077489|NCT02455661|DEVICE|TR Band (TM)|
214346435|NCT05071001|PROCEDURE|MRI|"This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:~1. a 3D-FLAIR imaging~2. a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)~3. an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).~4. An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.~5. Magnetization transfer imaging providing information about integrity of membranes."
214346436|NCT05794464|PROCEDURE|Catheter ablation and/or electrical cardioversion|Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
214346437|NCT04279808|PROCEDURE|dilator depth|For soft tissue dilation just after guidewire insertion in central venous catheterization through the right internal jugular vein, investigators will measure the distance between the skin puncture site and outside of anterior wall of the vein with real-time ultrasonography in the measured depth group. Next, practitioner will insert the dilator by the measured length and continue to insert the central venous catheter. For the conventional group as a control group, practitioner will perform the central venous catheterization with a manner used routinely by the practitioner.
214346438|NCT05216172|DRUG|AZD1656|active drug
214346439|NCT05216172|DRUG|Placebo|placebo
214346440|NCT03564912|DRUG|Capecitabine Oral Tablet [Xeloda]|2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
214346441|NCT00906672|DEVICE|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
214346442|NCT00906672|PROCEDURE|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
214954419|NCT02204436|OTHER|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
215077490|NCT02455661|DEVICE|AngioSeal|
215077491|NCT02455661|DEVICE|StarClose|
215077492|NCT07035054|BIOLOGICAL|low dose-1|PCV24 (low-dose 1) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, and the dosage is 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows: 4.0 μg per vial for serotypes 3, 6B, and 12F; and 2.0 μg per vial for the other 21 serotypes, namely 1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. After binding to carrier proteins, the polysaccharides of each serotype are adsorbed on an aluminum phosphate adjuvant (aluminum content: 0.125 mg per dose).
214954420|NCT01689753|DEVICE|TEGO connector®|
214954421|NCT01689753|DRUG|Trisodium citrate|
214954422|NCT06060340|DRUG|class II furcation defects management using propolis|"A full thickness flap will be elevated using muco-periosteal elevator to gain full access to the furcation defect. Then granulomatous tissue will be debrided from the osseous defect and the root surfaces will be carefully scaled and root planed by ultrasonic and hand instruments.~The diagnosis of the class II furcation defect was then confirmed using a Naber's probe.~Propolis preparation:~Pure propolis will then be mixed with saline to give a proper mix/consistency and applied to completely fill the furcation defect."
214954423|NCT00264290|DRUG|Valganciclovir|900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
214954424|NCT00264290|DRUG|Placebo|Placebo designed to resemble Valganciclovir
214954425|NCT04325165|DEVICE|DBS Implantation|Bilateral implantation of PPN DBS electrodes
214954426|NCT02044653|DRUG|GX-E2|Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg
214954427|NCT02044653|DRUG|GX-E2|Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg
214954428|NCT02044653|DRUG|GX-E2|Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg
214346443|NCT04396951|DEVICE|Active external overheating with heating plate, Aragonia ® MTC 400|It is a heating device that is adjustable in height up to 50 cm from the patient and generates radiant heat at low temperature (up to 39 ◦C) distributed evenly. It is equipped with an adjustable 0-9 potentiometer and has a skin temperature probe as a control and safety mechanism Measure during 6 hours with indirect calorimetry in first week
214346444|NCT04396951|DEVICE|Active external overheating with air blanket, Equator Level 1® de Smiths Medical|Composed of a unit that produces hot air and forced air adjustable from 38ºC to 43ºC. Sends hot forced air distributed by tubular blanket that convectively heats the patient by diffusing hot air directed at the patient through the textile pore of the air blanket Measure during 6 hours with indirect calorimetry in first week
214346445|NCT04318340|OTHER|Tapered applicator|An applicator inserted in 2 steps that tapers at the distal vagina
214346446|NCT04318340|OTHER|Standard applicator|A 2.6 cm standard applicator is inserted and sized up to a standard 3 cm applicator if tolerable.
214346447|NCT06465849|PROCEDURE|Dentin Etching time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 5 seconds in the etch-and-rinse application strategy.
214346448|NCT06465849|DEVICE|Scotchbond Universal Plus; 3M|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Scotchbond Universal Plus; 3M).
214346449|NCT06465849|DEVICE|Gluma Universal Bond; Kulzer|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Gluma Universal Bond; Kulzer).
214346450|NCT06465849|PROCEDURE|Dentin Etching time for 15 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 15 seconds in the etch-and-rinse application strategy.
214346451|NCT00167544|DRUG|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
214346452|NCT00167544|DRUG|Placebo|Saline
214346453|NCT00680316|DRUG|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
214346454|NCT00680316|DRUG|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
214346455|NCT04069975|OTHER|Sedation|The group of patients who did endoscopies with or without sedation. (This is a choice of themselves)
214346456|NCT01138332|GENETIC|western blotting|
214346457|NCT01138332|OTHER|laboratory biomarker analysis|
214346458|NCT03585244|OTHER|weekly weight|weekly weight data collection for six months
214346459|NCT01904812|OTHER|Questionnaire about quality of life and satisfaction|
214346460|NCT03408912|DIAGNOSTIC_TEST|FFR|FFR from CMR compared to invasive FFR
214346461|NCT04153266|OTHER|No intervention is planned for this study|No intervention was/is planned for this study. The study is questionnaire-based (observational).
214346462|NCT02580097|OTHER|MRI|MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
214346463|NCT00388687|DRUG|18F Fluoroazomycin Arabinoside (FAZA)|
214954429|NCT02044653|DRUG|NESP|Each Group of Hemodialysis (n=30) will be administered NESP 30ug
214346464|NCT02388633|PROCEDURE|Plasmapharesis|Clinically-indicated LDL apheresis
214346465|NCT01752192|DEVICE|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
214346466|NCT04626791|DRUG|Acalabrutinib|Given PO
214954430|NCT02044653|DRUG|MIRCERA|Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg
214954431|NCT03795285|DIAGNOSTIC_TEST|Expression of neutrophil CD64|Expression of neutrophil CD64 will be measured by Flow cytometry. In addition, sTREM-1 will be measured in the serum by ELISA
214954432|NCT03405168|DRUG|Moxifloxacin Hydrochloride 400mg Tablet|Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.
214954433|NCT03939650|DEVICE|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
214954434|NCT00951158|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|"This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression."
214954435|NCT00951158|DRUG|Conjugated Linoleic Acid|Phase I Dose Escalation Study
214346467|NCT04626791|DRUG|Bortezomib|Given SC
214346468|NCT04626791|DRUG|Cyclophosphamide|Given IV
214346469|NCT04626791|DRUG|Cytarabine|Given IV
214346470|NCT04626791|DRUG|Doxorubicin Hydrochloride|Given IV
214346471|NCT04626791|DRUG|Prednisone|Given PO
214346472|NCT04626791|BIOLOGICAL|Rituximab|Given IV
214346473|NCT04626791|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV
214346474|NCT01704339|DRUG|QUTENZA|Single treatment with topical capsaicin 8%
214954436|NCT00475293|DRUG|Panitumumab and CPT-11|"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"
214954437|NCT05693753|DEVICE|Use of XCM for the treatment of MAGRs with mCAF technique|After local anaesthesia, mCAF technique will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
214954438|NCT05693753|PROCEDURE|Treatment of MAGRs with CTG|After local anaesthesia, mCAF technique will be performed. CTG will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
214954439|NCT05012774|BEHAVIORAL|Speech Recognition Training|Training for each training arm takes place over 10 sessions carried out at home. on the participant's own computer without experimenter direct supervision. Pre- and post-training tests are carried out under experimenter supervision.
214954440|NCT06087497|OTHER|Early mobilization|Z stitch placement is standard of care to achieve vascular hemostasis after EP procedures which is followed by 4 hours of bedrest. In this study, we will compare patient satisfaction and bleeding complications with a shorter bedrest (1 hour instead of 4 hours)
214954441|NCT05811884|DEVICE|Rehabilitation|"The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements."
215077493|NCT07035054|BIOLOGICAL|low dose-2|"PCV24 (low-dose 2) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~3 types (3, 6B, 12F): 4.0 μg per vial 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 2.0 μg per vial After binding to carrier proteins, the polysaccharides of each serotype are adsorbed on an aluminum phosphate adjuvant with an aluminum content of 0.25 mg per dose."
214346475|NCT04144673|OTHER|Silver Hydrosol|Silver quantity will be 7 doses per day, with 50 mcg per dose.
214346476|NCT04144673|OTHER|Placebo|Placebo water with no active ingredients
214954442|NCT04838847|BIOLOGICAL|CVnCoV Vaccine|Intramuscular (IM) injection
214954443|NCT04648852|OTHER|Heart failure risk estimation|Evaluation by heart failure risk score
214954444|NCT06569030|BIOLOGICAL|spinal orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
214954445|NCT06558526|DIETARY_SUPPLEMENT|Apple pectin (DE 57%)|Dietary intervention with apple pectin. Participants will orally take the supplement once a day, after dissolving it in 100 ml of water, for 6 months.
215077494|NCT07035054|BIOLOGICAL|high dose|"PCV24 (high-dose) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~3 types (3, 6B, 12F): 8.0 μg per vial 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 4.0 μg per vial After binding to carrier proteins, the polysaccharides of each serotype are adsorbed on an aluminum phosphate adjuvant with an aluminum content of 0.25 mg per dose."
215077495|NCT07035054|BIOLOGICAL|positive control|PPV23 produced by Chengdu Institute of Biological Products is a formulation with each vial containing 0.5 ml, and the dosage is 0.5 ml per person per administration. It contains polysaccharides of the following pneumococcal serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, with each serotype containing 25 μg of polysaccharide. In addition, it contains sodium chloride and water for injection.
215077496|NCT06881953|OTHER|Questionnaire|The questionnaire will be completed on line by the participants (approx. 10 min).
214346477|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
214346478|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
214346479|NCT02532660|DRUG|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
214346480|NCT02532660|DRUG|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
214346481|NCT02532660|DRUG|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
214346482|NCT02532660|DRUG|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
214346483|NCT05727605|BEHAVIORAL|Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test|"Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.~Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy"
214346484|NCT05727605|DIAGNOSTIC_TEST|MRI|"Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI \& ASL~Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy"
214346485|NCT05727605|BEHAVIORAL|Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI|Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy
214346486|NCT05727605|OTHER|Toxicity scoring|During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.
214346487|NCT05847218|DRUG|RHN-001 (one tablet 750mg)|Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
214346488|NCT05847218|DRUG|RHN-001 (750mg * 2 Tablets)|Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
214346489|NCT03790891|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
214346490|NCT03131076|DIAGNOSTIC_TEST|IPMN follow up|Follow up with MRI and laboratory blood tests
214346491|NCT04993326|BEHAVIORAL|emPOWERed To Change Program|Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
214954446|NCT06558526|DIETARY_SUPPLEMENT|Placebo|Dietary intervention with maltodextrin. Participants will orally take the placebo (maltodextrin) once a day, after dissolving it in 100ml of water, for 6 months.
214954447|NCT02387229|DRUG|Rivaroxaban|15 mg
214954448|NCT02387229|OTHER|standard of care|
214954449|NCT04442061|DEVICE|Transcranial magnetic stimulation|"Before the stimulation, identification of a motor hotspot and active motor threshold (AMT) will be performed. The TMS will be applied on the intermittent theta-burst modality (iTBS), i. e., 2 s of TBS trains (30 pulses) repeated every 10 s for 190 s, with a total number of 600 pulses (Huang et al, 2005). The whole TMS session, including preparation, will last up to 1h.~The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue"
214954450|NCT04442061|DEVICE|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist.
214954451|NCT04442061|DEVICE|Neuronavigation|The neuronavigation system will allow to guide the stimulation using the individual anatomical MRI acquired with MRI, and to record the position and orientation of the coil during successive stimulations
214954452|NCT04442061|DEVICE|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
214954453|NCT04442061|GENETIC|Salivary samples|The DNA will be extracted from the salivary sample to genotyping analyses on the BDNF (Val66Met) and COMT (Val158Met) polymorphism
214954454|NCT04442061|OTHER|Clinical scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
214954455|NCT05800210|DEVICE|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
214954456|NCT06305559|DRUG|obicetrapib 10 mg + ezetimibe 10 mg FDC daily|Active treatment
214954457|NCT06305559|OTHER|Placebo|Baseline lipid modifying therapy
214954458|NCT00332774|DRUG|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
214954459|NCT00332774|DRUG|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
214954460|NCT00332774|OTHER|Nepafenac ophthalmic suspension vehicle|
214954461|NCT01939223|DRUG|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
214954462|NCT01939223|DRUG|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
214954463|NCT06318156|DIAGNOSTIC_TEST|Infrared thermal imaging|A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.
214954464|NCT05041075|DEVICE|Weighted Blanket|Weighted blankets provide Deep Pressure Stimulation (DPS) or Deep Touch Pressure (DTP) which has advantages in both physical and psychological domains.
214954465|NCT06625463|BEHAVIORAL|Home based cardiac rehabilitation|12 week home based cardiac rehabilitation include Physical exercise, dietary management, smoking cessation and stress management
214954466|NCT04786678|DEVICE|Cell phone notification|Habitual bed and wake times will be detected using a wearable for 4 weeks. Using habitual wake time, a minimum bedtime to achieve adequate sleep will be calculated (8 hours). If phone usage is detected after this minimum bedtime, participants will receive a notification informing them they are awake past their minimum bedtime and recommend they go to bed to obtain adequate sleep.
214954467|NCT03489629|DRUG|Trimethoprim Sulfamethoxazole (TMP/SMX)|"Dosing if \< 40 kg: 8 mg/kg trimethoprim/40 mg/kg trimethoprim sulfamethoxazole given twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing is ≥ 40 kg: 320 mg/1600 mg twice daily for 14 days during Days 1-14 and Days 29-42."
214346492|NCT00259051|DRUG|Omeprazole|
214346493|NCT02369029|DRUG|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
214346494|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is identified~3. Inject blue dye into patient's arm~4. Complete procedure (SLNB and/or ALND)"
214954468|NCT03489629|DRUG|Minocycline|"If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if \< 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42."
214678569|NCT05920850|OTHER|A culturally tailored shared decision-making tool|A culturally tailored shared decision-making tool that educates participants about the shared decision-making process
214954469|NCT03489629|DRUG|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 5 days during Days 1-5 and Days 29-33.
214954470|NCT03489629|DRUG|Chlorhexidine Gluconate|For subjects able to swish without swallowing, 0.12% chlorhexidine gluconate oral rinse will be used twice daily for 14 days during Days 1-14 and Days 29-42.
214954471|NCT03489629|BEHAVIORAL|Environmental Decontamination|"Subjects will be instructed to wipe down all high touch surfaces and medical equipment with surface disinfection wipes daily during Days 1-21 and Days 29-49.~Subjects will also be instructed to wash all linens and towels in hot water once weekly during weeks 1-3 and weeks 5-7."
214954472|NCT04185272|BIOLOGICAL|analysis of BTN and BTNL status|analysis of BTN and BTNL expression in colon cancer and hepatic metastasis
214954473|NCT05732402|DRUG|Povetacicept|Administered by subcutaneous injection every 4 weeks
215077497|NCT01940575|DEVICE|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
215077498|NCT01940575|DEVICE|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
215077499|NCT04088435|RADIATION|Intraoperative radiotherapy|The IORT component of this treatment is being delivered as per standard clinical practice. 20 Gy in one fraction will be delivered at the time of lumpectomy.
215077500|NCT03396367|BEHAVIORAL|PARTNER|The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
215077501|NCT03396367|BEHAVIORAL|Education Intervention|The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
215077502|NCT06892574|DEVICE|Active-VNS|A neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve.
215077503|NCT06892574|DEVICE|Sham VNS|A neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve, the actual intensity is 0 mA.
215077504|NCT00129610|BEHAVIORAL|Virtual Reality Therapy|
215077505|NCT00129610|BEHAVIORAL|Cognitive Behavior Therapy|
215077506|NCT06895590|DEVICE|Philips Advanced Monitoring Cuff (i.e. AMC)|Investigational, non-invasive upper arm cuff
215077507|NCT06896279|PROCEDURE|TI Stimulation|Participants will accept the TI stimulus for one month
215077508|NCT06896279|PROCEDURE|Sham Stimulation|Participants will accept the sham TI stimulus for one month
215077509|NCT06831305|DIAGNOSTIC_TEST|Comparison of microbiological sampling on natural nails|Comparison of microbiological sampling before and after hand desinfection
215077510|NCT06831305|DIAGNOSTIC_TEST|Comparison of microbiological sampling on methacrylic nails|Comparison of microbiological sampling on methacrylic nails
215077511|NCT06896292|BEHAVIORAL|Hybrid care model|"Participants will receive usual antenatal care (in-person), plus the digital support tool. A co-design process was used to develop the tool based on consumer feedback.~The tool is based on the recommended Assess/ask, Advise, Help approach to preventive care for smoking, nutrition, alcohol, physical activity and gestational weight gain.~Participants will be prompted (via SMS) to use the digital support tool at regular intervals throughout their pregnancy to self-assess health risks and be reminded of recommendations and available coaching services."
215077512|NCT06896292|OTHER|Usual Care|Participants will receive usual antenatal care (in-person), which is recommended to include the delivery of preventive care using the AAH model for smoking, nutrition, alcohol, physical activity and gestational weight gain.
215077513|NCT06895980|PROCEDURE|Non-surgical periodontal treatment, glycated hemoglobin measurement and application of OHIP-14SP survey.|Non-surgical periodontal treatment will be performed, with periodontal maintenance therapy at 3, 6, 9 and 12 months, with measurement of glycated hemoglobin at each time and application of the OHIP-14SP oral health-related quality of life survey.
215077514|NCT01556048|BEHAVIORAL|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
214954474|NCT03808103|BIOLOGICAL|Placebo|Orally, twice a day, for a period of fifteen days
214954475|NCT03808103|BIOLOGICAL|Bacteriophage preparation|Orally, twice a day, for a period of fifteen days
214954476|NCT06206954|BEHAVIORAL|MyHealthPath Tool|Tailored, brief online tool to help patients learn about weight treatment options
214954477|NCT06206954|BEHAVIORAL|MyHealthPath Guide|Informational material to help patients learn about weight treatment options
214678570|NCT05920850|OTHER|Flip chart|The use of a flip chart that reinforces the information provided in the video and shared decision-making tool
214954478|NCT04838457|BEHAVIORAL|Alcohol and CVD Management and Engagement through Telehealth and mHealth (ACME-TM)|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
214954479|NCT03965429|OTHER|Blood samples (additional tubes from care) longitudinal|Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).
214954480|NCT03965429|OTHER|Blood samples (additional tubes from care) at inclusion|"In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.~In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification."
214954481|NCT01557517|DRUG|Clobetasol Oral Rinse|Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.
214954482|NCT01557517|DRUG|Placebo oral rinse|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
214954483|NCT00442481|DRUG|Escitalopram|
214954484|NCT00442481|PROCEDURE|A baseline overnight polysomnography (oPSG)|
214954485|NCT03729622|OTHER|Low FODMAP Diet|Both arms will receive the intervention but at different time points.
215077515|NCT05643183|OTHER|Astmakompas|The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
215077516|NCT06895824|OTHER|Mindfulness Meditation|Somatic tracking is one aspect of most mindfulness meditation protocols, involving paying attention to the present non-judgementally, and focusing on breath and bodily sensations (e.g., sounds in the case tinnitus). This study employs this approach as a standalone intervention, in the form of a guided meditation recording.
215077517|NCT06766266|DRUG|Irinotecan liposome II combination therapy regimen|In the A arm, the combined treatment with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the neoadjuvant therapy phase before TURBT surgery.
214678571|NCT05920850|OTHER|Navigation support|Navigation support for participants who express interest in LDCT and quitting smoking.
214678572|NCT02897635|BEHAVIORAL|Individualized Integrative Medicine Intervention|
214954486|NCT06145529|OTHER|RT Functional HIIT circuit program (15 minutes) with or without gamification approach|"EG1 (RT Functional HIIT circuit program): This intervention involves a 15-minute Resistance Training (RT) Functional High-Intensity Interval Training (HIIT) circuit program. The focus is on functional movements performed at a high intensity within intervals.~EG2 (RT Functional HIIT circuit program with gamification): This intervention replicates the RT Functional HIIT circuit program from EG1 but incorporates gamification strategies. Gamification involves the application of game-like elements, such as points, rewards, and competition, to make the exercise routine more engaging and enjoyable for the participants.~Control Group (CG): Children in the control group continue with their regular Physical Education (PE) sessions, maintaining their usual routine"
214954487|NCT02349282|DIETARY_SUPPLEMENT|Calcifediol 10ug/day|
214954488|NCT02349282|DIETARY_SUPPLEMENT|Vitamin D3 20ug/day|
214954489|NCT02349282|DIETARY_SUPPLEMENT|Placebo|
214954491|NCT04698083|DIAGNOSTIC_TEST|Electrocardiography ,Tomographic imaging|Based on electrocardiographic follow-up analyses,the two main groups were compared in terms of rotation condition (i.e., Cwr, normal transition, or CCwr), electrocardiographic intervals, and laboratory findings In our study,CO-RADS5 was considered an advanced tomographic finding(e.g., multifocal ground glass opacities with consolidation, vascular thickening,crazy paving pattern,mixed pattern),while CO-RADS1,2,3, and 4 were considered non-advanced tomographic findings.
214954492|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
214346495|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is not identified (No localization)~3. Inject blue dye into breast (nothing in arm)~i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)"
214346496|NCT03140436|DRUG|sodium bicarbonate powders with grain size 65 µm|sodium bicarbonate powders with grain size 65 µm
214346497|NCT03140436|DRUG|sodium bicarbonate powders with grain size 40 µm|sodium bicarbonate powders with grain size 40 µm
214346498|NCT02830594|RADIATION|External Beam Radiation Therapy|Undergo palliative external beam radiation therapy
214346499|NCT02830594|OTHER|Laboratory Biomarker Analysis|Correlative studies
214346500|NCT02830594|BIOLOGICAL|Pembrolizumab|Given IV
214954493|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
214954494|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
214954495|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
214954496|NCT04170036|DIETARY_SUPPLEMENT|protein supplement|Protein supplement usage for at least three preceding months in varied amounts
214954497|NCT00814593|BIOLOGICAL|lymphokine-activated killer cells|Instilled into the tumor bed cavity
214954498|NCT00814593|DRUG|polifeprosan 20 with carmustine implant|Intracranial placement
214954499|NCT04078724|DIETARY_SUPPLEMENT|5-HTP|5-HTP that have Good Manufacturing Practice certification will be used and participants will be suggested to be take the 5-HTP supplementation at bedtime.
214954500|NCT04078724|OTHER|Without 5-HTP|Subject will not take 5-HTP
214954501|NCT01453790|BEHAVIORAL|Parent-Specific Depression Education and Motivation|Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
214954502|NCT01453790|BEHAVIORAL|General Depression Education-Motivation|General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
214954503|NCT03176641|OTHER|platelet-rich plasma|Autologous platelet-rich plasma gel applied during meniscus repair surgery
214954504|NCT03176641|OTHER|control|Meniscus repair surgery only
214954505|NCT03181685|DRUG|Progesterone 25 MG subcutaneous|A single subcutaneous administration per day from the day of oocyte retrieval
214954506|NCT03181685|DRUG|Micronized progesterone 200 MG|3 vaginal administrations per day from the day of oocyte retrieval
214954507|NCT03181685|DRUG|recombinant FSH|Controlled ovarian stimulation (COS)
214954508|NCT03181685|DRUG|Cetrorelix Acetate|Inhibition of Luteinizing Hormone (LH) premature surge during COS
214954509|NCT05516771|DEVICE|Tcore™ system|"The Tcore sensor is a double-sensor-heat-flux (DHF) thermometer and consist of two sensors separated by a known thermal resistance. One side is placed directly at the patient's skin and the other is facing the environment. After some equilibration time the core temperature can then be calculated. The sensors are placed above the eye and the sinus frontalis.~Intended use The Tcore system is a thermometer intended for non-invasive, continuous measurement of the core body temperature of children from 5 years of age, adolescents, and adults. The Tcore system consists of a sensor and an adapter. The adapter is reusable. The sensor is intended for single use. The Tcore system works in adjusted mode, i.e., the core body temperature is determined by a dual sensor.~Off-Label/Investigational Use In context of this clinical study the Tcore-system will be investigated outside its approved and intended use, namely in children below the age of five and toddlers."
214954510|NCT00915603|DRUG|Everolimus|Everolimus 10mg PO daily continuously for all 28 days of a cycle
214954511|NCT00915603|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
214954512|NCT00915603|DRUG|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
214954513|NCT00915603|DRUG|Placebo|Placebo PO daily continuously for all 28 days of a cycle
214954514|NCT00915603|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
214678573|NCT00227279|BIOLOGICAL|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
214954515|NCT00915603|DRUG|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
214954516|NCT03585712|DRUG|Norgestrel 0.075 mg|Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3
214346501|NCT05655793|DIAGNOSTIC_TEST|Tear Fluid collection (Schirmer's strip)|Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
214346502|NCT05655793|DIAGNOSTIC_TEST|Retinal imaging|The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
214346503|NCT05839769|DIAGNOSTIC_TEST|Evaluation of median nerve with ultrasound|ultrasound examination wrist
214346504|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
214346505|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
214346506|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
214346507|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
214954517|NCT01963091|DRUG|oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
214954518|NCT01963091|DRUG|saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
214954519|NCT02746094|DEVICE|8 bi-weekly LIESWT sessions|"LIESWT = Low-Intensity Extracorporeal Shock Wave Therapy~The treatment protocol consists of eight bi-weekly treatment sessions (weeks 0 ot 4). During each session 3600 shocks at 0.09 mJ/mm are applied. Shocks are applied to the penis shaft at the right corpus cavernosum and the left corpus cavernosum, and at the crura at the right crus and the left crus. 900 shocks are administered to each area. The treatment areas are the same for each session, so that at the end of the full treatment (8 sessions) each area will have received 7200 shocks at 0.09 mJ/mm.~In general, the patient is placed on an examination table. A series of focused shockwaves produced by the electromagnetic transducer are coupled to a patient's penile shaft and crura and are made to converge along the penis/crura volume. The operator controls treatment parameters including shockwave intensity and shockwave rate.~mJ = millijoule."
214954520|NCT03360214|DRUG|Bupivacaine Hydrochloride|For active drug, 0.25% marcaine, will be used.
214954521|NCT03360214|OTHER|Placebo Drug|For sham drug, 0.9% saline, will be used.
214954522|NCT03360214|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.
214954523|NCT03360214|OTHER|Placebo Device|Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.
214954524|NCT03360214|DRUG|Ropivacaine Hydrochloride|For active drug, 0.25% naropin, will be used.
214954525|NCT06518343|DIETARY_SUPPLEMENT|L-carnitine + Pomegranate extract|Participants will consume 1.5 grams L-carnitine with 1.6 grams pomegranate extract at one visit during one intervention period
214954526|NCT06518343|DIETARY_SUPPLEMENT|L-carnitine + Microcrystalline cellulose|Participants will consume 1.5 grams L-carnitine with 1.5 grams microcrystalline cellulose at one visit during one intervention period
214954527|NCT06192888|DRUG|Glofitamab|IV Glofitamab
214954528|NCT06192888|DRUG|Obinutuzumab|IV Obinutuzumab
214954529|NCT06192888|DRUG|Lenalidomide|Oral Lenalidomide
214954530|NCT06973330|DRUG|SOX regimen combined with Sintilimab and Apatinib|Patients who met the inclusion criteria were treated with SOX regimen combined with Sintilimab plus Apatinib every 3 weeks(4 cycles) followed by sintilimab+apatinib until disease progression or intolerable adverse reactions or death(up to 24 months).
214954531|NCT06055803|BEHAVIORAL|Intake Session|Each of the program components will have an individualized assessment with plan and goals set at the program intake visit.
214954532|NCT06055803|BEHAVIORAL|Individual Sessions|Individual sessions will occur in person or virtual every other week during the 12-week intervention with a health promotion specialist (nurse or exercise physiologist). These sessions will include review of progress towards goals, update exercise prescription, make plan for the next two weeks.
214346508|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
214346509|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
214346510|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
214346511|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
214346512|NCT05188846|OTHER|SDF|"1\. Group 1: cleaning the occlusal surface to be treated with toothbrush. Decayed tissue from the affected teeth will not be removed for the SDF group.~Clinical procedure for SDF application: it will apply according to the SDF manufacturer Instructions as follows:(1) the surrounding gingival tissues and lips will be protected with petroleum jelly to avoid staining and irritation,(2) the affected tooth will be isolated and keep dry with cotton rolls and saliva ejectors, (3) one drop of SDF (SDI RIVA STAR ), will be placed into a disposable dish, (4) SDF will be applied with a micro-sponge directly to the affected tooth surface(s), (5) allowed to soak in for 2 min, then air-dried. Then will be followed by the Potassium iodide (KI) liquid to decrease discoloration caused by SDF. The KI liquid will be reapplied until no more white perception observed to form."
214346513|NCT05188846|OTHER|SDF + ART (SMART technique )|2\. Group 2: SDF+ART clinical procedure: (1)cleaning the occlusal surface to be treated with toothbrush.,(2) carious dentin will be removed using a small excavator (Spoon excavator ),(3) the cavity will be cleaned and dried, (4)cavity walls and floor will be conditioned for 10s, then washed and dried, (5) SDF will be applied as mentioned above followed by cavity restoration using resin-reinforced glass ionomer restorative material (SDI RIVA ).
214346514|NCT05465889|DRUG|Oral sulfate solution (OSS)|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.
214954533|NCT06055803|BEHAVIORAL|Group Sessions|Group sessions for wellness and education will be delivered by medical multi-disciplinary staff in person or virtual every other week during the 12-week intervention.
215077518|NCT06766266|DRUG|Irinotecan liposome II combination therapy regimen|In the B arm, the combined therapy with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2 ) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the induction phase after TURBT surgery.
215077519|NCT01313845|DRUG|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
215077520|NCT01313845|DRUG|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
214346515|NCT05465889|DRUG|Polyethylene Glycol Electrolyte|Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.
214954534|NCT06055803|BEHAVIORAL|Graduation|At the conclusion of the 12-week intervention, there will be a graduation session to honor the participant's achievement and establish a plan for maintenance after the intervention
214954535|NCT06055803|BEHAVIORAL|Exercise|Participants will exercise as part of individual and group sessions. Participants will also be asked to exercise on their own, with a goal of working up to meeting US Physical Activity guidelines (150 minutes per week of moderate to vigorous exercise + 2 episodes of strength training).
214954536|NCT06666335|DRUG|Anakinra|Subcutaneous injections once daily for 6 months
214954537|NCT05169788|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
214954538|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-1Gy|1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.
214954539|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-2-3Gy|ILDR will be administered as single fractions within 10 days. The total dose of radiotherapy will be 2-3 Gy in 2-3 fractions. ILDR design is as above.
214954540|NCT06076135|DRUG|PD-1/PD-L1 Inhibitors|The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.
214954541|NCT05223829|DRUG|Brexanolone|Brexanolone will be administered as a continuous IV infusion over 20 hours under medical observation
214954542|NCT06949592|DIETARY_SUPPLEMENT|Placebo|Intake of 400 mg placebo (maltodextrin; encapsulated) in the morning (09:00)
214346516|NCT05077267|BIOLOGICAL|ABNCoV2 100ug|IM injection 100ug dose
214954543|NCT06949592|DIETARY_SUPPLEMENT|M_ML|Intake of 400 mg M\_ML (encapsulated) in the morning (09:00)
214954544|NCT06949592|DIETARY_SUPPLEMENT|M_ML|Intake of 400 mg M\_ML (encapsulated) in the evening (19:00)
214954545|NCT04421014|DIETARY_SUPPLEMENT|Ketone Ester drink|The main ingredient of the Ketone Ester drink \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)\] is regulated as GRAS (Generally Recognized as Safe) substance by the FDA (https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices\&amp;id=515). The Ketone Ester compound is already being sold in the market as a ketogenic supplement and is especially popular among athletes, such as cyclists (sold by the official website of the company TdeltaS(R) Global (https://www.deltagketones.com/products/g-ketone-performance). The dose and formulation (25 g of KE contained in 59 ml of a drink), daily scheme (3 times daily) and total duration (28 days) are identical to a previous safety human study. The Ketone Ester drink provided by DeltaG will be repackaged by the NIA Pharmacist into new bottles identical to the ones that will be used for the placebo to ensure the blinding of participants and researchers to the drink.
214954546|NCT04421014|DIETARY_SUPPLEMENT|Placebo: isocaloric dextrose drink|The main content of the Placebo will be an aqueous solution containing approximately 35 g of dextrose, a fruity flavor powder and stevia. We will also add Denatonium Benzoate (Bittrex) to match the bitterness of the Ketone Ester drink. The placebo will be prepared and dispensed by the NIA Pharmacist.
214954547|NCT04006262|DRUG|Nivolumab 10 MG/ML|"Neo-adjuvant treatment : 240 mg intravenous (I.V.) in 30 minutes - every 2 weeks - 6 cycles~\- Adjuvant treatment : 480mg I.V. in 30 minutes - every 4 weeks - 9 cycles"
214954548|NCT04006262|DRUG|Ipilimumab 200 MG in 40 ML Injection|Neo-adjuvant treatment : 1mg/kg over 30 minutes every 6 cycles - 2 cycles
214954549|NCT06671366|DEVICE|external and internal shoulder rotation using a Cybex dynamometer|"Measurement of the reproducibility, in this precise evaluation position, of the results obtained between the different tests carried out 30 minutes apart, and thus the reliability of each measurement in this test.~measures :~* Concentric internal rotation 60degrees/sec~* Concentric external rotation 60 degrees/sec~* Concentric internal rotation 180 degrees/sec~* Concentric external rotation 180 degrees/sec~* Eccentric internal rotation 60degrees/sec~* Eccentric external rotation 60degrees/sec"
214954550|NCT00594074|OTHER|white wine|3.25 ounces of white wine twice a day with lunch and dinner
215077521|NCT04005638|BIOLOGICAL|blood sample|45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
215077522|NCT04005638|BIOLOGICAL|urine sample|12 ml
214346517|NCT05077267|BIOLOGICAL|ABNCoV2 50ug|IM injection 50ug dose
214346518|NCT02911948|DRUG|Insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily
215077523|NCT06895850|OTHER|Eccentric cycling training|The training protocol for the ECC consisted of a 5-minute warm-up on a stationary ergometer (RS1 Go, Life fitness, USA) before completion of the prescribed workout. In the first two weeks, participants completed two sets of 10 minutes of eccentric cycling at an RPE between 9-11 with 2 minutes of inter-set rest. Then, during weeks 3-8, participants completed two sets of 15 min of eccentric cycling at an RPE between 13-15 with 2 min inter-set rest.
214346519|NCT02911948|DRUG|Insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily
214346520|NCT03887468|DEVICE|EvoCit|hemodialysis using the combination of the Evodial dialyzer with a citrate enriched dialysate
214346521|NCT03887468|DEVICE|EvoHep|hemodialysis using the combination of the Evodial dialyzer with a conventional bicarbonate based dialysate and systemic anticoagulation using unfractionated heparin
214346522|NCT05268146|BEHAVIORAL|Lifestyles|Co-creation process and participatory research; lifestyles
214954551|NCT01954199|PROCEDURE|Neurodynamic Group|"All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.~* In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;~* In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;~* In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner."
214954552|NCT01280682|DRUG|rituximab|anti-CD20 monoclonal antibody 125mg/m\^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
214954553|NCT03103217|BEHAVIORAL|brief CBT for anxious pregnant women|one off 3 hour session including psychoeducation, exploration of cognitions and experiential practice of behavioural techniques.
214954554|NCT04677387|BEHAVIORAL|Nalox-comm Training Module|The online communication module will be 30-60 minutes. Content will include: 1) using non-judgmental language, 2) how to raise the topic of overdose (OD) and naloxone with patients in a non-threatening manner; 3) videos modeling how to initiate the conversation with patients and caregivers; 4) considerations in how to communicate differently with patients versus caregivers; and 5) addressing pharmacists' perceived barriers to naloxone counseling. Pharmacists can receive continuing education credit (0.1 CEU) for completing the course.
214954555|NCT04677387|BEHAVIORAL|Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists|A 55 minute long online module with videos, didactic content, and quizzes that covers the following topics: risk factors for overdose (OD), how to respond to OD, how naloxone works, types of naloxone, how to administer naloxone, medico-legal issues, how to bill for naloxone, and strategies to address overdose. Pharmacists can receive continuing education credit (0.125 CEUs) for completing the course.
214954556|NCT06402357|DEVICE|Focal One high intensity focused ultrasound device|Participants will be treated with one session of high intensity focused ultrasound using the Focal One device.
214954557|NCT02057432|DEVICE|intra-operative MRI|Patients will undergo an MRI during surgery.
214954558|NCT04427488|OTHER|Morning Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
214954559|NCT04427488|OTHER|Evening Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
214954560|NCT04598308|DIAGNOSTIC_TEST|absolute flow and resistance measurements|"This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis~Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.~Intention to measure Q and Rmicro are mandatory to be included in this registry.~Use of drugs either during or after the procedure should also exactly identical to normal routine."
214954561|NCT02627482|DEVICE|Fetal heart rate monitor (Monica AN24)|"The AN24 is a portable, battery powered device, developed in the UK and designed to monitor passively an unborn baby in the antenatal period. The device is CE marked and is attached via a cable assembly which in turn attaches to five standard disposable electrodes placed on the abdomen of a pregnant woman. It is intended for ambulatory use in either the home or hospital environment.~The AN24 has had rigorous checks in the UK and has been used in many European countries. No hazards have been identified that could compromise the safety of, or cause harm to the fetus or the mother. The only potential issue identified is a local reaction under the electrodes. Nonetheless, the electrodes used are the standard disposable ECG electrodes, used routinely for adult ECG measurements."
214954562|NCT04350164|DRUG|Romiplostim|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
214954563|NCT04050085|BIOLOGICAL|Nivolumab|Given IV
214954564|NCT04050085|RADIATION|Radiation Therapy|Undergo radiation therapy
214346523|NCT00124527|DRUG|Irofulven + capecitabine|
214346524|NCT02866253|DRUG|DHEA|Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
214954565|NCT04050085|DRUG|TLR9 Agonist SD-101|Given intratumorally
215077524|NCT06895850|OTHER|Standar Rehabilitation|The training protocol for STD REHAB consisted of the same 5 min warm-up protocol used in ECC, followed by three sets of 8 repetitions of bicep curls, triceps extensions, shoulder abduction, bodyweight squats, deadlifts, and leg abductions with an elastic band with 2 min inter-set rest. The resistance of the elastic band tension was progressively increased according to the participant's tolerance based on RPE. ECC training was programmed for \~20-30 min, while STD REHAB lasted \~60 min per session.
214346525|NCT01204151|BEHAVIORAL|discrete-trial training|
214346526|NCT02679690|BEHAVIORAL|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
214346527|NCT02679690|BEHAVIORAL|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
214678574|NCT02333240|OTHER|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
214678575|NCT05173272|DRUG|Neoadjuvant Therapy|Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21
214954566|NCT03611101|COMBINATION_PRODUCT|¹³C-Methacetin Breath Test|A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
214678576|NCT05173272|RADIATION|CCRT|weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.
214954567|NCT03611101|DRUG|BMS-986036|Investigational drug for NASH treatment in Main BMS protocol
214954568|NCT03611101|DEVICE|BreathID MCS device|The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate.
214954569|NCT03838510|BEHAVIORAL|REBOOT|The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
214954570|NCT00983138|DRUG|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
215077525|NCT06597929|OTHER|Moderate-vigorous physical activity|The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program. This program consists of completing 4 length-standardised moderate-to-vigorous intense bouts per day (3 minutes each) of activities of daily living (sit-to-stand, going up/down stairs, walking fast indoors, and walking up small slopes) every day for 12 weeks. Once per week for 12 weeks, a physiotherapist will go to the patient\&#39;s home for a face-to-face session or videoconference. This physiotherapist will foster participants' independence and self-management. The PA intensity will be increased weekly by increasing the execution speed and including weights.
215077526|NCT06454825|DRUG|Intravenous drug|medications were applied intravenously to the groups 30 minutes before end of the procedure
215077527|NCT00737568|DRUG|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
215077528|NCT00737568|DRUG|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
215077529|NCT00737568|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
215077530|NCT00737568|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
214954571|NCT01879202|DRUG|Methylphenidate modified release|Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.
214954572|NCT01879202|DRUG|Maltodextrin|Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
215077531|NCT03317626|DIAGNOSTIC_TEST|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
214346528|NCT02556021|DRUG|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
214346529|NCT02556021|DRUG|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
214346530|NCT02556021|DRUG|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
214346531|NCT03137147|BEHAVIORAL|Intervention for Sleep and Pain in Youth|See arm description.
214678577|NCT05173272|RADIATION|Brachytherapy|The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
214678578|NCT01825044|DRUG|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
214954573|NCT04686825|DRUG|DA-8010 2.5mg (Fasting)|Test drug l : DA-8010 2.5mg (Fasting)
214954574|NCT04686825|DRUG|DA-8010 2.5mg (Fed)|Test drug ll : DA-8010 2.5mg (Fed)
214954575|NCT04686825|DRUG|DA-8010 5mg (Fasting)|Test drug llI : DA-8010 5mg (Fasting)
214954576|NCT04686825|DRUG|DA-8010 5mg (Fed)|Test drug lV : DA-8010 5mg (Fed)
214954577|NCT02629042|PROCEDURE|Partial endodontic treatment under local and/or locoregional anesthesia|The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
214954578|NCT02629042|DRUG|prednisolone|The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
215077532|NCT00748397|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
214346532|NCT03989817|DRUG|Vasoactive Intestinal Peptide (VIP) and Saline|12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
214346533|NCT01990469|DRUG|Gemigliptin|DPP-4 inhibitor
214346534|NCT01990469|DRUG|Gemigliptin placebo|Placebo of Gemigliptin
214346535|NCT00518024|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
214346536|NCT05520476|DEVICE|Neuroliten MVP system|The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.
214346537|NCT03052179|DIETARY_SUPPLEMENT|Poly-biotic|Before-after treatment
214346538|NCT03970109|DRUG|ANS-6637|200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
214346539|NCT03970109|DRUG|Placebo oral tablet|Placebo oral tablet
214954579|NCT04075136|DRUG|Ranibizumab|Intravitreal injection 0.5 MG Per 0.05 ML Injection.
214954580|NCT04075136|DEVICE|Photodynamic laser treatment (PDT)|PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.
214954581|NCT04075136|DRUG|Triamcinolone Acetonide|Intravitreal injection of 0.5ml-2mg
214954582|NCT04075136|DRUG|verteporfin|Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.
214954583|NCT04260568|OTHER|Semi-structured interviews|Patients with a diagnosis of 3PD will be sought from a multidisciplinary balance clinic. Consenting participants will take part in a face-to-face interview about their diagnosis. Data collection will consist of recorded semi-structured interviews, which will be transcribed.
214346540|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
214346541|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
214346542|NCT03578900|DRUG|Xeros|
214346543|NCT03578900|DRUG|Citric Acid based Mouthwash|
214346544|NCT04202159|DRUG|Perampanel|Perampanel tablets.
214346545|NCT04202159|DRUG|Perampanel|Perampanel oral suspension.
214346546|NCT00111943|DRUG|1% tenofovir gel|
214346547|NCT00142909|DRUG|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
214346548|NCT00142909|DRUG|Placebo|Lofexidine Placebo
214346549|NCT00617149|BEHAVIORAL|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
214346550|NCT03219112|OTHER|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
214346551|NCT01089140|DRUG|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
214346552|NCT01089140|DRUG|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
214346553|NCT01089140|DRUG|Saline solution|Saline placebo
214346554|NCT02855905|OTHER|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
214346555|NCT03500874|DRUG|FUDR|Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.
214346556|NCT03500874|DRUG|Oxaliplatin|Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
214346557|NCT03500874|DRUG|Leucovorin|Leucovorin 200mg/m2 ivd over 2 hours on Day 1
214346558|NCT03500874|DRUG|5FU|5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
214346559|NCT03500874|DRUG|Irinotecan|Irinotecan 180mg/m2
214346560|NCT02088996|DEVICE|longwave diathermy on high power and interferential therapy|
214346561|NCT02088996|DEVICE|longwave diathermy on low power|
215077533|NCT01126658|OTHER|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
215077534|NCT00248118|DRUG|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
214346562|NCT00841581|DRUG|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
214346563|NCT04243876|DIAGNOSTIC_TEST|paraoxanase enzyme level|presence of paraoxonase enzyme deficiency and associated troponin elevation
214346564|NCT03355079|DRUG|SmofKabiven® E|In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
214346565|NCT02396641|OTHER|Best Supportive Care Checklist|
214346566|NCT06535204|DIETARY_SUPPLEMENT|Aqueous extract of A. sylvestris leaves|Provided functional food made from Aqueous extract of A. sylvestris leaves
214346567|NCT06535204|DIETARY_SUPPLEMENT|microcrystalline cellulose|Provided placebo composed of microcrystalline cellulose instead of A. sylvestris leaf extract.
214954584|NCT00251498|DRUG|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
214954585|NCT02344771|PROCEDURE|Elective colon cancer surgery|
214346568|NCT05341089|DRUG|LY3502970|Administered orally.
214954586|NCT02394184|PROCEDURE|transcatheter aortic valve replacement|
214954587|NCT04281628|DRUG|Ketamine group:|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
214954588|NCT04281628|DRUG|Control group|where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
214954589|NCT01964716|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
214954590|NCT01964716|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
214954591|NCT05327751|DRUG|Celecoxib 200mg|200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle.
214954592|NCT05327751|DRUG|Capecitabine-based chemotherapy|Capecitabine-based chemotherapy
214954593|NCT05677958|DIETARY_SUPPLEMENT|125 mL Fortimel/Nutridrink Compact Protein|125 mL Fortimel/Nutridrink Compact Protein®\* two servings per day (300 kcal, 18 g protein per serving).
214954594|NCT05527899|DRUG|Zinc gluconate|30 and 60 mg/d of zinc gluconate
214954595|NCT03386188|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transitory inactivation of the posterior parietal cortex and measure of sensorimotor integration.
214954596|NCT03386188|DEVICE|Electrical Muscle Activity (EMG)|Electrodes for the collection of EMG activity will be glued on the skin next to the first interosseus dorsalis muscle, the Abductor digiti minimi, the Extensor carpi radialis and the Abductor pollicis brevis. EMG signals will be stored on computer for off-line analysis using Signal © software (Cambridge Electronic Design, Cambridge, UK)
214954597|NCT02535754|BEHAVIORAL|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
214954598|NCT02535754|BEHAVIORAL|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
215077535|NCT03408418|PROCEDURE|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
215077536|NCT03222154|DEVICE|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
215077537|NCT03222154|DEVICE|Placebo - Shock wave therapy|Simulation of shock wave therapy
215077538|NCT00855933|DEVICE|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (\~13% dry weight CPC)
215077539|NCT02882867|OTHER|Injuries in Swedish Youth Athletics. The KLUB-study.|
215077540|NCT00656188|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
215077541|NCT00656188|DRUG|Placebo|Matching placebo
215077542|NCT05258578|BEHAVIORAL|Tele-CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets).
215077543|NCT05258578|OTHER|Self-Help Resources|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation.
215077544|NCT06280872|OTHER|Physiological Based Cord Clamping|see Arm Description
214346569|NCT02228213|BIOLOGICAL|MIS416|Intravenous administration weekly for 52 weeks
214346570|NCT02228213|DRUG|Saline|Intravenous administration weekly for 52 weeks
214346571|NCT05536947|OTHER|Bread product (standard milled)|Bread rolls made from standard milled flour.
214346572|NCT05536947|OTHER|Bread Product (micro-milled)|Bread rolls made from micro-milled whole grain flour.
214954599|NCT02535754|BEHAVIORAL|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
214954600|NCT04235842|OTHER|Physical Exercise|Moderate-intensity continuous exercise training performed at cycle ergometer.
214954601|NCT04235842|OTHER|High-intensity interval training performed at cycle ergometer.|High-intensity interval training performed at cycle ergometer.
214954602|NCT02853071|DRUG|Estramustine|
214954603|NCT02853071|DRUG|standard practice|standard practice
214954604|NCT01474161|DRUG|GFT505 120mg - old formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
214954605|NCT01474161|DRUG|GFT505 120mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
214954606|NCT01474161|DRUG|GFT505 180mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
214954607|NCT01474161|DRUG|GFT505 240mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
214954608|NCT01474161|DRUG|GFT505 300mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
214954609|NCT01474161|DRUG|Placebo|hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
214954610|NCT03717649|DEVICE|Conventional 2-stage venous cannula|venous cannula
214954611|NCT03717649|DEVICE|Conventional 3-stage venous cannula|venous cannula
214954612|NCT03717649|DEVICE|Fenestrated 3-stage venous cannula|venous cannula
214346573|NCT05536947|OTHER|Bread Product (standard aleurone)|Bread rolls made from white flour/standard milled aleurone mix
214954613|NCT05541913|OTHER|Tele nursing|The intervention group in the study will be the parents of children who received routine care in the surgical service and who received tele-nursing service, who had undergone circumcision operation.After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
214954614|NCT02202889|BEHAVIORAL|Adequate Calcium Today|A school-randomized behavioral intervention study called the Adequate Calcium Today (ACT) project was conducted in sixth grade classrooms located in six states (Arizona, California, Hawaii, Indiana, Nevada, and Ohio).
214954615|NCT01234064|DEVICE|Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)|Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.
214954616|NCT01234064|DEVICE|No Graduated Compression Stockings|No stockings will be applied.
215077545|NCT06280872|OTHER|Differed Cord Clamping|see Arm Description
215077546|NCT00811005|RADIATION|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
214346574|NCT05536947|OTHER|Bread product (micro-milled aleurone)|Bread rolls made from white flour/micro-milled aleurone mix.
214346575|NCT06024447|PROCEDURE|Subgingival Instrumentation|Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
214346576|NCT04315311|DRUG|CREON|Capsule: Oral
214346577|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
214346578|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 60mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
214346579|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
214346580|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
214346581|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
214346582|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
214346583|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
214346584|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
214346585|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
214954617|NCT00121290|DRUG|SJG-136|Given IV
214954618|NCT00121290|OTHER|laboratory biomarker analysis|Correlative studies
214954619|NCT00121290|OTHER|pharmacological study|Correlative studies
214954620|NCT00102856|DRUG|Pramipexole|
214954621|NCT00102856|DRUG|Rivastigmine|
214954622|NCT01464619|OTHER|The Incredible Years Parenting Intervention|The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.
214954623|NCT01464619|OTHER|Delayed Intervention|Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
214954624|NCT02540161|DRUG|Sym004 - 18 mg/kg|Sym004 was dosed at 18 mg/kg intravenously every two weeks.
214678579|NCT01825044|DRUG|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
214678580|NCT02467595|DRUG|Rocuronium bromide 0.15 mg kg-1|Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
214346586|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 8 cycles. Then pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle until progression or intolerable toxicities.
214954625|NCT02540161|DRUG|Sym004 - 24 mg/kg|Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
214954626|NCT02263378|DRUG|ellagic acid + annona muricata|pills
214954627|NCT06613035|DRUG|Selinexor|Selinexor: 60 mg/day from days -9 to -5.
214954628|NCT06613035|DRUG|Melphalan|Selinexor: 60 mg/day from days -9 to -5.
214954629|NCT06613035|DRUG|Intravenous Busulfan|3.2 mg/kg on days
214346587|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 8 cycles.
214346588|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 8 cycles. Then dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle until progression or intolerable toxicities.
214346589|NCT02789787|PROCEDURE|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
214346590|NCT02789787|PROCEDURE|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
214346591|NCT04442555|DIETARY_SUPPLEMENT|HVMN Ketone Ester|Commercially available ketone supplement
214346592|NCT04442555|DIETARY_SUPPLEMENT|Maltodextrin|Commercially available maltodextrin supplement
214346593|NCT06290362|BEHAVIORAL|Cognitive Behavioural Theory-based group consultation|"Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009).~For three days a week over eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. The participants were connected to the live broadcast of the research team, and they interacted via text messages. In this interaction, further suggestions related to the goals of the week were given, previous assignments were checked, homework for the next session was given, personal experiences and the needs of the participants were determined, and necessary feedback was provided. Instagram had the feature of maintaining the records of all participants\&#39; attendance at these events."
214346594|NCT06164912|OTHER|Transcranial Magnetic Simulation with Pseudofeedback|Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.
214346595|NCT06164912|OTHER|Transcranial Magnetic Simulation with Neurofeedback|Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
214346596|NCT00564083|PROCEDURE|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
214346597|NCT01307501|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
214346598|NCT02445820|DRUG|HES|2500 mL of balanced HES 130/0.4
214346599|NCT02445820|DRUG|Crystalloid|2500 mL of balanced crystalloid.
214346600|NCT01847508|DEVICE|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
214346601|NCT01847508|DEVICE|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
214346602|NCT01704092|DRUG|Dexmedetomidine|
214346603|NCT05005611|DIETARY_SUPPLEMENT|Placebo|"A pack of powder without probiotics.~1 pack / day"
214678581|NCT02467595|DRUG|Rocuronium bromide 0.3 mg kg-1|Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
214678582|NCT02467595|DRUG|Fentanyl|Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
214678583|NCT02467595|DRUG|Propofol|Propofol 2.5 mg kg-1 was injected at I.V. line to patients
214954630|NCT06613035|DRUG|Fludarabine|30 mg/m² on days
214954631|NCT05799404|DIAGNOSTIC_TEST|ultra-high resolution CT|stapes footplate thickness measurement
214954632|NCT07010380|DEVICE|PTFinder Dual-Channel NIR Autofluorescence Imaging System|Ex vivo, non-contact imaging of resected thyroid/parathyroid specimens; captures near-infrared autofluorescence and overlays it on white-light video to highlight parathyroid glands (2-5 min per specimen).
214954633|NCT07010380|OTHER|Offline Machine-Learning Algorithm (PTFinder-AI Beta)|training/validation on de-identified NIR/RGB frames.
214954634|NCT07015268|DRUG|KLH-2109|"\- KLH-2109 tablet: Oral administration~\- Leuprorelin acetate placebo: Subcutaneous administration"
214954635|NCT07015268|DRUG|Leuprorelin acetate|"\- KLH-2109 placebo tablet: Oral administration~\- Leuprorelin acetate: Subcutaneous administration"
214954636|NCT05086341|DEVICE|My COPD|In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
214954637|NCT02929134|DRUG|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
214954638|NCT02929134|DRUG|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
214346604|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus salivarius AP-32|"A pack of powder with probiotics Lactobacillus salivarius AP-32~1 pack / day"
214954639|NCT07022171|DEVICE|transcutaneous auricular vagus nerve stimulation|Half of the patients are randomized to the arm receiving transcutaneous auricular vagus nerve stimulation for a period of six weeks. Transcutaneous auricular vagus nerve stimulation will be carried out as an adjuvant, i.e. in addition to the regular treatment of the participants. The intervention will take place three times a day from Monday to Friday. Each of the three daily sessions is going to last 30-60 minutes, depending on patient tolerance.
214346605|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Bifidobacterium animalis subsp. lactis CP-9|"A pack of powder with probiotics Bifidobacterium animalis subsp. lactis CP-9~1 pack / day"
214346606|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus rhamnosus LGG|"A pack of powder with probiotics Lactobacillus rhamnosus LGG~1 pack / day"
214346607|NCT04915469|OTHER|Standardized enhanced adherence counseling package|A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
214346608|NCT02005471|DRUG|Bendamustine|Bendamustine will be administered at a dose of 70 mg/m\^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
214346609|NCT02005471|DRUG|Venetoclax|"Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy."
214346610|NCT02005471|DRUG|Rituximab|"Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle."
214346611|NCT04295226|OTHER|Structured follow-up after stroke.|Stroke-nurse managed follow-up 3 and 12 months after stroke and multidisciplinary rounds resulting in individual treatment plans for stroke-related health problems.
214346612|NCT05306652|OTHER|Supervised physical activity|patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
214346613|NCT05306652|OTHER|Unsupervised physical activity|patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
214346614|NCT03478891|BIOLOGICAL|VRC-EBOMAB092-00-AB (MAb114)|VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
214954640|NCT07022171|DEVICE|sham transcutaneous auricular vagus nerve stimulation|Half of the patients are randomized to the arm receiving sham transcutaneous auricular vagus nerve stimulation for a period of six weeks. Sham transcutaneous auricular vagus nerve stimulation will be carried out as an adjuvant, i.e. in addition to the regular treatment of the participants. The intervention will take place three times a day from Monday to Friday. Each of the three daily sessions is going to last 30-60 minutes. The procedures for sham tVNS will be identical to tVNS, with the only exception that the sham tVNS will be performed with no current output
214954641|NCT07027332|DIAGNOSTIC_TEST|FibroScan® (Echosens, Paris, France)|A non-invasive liver elastography device used for clinical assessment. Liver steatosis and stiffness are measured in participants using the FibroScan device.
214954642|NCT07027111|DRUG|NVG-2089|Study drug
214346615|NCT03447418|PROCEDURE|Multiple breath nitrogen washout|Lung Clearance Index (LCI) will be performed in healthy volunteers with a multiple breath nitrogen washout device.
214346616|NCT01640691|BIOLOGICAL|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine~1. Administration route: Intramuscular Injection~2. Dosing schedule: 2 injections - at Day 1 and Day 22 separately~3. Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
214346617|NCT05794867|DIAGNOSTIC_TEST|clinical weaning criteria|Xray chest and calculation of thr rapid shallow breathing rate
214346618|NCT04979819|OTHER|Upper extremity endurance test (UULEX)|Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
214954643|NCT07027449|BEHAVIORAL|Screening and Referral Workflow|The Screening and Referral Workflow intervention will include screening eligible patients for employment-related needs and referring those who require support to community-based employment resources.
214954644|NCT05703464|DRUG|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
214954645|NCT02253576|OTHER|inhaled 7% hypertonic saline|Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
214346619|NCT05422911|DRUG|Abiraterone acetate|YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
214346620|NCT05422911|DRUG|Apalutamide|Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
214954646|NCT02253576|OTHER|inhaled nebulized normal saline|Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
214954647|NCT06703034|OTHER|Biological Sampling|"The procedures specifically carried out for the study during a single visit are as follows:~* 1 nasopharyngeal swab for the baseline measurement of the nasal IFN-I score and to check for the presence of infection~* Blood sample collection in:~o1 yellow tube (5mL) for anti-interferon antibody measurement o1 PAXgene tube (2.5mL) for the baseline IFN score without stimulation o3 green heparin tubes (12mL) for performing immune-functional tests o2 large purple tubes (20mL) for biological collection (if the patient provides specific consent) oA total of 39.5mL of venous blood will be collected for the study during a single visit.~* Stool collection at home by the patient, to be sent by mail to the Biological Resource Center (CRB) of the Hospices Civils de Lyon (HCL) within 10 days after the visit.~* A food frequency questionnaire composed of 159 items measuring the frequency of consumption of foods and drinks over the past 12 months to complement the analysis of the gut microbiota."
214346621|NCT05422911|DRUG|Enzalutamide|Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
214346622|NCT00060450|DRUG|nitric oxide for inhalation|Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
214346623|NCT00060450|DRUG|Placebo|Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
214346624|NCT03103555|DRUG|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
214346625|NCT03103555|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
214346626|NCT02045758|DEVICE|Fingerstick|
214954648|NCT03358680|DEVICE|noninvasive analgesia measurement|noninvasive analgesia measurement using index of consciousness(IOC2)
214954649|NCT00581425|BIOLOGICAL|Imiquimod and Interferon alpha|Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
214954650|NCT06731881|DEVICE|Nasal PDT|Two two-minute cycles will be provided by a member of the research team in the pre-operative area on the day of surgery. A saturated swab containing 0.01% methylene blue and 0.25% chlorhexidine gluconate will be applied to nares, which is then activated by light.
214954651|NCT06731881|COMBINATION_PRODUCT|Photosensitizer formulation only|Nares will be swabbed with Photosensitizer formulation (0.01% methylene blue with 0.25% chlorhexidine solution). Nasal swab cultures will be obtained before control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days). Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic LK Score will also be obtained before treatment at 2 weeks (+/-7 days).
214954652|NCT06731881|OTHER|Standard follow-up|All patients will receive standard post-operative wound follow up. This might include being advised to contact the GP or the hospital if there are any wound problems and, or, being invited to an out-patient clinic appointment.
214954653|NCT06731881|DIAGNOSTIC_TEST|Nasal culture|Nasal swab cultures will be obtained before Nasal PDT or control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days).
214954654|NCT06731881|DIAGNOSTIC_TEST|Flexible nasendoscopy|Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic Lund-Kennedy (LK) Score will also be obtained before Nasal PDT or control swabbing and at 2 weeks (+/-7 days).
214346627|NCT02045758|DEVICE|TAP20-C|
214346628|NCT05019586|DRUG|levofloxacin, amoxicillin, clarithromycin|Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
214346629|NCT05709743|BEHAVIORAL|Experimental: Within-Subjects Attentional Information|Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
214346630|NCT03662750|DIAGNOSTIC_TEST|Brain Imaging|"The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans."
214346631|NCT02555046|PROCEDURE|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
214346632|NCT02632578|BIOLOGICAL|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
214346633|NCT06664398|BEHAVIORAL|one HIIT|one HIIT high intensity interval training
214346634|NCT06664398|BEHAVIORAL|four HIIT|four HIIT high intensity interval training
214346635|NCT00932893|DRUG|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
214346636|NCT00932893|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
214346637|NCT00932893|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
214346638|NCT03975283|DRUG|Exparel 266 MG Per 20 ML Injection|266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
214346639|NCT03975283|DRUG|Bupivacaine Hcl 0.25% Inj|0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
214346640|NCT00443547|DEVICE|Vectra-T|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
214346641|NCT06074250|DIETARY_SUPPLEMENT|Fish oil|1500mg EPA +1000mg DHA daily
214346642|NCT06074250|DIETARY_SUPPLEMENT|Probiotics|Combination strain of lactobacillus and bifidobacteria
214346643|NCT06074250|BEHAVIORAL|Prebiotics|Dietary consult with follow-up to ensure target fiber intake is met.
214346644|NCT06074250|BEHAVIORAL|Diet Quality|one time dietary consult at enrollment to discuss strategies to improve overall diet.
214346645|NCT03763422|DRUG|Temozolomide|Oral Administration of Temozolomide
214346646|NCT03763422|RADIATION|Radiotherapy|50.4 Gy in 28 fractions over 6 weeks
214346647|NCT03763422|PROCEDURE|Surgery|Surgery
214346648|NCT01385345|DRUG|Vitamin D3 cholecalciferol|High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
214346649|NCT03813446|DEVICE|Device: RhythmPadBP|"Detection of heart rhythm and measurement of blood pressure~Intervention:~Patients will start by wearing a consumer SmartWatch (Huwaei SmartWatch 2, which has a CE mark) and a 60 second reading of their wrist Photoplethysmyograph (PPG) will be recorded. This will enable us to compare the PPG from the wrist with the fingertip data collected from the RhythmPadBP.~The watch will be cleaned with alcohol wipe in the same manner that the RhythmPadBP is cleaned between subjects use.~Patients will be asked to place their palms of both hands on RhythmPadBP and then the underlying heart rhythm and BP will be recorded. 12-lead ECG and BP reading will be obtained by standard devices for comparison."
214346650|NCT02945384|BEHAVIORAL|Creating Connections: Strong Families, Strong Brains|Dual-generation intervention
214346651|NCT03579329|PROCEDURE|Total Knee Arthroplasty|Effect of Total Knee Arthroplasty on Sarcopenia in Patients with Osteoarthritis in the Knee
214346652|NCT02803775|DEVICE|CRT Algorithm|Programming based on Electrogram measurement
214346653|NCT06454032|BEHAVIORAL|Fitness walking|Fitness walking for 12 weeks.
214346654|NCT06454032|BEHAVIORAL|Maintained lifestyle|Maintained their normal lifestyle, without exercise intervention.
214346655|NCT01903538|DEVICE|Cathodal transcranial direct current stimulation (tDCS)|Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
214954655|NCT06731881|OTHER|In-person review|On Week 2 (±7 days), the participant will undergo an in-person review conducted in the ENT Outpatient department, 2nd floor Southwark wing, Guy's Hospital by the CI, PI or Co-investigator. During this appointment, concomitant medications and use of post-operative antibiotics will be reviewed.
214954656|NCT06731881|OTHER|Telephone Follow-up|"On day 30, the research nurse will telephone participants from the ENT research office.~* Review of adverse events/adverse device effects~* Review of concomitant medications~* Signs and symptoms post-surgery~* Nasal washout~* Record any use of post-operative antibiotics, both local and systemic"
214954657|NCT02336347|DRUG|AVP-786|
214954658|NCT02336347|DRUG|AVP-923|
214346656|NCT01903538|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
214346657|NCT01704313|PROCEDURE|Interrupted|Interrupted suturing technique used aroudn the heel of the vascular anastomosis
214346658|NCT01704313|PROCEDURE|Continuous|Continuous suturing technique used for the anastomosis
214346659|NCT00203359|DRUG|etanercept given by perispinal administration|
214346660|NCT02301702|BIOLOGICAL|Tdap|Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
214346661|NCT02301702|BIOLOGICAL|Td|The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
214346662|NCT06094088|BEHAVIORAL|Heated Yoga|Heated yoga described in arm/group description
214346663|NCT06094088|BEHAVIORAL|Non-Heated Yoga|Non-heated yoga described in arm/group description
214346664|NCT04450264|BEHAVIORAL|African Immigrant Breast Cancer Education Program|African immigrant women are at significant risk for not participating in preventive screening, such as for breast cancer. Thus, this project will culturally adapt an existing evidenced-based, the Witness Project, by identifying potential barriers and guided by the Health Belief Model incorporate those findings into a group-based narrative education program for English and French-speaking African immigrant women. The program content will include: (1) information about the benefits of early detection of breast cancer screening, (2) education about disparities in breast cancer, (3) disparities in breast cancer screening among African immigrant women, and (4) will address the unique barriers and facilitators of African immigrant women identified in Aim 1 of this study. The program will use a culturally matched peer approach to educate and model successful experiences with mammography screening.
214346665|NCT05696899|OTHER|STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents|A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
214678584|NCT02467595|DRUG|Sevoflurane|After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
214678585|NCT01703819|DRUG|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
214678586|NCT01703819|OTHER|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
214678587|NCT00859898|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
214954659|NCT05612464|OTHER|No intervention|No intervention
214954660|NCT05663944|DRUG|Sirolimus 0.5Mg Tab|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
214346666|NCT02048332|BIOLOGICAL|Viral specific VST Infusion|"VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the below:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \>1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~* Evidence of PML or other CNS infection due to JC virus."
214346667|NCT05678634|BEHAVIORAL|Declarative learning with immediate feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 500 ms following a response (button press)
214346668|NCT05678634|BEHAVIORAL|Declarative learning with delayed feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 5000 ms following a response (button press)
214346669|NCT05678634|BEHAVIORAL|Probabilistic learning with immediate feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 500 ms following a response (button press)
214346670|NCT05678634|BEHAVIORAL|Probabilistic learning with delayed feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 5000 ms following a response (button press)
214954661|NCT05663944|DIAGNOSTIC_TEST|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be undertaken at Sir Peter Mansfield Imaging Centre, University of Nottingham at the start of the trial, and at the end, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
214954662|NCT05663944|PROCEDURE|1st Percutaneous or Endoscopic Ultrasound guided liver biopsy|After informed consent, participants will undertake up to a 8-week screening period to provide baseline data to ensure eligibility. During this period, participants will undergo blood tests, percutaneous or endoscopic ultrasound-guided liver biopsy, unless the participant has undergone a liver biopsy within the past 3 months, in which case the previous liver biopsy sample will be utilised for this study. They will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate with sirolimus when compared to placebo
214954663|NCT05663944|DRUG|Placebo 0.5mg capsule|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. The placebo is unmatched. Participants will start on a dose of 1mg daily (2 x 0.5mg capsules) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels, to maintain blinding of the research team members carrying out blood tests. Placebo doses will be adjusted randomly, in a pattern that mirrors the adjustments made to participants on sirolimus.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
214954664|NCT05663944|DIAGNOSTIC_TEST|Baseline Blood Tests|"During the initial clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
215077547|NCT00811005|RADIATION|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
215077548|NCT01960998|BEHAVIORAL|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
214954665|NCT05663944|DIAGNOSTIC_TEST|Baseline Clinical Examination|A thorough medical examination will be undertaken at the first clinical visit (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants are clinical stable. This will also serve as a comparator for future clinical examinations once participants have commenced the study drug.
215077549|NCT01960998|BEHAVIORAL|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
215077550|NCT03207321|DIETARY_SUPPLEMENT|Upma|A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
215077551|NCT04562402|PROCEDURE|Phacoemulsification|cataract surgery via phacoemulsification
215077552|NCT04562402|PROCEDURE|Endoscopic cyclophotocoagulation|Endoscopic ablation of the ciliary body
215077553|NCT02458131|BEHAVIORAL|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
214346671|NCT05678634|BEHAVIORAL|Word learning task with active feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names through trial and error guided by feedback. Each response will be followed by feedback either indicating that the response is correct or prompting the child to try again (i.e., to correct an error)
214678588|NCT00859898|DRUG|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
214678589|NCT00859898|DRUG|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
214678590|NCT00859898|DRUG|dapagliflozin matching Placebo|Tablets
214678591|NCT00859898|DRUG|metformin HCl Modified Release matching Placebo|Tablets
214346672|NCT05678634|BEHAVIORAL|Word learning task with passive feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names. Regardless of response accuracy on each trial, each response will be followed by a visual presentation of the correct response.
214346673|NCT01534598|DRUG|FdCyd + THU|Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown to be feasible in an expansion cohort of the previous trial.
214346674|NCT00811148|PROCEDURE|Tissue Bank|Collection of clinical data and tumor tissue.
214346675|NCT00175604|DRUG|Botox|The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
214346676|NCT06787040|OTHER|Resource-Stratified Protocol|The interventions are a set of protocols that accounts for varying levels of resources available at any given time for patients with severe traumatic brain injury across prehospital, ED, neurosurgery, and ICU. Protocols are available in the NIH-PMC website at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7055642/
214346677|NCT04218461|DIAGNOSTIC_TEST|PRE-DELIRIC model|To predict delirium according to risk factors in the PRE-DELIRIC model
214346678|NCT01724138|DRUG|Deferasirox|Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
214346679|NCT04295564|OTHER|Additional 2 weeks of CPAP|Subjects will be randomized to an additional 2 weeks of CPAP vs. discontinuing CPAP per usual care.
214954666|NCT05663944|DIAGNOSTIC_TEST|Week 1 - 5 Titration Blood Tests|"Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly bloods:~* full blood count,~* urea and electrolytes and~* liver function tests to check the study drug is not causing any significant organ damage.~* Sirolimus trough levels will be measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Therefore, participants will have a minimum of 3 weeks of blood tests during this period, The need for week 4 and 5 blood tests will be decided by the trial pharmacist who will be monitoring results.~Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding."
214346680|NCT01343550|OTHER|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
214346681|NCT00712023|DEVICE|warming device (a reusable, custom-made forced- air warming mattress)|"2=forced-air warming mattress~1=circulating-water mattress"
214346682|NCT05903144|OTHER|manual therapy|manual diaphragmatic release technique combined with breathing exercise
214346683|NCT05903144|OTHER|breathing exercise and prone position alone|deep breathing exercise and prone position
214346684|NCT01629004|OTHER|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
214346685|NCT01629004|OTHER|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
214678592|NCT02145156|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
214954667|NCT05663944|OTHER|Month 2 Clinical Examination|A thorough medical examination will be undertaken at Month 2 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
215077554|NCT02666651|DRUG|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
215077555|NCT02666651|OTHER|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
215077556|NCT00704483|DRUG|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
215077557|NCT00704483|DRUG|Sevelamer HCl|0.8 g tid
215077558|NCT00704483|DRUG|SBR759|1.5 g tid
215077559|NCT00704483|DRUG|Sevelamer HCl|1.6 g tid
215077560|NCT04703608|DRUG|Ivermectin|Ivermectin 0.3-0.4mg/Kg daily for 3 days.
214346686|NCT04075500|DEVICE|24-h Holter monitoring|Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).
214346687|NCT01016665|DRUG|Anastrozole|Tamoxifen 20mg and anastrozole 1 mg
214346688|NCT02374827|PROCEDURE|Standard postpartum tubal ligation|Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
214346689|NCT02374827|PROCEDURE|Complete Salpingectomy|Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
214346690|NCT00605436|BEHAVIORAL|Restorative yoga therapy|3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
214346691|NCT03228511|DEVICE|endoscope|It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
214346692|NCT01682460|DRUG|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
214346693|NCT05924152|DRUG|Adagrasib|Adagrasib
214346694|NCT05924152|DRUG|Eltrombopag + adagrasib|Eltrombopag + adagrasib
214678593|NCT02145156|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
214678594|NCT02145156|BEHAVIORAL|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
214954668|NCT05663944|DIAGNOSTIC_TEST|Month 2 Blood Tests|"During the Month 2 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
214954669|NCT05663944|OTHER|Month 4 Clinical Examination|A thorough medical examination will be undertaken at Month 4 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
214954670|NCT05663944|DIAGNOSTIC_TEST|Month 4 Blood Tests|"During the Month 4 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
214954671|NCT05663944|OTHER|Month 6 Clinical Examination|A thorough medical examination will be undertaken at Month 6 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants have remained clinically stable whilst on the study drug. At this visit, they will be asked to finish taking the study drug. They will also be asked about potential side effects in detail.
215077561|NCT04703608|DRUG|ASP|Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
214678595|NCT02253667|DEVICE|HFONC|
214678596|NCT02253667|DEVICE|Conventional oxygen therapy|
214678597|NCT06317272|OTHER|DIBH using ABC technique|Deep breath inspiration hold (DIBH) using Active Breathing Control (ABC) technique
215077562|NCT04703608|DRUG|Placebo|Non-identical placebo
214678598|NCT06317272|OTHER|DIBH using VC technique|Deep breath inspiration hold (DIBH) using Voluntary Coaching (VC) technique
214678599|NCT01302041|DRUG|Enzalutamide|Oral
214678600|NCT03697395|DIAGNOSTIC_TEST|Lung transplant recipient without MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant, but without consenting to be evaluated by hyperbolized gas MRI. Bronchoscopy sampling will be performed per usual lung transplant team protocol.
215077563|NCT00790166|DEVICE|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
215077564|NCT00790166|DEVICE|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
215077565|NCT00790166|DEVICE|CPAP + No added humidity|ambient humidity
215077566|NCT00791453|BEHAVIORAL|Education|Patients will receive literacy appropriate health information.
215077567|NCT00759356|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
215077568|NCT00759356|DRUG|KADIAN|2 x 100 mg, single-dose capsule
215077569|NCT00373165|DRUG|Ganciclovir|
215077570|NCT05514756|DEVICE|Active t-VNS|Active t-VNS at 8 Hz for up to 60 minutes will be applied to the left cymba conchae
214346695|NCT03575923|BEHAVIORAL|Urban street greening|The interventions are located on four publicly accessible sites; the total size of the floor area of green space in each of the intervention sites is small, ranging from 0.09 to 0.35 acres. Components of the interventions include tree and flower planting (expected to bloom by March 2018) and artificial tree decorations such as strings of small electric lights and tree socks (the interventions are hereafter collectively referred to as urban street greening). The total cost for all components across all four intervention sites is approximately £6,000, although this excludes artist fees connected to the project. All components of the interventions were implemented within a one week period in November 2017 by two arborists, two local artists, staff members at Southway Housing Trust, and local community members from Old Moat and a local school.
214346696|NCT06180564|OTHER|Intra-operative Infra-red thermography|. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature \>3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
214678601|NCT03697395|DRUG|Lung transplant recipient with MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant and with consenting to be evaluated by hyperbolized has MRI. Bronchoscopy sampling will be guided by the results of the hyper polarized gas MRI, different from the usual lung transplant team protocol. Administration of hyper polarized gas MRI is under FDA regulation by IND #129769 (PI, Yun Michael Shim, MD)
214954672|NCT05663944|DIAGNOSTIC_TEST|Month 6 Blood Tests|"During the Month 6 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
215077571|NCT05514756|DEVICE|Sham t-VNS|Sham t-VNS at 8 Hz for up to 60 minutes will be applied to the left earlobe
215077572|NCT05514756|OTHER|Baseline assessments|Baselines assessments with no stimulation will serve as control in this three-part crossover design
215077573|NCT03647150|DRUG|amoxicillin|At enrollment the child will receive a 1 week course of amoxicillin
215077574|NCT03647150|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
215077575|NCT03647150|BEHAVIORAL|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
215077576|NCT01388439|DRUG|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants \< 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants \> 38 weeks PMA. Dosing in infants \< 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants \> 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants \> 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
215077577|NCT01817699|OTHER|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
215077578|NCT01817699|DIETARY_SUPPLEMENT|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
215077579|NCT01713283|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
215077580|NCT01713283|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
215077581|NCT03243578|OTHER|None as this is an observational study|
215077582|NCT03262350|BEHAVIORAL|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
214678602|NCT00198341|PROCEDURE|Radiological Arm|Clinical Visit + X-Ray Chest
214954673|NCT05663944|PROCEDURE|2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy|All participants will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate when compared to their first biopsy.
214346697|NCT05363033|DEVICE|sarcopenia nursing guidance mobile application was developed|The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
214346698|NCT06780995|OTHER|Power Exercise for Stroke Recovery (POWER)|"POWER incorporates 3 progressive phases: Phase 1 Familiarization (Week 1) as a low-intensity version of the training program to acclimate participants to the movements (body weight resisted or light weights, RPE 2-3 Fairly light to Moderate). Phase 2 Strength (Weeks 2-5) progresses loads to achieve volitional fatigue within 6-8 repetitions (RPE 7-9 Very hard to Very very hard). Phase 3 Power (Weeks 6-10) will use intensities RPE 4-6 (Somewhat hard to Very hard), and exercises will be executed at the highest possible velocity to focus on muscle power. The Power phase is intentionally designed with exercises to emphasize functional movements such as fast sit to stands, lunging and calf raises."
214346699|NCT06780995|OTHER|Strength Training Engaging Guidelines to Enhance Total Health (STRENGTH)|"STRENGTH is based on current clinical practice guidelines for RET after stroke. It will include the same Familiarization week as the POWER program (Week 1), followed by progressive conventional RET involving 3 sets of 10-15 repetitions at moderate to high intensities (RPE 4-5 Somewhat hard to Hard) (Weeks 2-10). The external resistance will be progressed to maintain this target RPE range. STRENGTH is matched with POWER in length (60-minute sessions over 10 weeks), frequency (3x/week) and format (in-person supervision)."
214346700|NCT00639717|PROCEDURE|stem cell transplant|reduced intensity, matched unrelated donor stem cell transplant
214346701|NCT00639717|DRUG|tacrolimus (standard GVHD prophylaxis)|"Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant"
214678603|NCT00198341|PROCEDURE|Scannographic arm|Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
214678604|NCT00565695|DEVICE|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
214954674|NCT05663944|DIAGNOSTIC_TEST|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
214954675|NCT02467894|OTHER|Group-based Care|There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
214954676|NCT04672876|DRUG|Telotristat Ethyl Oral Tablet|XERMELO is a prescription pill, used along with somatostatin analog (SSA) therapy, for Carcinoid Syndrome diarrhea in adults who are not adequately controlled by SSA therapy. The drug is currently FDA-approved for this use but this study has received special approval from the FDA (under an Investigational Drug Application) to study telotristat ethyl in individuals with carcinoid tumors who plan to undergo surgery.
214954677|NCT00652717|DRUG|Ezetimibe|Ezetimibe 10 mg daily for 42 days.
214954678|NCT00652717|DRUG|simvastatin|simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
214954679|NCT02380963|DIETARY_SUPPLEMENT|Colorado Diet with soy protein foods.|"Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.~Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.~Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)"
214954680|NCT02380963|BEHAVIORAL|Colorado Diet with monetary payments|"Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.~Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.~Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend."
214346702|NCT00639717|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
214346703|NCT00639717|DRUG|etanercept|Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
214346704|NCT00639717|DRUG|methoxsalen|"Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped."
214954681|NCT00752869|DRUG|dutasteride|0.5mg by mouth one time per day for 1 year
214954682|NCT00752869|DRUG|placebo|one tablet per day for 1 year
214954683|NCT03795662|OTHER|No intervention|Obervational
214954684|NCT05546320|DRUG|Aspirin 100mg|Anticoagulation or anti-platelet or migraine medication therapy will be provided for different groups.
214954685|NCT05546320|DRUG|Metoprolol 25 Mg Oral Tablet|Metoprolol 25mg will be provided for the participants twice a day.
214954686|NCT05546320|DRUG|Clopidogrel 75mg|Clopidogrel 75mg will be provided for the participant once a day.
214954687|NCT05546320|DRUG|Rivaroxaban 20mg|Rivaroxaban 20mg will be provided for the participant once a day.
214954688|NCT00994799|DRUG|ranibizumab|10mg/ml intravitreal injection
214346705|NCT04246034|PROCEDURE|Microvascular Breast Reconstruction with Vascularized Lymph Node Transfer|simultaneous free abdominal flaps with VLNT from groin are transferred on a single pedicle for breast reconstruction and postmastectomy lymphedema
214346706|NCT05349617|BIOLOGICAL|CHIKV VLP/adjuvant|PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant
214346707|NCT05349617|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
214346708|NCT03726905|OTHER|respiratory muscles training|4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
215077583|NCT01743235|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
215077584|NCT01743235|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
215077585|NCT01743235|DRUG|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
214346709|NCT03726905|OTHER|sham respiratory muscles training|4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
214346710|NCT03726905|OTHER|aerobic training|12 weeks treadmill walking
214346711|NCT05190393|PROCEDURE|hemivertebra resection on convex side|Patients were used hemivertebra resection procedure to treat congenital cervical scoliosis.
214346712|NCT05190393|PROCEDURE|concave distraction group|Patients were used distraction and lateral opening procedure to treat congenital cervical scoliosis.
214346713|NCT03400540|DIAGNOSTIC_TEST|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
214346714|NCT01756092|PROCEDURE|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
214346715|NCT04207099|DEVICE|MolecuLight i:X Imaging Device|The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
214346716|NCT00724282|DRUG|Eszopiclone|Eszopiclone 3 mg by mouth daily at bedtime for 9 days
214346717|NCT00724282|DRUG|Placebo|Placebo by mouth daily at bedtime for 9 days
214346718|NCT04952324|OTHER|Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP|Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
214346719|NCT01820728|DRUG|DA-3801 Injection|
214346720|NCT01820728|DRUG|Gonal-F®|
214346721|NCT05518955|BEHAVIORAL|Virtual reality and eye mask|Participates will receive a virtual reality program 30 min before their sleep and combine with the sleep routine program for consecutive 2 nights in the ICU.
215077586|NCT02403635|DRUG|Midazolam|
214346722|NCT01505296|DRUG|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
215077587|NCT02403635|DRUG|ASP2151|
215077588|NCT00359944|DRUG|AC-3933|5mg twice daily
215077589|NCT00359944|DRUG|AC-3933|AC-3933, 20 mg twice daily
215077590|NCT00359944|OTHER|Sugar Pill|Sugar Pill twice daily
214346723|NCT01505296|PROCEDURE|Catheter ablation|Complete PVI
215077591|NCT03088748|DEVICE|Journey II posterior cruciate retaining total knee arthroplasty|
214346726|NCT03582176|DRUG|Lactose Placebo|One capsule by mouth twice per day
214346727|NCT03582176|DRUG|Ketotifen Fumarate 2mg|2 mg tablets (over-encapsulated into one capsule) by mouth twice per day
214346728|NCT03582176|DRUG|Ketotifen Fumarate 5mg|5 mg tablets (over-encapsulated into one capsule) by mouth twice per day
214346729|NCT02100176|OTHER|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
214346730|NCT02100176|DRUG|Rotigotine|Rotigotine 2-8 mg/24 h
215077592|NCT03088748|DEVICE|Journey II posterior bi-cruciate retaining total knee arthroplasty|
215077593|NCT03326414|PROCEDURE|Constant PEEP - low tidal volume|The respirator is set according to study protocol
215077594|NCT03326414|PROCEDURE|Constant PEEP - high tidal volume|The respirator is set according to study protocol
215077595|NCT03326414|PROCEDURE|constant tidal volume - low PEEP|The respirator is set according to study protocol
215077596|NCT03326414|PROCEDURE|constant tidal volume - high PEEP|The respirator is set according to study protocol
215077597|NCT00195520|DRUG|Totelle®|
215077598|NCT00993512|DRUG|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
215077599|NCT00993512|DRUG|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
215077600|NCT00993512|OTHER|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
214346731|NCT04764058|DRUG|Tienam 500|Imipenem and cilastatin sodium
214346732|NCT04764058|DEVICE|Infusion|Health caregivers give the drug to the patients and monitoring the infusion rate
214954689|NCT00994799|RADIATION|macular grid-pattern laser|macular grid-pattern laser therapy
215077601|NCT05865405|BEHAVIORAL|MS CATCH|Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
215077602|NCT03117790|DRUG|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
214346733|NCT01928719|DRUG|Reduced Nicotine Content Cigarettes|Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette
215077603|NCT03117790|DRUG|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
214346734|NCT01928719|DRUG|Same Nicotine Content Cigarettes|about 11.6 mg nicotine per cigarette
214346735|NCT04118153|DRUG|Abatacept|Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL) per dose.
214954690|NCT00573586|DEVICE|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
214954691|NCT01897766|DRUG|Somatropin|0.23 mg to 0.48 mg/kg/week
214954692|NCT02179749|DRUG|Mifepristone 1200 mg daily|Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
215077604|NCT00835640|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
215077605|NCT00835640|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
215077606|NCT01904149|DRUG|Placebo|Placebo single oral dose (first 8 hours)
214346736|NCT06223620|OTHER|review performance of water soluble contrast|review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
214954693|NCT02179749|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 8 week duration.
214954694|NCT02179749|DRUG|Placebo|Placebo tablets, Four tablets daily/am for 1-week duration.
214954695|NCT03588013|OTHER|Nutritional education|4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ \< -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.
214954696|NCT03588013|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food|If child remains WHZ \< -2 despite nutritional education then will be managed according to Pakistan's Community Management of Acute Malnutrition protocol. This will include provision of ready to use therapeutic food (RUTF) to the child at home with close follow up. Utilization of the RUTF will be monitored closely by bi-weekly home visits.
214954697|NCT03588013|PROCEDURE|Upper gastrointestinal endoscopy with biopsy|If child remains at WHZ \< -2 despite educational and dietary interventions, then will undergo medical evaluation for assessment of need for more advanced workup of malnutrition, including UGI endoscopy at AKUH. Results of the advanced work up, including the UGI endoscopy, will guide future management of these children.
214954698|NCT06811298|OTHER|Breast massage|The breast massage group will receive a 15-minute breast massage administered by the researchers at postoperative Day 0, Hour 3, and Hour 24. The aim of this intervention is to increase lactation. Following the interventions, mothers will be asked to breastfeed their infants, and the infants will be weighed both before and after breastfeeding.
214954699|NCT06811298|OTHER|Virtual Reality|Postpartum women who undergo virtual reality headset application will watch a 15-minute river and forest video using the headset on postoperative day 0, hour 3, and hour 24. This intervention aims to help them feel in a relaxing and soothing environment and to increase lactation. Following the interventions, mothers will be asked to breastfeed their infants, and the infants will be weighed both before and after breastfeeding.
215077607|NCT01904149|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
215077608|NCT01904149|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
215077609|NCT01904149|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
215077610|NCT01904149|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
215077611|NCT01904149|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
214346737|NCT04440553|BEHAVIORAL|Uniform random message delivery|The uniform random intervention group receives feedback and motivational messages chosen from the messaging banks with equal probabilities.
214346738|NCT04440553|BEHAVIORAL|Reinforcement learning message delivery|The adaptive intervention group receives messages chosen from the messaging banks by a reinforcement learning algorithm.
214346739|NCT01837381|PROCEDURE|TEA|Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol \[absolute alcohol\], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
214346740|NCT04933955|PROCEDURE|vital pulp therapy|pulpotomy
214346741|NCT02151279|OTHER|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
214346742|NCT02151279|OTHER|Control|
214346743|NCT02372201|OTHER|Hydro Colon Therapy plus probiotic|Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
214954700|NCT04131491|PROCEDURE|Lumbar puncture|Lumbar puncture for AD biomarker fluid analysis
214954701|NCT02780960|DEVICE|HPV self-testing|Patients will perform HPV testing themselves at home.
214346744|NCT00070473|DRUG|pemetrexed disodium|
214346745|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
214346746|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
214346747|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
214346748|NCT02701218|PROCEDURE|Canalith repositioning procedure|Canalith repositioning procedure; single or multiple cycles
214346749|NCT02250612|DRUG|1 drop of 0.375% SYL040012 (bamosiran)|
214346750|NCT02250612|DRUG|1 drop of 0.750% SYL040012 (bamosiran)|
214346751|NCT02250612|DRUG|1 drop of 1.125% SYL040012 (bamosiran)|
214346752|NCT02250612|DRUG|1 drop of 1.5% SYL040012 (bamosiran)|
214954702|NCT05887024|DEVICE|Radial Extracorporeal Shock wave Therapy|Shock wave therapy: (BECO) S/N 16B011375
214954703|NCT05887024|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|EME (Therapic 9400) TENS
214954704|NCT05887024|PROCEDURE|McKenzie Back exercises|Graduated Progressive back exercise program.
215077612|NCT01904149|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
215077613|NCT00497549|PROCEDURE|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
214954705|NCT05887024|DEVICE|electric heating pads|electrical conducting heat pack.
214954706|NCT02756364|DRUG|Fulvestrant|Fulvestrant IM injection.
214346753|NCT02250612|DRUG|1 drop of 0.5 % timolol maleate|
214346754|NCT01739829|DEVICE|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
214954707|NCT02756364|DRUG|Sapanisertib|Sapanisertib capsule.
214954708|NCT02655016|DRUG|Niraparib|Niraparib will be administered.
214954709|NCT02655016|DRUG|Placebo|Placebo will be administered.
214954710|NCT05451953|PROCEDURE|Apneic Oxygenation|Nasal cannula at a rate of 6L/min with 100% FiO2 during laryngoscopy and intubation attempt(s)
214954711|NCT05451953|PROCEDURE|Standard of Care|No respiratory support during laryngoscopy and intubation attempt(s) (current standard of care)
214954712|NCT02223364|DRUG|Peripheral nerve blocks with Bupivacaine|Subjects received Bupivacaine 0.5% preoperatively, then Bupivacaine 0.2% upon post anesthesia care unit (PACU) arrival via femoral nerve block, then Bupivacaine 0.25% via single-injection sciatic nerve.
214954713|NCT02223364|DRUG|Intra articular injection with Ropivacaine|Subjects received an intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Ropivacaine dose depended upon body weight: 50-74.9 kg: 200 mg, 75-99.9 kg: 300 mg, 100-125 kg: 400 mg.
215077614|NCT00497549|PROCEDURE|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
214346755|NCT01739829|DEVICE|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
214346756|NCT06134544|DIETARY_SUPPLEMENT|Isomaltooligosaccharides (IMO)|Patients will still receive standard treatment, including medicine and other invasive treatment.
214346757|NCT06133400|OTHER|Questionnaire|Questionnaire about socio-demographical status, health status and lifestyle habits
214346758|NCT06133400|OTHER|Physical measurements|Measurement of height, weight, waist circumference, blood pressure and skin pigmentation
214954714|NCT02223364|DRUG|Intra articular injection with liposomal bupivacaine|Subjects received an intra articular injection with liposomal bupivacaine, a total volume of 120 mL injected in the periarticular structures by the surgeon. Patients weighing 50-125 kg received 266mg of Liposomal Bupivacaine.
214678605|NCT01335568|PROCEDURE|Hepatocyte Matrix Implant|Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
214954715|NCT06026839|OTHER|Conventional nursing|Conventional nursing
214954716|NCT06618573|DRUG|Isoniazid/Pyridoxine|Treatment group received isoniazid 300mg and pyridoxine 10mg/day
214954717|NCT06618573|DRUG|Saccharum Lactis|Control group received placebo
214346759|NCT06133400|OTHER|Biological samples|Collect venous blood, saliva and stool samples
214346760|NCT04469179|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
214346761|NCT04469179|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
214346762|NCT01114568|DRUG|Ertugliflozin 10 mg tablet|A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
214346763|NCT01114568|DRUG|Ertugliflozin OC Fast|Formulation B) Ertugliflozin 10 mg OC Fast
214346764|NCT01114568|DRUG|Ertugliflozin OC Slow|Formulation C) Ertugliflozin 10 mg OC Slow
214346765|NCT05922358|COMBINATION_PRODUCT|Anti-allergic treatment|"For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg/ml, 0.1 mg/ml and 5 mg/ml were used in sequence for skin test. 5% GS was used as a negative control. Test results are read within 15 to 20 minutes.~Grade IV: Permanently stop using oxaliplatin; Grade I-II: Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid\*3dose) the day before the next cycle of oxaliplatin. The infusion rate is 50% of the original rate; if a grade II hypersensitivity reaction occurs again, the treatment method is the same as that of a grade III hypersensitivity reaction.~Grade III: Oral drugs are the same as above. 0.5h before oxaliplatin: dexamethasone 10mg iv, cimetidine 40mg iv, promethazine 25mg im. The first bag of 10% total amount of oxaliplatin + 5% GS500ml: 5ml/h\*1h, 45ml/h\*1h, then 225ml/h\*2 hours; then dexamethasone 10mg iv; the second bag of 90% total Oxa +5%GS500ml: 100ml/h\*0.5h, then 150ml/h\*3 hours."
214346766|NCT06104410|RADIATION|Standard fractioned dose|Total dose of 6 Gy in 2 or 4 single fractions of 1.5 Gy applied twice weekly.
214346767|NCT06104410|RADIATION|Experimental single dose|Total dose of 0.5 Gy, 1Gy, 1.5 or 2Gy in 1 single fraction.
214346768|NCT01427868|DRUG|LB80380 maleate salt|183 mg (150 mg as a free base)
214346769|NCT01427868|DRUG|LB80380 free base|150 mg
214346770|NCT04502329|OTHER|Diet|Energy Restriction Intermittent Fasting Diet
214346771|NCT01380340|OTHER|Seniors Early Intervention Planning and Discussion.|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
214346772|NCT03278015|DRUG|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
214346773|NCT03278015|DRUG|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
214346774|NCT03278015|DRUG|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
214346775|NCT04293146|PROCEDURE|pre-pectoral IBBR|The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.
214346776|NCT04293146|PROCEDURE|sub-pectoral IBBR|The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.
214346777|NCT05732454|DRUG|etrasimod|PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks
214346778|NCT05732454|DRUG|Placebo|PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
214346779|NCT05386160|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection of Ranibizumab；
214346780|NCT05386160|DEVICE|Phacoemulsification|Phacoemulsification
214346781|NCT02875587|DRUG|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
214346782|NCT02875587|DRUG|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
214346783|NCT01427244|DRUG|trastuzumab|monoclonal antibody
214346784|NCT01359553|OTHER|Intra-articular ultrasound imaging of knee joint during arthroscopy|
214346785|NCT01359553|OTHER|Non-invasive ultrasound imaging of knee|
214346786|NCT01359553|OTHER|Quantitative MRI imaging of knee|
214346787|NCT01359553|OTHER|Contrast-enhanced CT imaging of knee|
214346788|NCT02995603|DEVICE|Nano-X patient rotation|Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
214346789|NCT03089086|BIOLOGICAL|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to \<3 months apart in adolescents.
214346790|NCT05483348|PROCEDURE|Endometrial Ablation|Thermal endometrial ablation
214346791|NCT05483348|PROCEDURE|Repeated gynecological procedure|subsequent gynecological procedures such as hysterectomy for any benign indication, D\&C or repeat ablation.
214346792|NCT04649398|DRUG|Nimodipine|If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
214346793|NCT03876080|OTHER|Dry needling|The use of a solid filiform needle to treat trigger points
214346794|NCT03876080|OTHER|Sham needling|Simulated needling
214346795|NCT04840550|DRUG|Lansoprazole 15 mg|Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
214346796|NCT04840550|DRUG|Tegoprazan 25 mg|Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
214346797|NCT04098744|DRUG|Artesunate vaginal insert|Artesunate formulated as vaginal inserts, 200mg
214346798|NCT04098744|DRUG|Placebo vaginal insert|Placebo for artesunate vaginal inserts
214346799|NCT01627392|BEHAVIORAL|Smoking abstinence|6 hour smoking abstinence
214346800|NCT01093729|DRUG|HM11260C|HM11260C 0.5mcg/kg or Placebo
214346801|NCT01093729|DRUG|HM11260C|HM11260C 2mcg/kg or Placebo
214346802|NCT01093729|DRUG|HM11260C|HM11260C 4mcg/kg or Placebo
214346803|NCT01093729|DRUG|HM11260C|HM11260C 8mcg/kg or Placebo
214346804|NCT01093729|DRUG|HM11260C|HM11260C 14mcg/kg or Placebo
214346805|NCT05997238|DRUG|without triamcinolone|The preparation contains only the basic formula. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
214346806|NCT05997238|DRUG|20mg triamcinolone|20mg triamcinolone was added to the preparation. Mix 20mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
214346807|NCT05997238|DRUG|40mg triamcinolone|40mg triamcinolone was added to the preparation. Mix 40mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
214346808|NCT05997238|DRUG|80mg triamcinolone|80mg triamcinolone was added to the preparation. Mix 80mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
214954718|NCT00793546|DRUG|Bosutinib|300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
214954719|NCT00793546|DRUG|exemestane|25 mg tablet once daily
214954720|NCT00793546|DRUG|Exemestane|25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
214954721|NCT01334580|BEHAVIORAL|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
214954722|NCT01334580|BEHAVIORAL|Methadone Drug Counseling|Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
214346809|NCT04636255|PROCEDURE|Physical Characteristics|Body Weight, Height
214346810|NCT04636255|DIAGNOSTIC_TEST|Assessment of Heart rate variability|Holter 24h
214954723|NCT00113191|DRUG|Veronate|
214954724|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
214954725|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
214954726|NCT04312594|DRUG|Placebo|Patients were administered Placebo taken orally as tablets twice daily
214954727|NCT01841567|DEVICE|Mepilex border post. op|
214954728|NCT01841567|DEVICE|Mepilex border post op|
214954729|NCT01416155|DRUG|natalizumab|
214954730|NCT05400889|DRUG|tofacitinib|Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.
214954731|NCT00065195|PROCEDURE|Moving touch therapy|
214954732|NCT00065195|PROCEDURE|Nonmoving touch therapy|
214954733|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.
214954734|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
214954735|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 1000 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
214954736|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 1500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity, or withdrawal of consent.
214954737|NCT01573754|DRUG|Hydroxychloroquine|100 mg by mouth twice weekly
214954738|NCT01573754|PROCEDURE|Phlebotomy|450 mL every 2 weeks
214954739|NCT02061683|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
214954740|NCT03376373|BEHAVIORAL|neurofeedback|real-time feedback on accuracy of emotion recognition
214954741|NCT00908427|PROCEDURE|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
214954742|NCT00908427|PROCEDURE|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
214346811|NCT04636255|DIAGNOSTIC_TEST|Blood Pressure and Cardiac Autonomic Control|Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.
214954743|NCT00829829|OTHER|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
214954744|NCT00829829|DRUG|Rilonacept 80 mg|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
214954745|NCT00829829|DRUG|Rilonacept 160 mg|Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
214954746|NCT04068740|PROCEDURE|Surgical treatment of valvular heart disease|Valve replacement or repair
214954747|NCT04068740|DIAGNOSTIC_TEST|Virtual treatment|Virtual valve replacement or repair surgery
214954748|NCT02583867|BEHAVIORAL|Exercise|Subjects will engage in supervised exercise sessions for 12 weeks. Each week will consist of at least three exercise sessions with a total duration of weekly exercise of approximately 150 minutes.
214954749|NCT02984267|DEVICE|Ultrasound|Using ultrasound guidance to evaluate the spine prior to epidural placement
214954750|NCT02984267|OTHER|Palpation|Using palpation only to evaluate the spine prior to epidural placement
214954751|NCT00650416|DRUG|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
214954752|NCT00650416|DRUG|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
214954753|NCT02685072|DRUG|Progesterone (200 mgs BID)|Transdermal Nicotine Patch (TNP) + Progesterone
214954754|NCT02685072|DRUG|Placebo|TNP + Placebo
214954755|NCT03376217|OTHER|IPTp delivered by HSAs|Pregnant women will have the option to receive IPTp-SP from Health surveillance assistants (HSAs). SP is recommended in Malawi for prevention of malaria during pregnancy, but currently it is only available at antenatal clinics.
214954756|NCT00230919|BEHAVIORAL|Diet counseling|
214954757|NCT05989776|BEHAVIORAL|Informational brochure for patients and brief training for oncologists|For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
214954758|NCT04451668|DRUG|FT218|once nightly sodium oxybate extended release
214954759|NCT00190112|PROCEDURE|ventral cardiac denervation|
214954760|NCT03563664|PROCEDURE|Pre-treatment endometrial biopsy|Timed suction endometrial biopsy was obtained from participants via Wallach Endocell® 908014A endometrial cell sampler timed during the implantation window of the pretreatment cycle; followed by immunohistochemical staining using immunoperoxidase staining incorporating avidin-biotin complex (ABC) method.
214346812|NCT04636255|DIAGNOSTIC_TEST|Evaluation of Baroreflex Control|The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.
214346813|NCT04636255|DIAGNOSTIC_TEST|Cardiac Function and Structure|Echocardiogram
214346814|NCT04636255|DIAGNOSTIC_TEST|Assessment of Coronary Anatomy and Calcium Score|Angiotomography
214346815|NCT04636255|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).
214346816|NCT04636255|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary Exercise Test.
214346817|NCT04636255|PROCEDURE|Physical Training|Aerobic exercise: 48 sessions of 60 minutes: 5 minutes of warm-up, 40 minutes of exercise. Resistance exercise: 10 minutes of exercise and 5 minutes of recovery.
214346818|NCT02692248|DRUG|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
214346819|NCT02692248|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
214346820|NCT02692248|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
214346821|NCT02692248|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
214346822|NCT02692248|DRUG|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
214346823|NCT00492999|DRUG|dexamethasone|Given by hepatic arterial infusion
214346824|NCT00492999|DRUG|floxuridine|Given by hepatic arterial infusion
214346825|NCT00492999|DRUG|fluorouracil|Given IV
214346826|NCT00492999|DRUG|irinotecan hydrochloride|Given IV
214346827|NCT00492999|DRUG|leucovorin calcium|Given IV
214346828|NCT00492999|DRUG|oxaliplatin|Given IV
214346829|NCT06499870|PROCEDURE|Biopsy|Undergo biopsy
214346830|NCT06499870|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214346831|NCT06499870|PROCEDURE|Computed Tomography|Undergo CT
214346832|NCT06499870|DRUG|Enzalutamide|Given PO
214346833|NCT06499870|OTHER|Fluorine F 18 Piflufolastat|Undergo fluorine F 18 piflufolastat PET/MRI
214346834|NCT06499870|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
214346835|NCT06499870|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
214954761|NCT03563664|DRUG|Danazol|Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks.
214954762|NCT03563664|PROCEDURE|Post-treatment endometrial biopsy|Post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment, timed, processed and stained as described previously.
214954763|NCT04934982|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1\~2 cm of the parametrium and 1\~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
214954764|NCT04934982|OTHER|Total Abdominal Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1\~2 cm of the parametrium and 1\~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
214954765|NCT00701844|BEHAVIORAL|Writing A (Experimental informative writing)|Experimental informative writing
214346836|NCT06499870|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
214346837|NCT06499870|OTHER|Questionnaire Administration|Ancillary studies
214346838|NCT06499870|DRUG|Relugolix|Given PO
214954766|NCT00701844|BEHAVIORAL|Writing B (Experimental noninformative writing)|Experimental noninformative writing
214346839|NCT02488486|DEVICE|Automated postoperative sedation|
214346840|NCT02488486|DRUG|propofol|
214346841|NCT02488486|DRUG|remifentanil|
214346842|NCT05941650|DIETARY_SUPPLEMENT|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
214346843|NCT05941650|OTHER|Corn Starch|This group will receive 12 g of corn starch as a control group.
214346844|NCT04015648|BIOLOGICAL|ChAdOx1 Zika|Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
214346845|NCT06635473|BEHAVIORAL|Information support|The experimental group was given intervention measures. According to the general data survey, discharge readiness and self-efficacy assessment, parents were divided into low, middle and high discharge readiness groups and low, middle and high self-efficacy groups, respectively, using WeChat mini programs to push different content.
214346846|NCT06635473|BEHAVIORAL|Stress and coping|According to the results of self-efficacy and anxiety assessment, different interventions were based on different scores. Give encouragement and affirmation to parents with low anxiety and high self-efficacy. Parents with high anxiety and low self-efficacy should push stress relief methods such as mindfulness relaxation therapy in time. And through the wechat mini program to provide parents to respond to the pressure of the problem, the medical staff to give timely feedback.
214346847|NCT06635473|BEHAVIORAL|Specialist guidance|Carry out offline science popularization education and specialized training, and highly qualified specialist doctors and nurses will train parents, and parents will be assessed after training, and personalized guidance will be given according to the weak points of each parent\&#39;s assessment.
214346848|NCT06635473|OTHER|Social support and interaction|Support and encouragement for parents continue from admission to discharge, so that parents feel that even after discharge, there are people to accompany and support them.
214346849|NCT06635473|BEHAVIORAL|Parentage development|Since parents and children are separated during the hospitalization of preterm infants, we will create an environment where parents still play the role of parents, and stimulate parental competence through kangaroo care, parental touch, and breastfeeding.
214346850|NCT06634758|BEHAVIORAL|Nursing interventions based on the Watson Human Caring Model|In the literature review, it was noticed that nursing care based on the Watson Human Caring Model was applied to various patient groups but not to patients with MS.
214954767|NCT00701844|BEHAVIORAL|Writing C (Control informative writing)|Control informative writing
214954768|NCT00701844|BEHAVIORAL|Writing D (Control noninformative writing)|Control noninformative writing
214954769|NCT04547231|DIAGNOSTIC_TEST|Fractional flow reserve, Coronary CT angiography|"1. Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge.~2. Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).~3. Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan)."
214954770|NCT00742027|DRUG|Panobinostat|Panobinostat hard gelatin capsules.
214954771|NCT02634710|RADIATION|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
214954772|NCT05509010|PROCEDURE|CTCA|CTCA is performed as part of routine care procedure.
214954773|NCT04627961|DRUG|TAS-102|Eligible patients who consent to participate will receive oral TAS-102 bid for days 1-5 and 8-12 of a 28 day cycle.
214954774|NCT00681265|DRUG|glycerin|Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
214954775|NCT00681265|DRUG|polyethylene glycol 400/propylene glycol|Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
214954776|NCT01442727|DRUG|sodium selenite|200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
214954777|NCT01442727|DRUG|placebo|dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
215077615|NCT03193814|DRUG|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
215077616|NCT04193761|DIAGNOSTIC_TEST|taurine level|Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.
215077617|NCT00068250|DRUG|rituximab|375 mg/m2, intravenously three days prior to the first cycle of methotrexate
215077618|NCT00068250|DRUG|methotrexate|Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
215077619|NCT00068250|DRUG|temozolomide 100 mg/m^2|Temozolomide 100 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
215077620|NCT00068250|DRUG|temozolomide 150 mg/m^2|Temozolomide 150 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
215077621|NCT00068250|DRUG|temozolomide 200 mg/m^2|Temozolomide 200 mg/m\^2 per day by mouth for five days on weeks 4 and 8.
215077622|NCT00068250|RADIATION|radiation therapy|Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
215077623|NCT00068250|DRUG|post-radiation therapy temozolomide|Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
215077624|NCT00812006|DRUG|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
215077625|NCT00812006|DRUG|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
215077626|NCT01358812|DRUG|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL\* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
215077627|NCT02638389|DRUG|Sirolimus|evaluate the efficacy and safety of sirolimus in these patients
215077628|NCT01796990|BEHAVIORAL|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
215077629|NCT01796990|BEHAVIORAL|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
215077630|NCT00838825|OTHER|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
215077631|NCT00831740|OTHER|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
214346851|NCT01366833|RADIATION|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
214954778|NCT03863691|DRUG|Amisulpride 300 MG|A single dose of 300 mg amisulpride that looks identical to placebo control capsules.
214346852|NCT01366833|PROCEDURE|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
214346853|NCT05063344|DEVICE|Diagnostic Test: NOWDx Syphilis Test|For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.
214346854|NCT03666039|BEHAVIORAL|Trainings app|Sensorimotor trainings app for at home Training (tablet-based)
214346855|NCT02703883|DEVICE|BWST|BWST (six weeks, 3 times/week)
214346856|NCT03812146|BEHAVIORAL|PC-TIME|PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
214346857|NCT03812146|BEHAVIORAL|PC-TAU|PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
214346858|NCT05130658|DEVICE|Virtual reality treadmill training|C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
214346859|NCT05130658|OTHER|Treadmill Training|Conventional gait and balance training using treadmill.
214346860|NCT00377819|DRUG|alendronate|70 mg oral QW
214346861|NCT00377819|DRUG|Denosumab (AMG 162)|60 mg SC q 6 mos
214346862|NCT05133557|OTHER|Chewing gum containing xylitol and blackberry extract (BBE)|On the day of gum chewing, four pieces of gum were provided per the assigned group, and each volunteer was requested to chew the gum four times daily (i.e., at 9 am, 11 am, 1 pm and 3 pm). Each gum chewing interval was for 20 minutes.
214346863|NCT02091726|PROCEDURE|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
214346864|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
214346865|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-Refined rice|Subjects in the control group maintained their usual diet of refined rice
214346866|NCT04295733|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart
214346867|NCT01278277|DIETARY_SUPPLEMENT|Saffron supplementation|Saffron supplementation 20 mg
214346868|NCT01278277|OTHER|placebo|placebo supplementation
214346869|NCT03727750|DRUG|Gemtuzumab Ozogamicin|Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
214346870|NCT00093301|DRUG|Levosimendan|
214346871|NCT00093301|DRUG|Dobutamine|
214954779|NCT03863691|DRUG|Placebo oral capsule|A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.
214954780|NCT01994473|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg
214954781|NCT01994473|DRUG|Placebo|single oral dose placebo
214954782|NCT01994473|DRUG|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
214954783|NCT04786665|OTHER|Strawberry|Freeze dried strawberry powder
214954784|NCT04786665|OTHER|Placebo group|Comparative placebo powder
214954785|NCT01491269|BEHAVIORAL|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
215077632|NCT00831740|OTHER|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
215077633|NCT00235391|DRUG|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
215077634|NCT02924207|OTHER|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
215077635|NCT04042142|OTHER|glucagon|Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
215077636|NCT00000146|DRUG|Methylprednisolone|
215077637|NCT00000146|DRUG|Prednisone|
214954786|NCT06730204|DIETARY_SUPPLEMENT|Standardized nutritional management|The children will follow the five-step treatment principle of malnutrition. Diet + nutrition education is the basic way, which is successively promoted to diet + oral nutrition supplement, enteral nutrition, partial enteral nutrition + supplementary parenteral nutrition, and total parenteral nutrition. When a nutritional treatment does not meet 60% of the target energy requirements for 3 to 5 days, the upper step of the treatment can be selected. For infants or newborns, when 75-80% of the target amount cannot be reached for 3-5 days, the upper step of the treatment can be selected.
215077638|NCT04396769|BEHAVIORAL|FLOW-PA|Classes were designed to provide the opportunity to be physically activity at a moderate-vigorous level. Each station included exercise options to accommodate varying fitness levels and offer students choice. Heart rate monitors provided consistent biofeedback to students throughout the intervention. Participants were evaluated based on the number of minutes they spent each class between 60-80% of their maximal heart rate. Games were intermixed either as a station or as a break in the circuit (e.g. short game of tag half-way through the workout) to make physical activity enjoyable and engaging.
215077639|NCT04396769|BEHAVIORAL|PE class as usual|PE teachers were instructed to teach class as usual. Research staff were not involved in class activities or instruction. In this school district PE class as usual includes sports-based instruction in which students learn the rules to games and then practice playing.
215077640|NCT01838330|DIETARY_SUPPLEMENT|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
215077641|NCT01452230|BEHAVIORAL|Supervised physical activity|Supervised physical activity
215077642|NCT02227173|DRUG|BMS-986020|
214346872|NCT06496932|OTHER|Listen to music|Women in the intervention groups will listen to nature and bird sounds through over-the-ear headphones after spinal anesthesia for cesarean section until the suturing is completed.
214346873|NCT03523533|PROCEDURE|Angiocatheter|Placement of angiocatheter in internal jugular vein
215077643|NCT02227173|DRUG|Montelukast|
215077644|NCT02227173|DRUG|Flurbiprofen|
215077645|NCT02227173|DRUG|Digoxin|
215077646|NCT04746482|PROCEDURE|single visit root canal retreatment|cases that were subject to root canal retreatment performed in single visit
215077647|NCT04350671|DRUG|Interferon Beta-1A|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-β 1a in COVID-19 patients.
215077648|NCT04350671|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
215077649|NCT04350671|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
215077650|NCT01919047|DRUG|Betanis|Oral
215077651|NCT03349645|BIOLOGICAL|4 mL injection of AMPION™|4 mL injection of AMPION™
215077652|NCT01741831|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
215077653|NCT04965974|DEVICE|Digital blue light blocking filter|digital blue light blocking filter will be given to 80 dry eye subjects in mobile phones and laptops and 80 individuals will be without filters digital devices users
215077654|NCT02621177|BIOLOGICAL|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
215077655|NCT02621177|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
215077656|NCT00460954|DRUG|Sinemet® controlled release (Carbidopa/levodopa)|
215077657|NCT00174863|DRUG|SR31747A|
215077658|NCT02686151|DRUG|Letrozole|used after oocyte retrieval
215077659|NCT02686151|DRUG|Polygeline|used after oocyte retrieval
215077660|NCT02686151|DRUG|Sodium Chloride|used after oocyte retrieval
215077661|NCT02686151|DRUG|dexamethasone|used after oocyte retrieval
215077662|NCT05423574|PROCEDURE|robotic Trans Abdomino Pre Peritoneal prothesis repair|The treatment of primary and incisional ventral hernia using the robotic assisted laparoscopy technique
215077663|NCT01703689|BEHAVIORAL|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
215077664|NCT01703689|BEHAVIORAL|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
215077665|NCT04029389|DEVICE|Injection|Local corticosteroid injection
215077666|NCT04029389|DEVICE|Tibial nerve block|Tibial nerve block
215077667|NCT04029389|OTHER|Conservational therapy|Only exercise and foot insoles
215077668|NCT05948228|DRUG|giomer based bioactive gel|Application of bioactive gel to prevent white spot lesions in orthodontic patients
215077669|NCT05948228|DRUG|Fluoride gel|Application of fluoride gel to prevent white spot lesions in orthodontic patients
215077670|NCT02080039|DEVICE|Electrical Stimulation|
215077671|NCT05797038|DRUG|Tacrolimus for the treatment of IMN|Remission after tacrolimus treatment of IMN
214346874|NCT06471465|DRUG|Bevacizumab|Drug: bevacizumab IV
214346875|NCT06471465|DRUG|Placebo|Drug: placebo IV
214346876|NCT06471465|DRUG|Prednisolone|Drug: corticosteroids IV
215077672|NCT01686750|BEHAVIORAL|Integrated care centers|
215077673|NCT02956044|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
215077674|NCT02956044|DRUG|Metformin|1000 mg metformin
215077675|NCT02956044|DRUG|Glimepiride|4 mg glimepiride
215077676|NCT02956044|DRUG|Sitagliptin|100 mg sitagliptin
215077677|NCT00937144|DRUG|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
215077678|NCT00937144|DRUG|placebo|
215077679|NCT02181361|DRUG|hirudin plus aspirin|natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
214346877|NCT02068573|DEVICE|Ventilation|The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
214346878|NCT02068573|DEVICE|Placebo Ventilation|The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
214346879|NCT05222191|DRUG|Spironolactone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
214346880|NCT05222191|DRUG|Chlorthalidone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
214346881|NCT05222191|DRUG|Placebo|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
214346882|NCT00407992|DEVICE|Occipital nerve stimulation ON|Implant of an occipital nerve stimulator switched ON
214346883|NCT00407992|DEVICE|Occipital nerve stimulation off|Implant of an occipital nerve stimulator switched OFF
214346884|NCT00000974|DRUG|Pentamidine isethionate|
214954787|NCT06730204|DIETARY_SUPPLEMENT|Standardized nutritional management + short peptide ONS|"During the study period, an additional 3 months of short peptide ONS enteral nutrition intervention is expected to be performed in children enrolled from Dec 1, 2024 to Feb 28, 2025 to explore the improvement of the nutritional status of the children. Short peptide type ONS 30ml/(kg.d) will be taken orally for children under 3 years old, and 20ml/(kg.d) for children over 3 years old. Due to conditional restrictions, standardized nutritional management + short peptide ONS intervention is only carried out in this subgroup.~Inclusion criteria for short peptide ONS enteral nutrition intervention:~1. Male and female, age 1-10 years old~2. Pathological diagnosis is malignant solid tumor with untreated initial onset~3. It is expected to receive enteral nutrition intervention for 3 months~4. Clear consciousness, willing to cooperate, no serious dysfunction of major organ functions"
214346885|NCT01298791|BEHAVIORAL|Sitting|Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
214346886|NCT01298791|BEHAVIORAL|Standing|Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
214346887|NCT03546244|BEHAVIORAL|musical treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with musical treadmill
214346888|NCT03546244|BEHAVIORAL|Traditional treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with traditional treadmill
215077680|NCT02181361|DRUG|Warfarin|an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
215077681|NCT03956277|DEVICE|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
215077682|NCT04726033|DRUG|64Cu-DOTA-TLX592|TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
215077683|NCT04043754|PROCEDURE|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
215077684|NCT04043754|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
215077685|NCT05154136|DRUG|Etrumadenant|Capsule
215077686|NCT05154136|DRUG|Itraconazole|Capsule
215077687|NCT04860934|BEHAVIORAL|Dual Task Training Program Group|Fifteen patients will receive Dual Task Training Program. Total Period: 8 Weeks.
215077688|NCT04860934|BEHAVIORAL|Control Group|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
215077689|NCT01593995|DRUG|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
215077690|NCT03003221|BEHAVIORAL|AIR-P Dental Toolkit|The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
215077691|NCT03003221|BEHAVIORAL|Parent Training|The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
215077692|NCT01571050|DRUG|Purified water|Ingestion of 30 mL of purified water
215077693|NCT01571050|DRUG|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
215077694|NCT01571050|DRUG|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
214346889|NCT03388619|RADIATION|Prostate bed with integrated boost|Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed.
214954788|NCT02895139|DEVICE|Additive Manufactured Orthotic Device|The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.
214954789|NCT02895139|DEVICE|Moulded orthotic|The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.
214954790|NCT02895139|DEVICE|Milled orthotic|The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
214954791|NCT04209439|DRUG|30 ml %0.25 bupivacaine|Ultrasound-guided erector spinae plane block
214954792|NCT04209439|DRUG|Dexketoprofen-trometamol|50 mg Dexketoprofen-trometamol intravenous
214954793|NCT00477204|DRUG|Simvastatin|simvastatin 20 mg daily
214954794|NCT00477204|DRUG|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
214954795|NCT02464644|OTHER|Questionnaire|To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
214954796|NCT04484844|DRUG|TOKUYAMA SHIELD FORCE PLUS|Self-reinforcing (SR) monomer technology
214954797|NCT04484844|DRUG|Sodium Fluoride 5% Dental Varnish|5% NaF
214954798|NCT06718387|OTHER|PsychoEducation Program|6 sessions of PsychoEducational Program
215077695|NCT01571050|DRUG|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
215077696|NCT01571050|DRUG|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
214346890|NCT03388619|RADIATION|Prostate bed irradiation only|Radiation will be delivered to the prostate bed only.
214346891|NCT03388619|DIAGNOSTIC_TEST|Whole Body Bone Scan|At screening, if required by clinician.
214346892|NCT03388619|DIAGNOSTIC_TEST|18F-NaF PET Imaging|At screening, if required by clinician.
214346893|NCT03388619|DIAGNOSTIC_TEST|CT|Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.
214346894|NCT03388619|DIAGNOSTIC_TEST|mpMRI|mpMRI of the prostate bed at screening and 6 month follow up.
214954799|NCT05054699|DEVICE|Magnetic Seizure Therapy|Subjects will receive a train of magnetic pulses (between 600 and 1400 pulses) at 100Hz under general anaesthesia using a Magventure device with a Twin Coil
215077697|NCT00580034|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
214346895|NCT03388619|DRUG|ADT|After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).
214346896|NCT02721238|BIOLOGICAL|20% Albumin|
214346897|NCT02721238|OTHER|Plasmalyte|
214346898|NCT00938873|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
214954800|NCT05054699|DEVICE|Electroconvulsive Therapy|Subjects will receive a brief-pulse electrical stimulus (between 25 and 1008mC) under general anaesthesia using a ECT device
214954801|NCT03412006|DRUG|Fulacimstat (BAY1142524)|25 mg BAY1142524 are given twice daily over a treatment period of 6 months
214954802|NCT03412006|DRUG|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
214954803|NCT02620085|PROCEDURE|blood sampling|blood sampling
214954804|NCT02717442|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
215077698|NCT00580034|PROCEDURE|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
214346899|NCT04609254|DRUG|Paracetamol|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
214346900|NCT04609254|DRUG|Dexketoprofen|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
214346901|NCT04609254|DRUG|Ibuprofen|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
214346902|NCT04020731|BEHAVIORAL|Hypnosis|several blocks of hypnosis including entry into a hypnotic state (= induction), the hypnotic trance and the exit from hypnosis (= reassociation).
214346903|NCT00244738|DIETARY_SUPPLEMENT|Castor oil|Patients who received castor oil for labor induction
214346904|NCT00244738|DIETARY_SUPPLEMENT|Sunflower oil|Patients who received sunflower oil as a placebo
214346905|NCT01068431|OTHER|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
214346906|NCT03088384|DRUG|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
214346907|NCT00815841|DRUG|METHYLPHENIDATE|15-20mg during one of the two sessions
214346908|NCT04920760|DIETARY_SUPPLEMENT|Vitamin A supplement|The supplementation protocol will be the additional care established by World Health Organization (WHO) and the United Nations International Children ʹs Fund (UNICEF) for measles (1998)(i.e. of 200,000 IU, or 50,000-100,000 IU for children \> 1 or for infants of \< 1 year of age, respectively).
214346909|NCT01200121|DRUG|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
214346910|NCT01200121|OTHER|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
214346911|NCT04781972|DRUG|Methylphenidate|single dose of 10 mg or 15 mg
214346912|NCT04781972|DRUG|Placebo|Matching placebo
215077699|NCT05405491|OTHER|PCR based strategy|Early adjustment of antimicrobial therapy according to the results of a multiplex PCR-based testing, used in addition to standard microbiological culture of the tracheal aspirate, in immunocompromised patients with suspected VAP or HAP requiring MV
215077700|NCT05405491|OTHER|Standard care|Broad-spectrum antimicrobial therapy adjustment after results of standard microbiological culture of the tracheal aspirate in immunocompromised patients with suspected VAP or HAP requiring MV
215077701|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
215077702|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
215077703|NCT01231542|DRUG|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
215077704|NCT01231542|DRUG|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
214346913|NCT00235534|BEHAVIORAL|Immediate initiation of OCPs|
214346914|NCT00235534|BEHAVIORAL|Delayed initiation of OCPs|
214346915|NCT05970029|BEHAVIORAL|Communication style|The verbal communication between the nurse and the patient at the time of analgesic administration
214346916|NCT02575092|DRUG|Enalapril Maleate Tablets(as the program-based antihypertension)|
214346917|NCT02575092|DRUG|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
214346918|NCT02575092|DRUG|Placebo|
214346919|NCT01181934|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
214346920|NCT01181934|DRUG|placebo|placebo - three times daily during each treatment period
214346921|NCT01181934|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
214346922|NCT02003001|DRUG|Botulinum Toxin|
214954805|NCT02717442|DRUG|Placebo|Single intratympanic injection of placebo
214954806|NCT06137209|OTHER|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e7 cfu/ dose (Active)
214954807|NCT06137209|OTHER|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group B: Blis Q24 Serum at 1e6 cfu/ dose (Active)
214954808|NCT04026932|OTHER|Listening to unmodified music|Listening to unmodified music for at least 2 hours a day
214954809|NCT04026932|OTHER|Listening to modified tinnitus relieving sound|Listening to modified tinnitus relieving sound for at least 2 hours a day
214347598|NCT03881462|PROCEDURE|Axillary nerve block for artificial deltoid muscle palsy|"Axillary nerve block block (AXNB):~The ultrasound probe is placed transversally in the infraclavicular region with the arm in 90° abduction. The brachial plexus and its cords are identified l lateral to the brachial artery. The posterior cord is identified by ultrasound and is blocked - or, if the axillary nerve visible too - the axillary nerve is selectively blocked when it leaves the posterior cord and lies on the subscapular muscle accompanied by the posterior circumflex humeral artery. Using an in-plane technique, a short bevel connected to a nerve stimulator with the setting 0.5 mA current intensity, 0.1 ms impulse duration and 2 Hz impulse frequency for dual guidance, will be advanced until its tip is positioned near the nerve without eliciting motor contractions. After careful negative (for blood) aspiration local anesthetic will be applied until the targeted neuronal structure is surrounded by the injected fluid."
214347599|NCT02536508|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
214347600|NCT02536508|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
214347601|NCT02536508|DRUG|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate
214347602|NCT05245058|DRUG|SPH5030 tablets|SPH5030 tablets orally once or twice daily.
214347603|NCT01462734|PROCEDURE|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
214347604|NCT04483479|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
214347605|NCT01889420|DRUG|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~1. Everolimus daily for 28 days of a 28 day cycle;~2. Pomalidomide daily for 21 days of a 28 day cycle~3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
214347606|NCT06057896|DIETARY_SUPPLEMENT|inositol, phytoestrogens, cocoa polyphenols|myo-inositol, soy isoflavones and cocoa polyphenols
214347607|NCT04768010|DRUG|Misoprostol|Participants will started by receiving 100 micrograms of oral misoprostol twice daily. If adverse effects are not noted dose can be titrated up to 200 micrograms of misoprostol twice daily. Participants will receive a total of five doses.
214347608|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 2|Roquette Glucidex 2: Maltodextrins with high degree of polymerization
214347609|NCT05266690|DIETARY_SUPPLEMENT|Pharmacosmos Dextran 10|Pharmacosmos Dextran 10: Dextran with high degree of polymerization
214347610|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 40|Roquette Glucidex 40: Glucose syrup
214347611|NCT05266690|DIETARY_SUPPLEMENT|Promitor 70|Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
214347612|NCT01230697|DRUG|Sorafenib|Sorafenib 800mg/die oral
214347613|NCT05716581|DEVICE|Catheter ablation|Catheter ablation for atrial fibrillation will be done according to the current medical praxis. Pulmonary vein isolation using either radiofrequency or pulsed-field ablation will be done in all patients. In patients with non-paroxysmal AF, additional ablation lesions (posterior wall ablation, roof or mitral isthmus line, ablation of complex fractionated atrial electrograms) could be done based on the operator´s discretion
214347614|NCT05582863|OTHER|Virtual reality exercise intervention|The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
214347615|NCT05975190|OTHER|Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer|R\&R training provided on an MP3-player for daily practice
214347616|NCT04879238|BEHAVIORAL|BEING|60 minute yoga session that blends mindfulness techniques
214347617|NCT06300021|DIETARY_SUPPLEMENT|TPG capsule|A dietary supplement product in capsule form containing 300 mg Turmipure Gold®
214347618|NCT06300021|DIETARY_SUPPLEMENT|TPG ready to drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar
214347619|NCT06300021|DIETARY_SUPPLEMENT|TPG dairy analog|Ingredient stick containing 300 mg Turmipure Gold® mixed in 240 mL oat milk
214347620|NCT06300021|DIETARY_SUPPLEMENT|TPG probiotic drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in a 100 mL probiotic yogurt drink base
214347621|NCT06300021|DIETARY_SUPPLEMENT|TPG gummies|Pectin gummies containing 300 mg Turmipure Gold®
214347622|NCT06300021|DIETARY_SUPPLEMENT|TPG sport bar|Sport nutrition bar containing 300 mg Turmipure Gold®
214347623|NCT05588518|COMBINATION_PRODUCT|desensitizing agents -10% Propolis|"10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives."
214347624|NCT02460991|DEVICE|DEB-TACE|
214347625|NCT02460991|DRUG|Sorafenib|
214347626|NCT03064425|BIOLOGICAL|Vaginal and blood sample collection|The researchers will obtain approximately 20 mL of blood from participants. Participants will also undergo a pelvic exam where a sample of cells will be collected from the cervix using two small cytobrushes. In addition, a cervicovaginal lavage will be collected using saline.
214347627|NCT00273611|BEHAVIORAL|Pharmacist Education about Vitamin D|
214347628|NCT02360709|DEVICE|CRE8 sirolimus-eluting stent|The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
214347629|NCT03537924|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
214347630|NCT03537924|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
214347631|NCT00863850|DRUG|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled \[14C\] bendamustine will be given on day 1 of cycle 1 only.
214347632|NCT01318889|DRUG|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
214347633|NCT00434057|DEVICE|MelaFind(R)|Biopsy ratio comparison
214347634|NCT04174092|OTHER|completing self-questionnaires|completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism
214347635|NCT01540123|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
214347636|NCT01540123|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
214347637|NCT01391104|DRUG|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
214347638|NCT01391104|DRUG|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
214347639|NCT05878639|DRUG|3 bottles of Lactulose oral solution|Patients will take lactulose for bowel preparation.
214347640|NCT05878639|DRUG|3L-polyethylene glycol|Patients will take 3L-polyethylene glycol for bowel preparation.
214347641|NCT04933682|DRUG|ALXN2050|Oral tablet.
214347642|NCT04933682|DRUG|Fluconazole|Oral tablet.
214347643|NCT04933682|DRUG|Rifampin|Oral capsule.
214347644|NCT06535984|OTHER|White Noise|White Noise Group (n=30) The third researcher turned on white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the start of the eye examination and played it to the infants until the end of the examination.
214347645|NCT06535984|OTHER|Swaddling|Swaddling group (n=30) The third researcher swaddled each infant with its thin blanket. The swaddling involved bringing the infant's left hand close to the left buttock and wrapping it with the upper right end of the blanket. Similarly, she wrapped the baby's right hand with the upper left end of the blanket by bringing it closer to the right hip. She wrapped the baby's legs with the lower part of the blanket, ensuring that the baby's head could move freely.
214347646|NCT06535984|OTHER|White Noise+Swaddling|White Noise + Swaddling Group (n=30) The third researcher swaddled the infants in this group as described in the swaddling group and turned on the white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the examination started and played it to the infants until the examination was over.
214347647|NCT01525290|DRUG|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
214347648|NCT01525290|DRUG|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
214347649|NCT02308436|DEVICE|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries \& acidic challenges
214347650|NCT02473952|DRUG|IGIV-C|IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
214347651|NCT02473952|DRUG|Placebo|
214347652|NCT00455195|BIOLOGICAL|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
214347653|NCT00440765|DRUG|bortezomib|dose as determined (observational study) by treating physician
214347654|NCT04846504|BEHAVIORAL|MMBFM program with clinician coach support|Clinician-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed.
214347655|NCT04846504|BEHAVIORAL|MMBFM program with peer coach support|Peer-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed. Peers will be women with lived experience of perinatal depression who are trained on the coaching protocol.
214347656|NCT04846504|BEHAVIORAL|Patient facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
214347657|NCT04846504|BEHAVIORAL|Patient facing plus clinic facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams, plus recommendation of / referral to the Mindful Mood Balance for Moms study by OB clinicians at the 4 study sites. OB clinicians will choose from printed materials (e.g., flyers, posters in exam rooms and waiting rooms, prescription pads) and electronic medical record prompts (e.g., smart lists, dot phrases) to facilitate engagement in the Mindful Mood Balance for Moms course. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
214347658|NCT00025350|DRUG|gefitinib|
214347659|NCT06533241|PROCEDURE|renal biopsy|percutaneous renal biopsy procedure
214347660|NCT03669029|DRUG|Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg|Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
214347661|NCT03669029|DRUG|Golimumab treatment optimization.|Golimumab dosing will be optimized in patients without clinical response at week 6.
214347662|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
214347663|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
214347664|NCT02117570|BIOLOGICAL|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
214347665|NCT05454293|OTHER|One Talk at a Time: Race|This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.
214347666|NCT05454293|OTHER|One Talk at a Time: General|This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
214393558|NCT03813095|DRUG|Placebo|The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.
214393559|NCT03494374|DEVICE|UCBL orthosis|toe walking exercise
214393560|NCT01658488|OTHER|Non-fortified rice|Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
214393561|NCT01658488|OTHER|Iron-fortified Rice|Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
214955432|NCT06277739|PROCEDURE|Spinal Manipulative Therapy|The participant was placed in a side-lying position facing the clinician with the more painful side facing upward. The clinician passively flexed the participant's hips and knees to induce lumbar spine flexion until they felt the spinous process of the affected lumbar vertebrae begin to move. Next, the clinician passively rotated the participant's torso opposite to the side they were lying on until they felt rotation in the vertebra above the suspected lesion. The clinician applied a rapid thrust to the shoulder (anterior to posterior force) and pelvis (posterior to anterior force) resulting in a rotation force couple on the hypomobile segment. If a cavitation (ie, an audible pop) occurred, the treatment was considered complete. If no cavitation was produced, the participant was repositioned and the manipulation was attempted again. A maximum of 2 attempts per side was permitted. If no cavitation was produced after the 4 attempts (ie, 2 per side), the treatment was considered complete.
214955433|NCT06277739|OTHER|Sham Laser Treatment|The laser manufacturer (MedX Health Corp) provided a MedX 1100 system that did not deliver any significant amount of light energy or heat but otherwise appeared operational to participants and clinicians. The sham laser was delivered over the painful region with the study participant positioned as described for spinal manipulation and spinal mobilization treatments.
214955434|NCT02656511|DRUG|Dolutegravir|Dolutegravir 50 mg PO daily
214955435|NCT02656511|DRUG|Emtricitabine/Tenofovir|Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
214955436|NCT05548972|DEVICE|G7 Dual Mobility with Vivacit-E bearing|hip arthroplasty with G7 Dual Mobility Vivacit-E bearing
214955437|NCT05548972|DEVICE|G7 Dual Mobility Longevity bearing|hip arthroplasty with G7 Dual Mobility Longevity bearing
214955438|NCT03376126|OTHER|Minimal-invasive isolated limb perfusion|Minimal-invasive isolated limb perfusion
214955439|NCT05180565|DEVICE|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
214955440|NCT02831946|DEVICE|MODIFIED VICRYL PLUS|closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture
214955441|NCT02831946|DEVICE|DERMABOND GLUE|closing the intra-cuticular layer with Dermabond glue
214955442|NCT03519685|BEHAVIORAL|Contraceptive Training and Education|Staff at the student health center and local health centers where they refer for contraceptive services will receive a CME-accredited education and training session and technical assistance. The one-day session emphasizes evidence-based and patient-centered contraceptive counseling and provision. Students attending colleges assigned to the intervention arm will receive materials and resources designed to educate young people about contraceptive methods and where to access services.
214955443|NCT03519685|BEHAVIORAL|Placebo Nutrition Education|Students attending colleges assigned to the nutrition education arm will receive materials and resources designed to educate young people about the impacts of sugar on health.
214955444|NCT06645769|DRUG|Sodium Phenylbutyrate|will be compared to placebo
214955445|NCT06645769|OTHER|Placebo|will be compared to NaPB
214955446|NCT00916981|PROCEDURE|percutaneous autologous preosteoblast cells implantation|percutaneously injection of preosteoblast into the nonunion under radioscopic control
214955447|NCT00482170|DEVICE|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
214955448|NCT00482170|DEVICE|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
214955449|NCT05766683|DRUG|onabotulinumtoxinA at a depth of 2mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 2mm
214955450|NCT05766683|DRUG|onabotulinumtoxinA at a depth of 4mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 4mm
214955451|NCT02025270|BIOLOGICAL|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
214955452|NCT06149403|GENETIC|Experimental: OTL-203|Experimental: OTL-203: Autologous CD34+ enriched cell fraction that contains hematopoietic stem and progenitor cells transduced ex vivo using lentiviral vector encoding the human IDUA gene
214955453|NCT06149403|GENETIC|Active Comparator: Allo-HSCT|Active Comparator: Allogeneic hematopoietic stem cell transplantation
214955454|NCT04819841|GENETIC|nula-cel Drug Product|nula-cel is administered via IV infusion following a myeloablative conditioning regimen
214955455|NCT05090267|DIETARY_SUPPLEMENT|Probiotic Supplement|Participants will take a probiotic supplement or placebo for 90 days.
214955456|NCT05090267|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.
214955457|NCT06514911|PROCEDURE|primary closure following Laparoscopic cholodochotomy in management of CBD stones|primary closure of cholodochotomy incision in laparoscopic CBD exploration avoiding T-tube insertion
214955458|NCT06514911|PROCEDURE|T-tube drainage following Laparoscopic cholodochotomy in management of CBD stones|drainage of bile by T-tube insertion in laparpscopic CBD exploration
214955459|NCT04595279|BEHAVIORAL|Smoking sessions|Participants undergo topography and behavioral economic sessions where they can make choices to earn cigarette puffs by pulling plungers on experimental equipment
214393562|NCT00900627|DRUG|AZD8931|Tablet Oral bid
214393563|NCT00900627|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off (repeated cycles)
214393564|NCT00900627|DRUG|Placebo|Oral bid (twice daily)
215078108|NCT04358705|BEHAVIORAL|Online Experimental Marketplace (ETM)|"Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes."
214955460|NCT06126796|DIAGNOSTIC_TEST|CxBladder Monitor|CxBladder Monitor (CxbM) is an FDA-approved genomic biomarker test specifically designed for patients undergoing surveillance for NMIBC. The non-invasive urine test quantifies 5 measured biomarker genes (MDK, HOXA13, CDC2 (CDK1), IGFBP5, CXCR2) and incorporates this information into an algorithm to detect the presence or absence of bladder cancer.
214955461|NCT06126796|DIAGNOSTIC_TEST|Cystoscopy|Cystoscopy is the most common way surveillance has been performed for NMIBC. Cystoscopy is a procedure that allows your doctor to examine the lining of your bladder and the tube that carries urine out of your body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into your bladder.
214955462|NCT03571178|OTHER|Physical Therapy|Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
215078109|NCT04358705|OTHER|Aim 3 survey|"Consists of:~* A screener and demographic data collection.~* A tobacco product withdrawal scale~* Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~* The tobacco product withdrawal scale again~* Measurements of nicotine dependence and flavor preferences"
214347667|NCT06245785|PROCEDURE|transarterial chemoembolisation|Before TACE, hepatic arteriography was performed to evaluate the vascular anatomy and tumour vascularity. During TACE, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function. Laboratory assessments were performed every four to six weeks. Radiological evaluation using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) was recommended during weeks 4 and 8 after treatment and every 8 weeks thereafter. However, in clinical practice, the intensity of follow-up depends on an individual's baseline characteristics and response to the last treatment.
214347668|NCT05056103|DEVICE|TrachFlush|The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
214347669|NCT05540236|OTHER|auricular acupressure|The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points
214347670|NCT05540236|OTHER|sham auricular acupressure|The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
214347671|NCT04434404|DRUG|L-Carnitine 500Mg Oral Tablet|"eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months."
214347672|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
214347673|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
214347674|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
214393565|NCT04027790|DIAGNOSTIC_TEST|Epi proColon|Analysis of DNA methylation status for Septin9 and additional biomarkers
214393566|NCT03325335|DRUG|Midazolam premedication|Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia.
214955463|NCT06392295|RADIATION|Para Aortic Radiation Therapy: Photon Therapy|Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 50 grays (Gys) delivered in 25 fractions to the Clinical Tumor Volume (CTV).
214955464|NCT06392295|RADIATION|Para Aortic Radiation Therapy: Proton Therapy|Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 60 to 65 Gys delivered in 25 fractions to the Gross Tumor Volume (GTVn).
214955465|NCT06392295|DRUG|Androgen Deprivation Therapy|Androgen deprivation therapy will be administered as per standard of care.
214347675|NCT01019330|OTHER|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
214347676|NCT01019330|OTHER|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
214347677|NCT00546728|DRUG|Exenatide|exenatide 10 mcg twice daily
214955466|NCT06392295|DRUG|Androgen Receptor Signaling Inhibitor|Androgen receptor signaling inhibitor (ARSI) will be administered as per standard of care.
214955467|NCT06367738|DRUG|Psilocybin|Psilocybin 1-30 mg
214955468|NCT06104631|OTHER|BK003|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.
214955469|NCT06104631|OTHER|Placebo|The placebo product has the same composition in excipient, same form and same posology as BK003.
214955470|NCT05537428|BEHAVIORAL|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
214955471|NCT05339165|BEHAVIORAL|Psychotherapy|
214955472|NCT06315296|BEHAVIORAL|Behavioral Dietary Intervention|Follow a time-restricted diet
214955473|NCT06315296|OTHER|Text Message-Based Navigation Intervention|Receive interactive positive reinforcement messages
214955474|NCT06315296|OTHER|Internet-Based Intervention|Use txt4fasting platform
214955475|NCT06315296|BEHAVIORAL|Dietary Counseling and Surveillance|Receive counseling calls
214955476|NCT06315296|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214955477|NCT06315296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214955478|NCT06315296|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
214955479|NCT06315296|OTHER|Neurocognitive Assessment|Ancillary studies
214955480|NCT06315296|OTHER|Questionnaire Administration|Ancillary studies
214955481|NCT06315296|OTHER|Interview|Ancillary studies
214955482|NCT06315296|OTHER|Internet-Based Intervention|Use txt4fasting platform
214347678|NCT00546728|DRUG|Metformin|metformin 500 twice daily
214955483|NCT06315296|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214955484|NCT06315296|OTHER|Text Message-Based Navigation Intervention|Receive text messages about healthy eating habits and food suggestions
214955485|NCT06315296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214955486|NCT06315296|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
214955487|NCT06315296|OTHER|Neurocognitive Assessment|Ancillary studies
214347679|NCT02508311|DRUG|Oral Albuterol Extended Release|Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.
214347680|NCT02508311|DRUG|Placebo|Subjects will receive placebo tablets twice daily for 16 weeks.
214347681|NCT02637297|PROCEDURE|Hypnotherapy|Undergo hypnotherapy
214955488|NCT06315296|OTHER|Questionnaire Administration|Ancillary studies
214955489|NCT06315296|OTHER|Interview|Ancillary studies
214955490|NCT05061602|DIAGNOSTIC_TEST|Evaluation of biomechanics and viscoelastic properties of plantar fascia|The biomechanical and viscoelastic properties of the plantar fascia will be measured with the MyotonPRO device.
214955491|NCT05772611|BIOLOGICAL|Genetic and immunology tests|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes."
214955492|NCT04085159|BIOLOGICAL|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
214955493|NCT05735275|DRUG|SHR-A2102|All participants receive SHR-A2102 alone.
214955494|NCT02504047|PROCEDURE|T-Cell replete haplo-transplant|Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 \& 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
214955495|NCT06220487|DRUG|Prednisone, Olverembatinib, Blinatumomab, Chidamide|"Phase One. Induction Consolidation, for 1 year. 1.1 Pretreatment ×1 cycle. Prednisone，1mg/kg/d, from day 1 to 14;~1.2 Induction Therapy × 1 cycle. A: OlverembAtinib (at a dose of 40 mg Qod), from day 8 to 42. B: Blinatumomab (at a dose of 28 μg per day), from day 15 to 28. C: Chidamide (at a dose of 10 mg Qod), from day 9 to 41.~1.3 Consolidation Block × 5 cycles. A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42. B: Blinatumomab (at a dose of 28 μg perday) was administered from day 1 to 14. C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Two. Maintenance Therapy, for 3 years. 2.1 A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42.~C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Three. Follow-up, for 5 years."
214688142|NCT06772896|OTHER|Reordered PHQ-8|Participants will be administered the PHQ-8 somatic items separately from the psychological items, outside the context of a depression questionnaire.
214955496|NCT02891486|PROCEDURE|Spinal surgery|Elective spinal surgery performed
214955497|NCT00956488|BEHAVIORAL|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
214955498|NCT04008485|DEVICE|Magnetic Electric Impedance Spectroscopy Device to predict PTB|During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
214955499|NCT01539928|OTHER|Dual FDG-PET/CT|Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
214955500|NCT02108899|BEHAVIORAL|Retrieval practice effect using descriptive stories and free-call tests without feedback|"In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts."
214955501|NCT01658904|DRUG|Carfilzomib|
214955502|NCT01658904|DRUG|Melphalan|
214955503|NCT01658904|DRUG|Filgrastim|
214955504|NCT01459835|BEHAVIORAL|media diet|advice and tips and tools for healthy non violent TV viewing
214955505|NCT01459835|BEHAVIORAL|nutritional intervention|advice on healthy eating
214955506|NCT00892515|BEHAVIORAL|exercise intervention|
214955507|NCT00892515|OTHER|counseling intervention|
214955508|NCT00892515|OTHER|gas chromatography|
214955509|NCT00892515|OTHER|immunoenzyme technique|
214955510|NCT00892515|OTHER|immunologic technique|
214955511|NCT00892515|OTHER|laboratory biomarker analysis|
214955512|NCT00892515|OTHER|mass spectrometry|
214955513|NCT00892515|OTHER|physiologic testing|
214955514|NCT00892515|OTHER|questionnaire administration|
214955515|NCT00892515|OTHER|survey administration|
214955516|NCT00892515|PROCEDURE|dual x-ray absorptometry|
214955517|NCT00892515|PROCEDURE|magnetic resonance imaging|
214955518|NCT00892515|PROCEDURE|study of high risk factors|
214955519|NCT05497817|BEHAVIORAL|Algorithm|Current and/or former Care Partners of persons with dementia will be matched using an algorithm to other Care Partners who might provide emotional support.
214955520|NCT05497817|BEHAVIORAL|Random Match|Current and/or former Care Partners of persons with dementia will be randomly matched to other Care Partners who might provide emotional support.
214955521|NCT05208580|BEHAVIORAL|Virtual education|Participants undergo virtual education activities on an on-line platform 10-14 days before the surgery
214955522|NCT05208580|BEHAVIORAL|Contact education|Participants attend live educational classes 10-14 days before the surgery
214955523|NCT02334098|DIETARY_SUPPLEMENT|Omega-3 supplemented drink|"The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.~1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment."
214955524|NCT02334098|DIETARY_SUPPLEMENT|Smartfish|Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
214955525|NCT00080483|DRUG|Testosterone plus somatropin|AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
214955526|NCT00080483|DRUG|testosterone|AndroGel transdermally 5 g a day for two years
214955527|NCT04544839|DEVICE|ADLC attachment system with PEEK inserts|"Each patient will receive 2 implants in the canine region using a guided-surgery protocol and a pre-prepared surgical stent. A healing abutment of an adequate size will be placed on the implant for transmucosal healing. The flaps will be subsequently sutured around the healing abutments. Patients' existing prostheses will be adjusted. Suture removal will be performed one week post implant placement.~Three months later, implant level impressions will be made using the open tray technique. Each patient will be then be randomized using eCRF (electronic Case Report Form) to either ADLC group or LOC group. A final cast of the patients will be obtained and the attachments will be installed using an in-direct technique by a calibrated prosthodontists."
214955528|NCT05062720|RADIATION|Local consolidative therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
214955529|NCT03801577|DIETARY_SUPPLEMENT|Hepaxa|High concentrate EPA and DHA
214955530|NCT00161694|DIETARY_SUPPLEMENT|sucrose solution|
214347682|NCT02637297|OTHER|Questionnaire Administration|Ancillary studies
214688143|NCT03949049|DRUG|Citicoline|Citacoline as neuroprotector
214688144|NCT03949049|OTHER|Placebo|placebo group
214688145|NCT01653366|BEHAVIORAL|Physical Activity Goal Setting|"Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them."
214955531|NCT00694720|DRUG|AVE0657|capsules once a day at bedtime
214955532|NCT00694720|DRUG|placebo|capsules once a day at bedtime
214955533|NCT05415514|OTHER|Instrumented assessment of muscle function|During the instrumented evaluations, we will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
214347683|NCT05164822|OTHER|Necrotizing Vasculitis|"Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters."
214347684|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to enhance parent-infant reading quality (0-2 month visit)|The reading intervention will be provided at the baseline clinic well-visit (0-2 months), and is based on the SHARE/STEP approach.
214347685|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to encourage alternatives to digital media (6-month visit)|The digital media (screen time) intervention will be provided at the 6-month clinic well-visit and is based on Baby Unplugged materials (book and app content).
214347686|NCT02169674|BIOLOGICAL|EngerixB, GlaxoSmithKline Vaccines|
214347687|NCT03349710|BIOLOGICAL|Nivolumab|Specified dose on specified day
214347688|NCT03349710|DRUG|Cetuximab|Specified dose on specified day
214347689|NCT03349710|DRUG|Cisplatin|Specified dose on specified day
214347690|NCT03349710|RADIATION|Radiotherapy|Specified dose on specified day
214347691|NCT04336215|OTHER|Non-Interventional|This non-interventional study poses no additional risks to people with pre-existing conditions.
214347692|NCT03269474|PROCEDURE|Experimental Group|Subjects with EB diagnosis
214347693|NCT00001601|PROCEDURE|Electrocardiogram|
214347694|NCT00001601|PROCEDURE|Biopsies|
214347695|NCT00001601|PROCEDURE|Diagnostic imaging|
214347696|NCT04141306|OTHER|Administrative data|Evaluation of month and year of birth, sex, referent doctor and surgeon
214347697|NCT04141306|OTHER|Clinical data|Evaluation of diagnostic circumstances, vital status at last follow up
214347698|NCT04141306|OTHER|Histological data|Evaluation of Pathology report of thyroid surgery
214347699|NCT04141306|OTHER|Imaging data|Evaluation of scintigraphy, MRI, scan
214347700|NCT04141306|OTHER|Biological data|Evaluation of thyroglobulin, antithyroglobulin antibodies
214347701|NCT04141306|OTHER|Further treatment|Evaluation of surgery, radiotherapy, targeted therapy
214347702|NCT01906294|DRUG|antidiabetic treatment (ATC A10B)|
214347703|NCT03223363|DIAGNOSTIC_TEST|2D and 3D ultrasonography|All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
214347704|NCT01863277|DRUG|Melatonin|
214347705|NCT01863277|DRUG|placebo|
214955534|NCT02469012|DRUG|Combination #1|Sofosbuvir + Ribavirin
214347706|NCT01100164|DRUG|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
214347707|NCT01100164|DRUG|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
214347708|NCT02877290|DEVICE|non-invasive ventilation (NIV)|
214347709|NCT00607451|DRUG|Neu-120|Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
214347710|NCT01721018|BIOLOGICAL|HSV1716 Intra-pleural delivery|
214347711|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
214347712|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
214347713|NCT03135951|DRUG|SPI-2012|Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
214688146|NCT03645460|GENETIC|Direct intravenous injection of ivlv-ADA lentiviral vector|Injection of ivlv-ADA lentiviral vector at \~1x10\^9 per kg body weight
214688147|NCT07067775|DRUG|Vicagrel Capsules|Vicagrel Capsules qd per period, for two periods
214955535|NCT02469012|DRUG|Combination #2|Sofosbuvir + Daclatasvir
214955536|NCT02469012|DRUG|Combination #3|Sofosbuvir + Daclatasvir + Ribavirin
214955537|NCT02469012|DRUG|Combination #4|Sofosbuvir + Ledipasvir
214955538|NCT02469012|DRUG|Combination #5|Sofosbuvir + Ledipasvir + Ribavirin
214955539|NCT01476397|OTHER|Control infant formula|partially hydrolyzed whey infant formula consumed ad libitum throughout study
214955540|NCT01476397|OTHER|Test infant formula|partially hydrolyzed whey formula with probiotic
214955541|NCT06088745|BIOLOGICAL|Recombinant Herpes Zoster Vaccine|The active ingredient of the recombinant herpes zoster vaccine is varicella-zoster virus glycoprotein E fusion protein expressed in CHO cells by gene recombination technology. The LZ901 cell line carrying this gene is cultured in chemically defined medium. The harvest cell culture is purified by multi-step liquid chromatography. After Low pH incubation and virus removal filter package Nanofiltration inactivation/virus removal process, the bulk containing high-purity recombinant herpes zoster virus glycoprotein E is obtained. Finally, an alumina adjuvant is added to the formulated final product.
214955542|NCT06088745|BIOLOGICAL|Recombinant Herpes Zoster Vaccine Placebo|Alumina adjuvant
214955543|NCT01808222|DRUG|FACBC|Participants will receive a bolus of anti-\[18F\]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
214347714|NCT00955084|DRUG|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
214347715|NCT02585895|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once every 2 weeks
214347716|NCT02585895|PROCEDURE|Low-density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants received apheresis for LDL-C according the their physician's prescription and local custom.
214347717|NCT01692704|DRUG|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."
214347718|NCT06151262|DRUG|Trilaciclib+mFOLFIRINOX|This was a single-arm, exploratory study of the combination of Trilaciclib and mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line therapy. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every four cycles to assess tumor response.
214347719|NCT02738177|DRUG|Misoprostol|2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
214347720|NCT02738177|DRUG|Isosorbide-5-mononitrate|2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
214347721|NCT02738177|DRUG|misoprostol and Isosorbide-5-mononitrate|1tablets of misoprostol (i.e.200 ug) \& 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
214347722|NCT01757769|DRUG|Silodosin|8 mg daily for 24 weeks
214347723|NCT01281930|PROCEDURE|Full packing into abscess cavity|After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
214347724|NCT01281930|PROCEDURE|Wick placement into abscess cavity|After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
214347725|NCT00142480|DRUG|Capecitabine|Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
214347726|NCT00142480|DRUG|Oxaliplatin|Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
214347727|NCT00142480|DRUG|Bevacizumab|Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
214347728|NCT00142480|PROCEDURE|Radiation therapy|Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
214347729|NCT06019468|OTHER|Envolizumab combined with radiotherapy|Application of Envolizumab combined with radiotherapy for neoadjuvant treatment of locally advanced thymic cancer. Firstly, 20-40Gy radiation therapy was administered 10-20 times. Within one week after the start of radiation therapy, Envolizumab (300 mg, D1, Q3W, subcutaneous injection) was administered. Immunotherapy was maintained for 2-4 cycles, and surgery was performed after evaluation by the attending physician.
214347730|NCT05343702|DRUG|priming with rocuronium|Following induction (paralysis after onset of the induction effect) in routine rapid sequence intubation protocols While paralysis is applied, it is aimed to shorten the half-life of rocuronium by administering a subparalytic dose of rocuronium approximately 3-5 minutes before induction in the priming technique
214347731|NCT03682094|DRUG|VSL#3|Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
214688148|NCT07067775|DRUG|Clopidogrel Tablets|Clopidogrel Tablets qd per period, for two periods
214955544|NCT00386074|DRUG|NaFeEDTA, Electrolytic Iron|
214955545|NCT02254356|DEVICE|Zilver Flex Bare Metal Stent|
214347732|NCT05156138|OTHER|no interventions as it is a case control observational study|no interventions as it is a case control observational study
214347733|NCT04258020|DEVICE|BiPAP|Bilevel Positive Airway Pressure (BiPAP) oxygen administration
214347734|NCT04258020|DEVICE|HFNC|Heated High Flow Nasal Cannula oxygen administration
214347735|NCT02529774|DRUG|Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
214393567|NCT03325335|DRUG|Remifentanil infusion|Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
214688149|NCT06023589|BIOLOGICAL|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab
214688150|NCT06023589|OTHER|Placebo|Participants will be receiving subcutaneous injection of matching placebo
214955546|NCT05840549|PROCEDURE|TURP|TURP is an operation which can be performed under a general / regional anaesthetic. A cystoscope is passed into the urethra meatus, along the length of the urethra to the level of the prostate. The obstructing prostate lobes are resected using mono polar or bipolar energy to create a channel for improved urinary flow. Haemostasis is achieved by coagulation followed by insertion of a catheter for irrigation post procedure. Generally, patients stay for 1-2 nights post operatively. On the day of discharge the catheter is removed.
214347736|NCT02529774|DRUG|Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
214347737|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 60 mg dextrose
214347738|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 80 mg dextrose
214347739|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 100 mg dextrose
214347740|NCT04134442|DRUG|Bupivacaine Liposome Injection|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist)~2. Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
214347741|NCT04134442|OTHER|Standard Therapy|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist)~2. Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
214347742|NCT05921877|DIAGNOSTIC_TEST|venous sampling|venous sampling
214347743|NCT05570695|BEHAVIORAL|attention right training, ARTNF|In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.
214347744|NCT05570695|BEHAVIORAL|attention left training, ALTNF|In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.
214347745|NCT05570695|BEHAVIORAL|sham attention right training, ARTsham|During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).
214347746|NCT05570695|BEHAVIORAL|sham attention left training, ALTsham|During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
214347747|NCT04396886|DRUG|Bintrafusp Alfa|Bintrafusp alfa will be administered intravenously every 2 weeks
214347748|NCT00919282|DRUG|gemcitabine, folinic acid, 5-FU|gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
214347749|NCT05360875|PROCEDURE|Endometrial scratching|An intrauterine procedure that causes mild endometrial injury
214347750|NCT06038773|DIAGNOSTIC_TEST|Diagnosis|"Baseline data were presented with descriptive statistics. Sociodemographic information, pregnancy status, surgical history, exercise habits, gynecologic, obstetric, urologic and gastrointestinal history of the patients were evaluated with the Patient Information Form.Pain intensity was evaluated with the McGill pain questionnaire short form. At the same time, the patients drew the areas where they felt the most pain with the pain maps scale. Pain intensity during sexual intercourse was evaluated with the Visual Analog Scale (VAS).Sexual Abuse Items on the Questionnaire (Modified from Badgley)."
214347751|NCT04717011|DIAGNOSTIC_TEST|PCR test|PCR test in two different semen samples from each patient: first with positive diagnosis for COVID-19 and the second after negative diagnosis for COVID-19.
214347752|NCT00659633|DRUG|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
214347753|NCT00385931|DRUG|Valsartan and simvastatin|
214347754|NCT00986999|DRUG|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
214347755|NCT03836287|DRUG|Sofpironium Bromide Gel, 15%|Active
214347756|NCT03836287|DRUG|Vehicle|Vehicle gel
214347757|NCT00833989|DRUG|GSK249320|I.V. infusion
214347758|NCT00833989|DRUG|PLACEBO|Placebo
214347759|NCT02370654|BEHAVIORAL|Tai chi|
214347760|NCT02370654|BEHAVIORAL|Conventional exercise|
214502553|NCT05473416|OTHER|Pilates pelvic tilt exercise|Pilates pelvic tilt exercise consists; lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Pull your belly button in toward your spine, pushing your pelvis up toward the ceiling. Tighten your gluteus and hip muscles as you tilt your pelvis forward. Hold for 10 seconds.
214347761|NCT02494791|BEHAVIORAL|Questionnaire, Educational Material|Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
214347762|NCT00433069|DRUG|Pioglitazone|Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
214502554|NCT05473416|OTHER|Baseline treatment|Postural guidelines + proper lifting technique + stretch break Rest
214502555|NCT02235298|DRUG|Dapagliflozin|5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.
214955547|NCT05840549|PROCEDURE|UroLift|UroLift (Neotract) is a NICE-approved alternative to TURP that can be performed under local anaesthetic, sedation or general anaesthetic. The system comprises of two single-use components, a delivery device and an implant. The implant is made of a nitinol capsular tab, a polyethylene terephthalate monofilament and a stainless-steel end-piece. Again, a modified cystoscope is passed into the urethral meatus, along the length of the urethra to the level of the prostate. The delivery device deploys the implants into the prostate to 'pin' back the lobes of the prostate to create a channel for improved flow. Typically, 2-4 implants are used per procedure. Nine out of ten patients do not require a catheter post procedure
214955548|NCT04161105|PROCEDURE|Dry needling|Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.
214955549|NCT01251159|GENETIC|mutation analysis|
214955550|NCT01251159|GENETIC|polymerase chain reaction|
214955551|NCT01251159|OTHER|immunologic technique|
214955552|NCT01251159|OTHER|laboratory biomarker analysis|
214955553|NCT02641405|DEVICE|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
214955554|NCT02641405|DEVICE|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
214955555|NCT03474094|COMBINATION_PRODUCT|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery|"W1,W2, W3, W4 \& W5: RADIOTHERAPY. A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6 and W9: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W11: SURGERY. Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent"
214955556|NCT03474094|COMBINATION_PRODUCT|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy|"W1 and W4: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W7, W8, W9, W10 \& W11: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized."
214955557|NCT03474094|COMBINATION_PRODUCT|Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.|"W1,W2, W3, W4 \& W5: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W11 and W14: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval"
214955558|NCT05441891|OTHER|Auditory intervention filter-modulated group|"Intervention consisted of listening to classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).~The musical intervention was always performed with the same songs and in the same order using original CDs, heard through headphones (Beyerdynamic, DT 250 / 80 ohm. GMBH \& Co. KG, Theresienstr. 8 D-74072 Heilbronn, Germany). The music was played with a sound system (Panasonic MASH, No. SA-PM24. Hamburg, Germany). and filtered through an equalizer called Earducator (Hollagen Designs, PÍO. Box 43 7864 Bergvliet W.Cape - South Africa) that modulates music by alternating low and high tones with an unpredictable cadence, preventing habituation. It also allows very narrow band complementary filters to attenuate (by about 40 dB) abnormally perceived frequencies (hyper-hearing peaks): filters in: 1 kHz - 1,5 kHz - 2kHz - 3 kHz - 4 kHz - 8kHz."
214955559|NCT05418660|DRUG|Immunotherapy|At least 24 months with Pembrolizumab, Nivolumab or Atezolizumab in any treatment line
214955560|NCT00177645|PROCEDURE|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
214955561|NCT00599742|BEHAVIORAL|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
214955562|NCT00599742|BEHAVIORAL|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
214347763|NCT00433069|DRUG|Interferon Alfa-2a|Standard of care for chronic hepatitis C
214347764|NCT00433069|DRUG|Ribavirin|Standard of care for chronic hepatitis C
214347765|NCT04159688|DRUG|Alcohol|Alcohol Challenge
214347766|NCT00854451|DRUG|omeprazole plus amoxicillin|
214347767|NCT00854451|DRUG|omeprazole plus amoxicillin|
214347768|NCT00854451|DRUG|omeprazole plus amoxicillin|
214347769|NCT00854451|DRUG|omeprazole plus amoxicillin|
214502556|NCT02235298|DRUG|Metformin|500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL
214502557|NCT02235298|DRUG|Placebo|Placebo pill taken once daily to mimic Dapagliflozin
214502558|NCT01553487|OTHER|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
214502559|NCT00485693|DRUG|Bupivacaine HCl|150 mg Bupivacaine HCl
214502560|NCT00485693|DRUG|SKY0402|600 mg SKY0402 (study drug)
214502561|NCT02348866|OTHER|method of laundering and donning scrubs|
214502562|NCT01565187|BEHAVIORAL|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
214502563|NCT00845364|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
214347770|NCT03264872|BEHAVIORAL|Peer-Enhanced Motivational Interviewing|Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
214347771|NCT03264872|OTHER|Waitlist Control|After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
214347772|NCT00935025|DRUG|AZD1305|single and multiple oral doses, extended-release capsule
214955563|NCT01050335|BEHAVIORAL|Simuvision Simulator|Participants will perform common surgical procedures on the simulator
214955564|NCT04184596|OTHER|Discrete Choice Experiment|An online-based Discrete-Choice Experiment (DCE) using a survey for stated treatment preferences and socio-demographics. Furthermore, the neuropathic pain component will be assessed in all patients with the Numeric Pain Rating Scale instrument.
214955565|NCT04617405|OTHER|No interventions|No interventions
214955566|NCT05158842|DEVICE|Adult bubble CPAP oxygen therapy device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the patient. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the patient. Oxygen is delivered by a successfully tested, silicon-based, ergonomically designed adaptive version of nasal canula (nasal seal) inserted into the nostril of a patient.~The components are:~1. Adaptive version of nasal canula (nasal seal)~2. A nasal canula with connecting circuit system~3. Water-filled bottle with marking water pressure from10 to15 L/min.~Oxygen cylinder, central distribution through pipelines or by oxygen concentrator will be used as an oxygen source."
214955567|NCT00002773|BIOLOGICAL|allogeneic tumor cell vaccine|
214955568|NCT00002773|BIOLOGICAL|recombinant interferon alfa|
214347773|NCT00935025|DRUG|Placebo|single and multiple oral doses, capsule
214347774|NCT03663751|DRUG|Decitabine|low-dose decitabine: 5mg/m2 daily for 5 days
214347775|NCT04635722|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
214347776|NCT00137033|DRUG|Celecoxib|
214347777|NCT00137033|DRUG|Naproxen|
214347778|NCT00137033|DRUG|ASA|
214955569|NCT00002773|BIOLOGICAL|sargramostim|
214955570|NCT00002773|DRUG|cyclophosphamide|
214955571|NCT02134392|BIOLOGICAL|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
214955572|NCT03264534|PROCEDURE|limbal relaxing incisions|Manually performed surgical procedure
214347779|NCT04230473|BIOLOGICAL|single dose of CNCT19|"Dose A: 0.25 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
214347780|NCT05110859|OTHER|in-depth individual interviews|in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
214347781|NCT04699838|DRUG|Cisplatin|Cisplatin
214347782|NCT04699838|DRUG|Carboplatin|Carboplatin
214347783|NCT04699838|DRUG|Etoposide|Etoposide
214347784|NCT04699838|DRUG|Durvalumab|Durvalumab
214347785|NCT04699838|DRUG|Ceralasertib|Ceralasertib
214347786|NCT01805297|DRUG|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
214347787|NCT01805297|OTHER|Standard Vitrectomy|Surgical intervention
214347788|NCT00836641|BIOLOGICAL|prevenar|7-valent pneumococcal conjugate vaccine
214347789|NCT00836641|BIOLOGICAL|pneumovax|23 valent pneumococcal polysaccharide vaccine
214347790|NCT00951600|DRUG|oxcarbazepine 300 mg/5mL oral suspension|
214347791|NCT04095377|OTHER|No intervention, this is a retrospective study.|No intervention, this is a retrospective study.
214347792|NCT04892134|OTHER|blood sample|40-50 ml of blood is taken
214347793|NCT00832923|BEHAVIORAL|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
214347794|NCT01502501|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
214688160|NCT06203392|OTHER|Very low carbohydrate ketogenic diet|Very low carbohydrate ketogenic diet provided for six weeks
214688161|NCT06203392|OTHER|Mediterranean diet|Mediterranean diet provided for six weeks
214688162|NCT04339738|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214955573|NCT03264534|PROCEDURE|astigmatic keratotomy|femtosecond laser guided surgical procedure
214955574|NCT00462449|DEVICE|Functional Electrical Stimulation (FES) through the Ness H200|Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
214955575|NCT04978805|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
214347795|NCT02352311|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
214347796|NCT02352311|DRUG|AVODART|Dutasteride 0.5 mg
214347797|NCT02352311|DRUG|CIALIS|Tadalafil 5 mg
214347798|NCT02158299|DRUG|Avitene|
214347799|NCT02158299|DRUG|Sapylin|
214347800|NCT02158299|BEHAVIORAL|axillary drainage|
214347801|NCT02158299|OTHER|reexamine|
214347802|NCT05797285|DEVICE|human keratin graft|The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
214347803|NCT05591352|DIETARY_SUPPLEMENT|Chenopodium formosanum extracts sachet|consume 1 sachet per day
214347804|NCT05591352|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
214347805|NCT01757964|BIOLOGICAL|Bacteriotherapy|
214347806|NCT00126516|DRUG|Angiotensin II Receptor Antagonists|any dosage, frequency, and duration
214347807|NCT00126516|DRUG|Angiotensin-converting Enzyme Inhibitors|any dosage, frequency, and duration
214347808|NCT04021953|BEHAVIORAL|People Like Us Online Video Series Intervention|"People Like Us miniseries incorporates key sexual health messages to:~1. Increase viewers' knowledge and perceptions of HIV and other STI risk;~2. Address homophobia and sexual orientation disclosure;~3. Increase safer-sex negotiation self-efficacy;~4. Promote positive attitudes towards condom use and other safe sex behaviors;~5. Build skills and self-efficacy for practicing safer sex;~6. Provide information on HIV and other STI testing and its benefits;~7. Provide information on resources for HIV/STI testing and other mental health services;~8. Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men."
214955576|NCT05537649|DIETARY_SUPPLEMENT|Oatmeal porridge|Investigation of the impact of enzymatic modification of the molecular structure of starch by amylomaltase on the postprandial glycemic responses of an oatmeal porridge.
214955577|NCT02972749|BEHAVIORAL|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
214955578|NCT01941836|DRUG|ETC-1002|Patients receive ETC-1002
214955579|NCT01941836|DRUG|Ezetimibe|Patients receive ezetimibe
214347809|NCT04021953|BEHAVIORAL|Sexual Health Pamphlet (Standard of Care)|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
214347810|NCT05680103|RADIATION|lateral cephalometry|lateral x-ray beam to capture lateral cephalometry of patients
214955580|NCT03112733|DIAGNOSTIC_TEST|TFF3, SFRP4, Romo1, NFKB|Blood samples of all participants will be collected.
215078110|NCT04358705|OTHER|Cognitive Interviews|Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.
215078111|NCT04358705|OTHER|Supplemental Aim 1 Interviews|Participants from the preceding online survey (who identify as women from Aim 1/supplemental aim 1 survey) who agreed to be contacted for future study will be emailed an invitation to the eligibility screener. Individuals interested will complete a screener to ensure participants identify as women and to verify that they have ever used cigarillos. Eligible participants will be contacted to schedule a 60- to 90-minute Zoom interview about their tobacco, nicotine, and cannabis product use experiences, with particular focus on flavored cigarillo usage initiation, current use, and responses to potential flavor restrictions.
215078112|NCT03788447|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
215078113|NCT03788447|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
214347811|NCT02105948|DRUG|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
214347812|NCT02105948|DRUG|Placebo|Sterile 0.9% sodium chloride solution
214347813|NCT04169139|DEVICE|MIST (minimally invasive surgical therapy)|REPaiR Periodontal Therapy
214347814|NCT05284968|DRUG|Cell injection|All subjects will be treated with cell injection
214347815|NCT01873365|OTHER|Data collection|Case report forms (CRFs), logbooks and booklets.
214347816|NCT04051372|DIAGNOSTIC_TEST|Bronchoscopic Alveolar Lavage|"The diagnostic yield of different diagnostic methods for lung infection and non-infectious diseases under allo-HSCT patients.~1. Classic microbiological cultures designed for bacteria, fungi, and mycobacteria.~2. Detection of human cytomegalovirus (CMV) and EB virus in serum and BAL was tested using a Real-time PCR kit.~3. Detection of aspergillus galactomannan antigen 1,3-beta-D-glucan in serum and BAL was performed using an enzyme immunoassay method.~4. Cytological and pathogenic microscopic evaluation in BALF~5. Flow cytological analysis of T lymphocyte subsets in BALF and serum~6. Cytokine detection in BALF and serum~7. Microbiology detection in BALF by mNGS"
214688163|NCT04339738|DRUG|Cabozantinib S-malate|Given PO
214347817|NCT03447782|DRUG|Naltrexone HCl (Bulk) Powder|For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
214688164|NCT04339738|PROCEDURE|Computed Tomography|Undergo CT, spiral CT
215078114|NCT05571007|OTHER|True acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
214347818|NCT03369600|DEVICE|Supersonic Imagine Aixplorer SWE Ultrasound Imaging|Consented women will attend 2+ sessions where they will be imaged using the Supersonic Imagine Aixplorer for Shear Wave Elastography imaging.
214347819|NCT06495736|DIAGNOSTIC_TEST|Experimental: ROSE technique stain|The ROSE technical group uses Diff-Quick stain for diagnosis
214347820|NCT04747977|DRUG|OTX-DED|0.2mg dexamethasone ophthalmic insert
214347821|NCT04747977|DRUG|OTX-DED|0.3mg dexamethasone ophthalmic insert
214347822|NCT04747977|DRUG|OTX-DED|Hydrogel vehicle ophthalmic insert
214347823|NCT04928950|DRUG|Activated charcoal|Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
214347824|NCT03634774|OTHER|CHOICE+ Training Program|CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
214347825|NCT01587651|DRUG|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
214347826|NCT01587651|DRUG|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
214347827|NCT01587651|DRUG|Ticagrelor Maintenance Dose|one 90mg film coated tablet
214347828|NCT04838743|DRUG|IDegLira|"Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study."
214347829|NCT03277222|BIOLOGICAL|IN insulin|IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.
214347830|NCT03277222|BIOLOGICAL|Sterile Saline placebo|Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
214347831|NCT01696422|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
214347832|NCT01696422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
214347833|NCT01696422|OTHER|Placebo|Route:subcutaneous
214678614|NCT02367170|DEVICE|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
215078115|NCT05571007|OTHER|Sham acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
215078116|NCT05623254|OTHER|no comparator - TAU (Treatment-as-usual)|"Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) \[Time Frame: At Three-six months\]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)"
214347834|NCT01657422|BEHAVIORAL|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
214347835|NCT03069222|OTHER|Standard Rehabilitative Treatment|The patients will participate in standard but comprehensive SCI specific rehabilitation therapy provided by the SCI program at KIR. The therapy consists of 3 hours per day, 5 days a week. Motor function therapy includes standardized procedures for range of motion, passive and active muscle activities, and therapies to improve mobility. The treatment program for the enrolled patients will be standardized by Dr. Kirshblum, Director of the SCI program at KIR and a Co-Investigator of the study. Patients usually receive 4 weeks of rehabilitation treatment; however, if any of them are discharged earlier from KIR, their out-patient treatment activities will be monitored and the patients will be tested based on the planned schedule.
214347836|NCT03786679|DEVICE|Ultrasling ER III orthosis|Application of orthosis and start of rehabilitation after four weeks.
214347837|NCT03934502|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
214347838|NCT00355082|DRUG|lamotrigine, 300 mg/day|300 mg/day
214347839|NCT00355082|DRUG|lamotrigine, 250 mg/day|250 mg/day
214347840|NCT06127667|BEHAVIORAL|aerobic exercise|use of single bout of aerobic exercise
214347841|NCT05680168|DEVICE|Extracorporeal electromagnetic stimulation|Electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia).
214347842|NCT05680168|BEHAVIORAL|Pelvic floor exercises|Pelvic floor muscle training in serial training sessions with our therapist
215078117|NCT00827281|DRUG|D-cycloserine|Single dosage prior to sessions 3, 4 \& 5
215078118|NCT00827281|DRUG|Placebo|Single dosage prior to sessions 3, 4 \& 5
215078119|NCT05255042|OTHER|organ and tissue sample collection only|Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
215078120|NCT03620357|DEVICE|CGM|CGM Group: Dexcom G6 CGM
214347843|NCT02152267|DEVICE|tDCS|The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
214347844|NCT06114446|OTHER|simulation group|Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery
214955581|NCT06528509|BEHAVIORAL|AI-Generated Informative Videos|"Participants in the experimental arm will receive an AI-generated video designed to provide comprehensive information about cataract surgery. The video will cover key aspects of the procedure, including the nature of the surgery, potential risks, benefits, and postoperative care. The video will be produced in English for Cohort A, and translated into Bengali for Cohort B.~The video will be delivered to participants via a secure link sent to their mobile devices or email. Patients can watch the video at their convenience, and they are encouraged to view it as many times as necessary to fully understand the information provided. The video link will be provided once after the initial clinic appointment, but patients can access and watch the video multiple times.~The videos will be created using the Synthesia platform, which uses artificial intelligence to generate realistic, photo-realistic digital avatars that deliver the information in a personalized and engaging manner."
214955582|NCT06528509|BEHAVIORAL|Standard Written Information Brochures|Participants in the control arm will receive traditional written information brochures about cataract surgery. These brochures are designed to deliver detailed and essential information in a clear and understandable format. The brochures will be handed to participants during their face-to-face clinic appointment. Patients can read the material at their convenience and keep it for future reference. These brochures follow standardized guidelines and recommendations to ensure that all relevant information is included and presented in an accessible manner. The leaflet will be supplied in English for Cohort A, and Bengali for Cohort B.
214955583|NCT01915524|BIOLOGICAL|CV9202|Intradermal injection of CV9202
214955584|NCT01915524|RADIATION|local radiation|Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
214955585|NCT01160094|DRUG|Treatment|patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
214955586|NCT00970515|PROCEDURE|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
214955587|NCT00970515|PROCEDURE|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
214347845|NCT06114446|OTHER|immersive virtual reality|Participants will be educated with immersive virtual simulation f for postoperative nursing care of a patient who underwent colorectal surgery
214347846|NCT06114446|OTHER|observation|All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills
214347847|NCT00922493|OTHER|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.~An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
214347848|NCT03079804|OTHER|Experimental MWM|Mobilization with Movement
214347849|NCT03079804|OTHER|Experimental Thrust|Mobilization grade 5 (Thrust)
214347850|NCT03079804|OTHER|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
214347851|NCT05169879|PROCEDURE|coronal flaring|early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
214347852|NCT05169879|PROCEDURE|Non coronal flaring|No coronal flaring will be performed
214347853|NCT04323436|DRUG|Spartalizumab|Concentrate for solution for infusion
214955588|NCT02563691|RADIATION|stereotactic radiotherapy|"Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.~The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT."
214955589|NCT04667533|DRUG|Desidustat|"A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~1. Cohort I: Single-dose 100 mg~2. Cohort II: Single-dose 150 mg~3. Cohort III: Single-dose 200 mg"
214688165|NCT04339738|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
215078121|NCT03620357|DEVICE|SMBG|SMBG Group: Blood Glucose Meter
214347854|NCT04323436|DRUG|Capmatinib|Film-coated tablet
214347855|NCT04323436|DRUG|spartalizumab placebo|dextrose 5% in water (D5W) for infusion
214347856|NCT05853094|PROCEDURE|Ileostomy|Protective loop ileostomy after low anterior resection
214347857|NCT05853094|PROCEDURE|Transverse colostomy|Protective loop transverse colostomy after low anterior resection
214347858|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.
214347859|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.
214347860|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.
214347861|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.
214347862|NCT05038644|DRUG|XmAb18968 - Dose level -1|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
214688166|NCT04339738|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214688167|NCT04339738|BIOLOGICAL|Nivolumab|Given IV
214688168|NCT04339738|DRUG|Paclitaxel|Given IV
214688169|NCT04339738|OTHER|Quality-of-Life Assessment|Ancillary studies
214688170|NCT04339738|OTHER|Questionnaire Administration|Ancillary studies
214347863|NCT05038644|DRUG|XmAb18968 - Dose level 0 (starting dose)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
214347864|NCT05038644|DRUG|XmAb18968 - Dose level 1|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
214347865|NCT05038644|DRUG|XmAb18968 - Dose level 2|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
214347866|NCT05038644|DRUG|XmAb18968 - Dose level 3|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
214347867|NCT01745263|DRUG|Vitamin D3|2000 IU/d
214347868|NCT01745263|DRUG|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2~1 g/d"
214347869|NCT01745263|PROCEDURE|Strength Home Exercise|
214955590|NCT04333225|DRUG|Hydroxychloroquine|Weekly treatment in individuals at high risk
214955591|NCT02444039|DEVICE|SL-D301|Slit Lamp
214955592|NCT02444039|DEVICE|DC-4|Digital Camera Attachment
214955593|NCT02444039|DEVICE|SL-3G|Slit Lamp
214347870|NCT01745263|PROCEDURE|Flexibility Home Exercise|
214347871|NCT01383538|DRUG|FOLFIRINOX, IPI-926|"Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle."
214347872|NCT03971643|DRUG|vilobelimab|IV infusions of vilobelimab diluted in sodium chloride.
214347873|NCT01324492|DRUG|RAD001|
214347874|NCT01660763|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
214347875|NCT01660763|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
214347876|NCT04388982|BIOLOGICAL|low dosage MSCs-Exos administrated for nasal drip|Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
214347877|NCT04388982|BIOLOGICAL|mild dosage MSCs-Exos administrated for nasal drip|Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
214347878|NCT04388982|BIOLOGICAL|high dosage MSCs-Exos administrated for nasal drip|Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
214347879|NCT06189040|DRUG|BNT162b2 30µg|intramuscular administration of 30µg
214347880|NCT06189040|DRUG|BNT162b2 20µg|intramuscular administration of 20µg
214955594|NCT01485302|DRUG|SAR228810|"Pharmaceutical form:solution~Route of administration: intravenous"
214678615|NCT02367170|DEVICE|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
214955595|NCT01485302|DRUG|SAR228810|"Pharmaceutical form:solution~Route of administration: subcutaneous"
214955596|NCT04100590|DRUG|Cannabis|Smoked active cannabis (7% THC) vs. placebo inactive cannabis (0% THC)
214955597|NCT04707365|BIOLOGICAL|Tumor samples|for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
214955598|NCT04876976|DRUG|Cyanoacrylate, Isobutyl|using cyanoacrylate in the surgical repair of urethro-cutaneous fistula
214955599|NCT04876976|PROCEDURE|Classic surgical repair|classical repair of urethro-cutaneous fistula without the use of cyanoacryalte
214955600|NCT02295787|DRUG|Ketamine|Intranasal ketamine for late-life depression and suicidal ideation.
214347881|NCT06189040|DRUG|BNT162b2 6µg|intradermal administration of 6µg
214347882|NCT06189040|DRUG|mRNA-1273 100µg|intramuscular administration of 100µg
214347883|NCT06189040|DRUG|mRNA-1273 50µg|intramuscular administration of 50µg
214347884|NCT06189040|DRUG|ChAdOx1-S [Recombinant]|intramuscular administration of not less than 2.5 x 10\^8 infectious units
214347885|NCT03325712|DRUG|BI 705564|Film-coated tablet
214347886|NCT03325712|DRUG|Placebo|Film-coated tablet
214955601|NCT02295787|DRUG|Placebo|
214955602|NCT01703559|DRUG|Phentolamine Mesylate Ophthalmic Solution 1.0%|Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
214955603|NCT01703559|DRUG|Phentolamine Mesylate Ophthalmic Solution 0.5%|Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
214955604|NCT01703559|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
214955605|NCT04926506|DRUG|Xiyanping injection|Intramuscular injection of Xiyanping injection, 0.3mL / (kg.d) daily, Bid
214347887|NCT03325712|DRUG|Midazolam|Solution for injection
214347888|NCT00444782|BIOLOGICAL|GV1001|
214347889|NCT02692300|PROCEDURE|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or NeuroSENSE
214347890|NCT03174886|DRUG|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
214347891|NCT03174886|DRUG|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
214347892|NCT02848417|DRUG|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
214347893|NCT02848417|DRUG|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
214347894|NCT02848417|OTHER|Placebo|"Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
214347895|NCT04463641|DEVICE|Implantation of the Axone 4LV Lead|Implantation of the Axone 4LV Lead
214347896|NCT00952653|DRUG|Desvenlafaxine Succinate Sustained Release|50 mg DVS SR tablet days 1-6, period 2 only.
214955606|NCT00346736|PROCEDURE|Acupuncture (Procedure)|
214347897|NCT00952653|DRUG|Midazolam|4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
214347898|NCT05088213|PROCEDURE|suction mini percutaneous nephrolithotomy|18Fr suction sheath (Weili, China) was inserted, and 12Fr mini-nephroscope was used, kidney stones was fragmented by pneumatic lithotriptor (LithoClast Master, Switzerland) or Ho:YAG laser（0.8-1.0W\*20-30Hz）, and stone fragments was sucked out with the suction sheath.
214347899|NCT05088213|PROCEDURE|standard percutaneous nephrolithotomy|24-30Fr sheath was inserted, and 20Fr nephroscope (Richard Wolf, Germany) was used, kidney stones was disintegrated and sucked out by ultrasonic-lithotripter (LithoClast Master, EMS, Switzerland or ShockPluse-SE, Olympus).
214347900|NCT00202163|DRUG|DHEA|
214347901|NCT00202163|DRUG|Testosterone|
214347902|NCT00017381|BIOLOGICAL|rituximab|Given IV
214955607|NCT04212832|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
214955608|NCT04212832|OTHER|Standard pain|Standard pain follow up and monitorization
214955609|NCT04102683|BEHAVIORAL|Therapeutic recreation activity program|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
214955610|NCT01456364|DRUG|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
214955611|NCT01456364|DRUG|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients \< 75 years or a 5 mg maintenance dose per day for patients \>= 75 years
214955612|NCT02820181|DEVICE|novel tracheostomy bi-ties|The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
214347903|NCT00017381|DRUG|cyclophosphamide|Given IV
214347904|NCT00017381|BIOLOGICAL|filgrastim|Given SC
214955613|NCT02820181|DEVICE|traditional Tracheostomy ties|Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
214955614|NCT05911698|DEVICE|Fractional co2 laser|"The development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction.~These microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes."
214347905|NCT00017381|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
214347906|NCT00017381|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
214347907|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
214347908|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
214347909|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
214347910|NCT00760864|DRUG|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
214955615|NCT05237739|PROCEDURE|Non-Surgical Periodontal treatment (NSPT)|Participants will receive local anesthesia. Thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Treatment chair time will be recorded for each visit.
214955616|NCT05237739|PROCEDURE|Open Flap Debridement (OFD)|Patients will receive local anesthesia and intrasulcular incisions will be made by buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using piezo-electric/ultrasonic devices with specific thin and delicate tips
214347911|NCT02265237|DRUG|ombitasvir/paritaprevir/ritonavir|tablets
214347912|NCT02265237|DRUG|ribavirin|tablets
214347913|NCT04876508|OTHER|Accupressure|Patients in the experimental group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
214347914|NCT01898338|DRUG|Fosfomycin 2gr/6h iv|
214347915|NCT01898338|DRUG|Daptomycin 10mg/kg/24h iv|
214502564|NCT00845364|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
214502565|NCT00881296|DRUG|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
214502566|NCT00881296|DRUG|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
214955617|NCT00460746|DRUG|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
214955618|NCT05450406|OTHER|Physical activity|The participants will receive the possibility to attend weekly endurance, resistance and yoga exercise sessions administered by the Healthy Life Center. They will also receive personalized follow-up from the Healthy Life Center, and have the possibility to exercise at the local gym.
214955619|NCT03078309|DRUG|cannabis|single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)
214955620|NCT01068587|DRUG|MET/VEGFR2 inhibitor Foretinib|"PhaseI and Phase II Arm A:~Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I."
214347916|NCT04607967|DEVICE|High Flow Nasal Oxygen|"Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation."
214347917|NCT04781764|PROCEDURE|surgery|surgery
214955621|NCT01068587|DRUG|erlotinib hydrochloride|erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
214955622|NCT01068587|OTHER|laboratory biomarker analysis|Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
214347918|NCT03593668|DRUG|Metformin|"2-week dose adjustment period（0-2weeks）\[before meals\] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po."
214955623|NCT02811653|DEVICE|Brain MRI|
214955624|NCT02811653|OTHER|neuropsychological evaluation|
214955625|NCT02811653|BIOLOGICAL|Blood|
214955626|NCT03994237|OTHER|semi-structured interview|The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
214955627|NCT02356107|DRUG|5-hydroxytryptophan and Creatine monohydrate|
214955628|NCT01140828|DRUG|Rabeprazole|Rabeprazole 20mg once daily
214955629|NCT01140828|DRUG|Rabeprazole Placebo|one tab once daily
214955630|NCT06188845|OTHER|Kinesio taping|Kinesio taping is a non-invasive physical treatment, which is breathable, hypoallergenic and elastic. Because of the mechanical properties and physiological effects, Kinesio taping has been thought to relieve pain, reduce swelling, support and relax soft tissue, promote motor performance, and correct posture or abnormal movement patterns.
214347919|NCT03593668|DRUG|Benaglutide|"2-week dose adjustment period（0-2weeks） \[before meals\] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH"
214347920|NCT00650546|DRUG|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
214347921|NCT02495753|PROCEDURE|Vaginal Cleansing|The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
214347922|NCT02495753|PROCEDURE|Abdominal Cleansing|The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
214955631|NCT00822328|DIETARY_SUPPLEMENT|Yakult®300|"Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week."
214955632|NCT00822328|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
214955633|NCT03518411|OTHER|Cognitive Behavioral Therapy|One-Session Unified Protocol
214955634|NCT00789685|DRUG|Interferon Beta|Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
214678616|NCT02367170|PROCEDURE|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
214955635|NCT03031041|PROCEDURE|Ultrasound-guided short-axis hydrodissection with 5cc normal saline|Ultrasound-guided short-axis hydrodissection with 5cc normal saline between carpal tunnel and median nerve
214955636|NCT03031041|PROCEDURE|Ultrasound-guided long-axis hydrodissection with 3cc normal saline|Ultrasound-guided long-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve
214955637|NCT01296594|OTHER|Usual Care|Usual Care
214955638|NCT01296594|BEHAVIORAL|Contingency Management|This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
214955639|NCT00085813|DRUG|Ispinesib|
214955640|NCT03079076|DRUG|Bupivacaine|20 ml %0,25 bupivacaine bilaterally
214955641|NCT03079076|DRUG|Saline|2 ml saline subcutaneously bilaterally
214955642|NCT05908747|DRUG|surufatinib + gemcitabine + nab-paclitaxel|surufatinib: 250mg, QD po; nab-paclitaxel: 125mg/m2, I.V., D1/8/15, Q4W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1/8/15, Q4W
214955643|NCT03293446|DIAGNOSTIC_TEST|Urinary acidification test|Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
215078122|NCT01882010|DRUG|sargramostim|"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"
215078123|NCT01882010|DRUG|placebo|saline solution daily subcutaneous injection 56 days
215078124|NCT01882010|DIAGNOSTIC_TEST|Sham Comparator: Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
214347923|NCT01178853|DRUG|Warfarin|Warfarin 5 mg once daily
214347924|NCT01178853|DRUG|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
214347925|NCT01178853|DRUG|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
214347926|NCT01412008|DRUG|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
214347927|NCT03550313|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
214347928|NCT03550313|BIOLOGICAL|Prevnar 13|Pneumococcal conjugate vaccine
214347929|NCT02870790|DRUG|TDF/FTC|one pill daily
214347930|NCT05330962|OTHER|Framingham study cardiovascular disease 10-years risk assessment score|A personal interview questionnaire
214347931|NCT00839072|DRUG|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
214347932|NCT00839072|DRUG|Trazodone HCl|300 mg extended-release caplet, single dose
214347933|NCT04894604|DEVICE|Avance® Solo NPWT System|Application of the Avance® Solo NPWT System on up to 34 study Subjects, in accordance with the IfU for up to 14 days.
214347934|NCT00139750|DRUG|CP-526,555 (varenicline)|
214347935|NCT06197893|PROCEDURE|gingival unit graft+modified sling suture technique|The GUG was obtained from the maxillary premolar area. A sulcular incision including the marginal gingival tissue, and two vertical incisions, including the distal and mesial papillae, was made in the palatial parts of the premolars. Then, the incision lines were combined and a 1-1.5 mm thick graft of the desired dimensions was dissected. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique. First, the needle was passed through the graft slightly apical to the mesial papilla on the buccal side and removed from the lingual aspect including lingual papilla. Subsequently, on the distal side, the needle was passed from the lingual side to the buccal side, and it was passed through the graft slightly apical to the distal papilla and removed from the lingual gingiva again. Then it was knotted on the buccal graft by returning to the buccal starting point on the mesial side.
214955644|NCT06217744|BEHAVIORAL|Automated Intervention|Participants will receive 6 psychoeducational modules design to increase mental health literacy: Module 1: The Stigma of Mental Illness, Module 2: Understanding Mental Health and Mental Illness, Module 3: Information on Specific Mental Illnesses, Module 4: Experiences of Mental Illness, Module 5: Seeking Help and Finding Support, Module 6: The Importance of Positive Mental Health.
214955645|NCT06217744|BEHAVIORAL|Blended Intervention|Participants will receive the same materials as the Automated Intervention, as well as the possibility to attend psychoeducational sessions held by licensed psychologists.
214347936|NCT06197893|PROCEDURE|Gingival unit graft and conventional suture technique|The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique. Conventional suture technique includes a horizontal matrix suture and 2 simple sutures. First the coronal part of the dissected graft was fixed to the recipient bed with a horizontal matrix suture, then with 2 simple sutures along the vertical incision line from mesial and distal sides with 5/0 polypropylene suture.
214347937|NCT06197893|PROCEDURE|Conventional graft and modified sling suture technique|Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The exterier edges of the foil were drawn with a scalpel and the 1-1.5 mm thick graft was dissected from the donor site. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique.
214347938|NCT06197893|PROCEDURE|Conventional graft and conventional suture technique|Conventional graft obtained from the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique.
214347939|NCT04950101|OTHER|anal sampling|anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not
214347940|NCT04050293|DRUG|SPN-538|Patients will receive SPN-538
214347941|NCT04050293|DRUG|Placebo|Patients will receive Placebo
214347942|NCT00380068|DRUG|Ambrisentan|Oral tablets taken once daily.
214347943|NCT05234164|DEVICE|EXIST 6F NiTi Stent System FLEX|Subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent FLEX type. Subjects requiring treatment of the SFA will undergo an additional calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2 will be treated with the Exist 6F NiTi Stent FLEX type.
214347944|NCT05234164|DEVICE|EXIST 6F NiTi Stent System PULL|Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli grade 3 and 4 will be treated with the Exist 6F NiTi Stent PULL type.
214347945|NCT04207190|DRUG|Gemtuzumab Ozogamicin|Given IV
214347946|NCT04207190|OTHER|Quality-of-Life Assessment|Ancillary studies
214347947|NCT04207190|OTHER|Questionnaire Administration|Ancillary studies
214347948|NCT04207190|DRUG|Talazoparib|Given PO
214347949|NCT04207190|DRUG|Talazoparib Tosylate|Given PO
214347950|NCT02936557|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-054)"
214347951|NCT01297062|DRUG|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
214347952|NCT01297062|DRUG|Moxifloxacin|Oral Moxifloxacin (400 mg)
214347953|NCT01297062|DRUG|Placebo comparator|IV Placebo (matching volume of placebo)
214347954|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 14
214347955|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 23
214955646|NCT04399538|DRUG|PF-06865571|Tablet
214955647|NCT04399538|DRUG|PF-05221304|Tablet
214955648|NCT04399538|DRUG|Placebo|Tablet
214955649|NCT06366438|BEHAVIORAL|ABC-teen|See above
214955650|NCT06366438|BEHAVIORAL|ParentWeb|See above
214347956|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 8
214347957|NCT04783753|DRUG|Itraconazole|Subjects will receive itraconazole QD for 14 days
214347958|NCT04783753|DRUG|Carbamazepin|Subjects will receive carbamazepine BID for 23 days
214347959|NCT04783753|DRUG|Quinidine|Subjects will receive quinidine BID for 8 days
214347960|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular other name:PCV13i
214347961|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular other name:Prevnar
214347962|NCT01416792|PROCEDURE|Centrifugation|
214347963|NCT01416792|PROCEDURE|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
214347964|NCT02635841|DRUG|Deferiprone|Ferriprox (deferiprone) 100 mg/mL oral solution
214347965|NCT01458574|DRUG|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
214347966|NCT01458574|DRUG|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
214347967|NCT01458574|DRUG|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
214347968|NCT04110808|DRUG|hypotensive anaesthesia using Nitroglycerine|"effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure."
214347969|NCT02125786|RADIATION|Irradiation|Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.
214347970|NCT02125786|PROCEDURE|Surgery|When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.
214347971|NCT02125786|DRUG|^1^8F-Fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
214347972|NCT02125786|DRUG|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
214347973|NCT02125786|DEVICE|Photon therapy|Participants will receive one or both: Photon or proton therapy.
214347974|NCT02125786|DEVICE|Proton therapy|Participants will receive one or both: Photon or proton therapy.
214347975|NCT00582582|DRUG|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
214347976|NCT00582582|DRUG|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
214347977|NCT02526134|DEVICE|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
214347978|NCT06421233|OTHER|massage|Endorphin massage will be given for 15 minutes every 2 hours.
214347979|NCT02894021|PROCEDURE|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
214955651|NCT03850990|BEHAVIORAL|Placebo pill and no placebo pill|The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.
214347980|NCT02894021|PROCEDURE|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
214347981|NCT03943368|DEVICE|Ceevra Reveal|3D Digital models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source MR image.
214347982|NCT04964089|DRUG|KSI-301|Intravitreal Injection
214347983|NCT04964089|DRUG|Aflibercept|Intravitreal Injection
214347984|NCT04964089|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
214347985|NCT00870779|DRUG|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
214347986|NCT01042457|DRUG|Mycophenolate mofetil|Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
214347987|NCT06444282|OTHER|Emergency Care Action Plan|An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
214347988|NCT03969238|BEHAVIORAL|Helpline|This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
214347989|NCT05846724|DRUG|Pembrolizumab + Lenvatinib|single-arm study of pembrolizumab plus lenvatinib
214347990|NCT05658861|OTHER|Milk containing A1 and A2 beta-casein|Single dose of commercial milk
214955652|NCT04671056|DRUG|MGL-3196|MGL-3196 100 mg tablet administered orally in the morning for 13 days
214347991|NCT05658861|OTHER|Milk containing only A2 beta-casein|Single dose of A2 milk
214347992|NCT03445468|BIOLOGICAL|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
214347993|NCT03445468|BIOLOGICAL|IL-YANG Flu Vaccine Pre-filled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
214347994|NCT04411290|PROCEDURE|Total thyroidectomy (TT)|Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)
214347995|NCT06531447|DRUG|Cisplatin|Every 21 days 6 cycles
214347996|NCT06531447|DRUG|Gemcitabine|Every 21 days (First and 8th days) 6 cycles
214347997|NCT06531447|DRUG|Doxorubicin|Every 21 days 4 cycles
214347998|NCT06531447|DRUG|Cyclophosphamide|Every 21 days 4 cycles
214347999|NCT06531447|DRUG|Paclitaxel|Every 21 days 4 cycles or once a week for 12 weeks
214348000|NCT06288815|DIETARY_SUPPLEMENT|Oral fluid|"Postoperation~* Off IV fluid immediately postoperative~* Allow patients drink oral fluid as protocol for 24hr"
214348001|NCT06288815|DIETARY_SUPPLEMENT|IV fluid|"Postoperation~* IV fluid replacement as protocol for 24hr~* Allow patients drink oral fluid as usual"
214348002|NCT04867564|DIAGNOSTIC_TEST|Echocardiography|Traditional echocardiography and speckle tracking echocardiography (STE) before and 1, 6, and 12 months after RT
214348003|NCT01682837|DRUG|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
214348004|NCT01682837|DRUG|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
214348005|NCT01682837|DRUG|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
214348006|NCT01682837|DRUG|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
214348007|NCT03691805|DEVICE|tDCS|The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
214348008|NCT03691805|DEVICE|Sham tDCS|The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
214955653|NCT04671056|DRUG|Pioglitazone 15mg|Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state
214955654|NCT03420287|COMBINATION_PRODUCT|MPM Prepared From Allogenic Bone Graft|patients will receive a sticky bone which prepared by mixing the the growth factors of the patient with allogenic bone graft for cleft closure
214955655|NCT03420287|OTHER|Autogenous bone|patients will receive an autogenous bone graft from anterior iliac crest for cleft closure
214955656|NCT04659902|DIETARY_SUPPLEMENT|Protein form|Protein form and absence or presence of calcium manipulated
214348009|NCT05548595|DIETARY_SUPPLEMENT|Investigational|2 tablets are taken with water around the same time every day, ideally after a meal
214348010|NCT05548595|OTHER|Placebo|2 tablets are taken with water around the same time every day, ideally after a meal
214348011|NCT02012829|BEHAVIORAL|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
214955657|NCT01438372|DRUG|Intravenous iron sucrose|Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
214348012|NCT06057350|PROCEDURE|Tumor removal|Removal of incompletely removed early-stage colon cancer
214348013|NCT03787667|DIAGNOSTIC_TEST|CT or MRI based Radiomics|Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
214348014|NCT01813240|DRUG|Minocycline|
214348015|NCT01813240|DRUG|placebo|
214348016|NCT05528120|DRUG|VC004 Capsules|Oral administration after fasting/high-fat meal
214955658|NCT01438372|DRUG|Oral ferrous sulfate|Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
214955659|NCT01420016|OTHER|Prioritized Clinical Decision Support|Eighteen primary care clinics were blocked on size and on patient characteristics. Each clinic was randomly assigned to one of 2 study arms. All consenting PCPs were allocated to the study arm that their clinic was assigned to and the estimated 400 eligible adults with 10-year CVR \>= 10% under the care of each consenting physician were allocated to the same treatment arm as their PCP.
214955660|NCT01454414|OTHER|Permethrin Impregnated Uniforms|Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
214348017|NCT05528120|DRUG|VC004 Capsules|Oral administration after high-fat/fasting meal
214348018|NCT05872633|BEHAVIORAL|Online self-management intervention|
214955661|NCT04517578|OTHER|Survey|Participants will be asked to fill in an online survey that will be anonimized.
214955662|NCT04026711|DRUG|Mitoquinol|Mitoquinol (MitoQ) 40 mg per day for 12 weeks
214955663|NCT04026711|DRUG|Placebo oral tablet|Placebo daily for 12 weeks
214955664|NCT04184778|DEVICE|Smaller tube size|Comparing how tube size affect patient's experience of postoperative sore throat and hoarseness in men and women.
214955665|NCT03447964|OTHER|dosing of sphingolipids|\- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
214955666|NCT05112159|DRUG|IPG1094|The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.
214955667|NCT05112159|DRUG|placebo|Matching placebo tablets to IPG1094 50mg and 100mg
214348019|NCT05872633|OTHER|Care-as-usual|
214955668|NCT00636961|DRUG|Indacaterol 300μg|300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
214955669|NCT00636961|DRUG|Placebo|Matching placebo devices and hard gelatin capsules
214955670|NCT00019656|DRUG|perifosine|
214955671|NCT00405847|DRUG|Dexmedetomidine|
214955672|NCT05358977|BIOLOGICAL|Tisseel|Intraoperatively, the intervention side will receive topical administration of Tisseel to the blepharoplasty incision. A 2mL syringe of Tisseel product will be used as per the product monograph for an area of \< 8cm2. There will be no variation in surgical counselling or technique, with the exception of the use of Tisseel in one eyelid closure. Both eyelids will otherwise receive standard blepharoplasty surgical techniques. There will be no monitoring of compliance necessary, given the Tisseel will be utilized intraoperatively.
214955673|NCT03116009|DRUG|Screening for diabetes with 1-hour GCT and HbA1|They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
214955674|NCT02181218|DRUG|Romidepsin|
214955675|NCT02181218|DRUG|Gemcitabine|
214955676|NCT02181218|DRUG|Oxaliplatin|
214348020|NCT01316367|BEHAVIORAL|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~* Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~* Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~* Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
214348021|NCT01316367|BEHAVIORAL|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
214348022|NCT01638923|DRUG|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
214955677|NCT02181218|DRUG|Dexamethasone|
214955678|NCT02181218|DRUG|Pegfilgrastim|
214955679|NCT06263426|OTHER|HIV D+/R+|Receipt of kidney transplant from a deceased donor with HIV.
214955680|NCT06263426|OTHER|HIV D-/R+|Receipt of kidney transplant from a deceased donor without HIV.
214955681|NCT01904630|GENETIC|gene sequencing|Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
214955682|NCT00170014|DEVICE|Magnetocardiograph|
214955683|NCT06668103|DRUG|ABSK043 in combination with Firmonertinib|"Two potential dose levels ：400 mg twice daily （BID） and 800 mg BID) of ABSK043 are prespecified and firmonertinib will be administered orally at a fixed dose of 80 mg once daily (QD).~Patients in dose escalation cohort will receive the ABSK043, 400 mg BID and firmonertinib 80 mg QD as the starting dose for the combination therapy.~Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.~After Cycle 1, patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study."
214955684|NCT06618547|DEVICE|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser by Transepithelial Photorefractive Keratectomy
214955685|NCT02572960|DRUG|Valsartan|2 weeks of Valsartan 80 mg per day
214348023|NCT01638923|DRUG|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
214348024|NCT04336202|RADIATION|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
214348025|NCT01196975|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
214348026|NCT01196975|BIOLOGICAL|FluLavalTM-VB|Single intramuscular dose
214348027|NCT01196975|BIOLOGICAL|FluLavalTM-YB|Single intramuscular dose
214348028|NCT01365494|BIOLOGICAL|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
214348029|NCT03331120|DEVICE|ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)|Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
214348030|NCT05157646|BEHAVIORAL|Fitness tracker|Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
214348031|NCT01494051|BEHAVIORAL|Diet counseling|Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
214348032|NCT00554866|OTHER|blood sample and buccal swab sample|"one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
214348033|NCT01388387|OTHER|Tacrolimus pharmacokinetics|tacrolimus pharmacokinetics over 12 hours
214348034|NCT01736826|BIOLOGICAL|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
214348035|NCT01736826|BIOLOGICAL|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 \& 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
214393568|NCT03325335|DRUG|Propofol infusion|Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
214955686|NCT02572960|DRUG|Placebo Valsartan|2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
214955687|NCT02572960|DIETARY_SUPPLEMENT|Cholecalciferol|12 weeks of daily cholecalciferol treatment, 70 microgram per day
214955688|NCT02572960|DIETARY_SUPPLEMENT|Placebo cholecalciferol|12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
214393569|NCT00373295|DRUG|Baclofen|Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
214955689|NCT06080165|DRUG|Sirolimus|Experimental: Sirolimus Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and \< 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and \> 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on clinical labs of sirolimus levels. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.
214955690|NCT06080165|DRUG|Placebo|matching placebo
214955691|NCT03938688|PROCEDURE|Mesh placement with Transfascial Sutures|Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
214955692|NCT07016516|DRUG|PRT-064040 nasal spray|A single dose of PRT-064040 nasal spray at one of six dose levels
214955693|NCT07016516|DRUG|Placebo|A single dose of Placebo at one of six dose levels
214955694|NCT07016516|DRUG|PRT-064040 nasal spray|Multiple doses of PRT-064040 nasal spray at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
214955695|NCT07016516|DRUG|Placebo|Multiple doses of Placebo at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
214955696|NCT06618729|OTHER|Pea protein|Ingestion of a meal containing 40 g of protein from pea protein extrudate
214955697|NCT06618729|OTHER|Wheat protein|Ingestion of a meal containing 40 g of protein from wheat protein extrudate
214348036|NCT01736826|BIOLOGICAL|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
214348037|NCT02422277|DEVICE|LI-ESWT group|"The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week."
214348038|NCT02422277|DRUG|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
214348044|NCT02302079|DRUG|ASP8232|oral capsule
214348045|NCT02302079|DRUG|ranibizumab|intravitreal (IVT) injection
214348046|NCT02302079|DRUG|Placebo|oral capsule
214348047|NCT02302079|OTHER|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
214348048|NCT06667180|DEVICE|Low-intensity TMS|Low-intensity TMS will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 mT and frequency of 50 Hz in theta bursts.
214348049|NCT06667180|DEVICE|Transcranial Magnetic Stimulation Sham|The control group will receive the simulation of low-intensity TMS without magnetic field induction.
214348050|NCT04709536|DRUG|IBI306|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
214955698|NCT06618729|OTHER|Soy protein|Ingestion of a meal containing 40 g of protein from soy protein extrudate
214348051|NCT04709536|DRUG|Placebo|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
214348052|NCT05511987|DEVICE|Madela THOPAZ Digital Device|Digital drainage systems use electronic sensors to measure changes in pressure and thus may allow for quantification of the degree of air leak continuously and provide a graphical representation of the trend over time. Data on intrapleural pressure are also provided by some units. Together, these data may lead to expedited chest tube removal and hospital discharge with obvious financial implications.
214348053|NCT05511987|DEVICE|Atrium Analog Device|Analog drainage systems contain a sequentially numbered series of columns in the water seal chamber. The degree of air leak is assessed by observing the highest numbered column in which bubbling occurs. This provides a qualitative assessment at a specific point in time. This assessment, however, is subject to interobserver variability and does not account for variation over time.
214348054|NCT03320447|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
214348055|NCT03320447|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
214348056|NCT03320447|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
214348057|NCT03320447|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
214348058|NCT05699759|DRUG|K8|Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).
214955699|NCT06618729|OTHER|Chicken|Ingestion of a meal containing 40 g of protein from chicken
214955700|NCT00410059|DRUG|Erlotinib|150 mg by mouth daily x 28 days
214502567|NCT03413085|DEVICE|soft contact lens|"Group A~Group B"
214502568|NCT02463994|DRUG|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
214955701|NCT03748121|BEHAVIORAL|Pranayama assisted trauma-focused Cognitive Behavioral Therapy (TF-CBT)|The pranayama intervention is placed directly at the begin of the respective TF-CBT unit and will be repeated for 10 subsequent TF-CBT units. Pranayama contains the performance of Kapalabhati, Ujjayi, and/or Nadi Shodhana (for overall 1 minute) as well as following Kumbhaka (intentional respiratory reflex inhibition). Pranayama will be repeated 3 times before each TF-CBT unit.
214502569|NCT02463994|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
214502570|NCT04068272|DRUG|Bosentan|Eyedrop
214502571|NCT04068272|DRUG|Placebo|Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
214502572|NCT02309294|DEVICE|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
214348059|NCT05558059|DEVICE|Handheld Optical Coherence Tomography with OCT Angiography|"OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image.~OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients."
214348060|NCT06098521|BEHAVIORAL|CONSENT|The CONSENT program is a risk-, need- and responsivity (RNR) based CBT program primarily focused on reducing risk of sexual reoffending, that consists of 18-26 one-to-one sessions in correctional settings.
214348061|NCT05564663|BEHAVIORAL|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include downloading the PTSD Coach App for personal use and four, brief (\<20 minutes), weekly, individual support sessions. The sessions will focus on the instruction and encouragement of App use and activities (i.e., assessments, self-management strategies, and psychoeducational readings).
214348062|NCT05564663|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will consist of one brief session (with brochure) of PTSD and AUD psychoeducation and referral information for mental health clinics that provide PTSD services, with encouragement to schedule an appointment at one of the listed clinics to discuss PTSD-related symptoms.
214348063|NCT06053489|OTHER|general anesthesia with remimazolam|general anesthesia with remimazolam in pediatric patients undergoing ophthalmic surgery
214348064|NCT01461590|OTHER|Whole blood|30mls/kg transfused over fours hours
214348065|NCT01461590|OTHER|Whole blood|20mls/kg transfused over four hours
214348066|NCT01548456|PROCEDURE|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
214348067|NCT01548456|PROCEDURE|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
214348068|NCT03449303|OTHER|EOI|Topically-applied oil
214348069|NCT03449303|OTHER|Placebo|Topically-applied oil
214348070|NCT04541758|PROCEDURE|surgical treatment|surgical treatment and Conservative treatment
214348071|NCT04541758|PROCEDURE|Conservative treatment|Conservative treatment
214348072|NCT00852384|PROCEDURE|NIPPV and IRM|"* non invasive positive pressure support ventilation (NIPPV group)~* alveolar recruitment maneuver (IRM group)"
214348073|NCT04961333|BEHAVIORAL|Multidisciplinary Rehabilitation|Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
214348074|NCT03006328|BEHAVIORAL|GEM|Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.
214348075|NCT03006328|BEHAVIORAL|Enhanced Usual Care|Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
214348076|NCT01859455|DRUG|LGT209 50 mg|Active experimental drug
214348077|NCT01859455|DRUG|LGT209 300 mg|Active experimental drug
214348078|NCT01859455|DRUG|Placebo|Placebo comparator
214348079|NCT01859455|DRUG|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
214678617|NCT02367170|OTHER|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
214678618|NCT00032019|BIOLOGICAL|filgrastim|Cycle 1: 300 ug (BW \< = 70 kg) or 480ug (BW \>70 kg) sub Q injection Day 6 until ANC \> 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
214348080|NCT03556319|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
214348081|NCT03556319|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
214348082|NCT03872050|DIAGNOSTIC_TEST|No intervention apart from tests, including interview|No interventions
214348083|NCT02356016|BEHAVIORAL|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
214348084|NCT02356016|BEHAVIORAL|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
214348085|NCT02356016|OTHER|control (dietary counseling)|Monthly dietary counseling only
214348086|NCT00758953|DRUG|Danazol Once Weekly|semi-solid
214678619|NCT00032019|BIOLOGICAL|rituximab|375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
214348087|NCT00758953|DRUG|Danazol Twice Weekly|semi-solid
214348088|NCT00758953|DRUG|Placebo Once Weekly|semi-solid
214348089|NCT00758953|DRUG|Placebo Twice Weekly|semi-solid
214348090|NCT02568787|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
214348091|NCT02568787|DIETARY_SUPPLEMENT|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
214348092|NCT04352933|DRUG|Hydroxychloroquine - Daily dosing|"Active HCQ:~Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (\~3 months),~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
214393570|NCT00373295|DRUG|Marijuana|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
214348093|NCT04352933|DRUG|Hydroxychloroquine - Weekly Dosing|"Active HCQ:~Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months)"
214348094|NCT04352933|OTHER|Matched Placebo Hydroxychloroquine|"Matched placebo HCQ - daily dosing:~Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
214348095|NCT05740930|OTHER|Partition defocus myopia management spectacle lens|Participants in the intervention group will receive the partition defocus myopia management spectacles lens and receive follow-up checks.
214348096|NCT05740930|OTHER|Spectacle lenses with aspherical lenslets|Participants in the control group will receive the spectacle lenses with aspherical lenslets and receive follow-up checks.
214955702|NCT03748121|BEHAVIORAL|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
214955703|NCT02380118|DRUG|Olanzapine|Intramuscular injection
214955704|NCT02380118|DRUG|Haloperidol|Intramuscular injection
214955705|NCT02380118|DRUG|Midazolam|Intramuscular injection
214955706|NCT01530724|OTHER|Weight-loss diet strategy (+) exercise (PA)|Weight-loss diet strategy with a free gym membership; monthly 60-minute educational workshops; 3 sessions of workout per week of mostly aerobic training
214955707|NCT01530724|OTHER|weight loss (-) exercise (PA)|Weight-loss diet strategy without exercise
214955708|NCT07016932|BEHAVIORAL|Education with mobile application|"The I Can Do It Independently mobile application developed by the researchers includes two training videos on hand hygiene and menstruation management. Adolescents will be asked to play the games related to the training after watching the training videos. Thus, it is aimed for the participant to reinforce the training. The mobile application was developed by a multidisciplinary team of special education, nurse, midwife and software engineering academicians specifically for female adolescents with mild intellectual disabilities. Adolescents in the intervention group will be asked to use the mobile application for approximately 30 minutes every day. (https://play.google.com/store/apps/details?id=com.hookey.bagimsizyapabilirim\&pcampaignid=web\_share)"
214955709|NCT05749497|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
214955710|NCT00718068|DRUG|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
214955711|NCT00718068|DRUG|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
214955712|NCT07021378|DIETARY_SUPPLEMENT|Dietary Supplement|"Phase 1 (Neoadjuvant Chemotherapy):~Patients will receive 2 units of Impact oral supplement and 1 sachet of protein module daily, for 7 days prior to each chemotherapy cycle.~During the interval between the end of one cycle and 7 days before the next, 2 sachets of protein module per day will be maintained.~Phase 2 (Surgery):~2 units of Impact once daily, for 7 days prior to surgery.~Phase 3 (Radiotherapy):~2 units of Impact and 1 sachet of protein module daily, for 7 days prior to starting radiotherapy (RT), followed by 1 unit of Impact once daily throughout the course of RT.~Protein module: 13 g/day until the end of treatment."
214348097|NCT00338338|DRUG|Lacidipine 4 or 6 mg (oral)|
214348098|NCT00338338|DRUG|Amlodipine 5 or 10 mg(oral)|
214348099|NCT01849367|DEVICE|Eldith Neuroconn tDCS device|
214348100|NCT05843968|DRUG|Rituximab|"2 doses of rituximab 375 mg/m\^2(maximum 500mg/day) at 6 months intervals.~Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection."
214955713|NCT07021378|DIETARY_SUPPLEMENT|Dietary Supplement|"2 units of Impact oral supplement and 1 sachet of protein module once daily, starting 1 week before the initiation of radiotherapy (RT).~During RT: 1 unit of Impact and 1 sachet of protein module daily, until 1 week before the end of RT.~2 units of Impact and 1 sachet of protein module daily until the end of treatment, starting from 1 week before the end of RT.~Protein module: 13 g/day throughout the entire treatment period."
214955714|NCT07021378|OTHER|Control Cohort A|Control cohort A: According to the institutional routine nutritional orientation
214955715|NCT07021378|OTHER|Control cohort B|Control cohort B: According to the institutional routine nutritional orientation
214955716|NCT07022561|BEHAVIORAL|Social Prescribing|A social prescribing intervention is a non-clinical approach to improving health and wellbeing by connecting individuals to community-based services and activities that address social, emotional, and practical needs. These may include arts programs, physical activity, peer support, volunteering, or nature-based activities. Facilitated by a link worker or navigator, social prescribing is tailored to the individual and aims to enhance mental health, reduce isolation, and support overall wellness beyond traditional medical care.
214393571|NCT00373295|DRUG|Placebo|
214393572|NCT00830947|DEVICE|OrthoAccel Device|The OA device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
214348101|NCT05843968|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year.~Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks"
214348102|NCT06531954|DEVICE|Vagus nerve stimulation|Vagus nerve stimulation group: Vagus stimulation was applied bilaterally through the ear. taVNS was performed with the Vagustim device. The stimulation pulse width was 300 microseconds, the frequency was 10 Hz, and it was biphasic with a 20-minute duration. Electrodes were placed on the concha and tragus parts of the ear, and the current was increased through these electrodes until the participant felt pain.
214348103|NCT06531954|BEHAVIORAL|Breathing exercise|Breathing exercise group: The content of breathing exercises was planned as thoracic expansion exercises. These exercises were applied to the lower, middle, and upper lobes in 3 sets of 3x10 (90 times breathing in one area) and lasted for an average of 20 minutes. Participants were asked to inhale as deeply as possible into the relevant area, hold their breath for 3 seconds, and then slowly exhale the entire breath.
214348104|NCT06206005|OTHER|Observational study|evaluate implant survival, peri-implant outcome of 4 implant retained mandibular OVD after 10 years of function.
214955717|NCT07021833|DEVICE|Cryosa Procedure|The purpose of this study is to evaluate the safety and effectiveness of Cryosa System applied to the tongue and soft palate in patients with clinically diagnosed obstructive sleep apnea (OSA).
214955718|NCT07021469|OTHER|Sound origins|"Parents:~1. Playlists created by parents with lived experience for parents to use as ideas for music they could use for themselves or with baby on the unit.~2. Parent Journal: This journal provides a guide for using music and self-reflection. It also has the link for the playlists.~3. 'Musical gifts' created with the support of a music therapist from external family/ friends to the baby on the unit.~Nursing staff caring for families participating in the study:~1. Nurses shared playlist. Suggested creation of 3 playlists for nursing staff to create their own shared playlist using their music.~2. 'Ask me' badges. These badges are optional for nurses to wear during their shifts but will act as a symbol to parents that their nurse is available to speak to about music."
214955719|NCT07022990|OTHER|Educational brochure for deprescribing|"Study participant will be provided information (i.e., educational brochure) about one of the five medication classes participants may be taking that are known to have potential side effects for older adults: proton pump inhibitors (PPIs), benzodiazepine (BZs) and non-benzodiazepine sedative hypnotics (Z-drugs), first-generation antihistamines (FGA), and skeletal muscle relaxants (SMR) to determine their necessity."
214955720|NCT07021755|OTHER|midazolam|
214955721|NCT07027462|DIETARY_SUPPLEMENT|Mushroom blend|A mushroom blend that is targeted to improve gastrointestinal symptoms.
214955722|NCT07027462|OTHER|Placebo|Placebo product.
214348105|NCT02520934|DRUG|Miglustat|combine miglustat and ERT to see if neurologic manifestations can be improved
214955723|NCT07026903|BEHAVIORAL|resistance exercise and calorie restrictive diet|experimental group will be randomized to isCGM during the lifestyle intervention trial while control group will participate in the same lifestyle intervention but will not use isCGM
214955724|NCT07026617|OTHER|Rocabado's approach in addition to LLLT|The patients will recieve Rocabado's non-thrust manipulation: Non-thrust temporo-mandibular joint manipulations consisted of medial glide, lateral glide and anterior glide as described by Rocabado. Each glide was given for 10-15 repetitions for 5-6 times in a session. The grade of mobilization was beginning with Grade-1 or 2 and progressed to Grade-4 depending on subject condition. Total duration of mobilization was lasted for 20 minutes. in addition to low power gallium aluminum arsenide (GaAlAs).
214955725|NCT07026617|OTHER|control group|The patients will recieve Rocabado's non-thrust manipulation: Non-thrust temporo-mandibular joint manipulations consisted of medial glide, lateral glide and anterior glide as described by Rocabado. Each glide was given for 10-15 repetitions for 5-6 times in a session. The grade of mobilization was beginning with Grade-1 or 2 and progressed to Grade-4 depending on subject condition. Total duration of mobilization was lasted for 20 minutes. in addition to lplacebo ow power gallium aluminum arsenide (GaAlAs).
214955726|NCT07026786|BEHAVIORAL|Mindfulness Intervention|Those in the Mindfulness Intervention group will have a 30-minute Zoom session before surgery to learn simple mindfulness exercises like deep breathing, using senses, and staying focused on the present. After surgery, these participants will receive a refresher on the mindfulness curriculum.
214955727|NCT07021651|PROCEDURE|Erector Spinae Plane (ESP) block admistring|In the ESPB group, the probe was placed longitudinally at the level of the T5 transverse process, 2-3 cm lateral from the midline. The muscles were visualized superior to the transverse process ; then, the needle was inserted in the craniocaudal direction using the in-plane technique. A dose of 2 mL normal saline were injected into the two layers of the interfacial area under the erector spinae muscle, and the proper injection site was confirmed. After visualizing the linear spread of saline in the fascial plane, 20 mL of 0.25% bupivacaine was injected there for the block.
214955728|NCT07021651|PROCEDURE|Thoracic Paravertebral Block administring|In the TPVB group, the probe was placed 2-3 cm laterally and vertically of the T5 spinous process. Once the transverse process, corresponding paravertebral space, internal intercostal membrane, and pleura was identified , the needle was inserted in the lateromedial direction using the in-plane technique. After confirmation of pleural displacement with 2 mL saline, 20 mL of 0.25% bupivacaine was administered for the block.
214955729|NCT07022366|DRUG|Pimavanserin 10mg|Single dose of pimavanserin (10mg)
214955730|NCT07022366|DRUG|Placebo|Sucrose tablet
214348106|NCT02520934|DRUG|ERT|enzyme replacement therapy
214393573|NCT00830947|DEVICE|Sham Device|Inactive sham device that is held in the mouth for 20 minutes.
214678620|NCT00032019|DRUG|cyclophosphamide|750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
214955731|NCT00194194|BEHAVIORAL|moderate|moderate behavioral management with RD
214955732|NCT00194194|DEVICE|Resting Metablic Rate measurements|intensive behavior management
214348107|NCT04397081|OTHER|HPV test results|The human papillomavirus (HPV) test detects the presence of the human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The procedure includes taking samples of your cervical cells using a soft brush and a flat scraping device called a spatula. This doesn't hurt, and you may not even feel the sample being taken.
214348108|NCT06037759|DIAGNOSTIC_TEST|Cardiac Biomarkers|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
214348109|NCT06037759|DIAGNOSTIC_TEST|Lipidomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
214348110|NCT06037759|DIAGNOSTIC_TEST|Proteomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
214348111|NCT04859166|PROCEDURE|Organoids|A part of the tumor of approximately 1 cm3 will be removed from the primary tumor.
214348112|NCT02948985|OTHER|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
214348113|NCT01615445|DRUG|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
214955733|NCT07026032|OTHER|Biofeedback tool|Biofeedback tool (tongueometer) will be used for experimental group, where as for control group the intervention used in traditional exercises.
214348114|NCT01615445|DRUG|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
214348115|NCT02578394|DRUG|Anakinra 100mg and Placebo Depo-Medrone|Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
214393574|NCT01306565|DRUG|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
214678621|NCT00032019|DRUG|doxorubicin hydrochloride|10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
214678622|NCT00032019|DRUG|etoposide|50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
214955734|NCT07026032|OTHER|traditional exercises|traditional exercises were used for the control group
214955735|NCT07025993|OTHER|Muscle Energy Technique|Eccentric muscle energy technique was applied to subjects' cervical spine. The cervical spine will brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then subjects will asked to push their heads into the direction opposite that of the barrier. The therapist provided isometric resistance for 3- 5 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch.
214955736|NCT07025993|OTHER|Eccentric muscle energy technique|Eccentric muscle energy technique was applied to subjects' cervical spine. The cervical spine will brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then subjects will asked to push their heads into the direction opposite that of the barrier. The therapist provided isometric resistance for 3- 5 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch. Three to five repetitions will performed.
214955737|NCT00247988|DRUG|Weekly Taxotere with weekly carboplatin|
214955738|NCT01239082|PROCEDURE|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
214955739|NCT01239082|PROCEDURE|FIT|Annual FIT testing
214955740|NCT06728553|DRUG|MTX101|One 2 mg sublingual tablet of MTX101
214955741|NCT06728553|DRUG|Placebo|One sublingual tablet of placebo
214955742|NCT05690763|OTHER|XP-endo Finisher to use irrigation activation|XPF : The canals were flushed with 2.5 mL 2.5% NaOCl for 30 s and activated by a XPF instrument that was placed in the canal to 1 mm short of the WL and powered by the motor at 800 rpm (1 N-cm torque) for 30 s according to the manufacturer's instructions. Then the canals were rinsed with 2.5 mL of 2.5% NaOCl, followed by activation of the substance with the XPF instrument for 30 seconds, the same way as above. A new XP-endo Finisher file was used for each canal.
214955743|NCT05690763|OTHER|EndoActivator to use irrigation activation|The root canals were irrigated with 2.5 mL of 2.5% NaOCl for 30 s, followed by sonic activation of this solution with EndoActivator red tip size #25/0.04, inserted into the root canal 1 mm short of the WL, at 10,000 cpm/min. for 30 seconds. The EA polymer tip moved vertically from apical to coronal part of the canal during activation.
214955744|NCT00043563|BEHAVIORAL|Cognitive-Behavior Therapy|
214348116|NCT02578394|DRUG|Depo-Medrone 120mg and Placebo (Anakinra)|Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
214348117|NCT03086447|DEVICE|Investigational Contact Lens|Senofilcon C Toric
214348118|NCT03086447|DEVICE|Marketed Contact Lens|Air Optix for Astigmatism
214348119|NCT00217698|DRUG|cisplatin|
214348120|NCT00217698|DRUG|gefitinib|
214348121|NCT00217698|DRUG|gemcitabine hydrochloride|
214348122|NCT02006030|DRUG|ADI-PEG 20|
214348123|NCT02006030|DRUG|Transarterial chemoembolization|
214955745|NCT03373357|OTHER|Patient not SAHOS|"Phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.~* Cardiovascular events arisen during the duration of the study~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
214955746|NCT03373357|OTHER|Patient SAHOS sailed by the ventilation in PPC and not sailed|"Questionnaire of subjective evaluation of diurnal slumber: scale of Epworth and search for appearance of at least 2 of the following symptoms: sleep not salvage dealer, night-breathlessnesses, multiple awakenings, fatigue, disordersconfusions, nycturie, snore.~* Questionnaire of evaluation of the global quality of life of the SAHOS~* Appearance of new cardiovascular risk factors~* Cardiovascular events arisen during the duration of the study~* Modification of the current treatments~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
214955747|NCT06771102|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
214955748|NCT06771102|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
214955749|NCT04735796|DRUG|Drug：LM-102|Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.
214955750|NCT04869111|BEHAVIORAL|Brain Health Training|"1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.~3. Brain-Healthy Habits - daily reminders of habits you can track~4. BrainHQ - participants will gain temporary access to the exercise-based cognitive training of BrainHQ after completing their 3rd BrainHealth Index"
214955751|NCT05954936|OTHER|Risk factor|No therapeutic or diagnostic intervention will be provided; it is an observational study.
214955752|NCT04691206|OTHER|briefing objectives, intraoperative teaching, and debriefing feedback|A standardized step-wise operative curriculum amongst general surgeons will be implemented among all general surgery residents. Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID).
214348124|NCT00847873|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
214348125|NCT00847873|BEHAVIORAL|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
214348126|NCT03754023|DIAGNOSTIC_TEST|Urine-TIMP-IGFBP7 biomarker for AKI|Urine-TIMP-IGFBP7 biomarker for AKI
214348127|NCT04211103|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
214348128|NCT02790385|DEVICE|Negative Pressure Wound Therapy|
214348129|NCT02790385|OTHER|Standard Gauze Treatment|
214348130|NCT04382794|DRUG|Retrospective case-control analysis|Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
214348131|NCT03644979|OTHER|Skydiving|Tandem skydiving (with an experienced instructor)
214348132|NCT00955877|DRUG|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
214348133|NCT00955877|DRUG|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
214393575|NCT01306565|DRUG|High dose atorvastatin|80mg daily atorvastatin for 72 hours
214502573|NCT02309294|DEVICE|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
214502574|NCT02309294|DEVICE|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
214955753|NCT04039321|DRUG|ESPB group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
214348134|NCT00955877|DRUG|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
214348135|NCT01474135|DRUG|0.25% AR-12286 / 0.004% travoprost|
214348136|NCT01474135|DRUG|0.5% AR-12286, 0.004% travoprost|
214348137|NCT01474135|DRUG|0.004% Travoprost|
214348138|NCT04158401|DEVICE|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
214348139|NCT04793321|DEVICE|Baby carrier|"* It is made in china.~* It is made of Cotton-Polyester.~* It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~* It is suitable for newborn to 12-months baby~* It is available online at babyshopstores https://www.babyshopstores.com/"
214348140|NCT04793321|DEVICE|Biodex Balance System|"* The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~* It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~* The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance."
214348141|NCT04793321|OTHER|Infant mannequin|The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
214348142|NCT04793321|DEVICE|Biodex gait trainer 2 TM|"Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~* Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~* Heart Rate Monitoring~* Handrail~* Open Platform"
214348143|NCT04547972|OTHER|Higher-load resistance training|This intervention will have one arm and one leg of each participant training with \~80% of their one repetition maximum
214348144|NCT04547972|OTHER|Lower-load resistance training|This intervention will have one arm and one leg of each participant training with \~30% of their one repetition maximum
214955754|NCT04039321|DRUG|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
214955755|NCT00003418|DRUG|exemestane|
214955756|NCT00003418|DRUG|tamoxifen citrate|
214955757|NCT06820723|DRUG|CYB003|synthetic, deuterated isotopomer of psilocin
214955758|NCT06820723|DRUG|Placebo|Placebo orange drink solution
214348145|NCT02359721|DRUG|tablet clarithromycin 500 mg (Clarino-500) orally|orally
214678623|NCT00032019|DRUG|prednisone|60 mg/sq m PO bid days 1-5 of ea cycle
214678624|NCT00032019|DRUG|vincristine sulfate|0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
214955759|NCT05297929|DRUG|Irbesartan Tablet|Drug: Irbesartan Oral administration on an empty stomach／fed condition
214955760|NCT05543031|OTHER|Music-Integrated Phonological Awareness training program|We would like to observe the effect of the music integrated phonological awareness program on preschool cochlear implant users and to compare the phonological awareness skills of the study group with the control group before and after the online training. The program is prepared as 10 lessons. Participants were guided through online training for 5 weeks, with 20-minute sessions conducted weekly. The training was carried out via Zoom, a free virtual interview program. Each family had a computer.
214955761|NCT05543031|DIAGNOSTIC_TEST|Spectral-Temporally Modulated Ripple Test (SMRT)|Spectral-Temporally Modulated Ripple Test (SMRT) was used to assess the spectral discrimination ability of the study group.Speech stimuli were presented at a calibrated presentation level of 60 dB SPL in a quiet room. The child was positioned at 0° azimuth and 1-meter from the loudspeaker.
214955762|NCT05543031|DIAGNOSTIC_TEST|The Phonological Awareness Scale of Early Childhood Period (PASECP)|The Phonological Awareness Scale of Early Childhood Period (PASECP) was used to measure the sound awareness and sound discrimination skills of study group pre-post training. The test has 8 sub-dimensions.
214955763|NCT05543031|DIAGNOSTIC_TEST|Mismatch Negativity Test|Mismatch Negativity (MMN) was used to evaluate the central auditory system.The test was used for electrophysiological recordings of the study group.The standard stimulus presented as /ba/ (%80), and the rare stimulus presented as /da/ (%20) frequency. The onset (rise) and offset (fall) times of the stimuli are 10 ms, and the plateau time is 50 ms. The interval between stimuli for both responses was 1.1 ms. A 0.1-30 Hz filter was applied. The speech stimuli intensity was 70 dB SPL. Speech stimuli were presented at a 1-meter distance from the participant, with speakers placed at an angle of 0°.
214955764|NCT05543031|DIAGNOSTIC_TEST|Early Language Development (TELD-3)|Test of Early Language Development (TELD-3) measured children's receptive and expressive language skills both group for inclusion criteria.
214955765|NCT01994902|DEVICE|Coloplast test product|The Coloplast test product is a newly developed ostomy appliance
214955766|NCT01994902|DEVICE|SenSura Convex Light|The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
214348146|NCT01194141|BEHAVIORAL|Exercise training|aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
214678625|NCT01872741|PROCEDURE|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
214348147|NCT06045624|DRUG|OR-101 (Single ascending dose)|SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
214348148|NCT06045624|DRUG|OR-101 (Food effect)|Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
214348149|NCT06045624|DRUG|OR-101 (Multiple ascending dose)|MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
214348150|NCT06045624|DRUG|Placebo|Participants will receive matching placebo across Part A and C of the study
214955767|NCT05242133|DRUG|Pegylated interferon beta-1a|Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months
214955768|NCT05242133|DRUG|Interferon Beta-1A Prefilled Syringe|Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months
214955769|NCT06729944|DIAGNOSTIC_TEST|NGS|Tissue samples will be processed and analysed at the U.O. of Pathological Anatomy
214955770|NCT03419130|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
214955771|NCT03419130|OTHER|Laboratory Biomarker Analysis|Correlative studies
214955772|NCT03419130|BIOLOGICAL|Pembrolizumab|Given IV
214955773|NCT03419130|RADIATION|Radiation Therapy|Undergo conventionally fractionated RT
214955774|NCT04891627|DIAGNOSTIC_TEST|Gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
214955775|NCT06234527|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
214955776|NCT01065363|BEHAVIORAL|standardized exercise program and dietary counseling|Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
214955777|NCT05491863|OTHER|conservative physiotherapy plan|Physiotherapy plan consist of following exercises, Postural and Proprioceptive facilitation like weight-bearing actions for the upper and lower extremities. Sit to stand, standing , holding on to stand, free arms standing up, holding on standing and asked the patient to lift one leg, one leg standing, standing on balance board,Straight and sideways parallel bar walk, For the effected body side jumping on stable and dynamic surface,Upstairs and down stair activity performed on staircase.This program was given for 40 minutes with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
215078125|NCT02002936|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
214348151|NCT03394924|DRUG|EDP-305 1 mg|Two tablets daily for 12 weeks
214348152|NCT03394924|DRUG|EDP-305 2.5 mg|Two tablets daily for 12 weeks
214348153|NCT03394924|DRUG|Placebo|Two tablets daily for 12 weeks
214348154|NCT01842789|DEVICE|Acessa Procedure|Acessa Procedure
214348155|NCT03588572|DRUG|Venlafaxine hydrochloride capsules|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
214348156|NCT02783586|PROCEDURE|Quadratus Lumborum Block type II|Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
214348157|NCT02783586|PROCEDURE|Transversus Abdominalis Plane Block|Local anaesthetic injection between internal oblique and transversus abdominis muscle
214348158|NCT02783586|DRUG|Bupivacaine|20 ml of bupivacaine with adrenaline
214348159|NCT02783586|DEVICE|Ultraplex|A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
214348160|NCT00450424|OTHER|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
214502575|NCT02309294|DEVICE|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
214502576|NCT02309294|DEVICE|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
214955778|NCT05491863|OTHER|trunk stability exercise plan|"trunk stability exercise plan consist of three levels, Proprioception included supine abdominal draw was performed in 1st simple level ,3 sets per 20 repetitions were performed, A double knee to chest abdominal draw was performed with 3 sets per 20 repetition, Supine twist with 3 sets per 20 repetitions was performed.Balance training included pelvic bridging was 2nd complicated level performed with 3 sets per 4-6 repetitions,Twists with a medicine ball were performed with 3 sets per 10-20 repetitions.~for Stability Bridging with head lied on physio ball was performed in 3rd difficult level when holding the position for 4 to 6 seconds, then relaxed slowly for same time with 3 sets per 10 to 20 repetitions, Prone bridging was performed with 3 sets per 4 to 6 repetitions.~There was a 30 seconds to 1 minute break between the sets.This program was given for 1 hour with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)"
214955779|NCT01317524|DIETARY_SUPPLEMENT|Homogenized milk|900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
215078126|NCT00946725|DRUG|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
215078127|NCT00946725|DRUG|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
214348161|NCT00450424|OTHER|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
214348162|NCT00113438|DRUG|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
214678626|NCT01872741|PROCEDURE|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
214678627|NCT01673724|DRUG|pramipexole|pramipexole
214955780|NCT01317524|DIETARY_SUPPLEMENT|Unhomogenized milk|900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
214955781|NCT01317524|DIETARY_SUPPLEMENT|Skimmed Milk|900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
214955782|NCT03295175|DIAGNOSTIC_TEST|Hematoxylin-eosin and smooth muscle actin markers|"The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~1. Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~2. Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present."
214955783|NCT00596999|PROCEDURE|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
214955784|NCT03552042|BEHAVIORAL|Counterclockwise program|A group of older adults (aged 75+) will take part of a residential role-play game, in which they will relive their previous self, acting as if they were in the year 1989. The whole residential program, which will last one week, is designed to enhance this perception, including a retrofitted environment and social activities that will prime participants to relive that period.
214955785|NCT03552042|BEHAVIORAL|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
214955786|NCT02247271|BEHAVIORAL|Diabetes health coach support|Receives support from a trained peer health coach for a six month period
214955787|NCT02197442|DRUG|Valsartan|
214955788|NCT01343992|BEHAVIORAL|Bed rest|Patients will rest in bed ten minutes after the embryo transfer.
214955789|NCT01343992|BEHAVIORAL|No bedrest|Patients will not rest in bed after the embryo transfer.
214955790|NCT00467402|DRUG|agomelatine|
214955791|NCT00467402|DRUG|placebo|
214955792|NCT02529098|OTHER|fMRI|functional magnetic resonance imaging
214955793|NCT00467558|DRUG|Naltrexone|daily
214955794|NCT00467558|DRUG|Sugar pill|daily
214955795|NCT04679948|DRUG|Percoffedrinol®|Tablet
214955796|NCT04679948|DRUG|Coumadin®|Tablet
214955797|NCT04679948|DRUG|Antra MUPS®|Gastro-resistant tablet
214955798|NCT04679948|DRUG|Midazolam-ratiopharm®|Oral solution
214955799|NCT04679948|DRUG|BI 730357|Film-coated tablet
214955800|NCT00650286|DRUG|Modafinil Tablets 200 mg|200mg, single dose fed
214955801|NCT00650286|DRUG|Provigil® Tablets 200 mg|200mg, single dose fed
214955802|NCT02636439|BEHAVIORAL|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
214955803|NCT02636439|BEHAVIORAL|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
214955804|NCT00002267|DRUG|Rifabutin|
214955805|NCT03345888|OTHER|predictive power of end-tidal carbon dioxide|end-tidal carbon dioxide predicts resuscitation outcomes
214955806|NCT02371668|BIOLOGICAL|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
214955807|NCT02371668|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
214955808|NCT00002479|DRUG|tretinoin|
214955809|NCT00800111|PROCEDURE|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
214955810|NCT03361735|DRUG|Leuprolide Acetate|Intramuscular or subcutaneous injection
214955811|NCT03361735|DRUG|Goserelin Acetate|Subcutaneous injection
214955812|NCT03361735|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214955813|NCT03361735|RADIATION|Radium Ra 223 Dichloride|Given IV
214955814|NCT03361735|OTHER|Laboratory Biomarker Analysis|Correlative studies
214955815|NCT03361735|DRUG|Degarelix|Subcutaneous injection
214955816|NCT06956105|DEVICE|Modius Calm|The Modius Calm device is a transdermal neurostimulation product. It consists of a battery-powered headset designed to deliver low-level energy in the form of a neurostimulation waveform that modulates the activity of the vestibular cranial nerve. The active Modius Calm device utilizes a technology called electrical vestibular nerve stimulation (VeNS). In the envisaged configuration the device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current (a maximum of 1.5mA) to the skin behind the ears over the mastoid processes.
214955817|NCT06956105|DEVICE|Sham device|The sham device is identical in appearance. The Modius Calm sham device follows this pattern by applying some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device.
214955818|NCT04433923|DEVICE|Phototherapy with aluminum foil|
214955819|NCT04433923|DEVICE|Phototherapy without aluminum foil|
214348163|NCT01510847|DRUG|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
214955820|NCT00762034|DRUG|Pemetrexed|Induction therapy 500 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
214955821|NCT00762034|DRUG|Pemetrexed|Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
214955822|NCT00762034|DRUG|Paclitaxel|Induction therapy 200 mg/m\^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
214955823|NCT00762034|DRUG|Carboplatin|Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
214955824|NCT00762034|BIOLOGICAL|Bevacizumab|Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
214348164|NCT00006060|DRUG|standard gadolinium contrast|
214348165|NCT02386566|DRUG|natalizumab|As described in the treatment arm
214955825|NCT00762034|BIOLOGICAL|Bevacizumab|Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
214955826|NCT02671552|DRUG|Perflutren Protein-Type A Microspheres|Given IV
214955827|NCT02671552|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
214955828|NCT01225926|DEVICE|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
214955829|NCT01225926|DEVICE|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
214348166|NCT00364858|DRUG|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
214348167|NCT03149783|DRUG|Ropivacaine HCL|Ropivacaine injected after placement of catheters, then infused during the operation
214348168|NCT03149783|DRUG|sodium chloride|Placebo
214348169|NCT06534788|OTHER|Reciprocal Inhibition MET|Reciprocal Inhibition MET will be applied to the shortened piriformis muscle in supine and prone positions with participants using 30-50% of their maximum voluntary isometric contraction. It will include 30-50% isometric contraction of the muscle opposite to the muscle to be stretched for 7-10 seconds, followed by inhalation, exhalation and rest period of 5 seconds and then a stretch (through the new barrier with patients' assistance) of 10-60 seconds hold. RI-MET group will receive 3-5 repetitions.
214955830|NCT06485570|OTHER|creative drama training|"The trainings prepared by the researcher in line with the literature information on Environmental Theory, Self-Care Disability Theory and Adaptation Model will be carried out in 3 sessions with creative drama teaching method to the experimental group. The trainings will be planned in the classroom environment for 4 weeks and 2 lesson hours (100 minutes) for each session. At the end of the trainings, Knowledge Measurement Questionnaire and Perception of Nursing Profession Scale will be applied to the participants as a post-test to measure their level of knowledge about nursing theories. In the third stage of the study, semi-structured interviews will be conducted with the students from the experimental group after the applications in order to reveal the participants' views on teaching methods."
214955831|NCT06485570|OTHER|control|control group
214955832|NCT06154720|DRUG|Antibiotics|After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
214348170|NCT06534788|OTHER|Post-facilitation MET|Post-facilitation stretch technique for shortened piriformis muscle in supine and prone positions will be applied with participants using 20% of their maximum voluntary isometric contraction. It will include 20% maximal isometric contraction of the muscle to be stretched for 6-10 seconds, followed by a rapid stretch (through the new barrier) of 15 seconds hold. After stretch, the muscle is allowed to relax in the midrange for up to 30 seconds. PFS-MET group will receive 3-5 repetitions.
214502577|NCT04874259|PROCEDURE|Living donor liver transplantation|Living donor liver transplantation
214955833|NCT01956188|DIETARY_SUPPLEMENT|EPA and DHA supplementation|Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
214955834|NCT01956188|DIETARY_SUPPLEMENT|Placebo|Subjects will be given 3g/d of soy oil - 5 capsules per day.
214955835|NCT03351634|DEVICE|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck|The ACT system is a permanent implant designed for the correction of incontinence in patients.
214955836|NCT06480019|BEHAVIORAL|Interpersonal psychotherapy|Interpersonal psychotherapy is a first-line treatment and can also be used for the prevention of depression.
214955837|NCT05977855|OTHER|BPSDiary|The BPSDiary is a diary to register severity, hour, day and triggers of a number of BPSD (namely, agitation, aggression, delusions/hallucinations, insomnia, aberrant motor behavior).
214955838|NCT04198909|DIAGNOSTIC_TEST|Electrocochleography, electrophysiology thet for analyse the wave I generated by the auditory pathways|Electrocochleography is a technique that analyses the functionality of inner ear.
214955839|NCT06291129|PROCEDURE|Periodontal therapy|Supragingival scaling sessions were performed with ultrasonic scalers (Dabi Atlante, Rio de Janeiro, RJ, Brazil) to remove all calculus and biofilms, in addition to oral hygiene guidelines, including brushing technique and interdental cleaning with dental floss.
214348171|NCT06534788|OTHER|Conventional physical therapy|"TENS and hot pack application to provide heating effect over the painful area (10 minutes) Both groups will receive conventional physical therapy which they will be taught as a home plan. Following exercises are guided to the patient as home plan.~* Resisted abduction with Thera/resistance band~* Resisted bridging with Thera/resistance band~* Resisted clam exercise with Thera/resistance band"
214348172|NCT05904847|BEHAVIORAL|Application of The Theory of Planned Behaviour for Diabetes|In the study, diabetes education consisting of a total of 4 sessions structured according to the Planned Behavior Theory will be applied to the intervention group, and a standard diabetes education consisting of a single session containing information about diabetes on the website of the Ministry of Health will be applied to the control group. The training will be given face-to-face in groups of 10-15 people. After the training, the participants will be monitored for 3 months. To increase patient empowerment and self-efficacy, the intervention group will be followed up by phone calls every 15 days to increase motivation and answer questions.
214348173|NCT00201383|DRUG|cisplatin|
214348174|NCT01250860|OTHER|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
214348175|NCT01250860|BEHAVIORAL|Sham therapy|
214348176|NCT05517343|OTHER|Real-time endoscopic optical diagnosis|The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
214348177|NCT05882851|BEHAVIORAL|determination of the current nutritional status of patients|No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
214348178|NCT05430412|DEVICE|Adacolumn|The study will consist of 10 sessions of Adacolumn® treatment (once per week) and a follow-up period (from week 12 to week 40 since study inclusion).
214348179|NCT00627705|DRUG|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
214348180|NCT00627705|OTHER|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
214348181|NCT05253898|PROCEDURE|Pelvic floor Physical Therapy|Purpose of pelvic floor muscle education program is reduce the symptoms of stress urinary incontinence and improving quality of life.
214348182|NCT05253898|PROCEDURE|Therapeutic Yoga Training|Purpose of this group show the effectiveness of yoga therapy on stress urinary incontinence and quality of life.
214348183|NCT05812261|OTHER|Creating an electro-anatomical map|After the routine pulsed-field ablation procedure, the operator will create an electro-anatomical map using the ablation catheter and a 3D mapping system.
214348184|NCT03937167|OTHER|Psychotherapy group|Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
214348185|NCT06387043|OTHER|Balance exercises with Virtual Reality Glasses|Balance exercises with Virtual Reality Glasses
214348186|NCT06387043|OTHER|Balance Exercises with Stroboscopic Glasses|Balance Exercises with Stroboscopic Glasses
214348187|NCT06387043|OTHER|Balance Exercises with Visual-Based Metaphor Training|Balance Exercises with Visual-Based Metaphor Training
214348188|NCT06387043|OTHER|Traditional Balance Exercises|Traditional Balance Exercises
214348189|NCT03151434|DRUG|US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)|Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
214348190|NCT03151434|DRUG|US Guided Paravertebral Catheter (0.2% ropivicaine bolus)|Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
214348191|NCT03151434|DRUG|Thoracic Epidural (0.125% bupivicaine/hydromorphone)|Epidural catheter will be placed in the thoracic region prior to surgery.
214348192|NCT00265057|DRUG|ADH -1 (Exherin™)|
214348193|NCT04108312|DIAGNOSTIC_TEST|Anatomical MRI Scan|T1-weighted (T1w) magnetization prepared rapid gradient echo (MPRAGE) sequence (TR=8.776 milliseconds, TE=3.656 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution) and T2-weighted (T2w) CUBE sequence (TR=61.803 milliseconds, TE=3200 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution)
214955840|NCT05992402|BEHAVIORAL|ReBOOT program|This is a virtual cognitive intervention led by a clinical neuropsychologist. Participants will attend 2 one-on-one individual sessions and 4 group sessions prior to their epilepsy surgery. Groups will be made up of 3-10 participants. The intervention is designed to provide participants with information about possible changes and/or challenges they may experience after epilepsy surgery, as well as cognitive strategies to implement prior to surgery to increase effectiveness of compensation for any new cognitive difficulties that may be experienced following surgery.
214955841|NCT00437476|DRUG|LPV/r|Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
214955842|NCT00437476|DRUG|Nucleoside Reverse Transcriptase Inhibitors|NRTIs for 26 weeks (A) or 24 weeks (B)
214955843|NCT00437476|DRUG|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week (48 weeks)
214955844|NCT00437476|DRUG|Ribavirin|Ribavirin 1-1.2 g/day (48 weeks)
215078128|NCT04447599|OTHER|photography of conjunctival vessels|patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
215078129|NCT00106600|DRUG|Pixantrone IV infusion|
215078130|NCT01689623|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
214348194|NCT00438386|DRUG|Aripiprazole|
214348195|NCT04696796|PROCEDURE|Mediolateral Episiotomy with BasIQ-4 Surgical Knife|Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.
214678628|NCT01673724|DRUG|Bromocriptine|bromocriptine
214348196|NCT04696796|PROCEDURE|Mediolateral Episiotomy with Episiotomy Scissors|Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
214348197|NCT02269293|DRUG|Paclitaxel|
214348198|NCT02269293|DRUG|Carboplatin|
214348199|NCT02269293|DRUG|Selinexor|
214348200|NCT04590703|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
214348201|NCT04590703|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
214348202|NCT04105023|DIETARY_SUPPLEMENT|genistein|Administered orally once every 12 hours
214348203|NCT04105023|DIETARY_SUPPLEMENT|Placebo|Administered orally once every 12 hours
214348204|NCT06193993|DRUG|Abiraterone Acetate|Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.
214348205|NCT02142049|DRUG|Ibrutinib|Ibrutinib
214348206|NCT02142049|DRUG|DA-EPOCH-R|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
214955845|NCT02306369|BEHAVIORAL|Internetdelivered exposure-based CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, and adapted for adolescents and their parents. The feasibility of the treatment were tested in a pilot study during 2012. Components in the treatment are exposure for symptoms and parent training. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
214955846|NCT02083796|PROCEDURE|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
214955847|NCT02083796|PROCEDURE|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
214955848|NCT02083796|PROCEDURE|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
214955849|NCT02083796|PROCEDURE|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
214955850|NCT02217111|BEHAVIORAL|Adventures in Voice: Pediatric Voice Therapy|
214955851|NCT05496465|DRUG|ARS-1|A single treatment of ARS-1.
214955852|NCT05496465|DRUG|Placebo|A single treatment of placebo nasal spray
214955853|NCT01031017|DRUG|progesterone|ovules, 200mg per vagina, once a day from 18 weeks
214955854|NCT01031017|DRUG|placebo|placebo
214348207|NCT02142049|DRUG|Lenalidomide|Lenalidomide
214348208|NCT00186303|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
214955855|NCT06323343|OTHER|Video Intervention|Animated video delivered by text message to prepare parents to communicate with physicians at their upcoming appointment for a fetal anomaly concern.
214348209|NCT00186303|PROCEDURE|ablative allogeneic hematopoietic cell transplant|
214348210|NCT02501460|OTHER|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
214348211|NCT02501460|OTHER|Resistance training|"Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed."
214348212|NCT02501460|DIETARY_SUPPLEMENT|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
214348213|NCT02501460|OTHER|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
214348214|NCT00427050|DRUG|PEP005|
214348215|NCT02535065|DEVICE|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
214348216|NCT00748046|DRUG|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
214955856|NCT06323343|OTHER|Webpage links|Links to publicly available webpages about the fetal concerns clinic where the participants' appointments are scheduled.
214955857|NCT02652559|DEVICE|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
214955858|NCT02652559|DEVICE|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
214955859|NCT02652559|DEVICE|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
214348217|NCT05450432|DRUG|Ketamine|Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
214348218|NCT05450432|DRUG|Esketamine|After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
214348219|NCT04763122|OTHER|not applicable as it is a retrospective study|It is a retrospective study
214348220|NCT01601587|OTHER|A psychoeducational group intervention.|"The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:~1. What is mental health?~2. Treatment options: orientation about individual and group based treatment modalities.~3. Former patients experience with their own treatment, self-help and participation.~4. How to influence and participate actively in the treatment and patient rights.~5. What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?"
214348221|NCT05034692|PROCEDURE|Total laparoscopic with intracorporeal anastomosis by overlap method|After the intestinal canal was dissociated and vascularized, the intestinal canal was nuded and cut off, and the distal and proximal intestinal canals were overlapped by 6 cm
214348222|NCT05034692|PROCEDURE|Laparoscopic-assisted colectomy with extracorporeal anastomosis|After the corresponding colon and blood vessels were dissociated and treated, the carbon dioxide pneumoperitoneum was removed. The appropriate length of the incision was cut at the corresponding position of the abdomen, and the incision protector was placed. The tumor was lifted together with the free intestinal canal to the outside of the abdomen. The intestinal canals at the quasi-dismembered sites on both sides of the tumor were nuded, and the colon-colon functional end-to-end anastomosis was performed.
214955860|NCT02652559|OTHER|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
214955861|NCT02652559|OTHER|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
214955862|NCT00152243|DRUG|UFT (uracil, tegafur)|uracil-tegafur 360 mg per square meter per day orally 16 months
214955863|NCT00152243|PROCEDURE|Surgery alone|Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
214348223|NCT00974857|DEVICE|BCM|Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
214955864|NCT04255758|OTHER|Cycle Ergometer Exercise|25 minutes, 70% VO2max steady state cycle ergometry exercise
214955865|NCT03747718|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
214955866|NCT03747718|OTHER|Placebo|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
214955867|NCT03769701|PROCEDURE|self-monitoring capillary glucose (SMCG)|To measure the capillary glucose with a glucometer according to the assigned group.
214955868|NCT01299896|OTHER|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
214955869|NCT01299896|OTHER|Usual Care|Standard therapy to help participants with smoking cessation.
214955870|NCT04663932|PROCEDURE|immediate stenting group(one-step strategy)|Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
214955871|NCT04663932|PROCEDURE|deferred stenting group (two-step strategy)|Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
214955872|NCT03181945|OTHER|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
214955873|NCT03181945|OTHER|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
214955874|NCT05911789|RADIATION|Online adaptive radiation therapy|A dose of 45Gy will be delivered to planning target volume (PTV)
214348224|NCT00974857|OTHER|control group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
214348225|NCT05892354|DIETARY_SUPPLEMENT|Enteral immunonutrition|Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.
215078131|NCT01689623|DRUG|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
215078132|NCT01689623|DRUG|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
215078133|NCT04090034|PROCEDURE|Peptide Receptor Radionuclide Therapy|a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
215078134|NCT02749942|DEVICE|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
215078135|NCT02749942|DEVICE|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
214348226|NCT05892354|DIETARY_SUPPLEMENT|Standard enteral nutrition|Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
214348227|NCT00110617|DRUG|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
214348228|NCT00110617|DRUG|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
214348229|NCT03297840|BEHAVIORAL|Dialectical Behavioural Therapy (DBT)|Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
214348230|NCT01781572|DRUG|LEE011|LEE011 will be administered orally once daily
214348231|NCT01781572|DRUG|MEK162|MEK162 will be administered orally twice daily
214348232|NCT00454558|DRUG|Riociguat (Adempas, BAY63-2521)|Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
214348233|NCT01438866|OTHER|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
214348234|NCT01438866|OTHER|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
214348235|NCT00240318|DRUG|Rosuvastatin calcium|
214348236|NCT04937569|DRUG|Ivermectin Tablets|4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast
214348237|NCT02084966|PROCEDURE|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
214348238|NCT00045110|DRUG|erlotinib hydrochloride|given orally
214348239|NCT00045110|OTHER|laboratory biomarker analysis|correlative studies
214348240|NCT00045110|OTHER|pharmacological study|correlative studies
214955875|NCT03139409|PROCEDURE|adhesive bond with chlorhexidine|Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries
214955876|NCT03139409|OTHER|Time variable|Diagnosis and follow up will be immediate , 6 months later and 1 year
215078136|NCT01024491|DRUG|paroxetine|daily dose of paroxetine 15mg for 12 weeks
215078137|NCT01024491|DRUG|paroxetine|active daily treatment with paroxetine 20 mg
215078138|NCT01024491|DRUG|placebo|active daily treatment with placebo
214348241|NCT02367261|DEVICE|SPI implant|SPI implant - the original spiral implant
214348242|NCT02591654|DRUG|Pembrolizumab|Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.
214348243|NCT02591654|DRUG|FLT PET|FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
214348244|NCT05149274|DRUG|DWP14012 Tablet A|DWP14012 10mg
214348245|NCT05149274|DRUG|DWP14012 Tablet B|DWP14012 40mg
214348246|NCT03567538|PROCEDURE|Thoracic surgery|Thoracic surgery, pulmonary resection, minimally invasive thoracic surgery, video assisted thoracic surgery (VATS)
214348247|NCT06412276|BEHAVIORAL|Control|Food menu will be provided as is typical for the out of home outlet
215078139|NCT02130336|BEHAVIORAL|Aerobic interval training|
215078140|NCT02130336|BEHAVIORAL|Continuous moderate-intensity exercise|
215078141|NCT04901442|DEVICE|Aetrex L700 Speed orthotic|An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
215078142|NCT00996281|DRUG|Azilsartan medoxomil and chlorthalidone|Combination tablet.
214348248|NCT06412276|BEHAVIORAL|Product price promotions removed|Food menus with no price reductions to products
214348249|NCT06412276|BEHAVIORAL|Bulk buy reductions removed|Food menus with bundles provided but not at reduced prices
214348250|NCT06412276|BEHAVIORAL|Volume value pricing removed|Food menus with proportionate pricing for multi-size products
214348251|NCT06412276|BEHAVIORAL|No price-based incentives|Food menus with no price-based incentives offered
214348252|NCT04679129|DRUG|ASC42|Oral tablets
214348253|NCT04679129|DRUG|Placebo|Oral tablets
215078143|NCT00996281|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
215078144|NCT06294938|OTHER|Cacao fruit pulp|Cacao pulp puree
215078145|NCT06294938|OTHER|Dextrose|Dextrose beverage
215078146|NCT00403533|DRUG|20 mg of atorvastatin daily|
215078147|NCT01235923|DRUG|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
215078148|NCT01235923|DRUG|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
215078149|NCT04844658|DIETARY_SUPPLEMENT|NASAFYTOL®|Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
215078150|NCT04844658|DIETARY_SUPPLEMENT|FULTIUM® -D3 800|Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
214348254|NCT02438241|PROCEDURE|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
214348255|NCT02438241|PROCEDURE|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
214348256|NCT02438241|PROCEDURE|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
214348257|NCT05087940|DRUG|Add-on therapy|Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
214348258|NCT05450289|DRUG|Nigella Sativa Oil|In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
214348259|NCT05450289|DRUG|Allergen Specific Immunotherapy|In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
214348260|NCT05450289|DRUG|Standard pharmacotherapy|Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
214348261|NCT04431102|OTHER|PILATES METHOD|"It is intended that the Pilates program have a duration of four weeks and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule. In this sense the sessions of Pilates is adjusted to these assumptions and the Pilates monitor offers several schedules on diferent days of week.~The pregnant women assigned to the intervention group will be supervised by the midwifery of reference and trained by a Pilates monitor who will explain the training program and resolve the doubts raised by the women.~The therapeutic control will be carried out by telephone call and clinical history review between the eighth and tenth day."
214348262|NCT00102791|DRUG|ICA-17043|
214955877|NCT03817905|OTHER|Patient navigator|Intervention will utilize staff at the Seidman Cancer Center who are trained in patient navigation and have experience in navigating patients for breast cancer screening as well as sickle cell disease. The staff will undergo training for this study by study principal investigators which will include the target participant population, necessary steps in the navigation process and data that will be collected. In addition, they will receive brief training in supportive, listening technique. They will also be furnished with a telephone script for the initial participant contact.
215078151|NCT04844658|DRUG|Strandard of care treatment|Strandard of care treatment for Covid-19 infection
214348263|NCT00663312|BEHAVIORAL|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
214348264|NCT02133846|DRUG|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
214348265|NCT02133846|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
215078152|NCT03402971|DIAGNOSTIC_TEST|echocardiography|echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
214348266|NCT02133846|DRUG|Placebo|500mL 0.9% sodium chloride
214348267|NCT02133846|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
214348268|NCT06296719|OTHER|Chit-Chat|Participants will receive the 2 sessions of the Chit-Chat intervention on a weekly basis.
214348269|NCT00189631|PROCEDURE|UFT/LV|
214348270|NCT00189631|PROCEDURE|Observation|
214348271|NCT00178490|DRUG|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
214348272|NCT00931073|DRUG|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
215078153|NCT00504855|OTHER|Casting using Gortex (waterproof) cast padding materials|
215078154|NCT00504855|OTHER|Casting using cotton/cotton-poly cast padding materials|
215078155|NCT04022681|OTHER|BALLETS|Cohort were not exposed to any intervention. There information will be analysed from database searches.
215078156|NCT03236259|DIETARY_SUPPLEMENT|Brainport high dose|berry extract, high dose. Daily ingestion of capsule
214955878|NCT01586702|BEHAVIORAL|Patient centered structured support program|"Behavioural: Structured support program~Program with up to 8 outpatient appointments focusing on:~* Measurement of risk factors~* Assessment of medication intake~* Monitoring of antithrombotic therapy~* Joint agreement of an individual target plan~Target values for risk factors:~* Blood pressure \< 140/85 mmHg (\<130/80 in diabetics), normal circadian profile~* HbA1c \<7.5%~* Nicotine abstinence~* LDL \< 100mg/dl (\< 70mg/dl in high risk patients)~* Physical activity ≥ 30min \>2 x / week~Targets for pharmaceutical treatment:~* Platelet inhibitors for strokes / TIA of arterial etiology~* Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis~* Cumarins (INR 2-3) or new oral anticoagulants in AF patients~* Statin treatment in patients with LDL \>100mg/dl~Intervention strategies:~• According to Motivational Interviewing"
214955879|NCT03848897|OTHER|Metrology of motor behavior|Biomechanical, physiological, psychological and behavioral analyses
214955880|NCT02688803|DRUG|Dose dense AC-P|(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
214955881|NCT02688803|DRUG|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
214955882|NCT02688803|DRUG|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
214955883|NCT03116295|DRUG|Opicapone (OPC)|Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).
214955884|NCT05161026|OTHER|Bone osteodensitometry|Evaluation of bone osteodensitometry
214955885|NCT06364436|BEHAVIORAL|Reiki energy therapy|In order to perform distance Reiki application, the practitioner must have completed Reiki II level training according to the Traditional Usui Reiki system and must be attuned by a person with a Usui Reiki Master and Teacher degree. With harmony, the energy channels in the individual's body are opened and the harmonious individual becomes a tool of universal healing energy.
214955886|NCT02107313|DRUG|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
214955887|NCT02107313|DRUG|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
214955888|NCT03067922|OTHER|Non interventional study|Not applicable. No intervention will be done. it is an observational study assessing pain after mastectomy and the quality of life as assessed from validated questionnaires given to the patients at regular intervals
214955889|NCT04515277|DIETARY_SUPPLEMENT|40 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
214955890|NCT04515277|DIETARY_SUPPLEMENT|20 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
214955891|NCT04515277|DIETARY_SUPPLEMENT|0 g Gum acacia (FibregumTM)|300 mL of orange juice with breakfast (single use at visit)
214955892|NCT01913574|DEVICE|Acupuncture|Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
214955893|NCT01913574|PROCEDURE|Neurolytic celiac plexus block (NCPB)|An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
214955894|NCT02357745|PROCEDURE|Non surgical periodontal therapy|scaling and root planing
214955895|NCT06322277|OTHER|Analysis of biological sample|Confermation of type of infection with RT-PCR.
214955896|NCT02796521|OTHER|dietary counseling|Patients received individualized nutritional counseling encouraging them for enrichment
214955897|NCT02796521|OTHER|nutritional workshop with enrichment during a meal|Patients received in group nutritional informations for enrichment and are encouraged to try enrichment together during a meal.
214955898|NCT02712918|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.
214955899|NCT02712918|OTHER|Standard Care|Treatment as usual at the ward
214955900|NCT04098796|DRUG|Anti-PD-1 antibody|Sintilimab will be administered 200 mg intravenous drip, every 3 weeks. Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years.
214955901|NCT04098796|DRUG|XELOX|Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
214955902|NCT03222453|BIOLOGICAL|Hematopoetic stem cells|Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells
214955903|NCT00950729|PROCEDURE|Driving with running shoes|Participant was asked to do all the experiments with their own running shoes
214955904|NCT00950729|PROCEDURE|Plaster cast|The participant was ask to do all the experiments with a plaster cast molded on his right leg
214955905|NCT00950729|PROCEDURE|Driving with Aircast|The participant was ask to do all the experiments with a aircast on his right leg
214955906|NCT03295032|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention; in this study it is being delivered as a 4-week psycho-educational group to stroke survivors and carers.~Rather than attempting to control or ameliorate pain and suffering, ACT advocates that individuals remain open to internal private experiences (both positive and negative) and should focus on committing to a life which is congruent with their core values. Individuals learn to modify their relationship with these experiences, rather than change the experiences per se through processes such as mindfulness, acceptance and attention to values. This fundamental premise of ACT helps cultivate psychological flexibility."
215078157|NCT03236259|DIETARY_SUPPLEMENT|Brainport low dose|Berry extract, low dose. Daily ingestion of capsule
215078158|NCT03236259|DIETARY_SUPPLEMENT|Placebo|Maltodextrin. Daily ingestion of capsule
215078159|NCT06102135|DIETARY_SUPPLEMENT|Peptamen 1.3 PHGG|The amount of tube feed will be assess by the health Care Professional.
215078160|NCT00897403|OTHER|biologic sample preservation procedure|
215078161|NCT00897403|PROCEDURE|diagnostic colonoscopy|
214955907|NCT02085928|OTHER|Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching|"* The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).~* The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.~* The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon."
214955908|NCT05686460|BEHAVIORAL|ice massage|"After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. The Hegu point of the participating students was detected with the acupuncture point finder. Ice cubes whose dimensions were 2x2x2 cm were wrapped with gauze and placed in a plastic bag. Vaseline® jelly was spread on the application area. The application applied 2 minutes of ice massage 7 times at 15-second intervals. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test).~On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS)."
214955909|NCT05686460|BEHAVIORAL|music medicine|After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The volume of the music was adjusted based on the verbal feedback or facial expressions of the students. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test). On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).
214955910|NCT04297696|OTHER|Therapeutic exercises|A program including warm-up period and neuromuscular exercises is applied progressively in two phases.
214955911|NCT05573178|PROCEDURE|cardiac ganglion plexus ablation(cardioneuroablation)|Under the guidance of three-dimensional system, the located ganglion plexus was ablated with saline irrigating electrode. The upper limit of power was 40W, the upper limit of temperature was 43 ℃, and the washing rate of saline was 17ml/min. The site of vagal reaction during ablation was defined as the effective ablation site. The surgical end point of denervated interventional therapy is defined as the disappearance of vagal response at the effective ablation site or the ablation of each effective point discharge for at least 30 seconds.
214955912|NCT02561546|DRUG|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
214955913|NCT02561546|DRUG|Trans-catheter embolization|Trans-catheter embolization alone
214955914|NCT03745248|BEHAVIORAL|Aerobic training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 1 month
214955915|NCT03745248|BEHAVIORAL|Balance Training|Standard of care
214955916|NCT06788275|BEHAVIORAL|Aerobic exercise (MIT)|Patients allocated to the MIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will cycle continuously between the first and second ventilatory thresholds. The duration of each exercise session will be set according to the estimated energy expenditure of the long HIIT and short HIIT groups for each training block (energy expenditure-adjusted exercise sessions). All sessions will be supervised, and patients will be asked to avoid additional exercise. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
214955917|NCT06788275|BEHAVIORAL|Aerobic exercise (Short HIIT)|Patients allocated to the Short HIIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-repetition sets of 1-min above the second ventilatory threshold. Patients will perform 1- and 3-min active recovery periods below the first ventilatory threshold between repetitions and sets, respectively. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
214955918|NCT06788275|BEHAVIORAL|Aerobic exercise (Long HIIT)|Patients allocated to the Long HIIT will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-min high-intensity exercise bouts above the second ventilatory threshold separated by 4-min active recovery periods below the first ventilatory threshold. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
214955919|NCT06103071|PROCEDURE|Sweeping of membranes|After informed consent all the patients in interventional group will have sweeping of membranes from 37 weeks of pregnancy . It will be repeated weekly till 40 weeks.
215078162|NCT04640558|DEVICE|Muscle strength measurement|The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
215078163|NCT01920568|BIOLOGICAL|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
215078164|NCT01920568|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
215078165|NCT01920568|DRUG|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
214348273|NCT00931073|DRUG|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
214348274|NCT00931073|DRUG|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
214348275|NCT04638790|DRUG|Doxorubicin|25 mg/m2 i.v. day 1,15 for ABVD/AVD
214348276|NCT04638790|DRUG|Bleomycin|10,000 units/m2 i.v. days 1,15 for ABVD
214348277|NCT04638790|DRUG|Vinblastine|6 mg/m2 i.v. days 1,15 for ABVD/AVD
214348278|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. days 1,15 for ABVD/AVD
214348279|NCT04638790|DRUG|Etoposide|100 mg/m2 i.v. days 1-3
214348280|NCT04638790|DRUG|Doxorubicin|50 mg/m2 i.v. day 1 for EACODD-14
214348281|NCT04638790|DRUG|Cyclophosphamide|650 mg/m2 i.v. day 1
214348282|NCT04638790|DRUG|Vincristine|1,4 mg/m2 i.v. day 8
214348283|NCT04638790|DRUG|Dexamethasone|20 mg i.v. days 1-3
214348284|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. day 1 for EACODD-14
214348285|NCT02441452|OTHER|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
214348286|NCT04191902|BEHAVIORAL|orientation|patients will be oriented
214348287|NCT06663995|DRUG|Study Group|"It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy"
214348288|NCT06663995|DRUG|Control (placebo) group|"After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing)."
214348289|NCT06662604|BIOLOGICAL|Bone marrow stem cells concentrate , platelet rich fibrin , bone graft|All participants will be treated with Bone marrow stem cells concentrate , platelet rich fibrin , bone graft.
215078166|NCT01920568|DRUG|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
214348290|NCT06662604|BIOLOGICAL|platelet rich fibrin and bone graft|All participants will treated with platelet rich fibrin PRF , bone graft.
214348291|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.
214348292|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients also in this group remained in supine lying position. Median nerve mobilization was performed by placing the scapula in a depressed position with one hand while placing the elbow in 90° flexion, forearm in supination, and wrist and fingers in extension with the other hand. Then, the therapist passively abducted the shoulder into 90- 100° and available external rotation ROM of the arm. Then from this position, the therapist extended the elbow with or without contra lateral side bending of the neck (tensioner or slider technique, respectively). Patients performed 30 repetitions of slider median nerve mobilization by performing elbow extension and wrist extension, with the neck placed in ipsilateral side bending or performing elbow flexion and wrist flexion with the neck placed in contralateral side bending. \[35\]. Tensioner technique was performed by applying simultaneous elbow extension with contralateral side bending of the neck and hold for 15 sec and relax for 10 sec .
214348293|NCT06664658|PROCEDURE|peep 5|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
214393576|NCT00696085|BEHAVIORAL|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
215078167|NCT01920568|DIETARY_SUPPLEMENT|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
215078168|NCT01920568|DIETARY_SUPPLEMENT|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
215078169|NCT01517165|DRUG|Pioglitazone|
215078170|NCT01517165|DRUG|Placebo|
214955920|NCT00762190|DRUG|TAK-559 and insulin|TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
214955921|NCT00762190|DRUG|Insulin|TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
214955922|NCT05122780|PROCEDURE|Coronary angiography|coronary angiography will be performed via the transradial or transfemoral approach with the use of a 6F sheath. Coronary angiography will be performed within 90 minutes from hospital admission in patients presenting with persistent ST-segment elevation, and within 48 hours in patients presenting with non-ST-segment elevation. Unfractionated heparin (initial weight-adjusted intravenous bolus of 60 IU/Kg, with repeat boluses to achieve an activated clotting time of 250 to 300 seconds) was administered in all patients. If evidence of plaque rupture
214955923|NCT05122780|DIAGNOSTIC_TEST|OCT imaging|"OCT imaging will be performed in the culprit artery in all patients randomized to the precision medicine approach. A 0.014-inch guidewire will be placed distally in the target vessel and an intracoronary injection of 200 µg of nitroglycerine will be performed. Frequency domain OCT (FD-OCT) images are acquired by a commercially available system (C7 System, LightLab Imaging Inc/ St Jude Medical, Westford, MA) connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/ St Jude Medical, Westford, MA), which was advanced to the culprit lesion. The FD-OCT run will be performed using the integrated automated pullback device at 20 mm/s. During image acquisition, coronary blood flow will be replaced by continuous flushing of contrast media directly from the guiding catheter at a rate of 4 ml/s with a power injector in order to create a virtually blood-free environment."
214393577|NCT04908761|PROCEDURE|Transmuscular quadratus lumborum block|Patients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
214955924|NCT05122780|PROCEDURE|Percutaneous coronary intervention (PCI):|PCI with stent implantation will be considered in selected cases with evidences of plaque rupture
214955925|NCT05122780|DIAGNOSTIC_TEST|Acetylcholine provocative test|ACh will be administered in a stepwise manner into the left coronary artery (LCA) (20-200 μg) or into the right coronary artery (RCA) (20-50 μg) over a period of 3 min with a 2-3 min interval between injections. Coronary angiography will be performed 1 min after each injection of these agents and/or when chest pain and/or ischaemic ECG shifts were observed. The decision of testing with provocative test LCA or RCA as first will be left to the discretion of the physicians; both LCA and RCA will be tested if the first test was negative. Angiographic responses during the provocative test will be assessed in multiple orthogonal views in order to detect the most severe narrowing and/or analysed by using computerized quantitative coronary angiography (QCA-CMS, Version 6.0, Medis-Software, Leiden, The Netherlands).
214955926|NCT05122780|DIAGNOSTIC_TEST|TT-Echocardiography|TT-Echo will be used to calculate left and right ventricular and atrial dimensions, left and right ventricular systolic function, transmitral flow Doppler spectra, mitral and tricuspidal valve annulus tissue Doppler spectra, ejection time and stroke volume, inferior vena cava, aorta and pulmonary artery diameters and Doppler spectra, according to the recommendations of the American Society of Echocardiography.
214955927|NCT05122780|DIAGNOSTIC_TEST|TE/contrast echocardiography|In patients with angiographic evidence or suspicion of distal microembolization, TE-Echo consisting of an echocardiographic probe inserted in to the oesophagus will be used to detect a hidden cardioembolic source (i.e. left atrial thrombus); in patients with suspected left ventricular source of cardioembolism, contrast echocardiography consisting of a 0.3ml solution of SONOVUE will be used.
214955928|NCT05122780|DIAGNOSTIC_TEST|Cardiac magnetic resonance|CMR will be performed during hospital stay on a 1.5-T system equipped with a 32-channel cardiac coil. Patients underwent conventional CMR including cine, T2-weighted, first pass perfusion, and conventional breath-held late gadolinium enhancement (LGE).
214955929|NCT05122780|DIAGNOSTIC_TEST|Circulating biomarkers|Blood sampling for circulating biomarkers and miRNA expression profile at the time or within 12 hours of coronary angiography. Blood sampling will be processed and analysed in the research laboratory of the Department of Cardiovascular Science. Biological aliquots will be preserved at XBiogem Biobank at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (see section 33).
214955930|NCT05122780|DRUG|Antiplatelet Drug|acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily).
214955931|NCT05122780|DRUG|Statin|i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
214955932|NCT05122780|DRUG|Beta blocker|i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
214955933|NCT05122780|DRUG|ACEi/ARB|i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
214955934|NCT05122780|DRUG|CCB|i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate
214955935|NCT05122780|DRUG|Nitrates|i.e. nitroglycerine; dosages titrated on blood pressure, ECG, heart rate
214955936|NCT05122780|DRUG|Anticoagulant|i.e. warfarin; the selection of the anticoagulant agent will be based on the clinical scenario, contraindications etc
214955937|NCT00616876|DRUG|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
215078171|NCT04934709|DEVICE|Active PBMT-sMF|PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.
215078172|NCT04934709|DEVICE|Placebo PBMT-sMF|Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
214393578|NCT04908761|PROCEDURE|Placebo|For patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block.
214393579|NCT02291289|DRUG|Cetuximab|500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle
214348294|NCT06664658|PROCEDURE|peep 10|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
214348295|NCT06664593|OTHER|integrated perinatal mental health pathway|This observational study examines whether assessing psychosocial risk factors and screening for depression and anxiety at different time points during the perinatal period, using a stepped protocol, helps to more quickly detect women with depressive and anxiety symptoms.
214348296|NCT03891810|BEHAVIORAL|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
214348297|NCT01920295|DEVICE|Cryoballoon ablation|
214955938|NCT00616876|DIETARY_SUPPLEMENT|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
214955939|NCT04656301|DRUG|Psilocybin|A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
214955940|NCT03724019|DRUG|Ketamine|Administration of 0.5mg / kg ideal body weight of ketamine at induction of anesthesia in laparoscopic surgery.
214955941|NCT00811980|DRUG|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
214348298|NCT06612086|DRUG|Dapagliflozin (Forxiga)|we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient
214348299|NCT03294434|OTHER|Diffusion tensor Imaging (DTI)|Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
214678629|NCT01221467|DEVICE|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
214955942|NCT05165641|PROCEDURE|segmental spinal anesthesia|Spinal anesthesia was performed at a lower thoracic level with the patient in the sitting position. After local anesthesia with 1% lidocaine, the spinal puncture was done in the 10th thoracic intervertebral space (T 10) through a median approach. A 27 Gg pencil-point needle with an introducer was used (marquee). To identify T 10, the vertebra prominens (C7) was palpated and the spinous processes were palpated caudally \[ref}. Two senior anesthesiologists performed all the spinal punctures. The progression of the spinal needle was cautious and soft. The effort was made to stop the needle progression just after the tactile perception of the dura mater. Once the flow of cerebrospinal fluid was obtained, 1.5 ml of hyperbaric bupivacaine 5mg/ml (=7.5 mg) mixed with 0.5 ml of fentanyl 50 µg/ml (= 25 µg) was injected and the spinal needle removed.
214955943|NCT00469716|DRUG|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
214955944|NCT01575418|DRUG|Rectal formulation (RF) of tenofovir 1% gel|The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
214955945|NCT01575418|DRUG|Vaginal formulation (VF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy)propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
215078173|NCT01028534|DRUG|Olmesartan and Azelnidipine|"1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
215078174|NCT03262571|DIAGNOSTIC_TEST|Lung ultrasound|Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
215078175|NCT03240367|OTHER|Coutery|Stapler line bleeding control with coutery
215078176|NCT02060630|PROCEDURE|Open surgical revascularization|
215078177|NCT02060630|DEVICE|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
214348300|NCT00660010|DRUG|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
214678630|NCT04504032|DRUG|Rivaroxaban|Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.
214348301|NCT01287585|DRUG|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
214348302|NCT01287585|DRUG|Placebo|weekly, intramuscular, until disease progression or toxicity.
214348303|NCT01287585|OTHER|Best Supportive Care|treatment of disease-related symptoms throughout the study.
214348304|NCT05513638|DIAGNOSTIC_TEST|the clinical use of artificial intelligence in the diagnosis of prostate cancer|Each study site will enroll consecutive eligible patients and randomize them to either (a) a group with human-based interpretation or (b) a group with human-artificial intelligence interactive interpretation, both of which are utilized as standards of care.
214348305|NCT04286347|PROCEDURE|HCV, HBV, HIV tests|HCV, HBV, HIV testing during consultation with Anesthesiologist before a planned surgery
214348306|NCT05660525|DRUG|4 weeks of Nicotine lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
214348307|NCT05660525|DRUG|8 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
214955946|NCT01575418|DRUG|Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel|Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
214955947|NCT01575418|RADIATION|Radiolabeling of study drugs and semen|"Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing."
214955948|NCT02801461|DEVICE|extracorporeal shock wave therapy|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
214955949|NCT04849663|BIOLOGICAL|free fat graft|fat harvested from patient will be used to cover exposed root
214955950|NCT04849663|BIOLOGICAL|subepithelial graft|subepitheial graft harvested from palate
214955951|NCT02483988|DEVICE|NUsurface® Meniscus Implant|The NUsurface® Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network that supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
214955952|NCT03063619|DRUG|Afimoxifene|Applied topically
214348308|NCT05660525|BEHAVIORAL|QuitAid|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
214348309|NCT05660525|BEHAVIORAL|Smokefree TXT|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.
214348310|NCT05660525|BEHAVIORAL|Tobacco Quitline|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.
214348311|NCT05660525|DRUG|4 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch.
214955953|NCT03063619|OTHER|Laboratory Biomarker Analysis|Correlative studies
214678631|NCT04504032|DRUG|Placebo|Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
214955954|NCT03063619|OTHER|Placebo|Applied topically
214955955|NCT03063619|OTHER|Questionnaire Administration|Ancillary studies
214955956|NCT01360788|DRUG|Combination ipratropium/salbutamol or placebo (nebulization)|The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
214678632|NCT06121557|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
214678633|NCT06121557|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
214348312|NCT05660525|DRUG|8 Weeks Nicotine Lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
214348313|NCT04572347|OTHER|Observational|It is an observational study, and no intervention will be provided.
214348314|NCT00198640|PROCEDURE|Antibiotic use|
214348315|NCT01489579|BEHAVIORAL|Telephone Counseling for Tobacco Cessation|"The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)"
214348316|NCT01489579|BEHAVIORAL|Usual Care|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
214348317|NCT01746342|DEVICE|Effective continuous positive airway pressure (CPAP)|
214348318|NCT01746342|DEVICE|Sham continuous positive airway pressure (CPAP)|
214348319|NCT05321498|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week.
214348320|NCT05321498|DRUG|Placebo|Placebo will be delivered by subcutaneous injection once a week
214348321|NCT04392505|DRUG|Durvalumab Injection|Included patients will receive durvalumab (fixed dose, 1500mg Q4W) until progressive disease and no clinical benefit, intolerable toxicity or patient's wish, for a maximum duration of 12 months. Treatment with durvalumab should start \<5 weeks after last radiotherapy dosing.
214348322|NCT02026089|BIOLOGICAL|Varicella vaccine|Varivax 0.5ml subcutaneous injection
214348323|NCT06509906|DRUG|M9466|M9466 will be administered orally until progressive disease, unacceptable toxicity, death, or end of study.
214955957|NCT04156243|BIOLOGICAL|CD19 CARvac T cells|CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
214955958|NCT00731796|DEVICE|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
214348324|NCT06509906|DRUG|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks (q2w) until progressive disease, unacceptable toxicity, death, or end of study.
214348325|NCT06509906|DRUG|Folinic acid|Folinic acid will be administered intravenously q2w as per standard of care.
214348326|NCT06509906|DRUG|Fluorouracil (5-FU)|Fluorouracil will be administered intravenously as per standard of care.
214348327|NCT06509906|DRUG|Bevacizumab|Bevacizumab will be administered intravenously, q2w until progressive disease, unacceptable toxicity, death, or end of study.
214348328|NCT06509906|DRUG|Granulocyte colony stimulating factor (G-CSF)|G-CSF will be administered subcutaneously at every cycle of study intervention as per standard of care.
214955959|NCT03017391|DRUG|metoclopramide|metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity
214955960|NCT03017391|DRUG|granisetron|granisetron patch 3.1mg/24 hours, use until toxicity
214955961|NCT03017391|DRUG|Dexamethasone|dexamethasone 8 mg, last step in both algorithms
214955962|NCT03017391|DRUG|Granisetron 2Mg Tablet|granisetron 2 mg loading dose
214955963|NCT02052297|OTHER|GSK2634673F|GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
214955964|NCT06001853|DRUG|BM-MSC injection|BM-MSCs at the dose 10 x 106 in 1 ml per facet joint for a total of 2 joints
214955965|NCT06001853|DRUG|DSMO Injection|After 6 months, patients randomized to Arm B: DMSO will be unblinded and re-assigned to Arm A: treatment then be followed for 12 months.
214955966|NCT00002917|DRUG|paclitaxel|
214955967|NCT03620526|DRUG|Iloprost|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
215078178|NCT02309645|BIOLOGICAL|EVICEL® Fibrin Sealant|Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
215078179|NCT02309645|OTHER|Sutures Only|Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
215078180|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
215078181|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
215078182|NCT01502878|DIETARY_SUPPLEMENT|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
215078183|NCT06243003|RADIATION|HA-WBRT plus SBRT|hippocampal-avoidance whole brain radiotherapy (WBRT) followed by stereotactic body radiotherapy (SBRT)
215078184|NCT00035607|DRUG|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
215078185|NCT00035607|DRUG|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
214348329|NCT05422417|DEVICE|Prolonged intermittent theta burst stimulation (piTBS)|Participants in the prolonged dosage (1800 pulse) of intermittent TBS (iTBS) active stimulation group will receive 2-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
214348330|NCT05422417|DEVICE|20Hz rTMS|Participants in the 20 Hz rTMS (2000 pulse) active stimulation group will receive 2-week 2s- and-10s off, total 50 cycles at each hemisphere/session, at an intensity of 100% resting motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
214348331|NCT05422417|DEVICE|sham control|Half of the patients in the sham group received 2-week the same prolonged iTBS parameter stimulation (sham- prolonged iTBS), and the other half received the same 20 Hz rTMS parameter stimulation using a sham coil (sham-20 Hz rTMS), which also improved the blinding process
214348332|NCT03570684|DEVICE|Cable Tie|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
214348333|NCT03369548|OTHER|Apple|2 Renetta Canada apples and 2 placebo capsules/ day
214348334|NCT03369548|OTHER|Oats|40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules / day
214348335|NCT03369548|DIETARY_SUPPLEMENT|Lactobacillus reuteri NCIMB 30242|2 probiotic capsules and 40g cornflakes with semi-skimmed milk / day.
214348336|NCT03369548|OTHER|Cornflakes|40g cornflakes with semi-skimmed milk and 2 placebo capsules/ day.
214348337|NCT05829655|DRUG|Drug A (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
214348338|NCT05829655|DRUG|Drug B (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
214348339|NCT05829655|DRUG|Drug C (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
214348340|NCT05829655|DRUG|Drug D (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
214348341|NCT05829655|DRUG|Suvorexant (20mg/day)|Double blind administration of suvorexant once per day during residential stay until discharge.
214348342|NCT05829655|DRUG|Placebo|Double blind administration of placebo once per day during residential stay until discharge.
214348343|NCT06487455|DRUG|SPH7485|SPH7485： Orally, once daily, 50-400mg, 21 days per cycle
214348344|NCT04827576|DRUG|Magrolimab|Administered intravenously
214348345|NCT04827576|DRUG|Docetaxel|Administered intravenously
214348346|NCT06506669|PROCEDURE|Oral sedation|Oral medication for anxiolysis administered in the preoperative setting
214348347|NCT06506669|PROCEDURE|Placebo|A placebo pill with no active ingredients administered in the preoperative setting
214393580|NCT02291289|DRUG|FOLFOX induction regimen|Administered per the Investigator's discretion in accordance with locally approved prescribing information.
214393581|NCT02291289|DRUG|Fluoropyrimidine (5-FU/LV or capecitabine)|Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
215078186|NCT01367418|DRUG|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
215078187|NCT01367418|DRUG|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
214393582|NCT02291289|DRUG|Atezolizumab|800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
215078188|NCT00004552|DRUG|acamprosate (Campral)|
214393583|NCT02291289|DRUG|Vemurafenib|960 mg vermurafenib BID by mouth
215078189|NCT02056886|PROCEDURE|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
215078190|NCT03575117|BEHAVIORAL|Common-Sense Model (CSM) Be Well|Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.
215078191|NCT03575117|BEHAVIORAL|ACS usual messages|Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)
214348348|NCT06479447|OTHER|PORTAL-PTSD|Patients will be eligible if they are 18+ years, have had a primary care visit in the last 2 years, and have not been screened for PTSD in the last year. The validated PC-PTSD-5 (Primary Care Post Traumatic Stress Disorder-5) screener will be used. Clinics will implement visit-based and population health screening for patients enrolled in the patient portal who have not been screened for PTSD in the last year and have had a clinic appointment in the last 2 years. The PCBH care manager or patient navigator will follow-up with patients every 2 weeks to ensure they have been connected to care and re-measure their PTSD symptoms. The follow-up calls will continue until symptom remission, after which follow-ups will occur quarterly for 6 months. Primary care clinicians will receive training on trauma-informed care and PTSD management, and will be surveyed at baseline, immediately after training, and 6 months-post intervention to evaluate changes in their knowledge of trauma-informed care.
214348349|NCT06495853|PROCEDURE|Continuous Circumferential Reinforcement of the Anastomotic|The reinforcement began on the right side of the anterior wall of the anastomosis, 0.5 cm from the anastomotic line, with continuous full-thickness sutures spaced 1 cm apart. The suture ended with fixation of the suture tail using non-absorbable vascular clips. The decision to perform splenic flexure mobilization depended on the anastomotic tension and the length of the resected bowel segment. The superior mesenteric artery and vein were divided at their roots.
214348350|NCT03069482|DEVICE|Learn to Quit App|A smartphone app designed for individuals with serious mental illness. The main intervention components of the app are skills based on an intervention called Acceptance and Commitment Therapy that will (a) teach smoking cessation skills and (b) help cope with mental health symptoms. The app incorporates gaming features to keep users engaged, and a tracking component to record smoking habits and moods.
214348351|NCT03069482|DRUG|Nicotine patch|Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
214348352|NCT03069482|DRUG|Nicotine lozenge|Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
214348353|NCT03069482|BEHAVIORAL|Technical Coaching|Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (\~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
214348354|NCT03069482|DEVICE|NCI QuitGuide App|A smartphone app developed by the National Cancer Institute which uses recommendations contained in the US DHHS Clinical Practice Guidelines and smokefree.gov. NCI QuitGuide has the following intervention components: (a) psycho-education about the impact of smoking in health, (b) tracking of smoking habits, and (c) Tips for quitting (e.g., distraction strategies).
214348355|NCT01445938|DRUG|SAR97276A|"Pharmaceutical form:solution for injection~Route of administration: intramuscular"
214955968|NCT03620526|DRUG|Placebo|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
214955969|NCT05400044|PROCEDURE|Three dimensional maxillary bone augmentation|mixing of bone marrow aspirate concentrate with xenograft to show the bone quality and bone gain compared to the xenografts mixed with autografts
214955970|NCT02090283|DRUG|SD-101 dermal cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
214955971|NCT02360423|DEVICE|CRE8 sirolimus-eluting stent|The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
214955972|NCT02360423|DEVICE|RESOLUTE zotarolimus-eluting stent|The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
215078192|NCT03575117|BEHAVIORAL|NCI HealthyYouTXT--Get Active (HYT--GA)|Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
215078193|NCT01933230|DEVICE|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
215078194|NCT01643252|DRUG|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
215078195|NCT01643252|DRUG|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
215078196|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
215078197|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
215078198|NCT01741324|DIETARY_SUPPLEMENT|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
214348356|NCT01445938|DRUG|arthemeter + lumefantrine (ACTs)|"Pharmaceutical form:tablet~Route of administration: oral"
214348357|NCT04537923|DRUG|Tirzepatide|Administered SC
214348358|NCT04537923|DRUG|Insulin Lispro (U100)|Administered SC
214348359|NCT01261611|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
214348360|NCT01261611|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 of treatment cycle 1.
214348361|NCT01261611|DRUG|Placebo|I.M. injection on day 1 of treatment cycle 1.
214348362|NCT02527798|DRUG|Furosemide Cohort 1|furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
214348363|NCT02527798|DRUG|Furosemide Cohort 2|furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
214348364|NCT02527798|DRUG|Furosemide Cohort 3|furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
214955973|NCT03508349|DIAGNOSTIC_TEST|IST|Women in the control group will receive routine care, which does not include testing for malaria with a rapid diagnostic test unless symptomatic for malaria. Women in the intervention group will receive this additional testing for malaria at each antenatal care, regardless of whether she is symptomatic for malaria.
214955974|NCT00620646|DRUG|aspirin, clopidogrel|aspirin 100 mg plus clopidogrel 150mg qd
214955975|NCT00620646|DRUG|aspirin, clopidogrel, cilostazol|aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
214348365|NCT02527798|OTHER|Placebo|Sugar water will be administered in a equivalent volume as drug intervention.
214955976|NCT05269368|PROCEDURE|Wicking|Absorbable or non-absorbable wicking
214955977|NCT05269368|PROCEDURE|No wicking|No wicking after surgery
214955978|NCT03283046|DRUG|Nivolumab|"Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle."
214955979|NCT03283046|DRUG|Lenalidomide|"Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21."
214955980|NCT03283046|DRUG|Dexamethasone|Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
214955981|NCT03283046|DRUG|Ipilimumab|"Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion)."
214955982|NCT05054205|BEHAVIORAL|Motivational İnterviewing|"The most current version of Motivational İnterviewing (MI) is described in detail in Miller and Rollnick (2013) Motivational Interviewing: Helping people to change (3rd edition). Key qualities include:~MI is a guiding style of communication, that sits between following (good listening) and directing (giving information and advice).~MI is designed to empower people to change by drawing out their own meaning, importance and capacity for change.~MI is based on a respectful and curious way of being with people that facilitates the natural process of change and honors client autonomy."
214955983|NCT03096561|DIAGNOSTIC_TEST|blood draw from three different vessels|Patient in cardiac-arrest and cold exposure, diagnostic test: blood draw from three different vessels (central vein, artery, peripheral vein) and measuring of PR
214955984|NCT01653457|DRUG|Memantine|"Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:~* 1st week: 5 mg daily~* 2nd week: 10 mg daily~* 3rd week: 15 mg daily~* From 4th week up to 24th week: 20 mg daily"
214955985|NCT01653457|DRUG|Placebo|Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
214348366|NCT02498483|DRUG|Acetaminophen|Infants will receive 15 mg/kg of acetaminophen.
214348367|NCT03297788|RADIATION|SRS|"For SRS the dose prescription to the PTV will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
214955986|NCT01867515|OTHER|Acoustic distortion of speech|
214955987|NCT00019461|DRUG|carboxyamidotriazole|
214955988|NCT00019461|DRUG|chemotherapy|
214955989|NCT00926757|DRUG|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
214348368|NCT03297788|RADIATION|WBRT|WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
214348369|NCT05589051|DIETARY_SUPPLEMENT|Drink|Consume one tablet fully dissolved in 8 ounces. Take 2 tablets per day for adults (morning and evening) for 4 weeks
214348370|NCT03037710|DEVICE|HealthPatch|A multi-sensor device to collect continuous vital signs
214348371|NCT03215446|DRUG|maintenance of anaesthesia with propofol|
214348372|NCT03215446|DRUG|maintenance of anaesthesia with sevoflurane|
214348373|NCT06832007|DEVICE|AYO light glasses (experimental)|OUD patients are asked to wear AYO light therapy glasses (wavelength 470nm ± 2nm, irradiance 250 μW/cm2 or approx.1500 m-EDI) daily for 30 min after habitual wake-up times for two weeks.
214348374|NCT06832007|DEVICE|AYO light glasses (comparator)|The comparison group will wear the same AYO glasses but with lower intensity (1% light intensity) compared to the experimental group. This group will also self-administer 30 min of light from commercially available light glasses each morning for two weeks
214348375|NCT02248870|DRUG|Dexamethasone|Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
214348376|NCT02248870|DRUG|Saline|Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
214393584|NCT02291289|DRUG|Bevacizumab|5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
214393585|NCT02291289|DRUG|Trastuzumab|Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
214955990|NCT00926757|DRUG|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
214955991|NCT01737411|DRUG|solifenacin|
214955992|NCT01737411|PROCEDURE|cesa/vasa|surgical repair of USL
214348377|NCT05695365|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 16-week, twice/week supervised resistance exercise training program to increase strength. Each session will last \~60 minutes and begin and end with a 5-minute aerobic warm-up/cool-down on a cycle ergometer, elliptical, treadmill, or walked laps. Training will begin with a 1-week standard familiarization process to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 10 Keiser resistance machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension, abdominal crunch), with a 1-minute rest time between each set. Workload will begin at 50% of the estimated 1-RMs and increase by 5-10% after any session in which a participant completes 12 repetitions in all 3 sets. The workload will be tailored based on progressive increases in strength.
214348378|NCT06156930|OTHER|Intervention group lavender oil|The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
214348379|NCT06156930|OTHER|Placebo group sesame oil|The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
214955993|NCT03609814|DRUG|Clofarabine|Given IV
214955994|NCT03609814|DRUG|Fludarabine Injection|Given IV
214955995|NCT01637714|DRUG|Multi-strain probiotics|"* B. longum BORI: 1 x 109~* B. bifidum BGN4: 1 x 109~* B. lactis AD011: 1 x 109~* B. infantis IBS007: 1 x 109~* Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water"
214955996|NCT01637714|DRUG|Placebo powder|"same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water"
214955997|NCT01008774|DEVICE|Paxman Cooling Machine|Scalp cooling procedures
214955998|NCT01008774|DEVICE|Cold Caps|Scalp cooling procedures
214955999|NCT01292707|BEHAVIORAL|Control|Standard national training
214956000|NCT01292707|BEHAVIORAL|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
214956001|NCT01292707|BEHAVIORAL|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
214956002|NCT05639218|DRUG|Inclisiran|Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy
215078199|NCT02338895|DEVICE|Ultrasound|Ultrasound of inferior vena cava and kidneys
215078200|NCT06425939|OTHER|Force plate assessment|On Day 1, Day 45 and Day 90: 3x drop jumps, 2 min rest, 3x counter movement jumps, 2 min rest, 3x dynamic push-ups
215078201|NCT06425939|DEVICE|Whoop wrist band|Whoop wrist worn activity tracker (not a medical device) collects continuous data via smartphone app. This is a marketed device. This is not a device study.
215078202|NCT02154100|DIETARY_SUPPLEMENT|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
215078203|NCT02154100|DIETARY_SUPPLEMENT|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
215078204|NCT05837403|PROCEDURE|Platelet rich plasma injection|venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
215078205|NCT05837403|DRUG|Nitroglycerin ointment|application of the ointment twice daily
215078206|NCT05058573|OTHER|Control group (n=22)|Control group will be received only medical treatment
214348380|NCT05613660|DIETARY_SUPPLEMENT|Veg Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
214956003|NCT03908554|OTHER|WORKPLACE HEALTH PROMOTION PROGRAM|WHPP was PMR training, posture and breath exercises, and ergonomic suggestions.
214956004|NCT05105672|DRUG|Sintilimab|IV infusion
214956005|NCT05105672|DRUG|Cisplatin|IV infusion
214956006|NCT05105672|RADIATION|External Beam Radiotherapy (EBRT)|Undergo pelvic EBRT
214956007|NCT05105672|RADIATION|brachytherapy|brachytherapy
215078207|NCT02482194|BIOLOGICAL|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
215078208|NCT04669938|OTHER|oropharyngeal and intestinal microbiota|analysis of oropharyngeal and intestinal microbiota
215078209|NCT04669938|OTHER|host genotype|analysis of a part of host genotype
215078210|NCT04669938|OTHER|host immune factors|analysis of host immune factors
215078211|NCT04669938|OTHER|viral sequence|analysis of viral sequence
214956008|NCT05392595|OTHER|Cawthrone and cooksey exercises,Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Epley repositioning maneuver will be performed, also cervical stretches and Basic Balance exercises Following Exercises will be performed by patient in next session. Caw-Thorne and Cooksey exercise program. Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
214956009|NCT05392595|OTHER|Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Conventional treatment: Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.~Frequency: Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
214956010|NCT01624480|DRUG|Armodafinil|The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
214348381|NCT05613660|DIETARY_SUPPLEMENT|Bovine Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
214348382|NCT05613660|DIETARY_SUPPLEMENT|"Fish | Marine Collagen Peptide"|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
214348383|NCT05613660|DIETARY_SUPPLEMENT|Chicken Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
214348384|NCT00783744|DRUG|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
214956011|NCT03540069|BEHAVIORAL|Care Group Cervical Cancer Screening Education Curriculum|a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
214956012|NCT05964153|DIAGNOSTIC_TEST|Liquid Biopsy|Analysis of the circulating free DNA in blood patients affected by gliomas
214956013|NCT01742416|PROCEDURE|Ultrasound|Arterial cannulation facilitated by ultrasound.
214956014|NCT01742416|PROCEDURE|Palpation Method|Arterial cannulation by palpation method.
214956015|NCT02210325|DRUG|solithromycin|
214956016|NCT02210325|DRUG|ceftriaxone|
214956017|NCT02210325|DRUG|azithromycin|
214956018|NCT05737901|OTHER|Education Booklet|"Training titles and contents were created by listing the most common complications and needs of patients after CABG surgery. In the General Information section of the booklet, the definition of CAD, how CABG surgery is performed, the length of hospital stay, and what can be experienced in the hospital after surgery and in the home environment after discharge were discussed. In the Postoperative Self-Care Practices section, information about the healing process of the breastbone, pain management, medication, respiratory exercises, early nutrition, personal hygiene, protection from coronavirus-19, pulse control, postoperative heart attack, conditions to be reported, compression stockings use for varicose veins, physical activity, travel, sleep and rest, sexual life, and coping with stress and depression was presented. In the Postoperative Life section, training topics on exercise, nutrition, smoking, and alcohol use were included."
214348385|NCT00783744|DRUG|Glimepiride|Glimepiride 3 or 4 mg
214956019|NCT05737901|OTHER|Mobile application|"The logo and content of the Bypass e-Discharge application was visually designed, and the software was developed. In-app transactions were secured with end-to-end encryption by entering the username and password, and internet access was not required to use the application. The application was presented for expert opinion (3 patients, 1 academician, 2 nurses, 2 physicians) in order to investigate the user experience, and edits were made on its interface (such as adding the acceleration feature in videos, an additional button for stopping and starting videos, displaying video total time on the screen, and magnification of all buttons)."
214956020|NCT03498729|OTHER|Peripheral Blood Sample|30mL peripheral whole blood sample
214348386|NCT00783744|DRUG|Metformin|At least 850 mg od
214348387|NCT00783744|DRUG|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
214348388|NCT00920426|DRUG|GSK1265744 30mg|GSK1265744 30 mg
214956021|NCT01218815|PROCEDURE|IRA stenting in culprit lesion only|stenting
214348389|NCT00920426|DRUG|Placebo|Placebo to match GSK1265744
214348390|NCT00920426|DRUG|GSK1265744 5mg|GSK1265744 5mg
214348391|NCT03282981|DRUG|Timolol|Topical application of Timolol on non-healing diabetic foot ulcers
214348392|NCT03282981|DRUG|Non biologically active gel|Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
214348393|NCT01432366|OTHER|SC anti-TNF|Subcutaneous (SC) anti-TNF
214348394|NCT04222348|DRUG|Metformin|850-2550 mg every 24h.
214348395|NCT04222348|DRUG|Insulin Detemir|Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
214348396|NCT06034860|DRUG|MT-8421|Experimental treatment with MT-8421
214348397|NCT06034860|DRUG|Nivolumab|480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
214348398|NCT01545011|OTHER|Inspiratory muscle training|Inspiratory muscle training
214348399|NCT05615792|OTHER|No intervention|No intervention
214348400|NCT02345031|DRUG|AUT00063|600 mg, orally, once a day, for 4 weeks
214348401|NCT02345031|DRUG|Placebo|orally, once a day, for 4 weeks
214348402|NCT04156607|OTHER|Kinesio taping|For the fascia technique, one part of the band which were divided by 4 fans is adhered on Achilles tendon to the heel with a 0% stretch. Then the plantar fascia was stretched by the examiner and the toes were extended (ankle dorsiflexion, toe extension) and the divided part of the band was applied toward the metatarsal heads with paper-off technique (5-15%).
214348403|NCT04156607|OTHER|Sham taping|''I'' bant were cut from the middle point of the Achilles tendon to the metatarsal heads. The band was applied from the Achilles tendon to the metatarsal heads without any stretching of plantar fascia and band.
214348404|NCT00489606|DRUG|SK3530|
214348405|NCT02970500|DRUG|Methylphenidate HCl 10Mg SR|Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)
214348406|NCT02970500|DRUG|Placebo Group|Placebo
214348407|NCT05616533|OTHER|biopsy of tumor before treatment|samples obtained from biopsy will be used in the zebrafish PDX model
214348408|NCT02114593|BEHAVIORAL|Parent support program|Parent support program
214678634|NCT06121557|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
214956022|NCT01218815|PROCEDURE|IRA stenting|Complete IRA revascularization
214956023|NCT01915550|DRUG|Metformin|
214956024|NCT01915550|DRUG|Humulin Insulin Mixtard|
214956025|NCT03365518|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Sessions consist of CBT tools as well as sex therapy techniques and education. The CBT treatment was adapted from the mindfulness-based treatment, but all mentions of mindfulness have been replaced with CBT principles. The therapeutic content presented in this treatment arm is manualized.
214956026|NCT03365518|BEHAVIORAL|Mindfulness-Based Therapy|The mindfulness-based treatment was developed based on pre-existing mindfulness-based cognitive therapy treatment groups for sexual dysfunction developed by Dr. Lori Brotto at the University of British Columbia Sexual Health Laboratory, mindfulness in Sex therapy and Intimate Relationships (MSIR) treatment group developed by Kocsis and Newbury-Helps (2016), and expert input. Sessions consist of mindfulness-based training as well as sex therapy techniques and education. The therapeutic content presented in this treatment arm is manualized.
214956027|NCT03382405|BIOLOGICAL|mRNA-1647|Escalating dose levels
215078212|NCT02480491|OTHER|measuring cell freeDNA|measuring cell free DNA using PCR
215078213|NCT06324422|OTHER|Aerobic exercise intervention|Participants in this arm are randomized to perform 12 weeks of supervised high intensity progressive aerobic exercise comprising continuous and/or interval cycling-, rowing- or cross-trainer sessions, increasing from 30 minutes towards 60 minutes with intensity increasing from 65 to 90% of individual maximum heart rate. The 12 weeks of aerobic exercise are followed by 12 weeks of habitual lifestyle (follow up period).
215078214|NCT06324422|OTHER|Resistance exercise intervention|Participants in this arm are randomized to a 24-week waitlist control group. The control group will continue their habitual lifestyle throughout the 24 weeks. After 24 weeks, the waitlist control group will begin a 12 week supervised resistance exercise intervention comprising machine exercises in 3 to 5 sets with 2-3 minutes rest in between and a decrease from 12 to 6 repetitions in parallel with intensity increasing from 15RM (repetition maximum) to 8 RM.
214348409|NCT01900990|DEVICE|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
215078215|NCT05292209|DRUG|Riluzole 50 MG|Riluzole 50mg tablets
214348410|NCT06085170|DIAGNOSTIC_TEST|Acoustic Analysis by MDVP|Acoustic measurements: Acoustic analysis using Multidimensional voice program software (MDVP) will be carried out with the sustained /a/vowel for 9 seconds, for measuring frequency, jitter, shimmer and harmonic to noise ratio of the voice
214393586|NCT02291289|DRUG|Pertuzumab|Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
214393587|NCT02291289|DRUG|Cobimetinib|60 mg orally once daily for 3 weeks followed by a 1-week treatment break
214678635|NCT06121557|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|In the dose-escalation portion, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
214678636|NCT06121557|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
214956028|NCT03382405|BIOLOGICAL|mRNA-1443|Escalating dose levels
214956029|NCT03382405|OTHER|Placebo|Saline
214956030|NCT01041274|DRUG|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
214956031|NCT01041274|DRUG|Placebo|Placebo by mouth daily for 12 months.
214956032|NCT01041274|BEHAVIORAL|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
214956033|NCT01041274|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
214956034|NCT01041274|RADIATION|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
214348411|NCT04250649|PROCEDURE|subcutaneous tissue disinfection|"Skin and subcutaneous incision (up to the muscular fascia) with superficial blade scalpel, disinfection of the subcutaneous tissue with 3cc of Betadine solution, placement of the retractors, dissection and development of the delto-pectoral interval with deep blade scalpel.~When the joint is opened, bacteriological smears are taken from 5 sites in the two groups. 1) exposed subcutaneous tissue, 2) surgeon's gloves (distal end of fingers), 3) superficial blade, 4) deep blade, 5) retractors.~The rest of the shoulder surgery procedure does not differ from what is commonly performed.~The samples are sent to bacteriology for bacterial culture. Anaerobic research is done specifically for P. acnes. The results are considered negative after 10 days."
214956035|NCT04097769|DRUG|HX009|During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
214956036|NCT04654715|PROCEDURE|Gracilis flap interposition for rectouretral fistula management|Gracilis flap interposition is a surgery for rectouretral fistula
214956037|NCT02801799|DRUG|Varying infusion rates of Ropivacaine 0.2%|"Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.~The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.~The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).~We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter."
214956038|NCT02028780|DRUG|Placebo to dose|placebo
214956039|NCT02028780|DRUG|Idarucizumab|short infusion
214956040|NCT02028780|DRUG|Placebo to Idarucizumab|Placebo to Idarucizumab
214956041|NCT02028780|DRUG|dabigatran|2 capsules dabigatran
214956042|NCT02028780|DRUG|Idarucizumab|short infusion
214956043|NCT00777335|DRUG|Panobinostat - LBH589|Solution for infusion - 25mg/5ml
214956044|NCT00777335|DRUG|Panobinostat - LBH589|Hard gelatine capsules - 5mg and 20 mg
214956045|NCT01994707|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation
214956046|NCT01994707|PROCEDURE|Placebo|Deflated cuff on arm for 30 minutes.
214956047|NCT04656184|DRUG|ANAKINRA|The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature \<38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
214956048|NCT04656184|DRUG|Intravenous immunoglobulin|The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
214956049|NCT01945476|DRUG|midazolam premedication|"On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total."
214956050|NCT01302210|DRUG|Decolonization|5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
214956051|NCT04687540|DRUG|Tocilizumab|Baseline: Tocilizumab (infusion of 8 mg/kg bodyweight or a maximum of 800 mg) will be infused over 60 minutes at the end for the study day, therefore study visit 1 (study day 1) measurements are baseline.
214956052|NCT04687540|DRUG|Saline 0.9%|Participants are under influence of tocilizumab since the effect of the drug will last for 4 weeks. Participants will be infused with saline at study visit 2 (study day 21). Placebo to tocilizumab will be saline (NaCl 0.9%) as tocilizumab is a colorless solution and has to be diluted with NaCl 0.9% prior to administration
214348412|NCT02658643|PROCEDURE|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
214348413|NCT02658643|PROCEDURE|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
214348414|NCT01821469|BEHAVIORAL|psychoeducation|Bipolar disorders are educated to learn about their pathology
214348415|NCT01847703|PROCEDURE|Robotic surgery|Minimal invasive surgery performed with daVinci robotic system
214348416|NCT01847703|PROCEDURE|Abdominal surgery|Current gold standard
214348417|NCT04429516|DRUG|Morphine Sulfate|over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
214348418|NCT04429516|DRUG|Placebo oral tablet|capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
214956053|NCT01113307|BIOLOGICAL|Activated allogeneic white blood cells|The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).
214956054|NCT03637790|DRUG|PF-04965842|single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
214956055|NCT03637790|OTHER|rifampin|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842
214956056|NCT06031675|OTHER|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
214956057|NCT05205005|DRUG|Endocalyx|3,712mg (six capsules) of DSGP for eight weeks.
214956058|NCT05205005|DRUG|Placebo|Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
214956059|NCT00323843|DRUG|Isoproterenol|
214956060|NCT00909220|BEHAVIORAL|Behavioral Activation|Behavioral Activation included up to 16 weekly 50 minute psychotherapy sessions using BA (Addis \& Martell, 2004; Martell et al., 2001, 2010). Techniques included functional analyses to identify the antecedent and consequential aspects of low mood, and interventions such as monitoring daily activities, assessing pleasure/satisfaction and competence achieved via activities, assigning tasks that induce mastery or pleasure, and reducing skill deficits. Clinicians included postdoctoral fellows in clinical psychology (n = 2) or licensed clinical psychologists (n = 2).
214956061|NCT03675971|DRUG|Cannabinol|Postoperative pain treatment
214956062|NCT03675971|DRUG|Placebo oral capsule|Placebo comparator
214956063|NCT02437643|BEHAVIORAL|Weight Loss|Participants will be prescribed hypo-caloric diet prescription.
214348419|NCT03789266|PROCEDURE|drain ablation|drain ablation will be done in Aspiration mode or in non Aspiration mode
214956064|NCT02437643|DIETARY_SUPPLEMENT|Dairy Protein|Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
214956065|NCT02437643|BEHAVIORAL|Low intensity exercise|Participants in both groups will participate in chair exercises 3 times a week.
214956066|NCT01148459|BIOLOGICAL|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
215078216|NCT03350087|DEVICE|intermittent theta burst stimulation|"In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation"
215078217|NCT03350087|DEVICE|continuous theta burst stimulation|"In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation"
215078218|NCT03350087|DEVICE|iTBS+cTBS group|In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)
214348422|NCT01787617|BEHAVIORAL|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
214348423|NCT01787617|BEHAVIORAL|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
214348424|NCT00211679|DRUG|Botulinum Toxin Type A|
214348425|NCT03894865|OTHER|procedure1|The students will be asked to bend forward with his knees straight, feet together and hands freely and loosely hanged. if there was scoliosis the rib cage rotated and a hump appeared. Positive test indicated the presence of a rib hump and negative if there was any hump appeared
214348426|NCT03894865|OTHER|procedure2|Measurement of the angle of trunk rotation (ATR) by using a scoliometer HD smartphone application.
214348427|NCT04756765|DRUG|Talazoparib Tosylate|Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.
214348428|NCT05123274|BEHAVIORAL|Social Support Mobilization|Five main sessions and two booster sessions focused on providing accurate information about HIV medical care, increasing participants' feelings of resilience and self-worth, and mobilizing or creating social supports.
214348429|NCT05123274|BEHAVIORAL|Individual Care Counseling|Twenty-minute individual counseling session focused on HIV medical care
214348430|NCT01275625|DRUG|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
214348431|NCT01183663|DRUG|Lenalidomide|Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.
214348432|NCT01183663|DRUG|Bevacizumab|Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
214348433|NCT01183663|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily for 28 a day cycle.
214348434|NCT01183663|DRUG|Temsirolimus|Starting dose: 15 mg by vein every week for a 28 day cycle.
214348435|NCT01183663|DRUG|Lenalidomide|Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.
214348436|NCT01183663|DRUG|Oxaliplatin|Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.
214348437|NCT01183663|DRUG|Leucovorin|400 mg/m2 by vein on day 1 of a 21 day cycle.
214348438|NCT01183663|DRUG|5-fluorouracil|400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
214348441|NCT00249236|DRUG|Risperidone, oral tablets|
214348442|NCT01349569|DRUG|Lenalidomide|Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
214956067|NCT01148459|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly"
214956068|NCT01148459|BIOLOGICAL|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly."
214956069|NCT04565405|OTHER|Detergent|The tracheostomy inner cannulas will be washed with detergent.
214956070|NCT04565405|OTHER|Sterile water|The tracheostomy inner cannulas will be washed with sterile water.
214348443|NCT01349569|BIOLOGICAL|Allogeneic Myeloma Vaccine|A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
214348444|NCT01349569|BIOLOGICAL|Prevnar-13|Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.
214348445|NCT04798976|DRUG|neoadjuvant/adjuvant therapy|chemotherapy/endocrine therapy/surgery/radiotherapy
214956071|NCT00402623|DIETARY_SUPPLEMENT|quercetin|1000 mg quercetin within 24 hours
214956072|NCT00402623|OTHER|placebo|
214348446|NCT05564234|PROCEDURE|laparoscopy then primary cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score , if less than 8 primary cytoreductive surgery were done.
214348447|NCT05564234|PROCEDURE|laparoscopy then neoadjuvant chemotherapy followed by interval cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score and provides the histological diagnosis , if score more than 8 the patient were received neoadjuvant chemotherapy followed by interval cytoreductive surgery
214348448|NCT02883114|DRUG|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
214348449|NCT02883114|DRUG|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
214348450|NCT04898101|DRUG|Acalabrutinib|Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
214348451|NCT04898101|DRUG|Microtracer [14C]ACP-196|Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.
214348452|NCT01741623|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
214348453|NCT01741623|DRUG|Bisoprolol|10 mg tablet once a day
214348454|NCT00958269|DRUG|dutogliptin|100 mg QD
214348455|NCT00958269|DRUG|dutogliptin|200 mg QD
214348456|NCT00958269|DRUG|placebo|
214956073|NCT04866082|OTHER|questionnaire|Members of European Society of Intensive Care and European Society of ANaesthesiology and Intensive care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS
215078219|NCT03350087|DEVICE|sham theta burst stimulation|"In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation"
215078220|NCT03350087|DEVICE|VCT|"The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program"
214348457|NCT00958269|DRUG|sitagliptin|25 mg QD
214348458|NCT00958269|DRUG|sitagliptin|50 mg QD
214348459|NCT00829257|DRUG|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
214348460|NCT00829257|DRUG|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
214348461|NCT00829257|DRUG|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
214348462|NCT03701568|DRUG|dC/dT|Collection of retrospective data from TK2 patients previously treated with dC/dT
214348463|NCT01201590|DIETARY_SUPPLEMENT|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
214348464|NCT01201590|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
214348465|NCT05920551|OTHER|Gastrocnemius Stretching Exercises|The gastrocnemius stretching exercises will be performed by patients in the study group. These exercises will involve stretching the gastrocnemius muscle in a controlled manner to improve flexibility and reduce tension in the plantar fascia.
214348466|NCT05920551|OTHER|Standard care|Ultrasound therapy: A therapeutic ultrasound device will be used to apply ultrasound waves to the plantar fascia area for pain relief and to promote healing. The frequency, intensity, and duration of the ultrasound therapy will be determined by the treating physical therapist based on individual patient needs.Fascia strengthening exercises: Patients will be instructed to perform exercises targeting the intrinsic foot muscles and the plantar fascia to improve strength and function. Examples of these exercises include toe curls, towel scrunches, and arch lifts. Patients will be asked to perform these exercises daily, with the specific number of repetitions and sets determined by the physical therapist.
214348467|NCT02172508|DRUG|Tiotropium Inhalation Capsule|
214348468|NCT02172508|DRUG|Placebo Lactose Capsule|
214348469|NCT04883892|PROCEDURE|BMAC|"patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.~During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability"
214348470|NCT04883892|PROCEDURE|HA|patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.
214348471|NCT01495065|DRUG|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
214348472|NCT01495065|DRUG|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
214348473|NCT01495065|DRUG|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
214348474|NCT01495065|DRUG|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
214348475|NCT01495065|DRUG|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
214348476|NCT01495065|DRUG|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
214348477|NCT01495429|PROCEDURE|Central venous catheter|Placement of a peripherally inserted central venous catheter
214956074|NCT03573570|OTHER|Fortified rice kernels|The proposed project will leverage the existing state-run public distribution system (PDS) to provide fortified rice through Fair Price Shops (FPS) using a domestically manufactured rice grain (Fortified Rice Kernels: FRK). FRKs are grains made from rice flour, enriched with iron, zinc, Vitamin A, Vitamins B1, B3, B6, B9 and B12, and shaped like a conventional grain of rice. It is mixed into conventional rice in specified ratio of 1:100. The proposed study will be conducted as a cluster-randomized controlled trial, with baseline and follow-up surveys conducted 12-15 months apart. In the interim, 110 Treatment FPS, and all households receiving rice from them, will be randomly assigned to receive fortified rice, and another 110 randomly assigned Control FPS, and the households receiving rice from them, will continue receiving conventional rice and represents the status quo. This study will be conducted in one sub-district of Tamil Nadu with a population of about 1/2 million people.
214956075|NCT05868278|OTHER|Training method intervention|Traditional learning method will be used in the control group. In the experimental group, interactive learning method will be used.
215078221|NCT03350087|DEVICE|VCT+optimal rTMS group|In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
214348478|NCT01495429|PROCEDURE|Central venous catheter|Placement of a centrally inserted central venous catheter
214348479|NCT03775239|BEHAVIORAL|Mindfulness in Sex Therapy and Intimate Relationships (MSIR)|"Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing \& Exploring Week 3: Avoidance \& Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning"
214678637|NCT06121557|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a dose of 200mg (3mg/kg for participants whose weight is below 50kg) IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
214678638|NCT06121557|DRUG|Chemotherapeutic drug, ADC or PARP inhibitor|Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
214678639|NCT00771030|BIOLOGICAL|Brodalumab|Solution for subcutaneous or intravenous administration
214678640|NCT00771030|OTHER|Placebo|Solution for subcutaneous or intravenous administration
215078222|NCT00793559|DRUG|terlipressin|1 mg of terlipressin one time only
215078223|NCT00793559|DRUG|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
215078224|NCT02313727|DRUG|Pamidronate|intravenous infusion of pamidronate 60 mg
215078225|NCT02313727|OTHER|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
214348480|NCT03775239|BEHAVIORAL|Treatment-as-usual|"The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy."
214348481|NCT01941862|BEHAVIORAL|Psychoeducation and Cognitive Bias Modification|
214348482|NCT01694303|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
214956076|NCT03545633|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system.|"The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area.~Visible contractions will be induced by the device."
215078226|NCT03164317|OTHER|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
215078227|NCT03164317|OTHER|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
214348483|NCT02043496|BEHAVIORAL|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
214348484|NCT02043496|BEHAVIORAL|CBT-Guided Self Help|CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
214348485|NCT00260468|OTHER|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
214348486|NCT04483050|DEVICE|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
214348487|NCT02265562|DRUG|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
214348488|NCT02265562|DRUG|Placebo|60 minutes before the surgery 2 tablet of placebo inserted rectally
214348489|NCT02105116|DRUG|fludarabine phosphate|Given IV
214348490|NCT02105116|DRUG|cytarabine|Given IV
214348491|NCT02105116|BIOLOGICAL|donor lymphocytes|Undergo infusion of donor lymphocytes
214348492|NCT02105116|OTHER|laboratory biomarker analysis|Correlative studies
214348493|NCT02105116|DRUG|G-CSF|Given IV
214348494|NCT03667950|PROCEDURE|Hyperspectral Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
214956077|NCT00980733|DIETARY_SUPPLEMENT|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
214956078|NCT00980733|DIETARY_SUPPLEMENT|Yoghurt|Plain yoghurt same as in intervention group without fortification
214956079|NCT01983163|OTHER|Ketogenic diet (2.5 to 4:1)|Minimum ratio (2.5 to4:1) ketogenic diet causing ketosis will be given
215078228|NCT00446472|DRUG|Regranex®|Regranex gel will be used for a total of 16 weeks
215078229|NCT00446472|DRUG|Hydrogel|Placebo hydrogel will be applied for 16 weeks
215078230|NCT04210362|BEHAVIORAL|Workshops on responsive caregiving|Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
214348495|NCT00272857|GENETIC|Retrovirus Construct|This study will use an experimental gene transfer procedure performed in a laboratory to insert a new FA gene into the participant's bone marrow cells. The gene-corrected bone marrow cells will then be re-infused into the participant and participants will be observed for successful gene transfer
214348496|NCT03577600|PROCEDURE|QMRT with the Cytotron®|Cytotron® utilizes a combination of instantaneous magnetic field and RF at the safe, lowerend of the EM spectrum. Radiofrequency waves are computed based on individualized PD measurements of the target lesion(s) for therapeutic purpose. Its working principle is based on the underlying theory of magnetic resonance.
214348497|NCT06956287|DEVICE|LensHooke CA0|The intervention involves the use of the LensHooke CA0 sperm-wash device, which incorporates filtration and swim-up techniques to isolate motile and morphologically normal sperm with intact DNA integrity. It is used for sperm preparation in intrauterine insemination (IUI) cycles. The device is designed to reduce oxidative stress and facilitate physiological sperm selection, providing a potential improvement over conventional density gradient centrifugation (DGC).
214348498|NCT06956287|PROCEDURE|Density Gradient Centrifugation (DGC)|The control procedure involves the standard density gradient centrifugation (DGC) method, a widely accepted technique for sperm preparation in IUI. Semen samples are processed using commercially available gradient media to isolate progressively motile sperm. This method serves as the comparator to assess the clinical performance of the LensHooke CA0 device.
214348499|NCT02598492|OTHER|arterial blood gas|Just record clinical lab data
214348500|NCT01192906|DRUG|Placebo|Oral doses, once a day for 52 weeks
214348501|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
214348502|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
214348503|NCT05164159|DRUG|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 \~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
215078231|NCT03202355|DEVICE|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
215078232|NCT03202355|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
214348504|NCT05164159|DRUG|remimazolam group|In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
214348505|NCT00263666|BIOLOGICAL|Rotarix|Oral vaccination
214348506|NCT00263666|BIOLOGICAL|Placebo|Oral administration
214348507|NCT00263666|BIOLOGICAL|Tritanrix-HB+Hib|Concomitant routine vaccination, IM administration
214348508|NCT00263666|BIOLOGICAL|Polio Sabin|Oral administration, concomitant routine vaccination
214348509|NCT03112382|DRUG|zinc supplement plus vitamin A and E|
214348510|NCT03112382|DRUG|vitamin A and E|
214956080|NCT01983163|OTHER|Modified Atkin's diet|1:1 fixed ketogenic ratio Modified atkins diet will be given
214956081|NCT02187029|DRUG|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
214956082|NCT02187029|OTHER|Placebo|Daily dosing (tablet) for 14 days
214956083|NCT02187029|DRUG|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
214956084|NCT02187029|OTHER|Placebo|Daily dosing (tablets) for 14 days
214956085|NCT01449864|RADIATION|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
214956086|NCT00012389|DRUG|irinotecan hydrochloride|
214956087|NCT00012389|DRUG|oxaliplatin|
214956088|NCT00815503|DRUG|Ropivacaine|Approved by the Danish Medicines Agency
214348511|NCT04274608|DRUG|Botulinum toxin type A|Intragastric injection of Botulinum toxin type A
214348512|NCT04274608|BEHAVIORAL|Weight Management Program|12 week weight management program
214348513|NCT03261518|PROCEDURE|inferior vena cava ultrasound|Place the patient in the supine position. The degree of elevation of the head of the bed has not been shown to make a significant difference in measurements. The diameter of the IVC for calculation of the caval index should be measured 2 cm from where it enters the right atrium .An alternative way to visualize respiratory variation is to use M-mode, with the beam overlying the IVC 2 cm from the right atrium.The inspiratory and expiratory diameter can then be measured on the M-mode image, at the smallest and largest locations, respectively.
214348514|NCT00001768|DRUG|Intravenous immunoglobulin|
214348515|NCT00896168|DRUG|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
214348516|NCT00896168|DRUG|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
214348517|NCT01453816|PROCEDURE|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
214348518|NCT02492100|BEHAVIORAL|Multi-modality sexual dysfunction intervention|
214348519|NCT00563108|DRUG|Basiliximab|
214348520|NCT00563108|DRUG|Placebo|
214348521|NCT04654780|BEHAVIORAL|Taxes|"a High in food tax will be applied to study changes in purchasing and consumption behavior of participants in this group. The tax will correspond to a 20% increase over the market price, that is, a tax that reaches the levels recommended by the WHO."
214348522|NCT04654780|BEHAVIORAL|Subsidies|A subsidy will be applied to fruits and vegetables that means a reduction of 20% in their price, to study the changes in purchasing behavior and of the participants of said group.
214348523|NCT04654780|BEHAVIORAL|Control|Average or current food prices will apply. Based on the average of the values reported by three supermarkets
214348524|NCT05973110|BEHAVIORAL|Cognitive Remediation|In each of the 12 visits, participants will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for about 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
214348525|NCT05973110|BEHAVIORAL|Active Control|In each of the 12 visits, participants will complete exercises in virtual reality will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for around 10 to 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
214678641|NCT05503134|BIOLOGICAL|Universal Donor Natural Killer Cells|Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
214956089|NCT00815503|DRUG|Placebo|Saline
214956090|NCT00694356|BIOLOGICAL|Dalotuzumab|IV infusion
214956091|NCT06171516|BEHAVIORAL|iCBT|All participants will undergo 10 guided therapy sessions (once-weekly) with each session lasting 20 minutes. The therapy module will be given as an online self-learning source via videos in a website specifically developed for this training. The videos will divide the module content into several parts with each video lasting about 10 minutes.
214956092|NCT03349489|OTHER|Exercise 1|Participants will be admitted at the research center at 14:00. At 14:30, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
214956093|NCT03349489|OTHER|Exercise 2|Participants will be admitted at the research center at 14:00. At 15:20, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
214956094|NCT03349489|DEVICE|Dexcom G4 Platinum|The Dexcom G4 Platinum will be used to measure continuous glucose levels.
214956095|NCT03349489|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used.
214956096|NCT03349489|DEVICE|Insulin pump|Participant's insulin pump will be used to infuse insulin.
214348526|NCT01560390|DRUG|Rémifentamil + KETAMINE|All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.
214348527|NCT01560390|DRUG|ketamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
214348528|NCT01785329|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
214348529|NCT03377491|DEVICE|NovoTTF-200T|Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
214348530|NCT03377491|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
214348531|NCT03377491|DRUG|nab paclitaxel|nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
214348532|NCT05200195|PROCEDURE|Liver transplantation|Deceased or living donor liver transplantation for the cure of hepatocellular cancer on cirrhosis
214348533|NCT01021969|OTHER|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
214348534|NCT05561738|DIETARY_SUPPLEMENT|Nicotinamide Riboside Chloride|The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.
214348535|NCT05561738|DIETARY_SUPPLEMENT|Placebo|The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.
214348536|NCT05561738|OTHER|Standard of Care|Standard of Care
214348537|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
214348538|NCT03170960|DRUG|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
214348539|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
214956097|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
214348540|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
214348541|NCT05872347|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
214348542|NCT06027515|BEHAVIORAL|Prehabilitation Program|Multimodal prehabilitation program consisting of pre-surgical optimization of nutrition, physical function, and sleep health via individualized plans. Participants will also be supplied with Nestle Impact Advances Recovery Immunonutrition Drink.
214956098|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
214956099|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
214956100|NCT01247675|DRUG|Omnitrope|s.c., daily injection
214956101|NCT00954200|DRUG|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
214956102|NCT00954200|DRUG|ibuprofen|10mg/kg syrup - single dose
214348543|NCT00933569|DRUG|LACTIC ACID(ND)|treatment period: 21 consecutive days
214956103|NCT00639925|BIOLOGICAL|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
214956104|NCT05635877|DRUG|Esmolol|The treatment group was given Esmolol 0.5mg/kg load and 10μg /kg/min continuous pump
214956105|NCT05635877|DRUG|Placebo Comparator: Placebo Comparator:normal saline(0.9%)|The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
214348544|NCT02880800|DRUG|Morphine as IVPCA|"Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below:~Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours"
214348545|NCT02880800|DRUG|Hydromorphone as IVPCA|"Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below:~Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours."
214348546|NCT02880800|DRUG|Morphine|IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h)
214348547|NCT02880800|DRUG|Hydromorphone|Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h)
214348548|NCT05362864|PROCEDURE|Fracture fixation via Intramedullary Nailing|Fixation of trochanteric, sub-trochanteric, and shaft fractures and osteotomies.
214348549|NCT00057096|PROCEDURE|On-site vs. referral methods of care|
214393588|NCT02291289|DRUG|5-FU/LV|1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.
214348550|NCT02635633|DEVICE|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7\*(DEF-DM1) \[DEF = distance over EF; DM1 = distance over M1\]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
214348551|NCT01801020|OTHER|temperature measuremts|temporal artery temperature measurements will be taken from the forehead
214348552|NCT01801020|OTHER|temperature measuremts|different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
214348553|NCT05684328|PROCEDURE|WLI Then NBI Withdrawal|Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.
214956106|NCT00588705|BEHAVIORAL|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
214956107|NCT04075669|DIAGNOSTIC_TEST|Multiplex Strip PCR|Corneal scraping from patients will have its DNA extracted and eluted in the buffer. The DNA than mixed with the primer strips tube and be analyzed in Real-Time PCR machine. According to the record information from the hospital, the pathogen that usually found from endophthalmitis, keratitis, corneal ulcer diseases in our hospital is Pseudomonas sp., Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter sp., Pseudomonas aeruginosa, Acanthamoeba sp., Aspergillus fumigatus, Aspergillus flavus, Fusarium sp., and Candida albicans. And based on the report from Zhao et al (2014) Herpes Simplex Virus may be detected from patients with keratitis. Therefore in this study, we are trying to detect all of the pathogens simultaneously using the real-time PCR assay from patients corneal scraping who experience eye infections as mention above.
214956108|NCT04272047|OTHER|Knee Control+ program|15-20 minute training program to be performed at all team training sessions during the season.
214956109|NCT04272047|OTHER|Adductor strengthening program|Adductor strengthening program to be performed 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
214956110|NCT04272047|OTHER|Knee Control program|15-20 minute training program to be performed as per the team's usual routines (no intervention from the researchers).
214348554|NCT05684328|PROCEDURE|NBI Then WLI Withdrawal|Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.
214348555|NCT03902704|DEVICE|Cleverscope|the device is used in patients without difficult airways predictors
214348556|NCT03902704|DEVICE|Laryngoscope / Videolaryngoscope C-MAC® Storz|the device is used in patients with difficult airways predictors
214348557|NCT03008148|RADIATION|CCRT|CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
214348558|NCT03008148|DRUG|Temozolomide|Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
214348559|NCT03008148|DRUG|Siroquine|"1. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~2. Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
214348560|NCT04253522|BEHAVIORAL|Cognitive training|Rehabilitation program in standard ergotherapy and cognitive training with Covirtua Software and Transcranial random noise stimulation
214348561|NCT06182254|BEHAVIORAL|Experimental group: OPTIMISTIC follow-up|follow-up by nurses specialized in collecting the patient's point of view concerning his or her state of health, in addition to the usual conventional follow-up according to routine care directive interviews carried out preoperatively and at Days 1, 3, 14 and 28 postoperatively (modified QoR-15f score, PROMS...)
214956111|NCT05886907|DEVICE|Lehfilcon A multifocal toric contact lenses|Investigational silicone hydrogel contact lenses
214956112|NCT05886907|DEVICE|Samfilcon A multifocal toric contact lenses|Commercially available silicone hydrogel contact lenses
215078233|NCT06315036|OTHER|Developmental gymnastics|The DG exercise program ran from September 15, 2021, to May 15, 2022, in a well-equipped gymnasium. Led by trained teachers and gymnastics experts, sessions were held twice weekly (Tuesday and Thursday) for 60 minutes. The program focused on stability, locomotor skills, and manipulation, introducing children to DG fundamentals. It included circuit and station training, obstacle courses, and gradually increased exercise complexity. Sessions comprised a 15-minute warm-up, a 40-minute main session with skill practice and conditioning, and a 5-minute cool-down. The atmosphere was positive and friendly, with kid-friendly music and adapted procedures from previous research.
214956113|NCT05886907|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
214956114|NCT00405340|DRUG|Rituximab|Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.
214956115|NCT05582759|BEHAVIORAL|teleCBT-I + SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics, education on sleep hygiene and a four-week virtual cognitive behavioral therapy for insomnia intervention
214956116|NCT05582759|BEHAVIORAL|SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics and education on sleep hygiene
214348562|NCT06182254|OTHER|Control group: Usual conventional follow-up|usual conventional follow-up according to routine care (modified QoR-15f score will be administered to all patients at visit 0 and Day 35).
214348563|NCT03093831|DRUG|Ibrutinib|560mg administered orally once daily.
214348564|NCT06962176|PROCEDURE|Anterior Mitral Line Ablation|First pulmonary vein isolation (PVI) is performed - either as a first-time isolation (index procedure) or a re-isolation (in repeat procedures). Then a linear lesion is created on the anterior wall of the left atrium, from the roof line to the mitral annulus.
214348565|NCT06962176|PROCEDURE|Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion|Pulmonary vein isolation (PVI) is systematically carried out before any additional ablation lines are created - either as initial isolation or re-isolation. In this group the posterior mitral isthmus, a region between the left inferior pulmonary vein and the mitral annulus, is targeted. Endocardial ablation using a dual energy catheter (RF and PF) is combined with ethanol infusion in the vein of Marshall (VOM), which ablates the adjacent epicardial tissue to enhance lesion durability.
214348566|NCT02274714|OTHER|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
214348567|NCT00787657|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
214348568|NCT05566041|DRUG|RRx-001 + eLOOP Device|"RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device~Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy"
214348569|NCT05566041|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
214348570|NCT01281358|OTHER|HOP-ON|A programme of activities which promote motor development
214348571|NCT01281358|OTHER|SMILES|Details are provided on ways for parents to interact with their premature infants
214348572|NCT03319277|OTHER|Decreased opiate prescription|The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.
214348573|NCT03319277|OTHER|Routine opiate prescription|The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
214348574|NCT05428566|DIETARY_SUPPLEMENT|Pulse-based diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine and chickpeas) will be used."
214956117|NCT04084587|DEVICE|Retimax Vision Trainer|The Retimax Vision Trainer is an innovative method that aims to increase visual function in patients with eye diseases of various origins and nature, allowing the patient to exploit and optimize their residual visual potential. It is aimed at patients with visual impairments of different origins and severity, such as campimetric deficits, low vision of central origin, degenerative retinal diseases, amblyopia. (1,2) It consists of a device for recording bioelectrical responses evoked during the perception of structured visual stimuli and the control of the same by the patient through a sound biofeedback mechanism. This results in an increase in visual capacity, exploiting neuronal plasticity through the activation of alternative neuronal circuits.
214956118|NCT00124085|BEHAVIORAL|Disease Management|
214956119|NCT00124085|BEHAVIORAL|Disease Management + Educational Home Visits|
214956120|NCT03083808|DRUG|Pembrolizumab|"Pembrolizumab 200mg IV every 21 days~\+~Physician's choice chemotherapy with one of the following every 21 days:~* Docetaxel 75mg/m2 IV~* Pemetrexed 500mg/m2 IV (non-squamous only)~* Gemcitabine 1000mg/m2 IV on days 1 and 8"
215078234|NCT05526976|OTHER|PERISCOPE-care|Patients with planned elective surgery will be asked to complete the PERISCOP3E-Care questionnaire (modified-Althaus \& Kalkman, DN4, HADS, Stait-trait, NRS, MPI, EQ-5D-5L) preoperative. One month and three months post op the patients will be contacted to check if they developed persistend postoperative pain and they will also complete questionnaires (DN4, HADS, Stait-trait, NRS, MPI and EQ-5D-5L).
215078235|NCT01395121|DRUG|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
214956121|NCT02944474|DRUG|Lucerastat|Capsule for oral administration containing lucerastat
215078236|NCT02891681|DEVICE|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
215078237|NCT00831610|PROCEDURE|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
215078238|NCT00831610|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
214956122|NCT02944474|DRUG|Placebo|Placebo capsules matching lucerastat capsules
214956123|NCT02889770|OTHER|PEEP titration|Exposure to different PEEP levels
214956124|NCT05327595|DRUG|LY3549492|Administered orally.
214956125|NCT05327595|DRUG|Placebo|Administered orally.
215078239|NCT05211921|DEVICE|Multi-Gyn ActiGel Plus|vaginal gel
215078240|NCT06276881|BEHAVIORAL|Visual Stimulation|AI-guided visual stimuli presented on an electronic screen
215078241|NCT01382121|BEHAVIORAL|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
215078242|NCT01382121|BEHAVIORAL|Control|watching a video unrelated to the fitness test and self-efficacy
214956126|NCT05327595|DRUG|Atorvastatin|Administered orally.
214956127|NCT05327595|DRUG|Midazolam|Administered orally.
214956128|NCT05556941|BEHAVIORAL|Metacognitive Group Intervention|The investigators developed an initial Meta cognitive group intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored it to individuals with schizophrenia.
214956129|NCT05556941|BEHAVIORAL|Occupational therapy standard care|Occupational therapy standard care
214348575|NCT05428566|DIETARY_SUPPLEMENT|TLC diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber."
214348576|NCT05917405|DRUG|Fludarabine|30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
214348577|NCT05917405|DRUG|Busulfan|130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
214348578|NCT05917405|DRUG|ATG|Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
214348579|NCT05917405|DRUG|Clofarabine|30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
214348580|NCT02346383|DEVICE|preset program|Change to different present program using epidural and peripheral lead to cover pain
214956130|NCT00396474|OTHER|post GH treatment observational study|Intravenous glucose tolerance test (IVGTT)
214956131|NCT02700425|DEVICE|CRT Pacemaker|Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
214956132|NCT05621850|OTHER|Blood sample|Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol
214956133|NCT01301079|DRUG|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
215078243|NCT02632201|BIOLOGICAL|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
215078244|NCT02632201|BIOLOGICAL|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
215078245|NCT05636410|DIAGNOSTIC_TEST|Larynx and trachea ultrasound|After meeting enrolment criteria the larynx and trachea ultrasound will be performed at 32 and 42 weeks of gestation.
214348581|NCT06258967|DRUG|ciprofol|Patients receive ciprofol as general anesthesia induction drug, using the titrated anesthesia method.
214348582|NCT06258967|DRUG|propofol|Patients receive propofol as general anesthesia induction drug, using the titrated anesthesia method.
214348583|NCT01351285|DRUG|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
214348584|NCT00858065|BEHAVIORAL|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
214348585|NCT00858065|BEHAVIORAL|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
214348586|NCT03833999|DRUG|Ondansetron 8mg|ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
214348587|NCT03833999|DIAGNOSTIC_TEST|abdominal MRI|serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
214348588|NCT03833999|DRUG|Lactulose|Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
214348589|NCT03833999|DRUG|Placebo oral capsule|overcoated placebo tablet, identical to the ondansetron
214956134|NCT01301079|DRUG|Saline|Patients in group N (placebo) was administrated saline during surgery.
214956135|NCT03453814|OTHER|Music Therapy|Subjects will receive one hour of music twice a day for three days.
214956136|NCT04059939|OTHER|Reading|Small group reading instruction
214956137|NCT04059939|BEHAVIORAL|Anxiety Management|small group anxiety management skills instruction
214956138|NCT04059939|OTHER|Classroom Business as Usual|Classroom Business as Usual
214956139|NCT04059939|OTHER|Attention Control (math practice)|Attention Control (math practice)
214956140|NCT02477371|PROCEDURE|Fractional flow reserve-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values \> 0,8 are deferred.
214348590|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants
214956141|NCT02477371|PROCEDURE|Angiography-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.
214956142|NCT00002261|BIOLOGICAL|Smallpox Vaccine|
214956143|NCT00002261|BIOLOGICAL|HIVAC-1e|
214956144|NCT00002261|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214348591|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
214348592|NCT02597400|DRUG|Metformin|"* Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals"
214348593|NCT02597400|DRUG|HMS5552|"* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~* HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
214348594|NCT02323971|DRUG|Ticagrelor|
214348595|NCT04337710|PROCEDURE|Exclusive Enteral Nutrition|Mom's milk or donor milk at 60-80 ml/kg/day after randomization within the first 24 hours.
214348596|NCT04337710|PROCEDURE|Progressive Enteral Nutrition|Mom's milk or donor milk at 20-30 ml/kg/day after randomization within the first 24 hours.
214956145|NCT03377062|DIAGNOSTIC_TEST|EEG monitoring|Five-minute of EEG monitoring accompanied with auditory stimulation.
214956146|NCT05761457|OTHER|Cryopreserved autologous platelet transfusion|Autologous PLTs were collected and transfused as an individualized treatment approach, when the platelet is less than 20\*10E9/L or severe bleeding occurred.
214956147|NCT02857036|OTHER|rhythmic parameter recording|the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
214956148|NCT02857036|BEHAVIORAL|psychiatric assessment|different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
214956149|NCT04369963|PROCEDURE|Esophagogastroduodenoscopy and Colonoscopy with Biopsies|Participants will have an esophagogastroduodenoscopy and colonoscopy with biopsies. Biopsies from esophagogastroduodenoscopy will not exceed 16 pinch biopsies, biopsies from colonoscopy will not exceed 16 pinch biopsies. Participants will have anesthesia for both procedures.
214956150|NCT02496039|DRUG|NUEDEXTA®|NUEDEXTA® only
214956151|NCT05121805|PROCEDURE|Snare tip soft coagulation|Thermal ablation of the entire resection margin
214956152|NCT02968459|OTHER|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
214956153|NCT02968459|OTHER|0.9% Saline|Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
215078246|NCT01552616|PROCEDURE|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
215078247|NCT03434431|OTHER|Reverse dieting|
215078248|NCT01328834|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
215078249|NCT00002319|DRUG|Doxorubicin hydrochloride (liposomal)|
215078250|NCT00856206|BIOLOGICAL|Rilonacept|Rilonacept 160 mg subcutaneous injection once a week
214348597|NCT00710047|DRUG|ZD4054|one single 10mg dose
214348598|NCT03406247|DRUG|Nivolumab|"Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~\- nivolumab 240 mg every 2 weeks during 6 months"
214348599|NCT03406247|DRUG|Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~\- ipilimumab 1mg/kg IV every 6 weeks during 6 months"
214348600|NCT02330835|BEHAVIORAL|In the Drivers Seat|Multimedia student behavior management program for school bus drivers and school administrators
214348601|NCT02330835|BEHAVIORAL|School bus driver training videos|Basic bus driving safety videos
214348602|NCT01037920|BEHAVIORAL|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
214678642|NCT01839188|BIOLOGICAL|PR5I|Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Hepatitis B \[HB; Recombinant DNA\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
214956154|NCT04472494|BIOLOGICAL|Abatacept|Specified dose on specified days
214678643|NCT01839188|BIOLOGICAL|Pediacel®|Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
214956155|NCT04472494|OTHER|Placebo|Specified dose on specified days
214956156|NCT00571103|DRUG|acamprosate|Two 333mg tablets taken three times daily.
214956157|NCT02923401|OTHER|Exercise|"High-Intensity Interval Training (HIIT) Group: Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.There is a 5-minute warm up, followed by four 4-minute intervals. Between each interval, participant walks for 3 minutes. There is a 3 minute cool down.~Moderate-Intensity Continuous Training (MICT) Group: Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks."
214956158|NCT02923401|BEHAVIORAL|Questionnaires|Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
214956159|NCT02923401|BEHAVIORAL|Motivational Session|One (1) time each month, participant attends a motivational session for 12 weeks.
214678644|NCT01839188|BIOLOGICAL|NeisVac-C®|Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
214956160|NCT02923401|BEHAVIORAL|Phone Call|Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals. Each phone call should take about 15 minutes.
215078251|NCT00856206|OTHER|Placebo|Placebo subcutaneous injection once a week
215078252|NCT04783649|DIAGNOSTIC_TEST|Papanicolaou cytological test|Cervical smear stained using conventional Papanicolaou technique.
215078253|NCT04783649|DIAGNOSTIC_TEST|Local cytological test (H&E stain)|Cervical smear stained using conventional hematoxylin and eosin staining techniques
214348603|NCT01037920|BEHAVIORAL|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
214348604|NCT06097949|DEVICE|AcuPebble SA100|This device is not being used as an interventional device but simply a monitoring tool on patients already on CPAP therapy. The device is being used within the scope of it's intended purpose as a medical device to diagnose OSA.
214348605|NCT05803226|BEHAVIORAL|Slow Art Plus|Slow Art Plus involved a full 90-minute engagement, one that is built upon the existing Slow Art programme with added layers of mindfulness and self-compassion practices, as well as a response art activity that fosters symbolic dialogue and an emotional aesthetic experience between participants and the selected artwork.
214348606|NCT05244473|DRUG|brentuximab vedotin|Given into the vein (IV; intravenously)
214348607|NCT05244473|DRUG|Placebo|Given by IV
214348608|NCT05244473|DRUG|ART|Daily use of a combination of HIV medicines
214348609|NCT01003899|DRUG|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
214348610|NCT05048147|BEHAVIORAL|Community Mobilization|The Community Mobilization (CM) strategy will include: (1) Community advisory board \[comprising local community-based organizations, government officials, and residents\], that will provide leadership support and buy-in for adoption of Clean Fuel- Clean- Stove (CF-CS) use; (2) Trained MoH community health extension workers, community health officers, community mobilizers and health education officers, who will form community action teams (CAT) to facilitate the implementation of CF-CS use via provision of support, knowledge exchange and performance feedback to the primary cooks in participating households; (3) Community dialogues with residents and households focused on shared concerns on the significance and importance of CF-CS use.
214956161|NCT02923401|OTHER|Printed Materials|"High-Intensity Interval Training (HIIT) Group and Moderate-Intensity Continuous Training (MICT) Group: Participants receive written materials and instructions on how to perform their exercises.~Control Group: Participants receive written materials and counseling by an exercise physiologist."
214956162|NCT06462170|DIETARY_SUPPLEMENT|Boost Original meal replacement shake|One bottle of Boost Original meal replacement shake.
214956163|NCT01915901|DRUG|bismuth subsalicylate (Pepto-Bismol®)|524 mg bismuth subsalicylate twice a day (BID)
214956164|NCT01915901|DRUG|matching placebo (bismuth subsalicylate)|placebo twice a day (BID)
214956165|NCT01915901|DRUG|dimethyl fumarate (DMF)|dimethyl fumarate (DMF) twice a day (BID)
214956166|NCT05294965|DRUG|Fenoterol|Intravenous infusion
214956167|NCT05294965|OTHER|Mild cold exposure|Body surface cooling
214956168|NCT02699827|DRUG|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
214348611|NCT04389762|DIETARY_SUPPLEMENT|daily ingestion of Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
214348612|NCT01045629|OTHER|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
214956169|NCT02699827|DRUG|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
214956170|NCT02699827|DRUG|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
214956171|NCT02029482|DRUG|ACT-128800|
214956172|NCT02029482|DRUG|Placebo|
214956173|NCT04626258|DRUG|Fluconazole|Fluconazol once a month 150 mg capsule
214956174|NCT04626258|OTHER|L-Mesitran|The first month apply every day one sachet, the next five months apply every week one sachet.
214956175|NCT03954002|DIAGNOSTIC_TEST|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
214956176|NCT05588752|OTHER|TAP block|TAP block under ultrasound
214956177|NCT05345678|DRUG|Durvalumab|Dose: 1500mg Route: IV
214956178|NCT05345678|DRUG|Tremelimumab|Dose: 300mg Route: IV
214956179|NCT04786236|DEVICE|"Physiological Control Module for the Medtronic -HVAD Left Ventricular Assist Device"|Software, which sets the device speed according to physiological demand, is activated for the duration of the tests (up to 4 hours). Every patient provides his/her own control, because sequences with active control and with standard pump operation are subsequently performed in randomized order (determined by permutated blocks).
214348613|NCT06481501|BEHAVIORAL|ONE Mindfulness-Oriented Recovery Enhancement|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
214348614|NCT06266767|DRUG|Levobupivacaine and Fentanyl|Programmed Intermittent Epidural Bolus
214348615|NCT02291887|DRUG|Ranibizumab|Intravitreal injection of Ranibizumab
214348616|NCT02291887|DRUG|Aflibercept|Intravitreal injection of Aflibercept
214348617|NCT01512225|DRUG|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 28 days
214348618|NCT01512225|DRUG|Placebo Tablet|placebo tablet 10 mg orally three times daily for 14 days
214348619|NCT01512225|DRUG|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 14 days
214348620|NCT02489500|DRUG|Bortezomib|"Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1"
214348621|NCT02489500|DRUG|Melphalan|"Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0"
214348622|NCT02489500|DRUG|Neupogen|granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
214348623|NCT02489500|PROCEDURE|Stem Cell Collection|collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells
214956180|NCT03735407|DEVICE|C-Scan procedure|"The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,"
214956181|NCT01728441|DEVICE|Paclitaxel Eluting Stent|
214956182|NCT01728441|DEVICE|Paclitaxel Eluting Balloon|
214956183|NCT04186624|DRUG|Subacromial-subdeltoid bursa corticosteroid injection|1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
215078254|NCT04783649|DIAGNOSTIC_TEST|Validated HPV DNA Test|Digene HC2 HPV DNA Test
214348624|NCT02489500|PROCEDURE|Stem cell infusion|infusion of previously collected autologous stem cells
214348625|NCT05861934|BEHAVIORAL|Distant reiki group|ccording to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced twice a week for 6 weeks by researchers who have completed the Phase 2 training. The time of remote reiki application will be planned by talking with the patient.
214348626|NCT00963365|DRUG|AZD6765|Single oral dose and single IV infusion of AZD6765
214348627|NCT00963365|DRUG|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
214348628|NCT06014996|DEVICE|Pulsed Field Ablation (PFA) Therapy|In the test group, subjects will undertake PVI using the PFA system including a nanosecond-scale pulsed field generator (InRythm, Insight Lifetech, Shenzhen, China), a lotos catheter that is expandable over the wire (LotosPFA, Insight Lifetech), and a customized 12-French steerable sheath (InBridge, Insight Lifetech).
214348629|NCT06014996|DEVICE|Radiofrequency Ablation（RAF）Therapy|In the control group, subjects will undergo PVI using an RFA system including CARTO VISITAG Module and the THERMOCOOL SMARTTOUCH Catheter (Biosense Webster Inc., Diamond Bar, CA, USA). PVI was performed with AI values of 400-450 in the anterior, 300-350 at the posterior wall of the LA.
214348630|NCT06429748|DEVICE|rTMS|repetitive Transcranial Magnetic Stimultion
214348631|NCT06151353|DIAGNOSTIC_TEST|REMS|Bone health assessment using REMS, an ultrasound technology developed to measure bone mineral density and bone toughness without ionising radiation
214348632|NCT03884751|BIOLOGICAL|CAR-GPC3 T Cells|CAR-GPC3 T Cells injection
214348633|NCT04586101|DEVICE|Trainings application|Participants have to train with the developed trainings application over six weeks. For this, individual training plans are implemented in the application based on orthopedic joint status and training recommendations of a sports scientist.
214348634|NCT02863926|BIOLOGICAL|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
214393589|NCT02291289|DRUG|Capecitabine|1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.
214393590|NCT05742724|DRUG|Tetrahydrocannabinol-Cannabidiol Combination|Oral THC 0.1mg/kg and CBD 2.5mg/kg
214956184|NCT02624635|OTHER|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
215078255|NCT04783649|DIAGNOSTIC_TEST|Local HPV test|RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)
215078256|NCT04783649|DIAGNOSTIC_TEST|Colposcopy|Women with positive cytology results are referred to colposcopy and biopsy
215078257|NCT06145165|OTHER|Nerve block with ropivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
215078258|NCT06145165|COMBINATION_PRODUCT|Nerve block with liposomal bupivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
214348635|NCT06958094|OTHER|Gamified mobile health applications|"* Voice Volume Catcher: A game where players control a character's movement by modulating their voice volume. Louder or softer sounds move a basket to collect different types of fruits, encouraging continuous vocal engagement and fine control of breath intensity.~* Scream Go Hero: A voice-controlled platform game where players produce short or long vocalizations to make the hero character jump or move across obstacles. The game demands breath control and supports prolonged exhalations for larger jumps with an open glottis, which is beneficial for airway clearance.~* Chicken Scream: A voice-activated game where players guide a chicken character by varying their vocal intensity to make it walk, jump, and avoid enemies. Participants must dynamically adjust their breath pressure and vocal intensity while maintaining open-glottis breathing, promoting agility in respiratory control."
214348636|NCT06958094|OTHER|Conventional Airway Clearance Therapy|"* Autogenic Drainage: A technique where participants perform a series of controlled breathing cycles-deep inhalations followed by forceful exhalations-to mobilize mucus from the lower airways to the upper airways. The technique encourages breath control and helps clear secretions without the need for coughing, promoting efficient airway clearance.~* Active Cycle of Breathing Techniques (ACBT): In this technique, participants alternate between relaxed breathing, deep breaths, and huffing to mobilize and expel mucus from the lungs. It focuses on breathing control to loosen and expel secretions effectively while maintaining a steady airflow throughout the process.~* Positive Expiratory Pressure (PEP) Therapy: This technique involves exhaling against a resistance through a device, which helps to open the airways and prevent their collapse. The resistance promotes prolonged exhalations, facilitating the movement of mucus from the small airways to the larger airways for easier clearance."
214348637|NCT06958094|OTHER|Combination Treatment|"\- Gamified mHealth Apps (10 minutes):~Voice Volume Catcher~Scream Go Hero~Chicken Scream~\- Conventional Airway Clearance Techniques (10 minutes):~Autogenic Drainage~Active Cycle of Breathing Techniques (ACBT)~Positive Expiratory Pressure (PEP) Therapy"
214502578|NCT01878305|DEVICE|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
214956185|NCT02624635|OTHER|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ \[1.0278 - (0.0278 x number of repetitions)\] as was used by (Shirazi et al., 2007).
214956186|NCT02641275|OTHER|Structured self-management-training|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions
214956187|NCT02103699|DRUG|No intervention|This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
214956188|NCT05035875|DEVICE|ultrasonography|ultrasound assessment of diaphragm function
214956189|NCT01308463|DEVICE|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
214956190|NCT02477436|DRUG|Avanafil|"* One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~* Investigational products were administered prior to the sexual intercourse for total 8 weeks."
214956191|NCT02477436|DRUG|Placebo|"* One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.~* Placebos were administered prior to the sexual intercourse for total 8 weeks."
214956192|NCT03297021|DRUG|Ondansetron 4 MG|dose as per arm selection
214956193|NCT03297021|DRUG|Ondansetron 8mg|dose as per arm selection
214956194|NCT01191099|DEVICE|Pimonidazol|0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy
214956195|NCT04648657|DEVICE|Lung Ultrasound|Echography of Lungs based on artifacts study
214956196|NCT04648657|DEVICE|Electric impedance tomography|Low alternating electrical currents (usually \<5 milliampere at 50-80 kHz) applied through different pair of electrodes on thorax
215078259|NCT06145165|OTHER|Intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
215078260|NCT04584346|DIETARY_SUPPLEMENT|Liquigen MCT oil|MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values
214348638|NCT06957938|DRUG|Neoadjuvant Chemotherapy (NACT)|Neoadjuvant Chemotherapy with paclitaxel (or albumin - bound paclitaxel) and cisplatin
214348639|NCT06957938|DRUG|Neoadjuvant and maintenance Tislelizumab|Neoadjuvant and maintenance Tislelizumab
214348640|NCT06957938|RADIATION|Concurrent chemo-radiotherapy (CCRT)|Concurrent chemo-radiotherapy (CCRT), with cisplatin-based chemotherapy
214348641|NCT06957938|PROCEDURE|Surgery and adjuvant (chemo-)radiotherapy|Definitive surgery, with adjuvant (chemo-)radiotherapy, depending on pathologic findings.
214348642|NCT03199365|BEHAVIORAL|Behavioral Dietary Intervention|Undergo TSSC intervention sessions
214348643|NCT03199365|BEHAVIORAL|Behavioral Intervention|Undergo TSSC intervention sessions
214348644|NCT03363373|BIOLOGICAL|GM-CSF + Naxitamab|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody
214502579|NCT03520036|DRUG|MT-7117 low dose|MT-7117 low dose QD, oral, 16 weeks
214502580|NCT03520036|DRUG|MT-7117 high dose|MT-7117 high dose QD, oral, 16 weeks
214502581|NCT03520036|DRUG|Placebo|Placebo QD, oral, 16 weeks
214502582|NCT06682143|BEHAVIORAL|Virtual Reality (VR)|Participants will engage in a virtual reality greenspace activity for a period of 5 minutes
214502583|NCT06682143|BEHAVIORAL|Control|Participants will sit quietly for a period of 5 minutes
214502584|NCT00012259|DRUG|troxacitabine|
214956197|NCT01238419|DEVICE|Physiotulle|Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline
214348645|NCT05027477|DEVICE|Radical Prostatectomy|If you are in this group, you will get the standard of care treatment used to treat this type of cancer: radical prostatectomy. You will undergo this procedure as per standard clinical practice. A radical prostatectomy is a surgical procedure that removes the prostate gland. This is done by making a surgical incision and removing the prostate gland.
214348646|NCT05027477|DEVICE|TULSA Procedure|If you are in this group, you will get the TULSA Procedure. The TULSA Procedure is a minimally invasive procedure that uses directional ultrasound to produce very high temperature to ablate (destroy) targeted prostate tissue. The procedure is performed in a MRI suite (the physician can see the prostate at all times throughout the procedure) and uses the TULSA-PRO system to ablate prostate tissue. The procedure combines real-time MRI with robotically-driven directional thermal ultrasound to deliver predictable, physician-prescribed ablation of the prostate. Minimally invasive here means that the procedure is performed through natural openings in your body (the urethra) instead of creating larger openings like in traditional surgery.
214348647|NCT06042517|DEVICE|Ultrasound|The General Electric LOGIQ E10 ultrasound pulsed doppler imaging system and C1-6-D XDclear abdominal curvilinear probe will be used to administer ultrasound.
214348648|NCT06042517|DIAGNOSTIC_TEST|OGTT with unlabeled glucose and liver NMR|Subjects will undergo an OGTT with unlabeled glucose to measure liver glycogen concentration by NMR spectroscopy.
214348649|NCT06042517|DIAGNOSTIC_TEST|OGTT with carbon-13 labeled glucose and liver NMR|Subjects will undergo an OGTT with carbon-13 labeled glucose to measure liver glycogen synthesis rate by NMR spectroscopy.
214956198|NCT01238419|DEVICE|URGOTUL|Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
214678645|NCT01839188|BIOLOGICAL|RotaTeq®|Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
214348650|NCT06042517|DIAGNOSTIC_TEST|CGM glucose reading|A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.
214348651|NCT06042517|DIAGNOSTIC_TEST|HEC - Hyperinsulinemic-Euglycemic-Clamp|A constant i.v. insulin and variable glucose infusion will be used to determine insulin sensitivity of study participants.
214348652|NCT00290940|DRUG|CS-917|
214956199|NCT01514877|DRUG|Icotinib|Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
214956200|NCT03635008|DEVICE|tDCS|Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
214956201|NCT01912053|RADIATION|Therasphere® in association with Gemcitabine and Cisplatin|Therasphere® is a radioelement
214956202|NCT02640898|RADIATION|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
214348653|NCT00290940|DRUG|metformin hydrochloride|
214348654|NCT00290940|DRUG|pioglitazone|
214348655|NCT01259713|DRUG|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
214678646|NCT01839188|BIOLOGICAL|Prevenar 13®|Pneumococcal polysaccharide conjugate vaccine \[PCV; 13-valent, adsorbed\]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
214956203|NCT02640898|RADIATION|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
214348656|NCT01259713|DRUG|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
214348657|NCT06275646|OTHER|PRP layer|platelet rich plasma layer was applied in addition to dartos flap
214348658|NCT06275646|OTHER|dartos flap|dartos flap alone was used
214348659|NCT03001648|PROCEDURE|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
214678647|NCT05570916|DEVICE|Zip-stitch(R)|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
214956204|NCT02112019|PROCEDURE|Sialoendoscopy|
214956205|NCT02112019|DRUG|saline|
214956206|NCT02112019|DRUG|hydrocortisone|
215078261|NCT04584346|OTHER|Standard American Diet|Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
215078262|NCT04412733|DEVICE|Therapeutic Pulsed Ultrasound|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2). Pulsed ultrasound treatment were applied with 5-cm2 head Enraf-Nonius Sonopuls 434 ultrasound device.
215078263|NCT04412733|DEVICE|Sham Ultrasound|Control group received sham ultrasound treatment
215078264|NCT02442453|DRUG|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
215078265|NCT02442453|DRUG|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
215078266|NCT00358332|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
214956207|NCT06832202|DRUG|HLX22|HLX22 15mg/kg Q3W
214348660|NCT01477827|OTHER|None - observational study|
214348661|NCT03943732|DIAGNOSTIC_TEST|FilmArray Pneumonia|FilmArray Pneumonia testing of tracheal sample
214348662|NCT03422250|DEVICE|transcranial direct current stimulation (tDCS)|10 daily 25-minutes tDCS sessions over two weeks.
214348663|NCT00440050|DRUG|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
214348664|NCT00440050|DRUG|Placebo|2 placebo capsules twice a day for 18 months
214348665|NCT00579917|BEHAVIORAL|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
214348666|NCT00579917|BEHAVIORAL|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
214348667|NCT04233268|DIAGNOSTIC_TEST|Rapid Pathogen Detection|Rapid assays for pathogen detection on bronchoalveolar lavage fluid
214348668|NCT01780922|OTHER|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
214348669|NCT01780922|OTHER|Cranberry Extract Beverage|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
214348670|NCT01780922|OTHER|Non-Cranberry Beverage|Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
214348671|NCT03179228|DEVICE|Prostate Embolization|Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
214348672|NCT06111742|DEVICE|Bedside Entertainment and Relaxation Theater (BERT)|BERT is a Nebula Capsule Max portable projector that creates a familiar theater experience designed for children to divert attention away from procedures. It is fitted with a remote control that can be utilized to manage on-screen activities. BERT can be used with any wall, ceiling, or projector screen to create the theater experience with a large screen. It can also be used with assist devices, such as steering wheel and noise-canceling headphones.
214348673|NCT06346288|PROCEDURE|Breast Milk Sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of commercial risankizumab at pre-dose and 1 hour after dosing on Day 1, on Days 4 (± 1), 8 (± 2), 15 (± 3), 29 (± 3), and pre-dose on Day 57 (± 3)
214956208|NCT06832202|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan 5.4mg/kg Q3W
214348674|NCT06346288|DRUG|Risankizumab|Participants will have already been taking commercial risankizumab and will continue on commercial risankizumab. Participants will not be provided risankizumab from the study. Participants must have received at least 2 doses of 360 mg of risankizumab SC every 8 weeks postpartum prior to start of participation in this study.
214348675|NCT03929146|DRUG|Exparel|Patients will receive a local injection of liposomal bupivacaine near the end of their shoulder arthroplasty operation.
214348676|NCT03929146|PROCEDURE|Interscalene Nerve Block|Patients will undergo a pre-operative interscalene nerve block performed by the anesthesiology team.
214348677|NCT05069350|DRUG|bupivacaine 0.5% and oxubuprocaine|using each drug as surface anesthesia before intravitreal injections
214348678|NCT00328419|DEVICE|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
214348679|NCT00328419|DEVICE|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
214348680|NCT02059694|DRUG|Hyaluronidase|
214956209|NCT00898755|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214956210|NCT00898755|OTHER|Laboratory Biomarker Analysis|Correlative studies
214348681|NCT02059694|OTHER|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
214348682|NCT01826591|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
214348683|NCT01826591|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
214348684|NCT01826591|BEHAVIORAL|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
214348685|NCT05676684|DRUG|Dapagliflozin|A: Dapagliflozin 10 mg once daily
214348686|NCT05676684|DRUG|Spironolactone + Dapagliflozin|C: Dapagliflozin 10 mg once daily plus Spironolactone 25mg/every other day or 25mg/day (can be adjusted according to potassium and renal function)
214348687|NCT02766543|DEVICE|MRI-guided Transurethral Ultrasound Ablation|Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
214348688|NCT02057146|PROCEDURE|Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy|The intervention consists of mother-baby endoscopy of the bile and/or pancreatic duct with visual inspection, confocal laser microscopy, collection of fluid for cytology, and eventually biopsy.
214956211|NCT03776526|BEHAVIORAL|Fitbit® Alta HR Sleep monitoring|Patients will be fitted with a Fitbit® Alta HR after surgery, which will monitor sleep quality (sleep duration and number of awakenings) for the duration of hospitalization.
214956212|NCT03577379|OTHER|Whole Blood Fibrin Clot|For all patients assigned to the treatment group, 35mL of whole blood will be obtained during surgery by an anesthesiologist. 5 mL of the blood will be sent for pre-clot formation cell count evaluation for platelets, red blood cells and white blood cells. The remaining 30mL will be placed into a sterile container with a sintered glass cylinder supported by the lid for fibrin clot formation. The clot formation cups will be placed on a rotator at room temperature for 10 minutes at 125rpm. The fibrin clot will be removed and 5mL of the post-clot serum sent for post-clot formation cell count evaluation for platelets, red blood cells, and white blood cells.
214956213|NCT04414423|PROCEDURE|bone marrow concentrate alveolar cleft grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft combined with bone marrow concentrate
214956214|NCT04414423|PROCEDURE|Autogenous alveolar grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft
214348689|NCT01917526|DEVICE|oxygen mask|
214348690|NCT01917526|DEVICE|oxygen cannula|
214348691|NCT05633784|OTHER|Teleassistance|Support the nursing case manager through a structured teleconsultation program (telephone and videoconference support at least once a week)
214348692|NCT05633784|OTHER|Teleconsultation|Cardiological and Diabetological teleconsultation at the beginning of the program and in case of need during the program.
214348693|NCT05633784|OTHER|Telerehabilitation|Support from a physiotherapist (if needed)
214348694|NCT05633784|OTHER|Telemonitoring|Telemonitoring of patient vital signs (eg single electrocardiographic trace) and delay steps
214348695|NCT05633784|OTHER|mHealth|The support of an App for recording and monitoring parameters: delay treatment, clinical parameters such as glycemia, blood pressure, HR, symptoms, etc.
214348696|NCT05633784|OTHER|telepsycology|Psychological support (if necessary)
214348697|NCT05633784|OTHER|Quality of life|Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire
214956215|NCT03597321|BIOLOGICAL|prophylactic donor lymphocyte infusion (DLI)|DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
214956216|NCT04096001|DEVICE|Woebot-SUDs (W-SUDs)|Woebot-SUDs (W-SUDS), an artificially intelligence-powered conversational agent on a smartphone app, eliminates most current SUDs treatment barriers while simultaneously leveraging technology to enhance user experience and engagement. W-SUDs expands and refines existing SUDs treatments by adapting skills from cognitive behavioral therapy, motivational interviewing, and dialectical behavior therapy.
214956217|NCT05535426|DEVICE|Tetranite Implant Stabilization Material|Dental adhesive for increased implant stabilization
214956218|NCT02290847|BEHAVIORAL|Cognitive Processing Therapy (cognitive only version; CPT-C)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, \& Chard, 2008; Resick \& Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
215078267|NCT00358332|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
215078268|NCT05834400|BEHAVIORAL|The Optimal Lymph FLow (TOLF)|Participants in TOLF intervention will complete initial in-person 40-minute session on TOLF lymphatic exercise training and daily monitoring, and 3 virtual 15-minute telehealth sessions to enhance their skills over the course of 4 weeks. These sessions will be conducted by the TOLF interventionist of the study. For 4-week study duration, participants will be asked to practice the set of 8 lymphatic exercises twice a day.
214348698|NCT05633784|OTHER|Biochemistry evaluation|Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP
214348699|NCT05633784|OTHER|Clinical evaluation|6-minute-walking test, IMC, NYHA class, Ejection fraction
214348700|NCT05633784|OTHER|State of health of the patient|Severity Index and Comordbidity index
214348701|NCT04717596|OTHER|BC4Teens Care|Healthcare providers will be trained in contraceptive counseling and provision.
214348702|NCT00242034|PROCEDURE|CT and MRI with contrast|
214348703|NCT05547932|PROCEDURE|RIB+SAP blocks|RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
214678648|NCT05570916|DEVICE|Reference suture|Standard suture for vaginal cuff closure during laparoscopic hysterectomy
215078269|NCT05834400|BEHAVIORAL|Daily Monitoring|Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
215078270|NCT04583787|DIAGNOSTIC_TEST|99mTc-sestamibi myocardial perfusion SPECT|82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
215078271|NCT04583787|DIAGNOSTIC_TEST|82Rb-Chloride myocardial perfusion PET with CCTA|stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
214348704|NCT04603989|DRUG|HNC042 for Injection|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
214348705|NCT04603989|DRUG|Placebo Comparator|Placebo , Intravenous route , multiple ascending doses
214348706|NCT02796326|DEVICE|improved tracheal balloon dilatation|Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
214348707|NCT03056846|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
214348708|NCT03056846|DIETARY_SUPPLEMENT|Probiotic Combination|A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
214348709|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium bifidum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
214348710|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium longum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
214348711|NCT03210506|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
214678649|NCT02481037|OTHER|Primary care clinical pathway|Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
214956219|NCT05326438|BEHAVIORAL|CIRCLE mHealth app|For the intervention, participants will be given access to an mHealth sobriety app that has been modified for Alaska Native/American Indian people. The app allows people to track their sobriety, learn new recovery skills, track treatment plans, set reminders, journal about their recovery, and discover helpful videos and testimonials through an extensive resource library that includes culturally meaningful content, graphics, music, videos, recovery tools, and testimonials. Users can also participate in an interactive peer platform and/or participate in group chats to engage participants in facilitated discussions about sobriety, lifestyle changes, cultural content, and Community Reinforcement Approach skill-building.
214956220|NCT04717089|OTHER|overnight intensive recovery / extended post anaesthetic care in PACU|From January 2020, during COVID-19 first pandemics in Hong Kong, a bundle of interim measures was implemented with the joint efforts of the Department of Anaesthesia and Operating Theatre Services (A\&OT) and Intensive Care Unit (ICU), and two ordinary recovery beds were converted into extended post anesthetic care in PACU (ExRR), based on the concept of overnight intensive recovery (OIR) to provide level 2 intensive care to patients undergoing major or ultra-major operations or having multiple comorbidities warranted intensive care in the immediately postoperative periods. This was conducted over 3 pandemic waves in Hong Kong.
214956221|NCT03105557|DEVICE|Urinary collecting device|Urinary collecting device
214956222|NCT00948922|DRUG|Bortezomib|AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
214956223|NCT00948922|DRUG|Melphalan|AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes.
214956224|NCT00948922|PROCEDURE|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.
214956225|NCT00948922|DRUG|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
214956226|NCT00948922|PROCEDURE|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients. Allogeneic donor stem cells may also be cryopreserved if they cannot be infused fresh.
214956227|NCT03336931|DIAGNOSTIC_TEST|Molecular profiling and drug testing|"1. Laboratory analysis including:~   A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~2. Multi-disciplinary Tumour Board case discussion~3. Recommendation of personalised therapy"
214956228|NCT01994421|OTHER|Kinesiotape|
214956229|NCT03943797|BIOLOGICAL|Cultivated oral mucosal epithelial cell transplantation|Cultivated oral mucosal epithelial cell transplantation (COMET) will be used to treat severe limbal stem cell deficiency so as to restore the integrity of corneal surface
215078272|NCT05555797|DEVICE|308nm Excimer laser|Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)
215078273|NCT05555797|DRUG|Tazarotene Topical Gel|Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks
215078274|NCT05555797|DRUG|Betamethasone Valerate|.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
215078275|NCT03433833|DRUG|Digoxin|Digoxin oral route once daily for 24 weeks.
214348712|NCT05802459|OTHER|EORTC QLQ-C30|central generic questionnaire associated with different disease specific modules
214348713|NCT05802459|OTHER|EORTC QLQ-OG25|module to assess the quality of life in patients with esophagogastric disease.
214348714|NCT05802459|OTHER|GIQLI|Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.
214348715|NCT05802459|OTHER|SWAL QoL|Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.
214348716|NCT05802459|PROCEDURE|Videofluoroscopy|It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.
214678650|NCT02481037|OTHER|Asthma education|Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
214956230|NCT05313321|DEVICE|Primary total hip arthroplasty receiving the Insignia Stem|Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
214956231|NCT04838431|OTHER|Blood sample and ultrasound at first trimester|The blood sample and the ultrasound are part of the routine care for the aneuploidy screening at first trimester. We deepened the biochemicals and biophysical markers for predicting the risk for large for gestational age infants
215078276|NCT00534118|BIOLOGICAL|donor lymphocytes|Given IV
215078277|NCT06459089|BEHAVIORAL|Selection of the parent according to children preference|The children will select the parent who will accompany them during the anesthesia induction
215078278|NCT06459089|BEHAVIORAL|Bringing the favorite toy of the children that will accompany the child during their perioperative period|The children will bring tiheir favorite toy that will accompany them during their perioperative period
215078279|NCT02780856|DEVICE|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black \& white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
215078280|NCT00301535|DRUG|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
214956232|NCT00888797|DRUG|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
214956233|NCT02399969|OTHER|Battlefield Acupuncture|Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
214348717|NCT04621305|OTHER|normal saline|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
214348718|NCT04621305|DRUG|Bolus Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
214348719|NCT04621305|DRUG|Continuous Infusion Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
214348720|NCT05915728|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
214348721|NCT05915728|DRUG|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
214348722|NCT05915728|DRUG|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
214348723|NCT05915728|DRUG|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
214348724|NCT02073513|DEVICE|Kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
214348725|NCT02073513|DEVICE|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
214348726|NCT00934193|DRUG|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
214348727|NCT00934193|DRUG|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
214348728|NCT01055743|PROCEDURE|Radical resection|Radical resection of hepatocellular carcinoma
214348729|NCT01055743|DRUG|Fluorouracil Implants|Implanted during the surgical treatment
214348730|NCT06006182|OTHER|Grape Powder|Freeze-dried grape powder
214348731|NCT01891825|PROCEDURE|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
214348732|NCT01891825|PROCEDURE|Percutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
214502585|NCT02659124|DEVICE|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
215078281|NCT02850263|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
215078282|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
215078283|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
214348733|NCT03551652|DRUG|Pharmacokinetics of rocuronium induced neuromuscular block|Measurement of rocuronium induced neuromuscular block comparing patients aged \> 80 years with patients aged 18 to 50 years
214348734|NCT02431975|DRUG|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
214348735|NCT02431975|DRUG|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."
214348736|NCT02431975|DRUG|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."
214348737|NCT02431975|DRUG|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."
214348738|NCT06281691|DIAGNOSTIC_TEST|Xpert® Bladder Cancer Detection Test|A urine sample is analyzed with the Xpert® Bladder Cancer Detection Test
214348739|NCT02194426|DRUG|MP0250|Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
214348740|NCT00085410|DRUG|bortezomib|Given IV
214348741|NCT04255160|DRUG|Estradiol (mylan or vivelle dot patch)|Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
214348742|NCT04255160|OTHER|Placebo|A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
214348743|NCT02978027|BEHAVIORAL|Brief Advice|
214348744|NCT02978027|BEHAVIORAL|NIAAA Clinician's Guide|
214348745|NCT02978027|BEHAVIORAL|Motivational Interviewing (MI)|
214348746|NCT04196400|DRUG|steroid betamethasone|The steroid is injected using insulin needle in the subcutaneous tissue after finishing the repair
214348747|NCT02811562|DEVICE|manikin|
214348748|NCT02811562|DEVICE|fiberoptic bronchoscope|
214956234|NCT03917277|DEVICE|Musculoskeletal ultrasound|"Ankle sonographic examination will be performed using Samsung UGEO H60 ultrasound machine in use since 2016. In order to optimize reproducibility, all examinations will be performed by a single examiner. Multiplanar (longitudinal/transverse) scanning will be done in B- and PD-mode to identify pathologies defined by the OMERACT network in the following structures:~1. Talocrural joint:synovial fluid (scored 0-3);synovitis with synovial hypertrophy and PD signal (each scored 0-3); bone erosion with distance between cortices and presence/absence of DP signal~2. Tibialis anterior,tibialis posterior, extensor digitorum longus, fibularis brevis,fibularis tertius,and calcaneal tendons: presence/absence of tenosynovitis, thickening, hypoechogenicity, nodularity, fusiform aspect, and DP signal~3. Calcaneal enthesis: presence/absence of thickening,hypoechogenicity,calcification, cortical irregularity,and DP signal~4. Retrocalcaneal and calcaneal bursa: presence/absence of bursitis and DP signal"
215078284|NCT04216368|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
214348749|NCT02811562|DEVICE|pentax-airwayscope|
214348750|NCT05624242|PROCEDURE|cardiac magnetic resonance imaging|all patients had magnetic resonance imaging at baseline and during follow-up.
214348751|NCT01311492|BEHAVIORAL|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
214348752|NCT01311492|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
214348753|NCT02129738|DEVICE|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
214348754|NCT03953092|DRUG|YG1699|YG1699 at Multiple Doses
214348755|NCT03953092|DRUG|Placebos|Placebos
214348756|NCT02284737|PROCEDURE|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
214348757|NCT02284737|PROCEDURE|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
214348758|NCT02284737|DRUG|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
214348759|NCT00436059|DRUG|bortezomib|
214348760|NCT00463710|DRUG|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
214348761|NCT02293629|DRUG|BMS-986147|
214348762|NCT02293629|DRUG|Placebo matching BMS-986147|
214348763|NCT01415791|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
214678651|NCT02481037|OTHER|EMR embedded dashboard|An EMR embedded dashboard will deliver real-time feedback to clinicians.
215078285|NCT04216368|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
214348764|NCT05443035|PROCEDURE|Antimicrobial PDT and Papacarie Deproteinization|Selective removal of carious tissue with curette + antimicrobial PDT (methylene blue 5 Evilux, Color index 52015, Fórmula \& Ação + red laser at 660 nm) + deproteinization of enamel with Papacárie DuoTM + restoration.
214348765|NCT05443035|PROCEDURE|Conventional caries treatment|Selective removal of carious tissue with curette + restoration.
214348766|NCT05443035|PROCEDURE|Antimicrobial PDT and 5% NaOCl Deproteinization|Selective removal of carious tissue with curette + application of methylene blue and low-level laser (aPDT) + deproteinization of adjacent enamel with 5% NaOCl + restoration.
214956235|NCT05823103|DIAGNOSTIC_TEST|Shawki Septum Scoring System|Utilising the novel scoring system to facilitate feasibility and safety of hysteroscopic metroplasty for uterine septum
214956236|NCT05823103|DIAGNOSTIC_TEST|ESHRE ASRM Classification|Utilising the current classification before performing hysteroscopic metroplasty
214956237|NCT05030571|DEVICE|DPMAS|DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China)
214956238|NCT05030571|OTHER|standard treatment|standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.
214956239|NCT03519919|DEVICE|somofilcon A multifocal lens|contact lens
214956240|NCT00645671|DRUG|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
215078286|NCT01389531|PROCEDURE|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
214348767|NCT02464735|DEVICE|Polysomnography|
214348768|NCT00775918|DRUG|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
214348769|NCT05476146|PROCEDURE|Rerouting of the track in high anal fitula|Treatment of high anal fistula by rerouting
214348770|NCT04528511|DEVICE|Continuous Electronic Monitor|All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
214348771|NCT02120508|DEVICE|rTMS|To test the efficacy of this specific setting.
214348772|NCT04082949|BIOLOGICAL|autologous fibrin glue application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|The purpose of this study was to investigate effects of autologous fibrin glue (AFG) which was an injectable platelet concentration, on clinical parameters in the nonsurgical treatment of chronic periodontitis.Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The test group was administered AFG using a blunt dental injector in the subgingival region, as an adjunct to SRP Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
214502586|NCT02659124|PROCEDURE|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
214502587|NCT02424474|DEVICE|Genetic NIPT|Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.
214502588|NCT02424474|BIOLOGICAL|Regular serum screening|
214956241|NCT00645671|DRUG|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
214956242|NCT02567097|BEHAVIORAL|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
214956243|NCT03475758|DRUG|Goserelin|adding goserelin with chemotherapy
214956244|NCT02095197|DRUG|Triamcinolone 80mg|C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
214956245|NCT00507520|PROCEDURE|Full dose almonds|
214956246|NCT00507520|PROCEDURE|Half dose almonds+half dose muffin|
214956247|NCT00507520|PROCEDURE|Full dose whole wheat muffin|
215078287|NCT03640052|DRUG|Placebo oral capsule|Placebo capsule before sleep
215078288|NCT03640052|DRUG|LTM1201L|LTM1201L capsule before sleep
215078289|NCT03640052|DRUG|LTM1201LN|LTM1201LN capsule before sleep
215078290|NCT03640052|DRUG|LTM1201LB|LTM1201LB capsule before sleep
215078291|NCT03640052|DRUG|LTM1201LD|LTM1201LD capsule before sleep
215078292|NCT04422561|DRUG|Ivermectin Tablets|two doses 72 hours apart
215078293|NCT05039671|BEHAVIORAL|Measurement-based care (MBC)|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
214956248|NCT06144541|OTHER|Survey administration for Fitzpatrick skin type|Survey administration for Fitzpatrick skin type
214956249|NCT06144541|DEVICE|Measurement of ITA based on SkinColorCatch instrument|Measurement of ITA based on SkinColorCatch instrument
214956250|NCT05114564|DEVICE|Lens A (comfilcon A lens)|1 month
214956251|NCT05114564|DEVICE|Lens B (lehfilcon A lens)|1 month
214956252|NCT03278236|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
214956253|NCT00463008|DRUG|methotrexate|
214956254|NCT00463008|OTHER|pharmacological study|
214956255|NCT05667818|DRUG|Amlodipine besylate tablets (trade name: Norfloxacin ®）|Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
214348773|NCT04082949|OTHER|placebo application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The control group was administered placebo as an adjunct to SRP.Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
214348774|NCT00542802|DRUG|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
214348775|NCT00542802|DRUG|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
214348776|NCT02010840|BEHAVIORAL|Psychoeducation program|
214348777|NCT06579547|RADIATION|Low Dose Computer Tomography|Participants will undergo MRI scans of their skeletal system, followed by the Intervention of a Low Dose CT scan of the same body region for comparison purposes.
214348778|NCT00496041|PROCEDURE|Registry|A Registry will be used.
214348779|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|After the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
214348780|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
214348781|NCT02864082|DRUG|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
214348782|NCT02864082|DRUG|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
214348783|NCT02864082|DRUG|Vehicle for PAT-001 0.1%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
214348784|NCT02864082|DRUG|Vehicle for PAT-001 0.2%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
214348785|NCT03505632|DEVICE|Recruitment with low PEEP|Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .
214956256|NCT05667818|DRUG|Amlodipine besylate controlled-release tablets|Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9% Expiry date: October 24, 2024 Storage conditions: dark, sealed at room temperature. Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
214348786|NCT03505632|DEVICE|High PEEP without RM|Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)-152.4} for men and 45.5 + 0.91 × {height (cm) - 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
214348787|NCT05848141|BEHAVIORAL|Exercise training|This is a single site center-based supervised exercise intervention.
214348788|NCT05542355|DRUG|EXL01|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
214956257|NCT01462656|DRUG|Non-EZG containing AED polytherapy|AED polytherapy without EZG
214956258|NCT01462656|DRUG|EZG containing AED polytherapy|AED polytherapy including EZG
214956259|NCT01462656|DRUG|Non-EZG AED monotherapy|AED monotherapy without EZG
214956260|NCT01462656|DRUG|EZG AED monotherapy|Any off-label use of EZG as monotherapy
215078294|NCT02535299|DRUG|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
215078295|NCT02535299|DRUG|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
215078296|NCT02805400|OTHER|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
215078297|NCT04239222|DEVICE|Revo-M|Investigational energy storage and return prosthetic foot with using novel elastic elements.
215078298|NCT04239222|DEVICE|Taleo|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transfemoral amputee subjects
215078299|NCT04239222|DEVICE|Proflex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects
215078300|NCT05494736|DRUG|MK-8527|MK-8527 capsule taken by mouth.
214348789|NCT05542355|DRUG|Placebo|Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
214348790|NCT05542355|OTHER|SoC corticosteroid - Induction Period|Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
214348791|NCT05542355|OTHER|SoC corticosteroid - Tapering|"Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop."
214348792|NCT02362490|DRUG|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
214348793|NCT04678648|DRUG|RSC-1255 Dose Escalation|Phase 1a will enroll 30-40 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
214956261|NCT05437614|PROCEDURE|Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by Micropulse diode laser cyclophotocoagulation
214956262|NCT05437614|PROCEDURE|Cyclocryoablation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by cyclocryoablation
214956263|NCT00860080|DRUG|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
214348794|NCT04678648|DRUG|RSC-1255 Dose Expansion|Phase 1b will enroll 48-104 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
214956264|NCT00860080|DRUG|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
214956265|NCT01104987|DRUG|alendronate|One tablet of alendronate à 70 mg once a week during two years.
214956266|NCT03435627|DRUG|Somatropin|Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.
214956267|NCT03061487|PROCEDURE|Open Surgical Treatment of Aneurysm (Aneurysmectomy)|Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
215078301|NCT03029182|OTHER|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
215078302|NCT03029182|BEHAVIORAL|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
214348795|NCT06401148|BEHAVIORAL|Cardiac rehab intervention group|Participants will complete an 8-week cardiac rehabilitation programme supported by the onsite CR service.
214348796|NCT06543979|DRUG|lubiprostone , single arm|laxative
214348797|NCT06543979|PROCEDURE|biofeed back sessions|Biofeedback for participants with dyssynergic defecation and participants with reduced rectal sensations
214348798|NCT06543979|PROCEDURE|botox injection|Botulinum toxin injection for participants suffering from elevated anal canal pressure
214956268|NCT05951361|DEVICE|980nm Diode Laser|300 mW, 4 J/cm2, 2mm non-contact mode up to 10 sessions
214956269|NCT05951361|DRUG|"0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase"|three times daily for 4 weeks
214956270|NCT01825746|OTHER|Implementation of the MOHR assessment in primary care workflow|The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
214956271|NCT01765816|BEHAVIORAL|high intensity interval training|
214956272|NCT01765816|BEHAVIORAL|moderate intensity training|
214956273|NCT02460432|DEVICE|Paclitaxel-eluting metal Stent|Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
214956274|NCT02460432|DEVICE|Covered Metal Stent|Insertion of ComVi Biliary Covered Stent using ERCP
215078303|NCT01741025|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
215078304|NCT01741025|OTHER|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
215078305|NCT00192660|DRUG|Lamivudine|
215078306|NCT00192660|DRUG|Stavudine|
214348799|NCT01127178|DRUG|E7016 + TMZ|Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
214348800|NCT05410977|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
214348801|NCT05410977|OTHER|Electronic Health Record Review|Medical records reviewed
214348802|NCT06961981|BEHAVIORAL|Vinyasa Yoga|Each yoga session will begin with 2 minutes of integration poses (Child's Pose, Downward Facing Dog, Ragdoll, and Mountain Pose), followed by \~20 minutes of Sun Salutations A and B (up to 5 of each). The Standing Series, lasting \~25 minutes, will include various standing and balancing poses from the Journey into Power sequence. Seated and supine stretches (including seated stretches, a yoga inversion, a reclined twist) will last \~8 minutes, and the session will conclude with 5 minutes of Savasana for final relaxation.
215078307|NCT00192660|DRUG|Didanosine|
215078308|NCT00192660|DRUG|Zidovudine|
214348803|NCT06961890|BEHAVIORAL|Principals of cognitive behavioral therapy on guided changing hygiene and sugar comsuption habits|The twin pairs will also receive guidance on healthy sugar consumption and oral hygiene habits, as the first intervention among the dental interventions received. For the baseline assessment, each participant answered a questionnaire about their diet the day before and about oral hygiene, in addition to demonstrating how they perform it. Thus, the cognitive behavioral theory was applied, so that the participant can record the goals achieved weekly and monthly.
214348804|NCT05327803|DRUG|Epetraborole|500 mg taken orally QD
214348805|NCT05327803|DRUG|Placebo|Placebo taken orally QD
214348806|NCT05526001|BIOLOGICAL|ELIXCYTE|ELIXCYTE, a new investigational product developed by UnicoCell Biomed, contains allogenic Adipose-derived stem cells (ADSCs). The ADSCs of ELIXCYTE for subjects were obtained from donors, and the Sponsor followed the manufacturing and testing procedures described in chemistry, manufacturing and control (CMC) information in order to assure the quality of final products.
214348807|NCT05526001|DRUG|Saline|Placebo control used in the study.
214348808|NCT04481919|DRUG|Protocolized diuretic therapy|The urine sodium, urine creatinine and serum creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance.
214348809|NCT01919008|DRUG|FK949E|Oral
214348810|NCT05762588|DEVICE|Juggerknot with Broadband tape|The JuggerKnot system is comprised of a coreless sleeve structure and suture. The anchors are intended for use in soft tissue to bone fixation by bunching against the bone when deployed. The anchor sleeve material is polyester. Suture materials are ultra-high molecular weight polyethylene. The device has 510K FDA clearance.
214348811|NCT05779657|DRUG|Ketamine|Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
214348812|NCT05779657|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
214348813|NCT05779657|DRUG|Placebo|Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
214348814|NCT03621696|DRUG|Cisplatin|-100 mg/m\^2 intravenous push bolus (IVPB)
214348815|NCT03621696|RADIATION|Intensity modulated radiation therapy|-IMRT or IMPT can be used
214348816|NCT03621696|RADIATION|Intensity modulated proton therapy|-IMRT or IMPT can be used
214348817|NCT03621696|PROCEDURE|Surgery|-Standard of care
214348818|NCT03621696|OTHER|FACT-H&N|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
214348819|NCT03621696|OTHER|MD Anderson Dysphagia Inventory|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
214348820|NCT03621696|OTHER|University of Michigan Xerostomia Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
214348821|NCT03621696|OTHER|Scale of Subjective Total Taste Acuity|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
214348822|NCT03621696|OTHER|Neck Dissection Impairment Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
214348823|NCT06250751|BEHAVIORAL|Behavioral Exercise Training (BET) intervention|Introduce and refine concept of exercise and cardiovascular health by initiating walking or cycling and provide behavioral counseling sessions to foster support for adoption and maintenance of exercise, and to troubleshoot barriers. During the first two weeks, the study team will meet with participants twice per week (virtually) to introduce the intervention, familiarize men with the exercise program, exercise logs, resistance bands for strength training. Contact will drop to once per week during weeks 3-8 (total=10 contacts in weeks 1-8). Behavioral counseling will be delivered by the PI or the study coordinator for 30-40 minutes prior to 20-30 mins of an individual or group-based strength training class.
214348824|NCT05750953|BEHAVIORAL|eHealth@Hospital-2-Home|At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company. MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals. The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices. Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
214348825|NCT06513429|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells by intravenous infusion.
214348826|NCT04349553|BIOLOGICAL|ZH9PA and ZH9|150mL vaccine for oral administration
215078309|NCT00192660|DRUG|Tenofovir|
215078310|NCT00192660|DRUG|Abacavir|
215078311|NCT00192660|DRUG|Efavirenz (EFV)|
215078312|NCT00192660|DRUG|Nevirapine|
215078313|NCT00192660|DRUG|Indinavir|
215078314|NCT00192660|DRUG|Saquinavir|
215078315|NCT00192660|DRUG|Amprenavir|
215078316|NCT00192660|DRUG|Ritonavir|
215078317|NCT00192660|DRUG|Nelfinavir|
215078318|NCT00192660|DRUG|Tipranavir|
215078319|NCT00192660|DRUG|enfuvirtide (T20)|
214348827|NCT04349553|BIOLOGICAL|Placebo|150mL vaccine for oral administration
214348828|NCT04349553|BIOLOGICAL|ZH9PA|150mL vaccine for oral administration
214348829|NCT03011684|DRUG|Tamoxifen|Given orally
214348830|NCT03011684|DRUG|Letrozole|Given orally
214348831|NCT06005818|DRUG|Pembrolizumab injection|PD-1 antibody
214348832|NCT06326606|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
214348833|NCT06326606|DRUG|Placebo|Capsule with no active ingredients
214348834|NCT04459650|PROCEDURE|Platelet Rich Plasma system|Participants will receive PRP obtained with PRP harvesting kits on one side of the scalp and no injections on the other side of the scalp (split-scalp technique). The entire half of the intended scalp will receive inter-follicular injections of PRP under aseptic conditions at the amount of 0.05-0.1 ml/cm2 in a retrograde fashion from deep to superficial, at every centimeter throughout the treated site. For study purposes, Study Day 0 is defined as the first day of injection. Subsequently the patient will continue therapy every 4 weeks for a total of 3 injections (12 weeks).
214348835|NCT05360615|DRUG|Empagliflozin 10 MG|SGLT2 inhibitors
214348836|NCT05360615|DRUG|Placebo|Placebo
214348837|NCT06525181|OTHER|Generative Artificial Intelligence|Gen AI assisted symptom intake summarization
214348838|NCT06525181|OTHER|Standard weekly symptom intake|Standard weekly symptom intake performed by a physician
214348839|NCT04265053|DRUG|Indomethacin 25 MG/50 MG|Indomethacin is a nonsteroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and swelling from inflammation. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. Indomethacin is used to test COX as a potential mechanism explaining sex differences in CBF control. Indomethacin usage is IND exempt.
214348840|NCT04265053|DRUG|Placebo - Lactose|Participants will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit. Placebo usage is IND exempt.
214348841|NCT04265053|DRUG|Ganirelix Acetate|"Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3."
214348842|NCT04265053|DRUG|Testosterone Transdermal Product|In Aim 3, males receive this for 7-9 days of the ganirelix treatment.
214348843|NCT04265053|DRUG|Estradiol Topical|In Aim 3, females receive this for 7-9 days of the ganirelix treatment.
214956275|NCT03578445|DEVICE|EUS-guided microbiopsy|Use of EUS-guided through-the-needle microbiopsy forceps for obtainment of tissue from the wall of the cystic lesion
214956276|NCT03578445|DIAGNOSTIC_TEST|Next Generation Sequencing|Prevalence of genetic mutations in known cancer-associated genes in the microbiopsy tissue examined using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, USA). The multigene panel explores selected regions of 50 cancer-associated genes, among others KRAS, GNAS, CDKN2A and SMAD4 genes.
214956277|NCT05646732|DEVICE|TMS-fMRI|Participants will undergo simultaneous TMS and fMRI
215078320|NCT04067297|OTHER|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of \~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
215078321|NCT03449693|DIETARY_SUPPLEMENT|Magnesium Oxide Supplement|Magnesium Oxide tablet
214348844|NCT04265053|DRUG|Antacid|Participants will be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Participants will be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.
214348845|NCT02063724|BIOLOGICAL|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
214348846|NCT06572371|PROCEDURE|Laparoscopic pyeloplasty|The first trocar was inserted under vision through the same supraumbilical incision and the intraperitoneal cavity was inspected The second 5 mm trocar was placed in the midclavicular line 2 inches below the costal margin. The third 10 mm trocar was placed lateral to the rectus muscle at the level of the anterior superior iliac spine. In right-sided pyeloplasty, a fourth trocar was inserted below the xiphistemum for liver retraction. Incision of the line of Toldt and mobilization of the colon was the first step of the transperitoneal approach. A 4/0 polysorbe stay suture was taken in the lateral aspect of the ureter distal to uretero-pelvic junction obstruction to identify the correct orientation after dismembering the ureter. A full thickness anastomosis was started from the angle of V shape spatulation to the lower pole of the renal pelvis.
214348847|NCT06572371|PROCEDURE|Open pyeloplasty|"A flank incision with the patient in lateral position was undertaken in open pyeloplasty. After accessing the retro- peritoneum, the ureter was identified and traced cranially till the PUJ segment.~Traction sutures was placed on the renal pelvis followed by excision of the narrowing segment. The ureter was spatulated by approximately 2 cm and a reduction pyeloplasty was performed, where necessary. Anastomosis was undertaken using vicryl 4-0 sutures. The primary anastomotic site was sutured in interrupted fashion followed by a continuous running suture of the posterior wall. Next, antegrade DJ stenting was performed and the anterior wall was anastomosed. After haemostatic control a 22 Fr drain was placed in the surgical bed."
214348848|NCT01574300|OTHER|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
214956278|NCT02359279|DEVICE|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
214956279|NCT04324762|BEHAVIORAL|targetted implementation strategies|strategies at the individual and institutional level to promote implementation of an evidenced based innovation and de-implementation of an unnecessary, low value diagnostic test.
214956280|NCT01951573|DEVICE|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
214348849|NCT03582124|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo imaging
214348850|NCT03582124|DRUG|Panitumumab-IRDye800|Given IV
214348851|NCT03582124|OTHER|Pharmacokinetic Study|Correlative studies
214348852|NCT03582124|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214348853|NCT05087628|BIOLOGICAL|PRV-3279|Bi-specific antibody-based molecule
214348854|NCT05087628|OTHER|Placebo|Placebo
214348855|NCT04740294|DRUG|Magnesium Sulfate|Randomized to receive either magnesium sulfate or normal saline placebo.
214348856|NCT03516916|OTHER|Questionnaires on HRQoL and sociodemography|All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
214348857|NCT05688813|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and sacral erector spinae blocks were administered
214348858|NCT01715805|DRUG|Cariprazine|Cariprazine capsules 1.5 to 4.5 mg/day
214348859|NCT01715805|DRUG|Placebo|Dose-matched placebo capsule once per day
214348860|NCT01715805|DRUG|Antidepressant Therapy (ADT)|ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
214348861|NCT04936230|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
214348862|NCT04936230|PROCEDURE|Bone Scan|Undergo bone scan
214348863|NCT04936230|PROCEDURE|Computed Tomography|Undergo CT scan
214348864|NCT04936230|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214348865|NCT04936230|BIOLOGICAL|Pembrolizumab|Given IV
214348866|NCT04936230|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214348867|NCT04936230|OTHER|Questionnaire Administration|Ancillary studies
214348868|NCT04936230|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214956281|NCT01951573|DEVICE|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
214956282|NCT05849363|PROCEDURE|Posterior fossa decompression|Posterior fossa decompression：Posterior arch of atlas removal, decompression of cerebellum, detection of foramen magnum.
215078322|NCT03294239|PROCEDURE|Transurethral extraction of bladder stone(s)|Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
214348869|NCT04704336|BEHAVIORAL|Task-shifting strategy for HTN control (TASSH) protocol|The TASSH protocol include the following 4 steps: 1). Identify HIV patients with uncontrolled HTN: trained HIV nurses will take patients' medical history (whether or not they have a diagnosis of diabetes, heart attack, stroke, heart failure, smoking). 2) Next, they will measure the patients' weight, height, waist circumference and BP with a valid automated device following standard procedures and then conduct lab tests with point-of-care testing on blood glucose, lipids and urine dip stick. 3) Initiate lifestyle counseling and medication treatment every 1-3 months: The nurses will next counsel eligible patients on lifestyle behaviors for 20 to 30 minutes (increased intake of fruits and vegetables, moderate physical activity and reduce salt intake). 4). Refer patients with complicated HTN to physicians for further care
214348870|NCT03833544|OTHER|Exercise training|Progressive resistance training of hip, knee, and ankle flexors.
214348871|NCT05770544|DRUG|Entrectinib|"Adult and paediatric patients with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric patients with BSA \<1.51 m\^2 will receive entrectinib at a dose of 100 mg (BSA=0.43-0.50 m\^2) or 200 mg (BSA=0.51-0.80 m\^2) or 300 mg (BSA=0.81-1.10 m\^2) or 400 mg (BSA=1.11-1.50 m\^2).~Each cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
214348872|NCT04940325|DRUG|DS-1062a|First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)
214348873|NCT03541096|BEHAVIORAL|Winter Swimming|Supervised Winter Swimming in Copenhagen
214348874|NCT03541096|BEHAVIORAL|Control group|No winter swimming activities.
214348875|NCT06258213|DRUG|ABP-745|0.5, 5 or 25 mg tablet
214348876|NCT06258213|DRUG|Placebo|Placebo tablet
214348877|NCT05008354|DRUG|Pyridoxine|Pyridoxine tablet 40mg once daily
214348878|NCT05008354|DRUG|Placebo|Placebo tablet once daily
214348879|NCT02904304|DRUG|Desloratadine+Phenylephrine+Ibuprofen|01 tablet, orally, every 12 hours.
214348880|NCT02904304|DRUG|Placebo|01 tablet, orally, every 12 hours.
214348881|NCT04479813|DRUG|Moxonidine 0.2 MG|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
214348882|NCT04479813|OTHER|placebo|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
214348883|NCT02938000|DEVICE|Theraband with exercise video|Theraband exercise band for resistance training
214348884|NCT02938000|OTHER|usual care with advice to exercise|advice to exercise
214348885|NCT01821664|DEVICE|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
214348886|NCT03315000|DRUG|Vilanterol and Fluticasone Furoate|Same as vilanterol arm description
214348887|NCT03315000|DRUG|Fluticasone Furoate|Same as fluticasone arm description
214348888|NCT03315000|DRUG|Placebos|Same as placebo arm description
214678652|NCT04420455|DRUG|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
214348889|NCT01242475|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
214348890|NCT01242475|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
214348891|NCT03217045|OTHER|nutrition protocol introduction|Growth comparison of 2 cohorts of infants evaluated in a before-after design
214348892|NCT02810054|PROCEDURE|Minimally Invasive Surgical Techniques (MIST)|Using minimally invasive surgical techniques.
214348893|NCT02810054|PROCEDURE|Enamel Matrix Derivative (EMD)|Use of enamel matrix derivative for the treatment of intrabony periodontal defects.
214348894|NCT04559789|BEHAVIORAL|MindMate + Health Coaching|The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.
214348895|NCT04559789|OTHER|Health Education|Health education materials delivered electronically
214348896|NCT04445805|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, cognitive therapy, and relaxation. Treatment will be delivered via telemedicine.
214348897|NCT04445805|BEHAVIORAL|Perinatal-enhanced Behavioral Therapy for Insomnia|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, and metacognitive exercises. Treatment will be delivered via telemedicine.
214348898|NCT04445805|BEHAVIORAL|Attention Control|Will include education on sleep, circadian rhythms, and good sleep hygiene in addition to self-monitoring with sleep diaries.
214348899|NCT03101735|DRUG|Dimethyl Fumarate (DMF)|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
214348900|NCT06580574|DRUG|PD1/PDL1 antibody monotherapy, up to 24 weeks|non-specific, according to Drug Instructions
214348901|NCT06580574|COMBINATION_PRODUCT|Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks|Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd
214956283|NCT05849363|PROCEDURE|Posterior Compression-Distraction-Reduction-Fixation|"Posterior Compression-Distraction-Reduction-Fixation：After subperiosteal dissection, the facet joint was exposed. A 2-mm joint scraper with sharp edge was inserted into the joint capsule and rotated to remove the articular cartilage. A blunt-edged rotating distractor was then inserted into the joint space, and the facet was sequentially opened with larger and larger blunt rotating distractors. After distraction on one side, an appropriate-sized trial was placed into the contralateral facet, holding the distraction open. This was repeated back and forth with larger trials. These steps were repeated, and the facet joints were distracted up to the pre-planned distance of the odontoid tip above Chamberlain's line."
214956284|NCT00624689|DIETARY_SUPPLEMENT|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
214956285|NCT00297661|DEVICE|Sirolimus-eluting stent|
214348902|NCT06580574|PROCEDURE|Radical surgery|Radical surgery will be recommended per local treatment standards.
214348903|NCT00872144|DRUG|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
214956286|NCT00297661|DEVICE|Paclitaxel-eluting stent|
214956287|NCT05276583|BEHAVIORAL|Motivated Learning Task|"The Motivated Learning Task is split into two parts, the learning phase, and the test phase. During the learning phase participants are presented with 72 landscape images (targets) which they must memorise. Each image which participants are shown is associated with a reward amount. During the test phase participants are shown the 72 images they saw during the learning phase, known as targets, intermixed with 72 new images they did not see during the learning phase, known as lures. Participants must decide whether the image is old (i.e., they saw it during the learning phase) or new (i.e. they did not see it during the learning phase). After they have made their old/new decision, participants rate their confidence in their decision on a 3-point scale (i.e., guess, sure, very sure)."
214348904|NCT05831358|OTHER|Multiple Myeloma M-Protein Analysis|Participants will be screened with a blood test for monoclonal protein analysis
214348905|NCT05831358|OTHER|Multiple Myeloma Knowledge Questionnaires|Participants will complete two questionnaires to share their attitudes toward their screening experience and completion of knowledge questions to gauge community reception and participant multiple myeloma knowledge.
214348906|NCT05228574|DIETARY_SUPPLEMENT|Sodium chloride (NaCl)|Sodium chloride capsules 6 grams per day for 4 weeks.
214956288|NCT03387969|PROCEDURE|CSF sample|"for all patient CSF sample obtained for analysis , culture sensitvity and CSF-CRP.~also blood samples will be collected and analyzed for serum procalcitonin"
214956289|NCT01505231|DRUG|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.
214956290|NCT01505231|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
214956291|NCT00165217|DRUG|Capecitabine|
214956292|NCT00165217|DRUG|Thalidomide|
214956293|NCT01084902|DRUG|Latanoprost|once daily
214348907|NCT05228574|DIETARY_SUPPLEMENT|Placebo|Placebo capsules, 6 grams per day for 4 weeks.
214348908|NCT05228574|DRUG|Amiloride Hcl 5mg Tab|Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.
214348909|NCT03457532|DRUG|Gumarontinib Tablets|25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
214348910|NCT06295120|DRUG|Phenoxymethylpenicillin 1.2 MIE 4 times daily|The intervention is the duration of treatment with phenoxymethylpenicillin from 3 to 7 days. Dose and frequency of the treatment is the same in the different arms.
214348911|NCT04158375|BEHAVIORAL|Resistance Exercise|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Participants will complete 2 progressing to 4 sets of 8 to 12 repetitions per exercise, with 1 minute rest between sets. Participants will warmup for 5 minutes on a treadmill, cycle ergometer or elliptical at \~50% VO2 peak then begin resistance training. Resistance will be performed 4 days per week with lower body exercise on Monday and Thursday, and upper body on Tuesday and Friday. Wednesdays are a rest day. Participants will begin at 2 sets per exercise on weeks 1 and 2, then 3 sets for week 3, and 4 sets for weeks 4 to 12.
214956294|NCT01084902|DRUG|Brinzolamide|Two times daily
214348912|NCT06510075|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
214348913|NCT06510075|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
214348914|NCT06510075|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
214348915|NCT05856656|BEHAVIORAL|Music therapy|Music therapy is a technique of care, accompaniment and support, which aims to improve health and well-being.
214348916|NCT04242355|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
214348917|NCT06319443|DIETARY_SUPPLEMENT|Liquid vinegar|3.5 g acetic acid
214956295|NCT00866957|PROCEDURE|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
214956296|NCT06222970|PROCEDURE|Bone lid repositioning in course of sinus lift|"A full-thickness flap was elevated to access the lateral maxillary bone wall. Subsequently, a lateral access window was prepared using a piezoelectric device with specific bone tips, delimitating a trapezoidal bone lid.~Once the antrostomy was completed, the bone lid was gently removed with a Lucas surgical curette and anatomical tweezers, with great care to avoid damages to the Schneiderian membrane. The Schneiderian membrane was detached from the bone layer using specific sinus curettes. In case of sinus membrane perforation, the membrane was raised in all directions. All clinical cases received a cortical bone lamina to avoid graft particles displacement in the maxillary sinus. The elevated space was filled with chips of cortico-spongious bone. The antrostomy was then covered with the bone lid (osteotomy window), previously removed and preserved in physiological solution and fixed in the original anatomical position with a surgical glue. The flap was then repositioned and sutured."
214956297|NCT04164797|DRUG|endostar+chemoradiotherapy|antiangiogenic drug+chemoradiotherapy
214348918|NCT06319443|DIETARY_SUPPLEMENT|vinegar pill|0.022 g acetic acid
214348919|NCT06287359|OTHER|individual interviews|Qualitative research with individual interviews
214348920|NCT06001775|BEHAVIORAL|Patient Priorities Care|According to patientprioritiescare.org a Patient Priorities Care conversation helps to align healthcare decision-making and care by all clinicians with patients' own health priorities. Patient Priorities Care involves not only the health outcome goals that patients want to achieve, but also their preferences for healthcare.
214956298|NCT04164797|OTHER|chemoradiotherapy|chemoradiotherapy
214956299|NCT03526991|DEVICE|Spinal Cord Stimulator (SCS)|"The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
214956300|NCT05982197|DRUG|Curcumin Gel|Curcuma longa oral gel for prevention radiation induced oral mucositis
214348921|NCT05177770|DRUG|SRF617|SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.
214348922|NCT05177770|DRUG|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
214348923|NCT05177770|DRUG|zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
214348924|NCT05259436|BEHAVIORAL|Caregiver-child Intervention|"Intervention Groups:~1. Resilience Clinic (Benioff Oakland): 6 weekly interactive group-based visits in primary care that draws from the evidence-based Circle of Security Parenting along with the principles of mindfulness;~2. ABC Intervention (Lifelong): 10 weekly home visiting sessions. ABC is an empirically supported parenting program that focuses on improving maternal sensitivity;~   and,~3. Resiliency Family Program (Santa Barbara Neighborhood Clinic): 4 primary-care-based visits, every 2-3 weeks, that include psycho-education materials drawing from the culturally-responsive, evidence-based program, Madres a Madres."
214348925|NCT05259436|BEHAVIORAL|Enhanced Primary Care|Enhanced Primary Care (control group): This includes care coordination services for community resources in addition to usual care. Participants will be asked about any unmet social needs, e.g. food insecurity, financial strain, safe places to play. Those who endorse need will be offered navigational services to link to community resources.
214348926|NCT06129747|RADIATION|Radiation Therapy|"Weeks 1, 2 and 3~* Weeks 1, 2 and 3 will include 5 days of treatment.~* One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes."
214502589|NCT00758550|DEVICE|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
214502590|NCT00758550|DEVICE|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
214502591|NCT01588093|DRUG|Increlex|Increlex 120 micrograms/kg body weight single subcutaneous injection
214502592|NCT01588093|DRUG|0.9% Saline|Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
214502593|NCT06406426|DRUG|Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin|Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
214348927|NCT06083207|DRUG|IBI3003|Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
214348928|NCT03015792|DRUG|Dexamethasone|Given PO
214348929|NCT03015792|DRUG|Ibrutinib|Given PO
214348930|NCT03015792|OTHER|Laboratory Biomarker Analysis|Correlative studies
214348931|NCT03015792|DRUG|Lenalidomide|Given PO
214348932|NCT03015792|OTHER|Pharmacological Study|Correlative studies
214348933|NCT03015792|OTHER|Quality-of-Life Assessment|Ancillary studies
214348934|NCT02365467|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|
214348935|NCT03948724|BEHAVIORAL|Therapeutic education program|Patient will have 5 educational therapy workshops. The first educational therapy workshops will be realized at cycle 1 and the last one within 25 weeks after starting treatment
214348936|NCT03948724|BEHAVIORAL|Usual Information|Patient receive usual informations
214348937|NCT05093075|OTHER|Therapeutic Plasma Exchange|TPE procedures will be performed using a Spectra Optia ® apheresis machine (Terumo BCT, Lakewood, USA) according to usual-care procedures for apheresis. Venous access for the TPE procedures will be obtained through a double lumen dialysis catheter to provide adequate flow rates required for TPE. Regional citrate anticoagulation will be used for anticoagulation within the apheresis circuit. One to two grams of calcium chloride will be infused as per standard during TPE to prevent symptomatic hypocalcemia. Plasma volume will be calculated as per a standard formula whereby estimated plasma volume (in liters) = 0.07 x weight (kg) x (1 - hematocrit). In patients on dialysis, dialysis will be interrupted for the duration of the procedure. Antibiotics will be given after TPE to avoid clearance of the antibiotics. On the first day of TPE, a repeat dose of antibiotics will be administered after completion of TPE. Nurse clinicians trained in TPE will perform the TPE procedures.
214348938|NCT06300814|OTHER|Progressive relaxation exercise group|A video containing the progressive relaxation exercise was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group to whom progressive relaxation exercise would be applied, and the children applied progressive relaxation exercise (15 minutes of progressive relaxation exercise before bedtime for a total of 4 weeks, 5 days a week).
214348939|NCT06300814|OTHER|Music recital group|The link of the music recital (link) was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group, where the music concert will be applied, and the children listened to it (music concert was applied for 15 minutes before going to bed, 5 days a week for a total of 4 weeks).
214348940|NCT04043689|DEVICE|tACS (transcranial Alternate Current Stimulation)|"This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control"
214348941|NCT01022814|DEVICE|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
214348942|NCT02277782|DRUG|Hydromorphone|
214348943|NCT02277782|DRUG|Hyperbaric bupivacaine|
214348944|NCT02277782|DRUG|Fentanyl|
214956301|NCT05982197|DRUG|Standard Preparation|Standard preparation for prevention radiation induced oral mucositis
214348945|NCT03073889|PROCEDURE|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
214348946|NCT03073889|PROCEDURE|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
214348947|NCT03073889|DRUG|Ropivacaine|
214348948|NCT06108622|DIAGNOSTIC_TEST|cbc ,u\s renalor hepatic function test if needed|just blood sample if the case needed
214956302|NCT02627456|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites. PfSPZ Vaccine will be delivered by DVI in the pilot and main phases of the study. Participants will receive either 1 or 3 injections.
214348949|NCT02043782|DEVICE|Coloplast Test|Newly developed 1-piece convex ostomy product
214348950|NCT02043782|DEVICE|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
214348951|NCT02043782|DEVICE|Competitor soft convex|A commercially available soft convex product
214348952|NCT00709722|DRUG|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
214956303|NCT02627456|BIOLOGICAL|PfSPZ Challenge Material|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites used for CHMI trials. PfSPZ Challenge is not radiated, thus it is fully infections. It will be administered via DVI to participants in Arm 1c and 1d.
214348953|NCT04667117|BIOLOGICAL|Quadrivalent influenza vaccine|2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.
214502594|NCT03936023|DRUG|Saxagliptin|Saxagliptin dispensing claim is the exposure
214502595|NCT03936023|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
214502596|NCT01989416|DRUG|2% chlorhexidine wipe|The ICU patients will be bathing with 2% chlorhexidine wipe
214502597|NCT01989416|DRUG|Soap|The ICU patients will be bathing with Soap
214502598|NCT02278666|PROCEDURE|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
214348954|NCT04667117|DRUG|Ofatumumab|"Auto-injector containing 20 mg ofatumumab (20 mg/0.4mL) for subcutaneous (s.c.) administration.~* Participants in Cohort 1 received loading doses of 20 mg ofatumumab s.c. at Weeks 2, 3, and 4 in the Investigational Period. In the open-label Extension Period, they administered the first dose of ofatumumab at Week 6 and continued monthly dosing until the final dose at Week 26. Novartis supplied participants in Cohort 1 with ofatumumab treatment.~* Participants in Cohort 2 continued on their commercially prescribed ofatumumab treatment during the Investigational Period. In the open-label Extension Period, they continued to administer ofatumumab monthly until the final dose at Week 28. Cohort 2 participants in the extension could have either remained on their prescribed ofatumumab or switched to study supplied ofatumumab."
214348955|NCT04667117|DRUG|iDMT|Participants in Cohort 3 continued on their commercially prescribed injectable disease modifying therapy (iDMT) during the Investigational Period.
214348956|NCT05531539|DEVICE|WELMO sensors vest|Wearing of a vest equipped with lung auscultation and EIT sensors for signal acquisition and transmission
214348957|NCT05593835|DEVICE|METHIS Platform|The METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.
214348958|NCT05593835|OTHER|Goal-Oriented Care Training Program|The training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
214348959|NCT04571346|PROCEDURE|trans-obturator procedure|TOT procedure will be done using silicon-coated polypropylene tape that will be inserted at the mid-urethral portion. In group 1, a classical vertical vaginal incision will be done proximal to the external urethral meatus with dissection along the axis of the urethra till the mid-urethral zone that is identified by palpating the urethral catheter balloon through the vaginal at the bladder neck, while in group 2, two paramedian incisions will be done 1cm long in the anterior vaginal wall 2 cm apart parallel to the urethra till identification of the mid-urethral portion, communication will be done between the two incisions 1 cm wide in this area creating a tunnel where the tape will be placed, this technique provides healthy tissues proximal and distal to the tape that allows more stabilization and less migration. The rest of the procedure is the same as the standard procedure of Trans-obturator outside-in tension-free technique.
214348960|NCT06534151|DEVICE|CRT implantation|A CRT is a device (that looks like a pacemaker) that will be used to help the ventricles contract synchronously.
214348961|NCT05036616|DEVICE|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
214348962|NCT02418325|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
214348963|NCT02418325|OTHER|Liberation therapy|
214348964|NCT01634698|DIETARY_SUPPLEMENT|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
214348965|NCT05157191|OTHER|Observational|Observational
214348966|NCT01195012|BEHAVIORAL|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
214348967|NCT05136573|BEHAVIORAL|Combined Exercises|Combined Exercises
214348968|NCT00644722|DEVICE|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
214502599|NCT02278666|DEVICE|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
214502600|NCT02278666|DEVICE|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
214502601|NCT00223756|OTHER|Low Vision Intervention - Outpatient Training Program|Patients receive LV therapy as outpatients
214502602|NCT04565977|OTHER|Observational|Retrospective chart review
214956304|NCT02627456|DRUG|PBS and HSA Diluent|The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). Vials of sterile PBS (1.6ml) and HSA (0.5ml) will be shipped to the clinical site, where diluent composed of PBS and HSA is prepared. HSA is a licensed product which is approved for parenteral, IV administration to humans. The HSA lots are extensively tested to ensure that it is free of infectious agents as listed in the CoA and is approved for use by the Food and Drug Administration(FDA).
214956305|NCT02627456|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe.
214956306|NCT02627456|DRUG|Coartem|Artemether/lumefantrine (coartem) is a licensed antimalarial in the US and Mali for use for uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Artemether /lumefantrine is a Category C pregnancy drug. Thus all female participants will undergo pregnancy testing prior to receiving this drug.
214678653|NCT01220752|RADIATION|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
214956307|NCT02627456|DRUG|ASAQ|"ASAQ is a fixed dose artemisinin based combination therapy that is indicated and approved for the management of uncomplicated P. falciparum malaria. It has been shown to be as effective as artemether~/lumefantrine when taken at a once/day dosage."
214956308|NCT03610334|DRUG|IFB-088 (2.5-60.0mg) oral capsule|SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
214348969|NCT00644722|DEVICE|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
214348970|NCT05373394|OTHER|Test battery|motor and neuropsychological test battery
214348971|NCT02883725|OTHER|data collection|
214348972|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
214348973|NCT01306162|DRUG|Dabigatran etexilate|150 mg as single dose
214956309|NCT03610334|DRUG|Placebo (2.5-60.mg) oral capsule|SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
214956310|NCT03610334|DRUG|IFB-088 (15.0-50.0mg) oral capsule|MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
214956311|NCT03610334|DRUG|Placebo oral (15.0-50.0mg) capsule|MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
214956312|NCT00412789|DRUG|Patupilone|
214348974|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
214348975|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
214348976|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
214348977|NCT02626715|DRUG|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
214956313|NCT02020889|BIOLOGICAL|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
214956314|NCT02020889|DRUG|Placebo|Placebo will be available as 0.9% sodium chloride
214956315|NCT03653312|DEVICE|NMES|Neuromuscular electrical stimulation of the paretic lower limb during exercise
214956316|NCT01067417|DRUG|Hydroxychloroquine|Taken orally 2x200mg capsules once daily for 48 weeks
214956317|NCT01067417|DRUG|Placebo|Taken orally 2x200mg capsules once daily for 48 weeks
214956318|NCT04400149|DIAGNOSTIC_TEST|amniocentesis|amniocentesis will be performed to the pregnant women at 16-20 weeks who had a high-risk antenatal test. Furthermore, these women also give a blood sample (at 16-20 weeks) to compare the amniotic fluid and serum progesterone levels in association with pregnancy outcomes. We perform amniocentesis to evaluate genetic disorders in pregnant women who had his risk in the antenal test.
214956319|NCT01017081|OTHER|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
214956320|NCT01017081|OTHER|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
214348978|NCT02626715|DRUG|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
214348979|NCT01947946|BIOLOGICAL|Benralizumab|"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
214348980|NCT01947946|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
214348981|NCT03646786|DEVICE|Virtual reality tests|"The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~1. 10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~2. 10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~3. Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe"
214348982|NCT05013333|DEVICE|AED 3 with Uni-padz|Use of AED 3 with Uni-padz by lay rescuer
214348983|NCT04351438|DEVICE|Active Comparator: centrifuge TPE with citrate|Patients who received citrate-based anticoagulation with centrifuge TPE
214348984|NCT04351438|DEVICE|Active Comparator: Filter TPE with heparin|Patients who received heparin-based anticoagulation with filter TPE
214348985|NCT04351438|DRUG|Active comparator: Filter TPE with citrate|Patients who received citrate-based anticoagulation with filter TPE
214348986|NCT02539264|OTHER|Smoking|Influence of smoking on parameters derived from overnight PSG
214348987|NCT02539264|OTHER|Obesity|Influence of obesity on parameters derived from overnight PSG
214348988|NCT02539264|OTHER|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
214348989|NCT02959437|DRUG|Azacitidine|Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
214502603|NCT02617693|BEHAVIORAL|lifestyle intervention|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
214348990|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
214348991|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily.
214348992|NCT02959437|DRUG|INCB057643|INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
214348993|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
214348994|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
214348995|NCT02959437|DRUG|INCB059872|INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
214348996|NCT00864032|DRUG|Sorafenib|400mg twice daily
214348997|NCT03446443|DRUG|Honghe Fujie lotion|Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.
214348998|NCT03446443|DRUG|Metronidazole Suppositories|Before bedtime，wash the vaginal area and put 0.5g Metronidazole Suppositories into posterior vaginal fornix，once daily for 7days.
214348999|NCT01059760|BEHAVIORAL|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
214349000|NCT01059760|BEHAVIORAL|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
214349001|NCT02176135|DRUG|Auranofin|3 mg tablets
214349002|NCT00421252|DRUG|clopidogrel 600 mg|Clopidogrel load \> 2hrs pre-angiography
214349003|NCT00421252|DEVICE|arterial access sheath|randomize to 5Fr vs 6Fr
214349004|NCT03358667|PROCEDURE|augmentation peri-implant soft tissue|the implant was cover with a 2 mm cover screw for a tent effect or with a dermal membrane after implant insertion
214349005|NCT03335358|BEHAVIORAL|Dyadic (couples-based) positive psychology intervention|Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
214349006|NCT06163755|DRUG|Methylprednisolone 40 MG Injection|Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
214349007|NCT02000245|BEHAVIORAL|verbal expression for compassion|The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
214349008|NCT02000245|BEHAVIORAL|touch|The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
214956321|NCT04621032|DIAGNOSTIC_TEST|Polygraphy monitoring|All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.
214956322|NCT04621032|DIAGNOSTIC_TEST|laboratory tests|Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.
214956323|NCT00934245|BIOLOGICAL|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
214956324|NCT00934245|BIOLOGICAL|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
214956325|NCT04252885|DRUG|Lopinavir and Ritonavir Tablets|As indicated in arm/group descriptions
214956326|NCT04252885|DRUG|Arbidol|As indicated in arm/group descriptions
214956327|NCT05300334|DIAGNOSTIC_TEST|adenosine deaminase test|adenosine deaminase deficiency test
214349009|NCT05293080|OTHER|Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)|Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.
214349010|NCT05293080|OTHER|Usual care for atrial fibrillation|Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.
214349011|NCT00563199|BEHAVIORAL|nurse-delivered stage-matched smoking cessation counseling|
214502604|NCT02617693|OTHER|standard antenatal care|Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
214956328|NCT04816760|BIOLOGICAL|Peripheral blood samples|Peripheral blood samples at Day 0, Day 7, Day 14, Day 28, Day 90 and Day 180.
214956329|NCT03157076|DEVICE|Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)|The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
214349012|NCT02199262|OTHER|music intervention|reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.
214349013|NCT02199262|OTHER|reflexology|reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages
214349014|NCT02199262|OTHER|reminder|Implementation of a reminder of guidelines of agitation diagnosis and management
214502605|NCT03507972|RADIATION|ankle ultrasound|Ankle ultrasound performed during emergencies visit.
214502606|NCT03507972|RADIATION|Member MRI|Member MRI (without injection of contrast product) performed within 7 days following the trauma
214502607|NCT02574806|PROCEDURE|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
214349015|NCT04287374|BEHAVIORAL|Multi-component Well-being Intervention|The intervention asks participants to complete exercises based on three different skills. These skills include cognitive restructuring, gratitude and behavioral activation. After completing the program, participants will pick their favorite exercise to complete on a weekly basis for homework. In order to increase compliance with the homework, participants will complete a short plan in which they will identify when, where and with who they will complete the homework. The whole intervention takes approximately 20-30 minutes to complete.
214349016|NCT04287374|BEHAVIORAL|Study Skills|Participants are taught three different study skills/strategies. They are asked to make a plan to continue using these strategies after completing the intervention. The whole intervention takes approximately 20-30 minutes to complete.
214349017|NCT03661853|BEHAVIORAL|Control|60 minute psycho-education on alcohol and drugs.
214349018|NCT03661853|BEHAVIORAL|Functional Analysis|"Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use."
214349019|NCT03661853|BEHAVIORAL|Cognitive Restructuring|CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.
214349020|NCT03661853|BEHAVIORAL|Dealing With Cravings|DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.
214349021|NCT04094454|DEVICE|special tampon with a diameter of 28mm|patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy
214349022|NCT04094454|DEVICE|standard tampon with a diameter of 12-13mm|patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
214349023|NCT04529213|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
214349024|NCT04974216|DRUG|Tafasitamab|Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
214349025|NCT04974216|DRUG|Lenalidomide|Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
214349026|NCT04974216|DRUG|Rituximab|Administration: IV at 375mg/m2 C1 to C6: D1
214349027|NCT02428868|DRUG|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
214349028|NCT02428868|DRUG|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
214349029|NCT02428868|OTHER|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
214349030|NCT02978274|DRUG|MMF|MMF withdrawal by engraftment post haplo-SCT
214349031|NCT02978274|DRUG|MMF|MMF withdrawal by 2 month post haplo-SCT
214349032|NCT02401191|DRUG|FEX60/PE10|Pharmaceutical form:tablet Route of administration: oral
214349033|NCT05234138|OTHER|Blood Sample|Blood Sample
214349034|NCT06336096|DRUG|Suzetrigine|Tablet(s) for oral administration.
214349035|NCT06336096|DRUG|Suzetrigine|Tablet(s) and Suspension for oral administration.
214349036|NCT02320604|DRUG|Administration of study drug|i.v. administration of Ambisome in two different dossages
214349037|NCT02324933|DRUG|Fentanyl|Fentanyl Patient Controlled Analgesia for post-operative pain management
214349038|NCT01265069|DRUG|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
214349039|NCT01265069|DRUG|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
214349040|NCT00250887|DRUG|Gefitnib|
214349041|NCT01949480|PROCEDURE|Thoracotomy|
214349042|NCT01949480|PROCEDURE|Video-Assisted Thoracoscopic Surgery (VATS)|
214349043|NCT05208073|BEHAVIORAL|Cosmetic therapy|The cosmetic therapy in this study is once a week, 60 minutes each section for a total of 6-week. Cosmetic therapy uses the teaching materials to teach the subjects skincare and makeup operation steps and use the 10-minute limb stretching to relax their minds before the activity, and then lead the research subjects to use cotton pads to apply lotion and lotion. , female subjects used powder, eyebrow pencil, and lipstick (or lip balm) to complete weekly different-themed activities and hairstyling, while men performed weekly different theme activities and hairstyling.
214349044|NCT01265329|OTHER|Negative selection|Sperm selection to continue the treatment with healthy sperm
214349045|NCT05124457|DRUG|Insulin Detemir|Patients are to receive insulin detemir
214349046|NCT05124457|DRUG|Insulin NPH|Patients are to receive insulin NPH
214349047|NCT05819333|OTHER|Exercise Program + Respiratory Strength Training|Strength, Flexibility, Cardiovascular exercise + respiratory strength training
215078323|NCT03294239|PROCEDURE|percutaneous extraction of bladder stone(s)|Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
214349048|NCT05819333|OTHER|Exercise Program + Respiratory Relaxation Training|Strength, Flexibility, Cardiovascular exercise + respiratory relaxation training
214349049|NCT04833647|DIAGNOSTIC_TEST|Cardio-Pulmonary-Exercise-Testing (CPET)|Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
214349050|NCT04977167|DRUG|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
214349051|NCT04977167|DRUG|PD-(L)1 antibody|PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
214349052|NCT02542748|DRUG|Norepinephrine|norepinephrine injection
214349053|NCT02542748|DRUG|Ephedrine|Ephedrine injection
214349054|NCT05207059|BEHAVIORAL|HELMS Lifestyle Intervention|The HELMS life-course Interventions, namely 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management'), are developed to deliver care throughout the journey from preconception to postpartum periods. Screening involves health and risk assessments through physical and biomarker measurements, as well as emotion and sleep evaluations for mother, and developmental assessment for children. Body Size management encompasses education on weight status awareness and mother-child health implications, both mother-child weight tracking, healthy eating and physical activity guidance. Supplementation includes multi-micronutrient, vitamin D, calcium and/or Docosahexaenoic acid (DHA) supplements, which is phase-specific for mother, and vitamin D drops supplement for child. Specific case management comprises preconception sexual health and function management, pregnancy symptoms management, postpartum recovery management, infant growth monitoring and feeding management.
215078324|NCT00736775|DRUG|anti-Abeta|Intravenous single and multiple doses
214349055|NCT06208150|DRUG|Talquetamab|Talquetamab will be administered as a SC injection.
214349056|NCT06208150|DRUG|Pomalidomide|Pomalidomide will be administered orally.
214349057|NCT06208150|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
214349058|NCT06208150|DRUG|Elotuzumab|Elotuzumab will be administered intravenously.
214349059|NCT06208150|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
214349060|NCT06208150|DRUG|Bortezomib|Bortezomib will be administered as a SC injection.
214349061|NCT06400186|BEHAVIORAL|High intensity gait training in varying external environments|Participants will engage in two 45-minutes treadmill-based gait training sessions. These training sessions will occur on separate days. One session will be performed in a natural unmodified environment. One session will be performed in a movement amplification environment. The goal of each session will be to achieve 40-minutes of walking within a target heart rate range of 70-85% of estimated heart rate max. Each session will begin and end with a 2.5 minute warm-up and cool down respectively. Participants will be given rest breaks as needed.
214349062|NCT06400186|BEHAVIORAL|Treadmill walking in varying external environments|Participants will perform a series of treadmill walking trials. Each trial will consist of 400 total steps. The first 100 steps will be performed in a natural unmodified environment. The next 200 steps will be performed in 1 of 3 external environments (natural unmodified, movement amplification, or unpredictable lateral perturbations). The final 100 steps will be performed in a natural unmodified environment. Participants will be given rest breaks between trials.
214349063|NCT04065438|DEVICE|LIPOSORBER® LA-15|"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
214349064|NCT03391479|DRUG|Avelumab|Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).
214349065|NCT03391479|OTHER|Best Supportive Care|As required.
214349066|NCT01673139|BEHAVIORAL|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
214349067|NCT01673139|BEHAVIORAL|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
214349068|NCT01673139|BEHAVIORAL|Control|Given information on recommendations for physical activity.
215078325|NCT00736775|DRUG|placebo|Intravenous single and multiple doses
215078326|NCT01643161|BEHAVIORAL|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
215078327|NCT01643161|BEHAVIORAL|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
215078328|NCT06495840|OTHER|no intervention|no intervention
214349069|NCT06530823|DRUG|Pemigatinib and Durvalumab|Pemigatinib combined with Durvalumab Pemigatinib: 13.5mg, oral administration, once daily, swallow the entire tablet with or without food. Take for 2 weeks and then discontinue for 1 week. Durvalumab: 1500mg, intravenous infusion, once every three weeks. Each infusion should take over 60 minutes.
214349070|NCT04396613|PROCEDURE|Closure technique|Randomized assignment to one of three known, effective closure techniques
214349071|NCT04152733|DEVICE|High flow nasal cannula|Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
214956330|NCT06583798|PROCEDURE|Resurgery In Silicone Oil Filled Eyes|"* Alcon Luxor Biomicroscope with Non-contact BIOM (binocular indirect ophthalmomicroscope) viewing system was used.~* 2 ports were made in Pars plana.~* Top up of Silicone oil was done whenever needed.~* Membrane peeling with relaxing retinectomy / drainage retinotomy, haemostasis and endolaser were done under Silicone oil as required.~* After the re surgery, the patients were advised to maintain prone position."
214956331|NCT02048124|DEVICE|25g standard needle|
214349072|NCT03297268|OTHER|Intervention with Home-Based Caregivers|We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
214349073|NCT04637204|DRUG|Cabozantinib|oral therapy
214349074|NCT04637204|DRUG|Axitinib|oral therapy
214349075|NCT01262066|BEHAVIORAL|Lifeskills Workshop Intervention|Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
214349076|NCT06099106|DEVICE|SEPIOLA System|Implantation of the SEPIOLA device into the left atrial appendage.
214349077|NCT02506998|BIOLOGICAL|DLE|Adjuvant treatment
214956332|NCT02048124|DEVICE|25d ProCor needle|
214956333|NCT01073826|BEHAVIORAL|Sport|
214956334|NCT01073826|DRUG|Tocilizumab|
214349078|NCT02506998|OTHER|Second generation anti histamines + Nasal corticosteroids|Standard treatment
214349079|NCT06372093|DEVICE|Picterus Jaundice Pro|Picterus Jaundice Pro is a smartphone based screening tool for neonatal jaundice that takes images of the skin of the newborn chest where the Picterus Calibration Card is placed.
214349080|NCT00443248|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested twice with each subject.
214349081|NCT04780204|DRUG|Treatment|Tenofovir Alafenamide 25 mg oral once daily
214349082|NCT04491500|BEHAVIORAL|High attitude environment|The participants will go to 4000m altitude to work for two weeks.
214349083|NCT01881308|DRUG|TNF inhibitors|
214349084|NCT01881308|DRUG|Synthetic DMARD(s)|
214956335|NCT01073826|DRUG|Sitagliptin|
214956336|NCT06845215|PROCEDURE|Transversus abdominis plane (TAP) block|Ultrasound-guided TAP block
214956337|NCT06845215|PROCEDURE|Erector spina plane block (ESP)|Ultrasound-guided ESP block
214349085|NCT01881308|DRUG|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
214349086|NCT03291444|BIOLOGICAL|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
214349087|NCT03291444|BIOLOGICAL|peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
214349088|NCT03186846|DEVICE|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
214349089|NCT03186846|DEVICE|placebo|Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
214349090|NCT05501093|OTHER|sample collection|Blood, plaque, and other oral samples
214349091|NCT04455100|DRUG|SHR1459/Itraconazole|SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
214502608|NCT06110546|DRUG|Methadone group|Participants will be started on Methadone 5mg, 10mg or 15mg every 8 hours depending on Fentanyl drip rate (0-100mcg/hr, 100-200mcg/hr or \>200mcg/hr) or hydromorphone drip rate (0-1.5mg/hr, 1.5-3mg/hr, or \>3mg/hr).
214956338|NCT01351454|BEHAVIORAL|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
214956339|NCT01351454|BEHAVIORAL|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
214956340|NCT00563914|DRUG|ferroquine (SSR97193)|associated with artesunate
214956341|NCT00563914|DRUG|amodiaquine|associated with artesunate
214956342|NCT04425681|DRUG|Osimertinib|Treatment of LM With osimertinb
214956343|NCT04425681|DRUG|Bevacizumab|Treatment of LM With Bevacizumab
214349092|NCT02372396|BEHAVIORAL|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
214349093|NCT02372396|BEHAVIORAL|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
214349094|NCT02890381|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
214349095|NCT02890381|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
214349096|NCT06536881|BEHAVIORAL|Fasting|The dietician will review the patient's chemotherapy schedule, and confirm the fasting window (as windows may be 24, 26 or 48 hours; and chemotherapy start times can vary from patient to patient).
214349097|NCT05217732|DRUG|ZX-7101A|tablet
214349098|NCT05217732|DRUG|Placebo|Tablet
214349099|NCT00958035|DRUG|bimatoprost ophthalmic 0.03% solution|Apply one drop of study medication along the upper eyelid margin once daily in the evening
214349100|NCT00958035|DRUG|vehicle sterile solution (placebo)|Apply one drop of study medication along the upper eyelid margin once daily in the evening
214349101|NCT06442371|OTHER|High Intensity interval training + Quranic Listening|In this group, participants will receive protocol of High Intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down session along with Quranic listening meditation.
214349102|NCT06442371|OTHER|High intensity interval training|In this group, participants will receive only High intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down periods with no Quranic listening meditation
214956344|NCT03560063|PROCEDURE|Corin Optimised Positioning System|"Total hip replacement with implant positioning guided by Corin Optimised Positioning System.~The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient."
214956345|NCT03560063|PROCEDURE|Standard templating|Total hip replacement with implant positioning guided by standard templating. The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.
214956346|NCT06070493|OTHER|classic physiotherapy program|For individuals of control group, a hot pack was applied to the shoulder area for 15 minutes, while the individuals were in the sitting position. The conventional mode of transcutaneous electrical nerve stimulation was used. Frequency was adjusted in the range of 50-100 Hz, and the amplitude intensity was adjusted between 10-30 milliampere with the intensity of mild tingling without causing any excessive discomfort or contractions. Electrodes were placed at the anterior, posterior, superior, and inferior of the shoulder region. In the exercise program of the patients, joint range of motion exercises, stretching, scapular stabilization, rotator cuff, and shoulder muscle strengthening exercises were given.
214349103|NCT04349787|OTHER|Computer-aided diagnosis (CADx)|Optical diagnosis of colorectal polyps made with computer-aided diagnosis (CADx) using state-of-the-art machine learning methods and deep learning architectures.
214956347|NCT06070493|OTHER|Myofascial release|myofascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the lateral neck and shoulder, pectoral region, scapulothoracic area, and arm regions for 5 minutes for optimum benefit.
214956348|NCT03193970|BEHAVIORAL|Post-Operative Recovery Registry|Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
214349104|NCT04349787|OTHER|BLI Adenoma Serrated International Classification (BASIC)|Optical diagnosis of colorectal polyps made with BLI Adenoma Serrated International Classification (BASIC), both by exert endoscopists and novices.
214956349|NCT01438242|DEVICE|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
214956350|NCT05347966|OTHER|Brain Health PRO|BHPro is a 45-week, multidomain web-based formal educational program which has been designed to increase dementia literacy, convey best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health.
214956351|NCT02145910|DRUG|Vemurafenib|Given PO
214956352|NCT02145910|RADIATION|Whole-brain radiation therapy (WBRT)|Undergo WBRT
214956353|NCT02145910|RADIATION|Radiosurgery (SRS)|Undergo SRS
214349105|NCT02952924|DRUG|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
214349106|NCT02952924|OTHER|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
214349107|NCT02952924|DRUG|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
214349108|NCT03085563|DRUG|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
214349109|NCT03085563|DRUG|Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
214349110|NCT03825380|DRUG|Bimatoprost|Eyedrops
214349111|NCT03825380|DRUG|Lumigan®|Eyedrops
214956354|NCT01349088|DRUG|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
214956355|NCT01349088|DRUG|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
214956356|NCT01349088|DRUG|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
214349112|NCT04523545|DEVICE|cardiac ablation|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
214956357|NCT06331975|DIAGNOSTIC_TEST|Radiomic signature|Assessment of radiomic signature and tumor genetic profile in patients with Non Small Cell Lung Cancer (NSCLC)
214956358|NCT00000200|DRUG|Methadone|normal maintenance dose
214956359|NCT06438419|OTHER|Electrophysiological recordings|"Electrophysiological recordings will be made during a motor task in four different conditions:~1. without pharmacological treatment and without stimulation (Off condition),~2. without pharmacological treatment and during stimulation (DBS condition),~3. during pharmacological treatment and without stimulation (DOPA condition),~4. during pharmacological treatment and stimulation (DOPA+DBS condition)."
214956360|NCT04953715|OTHER|collection of body microbiome|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied.
214956361|NCT06363292|DRUG|PRO-231|Moxifloxacin 0.5% Ophthalmic solution.
214956362|NCT06363292|DRUG|VIGAMOXI®|Moxifloxacin 0.5% Ophthalmic solution.
214956363|NCT04375904|RADIATION|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) delivered in 8 fractions of 7.5 Gy. OAR constraints must be respected but a minimum dose coverage to 95% of the PTV will be allowed down to 75% and a minimum dose to 99% of the GTV allowed at 75%. Respiratory monitoring/active respiratory management will be used. Plans will be created and delivered using photon beams with energies between 6-10 MV.
214956364|NCT03345654|OTHER|Hearing Aids|The signal processing of newly fit hearing aids will be evaluated for acceptability based on the toolset, which takes additional patient information beyond hearing threshold (like cognition) to determine the optimal hearing aid signal processing strategies.
214956365|NCT04217317|DRUG|CPI 613|CPI-613 is to be given as 2-hr IV infusion via a central venous catheter. The starting dose of CPI-613 will be 2500 mg/m2 which was determined to be the MTD in the previous phase I clinical trial.
214956366|NCT04217317|DRUG|Bendamustine|Bendamustine at 90 mg/m2 is infused by IV over 10 minutes on Days 1 and 2 of each treatment cycle. Bendamustine is given immediately after CPI-613 administration.
214956367|NCT01690299|DRUG|Apremilast|Apremilast 30 mg tablet orally BID
214956368|NCT01690299|DRUG|Etanercept|Etanercept 50 mg evaluator/subject-blinded SC QW injection
214956369|NCT01690299|DRUG|Placebo tablet|Placebo tablets BID
214956370|NCT01690299|DRUG|Placebo injection|Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
214349113|NCT00329069|DRUG|atorvastatin (drug)|
214349114|NCT00891566|PROCEDURE|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
214349115|NCT04509947|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.
214349116|NCT04509947|BIOLOGICAL|Placebo|Placebo will be administered as IM injection.
214349117|NCT05469321|OTHER|None, pure observationnal study|None, pure observational study following the usual management of the patients
214349118|NCT04393883|DRUG|A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;|(A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
214956371|NCT02608242|DRUG|YH22189|
214956372|NCT02608242|DRUG|Twynsta 80/10mg|
214956373|NCT02608242|DRUG|Crestor 20mg|
214349119|NCT04393883|DRUG|B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;|(B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
214502609|NCT06110546|DRUG|Usual care|Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols
214956374|NCT05515991|OTHER|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|"SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.~Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals."
214956375|NCT05515991|OTHER|SUPPORT-DIALYSIS Only|SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.
214956376|NCT05499663|BEHAVIORAL|POSTHOC app|The POSTHOC app is a smartphone application that will deliver the Survivorship Care Plan and promote healthy lifestyle behaviors consistent with the individual's Care Plan
214956377|NCT04199923|BEHAVIORAL|Single leg immobilisation|Immobilisation with single leg suspension immobilisation
214349120|NCT00982462|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
214349121|NCT00982462|DIETARY_SUPPLEMENT|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
214349122|NCT04644354|DRUG|Nifedipine 10 mg|For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
214349123|NCT05930327|OTHER|Unconditional Cash Transfer (High-Value)|Monthly, Unconditional Cash Transfer ($325) for 4-months
214349124|NCT05930327|OTHER|Unconditional Cash Transfer (Low-Value)|Monthly, Unconditional Cash Transfer ($25) for 4-months
214956378|NCT06500026|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214956379|NCT06500026|DRUG|Topotecan|Administration by intravenous infusion for a cycle of 3 weeks.
214956380|NCT03836105|DRUG|cemiplimab|No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.
214956381|NCT06514573|DIETARY_SUPPLEMENT|Sodium Butyrate|Daily supplementation with 1 sachet per day for 16 weeks
214956382|NCT06514573|DIETARY_SUPPLEMENT|Placebo (cornstarch)|Daily supplementation with 1 sachet per day for 16 weeks
214349125|NCT02393079|DEVICE|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
214349126|NCT02393079|DEVICE|Sham|A SHAM identical helmet will be used in the control group.
214349127|NCT04763850|OTHER|Decline Walking with real-time Feedback|Participants are walking decline with self-paced speed on an instrumented treadmill with virtual reality projection under three conditions: without instruction, with instruction for an internal focus of attention and with real-time feedback of their frontal knee alignment
214349128|NCT02930239|OTHER|Gait rehabilitating with reduced bodyweight|Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.
214349129|NCT02930239|OTHER|Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital|Exercises for increased movement and circulation performed on a daily basis.
214349130|NCT04239313|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose vaccine.
214956383|NCT05080218|DRUG|Upadacitinib|Hold UPA x 2 weeks at time of COVID booster
214956384|NCT05080218|DRUG|Abatacept|Hold SQ ABA x 2 weeks at time of COVID booster
214349131|NCT04239313|BIOLOGICAL|Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose adjuvant.
214349132|NCT04239313|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.
214349133|NCT05496582|DIAGNOSTIC_TEST|No intervention|No intervention
214349134|NCT02804854|DRUG|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
214956385|NCT05080218|DRUG|Secukinumab|Hold SEC x 2 weeks at time of COVID booster
215078329|NCT06283810|BEHAVIORAL|psychotherapy of interpersonal relationships|"Group KIPT will be 1 session per week and each session will last 90 minutes. There will be 7 sessions in total, and a completion session will be held 2 weeks after the completion of Group KIPT. In order for the students in G1 to understand which group they are in, they will also be informed about the points to be considered regarding laughter therapy. An unstructured laughter intervention will be applied at the beginning or at the end of the sessions in which group IPT is applied.~Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect). Within the scope of work packages 3 and 4, KIPT application and other measurements will be made."
215078330|NCT06283810|BEHAVIORAL|laughter therapy|"Laughter therapy is 1 session per week and each session will last 40 minutes. A total of 8 sessions will continue. Each session will start with warm-up and deep breathing exercises and will continue with applause and childish games. Afterwards, games specific to each session will be added. Unstructured interviews will be conducted with G2 at the beginning or at the end of the session, suggesting that they were subjected to group CIPT. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect) when the interviews start."
215078331|NCT06283810|BEHAVIORAL|Plasebo|"After the initial data are collected, unstructured interviews about the interpersonal relationships of the person will be conducted by conducting individual interviews with each student for 2-3 sessions at the beginning of the study in case the student does not understand which group he/she is in. Afterwards, unstructured random interviews and laughter intervention will be conducted for a total of 8 sessions lasting 40 minutes, 1 session per week. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week, 8th week and 12th week (long-term effect) when the interviews start."
215078332|NCT04983875|BEHAVIORAL|BAC-Enhanced Letter|The BAC-Enhanced Letter intervention includes enhancing the standard mammography results letter with a few additional lines of text informing patients of their personal BAC status.
214956386|NCT05080218|DRUG|Tofacitinib|Hold TOF x 2 weeks at time of COVID booster
214956387|NCT05080218|DRUG|TNF Inhibitor|Hold SQ TNFi x 2 weeks at time of COVID booster
214956388|NCT05080218|DRUG|Canakinumab Injection|Hold CAN TNFi x 2 weeks at time of COVID booster
214956389|NCT05080218|DRUG|Baricitinib|Hold BAR x 2 weeks at time of COVID booster
214956390|NCT05080218|DRUG|Ixekizumab|Hold IXE x 2 weeks at time of COVID booster
214956391|NCT05197946|DIAGNOSTIC_TEST|MRI|Research unsedated MRI scans (outside of usual care) will be performed using a 3T Philips scanner at the F.M. Kirby Research Center. An MRI scanning protocol will be at the F.M. Kirby Research Center; the protocol will not last more than 1.5 hours. Acquisitions will include a triplanar survey, functional and anatomical multi-slice imaging of the brain as well as MRI of selected spinal levels. Protocols will be used that do not involve use of contrast agents and limit power/tissue absorption as well as otherwise remain within FDA and Kirby Center safety regulations. When possible, MRI will be performed within 3 months of initial survey/interview administration. If MRI is scheduled \>3 months after initial survey/interview administration, a brief survey will be re-administered to screen for changes in pain/clinical status.
214956392|NCT04313400|DRUG|1.1% w/w AMTX-100 CF-part1|AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient
214956393|NCT04313400|DRUG|Placebo|Topical cream manufactured to mimic AMTX-100 CF3
214956394|NCT04313400|DRUG|1.1% w/w AMTX-100 CF3-part2|AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
214956395|NCT02279290|BEHAVIORAL|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
214956396|NCT02279290|BEHAVIORAL|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
214956397|NCT02839031|BEHAVIORAL|"CBT (Cognitive-Behavioral Therapy)"|
214956398|NCT02839031|BEHAVIORAL|Control (telephonic support without CBT content)|
214956399|NCT05255445|BIOLOGICAL|Red Blood Cell (RBC) Transfusion|Simple RBC transfusion or partial manual exchange
214956400|NCT00949871|OTHER|communication analysis|
214956401|NCT00949871|OTHER|questionnaire administration|
214349135|NCT02232893|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
214349136|NCT02232893|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
214349137|NCT03906370|DIAGNOSTIC_TEST|Diagnostic criteria for MS|The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
214349138|NCT05860322|DIETARY_SUPPLEMENT|Inulin|"Inulin is a water soluble non-digestible carbohydrate, and it is available in more than 36,000 species of plants. It is often used as dietary fiber and has obtained the Generally recognized as safe status (GRAS) by the Food and Drug Administration (FDA)."
214349139|NCT05860322|OTHER|Placebo|Placebo control
214349140|NCT02282501|OTHER|enteral feeding by nasogastric tube.|method of administration enteral feeding by nasogastric tube.
214349141|NCT05706805|DEVICE|Naviscore|Patients in whom treatment with (Naviscore) has been attempted
214349142|NCT04572256|DRUG|Montelukast|The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
214956402|NCT00949871|PROCEDURE|psychosocial assessment and care|
214956403|NCT00949871|PROCEDURE|support group therapy|
214956404|NCT02748291|OTHER|Walking|"The intervention group will be asked to walk a minimum 6,000 steps per day (7 days a week).~Participants will be provided with a pedometer and daily diary to record step counts.~Weekly scores will be collected via telephone contact.~Followup questionnaires will be at 6, 12 and 24 months."
214349143|NCT04572256|DRUG|Placebo|An oral placebo will be taken daily for 6 months post surgery.
214349144|NCT03457259|DEVICE|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
214349145|NCT03457259|DEVICE|Midline|Pt. will receive midline
214956405|NCT02748291|OTHER|Department of Health Physical Activity Guidelines|"1. Adults should aim to be active daily. Over a week, activity should add up to at least 150 minutes (2½ hours) of moderate intensity activity in bouts of 10 minutes or more - one way to approach this is to do 30 minutes on at least 5 days a week.~2. Alternatively, comparable benefits can be achieved through 75 minutes of vigorous intensity activity spread across the week or combinations of moderate and vigorous intensity activity.~3. Adults should also undertake physical activity to improve muscle strength on at least two days a week.~4. All adults should minimise the amount of time spent being sedentary (sitting) for extended periods."
214956406|NCT01461473|DEVICE|Positive Airway Pressure (PAP)|Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.
214349146|NCT01358526|DRUG|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
214349147|NCT01358526|DRUG|Placebo|Placebo tablets to match OXN taken orally every 12 hours
214349148|NCT00745927|OTHER|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
214349149|NCT03765437|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214349150|NCT01990443|DRUG|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
214349151|NCT01990443|DRUG|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
214349152|NCT05218252|PROCEDURE|Posterior interosseous artery flap|The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
214349153|NCT05374980|DIETARY_SUPPLEMENT|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
214349154|NCT05374980|DIETARY_SUPPLEMENT|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
214956407|NCT01461473|DEVICE|Oral Appliance (OA)|Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
214956408|NCT01397149|DRUG|Placebo|Dosage form, frequency and duration exactly as experimental arm.
214956409|NCT01397149|DRUG|Eltrombopag|"Phase I:~Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to \> 400,000/µl).~Phase II:~Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I."
214956410|NCT00936676|DRUG|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
214349155|NCT02997566|OTHER|Autonomic evaluation|
214349156|NCT05268666|DRUG|JBI-802|LSD1/HDAC6 inhibitor
214349157|NCT05710601|PROCEDURE|Laparoscopy|Operative laparoscopies carried out according to the most recent national guidelines and following the good clinical practice of our operative unit.
214956411|NCT06635850|DRUG|Mosliciguat|Dose level 1, 2, or 3 for inhalation
214956412|NCT06635850|DEVICE|Dry Powder Inhaler|Dry powder inhaler for mosliciguat or placebo delivery
214956413|NCT06635850|DRUG|Placebo|Matching placebo for inhalation
214956414|NCT06203782|PROCEDURE|endoscopic stricturoplasty|Experimental Group: In the experimental group, 51 patients underwent endoscopic stricturoplasty. A transparent cap was mounted on the front end of the endoscope, and a needle knife was inserted through the working channel of the endoscope. Under direct visualization, a radial incision was made at the site of the stricture, with an effort to preserve normal mucosal tissue as much as possible. The stricture was gradually incised until the endoscope could smoothly pass through.
214956415|NCT06203782|PROCEDURE|endoscopic balloon dilation|Control Group: In the control group, 51 patients underwent endoscopic balloon dilation. The endoscope was advanced to the site of the stricture, and a dilation guidewire was inserted. After placing the balloon, it was progressively inflated with pressure, each inflation lasting 1-2 minutes, and this process was repeated 2-3 times until the endoscope and sheath could pass through the narrowed segment and enter the distal colon.
214956416|NCT04438616|PROCEDURE|dome magnetic attachment|"* All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia~* A crestal incision is made using No. 15 c blade .~* Full sequential drilling under copious saline irrigation will be made . insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(dome) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure"
214349158|NCT01259661|OTHER|A longitudinal intervention|In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
214349159|NCT05031702|DIETARY_SUPPLEMENT|Camellia Sinensis leaf extract|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
214349160|NCT05031702|COMBINATION_PRODUCT|Placebo|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
214349161|NCT00808379|DRUG|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
214956417|NCT04438616|PROCEDURE|flat magnetic attachment|"* All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia.~* A crestal incision is made using No. 15 c blade~* Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(flat) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure in 2 weak and after 12 weak by Denture satisfaction questionnaire"
214956418|NCT01637883|DRUG|benzydamine HCl|3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
214349162|NCT00808379|RADIATION|Additional Radiation boost to the primary tumor volume|15-20Gy
214349163|NCT04425564|DRUG|metronomic XELOX|
214349164|NCT04425564|DRUG|Classic XELOX|
214349165|NCT04425564|OTHER|Blood samples for pharmacological studies|
214349166|NCT05711654|BEHAVIORAL|Health coaching|Coaching interview will be held with patients at regular intervals.
214349167|NCT05490615|BEHAVIORAL|Virtual Mindfulness|Investigators have previously developed and tested a virtual mindfulness program. Six 1-hour weekly group sessions will be led on WebEx. Focus will be on skill building through the teaching of formal and informal mindfulness practices. The intervention, based on the MBSR curriculum, has been modified to make it more accessible for autistic adults. The curriculum developed for this program was designed with autistic advisors guiding the team on the length of meditations, the language used when giving instructions, and the range of techniques that would be most helpful for autistic adults. Each activity is presented as optional, recognizing that some people may find certain silent sensory experiences too distressing. Autistic advisors will participate in sessions as co-facilitators and multiple communication options will be available to group participants (text and audio, camera on or off).
214349168|NCT04112004|OTHER|Collecting sodium reports and outcome measures|
214349169|NCT04538729|BEHAVIORAL|Acne Vulgaris|Alternative medicine and complementary therapies that acne vulgaris patients apply without informing the doctor, how they learn these techniques, what make them use these techniques for their illness
214349170|NCT06086327|DRUG|68Ga-Pentixafor|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
214349171|NCT03577717|OTHER|computerized cognitive training|participants will be trained 30 minutes/day, 3 days/week for 4 consecutive weeks.
214349172|NCT03577717|OTHER|occupational therapy|participants will receive craft activities of occupational therapy for 30 minutes/day, 3 days/week for 4 consecutive weeks.
214956419|NCT01179932|OTHER|No Intervention Used|Our study is observational; therefore, there is no type of intervention being used.
214349173|NCT00291148|DRUG|paroxetine|
214349174|NCT00291148|DRUG|pregabalin|
214349175|NCT04690855|DRUG|Talazoparib|Talazoparib 1 mg Orally Day 1 to Day 28
214349176|NCT04690855|DRUG|Atezolizumab|Atezolizumab 840 mg IV over 60 minutes Day 15 of Cycle 1 then Day 1 and Day 15 of subsequent Cycles
214349177|NCT04690855|RADIATION|Radiation|Radiation 8 Gy will be given in 3 fractions QOD beginning Day 12, 13 or 14 of Cycle 1 but 24-72 hours prior to 1st dose of Atezolizumab
214349178|NCT03031652|DEVICE|Phacoemulsification|The device device used to provide and perform small profile entry for cataract extraction with or without option of insertion of a specified intraocular lens implant
214349179|NCT00527566|BIOLOGICAL|Mepolizumab|IV mepolizumab, 750 mg
214349180|NCT00156065|DRUG|Haloperidol|2-8 mg BID
214349181|NCT00156065|DRUG|Asenapine|5 or 10 mg BID
214956420|NCT01784926|PROCEDURE|Intraocular lens repositioning by scleral suturing|
214956421|NCT01784926|PROCEDURE|Intraocular lens exchange with retropupillary iris-claw lens|
214349182|NCT00156065|DRUG|Asenapine|5 or 10 mg BID
214349183|NCT02675361|BEHAVIORAL|Transition program|Participants will be part of a transition program with eight key components: 1. A transition coordinator; 2. Education on congenital heart disease (CHD), treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the Grown-Up Congenital Heart Disease (GUCH) program: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Transfer to Grown-Up Congenital Heart Disease clinic. The intervention will be implemented by specialized nurses at the outpatient clinic of pediatric cardiology. Overall, 60 to 90 minutes per patient are spent over the 2.5 years.
214349184|NCT04341701|PROCEDURE|MRI|The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent
214349185|NCT04225208|DRUG|[14C]-AZD4205, single 50 mg oral dose administrated on day 1|Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
214349186|NCT04473131|OTHER|No intervention|Only blood samples will be taken from participants for this study
214349187|NCT04757623|PROCEDURE|Purse string closure of Ileostomy|conventional proceedure
214956422|NCT04582201|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
214956423|NCT01014078|DRUG|Azithromycin Ophthalmic Solution, 1%|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
215078333|NCT04983875|BEHAVIORAL|Waitlist Control|Patients randomized to this group will receive a standard post-mammography results letter which does not include any information about their personal BAC status. However, participants randomized to this group will be informed of their personal BAC findings at the end of their study participation (approximately 6 months after mammography).
215078334|NCT03865108|PROCEDURE|Ultrasound imaging|This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
214349188|NCT03911492|PROCEDURE|SCPP Management => 65 mmHg|A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
214349189|NCT04942171|PROCEDURE|Atrial fibrillation catheter ablation group|"1. Pulmonary vein isolation~2. Additional treatment for lesions caused by non-pulmonary veins~3. Esophageal temperature monitoring to prevent damage to the esophagus~4. Evaluation of procedure time and radiofrequency ablation time~5. Evaluation of complications after the procedure~6. Rhythm follow-up after the procedure is conducted in accordance with the above study design.~7. Conduct a survey on cognitive function and emotion before and 12 months after the procedure"
214349190|NCT04942171|DRUG|Medical therapy group|"1. Use of beta-blockers or calcium channel blockers for pulse rate control~2. Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~3. If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~4. To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~5. Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure"
214349191|NCT06534632|OTHER|Mother's colostrum|Oropharyngeal administration of mother's colostrum
214349192|NCT06534632|OTHER|Placebo|Oropharyngeal administration of sterile water
214349193|NCT02417038|DEVICE|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
214349194|NCT04745169|BEHAVIORAL|8 week home-based exercise program|Participants will be asked to complete an 8-week home-based exercise program according to guidelines from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. At study baseline, participants will receive exercise equipment and an individualized exercise prescription from an exercise physiologist followed by 8 weekly phone calls from an exercise physiologist. Participant safety will be monitored.
214349195|NCT01292603|DRUG|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
214349196|NCT01292603|DRUG|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
214349197|NCT01292603|DRUG|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
214349198|NCT01292603|DRUG|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
214349199|NCT01292603|DRUG|rituximab [MabThera]|6 cycles of intravenous MabThera
214349200|NCT04296565|BEHAVIORAL|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff
215078335|NCT03865108|PROCEDURE|Cervical speculum examination|This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
214349201|NCT04296565|BEHAVIORAL|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
214349202|NCT01704417|DRUG|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
214349203|NCT01704417|DRUG|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
214349204|NCT00463190|DRUG|Biothree|
214349205|NCT05450848|DEVICE|StrataXRT|StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
214349206|NCT05450848|OTHER|Sorbolene|Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.
214349207|NCT01808690|DRUG|Metformin|
214349208|NCT01808690|DRUG|Placebo|
214502610|NCT05426109|OTHER|Peanut snacks|Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal peanut-containing (whole peanuts or peanut butter) snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
215078336|NCT03184493|DRUG|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
215078337|NCT03184493|DRUG|Celebrex|This group patients will receive celebrex.
215078338|NCT03184493|DRUG|Metformin|This group patients will receive metformin.
215078339|NCT05961969|PROCEDURE|Robotic surgery|"1. Patients with rectal cancer.~2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis"
215078340|NCT01712997|DRUG|Iloprost|
215078341|NCT01712997|DRUG|Bosentan|
214349209|NCT03664713|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|EMDR is an 8-phase psychological treatment composed of protocols and standardized procedures applicable to both adults and children. The eight phases (patient history, patient preparation, evaluation of the main aspects of the memory, desensitization of the traumatic memory, installation of the positive cognition, body scan, close and re-evaluation) and the protocol of the time line of past-present-future, allow a holistic evaluation of the image of the traumatic memory, and allow for the patient to be well-prepared before processing past events which underlie current pathology, current situations which cause perturbation, and challenges and possible future stimuli which might lead to the appearance of symptoms. (Shapiro, 2014)
214349210|NCT05651581|OTHER|Online module|online module including around 5 videos and several infographics covering the topics of symptoms transmission, prevention, vaccination, and treatment of the monkeypox virus.
214349211|NCT03434925|GENETIC|Multi-targeted next generation sequencing|Study directed at finding molecular predictors of recurrent colorectal adenomas also taking into account the intrinsic level of heterogenity imprinted in the internal differences in molecular profiles
214349212|NCT03870763|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
214349213|NCT03870763|DRUG|Peginterferon Beta-1a|Administered as specified in the treatment arm.
214349214|NCT03870763|DRUG|Placebo|Administered as specified in the treatment arm.
214349215|NCT05239234|OTHER|Inferior vena cava-Aorta diameter index|Before the induction of general anesthesia, inferior vena cava-Aorta diameter index and inferior vena cava collapsibility index will be measured.
214349216|NCT03312556|DEVICE|continuous positive airway pressure (CPAP)|Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
214349217|NCT03312556|DRUG|Placebo|Placebo pill or patch. Single dose
214956424|NCT01014078|DRUG|Placebo|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
214956425|NCT03678194|DEVICE|Smartphone Support System|6 weeks smartphone application with daily evaluations
214349218|NCT04432597|BIOLOGICAL|PRGN-2009 (Phase I)|On the phase I portion of the protocol PRGN-2009 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. The dose level given as booster will be the same dose participants will be receiving for D1, D15 and D29.
214956426|NCT05578677|OTHER|Biopsy technique|"* Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~* Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively."
214956427|NCT05302947|DRUG|Baricitinib Oral Tablet|Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
214956428|NCT05302947|DRUG|Tocilizumab Injection|Tocilizumab was administered by a single intravenous dose of 400 mg
214956429|NCT05302947|DRUG|Netakimab|Netakimab was administered by a single subcutaneous injection of 120 mg
215078342|NCT04460924|DRUG|Integrase strand transfer inhibitors|Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
214349219|NCT04432597|BIOLOGICAL|PRGN-2009 (Phase II)|On the phase II portion of the protocol PRGN-2009 will be administered on just Day (D)1 and D15.
214349220|NCT04432597|BIOLOGICAL|M7824|"Subjects enrolled to Arm 1B will receive M7824 (MSB0011359C) via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
214349221|NCT04432597|DIAGNOSTIC_TEST|MRI|MRI (with gadolinium) of the neck, chest, skull, and/or sinonasal, if indicated, will be used when computed tomography (CT) scan is not an option to follow the disease.
215078343|NCT04142424|DRUG|AZD2693|Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
215078344|NCT04142424|DRUG|Placebo|Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
215078345|NCT00434733|BIOLOGICAL|Pandemic influenza vaccine|
215078346|NCT05743556|DEVICE|HILT laserotherapy|application of high intensive laser therapy on cervical muscles
214956430|NCT05302947|OTHER|Standard of care therapy|SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
214956431|NCT04624802|BEHAVIORAL|maternal exercise|The maternal exercise is broadly practiced by pregnant women in China. It is designed by a team led by Shen Shanmei, a professor of Maternity Exercises at Department of Obstetrics and Gynecology of First Hospital in Korea.
214956432|NCT02298088|DRUG|Ticagrelor 180 mg|Ticagrelor, 180 mg as early as possible after the index event and not \>24 h post event followed by 90 mg twice daily for 12 months.
214956433|NCT02298088|DRUG|Clopidogrel|"300 mg clopidogrel as early as possible after the index event and not \> 24h post event, followed by 75mg/day for 12 months.~For patients with \> 75 years the recommended load dose is 75 mg instead 300 mg."
214956434|NCT02258906|DRUG|ulinastatin|
215078347|NCT05743556|DEVICE|TRT therapy|application of radiofrekvention therapy on cervical muscles
215078348|NCT03011970|DRUG|Oxytocin|
215078349|NCT03011970|DRUG|Placebo|
215078350|NCT02241213|DEVICE|Transcranial Magnetic Stimulation (TMS-r)|"10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI)."
214349222|NCT04432597|DIAGNOSTIC_TEST|Bone scan|Bone scans and other imaging assessments may also be performed as clinically indicated.
214349223|NCT04432597|DIAGNOSTIC_TEST|CT scan|Imaging of the neck, chest, skull, and/or sinonasal, if indicated, will be performed every 8 weeks. In the event of a partial response (PR) or complete response (CR) tumor imaging assessments may be performed every 3 months (+/- 2 weeks) at the discretion of the investigator.
214956435|NCT02258906|DRUG|normal saline|
214349224|NCT04432597|DIAGNOSTIC_TEST|Brain CT|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
214349225|NCT04432597|DIAGNOSTIC_TEST|Brain MRI|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
214349226|NCT04432597|PROCEDURE|Biopsy (Phase I)|"Where feasible, optional biopsies may be done at baseline as well as at week 9 and will likely be computed tomography (CT) guided. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy for phase I participants.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 9 (phase I participants)."
214349227|NCT04432597|PROCEDURE|Biopsy (Phase II)|"Where feasible, biopsies will be done at baseline as well as at week 4-5. Biopsies will be done by ear, nose and throat (ENT) under direct visualization. Where feasible at least 2 cores will be obtained. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 4-5 (phase II participants)."
214349228|NCT02891187|BEHAVIORAL|Telephone follow-up|Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
214349229|NCT02891187|BEHAVIORAL|Outpatient Clinic Visits|Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
214349230|NCT02820779|DEVICE|WILLIS|WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
214956436|NCT00496587|DRUG|Capecitabine|800 mg/m\^2 By Mouth Twice Daily On Days 1-21.
214956437|NCT00496587|DRUG|Gemcitabine|900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.
214956438|NCT00496587|DRUG|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
214956439|NCT00202943|PROCEDURE|TCRFVR and LAUP|
214956440|NCT02652702|PROCEDURE|circular stapler-assisted colostomy|procedure:circular stapler-assisted colostomy device:circular stapler
214956441|NCT02652702|PROCEDURE|conventional hand-stitching colostomy|procedure:hand-stitching colostomy
214956442|NCT01183416|DRUG|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are \~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
214956443|NCT02383355|DRUG|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
214956444|NCT02383355|DRUG|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
214956445|NCT02799277|DRUG|Testosterone|Effect of testosterone on moral decision making
214956446|NCT02799277|DRUG|Placebo|Effect of testosterone on moral decision making
214956447|NCT00275015|BIOLOGICAL|filgrastim|
214956448|NCT00275015|DRUG|carmustine|
214956449|NCT00275015|DRUG|cyclophosphamide|
214956450|NCT00275015|DRUG|cytarabine|
214956451|NCT00275015|DRUG|dexamethasone|
214956452|NCT00275015|DRUG|etoposide|
214956453|NCT00275015|DRUG|fludarabine phosphate|
214956454|NCT00275015|DRUG|melphalan|
214349231|NCT02420002|DRUG|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
214956455|NCT00275015|PROCEDURE|bone marrow ablation with stem cell support|
214956456|NCT00275015|PROCEDURE|peripheral blood stem cell transplantation|
214956457|NCT00275015|RADIATION|radiation therapy|
214956458|NCT04624607|DEVICE|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive transspinal stimulation and non-invasive brain stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
214956459|NCT04624607|DEVICE|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive brain stimulation and non-invasive transspinal stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
214956460|NCT01026337|GENETIC|mutation analysis|Correlative study
214956461|NCT01026337|OTHER|pharmacological study|Correlative study
214956462|NCT01026337|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
214956463|NCT01026337|DRUG|sunitinib malate|Given orally
214956464|NCT01026337|OTHER|immunohistochemistry staining method|Correlative study
214956465|NCT01026337|OTHER|laboratory biomarker analysis|Correlative study
214956466|NCT01146561|BIOLOGICAL|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
214956467|NCT01146561|OTHER|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
214956468|NCT04231968|DRUG|AK0529|AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
214956469|NCT04231968|DRUG|Matching placebo of AK0529|The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
214349232|NCT02420002|OTHER|Use of Hypnosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
214349233|NCT02420002|PROCEDURE|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
214956470|NCT05287854|DEVICE|Virtual reality headset|Once the patient is on the operating table, the nurse proposes the different possible VR scenarios and installs the RV headset and an audio headset.
214956471|NCT03510429|DIETARY_SUPPLEMENT|Postoperative Nutritional Supplement|Postoperative Nutritional Supplement (newly developed ketogenic drink: NDKD)
214956472|NCT03510429|OTHER|Routine post-op care|Routine post-operative care
214956473|NCT03123003|DEVICE|SonicBone Ultrasound|Bone age assessment by SonicBone Ultrasound. The patient needs to put his/her wrist in 3 positions.
214956474|NCT03123003|DEVICE|Wrist X-ray|Bone age assessment by Wrist X-ray
215078351|NCT02241213|DEVICE|Placebo Transcranial Magnetic Stimulation|10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
214349234|NCT02615223|PROCEDURE|cryoablation|Cryoablation therapy
214956475|NCT04745507|OTHER|Inpatient Equivalent Home Treatment|At-home psychiatric treatment by means of a multiprofessional clinic team (an equivalent to stationary psychiatric care).
214956476|NCT03326232|DEVICE|Continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
214956477|NCT01516645|DRUG|KHK2898|injection
214956478|NCT00629148|DRUG|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
214956479|NCT00629148|DRUG|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
214349235|NCT02615223|DRUG|Bicalutamide|bicalutamide
214349236|NCT02615223|DRUG|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
214349237|NCT03278665|DRUG|4SC-202 in combination with Pembrolizumab|4SC-202 in combination with Pembrolizumab
214349238|NCT05804773|DIAGNOSTIC_TEST|Non-invasive Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s)|"Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s) (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk. For neuro-injured patients with intracranial pressure monitoring (ICP), the lower limit of cerebral perfusion pressure (CPP = MAP - ICP) will be set at 50 mmHg"
214349239|NCT02247427|DEVICE|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
214956480|NCT02036541|DEVICE|AqueSys XEN 45 Glaucoma Implant|Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
214956481|NCT01778751|BEHAVIORAL|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
214956482|NCT05626257|OTHER|Xolair|There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
214956483|NCT00410618|PROCEDURE|cognitive assessment|
214956484|NCT00410618|PROCEDURE|magnetic resonance imaging|
214956485|NCT00410618|PROCEDURE|management of therapy complications|
214502611|NCT05426109|OTHER|No peanut-containing snacks|Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal non-peanut-containing high carbohydrate snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
214502612|NCT05793996|DRUG|Ferinject|The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.
214956486|NCT03960424|OTHER|Comprehensive Outpatient Management|Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.
214956487|NCT03960424|BEHAVIORAL|Diabetes Telemonitoring|Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.
215078352|NCT05482529|OTHER|Integrative omics|Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT\&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
215078353|NCT02381717|OTHER|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
215078354|NCT02381717|DRUG|bupivacaine|
215078355|NCT02381717|DRUG|morphine|
214502613|NCT05793996|OTHER|Diet therapy|Patients will receive diet therapy to correct latent iron deficiency
214956488|NCT05681637|OTHER|Breathing mixtures of O2 and N2 and monitoring SpO2 on each finger|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
214956489|NCT03609190|DRUG|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
214956490|NCT03609190|DRUG|Placebo|i.v. infusion of NaCl over 40 min
214956491|NCT04037852|DEVICE|robotic assisted nipple sparing mastectomy|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
214956492|NCT04037852|PROCEDURE|Endoscopic assisted nipple sparing mastectomy|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
214956493|NCT04037852|PROCEDURE|Conventional nipple sparing mastectomy|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
214956494|NCT01553435|DRUG|Dextromethorphan|The study medicines shall be administered via tube.
214956495|NCT01553435|DRUG|Placebo|The study medicines shall be administered via tube.
214956496|NCT01459393|DRUG|5-ALA Photodynamic Therapy|
214956497|NCT01459393|DRUG|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
214956498|NCT00868751|BIOLOGICAL|tocilizumab|"Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.~Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16."
214956499|NCT04910243|OTHER|Questionnaire Survey|Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.
214956500|NCT04183166|DRUG|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
214956501|NCT02707900|DRUG|Vorinostat|"At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.~Step 5 - Approximately 7- 10 days after the 4th dose of AGS-004 in Step 4 (Visit 11), ten (10) doses of VOR 400 mg will be administered at 72 hour intervals.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
214956502|NCT02707900|BIOLOGICAL|AGS-004|"Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
214956503|NCT06612502|BEHAVIORAL|Static stretching|The static stretching protocol comprised eight exercises, performed for 30 seconds per bilateral muscle group (with the exception of the sitting toe touch and butterfly stretch), and included the hip, knee, and ankle. The subjects were instructed to perform the following sequence of stretches: forward lunge, supine knee flexion, lateral quadriceps stretch, sitting toe touch, semi-straddle, straddle, butterfly stretch, and a straight knee ankle extensor wall stretch. Each subject completed each stretch before progressing to the subsequent one. The stretches were maintained until the subject experienced mild discomfort, but not pain.
215078356|NCT01316757|BIOLOGICAL|cetuximab|Given IV
215078357|NCT01316757|DRUG|paclitaxel|Given IV
214502614|NCT02577926|DRUG|Ruxolitinib|Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
214502615|NCT02577926|DRUG|BAT|BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
214678654|NCT05922267|OTHER|ACTIVE CYCLE OF BREATHING TECHNIQUES|"The participants in group A will be given ACBT with conventional chest physiotherapy .~Instruction for patient~* Try to keep your chest~* Take a long, slow and deep breath in, through your nose if you can.~* At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~* Breathe out gently and relaxed, like a sigh. Don't force the air out.~* Repeat 3 - 5 times.~* If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~* Huffing"
215078358|NCT01316757|DRUG|carboplatin|Given IV
215078359|NCT01316757|DRUG|erlotinib hydrochloride|Given PO
215078360|NCT01316757|OTHER|laboratory biomarker analysis|Correlative studies
215078361|NCT03232645|DEVICE|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
215078362|NCT00144248|DRUG|nevirapine|
215078363|NCT05897840|DEVICE|Fiber-optic probe CeVOX|Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
215078364|NCT01468233|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
214349240|NCT05247996|PROCEDURE|Transcatheter arterial chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
214349241|NCT05247996|DRUG|Multi-target Drug Therapy|Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight \< 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
214349242|NCT05247996|DRUG|Immunocheckpoint Inhibitor Therapy|Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
214349243|NCT05247996|PROCEDURE|Systemic Intravenous Chemotherapy|GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
214349244|NCT02188433|BEHAVIORAL|Quit immediately (QI) / cut down to quit (CDTQ)|Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
214349245|NCT04852081|DRUG|Palbociclib|Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
214349246|NCT04852081|DRUG|Ribociclib|Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
214349247|NCT04852081|DRUG|Abemaciclib|Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
214349248|NCT04852081|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
214349249|NCT04852081|DRUG|Anastrozole|Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
214349250|NCT04852081|DRUG|Tamoxifen|Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
214956504|NCT06612502|DEVICE|Fascia gun ( Short-time PMT )|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The short time PMT was applied for 2.5 minutes per muscle site for a total of 25 minutes.
214956505|NCT06612502|DEVICE|Fascia gun ( Long-time PMT )|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The long time PMT was applied for 4 minutes per muscle site for a total of 40 minutes.
214956506|NCT06612372|BEHAVIORAL|60-day-6° head-down bed rest|Throughout the bed rest period, subjects carried out all activities of daily living-eating, voiding, recreation, and testing
214956507|NCT05018988|DIETARY_SUPPLEMENT|Oral vitamin D spray|1 spray (10µg) /day for 12 weeks
214956508|NCT05018988|DIETARY_SUPPLEMENT|Placebo|1 spray / day for 12 weeks
214956509|NCT06673160|BEHAVIORAL|Pumping every 2 hours|The intervention will be pumping every 2 hours.
214956510|NCT06673160|BEHAVIORAL|breast pumping every 3 hours|The intervention will be pumping every 3 hours
214956511|NCT01956760|OTHER|Acupuncture and intradermal acupuncture|The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25\*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20\*8.0mm).attached to skin tape (10.0\*10.0mm). The needles were inserted 3.0\~5.0mm deep and maintained for 48\~72 hours
214956512|NCT04581018|OTHER|Health supplements|28 days of health supplements (synbiotic), 4g daily
214349251|NCT04852081|DRUG|Fulvestrant|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
214349252|NCT04852081|DRUG|Exemestane|Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
214349253|NCT04852081|DRUG|Alpelisib|Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
214349254|NCT02644460|DRUG|Abemaciclib|
214349255|NCT05155826|DEVICE|Virtual Reality Headset|The patient will benefit from the placement of Cook's balloon (standard care) with the placement of the virtual reality headset on the examination table with the launch of the software before the beginning of the procedure. The virtual reality helmet will be removed at the end of the procedure.
214349256|NCT01615731|DRUG|Mifepristone|200mg Mifepristone orally
214956513|NCT01415375|BEHAVIORAL|Prostate Cancer Screening Education|tailored telephone education on prostate cancer testing
214956514|NCT01415375|BEHAVIORAL|Fruit and Vegetable Intake Education|tailored telephone education about fruit and vegetable consumption
214956515|NCT06601738|OTHER|Isomeric Hand Grip Exercises|Patients will be instructed to squeeze and sustain the dynamometer for 2 min at 30% M.V.C. The dynamometer pointer which read the scale provided visual feedback to the subjects for the maintenance of the 30% M.V.C. This procedure will be repeated twice for each training session with a 5-minute rest in between.
214956516|NCT06601738|OTHER|Dynamic Hand Grip Exercises|Dynamic handgrip exercise was performed with both-sided, metronome-guided rhythmic hand contractions for 2min. The handgrip ring, closest to 20% of MVC, was chosen for DHE which was performed at a frequency of 30/min, acoustically indicated by a metronome beat.
214956517|NCT00623389|DEVICE|IST (Implanted Stimulator-Telemeter)|Pre-surgical exercise with surface electrical stimulation, surgery including electrode and IST- implanted pulse generator insertion, exercise and physical therapy with the implanted system, functional training and laboratory assessment of clinical and technical performance.
214956518|NCT04285216|OTHER|Dry Needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
214956519|NCT04285216|OTHER|Strain counter strain|Hot pack 10 mints, stretchings,Neck isometrics, Strain counterstrain(SCS)
214956520|NCT00405782|BEHAVIORAL|Moderate-Intensity Exercise|Exercise program designed by exercise physiologist
214956521|NCT02945696|PROCEDURE|laparoscopic guided nerve blocks|It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
214956522|NCT02945696|DRUG|Ropivacaine|Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
214956523|NCT03628716|BIOLOGICAL|CV301|"Prime with MVA-BN-CV301 (nominal titer 1.6 x 10\^9 Inf.U) given subcutaneously (SC) on Day 1 and Day 22. One dose = four 0.5 mL injections. One injection = nominal titer 4 x 10\^8 Inf.U in 0.5 mL.~Boost with FPV-CV301 (nominal titer of 1 × 10\^9 Inf.U in 0.5 mL, given SC every 21 days for 4 doses (on days 43, 64, 85, and 106), followed by boosts every 6 weeks until 6 months on trial (i.e., days 148 and 190), then every 12 weeks until completion of 2 years. One dose = one 0.5 mL injection."
214956524|NCT03628716|BIOLOGICAL|Atezolizumab|Atezolizumab fixed dose of 1200 mg intravenous on Day 1 of each 21-day cycle
214956525|NCT07006623|BEHAVIORAL|CoMBI-SMI|CoMBI-SMI (Cognitive Model for Behavioral Interventions - Severe Mental Illness) is a structured, team-based behavioral intervention for individuals with severe mental illness. It consists of four steps: (1) analyzing misunderstood behavior and identifying unmet core needs, (2) selecting the most relevant core need, (3) choosing appropriate nursing interventions, and (4) developing a CoMBI care plan. The model is based on cognitive-behavioral principles and personality-based formulations grounded in the DSM. It describes self-image, perception of others, triggers, and problematic behaviors. CoMBI-SMI is implemented by the entire team in a cyclical process, with periodic evaluation and a focus on consistent, team-aligned strategies.
214956526|NCT06866717|OTHER|Hybrid prehabilitation|"Hybrid prehabilitation group (15 sessions in total over 3 weeks): participants will complete 3 center-based sessions and 12 home-based sessions over three weeks. The home-based sessions will mirror those in the center-based group (initiation, training session, final session).~For the home-based component, participants will receive a cycle ergometer, pulse oximeter, activity tracker, and a tablet application for guidance throughout the program, remote monitoring and communication (TELEREHAPP). Home-based sessions include:~* Endurance training on the cycle ergometer (15 to 45 minutes per session).~* Strength training and balance exercises (30 minutes per session).~* Inspiratory muscle training (10 sets of 10 repetitions at 30% of maximal inspiratory pressure).~* Physical activity coaching with daily step count objective;~* Regular remote monitoring and support via the tablet application, with weekly check-ins from healthcare professionals."
214956527|NCT06866717|OTHER|Center-based prehabilitation|"Center-based prehabilitation group (15 sessions in total over 3 weeks): participants will attend 15 sessions in the center, over three weeks, comprising:~* 1 initiation session (approximately 3 hours) including preoperative patient education, instructions on the use of inspiratory muscle training device, endurance training on a cycle ergometer, strength training, and balance exercises.~* 13 endurance training sessions (1.5 to 2 hours each) focusing on endurance training (15 to 45 minutes), strength training (30 minutes), and inspiratory muscle training (10 sets of 10 repetitions at 30% of maximal inspiratory pressure).~* 1 final session (2 to 2.5 hours) with a review of the program and educational reinforcement."
214956528|NCT04989309|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.
214956529|NCT07013617|DEVICE|Transcutaneous Electrical Nerve Stimulation Device|Each participant will receive 20 minutes of TENS, Electrodes will be positioned around the patella with a 5 - 7 cm distance in between, The TENS settings include a continuous asymmetric biphasic square-pulse wave, a pulse width of 120 microseconds, and a pulse rate of 180 Hz.
215078365|NCT01468233|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
214349257|NCT01615731|OTHER|Hygroscopic cervical dilators|Dilapan-S osmostic cervical dilators inserted through the internal os
214349258|NCT01615731|DRUG|Misoprostol|400mcg buccal misoprostol 90 minutes pre-op
214349259|NCT01615731|DRUG|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically \~24 hours pre-op
214349260|NCT06204731|OTHER|Exercise and environmental conditions|Participants will engage in interval training and will reside and sleep at different altitudes for a period of 4 weeks. Aerobic and anaerobic capacity tests and an eccentric exercise test will be performed before and after the training intervention. Before and after the training program, somatic measurements will also be taken. Before and after the first and last workout, blood will be drawn for biochemical analysis.
214349261|NCT05921968|DRUG|Intravenous iron sucrose|"200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose)~o The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg"
214349262|NCT05921968|DRUG|Lactoferrin|100 mg twice daily orally before breakfast and dinner
214349263|NCT03586648|DEVICE|senofilcon A Multifocal|TEST Lens
214349264|NCT03586648|DEVICE|senofilcon A Sphere|TEST Lens Sphere
214349265|NCT03586648|DEVICE|etafilcon A Multifocal|CONTROL Lens
214349266|NCT03586648|DEVICE|etafilcon A Sphere|CONTROL Lens Sphere
214956530|NCT07013617|OTHER|Strength exercises for lower limb|Each participant will receive progressive strengthening program targeting the hip and knee, begin with 3 sets of 10 repetitions and progress to 3 sets of 20 repetitions.
214956531|NCT07013617|OTHER|Hamstring Stretch Muscle Energy Technique(MET) (General )|The participant will be supine and the leg will be taken into hip flexion until a tightness is felt then patient will be asked to push down with his lower leg and hold the contraction for 10 seconds then relax for 2 to 3 seconds then the therapist will take the patient's leg into further flexion for 30 seconds this will be repeated for 3 times each session .
214349267|NCT04480112|BEHAVIORAL|Technology based social interactions|Participants will be socially interacting using any available technology with members of the research team.
214349268|NCT04480112|OTHER|No research related technology based social interactions|No technology based social interactions with the research team.
214956532|NCT07013617|OTHER|Medial Hamstring Muscle energy technique(MET) stretch|The Participant will be supine' then the therapist will take his leg in flexion, abduction and external rotation at the same time until he feels tightness then he will ask the patient to push his leg down and in or toward him and hold the contraction for 10 seconds then relax for 2 to 3 seconds then therapist will take the patient's leg in more abduction 'external rotation and flexion for 30 seconds, this will be repeated for 3 times each session
214956533|NCT07013617|OTHER|Lateral hamstring Muscle Energy Technique(MET)Stretch|The Participant will be supine' then the therapist will take his leg in flexion, adduction and internal rotation at the same time until he feels a tightness then he will ask the patient to push his leg down and out or away from him him and hold the contraction for 10 seconds then relax for 2 to 3 seconds then therapist will take the patient's leg in more adduction 'internal rotation and flexion for 30 seconds, this will be repeated for 3 times each session
214956534|NCT07016308|DRUG|Sevoflurane|Sevoflurane will be administered via inhalation under low-flow anesthesia conditions. The concentration will be maintained at 2-3% (0.8-1 MAC) with a fresh gas flow of 1 L/min (50% oxygen and 50% air) after induction. Used in Group S (Sevoflurane Low-Flow Anesthesia Arm).
214956535|NCT07016308|DRUG|Desflurane|Desflurane will be administered via inhalation under low-flow anesthesia conditions. The concentration will be maintained at 4-6% (0.8-1 MAC) with a fresh gas flow of 1 L/min (50% oxygen and 50% air) after induction. Used in Group D (Desflurane Low-Flow Anesthesia Arm).
214956536|NCT07015944|OTHER|Non-specialist delivered Low intensity guided self-help (Khushi and Khatoon)|This is a manualised intervention comprising of 8 chapters. This is being further co-adapted to contexualise this for breast cancer survivours. The original manual is focused on stories of two breast cancer survivors , Mrs Khushi, means happiness) and Khatoon, means woman in Urdu, with depression and anxiety, describing how they help themselves using CBT strategies.
214956537|NCT07015944|OTHER|Moving on After Breast Cancer (ABC) plus|This is a high intensity manualised intervention consisting of 12 sessions (60-90 minutes). This manual offers practical support and advice on life after breast cancer, managing difficulties, mindfulness, addressing fatigue, understanding the participant's model of illness, improving personal effectiveness and social relationships. The sessions also include therapist delivered psychoeducation using a CBT model of case formulation and goal setting: identification and formulation of predisposing, precipitating, perpetuating and protective factors of depression and/or anxiety, helping participants to identify core beliefs, where necessary, using downward arrow technique, identifying, and challenging unhealthy thinking patterns at the level of core beliefs using cognitive restructuring, and problem-solving techniques
214349269|NCT02041195|DRUG|Setmelanotide|
214349270|NCT02041195|DRUG|Placebo|
214349271|NCT01719952|DRUG|Carbetocin|"IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group."
214349272|NCT01719952|DRUG|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
214349273|NCT00908479|BEHAVIORAL|Leg Exercise Program|Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
214349274|NCT00908479|BEHAVIORAL|Leg Management group|Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
214349275|NCT02395120|BEHAVIORAL|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
214349276|NCT02395120|BEHAVIORAL|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
214349277|NCT02395120|BEHAVIORAL|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
214349278|NCT02395120|BEHAVIORAL|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
214349279|NCT02395120|BEHAVIORAL|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
214349280|NCT01748929|DRUG|Albendazole|
214349281|NCT01748929|DRUG|Placebo|
214349282|NCT00674986|DEVICE|Accu-Chek 360° View Blood Glucose Analysis Tool|
214349283|NCT00674986|DEVICE|Accu-Chek Aviva Glucose Meter|
214349284|NCT01611701|PROCEDURE|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
214349285|NCT01611701|PROCEDURE|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s.
214956538|NCT07015944|DRUG|Standardised pharmacological treatment (antidepressants)|Patients will begin 12 weeks of sertraline treatment initiated at a daily dose of 50 mg for the first 4 weeks. After that, flexible titation of sertraline will be permitted, by 50mg increment every 1 to 2 weeks, as clinically indicated and tolerated to a maximum daily dose of 200 mg
214956539|NCT07015944|OTHER|Enhanced Treatment As Usual (E-TAU)|Participants in this arm will continue to follow their routine visits to healthcare facilities. They will be regularly monitored by trained research team and will be assessed at weeks 6,18,30, and 48. In addition to psychological assessment at each follow-up, this will include information leaflets based on a brief psychoeducational module to educate participants and families about the risks, symptoms, management, and referral support information for anxiety and depression
214956540|NCT07017660|OTHER|virtual reality glasses|Patients will be asked to wear virtual reality glasses starting three minutes before the procedure and until it is completed. With the virtual reality glasses, the patient will be shown a video of nature scenes and made to listen to the sounds of water and birds. Routine institutional procedures will be applied during the cystoscopy procedure.
214956541|NCT07017660|OTHER|No intervention|Routine institution procedures will be applied during the cystoscopy procedure.
214349286|NCT03321916|DEVICE|577-nm PASCAL laser|The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
214349287|NCT05166408|PROCEDURE|Buccinator myomucosal flap|Buccinator myomucosal flap for primary cleft palate palatoplasty
214349288|NCT05166408|PROCEDURE|Bardach two flap palatoplasty|Bardach two flap palatoplasty
214349289|NCT06369259|DRUG|Defactinib|Given by PO
214956542|NCT07019441|OTHER|Daily-Activity-Focused, Strategy-Based Educational Program|The proposed Educational Program will have one face-to-face education session and three follow-up telephone support sessions. Strategies to assist the people with dementia with daily activities, developed from our prior work, have been compiled into a Strategies Package. Healthcare professionals will deliver the program and work collaboratively with the carers to identify issues that arise during caregiving and problem-solve using the strategies included in the package. Carers are provided with support and are encouraged to locate an appropriate strategy using the Strategies Package to help them assist in a daily task in which they want their care recipient to engage.
214956543|NCT07019441|OTHER|Usual Carer support|This group will receive emotional support from trainers on the caring issues raised. It will include the same number of sessions as in the experimental group.
214956544|NCT07021625|DEVICE|Kunbot|A chatbot designed based on cognitive behavioral therapy for insomnia
214349290|NCT06369259|DRUG|Cetuximab|Given by IV
214349291|NCT06369259|DRUG|Avutometinib|Given by PO
214349292|NCT03328754|DEVICE|Powerscope placed bilaterally for class II correction|Powerscope placed bilaterally for class II correction
214349293|NCT03328754|DEVICE|Group 2 Forsus|Forsus placed bilaterally for class II correction
214349294|NCT02527668|DIETARY_SUPPLEMENT|Calcifediol|One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months
214349295|NCT02527668|DIETARY_SUPPLEMENT|Vitamin D3|One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months
214349296|NCT02527668|OTHER|Placebo|One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
214956545|NCT07021625|OTHER|Treatment as usual|Treatment as usual
214349297|NCT05463328|PROCEDURE|laparoscopic assisted pancreaticoduodenectomy|laparoscopic assisted pancreaticoduodenectomy.
214349298|NCT05463328|PROCEDURE|Open pancreaticduodenctomy|Open pancreaticduodenctomy
214349299|NCT02274779|DRUG|ELIGARD|"Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.~Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical."
214349300|NCT02141126|OTHER|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
214349301|NCT02141126|OTHER|Usual care|Standard inpatient 'usual care' physiotherapy
214956546|NCT07022197|DRUG|BAFF-R CART|"Biological: BAFF-R CART cells Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture BAFF-R CART cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with BAFF-R CART cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CART cells/kg will be infused on day 0.~Drug: Cyclophosphamide and fludarabine Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to BAFF-R CART cells infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 250 mg/m2/day on day -5, -4 and -3, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide."
214956547|NCT07022288|OTHER|LA ROCHE-POSAY CICAPLAST BALM, Standard cream|"After enrollment, the investigator will generate random serial numbers for grouping through simple randomization.~LA ROCHE-POSAY CICAPLAST BALM：8 weeks application It is a leave-on product. It should be applied to the face twice a day during the research period.~Standard cream:8 weeks application It is a leave-on product. It should be applied to the face twice a day during the research period."
214956548|NCT07022158|OTHER|The patients participating in the study were between 6 and 16 weeks of pregnancy. Height, body weight, and waist circumference were measured at the first antenatal visit at 2 weeks.|170 patients at 6-16th weeks of gestation were prospectively analyzed. Body mass index (BMI) and ABSI were calculated. Patients were analyzed according to the presence of GDM, GHT and preeclampsia at follow-up.
214956549|NCT02034760|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
214956550|NCT02034760|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
214349302|NCT01691066|BEHAVIORAL|Infant Toddler Years PRT|
214349303|NCT01464203|OTHER|CT coronary angiography|"CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~* coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~* contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries."
214349304|NCT01464203|OTHER|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
214349305|NCT05933031|DRUG|Tegoprazan 50 mg Triple Therapy|Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
214349306|NCT05933031|DRUG|Tegoprazan 100 mg Triple Therapy|Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
214349307|NCT05933031|DRUG|Lansoprazole Triple Therapy|Lansoprazole/Clarithromycin/ Amoxicillin BID peroral, 14 days
214486706|NCT06965088|BIOLOGICAL|Combined Intra-operative platelet-rich plasma with corticosteroid injection|Combined Intra-operative platelet-rich plasma with corticosteroid injection was administered around the surgical wound. Each patient had 10 ml of blood collected into a RegenKit A-PRP tube. The blood-filled tube was then placed into a RegenLab PRP centrifuge and spun for approximately 5 minutes to obtain platelet-rich plasma (PRP), yielding around 5 ml of injectable PRP. Once prepared, the PRP was stored in the collection tube and used within 4 hours from the time of blood draw to the time of injection. After the keloid excision and wound closure were completed, the PRP was aseptically aspirated from the tube using a sterile needle and injected into the intradermal layer along the wound edges using a 30G needle. The injection was performed in a sterile manner, with a dosage of 0.5 ml of PRP per 1 centimeter of wound length. For corticosteroid administration, triamcinolone acetonide (40 mg/ml) was used. The medication was injected into the intradermal layer using a 30G needle along the
214486707|NCT06965088|DRUG|Intra-operative corticosteroid injection|Intra-operative corticosteroid injection alone was administered around the surgical wound using triamcinolone acetonide (40 mg/ml). The injection was performed into the intradermal layer using a 30G needle, immediately after keloid excision and wound closure. The medication was injected along the wound edges following the suture line, at a dosage of 0.1 ml per 1 centimeter of wound length.
214486708|NCT04527094|DIAGNOSTIC_TEST|Prediction of postoperative respiratory failure using a machine learning|The performance of a machine learning model to predict postoperative respiratory failure after general anesthesia within postoperative day 7 was tested prospectively.
214486709|NCT04661423|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.
214486710|NCT06966349|DRUG|Systane Complete Preservative-Free|"One drop of Systane Complete Preservative Free will be instilled in each eye.~Higher order aberrations assessed before and after instillation."
214956551|NCT02034760|DIETARY_SUPPLEMENT|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
214486711|NCT06966349|DEVICE|Senofilcon A|"Daily disposable silicone hydrogel contact lenses indicated for myopia or hyperopia.~Higher order aberrations assessed before and after instillation."
214349308|NCT01187758|BEHAVIORAL|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
214349309|NCT02526693|DIAGNOSTIC_TEST|Pupillometer|The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.
214349310|NCT03009045|DRUG|Tedizolid|200mg oral tedizolid one pill per day
214349311|NCT03716713|DEVICE|CeraShield Endotracheal Tube|Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
214349312|NCT01585103|DEVICE|Cytosponge|An ingestible gelatin capsule containing a compressed mesh attached to a string. The capsule is swallowed and once in the stomach, the gelatin dissolves and a spherical mesh of 3 cm diameter is released. The mesh is withdrawn through the mouth by the attached string and a cytologic specimen is collected.
214349313|NCT02434692|DEVICE|ARGOS-IO system|Implantation of ARGOS-IO pressure sensor after IOL placement within the cataract surgical procedure on day 0 (V01)
214349314|NCT06535451|OTHER|Screening|Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).
214349315|NCT05275894|BEHAVIORAL|Implant hygiene instructions and removal of the prosthesis|Verbal instructions on implant hygiene practices and removal of the implant supported prosthesis
214349316|NCT05275894|PROCEDURE|Non-surgical peri-implantitis treatment /microsurgery|Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA) after applying local anestesia
214349317|NCT05275894|PROCEDURE|Implant surface decontamination 1(ultrasonic device)|Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).
214349318|NCT05275894|PROCEDURE|Implant surface decontamination 2 (air polishing)|Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).
214349319|NCT05275894|PROCEDURE|Implant surface decontamination 3 (electrolytic cleaning)|Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.
214349320|NCT05275894|DRUG|Antibiotic treatment (Metronidazole)|Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).
214349321|NCT05275894|PROCEDURE|Modification and polishing of the prosthesis|If necessary, modification and polishing of the prosthesis to make it cleanable.
214956552|NCT02034760|DIETARY_SUPPLEMENT|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
214956553|NCT02034760|DIETARY_SUPPLEMENT|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
214956554|NCT05700331|PROCEDURE|Fecal Microbiota Transplantation|"FMT performed at week 0, week-2 and week-4: FMT solution will be prepared using stool from a single donor or mixing of stool from multiple donors. Feces will be diluted with sterile saline (0.9%). This solution will be blended and strained with filter. The resulting supernatant will then be used directly as fresh FMT solution or stored as frozen FMT solution for future FMT.~Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.~2 study biopsies in total (from duodenum) will be obtained during FMT infusion via OGD."
214956555|NCT05700331|PROCEDURE|Sigmoidoscopy|Optional sigmoidoscopy will be done at week 0 and week 4, during which 2 study biopsies in total (obtained via sigmoidoscopy) will be obtained from the rectum.
214349322|NCT00716872|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|"SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep."
214349323|NCT00716872|BEHAVIORAL|Hypnosis recordings|Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
214349324|NCT03581305|DRUG|18F-FDOPA|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the dopaminergic (18F-FDOPA) system.
214349325|NCT03581305|DRUG|11C-DASB|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the serotonergic (11C-DASB) system.
214349326|NCT00778648|DIETARY_SUPPLEMENT|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily."
214349327|NCT00778648|DIETARY_SUPPLEMENT|Placebo|Four capsules of placebo daily.
214349328|NCT02201069|BEHAVIORAL|health coaching|
214349329|NCT01798927|DEVICE|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
214349330|NCT03302338|DRUG|SAFE group|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
214349331|NCT03302338|DRUG|placebo group|distilled water 20 ml/kg/day for maximum of 7 days.
214349332|NCT05415813|OTHER|Ischemic Compression|It includes conventional Physical therapy, hot packs (75°C) for 20 minutes, and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold, and 10-second relaxation between two repetitions) as a baseline treatment. For the Ischemic compression, the patient will be in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position physiotherapist will apply gradually increasing pressure to the Trigger points until the subject perceived the first noticeable pain. At that moment, the pressure will be maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure will be increased until the discomfort appears again. This process will be maintained for 90 seconds.
214349333|NCT05415813|OTHER|Ischemic compression with Muscle Energy Technique|The Participants will receive all the treatments given to the active comparator group and they will also receive the Muscle Energy Technique treatment in supine position and the practitioner will stabilize the shoulder of the affected side with one hand, while the ear/mastoid area of the affected side will be held by the opposite hand. The head and neck were then bent towards the contralateral side, flexed, and ipsilaterally rotated. The subjects will then shrug the stabilized shoulder towards the ear at a sub-maximal pain-free effort (20% of the available strength). The isometric contraction will be held for 7-10s. This position will be maintained for 30 seconds and repeated three to five times per treatment session. Treatment sessions will be given on alternate days.
214956556|NCT00856843|DRUG|BLI800|Solution for oral administration prior to colonoscopy
214956557|NCT00856843|DRUG|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
214956558|NCT00049075|DRUG|fludarabine phosphate|
214956559|NCT01540136|DRUG|Nedaplatin|Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
214956560|NCT01540136|DRUG|Cisplatin|Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
214956561|NCT04338191|DRUG|mFOLFOXIRI adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
214956562|NCT04338191|DRUG|mFOLFOX6 adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
214956563|NCT03587831|PROCEDURE|Vertical Sleeve Gastrectomy|Surgical Procedure: Vertical Sleeve Gastrectomy
214956564|NCT03587831|BEHAVIORAL|Lifestyle Modification Counseling|Behavioral Intervention: Lifestyle Modification Counseling
214956565|NCT06258187|DEVICE|Pedi-Cap|The neonatal resuscitation team will include or omit the use of Pedi-Cap during non-invasive positive pressure ventilation (PPV) for infants ≥30 weeks in the delivery room based on the randomized study arm each month.
214956566|NCT05304494|OTHER|Biomarker tests for participant profiling|Combination of digital and physical tests to objectify measures relevant for breathlessness
214956567|NCT02841956|OTHER|Electronic Screen + Education (Phase 1)|PHASE 1 Electronic Screening Arm + Targeted Education: Referral sources will receive the same standard targeted education as active comparator. In addition, the PQ-B (a 21 item screening questionnaire) will be administered to all patients at their first visit to the referral sites (e.g. intake) via an android tablet provided to the site for ease of administration and scoring. The investigators will provide multiple tablets per site so that the screening is available for more than one individual simultaneously and can be completed in any appropriate location. The investigators will allow paper-and-pencil administration for situations where it is more appropriate (e.g. emergency room).
214956568|NCT02841956|OTHER|Targeted Provider Education (Phase 1)|PHASE 1 Targeted Education Intervention: EDAPT standard targeted provider education1 focuses on increasing awareness about the signs of early psychosis \& building collaborative relationships with community members so community members see EDAPT as a rapid, effective source of help. It consists of a 2-hour workshop describing: 1) how to identify specific early symptoms \& changes associated with the onset of psychotic illness, 2) the benefits of early intervention on treatment outcomes in psychosis, 3) the structure, philosophy \& treatment model of the EDAPT Clinic, and 4) procedures for expeditious referral to our program. Case-based vignettes are reviewed to ensure understanding of the key symptoms.
214956569|NCT02841956|OTHER|Community Mobile Engagement (Phase 2)|PHASE 2 Community-based Mobile Engagement: Clinical assessment appointments will take place at the EDAPT clinic or within the community, wherever the individual would prefer. With patients deemed eligible for EDAPT services, the EDAPT clinician will obtain vitals and contact the EDAPT psychiatrist with a telemedicine-enabled laptop to complete the psychiatric evaluation remotely. The psychiatrist will prescribe medications and order labs, as indicated. The EDAPT clinician will follow up with the individual within 5 days to determine if the prescribed medication regimen has started.
214349334|NCT03750552|DRUG|ampreloxetine|Oral tablet, QD
214956570|NCT02841956|OTHER|Clinic based Engagement (Phase 2)|PHASE 2 Clinic-based Engagement: The clinical assessment appointment will be completed within the EDAPT clinic. If deemed eligible for EDAPT services, the individual will be scheduled for a clinic-based appointment with the EDAPT psychiatrist within 5 days, who will prescribe medications and order labs as indicated. The EDAPT clinician will follow up with the individual within 5 days of the psychiatric evaluation (by phone or in the clinic) to determine if the prescribed medication regimen has started.
214349335|NCT03750552|DRUG|Placebo|Oral tablet, QD
214349336|NCT00656591|DRUG|Methotrexate|Methotrexate
214349337|NCT06252129|OTHER|Subjects undergoing a lung specimen lymph node dissection|"A lobectomy specimen's resection will undergo systematic lymph node dissection either by the patient's treating thoracic surgeon and/or by a member of the pathology team.~The protocol for a standardized lymph node dissection consists of a series of blunt peribronchial dissections starting from the hilum to the periphery, with particular attention to points of airway bifurcation where intrapulmonary lymph nodes aggregate. By emphasizing the intrapulmonary lymph node map and a standardized dissection, the team will remove more lymph nodes from the lobectomy specimen, resulting in an accurate N staging."
214956571|NCT01934127|BIOLOGICAL|Investigational H7N1 vaccine GSK2789869A|One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
214956572|NCT01934127|BIOLOGICAL|Investigational H7N1 vaccine GSK2789868A|One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
214349338|NCT06252129|OTHER|Control group|Control group
214349339|NCT02776358|OTHER|High Fidelity Simulation|"A HFS session for an asthma attack require:~* a 5 minutes briefing session: case and equipments presentation and choice of participants~* 15 minutes of actual simulation~* 40 minutes of debriefing~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
214349340|NCT02776358|OTHER|Video case|"a video case (or video box) session in which students will attend a video-projection of a real case of an asthma attack and discuss with the trainer the different steps of the assessement and management of an asthma attack.~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
214349341|NCT03853629|OTHER|None. Not applicable|None. Not applicable
214349342|NCT05674422|DRUG|total neoadjuvant therapy|All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
214349343|NCT01702337|OTHER|Prevalence-based model|Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
214349344|NCT05833750|OTHER|Reflexology|In the intervention group, reflexology was applied to the feet twice a week for 8 weeks.
214349345|NCT01049113|DRUG|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
214349346|NCT00626522|DRUG|Aclidinium bromide and formoterol|once daily
214349347|NCT00626522|DRUG|Aclidinium bromide and formoterol placebo|once daily
214349348|NCT02449200|OTHER|Multimodal physiotherapy|Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
214349349|NCT04499092|OTHER|Personalized Neuropsychological treatment (CORE-ABI)|Personalized neuropsychological treatment. In the CORE-ABI intervention, the stimulation of cognitive functions will be provided based on a weekly evaluation of child's cognitive profile by a qualified neuropsychologist. Each session will have a duration of 45 min. While the first 30 minutes will be devoted to the stimulation of the most impaired cognitive function(s), the remaining 15 minutes will ensure the stimulation of the other cognitive subdomains. Domains addressed by the intervention will be the following: selective attention, sustained and divided attention, inhibition and shifting, visual-perceptual abilities, visual-spatial abilities, visual-constructional abilities, short-term memory, long-term memory, working-memory, categorization/reasoning/abstraction, problem-solving/planning and socio-emotional skills.
214349350|NCT04499092|OTHER|Sequential Neuropsychological treatment (SET-ABI)|"Sequential Neuropsychological Treatment. In the SET-ABI intervention, the stimulation of cognitive functions will be provided following a sequential order, identical for each child and for each session in each setting (neuropsychological treatment, speech therapy treatment and psychoeducational treatment). Each session will have a duration of 45 min.~Specifically, the first three weeks (weeks 1-3) of treatment will target attention; in weeks 4-6, the domain of visual-spatial and visual-constructional abilities will be addressed; in weeks 7-9, memory will be the target domain; in weeks 10-12, executive functions and socio-emotional skills will be addressed."
214349351|NCT03955601|DRUG|Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''|''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
214349352|NCT01766557|OTHER|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
214349353|NCT01766557|OTHER|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
214349354|NCT06957496|OTHER|Allergenic extracts|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
214349355|NCT02730494|DEVICE|Lcr Regenerans® vaginal capsules|
214349356|NCT02730494|DEVICE|Lcr Regenerans® vaginal tablet|
214956573|NCT01934127|BIOLOGICAL|Placebo|One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
214349357|NCT02156674|DRUG|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
214956574|NCT03825068|PROCEDURE|ESP Block|20 ml of lacal anaesthetics will be placed below the erector spinae muscle under ultrasound guide
214956575|NCT03825068|DRUG|general anesthetic|patient receive general anaesthetic only
214956576|NCT05112094|DEVICE|peripheral magnetic stimulation|peripheral magnetic stimulation at ipsilateral shoulder ((50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) ) + regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
214349358|NCT04232423|DRUG|Olanzapine 10 Mg ORAL TABLET|"* Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
214349359|NCT04232423|DRUG|Olanzapine 5 Mg ORAL TABLET|"* Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
214349360|NCT04232423|DRUG|Placebo ORAL TABLET|"* Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
214349361|NCT00001533|DRUG|cyclosporine|
214349362|NCT01562756|OTHER|HVLA-SM|High velocity, low amplitude spinal manipulation
214349363|NCT01490632|DRUG|Placebo|Administered orally
214349364|NCT01490632|DRUG|Baricitinib|Administered orally
214349365|NCT05253625|OTHER|Listening to a recorded lullaby.|A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.
214349366|NCT05232045|DRUG|Automated urinary output collection system group (tight monitoring of urine output)|Automated urinary output collection system group (tight monitoring of urine output)
214349367|NCT06518421|BEHAVIORAL|Neuropsychological assessments|"* Pain questionnaires such as Numerical Pain Rating Scale is one of the most widely used multidimensional pain scales to assesses a person's pain based on the words they use to describe their pain.~* Battery of Cognitive questionnaires = The cognitive test battery was designed to assess key cognitive abilities including attention, concentration, verbal learning and memory, verbal fluency, working memory and executive function as well as global cognitive functioning and fear and anxiety~* Mnemonic Simulation Test and Rey Auditory Verbal Learning Test are the neuropsychological assessments designed to evaluate recognition and verbal memory, respectively. Both tasks have been shown to be very sensitive to hippocampal engagement and damage.~* Memory-recall interview is an interview for the interviewees to recall the event from different perspectives, such as from the preadmission date, 2-week post- and 6-month post-surgical date. This supports the memory retrieval process."
214349368|NCT06518421|DIAGNOSTIC_TEST|MR Imaging|Magnetic Resonance Imaging is a noninvasive medical imaging test that produces detailed images of almost every internal structure in the human body, including the organs, bones, muscles and blood vessels. MRI scanners create images of the body using a large magnet and radio waves.
214349369|NCT05736341|DRUG|Remimazolam besylate|After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.
214349370|NCT05736341|DRUG|Midazolam|After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
214349371|NCT05356052|COMBINATION_PRODUCT|INOpulse|Patients will be treated by means of an INOpulse device using an INOpulse nasal cannula
214349372|NCT02805569|DEVICE|articulating stylet|patient who intubated with articulating stylet
214956577|NCT05112094|OTHER|physical therapy|regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
214956578|NCT02787733|DIETARY_SUPPLEMENT|Citrus flavonoid|Daily dose of 500mg divided over two capsules
214956579|NCT02787733|DIETARY_SUPPLEMENT|Placebo|Daily dose of 500mg divided over two capsules
214956580|NCT00429611|PROCEDURE|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
214956581|NCT03078127|OTHER|Baseline (Huff-Cough alone)|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
214956582|NCT03078127|DEVICE|Oscillatory Positive Expiatory Pressure Device|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
214956583|NCT03078127|DEVICE|Whole-Body Vibration Platform|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
214956584|NCT03078127|DEVICE|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
214956585|NCT05622227|DIAGNOSTIC_TEST|Drug: 68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of breast cancer by PET/CT.
214349373|NCT02805569|DEVICE|conventional stylet|patient who intubated with conventional stylet
214349374|NCT03822533|OTHER|Physiotherapist as primary assessor|Physiotherapist diagnose and treat the patient.
214349375|NCT03822533|OTHER|Physician as primary assessor|Physician diagnose and treat the patient.
214956586|NCT05903040|DRUG|Lasmiditan|Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks
214956587|NCT03203174|DEVICE|Microneedle|Microneedles are small needles used to create holes in the stratum corneum (top layer of skin) with relatively low amount of pain.
214956588|NCT03203174|DEVICE|Sham Microneedle|Flat roller with no needles on the roller
214956589|NCT03203174|DRUG|Botulinum Toxin Type A|Botulinum toxin type A will be applied to the palm
214956590|NCT03203174|OTHER|Saline|Saline applied to the palm
214956591|NCT05729581|BEHAVIORAL|The educational programme on sustainable and healthy diet and breastfeeding|In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)
214349376|NCT00780208|DRUG|Daytrana (methylphenidate patch)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
214349377|NCT04266782|OTHER|Exercise program followed by long walk in group|The subjects will be included in a training exercise program for three months followed by a long-walk in group
214349378|NCT04266782|OTHER|Exercise program followed by long walk in group (controls)|The controls matched for age will perform the same exercise program and long walk as the PD subjects
214349379|NCT04166994|BEHAVIORAL|Exercise and diet|IMPACT Intervention
214349380|NCT04166994|OTHER|No Intervention: Usual Care|No exercise or diet specialization.
214349381|NCT06788496|BEHAVIORAL|Art-based Beauty Appreciation Intervention Program (Learning to See Beauty)|The goals of the intervention program are to help individuals develop an aesthetic mindset, practice observation and appreciation skills, learn how to apply these skills to their day-to-day lives, practice emotion regulation with beauty, and incorporate more beauty into their lives. The program is designed to create a slow skill transfer from appreciation in art contexts to natural beauty and to everyday life. In the 14-day program, participants visit an art museum with guided audio, watch instructional videos about observing and appreciating beauty, and complete daily written or photo beauty journals that document the beauty they see. In addition, participants will watch video art showing how to find beauty in mundane objects, practice this in a beauty walk, and complete a planning session to include more beauty in their lives.
214486712|NCT06966349|DEVICE|Somofilcon A|"Daily disposable silicone hydrogel contact lenses indicated for myopia or hyperopia.~Higher order aberrations assessed before and after instillation."
214486713|NCT04323488|BEHAVIORAL|Lindamood-Bell Seeing Stars|Seeing Stars in a curriculum developed by Lindamood-Bell. It is published and openly available. It involves systematic training in the building blocks of skilled reading.
214956592|NCT03216603|BEHAVIORAL|Health literacy intervention group|In the health literacy intervention group all patients will receive self-management help using a motivating interviewing (MI) technique delivered by two MI and COPD trained nurses once a week for eight weeks after hospitalization. Subsequently, the contact between the patients and the nurses will be by follow up motivational telephone calls once a month or more if needed for four months (i.a a total of six months intervention period).
214956593|NCT05933564|OTHER|No intervention (cross-sectional study)|This is a cross-sectional study examining the association between cognitive reserve, pain catastrophizing, and cognitive function in geriatric patients with chronic pain; no intervention is being implemented or tested.
214956594|NCT03268018|DEVICE|Laser induced pressure wave calcium modification|A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
214956595|NCT01366638|DRUG|TMC435|100 mg capsule taken by mouth once daily for 12 weeks
214956596|NCT01366638|DRUG|Peginterferon alfa-2b (pegIFN alfa-2b)|PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
214956597|NCT01366638|DRUG|Ribavirin (RBV)|The dose of RBV given will be based on body weight. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
215078366|NCT03537365|DIETARY_SUPPLEMENT|Bovine Colostrum (BC) / intervention group|"Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first."
214956598|NCT04772521|BEHAVIORAL|General health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
214486714|NCT04665921|DRUG|SGN-STNV|Given into the vein (IV; intravenously)
215078367|NCT03537365|DIETARY_SUPPLEMENT|FM85 / control group|"Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed."
215078368|NCT02480166|DRUG|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
215078369|NCT02480166|DRUG|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
215078370|NCT00530829|DRUG|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
214349382|NCT06788496|BEHAVIORAL|Observation Program (Learning to Observe Life)|The active, matched control group will focus on developing pragmatic observation skills. Participants will be instructed to pay attention to and identify objects and elements in their surroundings without emphasizing their aesthetic value. For example, they should pay attention and count objects of the same colour they encounter, social behaviour, the people they pass on the street, or the types of buildings. The 14-day program includes a tourist trip with guided audio instruction, watching instructional videos about increasing observation skills and completing daily written or photo journals to document their observations. Further, participants will take an observation walk and plan to include more observation in their lives.
214349383|NCT02475408|DEVICE|Amplatzer vascular plug|
214349384|NCT02349295|DRUG|Placebo|Administered SC
214956599|NCT04772521|BEHAVIORAL|Personalized chat-based interactions|Individual chat-based interactions last 3 months and consist of 2 parts. First part is regular message. The schedule will be adjusted according to the participants' quitting and mental health status. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using the acceptance and commitment therapy (ACT) model for smoking cessation and reliving mental health problems. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
214956600|NCT04772521|BEHAVIORAL|Text message|Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
214956601|NCT04772521|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
214956602|NCT04772521|DRUG|Mailed nicotine replacement therapy (NRT)|Full course of NRT treatment (8 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
214956603|NCT06909591|OTHER|Self-assessment questionnaire|150 patients aged of 65 or older will pass the Lubben Social Network Scale questionnaire. The Duke Health Profile questionnaire will be also passed by the subject, for the convergent validity.
214956604|NCT04517773|OTHER|writting test|Patients will be invitated to fill a questionary about self-autonomy
214956605|NCT03350204|PROCEDURE|Meniscectomy|This will be to see what occurs in both kinetics and kinematics after you have a surgery and how this links on to osteoarthritis
214956606|NCT03350204|OTHER|Helathy control comparison|This group will be used to get a baseline for normal and natural walking, running and other several tasks which will be used as a comparison for the meniscus injury group.
214956607|NCT05837702|PROCEDURE|ESPB|Erector spinae plane block
214956608|NCT05837702|PROCEDURE|PVB|Paravertebral Block
214956609|NCT05837702|PROCEDURE|CONTROL|No block has been done
214956610|NCT01065064|PROCEDURE|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
214956611|NCT00211627|DEVICE|KEEPASLEEP enhanced breathing device|
214956612|NCT01612078|DRUG|Droxidopa|200mg/tab 2tablets, po, three times a week
214956613|NCT01612078|DRUG|Placebo|200mg/tab, po, three times a week.
214956614|NCT04939454|PROCEDURE|quadricipital biopsy|The primary endpoint will be evaluated by histological examination only. The technique of percutaneous biopsy using the modified Bergström needle technique is currently considered the best alternative in the context of research, as it allows sufficient material to be obtained for various analyses and is much less invasive than the reference technique (surgical biopsy). Indeed, unlike surgical biopsy which requires an operating room and is a relatively heavy procedure (two suture planes, skin incision of several centimeters, resting for 48 hours after the procedure...), percutaneous biopsy by the modified Bergström technique can be performed in a consultation room, requires only one stitch, and allows resumption of walking 30 minutes after the end of the procedure.
214349385|NCT02349295|DRUG|Ixekizumab 80 mg Q4W|Administered SC
214349386|NCT02349295|DRUG|Ixekizumab 80 mg Q2W|Administered SC
214349387|NCT04273230|OTHER|Microalbuminuria detection|Detection of microalbumin in urine
214486715|NCT06436625|OTHER|outpatient pulmonary rehabilitation|Patients undergo six weeks of an outpatient rehabilitation program in one of the rehabilitation centers (Therme Wien Med, Klinik Pirawarth in Wien).
214956615|NCT06133478|DRUG|NUV001 active cohort 1|6 participants will be assigned to receive active treatment
214956616|NCT06133478|DRUG|NUV001 active cohort 2|6 participants will be assigned to receive active treatment
214956617|NCT06133478|DRUG|NUV001 active cohort 3|6 participants will be assigned to receive active treatment
214956618|NCT06133478|DRUG|NUV001 active cohort 4|6 participants will be assigned to receive active treatment
214956619|NCT06133478|DRUG|NUV001 placebo cohort 1|2 participants will be assigned to receive placebo
214956620|NCT06133478|DRUG|NUV001 placebo cohort 2|2 participants will be assigned to receive placebo
214956621|NCT06133478|DRUG|NUV001 placebo cohort 3|2 participants will be assigned to receive placebo
214956622|NCT06133478|DRUG|NUV001 placebo cohort 4|2 participants will be assigned to receive placebo
214956623|NCT03277716|PROCEDURE|TACE|TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.
214349388|NCT01449305|DEVICE|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
214349389|NCT02939417|OTHER|Grape seed extract|Grape seed extract - collagen cross-linking agent
214349390|NCT06361147|OTHER|Psychoeducational program for ASD|6 psychoeducation trainings for Autism Spectrum Disorder
214349391|NCT01242488|BIOLOGICAL|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
214349392|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
214956624|NCT03277716|PROCEDURE|MWA|MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.
214956625|NCT03277716|DEVICE|MWA system|MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.
214956626|NCT03277716|DRUG|Chemoembolization|Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
215078371|NCT05166278|BEHAVIORAL|De-escalation training|The intervention will include training on verbal and nonverbal de-escalation techniques. The training will be prepared according to the recommendations of the Beta Project of the American Association for Emergency Psychiatry, the World Health Organization Quality Rights training to act, unite and empower for mental health and a handbook for the use of de-escalation skills in a hospital setting by Amdur E. The first part of the education is based on theoretical backgrounds: aggressive behavior in a psychiatric patient, risk factors, focusing on factors that can be modified, communication, de-escalation. The second part is a practical workshop. The training will be 16 hour duration in total. A short handbook and a list of verbal and non-verbal approaches will be prepared for all staff members involved in the training.
214956627|NCT03024827|DRUG|CanniMed® 1:20|A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.
214956628|NCT00269828|DRUG|paclitaxel|
214956629|NCT00269828|DRUG|paclitaxel poliglumex|
214956630|NCT00783328|DRUG|PF-00299804|Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
214956631|NCT00456820|DRUG|Wellbutrin XL|
214956632|NCT02273765|DRUG|Tenofovir + lamivudine + raltegravir|"In this arm, patients will receive the following medications :~* Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food"
214956633|NCT02273765|DRUG|Tenofovir + lamivudine + efavirenz|"In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~* Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight."
214956634|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
214956635|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections
214956636|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + AMA1-C1/Alhydrogel®|5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections
214956637|NCT01351948|BIOLOGICAL|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
214956638|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + MVA AMA1|5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 112. IM injections
214349393|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
214349394|NCT01242488|BIOLOGICAL|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
214349395|NCT01242488|BIOLOGICAL|CDP6038|60 mg sc at Weeks 0, 4 and 8
214349396|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 4 and 8
214349397|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 4 and 8
214349398|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
214349399|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
214349400|NCT01242488|OTHER|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
214349401|NCT06390098|DRUG|ASN51|Oral
214349402|NCT04183933|OTHER|Pilates Exercise|Pilates exercises will be given for 6 weeks, 3 days in a week.
215078372|NCT00998751|DRUG|oral masitinib|7.5 mg/kg/day
215078373|NCT00422149|DRUG|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
215078374|NCT00422149|DRUG|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
215078375|NCT00422149|DRUG|Placebo treatment|Placebo treatment
214349403|NCT04183933|OTHER|Combined Exercise|Combined exercise will be given for 6 weeks, 3 days in a week.
214349404|NCT05418621|DRUG|Enamel Matrix Derivative application|in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
214349405|NCT05418621|OTHER|Saline application|in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
214349406|NCT01889537|BEHAVIORAL|Virtual Reality|The patient will receive virtual reality during a burn care procedure
214349407|NCT02414893|PROCEDURE|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
214349408|NCT00786357|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
214349409|NCT00786357|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
214349410|NCT02148250|DRUG|U-500 insulin, 100 syringe units|Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
214349411|NCT02148250|DRUG|U-500 insulin, 200 syringe units|Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
214349412|NCT01529957|DRUG|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
214349413|NCT00958919|DRUG|naloxone|10 mg naloxone in 25 ml total volume
214956639|NCT00076258|BEHAVIORAL|SSRI + LD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
214956640|NCT00076258|BEHAVIORAL|SSRI + PHD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
214956641|NCT00391742|BEHAVIORAL|Brief intervention|
214956642|NCT04217642|PROCEDURE|Osteosynthesis|The specific surgical technique -osteosynthesis, hemiarthroplasty, or total hip arthroplasty- will depend on the characteristics of the proximal femur fracture in each patient.
214956643|NCT05837793|BEHAVIORAL|Modified frailty index|The mFI includes the following 11 items from the National Surgical Quality Improvement Program (NSQIP): diabetes; functional status (not independent); chronic obstructive pulmonary disease (COPD) or pneumonia; congestive heart failure; history of myocardial infarction; hypertension requiring medication; peripheral vascular disease or rest pain; impaired sensorium; history of either transient ischemic attack or cerebrovascular accident; history of cerebrovascular accident with neurologic deficit; and prior percutaneous coronary intervention, previous coronary surgery, or history of angina.
214956644|NCT01638403|DRUG|BF2.649|"BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
215078376|NCT04420572|DRUG|ozone injection|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
215078377|NCT04420572|DRUG|betamethasone|1ml betamethasone will be used for steroid injection.
215078378|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
215078379|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
214349414|NCT00958919|DRUG|normal saline|25 ml
214349415|NCT02811237|OTHER|HESTIA|"Management based on the HESTIA rule:~* If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
214349416|NCT02811237|OTHER|sPESI|"Management based on the simplified PESI score:~* If the sPESI score =0, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
214349417|NCT03722160|DEVICE|Solo TympanostomyTube Device|The Solo Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
214486716|NCT04614103|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.
214956645|NCT01638403|DRUG|Vigil|"Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
214956646|NCT01638403|DRUG|palcebo|"placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
214956647|NCT04166292|DEVICE|Stylage® XL Lidocaïne|"On V1 (D0), a total volume of 8 mL maximum can be used per subject on the whole face.~On V2 (M1), a possible touch-up can be made according to the injector and subject's opinion which cannot exceed 4 ml."
214956648|NCT02205697|BEHAVIORAL|Implementation intention|The intervention consists of an implementation intention whereby subjects create a unique plan to increase their fruit and vegetable intake by planning the where, when, and what to increase their fruit and vegetable intake.
214956649|NCT04202315|OTHER|Virtual Reality|Utilizing Virtual Reality during external fixator removal in outpatient clinic setting.
214956650|NCT04736641|OTHER|Survey study|Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JOAHDEQ) will be applied
214956651|NCT00591929|OTHER|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
214956652|NCT00401193|DRUG|Tranexamic acid tablets|3900 mg/Day
214956653|NCT00401193|DRUG|Tranexamic acid tablets|1950 mg/Day
214956654|NCT00401193|DRUG|Placebo tablets|
214956655|NCT04130074|DEVICE|duplex doppler ultra sound and CT|graded compression US done in different positions then take MSCT with contrast on abdomen to compare with
215078380|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
215078381|NCT00096148|DRUG|idarubicin|Given IV
215078382|NCT00096148|DRUG|cytarabine|Given IV
215078383|NCT00096148|BIOLOGICAL|bevacizumab|Given IV
215078384|NCT00096148|OTHER|laboratory biomarker analysis|Correlative studies
215078385|NCT01115894|DRUG|Naltrexone|100 mg oral dosage daily for 12 weeks
214349418|NCT00591292|DRUG|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
214349419|NCT03142074|OTHER|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
214349420|NCT03142074|RADIATION|ECG-gated CT|Image analysis of ECG-gated CT.
214349421|NCT01552213|OTHER|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
214486717|NCT04614103|BIOLOGICAL|LN-145|A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.
214486718|NCT06214793|DRUG|Taletrectinib|Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor, which has activity against mutations conferring resistance to crizotinib including in vitro and in vivo against the acquired ROS1 G2032R solvent front mutation. Taletrectinib has been shown to have anti-tumor activity against recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP dependent manner, in addition to completely inhibiting ACK, ALK, DDR1 and LTK at micromolar concentrations. Anti-tumor activity of taletrectinib was observed in two ROS1 rearranged lung cancer cell lines, glioblastoma cell line, and in NTRK-rearranged colorectal cancer cell lines.
214956656|NCT00398216|DRUG|DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor|
214956657|NCT00570960|DRUG|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
214956658|NCT00570960|BIOLOGICAL|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
214956659|NCT02820519|DRUG|Loxapine|Loxapine dose escalation according to tolerability and analgesic efficacy
214956660|NCT04959409|DRUG|Topical analgesia (EMLA or AMETOP)|Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
214349422|NCT01552213|OTHER|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
214956661|NCT00289588|DRUG|Mupirocin (drug)|
214349423|NCT00026533|DRUG|thalidomide|
214349424|NCT00695903|DRUG|daptomycin|daptomycin 10 mg/kg IV every 24 hours
214956662|NCT02267070|BEHAVIORAL|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
214956663|NCT02267070|BEHAVIORAL|Family psychoeducation|All immediate family members will be invited to family psychoeducation sessions.
214349425|NCT00695903|DRUG|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
214956664|NCT02267070|BEHAVIORAL|Cognitive training|The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.
214956665|NCT02267070|BEHAVIORAL|Aerobic exercise|Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
214956666|NCT03169478|PROCEDURE|multiple myoma IUB dilatation group|A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
214956667|NCT06288243|DIAGNOSTIC_TEST|Clinician-observed assessment tests|Turkish Modified Mann Swallowing Ability Test, which evaluates swallowing skills Standardized Mini-Mental Test assessing Cognitive Status Modified Rankin Scale to evaluate functionality
214956668|NCT01699724|DRUG|JZoloft|50 mg tablet on Day 1 of each period
214956669|NCT01699724|DRUG|sertraline ODT|50 mg tablet on Day 1 of each period
214956670|NCT01699724|DRUG|sertraline ODT|50 mg tablet on Day 1 of each period
214956671|NCT04282629|DRUG|Milrinone Injection|administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14
214956672|NCT04282629|OTHER|Placebo|administration of placebo (intravenous glucose 5%) from Day 4 to Day 14
214956673|NCT00415896|DEVICE|positive pressure ventilation|
214956674|NCT01048944|DRUG|Bupropion SR|150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
214956675|NCT01048944|DRUG|Nicotine Patch|Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
214956676|NCT01048944|DRUG|Placebo Patch and Placebo Pill|150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
214956677|NCT00528359|DRUG|quetiapine or olanzapine or risperidone or aripiprazole|
214956678|NCT00615810|DRUG|Atripla|Open label once daily for oral administration to be taken on an empty stomach
214956679|NCT00615810|DRUG|Kivexa plus Sustiva|Open label once daily for oral administration
215078386|NCT01115894|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
215078387|NCT01115894|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
215078388|NCT01115894|DRUG|Placebo|Placebo
215078389|NCT03091998|DRUG|CD-NP|Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
215078390|NCT03091998|OTHER|Placebo|Participants will receive an \~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
215078391|NCT00634712|DRUG|Candesartan|
215078392|NCT00634712|DRUG|Placebo|
215078393|NCT02885454|DRUG|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
215078394|NCT02885454|DRUG|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
215078395|NCT02885454|DRUG|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
215078396|NCT02885454|DRUG|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
215078397|NCT05192629|DRUG|Dexmedetomidine|Premedication by intranasal dexmedetomidine
215078398|NCT05192629|DRUG|Midazolam|Premedication by intranasal midazolam
215078399|NCT00503412|DRUG|AZD2171|oral 14C
214349426|NCT05877001|DRUG|Tislelizumab|200mg, IV, Q3W
214349427|NCT05877001|DRUG|Regorafenib|80 mg once daily for the first 3 weeks of each 4-week cycle
214349428|NCT05877001|OTHER|HAIC|OXA 85mg/m2 IA 0-4h +5-Fu 2000mg/m2 IA 4-48h，CF 200mg/m2 IV 2-4h， Q3W
214486719|NCT06273579|BEHAVIORAL|Expert instruction using AI tutor script|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. They will also be provided with a list of commands that the ICEMS uses. When the system detects an error in a student's performance for a given metric, the instructor must deliver this command using the exact wording provided by the ICEMS.
214486720|NCT06273579|BEHAVIORAL|AI-augmented personalized expert instruction|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. When the system detects an error in a student's performance for a given metric, the instructor will have the freedom to personalize and contextualize feedback without restriction to ICEMS wording.
214486721|NCT06297967|DRUG|Acetic Acid|The intervention treatment will consist of cleaning with water and soap, application of a compress soaked in 2% dilution of glacial acetic acid (CAS 64-19-7) for 15 minutes, irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the ulcer bed. Depending on the amount of exudate, more or less alginate will be added as a secondary dressing. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
214956680|NCT06410417|BEHAVIORAL|Shorten abstinence time|In the experimental group, male ejaculates once on human chorionic gonadotropin trigger day, and can be ejaculated on the second day if ejaculates fail.
214956681|NCT01844817|DRUG|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
214956682|NCT01844817|DRUG|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
214956683|NCT04227405|BEHAVIORAL|Connection to community services through case management|Case managers met with couple and conduct a needs assessment for the couple and their family. Then they developed an Individual and Couple Development Plan to take care of those needs, usually by accessing community services. Case managers met every 5 weeks with the couple to check on progress toward meeting the goals of the plan and assess for the present of any new needs.
215078400|NCT00790647|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
215078401|NCT00790647|DRUG|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
215078402|NCT00790647|DRUG|melphalan|100 mg/m2/dose D -2, D -1
215078403|NCT00790647|PROCEDURE|Stem Cell Infusion|infusion of previously collected autologous stem cells
214349429|NCT04723576|BEHAVIORAL|Stress First Aid|"Stress First Aid (SFA) is an evidence-based intervention to mitigate the psychosocial impact of COVID-19 on Health Care Workers (HCWs). SFA was initially developed for the United States Navy and Marine Corps as a framework of actions for peer support delivered by individuals without mental health training. SFA is designed to teach simple, supportive actions that can be seamlessly integrated into work environments. SFA training focuses on five essential principles: cover (restore and support a sense of safety), calm (encourage simple strategies such as breathing), connect (engage in and promote social support), competence (improve ability to address crucial needs and concerns), and confidence (increase hope and limit self-doubt and guilt). In this study, we are adapting the SFA model to include HCW-specific examples of SFA actions and case scenarios specific to the COVID-19 pandemic and will implement SFA using a train-the trainer model."
214349430|NCT00244075|DIETARY_SUPPLEMENT|nutritional supplement|either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr
214349431|NCT00244075|DRUG|recombinant human growth hormone (rcGH)|subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days
214349432|NCT00244075|BEHAVIORAL|exercise|either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
214349433|NCT03822299|DIETARY_SUPPLEMENT|healthy feces microbiota|Suspension of healthy feces microbiota in sterile saline solution
214349434|NCT00372463|BEHAVIORAL|6-week Online Diabetes Self-Management Educational Program|
214349435|NCT02097472|BIOLOGICAL|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
214349436|NCT02097472|BIOLOGICAL|Synflorix|"1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein"
214486722|NCT06297967|DRUG|Prontosan|The treatment includes ulcer cleansing with water and soap, application of ProntosanⓇ compress for 15 minutes, subsequent irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the wound bed. More or less alginate will be applied depending on the amount of exudate. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
214486723|NCT03218306|DEVICE|Surgical Pleth Index|Effector site concentration of remifentanil based on SPI
214486724|NCT03218306|OTHER|Clinical guidance|Effector site concentration of remifentanil based on hemodynamic data
215078404|NCT06595823|DRUG|Betadine|To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
215078405|NCT06605326|DRUG|Subcutaneous Treprostinil|Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
215078406|NCT06606184|PROCEDURE|Inspiratory muscle Training|Participants underwent a 12-week program consisting of inspiratory muscle training twice daily, incentive spirometry three times daily, and upper limb exercises along with marching in place for 30 minutes.
215078407|NCT06606184|PROCEDURE|Routine Care|Participants received routine care, which included encouragement to use incentive spirometry three times daily.
215078408|NCT06604819|DRUG|Ozone gel placed after closed sinus lifting then implant placed simultaneously.|The patient received closed sinus lifting using osteotomes then ozone gel is prepared. Pure olive oil was blasted with 25 μ/ml O3 gas for two days, or until the oil changed from a greenish-colored liquid to a whitish gel. The longevity Ext 120 ozone generator executed out this process then implants were placed.
215078409|NCT06604819|PROCEDURE|closed sinus lifting using osteotomes with simultaneous implant placement|The patient received closed sinus lifting using osteotomes with implant placed simultaneously.
214349437|NCT02097472|BIOLOGICAL|Pentavac|"Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection."
214349438|NCT02097472|OTHER|Saline|0.9% Sodium Chloride Injection, USP
214349439|NCT03966157|DEVICE|Nasal Bridle|Feeding tube secured with nasal bridle
214349440|NCT05464459|PROCEDURE|Novel elbow procedure|A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.
214349441|NCT00345904|BIOLOGICAL|Fluarix|
214349442|NCT02999776|DEVICE|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
214349443|NCT02999776|DRUG|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
214349444|NCT02999776|DRUG|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
214349445|NCT03392311|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
214349446|NCT03392311|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
214349447|NCT03305016|DRUG|TransCon hGH|Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
214349448|NCT05362903|OTHER|Inclisiran|Prospective observational cohort study. There is no treatment allocation. Patients administered Inclisiran by prescription will be enrolled.
214349449|NCT06402331|DRUG|FPI-2265|"Investigational treatment FPI2265 is a PSMA ligand radiolabelled with 225Ac.~Other Names:~225Ac-PSMA-I\&T"
214678655|NCT05922267|OTHER|SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION|The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
214956684|NCT04227405|BEHAVIORAL|TOGETHER Workshop|Couples were required to participate in a 20 hour workshop (8 sessions of 2 1/2 hours each)in groups of 3 to 8 couples. These groups were facilitated by a financial expert and a couples' expert. The workshop is interdisciplinary and psycho-educational. Couples learn about skills to improve their communication about stress and money problems, conflict resolution, individual and couple stress management in general and about money stress in particular, and financial management
214956685|NCT04227405|BEHAVIORAL|Employment Support Services|Only for those participants that were in need of employment support services. If the needs assessment conducted by the case manager indicated an employment or career need. After completion of the TOGETHER workshop, an employment case manager met with the participant, conducted an employment needs assessment and connected the participant with a workforce agency or one-stop employment centers. After doing so, the employment case manager followed through the various steps that the participant had to complete as part of the employment services for a period of 6 months
214956686|NCT03679143|DRUG|ZSP1273 100 mg|ZSP1273 tablet administered orally once daily under fasted condition
214956687|NCT03679143|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
214956688|NCT03679143|DRUG|ZSP1273 200 mg|ZSP1273 tablets administered orally once daily under fasted condition
214956689|NCT03679143|DRUG|Placebo 200 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
214956690|NCT03679143|DRUG|ZSP1273 400 mg|ZSP1273 tablets administered orally once daily in the fasting state
214349450|NCT05605964|DRUG|Relugolix|Relugolix tablet
214349451|NCT05605964|DRUG|Leuprolide Acetate|Leuprolide acetate injection
214349452|NCT04635605|DRUG|Methylene Blue|Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
214349453|NCT04635605|DRUG|Control Test|Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
214349454|NCT06962683|OTHER|Blood-Flow-Restriction Training|For the pBFR intervention, the Personalized Tourniquet System for Blood Flow Restriction from Delfi Medical Innovations Inc. (Vancouver, Canada) were used. The cuffs were applied to both lower extremities as far proximally as possible and were connected to the control device. Before starting the training program, the individual LOP was measured of both lower limb in a restring, laying position by the control device. The Intervention-Group performed the training at 80% of their individual LOP. The training was performed alternately on both lower extremities. The time intervals were set at five minutes occlusion and five minutes rest. Each leg received five intervals of BFR-induced occlusion training, resulting in a total 50 minutes of daily training. During the entire training period, the patient was in a resting position, laying in the hospital bed.
214349455|NCT06962683|OTHER|Sham-BFR|For the sham-BFR intervention, the Personalized Tourniquet System for Blood Flow Restriction from Delfi Medical Innovations Inc. (Vancouver, Canada) were used. The cuffs were applied to both lower extremities as far proximally as possible and were connected to the control device. Before starting the training program, the individual LOP was measured of both lower limb in a restring, laying position by the control device. The Control-Group was trained with a fixed pressure of 20 mmHg, independent of their individual LOP. The training was performed alternately on both lower extremities. The time intervals were set at five minutes occlusion and five minutes rest. Each leg received five intervals of BFR-induced occlusion training, resulting in a total 50 minutes of daily training. During the entire training period, the patient was in a resting position, laying in the hospital bed.
214349456|NCT06956495|DRUG|Tasipimidine|Tasipimidine solution
214349457|NCT06956495|DRUG|Tasipimidine placebo|Tasipimidine placebo solution
214349458|NCT06961682|DIETARY_SUPPLEMENT|MD|Red meats and sweets minimal consumption once or twice per month Eggs, cheese, poultry and yoghurt weekly consumption Fish and seafood two to three times per week Olive oil varing amount daily Vegetables and fruits daily consumption Legumes and whole grains (bread, pasta, rice and nuts )daily consumption Measure the effect of Mediterranean diet on patient with MetS to control hypertension, diabetes, obesity and dyslipidemia by measuring blood pressure mmHg regularly, Hba1c before, lipid profile LDL, HDL, TG weight (kg) and height (m) to calculate BMI wt kg/ht\^2 m and waist hip ratio by measuring waist and hip circumference before and after the MD
214349459|NCT06961799|DIAGNOSTIC_TEST|Multifactorial algorithm to predict fall risk|"In this new multifactorial algorithm we will add baseline data (personal characteristics, medical history, and physical and psychological measurements) to predict an older adults risk on falls. The accuracy of this new model will be tested with a 1-year follow up on falls.~The new algorithm is inspired by the study of Lusardi et al. (2017): Lusardi MM, Fritz S, Middleton A, Allison L, Wingood M, Phillips E, Criss M, Verma S, Osborne J, Chui KK. Determining Risk of Falls in Community Dwelling Older Adults: A Systematic Review and Meta-analysis Using Posttest Probability. J Geriatr Phys Ther. 2017 Jan/Mar;40(1):1-36. doi: 10.1519/JPT.0000000000000099. PMID: 27537070; PMCID: PMC5158094."
214349460|NCT03199729|OTHER|Slip-only training|Subjects in this arm will receive overground, slip specific perturbation training only. The total perturbation training trials received by this group will be 24 but the protocol will consist of a total of 70-75 trials (to match the training length and time of Combined slip and trip training group).
214349461|NCT03199729|OTHER|Trip-only training|Subjects in this arm consisting of a total of 24 trials of trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
214678656|NCT03452150|DRUG|D-0316|If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
214678657|NCT01419366|DRUG|Torrent's Donepezil Hydrochloride Tablets 10mg|
214956691|NCT03679143|DRUG|Placebo 400 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
214956692|NCT03679143|DRUG|ZSP1273 600 mg|ZSP1273 tablets administered orally once daily under fasted condition
214956693|NCT03679143|DRUG|Placebo 600 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
214956694|NCT03679143|DRUG|ZSP1273 900 mg|ZSP1273 tablets administered orally once daily in the fasting state
214956695|NCT03679143|DRUG|Placebo 900 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
214956696|NCT03679143|DRUG|ZSP1273 1200 mg|ZSP1273 tablets administered orally once daily in the fasting state
214956697|NCT03679143|DRUG|Placebo 1200 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
214956698|NCT03679143|DRUG|ZSP1273|ZSP1273 tablets administered orally once daily under fasted or fed condition
214956699|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
214956700|NCT03679143|DRUG|ZSP1273 Low Dose|ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
214956701|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
214956702|NCT03679143|DRUG|ZSP1273 Median Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
214956703|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
214956704|NCT03679143|DRUG|ZSP1273 High Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
214956705|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
214956706|NCT00869908|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214956707|NCT00869908|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214956708|NCT00869908|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214956709|NCT04845880|DIAGNOSTIC_TEST|Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2|Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
214349462|NCT03199729|OTHER|Combined slip+trip training|Subjects in this arm will receive training consisting of repeated exposure to both slips and trips with a total of 24 slips plus 24 trips to keep the number of trials of each perturbation same as the perturbation specific training groups (slip only and trip only), however, the total dose will be doubled. The total trials walked (perturbed + unperturbed) will be 75.
214956710|NCT00320268|DRUG|Quetiapine fumarate|
214956711|NCT03944278|DEVICE|Thulium Laser|Thulium laser for skin resurfacing procedures
214956712|NCT06462742|PROCEDURE|Microwave ablation (MWA) versus Liver Resection (LR)|"Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases.~Liver resection is a surgery to remove part of the liver to eradicate tumors."
214349463|NCT04669171|BIOLOGICAL|EO2463|Multiple dose of EO2463
214349464|NCT04669171|DRUG|lenalidomide|D1-21 of 4-weekly cycles
215078410|NCT06604988|BEHAVIORAL|Video-feedback intervention to promote positive parenting|"Each session will focus on three parental behaviours (that support child development) that have appeared clearly, frequently and consistently in the video (PICCOLO score of 2) in any of the 4 dimensions (affection, responsiveness, encouragement, teaching). Other aspects of parental behaviours that have scored 1 or 0 on the PICCOLO will also be considered, to increase their frequency or encourage their appearance. It is to be expected that all the behaviours collected in PICCOLO appear in one or more of the recordings, even if only occasionally. Behaviours that do not appear can be introduced through linking strategies with other behaviours in which parents show strength (for example, if a caregiver tends to name objects a lot, a link can be established between naming and asking the child the name of objects, if questions are behaviour that does not appear in the logs).~In each session, the caregiver is shown video clips that clearly show the positive parenting behaviours."
214349465|NCT04669171|BIOLOGICAL|rituximab|Multiple doses of rituximab
214349466|NCT06054724|OTHER|Yoga-Based Respiration Training|The selected asanas, believed to be beneficial for urinary incontinence, will be practiced with a focus on breath. After the assessment session, participants will engage in three days of face-to-face yoga sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
214349467|NCT06054724|OTHER|Pilates-Based Respiration Training|Before starting the 6-week practice protocol, participants will be taught the transversus abdominis muscle activation and centering, pilates-specific lateral costal breathing and other key elements of pilates. Pilates exercises chosen as beneficial for urinary incontinence will be performed with a focus on breath. After the assessment session, participants will engage in three days of face-to-face pilates sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
214349468|NCT04458051|DRUG|Tolebrutinib|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
214349469|NCT04458051|DRUG|Placebo|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
214349470|NCT06167681|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
214349471|NCT06033235|DIAGNOSTIC_TEST|CT scan in critically ill patients in the intensive care unit|CT scan in critically ill patients in the intensive care unit
214349472|NCT05539989|BIOLOGICAL|VPM1002 Vaccine|0.1 mL (2-8x10\^5 CFU)
214349473|NCT05539989|BIOLOGICAL|BCG Vaccine|0.1mL (0.075 Mycobacterium bovis)
214349474|NCT05539989|DRUG|Placebo|0.1 mL (sodium chloride for injection 0.9%)
215078411|NCT06605352|DIAGNOSTIC_TEST|The BIOFIRE®FILMARRAY® Pneumonia Panel|"The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes.~Using rapid diagnostic test to improve the proportion of antibiotics change, including escalation, de-escalation, discontinuation, or addition of antimicrobial medications in 24 hours within sample collection."
215078412|NCT06601868|DIETARY_SUPPLEMENT|R-Support Prepare & After nutritional supplement|R-Support is a nutritional supplement containing proteins, Vitamine A, Vitamine B6, Vitamine B11, Vitamine B12, Vitamine C, Vitamine D3, Vitamine E, IJzer, Koper, Selenium, Zink, Magnesium, Omega-3 and Beta-glucanen.
214349475|NCT03571295|DEVICE|King Vision aBlade|endotracheal intubation performed with King Vision aBlade
215078413|NCT06605976|BEHAVIORAL|DAX CoPilot Group|Participants in this group were given a license for DAX CoPilot and asked to use it for clinical documentation.
214349476|NCT03571295|DEVICE|direct laryngoscopy|endotracheal intubation performed with direct laryngoscopy
214349477|NCT03544034|BEHAVIORAL|HomeTeam Toolkit|"A multi-component intervention (8S's)~1. Safety at home through partnership.~2. Safety risk assessment at the admission~3. Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~4. Safety tools. Cognitive tools to support patient/family after discharge~5. Safety education. Enhanced Patient/ family medication safety education~6. Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~7. Safety through learning routines across the care continuum~8. Safety assessment after discharge"
214486725|NCT00704769|DRUG|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
214486726|NCT03990233|DRUG|BI 765063|mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor
214486727|NCT03990233|DRUG|BI 754091|mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
214486728|NCT06651515|BIOLOGICAL|Allogeneic Pancreatic Endocrine Cell Clusters|Allogeneic Pancreatic Endocrine Cell Clusters
214486729|NCT06599788|BEHAVIORAL|Standard work pace|Participants will work at a standard pace of one box per minute during the box carrying protocol
214956713|NCT05828316|BEHAVIORAL|Resilience-based intervention|resilience-based intervention is a curriculum that offers a careful selection of evidence-based exercises to build coping skills and promote thriving. The resilience-based intervention philosophy is that there are many routes to achieving greater resiliency. Each participants choose from a menu of exercises in the areas of goal-setting, emotional skills, social connection, health, meaning, and self-talk. The ability to choose exercises that fit their specific goals, interests, and schedules is important, because the most effective strategies are the ones that people actually do, which tend to be the ones that are most enjoyable and personally relevant. No single practice is going to work for everyone regardless of its proven benefits. resilience-based intervention makes improving well-being accessible, manageable and fun, by introducing a variety of bite-sized, exercises that participants can experiment with and find what works for them.
214956714|NCT00634296|OTHER|Inspiratory muscle added by aerobic to aerobic alone|Inspiratory muscle added by aerobic to aerobic alone
214349478|NCT02127801|DRUG|REGN1908-1909|
214349479|NCT02127801|DRUG|placebo|
214349480|NCT01360359|OTHER|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
214349481|NCT01360359|OTHER|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
214349482|NCT06481917|OTHER|Advance care plan|Scheduling of 2 home visits by an expert nurse in the month following the return home and proposal to carry out an advance care plan.
214349483|NCT06481917|OTHER|Ergonomic analysis|Ergonomic analysis throughout the intervention
214349484|NCT06481917|OTHER|Evaluation of intervention acceptability|Evaluation of intervention acceptability after each home visit with patients and caregivers using a questionnaire
214956715|NCT02207400|DRUG|Sodium bicarbonate and sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
214349485|NCT00222339|BEHAVIORAL|task-specific training|
214349486|NCT01316822|DRUG|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
214349487|NCT02494284|DRUG|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
214349488|NCT02494284|DRUG|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
214349489|NCT06100926|DEVICE|software|virtual reality scene
214349490|NCT05800392|DRUG|DEC103|The intervention is composed by two medications: An active sublingual pill and an active oral one.
214349491|NCT05800392|DRUG|Placebo DEC103|The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
214349492|NCT06010589|DRUG|DWJ1558|DWJ1558
214349493|NCT06010589|DRUG|DWC202310 and DWC202311|Co-administration of DWC202310 and DWC202311
214349494|NCT04329624|DRUG|Levosimendan|Levosimendan 2.5 mg/ml injection contains levosimendan 2.5 mg, povidone 10.0 mg, citric acid, anhydrous 2.0 mg and ethanol, anhydrous to 1.0 mL. Levosimendan injection is a clear, yellow to orange solution. Immediately after skin incision patients allocated to the verum group will receive a dose of 12.5 mg in 500 mL of levosimendan.
214349495|NCT04329624|DRUG|Placebo|"Placebo 2.5 mg/ml injection contains riboflavine sodium phosphate 0.4 mg, dehydrated alcohol 100 mg and water for injection to 1 mL.~Immediately after skin incision patients allocated to the placebo group will receive 500 mL of 5% Glucose."
214349496|NCT00207272|BEHAVIORAL|1170-1870 kcal/day liquid diet|
214349497|NCT00207272|PROCEDURE|Gastric bypass surgery|
214349498|NCT00207272|PROCEDURE|Biopsy.visceral adipose tissue|
214349499|NCT00207272|PROCEDURE|Biopsy.omental adipose tissue|
214349500|NCT00207272|PROCEDURE|Biopsy. subcutaneous abdominal adipose tissue|
214486730|NCT06599788|BEHAVIORAL|Reduced-pace work|Participants will work at a slower pace than the standard work pace of the box carrying protocol
214349501|NCT00207272|PROCEDURE|Blood sample|
214349502|NCT01362140|DRUG|Darbepoetin alfa|Administered by subcutaneous injection every 3 weeks
214349503|NCT01362140|DRUG|Placebo|Administered by subcutaneous injection every 3 weeks
214349504|NCT02090101|DRUG|ANAKINRA|
214349505|NCT05369585|DIETARY_SUPPLEMENT|TOTUM-63|5-g per day dose of TOTUM-63 supplement, a mix of 5 plant extracts. Daily dose for 8 weeks followed by a 4 weeks follow-up period without supplementation.
214349506|NCT01673802|DRUG|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
214349507|NCT01964573|DRUG|Rotigotine|"Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
214349508|NCT01964573|OTHER|Placebo|"Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.~Frequency:~Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
214349509|NCT06042829|DEVICE|Intubation using aerosol box|Intubation time and ease of intubation using aerosol box
214349510|NCT06042829|DEVICE|Intubation without aerosol box|Intubation time and ease of intubation without aerosol box
214349511|NCT06476366|DRUG|Azathioprine|azathioprine will be started at 0.3mg/kg orally daily. Anticipated response is after atleast 1 month so testing will be done thereafter ( after checking TPMT levels)
214349512|NCT06476366|DRUG|Methotrexate|Methotrexate will be started at 5mg/week and dose escalated by 2.5mg weekly to ultimately 10mg/week. Tablet Folic acid 0.5mg will be given orally daily, skipping the day of methotrexate
214486731|NCT06599788|BEHAVIORAL|Increased-pace work|Participants will work at a faster pace than the standard work pace of the box carrying protocol
214486732|NCT06599788|BEHAVIORAL|Additional rest breaks|Participants will work at the standard work pace during the box carrying protocol and have superimposed 5 minutes of rest every 30 minutes.
214349513|NCT03179839|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna."
214349514|NCT03179839|BEHAVIORAL|Psycho-education Program|As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
214349515|NCT03179839|DRUG|sertraline, fluvoxamine|The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
214349516|NCT02951104|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM) system|
214956716|NCT02207400|DRUG|Sodium fluoride|Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
214956717|NCT05420142|DIETARY_SUPPLEMENT|Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey|The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.
214956718|NCT03396822|DRUG|Gadoteridol|gadolinium MRI contrast
214956719|NCT04594655|PROCEDURE|surgery|colectomy
214956720|NCT03367975|OTHER|near infrared spectroscopy|
214956721|NCT03372382|DRUG|Ibuprofen|NSAID
214956722|NCT03372382|DRUG|Acetaminophen|analgesic
214956723|NCT03372382|DRUG|Norco|acetaminophen plus opioid
214956724|NCT00643981|BIOLOGICAL|MESENDO|"2 ml of the final cell mixture will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel."
214956725|NCT00920504|BEHAVIORAL|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
214956726|NCT00920504|OTHER|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
214956727|NCT01393418|OTHER|Cardiac Surgery|
214956728|NCT02574663|DRUG|TGR-1202|TGR-1202 oral daily dose
214349517|NCT03861962|OTHER|"DNA sequencing called new generation (or NGS)"|"Redo HLA-typings with a method exploring all the genes (add DQA1, DRB3 / 4/5, DPB1 and DPA1), i.e. DNA sequencing called new generation, when this has not been done after the graft as part of the standard care"
214349518|NCT05019339|BEHAVIORAL|Healthy HomeStyles|Comparison of 2 educational interventions
214349519|NCT05019339|BEHAVIORAL|Eat Healthy Be Active|Comparison of 2 educational interventions
214486733|NCT06653244|DRUG|Injection|dexmedimidine infusion
214486734|NCT06996717|DRUG|ESA|anemia management algorithm will successfully increase the number of patients in the target hemoglobin range
214486735|NCT06997731|PROCEDURE|Non -surgical treatment and oral hygiene instruction|Scaling and root planing which involves mechanical removal of sup-gingival calculus and necrotic cementum. Tis will be associated with oral hygiene instruction in the form of twice daily brushing for 2 minutes.
214678658|NCT05190575|DRUG|TST001|TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
214956729|NCT02574663|DRUG|nab-paclitaxel + gemcitabine|IV infusion
214956730|NCT02574663|DRUG|Oxaliplatin + Folinic acid + Fluorouracil|IV infusion
214956731|NCT02574663|DRUG|Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab|IV Infusion
214956732|NCT02834078|DIETARY_SUPPLEMENT|BGG|
214956733|NCT02834078|OTHER|Placebo|
214956734|NCT06552403|DIETARY_SUPPLEMENT|A modified 5:2 intermittent fasting diet|The modified 5:2 IF diet involves 2 nonconsecutive fasting days (25%-30% of the total required daily energy intake based on ideal body weight) and 5 days of habitual intake (limited total energy intake according to ideal body weight) per week, as well as a 4-week run-in period and a minimum of 6,000 steps of physical activity per day.
214956735|NCT02757352|DRUG|Ixekizumab|Administered SC
214956736|NCT02757352|DRUG|Placebo|Administered SC
214956737|NCT05305456|DRUG|Tanreqing capsule|3 capsules per time, 3 times a day
214956738|NCT05305456|DRUG|Tanreqing capsule simulator|3 capsules per time, 3 times a day
214956739|NCT02112409|PROCEDURE|cell salvage technique|blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
214956740|NCT02112409|PROCEDURE|acute normovolemic hemodilution|Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
214956741|NCT05581524|DEVICE|VASC|At day 0 the patient will undergo the VASC treatment procedure with VelexTM device. VelexTM venous catheter is inserted in the introducer and pushed in the desired position under echo guidance. At 7 days, 1, 3 and 6 months after the procedure, the patients will undergo a clinical examination and an echo-color doppler assessment.
214956742|NCT05119036|RADIATION|44 doses of radiation|Patients will receive 44 gray in 22 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 40 gray in 22 fractions to undissected areas of the neck at low-risk for occult disease.
214349520|NCT02256462|DRUG|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (\> 40kg 160/80/40 mg every 2 weeks or \< 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
214349521|NCT01546194|OTHER|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
214349522|NCT04153370|DEVICE|Airtraq|airtraq video laryngoscope was used for intubation of the infant
214349523|NCT04153370|DEVICE|glidescope|glidescope video laryngoscope was used for intubation of the infant
214349524|NCT04153370|DEVICE|c-mac|c-mac video laryngoscope was used for intubation of the infant
214349525|NCT04172792|DIETARY_SUPPLEMENT|high-caloric fatty diet|see arm/group description
214349526|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric fatty diet|see arm/group description
214349527|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric carbohydrate-rich diet|see arm/group description
214349528|NCT06340269|DEVICE|MEX-CD1 Dialysis|"MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in Slow low-volume continuous veno-venous hemodialysis. One treatment will last 3 hours and 20 minutes.~Patients enrolled are hospitalized in Intensive Care Unit."
214349529|NCT04445818|BEHAVIORAL|More appreciation|
214349530|NCT04445818|BEHAVIORAL|Less criticism|
214349531|NCT04445818|BEHAVIORAL|More Fruit and Vegetable|
214349532|NCT04818411|OTHER|Routine physical therapy treatment with the Stabilization exercises|The program was based on specific training of the transversely oriented abdominal muscles with coactivation of the lumbar multifidus at the lumbosacral region, training of the gluteus maximus, the latissimus dorsi, the oblique abdominal muscles, the erector spinae, the quadratus lumborum, and the hip adductors and abductors. Initially, we focused on the specific contraction of the transversely oriented abdominal muscles. After approximately 2 weeks, loading was progressively increased throughout the intervention period. The women were required to exercise for 30 to 60 minutes, 3 days a week, for 3-4 weeks.
214349533|NCT04818411|OTHER|Routine physical therapy treatment + High-velocity thrust manipulation|: For high-velocity thrust technique, a modified Chicago technique was used. For this procedure, the lumbopelvic region was targeted. The side to be treated was chosen, based on the subject's report of her most symptomatic side. The physical therapist, performed passively side bend the subject toward the painful side, rotate the upper body in the direction opposite to the side bending, and then deliver a quick posterior and inferior thrust at a grade V including a small-amplitude/high-velocity therapeutic movement. A maximum of 2 attempts per side was permitted if no pop was heard following the first attempt. If the subject showed improvement of 50% or less after the first treatment, the intervention was categorized as a failure, the examination and intervention were repeated, and the subjects were asked to return 2 to 4 days later. If the subject showed greater than 50% improvement, the intervention was categorized as a success, and study participation was concluded.
214349534|NCT04956393|BEHAVIORAL|Immediate 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
214956743|NCT05119036|RADIATION|54 doses of radiation|Patients will receive 54 gray in 27 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 50 gray in 27 fractions to undissected areas of the neck at low-risk for occult disease.
214349535|NCT04956393|BEHAVIORAL|Delayed 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
214349536|NCT06193421|DRUG|Ambroxol Hydrochloride|75mg slow release (SR), X16/day or 300mg X4/day oral capsules.
214349537|NCT05860465|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
214349538|NCT05860465|DRUG|SPH4336 Tablets Placebo|SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
214349539|NCT00413504|DRUG|Fondaparinux|
214956744|NCT03565003|DRUG|JAB-3068|25 mg,100 mg
214956745|NCT06581250|BEHAVIORAL|Reminder Messages|Dental clinic staff will use scripts to contact patients 24 and 48 hours before appointments. These scripts will guide staff in confirming the patient will appear for their appointment.
214956746|NCT06581250|BEHAVIORAL|Walk-in Visits|When contacting patients to schedule an appointment (by phone, email, text, or other methods), dental clinic staff will notify patients of times during which patients can walk-in for a dental visit, if convenient for them; otherwise, a regular appointment will be arranged. Scheduled appointments will continue to be available in addition to the walk-in hours.
214349540|NCT02116634|BIOLOGICAL|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
214349541|NCT05568992|DEVICE|AI system of optical detection of advanced adenomas|AI system of optical detection of advanced adenomas
214349542|NCT00417001|PROCEDURE|Aroma therapy|
214349543|NCT05034705|DEVICE|Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
214349544|NCT05034705|DEVICE|Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
214486736|NCT06997731|DRUG|Application of minocycline and hyaluronic acid gel.|application of minocycline and Gengigel® topical gel twice weekly for 3-week 1cc for each.
214956747|NCT06581250|BEHAVIORAL|Motivation-enhanced Communication|Participating clinic site staff will be trained in motivation-enhanced communication techniques using the guide for dental clinic sites and coaching. Topics to be included in the motivation-enhanced communication training are a) to determine what patients hope to gain from their dental care, steps needed to succeed, how the agency and client will work together to attain the goals, and b) to identify patient barriers to attending their visit (e.g., transportation, payment, do not understand need for visit, etc.), and what the agency and patient will do to overcome those barriers. Staff will be instructed to use these techniques with patients at every contact about an upcoming appointment.
214486737|NCT06997731|DRUG|local application of placebo gel|The placebo gel will be applied in the periodontal pocket twice weekly for 3-week 1cc for each.
214956748|NCT06954779|DRUG|Colgate Cavity Protection|1000ppm fluoride
214956749|NCT06954779|DRUG|TOM's Superior Sensitivity Relief Toothpaste|fluoride free
214956750|NCT06956079|PROCEDURE|EIP-first|EIP is applied for 20 minutes immediately after the initiation of one-lung ventilation, followed by conventional mechanical ventilation.
215078414|NCT06605235|PROCEDURE|Local Anesthesia|In Group A, patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure. Subjects in Group B received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites. In Group C patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites
214956751|NCT06956079|PROCEDURE|EIP-later|Conventional mechanical ventilation is applied for 20 minutes after the initiation of one-lung ventilation, followed by EIP application.
214956752|NCT06169163|OTHER|Exhaled breath sampling|Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.
214956753|NCT05714826|OTHER|Preop Intervention and Monitored Recovery|Perioperative Optimization of Senior Health (POSH) Program; patient monitoring by device orientation, initial intake, education; ERAS protocol, inpatient geriatric co-management; and remote monitoring with Acticare device; post-op continuity of care
214956754|NCT05714826|OTHER|Usual Care|ERAS, Usual referral and recovery care, and Standard follow-up protocol
214956755|NCT06955208|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Participants will undergo preoperative 3D MRE to quantify tumor stiffness and generate adhesion maps. MRE is performed as an adjunct to standard brain MRI, using 60 Hz vibration frequency and specialized elastogram processing software. The resulting stiffness and adhesion data are made available to the neurosurgical team for surgical planning.
214349545|NCT05629351|OTHER|Observational Group|"Demographic Data (Blood pressure, subcutaneous fat tissue, height, waist and hip circumference, and body weight, BMI (body mass index) and double product)~International Physical Activity Questionnaire (IPAQ)~Godin-Shephard Leisure-Time Physical Activity Questionnaire~The Dutch Eating Behavior Questionnaire~Pittsburg Sleep Quality Questionnaire~Perceived Stress Scale and Beck Depression Scale"
214349546|NCT06958081|DEVICE|Active transcranial direct current stimulation (tDCS)|2.0 mA anodal stimulation applied over FCz with cathode over Fp2 for 30 minutes using a transcranial direct current stimulation device.
214349547|NCT06958081|DEVICE|Sham transcranial direct current stimulation (tDCS)|Sham stimulation mimicking the sensations of tDCS; the current will be turned off after 30 seconds while maintaining electrode placement over FCz and Fp2.
214349548|NCT02032472|OTHER|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
214486738|NCT06995989|OTHER|energy conservation techniques with pursed lip breathing|"Group A will receive energy conservation techniques with pursed lip breathing with~1 session a day for total 5 days in a week. 1 session will consist of 3 cycles of pursed lip breathing for duration of 10 minutes with a break of 20 minutes in between. ECTs will be trained for 2 weeks. A detailed manual will be developed to ensure the consistency of the training for all subjects. Examples of interventions are training to use ergonomic principles along with pursed lip breathing. The subjects were trained to place their equipment at chest height; they were trained to work at paced speed and in some cases instructed to use technical aids."
214678659|NCT01094964|BIOLOGICAL|BCG solution|
214349549|NCT03955393|OTHER|18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
214956756|NCT06955208|PROCEDURE|Intraoperative Assessment and Recording|During surgical resection, the neurosurgical team will systematically assess and record tumor stiffness, adhesion to surrounding structures, vascularity, resection time, and technical difficulty using a standardized intraoperative scale. These intraoperative findings will be compared to preoperative MRE parameters to evaluate the diagnostic and predictive value of MRE.
214349550|NCT04297540|DEVICE|Active-tDCS group|Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
214486739|NCT06995989|OTHER|pursed lip breathing|pursed lip breathing
214678660|NCT01094964|BIOLOGICAL|recombinant interferon alfa|
214678661|NCT01094964|DRUG|epirubicin hydrochloride|
214678662|NCT01094964|DRUG|mitomycin C|
214678663|NCT01094964|OTHER|laboratory biomarker analysis|
214678664|NCT01094964|PROCEDURE|hyperthermia treatment|
214956757|NCT05182749|BIOLOGICAL|bacteriophage|A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution
214956758|NCT05182749|OTHER|Placebo|Placebo orally administered with sodium bicarbonate solution
214956759|NCT03638466|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Neural brain activity measured by fMRI
214956760|NCT03638466|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy (MRS)|Glutamate and GABA levels measured by MRS
214956761|NCT03638466|BEHAVIORAL|Point Subtraction Aggression Paradigm (PSAP) Task|Aggression score measured by the PSAP task
214956762|NCT03638466|DRUG|SPN-810|Treatment of SPN-810 (36 mg) on neuronal brain activity, GABA and Glutamate levels and on the aggression score
214956763|NCT03638466|DRUG|Placebo|Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
214956764|NCT06955780|OTHER|Emotional Freedom Techniques|Emotional Freedom Techniques
214956765|NCT00359320|PROCEDURE|pancreaticojejunostomy|
214956766|NCT03251482|DRUG|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion as a single dose on Day 1.
214956767|NCT03251482|DRUG|JNJ-64179375 0.6 mg/kg|JNJ-64179375 0.6 mg/kg IV infusion as a single dose on Day 1.
214956768|NCT03251482|DRUG|JNJ-64179375 1.2 mg/kg|JNJ-64179375 1.2 mg/kg IV infusion as a single dose on Day 1.
214956769|NCT03251482|DRUG|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
214956770|NCT03251482|DRUG|JNJ-64179375 A mg/kg|JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
214956771|NCT03251482|DRUG|JNJ-64179375 B mg/kg|JNJ-64179375 Dose B mg/kg IV as a single dose on Day 1.
214956772|NCT03251482|DRUG|JNJ-64179375 C mg/kg|JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
214956773|NCT03251482|DRUG|JNJ-64179375 D mg/kg|JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
214956774|NCT03251482|DRUG|Placebo JNJ-64179375|Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.
214956775|NCT03251482|DRUG|Apixaban placebo|Matching apixaban placebo administered orally twice a day for 10 to 14 days.
214956776|NCT03251482|DRUG|Apixaban 2.5 mg|Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.
214956777|NCT04242979|BEHAVIORAL|Questionnaire about albumin use in liver cirrhosis|"1. Permission to carry out the study will be obtained from the Faculty's Ethics Committee.~2. To achieve validity and reliability of the tool. It will be reviewed by two experts in the field of the study and necessary modification will be done.~3. A pilot study will be 10% done to test the clarity and feasibility of developed tool.~4. Each participant involved in the study will be assessed for his or her knowledge using (tool I).~5. Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~6. Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~7. Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians"
214956778|NCT02447328|DRUG|Fulvestrant|fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
214956779|NCT02830399|DEVICE|active rTMS-ECT|5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
214956780|NCT02830399|DEVICE|sham rTMS-ECT|5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
214956781|NCT02804048|OTHER|superficial heat pelvic floor muscle|Superficial heat application in the pelvic floor muscle
214956782|NCT02804048|OTHER|superficial heat low back|Superficial heat application in the low back
214956783|NCT02804048|OTHER|Pelvic Floor Muscle Training|Pelvic floor muscle training exercises
214956784|NCT02804048|OTHER|Manual therapy in iliopsoas, diaphragm and piriformis|Manual therapy in iliopsoas, diaphragm and piriformis for 10 minutes
214956785|NCT02804048|OTHER|Intra Vaginal Manual therapy|Intra Vaginal Manual therapy in the pelvic floor muscles
214956786|NCT02804048|OTHER|Electromyographic biofeedback|Electromyographic biofeedback in the pelvic floor muscles
214956787|NCT05705921|RADIATION|Radiotherapy standard|Standard moderately hypofractionated radiotherapy in prostate cancer
214956788|NCT05705921|RADIATION|Radiotherapy Hypo-FLAME|Ultra-hypofractionated focal lesion ablative microboost in prostate cancer
214349551|NCT04297540|DEVICE|Sham-tDCS group|Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
214956789|NCT06515626|BIOLOGICAL|CAR-T cell reinfusion|Subjects were identified according to their benefit from the first treatment and target expression Whether to accept multiple returns; CAR-T cell reinfusion dose was 1\~10×106 cells/kg, and the reinfusion dose could be adjusted according to the tolerance of the subjects Usually intravenous infusion, but also according to the need for local interventional treatment or injection treatment
214956790|NCT02204644|DRUG|Flumatinib 600mg qd|
214956791|NCT02204644|DRUG|Imatinib 400mg qd|
214956792|NCT01614444|OTHER|Active Acupressure Treatment|Participant will receive 8 active acupressure treatments.
214956793|NCT01614444|OTHER|Placebo Acupressure Treatment|Participants will receive 8 placebo acupressure treatments.
214956794|NCT04117542|OTHER|Observational|Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.
214956795|NCT06349239|OTHER|No intervention|Follow-up of disease
214956796|NCT00387972|DRUG|denagliptin (GW823093)|
214956797|NCT01329770|DIETARY_SUPPLEMENT|Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|"* Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)~* Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks"
215078415|NCT06606041|PROCEDURE|Dry Needling|This. minimally invasive technique is based on the insertion of a sterile, low-caliber, monofilament needle, without the injection or extraction of any additional substances, into hyperirritable muscle nodules. There are two categories within this technique, based on the depth at which the needle is inserted: superficial needling (or the Baldry technique), in which the needle is inserted up to the subcutaneous cellular tissue overlying the myofascial trigger point (up to 10 mm); and deep needling, where the needle is inserted into the muscle with the intention of reaching the myofascial trigger point. Reaching the trigger point was the investigators goal. Regardless of the technique selected, the aim is to generate controlled micro spasms in the affected muscle area, alternating with periods of muscle relaxation.
214349552|NCT05061121|OTHER|combined effect|Compare the short- and mid-term effects of Mulligan's SNAGs, Myofascial release, and their combination on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
214349553|NCT01201629|DEVICE|t DC stimulation|tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
214349554|NCT01201629|DEVICE|tDCStimulation|1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
214486740|NCT06997406|DIETARY_SUPPLEMENT|Inner ear support|"FB-1603 (150 mg): A cold water extract of Arthrospira maxima (a species of blue-green algae), rich in the antioxidant pigment C-phycocyanin (C-PC).~GABA (126 mg): A natural calming neurotransmitter that can help reduce nerve-related overactivity.~γ-Oryzanol (12 mg): A component from rice bran oil, known for its antioxidant properties.~Sesamin (12 mg): A compound from sesame seeds, with potential neuroprotective and anti-inflammatory benefits."
214678665|NCT01094964|PROCEDURE|quality-of-life assessment|
214678666|NCT03274336|BEHAVIORAL|questionnaire|questionnaire post preanesthetic interview
214956798|NCT01329770|DIETARY_SUPPLEMENT|Placebo|Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
214956799|NCT02362425|DRUG|N-acetylcysteine|
214956800|NCT02362425|DRUG|Placebo|
214956801|NCT00596453|DRUG|Ciprofloxacin hydrochloride|250 mg Ciprofloxacin hydrochloride twice a day for 14 days
214956802|NCT00596453|DRUG|Placebo|Placebo twice a day for 14 days
214956803|NCT06344689|OTHER|Surgical treatment|Patients underwent surgical treatment of ectropion were included in this study.
214956804|NCT04972422|DRUG|ZN-c3|ZN-c3 is a study drug
214956805|NCT05491681|BIOLOGICAL|intravenous delivery of allogeneic bone marrow-derived MSCs|MSCs
214956806|NCT01456546|DRUG|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
214956807|NCT01456546|DRUG|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
214956808|NCT05693324|BEHAVIORAL|Minority stress|Intervention based on Cognitive Behavioural and Compassion Focused Treatments
214956809|NCT00802672|DRUG|Ciclopirox Olamine Cream|topical cream
214956810|NCT00802672|DRUG|Loprox Cream 0.77%|topical cream
214956811|NCT00802672|DRUG|Placebo|topical cream
214956812|NCT03216369|OTHER|MRI|MRI perfusion imaging
214956813|NCT00463489|BEHAVIORAL|Lifestyle intervention|Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
214349555|NCT03153917|OTHER|melatonin and cortisol sampling|The study will take place over 15 days during which the nurses will wear an actigraphic wristband and will fulfill a sleep log. During 3 periods of 24 hours selected during these 15 days, including a 12h day shift (Day 2), a 12h night shift (Day 8) and a rest (Day 13), the participants will collect their urine by 4 to 8 hour periods, note the corresponding urine volumes and for each period, sample a 5 mL tube which will be analyzed later (6-sulfatoxymelatonin and urinary cortisol assays). The subjects will complete questionnaires at the beginning of the study (Horne and Ostberg, Insomnia Severity Index, Epworth, Pichot, Hospital Anxiety and Depression) and the days corresponding to the urine sampling (Karolinska and St Mary Hospital).
214349556|NCT05761431|DRUG|SYHX2008 injection|Subcutaneous administration on Day 1.
214349557|NCT05761431|DRUG|Octreotide Acetate Microspheres for Injection injection|Intramuscular administration on Day 1.
214349558|NCT05761431|DRUG|Sandostatin ® injection|Subcutaneous administration on Day 1.
214349559|NCT05761431|DRUG|Placebo to SYHX2008 injection|Subcutaneous administration on Day 1.
214349560|NCT02310750|DRUG|PF-06700841 oral solution/suspension|Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
214349561|NCT02310750|OTHER|Placebo|Matching placebo given during the single ascending and multiple dose periods
214349562|NCT02310750|DRUG|PF-06700841 tablet|PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
214956814|NCT00463489|BEHAVIORAL|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
214956815|NCT01220726|DRUG|Botox|Botox injection
214349563|NCT05801224|DEVICE|Nitric Oxide|20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.
214349564|NCT00762125|BEHAVIORAL|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
215078416|NCT06606041|PROCEDURE|Ischemic Compression|Ischemic compression is a conservative, manual technique used on myofascial trigger points, in which pressure should be exerted between 30 and 90 seconds on these same areas. It is suggested that it leads to the normalization of the biomechanical properties of muscle fibers, restoring the muscle\&#39;s functional condition and probably reducing the risk of injury. Thus, the therapeutic effects include the stimulation of mechanoreceptors, with pain attenuation mainly due to the depletion of specific neurotransmitters and temporary obstruction of local blood flow (local ischemia), followed by a rapid influx of oxygenated blood to the area under pressure relief,(37) which will cause an increase in muscle metabolism.
215078417|NCT06606041|PROCEDURE|Cross Tapes|Cross tapes, as the name implies, based on an equidistant intersection of three or four polyester tapes with a non-elastic adhesive acrylic coating, with the 3 lines oriented in a latero-medial direction. It is recommended that it be applied to the muscle area where the myofascial trigger point has been detected, at a 45º angle to the muscle fibers. Its application may have several purposes, such as muscle support, improving the stability of the fibers; pain relief, especially in areas where muscle tension and/or inflammation are present; aiding lymphatic drainage; promoting blood circulation. Before it is applied, the skin should be clean (disinfecting the area with alcohol) and dry, without any lotion or other ointments and the maximum period of use should not exceed 24 hours due to the risk of changes in position, either due to sweating or direct intervention by the patient himself.
214349565|NCT00762125|BEHAVIORAL|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
214349566|NCT00762125|BEHAVIORAL|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
214349567|NCT01018901|OTHER|Survey Administration|Patients complete survey
214349568|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
214349569|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
214349570|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
214349571|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
214349572|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
214349573|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
214956816|NCT01220726|DRUG|Placebo|Placebo injection
214956817|NCT02579382|DRUG|TDF|300 mg tablets administered orally once daily
214349574|NCT03738540|BEHAVIORAL|TALK study group|Telephone Delivered Intervention
214349575|NCT03738540|BEHAVIORAL|TALK control group|Telephone Delivered Intervention
214349576|NCT03298126|PROCEDURE|TR BAND removal protocol|To assess radial artery patency after specific protocol used as already described in previous section.
214349577|NCT01063257|DRUG|Clofarabine|"The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:~DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).~The DLa will be the following:~DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation."
214956818|NCT02579382|DRUG|Vesatolimod|Tablets administered orally once a week (every 7 days) for 12 doses
214956819|NCT02579382|DRUG|Placebo|Placebo administered orally once a week (every 7 days) for 12 doses
214956820|NCT03818009|OTHER|Assessment document|The anesthesiologist will evaluate through his sheet women's cognitive functions.
214349578|NCT05483426|OTHER|semi-structured Interviews|semi-structured interview conducted by a psychiatrist
214349579|NCT00395876|DRUG|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
214349580|NCT00395876|DRUG|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
215078418|NCT03919968|BEHAVIORAL|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
214349581|NCT01435577|DRUG|Tapentadol|30 mg per administration, maximum 12 administrations over 48 hours
214349582|NCT01435577|DRUG|Matching Placebo|Maximum 12 administrations over 48 hours
214349583|NCT00628771|BEHAVIORAL|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
214349584|NCT00628771|BEHAVIORAL|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
214349585|NCT05973526|PROCEDURE|Percutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using needles.
214349586|NCT05973526|PROCEDURE|Transcutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using the surface electrodos.
214349587|NCT04223011|BEHAVIORAL|In-Hospital Recovery Coach Intervention|The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
214349588|NCT01600157|PROCEDURE|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
214349589|NCT05108194|BEHAVIORAL|SMS Personalized Sleep Intervention|"All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions."
214349590|NCT04698980|DIAGNOSTIC_TEST|blood samples (venous and capillary at the fingertip)|For each participant, the intervention will be a fingertip sample to perform the STANDARD G6PD test and two blood samples on EDTA to perform the reference test
214349591|NCT06324435|DRUG|Apremilast|60mg/day
214678667|NCT03274336|BEHAVIORAL|face-to-face interview|Group A = face-to-face interview
214956821|NCT04077749|BIOLOGICAL|Femdophilus probiotic|Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.
214956822|NCT04077749|OTHER|Normal Saline|50 mL normal saline at room temperature
214956823|NCT05903755|DEVICE|speed dependent treadmill training on moderate speed|Experimental group will receive 14 session of speed dependent treadmill training on moderate speed (3 to 6) for 25 minutes along with strengthening, stretching and range of motion exercises.
214349592|NCT01658787|DEVICE|Endovascular aortic repair|Treatment with Gore Endovascular Aortic Products.
214678668|NCT03274336|BEHAVIORAL|brochure|after reading a brochure a face to face interview will take place
214678669|NCT03274336|BEHAVIORAL|movie|after seeing a film about the procedure a face-to-face interview will take place
214678670|NCT04841135|OTHER|Multiomics quantification|One time blood, stool and urine samples will be taken.
214678671|NCT04841135|OTHER|Polysomnography|Facultative polysomnography
214678672|NCT02416908|DRUG|Selinexor|
214678673|NCT02416908|DRUG|Cladribine|
214678674|NCT02416908|DRUG|G-CSF|
214678675|NCT02416908|DRUG|Cytarabine|
214956824|NCT05903755|DEVICE|speed dependent treadmill training on slow speed|Control group will receive 14 session of speed dependent treadmill training on slow speed (1 to 2) for 25 min along with physiotherapy.
214678676|NCT02416908|PROCEDURE|Bone marrow biopsy|
214678677|NCT00299533|DRUG|Fish oil (Super Omega-3, 4 caps/d) vs. placebo|
214349593|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
214349594|NCT04213196|DRUG|HSK21542|Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
214349595|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
214956825|NCT01437371|DRUG|- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
214956826|NCT04474054|DEVICE|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation will be performed using catheter ablation
214956827|NCT04825925|DEVICE|DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)|Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, the Platinum was infused. BAI (Bronchial Arterial Infusion ) chemotherapy was followed by DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with Vinorelbine were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
214956828|NCT05773339|OTHER|AIMS65 score|"The AIMS65 score consists of five factors:~(i)albumin (1 point for value less than 3.0 g/dL (30 g/L)). (ii)INR (1 point for value greater than 1.5) . (iii)altered mental status (1 point given if Glasgow coma score was less than 14 or if disorientation, lethargy, stupor, or coma was seen) (iv)systolic blood pressure (1 point for value less than 90 mmHg). (v)age (1 point for value greater than 65 years)."
214956829|NCT06454643|DRUG|Flucloxacillin and gentamicin|This intervention aimed to investigate the effectiveness of administering gentamicin in reducing the incidence of SSI.
214956830|NCT06454643|DRUG|Flucloxacillin and ceftriaxone|Control group
214956831|NCT05325372|PROCEDURE|axillary block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
214956832|NCT05325372|PROCEDURE|infraclavicular block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
214956833|NCT01044368|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
214956834|NCT02904395|OTHER|observational (no intervention)|
214956835|NCT00087464|DRUG|Emtricitabine|
214956836|NCT00087464|DRUG|Nevirapine|
214349596|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
214349597|NCT04213196|DRUG|HSK21542|Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
214956837|NCT00087464|DRUG|Tenofovir disoproxil fumarate|
214956838|NCT03026283|DEVICE|HeartFLow CT-FFR|Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
214349598|NCT04213196|DRUG|HSK21542|Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
214956839|NCT02328482|DRUG|Tehalose 30gr|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
214349599|NCT04213196|DRUG|HSK21542|Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
214349600|NCT04213196|DRUG|HSK21542|Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
214349601|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
214349602|NCT05062252|DEVICE|Mirror Medacta Shoulder System|Anatomic total shoulder arthroplasty system
214956840|NCT03782571|DEVICE|etafilcon a Test 1|1-DAY ACUVUE® MOIST
214956841|NCT03782571|DEVICE|etafilcon A Test 2|1-DAY ACUVUE® MOIST for ASTIGMATISM
214956842|NCT03782571|DEVICE|etafilcon A Test 3|1-DAY ACUVUE® MOIST MULTIFOCAL
214956843|NCT03782571|OTHER|Control|Bare Eye
214349603|NCT05062252|DEVICE|Medacta Shoulder System|Anatomic total shoulder arthroplasty system - standard configuration
214349604|NCT03705091|DIAGNOSTIC_TEST|Magnetic resonance imaging|ASL and DWI MRI
214349605|NCT04493398|PROCEDURE|Gracey curette.|Root planed was performed with curettes (Gracey SAS, Hu-Friedy, Chicago, IL, USA).
214349606|NCT04493398|PROCEDURE|Ultrasonic scaler.|Debridement was performed with an ultrasonic scaler (Piezon Master 400 Perio Slim Tip®; Electro Medical System, Nyon, Switzerland).
214349607|NCT04493398|PROCEDURE|Erythritol air-polishing.|Treatment was performed with a low abrasive erythritol powder (Air-flow powder plus®, EMS, Nyon, Switzerland ) applied through a Perio-Flow hand piece connected to an airflow unit (Air-Flow Master®, EMS, Nyon, Switzerland).
214956844|NCT00786253|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg on demand use
214956845|NCT00786253|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil daily dosing 10 mg
214956846|NCT04418050|PROCEDURE|Shoulder arthroplasty|Surgery consisting in replacement of gleno-humeral joint by a shoulder prosthesis
214956847|NCT00240968|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
214349608|NCT01892748|DRUG|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
214349609|NCT01892748|DRUG|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
214349610|NCT00550225|DRUG|GSK961081|GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
214349611|NCT00550225|DRUG|GSK961081 matching placebo|GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
214349612|NCT01934218|DEVICE|Gel-One|
214956848|NCT06365190|OTHER|transcranial magnetic stimulation|During treatment, the patient underwent cTBS targeting the left SMA for 14 consecutive days. Each treatment day comprised three rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
214956849|NCT06365190|DRUG|Pharmacotherapy（antiparkinsonian drugs）|Anti-Parkinson's disease drugs include compound levodopa, dopamine receptor agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, etc. Take dopaminergic agents regularly, with follow-up every 8 weeks including medication guidance and symptom assessment
214349613|NCT01934218|DEVICE|PBS|
214349614|NCT03910153|DIETARY_SUPPLEMENT|MSPrebiotic|MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
214956850|NCT01341899|PROCEDURE|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
214956851|NCT02442648|DRUG|Carfilzomib|Carfilzomib will be administered for desensitization per study protocol.
214956852|NCT02442648|DRUG|Rituximab|Rituximab will be administered for desensitization per study protocol.
214956853|NCT05645302|DRUG|Lidocaine Cataplasms|The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.
214956854|NCT03989336|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
214956855|NCT03989336|DRUG|nab-paclitaxel|Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
214956856|NCT03989336|DRUG|Platinum chemotherapy|Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
214956857|NCT03989336|DRUG|Sintilimab|Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
214956858|NCT02696486|BEHAVIORAL|Exercise Training|Study subjects will receive medically supervised aerobic and resistance exercise training for 1 hour per session, 3 times per week for 6 weeks at the Cardiac Rehab center and then transition to home or YMCA partnership based exercise with staff follow-up contact for an additional 3 weeks.
214956859|NCT00576524|DEVICE|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
214956860|NCT00576524|DEVICE|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
214956861|NCT03370965|DIAGNOSTIC_TEST|Neuro-ophtalmology examination|"Patients will first undergo a full neuro-ophthalmic examination which includes visual acuity, contrast vision, color vision, slit-lamp anterior segment and fundus examination as well as automatized visual field and optical coherence tomography of the optic nerves and retina.~Patients will then be admitted to the Neurology and Ophthalmologic Department for optic neuritis emergency treatment, 3-Tesla brain and medullar MRIs, and ancillary testing. Specific NMO antibodies (AQP-4 and MOG) will be tested in all patients. Neuro-ophthalmic examination will be repeated after 3 days of IV steroids in order to decide on further treatment."
214956862|NCT05621395|OTHER|E-OJ-01|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
214956863|NCT05621395|OTHER|Microcrystalline cellulose|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
214956864|NCT03140540|OTHER|TEE guided fluid therapy will be administered|Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta \<20 ,200ml colloid bolus to be administered.
214956865|NCT03140540|OTHER|Stroke volume variation guided intravenous fluid.|Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV \>10, 200 ml of colloid bolus to be given
214349615|NCT03910153|OTHER|Placebo|Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
214349616|NCT05892679|OTHER|acupressure|"Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks."
214678678|NCT02887105|OTHER|Standard neuropsychological assessment|
214956866|NCT05576961|DRUG|RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-6 to D-3 RX-af01: 2 capsules, bid, po, D-2 to D0 Treatment (Every 3 weeks) RX-af01: 1 capsule, bid, po, every day Toripalimab: 240mg, ivdrip, D1, every 3 weeks.
214956867|NCT05576961|DRUG|Mixed bacteria|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
214956868|NCT05576961|DRUG|High dose RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
214349617|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
214349618|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
214349619|NCT00241254|DRUG|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
215078419|NCT03919968|BEHAVIORAL|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
214678679|NCT02887105|OTHER|Brain MRI|
214956869|NCT05472571|OTHER|Forest bathing|The intervention consists of 11 consecutive sessions of forest bathing (one session per week), each one lasting about 2 hours. Each session involves an easy walk through a forest area, interspersed with non-intrusive activities of contact with the surrounding nature aimed at fostering mindfulness and the use of the five senses.
214956870|NCT04153474|PROCEDURE|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
214956871|NCT04153474|PROCEDURE|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
214956872|NCT01696656|DRUG|Drug prescription pattern|Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
214956873|NCT06408337|PROCEDURE|implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).|cleft palate repair surgery, all patients in the study will receive the standard treatment (uranostaphyllorrhaphy), with the only difference that patients assigned to the experimental study group will additionally have BIOCLEFT tissue obtained through tissue engineering grafted onto them. the lateral area of the palatine bone exposed when mobilizing the flaps. For the implant, the BIOCLEFT fabric will be placed in the area of exposed bone, sized to the size of the defect and sutured using uncoated, monofilament long-term absorbable synthetic suture.
214956874|NCT04382716|OTHER|No intervention|No intervention; observation only
214956875|NCT03646747|DIAGNOSTIC_TEST|MRI scan|Additional imaging using MRI scan
214956876|NCT02213380|PROCEDURE|method of anesthesia|"General anesthesia and regional anesthesia.~General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.~Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA"
214956877|NCT00730574|DIETARY_SUPPLEMENT|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
214956878|NCT01314027|DRUG|Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin|"Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.~Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months."
214956879|NCT01314027|DRUG|adjuvant chemotherapy with gemcitabine|Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
214956880|NCT02198508|DRUG|DFX(Deferasirox)|
214956881|NCT02198508|DRUG|DFP(Deferiprone)|
214956882|NCT00540839|DRUG|Montelukast sodium|Montelukast 4 mg OG or montelukast 4 mg CT
214956883|NCT00540839|DRUG|Placebo to montelukast|Placebo OG or CT
214956884|NCT00540839|DRUG|Fluticasone propionate|Fluticasone 50 mcg inhalation aerosol metered dose inhaler
214956885|NCT00540839|DRUG|Placebo to fluticasone|Placebo inhalation aerosol metered dose inhaler
214678680|NCT04530812|OTHER|Best Practice|Maintain usual diet
214956886|NCT00122525|PROCEDURE|Male Circumcision|
214956887|NCT04331834|DRUG|Hydroxychloroquine|"Hydroxychloroquine with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"
214956888|NCT04331834|DRUG|Placebos|"Placebo with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"
214956889|NCT03660891|DIAGNOSTIC_TEST|measuring neuromuscular block|During anesthesia patients are monitored with two instead of one NMT monitor. the difference in measured TOF-PTC is compared
214956890|NCT05468983|PROCEDURE|surgical ( implants placement)|4 implants were placed interforamen of the mandibular arch by using the surgical guide
214956891|NCT05703334|OTHER|Kinesio tap|Applied on pulmonary muscles :diaphragm muscle and abdominal muscle and sternocleinomastoid muscle 3 time per weak for 2 mounth
214956892|NCT02033707|DRUG|Hallucinogens and psychoactive substances|"One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects."
214349620|NCT00241254|DRUG|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
214349621|NCT05520580|PROCEDURE|Mother's push during CS|after uterotomy, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary
214349622|NCT04104867|DRUG|Itopride|the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
214349623|NCT04104867|DRUG|Domperidone|the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
214956893|NCT03132415|BEHAVIORAL|Get Connected|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.
214956894|NCT03132415|BEHAVIORAL|HIV Test Locator|The investigators will use a HIV/STI testing locator as the attention-control condition. The test locator provides a list of HIV testing sites in a city or zipcode.
214486741|NCT06677112|PROCEDURE|Selective surgical staging|Intraoperative Consultation, performed by pathologist and surgeon jointly. The uterus is inspected for extra-corpus spread (cervix, parametria, adnexa, distant). The surgical pathologist will evaluate the uterus according to the IOC Worksheet and promptly notify the surgeon of the results. The IOC will include evaluation for extra-corpus disease, lesion measurement, frozen section (to confirm measured lesion is malignant, cell type, and re-grading of tumor). Non-sentinel nodes will be handled according to institutional standard-of-care practice.
214956895|NCT00033319|DIETARY_SUPPLEMENT|folic acid|
214956896|NCT00033319|DRUG|acetylsalicylic acid|
214956897|NCT00288418|DEVICE|Central Venous Catheter|7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
214956898|NCT01676103|DIETARY_SUPPLEMENT|Tyrosine|Tyrosine supplementation (500 mg 2 x daily) for 7 days
214956899|NCT01676103|OTHER|Placebo Comparator:Sugar Pill|Placebo sugar pills (2x daily
214956900|NCT01516489|BEHAVIORAL|Stage 1|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
214956901|NCT01516489|BEHAVIORAL|Stage 2|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
214956902|NCT02073526|DRUG|Infliximab, adalimumab, certolizumab pegol|Patients are treated with the above mentioned drugs decided by clinicians
214956903|NCT06005753|PROCEDURE|Ostheosynthesis of acetabular fractures|The using of plate for fixation of acetabular fractures in surgical treatment
214956904|NCT03498313|DRUG|Transdermal Estradiol + Placebo|.1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test, plus twice daily placebo pills during the same time frame.
214956905|NCT03498313|DRUG|Oral Micronized Progesterone + Placebo|100mg oral micronized progesterone twice daily for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
214956906|NCT03498313|DRUG|Placebos|Twice daily placebo pills for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
215078420|NCT06605690|DRUG|Dalpiciclib and Letrozole Combined With Anlotinib|Dalpiciclib: 150mg orally, once daily, d1-d21, every 28 days as a cycle (3 weeks / 1 week off) Letrozole: 2.5mg orally once daily (continuous) Anlotinib: 12mg orally, once daily, d1-d14, every 21 days as a cycle (use 2 weeks/stop 1 week). One of the last cycles of the new auxiliary The combination of anlotinib is not included in the treatment regimen to ensure that the time interval between anlotinib withdrawal and surgery is more than 2-3 weeks.
215078421|NCT06606223|DIAGNOSTIC_TEST|serum ammonia test|precaution of withdrawal serum ammonia
214349624|NCT04104867|OTHER|Placebo|the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
214349625|NCT00059800|RADIATION|boron neutron capture therapy|
214349626|NCT00875836|DRUG|Buspirone|Flexible dose, up to 60 mg daily
214349627|NCT00875836|DRUG|Placebo|Flexible dose, up to 60 mg daily
214678681|NCT04530812|DIETARY_SUPPLEMENT|Kefir|Consume commercial kefir beverage
214349628|NCT01939028|PROCEDURE|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
214349629|NCT01939028|PROCEDURE|sentinel lymph node biopsy|Undergo SLN biopsy
214349630|NCT01939028|DRUG|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
214349631|NCT01939028|DRUG|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
214349632|NCT01939028|PROCEDURE|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
214956907|NCT01263067|BEHAVIORAL|Lifespan Integration Therapy|LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.
214349633|NCT01939028|PROCEDURE|lymphadenectomy|Undergo para-aortic lymphadenectomy
214349634|NCT00164437|BEHAVIORAL|educational CD-ROM|
214349635|NCT04214132|OTHER|Virtual Counselling Application using Artificial Intelligence|Intervention comprises of four Virtual Patients scenarios that aimed to improve nursing undergraduates communication skills in a clinical setting. These scenarios are based on authentic clinical cases (adapted from the real-life clinical case studies) focusing mainly on the communication aspects. Scenarios included 1) a middle-aged pregnant woman in her third trimester experiencing pain, 2) a middle-aged lorry driver who self-admitted to the hospital due to relapse of depressive symptoms, 3) changing a bloody dressing of a middle-aged male patient who had an operation 3 days ago, and 4) communicating with a fellow stressed student during their final preregistration clinical posting period.
214349636|NCT02792075|OTHER|5-year Follow-up|
214349637|NCT01275573|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.
214349638|NCT04226924|DRUG|Trehalose|90 mg/ml trehalose solution for IV infusion
214956908|NCT01263067|BEHAVIORAL|Lifespan Integration- Control|Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
214956909|NCT03654703|DRUG|Cyclophosphamide|cyclophophamide
214349639|NCT04333667|BEHAVIORAL|Intervention group|The intervention consists of 8 modules. Each week participants get access to a new module. Each module consists of psychoeducation and exercise parts. Most of the exercises are based on audio records. The content of the modules includes such themes as awareness and nonjudgement of senses, emotions, and thoughts. Participants can reach a psychologist on demand.
214349640|NCT03649828|DIETARY_SUPPLEMENT|probiotic milk fermented with kefir grains|Participants received probiotic milk fermented with kefir grains for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
214956910|NCT00184002|DRUG|Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone|"Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
214956911|NCT00160121|DRUG|Lanthanum carbonate|
215078422|NCT06602583|DIAGNOSTIC_TEST|Standard Dose Coronary angiography|The radiation exposure of this group would be collected from database of already done studies in the months prior to the initiation of the study (so as to prevent observer bias which may happen once the interventional cardiologist knows his inclusion in study, and may use a shorter or longer cine runs, thus influencing the outcomes). This would best represent the real-world data set, according to the routinely followed standard dose/ older low dose protocol.
215078423|NCT06602583|DIAGNOSTIC_TEST|New low dose angiography|a comparative arm where the patients being once eligible for the study; would undergo angiography using the new low dose protocol.
215078424|NCT06605547|PROCEDURE|Non-surgical periodontal treatment|The non-surgical periodontal treatment (scaling and root planing) was applied under local anesthesia using ultrasonic device and Gracey curettes. After scaling and root planing, periodontal pockets were irrigated using saline solution. Non-surgical periodontal treatment was completed in one or two sessions within 24 hours.
215078425|NCT06605547|DEVICE|Subgingival application of saline|For the subgingival saline application at the control sites, the insulin needle was filled with saline and the 29-gauge needle tip was gently placed into the periodontal pocket. The saline was injected into the periodontal pocket until it was seen to overflow from the gingival margin. Subgingival saline application was repeated on the 7th day.
214678682|NCT04530812|OTHER|Quality-of-Life Assessment|Ancillary studies
214678683|NCT04530812|OTHER|Questionnaire Administration|Ancillary studies
214349641|NCT03649828|DIETARY_SUPPLEMENT|curd|Participants received the curd for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
214349642|NCT06119633|PROCEDURE|Immediate tissue expander and lipofilling after mastectomy|Implant-based breast reconstruction and fat grafting after salvage or prophylactic mastectomy in patients previously exposed to radiation therapy on the breast as adjuvant treatment after breast conserving surgery (BCS) or on thoracic wall for Hodgkin Lymphoma (HL).
214349643|NCT01140191|DRUG|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
214349644|NCT02242747|DRUG|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
214349645|NCT02242747|DRUG|5% 5-FU|two applications a day for four weeks in a pre-determined area
214349646|NCT04838574|OTHER|15 years Follow-up group|Phone recruitment, screening interview and eligibility questionnaire. Patient inclusion during rheumatologic evaluation : questionnaire, examination and data collection in one of the 4 study hospital centers.
214349647|NCT04519918|BEHAVIORAL|AOA|AOA represents an invasive non-physiological technique.
214349648|NCT02001727|OTHER|13C-Urea breath test for Helicobacter Pylori|
214349649|NCT02001727|OTHER|Questionaire|
214349650|NCT06490484|DRUG|HSK16149 20mg BID|Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.
214349651|NCT06490484|DRUG|Pregabalin 150mg BID|Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.
214349652|NCT01573845|BEHAVIORAL|Healthy Eating + Eco-Friendly Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
214349653|NCT01573845|BEHAVIORAL|Healthy Eating Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
214349654|NCT06512662|PROCEDURE|Consultations with paramedics|"Patients of experimental arm will beneficiate of supplemental consultations with paramedics intervenants at 1 month, 3 months and 6 months after surgery :~* dietetician~* speech therapist~* psychologist~* advanced practice nurse~During these consultations, several scales will be performed to assess the patient's condition (anxiety, nutritional status, psychological condition, speech therapy status)."
214349655|NCT05989503|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titration at the discretion of the treating physician
214349656|NCT05989503|DRUG|SGLT2 inhibitor|Either empagliflozin or dapagliflozin 10 mg/day
214349657|NCT02955511|DEVICE|Blade MAC size 3|Patient will be intubated using the DL- Blade MAC size 3
214349658|NCT02955511|DEVICE|Blade MAC size 3.5|Patient will be intubated using the DL- Blade MAC size 3.5
214349659|NCT02955511|DEVICE|Inscope Blade size 3.5|Patient will be intubated using the Inscope Blade size 3.5
214349660|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy|
214349661|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Laser Ablation Therapy|
214349662|NCT03913741|DRUG|tisotumab vedotin|Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
214349663|NCT03955432|DEVICE|Reveal LINQ ICM System|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population.
214349664|NCT00700401|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms/week sc for 24 weeks
214349665|NCT00700401|DRUG|ribavirin [Copegus]|800mg po daily for 24 weeks
214349666|NCT05338788|OTHER|neck pain and dual task|"The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB)."
214349667|NCT04789057|DRUG|Atorvastatin 40 Mg Oral Tablet|p.o., once daily
214349668|NCT04789057|DRUG|Placebo|p.o., once daily
214349669|NCT01220557|BEHAVIORAL|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
214349670|NCT01220557|BEHAVIORAL|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
214349671|NCT02568527|DEVICE|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
214349672|NCT01044004|DRUG|Armodafinil|Armodafinil 150 mg/day for 13 weeks
214349673|NCT01044004|DRUG|placebo|Placebo 150mg/day for 13 weeks
214349674|NCT01044004|DRUG|Armodafinil|Armodafinil 150 mg/day for 13 weeks
214349675|NCT01044004|DRUG|placebo|Placebo 150mg/day for 13 weeks
214678684|NCT06532461|DEVICE|Mio Advanced infusions set|Insulin infusionsset fitting Medtronic 780 G insulin pump
214956912|NCT03800680|BEHAVIORAL|Diabetes Management Package (DMP)|"M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~* Complete all 24 GlycoLeap lessons and quizzes~* Weight Monitoring: Weigh at least once a week.~* Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~* Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~* Medication: Take medications as prescribed."
214956913|NCT03800680|BEHAVIORAL|M-POWER Rewards|A financial incentive program were participants can earn up to 516 M-Points (1 M-Point is equivalent to S$1) over the one-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
214956914|NCT00484926|DRUG|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
214956915|NCT00484926|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
214349676|NCT06705855|DEVICE|NIRS sensor placement|After written informed consent, the patient will be brought to the operating room. Skin tone will be assessed using the Monk scale. Prior to induction of general anesthesia, the right kidney will be located by surface ultrasound, the distance between the renal capsule and the skin will be measured, and a NIRS sensor will be placed on the skin overlaying the kidney. If the patient has had a right nephrectomy, the left kidney will be used. Additional NIRS sensors will then be placed over the patient's ipsilateral biceps and vastus lateralis muscles. The distance from the skin to the muscle tissue will be measured and recorded using ultrasound. NIRS sensors will also be placed on the patient's forehead to measure cerebral oximetry as is current practice at our institution for all cardiac surgeries requiring cardiopulmonary bypass.
214349677|NCT03969069|DEVICE|MAPLe|Additional assessment with MAPLe
214349678|NCT01913067|DRUG|Cabazitaxel|Intravenous, 25 mg/m2 every 3 weeks
214349679|NCT01913067|PROCEDURE|Contrast-enhanced whole brain MRI|Evaluation of the volumetric reduction in the size of the brain lesion(s).
214349680|NCT03715933|DRUG|INBRX-109|Tetravalent DR5 Agonist Antibody
214349681|NCT03715933|DRUG|Carboplatin|Chemotherapy
214349682|NCT03715933|DRUG|Cisplatin|Chemotherapy
214956916|NCT01005784|DRUG|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
214956917|NCT01005784|DRUG|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
214956918|NCT01579669|BEHAVIORAL|Use of toolkit|Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
214956919|NCT02515903|PROCEDURE|Intra-endoscopic surgery|Intra-endoscopic surgery for evacuation of ICH
214956920|NCT02515903|PROCEDURE|Placebo:stereotactic aspiration surgery|Placebo:stereotactic aspiration surgery for evacuation of ICH
214956921|NCT04959799|DRUG|Dalbavancin|Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.
214956922|NCT04999943|BIOLOGICAL|DC vaccine|EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
214956923|NCT01512589|RADIATION|Proton Beam Therapy (PBT)|1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
214956924|NCT01512589|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
214956925|NCT01512589|BEHAVIORAL|Questionnaires|Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
214956926|NCT05366114|OTHER|No intervention, additional video data collection only|No intervention will be used. Consenting participants will have video recordings taken during their exam of joint hypermobility which will be analyzed at a later time
214349683|NCT03715933|DRUG|Pemetrexed|Chemotherapy
214349684|NCT03715933|DRUG|5-fluorouracil|Chemotherapy
214349685|NCT03715933|DRUG|Irinotecan|Chemotherapy
214349686|NCT03715933|DRUG|Temozolomide|Chemotherapy
214349687|NCT05289362|DEVICE|Basket group|Under ERCP, the basket is preferentially used to remove the pancreatic duct stones, and then the balloon is used to evaluate the effect and remove the residual stones.
214349688|NCT05289362|DEVICE|Balloon group|Under ERCP, the balloon is preferentially used to remove the pancreatic duct stones, and then the basket is used to evaluate the effect and remove the residual stones.
214956927|NCT00527124|DRUG|cediranib maleate|Given orally
214956928|NCT00527124|DRUG|docetaxel|Given IV
214956929|NCT00527124|DRUG|prednisone|Given orally
214956930|NCT00527124|OTHER|laboratory biomarker analysis|Correlative studies
214956931|NCT05488769|DEVICE|Clareon Vivity extended depth of focus (EDOF) intraocular lens|Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
214349689|NCT04721054|DRUG|Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)|patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
214349690|NCT04721054|DRUG|general anesthesia effect on heart rate in Laparoscopic Cholecystectomy|patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
214678685|NCT06532461|DRUG|Novorapid|Randomized to either Novorapid or Humalog
214678686|NCT06532461|DEVICE|Extended wear insulin infusion (EWIS)|Insulin infusionsset fitting Medtronic 780 G insulin pump
214349691|NCT04561479|OTHER|Pulmonary Rehabilitation|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session. Training group will receive upper extremity aerobic exercise training using arm ergometer at 60-80% of maximal heart rate (dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale). Inspiratory muscle training (Powerbreathe® Wellness-Inspiratory Muscle Trainer) at 50-60% of maximal inspiratory pressure (MIP) and progressive resistance training at 30-60% of 1 RM (using proprioceptive neuromuscular facilitation techniques (flexion, abduction, external rotation/extension, adduction, internal rotation) for upper extremity resistance training; using sandback for knee extensors) will be performed during 24 sessions (3 day/week; 8 weeks)
214349692|NCT04561479|OTHER|Alternative Exercises|Control group will receive alternative upper extremity exercises combined with breathing exercises. Control group will perform alternative upper extremity exercises combined with breathing exercises during 3 days/week, for 8 weeks
214349693|NCT05246423|DIAGNOSTIC_TEST|Observation group|Patients with paroxysmal atrial fibrillation undergo cardiopulmonary exercise testing, echocardiography, 24-hour ambulatory electrocardiographic monitoring and plasma biomarkers' measurement
214349694|NCT01650259|DRUG|OAD|OAD except Trazenta tablets
214349695|NCT01650259|DRUG|Trazenta|Linagliptin
214349696|NCT00987974|DRUG|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
214349697|NCT00987974|DRUG|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
214349698|NCT00987974|DRUG|placebo|placebo for 3 days.
214349699|NCT00987974|DRUG|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
214349700|NCT00987974|DRUG|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
214349701|NCT00987974|DRUG|placebo 7 days|placebo 7 days
214349702|NCT01371344|DRUG|Tacrolimus granules|oral
214349703|NCT01371344|DRUG|Tacrolimus capsules|oral
214349704|NCT04984148|DIAGNOSTIC_TEST|CT|Contrast-enhanced thoracic computed tomography
214349705|NCT06180824|DRUG|Gelafundin|"Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment."
214349706|NCT06565507|DRUG|Oxfendazole single dose|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, as a single dose. Oxfendazole placebo will be used at days 4 and 7 to maintain blinding between the two intervention arms.
214349707|NCT06565507|DRUG|Oxfendazole three doses|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, in three days (1, 4 and 7)
214349708|NCT06565507|DRUG|albendazole plus praziquantel regime|Subjects will receive a combination of albendazole plus praziquantel, as a standard treatment for brain cysticercosis (neurocysticercosis), orally, for ten days. Albendazole will be given at 15/kg/d and praziquantel at 50/kg/d.
214349709|NCT04139395|DRUG|68Ga-Citrate PET/MRI|Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
214349710|NCT04139395|DRUG|67Ga-Citrate SPECT|67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan
214349711|NCT04139395|DEVICE|Positron Emission Tomography|Imaging with 68Ga-Citrate PET/MRI
214956932|NCT02239445|DRUG|chloral hydrate Group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
214956933|NCT02239445|DRUG|low dose dexmedetomidine group|Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
214349712|NCT04139395|DEVICE|Magnetic Resonance Imaging|Imaging with 68Ga-Citrate PET/MRI
214349713|NCT04139395|DEVICE|SPECT|Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
214349714|NCT06410066|OTHER|no intervention|
214349715|NCT04968548|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
214486742|NCT06677112|PROCEDURE|REFLEX|The surgeon will perform a side-specific lymphadenectomy when there is no mapping on a hemipelvis (no tracer uptake in nodes). If neither side has successful Sentinel Node mapping, the surgeon performs a complete pelvic lymphadenectomy. Surgeons will remove the para-aortic lymph nodes at their discretion.
214486743|NCT06619483|DRUG|BAY3018250 Dose 1|Single dose
214349716|NCT03467659|OTHER|Cracked whole wheat porridge|Large particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
214349717|NCT03467659|OTHER|Semolina wheat porridge|Large particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
214349718|NCT03467659|OTHER|Whole wheat flour porridge|Small particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
214349719|NCT03467659|OTHER|Refined wheat flour porridge|Small particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
214349720|NCT03467659|OTHER|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
214349721|NCT03467659|OTHER|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
214349722|NCT00323102|DRUG|Multihance|
214349723|NCT04537195|BEHAVIORAL|ADSMP-C|A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)
214956934|NCT02239445|DRUG|high dose dexmedetomidine group|Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
214349724|NCT03188939|PROCEDURE|single injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
214349725|NCT03188939|PROCEDURE|intracluster injection supraclavicular brachial pieuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
214349726|NCT03188939|PROCEDURE|double injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
214349727|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
214349728|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
214349729|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
214349730|NCT00966316|DRUG|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
214349731|NCT04418804|DIAGNOSTIC_TEST|Chest ultrasound|"Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient."
214349732|NCT03563495|OTHER|tissue engineered group|cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)
214486744|NCT06619483|DRUG|Placebo|Matching placebo to BAY3018250
214956935|NCT06107855|OTHER|Leg Press Resistance Training Machine|Participants used said unilateral leg press at 60% one-repetition max for either 3 sets x 5 reps, or 5 sets x 5 reps, at either maximal- or controlled-tempo-intent.
214486745|NCT06619483|DRUG|BAY3018250 Dose 2|Single dose
214956936|NCT00679848|DEVICE|RS2 (RESTORe Suturing System)|Suturing in stomach
214956937|NCT05044247|PROCEDURE|ESP blocks|ultrasound and fluoroscopy to identify the spread of drug
214349733|NCT03563495|PROCEDURE|autogenous bone graft group|
214486746|NCT04894864|DRUG|Opioid-Based Anesthesia-Analgesia Strategy|A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.
214486747|NCT04894864|DRUG|Opioid-free Anesthesia-Analgesia Strategy|A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
214486748|NCT04037007|PROCEDURE|Fistulotomy - High experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
214678687|NCT06532461|DRUG|Humalog|Randomized to either Novorapid or Humalog
214678688|NCT00163553|DRUG|Pethidine|
214678689|NCT00163553|DRUG|Placebo|
214956938|NCT00828269|PROCEDURE|Comparator: Fine needle aspiration biopsy|"Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit"
214349734|NCT02960529|PROCEDURE|extra-peritoneal high ligation of hernia|
214349735|NCT02960529|PROCEDURE|intraabdominal high ligation of hernia|
214349736|NCT02676869|DRUG|IMP321 (eftilagimod alpha)|"Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks"
214349737|NCT02676869|DRUG|Pembrolizumab|Administered according to the approved label.
214349738|NCT03183427|DIAGNOSTIC_TEST|MR of the brain|MR of the brain without gadolinium, incl. T2-weighted image
214349739|NCT01024322|DRUG|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
214956939|NCT00392756|DRUG|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
214956940|NCT04628000|OTHER|Vitamin D|Clinical Correlation
214349740|NCT01024322|DRUG|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
214956941|NCT02915250|DRUG|BioChaperone® Combo|Injection of BioChaperone® Combo
214349741|NCT01024322|DRUG|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
214349742|NCT00411567|DRUG|inhaled corticosteroid therapy|
214349743|NCT01415830|BIOLOGICAL|Anti-scorpion venom serum Birmex|the dose may be required for the patient according to clinical manifestations and evolution
214349744|NCT01415830|BIOLOGICAL|Anti-scorpion venom serum Alacramyn|The dose may be required fot the patient according to clinical manifestations and evolution
214349745|NCT03516318|BEHAVIORAL|SMART Connections|SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
214349746|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
214349747|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
214349748|NCT00781625|DIETARY_SUPPLEMENT|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
214956942|NCT02915250|DRUG|Humalog® Mix25|Injection of Humalog® Mix25
214956943|NCT02915250|DRUG|Humalog®|Injection of Humalog®
214956944|NCT02915250|DRUG|Lantus®|Injection of Lantus®
214956945|NCT02915250|DRUG|Placebo|Injection of 0.9% NaCl
214956946|NCT05825963|DIETARY_SUPPLEMENT|Psyllium|The participants select hamburgers randomly by themselves, with or without (control) 12 g of psyllium, each containing 85 g of hamburger bread, 160 g of 20% fat beef, 2.56 g of salt, and 1.28 g of pepper, and asked to consume them with 200 ml of water.
214956947|NCT06154421|PROCEDURE|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
214956948|NCT06154421|PROCEDURE|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
214956949|NCT05118763|DRUG|INNA-051|Liquid for intranasal administration
214956950|NCT05118763|OTHER|Placebo|Liquid for intranasal administration
214956951|NCT05682599|DRUG|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
214956952|NCT05682599|DRUG|Placebo|Placebo
214956953|NCT00632645|DRUG|Olanzapine|Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
214956954|NCT00632645|DRUG|Xenazine|Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
214349749|NCT06961435|BIOLOGICAL|Vedolizumab|Intravenous injection of VDZ (300mg/time) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of VDZ every 8 weeks to maintain treatment.
214678690|NCT04877015|DEVICE|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
214956955|NCT00632645|DRUG|Tiapridal|Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
214956956|NCT02075008|DRUG|QGE031|QGE031 120 mg/mL solution for subcutaneous injection
214956957|NCT00660595|DRUG|Quetiapine|Oral administration
214956958|NCT00660595|DRUG|Risperidone|Oral administration
214956959|NCT02711020|BEHAVIORAL|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
214349750|NCT04782323|DRUG|aQII-1|Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214678691|NCT04877015|DEVICE|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
214678692|NCT06138847|DIAGNOSTIC_TEST|electroencephalogram|Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages
214956960|NCT02711020|BEHAVIORAL|Personal Construct Therapy|"Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives."
214956961|NCT05784701|DRUG|TSCV (Full-strength)|TSCV (Full-strength)
214956962|NCT05784701|DRUG|TSCV (Half-strength)|TSCV (Half-strength)
214349751|NCT04782323|DRUG|aQII-3 Investigational|Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214349752|NCT04782323|DRUG|aQII-6 Investigational|Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214349753|NCT04782323|OTHER|aQII-7 Investigational|Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214349754|NCT04782323|DRUG|aQII-9 Investigational|Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214349755|NCT04782323|DRUG|aQII-10 Investigational|Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214349756|NCT04782323|DRUG|aQII-11 Investigational|Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214349757|NCT04782323|DRUG|Licensed QII Active Comparator|Biological/Vaccine: Licensed QII Licensed Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
214349758|NCT05104658|OTHER|Patient-targeted rehabilitation offers|In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
214349759|NCT06305351|DRUG|K-757 and K-833 QD|Both administered orally once daily
214349760|NCT06305351|DRUG|K-757 and K-833 BID|Both administered orally twice daily
214349761|NCT06305351|DRUG|Matching placebo to K-757 and K-833 QD|Both administered orally once daily
214349762|NCT06305351|DRUG|Matching placebo to K-757 and K-833 BID|Both administered orally twice daily
214349763|NCT05893992|DEVICE|Hearing aids with noise management features for listening in noise|Device for hearing loss compensation with digital noise management features
214349764|NCT05893992|DEVICE|Hearing aid for listening in quiet environments|Device for hearing loss compensation for listening in quiet environments
214349765|NCT04508322|DEVICE|HGA|Headgear Activator
214956963|NCT05784701|DRUG|Typbar-TCV|Typbar-TCV
214956964|NCT05784701|DRUG|Placebo|Placebo
214956965|NCT00898872|OTHER|cryopreservation|
214349766|NCT04508322|DEVICE|FA|Fixed Orthodontic Appliance
214349767|NCT03658720|DRUG|200 mg Ibuprofen acid orodispersible tablet|orodispersible tablet
214678693|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens with comfort additive|
214956966|NCT00493311|DRUG|IV Placebo|IV Placebo
214956967|NCT00493311|DRUG|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
214956968|NCT00493311|BIOLOGICAL|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
214678694|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens|
214956969|NCT02779075|DRUG|Saline|Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.
214678695|NCT01421290|PROCEDURE|Surgery|Knee surgery
214678696|NCT01421290|OTHER|Conservative comparator|Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
214956970|NCT02779075|DRUG|Exendin-9,39|Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
214349768|NCT06433687|DEVICE|HekaHeart platform medication management and remote monitoring|Onboarding to the HekaHeart platform which includes a personalized GDMT management plan along with remote monitoring kits including a scale, blood pressure cuff, and heart rate monitor. Patients engage in video and phone calls with clinicians who will use established standardized clinical protocols to guide medication and vital optimization. Once patients are determined to be maximally titrated on all GDMT, they are transitioned back to standard clinical care.
214349769|NCT01359735|BIOLOGICAL|HP802-247|High dose HP 802-247, applied at each visit (Week 1-13) or until healed
214349770|NCT01359735|BIOLOGICAL|Bacitracin Ointment|One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
214349771|NCT06560918|DEVICE|hearing aids|OTC devices for a week
214349772|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum|The therapist will coach parents in the context of clinic-based play activities and help parents identify contexts and activities at home where the parents could follow up on the program at home. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
214956971|NCT03999359|OTHER|Home-based Metacognitive Therapy|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
214486749|NCT04037007|PROCEDURE|Fistulotomy - Low experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
214486750|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation- High experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
214956972|NCT04299867|PROCEDURE|Bowel Surgery with Metronidazole|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
214956973|NCT05743777|DRUG|Pembrolizumab|400 mg IV q6 weekly for a maximum of 18 cycles
214956974|NCT05743777|DRUG|MET-4|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
214956975|NCT05743777|DRUG|Placebo|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
214349773|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum - Telerehabilitation|Parent-child interactions during activities at home will be observed through video conferencing. Parents will be encouraged to interact with their child using strategies aimed at increasing their child's attention and motivation, turn-taking routines, initiating and responding to joint attention, communication, etc. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
214349774|NCT04710797|PROCEDURE|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels~* The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve"
214956976|NCT04241016|PROCEDURE|Endoscopic sinus surgery (ESS)|Uncinectomy, middle meatal antrostomy by enlarging the natural maxillary ostium and partial ethmoidectomy or septoplasty according to clinical evaluation of the operator.
214956977|NCT04824742|PROCEDURE|Neoadjuvant PDT + radical surgery|Patients with cholangiocarcinoma will undergo radical surgery after photodynamic therapy
215078426|NCT06605547|OTHER|Subgingival application of i-PRF|For subgingival application of i-PRF at the test sites, the i-PRF taken into the insulin syringe, the 29-gauge needle tip was gently placed into the periodontal pocket and the i-PRF was injected into the periodontal pocket until it reached the gingival margin (until it overflowed from the sulcus). Subgingival i-PRF application was repeated on the 7th day.
215078427|NCT02141698|DRUG|TAK-438|TAK-438 tablets
215078428|NCT02141698|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
215078429|NCT02141698|DRUG|Esomeprazole|Esomeprazole tablets
214956978|NCT04824742|PROCEDURE|Radical surgery|Patients with cholangiocarcinoma will only receive radical surgery
214956979|NCT05333796|BEHAVIORAL|gait with leg length discrepancy|After attaching the surface electromyography(EMG) to bilateral back muscles, participants walk at a comfortable speed. The investigators will evaluate the effects of leg length discrepancy on the back muscle activation during gait.
214349775|NCT04710797|PROCEDURE|Comprehensive staging surgery with no Lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes"
214956980|NCT02347735|OTHER|No interventions, only data collection|Only data is collected from the subjects in both groups.
215078430|NCT06521515|DIAGNOSTIC_TEST|Lung Ultrasound Morphology Patterns|Two blinded investigators conducted daily lung ultrasound examinations. Each lung was scanned in six regions, categorizing ultrasound findings into four aeration patterns: normal (N-score 0), moderate (B1-lines score 1), severe (B2-lines score 2), and consolidation (C-score 3). The global LUS score ranged from 0 to 36. Patients were grouped into TLP if they exhibited a tissue-like pattern in any region or DBP if they displayed diffuse B-lines and shred signs in most regions. Localized TLPs indicated concentrated areas of non-aeration.
214349776|NCT02693444|DRUG|Lidocaine|
214486751|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation - Low experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
214956981|NCT04728698|DRUG|COVI-MSC|1 x 10\^6 MSCs/kg or 1.5 x 10\^6 MSCs/kg, depending on CRP level
214956982|NCT04728698|DRUG|Placebo|Equivalent volume of placebo will be administered
214956983|NCT05905081|OTHER|aerobic exercise|30-minutes aerobic exercise intervention on the bicycle ergometer. The exercise protocol includes 5 minutes of warm-up, 20 minutes of loading and 5 minutes of cool-down. The intensity of the exercise will be adjusted to be between 46% and 63% of the VO2max calculated according to the exercise programming guide published by the American College of Sports Medicine (ACSM), and the perceived effort level on the Borg scale will be 12-13. Warm-up and cool-down periods will be set to 46% of VO2max and Borg perceived exertion level below 9.
214956984|NCT03639129|DEVICE|Contrast-enhanced mammography|Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world
214956985|NCT03639129|PROCEDURE|Biopsy|Standard of care
214956986|NCT06163027|DEVICE|Shotblocker|Shotblocher will be administered during spinal needle injection
214956987|NCT06163027|OTHER|Shotblocker(Plasebo)|The back side of the shotblocher will be applied during spinal needle injection
214956988|NCT03416478|DIAGNOSTIC_TEST|ctDNA test|ctDNA test to find some possible mutation.
214956989|NCT03456687|DRUG|Exenatide|Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
214956990|NCT01057290|GENETIC|gene expression analysis|
214956991|NCT01057290|GENETIC|protein expression analysis|
214956992|NCT01057290|OTHER|fluorescence activated cell sorting|
215078431|NCT06660953|PROCEDURE|Erector Spinae Plane Block|For ESP, high frequency linear ultrasound probe was planned transversely to the midline and spinous features were visualized. Cervical C7 and T7 vertebrae at the lower end of the scapula, which were accepted as landmarks, were determined and marked with a sterile surgical drawing pen. According to these landmarks, the USG probe was moved 2-3 cm laterally towards the points where kidney transplantation was planned at the T10 vertebral level, and the transverse parts, trapezius, latissimus dorsi, serratus and erector spina muscles were visualized. Using the block needle that can be visualized on USG with in-plane surgery, the skin, subcutaneous tissue and trapezius, latissimus dorsi, serratus and erector spina muscles were passed in a cranio caudal direction and the needle location was confirmed by hydrodissection with 2-5 ml of serum. The distribution of the block procedure and the spread of local anesthetic were linearly visualized with 10 ml bupivacaine and 10 ml 0.9% saline.
214349777|NCT02693444|DRUG|Saline|
214349778|NCT02779257|DRUG|Pasireotide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
214956993|NCT01057290|OTHER|immunologic technique|
214956994|NCT01057290|OTHER|laboratory biomarker analysis|
214956995|NCT03440138|PROCEDURE|bariatric surgery (RYGB or SG)|laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity
214956996|NCT05795972|DIETARY_SUPPLEMENT|inulin|patients treated with standard therapy with a supplementation of Inulin 6g twice a day for 3 months.
214956997|NCT05795972|OTHER|standard therapy|control group (patients treated also with standard therapy)
214349779|NCT02779257|DRUG|Diazoxide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
214349780|NCT02719405|DIETARY_SUPPLEMENT|Lactobacillus GG|Lactobacillus GG
214349781|NCT02719405|DIETARY_SUPPLEMENT|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
214349782|NCT02719405|DIETARY_SUPPLEMENT|Amino Acid Formula|Amino Acid Formula
214349783|NCT02663128|DRUG|Lanabecestat|Administered orally
214349784|NCT03022357|OTHER|Patient assessment|Clinical examination, Examination, Questionnaires
214349785|NCT03022357|RADIATION|DATScan|In small subgroup
214349786|NCT03022357|RADIATION|Orbital X-Ray|If foreign body in eye needs exclusion
214956998|NCT05421780|DIETARY_SUPPLEMENT|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits as breakfast.
214956999|NCT05421780|DIETARY_SUPPLEMENT|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits as breakfast.
214957000|NCT05421780|DIETARY_SUPPLEMENT|control biscuits|Consumption of plain biscuits as breakfast.
214957001|NCT00970671|OTHER|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
214957002|NCT00970671|OTHER|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
214957003|NCT00970671|OTHER|No treatment|No laser treatment
214349787|NCT03022357|OTHER|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
214349788|NCT04475003|OTHER|Teaching|Teaching session about anaphylaxis
214957004|NCT02296762|DRUG|Sirolimus|Sirolimus tablets 2 mg
214957005|NCT03959527|DRUG|zoliflodacin|Dose: 3g, oral administration
214957006|NCT03959527|DRUG|ceftriaxone|Dose: 500mg, Intra-Muscular (IM) administration
214957007|NCT03959527|DRUG|azithromycin|Dose: 1g, oral administration
215078432|NCT06660953|PROCEDURE|Quadratus Lumborum Block (QLB)|The QL block II was done under aseptic technique, in lateral position with the side intended to block side up. A high frequency ultrasound linear probe covered in sterile sheath was placed anterior and superior to the iliac crest. The three anterior abdominal muscles were visualized. The external oblique muscle was followed posterolaterally until its posterior border was identified. Subsequently, the probe was tilted towards the attachment site of both the internal and external oblique muscles over the quadratus (QL) muscle until the midline of the thoracolumbar fascia was seen as a bright hyperechogenic line located between the posterior border of the quadratus lumborum muscle and the middle thoraco-lumbar fascia (anterior to latissiumus dorsi and erector spinae muscles). A 22-gauge Facet-tip SonoPlex needle of appropriate length estimated from the depth and length of required needle trajectory during scout scanning was inserted via in-plane technique. The needle was directed from a
215078433|NCT06658210|OTHER|soft tissue mobilization with pelvic floor muscle exercises|Group A will receive soft tissue mobilization and pelvic floor muscle exercises. Soft tissue mobilization technique will include abdominal myofascial release/trigger point release and deep scar mobilization to decrease pain and improve scar mobility
215078434|NCT06658210|OTHER|soft tissue mobilization without pelvic floor muscle exercises|Group B will receive soft tissue mobilization technique without pelvic floor exercises.
214349789|NCT01903655|OTHER|telomere length|
214349790|NCT05344105|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
214349791|NCT02886845|GENETIC|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
214349792|NCT00105027|OTHER|Standard Care|CRVO: observation; BRVO: standard care
214957008|NCT00258193|DRUG|MD-1100 Acetate|
214957009|NCT05644678|DEVICE|Fixed appliances|Metal brackets with a straight-wire prescription will be used. Patients will be treated conventionally.
214349793|NCT00105027|DRUG|intravitreal triamcinolone injection|1 mg dose
214349794|NCT00105027|DRUG|intravitreal triamcinolone injection|4 mg
214349795|NCT02313012|DRUG|CC-90003|CC-90003 PO once daily
214349796|NCT06645119|DIETARY_SUPPLEMENT|Whey Protein Supplement|Examining the independent effect of post-exercise dietary protein ingestion on bone metabolic markers.
214349797|NCT02826226|DEVICE|multiple-breath-washout test|
214957010|NCT05644678|PROCEDURE|Corticotomy|Patients will be treated in conjunction with a surgical intervention using metal brackets with a straight-wire prescription. Corticotomy (alveolar perforation and piezocision) will induce acceleration in canine traction movement during the orthodontic treatment in only one group.
214957011|NCT04200183|BEHAVIORAL|iACTwithPain (ACT+compassion)|This intervention will deliver a eHealth ACT and compassion-based therapy (iACTwithPain) designed for chronic pain
214957012|NCT04200183|BEHAVIORAL|ACT-only intervention|This intervention will deliver the iACTwithPain intervention but without the delivery of explicit compassion.
214957013|NCT00707980|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
214957014|NCT04116008|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
214957015|NCT04716621|OTHER|Early intervention|"The Pain Management Support System for Primary Care (PMSS-PC) generated best practice alerts and gave clinicians access to a pain assessment template, measures of psychological distress and substance use, guidelines for drug and non-drug therapies, and facilitated referrals. At implementation, clinicians at the practices were offered in-person and virtual education through six webinars on best practices for pain."
214957016|NCT04716621|OTHER|Delayed intervention|Delayed wait-list control group. The second arm involved three additional sites receiving the PMSS-PC intervention 6 months after the first arm. Initial outcomes from the PMSS-PC Experimental Intervention arm were compared to those of this Wait-list Control arm.
214957017|NCT03545932|OTHER|exercise program hydrogymnastics|4 months of practice hydrogymnastics
214349798|NCT02826226|DRUG|Bronchodilator Agents|
214349799|NCT02699281|DRUG|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
214349800|NCT02699281|DRUG|Placebo|um-PEA like placebo twice a day
214349801|NCT00194922|DIETARY_SUPPLEMENT|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
214349802|NCT01778465|BEHAVIORAL|Low salicylate diet|Participants followed a 7 days period under a Low salicylate diet
214349803|NCT01778465|BEHAVIORAL|Normal Diet|Participants followed a 7 days period under a Normal Diet
214957018|NCT00734461|DRUG|oxycodone and naltrexone|"tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone"
214957019|NCT04404348|BEHAVIORAL|Cognitive Training|Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.
214957020|NCT04404348|BEHAVIORAL|Placebo Control|Games are drawn from the set of research control games provided by Posit Science-Brain HQ.
214349804|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain Plus dexamethasone|Bupivacain 0.1%, 35 ml with dexmedetomidine 0.5 µG/kg on each side
214349805|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain|plain bupivacaine 0.25%, 25 ml bilaterally
214349806|NCT02715765|DEVICE|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
214349807|NCT02715765|DEVICE|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
215078435|NCT06662071|OTHER|Organoid culture|Organoid culture of tumor tissue obtained during patient surgery
214957021|NCT05587894|DRUG|Paxlovid 5 days|"Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19."
214957022|NCT05587894|DRUG|Paxlovid 10 days|Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
214957023|NCT05587894|DRUG|Veklury|"Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound."
214957024|NCT00190164|PROCEDURE|Macular hole surgery with alleviated positioning|Macular hole surgery with alleviated positioning
214957025|NCT00190164|PROCEDURE|Macular hole surgery with no alleviated positioning|Macular hole surgery with no alleviated positioning
214957026|NCT04168255|PROCEDURE|Double tamponade|Double tamponade procedure in retinal detachment with PVR and inferior breaks
214957027|NCT04061278|DRUG|4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy|4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
214957028|NCT04061278|DRUG|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy
214957029|NCT00680615|BEHAVIORAL|Tailored, enhanced condition|Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
214957030|NCT00680615|BEHAVIORAL|Usual Care|The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
215078436|NCT06659510|OTHER|education|ACCORDING TO THE RESULTS AFTER THE SURVEY APPLICATION, TRAINING WAS PROVIDED TO THE ADDICTIVE STUDENTS IN THE EXPERIMENT GROUP AND MESSAGES WERE SENT FROM WHATSAPP APPLICATION IN THE FOLLOWING 2 MONTHS AFTER THE TRAINING.
215078437|NCT06660329|DRUG|Janus Kinase Inhibitor|Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
215078438|NCT06661772|DIAGNOSTIC_TEST|Vancomycin trough concentration method|A blood sample for VTL was drawn 30 minutes before administration, prior to the fourth dose of vancomycin, under a complete aseptic technique, unless otherwise ordered by the medical team. Vancomycin serum concentrations were measured using a Human vancomycin ELISA Kit.
215078439|NCT06662331|PROCEDURE|Bilateral Sagittal Split Osteotomy|A surgical procedure to correct dentofacial deformities
214957031|NCT02479113|PROCEDURE|Blood sampling|At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine
214957032|NCT01152996|DRUG|Vortioxetine|Vortioxetine tablets
214957033|NCT00242515|PROCEDURE|CD8+ T-cell depleted donor lymphocyte infusion|
214957034|NCT01481402|DRUG|Liothyronine|Liothyronine 40 microgram per day
214957035|NCT01481402|DRUG|Liothyronine|3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
214957036|NCT02163681|DRUG|Hyperpolarized Helium-3 MRI of the chest|hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
214957037|NCT02695862|DRUG|Terlipressin|
214957038|NCT02072941|BEHAVIORAL|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
214957039|NCT01226017|OTHER|Measuring oxytocin level in blood|Blood sampling and instruments measuring anxiety and stress
214349808|NCT02715765|DEVICE|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
214349809|NCT05544968|DRUG|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells
214349810|NCT05544968|DRUG|GM-CSF|Hematopoietic agent that helps form white blood cells.
214349811|NCT00917046|BEHAVIORAL|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
214349812|NCT00917046|BEHAVIORAL|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
214349813|NCT00917046|BEHAVIORAL|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
214349814|NCT04107090|OTHER|lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
214349815|NCT04107090|OTHER|tracheal IL-6 level|tracheal IL-6 level was measured before and after recruitment maneuver
214349816|NCT04107090|OTHER|US guided lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
214349817|NCT02060890|OTHER|specialized tumor board recommendation|feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
214349818|NCT01517698|DRUG|Placebo|placebo to RO4917523 orally once a day for 12 weeks
214349819|NCT01517698|DRUG|RO4917523 0.5 mg|0.5 mg orally once a day for 12 weeks
214957040|NCT06525051|DRUG|Tiotropium|Tiotropium is a long-acting anticholinergic agent and has a bronchodilator effect. According to the COPD Gold 2024 guideline, it is one of the long-acting bronchodilator drugs used as the first choice in the treatment of group A COPD patients.
214957041|NCT05522946|OTHER|Gameplay between parent and child or adolescent with or without a disability|Parent and child or adolescent will play the game using the provided sensors for 10-15 minutes total. Depending on the cognitive and/or physical ability of the child or adolescent, the two may take turns wearing the sensors or if the child or adolescent does not have the physical or cognitive ability to deliberately touch the sensor, then the child or adolescent will wear the sensors and the parent will touch the sensors in order to move the game forward.
214349820|NCT01517698|DRUG|RO4917523 1.5 mg|1.5 mg orally once a day for 12 weeks
214349821|NCT04173533|DRUG|Oral azacitidine|Oral azacitidine (CC-486) 200 mg tablet
214349822|NCT04173533|DRUG|Matched placebo|Oral azacitidine (CC-486) matched placebo tablet
214349823|NCT02717793|OTHER|Strength testing|"isometric muscle strength~1RM measurement of muscle strength"
214349824|NCT04039516|DRUG|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
214349825|NCT04864015|DEVICE|Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable|Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
214349826|NCT00949026|DRUG|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
214349827|NCT00335660|DRUG|AV608|
214349828|NCT05273710|OTHER|Regular toast and juice|Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.
214349829|NCT05273710|OTHER|High phytate toast and juice|Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.
214349830|NCT05273710|OTHER|Regular toast and juice, with folic acid|Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
214349831|NCT05090072|BEHAVIORAL|Advance Directives|The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document
214349832|NCT05090072|BEHAVIORAL|Control|The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
214957042|NCT01471275|DRUG|Metformin|250 mg or 500mg three times a day
214957043|NCT01471275|DRUG|Jiangtangtiaozhi decoction|15 grams each time, twice a day, with boiled water
214957044|NCT03146741|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
214957045|NCT03783286|DRUG|Ivacaftor|Ivacaftor (Kalydeco®, Vertex Pharmaceuticals Inc.) was the first of a new class of drugs that improved CFTR gating dysfunction (2, 3, 4). For such mutations (G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D) that permit CFTR expression at the cell membrane but compromise its activity.
214349833|NCT00581529|RADIATION|IMRT|Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
214349834|NCT00801827|DRUG|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
214957046|NCT03683563|OTHER|4% sodium citrate|the catheter will be locked with 4% citrate solution after each dialysis session
214349835|NCT03387852|DRUG|SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
214349836|NCT03387852|DRUG|Dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
214349837|NCT03387852|DRUG|Fluticasone or Fluticasone/salmeterol combination|Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
214349838|NCT03387852|DRUG|Placebo for SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
214349839|NCT03387852|DRUG|Placebo for dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
214957047|NCT03683563|OTHER|30% sodium citrate|the catheter will be locked with 30% citrate solution after each dialysis session
214349840|NCT02596451|DRUG|Diclofenac Sodium gel, 1%|
214349841|NCT02596451|DRUG|Voltaren® Gel|
214349842|NCT02596451|DRUG|Placebo|
214349843|NCT05818449|OTHER|DigiNet intervention|"Patients with initial diagnosis of NSCLC stage IV in the model region receiving the following interventions:~* broad NGS-based molecular diagnostics and, based thereupon, personalized treatment information within the national Network Genomic Medicine (nNGM) lung cancer~* regular clinical follow-up visits and data documentation in the shared central digital database by participating physicians~* monthly assessment of patient-reported outcomes (PRO) on quality of life, anxiety, and depression~* incorporation of PROs into treatment by physicians~* treatment monitoring and counseling in the case of critical conditions by expert committee"
214349844|NCT00004093|DRUG|carboplatin|Carboplatin will be dosed at a target AUC of 5, and will be given on day 1 of each cycle
214349845|NCT00004093|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of each 21-day cycle of induction chemo (following carboplatin on day 1).
214349846|NCT00004093|DRUG|paclitaxel|Paclitaxel will be given on day 1 of each week for 6 weeks at a dose of 50 mg/m2.
214349847|NCT00004093|DRUG|vinorelbine|Vinorelbine will be given on day 1 of each week for 6 weeks at a starting dose of 10 mg/m2, escalating up to 15 mg/m2 if no dose limiting toxicities are observed.
214349848|NCT00004093|RADIATION|radiation therapy|Radiation will be given at a dose ranging between 45 to 66 Gy, depending on patient-specific characteristics.
214349849|NCT00004093|DRUG|Navelbine|Navelbine will be administered at a dose of 10-15 mg/m2 in 100 cc NS to be administered over 10 minutes I.V. (one dose weekly during radiation therapy)
214349850|NCT00004093|DRUG|Taxol|Taxol will be administered at a dose of 50 mg/m2 in 250 cc of NS or D5W over 60 minutes, following Navelbine (one dose weekly during radiation therapy)
214349851|NCT03590301|BEHAVIORAL|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.
214349852|NCT03590301|BEHAVIORAL|Healthy Toddler Parent Group|The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
214349853|NCT04695834|PROCEDURE|Neurolysis peroneal nerve|The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa
214349854|NCT04695834|OTHER|Maximal physiotherapy|Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
214957048|NCT03224624|OTHER|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
214957049|NCT05826535|DRUG|LYL314|CAR T-cell therapy
214957050|NCT05826535|DRUG|Fludarabine|Conditioning chemotherapy
214957051|NCT05826535|DRUG|Cyclophosphamide|Conditioning chemotherapy
214957052|NCT05345847|OTHER|Active Surveillance|Close monitoring of liver enzymes with steroid rescue strategy (watch and wait approach)
214957053|NCT05345847|OTHER|Early initiation|Immediate start of high-dose steroids
214957054|NCT01884545|BEHAVIORAL|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
214349855|NCT02182193|DRUG|BIBF 1120 capsules charge 1|
214349856|NCT02182193|DRUG|BIBF 1120 capsules charge 2|
214349857|NCT02182193|DRUG|BIBF 1120 drinking solution|
214349858|NCT04178551|OTHER|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
214957055|NCT01884545|GENETIC|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
214957056|NCT01884545|BEHAVIORAL|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
214349859|NCT04695223|DRUG|Arsenic Trioxide|Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)
214349860|NCT04631666|BIOLOGICAL|DZIF-10c|SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion
214349861|NCT04631666|OTHER|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
214349862|NCT02194621|DRUG|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
214349863|NCT02194621|DRUG|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
214349864|NCT02194621|DRUG|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
214349865|NCT02763384|DRUG|BL-8040|
214349866|NCT02763384|DRUG|Nelarabine|
214349867|NCT06299397|BEHAVIORAL|breastfeeding - humor training|Breastfeeding and humor-based practice will continue for 35-45 minutes, once a week for 2 weeks.
214349868|NCT06299397|OTHER|Control Group|After randomization, consent was obtained from the pregnant women determined that they agreed to participate in the study. The pregnant women in the control group were given a pre-test before starting the study, an interim test 1 month after the start, and a final test 3 months later.
214349869|NCT02493127|OTHER|Standard PCS|Subject completes the standard version of the PCS Questionnaire
214349870|NCT02493127|OTHER|Grip Strength|Research Assistant takes Grip Strength Measurements
214957057|NCT04499196|DRUG|GlucoCorticoid|Administering glucocorticoid
214349871|NCT02493127|OTHER|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
214957058|NCT05186051|DRUG|ZYIL1 capsule|NLRP3 inflammasome inhibitor
214957059|NCT05437445|DIAGNOSTIC_TEST|Plasma amino acid assay|Plasma amino acid analysis was performed on all the blood samples received in biogenetics lab at Aga khan university, Karachi during one year period.
214957060|NCT03816111|BEHAVIORAL|TEACH-PD Training Curriculum|The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.
214957061|NCT03816111|BEHAVIORAL|Current standard PD training|Current PD training materials and plan
214349872|NCT05437627|DIAGNOSTIC_TEST|The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults|"Assessment of stuttering severity: The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults will be applied for assessment of severity of stuttering. (3).~Automatic detection and severity assessment of stuttering using MATLAB version 8.1.0.604 R2013a (7). Stuttering detection system has three main steps which are acoustic processing, feature extraction and classification/recognition"
214349873|NCT02594891|DEVICE|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
214957062|NCT01411514|DRUG|Prednisone|Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
214957063|NCT01411514|DRUG|Placebo|Placebo tablets. They will be administered during 25 days
214957064|NCT02728817|PROCEDURE|End-cephalic vein to side-radial artery fistula creation|"* Circumferential dissection of the cephalic vein (4-5cm long)~* Longitudinal arteriotomy (\~10mm)~* End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture"
214957065|NCT02728817|PROCEDURE|RADAR fistula creation|"* Dissection of the anterior-medial aspect of the cephalic vein (\~15mm) without grasping or clamping the venous wall~* Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~* Ligation and section of the radial artery (distal)~* Longitudinal venotomy (\~10mm)~* End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture"
214957066|NCT04442152|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
214957067|NCT04041492|DIETARY_SUPPLEMENT|Supplementation with Vitamin D3 y K2|Supplementation at a dose of 1 capsule every 24 hours x 3 months
214957068|NCT00877539|DRUG|PF-03526299|Inhaled, two doses 4 hours apart
214957069|NCT00877539|DRUG|Placebo|Inhaled, two doses 4 hours apart
214957070|NCT00877539|DRUG|Fluticasone propionate|Inhaled
214957071|NCT04037293|DIAGNOSTIC_TEST|CIMT and baPWV measurement|All patients will receive carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) measurement at baseline and 5-year follow-up.
214957072|NCT00519584|DRUG|Ropivacaine|30 ml 0.5%
214957073|NCT00519584|DRUG|dex|8 mg (2 ml)
215078440|NCT06662266|DEVICE|Induce XT™ is a mixture of human cortical bone fibers and microparticulates that have been processed into Natural Matrix Protein® (NMP®) to which cancellous bone microparticulates have been added|"Bone graft material is required for successful foot and ankle fusion surgery. Current bone grafting materials include autogenous bone, Augment Bone Graft and demineralized bone matrix (DBM), each of which have limitations.~Induce XT is a novel bone graft material that can potentially be used in foot and ankle fusions that may overcome some of these limitations."
214349874|NCT02594891|DEVICE|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
214349875|NCT00959023|OTHER|laboratory biomarker analysis|
214349876|NCT00959023|OTHER|medical chart review|
214349877|NCT00959023|OTHER|questionnaire administration|
214349878|NCT02978365|OTHER|Questionnaires|Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).
214349879|NCT02978365|DEVICE|Isokinetic Strength Measurement|Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
214957074|NCT00519584|DRUG|Bupivacaine|30 ml 0.5%
214957075|NCT00519584|DRUG|Saline|0.9% saline; systemic and local
214486752|NCT03661255|BEHAVIORAL|PC CARES|PC CARES trains local residents to deliver the PC CARES curriculum in their own community. These facilitators will attend a 40 hour training, and then will deliver the 4 session PC CARES curriculum in their home village. To aid local facilitators, each session follows the same structure after a beginning ritual:(1) agreements/safe talk, (2)'small wins', (3)'what do we know?' (facilitator shares current research on suicide prevention or wellness) (4)'what do we think?' (participants have an opportunity to discuss their thoughts on the research presented), and (5)'what we want to do?' (participants identify what steps they can take in their village to make positive change).The content of learning circles (LCs) includes community-level conditions, evidence-based approaches, risk and protective factors that can prevent suicide and promote well-being.Each LC includes both primary and secondary prevention strategies.Teaching tools include charts, short films, and case studies.
214957076|NCT01648920|DEVICE|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
214349880|NCT04915963|DIETARY_SUPPLEMENT|Vitamin D supplementation|Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
214349881|NCT00003135|DRUG|fluorouracil|
214957077|NCT00441519|DRUG|aspirin|
214957078|NCT00441519|DRUG|omeprazole|
214957079|NCT02521792|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
214349882|NCT00003135|DRUG|pegylated liposomal doxorubicin hydrochloride|
214349883|NCT00003135|PROCEDURE|hyperthermia treatment|
214349884|NCT02169908|DEVICE|Thermotest|
214349885|NCT02169908|DEVICE|von Frey hairs|
214349886|NCT00325793|DRUG|Nicardipine|
214349887|NCT05918094|DRUG|Experimental dose: modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
214349888|NCT05918094|DRUG|Standard dose: standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
214349889|NCT01640756|DEVICE|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
214349890|NCT02037347|DRUG|Palifermin|
214349891|NCT01870271|BEHAVIORAL|Developmentally adapted cognitive processing therapy|
214349892|NCT00502125|PROCEDURE|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
214349893|NCT00006325|DRUG|Peginterferon alfa-2b|
214349894|NCT01579708|BEHAVIORAL|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
214349895|NCT03829904|DRUG|VGH-BPH1|A scientific Chinese granule powder
214957080|NCT03687866|GENETIC|non invasive prenatal testing|
214957081|NCT00685867|OTHER|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
214349896|NCT03829904|DRUG|Placebo (Corn starch pill manufactured to mimic VGH-BPH1)|Corn starch pill manufactured to mimic VGH-BPH1
214349897|NCT05503108|OTHER|Fasting Mimicking diet program|Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
214349898|NCT03266250|PROCEDURE|spinal anesthesia|Transthoracic echocardiography of inferior vena cava before spinal anesthesia
214349899|NCT01118208|OTHER|Blister packaging medications|Dispensing prescription medications on pre-filled blister package cards.
214349900|NCT01118208|OTHER|Dispense as usual|Dispensing prescription medications in standard pill bottles.
214349901|NCT02303964|BIOLOGICAL|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
214486753|NCT04174560|BIOLOGICAL|Norovirus GII.4 Challenge Pool|Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.
214486754|NCT06626958|BEHAVIORAL|Stress Ball|Stress Ball app
214957082|NCT00685867|BEHAVIORAL|Hand hygiene promotion|"* Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~* Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~* Isolation precautions according to the hospitals' capacity and strategy~* Additional basic infection control interventions (if necessary)"
214957083|NCT00114829|PROCEDURE|MR colonography with dynamic contrast uptake|
214957084|NCT02411734|BEHAVIORAL|Rehabilitation|Rehabilitation after hospitalization
214957085|NCT04506931|OTHER|SMS Survey|Participants will receive a SMS survey
214349902|NCT02303964|DRUG|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
214957086|NCT04506931|OTHER|IVR Survey|Participants will receive an IVR survey
214957087|NCT04506931|OTHER|CATI Survey|Participants will receive a CATI survey
214957088|NCT00192777|DRUG|Xeloda|
214957089|NCT00192777|PROCEDURE|External Beam Radiotherapy|
214957090|NCT00455676|PROCEDURE|Chevron osteotomy versus Scarf osteotomy|
214957091|NCT03454477|PROCEDURE|conventional open surgery|conventional open surgery
215078441|NCT06658834|DRUG|Dexamethasone Combined with romiplostim N01|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection once a week for up to 6 months.
215078442|NCT06658834|DRUG|Dexamethasone monotherapy|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
214957092|NCT03454477|PROCEDURE|endoscopic thyroidectomy|endoscopic thyroidectomy
214957093|NCT03454477|DEVICE|robotic thyroidectomy|robotic thyroidectomy
215078443|NCT06659016|DRUG|Fosfomycin 3 g|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months.
215078444|NCT06659016|DIETARY_SUPPLEMENT|Uroxin 4G|Dietary supplement of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
215078445|NCT06659016|DRUG|Combination of dietary supplement and fosfomycin|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months, combined with an oral formulation of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
214957094|NCT03121794|PROCEDURE|Ultrasonographic exam|The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks
214957095|NCT03121794|DEVICE|ultrasound machine|Regular ultrasound machine used at Cleveland Clinic
214957096|NCT00926432|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
214957097|NCT00926432|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
214957098|NCT01385540|BEHAVIORAL|Task-Based Functional Magnetic Resonance Imaging (fMRI)|Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
214957099|NCT00939588|DRUG|Aliskiren/ Valsartan|
214957100|NCT00939588|DRUG|Telmisartan/ Ramipril|
214957101|NCT02424994|OTHER|No intervention|
215078446|NCT06661096|PROCEDURE|TMJ arthroscopy|level I and level II TMJ arthroscopy
215078447|NCT06661018|DRUG|Coenzyme Q 10|participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
214349903|NCT00634608|OTHER|Health Information Prescription|The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
214349904|NCT03034577|DRUG|Sugammadex|Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
214957102|NCT01530802|PROCEDURE|clipping of uterine arteries during laparoscopic myomectomy|For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
214957103|NCT00000332|DRUG|Nimodipine|
214957104|NCT04575532|DEVICE|Use of the pinpointIQ solution (physIQ, Inc.)|Patients are monitored for 28 days post COVID19 diagnosis or COVID19 post-hospitalization discharge using the pinpointIQ solution.
214349905|NCT03034577|DRUG|Neostigmine|Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
214349906|NCT01892072|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
214349907|NCT05610553|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries to help to reduce intra-operative radiation, puncture time, etc..
214349908|NCT05610553|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
214349909|NCT02311179|DEVICE|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
214349910|NCT02311179|DEVICE|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
214349911|NCT04177758|DRUG|Vitamin D|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
214349912|NCT04177758|DRUG|Control|Patients randomized to the control will receive a placebo
214486755|NCT06627920|DEVICE|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor.|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor to estimate blood pressure, heart rate and oxygen saturation.
214957105|NCT00638092|DRUG|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
214957106|NCT00638092|DRUG|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
214957107|NCT02191345|BEHAVIORAL|Guided Imagery|Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
215078448|NCT06661018|DRUG|Placebo|participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
215078449|NCT06659770|DRUG|Zevorcabtagene Autoleucel|Zevorcabtagene Autoleucel is a novel fully human BCMA-targeting CAR-T therapy
215078450|NCT06660641|DEVICE|TaurolockTMHep100|1.35% taurolidine containing catheter losk solution
215078451|NCT06660641|DEVICE|0.9 % saline|placebo
215078452|NCT06660628|RADIATION|Large Segmentation Radiotherapy|Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
215078453|NCT06660628|DEVICE|DIBH|Deep Inspiration Breath Hold
215078454|NCT06660628|DEVICE|Surface guided radiation therapy|The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.
215078455|NCT06660628|DEVICE|laser alignment|Laser systems for virtual simulation and patient positioning in radiotherapy
215078456|NCT06660628|BEHAVIORAL|free breathing|Patients breathe calmly while radiotherapy instead of holding their breath.
215078457|NCT06658678|OTHER|Receiving an educational intervention|Patient not receiving any educational intervention
215078458|NCT06659159|DIAGNOSTIC_TEST|Gastric ultrasound|"The sequence in which the study is conducted will be as follows, the first examination (baseline examination) will take place immediately before the appointment and prescription of GLP-1 Analoga (before the first injection). During the examination the gastric content (quality/quantity) will be determined, secondly, a baseline for gastric emptying time after oral intake of 500ml of water is collected (patient drinks water, the stomach emptying will simultaneously be tracked with gastric ultrasound).~In accordance with the first endocrinological control examination (6-8 weeks after therapy initiation) the same gastric ultrasound examination is performed."
215078459|NCT05050617|DIAGNOSTIC_TEST|Point-of-care echocardiography|Subjects will undergo point-of-care echocardiography at the time of presentation/enrollment to assess for evidence of right sided heart dilation/strain.
215078460|NCT03537742|BIOLOGICAL|alirocumab|alirocumab 150mg Subcutaneous
215078461|NCT03537742|BIOLOGICAL|placebo|placebo to match alirocumab
215078462|NCT00223405|DEVICE|crown placement|
215078463|NCT04824768|DEVICE|Tecar Therapy|"CRet is a non-invasive diathermy technique that provides high frequency energy generating a thermal effect on soft tissues. Functional massage (FM) is a non-invasive manual therapy technique that combines rhythmical passive joint mobilization with compression of the muscular belly with the muscle-tendon insertions to be treated.~In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min F.M with passive ankle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (180-250VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 8.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
214957108|NCT04878939|OTHER|Power chain used for anterior segment retraction|Elastomeric chain rendering 160 g/side extending between mini-screw implant and a hook crimped on 0.017- by 0.025-inch stainless steel wire distal to the lateral incisor.
214957109|NCT04878939|OTHER|T-loop fabricated to perform anterior segment retraction|In the frictionless group, anterior segment retraction was done using closing T-loops fabricated from 0.017- by 0.025-inch titanium molybdenum alloy (TMA) wire rendering comparable retraction force.
214957110|NCT00351936|DRUG|Aripiprazole|
214957111|NCT00351936|DRUG|placebo|
214957112|NCT00279383|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
214957113|NCT06800339|DRUG|Nivolumab|This will be administered intravenously once every 3 weeks for up to 3 cycles (i.e. 9 weeks of total systemic therapy)
214349913|NCT05788549|BEHAVIORAL|Progressive Muscle Relaxation|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. The first application was done face to face with the researcher. Individuals were asked to perform subsequent applications at home.Educational booklet describing the progressive relaxation exercises with pictures was given to individuals, and a video prepared by the researcher was uploaded to their mobile phones. Individuals were asked to practice progressive relaxation exercises every day, at least once a day, in a quiet and peaceful environment for 30-minute sessions. The researcher sent reminder SMS messages to individuals twice a week for eight weeks to encourage regular practice of the progressive relaxation exercises. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed
214957114|NCT06800339|DRUG|Chemotherapy|Chemotherapy options include: carboplatin or cisplatin along with pemetrexed, paclitaxel or gemcitabine
214957115|NCT06800339|RADIATION|SBRT|Three fractions of radiation delivered every other day, for three total days. The final dose of radiation will happen within 7 days of starting chemoimmunotherapy
214957116|NCT06800339|PROCEDURE|Surgical Resection|Post treatment patient will be evaluated for surgical resection
214957117|NCT03557814|DEVICE|LED appliance during mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
214957118|NCT03557814|DEVICE|LED appliance after mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
214957119|NCT03557814|DEVICE|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
214957120|NCT02937636|OTHER|Stannous fluoride|Experimental dentifrice containing 0.454% w/w stannous fluoride \& 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride
214957121|NCT02937636|OTHER|Sodium monofluorophosphate|Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride
214957122|NCT00889915|DRUG|Methylphenidate transdermal system|Not specified in protocol; determined by local standard of care.
214957123|NCT00889915|DRUG|Lisdexamfetamine dimesylate|Not specified in protocol; determined by local standard of care.
214957124|NCT00889915|DRUG|Osmotic-release oral system methylphenidate (OROS MPH)|Not specified in protocol; determined by local standard of care.
214957125|NCT00889915|DRUG|Mixed amphetamine salts extended release|Not specified in protocol; determined by local standard of care.
214957126|NCT01786031|OTHER|metastasis biopsy|
214957127|NCT00770913|DRUG|E3810|20 mg taken orally, once a day for 8 weeks.
214957128|NCT00770913|DRUG|E3810|10 mg, taken orally, twice a day for 8 weeks.
214957129|NCT00770913|DRUG|E3810|20 mg taken orally, twice a day for 8 weeks.
214957130|NCT00596102|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine|Japanese Encephalitis purified inactivated vaccine
214957131|NCT00079885|DRUG|tigecycline|
214957132|NCT06278922|BEHAVIORAL|Seeking Safety + Signs of Safety toolkit|Signs of Safety is a Deaf-accessible toolkit to be used with the Seeking Safety treatment protocol. Seeking Safety is a manualized, non-exposure-based, cognitive behavioral therapy for trauma and addiction.
214957133|NCT06278922|BEHAVIORAL|Treatment as usual|NDT therapists come from a wide variety of training backgrounds, but each works with their clients to build on their existing strengths and provide support as clients develop new strategies and behaviors for overcoming adversity.
214957134|NCT04298307|OTHER|Intracoronary lithotripsy (ICL)|ICL using the Shockwave catheter.
214957135|NCT06726122|DEVICE|Profound Matrix|Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
214957136|NCT00359294|DRUG|PM00104|Intravenously over 1 hour daily for 5 days, every 3 weeks.
214957137|NCT00583011|DRUG|Local Anesthesia|Local anesthesia: 2 cc of 1% Lidocaine
214957138|NCT00583011|DRUG|Placebo Group|Placebo Group: 2cc Normal Saline
214957139|NCT05710510|BEHAVIORAL|Local Care + Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive 6 quarterly clinic visits with their local primary care provider focused on medical management of obesity."
214957140|NCT05710510|BEHAVIORAL|Team Care Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive an intensive 18-month group lifestyle intervention (30 total sessions) led by a study lifestyle coach via Zoom, and 6 quarterly 1:1 visits via Zoom with their lifestyle coach. Participants also receive 6 quarterly clinic visits with their local primary care provider; the study lifestyle coach joins the visits via telemedicine. All three parties may meet via telemedicine if needed. The group lifestyle intervention is led by obesity treatment specialists with relevant graduate training and experience."
214957141|NCT06621823|PROCEDURE|image-guided surgery technique|The identification of an image-guided surgery technique capable of intraoperatively detecting the presence of lymph node metastases would overcome the disadvantages and complications of extensive staging lymphadenectomies.
214957142|NCT06968650|BEHAVIORAL|Digital and Coordinated Maternial Care|The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app. InovCares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. It also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive behavioral therapy (CBT), interpersonal therapy, and compassion-focused therapy (CFT), along with peer-to-peer support and gamification. The study will evaluate the impact of these interventions on reported stress levels, depressive symptoms, sleep quality, and blood pressure (BP) among Black pregnant women.
214349914|NCT05788549|BEHAVIORAL|Relaxative Music|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. Individuals were asked to perform subsequent applications at home.Individuals were provided with a relaxing music file prepared by the researcher and were asked to listen to it at least once a day for 30 minutes in a quiet and calm environment. The researcher also sent reminder SMS messages twice a week for eight weeks to remind individuals. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed to listen to the relaxing music regularly. At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
214349915|NCT02574546|PROCEDURE|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
214349916|NCT00010491|PROCEDURE|Acupuncture|
214349917|NCT00010491|PROCEDURE|Moxibustion|
214349918|NCT04975373|DRUG|Intrauterine injection of hyaluronic acid|operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
214349919|NCT03441425|OTHER|Unexpected death|
214349920|NCT03119857|DRUG|Antiandrogen|
214349921|NCT03119857|DRUG|Antiandrogen+docetaxel|"Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.~Antiemetic therapy may be used if necessary."
214349922|NCT05715580|OTHER|Nursing information with a Protocol|"The nursing intervention will consist of providing information to the patient with a kidney transplant.~To do this, a Committee of experts, made up of the 6 nurses from the kidney transplant Consultations of the Community of Madrid (Spain), will carry out an Information Protocol for adults with a kidney transplant, which will cover the healthy lifestyle habits described by the bibliography"
214349923|NCT05715580|OTHER|Usual clinical practice|Nursing information following the usual clinical practice
214957143|NCT05633810|DRUG|Aspirin|40 mg non-enteric-coated tablet taken twice daily.
214957144|NCT05633810|DRUG|Aspirin Placebo|non-enteric-coated tablet taken twice daily.
214957145|NCT05633810|DRUG|Colchicine|0.5 mg tablet taken once daily
214957146|NCT05633810|DRUG|Colchicine Placebo|tablet taken once daily.
214349924|NCT04658251|GENETIC|Blood and/or skin biopsy|Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.
214349925|NCT01408160|DRUG|Cytarabine|Given IV
214349926|NCT01408160|BIOLOGICAL|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
214349927|NCT01408160|OTHER|Laboratory Biomarker Analysis|Correlative studies
214349928|NCT01408160|OTHER|Pharmacological Study|Correlative studies
214349929|NCT01815177|DEVICE|Arthroscopic transosseous fixation|
214349930|NCT01815177|DEVICE|Suture anchors|
214349931|NCT06019650|BEHAVIORAL|ECMAP|The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
214349932|NCT02571569|DRUG|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
214349933|NCT02571569|DRUG|BAY1093884|Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
214349934|NCT04482751|DRUG|Corifollitropin alfa|AMH will be measured during ovarian stimulation with corifollitropin alfa
214349935|NCT06371794|PROCEDURE|skin punch biopsy|skin punch biopsy (around 4 mm2) from each studied subject.
214349936|NCT01986257|BEHAVIORAL|Emotion Regulation Group Therapy (ERGT).|
214957147|NCT02946021|DEVICE|Head and neck garments for pneumatic compression device|Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
214957148|NCT02946021|DRUG|NIRFLI with ICG|Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
214957149|NCT03240185|BEHAVIORAL|deep breathing exercises|Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
214349937|NCT03557437|DRUG|Esomeprazole|Proton pump inhibitor
214349938|NCT03557437|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
214349939|NCT03557437|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
214349940|NCT06257069|DEVICE|Tremor Retrainer Smartphone Application|The Tremor Retrainer smartphone application uses the smartphone's built-in accelerometer to calculate a patient's tremor frequency when the smartphone is strapped to the patient's wrist. The application will provide auditory cues to the patient with a treatment frequency at 2/3 the patient's baseline tremor frequency for half a session, then 1/3 the patient's baseline tremor frequency for the second half of the session. Meanwhile, oscillatory movements will be continuously analyzed with frequency calculated and displayed relative to goal frequency, so that the patient receives continuous feedback via a visual dial as to whether they are meeting treatment goals. Intervention will consist of a one-week Tremor Retrainment Protocol.
214349941|NCT01365000|DRUG|NKTR118 Formulation 1|Oral dose, 25 mg
214349942|NCT01365000|DRUG|NKTR118 Formulation 2|Oral dose, 25 mg
214349943|NCT01365000|DRUG|NKTR118 Formulation 3|Oral dose, 25 mg
214349944|NCT01365000|DRUG|NKTR118 Formulation 1a|Oral dose, 25 mg
214349945|NCT01365000|DRUG|NKTR118 Formulation 3a|Oral dose, 25 mg
214349946|NCT03708198|DRUG|Liposomal Bupivacaine|intercostal block
214349947|NCT03925376|PROCEDURE|Redo cardiac surgery|Redo cardiac surgery is technically challenging due to scarring of tissues resulting in loss of tissue planes, adhesions, multiple comorbid factors and risk of injury during re-entry.Suggested techniques in coronary artery surgery with a left internal mammary artery include routing the graft through a slit in the pericardium to minimize the possibility of adherence to the sternal table.
214349948|NCT00778674|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
214349949|NCT01093352|PROCEDURE|Alveolar-decortication.|Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
214349950|NCT00093054|DRUG|Cranberry juice|TID dosage for UTI treatment
214349951|NCT00093054|DIETARY_SUPPLEMENT|Placebo cranberry juice|TID placebo dosage to match active comparator
214349952|NCT01697293|DRUG|Cyclophosphamide|Given IV
214349953|NCT01697293|DRUG|Doxorubicin Hydrochloride|Given IV
214349954|NCT01697293|OTHER|Laboratory Biomarker Analysis|Correlative studies
214957150|NCT04564924|RADIATION|DXA|Bone mineral density was examined in all cases and controls
214349955|NCT01697293|DRUG|Paclitaxel|Given IV
214349956|NCT01697293|PROCEDURE|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
214957151|NCT03236116|OTHER|Almonds|Participants will consume almonds everyday for 6 months.
214957152|NCT03236116|OTHER|Control (no nuts)|Participants will not be permited to consume any nuts for 6 months.
214957153|NCT00290654|DRUG|Tamoxifen|Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient
214349957|NCT01697293|DRUG|Triciribine Phosphate|Given IV
214349958|NCT06113250|DEVICE|shortwave diathermy|Shortwave diathermy (SWD) is a modality that produces heat by converting electromagnetic energy into thermal energy. pulsed shortwave diathermy (PSWD), uses high-frequency electromagnetic waves to heat tissues up to 5 cm deep. Heat is produced by the resistance of tissue to the passage of energy. Although it heats to the same depth as 1-MHz ultrasound, PSWD heats a much larger area than ultrasound does, making it ideal to heat larger joints, such as the elbow, shoulder, hip, knee, and ankle
214349959|NCT06113250|DEVICE|ultrasound waves|Ultrasound is sound with a frequency above 20,000 Hertz (Hz) and is undetectable by the human ear. However, clinical ultrasound uses much high frequencies of between 1 and 20 megahertz (MHz) and sometimes up to 75 MHz in specialized areas such as dermatology and ophthalmology. Clinically, ultrasound is used for a number of applications ranging from visualizing structures to allow safe insertion of lines and catheters to diagnostic imaging including the assessment of the movement of cardiac Production of ultrasound waves is the first part of the clinical ultrasound process. Ultrasound is generated by piezoelectric crystals. These crystalline materials contain randomly oriented electric dipoles, and when a force is applied that deforms the crystal, the dipoles are rearranged and a net charge induced across the crystal
214349960|NCT06113250|OTHER|traditional physical therapy program|splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises
214349961|NCT05802238|DRUG|Tranexamic acid (TXA)|1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
214957154|NCT00290654|PROCEDURE|Lumpectomy|A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.
214957155|NCT00290654|RADIATION|brachytherapy|Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
214957156|NCT02343432|DRUG|Triamcinolone|Triamcinolone
214957157|NCT02343432|DRUG|Epidural Volume|Epidural Volume
214957158|NCT02343432|DRUG|Bupivacaine|Bupivacaine
214957159|NCT02840227|PROCEDURE|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
214957160|NCT02840227|PROCEDURE|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
214957161|NCT01173900|BIOLOGICAL|Gardasil® HPV vaccine|0.5 ml given at 0, 2, 6 months
214957162|NCT02792335|DRUG|apixaban|
214957163|NCT02792335|DRUG|dabigatran|
214957164|NCT02792335|DRUG|rivaroxaban|
214957165|NCT02792335|DRUG|warfarin|
214349962|NCT05802238|OTHER|Saline|control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.
214349963|NCT03118960|DEVICE|Freedom Bed|This is an automatic rotational system in a bed designed to disburse capillary pressure
214957166|NCT00154843|DRUG|Lycopene|A: Lycopene15 mg/day ; B: Lycopene30 mg/day
214957167|NCT02496741|DRUG|Metformin and chloroquine combination|Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
214957168|NCT05177549|OTHER|Bilateral knee examination with Lachmeter®|Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee
214957169|NCT00651144|DRUG|Ezetimibe + Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
214957170|NCT00651144|DRUG|Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
214957171|NCT00651144|DRUG|Placebo|oral tablets; two ezetimibe placebo once daily for 14 days
214957172|NCT00651144|DRUG|Ezetimibe|oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
214957173|NCT00305422|DRUG|Quetiapine fumarate|
214957174|NCT00305422|DRUG|Risperidone|
214957175|NCT03706716|OTHER|decision aid developed for pelvic organ prolapse|Conversation based upon the inter face in the Electronic patient journal.
214957176|NCT02073539|DEVICE|Stryker ST104-747|760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US
214349964|NCT03118960|DEVICE|Group II Low Air Loss/Alternating Pressure Mattress|Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
214349965|NCT06196268|OTHER|core strengthening exercise|CSE will constitute of abdominal hollowing, Side Bridge, supine extension bridge, straight leg rise from prone, alternate arm and leg raise from quadruped, and prone bridge
214957177|NCT02073539|DEVICE|Shinchang SB-34p|, 850 x 2080 mm,Shinchang Co.,Busan,ROK
214957178|NCT06442202|DIETARY_SUPPLEMENT|Balanced Nutritional Diet|"Food was provided during the intervention period 3 (three) times each day, i.e. breakfast, lunch and dinner. The food menu used a 30-day menu cycle. The characteristics of the Balanced Nutrition Diet that have been provided based on the distribution of the composition of the macronutrients that will be intervened in are as follows: 45-55% carbohydrates, 15-20% protein, and 20-25% fat (Ministry of Health 2014). The type of diet and portions that were given were the same for each menu unless there were certain food restrictions or allergies, and then the type of food was adjusted specifically to that individual. The calories that will be given range from 300-400 Cal for breakfast, 400-500 Cal for lunch, and 300-500 Cal for dinner.~The choice of carbohydrates should be varied and prioritise complex carbohydrates such as whole grains. The choice of protein type is prioritised from low-fat protein sources and half of it is vegetable protein."
214957179|NCT06442202|BEHAVIORAL|Nutritional Education|Nutritional education is provided via online Zoom meetings with the help of educational media in the form of PowerPoint presentations/videos before entering the intervention period. The educational material that will be provided is regarding Guidelines for Balanced Nutrition, Food Safety, and Healthy Lifestyles (stress management and sleep time). The subject's understanding of the material provided was evaluated using an online quiz platform.
214957180|NCT03732222|PROCEDURE|Stretching the diaphragm muscle|Place the hands on the last costal cartilages and maintain the ascent of the ribs in the expiration.
214957181|NCT03732222|PROCEDURE|Impulse technique in rotation of cervical level 3 and 4|head to double chin position and then placed with neutral flexo-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
214957182|NCT03732222|PROCEDURE|Combined technique of diaphragm muscle stretch and cervical rotation impulse technique level 3 and 4|"The same initial position, hand placement and technique guidelines will be used, cited in each of the techniques performed in the intervention 1 group and the intervention 2 group."
214957183|NCT01398358|BEHAVIORAL|Parents of Preschoolers Series|"The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.~The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home."
214349966|NCT06196268|OTHER|Pilates exercise|Pilates includes hundreds, one leg stretch, shoulder bridge, hip twist, scissors, side kicks
214349967|NCT02587351|DRUG|Metoprolol succinate|Extended release Metoprolol succinate
214957184|NCT01398358|BEHAVIORAL|Incredible Years Series|"The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.~For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.~Teachers are trained in classroom management strategies."
214349968|NCT02587351|OTHER|Placebo|Matching placebo
214957185|NCT00748163|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
214957186|NCT00748163|DRUG|sunitinib malate|
214957187|NCT04127396|DRUG|Lenvatinib Pill|Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW)\>60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW\<60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)
214349969|NCT05369234|DIETARY_SUPPLEMENT|100% Aloe Vera Juice|George's 100% Aloe Vera Liquid Supplement
214349970|NCT05369234|COMBINATION_PRODUCT|Magic Mouthwash|Magic Mouthwash
214349971|NCT05369234|COMBINATION_PRODUCT|Salt and Baking soda rinse|Mouth rinse made with salt and baking soda
214349972|NCT05369234|DRUG|Carafate|Carafate taken as a slurry
214349973|NCT03156023|DRUG|Rozibafusp Alfa|Administered by subcutaneous injection once every 2 weeks.
214349974|NCT03156023|DRUG|Placebo|Administered by subcutaneous injection once every 2 weeks.
214349975|NCT03013010|DRUG|Tegafur-Gimeracil-Oteracil Potassium|The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
214349976|NCT03013010|RADIATION|Chemoradiotherapy|"Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
214349977|NCT03013010|PROCEDURE|Gastric resection|A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
214349978|NCT03013010|DRUG|Oxaliplatin|The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
214349979|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
214957188|NCT04127396|PROCEDURE|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
214957189|NCT04127396|DRUG|Sorafenib|Sorafenib capsules will be administered orally, 400 mg twice daily (BID) oral dosing.
214957190|NCT04127396|PROCEDURE|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
214349980|NCT01290367|PROCEDURE|Single injection of saline solution|Intradiscal control injection with saline solution
214957191|NCT02650492|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
214957192|NCT00635986|DRUG|Fentanyl|100 mcg Fentanyl intravenous or epidural route
214957193|NCT05206396|DIAGNOSTIC_TEST|TIL assessment in pre-existing histopathological specimens|TIL assessment in pre-existing histopathological specimens and their relation to complete pathological response and 1-year invasive disease-free interval
214957194|NCT00230984|BEHAVIORAL|education|
214957195|NCT00230984|DRUG|Oral dietary supplements (563 kcal/d), RESPIFOR|
214957196|NCT00230984|BEHAVIORAL|exercises on an ergometric bicycle 3 to 5 times a week|
214957197|NCT00230984|DRUG|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
214957198|NCT03148067|PROCEDURE|Intramedullary nailing for fracture fixation|
214957199|NCT01961167|DEVICE|Stenting of common and/or external iliacs|Balloon expandable stenting of iliac occlusive disease
214957200|NCT00964405|DRUG|GSK233705|Inhaled Long acting muscarinic receptor antagonist
214957201|NCT00964405|DRUG|Placebo|Matching placebo
214957202|NCT01357005|OTHER|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
214957203|NCT02559570|DRUG|Placebo|Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
214957204|NCT02559570|DRUG|LIN Dose A|Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
214957205|NCT02559570|DRUG|LIN Dose B|Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
214957206|NCT02559570|DRUG|LIN Dose C|Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
214957207|NCT02559570|DRUG|LIN 145 µg|Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
214957208|NCT00901082|BEHAVIORAL|Relaxation and information session|Relaxation and information session before the medial branch block
214957209|NCT00722683|PROCEDURE|Ultrasound Imaging with Contrast|"An ultrasound contrast agent, Definity, will be administered started through the IV line already in use. The imaging will be performed to map vascular flow.~The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times."
214957210|NCT01396551|DEVICE|Implantation of anchored Beacon transponder in the lung|Anchored Beacon transponder has an anchoring feature to secure it in the small airways of the lung.
214957211|NCT02591030|DRUG|GEMCIS|"At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~* Cisplatin 25 mg/m² over 1 hour at D1 and D8~* Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8."
214957212|NCT02591030|DRUG|mFolfirinox|"At D1 of each cycle, i.e. every 15 days for 6 months:~* Oxiplatin: 85 mg/m² (IP/120 minutes)~* Irinotecan: 180 mg/m² (IV/90 minutes)~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine \[calcium levofolinate\]) (IV/2 hours), via a Y connector at the same time as irinotecan~* 5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1"
215078464|NCT04824768|DEVICE|Sham Tecar Therapy|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min FM with passive ankle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 0.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
215078465|NCT03200977|OTHER|Non-Interventional|Non-Interventional
214349981|NCT01290367|PROCEDURE|Single injection of hyaluronic acid|Intradiscal control injection with hyaluronic acid
214957213|NCT06055153|DRUG|RC48+PD-1+platinum-based|"Phase I: Three subjects with HER2 overexpression (IHC 2+/3+) were initially enrolled. If dose-limiting toxicity (DLT) was observed in two of the three subjects, the study was continued from dose 1 to dose 2. If ≤1 DLT is observed in 3 subjects, continue to enroll 3 patients, and if ≤2 DLT is observed in 6 subjects, proceed to the second phase. If \> 2 cases of DLT are observed in 6 subjects, adjust to dose 2 for phase 2.~Dose 1: RC48 2.5mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~Dose 2: RC48 2.0mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~The second stage: sample size expansion stage. RP2D obtained at stage 1 continues to be enrolled in up to 20 patients until disease progression or intolerable toxicity occurs."
214957214|NCT04979416|BEHAVIORAL|Video messages|video messages aimed at increasing vaccination
214957215|NCT04668443|OTHER|Graphical Informed Consent (GIC)|The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.
214957216|NCT03056014|DRUG|N-acetyl cysteine|giving varying doses of NAC in order to determine which reduces oxidative stress.
214957217|NCT03056014|DIETARY_SUPPLEMENT|omega 6 Fish oil ( PUFA)|giving varying doses of PUFA in order to determine which reduces oxidative stress.
214957218|NCT03056014|DIETARY_SUPPLEMENT|Placebo|L-alanine placebo pill to determine if effect is supplement related or random effect.
214957219|NCT04805164|PROCEDURE|Corticotomy and use of the bone substitute : Cerament-G device.|Corticotomy and Cerament-G device
214349982|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
214349983|NCT01895465|DEVICE|Slitted diaper|A diaper where a slit is made through which a urine collection bag is pulled through
214349984|NCT05764850|GENETIC|Genome sequencing|"100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis."
214349985|NCT00034034|PROCEDURE|Acupuncture|
214349986|NCT02009475|OTHER|Interval exercise training|
214349987|NCT02009475|OTHER|Continues aerobic training|
214349988|NCT02010060|BEHAVIORAL|Aerobic Exercise Training|Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week \[KKW\]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
214349989|NCT02010060|BEHAVIORAL|Aerobic Exercise+ Physical Activity|The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
214957220|NCT04805164|PROCEDURE|Corticotomy|Corticotomy
214957221|NCT02934555|DRUG|Ubiquinol|300 mg Ubiquinol (3 mL liquid Ubiquinol).
214957222|NCT02934555|DIETARY_SUPPLEMENT|Ensure|50 mL Ensure
214957223|NCT01831271|OTHER|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
214957224|NCT01831271|OTHER|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
214957225|NCT00098540|DRUG|sorafenib tosylate|Given orally
214957226|NCT00098540|OTHER|laboratory biomarker analysis|Correlative studies
214957227|NCT00802321|DRUG|Dutasteride|Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
214957228|NCT02583412|BIOLOGICAL|Bexsero®|Multicomponent meningococcal B vaccine
214957229|NCT02583412|BIOLOGICAL|Havrix®|Hepatitis A vaccine
214957230|NCT00351559|DEVICE|AlloMap molecular expression testing|
214957231|NCT00351559|PROCEDURE|Right ventricular endomyocardial biopsy|
214957232|NCT02334826|PROCEDURE|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
214349990|NCT05739058|DEVICE|Violet-Blue Light Treatment / FlashHeal Device|"FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz."
214349991|NCT02498665|DRUG|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
214349992|NCT05911854|DEVICE|Multi-waved Locked System Laser|The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.
214349993|NCT05911854|DEVICE|Cold Compression therapy|The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.
214349994|NCT05911854|OTHER|complete decongestive therapy|"Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)"
214486756|NCT06872008|BEHAVIORAL|Hand Massage|"Hand massage to elderly people Hand massage application consists of five basic classical massages including efflorage, petrissage, friction, tapotman and vibration.~It is a massage that includes manipulation and is performed with western technique.~The researcher will collaborate with the institution's physiotherapist throughout the application. Hand massage in the literature Although there is no standard duration for how long the massage should be applied, studies have shown that the massage is applied for an average of 5-10 times, and in this study the massage application time was It was determined as 10 minutes in total, 5 minutes for each hand. Hand massage with baby oil will be performed 3 times a week for 4 weeks, for a total of 12 sessions."
214957233|NCT02334826|PROCEDURE|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
214957234|NCT01043484|DRUG|Bevacizumab + Capecitabine + Radiotherapy|Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
214957235|NCT01043484|DRUG|Capecitabine + Radiotherapy|Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
214957236|NCT04843540|DRUG|CTP-543|Rifampin as oral capsule
214957237|NCT05202535|OTHER|Aerobic exercise training|"Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment.~3x/week on alternate days for 8 weeks at 40-70% of HR Max"
215078466|NCT06599255|PROCEDURE|US-guided RSB and TAPB by one-puncture technique.|The probe will be positioned transversely in the midline of the abdomen, between the xiphoid process and the umbilicus, revealing the linea alba. It was then moved outward along the costal margin, demonstrating the rectus abdominis overlapping the transverse abdominis. A 22-gauge, 120-mm ultrasound-visible block needle will be inserted from the inner side . Under direct vision, we will reach the posterior rectus abdominis sheath and pierced the anterior layer of the posterior sheath. Saline was injected to adjust its position. After that, 15 mL of 0.25% bupivacaine will be administered (aspiration was performed for every 5 mL injection), and we will observe the local anesthetic spreading inward . Then, the needle will break through the posterior layer of the tendon, and saline will be injected to confirm the needle's placement in the transversus abdominis plane. After confirming the tip placement, 15 mL of 0.25% bupivacaine will be slowly injected. The needle tip will be advanced al
215078467|NCT06599255|PROCEDURE|multipont|", the probe will be moved outward along the costal margin until the external oblique muscle, internal oblique muscle, and transverse abdominis muscle will be visible \[9\]. The needle will be inserted in-plane until the tip was positioned in the plane between the internal oblique muscle and the transverse abdominis muscle. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.~For the RSB, the same technique will be done as one puncture technique. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution."
215078468|NCT06604416|OTHER|Forward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate forward walking.
214957238|NCT05202535|OTHER|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
215078469|NCT06604416|OTHER|Backward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate backward walking.
215078470|NCT06600282|DRUG|Parecoxib|Pharmacokinetic study under fasting conditions
215078471|NCT06606145|PROCEDURE|Lymphovenous Anastomosis|LVA involves connecting functional lymphatic vessels to nearby veins, allowing for the rerouting of lymphatic fluid into the venous system, thus improving lymphatic drainage.
214349995|NCT06447038|DIAGNOSTIC_TEST|albumin creatinine ratio|Albumin creatinine ratio, this test is routinely performed in urine.
214349996|NCT06663774|DIAGNOSTIC_TEST|Physical Fitness Tests|Ippon Reactive Agility Test (IRAT), Y-Balance Test, Upper-Quarter Y Balance Test, Flamingo Balance Test, Flamingo Balance Test, Standing Long Jump Test, 20m Sprint Test, Hand Grip Test, T-Agility Test, Nelson Hand Reaction Test, Judo Specific Fitness Test
214349997|NCT06663306|DRUG|Pemetrexed|Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks
214349998|NCT06663306|DRUG|Bevacizumab|Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.
214349999|NCT06663683|OTHER|Hip thrust|The subjects in Hip Thrust (HT) group will be instructed to perform low-load gluteus activation exercises, which included single-leg bridges, clamshells and quadruped hip extensions. One set of ten repetitions or steps will perform for each exercise. In this training program three stages which focused on enhancing hypertrophy and strength of the hip extensors in sequence. During the training period, the subjects will be instructed to maintain their usual daily activities and diet. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between the sessions. Hip thrust training 3 sets with 10 repetitions in each set and 2 minutes rest between each set.
214350000|NCT06663683|OTHER|Back squat|In Back Squat (BS) resistance training the subjects starts with the standing position with the feet flat on the floor, the knees and hips in a neutral, extended anatomical position, and the spine in an upright position with preservation of its natural curves. The squat movement will begin with the descent phase as the hips, knee and ankles flex. A common instruction will be given to the subjects to descend until the top of the thigh is at least parallel with ground and the hip joint is at least level with or slightly below the knee joint. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between sessions. Back squat training 3 sets with 10 repetitions in each set \& 2 minutes rest between each set.
214350001|NCT06662955|BEHAVIORAL|audible cues|Terminal knee extension exercise with audible cues
214350002|NCT06662955|BEHAVIORAL|Exercise|Terminal knee extension exercise
214350003|NCT05037396|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
214350004|NCT05166005|DRUG|vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
214350005|NCT05195996|DRUG|Propranolol|intravenous propranolol for case patients
214350006|NCT05195996|DRUG|Saline|intravenous saline for placebo
214957239|NCT02446847|DRUG|3BNC117|3BNC117 infusions
214957240|NCT02446847|OTHER|ART Interruption|Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.
214957241|NCT04958161|OTHER|Exercise Therapy|Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
214957242|NCT02193555|DEVICE|Etafilcon A, Senofilcon A|1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
215078472|NCT06606145|PROCEDURE|Vascularized Lymph Node Transfer|VLNT involves transferring healthy lymph nodes along with their blood supply to the affected lymphoedematous area, aiding in lymphatic fluid transport and potentially promoting lymphangiogenesis.
214350007|NCT01231711|BEHAVIORAL|Vets Prevail|"The intervention has two primary components that are both delivered over the Internet:~The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).~The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills."
214350008|NCT00726752|DRUG|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
214350009|NCT05854290|BEHAVIORAL|CRT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
214350010|NCT05854290|BEHAVIORAL|CBT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
214350011|NCT05854290|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
214350012|NCT05854290|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15-minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).~Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking."
214350013|NCT06063941|DRUG|1% Lugol's iodine solution|1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.
214957243|NCT01883661|BIOLOGICAL|BMMNC|Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
214957244|NCT04210739|DRUG|Betamethason Sodium Phosphate|Injection of betamethasone in chronic non bacterial prostatitis patients using Trans rectal Ultrasound
214957245|NCT00957489|OTHER|Dynamax appliance|
214957246|NCT00957489|OTHER|Twin-block appliance|
214957247|NCT05406271|DIAGNOSTIC_TEST|Intraoperative fluoroscopy|Impantation of hip prosthesis with intraoperative fluoroscopy
214957248|NCT01478607|DRUG|QUTENZA|A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
215078473|NCT06606145|PROCEDURE|Combined Lymphovenous Anastomosis and Vascularized Lymph Node Transfer|Combined simultaneous surgical intervention during which both VLNT and LVA are performed on the operated limb.
215078474|NCT06606145|PROCEDURE|Complex Decongestive Therapy|The current standard of care for most BRCL patients includes conservative measures known as Complex Decongestive Therapy (CDT), consisting of compression therapy with low-stretch bandages, manual lymphatic drainage, exercise, and skincare.
215078475|NCT06601647|PROCEDURE|adjuvant type|ropivacaine combined with adjuvant
215078476|NCT06608810|DRUG|nerve block with 0.5% ropivacaine|General anesthesia tracheal intubation was used. Induction was performed with midazolam 0.05ml/kg, etomidate 0.3-0.4mg/kg, sufentanil 0.3μg/kg-0.4μg/kg, and rocuronium bromide 0.8mg/kg, and after sufficient oxygen and denitration, the tracheal tube was placed by visual laryngoscopy, and the position of the tube was determined by auscultation of the lungs to determine the position of the catheter, and the respiratory sounds of the sides were symmetrically clear, so that the catheter was fixed and mechanical ventilation was performed. Anesthesia was maintained with remifentanil 0.1～0.3μg/(kg-min), propofol 2\~4mg/(kg-h) rate microinfusion pump for continuous infusion. BIS was kept between 40\~60. Intraoperative rocuronium bromide was given intermittently to maintain muscle relaxation. Perioperative fluid replacement followed the (4:2:1) rule in all patients. For maintenance of hemodynamic stability, ephedrine or atropine was administered, at the anesthesiologist's discretion, if verified a
215078477|NCT06606496|DEVICE|Bispectral index (BIS)|The bispectral index (BIS) monitor is a quantitative electroencephalographic (EEG) device that is widely used to assess the hypnotic component of anaesthesia, especially when neuromuscular blocking drugs are used. If necessary, it may be necessary to increase or decrease MAC (minimum alveolar concentration) in the testosterone group according to the BIS monitoring value.
214350014|NCT06063941|DRUG|5% Lugol's iodine solution|Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
214350015|NCT02590718|PROCEDURE|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
214350016|NCT01665235|DRUG|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
214350017|NCT01665235|DRUG|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
214350018|NCT01665235|DRUG|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
214350019|NCT01665235|DRUG|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
214350020|NCT03570398|OTHER|unenhanced abdomino-pelvic CT scan|unenhanced abdomino-pelvic CT scan
214350021|NCT03570398|OTHER|abdominal ultrasound|abdominal ultrasound
214350022|NCT01472198|DRUG|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
214350023|NCT01472198|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
214350024|NCT01472198|DRUG|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
214350025|NCT05308732|DRUG|Copaiba|A 10% and 15% aqueous solution of copaiba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula: 10% copaiba oil (Copaifera Officinalis Resin) and 15% liquid mint aroma 5% , tween 80 1%, Aqueous solution (Distilled water + 0.1% Nipagin) qsp 100%.
214350026|NCT03344679|DRUG|Bupivacaine 0.25%|Bupivacaine 0.25% for PECS block
214350027|NCT03344679|DRUG|Adenosine 12mg|Adenosine 12 mg for PECS block
214350028|NCT03344679|DRUG|Magnesium Sulphate 500 mg|Magnesium sulphate 500 mg for PECS block
214957249|NCT06041282|PROCEDURE|manipulation under anesthesia|After the anesthesia took effect, the patient was placed in the supine position, and the experienced surgeon stood at the head of the bed to release the affected limb by four angles of forward flexion, abduction, external rotation and internal rotation. After the operation is completed, 1ml de Bosson (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) is injected once.
214350029|NCT04473885|OTHER|Perturbation-based balance training|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
214350030|NCT04811430|DEVICE|Randomized Traditional|Traditional ultrasound guidance was utilized to insert Midlines on simulated veins blocks not live patients
214350031|NCT04811430|DEVICE|Cue(TM) Needle Tracking Technology|Cue(TM) Needle Tracking Technology with real time needle tip tracking is used to assist ultrasound guided midline insertions on simulated veins blocks not live patients
214350032|NCT02676102|BEHAVIORAL|Control Group|Generic Video about organ donation
214350033|NCT02676102|BEHAVIORAL|Targeted Intervention|an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
214350034|NCT02676102|BEHAVIORAL|Tailored Intervention|Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
214957250|NCT06041282|PROCEDURE|supervised home rehabilitation|The doctor instructs the patient in exercise training at the outpatient clinic. At each clinic visit, the doctor will guide the different stages of the movement. At the first visit, the doctor guides the patient through the first phase of the rehabilitation program to improve the patient's basic mobility. At the first month of follow-up, the second phase of rehabilitation program was guided, and the recovery of mobility was accompanied by muscle training, including wall climbing and muscle resistance exercises. 1ml Debossone (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) was injected once at the clinic. All the training required patients to do their best at home to complete 3 sets of 5 each. At the end of each day, the patient will upload a video to the platform, and the doctor will evaluate whether the patient's recovery is in place.
214350035|NCT00652158|DRUG|MLN8054|"10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days"
214350036|NCT00976599|DRUG|CP-690,550 + methotrexate|CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
214350037|NCT00976599|DRUG|Placebo + Methotrexate|Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
214350038|NCT00002507|DRUG|mitomycin C|
214350039|NCT00002507|DRUG|porfiromycin|
214350040|NCT00002507|RADIATION|brachytherapy|
214350041|NCT00002507|RADIATION|radiation therapy|
214350042|NCT04184193|OTHER|Pulmonary Rehabilitation|Patients will perform a comprehensive, inpatient pulmonary rehabilitation program for 4 weeks duration
214957251|NCT00779987|DRUG|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
214350043|NCT00022412|DIETARY_SUPPLEMENT|doxercalciferol|Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
214350044|NCT00022412|PROCEDURE|conventional surgery|Procedure: Prostatectomy for prostate cancer
214350045|NCT05125770|BIOLOGICAL|New crown vaccine|New Coronavirus vaccine
214350046|NCT00791765|BIOLOGICAL|Etanercept|Etanercept for subcutaneous injection.
214350047|NCT00791765|BIOLOGICAL|Placebo|Placebo for subcutaneous injection.
214350048|NCT04575896|DRUG|Glecaprevir/pibrentasvir|Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.
214350049|NCT00490191|DRUG|Somatropin|
214350050|NCT04942106|OTHER|Arm 1 - Side-lying position followed by Supine position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
214350051|NCT04942106|OTHER|Arm 2 - Supine position followed by Side-lying position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
214350052|NCT02754648|PROCEDURE|laparoscopic ovarian endometriotic cyst|
214350053|NCT01570101|DEVICE|CE Marked Sapheon Closure System|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
214350054|NCT02276846|DEVICE|Paclitaxel-Eluting Balloon|
214350055|NCT00215267|DRUG|praziquantel|
214350056|NCT02711774|DEVICE|ultrasonography|ONSD will be measured by a 6-13 MHz linear probe of the ultrasound machine.
214350057|NCT00103246|DRUG|silicon phthalocyanine 4|Participants receive topical silicon phthalocyanine 4 (Pc 4). One hour later, participants undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
214957252|NCT00779987|DRUG|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
214957253|NCT00524680|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
214957254|NCT02383303|BEHAVIORAL|Individual Development Account and financial education|The Program intervention includes a matched savings account (Individual Development Account) and financial education.
214350058|NCT03495050|DEVICE|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform
214957255|NCT05844072|PROCEDURE|Mobilization with movement|All participants will receive the MWM intervention with weight bearing ankle dorsiflexion range of motion measured prior to the intervention, immediately following the intervention, and 24 hours (+/- 3 hours) following the intervention. The participant will first place their foot on a 16-inch box to assist in performance of the intervention by the therapist. A licensed physical therapist (PT) will then stabilize the talus for a proper joint mobilization to be performed. The therapist will then mobilize the distal tib/fib in the posterior to anterior direction at end range DF reached through a forward lunge, using a Mulligan's mobilization belt around the distal tibia-fibula. The participant will perform 3 sets of 10 repetitions of the forward lunge and the PT will perform a bout of overpressure at end range during each repetition. Two other investigators will be on either side of participant to assist with balance during the intervention if needed.
214957256|NCT01472978|DRUG|metronidazole|Metronidazole, 500 mg three times a for 10 days
214350059|NCT04704375|DEVICE|Bio Electro-Magnetic Regulation (BEMER) Therapy|BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.
214957257|NCT00549471|OTHER|physiotherapy|CG children will undergo a program of intensive physiotherapy
214957258|NCT00549471|OTHER|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
215078478|NCT06607952|OTHER|scenario-based case videos teaching protocol|"Students in the experimental group will receive a new teaching method of scenario-based case video interventions. These videos cover five key scenarios: Triage, SDH and ETTC, AMI and D2B, COPD AE and TOCC, and Sepsis and the CVC Procedure.~This teaching method is grounded in experiential learning theory and critical thinking strategies, designed to guide students in learning emergency nursing through video experiences. In each class, the instructor will first introduce the foundational concepts of emergency nursing for each system. Students will then watch a 15-minute scenario-based case video. Afterward, the instructor will facilitate a 15-minute discussion using reflection sheets to promote experiential learning and critical"
215078479|NCT06607952|OTHER|traditional lecture-based teaching method|Students in the control group will receive traditional lecture-based instruction on the five topics: Triage, SDH and ETTC , AMI and D2B , COPD AE and TOCC , and Sepsis and the CVC Procedure. During the lectures, the instructor will encourage students to ask questions and engage in discussions to enhance understanding.
215078480|NCT06607198|DIAGNOSTIC_TEST|grading &amp; staging|To investigate the following pathological features of PitNET cell lineage-specific transcription factors, cell type specification by hormone production, proliferative index, p53, mitotic count, expression of somatostatin receptors
215078481|NCT06607198|DIAGNOSTIC_TEST|PitNET morphology analysis|Revision of the pre-surgical magnetic resonance images (MRIs): tumor maximum diameter, volume, sites of tumor extensions and invasion, and grading of cavernous sinus invasion
215078482|NCT06607198|DIAGNOSTIC_TEST|Radiomics|To investigate radiomics features of PitNETs
215078483|NCT06607198|DIAGNOSTIC_TEST|Molecular test: proteomics|To investigate on PitNets of molecular biomarkers Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\]
215078484|NCT06608251|DIAGNOSTIC_TEST|white matter lesion|According to the results of magnetic resonance, they were divided into white matter degeneration group and non-white matter degeneration group
215078485|NCT06607601|DRUG|Palbociclib|Treatment information in the electronic health record indicates initiation of palbociclib after metastatic diagnosis
215078486|NCT06607601|DRUG|Letrozole|Treatment information in the electronic health record indicates initiation of letrozole after metastatic diagnosis
215078487|NCT06608667|DEVICE|The study was retrospective and did not involve the application of interventions|The study was retrospective and did not involve the application of interventions
214957259|NCT02714556|OTHER|Physiologic measures of lung function|"Respiratory function tests:~Nitrogen multiple breath washout (N2MBW) measured with an ultrasonic flowmeter (Exhalyzer D with ICU insert, Eco Medics, Duernten, Switzerland) Forced oscillation technique (FOT) measured with a tremoFlo device (Thorasys, Montreal, Canada)"
214957260|NCT01047111|PROCEDURE|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
214957261|NCT04280614|BEHAVIORAL|Dialectical behaviour therapy (DBT)|DBT is based on the behavioural therapy principals focusing on four main modules: mindfulness, interpersonal effectiveness, emotional regulation and distress tolerance. The therapy is taught in a group and individual therapy model with coaching during periods of crisis. CBT is a standard model of therapy similar to DBT but is more direct in focusing clients on changing maladaptive behaviours or thoughts to effectively manage difficult emtions.
214957262|NCT01758042|PROCEDURE|Haploidentical Bone Marrow/Kidney|Combined bone marrow and kidney transplantation using a haploidentical donor.
214957263|NCT01066702|BIOLOGICAL|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
214957264|NCT01066702|PROCEDURE|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
214350060|NCT04704375|PROCEDURE|OMT (osteopathic manipulative treatment)|i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.
215078488|NCT06608654|DEVICE|endoscope application|Intrauterine bronchoscopy application for fetal distress during labor
214350061|NCT04704375|PROCEDURE|Light touch|Treaters will place their hands lightly on the subject's lumbar paraspinal muscles in the supine and prone positions in the same area as where one would place your hands for lumbar MFR technique for the same amount of time as it would take to perform MFR in this area (approximately 5 minutes). However, no lifting or action will be done. In addition, the subject will lie down on the BEMER mat (as they would do during a BEMER session), but the device will not be activated.
214350062|NCT02247609|GENETIC|Anti-CD19 CAR T cells|Autologous 4th generation withdrawable lentiviral-transduced anti-CD19-CAR T cells
214350063|NCT05309304|DRUG|Cefazolin|Cefazolin Injection - 2 g/100 mL or 3 g/150 mL
214350064|NCT01429532|PROCEDURE|phacoemulsification|Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)
214350065|NCT04525404|DIAGNOSTIC_TEST|MRI (heart, brain, lungs, liver)|MRI (heart, brain, lungs, liver)
214350066|NCT04525404|DIAGNOSTIC_TEST|Bloodwork|Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
214350067|NCT04525404|OTHER|Cognitive testing|NIH toolbox Cognitive Measures
214350068|NCT04525404|OTHER|Olfaction testing|Brief Smell Identification Test (BSIT)
214350069|NCT04525404|DIAGNOSTIC_TEST|Spirometry|Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
214350070|NCT04525404|OTHER|Walk Test|Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
214350071|NCT04543123|DEVICE|tDCS treatment|Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
214350072|NCT04543123|DRUG|Antidepressant Drug(escitalopram)|Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
214350073|NCT03477448|DRUG|Bleomycin|"an antibiotic derived from Streptomyces verticillus, has an antitumor, antibacterial, and antiviral activity that may be related to its ability to bind with DNA, causing bleomycin strand scission and elimination of pyrimidine and purine bases. The bleomycin hydrolase enzyme, which is known to inactivate bleomycin, is normally found in all body tissues but is present in very small amounts in skin .~* Intra-lesional bleomycin injection (IBI) has been used for the treatment of warts."
214350074|NCT03477448|DRUG|Purified Protein Derivative|"is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. It contains live, attenuated Mycobacterium bovis.~* Using this protein derivative for immunotherapy of warts is important for two major aspects. First, because the obligatory immunization program in many developing countries - with high prevalence of wart in many of them - includes BCG vaccination. PPD has a high prevalence of immunity in the general population. Second, although immunotherapy is generally an inexpensive method of treatment in wart patients, PPD, among conventionally used antigens, is the cheapest"
214350075|NCT03576547|DRUG|Dexamethasone|Given PO or IV
214350076|NCT03576547|DRUG|Ponatinib Hydrochloride|Given PO
214350077|NCT03576547|BIOLOGICAL|Rituximab|Given IV
214350078|NCT03576547|DRUG|Venetoclax|Given PO
214350079|NCT01461668|DRUG|Retapamulin|Two times a day for 5 days
214350080|NCT01461668|DRUG|Placebo|Two times a day for 5 days
214957265|NCT02079298|DRUG|Treatment with fluconazole.|
215078489|NCT00499330|PROCEDURE|lobectomy|
214350081|NCT01251003|BIOLOGICAL|Autologous cord blood|there is no minimum acceptable dose, and the maximum allowable dose will be 10x10(9)cells/kg given IV (in the vein), one time infusion
215078490|NCT00499330|PROCEDURE|segmentectomy or wedge resection|
215078491|NCT06608953|DEVICE|Enhanced external counterpulsation|A device applying external pneumatic cuff pressure to the lower limbs, thighs, and buttock sequentially in the diastolic phase synchronouslty with electrocardiography to assist the cardiac function via diastolic augmentation mechanism.
215078492|NCT06607133|PROCEDURE|surgery|patients undergo conventional/open thyroidectomy or endoscopic thyroidectomy for large benign thyroid nodules
215078493|NCT06607133|PROCEDURE|staged thermal ablation|patients undergo multiple sessions of thermal ablation for large benign thyroid nodules
215078494|NCT06589050|OTHER|"Toe flexor device experimental group"|This intervention group will perform toe flexion using a toe flexor (TF) device, which facilitates the shortening and stretching of the TF muscle-tendon units (MTUs) against resistance bands. While seated, participants will push a pedal down with their toes over two counts and release it over two counts.
214350082|NCT00931372|DRUG|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
214350083|NCT00931372|DRUG|Placebo|Subcutaneous injection
214350084|NCT02816580|OTHER|Blood collection|
214350085|NCT06117982|DRUG|Neupogen|Subcutaneous injection of 0.5 ml of Neupogen at a concentration of 300 micrograms/day for 4 consecutive days
214350086|NCT00379613|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
214957266|NCT02079298|DRUG|2. Treatment with both fluconazole and Ibuprofen.|
214957267|NCT02079298|DRUG|3. Treatment with ibuprofen.|
214957268|NCT02079298|OTHER|4. No treatment with either fluconazole nor ibuprofen.|
214957269|NCT00123656|DRUG|esomeprazole|esomeprazole dosed qam for 8 weeks
214957270|NCT00123656|DRUG|fluticasone|fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
214350087|NCT00379613|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
214350088|NCT02732418|DRUG|Depo-Provera CI|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
214350089|NCT02732418|DRUG|Depo-subQ 104|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
214350090|NCT03801239|DIAGNOSTIC_TEST|Urodynamic Study|during visit Week 0 patients had urodynamic study
214350091|NCT03801239|DIAGNOSTIC_TEST|OABSS questionnaire fulfilment|during visit Week 0 and Week 2 patients fulfilled OABSS
214350092|NCT03801239|DIAGNOSTIC_TEST|UDI-6 questionnaire fulfilment|during visit Week 2 patients fulfilled UDI-6 questionnaire
214350093|NCT03801239|DIAGNOSTIC_TEST|IIQ-7 questionnaire fulfilment|during visit Week 2 patients fulfilled IIQ-7 questionnaire
214350094|NCT00256581|PROCEDURE|Additional rest and stress image sets on new camera|
214350095|NCT05109299|OTHER|Miswak toothpaste|Dabur Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica'
214957271|NCT03706976|DEVICE|Tissue Oxygenation Monitoring|The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.
214957272|NCT00960973|DRUG|Menatetrenone|Menatetrenone 30 mg, 3 times a day for 4 weeks
214957273|NCT00960973|DRUG|Placebo|Placebo
214957274|NCT04221568|DRUG|Bupivacaine-fentanyl|local anathetic\&analgesic drugs
214957275|NCT04221568|DRUG|levobupivacaine-fentanyl|local anathetic\&analgesic drugs
214957276|NCT00312117|DRUG|Sodium bicarbonate|
214350096|NCT05109299|OTHER|Fluoride toothpaste|1450 ppm fluoride toothpaste
214957277|NCT00307853|DRUG|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
214957278|NCT00307853|OTHER|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
214957279|NCT00307853|OTHER|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
214350097|NCT03839251|DRUG|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
214957280|NCT06369610|DRUG|Abiraterone Acetate|Given abiraterone acetate
214957281|NCT06369610|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214350098|NCT03861013|BEHAVIORAL|Multidimensional stress prevention program (GeDStress)|The multidimensional stress prevention program (GeDStress) is composed of 8 session of 2-hour weekly sessions and integrated cognitive and behavioral strategies, mindfulness-based activities, emotional regulation and social skills exercises. Brief homework activities were given between sessions. The groups were composed by a maximum of 8 students and were led by two trained clinical psychologists.
214350099|NCT01024569|BEHAVIORAL|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
214350100|NCT05308251|PROCEDURE|Lichtenstein Mesh Hernioplasty|The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.
214350101|NCT02210364|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
214957282|NCT06369610|PROCEDURE|Computed Tomography|Undergo CT
214957283|NCT06369610|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given SC or IM
214957284|NCT06369610|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214957285|NCT06369610|PROCEDURE|Positron Emission Tomography|Undergo PET
214957286|NCT06369610|OTHER|Questionnaire Administration|Ancillary studies
214957287|NCT06369610|RADIATION|Radiation Therapy|Undergo radiation therapy
214957288|NCT00343655|DRUG|Atorvastatin|
214957289|NCT01607346|DRUG|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
214957290|NCT04920890|DEVICE|Radiofrequency therapy with manual therapy|Monopolar Capacitive Resistive Radio Frequency at 448 kHz (INDIBA®) (RFMCR) with manual therapy.
214957291|NCT00625183|DIETARY_SUPPLEMENT|selenomethionine|
214957292|NCT00625183|DRUG|capecitabine|
214957293|NCT00625183|DRUG|oxaliplatin|
214957294|NCT00625183|OTHER|laboratory biomarker analysis|
214957295|NCT00625183|OTHER|pharmacological study|
214957296|NCT00625183|PROCEDURE|adjuvant therapy|
214957297|NCT00625183|PROCEDURE|neoadjuvant therapy|
214957298|NCT00625183|PROCEDURE|therapeutic conventional surgery|
214957299|NCT00625183|RADIATION|radiation therapy|
214350102|NCT02210364|DRUG|capecitabine|capecitabine 150 mg tablets
214350103|NCT00302796|DRUG|Bioclavid|500 + 125 mg times 3 or 6
214350104|NCT00302796|DRUG|Placebo|
214350105|NCT01659931|DRUG|Montelukast|10 mg Tablet
214350106|NCT01659931|DRUG|Singulair|10 mg Tablet
214350107|NCT02676167|BEHAVIORAL|PrEP Intervention|
214350108|NCT05028218|DRUG|TQB3824 tablets|TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.
214350109|NCT04137042|DRUG|Saline|Intraoperative fluid therapy is administrated by using 0.9% saline
214350110|NCT04137042|DRUG|Balanced crystalloid|Intraoperative fluid therapy is administrated by using balanced crystalloid
214350111|NCT05184725|DEVICE|SaMD CARINAE|SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.
214350112|NCT05777642|DIETARY_SUPPLEMENT|Oxygen Nanobubble|This contains oxygenated nanobubbles made from lecithin and natural flavourings (Liquorice, glycerol, and citric acid)
214350113|NCT05777642|DIETARY_SUPPLEMENT|Placebo|This does not contain nanobubbles and is made from natural flavourings (Liquorice, glycerol, and citric acid)
214350114|NCT01219348|BIOLOGICAL|IDO peptide vaccination|Vaccination every second week
214350115|NCT00609687|PROCEDURE|Diagnostic Vitrectomy|"Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.~Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance."
214350116|NCT03754296|DEVICE|CATCHVIEW|Revascularization device
214350117|NCT03621605|BIOLOGICAL|VIB9600|"Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29)."
214350118|NCT03621605|DRUG|Placebos|Placebo administered by slow IV infusion or SC injection.
214350119|NCT04593446|DRUG|Oral Sulfate Tablet(ORA·FANGⓇ)|"Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery~Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery"
214350120|NCT04593446|DRUG|Sodium Picosulfate Solution(PicosolutionⓇ)|Sodium Picosulfate Solution(PicosolutionⓇ)
214957300|NCT06345391|OTHER|Co-creation|Participatory approach maximally and directly involving important stakeholders (bottom-up) to co-create a pain science education intervention for children living beyond cancer.
214350121|NCT00907153|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
214350122|NCT00907153|DRUG|Placebo|Placebo by mouth once daily for 12 weeks
214350123|NCT04546581|BIOLOGICAL|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is derived from the plasma of individuals who recover and develop neutralizing antibodies. Participants will receive a single infusion.
214957301|NCT06345391|OTHER|Concept Mapping|Concept mapping to create a pain science education intervention for children living beyond cancer.
214350124|NCT04546581|OTHER|Placebo|Participants will receive a single infusion of the placebo (saline).
214350125|NCT04546581|DRUG|Remdesivir|Remdesivir will be given to participants in both groups as standard of care (SOC).
214350126|NCT02212756|DRUG|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
214350127|NCT02212756|DRUG|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
214350128|NCT05629052|PROCEDURE|Pulmonary endarterectomy|Surgical removal of a chronic clot from the pulmonary artery
214957302|NCT05506514|OTHER|Water immersion|Comparison of 3 different water temperatures
214957303|NCT06653439|PROCEDURE|Bilateral ultrasound guided Subcostal Quadratus Lumborum Block|Bilateral ultrasound-guided subcostal quadratus lumborum block (20 mL, 0.25% bupivacaine, bilaterally) will be performed. All patients will receive multimodal analgesia, including a single dose of IV tenoxicam 20 mg. Additionally, 15 mg/kg IV paracetamol (based on IBW) will be administered at skin closure and continued every 6 hours postoperatively. A standardized IV PCA protocol will be initiated using a PCA device programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum of 0.1-0.15 mg/kg (IBW). Upon arrival in the PACU, patients with a resting NRS ≥4 will receive titrated IV morphine boluses of 0.03 mg/kg (IBW; max 10 mg) every 10 minutes until pain is controlled. In the surgical ward, patients with breakthrough pain (NRS ≥4) despite PCA use will receive IV tramadol 1-1.5 mg/kg (IBW) in 50-100 mg slow doses, not exceeding 400 mg/day.All patients will receive 8 mg dexamethasone and 0.15 mg/kg ondansetron (IBW) for PONV prophylaxis.
215078495|NCT06589050|OTHER|"Inclined Heel Rise experimental group"|This intervention group will perform single-leg heel rises on an inclined platform. Participants will place their hands against a barre for balance support, lift their heels over two counts, and lower them over two counts.
215078496|NCT02099877|DRUG|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
214957304|NCT06653439|PROCEDURE|Control|Patients in this group will not undergo plane blocks. IV morphine PCA multimodal analgesia will be provided: all patients will receive a single dose of IV tenoxicam 20 mg. Additionally, 15 mg/kg IV paracetamol (based on IBW) will be administered at skin closure and continued every 6 hours postoperatively. A standardized IV PCA protocol will be initiated for all patients using a PCA device, programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/kg (IBW). Upon arrival in PACU, patients with a resting NRS ≥4 will receive titrated IV morphine boluses of 0.03 mg/kg (IBW; max 10 mg) every 10 minutes until pain is controlled. In the ward, patients with breakthrough pain (NRS ≥4) despite PCA use will receive IV tramadol 1-1.5 mg/kg (IBW), administered slowly in 50-100 mg doses (max 400 mg/day). All patients will receive IV dexamethasone (8 mg) before induction and IV ondansetron (0.15 mg/kg IBW) near surgery end.
214957305|NCT06653439|DRUG|IV morphine PCA|A standardized IV PCA protocol will be initiated for all patients using a PCA device (Body Guard 575 pain manager, UK), programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/kg (IBW). No basal infusion will be used.
214957306|NCT03514979|BIOLOGICAL|Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination|Pneumococcal vaccines
214957307|NCT00842777|BEHAVIORAL|Parent manualized group treatment|"Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment"
214957308|NCT00842777|BEHAVIORAL|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
214957309|NCT01929954|BIOLOGICAL|Gintuit|One time placement of Gintuit over socket graft.
214957310|NCT01929954|DEVICE|Bio-Gide|One time placement of Bio-Gide over socket graft.
214957311|NCT03229967|DIAGNOSTIC_TEST|16S rRNA stool microbiome sequencing.|This is an observational cohort that will undergo gut microbiome sequencing.
214957312|NCT01187264|DRUG|Methotrexate|once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
214957313|NCT01687842|OTHER|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
214957314|NCT03118479|DRUG|Anastrozole Pill|10 mg of Anastrozole to be taken daily for 3 months.
215078497|NCT05596487|OTHER|repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.
214957315|NCT03118479|DRUG|Testosterone|Androgel 7.5 g to be applied transdermally daily for 3 months.
214957316|NCT03118479|DRUG|Placebo Oral Tablet|One tablet to be taken daily for 3 months
214350129|NCT05629052|PROCEDURE|Balloon pulmonary angioplasty|Catheter-based intervention to dilate occluded pulmonary vessels through the insertion and inflation of a small balloon
214350130|NCT05629052|DRUG|Pulmonary hypertension (PH)-specific medication|Treatment with any PH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
214350131|NCT05558033|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
214350132|NCT05558033|OTHER|Football Training|Routine football trainings
214350133|NCT01478867|OTHER|Detection of gluten in feces|Detection of Gluten in Feces
214957317|NCT03459859|DRUG|Pevonedistat|Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.
214957318|NCT03459859|DRUG|Cytarabine|Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.
214957319|NCT02348554|BEHAVIORAL|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
214678697|NCT03333785|BEHAVIORAL|eOncoNote|"* Diagnosis phase: The patient's nurse navigator will initiate an eOncoNote to the patient's PCP, inviting them to send any questions related to the patient's diagnostic process. The nurse navigator will initiate case closure after the diagnostic process has been completed (case will be open up to 4 months).~* Treatment phase: The patient's medical or radiation oncologist will initiate an eOncoNote to the patient's PCP inviting them to ask questions related to the patient's cancer treatment and/or request information related to the patient's co-morbidities. The oncologist will initiate case closure after the treatment has been completed.~* Survivorship phase: The patient's registered nurse within the Wellness Beyond Cancer Program will send an eOncoNote invitation to the patient's PCP inviting them to ask any questions as the patient transitions back to their care. The nurse will initiate case closure after one year."
214957320|NCT02348554|BEHAVIORAL|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
214350134|NCT04247620|BEHAVIORAL|DiaBetter Together|Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult, including (a) teaching and modeling strengths-based skills for goal-setting, problem-solving, and stress management; (b) guiding participants in obtaining support from their social support network (e.g., family, friends); (c) developing a plan for accountability around diabetes management and follow-up in adult care; (d) sharing his/her transition experiences and strategies for successfully navigating the adult healthcare system; (e) discussing how to prioritize diabetes self-care; and (f) assisting them in accessing diabetes-related resources (e.g., local diabetes groups, apps, social media). Contact will be in-person, by phone, email, text message, and/or video, approximately weekly for first 3 mos, approximately biweekly for next 3 mos, and approximately monthly for last 6 mos (while COVID-19 safety recommendations are in place, in-person meetings will not occur).
214350135|NCT04247620|BEHAVIORAL|Peer Mentor Delivery|Peer Mentors deliver the intervention to multiple young adult participants, each for 12 months. Peer Mentors may take on one or more participants at a time, and Peer Mentors may stay in their role in the study (delivering the intervention) for 1-3 years.
214350136|NCT00594269|DRUG|Risperidone|Discontinuation
214350137|NCT00594269|DRUG|Escitalopram|Discontinuation
214350138|NCT00594269|DRUG|Citalopram|Discontinuation
214350139|NCT00594269|DRUG|Sertraline|Discontinuation
214350140|NCT00594269|DRUG|Paroxetine|Discontinuation
214350141|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
214350142|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (90 mg) by single SC injection every other week
214350143|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week
214350144|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every other week
214350145|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
214350146|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
214350147|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h.
214350148|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
214350149|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
214350150|NCT01064037|DRUG|Placebo|Infusion during 48h
214350151|NCT01421563|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
214350152|NCT02062632|DRUG|Doxepin Hydrochloride|Given orally
214678698|NCT00658970|DRUG|KX2-391|2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
214678699|NCT00940342|DRUG|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
214957321|NCT01451554|BEHAVIORAL|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
214957322|NCT01451554|BEHAVIORAL|Usual Care|self-help booklets
214957323|NCT05699876|DRUG|Melatonin 6 MG|melatonin will be administered orally preoperatively as premedication
214957324|NCT05699876|DRUG|Gabapentin|melatonin will be administered orally preoperatively as premedication
214957325|NCT00942539|DRUG|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
214350153|NCT02062632|OTHER|Placebo|Given orally
214350154|NCT02062632|OTHER|Quality-of-Life Assessment|Ancillary studies
214350155|NCT02062632|OTHER|Questionnaire Administration|Ancillary studies
214957326|NCT00671125|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
214957327|NCT00671125|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
214957328|NCT00671125|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
214350156|NCT02212028|DRUG|prasugrel|the effects of whole tablets versus crushed tablets will be compared
214350157|NCT00978601|PROCEDURE|Multimodal analgesic protocol during minimally invasive myomectomy|Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.
214350158|NCT01043666|DRUG|YM178|oral
214350159|NCT01043666|DRUG|Placebo|oral
214350160|NCT01043666|DRUG|tolterodine ER|oral
214350161|NCT02280044|BIOLOGICAL|Rifaximin intervention|Rifaximin administered then Challenge with C jejuni
214350162|NCT02280044|BIOLOGICAL|Placebo intervention|Placebo administered then Challenge with C jejuni
214350163|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
214350164|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
214350165|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
214350166|NCT05119920|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
214350167|NCT03618238|DRUG|Anlotinib|12 mg daily for continus 14 days every 21 days
214350168|NCT04857268|DEVICE|wearable continuous ECG monitoring patch, ATP-C120|"ATP-C120 is a novel, single-lead ECG monitoring device which can continuously monitor the ECG signal as long as 14 days (11 days if the device is connected to the smartphone via Bluetooth) when attached to skin adjacent to the heart of patients. It weighs about 8.3 g, with a size of 84 × 39 × 8.3 mm.~When the device is attached to the patient, several predefined methods were utilized to prevent the occurrence of noise or signal loss. First, the skin was cleansed and disinfected using a 70% ethanol solution. Skin hair was removed if needed. Then the protection film was removed from the patient-side surface of the device. The device is placed at the left 3rd intercostal space 45 degrees tilted toward the inside."
214350169|NCT06831071|DRUG|Pimonidazole|Drug: Pimonidazole Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
214350170|NCT01085851|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
214350171|NCT01085851|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
214350172|NCT00581230|DEVICE|Laryngoscopy with RAMP|inflatable positioning ramp
214350173|NCT00581230|DEVICE|Laryngoscopy without RAMP|Laryngoscopy without RAMP
214350174|NCT02241967|DEVICE|4 Real sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp.
214350175|NCT02241967|DEVICE|2 Real Sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 2 real sessions of tDCS and 2 sham.
214350176|NCT02241967|DEVICE|1 Real Session of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 1 real sessions of tDCS and 3 sham.
214350177|NCT02241967|DEVICE|Sham Transcranial Direct Current Stimulation|Four sessions of sham tDCS; control intervention.
214350178|NCT05211765|DIAGNOSTIC_TEST|Superior vena cava transthoracic evaluation|The superior vena cava will be observed with a cardiac ultrasound machine, its diameter in different respiratory phases evaluated and compared with fluid response.
214350179|NCT05556863|DRUG|ELA026|Single dose of ELA026
214350180|NCT05556863|DRUG|ELA026|Multiple doses of ELA026
214350181|NCT00660842|PROCEDURE|carboplatin|AUC 6 IV day 1 every 21 days
214350182|NCT00660842|DRUG|paclitaxel|175 mg/m2 IV day 1 every 21 days
214350183|NCT00660842|DRUG|carboplatin|AUC 2 IV every week
214350184|NCT00660842|DRUG|paclitaxel|60mg/m2 IV every week
214350185|NCT02552524|DEVICE|rTMS active then rTMS placebo|A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo
214350186|NCT02552524|DEVICE|rTMS placebo then rTMS active|A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
214350187|NCT00575575|BEHAVIORAL|cognitive behavior therapy|cognitive behavior therapy once a week
214350188|NCT02031887|DIETARY_SUPPLEMENT|formula with synbiotics|
214350189|NCT02031887|DIETARY_SUPPLEMENT|formula without synbiotics|
214350190|NCT05134012|DRUG|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|\[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
214350191|NCT04988854|BEHAVIORAL|Facial expression video|Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.
214350192|NCT04517396|OTHER|Fenofibrate/fenofibric acid|The randomized intervention will be fenofibrate (Tricor) at a dose of 145 mg/d or dose-equivalent preparation of fenofibrate or fenofibric acid, for 10 days. In all cases, appropriate dose reductions will be implemented for patients with chronic kidney disease as per the approved preparation label. The intended duration of randomized treatment will be for 10 days.
214350193|NCT04517396|OTHER|Placebo|The control intervention will be a placebo, for 10 days.
214350194|NCT04517396|OTHER|Usual care|All participants will otherwise receive usual medical care
214350195|NCT01804920|DIETARY_SUPPLEMENT|D-serine|
214350196|NCT01804920|DIETARY_SUPPLEMENT|Placebo|
214350197|NCT03724643|OTHER|Protocolized wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 \< 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI \< 105 breaths/min/L). Respiratory distress signs included RR \> 30 breaths/min, SaO2\< 90%, HR \> 140 beats/min, or a sustained change in HR of \>20%, systolic BP \>200 mmHg or \<80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
214678700|NCT00940342|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly for four weeks
214678701|NCT03330743|BEHAVIORAL|Parent Mentor with Standard Education|Parent mentors will provide coaching based on the current guidelines around diet and physical activity
214350198|NCT06963164|OTHER|Helping Hand - Joint Protection Program|"Joint protection refers to a set of techniques and strategies that help reduce stress on the joints, manage pain, and prevent further joint damage. These techniques are particularly important for people with hand arthritis, as the small joints in the hands are often affected, leading to pain, stiffness, and difficulty performing daily tasks. Key principles of joint protection include:~1. Using larger, stronger joints whenever possible (e.g., using the forearm instead of the fingers to push open a door).~2. Reducing strain by spreading the load across multiple joints (e.g., carrying items with two hands instead of one).~3. Avoid tight gripping or pinching motions that can overstrain the joints.~4. Incorporating assistive devices to reduce effort during tasks (e.g., jar openers or ergonomic tools).~5. Pacing and prioritizing activities to avoid overuse of the joints and allow for adequate rest"
214350199|NCT01217710|BEHAVIORAL|Activity monitor/smartphone health coaching|Initial health coaching at enrollment will involve the collaborative creation of an action plan with personally relevant, specific actions for increasing physical activity. The short term goals will be rated for self-efficacy and modified to maximize likelihood of success. Health coaches will discuss important mediators of physical activity (e.g., self-efficacy, enjoyment, social support, problem-solving). Weekly coaching calls will involve discussion of progress toward goals and problem-solving of barriers utilizing a motivational interviewing approach. Motivational messages will also be developed and sent daily to participants via the smartphone. These messages will indicate the percentage of steps related to their daily goal.
214350200|NCT04088552|OTHER|"Go4Life-Physical Activity/Exercise Program Workout to Go 5"|"The Go4Life-Physical Activity/Exercise Program Workout to Go 5 Program is an exercise regimen provided to participants. Participants will be provided a booklet with exercise routines that requires minimal equipment and can be performed anywhere for approximately 30 minutes per session. Recommendation on staying active by increasing daily steps through walking will also be recommended as part of the regimen."
214350201|NCT04088552|BEHAVIORAL|ActuaYa Educational Sessions|The ActuaYa Educational Sessions will be delivered by a facilitator in 3 separate sessions with each session lasting 2.5 hours for a total of 7.5 hours administered for the study duration. Each session will be conducted in separate groups of 6-10 participants. Session 1 will discuss the impact of chronic disease in the older Hispanic community. Session 2 will discuss the communication and negotiation with the family and partner. Session 3 will discuss saying goodbye and having a plan for a healthy lifestyle.
214350202|NCT03042065|DEVICE|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
214350203|NCT03042065|DEVICE|jet nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
214350204|NCT02332720|DRUG|Grazoprevir|Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.
214350205|NCT02332720|DRUG|Uprifosbuvir|Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.
214350206|NCT02332720|DRUG|Elbasvir|Part A: one elbasvir 50 mg tablet taken q.d. by mouth.
214957329|NCT00852280|DEVICE|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
214957330|NCT04091204|DRUG|Olaparib tablets|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
214957331|NCT01108692|OTHER|Telecardiology|"Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups."
214957332|NCT01402986|OTHER|Placebo Q2W|Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
214957333|NCT01402986|BIOLOGICAL|Tralokinumab 300 mg, Q2W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
215078498|NCT06819995|PROCEDURE|Static guided implant placement with a 3D printed guide|3D-printed guides (E-Guide resin, EnvisionTEC®, Germany) (D4K Pro printer, EnvisionTEC®, Germany) performed by acommercial manufacturing center (Archimedes, Spain). All guides will be designed with guide sleeves. Finally, the guide will be post-processed and sterilized according to the manufacturer's recommendations.
215078499|NCT06819995|PROCEDURE|Static guided implant placement with a milled guide|Milled guides (anaxCAM PMMA Clear blanks, Anaxdent, Germany) (CORiTEC 150i PRO miller, Imes-icore®, Germany). All guides will be designed with guide sleeves. Finally, the guide will be post-processed and sterilized according to the manufacturer's recommendations.
214350207|NCT02332720|DRUG|Ruzasvir|Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.
214350208|NCT02332720|DRUG|MK-3682B|Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
214350209|NCT02332720|DRUG|Ribavirin (RBV)|Part B and Part C: RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.
214678702|NCT03330743|BEHAVIORAL|Parent Mentor with Positive Deviance|Parent mentors will provide coaching based on findings from the positive deviance study
214678703|NCT02028104|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
214678704|NCT05556382|RADIATION|radiation of brain tissue specimen and dna damage analysis|increasing doses of radiation on brain tissue specimen and analysis of related dna damage.
214957334|NCT01402986|OTHER|Placebo, Q2/4W|Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
214957335|NCT01402986|BIOLOGICAL|Tralokinumab 300 mg, Q2/4W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
214957336|NCT00280813|BEHAVIORAL|Supportive Treatment in Addiction Recovery (STAR)|
214350210|NCT04196179|DRUG|ANG3070|ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.
214350211|NCT04196179|DRUG|Placebo oral capsule|ANG-3070 placebo capsules visually match the drug product.
214350212|NCT06233513|BEHAVIORAL|Exp 3 Speaking Task|Participant will sit in front of a computer screen in a quiet room and to produce speech based on what is on the screen. Participant may see real words or nonsense words to read. Investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. This task takes about one hour to complete.
214957337|NCT01997970|BEHAVIORAL|Treadmill workstation|The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.
214957338|NCT01997970|BEHAVIORAL|Health talk|Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
214957339|NCT01085084|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
214350213|NCT05154864|PROCEDURE|SBUF-SMUF|Intra-operative continuous ultrafiltration
214350214|NCT03832010|DRUG|Crisaborole|Participants will be instructed to apply crisaborole to affected areas with eczema.
214350215|NCT03832010|DRUG|Hydrocortisone Ointment|Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
214350216|NCT03832010|DRUG|Triamcinolone ointment|Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.
214350217|NCT03832010|DRUG|Aquaphor|Participants will be instructed to moisturize all over the body with Aquaphor.
214350218|NCT01436058|BIOLOGICAL|mesenchymal stem cell|intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
214350219|NCT04788667|OTHER|A health education programme using a telerehabilitation platform|All patients enrolled in the study will receive information through the tele rehabilitation platform, although the experimental group will have specific training/education whereas the control group will only receive some general recommendations as control/sham
214350220|NCT06525194|BEHAVIORAL|Education|"An Interprofessional Education Program Based on the ARCS-V Motivation Model on the Theme of Chronic Disease Management and Patient Safety"
214350221|NCT00668122|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin XR 1000 mg orally once a day
214350222|NCT00668122|DRUG|Cipro IR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin IR 500 mg orally twice a day
214350223|NCT06237205|DRUG|Niraparib|a highly selective PARP1 and PARP2 inhibitor
214350224|NCT06491147|OTHER|Emergency front of neck access|"The algorithm in the DAS manual will be explained. Following this, the researcher will demonstrate the scalpel spark plug technique with a 4-step approach that is frequently used in skill teaching.~In step 1 of this approach, the technique will be demonstrated without any verbal explanation.~In the 2nd step, the technique will be demonstrated with verbal expression. In the 3rd step, the participant will be asked to have the trainer do it. In the 4th and last step, the participant will apply eFONA from start to finish."
214350225|NCT03326687|BEHAVIORAL|Treatment ABAB|Participants will perform the phases in the ABAB order.
214350226|NCT03326687|BEHAVIORAL|Treatment BABA|Participants will perform the phases in the BABA order.
214350227|NCT05582876|RADIATION|Radiopharmaceutical 68Ga-PSMA-11 PET/CT|The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.
214350228|NCT02207010|BIOLOGICAL|AZD1775|All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
214350229|NCT01332877|BEHAVIORAL|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
214350230|NCT01332877|BEHAVIORAL|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
214350231|NCT01412944|DRUG|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
214957340|NCT01085084|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
214957341|NCT02427802|DRUG|Gentamicin collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
214350232|NCT01412944|DRUG|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
214350233|NCT01990950|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
214350234|NCT05225493|BEHAVIORAL|Peer to peer feedback|HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
214350235|NCT05225493|DIAGNOSTIC_TEST|HIV rapid test|Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
214957342|NCT02427802|OTHER|Placebo|Matching collagen sponge
214957343|NCT02749799|DRUG|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
214957344|NCT01132300|DEVICE|Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)|Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
215078500|NCT01677598|DRUG|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
215078501|NCT03296137|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
215078502|NCT03296137|DRUG|Ipilimumab|One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
215078503|NCT03296137|DRUG|Nivolumab|4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
214350236|NCT04227015|DRUG|CTA101|CTA101 UCAR-T cell injection by intravenous infusion
214350237|NCT06489743|OTHER|6-minute walk test (6MWT)|6-minute walk test (6MWT) will be performed according to clinical standards
214350238|NCT05965011|OTHER|Exercise training|The intervention will be a combination of both supervised and unsupervised sessions. Participants in the Nordic Walking (NW) treatment group will attend 5 one-hour group sessions, which will incorporate coaching principles.
214350239|NCT04938245|DEVICE|Spinal Cord Stimulation|"Intraoperatively, stimulation at 12 Hz will be performed as the leads are moved into the targeted position. Amplitude will be increased to 15 mA maximum total until a response is seen on any electrode and held for 10 seconds. Stimulation and recording will be performed using the Neuralynx stim/record system.~Post-operatively, the electrodes will be tested for impedance by the clinical system and then they will be connected to the Neuralynx stim/record system. Electrode stimulation patterns will be applied with increasing amplitude until ECAPs responses are seen on recording electrodes. 42 Hz stimulation will be performed with an amplitude sweep of 0mA-10mA. At each amplitude, stimulation will be applied for 4 seconds followed by 2 seconds of rest. Pulse width will be varied from 30-450 microseconds to test effective amplitude. Bursting stimulation will be applied to detect differences in ECAPs as above."
214350240|NCT01672775|DRUG|AGS-16C3F|intravenous (IV) infusion
214350241|NCT05779995|DRUG|XW001|Inhalation solution
214678705|NCT02320799|BEHAVIORAL|interpersonal psychotherapy|Interpersonal psychotherapy is an evidence based, structured, brief psychotherapy which improves relationships in order to improve mood and reduce anxiety
214957345|NCT01894971|DEVICE|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|
214350242|NCT05779995|DRUG|Placebo|Inhalation solution with matched volume
214350243|NCT05840198|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
214350244|NCT05840198|OTHER|Treatment as usual|Youth in this condition receive treatment as usual from their health care providers
214350245|NCT06282341|OTHER|Race: Simulated marathon|Participants will take part in a race: simulated marathon. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
214350246|NCT06282341|OTHER|Race: Simulated trail|Participants will take part in a race: simulated trail. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
214350247|NCT06282341|OTHER|Race: Trail in nature|Participants will take part in a race: trail in nature. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
214957346|NCT02634983|DRUG|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
214957347|NCT02634983|DRUG|Placebo|Matching placebo
214957348|NCT00701571|PROCEDURE|Virtual Reality distraction|"Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is Snow World. In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities."
214957349|NCT02070978|DRUG|Atacicept 75 mg|Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
214957350|NCT02070978|DRUG|Atacicept 150 mg|Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
214957351|NCT02070978|DRUG|Atacicept 150 mg|Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
214957352|NCT03749109|DRUG|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg for daily releases
214957353|NCT03749109|DRUG|Placebo|Matching placebo
214957354|NCT00509353|DRUG|irinotecan hydrochloride|
214957355|NCT00509353|DRUG|vincristine sulfate|
214957356|NCT00509353|RADIATION|iobenguane I 131|
215078504|NCT03296137|DRUG|proleukin|2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
214350248|NCT04321837|DIETARY_SUPPLEMENT|Coral Complex 3|Coral-derived calcium supplement fortified with vitamin D3
214350249|NCT04321837|DRUG|Ibandronate|Bisphosphonate
214350250|NCT04321837|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3
214486757|NCT06870903|PROCEDURE|Extraperitoneal(transvaginal paracervical sentinel lymphadenectomy) group lymphadenectomy|The procedure begins with a vaginal incision in the lateral vaginal fornices (on both sides), which is then extended to allow placement of the V-NOTES apparatus. By identifying an appropriate cleavage plane, the obturator fossa is accessed to excise the obturator lymph nodes. Following this, an anterior colpotomy is performed to access the vesicocervical space, and a posterior colpotomy is made to open the rectouterine pouch. The V-NOTES apparatus is then placed to continue with the hysterectomy and bilateral salpingo-oophorectomy (BSO).
214486758|NCT06870903|PROCEDURE|Transperitoneal lymphadenectomy|In this arm, patients will undergo transperitoneal lymphadenectomy with V-NOTES. The procedure begins with anterior and posterior colpotomies, followed by placement of the V-NOTES apparatus. Hysterectomy is performed first, followed by peritoneal dissection and lymph node excision.
214486759|NCT06870123|DEVICE|TT cup and ST-C cup|Patients are allocated in 2 different group (one with ST-C Cup and another one with TT Cup)
214486760|NCT06868602|OTHER|psychoeducation|Although the literature investigating the effectiveness of exercise programs on quality of life, physical function and depression in sarcopenic individuals is extensive, no studies have been found in which psychoeducation programs are applied to sarcopenic individuals and their effectiveness is investigated. In this planned study,Researchers aim to observe what kind of results will emerge and in what direction the psychoeducation program will shape the treatment by applying both exercise and psychoeducation programs to sarcopenic individuals.
215078505|NCT03296137|DRUG|Cyclophosphamide|2 doses (60 mg/kg) prior to TIL infusion
214350251|NCT06636630|PROCEDURE|Quadruple scleral flap|Quadruple Flap Technique (Group B) A 360-degree peritomy will be performed to expose the underlying sclera. Following evisceration of the ocular contents, careful hemostasis will be achieved. Four muscular-tendinous flaps will be developed from the recti muscles. These flaps will be dissected under minimal tension to preserve their vascular supply. The prepared flaps will be draped over the implant in a manner that the edges slightly overlap, ensuring complete coverage. The flaps will be sutured together using silk sutures, securing the implant in place.The conjunctiva will be meticulously closed over the muscle flaps with continuous absorbable sutures to enhance the healing process and minimize postoperative discomfort.
214957357|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
214350252|NCT06636630|PROCEDURE|Double scleral flap|The double flap technique, which involves the creation of two scleral flaps to encase and secure the implant, has been a standard approach in many surgical settings. This method aims to cover the implant adequately, thereby minimizing exposure risks and enhancing the potential for implant motility.
214957358|NCT03178851|DRUG|Cobimetinib|Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit
214957359|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
214957360|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
214957361|NCT01804153|DRUG|Adipose-derived expanded stem cells|Intralesional application ASC
214957362|NCT03951753|DRUG|Tirzepatide|Administered SC
214957363|NCT03951753|DRUG|Semaglutide|Administered SC
214957364|NCT03951753|DRUG|Placebo|Administered SC
214957365|NCT05585554|RADIATION|MRIdian|Stereotactic MRI-guided On-table Adaptive Radiation Therapy delivered on MRIdian linac
214957366|NCT04633291|DEVICE|Novel swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
214957367|NCT04633291|DEVICE|Comparator swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
214957368|NCT00946127|PROCEDURE|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
214957369|NCT00946127|PROCEDURE|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
214957370|NCT02226120|DRUG|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
214957371|NCT04012346|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.
214957372|NCT04418089|DRUG|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
214957373|NCT04418089|DRUG|Placebo oral capsule|The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
214957374|NCT05313646|BIOLOGICAL|batch 1 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
214957375|NCT05313646|BIOLOGICAL|batch 2 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
214350253|NCT05531994|DRUG|Montelukast sodium oral thin films with water (T)|Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL
214350254|NCT05531994|DRUG|Montelukast sodium chewable tablets with water (R)|Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
214350255|NCT03892486|OTHER|The high PUFA diet group|Assumptions of nutritional intervention: in a randomized manner volunteers will be assigned to one of two groups: a control group which will receive general nutritional recommendations, based on the Polish nutrition pyramid, and the intervention group which will receive nutritional recommendations, based on the Polish nutrition pyramid and will consume at least 4 tablespoons of olive oil or 30 grams of nuts every day for 12 weeks.
214350256|NCT06030726|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
214957376|NCT05313646|BIOLOGICAL|batch 3 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
214957377|NCT00427219|DRUG|Ozarelix|Ozarelix 15 mg will be administered IM on Day 0 and Day 14.
214957378|NCT00427219|DRUG|Placebo|Placebo will be administered IM on Day 0 and Day 14.
214957379|NCT02910934|OTHER|Actellic CS|Indoor residual spray with Actellic CS
214957380|NCT04931719|COMBINATION_PRODUCT|PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
214957381|NCT04931719|COMBINATION_PRODUCT|PRP+ HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
214957382|NCT00200941|DRUG|Topiramate|
214957383|NCT01897519|DRUG|Placebo|Placebo infusion
214957384|NCT01897519|DRUG|ABT-719|Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
214957385|NCT03757403|DRUG|RDD1609|RDD1609 to be applied on the perianal area BID
214957386|NCT03757403|DRUG|Mebendazole 100 MG|Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
214957387|NCT00373802|DRUG|Phenylephrine|
214957388|NCT05277064|OTHER|Oral FOB|After induction of anesthesia and muscle relaxation, An investigator who has experiences of numerous fiberoptic intubations will measure the optimal preliminary insertion depth of the fiberoptic bronchoscope for oral fiberoptic intubation.
214957389|NCT02669043|DRUG|Ketamine|Intravenous ketamine 0.5mg/kg over 40 minutes
214957390|NCT02324621|DRUG|Oral ONC201|Given PO
214957391|NCT02324621|OTHER|pharmacological study|Correlative studies
214350257|NCT02419157|DRUG|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
214350258|NCT02419157|DRUG|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
214957392|NCT02324621|OTHER|laboratory biomarker analysis|Correlative studies
214957393|NCT03884270|BEHAVIORAL|Hypnotherapy|7 sessions of self-administered gut-directed hypnotherapy for functional dyspepsia
214957394|NCT03947593|OTHER|No Intervention|No intervention is being administered.
214957395|NCT01158105|DRUG|Bortezomib|1.6 mg/m2 IV infusion on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles.Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles.This maintenance dose will be administered on days 1 and 15.
214957396|NCT01880905|PROCEDURE|Measure of uteroovarian ligament length during gynecological surgery|
214957397|NCT00661453|DRUG|Valproic Acid and Levocarnitine|Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
214957398|NCT06197477|DEVICE|OurAir SQ 1750 - Mobile Air Purification System for indoor|Filtration device will be placed in classrooms. Computational Fluid Dynamics simulations will be used to find optimal position and operation mode for air purification systems in classrooms.
214957399|NCT06197477|DEVICE|Sham intervention|Filtration will be turned off in the control part of the study and then will be turned on during the intervention.
214957400|NCT04991038|DEVICE|DAISe Device|Thrombectomy using the DAISE device
214957401|NCT04991038|DEVICE|Trevo or Solitaire|Thrombectomy using TREVO or Solitaire device
214957402|NCT06463379|DRUG|Solumedrol|2 days pulse steroid injection 125 mg methylrednisolone
214957403|NCT02803359|PROCEDURE|Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold|
214350259|NCT02419157|DEVICE|Clearfil SE Bond|
214957404|NCT05047484|DRUG|ALXN2050|Powder-in-capsule (PIC).
214957405|NCT05047484|DRUG|Placebo|PIC.
214957406|NCT01309984|DRUG|Lusedra|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
214957407|NCT01309984|DRUG|Propofol|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
214957408|NCT05583786|DIAGNOSTIC_TEST|Tracing intracoronary electrocardiogram|icECG ST-segment shift remission time (τ-icECG) tracing during reactive-hyperemia, obtained immediately after a 1-minute upstream coronary artery balloon occlusion.
214957409|NCT05683925|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
214957410|NCT05683925|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
214957411|NCT05683925|DEVICE|Noninvasive transcutaneous earlobe stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
214957412|NCT02758197|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) course directly following medical treatment optimization. The MBSR course consists of eight weekly 2-hour sessions and one 6 hour session midway through the course and involves psychoeducation, relaxation techniques, gentle stretching (very mild form of yoga), and different forms of meditation. Participants will learn ways to better cope with their pain and the disability and distress related to it with a goal of reducing the stress response that is our body's normal reaction to pain. All sessions will be conducted by a psychologist or social worker with a minimum of 2 years of experience in chronic pain management, formal MBSR training and 2 years of experience leading MBSR groups.
214957413|NCT02157597|OTHER|NIRS based management|"1. Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair~2. Deepen anesthesia with volatile or intravenous agent.~3. Consider Extra-Corporeal Membrane Oxygenation (ECMO)."
214957414|NCT02157597|OTHER|Control|During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
215078506|NCT03296137|DRUG|Fludara|5 doses (25 mg/m2) prior to TIL infusion
215078507|NCT06611345|DEVICE|Tumor Treating Fields|Tumor treating fields will be used each day.
215078508|NCT06611345|DRUG|Durvalumab|Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).
215078509|NCT06611345|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
215078510|NCT06611345|DRUG|Cisplatin|Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
215078511|NCT06660784|DRUG|Nitric Oxide|Depending on the indication, the subjects will be given NO treatment or not. In ECMO assisted mechanical ventilation + NO treatment group, the subjects will be randomly assigned to NO treatment via ventilator or membrane oxygenator.
214350260|NCT02419157|DEVICE|Xeno V|
214350261|NCT00628732|DRUG|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
214350262|NCT05646875|OTHER|hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA
214350263|NCT01298960|DRUG|Somatropin|0.1 IU/Kg/day from day one of stimulation until rHCG triggering
214350264|NCT01761435|BIOLOGICAL|Influenza vaccine|"Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline."
214957415|NCT05302024|DRUG|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
214957416|NCT05388422|DEVICE|Application of 3D scanner to measure physical size in patients with severe cerebral palsy|Before starting the study, radiologic and clinical evaluation were performed. After measuring the patient's exact physical size by applying a 3D scanner, we manufacture hip brace in preventing progressive hip displacement in patients with severe cerebral palsy. After wearing for a week, follow-up radiologic and clinical evaluation were performed.
214957417|NCT05584085|BEHAVIORAL|ACT-DE|Acceptance and Commitment Therapy is a third-wave psychological therapy to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the ACT hexagonal model, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
214957418|NCT06111001|OTHER|Email use data collection|Participants will initiate the AirEmail v1 Digital Tool. Non-identifiable email use data will be collected.
214957419|NCT06111001|OTHER|AirEmail Tips and Tricks training|"Participants will watch the AirEmail Tips and Tricks training videos ahead of using the AirEmail v1 Digital Tool"
214957420|NCT06111001|OTHER|AirEmail v1 Digital Tool use|Participants will use the AirEmail v1 Digital Tool features as part of their routine email management in NHSmail, the NHS's Microsoft 365 Outlook platform.
214957421|NCT01037816|DRUG|FS-67 Patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
214678706|NCT02320799|BEHAVIORAL|treatment as usual|Clinic psychosocial treatment as usual
214350265|NCT05944419|DEVICE|Immediate implant surgery|Placement of immediate implant and immediate provisionalization after tooth extraction
214350266|NCT02169934|DRUG|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
214350267|NCT03965260|BIOLOGICAL|Bacterial samples from blood or peritoneal liquids|"For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance."
214350268|NCT02199782|OTHER|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
214350269|NCT02945865|OTHER|Pain assessment|Pain assessment with assessment tools
214678707|NCT03924024|DEVICE|Accelerated intermittent theta burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Stimulation intensity will be standardized to 80% of resting motor threshold.~Stimulation will be delivered to L-DLPFC using the Brainsway stimulator."
214678708|NCT04090931|PROCEDURE|Orthodontic treatment|leveling and aligning stage in orthodontics
214678709|NCT04534062|OTHER|PNF D2 technique|PNF D2 technique of bilateral upper limb will be performed
214678710|NCT02341170|RADIATION|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
214678711|NCT03719560|DRUG|Methotrexate|Systemic methotrexate
214678712|NCT03719560|DRUG|Cytarabine|Systemic cytarabine
214678713|NCT04982432|DRUG|Orismilast|Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties
214957422|NCT01037816|OTHER|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
214957423|NCT02938234|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
214350270|NCT04154124|DIAGNOSTIC_TEST|PET/MR scan|whole-body PET/CT scan and pelvic PET/MR scan (MR protocol will include three plane fast spin echo T2 weighted, DWI and dynamic contrast enhanced imaging). The ad interim assessment will use a pelvic PET/MR scan only (without PET/CT), to avoid the radiation associated with whole body CT. In the staging and post-nT assessment, the addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
214350271|NCT05127343|PROCEDURE|Sealing deep pits and fissures|Application of the pit and fissure sealant
214350272|NCT06370767|BEHAVIORAL|Bike-Share Travel Training|Half of the participants not assigned to the waitlist will begin the bike-share intervention arm immediately after the baseline research interview. The bike-share arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the bike-share intervention arm after an 8-week waiting period.
214350273|NCT06370767|BEHAVIORAL|Public Transportation Travel Training|Half of the participants not assigned to the waitlist or bike-share arm will begin the public transportation intervention arm immediately after the baseline research interview. The public transportation arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the public transportation intervention arm after an 8-week waiting period.
214350274|NCT01343368|DRUG|Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
214350275|NCT01343368|BIOLOGICAL|hematopoietic cell transplant|Conventional bone marrow transplant regimen.
214350276|NCT01343368|BIOLOGICAL|reduced intensity allogeneic HCT|A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
214350277|NCT02794402|DRUG|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
214350278|NCT02794402|BEHAVIORAL|Placebo|Placebo once weekly injections sc
214350279|NCT01178151|DRUG|Everolimus|10mg daily orally
214350280|NCT04116931|DRUG|Switch ticagrelor to clopidogrel|Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
214350281|NCT01436903|DEVICE|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
214350282|NCT02501343|DRUG|Sodium Bicarbonate Oral Capsule|Sodium bicarbonate 1680 mg will be administered prior to the meal
214350283|NCT02501343|DRUG|Placebo|Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
214350284|NCT00321854|DRUG|pramipexole|
214350285|NCT02123693|OTHER|Osteopathic manipulative treatment|
214957424|NCT06731062|DEVICE|EF192A|EF192A will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. EF192A will be reapplied to the participants' back in a naive area and removed after 48 hours.
214957425|NCT06731062|DEVICE|Saline solution|The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back in a naive area and removed after 48 hours.
214350286|NCT02123693|OTHER|Sham Therapy|
214957426|NCT06918808|BIOLOGICAL|DB-3Q|DB-3Q (IMP) is the frozen liquid formulation of acellular secretome proteins and extracellular vesicles isolated from human bmMSC and processed under current Good Manufacturing Process standards.
214957427|NCT06918808|BIOLOGICAL|Placebo|0.9% NaCl
214957428|NCT06920459|DEVICE|Alliance™ Glenoid|Total Shoulder Arthroplasty using the Alliance™ Glenoid implant
214350287|NCT02123693|OTHER|No Intervention|
214350288|NCT00396903|DEVICE|catheter|
214957429|NCT06006598|DRUG|BI 1584862|BI 1584862
214957430|NCT06006598|DRUG|Placebo matching BI 1584862|Placebo matching BI 1584862
214350289|NCT04363801|DRUG|DKN-01 300mg|Administered by IV infusion
214350290|NCT04363801|DRUG|DKN-01 600mg|Administered by IV infusion
214350291|NCT04363801|DRUG|DKN-01 400mg|Administered by IV infusion
214350292|NCT04363801|DRUG|Tislelizumab 200mg|Administered by IV infusion
214350293|NCT04363801|DRUG|Tislelizumab 400mg|Administered by IV infusion
214350294|NCT04363801|DRUG|Oxaliplatin|Administered by IV infusion
214350295|NCT04363801|DRUG|Capecitabine 1000mg/ m2 BID|Administered orally
214350296|NCT04363801|DRUG|Leucovorin Calcium|Administered by IV infusion
214350297|NCT04363801|DRUG|Fluorouracil|Administered by IV infusion
214350298|NCT06062680|DRUG|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
214350299|NCT01138904|DRUG|irinotecan, oxaliplatin|"OXIR: FOLFOX -\> FOLFIRI~IROX: FOLFIRI -\> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
214350300|NCT01138904|DRUG|oxaliplatin, irinotecan|"FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
214350301|NCT03204279|DRUG|Netupitant|Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
214957431|NCT06006598|DRUG|midazolam|midazolam
214957432|NCT06931691|DRUG|LNP023|Capsules for oral administration
214957433|NCT03973255|BEHAVIORAL|Rehabilitation|Posturography, Whole body vibration
214957434|NCT06367777|DEVICE|cervical a-tsDCS|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
214957435|NCT06367777|DEVICE|thoracic a-tsDCS|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
214957436|NCT06367777|DEVICE|sham tsDCS|Sham transcutaneous spinal direct current stimulation (s-tsDCS)
215078512|NCT06661382|BIOLOGICAL|Infiltrative treatment with CB-PRP|Injection of CB-PRP or placebo into the vulvar site. Three treatments are planned four weeks apart. Three and six months after the last treatment with CB-PRP/ placebo each participant will be re-evaluated by vulvoscopy and biopsy, and will be given validated questionnaires to assess satisfaction, symptoms, and quality of life, psychological state, and sexual function.
215078513|NCT06662344|BEHAVIORAL|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
215078514|NCT06662344|BEHAVIORAL|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
215078515|NCT06662344|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214350302|NCT03204279|DRUG|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
214350303|NCT03204279|DRUG|Netupitant|Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
214350304|NCT03204279|DRUG|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
214350305|NCT01603576|DEVICE|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
214350306|NCT06055296|OTHER|COMPRENDO Peer Navigation Intervention|"Parents randomized to the intervention, COMPRENDO, will receive culture, language, and health literacy-concordant pre-accrual, accrual, and post-accrual activities in person led by a peer navigator for up to 4 weeks. Visit 1 (V1) will provide anticipatory guidance and education on a) general concepts of pediatric cancer research (standard of care, clinical trials, randomization); b) informed consent/assent, research affiliations (e.g., Children's Oncology Group); c) clinical trial types (therapeutic, non-therapeutic); d) voluntariness; and e) frequently asked questions, resources. Navigators will follow a script supported by culture, language and health-literacy concordant handouts and graphic materials, decision aids, and short video-clips. Navigators also provide support with decision-making and answer parents' questions. Three follow-up peer navigator visits (V2, V3, V4) over 4 weeks are tailored to the parents' needs."
214350307|NCT03155607|BEHAVIORAL|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
214350308|NCT02119416|DRUG|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
214957437|NCT03215407|DRUG|Intra-articular Tocilizumab|Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
214350309|NCT02119416|DRUG|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
215078516|NCT06662097|DRUG|Bevonescein|Bevonescein is a sterile solution that is intravenously administered
215078517|NCT06657859|DRUG|GLM101|GLM101 IV infusion
214350310|NCT02119416|DRUG|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
214350311|NCT05271617|DIAGNOSTIC_TEST|VIDAS® NEPHROCLEAR™ CCL14|Measurement of CCL14 in sample aliquots after being subjected to different testing conditions
214350312|NCT02205710|OTHER|Computerized cognitive training|
214350313|NCT02205710|OTHER|Computerized games|
214350314|NCT04540536|OTHER|Continuous Glucose Monitoring|Participants will be provided with a Dexcom G6 continuous glucose monitor for the duration of the study.
214350315|NCT04540536|OTHER|Secure texting|A secure platform (TigerConnect) will be used for three-way communication between parents, participants, and clinical personnel
214350316|NCT04323852|DRUG|Vitamin D|Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
214957438|NCT03215407|DRUG|Intra-articular Compound Betamethasone|Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
214957439|NCT01529411|DRUG|Vinflunine|Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance \< 60ml/min).
214957440|NCT01529411|OTHER|Undefined (standard care)|All the current interventions used by each institution for the study disease.
214957441|NCT03341117|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 300 mg per capsule
214957442|NCT03341117|DRUG|Calcined magnesia|Calcined magnesia 300 mg per capsule
214350317|NCT04323852|DRUG|Placebo|Placebo
214350318|NCT03131388|DIAGNOSTIC_TEST|Access AMH Assay|
214350319|NCT03919383|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
214350320|NCT03919383|DRUG|Toripalimab|240mg intravenously every 3 weeks
214350321|NCT04589923|DEVICE|Lifelight® Data Collect Blood Pressure Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
214350322|NCT04589923|DEVICE|Lifelight® Data Collect Oxygen Saturation Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
214350323|NCT02739581|PROCEDURE|Endoscopic Variceal Ligation|
214350324|NCT02739581|DRUG|Non selective beta blocker|
214350325|NCT02739581|OTHER|Placebo|
214350326|NCT02345148|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
214350327|NCT05496881|OTHER|Exercise Group 1|Prescribed exercises will focus on mobility and balance.
214350328|NCT05496881|OTHER|Exercise Group 2|Prescribed exercises will focus on physical fitness.
214350329|NCT05496881|OTHER|Exercise Group 3|Prescribed exercises will focus on flexibility, range of motion, and muscle tone.
214350330|NCT04163705|DIAGNOSTIC_TEST|blood sample collection|Routine Laboratory Analysis
214350331|NCT01097538|OTHER|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
214350332|NCT01097538|OTHER|Total body recumbent stepper training|Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
214957443|NCT02013102|DRUG|Decitabine Injection|Decitabine Injection 20mg/m2/d\*5d, IV\> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d\*8d, IV\> 1h, one cycles per 4 weeks.
214350333|NCT04158531|DEVICE|ECoG sensing and stimulation|Implant electrodes and a sensing+stimulation device, and use this for suppression of seizure activity
214350334|NCT04501315|DIAGNOSTIC_TEST|Blood, cerebrospinal fluid and urine samples|In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.
214350335|NCT03979573|DIAGNOSTIC_TEST|Multiparametric MRI|Multiparametric prostate MRI (mp-MRI)
214350336|NCT03979573|DIAGNOSTIC_TEST|Radiomics|Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.
214350337|NCT03979573|DIAGNOSTIC_TEST|MR-guided Biopsy|MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.
214350338|NCT03979573|DIAGNOSTIC_TEST|Molecular Markers|Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
214350339|NCT06426537|DRUG|Colchicine 0.5 MG Oral Tablet|Oral administration of Colchicine in STEMI patients
214350340|NCT03455972|BIOLOGICAL|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)
214350341|NCT03455972|DRUG|Immunomodulatory drugs|Maintenance therapy
214350342|NCT06385158|DRUG|GS1-144 tablet|GS1-144 tablet is an NK3R antagonist.
214350343|NCT05387005|DIAGNOSTIC_TEST|UBT|H. pylori diagnostic test: C13 urea breath test
214350344|NCT05387005|DIAGNOSTIC_TEST|HPSA|H. pylori diagnostic test: H. pylori stool antigen test
214350345|NCT05387005|DIAGNOSTIC_TEST|UBT and HPSA|H. pylori diagnostic tests: H. pylori serology test, C13 urea breath test
214350346|NCT05387005|DIAGNOSTIC_TEST|Serology (two stage)|H. pylori diagnostic test: If H. pylori serology is positive, confirmation UBT will be done.
214350347|NCT04461002|OTHER|Retrospective analysis|Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
214350348|NCT04193800|OTHER|10-week rotation in primary care setting|Ten paramedics underwent a 10 week rotation into a GP practice in the Leeds area of South Yorkshire, England.
214957444|NCT00817505|DRUG|AZD1656|Single dose oral tablet
214957445|NCT00817505|DRUG|AZD1656|Single dose oral suspension
214957446|NCT06756776|DEVICE|Hot pack|The Hot Pack is a therapeutic intervention device designed to deliver localized heat to targeted areas of the body for a duration of 15 minutes. It provides deep, soothing heat that helps to relax muscles, increase blood circulation, and reduce pain and stiffness. The device is typically used to treat conditions such as muscle tension, joint pain, and chronic discomfort. By applying consistent heat, the Hot Pack promotes improved tissue flexibility and alleviates muscle spasms. It is user-friendly, ensuring safe and effective use when applied to affected areas, with adjustable heat settings to accommodate individual needs.
214350349|NCT04199949|BEHAVIORAL|Inactivity|On days 1 and 6 of each main trial, the participants will be asked to attend the laboratory after an overnight fast of at least 8 to 12h to undergo brachial and popliteal arteries FMD measurements (30 min apart) using duplex-Doppler ultrasound, followed by assessment of the hand grip strength of their non-dominant hand using a hand dynamometer.
214350350|NCT02773589|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy
214350351|NCT04829370|OTHER|PLT|The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled will be applied 2 mL PLT solution on the right face. Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed.
214350352|NCT04829370|OTHER|Saline|"The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled left face be applied 2 mL normal saline.~Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed."
214350353|NCT02813226|OTHER|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
214678714|NCT05277155|DIETARY_SUPPLEMENT|BEJO Red Ginger Extract|"BEJO Red Ginger Extract ingredients:~* Zingiber officinale var. rubrum (Rhizome extract) 80 mg~* Foeniculi vulgare Fructus (Fennel) 25 mg~* Menthae arvensis Folium (Mint) 5 mg~* Piper retrofractum Fructus (Javanese long pepper) 12.5 mg~* Honey 7500 mg"
214678715|NCT05277155|OTHER|Placebo|Placebo composition: Substance without active ingredient
214957447|NCT06756776|OTHER|Sustained Natural Apophyseal Glides (SNAG)|The Mulligan Sustained Natural Apophyseal Glides (SNAG) technique for the lumbar spine will be applied to participants in both groups. Participants will assume a stride standing position. The therapist will stand behind the participant as described by Mulligan, supporting the patient during the application of the technique and ensuring the required movement can be performed easily. The therapist will apply the mobilizing force parallel to the facet joint plane (in the cephalic direction) over the spinous processes of the respective symptomatic spinal levels in a sustained manner while the patient performs trunk flexion. The flexion position will be maintained for a few seconds, after which the participant will return to the starting position, with the therapist continuing to maintain the mobilizing force. Three sets of six repetitions will be performed on each symptomatic lumbar spinal level.
214957448|NCT06756776|OTHER|Passive Hamstring (HM) stretching|Passive Hamstring (HM) stretching will be performed by a physical therapist experienced in the treatment of chronic low back pain (CLBP) and trained in the study protocol. The procedure will follow manual therapy stretching standards \[22\]. First, the physical therapist will explain the procedure to the participant and reassure them that the stretching can be stopped if it becomes too difficult to tolerate. With the participant lying supine, the stretched limb will be placed in maximal, pain-free hip flexion with the knee flexed. The physical therapist will then slowly and gradually extend the knee to the maximal pain-free position. In this position, participants should feel an intense stretching sensation in the back of the thigh. If this position causes pain in the lower back, the hip flexion will be reduced to the maximal, pain-free range of motion (ROM). A stopwatch will be used to ensure that the final position is held for 1 minute for each limb.
214957449|NCT06756776|OTHER|Dry needling|"Subjects will be positioned prone on a treatment table with their feet over the edge of the table. Dry needling (DN) will be applied to the hamstring muscles at three locations, each for 1 minute, using a fast in-out, cone-shaped technique.~Subjects will receive DN three times a week. To standardize the approach and optimize the application of DN, the points will be located approximately close to the motor points of the hamstring muscles.~Two of the locations are in the long and short heads of the biceps femoris, at points located at 30% and 60% of a straight line from the ischial tuberosity to the fibular head. For the semitendinosus and semitendinosus muscles, the DN location will be selected at 60% of a straight line from the ischial tuberosity to the medial femoral epicondyle.~Disposable sterilized stainless steel needles (0.3×60 mm; DongBang AcuPrime Ltd, Korea) will be used."
214957450|NCT06756776|DEVICE|Transcutaneous Electrical Nerve Stimulation|The TENS (Transcutaneous Electrical Nerve Stimulation) unit is a therapeutic device designed to alleviate pain through the use of electrical impulses. It works by delivering low-voltage electrical currents via electrodes placed on the skin, targeting the affected area. These electrical pulses help to block pain signals sent to the brain and stimulate the production of endorphins, the body's natural pain relievers. The TENS unit is commonly used for managing both acute and chronic pain conditions, including muscle pain, joint pain, and nerve-related discomfort. The device is adjustable, allowing users to customize the intensity, duration, and frequency of the electrical stimulation to meet their individual needs. It is non-invasive, easy to use, and can be applied at home or in clinical settings for effective pain management.
214957451|NCT06946992|OTHER|video supported cooperative learning|Video supported cooperative learning will be used in the experimental group. The process will be student-centered. Students will support each other's learning. While practicing on the models in the form of cooperative learning, they will reinforce their practices by watching videos prepared for each psychomotor skill learning.
214957452|NCT04084899|DEVICE|Continuous Positive Airway Pressure therapy|Standard treatment with continuous positive airway pressure
214957453|NCT06955624|GENETIC|RNA and/or DNA methylation and/or protein analysis|RNA and/or DNA methylation and/or protein analysis from a blood sample or another tissue including dedifferenciation into induced pluripotent stem cells
214678716|NCT05232097|BEHAVIORAL|Behavioral therapy|Diaphragmatic breathing exercises
214350354|NCT01617421|BEHAVIORAL|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation \[9\]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
214350355|NCT06265103|OTHER|Clinical care and quality improvement|All eligible patients at each center will be included in the registry for clinical care, quality improvement and other activities that do not meet the regulatory requirements of human subjects research. Use of data for these purposes is not considered to be a human subjects research activity and will be covered under a Business Associates Agreement and a Participation and Data Use Agreement.
214350356|NCT02384759|DRUG|aflibercept|
214350357|NCT02384759|DRUG|LV5FU2|
214350358|NCT02368353|OTHER|Cognitive behavioral therapy|
214350359|NCT02368353|OTHER|Supportive therapy|
214350360|NCT00235976|DRUG|Gantacurium Chloride for Injection (AV430A)|
214957454|NCT06954974|DEVICE|CPAP device|CPAP device
214957455|NCT06954974|DEVICE|CPAP device and exercise|CPAP device
214957456|NCT06954974|OTHER|Exercise|"1. Retropalatal level: Phase I: • Open your mouth • Pronounce A for 5 seconds • Stop. Close your mouth. Procedure: 2 sets of 10 repetitions.~2. Retroglossal level: Phase I: • Push the tongue against the front of the palate • Move it back to perform a click sound, Phase II: • Move the tongue from right to left and from up to down The sequence of movement directions can be randomized to increase the challenge for repetitions., Phase III: • In this exercise, the tongue of the patient will scroll • Circle with the tongue on the inside of the lips • Draw 10 circles per set.~   Phase IV: • pressing the back of the tongue firmly on the oral cavity's floor for 8 seconds. Phase V: • Step 1, bite the tongue depressor. • Step 2, push the tongue against the tongue depressor and hold for 8 seconds. Procedure: 2 sets of 10 repetitions.~3. Deglutition level: Phase I: • Gently hold the tongue between the front teeth • Maintain this position Then, close your mouth and swallow. Phase II: • This vers"
214957457|NCT01313013|BEHAVIORAL|question prompt sheet|
214957458|NCT02845531|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator and Optimal Medical Therapy
214350361|NCT01595295|OTHER|non interventional|
214350362|NCT06293729|DRUG|NGGT006|Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).
214350363|NCT03043664|DRUG|Lanreotide|Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
214350364|NCT03043664|DRUG|Pembrolizumab|Keytruda (pembrolizumab) 200 mg IV every 3 weeks
214350365|NCT01440153|OTHER|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
214350366|NCT01440153|OTHER|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
214350367|NCT00000985|DRUG|Vidarabine|
214957459|NCT02845531|DRUG|Optimal Medical Therapy|
214957460|NCT04465812|BEHAVIORAL|Self-monitoring and personalized feedback on smartphone app|"1. Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~2. Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index \> 15 to assess detail clinical status and recommend outpatient visit if necessary;~3. Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS\>49 or SDS\>52 to assess detail clinical status and recommend outpatient visit if necessary;~4. Patients will complete cognitive training games every week on app;~5. Medical staff will send health information on app"
214957461|NCT01251497|BEHAVIORAL|diabetes self-management education|
214957462|NCT04394936|DRUG|Guselkumab|100 mg guselkumab administered subcutaneously
214957463|NCT04394936|DRUG|Placebos|Sodiumchloride 0,9% solution for injection
214350368|NCT00000985|DRUG|Acyclovir|
214350369|NCT00000985|DRUG|Foscarnet sodium|
214350370|NCT04699266|DEVICE|Assigned Intervention (POD F GF)|The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
214350371|NCT04745182|BEHAVIORAL|MASTERY|A 12-week, phone-delivered intervention utilizing positive psychology (PP), motivational interviewing (MI), and specific midlife modules (e.g., on time management, financial stress, caregiving stress, or occupational stress) to promote physical activity and well-being in mid-life adults.
214350372|NCT01063400|OTHER|Observation|monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
214350373|NCT01886898|OTHER|Infant formula|infant formula
214350374|NCT01886898|OTHER|Breastfeeding|
214678717|NCT05232097|BEHAVIORAL|Physiotherapy|Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
214678718|NCT05717920|DRUG|ADX-629 (Open-label)|ADX-629 (250 mg) administered twice daily for 90 days
214350375|NCT03902587|DEVICE|Samsung's E-cervix technology|While patients are having their routine cervical ultrasound assessments which requires a 5 minute time period, we will use the built-in software to obtain additional E-cervix measurements to evaluate the consistency of the cervical os. This will be done within the standard 5 minute period which is typically done to observe for dynamic changes. The measurements will be obtained with the same sonogram machine, using updated software.
214350376|NCT03798860|DIAGNOSTIC_TEST|blood samples|For performing the Luminex solid phase assay (SPA) test, 7.5 ml of patient whole blood are collected from a peripheral vein.
214350377|NCT01426165|DRUG|Magnesium Sulfate|8 grams over 4 or 8 hours depending on randomization
214350378|NCT06580665|PROCEDURE|Cryoablation|Patients undergo cryoablation.
214350379|NCT06580665|DRUG|Serplulimab|Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
214350380|NCT03593655|DEVICE|Dapivirine vaginal ring|Vaginal ring containing 25 mg of dapivirine
214350381|NCT03593655|DRUG|FTC/TDF|Tablet containing 200 mg FTC/300 mg TDF
214350382|NCT01631630|DRUG|Pioglitazone|Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
214957464|NCT06438666|DEVICE|Anodic Transcranial Direct Current Stimulation|This study will apply the anodic transcranial direct current stimulation over 20 children between 14-18 years old. The protocol that it will follow is the next one: 3 days to value the outcome measures, 4 days (1 sessions per day of 17 minutes and 30 seconds) to apply the protocol of anodic transcranial direct current stimulation (0,6 mA of intensity). It will use the EPTE V07 Bipolar System by IONCLINICS ®; 3 days to value the outcome measures studying the effects produced at the affected upper limb. Another evaluation will be realized 3 weeks after the last sessions of anodic transcranial direct current stimulation to know if the effects obtained last at medium-long term.
214957465|NCT05131022|DRUG|NX-5948|Oral NX-5948
214957466|NCT04351451|PROCEDURE|thyroidectomy|total thyroidectomy
214957467|NCT04396132|DIAGNOSTIC_TEST|Subjective Visual Vertical with Virtual SVV instrument|The deviation angle will be measured with 15, 30 and 45-degree head tilt to the left and right side while they are standing
214957468|NCT04237545|DEVICE|T3 short and restoration (prosthesis)|A qualified patient will be treated with a T3 short implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
214350383|NCT01631630|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like pioglitazone
214957469|NCT04237545|DEVICE|T3 standard length and restoration (prosthesis)|A qualified patient will be treated with a T3 standard length implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
214957470|NCT03727399|OTHER|blood withdrawal|Blood withdrawal
214957471|NCT05194683|BEHAVIORAL|Relational Letter Writing|The intervention consists of two interviews and a between-session writing task. In the first session, couples will be interviewed regarding their relationship story and preferences. Between the two sessions, each couple member will write a letter from their relationship point of view. In the second interview, the task is reviewed and paths for relationship improvement are outlined.
214957472|NCT00352625|DRUG|Ketoprofen Topical Patch 20%|
214957473|NCT01997801|DRUG|Ketamine infusion|Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
214957474|NCT01997801|DRUG|NS infusion|Normal saline will be infused intraoperatively.
214350384|NCT06580678|DRUG|KH001|topical application of KH001
214350385|NCT06580678|DRUG|Placebo|topical application of Water for Injection
214350386|NCT01981564|BEHAVIORAL|Asthma Express Intervention|Asthma Express clinic visit for asthma education + nurse home visit
214350387|NCT01981564|BEHAVIORAL|Standard Asthma Education Control Group|Asthma Express home nurse visits for asthma education
214350388|NCT04678466|BIOLOGICAL|flotetuzumab|CD123 x CD3 bispecific DART® antibody
214350389|NCT03961620|DEVICE|The SpotOn system that encompasses the registration unit (3M SpotOn Control Unit), disposable sensor (3M SpotOn Control Sensor) along with the cords and electric power unit.|Patients submitted to major surgical procedure will be assessed for core body temperature by employing SpotOn sensor device, before, during and after surgical procedure.
214350390|NCT05219149|BEHAVIORAL|Qualitative Interviews|Conduct qualitative interviews with patients and families who are considering treatment options for new or recurrent CNS tumors to identify specific barriers to full participation in treatment and clinical trial enrollment (e.g., transportation, childcare, ancillary expenses). Qualitative interviews will be structured to comprehensively address potential barriers but also open-ended to give patients and families freedom to discuss a wide range of challenges.
214350391|NCT03732209|BEHAVIORAL|Episodic future thinking|Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
214350392|NCT03732209|BEHAVIORAL|Control Thinking|Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
214957475|NCT01133704|BIOLOGICAL|sipuleucel-T|
214957476|NCT01133704|BIOLOGICAL|APC-Placebo|
214957477|NCT03963219|DEVICE|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
214957478|NCT03963219|DEVICE|Standard Bolus Calculator|Standard bolus calculator
214957479|NCT03271632|BIOLOGICAL|CAR T cells|Infusion of multi-CAR T cells
214957480|NCT00001296|DRUG|melphalan|
214957481|NCT00001296|DRUG|tumor necrosis factor|
214957482|NCT00001296|DRUG|interferon-gamma|
214957483|NCT00001296|PROCEDURE|hyperthermic isolated limb perfusion|
214957484|NCT00136214|DIAGNOSTIC_TEST|MR brain and neuropsychiatric tests|
214957485|NCT02841475|OTHER|Charlson comorbidity index|Charlson comorbidity index
214350393|NCT05046795|DRUG|Revefenacin 175 mcg in 3 ML Inhalation Solution|Revefenacin
214957486|NCT00565201|DRUG|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
214678719|NCT05182203|DRUG|biologic/targeted therapy|TNF inhibitors or the JAK inhibitors
214957487|NCT00565201|DRUG|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
214957488|NCT04985942|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
214957489|NCT04985942|DRUG|Placebo|Matching capsules administered orally, once daily.
214957490|NCT06517095|PROCEDURE|improved capsular polishing|In the polished group,utilize the OVDs to partially fill the peripheral capsule, causing the central posterior capsule to bulge, and then employ the double-ended Whitman Shepherd capsular polisher to meticulously polish both the anterior and equator of the capsule. This process also allows for simultaneous polishing of a portion of the posterior capsule. By rotating the polisher 180°along one side, followed by switching ends to cover the remaining 180° range, even the main incision site can be effectively addressed due to its curved tip design.
214957491|NCT06517095|PROCEDURE|the conventional I/A polishing|the conventional I/A polishing the capsule
214957492|NCT02232477|DRUG|Intrathecal recombinant human alpha iduronidase|Intrathecal recombinant human alpha iduronidase every 3 months
214957493|NCT05447455|PROCEDURE|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
214957494|NCT05447455|PROCEDURE|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
214957495|NCT03612479|BEHAVIORAL|KIDFIT Healthy|The KIDFIT Healthy intervention promotes the DASH diet, physical activity, limited screen time, and adequate sleep, through a combination of traditional in-person and electronic participant contacts. See NCT03405246 for details.
215078518|NCT01310543|BEHAVIORAL|Teens and Toddlers|The T\&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
215078519|NCT06669546|OTHER|Phase-locked auditory stimulation (PLAS)|"Intervention: Verum Phase-Locked Auditory Stimulation (PLAS) Using the SleepLoop Device.~The experimental intervention utilizes the SleepLoop device, a home-use, EEG-based system designed for phase-locked acoustic stimulation (PLAS). The device continuously monitors sleep through EEG (Fpz) alongside electrooculogram (EOG) and electromyogram (EMG) channels. The device employs a closed-loop algorithm that detects slow oscillations (SOs) in the EEG and delivers short sound stimuli (50 ms pink noise) during the positive half-waves of slow waves in slow-wave sleep (SWS). These stimuli are delivered through integrated headphones in the SleepLoop device. The intervention is applied during work days for 4 weeks. The algorithm is only active during SWS and does not deliver stimuli when the participant is awake, or in lighter sleep stages (N1, N2) or REM sleep. The intensity and algorithm sensitivity are individually calibrated for each participant to optimize stimulation."
215078520|NCT06669546|OTHER|Sham Phase-Locked Auditory Stimulation|Participants will undergo the same procedure as the real Phase-Locked Auditory Stimulation (PLAS) intervention. However, during the sham condition, the headphones are turned off, and no auditory stimulation is delivered.
214957496|NCT03612479|BEHAVIORAL|KIDFIT Safe|The KIDFIT Safe active control provides electronic material about safe home environments and activities (e.g., sun screen, choking hazards, pet safety) for children. See NCT03405246 for details.
214957497|NCT06503068|OTHER|Questionnaire|A questionnaire in both digital and written forms in both Arabic and English versions.
215078521|NCT06609070|DRUG|CHG0521 Oral Coating|The subjects will receive an oral coating of CHG0521 in the form of drops, in addition to the clinician\&#39;s standard treatment regimen, for a duration of 6 months or until confirmed progression, unacceptable toxicity, or any criteria for withdrawal from the trial.
214350394|NCT05046795|DRUG|Placebo inhalation solution QD|Placebo
214350395|NCT06634745|PROCEDURE|Standard Needle Irrigation (SNI)|"Standard Needle Irrigation (SNI):~Utilizes standard needle irrigation techniques for activating the antimicrobial solution within the root canal."
214350396|NCT06634745|PROCEDURE|Passive Ultrasonic Irrigation (PUI|"Passive Ultrasonic Irrigation (PUI):~Employs ultrasonic energy to enhance the activation and effectiveness of the antimicrobial solution in the root canal."
214350397|NCT06634745|PROCEDURE|EndoActivator (EA)|"EndoActivator (EA):~Uses a sonic activation device to facilitate the distribution and activation of the antimicrobial solution in the root canal."
214678720|NCT01832311|DRUG|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
214678721|NCT01327339|DRUG|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
214678722|NCT00813956|DRUG|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
214957498|NCT02849704|DRUG|Creon36™|Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.
214957499|NCT02731274|OTHER|Regular physical activity in Motor memory consolidation|After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training. For the analysis of the results, descriptive and inferential statistics were used.
214957500|NCT00559663|DIETARY_SUPPLEMENT|Green tea|"The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.~After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels"
214957501|NCT00559663|DIETARY_SUPPLEMENT|70% dark chocolate|"The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.~After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels."
214957502|NCT01290952|PROCEDURE|Off-pump bypass surgery|is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
214957503|NCT01290952|PROCEDURE|On-pump bypass surgery|is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
214957504|NCT02512172|DRUG|Oral CC-486|
214350398|NCT06634745|PROCEDURE|EDDY|"EDDY:~Involves the use of a sonic activation device that operates at high frequency to activate the antimicrobial solution within the root canal.~These descriptions focus on the general method and purpose of each intervention without delving into the specific procedural details already covered in the arm/group descriptions."
214957505|NCT02512172|DRUG|Romidepsin|
214957506|NCT02512172|DRUG|MK-3475|
214957507|NCT02149407|DRUG|Glycerin|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
214350399|NCT06635044|OTHER|intradialytic exercise|HD men came to the HD unit three times weekly to receive their dialysis session which consumed 3-4 hours. During the first two hours of the men's dialysis session, a pedal exerciser (RTL10273 Deluxe Folding Pedal Exerciser, Drive Medical Co. MPN) was utilized in performing leg cycling exercises while men were sitting. Before starting the session of intradialytic cycling, a 5-minute stretching of the lower limbs was performed as a warming up. Also, as cooling down, the same period of lower limbs' stretching was performed after ending intradialytic cycling
214957508|NCT02149407|PROCEDURE|Rectal stimulation|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
214957509|NCT02149407|OTHER|Control|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
214957510|NCT00481364|DRUG|atorvastatin|atorvastatin 40 mg/day
214957511|NCT00481364|DRUG|placebo|1 tb/day
214957512|NCT03603197|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
214957513|NCT03603197|DRUG|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
214957514|NCT04482907|DIETARY_SUPPLEMENT|Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.|Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP
214957515|NCT00328458|DRUG|EPO906 (epothilone B)|
214957516|NCT00006244|DRUG|melphalan|Given IV
214957517|NCT00006244|BIOLOGICAL|recombinant interferon alfa|Given SC
214957518|NCT00006244|BIOLOGICAL|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
214957519|NCT00006244|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
214957520|NCT03011437|OTHER|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
214957521|NCT06414772|OTHER|Use of MARTI application in addition with a classical consultation/support|Participants will use MARTI in order to establish the medical history during their waiting time.
214957522|NCT00208260|DRUG|FOLFIRI|FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
214957523|NCT00208260|DRUG|FOLFOX-4|FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
214957524|NCT00208260|DRUG|FOLFIRI-HD|High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
214957525|NCT00208260|DRUG|FOLFOX-7|FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
214957526|NCT00208260|DRUG|FOLFIRINOX|FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
214957527|NCT01909843|BIOLOGICAL|ALX-0171|Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
214957528|NCT03059537|DRUG|Oral chenodeoxycholic acid stimulation|oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
214957529|NCT03004768|DRUG|BMS-986165|Oral solution dose of 24 mg \[14C\] BMS-986165 containing approximately 100 micro Ci of TRA
214957530|NCT00829699|PROCEDURE|euinsulinemic euglycemic glucose clamp|euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
214957531|NCT00829699|PROCEDURE|euinsulinemic hyperglycemic glucose clamp|euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
214350400|NCT02271126|DEVICE|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
214350401|NCT02271126|DEVICE|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
214350402|NCT02271126|DRUG|Heparin|Anticoagulation provided to patients in ECMO
214350403|NCT02371954|BEHAVIORAL|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
214350404|NCT02371954|OTHER|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
214350405|NCT04182620|DEVICE|renal denervation|Renal denervation using the Paradise renal denervation system - a dedicated RDN catheter that delivers a circumferential ring of ablative ultrasound energy
214350406|NCT04182620|DEVICE|Catheter ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation
214350407|NCT05080790|DRUG|Dinutuximab Beta, Zoledronic acid, Interleukin-2|Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
214350408|NCT04777019|OTHER|Not applicable as standard of care Colonoscopy|Not applicable since not an intervention
214350409|NCT06636981|DRUG|Cohort2: ATRA+Toripalimab+TPC|Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.
214350410|NCT06636981|DRUG|Cohort1: ATRA+Toripalimab+chemo|Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.
214350411|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol + geranylgeraniol|Combination of ubiquinol and geranylgeraniol
214350412|NCT06640465|DIETARY_SUPPLEMENT|Geranylgeraniol|Geranylgeraniol alone
214350413|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol alone
214350414|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinone|Ubiquinone alone
214350415|NCT06640465|OTHER|Placebo|Placebo capsule
214350416|NCT06595888|RADIATION|Computed Tomography|X-ray by Computed Tomography
214350417|NCT06497491|BIOLOGICAL|GNR-086|GNR-086 is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
214350418|NCT06497491|BIOLOGICAL|Ilaris®|Ilaris® is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
214350419|NCT05577026|BEHAVIORAL|Educational intervention and prescription feedback|Brief educational intervention and patient and provider materials regarding prescription of opioids. Subsequent feedback on clinic prescription of opioids over 12 months.
214350420|NCT05577026|BEHAVIORAL|General information on treatment guidelines|Written information on guidelines and recommendations regarding prescription of opioids.
214957532|NCT00829699|PROCEDURE|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
214957533|NCT00829699|PROCEDURE|Hyperinsulinemic hyperglycemic glucose clamp|Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
214957534|NCT02417558|BEHAVIORAL|Alterniity Augmented Reality (AAR)|AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
214957535|NCT02417558|BEHAVIORAL|VideoGrade|Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
214350421|NCT06034990|OTHER|10-min online survey|This is a cross-sectional study. The data are collected by a 10-min online survey administered to included physicians which will be distributed via online channels such as such as official website or Facebook pages of Society of intensive care or Society of nephrology of corresponding countries.
214350422|NCT04738643|OTHER|Tobacco Use Treatment Service and Varenicline Management|The VM intervention builds upon the established TUT Service process. In addition to connecting the patient to TUT Service via electronic referral, it activates a medication management protocol that: 1) actively confirms no evidence of renal failure or pregnancy with oncology provider, 2) automates a referral to prescribing providers within the TUT Service team, prompting a call-back to patient within 24 hours, 3) provides written AVS instructions to contact TUT Service for initiation instructions and clinic appointment, and 4) pends a varenicline prescription to the medication list, ready for reconciliation by TUT Service prescribing clinicians. The protocol formalizes standard management principles for varenicline, including follow-up evaluation, pre-quit period duration, and side effect amelioration.
214350423|NCT05584215|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis Groups|Groups based on cognitive behavioural therapy for psychosis
214350424|NCT05979389|DRUG|Bicalutamide 50 mg|Bicalutamide capsules will be prepared from U.S. Pharmacopeia grade powder at a dose of 50 mg
214957536|NCT05917483|DIAGNOSTIC_TEST|Ultrasonography|Collect shoulder rotator cuff tendon ultrasound image during isotonic motion
214957537|NCT01834664|BIOLOGICAL|stem cell (MNCs )|Intra thecal transplantation of autologous stem cell \[MNCs \]Per dose at the interval
214957538|NCT05514613|OTHER|retrospektif study; The effect of tracheostomy tecnique method on complications|retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques
214957539|NCT00306410|DRUG|colecalciferol|
214957540|NCT00461929|PROCEDURE|bone marrow aspiration|
215078522|NCT06606678|OTHER|Exercise|supervised exercise training; twice a week for 12 months
214350425|NCT05979389|DRUG|Placebo|Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
214350426|NCT05222802|DRUG|ERAS-801|Administered orally
214350427|NCT03759873|BEHAVIORAL|Incentives|Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.
214350428|NCT03759873|BEHAVIORAL|Case Management|A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.
214350429|NCT05513872|DRUG|Nicotine Replacement Therapy (NRT) Sampling|Participants randomized to this condition will receive a 4-week nicotine replacement therapy (NRT) starter kit containing both nicotine lozenges and patches in their original packaging.
214350430|NCT05513872|BEHAVIORAL|Practice Quitting (PQ) Counseling|Practice Quitting (PQ) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. The goals of the counseling sessions are 1) to gradually expose patients to nicotine withdrawal symptoms through practice quitting, and 2) to reduce fear and avoidance of the physical sensations associated with nicotine withdrawal.
214350431|NCT05513872|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Motivational Interviewing (MI) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. Counseling content will incorporate MI-consistent principles, such as open questions, simple and complex reflections, and affirmations to facilitate participant statements in favor of behavior change. Discussion will focus on the motivational topics outlined in the USPHS guidelines for smokers not ready to quit: 1) relevance of smoking cessation or reduction to the individual, 2) risks of continued heavy smoking, 3) rewards of quitting and reduction, and 4) roadblocks to success, on a 5) repeated basis.
214350432|NCT04732403|OTHER|Patient Position|The patient will be placed in an angle on the surgical table during cystoscopy.
214350433|NCT06086223|PROCEDURE|ankle arthroscopy with ORIF|we will go for fixation of the fracture with association of scope intervention pre and post fixation
214350434|NCT06086223|PROCEDURE|fracture ankle fixation without ankle arthroscopy|we will go for fixation of the fracture alone with no scope intervention
214350435|NCT04336254|BIOLOGICAL|allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
214350436|NCT04336254|OTHER|Intravenous saline injection (Placebo)|Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
214350437|NCT04986553|DEVICE|Arthrex Clavicle Plates|Arthrex Clavicle Plate for treatment of clavicle fractures
214350438|NCT02676479|DEVICE|Uterine Lavage Group|"The PI places the Lavage Catheter per instructions for use~* Use of a tenaculum or cervical stitch is required~* Use of saline to wash the cervix is required~* Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix."
214957541|NCT03534739|OTHER|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
214957542|NCT03534739|OTHER|Light Touch Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
214350439|NCT06195917|DEVICE|Robotic-assisted Interventional Percutaneous transhepatic puncture|Robotic-assisted Interventional Percutaneous transhepatic puncture
214957543|NCT03534739|OTHER|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
214350440|NCT03579563|OTHER|AUD fitting|Prescription hearing aids will be fitted by audiologists using established procedures.
214350441|NCT03579563|OTHER|OTC+ fitting|Audiology professionals provide brief services to fit preset-based OTC hearing aids, which are simulated using prescription hearing aids.
214350442|NCT03579563|OTHER|OTC fitting|In this group, preset-based OTC hearing aids, which are simulated using prescription hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
214350443|NCT03579563|DEVICE|High-end HA|High-end hearing aids will be used.
214350444|NCT03579563|DEVICE|Low-end HA|Low-end hearing aids will be used.
214350445|NCT06634472|OTHER|AI|AI-enabled skin perforator segmentation tool
214350446|NCT02647359|DRUG|Ataluren|Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
214350447|NCT02647359|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
214350448|NCT06646666|DRUG|All-trans retinoic acid|10mg，tid，po (After apheresis and continued until post-infusion)
214350449|NCT06646666|DRUG|zanubrutinib|160mg，bid，po (prior to apheresis and continued until post-infusion)
214350450|NCT06646666|RADIATION|radiotherapy|If the patient's specific lesions are suitable for radiotherapy
214350451|NCT06646666|DRUG|CAR-T|CAR-T cell therapy
214678723|NCT03949582|OTHER|Test food containing different types of dietary protein|"The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum"
214957544|NCT02773420|PROCEDURE|HET Application|The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
214957545|NCT03231397|DRUG|Assess AAA rupture risk by PET-CTA scans|Assess AAA rupture risk by PET-CTA scans
214957546|NCT03231397|DRUG|18F-fludeoxyglucose (FDG)|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
214957547|NCT03231397|DIAGNOSTIC_TEST|11C-PBR28|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
214350452|NCT06646666|DRUG|PD-1 inhibitor|IV 200 mg on D1, Q3W
214350453|NCT02513563|DRUG|Carboplatin|Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
214350454|NCT02513563|DRUG|Paclitaxel|Participants will be treated with paclitaxel 175 mg/m\^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
214350455|NCT02513563|DRUG|AZD1775|Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
214350456|NCT06056180|OTHER|Balance Training|Participants will be given static and dynamic balance training with a balance platform game console (20 minutes) containing interactive video games based virtual reality for a total of 6 weeks.
214350457|NCT06056180|OTHER|Motor İmagery Training|For motor imagery training, two visualization scenarios will be created: anterior and posterior motor imagery. One of the visualization scenarios appropriate to each individual's needs will be used. Participants will be asked to perform kinesthetic or visual motor imagery in accordance with the scenario they listened to (10 minutes).
214350458|NCT06056180|OTHER|Action Observation Training|Action observation training will be done using video modeling method. The video content will include Nintendo Wii games in which the games that the person will play in that session are played by someone else and successful scores are achieved (10 minutes).
214350459|NCT05604430|DEVICE|731 Series Ventilator|FDA cleared ventilator indicated for use in the management of acute or chronic respiratory failure or during resuscitation.
214350460|NCT06089083|OTHER|Physical function assessment|Physical assessments of frailty will be conducted in person.
214957548|NCT06224218|PROCEDURE|Single Port Robotic Surgery|Single port Robotic surgery will remove the whole prostate
214957549|NCT06224218|PROCEDURE|Laser Surgery|Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.
214957550|NCT05348954|OTHER|EX-PLISSIT MODEL|The content of the program will include information about the anatomy and physiology of the male-female reproductive system, sexuality and sexual cycle physiology, factors affecting sexuality, postpartum changes, hormonal changes, breastfeeding and their effects on sexuality, and methods of contraception.
214957551|NCT04686708|OTHER|Emergency general surgical admissions|All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).
214350461|NCT06089083|OTHER|Self-reported Assessments and Questionnaires|Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study
214957552|NCT04076319|BEHAVIORAL|CAPABLE: Community Aging in Place-Advancing Better Living for Elders|"CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations."
214957553|NCT01962194|DEVICE|Deep Brain Stimulation|"In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, Activa PC+S, which has therapy equivalent to Activa PC, and has a new sensing programmer."
214957554|NCT05194241|BEHAVIORAL|One MORE|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
214957555|NCT00005822|DRUG|doxorubicin hydrochloride|Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
214957556|NCT00005822|DRUG|semaxanib|For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
214957557|NCT00005822|PROCEDURE|conventional surgery|Patients undergo a modified radical mastectomy.
214957558|NCT00005822|RADIATION|radiation therapy|Patients undergo radiotherapy to the chest wall and regional lymph nodes.
214957559|NCT00005822|DRUG|tamoxifen|Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.
214957560|NCT03403452|DRUG|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
214957561|NCT01054222|DRUG|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
214957562|NCT01054222|DRUG|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
214957563|NCT00824655|BIOLOGICAL|13vPnC|13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.
214957564|NCT00824655|BIOLOGICAL|13vPnC|13vPnC will be administered by intramuscular injection at approximately 12 months of age.
214957565|NCT06307405|DIAGNOSTIC_TEST|next generation sequencing|All the enrolled patients had undergone fiberbronchoscopy and sputum had been retained. The collected alveolar lavage fluid and sputum were examined for mNGS and routine etiology, respectively
214957566|NCT06477380|BEHAVIORAL|ACCEPT intervention|"* Training package (1 day)~* A toolkit/manual for clinicians to guide them through the disclosure process~* Trauma-informed changes to the physical environment~* Monthly trauma-focussed reflective group for care co-ordinators"
214350462|NCT06089083|PROCEDURE|Surgery (Standard of Care, Non-Interventional)|Surgical data will be reviewed via medical record
214350463|NCT03125720|OTHER|Image fusion of SPECT MPI and fluoroscopy venography|In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
214350464|NCT02214134|GENETIC|Tumour markers testing|
214350465|NCT05761223|DRUG|Phase Ia dose-escalation part of FB849 Monotherapy|At a given level dose once daily
214350466|NCT05761223|DRUG|Phase Ib dose-expansion of FB849 monotherapy|At recommended dose for expansion cohort once daily
214350467|NCT05761223|DRUG|Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab|At recommended dose for expansion cohort once daily in combination with pembrolizumab
214957567|NCT05391880|DRUG|BEBT-503 20mg|BEBT-503 capsule
214957568|NCT05391880|DRUG|BEBT-503 40mg|BEBT-503 capsule
214957569|NCT05391880|DRUG|BEBT-503 80mg|BEBT-503 capsule
214957570|NCT05391880|DRUG|BEBT-503 120mg|BEBT-503 capsule
214957571|NCT05391880|DRUG|BEBT-503 180mg|BEBT-503 capsule
214957572|NCT05391880|DRUG|placebo 20mg|placebo capsule
214957573|NCT05391880|DRUG|placebo 40mg|placebo capsule
214350468|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
214350469|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
214957574|NCT05391880|DRUG|placebo 80mg|placebo capsule
215078523|NCT06605300|DRUG|Intranasal Oxytocin (IN-OXT)|Subject assigned to receive intranasal administration of oxytocin (24 IU).
215078524|NCT06605300|DRUG|Intranasal Vasopressin (AVP)|Subjects assigned to receive intranasal administration of AVP (20 IU).
215078525|NCT06605300|DRUG|Intranasal Placebo|Subjects assigned to receive intranasal administration of placebo.
215078526|NCT05676151|BEHAVIORAL|Music Therapy|20-minute music-therapy-informed interventions (musical bingo, songwriting, lyric scramble) guided by a music therapist
215078527|NCT06661447|PROCEDURE|Tridimensional Onlay autologous bone graft|A thick block from the ramus area of the mandible are cut longitudinally with a microsaw into two thin pieces with the same surface area. The two thin block are used to rebuild the two wall of the future alveolar crest and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
215078528|NCT06661447|PROCEDURE|Tridimensional Onlay xenogeneic bone graft|A tridimensional Onlay xenogeneic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
215078529|NCT06661447|PROCEDURE|Tridimensional Onlay allogenic bone graft|A tridimensional Onlay allogenic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
215078530|NCT04926831|DRUG|capmatinib|150 mg and 200 mg tablets for oral administration
215078531|NCT06609018|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, soft contact lenses worn for one week
215078532|NCT06609018|DEVICE|Control Lenses (omafilcon A)|Daily disposable, soft contact lenses worn for one week
215078533|NCT03738501|OTHER|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
215078534|NCT03738501|OTHER|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
214350470|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
214350471|NCT05900882|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,8,15,22
214350472|NCT05900882|DRUG|Bortezomib|Bortezomib 1.3mg/m2 intravenously on d1,8,15,22
214350473|NCT05900882|DRUG|Lenalidomide|Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)
214350474|NCT05900882|DRUG|Dexamethasone|Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23
214350475|NCT06096597|DRUG|Clarix Flo|100 mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride
214350476|NCT06096597|DRUG|Placebo|10 mL of 0.9% preservative-free sodium chloride
214350477|NCT06082167|DRUG|Zanzalintinib|Specified doses on specified days
214350478|NCT06082167|DRUG|Zanzalintinib-matched Placebo|Specified doses on specified days
214350479|NCT06082167|BIOLOGICAL|Pembrolizumab|Specified doses on specified days
214350480|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
214957575|NCT05391880|DRUG|placebo 120mg|placebo capsule
214957576|NCT05391880|DRUG|placebo 180mg|placebo capsule
214957577|NCT04711343|DRUG|BAT2306|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
214957578|NCT04711343|DRUG|Cosentyx (US-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
214957579|NCT04711343|DRUG|Cosentyx (EU-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
214957580|NCT02797145|DRUG|Digoxin dose-adjusted|Serum digoxin concentration : 0.5 to 0.9 nanogram/mL
214957581|NCT02797145|DRUG|Standard dose|the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
214957582|NCT01533961|DRUG|SCYX-7158|
214957583|NCT01533961|DRUG|Placebo|
214957584|NCT04168320|RADIATION|SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)|Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
214957585|NCT05937516|DEVICE|Nasotracheal intubation with conventionally|Nasotracheal intubation will be applied conventionally to patients in this group.
215078535|NCT06607068|OTHER|None (Observational study)|None (Observational study)
214350481|NCT04278768|DRUG|Venetoclax|"Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.~This arm of the study has been closed to enrollment."
214350482|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
214350483|NCT05023252|OTHER|mobile application|VetThrive is a mobile smartphone application that monitors and transmits mobile sensor and utilization data. This app is deployed in Veteran patients who passively self-track their behaviors and psychiatric symptoms.
214350484|NCT05980442|DEVICE|Navigated total knee arthroplasty|Total knee arthroplasty with Columbus® total knee endoprosthesis using the OrthoPilot® Elite navigation system
214350485|NCT05980442|DEVICE|Robot assisted total knee arthroplasty|Total knee arthroplasty with Triathlon® total knee endoprosthesis using the MAKO® robot system
214350486|NCT03428711|DRUG|Mesoglycan Oral Tablet|"Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months."
214350487|NCT03428711|DRUG|Placebo Oral Tablet|Indistinguible placebo tablet
214350488|NCT04111549|OTHER|Home-based telehealth GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI via in-home video telehealth.
214350489|NCT04111549|OTHER|In-person GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI in person.
214350490|NCT04618718|DEVICE|cerebral embolic protection during TAVR|The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.
214957586|NCT05937516|DEVICE|Nasotracheal intubation with angled ETT using guidewire|a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
214957587|NCT04558671|OTHER|asthma exacerbations|to collect the number of asthma exacerbations between the 2 latent classes of patients within the year following bronchoscopy
214957588|NCT03504189|DEVICE|PregSense™|PregSense™ wearable device will be applied for maternal-fetal monitoring
214957589|NCT03504189|DEVICE|Cardiotocopraphy (CTG)|Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring
214957590|NCT04307524|PROCEDURE|laparoscopic repair|laparoscopic suture repair of cesarean scar niche
214957591|NCT04307524|DRUG|medical treatment in the form of combined hormonal contraception|"patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare"
215078536|NCT06607640|BEHAVIORAL|Increase outdoor activity time during specific time periods|"The specific time periods of outdoor activity found to be beneficial for myopia prevention will be used as the intervention target, and a one-year intervention will be initiated."
215078537|NCT00756795|BEHAVIORAL|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
214957592|NCT04595929|PROCEDURE|Staging laparoscopy|All patients undergo staging laparoscopy and peritoneal lavage.
214957593|NCT04595929|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
214957594|NCT04595929|DRUG|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
214957595|NCT04595929|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
214957596|NCT04595929|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
214957597|NCT04595929|PROCEDURE|Radical surgery|Radical gastrectomy with D2 - lymph node dissection.
214957598|NCT04595929|PROCEDURE|PIPAC|Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².
214957599|NCT04595929|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy according to indications.
214957600|NCT01398657|DRUG|Adjuvant Androgen-Deprivation Therapy|Short-term adjuvant androgen-deprivation therapy
214957601|NCT04336475|OTHER|orofacial exercise program|combined stretching\&strengthening exercise regimen
214957602|NCT01147562|PROCEDURE|Collection of biospecimen|Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
214957603|NCT01863342|PROCEDURE|CSI score < 40|
214957604|NCT01863342|PROCEDURE|CSI score ≥ 40|
214957605|NCT03565705|PROCEDURE|Open abdominal prostatectomy|Patients undergo standardized open abdominal prostatectomy.
214350491|NCT05505747|DRUG|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
214350492|NCT05505747|DRUG|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
214350493|NCT05671848|OTHER|Recordings of thalamic activity|Recordings of thalamic activity will be performed at home, in ecological conditions. They will be realized during 4 distinct conditions each week between M3 and M6 post implantation: at rest and during tremor-induced movements. For these recordings, stimulation will be either turned Off or On. Three successive recordings of 30 seconds separated by 1 minute will be made for each condition.
214957606|NCT02187237|DEVICE|YOLO TOUCH Low Level Laser|
214957607|NCT02456025|DRUG|Topical tacrolimus|Topical tacrolimus 0.01% twice daily for one month
214957608|NCT04618991|OTHER|Filling the Quebec Sleep Questionnaire|Filling the Quebec Sleep Questionnaire (QSQ) by the pre-surgery patient, then at 3 months post surgery and 1 year post surgery.
214957609|NCT03743727|DRUG|Combined therapy LDV and SOF|All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).
214957610|NCT02511132|BIOLOGICAL|Vigil|Vigil 1.0 x 10e7 cells/injection, minimum of 4 to a maximum of 12 administrations.
214957611|NCT02511132|DRUG|Temozolomide|oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)
214957612|NCT02511132|DRUG|Irinotecan|irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously
214957613|NCT02511132|DRUG|Gemcitabine|675 mg/m2 IV at a rate of 10 mg/m2/min on Day 1 and Day 8 every 21 days
214350494|NCT05813912|DRUG|Insulin Icodec|Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.
214957614|NCT02511132|DRUG|Docetaxel|75 mg/m2 IV administered on Day 8 and every 21 days
214957615|NCT03845621|DEVICE|Conventional Mouthguard|Use of a conventional custom-made mouthguard while playing water polo
214350495|NCT05813912|DRUG|Semaglutide|Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
214350496|NCT04380636|BIOLOGICAL|Pembrolizumab|intravenous (IV) infusion
214350497|NCT04380636|DRUG|Olaparib|oral tablets
214350498|NCT04380636|DRUG|Placebo for olaparib|oral tablets
214957616|NCT03845621|DEVICE|Occlusal-adjusted Mouthguard|Use of an occlusal-adjusted custom-made mouthguard while playing water polo
214957617|NCT03077425|BEHAVIORAL|Enhanced Usual Care (EUC)|Per Arm/Group Description, CHWs will provide a pamphlet and dental referral list to participants both groups.
214957618|NCT03077425|BEHAVIORAL|Intervention|Per Arm/Group Description, CHWs will a) conduct 6 home visits with mothers/families over a 12 month period along with follow-up phone support, and b) patient navigation support for child to receive 2 dental visits: one by 12 months of age and one by 18 months of age.
214957619|NCT05313399|DEVICE|Palatal Crib|An intraoral appliance approach can be used as an adjunct method to stop the habit. Appliances consisting of cribs in the anterior region are very efficient as reminders and physical restrainers. The palatal crib works as an obstacle in non-nutritive sucking and maintains the tongue in a more retruded position, halting its interposition between the incisors.
214957620|NCT05313399|DEVICE|bonded spur|Spur appliances change tongue action, close the open bite, and boost treatment stability, as it induces a permanent modification of the tongue's anterior rest posture by altering orofacial function, resulting in a change in form. Finally, the spur adjusts the sensory input to the brain. This proprioceptive change leads to an altered motor response, resulting in a new normal tongue rest posture (change in function) that allows the incisors to erupt
214957621|NCT05467852|DRUG|didroxyprogesterone|Didroxyprogesterone group: the first menstrual cycle after operation began on the 14th to 27th day of each menstrual cycle. Didroxyprogesterone 10mg bid was given orally. It was planned to use 6 menstrual cycles (if the patient was naturally pregnant during the medication, the drug could be stopped), and guide the patient to try pregnancy. The observation period was 12 menstrual cycles after operation. Control group: no drugs were used after operation, and the patients were guided to try pregnancy. The observation period was 12 menstrual cycles after operation. Subjects need to complete up to 6 follow-up visits, including the first month after operation, the first menstrual cycle d7-13 after operation, the fourth menstrual cycle d7-13 after operation, the seventh menstrual cycle d7-13 after operation, the 13th menstrual cycle d7-13 after operation and 1-2 months after termination of pregnancy
214957622|NCT04230772|PROCEDURE|Natural Orifice Specimen Extraction Surgery|In the experimental group, patients will be performed robotic colorectal resection with natural orifice specimen extraction.
214957623|NCT04230772|PROCEDURE|Traditional Robotic-assisted Surgery|In the active comparator group, patients will be performed traditional robotic-assisted colorectal resection.
214957624|NCT03188523|DRUG|MK-8504|After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
214350499|NCT04380636|DRUG|Etoposide|IV infusion
214350500|NCT04380636|DRUG|Carboplatin|IV infusion
214350501|NCT04380636|DRUG|Cisplatin|IV infusion
214350502|NCT04380636|DRUG|Paclitaxel|IV infusion
214350503|NCT04380636|DRUG|Pemetrexed|IV infusion
214350504|NCT04380636|RADIATION|Thoracic Radiotherapy|external beam radiation
214350505|NCT04380636|DRUG|Durvalumab|IV infusion
214350506|NCT05285553|DEVICE|MiSight 1 Day|Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.
214350507|NCT05285553|DEVICE|Proclear 1 day|"Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.~Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year."
214350508|NCT04643444|DIAGNOSTIC_TEST|Blood sampling|Testing for the presence of SARS-CoV-2 antibodies
214350509|NCT04643444|OTHER|Online Questionnaire|Questions on working place, risk profiles and PPE
214350510|NCT05894343|GENETIC|AAV-GAD|Bilateral infusion of AAV-GAD
214350511|NCT05695183|DEVICE|IV SafeLock|Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
214350512|NCT04818346|DRUG|INCB054707|INCB054707 will be administered once daily
214350513|NCT04818346|DRUG|Placebo|Placebo or INCB054707 will be administered once daily
214350514|NCT05608993|OTHER|High Intensity Intervention|The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.
214350515|NCT05608993|OTHER|Low Intensity Intervention|The Low Intensity intervention will include clinician education and EHR changes only.
214350516|NCT05178082|BEHAVIORAL|Educational Video-based Pain Program|Educational videos with 10 modules with information about pain.
214350517|NCT05178082|BEHAVIORAL|Empowered Relief Program|Educational online session for skills acquisition to manage pain. Empowered Relief TM by Beth Darnall ©2013-2022 Stanford University
214350518|NCT06957795|OTHER|Intensive Pelvic Floor Exercise Program|Intensive pelvic floor exercise program targeting the fast (tap) and slow twitch fibers (elevator) of the pelvic floor. The tap exercise will be performed by instructing the patient to quickly contract and release the pelvic floor muscles. For the elevator exercise, the patient will be asked to contract the pelvic floor muscles for 5 seconds and hold them for 5 seconds and then slowly relax them within 5 seconds. Patients will do the exercises as a home program. The exercise program will last for 6 weeks. One set of exercise will be counted as 10 taps and 10 elevator. In the first week, patients will be asked to do 5 sets of exercises per day and the number of sets will be increased by five for 6 weeks.
214350519|NCT03150056|DRUG|GSK525762|GSK525762 will be administered.
214350520|NCT03150056|DRUG|Abiraterone|Abiraterone will be administered.
214350521|NCT03150056|DRUG|Enzalutamide|Enzalutamide will be administered.
214957625|NCT00664365|DRUG|GSK958108|GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
214957626|NCT00664365|DRUG|Placebo|Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
214957627|NCT01983826|DIETARY_SUPPLEMENT|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
214350522|NCT03150056|DRUG|Prednisone|Prednisone will be administered as a concomitant medication in combination with abiraterone
214350523|NCT00986167|DRUG|Quetiapine XR|The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
214350524|NCT00965523|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m\^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
214350525|NCT00091312|DRUG|FOLFIRI regimen|
214957628|NCT01983826|OTHER|Placebo|Microcrystalline cellulose (daily) for 8 weeks
214350526|NCT00091312|DRUG|fluorouracil|
214350527|NCT00091312|DRUG|irinotecan hydrochloride|
214350528|NCT00091312|DRUG|leucovorin calcium|
214350529|NCT00091312|PROCEDURE|adjuvant therapy|
214350530|NCT01762046|DRUG|Glipizide|
214350531|NCT01762046|DRUG|Metformin|
214350532|NCT01762046|OTHER|Oral Glucose Tolerance Test|
214350533|NCT00991354|BIOLOGICAL|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
214350534|NCT00991354|BIOLOGICAL|IL-12 DNA plasmids|Adjuvant for HIV vaccines
214350535|NCT01581281|DRUG|Amitriptyline|Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
214350536|NCT01581281|DRUG|Topiramate|Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.
214350537|NCT01581281|DRUG|Placebo|Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
214350538|NCT02187991|DRUG|Paclitaxel|either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
214350539|NCT02187991|DRUG|Alisertib|40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
214957629|NCT06548503|DIETARY_SUPPLEMENT|Si.Pi.Mi product|Assumption of the product as detailed in the protocol
214957630|NCT06548503|OTHER|Placebo|Assumption of placebo
214957631|NCT02366299|DRUG|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
214957632|NCT02366299|DRUG|Propofol|Treatment of delirium by Propofol i.v. infusion
214957633|NCT05130996|DEVICE|dental prothesis|5 ranges of implants can be used : IDAll, IDBio, IDCam, IDMax, ID3
214957634|NCT02537600|DRUG|Cobimetinib + Vemurafenib combination treatment|Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
214957635|NCT04026750|DRUG|Pitolisant|Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
214957636|NCT01439243|DRUG|Donepezil|10 mg Tablet
214957637|NCT01439243|DRUG|Aricept®|10 mg Tablet
214957638|NCT02517736|DRUG|Sorafenib at a dose of 800 mg / day|
214350540|NCT03066336|DEVICE|Erchonia LunulaLaser|Active Low Level Laser Light Therapy
214350541|NCT02039050|DRUG|Tiotropium|
214350542|NCT02039050|DRUG|Aclidinium|
214957639|NCT02171429|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
214957640|NCT02171429|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
214957641|NCT02171429|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
214957642|NCT02171429|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
214957643|NCT00003007|BIOLOGICAL|recombinant interferon alfa|
214957644|NCT00003007|BIOLOGICAL|sargramostim|
214350543|NCT04916223|OTHER|Therapeutic massage|"The massage therapists were scheduled on a rotating schedule with two alternates scheduled for each day to ensure adherence to assigned study arm and to avoid therapist effect as much as possible. For each enrolled subject, the therapist assessed the subject and created a treatment plan depending on his/her individual needs and preferences. For example, if a subject reported bothersome lower extremity pain, the therapist might focus the massage on that lower extremity or might avoid massaging that lower extremity, depending solely on the preference of the subject. Massage duration was determined by the assigned study arm."
214350544|NCT04597320|DRUG|Fentanyl|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
214350545|NCT04597320|DRUG|Esketamine|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
214350546|NCT04597320|DRUG|Midazolam|"Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
214957645|NCT00003007|DRUG|cyclophosphamide|
214350547|NCT01319448|DRUG|Proguanil|Proguanil tablets, 1.5mg/kg/day
214957646|NCT00003007|DRUG|dexamethasone|
214957647|NCT00003007|DRUG|melphalan|
214957648|NCT00003007|PROCEDURE|peripheral blood stem cell transplantation|
214957649|NCT01455584|DRUG|HM781-36B tablets|Q1X28D/4W for HM781-36B tablets
214957650|NCT02380937|PROCEDURE|ablation for typical atrial flutter|ablation for typical atrial flutter
214957651|NCT02380937|DEVICE|Vision Ablation Catheter|
214957652|NCT03519126|OTHER|electrostimulation|Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.
214957653|NCT00640406|DEVICE|Dynamic Renal Stent plus Best Medical Treatment|percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
214957654|NCT00640406|DRUG|Best Medical Treatment|best medical treatment for hypertension secondary to renal artery stenosis according to local standards
214957655|NCT05438758|BEHAVIORAL|Almond Therapy|Participants will receive 12 remote session conducted by video or phone. Therapy sessions consist of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participants. Participants will also receive supportive text messages on selective days over the 3 months.
214957656|NCT05438758|DRUG|Intranasal ketamine (Esketamine)|Participants will receive 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks
214957657|NCT05438758|BEHAVIORAL|Treatment as Usual|Participants will continue to received the therapy that their treating physician felt was appropriate at the time of enrolment in the study. These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical activity or relaxation.
214957658|NCT05846568|BIOLOGICAL|GR1801|The injection solution GR1801 does not contain preservatives. The excipients include histidine/histidine hydrochloride (20mM), trehalose (90 mg/mL), disodium EDTA (0.372mg/mL) and polysorbate 80 (0.5 mg/mL). The pH value is 5.8 and each bottle contains 2mg of GR1801 protein. The packaging material is a borosilicate glass tube injection bottle (2mL) with a halogenated butyl rubber stopper for injection and an aluminum-plastic composite cap for antibiotic bottles.
214957659|NCT05846568|BIOLOGICAL|Human Rabies Immunoglobulin(HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin produced by BOYA-BIO, which are derived from human plasma, and then purified and filled in the injectable vial form.
215078538|NCT05118984|DRUG|Azithromycin capsule (Zithromax, Pfizer) (250 mg)|Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
215078539|NCT05118984|DRUG|Placebo|A treatment that has no active properties
215078540|NCT05272137|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
215078541|NCT03648489|DRUG|Paclitaxel|Please refer to arm/group description
214350548|NCT01319448|DRUG|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
214957660|NCT05846568|BIOLOGICAL|Rabies Vaccine|The Chinese licensed freeze-dried rabies vaccine produced by CHENGDA PHARMACEUTICALS for human use (Vero Cells) which is indicated for the rabies Post-exposure Prophylaxis (PEP) .
214957661|NCT02634632|BEHAVIORAL|Choosing to write advance directives|
214957662|NCT01763203|BEHAVIORAL|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
214957663|NCT01763203|BEHAVIORAL|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
214957664|NCT02187861|DRUG|Venetoclax|Venetoclax will be administered as per the schedule specified under arm description.
214350549|NCT01319448|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
214350550|NCT01390454|PROCEDURE|Ultrasound of the elbow 1, days 7 to 15|The primary endpoint is evaluated a first time via an ultrasound exam.
214957665|NCT02187861|DRUG|Bendamustine|Bendamustine will be administered as per the schedule specified under arm description.
214957666|NCT02187861|DRUG|Rituximab|Rituximab will be administered as per the schedule specified under arm description.
214957667|NCT06463197|BEHAVIORAL|Self-Administered Acupressure Group|Subjects will attend two weekly 120-minute of self-administered acupressure training according to the group allocation in a classroom at the School Nursing, the Hong Kong Polytechnic University. The subjects will be trained to perform self-administered acupressure by an acupuncturist. To enhance interaction and ensure the quality of teaching, each class will be conducted in a small group of 5 to 7 subjects. Participants in this group will learn the self-acupressure technique and passed fidelity check. The treatment protocol included 6 acupoints, namely, Baihui (GV20) and bilateral Fenchi (GB20), Neiguan (PC6), Shenmen (HT7), Shenxu (BL23) and Yongquan (KI1) (Table 1). Subjects were given an acupressure log to record their practice at home, and they were phoned twice a week to remind their practice during the 4-week treatment period.
215078542|NCT03648489|DRUG|TAK228|Please refer to arm/group description
215078543|NCT02701777|OTHER|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
215078544|NCT02701777|BEHAVIORAL|Training|The participant will be asked to perform exercises using their hands and arms.
215078545|NCT02701777|OTHER|Sham STDP|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
215078546|NCT02701777|OTHER|Multisite-STDP|Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
215078547|NCT03836833|DRUG|ABC/3TC/LPV/r granules (30/15/40/10 mgs)|"This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day"
214350551|NCT01390454|PROCEDURE|Ultrasound of the elbow 2, days 7 to 15|The primary endpoint is evaluated a second time by a second practitioner.
214350552|NCT01390454|PROCEDURE|Ultrasound of the elbow 3, days 45 to 90|A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
214350553|NCT00337714|PROCEDURE|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
214350554|NCT00337714|PROCEDURE|CVC cannulation|placement of conventional trilumen CVCs
214350555|NCT05974969|DRUG|BCD-264|a single intravenous infusion of BCD-264
214350556|NCT05974969|DRUG|Darzalex|a single intravenous infusion of Darzalex
214350557|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
214350558|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
214957668|NCT06463197|BEHAVIORAL|Sleep Hygiene Education group|The participants in this group will receive education on sleep hygiene. The treatment duration, frequency, and telephone follow-up schedule for the SHE group will be the same as the self-administered acupressure group (2 sessions, 2 hours each). Sleep hygiene education is often used as a comparison group in randomized controlled trials of self-help and psychological interventions for insomnia. The SHE group will provide subjects with the same amount of contact hours with the healthcare professional (instructor) in order to control the non-specific effects of practitioner-patient interaction in the self-administered acupressure group.
214957669|NCT02858271|DRUG|AKB-9778 subcutaneous injection|
214957670|NCT02406963|OTHER|Digital Photograph|A digital photograph sent by the family of the surgical site
214957671|NCT02406963|OTHER|Telephone Call|Standard telephone call with the nurse practitioner
214957672|NCT04332003|DEVICE|Remote Ischemic Conditioning (RIC) Treatment|RIC treatment will be delivered by an automated device that delivers the RIC treatment (manufactured by LifeCuff Technologies).
214957673|NCT00401128|DRUG|gemcitabine hydrochloride|
214957674|NCT00401128|DRUG|irinotecan hydrochloride|
214350559|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
214350560|NCT02082054|DRUG|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
214350561|NCT02082054|DRUG|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
214350562|NCT00198562|DRUG|Amlodipine, Losartan|amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
214350563|NCT00342862|DRUG|Amevive exposure|Observational
214957675|NCT00893074|DRUG|Dronabinol 30mg/day|10mg dronabinol administered 3x/day for 5 days
214957676|NCT00893074|DRUG|Dronabinol 60mg/day|20mg dronabinol administered 3x/day for 5 days
214957677|NCT00893074|DRUG|Dronabinol 120mg/day|40mg dronabinol administered 3x/day for 5 days
214957678|NCT00893074|DRUG|Placebo|placebo dronabinol administered 3x/day for 5 days
214957679|NCT00744718|DRUG|Bevacizumab|Bevacizumab 10 mg/kg every 3 weeks
214350564|NCT00549926|DRUG|Fluvastatin|
214678724|NCT06367270|DRUG|Pressured Intraperitoneal Aerosol Chemotherapy|PIPAC cycles will be scheduled every 6-8 weeks and 2 weeks after the last systemic chemotherapy administration. The bidirectional program for the combination of intraperitoneal and systemic chemotherapy is designed as follows: systemic chemotherapy followed by PIPAC two weeks later, followed by a one-week interval, and then systemic chemotherapy once again until three PIPAC cycles have been completed. Up to a one-week delay in returning to systemic chemotherapy after PIPAC and vice versa were considered acceptable. Systemic drug choice was based on previous chemotherapy exposure and the medical oncologists' decision. The study ends after the 3rd cycle of PIPAC.
214957680|NCT00744718|DRUG|Carboplatin|Carboplatin AUC 5 every 5 weeks
214957681|NCT04957212|DRUG|Trastuzumab|An initial dose of 8 mg/kg, followed by 6 mg/kg every 3-weeks
214350565|NCT00549926|DRUG|Pravastatin|
214350566|NCT00549926|DRUG|Pitavastatin|
214350567|NCT00549926|DRUG|Atorvastatin|
214350568|NCT05057533|OTHER|a questionnaire based on Rome IV Diagnostic criteria of IBS|"The Rome IV criteria for the diagnosis of IBS require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following~1. Related to defecation (may be increased or unchanged by defecation)~2. Associated with a change in stool frequency~3. Associated with a change in stool form or appearance The Rome IV criteria (May 2016) only require abdominal pain in defining this condition; discomfort is no longer a requirement owing to its nonspecificity, and the recurrent abdominal pain. \[2\] Supporting symptoms include the following:Altered stool frequency Altered stool form Altered stool passage (straining and/or urgency) Mucorrhea Abdominal bloating or subjective distention."
214350569|NCT01404572|DRUG|Atazanavir (current formulation)|Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
214957682|NCT04957212|DRUG|Pertuzumab|An initial dose of 840 mg, followed by 420 mg every 3-weeks
214957683|NCT04957212|DRUG|Carboplatin|A dose of AUC6 (area under the plasma concentration-time curve) every 3-weeks
214957684|NCT04957212|DRUG|Docetaxel|75 mg/m2 every 3-weeks
214957685|NCT06101355|OTHER|Telerehabilitation|"Intervention group is home exercise program supplemented with visual and video resources using telerehabilitation. With the exercises, there will be video links, exercise visuals, and written explanations. Videos and visuals of the exercises recorded by the physiotherapist and uploaded to the Rehab My Patient application.~Digital exercise forms will be prepared through the Rehab My Patient application. The intervention group will receive exercises, which prepared from the Rehab My Patient application ,digitally through WhatsApp. In this group, exercise sessions will be conducted with the physiotherapist once a week through video calls. Additionally, there will be one instance of messaging and one phone call for follow-up. Video calls and messaging will be conducted through WhatsApp."
214957686|NCT06101355|OTHER|Standard Home Based Exercise Group|Control group, standard home exercise program group , will receive the program as brochures. Although there will be no video supplement, the brochure will include visuals of the exercises. The control group will be monitored through three weekly voice calls.
214957687|NCT02768792|DRUG|pembrolizumab,|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
214957688|NCT01438112|BIOLOGICAL|CG0070 Adenovirus Vector|CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
214957689|NCT01438112|OTHER|Control Arm: Quadruple Choice|Quadruple Choice Treatment Options: (same as listed above)
214957690|NCT05126810|OTHER|Questionnaire Administration|Complete questionnaire
214350570|NCT01404572|DRUG|Atazanavir, powder for oral use 1 (POU1)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
214957691|NCT05419713|OTHER|Visual Stimuli for Space Perception|The visual environment (e.g., target locations and texture backgrounds) will be varied and human behavioral responses (judged distances) will be measured to reveal the space perception and cognitive processes underlying space perception and navigation.
214350571|NCT01404572|DRUG|Atazanavir (POU2)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
214350572|NCT00607334|BEHAVIORAL|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
214350573|NCT00607334|BEHAVIORAL|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
214350574|NCT03282890|OTHER|CHRP-BB|The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
214350575|NCT01870141|BEHAVIORAL|Cognitive-Behavioral Intervention|"1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:~* self-monitoring~* problem solving~* goal definition~* cognitive restructuring~* activation of personal and social resources"
214350576|NCT04179487|DIAGNOSTIC_TEST|OPTICA CTPA Protocol|Low dose CT pulmonary angiogram protocol
214350577|NCT06529107|BEHAVIORAL|intermittent catheterization protocol based on the best evidence|A best evidence-based protocol for intermittent catheterization after radical cervical cancer surgery
214957692|NCT05997095|OTHER|Neuromuscular electrical stimulation (NMES/0|NMES will be applied for 30 min and will be delivered using an approved, CE-marked device (Premier Combo Plus, Med-Fit Ltd, UK) using two large (7.5 × 13 cm) electrodes placed proximally and distally over the lateral quadriceps. The set protocols will be pre-programmed into to the device and the amplitude value will match the setting that was determined during a familiarisation visit
214957693|NCT03131726|DRUG|Simvastatin 40mg|see arm description
215078548|NCT03836833|DRUG|LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day"
215078549|NCT00813605|OTHER|FOLFIRI|"Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion"
215078550|NCT00813605|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
215078551|NCT00813605|OTHER|Placebo|Inactive dummy agent (to maintain blind)
215078552|NCT00813605|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
214957694|NCT05980013|DEVICE|Whole blood donation supine|Subjects will undergo a 1-unit whole blood donation in a supine position
214957695|NCT05980013|DEVICE|Whole blood donation reclined|Subjects will undergo a 1-unit whole blood donation in a reclined position
214957696|NCT06099041|DEVICE|Nd-YAG Laser for iris depigmentation|Nd-YAG Laser for iris depigmentation
215078553|NCT00445211|DRUG|Heparin|Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
215078554|NCT00445211|OTHER|Without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin.
214350578|NCT03910257|BEHAVIORAL|nutrition education module|12 activities of nutrition education module will deliver by the teacher. The activities consists of coloring my meal plate, playing pictures, story telling: Zizi and Ziko, pictures station, fruits and vegetables card, cooking class, planting bean sprouts, field visit to fruits and vegetables garden, making collages, dot to dot, watching video, making healthy snacks
214350579|NCT03273946|DRUG|Fluticasone propionate|Fluticasone propionate is an inhaled corticosteroid to be used via a pediatric spacer device with a face mask for prophylactic treatment of asthma.
214350580|NCT02541929|DIETARY_SUPPLEMENT|Docosahexaenoic acid|
214350581|NCT02999165|OTHER|Breast feeding|Infants on respiratory support will be allowed to attempt to breast feed (with a top up nasogastric tube feed if required).
214350582|NCT02999165|OTHER|Nasogastric feeding|The control intervention is feeding via nasogastric tube
214350583|NCT06435234|BEHAVIORAL|risky sexual behavior intervention|Intervening in risky sexual behaviors among college students
214350584|NCT00144703|DRUG|Sirolimus|
214350585|NCT00144703|DRUG|Tacrolimus|
214350586|NCT02638038|DRUG|INT131|INT- 131
214678725|NCT05185232|OTHER|Impact of gaps in care/loss to healthcare follow-up|There will not be a discrete intervention as part of this study but study investigators will be examining a set of primary and secondary outcomes in patients who have followed recommended cardiac care vs. those who have not.
214350587|NCT05715294|OTHER|Music Application|A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music Research and Promotion Society (TUMATA) was used. In the music application, the selecting instrumental music (ussak maqam which is Turkish Music Maqam) was used. The prepared Music CD will be played on the phones of patients with android processor phones. Patients will be told that they should listen to the music lying down and in a comfortable position, and that they should not use headphones while listening to music. Before going to bed, the patients will be listened to music composed in Ussak maqam for 50 minutes every day for 7 days.
214350588|NCT04075123|OTHER|CPAP|The two NRS strategies being compared will be initiated at the time of first extubation (NRS support practices prior to initial intubation will be as per local unit guidelines and practices) and all subsequent extubations (if applicable) until 32 weeks PMA. For instance, a unit adopting post-extubation NCPAP strategy will initiate this mode following the initial and all subsequent extubations until 32 weeks PMA whereas centres adopting post-extubation NIPPV will initiate NIPPV following initial and all subsequent extubations until 32 weeks PMA.
214350589|NCT00092131|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
214350590|NCT00092131|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
214350591|NCT04494152|DIAGNOSTIC_TEST|Transthoracic echocardiography|Standard Point-of-Care echocardiographic examination in the intensive care unit.
214957697|NCT04719598|BEHAVIORAL|congnitive behavioural therapy|CBT Sessions divide into three main components; 1) cognitive interventions, concerns with cognitive restructuring attempts to change maladaptive thought about thoughts about sleep into more adaptable . 2) Behavioral intervention: concerns with Relaxation training, stimulus control, and sleep restriction promote relaxation and help to establish healthy sleep habits. 3) Psychoeducational interventions: Providing information about the connection between thoughts, feelings, behaviors, and sleep.
214957698|NCT03124160|DRUG|Mona Lisa® NT Cu380 Mini|copper intrauterine device
214957699|NCT03124160|DRUG|ParaGard® TCu380A|copper intrauterine device
214957700|NCT05459337|BEHAVIORAL|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
214957701|NCT04512950|DRUG|Ringer's lactate|Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
214957702|NCT04512950|DRUG|0.9% saline|Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
214957703|NCT06304480|DIETARY_SUPPLEMENT|100g fermented Tofu|"* Participants will consume 100 g Miso fermented tofu per day which may be consumed any way i.e. fried, grilled, baked, etc to taste or prepared from the list of recipes provided.~* Participants will consume the first Study Product on the day of their Visit 3 (Day 0) and will consume their last Study Product the day prior to Visit 5 (Day 56).~* Participants will be instructed to return any unused Study Product at Visit 5 (Day 56)."
214957704|NCT06644079|DRUG|Tranexamic acid|Participants will self-apply topical tranexamic acid to the area where their disease is located 3 times daily for 21-28 days prior to their scheduled Moh's or excision surgery.
214957705|NCT00893139|DRUG|AL-38583 ophthalmic solution 0.05%|
214957706|NCT00893139|DRUG|AL-38583 ophthalmic solution 0.10%|
214350592|NCT04602533|DRUG|Durvalumab|Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
214486761|NCT06868602|OTHER|Exercise|Although the literature investigating the effectiveness of exercise programs on quality of life, physical function and depression in sarcopenic individuals is extensive, no studies have been found in which psychoeducation programs are applied to sarcopenic individuals and their effectiveness is investigated. In this planned study, Researchers aim to observe what kind of results will emerge and in what direction the psychoeducation program will shape the treatment by applying both exercise and psychoeducation programs to sarcopenic individuals.
214486762|NCT06866600|BIOLOGICAL|low dose CABG+iPSC-CMs|CABG+0.5×10\^8 iPSC-CMs
214486763|NCT06866600|BIOLOGICAL|High dose CABG/LVAD+iPSC-CMs|CABG+1.5×10\^8 iPSC-CMs or LVAD+1.5×10\^8 iPSC-CMs
214957707|NCT00893139|DRUG|AL-38583 vehicle|Inactive ingredients used as a placebo comparator
214957708|NCT03884309|OTHER|Experimental Hydrolyzed Protein Infant Formula|fed ad libitum
214957709|NCT01838772|DRUG|Pegylated-Interferon and Ribavirin|This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
214957710|NCT00608218|DRUG|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
215078555|NCT06058247|DIETARY_SUPPLEMENT|Active nutritional supplementation|"The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day.~NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active nutritional supplementation arm were protein supplementation at over 1.5 g/kg/day, calorie provision at over 20 kcal/kg/day, and energy adequacy of at least 80%. Energy target was estimated by multiplying the resting energy expenditure using the Harris and Benedict equation by an activity factor of 1.3 and a stress factor of 1.1. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%."
214957711|NCT00533221|DRUG|somatotropin|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
214486764|NCT06866600|OTHER|CABG/LVAD+Saline|CABG/LVAD+Saline
214350593|NCT04602533|DRUG|standard of care|"Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed."
214957712|NCT00533221|DRUG|Placebo|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
214957713|NCT06071546|DEVICE|MAIA|MAIA is a visual field testing device combining visual field tests, fixation loss correction by a real-time retinal tracker and confocal TrueColor fundus imaging (P/N AHMACME001)
214957714|NCT03522818|BEHAVIORAL|Manual Trigger|Will use the alarm as provided by the manufacture but parent has to manual trigger the alarm 1-2 hours after the child falls asleep.
214957715|NCT03522818|BEHAVIORAL|Normal|Will use the alarm as provided by the manufacture.
214957716|NCT02003755|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
214957717|NCT00667303|OTHER|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
214957718|NCT00667303|OTHER|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
214957719|NCT00667303|OTHER|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
214957720|NCT04095325|DEVICE|Ultrasound guided erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
214350594|NCT06073574|DIAGNOSTIC_TEST|Cardiac MRI|MRI Scans as specified in the corresponding arm group.
214350595|NCT02814318|BIOLOGICAL|Vaginal and rectovaginal swab cultures|The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
214350596|NCT05388903|DRUG|DS-2325a|Subcutaneous injection (starting dose 30 mg)
214350597|NCT05388903|DRUG|DS-2325a|Intravenous infusion (starting dose 100 mg)
214350598|NCT05388903|DRUG|Placebo|Subcutaneous injection
214350599|NCT05388903|DRUG|Placebo|Intravenous infusion
214350600|NCT02948179|PROCEDURE|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
214350601|NCT05609578|DRUG|Adagrasib oral dose of 400 mg twice daily tablets|oral dose of 400 mg twice daily tablets
214350602|NCT05609578|COMBINATION_PRODUCT|Pembrolizumab|IV infusion once every 3 weeks
214957721|NCT00102115|DRUG|Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)|
214957722|NCT03026829|DEVICE|CART sound therapy|"The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART"
214957723|NCT06439472|OTHER|Suboccipital Inhibition Technique|"The researcher will place their palms under the patient's head and use their fingers to contact the occipital condyles. Next, the researcher will place the 3rd and 4th fingers of each hand in the space between the occiput and the spinous process of C2. The metacarpophalangeal joints are at 90º flexion, with the base of the skull resting on their hands while they apply constant, non-painful pressure in a postero-anterior direction, keeping the 2nd, 3rd and 4th fingers together in extension. Afterwards, the researcher applies a light and gentle traction in a cephalad direction in order to relieve the suboccipital area. Once the suboccipital muscles have relaxed, the researcher gently removes the contact, leaving the participant's head resting on the table.~This technique is performed for 4 minutes."
214350603|NCT05609578|COMBINATION_PRODUCT|Chemotherapy: Pemetrexed|IV infusion once every 3 weeks
214957724|NCT06439472|OTHER|Sham Technique|The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 4 minutes.
214957725|NCT00078845|DRUG|Amifostine|500 mg three times a week.
214957726|NCT05660668|OTHER|Transbond LR|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond LR will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
214957727|NCT05660668|OTHER|Transbond XT|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond XT will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
214350604|NCT05609578|COMBINATION_PRODUCT|Cisplatin/Carboplatin|IV infusion once every 3 weeks
214350605|NCT04636190|DEVICE|Triathlon All-Polyethylene Tibia Knee|Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
214350606|NCT02998567|DRUG|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
214350607|NCT02998567|DRUG|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
214350608|NCT02998567|DRUG|ASTX727|In arm B2 (lung expansion) replacing guadecitabine
214486765|NCT06867900|DIETARY_SUPPLEMENT|Bifidobacterium Longum ES1|Oral administration of Bifidobacterium Longum ES1 for three months.
214350609|NCT05531214|BEHAVIORAL|Multidisciplinary Care Coordination Team|The intervention group will be patients whose primary care clinicians will be receiving guidance and recommendations from the multidisciplinary team consisting of cardiologists, nephrologists, and specialty pharmacists.
214350610|NCT04020913|DRUG|Somatropin injection|"Boys with short stature will be studied for measures of:~1. skeletal muscle strength, power, and endurance~2. muscle agility~3. lean body mass accrual~4. bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration"
214350611|NCT04849884|DEVICE|CORI™ KNEE TENSIONER|Robotic TKA procedure with the REAL INTELLIGENCE™ CORI™ Surgical System including the use of the CORI™ KNEE TENSIONER accessory.
214350612|NCT02522715|DRUG|Cabazitaxel|Given IV
214350613|NCT02522715|DRUG|Enzalutamide|Given PO
214350614|NCT02522715|OTHER|Laboratory Biomarker Analysis|Correlative studies
214350615|NCT02522715|OTHER|Pharmacological Study|Correlative studies
214350616|NCT02522715|DRUG|Prednisone|Given PO
214350617|NCT01808313|DRUG|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
214350618|NCT01437592|DRUG|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
214350619|NCT04724317|PROCEDURE|Steroid Group|Ultrasound guided shoulder intra-articular steroid injection
214350620|NCT04724317|PROCEDURE|Ozone Group|Ultrasound guided shoulder intra-articular Ozone injection
214350621|NCT04724317|PROCEDURE|PRF Group|Ultrasound guided shoulder intra-articular pulsed radiofrequency application
214350622|NCT03609827|DRUG|Melphalan|
214350623|NCT06386666|DEVICE|Disposable fibrous ring sutures|A new disposable fibrous ring suture device developed and produced by 2020 (Beijing) Medical Technology Co., Ltd
214350624|NCT03360253|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 in drops|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle
214350625|NCT03360253|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
214350626|NCT01211626|DRUG|ANA773|ANA773 Tosylate Capsule
214350627|NCT01211626|DRUG|Placebo|Matching Placebo Capsule
214957728|NCT03825081|DRUG|Brimonidine, pilocarpine|"1 drop of pilocarpine (0.5%)~1 drop of brimonidine (0.2%)"
214350628|NCT06971497|DEVICE|ActivBraid™Collagen Co-Braid suture (Zimmer Biomet)|ActivBraid™ is a suture made from approximately half ultra-high molecular weight polyethylene and and half collagen derived from cow skin. Collagen is the most abundant protein in our bodies and serves as the building block for tendons and bones. The collagen in ActivBraid™ is intended to enhance cell attachment and tissue integration which may improve the healing of a rotator cuff repair. ActivBraid™ suture has been shown to have equivalent strength as other high strength sutures used in orthopaedic procedures and has been approved by the Food and Drug Administration (FDA) for repairing tendons. ActivBraid™ is a commercially available product that has been and is used in humans. This is the first post-market clinical study with ActivBraid™.
214350629|NCT05814523|DRUG|Ganaxolone|Ganaxolone will be administered as IV solution.
214350630|NCT05814523|DRUG|Placebo|Placebo will be administered as IV solution.
214350631|NCT05814523|DRUG|Standard of care|A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
214350632|NCT03980470|DEVICE|TrueFidelity|"TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms."
214350633|NCT03999619|BEHAVIORAL|Move 2 Learn|10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
214350634|NCT00747799|DRUG|Sorafenib plus Cisplatin and 5-fluorouracil|"Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~* Sorafenib 400 mg bid per daily . Every 21-day cycles.~* Cisplatin 80 mg/m2 day d1, every 21 days cycle.~* 5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles"
214350635|NCT00497653|DRUG|DCI|D-chiro-inositol 1200mg twicely daily for 6 weeks
214350636|NCT00497653|DRUG|Placebo|Placebo, twice daily for 6 weeks
214350637|NCT05226208|DIAGNOSTIC_TEST|Visual analogue scale (VAS)|In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.
214350638|NCT05226208|DIAGNOSTIC_TEST|General anxiety scale (GAD-2) and survey|In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
214350639|NCT03815851|DEVICE|prophylactic drainage|place prophylactic drainage after surgery
214350640|NCT03815851|DEVICE|no prophylactic drainage|Not place prophylactic drainage after surgery
214957729|NCT01768559|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
214957730|NCT01768559|DRUG|Insulin glulisine QD|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
214957731|NCT01768559|DRUG|Insulin glulisine TID|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
214350641|NCT04360148|DIETARY_SUPPLEMENT|very-low-calorie-ketogenic-diet|VLCKD-group will undergone to VLCKD for 8 weeks. VLCKD is based on protein preparations of high biological value. Total daily energy intake is \< 800 kcal.Daily carbohydrate intake is lower than 30 g/day, while daily protein intake is approximately 1.2-1.5 g/kg of ideal body weight. The following four weeks, carbohydrates are gradually reintroduced, starting from foods with the lowest glycemic index (fruit, dairy products), followed by foods with moderate and high glycemic index (bread, pasta and cereals). The goal is to achieve a hypocaloric balanced diet (HBD), as well as the controlled group. From the 12th week to the 24 th week, all subjects enrolled will continue follow-up with HBD.
214350642|NCT04360148|OTHER|hypocaloric-balanced-diet|HBD-group will undergone to hypo caloric balanced diet for 24 weeks. Total daily average energy intake is 1500-1600 kcal/day. 30% of total daily energy is composed by lipids (10% MUFA, 10% PUFA, 10% SFA), 55% carbohydrates, while daily protein intake is approximately 0.8-1.5 g /kg of ideal body weight.
214350643|NCT05514431|PROCEDURE|Epidural|Traditional epidural catheter placement
214350644|NCT05514431|PROCEDURE|Dural Puncture Epidural (DPE) technique|Epidural catheters placed via DPE technique
214350645|NCT05514431|PROCEDURE|Combined Spinal-Epidural (CSE) technique|Epidural catheters placed via CSE technique
214350646|NCT04197947|DEVICE|Neuro Omega|"A neurophysiological navigation system NeuroOmegaTM (Alpha Omega. Israel) was implemented in our group and the operation of this system for aDBS experiment is proved to be successful (Fig 9, 10). This system was proved by both FDA and tFDA. The aDBS stimulation algorithm will be integrated with NeuroOmegaTM. The aDBS stimulation control will achieve through self-developed algorithms or built-in scripting of the system. We introduce NeuroOmega system to conduct the designed aDBS experiment for its multifunction and safety. Our group has established collaboration with Department of Eelectronic Engineering in Chang Gung University (Co-PI HL Chan) and BERTEC in National Ciao Tung University (Co-PI MD Ker). Three postdoctor fellows and one senior engineer have been working on the operation of this aDBS system.~All hardware and software problems could be sorted out in time."
214350647|NCT06036121|DRUG|ADRX-0706|Antibody drug conjugate targeting Nectin-4
214350648|NCT06173778|DRUG|semaglutide 2.4mg|Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
214350649|NCT06173778|DRUG|Placebo|Non-active medication, self-administered
214957732|NCT01768559|DRUG|Insulin Glargine (Mandatory background drug)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
214957733|NCT01768559|DRUG|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
214350650|NCT06173778|DRUG|Nicotine Replacement Therapy (NRT, nicotine patch)|Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
214350651|NCT06173778|BEHAVIORAL|Brief Smoking Cessation Counseling|Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
214350652|NCT03858803|BEHAVIORAL|Families Matter 2|Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.
214350653|NCT03858803|BEHAVIORAL|Living as a Safer Teen|Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.
214350654|NCT05353790|OTHER|Meals + snacks: control|8 weeks meal plans matched in calories (but not macronutrients or fiber) equivalent to 1 avocado + 1 cup of mango per day
214350655|NCT05353790|OTHER|Meals + snacks: Avocado mango|8 weeks meal plans provide1 avocado + 1 cup of mango per day
214350658|NCT06118814|OTHER|Body Awareness Therapy Exercise|Body awareness therapy exercises were applied to the subjects in this group.
214957734|NCT03486405|OTHER|Control group|Control group runners will receive the same graduated return to run intervals and 4-week home exercise program. However, they will receive no video education during the initial 10 weeks.
214350659|NCT06118814|OTHER|Virtual Reality Exercise|Virtual reality exercises were applied to the subjects in this group.
214350660|NCT06118814|OTHER|Core Stability Exercise|Core stabilization exercises were applied to the subjects in this group.
214350661|NCT06118814|OTHER|Home Exercise|Subjects in this group implemented a home exercise program.
215078556|NCT06058247|DIETARY_SUPPLEMENT|Conventional nutritional supplementation|The participants in conventional nutritional supplementation arm received conservative nutritional management without specific protein or caloric targets.
214350662|NCT03772990|DRUG|Calcium Chloride|Calcium Chloride
214350663|NCT03772990|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride
214350664|NCT06850558|PROCEDURE|Four parallel implants were installed in the interforaminal region|All participants administrated prophylactic antibiotics one day before implant placement and continued 7 days after surgery. Participants were asked to rinse their mouth with chlorhexidine mouthwash just before surgery and 7 days after surgery. Under local anesthesia, four implants were placed bilaterally in the interforaminal region. Four parallel implants (TioLogic, Dentaurum) were inserted in the inter-foraminal area using the submerged surgical approach and delayed loading protocol. By using the stereolithographic surgical guide the Implants were installed by the same surgeon with a minimum torque of 35 Ncm to give high initial stability. Relief was done in the mandibular denture over the implants and tissue conditioner (Visco-gel; DENTSPLY, Weybridge, UK) was used as a relining material. osseointegration was allowed to occur for a period of 3-6 months prior to final restoration.
214350665|NCT04479891|DRUG|pyrotinib tablet|single oral dose of SHR6390 or co-administered with itraconazole
214350666|NCT04479891|DRUG|Itraconazole capsule|200 mg itraconazole QD
214957735|NCT03486405|OTHER|Intervention group|Runners randomized to the intervention group will receive additional video tele-health instruction on how to transition to a non-rearfoot strike (NRFS) running pattern. Runners in the intervention group will have additional tele-health follow-ups at weeks 1, 2, 4,6, 8, and 10 using a tele-conferencing program and the Hudl Technique application. At each tele-health video follow-up participants will be emailed a questionnaire assessing their progress and function. At month 6 a final data collection session to include video analysis will be performed.
214957736|NCT04769674|OTHER|Sensory Integration Intervention through the STAR Frame of Reference|The individualized therapy program will be based on the results of the comprehensive evaluation. Intervention aligns with the STAR Frame of Reference fidelity measure and Ayres Fidelity Measure.
214350667|NCT00709384|PROCEDURE|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
214350668|NCT05577052|RADIATION|Metastatic vertebrae treated with SBRT|High-dose SBRT treatment
214350669|NCT04695301|OTHER|Rehabilitation protocol through a digital platform|During 3 months the patients will participate in a rehabilitation program through a digital platform
214350670|NCT03250962|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
214350671|NCT03250962|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
214350672|NCT01213017|DRUG|certolizumab pegol|400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
214350673|NCT03822923|OTHER|Experimental group|Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
214350674|NCT03822923|OTHER|Control group|Conventional treatment
214350675|NCT05043649|DRUG|Camsirubicin|The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
214350676|NCT02221206|DEVICE|Mini-Screw implant|Mini-screw implants (VectorTASTM8\*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
214957737|NCT02096562|OTHER|Patients use compression stockings for 10 days after surgery|patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
214957738|NCT02096562|OTHER|normal therapy - no compression stockings|the patients receive the common therapy according to S2 guidelines
214957739|NCT04837287|OTHER|Static Stretching Exercise for 10 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 10 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
214350677|NCT01954017|BIOLOGICAL|STP206|Live Biotherapeutic
214350678|NCT01954017|OTHER|Control|Sterile Water
214350679|NCT04598152|DEVICE|TDCS - transcranial direct current stimulation|TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
214350680|NCT05894200|OTHER|Glass Ionomer cement pit and fissure sealant, Silver Diamine Fluoride|GC Fuji 7, e-SDF
214350681|NCT03216837|DEVICE|Cathodal transcranial direct current stimulation|The primary intervention will be cathodal (inhibitory) tDCS over the contralesional M1. Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle. The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp. tDCS will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
214350682|NCT03216837|DEVICE|Sham transcranial direct current stimulation|Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle.The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp and then ramp down over 30 seconds to 0 milliamps. Sham will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
214350683|NCT02888405|OTHER|High-carbohydrate diet|
214350684|NCT02888405|OTHER|Low-carbohydrate diet|
214957740|NCT04837287|OTHER|Static Stretching Exercise for 30 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 30 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
214957741|NCT05621837|OTHER|MDSC quantification|Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
214957742|NCT00440635|DRUG|Bortezomib, tradename Velcade|
214957743|NCT00565890|DRUG|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
214350685|NCT00176098|PROCEDURE|Hypnoanalgesia; Hypnotic shielding|
214350686|NCT01748916|OTHER|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
214350687|NCT01748916|OTHER|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
214350688|NCT01748916|OTHER|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
214350689|NCT03351023|OTHER|no intervention-this was an observational study|
214350690|NCT04679220|PROCEDURE|Preheating|For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
214957744|NCT01679444|PROCEDURE|Magnetic Resonance Spectroscopy|
214957745|NCT05103306|DRUG|Empagliflozin 25 MG|Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor
214957746|NCT05103306|DRUG|INS|Basal insulin add on the background OADs
214957747|NCT00361803|DRUG|topotecan|topotecan
214957748|NCT00002071|DRUG|Epoetin alfa|
214957749|NCT04319926|DRUG|lidocaine topical system 1.8%|One topical system is applied to the subject's back for 12 hours.
214957750|NCT04319926|DRUG|lidocaine patch 5%|One generic lidocaine patch is applied to the subject's back for 12 hours.
214957751|NCT00657657|BIOLOGICAL|Engerix™-B|A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
214957752|NCT02903810|BIOLOGICAL|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
214957753|NCT05157555|OTHER|Data collection|Description: quality of life assessment
214957754|NCT01761929|RADIATION|Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
214957755|NCT03461783|DEVICE|Zorflex Activated Carbon Dressing|Antimicrobial dressing
214957756|NCT03461783|DEVICE|Standard of Care|foam, calcium alginate, hydrogel, or compressive dressings
214957757|NCT04396379|DEVICE|Implant an epicardial device to reshape the mitral valve annulus|The implant is intended to epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy), in patients with left ventricular dilation and mitral valve insufficiency in patients with ischemic or functional MR.
214350691|NCT02271386|BEHAVIORAL|Supporting Practice for ADHD (SPA)|"The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.~3\) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period."
214957758|NCT03489980|OTHER|coloring-type artistic task of a complex form|coloring-type artistic task of a complex form
214957759|NCT01541072|DRUG|Pegfilgrastim|Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
214957760|NCT01541072|DRUG|Filgrastim|Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils \>= 0.5 G/L)
215078557|NCT06897397|OTHER|Case Study|Students will be provided with information about the education plan flow chart, education plan content, and environment. 40 students assigned to the intervention group will be provided with information about EFM training based on the case method. Before the application, all groups will be provided with 4 hours of theoretical information about EFM interpretation via a power point presentation.
215078558|NCT06895083|OTHER|self ligating brackets|selfligating are new brackets
215078559|NCT06895304|DEVICE|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the upper limbs.
214350692|NCT00320346|BIOLOGICAL|Pandemic Influenza Vaccine|
214350693|NCT03346759|DEVICE|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
214350694|NCT03346759|DEVICE|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
214350695|NCT00000216|DRUG|Buprenorphine|
214350696|NCT04133844|BIOLOGICAL|Blood sample|Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
214678726|NCT04550507|BEHAVIORAL|Mindful sensory awareness intervention|The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
214957761|NCT00398047|DRUG|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
214957762|NCT06248684|OTHER|standardized prevention and therapy measures|Patients from the age of 65 years with an additional risk factor for postoperative delirium are assigned to a multidimensional standardized perioperative care protocol.
214957763|NCT05887960|OTHER|CBC and flow cytometry test for monocyte|all groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population
214957764|NCT02571062|DRUG|Fexinidazole|
214957765|NCT05195216|BEHAVIORAL|Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form|Online questionnaires were administered to individuals.
214957766|NCT01188668|DRUG|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
214957767|NCT01188668|DRUG|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
214957768|NCT04017117|PROCEDURE|under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh|comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
215078560|NCT06895304|DEVICE|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the upper limbs.
214350697|NCT06650527|BEHAVIORAL|Cognitive Empathy Training|Participants will engage in a mentalization activity by captioning photos of their care recipients, reflecting on what the care recipient might be thinking or feeling. Over 10 days, caregivers will take 3-5 daily pictures of their care recipient and caption each with descriptive text representing the recipient's inner voice. This task encourages caregivers to consider the care recipient's perspective and motivations behind their behavior or emotional experiences. Photos will be shared securely via encrypted email. Utilizing accessible smartphone technology, the study allows caregivers to capture and reflect on meaningful moments with their care recipients
214957769|NCT05538936|OTHER|Baby SPA|"Salus Per Aquam, Sanitas Per Aquam, Salut Per Aqua or Solus Per Aqua (SPA) means health that comes with water. Baby SPA is a physiotherapy method that stimulates the baby's motor movements through water (hydrotherapy) and performs it in an integrated way to balance the body, mind, and emotions. Baby SPA is applied in specially designed bathtubs. The size of the tub is designed in such a way that children can move their hands and feet freely and not be narrow. A neck ring/ring is used to keep the baby on the water surface during SPA treatment."
214957770|NCT05538936|OTHER|Massage|"The best way to communicate with a baby is to touch it. When babies are born, unlike their other senses, the most developed one is the sense of touch. Because this process begins while in the womb. The baby communicates by touch and begins to recognize his environment. The sense of touch is a priority for the development of all senses. They need to perceive their environment, especially in newborns and infancy periods. Touching the body in a systematic way for a therapeutic purpose is called Massage. Massage is soft touches to body tissues to relax muscles, accelerate circulation, reduce infantile colic symptoms and pain, regulate sleep, and increase its duration. Baby massage has many benefits such as reducing colic symptoms, increasing weight gain, providing motor development and coordination, strengthening the parent and baby bond, supporting growth and development, and reducing stress."
214350698|NCT06650527|BEHAVIORAL|Control Condition|In the control condition, participants will be asked to take 3-5 daily photographs of nature over 10 days. They will be asked to caption each photo with a description of what they see. This exercise will involve many of the same activities as the cognitive empathy training, except that participants will not be mentalizing or taking the the perspective of their PLWD or anyone else.
214957771|NCT05292014|DEVICE|ANGIOLITE|Patients in whom treatment with ANGIOLITE has been attempted
214350699|NCT06650527|PROCEDURE|Pre and post intervention blood spot collection|At their initial study visit, participants will provide a blood spot sample for measurement of C-reactive protein, pro-inflammatory cytokines and Epstein-Barr virus antibody titers.
214678727|NCT04550507|BEHAVIORAL|Mindful sensory awareness + mindful body awareness check-ins intervention|During the intervention period for Group B: Mindful Sensory \& Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
214957772|NCT04726774|BEHAVIORAL|Hypnosis|"Two sessions of hypnosis, about 30 minutes each, weekly provided, by a physician trained in medical hypnosis.~Each session was realized as possible during walking, according to the agreement and the physical status of the participant.~Each sessions of hypnosis includes 3 phases : induction, walk perception alteration and post-hypnotic suggestion."
214957773|NCT04726774|BEHAVIORAL|Rehabilitation program|Intensive physiotherapy for 2 weeks, with walking and balance exercises, (individual and group exercises). Education of risk of falling and prevention of falls.
214957774|NCT00902746|DRUG|NPC-01|"This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point."
214957775|NCT05601180|OTHER|Respicure®|Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.
214957776|NCT05601180|OTHER|Standard of care|standard treatment is prescribed by the treating physician.
214957777|NCT00303472|DRUG|Romiplostim|
214957778|NCT05622643|OTHER|MRI|Comparison between groups
214957779|NCT03474445|PROCEDURE|Volar Plate Osteosynthesis Aptus 2.5|Volar plating of distal radius fracture. Device: Aptus 2.5
214957780|NCT03474445|PROCEDURE|Volar Plate Osteosynthesis Inteos 2.5|Volar plating of distal radius fracture. Device: Inteos 2.5
214957781|NCT06226337|OTHER|listen music|During hysterosalpingography, women were listened to the Acemaşiran maqam as music via MP4 players and headphones.
214957782|NCT00084227|DRUG|Azithromycin/Chloroquine|
214957783|NCT00084227|DRUG|Atovaquone/Proguanil|
214957784|NCT00478075|DRUG|bortezomib|
214957785|NCT00478075|OTHER|immunologic technique|
214957786|NCT00478075|RADIATION|samarium Sm 153 lexidronam pentasodium|
214957787|NCT02334345|DRUG|Evoskin|Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
214957788|NCT02334345|DRUG|Trixiera|Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
214957789|NCT02739659|DEVICE|carbon-ion radiotherapy|
214957790|NCT00956332|BIOLOGICAL|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
214957791|NCT00956332|BIOLOGICAL|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
214957792|NCT00004067|BIOLOGICAL|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
214957793|NCT00004067|DRUG|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
214957794|NCT00004067|DRUG|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
214957795|NCT00004067|DRUG|taxol|175 mg/m2 IV every 21 days for 4 cycles
214957796|NCT01986738|RADIATION|Standard Radiation Therapy|Radiotherapy will be planned and delivered according to institutional standard of care.
214957797|NCT01986738|DEVICE|Active Breathing Control Device (ABC)|
214350700|NCT06650527|PROCEDURE|Pre and post intervention MRI session|In this study, caregivers will be positioned in a Siemens Trio 3T MRI scanner for functional imaging. They will view images of their care recipient care recipient, other similar care recipients care recipient, and photographs of friends or family members, pressing a button each time they see their care recipient care recipient's photo to monitor attention. The task involves viewing eight photos of four individuals with happy and neutral expressions, followed by rest periods. This sequence repeats five times, with each stimulus presented for 5 seconds and inter-trial intervals of 2, 3, or 4 seconds, totaling 11 minutes and 15 seconds. A subsequent 10-minute diffusion-weighted scan will assess brain white matter integrity, using 60 diffusion directions. All scans will be completed within 40 minutes.
214957798|NCT01986738|DEVICE|Computed Tomography Scan (CT)|
214957799|NCT02081001|DRUG|Novo Nordisk GlucaGen®|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
214350701|NCT00274534|DRUG|Tiotropium|
214957800|NCT02081001|DRUG|G-Pump™ (glucagon infusion)|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
214957801|NCT03295136|BEHAVIORAL|Health Promotion Training for Women Employees|Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
214957802|NCT04504747|OTHER|molecular analysis of blood and tumor|RNAseq, DNAseq, CTCs
214957803|NCT05531318|OTHER|Qualitative Interview|Participants will be interviewed about their experiences of substance use, post-traumatic stress and the way they regulate their emotions.
214957804|NCT02548468|DRUG|Fludarabine|Given IV
215078561|NCT06753071|DRUG|Pyridostigmine oral tablet|Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months
215078562|NCT06753071|DRUG|Placebo|Placebo oral tablet, twice daily, for 3 months
214350702|NCT00274534|DRUG|Salmeterol|
214957805|NCT02548468|RADIATION|Total-Body Irradiation|Undergo TBI
214957806|NCT02548468|BIOLOGICAL|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
214957807|NCT02548468|DRUG|Cyclophosphamide|Given IV
214957808|NCT02548468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
214957809|NCT02548468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
215078563|NCT05765149|OTHER|No intervention|This is an observational study, no intervention will be implemented.
215078564|NCT00990327|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
215078565|NCT00990327|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
214502616|NCT04302740|BEHAVIORAL|LEAP|The LEAP is a comprehensive, multidimensional, community-level intervention offered in Housing First settings that was developed using a CBPR framework. The LEAP principles, process, and components were conceptualized and operationalized by the CAB in the pilot study, and are outlined in a recently published articles in the American Psychologist and Journal of Community Psychology. Briefly, LEAP principles include recognizing and respecting community as a key unit of identity versus solely as individuals in a traditional research hierarchy; embracing cultural humility; practicing pragmatism and compassion; aiming to build equitable research partnerships with communities; acknowledging and promoting community strengths; and supporting relevant, sustainable, positive and community-led change.
214957810|NCT02548468|DRUG|Mycophenolate mofetil|Given IV
214957811|NCT02548468|DRUG|Tacrolimus|Given IV
214957812|NCT02609373|BEHAVIORAL|Sleep intervention|"Session 1: Intervener \& participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.~Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.~Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.~Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.~Booster sessions: At 8 \& 10 months: reinforcement, question answering, encouragement and monitoring."
214957813|NCT03596515|OTHER|Sensory Integration|Sensory Integration (SI) is a theory and framework conceptualized by Dr. Jean Ayres, a highly experienced occupational therapist, with its main objective as enhancing the brain's capacity to perceive and organize sensory information to produce a more normal, adaptive response; thus, to provide the foundation for mastering academic tasks.
214957814|NCT04813107|DRUG|APL-1202 in combination with tislelizumab|For those assigned to this group (1), each patient will receive 3 cycles of treatment prior to RC and each cycle is 3 weeks. On day 1 of each cycle, a single dose of 200 mg tislelizumab will be administered intravenously. APL-1202 will be administered orally TID daily for 3 weeks at the RP2D defined from Phase I.
215078566|NCT02240849|DEVICE|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
215078567|NCT02240849|DEVICE|Placebo general pillow|
215078568|NCT06411912|DRUG|NIDO-361|Tablets containing 100mg of NIDO-361 for oral administration.
215078569|NCT06411912|DRUG|Placebo|Placebo oral tablets
215078570|NCT03549871|DRUG|Fitusiran|Pharmaceutical form: solution for injection Route of administration: subcutaneous
215078571|NCT03549871|DRUG|BPA prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
215078572|NCT03549871|DRUG|Factor (FVIII or FIX) prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
215078573|NCT01827774|DEVICE|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
214957815|NCT04813107|DRUG|Tislelizumab alone|For patients assigned to this group (2), each patient will receive 3 cycles of treatments with a single dose of 200 mg tislelizumab administered on day 1 of each cycle, followed by RC.
214350703|NCT00850616|BIOLOGICAL|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
214350704|NCT00850616|BIOLOGICAL|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
214350705|NCT03277313|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
214957816|NCT01205880|DRUG|Calcitriol ointment|twice daily
214957817|NCT01205880|DRUG|Clobetasol spray|twice daily
214957818|NCT06453915|DRUG|18F-DPA-714|positron emission tomography scan using 18F-DPA-714 as an imaging tracer.
214957819|NCT06453915|DRUG|18F-FDG|positron emission tomography scan using 18F-FDG as an imaging tracer.
214957820|NCT05889572|DRUG|MaaT033|MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.
214957821|NCT01227239|DRUG|S-1|40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.
214957822|NCT01227239|DRUG|Oxaliplatin|40-60mg/m2/week intravenously on day 1, 8, 22 and 29.
214957823|NCT01227239|RADIATION|Radiation|Total dose is 50.4Gy (1.8Gy X 28 fractions)
214957824|NCT00873067|PROCEDURE|Additional Complex Fractionated Electrograms ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
214957825|NCT00873067|PROCEDURE|Standard atrial fibrillation ablation procedure|Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
214957826|NCT04306393|DRUG|Nitric Oxide Gas|"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio \>/= 300 for at least 24 hours consecutively."
214957827|NCT05816070|DRUG|IVIEW-1201|Four times per day for day 1-2 and three times per day for day 3-7
214350706|NCT01235039|DRUG|VIAject®25|Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
214350707|NCT01235039|DRUG|VIAject®7|One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
214957828|NCT05816070|DRUG|Ofloxacin Eye Drops|Four times per day for day 1-2 and three times per day for day 3-7
214957829|NCT05620914|DRUG|Patritumab deruxtecan|Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of brain metastasis
214957830|NCT00505063|BIOLOGICAL|Immunization Schedule patients <7 years.|"* Time 0 months: Prevnar 13 #1, Hib #1~* Time 1 months: Pediarix #1~* Time 2 months: Prevnar 13 #2, Hib #2~* Time 3-4 months: Pediarix #2~* Time 4-6 months: Draw post vaccine titers~* Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
214957831|NCT00505063|BIOLOGICAL|Immunization Schedule patients > or = to 7 years and <11 years of age|"* Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1~* Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2~* Time 2-3 months: Prevnar 13 #2, Hib #2~* Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
214957832|NCT00505063|BIOLOGICAL|Immunization Schedule patients > or = to 11 years of age|"* Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1~* Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2~* Time 2-3 months: Hib #2, Prevnar 13#2, Menactra~* Time 3-6 months: IPV, Draw post vaccine titers~* Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)"
214957833|NCT03919656|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)
214957834|NCT03919656|DRUG|Placebo Oral Tablet|Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
214957835|NCT03666741|DEVICE|AVR with or without CABG|Surgical aortic valve implantation with INSPIRIS RESILIA Aortic Valve™
214957836|NCT03370406|DRUG|5-fluorouracil|Intralesional injections of 50mg/ml over a 3 week period.
214957837|NCT03370406|DRUG|Calcipotriene|Topical application of .005% cream two (2) times daily for four (4) days one (1) day after each of three (3) 5FU injections..
214957838|NCT03473795|BEHAVIORAL|Questionnaire forms|The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
214350708|NCT01235039|DRUG|Insulin Lispro|One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
214350709|NCT02021279|DEVICE|MatriStem Pelvic Floor Matrix|
214350710|NCT02021279|PROCEDURE|native tissue repair|
214350711|NCT00746603|DRUG|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
214350712|NCT01311102|DRUG|Lidocaine|1.33 cc 2% liquid lidocaine
214350713|NCT01311102|DRUG|Normal Saline|1.33cc normal saline
214957839|NCT03473795|OTHER|Bio-specimen samples|Samples can include tissue, blood, urine, saliva, hair and nail clipping.
214350714|NCT00507793|DRUG|Sirolimus|
214350715|NCT00507793|DRUG|Cyclosporine|
214502617|NCT06670651|DEVICE|total knee arthroplasty device|total knee arthroplasty device with ultracongruent bearing surface
214350716|NCT03269812|PROCEDURE|laparoscopic assisted pull-through oeration|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
214350717|NCT02353793|DEVICE|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
214350718|NCT02353793|DEVICE|Cotton wool blanket|Using cotton wool blanket for patient warming
214350719|NCT02324491|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
214350720|NCT02324491|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
214957840|NCT05893888|DRUG|PRV211 (Intraoperative Cisplatin System)|PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.
214350721|NCT02132611|DEVICE|Diamondback 360® Coronary OAS Micro Crown|The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
214350722|NCT03136614|DEVICE|Arteriograph|
214350723|NCT06261151|OTHER|Clinical data collection|Clinical data of elderly patients with gastric cancer who underwent open gastrectomy were collected and analyzed.
214350724|NCT04377646|DRUG|Hydroxychloroquine|400 mg at day 1 and day 2, then 400 mg weekly up to 2 months
214350725|NCT04377646|DRUG|Hydroxychloroquine (placebo)|1 pill at day 1 and day 2, then 1 pill weekly up to 2 months
214350726|NCT04377646|DRUG|Zinc|15 mg per day up to 2 months
214957841|NCT05893888|DRUG|PRV111 (Cisplatin Transmucosal System)|PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive. In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.
214957842|NCT06570694|BEHAVIORAL|OverThinking|OverThinking is a mobile application ecological momentary intervention for iOS and Android, which has been designed for the reduction of experiential avoidance in rumination. The application primarily consists of psychoeducation content and related exercises intended to be delivered over a four-week period. In order to examine the effectiveness of the application during the course of the intervention and to examine user-experiences of using the application for the purpose of rumination intervention, a number of self-report tools are embedded.
215078574|NCT03193086|DRUG|Alemtuzumab|Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
215078575|NCT01644695|PROCEDURE|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
214350727|NCT04377646|DRUG|Zinc (Placebo)|1 pill per day up to 2 months
214350728|NCT04952545|DRUG|ALXN2050|Oral tablet.
214350729|NCT04952545|DRUG|Placebo|Oral tablet.
214350730|NCT05794854|OTHER|Abdominal aerobic endurance exercise|Subjects combined treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 days per wk for 10 weeks
214350731|NCT05794854|OTHER|Control training intervention|Subjects performed treadmill running (45 minutes) at 70% HRmax 4 days per week for 10 weeks
214350732|NCT00168025|DRUG|Immunoglobulins Intravenous (Human)|
214350733|NCT01176903|DRUG|Glycopyrrolate|pressurized metered dose inhaler
214350734|NCT01176903|DRUG|Tiotropium|inhalation powder, hard capsule
214350735|NCT01176903|DRUG|placebo|pressurized metered dose inhaler
214350736|NCT02096900|DRUG|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
214350737|NCT02096900|DRUG|Midazolam|
214502618|NCT05591534|RADIATION|Endorectal brachytherapy|Endorectal brachytherapy : 30 Gy in 3 sessions of 10 Gy delivered weekly
214957843|NCT06298383|DRUG|Trypsin, Bromelain and Rutoside|Flamogen is a combination of trypsin 48 mgs, bromelain 90mg and rutoside 100 mg in one tablet that provides an anti inflammatory, anti edematous activity. each patient will receive a single dose of 2 tablets one hour before treatment.
214350738|NCT03787940|DRUG|Isoniazid|standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
214350739|NCT00063947|DRUG|erlotinib hydrochloride|Given orally
214502619|NCT04177498|DRUG|Rigosertib Sodium|given PO or 72 hour continuous infusion
214502620|NCT04177498|OTHER|Quality-of-Life Assessment|Ancillary studies
214502621|NCT06305962|DRUG|177Lu-RAD204|177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses
214957844|NCT06298383|DRUG|Diclofenac Potassium|Non-steroidal anti inflammatory drug. cataflam is known for its potent anti inflammatory and analgesic properties. each patient will receive one tablet of cataflam 50 mg 1 hour before treatment.
214350740|NCT00063947|DRUG|gemcitabine hydrochloride|Given IV
214957845|NCT06298383|DRUG|Prednisolone Oral Tablet|Steroids are potent anti inflammatory drugs, patients are going to receive one tablet of 30 mg solupred one hour before treatment
214350741|NCT00063947|RADIATION|radiation therapy|Undergo radiotherapy
214350742|NCT00063947|OTHER|laboratory biomarker analysis|Correlative studies
214957846|NCT06298383|OTHER|Placebo|A tablet of Compacted powdered milk
214350743|NCT03919422|PROCEDURE|T2 paravertebral block|Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
214350744|NCT03919422|PROCEDURE|interscalene brachial plexus block and superficial cervical plexus block|An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
214350745|NCT03580265|DEVICE|laser phototherapy device with low level laser|The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.
214350746|NCT04383912|DRUG|Botox Injectable Product|The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
214350747|NCT04383912|OTHER|No intervention (placebo)|This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
214350748|NCT04719793|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
214350749|NCT04805125|BIOLOGICAL|Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)|intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
214957847|NCT05053100|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214957848|NCT05053100|OTHER|Electronic Health Record Review|Undergo electronic health record review
214957849|NCT04006405|DIAGNOSTIC_TEST|GAG score|blood and urine samples to determine GAG scores
214957850|NCT06526676|DEVICE|Cook Alpha TX2 Stent Graft, Cook Zenith TX2, and Cook Zenith Fenestrated Stent Graft|Physician-modified stent grafts that utilizes multiple stent grafts with a combination of fenestrations and/or branches
214957851|NCT06969274|PROCEDURE|Ultrasound guided sacral erector spinae plane block (SESPB)|Patients will receive an Ultrasound guided sacral erector spinae plane block (SESPB)
214957852|NCT06969274|PROCEDURE|Saddle block.|Patients will receive a Saddle block.
214957853|NCT04109456|DRUG|IN10018|100 mg or 50mg, orally once daily continuously;
214957854|NCT04109456|DRUG|Cobimetinib|60mg , orally once daily from day 1 to day 21 in a 28-day cycle
214957855|NCT04109456|BIOLOGICAL|Atezolizumab|biweekly 840 mg dose will be used in this study starting from Cycle 2.
214502622|NCT05044312|OTHER|Sleeping Disturbances|most common complaints of patients after surgery and may affect the ability to carry out daily activities, quality of life, and post-surgery recovery.
214350750|NCT04805125|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)|intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
214502623|NCT05014516|DRUG|129Xenon gas|Observational
214502624|NCT06266611|DRUG|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
214502625|NCT06266611|DRUG|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
214957856|NCT05820672|OTHER|No intervention|No intervention
214957857|NCT00349635|DRUG|Metformin and Metformin + Fenofibrate|
214957858|NCT02610530|PROCEDURE|Sleeve Gastrectomy with Ileal Transposition|Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
214957859|NCT02610530|PROCEDURE|Sleeve Gastrectomy with Transit Bipartition|Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
214957860|NCT02610530|OTHER|Medical Treatment|Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
214957861|NCT04881279|OTHER|Event|Ransomware attack
214957862|NCT04242407|DRUG|DMTS|DMTS applied before surgery and worn for 96 hours
214957863|NCT04242407|DRUG|Placebo|Matching patches that have no active drug applied before surgery and worn for 96 hours
214957864|NCT01125085|RADIATION|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)|"* Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy~* Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.~* Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.~* Total treatment duration is up to 4 weeks"
214957865|NCT02347072|DRUG|GFF MDI (PT003)|
214957866|NCT02347072|DRUG|Placebo MDI|
214350751|NCT04465006|OTHER|Hippotherapy Simulator|Patients in the hippotherapy simulator group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 45 minutes of Neurodevelopmental treatment exercises and 15 minutes of hippotherapy simulation exercise program were applied to the participants in this group.
214350752|NCT04465006|OTHER|Conventional Exercise|Patients in the conventionnal exercise group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 60 minutes of Neurodevelopmental treatment exercises were applied to the participants in this group.
214350753|NCT02157038|DEVICE|Pedometer|
214350754|NCT02157038|DEVICE|MRI|
214350755|NCT02662842|DEVICE|FlowSmart Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
214350756|NCT02662842|DEVICE|Current Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
214957867|NCT02347072|DRUG|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
214957868|NCT01397240|DRUG|Albis Tab|2 Tab, twice a day, 12 weeks
214957869|NCT01397240|DRUG|Placebo|2 Tab, twice a day, 12 weeks
214957870|NCT03632070|BEHAVIORAL|Data acquisition of functional abilities|MRI data, motor evoked potentials, and behavior data acquisition
214957871|NCT02022735|DEVICE|Deep Brain Stimulator|DBS will provide brain stimulation.
214957872|NCT02105519|BIOLOGICAL|Seasonal influenza vaccine (AdimFlu-S)|Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
214957873|NCT02780271|BEHAVIORAL|In-person education|Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
214957874|NCT02780271|BEHAVIORAL|E-communication|11 months of motivational text messages, emailed newsletters, and access to a website.
215078576|NCT05772663|OTHER|Personalized program of rehabilitation|"D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
215078577|NCT05772663|OTHER|Routine program of rehabilitation|"Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
215078578|NCT01133626|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
215078579|NCT01133626|DRUG|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
215078580|NCT01133626|DRUG|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
215078581|NCT01133626|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
215078582|NCT04285866|DRUG|Durvalumab|Durvalumab after chemoradiotherapy
215078583|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
215078584|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
214350757|NCT01592643|DEVICE|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
214350758|NCT04208022|OTHER|Respiratory evaluation|Hypermobility and Respiratory evaluation
214350759|NCT02534857|PROCEDURE|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
214350760|NCT02266069|OTHER|Care Pathway for Primary Palliative Care|Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
214350761|NCT02931734|DRUG|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
214957875|NCT02780271|BEHAVIORAL|Control|Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
214957876|NCT02738229|DRUG|Valacyclovir|
214957877|NCT02738229|DRUG|placebo|
214957878|NCT04685642|DRUG|Aspirin|Aspirin (100mg/day)
214957879|NCT04685642|DRUG|Atorvastatin|Atorvastatin (20mg/day)
214957880|NCT03021629|OTHER|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay|
214957881|NCT00043849|DRUG|Quetiapine|
214957882|NCT03752060|BEHAVIORAL|Resistance Exercise|Women assigned to the resistance exercise training group will complete progressive, full-body resistance exercise 3 times per week for 16 weeks.
214957883|NCT03752060|BEHAVIORAL|Aerobic Exercise|Women assigned to the aerobic exercise training group will complete progressive, aerobic exercise 5 times per week for 16 weeks. The aerobic training will progress first in duration, and then in intensity.
214957884|NCT02264938|DIETARY_SUPPLEMENT|Antioxidant|Oral supplemmentation with antioxidants
214957885|NCT01289301|DRUG|mTOR inhibitor (everolimus)|calcineurin-inhibitor based immunosuppression will be switched to immunosuppression based on m-TOR inhibitor (everolimus trough level 3-7ng/mL)
214350762|NCT02931734|DRUG|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
214350763|NCT02931734|PROCEDURE|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
214350764|NCT01995123|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
214350765|NCT01995123|BEHAVIORAL|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
214957886|NCT01289301|DRUG|cyclosporine or tacrolimus|calcineurin inhibitor (cyclosporine or tacrolimus) will be continued (trough level 60-90ng/mL resp 3-7ng/mL)
214350766|NCT01995123|BEHAVIORAL|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
214350767|NCT05967572|OTHER|Research processes;|"1. Before Inspection: information will be obtained and premature babies will be monitored by wearing a pulse oximeter device and their heart rate and oxygen saturation value will be recorded for control purposes. By making video recordings of each premature baby; PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded 3 minutes before the ROP examination. Babies will be fed and changed at least half an hour before the examination.~2. Inspection Sequence: PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded and evaluated from the video recording that continues with the start of the examination.~3. End of Inspection: Infants whose both eye examinations are completed and whose monitoring and video recording continue will be recorded and evaluated 3 minutes after the end of the examination, with PIPP pain score, PBIC comfort score, control oxygen saturation and heart rate values."
214350768|NCT00755482|DRUG|Aquamin F|
214350769|NCT00755482|DRUG|Placebo (maltodextran)|
214350770|NCT03362554|BEHAVIORAL|Controlled diet and exercise.|"The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through:~* Five exercise sessions per week at 70% VO2 max, using 400 kcal per session.~* Reduction of their standard diet by 5000 kcal per week~Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken."
214957887|NCT01215149|BIOLOGICAL|Ad35-ENV vaccine|Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
214957888|NCT01215149|BIOLOGICAL|Ad26.ENVA.01 vaccine|Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
214957889|NCT01215149|BIOLOGICAL|Placebo Control|Colorless 10mm Tris/HCl buffer
215078585|NCT03298984|DRUG|Alvocidib|IV bolus followed by IV infusion
215078586|NCT03298984|DRUG|Cytarabine|continuous infusion
215078587|NCT03298984|DRUG|Daunorubicin|IV bolus
214502626|NCT06266611|DRUG|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
214957890|NCT01219192|DRUG|M2ES|M2ES IV D1,8,15,21 every 28 days a cycle
214957891|NCT01219192|DRUG|M2ES|M2ES IV D1,8,15,21, every 28days a cyce.
215078588|NCT02851407|DRUG|Defibrotide|
215078589|NCT02851407|OTHER|Best Supportive Care|
215078590|NCT05730543|DRUG|Volbella or Juvederm Ultra XC filler|Hyaluronic acid filler
215078591|NCT04395638|DIETARY_SUPPLEMENT|3200IU Vitamin D3 per day for 8 weeks|3200IU Vitamin D3 per day for 8 weeks
215078592|NCT04395638|DIETARY_SUPPLEMENT|20,000IU Vitamin D3 per week for 8 weeks|20,000IU Vitamin D3 per week for 8 weeks
214957892|NCT01219192|DRUG|M2ES|M2ES 45mg IV D1,8,15,22 28days a cycle
214957893|NCT01219192|DRUG|M2ES 60mg|M2ES 60mg IV D1,8,15,22 every 28days a cycle
214957894|NCT02996890|BIOLOGICAL|MV-ZIKA|MV-Zika vaccine
215078593|NCT02633254|DEVICE|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
215078594|NCT00294645|OTHER|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
215078595|NCT00294645|OTHER|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
215078596|NCT03878030|DRUG|nusinersen|Subjects will receive nusinersen and be observed with motor assessments for 24 months
215078597|NCT04872933|OTHER|Kidney Beam Online Platform|Kidney Beam is a wellbeing digital health intervention platform that offers patients living with kidney disease a way to improve their physical activity and boost their mental health through live and on demand movement classes and expert educational videos, while remaining in their own home. Kidney Beam is led by specialist kidney professionals, including renal physiotherapists and renal counsellors, from a number of different NHS Trusts and backgrounds, as well as people living with kidney disease.
215078598|NCT01414101|DRUG|ISIS CRP Rx or Placebo|
214502627|NCT05175898|DEVICE|VA-ECMO|Treatment with veno-arterial extracorporeal membrane oxygenation
214502628|NCT05175898|DEVICE|ECMELLA|Treatment with veno-arterial extracorporeal membrane oxygenation plus Impella® micro-axial pump.
214957895|NCT02996890|OTHER|Placebo|physiological saline
214957896|NCT00225108|DRUG|Tinzaparin|
214957897|NCT05143606|OTHER|3D-printed airway simulator|Two self-directed training on a standard fiberoptic bronchoscope and a custom-made 3D airway simulator.
214957898|NCT05143606|OTHER|virtual reality software, AirwayEx|Two self-directed training on AirwayEx. With additional training as necessary.
214350771|NCT01554072|OTHER|Home based pulmonary rehabilitation with exercise|After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
214350772|NCT00157326|DRUG|tadalafil|
214350773|NCT00818948|DRUG|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
214350774|NCT05700799|BEHAVIORAL|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
214350775|NCT03680755|BEHAVIORAL|Internet-based intervention for dental anxiety|Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
214350776|NCT06161987|BEHAVIORAL|Early comprehensive rehabilitation|Patients randomized to the rehabilitation intervention group will be offered comprehensive rehabilitation plan containing 18 sessions of a structured outpatient-based exercise program over 6 weeks (3 times per week).
214350777|NCT05692388|OTHER|Patient and Community Stakeholder Interviews|Thirty in-depth face-to-face patient interviews, and ten in-depth structured stakeholder interviews will be conducted to explore and identify facilitators and barriers to self-care in African American adults with DKD experiencing MDA and living in the inner-city.
214350778|NCT05692388|OTHER|Cross-sectional Study Participants|Three hundred African American adults with DKD experiencing MDA and living in the inner-city will be recruited to participate in a cross-sectional study. All participants will complete a one-time survey, and blood samples and blood pressure readings will be obtained to assess clinical outcomes.
214350779|NCT05692388|OTHER|Focus Groups and Intervention Mapping|A subsample of patient interview/cross-sectional study participants will be invited back to participate in four focus groups (five participants/group) to review components of the intervention, give feedback on appropriateness, feasibility, acceptability, and likelihood of having an impact based on their lived experiences.
214350780|NCT02076464|BEHAVIORAL|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
214957899|NCT01615978|DRUG|liraglutide|5 mcg/kg daily for 14 days. Injected subcutaneously once daily
214957900|NCT01615978|DRUG|liraglutide|Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
214957901|NCT01615978|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
214957902|NCT01337817|OTHER|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
214957903|NCT01337817|OTHER|Ariva Wintergreen|Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
214957904|NCT03472001|OTHER|Reflection and feedback|2-hour training involving 10 written clinical cases to encourage students to practice thinking like a dermatologist in their clinical reasoning, and to help students build adequate illness scripts of skin diseases
214957905|NCT03472001|OTHER|Lecture|Traditional didactic lecture which uses the same clinical cases
214957906|NCT04528329|DRUG|Early-Dexamethasone|early use of dexamethasone as early as laboratory evidence of high inflammatory markers
214957907|NCT04528329|DRUG|Late dexamethazone|Use of dexamethasone on deterioration of the cases with increased severity
215078599|NCT05898308|DRUG|RiTUXimab Injection|"Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels."
214957908|NCT04878302|BEHAVIORAL|Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training)|Families assigned to the immediate treatment group will receive the telehealth-based Taming Tics Together protocol(created using well-established, evidence-based treatment protocols), which includes group (parent/caregiver-only, child/teen-only) and individualized one-to-one sessions to address tics and co-occurring diagnoses.
214957909|NCT03577132|DRUG|Neoadjuvant atezolizumab|"Atezolimumab~* At a fixed dose of 1200 mg as a 60-minute intravenous infusion (1st), then as a 30-minute intravenous infusion (2nd and 3rd)~* Every 3 weeks, for a total of 3 cycles prior to radical cystectomy"
214957910|NCT02094313|DRUG|Atorvastatin|The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
215078600|NCT00075725|DRUG|Cyclophosphamide|Given IV
215078601|NCT00075725|DRUG|Cytarabine|Given IT, SC, or IV
215078602|NCT00075725|DRUG|Daunorubicin Hydrochloride|Given IV
215078603|NCT00075725|DRUG|Dexamethasone|Given PO or IV
215078604|NCT00075725|DRUG|Doxorubicin Hydrochloride|Given IV
215078605|NCT00075725|DRUG|Leucovorin Calcium|Given IV
215078606|NCT00075725|DRUG|Mercaptopurine|Given PO
215078607|NCT00075725|DRUG|Methotrexate|Given IT or IV
214350781|NCT06165445|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.
214350782|NCT06165445|DEVICE|multichannel transcranial direct current stimulation (tDCS)|In multichannel tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through more than two and smaller round electrodes over the target regions.
214350783|NCT04481256|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
214350784|NCT04481256|DRUG|Bintrafusp alfa|Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
214350785|NCT04481256|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
214350786|NCT04481256|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
214350787|NCT05044663|OTHER|No intervention|This is an observational study
214350788|NCT06659523|DIETARY_SUPPLEMENT|EPS supplement intervention|31 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of 1.5 g powdered capsules of EPS.
214350789|NCT06659523|DIETARY_SUPPLEMENT|Placebo|29 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the placebo group, and were given for 12 weeks of one daily dose of placebo.
214350790|NCT06663748|DRUG|ARX788|2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
214350791|NCT05972447|PROCEDURE|Immediate implant placement of Ultrawide diameter dental implants|immediate placement of ultrawide diameter dental implants in a fresh extraction socket of mandibular molar teeth
214350792|NCT05052359|DIAGNOSTIC_TEST|Lectin-histochemistry retrospectively performed|Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)).
214350793|NCT06668493|DRUG|Nadofaragene Firadenovec|Repeat dose trial to investigate the safety and efficacy of nadofaragene firadenovec instilled into the renal pelvis
214350794|NCT06670547|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|Endoscopic retrograde cholangiopancreatography (ERCP)
214350795|NCT05819749|BEHAVIORAL|Diabetes Homelessness Medication Support Program in Spanish|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
214350796|NCT07020312|OTHER|Visualization training with neurofeedback|This technology uses electroencephalography (EEG) to measure brain activity through passive sensors placed on a cap aligned with the motor and frontal cortices. These sensors detect changes in electrical signals when patients imagine performing rehabilitation movements. The EEG data is sent to a computer, where iBrainTech™ software translates it into a virtual avatar that mimics the imagined actions. This real-time feedback-called neurofeedback-helps patients see how well they are engaging their brain during visualization. By turning the process into a video game controlled by brain signals, the platform motivates patients to focus deeply on visualizing the exercises. Repeated activation of these brain regions may help rebuild neuromuscular pathways, improve muscle control, and reduce the effects of Arthrogenic Muscle Inhibition (AMI), a common issue after orthopedic surgery.
214350797|NCT07020312|OTHER|Standard post-surgical rehabilitation therapy|Patients will follow a standard physical therapy protocol. The protocol will be assigned by their respective surgeon who conducted the procedure and will be specific to the procedure that the patient underwent.
214957911|NCT03062397|DRUG|JPI-289 Low-dose|JPI-289 Low dose will be intravenously administered during 24 hours
214957912|NCT03062397|DRUG|JPI-289 High-dose|JPI-289 High dose will be intravenously administered during 24 hours
214957913|NCT03062397|DRUG|Placebo|Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
214350798|NCT02863562|OTHER|Kinesio taping|Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.
214350799|NCT02863562|OTHER|Proprioceptive exercises|Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.
214350800|NCT02863562|OTHER|Placebo Kinesio taping|
214502629|NCT01421836|PROCEDURE|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
214502630|NCT01421836|PROCEDURE|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
214502631|NCT04537403|DRUG|Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
215078608|NCT00075725|DRUG|Pegaspargase|Given IM
215078609|NCT00075725|DRUG|Prednisone|Given PO or IV
215078610|NCT00075725|RADIATION|Radiation Therapy|Undergo radiation therapy
215078611|NCT00075725|DRUG|Thioguanine|Given PO
215078612|NCT00075725|DRUG|Vincristine Sulfate|Given IV
215078613|NCT02885857|DRUG|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
214957914|NCT03124537|BEHAVIORAL|App Experimental condition|This group were given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk. They were also asked to respond to two questions twice a day about their mood and energy levels.
214957915|NCT03124537|BEHAVIORAL|App Condition Control|This group received the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible. They were also asked to respond to two questions twice a day about their mood and energy levels.
214957916|NCT03120494|DRUG|Emtricitabine and Tenofovir|All subjects will be provided study drug for use daily for one year.
214957917|NCT06207760|DRUG|Minocycline|Minocycline (200 mg/day) for 8 weeks with a single daily administration (2 hard capsules of 100 mg)
214957918|NCT03171740|DRUG|Dexmedetomidine|Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)
214957919|NCT03171740|DRUG|Midazolam oral solution|Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)
214957920|NCT03171740|DRUG|Oral saline|Oral saline, 0.25ml/kg
214957921|NCT03171740|DRUG|Nasal saline|Nasal saline 0.01ml/kg
214957922|NCT02352376|OTHER|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
214957923|NCT02352376|OTHER|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
214957924|NCT02699476|BEHAVIORAL|Psycho-Social Therapy|
214957925|NCT02699476|DEVICE|Cognitive Behavioral Computer Training|
214957926|NCT02699476|BEHAVIORAL|Interactive Trainer-Subject Sessions|
214957927|NCT02699476|DEVICE|Active Control Games|
214957928|NCT02328794|BEHAVIORAL|E-cigarette free access|Participants in this arn will be given free access to e-cigarettes to help quit smoking
214957929|NCT02328794|BEHAVIORAL|E-cigarette/NRT/Zyban/Chantix Choice|Participants in this arn will be given free access to cessation aids to help quit smoking
214957930|NCT02328794|BEHAVIORAL|Outcome Incentive arm|Participants in this arm will be earn incentives across 6 months for verified abstinence.
215078614|NCT03267173|DRUG|Chimeric antigen receptor T cell|Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
214350801|NCT05116163|BEHAVIORAL|Individuation Intervention plus implicit bias educational modules|"Providers in the intervention are will be instructed to watch a brief set of freely available educational lessons and then they will meet with study team members to discuss their individuation countermeasure intervention. Providers will be given a choice of several individuation-related questions to better understand the unique characteristics of each patient. Once the provider decides on his/her choice phrases, the research team will assist with the development of a smart phrase (also called dot phrase) to allow them to incorporate this into a note. Once a week, providers in the intervention arm will receive an email reminding them to incorporate this question and the documentation into their encounters."
214350802|NCT05116163|OTHER|Implicit bias educational modules|Providers in the comparator arm will be given the same implicit bias educational modules to complete.
214350803|NCT07098091|DRUG|YD0293|YD0293 tablet for oral administration
214957931|NCT02328794|BEHAVIORAL|Loss framing incentive arm|Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
214957932|NCT02328794|BEHAVIORAL|Control|Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
214957933|NCT02801370|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
214957934|NCT02801370|DRUG|Sham Control|Simulated, single adminstration
214957935|NCT05558800|PROCEDURE|Implant placement|Implant placement with different surface types
214957936|NCT03681184|DRUG|Placebo|Placebo by SC injection
214957937|NCT03681184|DRUG|Lumasiran|Lumasiran by SC injection
214957938|NCT02509793|DRUG|Tetrabenazine|Xenazine, pill, dose to effect, three times a day, for 12 weeks
214957939|NCT02308371|DEVICE|Automated Pulse Pressure Variation|Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
215078615|NCT06232148|DEVICE|Type of surgery|
215078616|NCT06468527|DRUG|Diponecaftor|"Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day"
215078617|NCT06468527|DRUG|Placebo|Placebo once daily for 8 weeks. Oral administration.
215078618|NCT00869804|BEHAVIORAL|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
215078619|NCT00869804|BEHAVIORAL|Attention control|
214350804|NCT07098091|DRUG|YD0293 placebo|YD0293 placebo tablet for oral administration
214350805|NCT07126054|BEHAVIORAL|bibliotherapy|Bibliotherapy is a therapeutic approach that uses carefully prepared reading materials (My Surgery Story) to support individuals' understanding, coping, and anxiety, facilitated through guided reading and discussion.
214350806|NCT07127315|DRUG|Gonadotropin-releasing hormone agonist|Patients received chemotherapy plus a gonadotropin-releasing hormone agonist.
214957940|NCT00396383|DRUG|plerixafor|Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4\*10\^6 CD34+ cells/kg body weight had been collected.
214957941|NCT05318833|DRUG|HRS7415|Drug: HRS7415
214957942|NCT02703376|DRUG|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
214957943|NCT04968522|DRUG|Methylphenidate Hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.
214957944|NCT04968522|DRUG|Placebo|The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
214957945|NCT04968522|DRUG|Methylphenidate hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.
214957946|NCT04968522|DRUG|Methylphenidate Hydrochloride 18 MG|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.
214957947|NCT04968522|DRUG|Dexamphetamine sulfate|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
214957948|NCT00226525|PROCEDURE|skin sensitivity test|
214957949|NCT03116724|PROCEDURE|central venous catheterization through Rt. IJV|"* insertion at the intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head~* placement of the tip of the catheter 2 cm away from the junction between right atrium and superior vena cava using TEE~* measurement of the depth of the catheter at insertion point"
214957950|NCT01627795|DRUG|Oshadi D and Oshadi R|anti cancer agents
214957951|NCT03338244|DRUG|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
214957952|NCT03338244|DRUG|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
214957953|NCT04598295|DRUG|DS-01|synbiotic
214957954|NCT02725437|BIOLOGICAL|Clostridium difficile Vaccine|0.5 mL intramuscular injection
214957955|NCT02725437|BIOLOGICAL|Placebo|0.5 mL intramuscular injection
214957956|NCT04618809|BEHAVIORAL|Didactic Session|This session will include an overview of the approach to and management of older mGC patients patients through a case-based presentation.
214957957|NCT04618809|BEHAVIORAL|Comprehensive Geriatric Assessment, including an exploratory analysis to evaluate the use of fitness trackers for evaluation of functional status.|"* The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.~* The patient will receive a FitBit TM to wear for 4 days. Number of steps/day will be recorded."
214957958|NCT01447641|OTHER|Polysomnography|Overnight physiological recording of sleep
214350807|NCT07127315|DRUG|Chemotherapy|Patients received chemotherapy alone.
214957959|NCT01447641|OTHER|Actigraphy|Wristwatch activity to measure basic rest activity cycle and sleep efficiency
214957960|NCT02698709|OTHER|Analysis of anterior and posterior corneal surfaces|Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
214957961|NCT00159952|PROCEDURE|intensive insulin therapy|"control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.~treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL"
214957962|NCT03634527|BEHAVIORAL|Auricular Point Acupressure|Light touch using vaccaria seeds on specific points of the ear
214957963|NCT03634527|BEHAVIORAL|Control Auricular Point Acupressure-|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
214350808|NCT07127705|DIETARY_SUPPLEMENT|Placebo|2 capsules
214350809|NCT07127705|DIETARY_SUPPLEMENT|Chaga Mushroom|2 capsules
214350810|NCT07127705|DIETARY_SUPPLEMENT|Ginseng extract|2 capsules
214350811|NCT07127705|DIETARY_SUPPLEMENT|Olive extract|2 capsules
214350812|NCT07127705|DIETARY_SUPPLEMENT|Potassium Hydrogen Glucarate|2 capsules
214350813|NCT07126678|DRUG|zanubrutinib, bendamustine, and obinutuzumab|"Patients will receive combination therapy with zanubrutinib, bendamustine, and obinutuzumab over 6 cycles, with each cycle lasting 28 days. The specific dosing schedule is as follows: Bendamustine 70 mg/m²: administered intravenously on Days 2-3 of Cycle 1, and on Days 1-2 of Cycles 2-6. Obinutuzumab 1000 mg: administered intravenously on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 (every 28-day cycle). Zanubrutinib 160 mg orally twice daily (bid), continuously throughout Cycles 1-6.~Treatment is discontinued after 6 cycles, with no subsequent maintenance therapy."
214350814|NCT07128030|OTHER|Exercise|The experimental group completed a five-week supervised program combining moderate-intensity aerobic and resistance training (150 min/week). Intensity was monitored using the Borg and OMNI-Res scales after familiarization sessions. Adherence was encouraged through reminders, motivational messages, and follow-ups. Unlike prior studies, this intervention focused specifically on neurophysiological pain modulation. Sessions included step-based aerobic exercises and resistance training with elastic bands under safety protocols.
214350815|NCT07128251|PROCEDURE|TACE treatment|TACE treatment (cTACE): On-demand TACE therapy will be administered, with a maximum of 4 TACE sessions permitted.
214350816|NCT07128251|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706)|Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.
214350817|NCT07128251|DRUG|Bevacizumab|Bevacizumab Injection: 15 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.
214350818|NCT07126782|BIOLOGICAL|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
214350819|NCT07127731|BEHAVIORAL|Patient Portal Messaging|Participants will receive weekly messages via their patient portal including feedback on their step counts and step count goals based on data from their FitBits
214957964|NCT06977581|DRUG|PF-07275315|subcutaneous injection
214957965|NCT06977581|OTHER|Placebo|subcutaneous injection
214957966|NCT04302480|OTHER|Worksheets for ASP|The ASP intervention will cover the harms and misleading marketing strategies of ASPs and other related information.
214957967|NCT04302480|OTHER|Worksheets for SSB|The SSB intervention will cover the general information on SSBs, such as the sugar content of SSBs, nutrition labels and the harms of SSBs.
214957968|NCT04302480|OTHER|E-messages for ASP|In the subsequent month after the main intervention, students in the ASP group will receive 4-6 e-messages on ASPs, after which students will be invited to complete a 1-month follow-up assessment.
214957969|NCT04302480|OTHER|E-messages for SSB|In the subsequent month after the main intervention, students in the SSB group will receive 4-6 e-messages on SSBs, after which students will be invited to complete a 1-month follow-up assessment.
215078620|NCT02984241|BEHAVIORAL|eHealth Coping Skills Training|Access to a specialized coping skills training website
215078621|NCT02984241|BEHAVIORAL|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
215078622|NCT02984241|BEHAVIORAL|Coach Support|Access to a professional coach by phone
215078623|NCT04691141|DRUG|ATG-016|59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
215078624|NCT00391677|BEHAVIORAL|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
214350820|NCT07127731|BEHAVIORAL|FitBit EHR Linkage|Participants will receive FitBits and link this step count data with the Electronic Health Record (EHR)
214350821|NCT07126262|DRUG|Vosoritide|The vosoritide dose administered will be based on the participant's weight and will follow the weight-band dosing regimen approved for ACH
214350822|NCT07126262|DRUG|Placebo|Subcutaneous injection of recommended dose of placebo
214350823|NCT07128108|OTHER|Visual Transient Elastography (ViTE) Examination|Post-marketing product (Mindray Hepatus 9 Ultrasound Diagnostic System) for visual transient elastography examination in patients with liver injury.
214502632|NCT04537403|DRUG|Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
214502633|NCT05089461|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m\^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
214957970|NCT02704559|DRUG|DWC20155|
214957971|NCT02704559|DRUG|DWC20156|
215078625|NCT00391677|BEHAVIORAL|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
215078626|NCT03535662|DRUG|Orvepitant|Single oral dose
215078627|NCT03535662|DRUG|Itraconazole|Once daily dosing for 10 days
215078628|NCT01504633|DIETARY_SUPPLEMENT|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
215078629|NCT04333511|DEVICE|TPS (NEUROLITH)|6 treatments of TPS over 2 weeks
215078630|NCT04333511|DEVICE|Sham-TPS (NEUROLITH)|6 treatments of Sham-TPS over 2 weeks
215078631|NCT05807776|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d1, Q3W
214957972|NCT01990716|OTHER|Colonic Biopsy|"Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.~The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.~Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.~For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time."
214957973|NCT03935334|BIOLOGICAL|Biosimilar eptacog alfa, activated (AryoSeven)|A single dose of eptacog alfa biosimilar (AryoSeven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
214350824|NCT07126808|BEHAVIORAL|Simulation-Based CPR Workshop|A 4-hour, in-person simulation-based cardiopulmonary resuscitation (CPR) workshop designed for non-healthcare university students, following American Heart Association 2020 guidelines and the NLN Jeffries Simulation Framework. The training includes: (1) pre-briefing on OHCA and CPR importance; (2) instructor-led demonstration using manikins; (3) guided hands-on practice with real-time feedback; (4) scenario-based simulation with assigned team roles; and (5) structured debriefing for reflection and feedback. Skills practiced include scene safety, assessing responsiveness, high-quality chest compressions, rescue breathing, AED use, and team communication. Trainer-to-student ratio is approximately 1:6.
214350825|NCT07127523|OTHER|Social Skin|This group receives a cleanser, serum, and cream.
214350826|NCT07127523|OTHER|Placebo|This group receives a cleanser, serum, and cream.
214957974|NCT03935334|BIOLOGICAL|Eptacog alfa, activated (Novoseven)|A single dose of eptacog alfa (Novoseven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
215078632|NCT05807776|DRUG|Tislelizumab, Lenvatinib|"Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd."
215078633|NCT04768959|BEHAVIORAL|FelizMente|The intervention aims to improve well-being, without denying the existence of symptoms or problems, focusing on generating positive emotions and actions congruent with the person's values through 11 weekly 90-minute group sessions. The multi-component intervention manual was composed of evidence-based exercises of Positive Psychoterapy Interventions, Acceptance and Commitment Therapy and Mindfulness and was theory driven according the broaden-and-build-theory (Fredrickson, 2001) and the self-serving model of paranoia (Murphy et al., 2018). It was also informed by previous pilot studies carried out on people with paranoid tendencies (see Valiente et al., 2020) and with Severe Psyquiatric Condition samples.
215078634|NCT04579302|PROCEDURE|Serratus anterior block (SAB)|Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
215078635|NCT04579302|PROCEDURE|Erector spinae block|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
215078636|NCT04579302|DRUG|Saline (as a placebo)|Patients will receive a sham block with 20 ml saline (as a placebo)
214350827|NCT07126210|BEHAVIORAL|Family engaged, enhanced Diet intervention|"The family component includes health education via books, lectures, and short videos, parenting skills training, regular monitoring of child growth, and behavior goal setting through the mobile health platform. Motivational interviewing via telephone provides tailored behavioral support.~Kindergartens assist in health education, supervise dietary intake and physical activity, monitor children's growth monthly, and maintain communication with families.~Hospitals provide targeted health counseling and facilitate clinic access as needed.~The mobile health platform integrates modules for health education, smart growth curve tracking, behavior goal management, and home-school-hospital collaboration."
214350828|NCT07128069|DIETARY_SUPPLEMENT|Vitamin D 400IU|Low dose vitamin D (400 IU/day)
214502634|NCT03005119|DRUG|PTL201|Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
215078637|NCT04579302|DRUG|Bupivacaine|bupivacaine
214502635|NCT03005119|DRUG|Placebo Oral Capsule|Placebo seamless gelatin matrix green beads containing excipients only
214350829|NCT07128069|DIETARY_SUPPLEMENT|Vitamin D 4000IU|Moderate dose vitamin D (4000 IU/day)
214350830|NCT07126314|OTHER|Competition based Education Format|Residents will be organized into 3 teams, each competing to amass points for critiquing articles presented during journal club, for a prize.
214350831|NCT06934876|DIAGNOSTIC_TEST|Colorimetric carbon dioxide (CO2) detection|"All patients will undergo colorimetric carbon dioxide (CO2) detection. The reading will be assessed by a clinician at the bedside who will answer yes or no to the following question, asked after 7 breaths have been delivered following intubation: Is the color change consistent with a tube located in the trachea?"
214350832|NCT06934876|DIAGNOSTIC_TEST|Waveform capnography|"All patients will undergo waveform capnography. The reading will be assessed by a clinician at the bedside who will answer yes or no to the following question, asked after 7 breaths have been delivered following intubation:  Is the waveform consistent with a tube located in the trachea?"
214350833|NCT05156268|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
214350834|NCT05156268|DRUG|Olaparib|Olaparib will be administered orally at 300 mg every 12 hours.
214957975|NCT03731026|COMBINATION_PRODUCT|LightPath® Imaging System and 68Ga-RM2|"Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical."
214957976|NCT03731026|DRUG|68Ga-RM2|Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
214957977|NCT00897975|DIETARY_SUPPLEMENT|red yeast rice|600 mg 3 capsules bid
214350835|NCT06936709|DRUG|Colchicine 1.8 mg (loading dose) + Dextrose Oral Placebo|This intervention will be used for individuals in arm A of the study who will receive a loading dose of colchicine (1.8 mg) on postoperative day 0, and will then be given placebo oral dextrose pills to take twice daily on postoperative days 1-3
214350836|NCT06936709|DRUG|Colchicine 1.8 mg + 0.6 mg|This intervention is will be given to patients in arm B of the study who will receive a loading dose of colchicine (1.8 mg) on postoperative day 0, followed by a maintenance does of colchicine (0.6 mg) to be taken twice daily on postoperative days 1-3.
214350837|NCT06936709|DRUG|Dextrose Oral Placebo|This intervention will be for patients in arm C, the placebo arm. These patients will receive oral dextrose pills to be taken once on postoperative day 0, and twice daily on postoperative days 1-3.
214350838|NCT05780645|DRUG|ALXN2050 MR Prototype Tablet|Participants will receive various doses of the MR Prototype Tablet orally.
214350839|NCT05780645|DRUG|ALXN2050 Immediate Release (IR) Tablet|Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
214957978|NCT00897975|DRUG|phytosterol|phytosterol 450 mg 2 tabs bid with food
214957979|NCT00897975|BEHAVIORAL|therapeutic lifestyle program|TLC - 12 weeks
215078638|NCT02387801|DRUG|Ixekizumab|Administered SC
215078639|NCT02764723|DRUG|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
215078640|NCT02764723|DRUG|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
214350840|NCT05780645|DRUG|ALXN2050 MR Prototype Mini-Tablet|Participants will receive various doses of the MR Prototype Mini-Tablet orally.
214350841|NCT06544642|DRUG|ASP5502|Oral
214350842|NCT06544642|DRUG|Placebo|Oral
214350843|NCT04336579|BEHAVIORAL|Diaphragmatic Breathing|Simple diaphragmatic breathing exercise
214350844|NCT06280196|DRUG|BAT3306|One vial of 4 mL of concentrate contains 100 mg of BAT3306
214350845|NCT06280196|DRUG|EU-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
214350846|NCT06280196|DRUG|US-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
214350847|NCT06280196|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 21-day cycle of the study
214350848|NCT06280196|DRUG|Carboplatin|Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles
214350849|NCT05229068|BIOLOGICAL|RSV MAT|Single 120 µg dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
214957980|NCT00897975|DRUG|placebo|placebo
214957981|NCT04049006|OTHER|complex treatment|The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
215078641|NCT03281330|BEHAVIORAL|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
214350850|NCT05596305|BEHAVIORAL|educational psychiatry intervention|educational anti-stigma intervention related to psychiatric illness composed of a lecture, video, role models play, and open discussion
214678728|NCT03758677|DRUG|Apatinib|30 patients who progressed after EGFR-TKI treatment without T790M mutation will receive apatinib 250mg qd orally combine with chemotherapy , if the patient has a grade 3/4 adverse reaction during such treatment, apatinib should be reduced to 250mg orally once per two days. Chemotherapeutic agents are limited to platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel).
214678729|NCT00466752|DRUG|sorafenib tosylate|Given PO
214957982|NCT01558713|DRUG|Bupivacaine- Fentanyl - Normal Saline|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
215078642|NCT05807100|DIAGNOSTIC_TEST|Baseline Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
215078643|NCT05807100|DIAGNOSTIC_TEST|6th month Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
215078644|NCT00812201|DEVICE|No intervention is used. Collection of signals only.|Device received per standard of care.
215078645|NCT03889236|OTHER|Fasting mimicking diet Prolon|5-day fasting mimicking diet
215078646|NCT03889236|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Food supplement
215078647|NCT03889236|DIETARY_SUPPLEMENT|Placebo|Placebo
214350851|NCT03327766|DIAGNOSTIC_TEST|4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.|A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D \< 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
214350852|NCT05105594|OTHER|survey application|Fear of movement will be evaluated with the Kinesiophopia Causes Scale. It is a 20-question survey in which the causes of fear of movement are investigated. Functional Evaluation of Treatment of Fatigue Chronic Disease will be assessed by the Fatigue Questionnaire. It consists of 13 questions assessing the level of fatigue during daily activities in the last 7 days. Quality of Life will be assessed by the Lymphedema Quality of Life Questionnaire.
214350853|NCT00222534|DRUG|Acetazolamide|
214350854|NCT00222534|DRUG|Placebo|
214350855|NCT01114854|DRUG|Topiramate IR|
214350856|NCT01114854|DRUG|Topiramate ER|
214350857|NCT01877408|PROCEDURE|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
214350858|NCT01877408|DEVICE|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
214350859|NCT05750290|DRUG|CKD-702 in combination with irinotecan|CKD-702 and irinotecan will be intravenously administered every 2 weeks.
214350860|NCT00282620|DRUG|Magnesium L-lactate|
214350861|NCT00377234|DRUG|Risedronate|35mg po weekly for 12 weeks
214350862|NCT00377234|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 months
214957983|NCT01558713|DRUG|Ropivacaine-Fentanyl-Normal Saline|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
214957984|NCT01558713|DRUG|Levobupivacaine- Fentanyl- Normal Saline|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
214957985|NCT01558713|DRUG|Bupivacaine + Fentanyl|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
215078648|NCT04316078|OTHER|patient engagement platform|"1. Allows patients to receive the action plan as educational videos on demand.~2. Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan."
215078649|NCT01444027|BEHAVIORAL|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
214350863|NCT05365087|PROCEDURE|Transoral Fundoplication and Sleeve Gastrectomy|Transoral Fundoplication procedure completed prior to Sleeve Gastrectomy
214350864|NCT05365087|PROCEDURE|Gastric Bypass|Laparoscopic Roux-en-Y gastric bypass
214350865|NCT00157807|PROCEDURE|bipolar radiofrequency ablation of persistent and permanent AF|
214350866|NCT01880424|DRUG|Placebo|matching Placebo Capsules, Oral, once daily
214350867|NCT01880424|DRUG|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
214350868|NCT04897074|DEVICE|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
214350869|NCT06402734|BEHAVIORAL|Adherence to Gluten Free Diet|Participants with a diagnosed celiac disease were following a gluten-free diet. Study observed the adherence to the gluten-free diet for 6 weeks.
214350870|NCT04396834|DRUG|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
214350871|NCT04396834|DRUG|Placebo oral tablet|Placebo Oral Tablet (BID)
214350872|NCT03190473|DEVICE|DES|PCI with implantation of a DES
214350873|NCT03747926|DRUG|BI 705564|single-rising oral dose
214350874|NCT03747926|DRUG|Placebo|single-rising oral dose
214350875|NCT03248102|DIAGNOSTIC_TEST|Blowing into the mouthpiece|Blowing into the mouthpiece of diagnostic device
214350876|NCT04958018|DIETARY_SUPPLEMENT|Almonds|almond (Prunus dulcis) consumption
214350877|NCT04958018|DIETARY_SUPPLEMENT|Snack bars|324 calories/day, Nutri-Grain cereal bars, 120 kcal each
214350878|NCT04534595|OTHER|COVID-19|To study the experience of students and their families during the COVID-19 pandemic an online questionnaire will be utilized. This COVID-19 questionnaire will be administered at three time points: baseline, 6 months upon completion of the baseline questionnaire, and 12 months upon completion of the baseline questionnaire.
214678730|NCT00466752|GENETIC|microarray analysis|Correlative studies
214957986|NCT01558713|DRUG|Ropivacaine + Fentanyl|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
214957987|NCT01558713|DRUG|Levobupivacaine + Fentanyl|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
214350879|NCT01402453|BEHAVIORAL|Monetary Incentives|Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
214502636|NCT02147717|DEVICE|Laser stimulation|"Infants will be divided in 2 groups:~* Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS~* Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
214957988|NCT02024737|OTHER|MRI lung imaging (not an intervention per se but the focus of the study)|"The purpose of this pilot study is to determine short and long term reproducibility of a comprehensive set of functional imaging data; using hyperpolarised gas MRI, conventional MRI and lung physiology measurements in patients with moderate to severe COPD. In addition,how sensitive the imaging techniques are to changes in lung function after treatment with a standard (bronchodilator) inhaler will also be assessed (the bronchodilator foradil is a non-investigative medicinal product as it is a medicine with a known effect which will be used to induce a known response).~This pilot study will serve as a platform for future larger scale studies, aimed at better understanding of and intervention in early COPD."
214957989|NCT04318132|DEVICE|Nidek Mirante|The Nidek Mirante Optical Coherence Tomography (OCT) including scanning laser ophthalmoscope (SLO) function is an non-contact system for imaging the fundus and for axial cross sectional imaging of anterior and posterior ocular structures.
214957990|NCT04318132|DEVICE|Optovue RTVue XR Avanti|The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
214957991|NCT04318132|DEVICE|Optos P200DTx|The P200DTx scanning laser ophthalmoscope (SLO) is indicated for use as a widefield and retinal fluorescence and autofluorescence imaging ophthalmoscope to aid in the diagnosis and monitoring of diseases and disorders that manifest in the retina.
214957992|NCT04638803|DRUG|PRX-P4-003, (-)-FCF|sequential study
214957993|NCT00585325|DRUG|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
214957994|NCT00585325|OTHER|Placebo (0.9% Normal Saline)|.9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
214957995|NCT03662815|BIOLOGICAL|iNeo-Vac-P01|Neoantigen peptides
214957996|NCT03662815|OTHER|GM-CSF|immune adjuvant
215078650|NCT01485380|DRUG|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
214957997|NCT00617513|DRUG|Prucalopride|0.5 mg once daily
214957998|NCT00617513|OTHER|Placebo|o.d.
214957999|NCT00617513|DRUG|Prucalopride|1 mg o.d.
215078651|NCT05650138|OTHER|Jacobson's progressive muscular relaxation technique|subjects will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis for four weeks.
214958000|NCT00617513|DRUG|Prucalopride|2 mg o.d.
214958001|NCT02046278|DEVICE|LifeSeal™ Kit|
215078652|NCT05650138|OTHER|30 min walk|30 minutes walk twice a week for 4 weeks
214958002|NCT04424914|DIAGNOSTIC_TEST|Scintigraphy|scintigraphy
214958003|NCT03309514|BIOLOGICAL|Intracerebral microinjections|Stereotactic delivery of cell suspension into basal ganglia structures
215078653|NCT00621556|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
214958004|NCT04485637|OTHER|Communication with basic table|Communication showing only the normal range of blood pressure readings, which is often used but may make it hard to interpret numbers outside of the normal range
214958005|NCT04485637|OTHER|Communication with enhanced table|Communication with enhanced table, with reference information showing how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
214958006|NCT04485637|OTHER|Communication with enhanced graph|Communication with enhanced graph, showing reference information about how to interpret blood pressure readings (adapted from Blood Pressure UK) with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
214958007|NCT05138328|DEVICE|Treatment of basal cell carcinoma with Nd:YAG laser under imaging guidance of optical coherence tomography (OCT)|This will use optical coherence tomography (OCT) to assess the margins of basal cell carcinoma. Treatment will be completed by Nd:YAG laser.
214958008|NCT04697654|DRUG|TLC19|Hydroxychloroquine Liposome Inhalation Suspension
214958009|NCT04697654|DRUG|TLC19 Vehicle|Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)
214958010|NCT04869852|OTHER|Food|85g mango, 4x/week
214958011|NCT06384235|DRUG|LTC004|LTC004,45μg/kg,IV,Day 1,Q3W;
214958012|NCT03831269|DRUG|Azithromycin|Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
214958013|NCT03831269|OTHER|nbUVB|The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
214958014|NCT03173495|DIETARY_SUPPLEMENT|FRUCTOSE|Fructose-rich beverage with a high fat meal, without exercise.
214958015|NCT03173495|DIETARY_SUPPLEMENT|DEXTROSE|Dextrose-rich beverage with a high fat meal (control), without exercise.
214958016|NCT03173495|DIETARY_SUPPLEMENT|EXERCISE|45 minutes of 60% VO2peak aerobic exercise
214958017|NCT00003513|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214958018|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine|IM injection
214958019|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3|IM injection
215078654|NCT05581082|OTHER|Pragmatic, exploratory study of Precision Medicine|This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
215078655|NCT05524610|BEHAVIORAL|Sexual Function Screening Approach|"The screening approach will consist of:~1. Standardized use of the PROMIS SexFS Brief in a clinic setting. This tool assesses sexual interest/desire, arousal, discomfort/pain, climax, and satisfaction, among other SD concerns and has comparable sex-specific versions. It has been validated in adult cancer populations.~2. An implementation package to aid in successful implementation. The implementation package will be finalized in the non-trial portion of this study, which will include iterative intervention adaptation. The protocol will be amended as needed to include any relevant updates to the screening approach. Some components may vary per site."
215078656|NCT00737711|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
214502637|NCT02147717|DEVICE|Fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
214958020|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP vaccine without adjuvant|IM injection
214958021|NCT00674895|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
214958022|NCT01047124|OTHER|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
214958023|NCT02787681|DEVICE|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
214958024|NCT05413473|DEVICE|MR guided radiotherapy|MR guided radiotherapy using the Alberta linac-MR P3 system
214958025|NCT06007937|DRUG|Lorlatinib|Lorlatinib 100 mg orally daily
214958026|NCT06007937|DRUG|Ramucirumab|Ramucirumab 10 mg/kg intravenous infusion once every three weeks is a tolerable and safe dose.
214958027|NCT05880173|DIAGNOSTIC_TEST|FIB4|"Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography"
214958028|NCT06812832|DRUG|Simethicone 80 MG|Patients will receive simethicone 80mg four times per day for 2 weeks post-operatively.
214958029|NCT06812832|DRUG|Placebo|Patients in the control group will receive a placebo pill four times per day for 2 weeks
214958030|NCT03040349|BEHAVIORAL|Training|The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
214958031|NCT03040349|BEHAVIORAL|Provider and Patient Tools|Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
214958032|NCT03040349|BEHAVIORAL|E-blast and Webinars|In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
214350880|NCT01402453|BEHAVIORAL|Intrinsic Motivation|A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
214350881|NCT00450762|DRUG|gemcitabine|
214350882|NCT00450762|DRUG|carboplatin|
214350883|NCT01089426|DRUG|Omegaven™|1 g/kg/d of Omegaven until discontinuation of PN
214350884|NCT01089426|OTHER|Historical Controls|Standard of Care
214350885|NCT00479245|OTHER|Set of questionnaires (respondent)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
214350886|NCT02242474|DRUG|Anti-TNF suspended perioperatively|
214958033|NCT05584878|OTHER|Curodont repair Self- assembling peptide P11-4|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Curodont
214350887|NCT02242474|DRUG|Anti-TNFα continued perioperatively|
214502638|NCT04313816|OTHER|questionnaire|no intervention at all apart from filling a brief questionnaire
214958034|NCT05584878|OTHER|Ph-chi phosphorylated - nano-chitosan|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Ph-chi phosphorylated - nano-chitosan
214958035|NCT05584878|OTHER|"CCP-ACP  +ve control  Casein phosphopeptide amorphous calcium phosphate"|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by CCP-ACP
214350888|NCT01987648|PROCEDURE|Elective Craniotomy Patients|Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
214350889|NCT05697848|OTHER|Physiotherapy combined with Pain Education|Patients with chronic low back pain receive manual therapy treatment combined with Pain Education sessions.
214350890|NCT05697848|OTHER|Physiotherapy|Patients with chronic low back pain receive manual therapy treatment
214350891|NCT00675740|DRUG|rosiglitazone|tablets 4 mg daily
214958036|NCT06730191|PROCEDURE|soft tissue graft covering immediate dental implant|soft tissue graft covering immediate dental implant
214958037|NCT04746365|DRUG|ivermectin|ivermectin is anthelmintic
214958038|NCT04746365|DRUG|hydroxychloroquine|hydroxychloroquine is antimalarial.
214958039|NCT04746365|DRUG|Placebo|Standard treatments
214958040|NCT02897063|DRUG|Droxidopa|Single oral dose 300 mg
214958041|NCT02897063|DRUG|Midodrine|Single oral dose 10 mg
214958042|NCT02897063|DRUG|Placebo|sugar pill
214958043|NCT05390385|DIETARY_SUPPLEMENT|KE1 5g|5g of KE1 (KetoneAid, Falls Church, VA), diluted to 4 ounces
214958044|NCT05390385|DIETARY_SUPPLEMENT|KE1 10g|10g of KE1 (KetoneAid, Falls Church, VA), equal to 4 ounces
214350892|NCT00675740|BEHAVIORAL|physical exercise|stationary bike 5-6 times a week
214350893|NCT00675740|OTHER|control|control without intervention
214350894|NCT00000648|DRUG|Penicillin G potassium|
214502639|NCT03829436|DRUG|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
214502640|NCT03829436|DRUG|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily
214502641|NCT03829436|DRUG|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
214350895|NCT00000648|DRUG|Ceftriaxone sodium|
214350896|NCT02612948|DRUG|Quetiapine|escalating dose to prevent delerium.
214350897|NCT05800132|DEVICE|MammoScreen|Diagnostic reading aid for breast cancer screening
214350898|NCT01983293|DEVICE|QLV based implant strategy|
214350899|NCT01983293|DEVICE|Standard of care implant strategy|
214350900|NCT01921569|BEHAVIORAL|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
214350901|NCT01921569|OTHER|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
214350902|NCT01921569|OTHER|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
214678731|NCT00466752|OTHER|immunohistochemistry staining method|Correlative studies
214958045|NCT05390385|DIETARY_SUPPLEMENT|KE4 5g|5g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
214958046|NCT05390385|DIETARY_SUPPLEMENT|KE 10g|10g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
214958047|NCT05390385|OTHER|Placebo drink|Flavor-matched control placebo drink (KetoneAid, Falls Church, VA), 4 ounces
214958048|NCT00334295|DRUG|Fulvestrant|A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.
214958049|NCT02261103|DRUG|Pramipexole ER tablets|
214958050|NCT02261103|DRUG|Pramipexole IR tablets|
214958051|NCT02261103|DRUG|Placebo matching Pramipexole ER tablets|
214958052|NCT02261103|DRUG|Placebo matching Pramipexole IR tablets|
214958053|NCT02261103|OTHER|Standard high-fat breakfast|
214958054|NCT06517550|OTHER|positive end-expiratory pressure while mechanical ventilation|a parameter in ventilator
214958055|NCT01446250|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
214958056|NCT01446250|DRUG|Boceprevir|BOC 800 mg (4 x 200 mg soft gel capsules) administered orally
214350903|NCT05079620|DRUG|Ceftriaxone|If there is low risk for P. aeruginosa and/or methicillin-resistant staphylococcus aureus (MRSA), as deemed by the treating team: Ceftriaxone 2 g IV, every 24 hours for 5 days
214958057|NCT01446250|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
214958058|NCT01446250|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
214958059|NCT03383692|DRUG|DS-8201a|DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
214958060|NCT03383692|DRUG|Ritonavir|Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration
214958061|NCT03383692|DRUG|Itraconazole|Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration
214958062|NCT05216458|BEHAVIORAL|Emails and letter intervention|Emails and letters for households assigned to the treatment group
214958063|NCT05216458|BEHAVIORAL|Control group|No outreach during the intervention period.
214958064|NCT03600246|DEVICE|WATCH-PAT|WatchPAT is an FDA-approved portable diagnostic device that uniquely uses finger based physiology and innovative technology to enable simple and accurate Obstructive Sleep Apnea (OSA) testing while avoiding the complexity and discomfort associated with traditional air-flow based systems.
214958065|NCT02325921|DEVICE|Magnetic Resonance Imaging|One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences, but without contrast enhancement.
214958066|NCT01555710|DRUG|Carboplatin|AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
214958067|NCT01555710|DRUG|Palifosfamide-tris|130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
214350904|NCT05079620|DRUG|Amoxicillin clavulanic acid|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on ceftriaxone to the oral agent Amoxicillin + clavulanate (Augmentin) 875 mg PO or per feeding tube, twice daily for the remainder of 5 days
214350905|NCT05079620|DRUG|Cefepime|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Cefepime 2 g IV, every 8 hours for 5 days, plus vancomycin
214350906|NCT05079620|DRUG|Vancomycin|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Vancomycin IV, dosed by trough or AUC/MIC (area under the curve/minimum inhibitory concentration) monitoring for 5 days, plus cefepime. Order nasal MRSA swab and consider discontinuing vancomycin if MRSA swab is negative.
214350907|NCT05079620|DRUG|Levofloxacin|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on cefepime to levofloxacin PO or per feeding tube, 750 mg every 24 hours for the remainder of 5 days
214502642|NCT03829436|DRUG|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
214678732|NCT00466752|GENETIC|gene expression analysis|Correlative studies
214678733|NCT00466752|PROCEDURE|needle biopsy|Correlative studies
214678734|NCT00466752|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy
214678735|NCT00466752|OTHER|laboratory biomarker analysis|Correlative studies
214958068|NCT01555710|DRUG|Etoposide|100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
214958069|NCT01555710|DRUG|Carboplatin|AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
214958070|NCT05559944|BEHAVIORAL|Expressive Writing|Participants will be asked to write about the biggest body image or eating-related stressor they have experienced as a member of the LGBTQ+ community.
214958071|NCT05559944|BEHAVIORAL|Self-Affirmation|Participants will receive one new vignette per day describing a SM young adult experiencing severe body image stress in Alabama. Participants will be asked to write to this person and provide advice based on their own experience as a SM young adult. Vignettes will be identical across participants; however, they will be matched to participants' sexual identity, gender identity, and race/ethnicity.
214958072|NCT05559944|BEHAVIORAL|Control|Consistent with prior research participants will write about their routine daily activities since waking up for 20 minutes each day, sans emotional content.
214958073|NCT06450093|OTHER|Preformed stainless steel crown.|A well-fitted preformed stainless-steel crown will be chosen by measuring the mesiodistal dimension of the tooth or its contralateral counterpart, using a graduated periodontal probe for guidance. (6) Tooth preparation will be carried out with #835 diamond fissure bur to reduce occlusal surface up to 1 to 1.5 mm. The interproximal reduction will be made mesially and distally using #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. The selected crown size will be checked, and a trial fit will be done before cementation. The crown will be cemented using self-cured RMGI luting cement. The excess will be removed, and proper occlusion will be checked.
214958074|NCT06450093|OTHER|Preformed zirconia crown|The material for crown restoration for this group is the preformed zirconia crown. Tooth preparation will be started by occlusal reduction (1 to 1.5 mm) using #835 diamond fissure bur. The interproximal reduction will be done mesially and distally with #169 L tapered diamond bur in such a way that a straight probe passes freely through the contact area. Rounding of line angles will be done and a knife-edge finish margin of the proximal surface will be obtained avoiding any ledge formation. The selected crown will be placed and checked for a passive fit. Consistent firm finger pressure will be applied during cementation with self-cured RMGI luting cement. Finally, crown placement will be checked.
214958075|NCT06450093|OTHER|Preformed BioFlx crown|The prefabricated BioFlx crown will be used in this group. A similar-sized preformed crown will be selected. Tooth preparation will be carried out similarly to traditional SSCs with #835 diamond fissure bur for occlusal reduction by 1-1.5 mm including the central groove. The proximal preparation will be done mesially and distally with #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. Placement of the crown will be achieved by a snug fit. Crown cementation will be carried out using self-cured RMGI luting cement and the excess cement will be removed using a floss or an explorer. (13) Finally, crown placement will be checked
214958076|NCT02182154|DRUG|BIBF 1120 ES|
214958077|NCT02159885|OTHER|Telemonitoring|
214958078|NCT00893971|DRUG|PT001|Inhaled PT001, single dose
214958079|NCT00893971|DRUG|PT005|Inhaled PT005, single dose
214958080|NCT00893971|DRUG|PT003|Inhaled PT003, single dose
214958081|NCT00893971|DRUG|PT001 + PT005|Inhaled PT001 + PT005, single dose
214958082|NCT01685385|OTHER|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
214958083|NCT06513975|DEVICE|CART BP|A ring-type medical device worn by the subject that non-invasively measures systolic and diastolic blood pressure, as well as pulse rate.
214958084|NCT06513975|DEVICE|sphygmomanometer|Blood pressure measurement method utilizing a two-headed stethoscope, allowing two observers to simultaneously hear the Korotkoff sounds.
214958085|NCT06613178|DRUG|acetaminophen|Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded
214958086|NCT05150782|DIETARY_SUPPLEMENT|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin (2%), boswellia serrata (1.5%) and ascorbic acid (6%).
214958087|NCT00004832|DRUG|3,4-diaminopyridine|
214350908|NCT01747772|DEVICE|Shear Wave Sonoelastography|Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
214350909|NCT02111590|DRUG|Immunoglobulins|SCIG dosage is individualized for each patient according to previous IVIG dosage
214350910|NCT05197335|DEVICE|Chimaera short nail (length = 180 mm) in combination with one or two telescopic cephalic screws|The enrolled patients will proceed by undergoing the surgery necessary for the application of the medical device under observation (Chimaera), which coincides with the start of the treatment period.
214350911|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with bupivacaine|"drug: 20 ml 0.5%bupivacaine plus 20 ml 0.9% normal saline is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
214350912|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with Ketamine|"drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1mg\\kg ketamine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
214350913|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with Dexmedetomidine|"drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1µg\\kg dexmedetomidine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
214350914|NCT03768479|DEVICE|18F-FES-PET|18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant
214393591|NCT05290103|BEHAVIORAL|Game intervention|"Game intervention consists of 15-30 minutes digital health game playing at school and 2 weeks free usage of the digital health game during free time. In addition, after the 2 weeks period of game playing, 30-minute debriefing sessions with a research are held.~The digital health game includes visualized elements with sound effects that aim at increasing understanding about the consequences of tobacco product use and supporting refusal skills. The health game includes different mini-games and also textual information.~The debriefing sessions with a researcher include small group and group discussions about the themes presented in the game. A researcher leads and teachers facilitate the discussions. The debriefing sessions aim to connect the game experience with daily life situations."
214393592|NCT02615756|BEHAVIORAL|Exercise|
214678736|NCT00466752|GENETIC|western blotting|Correlative studies
214958088|NCT06434688|OTHER|Mental Fatigue:|The Mental Fatigue Scale (MFS) will be used to assess mental fatigue.
214958089|NCT06434688|OTHER|Body Awareness:|"Individuals' general body awareness will be assessed with the Body Awareness Questionnaire (BAQ).~Neck awareness of individuals will be assessed with the Fremantle Neck Awareness Questionnaire (FreBFA).~Short Form of the Five Facet Mindfulness Questionnaire (FFMQ - Short Form) will be used to assess people's mindfulness.~\- In-body awareness:~For the sense of interoception, the Multidimensional Assessment of Interoceptive Awareness Scale, which assesses interoceptive body awareness, will be used.~To evaluate proprioception, a Cervical Range of Motion (CROM) device is used.~The bucket test will be used to assess subjective visual verticality, which is one of the sub-dimensions of verticality perception.~Two scales will be used to assess people's awareness of weight transfer symmetry.~\- Out of Body Awareness:~Right-Left Confusion Hand Test will be used to evaluate the mental rotation skill within the scope of the sense of extroception."
214958090|NCT06434688|OTHER|Neck Disability Level|Neck disability index will be used to assess this parameter.
214958091|NCT06434688|OTHER|Quality Of Life|SF-12 will be used to assess quality of life.
214958092|NCT06434688|OTHER|Pain Assessment:|Pain intensity will be assessed by Visual Analog Scale (VAS). In addition, pain duration and pain frequency will be questioned. The Pain Self-Efficacy Questionnaire will be used to assess the confidence of people with chronic pain to perform certain tasks and behaviors despite their pain.
214958093|NCT06434688|OTHER|Physical Condition:|"Normal range of motion of the cervical region will be evaluated with the Cervical Range of Motion device.~New York Posture Rating Scale will be used to evaluate posture.~Symmetry of weight transfer to both lower extremities of the individuals in standing upright position will be evaluated."
214958094|NCT06434688|OTHER|Anxiety and Depression:|Beck Depression and Beck Anxiety scales will be used to assess depression and anxiety.
214678737|NCT00466752|GENETIC|RNA analysis|Correlative studies
214678738|NCT01851473|DRUG|cocaine|25 mg IV on days 1, 5, and 10
214958095|NCT02328573|BEHAVIORAL|Communal singing|
214678739|NCT01851473|DRUG|quinine|80 mg orally on days 7-10
214678740|NCT01851473|DRUG|acetazolamide|15 mg orally on days 2-5
214958096|NCT05512741|OTHER|Feces collection|"Feces will be collected, at home, by the patient., by using a collection kit. The stools are collected in the 2 last days before surgery.~After surgery, the first stool is collected, during the hospitalization, by using the same kit. Stools are conserved in the same condition, before being frozen in our local biologic ressources center."
214958097|NCT00492232|DRUG|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
214958098|NCT00492232|DRUG|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
214678741|NCT00239460|DRUG|Tiotropium|
214350915|NCT04326543|DIAGNOSTIC_TEST|Swanson, Noolan and Phelham - IV edition (SNAP-IV); Conners' Parent Rating Scales (CPRS)|"* Ratings on the Swanson, Nolan and Pelham Evaluation Scale - IV (Bussing et al., 2008), were assessed during baseline visit for participants at the time of research assessment, to exclude the presence of ADHD symptoms in the healthy subjects. This scale is composed of 26 items for ADHD symptoms and ODD and was administered at baseline and at follow-up visit.~* Temperament assessment: we used the Mary Rothbart's Temperament Questionnaire, a caregivers' report measure designed to provide a detailed assessment of temperament.~* ADHD Rating scales: the Long Version of Conners' Parent Rating Scale (Conners et al., 1998) was used to quantify ADHD comorbidity symptoms, as ODD and Anxiety traits, in the children and adolescents with ADHD.~* Salivary cortisol: Sampling was performed during one ordinary weekday between 7 and 8 o'clock, within 60' after nocturnal awakening."
214958099|NCT07015606|OTHER|Sciatic nerve mobilization with EMS|Patients in both groups will receive electrical muscle stimulation. In addition, the group A will receive sciatic neural mobilization and group B will receive femoral neural mobilization. Patients were not allowed to take medication for pain during the study or to receive any other form of treatment outside the study. EMS device was applied at a pulse frequency of 100 Hz. Placement of 2 surface electrodes will be used for stimulation over a session period of 15 minutes. The repetition of mobilization will be 10 times for 2 sets with 2 minutes rest in between the sets. The frequency of Electrical muscle stimulation and the duration of neural mobilization will be increased after every session up to 10 Hz and 3 mints respectively.
214958100|NCT07015606|OTHER|Femoral neural mobilization with EMS|Patients in both groups will receive electrical muscle stimulation. In addition, the group A will receive sciatic neural mobilization and group B will receive femoral neural mobilization. Patients were not allowed to take medication for pain during the study or to receive any other form of treatment outside the study. EMS device was applied at a pulse frequency of 100 Hz. Placement of 2 surface electrodes will be used for stimulation over a session period of 15 minutes. The repetition of mobilization will be 10 times for 2 sets with 2 minutes rest in between the sets. The frequency of Electrical muscle stimulation and the duration of neural mobilization will be increased after every session up to 10 Hz and 3 mints respectively.
214958101|NCT07015307|BEHAVIORAL|Sustainable Diet Program|Intervention based on the Mediterranean sustainable diet. It emphasizes the consumption of fish, fruits, and vegetables, while reducing the intake of meat and meat-derived products. The diet is tailored to the participants' health status, activity level, and nutritional requirements, following the recommendations of the Spanish Society of Cardiology and Endocrinology. Macronutrient and micronutrient goals follow national guidelines and are tracked using specialized dietary software.
214958102|NCT07015307|BEHAVIORAL|Supervised Physical Exercise Program|A 12-week supervised physical exercise program led by certified professionals in Sport Sciences. Exercise prescriptions are tailored individually based on baseline assessments and international guidelines from fields such as cardiology and metabolism. The sessions may include strength, endurance, or combined training. In the supervised period, the instructor guides the sessions, while during the unsupervised period, exercises are followed via an online platform that provides detailed explanations and graphics.
214958103|NCT07015307|BEHAVIORAL|Combined Sustainable Diet and Exercise Program|This experimental arm combines the dietary intervention based on the sustainable Mediterranean diet with the structured physical exercise program. Both components are personalized and adhere to national and international health and nutrition recommendations. The program includes a 12-week supervised phase and an unsupervised online phase, aiming to maximize improvements in metabolic, physical, and psychosocial health in older women with metabolic alterations.
214350916|NCT05148377|DRUG|Liquaemin|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
214350917|NCT05148377|DRUG|Heptar|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
214350918|NCT04431596|DEVICE|Forearm cooling|forearm immersion will be performed for active cooling assessment.
214350919|NCT04431596|OTHER|Mist-fan cooling|A mist-fan will be placed in front of the participant for active cooling.
214393593|NCT02409160|PROCEDURE|Standard Roux-en-Y gastric bypass|
214393594|NCT02336581|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
214393595|NCT02336581|BEHAVIORAL|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
214678742|NCT04965714|BIOLOGICAL|Nivolumab|Given IV
214393596|NCT02802020|DEVICE|Pancreatic fully-covered self-expanding metal stent (FCSEMS)|The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent.
214393597|NCT00285090|DIETARY_SUPPLEMENT|Calcium, Vitamin D|
214393598|NCT00285090|DIETARY_SUPPLEMENT|Calcium,Vitamin D|
214350920|NCT05168241|OTHER|song/melodica group|"The patients who were divided into groups according to their wishes to sing or play the melodica were given warm-up training before the song group (20 min. warm-up training including breathing exercises, 20 min. singing) and melodica group (20 min. breathing). warm-up training including exercises, playing melodica for 20 minutes) was given with the researcher under the leadership of an experienced music teacher.~For two weeks, a total of 40 minutes of song/melodica training was given per week. The singing group was given an assignment to sing for at least 20 minutes a day and the melodica playing group to play the melodica for at least 20 minutes a day. The patients were asked to do their song/melodica homework for at least 20-30 minutes a day, and then they were told about the follow-up papers.~Patients in the song/melody group were followed up by telephone twice a total of 15 days at the 5th and 7th weeks."
214958104|NCT07017556|BEHAVIORAL|Views on Information Resources for Kidney Transplantation Patients|"A pilot study to improve kidney transplant patient education. The study explores whether videos help patients to better understand and remember important information regarding the benefits and risks of receiving a kidney transplant.~Currently, patients receive transplant information through written materials, and clinician discussions. However, not everyone has the same level of language literacy and medical understanding, which can lead to critical knowledge gaps, misunderstandings, and misinterpretations.~Patients may also not know about lifelong medication needs, and complications which may follow transplantation, such as diabetes, making patient education and understanding essential.~This study explores whether video materials helps patients feel more informed and satisfied with the clinical information they receive, and whether they can better retain this information. The investigators aim to support more informed patients, making transplant education clearer, and accessible."
214958105|NCT06613321|DIAGNOSTIC_TEST|Respiratory function tests before introduction of vasodilator therapy|Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.
214958106|NCT06613321|DIAGNOSTIC_TEST|3 month follow up evaluation of response to treatment.|Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.
214958107|NCT05432895|DEVICE|Dynamic splint|Device treats plantar fasciitis and replacing boot immobilization which is quite benign
214958108|NCT07022470|RADIATION|3-Fraction HDR Brachytherapy|8 Gy per fraction for 3 fractions (total 24 Gy) for patients with locally advanced cervical cancer, based on individualized planning.
214958109|NCT07022470|RADIATION|4-Fraction HDR Brachytherapy|7 Gy per fraction for 4 fractions (total 28 Gy) as the standard-of-care brachytherapy regimen.
214958110|NCT07022626|PROCEDURE|CTCA|Computed Tomography Coronary Angiography (CTCA) performed prior to invasive coronary angiography (ICA)
214958111|NCT07021391|BEHAVIORAL|Primary care healthy food prescription plus incentive|Primary care healthy food prescription with $40 monthly incentive for four months to purchase 2 and 3 starred (via Guiding Stars) groceries at the supermarket
214958112|NCT07021508|DEVICE|Temporal Interference Stimulation|A non-invasive, non-invasive method of deep brain electrical stimulation utilizing high-frequency electric field interactions to produce a low-frequency envelope to modulate neural activity.
214958113|NCT07021508|DEVICE|Sham Temporal Interference Stimulation|The same machine was used as the temporal Interferenc real stimulus, with current creep only 20 seconds before stimulus onset to simulate the real stimulus sensation.
214958114|NCT07022613|OTHER|Mindfulness-Based Stress Reduction Program|"The Mindfulness-Based Stress Reduction (MBSR) program is considered to offer healthcare professionals working under high levels of stress the opportunity to develop knowledge and skills in consciously recognizing their emotions, compassionately accepting painful feelings without suppression, and transforming negative thoughts and emotions into more constructive ones.~In the first and last sessions, the Perceived Stress Scale (PSS), the Mindful Attention Awareness Scale (MAAS), the Self-Compassion Scale (SCS), and the Visual Analog Scale (VAS) will be administered, and saliva samples will be collected.~In the remaining sessions, only the VAS-one of the stress measurement parameters-will be verbally administered. In this way, participants will be informed weekly about the progression of their stress levels.~The program to be implemented in the study will consist of weekly sessions held over eight weeks. Each session will be conducted for groups of 10 participants, three consecutive days"
214958115|NCT07021417|BEHAVIORAL|Workshop|includes a single 4-hour session
214958116|NCT07021417|BEHAVIORAL|Course|Includes four weekly sessions totaling 8 hours (2 hours each)
214958117|NCT07022574|BEHAVIORAL|Low inflammation diet intervention|Autoimmune Protocol Diet intervention
214958118|NCT07022665|PROCEDURE|Appendicectomy|Appendicectomy for appendicitis
214350921|NCT05168241|OTHER|control group|"In the first interview, the pre-tests were applied by the researcher with the face-to-face interview technique. Afterwards, nursing education was given through the training guide prepared according to Pender's health promotion model. The control group was followed up and counseled by phone, twice a day, twice a day, in the 5th and 7th weeks.~Post-tests were applied at week 10 to evaluate the effectiveness of the interventions."
214958119|NCT07022665|PROCEDURE|Cholecystectomy|Cholecystectomy for cholecystolithiasis and/or cholecystitis
214958120|NCT07022665|PROCEDURE|Umbilical hernia repair|Any kind of umbilical hernia repair
214350922|NCT03929029|DRUG|Nivolumab (480 mg infusion)|Nivolumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
214393599|NCT00285090|DIETARY_SUPPLEMENT|Calcium, VitaminD|
214393600|NCT00285090|OTHER|Sugar Pill|
214958121|NCT07022665|PROCEDURE|Inguinal and/or femoral hernia repair|Any kind of inguinal and/or femoral hernia repair
214958122|NCT02453256|DRUG|Placebo|Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
214393601|NCT04217070|OTHER|Questionnaire|Questionnaire including demographic data, data regarding poisoning substance and outcomes of suicidal attempts
214393602|NCT04039074|BEHAVIORAL|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
214678743|NCT04965714|BIOLOGICAL|Pegargiminase|Given IM
214958123|NCT02453256|DRUG|Tocilizumab|Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
214958124|NCT07023185|DEVICE|Cold and Compression|External mechanical compression therapy (e.g., compression stockings) has been shown to reduce swelling and risk of deep vein thrombosis in the lower limbs following TKA.12,13 Combining advanced cryotherapy (continuous circulating cold flow) and dynamic compression may offer added benefits than either traditional cryotherapy (e.g., cold packs) or compression (e.g., stockings) alone.
214958125|NCT07023185|OTHER|SOC (Standard of care)|Patients enrolled in this arm will be discharged with 28 hydrocodone/APAP 7.5 mg pills taken every 6 hours as needed (or its MME equivalent), 1 identical refill if patient calls, and cold therapy (bag of ice or gel pack)
214958126|NCT07021404|OTHER|Semi-structured interview (Guideline for Suicide care and Evaluation =LOES)|"A semi-structured interview is utilized in general hospitals and other healthcare institutions by clinicians and nurses as part of the psychosocial assessment, with the aim of collecting standardized data on episodes of self-harm and individuals experiencing suicidal ideation.~The interview consists of two parts:~Part 1 is administered shortly after admission to the healthcare facility due to an episode of self-harm or reported suicidal thoughts. It is conducted by a trained nurse or psychologist. This section collects demographic information, characteristics of the self-harm episode, history of self-harm behavior, perceived social support, level of hopelessness, and current suicidal ideation.~Part 2 focuses on a more in-depth exploration of the individual's psychological state. It assesses underlying motives for the self-harm or suicidal thoughts, perceived personal and interpersonal problems, and current and current thoughts of self-harm."
214350923|NCT03929029|BIOLOGICAL|NeoVax plus Montanide|Montanide® is an activator of immunity that enhances response to vaccination through slow release of the peptides from the injection site and its ability to create an inflammation and stimulate the recruitment of specific cells of your immune system. Montanide® will be mixed with the personalized neoantigen vaccine
214350924|NCT03929029|DRUG|Ipilimumab|Ipilimumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
214350925|NCT03771976|PROCEDURE|Cesarean section|Risk of cesarean section between the cohorts
214350926|NCT03771976|PROCEDURE|No cesarean section|Vaginal birth rate between the cohorts
214350927|NCT00381966|DEVICE|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
214350928|NCT04035967|OTHER|Questionnaire|Impact on Family Scale (IPFAM), WeeFIM Pediatric Functional Independence Measurement, Nottingham Health Profile. State-Trait Anxiety Inven¬tory (STAI-I and STAI-II), PEDI (Pediatric Evaulation of Disability Inventory)
214350929|NCT04907708|DRUG|Metformin|Euglycemic agent
214350930|NCT04907708|DRUG|Insulin|Hypoglycemic agent
214350931|NCT05446987|OTHER|Position change and back massage|Changing the patient's position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the researcher applied a simple stroke of lower back massage for 5 minutes every 2 hours
214350932|NCT05446987|OTHER|Early ambulation|The patient ambulated after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle
214350933|NCT03283540|PROCEDURE|TaTME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This dissection can be achieved transanally starting down in the pelvis and going up in what is known as Transanal Total Mesorectal Excision
214350934|NCT03283540|PROCEDURE|TME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This surgery can also be done via an up-to-down approach beginning high in the abdomen and going low in the pelvis to achieve dissection around the mesorectum.
214350935|NCT02002403|DRUG|Danazol|
214350936|NCT02672631|OTHER|physical examination|Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)
214678744|NCT04965714|PROCEDURE|Resection|Undergo surgical resection
214678745|NCT05084547|OTHER|No intervention|No intervention
214678746|NCT02810002|DEVICE|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
214678747|NCT02810002|DEVICE|Control infantry boot|Training: infantry basic training in the control boots
214678748|NCT02017249|DRUG|arginine in powder form|
214958127|NCT07022301|DRUG|sintilimab combined with anlotinib|Patients who met the inclusion criteria were treated with Sintilimab plus anlotinib every 3 weeks until disease progression or intolerable adverse reactions or death(up to 24 months).
215078658|NCT00754091|DEVICE|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
215078659|NCT00127309|DRUG|Glutathione|
215078660|NCT02869698|PROCEDURE|Spectral Dynamic Imaging|
215078661|NCT02869698|DEVICE|Hybride electrode|
215078662|NCT02869698|DEVICE|Macro electrode|
215078663|NCT00840060|BEHAVIORAL|AMALS|Addressing multiple aspects of language simultaneously
215078664|NCT00840060|BEHAVIORAL|DTA|Discrete Trial Approach
215078665|NCT01263015|DRUG|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
215078666|NCT01263015|DRUG|Atripla|Atripla once daily on an empty stomach
214350937|NCT02672631|OTHER|DTI|Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion
214350938|NCT02672631|OTHER|ENMG|Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
214958128|NCT04673435|DEVICE|PermeaDerm for temporary coverage|See above
214958129|NCT04673435|DEVICE|FHCA for temporary coverage|See above
214350939|NCT00506259|DRUG|dTR Melatonin (NIH CC PDS)|
214350940|NCT00506259|DEVICE|Phototherapy (Bright Light)|
214350941|NCT00506259|DRUG|Melatonin CR|
214350942|NCT05311592|BEHAVIORAL|HERO Dads Program|The HERO Dads Program is a 4-week series of workshops for non-custodial fathers that focuses on improving parenting, offering job support, and financial counseling.
214350943|NCT03626155|BEHAVIORAL|Walking|Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline
214350944|NCT03626155|BEHAVIORAL|Seated Control|Participants will be asked to sit quietly and read during a 50 minute control period
214958130|NCT04673435|DEVICE|PermeaDerm over autograft|See above
214958131|NCT04673435|DEVICE|FHCA over autograft|see above
214958132|NCT07021612|DEVICE|JenaValve|JenaValve is a newly developed advanced TAVI system developed by Jenavalve Technology Inc.
214958133|NCT07021612|DEVICE|J-Valve|J-Valve is a newly developed advanced TAVI system developed by Genesis Medtech.
215078667|NCT01263015|DRUG|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
215078668|NCT01263015|DRUG|Abacavir/Lamivudine Placebo|matching placebo taken once daily
215078669|NCT01263015|DRUG|Dolutegravir placebo|matching placebo taken once daily
214350945|NCT04567472|BEHAVIORAL|Helping Ease Anxiety and Depression following Stroke|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
214393603|NCT04039074|BEHAVIORAL|Iyengar Yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
214393604|NCT04039074|BEHAVIORAL|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
214393605|NCT03671720|BIOLOGICAL|personalized DC vaccine|personalized vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous tumor cells, administered intranodally on day 1,8,15, with a combination of oral cyclophosphamide (50mg) every day except the day of vaccine administrations.Cycles are repeated every 21 days. Treatment is continued until disease progression or exhaustion of vaccine supply, whichever comes first.
214393606|NCT05173051|OTHER|Solid Medication intake vs. crushed medication intake|The swallowing ability for solid and crushed medications in stroke patients is evaluated.
214958134|NCT03737565|DEVICE|Optimax stent®|Percutaneous coronary intervention with Optimax stent®
214958135|NCT06703216|DRUG|Anakinra (Kineret®)|Pre-emptive Anakinra at the initial onset of CRS.
214958136|NCT06225791|BEHAVIORAL|MMS (90x2) + BCC or expanded BCC|Provision of 90-count bottles x 2, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
214958137|NCT06225791|BEHAVIORAL|MMS (180x1) + BCC or expanded BCC|Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
214958138|NCT06715852|BEHAVIORAL|PHYSBI: a 12-week physical exercise program|An individualized 12-week training program including 3 occasions/week of moderate-high intensity.
214958139|NCT06715852|BEHAVIORAL|Modified eHealth Lift: a digital, evidence based lifestyle-intervention for health promotion.|Through questionnaires, the patients answers questions regarding lifestyle habits and the results are converted into a health profile. A care manager will together with the patient decide appropriate health promoting activities to engage in.
214958140|NCT06887413|PROCEDURE|THROMBOASPIRATION WITH INDIGO SYSTEM|Subjects randomized to the treatment arm will be treated with the CAT RX as previously described.
214958141|NCT03590990|DIAGNOSTIC_TEST|Ultrasonsography, mammography, biopsy|Ultrasonsography of lump in breast Mammography of patents above 35 years Biopsy if indicated
214958142|NCT01216332|DRUG|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
214958143|NCT01216332|DRUG|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
214958144|NCT00312052|DRUG|E5555|50 mg or 100 mg E5555 tablets
214958145|NCT00312052|DRUG|Placebo|50 mg and/or 100 mg placebo tablets
215078670|NCT01263015|DRUG|Atripla placebo|matching placebo taken once daily on an empty stomach
215078671|NCT03927287|DIAGNOSTIC_TEST|Free PSA ratio test in patients after definitive treatment for localized prostate cancer|Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
215078672|NCT03571672|DRUG|DEFINITY|All subjects will receive a single dose of DEFINITY®
215078673|NCT02736513|DRUG|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
215078674|NCT01201616|OTHER|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
215078675|NCT01201616|OTHER|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
215078676|NCT00303446|DRUG|Dutasteride|Dutasteride 0.5 mg/day
214350946|NCT01577979|BEHAVIORAL|Text Message Reminder/Recall|Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
214958146|NCT06359197|DRUG|Caffeine Pill|Participants would take two Wake-Ups 200mg Caffeine tablets to meet the target dose of 400mg of caffeine. These are a registered natural health product with Health Canada (NPN 80003474). They are developed by Adrem Brands, which was established in 1951. Quality control testing is performed at a third-party independent lab, Nucro-Technics, which is audited by Health Canada and the US FDA. This ensures that the caffeine tablets comply with Health Canada standards. The tablets contain caffeine anhydrous-a processed, dehydrated form of caffeine-which allows for a standard dose per tablet. The tablets are sugar-free, which reduces the confounding effect of sugar on our results; thus, the investigators can be more confident that the obtained results are reflective of the association between caffeine and the CVD-related protein biomarkers.
214958147|NCT06359197|DRUG|Placebo|Participants would take two placebo pills to match the dosage of the intervention group. The investigators will use empty vegetable capsules from Health Bloom as the placebo for the control group. These capsules contain no contaminants or additives and are free from the common allergens. They are sugar-free-unlike most placebo pills, which reduces the confounding effect of sugar on our results. They are developed by Health Bloom, which is a Canadian company established in 2015. These capsules undergo testing at various stages of production to ensure purity and quality control. Each ingredient is tested prior to formulation, and the final capsules are subjected to thorough testing post-development. The capsules are white, and similar in appearance to the caffeine pill given to participants in the intervention group.
214958148|NCT06359197|DEVICE|TASSO+ Device|TASSO+ is a blood lancet device that uses negative pressure to draw capillary blood from the upper arm into a standard SST tube of volume 500μL. The small volume of blood collected makes this device less invasive than traditional collection methods. It is also safer and easier to use since it offers automated sample collection. TASSO manufactures a number of special devices for capillary blood sampling that have been validated as safe for consumer use, and the Tasso+ device is licensed with Health Canada for research use.
215078677|NCT00303446|DRUG|Placebo|Matched placebo
215078678|NCT06226168|OTHER|exercise and environmental conditions|Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.
214350947|NCT01577979|BEHAVIORAL|Parent Preference|Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
214958149|NCT06359197|DEVICE|Finger prick and collection on Whatman Protein 903 Saver Cards|The Whatman Protein 903 Saver Card is a specialized filter paper designed for the collection, storage, and elution of biological samples, including blood. It contains five half-inch circles that hold 75 to 80 µL of blood, making it an efficient and reliable method of obtaining dried blood spot (DBS) samples. The participant's finger will be pricked using a sterile, disposable lancet, and drops of blood will be collected on the Whatman 903 Protein Saver Card to fill nine ½ inch discs via capillary action. The blood spots will be allowed to dry at ambient temperature (21°C) for two hours. Whatman Protein 903 Saver Cards undergo strict quality control and GMP manufacturing standards, which ensures high quality and reproducibility.
215078679|NCT06226168|OTHER|exercise and environmental conditions|Passive exposure to normobaric hypoxia conditions. No training intervention. There will be a measurement of selected somatic indices and a quantitative measurement of bone mass indices (bone mineral density). A blood draw for biochemical analysis will be performed.
214350948|NCT04578990|OTHER|Walking intervention|"It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.~Depending on the data obtained in Visit 1, the speed will be determined for each patient and the degree of the initial slope that is comfortable when walking until it induces symptoms of moderate intermittent claudication. The progression of the intensity of the speed and incline of the slope will be increased progressively and individually for each patient."
214350949|NCT04578990|OTHER|Strength intervention|The training program consists of performing a training program with resistance exercises for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied. The same guidelines will be followed as in the walking exercise, but in this case, applying force stimuli. If symptoms of moderate intermittent claudication occur (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain disappears at the level of the lower limb. This sequence will be repeated until the strength training session is completed. The progression of force stimuli will be increased weekly depending on the subjective perception of the patient's effort and according to the guidelines set by our group of investigation.
214393607|NCT04509765|RADIATION|Linac Based VMAT TBI|Use of linac based Volumetric Arc Therapy (VMAT) to deliver Total Body Irradiation (TBI). The study intervention is a VMAT based delivery technique using a 6 MV photon beam from a Varian TrueBeam® (Palo Alto, CA) equipped with a Millennium multi-leaf collimation (MLC) system3. TBI will be delivered using a Varian TrueBeam linear accelerator with photon beam VMAT capability. VMAT is a radiation technique combining dynamic photon fluence modulation using multi-leaf collimation (MLC) with gantry rotation to deliver a highly conformal dose distribution with improved target coverage and sparing of organs at risk (OARs).
214393608|NCT02137538|DRUG|Letrozole|
214393609|NCT02137538|DRUG|Anastrozole|
214958150|NCT06359197|DEVICE|Intravenous Sampling|Blood will be collected from the medial cubital vein according to the standard venous blood sampling protocol into an EDTA tube with a volume up to 4mL.
214350950|NCT04578990|OTHER|Concurrent intervention|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli. If claudication symptoms occur moderate intermittent (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain in the lower extremity disappears. This sequence will be repeated until the 20 minutes established to end the session are completed concurrent training. The progression of the strength and resistance stimuli will be increased weekly depending on the perception subjective effort of the patient and according to the guidelines established by our research group.
214350951|NCT00957866|DRUG|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
214958151|NCT05521152|DRUG|Norepinephrine Bitartrate|"anesthesia resident (who will not be involved in patient management to ensure the blinding) will be responsible for preparing norepinephrine infusion or placebo as instructed in the envelope as follow: 1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion.~the attending anesthetist will be instructed to set the 2 syringe pumps on 2 mL/h continuous infusion following skin incision."
214958152|NCT05521152|DRUG|Placebo|Placebo
214958153|NCT06406413|DIAGNOSTIC_TEST|micro-movement; electroencephalogram; MRI|micro-movement; electroencephalogram; MRI
214958154|NCT00636636|DRUG|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
214958155|NCT00636636|DRUG|Placebo|Once daily; 300 mg and 600 mg tablets
214958156|NCT04777656|DIETARY_SUPPLEMENT|Phase1 : CDED/Modulen™IBD® + Maintenance therapy|from D0 until M2: Phase 1 (2 months run-in phase with CDED protocol + maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped until M2.)
214958157|NCT04777656|DIETARY_SUPPLEMENT|Phase2 and 3 :|from M2 until M4 CDED phase 2 (introduction of a selected number of additional food). From M4 until end of the study CDED phase 3 (enlargement of number of additional foods and allowance of some initially excluded foods).
214958158|NCT04151745|PROCEDURE|external pacemaker switched off|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
214958159|NCT03348098|DRUG|Apatinib|500 mg, po, qd. 12weeks
214958160|NCT03348098|DRUG|Paclitaxel|drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
214958161|NCT00189527|PROCEDURE|respiratory settings|
214958162|NCT04074382|OTHER|Online Questionnaires|We will use online questionnaires to complete research into functional outcomes after trauma
215078680|NCT04204356|BEHAVIORAL|Language treatment for improving discourse production|All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.
214958163|NCT04074382|OTHER|Qualitative Interviews|We will undertake qualitative interviews (remote or face to face) to shed more light on reasons for functional outcomes after trauma
214958164|NCT01537276|PROCEDURE|diagnose under real-time fluoroscopy|radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
214958165|NCT00524173|DRUG|Tenofovir & Emtricitabine|
214958166|NCT00524173|DRUG|Tenofovir|
214958167|NCT05475457|BEHAVIORAL|R3|Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
214958168|NCT01237327|DRUG|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
214958169|NCT01237327|DRUG|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
214958170|NCT02464865|DRUG|Thiamine 1|"If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks"
214958171|NCT02464865|OTHER|Non-thiamine|no symptoms and signs of thiamine deficiency
214958172|NCT02464865|DRUG|Thiamine 2|"If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks"
214958173|NCT04583358|DRUG|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
214958174|NCT04583358|OTHER|Placebo (oral)|Orally administered placebo comparator taken once daily
215078681|NCT04204356|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.
215078682|NCT05637892|OTHER|No intervention|This is a prospective observational study with no intervention
215078683|NCT00357617|DRUG|celecoxib|
215078684|NCT00357617|GENETIC|microarray analysis|
215078685|NCT00357617|GENETIC|protein expression analysis|
215078686|NCT00357617|OTHER|immunoenzyme technique|
215078687|NCT00357617|OTHER|immunohistochemistry staining method|
214350952|NCT05156658|DRUG|Etonogestrel (ENG) Subdermal Implants|Etonogestrel is available as a single, white/off-white, soft, radiopaque, flexible, ethylene vinyl acetate copolymer implant, 4 cm in length and 2 mm in diameter containing 68 mg of etonogestrel. Store at 25°C (77°F); excursions permitted between 15 and 30°C (59-86°F) \[see USP Controlled Room Temperature\]. Avoid storing ENG at temperatures above 30°C (86°F).
214350953|NCT04377165|BEHAVIORAL|Gamification|This will provide the user with the newsfeed function and the addition of a gamification function
214350954|NCT04377165|BEHAVIORAL|Newsfeed function|This will provide the user with reliable accurate information on the pandemic.
214350955|NCT03491644|DRUG|Titrated Oxygen|Restrictive treatment with oxygen.
214958175|NCT05638516|BEHAVIORAL|Vira mobile app intervention|The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.
214958176|NCT05638516|BEHAVIORAL|Vira mobile app intervention + coaching|"The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow."
214958177|NCT04633603|DEVICE|FeverFriend mobile application|Registration, documentation of patients profile, documentation of fever events, following advice regarding the patient and the care-giver, documentation of follow up notifications.
214958178|NCT04233671|BEHAVIORAL|Mindfulness based relapse prevention and peer mentoring|"Importantly, the treatment will utilize a group format. Group process can serve as a vital agent in breaking down client denial about drug abuse problems. Groups have also been shown to be suitable for treating problems commonly associated with substance abuse, including depression, isolation, and shame.~Additionally, groups intrinsically have many rewarding benefits, including reducing isolation and enabling members to witness the recovery of others. The eight-week group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, then followed by group sessions led by peer mentors for an additional four weeks."
214958179|NCT06907355|DRUG|Codeine|Codeine 10mg/5ml + Pseudoephedrine 7.5mg/5ml + Chlorphenamine 0.5mg/5ml: 10ml three times per day during 4 days
214958180|NCT06907355|DRUG|Levodropropizine|Levodropropizine 30mg/5ml: 10ml three times per day during 4 days
214958181|NCT06907355|DRUG|Ivy Leaves Cough Liquid|Ivy Leaf (Hedera Helix Extract) 35 mg/5ml: 10ml three times per day during 4 days
214958182|NCT06907355|DRUG|Placebo|Vitamins: 10ml three times per day during 4 days
215078688|NCT00357617|OTHER|laboratory biomarker analysis|
215078689|NCT00357617|PROCEDURE|biopsy|
215078690|NCT00357617|PROCEDURE|conventional surgery|
215078691|NCT00357617|PROCEDURE|neoadjuvant therapy|
215078692|NCT06041711|PROCEDURE|General anesthesia with propofol induction and sevoflurane maintenance|Surgical procedure is performed under general anesthesia with propofol induction and mainteined with sevoflurane inhalation.
215078693|NCT06041711|PROCEDURE|Regional anesthesia with neuroaxial blockage|Surgical procedure is performed under regional anesthesia. Patients are sedated with 2 mg intravenous midazolam. Combined spinal epidural anesthesia or spinal anesthesia with PENG block is used for anesthesia and analgesia.
215078694|NCT01748474|PROCEDURE|Supplemental oxygen via a mask|
215078695|NCT00593853|DRUG|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
215078696|NCT00593853|DRUG|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
215078697|NCT01952990|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
214350956|NCT03491644|DRUG|Liberal Oxygen|Liberal treatment with oxygen.
214350957|NCT05662033|DRUG|AZD6793|AZD6793 will be administered orally
214350958|NCT05662033|DRUG|Placebo|Placebo will be administered orally
214350959|NCT03326375|RADIATION|SBRT|Maximum dose : 60Gray (Gy) Fraction : 2 to 5
214958183|NCT01399476|PROCEDURE|Endoscopic Myotomy|Patients will receive the surgical procedure described in the summary (POEM).
214958184|NCT01399476|PROCEDURE|Endoscopic Myotomy for treatment of achalasia|Surgical procedure
214958185|NCT02483572|BEHAVIORAL|Functional Communication Training|Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
214958186|NCT03488069|OTHER|Survey|Submission of survey answers
214958187|NCT05433272|BIOLOGICAL|Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain|The Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain was developed by Sinovac Life Science Ltd. The antigen content of trivalent COVID-19 vaccine is a total of 18μg/0.5 ml, including 1200 SU/6 µg/0.5 ml for Prototype strain, 1200 SDU/6 µg/0.5 ml for Delta strain, and 1200 SOU/6 µg/0.5 ml for Omicron strain. The routine of administration is Intramuscular injection into deltoid region.
214958188|NCT05433272|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|The COVID-19 Vaccine (Vero Cell),Inactivated was manufactured by Sinovac Life Science Ltd.The antigen content of the active-controlled vaccine (CoronaVac) is 600 SU/3 µg/0.5 ml.The routine of administration is Intramuscular injection into deltoid region.
214958189|NCT03704012|BEHAVIORAL|Protocol of massage therapy and kinesiotherapy|Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
215078698|NCT04656795|DRUG|MT-7117|MT-7117
215078699|NCT02624193|BEHAVIORAL|MBSR Program|Mindfulness-based stress reduction, as described previously.
215078700|NCT02624193|BEHAVIORAL|HT Program|Health education curriculum, as described previously
214958190|NCT04811664|BIOLOGICAL|Moderna COVID-19 Vaccine|A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.
214958191|NCT03466879|DEVICE|SYNUS Pain Relief device|SYNUS Pain Relief is a handheld micro-current TENS device used for the temporary relief of sinus pain.
215078701|NCT04077372|BEHAVIORAL|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
214958192|NCT06719232|DEVICE|Catheter-Free Intravesical Instillation with a special syringe adapter|The intervention involves catheter-free intravesical instillation using a specialized urological adapter. This device is attached to a syringe and inserted approximately 6-8 mm into the urethral opening, allowing the instillation solution to reach the bladder without the need for catheterization.
214958193|NCT02163642|DEVICE|Cyranose® 320|Detection of patterns of specific Volatile Organic Compounds in exhaled air
214958194|NCT05052697|BIOLOGICAL|mIRV|Intramuscular injection
214958195|NCT05052697|BIOLOGICAL|bIRV AB|Intramuscular injection
214958196|NCT05052697|BIOLOGICAL|qIRV|Intramuscular injection
214958197|NCT05052697|BIOLOGICAL|QIV|Intramuscular injection
214958198|NCT05052697|BIOLOGICAL|bIRV AA|Intramuscular injection
214958199|NCT05052697|BIOLOGICAL|bIRV BB|Intramuscular injection
214958200|NCT04351477|DEVICE|Massage chair|Mechanical massage chair
214958201|NCT05885633|PROCEDURE|endometrial sampling with pipelle|Following oocyte retrieval while the patient was under anesthesia, endometrial tissue sampling was performed with the help of pipelle cannula. A portion of the endometrial tissue was put into RNA stabilization buffer (RNAlater) to be used in qPCR and stored at -20°C until the analysis. The remaining endometrial tissue was first fixed with 10% formalin, followed by paraffin blocking and prepared for immunohistochemical analysis.
214958202|NCT01657656|DIETARY_SUPPLEMENT|Vitamin D|
214958203|NCT01289574|DRUG|ASC-J9|Cream for twice daily topical application to the face
215078702|NCT04077372|BEHAVIORAL|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
215078703|NCT03823846|DRUG|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
215078704|NCT03823846|DRUG|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
214350960|NCT01944631|DEVICE|Placebo|Nasal spray saline
214350961|NCT01944631|DEVICE|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
214350962|NCT04806828|OTHER|Preoperative classification|Score of inguinal hernia
214350963|NCT05831332|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
214958204|NCT03710369|DRUG|Placebo|The placebo pill was compounded by McDonalds Pharmacy.
214678749|NCT02017249|DRUG|Silica and cellulose placebo powder|
214958205|NCT03710369|DRUG|Sildenafil|Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
215078705|NCT03823846|DRUG|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
215078706|NCT03823846|DRUG|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
215078707|NCT03823846|OTHER|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
215078708|NCT03823846|DRUG|normal analgesia pump administration|Dose of analgesia pump was added if needed.
215078709|NCT03823846|DRUG|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
215078710|NCT06303232|OTHER|MANUAL LYMPHATIC DRAINAGE|"MLD was performed after the moist heating of 10 minutes in supine position with both knees bent. It will start from the abdominal lymph drainage followed by the central lymph drainage.~Then, by stimulating the bilateral axillary lymph nodes, the flow of the fluid was directed to the axillary lymph node. Each session lasted for approximately 45 minutes, for 7 days"
214350964|NCT01621698|PROCEDURE|Early paravertebral block|In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
214350965|NCT01621698|PROCEDURE|Late Paravertebral block.|In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
214350966|NCT05154682|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone will be given every 4 hours as needed for 2 weeks after surgery
214350967|NCT05154682|DRUG|Acetaminophen 500Mg Tab|Acetaminophen will be taken every 4 hours for 2 weeks after surgery
214958206|NCT01590849|DRUG|Contraceptives, Oral, Combined (Yaz®)|"After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~* Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~* Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use."
215078711|NCT06303232|OTHER|THERAPEUTIC ULTRASOUND|The participants of group B will receive a treatment of manual lymphatic drainage and ultrasound after the moist heat of 10 minutes. After MLD of 45 minutes, ultrasound will be performed in small circular pattern from periphery to the center towards the areola with following parameters: Mode: pulsed, Frequency: 1MHz, Intensity: 1W/cm2, Time: 8 minutes. Treatment was given for 7 consecutive days
214350968|NCT05154682|DRUG|Naproxen 500 Mg|Naproxen will be taken every 12 hours for 2 weeks after surgery
214350969|NCT01271322|RADIATION|neoadjuvant radiochemotherapy in metabolic non responders|Metabolic non-responders, with a SUV decrease of less than 35%, discontinue induction chemotherapy and proceed to an intensified radiochemotherapy treatment
214350970|NCT04666129|DRUG|Relugolix|"(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day."
214350971|NCT04666129|DRUG|Abiraterone|Abiraterone acetate (1000 mg \[2 x 500-mg tablets\]) or fine-particle abiraterone acetate (500 mg \[4 x 125-mg tablets\]) will be administered orally once daily.
214350972|NCT04666129|DRUG|Prednisone|"(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required."
214350973|NCT04666129|DRUG|Methylprednisolone|For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
214350974|NCT04666129|DRUG|Apalutamide|Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
215078712|NCT00389350|DRUG|Extract of Green and Black Tea|
214350975|NCT04666129|DRUG|Docetaxel|Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
214350976|NCT04074785|DRUG|Abemaciclib|Abemaciclib 150 mg po bid
214350977|NCT04074785|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
214350978|NCT05197192|DRUG|Obinutuzumab|"Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v."
214350979|NCT05197192|DRUG|Venetoclax|"Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)"
215078713|NCT05671224|OTHER|Visual aid|Handout and video describing different types of induction of labor
214350980|NCT05197192|DRUG|Acalabrutinib|"Cycles 15-24: Days 1-28:~100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg)."
214350981|NCT00656838|BEHAVIORAL|Patients receives letter, phone call, office visit, educational materials|Behavioral
214350982|NCT05759234|DRUG|HS248 pieces|The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
214350983|NCT01280487|DRUG|ZSTK474|Daily oral dosing for 21 days each cycle
214350984|NCT05884697|OTHER|K-Talk Intervention (Storytelling and K-Bot)|The K-Talk intervention group receives a combination of a storytelling intervention and an artificial intelligence chatbot (K-Bot) education.
214350985|NCT05884697|OTHER|Storytelling Intervention|The storytelling intervention features 12 authentic stories from young Korean immigrants and Americans. Each video is about 3 minutes long and includes stories from 1st, 1.5, and 2nd generation young Korean individuals, highlighting their perceptions of HPV and HPV vaccines, and their experiences with HPV vaccination.
214350986|NCT05884697|OTHER|K-Bot Intervention|The K-Bot intervention is a conversational and button-based artificial intelligence Chatbot that is available in both English and Korean.
214958207|NCT00262002|BIOLOGICAL|MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
214350987|NCT05884697|OTHER|Written Information|The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.
214350988|NCT01640522|OTHER|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
214350989|NCT01640522|OTHER|Enhanced usual Care|
214350990|NCT05155865|DEVICE|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement
214350991|NCT05155865|DEVICE|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement
214350992|NCT00788840|DRUG|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
214350993|NCT00788840|DRUG|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
214350994|NCT00006123|BIOLOGICAL|trastuzumab|
214350995|NCT00006123|DRUG|carboplatin|
214350996|NCT00006123|DRUG|carmustine|
214350997|NCT00006123|DRUG|cisplatin|
214350998|NCT00006123|DRUG|cyclophosphamide|
214350999|NCT00006123|DRUG|thiotepa|
214958208|NCT00262002|BIOLOGICAL|MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
214958209|NCT00262002|BIOLOGICAL|MenACWY PS (MenACWY-CRM, polysaccharide vaccine)|MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
214958210|NCT00262002|BIOLOGICAL|HBV (Hepatitis B vaccine)|Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
215078714|NCT04203069|DEVICE|Control group : Day-time compression sleeve|"In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
214351000|NCT00006123|PROCEDURE|peripheral blood stem cell transplantation|
214351001|NCT00090389|PROCEDURE|Chinese Acupuncture|
214351002|NCT00791024|DRUG|CRC-Pharma 001|50 mg
214351003|NCT00791024|DRUG|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
214351004|NCT02388724|DRUG|Vonoprazan|Vonoprazan tablets
214351005|NCT02388724|DRUG|Lansoprazole|Lansoprazole capsules
214351006|NCT02388724|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
214958211|NCT00262002|BIOLOGICAL|Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)|Prevnar was administered IM in the anterolateral area of the left thigh.
214958212|NCT00262002|BIOLOGICAL|MMR (Measles, Mumps and Rubella vaccine)|MMR at 12 month of age, administered in the left arm.
214351007|NCT02388724|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
214351008|NCT05160051|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET Scan|68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.
214351009|NCT05917327|DEVICE|Low-volume continuous veno-venous haemodialysis|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. One treatment will last 4 hours. For non-hospitalized patients, the treatment is performed on an outpatient basis.
214351010|NCT02232113|DRUG|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
214351011|NCT02268201|DRUG|Advagraf|oral
214351012|NCT02268201|DRUG|Prograf|oral
214351013|NCT00384553|DRUG|Rituximab|
214958213|NCT00262002|BIOLOGICAL|DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)|DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
214351014|NCT00384553|DRUG|DHAP|
214351015|NCT00384553|DRUG|TEC|
214351016|NCT00384553|DRUG|autologous stem cell transplantation|
214351017|NCT04647851|OTHER|Remote exercise intervention Down syndrome|See arm description
214351018|NCT02425839|DEVICE|Ultrasound exam by Supersonic Shear Imaging® technique|Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
214351019|NCT02425839|DEVICE|EMG examination by electromyograph Keypoint system|Experimented neurologist performs EMG examination.
214351020|NCT02716974|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
214351021|NCT02716974|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
214351022|NCT02716974|DRUG|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
214351023|NCT02716974|PROCEDURE|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
214351024|NCT02716974|RADIATION|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
214351025|NCT02724553|DEVICE|Acrylic lens implantation|
214678750|NCT03046238|DRUG|Dexmedetomidine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
214958214|NCT00262002|BIOLOGICAL|Menjugate (Men C conjugated vaccine)|Menjugate was injected IM in the anterolateral area of the right thigh.
214351026|NCT03603665|BIOLOGICAL|NTM-1633|NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.
214351027|NCT03603665|OTHER|Placebo|0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
214351028|NCT03181880|DRUG|Aclidinium bromide/formoterol fumarate combination|"Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.~The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).~Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment."
214351029|NCT03181880|DRUG|Standard of Care|Brochodilators
214351030|NCT04068337|PROCEDURE|Aortic root replacement with Freestyle biological prosthesis with and without hemiarch replacement|Aortic root replacement with Freestyle biological prosthesis. Some patients receive additional hemiarch replacement performing an open anastomosis to the aortic arch under antegrade cerebral perfusion through axillary artery. Comparison with patients, who were cannulated and perfused systemically
214351031|NCT01717118|BIOLOGICAL|Bivalent Vaccines|
214351032|NCT01717118|BIOLOGICAL|Tetravalent Vaccine|
214351033|NCT05403580|DRUG|Olanzapine|Given PO
214958215|NCT01230099|BEHAVIORAL|Supportive Information Team Group|A minimum of two protocolized, interdisciplinary, informational support meetings led by palliative care clinicians will be arranged with family members or other patient surrogates who participate in decision-making for individual chronically critically ill patients.
214958216|NCT03501654|DEVICE|TecnisSymfony®|Patients received implantation of unilateral or bilateral TecnisSymfony® IOL after phacoemulsification by a single surgeon (MK Kim).
214351034|NCT05403580|DRUG|Placebo Administration|Given PO
214351035|NCT05403580|OTHER|Questionnaire Administration|Ancillary studies
214351036|NCT02605954|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
214351037|NCT02605954|DRUG|ABC/3TC|600/300 mg tablets administered orally once daily
214351038|NCT02605954|DRUG|Third Antiretroviral Agent|"Third antiretroviral agents could include one of the following:~* ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~* DRV+COBI or DRV/COBI FDC~* darunavir (DRV; Prezista®) + RTV~* lopinavir/ritonavir (LPV/r; Kaletra®)~* atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~* efavirenz (EFV; Sustiva®)~* etravirine (ETR; Intelence®)~* nevirapine (NVP; Viramune®)~* rilpivirine (RPV; Edurant®)~* dolutegravir (DTG; Tivicay®)~* raltegravir (RAL; Isentress®)~* fosamprenavir (FPV; Lexiva®) + RTV~* saquinavir (SQV; Invirase®) + RTV~* ATV (no booster)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG"
214351039|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants received access to three online lectures at the start of the first, third, and forth training week (each lasting 60 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
214351040|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants attended three live lectures at the start of the first, third, and forth training week (each lasting 90 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
214351041|NCT02561858|OTHER|acid load test|
214678751|NCT03046238|DRUG|placebo|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
214958217|NCT03623633|DRUG|denosumab|denosumab 60 milligrams subcutaneously every 6 months
214958218|NCT03623633|DRUG|alendronate|alendronate 70 milligrams weekly
214958219|NCT03623633|DRUG|raloxifene|raloxifene 60 milligrams daily
214958220|NCT01620333|DRUG|biphasic insulin aspart 50|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
214958221|NCT01620333|DRUG|biphasic insulin aspart 70|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
214958222|NCT06124105|DIAGNOSTIC_TEST|arterial blood gases|measurement of partial oxygen pressure in urine by arterial blood gas device
214958223|NCT05583045|OTHER|Olive Leaf Tea|Olive leaf tea (individual tea bags provided to participants with instructions of preparation)
214958224|NCT05583045|BEHAVIORAL|Lifestyle behavior change program (LBC)|"Lifestyle behavior change program as defined by America Diabetes Association on Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers(Association 2022)"
214958225|NCT05583045|OTHER|Placebo tea|Placebo tea containing 2,6g cellulose and a caramel coloring
214958226|NCT04000334|OTHER|MAP increased to optimize cerebral blood flow|MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
214958227|NCT04000334|OTHER|MAP between 65 and 85 mmHg|MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
214958228|NCT04774276|OTHER|cardiac rehabilitation protocol without occupational therapist|cardiac rehabilitation protocol without occupational therapist will be performed (usual practice before January 2021).
214958229|NCT04774276|OTHER|cardiac rehabilitation protocol with occupational therapist|"This intervention (occupational therapist) have been added since 2021 for all patients who need a cardiac rehabilitation protocol.~Occupational therapy is scheduled with sessions 3 times a week for 1 month."
214958230|NCT02278965|DRUG|Metformin|Metformin 850mg, oral, twice a day for 12 months
214958231|NCT02278965|DRUG|Omega-3 fatty acids|Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
214958232|NCT02179476|DEVICE|Glyder|The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation in one or two lumbar facet levels
214958233|NCT01891682|OTHER|Observational|Observational, Translational non-treatment study
214351042|NCT04063189|DRUG|Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen|Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23
214351043|NCT02734342|OTHER|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo \& Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
214351044|NCT04217863|BEHAVIORAL|GDP|Guided Disclosure Protocol
214351045|NCT03398005|DRUG|CaPre|4 x 1 g capsules administered orally once a day for 26 weeks
214351046|NCT03398005|DRUG|Placebo|4 x 1 g capsules administered orally once a day for 26 weeks
214351047|NCT05969093|DIAGNOSTIC_TEST|Tinel's Sign performed at different wrist positions|Participants will undergo the Tinel's Sign at different wrist positions while EMG activity and NCV are recorded to investigate the effect of wrist position on median nerve activity.
214678752|NCT06480045|PROCEDURE|Performed PECS II block with AI integrated USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with AI-integrated USG.
214958234|NCT02445131|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
214958235|NCT02445131|DRUG|GA101|"Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg~Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg."
214958236|NCT02445131|DRUG|CAL-101|"Induction: Cycle 2-6: d1-28: 150 mg p.o.~Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o."
215078715|NCT04203069|DEVICE|Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit|"In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
215078716|NCT03927313|DRUG|Linezolid|For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
215078717|NCT03927313|DRUG|High dose rifampicin|For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
215078718|NCT03927313|DRUG|Aspirin|For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
215078719|NCT03927313|DRUG|Standard of Care anti-tuberculous therapy|10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
215078720|NCT03927313|DRUG|Dexamethasone|Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
215078721|NCT00091338|BIOLOGICAL|MART-1 antigen|
215078722|NCT00091338|BIOLOGICAL|gp100 antigen|
215078723|NCT00091338|BIOLOGICAL|incomplete Freund's adjuvant|
215078724|NCT00091338|BIOLOGICAL|recombinant interleukin-7|
215078725|NCT02476084|OTHER|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
215078726|NCT02476084|OTHER|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
214958237|NCT01519973|RADIATION|SPECT/CT processed with Evolution for CardiacTM software|SPECT/CT to be compared with PET/CT
214958238|NCT02283580|OTHER|Single limb|"Low load, high-repetitive resistance training.~* single limb at a time (e.g., one arm or one leg)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise."
215078727|NCT02476084|OTHER|Biological samples collection|Draw of research blood samples.
215078728|NCT02476084|OTHER|Questionnaires|Administration of validated patients' questionnaires.
215078729|NCT02657681|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
215078730|NCT02657681|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
215078731|NCT03110653|DRUG|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
214958239|NCT02283580|OTHER|Two limb|"Low load, high-repetitive resistance training.~* two limbs at a time (e.g., both arms or both legs)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise."
214351048|NCT05804877|BEHAVIORAL|mindfulness-based cognitive therapy|Participants in the experimental group would be arranged to attend online mindfulness-based cognitive programs for eight weeks. Each week was divided into 3 parts, which were detailed mindfulness-based skills training with pictures or short videos, techniques application in different scenarios, and concepts consolidation through a web-based assignment.
214351049|NCT05804877|OTHER|Mental health education|The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
214351050|NCT01043770|BEHAVIORAL|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
214351051|NCT02216175|OTHER|SLIT to cow's milk|Sublingual immunotherapy
214351052|NCT02216175|OTHER|Low dose OIT|Oral Immunotherapy (low dose)
214351053|NCT02216175|OTHER|Conventional OIT to cow's milk|Oral Immunotherapy
214351054|NCT06386107|BIOLOGICAL|Thrombin Generation Assay (TGA)|Hemostasis is a complex process in which genetic or environmental conditions can cause shifts either towards pro-thrombotic states resulting in thrombosis, or towards pro-hemorrhagic states resulting in uncontrolled bleeding. Tests to assess a more global hemostatic profile, such as the TGA, have appeared as a more reliable alternative to assess the real hemostatic capacity of an individual. TGA is a global dynamic assay simultaneously and continuously measuring thrombin generation. It monitors the cleavage of a fluorigenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample.
214351055|NCT03084055|BEHAVIORAL|eMotion|eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity
214351056|NCT01206530|DRUG|Hydroxychloroquine|Dose:600 or 800 mg Route:PO daily Treatment Administration: Daily
214351057|NCT01206530|DRUG|Oxaliplatin|Dose: 85mg/m2 Route: IV infusion over 2 hours Treatment Administration: Day 1
214351058|NCT01206530|DRUG|Leucovorin|Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1
214351059|NCT01206530|DRUG|5-fluorouracil|Dose: 400mg/m2 Route: IV bolus immediately following leucovorin Treatment Administration Day 1
214351060|NCT01206530|DRUG|5-fluorouracil|"Dose: 2,400mg/m2 Route: IV continuous infusion over 46 hours immediately following bolus injection.~Treatment Administration: Days 1-2"
214351061|NCT01206530|DRUG|Bevacizumab|
214351062|NCT03429413|BEHAVIORAL|Protect Me 4 Application + External Quality Improvement Support|Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)
214351063|NCT03429413|BEHAVIORAL|Protect Me 4 Application Alone|During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.
214678753|NCT06480045|PROCEDURE|Performed PECS II block with conventional USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with conventional USG.
214678754|NCT01534832|DEVICE|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
214958240|NCT02570230|OTHER|NSS|NSS infusion
214958241|NCT02570230|DRUG|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
214958242|NCT04699825|OTHER|Cardiovascular and immunological changes|performing cardiac ultrasound, vascular doppler, and immunological study on cord blood sample
214958243|NCT01790516|DRUG|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
214351064|NCT05250180|OTHER|Animal Assisted Therapy|Patients enrolled in the study will be randomly scheduled to have a dog be a part of their PT and OT sessions on two days (one in the first week and one in the second week) during their stay. On these days, the therapist will lead the therapy session and integrate the dog at whatever level is appropriate based on the patient's level of functioning and therapy goals.
214351065|NCT05250180|OTHER|Control|treatment as usual as dictated by their treatment team
214351066|NCT03212469|DRUG|Durvalumab|"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
214351067|NCT03212469|DRUG|Tremelimumab|"Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
214351068|NCT03212469|RADIATION|SBRT|"Preliminary steps : Safety Runs~Safety run of the dual combination:~SBRT at C1D15.~Safety run of the triple combination:~SBRT at C1D15.~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
214351069|NCT00501384|DRUG|satavaptan (SR121463B)|
214351070|NCT04089644|DEVICE|closed-loop system|"Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
214351071|NCT04089644|DEVICE|Manual adjustment|"Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
214351072|NCT06571656|OTHER|FID123359 test formulation|Investigational product
214351073|NCT06571656|OTHER|FID123360 test formulation|Investigational product
214351074|NCT06571656|OTHER|FID123361 test formulation|Investigational product
214958244|NCT01790516|DRUG|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
214958245|NCT01790516|RADIATION|Radiation|daily radiation for 7 weeks
214958246|NCT03494244|PROCEDURE|Direct-to-implant breast reconstruction|Terminal prosthetic implanted at the time of mastectomy.
214958247|NCT03494244|DEVICE|Acellular dermal matrix|Banked tissue used to support the directly implanted breast prosthesis.
214351075|NCT06571656|OTHER|FID121843 ocular lubricant|Commercially available, preservative-free eye drops
214958248|NCT01048086|DRUG|Retinoic Acid|160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children \<12 kg.
214958249|NCT01048086|DRUG|Placebo|Placebo will be given in the same manner as retinoic acid in capsules that look identical.
214958250|NCT04460963|OTHER|Adrenomedullin|Adrenomedullin sample evaluation
214958251|NCT01554163|DRUG|Etoricoxib 30 mg|Etoricoxib 30 mg tablet once daily for 12 weeks.
214958252|NCT01554163|DRUG|Celecoxib 200 mg|Celecoxib 200 mg once daily for 12 weeks
214958253|NCT04239196|DRUG|tocilizumab and IV steroids combination|"Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.~Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week)."
214958254|NCT04239196|OTHER|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
214958255|NCT02922075|BIOLOGICAL|Connective tissue graft|A 1.5 mm thick soft tissue graft removed from the palate with determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
214958256|NCT02922075|BIOLOGICAL|Collagen matrix graft|A 15x20 mm collagen matrix trimmed according to determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
214351076|NCT05653505|OTHER|Remote Ischemic Conditioning|Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischemia in spatially distinct vascular territories.
214351077|NCT00511862|DEVICE|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
214351078|NCT03706599|BEHAVIORAL|Therapeutic education on fever|Session for therapeutique education on fever
214351079|NCT03706599|BEHAVIORAL|Therapeutic education on household accidents|Session for therapeutic education on household accidents
214351080|NCT00856856|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
214351081|NCT05550246|DRUG|Atomoxetine|Treatment given for 3 nights
214351082|NCT05550246|DRUG|Oxybutynin|Treatment given for 3 nights
214351083|NCT03814889|DEVICE|Vibration pattern|Vibration patterns applied to the affected limb based on pilot study results.
214351084|NCT03814889|DEVICE|No vibration|These patients will wear a glove with a blinking light instead of feeling vibrations.
214958257|NCT02922075|DEVICE|Immediate implant|A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque \> 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
214958258|NCT02922075|PROCEDURE|Tooth extraction|Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
214958259|NCT02922075|DEVICE|Immediate restoration|A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
214958260|NCT02922075|BIOLOGICAL|Bone regeneration|All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
214351085|NCT03589456|OTHER|No intervention|There are no interventions associated with this registry as it is purely observational.
214958261|NCT02922075|DRUG|Post operative medication|Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
214958262|NCT02922075|DEVICE|Definitive prosthesis|Definitive implant-supported restorations were performed 6 months after dental implant placement.
214958263|NCT02922075|OTHER|No soft tissue graft|No soft tissue graft was used
214958264|NCT04833400|DEVICE|ICRS|Patients undergo 30-minute aerobic training with ICRS, 3 sessions a week, for 4 weeks.
214958265|NCT04833400|DEVICE|TAET|Patients undergo 30-minute aerobic training with TAET, 3 sessions a week, for 4 weeks.
214958266|NCT02215499|DRUG|Placebo|
214958267|NCT02215499|DRUG|Sodium Oxybate|
214958268|NCT02215499|DRUG|JZP-386|
214958269|NCT01950156|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
214958270|NCT03111615|DRUG|Aromatase Inhibitors|"Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated"
214958271|NCT00037037|BIOLOGICAL|MAGE-10.A2|
214958272|NCT00037037|BIOLOGICAL|MART-1 antigen|
214351086|NCT02696317|DEVICE|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
214351087|NCT02696317|DEVICE|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
214351088|NCT06133894|BEHAVIORAL|Exercise program PERMANENTO inspired by developmental kinesiology|"The intervention is based on activation of reflexive movement patterns which ensures the original reflexive control of strength, mobility and stability. After birth, we cannot control our body movements - they are reflexes hard-wired into our brains and vitally important for proper development of our body (muscular system, vestibular system, sensory system, cardiovascular system or digestive system) as well as our brain and nervous systems. During early childhood, everything becomes integrated and works perfectly according to the original design. But this design is slowly abandoned due to for example sedentary lifestyle and replaced by compensatory movement patterns that are making us weaker and defective with all the consequences that are becoming more severe as we age. The aim is restore the original design and improve posture and other crucial components of functional fitness and move better and more."
214393610|NCT03294213|DEVICE|aScope 4 Broncho|"Investigator is asked: In your memory, compare your daily bronchoscope and the aScope 4 Broncho just evaluated on patients admitted to the OR or ICU undergoing at least one bronchoscopy procedure Patients will not be asked to consent to participate in this study, as no patient data are obtained and the CE-marked aScope™ 4 Broncho is used within its intended use"
214678755|NCT00541359|DRUG|bortezomib|Given IV
214678756|NCT00541359|DRUG|topotecan hydrochloride|Given IV
214958273|NCT00037037|BIOLOGICAL|NY-ESO-1 peptide vaccine|
214958274|NCT00037037|BIOLOGICAL|sargramostim|
214958275|NCT00037037|BIOLOGICAL|tyrosinase peptide|
215078732|NCT03110653|DRUG|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
215078733|NCT06495229|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
215078734|NCT04086368|DEVICE|Adolescent Lateral Entry Femoral Nail|The use of an less invasive implant that has the same accuracy.
215078735|NCT04086368|DEVICE|Pediatric LCP Hip Plate System|Open approach to the femur where the osteotomy and osteofixation with plate and screws are preformed
215078736|NCT02251717|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
215078737|NCT03780478|DRUG|Nerve block|0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
215078738|NCT03780478|DRUG|Placebo Saline Injection|Saline injection, total volume 2ml
215078739|NCT05858957|DRUG|Magnesium sulfate|magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M
214351089|NCT01925079|BEHAVIORAL|Intensive Education|"Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~1. Routine education at discharge.~2. 4 education brochures will be delivered to patients.~3. Calendar with healthy tips will be delivered to patients before discharge.~4. A follow-up brochure with medical expert letter.~5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~6. Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up."
214351090|NCT01925079|OTHER|Control|"Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~1. Routine education at discharge.~2. A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up."
214351091|NCT00484705|PROCEDURE|Electroacupuncture|
214351092|NCT00484705|PROCEDURE|Physical exercise|
214958276|NCT04884971|DRUG|Intestinal microbiota transplant (IMT)|Two size 00 capsules from a single lot will be taken daily. Approximately 2.0 x 10\^11 bacteria from a healthy donor are contained in each capsule.
214958277|NCT00784056|DRUG|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH\_DETINLYN Tangerine Mix)
214958278|NCT01777737|DRUG|Cotrimoxazole|24 weeks of treatment
214958279|NCT01777737|DRUG|Placebo|Identical capsules to cotrimoxazole
214958280|NCT04273932|DRUG|Lithium|Lithium aspartate of lithium carbonate will be administered by mouth.
214958281|NCT01146028|DRUG|Tizanidine|Tizanidine HCl Tablets 4 mg
214958282|NCT02739451|PROCEDURE|standard oxygen|"Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~* low-flow oxygen \[including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask\]~* or medium-flow oxygen \[Venturi masks and medium-flow facemasks\]"
214958283|NCT02739451|PROCEDURE|HFNO|The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher\&Paykel, Courtaboeuf, France).
214958284|NCT06188676|DRUG|Cyclophosphamide|Ciclofosfamida
214958285|NCT06188676|DRUG|Doxorubicin Hydrochloride|Adriamycin
214351093|NCT00484705|PROCEDURE|Untreated control|
214351094|NCT02535208|OTHER|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR \< 0.73.
214351095|NCT02535208|OTHER|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
214351096|NCT05003531|DRUG|IBI112 dose 2|Participants will receive placebo or dose 2 IBI112 SC
214958286|NCT06188676|DRUG|Etoposide Phosphate|Etopophos
214958287|NCT06188676|DRUG|Prednisolone|Prednisolonum
214958288|NCT06188676|DRUG|Rituximab|Chimeric Anti-CD20 Antibody
214351097|NCT05003531|DRUG|IBI112 dose 4|Participants will receive placebo or dose 4 IBI112 SC
214351098|NCT05003531|DRUG|IBI112 dose 1|Participants will receive placebo or dose 1 IBI112 SC
214958289|NCT06188676|DRUG|Vincristine Sulfate|Oncovin
214958290|NCT06188676|DRUG|Filgrastim|G-CSF
214958291|NCT06188676|DRUG|Pegfilgrastim|PEG-filgrastim
214958292|NCT06188676|DRUG|Nivolumab 40 mg in 4 ml Injection|Opdivo
214958293|NCT03034135|DRUG|Disulfiram/Copper|Disulfiram/copper gluconate is taken three times a day.
214958294|NCT03034135|DRUG|Temozolomide (TMZ)|TMZ is given per standard of care
214958295|NCT06070753|DRUG|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of EVT. Daily infusion for 10 consecutive days.
214351099|NCT05003531|DRUG|IBI112 dose 3|Participants will receive placebo or dose 3 IBI112 SC
214351100|NCT05003531|DRUG|placebo|Participants will receive placebo SC
214351101|NCT05118685|DRUG|Conjugated Estrogens vaginal cream 0,625mg|the particepant will receive vaginal estrogen cream one tube every night for 14 nights; then, one tube for 2 nights in 1 week (two tubes every week) for 10 weeks.
214678757|NCT00541359|OTHER|immunohistochemistry staining method|Correlative studies
214958296|NCT00565097|DRUG|Placebo|
214958297|NCT00565097|DRUG|Lanreotide|
214958298|NCT01972464|DRUG|Progesterone|oral micronized progesterone
214958299|NCT01972464|DRUG|Placebo|
214958300|NCT02526160|BIOLOGICAL|burosumab|solution for SC injection
214958301|NCT02526160|OTHER|Placebo|saline solution for SC injection
214958302|NCT04579003|OTHER|Mobilization|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization posterolateral glide for 30 secs with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
214958303|NCT04579003|OTHER|Mobilization with movement|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization with movement (MWM) 10 repetitions with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
214958304|NCT04501484|PROCEDURE|Magnetic Resonance-guided Focused Ultrasound VIM Thalamotomy|Ablation of contralateral VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel)
214958305|NCT00329693|DRUG|Norprolac|Placebo
214958306|NCT00329693|DRUG|Norprolac|Quinagolide
214958307|NCT00329693|DRUG|Norprolac|Quinagolide
214958308|NCT00329693|DRUG|Norprolac|Quinagolide
214958309|NCT00650819|DRUG|Ezetimibe + Simvastatin|ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
214958310|NCT00650819|DRUG|Simvastatin|simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
214958311|NCT00650819|DRUG|Ezetimibe|Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
215078740|NCT05858957|DRUG|Saline|100 ml saline infusion apply to the Group S
215078741|NCT03989973|DIAGNOSTIC_TEST|Gastroscopy|Gastroscopy
214351102|NCT05118685|COMBINATION_PRODUCT|platelet rich plasma|First, a topical anesthetic cream will be applied to the vaginal wall. Delaying the PRP injection for 20 minutes after anesthetics application achieved complete or near-complete analgesia for the procedure. Peripheral blood will be drawn from the arm and centrifuged to yield 5 cc of PRP. then PRP will be administered to the anterior vaginal wall using 27-G needles once every 3 weeks for 4 times and PRP is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
214351103|NCT01352338|DRUG|Lenalidomide, endoxan, prednisone|dose-finding
214351104|NCT01352338|DRUG|lenalidomide, endoxan, prednisone|oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
214351105|NCT03879720|PROCEDURE|Endoscope assisted endotracheal intubation [EAEI]|Endoscope assisted endotracheal intubation \[EAEI\] performed by anesthesiologist with endoscopist assistance.
214351106|NCT01850680|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
214351107|NCT01850680|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
214351108|NCT01850680|DRUG|methotrexate|Pharmaceutical form:capsule Route of administration: oral
214351109|NCT01850680|DRUG|folic acid|Pharmaceutical form:tablet Route of administration: oral
214351110|NCT05278273|DEVICE|NeurotrackerX|At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group.
214351111|NCT01920230|BEHAVIORAL|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams \& Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
214351112|NCT01920230|BEHAVIORAL|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
214958312|NCT06080672|OTHER|Experimental: Group 1 (dental examination-training-tooth brushing) Experimental: Group 2 (dental examination-training-plaque disclosing-tooth brushing)|All participants will be examined and their decay, filling and extracted teeth, plaque index and gingival index measurements will be recorded. Plaque disclosing will be applied to Group 2 after brushing training.
214958313|NCT04833426|DRUG|Testosterone gel|Topical gel containing testosterone
214958314|NCT04833426|DRUG|Placebo|Topical gel without active substance
215078742|NCT04233658|DRUG|Placebo|3x2 capsules / day
214351113|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
215078743|NCT04233658|DRUG|Cynara Scolymus|3x2 capsules / day
214351114|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
214678758|NCT00541359|OTHER|pharmacological study|Correlative studies
215078744|NCT03362788|DRUG|VKA|VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
215078745|NCT03362788|DRUG|NOAC|NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
215078746|NCT04436471|BIOLOGICAL|Gam-COVID-Vac|adenoviral-based vaccine against SARS-CoV-2
215078747|NCT06260969|DEVICE|balloon dilatation|Direct balloon dilation vs stenting vs embolectomy + tirofiban vs embolectomy + balloon dilation vs embolectomy + balloon dilation + intracranial stenting
215078748|NCT00606398|PROCEDURE|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
214351115|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
214351116|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
214351117|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
214351118|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
214351119|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
214351120|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
214351121|NCT00175682|DRUG|Prazosin HCL|See Detailed Description
214351122|NCT00907673|DEVICE|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
214351123|NCT04013815|PROCEDURE|erector spinae plane block with ropivacaine|The block is performed immediately before surgery. by an ultrasound guide, with the probe positioned longitudinally, the spinous process of T5 is identified. A peripheral block needle is inserted in the cephalo-caudal direction (caliber 21G and length 10 cm) and 3 ml of physiological solution are injected to confirm the injection site: fascial plane between the erector spinae muscle and the large rhomboid, near the tip of the transverse process of T5. Once the correct position of the needle tip has been confirmed, ropivacaine 0.75% 20 ml is injected.
214351124|NCT04013815|PROCEDURE|Intercostal nerve block with ropivacaine|The intercostal nerve block will be performed by the surgeon at the time of thoracotomy from the 4th to the 8th intercostal space, by injecting 20 ml of 0.75% ropivacaine (4 ml for each space). The injection is performed at about 2-3 cm from the spine.
214351125|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
214351126|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
214351127|NCT00413153|DRUG|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
214351128|NCT00413153|DRUG|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
214351129|NCT00000893|DRUG|Nelfinavir mesylate|
214351130|NCT00000893|DRUG|Efavirenz|
214351131|NCT02190331|OTHER|Interventional program postural correction training|The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.
214351132|NCT02190331|OTHER|Control Group physical education classes|Only performed the physical education classes
214351133|NCT04333394|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsules will be administrated once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with probiotic supplementation.
214351134|NCT04333394|OTHER|Placebo|The placebo capsules will be administered once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with placebo supplementation.
214351135|NCT02277106|DRUG|SAGE-547|
214351136|NCT02277106|DRUG|Placebo|
214351137|NCT06411457|DRUG|SHR-A1811+Adebrelimab|Assess the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer SHR-A1811 : 6.4mg/kg , q3w，d1, ivgtt Adebrelimab : 1200mg, q3w，d1, ivgtt
214351138|NCT01923727|BIOLOGICAL|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
214351139|NCT03670316|DRUG|Algorithm Treatment|Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
214351140|NCT03670316|OTHER|Quitline only|eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
214351141|NCT06031701|BEHAVIORAL|Neuro-psychosocial teleassistance program|The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. The intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.
214351142|NCT03620344|OTHER|ADH-Me Book and ADHD Informational Brochure|"Understanding ADHD information brochure published by American Academy of Pediatrics and a children's book about ADHD condition"
214351143|NCT03620344|OTHER|ADHD Informational Brochure Only|"Understanding ADHD information brochure published by American Academy of Pediatrics"
214351144|NCT03222518|DRUG|Paracetamol|21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
214351145|NCT03222518|DRUG|NSAID|14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
214351146|NCT03222518|DRUG|paracetamol-NSAID|21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
214351147|NCT06019312|DIETARY_SUPPLEMENT|Sanprobi IBS®|Patients will be treated with probiotics in combination with inulin, which is able to stimulate the growing of probiotic bacteria in gastrointestinal tract.
214351148|NCT05851365|DRUG|Hyperpolarized Bicarbonate (13C)|Given IV
214351149|NCT05851365|PROCEDURE|Magnetic Resonance imaging|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
214351150|NCT05974527|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Enrolled participants will receive an initial dose of BXCL501 180mcg. Following the FDA dosing suggestions, participants with mild or moderate hepatic impairment (Child-Pugh Class A or B) will receive a reduced initial dose of 120mcg and participants with severe hepatic impairment (Child-Pugh Class C) will receive a reduced initial dose of 90mcg. Geriatric patients (≥ 65 years old) will receive a reduced initial dose of 120mcg.
214351151|NCT03769142|PROCEDURE|All monitoring|All monitoring (TCD, BIS, NIRS) are collected from the healthy side, contralateral to the interventional side
214351152|NCT03780764|OTHER|"A Pre-adjusted edgewise brackets: 3M Gemini Unitek, 0.022 Roth prescription brackets"|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and tied with elastomers (figure of 8)."
214351153|NCT03780764|OTHER|"Self- ligating brackets: Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets"|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and held in place by bracket's gate in the self-ligating brackets side."
214351154|NCT05123508|DEVICE|2940nm and BBL treatment|2940nm and BBL treatment
214351155|NCT05123508|OTHER|Non-treatment side (Control)|No treatment
214351156|NCT00485485|DRUG|Imatinib Mesylate|400 mg by mouth daily
214351157|NCT00485485|DRUG|Docetaxel|60 mg/m\^2 by vein (IV) over 1 hour every 3 weeks
214351158|NCT01669629|DEVICE|delefilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
214351159|NCT01669629|DEVICE|etafilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
214351160|NCT05373251|DIAGNOSTIC_TEST|Whole genomic DNA/RNA tumour sequencing|"All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.~Participants with recurrence will have biopsy and subsequently will undergo rapid sequencing of RNA and DNA followed by bioinformatic analysis to identify somatic mutations or other abnormalities that might be drivers of an individual's cancer or predict response to therapies. These data will be compared to the literature and to a comprehensive database of drugs with the aim of identifying drugs most likely to target individual tumors based on the presence of mutated or abnormally expressed genes in the tumor. Any palliative systemic therapy treatment would be closely monitored for tolerability and response, as part of the general clinical care of someone on systemic therapy. The choice of systemic therapy will be up to the treating medical oncologist and the patient."
214351161|NCT03570294|DRUG|Atosiban|The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
214351162|NCT02324439|DRUG|Omega Nutrition cold-milled flaxseeds|Patients who are currently in clinical remission will receive a daily 20g dose of cold milled flaxseed as a dietary supplement to determine if this intervention prolongs clinical remission.
214351163|NCT00124904|BEHAVIORAL|Biofeedback|
214351164|NCT00124904|BEHAVIORAL|Kegel exercises|
214351165|NCT03774628|BIOLOGICAL|Chengdu Kanghua (one booster shot)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0
214351166|NCT03774628|BIOLOGICAL|Chengdu Kanghua (two booster shots)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
214351167|NCT01221597|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
214351168|NCT01221597|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
214351169|NCT02504073|OTHER|No intervention|No intervention
214351170|NCT03986112|BIOLOGICAL|carotid sonography and inferior vena cava sonography|Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
214958315|NCT05312138|DEVICE|Repetitive Transcranial Magnetic Stimulation|The treatment will be internally cooled 70 mm double coil and 110 mm round coil, accompanied by a physiotherapist and neurologist. The coil will be placed on the precentral gyrus. Practices will be held, with each session lasting 20 minutes. Cortical excitability will be provided by high frequency (HF) stimulation (5-Hz).
214351171|NCT06264050|DIAGNOSTIC_TEST|evalutaion scales|four scales will be administered to whom attend a psychological support group: BDI II (depression); Stai Y2 (trait anxiety); Cope NVI 25 (coping strategies) and Core OM (psychological state)
214486766|NCT06874543|OTHER|visceral osteopathic manual therapy|In the study, relaxation techniques, hepato-gastric ligamentum mobilization, pyloric valve mobilization, sphincter odi mobilization, sphincter ilio-jejunum mobilization, cecal valve mobilization, iliopsoas and iliacus mobilization, peritoneal mobilization, intestine, kidney, bladder, stomach, liver and bladder organ mobilizations will be applied to the experimental group patients as VOMT program. Until the next session, bladder mobilization will be taught as a home program and they will be asked to do it every day. After VOMT is applied by the physiotherapist once a week, a total of 4 times, the evaluation scales will be applied again. In order to see the long-term effect, the patients will be evaluated again in the first month and the third month after the end of the treatment. The forms will be filed as pre-treatment, post-treatment, first month and third month data and will be entered into the computer and recorded
214958316|NCT05312138|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|The treatment parameters will be applied with a pulse current time of 200 μsec, a fixed frequency of 10 Hz, a treatment time of 20 minutes, and a current intensity that the patient can tolerate, which will not cause flexion in the big toe or fan movement in the other fingers. Self-adhesive surface electrodes will be used for stimulation. During the treatment, the patient will lie on his back. The negative electrode will be placed 2 cm posterior to the medial malleolus and the positive electrode will be placed 10 cm proximal.
214958317|NCT00574691|DEVICE|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
214958318|NCT05897372|DRUG|ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib|Standard of care for diabetic kidney disease.
214958319|NCT06954753|PROCEDURE|Pancreatic surgery|Pancreatic resective surgery performed for pancreatic cystic lesions with high risk of malignant degeneration based on clinical, biochemical, and/or radiological features following current guidelines on pancreatic cystic lesions management.
214958320|NCT02261831|OTHER|obese patients|collection of blood sampling and biopsies
214351172|NCT05020639|DRUG|TQB3820 tablets|TQB3820 is a novel cereblon-modulating agent.
214486767|NCT06875050|OTHER|Mediterranean diet|Tailored dietary plan following Mediterranean diet to cover macronutrients needs according to recommended daily allowance (RDA) for age
214351173|NCT00251953|DRUG|Tesaglitazar|
214486768|NCT06875050|DIETARY_SUPPLEMENT|Fat soluble vitamins supplementation|Fat soluble vitamins supplementation (150 μg vitamin A, 2000 IU vitamin D, 100 mg vitamin E and 1000 μg vitamin K).
214486769|NCT06875050|DIETARY_SUPPLEMENT|Antioxidant Supplement|Antioxidant supplements in specific doses in oral liquid form (200 mg vitamin E, 300 mg vitamin C, 90 μg Se, 500 μg vitamin A, 30 mg zinc, 3 mg copper and 2000 IU vitamin D).
214958321|NCT02261831|OTHER|diabetic patients|collection of blood sampling and biopsies
214958322|NCT02261831|OTHER|patients free of obesity and diabetes|collection of blood sampling and biopsies
214958323|NCT02261831|OTHER|patients free type 2 diabetes|collection of blood sampling and biopsies
214958324|NCT02576977|BIOLOGICAL|Pembrolizumab|pembrolizumab 200 mg IV infusion
214486770|NCT06874179|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement 0|optic nerve sheath diameter (ONSD) measured via ultrasonography before intubation
214958325|NCT02576977|DRUG|Pomalidomide|pomalidomide 4 mg capsules
214958326|NCT02576977|DRUG|Dexamethasone|dexamethasone 40 mg tablets
214958327|NCT04428528|DEVICE|Photoacoustics Imaging System|Characterizing breast masses for photoacoustic markers measurements
214958328|NCT03102957|OTHER|functional MRI|
214958329|NCT04481594|DRUG|HPN-01|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
214351174|NCT00251953|DRUG|Metformin|
214351175|NCT00142493|DRUG|Propofol|1.2ug/ml
214351176|NCT00142493|DRUG|Thiopental Sodium|2.0ug/ml
214351177|NCT00142493|DRUG|Dexmedetomidine Hydrochloride|0.5ng/ml
214351178|NCT00142493|DRUG|Midazolam Hydrochloride|60ng/ml
214351179|NCT00142493|DRUG|placebo|intralipid, saline, saline with multi-Vit solution
214351180|NCT05526105|DIAGNOSTIC_TEST|Gastric Ultrasound|Gastric ultrasound in the supine and right lateral decubitus position for patients going for operative intervention with a protected airway.
214351181|NCT03299608|DIAGNOSTIC_TEST|Breath analysis|Spectrometric analysis of exhaled breath as screening for opportunistic respiratory infections
214351182|NCT04003116|DRUG|Oxygen gas|Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
214958330|NCT04481594|DRUG|Placebo|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
214958331|NCT02016911|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
214958332|NCT04508647|DRUG|Ublituximab|"Ublituximab will be administered as an intravenous infusion through a dedicated line. All infusions will be administered per institutional guidelines.~During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours. Cycle 1 days 8 and 15 will be over 3 hours, and Cycle 1 Day 22 will be over 90 minutes. During combination treatment with umbralisib, ublituximab will be administered over 90 minutes."
214958333|NCT04508647|DRUG|Umbralisib|Umbralisib will be administered orally once daily within 30 minutes of starting a meal.
214958334|NCT01013831|DRUG|Erlotinib Hydrochloride|Given PO
214351183|NCT02499874|DRUG|Efavirenz|oral Efavirenz 400mg
214351184|NCT02499874|DRUG|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
214958335|NCT01013831|OTHER|Laboratory Biomarker Analysis|Correlative studies
214958336|NCT01013831|OTHER|Pharmacological Study|Correlative studies
214958337|NCT04481763|DRUG|Camrelizumab|Camrelizumab is 200 mg iv. administered every 2 weeks for 3 cycles with radiotherapy ( 50gy, 25 times for 5weeks)
214958338|NCT04481763|RADIATION|radiotherapy|radiotherapy
214958339|NCT02425735|BIOLOGICAL|DC-CIK cells|DC-CIK cells will be used against tumor cells.
214958340|NCT02425735|BIOLOGICAL|γδ T cells|γδ T cells will be used against breast tumor.
214958341|NCT02425735|BIOLOGICAL|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against breast tumor.
214958342|NCT01156493|OTHER|Protein Hydrolyzed Premature Formula|Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
214958343|NCT00546169|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|haemorrhages in cholecystectomy
214958344|NCT02413671|DIETARY_SUPPLEMENT|Lupin Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.
214958345|NCT02413671|DIETARY_SUPPLEMENT|Whey Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.
214351185|NCT02499874|DRUG|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
214351186|NCT02499874|DRUG|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
214351187|NCT01877538|OTHER|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand \[11C\]donepezil
214351188|NCT00487162|PROCEDURE|intensive glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
214351189|NCT00487162|DRUG|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
214351190|NCT03229369|PROCEDURE|Isolated anatomic ACL reconstruction|Hamstrings free grafts using a two-incision intra-articular Anterior Cruciate ligament (ACL) reconstruction technique. Both ST and gracilis will be prepared with doubled strands, a standard quadrupled graft. The femoral tunnel will be performed in outside-in manner. The tibial tunnel will be drilled in the center of the ACL tibial footprint, sparing the ACL tibial stump, when possible. ACL graft will be first fixed in the femur and then in the tibia, both with an interference screw at 30 degrees of knee flexion.
214351191|NCT03229369|PROCEDURE|Combined Anterior Cruciate Ligament and Anterolateral Ligament reconstruction|Hamstrings free grafts using a two-incision ACL reconstruction with the addition of a gracilis prolongation for ALL reconstruction. ACL graft will exhibit a quadruple strand (tripled ST + single gracilis) and the ALL graft, a single strand with the gracilis prolongation. ALL tibial tunnel will be performed with a 5mm drill, 1cm distal to the articular level, midway from the fibular head and Gerdy Tubercle, crossing the tibia toward its anteromedial cortex, 1cm distal to the ACL tunnel. Femoral ACL and ALL tunnels are coincident and located posterior and proximal to the lateral epicondyle. Intra-articular surgery will be performed in the same manner as comparative group. Gracilis prolongation is routed through the tibial ALL tunnel and then retrieved in the anteromedial aspect of the tibia, 1cm distal to the ACL tunnel entrance. ALL is fixed in full extension and neutral rotation, tying both graft extremities with 3 knots.
214351192|NCT03432975|DRUG|Povidone-Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)
214958346|NCT02413671|OTHER|Reference|Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
214958347|NCT06955351|OTHER|Survey by Questionnaire|The questionnaire is designed to collect the following information: demographic data (including gender, age, education level, marital status, place of residence, and whether the respondent is a healthcare provider), the respondent's status of basic life support (BLS) training, attitudes and willingness to use an automated external defibrillator (AED), and their knowledge of emergency medical service regulations.
214958348|NCT03970655|DRUG|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1|Group 1 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the LEFT pterygopalatine fossa
214958349|NCT03970655|DRUG|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2|Group 2 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the RIGHT pterygopalatine fossa
214958350|NCT00523770|PROCEDURE|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
214958351|NCT05418907|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4
214351193|NCT03432975|DRUG|Saline Solution|The other side of the mouth will be irrigated with a sterile saline solution (control group)
214351194|NCT02211716|DEVICE|BeGraft Peripheral Stent Graft System|
214351195|NCT02278328|DRUG|STX209 (15mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose"
214351196|NCT02278328|DRUG|placebo|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
214351197|NCT02278328|DRUG|STX209 (30mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose"
214351198|NCT04611503|DRUG|subretinal injection of rAAV.hPDE6A|"The first 3 patients (C1) will receive the intermediate dose 1x1010 vg. After injection of the 3rd patient of C1, the DMC will give a go/no go decision. If 'nogo', a lower dose (5x109 vg) will be given to the next group of 3 patients (C2). The DMC will give a go/no go decision. In case of a go decision, 3 further patients (C3) will be treated with the same dose. In the case of a no-go decision, the next dose will be the minimal dose 1x109 vg. In case of a 'go' decision of the DMC after the third patient, the next 3 patients will receive a subretinal injection of vector at the highest dose 5x1010 vg. The DMC will give a go/no go decision after review of all safety data available at D30 of cohort 2. If safety data is considered favourably by the DMC, then 3further patients (cohort 3) will be treated with the same dose (5x1010 vg). Should any safety concerns arise, the last three patients (cohort 3) will receive the intermediate dose (1x1010 vg)."
214351199|NCT04955912|OTHER|music medicine|To reduce premenstrual symptoms by applying music medicine to people with premenstrual syndrome
214351200|NCT01347333|RADIATION|Stereotactic body radiosurgery|36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)
214351201|NCT01347333|RADIATION|Stereotactic Body Radiotherapy|26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)
214351202|NCT04817553|OTHER|exposure to COVID19|Observational study of IgG4 patients with pancreatobiliary involvement who were diagnosed with COVID19
214351203|NCT06423833|DIAGNOSTIC_TEST|Trendelenburg maneuver (TM)|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Trendelenburg maneuver (TM) in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
214351204|NCT06423833|DIAGNOSTIC_TEST|Passive leg raising test|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Passive leg raising (PLR) test in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
214351205|NCT03847324|OTHER|Pain Neuroscience Education|"This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors."
214351206|NCT03847324|OTHER|Multimodal Physiotherapy|This intervention will be divided in pain neuroscience education, orthopedic manual therapy and therapeutic exercise.
214351207|NCT03847324|OTHER|Usual Care|Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
214351208|NCT03834779|BEHAVIORAL|DOORS-CHW Intervention|"The behavioral intervention has been developed for a collaborative CHW and re-entry program intervention that targets HIV outcomes, substance use and recidivism in HIV+ jail releasees.~Participants will be randomized to the DOORS+CHW intervention versus TAU and all participants will undergo study follow-up visits at 3, 6 and 12 months. In other words, participants randomized to the intervention arm will meet with the CHW and a staff member from DOORS. One of the primary study aims is a randomized controlled trial of an intervention which has a reasonable probability of improving the health and well-being of the subject by improving linkage to social services and the HIV clinic. The control arm will receive standard of care (referrals to case management)."
214351209|NCT02500992|PROCEDURE|Transrectal sigmoidectomy|
214351210|NCT01708850|DRUG|Rivaroxaban|All specified in arm description. One arm study.
214351211|NCT02833168|OTHER|patient-filled questionnaires|All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
214351212|NCT02833168|DEVICE|spiromanometry|Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
214351213|NCT00847262|DRUG|Temisartan|Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
214351214|NCT00847262|DRUG|Amlodipine|Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
214351215|NCT00925613|DEVICE|LMA Proseal|"Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube."
214351216|NCT00925613|DEVICE|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
214351217|NCT05845138|DRUG|SHR-A1811 for injection ; capecitabine|SHR-A1811 for injection; Capecitabine tablets
214351218|NCT02043210|BEHAVIORAL|Standard Treatment as Usual|Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.
214486771|NCT06874179|DIAGNOSTIC_TEST|optic nerve sheath diameter measurement 1|optic nerve sheath diameter measurement 1 via ultrasonography after intubation 1st minute
214486772|NCT06874179|DIAGNOSTIC_TEST|optic nerve sheath diameter measurement 2|optic nerve sheath diameter measurement via ultrasonography after intubation 5th minute
214486773|NCT06874179|DIAGNOSTIC_TEST|optic nerve sheath diameter measurement 3|optic nerve sheath diameter measurement via ultrasonography after intubation 10th minute
214486774|NCT06874179|PROCEDURE|Pre-intubation oropharyngeal topical %10 lidocaine|Pre-intubation oropharyngeal topical %10 lidocaine
214958352|NCT00787163|PROCEDURE|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
214958353|NCT00035269|DRUG|Antibiotic|
214958354|NCT04639557|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target maternal mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
214958355|NCT01863719|DRUG|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
214486775|NCT06874179|PROCEDURE|Pre-intubation intravenous %2 lidocaine|Pre-intubation intravenous %2 lidocaine
214958356|NCT01863719|DRUG|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
214958357|NCT06490081|DRUG|Trilaciclib|During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
214958358|NCT00140036|PROCEDURE|Blood draw|
215094395|NCT06256146|OTHER|Food allergy desensitization / Oral Immunotherapy|"Participants consume increasing doses of allergenic food daily until they reach a maintenance dose. In the case of the High Dose Arm, participants will progress to a daily dose of either 1200 mg, 300 mg or 200 ml of egg, peanut or milk respectively.~Participants randomized to the Low Dose Arm also begin by consuming small amounts of the allergenic food, gradually increasing the daily dose. However, participants in this group only progress to 300 ml, 30 mg or 50 ml daily dose of egg, peanut or milk respectively.~The Cooked/Transformed Allergen Arm begins the desensitization with a cooked or transformed form of the allergen - muffins in the case of egg or milk, Bamba puffs in the case of peanut. Participants take increasing amounts of these products (one muffin for egg and milk and four Bamba puffs for peanut) then transition to egg, milk or peanut. Participants then continue their dose progression, getting to 1200 mg, 200 ml or 300 mg for egg, milk and peanut respectively."
214958359|NCT04705818|DRUG|Durvalumab|Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
214958360|NCT04705818|DRUG|Tazemetostat|Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
214351219|NCT02043210|BEHAVIORAL|CBT4CBT plus Standard treatment as usual|Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
214351220|NCT05668117|DEVICE|Depuy Synthes Advanced Retrograde femoral nail|The Advanced Retrograde Femoral Nailing System (RFNA) is designed to improve fixation and stabilization of distal femur and femoral shaft fractures by reducing toggle and loss of reduction.
214351221|NCT02779153|DRUG|Acthar low dose (40 U)|The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
214351222|NCT02779153|DRUG|Acthar high dose (80 U)|The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
214958361|NCT06300879|PROCEDURE|Performing totally laparoscopic proximal gastrectomy with esophagogastrostomy by fissure technique|"Surgical Operation:~1. Gastric Resection Range:Proximal gastrectomy, preserving 2/3 of the distal stomach.~2. Lymph Node Dissection Range:D1+ to D2 lymph node dissection.~3. Anastomosis Method: esophagogastrostomy by fissure technique.~4. Anastomosis Risk Management Plan:For a rupture with a maximum diameter less than or equal to 5mm, repair with 4-0/3-0 absorbable sutures and proceed with the anastomosis.For a rupture with a maximum diameter greater than 5mm or failed anastomosis, resect that part of the remaining stomach, change to proximal gastrectomy, and perform double-channel anastomosis.~5. Surgical Approach:Totally laparoscopic proximal gastrectomy."
214958362|NCT00431327|BEHAVIORAL|Peer coach phone call|
214958363|NCT05880095|OTHER|Unrestricted Mediterranean diet|Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.
214958364|NCT05880095|OTHER|Energy-reduced Mediterranean diet|Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.
214958365|NCT05880095|OTHER|Mediterranean diet with time-restricted eating|Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
214958366|NCT04808414|DRUG|QPX9003 for IV Infusion|antibiotic
214958367|NCT04808414|DRUG|Placebo for IV infusion|Placebo comparator
214958368|NCT03630133|DEVICE|Intracept System Ablation|Radiofrequency ablation using Intracept System
214958369|NCT03417752|OTHER|Exposure to firearm safety PSA|Exposed to firearm safety PSA
214958370|NCT03417752|OTHER|Exposure to health promotion PSA|Exposed to general health promotion PSA
214351223|NCT00289354|DRUG|Chromium Picolinate (600 mcg Cr) + biotin (2 mg)|
214351224|NCT02952352|BEHAVIORAL|Diabetes Prevention Program|Culturally adapted diabetes prevention program
214351225|NCT00408473|DRUG|Flecainide|
215078749|NCT05928832|OTHER|Follow-up by a case-manager and access to the internet platform|Patients in the intervention group receive an information letter on their discharge presenting the follow-up from which they benefit:call from the case-manager and access to the internet platform. The case-manager meets the patient and/or informal caregiver on the day of discharge from hospital. He recontacts the patient and/or informal caregiver within 7 days after returning home. A follow-up is offered to patients and caregivers following their return home, according to the objectives defined during the initial interview. The total duration of the support is 6 months maximum including at least 4 contacts with the case-manager,but this is refined and adapted with the patient, according to needs. Similarly, the frequency and methods (face-to-face or remote) of contact varies according to the needs of the patients and the stage of support, and is defined by the case-manager and patient. Patients and/or informal caregivers is also able to contact the case-manager 'on request'.
214351226|NCT01788748|DEVICE|bipolar radiofrequency and infrared|
214351227|NCT01788748|DEVICE|fractional bipolar radiofrequency|
214351228|NCT01059565|DRUG|AZLI|Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
214351229|NCT01059565|DRUG|Placebo|Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
214958371|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 15-21 days. She receives 3 sessions, in total. 5% Lidocaine cream is applied 30 minutes before each procedure. Each session consists of application of R11 handpiece to the episiotomy scar at Turbo3 Micro Short Pulse mode, with spot size of 2 mm, fluence of 9.5-10 j/cm2, frequency of 2 Hz and 4 pulses per point and 3 passes followed by PS03 handpiece at Basic Long Pulse mode, with spot size of 5 mm, energy of 800 mJ, frequency of 1.4 Hz and 4 pulses per point and 2 passes.
214958372|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System with Sham handpiece|The same procedure is applied above but with a sham handpiece and parameter presentations masked.
214958373|NCT03208894|DRUG|Furosemide Injection|efficacy of salbutamol and furosemide in TTN
214958374|NCT01759719|DEVICE|coronary angioplasty with PtCr stent implantation|PCI with deployment of at least 1 PtCr stent
214958375|NCT00409279|BEHAVIORAL|Information, counseling and support|individual-family consultation, support group, and ad hoc consultation
214351230|NCT02162420|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
214351231|NCT02162420|DRUG|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
214351232|NCT02162420|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
214351233|NCT02162420|RADIATION|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
214351234|NCT02162420|BIOLOGICAL|Stem Cell Transplant|Stem cell transplant on day 0.
214351235|NCT02162420|DRUG|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
214351236|NCT06290180|BEHAVIORAL|First Face for Mental Heatlh|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
214351237|NCT03435133|DRUG|Prasugrel|60 mg oral bolus plus oral 10 mg once daily
214351238|NCT03435133|DRUG|Ticagrelor|180 mg oral bolus plus oral 90 mg every 12 hours daily
214958376|NCT03942367|DEVICE|Active Device (vPatch)|Electrical stimulation inducing motor response at the pelvic-floor muscles. Stimulation will be delivered by vPatch device configured to motor intensity.
214958377|NCT03942367|DEVICE|Sham Device (vPatch)|Electrical stimulation inducing sensory response at the perineum.Stimulation will be delivered by vPatch device configured to sensory intensity.
214958378|NCT00813878|GENETIC|protein analysis|protein analysis
214958379|NCT00813878|GENETIC|protein expression analysis|protein expression analysis
214958380|NCT00813878|GENETIC|proteomic profiling|proteomic profiling
214958381|NCT00813878|OTHER|diagnostic laboratory biomarker analysis|Performed one time on study
214351239|NCT03638141|DRUG|Durvalumab|Durvalumab 1500mg IV every 4 weeks for up to a maximum of 13 cycles (about 12 months) or until confirmed disease progression.
214351240|NCT03638141|DRUG|Tremelimumab|Tremelimumab 300 mg IV in combination with Durvalumab 1500mg about 2 weeks after their first DEB-TACE.
214351241|NCT05725005|DRUG|ASN51|Oral capsule
214351242|NCT03733262|OTHER|De-prescribing Trial|Validated de-prescribing algorithms will be applied for any patients identified as taking one of the 9 study drugs in order to determine whether or not physician should consider a deprescribing trial. If they are are identified as candidates for deprescribing and consent to participate in the trial, they will enter the Deprescribing Trial group and begin the deprescribing trial.
214351243|NCT02945085|OTHER|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
214351244|NCT02945085|OTHER|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
214958382|NCT00813878|OTHER|immunohistochemistry staining method|Performed one time on study
214351245|NCT06962137|DRUG|zolbetuximab|The investigational product, Zolbetuximab, is a sterile lyophilized powder preparation with the chimeric monoclonal antibody Zolbetuximab as the active pharmaceutical ingredient.
214958383|NCT00813878|OTHER|liquid chromatography|Performed on samples collected one time on study
214958384|NCT00813878|OTHER|mass spectrometry|Performed on samples collected one time on study
214958385|NCT00813878|PROCEDURE|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
214958386|NCT00813878|PROCEDURE|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
214958387|NCT00813878|PROCEDURE|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
214958388|NCT00314808|DRUG|Dronabinol|Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
214958389|NCT00874159|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
214958390|NCT05676788|DEVICE|Hyperspectral Imaging|Identification of the intersegmental plane
214958391|NCT00964379|PROCEDURE|intraperitoneal or extraperitoneal colostomy|creation of colostomy
214351246|NCT06962137|OTHER|Retrospective cohort, no intervention|No intervention
214351247|NCT06961461|OTHER|AI-assisted quality control tool|"In this study, quality control personnel will be randomly divided into an experimental group and a control group, and will use artificial intelligence-assisted quality control and manual quality control to conduct quality control on the data collected from the epidemiological survey.~Experimental group: Quality control personnel will use the AI system to perform quality control on the questionnaire recordings.~Control group: The questionnaire content was checked by manually listening back to the recordings and errors were recorded manually."
214351248|NCT06962046|PROCEDURE|Virtual Reality|"* VR~* Spinal anaesthesia~* Limited propofol aiming for OAA/S of 4-5 (light sedation)"
214351249|NCT06962644|OTHER|Preeclampsia developed|Preecalmpsia will be defined as per study protocol
214351250|NCT05445804|DRUG|300 mg Cannabidiol|300 mg CBD in Medium Chain Triglyceride oil b.i.d.
214351251|NCT05445804|DRUG|600 mg Cannabidiol|600 mg CBD in Medium Chain Triglyceride oil b.i.d.
214351252|NCT05445804|DRUG|Placebo|Medium Chain Triglyceride oil
214958392|NCT04435899|OTHER|Physical exercise|Multi-modal exercise protocol
214958393|NCT03111277|DEVICE|Experimental: ExAblate Transcranial treatment|Patients' head will be placed in a device to hold it still for the treatment. Patients will lie headfirst on the ExAblate table. The ExAblate Transcranial helmet will be placed on their head. A device will be placed over their head to hold it and the helmet still. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. The space between the rubber diaphragm and the helmet will be filled with water. The water will be chilled to avoid heating of the scalp and skull during the ultrasound treatment. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area.
214958394|NCT04304508|DRUG|BAY2433334|Tablet, taken orally once a day.
214958395|NCT04304508|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
214958396|NCT02624882|PROCEDURE|Positive rapid GAS test|"If TDR positive, the child will be treated with antibiotics alone:~* Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins~* Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months."
214958397|NCT02624882|PROCEDURE|Negative rapid GAS test|Usual care
214958398|NCT03190785|OTHER|Benzoic acid washout and exposure|see above
215078750|NCT06010381|OTHER|Muscle energy technique|It was applied on the shoulder flexion and the external rotation. An isometric contraction of the agonist muscle (the muscle which requires stretching) for 7 seconds with gentle muscle contraction to avoid the risk of increasing the muscle tone. This contraction started just short of the restrictive barrier. After that, the patient is asked to relax for 2-3 seconds and then the therapist stretches the contracted muscle in the opposite direction for 30 seconds. This is repeated three repetitions for each muscle.
215094396|NCT04897607|BEHAVIORAL|Standard Care|Participants will be advised to quit smoking and offered a choice of nicotine replacement patches or varenicline. Participants are free to decline medication.
214351253|NCT06575140|DEVICE|Associative Peripheral Stimulation (APS) 1.0|Associative peripheral stimulation paired with rehabilitative exercises.
214351254|NCT06575140|DEVICE|Peripheral Neuromuscular Stimulation|Random peripheral stimulation paired with rehabilitative exercises.
214351255|NCT03526250|OTHER|Laboratory Biomarker Analysis|Correlative studies
214958399|NCT00869310|DRUG|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
214958400|NCT00869310|DRUG|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
215094397|NCT04897607|BEHAVIORAL|Precision pharmacotherapy|Participants will be advised to quit smoking and provided a medication recommendation on the basis of their nicotine metabolite ratio (NMR) test (i.e., nicotine replacement patches for slower metabolizers, varenicline for faster metabolizers). Participants are free to choose either medication or decline any medication.
214351256|NCT03526250|DRUG|Palbociclib|Given PO
214351257|NCT03526250|OTHER|Pharmacological Study|Correlative studies
214351258|NCT05653921|OTHER|In vivo confocal microscopy (IVCM)|In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
214351259|NCT06423703|DRUG|Cebranopadol|once daily for 3 days
214351260|NCT06423703|DRUG|Oxycodone IR|four times per day for 3 days
214351261|NCT06423703|DRUG|Placebo|three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
214958401|NCT05273229|OTHER|Virtual Gait|Virtual Gait: the patient will be placed in a standing position (with an ad-hoc designed help system) in front of a mirror (from the waist up) and a screen (from the waist down) where a video of legs walking on a treadmill will be projected and overcoming obstacles. Projected legs will be customized based on height, using the tibia length method.
215094398|NCT02323152|BEHAVIORAL|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
214958402|NCT05273229|OTHER|Physical exercise|"PE: it will be divided into two parts: in the first one, a gait technique training will be carried out and, in the second, a leg strength training, for 30 min. Exercises:~* Coordination exercises: normal and lateral parallel walking and walking with obstacles.~* Functional exercises such as climbing stairs, etc.~* Lower limb strength exercises. Strength exercises will be prescribed according to the guidelines of the American College of Sports Medicine (ACSM). Progression will be customized based on individual abilities."
214351262|NCT01903473|DRUG|Rapamycin|"Rapamycin will be started within 2 weeks after inclusion. Rapamycin will be given at 2-6 mg loading dose for one day, followed by approximately 1 mg daily to achieve a target trough level of 5 to 10 ng/mL. The frequency of trough level measurements will be done according to the investigator choice; Rapamycin may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.~Calcineurin inhibitor discontinuation within 2 weeks after rapamycin initiation. No other modification of immunosuppressive drugs and in particular no decrease in the dose of steroids (unless necessary for side effects)."
214958403|NCT05273229|OTHER|Sham Virtual Gait|only the placebo virtual gait.
214351263|NCT01903473|OTHER|T regulatory cells|"One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 60-90 days after first day of rapamycin administration and after calcineurin inhibitor discontinuation. The infusion procedure will take one hour.~Low-dose Il-2 (1x106 IU/day) will be started the day of DTI and will be continued for a period of 2months in order to expand infused donor Tregs."
214351264|NCT05646953|OTHER|Facial Beauty Oil|"Mode of Usage Step 1- Wash face, pat dry Step 2 - Gently massage 2-3 drops of Vasu Facial Beauty Oil over the face and neck till it gets absorbed and keep it overnight.~Step 3 - Use it for 60 days Frequency - Daily before going to bed. Route of Administration - Topical"
214351265|NCT01715987|DRUG|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
214351266|NCT01715987|DRUG|Entecavir|0.5mg oral daily for two years.
214958404|NCT04966650|BEHAVIORAL|5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT)|The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms.
214958405|NCT02688764|DRUG|PA21 (Velphoro®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
214958406|NCT02688764|DRUG|Calcium Acetate (Phoslyra®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
214958407|NCT04973709|DIAGNOSTIC_TEST|Confussion assessment method (CAM)|Participants enrolled in the Delirium group according to the CAM.
214958408|NCT04973709|DIAGNOSTIC_TEST|Dementia diagnosis|Participants enrolled in the Dementia group according to the CDR scores and MMSE scores and DSM4/5 criteria
215094399|NCT02323152|OTHER|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
215094400|NCT00544284|DRUG|bortezomib|
215094401|NCT00544284|DRUG|temozolomide|
215094402|NCT00544284|OTHER|pharmacological study|
215094403|NCT03995355|DEVICE|9618X investigational lipid eye drops|Test Eye Drops
214351267|NCT04126226|OTHER|Speech-language guidance|Speech-language guidance for speech enhancement and on food management in terms of consistency, volumes, utensils and temperature, beyond the care for safe and efficient swallowing.
214351268|NCT04126226|OTHER|Speech therapy exercises for swallowing|Use of lip exercises and facial muscles, laryngeal elevation maneuver and airway protection technique, 5 repetitions 3 times a day for a month.
214351269|NCT04126226|OTHER|Speech therapy exercises for speech|Use of over-articulation technique and glottal firmness exercise, 5 repetitions 3 times a day for a month.
214351270|NCT02742844|BIOLOGICAL|APZ2 application|Application of IMP on patients wound.
215094404|NCT03995355|DEVICE|Blink® Tears|Control Eye Drops
215094405|NCT01467388|PROCEDURE|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
214958409|NCT02113007|DRUG|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
214351271|NCT03345238|PROCEDURE|Deep Dry Needling|Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.
214351272|NCT01713413|DEVICE|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
214351273|NCT01713413|DEVICE|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
214351274|NCT03487835|OTHER|Kinesiotape|
214351275|NCT03487835|OTHER|No application|This group have no application during study time
214351276|NCT03934385|BEHAVIORAL|Mental Rehearsal|After each exposure session, participants complete three rehearsal/retrieval exercises that involve viewing images of spiders and completing multiple-choice and free-response questions. Exercises involve retrieving information specific to the spider exposures, reflecting on the experience, and highlighting expectancy violation (i.e., that the participant's feared outcome did not occur).
214351277|NCT03934385|BEHAVIORAL|Exposure|All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
214351278|NCT03699943|PROCEDURE|CaverStem|
214351279|NCT01108653|OTHER|Usual care sick-leave management|Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.
214351280|NCT01108653|OTHER|Structuralised sick-leave program|Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient's sick-leave and follow-up.
214351281|NCT03193164|DEVICE|Neuromuscular Electrical Stimulation|The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
214958410|NCT04733625|DRUG|Cholecalciferol|single injection of Vitamin D (200000 I.U
214958411|NCT04733625|DRUG|Placebo|placebo medication
214958412|NCT02118350|BEHAVIORAL|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
214958413|NCT04660786|DRUG|triamcinolone acetonide|local immunosuprresent
214958414|NCT04660786|DRUG|vitamin D|local immunomodulator
214958415|NCT01331707|DEVICE|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
214958416|NCT01331707|DEVICE|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
214958417|NCT00885378|DRUG|Saxagliptin plus metformin IR|Tablets, Oral, 2.5 mg, Twice daily, 12 weeks
214958418|NCT00885378|DRUG|Placebo plus metformin IR|Tablets, Oral, Placebo, Twice daily, 12 weeks
214958419|NCT06087315|OTHER|Multi-faceted oxygen systems strengthening interventions (different for each country)|The specific approaches are different in each country but broadly include efforts to: (1) strengthening policies, strategies, and governance of medical oxygen production, distribution, maintenance, and use; (2) building capacity of healthcare workers and technicians to use and maintain oxygen well, and (3) strengthening oxygen-related data acquisition and use for forecasting, budgeting, and monitoring.
214958420|NCT01759394|DRUG|Avatrombopag maleate 40 mg|"Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:~* Fed, Fed, Fasted; or~* Fed, Fasted, Fed; or~* Fasted, Fed, Fed~During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.~During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.~Randomization Phase consists of three single-dose treatment periods:~Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval."
214958421|NCT00349193|DRUG|laquinimod 0.3|laquinimod 0.3mg
214958422|NCT00349193|DRUG|laquinimod 0.6|laquinimod 0.6mg
214958423|NCT00349193|OTHER|Placebo|Blinded Placebo
214958424|NCT00060372|DRUG|ipilimumab|Given IV
214958425|NCT00060372|DRUG|therapeutic allogeneic lymphocytes|Given IV
214351282|NCT03193164|OTHER|Decubitus Position with the limbs raised to 20º|The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
214351283|NCT02797925|OTHER|Training|Long slow strength training of the tendon for 3 months to improve function
214958426|NCT00717795|BEHAVIORAL|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
214958427|NCT00717795|BEHAVIORAL|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
214351284|NCT04223180|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
214351285|NCT01558622|DRUG|dexketoprofen trometamol|50mg intravenous infusion
214351286|NCT01558622|DRUG|tramadol hydrochloride|100mg intravenous infusion
214351287|NCT01558622|DRUG|pethidine hydrochloride|50mg intravenous infusion
214351288|NCT01558622|DRUG|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
214351289|NCT01558622|DRUG|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
214351290|NCT01558622|DRUG|vitamin c|500mg intravenous infusion
214351291|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
214351292|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
214351293|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
214351294|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
214351295|NCT00868023|DRUG|Placebo|Placebo
214351296|NCT01968239|DRUG|Ranibizumab|comparison of different re-treatment criteria for intravitreal injection of ranibizumab
214351297|NCT00388414|DRUG|duloxetine|30-60mg of duloxetine daily
214351298|NCT00388414|DRUG|Placebo|Placebo pill once daily
214351299|NCT00408369|DRUG|DB289|
214351300|NCT01333124|RADIATION|chemoradiotherapy with Gemcitabine|All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
214351301|NCT01333124|RADIATION|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine
214958428|NCT01658254|OTHER|survey by email|"The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention."
214958429|NCT04750278|DRUG|FP-025 100 mg|FP-025 100 mg BID
214958430|NCT04750278|DRUG|FP-025 300 mg|FP-025 300 mg BID
214958431|NCT04750278|DRUG|Placebo|Placebo BID
214351302|NCT00981591|DRUG|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
214351303|NCT00981591|DRUG|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
214351304|NCT04273945|DRUG|Macitentan 10 mg|Participants will receive macitentan 10 mg film-coated tablets orally.
214351305|NCT04273945|DRUG|Macitentan 37.5 mg|Participants will receive macitentan 37.5 mg film-coated tablets orally.
214351306|NCT04273945|DRUG|Macitentan 75 mg|Participants will receive macitentan 75 mg film-coated tablets orally.
214958432|NCT05866679|DRUG|Hyperpolarized 13-C-pyruvate|Given by PO
214958433|NCT02349139|DRUG|ASN001: Escalating dose Part A|Androgen inhibitor
214351307|NCT04273945|DRUG|Placebo|Participants will receive matching placebo film-coated tablets orally.
214351308|NCT00522275|DRUG|lacosamide|50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
214351309|NCT02576067|DRUG|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
214958434|NCT03883776|DRUG|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
214958435|NCT03883776|DEVICE|PET/CT|"Part 1: Healthy volunteers will undergo consecutive whole-body PET scans, including one low-dose CT, for the first 90 minutes. At 150 ± 15 min and 300 ± 30 min post injection two additional static whole-body PET/CT scans will be acquired.~Part 2: Neuroendocrine tumor patients will undergo a dynamic PET scan for the first 45 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection."
214958436|NCT03883776|OTHER|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, venous blood samples will be obtained for metabolite analysis and activity measurements (only for patients) at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min, 120 ± 60 min).
214958437|NCT01730716|DEVICE|Human spinal cord stem cell implantation|Human spinal cord stem cell implantation in ALS patients.
214958438|NCT03987113|OTHER|Plasma concentration analysis during and after ex-vivo pulmonary reconditioning|The pulmonary endothelial dysfunction will be evaluated with plasma concentration of heparan sulphate, syndecan-1, endothelin-1 and i-NOS.
214958439|NCT04703010|DEVICE|Electroencephalography-Near infrared spectroscopy|Brain activity will be measured using 128-channel EEG and 2 channel NIRS during tactile stimulation (15 minutes sequence of vibrations) while the newborn is asleep.
214958440|NCT04703010|DEVICE|Magnetic resonance imaging|Structural (T1-T2), siffusion tensor imaging and blood-oxygen level dependant signal will be acquired in a subset of 40 subjects (20 minutes while asleep)
214678759|NCT05554900|PROCEDURE|preventive regenerative peripheral nerve interface reconstruction|Each RPNI unit consists of nerve stump and free autologous muscle graft that is cut off from healthy muscle of the amputated limb. The muscle graft is approximately 30×15×5 mm.The ends of the transected nerve are placed within the muscle belly of the free muscle grafts in an orientation that is parallel to the muscle fibers. Next, the nerve is secured distally with 6-0 non-absorbable monofilament sutures in an epimysial-to-epineurial fashion. The nerve is then wrapped around completely via muscle graft and epimysial securing sutures. All RPNI units are placed in areas remote from the surgical incision and from the weight-bearing surface of the limb.
214958441|NCT04703010|BEHAVIORAL|Psychometric testing|Cognitive evaluation at age 2 (Parental questionnaires on sensory profiles, executive functions and neurodevelopmental disorders screening, child tests : movement assessment battery, Laby, Head-toes-shoulders-knees)
214958442|NCT01775787|DRUG|Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor|Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco \& Menthol Flavor for 7-10 days or Tobacco \& Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
214958443|NCT00482482|BEHAVIORAL|psychoeducation|on weekly basis for 8 weeks
214958444|NCT00482482|BEHAVIORAL|Yoga|on weekly basis for 8 weeks
214958445|NCT02706145|OTHER|Social norming campaign|community-level, three-year social norming campaign, using traditional and emerging media, aimed at changing norms of violence among youth 10-24
214958446|NCT04424472|DIAGNOSTIC_TEST|Ultrasonography|Abdominal Ultrasonography
214958447|NCT04879706|OTHER|None planned|No intervention planned
214958448|NCT01523834|DRUG|Panobinostat|"Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).~Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted."
214958449|NCT04981197|BEHAVIORAL|Baduanjin exercise|Patients in the intervention group underwent a 12-week Baduanjin exercise programme consisting of 12 weeks of Baduanjin exercise, a 35-min Baduanjin exercise demonstration video, a picture-based educational brochure, and a performance record form.
214958450|NCT05725824|DEVICE|BTE hearing aid with compatible earmolds|Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = \~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.
215078751|NCT06010381|OTHER|Maitland mobilization|At the start of each session, the physical therapist examined the patient's ROM in all directions to obtain information about the end-range position and the end feel of the glenohumeral joint. Start with rhythmic mid-range mobilization with the patient in a supine position. The therapist's hands are placed close to the glenohumeral joint, and the humerus is brought into a position of maximal flexion in the sagittal plane. After 10 to 15 repetitions of intensive mobilization techniques in this end-range position, the direction of mobilization will be altered by varying the plane of elevation or by varying the degree of rotation. When alternating the direction of mobilization, other movements such as gliding techniques and distraction in that joint position were (inferior gliding, anterior gliding, and posterior gliding).
215078752|NCT06010381|OTHER|Traditional shoulder exercise|Traditional shoulder exercises in the form of shoulder range of motion exercises, stretching exercises and, scapular stabilization.
214351310|NCT02576067|DRUG|Placebo|
214351311|NCT06537453|OTHER|Virtual Care|Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.
214351312|NCT04773587|DRUG|Roflumilast Cream 0.15%|Roflumilast Cream 0.15% - Active
214351313|NCT04773587|DRUG|Vehicle Cream|Cream - Vehicle
214351314|NCT06333678|DRUG|Durvalumab|10 mg/kg IV every 2 weeks or 1500 mg/kg IV every 4 weeks for up to 12 months.
214351315|NCT06333678|DRUG|Sotorasib|960 mg, Patients who do not tolerate sotorasib at 960 mg can be dose reduced to 120 mg.
214958451|NCT00219219|DRUG|Zoledronic acid|
215078753|NCT04026360|OTHER|no intervention|
215078754|NCT00489736|DRUG|dronedarone (SR33589)|oral administration
215078755|NCT00489736|DRUG|amiodarone|oral administration
214958452|NCT04131582|COMBINATION_PRODUCT|Linagliptin + metformin and Empagliflozin + metformin|Linagliptin-Metformin 2.5/850mg once daily, Empagliflozin-Metformin 12.5/850mg one daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
214351316|NCT06850389|DEVICE|ChitoCare® medical Wound Healing Gel|ChitoCare® medical Wound Healing Gel is a medical device containing ChitoClear® chitosan. The device is indicated for the treatment of acute and chronic wounds and other skin conditions, including partial thickness burn wounds.
214351317|NCT06850389|DEVICE|ChitoCare® medical Healing Spray|ChitoCare® medical Healing Spray is a medical device containing ChitoClear® chitosan. The device is indicated for the treatment of acute wounds and other skin conditions.
214351318|NCT05808309|OTHER|Salivary sampling|Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)
214351319|NCT02372409|DEVICE|MRI-guided laser ablation|
214351320|NCT02372409|DRUG|Doxorubicin|
214958453|NCT04131582|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
214958454|NCT03207490|DEVICE|AMADEO|"Robot therapy: 1-Degrees-Of-Freedom (1DOFs) robot training for flexion and extention movements of the hand.~Standard rehabilitation therapy includes speech, physical, occupational therapies and group activities"
214958455|NCT00667914|PROCEDURE|geriatric work-up|Pre- and postoperative treatment of hip-fracture patients in an orthogeriatric unit(geriatric evaluation and management)
214958456|NCT00667914|PROCEDURE|Orthopedic care as usual|treatment in ordinary orthopedic unit
214958457|NCT06323213|DRUG|610|610 subcutaneously injection.
214958458|NCT06323213|DRUG|Placebo|Placebo subcutaneously injection.
215078756|NCT05110560|BEHAVIORAL|"Stay at Home Take a Step Program (SHTSP)"|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
215078757|NCT03262207|OTHER|Extraction genomic DNA|
214351321|NCT02372409|DRUG|Etoposide|
214351322|NCT02372409|DEVICE|Dynamic contrast-enhanced (DCE) MRI|
214351323|NCT02372409|DEVICE|Dynamic susceptibility contrast (DSC) MRI|
214351324|NCT01204892|PROCEDURE|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
214351325|NCT01204892|PROCEDURE|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
214351326|NCT05004324|BIOLOGICAL|FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
214351327|NCT05004324|BIOLOGICAL|Placebo|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
215078758|NCT03262207|OTHER|Analysis of methylation profiles of numerous GSI and TE|
214393611|NCT02702258|BEHAVIORAL|MB-BP|MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
214958459|NCT01616758|DRUG|GTx-024 9mg|
214958460|NCT03107559|DIAGNOSTIC_TEST|perfüsion index|Determination of the relationship between VAS values and PI in patients with normal delivery who undergo epidural analgesia
214958461|NCT04736719|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure group
214958462|NCT04736719|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
214958463|NCT03934918|OTHER|Treatment|Patients for IOL are sent home after placement of intracervical balloon
214958464|NCT05613959|DEVICE|Veress +|The Veress+ safety mechanism was used
214958465|NCT05613959|DEVICE|Conventional Veress|The Conventional Veress Needle was used
214958466|NCT03323697|OTHER|SZ-05|2.5g a day (3 capsules twice a day)
214958467|NCT03323697|DRUG|Escitalopram Pill|10 mg capsule plus 5 placebo capsules
214958468|NCT01247389|PROCEDURE|laparoscopic colectomy|Laparoscopic segmental colectomy with planned abdominal extraction site
214958469|NCT03282422|DEVICE|Home-based protocol in specific tasks|The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
214958470|NCT03282422|DEVICE|Upper-limb splint|In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
215078759|NCT03262207|OTHER|Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)|
215078760|NCT03262207|OTHER|Method of protein detection by immunostaining and flow cytometry|
215078761|NCT01127841|DRUG|Rituximab and Bendamustine|Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
215078762|NCT01684644|BEHAVIORAL|New Forest Parenting Programme|
214958471|NCT00222014|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
214958472|NCT00222014|PROCEDURE|Paracenthese|Paracenthese
215078763|NCT01684644|BEHAVIORAL|Treatment as usual|
215078764|NCT05181202|OTHER|Blood sampling|Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.
215078765|NCT04134117|BIOLOGICAL|Tisagenlecleucel|One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
214678760|NCT00700752|DEVICE|senofilcon A|silicone hydrogel contact lens
214958473|NCT04437797|PROCEDURE|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
214958474|NCT04437797|PROCEDURE|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
214351328|NCT04989790|OTHER|PICU Up!|PICU Up! incorporates the screening process for determining a patient's appropriate activity level into the daily rounding workflow for all PICU patients, with a tiered activity plan based on clinical parameters to individualize goals based on each child's unique needs. While the patient's PICU Up! level is based on objective criteria, the interprofessional team collectively determines the daily activity goal(s) through shared decision-making which is documented in the medical record on morning rounds. The intervention facilitates daily discussion of 1) analgesia; 2) extubation readiness testing; 3) sedation level and goal; 4) delirium screening and management; 5) mobility goal including physical and occupational therapy consultation by PICU Day 3; 6) sleep promotion; and 7) family engagement in mobility.
214351329|NCT05977140|DRUG|CDI-988|SARS-CoV-2 3CL protease inhibitor
214351330|NCT05977140|DRUG|Placebo|matching placebo
214351331|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.05%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.05%.
214351332|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.1%.
214351333|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.5%.
214351334|NCT05932693|OTHER|E-liquid coolant (WS-3, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 1.0%.
214351335|NCT05932693|OTHER|E-liquid coolant (WS-3, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 2.0%.
214351336|NCT05932693|OTHER|E-liquid coolant (menthol, 0.05%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.05%.
214351337|NCT05932693|OTHER|E-liquid coolant (menthol, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.1%.
214351338|NCT05932693|OTHER|E-liquid coolant (menthol, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.5%.
214351339|NCT05932693|OTHER|E-liquid coolant (menthol, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 1.0%.
214351340|NCT05932693|OTHER|E-liquid coolant (menthol, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 2.0%.
214678761|NCT00700752|DEVICE|balafilcon A|silicone hydrogel contact lens
214351341|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.05%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.05%.
214351342|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.1%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.1%.
214351343|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.5%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.5%.
214351344|NCT05932693|OTHER|E-liquid coolant (WS-23, 1.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 1.0%.
214351345|NCT05932693|OTHER|E-liquid coolant (WS-23, 2.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 2.0%.
214351346|NCT05932693|OTHER|E-liquid coolant (WS-23, 4.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 4.0%.
214351347|NCT00054535|BIOLOGICAL|aldesleukin|
214351348|NCT00054535|BIOLOGICAL|recombinant fowlpox-tyrosinase vaccine|
214678762|NCT05308485|OTHER|Events exposure questionnaire|Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
214351349|NCT00054535|BIOLOGICAL|vaccinia-tyrosinase vaccine|
214351350|NCT00733317|DRUG|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
214351351|NCT00733317|DRUG|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
214351352|NCT02759159|PROCEDURE|true acupuncture|"acupuncture at the four-gateacupoints, three times per week and last for 6 months"
214351353|NCT02759159|PROCEDURE|sham acupuncture|"acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months"
214351354|NCT00477191|DRUG|Etanercept|TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
214351355|NCT01116570|OTHER|Physical training|Physical training during 24 weeks
214351356|NCT01116570|OTHER|Control|No intervention
214678763|NCT03662334|DRUG|Rapid Acting insulin with pre-treatment of rHuPH20|Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
214678764|NCT03662334|DEVICE|Sham injection|A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
214678765|NCT02481518|DRUG|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
214678766|NCT02481518|OTHER|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
214351357|NCT05229692|DEVICE|NEUBIE|"Participants will be asked to undergo electrical stimulation with the NEUBIE at their treatment threshold. Treatment threshold will be described as uncomfortable, but not painful (a 7 out of 10 on a perceived intensity scale).~Session length: ≤ 30 minutes Treatment frequency: 2x per week for 5 weeks~Week 1 post-op (treatments 1-2) Activity: Passive Neubie on Abdominals \& Obliques~Weeks 2-3 (treatments 3-6)~* Passive Neubie~* Isometric movements with Neubie on abdominals and obliques~* Active mobilizations with Neubie on abdominals and obliques~Weeks 4-5 (treatments 7-10)~* Active mobilizations with Neubie on abdominals and obliques~* Core Strength Exercise circuit with Neubie on abdominals and obliques"
214351358|NCT04977882|PROCEDURE|abdominal drainage|19 Fr abdominal drainage placed intraoperatively in right colic gutter
214351359|NCT04977882|DRUG|Postoperative antibiotico-prophylaxis|Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
214958475|NCT01137656|DRUG|Acetylcholine and Blood|The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
214958476|NCT06236854|OTHER|Delirium assessment (observational, not interventional)|As an observational study, we will assess the presence of postoperative delirium in the enrolled patients, which will define their group membership.
214958477|NCT06407492|OTHER|Leech|The leeches used in the treatment were obtained from people producing in culture media. Leech therapy was applied to the patients once a week. Before coming to treatment, patients were warned not to use perfume or apply any chemicals on the skin. While no skin preparation was made before the treatment, in patients with cold legs, the area where the leech would be applied was heated to ensure easy adhesion of the leech. The leeches left on their own after approximately 40 to 38 minutes, but the leeches that did not release on their own until 60 minutes were removed by scraping them from the skin with the help of a gauze. The leeches used in the treatment were used only once and the used ones were disposed of by throwing them into medical waste bags. After the leeches were removed from the patient, the wound was covered with a printed bandage. Patients were instructed to remove the bandage after 10-12 hours.
214351360|NCT04977882|PROCEDURE|Laparoscopic radical right colectomy with CME and D3 lymphadenectomy (RRC)|the dissection starts over the landmark given by SMV. The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue. Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels. The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH. No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas. At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure. The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia. The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
214351361|NCT04977882|PROCEDURE|Laparoscopic standard D2 right hemicolectomy (STANDARD)|A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV). The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon. The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
214958478|NCT06407492|OTHER|Conventional Physiotherapy|Conventional physiotherapy applications were performed. Physiotherapy applications were performed with transcutaneous electrical nerve stimulation, hotpack and ultrasound.
214958479|NCT06407492|OTHER|Kinesiotape|"In this taping technique, skin color, 5cmX5m kinesio tape material was used. Again, the patient standing upright will be prepared in terms of clothing and skin. The standing patient will then be asked to lean forward. Taping will be done using a special muscle technique for this group. When applying tape to the right paravertebral region, first the lower end of the tape will be adhered 7 cm below the sacroiliac joint, at the level of the paravertebral muscles. When applying tape to the left paravertebral region, the same procedure will be done in reverse as on the right, and the tape will not be stretched at all. The third tape will be applied to the patient who is standing upright and bending slightly forward, passing over the sacroiliac joints and parallel to the ground, with the tape stretched by 25%."
214351362|NCT05725291|DRUG|AMT-116|Administered intravenously
214351364|NCT02131298|DRUG|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
214958480|NCT03184779|OTHER|Ski and Snowboard Safety Video|The ski and snowboard safety video (\~10 minutes) includes information on preparation, correct protective equipment use (e.g. helmets), and strategies for speed control and collision avoidance. Focus groups were conducted among parents, students, ski patrol, and ski instructors to inform the content and format of the video. Feedback and suggestions from focus groups were utilized to ensure that the video optimized information uptake from children and adolescents who watch the video. The Health Action Process Approach (HAPA) model was embedded throughout the video to ensure evidence-informed pathways towards positive behaviour change.
214958481|NCT02840773|OTHER|Peri-implanter sulcus fluid sampling|PISF sampling was made twice
214958482|NCT02840773|OTHER|Probing depth|The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
214958483|NCT02840773|OTHER|Crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
214958484|NCT02840773|OTHER|Presence of bleeding on probing|The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
215078766|NCT03324334|DIAGNOSTIC_TEST|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
215078767|NCT03324334|DIAGNOSTIC_TEST|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
214958485|NCT02840773|OTHER|Plaque index levels|The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
214351365|NCT02131298|DRUG|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
214351366|NCT06210256|PROCEDURE|unidirectional valve apparatus|In the unidirectional valve group, we attached the unidirectional valve device to the lumen's distal port when one-lung ventilation initiated.
214351367|NCT06210256|PROCEDURE|occluding the non-ventilated endobronchial lumen|In the closed operative lumen group, we closed the lumen's distal port of non-ventilated lung when one-lung ventilation initiated.
214351368|NCT03219983|DRUG|Ropivacaine|Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score \> 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
214351369|NCT03219983|DRUG|liposomal bupivacaine|A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
214351370|NCT00622167|DEVICE|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
214351371|NCT00622167|DEVICE|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
214351372|NCT03722134|PROCEDURE|MOCA|Great saphenous vein occlusion with a mechanochemical chateter which cause mechanical injury to vessel intima and gives sclerosant to the intima.
214351373|NCT03722134|PROCEDURE|EVLA|Great saphenous vein occlusion with a thermal laser chateter
214351374|NCT03722134|PROCEDURE|RFA|Great saphenous vein occlusion with a thermal radiofrequency chateter
214351375|NCT01930110|OTHER|60-minute exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
214351376|NCT01930110|OTHER|40-minute interval exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
214351377|NCT02357628|DEVICE|Wound treatment with RO-NPT|
214351378|NCT02357628|DEVICE|Wound Irrigation|
214351379|NCT05247151|OTHER|Oxytocin|Oxytocin nasal spray in a positive social setting.
214351380|NCT05247151|OTHER|Placebo|Placebo nasal spray in a positive social setting.
214351381|NCT06447064|OTHER|Cases & Controls|Participants will complete a brief online questionnaire at REDCap about their health, clinical history and lifestyle choices. The participant will only need to provide a photo ID and utility bill for ID verification, if the retailer cannot match participant details. After recruitment the participants purchase history in the past 6 years will be requested from the retailers.
214351382|NCT01990196|DRUG|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
214351383|NCT01990196|DRUG|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
214678767|NCT00590083|BIOLOGICAL|CTL administration|"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."
214678768|NCT04135261|DRUG|HBM4003|Intravenous (IV) administration
214678769|NCT00691197|DEVICE|Carboxymethylcellulose sodium and Glycerin|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
214958486|NCT04211558|DRUG|Ozanimod|Ozanimod
214958487|NCT02374619|DIETARY_SUPPLEMENT|Iron supplement Resoferon Ferrous Sulfate|Oral supplementation with one tablet of iron supplement \[Resoferon Ferrous Sulfate 125 (37) mg\]
214958488|NCT02374619|DIETARY_SUPPLEMENT|Placebo|
214958489|NCT04094116|PROCEDURE|ear wax syringing without pre ear oil treatment|Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment
214351384|NCT01990196|DRUG|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
214351385|NCT01990196|DRUG|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
214351386|NCT02188381|OTHER|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
214351387|NCT05318976|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
214351388|NCT05318976|DRUG|Placebo|Placebo will be delivered by subcutaneous injection once a week
214351389|NCT01115439|DRUG|artesunate plus sulfadoxine-pyrimethamine (AS+SP)|artesunate plus sulfadoxine-pyrimethamine (AS+SP)
214351390|NCT02325882|DRUG|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
214958490|NCT05345366|OTHER|non-applicable|non-applicable
215078768|NCT00438269|DRUG|Site-specific empiric regimens included: Meropenem|
214351391|NCT02325882|DRUG|Fentanyl 1|conventional fentanyl-based epidural PCA
214351392|NCT02325882|DRUG|Fentanyl 2|conventional fentanyl based intravenous PCA
215078769|NCT00438269|DRUG|Piperacillin/tazobactam|
214351393|NCT02983734|DRUG|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
214351394|NCT02983734|DRUG|Placebos|Sugar pill
214351395|NCT04226638|DIAGNOSTIC_TEST|Dynamic ultrasound|Diagnosis was based on clinic suspicion and positive ultrasonography dynamic maneuvers by reproducing pain and slipping rib exam
214351396|NCT03615157|OTHER|Exercise rehabilitation|Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
214351397|NCT05505838|DRUG|Patisiran|Patisiran administered by intravenous (IV) infusion
214351398|NCT02030977|DIETARY_SUPPLEMENT|Resveratrol|
214351399|NCT02030977|OTHER|placebo|
214351400|NCT00006127|DRUG|amifostine|
214351401|NCT00158743|DRUG|Anti-digoxin antibody (FAB fragment)|intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
214351402|NCT00158743|OTHER|sodium chloride|
214351403|NCT00337766|DRUG|Desmopressin (DDAVP)|
214351404|NCT00337766|DRUG|Placebo|
214351405|NCT00423124|GENETIC|HSV-TK|Infusion of genetically modified lymphocytes (1x10\^6-1x10\^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
214351406|NCT01011010|DRUG|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
214351407|NCT01011010|DRUG|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
214351408|NCT01011010|DRUG|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
214351409|NCT01011010|OTHER|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
214351410|NCT01011010|OTHER|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
214351411|NCT03633383|DEVICE|Transcatheter aortic valve|Self-expandable aortic valve prothesis
214351412|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 1|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
214351413|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 2|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
214351414|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 3|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
214351415|NCT03674177|DRUG|Placebo (Normal Saline)|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
214351416|NCT03701724|DEVICE|Systematic maintenance rTMS|Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
214351417|NCT03701724|DEVICE|rTMS course in case of relapse|Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
214351418|NCT03701724|DEVICE|sham rTMS|The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
214351419|NCT00522249|DRUG|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
214351420|NCT00522249|DRUG|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
214351421|NCT00522249|DRUG|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
214351422|NCT04321720|OTHER|3-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.
214351423|NCT04321720|OTHER|6-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.
214351424|NCT04321720|OTHER|12-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.
214351425|NCT04321720|OTHER|Warm water only|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
214678770|NCT00691197|DEVICE|Carboxymethylcellulose sodium|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
214958491|NCT01183507|BEHAVIORAL|NIA intervention|The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.
214351426|NCT03819335|DEVICE|mySugr app|mySugr is a mobile medical app for diabetes management. It has been developed by Roche Diabetes Care and it has two versions, free and Pro. It allows to carry out the diary of diabetes, including the collection and analysis of data on glycaemia, food, physical activity or insulin dose. In addition, it is compatible with continuous glucose measurement systems. It has the possibility to add functionalities such as estimation of HbA1c levels, more detailed data analysis or integration with Google Fit type motion sensors, as well as a bolus calculator, reminders for measuring blood glucose or photo gallery in the Pro version, which is the one that will be provided to the patients for the study.
214351427|NCT03819335|OTHER|Standard care|Face-to-face visits
214351428|NCT00714168|BEHAVIORAL|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
214351429|NCT00714168|BEHAVIORAL|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
214351430|NCT04135053|BIOLOGICAL|Lyophilised Neisseria lactamica|Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
214351431|NCT04025073|OTHER|Dietary Approaches to Stop Hypertension|The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.
214351432|NCT04025073|OTHER|Nutrition education program|The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
214351433|NCT04358445|OTHER|Magnesium-Rich Artificial Cerebrospinal Fluid|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
214351434|NCT00451854|PROCEDURE|Random, no advanced notice drug and alcohol testing|
214351435|NCT01436994|PROCEDURE|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
214351436|NCT01436994|PROCEDURE|Dose Titration|"The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil."
214351437|NCT01436994|DRUG|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
214351438|NCT01436994|DRUG|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
214351439|NCT01436994|DRUG|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
214351440|NCT02832323|BIOLOGICAL|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
214351441|NCT05084872|DRUG|Hydroxychloroquine|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
214351442|NCT01561248|DRUG|polyethylene glycol solution for daily bowel lavage.|At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
214678771|NCT06109116|OTHER|Self myofascial release+ Conventional PT|The participant will be asked to sit on a chair and feet resting on the ground. A tennis ball is used on the sole of each foot behind the metatarsal heads to the heel Conventional PT including Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise concentrating on the medial arch for 2 minutes in sitting position,with as much pressure as they could, pushing into discomfort but not pain Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 35 mins Type: Self myofascial release to improve hamstring flexibility
214678772|NCT06109116|OTHER|Conventional PT|"Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise .~Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins"
214351443|NCT01817049|BEHAVIORAL|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
214351444|NCT01817049|BEHAVIORAL|placebo attention control|
214958492|NCT01183507|BEHAVIORAL|TSE|The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
214351445|NCT03177304|OTHER|Web based IPT Training|
214678773|NCT03127202|DEVICE|Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)|Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.
214678774|NCT01097330|PROCEDURE|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
214678775|NCT01097330|DRUG|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
214958493|NCT06178042|COMBINATION_PRODUCT|MI Paste Plus|Briefly, a pea-sized amount of the cream was used once a day and was allowed to remain on the teeth for three minutes after conventional tooth brushing. Patient was advised to not to spit out the cream for 30 seconds to activate the product with saliva. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
214678776|NCT04742465|OTHER|Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
214958494|NCT06178042|COMBINATION_PRODUCT|Remin Pro|The cream must remain on the teeth for at least three minutes once daily after conventional tooth brushing. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
214958495|NCT06178042|COMBINATION_PRODUCT|Control|Patients instructed to follow a routine home care.
214958496|NCT00193739|DRUG|NACT|3 cycles of neoadjuvant chemotherapy
214351446|NCT01672632|OTHER|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
214351447|NCT02283866|DRUG|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
214351448|NCT02283866|DRUG|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
214351449|NCT03081455|DIAGNOSTIC_TEST|Diagnostic Test|Genetic Diagnostic Testing
214351450|NCT06246877|BEHAVIORAL|virtual reality applied group|"Before the K-wire is removed and dressed, the three-dimensional video that the child likes and wants to watch will be placed on virtual reality glasses and attached to the child.~During the procedure, the child will be allowed to watch videos through virtual reality glasses."
214958497|NCT00193739|PROCEDURE|Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|NACT followed by surgery
214958498|NCT00193739|DRUG|Inj.Cisplatin|Concurrent chemo radiotherapy
214958499|NCT00193739|RADIATION|Concurrent chemo radiotherapy|Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
214958500|NCT03252145|DEVICE|PhysioTouch|The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
215078770|NCT00438269|DRUG|Ciprofloxacin and cefazolin +/- metronidazole|
215078771|NCT00825058|DRUG|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
215078772|NCT00825058|DRUG|placebo|oral administration 12 hours intervals
215078773|NCT00825058|DRUG|paroxetine|oral 20 mg/day
215078774|NCT05499793|DIETARY_SUPPLEMENT|Zingiber Officinale powder|Ginger powder
215078775|NCT05499793|DIETARY_SUPPLEMENT|Placebo|Starch powder
214958501|NCT03252145|OTHER|Manual Lymph Drainage (MLD)|MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
214351451|NCT00863096|BIOLOGICAL|Gardasil|HPV vaccine
214351452|NCT02223234|BEHAVIORAL|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
214351453|NCT02223234|BEHAVIORAL|Control|Monthly emails on child health
214351454|NCT02223234|BEHAVIORAL|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
214351455|NCT03371420|DRUG|PU-AD|
214351456|NCT03371420|DEVICE|PET Scan|
214351457|NCT03371420|OTHER|Blood Draws|
214351458|NCT01846130|DIETARY_SUPPLEMENT|Leucine|
214351459|NCT01846130|BEHAVIORAL|Exercise|
214351460|NCT01846130|DIETARY_SUPPLEMENT|Whey protein|
214958502|NCT03286621|OTHER|Administration of five eye-tracking paradigms|All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
214958503|NCT03091738|DRUG|Ramelteon Pill|Patients with compensated cirrhosis and insomnia will be provided ramelteon
214958504|NCT01258478|OTHER|Rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
214958505|NCT01258478|OTHER|Usual care|Usual care
214958506|NCT03592849|PROCEDURE|UC-MSCs therapy|After history taking, physical examination, ultrasound examination and hysteroscopy examination，infertile women diagnosed with thin endometrium or endometrial scarring will be included in the clinical trial. A collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity during hysteroscopy, and participants will receive hormone replacement therapy before and after the treatment. Postoperative observations including ultrasound examination once a month for 3 times and hysteroscopy in the third month after first UC-MSCs therapy. Those whose endometrium is suitable for pregnancy will be recommended attempting conception actively. The next round of cell therapy will be conducted 3 cycles after the first month if the endometrial growth is unsatisfactory.
214958507|NCT03335683|DRUG|Lenidase|drug per os twice day for 7 days, or for 10 days
214958508|NCT04762394|BEHAVIORAL|The Child Behavior Checklist (CBCL),|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
214958509|NCT04240951|OTHER|Sweat patch|Flexible, epidermal, wearable skin patch to collect and analyze sweat
214958510|NCT02164643|DRUG|Flutemetamol (18F)|
214958511|NCT02164643|DRUG|Florbetapir (18F)|
214958512|NCT05660252|OTHER|Collaborative request|The relative is approached by the clinical team and an organ procurement coordinator together.
214958513|NCT03629808|PROCEDURE|4-6cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.
214351461|NCT04625543|DRUG|Sintilimab Injection plus Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; Sintilimab Injection 200mg on day 22; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
214351462|NCT04625543|DRUG|Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
214351463|NCT01445899|DRUG|PF-04523655 (Stratum I)|PF-04523655 (a small interfering RNA) - a single IVT injection
214351464|NCT01445899|DRUG|ranibizumab|6 monthly IVT injections of ranibizumab (Stratum II)
214351465|NCT01445899|DRUG|PF-04523655 (Stratum II)|6 monthly IVT injections of PF-04523655 (a small interfering RNA)
214351466|NCT03871647|DRUG|Beta blocker|perioperative beta blockers
214351467|NCT01094080|OTHER|standard infant formula|infants are fed a commercial formula
214351468|NCT01094080|OTHER|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
214351469|NCT01094080|OTHER|breast milk|infants are breast fed
214351470|NCT05725538|DEVICE|COVIDReApp Group|"The COVIDReApp group will be required to complete an exercise program guided by an m-health system for three times per week during 24 weeks. A 60-minute program, following the recommendations of the American College of Sports Medicine. The daily session will be divided into:~* Warm-up: 5 min. walking so that the patient can hold a conversation , monopodial balance exercise, core exercise and other respiratory and joint mobility exercises.~* Aerobic training: Walking for 10 to 20 min. so that the patient can maintain a conversation, but having to stop to breathe from time to time.~* Strengthening: It will focus on 7 exercises. a) squats, b) dead weight with stiff legs, c) lateral pull-ups, d) inverted flies, e) flies, f) unilateral rowing and g) lateral raises.~* Cool down: It will consist of stretching exercises. a) shoulders, b) triceps, c) chest, d) quadriceps, e) hamstrings, and f) back."
214351471|NCT05725538|OTHER|Control Group|Participants will receive the same intervention in the traditional way, they will receive the exercise program in paper format. They will receive a document with photos and descriptions of the exercises to be performed. Their doctors will determine if the patients will be able to exercise regularly and they will perform them for 24 weeks.
214351472|NCT01558154|DRUG|Chinese herbs|Chinese herbs special for depression
214351473|NCT01558154|PROCEDURE|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
214958514|NCT03629808|PROCEDURE|2-4cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.
214958515|NCT04238338|OTHER|monocyte / lymphocyte ratio|The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average
214958516|NCT03304106|DEVICE|Commercially available cochlear implant and AI system|Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
214351474|NCT01558154|OTHER|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
214351475|NCT01558154|DEVICE|Transcranial magnetic stimulation|Give magnetic stimulation at head
214958517|NCT04649879|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions. CP will be given as a slow infusion over 2 hours. CP neutralization titre of ≥ 1/640 or an ELISA reactivity against the Spike protein of SARS-CoV-2 by the Euroimmun commercial assay \>9 is desired. New antibody tests are under development and can be used instead if equivalence to neutralization or Euroimmun ELISA is demonstrated.
214678777|NCT04980183|DEVICE|Arthroscopic surgical robot|The surgeon performs cruciate ligament bone canal positioning and ligament reconstruction with the assistance of an arthroscopic surgical robot
214958518|NCT04649879|OTHER|Standard of care|Standard of care as determined by hospital practices for COVID-19 patients.
214958519|NCT00510055|PROCEDURE|subdermal manipulation ONLY|scars receive subdermal manipulation ONLY
214958520|NCT00510055|PROCEDURE|subdermal manipulation AND injection of a filler|scars receive subdermal manipulation AND injection of a filler
214351476|NCT05989633|OTHER|Dermocosmetic product: Selenium Disluphide Shampoo (Dercos DS)|to assess the benefit of Dercos DS in subjects with dandruff
214351477|NCT04402177|DRUG|Methyl Prednisolonate|Corticosteroid treatment
214351478|NCT00354874|DRUG|GW642444|drug
214351479|NCT00354874|DRUG|Placebo|placebo
214351480|NCT00354874|DRUG|salmeterol 50mcg|salmeterol
214351481|NCT02962713|PROCEDURE|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
214351482|NCT02962713|PROCEDURE|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
214351483|NCT02378168|OTHER|no intervention; retrospective study|
214351484|NCT05624658|COMBINATION_PRODUCT|Combined Lipid-lowering Therapy|the effect of high-dose combined lipid-lowering therapy (statins+ezetimibe vs statins+PCSK9 inhibitors) on the vulnerability characteristics of atherosclerotic plaques assessed using multimodal imaging (coronary artery computed tomography and optical coherence tomography), as well as biomarkers in patients with acute coronary syndrome for 52 weeks.
214351485|NCT00919269|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214351486|NCT00919269|OTHER|Laboratory Biomarker Analysis|Correlative studies
214351487|NCT04899518|DRUG|ALY688 Ophthalmic Solution|Ophthalmic Solution
214351488|NCT03882684|DIAGNOSTIC_TEST|In-situ imprinting detection|The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.
214351489|NCT02115958|BIOLOGICAL|cancer stem cell vaccine|
214351490|NCT05679492|BIOLOGICAL|Meplazumab foe injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
214958521|NCT00030485|DRUG|erlotinib hydrochloride|
214958522|NCT06274619|BIOLOGICAL|RSV A Memphis 37|RSV A Memphis 37 challenge agent
214958523|NCT06121531|DEVICE|Soft Contact Lens|Vision Correction
214958524|NCT02888990|DRUG|Dasatinib|
214958525|NCT02665741|DEVICE|Olympus transparent cap|distal colonoscope attachment
214958526|NCT02665741|DEVICE|Medivators Endocuff|distal colonoscope attachment
214958527|NCT02665741|DEVICE|Control|No distal colonoscope attachments
214958528|NCT06474572|DEVICE|Direct laryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a direct laryngoscope and table at xiphoid level
214678778|NCT04980183|DEVICE|Conventional arthroscopic cruciate ligament reconstruction|The surgeon performs conventional arthroscopic cruciate ligament reconstruction surgery without other auxiliary equipment
214678779|NCT03830801|DEVICE|IVLCM tethered capsule|Obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk using IVLCM tethered capsule
214958529|NCT06474572|DEVICE|Videolaryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a video laryngoscope and table at xiphoid level
214958530|NCT06474572|DEVICE|Direct laryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a direct laryngoscope and table at umbilical level
214958531|NCT06474572|DEVICE|Videolaryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a videolaryngoscope and table at umbilical level
214958532|NCT05883163|DEVICE|Stimit Activator 1|The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.
214958533|NCT01267929|PROCEDURE|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months.
214958534|NCT01267929|PROCEDURE|The conventional physical therapy|The children were randomly assigned to receive the conventional physical therapy for six months. Both experimental and control groups were measured their motor functions with GMFM-66 by an independent pediatric physical therapist who was blinded for treatment allocation at entry, the second month and the sixth month.
214958535|NCT04605653|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
214958536|NCT06454123|DEVICE|OTX-401|Evidence-based treatments for obesity and binge eating
214958537|NCT05996822|DRUG|ACF injection|AcF injection 1 month after a DXM injection
214958538|NCT01351207|OTHER|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
214351491|NCT05679492|OTHER|Normal saline|Normal saline
214678780|NCT05887856|OTHER|comprehensive educational program for reduction of Pre-Operative Anxiety|"BSEP 1 makes use of modern media and aims to educate patients and their carers through educational videos comprising of various aspect of surgical treatment.~1. Introduction to surgery by consultant surgeon, Patient to receive video of their own surgeon.~2. Introduction to Anesthesia.~3. What are different type of breast surgeries in cancer patients (General Video)~4. Specific video pertaining to the type of surgery patient is undergoing (Mastectomy, Breast Conserving Surgery, Breast Re Construction surgery)~5. Explanation of Methicillin-resistant Staphylococcus aureus Decolonization protocol~6. What to expect on Surgery Day~7. Virtual tour of Holding bay and Operation Room~8. Post-Operative care including wound care, drain management and common post-operative complications."
214958539|NCT03597191|OTHER|Exercises|Participants in the treatment group will be instructed in the spinal stabilization exercises (SSEs), modeled after the spinal stabilization exercise program designed by Hicks et al. (2005). The SSE program targets muscle activation of spinal stabilizers specifically, the transversus abdominus and lumbar multifidus muscles. Each exercise will be progressed by increasing repetitions and hold time.
214958540|NCT00071838|DRUG|Daclizumab|
214958541|NCT02352961|OTHER|Exclusive Intervention Strategy|"The Exclusive Intervention Strategy aimed at men aged 25 - 49 years and Active Follow-up strategy"
214958542|NCT01466075|DEVICE|Apollo Evolution Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
214958543|NCT00199849|BIOLOGICAL|NY-ESO-1 Plasmid DNA Cancer Vaccine|NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.
214958544|NCT02711566|DEVICE|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
214958545|NCT02711566|DEVICE|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
214958546|NCT00514982|DRUG|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
214958547|NCT00514982|DRUG|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
214958548|NCT00514982|DRUG|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
214958549|NCT00514982|DRUG|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
214958550|NCT00514982|DRUG|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
214958551|NCT00514982|DRUG|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
214958552|NCT01662856|BIOLOGICAL|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
214958553|NCT01662856|PROCEDURE|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
214958554|NCT05051891|DRUG|Orelabrutinib and R-CHOP|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
214958555|NCT05051891|DRUG|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
215078776|NCT02104271|PROCEDURE|Argon Plasma Coagulation|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
214351492|NCT00821418|DEVICE|PulseHaler treatment|treatment is for two weeks, 3 times per day
214351493|NCT00821418|DEVICE|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
214351494|NCT00407446|DRUG|sildenafil|
214351495|NCT03460223|BIOLOGICAL|MSC|conventional plus MSC or placebo treatment
214351496|NCT03413436|DRUG|Lobaplatin|at least one cycle adjuvant chemotherapy after esophagectomy
214351497|NCT03413436|DRUG|Cisplatin|at least one cycle adjuvant chemotherapy after esophagectomy
214351498|NCT06038565|DEVICE|RAM cannula ventilator CPAP|RAM cannula ventilator CPAP
214678781|NCT00083824|DRUG|Estrogens, Conjugated (USP)|0.625 mg/day QID for 3 years
214351499|NCT06038565|DEVICE|Occlusive interface bubble CPAP|Occlusive interface bubble CPAP
214351500|NCT02007850|DRUG|ropivacaine|Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
214351501|NCT02804542|OTHER|Observational|
214351502|NCT02804542|OTHER|Retrospective review|
214351503|NCT05008679|DRUG|Oseltamivir|at a dose of 75 mg twice daily
214351504|NCT02289300|DRUG|DCB-BO1202|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
214351505|NCT02289300|DRUG|Placebo|"The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
214351506|NCT02289300|DRUG|DCB-BO1202+Placebo|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
214351507|NCT01427075|PROCEDURE|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
214351508|NCT03969654|DEVICE|PERSONA Total Knee|Primary Total Knee Arthroplasty
214351509|NCT03969654|DEVICE|Vanguard Total Knee|Primary Total Knee Arthroplasty
214958556|NCT01944644|DEVICE|Active Low Field Magnetic Stimulation|Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
214351510|NCT03969654|DEVICE|NexGen Total Knee|Primary Total Knee Arthroplasty
214958557|NCT01944644|DEVICE|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
214958558|NCT01481883|DRUG|Raloxifene Hydrochloride|120mg daily - 1 capsule daily for 12 week trial
214958559|NCT01481883|DRUG|Placebo|1 capsule daily for 12 week trial
214958560|NCT00447551|DRUG|Poly-L-Lactic Acid|Deep dermal injection
214958561|NCT01347593|DRUG|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
214958562|NCT01259934|DRUG|Interferon-alpha2b - 1 year|Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
214958563|NCT01259934|DRUG|Interferon-alpha2b - 2 years|Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
214958564|NCT06079749|PROCEDURE|Simultaneous BTKA|Simultaneous BTKA
214958565|NCT06079749|PROCEDURE|Staged BTKA|Staged BTKA
214958566|NCT02096276|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires.
214351511|NCT02191982|BEHAVIORAL|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
214958567|NCT00313833|DRUG|Buprenorphine transdermal delivery system|
215078777|NCT02104271|PROCEDURE|Historical control|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
214351512|NCT03230916|DRUG|IMI/REL FDC|IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
214351513|NCT00383448|DRUG|Clofarabine|days -7 through -3: 40 mg/m\^2 intravenously over 2 hours
214351514|NCT00383448|PROCEDURE|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
214351515|NCT00383448|DRUG|Melphalan|day -2: 140 mg/m\^2 intravenously over 30 minutes
214351516|NCT00383448|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
214351517|NCT00383448|DRUG|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
214678782|NCT00083824|DRUG|Medroxyprogesterone 17-Acetate|2.5 mg/day QID for 3 years
214678783|NCT00083824|DRUG|Placebo|2 pills/day QID for 3 years
214958568|NCT02090777|BEHAVIORAL|Health Coach|
214958569|NCT03746405|DEVICE|repetitive transcranial magnetic stimulation|excitatory 5Hz rTMS will be used
214958570|NCT03746405|DEVICE|Sham repetitive transcranial magnetic stimulation|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
214958571|NCT05205499|DEVICE|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System|Subjects in this arm will be treated with IBS
214958572|NCT04719845|PROCEDURE|Endoscopic laser resection|Laser resection
214958573|NCT04719845|PROCEDURE|Dilatation|Dilatation
214958574|NCT04484194|BEHAVIORAL|Check Yourself - Oncology|A validated AYA-targeted electronic health assessment (eHA) screening tool for use in oncology clinics.
215078778|NCT00906451|DRUG|Simvastatin|Simvastatin
214351518|NCT00383448|DRUG|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR\<25 mL/minute corrected)
214351519|NCT00383448|DEVICE|Cyclosporine A|"Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).~CsA taper begins at day +100."
214351520|NCT00383448|DRUG|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
214351521|NCT01257867|DIETARY_SUPPLEMENT|Lithia water|Oral intake of approximately 2 litres (2L) daily for 4 weeks
214351522|NCT01257867|DIETARY_SUPPLEMENT|Natural spring water with negligible lithium levels|Oral intake of approximately 2 litres (2L) daily for 4 weeks
214958575|NCT03558685|BEHAVIORAL|Weight loss diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (\> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10% monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
214351523|NCT01128413|DEVICE|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
214351524|NCT01128413|DEVICE|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
214351525|NCT01128413|DEVICE|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
214351526|NCT01128413|BEHAVIORAL|CURVES Questionnaire|The CURVES (CardiovascUlar Response \& Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
214351527|NCT01128413|BIOLOGICAL|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, \& 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
214351528|NCT01128413|BIOLOGICAL|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a \>/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
214351529|NCT01128413|BIOLOGICAL|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
214351530|NCT01943201|DEVICE|new bedsheet|sleeping 5 nights on the new bedsheet
214351531|NCT01943201|DEVICE|conventional bedsheet|sleeping 5 nights on the conventional bedsheet
214351532|NCT00149253|DRUG|a single-dose of Etoricoxib before induction of anesthesia|
214678784|NCT05606822|OTHER|Observational|Collection of data from electronic health record
214678785|NCT06375330|DEVICE|PoliArt|PoliArt injections
214678786|NCT01858428|DEVICE|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
214958576|NCT04275453|DRUG|FDG|FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.
214958577|NCT04275453|DIETARY_SUPPLEMENT|Ketone Drink|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants
214958578|NCT04275453|OTHER|Ketogenetic Diet|Subjects needs to be on Ketogenetic diet
214958579|NCT06202014|RADIATION|concurrent radiotherapy with envafolimab and capecitabine|Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.Concurrent and sequential dose of envafolimab is 200mg subcutaneous injection weekly.Capecitabine is with a concurrent and sequential dose of 500-800 mg/m2 bid po , taken orally for 2 weeks and stopped for 1 week (standard concurrent dose is 800 mg/m2 bid po , but for patients ≥70 years of age, 500 mg/m2 bid po depending on physical status ) until progression or intolerance.
214958580|NCT00005959|BIOLOGICAL|filgrastim|
214958581|NCT00005959|BIOLOGICAL|rituximab|
214958582|NCT00005959|DRUG|cyclophosphamide|
214958583|NCT00005959|DRUG|doxorubicin hydrochloride|
214958584|NCT00005959|DRUG|prednisone|
214958585|NCT00005959|DRUG|vincristine sulfate|
214958586|NCT04089501|DIAGNOSTIC_TEST|Stool collection|Stool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.
214958587|NCT04089501|DIAGNOSTIC_TEST|Biopsy collection|3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care
214958588|NCT05755646|OTHER|Ice Plant Intensive Cream plus Standard Care|"This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome and on the use of the Ice Plant Intensive Cream for the prevention of hand-foot syndrome. The nursing consultation on the standard treatment includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day."
214958589|NCT05755646|OTHER|Standard Care|"This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome. The nursing consultation includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day."
214958590|NCT05772117|BEHAVIORAL|Chatbot-delivered interventions tailored to stage of changes|Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.
214958591|NCT05772117|BEHAVIORAL|Chatbot-delivered standard interventions|Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
214958592|NCT01673581|OTHER|Survey|
214958593|NCT05619315|OTHER|Charcoal -based whitening toothpaste|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
214958594|NCT05619315|OTHER|Calcium carbonate /perlite containing whitening toothpaste.|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using (calcium carbonate /perlite) containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
214958595|NCT01703169|DRUG|Eltrombopag|Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
214958596|NCT01465230|DRUG|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
214958597|NCT02014519|PROCEDURE|Blood sampling|A blood sample (2.5 mL) will be collected from all subjects
214958598|NCT02014519|OTHER|Data collection|Active questioning
214958599|NCT03875469|DEVICE|Centargo injector (BPI 1000045)|Contrast-enhanced computer tomography conducted with Centargo injector
214958600|NCT03875469|DEVICE|Stellant MP injector|Contrast-enhanced computer tomography conducted with Stellant MP injector
214958601|NCT02767778|DEVICE|REAL Pulsed ELF-MF stimulation|Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.
215078779|NCT05945134|OTHER|Visual and auditory feedback STS training|"30 minutes per session, 3 sessions per week, for a total of 3 weeks. The visual and auditory feedback signals will be given throughout the sit-to-stand movement. As the size of circle representing the weight bearing gets more even, and the mobile dot indicating the overall center of pressure moves forward and approaches the midline, the auditory cues will get louder to indicate proximity to the target. It allows the participants to adjust and relearn the correct weight shifting and symmetry.~The intensity will be adjusted based on different chair heights (e.g. 115%, 100%, 80% of lower leg length), various seat materials, and supported level of thigh (progressing from one-third of the length between the greater trochanter of the femur and the knee joint line to full support). The training program will be progressed according to the abilities of the participants."
215078780|NCT05945134|OTHER|Conventional STS training|30 minutes per session, 3 sessions per week, for a total of 3 weeks. All settings will be the same as the experimental group, except for the feedback. In the control group, the verbal cues will be given by the physical therapist and a mirror will be placed in front of the participant for visual feedback. During the sit-to-stand movement, participants will be asked to try to maintain the alignment in the midline.
215078781|NCT00951522|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
215078782|NCT00951522|DRUG|Placebo|Inhaled placebo in sterile saline
215078783|NCT02128243|DRUG|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
214678787|NCT01858428|DEVICE|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
214678788|NCT05822999|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
214958602|NCT02767778|DEVICE|SHAM Pulsed ELF-MF stimulation|SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
214351533|NCT00765193|OTHER|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
214351534|NCT02491008|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
214351535|NCT02491008|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
214958603|NCT04566718|DRUG|Metformin|metformin cessation
214678789|NCT05822999|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
214678790|NCT03358862|DEVICE|NaturalVue Multifocal Contact Lens|NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
214678791|NCT04253301|DEVICE|InnoVein Valve Treatment|Subjects will have the InnoVein Valve implanted
214678792|NCT02679066|DEVICE|Sugar-tong splint|Plaster immobilization including the elbow
215078784|NCT02128243|DRUG|Chemotherapy by Investigator's choice|"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT"
215078785|NCT01189058|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
215078786|NCT01189058|PROCEDURE|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for \>90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
215078787|NCT00535158|DRUG|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
214351536|NCT03077724|DRUG|Fish oil|Fish oil supplementation
214958604|NCT00947310|DEVICE|Standard ICD programming|Standard ICD programming
214958605|NCT00947310|DEVICE|High rate cutoff|Programming of a high rate cutoff
214958606|NCT00947310|DEVICE|Long delay|Programming of a prolonged delay
215078788|NCT04579172|PROCEDURE|Cervico- isthmic compression suture|Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.
214351537|NCT03077724|DRUG|Placebos|Olive Oil capsules
214678793|NCT02679066|DEVICE|Short forearm cast|Fiberglass immobilization with elbow free
214678794|NCT03605134|DIAGNOSTIC_TEST|level of cardiac troponin|blood test
214678795|NCT03605134|DIAGNOSTIC_TEST|diastolic function assessment|transthoracic echocardiography
214678796|NCT01088815|DRUG|Gemcitabine, nab-Paclitaxel, GDC-0449|"1. One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~2. Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
214958607|NCT03793647|DEVICE|Electrical muscle devise|evaluate two types of EMS stimulation of legs
214958608|NCT03319316|DRUG|Durvalumab|Combination of durvalumab + tremelimumab treatment
214958609|NCT03319316|DRUG|Tremelimumab|Combination of durvalumab + tremelimumab treatment
214958610|NCT00249418|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
214958611|NCT04529239|DEVICE|Abbott Freestyle Libre Pro|Continuous glucose monitoring device to analyze diabetes biomarkers.
214958612|NCT03420430|BIOLOGICAL|GL-ONC1|
214958613|NCT00005033|BIOLOGICAL|trastuzumab|
214958614|NCT00005033|PROCEDURE|conventional surgery|
214958615|NCT04875910|OTHER|Home-based exercise program|"The exercise program will include task specific training to improve balance and the training will progress every two weeks. A Physical therapist will be following up and monitoring the participants adherence to the training by audio or video call.~The exercise program for Week 1: Sit to Stand 5 times, Steps forward, backward and to the sides 5 times, 10 meters walk. 45 minutes session /3 times per week. Week 2: Sit to stand 10 times, Steps forward, backward and to the sides 5 times , Sit and reach 5 min for each hand and walk for 15 meters. 45 minutes session, 3 times per week. Week3 Sit to stand 10 times, Step on bench 5 times, Stand and reach 5 and walk for 15 meters. 45 minutes session, 3 times per week. Week 4 Stand and reach 5 times, Step on bench 10 times, climbing stairs (5 steps flight stairs up and down) and walk for 20 meters. 50 minutes session, 3 times per week."
214958616|NCT04761757|OTHER|Booklet of Scripts of Doctors|"The Booklet of Scripts for Doctors was used in the control arm. This tool was developed and tested to encourage shared decision-making in prescribing antidepressants within the Malaysian context."
214958617|NCT04761757|OTHER|Booklet of Scripts for Doctors and the Antidepressant Decision Aid for Major depressive disorder patients (ADAM)|"The Booklet of Scripts for Doctors along with the Antidepressant Decision Aid for Major depressive disorder patients, ADAM, was used in the intervention arm. The decision aid was developed as per the International Patient Decision Aid Standards (IPDAS) criteria to enhance patient understanding of risks and benefits of different antidepressants available within the Malaysian context."
214958618|NCT02372383|DRUG|Ethambutol|Anti-mycobacterial oral drug
214958619|NCT02372383|DRUG|Rifampin|Anti-mycobacterial oral drug
214958620|NCT02372383|DRUG|Azithromycin|Anti-mycobacterial oral drug
214958621|NCT02372383|DRUG|Pancrelipase|Pancreatic enzyme replacement therapy
214351538|NCT02065531|OTHER|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
214351539|NCT02065531|OTHER|Mobilization with impulse technique.|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
214351540|NCT01774565|DEVICE|Fully Automated Closed-Loop Insulin Delivery|
214351541|NCT01774565|DEVICE|Conventional insulin therapy|
214351542|NCT03204097|DRUG|placebo|Oral prophylaxis followed by placement of placebo gel
214351543|NCT03204097|DRUG|Alendronate|Oral prophylaxis followed by placement of Alendronate gel
214351544|NCT03204097|DRUG|Aloe Vera|Oral prophylaxis followed by placement of Aloe Vera gel
214958622|NCT01216878|DRUG|losartan potassium|100 mg tablet
214958623|NCT01442012|OTHER|Ear seeds|The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
214958624|NCT00631982|PROCEDURE|in vitro matuartion of oocytes|in vitro maturation of (immature) oocytes
214958625|NCT05076604|DRUG|Cardioplegia Solution|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
214958626|NCT05076604|DRUG|Microplegic Solution No. 1|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
214958627|NCT03258645|DRUG|Dabigatran|Oral anticoagulant (NOAC) thrombin inhibitor
214958628|NCT04033978|BEHAVIORAL|Cognitive remediation|10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
214958629|NCT04033978|BEHAVIORAL|psychosocial rehabilitation|10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
214958630|NCT05850702|DRUG|Lidocaine|inhale 5ml of 2% lidocaine by nebulization
214958631|NCT05850702|DRUG|Saline|inhale 5ml of saline by nebulization
214351545|NCT02570490|DRUG|sodium fusidate|
214958632|NCT05328453|DIAGNOSTIC_TEST|Fetal prenatal ultrasonographic evaluation.|Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
214958633|NCT01676051|OTHER|Skin culture|Culture swab used to culture skin adjacent to incision
214958634|NCT03013712|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
214351546|NCT02570490|DRUG|linezolid|
214351547|NCT04622579|DRUG|lenalidomide combined with rituximab|lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
214351548|NCT04974164|BIOLOGICAL|Inactivated COVID-19 Vaccine|Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen
214351549|NCT04532814|OTHER|Exercise|Cycling 60% VO2 max
214351550|NCT06273644|OTHER|Carbohydrates|Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.
214351551|NCT05322616|DRUG|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
214351552|NCT05322616|DRUG|Matching Placebo|Vehicle control
214351553|NCT05023304|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
214351554|NCT05023304|DRUG|Topical prednisolone acetate|Standard of care topical drop regimen with four week taper
214351555|NCT04370054|BIOLOGICAL|PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy|Single IV infusion
214351556|NCT04674345|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).
214351557|NCT04873375|DRUG|Cemiplimab|After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
214351558|NCT02515136|BEHAVIORAL|Stimulus-response|See summary
214351559|NCT04731649|BEHAVIORAL|Families Talking Together Plus (FTT +)|FTT + consists of three online intervention sessions of approximately 60-90 minutes each, that cover content from nine modules designed to teach parents effective communication skills, build parent-adolescent relationships, help parents develop successful monitoring strategies, and teach adolescents assertiveness, refusal skills, and how to use a condom correctly and every time.
214351560|NCT00722761|DRUG|drospirenone and ethinyl estradiol|Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
214351561|NCT00722761|DRUG|Placebo tablet|Placebo tablet (no active drug) given once daily for 24 weeks
214351562|NCT02407509|DRUG|VS-6766|
214351563|NCT02407509|DRUG|Everolimus|
214351564|NCT06505200|OTHER|No intervention|No intervention
214351565|NCT05054816|DEVICE|Investigational adaptive directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the investigational adaptive directional microphone strategy that is expected to improve sound quality of speech in a car.
214351566|NCT05054816|DEVICE|Comparator omnidirectional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator omnidirectional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
214351567|NCT05054816|DEVICE|Comparator fixed directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator fixed directional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
214958635|NCT01947101|BIOLOGICAL|Fecal Microbiota Transplant|Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
214351568|NCT01973881|PROCEDURE|T1 Weighted MRI (magnetic resonance imaging)|"Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations."
214351569|NCT06294704|OTHER|bariatric surgery|Having undergone bariatric surgery and on a closed-loop insulin pump after bariatric surgery
214351570|NCT03375619|OTHER|Long-Term Follow-Up of Participants who Received CAR-T cells|No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
214958636|NCT00882271|OTHER|Acupuncture|Ten Acupuncture treatments within six weeks
214958637|NCT01898169|OTHER|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
214958638|NCT01704755|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
214958639|NCT01704755|DRUG|Ribavirin (RBV)|Capsule
214958640|NCT03293745|BEHAVIORAL|Face to Face CBT-I (F2F)|CBT-I delivered in-person by the therapist.
214958641|NCT03293745|BEHAVIORAL|Telemedicine CBT-I (TM)|CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
214958642|NCT02348697|BIOLOGICAL|NOVOCART 3D|Autologous Chondrocyte Implantation
215078789|NCT04579172|PROCEDURE|Anterior wall uterine resection:|After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
215078790|NCT06276218|DEVICE|Clavicular brace|Clavicular brace for conservative treatment of closed midshaft clavicular fractures
215078791|NCT04035564|DRUG|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
215078792|NCT04035564|DRUG|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
215078793|NCT00892203|DRUG|BGG492|
215078794|NCT00892203|DRUG|Sumatriptan|
215078795|NCT00892203|DRUG|Placebo|
214351571|NCT05169970|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients with a low or intermediate risk Decipher score will receive radiation targeting the seminal prostate and seminal vesicles to a dose of 40 Gy in 5 fractions delivered every other day.
214351572|NCT05169970|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients with high risk Decipher scores will receive radiation targeting the prostate and seminal vesicles to a dose of 40 Gy in 5 fractions with a simultaneous integrated boost to 45 Gy of any dominant intraprostatic lesion as well as radiation to the pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered every other day.
214351573|NCT04915261|BEHAVIORAL|Lenient Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
214351574|NCT04915261|BEHAVIORAL|Strict Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
214351575|NCT06227585|DEVICE|REVEAL 475 System|The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration.
214958643|NCT03529708|RADIATION|3D CRT plus SBRT boost|Patients will receive urgent standard 3D conformal radiotherapy (3D CRT) of plus stereotactic boost to tumor causing spinal cord compression (SCC). Initial dose for 3D CRT will be either 8Gy in 1 fraction or 20Gy in 5 fractions, with SBRT boost dose15Gy in 2 fractions of 12Gy in 2 fractions (depending on 8Gy/1 or 20Gy/5 initial RT dose respectively), delivered within three weeks of first treatment.
215078796|NCT02958306|BIOLOGICAL|platelet rich plasma|PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
215078797|NCT00000729|DRUG|Foscarnet sodium|
215078798|NCT01640418|DEVICE|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
215078799|NCT01471418|DRUG|PET/CT with 18-FDG|FDG uptake
214351576|NCT06227585|DRUG|Bevonescein|All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.
214351577|NCT02075593|DRUG|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
214351578|NCT02222220|DRUG|Metoclopramide|30 mg/day during 4 weeks
214351579|NCT02222220|DRUG|placebo|
214351580|NCT01371318|OTHER|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
214351581|NCT02300714|PROCEDURE|oblique view approach|
214958644|NCT05223790|DEVICE|Pain measurement during care procedures in neonatal reanimation|Pain measurement during care procedures in neonatal reanimation
215078800|NCT03209076|PROCEDURE|Robotic|Robotic low anterior resection
215078801|NCT03209076|PROCEDURE|Laparoscopic|Laparoscopic low anterior resection
215078802|NCT02386215|BEHAVIORAL|HIV self-test|"Two self-test kits will be distributed to women, each containing the following:~* One standard OraQuick ADVANCE I/II test kit~* Written pre-test information including test instructions in written and pictorial form~* A phone number that participants can call to obtain additional information~* Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing"
214958645|NCT04105842|DEVICE|Delfilcon A|Participants wear delafilcon A contact lenses on a daily disposable basis.
214958646|NCT02087670|OTHER|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
214958647|NCT02087670|OTHER|exercise protocol no supervised|Exercise program at the community
214958648|NCT01639703|DRUG|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
214958649|NCT01272505|PROCEDURE|converntional SILC|
214958650|NCT01272505|PROCEDURE|Harmonic scalpel Single incision laparoscopic cholecystectomy|
214958651|NCT05100303|DRUG|Mitoxantrone Hydrochloride liposome injection|Mitoxantrone hydrochloride liposome will be administered by intravenous (IV) injections.
215078803|NCT03505788|DRUG|Acetazolamide|In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
215078804|NCT03505788|DRUG|Placebo|In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
215078805|NCT06149117|DRUG|"test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®"|Take one capsule orally every cycle(T or R)
215078806|NCT01394757|DRUG|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
215078807|NCT04690920|DRUG|Tocilizumab|Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
215078808|NCT02323841|PROCEDURE|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
215078809|NCT04126889|OTHER|questionnaire survey|questionnaire survey
215078810|NCT05731908|DRUG|BI 690517|BI 690517
214351582|NCT05672628|DEVICE|Oculus VR|During the first visit, the Oculus headset will be placed on the stroke survivor's head and demonstrate how to use the headset. participant will be then allowed to play a game using the hand controllers for up to 30 minutes. Finally, a copy of exercises for their home rehabilitation program will be provided. During the next rehabilitation visits, a trained research assistant will guide the stroke survivor with using the gaming headset. The session will be stopped every 20 minutes to make sure that the stroke survivor is feeling well and to give them a break. The stroke survivor may stop the session at any time. This session will last for an hour.
214351583|NCT00131157|PROCEDURE|expert support for interpretation of spirometry|
214351584|NCT03595345|PROCEDURE|Liver transplantation|Liver transplantation
214351585|NCT06532708|OTHER|5x Oxycodone Oral Tablets|Participants will be prescribed 5 doses of 5mg tablets of oxycodone for postoperative pain relief.
214351586|NCT06532708|OTHER|16x Oxycodone Oral Tablets|Participants will be prescribed 16 doses of 5mg tablets of oxycodone for postoperative pain relief.
214351587|NCT04948203|DRUG|Sirolimus|Triangular-shaped tablet
214351588|NCT03156049|PROCEDURE|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
214351589|NCT03156049|PROCEDURE|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
214958652|NCT05100303|DRUG|Cytarabine (LoDAC)|Low-dose or high-dose cytarabine (LoDAC) will be administered by intravenous (IV) injections.
214958653|NCT04264754|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
214958654|NCT03711305|DRUG|SHR-1316|SHR-1316 intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
214958655|NCT03711305|DRUG|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
214958656|NCT03711305|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
214958657|NCT03711305|DRUG|Placebo|Placebo intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
214958658|NCT01042392|DRUG|Aliskiren|150 mg Aliskiren as film-coated tablet
214958659|NCT01042392|DRUG|Ramipril|Ramipril 5 mg was given in capsule form.
214351590|NCT05039281|BIOLOGICAL|Atezolizumab|Given IV
214351591|NCT05039281|DRUG|Cabozantinib|Given PO
214351592|NCT07114692|BIOLOGICAL|Stromal vascular fraction transplantation|Subcutaneous fat was harvested from either the abdomen or the posterior inner thigh region and then digested with 600 U of collagenase (Shanghai Qiaoyuan Biological Pharmaceutical Co., Ltd, Shanghai, China) at 37°C and 150rpm for three hours. After enzymatic digestion, the lower aqueous phase liquid was aspirated to acquire the stromal vascular fraction (SVF). The SVF cell-pellet was washed and adjusted to 2×10\^6 cells/mL. Lidocaine cream will be applied to the expanded skin to achieve surface anesthesia. The skin was marked with methylene blue and a total of 0.5ml (around 1×10\^6 cells) were transplanted intradermally at the center of each 2cm×2cm squares. The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg.
214351593|NCT07114692|BIOLOGICAL|Normal saline injection|Lidocaine cream will be applied to the expanded skin to achieve surface anesthesia. The skin was marked with methylene blue and a total of 0.5ml 0.9% normal saline were transplanted intradermally at the center of each 2cm×2cm squares. The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg.
214351594|NCT07119853|OTHER|Microteaching|"Students in the experimental group watched the Advanced Life Support Team Dynamics Video. The video was uploaded to the university's education management system, and a student monitoring report was generated, ensuring that all students could watch it."
214351595|NCT07127614|DIAGNOSTIC_TEST|MRI|pre-operative MRI scan
214958660|NCT01042392|DRUG|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
214958661|NCT01042392|DRUG|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
214958662|NCT05802303|DRUG|17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)|In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06% w/w) 2 puffs thrice a day (each application contains 1.25 mg with 0.75 mg of the drug).
214958663|NCT05802303|DRUG|Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)|In the oral Estradiol group, all women will be given 2 mg of Estradiol valerate tablets, one tablets thrice a day within 30 days of injection triptorelin depot. Endometrial assessment will be performed on D10 of HRT. Please see the flow diagram (in the annexure) for details.
214958664|NCT03318367|OTHER|Educational Intervention|Complete virtual reality education module
214958665|NCT06212284|DRUG|Citalopram 20mg|Doses were delivered in gelatine capsules filled with microcrystalline cellulose.
214958666|NCT06212284|DRUG|Placebo|Doses were gelatine capsules filled with microcrystalline cellulose
214958667|NCT06350201|BEHAVIORAL|cognitive behavior therapy|Problem-solving therapy-based holistic emotion management interventions matched to individual symptoms
214958668|NCT06350201|OTHER|control group|Routine psychological care and guidance on mood management
214958669|NCT03928379|DRUG|LY3305677|Administered SC
214958670|NCT03928379|DRUG|Placebo|Administered SC
214958671|NCT04360473|OTHER|General anesthesia|Balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
214958672|NCT04360473|DRUG|Ketamine plus general anesthesia|ketamine 0.3 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
214678797|NCT04509856|BEHAVIORAL|Teach-back educational method|In the teach-back method, after teaching new information to the patient, the patients were asked to explain that new information in their own words. Then the patients' knowledge and the adequateness of their explanations were determined. The patient should repeat the instructions in their own words. In this way, the healthcare professional can evaluate how the patient understands the information. If the patient repeated the information correctly, the teach-back phase for that information was completed, and progression for new information was resumed. However, if there was a deficiency or error in the information, it was corrected and repeated by the healthcare professional.
214678798|NCT01346137|DRUG|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
214678799|NCT01803802|BEHAVIORAL|Expressive writing|Five sessions of 30 minutes of expressive writing
214678800|NCT02434887|DEVICE|KL029 Intimate Lubricant Gel|
214678801|NCT03562780|DRUG|Fortolin Tab 500mg|Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
214958673|NCT04360473|DRUG|Magnesium sulfate plus general anesthesia|Magnesium sulfate 40 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
214958674|NCT04360473|DRUG|ketamine plus magnesium sulfate plus general anesthesia|Ketamine 0.15 mg/kg plus magnesium sulfate 20 mg/kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane
214958675|NCT00079053|DRUG|erlotinib hydrochloride|
214958676|NCT00079053|PROCEDURE|adjuvant therapy|
214958677|NCT03476642|DRUG|Ropivacaine|injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
214958678|NCT03476642|DRUG|Epinephrine|injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
214958679|NCT05607316|DRUG|Metformin Hydrochloride|"Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily for the remainder of the study."
214958680|NCT05010317|BEHAVIORAL|Mindfulness and acceptance based therapy|This is a behavioral intervention that is aimed at building psychological flexibility among adolescents. It involves careful use of language, metaphors, experiential learning and mindfulness to develop skills that support values guided living. Participants learn to relate with their inner thoughts, feelings and urges in an open and elaborative way as conscious human beings and make choices that improve their lives even in the presence of such difficult experiences.
214958681|NCT05010317|BEHAVIORAL|Standard of care|Usual clinic based counselling offered as routine care to adolescents
214351596|NCT07127614|DIAGNOSTIC_TEST|Histo-Pathological examination of the resected tumor tissues|histo-pathological examination of the resected tumor tissues with the lymph nodes involved to determine the pathological depth of invasion
214351597|NCT07127770|DRUG|PF-07104091|Cyclin-dependent kinase-2 inhibitor
215078811|NCT06061276|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
215078812|NCT06061276|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
215078813|NCT06061276|DRUG|Camrelizumab|200mg intravenously every 2 weeks
215078814|NCT05933356|BEHAVIORAL|playing exergames|"will be provided with the individual brain training exergames three times a week and 30 minutes each time"
215078815|NCT05933356|OTHER|scheduled activities|scheduled activities
214351598|NCT07126652|DRUG|MF-59|MF-59 influenza vaccination
214351599|NCT07126652|DRUG|cell-based|cell-based influenza vaccination
214351600|NCT07126652|DRUG|egg-based|egg-based influenza vaccination
214351601|NCT07127341|DEVICE|Patient with removable functional appliance|Survey (quiz) for patient who had malocclusion and/or a dysfunction treated removable functional appliance about the treatment, before, during and after treatment
214678802|NCT03562780|DRUG|Panadol Caplet 500mg|Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
214678803|NCT01483092|DIETARY_SUPPLEMENT|inulin|20g/day for 4 weeks
214678804|NCT01483092|DIETARY_SUPPLEMENT|maltodextrin|20g/day for 4 weeks
214678805|NCT00395122|DEVICE|Retinal nerve fiber layer and macular thickness measurements|
214678806|NCT04681846|PROCEDURE|Staged approach using antibiotic-cement impregnated PMMA spacer|It will be prepared in the following manner. the cement will be mixed with vancomycin in a ratio of 2 gm to each 40 gm of the spacer. The spacer should be shaped into a cylinder before its solidification. The spacer should be as big as possible to fill the whole defect, without compromising the soft tissue and skin closure. Also, cement should wrap the two ends of bone extremities on 2 or 3 centimeters.
214351602|NCT07126275|DEVICE|Mirror App Journaling and Mood Tracking Study|Mirror is a mobile journaling app developed by the Child Mind Institute (CMI) for youth who want to explore and improve their mental health, particularly addressing symptoms related to depression. The Mirror app enables users to express their thoughts and emotions through multimodal entries (i.e., written, voice, selfie video) and provides prompts to facilitate journal entries using unique, emotionally supportive features to help users identify and process emotions. Users can also complete free-form, unguided journaling, and can complete daily mood tracking and see changes/progress over time.
214958682|NCT05514457|BEHAVIORAL|visual stimulation with I pad|"At the beginning of the study, for baseline condition, children will do 4 tests (visuo-spatial perception test, visual attention span, visual research, phonology tests).~In the first group of the study, the children will do visual research exercises on I pad 10 minutes per day during one month = remediation. They will also do 4 reading aloud tests, once a month, for 3 months. The remediation exercises will be realized during the first, second or third month."
214958683|NCT05514457|BEHAVIORAL|visual stimulation with lamp|"At the beginning of the study, for baseline condition, children will do the 4 tests like group 1.~In the second group of the study, the children will do reading aloud tests, with lamp adjusted with different parameters = remediation (passive visual stimulation of a specific frequency believed to promote visual processing of written symbols)."
214958684|NCT00421109|DRUG|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
214958685|NCT00421109|DRUG|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
214958686|NCT00421109|DRUG|Placebo|Encapsulated tablet. Once daily for 28 days
214958687|NCT02869893|DRUG|Secretin|
214958688|NCT02388087|DEVICE|ROX COUPLER|ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.
214958689|NCT02388087|PROCEDURE|Right heart catheterisation and routine care|Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
214958690|NCT05266482|OTHER|Personal report|In the intervention group, in addition to receiving the usual care, patients will receive personal reports on multiple time points. These reports include feedback on their PROs including reference scores of patients who previously underwent total knee replacement surgery.
214958691|NCT03182881|OTHER|Lymphatic Drainage|It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.
214958692|NCT03182881|OTHER|Myofascial Release|For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
214958693|NCT04462822|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
215078816|NCT05155618|PROCEDURE|INTERVENTION GROUP|Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
215078817|NCT00011362|DRUG|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
214958694|NCT04462822|DRUG|ADVAIR DISKUS® 250/50|2 inhalations of Test and Reference product in each study period
215078818|NCT00011362|DRUG|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was \>=2.4 on treatment day 14, or an additional two weeks of saline
215078819|NCT06099470|OTHER|Real-time synchronized telerehabilitation program (STP).|patient education, core stabilization exercises, strengthening exercises, stretching exercises
214351603|NCT07126067|PROCEDURE|Lung Ultrasound and PEEP Application|Application of Lung Ultrasound and PEEP After intubation, PEEP starts at 5 cmH2O. The first lung ultrasound (USG) is performed after 5 minutes. If the lung consolidation score is ≥2, PEEP increases by 2 cmH2O and is reassessed every 5 minutes until the score is \<2. If \<2, PEEP remains unchanged as the optimal level. This process is repeated after pneumoperitoneum, peritoneal deflation, and position changes. In Group U, PEEP is determined by USG, with a maximum of 20 cmH2O, a plateau pressure of 30 cmH2O, and a peak inspiratory pressure of 40 cmH2O.
214958695|NCT04995263|BEHAVIORAL|Sueña component 1: Sleep Hygiene Promotion|The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.
214958696|NCT04995263|BEHAVIORAL|Sueña component 2: Periodic Anxiety and Pain Screening|Every night, nursery staff will include anxiety and pain screenings as part of vital signs assessments, using visual analog scales for each one. If any screening is altered, clinical actions will be performed to alleviate symptomatology if deemed necessary, using clinical judgement.
214958697|NCT04995263|BEHAVIORAL|Sueña component 3: Hypnotics and Caffeine Regulation|The use of hypnotics will be standardized to be administered no later than at 22:00 PM; in the case of melatonin, its administration will be suggested at sundown, at 20:00 PM. Caffeinated drinks will be prohibited after 15:00 PM.
214958698|NCT04995263|BEHAVIORAL|Sueña component 4: Sleep Masks and Ear Plugs|Sleep masks and ear plugs will be available to all patients if they wish to use them. The nursery team will reinforce its use between 23:00 PM and 07:00 AM.
214958699|NCT04995263|OTHER|Sueña component 5: Personalized Psychoeducation|Two individualized, nurse-led psychoeducation PowerPoint presentations on sleep hygiene will be presented to patients, supported by educational material aimed at the patient and their families.
214958700|NCT04995263|DEVICE|Sueña component 6: Sleep Reports|Objective and subjective reports of sleep quality will be handed to attending psychiatrist, using data gathered with wearable devices (Fitbit Charge 4) and self-report questionnaires regarding perceived sleepiness and overall sleep. The psychiatrist in charge uses said information in the routine case management
215078820|NCT06099470|OTHER|Pre-recording non-synchronized telerehabilitation program (NSTP)|Pre-recording non-synchronized telerehabilitation program (NSTP)
215078821|NCT06099470|OTHER|Home non-supervised control group (HCG)|Home non-supervised control group (HCG)
215078822|NCT04081753|DEVICE|Remote monitoring of temperature|The patient will be set up with a remote monitoring device for temperature recording and the temperature will monitored remotely
215078823|NCT00012129|DRUG|liposomal annamycin|
214958701|NCT05654064|DRUG|Remifentanil-dexmedetomidine|Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
215078824|NCT06246019|DIAGNOSTIC_TEST|Early adoption of blood-based biomarkers for Alzheimer's disease|A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.
215078825|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose
215078826|NCT01098877|DRUG|PF-04634817|Oral solution, 1mg, single dose
215078827|NCT01098877|DRUG|PF-04634817|Oral solution, 3mg, single dose
214351604|NCT07126067|PROCEDURE|Application of PEEP with Dynamic Compliance|"Application of PEEP with Dynamic Compliance~* After endotracheal intubation, PEEP will be applied as 5 cmH2O.~* The first dynamic compliance (TV/Ppeak-PEEP) monitoring will be performed automatically by the ventilator (Mindray) 5 minutes after endotracheal intubation, and the PEEP value will be increased by 3 cmH2O. The obtained Cdyn value will be repeated after six respiratory cycles, and if there is an increase, the PEEP value will be increased by 2 cmH2O. When a decreasing trend is observed in the Cdyn value as a result of consecutive automatic measurements of 6 respiratory cycles, the PEEP value applied in the previous measurement will be determined as the most appropriate PEEP value for the participant."
214351605|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44
214351606|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection
214351607|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44
214351608|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44
214351609|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44
214958702|NCT05654064|DRUG|Dexmedetomidine-fentanyl|Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
214958703|NCT03269903|DEVICE|HILZO esophageal stent|A fully covered esophageal self-expandable metal stent for malignant dysphagia
214958704|NCT05649696|DRUG|Recombinant Staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
214958705|NCT05649696|DRUG|Normal Saline|Intravenous injection of normal saline is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
214958706|NCT03593330|OTHER|Transitional Care Programme|These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
214351610|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection
214351611|NCT06662916|BEHAVIORAL|Microbiota-Diversity Enhancing Diet on children with Autism Spectrum Disorder|Microbiota-Diversity Enhancing Diet on Children with ASD (MIND-DASE) suggested that increasing microbiota diversity through dietary interventions can have significant benefits on the neurodevelopmental outcomes of children with ASD
214958707|NCT00442234|DRUG|Monteplase|
214958708|NCT03845244|DEVICE|Flow reduction first|-10L/min q 1hr
214958709|NCT03845244|DEVICE|FiO2 reduction first|\- 0.1 q 1hr
214958710|NCT03845244|DEVICE|Simultaneous (flow and FiO2) reduction|-10L/min and -0.1 q 1hr
214958711|NCT03990311|OTHER|Sodium Restricted Meals|2 meals prepared with 2 g /day sodium restriction and adhering to dietary recommendations for a hemodialysis patients (phosphate and potassium restricted/ high protein content) 2 meals per day for first month of meal provision period followed by 1 meal per month in the second meal of meal provision period
214958712|NCT03990311|OTHER|Control|Usual Care
214958713|NCT06399016|DEVICE|augmented reality book|The story will be presented to the children in this application group in three dimensions. The augmented reality application will be supported by the researcher as it must be used under the supervision of an adult. When the tablet or phone is held to the pages of the book, the animations of these pages are displayed on the screen with sound. While the animation opens automatically when we hold the phone or tablet, the story can be listened to aloud at the same time.
215078828|NCT01098877|DRUG|PF-04634817|Oral solution, 10mg, single dose
215078829|NCT01098877|DRUG|PF-04634817|Oral solution, 30mg, single dose
215078830|NCT01098877|DRUG|PF-04634817|Oral solution, 100mg, single dose
215078831|NCT01098877|DRUG|PF-04634817|Oral solution, 300mg, single dose
215078832|NCT01098877|DRUG|PF-04634817|Oral solution, 600mg, single dose
215078833|NCT01098877|DRUG|PF-04634817|Oral solution, 900mg, single dose
215078834|NCT01098877|DRUG|PF-04634817|Oral solution, up to 900mg, single dose after food
215078835|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose after food
215078836|NCT02280824|PROCEDURE|CA-TAVR|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
215078837|NCT02280824|DEVICE|Amplatzer Duct Occluder|
215078838|NCT03120858|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
214351612|NCT06663982|PROCEDURE|Connective tissue graft + L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket. Following papilla incisions, an intra-sulcular incision on the vestibular side of the extraction socket will be extended with a #15c scalpel, creating a socket to insert the connective tissue graft (CTG). The CTG will be harvested from the palatal area following a specific incision technique to obtain a graft around 1.5 mm thick, which will be fixed with a mattress suture.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
214351613|NCT06663982|PROCEDURE|L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
214351614|NCT06663007|DRUG|RC48|During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.
214958714|NCT06399016|DEVICE|book|This group will be asked to just read the book without turning on the augmented reality feature of the book.
214351615|NCT06663007|DRUG|Envafolimab|During the treatment phase of the patient, the subjects received subcutaneous injections of Envafolimab (400 mg) every 3 weeks until the patient experienced disease progression or death.
214958715|NCT05362149|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
214958716|NCT05362149|DRUG|Enzalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
214958717|NCT05362149|DRUG|Apalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
214351616|NCT00274053|DRUG|tiotropium|
214351617|NCT05591417|PROCEDURE|Bilevel Erector spinae plane block|Patients will receive bilevel erector spinae plane block with bupivacaine
214958718|NCT05088681|OTHER|Rehabilitation program|The exercise intervention will consist of an individualized prescription of resistance training, balance training and cardiovascular exercises delivered for 20 session, one-hour, two/three times per week.
214958719|NCT05977101|BIOLOGICAL|MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
214958720|NCT05977101|OTHER|Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
215078839|NCT03349424|DRUG|Somatostatin|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
215078840|NCT02906449|BEHAVIORAL|Meditation Technique|Alertness training or relaxation training
215078841|NCT02324205|DEVICE|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
215078842|NCT02900638|BEHAVIORAL|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
215078843|NCT03659903|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy
215078844|NCT03255213|OTHER|Lingual Muscle Training|Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device
215078845|NCT05466500|PROCEDURE|Ultrasound guided axillary block with intravenous dexamethasone|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine plus 0.1mg/kg dexamethasone intravenous
215078846|NCT05466500|PROCEDURE|Ultrasound guided axillary block|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine
215078847|NCT06082596|DRUG|BEBT-908 for injection|"Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle."
215078848|NCT06320249|OTHER|High-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the high-frequency manipulation group, patients will undergo rotation-traction manipulation three times weekly. A total of 12 treatments for four weeks.
214958721|NCT00547924|BEHAVIORAL|Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
214351618|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexamethasone|Patients will receive bilevel erector spinae plane block with bupivacaine and dexamethasone
214958722|NCT04763616|DRUG|Isatuximab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
214958723|NCT04763616|DRUG|Cemiplimab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
214351619|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexmedetomidine|Patients will receive bilevel erector spinae plane block with bupivacaine and dexmedetomidine
214351620|NCT05591417|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
214351621|NCT05568394|OTHER|Manual therapy combinded with therapeutic exercise|"The treatment includes cervical mobilization and specific therapeutic exercises: craniocervical and cervical flexors and extensors, axioscapular muscles, and postural correction (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
214351622|NCT05568394|OTHER|Routine physical therapy|"The treatment includes routine physical therapy (e.g., modalities, range of motion and/or gentle stretching exercise) (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
214351623|NCT03817814|BEHAVIORAL|web-based questionnaire|Participants will complete a web-based questionnaire examining the decisions patients made about fertility preservation before and after treatment, the factors that influenced their decisions, and the ways in which patients pursue family building after treatment.
214351624|NCT04890028|RADIATION|F-DOPA PET/CT|"All subjects will be imaged~1 time injection of 2 MBq/kg of 18F-DOPA"
214351625|NCT04232254|BEHAVIORAL|Animal-based Protein Foods|Participants will consume animal-based protein foods.
214351626|NCT04232254|BEHAVIORAL|Skewed Protein Distribution|Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.
214958724|NCT03305692|DIAGNOSTIC_TEST|Optimization of CRT Device|Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
214958725|NCT01515696|DRUG|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
214958726|NCT01515696|DRUG|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
214958727|NCT05102435|OTHER|Tool Translation & Validation study|In this English version of POMA scale will be translated into Urdu.
214958728|NCT05205980|BEHAVIORAL|Perturbation training|Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
214958729|NCT03839329|BEHAVIORAL|Acceptance and Commitment Training|Acceptance and Commitment Therapy is an acceptance- and mindfulness-based psychotherapy that aims to foster psychological flexibility.
214958730|NCT00538226|DEVICE|External Electric Muscle Stimulation|
214958731|NCT03964259|DRUG|Intravenous fluids|Administration of post HDMTX intravenous fluids (IVF)
215078849|NCT06320249|OTHER|Low-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.
214351627|NCT04232254|BEHAVIORAL|Plant-based Protein Foods|Participants will consume plant-based protein foods.
214351628|NCT04232254|BEHAVIORAL|Balanced Protein Distribution|Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.
214351629|NCT04717934|DEVICE|GAL1906|hyaluronic acid dermal filler gel
214351630|NCT03574571|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
214351631|NCT03574571|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
214351632|NCT03574571|DRUG|Radium-223|Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
214351633|NCT06617455|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214351634|NCT06617455|DRUG|Fezolinetant|Given PO
214351635|NCT06617455|DRUG|Placebo Administration|Given PO
214958732|NCT02302040|BEHAVIORAL|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
214958733|NCT02302040|BEHAVIORAL|Self-guided|Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
214958734|NCT00665483|OTHER|Skin Prick Test|Skin Prick Test
214958735|NCT04850495|DRUG|Cyclophosphamide|Given IV
214958736|NCT04850495|DRUG|Doxorubicin Hydrochloride|Given IV
214958737|NCT04850495|DRUG|Prednisone|Given PO
214958738|NCT04850495|BIOLOGICAL|Rituximab|Given IV
214958739|NCT04850495|DRUG|Vincristine Sulfate|Given IV
214958740|NCT04850495|DRUG|Zanubrutinib|Given PO
214958741|NCT01309451|DRUG|Bevacizumab|intravitreal, 1.25mg., monthly
214958742|NCT01309451|DRUG|dexamethasone intravitreal implant|0.7mg, intravitreal every 4 months
214958743|NCT04274075|DRUG|GDC-9545 Tablet, Fasted: Treatment A|One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
214351636|NCT06617455|OTHER|Quality-of-Life Assessment|Ancillary studies
214958744|NCT04274075|DRUG|GDC-9545 Capsule, Fasted: Treatment B|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
214351637|NCT06617455|OTHER|Questionnaire Administration|Ancillary studies
214958745|NCT04274075|DRUG|GDC-9545 Capsule, Fed: Treatment C|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water within 30 minutes of eating a high-fat meal.
214958746|NCT05399316|DIETARY_SUPPLEMENT|Inulin|Natural fiber supplement extracted from chicory
214958747|NCT05399316|DIETARY_SUPPLEMENT|Maltodextrin|Natural non-fermentable sugar
214958748|NCT04541212|DIAGNOSTIC_TEST|Cardiac Imaging|Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test
214958749|NCT04541212|OTHER|Data Collection|Collection of retrospective data
214958750|NCT05934266|DEVICE|Use of n-hexyl cyanoacrylate for mesh fixation|Mesh fixation with tissue adhesive (n-hexyl cyanoacrylate) in open hernia repair
214958751|NCT05040919|OTHER|collection of medical and socio-demographic data|collection of medical and socio-demographic data
214958752|NCT02768922|OTHER|Aphasia telerehabilitation|Speech and language therapy delivered by speech-language pathologist via computer and telemedicine
214958753|NCT02768922|OTHER|Standard face-to-face aphasia rehabilitation|Speech and language therapy delivered by speech-language pathologist face-to-face (treatment as usual)
214958754|NCT04465084|OTHER|Case|Battery of standardised and normalised tests evaluating different cognitive functions Experimental language tasks MRI
214958755|NCT04465084|OTHER|Withness|Experimental language tasks MRI
214958756|NCT04685096|OTHER|Test product creme|twice daily application of creme containing 2% NMN
214958757|NCT04685096|OTHER|Reference creme|twice daily application of reference creme
214958758|NCT01826097|DEVICE|La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration|
214958759|NCT01648998|DRUG|Fludrocortisone|single dose 500 mg, capsule
214958760|NCT01648998|DRUG|Placebo|
214958761|NCT02731547|BEHAVIORAL|Education Against Tobacco School-Based Intervention|
214958762|NCT00328445|BEHAVIORAL|Positive Action|See publications
214958763|NCT05447910|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214958764|NCT06249607|OTHER|storytelling|Storytelling android program: Subjects in group A or the storytelling group will be given headphones to listen to stories for 30 min (i.e., between 9 and 10 pm). While the subject listens to the story, a relative will present in a corner of the room to record when they fell asleep, the relative will present again in the room to record the time of falling asleep. The intervention will be done 7 nights a week for a period of 6 weeks.
214958765|NCT06249607|OTHER|Mindfulness breathing|"android program: Individuals in group B are instructed to sit upright in a comfortable position with eyes closed, focus on diaphragm movements while breathing in a slow, deep, relaxed manner, and to nonjudgmentally acknowledge and accept unwanted thoughts, ideas or images and return attention to the diaphragmatic breathing. In this exercise, individuals are instructed to notice the physical sensations of breathing, both inhalations and exhalations, with a focus on the natural rate of respiration as opposed to forcibly controlling the breath. Duration: 5 minutes in duration per session, before sleep for 7 days a week for a total duration of 6 weeks"
214958766|NCT06249607|OTHER|Sleep hygiene|"Subjects in all groups will receive tips about healthy sleep~* Maintain a regular sleep routine.~* Avoid daytime naps.~* Don't stay in bed awake for more than 5-10 minutes.~* Don't watch TV, use the computer, or read in bed.~* Drink caffeinated drinks with caution.~* Avoid inappropriate substances that interfere with sleep.~* Clean fresh air.~* Have a quiet, comfortable bedroom."
214351638|NCT06994195|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214351639|NCT06994195|DRUG|Liposomal doxorubicin, Paclitaxel or Topotecan|Administration by intravenous infusion for a cycle of 4 weeks.
214351640|NCT07127562|BEHAVIORAL|Mindfulness intervention|"Intermittent period: from the first day to at least the 21st day, and up to the 28th day, continuous implementation~Content of intervention (daily completion):~1. Mindfulness breathing exercise (10 minutes) Content: Close your eyes to perceive the breath coming in and out, pay attention to the present moment, without judgment; Tools: Chinese voice-guided audio (nurses check room or patients scan code to play); Time: to be completed between 9am and 10am;~2. Body Scan Exercise (15 minutes) Content: gradually perceive the tension, pain or relaxation of each part of the body from head to toe; Tools: Chinese audio guidance, which can be played during the infusion or before going to bed; Time: between 7-8pm;"
214958767|NCT04233242|OTHER|Clinical management informed by HIV-1 genotypic resistance testing|"The study intervention will consist of the following components:~1. Genotypic resistance testing (GRT);~2. Review of GRT results by an expert committee providing a treatment recommendation;~3. GRT-based decision on further therapy (switch or maintain current ART regimen; choice of regimen); and~4. GRT-informed adherence support."
214958768|NCT06508060|DEVICE|Neosensory Wristband|"The Neosensory wristband consists of four vibratory motors built into the strap of the wristband (Figure 1a). The motors are linear resonant actuators (LRAs), vibrating at 175 Hz, capable of rising from 0 to 50% of their intensity within 30 ms. The motor intensity can be controlled with an eight bit resolution, meaning each motor can be controlled at 256 different intensities. At the highest intensity, each motor vibrates at 1.7 GRMS. The motors are separated from one another at a distance of 18.2 mm and 19.2 mm for the small and large wristband sizes, respectively (center-to-center distances).~The top of the wristband is a module that contains the power button, user setting buttons, a microphone, and a microcontroller. Bluetooth communication is used to create the corresponding vibrations on the wristband. While the study app plays the tones, it also sends a Bluetooth command to the wristband such that the wristband vibrates in the appropriate illusory location."
214958769|NCT06508060|OTHER|Tones only|Tones will be played through an app
214958770|NCT00090870|BIOLOGICAL|PEG-interferon alfa-2b|Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
214958771|NCT00090870|BIOLOGICAL|GM-CSF|GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
214958772|NCT00090870|DRUG|thalidomide|200mg daily by mouth
214958773|NCT01523327|OTHER|measuring protein creatinin ratio,serum uric acid|"A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method."
214958774|NCT00344838|DEVICE|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
214958775|NCT03522207|DIAGNOSTIC_TEST|polysomnography|BASELINE PSG Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
214958776|NCT03522207|DRUG|Trazodone|100 mg trazodone or placebo given once 30 minutes prior to 2nd PSG
214958777|NCT03522207|DRUG|Placebos|placebo per os 30 minutes prior to 2nd PSG
214958778|NCT03522207|DIAGNOSTIC_TEST|polysomnography|2nd psg, done 1 week after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
214958779|NCT03522207|DRUG|Trazodone|100 mg trazodone per os 30 minutes prior to 3rd PSG
214351641|NCT07127991|DEVICE|Medium Frequency Neuromuscular Electrical Stimulation (NMES)|"The medium-frequency NMES protocol, as reported in previous studies, consists of a carrier frequency of 2,500 Hz, a treatment frequency of 100 Hz, an ON time of 5 seconds (1 second ramp-up, 3 seconds contraction, and 1 second ramp-down), and an OFF time of 10 seconds. This stimulation protocol will be applied for 20 minutes per session (40 minutes of NMES per treatment day).~Two electrodes will be placed on each thigh, located at the motor point of the quadriceps muscle. Electrode positions will be marked with a semi-permanent marker to ensure consistent placement across sessions."
214351642|NCT07127991|PROCEDURE|Standard physical therapy|Participants of the fourth age (≥80 years old) will receive the standard physical therapy routinely provided during their hospitalization. This intervention involves passive mobilization of the lower limbs, specifically within the ranges of hip flexion, knee flexion and extension, and ankle flexion and extension. One set of 10 bilateral repetitions will be performed while the patient is under sedation in the ICU. Once the patient is awake, the mobilization protocol routinely used in the same unit will be followed.
214958780|NCT03522207|DRUG|placebos|100 mg placebo per os 30 minutes prior to 3rd PSG
214958781|NCT03522207|DIAGNOSTIC_TEST|polysomnography|3rd PSG, done 2 weeks after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
215078850|NCT06320249|OTHER|Cervical traction|The procedure for cervical traction is as follows: The patient assumes a sitting position, and a cervical traction device with a chin strap is applied. The patient is instructed to slightly flex their head forward, approximately 10-15 degrees, based on their comfort level and symptom relief. Traction force starts at 3 kg and increases gradually in increments of 0.5 kg, with a maximum weight not exceeding 6 kg. The cervical traction group will be subjected to cervical traction three times a week. A total of 12 treatments for four weeks.
215078851|NCT02748434|OTHER|Lipohypertrophy|
215078852|NCT02748434|OTHER|Normal Subcutaneous Tissue|
215078853|NCT01240525|OTHER|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
215078854|NCT01240525|OTHER|No DLI|Patients will not receive DLI as trial treatment
215078855|NCT01774097|BIOLOGICAL|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
215078856|NCT01774097|BIOLOGICAL|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
215078857|NCT06157541|BIOLOGICAL|Allogeneic cytomegalovirus-specific T cells|Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors
215078858|NCT06157541|DRUG|Pembrolizumab|A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
214351643|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale peppermint oil
214351644|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale lavender oil
214351645|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale ginger oil
214958782|NCT06252155|OTHER|Music|Mothers will listen to music for 30 minutes every day for 2 postpartum days. The type of music to be used in this study will be Turkish music . Turkish music will be preferred in the study because it is a part of the culture in which the study will be conducted. This type of music was preferred because it evokes feelings of happiness, laughter, joy, power, courage and heroism in the human soul. In deciding the type of music listened to in the study, expert opinion was taken from a faculty member teaching music therapy at a state university. During the music session, the mother will take a comfortable position on the sofa or bed. She will also be asked to close her eyes and imagine where she wants to be. She will also be asked to breathe slowly and deeply to regulate her breathing. The mother will be told to feel comfortable, to feel her body relax from head to toe while listening to music, to focus on the music and to free her thoughts.
214351646|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale placebo jojoba oil
214351647|NCT07126301|OTHER|Questionnaire Administration|Ancillary studies
214351648|NCT00404157|DRUG|Rituximab|
214351649|NCT06698666|DRUG|Rosuvastatin 10 mg tablet.|"The dose of rosuvastatin was derived from literature describing the doses at which the agents' targeted actions are effective and safe. The 10- mg rosuvastatin dose reflects the lowest prescribed therapeutic dose A serum cholesterol level will be drawn from the whole participants and sent to the central laboratories of El-Demerdash hospital at baseline and at week 12.~At each visit, participants will be requested to return all unused investigational products. Adherence to medication will be assessed by a pill count."
214351650|NCT06698666|DRUG|Sertraline Pill|Both control and intervention group will receive the sertraline as a standard therapy
214351651|NCT03277235|BEHAVIORAL|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
214351652|NCT03277235|BEHAVIORAL|Standard Care (in control arm)|standard care
214351653|NCT03399422|BIOLOGICAL|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
214351654|NCT03399422|PROCEDURE|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
214351655|NCT07032493|OTHER|Humidity-Ramp Protocol|Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which rectal temperature inflect is subsequently determined.
214351656|NCT07032493|OTHER|Above-inflection fixed-condition exposure (5%)|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' rectal esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
214351657|NCT07032493|OTHER|Below-inflection fixed-condition exposure (5%)|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual rectal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
214351658|NCT07032493|OTHER|Below-inflection fixed-condition exposure (10%)|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~10% lower than the participants' individual rectal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
214351659|NCT07032493|OTHER|Control fixed-condition exposure|Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.
214958783|NCT06852365|DIETARY_SUPPLEMENT|wheat dextrin|participants will take 15 grams per day for 12 weeks
214958784|NCT06852365|DRUG|Oral Contraceptives, Low-Dose|20 micrograms ethinyl estradiol and desogestrel 0.15mg
214958785|NCT06852365|DIETARY_SUPPLEMENT|Maltodextrin|participants will take 15 grams per day for 12 weeks
214958786|NCT05248178|BEHAVIORAL|CO-OP Procedures|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
214958787|NCT05248178|DEVICE|tDCS|Each session will begin with 20 minutes of anodal tDCS applied to the ipsilesional dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. The cathode will be placed over the contralesional supraorbital area. Direct current will be applied through two saline soaked sponges placed on the scalp. The tDCS device contains software for double-blinded delivery.
214958788|NCT05248178|BEHAVIORAL|Computer Cognitive Training Procedures|Individuals receiving computerized cognitive training will receive an equal dosage of 12, 45-minute sessions directly following the assigned tDCS condition. The online training software of BrainHQ will be used. BrainHQ is a well-recognized cognitive training program that targets the areas of attention, memory, processing speed, people skills, intelligence, and navigation. BrainHQ tracks progress and automatically grades difficulty as appropriate.
214958789|NCT05248178|DEVICE|sham tDCS group|Sham tDCS will involve the same preparation as in tDCS, but the current will ramp up for only 30 seconds and then return to zero. This method allows for sensations on the scalp associated with tDCS without inducing any neural changes.
215078859|NCT06527248|DIETARY_SUPPLEMENT|Nitrate group|Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
214351660|NCT06708182|BEHAVIORAL|SAGE LEAF Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
214351661|NCT06712251|DEVICE|Velocity pAVF System|The Velocity Percutaneous Arterio-Venous Fistula System consists of a percutaneous method designed to create an arteriovenous fistula for hemodialysis vascular access.
214351662|NCT07039929|DRUG|INCB000631|Oral; Tablet
214351663|NCT07039929|DRUG|Placebo|Oral; Tablet
214351664|NCT06720467|BIOLOGICAL|Intralesional injection of Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.)|Intralesional injection of 0.2 ml of 1/1000 solution of Candida albicans antigen using an insulin syringe directly into the warts; Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.). The same injection was repeated every 2 weeks until complete clearance for a maximum of six treatment sessions.
214351665|NCT06460311|OTHER|PEDAL and EMS|"Group A will receive EMS with Stationary cycle. EMS will be given at quadricep muscles. The pads will placed vertically in the midline along the knee and the pelvis. EMS will be given at frequency = 35 to 70 Hz, pulse duration = 100 μs, pulse period = 50 ms, Intervention will be will be performed for 60 minutes for 3 times or week for 4 weeks.~Conversely, the endurance training phase will involve securing the cycle seat while children cycle at their maximum capacity, aiming for a heart rate between 70% to 80% of their maximum. Prior to and following each session, stretching exercises targeting the calf, quadricep, and hamstring muscles will be administered, with a 10-second hold during both the warm-up and cool-down sessions. Pre and post measurements will be conducted to evaluate mobility and gait"
214351666|NCT06460311|OTHER|PEDAL|"In Group B, participants will exclusively receive the Pediatric Endurance and Limb Strengthening program without EMS. Similar to Group A, this program will incorporate the use of a stationary cycle. The warm-up and cool-down periods will also include a 10-second hold for each targeted muscle group. The intervention will consist of 60-minute sessions conducted three times per week over a span of four weeks.~Pre and post-assessments of gait and mobility will be conducted using the Gait Outcomes Assessment List (GOALTM) Questionnaire and the time up and go test."
214351667|NCT03216174|PROCEDURE|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
214351668|NCT06237283|BEHAVIORAL|Early shower|Start shower after drain removal
214351669|NCT04579367|DRUG|Bempedoic acid and/or its fixed-dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.
214351670|NCT07107217|DRUG|Camrelizumab|200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 10 times
214351671|NCT07107217|DRUG|Doxorubicin +cyclophosphamide+ filgrastimum|Doxorubicin 60mg/m² + cyclophosphamide 600 mg/m² on Day 1 of Cycles 1-4 (Q2W) of the first neoadjuvant phase of the study, IV infusion. filgrastim (G-CSF) subcutaneously on days 2-6 of Cycles 1-4
214958790|NCT06097871|DIETARY_SUPPLEMENT|Skin Nutraceutical Supplement|The Skin Nutraceutical Supplement is made with Nutrafol's patented Synergen Skin Complex®, which is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties combined to synergistically combat the multiple underlying factors that compromise skin health. These ingredients include Holy Basil, Maca, Curcumin, and Berberine in combination with other nutrients used to support skin health such as olive extract (20% hydroxytyrosol), konjac root (3% ceramides), vitamin A, B vitamins, and vitamin C.
214958791|NCT06097871|OTHER|Placebo pill|A placebo pill containing non-active ingredients
214958792|NCT05891886|DRUG|Oxygen Therapy|Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
214958793|NCT05891886|DEVICE|Non-rebreather mask|Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
214958794|NCT05319561|OTHER|Antibiotic Use Report|"The Antibiotic Use Report uses both text and graphics to communicate successes and improvement opportunities specific to the VAMC for which it is prepared. The graphs summarize overall antibiotic use over the previous year, with additional information regarding use of broad- and narrow-spectrum agents. Further, each Antibiotic Use Report compares or benchmarks the individual VAMC for which it is prepared to other VAMCs in the same Medical Complexity Group. This approach adapts and expands peer comparison, which has proven effective at reducing inappropriate antibiotic use in outpatient settings."
214958795|NCT02372942|DRUG|Lattoferrin|515 pregnant women using lattoferrin to prevent preterm delivery
214958796|NCT02372942|DRUG|Progesterone|515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
214958797|NCT05233579|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.
214958798|NCT06245798|PROCEDURE|transarterial chemoembolisation|During transarterial chemoembolisation（TACE）, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function
215078860|NCT06527248|DIETARY_SUPPLEMENT|Placebo group|Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
214351672|NCT07107217|DRUG|carboplatin + paclitaxel (CP)|carboplatin AUC 2 and paclitacel 80 mg/m² will be given on day 1 every 12 weeks of the second neoadjuvant phase of the study, IV infusion.
214351673|NCT07125495|OTHER|Suction tootbrush and distiled water|All tooth surfaces, oral mucosa, and the tongue and surrounding area were cleaned every 8 hours (3x1) with distilled water and a suction toothbrush. The aspiration feature of the suction toothbrush enabled oral care and simultaneous aspiration of oropharyngeal secretions.
214351674|NCT07125495|OTHER|suction tootbrush and .12% chlorhexidine gluconate|Every 8 hours (3x1) 15 ml of 0.12% chlorhexidine gluconate oral solution (Adıgüzel, 2015) will be used with a suction toothbrush to clean all tooth surfaces, the oral mucosa, and the tongue. The aspiration feature of the suction toothbrush allows for the aspiration of oropharyngeal secretions during oral care.
214958799|NCT06585085|BEHAVIORAL|In person PA sessions|Group B women will have access to a weekly program of 3 face-to-face PA sessions. The face-to-face sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. They will also be offered at one or more times depending on the number of groups. Locations and times will be specified on the online booking software. Women can only register for 3 sessions per week.
214958800|NCT06585085|BEHAVIORAL|Interactive videoconference PA sessions|Women in Group C will have access to a weekly program of 3 PA sessions via interactive videoconferencing. These sessions will have the same format as the face-to-face sessions with visualization of the APA professional, visualization of the participants (who can also choose to be masked). The PA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 3 sessions per week.
215078861|NCT04599959|DIAGNOSTIC_TEST|Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol|Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
215078862|NCT01888133|BEHAVIORAL|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
215078863|NCT01888133|BEHAVIORAL|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
214351675|NCT07125495|OTHER|Oral care sponge and with 15 ml of 0.12% chlorhexidine gluconate oral solution|All tooth surfaces, oral mucosa, and the tongue and surrounding tongue were cleaned with 15 ml of 0.12% chlorhexidine gluconate oral solution (Adıgüzel, 2015) every 8 hours (3x1) and an oral care sponge used in oral care in the intensive care unit. After oral care, oropharyngeal secretions were aspirated.
215078864|NCT03783468|OTHER|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
215078865|NCT05482620|PROCEDURE|Nordic walking program|Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.
215078866|NCT05482620|PROCEDURE|Educational sessions and usual care|Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
215078867|NCT02663466|PROCEDURE|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
215078868|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 lozenges|In this study, a lozenge formulation containing dairy based S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
214351678|NCT07126925|BEHAVIORAL|Personalized Fall Prevention Program|An intervention package featuring a comprehensive, multidimensional risk assessment using an improved form and a dynamic functional test (Obstacle Physical Activity Ability Test). The assessment guided the development of a personalized prevention plan, including targeted exercises, environmental adjustments, and enhanced patient/family education.
214351679|NCT07126925|BEHAVIORAL|Standard Fall Prevention Care|Standard hospital care for fall prevention, including universal precautions (e.g., clutter-free environment, non-slip footwear) and risk assessment using a standard hospital checklist.
214351680|NCT07127289|BIOLOGICAL|Autologous hematopoietic stem cell infusion|Autologous hematopoietic stem cell infusion (0.5-3.0×10\^6/kg)
214351681|NCT07128186|OTHER|follow-up observation|In this study, no additional interventions were administered to any enrolled participants; only 3-5 years of follow-up observation were conducted, with cognitive status data collected at both baseline and endpoint.
214351682|NCT07127822|DRUG|Iparomlimab and Tuvonralimab|Iparomlimab and tuvonralimab for experimental arm
214351683|NCT07127822|DRUG|First line chemotherapy plus PD-1/PD-L1 antibody|standard first-line chemotherapy（FOLFOX/XELOX/SOX）combined with PD-1/PD-L1 antibody for control arm
214958801|NCT06585085|BEHAVIORAL|In person and by videoconference (mixed format) PA sessions.|Women in Group D will have access to a weekly program of 3 mixed-format PA sessions, with 2 interactive distance learning sessions and 1 in-person session. The in-person sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. Locations and times will be specified on the online booking software. Women can only register for 1 face-to-face session per week. The other 2 sessions will be offered via interactive videoconferencing. These sessions will have the same format as the in-person sessions, with visualization of the APA professional, visualization of the participants. The APA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 2 videoconference's sessions per week.
214958802|NCT01985061|DRUG|BX2|
214958803|NCT01985061|DRUG|BX3|
214351684|NCT07128173|OTHER|Incubator Cover Group|"Incubator Cover Group: Neonatal information form was filled and consent was obtained.~Actigraphy and 24-hour sleep duration were recorded before incubator cover application.The incubators were covered with incubator covers for 24 hours.24-hour sleep durations were recorded again by actigraphy."
214958804|NCT01985061|DRUG|BX4-Suspended|Suspended
214958805|NCT02153151|OTHER|Cytology specimen|Correlative studies
214958806|NCT02153151|OTHER|Laboratory biomarker analysis|Correlative studies
214351685|NCT07128173|OTHER|Control Group|Control Group:Neonatal information form was filled and consent was obtained. Actigraphy and 24-hour sleep duration were recorded. No practice other than routine medical treatment follow-up and nursing care was performed.24-hour sleep durations were recorded again by actigraphy.
214351686|NCT07126821|OTHER|No Interventions|No Interventions
214351687|NCT07127224|DIAGNOSTIC_TEST|Olfactory stimulation|"Olfactory stimulation (sniff test) combined with auditory and somatosensory stimulations during bedside neurophysiological assessments to evaluate neurological prognosis in ICU patients."
214958807|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)|Patients will receive pericapsular nerve group (PENG) block with supra-inguinal fascia iliaca (SIFIC) block.
214958808|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)|Patients will receive pericapsular nerve group (PENG) block with lateral femoral cutaneous nerve (LFCN) block.
214958809|NCT03079414|PROCEDURE|Invasive Electrophysiology Study|Invasive electrophysiology studies will be performed using four catheters placed in the right ventricular apex, the coronary sinus, the His bundle region, and the high right atrium. Standard induction protocols for supraventricular and ventricular arrhythmias will be utilized in the absence and presence of isoproterenol. Long-short ventricular extra-stimuli will also be delivered to screen for bundle branch reentrant ventricular tachycardia. The study is considered observational as the participating sites perform electrophysiology studies in this patient population as part of standard clinical care.
214351688|NCT07126119|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125mg/m\^2 IV will be administered on Day 1 every 3 weeks for 2-3 cycles
214958810|NCT04156906|BIOLOGICAL|D+ RH genotype matched red cell units for transfusion|Chronically transfused patients with SCD and anti-D will receive D+ RH genotyped matched red cell units for transfusion in addition to standard C, E, and K antigen matching and being hemoglobin S negative, which is the Children's Hospital of Philadelphia institutional standard of care for patients with SCD. RH genotyping of donor units will be performed by the New York Blood Center (NYBC) Immunogenetics laboratory.
214958811|NCT05940961|DRUG|Inotuzumab Ozogamicin|intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
214958812|NCT02588092|DRUG|ADCT-301|Intravenous infusion
214958813|NCT06194058|OTHER|rapid sequence anesthetic induction|Rapid sequence induction and intubation (or crash induction) is a process for inducing general anesthesia when the patient is at a high risk of pulmonary aspiration. It aims at minimizing the time between giving the induction drugs and securing the tube, during which period the patient's airway is essentially unprotected.
214351689|NCT07126119|DRUG|Tislelizumab|Tislelizumab 200mg iv will be administered on Day 1 every 3 weeks for 2-3 cycles.
214351690|NCT07126119|PROCEDURE|Radical nephroureterectomy (RNU)|Radical nephroureterectomy (RNU) will conducted after the completion of neoadjuvant therapy.
214958814|NCT04536272|DRUG|Heparin|Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
214958815|NCT04536272|DRUG|LMWH|Administration of LMWH guided by weight and renal function during ECLS.
214958816|NCT01090141|DRUG|Micafungin|100 mg IV infusion over 1 hour
214958817|NCT01090141|DRUG|Micafungin|300 mg IV infusion over 1 hour
214958818|NCT01030718|DRUG|dasatinib|Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
214958819|NCT01294059|DRUG|Milnacipran|50 mg BID Oral x 6 Weeks
214958820|NCT05435781|DRUG|Hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
214958821|NCT05435781|DRUG|Placebo for hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
214958822|NCT00423813|DRUG|placebo|Oral Solution
214958823|NCT00423813|DRUG|Xyrem®|two doses
214958824|NCT01638195|DEVICE|Focused Ultrasound|Focused Ultrasound
214351691|NCT07126184|DIAGNOSTIC_TEST|Extended Cardiac Monitoring|This observational study involved the use of standard cardiac monitoring methods to detect atrial fibrillation in patients initially diagnosed with cryptogenic ischemic stroke. Monitoring techniques included 12-lead ECG, 24-hour Holter monitoring, and implantable loop recorders (ILRs). No experimental interventions were assigned; patients received routine clinical care.
214351692|NCT07127133|DEVICE|Insole and ankle device|Device that is worn as a shoe insole and around the ankle which will measure gait parameters to detect cognitive decline
214351693|NCT07127146|OTHER|PET-MRI exam with administration of [11C]Carfentanil|Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]Carfentanil and will last for 51 minutes in a resting state. The dose will be 250 MBq/kg +-10 %.
214958825|NCT00607659|OTHER|No intervention, only observational|No intervention, only observational
215078869|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 dairy free lozenges|In this study, a lozenge formulation containing dairy free S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
215078870|NCT01588314|DRUG|Gabapentin|gabapentin 100 mg capsules
215078871|NCT01588314|DRUG|placebo|compounded placebo capsules
215078872|NCT03571802|DRUG|Simvastatin|"* The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~* There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
215078873|NCT05346965|BEHAVIORAL|Musical training|The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.
215078874|NCT02117895|PROCEDURE|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
215078875|NCT02117895|PROCEDURE|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
214351694|NCT07127146|OTHER|PET-MRI exam with administration of [11C]Yohimbine|Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]Yohimbine and will last for 70 minutes in a resting state. The dose will be 370 MBq/kg +- 10 %.
214351695|NCT07127354|DRUG|Continue GLP/GIP|Continue GLP-1 or GIP-based therapy as prescribed prior to the procedure.
214958826|NCT05435560|DRUG|Dexmedetomidine|During the imaging scan subjects will receive an initial bolus of dexmedetomidine over 10 minutes. After the bolus has been administered, a constant infusion of dexmedetomidine will be maintained for the remainder of the scan (about 60 minutes).
214958827|NCT05435560|DRUG|Saline|During the imaging scan subjects will receive an initial bolus of saline over 10 minutes. After the bolus has been administered, a constant infusion of saline will be maintained for the remainder of the scan (about 60 minutes).
214958828|NCT02074332|BEHAVIORAL|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight\&obese students Family physical activities Parent involvement
214958829|NCT02074332|BEHAVIORAL|Health education|Knowledge of obesity prevention and control
214958830|NCT05334459|RADIATION|radiotherapy|"Oligometastatic disease (defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems)~* Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc) (if there is, based on institutional practice)~  o ER / PR /Her2 /Ki67 study)~* Collection of CTC.~* Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~* All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~  o Denosumab, Biphosphonate for bone metastasis~* RT to metastatic side (if visible). Continue Systemic therapy~* 12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~* ST will be continued until progression and/or unmanageable toxicity.~* Radiologic evaluation every 3-6-month based on institutional practice."
215078876|NCT01303146|DRUG|rhARSA|intravenous infusion 100U/kg every other week for 18 months
215078877|NCT00221715|DEVICE|femoropopliteal artery bypass|Bypass by autologous saphenous vein
215078878|NCT00221715|DEVICE|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
215078879|NCT00369005|PROCEDURE|Red blood cell transfusion guidelines|
215078880|NCT03122353|DRUG|Calcipotriene and betamethasone suspension|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
215078881|NCT03122353|DRUG|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
215078882|NCT03122353|DRUG|Placebo|vehicle used as placebo
215078883|NCT03216304|DRUG|100 mg safinamide|"Safinamide will be administered as follows:~* Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~* Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~* Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
215078884|NCT03216304|DRUG|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~\- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
215078885|NCT03216304|DRUG|20 mg rosuvastatin calcium period 2|\- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
215078886|NCT03469830|OTHER|SSCP|Insert
215078887|NCT03469830|OTHER|SPMS|Pressure therapy
215078888|NCT03664674|DRUG|OTO-104|Single intratympanic injection of 12 mg dexamethasone
215078889|NCT03664674|DRUG|Placebo|Single intratympanic injection of placebo
214351696|NCT07126197|PROCEDURE|lymphovenous bypass at diseased foot dorsum|A lymphovenous bypass procedure using a lymphangiography dye (Patent Blue V or indocyanine green), 0.2 mL was injected into the skin at the toe webspaces preoperatively. 8,13,14 The paths of lymphatic vessels were traced. On the foot dorsum of the affected limb, a horizontal incision of 2-3 cm was made close to the lymphatic vessel's pathway. Under the surgical microscope, suitable lymphatic and venous vessels were identified, usually located above the deep fascia (on the superficial side, ensuring that the extensor hallucis longus tendon remains unexposed). The coaptation between the lymphatic vessels and venules followed the same principles as those for vascular anastomosis by using higher magnification under the surgical microscope (approximately 20×), finer microsurgical instruments, and 11- or 12-0 nylon sutures.
214351697|NCT07127783|BEHAVIORAL|Active Recovery|Participants will receive postoperative instructions to follow an active recovery protocol focused on increasing activity level, core strength exercises, and pelvic floor exercises focused on urinary and bowel symptoms. Exercises are to be completed twice per day for the 12 weeks following surgery.
214351698|NCT07127783|BEHAVIORAL|Standard Postoperative Instructions|Standard of care postoperative instructions covering incision care, pain control, dietary instructions, and emergency precautions. Also includes guidelines regarding pelvic rest and lifting restrictions.
214351699|NCT07127393|OTHER|Food|Meal with seaweed
214351700|NCT07126366|OTHER|S-PRG Barrier coat|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession or temporary sensitivity due to whitening.
214351701|NCT07126366|OTHER|S-PRG Prophylaxis paste|S-PRG Prophylaxis paste is a bioactive Giomer-based paste containing S-PRG particles that release six therapeutic ions-fluoride, strontium, borate, aluminum, sodium, and silicate each contributing to remineralization, antibacterial effects, and dentin sensitivity reduction.
214958831|NCT04160637|DIAGNOSTIC_TEST|Immediate postoperative PTH serum sampling and cut-off value identification|The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.
214958832|NCT03385551|DRUG|Estradiol|Estradiol or Promestriene depending on the arm
214351702|NCT07127965|BEHAVIORAL|Goal Setting and Exercise Intensity Intervention|Participants' goal-setting and exercise intensity are manipulated based on group assignment.
214351703|NCT07126730|DEVICE|EXOPULSE Mollii Suit + Exercise|First, spasticity will be evaluated using the Modified Ashworth Scale (MAS). Based on this evaluation, the stimulation intensity for each muscle group will be determined and recorded in the system. Once patients put on the EXOPULSE Mollii Suit and the stimulation begins, they will undergo a personalized exercise program including strengthening, balance, and gait training with scheduled rest intervals. All MS patients will undergo treatment three days per week (with at least one day between sessions) for one hour per day over four weeks.
214351704|NCT07126730|DEVICE|EXOPULSE Mollii Suit|First, spasticity will be evaluated using the Modified Ashworth Scale (MAS). Based on this evaluation, the stimulation intensity for each muscle group will be determined and recorded in the system. Patients will wear the suit and receive stimulation while resting for 60 minutes. All MS patients will undergo treatment three days per week (with at least one day between sessions) for one hour per day over four weeks.
214958833|NCT00135590|DIETARY_SUPPLEMENT|Protein pulse-feeding|Dietary protein (80% of daily intake) was consumed in one meal (12.00h)
214351705|NCT07126236|DRUG|Epcoritamab|Patients will receive 12 cycles of Epcoritamab monotherapy.
214351706|NCT07126236|DRUG|Epcoritamab, tafasitamab and lenalidomide|Patients will receive 3 cycles of Epcoritamab monotherapy and then 12 cycles of Epcoritamab, Tafasitamab and Lenalidomide.
214958834|NCT00135590|DIETARY_SUPPLEMENT|Spread diet|Dietary protein was spread over the four meals.
214958835|NCT04883684|OTHER|Personal health wallet service for Chronic Patients in Emergency Department|Patients(caregivers) will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
214958836|NCT00565175|DRUG|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
214958837|NCT00565175|DRUG|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
214958838|NCT00134758|DRUG|Ursodeoxycholic acid|"During 2 years :~* between 40 and 50 kg : 500 mg/day~* between 51 and 75 kg : 750 mg/day~* between 76 and 100 kg : 1000 mg/day"
214958839|NCT00134758|DRUG|Placebo|"During 2 years :~* between 40 and 50 kg : 2 tabs/day~* between 51 and 75 kg : 3 tabs/day~* between 76 and 100 kg : 4 tabs/day"
214958840|NCT04891926|DIAGNOSTIC_TEST|ICIQ FLUTS Questionaires|Questionnaire observing the impact on voiding disfunctions
214958841|NCT04891926|DIAGNOSTIC_TEST|Frequency Volume Chart|Frequency Volume Chart measures the voided volumes and fluid intake during 3 days in order to observe patients bladder capacity, total and nighttime voided volume and voiding frequency
214958842|NCT04891926|DIAGNOSTIC_TEST|Renal Function Profile|The RFP is a 24-hour urine analysis in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. This RFP was collected on a separated day to the FVC. Daytime samples were taken between 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The night-time samples were taken between 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8), and the volume of each interim void, was noted to calculate the 24h, daytime and night-time urine volume and diuresis rate. On each of this 8 samples, creatinine, osmolality, sodium and urea concentration were analysed. Subsequently, the renal clearance of creatinine, solutes, sodium and potassium (Usubst x Uflow / Psubst) and FWC (urine flow - solute clearance) were calculated.
214958843|NCT04891926|DIAGNOSTIC_TEST|Blood Analysis|Blood analysis in order to observ postmenopausal state, osmolalitity and sodium.
214958844|NCT04946526|DIETARY_SUPPLEMENT|Broccoli seed extract|2 capsules, one dose
214351707|NCT07126613|BEHAVIORAL|Mobile Health Intervention to Reduce Alcohol Use Among Young Adults|"The mobile just-in-time adaptive intervention consists of 1) a digital participant dashboard and 2) tailored messages delivered to the participant's cellphone addressing the individual and ecological contexts of alcohol use.~The web-based intervention dashboard includes: 1) a drink counter for participants to log the number and type of drinks (e.g., beer, wine, mixed drink) they consume in a drinking occasion; 2) a calendar which summarizes the number of days on which a participant has consumed alcohol and the number of drinks consumed over the study period, broken out by drink type; 3) a log where participants can set drinking-related goals and update their progress on those goals; and 4) national and local substance use resources.~Participants will receive messages tailored to their drinking situation and ecological context during high-risk drinking times."
214958845|NCT04946526|DIETARY_SUPPLEMENT|Broccoli seed extract with mustard seed powder|2 capsules, one dose
214958846|NCT03494049|PROCEDURE|Veil sparring HoLEP|"Early mucosal incision; lateral to the Veru and proximal to the apical bulge of the adenoma, followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
214958847|NCT03494049|PROCEDURE|Standard HoLEP|Holmium laser enucleation of the prostate in the standard approach described by Elhilali et al 2010
214958848|NCT04125940|DIETARY_SUPPLEMENT|Resync|The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.
214958849|NCT04125940|DIETARY_SUPPLEMENT|Resync + Collagen|17g Collagen + 2g Resync + 1g Carbohydrate
214958850|NCT04125940|OTHER|Placebo|12oz water + food coloring
214958851|NCT04040465|DRUG|Aspirin|Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
214958852|NCT03860766|OTHER|Photobiomodulation|An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
214958853|NCT03848793|DRUG|HS-20004|treatment
214958854|NCT04054674|PROCEDURE|Abutments with flat occlusal scheme preparation restored by lithium disilicate crowns|Clinical trials lacks information about flat occlusal preparation design in case of endodontically treated teeth. Therefore, this is tested during preparation when compared to planer occlusal preparation while the final restoration in both arms is lithium disilicate (e.max) crowns.
214958855|NCT00683306|DRUG|ZD1839 (Iressa)|Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
214958856|NCT04150120|DEVICE|e-health device with application|In this project we focus on eHealth solutions for patients and/or their families in situations where they could benefit from enhanced communication options with specialist staff. In this design space we use a model where a 4G-enabled tablet computer is lent to the families for the length of the study, thus avoiding economic requirements on the families and keeping the equipment uniform. The tablets run an application that enables multiple forms of direct and bi-directional communication in real-time with specialist staff at the hospital. For the staff, the technical situation is different; here we have in earlier demonstrators used web-based solutions accessed with existing computer equipment.
214958857|NCT03883477|DEVICE|Endoscopic Release|Retrograde endoscopic release of the A1 pulley for treatment of trigger finger will be performed using a commercially available device by A.M. Surgical, Inc. This device has been cleared for marketing, sale and use by the U.S. Food and Drug Administration (FDA) for use as an Orthopedic manual surgical instrument based on its similarity in structure and function to previously used devices.
214958858|NCT03883477|PROCEDURE|Standard Open Release|Standard open surgical release of the A1 pulley for treatment of trigger finger.
214958859|NCT01682018|DEVICE|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
214958860|NCT03853291|BEHAVIORAL|PICT Workbook|PICT Workbook: The PICT workbook is a 31-page manual, which includes: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set. Participants in the intervention condition also attended four weekly 30-minute sessions with an interventionist through a combination of online (video observation) and telephone coaching to go over the Workbook.
214958861|NCT03853291|BEHAVIORAL|Information Pamphlet|Pamphlet with information about pain and dementia and links to Alzheimer's Association
214958862|NCT05007171|DEVICE|Very low calorie diet|During 3 weeks in hospital patients will eat prepared very low calorie diet composed of 50-60% complex carbohydrates with low carbo-glycemic index, 20-25% proteins and 25-30% fat
214958863|NCT03610880|DRUG|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
214958864|NCT03610880|DRUG|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
214958865|NCT02069106|DIETARY_SUPPLEMENT|Pro-Omega LDL|
214958866|NCT02069106|OTHER|Placebo|
214958867|NCT00777062|DRUG|VIVITROL (Naltrexone extended-release injectable suspension)|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
214958868|NCT00777062|DRUG|Placebo|Placebo injection at the start of weeks 2 and 6.
214958869|NCT01256099|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
214678807|NCT05805969|OTHER|Accommodating variable-resistance training|"The training was conducted twice weekly for six successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
214678808|NCT05805969|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with juvenile idiopathic arthritis (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
214486776|NCT06873984|OTHER|compression products|"Compression Group (CG):~Participants received individually fitted, round-knit compression stockings with a pressure of 23-32 mmHg (Class 2, RAL-GZG standard).~Compression garments were selected based on circumference measurements taken in the morning to ensure proper fit.~Participants were instructed to wear the stockings for approximately 9 hours per day.~The compression garments were provided by the same manufacturer (Medi GmbH \& Co., Bayreuth, Germany).~Additionally, participants were advised to engage in daily physical activity (walking for at least 20 minutes per day) while wearing compression.~Comprehensive education was provided on skin care, self-manual lymph drainage (simple lymph drainage, SLD), and lymphedema prevention."
214958870|NCT01256099|BEHAVIORAL|Brief Internet-CBT for insomnia, without support|No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
214678809|NCT00745264|DRUG|Diractin|100 mg Ketoprofen to 2 joints
214678810|NCT00745264|DRUG|Diractin|400 mg ketoprofen to 4 joints
214958871|NCT01256099|BEHAVIORAL|Therapist Guided Internet-CBT for depression|An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
215078890|NCT01101971|OTHER|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
215078891|NCT05857033|OTHER|Buccal and direct palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and direct palatal injection
215078892|NCT05857033|OTHER|Buccal and indirect palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and indirect palatal injection
215078893|NCT05857033|OTHER|Buccal and direct palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and direct palatal injection
215078894|NCT05857033|OTHER|Buccal and indirect palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and indirect palatal injection
214958872|NCT04966819|OTHER|Survivorship Care Initiative|"The survivorship initiative will consist of:~(A) Regular meetings with the rectal cancer oncology pivot nurse (IPO). These meetings present an opportunity for patients to discuss any treatment-related distress or late and long-term side-effect.~(B) Identification of a primary care physician. If the patient is not known to a Primary care physician (PCP), the IPO will add the patient to an accelerated waitlist.~(C) Development of an individualized survivorship plan. During meetings with the oncology pivot nurse, a survivorship care plan will be populated, included information on patient risk factors, treatments completed, pathology findings, and future surveillance planned. This document will be reviewed by the treating colorectal surgeon, and will be subsequently shared with the oncology team, the PCP and the patient (if the patient desires).~(D) Educational resources for patients. Patients will be offered educational materials to help address their specific needs."
215078895|NCT02174523|DRUG|40mg lurasidone|
215078896|NCT02174523|DRUG|placebo|
215078897|NCT05327634|OTHER|self-questionnaire|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
214486777|NCT06347809|OTHER|Non-Interventional Study|Non-Interventional Study
214486778|NCT06693076|PROCEDURE|Laparoscopic cholecystectomy|The intervention in this study is urgent, not elective. The conditions for the surgery are therefore different: any time of day, the surgeon on shift, the state of the patients.
214678811|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
214678812|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
214678813|NCT02601781|PROCEDURE|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
214678814|NCT02601781|DEVICE|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
214958873|NCT03658642|BEHAVIORAL|Clinical Decision Support (CDS)|This clinical decision support tool will improve the clinician's ability to identify those with OUD, initiate BUP and refer the patient to ongoing Medication Assisted Treatment (MAT)
214351708|NCT07126093|COMBINATION_PRODUCT|focal high-intensity focused ultrasound therapy combined with standard novel hormonal therapy|The participants in the intervention arm will receive HIFU combined with standard NHT. Depending on the location of the lesion, tumor load and the pathological conditions, hemicglandular ablation or focal ablation was selectively administered. The safe boundary was set at 3mm, with a power of 300W and a pulse width of 30ms. Novel endocrine therapy was given after HIFU treatment
214351709|NCT07126093|OTHER|Standard novel hormonal therapy only|Participants in the control arm will receive standard NHT.
214351710|NCT07127653|OTHER|Retinol-Based Day Cream|A commercially available day cream containing retinol and moisturizing ingredients. Applied twice daily (morning and evening) to the full face for 4 weeks.
214351711|NCT07127653|OTHER|Lotion and Toner Bundle|A skincare regimen including a dermalift toner and a milky lotion. Applied twice daily (morning and evening) to the full face for 4 weeks.
214351712|NCT07126561|DRUG|Trastuzumab Deruxtecan|Do not substitute trastuzumab deruxtecan with trastuzumab or ado-trastuzumab emtansine. Do not administer as an intravenous push or bolus. Trastuzumab deruxtecan is not compatible with sodium chloride 0.9% solution for infusion. During treatment, patients should be observed for infusion-related reactions (IRRs). For additional information on the management of IRRs
214351713|NCT07127120|DIETARY_SUPPLEMENT|Prebiotic fiber blend|"Proprietary blend of 5 prebiotic fibers and normal bar excipients Product name: NeuroFiber Dosage form: Single bar/day~Storage conditions:~The Study Product delivered by Sorridi to patient/subject at the beginning of study. Any remainder will be collected by Sorridi at end of study.~Product is to be stored at room temperature in the patient's/subject's homes.~The bar will be produced and packaged at a licensed contract manufacturer experienced in producing nutritional supplements.~Labelling will be carried out by Sorridi Therapeutics."
214351714|NCT07127276|OTHER|Mobile application GERDCare|Features of GERDCare that support management of GERD
214351715|NCT06940518|DRUG|Ivonescimab|Given by IV
214351716|NCT02639702|DRUG|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
214678815|NCT05087823|DIETARY_SUPPLEMENT|Lipid Challenge|For the lipid challenge, participants consume 100 grams of a long chain triglyceride emulsion in the form of liquid drink, which is the commercially available brand called Calogen, from Nutricia, Inc.
214958874|NCT00098670|BIOLOGICAL|alemtuzumab|Given SC
214958875|NCT00098670|BIOLOGICAL|rituximab|Given IV
214958876|NCT00098670|DRUG|fludarabine phosphate|Given IV
214958877|NCT06224686|OTHER|conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.
214958878|NCT06224686|OTHER|motor imagery based on action observation treatment|First, the therapist explained the purpose and principle of the intervention method to the patient, keeping the surrounding environment quiet and comfortable to avoid the patient's mood fluctuations due to external interference. Then start the treatment, the video recorded in advance was given to the patient to watch, the playback device is a ipad. The content includes lip and tongue muscle relaxation exercises, healthy people eating, chewing, swallowing, drinking and other images. At the same time, the guidance was played, which was consistent with the content in the video. The video was played 3 times consecutively for 30 min each time, once a day for 14 days.
214958879|NCT01187277|BEHAVIORAL|conventional therapy|conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
214958880|NCT01187277|DEVICE|conventional plus robotic gait assisted therapy|individual physiotherapy +individual occupational therapy+ robotic gait assisted therapy
214958881|NCT00232518|PROCEDURE|Infection with hookworm larvae|
214958882|NCT03762681|DRUG|RO7239958|Solution for injection, subcutaneous use (SC).
214958883|NCT03762681|OTHER|Placebo|Sodium chloride solution for injection, SC
214958884|NCT02137226|DRUG|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
214351717|NCT00738777|DRUG|Anastrozole|1 mg,QD,PO
214351718|NCT00738777|DRUG|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
214351719|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
214351720|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
214958885|NCT02137226|DRUG|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
214958886|NCT03290391|OTHER|Rapid ART initiation|The infectionist will streamline the approval with the ultimate goal of starting participants on ART while they are still hospitalized at the City Addiction Hospital.
214958887|NCT03290391|DRUG|Pharmacotherapy for opioid use disorder|Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
214958888|NCT03290391|BEHAVIORAL|Strengths-based HIV case management|Strengths-based case management: 10 sessions over 12 months in which a trained case manager (CM) meets individually with patients to motivate them to engage in HIV medical care by supporting the recognition of their own strengths to make positive changes in their lives and ultimately improve their HIV outcomes.
214351721|NCT05836766|DRUG|Y-6 sublingual tablets|Take Y-6 sublingual tablets for 28 days continuously.
214351722|NCT05836766|DRUG|Placebo tablets of Y-6 sublingual tablet|Take Placebo tablets of Y-6 sublingual tablet for 28 days continuously.
214351723|NCT06963060|DRUG|Gemcitabine nab-PaclitaxelLenvatinibTislelizumab|"Receive Gemcitabine (1000 mg/m² IV on Days 1 and 8) and nab-Paclitaxel (125 mg/m² IV on Days 1 and 8) every 3 weeks.~Take Lenvatinib (4-8 mg orally daily on Days 1-21).~Receive Tislelizumab (200 mg IV on Day 1) every 3 weeks."
214351724|NCT02707354|DEVICE|Probe based confocal laser endomicroscopy (Cellvizio)|"The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data."
214958889|NCT04270695|BEHAVIORAL|blood flow restriction|an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver.
214958890|NCT04270695|BEHAVIORAL|sham blood flow restriction|an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs without inflation. All participants are instructed to perform abdominal draw-in maneuver.
214958891|NCT05462236|DRUG|Tinodasertib|MNK inhibitor
214958892|NCT05462236|DRUG|Pembrolizumab|PD-1 Inhibitor
214958893|NCT05462236|DRUG|Irinotecan|Topoisomerase inhibitor
214958894|NCT00507988|BEHAVIORAL|Complex Problem Solving Training|10 sessions of 45 minutes complex problem solving training over 3 weeks (including 30 minutes of computerized planning and problem-solving training with Plan-A-Day and 15 minutes group session for transfer to everyday situations)
214958895|NCT00507988|BEHAVIORAL|Basic Cognitive Training|10 sessions over 3 weeks of 45 min basic cognitive training (including 45 min computerized training of attention, processing speed, memory)
214958896|NCT00003896|DRUG|cisplatin|
214958897|NCT00003896|DRUG|liposomal doxorubicin|
214958898|NCT00003896|DRUG|paclitaxel|
214958899|NCT02373137|PROCEDURE|DSAEK|
214958900|NCT02373137|PROCEDURE|DMEK|
214351725|NCT02565290|DIETARY_SUPPLEMENT|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
214351726|NCT02565290|DIETARY_SUPPLEMENT|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
214351727|NCT04386681|BEHAVIORAL|Reentry Continuum for Brain Injury (RCBI)|"Pre-Release RCBI Treatment Procedures (BICS and ICAN). BICS: consists of 12 weekly two- hour sessions. Sessions focus on brain injury education, coping skills for the various symptoms of brain injury, depression management, stress management, and self- advocacy.~ICAN: delivered once a week for 6 weeks for 2 hours per session. ICAN primarily focuses on poor perspective-taking and inability to make social inferences about others' behaviors that are related to negative attributions, and employs role playing exercises and a novel perspective-positioning technique to elicit affective and cognitive empathy to alter negative attributions and reduce anger.~Post-Release RCBI Resource Facilitation. Working with their resource facilitator, alongside their corrections case manager, to work on brain injury specific reentry planning, resource, and needs identification."
214958901|NCT02373137|DEVICE|Endoserter|The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
215078898|NCT00794365|DRUG|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
214351728|NCT05445284|BEHAVIORAL|Group education sessions for parents plus usual diabetes care|≥3 in person/virtual group education sessions for parents in addition to usual diabetes care, every 3 months for 12 months
214351729|NCT05445284|OTHER|Usual diabetes care|Usual diabetes care, every 3-month for 12 months
214351730|NCT03044067|OTHER|Pain neuroscience education + Exercise|A session of Pain neuroscience education + Exercise covers the activity, strength and endurance of lower and upper muscles of the extremities. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
214351731|NCT03044067|OTHER|Exercise|A session of exercise covers the activity, strength and endurance of lower and upper muscles of the extremities.
214486779|NCT06692621|DRUG|Oxytocin|Medicines were administered in appropriate doses
214486780|NCT06692621|DRUG|Carbetocin|Medicines were administered in appropriate doses
214958902|NCT02373137|DRUG|Prednisolone|Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
214958903|NCT02373137|DRUG|Ofloxacin|Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
215078899|NCT02131376|PROCEDURE|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
215078900|NCT02131376|PROCEDURE|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
215078901|NCT01839240|DRUG|azacitidine|Given IV or SC
215078902|NCT01839240|DRUG|cytarabine|Given IV
215078903|NCT01839240|DRUG|mitoxantrone hydrochloride|Given IV
215078904|NCT01839240|OTHER|laboratory biomarker analysis|Correlative studies
215078905|NCT01274780|DRUG|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
215078906|NCT01274780|DRUG|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
214958904|NCT02373137|DRUG|Tropicamide|Tropicamide is a prescription drug used to dilate pupils during an eye exam.
214958905|NCT02373137|DRUG|Phenylephrine|Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
214958906|NCT02373137|DEVICE|Jones Tube|The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.
214958907|NCT00100152|DRUG|MK0752, (Notch Inhibitor)|
215078907|NCT05737420|DIAGNOSTIC_TEST|Video call|The on-call neurologist can see and communicate with the patient via live stream video-call.
214351732|NCT04226430|DEVICE|Cytokine aphaeresis|The Cytosorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Before the start of the Cytosorb therapy, adequate anti-coagulation was confirmed when target partial thromboplastin time (PTT) of 60±80 seconds, or an activated clotting time (ACT) of 180±210 seconds was achieved with systemic heparin. Antibiotics were administered after each Cytosorb therapy whenever possible.
214351733|NCT02647112|OTHER|Bladder EpiCheck|Urine test for the monitoring of bladder cancer recurrence
214351734|NCT03150472|DEVICE|Graft Matrix|Both Graft matrix products are supplied sterile, for single use only and packed in vials or a syringe-like applicator. All products consist of the same bone graft particles with the only variants being due to different amounts per package or different containers.
214351735|NCT02522494|BEHAVIORAL|Pamphlet|An educational intervention delivered prior to patients' visits with primary care physicians.
214351736|NCT02522494|BEHAVIORAL|Video|An educational intervention delivered prior to patients' visits with primary care providers.
214351739|NCT01764165|OTHER|Oxygen|oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
214958908|NCT00985686|OTHER|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
214958909|NCT04692116|DEVICE|ExAblate treatment|Subthalamotomy using the ExAblate
214958910|NCT01670045|DRUG|Tocilizumab|Tocilizumab in accordance with the licensed label recommendation.
214486781|NCT06693674|DRUG|Entresto Pill|Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).
214958911|NCT02494648|DEVICE|POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]|CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).
214958912|NCT02494648|OTHER|Control|
214958913|NCT02538406|OTHER|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
214958914|NCT04008888|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Stem Cell Transplant: Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients.
214958915|NCT04008888|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2|Autologous hematopoietic stem cell transplantation :Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day followed collecting CD34+ peripheral blood stem cells . Day 0 Infusion of autologous stem cells. Patients during 3-6 months after the 1st SCT will undergo a 2nd SCT. Patients who had not enough PBSC will undergo a 1st SCT.
214351740|NCT01764165|OTHER|High flow of room air|Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
214351741|NCT00898118|GENETIC|polymerase chain reaction|
214351742|NCT00898118|OTHER|flow cytometry|
214351743|NCT00898118|OTHER|laboratory biomarker analysis|
214351744|NCT00898118|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214351745|NCT03837652|OTHER|Use of bone-borne palatal expander & maxillary osteotomy|Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae
214486782|NCT06693674|OTHER|Placebo|Patients taking placebo tablets will take 1 tablet orally, twice daily
214486783|NCT06044571|OTHER|Prescriptive|Prescriptive A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals, Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs), will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs)will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapist: 40 min).
214486784|NCT06044571|BEHAVIORAL|Behavioral|Behavioral Health coaches have a bachelor's degree and take a 6-8-week certification program. Behavioral Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.
214486785|NCT06693570|OTHER|Intact Fish Skin Graft (IFSG) + Standard of Care|Participants will receive weekly applications of MariGen and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214351746|NCT06635382|OTHER|Universal single bond adhesive|Will be applied and light cured for 20 seconds.
214958916|NCT04008888|DRUG|Melphalan Given IV|conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m\^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes
214351747|NCT06635382|OTHER|DMSO|DMSO application on tooth followed by active application of universal single bond adhesive and light cured for 20 seconds.
214351748|NCT00159211|DRUG|UMULINE NPH|UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
214958917|NCT04008888|DRUG|Fludarabine Injection|conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
214958918|NCT04008888|DRUG|PI and dexamethasone as maintenance therapy|Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
214958919|NCT04008888|DRUG|PI+IMids+Dexamethasone as Consolidated Chemotherapy|Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11\&12 of each 21-day.
215078908|NCT01025362|BEHAVIORAL|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
214351749|NCT00159211|DRUG|pioglitazone|30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
214351750|NCT06781723|BEHAVIORAL|Resistance Exercise|Participants will perform leg press and leg extension immediately prior to ingestion of rice and beans or isolated mixture.
214351751|NCT06781723|DIETARY_SUPPLEMENT|Isolated Mixture|Participants will ingest isolated mixture of crystalized amino acids, maltodextrin, fiber and oil immediately after resistance exercise.
214351752|NCT06781723|OTHER|Rice and Beans|Participants will ingest cooked rice and beans meal immediately after resistance exercise.
214351753|NCT05924646|DIETARY_SUPPLEMENT|Sodium Chloride Capsules|Table salt in slow release capsules.
214351754|NCT05924646|OTHER|Microcystalline Cellulose Capsules|Microcrystalline Cellulose Capsules (Placebo)
214351755|NCT00254254|DRUG|Exenatide - Exenatide - Placebo|Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
214351756|NCT00254254|DRUG|Exenatide - Placebo - Exenatide|Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
214351757|NCT00254254|DRUG|Placebo - Exenatide - Exenatide|Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
214351758|NCT05549401|DRUG|CKD-348(4) F1|QD, PQ
214351759|NCT05549401|DRUG|CKD-348(4) F2|QD, PQ
214351760|NCT05549401|DRUG|CKD-828, D097, D337|QD, PQ
214351761|NCT06041724|DRUG|Envafolimab combined with recombinant human endostatin and first-line chemotherapy|"Envafolimab: 300mg day1, s.c. Q3W; Recombinant human endostatin: 210mg day1, Intravenous pump for 72 hours, Q3W; Temozolomide: 150 mg/m2 d1-5, i.v. Q3W; Cisplatin: 25 mg/m2 d1-3, i.v. Q3W.~All of the above drugs were used for 6 cycles, and then Envafolimab and recombinant human endostatin continued only in patients with no progression in the first stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 2 years."
214351762|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
214351763|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
214351764|NCT03930472|BEHAVIORAL|Market vouchers|Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.
214351765|NCT03045666|OTHER|Exercise program|patients who are stable on Macitentan therapy (received in both groups before enrollment) and will exercise at a pulmonary rehabilitation program twice a week for 12 weeks
214351766|NCT06395662|OTHER|Observational|Search for biomarkers
214351767|NCT03991611|OTHER|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
214351768|NCT03991611|OTHER|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
214351769|NCT03991611|OTHER|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
214351770|NCT03991611|OTHER|6 months follow-up to assess the prevalence of PTSD symptoms|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 items during the telephone follow-up, 6 months after ICU discharge .
214351771|NCT03991611|OTHER|1 year follow-up to assess psychiatric morbidity|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
214958920|NCT00501137|BIOLOGICAL|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
214958921|NCT03092648|BIOLOGICAL|Bronchial basal cell|autologous bronchial basal cell transplantation
214958922|NCT00537290|DRUG|Rituximab|Rituximab 1000mg IV on Days 0 and 15
214351772|NCT02239679|DRUG|Aminolevulinic Acid|20% ALA applied to face for one hour prior to 10 J/cm2 blue light
214958923|NCT00193557|DRUG|Bortezomib|
214958924|NCT04326387|DIAGNOSTIC_TEST|SAMBA II (Diagnostic for the Real World)|Point of care Isothermal-PCR Viral RNA Amplication for virus detection
215078909|NCT01025362|BEHAVIORAL|Standard care|Child Health Services offered standard care
215078910|NCT03403985|DRUG|Calcium Hydroxide (Ca(OH)2)|Ca(OH)2 will be used in this group
214351773|NCT02239679|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
214351774|NCT02239679|DEVICE|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
214351775|NCT02239679|PROCEDURE|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
214351776|NCT01227681|DRUG|G-CSF|G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
214351777|NCT01227681|DRUG|Placebo|Sodium Chloride (NaCl) 0.9 %
214351778|NCT05129826|BEHAVIORAL|the association between periodontitis and malnutrition status|be determine the association between periodontitis and malnutrition status in older adult.
214486786|NCT06693570|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214958925|NCT04326387|DIAGNOSTIC_TEST|Public Health England Gold Standard|Reverse Transcription PCR
214351779|NCT04572048|OTHER|Single-day NRP Training|NRP training course completed in one single day of 8 hours
214351780|NCT04572048|OTHER|longitudinal NRP training|NRP training course completed over one year by attending nine 30-minute modules.
214351781|NCT02102308|OTHER|Exercise|Multicomponent exercise
214351782|NCT02102308|OTHER|Education classes|
214351783|NCT00152776|DRUG|ovaria comp 10 globuli 3 times per day 24 weeks|order of intervention and placebo varies between Groups I-III
214351784|NCT05461222|DEVICE|"Balt Goldballoon"|"Fetal endoscopic tracheal occlusion (FETO) is a procedure where a balloon is placed in the main airway or windpipe of the fetus, to help with the development of the lungs. This is performed using a fetoscope, a small camera that is inserted into the amniotic cavity and deploying the FETO Goldballoon into the fetal trachea."
214351785|NCT02725632|DEVICE|CPAP|The patients on CPAP treatment will be followed-up for 1 month.
214351786|NCT03857659|DIAGNOSTIC_TEST|Point-of-care ultrasound (POC-US)|POC-US evaluation will be conducted using the portable ultrasound machine, which is capable of straight-line measurements for assessment of the amniotic fluid, as well as ellipse measurements for determination of abdominal circumference. POC-US evaluation will be conducted every 4 weeks from 28-36 weeks.
214351787|NCT03857659|DIAGNOSTIC_TEST|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
214351788|NCT03857659|DIAGNOSTIC_TEST|Formal ultrasound|Formal growth ultrasound performed between 36-38.6 weeks by RDMS.
214351789|NCT00231634|DRUG|topiramate|
214486787|NCT06418997|BEHAVIORAL|CBI|CBI sessions follow a detailed manual to teach a group of peers cognitive and behavioral strategies that they may utilize in their daily lives, often based around the cognitive-behavioral model as a teaching tool. CBI aims to develop cognitive-behaviorally-based skills and habits in participants, such as behavioral activation, mood tracking, the identification and reframing of automatic thoughts, and assertion training.
214486788|NCT03740191|OTHER|EPIC questionnaire|The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.
214486789|NCT03740191|RADIATION|kV x-ray images|After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.
214486790|NCT03740191|RADIATION|Conebeam CT|For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.
214486791|NCT02823327|GENETIC|Laboratory Biomarker Analysis|Correlative studies
214486792|NCT02823327|OTHER|Medical Chart Review|Medical chart review is performed
214486793|NCT06828653|DEVICE|Part A First Wear Period: Traditional AFO(s)|Participants are randomized to wear traditionally produced AFOs during Weeks 1 through 3.
214486794|NCT06828653|DEVICE|Part A First Wear Period: Digital AFO(s)|Participants are randomized to wear digitally produced AFOs during Weeks 1 through 3.
214486795|NCT06828653|DEVICE|Part A Second Wear Period: Traditional AFO(s)|Participants wear traditionally produced AFOs during Weeks 4 through 6.
214486796|NCT06828653|DEVICE|Part A Second Wear Period: Digital AFO(s)|Participants wear digitally produced AFOs during Weeks 4 through 6.
214486797|NCT06828653|DEVICE|Part B Long-term Evaluation Period: Traditional AFO(s)|Participants are randomized to wear traditionally produced AFO(s) during Weeks 7 through 14.
214486798|NCT06828653|DEVICE|Part B Long-term Evaluation Period: Digital AFO(s)|Participants are randomized to wear digitally produced AFO(s) during Weeks 7 through 14.
214486799|NCT06062160|OTHER|Therapeutic Touch|Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
214351790|NCT01815268|BIOLOGICAL|HD Vaccine|Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
214958926|NCT04326387|DIAGNOSTIC_TEST|Cambridge Validated Viral Detection Method|Reverse Transcription PCR
214958927|NCT04326387|DIAGNOSTIC_TEST|Radiological Detection|Chest X-ray \& CT Scan detection of viral infection in the lungs
214958928|NCT05022888|DEVICE|regional tissue saturation|tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle. The NIRS probe will be used in these areas.
214958929|NCT05387694|OTHER|Thrombotic risk assessment|Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +/- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.
214958930|NCT04388176|DRUG|C21|C21 as first treatment
214958931|NCT04388176|DRUG|C21|C21 as second treatment
214958932|NCT04388176|DRUG|Placebo|Placebo as second treatment
214958933|NCT04388176|DRUG|Placebo|Placebo as first treatment
214958934|NCT01064362|DRUG|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
214958935|NCT01064362|DRUG|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
214958936|NCT02829385|DRUG|Apatinib and XELOX combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
214958937|NCT04626661|DEVICE|COMET measurement system|Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.
215078911|NCT03403985|DRUG|Mineral Trioxide Aggregate|MTA will be used in this group
215078912|NCT00410319|BEHAVIORAL|Fear-reducing Information|
214351791|NCT01815268|BIOLOGICAL|SD Vaccine|Nursing home residents are allocated to receive standard-dose vaccine.
214351792|NCT01815268|BIOLOGICAL|Free Vaccine|Nursing home facilities are provided free standard-dose vaccine for their staff.
214351793|NCT01815268|BIOLOGICAL|Usual Care|Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
214351794|NCT04879901|DIAGNOSTIC_TEST|surface EMG|surface EMG estimation with Carrying backpacks forward or backward
214351795|NCT01339754|DRUG|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks
214486800|NCT04712903|DRUG|Durvalumab|Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
214351796|NCT01339754|DRUG|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
214486801|NCT04712903|DRUG|Cisplatin|Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
214958938|NCT01966302|DRUG|BPS-314d-MR|15-150 mcg po BID,
214958939|NCT00944632|DRUG|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
214958940|NCT00944632|DRUG|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
214958941|NCT03523858|DRUG|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
214958942|NCT04453410|OTHER|Questionnaire Quality-of-recovery 15 (QoR-15)|Children will use the questionnaire Quality-of-recovery 15 (QoR-15)
214958943|NCT02736708|DEVICE|probe based confocal laser endomicroscopy|real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
214958944|NCT00250809|PROCEDURE|Placement of a central venous catheter|Placement of a central venous catheter
214958945|NCT02787083|DRUG|Mirabegron|
215078913|NCT00410319|BEHAVIORAL|Symptom-based exercise|
215078914|NCT03071484|DEVICE|Transcranial Direct Current Stimulation|The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.
214486802|NCT04712903|DRUG|Etoposide|Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
214486803|NCT04712903|DRUG|Carboplatin|Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
214486804|NCT03741140|DIAGNOSTIC_TEST|Motivation tests|Motivation tests will characterize elementary deficits of motivation
214958946|NCT02787083|DRUG|Placebo|
214958947|NCT02710084|DRUG|Oxytocin|Intranasal oxytocin
214958948|NCT02710084|DRUG|Saline|Placebo
214958949|NCT03210051|DEVICE|Remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
214958950|NCT03210051|PROCEDURE|Endovascular treatment|Endovascular treatment include strategies that used to recanalize the occluded artery. Strategies often used include thrombectomy, intra-arterial thrombolysis, stenting and balloon angiography.
214958951|NCT00275665|DRUG|Valganciclovir|
214958952|NCT02305524|DEVICE|ETView VivaSight SL|Intubation using ETView VivaSight SL
214351797|NCT02573974|OTHER|Samples|Blood samples, muscle biopsy and sample of hair
214351798|NCT01923259|DRUG|Donepezil|Donepezil Hydrochloride tablets,23 mg
214351799|NCT01991626|DIETARY_SUPPLEMENT|micronutrient powder|
214958953|NCT02305524|DEVICE|Macintosh laryngoscope|intubation with macintosh laryngoscope with conventional tube
214958954|NCT00844662|DRUG|Fermagate|Film coated tablet 500mg
214958955|NCT00844662|DRUG|Sevelamer hydrochloride|Tablet 800mg
214958956|NCT03162328|DEVICE|PowerSleep Stim|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
214351800|NCT01991626|DIETARY_SUPPLEMENT|micronutrient powder (containing FeSO4), phytase|
214351801|NCT01991626|DIETARY_SUPPLEMENT|Iron pyrophosphate (FePP)|
214351802|NCT01991626|DIETARY_SUPPLEMENT|Iron sulphate|
214351803|NCT00276471|DEVICE|Implantable pulse generator and electrodes|
214351804|NCT03989466|BIOLOGICAL|Alemtuzumab|Given IV
214351805|NCT03989466|DRUG|Itacitinib|Given PO
214351806|NCT01469533|OTHER|Spinal mechanical manipulation intervention|Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (\<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
214351807|NCT01469533|OTHER|Sham manipulation intervention|Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
214958957|NCT03162328|DEVICE|PowerSleep Sham|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
214958958|NCT03438864|DEVICE|Electrotherapy, interferential current|Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
214958959|NCT03438864|OTHER|Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
214958960|NCT05132790|DRUG|SHR-1316 at a dose 20mg/kg q3w|Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin
214958961|NCT05132790|DRUG|SHR6390 at a dose of 150mg orally, daily|SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT
215078915|NCT04165473|BEHAVIORAL|Training Program for Developing Social- and Personal Resources|"The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants."
214351808|NCT03528538|DIETARY_SUPPLEMENT|AlphaFen fenugreek 400 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
214351809|NCT03528538|DIETARY_SUPPLEMENT|AlphaFen fenugreek 500 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
214351810|NCT03528538|OTHER|Placebo|rice flour in a vegetable/ cellulose capsule
214351811|NCT02047045|PROCEDURE|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
214351812|NCT02047045|DRUG|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 32 weeks.
214958962|NCT05132790|RADIATION|SBRT|radiation therapy for breast cance before surgery.
214958963|NCT00078910|DRUG|exisulind|
214958964|NCT00078910|PROCEDURE|conventional surgery|
214958965|NCT00078910|PROCEDURE|neoadjuvant therapy|
214958966|NCT05916365|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously
214958967|NCT06011824|OTHER|Blood draw|10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)
214958968|NCT04369599|DEVICE|V/Q System|With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.
214351813|NCT03548298|PROCEDURE|ARAT|After confirmation of GERD, participants will undergo to ablation with Hybrid-APC (ARAT). Participant will be admitted to hospital 24 hrs before procedure. Technique consist in ablation with hybrid-APC, submucosal injection of saline solution with methylene blue at 3-4 cm from 60-70% cardias and 1 cm esophageal. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic, esophageal manometry and pHmetry up to 1 year after procedure.
214351814|NCT03565510|DIETARY_SUPPLEMENT|High-Protein Diet|The high-protein diet is composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement.
214351815|NCT03214367|DRUG|LY900014|Administered SC
214351816|NCT03214367|DRUG|Insulin Lispro|Administered SC
214351817|NCT03214367|DRUG|Insulin Glargine|Administered SC
214351818|NCT03214367|DRUG|Insulin Degludec|Administered SC
214351819|NCT02634411|DRUG|8 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days."
214351820|NCT02634411|DRUG|15 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days."
214351821|NCT03508843|BEHAVIORAL|interactive virtual presence|installing the car seat with advice via interactive virtual presence
214351822|NCT03527225|OTHER|Music|The patient's preferred music will be played during the first radiotherapy treatment session from speakers located inside the treatment room. The duration of the music will be 10 to 20 minutes. The music will be turned off at the patient's request if it bothers them. Length of music playing and if the patient requested that it be turned off, will be recorded.
214351823|NCT02421484|BIOLOGICAL|Allogeneic mesenchymal stromal cells|The allogeneic mesenchymal stromal cells will be administered intravenously.
214351824|NCT05597501|BEHAVIORAL|manual-based group interventions|weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis\&logotherapy
214351825|NCT04592770|BEHAVIORAL|Nature based walk therapy|10 minutes stretching exercises followed by walk in nature for 50 minutes
214351826|NCT04592770|BEHAVIORAL|Sit in nature|Sit in nature for 60 minutes
214351827|NCT00765843|DEVICE|orthoses|orthoses are provided for use in standardized shoes that all subjects receive
214351828|NCT01654432|OTHER|Paravertebral Blocks (PVB)|
214351829|NCT04278092|DRUG|Paclitaxel|Paclitaxel 175 mg/m2, q21
214351830|NCT04278092|DRUG|Cetuximab|Cetuximab 400mg/m2 loading dose followed by weekly 250mg/m2
214351831|NCT03555396|BEHAVIORAL|SMART Couples 2|The intervention will consist of 4 sessions with activities designed to strengthen communication and support within the couple to improve adherence to antiretroviral therapy and increase linkage to drug treatment services. The activities are based on cognitive-behavioral therapy. Participants' adherence will be monitored continuously through electronic monitoring devices and surveys completed at baseline and follow-up periods.
214351832|NCT03555396|BEHAVIORAL|Standard of Care|Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
214351833|NCT03878940|DIAGNOSTIC_TEST|Abdominal ´yes-no´ pathway|A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
215078916|NCT02142517|PROCEDURE|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
214351834|NCT03200938|DEVICE|formocresol and zinc oxide.|Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
214351835|NCT03200938|DEVICE|PBS CIMMO cement.|Removal of the coronary pulp from primary molar teeth, use of PBS cement
214486805|NCT06689995|OTHER|Bio-immune Capsule|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days Dose: 100 mg
214486806|NCT06689995|OTHER|Placebo|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days
214486807|NCT06631131|DEVICE|Distalization with clear aligners supported by Class II elastics|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. ). In group 1, with the beginning of the movement of the upper first molars, Class II intermaxillary elastics were used from precision cuts of the upper canines to the buttons on the lower first molars for supporting distalization movement.
215078917|NCT02142517|PROCEDURE|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
214351836|NCT05078190|OTHER|Social Determinants of Health|The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
214351837|NCT06279182|BEHAVIORAL|Barre Stretching Intervention|The Barre stretching intervention will consist of a 15-minute recorded video session with static and isometric movements focused on the hands, wrists, shoulders, and neck combined with breathing exercises throughout each movement. A 15-minute Barre stretching video will be selected for this study because static and isometric stretching should be held for 10-15 seconds per movement and repeated 2-3 times for increasing blood flow and circulation which can improve heart rate variability (HRV), increase muscle suppleness in preparation for muscle activation through patient care, and reduce stress levels through regulation of the rate, depth, and pattern of breathing. The duration of 15-minutes provided the participants with adequate time to complete each stretching movement for a total of 45 seconds with 15 seconds rest between movements. There will be fifteen targeted stretching movements focused on the hands, wrists, shoulders, and neck region.
214958969|NCT05000866|BEHAVIORAL|Communication skills training video|The communication skills training video component is designed to be self-delivered. Four couples are depicted in separate scenes discussing HIV testing, drug use, sexual agreements, and drug use during sex. Each scene is viewed twice. In the initial viewing, the couple in the video makes one or more communication errors. The scene is subsequently viewed a second time and the couple utilizes more effective communication skills, resulting in a more adaptive resolution. Each scene is introduced by a narrator who points out communication errors and orients viewers to skills utilized in adaptive versions of each scene.
214958970|NCT05000866|BEHAVIORAL|Drug use module|The substance use module is administered after step 5 of CHTC and prior to the delivery of rapid HIV-test results. The couple was first asked to fill in a calendar for the past 30 days, indicating each day on which either member used drugs or consumed alcohol. Completion of the calendar is done through an ACCESS database to facilitate remote intervention delivery. After completion of the calendar, the HIV tester asked a series of debriefing questions designed to elicit the couples' perspective on their use, establish the couple's goals and limits for drug use, and make plans to achieve these goals.
214958971|NCT04767854|BEHAVIORAL|OA school|Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
214351838|NCT00709280|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
214351839|NCT00709280|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
214351840|NCT03512340|DRUG|SRF231|SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
214351841|NCT05703282|DRUG|AD-104-A|PO, Single-Dose, AD-104-A
214486808|NCT06631131|DEVICE|Distalization with clear aligners supported by miniscrew|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. In group 2, IZC miniscrews were inserted in the IZC region between the upper molars in both sides before first molar movement started. The same intramaxillary elastics were used from precision cuts of the upper canines to the IZC miniscrew for supporting distalization movement.
214486809|NCT05244317|DEVICE|cast|the cast of the upper limb from just below elbow joint to the knuckle of fingers
214958972|NCT04767854|OTHER|Virtual Training mobile health application|Individually tailored home exercise programs delivered through a mobile health application
214958973|NCT04767854|OTHER|Usual care|Individually tailored exercise programs conducted in weekly supervised individual or group sessions
214351842|NCT04770714|DIAGNOSTIC_TEST|Breast MRI|Standard of Care Breast MRI
214486810|NCT05244317|DEVICE|splint|Removable splint
214958974|NCT05078749|OTHER|Exercise training group|A regular advanced exercise program will be given and followed.
214486811|NCT06630780|RADIATION|Head and Neck Cancers|All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.
214678816|NCT05087823|DIETARY_SUPPLEMENT|Glucose Challenge|For the glucose challenge, participants consume 75 grams of glucose in 200 milliliters of water, which is the World Health Organization (WHO) recommended drink for the Oral Glucose Tolerance Test.
214678817|NCT05087823|DIETARY_SUPPLEMENT|Mixed Meal Challenge|For the mixed-meal challenge, participants consume 237 milliliters of the Ensure Enlive nutrition drink , which contains 11 grams of fat, 22 grams of sugar and 20 grams of protein.
214958975|NCT05078749|OTHER|Control training group|Basic exercises will be given at the beginning and will do the same exercises
214958976|NCT00000841|DRUG|Indinavir sulfate|
214958977|NCT00000841|DRUG|Lamivudine|
214958978|NCT00000841|DRUG|Stavudine|
214958979|NCT00000841|DRUG|Zidovudine|
214958980|NCT00282152|DEVICE|B-STN DBS|Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
214958981|NCT00282152|DRUG|Optimal drug therapy|The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
214958982|NCT03301831|BEHAVIORAL|Resourcefulness Training|Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
214958983|NCT01084213|DRUG|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
214958984|NCT01084213|DRUG|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
214958985|NCT00614757|DRUG|N-acetylcysteine 20% 4ml|N-acetylcysteine 20% 4ml
214958986|NCT00614757|DRUG|N-acetylcysteine 20% in 4 ml|N-acetylcysteine 20% in 4 ml
214958987|NCT01124370|DEVICE|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
214351843|NCT04770714|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|Standard of Care Contrast Enhanced Mammography
214351844|NCT04117087|DRUG|KRAS peptide vaccine|"1. KRAS peptide vaccine will be administered on cycle 1 (days 1, 8, 15) and R-Cycle 2 Day 1 (R-C2D1). Boost vaccinations with will be administered every 28 days at Reinduction cycle 5, 7, 9, 13. Extended vaccinations will be administered on Reinduction cycles 15 to 18, 19 and beyond (180 days ± 30 days for a total of 5 years on study.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
214958988|NCT01538537|DRUG|rigosertib sodium|ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
214958989|NCT00082095|DRUG|Pegylated liposomal doxorubicin|Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.
214958990|NCT00082095|DRUG|Capecitabine|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
214958991|NCT02760121|DRUG|Acetazolamide|
214958992|NCT02760121|DRUG|Methazolamide|
214958993|NCT02760121|DRUG|Placebo|
215078918|NCT05287841|PROCEDURE|Batten batten graft|The batten grafts are autologous grafts from the patients' own tissue, produced from nasal septal quadrangular cartilage. This will be obtained during the septoplasty portion of the procedure. The batten graft will be used to stabilize the internal nasal valve and prevent nasal valve collapse on inspiration.
214351845|NCT04117087|DRUG|Nivolumab|"1. Nivolumab will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of each 21 day cycle. Boost Phase will be administered every 28 days on cycles 5 thru 14.~2. Drug: 3mg/kg IV, 480 mg IV"
214351846|NCT04117087|DRUG|Ipilimumab|"1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of Cycles 1 and 3 of the study.~2. Drug: 1mg/kg IV"
214351847|NCT03913364|DIETARY_SUPPLEMENT|Probiotic|B. bifidum 900791-containing ice cream
214958994|NCT00489437|DEVICE|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
214351848|NCT03913364|DIETARY_SUPPLEMENT|Placebo|Placebo ice-cream
214351849|NCT03599063|BIOLOGICAL|PF-06946860|PF-06946860 administered subcutaneously
214958995|NCT00489437|PROCEDURE|Clinical Prediction Score-HIT Score Card|"1. clinical prediction rule~2. rapid immunoassay"
214958996|NCT04013880|DRUG|CDA Inhibitor E7727/Decitabine Combination Agent ASTX727|Given by mouth
214958997|NCT04013880|DRUG|IDH-1 Inhibitor FT-2102|Given by mouth
215078919|NCT05287841|PROCEDURE|Septoplasty|A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.
215078920|NCT05287841|PROCEDURE|Inferior Turbinate Reduction|The bilateral inferior turbinates will be surgically ablated.
214351850|NCT03599063|OTHER|Placebo|Placebo, administered subcutaneously
214351851|NCT04829344|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
214351852|NCT04829344|DRUG|Placebo|Placebo Topical Ophthalmic Solution
214351853|NCT05935501|DEVICE|Formaderm Young|Dermal filler injection to facial areas.
214351854|NCT05935501|DEVICE|Restylane|Dermal filler injection to facial areas.
214351855|NCT04992715|DIAGNOSTIC_TEST|[99mTc]-NM01 SPECT/CT|Technetium-99m radiolabelled anti-PD-L1 single-domain antibody (NM01) single-photon emission computed tomography (SPECT)/computed tomography (CT)
214351856|NCT06060691|DRUG|Kaempferol|Kaempferol
214351857|NCT01847846|DEVICE|CPAP mask - prototype|prototype mask, wore for all sleeps for 4 and 8 weeks (as randomly selected). Mask to be used in conjunction with participant's usual prescribed CPAP settings.
214351858|NCT06503276|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm
214351859|NCT06503276|RADIATION|Ultra-low dose radiotherapy|2 Gy radiotherapy will be administerd twice in the first cycle
214351860|NCT00448539|DRUG|Rufinamide|Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
214351861|NCT02103439|DRUG|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
214351862|NCT02103439|DRUG|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
214351863|NCT02606838|DEVICE|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
214351864|NCT00426504|PROCEDURE|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
214351865|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied once daily for six weeks
214351866|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied twice daily for six weeks
214351867|NCT02186119|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
214351868|NCT02186119|DRUG|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
214351869|NCT02186119|OTHER|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
214351870|NCT02105506|DRUG|Tachosil patch|
214351871|NCT02485470|OTHER|MPACT|Maintaining Physical Activity during Cancer Treatment
214486812|NCT06632028|OTHER|artificial intelligence assisted spinal rehabilitation|In artificial intelligence-based rehabilitation, it is more advantageous compared to other treatment methods in terms of the fact that technology applications can be designed according to the level and abilities of the individual and that the parameters such as duration, intensity, difficulty and speed of the treatment can be flexibly configured for the therapist and the patient.
214678818|NCT02722577|PROCEDURE|Radio-frequency Ablation|A procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats.
215078921|NCT04694352|OTHER|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
215078922|NCT04694352|OTHER|Conventional Physical therapy|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour"
215078923|NCT01825395|DRUG|3, 4-Diaminopyridine|
215078924|NCT01823783|OTHER|Muscle biopsy|Muscle biopsy
215078925|NCT03647410|DEVICE|lumbopelvic fixation|Sacral fractures fixed with lumbopelvic fixation or novel adjustable plate were divided into two groups. Surgical time, intraoperative blood loss, frequency of intraoperative fluoroscopy, reduction quality, related complications, and functional outcome were reviewed.
215078926|NCT03932864|BIOLOGICAL|MGTA-145|MGTA-145 will be given in various doses intravenously
215078927|NCT03932864|BIOLOGICAL|plerixafor|240 µg/kg subcutaneously
215078928|NCT03932864|BIOLOGICAL|Placebo|Placebo will be given in various doses intravenously
215078929|NCT05901480|GENETIC|OTOV101N+OTOV101C Injections|The gene therapy of OTOV101N+OTOV101C injection via intracochlear injection.
214351872|NCT04955639|OTHER|Control|Standard of Care - Control Smoking Cessation Program
214351873|NCT04955639|OTHER|Pivot|Pivot Program Smoking Cessation Program
214351874|NCT04447404|DRUG|DUR-928|IV infusion
214351875|NCT04447404|DRUG|Placebo|IV infusion
214351876|NCT05509829|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy using PICO14.
214351877|NCT01369342|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
214351878|NCT01369342|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
214351879|NCT01369342|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
214351880|NCT06495775|DEVICE|quickfact|fecal sampling
214678819|NCT00396227|DRUG|vildagliptin|vildagliptin as add-on to metformin
215078930|NCT00937404|BIOLOGICAL|Poliorix|All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
215078931|NCT02853812|OTHER|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
215078932|NCT03150576|DRUG|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
215078933|NCT03150576|DRUG|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
214351881|NCT01816594|DRUG|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
214351882|NCT01816594|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
214351883|NCT01816594|DRUG|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
214351884|NCT01816594|DRUG|BKM120 Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
214351885|NCT01951430|DRUG|Antibiotic and antifungal drugs|
214351886|NCT01643694|BEHAVIORAL|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
214351887|NCT03905655|DRUG|Placebo Oral Tablet|Number of placebo tablets administered orally depends on the arm
214351888|NCT03905655|DRUG|Nitazoxanide|Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm
214351889|NCT01089972|DEVICE|22 gauge catheter|radial artery cannulation using 22 gauge catheter
214351890|NCT01089972|DEVICE|20 gauge catheter|radial artery cannulation using 20 gauge catheter
214958998|NCT00616447|DEVICE|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
214958999|NCT00616447|DEVICE|placebo sham|Sham treatment will mimic active treatment mentioned above.
214959000|NCT03095352|BIOLOGICAL|Pembrolizumab|200 mg Given IV
214959001|NCT03095352|DRUG|Carboplatin|Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
214959002|NCT03095352|BIOLOGICAL|Trastuzumab|For HER2+ patients: IV every 3 weeks using standard approved dosing
214959003|NCT06658808|BEHAVIORAL|Promoting Community Conversations About Research to End Suicide|Promoting Community Conversations About Research to End Suicide (PC CARES) trains local community health workers to facilitate a series of five 3-hour Learning Circles (LCs) over \~6 months to develop a 'community of practice' (CoP), whereby trusted adults of youth (a) learn about SPBPs; (b) tailor the SPBPs to their culture and community; (c) build cross-sector relationships (parents, teachers, etc.), and (d) do more to prevent suicide. Each session shares evidence-based, actionable ways to enhance social support, reduce harm/risk, and promote help seeking, which participants adapt and apply in their daily interactions with youth.
214959004|NCT05817721|DRUG|Proton pump inhibitor|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not
214959005|NCT05817721|DEVICE|LAMS-implantation|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis
214959006|NCT03268005|DRUG|Faster-acting insulin aspart|Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
214959007|NCT03268005|DRUG|Insulin aspart|Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
215078934|NCT02979509|OTHER|Endoscopic ultrasound- (EUS) guided tissue sampling|EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
214351891|NCT03898206|OTHER|Breaking up sitting with walking breaks|See Breaking up sitting with walking breaks arm description
214351892|NCT03898206|OTHER|Prolonged sitting|See Prolonged sitting arm description
214351893|NCT01334801|PROCEDURE|Blood Draw|"Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:~1. BNP (Brain Natriuretic Peptide)~2. (PFA) Platelet Function Analyzer 100~3. von Willebrand Factor (vWF) antigen~4. (vWF) multimers~5. (vWF) \*activity by latex aggregation~6. Plasma stored for development of new testing approaches"
214351894|NCT01064739|DIETARY_SUPPLEMENT|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
214351895|NCT01064739|OTHER|Fixed Sodium Diet|Fixed sodium low monoamine diet
214351896|NCT05762835|BEHAVIORAL|Virtual family-centered rounds (FCR)|"Parents will be given the option to join FCR virtually or in-person; this intervention is changing the behavior of how providers deliver healthcare and how parents engage in their child's care.~The NICU team members will use a computer with a speaker and pan-tilt-zoom camera, mounted on a stand with wheels to launch telehealth connections using the secure application called ExtendedCare. From within this telehealth connection, a NICU team member will send an electronic message (e.g. via text or email) to the subscribed parent(s) and wait for the parent to join the visit to establish a secure videoconference. The message to the parent includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. FCR will then proceed in usual fashion with the NICU team members and - if in attendance - parent(s)."
214351897|NCT04287023|OTHER|individual physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - individual
214678820|NCT00396227|DRUG|thiazolidinedione (TZD)|TZD add-on to metformin
214351898|NCT04287023|OTHER|group physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - groups of 10 patients
214351899|NCT02742948|DRUG|ceftriaxone|IV ceftriaxone (2g) will be given to all participants
214351900|NCT02322957|DRUG|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
214351901|NCT05940532|DRUG|Sugemalimab and Chemotherapy|"Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years."
214351902|NCT03667053|DRUG|dasiglucagon|glucagon analog
214351903|NCT03667053|DRUG|placebo|placebo for dasiglucagon
214351904|NCT03667053|DRUG|GlucaGen HypoKit|native glucagon
214351905|NCT02202226|DRUG|Lu AF35700|
214351906|NCT02202226|DRUG|Placebo|
214351907|NCT01292928|DEVICE|Stent implantation|Stent implantation during the index procedure.
214351908|NCT00130533|DRUG|Capecitabine|
214351909|NCT02468427|OTHER|hands-on teaching|Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
214351910|NCT02468427|OTHER|Frontal teaching|Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
214351911|NCT01602887|DRUG|PD-0332991|isethionate hard capsule, 125 mg, single dose
214351912|NCT01602887|DRUG|PD-0332991|"freebase hard capsule with a small particle size, 125 mg, single dose"
214351913|NCT01602887|DRUG|PD-0332991|"freebase hard capsule with a large particle size, 125 mg, single dose"
214351914|NCT01602887|DRUG|PD-0332991|oral solution, 50 mg, single dose
214351915|NCT00944138|BEHAVIORAL|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
214351916|NCT03952832|DRUG|Leflunomide|Given PO
214351917|NCT03952832|OTHER|Quality-of-Life Assessment|Ancillary studies
214351918|NCT03952832|OTHER|Questionnaire Administration|Ancillary studies
214351919|NCT02139033|DRUG|Retaine™|
214351920|NCT02941302|PROCEDURE|Detecting of Biological Borders of Gliomas|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
214351921|NCT00568529|DRUG|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
214351922|NCT06061510|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids|Participants in the intervention group took fish oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
214351923|NCT06061510|DIETARY_SUPPLEMENT|corn oil|Participants in the placebo group took corn oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
214351924|NCT02105363|OTHER|measure of skin movement on surface of the back|
214351925|NCT02105363|OTHER|Measurement of skin movement on surface of back|
214351926|NCT03263429|DRUG|Glutaminase Inhibitor CB-839|Given by mouth
214351927|NCT03263429|BIOLOGICAL|Panitumumab|Given by vein
214351928|NCT03263429|DRUG|Irinotecan Hydrochloride (phase I only)|Given by vein
214351929|NCT03263429|OTHER|Laboratory Biomarker Analysis|Correlative studies
214351930|NCT03263429|OTHER|Pharmacological Study|Correlative studies
214351931|NCT03263429|DEVICE|Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans|During phase II at baseline and day 28 of cycle 1
214351932|NCT03305120|OTHER|pain VAS evaluation|each patient has to answer to a questionnaire about pain
214351933|NCT04117932|DRUG|Ustekinumab|Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
214351934|NCT01605617|DRUG|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
214351935|NCT01605617|DRUG|Placebo|PTNS + placebo for 12 weeks
214351936|NCT01605617|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
214351937|NCT03286374|BEHAVIORAL|Occupational rehabilitation|"The participants in the occupational rehabilitation program get both practical and theoretical intervention in groups. Four main interventions; cognitive therapy, physical activity, diets and training in work-oriented approach. The rehabilitation stay is as followed:~1. Four weeks with an institutional stay at Muritunet (BL)~2. Follow-up;~   1. Eight weeks, telephone contact between therapist at Muritunet and the participant.~  2. 16 weeks, video conference on SKYPE between all the participants and a therapist. Lecture on diets.~  3. 28 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T1)~  4. 40 weeks, telephone contact between therapist at Muritunet and the participant.~  5. 52 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T2)"
214959008|NCT03268005|DRUG|Insulin degludec|Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
214959009|NCT03268005|DRUG|Metformin|Only participants who took metformin before the study should take metformin tablets, same dose as before the study
214959010|NCT05211141|DEVICE|HLS KneeTec Deep Dish|total knee arthroplasty with HLS KneeTec Deep Dish prosthesis
214959011|NCT07002307|OTHER|Warm water at 35 oC|The placebo for the control group
214959012|NCT07002307|OTHER|Coffee|Instant coffee, Nescafé Gold Blend, manufactured by Nestlé Coffee Brand, Nestlé Global
214959013|NCT07002307|OTHER|Honey-sweetened coffee|Instant coffee plus raw dark amber honey produced by Apis mellifera adansonii
214959014|NCT07002307|OTHER|Green tea|Qualitea Natural Green Tea, packed by Qualitea Ceylon (PVT) LTD
214959015|NCT07002307|OTHER|Honey-sweetened green tea|Green tea plus honey
214959016|NCT07002307|OTHER|Black tea|Lipton Yellow Label Black Tea
214351938|NCT02935335|DRUG|Menotrophin|
214959017|NCT07002307|OTHER|Honey-sweetened black tea|Black tea plus honey
214351939|NCT02234531|DEVICE|EVER TEACHER|"The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment."
214351940|NCT02234531|DEVICE|NEVER TEACHER|The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
214351941|NCT03721991|DIETARY_SUPPLEMENT|Gama amino butyric acid (GABA)|food supplement Gama amino butyric acid (GABA) as capsules
214351942|NCT03721991|DIETARY_SUPPLEMENT|placebo|matching placebo
214351943|NCT01210391|OTHER|Extensively hydrolyzed whey infant formula|New hydrolyzed infant formula.
214959018|NCT06337292|DEVICE|Incisional Negative Pressure Wound Therapy (NPWT)|Participants in the treatment group will be standardized and will receive incisional NPWT using the any incisional VAC system that can apply 75-125mmHg continuous suction to the incision. The VAC sponge will be placed over the surgical wound at least 2cm in width and \>3cm in length.
214959019|NCT06880874|DRUG|Enlicitide|Oral Tablet
214351944|NCT01210391|OTHER|Extensively hydrolyzed casein infant formula|Commercially available infant formula.
214351945|NCT04760093|DIETARY_SUPPLEMENT|Low polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.
214351946|NCT04760093|DIETARY_SUPPLEMENT|High polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.
214351947|NCT05771753|OTHER|Stretching Exercises|6 stretching exercises 2 repetitions x1 set, 3 days/week and targeted muscles stretching (Lower Back, Lower limb)
214351948|NCT05771753|OTHER|Dynamic core stabilizing exercises|This group received core stabilizing exercises 2 repetitions x1 set, 3 days/week and the targeted muscles were abdominals, lower back, and lower limb.
214959020|NCT06474273|DRUG|Methylprednisolone|IV Methylprednisolone
214959021|NCT06474273|DRUG|Prednisone|Oral prednisone augmentation
214959022|NCT06736899|DEVICE|Orbital Atherectomy System Treatment|Percutaneous coronary intervention of a calcified bifurcation coronary lesion with balloon angioplasty followed by drug eluting stent. Selection of balloon type is at operator´s discretion. Baseline and post dilation OCT will be performed.
214959023|NCT06736899|DEVICE|Balloon System Treatment|Percutaneous coronary intervention of a calcified bifurcation coronary lesion with Orbital Atherectomy followed by drug eluting stent. Baseline and post dilation OCT will be performed.
214959024|NCT00399295|DRUG|Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.|
214959025|NCT03057717|OTHER|2D ultrasound assessment|2D ultrasound assessment of fetal thymus size with measurements of the maximum transverse diameter and thymus perimeter
214959026|NCT03391804|DRUG|ALLN-177|ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks
214959027|NCT05140252|BEHAVIORAL|Breast cancer decision aid|The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.
214959028|NCT01857804|DRUG|Amoxicillin|In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
214351949|NCT06111716|OTHER|Mindfulness- Based Childbirth Education|Mindfulness- Based Childbirth Education Group includes; Women were given eight-week birth preparation training. In this training, in addition to information about birth, mindfulness, mindfulness attitudes and practices, mindfulness in daily life, mindfulness in pregnancy and postpartum period, mindfulness breastfeeding and meditation practices were included.
214959029|NCT01857804|DRUG|Chlorhexidine gluconate|The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
214959030|NCT01857804|DRUG|Saline|The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
215078935|NCT04854031|DEVICE|Cochlear Implants|Individuals with cochlear implants will be tested on their hearing ability. Auditory recordings of speech will be played to participants from a loudspeaker. Recordings will be edited to add competing noise sources and to adjust talker voice pitch. Synthetic sounds will be manipulated to control auditory cue salience in detection tasks.
215078936|NCT04410666|OTHER|Green Tea mouthwash|"an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C, in sterile glass containers.~Each application was 10 ml. applied for 1 minute."
215078937|NCT04410666|OTHER|Placebo Mouthwash|distilled water
214959031|NCT06840041|DIAGNOSTIC_TEST|Vaginal swab and culture|Participants will undergo vaginal swab collection both pre-operatively, immediately prior to the cesarean section, and post-operatively, within a defined timeframe after the procedure. The swabs will be collected using sterile swabs, following standardized procedures to ensure accurate sampling of the vaginal microbiota. The collected samples will then be sent to a designated laboratory for culture and analysis. This process will identify and characterize the bacterial composition of the vaginal microbiota, allowing researchers to investigate potential correlations between specific microbial profiles and the development of post-cesarean section wound infections
214959032|NCT06795243|PROCEDURE|PAIN NEUROSCIENCE EDUCATION AND THERAPEUTIC EXERCISE PROGRAM|"PAIN NEUROSCIENCE EDUCATION~1\. Introduction to the knowledge of pain in the XXI century. Pain as an alarm system.~Types of pain. Differences between acute and chronic pain. 3. Chronic pain. Concepts of kinesiophobia, catastrophism and fear avoidance, self-determination and neuroplasticity.~4\. Main pain management tools based on scientific evidence. 5. . Transtheoretical model of change. Adherence to treatment, importance as a determinant in health.~6\. Messages for home. Strategies of active coping in the maintenance stage.~THERAPEUTIC EXERCISE PROGRAM 10-min warm-up. Joint mobility exercises with dual task or gamification. 30-min main part. Sequence of balance work between strength and body flexibility dosed according to the specific needs of each participant.~10-min cool down including breathing exercises and motor imagery. Home exercise program: walking (150 minutes in total, 3 days alternating with the face-to-face sessions)."
214959033|NCT06795243|PROCEDURE|USUAL CARE|"The treatment provided is mainly pharmacological, adjusted to the symptomatic profile of theses patients.~Conventional medical care is based on hormonal, pharmacological and/or surgical treatment and is carried out on an individualized basis depending on the severity of the disease and the patient's needs, especially in matters of desire to become pregnant. Surgical treatment is carried out when pharmacological therapy (hormonal or anti-inflammatory) is ineffective or involves adverse events."
214959034|NCT06854185|BEHAVIORAL|Paso Program|The Paso Program is a behavioral weight loss program. It consists of a series of 16 one-hour-long semi-structured group counseling sessions led by a health educator every 1-2 weeks over 26 weeks. Each session has a curriculum with a counselor's guide and patient facing materials, covers specific topics (eating, physical activity, behavioral change strategies). Teaching methods include discussions, practice activities, demonstrations. The program is delivered to groups of 8 to 14 participants, classes are offered primarily in-person with the option of virtual attendance.
214351950|NCT06111716|OTHER|Information-Based Birth Education|In the Information-Based Birth Education Group, women were given 4-week (4 hours per week) birth preparation training. The education given was not based on a philosophy or method.
214351951|NCT06270966|DEVICE|Virtual Reality Cognitive Remediation|"Participants will undergo a 3-months cognitive remediation program using fully immersive VR with two sessions per week. Each session will last a maximum of sixty minutes and will be supervised by expert health professionals. The experimental group participated in an immersive VR-based CR program using the CEREBRUM software designed by clinicians and experts specializing in cognitive rehabilitation.~CEREBRUM provides 52 exercises: Attention, Working Memory, Memory and Learning and Cognitive Estimates. The intervention included 24 sessions."
214351952|NCT03842657|COMBINATION_PRODUCT|anticoagulation of the dialysis circuit|Each patient included in this study will receive two heparin-free dialysis sessions with heparin-grafted membrane (control group) or RCA with calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance (experimental group), alternatively
214959035|NCT00357890|DEVICE|Insulin pump therapy|CSII initiated within 1 month of diagnosis
214959036|NCT00357890|DRUG|Multiple daily injections using insulin glargine + rapid acting analog|MDI as control
214959037|NCT06799078|OTHER|Observation while participants receive treatment by their primary care provider|Participants complete a consultation with a psychiatrist who makes some recommendations for the treatment of their depression. The participant's primary care provider decides whether to implement some of these recommendations.
214959040|NCT00845676|DRUG|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
214959041|NCT01892904|DRUG|EE20/DRSP(BAY86-5300)|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
214959042|NCT06891833|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
214959043|NCT06891833|DRUG|Pertuzumab|Administration by intravenous infusion for a cycle of 3 weeks.
214959044|NCT06891833|DRUG|Taxane|Administration by intravenous infusion for a cycle of 3 weeks.
214351953|NCT03806270|DRUG|Midazolam|Demizolam 15mg/ml ampules, given orally with cherry juice
214351954|NCT03806270|DRUG|Hydroxyzine Dihydrochloride|Atarax 2mg/ml syrup, given orally
214351955|NCT03552874|OTHER|The Performance of Upper Limb Questionnaire (PUL)|
214959045|NCT05635097|BEHAVIORAL|Motivational Interviewing counseling on the Mediterranean diet and weight checks at regular intervals|Each participant will meet virtually on Zoom with the DNP project leader and receive 1:1 counseling on pairing the Repnho smart scale and tape measure with the Renpho application. The expectations of the weight management program will be explained in detail during the first session, which will last one hour (session one= week zero). The weight loss goal will be at least 1-2 pounds per week as recommended by the Centers for Disease Control and Prevention (CDC) (2022).
214959046|NCT02559726|PROCEDURE|Echocardiography (TEE)|
214959047|NCT02559726|DEVICE|Magnetic resonance imaging (MRI) with gadolinium enhancement|
214351956|NCT00845663|DRUG|Certolizumab pegol|Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
214351957|NCT00845663|DRUG|Certolizumab pegol|Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
214351958|NCT00820833|OTHER|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
214351959|NCT00820833|OTHER|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
214351960|NCT00622128|BEHAVIORAL|Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients
215078938|NCT05875753|DIAGNOSTIC_TEST|68Ga-FAPI-FS PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-FAPI-FS. The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-FAPI-FS administration."
214351961|NCT06095570|DRUG|Ciprofol|For induction of anesthesia, an experimental dose of ciprofol was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
214351962|NCT06095570|DRUG|Remimazolam|For induction of anesthesia, an experimental dose of remimazolam was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
214351963|NCT06579742|DIETARY_SUPPLEMENT|Live Conscious Beyond Collagen|Participants in the experimental arm will take 1 scoop (10.4 g) of Live Conscious Beyond Collagen supplement mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
214351964|NCT06579742|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo comparator arm will take 1 scoop (10.4 g) of the placebo product (Maltodextrin) mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
214351965|NCT00675389|BEHAVIORAL|Peer Health Workers Intervention|Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for \~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
214486813|NCT06632028|OTHER|conventional therapy|In cervical disc herniation, non-invasive physical therapy applications such as laser treatment, hot-cold treatment methods, Transcutaneous Electrical Nerve Stimulation (TENS), interferential currents, manual therapy applications, kinesiological taping and exercise therapy, as well as painkillers and nonsteroidal anti-inflammatory drugs and antidepressive drugs are among the most preferred methods in treatment.(6)
214486814|NCT06631898|OTHER|SaaTwae Bio-Natural Moisturizing Cream|A 0.04 gm of test products along with controls (negative and positive) will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
214678821|NCT00864227|BIOLOGICAL|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 40 mg/m\^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide: 50 mg/kg IV on Day -6~* Total body irradiation: 200 centigray (cGy) on Day -1"
214678822|NCT00864227|BIOLOGICAL|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:~* Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~* MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm\^3 for three consecutive measurements, each on different days."
214678823|NCT03344328|DRUG|Bortezomib|The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.
214678824|NCT04281927|DEVICE|Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)|Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
214678825|NCT03153397|OTHER|Nutraflora scFOS|prebiotic fiber (Nutraflora scFOS via Vital AF)
214678826|NCT03153397|OTHER|Osmolite|non-prebiotic fiber containing formula (Osmolite)
214678827|NCT03977389|PROCEDURE|Total wrist denervation|Study of the files
214678828|NCT04590729|BEHAVIORAL|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
215078939|NCT01465217|BEHAVIORAL|text message medication reminders|daily medication reminders for one month
215078940|NCT00230282|DRUG|Alemtuzumab|3 to 30 mg, IV
215078941|NCT00230282|DRUG|Fludarabine|\[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl\]methoxyphosphonic acid
215078942|NCT00230282|DRUG|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
214351966|NCT00675389|BEHAVIORAL|Peer Health Workers and Mobile Phone Intervention|In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
214351967|NCT01310387|BEHAVIORAL|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
214959048|NCT02559726|DEVICE|Magnetic resonance imaging (MRI) without gadolinium enhancement|
214959049|NCT02559726|PROCEDURE|3D electrocardiographic mapping (ECM)|
214351968|NCT04049630|DRUG|LEV 1 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
214486815|NCT06686875|OTHER|Questionnaire|Patients will receive a link to a web-based questionnaire on the prevalence and characteristics of pain symptoms including the PainDETECT questionnaire.
214959050|NCT03386604|DIETARY_SUPPLEMENT|Whey protein|whey protein 40 g: energy value 160 kcal; carbohydrate 10 g; 25g proteins; total fat 2.3g; saturated fats 1.1 g; trans fat 0 g; dietary fiber 0 g; sodium 157 mg; calcium 264 mg.
214486816|NCT06687343|DIETARY_SUPPLEMENT|EAA Supplement|Dissolved in water and ingested 4 times a day
214351969|NCT04049630|DRUG|LEV 1,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
214351970|NCT04049630|DRUG|LEV 2,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
214351971|NCT04049630|DRUG|Placebo|5 tablets of placebo will be administrated to the participants.
214351972|NCT06429176|DRUG|SPL84|SPL84 solution for nebulization
214351973|NCT06429176|OTHER|Placebo|Placebo solution for nebulization
214486817|NCT06687343|DIETARY_SUPPLEMENT|NEAA Supplement|Dissolved in water and ingested 4 times a day
214486818|NCT06687343|DIETARY_SUPPLEMENT|Maltodextrin Supplement|Dissolved in water and ingested 4 times a day
214486819|NCT06687603|DEVICE|EsoCheck|FDA-approved, non-endoscopic, encapsulated swallowable balloon. EsoCheck will produce a sample which will subsequently be tested with EsoGuard assay. The EsoCheck is performed and completed in approximately 5 minutes.
214486820|NCT06687603|DIAGNOSTIC_TEST|EsoGuard|Approved laboratory, methylated DNA panel that detects esophageal neoplasia. The EsoGuard assay tests the EsoCheck samples to detect BE in GERD participants.
214486821|NCT06691256|DEVICE|HiDO-ALZ|HiDO-ALZ platform, an AI-driven medication dispensing and observation system designed to improve adherence in individuals with dementia and diabetes.
214486822|NCT06871319|DIAGNOSTIC_TEST|periapical x-ray, orthopantomography|Radiographic exams such as periapical x-rays and orthopantomography are necessary to evaluate the root canal system of teeth.
214486823|NCT06871527|DRUG|fruquintinib + tislelizumab + FOLFOX|"phase Ib: fruquintinib (3+3 dose escalation design): L1: 3 mg/d, L2: 4 mg/d, L3: 5 mg/d, qd po, D1-14, Q3W; tislelizumab: 200mg, I.V., D1, Q2W; 5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours,Q2W; leucovorin : 400mg/m2, I.V., D1, Q2W; Oxaliplatin: 85mg/m2, ivgtt 2h, D1, Q2W.~phase II: fruquintinib: RP2D; tislelizumab: 200mg, I.V., D1, Q2W; 5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours,Q2W; leucovorin: 400mg/m2, I.V., D1, Q2W; Oxaliplatin: 85mg/m2, ivgtt 2h, D1, Q2W."
214486824|NCT06872242|DIAGNOSTIC_TEST|Polysomnography|Polysomnography after enrollment for suspected obstructive sleep apnea
214678829|NCT04590729|BEHAVIORAL|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
214959051|NCT03386604|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin energy value 160 kcal.
214959052|NCT05524480|BEHAVIORAL|Salud en Mis Manos - Dissemination and Implementation Assistance|The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).
214959053|NCT05524480|BEHAVIORAL|Salud en Mis Manos- Usual Implementation Practice|The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
214351974|NCT06634485|DEVICE|ultrasound, spirometry|"Ultrasound assessment of~1. diaphragmatic excursion:-the probe will be angled medially ,cranially , and dorsally so that the ultrasound beam reaches the posterior third of the diaphragm, in B-mode.Then, then M-mode exploration line will be placed perpendicular to the diaphragmatic dome to obtain maximum excursion .~2. (Tdi) will be measured using a high-frequency linear probe (10 MHz) placed on (ZA).The probe will be angled perpendicular to the lateral chest wall and placed between the midaxillary and anterior axillary lines at the eighth or ninth intercostal space.~3. Quadricep\|rectus femoris muscle assessment will be done by placing the transducer perpendicular to the long axis of the thigh.~   * Spirometry:-will be performed thrice by experienced technicians at our pulmonary function laboratory. Patients will be asked to take a maximal inspiration and then to forcefully expel air for as long and as quickly as possible."
214351975|NCT06634810|BEHAVIORAL|Self-Management Support|The intervention will be delivered by CHWs in person and supplemented with telephone or video encounters over 6 months. The intervention comprises six core elements: engagement, intake, self-management assessment, barrier screening, actions to address identified barriers, and follow-up/maintenance support.
214351976|NCT06634810|BEHAVIORAL|COPD Education|The attention control is where CHWs will provide COPD education using the COPD 1-2-3 booklet. The attention control will consist of 6 CHW visits (approximately 1 per month) with the patient and care giver in their home or via video conference, per patient preference.
214351977|NCT05735236|DEVICE|BFR Cuff|The BFR cuff will be applied to the proximal thigh of the surgical leg while the patient completes specified physical therapy exercises.80% occlusion pressure will be determined by PT's in clinic through the use of a Delphi unit. Subjects will then be able to use the Saga Fitness app to adjust this pressure if it differs from the automatic calibrated pressure.
214351979|NCT00262275|DRUG|Aspirin, Clopidogrel|
214351980|NCT05913856|OTHER|Normal saline|Normal saline will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
214351981|NCT05913856|OTHER|Chlorhexidine|15ml of 0.12% chlorhexidine will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
214351982|NCT06273735|DIAGNOSTIC_TEST|Pre- and postoperative determination of troponin as part of the study and 24-month FU survey|An intervention is carried out as part of the normal clinical procedure regardless of the study measurement parameters.
214351983|NCT01314118|DRUG|abiraterone acetate in combination with prednisone|Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
214351984|NCT04321408|DRUG|Ziconotide Injection|Intrathecal analgesia with Ziconotide
214351985|NCT06434597|DRUG|SPH5030|SPH5030：Oral, QD, 600mg
214351986|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire between diagnostic annoucement and first line treatement
214351987|NCT05267041|BIOLOGICAL|Blood sample|One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
214351988|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after first line treatment
214351989|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire before second line treatment
214351990|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after second line treatment
214351991|NCT06582121|OTHER|Polysomnography|An overnight sleep study
214351992|NCT05898217|OTHER|Dairy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
214351993|NCT05898217|OTHER|Soy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
214351994|NCT05898217|OTHER|Almond Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
214351995|NCT05898217|OTHER|Oat Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
214959054|NCT02706353|DRUG|APX005M|"Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.~Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase."
214959055|NCT02706353|DRUG|Pembrolizumab|Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
214959056|NCT02394236|OTHER|Aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
214959057|NCT00311454|DRUG|T.R.U.E.Test|
214959058|NCT00199576|DRUG|Methylprednisolone|
214959059|NCT00162227|DRUG|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
214959060|NCT03061240|DEVICE|Smart pain assessment tool|We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
214351996|NCT05545072|DRUG|Dupilumab|Dupilumab will be administered subcutaneously at a dose of 300 milligrams (mg) in a 2 milliliter (mL) solution every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
214351997|NCT05545072|DRUG|Placebo|A placebo to match dupilumab will be administered subcutaneously every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
214351998|NCT05545072|DRUG|Intranasal Corticosteroid Sprays (INCS)|All participants will undergo standardized background therapy with intranasal corticosteroid sprays (INCS) per standard of care (SoC). This will continue throughout the entire study. Participants either receive fluticasone propionate or mometasone furoate.
214351999|NCT05909332|DRUG|Antivascular therapy|BP102 (anti VEGFR)
214352000|NCT05909332|DRUG|Chemotherapy|ddEC-P
214959061|NCT05367882|DIAGNOSTIC_TEST|ELISA|collection of blood samples from critically ill COVID-19 patients, then serum samples are collected after centrifugation measuring IL-6, IL-10 and IP-10 by ELISA
214959062|NCT06268496|OTHER|serum formula 2039125 03|application twice a day of the tested product (in the morning and evening) to the face for 3 months
214352001|NCT04583995|BIOLOGICAL|SARS-CoV-2 rS/Matrix M1-Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
214352002|NCT04583995|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
214352003|NCT04583995|BIOLOGICAL|Licensed seasonal influenza vaccine|Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.
214959063|NCT00481767|BIOLOGICAL|Cervarix|The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
214959064|NCT00481767|DRUG|Placebo Al(OH)3|Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
214959065|NCT02778841|OTHER|Exercise|This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
214959066|NCT02358018|DRUG|68Ga-DOTATOC PET/CT Scan|Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately \~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
214959067|NCT03601741|OTHER|Daily Antimicrobial Stethoscope Diaphragm Cover|Patients will receive package with instructions to use stethoscope cover, and are then instructed to switch in 7 days
214959068|NCT03601741|OTHER|Uncovered Stethoscopes|Patients receive instruction to begin with no covers, and are then instructed to switch in 7 days
214352004|NCT06382298|OTHER|COTTONSEED OIL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as cottonseed oil for 28 days.
214352005|NCT06382298|OTHER|MATCHED PUFA DIET|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs from oils with similar fatty acid composition as CSO for 28 days.
214352006|NCT06382298|OTHER|CONTROL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
214959069|NCT05479838|PROCEDURE|Percutaneous coronary intervention|Coronary angiography will be performed via the femoral or radial artery, and primary PCI will be performed using standard guide catheters, guide wires, balloon catheters, and stents according to current guidelines. All PCI interventions performed by invasive cardiologists. The primary PCI type and contrast amount will be decided by the medical team. All patients will be treated by administering non-ionic, monomeric, low-osmolar iodinated iohexol as an intravascular contrast agent .
214959070|NCT00092963|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
214959071|NCT00092963|DRUG|Comparator: placebo / Duration of Treatment: 1 day|
214959072|NCT04052321|OTHER|3D optical surface scan|A 3D optical surface scan is acquired utilizing a handheld 3D scanner. Such a scanner is comparable to an ordinary photo camera, however, it also records depth.
214959073|NCT02506699|OTHER|analgesic effect of rTMS|
214959074|NCT00536770|DRUG|placebo + gemcitabine + erlotinib|
214959075|NCT00536770|DRUG|Placebo + gemcitabine|
214959076|NCT00536770|DRUG|calcitriol + gemcitabine|
214352007|NCT05444504|DEVICE|Cup|an insertable vaginal cup ('cup')
214352008|NCT05444504|DEVICE|Cup+|the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
214352009|NCT04535401|PROCEDURE|Biopsy|Undergo tumor biopsy
214352010|NCT04535401|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214352011|NCT04535401|PROCEDURE|Diagnostic Imaging|Undergo imaging
214352012|NCT04535401|DRUG|Elimusertib|Given PO
214352013|NCT04535401|DRUG|Fluorouracil|Given IV
214352014|NCT04535401|DRUG|Irinotecan Hydrochloride|Given IV
214352015|NCT04535401|DRUG|Leucovorin Calcium|Given IV
214352016|NCT04983615|DRUG|fentanyl-based sedation|fentanyl-based sedation instead of midazolam-based sedation in ventilated patients
214352017|NCT04983615|DRUG|midazolam-based sedation|midazolam-based sedation
214959077|NCT00536770|DRUG|calcitriol + gemcitabine + erlotinib|
214352018|NCT06317051|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin will be administered as a comparator to the placebo to assess its effects on weight reduction
214352019|NCT06317051|DRUG|Pitavastatin 4 Mg Oral Tablet|Pitavastatin tablets will be administered as a comparator to Rosuvastatin/Ezetimibe 10mg/10mg tablets to assess and compare their effects on LDL concentrations
214352020|NCT06317051|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin/Ezetimibe 10mg/10mg tablets will be administered as a comparator to pitavastatin to assess and compare their effects on LDL concentrations
214486825|NCT06873919|OTHER|Geriatric assessment|The tertiary hospital's geriatrics department is implementing a one-year mobile team composed of a geriatrician and a nurse to conduct geriatric assessments (Anamnesis and heteroanamnesis - Clinical examination - Medication review - Proposed management plan provided to the general practionner, who independently decides which recommendations to implement) in three nursing homes. This non-randomized pilot project aims to establish a new standard of care for residents selected by their primary care physician. The project is accompanied by a clinical study designed to assess the feasibility, effectiveness, and acceptability of this intervention. Prospectively collected data will also help define key indicators for a future large-scale study focusing on cost-effectiveness.
214486826|NCT06875115|DEVICE|laser acupuncture|laser acupuncture on acupoints
214959078|NCT04017715|OTHER|Experimental: warm up|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
215078943|NCT03448666|COMBINATION_PRODUCT|Pembrolizumab|Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
214352021|NCT06317051|DRUG|Placebo|The placebo tablets are visually identical to the active drug tablets and will be administered as a comparator to Dapagliflozin.
214352022|NCT05003349|OTHER|Occlusal Splint (OS).|OS will be made of heat-cured acrylic by the same specialized dentist. These intraoral devices will be flate, rigid, will cover the entire dental arch, and will have the lowest possible height. The perimeter of the splint will have at least 11 dental contacts, light, symmetrical and pinpoint as possible. The patients will be instructed to use the splint every night during the study Two supervisions will be carried out 30 and 60 days after the use of the OS, in order to stabilize the contact points.
214352023|NCT05003349|OTHER|Pain Neuroscience Education (PNE).|"A power point presentation with metaphors and animated videos will be used. The PNE will be held in 10 sessions of 20 minutes each. The intervention will be developed using content according to the book Explain Pain and the web page www.retrainpain.org."
214352024|NCT05003349|OTHER|Motor Imagery (MI).|"The participants will have to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The procedure will begin with a familiarization test with the Basic level followed by a laterality discrimination task. It will be performed using 20 images, with 5 seconds for each image, beginning with the Vanilla program and progressively increasing the difficulty using the Context and Abstract programs. The estimated time to complete the task will be about 10 minutes per session."
214352025|NCT05003349|OTHER|Action Observation (AO).|The patients will see videos showing the jaw and cervical exercises with the same series and repetitions that they will actively perform in the session. Therefore, the training of the action observation will be carried out dynamically. The patient will be asked to think and visualize the movement that he/she will have to perform later. It is estimated 10 minutes per session for the AO.
214486827|NCT06296394|OTHER|Parenthood|The intervention group will consist of participants who became first time parents to children under 5 years of age.
215078944|NCT05785533|OTHER|Smartphone App|App that provides recovery guidance based on pain and functional outcomes
214486828|NCT01487928|DIETARY_SUPPLEMENT|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
214486829|NCT04732416|DRUG|HM15136|Low dose of HM15136/ High dose of HM15136, SC injection, weekly
215078945|NCT05785533|OTHER|Standard of Care|Paper based discharge instruction that provide information on pain management
215078946|NCT04762043|DEVICE|Experimental System: MyoVoice|Person-centric augmentative and alternative communication (AAC) system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.
215078947|NCT04762043|DEVICE|Reference System: Electrolarynx|Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
215078948|NCT04132830|OTHER|In Utero HIV Exposure|Born to mother who had HIV infection during pregnancy.
215078949|NCT04132830|OTHER|No In Utero HIV Exposure|Born to mother who did not have HIV infection during pregnancy.
214486830|NCT05454241|DRUG|Anti-CD7 CAR-T|Universal CAR-T cells targeting CD7
215078950|NCT00090233|BIOLOGICAL|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
215078951|NCT00090233|BIOLOGICAL|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
215078952|NCT04863248|DRUG|Trilaciclib|Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
215078953|NCT04863248|DRUG|Placebo|Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
215078954|NCT04863248|DRUG|Docetaxel|Docetaxel administered IV on Day 1 of each 21-day cycle.
214959079|NCT04017715|OTHER|Experimental: cool down|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
214352026|NCT05003349|OTHER|Jaw and Neck Exercises (JNE)|A jaw and neck exercise program will be carried out in 3 series of 10 repetitions per session will be planned with 1minute rest between exercise. The exercises will be executed with a total time per session of 20 minutes, initially in the clinic and later at home. In the clinic, verbal and tactile instructions will be provided for the correct execution of the exercises and later they will be sent through WhatsApp and / or mail to perform them at home.
214352027|NCT05003349|OTHER|Counselling.|Counselling include education about the anatomical, biomechanical and psychosocial factors relationed with temporomandibular disorders, guidance regarding the parafunction jaw activities for eg will be taught the resting postural position of the mandible (teeth apart, lips slightly touching and tongue not pushing against the teeth).
214352028|NCT04516122|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214352029|NCT04516122|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
214352030|NCT00153764|DRUG|Cooper Complete One-A-Day Vitamin Supplement|
214352031|NCT05585307|DRUG|Bavtavirine|Administered orally
214352032|NCT05585307|DRUG|B/F/TAF|Administered orally
214352033|NCT05585307|DRUG|Standard of Care (Substudy 01)|"Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)"
214959080|NCT04017715|OTHER|No intervention: control|sprint exercise and general stretching as conventional protocol as follows in star club
214959081|NCT00720070|PROCEDURE|positron emission tomography/computed tomography|Patients undergo PET/CT scan
214959082|NCT00720070|PROCEDURE|therapeutic conventional surgery|Patients undergo neck dissection
214959083|NCT01142947|DRUG|beclomethasone dipropionate|160 mcg twice a day (320 mcg per day total)
214959084|NCT01681953|DRUG|Lamazym|ERT, i.v. infusions weekly
214959085|NCT01681953|DRUG|Placebo|Infusions weekly
214959086|NCT00734708|DRUG|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
214959087|NCT00734708|DRUG|Placebo|Control
214959088|NCT02099253|DRUG|Dexmedetomidine 01|Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
214959089|NCT02099253|DRUG|Dexmedetomidine 02|Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
214352034|NCT05585307|DRUG|GS-1720|Administered orally
214352035|NCT05585307|DRUG|Standard of Care (Substudy 02)|"Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC"
214352036|NCT05585307|DRUG|GS-6212|Administered orally
214352037|NCT05585307|DRUG|Standard of Care (Substudy 03)|Antiretroviral therapy, administered orally
214352038|NCT05978843|BEHAVIORAL|Monetary benefit to purchase fruits and vegetables|Participants will receive varying benefit amounts to purchase fruits and vegetables.
214352039|NCT05680129|DRUG|Ecnoglutide high dosage|Administered subcutaneously
214352040|NCT05680129|DRUG|Ecnoglutide low dosage|Administered subcutaneously
214959090|NCT00254215|BEHAVIORAL|high protein & low glycemic index diets|
214959091|NCT04378569|DRUG|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
214959092|NCT04378569|DRUG|ARQ-252 cream 0.1%|ARQ-252 cream 0.1%
214959093|NCT04378569|DRUG|ARQ-252 Vehicle Cream|ARQ-252 Vehicle Cream
214959094|NCT03076112|DRUG|Ipragliflozin|Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
214959095|NCT03076112|DRUG|Sitagliptin|Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
214959096|NCT03972215|DRUG|Berberine Chloride|Traditional Chinese Medicine
214959097|NCT03972215|DRUG|Placebo|Placebo Control
215078955|NCT05569538|DRUG|Bomedemstat|Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
215078956|NCT04101539|DEVICE|OPTIMA-guided catheter ablation|Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
214352041|NCT05680129|DRUG|Dulaglutide|Administered subcutaneously
214352042|NCT05680129|DRUG|Metformin|Administered orally
214352043|NCT05875623|OTHER|MALPIP criteria|In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients
214352044|NCT05064878|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral aqueous solution of Fenfluramine Hydrochloride.
215078957|NCT04101539|DEVICE|Standard PVI|Standard PVI for AF.
215078958|NCT01691105|OTHER|AD + Integrated Tobacco Order Set|"Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
215078959|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (reproducibility)|The experienced examiner performed tests on 20 healthy subjects
215078960|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (availability)|Two examiners performed the test on one healthy subject with both devices for ten consecutive days.
215078961|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (Accuracy)|200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
215078962|NCT05950516|DRUG|Semaglutide|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
215078963|NCT05950516|DRUG|Semaglutide Pen Injector [Ozempic]|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
215078964|NCT01766895|OTHER|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
214352045|NCT05064878|DRUG|Matching ZX008 Placebo|Matching ZX008 placebo is supplied as an oral solution.
214352046|NCT06038123|DEVICE|China market released 3.0T Magnetic resonance (MR) conditional CIED systems|To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment when subjects receive 3.0T MRI scans without positioning restrictions (MRI scans may occur anywhere on the body)
214352047|NCT06088771|BIOLOGICAL|Dupilumab|Dupilumab will be administered at the recommended initial dosage of 600 mg (two 300 mg injections) on Day 1.
214352048|NCT06088771|BIOLOGICAL|Cemiplimab|Cemiplimab will be administered at the recommended dosage of 350 mg, as an intravenous infusion, over 30 minutes on Day 1.
214352049|NCT06230757|DRUG|Psilocybin 25mg|25mg psilocybin capsule
214352050|NCT06230757|DRUG|Placebo (active placebo)|1mg psilocybin capsule
214352051|NCT01360606|RADIATION|Stereotactic Body Radiation Therapy|"SBRT:~Patients will receive one of the following radiation regimens:~* 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~* 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~* 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
214393612|NCT06163716|BEHAVIORAL|Multidomain intervention (MD-Int) group|The MD-Int program included: 1) individual follow-up visits every three months for cardiovascular risk factor monitoring and nutritional counselling with primary health care providers; 2) two nutritional workshops led by a nutritionist; 3) 20 hours of cognitive stimulation delivered through group sessions and 4) 40 hours of individual cognitive training exercises. Participants in the MD-Int group received recommendations to practice 2 to 6 hours of physical exercise per week and get involved in sports activities. Social stimulation was promoted through group activities.
214393613|NCT04376983|BEHAVIORAL|Telerehabilitation for patients with a cardiac resynchronisation device|Using the device-measured physical activity to create tailored motivational messages and tips to the patients to increase physical activity
214393614|NCT00962585|DRUG|Placebo|
214393615|NCT00962585|DRUG|S-equol|"Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~* S-equol 10 mg BID (20 mg total daily dose)~* S-equol 50 mg BID (100 mg total daily dose)~* S-equol 150 mg BID (300 mg total daily dose)"
214352052|NCT06962189|DRUG|chemoimmunothrapy|Patients will receive 3-4 cycles of induction therapy with Sintilimab combined with platinum-based doublet chemotherapy, followed by multidisciplinary team (MDT) evaluation. For patients deemed eligible for radical lung primary lesion resection, surgery should be performed within 4-6 weeks after completing the final cycle of chemoimmunotherapy. The timing of radiotherapy for metastatic lymph nodes will be determined by MDT discussion. If deemed inoperable after induction therapy by MDT, definitive radiotherapy will be administered subsequently. All patients, in the absence of contraindications, will receive PD-1 inhibitor maintenance therapy for 1 year following local treatment.
214352053|NCT06962605|BEHAVIORAL|Moderate-intensity continuous running (MICE: 60% V̇O2max)|Participants run continuously for 40 minutes at moderate intensity (60-65% V̇O2max)
214352054|NCT06962605|BEHAVIORAL|5-minute interval running (5MIN)|Participants run for 40 minutes at average moderate intensity with 5-minutes slow and fast cycles where speed is increased and decreased by 20%.
214352055|NCT06962605|BEHAVIORAL|2-minute interval running (2MIN)|Participants run for 40 minutes at average moderate intensity with 2-minutes slow and fast cycles where speed is increased and decreased by 20%.
214352056|NCT06962605|BEHAVIORAL|Resting control|Participants sit for 40 minutes in a comfortable position
214959098|NCT01715701|PROCEDURE|Paravertebral nerve blockade|Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
214959099|NCT01715701|PROCEDURE|Intercostal nerve blockade|Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
215078965|NCT02516293|BEHAVIORAL|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
215078966|NCT05731076|BEHAVIORAL|Self-management support nutrition and exercise intervention|Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
215078967|NCT03263923|BEHAVIORAL|Cognitive behavioral intervention and journaling|Cognitive behavioral skills training and 4 weeks of online journaling
215078968|NCT03263923|BEHAVIORAL|Reflective journaling|"Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling"
215078969|NCT03362931|DEVICE|XEN45|XEN45 unilaterally implanted in the study eye
214352057|NCT06961604|DRUG|NaF PET-CT|Following a non-cardiogenic thromboembolic stroke, patients will undergo NaF PET-CT imaging to identify the culprit plaque and any other vulnerable plaques at high risk for rupture
214352058|NCT06961721|BIOLOGICAL|Herpes Zoster Vaccine, Live|assigned to the vaccine group and placebo group in a 2:1 ratio.
214352059|NCT06961721|BIOLOGICAL|Placebo|assigned to the vaccine group and placebo group in a 2:1 ratio.
214352060|NCT06961942|OTHER|Training|A structured teaching module for fellows in training will be prepared and conducted at three university centres, namely University Hospitals Leuven, Ljubljana University Medical Centre, and CHU de Bordeaux. The training module will include short endoscopic videos (different from the pre- and post-training set), which participants will score in real-time using a polling application. This will be followed by a step-by-step demonstration of each scoring principle with explanations of the reasoning behind specific scores. Each scoring system will be reviewed in a short training video that provides a structured demonstration, highlights common pitfalls, and showcases typical IBD-associated endoscopic features. After the video training, participants will have the opportunity to ask questions to the experts.
214352061|NCT06962215|OTHER|Paramedic training|"Nurses and care assistants at the centers randomized to the with training arm will undergo a day-and-a-half of training to help them support patients diagnosed with brain tumors. Training consists of half a day of theory, followed by a day of simulation."
214352062|NCT06961578|PROCEDURE|C1-2 instrumentation|"Surgical fracture stabilization with a posterior screw-rod system from C1-2 from a posterior approach.~The routine surgery commonly lasts approximately 100 minutes and requires a hospital stay of about 6 days. An additional external bracing in the postoperative setting is not required."
214393616|NCT00883103|DRUG|2% Lidocaine jelly|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
214393617|NCT00883103|DRUG|Plain aqueous gel|Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
214959100|NCT01715701|PROCEDURE|Patient Controlled Analgesia|Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
214959101|NCT00003197|DIETARY_SUPPLEMENT|green tea extract|
214959102|NCT01436487|BIOLOGICAL|MultiStem|single infusion 1-2 days following ischemic stroke
214959103|NCT01436487|BIOLOGICAL|Placebo|single infusion 1-2 days following ischemic stroke
214959104|NCT04418362|OTHER|Neurofeedback training|A home-based self-administered neurofeedback intervention taking place 4-6 times per week for 8 weeks.
214959105|NCT02658266|BEHAVIORAL|Home based resistance training|The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
214352063|NCT06961578|OTHER|External immobilization with rigid cervical collar|External immobilization with a rigid cervical collar for 12 weeks. Compliance is monitored through patient diaries, recognizing the real-world challenges of consistent brace use. Lack of adherence is considered to reflect routine clinical practice. A typical drawback of the conservative intervention in daily practice is the absolute reliance on patient compliance to wear the collar continuously for at least 12 weeks, which poses a significant challenge to this treatment strategy.
214352064|NCT06093113|BEHAVIORAL|Alba - Youth in grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains five main sections: Learning, Self-assessment, Manage symptoms, Find support and a Personal space.
214352065|NCT06093113|BEHAVIORAL|Control website|The website will contain information about grief and grief reactions similar to some of the information given in the app.
214352066|NCT04597190|DRUG|Selective serotonin reuptake inhibitor|Prescribers and patients choose among three selective serotonin reuptake inhibitors (SSRI), sertraline, paroxetine, or fluoxetine based on patient's treatment history (i.e., failed SSRI trials due to side-effects or lack of efficacy) and preference. If a patient experiences problematic side effects after taking their choice of SSRI, the provider may switch them to another of the SSRI options during the first 8 weeks of follow-up. Patients on any antidepressant (including SSRIs) at enrollment will be cross-tapered over four weeks to either fluoxetine, sertraline or paroxetine (i.e., the old drug will be tapered down while the new drug is tapering up).
214352067|NCT04597190|DRUG|Serotonin-norepinephrine reuptake inhibitor|Prescribers will prescribe venlafaxine.
214959106|NCT03374839|DRUG|TIL + IL-2 + Nivolumab|"The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days."
214959107|NCT01140971|DRUG|Misoprostol|Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
214352068|NCT04597190|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy will be delivered during six 30 minute sessions. The first session includes psychoeducation about symptoms of PTSD, provides a treatment rationale for approaching the trauma memory, and discusses the use of writing as a means of doing so. In sessions 2-6, patients will write about the memory of their worst traumatic event for 20 minutes, with a focus on details of the event and thoughts and feelings that occurred during the event. Patients are directed to write about the same trauma memory during each session. The session ends with the therapist instructing the patient to allow themselves to experience any trauma-related memories, images, thoughts, and feelings in the interval between sessions. The therapist reads the narrative between sessions to make sure instructions were followed. Feedback about the narrative is provided to the patient at the beginning of sessions 3-6. This feedback is used to prompt the patient for writing in the current session.
214352069|NCT05826379|BEHAVIORAL|Adaptive Daily Goal Setting|Daily step goals displayed by the study application
214352070|NCT05826379|BEHAVIORAL|Interim Goal Prompt|Short-term step goals
214352071|NCT06076642|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
214352072|NCT06076642|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
214352073|NCT06375265|BEHAVIORAL|digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|Preoperative hybrid intervention (in-person or via phone/video) over 4 weeks, and at 2 weeks, and 1 month after surgery using content from the CBT-I Coach app from Veteran Affairs.
214352074|NCT06375265|BEHAVIORAL|Sleep Health Education|Sleep Health Education materials provided
215078970|NCT00908869|DRUG|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."
215078971|NCT00005631|BIOLOGICAL|filgrastim|
215078972|NCT00005631|BIOLOGICAL|rituximab|
215078973|NCT00005631|DRUG|carboplatin|
215078974|NCT00005631|DRUG|etoposide|
215078975|NCT00005631|DRUG|ifosfamide|
215078976|NCT05385081|OTHER|genomic profiling|next generation sequencing
214352075|NCT06294184|DEVICE|tdcs lDLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
214352076|NCT06294184|DEVICE|tdcs rVLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
214352077|NCT06294184|DEVICE|Sham|The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
214352078|NCT04420221|BIOLOGICAL|Sa-5Ag half dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1, administered intramuscularly.
214352079|NCT04420221|BIOLOGICAL|Sa-5Ag full dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1, administered intramuscularly.
214352080|NCT04420221|BIOLOGICAL|Sa-5Ag half dose adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1, administered intramuscularly.
214959108|NCT01140971|DEVICE|Foley|After Foley introduction, every 6 hours vaginal exam was performed. The cases on Bishop score increase or occurred spontaneous exit of catheter or spontaneous labour had been initiated are considered success.The failure was adopted if after48 hours occurred no cervical modifications.
214959109|NCT01962948|DRUG|paclitaxel|Given IV
214959110|NCT01962948|DRUG|ganetespib|Given IV
215078977|NCT05879770|OTHER|suture material|Some patients have had a shouldice repair with wire in the past and others with Prolene.
215078978|NCT02061397|DRUG|Simvastatin|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
214352081|NCT04420221|BIOLOGICAL|Sa-5Ag full dose adjuvanted|A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.
214352082|NCT04420221|BIOLOGICAL|Placebo|One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo Groups 1 to 3 (Dose-escalation epoch) and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo Group 4 (Dose-escalation epoch) and Group PoP: Placebo, administered intramuscularly.
214352083|NCT06008717|DEVICE|active subthalamic nucleus deep brain stimulation plus optimal drug therapy|active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy
214959111|NCT01962948|OTHER|laboratory biomarker analysis|Correlative studies
214959112|NCT02422004|OTHER|Range of motion|25 range of motion exercises of the ankle, 5 times per day.
214959113|NCT02422004|OTHER|Delayed weight-bearing|No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
215078979|NCT02061397|DRUG|Sirolimus Oral Product|Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
214352084|NCT06008717|DEVICE|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy|optimal drug therapy alone with DBS device turned off
214352085|NCT04935307|DIAGNOSTIC_TEST|MRI and paraclinical tests|The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.
214486831|NCT04889989|DEVICE|Microwave Ablation|Percutaneous microwave ablation using the NeuWave Microwave Ablation System for non-small cell lung cancer or oligometastatic lung tumors
215078980|NCT02061397|DRUG|Everolimus Oral Product|Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
215078981|NCT05308498|DIAGNOSTIC_TEST|ESView software with proscan|Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
215078982|NCT05308498|DIAGNOSTIC_TEST|Rapid software with SBI|Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
214352086|NCT00460889|PROCEDURE|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
214393618|NCT03638856|DRUG|Misoprostol 200Mcg Tab|patient takes 2 tab of 200 mcg of Misoprostal 3 hr before hysteroscopy
214393619|NCT03449459|DIETARY_SUPPLEMENT|oral probiotics|"Culturelle™ DIGESTIVE HEALTH 30 CT(VCAP)(10 Billion Claim) which consists of 100% Lactobacillus rhamnosus GG, 1 tablet, q.d., for 3 months.~Subjects will take conventional therapy at the same time."
214393620|NCT03449459|DRUG|aerosol inhaled amikacin|"0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time."
214959114|NCT00073762|DRUG|DVS-233 SR|
214959115|NCT02407847|OTHER|care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
214959116|NCT03823820|OTHER|Bioimpedance Analyser|Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.
214959117|NCT03114085|DRUG|Capecitabine|Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
214959118|NCT03114085|DRUG|Apatinib|Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
214959119|NCT02759094|DEVICE|Treatment with RefluxStop|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
214959120|NCT03630705|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration : Intramuscular
214959121|NCT03630705|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular
215078983|NCT05967546|OTHER|Observational|No interventions will be given to patients.
215078984|NCT02145104|DRUG|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
215078985|NCT04341545|OTHER|Placebos|Placebo 4 tablets a day for one week.
215078986|NCT04341545|DRUG|Letrozole tablets|Letrozole 10mg daily for one week.
215078987|NCT02670798|PROCEDURE|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
215078988|NCT02217371|OTHER|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
215078989|NCT03000777|DIETARY_SUPPLEMENT|melatonin plus zinc|Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks
214352087|NCT02125526|DEVICE|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
214352088|NCT06351358|DEVICE|Sculptra treatment|Subjects will receive treatment of Sculptra at baseline. Subjects will receive a second treatment of Sculptra at Week 4 visit. At the Week 8 visit, subjects will receive an optional treatment of Sculptra.
214352089|NCT06351358|DEVICE|Restylane Treatment|Subjects will receive treatment Restylane Lyft or Restylane Contour at baseline. Subjects will receive an optional touch-up of Restylane Lyft or Restylane Contour at Week 4 visit.
214352090|NCT02773615|PROCEDURE|Cardiac computed tomography|Non-invasive CT scan of the heart
214678830|NCT03418662|DEVICE|EndoRings device|Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
215078990|NCT03000777|OTHER|Placebo|Isomaltose o.d. 1 hour before going to bed during 16 weeks
215078991|NCT05639101|OTHER|Clinical Decission support system management & mobile App Intervention Group|"The clinicians treating the patients will use a clinical decision support system that includes predictive models associated with the level of risk of exacerbation. This models have been obtained in asthmatic patients by applying data mining techniques and multilevel analysis in the study of the influence of clinical characteristics and the environment of each subject.~The patients will use a mobile app to help manage their symptoms."
215078992|NCT00701298|BIOLOGICAL|peginterferon alfa-2b|Given SC
215078993|NCT00701298|DRUG|decitabine|Given IV
215078994|NCT00701298|OTHER|laboratory biomarker analysis|Correlative studies
215078995|NCT02539498|DEVICE|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
215078996|NCT05597644|PROCEDURE|Trans-arterial uterine artery embolization|transarterial angioembolization of uterine artery
214352091|NCT02284438|DEVICE|Endotracheal tube|Three endotracheal tubes with different surfaces will be used
214352092|NCT01792063|DRUG|Sevoflurane|
214352093|NCT01792063|DRUG|Sevoflurane|
214352094|NCT01921673|DRUG|Dovitinib and docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
214352095|NCT02868359|OTHER|No Intervention|The study is observational.
214352096|NCT04653103|PROCEDURE|Liver biopsy|Biopsy of the liver to assess for Non-alcoholic steatohepatitis
214352097|NCT04913753|PROCEDURE|CBEU|Patients in the control group will have bacterial culture and double J removal will be performed as usual. .
214352098|NCT04913753|PROCEDURE|No CBEU|Patients in the experimental group will have bacterial culture and double J removal will be performed as usual. .
214678831|NCT03461289|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
214678832|NCT05457530|DRUG|DOR/3TC/TDF|100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
214678833|NCT05457530|COMBINATION_PRODUCT|DOR + FTC/TAF|100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)
215078997|NCT02802241|DRUG|placebo|
215078998|NCT02802241|DIETARY_SUPPLEMENT|peppermint oil|
215078999|NCT01453738|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
215079000|NCT01453738|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
215079001|NCT02865889|PROCEDURE|Laparoscopy in Gynecologic Oncologic Indications|
215079002|NCT02865889|PROCEDURE|Conventional surgery (abdominal radical surgery)|
215079003|NCT00075387|DRUG|Carboplatin|Given IA
215079004|NCT00075387|DRUG|Cyclophosphamide|Given IV
215079005|NCT00075387|DRUG|Etoposide Phosphate|Given IV
215079006|NCT00075387|OTHER|Quality-of-Life Assessment|Ancillary studies
215079007|NCT00075387|DRUG|Sodium Thiosulfate|Given IV
215079008|NCT01655043|DRUG|Regadenoson|Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
214352099|NCT01618864|DEVICE|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
214959122|NCT03630705|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
214959123|NCT03630705|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214352100|NCT04347681|OTHER|convalescent plasma from recovered COVID 19 donor|After obtaining informed consent, Eligible Patients who have severe COVID-19 and have not recovered yet will be infused with the donated convalescent plasma (10-15 ml/kg body weight of recipient)19 at least once \& if possible, daily, for up to 5 sessions.
214352101|NCT03074630|DRUG|Dapagliflozin|5 weeks 10mg dapagliflozin once daily
214352102|NCT03074630|DRUG|Rosuvastatin|9 weeks 10mg dapagliflozin once daily
214352103|NCT03353935|OTHER|Validated questionnaires|Patients were administered pre- and post-operatively the three validated questionnaires ((FSFI, ICIQ-UI short form Italian, NBD score) investigating sexual, urinary, and fecal function, respectively.
214352104|NCT03658174|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice containing approximately 5-6 mmol of inorganic nitrate
214959124|NCT03630705|BIOLOGICAL|Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine|Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
214959125|NCT03630705|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214959126|NCT03630705|BIOLOGICAL|Rotavirus Vaccine, Live, Pentavalent|Pharmaceutical form: Oral solution Route of administration: Oral
214959127|NCT03630705|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
214959128|NCT04851366|BEHAVIORAL|PROCARE+ (with add-on modules)|The modules will mainly consist in therapy sessions to provide the adolescents with tools to confront risk situations such as communication skills, coping skills to manage stress, etc. The group will include education about discussing thoughts, feelings, and behaviour as parts of emotion, and emphasis on providing support around the specific risks factors detected.
214959129|NCT04851366|BEHAVIORAL|PROCARE (UP-A for selective purposes)|This core intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
214959130|NCT04851366|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
214959131|NCT03864991|DEVICE|e-device for step count (fit-bit)|Patients in this group will receive fitbit device to count their daily steps and record it into their log books.
215079009|NCT01655043|DRUG|gadofoveset trisodium|All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
215079010|NCT01245881|DEVICE|Non-ablative fractional photothermolysis laser|"* Wavelength: 1,550 nm;~* Energy: 15 mJ/MTZ;~* Total coverage: 20%;~* Total density: 1,048 MTZs/cm2;~* Density per pass: 131 MTZ/cm2;~* Number of passes: 8."
215079011|NCT01245881|OTHER|broad-spectrum sunblock (SPF 50+)|
215079012|NCT03150069|OTHER|Interview|In-person or telephone in-depth interview
215079013|NCT02927925|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
215079014|NCT02062892|DRUG|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
214352105|NCT03658174|DIETARY_SUPPLEMENT|Nitrate-free beetroot juice|70mls of concentrated beetroot juice that has been nitrate-depleted
214352106|NCT01196338|BEHAVIORAL|Early weight-bearing and range of motion exercises|"* 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;~* At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;~* After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis."
214352107|NCT01196338|BEHAVIORAL|non-weight bearing, no range of motion|"* 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;~* At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;~* After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis."
214959132|NCT03864991|BEHAVIORAL|e-messages for log book|Patients in this group will receive e-messages to maintain their log books as per instruction for blood sugar levels and send back weekly through snap shot.
214959133|NCT03864991|BEHAVIORAL|e-messages for log book & fit-bit|Patient in this group will receive e-messages to maintain their log books for blood sugar levels as well as use fitbit device and maintain their log book for daily step count and send back weekly through snap shot.
214959134|NCT05686863|DRUG|Remimazolam|Remazolam for sedation in children undergoing bidirectional endoscopy
214959135|NCT05686863|DRUG|Esketamine|Esketamine
214959136|NCT05686863|DRUG|Propofol|Propofol
214959137|NCT05686863|DRUG|remifentanil|remifentanil
214959138|NCT01684176|BEHAVIORAL|Complex tailored intervention|
214959139|NCT01684176|BEHAVIORAL|Usual care|
214959140|NCT01856738|DRUG|Rivastigmine|Capsule. Dose 3,0 - 6,0 mg BID
214959141|NCT01856738|DRUG|Placebo (for rivastigmine)|Capsule. Dose 3,0 - 6,0 mg BID
214352108|NCT05040009|BEHAVIORAL|integrated foot care program|"1. Regular foot care and examination by an adequately trained professional: -~2. Structured education:~Educational modality will be provided to patients in a structured way. This will take many forms: one-to-one verbal education session last around 30 min motivational interviewing, video education, booklets, pictorial education via animated drawing or descriptive images structured foot care education consists of information on:~1. Foot ulcers and their consequences~2. Preventative foot self-care behaviors~3. Wearing adequately protective footwear~4. Undergoing regular foot checks~5. Practicing proper foot hygiene~6. Seeking professional help in a timely manner after identifying a foot problem~3-Adequate footwear 4-Foot-related exercises and weight-bearing activity 5-Foot examination and screening 6- Instructions about foot self-management"
214352109|NCT01722968|DRUG|Bevacizumab|15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
214352110|NCT01722968|DRUG|Paclitaxel|80mg/m2 iv weekly
214678834|NCT05457530|DRUG|BIC/FTC/TAF|Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
214678835|NCT03911570|DRUG|Glucosamine Sulfate|Therapy with the prescription formulation of crystalline glucosamine sulfate
214959142|NCT03911076|BIOLOGICAL|PVX-2|pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)
214959143|NCT03911076|OTHER|Placebo|PBS and PGC
214959144|NCT00448214|DRUG|YM150|Oral
214959145|NCT00448214|DRUG|warfarin|Oral
214959146|NCT03970759|DRUG|Stannous Fluoride Dentifrice|Experimental stannous fluoride (0.454%) dentifrice
214959147|NCT03970759|DRUG|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
214959148|NCT03970759|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
214959149|NCT04655729|DRUG|Infliximab|Blood collection
214678836|NCT03787004|DRUG|CNTX-6970|Oral dose CNTX-6970
214959150|NCT03944863|DRUG|Antibiotics|
214959151|NCT04560868|DEVICE|Control mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence.
214959152|NCT04560868|DEVICE|Experimental mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence. Experimental participants also receive additional content designed to motivate smoking reduction/quitting and provide skills training.
214959153|NCT04560868|DRUG|Nicotine patch|Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.
215079015|NCT02062892|DRUG|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
215079016|NCT05133869|DEVICE|Metacognitive training + direct training|"The intervention will consist of a combination of direct training of the impaired cognitive function(s) and metacognitive strategy training for 42 days (6 weeks). Direct training will be done with the computer program Rehacom for 20 minutes, 5 times a week. Metacognitive strategy training will be given on a weekly or biweekly basis (6-10 sessions) by a trained therapist at Adelante.~Rehacom is a brain training program developed to improve a variety of cognitive functions with the use of game-like cognitive training modules. During the intervention the participant should train with Rehacom for approximately 600 minutes in total.~In addition to the direct training, the participant receives six to ten sessions of metacognitive strategy training. During this training they are taught strategies by a therapist to improve their performance on the Rehacom modules and on daily life functioning. Each metacognitive strategy is linked to one of the Rehacom modules."
215079017|NCT01263392|DEVICE|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
215079018|NCT05293444|DIETARY_SUPPLEMENT|Maltodextrine|400 ml at 10PM night before surgery(12.5g/100ml) 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.
214352111|NCT05022030|DRUG|mCapOX plus cetuximab|capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w
214352112|NCT05022030|DRUG|mFOLFOX6 plus cetuximab|oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w
214393621|NCT03449459|BIOLOGICAL|combined vaccination|"Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug Administration(CFDA) are vaccinated at different body sites by professional nurses.~The interval between two vaccinations is 3-5 days to avoid the overlap of adverse events.~Subjects will take conventional therapy at the same time."
214393622|NCT03503838|BEHAVIORAL|Online Yoga|12 weeks of online yoga; 60 min/week
214393623|NCT00415493|OTHER|Cold-dry air provocation|15 minute exposure to cold-dry air by nasal mask
215079019|NCT05293444|OTHER|overnight fasting|no intervention
214393624|NCT00415493|OTHER|Warm-moist air provocation|15 minute exposure to warm-moist air by nasal mask
214393625|NCT05594355|DRUG|TEBOFORTAN|TEBOFORTAN 240 mg is administrated 1 tablet per day
214393626|NCT05346796|BEHAVIORAL|Survivorship Care Plan-Personal Health Record (SCP-PHR)|The SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
214393627|NCT05887284|RADIATION|low dose radiotherapy (0.5 Gy)|12 times 0.5 Gy
214393628|NCT05887284|RADIATION|mock radiation treatment|6 times 0.0 Gy
214393629|NCT05887284|RADIATION|low dose radiotherapy (1.0 Gy)|6 times 1.0 Gy
214393630|NCT06176820|DRUG|Vaginal Gel|Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
214393631|NCT06176820|DRUG|Vaginal lubricant|Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
214393632|NCT05464576|DIAGNOSTIC_TEST|MRI|Using the MRI in the diagnosis of the bladder cancer (invasive or not)
215079020|NCT01567592|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
215079021|NCT00000344|DRUG|Buprenorphine/naloxone|
215079022|NCT02229214|DRUG|Qsymia|
214352113|NCT05976074|DEVICE|Apple Watch|The smartwatch will collect data including accelerometry, heart rate, activity, move time, exercise time, stand time, steps, walking and running distance, heart rate variability, respiratory rate, six-minute walk, and flights climbed. During sleep, the smartwatch will collect daily nighttime physiologic data such as time in bed, average sleep time, sleep efficiency, wake after sleep onset, nocturnal heart rate, and nocturnal respiratory rate.
214352114|NCT05976074|OTHER|BrainRISE app|The app will play a prerecorded video, which will walk participants through tasks which include holding your arms in different postures, repeating different vowel sounds and phrases as prompted, and tracing different patterns on the phone screen. The tasks are video and audio recorded while being completed. Completing the tremor assessment tasks will take about 10 minutes.
214352115|NCT04224389|PROCEDURE|transoral resection|The technique of transoral surgery will be left to the choice of the surgeon according to the equipment and the experience of the team and will be gathered. The options are: transoral surgery robot-assisted, endoscopic laser transoral surgery, transoral laser surgery classical instruments. The exact description of the resected area will be collected. of the cross-sections will be made for extemporaneous analysis if necessary in lateral margins and deep until complete excision.
214352116|NCT04224389|RADIATION|IMRT|Intensity modulation radiotherapy (RCMI or IMRT) will be performed using techniques static or rotational (arctherapy, tomotherapy). Restraint is recommended with thermoformed mask
214959154|NCT03094793|OTHER|abnormal EEGs|"This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.~Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention."
214959155|NCT02136459|OTHER|Small Tube size|An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
215079023|NCT02229214|DRUG|Placebo|
215079024|NCT01579825|OTHER|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
215079025|NCT02017392|DRUG|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
214352117|NCT02879812|OTHER|Performance Feedback Reports|Medical directors will be provided performance feedback reports that are a summary of clinical performance of transplant and racial disparity performance over a period of time aimed at providing information to allow them to assess and adjust their transplant performance. The report will emphasize tailored facility-specific information on the mean time on dialysis for patients in that facility and transplant access performance measures, such as wait listing and transplantation, including the magnitude of racial disparity, detailing when a facility is performing below the national or regional average.
214393633|NCT04288674|OTHER|Retrospective data collection of demographics|Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.
214393634|NCT04288674|OTHER|Retrospective data collection of underlying diseases|Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.
214393635|NCT04288674|OTHER|Retrospective data collection of duration of hospitalization|Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.
214678837|NCT03787004|OTHER|Placebo|Oral dose placebo
214678838|NCT05113823|PROCEDURE|Simulation Training|Simulation Training using High and Low Fidelity Simulator
214959156|NCT02136459|OTHER|Large Tube size|An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
214959157|NCT00328588|DRUG|YM155|IV
214959158|NCT03925337|DEVICE|Computer Aided Diagnostic Software|The research software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the automatic polyp detection system is installed on a computer system unit that utilizes an an operating system.
214959159|NCT04260997|DIETARY_SUPPLEMENT|Lactobacillus gasseri BNR17™ capsule|Once per day (QD), 12 weeks
215079026|NCT01057225|DRUG|carfilzomib|Given IV
215079027|NCT01057225|DRUG|cyclophosphamide|Given orally
215079028|NCT01057225|DRUG|thalidomide|Given orally
215079029|NCT01057225|DRUG|dexamethasone|Given orally
215079030|NCT00969761|DRUG|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
215079031|NCT00969761|DRUG|BI 6727|low to high dose
215079032|NCT03262025|PROCEDURE|Operated|Patients were either managed conservatively or underwent emergency laparotomy
215079033|NCT01635673|OTHER|Exercise intervention|Whole body vibration exercise 3 times per week
215079034|NCT00559468|DRUG|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
215079035|NCT00559468|DRUG|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
215079036|NCT00559468|DRUG|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
215079037|NCT00559468|DRUG|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
215079038|NCT05540769|PROCEDURE|catheter guided ASD closure|transcatheter secundum ASD device closure
215079039|NCT01953549|PROCEDURE|physical fitness training|
215079040|NCT01953549|PROCEDURE|relaxation|
215079041|NCT02478840|DRUG|Lamazym|recombinant human alpha-mannosidase
215079042|NCT02753621|BEHAVIORAL|Group singing|Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
215079043|NCT02753621|BEHAVIORAL|Facilitated Discussion Group|Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
214352118|NCT02879812|OTHER|Educational Video for Staff|Dialysis facility staff will watch a \~10 minute educational video that describes the role of dialysis staff in improving transplant access, the new kidney allocation policy, and how the new policy impacts minority patients and those on dialysis for a substantial period of time.
214959160|NCT04260997|OTHER|Placebo capsule|Once per day (QD), 12 weeks
214959161|NCT04394702|OTHER|One Shape Single-file rotary system|rotational single file system used for mechanical debridement of root canals
214959162|NCT04394702|OTHER|manual stainless steel K-file|sequential manual filing with stainless steel K-files
214959163|NCT00279344|DRUG|Fentanyl (Matrifen)|
214959164|NCT03161730|OTHER|McGrath videolaryngoscopy|Participants perform three intubation attempts using McGrath videolaryngoscope in the normal and cervical immobilized manikin by novice
214959165|NCT03161730|OTHER|Pentax videolaryngoscopy|Participants perform three intubation attempts using Pentax Airway Scope in the normal and cervical immobilized manikin by novice
214352119|NCT02879812|OTHER|Educational Video for Patients|Dialysis facilities will receive a \~10 minute educational video targeted to dialysis patients to explain the transplant process and allocation policy.
214352120|NCT02879812|OTHER|Educational Webinar|Education for medical directors and facility staff about the kidney allocation policy will be discussed in a webinar and information will be hosted on a website for participants to access. The seminar will be roughly 45 minutes, and CME will be offered.
214352121|NCT02879812|OTHER|Standard Care|Dialysis facilities will conduct standard or usual care and education regarding transplantation.
214352122|NCT02879812|OTHER|United Network for Organ Sharing (UNOS) Pamphlet|Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
214352123|NCT05932745|OTHER|E-liquid coolant (No WS-3) for non-menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
214352124|NCT05932745|OTHER|E-liquid coolant (No WS-3) for low menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
214352125|NCT05932745|OTHER|E-liquid coolant (No WS-3) for high menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
214352126|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for non-menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
214352127|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for low menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
214352128|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for high menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
214352129|NCT05932745|OTHER|E-liquid coolant (High WS-3) for non-menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
214352130|NCT05932745|OTHER|E-liquid coolant (High WS-3) for low menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
214352131|NCT05932745|OTHER|E-liquid coolant (High WS-3) for high menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
214959166|NCT03161730|OTHER|Macintosh laryngoscopy|Participants perform three intubation attempts using Macintosh laryngoscope in the normal and cervical immobilized manikin by novice
214352132|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for non-menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
214352133|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for low menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
214352134|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for high menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
214352135|NCT05932745|OTHER|E-liquid coolant (High WS-23) for non-menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
214352136|NCT05932745|OTHER|E-liquid coolant (High WS-23) for low menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
214352137|NCT05932745|OTHER|E-liquid coolant (High WS-23) for high menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
214352138|NCT02085408|DRUG|Daunorubicin|Given IV
214352139|NCT02085408|DRUG|Cytarabine|Given IV
214678839|NCT02333955|DRUG|GCS-100|3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
214678840|NCT03138850|DEVICE|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
214959167|NCT00134966|DRUG|capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)|
214352140|NCT02085408|DRUG|Clofarabine|Given IV
214352141|NCT02085408|DRUG|Decitabine|Given IV
214352142|NCT02085408|OTHER|Observation|Undergo clinical observation
214352143|NCT02085408|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
214959168|NCT04445090|DRUG|BI 1569912|BI 1569912
214959169|NCT04445090|DRUG|Placebo|Placebo
214959170|NCT03835507|DRUG|recombinant human erythropoietin(rhEPO)|Injection of erythropoietin every months (total 12 months)
214959171|NCT02710487|BEHAVIORAL|REMSA|Awakening from REM sleep during the last hour of the sleep period
214959172|NCT02710487|BEHAVIORAL|NREMSA|Awakening from N2 (NREM) sleep during the last hour of the sleep period
214959173|NCT06548854|DRUG|STC314 Injection/STC314 Injection Placebo|All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.
214959174|NCT03803163|DRUG|TransCon Treprostinil|
215079044|NCT03937648|DRUG|COL-144 50mg|COL-144 50mg
215079045|NCT03937648|DRUG|COL-144 100mg|COL-144 100mg
215079046|NCT03937648|DRUG|COL-144 200mg|COL-144 200mg
215079047|NCT03937648|DRUG|COL-144 400mg|COL-144 400mg
215079048|NCT03937648|DRUG|Placebo|Placebo
214486832|NCT06697587|BEHAVIORAL|Enhanced Cognitive Reappraisal and Emotion Awareness Training (eCREAT)|"eCREAT features psychoeducational content on anger management, practical exercises, and homework assignments, all supported by an online therapist who provides text-based feedback. The protocol builds on a previously evaluated protocol for maladaptive anger (ClinicalTrials.gov; ID: NCT03858296) with added focus on anger inhibition.~eCREAT is based on the two-stage model of maladaptive anger inhibition (Burns et al., 2008), which posits that suppressed anger may rebound and return as angry fantasies and ruminations. To address these core mechanisms, the treatment includes training on adaptive anger processing and expression and strategies for disrupting anger ruminations. These added treatment components are based on established protocols for depressive rumination, and assertive expression of emotion, adapted for an anger context. Additionally, the treatment also focuses on how to flexibly shift between different emotion regulation strategies depending on contextual demands."
214959175|NCT05118997|DEVICE|IRRAflow|IRRAflow consists of a control unit and disposables (dual-lumen catheter and tube set) to offer an integrated and synchronized active fluid exchange system. Active fluid exchange is the combination of traditional gravity-driven drainage with periodic, controlled irrigation of the catheter probe to exchange any pathological fluid collection with neutral physiological fluids.
214959176|NCT05118997|DEVICE|EVD|An external ventricular drain (EVD), also known as a ventriculostomy or extraventricular drain, is a device used in neurosurgery to treat hydrocephalus and relieve elevated intracranial pressure when the normal flow of cerebrospinal fluid inside the brain is obstructed.
214959177|NCT06171529|DEVICE|CTM|CTM Flow is stored in 1cc vials and is stable at room temperature and does not need to be refrigerated. CTM Flow will be supplied to and stored at the IHTSC Beltway Surgery Center. Product will be stored at room temperature without continued temperature control. All product will be kept in the Beltway Surgery Center and will not be separated from the marketed non-study CTM. Treating Surgeons will remain blinded to the treatment group, but will ensure that only the injection is billed to patients and the CTM or saline are provided at no cost. Lexie Reissaus, CCRP will track drug accountability.
214959178|NCT06171529|OTHER|Placebo|placebo/Saline control injection
214959179|NCT01116622|DRUG|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
214959180|NCT01116622|DRUG|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
214959181|NCT04727528|DRUG|Sodium zirconium cyclosilicate|Investigational medicinal product
214959182|NCT04727528|DRUG|Placebo|Plabeco comparator
214959183|NCT05236855|DIAGNOSTIC_TEST|Spectoscropy testing of urine specimen|Urine samples will be independently tested by I R Spectroscopy and those results are to be compared with standard testing procedures for HPV
214959184|NCT01355562|DRUG|Interleukin-2 (IL-2)|Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
214486833|NCT06696573|DRUG|Prophylactic NSAID Administration|Participants in this arm will receive a prophylactic dose of a non-steroidal anti-inflammatory drug (NSAID) prior to the onset of pain during medical abortion procedures for pregnancies between 13 and 22 weeks. The intervention aims to reduce pain intensity throughout the process. The NSAID administration involves a specific dosage and schedule, adhering to safety guidelines and monitored for potential side effects.
214959185|NCT00022750|BEHAVIORAL|Nurse Case Manager and Community Health Worker Team|
214959186|NCT01763827|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214959187|NCT01763827|DRUG|Ezetimibe|Administered orally once a day
214959188|NCT01763827|BIOLOGICAL|Placebo to Evolocumab|Administered by subcutaneous injection
215079049|NCT03305081|DEVICE|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
214959189|NCT01763827|OTHER|Placebo to Ezetimibe|Administered orally once daily
214959190|NCT05006274|DEVICE|Persona Trabecular Metal Tibia|Total knee arthroplasty
214959191|NCT05006274|DEVICE|Verasense technology|Instrumented tibial trial component
214959192|NCT05006274|DEVICE|MUVR|Knee motion and gait sensing wearable device
214959193|NCT02906579|DRUG|Matching Placebo|
214959194|NCT02906579|DRUG|IW-1973|
214959195|NCT05381454|DRUG|Mitoquinone/mitoquinol mesylate|Mitoquinone/mitoquinol mesylate
214959196|NCT03343366|DRUG|Metronidazole|Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days
214959197|NCT03343366|PROCEDURE|Scaling Root Planing|SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.
214959198|NCT03343366|BEHAVIORAL|Oral Hygiene Instructions|OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
215079050|NCT04600505|DRUG|Treatment A|Participants will receive 2 inhalations of BGF MDI with propellant 1.
214959199|NCT01127048|DRUG|Suppositories containing Ivy leaves dry extract|Suppositories containing Ivy leaves dry extract
214959200|NCT01127048|DRUG|Placebo|Suppositories containing no Ivy leaves dry extract
214959201|NCT01826981|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
214959202|NCT01826981|DRUG|SOF|SOF 400 mg tablet administered orally once daily
214959203|NCT01826981|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214959204|NCT01826981|DRUG|Peg-IFN|pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
214959205|NCT01826981|DRUG|GS-9669|GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
214959206|NCT01826981|DRUG|VEL|Velpatasvir (VEL) tablet(s) administered orally once daily
214959207|NCT00168428|BIOLOGICAL|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
215079051|NCT04600505|DRUG|Treatment B|Participants will receive 2 inhalations of BGF MDI with propellant 2.
215079052|NCT04600505|DRUG|Treatment C|Participants will receive 2 inhalations of BGF MDI with HFA propellant.
214959208|NCT00168428|OTHER|placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
214959209|NCT02030119|BEHAVIORAL|Financial Incentives|
214352144|NCT06125392|DIAGNOSTIC_TEST|Coronary physiology assessment|Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and papaverin or adenosine, Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and acetylcholine.
214352145|NCT06121661|DEVICE|APPRAISE Trauma Clinical Decision Support System|Real-time bedside decision-support system for trauma patient management
214352146|NCT01391962|DRUG|Cediranib|Cediranib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
214486834|NCT06696573|DRUG|On-Demand NSAID Administration|Participants in this group will receive a non-steroidal anti-inflammatory drug (NSAID), such as Ibuprofen, in oral tablet form at a dose of 400 mg. The drug will be administered as needed when participants report experiencing pain during the medical abortion process for pregnancies between 13 and 22 weeks. The goal of this intervention is to provide pain relief in response to individual needs, with administration and dosage adjusted as clinically indicated. Monitoring will occur to assess the efficacy, safety, and patient response to the on-demand approach.
214486835|NCT06226948|DEVICE|CGM|Participants will wear CGM monitors for 10 days.
214678841|NCT03138850|DEVICE|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
214959210|NCT02030119|BEHAVIORAL|Daily feedback|
214959211|NCT03681899|OTHER|Questionnaires|"* Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));~* Medical and surgical history (Charlson Comorbidity Scale);~* Assessment of oral/dental condition~* Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);~* Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);~* Autonomy evaluation (Lawton and Katz scales);~* Mobility assessment (anamnestic evaluation);~* Evaluation of Thyme (GDS 4 items);~* Psycho-behavioral disorders,~* Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data)."
215079053|NCT03866785|DIAGNOSTIC_TEST|interview|The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
215079054|NCT03866785|DIAGNOSTIC_TEST|Adult Physical Activity Questionnaire (APAQ)|The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
214352147|NCT01391962|DRUG|Sunitinib|Sunitinib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
214352148|NCT01391962|OTHER|Prochlorperazine|10mg every 6 hours orally as needed for nausea,
214352149|NCT01391962|OTHER|Promethazine|12.5-25mg intravenous every 6 hours as needed for nausea.
214486836|NCT06226948|DIAGNOSTIC_TEST|Visualization|Enriched visualization of SCORE2 CVD risk.
214486837|NCT04046549|DRUG|Belatacept|Protocol versions 1 through 4: Belatacept 10 mg/kg by intravenous (IV) infusion on post-op Day 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), and at the end of Weeks 2, 4, 8 and 12; then 5 mg/kg IV every 4 weeks from Week 16 to Week 48.
214678842|NCT03138850|DEVICE|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
214959212|NCT03701438|BIOLOGICAL|Influenza Vaccine|Administered per standard of care using a vaccine licensed and recommended in the site's country
214959213|NCT03230435|OTHER|Treatment settings as usual.|Treatment according to guidelines and the local instructions (psychotherapy and dietary guidance).
214959214|NCT00759655|BIOLOGICAL|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
214959215|NCT00193583|DRUG|Topotecan|
214959216|NCT00193583|DRUG|Carboplatin|
214959217|NCT02330185|DEVICE|ultrasonography|spinal anesthesia guided with ultrasonography
214959218|NCT06267820|DRUG|Bupivacain|analgesia
214678843|NCT03311685|DEVICE|vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
214959219|NCT06267820|DRUG|Ketorolac|analgesia
215079055|NCT03866785|DEVICE|Activity actigraph|An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
214352150|NCT01391962|OTHER|Benzodiazepine|If promethazine is inadequate, add benzodiazepine until acute nausea is controlled.
214352151|NCT01391962|OTHER|Filgrastim|Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
214352152|NCT01391962|OTHER|Sargramostim|Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
215079056|NCT03866785|OTHER|Peer training|"The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~* Skills in physical activity advice~* Knowledge of functional signs (symptoms)~* Knowledge to examine heart rate and perceived effort rate"
215079057|NCT03866785|OTHER|Physical Activity Program|"During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months."
215079058|NCT01192269|DIETARY_SUPPLEMENT|DHA (docosahexaenoic acid)|1 x 950 mg capsules per day orally, each capsule providing \~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
215079059|NCT02154620|PROCEDURE|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
215079060|NCT02154620|DEVICE|Synthes TCP volar plate|
215079061|NCT00992381|DRUG|PN400|500mg Naproxen and 20mg esomeprazole
215079062|NCT00992381|DRUG|Naprosyn|500mg Naproxen
214352153|NCT01391962|OTHER|Lomotil|2.5mg plus atropine sulfate 0.025mg/tablet dosed according to package insert.
214959220|NCT05736692|BEHAVIORAL|Brief Sleep Intervention|A \~50-minute semi-structured intervention based on the behavioral sleep medicine literature, particularly for adolescent insomnia, focused on key elements that can be addressed in one session. Treatment elements include engaging motivation, goal setting, barrier identification, problem-solving, pre-planning, self-monitoring, and setting rewards. The interventionist will be sensitized to barriers to sleep quality and quantity particularly relevant during adolescence, including job/work, homework, and social obligations, use of nicotine and caffeine, and social media and electronic devices. The interventionist will converse primarily with the adolescent, but parents will remain in the room as a support in problem-solving and executing therapeutic plans.
214959221|NCT00187785|BEHAVIORAL|Spanish speaker level|
214959222|NCT04301739|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
214959223|NCT04301739|DRUG|nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|chemotherapeutics
214959224|NCT04301739|DRUG|Placebo|Placebo
214959225|NCT04974229|OTHER|In line with the Dutch guideline for non-specific low back pain, Standard usual care for non-specific low back pain was applied.|In line with the Dutch guideline for non-specific low back pain, Standard usual care or non-specific low back pain was applied.
214959226|NCT03559751|OTHER|VLN cigarettes (A)|0.4mg nicotine / g tobacco king size filter cigarette
215079063|NCT05004038|BIOLOGICAL|BCG Vaccine AJVaccines|Single intradermal injection of BCG Vaccine according to published Summary of Product Characteristics
215079064|NCT02028117|BIOLOGICAL|Enadenotucirev|Oncolytic Virus
214959227|NCT03559751|OTHER|Usual Brand Cigarettes (B)|Usual brand king size non-menthol cigarettes
214959228|NCT03559751|DRUG|Nicotine gum (C)|4 mg nicotine gum
214959229|NCT01352273|DRUG|MEK162 + RAF265|
214959230|NCT00593424|OTHER|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
214352154|NCT01391962|OTHER|Loperamide|4mg by mouth (PO) after first unformed stool with 2mg PO every 2 hours as long as unformed stools continue.
214352155|NCT01391962|OTHER|Vitamin B6|50-150mg orally each day for hand-foot syndrome.
214352156|NCT01391962|OTHER|Aquaphor|Topical emollient for hand-foot syndrome.
214352157|NCT01391962|DRUG|Acetaminophen|Analgesic for hand foot syndrome as needed.
214352158|NCT01391962|DRUG|Levothyroxine|Replacement therapy for participants with increases in thyroid-stimulating hormone.
214352159|NCT01391962|DRUG|Warfarin|2mg daily for prophylaxis of thrombosis.
214352160|NCT03695497|PROCEDURE|Direct anterior approach|total hip arthroplasty with DAA
214352161|NCT03695497|PROCEDURE|Direct Lateral Approach|total hip arthroplasty with DLA
214352162|NCT04267705|OTHER|Control|This group will receive a cup of rice 7 days/week over a 12-week period
214352163|NCT04267705|OTHER|Black bean|This group will receive a cup of black bean7 days/week over a 12-week period
214352164|NCT04267705|OTHER|Chickpea|This group will receive a cup of chick pea 7 days/week over a 12-week period
214352165|NCT05845333|OTHER|Decision task|Participants will complete a simple and/or moral decision making functional MRI task.
214352166|NCT04876248|BIOLOGICAL|Belantamab Mafodotin|Given IV
214352167|NCT04876248|DRUG|Lenalidomide|Given PO
214352168|NCT05815108|OTHER|NO INTERVENTION|NO INTERVENTION
214352169|NCT00933231|DRUG|tacrolimus|Standard dose, Oral
214352170|NCT00933231|DRUG|tacrolimus|Low dose, Oral
214352171|NCT00933231|BIOLOGICAL|Simulect|IV
214352172|NCT00933231|DRUG|Cellcept|Oral
214352173|NCT00933231|DRUG|Corticosteroids|IV and Oral
214352174|NCT00933231|DRUG|Ramipril|Oral
214352175|NCT00933231|DRUG|Irbesartan|Oral
214352176|NCT05565716|OTHER|Support Person|"Prior to randomization, participants will select their preference of the type of support person if they are assigned to this arm 1) a person they have close relationship with, or 2) a Peer Mentor, an individual who has successfully monitored their blood pressure at home using the study's equipment and also has diabetes, kidney disease, and high blood pressure. The Peer Mentor works with the research study team.~This will be provided with the same weekly blood pressure feedback that the participants will receive. The support person is encouraged to reach out to the participant at least weekly."
214352177|NCT05565716|OTHER|Social Norms|Participants will receive weekly text messages that includes their individualize blood pressure performance statistics, included frequency of blood pressure monitoring and average blood pressure, and compare it to goals provided at the beginning of the study, as well as the week prior. Participants will also has access to a leaderboard that displays blood pressure performance information all people in the study in an anonymous fashion.
215079065|NCT02470143|BEHAVIORAL|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
215079066|NCT01571284|DRUG|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
215079067|NCT01571284|DRUG|FOLFIRI|irinotecan, 5-FU and leucovorin
215079068|NCT02101684|DRUG|Orteronel 300mg BID|
215079069|NCT06065059|DRUG|TNG348|Ubiquitin Specific Peptidase 1 (USP1) inhibitor
215079070|NCT06065059|DRUG|Olaparib|PARP inhibitor
215079071|NCT06072300|BEHAVIORAL|Physical activity calorie equivalent labelling|Physical activity calorie equivalent labelling on beverage vending machines
215079072|NCT00002211|DRUG|Nelfinavir mesylate|
215079073|NCT00002211|DRUG|Delavirdine mesylate|
215079074|NCT00002211|DRUG|Stavudine|
215079075|NCT00002211|DRUG|Didanosine|
214959231|NCT00593424|OTHER|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
214959232|NCT04983290|DIETARY_SUPPLEMENT|weancare-domus|Participants belonging to the experimental group will receive at home a set of foods that allows to receive the right amount of proteins and energy in a modified texture form to be prepared by themselves or by their caregivers
214959233|NCT06331832|BIOLOGICAL|IGM2323|Imvotamab is a recombinant monoclonal antibody of the IgM kappa isotype that targets the human CD20 antigen. Its component J-chain is fused to a single chain Fv antibody fragment which targets human CD3ε.
214959234|NCT02793947|DRUG|Ropivacaine|400 mg of 0.75% ropivacaine (53.33 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
214959235|NCT02793947|DRUG|Epinephrine|0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
214959236|NCT02793947|DRUG|Morphine|5 mg of 0.5 mg/mL morphine sulfate (10 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
214959237|NCT02793947|DRUG|0.9% sodium chloride solution|36.07 mL 0.9% sodium chloride solution will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
214959238|NCT03321201|PROCEDURE|Cauterization|To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.
214959239|NCT03321201|PROCEDURE|Fibrin glue|Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
214959240|NCT03457818|DRUG|Denosumab 60 mg/ml [Prolia]|Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
214959241|NCT03457818|OTHER|Placebo|Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
214959242|NCT00151437|DRUG|Pegvisomant treatment|
214959243|NCT00151437|PROCEDURE|Medical History, demographics|
214959244|NCT00151437|PROCEDURE|Sign and symptoms: questionnaire|
214959245|NCT00151437|PROCEDURE|Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT|
214959246|NCT00151437|PROCEDURE|MRI|
214959247|NCT04658433|DIETARY_SUPPLEMENT|300 mg of omega3-FA|The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.
214959248|NCT00004763|DRUG|leuprolide|
214959249|NCT00004763|DRUG|Ethinyl estradiol/norethindrone|
214959250|NCT02179047|PROCEDURE|coronary angiography|percutaneous coronary intervention. coronary angiography.
214959251|NCT05074524|DEVICE|Repetitive Transcranial Magnetic Stimulation|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
214959252|NCT05074524|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
214959253|NCT02868021|DEVICE|Strength testing|Test the strength of subject's lower extremity muscles on the dynamometer system
214959254|NCT02868021|BEHAVIORAL|Short Physical Performance Battery (SPPB)|The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
214959255|NCT02868021|BEHAVIORAL|Six-minute walk (SMW)|Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
214959256|NCT02868021|BEHAVIORAL|Numerical pain scale|Measure pain using an 11-point numerical pain scale.
214959257|NCT02868021|BEHAVIORAL|Self-assessed function|Using the Late Life Function and Disability Instrument.
214959258|NCT02868021|PROCEDURE|Muscle biopsies|During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
214959259|NCT02868021|DEVICE|Determination of 1 Repetition Maximum (1-RM)|Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
214959260|NCT02868021|DEVICE|Blood flow restriction exercise|Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
214959261|NCT02868021|BEHAVIORAL|Borg CR10 scale|Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
214959262|NCT01727856|DEVICE|Rehabilitation Measurement Tool|The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
214352180|NCT02388386|DEVICE|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
214352181|NCT04112147|DRUG|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
214352182|NCT04112147|DRUG|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
214352183|NCT04112147|DRUG|Placebo oral capsule|Patients will receive 12-week of 100mg BID Antroquinonol placebo
214352184|NCT06111950|OTHER|Blood samples|Blood samples of 5 ml to 15 ml depending on their weight
214352185|NCT06111950|OTHER|Skin biopsies|Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.
214959263|NCT03212014|OTHER|LSVT-BIG|LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
214959264|NCT03212014|OTHER|POWER|Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
214959265|NCT03212014|OTHER|Traditional rehabilitation|traditional exercise models in currently clinical use
214959266|NCT04911595|DIAGNOSTIC_TEST|exercise oximetry|transcutaneous oxygen pressure is measured at the skin level on chest , buttocks and calves during a walking test 3.2 km\*:h 10% slope. From the test result the decrease from rest of oxygen pressure (DROP) index is calculated to estimate muscle ischemia
214959267|NCT04911595|DIAGNOSTIC_TEST|thallium scintigraphy|Muscle thallium fixation is measured immediately after a walking test 3.2 km\*:h 10% slope and at 4 hours after the test. From the test result the difference of late and early radioactivity is calculated at the buttock and calf level and normalized to total body radioactivity to estimate muscle ischemia
214959268|NCT00941200|BIOLOGICAL|Blood collection|
214959269|NCT05927168|DEVICE|TENS|TENS will be applied to the experimental group 45 minutes before the chest tube is removed and another 15 minutes after the chest tube is removed. Patients' pain scores will be evaluated using the Numerical Pain Scale (SAS) just before the TENS procedure, while the chest tube is removed, and 5 minutes after the TENS application is finished.
214959270|NCT01393522|DRUG|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
214959271|NCT01393522|DRUG|Placebo|Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down
214959272|NCT02936089|OTHER|Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT)|"For CT, patients were treated with high dose cytarabine (HDAC), cytarabine at a dosage of 1-3 g/m2 q12 h ×6 doses, for 4-6 cycles.~For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT."
214959273|NCT02936089|OTHER|Consolidation with auto-HSCT or HLA-matched HSCT|"For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT.~For HLA-matched HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to HLA-matched HSCT. HLA-matched donors were available in these patients."
214959274|NCT02936089|OTHER|allogeneic HSCT|For allogeneic HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to allogeneic HSCT, including HLA-matched and haploidentical transplantation.
214959275|NCT02080208|DEVICE|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
214959276|NCT01912794|OTHER|Sensory Intervention|"1. full sensory information, whose participants will practice balancing tasks without constraint sensory body;~2. sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;~3. control, whose participants will exercise activities involving cognitive and upper limbs."
215079076|NCT04213781|DEVICE|HappyMed Video Glasses|HappyMed allows the immersion of patients in films, cartoons or concerts.
214352186|NCT06111950|OTHER|Fetal samples|Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage
214352187|NCT01672801|DRUG|Placebo|oral administration
214486838|NCT04046549|DRUG|VIB4920|"Protocol versions 1 and 2: VIB4920 1500 mg by IV infusion on post-op Days 1 and 14, and at the end of Weeks 4, 6, 8 and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.~Protocol versions 3 and 4: VIB4920 1500 mg by IV infusion on post-op Days 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), Week 2, and at the end of Weeks 4, 6, 8, and 10; then 1500 mg every 4 weeks from Week 12 to Week 48."
214352188|NCT01672801|DRUG|Nimodipine|oral administration
214352189|NCT05643001|OTHER|In-patient and out-patient electronic health record alert|Electronic health record best practice alert which suggests measurement of LDL and HbA1c (in-patient) and referrals to sleep study and audiology (out-patient)
214352190|NCT00481429|DRUG|Rosiglitazone|Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
214352191|NCT00837863|DRUG|Somatropin|ALTU-238 0.3 mg/kg daily
214352192|NCT00837863|DRUG|Somatropin|ALTU-238 0.6 mg/kg daily
214352193|NCT00837863|DRUG|Somatropin|ALTU-238 0.9 mg/kg daily
214678844|NCT01742962|PROCEDURE|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
214678845|NCT01250067|PROCEDURE|Motor-related cortical potential (Procedure)|
214352194|NCT00837863|DRUG|Somatropin|Nutropin AQ 0.043 mg/kg daily
214352195|NCT02765529|PROCEDURE|Blood sampling|
214352196|NCT06529952|PROCEDURE|hysteroscopic surgery by resection and endocoagulation|resection of lower edge, resection of upper edge and endocoagulation
214959277|NCT00642005|PROCEDURE|Fisher and Paykel Humidifier (MR860)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
214959278|NCT00642005|PROCEDURE|Standard insufflation|No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
214959279|NCT04136483|BEHAVIORAL|CBT-I|The theoretical framework is cognitive-behavioral therapy that includes sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive interventions and relaxation. The intervention has been adapted to adolescents by reducing the amount of psychoeducational information and the interventions related to changing cognitions. It involves six weekly face-to-face individual sessions with a therapist, supported by a participant workbook that contains information, work- sheets, and at-home tasks. Clinical psychologists or graduate clinical psychologists in training delivered the intervention sessions under supervision by the first author. Parents/care-givers were given information about the components, but did not take active part of the intervention.
214959280|NCT01955239|RADIATION|Intensity-modulated Radiotherapy|
214959281|NCT02816320|OTHER|Hospitalization|Patients who were hospitalized in acute care
214959282|NCT05991960|DEVICE|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
214959283|NCT00551395|PROCEDURE|selective laser trabeculoplasty - early completion|180 degrees of laser on day 1 and other 180 degrees on day 2.
214959284|NCT00551395|PROCEDURE|Selective laser trabeculoplasty - late completion|180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
214959285|NCT01923324|BEHAVIORAL|Physician telephone consultation|Pain physician support for family physician treating patient
214959286|NCT01923324|BEHAVIORAL|Usual family physician care|Usual family physician care without telephone consultation with pain physician
214959287|NCT01731327|DRUG|tofacitinib modified-release (MR) formulation|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
214352197|NCT06529952|PROCEDURE|hysteroscopic surgery by endocoagulation only|hysteroscopic endocoagulation to the base of the niche by roller ball
214352198|NCT06529952|DRUG|hormonal treatment|using 3rd generation contraceptive pills
214393636|NCT05253690|PROCEDURE|balloon catheter insertion approach for labor induction|Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
214393637|NCT05548959|DIAGNOSTIC_TEST|Pneumatonometry after microshunt implantation|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
214393638|NCT05548959|DIAGNOSTIC_TEST|Pneumatonometry after ab interno trabeculectomy|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
214393639|NCT00594906|DRUG|Teriparatide|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
214393640|NCT00594906|DRUG|Placebo|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
214393641|NCT02165904|BIOLOGICAL|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
214393642|NCT01450280|BIOLOGICAL|ChAd63 CS|ChAd63 CS 5x10\^9 vp intra-muscularly Day 0
214393643|NCT01450280|BIOLOGICAL|ChAd63 CS, MVA CS|ChAd63 CS 5x10\^9 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
214393644|NCT01450280|BIOLOGICAL|ChAd63 CS|ChAd63 CS 5x10\^10 vp intra-muscularly Day 0
214393645|NCT01450280|BIOLOGICAL|ChAd63, MVA CS|ChAd63 CS 5x10\^10 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
214393646|NCT00951860|OTHER|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
214393647|NCT00252928|OTHER|Sodium dichloroisocyanurate (NaDCC) tablets|Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
214393648|NCT00252928|OTHER|Placebo|Placebo
214393649|NCT01033773|DRUG|Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin|Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.
214393650|NCT01033773|BEHAVIORAL|Diabetes survival skills self-management education|Survival skills DSME based upon current JCAHO and ADA joint recommendations for persons with diabetes prior to discharge to the outpatient setting was initiated in the ED and continued at the follow-up encounters.
214393651|NCT03306186|DEVICE|HemoSpec|Blood sampling for analysis
214393652|NCT02123290|DRUG|DSM265 400mg|
214393653|NCT02123290|DRUG|DSM265 xmg|Dose of DSM265 to be determined based on the results of the first cohort
214393654|NCT02123290|DRUG|DSM265 ymg|Dose of DSM265 to be determined based on the results of the second cohort
214352199|NCT04578262|PROCEDURE|Epley Manoeuvre|This manoeuvre is constituted by five steps. In the first step, while the patient is in supine posture the head will be positioned 45 degrees turned towards the unaffected ear and the head slightly overhang on the edge of the couch. In this second step maintaining the previous position of the head, physiotherapist will turn head 45 degrees turned towards the affected ear. Next, in the third step, the whole body will turn until is located 135 degrees from the baseline supine position. In the fourth step, while the head keeps turned to the affected ear the subject will be incorporated until he is sitting. In the fifth step, while the subject is seated with the head in neutral position the chin will be bended 20 degrees. Each procedure will be held among 30 seconds or two minutes, while the dizziness or the nystagmus vanish. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
214352200|NCT04578262|PROCEDURE|Sham Manoeuvre|The sham manoeuvre consist is going to star with the participant in a neutral seated position. Sum to it, head is rotated 45 degrees towards the unaffected vestibule. After that, the participant will be guided by the physiotherapist to a lateral decubitus position towards the affected side on which his nose will be pointing above. To conclude, the seated position will be reached again without head rotation. Each position of the sham manoeuvre will be maintained along one minute. During all the process the videonystagmography glasses will be dressed by participants and they will be indicated not to close eyes in the intervention. After the execution of the manoeuvre, also this group will be evaluated 48 hours after. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
214352201|NCT00504270|DRUG|Placebo|po daily
214352202|NCT00504270|DRUG|RG3421 120mg|120mg po daily
214352203|NCT00504270|DRUG|RG3421 20mg|20mg po daily
214959288|NCT01731327|DRUG|tofacitinib modified-release (MR) formulation|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
214959289|NCT05516238|OTHER|Case management|Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.
214959290|NCT03832829|DEVICE|Indirect composite restoration|Restoration of tooth with extensive substance loss
214959291|NCT06118463|DIAGNOSTIC_TEST|Detection of serum AUNIP expression|The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
214959292|NCT00116714|DRUG|DMARD|All subjects were required to initiate, add or change DMARD therapy at study entry.
214959293|NCT01085708|DRUG|rabeprazole|10 mg normal tablet
214959294|NCT01085708|DRUG|rabeprazole|Type 1 granule containing rabeprazole 10 mg
214959295|NCT01085708|DRUG|rabeprazole|Type 2 granules containing rabeprazole 10 mg
214959296|NCT01085708|DRUG|rabeprazole|Type 3 granules containing rabeprazole 10 mg
215079077|NCT04213781|DRUG|Propofol|The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.
215079078|NCT04213781|DRUG|Sufentanil|0.1 µg/kg
215079079|NCT04065074|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
214352204|NCT00687037|DRUG|Cetylpyridinium chloride|
214486839|NCT04046549|DRUG|Thymoglobulin|"Protocol versions 1 and 2: Thymoglobulin 3.0 mg/kg by intravenous (IV) infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0) (1 dose).~Protocol versions 3 and 4: Thymoglobulin 1.5 mg/kg by intravenous infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0), prior to VIB4920+belatacept infusion on post-op Day 1, on post-op Day 2, and prior to VIB4920+belatacept infusion on post-op Day 3 or 4."
214959297|NCT03479008|DIAGNOSTIC_TEST|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
214959298|NCT00677313|DRUG|metreleptin|metreleptin injection
214959299|NCT01726465|DRUG|Methylprednisolone|Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
214959300|NCT01726465|DRUG|N-acetylcysteine|Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°-110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
214959301|NCT02876861|PROCEDURE|Radical nephroureterectomy|Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff
214959302|NCT02876861|PROCEDURE|Distal ureterectomy|Distal ureterectomy.
215079080|NCT02241811|DRUG|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
215079081|NCT02241811|DRUG|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
214352205|NCT06189417|BEHAVIORAL|Health Extension Led club based Intervention|The Health Extension Workers-led club-based intervention primarily focuses on equipping individuals with the necessary knowledge and skills to enhance their self-management behavior. The intervention encompasses education on adopting healthy eating habits, promoting regular exercise, effectively managing weight, and supporting smoking cessation. It emphasizes the importance of regular blood sugar level monitoring, limiting alcohol intake, and reducing sedentary behavior. The intervention also includes counseling to provide guidance and support in adopting and maintaining healthy behaviors. Additionally, it highlights the significance of adhering to medication regimens for optimal health outcomes. If additional medical attention is required, the intervention provides referral services to nearby health facilities.
214352206|NCT06237972|PROCEDURE|4-week Perturbation-based balance training|Participants will be asked to walk over a six by two meters computer-controlled movable platform at a self-selected speed. Slip-like perturbations will be induced by the device software that moves the platform 12 inches forward at 0.46 m/s with an acceleration of 9.4 m/s2. Participants will be secured in a safety harness which will be attached to the overhead arch of the platform. Participants will be asked to go to the experimental study cite 11 times. A baseline screening, 8 training sessions, a post-training screening, and a 2 months folow up screening
214959303|NCT02876861|DRUG|Neoadjuvant Chemotherapy|Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
214959304|NCT04811859|OTHER|Inspiratory Muscle Training|Inspiratory Muscle Training is a form of resistance (weight) training which strengthens the muscles that you use to breathe. When these muscles are strengthened regularly for a period of a few weeks they adapt, becoming stronger and being able to work for longer.
214959305|NCT01310127|DRUG|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
214959306|NCT01310127|DRUG|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
214959307|NCT04032795|DIETARY_SUPPLEMENT|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day)for 6 weeks
214959308|NCT04032795|DIETARY_SUPPLEMENT|Placebo|Placebo-controlled group take he placebo capsules that are identical in shape, color, and taste to LBP tablet.
214959309|NCT03534167|BEHAVIORAL|TODAY! App and Coaching|"The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based."
214959310|NCT00412932|DRUG|Olmesartan medoxomil|Tablets
214959311|NCT00412932|DRUG|Olmesartan medoxomil/hydrochlorothiazide|Tablets
215079082|NCT06438016|BEHAVIORAL|Stress Management Training|The intervention will comprise of 4 sessions delivered over 4 weeks. The training session will be structured as follows: Session 1 - Psychoeducation relating to stress and its effects. Session 2 - Behavioral techniques to cope with stress 1, Session 3 - Cognitive techniques to cope with stress and Session 4- Behavioral techniques to cope with stress. Both verbal and written means will be used to provide this training.
215079083|NCT00871117|BIOLOGICAL|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
215079084|NCT00871117|BIOLOGICAL|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
215079085|NCT00871117|BIOLOGICAL|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
215079086|NCT04260763|BEHAVIORAL|Social Cognition Group|Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
214352207|NCT06237972|DEVICE|Neuromuscular electrical stimulation|NMES will be applied on tibialis anterior and quadriceps muscles during perturbation-based balance training.
214352208|NCT03726034|BEHAVIORAL|Life Story Book|The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.
214393655|NCT02662595|OTHER|SMS reminder message|
214393656|NCT02662595|OTHER|Voice call + SMS message|
214959312|NCT01302795|DRUG|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
214352209|NCT03726034|BEHAVIORAL|Self-selected social activities|To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
214352210|NCT01518868|DEVICE|Investigational contact lens|Worn on a daily wear basis for one week.
214352211|NCT01518868|DEVICE|PureVision contact lens|Worn on a daily wear basis for one week
214486840|NCT04046549|DRUG|Methylprednisolone|"Protocol versions 1 and 2: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6.~Protocol versions 3 and 4: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, 6 and 7. Participants may be tapered to at least 20 mg per day on Day 8, to at least 10 mg per day on Day 15, and to at least 5 mg per day on Day 22. Discontinuation of prednisone following the post-op Day 28 visit."
214486841|NCT06632379|DRUG|Atorvastatin 10 mg|Participants will be assigned to 10 mg Atorvastatin
214486842|NCT06632379|DRUG|Placebo|Participants will be assigned to identical appearing placebo
214486843|NCT07031349|DEVICE|MARPE|Adult patients with maxillary constriction underwent maxillary expansion using a miniscrew-assisted rapid palatal expander (MARPE).
214352212|NCT02774057|DRUG|Captafer®|"2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems"
214352213|NCT02774057|DRUG|Iron Sulfate|195 mg Iron supplement
214352214|NCT02273141|DRUG|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
214352215|NCT02273141|DRUG|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
214486844|NCT07038954|OTHER|Stone Composition Analysis|This intervention involves the compositional analysis of kidney stone fragments retrieved during surgical procedures. The stone samples are analyzed using X-ray diffraction (XRD) and infrared spectroscopy (IR) to determine their crystal composition. This is a non-invasive, laboratory-based diagnostic procedure. No drug, device, or therapeutic intervention was administered to participants as part of this observational study.
214486845|NCT06703710|DRUG|JW2286|a single administration of JW2286 per dose
214959313|NCT05114187|OTHER|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. Ten selected multimedia e-learning lessons;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete the intervention. The total time to complete is approximately 5-6 hours."
214959314|NCT05114187|OTHER|Education Control|"Participants in the control group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. One selected multimedia e-learning lesson;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete. The total time to complete is approximately 1-2 hours.~Note: All participants will receive access to all e-learning at the conclusion of the study."
214352216|NCT00373594|DRUG|Rituximab|
214352217|NCT00373594|DRUG|Fludarabine|
214352218|NCT00492284|DRUG|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
214959315|NCT04120181|OTHER|There is no intervention.|There is no intervention.
214352219|NCT00492284|DRUG|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
214352220|NCT00492284|DRUG|ranibizumab|0.5 mg intravitreal injection
214486846|NCT06703710|DRUG|Placebo of JW2286|a single administration of Placebo of JW2286 per dose
214486847|NCT06715085|DRUG|Plasma Rich in Growth Factors (PRGF)|The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.
214486848|NCT06715085|DRUG|Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.|The corticosteroid solution application consists of two series of infiltrations of solution of corticosteroid (Celestone Cronodose injectable suspension \[betamethasone\]) and saline solution in the epidural space and in the facets, with a periodicity of one month between them.
214678846|NCT03025191|BEHAVIORAL|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
214352221|NCT00492284|DRUG|dexamethasone|0.5 mg intravitreal injection
214352222|NCT02287935|PROCEDURE|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
214352223|NCT02287935|PROCEDURE|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
215079087|NCT04260763|DEVICE|Novel Mobile App|"The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking."
215079088|NCT01984645|OTHER|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
214352224|NCT05281380|DIETARY_SUPPLEMENT|GIKAVI|Two tailormade supplements for patients; one for that underwent esophagectomy and one for (sub-)total gastrectomy.
214352225|NCT02086357|PROCEDURE|SWUE|
214959316|NCT05704270|BEHAVIORAL|Multi-domain adaptive cognitive training|The multi-domain adaptive cognitive training covers seven aspects of fundamental cognitive function, including sensory perception, cognitive flexibility, attention, memory, language, logic calculation, and emotion recognition and management. A self-adaptive algorithm is embedded in the tablet-based cognitive training platform, which will help deliver suitable tasks at the right difficulty level for each participant according to their personal profile and real-time performance. The intervention dosage is 30 minutes per time, 5 times a week.
214959317|NCT05704270|BEHAVIORAL|Basic cognitive training with no difficulty change|The basic cognitive training for the control arm will also be delivered via a tablet. The training tasks will be fixed at a primary difficulty level without adaptive algorithm. The intervention dosage is also 30 minutes per time, 5 times a week.
214959318|NCT00005587|RADIATION|radiation therapy|
214959319|NCT01945047|DRUG|Ketamine|Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
214959320|NCT01945047|DRUG|Midazolam|Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
214959321|NCT03412292|DRUG|MAX-40279|"MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S.~MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light.~MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses."
214959322|NCT03619655|PROCEDURE|SPECT CT|MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.
214959323|NCT03619655|DRUG|18F-DCFPyL PET/CT|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
214959324|NCT03619655|DRUG|18F-NaF PET/CT|A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
214959325|NCT03619655|PROCEDURE|WB-MRI|Whole body MRI exam (total examination time \< 50 minutes)
214959326|NCT03331263|DRUG|Chlorhexidine Gluconate|2% CHG
214959327|NCT03430908|OTHER|Blind Gastric Tube Placement|The provider will be blinded to the ultrasound imaging throughout the entire insertion. This blind insertion process is the standard of care currently practiced at MSKCC. After the provider verbalizes that they have completed the insertion the investigators will stop the ultrasound imaging and complete the data form. No information will be given to the provider about the location of the gastric tube as to not deviate from the standard of care. The only time that information will be provided to the practitioner inserting the tube will be if the tube is positioned in any of the following positions that are thought to be potentially injurious if unrecognized. These positions include intrapulmonary, cranial, nasal or oral pharyngeal placements and diverticular or hiatal hernia sac coiling and remain unrecognized by the practitioner. These are considered positions that have the potential for injury and therefore will be divulged to prevent ensuing injury.
214352226|NCT00934466|DRUG|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
214352227|NCT00934466|DRUG|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
214959328|NCT01581515|DEVICE|Promus Element everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
214959329|NCT01581515|DEVICE|Xience Prime everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
214352228|NCT00934466|DRUG|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
214352229|NCT00934466|DRUG|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
214352230|NCT00934466|DRUG|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
214352231|NCT01556438|BIOLOGICAL|Tabalumab|Administered IV
214352232|NCT01556438|DRUG|Bortezomib IV|Administered IV
214352233|NCT01556438|DRUG|Bortezomib SC|Administered SC
214352234|NCT01556438|DRUG|Dexamethasone|Administered orally
214352235|NCT00529399|DRUG|GAD-Alum|Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
214352236|NCT00529399|DRUG|GAD-Alum and Aluminum hydroxide|Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
214352237|NCT00529399|DRUG|Aluminum hydroxide|Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
214959330|NCT01490840|OTHER|Physical exercise|Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.
214959331|NCT00826566|DIETARY_SUPPLEMENT|Caffeine|2 times 250 mg caffeine per day
215079089|NCT06225024|DEVICE|ESWT|Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
215079090|NCT06225024|DRUG|BoNT A|BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
214352238|NCT01494402|DRUG|D961S|Oral gelatine capsule
214352239|NCT01494402|DRUG|Esomeprazole|Oral HPMC capsule
214352240|NCT01494402|DRUG|Buffered acetylsalicylic acid|Tablet
214352241|NCT03998826|DRUG|Piroxicam|20mg piroxicam
214352242|NCT03998826|DRUG|Placebo|placebo
214352243|NCT03778229|DRUG|osimertinib|osimertinib (80 mg oral OD).
214352244|NCT03778229|DRUG|savolitinib|savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
214352245|NCT03778229|DRUG|placebo|placebo to osimertinib (oral OD)
214352246|NCT03726346|DEVICE|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
214352247|NCT02734212|BEHAVIORAL|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
214352248|NCT02734212|OTHER|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
214352249|NCT04862793|DEVICE|Colonoscopy Progression Score (CoPS)|The Colonoscopy Progression Score consists of five different aspects: Travel length, Tip progression, chase efficiency, shaft movement without tip progression and looping.
214352250|NCT04862793|DEVICE|Colonoscopy Retraction Score (CoRS)|The Colonoscopy Retraction Score consists of three different aspects: Tip Retraction, Retraction Efficiency, and Retraction Distance.
214352251|NCT02319499|DIETARY_SUPPLEMENT|Zinc Alone|Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)
214352252|NCT02319499|DIETARY_SUPPLEMENT|Iron and Zinc|Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)
214352253|NCT02319499|DIETARY_SUPPLEMENT|Iron, Zinc and Vitamin A|Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A
214352254|NCT02319499|OTHER|Placebo|Placebo group received no minerals/vitamin
214352255|NCT05256589|DIAGNOSTIC_TEST|Sona Saliva C-19 Rapid Self-test|Rapid Antigen diagnostic device performance comparative to RT-PCR
214959332|NCT00826566|DIETARY_SUPPLEMENT|placebo|2 times 250 mg per day
215079091|NCT03416920|OTHER|Wellframe|Wellframe mobile phone app
215079092|NCT01648296|DRUG|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
215079093|NCT03385265|BEHAVIORAL|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
214352256|NCT04313881|DRUG|Magrolimab|Administered intravenously
215079094|NCT03385265|OTHER|Standard of Care|Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
214352257|NCT04313881|DRUG|Azacitidine|Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
214352258|NCT04313881|DRUG|Placebo|Placebo to match magrolimab administered intravenously
214352259|NCT00736372|DRUG|PX-12|Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
214352260|NCT03370653|DRUG|Odiparcil|Investigational product: odiparcil 250 mg tablets
214352261|NCT03370653|OTHER|Placebo|Comparator: placebo tablets similar to odiparcil 250 mg tablets
214352262|NCT00177554|DRUG|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
214352263|NCT00021762|BIOLOGICAL|HIV-1 Immunogen|
214352264|NCT00021762|PROCEDURE|Structured Treatment Interruption|
214352265|NCT03061253|OTHER|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
214352266|NCT03061253|OTHER|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
214959333|NCT03659123|BEHAVIORAL|standardized geriatric intervention|"Nutritional care is based on:~* A personalized evaluation of nutritional balance and nutritional needs of the patient~* A weekly follow-up of weight and nutritional intake~Total-body rehabilitation is based on:~* 2 to 3 times a week: strength exercise~* 2 to 3 times a week: endurance exercise, 20 to 45 min each sequence~* 2 times a week: respiratory physiotherapy Pharmaceutical conciliation and optimization according STOPP/START criteria During peri-operative time, the nurse contacts the surgical team for transmission of patient's personal data, physical medication conciliation results During rehabilitation time and hospital-home transition time, the nurse contacts the rehabilitation team for transmission of patient's personal data and care course, physical (nutritional, functional and/or comorbidities), medication conciliation results."
214352267|NCT03061253|OTHER|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
214352268|NCT00421499|DRUG|dark chocolate|
214352269|NCT04006327|OTHER|No intervention will be provided as this study is a cross-sectional observational study.|This item is not applicable because this study is a cross-sectional observational study and no intervention will be provided to participants.
214352270|NCT03664076|DIAGNOSTIC_TEST|COMISS score|cow's milk protein symptoms score awareness tool to select cow's milk protein allergy in infants
214352271|NCT00909012|DIETARY_SUPPLEMENT|high oleic sunflower oil|placebo, which does not provide DHA
214352272|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
214352273|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
214352274|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
214352275|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
214352276|NCT05688904|DRUG|Imipramine|Topical 4% Imipramine
214352277|NCT05688904|OTHER|Vehicle|Vehicle
214352278|NCT05088928|DRUG|Apixaban|Direct Acting Oral Anti coagulant
214352279|NCT05088928|DRUG|Rivaroxaban|Direct Acting Oral Anti coagulant
214352280|NCT00450827|BIOLOGICAL|bevacizumab|
214352281|NCT00450827|BIOLOGICAL|filgrastim|
214352282|NCT00450827|PROCEDURE|autologous hematopoietic stem cell transplantation|
214352283|NCT00450827|RADIATION|iodine I 131 monoclonal antibody 3F8|
214352284|NCT05432648|DIETARY_SUPPLEMENT|Green bean puree|Green bean contains both soluble and insoluble fiber, which may have different extent of influence on the gut microbiome. Using a real food rather than a purified fiber such as pectin is more practical and more acceptable to families.
214959334|NCT00356109|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
214959335|NCT00356109|DRUG|Injectable insulin|patient specific dose, injected, before meals, 6 months
214352285|NCT06478784|OTHER|Resistance training|"The experimental group (ACTIVE GROUP) will perform a circuit-based muscular strength program at high intensity three days per week for 10 weeks.~Each session will last approximately 45 minutes.~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
214352286|NCT06478784|OTHER|Low aerobic training|"Patients assigned to this group will perform exercise in static bicycle during 45 minutes three days a week, with a duration of 10 weeks.~This second group, despite performing the aerobic exercise, is considered control, since they will perform low-intensity aerobic exercise (50% of the maximum power developed in cycloergometer)~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
214959336|NCT00356109|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 6 months
214959337|NCT00818155|DRUG|desvenlafaxine succinate SR|desvenlafaxine succinate SR
214959338|NCT00818155|OTHER|Placebo|
214959339|NCT04485078|DIAGNOSTIC_TEST|Pressure pain threshold|The PPT assessments of spine will be performed over the spinous process and 2 cm right and left side of the corresponding spinous process. The regional PPT scores will be composed from sum of all PPT values for related segments at spine. The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
214352287|NCT06275204|DRUG|Bismuth-based quadruple therapy|"Participants who are positive with H. pylori will receive bismuth-based quadruple therapy:~Antibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
214352288|NCT06275204|DRUG|Levofloxacin-based quadruple therapy|"In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment:~Antibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
214352289|NCT06275204|DRUG|Standard triple therapy|"Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg."
214959340|NCT04485078|DIAGNOSTIC_TEST|Temporal summation|TS will be evaluated over the trapezius muscle, sacroiliac joints, C7, T6, and L3 levels at spine with manuel algometer. TS scores will be calculated for each spine level as the sum of three values which measured over the spinous process and 2 cm right and left side of corresponding level. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
214352290|NCT06275204|DRUG|Levofloxacin-based triple|"Participants with treatment failure will be recommended second line treatment - levofloxacin-based:~Antibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg"
214959341|NCT04485078|DIAGNOSTIC_TEST|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 70C water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
214352291|NCT04385953|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
214352292|NCT02361853|OTHER|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
214959342|NCT04485078|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
214959343|NCT04485078|OTHER|Bath Ankylosing Spondylitis Disease Activity Index|Standardized questionnaire to determine the level of disease activity in AxSpa patients
214959344|NCT04485078|OTHER|Ankylosing Spondylitis Quality of Life|Standardized questionnaire to investigate the quality of life in AxSpa patients
214352293|NCT02361853|OTHER|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
214352294|NCT02361853|OTHER|Exposure: abundance of Immature monocytes counts in blood samples|
214352295|NCT02361853|OTHER|Exposure: abundance of Immature neutrophils counts in blood samples|
214352296|NCT00095264|DRUG|Darbepoetin Alfa|
214352297|NCT02741960|DRUG|metformin|500 mg metformin three times daily
214678847|NCT03025191|BEHAVIORAL|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
214959345|NCT04485078|OTHER|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability
214959346|NCT04485078|OTHER|Beck Depression Inventory|Standardized questionnaire to investigate the depression
214959347|NCT04485078|OTHER|Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue
214959348|NCT04485078|OTHER|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
214959349|NCT04485078|OTHER|Fibromyalgia Rapid Screening Tool|Standardized questionnaire to detect fibromyalgia
214959350|NCT04485078|OTHER|Visual analogue scale|global pain score on a 0 to 10
214959351|NCT00362947|DRUG|LMWH parnaparin subcutaneously|
214352298|NCT02741960|DRUG|placebo|500 mg placebo three times daily
214352299|NCT01360151|DRUG|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
214678848|NCT03025191|BEHAVIORAL|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
214959352|NCT01792765|OTHER|Ultrasound guidance|Patient will have intraoperative ultrasound .
214959353|NCT01075997|DEVICE|cell phone delivered tele-educational|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.
214352300|NCT00607555|DEVICE|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
214352301|NCT00333463|BEHAVIORAL|Intervention|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
214352302|NCT06198569|OTHER|PNF EXERCISES|"Scapular PNF exercise training (6 Weeks) Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Scapular patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization"
214352303|NCT06198569|OTHER|strength exercises|"Upper limb exercise training (6 Weeks) 3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down~Upper extremity movements - Scapular retraction - Shoulder flexion - Shoulder extension - Shoulder abduction - Shoulder adduction Resistant exercise training with Theraband and weights"
214352304|NCT03131518|BEHAVIORAL|Access to an e-bicycle with trailer|Participants will be provided with an e-bike with trailer for 3 months.
214352305|NCT03131518|BEHAVIORAL|Access to a longtail bicycle|Participants will be provided with a longtail bike for 3 months.
214352306|NCT03131518|BEHAVIORAL|Access to a traditional bike with trailer|Participants will be provided with a traditional bicycle with trailer for 3 months.
214678849|NCT03025191|BEHAVIORAL|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
214959354|NCT01075997|DEVICE|cell phone|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
214959355|NCT04214366|RADIATION|Carbon ion irradiation|22 x 3 Gy(RBE) Carbon Ions
214959356|NCT04214366|RADIATION|Bimodal irradiation|25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost
214959357|NCT00594893|PROCEDURE|Mini Incision Approach|Mini Incision Approach
214959358|NCT00594893|PROCEDURE|2 Incision Approach|2 Incision Approach
214959359|NCT00823030|PROCEDURE|Urodynamic study|A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
214959360|NCT00823030|DRUG|Lidocaine|20 cc of alkalinized lidocaine will be injected after the first UDS
214959361|NCT00823030|OTHER|Normal Saline|20 cc of normal saline will be injected into the bladder after the first UDS
214959362|NCT02749227|DRUG|Pasireotide LAR|"Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained."
215079095|NCT05726565|OTHER|multidisciplinary cardiac rehabilitation|A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
215079096|NCT01949025|OTHER|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
215079097|NCT01560637|DRUG|UT-15C (treprostinil diolamine)|UT-15C extended release oral tablet three times daily
214959363|NCT02640313|DRUG|18F-choline PET-MR imaging|Dynamic and static 18F-choline PET-MR imaging
214959364|NCT02800369|BIOLOGICAL|ZFN-603 and ZFN-758|Each suppository contain 500 µg of ZFN-603 or ZFN-758
214959365|NCT03639857|DEVICE|532nm laser|532nm laser will be used to treat the lesion in this study arm.
214959366|NCT03639857|DEVICE|1064nm laser|1064nm laser will be used to treat the lesion in this study arm.
214959367|NCT03639857|DRUG|Topical corticosteroid|The topical corticosteroid will be used to treat the lesion in this study arm.
214959368|NCT03836157|DRUG|Mirvetuximab Soravtansine|The dose will not be recalculated unless the patient has ±10% weight change.
214959369|NCT03836157|DRUG|Bevacizumab|Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.
214959370|NCT02805296|OTHER|Light irradiance|Comparison of double vs. single phototherapy
214959371|NCT04887350|BEHAVIORAL|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.
214959372|NCT04887350|BEHAVIORAL|Problem Solving Therapy (PST).|Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.
214959373|NCT03245320|DEVICE|Integra TITAN™ Total Shoulder Generation 1.0|Total Shoulder Arthroplasty or Hemiarthroplasty
214959374|NCT05978219|DRUG|Mirtazapine Tablets|Mirtazapine tablet form, orally, once or twice daily, 15-45 mg
215079098|NCT00888524|PROCEDURE|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
215079099|NCT00888524|PROCEDURE|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
215079100|NCT02817113|DRUG|NC-6004|One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
214352307|NCT02935062|BEHAVIORAL|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
214352308|NCT02935062|BEHAVIORAL|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
214352309|NCT02935062|BEHAVIORAL|Placebo Therapy|No intervention to improve speech.
214352310|NCT01734681|DRUG|G-202|
214352311|NCT04732286|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
214352312|NCT04732286|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
214959375|NCT01054495|DRUG|Acupuncture|"The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes."
214352313|NCT05627180|BEHAVIORAL|Tailored Health Literacy follow-up in cancer|"1. Participants are invited to a consultation with the project nurse where the project nurse will use baseline data to identify the patient's HL needs, QOL, symptom burden and issues related to self-management of their cancer and treatment. These data will be used together with an interview questionnaire specifically developed to communicate HL needs (i.e. CHAT), which form the basis for the individualized HL support.~2. Actions: Based on results of the consultation, the project nurse and the patient will use a worksheet of possible actions to identify those most relevant to the patient's individual needs. Based on this, different self-management tasks and actions will be offered, and an individual tailored follow-up plan will be made. The patient and the project nurse will use a workbook containing information on the follow-up plan that will be added into medical record.~3. Telephone/digital conversations with the project every second month for a period of 9 months."
214352314|NCT04027556|OTHER|low dose CT contrast media - lean body weight|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.
214352315|NCT04027556|OTHER|Standard dose CT contrast media|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.
214352316|NCT03521960|DRUG|Buspirone oral capsule|15 milligrams, three times daily
214352317|NCT03521960|DRUG|Placebo oral capsule|0 milligrams (placebo), three times daily
214959376|NCT01054495|DEVICE|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
214959377|NCT01054495|DEVICE|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
214959378|NCT01463943|OTHER|Probiotic|
214959379|NCT01463943|OTHER|Probiotic|
214959380|NCT01463943|OTHER|Probiotic|
214352318|NCT05812651|OTHER|Inspiratory muscle fatigue|"Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation."
214352319|NCT03818412|PROCEDURE|Archival tumor tissue collection and blood draws|Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.
214393657|NCT01398436|PROCEDURE|central venous catheter positioning in right atrium|A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
214393658|NCT01940653|DRUG|Progesterone|"Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred."
214959381|NCT02136901|DEVICE|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
214959382|NCT02136901|DRUG|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
214959383|NCT02136901|DRUG|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
214959384|NCT02136901|DRUG|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
214959385|NCT04835064|DRUG|Nab paclitaxel|Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15
214393659|NCT02589041|PROCEDURE|intraneural sciatic nerve injection|"A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication."
215079101|NCT02817113|DRUG|Cetuximab|One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
215079102|NCT02817113|DRUG|5-FU|One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
215079103|NCT00716430|BEHAVIORAL|Quality Improvement Programme|Quality Improvement training programme
215079104|NCT00567671|PROCEDURE|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
214352320|NCT04656626|BEHAVIORAL|brief mindfulness based intervention|The 20 minute daily mindfulness sessions for 2 weeks consist of the following guided meditation practices: 1. Bring your attention to a primary object of focus 2. Maintain a moment-moment awareness 3. When your mind naturally drifts into thinking (mind wandering); just notice you are thinking, and then bring your attention back to your object of focus 4. When a strong sensation arises, again, notice the sensation or emotion and return to your breath. 5. As you gain confidence, you may practice maintaining this focus while observing thoughts flowing through your mind or sensations in your body while showing no concern for the content 6. You may even label your thoughts 7. Thank yourself for your efforts and for taking this time.
214959386|NCT04835064|DRUG|Gemcitabine|Intravenous infusion of 1000 mg/m2 was given for more than 30min on days 1, 8, and 15, and repeated every 4 weeks
214352321|NCT04656626|BEHAVIORAL|Progressive muscle relaxation|"Control group:~Control group will be given an mp3 audio recording of a 20-minutes of progressive muscle relaxation will be sent directly as SMS messages and emails to be heard by the participants through their personal device of their choice, such as a smart phone."
214352322|NCT00517712|DRUG|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
214352323|NCT03359265|DEVICE|underpants|
214352324|NCT01850225|DEVICE|Auditory brainstem implant|
214352325|NCT02415816|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
214352326|NCT01733056|BIOLOGICAL|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
214352327|NCT01408368|PROCEDURE|Bilateral subtotal thyroidectomy|The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
214352328|NCT01408368|PROCEDURE|Total thyroidectomy|The intervention consisted of total extracapsular thyroidectomy.
214352329|NCT03185611|DRUG|Rifaximin|Antibiotics
214352330|NCT03185611|DRUG|Azathioprine|immunomodulator
214352331|NCT05991752|DIAGNOSTIC_TEST|ROMA score evaluation|Every 4 months, for 3 years, patients in the experimental group will done a biological examination based on assessment of the ROMA score (CA125+HE4 assay).
214352332|NCT04551170|DRUG|Theophylline|oral theophylline
214352333|NCT04551170|DRUG|Placebo|Placebo capsule or elixir
214352334|NCT01118390|DEVICE|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
214352335|NCT01118390|OTHER|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
214352336|NCT01910129|DEVICE|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
214959387|NCT04835064|DRUG|mFOLFIRINOX|Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
214959388|NCT00091468|DRUG|Transdermal nicotine patch|double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
215079105|NCT00567671|PROCEDURE|Sham comparator|Sham treatment
214352337|NCT03543826|COMBINATION_PRODUCT|Protocol for rocuronium neuromuscular block|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
214352338|NCT04938895|BEHAVIORAL|Black Respondents Exposure to a Photo|Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
214352339|NCT06963008|DRUG|inhaled BMD003(CFTR mRNA)|BMD003 is the world's first freeze-dried CFTR Mrna product (stored at 2-8 ℃), which is reconstituted with injection water before use, nebulized through a vibrating sieve atomizer, and inhaled into the lungs through the mouth and nose.
214352340|NCT05888597|DRUG|L-menthol|(Sigma-Aldrich, St. Louis, US)
214959389|NCT00091468|DRUG|Placebo transdermal patch|placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
214959390|NCT04824937|DRUG|Telaglenastat|Capsule, taken by mouth
214959391|NCT04824937|DRUG|Talazoparib|Capsule, taken by mouth
214352341|NCT05888597|OTHER|Placebo|Strawberry scent (Sigma-Aldrich, St. Louis, US)
214393660|NCT02589041|DRUG|Ropivacaine 1%|
214393661|NCT04651452|BEHAVIORAL|Value Affirmation|Participants will complete writing tasks regarding their personal values.
214959392|NCT06077162|OTHER|Diabetes Nutrition Education Classes|Diabetes nutrition education offered by registered dietitian in group-based classes.
214959393|NCT06077162|OTHER|Healthy Food Security Resource|Participants offered security resource which is a $30.00 Aldi (grocery store) gift card provided weekly for 12 weeks.
214959394|NCT00079651|BEHAVIORAL|Montessori-based dementia programming|
214959395|NCT02364297|DEVICE|Early TIPS|TIPS (first 5 days)
215079106|NCT00675818|DEVICE|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
215079107|NCT00675818|DEVICE|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
214959396|NCT05272553|OTHER|Narrative Exposure Therapy|NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for trauma-spectrum disorders; it aims to reduce symptoms of traumatic stress in individuals who continue to suffer from past experiences of traumatic stressors; NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.
214959397|NCT02186158|DRUG|Vitamin C|
214959398|NCT02186158|DRUG|Placebo|
214959399|NCT01025284|DRUG|LY2523355|Administered intravenously as a 1-hour infusion
214959400|NCT01025284|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Administered subcutaneously
214959401|NCT02381613|OTHER|Baked beef|A meal based on baked beef
214959402|NCT02381613|OTHER|Baked herring|A meal based on baked herring
214959403|NCT02381613|OTHER|Pickled herring|A meal based on pickled herring
214959404|NCT05482503|DEVICE|12-Lead ECG(I-lead)|All participants will simultaneously record 12-lead ECGs(I-lead)
214959405|NCT00905567|DRUG|Topiramate 2 x 25 mg tablet|
215079108|NCT03411200|BEHAVIORAL|Multimodal and exercise-based intervention|"The multimodal and exercise-based intervention is comprised of:~1. Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~2. Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~3. Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~4. A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session."
215079109|NCT03241771|BEHAVIORAL|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
215079110|NCT01015235|DRUG|Placebo|Subcutaneous infusion-once over 4 hours
214959406|NCT00905567|DRUG|Topamax® Tablet 2 x 25 mg|
214678850|NCT00081289|RADIATION|Radiation Therapy|Pelvic radiation therapy given once daily 5 days a week for 6 weeks, 45 Gy in 25 fractions + boost of 5.4 Gy in 3 fractions for a total dose of 50.4 Gy.
214959407|NCT02753816|DRUG|Tranexamic Acid|
215079111|NCT01015235|DRUG|KAI-1678|Subcutaneous infusion-once over 4 hours
215079112|NCT01015235|DRUG|Ketorolac Tromethamine|Active comparator, IV infusion, once
215079113|NCT00926731|DRUG|AZD1152|Variable dose via a 7-day continuous infusion
215079114|NCT00926731|DRUG|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
215079115|NCT02323204|BEHAVIORAL|Link for Injured Kids|Psychological First Aid
215079116|NCT02323204|OTHER|So you've been in an accident|Educational materials
214678851|NCT00081289|DRUG|Capecitabine 1650 mg/m^2/day|825 mg/m\^2 q12 hours (1650 mg/m\^2/day) orally 5 days per week during radiotherapy.
214678852|NCT00081289|DRUG|Capecitabine 1200 mg/m^2/day|600 mg/m\^2 q12 hours(1200 mg/m\^2/day) orally 5 days per week during radiotherapy.
214959408|NCT02753816|DRUG|Placebo Comparator|
214959409|NCT03046771|BEHAVIORAL|Transport PLUS group|The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
214959410|NCT02542397|GENETIC|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
214959411|NCT04028323|DRUG|Terlipressin|Terlipressin should be administrated intravenously while monitoring heart rate and blood pressure daily.
214959412|NCT04028323|DRUG|Octreotide|Octreotide should be continuously intravenously administrated while monitoring heart rate and blood pressure daily.
214959413|NCT00389467|DEVICE|Merci Retriever and Penumbra System|"The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).~The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2)."
214959414|NCT04985227|OTHER|Home weight monitoring|Parents will be provided with weighing scales to weigh their infant at home and plug in the weight in the patient portal for review by their primary care provider.
214959415|NCT04485663|DRUG|ALG-010133|Single or multiple doses of ALG-010133
214959416|NCT04485663|DRUG|Placebo|Single or multiple doses of Placebo
215079117|NCT00395135|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
215079118|NCT00395135|DRUG|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
215079119|NCT00597363|DEVICE|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH \& Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
215079120|NCT00597363|OTHER|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
215079121|NCT01683513|DRUG|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
214352342|NCT03595904|BEHAVIORAL|E-Motivate group|Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders). They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy. The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).
214959417|NCT04241510|DEVICE|Kinesio Taping|Kinesio Taping is a special taping method developed by Dr. Kenzo Kase in 1973. This technique triggers natural healing responses of human body by activating nervous and circulatory systems. The tapes are thin, latex-free, cotton, porous and anti-allergenic, with equal thickness of epidermis. It has elastic properites which allows the tape to elongate to %55-60 of its original lenght. Tape can be used up to 1 week even after sweating or cleaning with water. There are different application techniques for different purposes. Facilitation technique facilitates muscle contractions and supports muscle function. Mechancial correction technique is used for joint positioning and correcting motion of muscle-joint dynamics.
214959418|NCT01164150|RADIATION|45 Gy/25 fractions|Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
214959419|NCT02362191|DEVICE|Alternating Current Stimulator|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
214959420|NCT02208076|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
214959421|NCT02320708|DRUG|Acetaminophen (ACE) (1000 mg)|2 Test ACE 500 mg tablets taken orally one time
214959422|NCT02320708|DRUG|Commercial ACE (1000 mg)|2 ACE 500 mg caplets taken orally one time
214959423|NCT02320708|DRUG|Commercial Ibuprofen (IBU) (400 mg)|2 IBU 200 mg soft-gels taken orally one time
214959424|NCT02320708|DRUG|Placebo|2 placebo caplets for acetaminophen taken orally one time
214959425|NCT02320708|DRUG|Placebo|2 placebo soft-gels for ibuprofen taken orally one time
214959426|NCT02320708|DRUG|Placebo|2 placebo tablets for Test acetaminophen taken orally one time
214959427|NCT01738919|PROCEDURE|Conservative treatment with splinting for 6 weeks.|Aluminum Karstam splints are used.
214959428|NCT01738919|PROCEDURE|Operative treatment with extension block technique|Surgery with extension block technique. 6 weeks.
214959429|NCT02133833|DEVICE|Quantum Spectrum Radiation Emitter|The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
214352343|NCT03595904|BEHAVIORAL|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy. In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
214959430|NCT04632459|DRUG|pembrolizumab plus ramucirumab|"Patients will continue to receive study treatment, until they demonstrate objective disease progression (determined by modified RECIST 1.1) or until they meet any other discontinuation criteria.~* Ramucirumab 8mg/kg on q2W~* Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~* If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles."
214959431|NCT03200561|DRUG|Prednisolone|Prednisolone 2mg/Kg/day for 5 days
214959432|NCT03200561|BIOLOGICAL|immunoglobulin|immunoglobulin 2g/Kg for 12 hours
214352344|NCT01392560|DRUG|BI 10773|Oral once daily
214959433|NCT02716792|DRUG|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
214959434|NCT00024440|BIOLOGICAL|filgrastim|
214959435|NCT00024440|BIOLOGICAL|oblimersen sodium|
214959436|NCT00024440|DRUG|cyclophosphamide|
214959437|NCT00024440|DRUG|fludarabine phosphate|
214959438|NCT01473940|BIOLOGICAL|ipilimumab|Given IV
214959439|NCT01473940|DRUG|gemcitabine hydrochloride|Given IV
214959440|NCT01473940|OTHER|laboratory biomarker analysis|Correlative studies
214959441|NCT06488898|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|"Investigational medicinal product: Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an advanced therapy medicinal product under European regulation (Article 2(1) of Regulation (EC) No 1394/2007 of the European Parliament and the Council of November 13 th 2007 about advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).~Administration form: Local injection by means of a catheter placed inside the previously excluded aneurysmal sac.~Administration dose: 1x10000000 cells/kg patient weight.~Administration guidelines: single infusion on the endovascular day AAA intervention."
214959442|NCT06358118|DRUG|Buyuan Zhixiao Formula|Buyuan Zhixiao Formula
214959443|NCT06358118|DRUG|Placebo|The placebo contains 10% of the active ingredients of the Chinese medicine group
214352345|NCT06196762|DRUG|XKH002 Injection|240 mg/4 mL/vial（60 mg/mL）
214352346|NCT04582630|DIETARY_SUPPLEMENT|omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
214352347|NCT03362905|DRUG|Lidocaine topical|Local anesthetic for reduction of IUD associated pain
214678853|NCT00081289|DRUG|Irinotecan|50mg/m\^2 IV over 1 hour on days 1, 8, 22, and 29
214959444|NCT06080542|PROCEDURE|Aerobic|This session will consist of an aerobic training session performed on a cycle ergometer.
214959445|NCT06080542|PROCEDURE|High-intensity interval training|This session will consist of a HIIT performed with elastic bands
215079122|NCT03897296|DIAGNOSTIC_TEST|High resolution anorectal manometry, water perfused catheter|High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
214352348|NCT04051346|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
214352349|NCT04051346|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
214352350|NCT05414682|OTHER|MIND+SOUL Diet|The MIND+SOUL Diet is an adapted brain-healthy soul food diet.
214352351|NCT06374212|DRUG|Anifrolumab|900mg maintenance dose every 4 weeks for 12 weeks then 600mg loading dose every 4 weeks until week 20
214959446|NCT05936021|PROCEDURE|Algorithm model-based Aranesp doses|Patients will receive doses calculated by the algorithm instead of by the standard of care procedures. Model-based Aranesp doses will be computed at the same time that doses based on the dialysis anemia protocol are determined. The model-based doses will be administered instead of the protocol-based doses and in the same way and at the same time as the protocol-based doses would have been. The model-based dosing will be more flexible than the protocol-based dosing. Some constraints in the protocol-based dosing were created to prevent patients from achieving high Hb levels. The model-based dosing will also prevent these high Hb values but will do so by predicting a patient's Hb level into the future and then using these predictions to determine doses to reduce Hb variability and to reduce the amount of Aranesp used.
214959447|NCT05936021|PROCEDURE|Standard of care|Current standard of care guidelines are followed for erythropoiesis-stimulating agents to control anemia in dialysis patients
214959448|NCT03744403|DRUG|CS1001|In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.
214352352|NCT02683538|DEVICE|Separable cluster electrode (Octopus®)|Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
214352353|NCT02623673|DRUG|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
214352354|NCT00572234|DRUG|bupropion SR|12 week course of bupropion SR 150 mg, BID
214352355|NCT05331261|PROCEDURE|Total diz replacement ameliyatı|Breath exercises
214352356|NCT03143218|BIOLOGICAL|RABIPUR®|Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
214352357|NCT03143218|BIOLOGICAL|RTS,S/AS01|Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
214352358|NCT03143218|DRUG|SMC with SP+AQ|Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
214352359|NCT03143218|DRUG|SMC placebo|Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
214352360|NCT04775446|OTHER|Data collection|Data entered in a secure computer database
214352361|NCT05637138|DEVICE|tcpCO2 measure|Measurement of tcpCO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
214352362|NCT05637138|DEVICE|tcpO2 measure|Measurement of tcpO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
214352363|NCT05637138|DEVICE|measurement of tissue conductivity to CO2: KS|measurement of tissue conductivity to CO2: KS by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
214352364|NCT05637138|DEVICE|measurement of microcirculation|measurement of microcirculation by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
214486849|NCT07038057|DIETARY_SUPPLEMENT|Short peptide enteral nutrition|Short peptide formula enteral nutrition was initiated within 48 hours after admission to the ICU. For patients with poor swallowing function or no consciousness, nasogastric tubes were placed. Starting from low-calorie or nourishing feeding, 70% of the target energy should be achieved within 7 days, and the protein should be 1.2-1.5 g/kg/d. Due to the large individual differences in energy expenditure among patients with sepsis, the indirect calorimetry (IC) method was used to determine energy expenditure. If the IC method is not feasible, the calculation formula based on body weight: 20-25 kcal/kg/d should be applied for calculation. If the patient is not transferred out of the ICU after 7 days, continue to gradually increase to the target energy and protein requirements under tolerable conditions, and gradually transition to whole protein nutrition after 7 days.
214352365|NCT00472095|OTHER|Fotonovela|
214486850|NCT07038057|DIETARY_SUPPLEMENT|Whole protein enteral nutrition|The whole protein formula enteral nutrition was initiated within 48 hours of admission to the ICU, and the rest were same.
214486851|NCT07040098|DRUG|Sintilimab|PD-1 inhibitor
214486852|NCT07040098|RADIATION|Short-course radiotherapy|Pelvic radiation, SCRT, 5 Gy x 5 alone
214486853|NCT07040098|RADIATION|Long-course concurrent chemoradiotherapy|Pelvic radiation, 50 Gy in 25 fractions over 5 weeks, concurrently with capecitabine (825 mg/m2, twice a day).
214486854|NCT07040098|COMBINATION_PRODUCT|CAPOX|chemotherapy regimen, Oxaliplatin 130 mg/m2 IV day 1，Capecitabine 1000 mg/m2 twice daily PO for 14 days(3 weeks per cycle)
214486855|NCT06881810|DRUG|Oxytocin nasal spray|Syntocinon® nasal spray is applied according to description in arms section
214486856|NCT06881810|OTHER|Placebo|Placebo nasal spray is applied according to description in arms section
214959449|NCT01754324|DRUG|Methadone|The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
214959450|NCT01147718|BIOLOGICAL|digoxin plus albiglutide|A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
214959451|NCT00547248|BIOLOGICAL|Synflorix|Intramuscular injection, 1 dose
214959452|NCT00547248|BIOLOGICAL|Tritanrix-HepB|Intramuscular injection, 1 dose
214959453|NCT00547248|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix-Hep B before injection
214959454|NCT00547248|BIOLOGICAL|Polio Sabin|Oral, 1 dose
214959455|NCT00547248|BIOLOGICAL|Poliorix|Intramuscular injection, 1 dose
214959456|NCT00547248|BIOLOGICAL|Prevenar (Wyeth)|Intramuscular injection, 1 dose
214352366|NCT00472095|OTHER|Placebo Fotonovela|
214352367|NCT04475744|DRUG|G-CSF treatment for Bone marrow derived stem cell Mobilization|Mobilization treatment. On the fifth day, collection will be started.
214486857|NCT06886776|BEHAVIORAL|Implementation package (training and facilitation)|"Training includes an initial presentation on S.A.F.E. Firearm, S.A.F.E. Firearm informational guides and other resources to support delivery, and recommendations for additional, optional self-guided learning resources.~Facilitation will last twelve months at each site. It may involve 1) a pre-implementation readiness assessment for each clinic to identify potential implementation barriers and develop relationships with constituents; 2) kick-off meetings at the launch of the trial, at which clinic staff will identify how and where S.A.F.E. Firearm will be implemented within the clinic; 3) goal-setting within the first few months of the program; 4) trouble-shooting to address barriers identified during the pre-implementation readiness assessment and emergent challenges; and 5) designing a sustainment plan to maintain S.A.F.E. Firearm for future years."
214959457|NCT04934163|OTHER|Flow rate setting of high-flow nasal cannula (initially 60L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 60L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
214959458|NCT04934163|OTHER|Flow rate setting of high-flow nasal cannula (initially 40L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 40L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
214959459|NCT00197431|DRUG|S-1|
214959460|NCT04221269|BEHAVIORAL|Enhanced Treatment as Usual|Routine community care plus assessment feedback reports to clinicians.
214959461|NCT04221269|BEHAVIORAL|Coping Long-term with Active Suicide Program for Schizophrenia|Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
214959462|NCT02020369|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
214959463|NCT06161714|DRUG|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|4% articaine with 1:100,000 epinephrine buccal infiltration
214959464|NCT06161714|DRUG|Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml|2% Lidocaine with 1:100,000 epinephrine buccal infiltration
214959465|NCT00534248|BIOLOGICAL|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
214486858|NCT06808009|DRUG|Lactulose|Syp lactulose
214959466|NCT00534248|BIOLOGICAL|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
214959467|NCT05833919|DRUG|Eribulin Mesylate|"The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes.~The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date"
214352368|NCT04475744|PROCEDURE|Platelet Rich Plasma ovarian injection|Mobilized peripheral blood will be obtained to prepare the PRP for injection. Both ovaries will be injected when proper anatomical access can be assessed.
214352369|NCT05238935|OTHER|prescribed physiotherapy course|provide full assessment and treatment program as postoperative rehabilitation management
214486859|NCT06808009|DRUG|Rifaximin|Rifaximin
214486860|NCT06808009|OTHER|Standard Medical treatment|Standard Medical treatment
214486861|NCT07038005|DRUG|SPGL008|Biological product
214959468|NCT05833919|DRUG|Capecitabine|Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.
214959469|NCT01534117|BIOLOGICAL|Platelets|1 unit of platelets
214959470|NCT01534117|DRUG|DDAVP|Desmopressin 0.3mcg/kg IV x 1
214959471|NCT02532257|DRUG|Ibrutinib|Given PO
214959472|NCT02532257|OTHER|Laboratory Biomarker Analysis|Correlative studies
214959473|NCT02532257|DRUG|Lenalidomide|Given PO
214959474|NCT02532257|BIOLOGICAL|Rituximab|Given IV
214959475|NCT02849171|DEVICE|PET scan|
214959476|NCT02849171|RADIATION|C-Choline|
214959477|NCT04727736|DRUG|18F-DCFPyL|18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
214959478|NCT03204617|BIOLOGICAL|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM)|Vaccine DNA.HTI 0.5mL at weeks 0, 4 and 8 + Vaccine MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM).
214959479|NCT03204617|BIOLOGICAL|At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)|At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
214959480|NCT03204617|DRUG|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
214352370|NCT01752504|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
214959481|NCT05695963|OTHER|Clinical assessment|RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
214959482|NCT05695963|BEHAVIORAL|auto-questionnaires|To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
214959483|NCT05695963|DEVICE|Ecological Momentary Assessment (EMA)|4 electronic interviews administred per day during 14 days by a study-dedicated Android OS smartphone
214959484|NCT05695963|DEVICE|activity-rest cycle|To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
214959485|NCT00988104|BEHAVIORAL|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
214959486|NCT00988104|BEHAVIORAL|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
214959487|NCT00459810|DRUG|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
214959488|NCT00459810|DRUG|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
214959489|NCT02259400|DEVICE|NSIPPV|In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)\< 0.3.
214959490|NCT02259400|DEVICE|BiPAP|In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 \< 0.3.
214959491|NCT03905837|DRUG|Lidocaine|Intravenous or paravertebral lidocaine
214959492|NCT03905837|DRUG|Remifentanil|intravenous remifentanil
214352371|NCT03436394|DRUG|Evobrutinib|Subjects will be administered a single oral dose of evobrutinib under fasting conditions.
214352372|NCT01182753|RADIATION|carbon ion therapy|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
214352373|NCT01182753|RADIATION|proton therapy|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
214959493|NCT00315614|BIOLOGICAL|Islet Transplantation and Bone Marrow|Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
214959494|NCT00697593|DRUG|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
214352374|NCT04158947|DRUG|Afatinib|"Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy"
214352375|NCT04158947|DRUG|T-DM1|"Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
214352376|NCT05867446|BEHAVIORAL|pecha kucha|pecha kucha training
214352377|NCT05934734|OTHER|No intervention|This is an observational cross-sectional study. No intervention will be provided. Participants will be assessed and stratified into four cohorts based on self-reported symptom severity of thoracic outlet syndrome using a visual analog scale (VAS) to investigate the relationship between symptom severity and upper extremity function/neural integrity.
214352378|NCT00374842|BIOLOGICAL|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
214959495|NCT01618786|OTHER|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
214959496|NCT01618786|OTHER|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
214959497|NCT06008210|BEHAVIORAL|Decision Support Intervention|The participants will receive two 60-minute consultation sessions delivered by a trained nurse in four weeks at home. Participant's family members will be encouraged to attend the sessions. In the first session, the nurse will explore the participant's understanding of the current health condition, introduce the concept of advance care planning and discuss their decisional needs for end-of-life care decision-making. In the second session, the nurse will ask the participants to complete a value clarification exercise individually.
214959498|NCT06008210|BEHAVIORAL|Health Coaching|The participants will receive two 60-minute health coaching sessions delivered by a trained nurse in four weeks at home. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes.
214959499|NCT02964338|DRUG|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
214959500|NCT02964338|DRUG|Placebo|Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
214959501|NCT00112918|BIOLOGICAL|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
214959502|NCT00112918|DRUG|Capecitabine|Film-coated tablets
214959503|NCT00112918|DRUG|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
214959504|NCT00112918|DRUG|Leucovorin calcium|Administered as a 200 mg/m\^2 infusion over 2 hours.
214959505|NCT00112918|DRUG|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
214959506|NCT02974348|DRUG|Arthemeter-lumefantrine|Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.
214959507|NCT02974348|DRUG|Artesunate mefloquine|Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs
214959508|NCT02974348|DRUG|Dihydroartemisinin piperaquine|Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs
214959509|NCT02974348|DRUG|Paracetamol|Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation
214959510|NCT02974348|DRUG|Amoxicillin|Amoxicillin is an antibiotic with no reported activity on plasmodium
214959511|NCT02974348|DRUG|Quinine|quinine sulphate is an antimalaria drug administered as a second line or rescue drug
214959512|NCT00741598|DRUG|Galantamine-ER|Galantamine-ER 8 to 24 mg per day for 16 weeks
214959513|NCT00741598|DRUG|Galantamine placebo|Galantamine placebo 8 to 24 mg per day for 16 weeks
214352379|NCT00374842|BIOLOGICAL|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
214959514|NCT02742025|OTHER|Inclusion visit|This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
214959515|NCT02742025|OTHER|Nurse consultation|This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
214959516|NCT02742025|OTHER|Telephone contact|A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
214959517|NCT02742025|PROCEDURE|Coronarography on day 0|This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
214959518|NCT02425423|DIETARY_SUPPLEMENT|New thickened formula|
214959519|NCT03566381|DEVICE|Application of a soft patch composed of medical-grade silicone that collects sweat during a subject's natural behaviors.|This device contains sweat sensors embedded in an elastomer and is applied to the skin with a medical grade adhesive.
214959520|NCT05667168|PROCEDURE|physiotherapy approach|The therapy will take place 2-3 times a week; the therapeutic unit will last 45 minutes and will be oriented towards one therapeutic approach from the above list. The total number of therapy sessions will be limited to 3 months (i.e. three months, 2-3 times a week). After completion of the 3-month therapy, a follow-up examination will be performed again by kinesiological analysis, questions about the intensity of tinnitus according to a numerical scale and quality of life by a selected questionnaire.
214959521|NCT05091996|PROCEDURE|Post-isometric muscle relaxation technique|"1: Therapist (T) abducted the patients' (P) mandible until the functional barrier. P performed isometric tension of the mandibular adductors with about 20% of the maximum force, balanced by the T. After 10 secs of isometric tension, P relaxed his muscles, and T abducted the mandible to a new functional barrier. During one treatment, the cycle was repeated 3 times, each time starting from the previously obtained barrier.~2: T performed passive lateral translation of the mandible until the functional barrier. P performed isometric tension with about 20% of maximum force, as to initiate the movement of the mandible towards the resting position. T balanced the force generated by the P. After 10 secs of isometric tension, P relaxed his muscles and T deepened the lateral movement of the mandible until a new functional barrier was reached. During one treatment, the cycle was repeated 3 times, both to the right and left side, each time starting from the previously obtained barrier."
214959522|NCT05091996|PROCEDURE|Myofascial release technique|The myofascial release procedure was performed successively in the area of: the anterior parts of the temporal muscles , the superficial parts of the masseter muscles and the sternocleidomastoid muscles.During one session, the above cycle was repeated six times on both sides separately. The was lying on his back, with his head turned to the side.The therapist was behind the patient's head, using the pad of the first finger placed on the skin in the area of the initial attachment of a worked muscle, he took out the tissue slack, moving the tissues towards the perceptible limitation of mobility (caudal direction).Reaching the tissue barrier, he kept the tension of the sliding structures, shifting them until the physiological tissue barrier.A single application of the myofascial release procedure consisted of one movement moving the soft tissues along the muscle
214352380|NCT02186951|DRUG|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
214352381|NCT02186951|DRUG|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
214352382|NCT01681589|DEVICE|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
214959523|NCT00030628|RADIATION|radiation therapy|
214959524|NCT00030628|PROCEDURE|surgery|
214959525|NCT00030628|RADIATION|WBRT|
214959526|NCT00387283|DRUG|AVI-4020 Injection|
214959527|NCT01597297|DRUG|BIIB041 (PR Fampridine)|10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
214959528|NCT01597297|OTHER|Placebo|Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
214959529|NCT03747783|PROCEDURE|Radical Operation|The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.
214959530|NCT03974529|BEHAVIORAL|Intensive running|The patients who are assigned to this group will be required to finish a 90 minutes of training protocol, containing 30 minutes' warm-up stretching, and 60 minutes of supervised progressive aerobic endurance track running. The training takes place two time per week, for 24 weeks.
214959531|NCT03974529|BEHAVIORAL|Physiotherapy|The patients who are assigned to this group will be required to finish a 60 minutes of physiotherapy session. The training takes place once per week, for 24 weeks.
214959532|NCT05972642|DEVICE|HIFU-treatment|The investigator will sedate the subject and perform the HIFU procedure with the investigational medical device according to the pre-established procedure plan (see Table 11 for procedure plan) (procedure may take up to 2 hours). During the procedure, the investigator may modify the pre-established procedure plan by checking in with the subject occasionally to assess the presence of heat and pain at the site of the investigational device application.
214959533|NCT06056453|BEHAVIORAL|Interpersonal Psychotherapy|IPT group-virtual
214959534|NCT02869477|OTHER|Data collection|
214352383|NCT01681589|DEVICE|Control Group|This group will receive Sham TDCS
214486862|NCT06728280|DEVICE|deep transcranial magnetic stimulation with H1coil|Participants will receive dTMS treatment with H1 coil
214486863|NCT06728280|DEVICE|deep transcranial magnetic stimulation with H7 coil|Participants will receive dTMS treatment with H7 coil
214959535|NCT00612651|DRUG|Temodar and SCH 66336|2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated \& escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle \& escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning \& evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 \& 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
214959536|NCT04455217|OTHER|data collection from patients with FAI (occuring January 2000 until December 2019)|data collection from patient files (data regarding surgery, adverse events, infections, demographic data)
214959537|NCT02146209|DRUG|Metronidazole benzoate|Single oral dose of 400 mg
214959538|NCT02146209|DRUG|Flagyl 125 mg/5 ml oral suspension|Single oral dose of 500 mg (20 ml suspension)
214959539|NCT02146209|DRUG|Flagyl 400 mg Tablets|Single oral dose of 400 mg
214959540|NCT00587795|DEVICE|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
214959541|NCT00587795|OTHER|Placement of sugar tong splint or plaster cast|Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
214959542|NCT00700024|DRUG|Testim|50 mg/dose7day
214959543|NCT00700024|BEHAVIORAL|Strength training|three times a week
214959544|NCT00700024|DRUG|placebo|placebo
214352384|NCT01681589|OTHER|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
214352385|NCT02907346|BEHAVIORAL|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
214352386|NCT02696148|DRUG|liraglutide|For subcutaneous (s.c., under the skin) injection once daily.
214352387|NCT02696148|DRUG|placebo|For subcutaneous (s.c., under the skin) injection once daily.
214352388|NCT01913600|DEVICE|Resolute Integrity Stent|Drug eluting stent (DES)
214352389|NCT00793468|DRUG|GSK598809|GSK598809 once daily for 12 weeks
214486864|NCT06880458|OTHER|Oral health education|The participants will receive oral health education from multiple different sources, including the Know Your OQ website (https://www.knowyouroq.com/).
214959545|NCT03059732|OTHER|Treatment|Observe the treatments of gastric cancer in each group
214959546|NCT02826161|DRUG|Napabucasin|Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
214959547|NCT02826161|DRUG|Paclitaxel|Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m\^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
214959548|NCT05515237|BEHAVIORAL|Grade 2-5 CI Therapy + Sensory Components|All participants will receive CI Therapy + Sensory Components over a 2-3 weeks time frame. The treatment intervention will apply all CI Therapy treatment components to include: 1) a behavioral set of techniques called the Transfer Package (TP) to promote carry-over of skills that were gained in the laboratory into the participant's life situation, 2) the use of motor training called shaping to make progress in small approximations 3) the use by the participant of a mitt on the less-affected hand to encourage use of the more-affected hand and 4) home skills and home work will be provided each day for at least 30 minutes. Sensory component training strategies will be added to stimulate sensory input through the more-affected arm an dhand as well as to train sensory discrimination skills.
214959549|NCT03786900|BIOLOGICAL|Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727|
214959550|NCT05641935|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
214959551|NCT05641935|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
214959552|NCT05641935|PROCEDURE|Computed Tomography|Undergo CT
214959553|NCT05641935|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214959554|NCT05641935|OTHER|Electronic Health Record Review|Review electronic medical record
214959555|NCT06404749|DIETARY_SUPPLEMENT|fungal fiber|fungal fiber from mycelium
214959556|NCT06404749|DIETARY_SUPPLEMENT|inulin|long chain, degree of polymerization DP\>23
214959557|NCT05258682|DRUG|Bromelains|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
214959558|NCT05258682|DRUG|Acetylcysteine|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
214959559|NCT05100381|OTHER|dry needling|The patients will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. Two lengths of sterile, disposable, 0.30 mm x 75 mm and 0.30 mm x 50 mm solid filament needle (Tony, China) will be used in this study. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted into the lumbar multifidus muscle, 1.5 - 2 cm lateral to the spinous process of two or three painful segments, perpendicular to lamina (after piercing the skin, needles are directed inferomedially). The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes.
214959560|NCT05100381|OTHER|sham (placebo) dry needling|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
214959561|NCT00565552|DRUG|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
214959562|NCT04084002|OTHER|physical activity measurement|Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)
214352390|NCT00793468|DRUG|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
214486865|NCT06877195|PROCEDURE|CABG|Aortocoronary bypass procedures with venous grafts on right coronary territory
214959563|NCT00003115|DRUG|hydromorphone hydrochloride|
214959564|NCT04283435|DRUG|Sildenafil Citrate|Sildenafil Citrate 50 mg tablets taken from the first day of the cycle till the day we start progesterone (we stop 3 days before embryo transfer)
214959565|NCT04283435|OTHER|Placebo|Placebo tablet (multivitamins),Pregnacare vitamins (Vitabiotics,UK)
214959566|NCT04283435|DRUG|Estradiol Valerate|Estradiol valerate tablets 2mg every 8 hours daily starting from the fist day of the cycle till 12th day of the menstrual cycle.
214959567|NCT02472158|DEVICE|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
214959568|NCT02472158|DEVICE|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
214959569|NCT06643585|DRUG|Trastuzumab-Deruxtecan|Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier
214959570|NCT06643585|OTHER|Physicians Choice (PhC).|Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)
214959571|NCT03288545|DRUG|enfortumab vedotin (EV)|Intravenous (IV) infusion on days 1 and 8 every 21 days
214959572|NCT03288545|DRUG|pembrolizumab|IV infusion on day 1 every 21 days
214959573|NCT03288545|DRUG|cisplatin|IV infusion on day 1 every 21 days
214959574|NCT03288545|DRUG|carboplatin|IV infusion on day 1 every 21 days
214959575|NCT03288545|DRUG|gemcitabine|IV infusion on days 1 and 8 every 21 days
214959576|NCT05753735|DRUG|Piperacillin/Tazobactam|Piperacillin/Tazobactam 3.375 g IV every 6 hours while inpatient following surgery, not to exceed 10 days
214959577|NCT05753735|DRUG|Amoxicillin/ Clavulanic acid|Amoxicillin/ Clavulanic acid 875/125 mg every 12 hours after discharge to complete 10 days total antibiotics
214959578|NCT05964907|DEVICE|Light Source B: Visible Light solar simulator (VL + UVA1)|Patients will be radiated with light source B (Visible light solar simulator)
214959579|NCT05964907|DEVICE|Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)|Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)
214959580|NCT04990271|DRUG|Conbercept ophthalmic injection|Monthly injection of Conbercept from 0\~5 months
214352391|NCT00793468|DRUG|Placebo|Placebo once daily for 12 weeks
214393662|NCT04651452|BEHAVIORAL|Reflective Journaling|Participants will complete writing tasks regarding their least important values and discuss why they may be important to others. They will also describe aspects of daily life.
214393663|NCT05891418|BEHAVIORAL|Two informational emails with plan information|Informational emails about the benefits of Cost-Sharing Reduction Silver plans.
214393664|NCT05891418|BEHAVIORAL|Standard notice of eligibility determination|No extra outreach during intervention period.
214393665|NCT03545815|BIOLOGICAL|anti-mesothelin CAR-T cells|Cells will be infused on day 0.
214959581|NCT03372642|DEVICE|Subtalar endorthesis|Subtalar arthroereisis with endorthesis for pediatric flexible flat foot
214959582|NCT04053244|BEHAVIORAL|internet-based cognitive behavioural therapy|Designed for general clinical use (but not specifically cardiac patients), it consists of 5 online modules outlining cognitive-behavioural skills for depression, completed over 7-8 weeks. The participants will be guided step-wise through the modules by the therapist. Participants can work more or less at their own pace, but are expected to proceed to the next module within 1-2 weeks. Because the content is identical for each participant, fidelity to the web-based component of the intervention is ensured.
214959583|NCT00770471|DRUG|temozolomide|
214959584|NCT00770471|DRUG|veliparib|
214959585|NCT00770471|GENETIC|DNA methylation analysis|
214959586|NCT00770471|GENETIC|gene expression analysis|
214959587|NCT00770471|GENETIC|mutation analysis|
214959588|NCT00770471|GENETIC|proteomic profiling|
214959589|NCT00770471|OTHER|high performance liquid chromatography|
214959590|NCT00770471|OTHER|immunoenzyme technique|
215079123|NCT04093765|DIAGNOSTIC_TEST|Ultrasensitive Rapid Diagnostic Test (URDT)|"Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~* collection of 3x1cm dried blood spots on filter paper~* administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~* collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~* 1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12."
215079124|NCT04093765|DRUG|Antimalarials|"A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary."
215079125|NCT03895398|OTHER|nutrition and psychosocial intervention with community participatory|community participation to ensure the intervention is given to the study subject (underfive children)
215079126|NCT04072601|DRUG|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
215079127|NCT04072601|DRUG|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
215079128|NCT03831880|DRUG|Genotropin|Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily
215079129|NCT03831880|DRUG|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
214959591|NCT00770471|OTHER|laboratory biomarker analysis|
214959592|NCT00770471|OTHER|mass spectrometry|
214959593|NCT00770471|OTHER|pharmacogenomic studies|
214959594|NCT00770471|OTHER|pharmacological study|
214959595|NCT00770471|PROCEDURE|adjuvant therapy|
214959596|NCT00770471|RADIATION|radiation therapy|
214959597|NCT01981811|DRUG|Aripiprazole|
214959598|NCT01981811|DEVICE|Ingestible Event Marker (IEM)|
214959599|NCT01534416|DRUG|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
214959600|NCT01534416|DRUG|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
214959601|NCT00435461|DRUG|Fluticasone furoate and fexofenadine|Fluticasone furoate and fexofenadine
214959602|NCT00289224|BIOLOGICAL|bivalent killed whole cell oral cholera vaccine|"Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
214959603|NCT00289224|BIOLOGICAL|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
214959604|NCT04031326|BEHAVIORAL|LENA Home|LENA Home is a 13-week curriculum designed to add an early-language focus to existing home visiting or parent education programs for children ages birth to three. It employs LENA wearable audio recorder technology and targeted content to help parents and other caregivers increase interactive talk. There are 13 weekly one-on-one sessions, including modules on parent-child reading and increasing verbal interaction during typical home activities. Sessions include videos, practical techniques, and feedback from LENA recordings via intuitive reports to help parents talk more with their children. LENA Home reports provide data on adult words spoken to the child (AWC) and conversational turns (CTC). LENA Home has been shown to increase interactive talk and child language ability and informs parents how much they are talking with their children in an objective way.
214959605|NCT01734057|DRUG|recombinant human thrombopoietin (rhTPO); rituximab|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day)
215079130|NCT00384319|DEVICE|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
215079131|NCT02844335|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
215079132|NCT02844335|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
215079133|NCT00334360|DRUG|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
215079134|NCT00334360|DRUG|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
215079135|NCT00334360|DRUG|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
215079136|NCT00334360|DRUG|Control|No drugs given during controlled hypothermia
215079137|NCT04811105|PROCEDURE|steam ablation|32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
214352392|NCT04764396|COMBINATION_PRODUCT|Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)|The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.
214352393|NCT04764396|DRUG|Saline|FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
215079138|NCT05785637|PROCEDURE|Polygraphy diagnostic at home|Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
215079139|NCT01317537|OTHER|Electronic personal health record|
214352394|NCT05218005|DIAGNOSTIC_TEST|Research-based genetic test for Familial Hypercholesterolemia|Next-generation targeted sequencing assay to identify DNA variants in genes known to cause Familial Hypercholesterolemia
214352395|NCT05020223|OTHER|Vital pulp therapy|Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
214352396|NCT00848679|DRUG|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
214352397|NCT00848679|DRUG|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
214352398|NCT03986853|PROCEDURE|Blood sampling|Blood sampling under general anesthesia
214352399|NCT02647398|BEHAVIORAL|Vigorous aerobic training|Supervised vigorous aerobic training
214959606|NCT01734057|DRUG|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
214352400|NCT06482372|DEVICE|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation at both cerebral hemisphere
214959607|NCT03163316|OTHER|Unenhanced magnetic resonance imaging.|"The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.~The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.~Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination."
215079140|NCT01151735|DRUG|C-1-esterase|1000 units of C-1-esterase inhibitor
215079141|NCT01151735|DRUG|C-1-esterase|1500 units of C-1-esterase inhibitor
214486866|NCT06890078|OTHER|Biological sampling|Mouthwash, nasopharyngeal swab, blood sampling
214486867|NCT06730321|OTHER|Observations on clinicopathological factors influencing the assessment score of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
214486868|NCT06730074|DEVICE|Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD)|This is the first socially assistive robotic platform developed specifically for people with PD. If successful, this platform could be incorporated into the clinical toolbox at Adi Negev and other centres.
214486869|NCT07040085|DRUG|Y-6|each tablet of Y-6 contained 6 mg of dexborneol and 25 mg of cilostazol; Both groups took one tablet q12h for 28 days.
215079142|NCT01151735|DRUG|placebo|placebo
215079143|NCT06289088|OTHER|First Intervention|Firstly, For individuals with low back pain, all measurements will be evaluated without wearing any orthosis. The waist circumference of individuals with low back pain will be measured and the orthosis was adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the measurements will be repeated. Then, the person will be asked to wear the orthosis without any intervention.
215079144|NCT06289088|OTHER|Second Intervention|Firstly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be repeated. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis.
215079145|NCT06289088|OTHER|Third Intervention|Firstly, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be done. The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis. Lastly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotis. After waiting with the orthosis for half an hour, all measurements will be evaluated.
215079146|NCT06391281|OTHER|Education|The patient receiving hemodialysis treatment will be given fistula self-care training in 2 sessions. An educational booklet will be provided after the training.And routine care
215079147|NCT06086444|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
214352401|NCT00344123|DRUG|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
214352402|NCT00344123|DRUG|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
214352403|NCT02653482|DRUG|Dapagliflozin|
214352404|NCT02653482|DRUG|Dapagliflozin matching placebo|
214352405|NCT01771198|DRUG|SIMVASTATIN|SIMVASTATIN tablet of 40mg once a day during 30 days
214352406|NCT02786082|DRUG|20mg Azilsartan Tablets|Strength: 20mg, oral administration 1 tablet/ day
214352407|NCT02786082|DRUG|40mg Azilsartan Tablets|Strength: 40mg, oral administration 1 tablet/ day
214959608|NCT00868647|PROCEDURE|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
214959609|NCT01889368|DIETARY_SUPPLEMENT|Grape Seed Extract|300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
214959610|NCT01889368|DIETARY_SUPPLEMENT|Placebo|300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
214959611|NCT04273997|DRUG|Metronidazole 10% ointment|Metronidazole 10% ointment
214959612|NCT04273997|DRUG|Placebo ointment|Placebo ointment
214959613|NCT04814589|DRUG|ezetimibe tablets|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
214352408|NCT04717804|OTHER|AIP CT|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
214352409|NCT04717804|OTHER|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
214352410|NCT02283060|DRUG|Stribild|To be administered orally, once daily with food.
214352411|NCT02283060|DRUG|Atripla|To be administered orally, once daily at bedtime on an empty stomach
214352412|NCT04654416|DRUG|Corticosteroid with or without colchicine|We describe the clinical outcome of patients treated with corticosteroid and colchicine
214352413|NCT00105326|DRUG|paliperidone ER|
214352414|NCT03766022|DEVICE|Neo dental implant Alpha Bio Tec. Ltd.|Neo dental implant is used to restore missing teeth
214486870|NCT07040085|DRUG|Y-6 placebo|each tablet of Y-6 placebo contained 0.06 mg of dexborneol and 0 mg of cilostazol. Both groups took one tablet q12h for 28 days.
214486871|NCT07039552|PROCEDURE|risk-reducing salpingo-oophorectomy (RRSO)|The proportion of BRCA1/2 germline mutation carriers in the high-risk population of ovarian cancer who undergo risk-reducing salpingo-oophorectomy (RRSO). RRSO refers to the preventive surgical removal of both fallopian tubes and ovaries to reduce the risk of ovarian cancer, fallopian tube cancer, and peritoneal cancer.
214959614|NCT04814589|DRUG|ezetimibe tablets(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
214959615|NCT00837967|DRUG|Symbicort Turbuhaler|160/4.5μg for 3 days
214959616|NCT00837967|DRUG|Terbutaline Turbuhaler|0.4 mg for 3 days
214959617|NCT01149031|DEVICE|LOW LEVEL LASER SYSTEM|LASER DIODE CLASS 3B,OMEGA XP
214959618|NCT05098366|DRUG|Furosemide|0.1mg/kg (max 5mg) of IV furosemide
215079148|NCT06086444|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
214352415|NCT02429063|OTHER|Bright White Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
214352416|NCT02429063|OTHER|Dim Red Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
214352417|NCT03146520|DEVICE|EarlyTect Colon Cancer|SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit
214352418|NCT04657211|OTHER|Prospective observational cohort study|prospective observational cohort study
214352419|NCT05009992|DRUG|ONC201|Given orally (PO)
214352420|NCT05009992|RADIATION|Radiation Therapy|Undergo radiation therapy
214352421|NCT05009992|DRUG|Paxalisib|Given PO
214352422|NCT03815721|DEVICE|Stimulette r2x+|device for repetitive transcutaneous spinal cord stimulation
214352423|NCT03776136|DRUG|lenvatinib|Administered orally once a day during each 21-day cycle.
214352424|NCT03776136|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
214959619|NCT05098366|DRUG|Normal saline|20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
214959620|NCT02589847|BIOLOGICAL|RBX2660|suspension of intestinal microbes
214959621|NCT02589847|DRUG|Standard of Care Antibiotics|Standard of Care Antibiotics
214959622|NCT03110978|BIOLOGICAL|Nivolumab|Given IV
214959623|NCT03110978|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
214959624|NCT04759911|OTHER|Quality-of-Life Assessment|Ancillary studies
214959625|NCT04759911|OTHER|Questionnaire Administration|Ancillary studies
214959626|NCT04759911|DRUG|Selpercatinib|Given PO
214959627|NCT04759911|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214959628|NCT06411210|DRUG|Semaglutide Pen Injector|Escalated to 2.4mg or max tolerated dose
214959629|NCT06411210|DRUG|Placebo|Matched placebo.
214959630|NCT05364086|PROCEDURE|Biospecimen Collection|Undergo collection of tumor, blood, saliva and stool samples
214959631|NCT05364086|OTHER|Electronic Health Record Review|Review of medical records
214959632|NCT05364086|OTHER|Interview|Complete an interview
214959633|NCT05364086|OTHER|Quality-of-Life Assessment|Ancillary studies
214959634|NCT05364086|OTHER|Questionnaire Administration|Complete questionnaires
214959635|NCT02074800|DRUG|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
214959636|NCT02074800|DRUG|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
214352425|NCT07119892|BEHAVIORAL|Lifestyle Modification (Exercise + Diet)|Participants received a 12-week supervised aerobic exercise program (5 sessions per week at 70% of age-predicted maximum heart rate) and dietary counseling with a calorie-restricted Mediterranean-style diet of 1,200 kcal/day. The intervention was culturally adapted, including modifications for Ramadan.
214352426|NCT07127484|PROCEDURE|Hemoadsorption|Patients in intervention group will receive standard treatment plus hemoadsorption therapy administered once on days 1, 3, and 5 following enrollment.
214352427|NCT07128290|DRUG|CISGEM + Rilvegostomig|"Administration of 4 cycles pre-operative and 4 cycles post-operative of Cisplatine associated to Gemcitabine with rilvegostomig~RILVEGOSTOMIG : For each cycle one administration at D1 every 3 weeks~• 750 mg IV administration over 60 minutes (up to a total of 90 minutes). CISGEM: For each cycle administration at D1 and D8 every 3 weeks~* Cisplatine 25 mg/m² in 1 hour IV in 1000 ml NaCl 0,9 % then 500 ml NaCl 0,9 %~* Gemcitabine 1000 mg/m² en 30 mn IV dans 250 ml NaCl 0,9 %"
214352428|NCT07126223|BEHAVIORAL|Hot water foot bath|A 20-minute hot foot bath therapy using a specially designed foot spa device (41°C) applied in the early postoperative period. Follow-up includes pain evaluation via Numeric Rating Scale (NRS) and monitoring of first flatus time.
214352429|NCT07126132|PROCEDURE|Coronary Angiography|Standard coronary angiography was performed via the radial or femoral approach on all participants to assess the presence and severity of coronary artery disease. Angiograms were used to determine coronary stenosis, which formed the basis for classifying participants into the CAD group (≥50% stenosis) or the control group (\<50% stenosis).
214352430|NCT07126132|DIAGNOSTIC_TEST|Hpx•apoB Product Measurement|Fasting blood samples were collected from all participants to measure the novel Hpx•apoB product. Plasma hemopexin (Hpx) was quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and apolipoprotein B (apoB) was measured using standard automated methods. This biomarker was the primary variable of interest for its association with CAD.
214352431|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
214352432|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
214678854|NCT00081289|DRUG|Oxaliplatin|50mg/m\^2 IV over 2 hours on days 1, 8, 15, 22, and 29
214959637|NCT02074800|DRUG|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
214959638|NCT03376113|BEHAVIORAL|the volitional help sheet|A sheet includes two columns: one shows critical situations that easily trigger self-harm; other one shows appropriate solutions for patients to prevent self-harm.
214959639|NCT05735639|DRUG|Dalteparin Sodium|Low molecular weight heparin
214959640|NCT05735639|DRUG|Tinzaparin Sodium|Low molecular weight heparin
214352433|NCT00613951|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
214352434|NCT00613951|DRUG|metformin|Tablets, 1500-2000 mg/daily
214352435|NCT05916196|DRUG|18F-Fluoroestradiol|18F-FES PET/CT
214352436|NCT03016871|DRUG|Carboplatin|Given IV
214959641|NCT05735639|DRUG|Enoxaparin Sodium|Low molecular weight heparin
214959642|NCT05735639|DRUG|Rivaroxaban|Direct oral anticoagulant
214959643|NCT05735639|DRUG|Apixaban|Direct oral anticoagulant
214959644|NCT05735639|DRUG|Dabigatran Etexilate|Direct oral anticoagulant
214959645|NCT06355726|BIOLOGICAL|Plasma Exchange|Plasma exchange session will be done on alternate day to a maximum of 5 sessions. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session,no improvement in clinical condition and Intolerant to PLEX procedure
214959646|NCT06355726|OTHER|Standard Medical Treatment|Standard Medical Treatment
215079149|NCT03984149|OTHER|Observational study|Observational study: There is no intervention.
214352437|NCT03016871|DRUG|Etoposide|Given IV
214352438|NCT03016871|DRUG|Ifosfamide|Given IV
214352439|NCT03016871|OTHER|Laboratory Biomarker Analysis|Correlative studies
214352440|NCT03016871|BIOLOGICAL|Nivolumab|Given IV
214352441|NCT05035901|OTHER|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
214678855|NCT00081289|PROCEDURE|Surgery|All patients will undergo surgery four to eight weeks following the completion of radiation therapy. The choice of procedure abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis is at the discretion of the surgeon.
214678856|NCT00081289|DRUG|Folinic Acid|400 mg/m\^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.
214959647|NCT04003376|DEVICE|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
214959648|NCT04003376|DRUG|Triamcinolone Acetonide 10mg/mL|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide
214959649|NCT04003376|BIOLOGICAL|platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
214959650|NCT04003376|DRUG|vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
215079150|NCT04862949|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
214352442|NCT06669936|DRUG|Fecal microbiota transplantation ± bezlotoxumab|Co-administration of bezlotoxumab and FMT in patients with recurrent C. difficile infections who failed FMT alone.
214352443|NCT06669052|DIETARY_SUPPLEMENT|30 mg liposomal iron, capsules|a dietary supplement capsule, of mainly 30 mg liposomal iron, and Vitamin C 70mg, vitamin D3 400IU, vitamin B6 1.75 mcg, Folate 1000 mcg, b=vitamin B12 10 mcg. all in capsulated in 1 Hard gelatin capsule
214959651|NCT01602705|OTHER|Usual care|Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
214959652|NCT01602705|OTHER|Feedback of Performance|Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
214959653|NCT01602705|OTHER|Feedback of Performance + Health Psychology Informed Intervention|Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
214959654|NCT00551525|RADIATION|Radiotherapy|3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa begins 12 weeks (+/- 1 week) after Samarium 153 administration. Daily tumor doses of 1.8 - 2.0 Gy per day, 5 days per week x 7-8 weeks.
214959655|NCT00551525|DRUG|Samarium 153|Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
214959656|NCT03072823|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
214959657|NCT03072823|DIETARY_SUPPLEMENT|placebo|olive oil ethyl esters
214959658|NCT05787743|OTHER|Facial cream with 2% palm tocotrienols extract|Apply on the face twice a day
214959659|NCT05787743|OTHER|Base cream|Apply on the face twice a day
215079151|NCT01304368|PROCEDURE|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
215079152|NCT01852825|BIOLOGICAL|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
215079153|NCT01852825|OTHER|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
214352444|NCT06670352|DRUG|Placebo|QD or BID, 24-weeks fixed dose.
214352445|NCT06670352|DRUG|HSK39297 50mgBID|24-weeks fixed dose.
214352446|NCT06670352|DRUG|HSK39297 100mgBID|24-weeks fixed dose.
214352447|NCT06670352|DRUG|HSK39297 200mgQD|24-weeks fixed dose.
214352448|NCT05624775|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will cook and engage virtually (with video and sound on) from their home kitchens via the digital platform. Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($20 per class = $100 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions. Recipes will provide enough food for a family of four. clinic patients
214352449|NCT07127367|BEHAVIORAL|Memory Training|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
214959660|NCT04676724|DRUG|GSK3228836|Participants will be administered GSK3228836.
214959661|NCT04676724|DRUG|PegIFN|Participants will be administered PegIFN.
214959662|NCT04676724|DRUG|NA therapy|Participants will continue to receive their NA therapy for the duration of the study.
214959663|NCT00287729|DRUG|Pirfenidone|2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
214959664|NCT00287729|DRUG|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
214959665|NCT03190980|OTHER|5% glucose|Neonates will receive 5% glucose, then heel prick wil be performed during which pain will be assessed
214959666|NCT03190980|OTHER|30% glucose|Neonates will receive 30% glucose, then heel prick wil be performed during which pain will be assessed
214959667|NCT03190980|OTHER|Placebo|Neonates will receive sterile water, then heel prick wil be performed during which pain will be assessed
214959668|NCT04321486|OTHER|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.
214959669|NCT05979480|DIAGNOSTIC_TEST|Dual energy X-ray absorptiometry (DXA)|DXA scan to assess bone mineral density, fat mass and muscle mass.
214959670|NCT00552708|DRUG|COREG CR|
214959671|NCT00552708|DRUG|Lisinopril|
214959672|NCT00003367|DIETARY_SUPPLEMENT|green tea|
214959673|NCT00003367|DIETARY_SUPPLEMENT|soy protein isolate|
214959674|NCT00003367|DIETARY_SUPPLEMENT|vitamin E|
214959675|NCT04455737|OTHER|injection of indigo carmine|Ex vivo intra-arterial injection of 20 ml indigo carmine solution (10mL, 0.4% indigo carmine with 10mL, 0.9% saline solution) in the transanal total mesorectal excision specimen via the inferior mesenteric artery.
214959676|NCT02890563|DEVICE|Class II Compression Stockings|
214959677|NCT01150903|OTHER|no intervention|non-interventional study
214959678|NCT01150903|OTHER|no intervention|non-interventional study
214959679|NCT02078596|DRUG|Divalproex|Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
214959680|NCT03864523|DRUG|Pioglitazone|
214959681|NCT01537380|DRUG|Cefazoline|Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
214959682|NCT00457288|DRUG|TF 002|
215079154|NCT01852825|BIOLOGICAL|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
215079155|NCT00000627|DRUG|Fluconazole|
215079156|NCT05341999|OTHER|cold saline (cryotherapy)|using 20ml of 2.5°C cold saline for 5 min
214959683|NCT05413226|DIETARY_SUPPLEMENT|Celastrol|Four increasing doses of Celastrol to each of five men.
214352450|NCT07127068|DIETARY_SUPPLEMENT|Omega-3 Suplementation|The intervention group will receive a daily oral supplementation of 2000 mg omega-3, which will not be administered to the control group. Blood samples will be collected from all participants at baseline and at the end of the study to evaluate selected serum parameters. To minimize nutritional variability, individualized diets appropriate for coronary artery disease and chronic kidney disease were prescribed to both groups at the beginning of the study. Unlike many other intervention studies, this trial specifically targets end-stage renal disease patients and includes an evaluation of the intervention's impact in relation to dialysis initiation.
215079157|NCT05341999|DRUG|Ibuprofen 400 mg|patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
214352451|NCT07127068|OTHER|No intervention|Participants in the control group will not receive any dietary supplementation. Blood samples will be collected at baseline and at the end of the study to assess selected biochemical parameters. Standard dietary care appropriate for coronary artery disease and chronic kidney disease will be maintained throughout the study.
214959684|NCT05073445|BEHAVIORAL|SDNN measurement|SDNN measurement during pediatric simulation
215079158|NCT05341999|OTHER|Final irrigation with normal saline|final irrigation will be done using normal saline at room temperature.
215079159|NCT03679637|BEHAVIORAL|Tablet-based aphasia therapy|patients will independently practice with a speech app during hospitalisation
215079160|NCT05184465|PROCEDURE|spinal anesthesia|"The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back."
214959685|NCT04204304|DRUG|Isotretinoin|ISO
215079161|NCT01327274|DEVICE|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI \> 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (\< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
214959686|NCT04408651|BEHAVIORAL|LIIT.CI ACT|4-week online self-management intervention based on Acceptance and Commitment Therapy and adapted to people with chronic medical conditions
214959687|NCT04408651|BEHAVIORAL|LIIT.CI CFT|4-week online self-management intervention based on Compassion-Focused Therapy and adapted to people with chronic medical conditions
214393666|NCT01182168|DRUG|gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)|Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
214393667|NCT01074749|DEVICE|Accent Pacemaker|Implantation of pacemaker
214959688|NCT04475627|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR) imaging at 1.5T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
214959689|NCT04475627|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR) imaging at 3T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
215079162|NCT05594069|OTHER|triple pre-rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
215079163|NCT05594069|OTHER|triple rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
215079164|NCT00911092|PROCEDURE|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
215079165|NCT00911092|RADIATION|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
214393668|NCT02490696|DEVICE|Miso PET scan|2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
214959690|NCT05261243|DIAGNOSTIC_TEST|EEG / questionnaires / working memory task|EEG resting state measurements and analysis of frequency bands (gamma, beta, alpha, theta), peak frequencies and connectivity measures / questionnaires for depression, anxiety, social activities, cognition, pain, sleep, fatigue / digitalized block-tapping task
214959691|NCT02447471|DEVICE|Nexfin|Nexfin cuff placed on finger to measure blood pressure
214959692|NCT06304974|DRUG|BL-B01D1|Administration by intravenous infusion
215079166|NCT00911092|DRUG|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11~* Day 1 to day 4: Fluorouracil 1 gr/m²/day~* Day 1 or 2: Cisplatin 75 mg/m²"
214393669|NCT02490696|DEVICE|FAZA PET scan|2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
215079167|NCT05832112|PROCEDURE|VATS/RATS lobectomy|"Consenting patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, aside from the ports that will be placed in the subcostal plane. The characteristics of both the patient and the case, will determine the number of incisions from 1-4.~The Davinci Xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. Once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. A 24 Fr soft chest tube will be left in place, as in the standard VATS/RATS lobectomy procedure. The incision closure will be done in a standard manner."
214352452|NCT07126379|BEHAVIORAL|Family Foundations|FF is an 8-session program for families of children aged 0-12 years targeting parent mental health and family conflict. It will be delivered via telehealth by an allied health professional (i.e., social work, psychology, counselling qualification) trained in FF. The 8 sessions can be delivered flexibly (1 or 2 sessions per week). The duration between sessions can vary as per the needs of the family. We are allowing up to 11 weeks from randomisation for FF to be completed. FF is a manualised program which provides instruction on discussion activities, skills practice, video and workbook exercises for every session. Sessions are based around the content areas of: emotion regulation, stress management, healthy communication, coparenting, conflict resolution, and problem solving.
214959693|NCT06304974|DRUG|Irinotecan|Administration by intravenous infusion
215079168|NCT06535022|DIETARY_SUPPLEMENT|Cyclic enteral daytime feeding with ketogenic nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|Nighttime fasting and ß-hydroxybutyrate supplementation
215079169|NCT03789032|DRUG|Vadadustat|Vadadustat 300 mg
214352453|NCT07126379|BEHAVIORAL|Family Life Check-In|Families allocated to Family Life Check In will receive this condition from a Clinical Research Nurse, employed at the Primary site (deakin University) with 2 weeks of randomisation. This brief intervention will be comparable to care typically provided to parents/caregivers seeking support for mental health difficulties and/or family/parent relationships issues from a community health service at intake. Family Life Check-In involves a brief (\~30 minute) telephone consultation involving: a) an assessment of the families' needs with one or all parents, b) referral to local services including GP to discuss a mental health care plan, c) provision of reputable Australian web-based resources about supporting children during crises (Raising Children Network, Phoenix Disaster Recovery), and (d) telephone and online support services (BeyondBlue; Lifeline, PANDA, MensLine, KidsLine, Parentline).
214352454|NCT07126340|OTHER|Foot massage and cold application|The patient will receive both cold application and foot massage after total knee arthroplasty.
214352455|NCT07126340|OTHER|Cold application|After total knee arthroplasty, the patient will receive routine cold application.
214352456|NCT07128160|OTHER|Clinical and Demographic Assessment|"1. Expanded Disability Status Scale (EDSS) (Kurtzke, 1983): This scale will be used for neurological disability assessment~2. Multiple Sclerosis Functional Composite (MSFC): This composite will be used for the assessment of functional performance in patients with MS. It includes: a) Timed 25-foot walk (T25FW), b) Nine-hole peg test (9HPT) for both hands, and c) Paced auditory serial addition test (PASAT).~3. Toronto Alexithymia Scale (TAS-20): This scale reports Alexithymia. It is a 20-item self-report questionnaire measuring three domains: Difficulty identifying feelings (DIF), Difficulty describing feelings (DDF), and externally oriented thinking (EOT). A score ≥ 61 indicates alexithymia (Bagby, Parker \& Taylor, 1994).~4. Montreal Cognitive Assessment (MoCA), (Nasreddine ZS et al, 2005): a 30-point tool that investigates visuospatial abilities, language, attention, memory, abstraction, and orientation, with scores \<26 suggestive of mild cognitive impairment"
214352457|NCT07128160|OTHER|Corticospinal Inhibition Assessment|"Corticospinal inhibition will be evaluated using Transcranial Magnetic Stimulation (TMS) (Ayache et al., 2022; Chalah et al., 2018). All TMS assessments will be conducted according to international safety guidelines. The following parameters will be measured:~1. Motor Evoked Potentials (MEPs) will be recorded from the abductor pollicis brevis muscle.~2. Cortical silent period (CSP) will be assessed to measure corticospinal excitability and inhibition.~3. The interhemispheric inhibition (IHI) is a parameter reflecting the transcallosal GABA-mediated inhibitory activity. It will be obtained at complete muscle rest using figure-of-eight coils (MC-B70; MagVenture), connected with a MagPro\_R20 (Medtronic Inc., USA) generator connected to a butterfly coil."
214959694|NCT06304974|DRUG|paclitaxel|Administration by intravenous infusion
214959695|NCT06304974|DRUG|docetaxel|Administration by intravenous infusion
214959696|NCT01341288|DEVICE|EUCLIDIAN Robot|EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
214959697|NCT04912479|DEVICE|connected watch|connected watch that provide to patients with information on their sleep quality and their performed activities
214959698|NCT05593770|DRUG|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
214959699|NCT05593770|DRUG|Placebo|Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
214959700|NCT02237040|PROCEDURE|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
215079170|NCT03789032|DRUG|Rabeprazole|Oral Rabeprazole
215079171|NCT01529580|BEHAVIORAL|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
214959701|NCT06532123|DEVICE|continence muscles resistance device|The c-RED consists of a noncompliant cylindrical balloon (intra-anal balloon) that is connected to a small compliant balloon (external balloon) by a 2 mm diameter tube and a stopcock to allow for air to be filled and sealed in the system. The system is prefilled with air to determine the amount of air needed for a given internal pressure, or desired resistance of the intra-anal balloon. This is determined using a sphygmomanometer gauge in a sealed system.
214959702|NCT06056830|DRUG|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
214959703|NCT03192410|BEHAVIORAL|Dietary intake|Intake of nutrients, foods, food groups, beverages; dietary patterns.
214959704|NCT03192410|BEHAVIORAL|Lifestyle factors|Physical activity; smoking; alcohol use; educational level.
214959705|NCT03192410|BIOLOGICAL|Blood biomarkers|Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
214959706|NCT03192410|BIOLOGICAL|Health|Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
214352458|NCT07128160|OTHER|Radiological Assessment|"All patients will undergo brain and spinal cord Magnetic Resonance Imaging (MRI) using a 1.5T scanner. Brain MRI sequences include: T1-weighted, T2-weighted, FLAIR, and post-contrast sequences. Spinal MRI (cervical and thoracic) includes T2-weighted and STIR sequences. Radiological assessment focused on:~* Number and location of T2/FLAIR lesions~* Presence of contrast-enhancing lesions~* Degree of brain atrophy (qualitatively)~* Spinal cord lesion load A neuroradiologist will review MRI findings, blinded to the clinical and neuropsychological data"
214352459|NCT07127042|DRUG|Low-dose BT-114143|Intravenous infusion of BT-114143 Injection is started 10-15 minutes before skin incision at a Low-dose BT-114143, and 50mL of normal saline is administered intravenously 3 hours (±10 minutes) after the end of the surgery.
214959707|NCT03192410|GENETIC|DNA|SNPs (GWAS)
214959708|NCT03192410|BIOLOGICAL|Mental well-being|Cognitive function; dispositional optimism; depression.
214959709|NCT03905681|DEVICE|Transcutaneous Electrical Nerve Stimulation|Application of TENS pads and wearing of the TENS device.
214959710|NCT00123682|PROCEDURE|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
214959711|NCT00123682|PROCEDURE|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
214959712|NCT00123682|PROCEDURE|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
214959713|NCT00123682|PROCEDURE|Self-help|Project staff send out self-help materials for smoking cessation
214959714|NCT00869973|DRUG|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
214959715|NCT00869973|DRUG|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
214959716|NCT05446142|DRUG|Encorafenib capsule formulation (CAP)|A single encorafenib dose of the CAP formulation
214959717|NCT05446142|DRUG|Encorafenib first formulation|first formulation
214959718|NCT05446142|DRUG|Encorafenib second formulation|second formulation
214959719|NCT05446142|DRUG|Rabeprazole tablet|Proton-pump inhibitor
214959720|NCT04623502|OTHER|13C-Glucose|Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
214959721|NCT04623502|OTHER|13C-Acetate|Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
214959722|NCT04623502|OTHER|13C-Lactate|Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
214959723|NCT04623502|OTHER|13C-Glutamine|Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
215079172|NCT05410847|DRUG|Camrelizumab Nab-Paclitaxel S-1|Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
214959724|NCT04623502|OTHER|13C-Fructose|Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
214959725|NCT06226519|DIAGNOSTIC_TEST|11C-MET-PET/RMN|60 children and/or adolescents (≤18 years) with a diagnosis of brain tumor (medulloblastoma, other embryonal tumors or high-grade gliomas), who have followed the contemporary adjuvant therapy protocol of post-surgical chemo and radiotherapy and completed radiotherapy for at least 6 months will undergo a brain MET-PET/MRI.
214959726|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
214959727|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
214959728|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
214959729|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
214959730|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
214959731|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
214959732|NCT05717205|DIAGNOSTIC_TEST|technetium scitigraphy|patients will have a technetium scintraphy confirming or ruling out gastroparesis. Then the patients will have a gastroscopy with tissue samples from antrum and fundus. During gastroscopy an endo-flip ballon will meassure the distensibility in pylorus.
214959733|NCT02895191|DRUG|ulinastatin|Patients will receive the study drugs for 7 to 14 days
214959734|NCT02895191|DRUG|placebo|Patients will receive the placebo for 7 to 14 days
214959735|NCT01310582|DRUG|Desflurane|
214959736|NCT01310582|DRUG|Sevoflurane|
214959737|NCT04711694|BEHAVIORAL|Minfulness-based Intervention|"The proposed MBI is an adaptation from the Mindfulness Based Stress Reduction (MBSR) and Mindfulness based Cognitive Therapy (MBCT) programs to youth. This MBI consists of a total of twelve 90 minutes long sessions, the first 8 being the intervention per se and the last 4 a proposition to the transition to regular practice and a chance to better integrate mindfulness in daily life.~A theme regarding mindfulness is addressed in each session, through meditation practices and exercises. Between sessions, participants are invited to practice at home, using an application designed for this study (the MindApp), where participants can find the recorded practices. Investigators have access to participants' use of the meditation recordings and expect that these data will provide a more objective measure of the amount of home practice."
214959738|NCT06164483|DIAGNOSTIC_TEST|Auditory test|"The patients will perform:~Pure Tone Auditory test + Tympanometry and Stapedial Reflex~* Speech Perception test~* In case of tinnitus: tinnitus questionnaire and acuphenometry~* DPOAEs~* ABR"
214959739|NCT06164483|OTHER|CSF sampling|Cerebrospinal Fluid will be collected by lumbar puncture and analyzed
214959740|NCT02255071|DEVICE|Acupressure wristband|A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
214959741|NCT02255071|DEVICE|Sham wristband|A wristband over wrist but no acupressure for seven days.
214959742|NCT05942521|BEHAVIORAL|Very brief extinction|"The very brief extinction presents a very short (33ms) repetitive sequence of alcohol cues, followed by a masking stimulus(117ms), which masks the alcohol cues. In the case of repeated exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
214959743|NCT05942521|BEHAVIORAL|Clearly visible extinction|"The clearly visible extinction presents a repetitive sequence of alcohol cues(150ms) without a masking stimulus. In the case of repeat exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of conscious processing."
215079173|NCT04413903|PROCEDURE|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
215079174|NCT02577770|DEVICE|acupuncture|therapeutic acupuncture treatment with actual needles
214959744|NCT05942521|BEHAVIORAL|Very brief neutral extinction|"The very brief neutral extinction presents a very short (33ms) repetitive sequence of neutral cues, followed by a masking stimulus(117ms), which masks the neutral cues. In the case of repeated exposure to neutral stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
214959745|NCT00547157|DRUG|Panitumumab|Arm 2 consists of panitmumab plus RT
214959746|NCT00547157|DRUG|Cisplatin|Cisplatin
214959747|NCT00110357|DRUG|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
215079175|NCT02577770|DIETARY_SUPPLEMENT|200mg caffeine|8g coffee, po
215079176|NCT02577770|DIETARY_SUPPLEMENT|400mg caffeine|16g coffee, po
215079177|NCT02577770|DIETARY_SUPPLEMENT|Decaffeinated|decaffeinated coffee, po
215079178|NCT03442257|BEHAVIORAL|SMS|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
215079179|NCT06079060|DEVICE|Synthetic Nitrile Condom (61mm)|61mm width Synthetic Nitrile Condoms
215079180|NCT06079060|DEVICE|Control Latex Condom|61mm width Natural Rubber Latex Condom
215079181|NCT05585229|DRUG|Psilocybin-assisted Psychotherapy|Participants will complete a 8-week structured psychotherapeutic intervention involving administration of 25mg and 37.5mg PEX010 on two separate occasions.
215079182|NCT03826836|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
215079183|NCT04854967|OTHER|Rescind home oxygen order|A note will be entered in the medical record describing the participants randomization into the intervention group. The note will be signed by study staff and will accompany the discontinuation of the patient's home oxygen by a study clinician.
214959748|NCT00110357|DRUG|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
214352460|NCT07127042|DRUG|High-dose BT-14143|Intravenous infusion of BT-114143 Injection is started 10-15 minutes before skin incision at a High-dose BT-114143, and 50mL of normal saline is administered intravenously 3 hours (±10 minutes) after the end of the surgery.
214959749|NCT04727593|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|Experimental group: MBCT is program developed by Zindel Segal, Mark Williams, and John Teasdale , based on Jon Kabat-Zinn's Mindfulness-based Stress Reduction (MBSR) program. Participants learn to acknowledge their unhelpful thoughts and feelings, allowing the mind to move from an automatic and spiraling thought pattern to a more conscious emotional processing. Mindfulness practices include breath awareness, sitting and walking meditations, and mindful yoga. In this study, the following MBCT structure will be followed: group setting of 12 participants (maximum); 8 online weekly meetings of 2 hours via a videoconference platform (e.g., Cisco Webex), each one mediated by a trained mindfulness instructor(s); daily home practice of the learned skills; 2 hours of retreat after the fifth week; 6 months of home practice; 4 monthly consolidation sessions of 90 minutes each.
214959750|NCT04727593|OTHER|Treatment as Usual|In this case, participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral, and intervention for people with significant distress difficulties. Regarding pharmacological intervention, medication intake will be monitored during the study and changes will be registered. The engagement in non-pharmacological interventions such as psychological and psychosocial interventions will also be monitored.
214959751|NCT04793477|DEVICE|instrumentation technique in pulpectomies|comparison of three file systems for pulpectomies in primary molars
214959752|NCT04133597|DEVICE|social media stimuli (Line app)|social media stimuli (Line app) with texting messages or calls
214959753|NCT02091401|DEVICE|Springfusor infusion pump|
214959754|NCT02091401|OTHER|IV administration|
214959755|NCT02091401|DRUG|Magnesium Sulfate|
214959756|NCT03382418|BIOLOGICAL|gp145 C.6980 Vaccine|Administered by intramuscular injection in the deltoid.
214959757|NCT03382418|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9%; Administered by intramuscular injection in the deltoid.
214959758|NCT03382418|BIOLOGICAL|Aluminum Hydroxide Adjuvant|Administered by intramuscular injection in the deltoid.
214959759|NCT02217852|DRUG|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
215079184|NCT04854967|BEHAVIORAL|Provider Education|A note will be entered in the medical record informing the patient's individual medical providers (i.e. primary care provider, pulmonologist) of their randomization into the intervention group. The note will include the evidence-base for oxygen use among patients with COPD.
214352461|NCT07127042|DRUG|Tranexamic Acid (IV)|Intravenous infusion of TXA is started 10-15 minutes before skin incision at a dose of 20mg/kg, and intravenous infusion of TXA is initiated 3 hours (±10 minutes) after the end of the surgery at a dose of 1g.
214959760|NCT02217852|DRUG|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
214959761|NCT02217852|DRUG|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
214959762|NCT02217852|DRUG|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
214959763|NCT02654158|DRUG|Low-dose of Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
214959764|NCT02654158|DRUG|High-dose of Fuganlin Oral Liquid|"less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day"
215079185|NCT04854967|BEHAVIORAL|Patient Education|"The patient will receive a patient education page about discontinuation of home oxygen after recovery from a hospitalization that was developed by Consumer Reports in conjunction with the Choosing Wisely Campaign."
215079186|NCT04854967|BEHAVIORAL|Teach-to-goal inhaler training|Teach-to-goal (TTG) inhaler training is a patient-centered education strategy that has been shown to decrease inhaler misuse and decrease acute care utilization. The training is tailored to the patient and meets guideline recommendations for assessment and instruction of inhaler technique. The rounds of assessment and demonstration can be completed until acceptable skill level is attained and tailored to the specific medication prescribed.
215079187|NCT04854967|BEHAVIORAL|Pursed lip breathing|Pursed lip-breathing will be taught to the participants randomized to the intervention arm. This simple technique relieves breathlessness and has been shown to improve functional capacity in patients with COPD. Participants will be given an instructional handout to refer to after the visit.
214352462|NCT07126145|OTHER|Not applicable- observational study|no interventions were involved
214393670|NCT05571995|BEHAVIORAL|TRIMOSH|TRIMOSH will improve the knowledge, attitude and practice on occupational and health
214959765|NCT02583022|DRUG|PAC-14028 cream 1.0%|Topical application
214959766|NCT02583022|DRUG|PAC-14028 cream vehicle|Topical application
214959767|NCT02583022|DRUG|Elidel cream 1%|Topical application
214959768|NCT05116371|DRUG|150 mcg levonorgestrel/30 mcg ethinyl estradiol|concurrent use of COC with Nexplanon
214959769|NCT03011177|DRUG|Teneligliptin|teneligliptin 20mg qd
214959770|NCT03011177|DRUG|Linagliptin|linagliptin 5mg qd
214959771|NCT04633226|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL sterile suspension for intramuscular injection.
214959772|NCT01151345|DRUG|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
214352463|NCT07127198|DIETARY_SUPPLEMENT|Beverage Variant 1 (low gelation properties)|The first interventional product for this study is a drink containing protein and fiber at a concentration 1. It will come in a ready to drink format for the participants.
214959773|NCT01151345|DRUG|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
214959774|NCT02536105|DRUG|Methylphenidate HCl ER tablets 1|
214959775|NCT02536105|DRUG|Placebo|
214959776|NCT02536105|DRUG|Methylphenidate HCl ER tablets 2|
214959777|NCT02536105|DRUG|Methylphenidate HCl ER for suspension|
214959778|NCT06333028|DEVICE|enVista Aspire EA IOLs|Subjects bilaterally implanted with enVista Aspire EA IOLs
214959779|NCT04585243|DEVICE|Evalyn Brush|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
214959780|NCT02950922|DRUG|RVT-501 0.2% ointment|
214959781|NCT02950922|DRUG|RVT-501 0.5% ointment|
214959782|NCT02950922|OTHER|Vehicle ointment|Placebo comparator
215079188|NCT04234789|DIAGNOSTIC_TEST|cardiopulmonary exercise testing with dynamic hyperinflation maneuver|test performed as recommended by ATS guidelines
215079189|NCT04234789|DIAGNOSTIC_TEST|spirometry|test performed as recommended by ATS guidelines
214486873|NCT06296082|DRUG|Botulinum toxin type A|Botulinum toxin type A injections are a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a chimical disruption of dysfunctional endplates.
214486874|NCT06296082|OTHER|Dry Needling|Dry Needling is a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a mechanical disruption of dysfunctional endplates.
214959783|NCT01083992|DRUG|Galvus (vitagliptin)|Galvus (vitagliptin)
214959784|NCT01083992|DRUG|Galvus + vitamin D|Galvus + vitamin D
214352464|NCT07127198|DIETARY_SUPPLEMENT|Beverage Variant 2 (medium gelation properties)|The first interventional product for this study is a drink containing protein and fiber at a concentration 2. It will come in a ready to drink format for the participants.
214352465|NCT07127198|DIETARY_SUPPLEMENT|Beverage Variant 3 (high gelation properties)|The first interventional product for this study is a drink containing protein and fiber at a concentration 3. It will come in a ready to drink format for the participants.
214959785|NCT06289777|PROCEDURE|TEVAR|minimally invasive endovascular intervention to treat aortic dissection
214959786|NCT04464408|DRUG|Favipiravir|1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily
214486875|NCT04012567|DEVICE|Investigational device: Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material made of PLGA, β-TCP and calcium sulfate, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery. Its open structural design enables rapid bone ingrowth to make the screw integrated with bone tissues so as to promote healing.
214959787|NCT04464408|DRUG|Placebo|(9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)
214486876|NCT04012567|DEVICE|Control device: BIOSURE HA Interference Screw|BIOSURE HA Interference Screws and Drivers are designed for durability and reduced screw breakage. Both the screws and driver have been enhanced to allow screws to fully seat on the driver all the way to the tip of the screw, helping stress distribution and force transfer. The screw design also incorporates a consistent wall thickness throughout the length of the screw for added durability and features a tapered body for ideal ease of insertion.
214486877|NCT05786131|PROCEDURE|Culprit-lesion revascularization|Percutaneous coronary intervention of culprit-lesion
214486878|NCT05786131|PROCEDURE|Non-culprit-lesion revascularization|Complete percutaneous coronary intervention of all angiographically significant non-culprit lesions
214959788|NCT00099632|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate|200mg/300mg as one tablet taken orally once daily
214959789|NCT00099632|DRUG|Lamivudine/Zidovudine|150mg/300mg as one tablet taken orally twice daily
215079190|NCT04234789|DIAGNOSTIC_TEST|pletysmography|test performed as recommended by ATS guidelines
215079191|NCT04234789|DIAGNOSTIC_TEST|forced oscillometry technique|test performed as recommended by ATS guidelines
214486879|NCT06735690|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHSCT
214959790|NCT00099632|DRUG|Lopinavir/Ritonavir|133.3mg/33.3mg as three capsules taken orally twice daily
214959791|NCT00099632|DRUG|single dose Nevirapine|one 200 mg tablet taken orally
214959792|NCT05471336|PROCEDURE|Enteral Feeding|Feeds of expressed breast milk or donor breast milk will be given. Formula feeds will not be permitted. If the parents do not wish to provide donor milk, whatever volume of expressed mother's milk is available will be given up until the required volume. Feeds will be administered via orogastric or nasogastric tube and administered over 30 minutes.
214959793|NCT03768921|OTHER|PEEP Titriation|The alveolar recruitment maneuver PEEP reaches a maximum of 25 cmH2O, with recruitment being performed progressively, where the pressure variation is maintained at 15 cmH2O and the PEEP increase progressively occurs at 2 cmH2O every 2 minutes and Ventilatory mode with Controlled Pressure Ventilation. After the alveolar recruitment maneuver, the PEEP titration or determination will be performed, where the PEEP of 2 cmH2O will be reduced every 2 minutes and the variables after the alveolar recruitment maneuver and PEEP maintenance will be checked in the TIMPEL brand equipment at the point where the patient has better alveolar recruitment, with fewer alveolar collapsing points and pulmonary hyperdistension.
214352466|NCT07127198|OTHER|Control group (no gelation property)|The control product for this study is a drink containing protein and fiber. It will come in a ready to drink format for the participants.
214352467|NCT07127055|OTHER|No intervention|Control group will take standard diet
214352468|NCT07127055|OTHER|gluten free diet|This group received gluten free diet
214352469|NCT06675500|DRUG|Magnesium sulphate|Intravenous Magnesium sulphate followed by oral tablets of Magnesium sulphate
214486880|NCT06735690|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
214959794|NCT05212480|DIETARY_SUPPLEMENT|Zinc|For each patient included, a prescription regimen of zinc (in bisglycinate form) is proposed at a dose of 25 mgtwice a day for 15 days for the intervention arm. This dose of zinc is to be taken away from meals.
214959795|NCT05212480|DIETARY_SUPPLEMENT|Placebo|For each patient included, a prescription of an identical to the intervention arm concerning shape, smell, taste and color pill of placebo . This dose of zinc is to be taken away from meals.
214959796|NCT02900664|BIOLOGICAL|PDR001|Powder for solution for infusion
214959797|NCT02900664|BIOLOGICAL|ACZ885|Solution for injection
214959798|NCT02900664|BIOLOGICAL|CJM112|Solution for infusion
214959799|NCT02900664|DRUG|TMT212|Tablets
214959800|NCT02900664|DRUG|EGF816|Tablets
214959801|NCT02432209|OTHER|Caloric Restriction|Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
214959802|NCT02432209|DRUG|Orlistat|Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.
214959803|NCT02432209|OTHER|Moderate physical activity|All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
214959804|NCT02611765|DRUG|Benzathine penicillin G intramuscular 7.2 million units|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
214959805|NCT02611765|DRUG|Benzathine penicillin G intramuscular 2.4 million units|A single dose of intramuscular 2.4 million units of benzathine penicillin G
214959806|NCT06222177|DIAGNOSTIC_TEST|Pathophysiologic evaluation|High-resolution manometry and pH study
214959807|NCT06099925|DRUG|Hetrombopag|All the recruited 48 patients will take hetrombopag 5mg/day within 24 hours after chemotherapy
214959808|NCT00311922|BEHAVIORAL|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
214352470|NCT06675500|DRUG|Placebo|Intravenous infusion of Normal saline 0.9 followed by starch oral tablets
214352471|NCT03822858|DRUG|Intrathecal MSC-NP injection|"Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
214352472|NCT04919135|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
214352473|NCT04919135|DRUG|standard frailty treatment and supplementary medication|Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
214352474|NCT06715605|BIOLOGICAL|tolerogenic dendritic cells (tolDC)|In brief, clinical-grade tolDC vaccines will be prepared from leukapheresis starting material of non-mobilized blood and subsequent immunomagnetic selection of CD14+ monocytes using a CliniMACS device. CD14+ monocytes will then be cultured in GMP-grade cell culture medium supplemented with 2% human AB serum, GM-CSF, IL-4 and 1 alpha,25 dihydroxyvitamin D3. At day 4, tolDC will be stimulated using a cytokine cocktail to induce a migratory phenotype. At day 6, tolDC will be harvested, loaded with antigen, resuspended, and cryopreserved. Separate aliquots of the cell product are prepared for final quality control and quality assurance (QC/QA) assessment. This includes cell count, viability, phenotypic analysis using flow cytometry, and induction of T cell hyporesponsiveness in allo-MLR.
214486881|NCT06735690|PROCEDURE|Biospecimen Collection|Undergo blood and optional CSF sample collection
214486882|NCT06735690|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214486883|NCT06735690|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214486884|NCT06735690|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214486885|NCT06735690|PROCEDURE|Echocardiography|Undergo ECHO
214486886|NCT06735690|PROCEDURE|Leukapheresis|Undergo leukapheresis
214486887|NCT06735690|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214486888|NCT06735690|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214959809|NCT00311922|BEHAVIORAL|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
214959810|NCT05295199|OTHER|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
214959811|NCT00039299|BIOLOGICAL|therapeutic autologous lymphocytes|
214959812|NCT01486823|DRUG|MLDL1278A|Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
214959813|NCT01486823|DRUG|MLDL1278A|Single subcutaneous dose of 360 mg MLDL1278A.
214959814|NCT02303197|DRUG|ChiNing decoction|ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
214486889|NCT06735690|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
214486890|NCT06735690|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214486891|NCT06735690|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214486892|NCT06735690|OTHER|Transplant Conditioning|Given HSCT conditioning regimen
214486893|NCT06735690|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
214959815|NCT00882661|DEVICE|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
214959816|NCT00882661|DEVICE|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
214352475|NCT06715605|BIOLOGICAL|Standard-of-care|Standard-of-care on first-line treatment such as interferon-beta, glatiramer acetate, teriflunomide, dimethylfumarate, ponesimod and ozanimod.
214352476|NCT06704399|OTHER|Acceptance and Commitment Therapy-Based Psychoeducation|Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group.
214352477|NCT06704399|OTHER|control group|No intervention will be applied to the control group.
214352478|NCT07044557|OTHER|Withholding perioperative Dexamethasone|Patients will not receive perioperative Dex before, during, and up to 3 weeks after surgery.
214352479|NCT07038642|BEHAVIORAL|Pharmacy Clinical Decision Support System for Asthma Management|A pharmacy clinical decision support system that generates individualized advice for asthma patients is provided to the pharmacist/RPht/assistant/student.
214352480|NCT07049783|BEHAVIORAL|Exercise|A single standardized, in-lab, 30-minute monitored treadmill exercise session
214352481|NCT04722965|PROCEDURE|Fistulotomy with marsupialization|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. Wound edges are sutured to the bottom of the fistula using interrupted sutures of vicryl 3-0 completing the marsupialization.
214352482|NCT04722965|PROCEDURE|Fistulotomy with open wound|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. The wound is left open.
214352483|NCT06758544|DRUG|Oncolytic virus VRT106|VRT106, IV
214352484|NCT06758544|DRUG|Chemotherapy|21 days/cycle, administered up to 6 cycles
214352485|NCT07127796|OTHER|Dietary Supplement - Fish-derived Vitamin D|"Cholecalciferol (vitamin D3). Other components: polyunsaturated fatty acids (PUFA), arabic gum, maltodextrin, pea protein hydrolisate, hard gelatine capsules.~The fish derived vitamin D extract was obtained from sardines (Sardina pilchardus) waste ( whole fish) recovered by CNR-IRBIM (Centro Nazionale delle Ricerche-Istituto per le Risorse Biologiche e le Biotecnologie Marine) and sourced from a professional fishing fleet operating in the Adriatic Sea (Central Mediterranean). Fishes have been homogenized, freeze dried and extracted by using a Supercritical Fluid Extractor (SFE-CO2) in the laboratories of ENEA (Agenzia nazionale per le nuove tecnologie, l'energia e lo sviluppo economico sostenibile), then analyzed for the content of vitamin D3 and other bioactives by HPLC-DAD technique in the laboratories of University of Camerino and finally microencapsulated in the laboratories of University of Piemonte Orientale for the preparation of final supplement."
214486894|NCT06779565|DEVICE|Hyflex EDM system|A rotary file system
214352486|NCT07127796|OTHER|Dietary Supplement - Synthetic Vitamin D|Cholecalciferol (vitamin D3). Other components: medium-chain triglycerides, alfpha-tocopherol acetate, hard gelatin capsules.
214352487|NCT07126496|OTHER|Internet-Based Intervention|Receive information via online text
214352488|NCT07126496|OTHER|Questionnaire Administration|Ancillary studies
214959817|NCT01379105|OTHER|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
214959818|NCT01379105|OTHER|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
214959819|NCT05872061|OTHER|Acceptability of food-to-food fortified (FtFF) instant porridge flours|This study will evaluate the market potential of a food-to-food fortified (FtFF) flour.
214959820|NCT01720485|DRUG|Desloratadine + Prednisolone|1 tablet 3 times a day
214959821|NCT01720485|DRUG|Dexchlorpheniramine + Betamethasone|1 tablet 3 times a day
214959822|NCT03134911|DRUG|DOAC or VKA|6 months - 2 years
214959823|NCT03134911|DRUG|VKA|6 months - 2 years
214959824|NCT01087203|BIOLOGICAL|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
214959825|NCT01087203|BIOLOGICAL|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
214959826|NCT06272825|OTHER|Virtual reality|VR-based exercise program will be applied in addition to the conventional rehabilitation program, 5 days a week for a total of 3 weeks.
214352489|NCT07126496|OTHER|Virtual Technology Intervention|Receive information via ALEX Research Portal and vCHE
214393671|NCT06073028|OTHER|20-minute gait training|All subjects undergo two 20-minute gait trainings using two different kinds of auditory cueing (temporal or spatial), one week apart (D1 and D8).
214393672|NCT02678520|RADIATION|3-D Conformal Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
214393673|NCT02678520|RADIATION|Intensity Modulated Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
214393674|NCT02678520|DRUG|Casodex, Zoladex , Lupron|"Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months."
214393675|NCT04615208|DIAGNOSTIC_TEST|suspected of COVID-19 infection|suspected of COVID-19 infection
214393676|NCT01154049|BIOLOGICAL|sm14 antigen plus adjuvant GLA|Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
214352490|NCT07128134|DEVICE|Low Level Laser Therapy|"Although low-level laser therapy has been applied in cases of periodontitis, there are only a limited number of studies investigating its additional benefits in implants with peri-implantitis. This study aims to contribute to the literature on this subject.~In addition to surgical periodontal treatment, low-level laser therapy (LLLT) was applied three times (on the same day as the initial treatment, on the third day, and on the seventh day) to the implants in the test group diagnosed with peri-implantitis. The 940 nm indium gallium arsenide phosphor diode laser (Epic Biolase, Irvine, CA, USA) will be applied perpendicular to the periodontal pocket for 20 seconds at a fixed distance of 15 mm and a continuous wavelength (3.41 J/cm2 application with a 1.76 cm2 spot and 0.3 W average output)."
214352491|NCT07128134|PROCEDURE|Non-surgical Periodontal Treatment|Peri-implantitis diagnosis will be made in the control group, and non-surgical periodontal treatment of implants will be performed using titanium curettes (Hu-Friedy, Chicago, IL, USA).
214352492|NCT07126886|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
214486895|NCT06779565|DEVICE|Reciproc VDW system|A reciprocating file system
214486896|NCT06734312|DEVICE|Gastric Fundal Mucosal Ablation (GFMA)|Endoscopic Gastric Fundal Mucosal Ablation (GFMA) after discontinuation of GLP-1 therapy
214352493|NCT07126886|OTHER|XPURT + SOC|Participants will receive weekly applications of XPURT and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
214352494|NCT07127913|DEVICE|Device: Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
214352495|NCT07127913|DEVICE|Device: Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
214352496|NCT07127913|DEVICE|Device: Stimulation -ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered with a fixed duty cycle
214352497|NCT07126717|DIETARY_SUPPLEMENT|Placebo|Food-grade maltodextrin
214352498|NCT07126717|DIETARY_SUPPLEMENT|Zynamite® S|Water-soluble mango leaf extract standardized to 60% of mangiferin
214486897|NCT06734390|OTHER|Bladder Neck Surgery|Bladder Neck Surgery regroups many surgical procedures to cure urinary incontinence.
214486898|NCT06736015|DIETARY_SUPPLEMENT|Myo-Inositol 600 mg + Selenium 83 mcg|Myo-Inositol 600 mg + Selenium 83 mcg: 1 tablet once a day for 6 months
214486899|NCT06735235|DRUG|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
214486900|NCT06735235|DRUG|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
214486901|NCT06735235|DRUG|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
214486902|NCT06735235|DRUG|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
214486903|NCT06736496|DRUG|Nalbuphine|patients will receive : nalbuphine administered at a dose of 0.2 mg / kg IV bolus dose before induction and intermittent doses of 0.5 mg/kg if MAP and HR greater than 20% of the base line value.
214486904|NCT06736496|DRUG|Dexmedetomidine|patients will receive : Dexmedetomidine infusion at rate of 0.5mcg/kg/h initiated 10 min before induction and ketamine iv bolus dose of 0.35 mg/kg and Lidocaine iv bolus dose of 1mg/kg administrated before skin incision.
214486905|NCT06736353|DRUG|Beta Blocker Therapy or No Therapy (Control)|Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction
214486906|NCT06736353|DRUG|RAAS blocker Therapy or No therapy (Control)|RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction
214486907|NCT06736353|DRUG|Statin Therapy or No Therapy (Control)|Statin therapy or no Statin therapy initiated after type 2 myocardial infarction
214486908|NCT06736353|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or no antiplatelet therapy initiated after type 2 myocardial infarction
214486909|NCT06736353|DRUG|Dual Antiplatelet Therapy or No Therapy (Control)|Dual Antiplatelet Therapy or no Dual Antiplatelet Therapy initiated after type 2 myocardial infarction
214486910|NCT06734533|OTHER|Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc|Anlotinib (8/10/12 mg daily, Day 1-14 of each cycle) was administered orally to fasting patients, with dose reductions to 10 mg or 8 mg in cases of intolerable toxicity. Combination agents included eribulin, nab-paclitaxel, etoposide, capecitabine, pembrolizumab, sintilimab, or fulvestrant, among others.
214486911|NCT06734832|BIOLOGICAL|bivalent enterovirus vaccine (Vero cell), inactivated|Two doses are administered with a one-month interval between each dose.
214959827|NCT06272825|OTHER|conventional rehabilitation|The conventional exercise program will include 20 minutes(Transcutaneous Electrical Nerve Stimulation) TENS with conventional method, 4 minutes continue ultrason, 20 minutes hot pack.
214959828|NCT00893529|DIETARY_SUPPLEMENT|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
214352499|NCT06183931|DRUG|ALXN2220|Participants will receive ALXN2220 via IV infusion.
214352500|NCT06183931|DRUG|Placebo|Participants will receive placebo via IV infusion.
214352501|NCT06750588|DRUG|bacteriophage preparation|NTR-101 will be given orally to participants once daily for 7 days
214486912|NCT06734832|BIOLOGICAL|Enterovirus Type 71 Vaccine (Vero Cell), Inactivated|Two doses are administered with a one-month interval between each dose.
214486913|NCT06779383|OTHER|pilates mat exercises|The Pilates exercises were performed on mats. The functional performance on one-leg stance (OLS), five-times-sit-to-stand (STS) and 6-min walk (6 MW) tests was evaluated before and after the 12-week Pilates training or control follow-up period.
214486914|NCT00766948|OTHER|There is no intervention, this is a biorepository.|There are no interventions in this study.
214486915|NCT06328114|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will experience two accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
214486916|NCT04319887|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
214486917|NCT06778928|PROCEDURE|laparoscopic cholecystectomy|Posterior wall sparing of laparoscopic cholecystectomy in cirrhotic patients
214959829|NCT00893529|DIETARY_SUPPLEMENT|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
215079192|NCT03008902|PROCEDURE|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
214352502|NCT06750588|DRUG|Bacteriophage preparation|NTR-101 will be given orally to participants once daily for 7 days
214352503|NCT06750588|DRUG|bacteriophage preparation|NTR-101 will be given orally to participants twice daily for 7 days
214352504|NCT06750588|DRUG|bacteriophage preparation|NTR-101 will be given orally to participants three times daily for 7 days
214959830|NCT05720429|OTHER|Psychoeducational program|"A psychoeducational program consisting of 11 one-hour sessions, with a weekly or biweekly frequency, each one regarding specific tools and skills to promote emotional well-being, self-care, and the ability to deal with stressful situations. They are conducted by community psychologists, who will give a brief theoretical introduction and then conduct practical group exercises that apply the concepts introduced. Every session ends with a relaxation exercise and some habits that the participants can incorporate into their daily life.~Session Index: (1) Emotional management;(2) Thought management; (3) Stress management; (4) Communication skills, active listening, and empathy; (5) Self-care; (6) Individual/group self-esteem; (7) Anxiety/coping with panic. Mindfulness; (8) Activating motivation; (9) Problem-Solving; (10) Positive psychology and emotional intelligence; (11) Emotional expression through art."
214959831|NCT02273128|GENETIC|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
214959832|NCT04283253|DEVICE|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
214352505|NCT07059013|DEVICE|Chatbot|"The Chatbot will be designed using open-source conversational AI, such as GPT. The Chatbot will include three modules: individual strength, information, and Peer Networks.~1. Individual Strength Include eight positive psychology exercises: positive introduction, personal strengths, using strengths, three good things, gratitude letter/visit, hope and optimism, active/constructive responding, and savoring.~2. Information Include available healthcare services, parenting skills for children with ASD, the health information for ASD, the financial assistance provided by public and private funding, educational resources, and community resources.~3. Peer Networks Participants can share their experiences about adapting after their child's diagnosis and read others' sharing."
214959833|NCT00210886|DRUG|levofloxacin|
215079193|NCT05270330|OTHER|This is an observational study, we don't have any interventions.|No intervention
214352506|NCT07059117|OTHER|Hedonic mapping|During the first session, participants will be presented with risotto samples differing in MSG content and thus umami taste intensity, assigned based on Booth's method (Booth et al., 1983). Based on these individual ratings, umami taste intensities of the ad libitum test meals will be calculated per participant.
214352507|NCT07059117|OTHER|Ad libitum risotto test meal|During the ad libitum test meal, participants will be presented with 800 grams of risotto with either high-, low-, or optimum umami taste intensity.
214352508|NCT06598579|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a form of psychotherapy that combines principles of cognitive therapy with mindfulness practices focused on increasing non-judgemental awareness of the present moment. It was designed to help individuals, particularly those with depression, stop rumination and a cycle of negative thought patterns that lead to emotional distress including depression. It is a well established depression EBT. The Vietnamese version of the program (MBCT-VN) is a group treatment involving from five to ten participants (depending on how many participants are able to be recruited) per group.
214352509|NCT06598579|BEHAVIORAL|Treatment-as-usual involving Buddhist meditation|MBCT and other mindfulness interventions were originally derived from Buddhist meditation, modifed to be non-secular and focused on treatment of depression and other mental health and behavioral problems rather than on spiritual development. In the present study, a treatment-as-usual condition involving Buddhist meditation will be used. The project will assess the characteristics of the Buddhist meditation delivered for the control group participants at pagoda meditation retreats but will not influence this control condition in any way.
214352510|NCT01329029|DRUG|Roflumilast|500 µg, once daily
214486918|NCT06741033|DIAGNOSTIC_TEST|Conventional physiotherapy|Conventional physiotherapy of medial knee osteoarthritis patients: Isometric exercises, strengthening exercises, stretching exercises and electrotherapy.
214959834|NCT03182491|DIAGNOSTIC_TEST|Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)|Analysis of biomarkers and basophil activation test
214959835|NCT03070756|DEVICE|Minimal-Intervention - Specification of device settings|\- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration \<=15 min, softPAP Level is selected based on patient comfort
214959836|NCT05305989|DRUG|Belumosudil 200 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
214959837|NCT05305989|DRUG|Belumosudil 200 mg BID|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
214959838|NCT05305989|DRUG|Belumosudil 400 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
214959839|NCT00182533|DRUG|Sertraline|25 - 200 mg/day x 16 weeks
214959840|NCT00182533|DRUG|Placebo|25 - 200 mg/day x 16 weeks
215079194|NCT00724854|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
215079195|NCT00724854|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
214352511|NCT01329029|DRUG|Placebo|once daily
214352512|NCT07066124|BEHAVIORAL|Progressive Relaxation Exercises training was given to the pregnant women in the intervention group and their practice was provided for six weeks.|Progressive Relaxation Exercises training was given to the pregnant women in the intervention group and their practice was provided for six weeks. After the first encounter, Pittsburgh Sleep Quality Index and Quality of Life Scale were re-administered to the pregnant women in the third and sixth weeks to evaluate their sleep and quality of life.
214352513|NCT06854601|DRUG|Mexidol|125 mg tablets
214959841|NCT01179646|DRUG|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
214959842|NCT04468113|DEVICE|Tumark® Vision clip|Suspicious intramammary lesion is marked with clip
214959843|NCT02182830|DRUG|Empagliflozin low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
214959844|NCT02182830|DRUG|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
214352514|NCT06854601|DRUG|Placebo|Placebo tablets
214959845|NCT02182830|DRUG|Empagliflozin high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
214959846|NCT00149032|PROCEDURE|DLI sensitized against antigens expressed by the host.|
214352515|NCT06854601|DRUG|Mexidol + Placebo|Combination of Mexidol and Placebo
214352516|NCT06770777|BEHAVIORAL|Tiered whole health support for people living with COPD|The website design allows study participants to choose the intervention tier(s) that meets their needs. There are three tiers from Tier 1: Information only, Tier 2 Reflective Writing, and Tier 3 LCSW Psychotherapeutic Intervention. Participants will also be able to choose multiple tiers if they are interested in continuing their participation. First Tier: The website offers standardized information about COPD care, healthcare navigation, and whole-person care. Information includes symptom management, disease progression and trajectory, healthcare navigation concepts, and directs people to the VA website with information about whole-person care. Second Tier: If participants choose, they can also select writing prompts with opportunities to reflect on their whole-person care and adjustment to illness. Third Tier: People living with COPD can also select to have asynchronous interaction with a licensed clinical social worker providing the narrative-based psychotherapeutic intervention.
214352517|NCT07076134|OTHER|FCHVs and FLHWs in a community managing HTN using primary care based approach and mobile health technology|Our intervention utilizes FCHVs as a bridge between the community and health facilities to improve HTN care. FCHVs and FLHWs will receive 2 days of training to use an Android app. The app provides prompts for BP measurement and educational content on healthy lifestyles. For 3 months, FCHVs will conduct bimonthly meetings, measure BP, height, and weight, provide awareness and enter sociodemographic details of participants into the app. Participants with BP ≥130/85 mmHg (unmedicated) or ≥120/80 mmHg (on medication) will be referred to a nearby health facility by FCHVs. The data entered by FCHVs will be linked to FLHWs' terminals. FLHWs will enter required information about medication use, referrals, and follow-ups into the app and take necessary actions for the treatment of referred patients. The intervention includes 795 participants from 10 clusters with BP ≥130/85 mmHg. Data on BP, medication adherence, quality of life, and physical activity will be collected at baseline and endline.
214959847|NCT01738256|BEHAVIORAL|Wellbeing intervention (ACT)|The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.
214959848|NCT01738256|BEHAVIORAL|Wellbeing intervention (Internet)|The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).
214959849|NCT01738256|BEHAVIORAL|No intervention|No intervention
214959850|NCT00198809|DRUG|Biolean + Diet education|
214959851|NCT00198809|DRUG|Biolean Free + Diet education|
214959852|NCT00198809|DRUG|Placebo + Diet education|
214959853|NCT04649970|PROCEDURE|Antegrade double-J stent|After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.
214352518|NCT06384508|BEHAVIORAL|SHINE-VR|"The SHINE-VR takes place after trauma processing, e.g. after module 6 of TF-CBT or processing of the traumatic event with EMDR, and is followed by the rest of the regular treatment. SHINE-VR consists of the following 3 VR sessions à 45min:~* Introduction: getting acquainted with VR, playing a VR game developed for the feasibility study (Krupljanin et al., in preparation), receiving psychoeducation about seeking help.~* Shame: virtual group therapy setting, psychoeducation about shame, virtual peers sharing thoughts of shame and their learnings/positive affirmations.~* Self-compassion: practicing self-compassion using an immersive perspective-changing task in VR."
214959854|NCT02145637|DRUG|Afatinib plus Ruxolitinib combination therapy|
214959855|NCT00154375|DRUG|Imatinib mesylate|Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
214959856|NCT00154375|DRUG|Hydroxyurea|
214959857|NCT05309330|OTHER|No Intervention|This is a non-interventional study.
214959858|NCT06015919|BEHAVIORAL|dash diet|"* Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~* Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~* Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs."
214959859|NCT06015919|DEVICE|Acupuncture|acupuncture
214959860|NCT02348008|DRUG|MK-3475|Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
214959861|NCT02348008|DRUG|Bevacizumab|Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
214959862|NCT02348008|DRUG|MK-3475|Arm B: Phase II Treatment: 200mg IV
214352519|NCT07099339|BEHAVIORAL|Behavioral Therapy|Behavioral Therapy in form of: Learning and advices, Dietary modifications, Toilet pattern modification, Motivational rewarding system, and Diary documentation.
214352520|NCT07099339|OTHER|Kegel Exercise|Kegel Exercise done by contracting and relaxing pelvic floor muscles for seconds with hold and repetitions.
214352521|NCT07099339|DEVICE|Pudendal Nerve Electrical Stimulation|Pudendal Nerve Electrical Stimulation applied bilateral to the right and left pudendal by inserting rectal stimulator electrode anally with the other surface electrode at sacral region.
214352522|NCT07099339|DIAGNOSTIC_TEST|Anal Sphincter Muscle Activity Peak|Anal Sphincter Muscle Activity Peak was evaluated using anal pressure sensor (in mmHg) = anal squeeze pressure during maximum voluntary contraction - resting anal pressure at rest or resting tone as baseline activity
214959863|NCT02348008|DRUG|Bevacizumab|Arm B: Phase II Treatment: administered at the maximum safe dose of 10mg or 15mg as established in the Phase 1b dose escalation cohort study.
214959864|NCT06179043|BEHAVIORAL|Nutrient warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* Labels that read high in sugars and high in calories~* A label that reads high in sugars"
214959865|NCT06179043|BEHAVIORAL|Text-only health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay"
214959866|NCT06179043|BEHAVIORAL|Graphic health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay and contains graphics illustrating obesity, type 2 diabetes, and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay and contains graphics illustrating type 2 diabetes and tooth decay"
214959867|NCT06179043|BEHAVIORAL|Control labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A neutral bar code label~* A neutral quick response (QR) code label (not scannable)"
214959868|NCT01909141|DRUG|induction of ovulation using letrozole-pioglitazone-metformin|induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
214959869|NCT01909141|DRUG|induction of ovulation using clomiphene citrate-pioglitazone-metformin|induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.
214959870|NCT01909141|RADIATION|transvaginal ultrasound|transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of \> 18 mm or till day 20 of the cycle
214959871|NCT01909141|OTHER|body mass index (BMI) calculation|BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
214959872|NCT01909141|OTHER|day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
214959873|NCT01909141|OTHER|pretreatment blood urea and serum creatinine|blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
214959874|NCT01909141|OTHER|serum estradiol (E2) on day 12|serum E2 will be assayed on day 12 of the cycle for all women.
214959875|NCT01909141|OTHER|serum progesterone on day 21|serum progesterone will be assayed on day 21 for all women to monitor ovulation.
214959876|NCT01909141|OTHER|blood urea and serum creatinine every month|blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
214959877|NCT06596876|DRUG|HRG2010; Sustained-release Carbidopa/Levodopa administered placebo|Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.
214959878|NCT06596876|DRUG|Sustained-release Carbidopa/Levodopa; HRG2010 placebo|Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.
214959879|NCT04672044|DEVICE|Active rTMS and exercise|active
214959880|NCT04672044|COMBINATION_PRODUCT|Sham rTMS+Exercise|sham
214959881|NCT06137820|DEVICE|Cetilar® (topical cream)|Topical cream twice daily for 30 days. An average amount of 5 g per day.
214959882|NCT06137820|DEVICE|Cetilar Placebo|Cetilar placebo cream matching to Cetilar®. Topical cream twice daily for 30 days. An average amount of 5 g per day
214959883|NCT06655441|DRUG|3% trehalose|ophthalmic solution with 3% trehalose in sterile saline in multi dose preservative free bottles
214959884|NCT00545935|DRUG|Methylenblue-Amodiaquine (MB-AQ)|For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
214959885|NCT00545935|DRUG|Methylenblue-Artesunate (MB-AS)|3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
214959886|NCT00545935|DRUG|Artesunate-Amodiaquine (AS-AQ)|For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
215079196|NCT00147862|DRUG|Tranexamic Acid|
214352523|NCT07099339|DIAGNOSTIC_TEST|Bowel Diary Documentation|"Defecation Frequency and Fecal Leakage Episodes collected from the Bowel Diary that documenting bowel events daily through a period of time a week."
214352524|NCT07097558|OTHER|Mandala coloring group|The mandala painting intervention will be administered twice a week for 8 weeks for the mandala coloring group.
214352525|NCT07097558|OTHER|Music listening group|The music listening group will listen to classical music twice a week for 8 weeks for 30 minutes, twice a day.
214352526|NCT07097558|OTHER|control group|The control group will not receive any intervention.
214393677|NCT03202030|PROCEDURE|Immediate dentoalveolar restoration|Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
214393678|NCT03202030|PROCEDURE|Demineralized bovine bone|Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
215079197|NCT00025428|DRUG|carboplatin|
215079198|NCT00025428|DRUG|cyclophosphamide|
215079199|NCT00025428|DRUG|doxorubicin hydrochloride|
215079200|NCT00025428|DRUG|etoposide|
215079201|NCT00025428|DRUG|vincristine sulfate|
215079202|NCT00025428|PROCEDURE|adjuvant therapy|
215079203|NCT00025428|PROCEDURE|conventional surgery|
215079204|NCT00025428|PROCEDURE|neoadjuvant therapy|
214959887|NCT02169297|PROCEDURE|Ultrasound-guided Sub-Paraspinal Block|Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter \[maximum pump infusion rate\]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
214959888|NCT02169297|PROCEDURE|PCA only|Patients received intravenous PCA post-operatively
214959889|NCT06240299|PROCEDURE|Neurofeedback|A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen
214959890|NCT04207944|DRUG|Sulindac 400 MG|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
214959891|NCT04207944|OTHER|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
214959892|NCT06670365|OTHER|Heat acclimation by warm-water immersion|Participants will be immersed in a whirlpool tub to the shoulder level in a circulated water bath maintained at \~40°C until their core temperature achieves a steady-state of 38.5°C for 60 minutes. The warm-water immersion protocol will be repeated for 6 more consecutive days.
214959893|NCT05446272|DEVICE|NIV-NAVA|Infants in the intervention arm will be managed with non-invasive neurally adjusted ventilatory assist (NIV-NAVA) using FDA-approved servos with associated FDA-approved Edi catheter.
214959894|NCT05446272|DEVICE|NS-NIPPV|Infants in the active comparator arm will be treated with non-synchronized non-invasive positive pressure ventilation (NIPPV) through FDA-approved ventilators currently in use at each site.
214959895|NCT00743678|DRUG|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
214959896|NCT02152098|PROCEDURE|Acute Early onset of rehabilitation|Early onset of rehabilitation
214959897|NCT02152098|PROCEDURE|Acute Delayed onset of rehabilitation|Delayed onset of rehabilitation
214959898|NCT02152098|PROCEDURE|Chronic Exercise|Exercise
214959899|NCT02152098|PROCEDURE|Chronic Control|Control
214959900|NCT01181947|DEVICE|TEVAR|Thoracic endovascular aneurysm repair
214959901|NCT03715452|DEVICE|DyeVert Plus Contrast Reduction System|The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.
214959902|NCT06363448|PROCEDURE|Yamani Technique versus Prolene Mesh for Intraocular Lens Scleral Fixation in Aphakia|Patients were divided into two groups to undergo classic ab externo two-point scleral fixation or flanged haptics as described by Yamani or the 2\*2 proline mesh technique.
214959903|NCT00792116|BEHAVIORAL|Gum Chewing|
214959904|NCT07018791|DIAGNOSTIC_TEST|Standard TMD Assessment|This is the conventional diagnostic and management approach for TMD, focusing on physical evaluation and symptom tracking without the use of any visual or art-based tools. It serves as the baseline for comparison in this study.
214959905|NCT07018791|DIAGNOSTIC_TEST|Artistic Pain Exploration (APE) Method|This approach involves showing patients three expressive paintings and asking them to select the one that best resonates with them. A guided interview follows, using the artwork to explore the patient's pain characteristics, emotional impact, and functional limitations. This method aims to provide a richer, more personalized understanding of the patient's pain experience.
214959906|NCT05171660|DRUG|Sintilimab|Sintilimab Injection: 200 mg, i.v., D1, Q3W
214959907|NCT05171660|DRUG|Bevacizumab|intravenous bevacizumab (7.5 mg/kg, day 1) in each 21-day cycle
214959908|NCT05171660|DRUG|Oxaliplatin|intravenous oxaliplatin (130 mg/m2, day 1) in each 21-day cycle
214959909|NCT05171660|DRUG|Capecitabine|oral capecitabine (1 g/m2, days 1-14) in each 21-day cycle
214959910|NCT07021950|DRUG|AK112|AK112：20mg/kg，Q2W。Administered over 60 minutes (±10 minutes). For intolerable cases, infusion duration may extend up to 120 minutes. During treatment, dosing delays are allowed for up to 12 weeks (calculated from the last dose). AK112 may be resumed after 12 weeks under the following conditions: If treatment is paused due to glucocorticoid tapering for managing immune-related adverse events (irAEs);If treatment is paused due to adverse events unrelated or deemed unrelated to AK112; Resumption is permitted only if the investigator judges continued therapy beneficial, following discussion with relevant medical personnel.
214959911|NCT07021950|DRUG|FOLFIRI|FOLFIRI：Irinotecan, 180 mg/m² IV over 30-90 minutes (Day 1); Leucovorin (LV), 400 mg/m² IV over 2 hours (Day 1); 5-FU, 400mg/m²IV Day1, then 1200 mg/(m².d) ×2 days (total 2400 mg/m² ,IV over 46-48 hours).Q2W.
215079205|NCT03986580|DEVICE|Annular closure device|Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
215079206|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
215079207|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
215079208|NCT01095653|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
215079209|NCT01095653|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
215079210|NCT01184833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
214352527|NCT06496867|PROCEDURE|Early Internal Fixation|Early internal fixation of the LC1 fragility fracture of the pelvis will be defined as percutaneous anterior and/or posterior pelvic internal fixation with cannulated screw(s), medullary implant(s), or sacroiliac joint fusion device(s). The implant number, design, diameter, thread type (fully-threaded or partially-threaded), sacral segment (S1, S2, S3, or any combination there of), length, trajectory including sacroiliac or transsacral-transiliac, application with or without a washer, and ingrowth or ongrowth surface designs will be at the discretion of the treating surgeon.
214352528|NCT06496867|OTHER|Nonoperative Care with Early Rehabilitation|Nonoperative care with early rehabilitation will consist of nonoperative treatment of the pelvis fracture, including early consultation of the physical therapist, physiotherapist, or local equivalent rehabilitation provider at the time of randomization for a first attempt at mobilization of the patient within 24 hours of randomization. Patients who are unable to ambulate with assistance after five or more days of attempted mobilization by rehabilitation providers may be considered for delayed internal fixation treatment at the discretion of the patient and the treating surgeon. Delayed internal fixation after five or more days of attempted mobilization by rehabilitation providers will not be considered a treatment crossover event.
214352529|NCT07100405|DRUG|PD-1 inhibitor|An approved agent (e.g., Pembrolizumab, Nivolumab, Sintilimab, Tislelizumab, etc.) will be selected based on clinical practice and administered at standard doses and schedules.
214352530|NCT07100405|PROCEDURE|TACE|TACE is performed by using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
214352531|NCT04980482|DRUG|AB-729|subcutaneous injection
214352532|NCT04980482|DRUG|Peg-IFNα-2a|subcutaneous injection
214959912|NCT07021950|DRUG|Bevacizumab|Bevacizumab：5 mg/kg，Q2W. The initial intravenous infusion should last approximately 90 minutes. If the first infusion is well tolerated, the duration of the second infusion can be reduced to approximately 60 minutes. Should the participant also tolerate the 60-minute infusion well, then all subsequent infusions may be administered over a period of approximately 30 minutes. Continuous monitoring for potential infusion-related reactions during the drip is required; if an infusion-related reaction occurs, the infusion rate should be promptly reduced or the infusion temporarily halted.
214959913|NCT07022223|DRUG|orelabrutinib combined with rituximab regimen|"All participants will receive induction therapy with the orelabrutinib and rituximab regimen. The treatment cycle is 28 days, with a total of 6 cycles. The induction treatment period is as follows:~Cycle 1: Rituximab, 375 mg/m², on Day 1. Cycles 2-6:Orelabrutinib, 150 mg, once daily orally, from Day 1 to Day 28. Rituximab, 375 mg/m², on Day 1.~Patients who achieve a partial response (PR) or better will enter a 2-year maintenance period with orelabrutinib."
214959914|NCT07022236|DIAGNOSTIC_TEST|Thyroid profile|Thyroid dysfunction in patients undergoing hemogdialysis in sohag university hospital
214959915|NCT07021521|DRUG|0 mg/kg Midazolam (Control Group)|"* Intravenous administration of volume-matched normal saline (0 mg/kg midazolam equivalent)~* Administered as single bolus prior to epidural anesthesia~* Served as active comparator for dose-response evaluation"
214959916|NCT07021521|DRUG|0.01 mg/kg Midazolam Group|"* Intravenous midazolam at 0.01 mg/kg (diluted in normal saline)~* Administered as single bolus over 2 minutes~* Manufacturer: Jiangsu Enhua Pharmaceutical Co., Ltd. (Approval H19990027)"
214959917|NCT07021521|DRUG|0.02 mg/kg Midazolam Group|"* Intravenous midazolam at 0.02 mg/kg~* Identical administration protocol as 0.01 mg/kg group~* Primary focus: Intermediate dose efficacy/safety assessment"
214959918|NCT07021521|DRUG|0.03 mg/kg Midazolam Group|"* Intravenous midazolam at 0.03 mg/kg (maximum tested dose)~* Special hemodynamic monitoring due to dose-dependent MAP effects~* Primary focus: Optimal dose determination"
214959919|NCT07021924|OTHER|Fu's subcutaneous needling|"A single-use Fu's Subcutaneous Needling (FSN) device was employed. Participants were instructed to lie supine with the tested upper limb extended in a neutral position. After a 15-minute resting period, the FSN needle was fully inserted into the subcutaneous tissue layer at the acupoint Xialian (LI18) along the Large Intestine Meridian, with the needle tip oriented toward the radial styloid process.~The needle core was retracted into the soft tube, and the needle was then manipulated by swinging the handle left and right in a fan-shaped manner, with a sweep angle of approximately 60 degrees (30 degrees in each direction) relative to the insertion axis. The swaying movements was performed 50 times back and forth (100 cycles/min) over a duration of 2 minutes.~The needle was retained in place for 15 minutes before being removed. After needle removal, participants remained resting for 3 minutes before getting up, marking the end of the experimental procedure."
215079211|NCT04720274|DEVICE|Electromyopathy (EMG) Shorts|Participants will be asked to complete physical activities while wearing EMG shorts
215079212|NCT00171925|DRUG|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
215079213|NCT00171925|DIETARY_SUPPLEMENT|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
215079214|NCT02692040|DRUG|G3215|Gut hormone analogue
215079215|NCT02692040|DRUG|Placebo|0.9% saline
214352533|NCT06573983|OTHER|Strengthening (Physical Therapy, Gerofit)|Individuals with physical fall risk will be referred to strengthening interventions available within the VHA. These may include Physical Therapy or Gerofit (a supervised exercise program).
214352534|NCT06573983|OTHER|Cognitive Behavioral Therapy (Clinical Psychology, Occupational Therapy)|Individuals with psychological fall risk will be referred psychological interventions such as cognitive behavioral therapy, which focuses on guided talking. This can be performed by VHA occupational therapists and clinical psychologists.
214352535|NCT06573983|OTHER|Medication Reconciliation (Clinical Pharmacology)|Individuals with pharmacological fall risk will be referred to clinical pharmacology for medication reconciliation. This includes examining the current medication list and deprescribing medications, if appropriate.
214352536|NCT06573983|OTHER|Home Safety Modification (Occupational Therapy)|Individuals with environmental fall risk will be referred to occupational therapy for home safety assessments and modifications. This will involve modifying components within the home to reduce potential fall risk factors.
214352537|NCT07105215|DRUG|RC278|Intravenous (IV) administration of RC278 Q3W. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.
214959920|NCT07021924|OTHER|Acupuncture|"Participants were instructed to lie supine with the tested upper limb extended in a neutral position. According to WHO standard acupoint locations, the acupuncture needle was inserted at Xialian (LI18), located 4 cun below Quchi (LI11) on the line connecting Hegu (LI4) and Quchi (LI11). A 30-gauge, 1.5-inch acupuncture needle was used, and insertion continued until the Deqi sensation was achieved.~The needle was retained for 15 minutes before being removed. After a 3-minute post-removal rest period, participants were allowed to rise, completing the procedure."
214352538|NCT07105748|DRUG|Camrelizumab|Camrelizumab will be administered by IV, 200 mg every 2 weeks.
214352539|NCT07105748|DRUG|Rivoceranib (Apatinib)|Rivoceranib will be administered by oral 250 mg once daily.
214352540|NCT07105748|PROCEDURE|HAIC|FOLFOX regimen (oxaliplatin, 85 mg/m2 from hour 0-2 on day 1; leucovorin, 400 mg/m2 from hour 2-3 on day 1; and ﬂuorouracil, 400 mg/m2 bolus at hour 3 on day 1 and 2,400 mg/m2 over 24 hours) via infusion via the hepatic artery. HAIC was repeated once every 4 weeks for up to 6 cycles. Camrelizumab plus rivoceranib will be administered 1-3 days after HAIC.
214959921|NCT07022145|PROCEDURE|Endovascular repair|Endovascular repair using proximal stent-graft or proximal stent-graft combined with distal stent for TBAD patients
214959922|NCT07022444|DEVICE|IOL-MASTER 700|patients who were diagnosed cataract would go through tests with IOL-MASTER 700 to achieve ocular biometry parameters.
214959923|NCT07021820|DIAGNOSTIC_TEST|MSOT|Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin or haemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT illuminates the tissue with near-infrared light of transient energy, which is absorbed and leads to thermoelastic expansion of certain molecules. This expansion generates ultrasound waves that are detected by the same device. The multispectral illumination and unmixing then enable the precise localization and quantification of muscle-specific subcellular structures. MSOT has already shown the potential to visualize the muscle structure and clinical extent of muscle disease in patients with Duchenne muscular dystrophy, spinal muscular atrophy and the late-onset Pompe disease (LOPD) and to distinguish these patients from healthy volunteers. To date, there is no optoacoustic data on CNM.
214959924|NCT07022327|DRUG|Ivacaftor 150 MG (milligrams)|Ivacaftor is a CFTR potentiator approved for the treatment of cystic fibrosis in patients with specific gating mutations. In this observational, single-patient study, Ivacaftor is being used off-label in an adolescent without a cystic fibrosis-associated CFTR mutation to evaluate its potential impact on chronic pancreatitis. The intervention is not assigned by the study team but is part of the participant's ongoing medical care. The study monitors clinical outcomes and wearable health data over a 12-month period.
214959925|NCT07022080|DIAGNOSTIC_TEST|68Ga-grazytracer PET/CT Scan|The imaging agent 68Ga-grazytracer used in this project is synthesised in accordance with the standards for the production of radiopharmaceuticals with reference to the Chinese Pharmacopoeia (18F-FDG quality standard). pH value is between 5.0-8.0; radiochemical purity is not less than 95%, and the content of bacterial endotoxin per mL of solution is less than 15EU; the concentration of radioactivity is not less than 37MBq/mL; the solvent The residual amount of solvent complies with the regulations. Specification: 185\~1850 MBq/ml Characteristics Colourless and transparent, no visible particles. Physical half-life: 68 minutes for 68Ga. Stable for 3 half-lives from the time of labelling. Method of administration: Intravenous. Dose: 0.05Ci/kg, followed by a 5 mL saline flush.
214959926|NCT07021768|DEVICE|Laser Auriculotherapy|French Laser Auriculotherapy using the ECCO REABILITY device and dual pen with red laser with 660 nm wavelength, both manufactured by Ecco Optical Fibers and Devices, using the ideal Nogier Frequency for each region with application of 2 J per point with 100 mW power. For the active group, a 120 mW active tip, red laser with 660 nm, pulse width of 1.2 milliseconds will be used.
214959927|NCT07022912|OTHER|educational healthcare intervention|This intervention will be applyed at the beginning of the study
214959928|NCT07022912|DIAGNOSTIC_TEST|Objective assessment of GI motility|Objetive assessment of gastrointestinal dysmotility in GI organs (esophagus, stomach, small bowel) will be performed using state of the art tests.
214352541|NCT07113249|OTHER|Foam Rolling (FR)|For the FR, participants were asked to place the roller behind their leg. Three sets, each lasting 60 seconds, with a 30-second break between sets, were performed, for a total of 90 rolls per set.
214352542|NCT07114003|BEHAVIORAL|virtual reality application|The Oculus Meta Quest Pro is a virtual reality headset with 256 GB of storage. Its LCD screen offers a resolution of 1800 x 1920 pixels per eye and supports refresh rates from 90 Hz to 120 Hz. It is powered by a Qualcomm Snapdragon XR2+ processor. It features eye tracking and facial tracking, controllers with TruTouch haptics and precision tracking, and built-in 3D spatial audio support. The program, which will be played through the VR headset, is designed to use licensed programs featuring nature scenes (forest, sea, beach, etc.) and relaxing music for 20-30 minutes. The program content will be created by selecting nature sounds and music known to be effective in reducing stress and anxiety. To ensure the program's internal validity, the opinions of healthcare professionals with clinical experience will be obtained to assess whether the program achieves the intended relaxing effect.
214678857|NCT00081289|DRUG|Fluorouracil|"5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.~5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles."
214959929|NCT07022912|DIAGNOSTIC_TEST|Evaluation of GERD severity|Objective evaluation of GERD severity on PPI therapy will be performed.
214959930|NCT07022067|DEVICE|Telemonitoring app|periodic measurement of blood pressure and body weight
214959931|NCT07022314|DEVICE|FIZE kUO®|FIZE kUO® is a commercially available, non-invasive device used for continuous, minute-by-minute real-time urine output monitoring in patients with an indwelling Foley catheter. In this observational study, the device is used during and after cardiac surgery as part of routine clinical care. Urine output data, along with additional clinical parameters, are collected throughout the study for research analysis.
214678858|NCT00081289|DRUG|Oxaliplatin|85 mg/m\^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
214352543|NCT07109427|OTHER|Annual PSA Health Maintenance Reminder|The annual health maintenance reminder does not mandate PSA screening for eligible patients. Instead, it recommends that primary care providers (PCPs) initiate a shared decision-making discussion with their patients. As part of this conversation, patients will be informed of their individual risk factors-including race, family history, and germline mutations-and can then make an informed choice about whether to proceed with PSA screening.
214959932|NCT07021781|OTHER|MedQuest mobile application|Participants in this group will complete standardized questionnaires and scales using the MedQuest mobile application. Physicians will provide patients with a QR code, allowing them to access assigned digital questionnaires on their personal mobile devices or provided tablets. The application facilitates the digital input of patient responses. Following completion, the MedQuest application automatically processes the questionnaire data and utilizes an integrated artificial intelligence system (Claude 3.5 Sonnet, version from 22.10.2024) to generate recommended International Classification of Functioning, Disability and Health (ICF) codes. The application also provides an integrated calculator for questionnaire scores. This intervention aims to streamline the assessment process, reduce completion time, and enhance the efficiency and accuracy of ICF coding through AI integration.
214352544|NCT07116083|DIAGNOSTIC_TEST|µQFR|Patients with bifurcation lesions undergoing single-stent intervention are recruited. Wire-based FFR and intravascular imaging is performed, according to current guidelines, to guide PCI strategy. Angiography will be saved anonymously and sent to an independent core lab for µQFR calculation. Operaters are blinded to µQFR results.
214352545|NCT07114016|DRUG|Glucosamine Hydrochloride|GlcN.H is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan known for its immunoregulatory capacity and anti-inflammatory effects.
214352546|NCT07114016|DRUG|Triamcinolone Acetonide|Topical corticosteroid (triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, anti-allergic, and immunosuppressive properties which is used commonly in topical formulations)
214352547|NCT00680407|OTHER|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
214959933|NCT07021781|OTHER|Traditional Paper-Based Questionnaires|Participants in this group will complete all standardized questionnaires and scales (e.g. SF-36, Barthel Index, etc.) manually on printed paper forms. Physicians will complete the forms and patients will complete their responses with a pen or pencil. Subsequent evaluation and processing of these questionnaires will be performed by physicians via the Medquest application, followed by manual identification and recording of International Classification of Functioning, Disability, and Health (ICF) codes based on clinical judgment and established guidelines. This method represents the traditional approach to patient assessment and data collection.
214959934|NCT07022249|DEVICE|Intrasaccular Embolization Device|This is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.The intended therapeutic effect of this device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
214959935|NCT07021534|BIOLOGICAL|NKG2D CAR NK and NKG2D CAR T cells|"* NKG2D CAR-NK cells (hepatic artery infusion, D0 dose: 1×10⁹ cells,D1 dose: 1×10⁹ cells)~* NKG2D CAR-T cells (Over a two-day period, CAR-T cells are administered via intravenous infusion on two consecutive occasions.In the initial phase, rapid titration dose escalation was performed with 1 case per group.The initial dose is set at 1.5×10⁷/kg. If grade 2 or higher cytokine release syndrome (CRS) or related adverse events (AEs) occur, the 3+3 dose escalation protocol will be initiated. If not, the starting dose for escalation will be set at 3×10⁷/kg per administration of-T CAR cells, with subsequent escalations to 5×10⁷/kg per administration and 7×10⁷/kg per administration.)~Chemotherapy:~If you are treated with autologous CAR-NK cells, lymphodepleting chemotherapy with FC is usually not required. If you are treated with allogeneic NKG2D CAR-NK cells derived from umbilical cord blood of a healthy donor, the researchers will adjust the FC chemotherapy dosage or choose another appropriate"
215079216|NCT05482178|BEHAVIORAL|Resistance exercise training plus hypocaloric diet|"The exercise program included 3 phases of progressive intervention: 1) Adaptation which included 3-4 days per week at 60% of maximum heart rate, 2) Development phase which included 5 days per week at 75-85% of maximum heart rate and the last one, 3) Maintenance phase which included 5 days per week at 75-90% of maximum heart rate. The control and follow up will be through text message exchanges at least once a week or as many as necessary.~On the other hand, the diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day)."
215079217|NCT05482178|BEHAVIORAL|Hypocaloric diet|The diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day).
215079218|NCT02674282|PROCEDURE|ACL reconstruction|ACL reconstruction with hamstrings autograft.
214352548|NCT00680407|DRUG|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
214352549|NCT00680407|DRUG|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
214352550|NCT07118748|OTHER|Share making decision tool|the experimental group will apply the delegation protocol, but if the protocol recommends antibiotic therapy, the researchers will propose a shared decision using a specific tool to determine with the patient whether to deliver the antibiotic
214352551|NCT07118748|OTHER|Delegation protocol|the control group will apply the delegation protocol alone
214352552|NCT07117942|DRUG|Fermented Deglycyrrhizinated Licorice (FDGL)|Fermented Deglycyrrhizinated Licorice (FDGL) in oral powder capsules; prepared through three consecutive steps: fermentation of licorice roots, removal of glycyrrhizinic acid content (deglycyrrhizination), and lyophilization according to EUROPEAN PATENT SPECIFICATION Ep 1 925 312 B
214352553|NCT07118111|PROCEDURE|Resin infiltration|Application of a low-viscosity resin infiltrant to the anterior teeth affected by enamel defects. This procedure aims to reduce dental hypersensitivity and improve esthetic appearance.
214352554|NCT07121556|DEVICE|MFAT + HA left knee - MFAT + placebo right knee|The left knee will be treated with an injection of high-molecular-weight hyaluronic acid (4 cc) and microfragmented autologous adipose tissue (6 cc), harvested from the abdominal site.The right knee will be treated with microfragmented autologous adipose tissue (6 cc), also harvested from the abdominal site by liposuction and microfragmentation, combined with an injection of 4 cc of saline (NaCl 0.9%)
214352555|NCT07121556|BIOLOGICAL|MFAT + HA right knee - MFAT + placebo left knee|The right knee will be treated with an injection of high-molecular-weight hyaluronic acid (4 cc) and microfragmented autologous adipose tissue (6 cc), harvested from the abdominal site.The left knee will be treated with microfragmented autologous adipose tissue (6 cc), also harvested from the abdominal site by liposuction and microfragmentation, combined with an injection of 4 cc of saline (NaCl 0.9%)
214352556|NCT07118189|DEVICE|N95 masks and indoor air cleaner|Participants who are randomized into the intervention will receive N95 masks to be worn outdoors and an indoor air cleaner in the room that the participant spends the most time in their home. Both intervention and control arms will receive education.
214352557|NCT05568459|OTHER|Non-Interventional|No study treatment will be administered in this study.
214352558|NCT07121868|DRUG|Test Product (Vocarzine)|hard capsule formulation
214352559|NCT07121868|DRUG|Reference (R) Reagila ®|hard capsule formulation
214352560|NCT07122817|OTHER|Assessment|The group to be evaluated is comprised of individuals over 65 years of age, who can independently carry out their daily living activities, and whose cognitive level is sufficient to understand and answer the surveys and tests in the study.
214352561|NCT07126639|DRUG|bedaquiline|Administer 400 mg orally once daily for the first two weeks, followed by 200 mg orally three times a week for the subsequent 22 weeks.
214959936|NCT07021911|RADIATION|Radiotherapy|Conventional fractionated radiotherapy, moderate hypofractionated radiotherapy, stereotactic radiotherapy (SABR)
214959937|NCT07023159|OTHER|Demographics|The demographic profile of each patient was documented, including age and sex, to examine potential associations with survival and neurological outcomes.
214959938|NCT07023159|OTHER|Comorbidities|Data on pre-existing chronic conditions were recorded, such as hypertension, diabetes mellitus, coronary artery disease, chronic kidney disease, and malignancy, in order to assess their potential impact on prognosis following OHCA.
214959939|NCT07023159|OTHER|Prehospital Variables|Several prehospital factors were evaluated, including whether the cardiac arrest was witnessed, whether bystander CPR was performed, the time from collapse to the initiation of CPR, and the time from collapse to EMS arrival. Additionally, the durations of no-flow (i.e., time without any CPR) and low-flow (i.e., time with CPR but without ROSC) were noted. The initial cardiac rhythm was categorized as ventricular fibrillation or pulseless ventricular tachycardia (VF/pVT), asystole, or pulseless electrical activity (PEA). Airway management methods used in the field were documented and classified as bag-valve-mask (BVM), supraglottic airway devices (SGAs), or endotracheal intubation (ETI). Other recorded interventions included prehospital defibrillation, administration of epinephrine (including total dosage), and use of mechanical chest compression devices. Whether ROSC was achieved prior to arrival at the emergency department was also noted.
214959940|NCT07023159|DIAGNOSTIC_TEST|Hematological Parameters|These included white blood cell count (WBC), hemoglobin level, platelet count, mean platelet volume (MPV), and differential counts such as neutrophils, monocytes, and eosinophils.
214959941|NCT07023159|DIAGNOSTIC_TEST|Biochemical Parameters|Measurements included creatinine, urea, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), sodium, potassium, chloride, calcium, and troponin-I levels.
214352562|NCT07126639|DRUG|Pretomanid (Pa)|Administer 200 mg orally once daily for six months.
214352563|NCT07126639|DRUG|linezolid|Administer 600 mg orally once daily for six months.
214352564|NCT07126639|DRUG|Moxifloxacin (M)|Administer 400 mg orally once daily for six months.
214959942|NCT07023159|DIAGNOSTIC_TEST|Arterial Blood Gas Parameters|The primary clinical outcomes recorded for each patient included return of spontaneous circulation (ROSC), 28-day survival or mortality, and neurological status, which was later assessed using the Cerebral Performance Category (CPC) scale.
214959943|NCT07022509|OTHER|proceduder surgery|"The single-incision lateral sulcus mammoplasty is a breast-conserving surgical technique that involves making a single incision along the lateral aspect of the inframammary fold or within the natural skin crease of the lateral sulcus. This approach provides direct access to the lateral quadrants of the breast, which are commonly affected in breast carcinoma, allowing for effective tumor excision while preserving the breast contour.~In SILSM, the incision is carefully planned to align with natural anatomical lines, ensuring optimal cosmetic results and minimal visible scarring. Through this lateral access point, the surgeon performs both tumor resection and glandular reshaping. The technique often involves mobilization and rearrangement of the remaining breast tissue to fill the defect left by the tumor excision, thereby maintaining breast symmetry and volume.~This techn"
215079219|NCT01103154|DRUG|carvedilol|6.25mg per day, increase to 6.25mg bid
215079220|NCT01103154|DRUG|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
215079221|NCT02252185|DEVICE|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson \& Johnson Medical Suzhou Ltd.
215079222|NCT02252185|DEVICE|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
215079223|NCT02752958|DRUG|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
214352565|NCT07126639|DRUG|Delamanid (D)|Administer 100 mg orally twice daily for six months.
214352566|NCT07126639|DRUG|Levofloxacin|Administer 800 mg orally once daily for six months.
214352567|NCT07126639|DRUG|clofazimine|Administer 100 mg orally once daily for six months.
214352568|NCT07127003|PROCEDURE|Immediate Lymphatic Reconstruction|Preserved lymphatic channels are connected to nearby veins to prevent lymphedema during the axillary lymph node dissection.
214352569|NCT07126587|BEHAVIORAL|Nutrition Education and Food Delivery|Healthy frozen meals, produce boxes, and nutrition counseling
214352570|NCT07126587|BEHAVIORAL|Physical Activity Comparator|Physical activity counseling, mHealth text messaging
214352571|NCT07128212|DRUG|Atorvastatin 10 mg daily|Oral atorvastatin 10 mg administered once daily at 18:00 (6 p.m.) for 24 months. Dose form: tablet. Route: oral. Indicated for participants with WMH. Adherence monitored by pill count and diary. No dose titration planned.
214352572|NCT07128212|DRUG|Placebo matching atorvastatin|Placebo tablet matching atorvastatin in appearance and packaging, containing inactive excipients only; taken orally once daily at 18:00 for 24 months.
215079224|NCT00883870|DRUG|mesenchymal stem cells|Intramuscular injection
215079225|NCT00883870|DRUG|Plasmalyte A|Intramuscular injection
214959944|NCT07022509|OTHER|Technique surgery|"The matrix rotation flap is a versatile oncoplastic surgical technique employed in the reconstruction of partial breast defects following tumor excision. This method involves the creation of a rotational skin and glandular flap, mobilized from adjacent breast tissue, typically using an inferolateral or inferomedial pedicle. The flap is designed in a curvilinear or semicircular fashion, allowing it to rotate into the defect site while maintaining adequate vascular supply.~The MRF technique is particularly useful for defects in the lower quadrants of the breast, where direct tissue advancement may be limited. The surgeon carefully outlines a skin paddle adjacent to the resection cavity and undermines the surrounding breast parenchyma. The flap is then rotated and inset into the tumor bed to fill the defect, with the skin paddle contributing to both volume replacement and skin resurfacing if required.~This approach provides robust coverage of the surgical cavity, helps restore breast co"
214959945|NCT06630858|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.
214959946|NCT06630858|PROCEDURE|Intrathecal Morphine|Intrathecal morphine will be performed (a total of 0.2 mg of morphine sulfate + 7.5 mg isobaric bupivacaine).
214352573|NCT07126405|OTHER|PROvider ReMote ObsTetric-Related Employment Education (PROMOTE)|An on-demand 30-minute web-based training for clinical team members that provides a high-level summary of federal employment laws, work note templates embedded into the electronic health record (EHR) that prompt the clinician team member to include relevant information, and a patient-facing infographic designed to facilitate clinician counseling.
214352574|NCT07127588|OTHER|Simulation based clinical ultrasound education|At the two hands-on teaching seminars, GPs in the intervention arm will receive training in five different clinical ultrasound examinations using an ultrasound phantom and an ultrasound simulator (Simbionix U/S Mentor). At the start of the first course day (8 hours), three basic modules will be conducted on the simulator, aimed at training hand-eye coordination and developing fundamental skills in probe movement, enhancing three-dimensional perception, and learning to use the various settings on the ultrasound simulator to achieve optimal imaging. At the first course day, the five clinical ultrasound examinations will be trained through a total of 13 simulation cases. On the second course day (4 hours), the participants will repeat the 13 simulation cases.
214352575|NCT07127588|OTHER|Traditional ultrasound education|At the two hands-on teaching seminars, GPs in the control arm will receive training in five different clinical ultrasound examinations as according to an established and validated training program. At the start of the first course day (8 hours), the five clinical ultrasound examinations will be trained using healthy volunteers and still pictures for visualizing pathology. On the second course day (4 hours), the participants will train by repeating the five clinical ultrasound examinations on healthy volunteers.
214352576|NCT07127107|DRUG|Non-steroidal anti-inflammatory drugs (NSAIDs)|"For mild and moderate migraines e.g Ibuprofen and aspirin.~* Aspirin: Peroral (PO) tablet with standard dosages of 325 mg, 500 mg, and 400 mg effervescent; treatment dosage of up to 1000 mg~* Ibuprofen: PO tablet with standard dosages of 200 mg, 400 mg, 600 mg, and 800 mg; treatment dosage of 200 to 800 mg"
214352577|NCT07127107|OTHER|Manual therapy techniques|"Cranial manipulative osteopathy: Tension release of cranial sutures is applied while the patient in supine lying position, a pressure of 200g to3kg is applied with both thumbs for 30-40 sec or till release occurs. it includes:~1. Coronal suture The head is directed to one side and the pressure is applied with both thumbs directed parallel to each otheralong the coronal suture.~2. Sagital suture distraction The head is in the central position and the pressure is applied with both thumbs directed parallel to each other along the sagittal suture.~3. Squamous suture distraction The head is directed to one side and the pressure is applied with both thumbs parallel along the squamous suture.~4. Lamboidal suture distraction:~   The head is directed to one side and the thumbs directed parallel to each other along the lamboidal suture.~5. Occipitomastoid suture distraction The head is directed to one side and both thumbs directed parallel to each other along occipitomastoid suture."
214352578|NCT07126171|DRUG|Reduning injection|reduning Injection, intravenous drip, 20 ml per time, once a day;
214352579|NCT07126171|DRUG|The simulant of Reduning Injection|The simulant of Reduning Injection, for intravenous drip, 20 ml per time, once a day
214352580|NCT07127497|BIOLOGICAL|Sintilimab combined with XELOX|Sintilimab (3 mg/kg, IV, qd for patients with body weight \< 60 kg; 200 mg, IV, qd for patients with body weight ≥ 60 kg) combined with XELOX (oxaliplatin 130 mg/m2, IV, qd + capecitabine 1000 mg/m2, bid, d1 - d14, q21d) for 2-4 courses
214352581|NCT07127809|BEHAVIORAL|Mindfulness Practice|Participants in this group will engage in a structured mindfulness practice program delivered via a custom-developed mobile app. The intervention includes guided mindfulness exercises such as meditation, breathing techniques, and body awareness, designed to be practiced daily alongside routine nursing duties. The program aims to enhance psychological capital and reduce job burnout symptoms over a 40-day intervention period, with follow-up assessments at 2 and 4 months post-intervention.
214678859|NCT02886026|DEVICE|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
214959947|NCT06630858|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine-PCA will be applied postoperatively for 24 hours . IV-PCA: The requested dose will be 1mg morphine, the lock-in time will be 6 minutes, the 4-hour limit will be 20 mg morphine.
214959948|NCT06686654|BIOLOGICAL|Investigational hMPV/RSV vaccine|Investigational hMPV/RSV vaccine administered intramuscularly
214959949|NCT06686654|BIOLOGICAL|Investigational hMPV vaccine (monovalent)|Investigational hMPV vaccine (monovalent) administered intramuscularly
214959950|NCT06686654|BIOLOGICAL|Investigational RSV vaccine (monovalent)|Investigational RSV vaccine (monovalent) administered intramuscularly
214959951|NCT06686654|BIOLOGICAL|Licensed RSV Vaccine|Licensed RSV vaccine administered intramuscularly
214959952|NCT06686654|BIOLOGICAL|Placebo|Placebo administered intramuscularly
214959953|NCT06628453|DEVICE|CGM|Real-time continuous glucose monitoring
215079226|NCT02003066|PROCEDURE|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
214352582|NCT07126665|DRUG|MHB088C for Injection|Intravenous administration
214352583|NCT07126665|DRUG|MHB039A for Injection|Intravenous administration
214352584|NCT07126457|OTHER|RIS system|The RIS system based on the Internet of Things consists of three aspects: one-way output management of the large database of head and neck tumors, two-way interaction management of artificial intelligence applications, and popular science dissemination for the general public.
214959954|NCT07023237|PROCEDURE|pulsed field ablation|"Pulsed electric fields refer to the generation of high-voltage electric fields with pulse widths ranging from milliseconds to microseconds or even nanoseconds. These fields release extremely high energy in a very short time, creating a large number of irreversible micropores in the cell membrane and even intracellular organelles such as the endoplasmic reticulum, mitochondria, and nucleus. This ultimately leads to apoptosis of the diseased cells, achieving the desired therapeutic effect.~By inserting a pulsed ablation catheter into the patient's body and reaching the target lesion, the pulsed energy is delivered to the ablation catheter via a cardiac pulsed field ablation device, thereby achieving the therapeutic goal of pulsed field ablation."
214959955|NCT06842953|OTHER|Simulated indoor overheating|Older adults are exposed to a 10-hour simulated exposure
214959956|NCT06843681|DRUG|Trastuzumab combined with taxane neoadjuvant therapy|Trastuzumab combined with taxane neoadjuvant therapy
214959957|NCT01680653|DRUG|Mini-glucagon|Mini dose glucagon given for glucose \<70 mg/dl at a dose of 1unit/year of age
214959958|NCT01680653|DEVICE|Remote monitoring|Provides real-time continuous glucose monitoring
214959959|NCT01680653|DIETARY_SUPPLEMENT|Carbohydrates|16 grams of carbohydrate
214959960|NCT00417638|DEVICE|Endovascular cooling by the Celsius Control System|
214959961|NCT00417638|OTHER|Standard of care|
214352585|NCT07127848|PROCEDURE|Septoplasty with Mucotomy|Subtotal reconstruction of the nasal septum accompanied by radiofrequent nasal mucosal reduction of the inferior turbinates.
214959962|NCT00000213|DRUG|Fluoxetine|
214959963|NCT02477878|BIOLOGICAL|BPX-501|Biological: T cells transduced with CaspaCIDe suicide gene
214959964|NCT02477878|DRUG|Rimiducid|Rimiducid administered to treat GVHD
214352586|NCT07127848|PROCEDURE|Septoplasty with Turbinectomy|Subtotal reconstruction of the nasal septum accompanied by surgical resection of the inferior turbinates.
214352587|NCT07127848|PROCEDURE|Septoplasty with Valvuloplasty|Subtotal reconstruction of the nasal septum accompanied by surgical intervention by placing a flare sutture in the internal nasal valve area.
214959965|NCT04003051|OTHER|Internet-Based Intervention|Use Project Prepare website
214959966|NCT04003051|OTHER|Quality-of-Life Assessment|Ancillary studies
214959967|NCT04003051|OTHER|Questionnaire Administration|Ancillary studies
214959968|NCT05311020|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
214959969|NCT05311020|DIETARY_SUPPLEMENT|Pitaya Ovule Extract Drink|consume 1 bottle per day
214959970|NCT01899820|DRUG|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
214959971|NCT01899820|DRUG|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
214959972|NCT02580253|DRUG|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
214959973|NCT02580253|DRUG|mFOLFOX6|Oxaliplatin,Fluorouracil
214352588|NCT07126756|DEVICE|STAR S4 IR Excimer Laser System|LASIK with iDesign
214959974|NCT02646319|OTHER|Laboratory Biomarker Analysis|Correlative studies
214959975|NCT02646319|DRUG|Nanoparticle Albumin-Bound Rapamycin|Given IV
214959976|NCT02646319|OTHER|Quality-of-Life Assessment|Ancillary studies
214959977|NCT02488018|BIOLOGICAL|Provision of experimental honey|"Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.~25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight."
214959978|NCT03060057|DEVICE|U2 Knee™ System|The United U2 Knee™ System consists of several components and for this clinical evaluation it includes the (1) Femoral Component, (2) Tibial Insert, 3) Tibial Baseplate, and the 4) Patella.
214959979|NCT01386931|PROCEDURE|EUS-guided FNA performed with on-site Cytopathologist|Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
214352589|NCT07126756|DEVICE|VisuMax 400 Surgical Laser|small incision lenticule extraction technique
214352590|NCT07126249|DRUG|pimicotinib capsules|pimicotinib capsules
214959980|NCT01386931|PROCEDURE|EUS-guided FNA performed without on-site Cytopathologist|In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
214959981|NCT02537665|OTHER|heating precondition|
214352591|NCT06531356|BIOLOGICAL|autologous amniotic fluid|10 cc of amniotic fluid aspirated after opening uterine incision in cesarean section, then Injected in edges of skin before closure
214352592|NCT06531356|OTHER|No amniotic fluid injected in skin edges|conventional closure of skin
214959982|NCT01850394|DRUG|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
214959983|NCT01850394|DRUG|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
214959984|NCT01151969|BEHAVIORAL|"New multicomponent 7H intervention"|The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
215079227|NCT02003066|PROCEDURE|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
215079228|NCT00594542|DRUG|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
214352593|NCT06167031|OTHER|chatbot facilitated teaching|"The experimental group will use chatbot to facilitate teaching."
214352594|NCT06167031|OTHER|lecture-based teaching|The control group only receives lecture-based teaching.
214352595|NCT06953674|DRUG|Normal Saline (0.9% NaCl)|For the primary purpose of fluid therapy or resuscitation in the emergency room and during hospitalization. The interventions will be administered intravenously whenever isotonic intravenous fluid administration is ordered by the treating provider for fluid resuscitation and/or maintenance in the emergency room and during inpatient hospitalization. Assignment to the intervention arm will be adhered to from enrollment to discharge. The total volume, rate, initiation, cessation, and co-interventions will be left to the discretion of the treating provider. Adherence will be ensured by dual interventions at the level of pharmacy IV fluid supply and physician order. The fluids will be physically administered according to the standard intravenous procedures and those outlined in the manufacturer's instructions.
214486919|NCT06741033|COMBINATION_PRODUCT|Toe-in gait modification|A specific alteration in walking pattern where the toes are directed inward during walking. This modification should be clearly defined, including the degree of inward rotation of the foot and how it is taught and monitored in participants. Toe-in gait modification basically includes decrease foot progression angle from baseline through internal foot rotation. Participants are instructed to increase the Toe-in angle of their study limb by 5 degree and walk at least 5-10 minutes (progressed to 15-20 min after 4 week) with this progression angle.
214486920|NCT06738680|DIAGNOSTIC_TEST|LAFOV system (an innovative, latest-generation system) scan|To collect data from the LAFOV system (an innovative, latest-generation system) during the PET scan planned as part of your treatment.
214678860|NCT02886026|DEVICE|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
214959985|NCT02440048|DEVICE|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
214959986|NCT02440048|DEVICE|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
214959987|NCT00233584|PROCEDURE|Pulmicort (budesonide) pMDI|
214959988|NCT02587767|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
214959989|NCT02587767|DEVICE|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
214959990|NCT03571607|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
214959991|NCT04000126|DEVICE|Pupil reflex dilation measurement (PRD)|Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
214959992|NCT04000126|DEVICE|PPI (Pupillary Pain Index)|Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
214959993|NCT04000126|DRUG|lidocaine|1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
214959994|NCT04000126|DRUG|Placebo|100ml 0,9% NaCl iv 10min before intubation
214959995|NCT04000126|DEVICE|Bispectral Index (BIS)|Bispectral Index will be monitored to assess the depth of anaesthesia
214959996|NCT04000126|DEVICE|HR|HR in beats/min will be measured by the electrocardiogram monitor
214959997|NCT04000126|DEVICE|BP|BP will be measured automatically by an occluding upper arm cuff
214959998|NCT00640419|DRUG|ABT-089|Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
214959999|NCT00640419|DRUG|placebo|Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
214960000|NCT04220801|DRUG|ZM-H1505R|Single oral doses of 300, 450, 600, 750, and 900 mg of ZM-H1505R or placebo and multiple oral doses of 450, 600, and 750 mg of ZM-H1505R or placebo will be administered in a fasted state, or in the case of Cohort 3 (Part 1), a second dose of 600 mg will be administered in the fed state. During each SAD and MAD dosing period, 2 subjects in each cohort will receive placebo instead of ZM-H1505R. The dose levels may be adjusted based on the safety and tolerability obtained from the previous cohort.
214960001|NCT00074815|DRUG|Serotonin reuptake inhibitors management|"Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI."
214960002|NCT00074815|BEHAVIORAL|Cognitive behavioral therapy by a psychologist|CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.
215079229|NCT00845260|BEHAVIORAL|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
215079230|NCT00845260|BEHAVIORAL|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
214352596|NCT06953674|DRUG|balanced crystalloid|For the primary purpose of fluid therapy or resuscitation in the emergency room and during hospitalization. The interventions will be administered intravenously whenever isotonic intravenous fluid administration is ordered by the treating provider for fluid resuscitation and/or maintenance in the emergency room and during inpatient hospitalization. Assignment to the intervention arm will be adhered to from enrollment to discharge. The total volume, rate, initiation, cessation, and co-interventions will be left to the discretion of the treating provider. Adherence will be ensured by dual interventions at the level of pharmacy IV fluid supply and physician order. The fluids will be physically administered according to the standard intravenous procedures and those outlined in the manufacturer's instructions.
214352597|NCT06947980|DRUG|Placebo Comparator|Placebo subcutaneous injection
214352598|NCT06947980|BIOLOGICAL|CM512|CM512 subcutaneous injection
214352599|NCT06952049|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be randomized to listen to a three-minute recording about different pain management strategies (e.g., ice, rest) to promote overall well-being.
214352600|NCT06952049|BEHAVIORAL|Mindfulness without Psychoeducation|In the mindfulness without psychoeducation intervention, participants will be randomized to listen to a three-minute mindfulness practice consisting of 1 minute of mindful breathing, 1 minute of mindful mapping, and 1 minute of mindfulness of personal meaning.
214352601|NCT06952049|BEHAVIORAL|1 Minute Psychoeducation with 2 Minutes of Mindfulness (Pain Focus)|In the 1 Minute Psychoeducation with 2 minutes of Mindfulness (Pain Focus) intervention, participants will be randomized to listen to a 1 minute of psychoeducation about mindfulness, 1 minute of mindful breathing and 1 minute of mindful mapping.
214960003|NCT00074815|BEHAVIORAL|Instructional cognitive behavioral therapy by a psychiatrist|"The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor best practice treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy."
214960004|NCT05433545|OTHER|Questionnaire|Adolescents with spinal deformity will be asked to fill out a new questionnaire measuring the quality and quantity of adherence to specific physiotherapy exercises performed at home. Patients will be recruited at an outpatient service dedicated to the treatment of vertebral deformities during the monthly sessions with the physiotherapist
214960005|NCT04715191|GENETIC|CARE T cells|"Four different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL0: 1x10\^7/m\^2 DL1: 3x10\^7/m\^2 DL2: 1x10\^8/m\^2 DL3: 3x10\^8/m\^2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
214960006|NCT04715191|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
214960007|NCT04715191|DRUG|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
214960008|NCT05840016|DRUG|AK112, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
214960009|NCT05840016|DRUG|Tislelizumab, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
214960010|NCT06342115|DRUG|Ceftolozane-Tazobactam|In the intervention arm 3g of ceftolozane-tazobactam are given intravenously every 8 hours. Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
214960011|NCT06342115|DRUG|Meropenem|The comparator arm consists of 2g of meropenem given intravenously every 8 hours.Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
214960012|NCT00954525|DRUG|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
214960013|NCT00954525|DIETARY_SUPPLEMENT|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
214960014|NCT05830539|DRUG|IN10018+PLD|IN10018 orally once daily; PLD 40mg/m2, Q4W
214960015|NCT05830539|DRUG|IN10018+PLD+Toripalimab|IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W
214960016|NCT05762809|DIAGNOSTIC_TEST|Tampa Scale of Kinesiophobia (TSK-17)|The Tampa Scale of Kinesiophobia (TSK-17) was developed as a self-reported checklist to measure fear of pain during movement and fear of reinjury. The TSK-17 consists of 17 questions. Standardized answer options are given as a 4-point Likert scale, and each question is assigned a score from 1 to 4. A normalized score between 17 and 68 points is calculated. A score of 37 or over indicates kinesiophobia.
214352602|NCT06952049|BEHAVIORAL|1 Minute Psychoeducation with 2 Minutes of Mindfulness (Meaning Focus)|In the 1 Minute Psychoeducation with 2 minutes of Mindfulness (Meaning Focus) intervention, participants will be randomized to listen to a 1 minute of psychoeducation about mindfulness, 1 minute of mindful breathing and 1 minute of mindfulness of personal meaning.
214960017|NCT05762809|DIAGNOSTIC_TEST|Knee injury and Osteoarthritis Outcome Score (KOOS)|The KOOS consists of five subscales - Symptoms (S), Pain (P), Functional activities of daily living (ADL), Sport and Recreation Function (Sport/Rec) and Knee-Related Quality of life (QOL) - and total KOOS Outcome (O) scores. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
214960018|NCT05762809|DIAGNOSTIC_TEST|Oxford Knee Score (OKS) scoring|OKS consists of 12 questions. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A score of 40-48 indicates no symptoms or satisfactory joint function, 30-39 moderate knee arthritis, 20-29 moderate to severe knee arthritis, and 0-19 severe knee arthritis.
215079231|NCT00853125|BIOLOGICAL|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
215079232|NCT00853125|DRUG|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
215079233|NCT01545882|DRUG|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
215079234|NCT00711490|DRUG|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
214352603|NCT06952049|BEHAVIORAL|2 Minutes of Psychoeducation with 1 Minute of Mindfulness|In the 2 Minutes of Psychoeducation with 1 Minute of Mindfulness intervention, participants will be randomized to listen to a 2 minute of psychoeducation about mindfulness and 1 minute of mindful breathing.
214960019|NCT05762809|DIAGNOSTIC_TEST|Quadriceps and hamstring muscle isokinetic strength|Quadriceps and hamstring muscle strength at 60˚/s and 180˚/s were measured with an isokinetic dynamometer. For 180˚/s, five trial and fifteen testing repetitions were used, and for 60˚/s, three trial and three testing repetitions were used. The resting time between trial and testing was two minutes, between different speeds one minute, and between legs two minutes. The maximum peak torques were used in the statistical analysis.
215079235|NCT02599649|DRUG|Lirilumab|3 mg/kg by vein every 4 weeks.
215079236|NCT02599649|DRUG|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
215079237|NCT02599649|DRUG|Azacitidine|75 mg/m\^2 by vein for 7 days of a 28 day cycle.
215079238|NCT03746600|BEHAVIORAL|Project TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
214352604|NCT06954818|BIOLOGICAL|A zoster mRNA vaccine SYS6017|SYS6017 is an investigational lipid nanoparticle (LNP)-coated mRNA vaccine encoding the glycoprotein E (gE) of VZV, and indicated for active immunization for the prevention of zoster caused by the reactivation of latent VZV.
215079239|NCT00252226|DRUG|Quetiapine|
215079240|NCT03023826|DRUG|LY3202626 (R-Fasting)|Administered orally
215079241|NCT03023826|DRUG|LY3202626 (T1-Fasting)|Administered orally
215079242|NCT03023826|DRUG|LY3202626 (T1-Fed)|Administered orally
215079243|NCT01333670|DEVICE|Prontosan wound irrigation solution|"* cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~* dressing with Prontosan Wound Irrigation solution"
215079244|NCT01333670|DRUG|Isotonic solution (saline or lactated ringer)|"* cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~* dressing with isotonic solution"
215079245|NCT06372522|DRUG|Pitocin Injectable Product|The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).
214352605|NCT06954818|OTHER|Placebo|saline solution
214352606|NCT07126353|OTHER|prospective observational study (clinical, hormonal and auxological data)|We collect clinical, hormonal and auxological data and compare them between the two groups.
214352607|NCT06100874|DRUG|Sacituzumab Govitecan|Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.
214352608|NCT06100874|DRUG|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.
215079246|NCT01693874|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction
215079247|NCT01693874|BEHAVIORAL|control (health education)|health education
215079248|NCT05615987|DRUG|Onabotulinumtoxina for Injection|200iu/2ml in both groups
214352609|NCT06100874|DRUG|Trastuzumab and Hyaluronidase-oysk|Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.
215079249|NCT00150358|DRUG|Sildenafil Citrate|
215079250|NCT00977938|DRUG|Placebo & Aspirin|
215079251|NCT00977938|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|
215079252|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
215079253|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
215079254|NCT02109874|BIOLOGICAL|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
215079255|NCT02109874|BIOLOGICAL|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
215079256|NCT04161963|DEVICE|SD-OCT|Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
214352610|NCT07126509|PROCEDURE|Partial Pleurectomy|A partial pleurectomy is a surgical procedure where part of the pleura, the lining of the lung cavity, is removed. This may be done to remove tumors, excess tissue, or to treat lung complications.
214352611|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo HF-WBI
215079257|NCT04161963|DEVICE|OCT-A|swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
215079258|NCT02937298|DIETARY_SUPPLEMENT|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
215079259|NCT02937298|DIETARY_SUPPLEMENT|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
215079260|NCT02937298|DIETARY_SUPPLEMENT|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
214352612|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo CF-WBI
214352613|NCT01266642|RADIATION|Hypofractionated Radiation Therapy|Undergo HF-WBI
214352614|NCT01266642|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214352615|NCT01266642|OTHER|Quality-of-Life Assessment|Ancillary studies
215079261|NCT02937298|DIETARY_SUPPLEMENT|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
215079262|NCT05008575|BIOLOGICAL|anti-CD33 CAR NK cells|6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion
215079263|NCT05008575|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
215079264|NCT05008575|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
214352616|NCT01266642|OTHER|Questionnaire Administration|Ancillary studies
214352617|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo HF-WBI
214352618|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo CF-WBI
214352619|NCT03854461|BEHAVIORAL|Personalised dietary advice and educational material|As within arm/group description
214960020|NCT05762809|DIAGNOSTIC_TEST|Single-leg hop test|The single-leg hop test (SLHT) for distance was used for lower limb functional testing. The test started with the participant standing on one leg, toes behind a marked line, and hands on hips throughout to avoid aiding the jump by swinging the arms. The participant was instructed to jump as far as possible and land on the same leg without losing balance. If the patient made contact with the ground with the contralateral limb, lost balance, or made additional hops after landing, the distance was not measured and the jump void. The distance was measured from the starting line to the heel of the leg being tested. For both legs, three trials and three jumps for maximal effort were allowed. The longest distance for both the left leg and the right leg were used in the statistical analysis.
214352620|NCT03854461|BEHAVIORAL|Educational material|As within arm/group description
214486921|NCT06736782|BEHAVIORAL|Self-Empowerment Care Intervention Group|"The intervention emphasizes four key principles: hydration, exercise, dietary support, and defecation care. Each component is designed to address fundamental needs and promote independence in activities of daily living (ADLs).~Individualized care plans will be developed in collaboration with healthcare professionals and caregivers to ensure alignment with participants' functional capabilities and personal goals."
214960021|NCT05762809|DIAGNOSTIC_TEST|Y-balance test|The Y-balance test (YBT) (Move2Perform, United States) for anterior reach was used to measure dynamic balance. Participants performed three trials to familiarize themselves with the test, and then undertook three tests. The test started with the participant standing barefoot on the testing kit. The patients had to push a wooden box with the contralateral leg as far as possible with continuous movement and return to their starting position without losing balance. The longest distance achieved was used in the statistical analysis.
214960022|NCT05762809|DIAGNOSTIC_TEST|Anthropometric measurements|Body mass (kg) and height (cm) were measured, and the body mass index (BMI) was calculated as kg/m2.
214352621|NCT00924287|DRUG|in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
214352622|NCT00924287|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
214352623|NCT00924287|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
214352624|NCT00924287|DRUG|Mesna|3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
214352625|NCT05884346|OTHER|Ultrahigh-frequency ultrasound|Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease
214352626|NCT00275795|PROCEDURE|NAET Procedures|
214352627|NCT03034642|PROCEDURE|Bronchoscopy with bilateral bronchoalveolar lavages|Bronchoscopy with bilateral bronchoalveolar lavages
214352628|NCT02062268|BEHAVIORAL|health education & law enforcement|
214352629|NCT01785303|BEHAVIORAL|CBT-I|Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
214486922|NCT06736782|BEHAVIORAL|Control Group|"Standard caregiving practices without emphasis on structured hydration, exercise, or dietary programs.~General assistance with ADLs as per existing care routines in the respective facilities."
214486923|NCT06740331|BEHAVIORAL|Analysis of social cognition, memory functioning, and executive functioning processes|Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
214486924|NCT06549933|OTHER|Criostymulation|"Method: Cryosauna. Temperature: -160°C. Duration: 5 days. Session Timing: 9:00 a.m.~Session Length: 3 minutes per day"
214486925|NCT06737185|OTHER|EAFS4T: modification with evolutionary algorithm of tonotopic-based fitting|Comparison of FS4T and EAFS4T
214486926|NCT06737133|PROCEDURE|Surgery|Rhinoplasty
214486927|NCT06162052|OTHER|Tele-Rehabilitation|Technology will be used to enhance rehabilitation.
214960023|NCT05784402|DRUG|Semaglutide J|Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.
214960024|NCT05784402|DRUG|Semaglutide C|Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.
214960025|NCT05573256|BEHAVIORAL|Lavender oil inhalation|Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.
214960026|NCT05573256|BEHAVIORAL|Sleep hygiene education|Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.
214960027|NCT03161522|DRUG|Capecitabine|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
214960028|NCT03161522|DRUG|Chemotherapy|Receive induction chemotherapy
214960029|NCT03161522|PROCEDURE|Conventional Surgery|Undergo surgery
215079265|NCT03373890|BEHAVIORAL|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
214352630|NCT01785303|PROCEDURE|CPAP|CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
214352631|NCT03457753|DRUG|Riluzole Oral Soluble Film|Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
214352632|NCT00783926|BIOLOGICAL|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
214960030|NCT03161522|DRUG|Fluorouracil|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
214960031|NCT03161522|RADIATION|Radiation Therapy|Undergo RT
214960032|NCT02760524|BEHAVIORAL|NET Intervention|Neuro-emotional Technique
214352633|NCT00735995|BEHAVIORAL|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
214352634|NCT00735995|BEHAVIORAL|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
214960033|NCT06346418|GENETIC|WES analysis|"Whole-exome sequencing will be performed as the first approach in all the recruited patients. First, we will analyze different subsets of genes, belonging to:~1. Maternal effect genes as SCMC components and other related genes;~2. Genes essential in the maturation of the oocyte and zygote progression through the early phases of the embryogenesis or highly expressed at different stages of oocyte maturation;~3. Genes with known and potential roles in the establishment and control of genomic imprinting and involved in DNA methylation reactions.~Subsequently, variants with a high pathogenicity score will be analyzed, to identify any genes that may be associated with the phenomenon, but do not belong to the previously described categories of genes. Finally, we will conduct a whole genome sequencing (WGS) analysis on a selected subgroup of BWS mothers with peculiar clinical histories and negative WES analysis, to explore all the noncoding and regulatory regions not targeted by WES."
214960034|NCT06346418|GENETIC|whole-genome methylation analysis|A whole-genome methylation analysis will be performed to identify methylation changes in women with reproductive problems including those with offspring affected by BWS
214960035|NCT05153083|PROCEDURE|Open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Each participating center will be able to use its preferred European Conformity marked device, for cryoablation according to their normal clinical practice and according to the instructions for use.
214960036|NCT06382142|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214960037|NCT06382142|DRUG|Eribulin|Administration by intravenous bolus for a cycle of 3 weeks.
214960038|NCT06382142|DRUG|Vinorelbine|Administration by intravenous infusion for a cycle of 3 weeks.
214960039|NCT06382142|DRUG|Gemcitabine|Administration by intravenous infusion for a cycle of 3 weeks.
214960040|NCT06382142|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
214960041|NCT06126640|DRUG|SHR-A1811|Lyophilized powder injection, 100mg / bottle, intravenous drip
214960042|NCT06126640|DRUG|Trastuzumab Emtansine|Lyophilized powder injection, 160mg / bottle, 100mg / bottle, intravenous drip
214960043|NCT05964283|OTHER|Questionnaire|This questionnaire consists of (five) main parts. The first part is about personal information, the second part is about fluid administration in various settings (emergency room, operating room, and intensive care unit), the third part is about fluid administration behaviors, the fourth part is about workplace location, and the fifth part is about a case study. Filling out this questionnaire will take approximately 60 minutes of your time.
214960044|NCT04831060|PROCEDURE|Periodontal or peri-implantitis treatment|"For Cases :~* Inclusion; Bacterial sampling, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~* Non-surgical periodontal or peri-implantal treatment~* At 3 months = periodontal or peri-implantal reevaluation; Bacterial sampling, gingival fluid and unstimulated saliva collection~* If periodontal or peri-implantal pockets greater than 5mm and bleeding persist: surgery and gingival explant sampling~* At 3 months post-surgery = periodontal or peri-implantal re-evaluation; Bacterial sampling, gingival fluid and unstimulated saliva collection~* Maintenance"
214960045|NCT04831060|PROCEDURE|Control treatment|"For Controls:~* Inclusion; Bacterial sampling, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~* Plastic or pre-prosthetic surgery = gingival explant sampling~* Healing control at 15 days"
214960046|NCT01713062|DEVICE|Vitelene|THA
214960047|NCT01713062|DEVICE|XLPE|THA
214960048|NCT04513145|DRUG|Ropivacaine injection|Ropivacaine is a local anesthetic that is FDA approved for local anesthetic nerve block.
214960049|NCT04513145|DRUG|Saline Injection|Saline will be used as a placebo injection
214352635|NCT02621931|DRUG|Fremanezumab|Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
214960050|NCT04513145|PROCEDURE|Total Knee Arthroplasty|All subjects participating in this study will undergo primary total knee arthroplasty
214960051|NCT06778525|OTHER|Exercise|Personalized neuromuscular exercises, according to the patient's specific needs.
214960052|NCT06778525|OTHER|SmartPose|Virtual reality application containing rehabilitative games developed for individuals in need of exercise.
214960053|NCT04789681|DRUG|Canakinumab|Given SC
214960054|NCT04789681|OTHER|Quality-of-Life Assessment|Ancillary studies
215079266|NCT02142283|DEVICE|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
215079267|NCT02142283|OTHER|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
215079268|NCT04490980|DRUG|butorphanol|Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
215079269|NCT00509860|DRUG|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
215079270|NCT01760330|DRUG|IV acetaminophen|
215079271|NCT01760330|DRUG|Placebo|
215079272|NCT01384448|PROCEDURE|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
215079273|NCT01384448|PROCEDURE|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
215079274|NCT01887821|DRUG|Chloroquine|
214960055|NCT02234934|BIOLOGICAL|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10\^6 cells per kg of body weight transduced ex vivo with 1 x 10\^8 IG/mL of lentiviral vector to achieve \> 0.3 integrated copies per cell."
214960056|NCT06347900|DIAGNOSTIC_TEST|Pentacam (corneal topographic changes detection), Polysymnography|Pentacam for recording corneal parameters in different stages of OSA patients. Polysymnography for for detction of hyponea, oxygen saturation and desaturation and staging of OSA in different patients.
214352636|NCT02621931|DRUG|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
214352637|NCT00872352|PROCEDURE|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
214352638|NCT01912612|DRUG|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
214960057|NCT01878617|RADIATION|Craniospinal Irradiation with boost to the primary tumor site|All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
214352639|NCT04390737|DRUG|HH2853 Tablets|Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
214352640|NCT01588184|DRUG|Bevacizumab|Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
214960058|NCT01878617|DRUG|Cyclophosphamide|Route of Administration (ROA): Intravenously (IV)
214960059|NCT01878617|DRUG|Cisplatin|ROA: IV
214960060|NCT01878617|DRUG|Vincristine|ROA: IV
214960061|NCT01878617|DRUG|Vismodegib|ROA: Orally (PO)
214960062|NCT01878617|DRUG|Pemetrexed|ROA: IV
214960063|NCT01878617|DRUG|Gemcitabine|ROA: IV
214960064|NCT01878617|OTHER|Aerobic Training|
214960065|NCT01878617|OTHER|Neurocognitive Remediation|
214960066|NCT04252547|OTHER|Kangaroo Care|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.
214960067|NCT04252547|OTHER|Control|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before feeding when they are included in the study and then they will be breastfed by their mothers. The chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. Also, the infant's heart rate and oxygen saturation will continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weighed without a diaper change and his/her weight will be recorded. When the care process is over, it will be taken back in the incubator to sleep.
214960068|NCT05130216|OTHER|Genicular Nerve Radiofrequency Ablation|Radiofrequency Ablation (RFA)
214960069|NCT04865419|DRUG|AZD0466|AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
214960070|NCT04865419|DRUG|Voriconazole|Voriconazole film-coated tablet will be administered orally.
214960071|NCT05192395|DRUG|DWJ1525|DWJ1525
214960072|NCT05192395|DRUG|DWP16001|DWP16001
214960073|NCT05192395|DRUG|DWC202101|DWC202101
214960074|NCT00261898|PROCEDURE|Increase sleep|
214960075|NCT02617134|BIOLOGICAL|anti-MUC1 CAR-T cells|
214352641|NCT06088940|DIETARY_SUPPLEMENT|Multistrain Probiotic|The probiotic capsule contains Lactobacillus and Bifidobacterium strains, ingested orally once daily.
214960076|NCT04792060|PROCEDURE|Hook plate|We used titanium 2.4 mm hooked distal ulnar locked plate used for fixation of distal ulna fractures , this plate have low profile which is anatomically precontoured
214960077|NCT02382809|DRUG|DC071|Mouthwash, twice daily
214960078|NCT02382809|DRUG|Placebo|Mouthwash, twice daily
215079275|NCT01887821|DRUG|Dihydroartemisinin/Piperaquine|
215079276|NCT05783076|DRUG|Stereotactic body radiation therapy|Details have been shown in arm descriptions.
215079277|NCT05783076|DRUG|adoptive cell therapy with vNKT cells|Details have been shown in arm descriptions.
215079278|NCT02839226|DRUG|AR/101|
215079279|NCT02839226|DRUG|Placebo|
214352642|NCT06088940|OTHER|Placebo|Placebo is composed of maltodextrin, that is an identically formulated and packaged inactive substance
214352643|NCT02640768|OTHER|educational training|implementation of a structured educational program for physicians and nurses
214352644|NCT00881387|BIOLOGICAL|rituximab|Given IV
214352645|NCT00881387|DRUG|gemcitabine hydrochloride|Given IV
214352646|NCT00881387|DRUG|vinorelbine ditartrate|Given IV
214352647|NCT04380402|DRUG|Atorvastatin|Atorvastatin 40 mg tablet
214352648|NCT03939052|DIETARY_SUPPLEMENT|Free amino acids intake|Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
214352649|NCT04139070|DRUG|Bleomycin|Electroporation in combination with systemically administered bleomycin
214352650|NCT05552651|DRUG|Envafolimab|300mg,sc,d1,Q3W;
214352651|NCT05552651|DRUG|Albumin-Bound Paclitaxel|130mg/m2,iv,D1,D8,Q3W
214960079|NCT05163938|DEVICE|REThink Therapeutic Game|"Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)"
214960080|NCT05163938|DEVICE|Treatment as Usual|Treatment As Usual: In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
214960081|NCT05285059|BEHAVIORAL|ASRT task|"The ASRT (Alternating Serial Reaction Time) task is a computerized behavioral task measuring implicit learning. This task consists of 20 series of trials lasting 2 minutes each.~In each trial, a stimulus is displayed on the screen in one of the four possible predefined locations. The participant must press a button to indicate the position of the stimulus on the screen. Response content and response time are recorded.~At the end of every trial, the participant can take a break and resume the task whenever ready. The task lasts about 45 to 50 minutes."
214352652|NCT05552651|DRUG|Carboplatin|AUC=5, iv,D1,Q3W
214352653|NCT04953390|DEVICE|Phonak Audeo hearing aid|Commercially available hearing aid with three different microphone settings: DIR1, DIR2, and DIR3
214352654|NCT04953390|DEVICE|Phonak hearing aid with multiple directionality settings, adjustable via a mobile app|Commercially available hearing aid with multiple directionality settings which will be adjustable by user via a mobile app during a home trial period.
214352655|NCT02921529|OTHER|TEAS|Electric stimulation was given through electrode attached to specific acupoints
214352656|NCT02921529|OTHER|false stimulation|Electrodes were attached to specific acupoints without electric current
214352657|NCT05890443|BEHAVIORAL|Exercise|Before starting the research, self-management training in rehabilitation was given to both groups. While the exercise practices were carried out in the experimental group, encouraging reminders were made by following the background web page created in the experimental group.
214486928|NCT06739733|DIAGNOSTIC_TEST|SRG|Soft robotic gloves stimulation 30-minute sessions, 5 times per week upto 8 week Soft robotic gloves are assistive devices designed to enhance hand function for individuals with disabilities or injuries. These gloves use flexible materials, such as silicone or fabric, combined with pneumatic or cable-driven mechanisms to mimic natural hand movements. They provide assistance for gripping, holding, or manipulating objects, often controlled by sensors or user inputs. Soft robotic gloves are lightweight, adaptable, and offer rehabilitation potential, helping restore motor function in conditions like stroke or spinal cord injury. They are increasingly used in clinical and home-based therapy settings.
214486929|NCT06739733|DIAGNOSTIC_TEST|EMS|"Electrical muscle stimulation 30-minute sessions, 5 times per week upto 8 weeks.~Electrical Muscle Stimulation (EMS) is a technique that uses electrical impulses to contract muscles, often used for rehabilitation, strength training, or pain management. Electrodes placed on the skin deliver controlled currents to target specific muscle groups, mimicking natural nerve signals. EMS is commonly used in physiotherapy to prevent muscle atrophy, improve circulation, and enhance recovery after injury. It is also utilized in fitness and sports for performance enhancement. Safe and non-invasive, EMS can be adjusted for therapeutic or functional goals."
214486930|NCT06303544|BEHAVIORAL|Wedge 1|Wedge1 will receive intervention consisting of culturally based physical activity module, built environment, community healthy lifestyle promotion
214960082|NCT01491867|DRUG|travoprost 0.003%|Instillation of travoprost 0.003% 1/die in both eyes for 3 months
214960083|NCT03517241|DIAGNOSTIC_TEST|functional magnetic resonance imaging (fMRI)|Retinotopic mapping using functional magnetic resonance imaging (fMRI) is based on MR images acquired with blood-oxygenation-level-dependent (BOLD) contrast to reveal areas of neuronal activity in the visual cortex
214960084|NCT03517241|DIAGNOSTIC_TEST|Microperimetry (MP)|MP allows localized testing of retinal sensitivity of foveal, parafoveal and even more peripheral macular regions
214960085|NCT03517241|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
214352658|NCT02478294|PROCEDURE|Thoracoscopic LAA Excision plus AF Ablation|In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
214352659|NCT02478294|DRUG|Warfarin or Novel Oral Anticoagulants|In this group, patients receive warfarin or novel oral anticoagulants
214960086|NCT03517241|DIAGNOSTIC_TEST|Blue light fundus autofluorescence imaging (FAF)|Fundus autofluorescence imaging (FAF), is a non-invasive diagnostic technique focusing on the fluorescent properties of pigments in the retina to generate images.
215079280|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
215079281|NCT02052726|BIOLOGICAL|Placebo|Placebo administered at Month 0, 1, and 3.
215079282|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
214352660|NCT05912400|DIAGNOSTIC_TEST|Blood draw|• An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.
214352661|NCT05912400|OTHER|FACIT-F and Pain Scales|• Questionnaires regarding pain and fatigue will be provided for the subject to review and answer.
214352662|NCT04997005|DEVICE|AMIStem-P|Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant
214960087|NCT03517241|DIAGNOSTIC_TEST|Visual testing|Best-corrected visual acuity will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Reading acuity and reading speed will be examined using Radner Reading Charts. Reading acuity is measured in logRAD unit (= reading equivalent of logMAR) and in critical font size (critical reading size), reading speed is measured in words per minute (wpm). Contrast sensitivity will be determined using Pelli-Robson contrast sensitivity charts.
214960088|NCT05036798|DRUG|Tislelizumab|"Chemotherapy regimen:~Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2 Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD"
214960089|NCT02902042|DRUG|Encorafenib|Dose determined in phase I. Start dose: 450 mg qd
214960090|NCT02902042|DRUG|Binimetinib|Dose determined in phase I. Start dose: 45 mg bid
214960091|NCT02902042|DRUG|Pembrolizumab|Dose determined in phase I. Start dose: 200 mg q3w
214960092|NCT02902042|DRUG|Pembrolizumab alone|200 mg q3w
214960093|NCT05687721|DRUG|copanlisib|intravenous infusion (IV) at 60 mg on Day 1, 8 and 15 of each 4-week treatment cycle for up to 26 cycles
215079283|NCT02052726|BIOLOGICAL|placebo|Placebo administered at Day 1, 8, and 30.
215079284|NCT01128348|BEHAVIORAL|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
215079285|NCT04281225|BEHAVIORAL|Attention to Variability (ATV)|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and behavior that occur throughout the day, and to notice changes they experience with their hearing loss symptoms; noticing if it is better or worse and to ask why it may be.
215079286|NCT04281225|OTHER|Placebo|Participants are told that the device they will be testing will improve their hearing, when in fact the device is not a hearing aid but just a metallic earring.
215079287|NCT00717522|DRUG|Pomalidomide|
215079288|NCT02943356|DRUG|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
215079289|NCT01894880|PROCEDURE|early SSC|bonding straight after birth
215079290|NCT01894880|PROCEDURE|late SSC|bonding after termination of operation
214960094|NCT05687721|DRUG|Avelumab|800 mg intravenous infusion on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
215079291|NCT00314717|BEHAVIORAL|Control diet|
215079292|NCT00314717|BEHAVIORAL|Low GI diet|
214352663|NCT01092338|DRUG|Cholecalciferol (Vit D3)|To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
214960095|NCT06525558|PROCEDURE|Intestinal resection|This study does not add additional risks for patients as the resected specimen is collected during the surgery in accordance with standard clinical practice.
214960096|NCT05395624|DRUG|18F-OP-801|18F Hydroxyl Dendrimer
214960097|NCT06183424|PROCEDURE|Transcranial Direct Stimulation|2 mA, 20 min, 5 days
214960098|NCT02083302|BEHAVIORAL|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
214960099|NCT02083302|BEHAVIORAL|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|"Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention."
214960100|NCT02083302|BEHAVIORAL|SCREAM Theater Dose 4|Booster Session
214960101|NCT06253247|COMBINATION_PRODUCT|NanoChitosan impregnated Calcium Hydroxide|NanoChitosan impregnated Calcium Hydroxide used as an intracanal medication fro 7 days
214960102|NCT01630083|DRUG|epirubicin|Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.
214960103|NCT01630083|DRUG|oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.
215079293|NCT03243214|DEVICE|TMS|Real or Sham TMS will be given to the PD-MCI patient
215079294|NCT03243214|DEVICE|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
215079295|NCT05235958|OTHER|non-linear periodized exercise (NLPE)|Aerobic training derived from professional sports, that is characterized by variable periodization of training frequency, volume and intensity according to individual factors, such as physical and mental readiness, training progress and performance level
215079296|NCT05235958|OTHER|Exercise counselling|Standard recommendations for exercise and physical activity, that are individualized according to a medical health and fitness profile
215079297|NCT04177420|DEVICE|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
215079298|NCT04177420|DEVICE|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
215079299|NCT04177420|DEVICE|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
215079300|NCT04177420|DEVICE|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
215079301|NCT03521713|DRUG|EPORON|"* Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS"
215079302|NCT03521713|DRUG|EPREX|"* Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS"
215079303|NCT00460759|DRUG|Moxifloxacin|
215079304|NCT00460759|DRUG|Rifapentine|
215079305|NCT01371253|OTHER|Nintendo wii balance training|
215079306|NCT01371253|OTHER|EVA-soles|
215079307|NCT06086860|OTHER|Mulligan mobilization with dry needling.|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
215079308|NCT06086860|OTHER|Mulligan mobilization without dry needling|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
215079309|NCT04804657|DIETARY_SUPPLEMENT|Sage extracts Cognivia|Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
214352664|NCT03984799|PROCEDURE|Bronchoscopy|Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
214352665|NCT01454206|BEHAVIORAL|iSBIRT|"Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use."
214960104|NCT01630083|DRUG|capecitabine|The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
214960105|NCT01630083|DRUG|zolbetuximab|Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
214960106|NCT05431491|DEVICE|Ultrafiltration|Ultrafiltration through much smaller intravenous cannula than what has previously been used.
214352666|NCT03114826|GENETIC|To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
214352667|NCT05100082|DRUG|Cabozantinib|Cabozantinib tablets
214352668|NCT06094634|BEHAVIORAL|The Brief Alcohol Intervention (BAI): Behavioral|The BAI draws from Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) and comprises 2 in-person face-to-face sessions and 2 booster telephone sessions by a trained counselor.
214352669|NCT02980159|OTHER|Triage liaison physician|A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
214352670|NCT05854511|DRUG|Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets|Daclatasvir 30 mg orally once daily plus Sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks.
214352671|NCT05688995|BIOLOGICAL|Naser Al-Husban|COVID-19 vaccines
214352672|NCT01443481|DRUG|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
214352673|NCT00176579|PROCEDURE|dual x-ray absorptiometry|Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density
214352674|NCT02288468|DEVICE|Vercise™ Deep Brain Stimulation System|"The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.~The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit."
214960107|NCT04650178|OTHER|Quality-of-Life Assessment|Ancillary studies
214960108|NCT04650178|OTHER|Questionnaire Administration|Complete questionnaire
214960109|NCT04208412|DRUG|KVD900|KVD900 tablet 600 mg
214960110|NCT04208412|OTHER|Placebo|KVD900-matched Placebo Tablet
214960111|NCT02733341|DRUG|Cangrelor|
214960112|NCT02733341|DRUG|Ticagrelor|
214960113|NCT05415462|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214960114|NCT05415462|BIOLOGICAL|Fluarix Tetra|Sterile suspension for injection
214960115|NCT00288444|DRUG|Lonafarnib|
214960116|NCT00288444|DRUG|Docetaxel|
214960117|NCT03621241|DIAGNOSTIC_TEST|Flow cytometry|Flow cytometry
214486931|NCT06735443|DRUG|Bupivacaine with Dexmetedomidine|children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with dexmedetomidine 0.5μg/kg. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
214960118|NCT04342013|OTHER|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
214960119|NCT03616392|DRUG|D308, CKD-501|"1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg"
214960120|NCT00647036|DIETARY_SUPPLEMENT|Isonitrogenous Vaminolact|Isonitrogenous Vaminolact
214960121|NCT00647036|DRUG|Dipeptiven (L-glutamine- Lalanine)|0.6g/kg/day
214960122|NCT02450422|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
214960123|NCT02450422|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
214960124|NCT01480817|DRUG|Sorafenib|Sorafenib 400mg po bid
214960125|NCT01480817|PROCEDURE|TACE for HCC with portal vein invasion|The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
214960126|NCT03838029|DRUG|Propranolol and etodolac|A perioperative combined drug regimen
214960127|NCT03838029|OTHER|Placebo|Placebo
214960128|NCT03749408|DRUG|bupivacaine plus mannitol|local anesthesia
214960129|NCT03749408|DRUG|bupivacaine alone|local anesthesia
214352675|NCT03102814|BEHAVIORAL|Current rehabilitation|The control group will receive the rehabilitation currently offered at each of the participating centers.
214352676|NCT03102814|BEHAVIORAL|The BRIDGE program|The experimental group will additionally receive the BRIDGE program, which comprises motivational interviewing, structured goal-setting, tailored follow-up, plans for self-management, and individualised written feedback that participants can use to monitor their progress and share with important care givers.
215079310|NCT04804657|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
215079311|NCT01213186|DRUG|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5\*10E6/kg for 48 weeks.
215079312|NCT01213186|DRUG|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5\*10E6/kg for 48 weeks.
215079313|NCT03369899|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
215079314|NCT01498627|BIOLOGICAL|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
215079315|NCT01498627|OTHER|Data collection|PGRx information system
214352677|NCT06393049|OTHER|Hyperglycaemic clamp|"Following an overnight fast, the investigators will perform simultaneous samples from the arterial line, the venous line, and microdialysis and consider these samples as baseline values.~If the patient's blood glucose level is at 8-10 mmol/L at baseline, the investigators will not proceed with the intervention and instead evaluate if the intervention can take place the following day.~After baseline values are measured, intravenous glucose 20% (200g/1,000 ml) is infused to raise the glucose levels in both plasma and extravascular glucose compartments with approximately 3 mmol/L."
214352678|NCT03248739|DEVICE|Clear Bactiseal 'large' catheter (EVD)|Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
214352679|NCT03248739|DEVICE|Orange Bactiseal 'small' catheter (EVD)|Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
214352680|NCT00293735|DRUG|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours"
214960130|NCT02394015|DRUG|Trabectedin and Pegylated Liposomal Doxorubicin|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
214960131|NCT05535400|BEHAVIORAL|Physical-Psychological Integrative Intervention|The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program. And the content of the intervention includes eight different sessions, including Session 1- Orientation and engagement, Session 2- Awareness and Acceptance; Session 3- Non-judgement; Session 4- Stay present and let go; Session 5- Our thoughts are not real \& Response without reacting; Session 6- Empowerment of self-management and discuss pain management; Session 7- Seek out pleasant things and social support and Session 8- Review the intervention and end the programme.
215079316|NCT02998905|DRUG|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
214352681|NCT00293735|DRUG|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
214352682|NCT05596591|DEVICE|Focused extracorporeal shockwave therapy|High energy level shockwaves (between 0.28-0.60 mJ/mm\^2) will be focused over the subchondral bone with the bone marrow lesion, previously localized on MRI.
215079317|NCT02998905|DRUG|Acetylsalicylic Acid|Acetylsalicylic acid 81 mg/day
215079318|NCT01410669|BEHAVIORAL|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
215079319|NCT02664051|DRUG|Nalcrom|"Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom"
215079320|NCT02664051|DRUG|placebo|100mg 4x2 daily mannitol
215079321|NCT03334279|OTHER|Cigarette smokers|frequent cigarette smoking for not less than 5 years
215079322|NCT03334279|OTHER|Simultaneous cigarette and cannabis smokers|frequent cigarette and cannabis smoking for not less than 5 years
215079323|NCT04304794|PROCEDURE|Administration of iodinated contrast media|Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
215079324|NCT04304794|DRUG|Prophylactic administration of antithyroid drugs before iodinated contrast media exposure|13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
215079325|NCT05938920|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
215079326|NCT05938920|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
215079327|NCT03473964|DRUG|H.P. Acthar gel|"H.P. Acthar gel:~Injection 40 mg twice weekly"
215079328|NCT02157792|DRUG|M6620|
215079329|NCT02157792|DRUG|Gemcitabine|
215079330|NCT02157792|DRUG|Cisplatin|
215079331|NCT02157792|DRUG|Etoposide|
215079332|NCT02157792|DRUG|Carboplatin|
214352683|NCT05451654|DRUG|Placebo|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
214352684|NCT05451654|DRUG|Experimental drug|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
214352685|NCT04376021|BEHAVIORAL|Babywearing|Increase mother-infant physical contact through babywearing
214352686|NCT03588533|DRUG|Trastuzumab|"* Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks"
214352687|NCT03588533|DRUG|Capecitabine|\- Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
214352688|NCT03588533|DRUG|Cisplatin|\- Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks
214352689|NCT03461003|OTHER|NICHE method|Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.
214960132|NCT05535400|DEVICE|Brief online didactic education|Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
214960133|NCT01343784|OTHER|Urinary voiding assessment after midurethral sling|Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
214960134|NCT03581370|DRUG|1 hour infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.
214960135|NCT03581370|DRUG|4 hours infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours
214352690|NCT03461003|OTHER|Usual care|Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.
214486932|NCT06735443|DRUG|Bupivacaine with Tramadol|children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with 1 mg/kg of tramadol. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
214960136|NCT02439788|DRUG|cyclophosphamide|500 mg/m2/day x 2 days; for patients \<12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
214960137|NCT02439788|DRUG|Fludarabine|30 mg/m2/day x 3 days; for patients \<12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
214960138|NCT02439788|GENETIC|GINAKIT Cells|"* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future."
214960139|NCT02786706|DEVICE|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
214960140|NCT01348100|DRUG|Iloperidone crystalline formulation|Iloperidone was formulated as 100 µm crystals for IM depot injection.
214960141|NCT01348100|DRUG|Iloperidone microparticle formulation|Iloperidone was formulated as microparticles for IM depot injection.
214960142|NCT01348100|DRUG|Oral iloperidone|Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.
214960143|NCT04292145|BEHAVIORAL|Relaxation Application|The use of an application for relaxation.
214960144|NCT04292145|BEHAVIORAL|Relaxation Only|The individual's personal method to relax.
215079333|NCT02157792|DRUG|Irinotecan|
214352691|NCT03461003|DRUG|Amlodipine|Calcium-channel blocker; antihypertensive
214352692|NCT03461003|DRUG|Lisinopril|Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive
214352693|NCT03461003|DRUG|Hydrochlorothiazide|Thiazide diuretic; antihypertensive
214352694|NCT03461003|DRUG|Losartan|Angiotensin II receptor blocker (ARB); antihypertensive
214352695|NCT03489304|DRUG|Zaleplon|non-benzodiazepine hypnotic agent
214352696|NCT01898819|DRUG|Dexmedetomidine|
214352697|NCT01898819|DRUG|saline|
214352698|NCT00228020|DRUG|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
214352699|NCT00228020|DRUG|MMF, cyclosporine, steroids|
214352700|NCT03583918|DEVICE|HighThroughput Micro Coring Device|Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
214352701|NCT05564013|DEVICE|Virtual reality|Up to 25 minutes of virtual reality exposure in supine position
214352702|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Human Milk|Comparing formula and human milk
214352703|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Formula|Comparing formula and human milk
214352704|NCT02635815|PROCEDURE|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
214352705|NCT00243724|DRUG|Esomeprazole|
214352706|NCT01107574|DRUG|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
214352707|NCT01107574|PROCEDURE|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
215079334|NCT05290454|OTHER|mNGS-guided treatment|mNGS detect the causative microorganisms using appropriate lower respiratory tract (LRT) specimen. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Clinicians apply the definitive treatment based on mNGS results, as well as results of conventional microbiology diagnostic techniques.
214352708|NCT01107574|OTHER|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
214352709|NCT02747134|BEHAVIORAL|Emotion Regulation and Mindfulness skills|
214352710|NCT02014857|PROCEDURE|Gingival Crevicular Fluid Sampling|
214352711|NCT05959850|DRUG|Ambroxol|Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).
215079335|NCT00545220|BEHAVIORAL|problem-solving training|
214352712|NCT05959850|DRUG|Placebo|Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
214352713|NCT04256733|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
215079336|NCT00545220|BEHAVIORAL|sham intervention|
215079337|NCT02272751|BEHAVIORAL|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
214352714|NCT04256733|BIOLOGICAL|Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer|Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
214352715|NCT05579860|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
214960145|NCT04886245|OTHER|Video sequences|"videos will be made of each participant, during the realization of 5 movements that are the simple closure of the eyelids, the forced closure of the eyelids, the labial protrusion on the sound \[o\], the labial protrusion on the sound \[pu\] and the wide smile uncovering the teeth.~Then, a video sequence will be realized thanks to the dedicated software Tobii Pro Lab®."
214960146|NCT03826966|DEVICE|reSET|reSET is a mobile app created by Pear Therapeutics, Inc., which has previously been approved by the FDA.
214960147|NCT02966756|DRUG|Venetoclax|Tablet; Oral
214960148|NCT00159107|DRUG|Acamprosate|Acamprosate
214960149|NCT00159107|BEHAVIORAL|Integrative behavior therapy|Integrative behavior therapy
214960150|NCT00159107|DRUG|Placebo|Placebo
214960151|NCT03953599|BIOLOGICAL|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
215079338|NCT02272751|BEHAVIORAL|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
215079339|NCT04341987|BEHAVIORAL|brief Imagery Rehearsal Therapy|Two-sessions of behaviorally-based imagery rehearsal therapy.
215079340|NCT04341987|OTHER|Treatment As Usual|may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
215079341|NCT05999110|OTHER|Physical Exercise|The intervention includes a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. All participants also receive a nutritional advice session and a behavioral changes session.
215079342|NCT01582737|DRUG|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner
215079343|NCT03255538|OTHER|DFM: Mean pressure|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
215079344|NCT03255538|OTHER|DFM: Mean pressure - 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
215079345|NCT03255538|OTHER|DFM: Mean pressure + 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
215079346|NCT05330858|DRUG|ESK-001|Oral tablet or liquid
215079347|NCT05330858|DRUG|Rabeprazole|Oral Tablet
215079348|NCT06426368|DIAGNOSTIC_TEST|ST2|ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure
215079349|NCT01289223|DRUG|Bendamustine IV|
214352716|NCT04289857|OTHER|Neurodynamic training|Starting from a sitting position on a stretcher, with dorsolumbar flexion, it is required to maintain that posture throughout the exercise. Sliding with the straight leg sitting consists of performing alternate movements. First, knee extension and dorsal ankle flexion will be performed, increasing neural tension, combined with cervical extension (to decrease neural tension) in the first instance. Subsequently, knee flexion and plantar ankle flexion (decreasing neural tension) combined with cervical flexion (increasing neural tension) will be performed. The dosage of the technique will be: two seconds for each movement, with 10 repetitions of each one. All sessions will be led by one of the group's researchers.
214960152|NCT03126253|DIAGNOSTIC_TEST|Anemia|"Hemoglobin level will be used as the parameter for diagnosing anemia. The HemoCue system was used to estimate the concentration of hemoglobin in capillary blood. WHO guidelines for the diagnosis of anemia that were adopted by the Demographic Health Surveys will be used in this study. Briefly, a hemoglobin concentration of less than 70 g/L will be consider to define severe anemia, 70-99 g/L for moderate anemia, and 100-109 g/L will be presumed to correspond to mild anemia. The above-mentioned classification of anemia as severe moderate and mild categories is based on blood hemoglobin cutoffs (will be adjusted for altitude and smoking) recommended by the Center for Disease Prevention of United States; this classification has also been adopted by the World Health Organization."
214352717|NCT05845229|DIETARY_SUPPLEMENT|High-N-acylethanolamine meal|Milk (150 mL), white bread (46 g), jam (10 g), cocoa powder (15 g), whole-grain cereals (30 g).
214352718|NCT05845229|DIETARY_SUPPLEMENT|Low-N-acylethanolamine meal|Milk (150 mL), whole-grain bread (80 g), jam (10 g), butter (5 g), instant coffee (2 g), dried apples (30 g).
214352719|NCT00270218|BIOLOGICAL|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
214486933|NCT06734481|DRUG|Sodium bicarbonate pleural lavage|All participants will receive a standardized antimicrobial therapy regimen, with antibiotics selected based on susceptibility testing. Within 2 days of initiating treatment, all patients will undergo catheter placement for continuous drainage of pleural effusion. Participants will receive a daily intrapleural injection of 200 mL of 2.5% sodium bicarbonate in 7 days. For patients with ultrasound evidence of pleural effusion loculations or drainage tube obstruction, intrapleural administration of urokinase may be performed at the discretion of the treating physician to ensure effective drainage.Following each daily injection, the catheter will be clamped for 2 hours before resuming continuous drainage, a process that will continue for 7 days.
214960153|NCT01129804|BEHAVIORAL|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
214960154|NCT03882957|BEHAVIORAL|Sustained attention|participants will complete a sustained attention task
214960155|NCT03882957|BEHAVIORAL|media multi-task|participants will complete multiple media tasks at the same time
214960156|NCT03882957|OTHER|Video|participants will watch a video of media tasks being completed
214960157|NCT04442698|PROCEDURE|Mini-Gastric Bypass Original Technique|Follow up of the Surgical procedure outcomes in diabetics. Procedure Mini-Gastric Bypass Original Technique
214960158|NCT02974803|DRUG|Dabrafenib|Dabrafenib 150 mg twice a day until progression or unaccepted toxicity.
214960159|NCT02974803|DRUG|Trametinib|Trametinib 2 mg once daily until progression or unaccepted toxicity.
214960160|NCT06277713|BEHAVIORAL|Standing interruptions|A mobile sit-to-stand desk will be installed at the workplace and participants are instructed to alternate their working position every 30 minutes during two working days (8h).
215079350|NCT01289223|OTHER|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
215079351|NCT01221025|DRUG|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
215079352|NCT00871546|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
215079353|NCT00871546|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
215079354|NCT00871546|BIOLOGICAL|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
215079355|NCT01124227|DRUG|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
215079356|NCT01361074|BEHAVIORAL|In Vivo Exposure for Animal Phobia following Öst´s guidelines|"In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way."
215079357|NCT01361074|BEHAVIORAL|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|"Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli."
215079358|NCT00846989|DRUG|RKI983A|RKI983 0.05 % twice daily
215079359|NCT00846989|DRUG|RKI983A|RKI983 0.1 % twice daily
215079360|NCT00846989|DRUG|Latanoprost|Latanoprost 0.005 % once a day
215079361|NCT00034164|DRUG|S-8184 Paclitaxel Injectable Emulsion|
215079362|NCT00137696|BIOLOGICAL|Vaccination with inactivated polio vaccine|
214352720|NCT00270218|BIOLOGICAL|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
214352721|NCT00270218|BIOLOGICAL|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
214352722|NCT00270218|BIOLOGICAL|PBS|phosphate buffered saline
214352723|NCT05795725|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
214352724|NCT05795725|PROCEDURE|Colonoscopy|Colonoscopy procedure
214352725|NCT04542343|BEHAVIORAL|Change in knowledge, motivation, skills, resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges.
214352726|NCT02539342|DRUG|Caphosol|"Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:~* Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.~  o Participants may increase the use to 6 times per day if you have symptoms of mucositis.~* Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.~  * For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.~ * For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.~* Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.~* Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed"
214352727|NCT02539342|DRUG|Biotene|"• Use 5 to 10 mL of Biotene to swish and spit~o For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Prior to swabbing the patient's mouth, pour Biotene into a cup and using the medical sponge, soak up the solution and use the swab to coat the inside of the patient's mouth. Repeat with a second swab."
214352728|NCT02300753|DRUG|EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol
214352729|NCT03722251|BEHAVIORAL|Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing|
214960161|NCT06277713|BEHAVIORAL|Exercise bout|Participants will perform a continuous aerobic exercise bout for a duration of 60 minutes at a moderate intensity, which is defined as 60% of their maximal oxygen uptake (VO2max).
214960162|NCT06277713|BEHAVIORAL|Sedentary|Participants are instructed to minimise any behaviour that is not sedentary during two working days (8h).
214960163|NCT02333422|OTHER|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
214960164|NCT01608672|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
214960165|NCT02259699|OTHER|Decision Aid|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
214960166|NCT04186221|DEVICE|OCS Liver System|OCS Liver System for preserving and assessing donor livers for transplantation
214960167|NCT04932343|DIAGNOSTIC_TEST|cohort study|no intervention
214960168|NCT05471427|DRUG|Taxane chemotherapy|Patients underwent taxane chemotherapy according to clinical practice for metastatic prostate cancer
214960169|NCT04551768|DRUG|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
214960170|NCT04551768|DRUG|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
214352730|NCT06388525|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|
214352731|NCT02566031|DRUG|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
214352732|NCT02566031|DRUG|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
214960171|NCT02897466|OTHER|Direct Antimicrobial Susceptibility Testing|An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
214960172|NCT00543673|OTHER|Milk based formula A|feed as per HCP directions
214960173|NCT00543673|OTHER|#2 Standard formula|Feed as per HCP directions
214960174|NCT00543673|OTHER|#3 Human Milk|Feed as per HCP directions
214960175|NCT00543673|OTHER|Milk based formula C|Feed as per HCP direction
214960176|NCT05624190|DRUG|Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)|The administration of rhTNK-tPA will be infused constant and slowly over 15min (0.125 mg/kg, Max 12.5mg) through a microcatheter.
214960177|NCT05624190|OTHER|Best Medical Management|Best Medical Management
214960178|NCT02158377|DEVICE|Trabecular metal dental implants (TM)|Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
215079363|NCT00137696|PROCEDURE|Collection of serum|
215079364|NCT03730545|DIETARY_SUPPLEMENT|enteral immunonutrition|Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.
214960179|NCT02158377|DEVICE|Tapered screw-vent implants (TSV)|Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
215079365|NCT05189249|OTHER|No intervention performed|No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
215079366|NCT04702906|OTHER|standard treatment|Standard treatment if indicated.
214960180|NCT05185635|DIAGNOSTIC_TEST|Neuropsychological testing|potential participants will complete the following: Mini-Mental State Examination (MMSE), Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7- item (GAD-7) as part of the screening process. Additionally to the pre-screening instruments, participants will complete the following neuropsychological tests: Bi-dimensional Acculturation Scale, Bilingual Dominance Scale, Verbal Fluency Tests, Boston Naming Test, Symbol Digit Modalities Test, Brief Test of Attention, Who-UCLA Auditory Verbal Learning Test, Rey-Osterrieth Complex Figure, Modified Wisconsin Card Sorting Test, Stroop Color and Word Test, Trail Making Test, Word Accentuation Test, Clock Drawing Task, Bells Test, Test of Memory Malingering, and the Five Point Test.
214960181|NCT01134393|DRUG|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
214960182|NCT00567424|DRUG|GW273225|
214352733|NCT06276192|OTHER|Digital Physiotherapy (diSAID)|"The diSAID is developed by the research group and is a modified version of a previously tested exercise program for patients with subacromial pain. The diSAID is distributed in three stages with; Information about subacromial pain, effects of exercise, pain management and ergonomics in everyday living and at work. The training includes exercises for the rotator cuff and scapular stabilizers as well as posterior shoulder stretch. The exercises are performed 1 time/day during twelve weeks with a progression of dose, load and complexity continuously. Pain while performing the exercise program is accepted up until NRS 5 out of 10.~During ongoing treatment, there is the opportunity for counselling, individualization of exercises, adjustment of dose and load based on stated instructions from the treating physiotherapist.~Adherence, levels of pain and function is reported continuously by the patient via the digital platform."
214960183|NCT00013377|PROCEDURE|Low vision|
214960184|NCT05042986|DRUG|.[14C]-SKI-O-703|Single oral dose of 200 mg (100 μCi in 200 mg salt \[0.5 μCi/mg as salt\], equivalent to 100 μCi in 142 mg active \[0.7 μCi/mg as active\]) of \[14C\]-SKI-O-703 containing approximately 100 μCi of \[14C\]-SKI-O-703 per capsule after an overnight fast.
214960185|NCT00652808|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
214352734|NCT06276192|OTHER|Traditional Physiotherapy|Patients in the active control group are offered the usual treatment practice that is currently offered by physiotherapists in primary care. No predetermined directives for the active control group are defined prior to the study and can contain; home exercise programs, manual therapy and other techniques. The treating physiotherapists in this group are not involved in the digital treatment. The choice of interventions, amounts of visits and adherence is checked retrospectively via patient data and medical records.
214352735|NCT06389604|OTHER|Heat acclimation|Daily repeated heat exposure to assess the effects of combined passive and active heat acclimation
214960186|NCT00652808|DRUG|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
214960187|NCT01109134|DRUG|tirofiban intracoronary bolus-only|administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
214960188|NCT01109134|DRUG|tirofiban intravenous bolus plus infusion|administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
214960189|NCT00437372|DRUG|Sunitinib|"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."
214960190|NCT00437372|RADIATION|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
214352736|NCT03669848|OTHER|Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
214960191|NCT04233437|DRUG|MLC1501|MLC1501 capsules (4 capcules (2000 mg) twice a day)
214960192|NCT04233437|DRUG|CYP Cocktail|Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg
214960193|NCT04233437|DRUG|Transporter Cocktail|Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg
214960194|NCT03367234|BEHAVIORAL|Individual Therapy Sessions|One-on-one sessions with a counselor
214960195|NCT03367234|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy techniques delivered by a behavioral health consultant (BHC)
214960196|NCT03367234|BEHAVIORAL|Medication-Assisted Treatment|Buprenorphine or Extended-Release Naltrexone
214960197|NCT03367234|BEHAVIORAL|Peer Recovery Specialist Support|Individual and/or group sessions with a certified peer recovery specialist
214960198|NCT03367234|BEHAVIORAL|Group Therapy Sessions|Group therapy sessions
214960199|NCT03367234|BEHAVIORAL|Psychiatric Consultation|Access to psychiatric consultation
214960200|NCT03367234|BEHAVIORAL|Contingency Management|Rewards for engagement in specified recovery behaviors
214960201|NCT00531947|DRUG|Selegiline Transdermal System|EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
214960202|NCT00531947|DRUG|Placebo|Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
214960203|NCT01590316|DEVICE|Cerebral NIRS oximetry|Cerebral NIRS oximetry during the first 72 hours of life.
214960204|NCT01800799|DRUG|Baktar 800mg h.s.|Antimicrobial agent (Baktar 800mg h.s.)
214960205|NCT01800799|DRUG|Celecoxib 200mg QD|Anti-inflammatory agent (Celecoxib 200mg QD)
214960206|NCT03240276|OTHER|Standard ICSI procedure for sperm injection into oocyte|The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes
214960207|NCT03240276|DEVICE|MSOME|Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification
214960208|NCT03240276|OTHER|IMSI Procedure|Injection of sperm that has been selected by the MSOME method into oocytes
214960209|NCT03775967|DIAGNOSTIC_TEST|sialic acid|sialic acid level estimation in salivary samples
214960210|NCT03775967|DIAGNOSTIC_TEST|IL10|IL10 estimation in salivary samples
214960211|NCT00226798|DRUG|Capecitabine (Xeloda)|
215079367|NCT04702906|DRUG|"trimetazidine hydrochloride metacardia ® 20 mg tablet"|"trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)"
215079368|NCT04832906|DRUG|Ulipristal Oral Tablet|A selective progesterone receptor modulator (SPRM), as a medical line of treatment for uterine fibroids. Due to its selective anti-proliferative and pro-apoptotic action, Ulipristal Acetate (UA) is assumed to be effective in reducing abnormal uterine bleeding (AUB) and fibroid size.
214352737|NCT06155968|PROCEDURE|QL block|"The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles.."
214352738|NCT06155968|DRUG|PCA|the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min
214352739|NCT04639453|DIAGNOSTIC_TEST|Trunk strength with hand-held dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various trunk muscle groups in flexion, extension, and lateral (N).
214352740|NCT04639453|DIAGNOSTIC_TEST|Balance Assessment in Sitting and Standing test (BASS)|"The BASS is a test to assess static and dynamic sitting and standing balance, which has been validated for post-stroke hemiparetic patients. Each test is evaluated by a score from 0 (patient needs external support) to 4 (stable without external help) for static condition and from 0 (no possibility to pick up objects) to 3 (objects picked up without external help) for dynamic condition. The maximal score (sitting, standing, static and dynamic) is 14 points."
214486934|NCT06734481|DRUG|Saline pleural lavage|All participants will receive a standardized antimicrobial therapy regimen, with antibiotics selected based on susceptibility testing. Within 2 days of initiating treatment, all patients will undergo catheter placement for continuous drainage of pleural effusion. Participants will receive a daily intrapleural injection of 200 mL of saline in 7days For patients with ultrasound evidence of pleural effusion loculations or drainage tube obstruction, intrapleural administration of urokinase may be performed at the discretion of the treating physician to ensure effective drainage. Following each daily injection, the catheter will be clamped for 2 hours before resuming continuous drainage, a process that will continue for 7 days..
214960212|NCT03513783|OTHER|measurement of human movement|"The objective measurement of human movement through the use of kinematic markers and electromyography is a clinical exam commonly performed to analyze the movements of patients with motor control disorders. The different steps are the following:~* A clinical exam is performed by the Physical Medicine \& Rehabilitation clinician (passive range of motion , spasticity, muscular force, etc.).~* Intramuscular and surface electromyography and kinematic markers are placed on the upper limb of the participant. A maximum of two intramuscular electrodes will be inserted with guiding of an echography system.~* The participant will be asked to perform several upper limb movements: specifically, he will be asked to perform consecutive cycles of elbow extension-flexions with the shoulder at different levels of abduction. Times of rest will be given to the participants.~Time of the procedure is estimated to 1h, with only about 2 minutes of active effortless movements from the participants."
214960213|NCT00282685|PROCEDURE|Intraarterial bone marrow progenitor cell transplantation|catheter delivery of stem cells
214960214|NCT00529178|DRUG|Pravastatin|
214960215|NCT04615078|DEVICE|ETAPES Program|"The Chronic Care Connect Pneumology is a remote medical monitoring solution, combining:~* A technical solution for the transmission and analysis of ventilator data, leading to alerts generated by an algorithm ;~* An organizational solution relying on a nurse call center."
214960216|NCT03326297|OTHER|Osteopathy manual therapy|Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
214960217|NCT03326297|BEHAVIORAL|Measures to support and education to the family|Pedagogical intervention in parents and health education
214960218|NCT02018302|DRUG|Triheptanoin|
214960219|NCT04529317|DIETARY_SUPPLEMENT|Quinoa and quinoa-based food|"Products created replaced grains, legumes, tubers, also farinaceous commonly consumed by the participants and only the cereal fraction was modified, similar products based on quinoa flour were created.~Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche, sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of the recipe. Each subject received the equivalent of what they consumed according to their regular diet dietary records."
214960220|NCT01119820|OTHER|Tissue Donation|Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
214960221|NCT04035122|OTHER|Robotic Treatment|The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.
215079369|NCT04832906|PROCEDURE|Uterine artery embolization|Selective embolization of uterine arteries bilaterally, using polyvinyl alcohol (PVA) particles administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected.
215079370|NCT02520258|OTHER|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
215079371|NCT02520258|OTHER|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
215079372|NCT04038892|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
215079373|NCT04038892|OTHER|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
214352741|NCT04639453|DIAGNOSTIC_TEST|Timed Up and Go test|The participant sits on a chair, gets up, walks 3m, makes a half turn in 1m2, walks 3m and comes back to sit on the chair. The time (s) to complete the task is measured.
214486935|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 14 day
214486936|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + low dose amoxicillin|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 2 times/day, oral, for 14 day
214486937|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin（H-KA-10d）|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 10 day
214960222|NCT04035122|OTHER|Conventional Treatment|The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.
214960223|NCT00614978|DRUG|lapatinib and temozolomide|Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
214960224|NCT03731390|DRUG|GR1405 injection|Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
214960225|NCT00123994|BEHAVIORAL|Tai Chi classes|
214960226|NCT00123994|BEHAVIORAL|Hydrotherapy classes|
214960227|NCT04285905|OTHER|Access to Fast Track TB clinic|Male partner can attend clinic with dedicated services for men
214960228|NCT04285905|OTHER|Information leaflet for male partner|Female participants will be provided with a letter asking their male partner to attend the clinic for tuberculosis screening
214960229|NCT04285905|OTHER|Home sputum collection|Female participants will be provided with sputum cups to take home and collect a sample of sputum from their male partner
214960230|NCT04285905|OTHER|Home HIV testing|Female participants will be provided with an oral HIV self-test kit to be given to their male partner with instructions for use
214960231|NCT04285905|OTHER|Financial incentive|Female participants will be provided with a voucher for MKW5000 which can be redeemed when the male partner attends the clinic for TB testing
214960232|NCT03397602|BEHAVIORAL|standard care + moderate-intensity continuous exercise training|Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
214960233|NCT03397602|BEHAVIORAL|standard care + high-intensity interval training|Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
214960234|NCT03828214|DEVICE|Robotic exoskeleton for walking assist|Participants will have two testing sessions in this within-subject design experiment. The conditions under which walking will be evaluated are control (normal) walking, walking with the exoskeleton assistance and walking immediately following exoskeleton walking. The conditions under which stair walking (ascending and descending) will be evaluated include control (normal) stairs and exoskeleton assisted stairs. Assistance is provided by The Honda Walking Assist (HWA) System is a robotic device developed by Honda R\&D Corporation ®, Japan. The devices computer-activated motors use hip angle information to guide assistance delivered through the thigh straps to the legs in time with the walking cycle. The maximum torque delivered is 4 Newton-meters.
214486938|NCT06734013|DIAGNOSTIC_TEST|Molecular diagnostic|RNA will be analysed using a Real-Time PCR expression card (TaqMan Real-Time PCR assay technology - Thermo Fisher Scientific). The analysis will be performed using a Real-Time Light Cycler 480 (Roche). The expression card will be customised for the study, including the genes cxcl9/10, cav-1, rhoj, cdh5, cd96, tnfsf8, il-21r, vcam, klrk1
214960235|NCT03143777|DEVICE|Sara Combilizer|Combined tilt table and stretcher chair
214960236|NCT05103800|BEHAVIORAL|invasive interventions|listening the white noise during the invasive interventions
214960237|NCT05019573|DIETARY_SUPPLEMENT|Black tea|Black tea twice a day for 4 weeks
214960238|NCT05019573|DIETARY_SUPPLEMENT|Placebo|Placebo tea twice a day for 4 weeks
214960239|NCT04721639|OTHER|Sphinx Yoga Therapy|Sphinx Pose Yoga is among the best beginner Yoga Poses that relieve Lower Back Pain. It extends the back gently and activates muscles along the spine. The subject will be asked to lay down on their stomach with feet set hip-width apart, the elbows positioned under the shoulders, and the legs held together. The chin should be pointing towards the floor. Next, the subject is required to pull up the kneecaps, squeezing the thighs and buttocks, pressing the pubic bone into the floor and dropping shoulders back away from the neck and pushing the chest forward. In this position, the subject is asked to breathe and hold the pose for two to six breaths. By the end, the subject will be required to exhale, bringing the elbows to the sides and slowly lowering the chest and head to the floor.
214960240|NCT04646811|PROCEDURE|Tricuspid valve|Clip for the tricuspid valve implantation on top of best medical therapy
214960241|NCT04646811|OTHER|Best medical treatment|Best medical therapy alone
214960242|NCT00305565|DEVICE|VNS Therapy|Received output current of 0.25 milliamps (mA)
214960243|NCT00305565|DEVICE|VNS Therapy|Received output current of 0.5-1.0 mA
214352742|NCT04639453|DIAGNOSTIC_TEST|Modified Functional Reach Test (MFRT)|The MFRT is a dynamic seated balance test that measures the trunk's ability to move forward, to the paretic and non paretic side (cm).
214352743|NCT04639453|DIAGNOSTIC_TEST|Joint Position sense test (trunk)|The joint positional sense test of the trunk consists in evaluating the positional error of the trunk in the sagittal plane (mm) and in the frontal plane (mm) during a trunk flexion posture (target position).
214960244|NCT00305565|DEVICE|VNS Therapy|Received output current of 1.0-1.5 mA
214352744|NCT04639453|DIAGNOSTIC_TEST|Unstable sitting in a seesaw|This test evaluates the balance capacities of the subject in an unstable sitting position on a seesaw (mediolateral or anteroposterior instability) with forceplate and phone application using center of pressure variables: total displacement (mm), area (mm2), deltas (mm), mean velocity (mm/s) et maximal velocity (mm/s).
214352745|NCT06333925|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS)|10 Hz rTMS over the right dorsal lateral prefrontal cortex (dlPFC)
214352746|NCT06333925|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS)|inactive rTMS over the right dorsolateral prefrontal cortex (dlPFC)
214352747|NCT06333925|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about misophonic sound triggers in order to feel less emotional arousal.
214352748|NCT02962687|BEHAVIORAL|Care management via videoconference|12-week nurse care management for medically complex Veterans with CI delivered via videoconference
214352749|NCT02962687|BEHAVIORAL|Care management via telephone calls|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
214960245|NCT05708040|DEVICE|InPen Medtronic|Patients with DM1 ≥ 18 years of age who initiate Inpen system.
214960246|NCT05708040|DEVICE|Minimed 780G system|Patients with DM1 ≥ 18 years of age who initiate Minimed 780G system.
214352750|NCT02766751|BEHAVIORAL|HIVPASS|The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
214960247|NCT02335385|PROCEDURE|single incision laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
214960248|NCT02335385|PROCEDURE|conventional transperitoneal laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
214960249|NCT04687189|DEVICE|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
214960250|NCT02364076|DRUG|Pembrolizumab|Administration of 200 mg MK-3475 once every 3 weeks
214960251|NCT02364076|DRUG|Epacadostat|100mg taken by mouth twice daily
214960252|NCT03056612|OTHER|Observation protocol|The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
214960253|NCT00420628|DRUG|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
214960254|NCT00420628|DRUG|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
214960255|NCT01830933|OTHER|BreastCARE|Physician Report. At the time of an individual participant's visit to her primary care physician and her completion of the assessment tool, her physician will receive a physician report. The physician report is designed to facilitate communication about breast cancer risk during the primary care visit and to provide tailored risk reduction recommendations.
214960256|NCT04786405|BEHAVIORAL|Mindfulness meditation|Participants in the mindfulness meditation condition will practice a breath and body focused meditation.
214960257|NCT04786405|BEHAVIORAL|Clinical hypnosis|Participants in clinical hypnosis will be guided in a hypnosis practice with suggestions tailored towards shifting pain appraisals.
214960258|NCT01372540|DRUG|Carfilzomib|Given IV
214960259|NCT01372540|DRUG|Filanesib|Given IV
214960260|NCT01372540|OTHER|Laboratory Biomarker Analysis|Correlative studies
215079374|NCT04038892|OTHER|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
215079375|NCT00093886|DRUG|clevidipine|
215079376|NCT00093886|DRUG|nitroglycerin|
214352751|NCT02766751|BEHAVIORAL|Health Education|The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
214352752|NCT05780203|BEHAVIORAL|One session exposure treatment|One session exposure treatment during which patients will be confronted with a height-related situation.
214486939|NCT06735378|OTHER|Intradialytic Cycling|The impact of interdialytic exercise on cardio protection during HD has never been studied. This approach may enhance cardiovascular benefits and overall physical fitness, thereby contributing to better health outcomes in individuals undergoing HD.
214960261|NCT04690634|PROCEDURE|laparoscopic sleeve gastrectomy (LSG)|Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
214960262|NCT00001338|DRUG|FLAC chemotherapy with GM-CSF|
214960263|NCT03043963|BEHAVIORAL|Sleep Extension|Lengthen the duration of sleep time.
214960264|NCT03043963|BEHAVIORAL|Sleep Timing|Regularize the timing of the sleep period.
214960265|NCT01290575|DRUG|Placebo|capsule, Oral, 0.0mg, twice daily, 14 day
214960266|NCT01290575|DRUG|Placebo|Capsule, Oral, 0.0mg, once daily, 14 day
214960267|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 15mg, twice daily, 14 day
214960268|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 60mg, twice daily, 14 day
214960269|NCT01290575|DRUG|BMS-820132|Capsule, oral, 150mg, twice daily, 14 day
214960270|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 300mg, twice daily, 14 day
214960271|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 450mg, twice daily, 14 day
214960272|NCT01290575|DRUG|BMS-820132|Capsule, Oral, To be determined (TBD), once daily, 14 day
214960273|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 5 mg, twice daily, 14 day
214960274|NCT03457623|OTHER|Innovative Supported|addition of connected tools and stronger accompaniment to improve quality of life
214960275|NCT03307460|DRUG|68Ga-NOTA-AE105|PET/MRI scan
214960276|NCT02481752|OTHER|Approach Avoidance Training|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
214960277|NCT02481752|OTHER|SHAM Training|
214960278|NCT00362661|DRUG|Cortisol|Cortisol 10 mg/d for 3 months
214352753|NCT05780203|BEHAVIORAL|Sham Cognitive Bias Modification training|Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.
214352754|NCT05780203|BEHAVIORAL|Active Cognitive Bias Modification training|Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
214352755|NCT02479412|DRUG|800 μg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
214960279|NCT01770821|OTHER|Dietary supplement and/or physical training|
214352756|NCT02479412|DRUG|250 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
214352757|NCT02479412|DRUG|58 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
214960280|NCT06253910|OTHER|Patients selection|Patient selection were selected according to selected criteria.
214960281|NCT06253910|OTHER|Recall visits|Following the operations, periodontal measurements were measured at the baseline, third month, first and second years.
214960282|NCT01462864|BEHAVIORAL|Structured Lifestyle Education|A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
214960283|NCT01324921|OTHER|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
214960284|NCT01324921|OTHER|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
214960285|NCT01324921|OTHER|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
214352758|NCT02479412|DRUG|Placebo once daily|Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
214352759|NCT02479412|DRUG|Salbutamol|Inhalation as needed
214352760|NCT04758312|BEHAVIORAL|MY-Skills Mobile|Yoga and Self-Management Education
214352761|NCT02549898|DRUG|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
214352762|NCT02549898|DRUG|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
214960286|NCT01816932|PROCEDURE|Home Visit|The intervention is the location of the insertion visit.
214960287|NCT01816932|PROCEDURE|Office visit|
214486940|NCT06734143|DIAGNOSTIC_TEST|Neuropad|Neuropad examination was performed in all patients, after 10 minutes of rest without socks in a well-temperatured room. The result was considered normal if there was a complete color change and abnormal if there was no or incomplete color change.
214960288|NCT01504373|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be placed in the NAVA mode of ventilation.
214960289|NCT04633772|DRUG|Angiotensin-(1-7)|Intravenous supplementation of Angiotensin-(1-7)
214960290|NCT04633772|DRUG|Placebo|NaCl 0.9%
214960291|NCT03163537|DEVICE|HealthPatch|Smart patch that is able to measure stress real time using an algorithm between HR and HRV
214960292|NCT01789801|PROCEDURE|RAP palpation only|Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.
214960293|NCT01789801|PROCEDURE|RAP with ultrasound guidance|Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
214960294|NCT02748629|DEVICE|Covidien Parietex ProGrip Self-Fixating Mesh|
214960295|NCT02748629|DEVICE|Lightweight Polypropylene Mesh (<38g/m2 after absorption)|Serag Wiessner SERAMESH® PA 15x10 cm
214960296|NCT00096759|BEHAVIORAL|Tai Chi Chih|
214960297|NCT00096759|BEHAVIORAL|Relaxation training|
214960298|NCT02118259|OTHER|Before-after study|"The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.~The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.~The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.~During the second observational phase, the same data as in the first observational phase will be collected a second time."
214960299|NCT00040144|DRUG|ACH126, 433|
214352763|NCT02549898|OTHER|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
214352764|NCT02549898|OTHER|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
214960300|NCT01547052|BEHAVIORAL|DBT for children|intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
214960301|NCT01547052|BEHAVIORAL|Enhanced Supportive-Educational therapy|weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
214960302|NCT02984644|DRUG|Dapagliflozin|Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
214352765|NCT00458328|DRUG|Z-338|
214352766|NCT04117035|PROCEDURE|Gamma Knife Radiosurgery (GKRS) personalised procedure|Personalised GKRS treatment
214960303|NCT02984644|DRUG|Placebo|Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
214960304|NCT00360009|PROCEDURE|DBS of the STN|Patients undergo Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's Disease, using a Medtronic 3387 device.
214960305|NCT00360009|PROCEDURE|DBS of the GPI|Patients undergo Deep Brain Stimulation (DBS) of the globus pallidus interna (Gpi) to treat Parkinson's disease, using a Medtronic 3387 device.
214960306|NCT02414217|BEHAVIORAL|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
214960307|NCT02414217|BEHAVIORAL|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
214960308|NCT04110886|DRUG|HSK21542|Single dose, injection, starting dose of 0.2ug escalating up to 20ug
214960309|NCT04110886|DRUG|Placebo|Single dose, injection matching placebo
214960310|NCT03620383|PROCEDURE|Topical Heat|Warm heat pack applied topically in participant hand.
214960311|NCT04636411|DIETARY_SUPPLEMENT|Oral Magnesium Supplementation|250 mg of elemental magnesium daily for three months
214960312|NCT04636411|OTHER|Standard Care for diabetic patients|Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines
214960313|NCT05095311|DRUG|Cetirizine HCl|Eight participants will be administered 10 mg of cetirizine HCl to examine whether this drug can improve their oxyhemoglobin saturation during exercise.
214960314|NCT05095311|OTHER|Placebo|The placebo pill is a sugar-free gelatin pill casing. The placebo inhaler contains isotonic saline.
214960315|NCT02009371|DEVICE|Bright Light therapy|In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
214960316|NCT02009371|DEVICE|dim Red Light therapy|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
215079377|NCT06252896|OTHER|INSTRUMENTAL-ASSISTED SOFT TISSUE MOBILIZATION TECHNIQUE|After all evaluations were made, IASTM was applied to the individuals in the intervention group for five minutes each, for a total of 20 minutes, on the quadriceps and hamstring muscles of both extremities, respectively.
215079378|NCT06252896|OTHER|NO INTERVENTION|The control group waited for 30 minutes after the initial measurements and all measurements were repeated.
214352767|NCT04117035|PROCEDURE|GKRS standard care|Standard GKRS treatment
214352768|NCT05625048|OTHER|Transperinal ultrasound guided instruction in pelvic floor muscle training|The physiotherapists uses transperinal ultrasound as a biofeedback or pedagogical tool to improve the muscle contractions and visualize the muscle work.
214352769|NCT04969250|BIOLOGICAL|Moderna mRNA-1273 COVID-19 vaccine|100 µg intramuscular injection
214352770|NCT04969250|BIOLOGICAL|Pfizer BNT162b2 COVID-19 vaccine|30 µg intramuscular injection
214352771|NCT06236022|DRUG|Sirolimus|at a dose of 2 mg once daily
214352772|NCT00617760|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle
214352773|NCT00617760|BIOLOGICAL|7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|PCV7 (0.5 ml) to be administered in the right thigh muscle
214960317|NCT03328598|BEHAVIORAL|Positive psychology therapy group|This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.
214960318|NCT03328598|BEHAVIORAL|Resilience promotion therapy group|The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
214960319|NCT03328598|OTHER|Controlled routine activity|Conventional community activities is viewed as an active comparator for controlled group.
215079379|NCT00517439|DRUG|Copegus|1000/1200mg po daily for 24 weeks
215079380|NCT00517439|DRUG|Pegasys|180 micrograms sc weekly for 24 weeks
215079381|NCT00517439|DRUG|Pegasys|90 micrograms sc weekly for 24 weeks
215079382|NCT00517439|DRUG|RO4588161|1000mg po bid for 24 weeks
215079383|NCT00517439|DRUG|RO4588161|500mg po bid for 24 weeks
215079384|NCT00517439|DRUG|RO4588161|1500mg po bid for 24 weeks
214352774|NCT00617760|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
214352775|NCT03942250|BIOLOGICAL|REGE pro dressing|REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
214352776|NCT01495767|OTHER|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
214960320|NCT03941145|BEHAVIORAL|Reduced-Exertion High-Intensity Interval Training (REHIT)|REHIT is a type of Sprint Interval Training (SIT) that has been shown to be efficacious at improving maximal aerobic capacity using a minimal volume of exercise.
214960321|NCT01319942|OTHER|Radiotherapy combined with sorafenib|Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
214960322|NCT00007995|BIOLOGICAL|filgrastim|
214960323|NCT00007995|BIOLOGICAL|recombinant interferon alfa|
214960324|NCT00007995|BIOLOGICAL|sargramostim|
214960325|NCT00007995|DRUG|busulfan|
214960326|NCT00007995|DRUG|cyclophosphamide|
214960327|NCT00007995|DRUG|melphalan|
214960328|NCT00007995|PROCEDURE|autologous bone marrow transplantation|
214960329|NCT00007995|PROCEDURE|bone marrow ablation with stem cell support|
214960330|NCT00007995|PROCEDURE|peripheral blood stem cell transplantation|
214486941|NCT06736106|OTHER|screening|Comprehensive screening of bone metabolic status and bone fragility in the largest cohort to date of patients with degenerative spinal diseases
214960331|NCT05451394|OTHER|ROAF|"Use of the method Ressource Optimisation of Armed Forces (ROAF). 6 one-hour workshops"
214960332|NCT05451394|OTHER|Active Comparator|6 one-hour workshops on cognitive process
214960333|NCT00205998|DEVICE|Locking Compression Plate 2,4mm|
214960334|NCT00205998|DEVICE|Locking Compression Plate 3,5mm|
214960335|NCT00561691|DRUG|nimotuzumab|monoclonal antibody
214352777|NCT02854774|BEHAVIORAL|Muscle activation exercises|Activation of either muscles activating the knee or hip.
214352778|NCT03691467|DEVICE|immediate dental implant|immediate dental implant placement in freshly extracted socket.
214352779|NCT03691467|DRUG|Hyaluronic Acid|topical application of hyaluronic acid
214352780|NCT03958370|OTHER|Fitbit|Fitbit use during physical therapy session
214352781|NCT00574587|DRUG|Vorinostat|Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
214486942|NCT06091540|BEHAVIORAL|Feasibility and Efficacy of Individual SH+ Intervention|The key parameter of interest will be the extent of psychological distress encountered by the participants. In addition, various secondary outcomes will also be evaluated, encompassing depression, anxiety, post-traumatic stress disorder (PTSD) symptoms, psychosocial well-being, and grief levels. The evaluation of the intervention's effectiveness on the sample of interest will hinge on the comparison of scores obtained during the pretest and posttest measurement phases.
214486943|NCT06173102|DEVICE|Cranial Orthosis|Early versus usual reception of orthosis.
214960336|NCT02362737|BEHAVIORAL|Active and Healthy Brotherhood (AHB)|Participants will attend group sessions led by trained group facilitators. The group sessions will be \~16 weekly meetings of \~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
214960337|NCT01998347|DRUG|Paclitaxel liposome|
214960338|NCT01998347|DRUG|Cisplatin|
214960339|NCT01998347|DRUG|5-fluorouracil|
214960340|NCT00311753|DRUG|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
214960341|NCT00311753|DRUG|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
214960342|NCT02932813|BEHAVIORAL|THINK Program|Lessons and laboratory sessions will be 60 minutes, followed by physical activity sessions lasting 60 minutes. Laboratory activities include assessing heart rate, making healthy meals, learning portion sizes, brain challenges, and more. To improve physical activity participation, a wide selection of developmentally appropriate and multiculturally sensitive activities will be offered, such as sports, games, obstacle courses, and dance.
214960343|NCT02579317|BEHAVIORAL|Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
214960344|NCT02579317|BEHAVIORAL|Non-Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
214960345|NCT04932135|DIAGNOSTIC_TEST|Continuous heart rate monitoring|Continuous heart rate monitoring with a wrist worn fitnesstracker
214960346|NCT02009423|DRUG|Masitinib|
214960347|NCT02009423|DRUG|Placebo|
214960348|NCT06408779|PROCEDURE|mitral valve repair|coronary artery bypass grafting concomitant mitral valve repair
214960349|NCT03655600|OTHER|Self-administered acupressure|Self-administered acupressure learned through app for reduction of need for opioids post-surgery in breast cancer patients
214960350|NCT01766908|OTHER|Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery|None to add
214960351|NCT01540513|DRUG|NM404|"injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging~Other Names:~PET imaging with I-124 NM404"
214960352|NCT01540513|DRUG|NM404|injection of an experimental imaging agent, 5mCi I-124NM404
214960353|NCT00332306|DRUG|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients \<60kg, 400mg patients \> 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
214960354|NCT00332306|DRUG|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients \< 60kg, 400 mg OD patients \> 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
214960355|NCT04030234|DRUG|Intensive BP treatment group|"Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics"
214352782|NCT00574587|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 12 weeks
214352783|NCT00574587|DRUG|Trastuzumab|Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
214960356|NCT04030234|DRUG|Standard BP treatment group|Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
214352784|NCT00574587|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
214960357|NCT03541707|DEVICE|Deep TMS Brainsway's H coil|"During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes."
214960358|NCT01643278|DRUG|Dasatinib|Given PO
214960359|NCT01643278|BIOLOGICAL|Ipilimumab|Given IV
215079385|NCT05800028|BEHAVIORAL|Learning new information|The purpose of this study is to test the effects of different social contexts when learning new information. Participants in the AD, SPPA, and HC experimental groups will be given tests to learn verbal information (location of drawings in a grid). The learning phases of these tests are presented in the form of a memory game in which participants are asked to make pairs of drawings by finding the second copy of the proposed pair by trial and error in a grid. After learning, a task of recognizing the position of the drawings in the grid is performed. Each participant will carry out this learning in three different conditions: 1) learning alone, 2) learning by observation of the reconstruction of the pairs of images by a partner, and 3) collaborative learning in which the two game partners discover and reconstruct the pairs together.
215079386|NCT03546504|BEHAVIORAL|Procedure alteration and occupational therapy|Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
215079387|NCT04092907|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
215079388|NCT04092907|DRUG|placebo|Ophthalmic Solution
215079389|NCT01161550|DRUG|Granulocyte colony-stimulating factor (G-CSF)|
215079390|NCT01161550|DRUG|Cladribine|
215079391|NCT01161550|DRUG|Cytarabine|
215079392|NCT01161550|DRUG|All-Trans Retinoic Acid (ATRA)|
214352785|NCT00574587|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
214352786|NCT00574587|PROCEDURE|Surgery|Surgical excision of tumor from breast
215079393|NCT01161550|DRUG|Midostaurin|
215079394|NCT02981407|BIOLOGICAL|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
214352787|NCT06336668|DIETARY_SUPPLEMENT|Human milk-based HMF|The study subject will be fed human milk fortified with a human-milk-based HMF.
214352788|NCT03973619|PROCEDURE|Labial Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft (labial graft).
214352789|NCT03973619|PROCEDURE|Jugal Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft(inner cheek - jugal graft).
214352790|NCT00722891|DEVICE|Purevision Lenses with ReNu Multiplus|Purevision lenses using ReNu Multiplus lens solution for 28 days
214352791|NCT00722891|DEVICE|Purevision Lenses with Optifree RepleniSH|Purevision lenses using Optifree RepleniSH lens solution for 28 days
214352792|NCT05095753|DEVICE|Earbud|In ear headphone with embedded infrasonic hemodynography technology
214352793|NCT00403832|DEVICE|intraocular lenses: Two foldable, acrylic, sharp edged IOLs: AcrySof™ (AcrySof SA60AT, Alcon), and Akreos adapt™ (Bausch & Lomb)|
214486944|NCT06742554|DRUG|Buprenorphine transdermal patch|"Buprenorphine Transdermal Patch (10 mg): Applied once before surgery for continuous pain control.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine."
215079395|NCT05736705|PROCEDURE|Endoscopic Submucosal Dissection|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the monopolar electrocautery knife.
215079396|NCT05736705|DEVICE|Bipolar electrocautery knife|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the bipolar electrocautery knife.
215079397|NCT05479344|BEHAVIORAL|A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
214352794|NCT02040116|DRUG|Rituximab Infusion|Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
214352795|NCT00127374|BEHAVIORAL|Dietary and physical activity modifications|
214960360|NCT01643278|OTHER|Laboratory Biomarker Analysis|Correlative studies
214960361|NCT01643278|OTHER|Pharmacological Study|Correlative studies
214960362|NCT03327038|BEHAVIORAL|Web-Based Cognitive Behavioral Therapy|Patients will receive access to a 5-week web-based CBT program entitled 'Mood Gym'. The program is derived from traditional, therapist-directed cognitive behavioral therapy. The program consists of 5 modules, and patients will asked to complete 1 module per week over, during weeks 2-6 over their intervention period.
214960363|NCT03327038|OTHER|Short Questionnaires|Patients will receive emails to complete bi-weekly, web-based questionnaires at weeks 2, 4, and 6 of their intervention period. The short questionnaires will ask to patients to self-report their Depression (PHQ-9) and Anxiety (GAD-7) symptoms; along with their Crohn's Disease activity (PRO-2) or Ulcerative Colitis Disease Activity (MAYO-6).
214960364|NCT03327038|BEHAVIORAL|Nurse Monitoring|Patient responses to the short questionnaires will be monitored by an IBD advanced practice nurse. The IBD nurse will determine if there are elevations in anxiety, depression, and disease activity over the intervention period. Based on patient responses to the short questionnaires, the nurse will follow-up with patients via email or telephone to address patient symptoms. If there are clinically important changes in the patients' disease activity the nurse may also arrange for the patients to receive expedited outpatient follow-up with their gastroenterologist.
214960365|NCT03327038|OTHER|Detailed Questionnaires|Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CACHE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GAD-7) symptoms.Quality of Life will be measured using the 10 item Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which has a total score range of 10 to 70, with higher scores indicating better quality of life. Patient Satisfaction with Health Care in IBD will be measured using the 32 item CACHE Questionnaire, which scores from 0 -least satisfaction to 100-highest satisfaction.
214960366|NCT03327038|OTHER|Screening Form|Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms. Their depression symptoms will be reported on the 9-item Patient Health Questionnaire (PHQ-9), which has a total score ranging from 0 to 27, with scores of 5, 10, 15 and 20 representing cut points for mild, moderate, moderately severe, and severe depression. Their generalized anxiety symptoms will be reported on the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), which has a total score ranging from 0 to 21, with scores of 5, 10, and 15 representing cut points for mild, moderate, and severe anxiety. Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
214960367|NCT01341093|BEHAVIORAL|educational program+telephone follow up|Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.
214960368|NCT01341093|BEHAVIORAL|Usual care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
214960369|NCT02893046|OTHER|No intervention|
214960370|NCT03472612|OTHER|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA
214960371|NCT04633499|BEHAVIORAL|Social Cognition Task|Two paradigms will be tested: visual perspective taking and reading the mind in the eyes.
214960372|NCT04633499|DEVICE|tDCS|tDCS either over the dmPFC or the rTPJ.
214960373|NCT02969083|PROCEDURE|RNU|Radical surgical removal by open or laparoscopic access
214960374|NCT02969083|DRUG|Gemcitabine/Cisplatin|Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
214960375|NCT02969083|DRUG|M-VAC Protocol|Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
214960376|NCT04966078|PROCEDURE|liposuction|suction-assisted liposuction
214960377|NCT04966078|PROCEDURE|surgical excision|periareolar surgical excision
214960378|NCT03482908|BEHAVIORAL|Early healthy lifestyles|Patient reported data to identify parenting practices and child behaviors associated with child's obesigenic risk in the future
214960379|NCT03482908|BEHAVIORAL|Responsive parenting curriculum|Information from the American Academy of Pediatrics Healthy Active Living for Families (HALF) program supplemented with messages from the INSIGHT study, that were written at the 5th grade reading level, with messages focused on 4 categories: 1) feeding the baby 2) soothing the baby 3) sleep health and 4) playing with the baby
214960380|NCT03482908|BEHAVIORAL|Data sharing/coordination|Data integration into child's electronic health record that is shared between settings (WIC and GHS PCPs) with display and documentation features that informs counseling.
214960381|NCT01184170|BEHAVIORAL|overfeeding|Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
214352796|NCT00698490|BIOLOGICAL|Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141|Intramuscular injection, 3 doses, 2 different formulations
214352797|NCT00698490|BIOLOGICAL|Herpes simplex virus containing gD-Alum|Intramuscular injection, 3 doses
214352798|NCT00443976|DRUG|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
214352799|NCT06002165|BEHAVIORAL|Usual Care|"All clinics in North Carolina Perinatal Region IV have access to Severe HTN Bundle resources on the AIM website (https://saferbirth.org/psbs/severe-hypertension-in-pregnancy) and the locally adapted Outpatient HTN Bundle resources on the North Carolina Perinatal Region IV Provider Support Network website (https://www.mombaby.org/outpatient-bundle-for-severe-hypertension/). At baseline, the clinical leadership of all enrolled sites will receive direct communication via email that describes and provides links to the available resources. This will constitute usual care."
214352800|NCT06002165|BEHAVIORAL|ACHIEVE Multi-component Implementation Strategy|The intervention is comprised of four implementation strategies: facilitation/coaching, training, simulation, and delivering educational materials. The ACHIEVE study team, primarily the Nurse Coordinator, will engage teams within each clinic to participate in quality improvement activities utilizing these four strategies. The Nurse Coordinator will train the providers/staff on the O-HTN bundle components, facilitate corresponding office systems and workflow changes, and conduct simulations of patients with severe hypertension so care teams can practice the steps involved in recognizing and responding to episodes of severe hypertension in a timely manner.
214960382|NCT02721498|PROCEDURE|Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)|An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)
214960383|NCT02721498|OTHER|Rest period|A 30-60 minute of resting
214960384|NCT01390571|DRUG|olaparib|
214960385|NCT01390571|DRUG|temozolomide|
214960386|NCT01390571|GENETIC|gene expression analysis|
214960387|NCT01390571|GENETIC|protein expression analysis|
214352801|NCT04515186|DRUG|Meglumine Antimoniate|Vials of a 5mL solution. Each vial contains 405 mg of Sb5+ corresponding to 8.1% Sb5+ (81 mg/mL).
214352802|NCT04515186|DRUG|Miltefosine|50 mg capsule
214352803|NCT04515186|DEVICE|Thermotherapy machine|Localized Current Field radio-frequency generating device
214352804|NCT01155947|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
214352805|NCT03775850|BIOLOGICAL|EDP1503|4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)
214352806|NCT03775850|BIOLOGICAL|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
214352807|NCT04642638|DRUG|INO-4800|INO-4800 was administered ID on Day 0 and Day 28.
214352808|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
214352809|NCT04642638|DRUG|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
214960388|NCT01390571|OTHER|laboratory biomarker analysis|
214960389|NCT01390571|OTHER|pharmacological study|
214960390|NCT01390571|PROCEDURE|diffusion-weighted magnetic resonance imaging|
214352810|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
214352811|NCT00511004|DRUG|Albendazole|Comparing 400 mg to 800 mg dose
214352812|NCT00511004|DRUG|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
214352813|NCT00990652|DRUG|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
214352814|NCT00990652|DRUG|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
214960391|NCT01390571|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214960392|NCT01390571|PROCEDURE|therapeutic conventional surgery|
214960393|NCT00502853|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
214960394|NCT00502853|DRUG|Methotrexate|10-25mg/week
214960395|NCT01634308|DRUG|Novosis(bongros/BMP-2)|
214960396|NCT01634308|DRUG|Bio-oss|
214960397|NCT03145051|OTHER|Saline solution|a nasal irrigation care
214960398|NCT03145051|OTHER|Respimer Netiflow|a nasal irrigation care
214960399|NCT05096962|DIAGNOSTIC_TEST|Quantitative analysis of SARS-CoV-2 antibodies|The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).
214960400|NCT05096962|DIAGNOSTIC_TEST|Cellular immunity|Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.
214960401|NCT03605472|OTHER|cervical ultrasound|cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
214960402|NCT04955613|DEVICE|MyMove/VR system|"The treatment system consists of two lightweight MyMove bands and Virtual-Reality (VR) gear. Proprietary software and content allow tracking of performance in real-time, with feedback to both the patient and treating - personnel.~MyMove is a wearable device that allows patients with loss of upper limb function to operate computers, cellular phones, and similar devices. The technology is non-invasive and does not involve risk to the patient.~Virtual-Reality (VR) gear is a wearable computer running within goggles that project content and allow for interaction using controllers."
214960403|NCT04955613|DEVICE|Mirror therapy|Mirror therapy or mirror visual feedback is a therapy for pain or disability that affects one side of the patient more than the other side
214960404|NCT02860390|OTHER|Denver Health Asthma Management Program|text message (SMS) support including educational, motivational, and resource content.
214960405|NCT02860390|OTHER|Person of Support|Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
214960406|NCT02867800|DRUG|Diphenhydramine|"(Standard of Care) Premedication~Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)"
214960407|NCT02867800|DRUG|Acetaminophen|"(Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)"
214960408|NCT02867800|DRUG|Methylprednisolone|"(Standard of Care) Premedication~Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours"
214352815|NCT05795595|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
214352816|NCT05809037|DEVICE|transcutaneous auricular vagus nerve stimulation|In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.
214352817|NCT05809037|DEVICE|Sham stimulation|In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.
214352818|NCT00517738|OTHER|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
214352819|NCT00517738|OTHER|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
214352820|NCT03902379|OTHER|Internet-Based Intervention|Receive CCI intervention
214352821|NCT03902379|OTHER|Quality-of-Life Assessment|Ancillary studies
214352822|NCT03902379|OTHER|Questionnaire Administration|Ancillary studies
214352823|NCT03902379|OTHER|Survey Administration|Ancillary studies
214352824|NCT00578994|DEVICE|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
214352825|NCT04622696|DIAGNOSTIC_TEST|Ultrasound imaging|Subjects in the performance cohort will undergo ultrasound imaging to assess the visibility of the HydroMARK Breast Biopsy Marker at 6-12 weeks post-implant. There is no intervention in the safety cohort (retrospective chart review).
214960409|NCT02867800|DRUG|Meperidine|"(Standard of Care) Premedication~Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)"
214960410|NCT02867800|DRUG|Alemtuzumab|"(Standard of Care) Immunosuppression~Alemtuzumab:~A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third."
214960411|NCT02867800|DRUG|Thymoglobulin|"(Standard of Care) Immunosuppression~Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed."
214960412|NCT02867800|DRUG|Fludarabine|"(Standard Conditioning Regimen)~Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes."
214960413|NCT02867800|DRUG|Melphalan|"(Standard Conditioning Regimen)~Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete."
214960414|NCT02867800|DRUG|Thiotepa|"(Standard Conditioning Regimen)~Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour."
214960415|NCT02867800|DRUG|Cyclosporine|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml."
214960416|NCT02867800|DRUG|Tacrolimus|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml."
214960417|NCT02867800|DRUG|Methotrexate|"(Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight."
214960418|NCT02867800|DRUG|Abatacept|"(Investigational)~Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted."
214960419|NCT02867800|PROCEDURE|Marrow infusion|"(Standard)~A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer"
214960420|NCT02867800|DRUG|Sirolimus|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
214352826|NCT01703364|DRUG|Lenalidomide|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
214352827|NCT05428735|PROCEDURE|Embolization|Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
214352828|NCT02497573|OTHER|Diffuse Weighted MRI|The DW MRI scans will be used to measure ADC and to calculate change in ADC between the 2 scans. Each scan will take approximately 30 minutes. Images will be acquired and analysed as per the separate scanning protocol.
214486945|NCT06742554|DRUG|Tramadol|"Tramadol: Administered orally or intravenously at a standard dose of 100 mg every 8 hours, based on patient-reported pain levels.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine."
214486946|NCT03950076|DRUG|Edoxaban|Edoxaban 60mg (or 30mg as determined by clinical criteria)
214352829|NCT01374542|PROCEDURE|Respiratory endoscopy|Bronchoscopy, thoracoscopy, endobronchial ultrasound
214352830|NCT03695172|DRUG|Ropivacaine|Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine
214352831|NCT03695172|PROCEDURE|TAP block|Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
214352832|NCT03695172|BIOLOGICAL|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
214352833|NCT03695172|PROCEDURE|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
214352834|NCT02486328|DRUG|Midazolam|Dosage adjustment
214352835|NCT02486328|DRUG|Meperidine|Dosage adjustment
214352836|NCT02486328|DRUG|Remifentanil|Dosage adjustment
214960421|NCT02867800|DRUG|Mycophenolate Mofetil|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
214960422|NCT04792307|OTHER|Neuromuscular electrical stimulation , no high protein ice cream supplementation|"A trained operator applies Neuromuscular electrical stimulation treatment to one leg, for approximately 30 minutes per session, three sessions per week with or without high protein ice cream. Treatment can stimulate the nerve controlling the vastus lateralis muscle in the thigh or the nerve controlling the tibialis anterior muscle in the lower leg, or both. In our study, we will aim to stimulate both nerves and muscle groups, on the basis that the maximal effect with result from the maximal amount of muscle stimulated.Treatment is adjusted to generate a specific force and maintained for up to 5 minutes, followed by a rest period and then repeated three times over the typical 30-minute session. The stimulation can vary according to the frequency (pulses per second, typically 10-50Hz).~Additional protein supplementation: high protein ice cream :a single doses of a high protein supplement after each bout of neuromuscular electrical stimulation,"
214960423|NCT01937585|BEHAVIORAL|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
214352837|NCT02486328|DRUG|Propofol|Dosage adjustment
214352838|NCT05406687|OTHER|Health Navigator Model|The Health Navigator Model will be a longitudinal, person-centered and community-based intervention focused on addressing both primary and secondary cancer prevention, as well as reducing wider barriers to healthcare. Health Navigators (HNs) will be professionals who have a background in social care and an understanding of the local user population, and will be embedded in settings familiar and accessible to people experiencing homelessness. The primary aspects of the HN role will be to identify the health needs and barriers of users, promote cancer awareness and education, facilitate timely access to healthcare services and cancer screening, provide practical assistance, delivered through regular in-person meetings, and utilize wider stakeholders, including healthcare professionals, to deliver the intervention. A comprehensive training package will be delivered to the HNs, covering population specific knowledge, interpersonal skills, cancer education and local resources.
214352839|NCT06372470|OTHER|Zestril|N/A, this is an observational study.
214960424|NCT01937585|BEHAVIORAL|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
214960425|NCT01392456|PROCEDURE|Insertion of two screw type dental implants|Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
214960426|NCT02485756|OTHER|Educational handout|Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
214960427|NCT03932916|DRUG|Donepezil Pamoate for Injection 17mg|A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.
214960428|NCT03932916|DRUG|Donepezil Pamoate for Injection 34mg|A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.
214352840|NCT05672992|OTHER|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
214352841|NCT03936686|OTHER|Survey tool to assess CVD risk factor knowledge|The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.
214352842|NCT02968784|DEVICE|ExAblate MRgFUS|ExAblate treatment of prostate cancer less than or equal to Grade 7
214352843|NCT01143948|DRUG|Glargine & Glulisine|Basal Glargine \& bolus Glulisine
214352844|NCT01143948|DRUG|Regular insulin|Sliding scale regular insulin
214352845|NCT01143948|DRUG|NPH & regular insulin|Basal NPH \& bolus regular insulin
214352846|NCT04084808|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
214352847|NCT04084808|BEHAVIORAL|Cognitive flexibility|"Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise."
214352848|NCT04084808|PROCEDURE|Brain oxygenation|"Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~\[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). \] Measured with near-infrared spectroscopy (NIRS)."
214352849|NCT04084808|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
214352850|NCT04084808|PROCEDURE|Blood glucose|Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
214352851|NCT04084808|BEHAVIORAL|Perceived exertion|Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, \& Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
214352852|NCT04084808|BEHAVIORAL|High Intensity Interval Training bouts|6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
214352853|NCT03461068|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.
214352854|NCT03461068|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.
214352855|NCT01754831|DEVICE|Fluoride varnish|Topical application of fluoride varnish on present teeth
214352856|NCT06242444|DRUG|Experimental Dentifrice|Dentifrice containing 1150 ppm fluoride and 5% KNO3.
214352857|NCT06242444|DRUG|Placebo Control Dentifrice|Dentifrice containing 0 ppm fluoride and 5% KNO3.
214352858|NCT06242444|DRUG|Reference Dentifrice|Dentifrice containing 1100 ppm fluoride as SnF2.
214486947|NCT03950076|OTHER|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy as determined by the local investigator includes i) No antithrombotic therapy ii) Antiplatelet monotherapy, including de novo indication for antiplatelet monotherapy during course of the study
214960429|NCT03932916|DRUG|Donepezil Hydrochloride 5mg|A tablet of 5mg Donepezil Hydrochloride will be administered once.
214960430|NCT05061433|OTHER|Mobile Integrated Healthcare/Community Paramedicine (MIH/CP) Support|MIH/CP provider and their team will offer additional support and connection to resources after patient is discharged from hospital.
214960431|NCT02147392|DRUG|[11C]ER-176|
214960432|NCT00463125|DRUG|Platelet Gel|
214486948|NCT06891573|BEHAVIORAL|Lifestyle Management|For 16 weeks, participants will receive exercise, cognitive training, nutrition education, and disease education through a smartphone app, and the content and intensity of the intervention will be adjusted every four weeks through an assessment of frailty symptoms through the app.
214486949|NCT06888973|BIOLOGICAL|Mesenchymal Stem Cells|allogeneic bone marrow-derived mesenchymal stem cells therapy
214960433|NCT03189069|DRUG|Apixaban|Treatment for NVAF patients
214960434|NCT03189069|DRUG|Dabigatran|Treatment for NVAF patients
214960435|NCT03189069|DRUG|Rivaroxaban|Treatment for NVAF patients
214960436|NCT03189069|DRUG|Warfarin|Treatment for NVAF patients
214486950|NCT06888973|OTHER|Placebo|0.9% Saline as placebo
214960437|NCT04798872|OTHER|Web-based educational program|The mothers and fathers will be provided a website that consist of 6 session. at the end of the session, the lactation consultant will do video call to the mothers to discuss the questions from mothers and fathers. after delivery, telephone counseling will be conducted by lactation consultant to mothers at 2, 4, and 6. weeks postpartum
214960438|NCT00758134|DRUG|Trastuzumab (Herceptin)|Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
214960439|NCT01315795|DRUG|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
215079398|NCT05285475|OTHER|Exercise and Water Intake|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
215079399|NCT02466074|DRUG|Acetazolamide|see arm description
215079400|NCT02466074|DRUG|Placebo|Placebo arm
215079401|NCT01617135|DRUG|CVT-301|
215079402|NCT01617135|DRUG|Placebo|
215079403|NCT01617135|DRUG|Sinemet (carbidopa/levodopa)|
215079404|NCT01617135|DRUG|CVT-301|
215079405|NCT01421316|RADIATION|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
214352859|NCT02208180|BEHAVIORAL|Return of genomic results on cardiovascular disease risk|"Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study."
214678861|NCT00916721|DRUG|Propranolol|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
214960440|NCT02588664|OTHER|COMPASS Intervention|"* A Post-Acute Coordinator (PAC) will visit each patient prior to discharge from the hospital.~* Patient will receive a follow-up telephone call two days after having been discharged.~* 7-14 days after discharge, the patient will attend post-acute stroke clinic visit and receive an assessment from an Advanced Practice Provider (APP), a brief patient-reported functional assessment to generate an individualized Care Plan, and referrals from an APP. The patient's primary caregiver will be assessed to ensure caregiver availability and ability to support the patient and the caregiver's ability to cope with the new challenges of caregiving.~* Patient will receive a call at 30 and 60 days post-discharge for follow-up of functional status, recovery, risk factor management and their access or utilization of recommended services."
214960441|NCT04565821|DEVICE|IPD Probe via TNIT|A total of 10 healthy adult volunteers will be enrolled in this study. All consented participants will be receive the same intervention. A Nasal tube will be inserted through nares until reaching the small intestine. This will be confirmed by m-mode OCT. Once secured, we will start infusing Ionic solution into the intestine so that IPD Probe can measure the potential difference between this and the control reading. The control reading is measured by infusing the same ionic solution subcutaneously on large muscle groups.
214960442|NCT04400981|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
214960443|NCT04400981|OTHER|standard medical therapy|"Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
214960444|NCT00002823|DRUG|cisplatin|
214960445|NCT00002823|DRUG|etoposide|
214960446|NCT00002823|DRUG|vinblastine sulfate|
214960447|NCT00002823|DRUG|vindesine|
214960448|NCT00002823|DRUG|vinorelbine tartrate|
214960449|NCT00002823|RADIATION|radiation therapy|
214960450|NCT00429650|BEHAVIORAL|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
214352860|NCT01303666|PROCEDURE|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
214352861|NCT01303666|PROCEDURE|TI of the knee|"This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles."
214352862|NCT00054353|DRUG|fludarabine phosphate|Given IV
214486951|NCT06891326|DEVICE|sham transcranial Alternating Current Stimulation|we use fade-in, short-stimulation, fade-out (FSF) stimulation pattern, with 60s-long fade-in/out periods, 2.0mA peak current at the beginning and the end of stimulation session
214352863|NCT00054353|DRUG|melphalan|Given IV
214352864|NCT00054353|RADIATION|total-body irradiation|Undergo TBI
214352865|NCT00054353|DRUG|mycophenolate mofetil|Given PO
214352866|NCT00054353|DRUG|cyclosporine|Given PO
214352867|NCT00054353|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
214352868|NCT00054353|PROCEDURE|peripheral blood stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
214352869|NCT00054353|OTHER|laboratory biomarker analysis|Correlative studies
214352870|NCT01048528|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
214486952|NCT06891326|DEVICE|active tACS|The active tACS protocol lasted for 40 min of continuous sine-wave stimulation with the frequency of 10Hz and an amplitude ranging from 1.5mA to 2.0mA, adjusted according to the tolerability among individuals.
214486953|NCT06890546|DIETARY_SUPPLEMENT|Nigella Sativa Oil capsule|8 weeks 2 x 900 mg Nigella Sativa oil capsule daily
214486954|NCT06890546|BEHAVIORAL|Diet|Low calorie diet intervention
214486955|NCT06745271|DRUG|[14C]-tebapivat|Oral Capsule
214960451|NCT00429650|BEHAVIORAL|diet|Use a prescribed diet to maintain weight loss
214960452|NCT00429650|BEHAVIORAL|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
214960453|NCT00553527|PROCEDURE|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
214960454|NCT02720861|GENETIC|DNA sequencing|withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene
214960455|NCT04848753|COMBINATION_PRODUCT|Toripalimab combined with cisplatin and paclitaxel|Specified doses on specified days.
214960456|NCT04848753|COMBINATION_PRODUCT|Placebo combined with cisplatin and paclitaxel|Specified doses on specified days.
214960457|NCT01429298|DRUG|Hydromorphone|2 mg IV hydromorphone over to 2-3 minutes
214960458|NCT01429298|DRUG|Usual care|Attending administers IV opioid of his choosing
214960459|NCT02852057|DRUG|timolol maleate and dorzolamide hydrochloride|Timolol maleate and dorzolamide hydrochloride loaded contact lenses
214960460|NCT01734590|DIETARY_SUPPLEMENT|Carbohydrate based food mix 1|Carbohydrate based food
214960461|NCT01734590|DIETARY_SUPPLEMENT|Carbohydrate based food mix 2|Carbohydrate based food
214960462|NCT01734590|DIETARY_SUPPLEMENT|Control carbohydrate based food|Carbohydrate based food
214960463|NCT03592784|BEHAVIORAL|Food Order Therapy|Instructing patient to, whenever possible, eat carbohydrates at the end of their meal.
214960464|NCT03592784|BEHAVIORAL|Medical Nutrition Therapy|Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.
214960465|NCT02420483|OTHER|Cardiopulmonary resuscitation chest compressions|
214960466|NCT00029861|DRUG|Rimonabant (SR141716)|
214960467|NCT03433859|DRUG|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose
214960468|NCT03433859|OTHER|Topical Aluminium Chloride (cosmetic product)|Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb
214960469|NCT03214549|PROCEDURE|gull wing preparation of laminates veneers|preparation involving mesial and distal extension further lingualy.
214960470|NCT03214549|PROCEDURE|conventional preparation of laminates veneers|preparation not involving mesial and distal extension further lingualy.
214960471|NCT03075189|DIETARY_SUPPLEMENT|Whey protein supplement|"During hospitalization the intervention group will receive a whey protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Both groups have diet registration and testing at baseline, discharge and follow-up."
214678862|NCT00916721|DRUG|Placebo|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
214960472|NCT00619125|OTHER|palm pilot recording responses to questionnaires|Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
214960473|NCT00143468|BEHAVIORAL|mechanical ventilation|measurement of specific lung elastance during mechanical ventilation
214960474|NCT03927586|OTHER|cognitive training|We will be using commercialized cognitive-based training programs in order to facilitate several cognitive functions. We will be targeting attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance different types of cognitive functions. Cognitive program difficulty will be adjusted automatically and continuously based on each participant's level of performance.
214960475|NCT03927586|OTHER|physical exercise training|The physical exercise programs will involve balance or strength training or aerobic exercises. These may include (but not limited to) stepping, walking, dancing, ball kicking and throwing, and etc. The exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period. The exercise intensity will be progressed as the participants improve their performance throughout practice. To prevent exercise-induced injuries, vital signs and the Borg Perceived Exertion Scale will be monitored and recorded in each training session. If the training therapist observed that the exercise may be too intense for the participants, he/she will immediately reduce the training intensity.
214960476|NCT04086381|DIETARY_SUPPLEMENT|Creatine monohydrate|5 grams of creatine monohydrate, four times daily, for 9 consecutive days.
214960477|NCT04086381|DIETARY_SUPPLEMENT|placebo cellulose|oral ingestion of placebo containing 20 gram cellulose daily
214960478|NCT00696995|DRUG|biphasic insulin aspart 30|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
214960479|NCT00453830|PROCEDURE|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
214960480|NCT01171469|BIOLOGICAL|Dendritic Cells|5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
214960481|NCT01171469|DRUG|Imiquimod|Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
214960482|NCT05111938|BEHAVIORAL|Friends, Family, and Food App (F3A-App)|
215079406|NCT00864669|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
214352871|NCT03843229|DRUG|Cinobufacini injection|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
214352872|NCT03843229|PROCEDURE|Transarterial Chemoembolization(TACE)|TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
214352873|NCT03843229|DRUG|cinobufacini tablet|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
214486956|NCT06745271|DRUG|[13C2,15N3]-tebapivat|Intravenous Solution
214486957|NCT05578651|DEVICE|SternaLock XP|Plating system with cable cerclage bands that is used in the stabilization and fixation of fractures of the anterior chest wall, including sternal fixation following sternotomy
214486958|NCT06892392|PROCEDURE|ICG administration|"For the administration of ICG, it is necessary to perform a gastroscopy by the Digestive Service of each center, with sedation 24 h before surgery. For this, the lesion is located by gastroscopy, after which it is injected in 4 quadrants in the submucosa, with a total volume of 2 ml.~To prepare the ICG, 0.5 ml (containing 0.625 mg of ICG) is dissolved in 1.25 mg/dl of sterile water"
214486959|NCT06742255|DRUG|Stellate Ganglion Block|Stellate ganglion block is an injection of local anesthetic at the level of the neck to target the stellate ganglion, a sympathetic ganglion to interrupt abnormal autonomically-mediated pain in patients resistant to medical treatment
214486960|NCT06744205|BIOLOGICAL|Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1|"* Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection"
214960483|NCT01603199|DIETARY_SUPPLEMENT|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
214960484|NCT04910737|PROCEDURE|extended posterior circumferential decompressive surgery|After the pedicle screws were implanted, laminectomy was performed. Kyphotic correction was done through a temporary rod to reduce the tension of spinal cord. The posterior 1/3 of the vertebral body was resected using a high-speed drill, preserving the anterior wall of the spinal canal to protect the cord from disturbance. The dissection of adhesion at the anterior side of spinal cord was to be done through a posterolateral direction. The region of posterior resection was expanded, including bilateral residual articular processes, transverse processes and pedicles. Slightly press down the ossified lesion, and detach it from the dura mater (perform a sharp dissection if necessary) followed by completely removal. If cerebrospinal fluid leakage was encountered during the process, autologous fat, fascia or gelatin sponge can be applied locally for packaging.
214960485|NCT04542811|OTHER|Acupuncture|Acupuncture is a complementary therapy modality which is used by needle inserted the specific points on the body.
214960486|NCT05735405|BEHAVIORAL|Neuropsychological evaluation|Each participant will undergo a complete neuropsychological evaluation, both before and at the end of the clinical trial, with the aim of detecting any changes or improvements.
215079407|NCT00864669|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
215079408|NCT00325676|DRUG|Pantoprazole|
215079409|NCT00355342|DRUG|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
215079410|NCT00355342|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
215079411|NCT00355342|DEVICE|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
214352874|NCT03317977|BEHAVIORAL|Reach for Control|In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
215079412|NCT01740544|OTHER|Cathodal tDCS|Cathodal tDCS applied over the right PPC
215079413|NCT01740544|OTHER|Sham tDCS|Sham tDCS applied over the right PPC
214352875|NCT03317977|BEHAVIORAL|MATCH|Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.
214486961|NCT06744205|BIOLOGICAL|TIV mRNA-neuraminidase (NA)|"* Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection"
214486962|NCT06744205|BIOLOGICAL|TIV mRNA-HA Vaccine 2|"* Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection"
214486963|NCT06744205|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe~* Route of administration: Intramuscular injection"
214678863|NCT01797029|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
215079414|NCT00299780|DRUG|Stem cell mobilization|
215079415|NCT01034371|PROCEDURE|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
214352876|NCT02246517|DRUG|N2O|
214352877|NCT02246517|DRUG|Oxygen|
214352878|NCT02076152|DEVICE|FMISO PET|
215079416|NCT01034371|PROCEDURE|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
214352879|NCT02076152|DEVICE|MRI|"MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2\*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
214678864|NCT01797029|BIOLOGICAL|Placebo|A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
214960487|NCT05735405|BIOLOGICAL|BDNF evaluation|During the first and last clinical trial session, each participant will undergo two blood samples, one before and one at the end of the ride, to check levels of Brain Derived Neurotrophic Factor (BDNF).
214960488|NCT05735405|BEHAVIORAL|Pedaling as a moderate intensity aerobic exercise|During each session, each participant will perform 30 minutes of pedaling as a form of moderate intensity physical activity.
214960489|NCT05735405|OTHER|Cognitive Training|During each session, each participant will carry out 60 minutes of cognitive training through specific exercises for the attentional, executive and working memory functions.
214960490|NCT05735405|DIAGNOSTIC_TEST|VO2 assessment|"To determine the individual moderate intensity for each patient, a VO2 consumption assessment will be made. The examination will be carried out using an exercise bike and a mask for the calculation of metabolic oxygen consumption.~The 3 MET threshold to reach in pedaling will be calculated (to define it of moderate intensity), in order to elicit the release of BDNF."
214960491|NCT01330199|OTHER|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
214960492|NCT06443047|DEVICE|TTS suturing system|The use of TTS suturing system could allow a quick, complete endoscopic closure of colonic post-ESD defects, providing relevant clinical and medico-economic benefits.
214960493|NCT04839432|BEHAVIORAL|implementation of albumin solution in the priming of the cardiopulmonary bypass machine|In March 2019, the investigators initiated a new priming fluid policy strategy aiming at replacing our traditional pure crystalloid fluid administration for an albumin one in order to decrease the relatively high-rate of observed pulmonary complications
214960494|NCT04324515|PROCEDURE|Robotic gastric bypass with or without cholecystectomy|Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy
214960495|NCT02008006|DRUG|BeEAM|"High Dose Chemotherapy (HDT) containing :~* Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)~* Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)~* Melphalan 140 mg/m2 on D-2~HDT will be followed by an Autologous Stem Cell Transplantation on D0"
214960496|NCT05420831|PROCEDURE|Vaginal|Sacrospinous hysteropexy using the synthetic mesh
214960497|NCT05420831|PROCEDURE|Laparoscopic|Laparoscopic Sacrohysteropexy
214960498|NCT03052348|OTHER|Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
214960499|NCT03052348|OTHER|Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
214960500|NCT01270360|DEVICE|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
214960501|NCT00002073|DRUG|Epoetin alfa|
214960502|NCT02461056|DRUG|Ibuprofen|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
214960503|NCT02461056|DRUG|Hydromorphone|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
214960504|NCT02614508|DRUG|Buparlisib|Given PO
214960505|NCT02614508|DRUG|Ibrutinib|Given PO
215079417|NCT01034371|PROCEDURE|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
215079418|NCT04415996|OTHER|HVLA L3/4|"The participant will be lateral decubitus and the investigator will locate the third lumbar vertebra. Then with one hand the investigator will contact the interspinous space underlying L3 and with the other hand he will take the top leg into flexion until the investigator feels tension in L3/L4 joint. Then he puls the tables´s arm until felling tension in the region to be manipulated. Afterwards the investigator will globally rotate the participant in the horizontal plane and will approach to the L3/L4 joint. With one arm the investigator will contact the deltopectoral groove and with the other one will contact the external iliac fossa. Finally, the investigator will compress and rotate the pelvis and will apply an impulse in a rapid rotation, without losing the parameters with a body drop allowed by the flexion of the knees and the contraction of the large pectorals."
214352880|NCT02076152|DRUG|Bevacizumab|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
214960506|NCT02614508|BIOLOGICAL|Ofatumumab|Given IV
214960507|NCT06004323|BEHAVIORAL|Digital health literacy intervention|Participants from the intervention group will be invited to join virtual or face-to-face training, watch short videos on social media, participate in virtual bi-weekly group discussion, and fill in questionnaires for five times during the course of the study
214960508|NCT06467539|DRUG|DAOIB plus AO|oral, for 24 weeks
214960509|NCT06467539|DRUG|DAOIB plus placebo|oral, for 24 weeks
214352881|NCT02076152|DRUG|CCNU|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
214352882|NCT03346876|PROCEDURE|Nuss surgery|surgical correction for pectus excacatum
214352883|NCT02635880|DEVICE|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
214352884|NCT00278434|DRUG|Zoledronate|
214960510|NCT02226263|DIETARY_SUPPLEMENT|probiotics Lactobacillus acidophilus boucardii|Using sterile technique, the probiotic with 1x109 \[CFU\] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
214960511|NCT03448172|DRUG|[14C]PF-05221304|a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)
214960512|NCT05709405|OTHER|Reading intervention|"The intervention will use a reading program called Lesing for alle (Reading for all) based on the research of Accessible Literacy Learning (ALL) which is an evidence-based approach, designed to teach reading skills to students with various intellectual disabilities, including autism spectrum disorders"
214960513|NCT04129294|DRUG|NS-089/NCNP-02|"NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~\[Part 1\] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks \[Part 2\] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks."
214960514|NCT03387657|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
214960515|NCT03387657|DRUG|Hydrochlorothiazide|"Pharmaceutical form: Tablet~Route of administration: Oral"
214960516|NCT02983253|OTHER|blood sample|none, only laboratory tests on blood serum
215079419|NCT04415996|OTHER|Sham|The participant will be in lateral decubitus and the top leg and knee will be flexed until the foot reaches the popliteal region of the other leg. There won't be applied any tension in no structure. This intervention will be applied during 20 seconds each side.
215079420|NCT02087813|DRUG|Alpha1-antitrypsin|
215079421|NCT02087813|DRUG|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
214960517|NCT04229771|DRUG|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
215079422|NCT03790800|DRUG|urapidil|A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.
215079423|NCT03204552|OTHER|No intervention (observational study)|No intervention (observational study)
215079424|NCT04348175|DRUG|Setmelanotide|Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.
215079425|NCT00951249|BEHAVIORAL|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
214352885|NCT00278434|OTHER|Placebo (Saline)|
214352886|NCT03199625|BEHAVIORAL|Cognitive therapy|
214352887|NCT03199625|BEHAVIORAL|Behavior therapy|
214960518|NCT04229771|DRUG|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
214960519|NCT06005090|PROCEDURE|Far Cortical Locking Technique|Apart from the traditional 3 point fixation of the locking screw this technique compromises two point fixation of the screw where one into the plate and the other is into the far cortex of the diaphysis. The near cortex was widened by 3.2 mm of dirll bit to eliminate the fixation of the screw into the near cortex
214960520|NCT02903420|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
214960521|NCT06351085|BEHAVIORAL|Pre-Visit Planner|The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process.
214960522|NCT06351085|BEHAVIORAL|Pre-Visit Planner + MyChart|The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process as well as testing if watching educational videos about the Lung Cancer Screening (LCS) process prior to talking to an LVN will help with LCS uptake.
214960523|NCT00227019|DRUG|Bevacizumab|15 mg/kg, IV over 10 minutes every 3 weeks
214960524|NCT00227019|DRUG|Pemetrexed|500 mg/m²; IV over 10 minutes every 3 weeks
214352888|NCT03199625|DRUG|SSRI antidepressants|
214352889|NCT00005076|BIOLOGICAL|cetuximab|
214352890|NCT00005076|DRUG|irinotecan hydrochloride|
214352891|NCT00496665|DRUG|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
214352892|NCT00496665|DRUG|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
214352893|NCT00496665|DRUG|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
214352894|NCT05080400|DIETARY_SUPPLEMENT|White rice|Jasmine rice 179g of cooked weight
214352895|NCT05080400|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
214352896|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
214352897|NCT00727272|DRUG|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
214352898|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
214352899|NCT03680599|BEHAVIORAL|Connection to Health for Smokers|Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.
214352900|NCT03680599|BEHAVIORAL|Enhanced Standard of Care|Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators
214352901|NCT05595304|PROCEDURE|prosthetic refunctioning|Active treatment followed by regular interventions
214960525|NCT00227019|DRUG|Vitamin B12|1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed
214960526|NCT00227019|DRUG|Folate|350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose
215079426|NCT00951249|BEHAVIORAL|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
215079427|NCT00951249|BEHAVIORAL|Peer health care system navigators|HIV/STI treatment and other medical and social services
214352902|NCT05595304|PROCEDURE|conventional prosthetic treatment|new prosthesis
214352903|NCT00242112|PROCEDURE|MRI Prostate|
214960527|NCT00227019|DRUG|Dexamethasone|4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
214960528|NCT02555085|BIOLOGICAL|BIIB063|Single ascending IV dose
214960529|NCT02555085|OTHER|Placebo|Single dose
214960530|NCT03812445|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus,Bifidobacterium lactobacillus,Lactobacillus paracasei,Lactobacillus rhamnosus and Lactobacillus fermentium with does of 8\*10\^9 Colony-Forming Units(CFU) \*2/d for 3 months.
214960531|NCT01454011|DRUG|Testosteron 250mg injection|The combination of 4 different testosterone esthers (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate) injected in 3 weeks intervals.
215079428|NCT00951249|BEHAVIORAL|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
215079429|NCT06352528|DRUG|Repotrectinib|Specified dose on specified days
215079430|NCT05648149|BEHAVIORAL|hierarchical multi-dimensional cognitive training scheme based on computer|The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
215079431|NCT01416441|DRUG|Aripiprazole|Aripiprazole tablets orally once daily.
215079432|NCT01666639|BEHAVIORAL|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
214352904|NCT01736228|DEVICE|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
214352905|NCT02882568|BIOLOGICAL|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
214352906|NCT02573519|RADIATION|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) \[11C\]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
214486964|NCT06744205|BIOLOGICAL|Quadrivalent Influenza Vaccine High Dose|"* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe~* Route of administration: Intramuscular injection"
214960532|NCT01454011|DRUG|Testosterone 50mg transdermal application|Application of testosterone 50mg transdermal gel in every night
214486965|NCT06741527|DEVICE|Integrity Implant System|Integrity Implant System used for Rotator Cuff Repair
214486966|NCT06742138|DRUG|QL2109|QL2109 will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
214486967|NCT06742138|DRUG|Pomalidomide|Intervention Description：Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle
214960533|NCT05123352|OTHER|collection of biological samples and clinical data|blood and feces samples
214960534|NCT06810167|DRUG|Tenapanor|CF patients with CFrC will ingest one 50 mg tablet of tenapanor twice daily for 4 weeks.
214960535|NCT06650566|DRUG|LM-299|Q2W/Q3W,Intravenous Drip
214960536|NCT03510897|DRUG|teprasiran|IV injection
214960537|NCT03510897|DRUG|Placebo|isotonic saline
214960538|NCT03786185|BEHAVIORAL|MusicPlast|"Each subject will receive 20 sessions of the computerized training based on a simplified music reading protocol. The training will be provided via a smartphone or a tablet. Each training session will last for 20 minutes and the log file will be directly available to the researcher, allowing him/her to follow subject's timely participation. The stimuli used in the training protocol will consist of a visual image showing a circle on top of a background of 5 horizontal lines. The auditory part of the stimulus will consist of piano melodies of known songs. The position of the circle within the five lines will either follow the rule the higher the pitch of the tone, the higher the position of the circle or it will violate the above rule. The task requires audiovisual integration."
214960539|NCT03786185|BEHAVIORAL|MusicPlast Control|Each subject will receive 20 sessions of the computerized training within a period of 4 weeks, aiming to train visual search via spot-the-difference tasks and identification of dissonance in music. Auditory and visual stimuli are concurrently presented, but do not require audiovisual integration.
214960540|NCT05849792|BEHAVIORAL|Exercise and psychological intervention|"Physical Exercise Intervention~Sixty-minute sessions were delivered via internet, three times per week (1 supervised) over the first four weeks of the COVID-19 home confinement. The intervention was a multicomponent exercise program lead by a specialist in fitness composed of aerobic, resistance, balance, coordination, mobility and stretching exercises. Each multicomponent exercise session consisted of a 10 min warm-up, 40 min of moderate to vigorous intensity physical activity, and 10 min cool down.~Psychological intervention~The internet-based-psychological intervention provided to different component of Cognitive Behavioral Therapy (CBT) guided and recorded by a sport neuro-psychologist specialist. The iCBT is based on the protocol for face-to-face CBT for depression. The program consisted of 4 weeks composed of 2 weekly video-guided sessions, with a maximum duration of 30 minutes. iCBT was focused on 4 main axes of action physiological, emotional, behavioral and cognitive."
214352907|NCT02573519|DEVICE|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~1. A wireless electromagnetic capsule to be swallowed by the subject~2. A portable detector plate comprising four sensors worn in a belt around the waist~3. Specific software for visualizing and analyzing data"
214352908|NCT02573519|DRUG|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
214352909|NCT02573519|DEVICE|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
214352910|NCT00651664|DRUG|alisertib|Alisertib (MLN8237) capsules
214352911|NCT03438162|BEHAVIORAL|Education|Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
214352912|NCT04027153|OTHER|Fee based delivery|Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
214352913|NCT01988246|DRUG|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
214960541|NCT01476306|OTHER|Telemedicine|Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
214960542|NCT01476306|OTHER|Usual care|Patients in this group will receive care as they usually do with the physician.
214960543|NCT02005900|DRUG|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART|Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
214960544|NCT01350375|DRUG|Botox|
214960545|NCT01350375|DRUG|Saline|
214960546|NCT05398705|DRUG|Cepharanthine|Low-dose: Day 1\~5: 20mg, Q8H X 5 days (60mg/day)+SMT
214960547|NCT05398705|DRUG|Placebo|"Day 1\~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc."
214960548|NCT05398705|DRUG|Cepharanthine|"High-dose: Day 1\~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc."
214960549|NCT03092791|BIOLOGICAL|Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)|sIPV intramuscular injection
214960550|NCT03092791|BIOLOGICAL|Reference IPV|Reference IPV intramuscular injection
214960551|NCT03092791|BIOLOGICAL|sIPV Placebo|sIPV placebo-matching intramuscular injection
214960552|NCT04093557|OTHER|Orton Score|Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.
214960553|NCT04093557|OTHER|Typical Standard of Care|Clinician usual practice of prescribing bowel preps to patient
214960554|NCT04608890|DIAGNOSTIC_TEST|Eye-tracking video test|An eye-tracking-based test will be administered to patients. It lasts 10 minutes. It consists in several screens passing by to identify objects at a certain time by a mouse clic or touchpad.
214960555|NCT02151214|OTHER|Parenteral nutrition|Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted
214960556|NCT06266949|DIAGNOSTIC_TEST|SONDA|Perimetry based visualfield analysis
214960557|NCT03247881|OTHER|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
214960558|NCT03247881|OTHER|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
214352914|NCT01988246|DRUG|Sham|Sham injection. No actual injection. No medication is used.
214352915|NCT01027546|DRUG|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
215079433|NCT01666639|BEHAVIORAL|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
215079434|NCT05052437|DRUG|Utidelone Injection; capecitabine|8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
215079435|NCT05052437|DRUG|Utidelone|8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
215079436|NCT04627675|DRUG|CORVax|DNA-encodable coronaviral vaccine
215079437|NCT04627675|DRUG|IL-12 plasmid|cytokine
215079438|NCT04627675|DEVICE|Cliniporator|electroporation system
215079439|NCT02653495|BIOLOGICAL|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
215079440|NCT01399892|DIETARY_SUPPLEMENT|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
214960559|NCT00797394|DIETARY_SUPPLEMENT|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
214960560|NCT00797394|DIETARY_SUPPLEMENT|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
214960561|NCT01284751|OTHER|MDI - self-rating inventory|MDI with 12 questions to be completed approximately 1 week before surgery
214960562|NCT03743844|BEHAVIORAL|Compassion-focused psychoeducation group|Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
214960563|NCT04539548|DRUG|Dextenza Ophthalmic Insert|0.4mg insert for intracanalicular use
215079441|NCT02952482|PROCEDURE|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
215079442|NCT02648451|DIETARY_SUPPLEMENT|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
215079443|NCT00046163|DRUG|midodrine hydrochloride (ProAmatine®)|
215079444|NCT03251859|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
215079445|NCT03251859|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg daily
215079446|NCT00860834|BEHAVIORAL|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
214960564|NCT04539548|DRUG|Prednisolone acetate ophthalmic suspension USP 1%|"1 drop at end of surgery, followed by:~1 drop 4 x QID for one week.~1 drop 3 x QID for one week.~1 drop BID for one week.~1 drop QD for one week"
214960565|NCT00104793|DRUG|carboplatin|
214960566|NCT00104793|DRUG|irinotecan hydrochloride|
214960567|NCT02868736|DEVICE|Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test|
214352916|NCT03839953|BEHAVIORAL|Supervised Exercise Program|This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
214352917|NCT03839953|OTHER|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
214352918|NCT00688636|DRUG|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
214352919|NCT00688636|DRUG|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
214352920|NCT01572727|DRUG|Paclitaxel|intravenous paclitaxel 80 mg/m2 per week given until progression
214960568|NCT02491970|DRUG|Fluticasone/Formoterol|
214960569|NCT02491970|DRUG|Fluticasone/Salmeterol|
214960570|NCT05887362|BEHAVIORAL|Hand Reflexology|Reflexology is a well-known, safe, and noninvasive alternative medicine technique. It alludes to a treatment that is applied to particular areas of the hands and feet. The compression on the hands or feet serves as a sensor linked to particular body areas. These sensors are activated by the reflexology technique to improve blood flow, energize, relax, and maintain homeostasis.
214960571|NCT06988423|DRUG|CRS3123 200 mg capsule|CRS3123 200 mg capsule given as a single oral dose
214960572|NCT04741646|DRUG|Ferric Citrate|Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC will be supplied as 200 tablets in 400cc high-density polyethylene bottles.
214960573|NCT04741646|DRUG|Placebo|Placebo to match Ferric Citrate tablets
214960574|NCT06197646|DEVICE|Cartoon characters inhaler mask|Cartoon characters inhaler mask
214960575|NCT00781924|PROCEDURE|biopsy|ultrasound guided biopsy of tumors.
214960576|NCT02589834|OTHER|Quran group|
215079447|NCT00860834|BEHAVIORAL|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
215079448|NCT05079633|BIOLOGICAL|Homologous boost schedule|1st dose mRNA 1273 , 2nd dose mRNA 1273
215079449|NCT05079633|BIOLOGICAL|Heterologous boost schedule|1st dose mRNA 1273 , 2nd dose MVC COV1901
215079450|NCT02796885|OTHER|no intervention - observational study|
215079451|NCT04125056|DRUG|Hydronidone Capsule(Specification: 30 mg / grain）|Test group
215079452|NCT04125056|DRUG|Hydronidone Capsule(Specification: 15 mg / grain）|Control group
215079453|NCT00313768|DRUG|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
215079454|NCT00313768|DRUG|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
215079455|NCT01696344|PROCEDURE|PVAI|
214960577|NCT05817214|DRUG|Cadonilimab|All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1
214352921|NCT01572727|DRUG|BKM120 matching placebo|"Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area."
214352922|NCT01572727|DRUG|BKM120|Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
214352923|NCT02020954|PROCEDURE|ECG, echocardiography, cardiac MRI, sera biomarkers|
214352924|NCT03734731|DEVICE|Monochromatic Infrared Photo Energy (MIRE)|Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve
214352925|NCT03734731|DEVICE|Transcutaneous Electrical Nerve Stimulation|Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve
214352926|NCT03734731|DRUG|Opioids|Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
214352927|NCT03734731|DRUG|Cannabis|Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
214960578|NCT05817214|DRUG|Anlotinib|All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.
214960579|NCT05817214|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|All Participants will have subcutaneously injection of granulocyte-macrophage colony-stimulating factor from day 1 to day 14, then take a 7 days break.
214960580|NCT01860144|DRUG|Bevacizumab|
214960581|NCT05168072|DEVICE|m-Health app|M-Health app is used to set weight loss targets and record body weights online. Participants learn the calories they consumed by using the m-Health APP and follow the APP for physical exercise
214960582|NCT05168072|OTHER|conventional outpatient obesity management|Diet and exercise guidance
214960583|NCT03601572|OTHER|No intervention|No intervention
214960584|NCT06294444|OTHER|Constraint Induced Movement Therapy|Group A: This group patients will be treated with mCIMT, the forced use of the affected arm by restraining the unaffected arm, with a sling or a hand splint, during dedicated exercise sections or usual ADLs (90% of waking hours).Massed practice (eight hours of exercise) of the affected arm through a shaping method, where shaping involves a commonly operant conditioning method in which a behavioural objective (in this case 'movement') is approached in small steps of progressively increasing difficulty. The participant is rewarded with enthusiastic approval for improvement, but never blamed or punished for failure. This therapy will be given 4hrs daily for 6 weeks. The results will be based upon pre and post evaluation.
214960585|NCT06294444|OTHER|Mirror therapy|Group B: These patients will be treated with mCIMT and mirror therapy. Children were taught repetitive symmetrical upper limbs exercises: with modelling-clay in each hand to elicit bilateral thumb-finger pinch and grasping. They performed these during a 15-minute daily routine at home with mCIMT (forced use of arm and massed practice 4hrs of exercise of affected arm). This combination of therapy will be given for 6 weeks. The results will be seen through pre and post evaluation.
214960586|NCT03679819|DEVICE|HR-TRUS|Medical procedures to be performed in the study consist of subject preparation and prostate imaging. The HR-TRUS exam will be done with a transrectal probe either the day before surgery, or in the OR right before surgery. The exam will be done in the same manner as during a regular transrectal ultrasound exam and no invasive procedures will be associated.
214960587|NCT03852498|GENETIC|Lenti-D|Participants received a single IV infusion of Lenti-D Drug Product.
214352928|NCT04556708|OTHER|salin irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
214352929|NCT04556708|OTHER|ozonated water irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
214352930|NCT04556708|OTHER|chlorhexidine irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
214352931|NCT04053764|DRUG|Crizanlizuamb|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
214486968|NCT06742138|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
214486969|NCT06742138|DRUG|DARZALEX FASPRO®|DARZALEX FASPRO® will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs
214960588|NCT05447767|DEVICE|KIT BMAC|intra-articular infiltration of BMAC
214960589|NCT05447767|DEVICE|KIT BMAC|intra-articular and intra-osseous infiltration of BMAC
214960590|NCT05447767|DEVICE|at-SVF FIDIA|intra-articular infiltration of at-SVF
214960591|NCT05447767|DEVICE|at-SVF FIDIA|intra-articular and intra-osseous infiltration of at-SVF
214960592|NCT06608095|BEHAVIORAL|hypothermia group|Minimize the temperature of the thermometric tank or thermometric catheter for rapid temperature control. Use a thermometric catheter to monitor changes in the patient's core body temperature in real time. When the core body temperature drops to 34 ℃, adjust the target temperature of the temperature-controlled water tank to 34 ℃ and adjust the target temperature of the temperature-controlled water tank in real time according to the patient's core body temperature. Keep the core body temperature around 34 ℃. Maintain the body temperature at 34℃ for at least 24 hours after the patient resumes autonomous circulation. After the patient has resumed voluntary circulation for 24 hours, the rewarming process can begin. The target temperature of the temperature control tank will increase at a rate of 0.2°C/h. After reaching 36°C, maintain the current temperature. Once 36°C is reached, the current temperature is maintained until autonomic circulation has been restored for 5 days.
214352932|NCT04053764|DRUG|Standard of Care|HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
214352933|NCT06216457|DEVICE|AI software for Stroke|AI Software for Non-Contrast Head CT (Computed Tomography) and CT Angiography, utilized for Code Stroke screening, notification and triage.
214352934|NCT04313231|DIAGNOSTIC_TEST|Next Generation Sequencing|"Sequencing of patient samples will be performed in the facilities of ZIMCL. Following DNA extraction, the sequencing of granulocytes as well as of lymphocytes (control) will be carried out. IN addition to whole exome sequencing, a panel from SOPHIA GENETICS (which is also available for routine diagnostics) will be applied including the following MDS specific genes: ASXL1, BRAF, CBL, CEBPA, CSF3R, DNMT3A, EZH2, FLT3, HRAS, IDH1, IDH2, KRAS, MPL, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1, ZRSR. Each patient sample will be bulk sequenced, meaning that relevant mutations are detected down to an allele frequency of 2%."
214352935|NCT04313231|DIAGNOSTIC_TEST|Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction|"Inflammasome activation is quantified by analyses of inflammasome-associated cytokine patterns. Multiplex assays for the quantification of the inflammasome-specific cytokines will be done from serum as well as from supernatants the stimulated blood cells. Cytokine quantification is carried out with Luminex FlexMap 3D. Serum cytokine levels will be quantitated in parallel.~Quantification of RNA expression levels of inflammasome-related gene products will be performed by qPCRs from unstimulated and stimulated (=cryotube) blood cells. The necessary RNA extraction will be performed using a RNA extraction kit."
214352936|NCT04313231|DIAGNOSTIC_TEST|flow cytometry|A detailed evaluation of the individual immune status is being conducted by the analysis of two specialized panels: Panel A provides a broad overview over various immune cell populations, while Panel B identifies T-cell sup-populations.
214486970|NCT06743737|DEVICE|Digital skin test reading device|The device to be studied measures optically the size of the wheals from skin tests (SPT) performed for the diagnosis of allergen sensitization.
214960593|NCT06608095|BEHAVIORAL|normothermia group|Set the temperature of the temperature-controlled water tank or the in vivo cooling catheter to 37°C to maintain the patient's core temperature between 36.5-37.5°C. Real-time monitoring of the patient's core temperature changes through the thermometric urinary catheter, and real-time adjustment of the temperature of the temperature-controlled water tank. The patient's temperature was maintained between 36.5-37.5°C after the patient resumed voluntary circulation until the end of temperature control 5 days after the recovery of voluntary circulation.
214960594|NCT06609031|PROCEDURE|endoscopic mucosal resection|The SSLs less than 10mm in size in this group will be treated by EMR
214960595|NCT06609031|PROCEDURE|Cold snare polypectomy|The SSLs less than 10mm in size in this group will be treated by CSP
214960596|NCT02115061|DEVICE|Treatment: coil + cyanoacrylate|This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
214960597|NCT02115061|DEVICE|Treatment: cyanoacrylate|This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
214960598|NCT03025347|OTHER|Control|Participants complete a resting control condition instead of a run.
214960599|NCT03025347|OTHER|Exercise|Participants complete a 60 minute run at 70% of their maximal oxygen uptake
214960600|NCT04532411|OTHER|Personal Protective Testing Booth|Health personnel who utilize the Hexapod will remain in the booth and utilize durable gloves attached to ports through a plexiglass wall in order to administer a nasal swab for SARS-CoV-2 (COVID-19) testing. Patient escorts and housekeeping/sanitation staff perform additional tasks outside of the booth such as escorting the patient to the correct testing bay and dropping off testing vials and printed information, collect samples and deposit in the appropriate location after testing is complete, and sanitizing the patient bay before a subsequent patient is tested there.
214960601|NCT01403259|DRUG|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
214960602|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
214960603|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 50 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
214486971|NCT06892626|PROCEDURE|RIRS|RIRS performed in lithotomy position for which guide wire pass to the kidney, then passing ureteral dilators up to 14F and ureteral access sheath. Dusting stones by RIRS and holmium laser Fiber 200 mm, at the end of operation DJ was fixed.
214486972|NCT06892626|PROCEDURE|PNL|PNL performed in prone position, after passing guide wire and ureteric catheter in lithotomy position. Puncture to the kidney, passing 2 wires, then using renal dilators and access sheath to enter kidney by nephroscopy, fragment stones by pneumatic and remove stones, then place nelaton 28F at end of operation
214960604|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
214960605|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 200 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
214960606|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 300 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
214960607|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 450 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
215079456|NCT01696344|PROCEDURE|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
215079457|NCT00042068|DRUG|Meloxicam|
215079458|NCT04855955|DRUG|Adipose-Derived Mesenchymal Stem Cells|
214486973|NCT06894186|OTHER|Gaenial universal injectable|GC Gaenial universal injectable advanced injectable composite with nano sized filler that merge the adaptation of flowable composite and mechanical properties of hybird composite
214960608|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 600 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
215079459|NCT05111106|DEVICE|Symfony IOL|Implantation of Intraocular lens with extended depth of focus.
215079460|NCT06127355|DRUG|500 mg of ursodeoxycholic acid (UDCA)|Administration of 500 mg of ursodeoxycholic acid (UDCA) /day
214352937|NCT04313231|DIAGNOSTIC_TEST|Metagenomics of stool samples|DNA will be extracted from frozen fecal samples applying a bead-beating method using a GNOME DNA Isolation Kit (MP Biomedicals). DNA quality will be assessed using an Agilent 4200 TapeStation (Agilent Technologies). After final precipitation, DNA samples will be re-suspended in TE buffer and stored at -80 °C for further sequencing analysis. To this end, sequencing libraries will be generated using a Nextera XT DNA Sample Prep Kit (Illumina). Library quality will be confirmed using an Agilent 4200 TapeStation. Whole-genome shotgun sequencing of fecal samples will be carried out on a HiSeq2500 platform (Illumina).
214352938|NCT04313231|DIAGNOSTIC_TEST|Clinical/demographic data|Demographic and clinical data include: age, age at initial diagnosis, sex, diagnosis, actual comorbidities, medication at inclusion in study, cytogenetic and molecular profiles and standard laboratory parameters (blood count, differential leukocyte count, biochemistry, iron status, inflammatory markers like CRP, albumin, fibrinogen).
214352939|NCT04313231|OTHER|Elicitation of the HRQoL|Evaluation of HRQOL, of functional activities and of performance status will be done by the patient and/or the physician using validated scores.
214352940|NCT04657146|OTHER|Biorepository|"Tumor collection (\> 1cm3): Intraoperatively~Peripheral blood collection:~* Intraoperatively (60mL)~* Post-resection (30mL)~* Post- standard of care treatment (30mL)~Bone marrow aspiration:~* Intraoperatively (10mL)~* Post-resection (5mL)~* Post- standard of care treatment (5mL)"
214352941|NCT03872349|OTHER|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
214352942|NCT03872349|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
214960609|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
214960610|NCT07023133|BEHAVIORAL|Weight loss|All participants will have self selected for bariatric surgery and their weight loss and mitochondrial function will be measured in this study.
214960611|NCT06624969|OTHER|virtual reality|Virtual reality program to reduce pain in orthopedic fractures
214352943|NCT02384954|BIOLOGICAL|Rituximab|Intravenous infusion 375 mg/m\^2.
214960612|NCT07021729|DRUG|Clarithromycin|Drug regimens will be given for 14 days, and omeprazole for 6weeks
214352944|NCT02384954|BIOLOGICAL|N-803|Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.
214352945|NCT05509296|DEVICE|SINOMED CBC|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
214352946|NCT05509296|DEVICE|NSE Coronary Dilatation Catheter|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
214352947|NCT04541238|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging
214352948|NCT00003951|DRUG|exatecan mesylate|
214352949|NCT05638867|DRUG|Aspirin + Clopidogrel + Rivaroxaban|Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily
214352950|NCT05638867|DRUG|Aspirin + Clopidogrel|Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily
214960613|NCT07021729|DRUG|Levofloxacin|Drug regimens will be given for 14 days, and omeprazole for 6weeks
214960614|NCT07022691|DEVICE|Lafayette dynamometer:|Lafayette dynamometer will be used for assessment of muscle strength Flexible tape measurement will be used for assessment of WC and hip circumference.
214960615|NCT07023068|DIAGNOSTIC_TEST|68Ga-DPA PET/CT|Use 68Ga-DPA PET/CT in the diagnosis of lung cancer
214960616|NCT07022977|BIOLOGICAL|MET233|For subcutaneous administration
214960617|NCT07022977|BIOLOGICAL|Placebo|Sterile 0.9% (w/v) saline for subcutaneous administration
214960618|NCT07020572|BEHAVIORAL|Brief Interpersonal Psychotherapy - Adolescent Skills Training (B-IPT-AST)|This is an adolescent depression prevention program consisting of 6 sessions (4 group and 2 individual sessions).
214960619|NCT07020572|BEHAVIORAL|Services as usual (SAU)|Services as usual (SAU) involves any mental health services adolescents decide to receive in primary care or in the community. It is possible that adolescents in SAU may decide not to participate in any mental health services.
214960620|NCT07022860|BIOLOGICAL|Platelet-rich fibrin (PRF)|Platelet-rich fibrin (PRF) is an autologous blood-derived material prepared by centrifuging the participant's venous blood without anticoagulants. The PRF clot is then compressed into a membrane and inserted into the extraction socket. It serves as a scaffold rich in platelets and growth factors to support bone regeneration and healing.
214960621|NCT07021846|RADIATION|hypofractionated radiotherapy with tumor bed boost|hypofractionated radiotherapy with concomitant/simultaneous tumor bed boost
214960622|NCT07022873|OTHER|ACT-ED: Acceptance and Commitment Therapy based eating disorder prevention program|This intervention protocol was developed specifically for women who have body dissatisfaction and disordered eating behaviors. Based on the psychological flexibility model (hexaflex), it is designed to improve people's body image flexibility using Acceptance and Commitment Therapy techniques. Interventions related to the dimensions of the hexaflex were made during each session. The first session covers values and goal setting. The second session includes creative hopelessness, acceptance, and self-compassion. The third session covers defusion and mindfulness. The last session focuses on self-as-context exercises and the combined use of skills for committed action.
214960623|NCT07022522|DEVICE|5Hz stimulation on the STN motor subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the motor subregion of the subthalamic nucleus at a low frequency of 5Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the motor subregion using neuroimaging verification.
215079461|NCT06127355|OTHER|500 mg of Placebo|Administration of 500 mg of placebo /day
214960624|NCT07022522|DEVICE|5Hz stimulation on the STN associative subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the associative subregion of the subthalamic nucleus at a low frequency of 5Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the associative subregion using neuroimaging verification.
214352951|NCT04291963|PROCEDURE|DGG + TUN|In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation
214352952|NCT04291963|PROCEDURE|SCTG + TUN|In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
214352953|NCT00566267|DRUG|simvastatin 20 mg/ezetimibe|see protocol
214352954|NCT03288662|OTHER|CT and histopathological classification|Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
214352955|NCT00890955|DRUG|Amrubicin|"* Dose Level -1: 20mg/m2~* Dose Level 1: 25mg/m2~* Dose Level 2: 30mg/m2~* Dose Level 3: 35mg/m2~* Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
214352956|NCT00890955|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
214352957|NCT01612403|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
214960625|NCT07022522|DEVICE|130Hz stimulation on the STN motor subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the motor subregion of the subthalamic nucleus at a high frequency of 130Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the motor subregion using neuroimaging verification.
214960626|NCT07022522|DEVICE|130Hz stimulation on the STN associative subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the associative subregion of the subthalamic nucleus at a high frequency of 130Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the associative subregion using neuroimaging verification.
214960627|NCT07022522|DEVICE|No stimulation|"In this control arm, Parkinson's disease patients will not receive active deep brain stimulation, with the DBS system maintained in an off state throughout the testing period."
214960628|NCT07022431|OTHER|Interval strength training|"The intervention involves interval strength training with biofeedback and real-time decision-making for Alzheimer\&amp;amp;#39;s patients. Participants will complete 24 sessions, each including a circuit of strength exercises using rotational inertial devices (flywheels). Exercises, such as leg press, seated row, and bicep curl, will be randomly ordered, with load progression based on performance stability. Each session includes five sets per exercise, performed in a circuit, with a total of 15 sets over approximately 45 minutes. Real-time monitoring using a rotary encoder will track effort, and participants will continue each set until a 30% drop in average power is detected, ensuring consistent relative effort across sets.~Additionally, participants will engage in cognitively demanding tasks during training by verbally reporting the average power of the previous repetition while performing the next one. This dual-task approach aims to maximize both physical and cognitive engagement."
214960629|NCT07021638|OTHER|EMMVIES program|Walking Training at Home in VIrtual Reality for Children with Chronic Illnesses Impacting Physical Health
214960630|NCT07021690|OTHER|High glyceamic index meal|Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with high glycemic index.
214960631|NCT07021690|OTHER|Low glyceamic index meal|Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with low glycemic index.
214960632|NCT07021703|BIOLOGICAL|Freeze-dried Human Rabies Vaccine（Human Diploid Cell）, Essen|"This vaccine is produced by Ningbo Rongyu Biological Pharmaceutical Co., Ltd.. Participants will receive AIM2301 by intramuscular injection.~Receive on the day 0, 3, 7, 14 and 28, a total of 5 doses"
214352958|NCT01692340|OTHER|Isotopically labeled lycopene, phytoene or phytofluene|We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
214960633|NCT07021703|BIOLOGICAL|Freeze-dried Human Rabies Vaccine（Human Diploid Cell），Zagreb|"This vaccine is produced by Ningbo Rongyu Biological Pharmaceutical Co., Ltd.. Participants will receive AIM2301 by intramuscular injection.~Receive 2 doses on day 0, 1 dose on day 7 and day 21, a total of 4 doses."
215079462|NCT01209455|DRUG|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
214352959|NCT06041035|DRUG|QLS31905|Administered as an intravenous infusion.
214352960|NCT06041035|DRUG|Nab paclitaxel|125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
214352961|NCT06041035|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
214352962|NCT06041035|DRUG|Oxaliplatin|85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
214352963|NCT06041035|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.
214352964|NCT06041035|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
214352965|NCT01557413|PROCEDURE|Intramedullary nail|the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.
214960634|NCT07022808|OTHER|Synchronous Group exercise|Participants will participate in the TEEMS biweekly for 8 weeks (synchronous intervention). The synchronous group will attend sessions 2 times per week, with all sessions recorded. The sessions will be 60-minutes total, including 45-minutes of physical activity. Recorded sessions will be made available for participants to use on their own at the end of each week, building a video of 16 videos. The program will be taught by a rehabilitation clinician with expertise in SCI and adapted exercise while our co-instructor will offer peer guidance and demonstrate lived translation of movement with an SCI. Class will take place over a web-based platform (such as Zoom).TEEMS instructors also orient participants to the Borg Rate of Perceived Exertion (RPE, 6-20 scale) to be used as an self-exertion check throughout class and to be recorded in a provided logbook. RPE is used as a self-assessment of moderate-vigorous intensity exercise.
214960635|NCT07022808|OTHER|Asynchronous exercise (Control)|Participants will participate in the TEEMS biweekly for 8 weeks (asynchronous video library). The asynchronous, control group will be provided with 2 recorded videos weekly that align with the synchronous group sessions, building a 16 video library as well. The sessions will be 60-minutes total, including 45-minutes of physical activity. The program will be taught by a rehabilitation clinician with expertise in SCI and adapted exercise while our co-instructor will offer peer guidance and demonstrate lived translation of movement with an SCI. Class will take place over a web-based platform (such as Zoom).TEEMS instructors also orient participants to the Borg Rate of Perceived Exertion (RPE, 6-20 scale) to be used as an self-exertion check throughout class and to be recorded in a provided logbook. RPE is used as a self-assessment of moderate-vigorous intensity exercise.
214960636|NCT07022834|DRUG|Dabrafenib or Trametinib and Clofarabine|"Drug: Dabrafenib or Trametinib Dabrafenib: 3-5 mg/kg/day; Trametinib: 0.025mg/kg/day~Drug: Clofarabine Consolidation therapy: 25 mg/m2/d, days 1-5 Maintenance therapy: 25 mg/m2/d, days 1-2"
214960637|NCT07022652|PROCEDURE|Esophageal cancer resection|Esophageal cancer resection
214960638|NCT07021677|DRUG|Daratumumab Injection|"Patients will receive intravenous daratumumab (16mg/kg per dose) once weekly for 2 doses. After 2 doses, they will undergo bone marrow examination for flow-cytometric MRD. Those who become MRD negative (less than 0.01% by flow-cytometry), will be off-study and continued on conventional treatment regimen as per institution policy. Hence, total duration in those who become MRD negative will be 3 weeks.~However, those who are still MRD positive (more than or equal to 0.01% by flowcytometry) after two doses, will be given two additional once weekly doses of intravenous daratumumab (16mg/kg per dose). In patients who receive two additional doses, bone marrow aspirate for MRD analysis will be done 7 days after fourth dose of daratumumab. Irrespective of MRD result after fourth dose, patients will be continued on conventional treatment regimen"
214960639|NCT07022587|DEVICE|Sirolimus-eluting bioresorbable scaffolds|The Firesorb BRS (MicroPort Medical, Shanghai, China) is a balloon-expandable scaffold with a highly crystallized PLLA backbone, abluminally coated with a poly(D, L-lactide) (PDLLA) matrix incorporating sirolimus (4 μg/mm) through highly accurate and precise point spraying techniques. The scaffold thickness is 100 μm for devices with diameters of 2.5 and 2.75 mm, and 125 μm for those ranging from 3.0 to 4.0 mm in diameter. There are two radiopaque markers at each end of the scaffold, which can identify the position of the stent under X-ray monitoring and help to accurately locate the scaffold.
214960640|NCT07022587|DEVICE|Sirolimus-eluting stents|The Firehawk™ stent (MicroPort Medical, Shanghai, China) is a third-generation balloon-expandable L605 cobalt chromium stent with abluminal grooves containing a biodegradable polymer, which provides controlled release of the anti-proliferative medicinal substance sirolimus. The polymer is biodegradable, leaving only the metallic stent as a permanent implant. The stent is mounted on a rapid exchange delivery catheter system. The unique abluminal grooves are scored at the outer surface of the struts (total strut thickness: 86 μm), with an average sirolimus dosage of 3 µg/mm stent lengths.
214960641|NCT07022496|DRUG|Caffeine (200 mg)|caffeine tablets
215079463|NCT01209455|DRUG|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of \~12 mg/l. To achieve a desired concentration of \~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
215079464|NCT01209455|DRUG|Paracetamol|To achieve a local paracetamol concentration of \~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
215079465|NCT02662153|OTHER|Observation only|No intervention.
215079466|NCT00953680|DRUG|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
215079467|NCT00953680|DRUG|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
215079468|NCT00953680|DRUG|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
215079469|NCT03359057|DRUG|ethinyl estradiol + levonorgestrel + folic acid|One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).
215079470|NCT03359057|DRUG|Folic Acid|One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).
215079471|NCT00858741|RADIATION|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
215079472|NCT00858741|RADIATION|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
215079473|NCT06137378|BIOLOGICAL|KEYTRUDA®|200 mg KEYTRUDA® i. v. in 3-week cycle (q3w)
215079474|NCT01360398|PROCEDURE|Blood sample|Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
215079475|NCT01360398|PROCEDURE|Sputum sample|Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
214352966|NCT01557413|PROCEDURE|Locked plate|the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
214352967|NCT02596815|PROCEDURE|Median Nerve Neural Mobilization|Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
214486974|NCT06892808|PROCEDURE|Non-Surgical Periodontal Therapy|"Under local anesthesia, full-mouth debridement (supragingival and subgingival scaling and root planing, FM-SRP) was performed by an experienced periodontist, initiated within 48 hours post-atrial fibrillation ablation and completed in two sessions within 48 hours. Polishing was performed using a rubber cup with prophylaxis paste. The procedure utilized Gracey curettes and piezoelectric ultrasonic tips combined with a force-controlled system.~Postoperative Care Immediate Care: Local Adjunctive Therapy: 2% minocycline gel was injected into deep periodontal pockets (PD ≥5mm). Antimicrobial Rinse: 0.12% chlorhexidine solution (15 mL, 30-second rinse twice daily) for 14 days.~Follow-Up Intervention At the 6-month follow-up, additional oral debridement was performed in the intervention group if indicated by the presence of bleeding points and/or increased probing pocket depth (PPD)."
214960642|NCT07022496|DRUG|triptans|Sumatriptan
214960643|NCT07022496|DRUG|NSAID (Nonsteroidal anti-inflammatory drugs)|Aspirin 250 mg, 81 mg, 75 mg
214960644|NCT07022496|DRUG|Paracetamol (acetaminophen)|Paracetamol 250 mg
214960645|NCT07023263|DEVICE|Schnider+ Mİnto|Patients assigned to the Standart TCI model Group would have Schnider + Minto models throughout the surgery. The patients would be monitorized with anesthesia depth, analgesia monitoring, NIRS, and recovery parameters.
214960646|NCT07023263|DEVICE|Eleveld|Patients assigned to the Eleveld TCI model Group would have Eleveld+Eleveld models throughout the surgery. The patients would be monitorized with anesthesia depth, analgesia monitoring, NIRS, and recovery parameters.
214960647|NCT07021716|OTHER|No Interventions|No Interventions
214960648|NCT07021599|DIAGNOSTIC_TEST|Tailored AI echocardiogram analysis and reporting system|In the AI analysis and reporting pathway, sonographers only need to acquire the echocardiogram images, then the AI algorithm will complete the analysis and report drafting for final endorsement by experienced cardiologists. To ensure blinding of group assignment to the endorsing experienced cardiologists, measurement format and reporting phrases and interface used by AI and sonographers will be standardized.
214960649|NCT07023250|OTHER|manual dexterity and coordination skills|"The outcomes were assessed by the use of Bruininks-Oseretsky Test scale of motor proficiency (BOT-2) subtests (3,4\&7) for Manual Dexterity, Bilateral Coordination and Upper Limb Coordination respectively. The Bruininks-Oseretsky Examination of Motor Proficiency, Second Edition, evaluates motor performance in various areas such as Manual Dexterity, Bilateral Coordination and Upper Limb Coordination.~It utilizes subtests and complex structures to diagnose developmental and coordination issues among individuals aged four to twenty-one years old. The test is norm-referenced and purpose-oriented to assess motor abilities. The reliability and validity of the test were 0.78 and 0.84, respectively (Kosari et al., 2013; Ebrahimi et al., 2017; Yassin et al., 2020)."
214960650|NCT07022795|BEHAVIORAL|Educational video combined with daily surveys|Participants will receive the same educational intervention as those in the other arm and will also undergo an ecological momentary assessment (EMA) intervention. This will involve receiving multiple messages per day on their mobile phones, each linking to an online survey designed to capture real-time data on their current oral behaviors. The intervention aims to increase participants' awareness of these behaviors by prompting them to reflect on and report them throughout the day.
214960651|NCT07022795|BEHAVIORAL|Educational video only|"Participants will be provided with an educational video on recognizing and managing oral behaviors such as clenching, prolonged tooth contact, and keeping the jaw tense, etc.~The goal is to increase awareness and promote behavior change to reduce strain to the masticatory muscles and the temporomandibular joint."
214960652|NCT06698471|OTHER|Community worker training|Training community workers in Self Help Plus intervention, a 5 session self-help intervention based on Acceptance and Commitment Therapy
214960653|NCT06698471|OTHER|Referral to Health System|Referral to Health System of Senegal
214960654|NCT03013413|PROCEDURE|Shear Wave Elastography|Undergo ultrasound-based elastography imaging using the Aixplorer system
214960655|NCT03013413|PROCEDURE|Ultrasound Elasticity Imaging|Undergo ultrasound-based elastography imaging using the Aixplorer system
214960656|NCT03013413|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo standard of care ultrasound-guided prostate biopsy
214960657|NCT06877650|DRUG|JMT108|Intravenous (IV) administration every two weeks (D1, D15) in a 4-week cycle.
214960658|NCT06171594|COMBINATION_PRODUCT|Chlorhexidine mouthwash|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of Chlorhexidine (CHX) mouthwash on healthy control and people with dental erosion (PwDE). This study aims to explore mouthwash's effect on oral microbiome recovery in WMS and salivary pellicle and its impact on blood pressure and arterial stiffness in healthy controls PwDE
214960659|NCT05644977|DRUG|Emraclidine|Oral tablets
214352968|NCT02596815|DEVICE|Goniometer|
214352969|NCT06344312|DRUG|Yangxue Qingnao Granules|When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
214960660|NCT05644977|DRUG|Placebo|Oral tablets
214960661|NCT03207308|DIETARY_SUPPLEMENT|Vitamin A supplementation|200,000 IU of preformed vitamin A
214960662|NCT06730984|OTHER|Endoscopy-Assisted Tracheal Intubation|Tracheal Intubation Under Endoscopic Guidance
214960663|NCT06730984|OTHER|Traditional Tracheal Intubation|Tracheal Intubation Under Video Laryngoscopy
214960664|NCT02514200|PROCEDURE|Topography-based CXL (KXL2)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
214960665|NCT02514200|PROCEDURE|Conventional pulsed CXL (pCXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
214960666|NCT02514200|DRUG|Riboflavin|Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
214960667|NCT02514200|DEVICE|Avedro KXL II|The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
214960668|NCT00980655|BIOLOGICAL|13vPnC|"0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.~Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose."
214960669|NCT00980655|BIOLOGICAL|23vPS|0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
214960670|NCT05861206|OTHER|GT-MW group (5% Green tea), WT-MW group (5% White tea),EO-MW group (Listerine mouthrinse)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (5% Green tea, 5% White tea or Listerine mouthrinse) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
214960671|NCT05861206|OTHER|CHX-MW group (0.12% CHX, as a positive control group)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (0.12% CHX) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
214960672|NCT06006377|OTHER|electrotherapy|hotpack electrotherapy ultrasound exercises
214960673|NCT06006377|OTHER|Backup therapy|The backup spine health device is in the form of a mat and provides segmental electrical stimulation to the spines. At the same time, the mat can heat up to 40 degrees during the treatment process. Backup spine health device is very effective in both reducing pain and strengthening the muscles with electrical stimulations by reaching even the deep muscles around the spine. Sessions consist of 30 minutes
214960674|NCT01415726|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 \~ 7 hrs.
214960675|NCT04439058|OTHER|ultrasound guided left stellate ganglion block|"Stellate Ganglion Block (SGB) has several established clinical indications Under complete aseptic precautions an ultrasound guided left stellate ganglion block was performed. (paratracheal technique ) ( ) The patient was placed in the supine position with the head in the neutral position and slightly extended. An initial scanning was done with the ultrasound to identify the structures in this area.~The US probe was placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra was identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia were sought anterior to the C6 vertebral body and deep to the carotid artery. After skin infiltration with local anesthetic, the needle was inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
214960676|NCT06386159|OTHER|Comprehensive Intervention or Comprehensive Intervention Combined with Electrical vagus nerve stimulation|Comprehensive intervention includes multidisciplinary collaboration, screening and assessment, oral sensory training, oral motor training, respiratory training, and feeding management. Transcutaneous electrical stimulation of the vagus nerve at the lateral neck was performed by rehabilitation therapists. The cervical vagus nerve accompanies the carotid artery and is located at the groove between the trachea and the sternocleidomastoid muscle, which can be located by touching the carotid pulse. The two electrodes were pasted along the path of the cervical vagus nerve.
214960677|NCT00552890|OTHER|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
214960678|NCT00552890|OTHER|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
214960679|NCT02992756|DRUG|Growth Factors|one dose 3-6 mL of PRP obtained by PRGF Endoret
214960680|NCT04692272|BEHAVIORAL|Exercise in the XBOX kinect|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
214486975|NCT06892808|PROCEDURE|Background Periodontal Care|All study participants received oral hygiene instruction using the modified Bass technique. At baseline, supragingival deposits (dental plaque and calculus) were removed with an ultrasonic scaler or rubber cup with prophylaxis paste. To maintain blinding, simulated subgingival instrumentation sounds were played during the procedure for control group participants.
214960681|NCT02599064|DRUG|RXI-109|RXI-109 dosed intravitreally to subjects with NVAMD
214960682|NCT05194943|PROCEDURE|revisional bariatric surgical procedures|Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
214352970|NCT03400891|BEHAVIORAL|Program based on the theory of planned behaviour|14 sessions of one hour to work TPB constructs: attitude, subjective norms, perceived behavioural control and intention.
214352971|NCT06028269|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone) during movement
214960683|NCT01796275|BEHAVIORAL|Core intervention program|
214960684|NCT01796275|BEHAVIORAL|Booster session|
214960685|NCT01796275|BEHAVIORAL|Control only (Tea gathering)|
214960686|NCT00814723|DRUG|fluvastatin|80 mg MR, 12 weeks
214960687|NCT00814723|DRUG|Fluvastatin plus ezetimibe|fluvastatin 80 mg MR plus ezetimibe 10 mg
214960688|NCT00622492|OTHER|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
215079476|NCT01360398|PROCEDURE|Nasopharyngeal swab|Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
215079477|NCT01360398|PROCEDURE|Urine sample|Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
214960689|NCT01353391|DRUG|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
215079478|NCT01360398|PROCEDURE|End tidal breath sample|Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
215079479|NCT01360398|OTHER|Data collection|Patient interview, diary cards review and questionnaires completion
214352972|NCT01474681|BIOLOGICAL|HSC835|
214352973|NCT00907829|DRUG|lidocaine|comparison of the effect of the drug to help improve finger function
214352974|NCT00907829|DEVICE|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
214352975|NCT02457039|PROCEDURE|Dense cranial electroacupuncture stimulation|"DCEAS is a is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz)."
214960690|NCT01353391|DRUG|Placebo Comparator|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
214960691|NCT03939533|DRUG|CUTAQUIG|Human normal immunoglobulin
215079480|NCT01360398|OTHER|Tests|Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
214486976|NCT06888648|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
214486977|NCT06888648|DRUG|mFOLFIRINOX Treatment Regimen|continuous intravenous infusion of fluorouracil 2400mg / m², for 46 hours, leucovorin 400mg / m², irinotecan 135mg / m², and oxaliplatin 68mg / m², every 2 weeks
214486978|NCT06888648|DRUG|Sintilimab injection|Sintilimab Injection, 200mg, intravenous infusion, every 3 weeks
214486979|NCT06668077|DEVICE|iTBS of the left DLPFC|Participants will receive a 3 minutes active theta burst transcranial magnetic stimulation (iTBS) of the DLPFC of the left hemisphere while not performing any other task
214486980|NCT06668077|DEVICE|iTBS of the vertex|Participants will receive a 3 minutes active theta burst transcranial magnetic stimulation (iTBS) of the vertex while not performing any other task
214960692|NCT00774072|DRUG|Tobramycin (Gernebcin®)|1 ml / day in each nostril
214960693|NCT06751446|OTHER|Scenario-based Simulation Skill Training|Scenario-based simulation is an educational approach that immerses students in realistic clinical scenarios, allowing them to practice decision-making and problem-solving in a safe, controlled environment. It challenges students to assess patient data, identify priorities, and implement interventions. Through guided debriefing sessions, students reflect on their actions, justify their decisions, and explore alternative strategies.
214960694|NCT06751446|OTHER|Traditional Skill Training|Traditional skill training in nursing education focuses on developing core technical skills through direct instruction, demonstrations, and hands-on practice. It emphasises mastery of essential tasks and conducting patient assessments. Students follow standardized protocols and procedures to ensure patient safety and accuracy in their practice
214960695|NCT03020628|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
214960696|NCT03020628|BIOLOGICAL|NBP607-TIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
214960697|NCT05602740|DEVICE|Harmony|Passive recording of the head pulse
214960698|NCT03191565|OTHER|Paper diary sheet|Writing skill-use and symptoms on a week matrix type sheet
214960699|NCT03191565|DEVICE|Monsenso DBT-app and IT monitoring program|Entering skill-use and symptoms on a smartphone with Monsenso DBT-app and IT monitoring program
214960700|NCT03232216|DIETARY_SUPPLEMENT|Vitamin D3.|Vitamin D3 50.000 UI in each packet of powder for oral solution.
214960701|NCT03232216|DIETARY_SUPPLEMENT|Placebo|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
215079481|NCT00944814|DIETARY_SUPPLEMENT|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
214352976|NCT02457039|PROCEDURE|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Wai-Guan (TE5), Zhong-Wan (CV12), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation. No electrical stimulation is delivered."
214352977|NCT02457039|PROCEDURE|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (GB17), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (GB17) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
214352978|NCT02457039|DRUG|Cytoxan-containing chemotherapy regimens|"Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) \[Adriamycin + Cytoxan\], TC (x4) \[Taxotere + Cytoxan\], AC-P (4+4) \[Adriamycin + Cytoxan + Paclitaxel\], TAC (x6) \[Taxotere + Adriamycin + Cytoxan\], or AC-PH (4+4) \[Adriamycin + Cytoxan + Paclitaxel + Herceptin\]."
214352979|NCT04421781|OTHER|Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT|Patients were treated using dedicated post-EBRT parameters (5-s pulse, 5-s waiting period, 90% of the acoustic power). Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
214960702|NCT00823758|BEHAVIORAL|Focus Groups|6 to 8 participants per group.
214960703|NCT00823758|BEHAVIORAL|Personal Interviews|Conducted by phone and audiotaped.
214960704|NCT01472133|OTHER|Recording of 12 lead ECG|Recording of 12 lead ECG
214960705|NCT01472133|OTHER|Recording of lying and standing blood pressure|Recording of lying and standing blood pressure
214960706|NCT01472133|OTHER|Recording of chest wall movement|Recording of chest wall movement
214960707|NCT01472133|OTHER|Recording of heart rate variability|Done during deep breathing and a valsalva manoeuvre
214960708|NCT01472133|OTHER|Recording of ECG and Pulse oximeter waveform at rest|For 10 mins
214960709|NCT01472133|OTHER|Recording of ECG and Pulse oximeter waveform during exercise|Recording of ECG and Pulse oximeter waveform during exercise
214960710|NCT06305663|DEVICE|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
214960711|NCT06305663|DEVICE|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens
214960712|NCT06890143|DRUG|Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks|"①Dapagliflozin+Standard Treatment for 12 weeks. Dapagliflozin therapy (Farxiga®, 10 mg tablets) is administered orally once daily,with dose adjustment based on body weight: 5 mg/day for participants ≤30 kg; 5 mg/day initially (first week), then increased to 10 mg/day for participants \>30 kg Standard Treatment:standard renin-angiotensin-aldosterone system inhibitor (RAASi) therapy(The dosage will be maintained at the pre-enrollment level throughout the entire treatment period, with no adjustments made during therapy.),This combined therapy will be administered for 12 weeks.~② Washout period for 4 weeks Participants should maintenance RAASi therapy while discontinuing dapagliflozin.~③Standard Treatment alone for an additional 12 weeks. To ensure compliance, all participants are required to complete a daily medication log.If any adverse events (AEs) occur, appropriate clinical interventions will be promptly implemented"
214352980|NCT03998618|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
214960713|NCT06890143|DRUG|Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks|"①Standard Treatment for 12 weeks Standard Treatment:Standard renin-angiotensin-aldosterone system inhibitor (RAASi) therapy alone for 12 weeks.(The dosage will be maintained at the pre-enrollment level throughout the entire treatment period, with no adjustments made during therapy.)~②Washout period for 4 weeks Participants should maintenance RAASi therapy while discontinuing dapagliflozin.~③Dapagliflozin+Standard Treatment for 12 weeks Dapagliflozin therapy (Farxiga®, 10 mg tablets) is administered orally once daily,with dose adjustment based on body weight: 5 mg/day for participants ≤30 kg; 5 mg/day initially (first week), then increased to 10 mg/day for participants \>30 kg.This combined therapy will be administered for 12 weeks To ensure compliance, all participants are required to complete a daily medication log.If any adverse events (AEs) occur, appropriate clinical interventions will be promptly implemented"
214960714|NCT06039501|BEHAVIORAL|Family Perspective Program|The program involves regular meetings between families and an ICU support counselor. The ICU support counselor is a trained expert in providing culturally competent emotional and/or spiritual support. The ICU support counselor will support families and also learn and summarize family perspectives in a standardized report. ICU care team members will be prompted to perspective take as they review reports prior to regular routine meetings between families and the ICU care team.
214960715|NCT06774807|OTHER|Saline infusion|Saline/NaCl (9mg/ml) intravenous infusion
214960716|NCT06774807|OTHER|Saline injection|Saline/NaCl (9mg/ml) subcutaneous injection
214960717|NCT06774807|OTHER|1nmol antagonist infusion|GLP-2 (1-33)/GLP-2(3-33) 1 nmol/kg/min
214960718|NCT06774807|OTHER|4 nmol antagonist infusion|GLP-2 (1-33)/GLP-2 (3-33) 4 nmol/kg/min
214960719|NCT06774807|OTHER|Agonist injection|GLP-2(1-33) subcutaneous injection
214960720|NCT00305409|DRUG|Synbiotic (Synergy I / B.longum)|
214960721|NCT05225415|DRUG|CT1812|Orally administered CT1812
214960722|NCT04091386|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice
214960723|NCT01538849|DRUG|Esomeprazole 40mg|1 tablet = Esomeprazole 40 mg
214960724|NCT01538849|DRUG|YH4808 A mg|1 tablet = YH4808 A mg
214960725|NCT01538849|DRUG|YH4808 B mg|1 tablet = YH4808 B mg
214960726|NCT01538849|DRUG|YH4808 C mg|YH4808 C mg = 2 x YH4808 B mg
214960727|NCT06843785|OTHER|Squat with knees over toes|Participants are instructed to stand comfortably with feet pelvis-width apart and approximately 15-30° to the side with arms extended in front of them. Participants are asked to squat to their most comfortable point, looking straight ahead, without heels leaving the floor, and to hold the position for 2 seconds before returning to the original standing position. The distance between the hips and the floor is measured vertically using a ruler for squat depth. Three trials are performed and the average of the three trials is used for further analysis.
214352981|NCT03998618|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
214352982|NCT01587664|DEVICE|NewBreez ILP|NewBreez ILP implantation
214352983|NCT01126983|DEVICE|Suture|Suture (2.0 Mono-filament nylon suture) will be used to secure the leads to the skin. Benzoin and Steri-strips will also be used.
214352984|NCT01126983|DEVICE|Lead Anchor|Suture (2.0 Mono-filament Nylon suture) will be applied over the lead anchor(Lead Anchor St.Jude Medical Co, model-long, No# 1106) to the skin. Benzion and Steri-strips will also be used.
214352985|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
214352986|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
214352987|NCT02047019|DRUG|Candesartan Cilexetil|Candesartan Cilexetil, 16 mg, capsule, orally, once daily
214352988|NCT02047019|DRUG|Candesartan matching placebo|Candesartan matching placebo, capsule, orally, once daily
214352989|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
214352990|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
214960728|NCT06843785|OTHER|Squat where the knee does not pass the toes|In the limited squat exercise, the position of the most anterior part of the knee is not allowed to extend beyond the toes. In the limited squat exercise, a wooden board is placed just distal to the first toe of each foot, and the 60 cm wide wooden board restricts knee movement. Participants are instructed to stand comfortably with their feet pelvis-width apart and approximately 15-30° to the side, and their arms extended in front of them. Participants are asked to squat to 90° of knee flexion, looking straight ahead, without the heels leaving the floor, and to hold the position for 2 seconds, then return to the original standing position. Squat depth is determined by measuring 90° of knee flexion using a goniometer placed on the knee and measured vertically between the hip and the floor using a ruler. Three trials are performed, and the average of the three trials is used for further analysis.
214960729|NCT06843785|OTHER|control|Participants will not be subjected to any intervention and will not be asked to perform any action.
214960730|NCT06880666|PROCEDURE|Minimally invasive laparoscopic pull-through surgery|Conventional laparoscopic pull-through (CLP) surgery utilizes 3-5 small abdominal incisions for the placement of trocars, allowing the insertion of a laparoscopic camera and surgical instruments. After establishing pneumoperitoneum, the aganglionic segment is identified, and the colon is mobilized by dividing the lateral attachments using laparoscopic energy devices. The rectal dissection is performed circumferentially down to the level of the pelvic floor while preserving the mesenteric blood supply. A transanal approach is then used to complete the dissection, pull the mobilized bowel through the anus, and resect the aganglionic segment. A coloanal anastomosis is created, typically with absorbable sutures. Single-incision laparoscopic pull-through (SILS) follows the same principles but is performed through a single umbilical incision using a multi-port device; instruments and a camera are inserted through the same access point.
214960731|NCT06745648|PROCEDURE|Arm A - Carotid Sinus Massage + Trendelenburg (CSM+T)|Manual stimulation of the carotid sinus area combined with head-down tilt positioning to activate baroreceptors for headache relief.
214352991|NCT00319098|BIOLOGICAL|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
214960732|NCT06745648|PROCEDURE|Arm B - Sham CSM+T|Light neck contact, avoiding carotid sinus pressure, paired with identical body positioning to mimic the experimental intervention.
214352992|NCT00319098|BIOLOGICAL|Fluarix|One intramuscular injection
214352993|NCT00319098|BIOLOGICAL|Placebo|One intramuscular injection
214352994|NCT01528189|OTHER|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
215079482|NCT00944814|DIETARY_SUPPLEMENT|LNS without zinc|LNS containing no zinc
215079483|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-1|Section 1: Deep breathing exercises: A deep breath is taken as far as possible by raising the arms up to the sky. Breathing is held for 4-5 seconds after deep inspiration. Breathing is performed rhythmically and slowly, while the arms are placed in a normal position. After deep inspiration, one can exhale either by forming the lips in the whistling position or by laughing. In each deep breathing exercise technique, the expiration time of the exhalation process should be longer than the inspiration time.
214960733|NCT06821087|DRUG|Ketamine only|Participants in this arm will receive four intramuscular (IM) ketamine injections over a two-week period. The initial dose will be 0.5 mg/kg during the first session, increasing to 0.65 mg/kg in the second session, and 0.75 mg/kg for the third and fourth sessions. Injections will be administered at least three days apart.
214352995|NCT01528189|OTHER|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
214352996|NCT05229289|OTHER|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
214352997|NCT05229289|OTHER|Fecal Microbiota Transplant|Fecal Microbiota Transplant
214352998|NCT06167187|PROCEDURE|bilateral inferior alveolar nerve block|Placing the tip of the thumb or forefinger into the coronoid notch (retromolar fossa) to help visualize the vertical height at which the needle will enter, and retracting the cheek to expose the pterygomandibular triangle. Placing the barrel of the syringe over the contralateral lower 1st and 2nd premolars and resting the side of the needle tip against the lateral edge of the pterygomandibular raphe, aiming the tip of the needle into the pterygomandibular triangle, with the bevel facing the ramus. Advancing the needle tip slightly into the mucosa until it is stopped by the ramus (typically after about 2 to 2.5 cm of insertion) and withdrawing needle 1 mm away from bone. Aspirating to rule out intravascular placement. If aspiration reveals intravascular placement, withdrawal of the needle will be done 2 to 3 mm, then reaspirating prior to injection. Slowly injecting about 2 to 4 milliliters of bupivacaine 0.5% anesthetic in each side..
214352999|NCT06167187|DRUG|Ketorolac and fentanyl|in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
214353000|NCT03719456|PROCEDURE|Retrograde Intrarenal Surgery|
214353001|NCT00604253|DRUG|insulin detemir|
214353002|NCT00604253|DRUG|insulin NPH|
214353003|NCT01968213|DRUG|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
214960734|NCT03516708|DRUG|Epacadostat|Drug provided.
214353004|NCT01968213|DRUG|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
214353005|NCT06496893|DIETARY_SUPPLEMENT|IP 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
214353006|NCT06496893|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
214960735|NCT03516708|RADIATION|Short-course radiation therapy|Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
214960736|NCT03516708|DRUG|CAPOX chemotherapy|Standard of care
214960737|NCT03516708|DRUG|FOLFOX chemotherapy|Standard of care
214960738|NCT00472485|PROCEDURE|eye movement therapy|
214960739|NCT04135313|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14
214960740|NCT04135313|DRUG|Oxaliplatin|130 mg/m2 iv day 1
214960741|NCT04135313|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
215079484|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-2|Section 2: Warm-up exercises (10 minutes): Hands are clapped by holding parallel to each other. The fingertips and the palms touch each other, stimulating the acupuncture points on both hands, and the individual's energy level rises. In order to further raise the energy level and synchronize the movements of the group, a rhythm is added in the form of 1-2, 1-2-3. After several rhythmic hand-clapping movements, one more movement is added. Hands are clapped by swinging left and right. Then, an audible rhythm in the form of ho, ho, ha-ha-ha is also added to the hand-clapping movement. People in the group look at each other, and smile.
214353007|NCT02173977|OTHER|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
214353008|NCT02173977|OTHER|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
214960742|NCT04135313|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions
214960743|NCT04135313|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
214960744|NCT02675270|BEHAVIORAL|Phonological|This treatment involves picture viewing and word repetition.
214960745|NCT02675270|BEHAVIORAL|Orthographic|This treatment involves picture viewing, reading, and writing.
214960746|NCT02675270|BEHAVIORAL|Semantic|This treatment involves learning about the semantic features (meaning) of each trained word.
214960747|NCT02675270|BEHAVIORAL|Lexical|This treatment involves learning about the lexical features (letters and sounds) of each trained word.
214960748|NCT02675270|BEHAVIORAL|Untrained|These words are not trained during the treatment phase.
214960749|NCT06887777|DRUG|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|The patients will orally take a dose of 200 mg/kg/day three times a day during meals: breakfast, lunch or afternoon snack and diner for 6 months.
214960750|NCT06559228|OTHER|ConnectedNest|Participants will receive a secure message to register and download ConnectedNest's patient app, EmpowerNest. They will be asked to complete a set of modules at baseline through ConnectedNest to understand their health related social needs and programs available to meet those needs. They will receive basic training on the functionality and services available within the app and asked to use the app to identify and connect with needed social and community services for 90 days. Participants will be directed to complete a survey at baseline, 30, 60, and 90 days to collect patient-reported outcomes.
214353009|NCT03044301|COMBINATION_PRODUCT|Intramuscular ZENEO® injection|Sodium Chloride (0.9 %)
214353010|NCT03044301|COMBINATION_PRODUCT|Subcutaneous high ZENEO® injection|Sodium Chloride (0.9 %)
214353011|NCT03044301|COMBINATION_PRODUCT|Subcutaneous low ZENEO® injection|Sodium Chloride (0.9 %)
214353012|NCT04303897|DEVICE|XEN Glaucoma Stent|Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
214353013|NCT05312775|PROCEDURE|Double-layer uterine closure|In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
214502643|NCT06215391|DEVICE|3d printed mask|"* Concurrent, prospective, non-randomized inclusion, cross-over design. A minimum of 6 patients will be included for each group, COPD, and ALS.~* T0: Patient enrollment (informed consent signing), retrospective review of the respirator log (1 month prior), variable extraction (extracting EDF files from the respirator log and data obtained from ResScan).~* During the first week, a 3D scan of the patient's face will be conducted, and the personalized 3D-printed mask (M3D) will be manufactured.~* Once ready, the mask will be fitted, and the 1-month evaluation period will begin (T1: after 1 month of M3D use). The respirator card will be downloaded in the same manner as at T0, and a respiratory polygraphy (RP) will be scheduled.~* T2: At the end of the study month, the patient will resume using a similar MC, which is new and well-fitted. After one month of MC use, the respirator log will be reviewed, and a new RP will be conducted."
214960751|NCT06559228|OTHER|Standard of care|Participants will be directed to complete a survey at baseline, 30, 60 and 90 days to collect patient-reported demographics, cancer characteristics and outcomes metrics
214960752|NCT06766136|BEHAVIORAL|Asthma education program|An educational program based on the Roy Adaptation Model in addition to standard asthma treatment.
214960753|NCT06929481|DEVICE|Cell free DNA (cfDNA) blood test|"The intervention is a novel blood test that evaluates circulating cell free tumor DNA (cfDNA) and detects colorectal cancer (CRC). Recently, the cfDNA test has been shown to have 83% sensitivity and 90% specificity for CRC detection, and 13% sensitivity for advanced polyp detection, heralding a new screening strategy postulated to be highly convenient and acceptable. The cfDNA test is made by Guardant Health, FDA approved for average risk colorectal cancer screening, and marketed with the brand name Shield. Patients opting for the cfDNA test will also be requested to complete an at home FIT."
214960754|NCT06929481|OTHER|At home Fecal Immunochemical Test (FIT) or Colonoscopy|The usual care group will be offered standard colorectal cancer screening options to choose from: at home FIT or colonoscopy.
214960755|NCT06178653|OTHER|Pulmonary Rehabilitation|Pulmonary rehabilitation consists of diaphragmatic, pursed-lip, and segmental breathing techniques, and also included inspiratory muscle training (will adjust 30% of maximal inspiratory pressure value)
214960756|NCT06178653|OTHER|Trunk Control Training|Trunk Control Exercises will be based on the neurodevelopmental process. Exercises will progressively include activities such as stretching, turning, etc. while sitting on different surfaces (firm/soft).
214960757|NCT06408311|COMBINATION_PRODUCT|ENC-201-CED hPI|macro-encapsulated human primary islets
214960758|NCT06618963|DRUG|Omalizumab Injection|Omalizumab is a monoclonal antibody FDA-approved for treatment of food allergy.
214960759|NCT04030325|BEHAVIORAL|Sequential Personalized Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
214960760|NCT04030325|BEHAVIORAL|Simultaneous Personalized Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
214960761|NCT04030325|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking events
214960762|NCT01124292|PROCEDURE|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
214960763|NCT01124292|DEVICE|Usability assessment|"Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.~Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions."
214960764|NCT04565899|OTHER|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
214353014|NCT05312775|PROCEDURE|Single-layer uterine closure|The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
214353015|NCT04163302|BIOLOGICAL|CD19-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
214353016|NCT02440958|DRUG|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
214353017|NCT04520984|OTHER|Integrated ambulatory palliative and nephrology care|"Monthly ambulatory care visits with the kidney palliative care team in the intervention group for three months.~The intervention in this study is addition of a palliative care team to the care team of the subject. This intervention will not change or impact their regular nephrology care. The subjects in the intervention arm will be seen by the palliative care team three times over the 12-week study period (once per month).The intervention will be delivered by a physician trained in both palliative care and nephrology, the PI of the study."
214353018|NCT04520984|OTHER|Standard nephrology care|Standard nephrology care
214353019|NCT05093036|OTHER|Variations in PrEP care delivery at public health services|Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring
214960765|NCT00348036|BEHAVIORAL|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
214960766|NCT00348036|OTHER|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
214960767|NCT03373461|DRUG|LNP023|LNP023 5, 25, 100 mg capsles
214960768|NCT03373461|OTHER|Placebo|Matching placebo to LNP023
214960769|NCT02893111|DRUG|Bortezomib|Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
214960770|NCT06880549|BIOLOGICAL|mRNA-4106|Intramuscular Injection
214960771|NCT06880549|BIOLOGICAL|Nivolumab/Relatlimab|Intravenous infusion
214960772|NCT06050330|DIAGNOSTIC_TEST|skin biopsy|Paraffin sections,5 Um thick will be prepared from the skin samples and will be analyzed for light microscopy
214960773|NCT03300180|BEHAVIORAL|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
214960774|NCT03300180|OTHER|Screening Only|The patients in this group will receive screening for AD coupled with letters sent to the dyads and the primary care PCP informing them of the results of the screening
214960775|NCT02578459|DEVICE|Intrathecal Drug Delivery System|The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.
214960776|NCT02578459|OTHER|Conventional Medical Management|Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
214960777|NCT01475032|DRUG|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
214353020|NCT01899846|DRUG|Hydroxyprogesterone caproate 250 mg/ml|
214353021|NCT01994330|DRUG|desmopressin|0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
214353022|NCT02457572|PROCEDURE|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
214960778|NCT01475032|DRUG|Beclomethasone (BDP)|Beclomethasone (BDP) for 12 weeks
214960779|NCT01475032|DRUG|Beclomethasone (BDP) + Formoterol Fumarate (FF)|free combo Beclomethasone (BDP) + FF for 12 weeks
215079485|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-3|"Section 3: Childish games (10 minutes): Childish games are used that will help to laugh for no reason, just like a child. Imagining these games and plays, the arms are raised upwards in the form of a Y with palms facing the sky, motivating the group by saying very good (clap), very good (clap), yes. The leader of laughter yoga speaks out very good (clap), very good (clap), hey (arms to the right and left) to keep the group's energy high and generate enthusiasm in the deep breathing exercises and laughter exercises sections. According to the energy and desire of the group, this section is completed after about 10 minutes."
214353023|NCT02457572|OTHER|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
214353024|NCT04029922|DRUG|MT-5111 (experimental study drug)|Experimental treatment with MT-5111
214960780|NCT01636089|DRUG|bicarbonates|sodium bicarbonates 1,4%
214960781|NCT01636089|DRUG|saline|sodium chloride 0,9%
214960782|NCT03157726|PROCEDURE|Transurethral plasmakinetic enucleation of prostate|Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
214960783|NCT03157726|PROCEDURE|transurethral resection of prostate|"Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH."
214960784|NCT03922204|DRUG|MCLA-145|full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137
214960785|NCT03922204|DRUG|Pembrolizumab (Keytruda)|Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W.
214353025|NCT04325750|PROCEDURE|TECAR Therapy|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
214353026|NCT04325750|OTHER|Placebo|simulated TECAR Therapy (machine off)
214502644|NCT06522893|OTHER|Percutaneous neuromodulation|Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
214960786|NCT01486186|DRUG|Traditional Chinese Medicine|A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
214960787|NCT01486186|DRUG|placebo chinese medicine|There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
214960788|NCT00222222|PROCEDURE|vein puncture|comparison of different inflammatory markers in the blood of septic patients
214960789|NCT00220233|DRUG|olmesartan medoxomil|
214960790|NCT00220233|DRUG|amlodipine|
214960791|NCT00220233|DRUG|hydrochlorothiazide|
214353027|NCT03600337|BEHAVIORAL|Working to Optimize Wellness in Tees with PCOS (WOW)|5 week, 75 minutes weekly, integrated mindfulness-based mental and physical health promotion intervention
214960792|NCT00461097|DRUG|Egg oral immunotherapy|Egg white solid powder
214960793|NCT00461097|DRUG|Control Group|Placebo for egg white solid
214960794|NCT03818776|DRUG|Durvalumab|Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody immunotherapy for lung cancer. Participants will receive 1500mg durvalumab via intravenous (IV) infusion Q4W for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48 unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. (N.b. If a participant's weight falls to 30kg (≤30 kg)), then the participant should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W after consultation between Investigator and Study Physician, until the weight improves to above 30 kg \>30 kg, at which point the participant should start receiving the fixed dosing of durvalumab 1500 mg Q4W).
214960795|NCT03818776|RADIATION|Proton beam therapy RT|Proton beam therapy is a type of RT where the proton stops at a specific depth according to its energy which allows for a sufficient tumor dose that may improve local control and survival while sparing normal organs at risk, such as the heart, lung, and spinal cord.
214960796|NCT01941537|DRUG|ILV-094|IV infusion of ILV-094
214960797|NCT01941537|DRUG|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
214960798|NCT00857961|DRUG|Testosterone MD-Lotion|Administered Topically
214960799|NCT04544553|OTHER|SMS reminder|The group receives reminder for the follow-up at 1 week and 2 days prior to their scheduled appointments.
214353028|NCT05119959|OTHER|ECD intervention for CHEUs|The bi-weekly community health worker-delivered ECD 1 hour intervention using the modules from the SUPERCDZ curriculum which is a Zambian adaptation of UNICEF's Nurturing Care Framework
214353029|NCT05119959|OTHER|Usual care for CHEUs|No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.
214353030|NCT01158131|BEHAVIORAL|Balance after Baby Lifestyle Intervention Program|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
214960800|NCT04544553|OTHER|No SMS reminder|The group did not receives any SMS regarding scheduled appoinments.
214960801|NCT03654391|DIETARY_SUPPLEMENT|InnoSlim|Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
214960802|NCT03654391|DIETARY_SUPPLEMENT|Placebo|Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
214960803|NCT03051373|DRUG|nanoparticle albumin-bound paclitaxel, S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
214960804|NCT03051373|DRUG|Gemcitabine, cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
214960805|NCT04272957|DRUG|HMPL-306|HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
214502645|NCT04354389|DRUG|DAS181|4.5 mg b.i.d
214502646|NCT04354389|DRUG|Placebo|q.d. or b.i.d.
214502647|NCT04354389|DRUG|DAS181|4.5 mg q.d.
214960806|NCT05635422|DIAGNOSTIC_TEST|isokinetism test|measure of muscular fatigability by isokinetism
214960807|NCT04293835|DIAGNOSTIC_TEST|Whether to have intestinal-related disease|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
214960808|NCT03865719|BEHAVIORAL|Healthy Habits for Life|Healthy Habits for Life: 11-session, 6 month, one-on-one, dietician-lead weight management manualized treatment.
214960809|NCT02557516|DRUG|monalizumab|"During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks."
214960810|NCT02530918|DRUG|DS-7080a|1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
214960811|NCT02530918|DRUG|Ranibizumab|0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
214960812|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)\] given one month apart
214960813|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)\] given one month apart
214960814|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)\] given one month apart
214960815|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[High Dose WN-80E API (50 µg)\] given one month apart
214960816|NCT05202015|DRUG|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|MRI of the liver accoring to our institutional daily routine protocol
214960817|NCT03280745|DRUG|Hypertonic saline|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
214353031|NCT06294301|BIOLOGICAL|LP-005 Dose 1 (Single)|A single dose of LP-005 (Dose 1) was administered intravenously.
214353032|NCT06294301|BIOLOGICAL|LP-005 Dose 2 (Single)|A single dose of LP-005 (Dose 2) was administered intravenously.
214353033|NCT06294301|BIOLOGICAL|LP-005 Dose 3 (Single)|A single dose of LP-005 (Dose 3) was administered intravenously.
214353034|NCT06294301|BIOLOGICAL|LP-005 Dose 4 (Single)|A single dose of LP-005 (Dose 4) was administered intravenously.
214353035|NCT06294301|BIOLOGICAL|LP-005 Dose 5 (Single)|A single dose of LP-005 (Dose 5) was administered intravenously.
214353036|NCT06294301|BIOLOGICAL|LP-005 Dose 6 (Single)|A single dose of LP-005 (Dose 6) was administered intravenously.
214353037|NCT06294301|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered intravenously.
214353038|NCT06294301|BIOLOGICAL|LP-005 Dose 7 (Multiple)|LP-005 (Dose 7) was administered multiple times intravenously.
214353039|NCT06294301|BIOLOGICAL|LP-005 Dose 8 (Multiple)|LP-005 (Dose 8) was administered multiple times intravenously.
214960818|NCT03280745|DRUG|0.9% saline|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
214960819|NCT03734445|DIETARY_SUPPLEMENT|Vitamin Supplement|Subjects will be randomly allocated to a supplementation of vitamin C 1000mg, vitamin D 400 IU and zinc 10 mg or an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
214960820|NCT03734445|OTHER|Placebo|Subjects will be randomly allocated to a supplementation of an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
214960821|NCT01623024|DRUG|Vitamin D|20.000 UI/week for 96 weeks
214960822|NCT01623024|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling for 96 weeks
214960823|NCT06922448|DRUG|BLU-808|BLU-808 tablets
214960824|NCT06922448|DRUG|Placebo|Placebo tablets
214960825|NCT06918132|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
214960826|NCT06918132|BIOLOGICAL|Cemiplimab|Given IV
214353040|NCT06294301|BIOLOGICAL|LP-005 Dose 9 (Multiple)|LP-005 (Dose 9) was administered multiple times intravenously.
214353041|NCT06294301|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times intravenously.
214353042|NCT05972096|BEHAVIORAL|Combination DBT, self-compassion and contextual-based skills|Psychotherapy combination. Skills of DBT plus self-compassion and contextual skills
214353043|NCT04290026|DRUG|metoclopramide versus granisetron|ِِِِAssessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section by us
214353044|NCT01538381|DRUG|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
214353045|NCT01538381|OTHER|Observation|Observation
214353046|NCT05131048|OTHER|conventional group|this group will perform conventional therapy
214353047|NCT05131048|OTHER|experimental group|this group will perform home based exercises
214353048|NCT02368249|DRUG|Terlipressin|Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
214960827|NCT06918132|BIOLOGICAL|Fianlimab|Given IV
214960828|NCT06918132|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214960829|NCT06918132|PROCEDURE|Surgical Procedure|Undergo SOC surgery
215000360|NCT07113899|OTHER|Approach to spirituality through hope and acceptance|"This study is a prospective longitudinal research study. The sample consisted of two groups: the Intervention Group, which included patients from the community palliative care support team (ECSCP-BM), and the Control Group, with primary health care selected patients from the family health units Nautilus and Coimbra Centro (CSP), with serious illness, comorbidities, and a poor prognosis. The patients chosen from ECSCP-BM were made up only of new patients referred to the team without any prior home consultations. The first questionnaire application took place during the first visit, and the second one was administered fourteen days later. The Primary Health Care patients were selected by invitation, and the questionnaire was administered. It included sociodemographic data, clinical data, the Herth Hope Index and open questions.~During the palliative care team's home visit, spirituality was addressed in in the clinical history through the assessment of hope and acceptance."
214960830|NCT06842732|BEHAVIORAL|Maternal Administered Malnutrition Monitoring System - Infant and Young Child Feeding (MAMMS IYCF) intervention|All caregivers randomized to the MAMMS-IYCF arm will be given two MUAC tapes after being trained by skilled study staff and their contact information will be entered into the online MAMMS-IYCF platform. The frequency of messages will be weekly. This will be a two-way SMS system, including health messages on age appropriate IYCF. These messages will also prompt caregivers to measure their child's MUAC, return the color outcome of the measurement to the clinic via the SMS system, and they will also be able to ask any health questions that they may have through the SMS. During follow-up, any caregiver who returns a MUAC measurement via SMS that suggests their child is wasted, will receive an SMS response asking them to come to the clinic with their child as soon as possible. At this visit, the wasting status of the child will be confirmed by a study staff, and if treatment is indicated they will be enrolled into nutritional care provided by MOH nutritionists.
214960831|NCT06842732|BEHAVIORAL|Standard of Care (SOC)|To promote high fidelity to current guidelines, all families randomized to the SOC arm will be enrolled into a one-way SMS service that will send them automated reminders before necessary routine EID or HIV care visits and research clinic appointments on day 90 and 180. During these routine clinic visits, study staff will ensure that the MUAC of SOC children are measured, and that treating clinicians (MOH nutritionists) are made aware if wasting is identified. Staff will ensure that SOC children are enrolled into nutritional care if they are wasted. This additional support means it is likely that SOC children in this study will receive care that is more adherent to current recommendations than is typical for many children. This enhanced SOC is necessary to ensure we are comparing the MAMMS-IYCF to current guidelines. The SMS messaging service will be free of cost to the caregivers as they will not incur any charges to send or receive messages while enrolled in the trial.
214353049|NCT02368249|DRUG|Placebo|Patients are receiving a post-operative intravenous Ringer's lactate solution
214960832|NCT04467983|DRUG|Denosumab Injection|Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
214960833|NCT04467983|DRUG|Abaloparatide|Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
214960834|NCT02480881|DRUG|BMS-663068|Investigational product
214960835|NCT02480881|DRUG|Oral Contraceptive|Subject's existing combination OC tablet containing EE and progestin
214353050|NCT02558010|DRUG|Methadone|Perioperative IV methadone to be given
214960836|NCT02480881|DRUG|Loestrin 1.5/30|OC containing EE and norethindrone acetate (NEA)
214960837|NCT06363019|BEHAVIORAL|Supporting at-risk Mothers Across perinatal period: a Randomized controlled Trial (SMART) mobile application|The intervention is delivered through the SMART mobile application. It contains educational information in audio, visual, article format; on parenting, pregnancy and managing emotional well-being. There is also a peer support feature where participants can speak to experienced mothers via the SMART app. There is also a forum feature where participants can interact with other mothers.
214353051|NCT02558010|OTHER|Normal Saline|control arm
214353052|NCT02558010|DRUG|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
214960838|NCT03606057|DRUG|JNJ-64565111|Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.
214960839|NCT03606057|DRUG|Moxifloxacin|Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.
214960840|NCT03606057|DRUG|JNJ-64565111-matching Placebo|Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.
214960841|NCT03606057|DRUG|Moxifloxacin-matching Placebo|Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
215000361|NCT07113574|DRUG|Meropenem 1000 mg|Administration of meropenem after intraperitoneal administration via cycler-therapy in APD patients without peritonitis
215000362|NCT07113574|DRUG|Aztreonam 2000 mg|Administration of aztreonam after intraperitoneal administration via cycler-therapy in APD patients without peritonitis
215000363|NCT07113574|OTHER|automated peritoneal dialysis with following long time dwell|The cycler therapy, followed by a prolonged dwell, will be performed as outlined in the study protocol.
215000364|NCT07113574|DIAGNOSTIC_TEST|Sampling|The sampling of blood, dialysate, and urine will be performed as outlined in the study protocol.
215000365|NCT07116304|DRUG|Lidocaine, a local anaesthetic.|it will be given as a pretreatment prior to injection of propofol, with a tourniquet applied.
215000366|NCT07116304|DRUG|Parecoxib 40mg|atients in this group will receive IV parecoxib 40 mg (the standard full dose for an adult) diluted to a total volume of 5 mL with normal saline.
215000367|NCT07115095|DRUG|TP Chemotherapy + Trastuzumab + Pertuzumab|Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2. Targeted therapy: Trastuzumab (8 mg/kg) intravenously and Pertuzumab (initial dose 840 mg, subsequent doses 420 mg) intravenously. This regimen was repeated every 21 days for 6 cycles.
215000368|NCT07115095|DRUG|TP Chemotherapy + Trastuzumab|Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2. Targeted therapy: Trastuzumab (8 mg/kg) intravenously. This regimen was repeated every 21 days for 6 cycles.
214353053|NCT05774964|DRUG|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area
214353054|NCT05774964|DRUG|S1|Orally on d2-d15 at 20 mg three times daily
214353055|NCT05774964|DRUG|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
214353056|NCT05774964|DRUG|Metronidazole|Metronidazole 0.4g/time, qd
214353057|NCT05774964|DRUG|Vitamin A|Vitamin A 5,000 units/time, qd
215000369|NCT07114367|DRUG|NB02 (Poseltinib)|Dose Level 1, Dose Level 2, Dose Level 3
215000370|NCT07114172|DIAGNOSTIC_TEST|68Ga-ACC-DE/68Ga-FASN-DE/68Ga-ACLY-DE PET/CT|Recruit 15 healthy adult volunteers, divided into three groups, to undergo dynamic PET/CT (1 hour) and static PET/CT (2 hours and 3 hours) imaging with 68Ga-ACC-DE, 68Ga-FASN-DE, or 68Ga-ACLY-DE, respectively, to assess safety, biodistribution, and radiation dosimetry, laying the foundation for subsequent studies.
215079486|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-4|"Section 4: Laughter exercises (15 minutes): This section contains a variety of laughter exercises that will laugh, such as greetings, laughter cream, exploding balloon laughter, preparing and drinking strawberry milk, bonuses, hot soup, lion, aloha, bird, appreciation, elevator, and cream pie. A laugh is raised by doing only laughter exercises for no reason at all. At the end of this section, relaxation is achieved for about three minutes using deep breathing exercises. The group is given verbal guidance Put your hand on your heart, feel your heartbeat, let's exhale with a smile, make a wish or pray, smile as if we had achieved our wish, and the laughter yoga session is terminated."
215079487|NCT06193408|DRUG|VR-AD-1005|oral capsule
215079488|NCT06193408|DRUG|Placebo|oral capsule
214353058|NCT05774964|DRUG|Folic acid|Folic acid 5 mg/time, qd
214353059|NCT05767944|OTHER|local anaesthesia infiltration|Infiltration of 150 mg of lidocaine solution per ray at site of surgical incision for flexor tendon repair in the palm, the 2 proximal \& distal phalanges
214960842|NCT05419167|BEHAVIORAL|STEP-COVID|The program is offered by two facilitators to groups of three to six women, online in a synchronous mode. The intervention is divided into two phases, each including three sessions. The first 3 sessions aim to explore how the participants feel, to better understand what makes them feel this way, to allow them to exchange with other people who are going through similar experiences, and to support the ability to manage stress and more unpleasant emotions. The following three sessions aim to enable participants to refocus on their experience of pregnancy and motherhood by giving them the opportunity to reflect upon how they wish to be as mothers, upon how their personal history influences their experience of pregnancy and motherhood, upon the moments that, as mothers, might be the most pleasant and those that will require more adaptations, and upon identifying the needs they have or expect to have after childbirth as well as the resources available to them to meet these needs.
214960843|NCT02252302|OTHER|Rest (Sitting on chair)|Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
214960844|NCT02252302|OTHER|Cycling exercise|Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
214960845|NCT02252302|DRUG|Salbutamol inhalation|Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
214960846|NCT02252302|DRUG|Placebo inhalation|Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
214960847|NCT02252302|OTHER|Diesel Exhaust Exposure|Participants will be exposed to PM2.5 of 300 μg/m3
214960848|NCT02252302|OTHER|Filtered air|Participants will be breathing filtered air
215079489|NCT02227953|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
215079490|NCT02227953|DEVICE|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
215079491|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
214353060|NCT05767944|OTHER|brachial plexus block|ultrasound-guided infiltration of local aesthetics around brachial plexus trunks \& divisions
214353061|NCT05984953|DRUG|statin|40 mg of rosuvastatin daily for 8-12 weeks
214353062|NCT05984953|DRUG|evolocumab|140 mg evolocumab every 2 weeks (26 weeks)
214353063|NCT03070613|DRUG|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
214353064|NCT02698072|OTHER|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
214353065|NCT02698072|DEVICE|Dry needling|Dry needling needle AGUPUNT®
214353066|NCT02698072|DEVICE|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
214502648|NCT02933294|PROCEDURE|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
214502649|NCT02933294|PROCEDURE|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
214502650|NCT04810390|DRUG|Bilastine|Ophthalmic solution 0.6%
214502651|NCT04810390|DRUG|Placebo|Ophthalmic solution
214502652|NCT03102034|BIOLOGICAL|D46/NS2/N/ΔM2-2-HindIII|10\^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops
215079492|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
215079493|NCT01258153|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
215079494|NCT00624780|DRUG|Pregabalin|Pregabalin 150-300 mg given twice a day
215079495|NCT00624780|DRUG|Lorazepam|Lorazepam 3-4 mg given twice a day
215079496|NCT00624780|DRUG|Pregabalin|Pregabalin 450-600 mg given twice a day
215079497|NCT00624780|DRUG|Placebo|Placebo
215079498|NCT00106574|DRUG|Placebo|iv every 4 weeks
215079499|NCT00106574|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
215079500|NCT00164957|DEVICE|continuous pump feeding|
215079501|NCT00164957|OTHER|intermittent bolus feeding|
215079502|NCT05632588|OTHER|Observational study|Observational surveillance study
214502653|NCT03102034|BIOLOGICAL|Placebo|Isotonic diluent; administered as nose drops
215079503|NCT01514240|DRUG|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
215079504|NCT01514240|DRUG|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
215079505|NCT00922155|DEVICE|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
215079506|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
214353067|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
214353068|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
214353069|NCT00295750|DRUG|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
214353070|NCT01566045|PROCEDURE|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
214353071|NCT01566045|PROCEDURE|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
214353072|NCT05323318|OTHER|Neuropsychological Sequelae|Neuropsychological Sequelae after SARS-CoV-2 symtomatic infection
214353073|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet [Xarelto]|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet \[Xarelto\].
214353074|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
214353075|NCT04164992|DEVICE|EUSRA electrode needle connected to a radiofrequency generator (VIVA RF generator; STARmed, Seoul, S. Korea)|The operative needle (EUSRA-STARMED) is a novel monopolar 18 gauge radiofrequency ablation (RFA) electrode that is placed in the echoendoscope operative channel. It is 140 cm long with a sharp conical 1 cm tip for energy delivery. The needle is associated with an internal cooling system connected via a pump to an external cold saline solution source (0 °C) that prevents the charring of the tip and improves the ablation accuracy.
214353076|NCT02248298|DRUG|2h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 2 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
214353077|NCT02248298|DRUG|3h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
214353078|NCT02248298|DRUG|3hr-MAL-PDT|an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
214353079|NCT04588350|DEVICE|i-SEP autotransfusion system|Intraoperative recovery and washing of the processed blood by i-SEP autotransfusion system in surgeries where a bleeding is expected
215000371|NCT07118397|OTHER|dry needling|Dry needling involved the insertion of fine needles into identified myofascial trigger points within the plantar fascia and associated muscles. The technique aimed to release muscle tightness and alleviated pain by stimulating the trigger points. Needles were inserted perpendicularly to the skin at the identified trigger points, with the depth of insertion typically ranged from 35 to 70 mm, with 0.30mm diameter.
215000372|NCT07118397|OTHER|kinesiology taping|Kinesiology Taping was applied using an I-shape technique. The taping began from the metatarsal head, extending through the plantar fascia and along the Achilles' tendon to the calf muscle. The application involved specific tension levels to support the plantar fascia and improve functional movement. The taping was applied with the foot in a slightly dorsiflexed position to ensure proper adherence and function.
214353080|NCT02439710|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
214502654|NCT01203293|BEHAVIORAL|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
215000373|NCT07121049|BEHAVIORAL|Strength training|Through systematic muscle training and promotion of outdoor activities, the program integrates early childhood education college students with kindergartens to promote the all-round development of children and establish habits to prevent myopia.
215000374|NCT07120009|PROCEDURE|selective caries removal|The caries is not completely removed but covered with a remineralizing material. Its purpose is to maintain pulp vitality.
215000375|NCT07120009|PROCEDURE|partial pulpotpmy|Complete cleaning of the caries resulting in pulp expose. pulp tissue is surgically removed by 1-3 mm.The aim is to remove the inflamed superficial pulp tissue to allow healing from the underlying healthy tissue.
215000376|NCT07118800|DRUG|FOLFOX4s|"6 cycles of FOLFOX4s intravenously: Oxaliplatin 85mg/m² over 2h, folinic acid 400mg/m2 (or L-folinic acid 200 mg/m2) over 2h, Fluorouracil bolus 400mg/m², Fluorouracil: 2400mg/m² over 46h, every 14 days for 12 weeks (max: 6 cycles). FOLFOX4 regimen will be started 2-4 weeks after completion of radiotherapy"
215000377|NCT07118800|RADIATION|Short Course Radiotherapy|25Gy in 5 fractions of 5Gy delivered in one week (short-course radiotherapy)
215000378|NCT07121140|PROCEDURE|Home Blood Transfusion|Participants will be provided with transfusion of blood products, specifically red blood cells and platelets, in the home setting.
215000379|NCT07121504|DEVICE|Hybrid closed-loop insulin delivery system|Perioperative patients with T2D receiving parenteral nutrition will receive hybrid closed-loop insulin delivery system for glycemic management.
214353081|NCT03349450|BIOLOGICAL|DPX-Survivac|DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
214353082|NCT03349450|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
214960849|NCT02778022|BEHAVIORAL|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
214960850|NCT03576443|DRUG|Idelalisib|Idelalisib 150 mg x 2 p o
214960851|NCT03092570|DEVICE|With stimulation|ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions
214960852|NCT03092570|DEVICE|No stimulation|ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.
214960853|NCT06955312|BEHAVIORAL|Experimental|Description: After collecting the pre-test data, pregnant women in the experimental group will be informed about the paint-by-numbers activity, and the materials to be used will be introduced. Participants in the experimental group will be asked to choose one of the 40x50 cm paintings. They will then be instructed to complete the painting. Pregnant women will be asked to paint the selected canvas at their convenience over approximately five days. Once the paint-by-numbers activity is completed, participants will be asked to fill out the post-test questionnaires, and final data from the experimental group will be collected, marking the end of the data collection process. After data collection, participants will be gifted their completed paintings, which they can hang in their children's rooms.
214960854|NCT00006929|DRUG|suramin|Given IV
214960855|NCT00006929|DRUG|carboplatin|Given IV
214960856|NCT00006929|DRUG|paclitaxel|Given IV
214960857|NCT00006929|OTHER|pharmacological study|Correlative studies
214960858|NCT00006929|OTHER|laboratory biomarker analysis|Correlative studies
214960859|NCT05306717|OTHER|Questionnaire|The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year. The impact of the QPGE on the satisfaction scores will be systematically evaluated by a self-questionnaire for patients at the end of hospitalization. The QPGE is administered by a nurse during the reception interview of the patient in the unit.
214960860|NCT04940663|BEHAVIORAL|EMA|Participants will complete surveys about their feelings and social habits through a smartphone app (EMA)
214960861|NCT04646018|OTHER|Lumbar Spine Manipulation|Lumbar non-thrust manipulation is a passive movement that is performed with a rhythm and a grade in a manner in which the patient is able to prevent the technique from being performed.
214960862|NCT04646018|OTHER|Sham Manipulation|Lumbar non-thrust manipulation without force applied
214960863|NCT05643989|PROCEDURE|Stoma formation|Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.
214960864|NCT05643989|PROCEDURE|Endoscopic self-expandable metal stent placement|The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.
214960865|NCT03287115|OTHER|Broccoli consumption|All subjects will eat broccoli on day 11
214960866|NCT05710146|DRUG|Tranexamic acid|1 injection of 15mg/kg of TXA in 100mL of normal saline
214960867|NCT05710146|DRUG|Placebo|1 injection of 100mL of normal saline
214960868|NCT00588146|DRUG|Pegylated Interferon Alpha2b|Weekly subcutaneous injection of 1 microgram/kg/week
214353083|NCT03349450|DRUG|Cyclophosphamide 50mg|Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
214960869|NCT00588146|OTHER|Standard care|Standard care
214960870|NCT02823470|DRUG|LUM/IVA|LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
214960871|NCT02823470|DEVICE|activated smart device|
214960872|NCT02823470|DEVICE|de-activated smart device|
214353084|NCT00936858|DRUG|RAD001|
214353085|NCT01289912|DRUG|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
214960873|NCT03442725|DRUG|Telotristat etiprate|Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
214960874|NCT00463801|DRUG|Daptomycin|
214960875|NCT00826098|BIOLOGICAL|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
214960876|NCT05349019|OTHER|Observational|This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.
214960877|NCT02667314|BEHAVIORAL|Jigsaw puzzles|"Intervention period 1: Participants are asked to solve jigsaw puzzles at home 6 times per week for at least 1 hour over a period of 5 weeks.~Intervention period 2 (voluntary): Participants receive the possibility to solve jigsaw puzzles free-of-charge at home for a period of at least 3 month before the 1.5-year follow-up."
214960878|NCT02667314|BEHAVIORAL|Cognitive health counseling|Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline, and four telephone calls for expert monitoring (three calls during the 5-week period between pre- and posttest, and one call 12 month later)
214960879|NCT04241913|BEHAVIORAL|Mom Power Intervention|Mom Power is a 10-week therapeutic intervention for at-risk families that incorporates elements of several evidence based practices. It combines didactic material with mindbody self-care skills and in vivo practice to improve the quality of attachment between parent and child, and to reduce the psychopathology of at-risk parents. The child team component provides each child with one-on-one care focusing on meeting the child's social-emotional needs and providing attachment-related experiences within a developmental framework.
214960880|NCT00935077|OTHER|PPCM Asthma|Pharmacists collaborate with physicians to manage asthma
214960881|NCT00935077|OTHER|24 Month PPCM BP|Pharmacists collaborate with physicians for 24 months to manage hypertension.
214960882|NCT00935077|OTHER|9 Month PPCM BP|Pharmacists collaborate with pharmacists for 9 months to manage hypertension
214960883|NCT05077553|DIETARY_SUPPLEMENT|TCI999 probiotic sachet|Testing product
214960884|NCT05077553|DIETARY_SUPPLEMENT|Placebo sachet|Blank
214960885|NCT02315664|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.
214960886|NCT02315664|BEHAVIORAL|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
214960887|NCT02575378|DRUG|Metronimic chemotherapy plus Chinese Traditional Medicine|Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
214960888|NCT02575378|DRUG|Metronimic chemotherapy|Capecitabine 300mg/m2, twice a day, everyday
214960889|NCT01451099|BIOLOGICAL|Autologous cultured dermal cells|A piece of occipital scalp is taken from the subject. The dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
214960890|NCT02922465|DRUG|K-877|
214960891|NCT02922465|DRUG|Clopidogrel|
214960892|NCT02501161|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
214960893|NCT02501161|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
214960894|NCT04288882|DEVICE|Enteroscopy|Role of Balloon-Assisted Enteroscopy (BAE) in management of Small Intestinal Disorders
214960895|NCT03159299|BEHAVIORAL|Yo Puedo + mHealth|This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.
214960896|NCT03450408|PROCEDURE|Method of placement of Foley bulb transcervical dilator|This trial will assess two methods used to place a Foley bulb transcervical dilator.
214960897|NCT05695729|OTHER|PLYOMETRIC EXERCISE PROGRAM|"This group will perform following exercises in first four weeks. Reverse overhead throw Rotational wall throws Overhead medicine ball Chest passes Resistance tubing 90-90 external rotation~Frequency~* Rest between Exercises-: 60-120 Seconds~* Rest between Set of Exercise-: 45-60 Seconds after four weeks rest between exercise and rest between set of exercise will be reduced:~* Rest between Exercises-: 45-60 Seconds~* Rest between Set of Exercise-: 20-30 Seconds~Tools used:~Medicine Ball, Resistance band"
214960898|NCT05695729|OTHER|CONVENTIONAL EXERCISE PROGRAM|"This group will perform following exercise through out the session with different frequencies after 4 weeks Bench presses Triceps kickbacks bicep curls Overhead presses Push-ups~Frequency:~Rest between Exercises-: 60-120 Seconds Rest between Set of Exercise-: 45-60 Seconds~After 4 weeks the frequency will be:~Rest between Exercises-: 45-60 Seconds Rest between Set of Exercise-: 20-30 Seconds"
214960899|NCT03843320|DEVICE|SAPIEN 3|Transcatheter aortic valve replacement
214960900|NCT03843320|DEVICE|SAPIEN XT|Transcatheter aortic valve replacement
214960901|NCT03843320|DEVICE|INSPIRIS RESILIA|Surgical aortic valve replacement
214960902|NCT03843320|DEVICE|EDWARDS INTUITY|Surgical aortic valve replacement
214960903|NCT03843320|DEVICE|Carpentier-Edwards PERIMOUNT Magna-Ease|Surgical aortic valve replacement
214960904|NCT00451113|DRUG|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
215000380|NCT07121504|DEVICE|conventional insulin pumps combined with CGM|Perioperative patients with T2D receiving parenteral nutrition will receive conventional insulin pumps combined with CGM for glycemic management.
215000381|NCT07121192|BIOLOGICAL|Flu mRNA (Formulation A)|One dose of Flu mRNA (Formulation A) received intramuscularly.
215000382|NCT07121192|BIOLOGICAL|Flu mRNA (Formulation B)|One dose of Flu mRNA (Formulation B) received intramuscularly.
215000383|NCT07121192|COMBINATION_PRODUCT|Comparator 1|One dose of Comparator 1 received intramuscularly.
215000384|NCT07121192|COMBINATION_PRODUCT|Comparator 2|One dose of Comparator 2 received intramuscularly.
215000385|NCT07121192|COMBINATION_PRODUCT|Comparator 3|One dose of Comparator 3 received intramuscularly.
215000386|NCT07119372|BIOLOGICAL|BCD-131 (pegdarbepoetin beta)|BCD-131 (pegdarbepoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 52 weeks
214353086|NCT01289912|DRUG|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
214353087|NCT01953081|DRUG|TD-8954|
214353088|NCT01953081|DRUG|Metoclopramide|
214353089|NCT00626431|DRUG|Leuprolide acetate - Formulation A|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
214353090|NCT00626431|DRUG|Leuprolide acetate - Formulation B|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
214960905|NCT05691777|DEVICE|Hand and shoulder task|"Hand task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform flexion / extension movements of the fingers of the right hand at 0.5 Hz.~Shoulder task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform alternating movement of abduction and adduction of the right shoulder at 0.5 Hz with the elbow flexed."
214960906|NCT00399698|DRUG|Risperdal|
214960907|NCT01236625|PROCEDURE|Adhesiolysis|Blunt or sharp dissection of adhesive tissue.
214960908|NCT04076852|OTHER|Administration of questionnaires|"According to clinical practice, the following questionnaires are administered:~* Y-GTSS~* Y-BOCS or cY-BOCS"
214960909|NCT04023214|DIAGNOSTIC_TEST|Peripheral (digital) arterial tonometry|This will be measured using the EndoPAT system (Itamar Medical)
214960910|NCT00000311|DRUG|Buprenorphine|Medication and Behavioral
214960911|NCT00000311|DRUG|methadone|medication and behavioral
214960912|NCT00696319|OTHER|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
214960913|NCT00696319|OTHER|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
214960914|NCT01718587|PROCEDURE|stem cell transplantation through interventional procedure|interventional procedure once
214960915|NCT01718587|DRUG|antiviral therapy (lamivudine, other antiviral drugs)|lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
214960916|NCT01973517|DRUG|Feraheme|Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
214960917|NCT01973517|DRUG|Gadolinium-based contrast|Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
214960918|NCT00361608|DEVICE|EarlySense ES 16|
214960919|NCT04820296|OTHER|Solution-Oriented Approach|First Session: Sharing thoughts about perception of childbirth, Creating positive goals, Informing about Birth, Birth Process, Basic Breathing Exercises and Deep Relaxation Exercises, Homework Second Session: Evaluating homework, Sharing thoughts about fear of childbirth, Miracle Question Technique, Evaluating with the Rating Questions Technique, Reframing the problem, Briefing on 'Body-Mind Connection at Birth, Fear-Tension-Pain Cycle, Hormones of Birth' and Breathing exercises, Homework Third session: Evaluating homework, Sharing thoughts about positive birth story, Information on symptoms indicating that the childbirth is approaching, pushing techniques, delivery positions, endorphin massage and breathing exercises (4/8 breaths, full breath when baby moves), Homework Fourth Session: Evaluating homework, Mother Baby Friendly Caesarean and Breathing exercises (3 candles a feather breath), Sharing feelings about the counseling process
214960920|NCT03814902|DEVICE|Electronic Tracking Device|This commercially-available electronic tracking device uses Global Positioning System (GPS) technology to display the wearer's location on a mobile phone, tablet, or computer. The device may be securely attached to clothing and is designed to be worn by children with developmental disabilities. Parents may use the associated application to view the child's location when the device is turned on and active.
214960921|NCT03604848|DRUG|WHO-approved MDR-TB regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
214353091|NCT00620841|OTHER|genotyping|Restriction fragment lenght polymorphisms
214960922|NCT03604848|DRUG|NGS-guided regimen: Regimen A|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
214353092|NCT03753165|OTHER|High intensity interval exercise|High intensity interval exercise at 80% of the maximal heart rate derived from the maximal graded exercise. Each individual will undergo 12 sessions of HIIE over a period of six weeks
214353093|NCT00398008|DRUG|Buprenorphine/Subutex|Opioid agonist medication to treat opiate dependence
214353094|NCT00398008|DRUG|Naltrexone|Opioid antagonist medication to treat opiate dependence
214353095|NCT00398008|BEHAVIORAL|Drug counseling|DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
214960923|NCT03604848|DRUG|NGS-guided regimen: Regimen B|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
214353096|NCT05252767|BEHAVIORAL|Patient Engagement Tools|Experimental participants will receive the patient engagement tools or the educational guide after randomization. The participants in the experimental cohort will utilize the tools between visits with their clinic providers. During visits, clinic providers will review the completed tools with participants.
214353097|NCT05252767|BEHAVIORAL|Educational Guide|Control participants will receive a brief educational guide about pain management.
214353098|NCT01683864|DRUG|positive cytology with HIPEC|HIPEC with mytomycin and cisplatin
214353099|NCT03512665|DIETARY_SUPPLEMENT|Full dose supplement|A 7ml vial composed of a mixture of pine, macadamia and pomegranate oils.
214353100|NCT03512665|DIETARY_SUPPLEMENT|Low dose Supplement|A 7 mL vial composed of a mixture containing 50% study supplement (Pine, macadamia and pomegranate oils) and 50% sunflower oil.
214486981|NCT06668077|BEHAVIORAL|Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation after the iTBS, Rossi et al., 2009). Images of food and non-food appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, otherwise 1 point will be lost. Participants must respond as quickly and accurately as possible. Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
214960924|NCT03604848|DRUG|NGS-guided regimen: Regimen C|"Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, \>70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, \>70kg 1200 mg daily;"
214960925|NCT03957486|OTHER|arterila cannulation on same arm|arterila cannulation on same arm receiving continous hemoglobin monitoring
214960926|NCT03957486|OTHER|arterila cannulation on different arm|arterila cannulation different arm receiving continous hemoglobin monitoring
214960927|NCT01990573|DRUG|0.3mg/kg IV methadone HCl|Group I will receive 0.3mg/kg IV methadone HCl
214960928|NCT01990573|DRUG|0.4mg/kg IV methadon HCl|Group II will receive 0.4mg/kg IV methadone HCl.
215079507|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
215079508|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
214960929|NCT01990573|OTHER|control no methadone|The control group will not receive methadone.
214960930|NCT00144560|DRUG|MRA(Tocilizumab)|
214960931|NCT06106880|DRUG|Wintergreen Throat Spray and Aspirin Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet"
215079509|NCT01247532|BEHAVIORAL|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
215079510|NCT02064972|OTHER|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
215079511|NCT04054804|DIAGNOSTIC_TEST|D-Foot|A digital foot check i assessed by using the software D-Foot.
215079512|NCT03874390|OTHER|ozone|gaseous ozone was applied on periodontal pocket two times in one week.
215079513|NCT02045693|DRUG|Methadone|
215079514|NCT02045693|DRUG|DCV 3DAA FDC|
215079515|NCT02045693|DRUG|BMS-791325|
215079516|NCT02045693|DRUG|Buprenorphine|
215079517|NCT02045693|DRUG|Naloxone|
214353101|NCT03512665|OTHER|Control Oil|A 7ml vial composed of sunflower oil with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups.
214353102|NCT01840540|DRUG|Arterial infusion of autologous mesenchymal stem cells|
214353103|NCT02199028|DRUG|Hyaluronidase|150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.
214353104|NCT02199028|OTHER|Control|No hyaluronidase administered into insulin infusion set.
214353105|NCT01881126|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
214353106|NCT01881126|DRUG|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
214353107|NCT01881126|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
214353108|NCT01881126|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
214353109|NCT00867217|DIETARY_SUPPLEMENT|High Dose Vitamin D|High Dose Vitamin D3 (3 capsules of 10,000 IU) weekly for 24 weeks.
214353110|NCT00867217|DIETARY_SUPPLEMENT|Placebo|Placebo comparator
214353111|NCT00867217|DIETARY_SUPPLEMENT|Standard Dose Vitamin D3|Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)
214353112|NCT00867217|DRUG|Letrozole 2.5mg|All subjects received letrozole as standard of care.
214486982|NCT04386746|DRUG|Gemcitabine|1g gemcitabine in 50ml sterile water; instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
215079518|NCT00030771|DRUG|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
215079519|NCT00030771|RADIATION|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
215079520|NCT00030771|PROCEDURE|Surgery|3-4 weeks after termination of radiotherapy
215079521|NCT00549900|BIOLOGICAL|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
215079522|NCT02194920|PROCEDURE|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
215079523|NCT02502604|BEHAVIORAL|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
214353113|NCT02859857|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
214960932|NCT06106880|DRUG|Aspirin Throat Spray and Placebo Tablet|"The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
214960933|NCT06106880|DIETARY_SUPPLEMENT|Wintergreen Throat Spray and Placebo Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
214960934|NCT06106880|OTHER|Placebo Throat Spray and Placebo Tablet|"The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
214960935|NCT05182801|DIETARY_SUPPLEMENT|Placebo sachet|Blank
214960936|NCT05182801|DIETARY_SUPPLEMENT|Banana flower extract sachet|Happy Angel Banana Flower Extract sachet
214960937|NCT02121548|BEHAVIORAL|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
214960938|NCT02121548|BEHAVIORAL|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
214960939|NCT04854759|DRUG|Amantadine Hydrochloride|100 mg, capsule
214960940|NCT04854759|DRUG|Placebo|100 mg, capsule
214960941|NCT02307149|BIOLOGICAL|CAVATAK|CAVATAK is a preparation of CVA21
214960942|NCT02307149|DRUG|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
214960943|NCT04945564|PROCEDURE|Oxygen therapy and physical therapy|Patients receive oxygen therapy and physical therapy
214960944|NCT04945564|DEVICE|Oxygen therapy|Patients receive oxygen therapy
214960945|NCT01768065|DEVICE|Nasal Expiratory Positive Airway Pressure Device|assigned to Nasal Expiratory Positive Airway Pressure arm
214353114|NCT02791724|BEHAVIORAL|Desiconnect|Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.
214353115|NCT02791724|OTHER|CAU|Care as Usual
214960946|NCT01768065|DEVICE|placebo sham|
214960947|NCT03112226|OTHER|GnRHant + E2|GnRH antagonist with estradiol add-back
214960948|NCT03112226|OTHER|GnRHant + Placebo|GnRH antagonist with placebo add-back
214960949|NCT00447096|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS).
214960950|NCT00886366|DRUG|AZD6714|Oral single doses a-h suspension
214960951|NCT00886366|DRUG|Placebo|Oral single doses suspension
214960952|NCT00886366|DRUG|AZD6714|Oral single doses a-d suspension
214960953|NCT00886366|DRUG|AZD6714|Oral single doses d and g suspension
215000387|NCT07119372|BIOLOGICAL|Mircera (methoxypolyethylene glycol-epoetin beta)|Mircera (methoxypolyethylene glycol-epoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 52 weeks
215000388|NCT07120204|DRUG|Corticosteroid Injection|The symptomatic foot will be prepared with povidone-iodine and draped in a sterile manner. A sterile-covered ultrasound probe will be placed over the heel to visualize the calcaneus, plantar fascia, and any calcaneal spur. Subsequently, 1 mL of triamcinolone acetonide 40 mg (KENACORT-A IM/Intra-articular Retard 40 mg ampoule) and 1 mL of 2% lidocaine (Aritmal 2% ampoule) will be injected over the plantar fascia.
215000389|NCT07120204|PROCEDURE|Radiofrequency thermocoagulation|The patient will be in the lateral decubitus position with the symptomatic foot below. The foot was prepared with povidone-iodine and draped under sterile conditions. A sterilized ultrasound probe was placed over the heel to visualize the calcaneus, plantar fascia, and calcaneal spur. A 10 cm long radiofrequency (RF) needle with a 5 mm active tip was advanced in-plane under ultrasound guidance toward the tip of the calcaneal spur. Sensory stimulation at 50 Hz elicited paresthesia in the medial calcaneus, while motor stimulation at 2 Hz did not produce any muscle contractions. The RF generator (Beijing Neo Science Co., RFE 4b) was set to 80 °C for 90 seconds, and the RFA procedure was initiated.
215000390|NCT06921980|OTHER|Brain function and psychological assessment|Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.
215000391|NCT02259621|DRUG|Nivolumab|Anti-PD-1 Therapy
215000392|NCT02259621|DRUG|Carboplatin|Anti-PD-1 Therapy
215000393|NCT02259621|DRUG|Paclitaxel|Anti-PD-1 Therapy
215000394|NCT02259621|DRUG|Ipilimumab|Anti-PD-1 Therapy
214353116|NCT02464449|BEHAVIORAL|Behavioral: AI-CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.
214353117|NCT02464449|BEHAVIORAL|Behavioral: Standard Telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
214353118|NCT01655030|DIETARY_SUPPLEMENT|creatine monohydrate|
214353119|NCT01655030|DIETARY_SUPPLEMENT|placebo|
214353120|NCT00208416|PROCEDURE|DePuy MI System|A minimally invasive surgical technique used in total hip replacement.
214960954|NCT03958188|OTHER|Standardized computerized tomography (CT) reading grid for preoperative planning|"Using the standardized reading grid, the following data will be collected:~* Small Intestine: tumor, parietal thickening, occlusive syndrome, proximity of the tumor with the ileocecal valve.~* Mesenteric mass: presence, size, shape, contours, calcifications, enhancement, superior mesenteric arterial invasion and number of non-invaded arterial arteries.~* Mesentery: moniliform venous dilatations, combed appearance.~* Duodenal invasion.~* Lymphadenopathies (Mesenteric, Right mesocolic and Retropancreatic): presence, size, shape, enhancement~The anonymized CT exam will be reviewed by an expert radiologist and a radiology resident from imaging department of the Hospital."
214960955|NCT02408731|DRUG|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
214960956|NCT03089645|BIOLOGICAL|MEDI5083 monotherapy|Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab
214960957|NCT03089645|BIOLOGICAL|MEID5083 with Durvalumab or Tremelimumab|Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab
214960958|NCT03089645|BIOLOGICAL|Medi5083 with Durvalumab and Docetaxel|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel
214960959|NCT00568217|DRUG|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius
214353121|NCT00208416|PROCEDURE|Conventional surgical technique|A conventional surgical technique used in total hip replacement
214353122|NCT02567084|DEVICE|"CERAMENT™ |BONE VOID FILLER"|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
214960960|NCT04587141|DRUG|Sucrosomial iron|This is an oral iron formulation commercially available as an integrator
214960961|NCT04587141|DRUG|Ferric Gluconate|This is a commercially available iron formulation for parenteral administration
214960962|NCT04587141|DRUG|Ferric carboxymaltose|This is a commercially available iron formulation for parenteral administration
214960963|NCT00878579|DEVICE|PDS System|Percutaneous Dynamic Stabilization System
214960964|NCT00878579|DEVICE|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
214960965|NCT02705378|DRUG|Polyethylene glycol|Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
214353123|NCT02351531|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
214486983|NCT04386746|DRUG|Docetaxel|37.5mg docetaxel in 50ml normal saline solution (NSS); instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
214960966|NCT02705378|DRUG|naloxegol|Intervention would be given by OG or NG tube
214960967|NCT04541329|BIOLOGICAL|Tildrakizumab|IL-23 inhibitor
214960968|NCT03335813|DEVICE|Endoesophageal Brachytherapy|Balloon repositioning, multichannel brachytherapy applicator which has 6 channels instead of 3-tubes which will be used to deliver localized radiation
214960969|NCT06501807|DRUG|Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks).
214960970|NCT00638469|RADIATION|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body half
214960971|NCT00638469|OTHER|No treatment|no UV exposure
214960972|NCT04497532|OTHER|Diet as suited for gestational diabetes mellitus|Diet that consists of complex carbohydrates, and a regimen that includes 6 meals per day, as tailored gor gestational diabetes.
214960973|NCT03476057|DIAGNOSTIC_TEST|Device： NGS sequencing cfDNA|NGS sequencing cfDNA and Tumor Burden
214960974|NCT04256564|PROCEDURE|Central venous catheterization|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance
214960975|NCT00961779|DRUG|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
214960976|NCT00961779|DRUG|Placebo|Normal saline infusion
214960977|NCT01557478|DRUG|Melatonin|20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
214960978|NCT01557478|DRUG|match placebo|placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
214960979|NCT00997347|DRUG|Mifepristone and misoprostol|"200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone"
214353124|NCT01438502|DRUG|HyperHAES® (hypertonic saline/HES)|After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
214353125|NCT02339961|RADIATION|Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall
214960980|NCT02210520|DEVICE|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
214960981|NCT02210520|DEVICE|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
214960982|NCT02210520|DEVICE|laser|1 W/cm², 2 minutes in 6 points around the back spine
214960983|NCT06053632|BEHAVIORAL|Low-load and high-velocity - lying prone - eccentric hamstring exercise|Low-load and high-velocity - lying prone - eccentric hamstring exercise 3 times per week for 4 weeks.
214960984|NCT01747096|DRUG|68-Ga-DOTANOC|
214960985|NCT02063594|DRUG|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
214960986|NCT02063594|DRUG|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
214960987|NCT02168023|DEVICE|DACC impregnated dressing|DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
214960988|NCT02168023|DEVICE|Standard surgical dressing|Standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
214353126|NCT02341417|DRUG|Cinacalcet|Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
214960989|NCT00975546|OTHER|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
214960990|NCT00975546|PROCEDURE|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
214960991|NCT04403555|DRUG|Ivermectin|Ivermectin treatment
214960992|NCT03162042|PROCEDURE|Tumor removal|Surgery
214960993|NCT06376708|OTHER|platelet rich fibrin|platelet rich fibrin
214353127|NCT00694603|DRUG|Cetuximab|Given intravenously once per week.
214960994|NCT06376708|OTHER|Polyether ether ketone|Polyether ether ketone
214353128|NCT00109538|DRUG|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
214353129|NCT00109538|OTHER|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
214353130|NCT04087538|DIAGNOSTIC_TEST|Troponin T and I|Does the use of troponin T or I increase the number of patients referred to coronary angiography
214960995|NCT03630159|BIOLOGICAL|Tisagenlecleucel|Gene modified autologous T cells
214960996|NCT03630159|DRUG|Pembrolizumab|anti PD-1
214960997|NCT02660437|OTHER|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; \~30min).
214960998|NCT02364583|DRUG|Primaquine|Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
215079525|NCT03036436|BEHAVIORAL|Intervention|A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
215079526|NCT00030277|PROCEDURE|high-intensity focused ultrasound ablation|
214960999|NCT05495308|PROCEDURE|neoadjuvant treatment|We study the number of patients who achive a complete pathological response after neoadjuvant treatment with radiochemotherapy.
214961000|NCT00006329|PROCEDURE|Minimally invasive radioguided parathyroidectomy|
214961001|NCT04398810|PROCEDURE|robotic single port cholecystectomy|"1. Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~2. Residual gas aspiration~3. Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~4. Warming of the washing solution in the abdominal cavity"
214961002|NCT02962232|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|treatment group
214961003|NCT02962232|DEVICE|PTA catheter|control group
214961004|NCT04070248|OTHER|No intervention|No intervention
215079527|NCT01960088|DRUG|HPV vaccine|
215079528|NCT03506919|DRUG|Allopurinol|Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
214961005|NCT05603585|DIETARY_SUPPLEMENT|Optimal protein supplementation to achieve 80% protein adequacy.|Additional protein required and delivered by adding protein powder and given in bolus feeds
214961006|NCT00780780|DRUG|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
214961007|NCT00780780|DRUG|triamcinolone intravitreal injection|triamcinolone intravitreal injection
214961008|NCT02637310|DRUG|N02RS1 1200mg|1200mg/day, Three times a day orally, 2 tablets once, 7 days
214961009|NCT02637310|DRUG|Placebo|1200mg/day, Three times a day orally, 2 tablets once, 7 days
214961010|NCT01691417|DEVICE|Intermittent Sequntial Pnumatic Compression Leg Sleeves|
215079529|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
215079530|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from CKD|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
215079531|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish CKD from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
214961011|NCT01957579|DRUG|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
214961012|NCT00124891|DRUG|Double-blind investigational anti-arrhythmic|
214961013|NCT00124891|DRUG|GAP-486|
214961014|NCT00652145|DRUG|mesalamine|Increase dose by 2.4gm per day over baseline dose
215079532|NCT03659149|DRUG|CKD-333 formulation I|1 tablet administered before the breakfast(single-dose)
215079533|NCT03659149|DRUG|CKD-333 formulation II|1 tablet administered before the breakfast(single-dose)
215079534|NCT03659149|DRUG|CKD-330+D086|2 tablet administered before the breakfast(single-dose)
214961015|NCT00635934|DEVICE|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
214961016|NCT01639144|BIOLOGICAL|PRP and PPP|Autogenous PRP and PPP
214961017|NCT05868681|DEVICE|Delos instrument (computerized balance board)|"Proprioceptive training using Delos instrument (computerized balance board).~Static and dynamic evaluation through Delos with the Riva method; Physiatric visit; Clinical scores (AOFAs); Functional scores (SPPB); SF12 satisfaction."
214961018|NCT04346407|DRUG|Dronabinol 2.5mg Cap|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
214961019|NCT04346407|DRUG|Placebo|Placebo capsule daily starting with pre-op cocktail and continued twice daily for three days after surgery
215079535|NCT02218086|DEVICE|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
214353131|NCT02002169|OTHER|Shower Technique Protocol|Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
214353132|NCT02002169|OTHER|Standard CVC Care|Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
214353133|NCT03549650|DRUG|Pentosan Polysulfate Na 100Mg Cap|"Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
214961020|NCT02554045|DRUG|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
214961021|NCT02554045|DRUG|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
214961022|NCT03717779|DIAGNOSTIC_TEST|lung ultrasound|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
214961023|NCT04608916|PROCEDURE|Using surgical diathermy to make skin incision|Using surgical diathermy to make skin incision during shoulder arthroplasty
214961024|NCT04608916|PROCEDURE|Using scalpel blade to make skin incision|Using scaple blade to make skin incision during shoulder arthroplasty
214961025|NCT00064103|BIOLOGICAL|Ad5CMV-p53 gene|Given intramucosally or as oral rinse
215079536|NCT02218086|DEVICE|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
215079537|NCT02218086|DEVICE|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
215079538|NCT02218086|DEVICE|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
215079539|NCT02218086|DEVICE|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
215079540|NCT02218086|DEVICE|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
215079541|NCT02218086|DEVICE|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times \~15minutes within y few weeks.
215079542|NCT02833753|DRUG|Oxaliplatin|"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)"
214961026|NCT00064103|OTHER|laboratory biomarker analysis|Correlative studies
214961027|NCT01757860|DRUG|CARD-024|Comparison of different dosages of drug
214961028|NCT01757860|OTHER|Drug Carrier|Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
214961029|NCT02022046|OTHER|Methylation biosignature|Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
214961030|NCT00160056|PROCEDURE|Hypoglycemia|
214961031|NCT02608996|DRUG|Nesiritide|This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
215079543|NCT03677466|DRUG|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
214961032|NCT02608996|DRUG|Placebo|For comparison to elucidate the true effect of nesiritide
214961033|NCT01751321|DRUG|Sitagliptin, placebo|sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
214961034|NCT06202703|DRUG|Pneumococcal Vaccine|vaccination with pneumococcal vaccine (PCV13)
214961035|NCT03999957|OTHER|Telehealth web conferencing|Pediatric patient specific case discussions for enrolled pediatric patients at hospice staff interdisciplinary team meeting every 15 days for 60 min sessions via telehealth
214961036|NCT03975504|DEVICE|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
214961037|NCT03975504|DEVICE|artificial intelligence (AI)|AI was performed in high-risk individuals recruitment and lung nodules management
214961038|NCT03975504|DIAGNOSTIC_TEST|autofluorescence imaging (AFI)|AFI applied in screening of centrally located SCC.
214353134|NCT03549650|DRUG|Placebo oral capsule|"Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
214961039|NCT04064203|OTHER|Oral glucose tolerance test|50 grams OGTT
214961040|NCT04064203|OTHER|Clamp experiment|insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT
214353135|NCT04298138|BIOLOGICAL|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
214353136|NCT05234684|DRUG|Orelabrutinib + R-CHOP|The orelabrutinib is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
214961041|NCT00983645|DRUG|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
214961042|NCT00983645|DRUG|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
214961043|NCT01060189|DRUG|Ulinastatin|
214961044|NCT01060189|DRUG|Tranexamic Acid|
214961045|NCT01060189|DRUG|Saline Solution|
214961046|NCT05216445|BEHAVIORAL|Mindfulness Training|The Mindfulness Training will be an 8-week course, with group-based online weekly sessions. The mindfulness training, translated and adapted in Urdu, includes 8 guided audio meditations and one introductory audio recording which gives the participants an overview and introduction of the forthcoming 8-week training (e.g what mindfulness is, some common terms used repeatedly). It also includes 8 chapters, corresponding to each week and a workbook to record home practice. The training will start with an online group session after which the participants will be emailed the 1st week's reading material (chapter 1), audio recordings (for that week), home practice (for that week). At the start of every week, the participants will be emailed the required material for that week. Online sessions will be conducted weekly. The participants will also be sent poems and/or quotations relating to the week's theme and based on the session proceedings.
214961047|NCT00000757|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214961048|NCT06517498|OTHER|No Intervention|No Intervention will be conducted
214961049|NCT01304134|DRUG|Oxycodone|dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
214961050|NCT01304134|DRUG|Morphine|dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
214961051|NCT04464967|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
214961052|NCT04464967|DRUG|Trastuzumab|HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
214961053|NCT04464967|DRUG|Cetuximab|EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
214961054|NCT01520207|DRUG|Mannitol (20%)|0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
214961055|NCT01520207|DRUG|0.9% saline|1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
215000395|NCT06919198|DRUG|Ketamine|ketamine 2.5 mg/kg
215000396|NCT06915844|BEHAVIORAL|SHARP Tanzania|Building on existing adolescent health services, including HPV+, this intervention adds desired services for adolescent health education, screening, counseling, and referrals. In addition, this intervention has strategic community engagement to identify out of school girls with limited access to existing integrated health services available in schools, community sensitization activities, and training for healthcare workers.
215000397|NCT07122323|PROCEDURE|robotic arm-assisted total hip replacement|using robotic total hip replacement in patients with Legg-Calvé-Perthes disease
215000398|NCT07122323|PROCEDURE|conventional total hip replacement|applying conventional total hip replacement in patients with Legg-Calvé-Perthes disease
215000399|NCT07119294|DIAGNOSTIC_TEST|FAPI PET/MR|FAPI PET/MR prior surgery or during recurrence suspiscion
215000400|NCT07123168|BEHAVIORAL|Triangle Hierarchical Management|A nurse-led, risk-stratified management model where patients are categorized into high-, medium-, or low-risk tiers. High-risk patients receive intensive professional care (90%) and minimal self-management education (10%); medium-risk patients receive a balanced approach (50% each); and low-risk patients focus on self-management education (90%) with minimal professional care (10%). The intervention is delivered by trained nurses over 24 weeks.
215000401|NCT07123168|BEHAVIORAL|routine care|Standard nursing management for hemodialysis patients, including monthly monitoring, routine assessments, and general health education sessions. This care does not involve risk stratification or tailored interventions.
214353137|NCT05234684|DRUG|Placebo + R-CHOP|The placebo is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
214486984|NCT06747026|DRUG|initial Sequential iRT|"For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days."
214502655|NCT01203293|BEHAVIORAL|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
214961056|NCT02224612|DEVICE|Medline Pediatric Face Masks|Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
215079544|NCT03677466|PROCEDURE|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
215079545|NCT02313870|DRUG|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
214961057|NCT02224612|DEVICE|KC Childs Mask|KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
214961058|NCT04203212|DRUG|Goserelin Acetate|Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months
215079546|NCT02313870|DRUG|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
214353138|NCT05224414|BEHAVIORAL|Cognitive bias modification for interpretation bias|Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
214353139|NCT05224414|BEHAVIORAL|Psychoeducation|Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
214502656|NCT00558454|DRUG|Iron|Ferrous succinate mixture
214961059|NCT00423280|DRUG|6R-BH4|6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
214961060|NCT01706835|DRUG|aldoxorubicin|
214961061|NCT00473057|OTHER|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
214961062|NCT05177640|DRUG|99mTc-Duramycin|This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
214961063|NCT04812184|DEVICE|Tape Face Mask|Adding tape to face mask
214961064|NCT02630563|DRUG|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
214961065|NCT02630563|DRUG|Cyclosporine|Cyclosporine will be administered as per center practice.
214961066|NCT02630563|DRUG|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
215079547|NCT00211835|BEHAVIORAL|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
215079548|NCT00211835|BEHAVIORAL|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
215079549|NCT06210542|DRUG|ceftazidime avibactam|"Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \&gt; 50ml/min was 2.5g (2g/0.5g), once every 8 hours, and the infusion time was 2 hours.~Patients with renal injury adjust the dosage according to eCrCL"
215079550|NCT02946567|OTHER|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
215079551|NCT02946567|OTHER|Generic Game|Participants will play a generic game without any particular information about hearing health care.
214961067|NCT04819789|OTHER|Fermotein™ dry powder porridge|At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
214961068|NCT04819789|OTHER|Fermotein™ wet porridge|At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
214961069|NCT04819789|OTHER|Fermotein™ modified wet porridge|At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
214353140|NCT03335462|OTHER|Paravertebral injections|Paravertebral injections will be performed in the thoraco-lumbar plexus area under CT guidance
214961070|NCT04819789|OTHER|Mycoprotein porridge (matching control)|At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
214961071|NCT01684514|DEVICE|Confocal laser endomicroscopy|"Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image."
214961072|NCT04330144|DRUG|Hydroxychloroquine as post exposure prophylaxis|1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
214961073|NCT04330144|OTHER|Others(No intervention)|No treatment. Close monitoring and quarantine.
214961074|NCT02853526|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
214961075|NCT02853526|DRUG|Propranolol|Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
214961076|NCT02853526|PROCEDURE|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
214961077|NCT02853526|DRUG|Warfarin|Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
214961078|NCT04474808|OTHER|L-Arginin containing foot cream|The participants apply one foot (randomized assignment) with the study cream twice a day (morning and evening) over a period of six weeks.
215079552|NCT03000543|BIOLOGICAL|Vaccine|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
215079553|NCT01430325|DRUG|Hyperbaric Oxygen (1.5 atm abs)|Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
214353141|NCT03335462|OTHER|CT scan|CT scan will be performed as the needles are kept in their position after injecting the contrast
214353142|NCT04819269|DRUG|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
214353143|NCT04819269|DRUG|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
214353144|NCT04060394|DRUG|Phase I and Phase II: LAE001/prednisone + afuresertib|In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
214353145|NCT05046184|DRUG|Ketamine Hydrochloride|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of ketamine (0.5 mg/kg). Ketamine will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
214353146|NCT05046184|DRUG|Midazolam injection|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of midazolam (0.02 mg/kg). Midazolam will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
214353147|NCT04403698|DRUG|Alendronate Effervescent Oral Tablet|At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
214353148|NCT05583591|DEVICE|Combined cataract surgery with Hydrus microstent|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
214961079|NCT04474808|OTHER|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the control cream twice a day (morning and evening) over a period of six weeks.
215079554|NCT01430325|DRUG|Sham Chamber Session|Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
215079555|NCT01007123|DRUG|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
215079556|NCT00279838|PROCEDURE|Computer Assisted Navigation Knee Replacement|
214353149|NCT05583591|DEVICE|Combined cataract surgery with iStent Inject W|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
214353150|NCT03152552|DRUG|LIK066|LIK066 was supplied in different doses as tablets taken orally.
214353151|NCT03152552|DRUG|Placebo|Placebo was supplied as tablets and capsules taken orally.
214353152|NCT03152552|DRUG|Empagliflozin|Empagliflozin was supplied as capsules taken orally.
214353153|NCT02964845|BEHAVIORAL|WISH with CHW and referral to HFM|6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.
214353154|NCT02964845|OTHER|Enhanced Treatment as Usual|Linkage to Primary care.
214353155|NCT01047839|BIOLOGICAL|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
214353156|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
215079557|NCT02574013|DEVICE|Endoractor®|Endoscopic sponge for retraction of small intestine
215079558|NCT00820482|DRUG|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
214353157|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
214353158|NCT03525366|OTHER|Radiofrequency ablation|Radiofrequency Ablation (RFA) as an intervention is part of standard of care at Memorial Herman Hospital, Houston.
214353159|NCT06338696|OTHER|No intervention|No intervention
214353160|NCT00567242|BEHAVIORAL|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
214353161|NCT00567242|BEHAVIORAL|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
214353162|NCT04899349|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
214353163|NCT04899349|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
214353164|NCT04899349|DRUG|Metformin XR|Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
214353165|NCT04899349|DRUG|Dapagliflozin + metformin XR|Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily
214353166|NCT04899349|DRUG|Dapagliflozin|Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
214353167|NCT06175065|DRUG|RLS-0071|RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.
214353168|NCT06175065|DRUG|Placebo|Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.
214353169|NCT06437769|OTHER|reiki|effect of reiki application to women who have been hospitalized by ceserean during the hospitlalization process on anxiety depression comfort and breastfeesing
214961080|NCT02829658|BEHAVIORAL|Psychologic test|Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
214353170|NCT01857531|DRUG|Ganaxolone|"Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."
214353171|NCT01857531|DRUG|Nicotine Patch|"Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."
214353172|NCT06072196|DRUG|Novel hormonal therapy|As provided in real-world setting
214353173|NCT06966388|DRUG|Azelaic Acid|A thin layer of Azelaic acid should be applied to the entire area of radiation treatment twice daily, each day of the week (including weekends) starting one week prior to the start of radiation, then during the entire course of radiation treatment (usually 3-5 weeks), and for 3 weeks following the completion of radiation treatment.
214353174|NCT05054023|DRUG|Soulagel®|topic gel
214353175|NCT05054023|DRUG|Arthrosyl®|topic gel
214353176|NCT05914610|DRUG|Envolimab|Envolizumab 300mg, D1, ih, Q3W 4-6cycles
214353177|NCT05914610|DRUG|Fruquintinib|Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
214353178|NCT05914610|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
214353179|NCT05914610|DRUG|Tegafur|Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles
214353180|NCT05665777|DRUG|Qingyan Lihou Decoction|Chinese medicine granules
214961081|NCT02829658|OTHER|No intervention|No intervention
214961082|NCT01289327|DRUG|Sedation with Propofol or Midazolam+Alfentanil for FFB|Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (\~2 minutes) or according to clinical judgment.
214961083|NCT03320265|DRUG|PC-mAb|Monthly treatment for 3 months (4 administrations)
214961084|NCT03320265|DRUG|Placebo|Monthly treatment for 3 months (4 administrations)
214353181|NCT05665777|OTHER|Placebo|Placebo granules
214353182|NCT02726451|OTHER|Basic Skin Care|Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
214353183|NCT02726451|OTHER|Active Skin Care|Sensi Peel®, Rejuvenating Serum, and C\&E Strength Max skin care products (PCA SKIN®) in addition to the Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
214353184|NCT02089672|DEVICE|Catheter ablation|This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
214353185|NCT04987515|PROCEDURE|fenestration decompression combined with secondary curettage|First，fenestration decompression was performed. then, patients return every 3 months for follow up. If the cystic cavity area was gradually reduced after one year of follow-up, patients should be considered for secondary curettage surgery.
214961085|NCT03575247|DRUG|Glucocorticoids|Long-term use of glucocorticoids
214961086|NCT00144443|BEHAVIORAL|Basic home repair|
214961087|NCT00144443|BEHAVIORAL|Asthma Trigger Education|
214353186|NCT06540443|DRUG|MPB-2043 of 0.5 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
214353187|NCT06540443|DRUG|MPB-2043 of 1.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
214353188|NCT06540443|DRUG|MPB-2043 of 2.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
214353189|NCT06540443|DRUG|MPB-2043 of 3.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
214961088|NCT01013714|PROCEDURE|Cardiac Sympathetic Denervation (CSD)|Cardiac sympathetic denervation is performed using an endoscopic procedure called VATS (video-assisted thoracoscopic sympathectomy). The surgeon removes the lower half of the stellate ganglia in addition to the thoracic ganglia of T2 - T4 on both the right and left side. The VATS procedure provides a minimally invasive endoscopic approach that is safe and effective. The procedure can be completed in less than 45 minutes on each side.
214961089|NCT01013714|DRUG|Routine Care|Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
214961090|NCT03419117|PROCEDURE|ESP block|An ESP block will be performed prior to surgery for postoperative pain control
214961091|NCT03419117|PROCEDURE|Placebo|A sham ESP block will be performed before surgery in the placebo group
214961092|NCT03615261|BEHAVIORAL|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy \& attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing \& strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
214961093|NCT04583007|DRUG|Lanadelumab 150 mg|TAK-743-6001: Participants will receive subcutaneous (SC) injection of lanadelumab at a dose of 150 milligrams (mg) at the same frequency (for every 2 weeks \[Q2W\] or for every 4 weeks \[Q4W\]) given at the completion of SPRING study until benefit-risk no longer favors the individual participant or an appropriate alternative therapy becomes available or lanadelumab 150 mg/ 1 milliliter (mL) becomes commercially available or the participants turns 12 years of age or participant chooses to discontinue treatment. For participants aged 6-12 years, a dose frequency may be modified based on a benefit-risk assessment and medical decision from the treating physician.
214961094|NCT04583007|DRUG|Lanadelumab 300 mg|TAK-743-5012: Participants will receive SC injection of lanadelumab in prefilled syringe at a dose of 300 mg, Q2W or Q4W if well controlled for 26 weeks across Study TAK-743-3001 and this (TAK-743-5012) program.
214961095|NCT03100656|OTHER|A breakfast sandwich|A meat-based breakfast sandwich
215079559|NCT00820482|DRUG|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
215079560|NCT03208907|DRUG|CQ coadministered with PQ|113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
215079561|NCT03208907|DRUG|DHA-PQP coadministered with PQ|In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
215079562|NCT03208907|DRUG|CQ and PQ starting on Day 42|98 subjects in a 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
214353190|NCT06101199|OTHER|Acute Intermittent Hypercapnic Hypoxia|15 x \[1 min 9% O2, 4% CO2, and balance N2, followed by 1.5 min normoxia\];
214353191|NCT06101199|OTHER|Transcutaneous spinal cord stimulation|Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of \~25-35 mA and a pulse width of 400 µsec, using a biphasic symmetric waveform. Paired with Respiratory Resistance Training and Hand Grip Strength Training.
214353192|NCT06101199|OTHER|SHAM Acute Intermittent Hypercapnic Hypoxia|Normoxia for the amount of time AIHH is delivered.
214353193|NCT06101199|OTHER|SHAM Transcutaneous spinal cord stimulation|"Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of 0mA and a pulse width of 400 µsec,using a biphasic symmetric waveform.~Paired with Respiratory Resistance Training and Hand Grip Strength Training."
214353194|NCT04429607|DEVICE|Erbium:YAG Laser|Erbium:YAG 2940nm will be performed using single spot, multiple pulses on lesions.
214353195|NCT04429607|DEVICE|Pulsed Dye Laser|PDL will be performed using settings of 6-10 J/s2 on lesions.
214353196|NCT04429607|DEVICE|Nd:YAG Laser|Nd:YAG 1064nm will be performed using settings of 60-110 J/s2 on lesions.
214353197|NCT04429607|PROCEDURE|Electrodessication and curettage|Electrodessication and curettage will be performed using an epilating needle, followed by curettage on lesions.
214353198|NCT05758753|DEVICE|Quantitative Sensory Test|Quantitative Sensory Test (Medoc Ltd, Israel), QST is a non-invasive neurophysiological method that refers to a group of procedures that assess the perceptual responses to systematically applied and quantifiable sensory stimuli (modalities including heat, cold and vibration) for the purpose of characterizing somatosensory function or dysfunction. For this test, subjects will be seated comfortably on a chair in a quiet room, or laying supine in a horizontal examination chair, with ambient temperature of 24-25◦ C. Medial upper eyelid; just below the supraorbital notch, nasolacrimal sac area; 4-5 mm medial to nasal cantus, and non-dominant forearm will be used as test sites. Patients will be instructed in detail of the nature of the test and the need to react attentively and promptly to change in temperatures.
214353199|NCT06495684|DEVICE|Anodal tDCS + Social Learning|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
214353200|NCT06495684|BEHAVIORAL|Placebo Anodal tDCS + Social Learning|Social learning tasks are completed on a computer and consist of viewing video modeling of social interactions, facial emotion detection practice, and videos for emotion and empathy learning.
214486985|NCT06747026|DRUG|initial Concurrent iRT|"For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy concurrently with RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy concurrently with RT."
214961096|NCT03446378|DEVICE|Anodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
214961097|NCT03446378|BEHAVIORAL|Physical therapy|all patients will be submitted to a protocol of exercise with differents levels according with motor learing and neuroplasticity principles. All physical therapists were trained before the study.
214961098|NCT03446378|DEVICE|Cathodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
214961099|NCT03446378|DEVICE|Sham tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
214961100|NCT02154932|DRUG|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
214961101|NCT02154932|DRUG|single dose misoprostol|1 dose, 1 hours, prior surgery
214961102|NCT06004271|OTHER|exercise|"Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching"
214961103|NCT06004271|OTHER|exercise and taping|When applying kinesiology taping to the gluteus medius, first of all, for its anterior fiber, the tape portion will be attached lateral to the Spina iliaca anterior superior by giving a slight slope downwards from the crista iliaca with 50-75% tension. For the posterior fiber; Starting from the trochanter major, 50-75% tension will be applied along the muscle fiber.
214961104|NCT06004271|OTHER|placebo|In the placebo tape application, the kinesiological tappings will be adhered horizontally without tension along the long line of the Tensor facie late muscle. The application to the ankle will be attached horizontally, without tension, slightly above the lateral malleolus.
214961105|NCT03289247|DEVICE|tissue adhesive (Leukosan®)|Tissue ahaesive
214961106|NCT00447525|BIOLOGICAL|REVAXIS®|
214961107|NCT00447525|BIOLOGICAL|DT-Polio®|
214961108|NCT02061813|DRUG|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
214961109|NCT02061813|DRUG|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
214961110|NCT02061813|DRUG|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
214961111|NCT02061813|DRUG|Placebo|
214961112|NCT05006456|DEVICE|Catheter ablation|Subjects will undergo catheter ablation using the new technologies, including THERMOCOOL SMARTTOUCH® SF catheter with Visitag SURPOINT, QDOT catheter and HELIOSTAR catheter when they are used in conjunction with Carto system for AF ablations.
214961113|NCT01772927|DIETARY_SUPPLEMENT|Parenteral Nutrition|Protein and energy intakes
214961114|NCT03607877|BEHAVIORAL|Pedometer walking training and positive education|"Intervention: (1)Positive education: Six psychosocial sessions were designed to enhance elders' positive emotion, motivation and self-efficacy to walk.~(2) Pedometer walking training: walk at least 30 minutes per day and at least three times per week with family support and exercise companions."
214961115|NCT03607877|BEHAVIORAL|Pedometer walking with training|Intervention:walk at least 30 minutes per day and at least three times per week with family support and exercise companions.
214961116|NCT03607877|BEHAVIORAL|pedometer walking|Intervention: pedometer walking at least 30 minutes per day and at least three times per week
214961117|NCT03002545|DIETARY_SUPPLEMENT|Magnesium citrate|
214961118|NCT03002545|DIETARY_SUPPLEMENT|Placebo|
214961119|NCT02702843|PROCEDURE|Laparoscopic cholecystectomy with Xenon light|Standard laparoscopic cholecystectomy with white light
214961120|NCT02702843|PROCEDURE|Laparoscopic cholecystectomy (fluorescent cholangiography)|Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
214961121|NCT01495052|DIETARY_SUPPLEMENT|organic naked oat with whole germ (ONOG)|The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
215079563|NCT03208907|DRUG|DHA-PQP and PQ starting on Day 42|95 subjects in a 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
214486986|NCT06747026|DRUG|RT with maintenance of ICI|For post-treatment progressive NSCLC, salvage radiotherapy performed during immunotherapy.
214353201|NCT06961695|BEHAVIORAL|VR Mindfulness-Based Relaxation|"VR Mindfulness-Based Relaxation is a behavioral intervention that utilizes a VR application designed to reduce anxiety and promote relaxation. Participants in the experimental group will undergo a single VR session, scheduled on the day of hospital admission (one day prior to surgery).~The session lasts approximately 10 minutes and features an immersive beach environment combined with an audio-guided mindfulness exercise focused on breath awareness. Following the session, participants will engage in a brief, structured debriefing, during which they will reflect on what they felt, what they discovered, and how they can apply these insights during their hospital stay.~Participants will also be instructed to practice the 4-1-4 breathing technique three times per day during hospitalization. This technique involves inhaling for 4 seconds, holding the breath for 1 second, and exhaling for 4 seconds. It is intended to promote relaxation and support autonomic nervous system regulation."
214961122|NCT05048043|BEHAVIORAL|Computer-assisted Behavior Intervention|"The CABI includes a serious game called ATHEMOS that is designed to help students rehearse skills that ameliorate impairments associated with ADHD, including organization, scheduling, and note taking strategies. Once students have some experience with the game, a teacher consultee will help students actively transfer skills learned in the game to real-world classroom demands."
214353202|NCT05784350|DRUG|fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone|"group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia."
214353203|NCT04457648|DEVICE|manuka honey 16% eye drops ( Optimel )|16% manuka honey eye drops, australian FDA approved
214353204|NCT04457648|DEVICE|systane eye drops|systane lubricant eye drops
214961123|NCT05048043|BEHAVIORAL|Challenging Horizons Program|The Challenging Horizons Program is an established psychosocial intervention package for young adolescents with ADHD, focusing on academic and behavioral impairments.
214961124|NCT02427854|BEHAVIORAL|Education by animated training video|Training performed by watching an animated educational video.
214961125|NCT02427854|PROCEDURE|Interactive hands-on bedside training|Training performed as a traditional bedside training supported by a trainer in person.
214353205|NCT05585424|OTHER|AOT intervention|"The treatment will last 4 weeks, with an intensity of 3 sessions per week. During the sessions the MCI patient will observe his MCI partner and perform a programme of upper limb motor activities. At the same time the mild patient imitates the movement performed by the physiotherapist, all based on the AOT.~The activities will be based on items of the FUGL-MEYER scale. The sessions will last between 15 and 20 minutes and will be held three days a week. The intervention will last 5 weeks, with an initial assessment, 11 intervention sessions and a final assessment."
214353206|NCT02808455|DRUG|(Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
214353207|NCT02808455|DRUG|(Treatment B)|A single 80-mg oral solution dose of pacritinib
214353208|NCT00251810|DEVICE|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
214353209|NCT02399579|OTHER|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
214353210|NCT01289067|DRUG|Satraplatin|Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
214353211|NCT04656847|DRUG|in daily everyday routine practice|patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.
214961126|NCT00892463|DRUG|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
214961127|NCT06203535|OTHER|Aerobic training|In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities range from 60 to 75 percent of heart rate reserve during a 35-minute group cumulative exercise session.
214961128|NCT03291951|BEHAVIORAL|Resistance training|The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
214961129|NCT03783377|DRUG|ARO-APOC3|single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections
214961130|NCT03783377|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
214961131|NCT01156688|DRUG|Misoprostol|sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
214486987|NCT06747026|DRUG|RT after discontinuation of ICI|For post-treatment progressive NSCLC, salvage radiotherapy performed during within 90 days after the cessation of immunotherapy.
214961132|NCT01156688|DRUG|Misoprostol|buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
214961133|NCT00350077|DRUG|Intravenous Vitamin C|vitamin C IV during 24 hour period following burn
214961134|NCT00350077|DRUG|Vitamin C|IV vitamin C
214961135|NCT00264485|DRUG|E-TRANS Fentanyl hydrochloride; Morphine|
214353212|NCT03506971|OTHER|Psychologist's evaluation|The research coordinator psychologist will evaluate: the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.
214961136|NCT02992860|DRUG|JNJ-56022473|JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by \> 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
214353213|NCT03506971|OTHER|Pediatric Nurse's interventions|"Pediatrics nurses perform preventive home visits that are based on : joint observation with the parents of the baby, play with the baby and his parents, interview with the parents on their parenthood~Rhythm of home visits:~* 1 every month from birth to 1 year~* 1 every 2 months from 1 year to 2 years~* 1 every 3 months from 2 years to 4 years"
214353214|NCT03506971|OTHER|Joint home visits|"Coordinating psychologist and the referent pediatric nurse will perform home visits. During this time, the psychologist evaluate : the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.~Rhythm of joint home visits:~* 1 at 4 months~* 1 at 24 months"
214353215|NCT03273413|DRUG|Pravastatin|Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
214353216|NCT03273413|DRUG|Placebo|Inactive tablet
214353217|NCT01737580|DRUG|resiquimod|
214353218|NCT01737580|DRUG|placebo gel|
214353219|NCT03301051|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
214353220|NCT03301051|BIOLOGICAL|Placebo|Single dose of a Placebo
214961137|NCT02992860|PROCEDURE|Bone marrow analyses and CBC with differential|Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
214353221|NCT02042235|BEHAVIORAL|Parent-implemented intervention|In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
214353222|NCT06463288|PROCEDURE|Jacobsons Breathing Technique|Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
214353223|NCT06463288|PROCEDURE|Pranayama Technique|Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
214353224|NCT00047879|BIOLOGICAL|PEG-interferon alfa-2b|0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
214353225|NCT00047879|DRUG|Thalidomide|Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
214353226|NCT02748915|OTHER|Electrophysiological and psychoacoustic tests|
214353227|NCT06015854|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Patients will receive three immunizations, with an interval of 3 weeks between each immunization at weeks 0, 3 and 6. Each vaccination will be given as two injections; 1 injection in each leg. The injections will be administered intramuscularly in the upper legs, preferably in the m. vastus lateralis.
214353228|NCT01785238|OTHER|renal echography|renal echography to analyse the kidney
214353229|NCT01785238|OTHER|Blood sampling|Blood sampling to analyse different parameters of renal function
214961138|NCT02992860|OTHER|Flow cytometry analyses|Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
214961139|NCT02992860|OTHER|Central biobanking|Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
214961140|NCT02992860|PROCEDURE|Histopathology analysis|A bone marrow biopsy is taken whenever it seems necessary to the investigator.
214961141|NCT02992860|GENETIC|Cytogenetic analysis|The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
214961142|NCT02992860|PROCEDURE|Serum chemistry|For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
214961143|NCT02992860|PROCEDURE|Automated CBC|For CBC a minimum of 3 ml of peripheral blood have to be collected.
214961144|NCT02992860|PROCEDURE|Pregnancy Test|Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
214353230|NCT01785238|OTHER|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
214353231|NCT01785238|OTHER|Blood pressure measurement|
214353232|NCT05744687|DRUG|SPH4336 Tablets 400mg|"SPH4336 Tablets ：Orally, 400mg once a day; 28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
214353233|NCT05744687|DRUG|SPH4336 Tablets Placebo|"SPH4336 Tablets Placebo：Orally,28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
214353234|NCT00026273|DRUG|FOLFIRI regimen|
214353235|NCT00026273|DRUG|fluorouracil|
214353236|NCT00026273|DRUG|irinotecan hydrochloride|
214353237|NCT00026273|DRUG|leucovorin calcium|
214353238|NCT02672046|OTHER|Assessment at the Clinic of Sports Injuries|Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
214353239|NCT00035126|DRUG|epothilone b|
214353240|NCT05915702|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
214961145|NCT06251141|PROCEDURE|Gum Health gel|Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket with normal saline, and filling the socket with the Gum Health gel
214961146|NCT06251141|PROCEDURE|Gel foam|Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket
214961147|NCT05411835|DIETARY_SUPPLEMENT|Nutritional Ketone Supplement|Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener
214961148|NCT05411835|DIETARY_SUPPLEMENT|Isocaloric Placebo Supplement|Maltodextrin with flavors and stevia sweetener
214353241|NCT05915702|DRUG|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
214353242|NCT05915702|DRUG|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
214961149|NCT00452660|DRUG|Exjade|
214961150|NCT05763914|BEHAVIORAL|Change in the incidence of hand eczema|Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.
214961151|NCT05763914|BEHAVIORAL|Change in severity of hand eczema|Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.
214961152|NCT05763914|BEHAVIORAL|Change in the number of self-reported days with absence from work due to having hand eczema|Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.
214961153|NCT05763914|BEHAVIORAL|Change in the number of participants being forced to change their job due to having hand eczema|Self-reported change of job due to having hand eczema. Change between baseline and 6 months.
214961154|NCT05763914|BEHAVIORAL|Change in The Quality Of Life in in relation to hand eczema|Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.
214961155|NCT05763914|BEHAVIORAL|Change in the level of knowledge regarding skin care and protection.|Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.
214961156|NCT00777166|DRUG|oxytocin|oxytocin 5 units diluted with normal saline to a total volume of 10 mL
214961157|NCT00777166|DRUG|oxytocin|oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
214961158|NCT02632370|DRUG|Gliolan®|single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
214353243|NCT05915702|DRUG|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
214353244|NCT02818881|OTHER|High-speed yoga|
214353245|NCT02818881|OTHER|Low-speed yoga|
214353246|NCT06288984|DEVICE|active rTMS|The magnetic stimulation coil was tangent to the scalp and kept parallel for 10 minutes a day, 5 days a week for 4 weeks
214353247|NCT06288984|DEVICE|sham rTMS|The magnetic stimulation coil was tangent to the scalp and kept perpendicular for 10 minutes a day, 5 days a week for 4 weeks
214961159|NCT02632370|PROCEDURE|Fluorescence-Guided Surgery|performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
214961160|NCT00558012|DRUG|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
214961161|NCT00558012|DIETARY_SUPPLEMENT|Vitamin D 800 IU/daily|Daily divided dose
214961162|NCT00558012|DIETARY_SUPPLEMENT|Calcium 1200 mg/daily|supplement plus diet
214961163|NCT03454087|OTHER|Enteral Dextrose Infusion|A standard solution of 50% Dextrose (0.85 kcal/mL) will be infused via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
214961164|NCT03454087|OTHER|Free Water Infusion|An infusion of free water will be initiated via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
214961165|NCT01965002|DEVICE|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue
214961166|NCT01965002|DRUG|Aspirin|325 mg PO for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
214961167|NCT01965002|DRUG|Enoxaparin|40 mg by subcutaneous (SC) administration, for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
214961168|NCT01105104|DEVICE|MedMinder System|Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.
214961169|NCT01105104|DEVICE|MedMinder System - deactivated|Participants will receive a one-way reminder unit that will remotely transit information on medication adherence
214961170|NCT01724177|DRUG|Lenalidomide|25 mg of Lenalidomide administered orally once daily
214961171|NCT01773018|DRUG|Volitinib|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
214961172|NCT00700375|DRUG|Sodium bicarbonate|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
214961173|NCT00700375|DRUG|Sodium Chloride|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
214961174|NCT04226300|PROCEDURE|Laparoscopic|A transversus abdominis nerve block will be placed laparoscopically.
214961175|NCT04226300|PROCEDURE|Ultrasound|A transversus abdominis nerve block will be place by ultrasound
214961176|NCT03592836|DRUG|Loop Diuretics|intravenous administration of diuretics
214961177|NCT05063084|PROCEDURE|Optiflow - HFNO|Pre-oxygenation: HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2 Oxygenation: during the tracheal intubation, HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2
214961178|NCT05063084|PROCEDURE|Classic|Pre-oxygenation: with facemask during 2 min with 100% FiO2, flow 6 to 8L/min. No oxygenation during the tracheal intubation
214961179|NCT02431312|BIOLOGICAL|INO-1800|INO-1800 delivered by EP
214961180|NCT02431312|BIOLOGICAL|INO-9112|INO-9112 delivered by EP
214961181|NCT02431312|DRUG|Nucleos(t)ide Analogue Treatment|Continued treatment with nucleos(t)ide analogue
214961182|NCT00496158|DRUG|Clevudine|
214961183|NCT00496158|DRUG|Adefovir|
214961184|NCT02999334|BEHAVIORAL|Group Antenatal Care|To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
214961185|NCT06090968|PROCEDURE|Umbilical cord milking|20 cm of umbilical cord would be milked towards the infant with intact umbilical cord. The cord milking will be done four times. The entire procedure can be done in 15-20 seconds
214961186|NCT06090968|PROCEDURE|Immediate cord clamping|clamping the umbilical cord as soon as possible (average 30 seconds)
214353248|NCT05920369|OTHER|low-energy extracorporeal shockwave and a tailored exercise program|"the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.~Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises"
214353249|NCT05920369|OTHER|low-energy extracorporeal shockwave|the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.
214353250|NCT05920369|OTHER|tailored exercise program|Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises
214353251|NCT04146714|OTHER|Substance use questionnaire|Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
214353252|NCT04146714|OTHER|Physical activity questionnaire|Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
214353253|NCT03106818|DRUG|bupivacain with magnesium sulphate|will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
214353254|NCT03106818|DRUG|Bupivacaine only|will receive bupivacain 0.125% infusion in the presternum , for 48 hours
214353255|NCT03106818|DRUG|conventional|only conventional post operative analgesics will be used
214353256|NCT06961734|BEHAVIORAL|follicular group|Exercised at Fatmax intensity four times per week and plus three additional exercise during the late follicular phase of each cycle.
214353257|NCT06961734|BEHAVIORAL|luteal group|Exercised at Fatmax intensity four times per week and plus three additional exercise during the mid- luteal phase of each cycle.
214486988|NCT06746818|BEHAVIORAL|Heart Math interventions|". The key components of Heart Math interventions include:~1. Heart Rate Variability (HRV) Training: This involves biofeedback techniques to help individuals learn how to control their heart rate and promote emotional balance.~2. Quick Coherence Technique: Participants are guided through a series of steps to shift their emotional state from stress to calmness, facilitating a sense of peace and emotional clarity.~3. Focus on Positive Emotions: Encouraging individuals to cultivate feelings like gratitude and compassion can enhance resilience and overall mental well-being.~4. Mindfulness Practices: Incorporating mindfulness helps individuals become more aware of their thoughts and feelings, allowing them to respond to stressors more effectively."
214486989|NCT06746480|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date is Days 1 through 3.
214961187|NCT01243918|OTHER|Oxygen therapy delivery systems|T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
214961188|NCT01443234|OTHER|OxIGen|Internet-based intervention with 12 sessions over 4 weeks
214353258|NCT06961734|BEHAVIORAL|Control group|Exercised at Fatmax intensity four times per week.
214353259|NCT05427279|DIETARY_SUPPLEMENT|Placebo|The participant will consume a supplemental dose of a placebo (20g maltodextrin with 50mg vitamin C)
214961189|NCT01443234|OTHER|OxIGen: control version|A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
214353260|NCT05427279|DIETARY_SUPPLEMENT|Hydrolized Collagen|The participant will consume a supplemental dose of Hydrolized collagen (20g with 50mg vitamin C)
214353261|NCT05427279|DIETARY_SUPPLEMENT|PrimaColl|The participant will consume a supplemental dose of PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)
214353262|NCT05427279|DIETARY_SUPPLEMENT|Whey protein|The participant will consume a supplemental dose of whey protein (20g whey isolate with 50mg vitamin C)
214486990|NCT06747767|PROCEDURE|Arthroscopy|Arthroscopy
214486991|NCT06747767|PROCEDURE|Open reduction|Open reduction
214486992|NCT06747754|OTHER|Establishment of a Database of HIV Patients|Establishment of a database that allows for systematic and continuous collection of data relating to clinical, laboratory and treatment characteristics of patients with HIV-1 for research purposes.
214486993|NCT06742268|OTHER|Single vision spectacles|Other interventions for myopia treatment, except for glasses, will not be provided.
214486994|NCT06741371|PROCEDURE|Monocryl|Closure of the uterine scar by monofilament suture material
214961190|NCT01705080|DEVICE|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
214961191|NCT05361967|DEVICE|The Tack Endovascular System|The Tack Endovascular System is designed to treat vascular dissections with Tack implant(s) following angioplasty.
214961192|NCT04565548|OTHER|Educational program for hypertensive patients|The theory-guided program consisted of one session of health education, self-developed leaflet, and weekly text messaging for 12 weeks.
214961193|NCT04565548|OTHER|Usual care|One standardized health education and a leaflet developed by the Health Bureau. As similar as the intervention group, weekly text messaging will be delivered, but the content is not related to the blood pressure control.
214961194|NCT00856791|DRUG|ON 01910.Na|
214353263|NCT06562569|DEVICE|non-invasive cervical vagal nerve stimulation ncVNS|The ncVNS device is a rechargable, handheld device that generate a proprietary frequency-modulated electrical stimulus at low voltage (max 24V) with a max current output of 60mA. The signal consists of 1ms bursts of 5kHz sine waves repeated at 25Hz. Two stainless steel contact surfaces coated with conductive gel deliver the stimulus to the neck in the vicinity of the vagus nerve.
214961195|NCT04846270|DEVICE|TENA SmartCare Change Indicator|Each participating subject will be provided with TENA SmartCare Change Indicator and incontinence products for the duration of the investigation. Each participating subject will be allocated to the incontinence type(s) that are considered most suitable.
214961196|NCT00329095|DRUG|travoprost, latanoprost, or bimatoprost|
214961197|NCT00329095|DRUG|Additional ocular hypotensive medication|
214961198|NCT00789607|DEVICE|Transrectal APT Device or Transperineal Device will be used|Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
214353264|NCT04647526|DRUG|[Lu-177]-PNT2002|Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles
214353265|NCT04647526|DRUG|Abiraterone|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
214961199|NCT00789607|DEVICE|TRUS probe|Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
214961200|NCT00206427|DRUG|GW572016|Lapatinib, 500 mg
214961201|NCT00206427|DRUG|lapatinib|Lapatinib 500 mg PO
214961202|NCT00455000|BIOLOGICAL|PF-04360365|Monoclonal antibody
214961203|NCT00455000|DRUG|Placebo|Placebo
214961204|NCT00003843|DRUG|irinotecan hydrochloride|
214961205|NCT00003843|GENETIC|mutation analysis|
214961206|NCT00003843|GENETIC|polymorphism analysis|
214961207|NCT01999985|DRUG|Dasatinib - 1A|1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.
214961208|NCT01999985|DRUG|Afatinib - 1A|1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.
214961209|NCT01999985|DRUG|Dasatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
214961210|NCT01999985|DRUG|Afatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
214961211|NCT03784391|DRUG|Lampit (Nifurtimox, BAYA2502)|Nifurtimox is a drug already approved in some South American countries since more than 45 years
214961212|NCT02653157|OTHER|MDR-GNB|
214961213|NCT06366646|OTHER|Competency-based intervention|90 head nurses and their assistants received the competency-based intervention program
214353266|NCT04647526|DRUG|Enzalutamide|Enzalutamide (160 mg orally qd)
214961214|NCT00281697|DRUG|Bevacizumab|The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
214961215|NCT00281697|DRUG|Placebo|
214961216|NCT00281697|DRUG|Standard chemotherapy|"Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle."
214961217|NCT06357520|DRUG|Baxdrostat|Baxdrostat tablet will be administered orally.
214961218|NCT06357520|DRUG|Itraconazole|Itraconazole capsule will be administered orally.
214961219|NCT00828061|DRUG|Placebo|Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
214961220|NCT00828061|DRUG|prednisone|Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
214961221|NCT00828061|DRUG|prednisone|Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
214961222|NCT05545423|OTHER|instrumented assisted soft tissue mobilization|the appropriate Graston technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and invested the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sternocleidomastoids and upper fibers of trapezius muscles. The IASTM technique was applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, following immediately by an additional 20-seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds.
214961223|NCT05545423|OTHER|traditional therapy|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises
214961224|NCT01824888|DRUG|JUC solution|1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
214961225|NCT01824888|DRUG|propan-2-ol|1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
214961226|NCT01400906|DRUG|100 micrograms Fluticasone propionate|100 micrograms micronized drug blended with lactose in dry powder inhalator
214961227|NCT01400906|DRUG|500 micrograms Fluticasone propionate|500 micrograms micronized drug blended with lactose in dry powder inhalator
214961228|NCT01400906|DRUG|lactose powder|lactose powder in dry powder device : placebo comparator
214353267|NCT03797378|OTHER|eM2M|The eM2M intervention involves three 60-minute sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
214353268|NCT06559488|DRUG|Bevacizumab Injection [Avastin]|Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.
214353269|NCT06559488|PROCEDURE|Pars Plana Vitrectomy|routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients
214353270|NCT06372275|BEHAVIORAL|Values Clarification Mobile Application|Participants in the intervention group will be asked to answer a series of values clarification writing prompts related to physical activity once a day over four weeks.
214353271|NCT06372275|BEHAVIORAL|Self-Reflection Mobile Application|Participants in the control group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to physical activity.
214961229|NCT00619372|DRUG|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
214961230|NCT00619372|DRUG|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
214961231|NCT00619372|DRUG|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
214961232|NCT00619372|DRUG|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
214961233|NCT00619372|DRUG|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
214961234|NCT00619372|DRUG|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
214961235|NCT02474134|DRUG|Interferon beta-1b (PF530, Betaferon)|Single subcutaneous administration
214961236|NCT02418793|DRUG|MOD-5014|Long Acting Factor VIIa
214961237|NCT03130959|BIOLOGICAL|Nivolumab|Specified dose on specified days
214961238|NCT03130959|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214961239|NCT04013295|OTHER|Prize-linked savings|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
214961240|NCT00437060|PROCEDURE|Cognitive Assessment|Ancillary studies
214961241|NCT00437060|PROCEDURE|Diffusion Tensor Imaging|Correlative studies
214961242|NCT00437060|OTHER|Laboratory Biomarker Analysis|Correlative studies
214961243|NCT00437060|OTHER|Pharmacological Study|Correlative studies
214961244|NCT00437060|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
214961245|NCT01019460|PROCEDURE|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
214961246|NCT06092034|GENETIC|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
214961247|NCT04964336|OTHER|Analysis of B cells|B cells from blood and cerebrospinal fluid will be analyzed using RNA-seq
214961248|NCT03444259|PROCEDURE|Cardiac surgery|Open heart surgery
214961249|NCT04053907|OTHER|Community Case Management|Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.
214961250|NCT04053907|OTHER|Weekly fever screening and treatment|Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.
214961251|NCT04053907|OTHER|Monthly malaria screening|CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).
214961252|NCT04053907|OTHER|MDA|CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
215079564|NCT05238259|DEVICE|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
214961253|NCT03601156|DEVICE|intraarterial chemoembolization|
214961254|NCT03601156|DEVICE|intravenous chemotherapy|
214961255|NCT06465771|BEHAVIORAL|Youth-led NCD risk reduction intervention|With the help of Youth (students of grades 9 and 10), their parents and other stakeholders, including teachers, headteachers, and canteen staff through qualitative interviews, we will develop an intervention focuses on NCD risk reduction among younger peers (students of grades 5 and 6). A nutritionist will train the youth on how to deliver the intervention among their younger peers.
215079565|NCT05238259|DEVICE|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the pateint to easily roll wrist back and forth focusing on the wrist and arm
214353272|NCT06649292|DRUG|SHR-A1904|SHR-A1904
214353273|NCT06649292|DRUG|Paclitaxel, Docetaxel, Irinotecan|Paclitaxel, Docetaxel, Irinotecan
214353274|NCT06412731|OTHER|Cera-bur|Dental caries removal using a low-speed handpiece and a ceramic bur and restoring the cavity with Glass ionomer filling material
214353275|NCT06412731|OTHER|Brix3000|Chemical-dissolving active dental caries and hand instrument used for removing the lesion then restoring with Glass ionomer filling material
214353276|NCT06412731|OTHER|E-SDF|Arresting the infected dentin and the demineralized lesion covered with Glass-ionomer filling
214353277|NCT06124625|PROCEDURE|Rehabilitation combined to a digital maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week maintenance program (2 sessions per week à 90 minutes, digital and live). The multimodal programs consist of physiotherapy, training therapy, medical support, cognitive training, education and psychological support.
215079566|NCT02060994|OTHER|No intervention|No intervention
214353278|NCT06124625|PROCEDURE|Rehabilitation without maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week usual care period.
214353279|NCT06561529|DEVICE|Gastric Bypass Stent System|The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity holds potential as a non-invasive technique for managing hepatic fibrosis. This clinical investigation will be used to evaluate the safety and performance of the investigational device for the intended use.
214353280|NCT02167022|OTHER|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
214353281|NCT03956498|OTHER|Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy|"* Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~* Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24."
214353282|NCT05094960|DIAGNOSTIC_TEST|Blood samples|5 blood samples for each patient during CABG (coronary artery bypass grafting) surgery pre/on/post cardiopulmonary bypass machine
214353283|NCT00435370|DRUG|Tropisetron|10 mg/day
214353284|NCT00435370|DRUG|Placebo|placebo
214961256|NCT01960062|DEVICE|Diabetes software and device|USB cord, CD-rom, and application to allow communication with provider
214961257|NCT01168609|PROCEDURE|Primary percutaneous coronary intervention|Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
214961258|NCT01023347|DRUG|Paclitaxel (Genexol®)|
214961259|NCT01023347|DRUG|Paclitaxel loaded polymeric micelle (Genexol-PM®)|
214961260|NCT02384538|BIOLOGICAL|ABT-981|ABT-981 administered by subcutaneous injection
214353285|NCT00435370|DRUG|Risperidone|6mg/day
214353286|NCT04584372|DIETARY_SUPPLEMENT|High-nitrate intervention|The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).
214353287|NCT04584372|DIETARY_SUPPLEMENT|Low-nitrate intervention|The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.
214353288|NCT01965834|DRUG|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \< 50 mL/min will receive a reduced dose of 54 mg orally daily.
214353289|NCT01468402|PROCEDURE|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
214353290|NCT00345774|DRUG|PRX-08066|
214353291|NCT02863640|DEVICE|Color retinography|
214961261|NCT02384538|BIOLOGICAL|Placebo for ABT-981|Placebo for ABT-981 administered by subcutaneous injection
214961262|NCT03457324|DRUG|JCM-16021|This prescription with seven ingredients.
214353292|NCT02863640|DEVICE|Optical coherence tomography|
214353293|NCT02863640|DEVICE|Fundus autofluorescence imaging|
214353294|NCT03943095|OTHER|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
214353295|NCT03943095|OTHER|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
214353296|NCT02858739|DEVICE|BIOFREEDOM STENT|
214353297|NCT00008853|BIOLOGICAL|GBS III-TT-SSI|
214961263|NCT03457324|DRUG|Placebo|Placebo
215079567|NCT03333148|DRUG|Nestle IMPACT Immunonutrition|Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
215079568|NCT03333148|OTHER|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
215079569|NCT01546441|BEHAVIORAL|interprofessional assessment|assessment by interprofessional team
214353298|NCT00008853|BIOLOGICAL|GBS III-TT-MPHL|
214353299|NCT05282524|DEVICE|Transvaginal ultrasound performed by a woman herself (with remote healthcare professional supervision)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
214486995|NCT06741787|DRUG|Patients desensitized by sublingual spray|Drug: Oraltekzc®️(Canis familiari), Oraltek®️(Felis domesticus), Oraltek®️(Alternaria alternata), dosage form: sublingual spray.
214961264|NCT01349530|OTHER|Evaluating of usual care|RESEARCH IN CURRENT CARE
214961265|NCT01349530|OTHER|Evaluation of CREATIF|RESEARCH IN CURRENT CARE
214961266|NCT02103023|DRUG|Imiquimod ointment|5% 250mg imiquimod ointment
214961267|NCT02103023|DRUG|Aqueous cream|aqueous cream
214961268|NCT02103023|BIOLOGICAL|Intradermal influenza vaccine|intradermal trivalent influenza vaccine (Intanza15)
214961269|NCT02103023|BIOLOGICAL|Intramuscular influenza vaccine|intramuscular trivalent influenza vaccine (Vaxigrip)
215079570|NCT01546441|BEHAVIORAL|usual care|usual care in primary care clinic
215079571|NCT06277349|DEVICE|Toric multifocal IOL|Implant of Multifocal toric intraocular lens only
214353300|NCT02612402|DEVICE|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
214353301|NCT02612402|DEVICE|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
214353302|NCT01735123|DIETARY_SUPPLEMENT|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
214353303|NCT03585647|PROCEDURE|hip arthroplasty|Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
214353304|NCT06025331|PROCEDURE|BIO-RSA|Bony increased offset-reversed shoulder arthroplasty(BIO-RSA) will be performed.
214353305|NCT06025331|PROCEDURE|RSA|Conventional reversed shoulder arthroplasty(RSA) will be performed.
214353306|NCT02293187|DIETARY_SUPPLEMENT|vitamin D3|Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level \<70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
214353307|NCT02293187|OTHER|Placebo|Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
214961270|NCT03061578|DIAGNOSTIC_TEST|Tear Film Imager|Ocular surface imaging assessment by the Tear Film Imager (TFI)
214961271|NCT03061578|DIAGNOSTIC_TEST|Low Humidity Environmental Exposure Chamber (LH-EEC)|Subjects will enter the LH-EEC (\<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.
214961272|NCT04446429|DRUG|Proxalutamide|200 mg q.d.
214961273|NCT04446429|OTHER|Standard of Care|Standard of care as determined by the PI
214961274|NCT05689853|DRUG|AK119|AK119 is an anti-CD73 monoclonal antibody.
214961275|NCT05689853|DRUG|AK112|AK112 is a bispecific monoclonal antibody against VEGF and PD-1.
214353308|NCT01053208|DRUG|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
214961276|NCT03259152|DRUG|Denosumab|Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
214961277|NCT00179764|PROCEDURE|Immunoablative Hematopoietic PBSC Transplant|Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
214961278|NCT00179764|PROCEDURE|Busulfan pharmacokinetics|Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion
214353309|NCT01875926|BIOLOGICAL|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
214961279|NCT00179764|RADIATION|Central Nervous System (CNS) prophylaxis radiation|"* Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.~* Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant."
214961280|NCT04984122|PROCEDURE|LEEP|According to the size of the cervix, a loop electrode size was selected. The electrical power for the loop electrode was set to 50 W cut and 45 W coagulation in blended mode. LEEP was performed by carefully passing the loop around the transformation zone from 12 o'clock to 6 o'clock. An additional top-hat excision was performed in patients with a lesion deep in the cervical canal. After completion of the excision, hemostasis was exclusively obtained using the ball electrode in spray coagulation mode. No suturing or other methods were used for hemostasis.
214961281|NCT02617498|DEVICE|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.
214353310|NCT01875926|BIOLOGICAL|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
214353311|NCT01875926|BIOLOGICAL|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
214353312|NCT00074035|DRUG|pentostatin|4 mg/sq m IV infusion over 20-30 min q 2 weeks
214353313|NCT05652062|DEVICE|Prizvalve® system|Transcatheter valve-in-valve replacement
214353314|NCT04597853|DIAGNOSTIC_TEST|Assessment of lung mechanics and heart-lung interactions|Impedance tomography, right-heart catheterization, oesophageal pressure measurements, indirect calorimetry and classic mechanical ventilation parameters
214353315|NCT03784339|OTHER|Physiotherapy + education|Participants will take part in a 30 minute education session surrounding fear of movement and catastrophizing thoughts. They will then receive standard care, which will involve strength exercises and taping if needed.
214353316|NCT03784339|OTHER|Physiotherapy|Standard physiotherapy care
214353317|NCT01097967|OTHER|CPAP|
214353318|NCT01396967|DEVICE|surgery|cataract surgery
214353319|NCT04414982|BEHAVIORAL|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
214353320|NCT04414982|BEHAVIORAL|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
214961282|NCT02617498|DEVICE|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
214961283|NCT01214993|DRUG|GSK1349572|GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
214353321|NCT05614297|DIAGNOSTIC_TEST|Knee joint laxity test|Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
214961284|NCT01214993|DRUG|Placebo|Placebo is a tablet with no drug in it.
214961285|NCT01214993|DRUG|Iohexol Injection|Iohexol is an FDA approved radiologic contrast medium
214961286|NCT01214993|DRUG|Para-aminohippurate infusion|Para-aminohippurate is an agent to measure effective renal plasma flow.
214961287|NCT06165237|DRUG|BR6001-1|One tablet administered alone, Once a day
214961288|NCT06165237|DRUG|BR6001-2|One tablet administered alone, Once a day
214961289|NCT04188886|OTHER|Practice survey|Practice survey on
214353322|NCT00874861|BIOLOGICAL|Peptide vaccine + Poly-ICLC|"Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.~Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical \& Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine."
214353323|NCT04241861|OTHER|Respiratory support (High-flow oxygen therapy)|Noninvasive respiratory support respiratory support
214353324|NCT04241861|OTHER|Respiratory support (Helmet PSV)|Noninvasive respiratory support respiratory support
214353325|NCT04241861|OTHER|Respiratory support (Helmet CPAP)|Noninvasive respiratory support respiratory support
214353326|NCT01535716|BEHAVIORAL|hemodynamic optimization strategy driven by the ECOM|"goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) \& cardiac index (CI).~goals:~* SVV \< 11%~* IC \> 2,2 ml/min/m²~During the anesthesia"
214353327|NCT01535716|BEHAVIORAL|standard management strategy|"goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~* Diuresis \> 0,5ml/kg/h~* Blood pressure , PAM \> 65 mmHg~* Pulse pressure variation~* CVP 8 to 12 cmH20~* Visual aspect of the heart~* Overload signs During the anesthesia"
214353328|NCT05186623|DRUG|Vedolizumab, Ustekinumab, or Tofacitinib|Drug administration and prospective follow-up for evaluating response
214353329|NCT01060982|DEVICE|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
214961290|NCT01014052|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
214961291|NCT03839615|PROCEDURE|guided bone regenerations|"intra oral procedures.~* Flap will be done.~* In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~* In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
214353330|NCT03411967|DRUG|Apatinib|apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.
214353331|NCT03411967|DRUG|Docetaxel|Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment
214961292|NCT02706080|OTHER|emergency|
214961293|NCT02966717|DRUG|Rituximab|Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer.
214961294|NCT02966717|DRUG|conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
214961295|NCT02966717|DRUG|Mesenchymal stem cells|Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation.
214961296|NCT04215796|DEVICE|ReX-C system|CFTR modulators are dispensed to patients via ReX-C system
214353332|NCT01327326|DRUG|Naltrexone|Oral, 50 mg, 1 Time Dose
214353333|NCT01327326|DRUG|Placebo|Oral, 1 Time Dose
214353334|NCT03083587|BEHAVIORAL|Normal lifestyle|Normal lifestyle
214961297|NCT01853683|PROCEDURE|Conservative Management|
214961298|NCT01853683|PROCEDURE|Operative Management|
214961299|NCT05567471|BIOLOGICAL|BBV154 Intranasal Vaccine|Administered BBV154 vaccine in form of drops (0.5 mL) via intranasal route
214961300|NCT05567471|BIOLOGICAL|Intramuscular vaccine COVAXIN|Administered BBV152 vaccine via intramuscular route
214961301|NCT05567471|BIOLOGICAL|Covishield|Administered vaccine via intramuscular route
214961302|NCT05971264|DIAGNOSTIC_TEST|Near infrared-spectroscopy|Comparison of regional intestinal oxygen saturation (measured with near infrared-spectroscopy) and indirect intraabdominal pressure measurement (bladder pressure) in muscle-relaxed, sedated patients compared to awake, non-sedated patients.
214961303|NCT02256917|BIOLOGICAL|Human cl rhFVIII|
214961304|NCT03090061|DIAGNOSTIC_TEST|Light induced fluorescence intraoral camera|assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
215079572|NCT06277349|DEVICE|Non-toric multifocal IOL|Implant of non-toric multifocal lens plus incisional surgery
214353335|NCT03083587|BEHAVIORAL|Exercise|Mild exercise 3 min every half hour
214353336|NCT03083587|PROCEDURE|muscle and fat biopsy|Biopsy under local anesthesia
214353337|NCT03083587|DEVICE|Continuous glucose monitoring|Glucose concentrations during the study period
214353338|NCT03083587|DEVICE|Activity monitoring (ActivePal)|Objective measurements of standing and sitting time
214353339|NCT00895401|DIETARY_SUPPLEMENT|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
214961305|NCT03090061|DIAGNOSTIC_TEST|Visual-tactile assessment method according to FDI criteria|assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
214961306|NCT06479408|OTHER|progressive muscle relaxation (PMR) technique and vestibular rehabilitation exercises|A will be treated by progressive muscle relaxation (PMR) technique as a mean of stress relaxation and vestibular rehabilitation exercises for postural stability through Swiss ball, BOSU ball, balance board etc. Other components of vestibular rehab including gaze stability enhancement, improvement in vertigo and activities of daily living will also be focused.
214961307|NCT06479408|OTHER|virtual reality (VR)|virtual reality (VR) based intervention program where three dimensional-3D environments will be used reduce stress and improve balance. A Simulator Sickness Questionnaire (SSQ) will be filled by participants before and after each session of VR to discriminate whether VR is provoking the symptoms or not.
214961308|NCT03756597|DEVICE|ReCIVA|The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.
214353340|NCT00895401|OTHER|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
214353341|NCT03584698|DRUG|Misoprostol 100Mcg Tab|women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
214353342|NCT03584698|DRUG|Evening Primrose Oil 1000 MG|women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
214353343|NCT00789087|PROCEDURE|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
214353344|NCT00789087|PROCEDURE|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
214353345|NCT03877445|DEVICE|exposition half-face|Patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control. The effect of blue light on the melasma lesions will be assessed from Day 1 to Day 6 using chromametry and a modified Melasma Area and Severity Index on standardized photographs
214353346|NCT06362681|OTHER|Fluoride|Application of remineralizing agents on teeth and molars with MIH during 24 months of follow-up.
214353347|NCT00415987|PROCEDURE|Hematopoietic Stem Cell Transplantation|
214353348|NCT02023970|DEVICE|Patients receiving animal-derived bioprosthetic heart valves.|
214353349|NCT02023970|OTHER|Echocardiography (1)|
214353350|NCT02023970|OTHER|Echocardiography (2)|
214353351|NCT02023970|OTHER|Echocardiography (3)|
214353352|NCT02023970|BIOLOGICAL|Blood sample (1)|
214353353|NCT02023970|BIOLOGICAL|Blood sample (2)|
214353354|NCT02023970|BIOLOGICAL|Blood sample (3)|
214353355|NCT06397469|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
214353356|NCT06397469|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
214353357|NCT04195503|PROCEDURE|Liver Transplantation|Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
214353358|NCT05400798|DEVICE|Adipose Derived Regenerative Cells|single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
214353359|NCT05400798|DEVICE|Corticosteroid|a single corticosteroid injection into the associated subacromial space
214353360|NCT05134454|DIAGNOSTIC_TEST|Extended ECG investigation|At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.
214353361|NCT02993068|OTHER|Educational Intervention|Watch genetic testing online educational video
214353362|NCT02993068|OTHER|Genetic Counseling|Receive post-telephone genetic counseling
214353363|NCT02993068|OTHER|Genetic Counseling|Receive pre-telephone genetic counseling
214353364|NCT02993068|OTHER|Laboratory Biomarker Analysis|Correlative studies
214353365|NCT02993068|OTHER|Questionnaire Administration|Ancillary studies
214353366|NCT03373604|DRUG|18F-MK-6240|18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
214353367|NCT03373604|PROCEDURE|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
214353368|NCT05790343|BEHAVIORAL|BAPHYC|Nine weekly peer led group meetings
214353369|NCT06572436|BEHAVIORAL|Multimedia information training|The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
214353370|NCT01065961|DRUG|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
214353371|NCT01065961|DRUG|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
214961309|NCT03756597|DEVICE|CASPER|Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line
214353372|NCT02465593|DRUG|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
214961310|NCT05149547|DIAGNOSTIC_TEST|blood culture versus mNGS detection|peripheral 4ml for mNGS detection
214961311|NCT04806321|OTHER|Project SOLVE|This 30-minute, self-guided, digital program is designed to help adolescents solve, rather than be overwhelmed by, everyday problems.
214961312|NCT04806321|OTHER|Project SUCCESS|This 30-minute, self-guided, digital program is designed to help adolescents develop study skills.
214961313|NCT04252963|DRUG|MUCOLASE tablet (streptokinase • streptodornase)|streptokinase • streptodornase 5mg
214961314|NCT04252963|DRUG|Placebo|Placebo of MUCOLASE tablet
214961315|NCT01075919|DIETARY_SUPPLEMENT|n-3 PUFAs|1 g DHA-rich fish oil taken daily for 12 weeks
214961316|NCT01075919|DIETARY_SUPPLEMENT|Placebo|1 g olive oil taken daily for 12 weeks
214961317|NCT01075919|DIETARY_SUPPLEMENT|n-3 PUFAs|1 g EPA-rich fish oil taken daily for 12 weeks
214961318|NCT05206383|BEHAVIORAL|Positive message - placebo|"Subjects who will be told that the applied plastering method significantly increases muscle strength (positive message - placebo)."
214353373|NCT02465593|DRUG|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
214353374|NCT02465593|DRUG|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
214353375|NCT02465593|PROCEDURE|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
214353376|NCT02465593|RADIATION|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
214961319|NCT05206383|BEHAVIORAL|Negative message - nocebo|"Subjects who will be told that the applied plastering method has no effect on muscle strength (negative message - nocebo)."
214961320|NCT05206383|BEHAVIORAL|Neutral message|"Subjects who will be told that the applied plastering method is currently under investigation and the investigators do not know its effects (neutral message)."
214961321|NCT03124498|BIOLOGICAL|CIK Cell|Autologous cytokine-induced killer (CIK) cell
214961322|NCT03283332|OTHER|No intervention|
214961323|NCT06955039|OTHER|Sand Activites|Exercises included walking, jogging, striding, bounding, galloping, and short sprints.Exercise intensity (running speed) was controlled using a stopwatch and predefined running distances on the sand-based exercise court.
214961324|NCT06955039|OTHER|Towel Curl Exercises|The experimental group will perform Towel Curl Exercises Sand .In Week 1-4 the exercises will conducted without weights while in weeks 5-8 the exercise included the use of dumbbells weighing 2kg.this exercises will conducted in a sitting position on a slick surface.
214961325|NCT06955039|OTHER|(TCE)|The control group will only perform towel curl exercises In Week 1-4 the exercises will conducted without weights while in weeks 5-8 the exercise included the use of dumbbells weighing 2kg.this exercises will conducted in a sitting position on a slick surface.
214961326|NCT03692923|OTHER|virtual community|
214961327|NCT00313586|DRUG|Azacitidine|Given SC
214961328|NCT00313586|DRUG|Entinostat|Given PO
214961329|NCT00313586|OTHER|Laboratory Biomarker Analysis|Correlative studies
214961330|NCT05916053|DIETARY_SUPPLEMENT|Vitamin D supplementation|50.000 IU of vitamin D supplementation was prescribed for deficient/insufficient participants for a 3 month period.
214961331|NCT05084976|BEHAVIORAL|COVID 19 vaccine counseling|After surveys are completed, pulmonary provider (nurse practitioner or physician) will provide counseling via phone or in person about the COVID 19 vaccine. Safety, efficacy and side effects will be reviewed.
214961332|NCT03076996|BEHAVIORAL|Online support group|"Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.~The m/eHealth intervention components include:~* Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis~* Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis~* Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
214961333|NCT06192238|PROCEDURE|adrenal venous sampling|Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
214961334|NCT01027468|DRUG|Bevacizumab|intraocular bevacizumab injection
214961335|NCT03117361|DRUG|plitidepsin|Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
214961336|NCT03117361|DRUG|Bortezomib|BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
214961337|NCT03117361|DRUG|Dexamethasone|DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
214961338|NCT03153800|BIOLOGICAL|bronchial basal cells|Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
214961339|NCT01869088|DRUG|Recombinant Human Adenovirus Type 5 Injection|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery
214353377|NCT01496352|DRUG|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
214353378|NCT01496352|DRUG|Placebo|DFA-02 placebo
214353379|NCT00710424|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
214353380|NCT00710424|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
214961340|NCT01869088|PROCEDURE|Transartery Chemoembolization|Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
214961341|NCT01999764|DRUG|QLT091001|QLT091001 administered orally at multiple time points.
214961342|NCT01999764|OTHER|Placebo|Placebo is administered orally at multiple time points.
215079573|NCT01512680|BEHAVIORAL|Education to Functional Insulin Therapy|"* Intake of Continuous Glucose Monitor for 5 to 7 days~* Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~* 1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~* 3 months after the training: Blood sampling, vital signs and data on diabetes~* 6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~* 9 months after the training: Blood sampling, vital signs and data on diabetes~* 1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~* 12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
214353381|NCT05699434|BEHAVIORAL|Obstetrics and Gynecology residents and experts'|Obstetrics and Gynecology residents and experts' knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey (Istanbul)
214353382|NCT06050460|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
214353383|NCT06050460|OTHER|Placebo for SA55 injection|Placebo for Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
214353384|NCT04132609|BEHAVIORAL|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
214353385|NCT04132609|BEHAVIORAL|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
214353386|NCT02220972|DRUG|Perampanel|
214486996|NCT06741943|DEVICE|insulin pump (model: AR-B200A)|USE insulin pump (model: AR-B200A) and continuous glucose monitoring (FreeStyle Libre)
214486997|NCT06741839|PROCEDURE|Confocal laser endomicroscopy guided pleural biopsy using medical thoracoscopy|After the completion of the routine thoracoscopic examination, the biopsy location was determined based on the results of chest CT/ ultrasound. The benign and malignant states of pleural lesions were explored by nCLE and image records were collected. Then, the biopsy tissues were collected under the guidance of nCLE.
214486998|NCT06741839|PROCEDURE|Plerual biopsy using medical thoracoscopy|After the completion of the routine thoracoscopic examination, the biopsy location was determined according to the results of chest CT/ ultrasound, and random pathological biopsy was performed, and biopsy tissues were collected by biopsy forceps.
214961343|NCT00988000|OTHER|telephone consultation|alternative to face to face consultation for new referrals
214961344|NCT00988000|OTHER|No intervention|no alternative to face to face consultation
214353387|NCT02220972|DRUG|Placebo|
214961345|NCT00701688|DRUG|Palifermin|Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
214961346|NCT04611139|DRUG|SP-2577|Daily oral doses
214961347|NCT04611139|DRUG|Pembrolizumab|200mg Q3W by IV infusion
214961348|NCT00095342|DRUG|TMI-005|
214961349|NCT06307834|BEHAVIORAL|Neurofeedback - based therapy|This intervention will include mental practice of various hand movements accompanied by guided visual feedback, aimed at regulating brain activation patterns to facilitate the restoration of hand movements. We will also incorporate EMG signals to control a hand exoskeleton.
214961350|NCT06307834|BEHAVIORAL|Standard hand exercise therapy|This intervention will include engaging in a set of particular hand exercises with the aim of enhancing hand movements.
214961351|NCT00898794|BIOLOGICAL|bevacizumab|
214961352|NCT00898794|OTHER|coagulation study|
214961353|NCT00898794|OTHER|laboratory biomarker analysis|
214486999|NCT06729983|PROCEDURE|Prophylactic Conjoint Tendon Lengthening|During a standard reverse shoulder arthroplasty procedure, the conjoint tendon will be incised and lengthened prophylactically
214487000|NCT06729983|PROCEDURE|Standard Reverse Shoulder Arthroplasty|A standard reverse shoulder arthroplasty procedure will be performed
214487001|NCT05543083|BEHAVIORAL|Cognitive-Behavioral Therapy followed by Exercise Training|6-week group CBT (cognitive-behavioral therapy; 1 hour/week for 6 weeks) followed by 6-week group exercise training (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
214961354|NCT00898794|OTHER|platelet aggregation test|
214353388|NCT02860728|BEHAVIORAL|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
214961355|NCT02957617|DRUG|BIIB074|Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
214961356|NCT03280056|BIOLOGICAL|NurOwn® (MSC-NTF cells)|"NurOwn® (MSC-NTF): One course of treatment that includes three separate intrathecal injections of 100-125 x 10\^6 cells every 8 weeks~NurOwn® (MSC-NTF): Autologous, bone marrow-derived, mesenchymal stem cells secreting neurotrophic factors"
214961357|NCT03280056|OTHER|Placebo|"One course of treatment that includes three separate intrathecal injections of Placebo every 8 weeks~Placebo: liquid solution in syringe for injection"
214961358|NCT03280056|OTHER|Bone Marrow aspiration|Bone Marrow aspiration
214961359|NCT03235323|DEVICE|External Counterpulsation|ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.
214961360|NCT02950116|DEVICE|Perform three multiple breath nitrogen washout tests (N2-MBW-test)|"* Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~* Patient's breathing pattern is stable for a minimum of 5 breaths~* Start of washout by inhaling 100% oxygen (initiated by lab technician)~* Continuous stable breathing pattern until end of washout test~* End target = 1/40th of start N2 concentration~* To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~* Three N2-MBW-tests are performed consecutively. Time between each test is \[duration of the previous test\*1.5\] (e.g. test duration = 6 min., time to next test = 6\*1.5 = 9 min.)"
214961361|NCT06452602|DRUG|Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy|"Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：CR+PR~Adebrelimab plus concurrent chemoradiotherapy:~Adebrelimab：1200mg, IV，q3w, until PD; Nab-paclitaxel：175mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Radiotherapy：50.4Gy/1.8Gy/28f."
214961362|NCT06452602|DRUG|Induction immunochemotherapy followed by concurrent chemoradiotherapy|"Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：SD+PD~Concurrent chemoradiotherapy:~Oxaliplatin：85 mg/m2，IV，d1，d15，d29; Leucovorin：400mg/m2，IV，d1，d15，d29; 5-FU：400mg/m2，IV，d1，d15，d29; 5-FU：1600mg/m2，CIV48h，d1，d15，d29; Radiotherapy：PTV/PGTV:50.4Gy/59.92Gy/28f."
214961363|NCT06344559|DEVICE|transcranial magnetic stimulation|"The study intervention involves modulation of cortical excitation to inhibition (E/I) balance in the right frontal eye field (FEF) by means of 2 trains of spaced continuous or intermittent theta burst stimulation (cTBS, iTBS, respectively) using a transcranial magnetic stimulation device. The endpoint of this stimulation will be a decrease (cTBS) or increase (iTBS) in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2016).~In separate sessions, all participants will receive either active or stimulation to the FEF. The Investigators will contrast the effects of both iTBS and cTBS to sham stimulation and to each other."
214961364|NCT02144077|DRUG|BF-200 ALA|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
214961365|NCT02144077|DRUG|methyl-aminolevulinate|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
214961366|NCT05485714|OTHER|Reviewing records retrospectively of patients undergoing screening endoscopy|Reviewing records retrospectively of patients undergoing screening endoscopy to assess Baveno VI, expanded Baveno VI, Platelet count/spleen diameter and other non-invasive predictors of esophageal varices or varices needing treatment
214961367|NCT00000173|DRUG|Donepezil|
214961368|NCT00000173|DRUG|Vitamin E|
215079574|NCT06030492|DRUG|packing placental site with hydrogen peroxide soaked towels|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution"
214353389|NCT03701750|DRUG|Low Molecular Weight Heparin (enoxaparin sodium)|enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
215079575|NCT06030492|DRUG|normal Saline|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution"
215079576|NCT04303143|BEHAVIORAL|Self-Hypnosis|Self-Hypnosis
215079577|NCT04303143|BEHAVIORAL|Direct Autonomic Experience Control|Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
215079578|NCT03587025|DRUG|Amitriptyline|Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.
215079579|NCT03587025|DRUG|Placebo|Placebo
214353390|NCT02433353|DRUG|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
214353391|NCT02433353|BEHAVIORAL|EMDR|psychotherapy
214353392|NCT02433353|DRUG|Placebo|Look-alike venlafaxine XR tablets containing no active drug
214353393|NCT03212105|BEHAVIORAL|60 Second Video|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
214353394|NCT03212105|OTHER|Educational Brochure|The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
214353395|NCT01962493|OTHER|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
214353396|NCT01962493|OTHER|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
214353397|NCT01962493|DRUG|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
214353398|NCT01431677|PROCEDURE|Muscle Biopsy|
214353399|NCT03745664|DRUG|Methylprednisolone Sodium Succinate|During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
214353400|NCT03745664|DRUG|Saline Solution for Injection|During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
214961369|NCT04456400|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography (MSOT)|cMSOT-2 system is indicated for measurement of the Multispectral Optoacoustic Tomography (MSOT) values in the bowel wall of patients with an established diagnosis of inflammatory bowel disease (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC). The MSOT values provided may be used as an aid to the assessment of inflammatory disease activity in the bowel wall.
214961370|NCT04659057|DRUG|Nebulized Lidocaine|will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).
214961371|NCT04659057|DRUG|Nebulized dexmedetomidine|will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).
214961372|NCT04659057|DRUG|Nebulized lidocaine and dexmedetomidine|will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.
214961373|NCT04659057|OTHER|Placebo|will receive nebulized saline 0.9% (5 ml) as control group.
214961374|NCT00610168|BIOLOGICAL|Boostrix TM|Single booster dose of vaccine
214961375|NCT01038102|OTHER|PUFA Diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
214961376|NCT01038102|OTHER|SFA diet|Diet high in saturated fat (15E%)
214961377|NCT00330694|OTHER|ParkNet|Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
214961378|NCT00330694|OTHER|Usual Care|No altered organisation of physiotherapy care in Parkinson's Disease
214961379|NCT06142344|DEVICE|Quiremspheres™|The intervention comprises two steps. Initially, the patient will undergo mapping angiography and a Ho-166 scout dose. If deemed eligible, the patient will proceed to 166-Ho radioembolization.
214961380|NCT06371690|OTHER|Web-Based Double-Eye Control Program|Web-Based Double-Eye Control Program, a web-based drug dose calculation program, is compatible with smartphones, tablets and computers. On the interface of the website, the nurse is required to enter data such as the age, weight, medications and doses ordered by the physician of the patient. When all these data are entered, the amount of medication that the nurse should give and whether the ordered dose is within the safe dose range for the patient are calculated by the program, so that the nurse can control her own calculations. On the other interface of the website, there are medication instructions uploaded by the researchers. With this interface, nurses access all pharmacological information about especially high-risk drugs (indications, contraindications, interacting drugs and fluids, fluids to be used for diluting, medication route, medication pace, etc.) and information that will enable the medication to be carried out in a standard way.
214961381|NCT04135755|OTHER|no drug intervention|no drug or treatment intervention
214961382|NCT02494856|DRUG|Surgery with Naproxen|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
214961383|NCT02494856|DRUG|Surgery with Naproxen and Esomeprazole|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
214961384|NCT06024811|BEHAVIORAL|supporting nursing care|Supportive nursing care was applied during the intrapartum period. Latent Active Transition phase,birt, postpartum period
214961385|NCT00943592|DRUG|Clofarabine|Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
214961386|NCT00943592|DRUG|Melphalan|Doses ranging from 100 to 140 mg/m2
215079580|NCT00460278|DRUG|XL418|
215079581|NCT00149994|DRUG|Cyclosporine A|
214487002|NCT05543083|BEHAVIORAL|Exercise Training followed by Cognitive-Behavioral Therapy|6-week group exercise training (1 hour/week for 6 weeks) followed by 6-week group CBT (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
214353401|NCT01732367|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
214353402|NCT01732367|DRUG|Tenofovir|Tenofovir 300mg QD for 96 weeks
214353403|NCT04514159|DRUG|ZN-c5|ZN-c5 is the study drug.
214353404|NCT04514159|DRUG|Abemaciclib|Abemaciclib (VERZENIO®) is an approved drug.
214353405|NCT05343039|DEVICE|Non-invasive Transcutaneous Nerve Stimulation (tVNS)|Participants will engage in 25-minute tVNS sessions every day for 30 days.
214353406|NCT05343039|DEVICE|No Intervention|Participants will not receive any intervention.
214487003|NCT05543083|BEHAVIORAL|Cognitive-Behavioral Therapy Only|6-week group CBT (1 hour/week for 6 weeks), with continuation of group CBT for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
214961387|NCT00943592|DRUG|Campath|20mg/d x5
214961388|NCT00943592|PROCEDURE|Stem Cell Transplant|Infusion of donor, bone marrow and auto.
214961389|NCT00500734|PROCEDURE|Blood Sample|One time blood draw of 2 teaspoons.
214961390|NCT06432101|OTHER|Acupuncture combined with oral hydroxychloroquine sulfate tablets|Acupuncture combined with oral hydroxychloroquine sulfate tablets
214961391|NCT02215889|PROCEDURE|Liver transplantation|
215079582|NCT00149994|DRUG|Tacrolimus|
215079583|NCT00149994|DRUG|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
215079584|NCT00149994|DRUG|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
214353407|NCT03311438|OTHER|Oral health intervention program|Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
214353408|NCT05626400|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
214353409|NCT02245152|DIETARY_SUPPLEMENT|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
214353410|NCT02245152|BEHAVIORAL|Child's health and nutrition topics|"After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children."
214353411|NCT02245152|BEHAVIORAL|National policy well-baby visits|
214353412|NCT05112926|DEVICE|Embosphere Microspheres|Embosphere Microspheres are 100-300μm small, compressible, hydrophilic, biocompatible spheres made of acrylic polymer and porcine-derived gelatin used for embolization of geniculate artery.
214353413|NCT01817413|PROCEDURE|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
214487004|NCT05543083|BEHAVIORAL|Exercise Training Only|6-week group exercise training (1 hour/week for 6 weeks), with continuation of group exercise for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
214487005|NCT02322905|BEHAVIORAL|Emotion Regulation Therapy|8 sessions of ERT
214487006|NCT05722561|BEHAVIORAL|Telehealth Motivational Counseling|At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15\~20 minutes each.
214487007|NCT05722561|DRUG|Nicotine Replacement Product|Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.
214961392|NCT05779787|PROCEDURE|TAVR Aligned|Investigate the feasibility of coronary re-engagement after commissural alignment technique in terms of success rate (%) and procedure complexity taking into account radiations, time and contrast used.
214961393|NCT05779787|PROCEDURE|TAVR Random|TAVR Random Feasibility comparison of coronary re-engagement between the randomly implanted Navitor valve (unaligned) and the others implanted with the commissural alignment technique in terms of success rate (%) and complexity of the procedure, taking into account radiation, time and contrast used
214961394|NCT04026230|DRUG|Atorvastatin 80mg|Capsules including 80 mg of atorvastatin
214961395|NCT04026230|DRUG|Placebo oral capsule|Similar capsules as in the atorvastatin arm, but without the active ingredient
214961396|NCT01247350|DRUG|LY3009104|Administered orally
214961397|NCT01247350|DRUG|Placebo|Administered orally
214961398|NCT03118817|DRUG|HM95573|"Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops"
214961399|NCT05701540|DRUG|Tegoprazan|Tegoprazan 50mg tablet
214961400|NCT05701540|DRUG|Esomeprazole|"Esomeprazole 20mg tablet~1. For patients with ERD: two Esomeprazole 20mg tablets~2. For patients with NERD: one Esomeprazole 20mg tablet"
214961401|NCT00169104|DRUG|G-CSF|5 mcgm/kg daily Monday through Friday weeks 3-14
214353414|NCT01817413|PROCEDURE|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
214961402|NCT00169104|DRUG|trastuzumab|4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
214961403|NCT00169104|DRUG|vinorelbine|25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
214961404|NCT00169104|DRUG|G-CSF|5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
214961405|NCT00169104|DRUG|saline placebo|Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
214961406|NCT01457417|DRUG|DKN-01|DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
214487008|NCT05722561|DEVICE|National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).|Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.
214961407|NCT00324662|DEVICE|Implantable cardioverter-defibrillator|
214961408|NCT03646968|DRUG|Anlotinib and Docetaxel|Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)
215079585|NCT00149994|DRUG|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
214961409|NCT03246022|OTHER|continuous positive airway pressure|Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
215079586|NCT03221608|PROCEDURE|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
214353415|NCT03620942|DRUG|Phenylephrine|"Phenylephrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 25mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 25 to 75mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min."
214961410|NCT05624411|DEVICE|CU T380A IUD|post-placental insertion of intrauterine contraceptive device
215079587|NCT03221608|PROCEDURE|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
214961411|NCT05624411|DEVICE|multiload 375 IUD|post-placental insertion of intrauterine contraceptive device
214961412|NCT01540981|DEVICE|MIST Therapy|FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
215079588|NCT04394273|OTHER|Exercise|stabilization exercise
215079589|NCT01978249|PROCEDURE|Systemic chemotherapy|
215079590|NCT01978249|PROCEDURE|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
215079591|NCT00297102|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
215079592|NCT00297102|DRUG|Placebo|once daily
214961413|NCT01540981|OTHER|Standard of Care|Standard of Care consists of pressure relief, wound cleansing and dressing as needed
214961414|NCT01114009|PROCEDURE|Lung recruitment maneuver|Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
214961415|NCT01114009|PROCEDURE|Lung protective strategy group|Lung protective strategy group received Lung protective strategy without recruitment maneuver
215079593|NCT05705375|OTHER|Waterpipe size|Participants will have 3 lab visits where they are allocated (random order) to smoke a small waterpipe in one visit, smoke a medium waterpipe in a second visit and smoke a large waterpipe in a third visit.
215079594|NCT04526717|DRUG|MPT0B640|Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)
215079595|NCT00418275|GENETIC|Recombinant Human Plasminogen Activator (HTUPA)|
215079596|NCT05719506|OTHER|normal saline without drug|nebulizer session with normal saline only preoperative
215079597|NCT05719506|DRUG|Dexmedetomidine|nebulizer session with dexmedetomidine preoperative
214961416|NCT05082337|DEVICE|SAVVY guidewire|The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment
214487009|NCT06749379|OTHER|Presence and stages of lipedema were diagnosed with examination.|Lipedema stage characteristics: stage 1: Smooth skin with a uniform increase in subcutaneous tissue; stage 2: Irregular skin surface with indentations and nodular alterations in the subcutaneous tissue; stage 3: Significant increase in circumference accompanied by loose skin/tissue ('dewlap').
214961417|NCT04697290|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 2E6、6E6、1E7、3E7 cells/kg.
214961418|NCT01911754|BIOLOGICAL|H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)|
215079598|NCT05719506|DRUG|Ketamine|nebulizer session with ketamine preoperative
215079599|NCT02235675|DEVICE|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
215079600|NCT05108454|DRUG|Multiple micronutrient supplementation|Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
215079601|NCT03960086|OTHER|Podoactiva cutom-made foot orthoses|Children had to use the orthotics daily during the intervention period
215079602|NCT03960086|OTHER|Podoactiva heel lifts|Children had to use the orthotics daily during the intervention period
215079603|NCT01773551|OTHER|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
214353416|NCT03620942|DRUG|Ephedrine|"Ephedrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 2mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 2 to 6mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min."
214487010|NCT06751121|DRUG|DWP14012 40mg|DWP14012 40 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
215079604|NCT00162500|BIOLOGICAL|Peptide Vaccine (MUC-1)|
215079605|NCT03226756|DRUG|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
215079606|NCT02821377|DRUG|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
215079607|NCT02821377|DRUG|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
215079608|NCT02821377|PROCEDURE|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
214353417|NCT03620942|DEVICE|ADIVA System|"1. When systolic blood pressure (SBP) is 100-110% of baseline, 25mcg phenylephrine (infusion) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion) is given if heart rate \< 60 beats/min;~2. When SBP is 90-100% of baseline, 25mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~3. When SBP is 80-90% of baseline, 50mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 4mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~4. When SBP \< 80% of baseline, 75mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 6mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min."
214353418|NCT03620942|DEVICE|DIVA System|"DIVA system works as below:~1. When systolic blood pressure is between 90 to 100% of baseline, 25mcg phenylephrine (bolus) will be given if heart rate ≥ 60 beats/min, whereas 2mg ephedrine (bolus) will be given if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 50mcg phenylephrine (infusion or bolus) will be given if heart rate ≥ 60 beats/min, whereas 4mg ephedrine (infusion or bolus) will be given if heart rate \< 60 beats/min."
214353419|NCT04075435|DRUG|high CBD/low THC sublingual solution|Hemp derived solution to be administered sublingually twice daily.
214353420|NCT07121569|DRUG|Oral lumbrokinase DLBS1033|DLBS1033: 490 mg, DISOLF film-coated tablet, Dexa Medica, 2 tabs t.i.d
214353421|NCT07121569|DRUG|Placebo|Placebo by Dexa Medica, 2 tabs t.i.d.
214353422|NCT07120269|DIAGNOSTIC_TEST|Nasal swab to collect material for RT-PCR SAA evaluation|Nasal swab for parallel identification of SARS-Cov2 and SAA expression
214961419|NCT04849117|PROCEDURE|Ultrasound guided Bilateral Transversus Thoracis Muscle Plane block|"In the TTMP block group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal. Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected single-shot in the tranversus thoracis muscle plane. The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously."
214961420|NCT02589509|BEHAVIORAL|Direct-attention training using web-based BrainHQ|"BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame."
215079609|NCT03354884|DRUG|cabozantinib|cabozantinib 60 mg orally once daily
214961421|NCT02589509|BEHAVIORAL|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
214961422|NCT01589367|DRUG|Metformin|Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
214961423|NCT01589367|DRUG|Placebo|Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
214353423|NCT07122349|DEVICE|Cannabis Impairment Test|Automated Drug Recognition Expert Ocular Tests administered via VR Headset, includes test for Lack of Smooth Pursuit, Horizontal and Vertical Gaze Nystagmus, Lack of Convergence, and Pupillary Rebound Dilation. Tests are preceded by an automated system calibration process.
214961424|NCT04687111|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor
214961425|NCT04687111|DRUG|Valsartan|Valsartan is an Angiotensin Receptor Blocker
214961426|NCT01224275|OTHER|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
214961427|NCT04951908|DIAGNOSTIC_TEST|MRI|MRI of TMJ
214961428|NCT03212859|BEHAVIORAL|Coach2Move|"Coach2Move is a multicomponent physiotherapeutic approach in addition to usual care physiotherapy consisting of:~* Extensive intake during which not only impairments and disabilities, but wishes, barriers and facilitators considering physical functioning are profoundly examined.~* Motivational interviewing is used to find and deal with barriers for becoming physically active and shared-decision making in goal setting.~* The approach is patient focused (tailor made) and goal-oriented: the physiotherapist coaches the patient and the environment in reaching and maintaining their own goals.~* In consultation with the patient, a stratified intervention is chosen by picking the best fitting option out of three patient-tailored intervention profiles with a predefined number of intervention sessions."
215079610|NCT05545995|OTHER|embryo selection|The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
215079611|NCT03873961|DEVICE|High-intensity laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
215079612|NCT03873961|DEVICE|Low-level Laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
215079613|NCT02947165|DRUG|NIS793|Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
215079614|NCT02947165|DRUG|PDR001|Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
215079615|NCT02031835|PROCEDURE|BWSTT (3 days a week for maximum of 20 minutes session)|
215079616|NCT01789060|OTHER|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
215079617|NCT04316611|DRUG|Potassium chloride|Direct intravenous injection (IVD) 20 mmol potassium chloride
215079618|NCT01872039|DRUG|Perdipine injection|IV
214353424|NCT07123402|DRUG|TRD205 tablets|orally ;Take TRD205 1 tablets and Placebo 2 tablets
214353425|NCT07123402|DRUG|TRD205 tablets|orally ;Take TRD205 2 tablets and Placebo 1 tablets
214353426|NCT07123402|DRUG|TRD205 tablets|orally ;Take TRD205 3 tablets and Placebo 0 tablets
214353427|NCT07123402|DRUG|Placebo|orally ;Take Placebo 3 tablets
215079619|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after anaesthesia induction|after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
215079620|NCT02757443|DRUG|5% Glucose after anaesthesia induction|after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
214353428|NCT07126080|BEHAVIORAL|Incontinence Coping Training|"Intervention: Women in the experimental group will receive a four-week training program on managing urinary incontinence. The training will cover the following topics:~* Definition, types, and risk factors of urinary incontinence~* Treatment and prevention of urinary incontinence~* Symptoms of urinary incontinence and non-drug management strategies (addressing eating and toilet habits, such as limiting caffeinated beverages and cautioning spicy foods)~* The importance and implementation of Kegel exercises After the training, the experimental group will be reminded to practice Kegel exercises, and post-tests will be administered at 1 and 3 months. The control group will also receive post-tests at 1 and 3 months. Training will be conducted individually online."
214353429|NCT07126158|RADIATION|Stereotactic body radiotherapy|MRIdian and Ethos (adaptive radiation platforms)
214353430|NCT07126158|DRUG|Defactinib|Taken with 30 minutes of a meal
214353431|NCT07126158|DRUG|Avutometinib|Can be taken without regard to food.
214353432|NCT07126704|DRUG|FB-101|FB-101 10mg
214353433|NCT07126704|DRUG|Placebo for FB-101|Placebo for FB-101
214353434|NCT07127601|PROCEDURE|Ultrasound guided erector spinae plain block (ESPB).|Depending on the size of patient, either a 27 g 3 cm hypodermic needle or a 21 g 5 or 10 cm short bevel needle was used. All blocks were performed with the ultrasound guidance in the parasagittal position and with continuous in-plane needle visualization. The local anesthetic was deposited in the fascial plane deep to the erector spinae muscle superficial to the transverse processes, after confirming the correct tissue plane by hydro-dissection. protocols for choosing 0.25% bupivacaine with a dose of 0.5ml/kg was determined by the age and weight of the patient.
214353435|NCT07127172|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
214353436|NCT07127172|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
214353437|NCT07126743|OTHER|exposure to organic pollutant|Small samples of subcutaneous and visceral adipose tissue will be analyzed for the presence and concentration of specific organic pollutants using validated analytical chemistry methods, such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS).
214961429|NCT03212859|BEHAVIORAL|Usual Care|"Usual care physiotherapy among older adults:~* Intake of 30 minutes consisting of examining medical history, physical functioning and functional exercises to assess the demand for care.~* Use of treatment modalities to enhance physical functioning (strength, mobility, coordination, balance etc.)~* Consultation and advisory role in relation to the functional status of geriatric patients and his/her relations.~* Collaborate with other disciplines in a multidisciplinary context."
215079621|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate added to cardioplegia|together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
214353438|NCT07128264|BEHAVIORAL|Laughter Yoga|"Laughter eliminates feelings such as hopelessness, anger, and anxiety, thereby alleviating stress, depression, and anxiety, raising the pain threshold, reducing stress, accelerating blood circulation, strengthening immunity, improving quality of life, strengthening memory, reducing tension, and relaxing muscles. Based on these positive effects, laughter yoga is a complementary treatment method that combines humor and laughter. Laughter yoga sessions will be conducted online via Microsoft Teams in a quiet and peaceful environment at home.~The first 10-minute section consists of warm-up exercises (warming up and clapping). The second 10-minute section consists of deep breathing exercises that prepare the lungs for laughter. The third 10-minute section consists of childlike games that induce laughter without humor. The fourth and final 15-minute section consists of laughter exercises that enable laughter without any jokes, comedy, or humor."
214353439|NCT07126964|OTHER|40-hour prone session (intervention)|Patients will undergo PP sessions lasting for 16 hours. Maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions in the comparator group, to last a maximum of 24 hours.
214961430|NCT05460949|OTHER|HOLD RELAX STRETCHING OF ILIOPSOAS|"10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~• The stretching exercise was performed 2 times a week for 8 weeks. 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
215079622|NCT02757443|DRUG|5% Glucose|together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
215079623|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
215079624|NCT02757443|DRUG|5% Glucose after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
215079625|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after ICU admission|immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
215079626|NCT02757443|DRUG|5% Glucose after ICU admission|immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
215079627|NCT05819307|DEVICE|OCT/FLIM|OCT/FLIM imaging of the retina
215079628|NCT00613925|DEVICE|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
215079629|NCT00613925|DEVICE|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
215079630|NCT01741142|DRUG|ABT-436|Subjects receiving ABT-436
215079631|NCT01741142|DRUG|Escitalopram|Subjects receiving escitalopram
215079632|NCT01741142|DRUG|Placebo|Subject receiving placebo
214353440|NCT07126964|OTHER|16-hour prone session (control)|Patients will undergo PP sessions lasting for 16 hours. Maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions in the comparator group, to last a maximum of 24 hours.
214353441|NCT07128043|DEVICE|ultrasound therapy and cassava wax hot immersion|participants sat in a comfortable position with their hand placed on a pillow or cushion. Ultrasound gel was applied to the base of the painful finger, and ultrasound therapy was performed for 5 minutes at a frequency of 3 MHz and an intensity of 0.5-1 W/cm. Afterward, the hand was cleaned and immersed in cassava wax heated to 125°F (51.7°C). The affected hand was dipped into the wax for 3 seconds, then removed. This process was repeated for 10 cycles. The hand was then wrapped in a plastic bag and a towel for 15 minutes before the wax was removed and peeled off.
214353442|NCT07128043|DEVICE|ultrasound therapy|1\. ultrasound therapy Ultrasound gel was applied to the base of the painful finger, and ultrasound therapy was performed for 5 minutes at a frequency of 3 MHz and an intensity of 0.5-1 W/cm.
214353443|NCT07127679|OTHER|Two minutes before the ROP examination, 2 mL of freshly expressed breast milk was administered to infants in the experimental group using a syringe, placing the milk on the front of the tongue. As par|Data were collected using the premature infant information form, the premature infant vital signs record form, the Premature Infant Pain Profile (PIPP), and the Neonatal Stress Scale. Two minutes before the ROP examination, 2mL of freshly expressed breast milk was administered to infants in the experimental group using a syringe, placing the milk on the front of the tongue. As part of routine care, all infants were swaddled and given a pacifier before the procedure. Video recording began 3 minutes prior to the ROP examination and continued until the infant stopped crying post-examination. Recordings were assessed by two independent observers to determine pain and stress scores, as well as parameters such as heart rate, oxygen saturation, perfusion index, and duration of crying.
214353444|NCT07127757|DEVICE|Wavelight Plus LASIK|Wavelight plus LASIK is an advanced laser eye surgery technology designed to enhance visual outcomes through personalized treatment plans. This system integrates comprehensive diagnostics, including biometry, tomography, and wavefront measurements, to create a tailored ablation profile for each patient.
214487011|NCT06751121|DRUG|DWC202301 30mg|DWC202301 30 mg, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
214487012|NCT06751121|DRUG|Amoxicillin 1000mg|Amoxicillin 1000 mg(2 capsules of 500mg), capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
214487013|NCT06751121|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
214961431|NCT05460949|OTHER|WILLIAM'S PROTOCOL|Pelvic tilt Single Knee to chest Double knee to chest Partial sit-up Hamstring stretch Hip Flexor stretch Squat Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols.
214961432|NCT02762071|DRUG|Liposomal bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
214961433|NCT02762071|DRUG|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
214961434|NCT00141518|DRUG|Levodopa-carbidopa intestinal gel (LCIG)|
214961435|NCT00141518|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
214961436|NCT00141518|DEVICE|percutaneous endoscopic gastrostomy tube (PEG tube)|
214961437|NCT00141518|DEVICE|jejunal extension tube (J-tube)|
214487014|NCT06751121|DRUG|DWC202301 30mg placebo|DWC202301 30 mg placebo, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
214961438|NCT02106780|DRUG|14C-labeled ASP1707|oral
214961439|NCT02821429|OTHER|Combined Thoracic Echography Record|This examination will be done to do the longitudinal follow-up of the patient
214961440|NCT04361760|DEVICE|single-puls TMS|Medical Device (MD): MagPro X100
214961441|NCT04361760|DEVICE|sham stimulation|Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.
214961442|NCT02768168|DRUG|dezocine|receive dezocine 0.1 mg/kg
214961443|NCT02768168|OTHER|normal saline|receive matching placebo (equal volume of normal saline)
214961444|NCT01101750|BIOLOGICAL|Quadrivalent HPV for types 6, 11, 16 and 18|"Per standard of care, Gardasil 0.5ml IM injection on day one, month 2, and month 6.~Serum samples on day one, month 3 and month 7."
214961445|NCT02816073|DEVICE|Pan-retinal photocoagulation using pattern scanning laser|Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
214961446|NCT02725658|DEVICE|DOSI|Breast tissue properties scanning
214961447|NCT01806168|DEVICE|rTMS|Magstim Super Rapid-2
214961448|NCT02693262|DEVICE|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
214961449|NCT02693262|DEVICE|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
214961450|NCT01753713|DRUG|dovitinib|Given PO
215079633|NCT04346979|OTHER|Telerehabilitation-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. Respiratory exercise was added to the training protocol. Individuals were asked to participate in the study via telerehabilitation system and aimed to do their exercises with a physiotherapist.
215079634|NCT04346979|OTHER|Video-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The respiratory exercise was added to the training protocol. Video recordings containing only yoga and mindfulness training were sent to individuals. The participants were supervised by the researcher.
215079635|NCT03828422|DIAGNOSTIC_TEST|imaging|
215079636|NCT03969056|BEHAVIORAL|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
215079637|NCT03969056|BEHAVIORAL|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
215079638|NCT04308434|OTHER|CSD190601-11|Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product
214353445|NCT07127328|DEVICE|Patient with removable funcitonal appliance|Patients who have a malocclusion and/or a dysfunction treated by removable functional appliance
214353446|NCT07127575|DEVICE|Resistance Breathing Device|The AIRpen is a multifunctional stress management tool that helps users engage in diaphragmatic breathing at differing resistance levels, as well as other common stress relieving behaviors such as fidgeting
214353447|NCT07127575|DEVICE|Electronic Resistance Breathing Device|The Smart AIRpen functions just as the original AIRpen device and has been augmented with sensors to measure use patterns to determine whether the AIRpen is being used for fidgeting or breathing.
214353448|NCT06483373|DRUG|SPH7854|SPH7854： Orally, 50-3200mg
214353449|NCT06483373|DRUG|Placebo|Placebo：Orally；
214353450|NCT05237141|DRUG|Etonogestrel implant|Implant insertion in second menstrual cycle prior to ovulation
214353451|NCT06273774|DRUG|MK-8189|Oral Tablet
214353452|NCT06273774|DRUG|Placebo|Oral Tablet
214353453|NCT06365580|DRUG|Kylo-0603 capsule|Administrated orally.
215079639|NCT04308434|OTHER|CSD190601-12|Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product
215079640|NCT04308434|OTHER|CSD190601-13|Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product
215079641|NCT04308434|OTHER|CSD190601-14|Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product
215079642|NCT04308434|OTHER|CSD190601-15|Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product
215079643|NCT04308434|OTHER|CSD190601-16|Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product
215079644|NCT04308434|OTHER|CSD190601-17|Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product
215079645|NCT04308434|OTHER|CSD190601-21|Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product
215079646|NCT04308434|OTHER|CSD190601-22|Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product
215079647|NCT04308434|OTHER|CSD190601-23|Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product
215079648|NCT04308434|OTHER|CSD190601-24|Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product
214353454|NCT06365580|DRUG|Placebo|Administrated orally.
214353455|NCT01420406|OTHER|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
214353456|NCT01420406|OTHER|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
214353457|NCT01420406|OTHER|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
214353458|NCT01420406|OTHER|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
214353459|NCT01297933|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
214353460|NCT01823718|BIOLOGICAL|Injection of allogenic CTL EBV specific|
214353461|NCT02258477|DIETARY_SUPPLEMENT|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
214353462|NCT02258477|DIETARY_SUPPLEMENT|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
214353463|NCT02258477|DIETARY_SUPPLEMENT|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
214353464|NCT02258477|DIETARY_SUPPLEMENT|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
214353465|NCT05163808|DRUG|zatolmilast|Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo
214353466|NCT05163808|DRUG|Placebo|Placebo
215079649|NCT04308434|OTHER|CSD190601-25|Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product
215079650|NCT04308434|OTHER|CSD190601-26|Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product
215079651|NCT04308434|OTHER|CSD190601-27|Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
215079652|NCT03245268|PROCEDURE|Balloon pulmonary angioplasty|BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
215079653|NCT01880749|DRUG|RAD001|
215079654|NCT00252694|DRUG|candesartan|32 mg oral tablet
215079655|NCT05985213|OTHER|data collection and follow-up|"Main measures and data collection methods:~1. Recording of baseline demographic and clinical information of the participants.~2. Multimodal magnetic resonance imaging~3. blood pressure variability.~4. neuropsychological testing~5. Blood samples collection"
215079656|NCT06223256|DRUG|NBL-028|Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
214353467|NCT04787757|PROCEDURE|Percutaneous cardiac procedure|Collection and analysis of intraprocedural information to provide artificial intelligence algorithms
214353468|NCT04414696|BEHAVIORAL|Exercise intervention|eHealth exercise intervention for postpartum women at increased risk of depression
214353469|NCT04298567|DRUG|Rivaroxaban (Xarelto,Bay 59-7939)|Rivaroxaban (2.5 mg \[BID\])
214961451|NCT01753713|OTHER|laboratory biomarker analysis|Correlative studies
214353470|NCT04298567|DRUG|Acetylsalicylic acid(ASA)|ASA (75mg \[QD\]; dose according to local label.
214961452|NCT06166017|OTHER|Exposure to minimal amount of lingual keratinized tissue width|measurement of clinical parameters
214961453|NCT02761018|BEHAVIORAL|Behavioral: Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
214961454|NCT02761018|BEHAVIORAL|Fitness Tracker|will use a fitness tracker and will be able to see other member's daily and weekly results
214353471|NCT04846608|OTHER|Observation|Observation
214353472|NCT06660823|DRUG|L-thyroxine|"Patients who show signs of delayed recovery defined as either prolonged ventilation for 48 hours or delayed conscious level recovery for 48 hours despite exclusion of muscle relaxants and/or sedative drugs. Those patients will undergo CT brain, CT chest and neurological examination to exclude structural damage as per institutional protocols. Also, metabolic profile screening including full kidney function, full liver function, electrolyte to exclude correctable metabolic abnormalities. and thyroid profile (TSH, free T3, free T4) sick euthyroid patients who are having normal FreeT3, normal Free T4, low TSH and low level of free T3 or freeT4 will be included in the study according lab reference.Daily assessment of conscious level according to Glasgow Coma Scale (GCS) and spontaneous breathing trial by ICU consultant (the investigator) till ICU discharge.~Patients will receive levothyroxine via Ryle, dose of 25 to 50 ug/ day according to BMI."
214353473|NCT06660823|DRUG|Placebo Oral Tablet|patients will receive placebo oral tablet
214961455|NCT05722730|PROCEDURE|Pilates Exercises|The intervention group will perform an exercise protocol based on the Pilates method, by a physiotherapist specialized in Pilates and independent of the researchers, using the method's own equipment, with a frequency of 2x/week, for 12 weeks in therapeutic sessions of identical protocols lasting 60 min.
214961456|NCT03810157|DEVICE|Laser-assisted hatching system|The ZP was thinned or drilled with the Laser-assisted hatching system. The laser pulse was 0.296 ms. Laser aperture was 8μm.
214961457|NCT00338091|DRUG|Benazepril|
214961458|NCT00338091|DRUG|Losartan|
214961459|NCT00336934|DIETARY_SUPPLEMENT|pomegranate juice|Given orally daily.
214961460|NCT00336934|OTHER|placebo|Given orally daily.
214961461|NCT02438280|DEVICE|AcceleDent, Vibrational Device|20 minutes of vibration each day
214961462|NCT00297700|BEHAVIORAL|Active referral|
214961463|NCT02485327|DRUG|Technosphere Insulin SAR439065 Afrezza®|"Pharmaceutical form: dry powder~Route of administration: oral inhalation"
214961464|NCT01100723|OTHER|Cinacalcet, active vitamin D analogue|Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
214353474|NCT06427668|DRUG|SPG302|synthetic small molecule
214353475|NCT06427668|DRUG|Placebo|Placebo
214353476|NCT00214877|DRUG|Methylene Blue|
214353477|NCT06035601|DEVICE|EHR-integrated texting platform (Urotrust)|"* An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI~* Evidence-based prevention education material on recurrent UTIs~* 5 standing orders for urinalysis and urine culture in the EHR upon enrollment~* Standard-of-care management for recurrent UTI"
214487015|NCT06751121|DRUG|DWP14012 40mg placebo|DWP14012 40 mg placebo, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
214487016|NCT06750081|OTHER|Physical Therapy|Exercises to improve locomotor abilities of children with CP
214961465|NCT00347178|PROCEDURE|Laser Peripheral Iridotomy|
214961466|NCT02533700|DRUG|CEOP/IVE/GDP chemotherapy regimen|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4"
214961467|NCT02533700|DRUG|CEOP chemotherapy regimen for 6 cycles|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses"
214961468|NCT03765060|PROCEDURE|Monomax® 2/0 HR26|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle.~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
214961469|NCT03765060|PROCEDURE|Monomax® 1 HR48|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle.~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
214961470|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Low support, high Positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 5 cmH2O
214961471|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Low support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
214961472|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Zero support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with 0 pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
214961473|NCT05534828|DIAGNOSTIC_TEST|A consultation|A consultation at three months of discharge from the intensive care unit in the population of patients surviving a multivalent intensive care unit stay
214353478|NCT06035601|OTHER|Usual care|• Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms) and follow up visits as determined by patients and their providers.
214353479|NCT05546281|OTHER|No intervention|No intervention
214961474|NCT02134795|DEVICE|TNM Device|The noninvasive device is worn like a music headset and the patient lies back on a wedge pillow while the device is active. Each session lasts under 20 minutes.
214961475|NCT02027077|BEHAVIORAL|Control group|No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention
214961476|NCT02027077|BEHAVIORAL|Lifestyle counselling|Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
214961477|NCT02904083|BEHAVIORAL|self assessment of adherence|
214961478|NCT01985100|OTHER|hyperbaric oxygen chamber|
214961479|NCT02862938|DRUG|NT-501 ECT implant|NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
214961480|NCT02862938|OTHER|Sham|Sham surgery
214961481|NCT00639262|DRUG|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
214961482|NCT00639262|DRUG|Temozolomide|For Cohort 2 - Gliomas only.
214961483|NCT00639262|RADIATION|Radiotherapy|Radiation Therapy (XRT)
214961484|NCT06382129|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214961485|NCT06382129|DRUG|Docetaxel|Administration by intravenous infusion for a cycle of 3 weeks.
214961486|NCT04802824|OTHER|PET/CT|18F-fluoropivalate PET/CT scan.
214961487|NCT04709497|PROCEDURE|viscotrabeculotomy (VT)|viscotrabeculotomy (VT)
214961488|NCT04709497|PROCEDURE|visco-circumferential-suture-trabeculotomy (VCST) .|visco-circumferential-suture-trabeculotomy (VCST)
214961489|NCT04709497|PROCEDURE|combined VT-Trabeculectomy with MMC (VT-Trab).|combined VT-Trabeculectomy with MMC (VT-Trab).
214353480|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a single ascending dose
214353481|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a multiple ascending dose
214353482|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a single dose after intake of a high-calorie, high-fat breakfast
214961490|NCT02990871|OTHER|early neurological rehabilitation|start of neurological rehabilitation between 3rd and 15th day after ABI
214353483|NCT06669429|DRUG|placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
214353484|NCT06669429|DRUG|placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
214353485|NCT06669429|DRUG|Placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast
214353486|NCT03958136|PROCEDURE|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis
214353487|NCT03958136|BIOLOGICAL|Biomarkers blood, urine and microbiota samples|Biomarkers blood, urine and microbiota samples for multi-omic analysis
214353488|NCT03958136|BEHAVIORAL|Patient Reported Outcome (PRO)|Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
214353489|NCT06669000|DIAGNOSTIC_TEST|Standard X-Rays|\- Standard X-Rays: feet (Month 0)
214961491|NCT02990871|OTHER|no-early neurological rehabilitation|start of neurological rehabilitation between 20th and 90th day after ABI
214961492|NCT02434159|OTHER|Heart scan|
214961493|NCT04470479|DRUG|Pilocarpine Hydrochloride|Oral pilocarpine hydrochloride 5mg tablets were administered four times a day for 10 weeks to half the group of selected patients. The other half ingested placebo in the same way. At the end of this period and after two weeks of washing out the medications, the patients had to invert the treatments.
214353490|NCT06669000|DIAGNOSTIC_TEST|Ultrasound|\- Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.
214487017|NCT06750081|OTHER|Designed rehabilitation program|Program of exercises to enhance abilities
214487018|NCT06750250|OTHER|Patient education|"The group A will be Education and Self-Management. Patient Education: Providing information on the benefits of physical activity, proper exercise techniques, and self-care strategies.~Self-Management Programs: Empowering women to take an active role in managing their health and fitness. Frequency: 3 session/ month, Intensity: Mild to moderate, Type: Walking Time: 30 to 45mints /sessions"
214961494|NCT04470479|DRUG|Placebo|Placebo
214961495|NCT04388124|DRUG|Bosentan|vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
214961496|NCT04388124|DRUG|Placebo|Placebo
214961497|NCT03066778|BIOLOGICAL|Pembrolizumab|IV infusion on Day 1 of each cycle prior to chemotherapy
214961498|NCT03066778|DRUG|Normal saline solution|IV infusion on Day 1 of each cycle prior to chemotherapy
214961499|NCT03066778|DRUG|Carboplatin|IV infusion on Day 1 of each cycle
214961500|NCT03066778|DRUG|Cisplatin|IV infusion on Day 1 of each cycle
214961501|NCT03066778|DRUG|Etoposide|IV infusion on Days 1, 2 and 3 of each cycle
214961502|NCT05361135|DIAGNOSTIC_TEST|PET/CT|Enhanced imaging with PET/CT
214961503|NCT01817166|DRUG|Vitamin D|Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
214961504|NCT01817166|DRUG|Placebo|Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
214353491|NCT06669000|DIAGNOSTIC_TEST|DECT of feet|DECT of feet: in tophaceous patients only (Month 0, Month 24)
214353492|NCT06669000|BIOLOGICAL|DNA sample|DNA will be collected at Month 0
214353493|NCT06669000|BIOLOGICAL|Serum collection|\- Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.
214353494|NCT07127627|DEVICE|PET/CT|positron emission tomography/computed tomography
214353495|NCT06932341|OTHER|Non-interruptive|Non-interruptive BPA (appears as a visual cue but does not require clinicians to alter workflows) directing clinicians to reference the EHR-embedded, evidence-based clinical guideline for the care of bronchiolitis.
214961505|NCT01817166|OTHER|Imaging|All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
214961506|NCT01817166|BIOLOGICAL|Lumbar puncture|A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
214961507|NCT01817166|BIOLOGICAL|Blood sampling|Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
214961508|NCT01817166|BIOLOGICAL|Urine samples|Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
214961509|NCT00494429|DRUG|Morphine|Gestational Age\< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
214961510|NCT00494429|DRUG|Morphine|Gestational Age\>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
214961511|NCT02328937|DEVICE|etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
214961512|NCT02328937|DEVICE|lotrafilcon B|
214961513|NCT02328937|DEVICE|comfilcon A|
214961514|NCT02006199|BEHAVIORAL|mindfulness meditation|8 weeks of mindfulness meditation specified for OCD patient
214961515|NCT01888250|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
214961516|NCT00825838|DIETARY_SUPPLEMENT|Chronic consumption of chili pepper extract|6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
214961517|NCT00825838|DIETARY_SUPPLEMENT|Chronic consumption of matching placebo|0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
214961518|NCT04039659|DEVICE|Negative-pressure wound therapy (PICO)|After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
214961519|NCT01727362|OTHER|Usual care + acupuncture|Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
214353496|NCT06932341|OTHER|Interruptive|Interruptive BPA (requires clinicians to interact with the alert to continue the workflow) directing clinicians to reference the EHR-embedded, evidence-based clinical guideline for the care of bronchiolitis.
214353497|NCT03602417|DEVICE|Flare type stent|Flare type has a wide diameter at proximal portion to prevent stent migration.
214353498|NCT03602417|DEVICE|Conventional D-type stent|This stent is an original full covered stent to treat malignant colorectal obstruction.
214353499|NCT00999258|DRUG|sirolimus|"The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care."
214353500|NCT05632510|DIAGNOSTIC_TEST|The Edinburgh Postnatal Depression Scale (EPDS)|The Edinburgh Postnatal Depression Scale (EPDS) is a self-administered questionnaire of 10 items, is recommended by the NICE guideline and French National Authority for Health for screening peripartum women, validated in French and well accepted.
214353501|NCT04462861|DEVICE|Central venous access device (CVAD) Snuggie Securement Device|Participants will be given a prototype of a CVAD securement device for a three week trial. Descriptive data relating to user satisfaction will be collected at 1 and 3 weeks
214353502|NCT06012734|DRUG|LB-100|IV on day 1 and day 3
214353503|NCT06012734|DRUG|Atezolizumab|IV on day 1
214487019|NCT06750250|OTHER|Aerobics|Treadmill: A manual Treadmill intervention involves moderate-intensity aerobic exercise on a treadmill for 15 minute with the heart rate gradually reaching 75-85% of the maximum. Training frequency was not specified. It significantly reduced menstrual pain intensity 3 session per month. Stationary Bicycling: Start with gentle, low-intensity cycling and gradually increase as comfort allow the duration of exercise 10 mints per month. Running : The running is a low intensity effort of short to moderate duration 10 to 15 mints per mile
214487020|NCT06781606|PROCEDURE|Penile transplantation|The penile transplantation will take place at the Edouard Herriot hospital, part of the Hospices Civils de Lyon. It will be carried out on the same day or the day after the harvesting depending on the timing of the harvesting.
214961520|NCT01727362|OTHER|Usual care|Patients of this group receive usual care only
214961521|NCT00057525|BIOLOGICAL|Anthrax|Doses will range from 5 \_g to 100 \_g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
214961522|NCT00057525|BIOLOGICAL|Alhdryogel or PBS|Doses will range from 5 \_g to 100 \_g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
214961523|NCT01440985|DRUG|Nicotine|Nicotine Gum 2 mg, Lot number GD922A
214961524|NCT01440985|DRUG|Nicotine|Nicotine gum 4 mg, Lot number GC962A
214961525|NCT01440985|DRUG|Nicotine|Nicotine Microtab 2 mg, Lot number GB196G
214353504|NCT05542043|OTHER|Data collection|"The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction.~Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode.~Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode.~Data on peripartal and postpartum surgical measures."
214487021|NCT06780826|DRUG|Atezolizumab|Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle
214961526|NCT03445403|OTHER|Offset analgesia|Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
214961527|NCT04931771|DEVICE|vFFR guided revascularization|3D-angio-based vessel FFR (CAAS, Pie Medical Imaging, Maastricht, The Netherlands) uses 3-Dimensional Quantitative Coronary Angiography (3D-QCA) for functional assessment of coronary stenosis. vFFR is calculated using two angiographic views with at least 30 degrees difference in rotation/angulation to generate the 3D reconstruction of the coronary artery.
214961528|NCT04931771|DEVICE|FFR guided revascularization|Fractional flow reserve (FFR) is a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis (narrowing, usually due to atherosclerosis) to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle (myocardial ischemia)
214487022|NCT06780826|DRUG|Etoposide|Etoposide,intravenous infusion, 100mg/m,21 days per cycle
214961529|NCT02448745|DEVICE|Insecticide treated wall lining|Polypropylene non-woven fabric.
214961530|NCT00005069|DRUG|arsenic trioxide|
214961531|NCT03058471|DRUG|Methotrexate|methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
214961532|NCT03058471|DRUG|NSAID|this arm will be given NSAID to the tolerable full dose with pantoprazole
214961533|NCT03058471|DRUG|Steroids|inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
214961534|NCT05995587|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
214961535|NCT01651754|BIOLOGICAL|Seasonal influenza vaccination|single dose of influenza vaccination
214961536|NCT02091414|DRUG|mycophenolate mofetil (MMF)|1.0 g PO BID
214961537|NCT02091414|DRUG|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
214961538|NCT02091414|DRUG|corticosteroids|As per the practice of each participating center
215079657|NCT01157325|PROCEDURE|Neuraxial analgesia|Neuraxial analgesia will be given at any time if the parturient requested analgesia
215079658|NCT01157325|PROCEDURE|Non-neuraxial analgesia|No neuraxial analgesia will be given to those who will not want to an analgesia
214487023|NCT06780826|DRUG|Carboplatin|carboplatin,intravenous infusion, AUC=5, 21 days per cycle.
214487024|NCT06744725|DEVICE|Pleural biopsy using dual-function semirigid thoracoscopy|Patients will receive pleural biopsy using dual-function semirigid thoracoscopy.
214487025|NCT06744725|DEVICE|Pleural biopsy using semirigid thoracoscopy|Patients received pleural biopsy using semirigid thoracoscopy
214487026|NCT05217927|DRUG|Rimegepant 75mg daily dosing|Daily
214487027|NCT05217927|DRUG|Rimegepant 75mg every other day dosing|Every other day
214487028|NCT05217927|DRUG|Placebo comparator dosing|Placebo comparator
214487029|NCT05951452|OTHER|Blood samples for testosterone and SHBG measurements|"Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at:~* t0 corresponding to the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
214487030|NCT05951452|OTHER|Saliva samples for oxytocin measurements|"Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples:~* t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
214961539|NCT03029455|DRUG|VX-659|
214961540|NCT03029455|DRUG|Tezacaftor|
214961541|NCT03029455|DRUG|Ivacaftor|
214961542|NCT03029455|DRUG|VX-659 Matching Placebo|
214961543|NCT03029455|DRUG|Triple Combination (TC) Matching Placebos|
214961544|NCT02237989|DRUG|paracetamol|1500 mg
214961545|NCT02237989|DRUG|paracetamol+native collagen type 2|paracetamol (1500 mg) + native collagen type 2 (10mg)
214961546|NCT03665077|DIAGNOSTIC_TEST|Initial blood draw|At baseline, patients will undergo a blood draw.
214961547|NCT03665077|DIAGNOSTIC_TEST|Initial SWE ultrasound|At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.
214961548|NCT03665077|DIAGNOSTIC_TEST|Blood draw at three months|Blood drawn at three months to evaluate oxylipins.
214961549|NCT03665077|DIAGNOSTIC_TEST|Blood draw at six months|Blood drawn at six months to evaluate oxylipins.
214353505|NCT01551732|BEHAVIORAL|ACT|10 session manualized cognitive behavioral anger control therapy
214353506|NCT01551732|BEHAVIORAL|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
214353507|NCT02327754|DRUG|Topiroxostat BID, (Oral daily dosing for 28 weeks)|The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.
214353508|NCT02327754|DRUG|Placebo BID, (Oral daily dosing for 28 weeks)|Subjects randomized to the placebo arm will receive placebo.
214353509|NCT00550485|DRUG|escitalopram|escitalopram 4 mg
214353510|NCT00252655|DRUG|Rapamune and Prograf|
214353511|NCT06073730|PROCEDURE|Experimental: Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 600mg/d, d8-14 (FLT3/ITD mutation positive patients)
214961550|NCT03665077|DIAGNOSTIC_TEST|SWE ultrasound at six months|SWE ultrasound at six months to evaluate tendon stiffness.
214961551|NCT00403026|DRUG|Bevacizumab ( Avastin)|
214961552|NCT05177068|DRUG|fruquintinib + sintilimab + SOX|fruquintinib: 4mg/d, qd po, d1-14, q3w; sintilimab: 200 mg/d, IV d1, q3w; S-1: BSA\<1.25 m2, 40mg twice/day; BSA1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, d1-14, q3w; oxaliplatin: 130mg/m2, ivgtt 2-6h, d1, q3w
214961553|NCT06251921|PROCEDURE|Restoration|with resin-based composite
214961554|NCT01643486|OTHER|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
214961555|NCT01643486|OTHER|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
214961556|NCT00558805|BEHAVIORAL|FISP + Usual Care|
214961557|NCT00558805|BEHAVIORAL|Usual Care|
214961558|NCT05335655|DRUG|Dexmedetomidine injection|IV initial bolus and trans operative dexmedetomidine infusion.
214961559|NCT05335655|DRUG|Sodium Chloride 0.9% infusion|IV initial bolus and trans operative infusion of 0.9% saline solution.
214961560|NCT02217670|DRUG|Metformin 1000 mg granules|
214961561|NCT02217670|DRUG|Metformin 1000 mg film-coated tablets|
214961562|NCT05631145|OTHER|MT Combined With XKSA|Morita therapy (MT) comprised bed rest and light work. Xingnao Kaiqiao self-administered acupressure (XKSA) stimulates nine acupoints including Baihui, Sishenchong, Shenmen, Neiguan, Hegu, Taichong, Jianjing, Shenshu, and Yuji.
214353512|NCT06073730|PROCEDURE|Active Comparator: Standard dose of Venetoclax + Azacitidine|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-28 Azacitidine (AZA) 75mg/m2/d, d3-9
214353513|NCT00265369|DRUG|Spores of Bacillus Clausii Probiotic Strain|
214353514|NCT04935502|OTHER|Home based exercises with postural and ergonomic training|Group A will be treated with stretching and strenghtening exercises for 40 minutes along with postural and ergonomic training for 15 minutes session 3 days/week for 4 week.
214678865|NCT03021525|PROCEDURE|Individualized Goal Directed Therapy|The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in \<15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.
214961563|NCT05631145|OTHER|MT|Morita therapy (MT) comprised bed rest and light work.
214353515|NCT04935502|OTHER|Home based exercises|Group B will be given stretching and strengthening exercises for 40 minutes, every alternate day (3 days per week) for 4 weeks.
214961564|NCT00004057|DRUG|L-778,123|
214961565|NCT00004057|DRUG|paclitaxel|
214961566|NCT01570257|PROCEDURE|lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus|in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
214353516|NCT04769167|OTHER|Stool and Blood Specimen Collection|Stool and Blood specimens will be collected at 3 designated time points
214353517|NCT04769167|OTHER|Follow-up Medical Record Review|Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.
214353518|NCT02807896|OTHER||This study is cohort.
214353519|NCT04367350|DIAGNOSTIC_TEST|laboratory biomarkers|creatine kinase, troponin, urine myoglobin, and autoimmune antibodies
214961567|NCT03910881|OTHER|Open-platform patient support system (PSS) app|The PSS app enables tracking and visualization of patient-selected health outcomes and sharing of select outcomes with family and providers. The CF clinical team and the family jointly decide which aspects of daily life to track, how often, and the content and frequency of patient-generated reports. Examples of daily care that can be tracked include symptoms (respiratory, gastrointestinal, pain), energy level, appetite, sleep, exercise, mood, medications, therapies, school/work attendance. Prior to a clinic visit, the patient/family generates a report of the outcomes they have been tracking, to help prepare for the visit and identify successes and areas of struggle. This information facilitates meaningful conversations during the visit and promotes shared decision-making. Patients/families can view their progress at any time and share selected outcomes with family and friends as often as desired.
214353520|NCT04367350|DIAGNOSTIC_TEST|muscle ultrasound|Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)
214961568|NCT04785898|DIAGNOSTIC_TEST|ID Now™ COVID-19 Screening Test|"Patients, meeting the eligibility criteria, are selected consecutively in the emergency room. The investigating doctor delivers the written information note, answers the patient's questions and obtains his free, informed and express consent. The patient has sufficient time to reflect to make the decision to participate in the study. His oral, free, informed and express consent will be traced in the computerized medical file on the day of its inclusion in the COVID-IDNow protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."
214961569|NCT01089010|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
214353521|NCT01625897|DRUG|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
214353522|NCT01625897|DRUG|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
214353523|NCT02358603|DIAGNOSTIC_TEST|Chronotropic Incompetence Diagnostic Algorithm|
214353524|NCT04443023|DEVICE|chosen TAVI valve|chosen TAVI valve
214353525|NCT06388668|DIAGNOSTIC_TEST|Lipid panel|Lipid panel measuring levels of LDL, non-HDL and apoB
214353526|NCT05071118|DRUG|Pregabalin 150mg|pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery
214353527|NCT05071118|DRUG|Placebo|The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
214353528|NCT03722186|DRUG|SHR-1603|SHR-1603 monotherapy
214353529|NCT01744522|PROCEDURE|Leech therapy|Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
214353530|NCT02414048|DRUG|Pimonidazole|Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
214353531|NCT02985866|DEVICE|Artificial Pancreas|Use of CTR at home for 3 months
214353532|NCT02985866|OTHER|Sensor Augmented Therapy|Use of personal pump with study CGM \& glucometer at home for 3 months
214961570|NCT01089010|DRUG|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
214353533|NCT02008890|BIOLOGICAL|Secukinumab 300mg|Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
214353534|NCT02008890|BIOLOGICAL|Secukinumab 150mg|secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
214353535|NCT02008890|BIOLOGICAL|Placebo|secukinumab placebo s.c. (two PFS injections of placebo) self-administered
214353536|NCT06022757|DRUG|XNW5004|XNW5004 an EZH2 inhibitor, BID, administered in continuous
214353537|NCT06022757|DRUG|KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection|KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
214961571|NCT01089010|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
214961572|NCT02812082|OTHER|web-based patient education|
214961573|NCT02812082|BEHAVIORAL|questionnaire|
214961574|NCT02008136|DRUG|Botulinum Toxins|intramuscular injections
214961575|NCT02959918|DRUG|SEL-212|SEL-212, biologic
214961576|NCT02959918|DRUG|SEL-037|SEL-037, biologic
214961577|NCT02959918|DRUG|SVP-rapamycin (SEL-110)|SVP-rapamycin, biologic
214961578|NCT05830890|PROCEDURE|Sentinel lymph node biopsy|After the total mesorectal excision, the indocyanine green was injected around the tumor via the anus. The fluorescence laparoscope was used to visualize and locate the sentinel lymph node, which was then removed and sent for rapid frozen pathological examination. Subsequently, a lateral lymph node dissection was performed.
214961579|NCT05830890|DRUG|Indocyanine green solution|Indocyanine green was injected around the tumor via the anus to visualize the sentinel lymph nodes under the fluorescence laparoscope.
214961580|NCT05830890|DEVICE|fluorescence laparoscope|The fluorescence laparoscope was used to visualize and locate the sentinel lymph node.
214961581|NCT05830890|DIAGNOSTIC_TEST|pathological examination|The surgical specimens and sentinel lymph nodes were routinely examined for pathology.
214961582|NCT05830890|DIAGNOSTIC_TEST|rapid frozen pathological examination|The lateral green fluorescence imaging sentinel lymph nodes found during surgery was sent to make cryosections. And then a pathologist makes a rapid diagnosis under a microscope。
214353538|NCT02077764|PROCEDURE|OCT and coronary angiography|
214353539|NCT02077764|PROCEDURE|Right heart cat.|
214353540|NCT02077764|RADIATION|PET|
214353541|NCT02077764|PROCEDURE|Echocardiography|
214353542|NCT02077764|PROCEDURE|exercise test|
214353543|NCT02077764|OTHER|blood samples|
214353544|NCT02207816|PROCEDURE|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
214353545|NCT02207816|BIOLOGICAL|Malaria Vaccine 257049 (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
214353546|NCT02207816|BIOLOGICAL|Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
214353547|NCT02207816|BIOLOGICAL|Cell-culture rabies vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
214353548|NCT02207816|BIOLOGICAL|TritanrixHepB/Hib (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
214353549|NCT02207816|BIOLOGICAL|Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)|Administered orally, during the MALARIA-055 study (NCT00866619).
214353550|NCT01200212|DRUG|Taxane, Avastin|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
214353551|NCT01200212|DRUG|Taxane, Avastin, Xeloda|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
214353552|NCT02514629|DRUG|Placebo|
214961583|NCT05830890|PROCEDURE|total mesorectal excision|"1. Sharply dissect the vascular interface between the pelvic fascia parietal layer and the visceral layer around the mesentery under direct vision to ensure that the rectal mesentery of the resected specimen is intact and tearless.~2. For medium and low rectal cancer: the distal intestinal tube of the tumor should be resected ≥ 2 cm.~3. TME or mesenteric distal resection margin ≥ 5 cm away from the tumor."
214961584|NCT06071741|PROCEDURE|Percutaneous Coronary Intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
214353553|NCT02514629|DRUG|Metformin|
214353554|NCT02514629|DRUG|Testosterone Undecanoate|
214353555|NCT02514629|DRUG|Metformin + Testosterone Undecanoate|
214353556|NCT01354158|DRUG|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
214353557|NCT00686166|BIOLOGICAL|cetuximab|"Chemotherapy cycle 1: Cetuximab, 400 mg/m\^2, IV, Day 1; Cetuximab, 250 mg/m\^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m\^2, IV, Days 50,57,64,71,78"
214353558|NCT00686166|DRUG|capecitabine|"Chemotherapy Cycle 1: Capecitabine, 1650 mg/m\^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m\^1, PO, Monday-Friday (Day 50-84)"
214487031|NCT02722512|BIOLOGICAL|Heat Shock Protein Peptide Complex-96 (HSPPC-96)|The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.
214487032|NCT02722512|PROCEDURE|Tumor Resection|Clinically-indicated removal of the tumor
214353559|NCT00686166|DRUG|oxaliplatin|"Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m\^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m\^2, IV, Days 50,57,71,78"
214353560|NCT00686166|PROCEDURE|therapeutic surgical procedure|Surgical resection
214353561|NCT00686166|RADIATION|radiation therapy|IMRT (intensity-modulated radiation therapy)
214353562|NCT01260220|PROCEDURE|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
214487033|NCT02722512|RADIATION|Radiation|Focal Radiation Therapy
214487034|NCT06764797|DEVICE|Transcranial Direct Current Stimulation|tDCS will be used during the sessions. The anodal tDCS (2 mA) will be applied for 20 minutes. Continuous, direct currents. The anodal electrode will be positioned over the ipsilesional primary motor cortex (M1) (C3 or C4, international 10-20 system) of the affected hemisphere and the cathodal electrode over the contralateral orbit.
214487035|NCT06764797|DEVICE|Virtual reality|The VRMT group will receive VRMT game-based training using their non-affected upper limb. using a semi-immersive motion-tracking device.
214487036|NCT06764797|DEVICE|Transcranial Direct Current Stimulation compined with virtual reality based mirror therapy|20 minutes of tDCS during 45 minutes of VRMT games.
214487037|NCT06764797|OTHER|Conventional physical therapy|45 minutes of conventional physical therapy with sham tDCS
214961585|NCT03642600|DIETARY_SUPPLEMENT|dietary advice plus myo-inositol and folic acid|dietary advice and lifestyle interventions and myo-inositol
214961586|NCT03642600|DRUG|dietary advice plus Liraglutide Pen Injector|dietary advice and lifestyle interventions and liraglutide pen injector
214961587|NCT03231306|DRUG|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
214961588|NCT05534815|BEHAVIORAL|Employment-based abstinence reinforcement|Participants will earn stipends for working with the employment specialist and wage supplements for working in a community job, but the stipends and wage supplements will depend on providing drug-free urine samples.
214961589|NCT03724045|DIETARY_SUPPLEMENT|Back Side of the Moon|"The procedures are: several measurements will be performed, including some which are not part of the Standard Operating Procedure, hence causing it to be considered interventional.~Follow-up during consultation on pneumology until max. 6 months post-admission on the ICU."
214961590|NCT06803043|BEHAVIORAL|SAH|"SAH is a group trauma informed intervention that uses motivational strategies and self-monitoring of one's thoughts and responses. It provides a unique fusion of interventions for trauma and IPV and consists of 12 two-hour weekly sessions. Throughout the program, group members complete in-session practice exercises and are provided practice assignments to consolidate and apply information learned in group."
214961591|NCT06803043|BEHAVIORAL|TAU|TAU is a court mandated 20 week, psychoeducational/directed program that emphasizes the sharing of power and control in relationships and personal accountability. Topics also focus on equality wheels, substance abuse impacts, culture and socialization impact on gender roles, defense mechanisms versus coping skills, triggers for stress and anger, and healthy versus unhealthy communication.
214961592|NCT05469620|DIETARY_SUPPLEMENT|Meal|Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.
214961593|NCT05469620|OTHER|Education|Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.
215079659|NCT05783921|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"TQB2618 injection is an Anti TIM-3 (T-cell immunoglobulin and mucin domain-3) monoclonal antibody.~Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
215079660|NCT05783921|DRUG|Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
215079661|NCT00434083|DRUG|sumatriptan|
215079662|NCT00434083|DRUG|naproxen sodium|
215079663|NCT04881929|DRUG|KN026|KN026 in Combination With Docetaxel
215079664|NCT05146713|DIETARY_SUPPLEMENT|Propolis nanoparticles extract solution|20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.
215079665|NCT05146713|DRUG|sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
215079666|NCT00785551|DRUG|quinine sulfate|2 x 324mg given in one dose to healthy subjects
215079667|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
215079668|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
215079669|NCT03618940|BEHAVIORAL|Knowledge and Attitude on burn prevention|"1.Introduction to Home Safety~2 Fire Safety \& Burn Safety (Cooking Safety, Safety around Motorcycle Exhaust \&First Aid for Minor Burns~3 Electrical Safety (Safety around Electrical \& Appliances \& Outlets)~4 Firecrackers Safety (Safety around Firecrackers \& Open Flames)~5\. Escaping from Fire (Escaping from Fire, Calling for Help, Stop, Drop \& Roll, Emergency Calling Number (By Fire Department Kuala Lumpur), Show equipment/gear that firefighters use, Demonstrate how to use the fire extinguisher, Crawl low in smoke"
214353563|NCT01260220|PROCEDURE|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
215079670|NCT02024269|BIOLOGICAL|Adipose Derived Stem Cells|
214353564|NCT06151145|BEHAVIORAL|Usual care|Participants in usual care will be emailed monthly educational modules with information on maintaining weight loss.
214353565|NCT06151145|BEHAVIORAL|SELF|"The SELF group will receive a wireless smart body weight scale and wearable physical activity tracker, and text messages."
214353566|NCT06151145|BEHAVIORAL|STEP|The STEP intervention consists of 4 steps that are progressive and based on response to treatment. Step 1: Digital health intervention. The first step will be the digital health intervention as described under SELF. Step 2: Monthly, in-person counseling. Participants who move to Step 2 will be provided with monthly, in-person counseling. Step 3: Twice per month counseling. Step 3 will be twice-monthly counseling, spaced at every other week. Step 4: Meal replacements. Participants will be prescribed a partial meal replacement program.
214353567|NCT00360308|DRUG|Placebo|
214353568|NCT00360308|DRUG|E2007|
215079671|NCT01332838|PROCEDURE|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
215079672|NCT01332838|DEVICE|compression stockings (Sigvaris )|Specialized monoleg compression
215079673|NCT04016558|BEHAVIORAL|StreamLine|"StreamLine is an education/disease management program that focuses on systematic methods to identify and resolve specific blood glucose problems, primarily through changes in carbohydrate consumption, and use of basal and bolus insulin. Participants will attend a brief, four-hour meeting with a Certified Diabetes Educator (CDE) and, using standardized blood glucose data, will learn how to employ a five-point blood glucose management system to identify and resolve blood glucose problems (e.g., excursions, lows) that have the greatest HbA1c or hypoglycemic impacts.~Participants will then meet individually (30 minutes) with their CDE to review their blood glucose data, identify a specific blood glucose problem, and use the five-point program to create a plan to address the problem. Four additional individual meetings (30 minutes) will occur at approximately two to three-week intervals to best support individualized and participant-tailored management-change efforts."
214353569|NCT00360308|DRUG|E2007|
214353570|NCT00822029|DRUG|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
214353571|NCT00822029|OTHER|PLACEBO|patient receiving one tablet (oral use) placebo by week
214353572|NCT00400010|BEHAVIORAL|Expert System Intervention|Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
214353573|NCT06470932|DIAGNOSTIC_TEST|Follow-up consult|Patients will be ask to participate to a follow-up consult
214487038|NCT05974553|BEHAVIORAL|Dialectical Behavior Therapy for Justice-Involved Veterans|16 weeks of Dialectical Behavior Therapy for Justice-Involved Veterans, including weekly 60-minute group therapy and biweekly 30-minute individual case management
214487039|NCT05974553|BEHAVIORAL|Supportive Group Psychotherapy for Justice-Involved Veterans|16 weeks of clinician-facilitated supportive group psychotherapy for justice-involved Veterans, including weekly 75-minute group psychotherapy (20 hours total intervention). All interventions delivered via telehealth.
214487040|NCT06765798|OTHER|Group A : receive neural mobilization for radial nerve , mulligan mobilization with movement and conventional Therapy|Group A :Neural Mobilization for radial nerve, Mulligan Mobilization with Movement and Conventional neural mobilization for radial nerve: The physiotherapist holds the patient's arm and wrist while the patient reclined on his side then depress the shoulder, extend the elbow and then internally rotated the patient's arm. The patient's wrist, thumb, and fingers were all flexed, and the patient's ulnar was brought to deviation. While the patient's position was maintained, and the arm was abducted and then contralateral cervical side bending Mulligan mobilization with movement manual lateral glide MWM with gripping: Patient: Supine with upper limb fully supported on a treatment table. Treated body part: Relaxed extension of the elbow, shoulder internal rotation, with pronation of the forearm. Hands loosely around the grip dynamometer handles. Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session, conventional ; Ultrasound therapy , stretching and strengthening for
214487041|NCT06765798|OTHER|Group B receive neural mobilization for radial nerve and conventional|Group B receive neural mobilization for radial nerve and conventional neural mobilization for radial nerve: The physiotherapist holds the patient's arm and wrist while the patient reclined on his side then depress the shoulder, extend the elbow and then internally rotated the patient's arm. The patient's wrist, thumb, and fingers were all flexed, and the patient's ulnar was brought to deviation. While the patient's position was maintained, and the arm was abducted and then contralateral cervical side bending conventional ; Ultrasound therapy , stretching and strengthening for wrist flexors and extensors
214487042|NCT06765798|OTHER|Group C receive Mulligan mobilization with movement and conventional|"Group C receive Mulligan mobilization with movement and conventional~Mulligan mobilization with movement manual lateral glide MWM with gripping: Patient: Supine with upper limb fully supported on a treatment table. Treated body part: Relaxed extension of the elbow, shoulder internal rotation, with pronation of the forearm. Hands loosely around the grip dynamometer handles. Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session, conventional ; Ultrasound therapy , stretching and strengthening for wrist flexors and extensors"
214961594|NCT01592123|PROCEDURE|The active anterior rhinomanometry|In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
214961595|NCT01592123|BEHAVIORAL|The Pittsburgh Sleep Quality Index (PSQI)|PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score \>5 is considered to be suggestive of significant sleep disturbance.
214353574|NCT04224077|DIAGNOSTIC_TEST|Optimisation of DTI sequences|Optimisation of DTI sequences in the study of lumbar roots by MRI
214353575|NCT03244527|DIETARY_SUPPLEMENT|BCAA supplement|Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.
214487043|NCT06765798|OTHER|Group D receive conventional|"Group D receive conventional :~Ultrasound therapy , stretching and strengthening for wrist flexors and extensors"
214961596|NCT01592123|BEHAVIORAL|The Beck Anxiety Inventory (BAI)|The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
214961597|NCT01592123|BEHAVIORAL|The Van Dream Anxiety Scale (VDAS)|The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
214961598|NCT02999841|DRUG|Acarbose|1-2 week: 50mg tid; 3-24 week: 100mg tid.
214961599|NCT02999841|DRUG|Vildagliptin|1-24 week: 50mg bid
214353576|NCT03244527|OTHER|Aerobic exercise|The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
214353577|NCT02125175|RADIATION|Hypofractionated IMRT boost Radiotherapy|
214961600|NCT02306850|DRUG|Pembrolizumab|At the Treatment Initiation Visit (Baseline/Day 1), subjects will begin treatment with IV pembrolizumab 200 mg infusions every 3 weeks. As in previous pembrolizumab trials, eligible subjects will receive at least 24 weeks of therapy and may receive up to 2 years of pembrolizumab therapy depending on response to treatment.
214961601|NCT00237692|BEHAVIORAL|Nurse Behavioral intervention with Home BP Telemonitoring|Nurse-administered behavior intervention
214961602|NCT00237692|BEHAVIORAL|Nurse Medication Management with Home BP Telemonitoring|Nurse administer medication management according to hypertension decision support
214961603|NCT00237692|BEHAVIORAL|Nurse Combined intervention with Home BP Telemonitoring|Combination of the nurse administered tailored behavioral \& medication management
214353578|NCT01889953|OTHER|EUS-guided biliary drainage|"Based on the patient's condition, the will receive:~* Rendezvous technique~* Direct transluminal access transesophageal technique~* Direct transluminal access transduodenal technique~* or direct transluminal access using transgastric approach"
214353579|NCT06326515|BEHAVIORAL|psychoeducation|"To identify and recognize the cognitive distortions To explore the automatic thoughts and emotions about illness Evaluate and respond to thoughts, emotions, and beliefs Automatic thought records were used by patients with some help from therapist (Chattopadhyay et al., 2017).~The cognitive errors were corrected using individual cognitive strategies (Chattopadhyay et al., 2017)."
214353580|NCT06326515|BEHAVIORAL|Stigma Reduction and Relapse Management|"To improve ability to effectively cope with lapse and relapse (Brown \& Vanable, 2008).~To improve relapse management skills (Brown \& Vanable, 2008). Emphasized skill development to cope with OUD-related stressors (Zhang, 2021). To change their conception of OUD (Tshabalala \& Visser, 2011). To change their sense of self-worth and to empower them with more adaptive ways of thinking (Tshabalala \& Visser, 2011).~To deal with their experience of stigma (Tshabalala \& Visser, 2011)."
214353581|NCT01656551|DRUG|Gemcitabine|
214353582|NCT01656551|DRUG|Pemetrexed|500 mg/m2 day 1 every 3 weeks
214487044|NCT04258189|DRUG|JNJ-64417184|Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
214487045|NCT05682235|OTHER|Therapeutic exercise AND pain neurophysiology education|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group and talks on healthy habits to the placebo group participants.
214487046|NCT05682235|OTHER|Sham|Talk about healthy habits
214961604|NCT01456143|DEVICE|High Resolution Microendoscopy (HRME)|High Resolution Microendoscopy imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer.
214961605|NCT01456143|OTHER|Proflavine hemisulfate|0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa
214961606|NCT05391555|DRUG|Remifentanil Hydrochloride|Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes.
214961607|NCT05391555|DEVICE|Pupillometry measurement|Pupillary measurements were taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.
214487047|NCT06788093|BEHAVIORAL|ED Clinical Decision Support (CDS-ED)|The ED-CDS intervention is designed as a discrete decision support aid to influence initial antibiotic decision-making in the ED. This intervention will feature a clinician-facing LRTI dashboard for end-users that assimilates relevant clinical data (e.g., vital signs, select diagnostic tests, links to reference information) and offers tailored suggestions for antibiotic initiation, related diagnostic testing, and in those receiving antibiotics, preferred options and alternatives for antibiotic choice, route, dose, and duration.
214502657|NCT00843934|DRUG|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
214961608|NCT04032834|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a mouthpiece and dose-specific VR647 Smart Cards designed specifically for this trial.
214961609|NCT04032834|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a facemask and dose-specific VR647 Smart Cards designed specifically for this trial.
214961610|NCT04032834|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
214961611|NCT04032834|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
214961612|NCT04032834|COMBINATION_PRODUCT|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
214961613|NCT04032834|COMBINATION_PRODUCT|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
214961614|NCT02378974|BIOLOGICAL|Cordstem-ST|
214961615|NCT02378974|BIOLOGICAL|Placebo|
214961616|NCT02238756|BIOLOGICAL|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
214961617|NCT02238756|BIOLOGICAL|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
214961618|NCT02238756|BIOLOGICAL|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
214961619|NCT00784589|DRUG|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
214961620|NCT00784589|DRUG|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
214353583|NCT01656551|DRUG|Cisplatin|60 mg/m2 day 1 every 3 weeks
214961621|NCT04397549|OTHER|Cervical erector spinae plane block|Cervical erector spinae plane block will be administered before the surgery
214961622|NCT04397549|DEVICE|Intravenous morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
214961623|NCT04708899|BEHAVIORAL|arabic version of differential processing training program|comprehensive training program for central auditory processing disorder contains auditory and linguistic tasks (language organization, phonemic and phonetic awareness, dichotic listening,temporal patterning and auditory discrimination).
214961624|NCT04708899|BEHAVIORAL|Arabic computer based auditory traing program(CBAT)|comprehensive computer based traing program for central auditory processing disorder contains auditory memory, temporal processing, dichotic listening , selective attention and phonemic awareness games.
214961625|NCT00920413|DIETARY_SUPPLEMENT|Vitamin C|vitamin C 500mg orally once a day
214961626|NCT00920413|DIETARY_SUPPLEMENT|placebo|
214961627|NCT05937620|DIAGNOSTIC_TEST|99mTC nanocolloid albumin injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
214961628|NCT05937620|DIAGNOSTIC_TEST|ICG injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
214961629|NCT00685360|DRUG|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
214961630|NCT00685360|DRUG|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results."
214961631|NCT00685360|DRUG|Placebo|Placebo tablets matching 50-mg tablets of delamanid
214961632|NCT03023267|BEHAVIORAL|Music therapy and Kangaroo care|Mother holding baby in skin to skin position while singing
214353584|NCT00440648|DRUG|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
214353585|NCT00440648|DRUG|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
214353586|NCT02278094|DEVICE|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
214353587|NCT02278094|DEVICE|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
214353588|NCT02278094|PROCEDURE|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
214678866|NCT03021525|PROCEDURE|Control Group|Patients in the control group will be treated according to established basic treatment goals (heart rate \<100 bpm, mean arterial pressure \>65 mmHg, SpO2\>94%, and core temperature \>36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
214961633|NCT03023267|BEHAVIORAL|Kangaroo Care alone|Mother holding baby in skin to skin position without singing
214961634|NCT01630018|DRUG|Topotecan|1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
214961635|NCT01630018|DRUG|Belotecan|0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
214961636|NCT05977088|DEVICE|Repetetive Transcranial Magnetic Stimulation|".Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group."
215079674|NCT04016558|BEHAVIORAL|TunedIn|"TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
214678867|NCT00855530|DRUG|amibegron (SR58611A)|oral administration of 300 mg twice daily
214678868|NCT01628991|BEHAVIORAL|behavioural program|interventional behavioural program
214353589|NCT02278094|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
214961637|NCT05407415|OTHER|Kardia Mobile 6L Device|"The KardiaAL is a software analysis library intended to assess ambulatory electrocardiogram (ECG) rhythms from adult subjects. The device supports analyzing data recorded in compatible fonnats from any ambulatory ECG devices such as event recorders, or other similar devices. The library is intended to be integrated into other device software. The library is not intended for use in life supporting, or sustaining systems, or ECG monitors, or cardiac alarm, or OTC use only devices.~The KardiaAI library provides the following capabilities:~* ECG noise filtering,~* heart rate measurement from ECGs,~* detection of noisy ECGs, and~* ECG rhythm analysis for detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia (when prescribed or used under the care of a physician)."
214961638|NCT04298827|OTHER|Unimodal|Patients will receive physical therapy alone.
214961639|NCT04298827|OTHER|Trimodal|Patients will receive physical therapy, nutrition counseling, and cognitive behavioral therapy in the form of group counseling.
214961640|NCT06955052|OTHER|"Minds In Motion The Maze"|"Minds in Motion the Maze is a program that combines physical activity with cognitive training. Research suggests that MIM can positively impact balance and gait in children with Down syndrome. Some potential benefits include:~* Improved balance and stability~* Enhanced gross motor skills~* Better coordination and overall physical function~* Increased confidence in physical abilities~The program's effectiveness may vary depending on individual needs and program implementation."
214961641|NCT06955052|OTHER|conventional treatment|"Document any specific motor challenges or deficits typical in children with down syndrome.~walk for 10 to 20 minutes warm up for 5 minutes cool down for 5 minutes rest period as per the subject convenience 6 stretching exercise performed during the warm and cool down period ,standing with feet together, standing with feet shoulder apart sitting with feet together ,sitting with feet shoulder width apart standing with only on leg extended , sitting with only one leg standing extended"
214961642|NCT06955585|DEVICE|Proluxx Artificial Tear Spray|Topical artificial tear spray applied to closed eyelids four times daily for 28 days.
214961643|NCT06955078|OTHER|Visual Motor Integration|"The Beery Visual Motor Integration will be used to measure the integration of visual perception and motor skills as the participant children imitated and copied a developmentally sequential series of geometric forms using pencil and paper. As the task progressed, the levels of difficulty in geometric forms increased.~VP task will be used to measure an individual's visual abilities without the integration of fine motor skills. Children will be asked to point to the item in the array, which was identical to the target figure. The choices will be written on answer sheets by experimenters or children themselves. Elapsed time will be recorded beginning with Item 7, and the task discontinued after 3 minutes. Children will be told to connect dots and to draw within provided borders. Elapsed time was recorded beginning with Item 7 and the task ended up after 5 minutes."
214961644|NCT06955897|OTHER|Observational|Observational
214961645|NCT06954961|DRUG|D-0502|"* Dosage form: Tablet~* Administration route: Oral, once a day"
214961646|NCT06954961|DRUG|Fulvestrant|"* Dosage form: Injection~* Administration route: Intramuscular injection, once a month, and another dose administered two weeks after the first dose"
214961647|NCT06954922|BEHAVIORAL|memory-based exercise and training intervention|The experimental group will be given memory-based exercises that will last approximately 15-20 minutes every day for 2 months. Four sessions of epilepsy training will be given, one session per week.
214961648|NCT06954922|BEHAVIORAL|educational initiative about epilepsy|This group will be given 4 sessions of epilepsy training, one session per week.
214961649|NCT03052569|DRUG|RXDX-105|Oral Capsules
214353590|NCT00002933|DRUG|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
214353591|NCT00066248|DRUG|cyproheptadine hydrochloride|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
214353592|NCT00066248|DRUG|megestrol acetate|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
214353593|NCT01217073|DRUG|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
214353594|NCT01217073|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
214353595|NCT01217073|DRUG|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
214678869|NCT01628991|DEVICE|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
214678870|NCT01202110|DRUG|Propranolol|
214678871|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
214678872|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
214961650|NCT04892017|DRUG|Inlexisertib|Oral Tablet Formulation
214961651|NCT04892017|DRUG|Trametinib|Oral Tablet Formulation
214961652|NCT04892017|DRUG|Binimetinib|Oral Tablet Formulation
214961653|NCT04892017|DRUG|Sotorasib|Oral Tablet Formulation
214961654|NCT02546128|DEVICE|Extra-Corporeal Shockwave Therapy (ESWT)|The use of ESWT from a commercially available machine at approved settings already in routine clinical use
214961655|NCT02546128|OTHER|structured rehabilitation programme|a structured and standardised rehabilitation programme specific to the tendon in question - already in routine clinical use
214353596|NCT01217073|DRUG|Metformin|Metformin 500 mg oral tablet administered once or twice daily
214353597|NCT01217073|DRUG|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
214353598|NCT00042679|DRUG|Gemcitabine|
214353599|NCT00042679|DRUG|Carboplatin|
214353600|NCT00042679|DRUG|LY900003|
214961656|NCT00652847|DRUG|ezetimibe|ezetimibe 10 mg/day for a six week course of treatment.
214961657|NCT00652847|DRUG|statins|patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
214961658|NCT04051541|OTHER|Agitated saline push|Push of agitated saline to simulate adenosine used for supraventricular tachycardia
214961659|NCT00963976|DRUG|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
214961660|NCT03249168|DRUG|Duloxetine 60mg|tablet
214961661|NCT03249168|DRUG|Placebo|Tablet
214961662|NCT02627573|PROCEDURE|Unrelated allogeneic stem cell transplantation|
214961663|NCT02627573|DRUG|Busulfan|
214961664|NCT02627573|DRUG|Fludarabine monophosphate|
214961665|NCT02627573|DRUG|Tacrolimus|
214353601|NCT04022200|DEVICE|Paclitaxel DCB|The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
214353602|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1mg, tid
214353603|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
214353604|NCT01569516|DRUG|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
214353605|NCT01569516|DRUG|Placebo|0mg, tid
214353606|NCT03399760|BIOLOGICAL|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
214353607|NCT03399760|PROCEDURE|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
214961666|NCT02627573|DRUG|Mycophenolate mofetil|
214961667|NCT02627573|DRUG|Cyclophosphamide|
214353608|NCT03631186|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
214353609|NCT04111081|OTHER|Auricular pressure|Select related auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
214502658|NCT00843934|DRUG|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
214502659|NCT00785200|OTHER|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
214502660|NCT00785200|OTHER|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
214502661|NCT00347204|DRUG|ketorolac (Acular LS)|
214502662|NCT00347204|DRUG|Nepafenac (Nevanac)|
214502663|NCT03382470|OTHER|Antimicrobial stewardship advice|A basic antimicrobial stewardship team will be created at each site. The team will provide advice on the treatment of urinary tract infections and asymptomatic bacteriuria during the second half of the study.
214961668|NCT02627573|DRUG|Thymoglobulin|
214961669|NCT03227393|BEHAVIORAL|Yoga training|Subjects will complete in class yoga training weekly for 8 weeks with additional practice at home
214961670|NCT05346237|BEHAVIORAL|Quality of life questionnaire|Filling out questionnaires, measuring maximum phonation and diadochokinesis
214961671|NCT03654729|DRUG|Calmangafodipir (2 µmol/kg)|Solution in 20 mL single dose glass vials
214961672|NCT03654729|DRUG|Calmangafodipir (5 µmol/kg)|Solution in 20 mL single dose glass vials
214961673|NCT03654729|DRUG|Placebo|Solution in 20 mL single dose glass vials
214961674|NCT04655781|PROCEDURE|idiopathic macular hole (MH) surgery|Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns
214961675|NCT06101186|OTHER|NPECP based on NSM|A comprehensive training booklet which integrated NPECP and NSM principles was sent to five experts for their evaluation and feedback. Among these experts, one was a physician who specialized in obstetrics and gynecology while the remaining individuals were nurses. Group training sessions were conducted online, with each group comprising 4-6 participants. These sessions spanned four weeks, with each session being held weekly and lasting for approximately 60-90 minutes. The training covered various topics - including pregnancy, pregnancy-related changes, pregnancy danger signs, premature birth, stress, stress symptoms, stress coping strategies, childbirth, the postpartum period and the challenges of parenting (particularly when dealing with a pre-term baby)
214961676|NCT05678712|DEVICE|Access to CGM data (Dexcom G6)|Acces to CGM data (not blinded CGM)
214353610|NCT04111081|OTHER|Shame auricular pressure|Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
214353611|NCT05599529|OTHER|Differential attainment|Differential attainment related to covid, ethnicity and international graduate status
214353612|NCT06213025|BEHAVIORAL|web-based Educational program promoting response and willingness to handle elderly|promote the response and willingness of gerontological nurses in handling elderly abuse cases. By employing a rigorous experimental design, this research seeks to contribute evidence-based insights that can inform educational strategies to empower nurses in safeguarding the well-being of elderly individuals.
214961677|NCT05606432|OTHER|Instructor-led, one-on-one M2M exercise group|Participants will attend 3 exercise sessions per week for 24 weeks. Each session will last 15 - 40 minutes. Increasing by 5 - 10 minutes each week. Each session will last from 25 to 50 minutes by increasing 5 to 10 minutes each week. The exercise program will focus on improving cardiorespiratory fitness using a series of movement patterns accompanied by music. The program will be tailored to individuals' abilities (e.g., use of arms only vs. truck movement together; slow vs. fast tempo music). The exercise will be prescribed at a moderate intensity level (working somewhat hard with increased heart rate and breathing rate). For the follow-up phase (weeks 25-36), participants will receive the recorded M2M exercise sessions between the M2M instructors and themselves to continue to exercise for the remaining 12 weeks.
214961678|NCT05606432|OTHER|Self-guided control with pre-recorded standard exercise videos|Participants will exercise for 36 weeks using pre-recorded exercise videos. The videos include warm-up, flexibility, muscular strength, aerobic endurance, balance, and cool-down.
214961679|NCT04998214|DIAGNOSTIC_TEST|liver function , prothrombin time , INR , US .|analytic
214961680|NCT02562586|DEVICE|Closed Suction Drainage System|patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
214961681|NCT06153615|OTHER|EEG (64 electrodes)|EEG recording while awake, at rest then during an attentional cognitive test
214961682|NCT06153615|OTHER|Cognitive task (SART)|Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)
214961683|NCT06153615|OTHER|Pupillometry and eye tracking|Study of pupil size and gaze path during the cognitive test (correlated with alertness)
214961684|NCT06153615|OTHER|Thoracoabdominal belts|Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)
214961685|NCT06105814|DEVICE|Rapid diagnostics|Sputum sampes will in addition to standard diagnostics be investigated using a rapid diagnostic plattform (FilmArray)
215079675|NCT04016558|BEHAVIORAL|FixIt|"FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
214353613|NCT02451800|OTHER|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
214353614|NCT02451800|OTHER|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
214353615|NCT02451800|OTHER|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
214353616|NCT02564523|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)
214353617|NCT02564523|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL IM injection of (1x10\*8 infectious units)
214353618|NCT02564523|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline
214353619|NCT03403725|DRUG|MEN1309|MEN1309 solution for intravenous infusion once every 3 weeks
214961686|NCT04323384|DEVICE|Biotene® Oralbalance Moisturizing Gel|Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.
214353620|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
214353621|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
214961687|NCT06458907|DEVICE|TricValve® Transcatheter Bicaval Valve System|TricValve® Device (Device) Group subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies.
215079676|NCT02542891|OTHER|Blended CBT|
215079677|NCT02542891|OTHER|Treatment as Usual (TAU)|
214353622|NCT00373334|DRUG|placebo|placebo
214353623|NCT05005832|OTHER|multi day walking|Over the course of 14 days, the pilgrims will cover a distance of about 300 km.
214353624|NCT04862143|DRUG|Alpelisib|Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.
214353625|NCT04862143|DRUG|Fulvestrant|Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.
214353626|NCT04862143|DRUG|Goserelin|Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
214353627|NCT06530914|DRUG|MRG003 combined with Pucotenlimab|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
214353628|NCT06530914|DRUG|MRG003 combined with Pucotenlimab+Cisplatin|All interventions all drugs intravenous infusion, once every 3 weeks, a total of 3 cycles.
214961688|NCT06458907|DRUG|Optimal medical therapy|Optimal medical therapy
214353629|NCT06215274|OTHER|Relationship of the cognitive leisure activity levels, cognitive function, and MRI characteristics.|The cognitive leisure activity levels, cognitive function, and MRI characteristics in people in the preclinical stage of Alzheimer's Disease (AD).
214353630|NCT04272268|DEVICE|Nasal High flow Oxygen|If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
214353631|NCT03174223|DRUG|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
214961689|NCT00308516|DRUG|5-Fluorouracil|"Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15"
214961690|NCT00308516|DRUG|Bevacizumab|"Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15"
214961691|NCT00308516|PROCEDURE|Radiation Therapy|radiation 1.8 Gy/day or 28 fractions weeks 1-6
214961692|NCT00308516|DRUG|Oxaliplatin|"Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15"
214961693|NCT00308516|DRUG|Leucovorin|"Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15"
214961694|NCT01563198|BEHAVIORAL|Comfort Talk®|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
214961695|NCT04306497|DRUG|TCM prescriptions|TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
214961696|NCT04560556|DIAGNOSTIC_TEST|Point-of-Care (POC) Rapid HIV Test|Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
214961697|NCT04560556|DIAGNOSTIC_TEST|Fourth Generation Antigen/antibody (Ag/Ab) HIV Test|Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
214961698|NCT01443741|OTHER|Therapeutic education|Specific program for FIT Therapy and specific program for traditional way
215079678|NCT00123097|COMBINATION_PRODUCT|Chlorinated polyethylene elastomer|Chlorinated polyethylene
214961699|NCT02892617|OTHER|Bacteriological analysis of disc|
214961700|NCT01589419|DRUG|veliparib|see arm description
214353632|NCT02123654|DRUG|Daclatasvir|
214961701|NCT01589419|DRUG|capecitabine|see arm description
214961702|NCT01589419|RADIATION|radiation|see arm description
214961703|NCT00014612|PROCEDURE|axillary lymph node dissection|
214961704|NCT00014612|PROCEDURE|lymphoscintigraphy|
214961705|NCT00014612|PROCEDURE|therapeutic conventional surgery|
214961706|NCT00014612|RADIATION|radiation therapy|
214961707|NCT01000974|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
214961708|NCT01000974|BIOLOGICAL|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
214961709|NCT01000974|BIOLOGICAL|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
214961710|NCT01000974|BIOLOGICAL|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
214961711|NCT01000974|BIOLOGICAL|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
214961712|NCT01000974|BIOLOGICAL|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
214961713|NCT01000974|BIOLOGICAL|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
214961714|NCT01000974|BIOLOGICAL|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
214961715|NCT02750332|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
215079679|NCT05940545|DRUG|Favipiravir|Small molecule antiviral
215079680|NCT05940545|DRUG|Ribavirin|Small molecule antiviral
215079681|NCT01094353|PROCEDURE|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
215079682|NCT01094353|PROCEDURE|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
214961716|NCT02397941|OTHER|Ultrasound|ultrasound measures
214961717|NCT02019342|OTHER|FACE quality improvement initiative (see below)|Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.
214961718|NCT02019342|OTHER|Pre-quality improvement initiative|Patients in the pre-quality improvement initiative arm would receive current standard practice.
214961719|NCT01882296|DRUG|AGSPT_10|AGSPT 10mg for 7days administration
214961720|NCT01882296|DRUG|AGSPT_20|AGSPT 20mg for 7days administration
214961721|NCT01882296|DRUG|AGSPT_40|AGSPT 20mg x 2tablet for 7days administration
214961722|NCT01882296|DRUG|Pantoprazole_20|Pantoprazole 20mg for 7days administration
214353633|NCT02123654|DRUG|Asunaprevir|
214961723|NCT01882296|DRUG|Pantoprazole_40|Pantoprazole 40mg for 7days administration
214961724|NCT00621257|DIETARY_SUPPLEMENT|ergocalciferol|8000 units/ml
214353634|NCT02123654|DRUG|DCV 3DAA|
214353635|NCT02123654|OTHER|Placebo for DCV 3DAA|
214353636|NCT02123654|OTHER|Placebo for Daclatasvir|
214353637|NCT02123654|OTHER|Placebo for Asunaprevir|
214353638|NCT02828722|OTHER|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
214353639|NCT02828722|OTHER|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
214961725|NCT00621257|DIETARY_SUPPLEMENT|Cholecalciferol|400 units per drop
214961726|NCT01255904|DRUG|Chloral Hydrate|Oral chloral hydrate 50 mg/kg
214961727|NCT01255904|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg
214353640|NCT03019211|OTHER|Exercise|
214353641|NCT02019160|DRUG|25% AgNO3 solution followed by 5% NaF varnish|Dosage of 4.4μg±1.4μg fluoride per use
214353642|NCT02019160|DRUG|38% SDF solution followed by placebo varnish|Dosage of 8.8μg±2.8μg fluoride per use
214678873|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
214961728|NCT01255904|OTHER|Oral placebo|Oral saline administered
214961729|NCT01255904|OTHER|Intranasal placebo|Intranasal saline administered
214961730|NCT05074134|DRUG|[14C]-TNP-2092|Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).
214961731|NCT02453880|BEHAVIORAL|Web-based Cognitive Behavioral Therapy|"Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session."
214961732|NCT03762577|OTHER|Ground-based walking training|Patients will attend a 2-day 30-minute ground-based walking training under the supervision of a physiotherapist. Patients will walk for 1-2 days in a week without supervision. According to the Modified Borg Scale, the dyspnea intensity will be 3-4 (medium to slightly difficult) and the heart rate will be completed to not exceed 120 min / pulse. Heart rate of patients will be followed by finger type pulse oximeter
214961733|NCT02651870|DRUG|Candesartan 16mg|
214961734|NCT02651870|DRUG|Amlodipine 5mg|
214961735|NCT02651870|DRUG|Amlodipine 10mg|
214961736|NCT05470244|OTHER|Routine Physical Therapy and Intra-venous analgesic regimen|ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
214961737|NCT05470244|OTHER|Transcutaneous Electrical Nerve Stimulation along with Routine Physical Therapy and Intra-venous analgesic regimen|High frequency stimulations via Transcutaneous Electrical Nerve Simulator will be applied. ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
214961738|NCT00581061|DRUG|Vesicare|Vesicare will be taken daily for one or three months, depending on symptoms of subject.
214961739|NCT00370591|DRUG|Salmeterol/fluticasone propionate and fluticasone propionate|
214961740|NCT02214940|DRUG|BI 11634|
214961741|NCT02214940|DRUG|Placebo|
214961742|NCT01005862|BIOLOGICAL|PF-04360365|10 mg/kg, single dose administered intravenously
214961743|NCT01005862|DRUG|Placebo|Placebo
214961744|NCT02791529|PROCEDURE|Electrocautery|Skin incision performed by electrocautery
214961745|NCT02791529|PROCEDURE|Scalpel|Skin incision performed by scalpel
214961746|NCT00568737|DRUG|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
214961747|NCT00568737|DRUG|Placebo|0.9% sodium chloride
214961748|NCT01861353|OTHER|Cranberry-lingonberry juice|
214961749|NCT01861353|OTHER|Placebo juice|Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
214961750|NCT00632125|DRUG|HX575 recombinant human erythropoietin alfa|HX575 epoetin alfa i.v. will be administered according to the SmPC
214961751|NCT04438408|OTHER|questionaires|patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.
214961752|NCT00827788|DRUG|Iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
214961753|NCT00827788|DRUG|Iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
214961754|NCT02872909|DEVICE|Ambulight (Ambicare Health)|"battery-operated low irradiance red light LED (skin cancer plaster)"
214353643|NCT03725917|OTHER|Physiotherapy protocol|The intervention will consist of a physiotherapy protocol twice a week for twelve weeks. The protocol will be done in three phases, constituting each month, a phase of the protocol. The first two phases will include therapeutic exercise of progressive difficulty and manual therapy, while the last phase will include only one week of manual therapy and therapeutic exercise, the last three weeks being composed only of therapeutic exercise
214961755|NCT02916953|DEVICE|AGN1 Femoral Local Osteo-Enhancement Procedure|A procedure that is intended to increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck. Local treatment of the proximal femur with AGN1 is intended to be adjunctive to appropriate systemic therapy and overall osteoporosis management as directed by the patient's treating physicians.
214353644|NCT03591341|DIAGNOSTIC_TEST|melatonin level in pumped breast milk|diagnostic test of melatonin level in pumped breast milk
214353645|NCT01726192|PROCEDURE|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
214353646|NCT01726192|PROCEDURE|Placement of a femoral neurostimulating catheter|
214353647|NCT03885531|DEVICE|Total knee arthroplasty with Journey II CR Total Knee System|TKA with Journey II CR Total Knee System
214487048|NCT06788093|BEHAVIORAL|Transitions Clinical Decision Support (CDS-Tr)|The CDS-Tr intervention is designed as a longitudinal decision support aid to influence initial and ongoing (i.e., continuation, discontinuation, escalation, or de-escalation) antibiotic decision-making in the hospital setting. This intervention will also feature the LRTI dashboard along with additional tailored suggestions and recommendations for antibiotic decision-making upon hospital admission, and for those receiving antibiotics, at the time of discharge. Additionally, CDS-Tr will be active at the time of any service transition (i.e., hospital to intensive care or vice versa) and at pre-specified time points (e.g., approximately 48 hours and 120 hours following ED triage for encounters remaining in the hospital).
214353648|NCT05194774|PROCEDURE|Greater Trochanter epiphysiodesis|epiphysiodesis by cortical screw and washer
214353649|NCT03771482|BEHAVIORAL|Quiztime modules|Text Messaging or Email system
214353650|NCT03031938|DRUG|Investigational medical product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
214353651|NCT06388343|OTHER|Evaluation of Children's Listening and Processing Skills|The Evaluation of Children's Listening \& Processing Skills (ECLiPS; (Barry \& Moore, 2021; Barry et al., 2015; Petley et al., 2021) is a caregiver-report outcome measure to profile auditory and cognitive real-world abilities important for successful listening and (auditory) processing.
214487049|NCT06768645|BEHAVIORAL|Diabetic foot care education delivered using the Pecha Kucha method|"The study commenced after obtaining ethical approval and written consent from the relevant institution. The Pecha Kucha presentation was prepared by the researcher, adhering to established literature and the specific requirements of the technique. The education covered six key topics: 1) Diabetes and Foot Problems, 2) Daily Foot Care, 3) Appropriate Socks, 4) Appropriate Footwear, 5) Nail Care, and 6) Daily Life Precautions. Expert opinions were sought from four academics (S.Ö; K.L; Z.Z; G.F) with expertise in the field to establish content validity for the final version of the Pecha Kucha diabetic foot care presentation. Following expert approval, a pilot study was conducted with 10 diabetic patients who met the sample group criteria. Feedback from these patients regarding system functionality, clarity, and flow was incorporated to finalize the presentation. Afterward, the finalized Pecha Kucha Information training was delivered to the experimental group. The presentations were cond"
214487050|NCT06768645|BEHAVIORAL|traditional diabetic foot care education|traditional diabetic foot care education
214487051|NCT06792578|PROCEDURE|Surgical Start Time|This intervention focuses on the retrospective analysis of the association between surgical start times (morning, afternoon, and nighttime) and postoperative outcomes in non-cardiac surgeries. The study evaluates how the timing of surgery impacts mortality, complications, transfusion rates, and ICU admissions in a tertiary hospital setting
214487052|NCT06791460|DRUG|Pegylated liposomal doxorubicin plus adebrelimab with mirabegron|Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle orally with daily mirabegron until intolerance or disease progression.
214961756|NCT01671137|OTHER|Lactobacillus Rhamnosus Strain GG|Lactobacillus Rhamnosus Strain GG
214353652|NCT06388343|BEHAVIORAL|Multidisciplinary behavioral assessment|By collecting behavioral measures, the investigators wish to understand the functional implications of the presented problems. Children will complete various well-chosen tasks using a tablet, in the presence of a trained clinician. Tablets are used as they are ubiquitous, cost-effective, and have excellent quality audio output. The investigators will apply the concept of differential testing (Dillon \& Cameron, 2021; Lagacé et al., 2010) to narrow down the range of deficits that lead to deficient scores. The investigators distinguish four (partly overlapping) categories of behavioral measures: 1) auditory processing, 2) (nonsense) speech sound processing in quiet and in noise, excluding semantics, 3) meaningful speech in quiet and in noise, language processing, and 4) neurocognitive (including attention, memory, processing speed) processing.
214353653|NCT05981274|DIAGNOSTIC_TEST|serum biomarker.|serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)
214353654|NCT03984669|DIAGNOSTIC_TEST|The Juvenile Disease Activity Score (JADAS)|The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.
214961757|NCT04747249|OTHER|Psychological support|Psychological care will be based on a monthly interview lasting approximately 45 minutes for 6 months.
214961758|NCT02727179|PROCEDURE|Liver resection|The investigators perform an anatomical liver resections or wedge resections depending on tumour's location and tumour's characteristics
214961759|NCT06277570|OTHER|conventional physiotherapy|Conventional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.
214961760|NCT06277570|OTHER|NMES|Neuromuscular Electrical Stimulation (NMES) is a non-invasive method that activates intramuscular nerve branches and produces visible contractions through surface electrodes placed on skeletal muscles.
214353655|NCT03984669|BIOLOGICAL|(1-3)-ß-D-Glucan (BDG) assay (Fungitell)|Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers
214353656|NCT03876652|DEVICE|Pacemaker with Closed Loop Stimulation (CLS)|In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
214353657|NCT01921439|BEHAVIORAL|Personalized Feedback|Personalized feedback reflecting the participant's current level of nicotine addiction, money spent on cigarettes, time spent smoking, and health effects of smoking.
214353658|NCT00454051|DRUG|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
214353659|NCT00454051|DRUG|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
214487053|NCT06791460|DRUG|Pegylated liposomal doxorubicin plus adebrelimab|Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle until intolerance or disease progression.
214487054|NCT06786260|OTHER|Interventional Diet|Low salt, limited caffeine, high potassium, low phosphate, and limited protein and carbohydrate intake along with adequate water intake diet
214487055|NCT06792253|DRUG|Ifupinostat Hydrochloride for Injection|Ifupinostat Hydrochloride for Injection,dosage of administration:18.5mg/m\^2,frequency and duration of administration:Medication is administered on days 1, 3, 5, 8, 10, and 12 of each cycle,with a 21-day or 42-day cycle duration.
214502664|NCT05927220|DIAGNOSTIC_TEST|Biopsy Specimens Histopathology|paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists
214678874|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
214678875|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
214961761|NCT06277570|OTHER|Superimposed NMES|Superimposed NMES technique is the use of NMES with voluntary muscle contraction.
214961762|NCT00540644|DRUG|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
214961763|NCT00540644|DRUG|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
214961764|NCT00540644|DRUG|Prednisone|50 mg p.o. Q.O.D.
214961765|NCT02085265|DRUG|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
214502665|NCT02222493|BIOLOGICAL|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
214353660|NCT03627481|PROCEDURE|Endoscopic sinus surgery|Endoscopic sinus surgery for nasal polyposis
214353661|NCT03681626|PROCEDURE|no tracheal suction|No tracheal suctioning during extubation
214353662|NCT03681626|PROCEDURE|tracheal suction|tracheal suctioning during extubation
214353663|NCT02136277|DRUG|Hartmann's solution|Administered in 250ml boluses, until cardiac output has been optimised.
214353664|NCT04566029|BIOLOGICAL|Blood test|The patients' blood will be collected in four 5mL heparinized tubes
214353665|NCT04566029|BIOLOGICAL|Stool sample|The patients' stools will be collected at home
214353666|NCT04566029|OTHER|Questionnaires|At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE
214353667|NCT06302166|OTHER|High Intensity Circuit training (HICT)|High Intensity circuit training consisting of circuits of high intensity exercises and progressed up to 8 weeks will be provided.
214502666|NCT02222493|BIOLOGICAL|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
214502667|NCT01894217|GENETIC|Genetic testing and reporting for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele; reporting of test results to provider and participant
214502668|NCT00405158|PROCEDURE|Acupuncture treatment|
214502669|NCT00405158|PROCEDURE|Administration of oxytocin nasal spray|
214502670|NCT00405158|PROCEDURE|Improved breast milk removal|
214502671|NCT00405158|PROCEDURE|Warmth applied to breasts|
214502672|NCT00405158|PROCEDURE|Breast massage|
214502673|NCT00405158|DRUG|Anti-pyretic medication, paracetamol|
214502674|NCT00405158|DRUG|cefadroxil|
214502675|NCT00405158|DRUG|penicillin|
214502676|NCT00405158|DRUG|flucloxacillin|
214502677|NCT05606484|OTHER|Exercise with non-immersive virtual reality|Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
214502678|NCT05606484|OTHER|Exercise with a static pedal|Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
214502679|NCT01724996|OTHER|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
214502680|NCT01125124|DRUG|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
214502681|NCT01259557|DRUG|Botulinum Toxin Type A|2 times, Intra-muscular injection, Maximum dosage total 60U
214502682|NCT06064669|DRUG|Metformin pretreatment before ovarian stimulation|The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
214502683|NCT06064669|DRUG|Placebo pretreatment before ovarian stimulation|The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
214353668|NCT06302166|OTHER|Intermittent Fasting (IF)|Time restricted feeding will be used in which the intervention will begin with a 12:12 window leading to a 16:8 IF protocol.
214353669|NCT06302166|OTHER|Combination of HICT and IF|The participants will follow both HICT and IF for 8 weeks.
214353670|NCT01431625|OTHER|Combined Training (endurance and strength exercises)|"All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:~1. .- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.~2. \- Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient."
214353671|NCT00794612|DRUG|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
214353672|NCT02049073|DRUG|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
214353673|NCT02049073|DRUG|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
214353674|NCT03881735|DRUG|Enasidenib|Given PO
214353675|NCT03881735|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
214487056|NCT06792253|DRUG|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:Medication is administered on day 1 of each cycle or every third cycle, with a 21-day cycle duration.
214961766|NCT02085265|DRUG|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
214961767|NCT03227731|DRUG|Truvada|Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
214961768|NCT06453395|OTHER|Patients were grouped according to tumor location|Patients were grouped according to tumor location
214961769|NCT01222208|DIETARY_SUPPLEMENT|Oral Nutrition with dextrose and pressurized whey protein|Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.
214961770|NCT01222208|DIETARY_SUPPLEMENT|Peripheral Parenteral Nutrition|Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
214961771|NCT04348097|DEVICE|Activator instrument|activator instrument was placed perpendicular over the identified trigger point and 10 thrusts were delivered, with a rate of one thrust per second
214961772|NCT04348097|DEVICE|dry needle|By wrist flexion and extension movements, the trigger point was needled in different directions and tried to elicit at least one local twitch response during the procedure and patient's familiar referral pain was tried to obtain . Each dry needling procedure lasted 1-2 minutes
214353676|NCT02628054|BIOLOGICAL|Typhoid Vaccine|Typhoid Vaccine injection given 7 days apart
214353677|NCT02628054|BIOLOGICAL|Placebo|Saline injection given 7 days apart
214353678|NCT04338100|PROCEDURE|Follow-up at 14 days|Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death)
214353679|NCT01571362|DRUG|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
214353680|NCT01571362|DRUG|Placebo|oral placebo, divided into symmetric doses and administered twice daily
214353681|NCT06442553|DEVICE|GRR laser|A total of 15 sessions were applied to each patient for three weeks, five times per week.
214487057|NCT06792253|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection,dosage of administration:1g/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
214353682|NCT06442553|DEVICE|Nd:YAG laser|A total of 10 sessions, five sessions per week, were applied
214353683|NCT00401570|DRUG|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
214353684|NCT00401570|DRUG|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
214353685|NCT00406835|PROCEDURE|Whole-Brain Radiation Therapy, Stereotactic Radiosurgery|
214487058|NCT06792253|DRUG|Oxaliplatin Injection|Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
214487059|NCT06792253|DRUG|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on days 1,2,and 3 of each cycle, with a 21-day cycle duration.
214678876|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
214961773|NCT02752360|PROCEDURE|Biodegradable Stenting Anastomoses|Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
214353686|NCT01815164|BEHAVIORAL|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
214353687|NCT01815164|BEHAVIORAL|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
214353688|NCT05484674|PROCEDURE|Deroofing and laser|Deroofing and laser to axilla
214353689|NCT02969889|DEVICE|Airtraq|video laryngoscope with a channel
214961774|NCT02752360|PROCEDURE|Double-layer Hand Sutures|Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
214961775|NCT00809094|DRUG|N-acetylcysteine (NAC)|
214961776|NCT00809094|DRUG|Placebo|
214961777|NCT02768402|DEVICE|Caisson TMVR System|Transcatheter mitral valve replacement is a percutaneous procedure used to treat mitral valve regurgitation with a prosthetic valve implantation.
214961778|NCT02812589|OTHER|Diffusion tensor imaging (DTI) in Breast MRI|
214961779|NCT01707628|BIOLOGICAL|influenza vaccination with influenza vaccine|
214961780|NCT02956538|DRUG|Thalidomide|
214961781|NCT02956538|DRUG|placebo(for thalidomide)|sugar pill manufactured to mimic thalidomide 100mg tablet
214961782|NCT02794688|PROCEDURE|Ductal lavage therapy|"1. Patient lies in supine position, with routine sterilizing and draping procedure.~2. Local anesthesia with 2ml lidocaine (1%) around the nipple.~3. Identification of 4-5 openings of the lactiferous ducts from the nipple.~4. Insertion of all infusion cannula (21-23G ) into the identified openings of the lactiferous ducts.~5. Start the infusion pump with 15ml irrigation solution (2% Lidocaine 5ml, Triamcinolone acetonide 40mg，0.9% saline 10ml and ceftriaxone 1.0g). If the patients had elevated white blood cell count and fever (\>38 celsius degree), oral intake or infusion of antibiotics were allowed, when necessary.~6. The patient returns to the clinic the next day, with the irrigation solution staying in the lactiferous ducts overnight, and receives breast massage.~7. Repeat step 1-6 every other day for 2 weeks.~8. Fine needle aspiration is allowed. Oral intake of corticosteroids, excisional drainage or surgery are not allowed."
214961783|NCT04009304|BEHAVIORAL|OSNAP|Afterschool practice and policy change to support healthy eating and physical activity
214961784|NCT03731949|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography to assess placental volume
214961785|NCT04799262|DRUG|Tofacitinib 5 MG|Oral tofacitinib at the dose of 5mg twice a day was given for 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if\<10 the daily GC dosage was decreased by 2.5mg; if\>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
214961786|NCT05063578|DRUG|Lidocaine 2% Injectable Solution|Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
215079683|NCT04687592|PROCEDURE|reduction and fixation|"* Reduction: one trial of closed reduction under anaesthesia and image control. Open reduction will be done by anterolateral or lateral approach if closed reduction failed~* Fixation: internal fixation of the fracture by appropriate implant according to the fracture state"
214353690|NCT02969889|DEVICE|ILMA|
214353691|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
214353692|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
214353693|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
214353694|NCT04022668|RADIATION|Coronary angiogram|Routine coronary angiogram, if indicated
214353695|NCT00209417|DRUG|Iodixanol 320-Arm 1|
214353696|NCT00209417|DRUG|Iopamidol 300-Arm 2|
214961787|NCT06238219|DRUG|Neuromuscular Blocking Agent|Administration of any neuromuscular blocking agent for surgery under general anesthesia
214961788|NCT01515098|DIETARY_SUPPLEMENT|Freeze-dried blueberries|Wild blueberries, freeze-dried and pulverized
214961789|NCT01515098|DIETARY_SUPPLEMENT|Dextrose Placebo|Placebo developed to closely match blueberry powder.
214961790|NCT00397189|DRUG|Circadin|Prolonged release melatonin 2 mg
214961791|NCT00397189|DRUG|placebo circadin|placebo circadin tablets
214961792|NCT03472937|PROCEDURE|Transcervical Foley catheter placement for cervical ripening|Subjects will be randomized have cervical ripening with a transcervical Foley catheter in either the inpatient or outpatient setting.
214961793|NCT00172445|PROCEDURE|blood sampling, neck lymph node biopsy|
214961794|NCT02620683|DRUG|Lidocaine|See above
214961795|NCT01535443|DRUG|Bromfenac|Drug: Bromfenac Other names: PRO-155
214961796|NCT02951026|OTHER|Not applicable (no therapy is administered as part of this study)|"No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study."
214961797|NCT01788319|PROCEDURE|lasertrabeculoplasty|
214961798|NCT03703752|DIAGNOSTIC_TEST|Multi-detector CT scan|This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
215079684|NCT01342965|DRUG|Erlotinib|Erlotinib was supplied as tablets.
215079685|NCT01342965|DRUG|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
214353697|NCT06162767|PROCEDURE|Esophagectomy by Ivor-Lewis Procedure|Esophagectomy was conducted by Ivor-Lewis Procedure.
214353698|NCT06162767|PROCEDURE|Esophagectomy by Optimized Sweet Procedure|Esophagectomy was conducted by Optimized Sweet Procedure.
214353699|NCT04931927|BEHAVIORAL|Making Connections Intervention-Telehealth (MCI-T)|Single session telehealth engagement intervention plus telehealth treatment as usual (TAU) \[MCI-T +TAU\]
214353700|NCT04931927|BEHAVIORAL|Treatment as usual (TAU)|Telehealth treatment as usual without the single session telehealth engagement intervention
214961799|NCT05434663|DRUG|SUSTOL|SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles.
214961800|NCT00192972|PROCEDURE|Catheter ablation (pulmonary vein isolation)|
214961801|NCT05924659|OTHER|Cerabral training|1 week of cerebral training (neurofeedback or sham)
214961802|NCT05234268|OTHER|Manual Cervical Traction|"Time: 20 minutes Duration: thrice a week for 4 weeks.~Position:~The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion."
214961803|NCT05234268|OTHER|Passive Accessory Intervertebral Movements|"Time: 20 minutes Duration: thrice a week for 4 weeks~Position:~Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension.~Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra."
214961804|NCT05234268|OTHER|Active Strength Training|"Time: 20 minutes Duration: thrice a week for 4 weeks. The progression of exercises will be done using different colors of Thera-band indicating varied resistance. (A) Resistive lateral flexion of uninvolved side.~Position:~The patient is in sitting position. By the help of thera-band patient will actively flex the neck against resistance on the uninvolved side."
214961805|NCT03216707|DEVICE|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
214961806|NCT03216707|DEVICE|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
214961807|NCT03216707|DEVICE|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
214961808|NCT03216707|OTHER|Capsaicin cream|Capsaicin cream
214961809|NCT02997605|DRUG|GlucoCorticoid|"After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone."
214353701|NCT05278910|OTHER|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour
215079686|NCT04355533|BIOLOGICAL|serology test|volume according to child weight
215079687|NCT04355533|BIOLOGICAL|nasopharyngeal swab|nasopharyngeal swab for PCR
214353702|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Roasted wheat flour|Assign fish oil and roasted wheat flour
215079688|NCT04355533|BIOLOGICAL|rectal swab|rectal swab for PCR
215079689|NCT04355533|BIOLOGICAL|saliva sample|for biocollection
215079690|NCT06478797|OTHER|Fluid|Sepsis will be treated with standardized therapy protocol, where participants receive fluids (balanced or non-balanced crystalloids, or colloids) to be resuscitated. Specifically, they will receive 40-60 ml/kg of fluids before the initiation of inotropes.
214353703|NCT05278910|DIETARY_SUPPLEMENT|Soybean oil + Vegetable and fruit extracts|Assign soybean oil and vegetable and fruit extracts
214353704|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Vegetable and fruit extracts|Assign fish oil and vegetable and fruit extracts
215079691|NCT06478797|DRUG|Adrenalin|Sepsis will be treated with early inotropes, where participants will receive adrenaline at a dose of 0.05 - 0.1 mcg/kg/min via peripheral intravenous, intraosseous, or central venous routes after the first fluid bolus of 20 ml/kg
215079692|NCT05335187|DEVICE|micro-macro electrode implantation|One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
215079693|NCT03250078|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
215079694|NCT02655523|DRUG|Triamcinolone|1 mL of 40 mg of Triamcinolone
214353705|NCT00598429|DRUG|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
214487060|NCT06792253|DRUG|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
215079695|NCT02655523|DRUG|Dexamethasone|1 mL of 4mg of Dexamethasone
214487061|NCT06792253|DRUG|Carboplatin Injection|Carboplatin Injection,,dosage of administration:single dose ≤800 mg (calculated based on AUC=5),frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
214678877|NCT01671436|BEHAVIORAL|Central Meditation and Imagery Therapy|
214678878|NCT00530699|DRUG|AZD1152|intravenous
215079696|NCT02655523|DRUG|Normal Saline|1 mL of preservative free normal saline
214353706|NCT02071173|DEVICE|ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead|"The ACUITY X4 leads are intended for chronic left ventricular pacing and sensing. The leads have 3 tip configuration designs (straight tip, short tip spiral, and long tip spiral), which is intended to provide choices for patients with different anatomies.~The RELIANCE 4-FRONT leads are designed for right-side heart applications within the ventricle, atrium, and superior vena cava. It is intended for permanent sensing, pacing, and defibrillation when used with a compatible implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).~Subjects were allowed to receive both the ACUITY X4 and RELIANCE 4-FRONT lead."
214353707|NCT01508468|DRUG|symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)|Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
214353708|NCT01508468|DRUG|experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)|NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
214961810|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy with and without laryngeal restriction|To reduce the laryngeal movement and St.Eso excursion we will use a device constructed in our laboratory which can induce an adjustable resistance to excursion of the larynx. This handmade device that is worn around the neck consists of a band and a concave plastic disk which serves as a support structure for an inflatable polyethylene bag which is connected to a hand pump and pressure gauge. When worn around the neck the inflatable bag rests in position on the thyroid cartilage with a portion of it hung over above the cartilage creating resistance to its superior excursion when fixed by closure straps. A known external force may be applied to the thyroid by partially inflating the bag to a specific pressure reading on the gauge. The soft and compliant bag conforms to the larynx while applying a resistive force to anterior and superior distraction of the hyolaryngeal complex during swallowing.
214961811|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy before and after six weeks of using swallow muscle exercising device|Use the previously mentioned wearable device (sRED) and exercise regimen described previously for studying the effect of increase in anterosuperior excursion of the larynx/St.Eso on St.Eso peristaltic function.
214961812|NCT02170857|DRUG|Hyaluronic Acid|This material will be used in conjunction with the ordinary surgical procedure
214961813|NCT00232557|DEVICE|TLC-Asthma|Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
214961814|NCT00232557|DEVICE|TLC-health education|A telephone-linked communication system (TLC) to provide general health education.
214961815|NCT03629145|BEHAVIORAL|Live Music Therapy|Investigator will begin play live guitar and voice music.
215079697|NCT02655523|DRUG|Bupivacaine|2 mL of 0.5% bupivacaine
215079698|NCT01262170|DIETARY_SUPPLEMENT|CigRx Lozenge|lozenge made of dietary supplements
215079699|NCT01262170|OTHER|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
215079700|NCT00226408|DRUG|Interferon-alpha-2b|
215079701|NCT02775942|BIOLOGICAL|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
215079702|NCT02775942|BIOLOGICAL|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
215079703|NCT02775942|BIOLOGICAL|IPOVAC, 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
215079704|NCT02775942|BIOLOGICAL|IPOVAC, 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
214961816|NCT03629145|BEHAVIORAL|Recorded Music Therapy|Investigator will play recorded music.
214961817|NCT05013580|PROCEDURE|Guided bone regeneration (GBR)|Bone grafts will be placed in the patient's jawbone, along with a membrane to cover the bone grafts. A horizontal incision over the edentulous ridge crest will be made along with vertical incisions if indicated. Buccal and lingual full thickness mucoperiosteal flaps will be reflected to expose the alveolar bone. Intra-marrow penetration (decortication of the alveolar bone to increase vascular supply to the bone grafts) at the surgical site alveolar bone will be made with a high-speed hand piece and diamond bur. Bone allograft material will be placed to fill the alveolar bone defect. The bone graft will then be covered with a membrane and secured with sutures.
214961818|NCT05510414|BEHAVIORAL|psychological intervention based on psychological capital|Psychological capital would be modified via various training programs in order to manage burnout among nurses. When the four core psychological resources are combined, they may form a higher-order construct that predicts attitudes and performance more strongly than any of the four components by themselves .
214961819|NCT04612283|OTHER|NGA-01 gel|NGA-01 is a gel formulation with mostly herbal active ingredients
215079705|NCT01175434|OTHER|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
215079706|NCT02306304|OTHER|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
215079707|NCT03887520|DIAGNOSTIC_TEST|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
215079708|NCT04213144|DEVICE|Magdent Cap MED|Magdent is intended to be used for accelaration of soft tissue and bone healing
215079709|NCT04213144|DEVICE|Sham MED|Sham MED is intended to be used for soft tissue healing
214961820|NCT04612283|OTHER|Placebo|A Placebo with no active ingredients
214961821|NCT05344222|DEVICE|Infrared LED|The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
214961822|NCT05344222|DEVICE|Similar device - Infrared ED|For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
214961823|NCT01059773|DRUG|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients \> 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
214961824|NCT01059773|DRUG|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
214961825|NCT04474262|BIOLOGICAL|Albumin|Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)
214961826|NCT04474262|DRUG|Midodrine Oral Tablet|Midodrine 7.5 mg to 10 mg TDS (keeping the target MAP above 70 mmHg).
214353709|NCT04118348|BEHAVIORAL|Best Practice Alert|An Epic screen pops up for a provider during an eligible 9-11 year-old patient's visit. A prompt requires that the provider respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test.
214961827|NCT04474262|OTHER|Placebo|Placebo
214961828|NCT02356757|BEHAVIORAL|Personalized Behavioral Intervention|The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
214961829|NCT02356757|BEHAVIORAL|Current Best Practice|CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
214961830|NCT00004268|DRUG|midodrine|
214961831|NCT04308876|OTHER|Manual therapy|Manual therapy includes techniques applied to elbow joints and surrounding tissues
214961832|NCT04308876|OTHER|Strengthening exercises|Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
214961833|NCT03866356|BEHAVIORAL|intervention group|The women in the intervention group were provided care according to SICP
214961834|NCT04530669|DEVICE|High Tone Power Therapy|"High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort."
214961835|NCT04530669|OTHER|exercise program|physical therapy conventional selected exercise program inform of functional activities of daily living
214961836|NCT01299883|OTHER|Integrated vs Non-integrated Risk Education|Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
214961837|NCT05218200|OTHER|deep breathing and coughing exercises with triflo|patients will be given triflo. A video of the application of deep breathing and coughing exercises with triflo prepared by the researchers will be prepared. The video will be sent to the patients' phones. It will be ensured that the patients do the exercises every hour by watching the video and they will be followed.
214961838|NCT02870192|PROCEDURE|Laparoscopic ventral mesh rectopexy|Laparoscopic opening of the Daglous pouch, dissection till reach the levator ani muscle, mesh implementation and fixation, closure of the daglous. The mesh implemented may be synthetic or biological mesh.
214961839|NCT01602991|PROCEDURE|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
214961840|NCT01602991|PROCEDURE|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
214961841|NCT02720276|OTHER|Training after acute stroke|Outdoor walking: Participants will receive daily training instructions via Short message Service (SMS) over 12 weeks. The walks are increased in frequency and intensity. The intensity are rated using the Borg scale to 12-15. The first 2 weeks begins with daily walks of 10 minutes. The last 4 weeks the walk training will partly be performed in intervals in combination with conventional outdoor walks. The interval training includes warming-up (5 minutes), fast walking for 4 minutes alternated with slower walking for three minutes. This is repeated 3 times, followed by cooling down for about five minutes. Strength training: to repeatedly get up from sitting. Number of repetitions will increase from 5-20 per set and will be performed daily in 3 sets with a short rest between each set.
214961842|NCT02842476|DEVICE|Disposable Sensor|Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
214961843|NCT02842476|DEVICE|Reusable Sensor|Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
214961844|NCT02842476|DEVICE|Control Pulse Oximetry|A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
214961845|NCT00235573|DIETARY_SUPPLEMENT|Vitamin B12|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.
214961846|NCT02871141|PROCEDURE|electroconvulsive therapy|electroconvulsive therapy
214961847|NCT02871141|DRUG|Antidepressant|Antidepressant
214961848|NCT04642417|OTHER|dietary fiber literacy|education
214961849|NCT04642417|OTHER|routine care|routine care
214961850|NCT05474183|DRUG|Ketamine|drug
214961851|NCT01787669|DRUG|Avastin (Bevacizumab)|Avastin (Bevacizumab) administered intravitreally
214961852|NCT01787669|DRUG|Ozurdex (dexamethasone)|Ozurdex (dexamethasone) given intravitreally
214961853|NCT04635930|OTHER|Taping plus Traditional exercises|The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.
214961854|NCT01427270|DRUG|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
214961855|NCT01427270|DRUG|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
214961856|NCT01427270|DRUG|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
214961857|NCT05888480|OTHER|The end-of-life communication skills training|Training methods include lectures, video demonstrations, and simulation in small groups (4-5 trainees per group with multidisciplinary roles). Written and audiovisual learning materials will be offered. Each session will be 150 minutes, including lectures and video demonstration (90 min/session) and simulation and feedback (60 min/session). One session will be conducted in two weeks. Totally there will be four sessions completed in 8 weeks.
214961858|NCT05888480|OTHER|Routine training activity|Routine training activities arranged by relevant departments in hospitals
214961859|NCT06300099|DRUG|Dexamethasone|Dexamethasone as adjunct to serratus anterior plane block.
214961860|NCT06300099|DRUG|Dexmedetomidine|Dexmedetomidine as adjunct to serratus anterior plane block.
215079710|NCT02868034|BEHAVIORAL|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
215079711|NCT02868034|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
214961861|NCT06135844|DRUG|Purell Hand Sanitizer|Active ingredient. Ethyl alcohol 70%
214961862|NCT06135844|DRUG|Medical Grade Mineral Oil|Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.
214961863|NCT00959465|BIOLOGICAL|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
214961864|NCT06133998|DEVICE|incentive spirometer with aerobic exercises|"Group A: Aerobic exercise (running, jugging, cycling, walking) will be given to the group A for the checking the effect of incentive spirometer~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung. This schedule will be following supervised exercise training for a minimum 60 minutes 3 days a week in moderate patient,75 minutes in moderate to vigorous patients and 150 minutes in healthy patients~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire."
214961865|NCT06133998|DEVICE|incentive spirometry without aerobic exercises|"Group B: In group B we will check the effects of incentive spirometer without the aerobic exercise.~* In aerobic exercise following treatment protocol will be involve~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire.~* We will check the chest expansion by measuring tap."
214353710|NCT04118348|BEHAVIORAL|Health Maintenance Topic|An Epic health maintenance topic appears for a provider during an eligible 9-11 year-old patient's visit. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
214961866|NCT04335058|DRUG|Lactoferrin + Iron Supplement|Lactoferrin 100 mg twice daily +oral iron
214961867|NCT04335058|DRUG|Iron Supplement|Oral iron supplement alone
214961868|NCT01153217|DRUG|Switch from tenofovir to abacavir|Switch from tenofovir to abacavir
214961869|NCT00660296|OTHER|Air insufflation use in colonoscopy|Air insufflation for colonic distension
214961870|NCT00660296|OTHER|CO2 use in colonoscopy|Co2 insufflation for colonic distension
214961871|NCT01861769|OTHER|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
214961872|NCT01861769|OTHER|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
214961873|NCT01029262|DRUG|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
214961874|NCT01029262|OTHER|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
214961875|NCT05102669|OTHER|analysis of immunological response|collection and analysis of SARS-CoV2 Spike specific blood cells
214961876|NCT05102669|DIAGNOSTIC_TEST|analysis of serum antibodies|analysis of anti-SARS-CoV2 Spike specific antibodies
214961877|NCT03410992|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
214353711|NCT00001048|DRUG|Filgrastim|
214353712|NCT00001048|DRUG|Cytarabine|
214961878|NCT03410992|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
214961879|NCT03301987|OTHER|Therapeutic exercise|30 minutes per day of therapeutic exercise
214961880|NCT04637841|OTHER|Kinesiology Taping Appliying|"Kinesiology tape will be applied to left foot plantar fascia of the participants in diabetes mellitus and control group.~During taping, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position. A Palm Shape taping procedure will be applied to the plantar fascia."
214353713|NCT00001048|DRUG|Zidovudine|
214353714|NCT00001048|DRUG|Zalcitabine|
214961881|NCT04637841|OTHER|Myofascial Release Technique Appliying|"Myofascial release technique will be applied (during 5 minutes) to right foot plantar fascia of the participants in diabetes mellitus and control group~During appliying technique, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position."
214961882|NCT01508247|BIOLOGICAL|inactivated vaccine (Vero Cell) against EV71|inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
214961883|NCT01508247|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, on day0, 28
214961884|NCT03436017|OTHER|Metabolomic approach|Biological samples (blood and urine) for a multimodal metabolomic approach
215079712|NCT02868034|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
215079713|NCT02868034|BEHAVIORAL|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
215079714|NCT01892787|DRUG|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
215079715|NCT01892787|DRUG|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
215079716|NCT03538444|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder
214353715|NCT00001048|DRUG|Didanosine|
214353716|NCT01792011|DEVICE|PVI-guided fluid management|In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
214353717|NCT01738048|PROCEDURE|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
214353718|NCT01491854|OTHER|Bloodsampling|Bloodsampling
214353719|NCT01636882|BIOLOGICAL|CVA21|
214353720|NCT03404128|OTHER|Questionnaires|Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
214353721|NCT05496127|OTHER|Sensorimotor Exercises and Yoga|Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
214353722|NCT04868266|OTHER|end tidal carbon dioxide monitoring|We will monitor end tidal carbon dioxide with capnography during minimal sedation
214353723|NCT00121238|DRUG|cilengitide|Given IV
214353724|NCT02071004|DRUG|DS-1040b|IV of 6 mg given once over 30 minutes
214353725|NCT02071004|DRUG|Aspirin|Dispersible tablet, 300mg \& 75 mg, once daily for 5 days
214353726|NCT02767115|DIETARY_SUPPLEMENT|2% GSE mucoadhesive gel|2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
214353727|NCT02767115|OTHER|GSE free mucoadhesive gel|GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
214353728|NCT04700293|DIETARY_SUPPLEMENT|AYMES AMSTERDAM|AYMES AMSTERDAM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
214961885|NCT02260817|DRUG|11C-choline Injection|"1. Choline C11 Injection for PET/CT Imaging Protocol:~   * 15 - millicuries (mCi) 11C-choline IV Injection~  * PET images skull base to mid thigh with 3 min per bed position~  * Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol~  * Fusion of PET and CT images~2. Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:~   * No IV contrast~  * High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs~  * Fusion of coronal and PET images"
214961886|NCT05869370|OTHER|High intensity resistance training|Twelve weeks of resistance training twice a week.
214961887|NCT05869370|OTHER|Low intensity resistance training combined with blood flow restriction|Twelve weeks of resistance training with blood flow restriction twice a week.
214961888|NCT02048150|BIOLOGICAL|anti-PSMA monoclonal antibody MDX1201-A488|Given IV
214961889|NCT02048150|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
214353729|NCT02703350|DRUG|LY900014|Administered subcutaneously (SC)
214353730|NCT02703350|DRUG|Insulin Lispro|Administered SC
214353731|NCT02943148|OTHER|Davey score for striae gravidarum|
214353732|NCT03812796|DRUG|Domatinostat|"Domatinostat is an oral tablet which will be given at a variable dose during the Phase IIA safety run in phase of the trial.~During the Phase IIB efficacy phase of the trial patients will be treated with domatinostat at the safe and tolerated combination dose identified during the Phase IIA safety run in phase."
214353733|NCT03812796|DRUG|Avelumab|Avelumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 10mg/kg every two weeks on the first day of a two week cycle. (Day 1 q 14d) from Cycle 2 onwards.
214353734|NCT06095726|BEHAVIORAL|Peppermint Inhalation|The researcher applied two drops (0,2ml) of 2% essential oil of peppermint on a piece of cotton. Then, each child was instructed to take three breaths of the essence that had been put on a piece of cotton before starting chemotherapy session with three minutes. In addition, the piece of cotton with peppermint essence was kept at bed side table to use by child as needed throughout the chemotherapy session. Inhalation of peppermint essence was applied for three consecutive chemotherapy sessions.
214353735|NCT06095726|BEHAVIORAL|Swedish Massage|Children were received Swedish massage therapy for twenty minutes prior to chemotherapy session in a private and special room with effleurage, petrissage, friction, and tapotement and vibration movements for three consecutive chemotherapy sessions. The researcher applied facilitating olive oil in hands and pre warmed before applying massage. The massage technique was applied in prone position with mild to moderate pressure with guidance by the child's feedback and tolerance by using non-scented olive oil. Children's privacy was considered.
214353736|NCT01026974|BIOLOGICAL|rMenB|
214353737|NCT01026974|BIOLOGICAL|rMenB+OMV NZ|
214353738|NCT02077257|DRUG|Rosuvastatin|Rosuvastatin 20 mg/d compared to 10 mg/day
214353739|NCT04301336|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
214353740|NCT04301336|DRUG|Vit D|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
214353741|NCT04301336|DRUG|Zinc sulfate|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
214961890|NCT02048150|OTHER|diffuse optical imaging|Undergo IOOI
214961891|NCT02048150|OTHER|pharmacological study|Correlative studies
214961892|NCT02048150|OTHER|Laboratory Biomarker|Correlative studies
214961893|NCT02048150|OTHER|Questionnaire|Ancillary studies
214353742|NCT04301336|DRUG|Statins (Cardiovascular Agents)|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
214353743|NCT04301336|DRUG|Hydroxy Urea|50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
214961894|NCT04435808|DRUG|Hydroxychloroquine|"Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria. Subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).~Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily"
214353744|NCT04301336|DRUG|Folic Acid Supplementation|Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
214353745|NCT04301336|DRUG|Morphine Sulfate|Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
214961895|NCT03299101|OTHER|Prehabilitation|Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
214961896|NCT05184348|RADIATION|Narrow band Ultraviolet B phototherapy group|3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
214961897|NCT05184348|DRUG|Acitretin group|dose of 0.5-1 mg per kg per day orally for 3 month.
214961898|NCT05184348|COMBINATION_PRODUCT|Acitretin plus Narrow band Ultraviolet B phototherapy group|Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
214961899|NCT02457195|DRUG|granisetron|Application granisetron transdermal patch preoperatively
214961900|NCT02937181|DRUG|Ceftaroline|IV Ceftaroline will be given for 72 hours
214961901|NCT02104427|DRUG|TG-0054 combined with G-CSF|
214961902|NCT03163641|DEVICE|Acuvue Oasys|Bandage Contact Lens
214961903|NCT03163641|DEVICE|Ocular Bandage Gel|0.75% crosslinked HA
214961904|NCT02909790|DEVICE|Curve Low Level Laser Therapy|"Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.)."
214961905|NCT01896193|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
214961906|NCT01896193|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214961907|NCT05886114|BEHAVIORAL|Structured Multi-domain Intervention|Structured Multi-domain Intervention (SMI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
214961908|NCT05886114|BEHAVIORAL|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
214961909|NCT01793038|DRUG|Aromatase inhibitor (litrezole) plus uFSH arm|literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
214961910|NCT01793038|DRUG|clomiphene citrate-uFSH arm|clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
214353746|NCT04301336|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
214353747|NCT04694274|DEVICE|stabilization splint|The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.
214353748|NCT04694274|PROCEDURE|physical therapy|Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.
214353749|NCT04694274|DEVICE|placebo splint|The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
214353750|NCT00303966|DRUG|sorafenib tosylate|Given orally
214353751|NCT00325468|DRUG|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
214961911|NCT04682899|DRUG|procalcitonin-guided antibiotic therapy|In procalcitonin group, clinican make a decision of antibiotic precription based on the results of procalcitonin.
214961912|NCT04682899|DRUG|guideline-guided antibiotic therapy|In guideline group, clinican make a decision of antibiotic precription based on the recommendations of GOLD guideline.
214961913|NCT05961631|OTHER|Bio-electrical Impedance Analysis|Variable measured: Fluid accumulation (FA), volume excess (VE), total body weight (TBW), extracellular water (ECW), intracellular water (ICW)
214961914|NCT06444334|RADIATION|low level Diode Laser|Group 2 was exposed to laser irradiation following implant insertion for 3 sessions: Immediately after implant insertion, 2 days after implant insertion and 1 week after insertion , using a red Diode(gallium-aluminun-arsenide) LLLT using calibrated diode laser device
214961915|NCT06444334|PROCEDURE|PRF platelet rich fibrin|The preparation method of PRF was performed in accordance with the protocol developed by Choukroun et al 2001. PRF was withdrawn and processed from the same operated-on patient's blood; 6ml IV blood withdrawn from the antecubital vein in to two sterile 3ml red vacutainer tubes without anticoagulant, followed by a 12 minute centrifuge with 3000 RPM producing a platelet rich fibrin clot, which is then incised \& separated with 2mm basal layer of RBCs rich in growth factors
214961916|NCT06538987|PROCEDURE|percutaneous epicardial ablation|Epicardial catheter ablation is often necessary for the successful treatment of scar-induced ventricular tachycardia (VT), especially in patients with nonischemic cardiomyopathy (NICMP) where scarring is more extensive on the mid-myocardial or epicardial surface. Because epicardial mapping can be painful and patient movement can limit mapping and safe epicardial access, a common strategy for these patients is general anesthesia.
214353752|NCT03588208|OTHER|Progressive resistance training program|Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.
214353753|NCT03588208|OTHER|Educational Program|Structured education program were performed during one hour class once a week for five weeks
214353754|NCT03280121|DEVICE|EsophyX ZR transoral device|TIF
214353755|NCT03033823|DRUG|Magnesium|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
214961917|NCT05969990|OTHER|tryptophan metabolites in plasma|we will investigate the tryptophan metabolites in plasma of children with migraine
214961918|NCT00984269|PROCEDURE|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
214961919|NCT05817188|OTHER|No intervention|No intervention was applied
214961920|NCT03147118|DIAGNOSTIC_TEST|Arthrogram|Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 radiograph views of the thumb.
214961921|NCT04544098|DRUG|177Lu-DOTATATE|The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
214961922|NCT00243971|DRUG|SPM 962|
214961923|NCT01858207|PROCEDURE|Transcatheter Arterial Chemoembolization|traditional TACE, conventional TACE
214353756|NCT03033823|DRUG|Placebo Oral Tablet|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
214353757|NCT03592511|DIETARY_SUPPLEMENT|WGPF-burger|Volunteers consumed a WGPF-burger daily
214353758|NCT03592511|DIETARY_SUPPLEMENT|Control-burger|Volunteers consumed a Control-burger daily
214487062|NCT06737926|BEHAVIORAL|Sensorimotor Training Exercise|Participants will perform sensorimotor training exercises designed to improve balance, reduce pain intensity, and enhance functional exercise capacity. The program will include progressive exercises focusing on proprioception, neuromuscular coordination, and functional mobility. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
214487063|NCT06737926|BEHAVIORAL|Conventional Exercise Therapy|Participants will undergo conventional exercise therapy, including stretching, strengthening, and aerobic exercises, based on standard physiotherapy protocols. The therapy aims to maintain joint mobility, reduce stiffness, and improve general physical fitness. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
214961924|NCT01858207|PROCEDURE|Radiofrequency ablation|simultaneous multiple electrodes and switching RF controller
214961925|NCT01858207|DRUG|Doxorubicin|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
214961926|NCT05919550|DRUG|search for a clozapine intake|search for a clozapine intake
214961927|NCT05384470|DRUG|Marihuana|Two doses of marijuana given.
214961928|NCT05384470|DEVICE|BID2 Instrument - breathalyzer|The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
214961929|NCT03707938|DRUG|Brigatinib|Given PO
214961930|NCT03707938|PROCEDURE|Local Consolidation Therapy|Undergo local consolidative therapy
214961931|NCT02028507|DRUG|Palbociclib|
214961932|NCT02028507|DRUG|Capecitabine|
214961933|NCT02028507|DRUG|Exemestane|
214961934|NCT02028507|DRUG|Fulvestrant|
214961935|NCT04298606|OTHER|Quality-of-Life Assessment|Ancillary studies
214961936|NCT04298606|OTHER|Questionnaire Administration|Ancillary studies
214961937|NCT04298606|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
214961939|NCT03547037|DRUG|JNJ-63723283|JNJ-63723283 will be administered intravenously.
214353759|NCT06787417|PROCEDURE|Restricted Kinematically-aligned Arthroplasty|Robot Assisted with Restricted Kinematically-Aligned TKA.
214353760|NCT06787417|PROCEDURE|Mechanically-Aligned Arthroplasty|Robot Assisted with Mechanically Aligned TKA.
214353761|NCT04029974|DEVICE|ErigoPro|Robotic tilt-stepper lower extremity movements at the cadence of 0, 40, and 80 steps/minute.
214487064|NCT06740565|PROCEDURE|thoracic endovascular aortic repair|stent-graft implanted to seal the proximal entry tear of type B aortic dissection
214487065|NCT06740825|DRUG|Quizartinib|Single oral dose of 60 mg
215079717|NCT03538444|DEVICE|Sham rTMS|Participants will undergo procedures that mimic rTMS, but that are inactive.
214961940|NCT03547037|DRUG|Erdafitinib|Erdafitinib will be administered orally.
214961941|NCT05463588|OTHER|Exercising with virtual reality glasses|"GIVE PATIENTS EXERCISE WITH A 360 DEGREE EXERCISE VIDEO INSIDE VIRTUAL REALITY EYES.~Exercising with the training material taught at the beginning of the training"
214353762|NCT03640208|BEHAVIORAL|Education presented by trained caregiver|After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
214353763|NCT04863092|BEHAVIORAL|Educational Intervention|The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
214353764|NCT06240455|DRUG|WP1302|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
214353765|NCT06240455|DRUG|WP1302 placebo|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
214487066|NCT06740825|DRUG|Rufinamide|Twice daily (BID) dose of 400 mg on Days 1 through 32
214487067|NCT06740162|BEHAVIORAL|PACE Program|The PACE program is a 16-week inclusive exercise program taught and adapted by certified Inclusive Fitness Specialists. Study participants, called athletes, will engage in the fitness class with non-study participants with and without disabilities. Athlete participants will also meet weekly with their coaches (also study participants) to discuss goal setting and interact with the web-based dashboard.
214961942|NCT01116752|OTHER|Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)|In addition to glycemic control in 2 groups, all children \<1 year old and 25% of those \>1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
214961943|NCT00371475|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary 38 mm Stent
214487068|NCT06736756|OTHER|Stretch Exercise|To stretch Tensor fascia lata muscle,each participant starts with side lying position with the tested limb upmost. The lower limb (non-tested) is kept in hip and knee flexion to ensure stability. The tested limb is then taken into hip extension and adduction with knee extended. The exercise is held for 60 seconds and repeated 5 times with 10 seconds break intervals.
214961944|NCT00371475|DEVICE|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
214961945|NCT01750060|DRUG|Fentanyl|
214961946|NCT01750060|DRUG|Naltrexone|
215079718|NCT01509677|DRUG|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
215079719|NCT01509677|DRUG|Placebo|tablet, once daily, oral administration in the morning after breakfast
214961947|NCT05359614|DEVICE|CoolSculpting Elite combined with CoolTone Treatments|Coolsculpting treatment combined with Cooltone treatments for the banana roll region of the buttocks.
214961948|NCT05359614|DEVICE|CoolSculpting Elite|Coolsculpting treatment alone for the banana roll region of the buttocks
214961949|NCT02378948|DIETARY_SUPPLEMENT|Liquid oral feeding|Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
214961950|NCT05385341|OTHER|Telerehabilitation (Tele RCV)|20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training associated with educative sessions.
214961951|NCT05385341|OTHER|Rehabilitation (RCV)|20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.
214961952|NCT00579332|DIETARY_SUPPLEMENT|brassica intervention|diet and phyto-chemical intervention
215079720|NCT04920591|OTHER|doll treatment|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy."
215079721|NCT02033590|DEVICE|Biodegradable (purified) surgical silk scaffold|
215079722|NCT01985490|PROCEDURE|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
215079723|NCT02124512|DRUG|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
215079724|NCT02124512|OTHER|Placebo|80 mg placebo once daily
215079725|NCT05020964|DRUG|Trastuzumab and Pyrotinib|"Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs."
215079726|NCT01735669|DRUG|Remifentanil|
215079727|NCT01735669|DRUG|Nitrous Oxide|
214961953|NCT03864003|BEHAVIORAL|Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care|In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (\>50 years) from a rural area that has been identified as under-resourced for hearing health care.
214961954|NCT00467207|DRUG|Botulinum Toxin A|
215079728|NCT00792662|DRUG|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
215079729|NCT00792662|DRUG|Placebo|Standard inactive pill.
215079730|NCT05926349|DRUG|Andexanet alfa|Andexanet is a recombinant version of human FXa
215079731|NCT05926349|DRUG|Usual Care|As per the label of the chosen usual care product(s) and/or usual care standards.
215079732|NCT05352698|DIAGNOSTIC_TEST|NT ProBNP (Roche)|This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
214353766|NCT06240455|COMBINATION_PRODUCT|methimazole|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
214353767|NCT06288438|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
214353768|NCT06288438|OTHER|Physical Therapy Interventions|Strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise.
214353769|NCT06288438|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene, etc.
215079733|NCT00097162|PROCEDURE|Anodal stimulation|
215079734|NCT05602675|DRUG|LY3871801|Administered orally.
215079735|NCT05602675|DRUG|Methotrexate|Administered orally.
215079736|NCT05602675|DRUG|Warfarin|Administered orally.
214353770|NCT06288438|OTHER|Health Status Updates|Health Status Updates will be completed by a trained assessor. The assessor will ask about adverse events, general health topics, medication changes, and changes in social circumstances.
214353771|NCT06288438|OTHER|Physical Therapy Consult|Participants in the control condition will be offered a physical therapy consult at the end of their 24 week study involvement.
214961955|NCT00467207|BEHAVIORAL|Resistance training|
215079737|NCT05602675|DRUG|Dextromethorphan|Administered orally.
215079738|NCT05602675|DRUG|Midazolam|Administered orally.
215079739|NCT05602675|DRUG|Repaglinide|Administered orally.
215079740|NCT05616819|OTHER|Active light exposure|Active light at the wave length of 470nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a method to regulated circadian rhythm.
214353772|NCT06636461|PROCEDURE|microfragmented adipose tissue loaded on allograft|microfragmented adipose tissue loaded on allograft on ridge preservation
214353773|NCT05762302|DIAGNOSTIC_TEST|MeMed BV test|Following the MeMed BV test result, the clinician will decide whether or not to prescribe an antibiotic for your condition
214353774|NCT06340906|OTHER|Electroacupuncture|EA at 10 standardized acu-points that were chosen for their therapeutic effects: Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6), Shenmen (HT7), Hegu (LI4) bilateral, Zusanli (ST36), Sanyinjiao (SP6), Zhaohai (KI6), Taichong (LR3) bilateral, Tian Shu (ST25) bilateral.
215079741|NCT05616819|OTHER|Placebo light exposure|Placebo light at the wave length of 578nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a control to investigate the regulation of circadian rhythm.
215079742|NCT00633568|DRUG|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
215079743|NCT00633568|DRUG|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
215079744|NCT04202224|DRUG|Ibuprofen 400 mg and Acetaminophen 500 mg|Analgesia.
215079745|NCT04202224|DRUG|Glucose|Placebo.
215079746|NCT04202224|OTHER|No drug|Standard surgical procedure without any preoperative medication.
215079747|NCT05190354|DEVICE|Xtremity Polymer Prosthetic Socket|Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
215079748|NCT02362516|DRUG|BI 425809|
215079749|NCT04015037|COMBINATION_PRODUCT|placebo or drug|Group A and B (medicated or placebo)
215079750|NCT03660228|OTHER|Peri-Transfusion QOL Assessment|Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
215079751|NCT04811443|DRUG|Empegfilgrastim|Extimia®
214353775|NCT01887938|BIOLOGICAL|HGT-1110|Participants will receive IT injection of HGT-1110.
214353776|NCT05398029|DRUG|VERVE-101|Intravenous (IV) infusion.
214353777|NCT01345006|BIOLOGICAL|MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
214353778|NCT04001673|BEHAVIORAL|Pharmacist's intervention|Information about bDMARDs management.
214353779|NCT00193700|DRUG|Testosterone Gel (1%)|
214353780|NCT02701985|DRUG|Placebo|Matching-placebo capsules will be administered orally, 2 times a day with food.
214961956|NCT05376072|OTHER|Electromyographic Biofeedback|"The players performed 10 work sessions with EMG-BF. Each session was divided into three phases: (a) three trials without receiving feedback, (b) between six and ten trials with feedback of electromyographic activity, (c) three trials without feedback. In each trial, isometric contractions of the vastus lateralis were performed.~During maximum effort isometric contraction, the software associated with the ProComp Infiniti biofeedback unit collects the amplitude, the mean and maximum electromyographic signal, and also the contraction and tightening times. The contrac-tion time comprises the interval between the start of the contraction and achievement of the desired muscle tension. The tightening time is the period in which the tension voluntarily reached is maintained. For this study, the maximum and mean elec-tromyographic activity values were considered, calculated during the muscle tension time and maintained during each trial."
214353781|NCT02701985|DRUG|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
214353782|NCT06733103|BEHAVIORAL|Stroke Cognitive Behavioural Therapy|This is the only intervention in this clinical (feasibility) study
215079752|NCT00826358|DRUG|ABT-143|Once, please see Arm Description for more details.
215079753|NCT00826358|DRUG|ABT-335|Once, see Arm Description for more detail
215079754|NCT00826358|DRUG|rosuvastatin|once, see Arm Description for more detail
215079755|NCT01483534|DEVICE|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
215079756|NCT00279097|DEVICE|High Frequency Chest Wall Oscillation|
214961957|NCT03613792|DRUG|Remifentanil|Opioid analgesic
214961958|NCT03613792|DRUG|Fentanyl|Opioid analgesic
215079757|NCT03379987|DRUG|PVB morphine|The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.
215079758|NCT03379987|DRUG|PVB bupivacaine|the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
214353783|NCT05893758|DEVICE|The Cera™ PFO Occluder|The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
214353784|NCT05166161|DRUG|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
214353785|NCT06807047|OTHER|Epilepsy Management at School Mobile Health Application|Teachers who meet the inclusion criteria will use the EpiSchool
214961959|NCT03613792|DRUG|Midazolam|Benzodiazepine
214961960|NCT03613792|DRUG|Ketamine|Analgesic
214961961|NCT06073509|DIAGNOSTIC_TEST|Screening for atrial fibrillation and other cardiac arrhythmias and diseases|"In addition to retrospective data collection based on a medical questionnaire, a 5-year post-RT cardiovascular screening will include:~* connected smartwatches for atrial fibrillation screening~* complete ECG for other cardiac arrhythmias~* echocardiography for other cardiac diseases (including cardiac dysfunction, cardiomyopathy, valvulopathy, ...)"
214353786|NCT06807047|OTHER|Digital Epilepsy Education Guide|Teachers who meet the inclusion criteria will use the EpiGuide
214353787|NCT06421987|DEVICE|Near Infrared Spectroscopy (NIRS)|NIRS is a portable, non-invasive, brain imaging device.
214353788|NCT05363813|DEVICE|M/L-10 Multi-Fire Clip Applier and M/L-10 Clip Cartridge (Multi-Fire Clip System)|Permanent ligation of vessels and ducts as part of minimally invasive laparoscopic surgery.
214353789|NCT05893914|PROCEDURE|Dry Needling and intramuscular electrical stimulation to trigger points|Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.
214353790|NCT04059926|OTHER|insert apossing lumen metal stent|insert apossing lumen metal stent
214353791|NCT03761602|OTHER|Not applicable (for observational studies)|This study is an observational study. No intervention will be administered for research purposes.
214353792|NCT05467553|DRUG|Ursodeoxycholic acid|Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
214353793|NCT05467553|DRUG|Ropeginterferon alfa-2b|P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
214353794|NCT05467553|DRUG|Tenofovir Alafenamide|TAF 25 mg PO QD for 60 weeks
214353795|NCT05721859|DEVICE|revision hip arthroplasty|revision hip arthroplasty
215079759|NCT05777122|DRUG|lignocaine gel|pharmacological ,topical anesthetic gel
215079760|NCT05777122|OTHER|sugar free chewing gum|non pharmacological
215079761|NCT02724735|DRUG|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
215079762|NCT04708132|PROCEDURE|Screw retained restoration|Hybrid prosthesis
215079763|NCT04708132|PROCEDURE|implant-retained ball overdentures|Removable prosthesis
215079764|NCT04344496|OTHER|PAM50|PAM50 results is as one of the references for the physicians and the participants to choose adjuvant treatments.
214961962|NCT02811991|DRUG|Paracetamol injection|325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
214961963|NCT02811991|DRUG|Normal Saline injection|32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
214961964|NCT02811991|DRUG|Morhpine PCA|Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.
214961965|NCT01543802|DRUG|pazopanib|Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
214961966|NCT01995344|DRUG|Cyclophosphamide|
214961967|NCT01995344|DRUG|Fludarabine|
214353796|NCT03913611|OTHER|Accelerated rehabilitation protocol|Patients in this group will undergo an accelerated rehabilitation protocol, without movement restrictions. Movement restriction will instead be governed by patient comfort.
214961968|NCT01995344|GENETIC|Tumour Infiltrating Lymphocytes|
214961969|NCT01995344|DRUG|Interleukin-2|
215079768|NCT04283942|BEHAVIORAL|Intermittent calorie restriction (ICR)|"Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
214961970|NCT00551174|DRUG|ibandronate [Bonviva/Boniva]|3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
214961971|NCT00551174|DRUG|ibandronate [Bonviva/Boniva]|2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
214961972|NCT02604030|OTHER|Upper limb function|Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
214961973|NCT03850834|DRUG|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
214961974|NCT03850834|DRUG|placebo enteric-coated tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
214961975|NCT03210012|DIAGNOSTIC_TEST|Transthoracic echocardiography|Diagnostic test done prior and after the dive
214961976|NCT03210012|DIAGNOSTIC_TEST|Blood samples|Diagnostic test done prior and after the dive
214961977|NCT04758195|PROCEDURE|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
214961978|NCT04758195|OTHER|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
214961979|NCT02783313|DEVICE|Pathogen reduced plasma-stored platelet concentrates|Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
214961980|NCT02783313|OTHER|Plasma-stored platelet concentrates|Platelet concentrates stored in plasma
215079769|NCT04283942|BEHAVIORAL|Continuous calorie restriction (CCR)|"Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × \[height (cm) - 100\] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
215079770|NCT06115486|OTHER|Control Arm ACSM Guidelines|The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
214353797|NCT03913611|OTHER|Traditional rehabilitation protocol|Patients in this group will undergo a traditional rehabilitation protocol, with movement restrictions and sling use for 6 weeks following surgery.
214353798|NCT03348748|OTHER|Laboratory Biomarker Analysis|Correlative studies
214353799|NCT03348748|OTHER|Quality-of-Life Assessment|Ancillary studies
214961981|NCT02204345|DRUG|Carboplatin|Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
214961982|NCT02204345|DRUG|Paclitaxel|Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
214961983|NCT02204345|DRUG|RO5479599|RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
214961984|NCT05903638|BEHAVIORAL|Mindfulness-Based Stress Reduction course|8-week, 26-hour, virtual mindfulness course
214961985|NCT03698539|BEHAVIORAL|hand gestures|We observe the use of spontaneous hand gestures in all the groups.
214961986|NCT04687826|OTHER|Goal directed fluid therapy|Patients in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique.
214353800|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest-dose of SBRT
214961987|NCT04687826|OTHER|Liberal fluid therapy|Patients in 2017 got liberal intraoperative fluid therapy influenced by their anaesthesiologist.
214961988|NCT01639248|DRUG|ENMD-2076|250 mg per day in oral capsules in 28 day continuous cycles
214961989|NCT01858415|DEVICE|TriPollar|
214961990|NCT02420262|DRUG|insulin degludec/liraglutide|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
214961991|NCT02420262|DRUG|insulin glargine|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
214961992|NCT02420262|DRUG|insulin aspart|Injected s.c./subcutaneously (under the skin) before each main meal.
214961993|NCT00712894|DRUG|Diltiazem|Intracoronary Infusion 400-2000ug
214961994|NCT00712894|DRUG|Verapamil|Intracoronary Infusion 200-1000ug
214961995|NCT00712894|DRUG|Nitroglycerin|Intracoronary Infusion 200-1000ug
214961996|NCT04240561|DEVICE|High level of signal manipulation|Hearing aid will be programmed to a high level of signal manipulation.
214961997|NCT04240561|DEVICE|Low level of signal manipulation|Hearing aid will be programmed to a low level of signal manipulation.
214961998|NCT05974228|DEVICE|Bioactive glass wound dressing|Bioactive glass wound dressing is a dressing covered on the wound bed
214961999|NCT05945121|OTHER|Cardio-oncology program|Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
214962000|NCT05762640|DRUG|Ruxolitinib|"Form: tablets, 50 mg/m2/day in two administrations. Maximum dose is 100 mg/day. Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.~Duration of treatment: until D-1 of conditioning for allogeneic HSCT OR 9weeks for patients who are not eligible for HSCT."
214962001|NCT04979533|DEVICE|Insufflator oxygen tubing|high flow, low pressure oxygen with pressure relief valve and luer Lock connections delivered at 15 L/min through surgeon's laryngoscope.
214962002|NCT05050448|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
214962003|NCT05050448|DRUG|1% Diclofenac Topical Gel|Topical pain-relief gel
214353801|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest- or higher-dose of SBRT
214962004|NCT00986323|DEVICE|Temperature controlled Laminar Airflow (TLA)|Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
214962005|NCT00986323|DEVICE|Placebo TLA|Placebo TLA (without filtration and TLA function)
214962006|NCT00833404|DRUG|Nicotine transdermal patch|8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
214962007|NCT01770808|DIETARY_SUPPLEMENT|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.
214353802|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo highest-dose of SBRT
214962008|NCT01770808|DIETARY_SUPPLEMENT|AquaPT|AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.
214962009|NCT01770808|DIETARY_SUPPLEMENT|Placebo|Subjects swallowed 4 capsules/day for six weeks.
214962010|NCT04957784|OTHER|questionnaire survey|Understand the current situation of hypertension management in a poor county in Shanxi Province through questionnaire surveys, and explore the factors that affect patients' blood pressure control based on local conditions
214962011|NCT05963932|DRUG|BMS-986419 DR Capsule|Specified dose on specified days
214962012|NCT05963932|DRUG|BMS-986419 IR Tablet|Specified dose on specified days
214962013|NCT02540122|DEVICE|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
214962014|NCT02540122|DEVICE|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
214962015|NCT02540122|DEVICE|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
214962016|NCT02540122|DEVICE|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
214962017|NCT06109350|OTHER|Supporting play exploration and early developmental intervention(SPEEDI)|SPEEDI will be performed by the parents
214962018|NCT06109350|OTHER|Standard care|Standard care will be performed by the parents
214962019|NCT00835835|OTHER|Body-weight supported treadmill training +/- Lokomat assistance|walking
214962020|NCT00835835|OTHER|Usual Care - no active intervention|No treatment used for comparison
214962021|NCT04262063|BEHAVIORAL|Tell play do technique|it apply the concept of learning by doing .children will enjoy playing with customized dental models
214353803|NCT03348748|PROCEDURE|Thoracic Surgical Procedure|Undergo thoracic surgery
214962022|NCT04262063|BEHAVIORAL|tell show do|Tell: your dentist explaining to you what they'd like to do Show: showing you what is involved (e. g. showing the equipment and demonstrating it on a finger) Do: performing the procedure
214962023|NCT00436826|DRUG|Cladribine|Participants were administered with cladribine tablets orally as cumulative dose.
214962024|NCT00436826|DRUG|Placebo|Participants were administered with placebo orally.
215079771|NCT06115486|OTHER|Experimental Arm 6-12-25 repetitions per set|The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
215079772|NCT04685707|DEVICE|Visual feedback monitoring system (HFFS)|Participants will follow the exercise monitoring system's instructions displayed on a TV. Treadmill walking speed will be set at a comfortable walking speed.
214353806|NCT00922454|PROCEDURE|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment."
214962025|NCT00436826|DRUG|Interferon-beta (IFN-beta)|Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
214353807|NCT00922454|DEVICE|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
214353808|NCT00922454|DEVICE|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
214353809|NCT04769076|COMBINATION_PRODUCT|Paclitaxel（Albumin-bound）|Three courses of albumin-bound paclitaxel combined with cisplatin and PD-1 monoclonal antibody neoadjuvant treatment followed by cisplatin combined with IMRT (intensity modulated conformal radiotherapy) concurrent radiotherapy and chemotherapy
214962026|NCT05689567|DEVICE|DEFOG glasses(peripheral focus-out glasses)|Subjects in the intervention group will wear peripheral focus-out glasses ≧8 hours a day and ≧5 days a week.
214962027|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
214962028|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
214353810|NCT01640808|DRUG|NIK-333(peretinoin)|600mg (8 x 75mg capsules) orally, twice a day
214962029|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
214487069|NCT06799793|DEVICE|GI Genius|GI Genius software component is an artificial intelligence-based medical device that has been trained to process colonoscopy images containing regions consistent with colorectal lesions such as polyps, including those with flat morphology (nonpolyp).
214962030|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
215079773|NCT04685707|OTHER|Control|Participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting the treadmill speed (walking speed).
215079774|NCT03014310|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
214353811|NCT01640808|DRUG|Placebo|Placebo (8 x Placebo capsules) orally, twice a day
214353812|NCT04166357|DIAGNOSTIC_TEST|neuromuscular ultrasound|Neuromuscular ultrasound refers to a field in medicine in which ultrasound is used to diagnosis and guide treatment for people with neuromuscular diseases. Neuromuscular ultrasound is often combined with electrodiagnosis, and particularly nerve conduction studies and EMG, to improve the accuracy of diagnosis and add anatomic information to the functional information obtained with electrodiagnosis. It has been demonstrated that neuromuscular ultrasound adds value to the diagnosis of nerve disease in over 80% of cases.
214353813|NCT06367621|DEVICE|iStatis Syphilis Antibody Test|1500 stored samples (plasma/serum) will be tested in a routine testing environment using the iStatis Syphilis Antibody Test diagnostic device. Results of tests will not be used for patient management decisions (observaltional).
214353814|NCT03257826|DEVICE|kirschner wire|retrograde percutaneous kirschner wire was applied to stabilize the tibia.
214487070|NCT06799793|OTHER|Colonscope Olympus|Colonoscopy with one of the Olympus colonoscopes supplied to the IRCCS AOUBO Gastroenterology Unit without the aid of the CAD system
214487071|NCT06740955|RADIATION|hypofractionated postoperative radiotherapy|hypofractionated radiotherapy with a total dose of 52.5Gy, 3.5 Gy/ fraction, 15 fractions, 5 fractions per week,
214962031|NCT00784719|DRUG|Cyclosporine|Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
214962032|NCT00784719|DRUG|CP-690,550 Vehicle|Ophthalmic topical solution, dosed at least once/day, 8 weeks
214962033|NCT01358786|PROCEDURE|quilting suture|"* quilting sutures and drains~* quilting sutures but no drains"
214962034|NCT04396899|BIOLOGICAL|EHM implantation|Implantation of EHM on dysfunctional left or right ventricular myocardium in patients with HFrEF (EF \<35%).
214962035|NCT04892199|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.
215079775|NCT03014310|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
215079776|NCT03014310|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
215079777|NCT05008731|DRUG|Botulinum toxin|100 units (0.5ml) in 1 injection
214962036|NCT04892199|DRUG|Semaglutide-placebo|"The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study."
214962037|NCT04060797|DEVICE|endovascular denervation|Treating with endovascular denervation (EDN) at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
215079778|NCT05008731|OTHER|Placebo|Placebo 0.5 ml in 1 injection
214353815|NCT04778033|OTHER|Sperm collection|Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. The sample will be analyzed for macroscopic and microscopic features in the IVF laboratory and will be discarded immediately afterwards.
214353816|NCT04391023|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique in which a very weak electrical current (2 mA) is applied to the scalp at the beginning of the session and then remains at 0 mA for the duration of the session to control for placebo-like effects. The anode and cathode will both be placed over the cerebellum.
214487072|NCT06740955|RADIATION|Conventionally fractionated postoperative radiotherapy|Conventionally fractionated radiotherapy with a total dose of 60 Gy, 2 Gy/ fraction, 30 fractions, 5 fractions per week,
214487073|NCT06788808|OTHER|Comparison between groups|Ultrasound images acquired during routine ultrasound scans performed in healthy fetuses and in fetuses found to have CNS malformations will be reviewed. Ultrasound images acquired from January 2000 to May 2021 will be analyzed until a sample size of approximately 80 patients is reached, who will be divided into 2 groups: group A (patients whose fetus has CNS malformations) and group B (healthy patients whose fetus has no anatomical CNS abnormalities).
215079779|NCT05868863|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~* Analgesic intake before and after the procedure~* Functional criteria: early rising, walking"
215079780|NCT05706233|PROCEDURE|Erector Spina Plane Group|ESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.
215079781|NCT05706233|PROCEDURE|IV analgesic intervention|IV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS \> 3, 20 mg if NRS \> 5, 30 mg if NRS \> 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.
215079782|NCT04571307|PROCEDURE|cryotherapy|comparison between cryotherapy and surgery
215079783|NCT01638052|DRUG|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
215079784|NCT01011491|OTHER|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 \& 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
215079785|NCT01011491|OTHER|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 \& 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
215079786|NCT04886544|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
215079787|NCT01054937|DRUG|4SC-203|i.v. administration
215079788|NCT01054937|DRUG|Placebo|i.v. administration
215079789|NCT05019612|PROCEDURE|Laparoscopy: A minimal invasive surgery|A low-risk minimal invasive surgery performed in the pelvis using small incisions. With the aid of a laparoscope, the operator views the affected area in real-time. Beyond that, the camera sends images to a video monitor. The operator obtains endometriosis and biopsy samples with small surgical instruments. Before laparoscopy, individuals are provided with a general anaesthetic to relax muscles and prevent pain during surgery.
215079790|NCT05117619|BEHAVIORAL|HOME for Us|HOME is an in-home, family inclusive, rehabilitation intervention in 8 sessions. Six of the sessions will be in-home and 2 will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
214353817|NCT04391023|BEHAVIORAL|Balance Training|The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.
214353818|NCT04391023|DEVICE|2 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (2 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
214962038|NCT04060797|DEVICE|PTA|Treating with balloon dilation or stent implantation which were Percutaneous transluminal angioplasty (PTA)
214962039|NCT02482883|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized \[active stimulation vs non-active (placebo) stimulation\], for an initial period of 10 days.
214962040|NCT02797509|BEHAVIORAL|Psychosocial Skills-Based Intervention|Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
214962041|NCT01698944|DRUG|somatropin|Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
214962042|NCT00015652|DRUG|Ribavirin|
214962043|NCT00015652|DRUG|Aldesleukin|
215079791|NCT05117619|BEHAVIORAL|Attention-control condition|The Attention-control condition consists of educational materials presented over 8 contacts. Two of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
215079792|NCT00926133|OTHER|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
214678879|NCT01003587|BEHAVIORAL|District health information package|"The intervention package consists of:~* A report on disease burden, disease control priorities and health system performance in India~* Condensed fact sheet based on the report~* District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~* Customized speech for district level officials detailing key actions to reduce deaths~* Reminder materials including poster version of the DRCs and video on key points and actionable messages"
214962044|NCT00015652|DRUG|Peginterferon alfa-2b|
214962045|NCT01643447|DRUG|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
214962046|NCT01643447|DRUG|Diammonium glycyrrhizinate|
214962047|NCT03163719|DIAGNOSTIC_TEST|CK and Lactate dosages|"A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a tube bottom. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a tube bottom."
214962048|NCT01911702|OTHER|Standard fluidic resuscitation.|"Goals:~1. arterial pressure mean ≥ 65 mmHg or equal to the pre-operative~2. diuretic rhythm ≥ 1 ml / Kg / h~3. venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%~4. BE\> - 3~5. Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg."
214962049|NCT01911702|OTHER|Volemic small treatment|"Goals of the treatment:~1. arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values~2. diuretic rhythm ≥ 0.5 ml / kg / h~3. venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG~4. BE\> - 5~5. PVC goal not necessary~To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be \> 10-15 ml / kg / h an infusion of furosemide should be initiated"
214962050|NCT03459508|DIAGNOSTIC_TEST|Ophthalmological examination|Detailed anterior segment examination using slit-lamp biomicroscopy for signs of anterior uveitis, and detailed fundus examination using slit-lamp fundus biomicroscopy with + 90 diopter lens searching for signs of vasculitis and posterior uveitis.
214962051|NCT04245618|DRUG|neoadjuvant chemotherapy ( cisplatin - gemcitabine)|Neoadjuvant chemotherapy before TURBT
214962052|NCT05645107|DRUG|Xembify|SC infusion pump
214962053|NCT05645107|DRUG|Placebo|SC infusion pump
214962054|NCT05781087|DIAGNOSTIC_TEST|Optical coherence tomography and pressure wire assessment|Non-culprit coronary arteries
214962055|NCT05781087|DIAGNOSTIC_TEST|Cardiac magnetic resonance angiogram|1.5T
214962056|NCT04061746|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Patients in Group A will receive a single MSCs infusion
214962057|NCT04061746|OTHER|Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)|Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
214962058|NCT06620185|BIOLOGICAL|FLUENZ|LAIV (Intranasal Influenza Vaccine)
214962059|NCT06620185|BIOLOGICAL|Influenza challenge virus|Influenza challenge virus (H3N2 strain)
214962060|NCT03428399|OTHER|Psychosocial variables|The investigators will assess mental health history and self-reported psychosocial variables as hypothesized risk and protective factors for body image and depression severity in breast reconstruction patients, before and after their mastectomy and breast reconstruction surgery. Mastectomy and breast reconstruction will be received in the context of routine medical care. Thus, this is not a psychological intervention, but rather observational measures assessed pre- and post routine care for breast reconstruction patients.
214962061|NCT04819750|DEVICE|MusicCare® device|The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
214962062|NCT04819750|DEVICE|Headphones with noise reduction|Headphones with noise reduction without music
214962063|NCT03315494|DRUG|SKI-O-703 capsule|SKI-O-703 200 mg capsule with no inactive excipients.
214962064|NCT03315494|DRUG|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose.
214962065|NCT02716922|PROCEDURE|Cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)
214962066|NCT06308900|OTHER|Clinical simulation|Carrying out a total of 9 clinical simulation in three days, one day a week, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
214962067|NCT00157001|PROCEDURE|Photopheresis Post Angioplasty|
214962068|NCT03463252|DRUG|Progesterone|MPA oral 250mg-500mg qd for 3 months per cycle
214962069|NCT03463252|DEVICE|Mirena®|levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle
214962070|NCT03463252|DRUG|GnRH agonist|GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
214962071|NCT00544908|DRUG|dasatinib|
214962072|NCT00544908|OTHER|immunoenzyme technique|
214962073|NCT00544908|OTHER|immunohistochemistry staining method|
214962074|NCT00544908|OTHER|laboratory biomarker analysis|
214962075|NCT00544908|PROCEDURE|quality-of-life assessment|
214962076|NCT00285766|DRUG|Selegiline Transdermal System|
214962077|NCT01038154|DRUG|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
214962078|NCT03131687|DRUG|tirzepatide|Administered SC
214962079|NCT03131687|DRUG|Dulaglutide|Administered SC
214962080|NCT03131687|DRUG|Placebo|Administered SC
214962081|NCT00000267|DRUG|Risperidone|
214962082|NCT03873311|DRUG|Azacytidine, HAG Regimen|Azacytidine（75mg/m2 QD for 7 days）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) for 14 days), Cytarabine 10mg/(m2.d) for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d) for 14 days until absolute neutrophil count(ANC) ≥ 10X109／L)
214962083|NCT03873311|DRUG|Azacytidine|Azacytidine 75mg/m2 QD for 7 days.
214962084|NCT00826150|BIOLOGICAL|BC-819|"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."
214962085|NCT04962035|OTHER|Neurocognitive Follow-up|Standard clinical and parent-reported outcomes on cognitive development, temperament and overall health conditions.
214962086|NCT03603561|DEVICE|cTBS|In the cTBS arm, the patients will receive 5 daily session cTBS (5 times uninterrupted train of 900 pulses) separated by a 15 min interval. Patients will be treated with in total 20 cTBS sessions over the right dorsolateral prefrontal cortex, spread over 4 days. A stimulation intensity of 100 % of the resting motor threshold (rMT) of the right abductor pollicis brevis muscle will be used.
214962087|NCT03603561|DEVICE|Sham cTBS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
214962088|NCT01085240|OTHER|Mission Possible|The intervention focuses on leisure education, exercise and community re-integration.
214962089|NCT00355511|BEHAVIORAL|education: disease, medication, self-care, diet|education on heart failure self care; medication initiation and titration, frequent follow-up
214962090|NCT03381859|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Hepatitis C Virus direct-acting antiviral
214962091|NCT02393235|OTHER|doppler ultrasonography|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
214962092|NCT03188783|DRUG|GDC-0853|GDC-0853 tablets orally, either a single dose or twice-daily.
214962093|NCT03188783|DRUG|Placebo|GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
214962094|NCT01654263|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.
214962095|NCT01904032|DRUG|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
214962096|NCT01904032|DRUG|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
214962097|NCT01340742|PROCEDURE|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
214962098|NCT01340742|PROCEDURE|Control|Cuff placed on arm uninflated for 30 minutes.
214962099|NCT00147511|DRUG|linezolid|
214962100|NCT02635256|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
214962101|NCT05340296|BEHAVIORAL|Acute Youth Connect|This intervention is being piloted will be revised with feedback from the first 5-10 patients who complete it. At the time of registration, the protocol is as follows: Roughly one week prior to discharge, the patient and a parent/caregiver will together nominate 3-4 trusted adults in the patient's life to serve as their post-discharge support team. Consenting nominees will then attend a 45-90 minute training on how to provide social support to the patient. Each adult support will also receive weekly (3-15 minute) check in calls from study staff to monitor progress and concerns. Each patient will also attend 3 interactive sessions with a study interventionist, and will be encouraged to bring an adult from their support team. These sessions will be evenly spaced throughout the post-discharge intervention period. Adolescents will receive weekly reflection-prompting text messages to practice skills taught in the interactive sessions.
214962102|NCT00596050|DRUG|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
214962103|NCT00596050|DRUG|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
214962104|NCT04087369|OTHER|Bundled NCD WHO PEN Intervention|In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population. In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.
214962105|NCT02106741|BEHAVIORAL|Relaxation acupressure|"The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
214353819|NCT04391023|DEVICE|4 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (4 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
214353820|NCT00002109|DRUG|Thymopentin|
214962106|NCT02106741|BEHAVIORAL|Stimulating acupressure|"The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
214962107|NCT00700128|DRUG|frovatriptan|Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.
214962108|NCT00700128|DRUG|frovatriptan|frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.
214962109|NCT00700128|DRUG|placebo|placebo
214962110|NCT04877418|PROCEDURE|TeleCIMT|Mode applied remotely, through the principles and components of the CIMT protocol.
214962111|NCT00768287|BIOLOGICAL|IB1001|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery
214962112|NCT00768287|BIOLOGICAL|nonacog alfa|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
214962113|NCT01468571|DRUG|Spironolactone|50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
214962114|NCT01468571|DRUG|Placebo|"Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks."
214962115|NCT00704977|PROCEDURE|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|"The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs."
214962116|NCT04858867|RADIATION|rhTSH-stimulated I-124 dosimetry|"Preparation:~* Low iodine diet 7 days prior to I-124 ingestion until 24 hours post-ingestion~* Thyrogen injections 24 and 48h prior to I-124 ingestion~Procedures following Jentzen et al:~* Ingestion of capsule with 37±10% MBq I-124~* I-124 PET/CT at 24 and 96h post-ingestion~* Blood draws at 2, 24 and 96h post-ingestion~* Whole body counting at 2, 24 and 96h post-ingestion"
214962117|NCT04858867|RADIATION|Intra-therapeutic I-131 dosimetry|"Procedures following EANM guidelines:~* I-131 SPECT/CT at 2, 6, 24, 96 and 144h post-ingestion~* Blood draws at 2, 6, 24, 96 and 144h post-ingestion~* Whole body counting at 2, 6, 24, 96 and 144h post-ingestion"
214962118|NCT00065273|DRUG|risperidone|
214962119|NCT00065273|DRUG|clozapine|
214962120|NCT00065273|DRUG|olanzapine|
214962121|NCT00470561|DRUG|Aspirin|Two 325 mg doses of aspirin per day for 6 months
214962122|NCT00470561|DRUG|Placebo|Two placebo pills per day for 6 months
214962123|NCT02088892|DRUG|BCG SSI|Intradermal injection
214962124|NCT02088892|DRUG|BCG Tice|Intradermal injection
214962125|NCT04130152|DRUG|Palbociclib|Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle
214962126|NCT04130152|DRUG|Letrozole|Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
215079793|NCT01811602|OTHER|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
215079794|NCT01811602|OTHER|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
214353821|NCT00002109|DRUG|Stavudine|
214353822|NCT00002109|DRUG|Zidovudine|
214353823|NCT00002109|DRUG|Zalcitabine|
214353824|NCT00002109|DRUG|Didanosine|
214353825|NCT04009291|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
214353826|NCT04009291|COMBINATION_PRODUCT|Placebo for TransCon PTH|Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
214353827|NCT05758337|DEVICE|Vibropneumostimulation|New vibrators and techniques of vibropneumostimulation of periimplant tissues have been developed, which will allow us to develop a new concept of the relationship of bone remodulation processes around implants of various designs.
214487074|NCT04476953|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient.
214487075|NCT04476953|DRUG|Fisetin|\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days
214353828|NCT05191940|RADIATION|Particle-therapy using protons or carbon ions|According to the radiation plan (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
214962127|NCT05450172|OTHER|QoR-15 questionnaire|The QoR-15 is a 15-item questionnaire on postoperative quality of recovery. The DN4 is a 10-item questionnaire on neuropathic pain. Both questionnaires will be given to the patients preoperatively, on postoperative days 2 and 3, and 1, 3 and 6 months after surgery.
214962128|NCT06048393|DRUG|SA55 nasal spray|"The novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray (SA55 nasal spray) is provided by Beijing Kexing Zhongwei Biotechnology Co., Ltd. The main component of this product is the novel coronavirus broad-spectrum neutralizing antibody, which is a colorless to pale yellow solution. Each milliliter contains 5mg of broad-spectrum neutralizing antibody against novel coronavirus. Excipients include histidine hydrochloride, arginine hydrochloride, histidine, sucrose, polysorbate 80 (II), hydroxypropyl cellulose, glycerol, and benzalkonium chloride (concentration 0.005%).~20 sprays per bottle, approximately 100 sprays per bottle μ L. Containing 0.5 mg of broad-spectrum neutralizing antibody against novel coronavirus."
214353829|NCT05191940|DIAGNOSTIC_TEST|Blood sampling|Evaluation before treatment-start, after treatment and follow-up period.
214353830|NCT05191940|DIAGNOSTIC_TEST|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
214353831|NCT05191940|DIAGNOSTIC_TEST|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
214353832|NCT05191940|DIAGNOSTIC_TEST|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For treatment planning as well as for follow-up radiological tumor assessment.
214353833|NCT05918705|PROCEDURE|Ultrasound optic nerve sheath diameter / eyeball transverse diameter ratio|"Ocular ultrasonography will be performed once daily on patients diagnosed with sepsis associated encephalopathy at the bedside by two experienced examiners, who will be blinded to patients' clinical data, following the CLOSED protocol for ONSD sonography.~ONSD will be measured at 3 mm behind the merging point of the nerve from the papilla optic disc. The maximum external diameter of ONSD will be measured in the transverse plane perpendicular to the optic nerve and the maximum diameter of ETD (parallel lens) on this plane will be measured.~Two measurements will be taken for each eye; horizontal and vertical. The sequence for measurements will be left eye horizontal; left eye vertical; right eye horizontal; right eye vertical.~The ONSD measurements in the transversal and the sagittal plane for each eye measured by the two examiners will be averaged. Then, ETDs measurements will be averaged to obtain averaged ONSD/ETD ratio as a data to record the mean values of ONSD/ETD ratio."
214353834|NCT06486922|BEHAVIORAL|StEP OUT|The details of program structure and content will evolve as the study progresses based on feedback from participants, interventionists, and the community advisory board. Initially, we will plan to have 5 formal sessions structured as groups with multiple participants receiving the session simultaneously, primarily via remote videoconference, though sessions may occur individually, based on participant schedule and preference. All sessions are designed to be supportive, educational, and interactive, with opportunities to practice skills and discuss feeding and parenting concerns.
214353835|NCT05092516|DEVICE|Active tDCS|2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.
214353836|NCT05092516|DEVICE|Sham tDCS|Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.
214962129|NCT01616160|DRUG|mometasone furoate|2 sprays/nostril BID
215079795|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg"
215079796|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg"
215079797|NCT05540561|OTHER|blood collection|Biological analyses in the framework of care with conservation of blood samples
215079798|NCT03387995|DEVICE|LVIS stent|The paitents treated by LVIS stent implantation.
215079799|NCT03387995|DEVICE|Solitaire stent|The paitents treated by Solitaire stent implantation.
215079800|NCT03387995|DEVICE|Enterprise stent|The paitents treated by Enterprise stent implantation.
215079801|NCT03387995|DEVICE|Neuroform stent|The paitents treated by Neuroform stent implantation.
215079802|NCT03387995|DEVICE|Flow diverter (FD) stent|The paitents treated by Enterprise FD implantation.
215079803|NCT04644237|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
214353837|NCT06647095|DIETARY_SUPPLEMENT|D-Limonene Gelcaps|Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups
214353838|NCT06647095|DIETARY_SUPPLEMENT|Fish Oil Concentrate, 1000 Mg Oral Capsule|Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
214353839|NCT05279495|DEVICE|In a double-blinded fashion, 250 mg CANNAXR cream|Determining the Efficacy of topically applied CANNAXR cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg TOPICAL CBD CANNAXR Cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
214353840|NCT05279495|DEVICE|Topical VEHICLE cream|Determining the Efficacy of topically applied VEHICLE cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
214353841|NCT05833737|DRUG|Belantamab mafodotin|Injection for refractory/relapsed multiple myeloma
214353842|NCT05799157|DRUG|VDMN-21 Patch Low Dose|Microneedle patch containing 125 mcg of active drug
214962130|NCT04288427|DRUG|Finasteride|Patients who are candidates to receive 5ARI therapy, Finasteride, for clinical medical management of lower urinary tract symptoms will begin treatment once deemed eligible. They will be assess every 6 months for changes in urinary symptom scores and their responsiveness to the Finasteride treatment will be assessed at the 12-month time point. MRIs of prostate taken at the start of study and at the 3 year time point will assess prostate size and changes in size as well as degree of inflammatory changes. Gene expression of SRD5A2 as well as methylation pattern will be tested on prostate tissue samples, where hormonal androgen/estrogen levels will also be assessed as they are in blood samples.
214962131|NCT04074330|DRUG|TAK-981|TAK-981 intravenous infusion.
214962132|NCT04074330|DRUG|Rituximab|Rituximab intravenous infusion.
214962133|NCT03643302|DEVICE|Version BF-1T26 electronic bronchoscope|Interventions involving the therapy of airway clearance and bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
214962134|NCT03109626|DIETARY_SUPPLEMENT|DHA|
214962135|NCT03034837|DRUG|resin sealant|Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.
214962136|NCT03034837|DRUG|ART sealant|"Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once."
214962137|NCT05056155|OTHER|Systane Complete|Propylene glycol 0.6% eye drops for replenishing deficiencies in both the lipid and aqueous layers of the tear film
215079804|NCT06556238|OTHER|Nicotine Metabolite Ratio|Blood specimens will be drawn, in clinic, by clinical staff trained in blood collection (e.g., certified medical assistant, nurse). Through regular clinic procedures, lab staff will ship for processing to Quest. Quest uses liquid chromatography tandem mass spectrometry with a limit of detection of 2ng/ml for all analytes and will quantify NMR within 3-6 days of sample arrival. Samples will be consumed during testing. Results of NMR will be returned to primary care providers, and NMR-informed medication recommendations will be made to participants.
214353843|NCT05799157|DRUG|VDMN-21 Patch High Dose|Microneedle patch containing 250 mcg of active drug
214353844|NCT05799157|DRUG|Vehicle Patch|Placebo microneedle patch containing no active drug (i.e., placebo)
214353845|NCT06695637|RADIATION|active cTBS|"Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique which employs magnetic fields to stimulate neural activity in the brain. cTBS is a specific TMS protocol, wherein bursts of high-frequency magnetic pulses are repeatedly applied in a rhythmic pattern, mimicking the theta rhythm of neural oscillations. Studies suggest that cTBS has the potential to modulate cortical excitability and synaptic plasticity, leading to alterations in targeted brain function.~Baseline measures will be collected to develop individualized targets for stimulation and also understand how brain structure and activity may change in response to cTBS."
214353846|NCT06695637|RADIATION|sham cTBS|The intervention group receives cTBS and the control group receives sham stimulation using the sham option in the coil that makes the same noise and feeling without delivering significant amount of magnetic energy into the brain. Both groups are exposed to drug and neutral pictures before and after receiving stimulation. People in the active group will receive cTBS with corrected individualized stimulation intensity to have 1 V/m in targeted brain regions while in the sham group people will only receive sham condition with a similar look, sound, and feel of active stimulation.
214353847|NCT05110183|DEVICE|electrical stimulation|A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.
214353848|NCT05110183|OTHER|optical stimulation|Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.
214353849|NCT05110183|OTHER|combined optical and electrical stimulation|A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.
214487076|NCT05120505|DRUG|Metformin|The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.
214487077|NCT05120505|DRUG|Placebo|The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
214962138|NCT00005802|BIOLOGICAL|aldesleukin|
214962139|NCT00005802|BIOLOGICAL|filgrastim|
214962140|NCT00005802|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214962141|NCT00005802|DRUG|cytarabine|
215079805|NCT02349191|PROCEDURE|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
215079806|NCT05756114|BEHAVIORAL|Support Group|Support Group condition, meetings will be held online via HIPAA-compliant Zoom and run by a trained SMART Recovery meeting facilitator
215079807|NCT05756114|OTHER|Psychoeducational Email|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
215079808|NCT01779869|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (\<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
215079809|NCT06022965|OTHER|Best Practice|Receive SOC
215079810|NCT06022965|OTHER|Comprehensive Geriatric Assessment|Complete CARG-GA
215079811|NCT06022965|OTHER|Electronic Health Record Review|Ancillary studies
215079812|NCT06022965|OTHER|Questionnaire Administration|Ancillary studies
215079813|NCT06022965|OTHER|Supportive Care|Receive GA-based interventions
215079814|NCT06022965|OTHER|Telemedicine|Receive GA-based interventions via telemedicine
215079815|NCT01330979|DRUG|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
214962142|NCT00005802|DRUG|etoposide|
215079816|NCT05009641|DIETARY_SUPPLEMENT|L-carnitine|
214962143|NCT00005802|DRUG|fludarabine phosphate|
214962144|NCT00005802|DRUG|methotrexate|
214353850|NCT05195645|DRUG|Abatacept 250 MG|Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
214353851|NCT02189798|DEVICE|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
214353852|NCT02189798|DEVICE|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
214353853|NCT05140941|DRUG|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet|One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
214353854|NCT06479161|DRUG|Tranexamic acid|1.95 grams oral
214353855|NCT03529604|OTHER|Saliva sampling|Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
214353856|NCT03529604|DIAGNOSTIC_TEST|ELISA|Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
214353857|NCT03529604|DIAGNOSTIC_TEST|HPLC|High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
214353858|NCT01380483|DRUG|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
214353859|NCT01380483|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
214353860|NCT04543110|DRUG|Durvalumab|Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
214353861|NCT04543110|RADIATION|Immune Modulating Radiation|Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
214353862|NCT01299246|PROCEDURE|Michigan Neuropathy Screening Instrument|Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
214962145|NCT00005802|DRUG|mitoxantrone hydrochloride|
214962146|NCT00005802|DRUG|therapeutic hydrocortisone|
214962147|NCT00005802|RADIATION|radiation therapy|
214353863|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour
214962148|NCT01903993|DRUG|Docetaxel|Participants received starting dose of 75 mg/m\^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
214962149|NCT01903993|DRUG|Atezolizumab|Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram \[mg/kg\]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
215079817|NCT01341808|BIOLOGICAL|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
215079818|NCT02202213|DRUG|Placebo|
215079819|NCT02202213|DRUG|Lu AF11167|
215079820|NCT00222430|PROCEDURE|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
215079821|NCT00222430|PROCEDURE|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
215079822|NCT01244594|OTHER|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
215079823|NCT02367001|OTHER|Normal invitation|No modification and signed by the coordinating doctor as usual
214353864|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours
214353865|NCT00179023|DRUG|Pseudoephedrine|30mg tablet,VO. Single dose.
214502684|NCT06064669|DRUG|Metformin pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
214962150|NCT00184093|DRUG|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
214962151|NCT01925976|BEHAVIORAL|Individualized dietetic intervention-eating habits|The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
214962152|NCT02130388|DIETARY_SUPPLEMENT|Zinc|
214962153|NCT01564992|OTHER|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
215079824|NCT02367001|OTHER|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
215079825|NCT02367001|OTHER|Revised invitation signed by the attending physician|signature typed or typed + handwritten
215079826|NCT05195957|PROCEDURE|Robotic tranversus abdominis release operation|Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
215079827|NCT05195957|PROCEDURE|Open transversus abdominis release operation|Original open TAR using midline incision.
214353866|NCT01820676|DEVICE|iUni G2+|The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
214353867|NCT02145546|DRUG|Amiodarone|Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
214353868|NCT02145546|DRUG|Propafenone|150mg per 8 hours, 3 times per day
214962154|NCT03327857|BIOLOGICAL|Neihulizumab (ALTB-168)|"Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.~Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks."
214962155|NCT05838911|OTHER|Study Group chest physiotherapy program combined with neuromuscular electrical stimulation (NMES)|The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
214962156|NCT05838911|OTHER|Control Group Chest physical therapy|The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
214962157|NCT05859308|OTHER|Virtual Reality Pixel Plucker|A virtual reality task where participants wear the Virtual Reality headset and respond to targets.
214962158|NCT05859308|OTHER|Rock Steady Boxing|An in-person boxing class designed for individuals with Parkinson's disease.
214962159|NCT05219604|DRUG|DiphenhydrAMINE Injectable Solution|Intravenous infusion of diphenhydramine 50 mg.
214962160|NCT05441553|GENETIC|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
214962161|NCT01492192|DRUG|18F-RGD-PET-CT and perfusion CT scans on 3 occasions|"Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions"
215079828|NCT00551915|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
215079829|NCT00551915|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
215079830|NCT00551915|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
214353869|NCT02145546|DRUG|Sotalol|80mg twice per day.
214353870|NCT02184793|DEVICE|EMD (Inclinomax)|EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
215079831|NCT00551915|BIOLOGICAL|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
214353871|NCT05475418|PROCEDURE|Adipose tissue derived exosomes|200-300ml of the subject adipose tissue before centrifugation was collected, and the extracellular vesicles were retained after tissue homogenate and filter screening. The extracellular vesicles were mixed with sterile hydrogel and applied directly to the wound surface, and the wound was covered with an inert protective dressing.
214353872|NCT02147548|DRUG|etifoxine|
214353873|NCT02147548|DRUG|lorazepam|
214962162|NCT00717652|DRUG|arbutin, tretinoin, triamcinolone|arbutin, tretinoin, triamcinolone
214962163|NCT00717652|DRUG|Triluma|Hydroquinone, Fluoncinolone, Tretinoin
215079832|NCT00551915|BIOLOGICAL|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
215079833|NCT02233738|BEHAVIORAL|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
215079834|NCT02233738|BEHAVIORAL|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
215079835|NCT01996267|DRUG|PTC+Pertuzumab|Cycle repeated every 21 days
215079836|NCT01996267|DRUG|FEC-T+Pertuzumab|Cycle is repeated every 21 days
215079837|NCT00096174|BIOLOGICAL|cetuximab C225|400 mg/m\^2 IV over 120 minutes on Day 1, 250 mg/m\^2 IV over 60 minutes on Day 8, then weekly
215079838|NCT00096174|DRUG|cisplatin|75 mg/m\^2 IV over 30-60 minutes starting day 15 every 3 weeks \* 3 (Days 1, 22, and 43 of radiation therapy (RT))
214962164|NCT05858866|OTHER|Piper Fatigue Scale|The Piper Fatigue Scale (PFS) was developed by Piper et al. to measure fatigue in a multi-dimensional manner. The scale assesses the behavioural, affective, sensory and cognitive/mood attributes of fatigue and contains 22 items and 5 open-ended questions. Each item is scored between 0 and 10 using a Visual Analogue Scale. Sub-scale scores are obtained by dividing the scores from the sub-scale items by the number of the items in the sub-scale. The same method is used to calculate the total score
215079839|NCT00096174|RADIATION|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d \* 7 weeks (35 fractions)
215079840|NCT03315104|BIOLOGICAL|FLU-IGIV|Single dose, sterile liquid formulation for IV administration.
215079841|NCT03315104|OTHER|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration.
214353874|NCT02147548|DRUG|Placebo|
214353875|NCT04459026|PROCEDURE|combination|instillation and infiltration of ropivacaine
214353876|NCT04459026|PROCEDURE|infiltration|local infiltration ropivacaine
214487078|NCT06795542|PROCEDURE|lumbosacral transforaminal epidural injection at the level of L4-5, L5-S1, or S1 neural foramina|The most widely used injection therapy is epidural injection of steroids, by either the interlaminar route or the caudal route. More contentious are transforaminal injections of steroids. These involve the injection of steroids directly and accurately onto the affected spinal nerve, under radiologic guidance. Meanwhile, transforaminal injection of steroids has been shown to be more effective than interlaminar injection of steroids
214353877|NCT04459026|PROCEDURE|instillation|intraperitoneal ropivacaine instillation
214962165|NCT01918657|DRUG|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at \~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
214962166|NCT01918657|DRUG|walnut powder|escalating doses of walnut powder
214962167|NCT03789097|DRUG|Pembrolizumab|200 mg administered as an IV infusion over 30 minutes Q3W
214962168|NCT03789097|DRUG|Flt3L|an immune cell growth factor. CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains a nominal 2.5 mg/mL CDX-301 protein in a 1 mL volume of buffered solution composed of sodium phosphate and sodium chloride, with a pH of 7.0.
214962169|NCT03789097|RADIATION|Radiation|The target site will get 2 small treatments of radiation.
214962170|NCT03789097|DRUG|Poly ICLC|an immune cell activating factor. vials containing 1 ml of 2 mg/mL
214962171|NCT02509975|DEVICE|Prostate artery embolization.|Embolization of the prostatic vasculature with OCL 503 using a microcatheter.
214962172|NCT00108290|DRUG|Chemotherapy|
214962173|NCT02510612|DRUG|Dexmedetomidine|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
214962174|NCT02510612|DRUG|placebo|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
214962175|NCT05030636|PROCEDURE|Acute moderate to vigorous exercise performed at a specific moment of the day|Treadmill (30 minutes) at 70% of maximal aerobic capacity
214962176|NCT02309957|DEVICE|BioMatrix CRD|
214962177|NCT00511485|DRUG|Vintafolide|Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
214962178|NCT00511485|DRUG|Etarfolatide|
214962179|NCT02497508|DRUG|nivolumab|
214962180|NCT00401518|DEVICE|Non-randomized ACADIA® Facet Replacement System|Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
214962181|NCT00401518|DEVICE|Randomized ACADIA® Facet Replacement System|Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
215079842|NCT01945645|BEHAVIORAL|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
214353878|NCT04429308|PROCEDURE|Photodynamic Therapy|Photodynamic Therapy consists of (Levulan Kerastick (aminolevulinic acid HCL) topical solution, 20% + BLU-U Photodynamic Light Therapy)
214353879|NCT04429308|DRUG|Chemical Peels|Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured Ethyl Alcohol AND 35% Trichloroacetic acid peels
214353880|NCT04790318|PROCEDURE|Trans-incisional Quadratus lumborum block|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume was limited to 20 ml
214487079|NCT06743061|BEHAVIORAL|Post-Op Follow Up|Post Arthroscopic Biceps Tenotomy and Subacromial Decompression in Chronic Massive Rotator Cuff Tears.
214502685|NCT06064669|DRUG|Placebo pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
214962182|NCT00401518|DEVICE|Randomized Instrumented posterolateral fusion (PLF)|Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
214962183|NCT00972283|DRUG|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
214962184|NCT00972283|DRUG|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
214962185|NCT00972283|DRUG|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
214962186|NCT04411758|DIETARY_SUPPLEMENT|Propolis|Four capsules (400mg/day) containing dry EPP-AF® green propolis extract for 2 months and after washout, more two months crossover
214962187|NCT04411758|DIETARY_SUPPLEMENT|Placebo|Four capsules (400mg/day) containing magnesium stearate, silicon dioxide and microcrystalline cellulose for 2 months and after washout, more two months crossover
214962188|NCT00019357|BIOLOGICAL|aldesleukin|
214962189|NCT00019357|BIOLOGICAL|therapeutic autologous lymphocytes|
214962190|NCT00019357|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214962191|NCT02601222|DRUG|Runzao zhiyang capsule|Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
214962192|NCT02601222|DRUG|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
214353881|NCT04790318|PROCEDURE|Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
214353882|NCT03958344|DRUG|Prednisolone|Oral Tablet
214962193|NCT02601222|DRUG|Urea cream|Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
214962194|NCT02382315|BEHAVIORAL|Fear of Cancer Recurrence Intervention|A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
214962195|NCT02858232|BIOLOGICAL|MASCT-I|Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
214962196|NCT01738529|DEVICE|CLE ileocolonoscopy|The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
214962197|NCT06319729|DRUG|CDD-2105|A Chinese herbal medicine formula containing four granular herbs.
214962198|NCT06319729|DRUG|Placebo|Placebo
214962199|NCT01242241|DRUG|Propofol|Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
214962200|NCT01242241|DRUG|Propofol|This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
214353883|NCT03958344|DRUG|Triamcinolone + Betamethason|A compound long acting and short acting injectable steroid
214353884|NCT02513017|BEHAVIORAL|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
214353885|NCT03332524|DRUG|SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg|2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
214353886|NCT03332524|DRUG|2 capsules Ibuprofen and 1 placebo|Ibuprofen and placebo
214487080|NCT06735092|OTHER|Exercise-Only Group (Control Group)|Participants in this group will only undergo a standardized exercise protocol. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
214502686|NCT05048758|OTHER|No intervention|No intervention
214502687|NCT00167921|DRUG|Premarin® Vaginal Cream|
214502688|NCT00167921|DRUG|Premarin® oral tablets|
214502689|NCT00160498|DRUG|Lercanidipine|
214502690|NCT03853538|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one hemiface.
214502691|NCT03853538|OTHER|Semisolid vaseline|Product is applied to one hemiface.
214502692|NCT03132298|OTHER|Implicit Theories of Personality Program|This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
214353887|NCT03332524|DRUG|capsule Chlorpheniramine 4mg and 1 Placebo|Chlorpheniramine 4mg and one capsule Placebo 3/72days
214353888|NCT02834780|DRUG|H3B-6527|H3B-6527 by mouth once or twice daily at specified doses.
214353889|NCT06962722|OTHER|Upper limb motor control training (uMCON)|The exercise program protocol was determined using elbow flexion (Biceps brachii) and elbow extension (Triceps) on a special platform developed for the arm. In this computer-based exercise, participants are asked to follow a small ball on the screen in different lines at certain percentages of maximum muscle strength (10%, 25%, 50%, and so on). Neuromuscular training will be worked on with this exercise.
214353890|NCT03449030|DRUG|TAK-164|TAK-164 intravenous infusion.
214353891|NCT03449030|DRUG|89Zr-TAK-164|89Zr-TAK-164 intravenous infusion
214353892|NCT02165150|OTHER|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
214353893|NCT02755987|DRUG|ANG1005|
214353894|NCT00081367|BEHAVIORAL|CBT|Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
214353895|NCT00081367|BEHAVIORAL|Standard care alone|Participants will receive standard care for suicide prevention.
214353896|NCT02415400|DRUG|Apixaban|
214353897|NCT02415400|DRUG|vitamin K antagonist|
214353898|NCT02415400|DRUG|Acetylsalicylic acid|
214353899|NCT02415400|OTHER|Acetylsalicylic acid placebo|
214962201|NCT05515510|OTHER|FU-APP|"FU-APP is a web-based application using the guidelines and oral health recommendations provided by the current German Ratgeber 2020. It provides information related to oral health care for the parents of children between 6 to 72 months of age. An account was made on a certified online web-development platform and an application was developed on it.~This application serves as a practical guide for the parents of children under 6 years of age. It provides all the essential German guidelines related to first dental visits, expected dental findings, practical brushing technique steps, plaque disclosing activity, motivational brushing video, nutritional facts and behavioral habits to be avoided. It is a complete package of essential information and with high quality content that promotes prevention of ECC at an early age."
214353900|NCT03095040|DRUG|CM082 combined with everolimus|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles
214353901|NCT03095040|DRUG|CM082|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles
214353902|NCT03095040|DRUG|Everolimus|Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles
214353903|NCT04570826|OTHER|Meditation.|The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.
214962202|NCT05515510|OTHER|Oral health recommendations|"Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020"
214962203|NCT02516956|OTHER|Breakfast consumption|Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
214353904|NCT04570826|OTHER|Scientific descriptions about meditation.|The control group received scientific descriptions about meditation.
214353905|NCT02270450|PROCEDURE|therapeutic conventional surgery|Undergo abdominal surgery
214353906|NCT02270450|PROCEDURE|gastrointestinal complications management/prevention|Undergo non-surgical management
214353907|NCT02270450|OTHER|quality-of-life assessment|Ancillary studies
214962204|NCT02516956|OTHER|Blood tests|On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
214962205|NCT02516956|OTHER|Food choices and energy intakes assessments|Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
214962206|NCT02516956|OTHER|Attention tests|On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
214962207|NCT02516956|OTHER|fRMI tests|On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
214962208|NCT01633099|DRUG|Decitabine|"1. Number of Cycles: 4 cycles.~2. Dose and drug delivery(decitabine):~The 1st cycle: 20 mg/m2, (iv,\>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.~If bone marrow blast cells\<5%, the following cycle:decitabine 20 mg/m2, (iv,\>1h) on d1-5 of each 28 day cycle.~If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,\>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,\>1h, on d1-3 of each 28day cycle)."
214962209|NCT02600611|DRUG|iclaprim|Experimental treatment
214962210|NCT02600611|DRUG|vancomycin|Active comparator
214962211|NCT00630201|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
214962212|NCT02317484|DRUG|Ipragliflozin (SGLT2 inhibitor)|
214962213|NCT03167255|DRUG|NS-065/NCNP-01|Received during weekly intravenous infusions
214353908|NCT02363738|DRUG|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
214353909|NCT02363738|OTHER|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
214353910|NCT06110923|DRUG|CKD-846|once administration of Investigational Product
214353911|NCT06110923|DRUG|D091|once administration of Investigational Product per day
214353912|NCT05903001|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Ultrasound of the Diaphragm at the end of inspiration and expiration
214353913|NCT05903001|DIAGNOSTIC_TEST|Intercostal Muscle Ultrasound|Ultrasound of the Intercostal Muscles at the end of inspiration and expiration
214353914|NCT05903001|DIAGNOSTIC_TEST|Borg scale|Questionnaire for Perceived Exertion (Borg Rating of Perceived Exertion Scale)
214353915|NCT05903001|DIAGNOSTIC_TEST|MRC Breathlessness Scale|The MRC Dyspnoea Scale allows the patients to indicate the extent to which their breathlessness affects their mobility.
214353916|NCT05903001|DIAGNOSTIC_TEST|Respiratory Questionaire|Specialized respiratory questionnaire with different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain)
214353917|NCT05903001|DIAGNOSTIC_TEST|GINA classification of Asthma|Patients are classified according to the GINA classification of Asthma.
214353918|NCT05903001|DIAGNOSTIC_TEST|Measurement of respiratory mouth pressure|Inspiratory and expiratory Measurement of respiratory mouth pressure
214353919|NCT05903001|DIAGNOSTIC_TEST|SNIP|Measurement of Sniff Nasal Inspiratory Pressure
214962214|NCT03358381|PROCEDURE|the gap balance type of total knee arthroplasty|A gap balance type of total knee arthroplasty surgery will be performed.The gap balance group will receive this kind of intervention.
214962215|NCT03358381|PROCEDURE|the measured resection type of total knee arthroplasty|A measured resection type of total knee arthroplasty surgery will be performed.The measured resection group will receive this kind of intervention.
214962216|NCT03507985|OTHER|Two tests evaluating memory and attention|"The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap"
214962217|NCT05552053|DEVICE|MWSH plus Candlelit Care|Candlelit Care is a virtual perinatal mental health application that builds on cognitive behavioral therapy (CBT) to provide Black, Indigenous and POC women and birthing parents access to culturally affirming mental health support during pregnancy. Driven by an integrated care team, women have access to self-guided therapeutic tools, peer coaching and education about perinatal mood disorders as a primary resource. This convenient and trauma informed app allows parents to see if their mental health symptoms warrant further treatment in a secure setting. The app also provides education of role transitions, discussion of types of interpersonal conflicts common around childbirth (including racial discrimination) and techniques for resolving them, and role-playing with feedback from other parents during groups. The goals are to improve self-advocacy skills; patient communication with medical providers and provide a support network with other Black pregnant women.
214962218|NCT05552053|DEVICE|MWSH|The Maternal Wellness Self Help (MWSH) app was created to help individuals to manage perinatal depression and anxiety. The app is designed is to meet the emotional needs of those who are pregnant, want to become pregnant or have given birth. This psycho-educational app informs and normalizes the range of emotional responses throughout the reproductive journey. By learning about perinatal mental health, this app hopes to empower patients to understand and name their experiences.
215079843|NCT01844102|DEVICE|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
215079844|NCT06390540|OTHER|Exercise|During the training, verbal information will be given about the importance of exercise, exercise barriers, and the potential benefits of exercise on the mother and baby in the postpartum period. In the training, the points that the mother should pay attention to before exercise will also be discussed. In the following process, videos containing deep breathing and relaxation exercises will be sent to women. The videos will be recorded by the researchers at Ankara University Physiotherapy application laboratory. Recording videos will be delivered to women through social networks. Women will be allowed to do these exercises for a total of 8 weeks.
215079845|NCT06605365|DEVICE|CX-HA and CS|Sterile Isotonic ophthalmic solution
215079846|NCT06605742|OTHER|Consultancy|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects
214353920|NCT05903001|DIAGNOSTIC_TEST|6-minute walking distance|The maximum walking distance achieved in 6 minutes
214353921|NCT05903001|DIAGNOSTIC_TEST|60 seconds sit-to-stand test|number of repetitions achieved in sitting down and standing up in 60 seconds
214678880|NCT03201328|OTHER|Audio-vestibular examination|Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
214353922|NCT05903001|DIAGNOSTIC_TEST|Electromyography|electromyography of the muscles of respiration via superficial electrodes
214353923|NCT05903001|DIAGNOSTIC_TEST|Lung Function|Measurement of lung function via body plethysmography
214353924|NCT05903001|DIAGNOSTIC_TEST|CAT-Questionnaire|COPD Assessment Test (CAT)
214353925|NCT05903001|DIAGNOSTIC_TEST|European Society of Cardiology (ESC)/ European Respiratory Society (ERS) risk group|Patients with pulmonary hypertension are classified according to the ESC/ERS risk group.
214353926|NCT03731689|DRUG|Intrauterine lavage therapy|Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
214353927|NCT03731689|DRUG|Intrauterine gel-injection therapy|Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.
214353928|NCT04458948|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.
214353929|NCT04458948|DRUG|Azithromycin|Azithromycin 500 mg, IV or po for 5 days
214353930|NCT03998787|OTHER|Neurophysiological assessment|Kinematic analysis of movement and transcranial magnetic stimulation
214962219|NCT02282163|DRUG|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
214353931|NCT02087163|DEVICE|Movement Enhancement Technique|Conventional Orthodontic treatment
214353932|NCT02087163|DEVICE|Clear Aligner|Orthodontic treatment with Clear Aligner
214962220|NCT04231240|DEVICE|Measure of ACT with IStat|Measure of ACT with a point of care device named IStat
214962221|NCT04748952|DEVICE|Densah burs|Osseodensification is a non-excavating implant site preparation technique. It creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects. The autografting occurs along the entire length of the osteotomy through a hydrodynamic process with the use of irrigation. The result is a consistently cylindrical and densified osteotomy.
214962222|NCT03895450|BEHAVIORAL|Aerobic Exercise Protocol|Participants randomized to AEP will be asked to exercise 30 minutes per day or until symptom exacerbation, 5 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.
214962223|NCT03895450|BEHAVIORAL|Stretching Protocol|Participants will follow a stretching protocol for 30 minutes a day, 5 days a week. Individuals in the SP group will be given a booklet explaining a low-impact breathing and stretching program developed at the University of Buffalo. All stretches will explained and demonstrated by a member of the study team prior to commencement of the program. Stretches focus on lower extremity muscles. During the protocol HR should be low as to not exceed 50% of age predicted max. A HR monitor will be worn during stretching.
214353933|NCT03157713|BEHAVIORAL|Goal-Directed Financial Incentives|Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
214502693|NCT03132298|OTHER|Control Program|This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
214502694|NCT03298789|OTHER|Activation exercise|Two series of 4 activation exercise will be included in the intervention.
214962224|NCT04203251|DEVICE|Caption Health Guidance Technology|
214962225|NCT01603407|DRUG|Prednisone|daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
214962226|NCT01603407|DRUG|Prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
214962227|NCT01603407|DRUG|Deflazacort|daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
214962228|NCT05615142|RADIATION|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 6 Gy/3f with conventional external beam radiation.
214962229|NCT05615142|RADIATION|stereotactic body radiation therapy|Partial SBRT at dose escalation levels: 10 Gy/1f, 20 Gy/2f, 30 Gy/3f.
214962230|NCT05615142|DRUG|PD-1 Inhibitors|Patients will receive treatment with PD-1 inhibitor (dose as recommended in the instruction manual) every 3 weeks for a maximum of 48 months.
214962231|NCT05867225|PROCEDURE|Laparoscopic hiatal hernia repair|laparoscopic hiatal hernia repair has replaced the traditional laparotomic or thoracotomic approach, and has resulted in a reduction of length of hospital stay and morbidity, and increased patients' acceptance
215079847|NCT06605261|OTHER|Yoga (intervention) group|The yoga (intervention) group comprises 64 women with breast cancer who have been randomly assigned and are undergoing endocrine therapy. To alleviate arthralgia and vasomotor symptoms (hot flashes, night sweats), a structured yoga program will be administered during the initial months of endocrine therapy, consisting of 60-minute sessions, 4 days per week, for a duration of one month.
215079848|NCT06605313|DEVICE|SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System|Transcathether Edge-to-Edge repair for tricuspid regurgitation with SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System.
215079849|NCT05209451|BEHAVIORAL|Digital, evidence-based behavioral health program for smoking cessation|Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.
215079850|NCT05209451|OTHER|Bluetooth enabled iPad|Bluetooth enabled iPad with data plan coverage that provides a personal Wi-Fi (Internet) hot spot for all home devices and allows for up to 64 GB of cellular data.
215079851|NCT05209451|BEHAVIORAL|Coaching Support|Six coaching calls, 15-20 minutes each in duration. The research coach will use motivational interviewing and goal setting to enhance the participant's technology access and use and digital literacy.
215079852|NCT06661486|BEHAVIORAL|Uniformed intervention group|The investigators provide lifestyle intervention through a health education programme which is in a group setting. The sessions consisted of short talks on a health-related topic targeting lifestyle factors associated with dementia risk, followed by group activities that required interactions, cognitive engagement, and the acquisition of certain skills (for example, how to read food labels, how to measure blood pressure, how to recognize signs of depression, et al).
214353934|NCT03157713|BEHAVIORAL|Enhanced Usual Care|Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
214502695|NCT03298789|OTHER|7 series of static stretching|7 series of 4 20 seconds static stretches will be conducted.
214962232|NCT00574093|DRUG|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
214962233|NCT03648138|BEHAVIORAL|Sugary drink warning labels|This information appears in the description of the study arms.
214962234|NCT02500719|DEVICE|Computational Model - Real-time Support Vector Machine|A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
214962235|NCT03127709|BEHAVIORAL|Trail Making Test, Parts A & B|Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
214962236|NCT03127709|BEHAVIORAL|Brief Test of Attention|Assesses auditory working memory
214962237|NCT03127709|BEHAVIORAL|Symbol Span|Assesses visual working memory
214962238|NCT03127709|BEHAVIORAL|Controlled Oral Word Association Test|The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
214962239|NCT03127709|BEHAVIORAL|The Hopkins Verbal Learning Test-Revised|HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
214962240|NCT03127709|BEHAVIORAL|Brief Visuospatial Memory Test-Revised|The BVMT-R is a test of visuospatial learning and memory.
214962241|NCT03127709|BEHAVIORAL|Hospital Anxiety and Depression Scale|The HADS is a brief assessment validated in many cancer populations.
214962242|NCT03127709|BEHAVIORAL|McGill Quality of Life Scale|This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
214962243|NCT03127709|DIAGNOSTIC_TEST|MR Brain Imaging|Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
214962244|NCT03127709|DIAGNOSTIC_TEST|Resting state functional MRI|Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
214962245|NCT03127709|BEHAVIORAL|Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)|This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.
214962246|NCT03074461|PROCEDURE|Side-to-End Anastomosis|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
214962247|NCT03074461|PROCEDURE|Transverse Coloplasty|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
214962248|NCT03125850|OTHER|randomized to day ward|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
214962249|NCT03125850|OTHER|randomized to inpaitent|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
214502696|NCT05508607|OTHER|CDI-risk Classification Tool|This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
215079853|NCT06661486|BEHAVIORAL|Individualised intervention group|On top of the uniformed intervention group, the individualised intervention group receives also 1:1 sessions every 3 months within 2 years. Participants will review the knowledge taught in the group sessions individually and the investigator will address the participant's concerns and provide advice to the participant for a better lifestyle accordingly.
215079854|NCT06661148|DRUG|EPI-003|Intravenous (IV) infusion.
215079855|NCT06661317|OTHER|no intervention|no intervention
215079856|NCT06662175|DRUG|Hyperbaric bupivacaine|Group A (Unexposed) will received 2 ml of intrathecal bupivacaine
215079857|NCT06662175|DRUG|hyperbaric bupivacaine and dexmedetomidine|Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
215079858|NCT06607250|RADIATION|MRI|All enrolled patients underwent multiparametric magnetic resonance imaging, encompassing T2-weighted imaging (T2WI) and magnetic resonance diffusion-weighted imaging (DWI), in the coronal, sagittal, and axial planes.
215079859|NCT06608056|DRUG|Pain management after surgery|Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
215079860|NCT05469243|DRUG|Psychedelic|retrospective survey of previous use
215079861|NCT00027378|DRUG|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
215079862|NCT00027378|DRUG|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
214353935|NCT03157713|BEHAVIORAL|Outcome-based Financial Incentives|Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to \<2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to \<5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to \<5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
214353936|NCT04227782|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging
214962250|NCT03746639|OTHER|physiotherapy modalities|"The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 ."
214962251|NCT05178693|DRUG|ASTX727|Cedazuridine 100mg + 35mg decitabine
214353937|NCT04227782|OTHER|Stable Isotope Study|Stable Isotope study
214962252|NCT05178693|RADIATION|Lutathera|Peptide receptor radionuclide therapy (PRRT)
214962253|NCT04420117|OTHER|Perioperative assessment of physical capacity|Evaluation of physical capacity with the Short Physical Performance Battery (SPPB) questionaire
214962254|NCT01245153|OTHER|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught for foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water starting at 10 cc. Then the volume is progress to 15 cc in 3rd week and 20 cc in 5th week
214962255|NCT01245153|OTHER|Pelvic floor muscle training (PFMT)|Standard pelvic floor muscle exercise (Pelvic floor muscle training;PFMT) is assigned for 6 weeks.
214962256|NCT01473706|OTHER|Consumer Mini Nutritional Assessment|A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
214962257|NCT01990768|DRUG|1 gram Tranexamic Acid (TXA)|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
214962258|NCT01990768|DRUG|2 grams TXA|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
214962259|NCT01990768|DRUG|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
214962260|NCT03418597|PROCEDURE|Deep local anesthesia + Virtual reality|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne). Patient will have a 3-D immersive experience, created using a visual and audio headset and a software labelled as medical device.
214962261|NCT03418597|PROCEDURE|Deep local anesthesia alone|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne).
214962262|NCT05393297|DIAGNOSTIC_TEST|Imaging: Intra-treatment FDG-PET-CT and MRI|FDG-PET-CT and MRI scan will be used during radiotherapy to assess early treatment response and identify tumours eligible for dose-escalation.
214962263|NCT05393297|RADIATION|Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation|Tumours eligible for dose-escalation (boost), as seen on intra-treatment FDG-PET-CT and MRI scan, will receive 76.9 Gy to the residual gross primary tumour. The radiotherapy plan will be replanned to incorporate the simultaneous-integrated-boost to the GTVp which will be delivered over the last 3 weeks of treatment
215079863|NCT05605691|DEVICE|Renuvion APR System|"The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.~Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System."
215079864|NCT06658626|DRUG|[¹⁴C]Enlicitide chloride|IV Injection
215079865|NCT05985278|DRUG|[ Lu-177]-Catalase|\[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
215079866|NCT06606132|OTHER|Exercise|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person\&#39;s condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
215079867|NCT06607614|OTHER|Colorectal Cancer Screening Fecal Immunochemical Test|Fecal Immunochemical Test
215079868|NCT00659217|BIOLOGICAL|mesenchymal stem cell|Autologous MSC transplantation
214353938|NCT03882476|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for sepsis detection
214353939|NCT02469194|OTHER|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
214353940|NCT02101892|DRUG|Amitriptyline|per os, daily, evening
214353941|NCT02101892|DRUG|placebo|per os, daily, evening
214353942|NCT04210453|DRUG|Vitamin C|"Participants in Vitamin C group are administered IV vitamin C diluted in 100 cc normal saline 1 day before surgery, at rewarming during surgery, 3 hours after surgery, and every 6 hours thereafter until postoperative 24 hours."
214962264|NCT00966732|BEHAVIORAL|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
214962265|NCT05500014|OTHER|Biofortified potato, not genetically modified|Cooked potato, not genetically modified, with the addition of an acqueous solution of 57FeSO4 (3 mg in total).
214962266|NCT00415324|DRUG|eribulin mesylate|Given IV
214962267|NCT00415324|DRUG|cisplatin|Given IV
214962268|NCT00415324|OTHER|laboratory biomarker analysis|correlative study
214962269|NCT00415324|OTHER|pharmacological study|correlative study
214962270|NCT04029259|DIAGNOSTIC_TEST|Brain MRI|Brain MRI diagnoses tromboembolic lesions or bleeding to the cerebrum and is part of preoperative diagnostic tests before carotid surgery. After surgery brain MRI may present New lesions related to surgery, clinically significant or insignificant. Our goal is to evaluate the relevance of this modality in carotid surgery..
214962271|NCT03538691|DRUG|Brexpiprazole|Administered as tablets.
214962272|NCT03538691|DRUG|Antidepressant therapy|"Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules."
214962273|NCT03915483|DEVICE|transcranial direct current stimulation (tDCS)|sham or real tDCS for 10 minutes of 1.5 milliampere (mA) tDCS targeting the prefrontal and the posterior parietal cortex
214962274|NCT05424354|DEVICE|Altrazeal (R) Transforming Powder Dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with Altrazeal TPD.
214962275|NCT05424354|OTHER|Standard of Care burn dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with the institution's standard of care burn dressing.
214962276|NCT06597084|DRUG|ESL 800 mg|800 mg ESL tablets for oral administration. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
214962277|NCT06597084|DRUG|Placebo|Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
214962278|NCT04450914|BEHAVIORAL|CV Prevention Choice Tool|The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.
214962279|NCT04450914|BEHAVIORAL|Implementation Facilitation Strategies|During the active implementation stage, health systems will deploy tailored implementation facilitation and other tailored implementation strategies aimed at increasing adoption and use of shared decision making using CV Prevention Choice.
214962280|NCT01583283|DRUG|ACY-1215|Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
214962281|NCT01583283|DRUG|lenalidomide|Dosed on Days 1-21 of a 28 day cycle.
214962282|NCT01583283|DRUG|Dexamethasone|Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.
214353943|NCT04210453|DRUG|Control (Normal saline)|"Participants in Control group are administered IV 100cc normal saline at the same timepoint as above."
214678881|NCT03201328|OTHER|Videonystagmoscopic study|Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
214962283|NCT05907187|BEHAVIORAL|Cervical Cancer Prevention Education|Participants will receive in-person, one-time health education on the importance of cervical cancer screening using a short intervention/educational script; and motivation to encourage women to have human papillomavirus (HPV) screening. Participants will also be informed of the nature and risks of HPV infection, and the importance of seeing a doctor including having a gynecologic exam.
214962284|NCT00696007|DRUG|Gemcitabine and cisplatin|"Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²"
215079869|NCT04435639|OTHER|Manual lymph drainage.|"Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period."
215079870|NCT04435639|PROCEDURE|Coban compression bandage..|Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
215079871|NCT04435639|DEVICE|Adjustable Compression Sleeve|Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
214353944|NCT03580876|DRUG|addition of azathioprine|impact of addition of azathioprine after a switch of a second anti-TNF agent
214353945|NCT03580876|DRUG|Switch to a second anti-TNF drug alone|Switch to a second anti-TNF drug alone without addition of azathioprine
215079872|NCT06598228|OTHER|No Intervention: Observational Cohort|no intervention
214678882|NCT03201328|OTHER|Posturographies study|(stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
214678883|NCT04743882|OTHER||
214678884|NCT03403101|DRUG|S1|"Patients are planned to receive the SIRIOX regimen including S-1 (BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; oral twice daily on days 1-7, days 15-21）of every cycle.~• 28 days a cycle."
214353946|NCT00680212|DIETARY_SUPPLEMENT|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
214353947|NCT00680212|DIETARY_SUPPLEMENT|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
214353948|NCT03282227|DRUG|M207 Microneedle System|M207 Microneedle System 3.8 mg
214353949|NCT05949762|PROCEDURE|Venetoclax in Combination With Azacitidine and HA Regimen|"Patients diagnosed with primary AML based on morphology, immunophenotyping, and history and meeting the inclusion exclusion criteria were induced with Venetoclax in combination with Azacitidine and HA regimen.~Details for:~Venetoclax 200mg d1-10 Azacitidine 100mg/d (or 50-75mg/m2/d), d2-7 Hautriacontin 2mg/m2/d, d3-7 Cytarabine 100mg/m2/d, d3-8 (infusion 24h)"
214353950|NCT05475951|DIAGNOSTIC_TEST|Biomarker measurement of pannexin-1 and gasdermin-D|These biomarkers were measured in the placental and adipose tissues of the participants.
214353951|NCT00739349|DRUG|NOVA22007 ''Cyclosporine''|Cyclosporine 0.05% Ophthalmic Cationic Emulsions
214353952|NCT00739349|DRUG|NOVA22007 ''Cyclosporine''|Cyclosporine 0.1% Ophthalmic Cationic Emulsions
214353953|NCT00739349|DRUG|vehicle/placebo|vehicle/placebo
214962285|NCT00696007|OTHER|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
214962286|NCT05542251|BEHAVIORAL|Parent Educational Program|The intervention is a series of 9 educational modules delivered via social media that will teach participants: 1) principles of infant learning, 2) principles of infant motor learning, and 3) principles of positive parenting.
214962287|NCT04930614|OTHER|Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour|Digital survey to estimate the associated risk factors for HIV infections in transgender and non-binary people in Flanders and Brussels (Belgium)
214962288|NCT00431145|DRUG|Niacin|
214353954|NCT04330638|OTHER|Usual Care|Usual Care
214353955|NCT04330638|DRUG|Anakinra|Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first
214353956|NCT04330638|DRUG|Siltuximab|Siltuximab will be given via single IV infusion at a dose of 11 mg/kg
214353957|NCT04330638|DRUG|Tocilizumab|Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection
214353958|NCT02697253|DRUG|Exendin 9-39 and Sitagliptin|"Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
214353959|NCT02697253|DRUG|Placebo|"Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours."
214353960|NCT00856050|DRUG|letrozole|Taken orally once a day continuously
214353961|NCT03813940|BIOLOGICAL|HPV Vaccine,135μg/0.5ml|HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
214353962|NCT03813940|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
214353963|NCT05315193|OTHER|Structured In-patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
214962289|NCT00431145|DRUG|Niacin+Statin|
214962290|NCT04329325|BIOLOGICAL|Blinatumomab|Please see detailed summary.
214962291|NCT04329325|DRUG|dasatinib|Please see detailed summary.
214962292|NCT04329325|DRUG|dexamethasone|Please see detailed summary.
214962293|NCT04329325|DRUG|methotrexate|Please see detailed summary.
214962294|NCT02185807|PROCEDURE|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians.
214962295|NCT02185807|PROCEDURE|control group|The control patients receive verbal information and discussion from their physicians.
214962296|NCT03762005|OTHER|CRT guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to capillary refill time (CRT)
214962297|NCT03762005|OTHER|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to lactate levels
214962298|NCT00768885|DEVICE|PureVision 1|Currently marketed PureVision soft contact lens.
214962299|NCT00768885|DEVICE|PureVision 2|Alternate design soft contact lens.
214962300|NCT00370097|DRUG|FLOVENT (fluticasone propionate) HFA|FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.
214962301|NCT00370097|DRUG|Placebo HFA|Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.
214962302|NCT00897871|DRUG|carboplatin|
214962303|NCT00897871|DRUG|cyclophosphamide|
214962304|NCT00897871|DRUG|etoposide phosphate|
214962305|NCT00897871|GENETIC|gene expression analysis|
214962306|NCT00897871|GENETIC|polymorphism analysis|
214962307|NCT00897871|OTHER|pharmacological study|
214353964|NCT05315193|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
214962308|NCT01588405|DRUG|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
214353965|NCT03119324|DEVICE|B-Cure® diode laser|B-Cure laser® (Good Energies, Haifa, Israel) 808nm diode laser application in contact mode over painful area twice a day for 7 consecutive days
214353966|NCT03119324|DEVICE|B-Cure® diode laser sham device|B-Cure laser® (Good Energies, Haifa, Israel) application by sham device twice a day for 7 consecutive days
214962309|NCT01027377|DRUG|rFVIIIFc|Single dose
214962310|NCT01027377|DRUG|rFVIIIFc|Single dose
214962311|NCT02853045|DRUG|period with drug (trade name) then period with generic|"The list of drugs is detailed in the study description"
214962312|NCT02853045|DRUG|period with generic then period with drug (trade name)|"The list of drugs is detailed in the study description"
214962313|NCT04551560|OTHER|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
214962314|NCT06481124|DEVICE|electrical impedance tomography|Measurement of ventilation and perfusion during mechanical ventilation with different positive end-expiratory pressure by electrical impedance tomography
214962315|NCT04215692|DIAGNOSTIC_TEST|Pulmonary ultrasound|Pulmonary ultrasound is a basic application of critical ultrasound, defined as a loop associating urgent diagnoses with immediate therapeutic decisions.
214962316|NCT06612580|DRUG|68Ga-AAZTA-NI-093|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT.
214962317|NCT06612749|OTHER|Integrative medicine including manual and/or mind-body treatments|Referred HCPs are recommended a multi-modal IM program, include at least one of the following: acupuncture; manual-movement therapies (e.g., acupressure, Anthroposophic medicine touch therapies, reflexology, Qi Gong, and Feldenkrais method); and mind-body medicine (e.g., relaxation and breathing techniques).
214962318|NCT06612684|DEVICE|Piezoelectric syndesmotomy|Syndesmotomy, the first phase of tooth extraction, will be provided by a piezoelectric device instead of manual instruments.
214962319|NCT06867926|OTHER|Cardiac rehabilitation|Individuals diagnosed with coronary artery disease will engage in a programme of cardiac rehabilitation.
214962320|NCT07022964|DRUG|CD5 CAR-T cells infusion|Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
214962321|NCT03479944|PROCEDURE|FLACS|Femtosecond laser assisted cataract surgery consisting of LenSx® and Centurion® combination
214353967|NCT03119324|DRUG|Nimesulide Ratiopharm® and Flexiban®|Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
214353968|NCT00003954|DRUG|melphalan|Given IV
214353969|NCT00003954|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
214353970|NCT00003954|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
215079873|NCT06607211|DIAGNOSTIC_TEST|Transcranial Color-Coded Doppler (TCCD)|As part of the clinical practice, the examination will be performed with ultrasound machines that have presets for TCCD, using a low-frequency sector probe (2-25 MHz) with a transtemporal approach to obtain a scan through the midbrain plane. Through the use of Color Doppler and Pulsed-Wave Doppler, a spectral doppler waveform of the M1 segment of the middle cerebral artery velocity is obtained bilaterally. If hypoperfusion signs are discovered, TCCD will be repeated to assess the effects of each intervention.
214353971|NCT00003954|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
214353972|NCT00003954|RADIATION|total-body irradiation|Undergo TBI
214353973|NCT00003954|PROCEDURE|peripheral blood stem cell transplantation|Undergo donor PBSCT
214353974|NCT00003954|DRUG|cyclosporine|Given IV and PO
214353975|NCT00003954|DRUG|mycophenolate mofetil|Given PO
214962322|NCT03479944|PROCEDURE|Manual conventional surgery|Removal of cataractous lens by phacoemulsification
214962323|NCT03479944|DEVICE|CENTURION® Vision System|Phacoemulsification aspiration platform for use during cataract surgery
215079874|NCT06606652|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
215079875|NCT06606652|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
215079876|NCT01513603|DRUG|CLAG-M|IV times 5 days
214353976|NCT00003954|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
214962324|NCT03479944|DEVICE|LenSx®|Femtosecond laser system used for continuous curvilinear capsulorhexis (CCC) and lens fragmentation during cataract surgery
214962325|NCT00729300|DRUG|placebo|0mg daily
214962326|NCT00729300|DRUG|disulfiram|250mg daily
215079877|NCT01513603|DRUG|CLAG-M|Chemotherapy
215079878|NCT04906720|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
215079879|NCT06607393|DRUG|Pembrolizumab|
215079880|NCT06607393|DRUG|Pemetrexed|
215079881|NCT06607393|DRUG|Cisplatin|
215079882|NCT06607393|DRUG|Carboplatin|
215079883|NCT06604910|DIETARY_SUPPLEMENT|branched chained amino acid|patients undergoing branched chained amino acid
215079884|NCT00899717|PROCEDURE|Occlusal adjustment|modification of occlusal surfaces
215079885|NCT00899717|PROCEDURE|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
214962327|NCT02963636|OTHER|Pharmacist clinical intervention|Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
214353977|NCT06224452|DRUG|ibrutinib exposure|We will extract all atrial fibrillation cases involving adult patients associated with ibrutinib exposure with an available ibrutinib daily dose
214962328|NCT05834127|OTHER|Aerobic exercise|"Group A will receive aerobic exercise in the form of warm up and cool down (both for 5 min)~* Treadmill (30 min) based on Target Heart Rate (calculated using Karvina formula at 60%-70% of heart rate reserve).~* Treatment will be given 3 times a week for 1 month"
214962329|NCT05834127|OTHER|Yoga Exercises|"Group B will receive yoga movements for 40 min, 3 times a week for 1 month.~* They will be given yoga movements, including 10 min of Kapalbharti Pranayama which includes automatic inhalation with short and forceful exhalations.~* 20 min of yoga movements (Cat-cow pose, Child's pose, Plank pose, Cobra pose - each for 5 min).~* 10 min of meditation/relaxation in Savasana pose"
214962330|NCT02870556|DEVICE|cervical epidural analgesia|
214962331|NCT06087705|DEVICE|Intra-articular injection of hyaluronic acid|"The injection must necessarily be performed by a practitioner in compliance with the rules of asepsis.~Procedure of use:~* Before the injection, a rigorous prior disinfection of the area to be treated will be carried out.~* Check the integrity of the sterility protector.~* Take the syringe and remove the protective tip.~* Hold the syringe body and insert a sterile intra-articular injection needle into the Luer-Lock system.~* Gently turn the needle clockwise to secure the needle in the Luer-Lock system.~* A visual check of the attachment of the needle will be carried out.~* Remove the needle cap.~* Inject slowly."
214962332|NCT00819481|DEVICE|3DKnee™ System|Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
214962333|NCT06239181|BEHAVIORAL|Breathing Exercises|The patients in the intervention group scheduled for angiography were administered the Beck Anxiety Scale, and then they underwent conscious, deep breathing exercises along with synchronized breathing training. The face-to-face teaching and application of the breathing exercises took an average of 15-20 minutes. Additionally, routine treatment was applied. For both the intervention and control groups, the Beck Anxiety Scale was administered again after the completion of the coronary angiography procedure, once stabilization was achieved.
214962334|NCT06239181|OTHER|no intervention/routine procedure|Beck Anxiety Scale was administered to the control group before coronary angiography. No intervention was performed in between. The routine procedure of the hospital continued. Beck Anxiety Scale was administered again after leaving the procedure.
214353978|NCT01161316|DRUG|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|"Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
214487081|NCT06735092|OTHER|Exercise + Forearm Counterforce Brace Group|Participants in this group will undergo a standardized exercise protocol and will be provided with a counterforce forearm brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
214962335|NCT04823390|DRUG|Midazolam-Fentanyl combination|Sedation is given to patients undergoing cataract surgery under local anesthesia
214962336|NCT04760535|DEVICE|Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)|Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
214962337|NCT04760535|DEVICE|Tooth-borne Hyrax-type maxillary expander|The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
215079886|NCT06454890|BIOLOGICAL|Anti-Trop2 CAR-NK cell|chemotherapy followed by Trop2 CAR-NK infusion
214353979|NCT01161316|DRUG|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.|"Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
214353980|NCT01726868|DEVICE|Liposorber LA-15 System|Six sessions of blood purification treatment with Liposorber LA-15 System.
215079887|NCT03199053|DRUG|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
215079888|NCT03199053|DRUG|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
215079889|NCT03199053|DRUG|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
215079890|NCT02769338|OTHER|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
214678885|NCT03403101|DRUG|Oxaliplatin|"Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.~• 28 days a cycle"
214678886|NCT03403101|DRUG|Irinotecan|"Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle.~• 28 days a cycle"
214678887|NCT05882162|PROCEDURE|Coronectomy|Removal of crown part of the mandibular third molar
214353981|NCT00149513|BEHAVIORAL|Targeted Case Management|A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
214962338|NCT01440634|OTHER|Supervised exercise Program|Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
214962339|NCT02029274|DRUG|BAF312|BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
214962340|NCT02029274|DRUG|Placebo|Matching placebo to BAF312 as tablets for oral administration.
214353982|NCT00149513|BEHAVIORAL|Usual care|Participants will receive usual care.
214353983|NCT04474236|OTHER|thoracic lung ultrasound|Patients will be recruited the day of their hospital admission. All patients will be assessed by thoracic Computed Tomography scan then immediately before/after CT scan, patients will be clinically assessed (Q-SOFA, SpiO2/FiO2) and a lung ultrasound evaluation (mean time of evaluation 7 min +/- 3 min; fully respect of COVID-19 barrier measures) will be performed by an investigator. Patients clinical status and outcomes will be extracted from patient's medical file at day 1 and day 28 from patient's admission by investigators blinded from previously recorded lung ultrasound data.
214353984|NCT02666950|DRUG|Cytarabine|Given SC
214353985|NCT02666950|OTHER|Laboratory Biomarker Analysis|Correlative studies
214353986|NCT02666950|OTHER|Pharmacological Study|Correlative studies
214353987|NCT02666950|OTHER|Quality-of-Life Assessment|Ancillary studies
214353988|NCT02666950|OTHER|Questionnaire Administration|Ancillary studies
214353989|NCT02666950|DRUG|WEE1 Inhibitor AZD1775|Given PO
214353990|NCT00832273|DEVICE|ELAD®|liver assist system
214353991|NCT04395105|DRUG|High-Dose Dexamethasone|IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10
214962341|NCT06880809|BEHAVIORAL|Bridge the Gap (BTG) - Black Youth Group|Participants will complete a group intervention, rooted in the Collaborative Assessment \& Management of Suicidality (CAMS) evidence-based model, driven by their own unique identification of suicide drivers.
214962342|NCT06877949|DIAGNOSTIC_TEST|FDG-PET/CT|FDG-PET/CT is used regulary for a continuous, long term monitoring
214353992|NCT00989287|BIOLOGICAL|GSK2340272A|Two intramuscular injections in the deltoid region of the non-dominant arm.
214353993|NCT00989287|BIOLOGICAL|GSK2340269A|Two intramuscular injections in the deltoid region of the non-dominant arm.
214353994|NCT04949373|DEVICE|High-intensity laser therapy (HILT)|"High intensity laser therapy-Patients will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program will be performed on each session.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
214353995|NCT04949373|DEVICE|Sham High-intensity laser therapy (sham HILT)|"Sham high intensity laser therapy-Participants will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
214353996|NCT05263011|OTHER|Avocado|1 avocado as evening snack
214353997|NCT05263011|OTHER|low fat yogurt|1 serving of low fat yogurt matching calories of 1 avocado
214353998|NCT05263011|OTHER|low fat yogurt + fiber +fat|low fat yogurt mixed with ultra processed olive oil + fiber supplement, equivalent to fat and fiber content in 1 avocado
214353999|NCT05353283|BEHAVIORAL|Motivational Interviewing Counselling|Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test
214354000|NCT05353283|DEVICE|Point-of-care Urine Tenofovir Measurement|Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.
214354001|NCT05899933|PROCEDURE|Non-surgical peri-implant therapy|"2 weeks after baseline examination, non surgical therapy will be applied in implants diagnosed with peri-implantitis prior to enrollment in surgical therapy.~Firstly, participants will be instructed in oral hygiene. Professional supragingival and subgingival debridement of implants/ teeth, including the selected for the study implants, will be performed. Local anesthesia will be performed, when needed. Targeted implants will be treated with PEEK-coating ultrasonic tips (Instrument PI; EMS), titanium curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), rubber cup and polishing paste. Possible adjustments to implant-borne prostheses will be considered, whenever possible. Re-evaluation of non-surgical therapy will be performed after 6 weeks.~At the 6-week reevaluation, participants with peri-implant probing pocket depth ≥5 mm and bleeding on probing and/or suppuration in patients with full mouth plaque score ≤20% will proceed to surgical therapy."
214678888|NCT05882162|PROCEDURE|Pulp Capping with calcium silicate|Application of a pulp capping material (BiodentineTM, Septodont, St Maur-des-Fosses, France) on pulp tissue to preserve the vitality of the residual pulp and prevent inflammation
214678889|NCT02167204|PROCEDURE|Computed Tomography|Undergo 18F-FLT PET/CT
214962343|NCT06877949|DIAGNOSTIC_TEST|CE-CT|CE-CT is used regulary for a continuous, long-term monitoring
214962344|NCT06892990|DIAGNOSTIC_TEST|TXI mode vs. WLE mode|Experimental use of TXI mode compared to standard use of WLE to assess inflammatory activity in patients with IBD during ileocolonoscopy. Both endoscopy modes are used during the same ileocolonoscopy on the same patient.
214354002|NCT05899933|PROCEDURE|Implantoplasty|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy) and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implantoplasty will be applied using tungsten carbide burs of various shapes and sizes (Peri-implantitis Kit; Meisinger) followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
214962345|NCT04758247|DEVICE|TheraNova Neuromodulation System|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
214962346|NCT05803759|DIETARY_SUPPLEMENT|Allicor|Each capsule contains 150 mg dried garlic powder
214962347|NCT05803759|DRUG|Placebo|Capsules manufactured to mimic Allicor 150 mg capsules
214354003|NCT05899933|PROCEDURE|Erythritol Air-abrasive device|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implant surface decontamination with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS) will be applied followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
214354004|NCT05899933|PROCEDURE|Prophylaxis|Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
214354005|NCT00491049|DRUG|0.5% levofloxacin eye drops|
214354006|NCT06470529|DEVICE|drug eluting stents|different types of drug eluting stents
214354007|NCT04251000|DEVICE|Joovv Mini|the smallest photomodulation device in the Joovv infrared light product line.
214354008|NCT05276466|DIAGNOSTIC_TEST|Polymerase Chain Reaction and Next-Generation DNA Sequencing|"The qPCR Rapid Screening Panel is a quantitative real-time PCR test for bacteria and fungi.~Next-Generation DNA Sequencing is the Comprehensive Sequencing test will detect virtually all microbial organisms and fungal pathogens that may be present in patient specimens."
214354009|NCT02436148|OTHER|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
214354010|NCT06454747|DRUG|SM-030 gel 0.64%|Topical application to face twice daily for 12 weeks.
214354011|NCT06454747|DRUG|Placebo gel|Topical application to face twice daily for 12 weeks.
214354012|NCT06454747|DRUG|SM-030 gel 0.08%|Topical application to face twice daily for 12 weeks.
214678890|NCT02167204|RADIATION|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
214962348|NCT03678415|BEHAVIORAL|Community-Based Primary Mental Health Care (CBPMHC) package|According to the intervention package, after receiving training, the service providers will start providing service according to learning to the enrolled mothers. The intervention package has developed in many maternal and psychosocial supports like psycho-educational communication about pregnancy complications, danger signs, birth preparedness; psycho-social support including information about psycho-education, graded activities and different types of alternative thoughts. Besides, in this regard the investigators included anxiety and depression disorders symptoms, postpartum mood disorders like postpartum blue, postpartum psychosis, etc. The primary healthcare service provider's provide intervention along with their daily routine and investigators follow it up by their visits.
214962349|NCT05730855|DIAGNOSTIC_TEST|Real-time Polymerase Chain Reaction technique|Real-time Polymerase Chain Reaction technique
214962350|NCT02547896|DRUG|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
214354013|NCT00697749|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
214354014|NCT00697749|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
214354015|NCT05387291|BEHAVIORAL|Intervention group|The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.
214354016|NCT05387291|BEHAVIORAL|Control group|The control group will receive the usual intervention of the center.
214354017|NCT03989804|BEHAVIORAL|Targeted follow-up|2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
214354018|NCT05956119|DEVICE|dry needling + physiotherapy (standard/usual care)|same that arm descrption
214678891|NCT02167204|PROCEDURE|Positron Emission Tomography|Undergo 18F-FLT PET/CT
214962351|NCT02547896|DRUG|Diclofenac|The patients will receive only diclofenac
214354019|NCT05956119|OTHER|sham dry needling + physiotherapy (standard/usual care)|same that arm description
214354020|NCT03743038|DRUG|FMX101 vehicle|FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
214354021|NCT03743038|OTHER|Hydro-alcohol solution|Hydro-alcohol solution based vehicle (Test Article B)
214678892|NCT00991172|DRUG|REGN475|Single Subcutaneous injection dose level 1
214678893|NCT00991172|DRUG|REGN475|Single subcutaneous injection dose level 2
214678894|NCT00991172|DRUG|Placebo Injection|Placebo Subcutaneous injection
214678895|NCT04073823|DEVICE|Flexitouch Plus|Flexitouch Plus full arm and core treatment
214962352|NCT03027076|PROCEDURE|Genitourinary Specimen Collection|Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)
214962353|NCT03027076|PROCEDURE|Collect midstream urine samples|Collect midstream urine samples
214962354|NCT05859282|BEHAVIORAL|Survey|A short 25-item tool was developed and can be applied in clinics to assess the awareness of pregnancy hypertension.
214962355|NCT02735473|DRUG|Choline bitartrate|
214962356|NCT02735473|DRUG|Placebo|
214962357|NCT07022847|OTHER|Non-invasive Monitoring|All participants will undergo non-invasive measurement of Pleth Variability Index (PVI) and routine blood pressure monitoring before and during hemodialysis sessions. No treatment or experimental intervention will be applied.
214962358|NCT02544958|DEVICE|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
214962359|NCT03545269|DRUG|CartiLife®|CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted the volume of 1 cm3 per the capacity of the syringe to the affected area through injection with fibrin adhesive through minimal arthrotomy.
214962360|NCT03545269|PROCEDURE|Microfracture|The surgery is performed by arthroscopy, after the joint is cleaned of calcified cartilage. Through use of an awl, the surgeon creates tiny fractures in the subchondral bone plate.
214962361|NCT02992184|DEVICE|HCV RNA detection with Genedrive assay|
214354022|NCT04584060|COMBINATION_PRODUCT|ERAS protocols|ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter
214962362|NCT02992184|DEVICE|HCV RNA detection with RealTime HCV|
214962363|NCT00000356|DRUG|LAAM|
214962364|NCT04274309|DEVICE|EndoSWIR|Exposition of the respected tissues to the camera
214962365|NCT03009253|OTHER|order of treatment|the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
214962366|NCT00401427|DRUG|trastuzumab|
214962367|NCT00401427|DRUG|vinorelbine|
214962368|NCT04551365|BEHAVIORAL|Lifestyle changes|Interdisciplinary rehabilitation programmes 5 days per week, for 4-6 weeks. The aim of the rehabilitation programme is to improve lifestyle through improved planning of activities of daily life, improved planning of food intake, increased physical activity, and weight loss. The focus is on physical and mental well-being and reinforcing participation in social activities. Patients are encouraged to carry on with their lifestyle changes after dismission from the program. Total duration 14 weeks
214962369|NCT04551365|DIETARY_SUPPLEMENT|Chitosan|Daily intake of chitosan supplement. Daily dose: 4 capsules(1,5 g chitosan) twice at main meals; total 3 g Duration: 12 weeks
214962370|NCT04551365|OTHER|Placebo|Daily intake of placebo (Microcrystalline cellulose (MCC), and native maize food starch (FS)) Daily dose: 4 capsules(0.75 g MCC + 0.75 g FS) twice at main meals; total 3 g Duration: 12 weeks
214962371|NCT04651166|DRUG|Tranexamic acid|1g tranexamic acid mixed in 100mL saline or lactated ringer
215079891|NCT04266964|PROCEDURE|Manual examination|"With the patient in a supine position, squeeze the skinfold between your thumb and pointfinger on the inner aspect of the middle third of the thigh and on the inner aspect of the middle third of the calf.~Place your hand under the proximal calf and the heel and move the leg into maximum flexion at the hip and knee joints. After the response, if any, is completed, move the limb back into full extension. Each of these movements lasts for one second."
215079892|NCT05974657|OTHER|Probiotic Lactobacillus acidophilus LA85|Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
214354023|NCT04584060|COMBINATION_PRODUCT|Early oral feeding|Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward
214354024|NCT04584060|COMBINATION_PRODUCT|Prophylaxis against DVT|Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
214354025|NCT01300546|DRUG|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
214962372|NCT04651166|DRUG|Placebo|100mL saline or lactated ringers
214962373|NCT05080725|OTHER|TelePEPP intervention|TelePEPP sessions will be conducted twice per week by a Speech Language Pathologist and/or graduate student clinician, on the study team. This clinician will deliver the intervention from the NYU Voice Center using the web conferencing software Webex (institutional license) on a Dell desktop computer with a 3.1 GHz intel core processor and high definition camera. Each exercise set will include 40 repetitions (10 reps of effortful swallows, tongue hold swallows, effortful pitch glides and maximal posterior tongue presses). All exercises are widely-adopted by clinicians as standard of care exercises. The number of sets will be gradually increased as tolerance builds \[2 sets in week 1, 3 sets in week 2, 4 sets in weeks 3+\].
214962374|NCT05988346|PROCEDURE|abdominal plastic intervention|According to international guidelines, authors will remove the superficial abdominal fat from the patients enrolled in the study.
214962375|NCT04437446|DIAGNOSTIC_TEST|Case Group|The additional examination corresponds to an OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.
214962376|NCT04437446|DIAGNOSTIC_TEST|Control Group|"The additional examinations correspond to:~* OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.~* OCT: non-invasive examination, without potential risks, without radiation, using infrared light. The patient must sit in front of a screen and a contact is taken without contact in about ten seconds.~* Visual field"
214962377|NCT03682029|DIETARY_SUPPLEMENT|Vitamin C (ascorbic acid)|Monotherapy with oral vitamin C supplementation to elevate plasma vitamin C level to the upper end of the physiological range.
214962378|NCT03682029|OTHER|Placebo|Placebo
214962379|NCT02859519|DRUG|MOB015B|MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
214962380|NCT02859519|DRUG|MOB015B Vehicle|MOB015B Vehicle without the active ingredient Terbinafine
214962381|NCT03229317|OTHER|Plethysmography|Lung plethysmography
214962382|NCT02007655|DRUG|Eliquis|
214962383|NCT00792714|DRUG|Mannitol|400mg twice daily for 7 days
214962384|NCT05392777|DIAGNOSTIC_TEST|Residual syntax score|residual syntax score will be calculated as the conventional syntax score from the web based tool, but subtract the score of the culprit lesion(s) that are fixed (stented) in the index procedure.
214354026|NCT01300546|DRUG|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
214354027|NCT02820623|BEHAVIORAL|Self-report|
214354028|NCT02820623|BEHAVIORAL|Chart-Stimulated Recall|
214354029|NCT02820623|BEHAVIORAL|Behavioral Rehearsal|
214354030|NCT06147102|PROCEDURE|Surgery|Surgical treatment for the unruptured intracranial aneurysm
214354031|NCT06147102|PROCEDURE|Endovascular|Endovascular treatment for the unruptured intracranial aneurysm
214354032|NCT04568538|OTHER|Training program|"A training program and booklet content for the education to be given to mothers includes the following topics.~* What is shaken baby syndrome and what is its cause?~* What are the harms caused by shaken baby syndrome?~* How is shaken baby syndrome understood?~* What problems can shaken baby syndrome cause?~* What are the measures to be taken? For the training and the content of the booklet, expert opinion was obtained from 10 academic members who are experts in the field of Child Health. An evaluation form was created for pre-test and post-test measurements. Expert opinions were also received for these forms.~Mothers of 2-4 months old babies who applied to Akdeniz University Hospital Pediatric Outpatient Clinic for check-up were randomized with a sealed envelope and accepted the study. In this way, intervention and control groups can be determined. After the pre-test is done in the intervention group, 2-month training, booklet and tele-consultancy services will be provided."
214962385|NCT00830583|PROCEDURE|blood test|There is only a blood test at the beginning.
215079893|NCT01778335|PROCEDURE|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
215079894|NCT01549808|OTHER|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
214354033|NCT03586635|OTHER|neurological exam|"Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application"
214354034|NCT04385732|DEVICE|2D or 3D Melanoma Surveillance Photography|Total body imaging using 2D or 3D Melanoma Surveillance Photography plus digital dermoscopy.
214354035|NCT05450874|PROCEDURE|hepatectomy|
214354036|NCT03483636|DRUG|Lemborexant|Film-coated oral tablet
214354037|NCT03483636|DRUG|Alcohol|0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).
214354038|NCT03483636|DRUG|Placebo|Film-coated oral tablet
214354039|NCT03729219|BIOLOGICAL|E. coli ETVAX|Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.
214354040|NCT03729219|OTHER|Placebo|Oral suspension
214354041|NCT04587440|OTHER|Pelvic inclination measurement|Ultra-sound based measurements of the pelvic inclination lying, standing and seating position. EOX X-ray in seating position.
214354042|NCT02920905|DRUG|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
214487082|NCT06735092|OTHER|Exercise + Wrist Brace Group|Participants in this group will undergo a standardized exercise protocol and will be provided with a wrist brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
214487083|NCT06738342|OTHER|CHX 0.09% + Citrox + HA|The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
215079895|NCT01549808|OTHER|mobilization|sitting, standing and walking
215079896|NCT02966964|DRUG|DWPUR001|
214487084|NCT06738342|DRUG|CHX 0.12%|The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
214487085|NCT06739239|DEVICE|Extra-Vascular Implantable Cardioverter Defibrillator|The pulse generator is implanted along the patient's left midaxillary line, and the lead is positioned substernally.
214487086|NCT06738654|PROCEDURE|robot-surgery|Breast-conserving surgery for breast cancer using single-port robotic surgery.
214962386|NCT01243177|DRUG|Lacosamide|"Lacosamide:~* Strengths: 50 mg / 100 mg~* Form: tablets~* Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose~* Duration: up to 118 weeks"
215079897|NCT02966964|DRUG|Placebo|
214962387|NCT01243177|DRUG|Carbamazepine-Controlled Release|"Carbamazepine-CR:~* Strengths: 200 mg~* Form: tablets~* Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose~* Duration: up to 118 weeks"
214962388|NCT01899105|DRUG|lumacaftor|
214962389|NCT01899105|DRUG|ivacaftor|
214354043|NCT02920905|DRUG|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
214354044|NCT02920905|DRUG|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
214354045|NCT02239783|DEVICE|total hip arthroplasty implant|
214354046|NCT06496152|OTHER|questionnaire|online form used to collect all information used in questionnaire
214354047|NCT03913585|BEHAVIORAL|Lifestyle intervention|Upon inclusion and consent all patients receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is systematically registered and collated with existing Electronic Patient Record (EPR) data and the patients risk of developing a lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All patients receive digital feedback including a personal health profile and targeted advice. Patients at high risk of lifestyle-related disease(s) are offered targeted prevention activities at the GP including a health examination and if needed a health dialog. Patients with health risk behavior are offered behavior counselling in the municipality and community health services, if necessary. Patients diagnosed with a lifestyle related disease and patients with a healthy lifestyle are not offered any further services.
214354048|NCT03985618|PROCEDURE|Caesarean section|Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
214354049|NCT03985618|PROCEDURE|Induction of Labour|Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
214962390|NCT02107950|BIOLOGICAL|DCVAC/OvCa in parallel with chemotherapy|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
214962391|NCT02107950|DRUG|Standard of Care|Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
214354050|NCT00006154|DRUG|Indinavir sulfate|400 mg tablets equaling 1600 mg daily
214487087|NCT06738654|PROCEDURE|traditional open surgry|Breast-conserving surgery for breast cancer using traditional open surgery.
214962392|NCT02801981|DRUG|GSK2230672|It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
214962393|NCT02801981|DRUG|Placebo|It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
214962394|NCT06795100|OTHER|Pre-inclusion|Information and presentation of the proposed study to participants during the anesthesia consultation scheduled prior to surgery, including provision of the information document and consent form. Trial participants will have at least 2 days to decide whether or not to take part in the trial.
214962395|NCT06795100|OTHER|Inclusion|"Participants will be welcomed according to the usual process in the digestive, hepatic, urological, or gynecological surgery service. The inclusion visit will coincide with the pre-anesthesia visit during which the absence of contraindications for starting the study will be verified, particularly the occurrence of any health changes since the anesthesia visit that would contraindicate anesthesia or lidocaine administration. During this visit, participant consent will be obtained. The informed consent form must be signed no later than the morning of the intervention.~For women of childbearing age, the absence of current pregnancy will be verified orally for each participant included. A pregnancy test may be performed if the participant so wishes, but a systematic test is not justified."
214962396|NCT06795100|DRUG|Lidocaine|Induction of anesthesia will be at the discretion of the attending anesthesiologist, with a lidocaine bolus of 2 mg/kg administered over 1 minute, followed by a continuous IV infusion of 2 mg/kg/h.
215079898|NCT02213848|DRUG|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
215079899|NCT02213848|DRUG|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
215079900|NCT00091130|BIOLOGICAL|HspE7|Given SC
215079901|NCT00091130|OTHER|placebo|Given SC
214354051|NCT00006154|DRUG|Ritonavir|100 mg liquid capsules equaling 400 mg daily
214354052|NCT00006154|DRUG|Abacavir sulfate|300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
214354053|NCT00006154|DRUG|Efavirenz|200 mg capsules equaling 600 mg daily
214354054|NCT00006154|DRUG|Stavudine|30-40 mg capsules equaling 60 or 80 mg daily
214354055|NCT00006154|DRUG|Didanosine|250-400 mg E.coated tablets equaling 250 or 400 mg daily
214354056|NCT00006154|DRUG|Aldesleukin|Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
214962397|NCT06795100|OTHER|Pharmacokinetic study of intravenous lidocaine|Blood samples of 3 mL will be collected in heparinized tubes without gel of 4 ml at 30, 60 and 120 minutes after the start of lidocaine infusion, then every two hours during surgery, and two finals samples at 15 and 60 minutes after the infusion stops.
214962398|NCT06795100|OTHER|Pain|. Maximal pain reported in the post-anesthesia care unit (PACU) and maximal pain at rest and with movement at 24 hours post-extubation will be recorded.
214962399|NCT06795100|OTHER|adverse effects/events|Any adverse effects/events will be documented from the start of lidocaine administration until 24 hours post-extubation,
215079902|NCT00091130|OTHER|laboratory biomarker analysis|Correlative studies
215079903|NCT00349323|BEHAVIORAL|Community directed treatment|
215079904|NCT03836430|BEHAVIORAL|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
214354057|NCT01432119|DEVICE|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
214354058|NCT01432119|DRUG|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
214354059|NCT01432119|DRUG|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
214354060|NCT01432119|PROCEDURE|Break-Through Scan|"Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
214354061|NCT03364205|BEHAVIORAL|solution-focused interview technique|This approach helps an individual make decisions about behavioral change, focusing particularly on his or her past achievements and looking forward to a time when the problems cease to exist.
214354062|NCT06361082|PROCEDURE|ACL reconstruction|ACL reconstruction
214354063|NCT03690505|BEHAVIORAL|Interviews|informant-based questionnaire semi-structured individual interviews focus group interviews
214354064|NCT02599194|DRUG|18F-FSPG|Administered intravenously (IV)
214354065|NCT02599194|DRUG|18F-FDG|Administered intravenously (IV)
214354066|NCT00249951|DRUG|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
214354067|NCT01087008|DRUG|zoledronic acid|Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
214354068|NCT01087008|OTHER|No treatment control|Patients doesn't receive treatment
214354069|NCT05978765|DEVICE|Dry Cupping|treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.
214962400|NCT06795100|BIOLOGICAL|biological blood test|A biological blood test, not performed in routine practice, will be carried out to measure the following parameters: albumin, ASAT, ALAT, PAL, GammaGT, total and conjugated bilirubin, creatinine, with calculation of GFR.
214962401|NCT03663933|DRUG|Immunosuppression Only Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2
214678896|NCT04073823|DEVICE|Flexitouch Plus FT with software modification|Flexitouch Plus full arm and trunk/chest treatment
214962402|NCT03663933|DRUG|Reduced Intensity Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -11 and -7, cyclophosphamide:3 mg/kg orally daily on days -11 through -4 Busulfan IV, pharmokinetically dosed, on days -3 and -2.
214962403|NCT03663933|DRUG|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, Mesna: 25-50 mg/kg weight based dosing, Tacrolimus 0.02 mg/kg on days +5 through +90, and mycophenolate mofetil (MMF) 15 mg/kg on days +5 through +25
214962404|NCT03663933|PROCEDURE|Allogeneic HSC|Stem cell transplant
215079905|NCT00521430|BIOLOGICAL|anti-thymocyte globulin|
215079906|NCT00521430|DRUG|busulfan|
214354070|NCT05978765|OTHER|Myofascial Release|e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8
214354071|NCT01233791|DRUG|Vaginal Diazepam Suppository|10mg compounded vaginal suppository
214354072|NCT01233791|DRUG|Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
214354073|NCT03792113|PROCEDURE|Periodontal Flap Surgery|Periodontal access flap surgery will be performed in both test site followed by control site in each subject
214354074|NCT03792113|OTHER|Autologous fibrin glue|Autologous fibrin glue procured from the subject's own venous blood will be used to approximate periodontal flaps following access periodontal surgery
214354075|NCT03792113|OTHER|4-0 silk suture|Conventional 4-0 black silk suture will be used to approximate periodontal flaps following access flap surgery
214354076|NCT03456193|PROCEDURE|LA transplant|"The proposed study treatment will include three central components:~* Harvest of the left atrium and pulmonary veins from a suitable donor~* Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis~* Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient."
214354077|NCT04730297|DRUG|paracetamol 500 mg plus codeine 30 mg preoperative administration|each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg
214354078|NCT04730297|DRUG|ibuprofen 400 mg preoperative administration|each patient 30 minutes before surgery received ibuprofen 400 mg
214354079|NCT04730297|DRUG|Placebo oral tablet preoperative administration|each patient 30 minutes before surgery received placebo
214354080|NCT06193876|OTHER|Petitgrain and ylang-ylang essential oil|Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.
214354081|NCT00205569|BEHAVIORAL|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
214354082|NCT03755453|DEVICE|Hearing aid: Phonak Audéo B90-Direct|Hearing aids will be fitted to the participants individual hearing loss.
214354083|NCT03655353|DIAGNOSTIC_TEST|ABY-PET|Diagnostic PET for HER2 expression
214354084|NCT03047668|DIETARY_SUPPLEMENT|diet with/without supplementation|diet with/without supplementation with PUFAs
215079907|NCT00521430|DRUG|cyclosporine|
215079908|NCT00521430|DRUG|fludarabine phosphate|
215079909|NCT00521430|DRUG|methotrexate|
215079910|NCT00521430|DRUG|methylprednisolone|
215079911|NCT00521430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
215079912|NCT00521430|PROCEDURE|peripheral blood stem cell transplantation|
214354085|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5555 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
214354086|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5553 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
214354087|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine, 4444 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
214354088|NCT00911872|DEVICE|collagen (EVOLENCE)|injectable collagen
214354089|NCT04517266|RADIATION|omit of IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
214962405|NCT03191825|OTHER|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
214962406|NCT03191825|OTHER|Lapse management system triggered from web-page|"The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status every time they log on to Endre (the digital smoking cessation counsellor). Participants that report a lapse is routed to a fully automated counselling session delivered by web."
214962407|NCT03191825|OTHER|Lapse management system triggered by SMS-textmessage|The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status in a textmessage (SMS) sent each evening. Participants that report a lapse, receives a new SMS with a link to a fully automated counselling session delivered by web.
215079913|NCT00219882|DRUG|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
215079914|NCT05502159|DRUG|M-TAPA|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
215079915|NCT05502159|DRUG|EOB|In the supine position, a high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the midaxillary line between the spina iliaca anterior superior and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected under the external oblique muscle of the block needle and the block location will be confirmed. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be administered. The same procedure will be applied to the other side (40 ml of 0.25% bupivacaine in total).
215079916|NCT05764473|OTHER|The impact of MedDiet on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
215079917|NCT05764473|OTHER|The impact of UCLP on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
215079918|NCT01359761|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
215079919|NCT01524003|PROCEDURE|cryotherapy|cryotherapy treatment of the uterine cervix
215079920|NCT01524003|PROCEDURE|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
214354090|NCT04517266|RADIATION|IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
214354091|NCT03708939|DIETARY_SUPPLEMENT|Glucose|Daily consumption of 5g of glucose, for 14 days.
214354092|NCT03708939|DIETARY_SUPPLEMENT|Aspartame|Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.
214354093|NCT03708939|DIETARY_SUPPLEMENT|Sucralose|Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.
214354094|NCT03708939|DIETARY_SUPPLEMENT|Saccharin|Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.
215079921|NCT01476319|OTHER|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
215079922|NCT05884112|DEVICE|"MAGSTIM reprtitive Transcranial Magnetic Stimulator (rTMS) System"|iTBS is a new treatment method for depression. It uses the principle of magnetoelectricity to intermittently stimulate local brain nerves. In recent years, domestic and foreign studies have confirmed its efficacy and safety for depression. In addition, research has also It shows that iTBS has better therapeutic effect and efficiency than the previous regular rTMS.
214354095|NCT03708939|DIETARY_SUPPLEMENT|Stevia|Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.
214354096|NCT03708939|OTHER|No Supplement|Follow up without any dietary supplementation.
214354097|NCT04748744|COMBINATION_PRODUCT|Butyrylcholinesterase|Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases
214354098|NCT03094572|OTHER|visual motor tasks|"This exercise involves manipulating an object that corresponds to a racket, this racket has a virtual avatar that animated a virtual ball. The purpose is to make it bounce to a given height. This comes close to ping-pong game."
214962408|NCT06926738|OTHER|Upper Thoracic Manipulation|"Segmental mobility will be assessed using posteroanterior central vertebral pressure and posteroanterior unilateral vertebral pressure. It will be done while the patient lies in a prone position and the examiner stands at the level of the patient's head.~Afterwards, the subjects in the thoracic manipulation group will be asked to lie in a prone position on a standard examination table and they were marked on both sides of the zygapophyseal joint of the selected segments including levels from T1- T4. Subjects will then be instructed to perform deep inhalation and exhalation and at the end of exhalation, the Clinician will perform thoracic manipulation (screw thrust technique) at the selected segmental level/s. This maneuver will be repeated for a maximum of two attempts in case of no hearing of a pop sound. It will be performed by an experienced physiotherapist with more than 10-year experience."
214962409|NCT06926738|OTHER|Sham Comparison|"Segmental mobility will be assessed using posteroanterior central vertebral pressure and posteroanterior unilateral vertebral pressure. It will be done while the patient lies in a prone position and the examiner stands at the level of the patient's head.~Afterwards, the subjects in the thoracic manipulation group will be asked to lie in a prone position on a standard examination table and they were marked on both sides of the zygapophyseal joint of the selected segments including levels from T1- T4. Subjects will then be instructed to perform deep inhalation and exhalation and at the end of exhalation, the Clinician will just the place the hands on the selected levels in the same hand placement of Thoracic manipulation group (screw thrust technique) without applying the manipulation. It will be performed by an experienced physiotherapist with more than 10-year experience."
214962410|NCT02417857|PROCEDURE|Laparoscopic Cholecystectomy (Single Incision)|We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
214962411|NCT02417857|PROCEDURE|Laparoscopic Cholecystectomy (Conventional)|We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
214962412|NCT05058846|PROCEDURE|Biospecimen Collection|Undergo blood, tissue, and saliva collection
214962413|NCT05058846|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRCP
214962414|NCT05058846|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214962415|NCT05058846|PROCEDURE|Endoscopic ultrasound|Undergo endoscopic ultrasound
214962416|NCT05058846|OTHER|Questionnaires|Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire
214962417|NCT06948617|DEVICE|digital intraoral scanner|Alginate impressions were obtained with an irreversible hydrocolloid impression material (Cavex Impressional; Cavex Holland, Haarlem, The Netherlands) and standard plastic trays. For each impression, the time required to mix the material and complete a full-mouth (maxillary and mandibular arches) impression was recorded.
214962418|NCT06948617|DEVICE|Alginate Impression|Alginate impressions were obtained with an irreversible hydrocolloid impression material (Cavex Impressional; Cavex Holland, Haarlem, The Netherlands) and standard plastic trays. For each impression, the time required to mix the material and complete a full-mouth (maxillary and mandibular arches) impression was recorded.
214962419|NCT06949709|BEHAVIORAL|Fasted-exercise|Breakfast intake before 30 min brisk walking on a treadmill
214962420|NCT06949709|BEHAVIORAL|Fed-exercise|30 min brisk walking on a treadmill before breakfast intake
214962421|NCT06955572|DIAGNOSTIC_TEST|Patients with colorectal cancer|Analysis of the lower fecal gene count (fGC) compared with the control group
214962422|NCT06955572|DIAGNOSTIC_TEST|Patients with Parkinson's disease|Analysis of the lower fecal gene count (fGC) compared with the control group
214962423|NCT06955572|DIAGNOSTIC_TEST|Patients with non-alcoholic steatohepatitis|Analysis of the lower fecal gene count (fGC) compared with the control group
214962424|NCT06955572|DIAGNOSTIC_TEST|Patients with obesity|Analysis of the lower fecal gene count (fGC) compared with the control group
214962425|NCT06955572|DIAGNOSTIC_TEST|Healthy volunteers|Determination of the number of bacterial faecal genes (fGC, fecal Gene Count) inferior reference
214962426|NCT06956131|DIETARY_SUPPLEMENT|Casein Protein Isolate Drink|30 g protein equivalent of casein protein isolate dissolved in \~250 mL of water
214962427|NCT06956131|DIETARY_SUPPLEMENT|Whey Protein Isolate Drink|30 g protein equivalent of whey protein isolate dissolved in \~250 mL of water
214962428|NCT06956131|DIETARY_SUPPLEMENT|Soy Protein Isolate Drink|30 g protein equivalent of soy protein isolate dissolved in \~250 mL of water
214962429|NCT06956131|DIETARY_SUPPLEMENT|Maltodextrin Drink|30 g carbohydrate equivalent of maltodextrin powder dissolved in \~250 mL of water
214962430|NCT06955273|DEVICE|Corsano CardioWatch 287-2|Patients receive monitoring of their heart rhythm by the CardioWatch 287-2 next to monitoring of their heart rhythm by either a 24-48 holter or a short in-clinic 12-lead ECG monitoring.
214487088|NCT06894953|DEVICE|Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)|AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Personalised AMPER is personalised to preferences and age of the participant.
214678897|NCT00764842|DEVICE|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
214678898|NCT05819632|OTHER|curcumin gel 2%|curcumin gel 2%
214962431|NCT06955858|DRUG|Recombinant Human Thrombopoietin（rhTPO）|"G-CSF will be administered at a dose of 10 μg/kg/day subcutaneously for 7-10 days post-chemotherapy.~rhTPO is started on the same day as G-CSF at 300 U/kg/d and injected subcutaneously until the stem cell collection was completed."
214962432|NCT06955026|OTHER|Hockey slideboard combined with BFR training|Hockey slideboard combined with BFR training
214962433|NCT06955026|OTHER|Hockey slideboard|Hockey slideboard
214962434|NCT06955663|BEHAVIORAL|Exercise training|12 week exercise intervention + cardiopulmonary exercise test (CPET) + wearable activity monitor
215079923|NCT05884112|DEVICE|sham control|sham control
215079924|NCT00119912|PROCEDURE|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
215079925|NCT00119912|PROCEDURE|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
214962435|NCT06956118|DEVICE|Intervention (VeNS Stimulation) Device|The Modius Sleep device is a non-invasive, battery-powered headset that delivers low-level electrical stimulation (up to 1.0 mA at 0.25 Hz) to the skin behind the ears over the mastoid processes. It is worn like headphones and used for 30 minutes per session, five times per week for four weeks, under clinical supervision. Participants are assisted by a staff member to position the electrodes and adjust stimulation intensity in 0.1 mA steps, up to a maximum of 1.0 mA. The headset is turned on manually, and participants are encouraged to set it up independently after initial guidance. Sessions take place while seated, and participants remain supervised throughout to ensure correct use and safety.
214962436|NCT06956118|DEVICE|Control (Sham Stimulation) Device|The sham version of the Modius Sleep device is visually and operationally identical to the active device to preserve blinding. It delivers a brief initial stimulation (30 seconds, with a 20-second taper) at 0.8 Hz to mimic the sensation of the active device without providing ongoing vestibular modulation. The appearance, placement, and user experience are the same, and participants are informed that the sensation may fade during use. Like the intervention device, the sham is used under supervision in the clinic for 30-minute sessions, ensuring identical procedures across both groups. This design maintains blinding while minimizing any physiological effects from the sham stimulation.
214962437|NCT06954844|DEVICE|Transcutaneous non-invasive vagus nerve stimulation (tVNS)|To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established conventional stimulation protocol (30 s ON, 30s OFF, 25 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany). Stimulation intensity will be pre-set for each participant for the following stimulation period to correspond to a mild pricking sensation determined with a staircase procedure in the lab session.
214962438|NCT06954844|DEVICE|Low intensity stimulation|The electrode will be placed at the cymba conchae, but only receive a low-intensity stimulation below the perception threshold (0.1mA, 1s ON, 30s OFF, 1 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany).
214962439|NCT06956001|DRUG|Firmonertinib Mesilate Tablets|Usage and dosage: oral, 240mg, QD。 Medication duration: 21 days as a cycle, until intolerable toxicity, loss of clinical benefit, disease progression (confirmed by BICR), death or other anti-tumor treatment (whichever occurs first).
214962440|NCT06956001|DRUG|Pemetrexed Disodium for Injection|Usage and dosage: 500mg/m2, intravenous infusion. Medication duration: 21 days as a cycle, D1 administration, until the occurrence of intolerable toxicity, loss of clinical benefit, disease progression (confirmed by BICR), death or other anti-tumor treatment (whichever occurs first).
214962441|NCT06956001|DRUG|Cisplatin for injection|Usage and dosage: 75 mg/m2, i.v. Medication duration: 21 days as a cycle, D1 administration, up to 4 cycles.
214962442|NCT06956001|DRUG|Carboplatin Injection|"Usage and dosage: give the drug according to AUC 5 mg/ml, intravenous drip.~Medication duration: 21 days as a cycle, D1 administration, up to 4 cycles."
214962443|NCT06956092|BIOLOGICAL|Glofitamab treatment|eceive Glofitamab treatment as per the instructions in the package insert.
214962444|NCT06955676|OTHER|treadmill exercise|Intervention consists of exercises only. Participants in this group will walk on a treadmill. The heart rates of the participants will be monitored with a heart rate monitor while exercising in order to maintain moderate-intensity.
214962445|NCT06955676|OTHER|cycle ergometer exercise|Intervention consists of exercises only. Participants in this group will cycle on an ergometer. The heart rates of the participants will be monitored with a heart rate monitor while exercising in order to maintain moderate-intensity.
214962446|NCT06465745|DEVICE|AltaValve System.|Transcatheter Mitral Valve Replacement.
214962447|NCT05483075|BEHAVIORAL|HCP-Guided Exercise Training Program|"Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).~Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.~The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR)."
214962448|NCT02250456|PROCEDURE|Echo doppler|vascular ultrasound explorations
214962449|NCT00159770|DRUG|ziprasidone versus olanzapine , risperidone or quetiapine|
214962450|NCT00159770|BEHAVIORAL|Panss , CGI-C, UKU-SERS-Pa|
214962451|NCT00159770|PROCEDURE|Blood tests|
214962452|NCT06298955|DRUG|OMS906 study drug|OMS906 study drug repeat-dose 5mg/kg IV administration at 8-week intervals
214962453|NCT05251233|DRUG|Placebo|Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
214962454|NCT05251233|DRUG|Pantoprazole|The study will use commercial supply.
214962455|NCT04047732|BIOLOGICAL|KB105|KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel
214962456|NCT02475772|DRUG|Cisplatin and doxorubicin|The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
214962457|NCT02475772|PROCEDURE|Cisplatin and doxorubicin|intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
214487089|NCT06894953|DEVICE|Non-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)|AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Non-personliased AMPER is not personalised to preferences or age of the participant.
214962460|NCT03413475|BEHAVIORAL|quality of life|
214962461|NCT03233815|DRUG|Propofol|Propofol anesthesia Dose: 4-6mg/kg/h
214962462|NCT03233815|DRUG|Sevoflurane|Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
214962463|NCT03351088|PROCEDURE|DVC ligation|Ligation of the dorsal vascular complex during robot-assisted radical prostatectomy
214962464|NCT02271217|DRUG|Placebo|
214962465|NCT02271217|DRUG|dalfampridine-ER 7.5mg|
214962466|NCT02271217|DRUG|dalfampridine-ER 10mg|
214962467|NCT01572714|BEHAVIORAL|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
214962468|NCT01572714|BEHAVIORAL|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
214962469|NCT01572714|BEHAVIORAL|Physical Activity Plus Fatigue Management Education Program|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
214962470|NCT06487715|DRUG|albumin-bound paclitaxel (260 mg/m2, d1)|260 mg/m2, d1)
214962471|NCT06487715|DRUG|S-1|80 mg/m2, d1-14
214962472|NCT06487715|DRUG|sintilimab|200 mg, d1
214962473|NCT06487715|DRUG|bevacizumab|First two cycles : intraperitoneally 7.5 mg/m2 Maintenance period: intravenously 7.5 mg/m2
214962474|NCT02546869|DRUG|Lebrikizumab|Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
214962475|NCT02546869|DEVICE|Prefilled Syringes|
214962476|NCT01008865|PROCEDURE|Studer Pouch orthotopic urinary diversion|
214962477|NCT01008865|PROCEDURE|T-Pouch orthotopic urinary diversion|
215079926|NCT06229665|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
215079927|NCT04720040|DEVICE|Mind STIM|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
215079928|NCT04883710|OTHER|Gene therapy|This is a prospective patient registry.
214354099|NCT03684629|BEHAVIORAL|the response of KPI and corresponding suggestion|Standardized templates of medical record, evidence-based clinical pathway, and written care protocols are applied in all hospitals.The KPI of the AIS patients who were admitted to a single hospital continuously at the time of hospitalization were studied. Feedback system of performance measures: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system since that month into the group. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the corresponding monthly KPI. The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Expert online consultation: based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month.
214354100|NCT01872169|OTHER|Disordered eating screening questionnaire|
214962478|NCT04854005|PROCEDURE|Breast surgery|Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice.
214962479|NCT06957548|DIAGNOSTIC_TEST|Cardiometabolic disease|Cardiometabolic disease screening
214962480|NCT02939209|DRUG|Hydromorphone Hcl 2Mg Tab|Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
214962481|NCT02939209|DRUG|Placebo|Patients may be randomized to placebo.
214962482|NCT05341050|DRUG|TKI|halve dose of 2G-TKI for 12 months and then withdrawal for 12 months
214962483|NCT00707967|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
214962484|NCT00707967|BIOLOGICAL|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
214962485|NCT00707967|BIOLOGICAL|Control vaccine with physiological saline|Intramuscular injection, 2 doses at 0, 1 month
214962486|NCT00920777|BEHAVIORAL|CBT|Individual Cognitive Behavior Therapy during 16 weeks
214962487|NCT00920777|BEHAVIORAL|CBT|Individual Cognitive Behavior Therapy during 8 weeks
214962488|NCT00920777|BEHAVIORAL|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
214962489|NCT02319252|DEVICE|Gastric tube (Nutricia Flocare® Pur Tube Enlock)|Nutricia Flocare® Pur Tube Enlock, Ch. 12
214962490|NCT02319252|DEVICE|Jejunal tube (Nutricia Flocare® Bengmark®)|Nutricia Flocare® Bengmark®, Ch. 10
214962491|NCT04380376|DRUG|Melphalan|Inhalations with low doses of Melphalan for 7-10 consequent days
215079929|NCT05985876|BEHAVIORAL|KULEA-NET application|African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in the intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: the text messages, knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.
215079930|NCT05985876|BEHAVIORAL|Control Group: Usual Care|Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive standard Babyscripts app only without the KULEA-NET tile. Information from the ACOG about the maternal and infant health benefits of breastfeeding will also be provided (e.g., they will get pamphlets on the importance of breastfeeding as well as lactation consultation).
215079931|NCT01824823|DRUG|afatinib|Given PO
215079932|NCT01824823|OTHER|placebo|Given PO
215079933|NCT00218582|BEHAVIORAL|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
214962492|NCT04380376|OTHER|Standard of care|the patients will receive only SOC (standard of care) treatment
214962493|NCT03018275|BIOLOGICAL|Roseomonas mucosa|R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.
214962494|NCT02245815|DIETARY_SUPPLEMENT|use probiotics boucardii|group A was administered the lactobacillus acidophilus boucardii probiotic (1x10⁹ colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
214962495|NCT02245815|DIETARY_SUPPLEMENT|use probiotics Multi-species|Group B was administered multi-species probiotic (1x10⁹colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
214962496|NCT03117634|DRUG|Treat and Extend with Aflibercept 2mg|Drug treatment regime which allows extension of treatment interval based on disease activity
214962497|NCT03117634|DRUG|Fixed Dosing with Aflibercept 2mg|Fixed 8 weekly dosing regime throughout the study duration
215079934|NCT00218582|BEHAVIORAL|Standard psychiatric day treatment|Individual counseling, groups, medication
215079935|NCT02593422|BEHAVIORAL|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
214354101|NCT04885023|OTHER|Hippotherapy|The hippotherapy program for 10 weeks
214354102|NCT00596440|DRUG|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
214354103|NCT01247129|PROCEDURE|Delay procedure of SIEA flap.|Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
214354104|NCT05717933|DIAGNOSTIC_TEST|thyroid hormones|Thyroid function among pediatric patients with type1 diabetes mellitus at the first presentation, from patients' characteristics to disease severity
214962498|NCT01919164|DRUG|Sprifermin|Participants received Sprifermin as intra-articular injection.
214962499|NCT01919164|DRUG|Placebo|Participants received Placebo matched to sprifermin as intra-articular injection.
214962500|NCT01736735|DRUG|CLP|
214962501|NCT01736735|DRUG|placebo|
214962502|NCT00458315|DRUG|Cisplatin|
214962503|NCT00458315|DRUG|Paclitaxel|
214354105|NCT01913418|DRUG|Suan-Zao-Ren Tang|SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
214678899|NCT02749370|DRUG|Etanercept|Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
214678900|NCT02101411|DIAGNOSTIC_TEST|PRU(Platelet reactivity unit)|measure by VeryfyNow.
214962504|NCT00458315|DRUG|Gemcitabine|
214962505|NCT00458315|DRUG|Avastin (Bevacizumab)|
214962506|NCT01398852|DRUG|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
214962507|NCT01398852|DEVICE|VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
214962508|NCT04074434|DEVICE|Study Watch|Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
214962509|NCT00435110|PROCEDURE|standard ventilatory settings|
214962510|NCT00435110|PROCEDURE|PEEP and FiO2|
214354106|NCT01913418|DRUG|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
214354107|NCT01029223|DRUG|ivabradine|
214354108|NCT01029223|DRUG|metoprolol|
214354109|NCT01029223|DRUG|placebo|
214354110|NCT04413890|DRUG|Dinoprostone vaginal gel|Prostaglandin gel 0.5, 1 or 2 mg
214354111|NCT01325168|DRUG|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
214354112|NCT01325168|DRUG|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
214962511|NCT03531723|OTHER|Measuring the size of the 3rd ventricle by ultrasound|The surveillance of the clamping test is essentially clinical. No cerebral imaging is performed systematically in our service protocol.The study consisted of including ultrasound measurements during the usual weaning protocol of the service.All patients receiving a SEV withdrawal test will be included. Inclusion begins when the clinician in charge of the patient initiates the withdrawal test. The measurements will be performed blindly by a trained physician who does not participate in the patient's care. Four measurements will be made, with recording of ultrasound loops
214962512|NCT04052607|DRUG|LH Suppression|Stimulation protocols
214962513|NCT00532909|DRUG|Vandetanib|100mg or 300mg By mouth every day continuous
214962514|NCT00532909|DRUG|Capecitabine|Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
214962515|NCT00532909|DRUG|Oxaliplatin|dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
214962516|NCT00532909|DRUG|Bevacizumab|Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
214962517|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
214354113|NCT00611013|DEVICE|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
214354114|NCT03166761|DRUG|Dexamethasone|Dexamethasone injection into the sacroiliac joint
215079936|NCT02593422|BEHAVIORAL|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
214354115|NCT03166761|DRUG|Triamcinolone Acetonide|Triamcinolone injection into the sacroiliac joint
214487090|NCT06742645|BEHAVIORAL|Brief Motivational Interviewing|"Brief Motivational Interviewing (BMI), the object of the training and of the present research study, is an interview methodology that includes the intervention on the motivation to change of subjects with risky behaviors for their health, in order to obtain changes in their lifestyle and maintain correct behaviors for health over time (1). The BMI is mainly based on the Transtheoretical Model of Change by Di Clemente CC. and Prochaska JO (2).~In particular, the BMI has been defined by its creators, Miller and Rollnick, as a collaborative style of conversation aimed at strengthening motivation and commitment to change (3), both through defined attitudes, strategies and techniques, and through the exploration of ambivalence or internal fracture, which together with availability and a sense of self-efficacy (4) provides a framework of personal motivation."
214962518|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
214962519|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
214962520|NCT01686945|DRUG|placebo|Placebo semaglutide. For oral administration.
214962521|NCT01686945|DRUG|placebo|Placebo semaglutide with carrier. For oral administration.
214962522|NCT00302536|DRUG|Tacrolimus|Tacrolimus
214962523|NCT03902093|DIAGNOSTIC_TEST|Morphology changes with extended wear hearing aid|Possible changes in morphology due to wearing an extended wear hearing aid device will be assessed with imaging
214962524|NCT06034197|DRUG|VGT-309|0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
214962525|NCT04356157|BEHAVIORAL|Behavioural change interventions|"The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive."
215079937|NCT04347473|DRUG|Ilumya Injectable Product|IL-23 injection
215079938|NCT02098369|BEHAVIORAL|Written education material (basic)|Education material on COPD distributed to all participants.
215079939|NCT02098369|BEHAVIORAL|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
215079940|NCT02098369|BEHAVIORAL|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
215079941|NCT02098369|BEHAVIORAL|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
215079942|NCT00420615|DRUG|Patupilone and Omeprazole|
214354116|NCT00229125|DRUG|Gabapentin|
214354117|NCT00229125|DRUG|Lorazepam|
214354118|NCT00223418|DRUG|aripiprazole|
214354119|NCT00827450|DIETARY_SUPPLEMENT|Ctl|Control, isocaloric diet; no coffee
214354120|NCT00827450|DIETARY_SUPPLEMENT|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
214354121|NCT00827450|DIETARY_SUPPLEMENT|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
214354122|NCT00827450|DIETARY_SUPPLEMENT|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
214354123|NCT00827450|DIETARY_SUPPLEMENT|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
214354124|NCT03459430|OTHER|Core stability training|Effect of different core stability programs using diverse training intensities
214354125|NCT05214872|DIAGNOSTIC_TEST|laboratory parameters - complete blood count|"the complete blood count was analyzed using Sysmex K-4500 Automated Hematology Analyzer (by GMI Inc., USA):~* hemoglobin (HGB) \[g/dl\];~* red blood count (RBC) \[10\^12/l\];~* hematocrit (HCT) \[l/l\];~* white blood cells (WBC) \[10\^9/l\];~* platelet count (PLT) \[10\^9/l\]"
214354126|NCT05214872|OTHER|body mass index (BMI) [kg/m^2] calculation|body mass index (BMI) \[kg/m\^2\] was calculated by dividing a person's weight (post-HD weight in HD group) \[kg\] by the squared their body height \[m\]
215079943|NCT00420615|DRUG|Patupilone + Midalzolam|
215079944|NCT03975127|OTHER|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
215079945|NCT00033709|DRUG|temozolomide|
214354127|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (1)|"Serum concentration of:~* advanced glycation ends products (AGE) \[µg/mg protein\];~* 3-nitrotyrosine (3-NT) \[µmol/mg protein\];~* advanced oxidation protein products (AOPP) \[µmol/mg protein\];~* carboxymethyle(lysine) (CML) \[µg/mg protein\]~were determined with the enzyme immunoassay methods (ELISA) using Shanghai Sunred Biological Technology Co kits, China."
214354128|NCT05214872|DIAGNOSTIC_TEST|metalloproteinases|"metalloproteinases in the serum \[ng/ml\]:~* metalloproteinase 9 (MMP-9) in the serum was determined by the ELISA method using the Quantikine Human MMP-9 (total) kit, by R\&D Systems, Canada;~* tissue inhibitor of metalloproteinase 1 (TIMP-1) in the serum - was determined by the ELISA method using the Quantikine Human TIMP-1 kit, manufactured by R\&D Systems, Canada;~* the MMP-9/TIMP-1 ratio was calculated by the quotient of the MMP-9 and the TIMP-1 concentration."
214354129|NCT05214872|DIAGNOSTIC_TEST|parameters of lipids metabolism in the serum|"* total cholesterol (T-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* low-density lipoprotein cholesterol (LDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* high-density lipoprotein cholesterol (HDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* triglycerides (TG) \[mg/dl\] - were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* the concentration of low-density lipoprotein (LDL-C) cholesterol - was determined from Friedewalds' equation (LDL-C \[mg/dl\] = total cholesterol (T-C) \[mg/dl\]- HDL-C \[mg/dl\]- TG\[mg/dl\]/5)."
214487091|NCT06742645|BEHAVIORAL|Standard of Care (SOC)|Standard of Care (SOC) - The health workers of the Navile Community House carry out the outpatient visit and after having identified the health problems they propose a possible treatment. The users belonging to the control arm will complete the SF-36 questionnaire
214962526|NCT01543568|DRUG|aflibercept 2.0 mg|Intravitreal aflibercept injection 2.0 mg
214962527|NCT03025113|DRUG|ketoprofen and cyclobenzaprine association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
214962528|NCT03025113|DRUG|Cyclobenzaprine|The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
214962529|NCT00253006|PROCEDURE|Tissue examination for protein- and mRNA-expression of NO|
214962530|NCT05249387|DRUG|A-967079 and BAM8-22 application|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
214962531|NCT05249387|DRUG|A-967079 and BAM8-22 application after 5 minutes.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
214962532|NCT05249387|DRUG|A-967079 application.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
214962533|NCT05249387|DRUG|Vehicle and BAM8-22 application.|Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
214962534|NCT00667992|DRUG|Budesonide HFA|standard daily inhaled dose
214962535|NCT00667992|DRUG|Budesonide CFC|standard daily inhaled dose
214962536|NCT03206840|BEHAVIORAL|"control, meditation, hypnosis."|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
214962537|NCT03627078|OTHER|motor interference therapy|
214962538|NCT03627078|OTHER|Relaxation exercises|In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
214962539|NCT02945735|BEHAVIORAL|Attention Modification|Feedback according to participants' viewing patterns, in order to modify their attention.
215079946|NCT00033709|DRUG|thalidomide|
215079947|NCT03908372|DRUG|Docetaxel|Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles
215079948|NCT03908372|DRUG|Cisplatin|Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy
214487092|NCT06741579|DEVICE|Peripheral Nerve Stimulation|The Nalu Peripheral Nerve Stimulator is an FDA-approved, surgically implanted PNS device meant to provide a drug-free pain management approach for patients experiencing chronic neuropathic pain.
214962540|NCT03750877|PROCEDURE|median approach|spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.
214962541|NCT03750877|PROCEDURE|paramedian approach|In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.
215079949|NCT03908372|RADIATION|IMRT|IC+IMRT arm:the patients with complete response will receive 60Gy to the gross target volume of nasopharynx, partial response 64Gy, and the absence of response or stable will receive 70Gy. CCRT arm: 70Gy to the gross target volume of nasopharynx.
214354130|NCT05214872|DIAGNOSTIC_TEST|parameters of iron metabolism|"* iron concentration \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* total iron-binding capacity (TIBC) \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* the unsaturated iron-binding capacity (UIBC) \[mg/dl\] was determined by an equation in which iron concentration in plasma is subtracted from TIBC \[mg/dl\];~* ferritin \[ng/ml\] concentration was determined with the Modular E-170 biochemical analyzer from Roche Diagnostics, USA."
214354131|NCT05214872|DIAGNOSTIC_TEST|selected inflammatory markers|"* high-sensitivity C-reactive protein (hsCRP) \[mg/l\] was measured using DADE Behring, USA and the DADE nephelometer Behring Analyzer II;~* neopterin \[nmol/l\] was determined by using the Neopterin ELISA kit, DRG International, Inc., USA;~* interleukin 18 (IL-18) \[pg/ml\] concentration was determined by Colorimetric Sandwich ELISA, Quantikine Human IL-18 R\&D Inc., USA."
214354132|NCT05214872|DEVICE|carotid intima-media thickness (IMT)|"carotid intima-media thickness (IMT) \[mm\] was measured by The Accuson CV 70 system (Siemens) with a 10 megahertz (Mhz) transducer.~Two longitudinal projections were assessed (anterolateral and posterolateral). The distal 1 cm of the common carotid artery just proximal to the bulb was measured by means of a computer analysis system (Medical Imaging Applications, LLC)."
214487093|NCT06741579|PROCEDURE|Conventional Care Regimen|CMM-Only participants will receive conventional medical management for the duration of their time in the study.
214487094|NCT06750692|OTHER|Procedure: Mirror therapy|The first group of participants will receive a total of 20 sessions of upper extremity mirror therapy program, 5 sessions per week for 4 weeks.
214962542|NCT05418439|DIETARY_SUPPLEMENT|Drink Poppi Soda|Drink Poppi Vinager Soda
214962543|NCT01288651|DRUG|Ferricarboxymaltose|"Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration.~Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject)."
214962544|NCT01222312|DRUG|Cisplatin|75 mg/m2, d1 every 3 weeks
214962545|NCT01222312|DRUG|Oxaliplatin|85 mg/m², d1 every 2 weeks
214962546|NCT01222312|DRUG|Docetaxel|75 mg/m2, d1 every 3 weeks
214962547|NCT01222312|DRUG|Docetaxel|50mg/m2, d1 every 2 weeks
214962548|NCT01431313|DRUG|Inhaled Nitrite|Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
214962549|NCT00301912|BIOLOGICAL|filgrastim|
214962550|NCT00301912|DRUG|busulfan|
215079950|NCT01633515|PROCEDURE|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
215079951|NCT04929925|DIAGNOSTIC_TEST|serum procalcitonin in acute bacterial meningitis|Serum Procalcitonin estimation will be done by Cobas e411Roch diagnostic,Switzerland apparatus by immunoassay method (electrochemiluminescence immunoassay) by using sample serum or plasma heparin or EDTA with reference range less than 0.5ng/ml ( no sepsis) but 0.5-2ng/ml)follow up is recommended) and more than 2 (sepsis)
214962551|NCT00301912|DRUG|fludarabine phosphate|
214962552|NCT00301912|DRUG|methotrexate|
214962553|NCT00301912|DRUG|tacrolimus|
214962554|NCT00301912|PROCEDURE|allogeneic bone marrow transplantation|
214962555|NCT00301912|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214962556|NCT00301912|PROCEDURE|peripheral blood stem cell transplantation|
214962557|NCT02748057|DRUG|Ezetimibe|
214962558|NCT02748057|DRUG|Rosuvastatin|
214962559|NCT01418911|OTHER|questionnaire|questionnaire only
214962560|NCT04063735|DIETARY_SUPPLEMENT|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia supplement for 3 months
214962561|NCT04063735|DIETARY_SUPPLEMENT|Placebo|Placebo was given to participants.
214962562|NCT02403050|DEVICE|Fiducial markers|2 fiducial markers (Visicoils) to be placed in the tumor area
214354133|NCT05214872|DEVICE|non-invasive cardiological examinations|"For non-invasive cardiological examinations, the Portapres device (Finapres Medical Systems (FMS), the Netherlands), the SphygmoCor tonometer (AtCor Medical), the Colin blood pressure monitor (BMP)-7000 (Japan) were used.~Main assessed variables: heart rate (HR) \[beats per minute \[bpm\]\]; ejection duration (ED) \[millisecons\]; peripheral systolic (pSBP) and diastolic blood pressure (pDBP) \[mm Hg\]; peripheral mean arterial pressure (pMAP) \[mm Hg\]; peripheral end-systolic pressure (pESP) \[mm Hg\]; central systolic (cSBP) and diastolic blood pressure (cDBP) \[mm Hg\]; central mean arterial pressure (cMAP) \[mm Hg\]; central augmented pressure (cAP) \[mmHg\]; central mean pressure of diastole (cMPD)\[mm Hg\]; central mean pressure of systole (cMPS) \[mm Hg\]; central end-systolic pressure (cESP) \[mm Hg\]."
214354134|NCT05214872|DEVICE|vessel stiffness assessment|"The following parameters of vessel stiffness were assessed by Pulse Trace 2000 (Micro Medical Ltd., Rochester, Kent, United Kingdom):~* reflection index (RI) \[in percentages \[%\]\];~* vascular stiffness index (SI) \[m/s\];~* peripheral pulse pressure (pPP) \[mm Hg\];~* central puls pressure (cPP) \[mm Hg\]~* peripheral pulse pressure/central pulse pressure (pPP/cPP ratio)."
214354135|NCT05214872|OTHER|cardiovascular (CV)-related death recording during 2-year follow-up|During a 2-year follow-up from the enrollment to this study, CV-related fatal incidents history has been recorded for each subject separately. The primary endpoint was fatal acute myocardial infarction (AMI) or acute ischemic stroke or any unexpected or sudden death only if autopsy proved CV-related. If there was doubt about the cause of death or there was no contact with the patient during the two years from study enrollment, that patient was excluded and not considered further.
214354136|NCT05214872|DIAGNOSTIC_TEST|glucose (Glu)|glucose (Glu) \[mg/dl\] was assessed in the serum by a routine technique using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
214354137|NCT05214872|DIAGNOSTIC_TEST|klotho|klotho \[ng/ml\] - was analyzed in the serum by Human KL(Klotho) \[ng/ml\] ELISA Kit, Shanghai Sunred Biological Technology Co kit, China.
214354138|NCT05214872|DIAGNOSTIC_TEST|fibroblast growth factor 23 (FGF-23)|FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.
214354139|NCT05214872|DIAGNOSTIC_TEST|parameters of calcium and phosphate metabolism|"* total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
214354140|NCT05214872|DIAGNOSTIC_TEST|liver enzymes activity assessment|"activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
214354141|NCT05214872|DIAGNOSTIC_TEST|total protein and albumin|"* total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
214354142|NCT05214872|DIAGNOSTIC_TEST|creatinine and urea|"* creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
214354143|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (2)|myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.
214962563|NCT03308604|DRUG|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|"Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later.~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg."
214962564|NCT03308604|RADIATION|External beam radiotherapy (EBRT)|to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases
214962565|NCT03308604|RADIATION|Uterovaginal brachytherapy|15 Gy (maximal interval between EBRT and brachytherapy: 14 days).
214962566|NCT03308604|DRUG|Chemotherapy (cisplatin)|Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
214962567|NCT03834025|BEHAVIORAL|Phase 1 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation.
214962568|NCT03834025|BEHAVIORAL|Phase 1 Condition 2|Providers assigned to this condition will be sent recruitment materials that include an additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2).
214962569|NCT03834025|BEHAVIORAL|Phase 1 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3).
214962570|NCT03834025|BEHAVIORAL|Phase 1 Condition 4|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4).
214962571|NCT03834025|BEHAVIORAL|Phase 2 Condition 1|Providers who enroll in the study and are assigned to this condition will be in this group. Other than the opportunity to participate in a learning collaborative, participants receive no compensation.
214962572|NCT03834025|BEHAVIORAL|Phase 2 Condition 2|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.
214354144|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (3) sRAGE|soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.
214354145|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups|"* methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA."
214354146|NCT05214872|DIAGNOSTIC_TEST|selected electrolytes assessment|"* potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
214354147|NCT05214872|DIAGNOSTIC_TEST|NT-pro-brain natriuretic peptide (NT-proBNP)|NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.
214354148|NCT05214872|OTHER|estimated glomerular filtration rate (eGFR) calculation|eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.
214354149|NCT04364646|BEHAVIORAL|Personalized Integrated Chronotherapy|Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
214354150|NCT00187018|BIOLOGICAL|Bone marrow transplant|
214962573|NCT03834025|BEHAVIORAL|Phase 2 Condition 3|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
214354151|NCT00479011|PROCEDURE|fluid management based on arterial pulse pressure variation|
214354152|NCT04837066|DIAGNOSTIC_TEST|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
214354153|NCT01864564|OTHER|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
214962574|NCT04835961|OTHER|Maintenace and As needed|This study will record the use of budesonide / formoterol either as maintenance treatment or / or as needed according to standard clinical practice and at the discretion of the treating physician.
214354154|NCT05883813|PROCEDURE|sustained natural apophyseal glides (SNAGS)|SNAGS will be given with patient in sitting position and the therapist will be standing behind the patient. The therapist will place the thumb on the spinous process of the vertebra. Move spinous process upward towards the eyeball direction \& maintain the glide and ask the patient to turn (rotation) his head slowly in painful direction, sustain the mobilization until head turn to the midline. Three repetitions of each glide will be given and each glide will be maintained for 10 seconds at end range.
214354155|NCT05883813|PROCEDURE|suboccipital muscle release|Sub-occipital muscle release will be applied with the patient in the supine position with the eyes closed and the physiotherapist's hands placed under the patient's head, in contact with the sub-occipital muscles. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.
214962575|NCT00030966|DRUG|Natalizumab|Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
214354156|NCT05883813|PROCEDURE|Supplemental therapy|General warm-up exercises, TENS, hot pack, trapezius stretching
214354157|NCT04706468|DRUG|TG-1000|Capsules taken orally
214354158|NCT02156713|BEHAVIORAL|CIMT Camp|
214354159|NCT02048228|DRUG|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19\*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
214354160|NCT02048228|DRUG|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
214354161|NCT02269670|DRUG|everolimus|Given PO
214354162|NCT02269670|DRUG|anastrozole|Given PO
214354163|NCT02269670|DRUG|letrozole|Given PO
214354164|NCT02269670|DRUG|tamoxifen citrate|Given PO
214354165|NCT02269670|DRUG|fulvestrant|Given IM or PO
214354166|NCT02269670|DRUG|megestrol acetate|Given PO
214962576|NCT00030966|DRUG|Placebo|Placebo monthly infusion for up to 116 weeks.
214962577|NCT01084057|DRUG|vorinostat|Given orally
214962578|NCT01084057|DRUG|ixabepilone|Given IV
214962579|NCT01084057|OTHER|laboratory biomarker analysis|Correlative studies
214962580|NCT01084057|OTHER|pharmacological study|Correlative studies
214962581|NCT04235426|DRUG|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
214962582|NCT04235426|PROCEDURE|30 patients went to surgical procedure|30 patients went to surgical RELEASE OF TRANSVERSE VOLAR LIGAMENT.
214962583|NCT04235426|OTHER|Injection|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
214354167|NCT05041673|DRUG|Metformin|Antidiabetic drugs
214354168|NCT00941330|DRUG|Exemestane|25 mg daily by mouth for 6 to 12 months.
214354169|NCT00941330|DRUG|Docetaxel|Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
214354170|NCT00941330|DRUG|Cytoxan|Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
214962584|NCT02588586|DRUG|3BNC117|3BNC117 infusions
214962585|NCT02588586|OTHER|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
214962586|NCT03065686|GENETIC|identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
214962587|NCT03516162|OTHER|There is no study-specific intervention|There is no study-specific intervention
214962588|NCT05554640|DEVICE|Acuvue® Oasys MAX 1-Day|TEST Lens
215079952|NCT04951271|BEHAVIORAL|Solution focused approach|The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
214354171|NCT05732233|DEVICE|Ultivision AI|Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas) in adult patients undergoing colorectal cancer screening and surveillance examinations.
214354172|NCT05692024|DRUG|Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.|Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.
214354173|NCT05692024|DRUG|Placebo|Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
214354174|NCT03558867|DRUG|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
214354175|NCT03558867|DRUG|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet
215079953|NCT04994730|BEHAVIORAL|Quality of life according to the reconstruction technique|"For this retrospective analysis, 118 patients could be included, 17 of whom had undergone ante-brachial free flap reconstruction, 16 of whom had undergone this reconstruction within the last 2 years.~The primary endpoint: Analysis of the quality of life score according to the reconstruction technique (free ante-brachial flap versus others) will be performed by a Wilcoxon-Mann-Whitney test."
214354176|NCT03508453|BIOLOGICAL|IC14|Monoclonal antibody against CD14
214962589|NCT05554640|DEVICE|Dailies Total 1|CONTROL Lens
214354177|NCT03508453|OTHER|Placebo|sterile normal saline for injection prepared to be identical to study drug
214354178|NCT02693665|BEHAVIORAL|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
214354179|NCT02322944|BEHAVIORAL|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
214354180|NCT02322944|BEHAVIORAL|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
214962590|NCT02871622|DEVICE|BioMatrix AlphaTM|Cobalt Chromium BA9 TM drug-eluting stent
214354181|NCT03630666|DRUG|IADT|Patient will receive one injection of IADT at randomization
214354182|NCT03630666|COMBINATION_PRODUCT|IADT + radiotherapy|Patient will receive one injection of IADT at randomization then will receive irradiation 3 months after injection of IADT
214354183|NCT03656133|RADIATION|Radiotherapy fractionation|Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)
214354184|NCT06736275|DRUG|SXRN|"SXRN is a naked plasmid DNA drug targeting miRNA. Accelerated titration and 3+3 dose escalation:In light of ethical considerations and with the aim of minimizing the number of patients possibly exposed to potentially ineffective doses, an accelerated titration strategy will be implemented in the early dose escalation phase (2 mg dose group) in this study, with only 1 subject enrolled. If no DLT occurs to the 3 subjects under the given dose in the DLT valuation window (the 1st cycle, 3 weeks), the study will proceed to the next dose (dose escalation in the same subject is not allowed); if one subject develops DLT, 3 additional subject s will be included to the current dose group; if ≥2 DLTs occur in the dose group with 3 or 6 subject s, the dose escalation will be stopped. The decision is made by discussion among the investigators whether to terminate the escalation or consider adjusting the dose for exploration."
214354185|NCT00655980|DRUG|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
214354186|NCT00655980|DRUG|Nitrous oxide and placebo|
214487095|NCT06750692|DEVICE|Device: Low Frequency rTMS Protocol|Repetitive Transcranial Magnetic Stimulation (rTMS) will be applied at an intensity of 100-110% of the resting motor threshold and low frequency (1 Hz) to the contralateral M1 upper extremity motor cortex region for a total of 20 sessions, 5 sessions per week for 4 weeks. rTMS application is planned to provide magnetic stimulation with the stimulator of the Magventure MagPro R30 device.
214962591|NCT02315144|DRUG|TV48108|TV48108 15, 60, 120 μg
214962592|NCT02315144|DRUG|Placebo|Placebo Comparator
214962593|NCT02752438|DEVICE|HFOV|HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
215079954|NCT00481325|DRUG|pexacerfont|Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
214354187|NCT00655980|OTHER|standard of care|
214962594|NCT00752336|BEHAVIORAL|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
214962595|NCT00494546|PROCEDURE|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
214962596|NCT03014271|BEHAVIORAL|Sources of Strength (SOS) Prevention Program|Sources of Strength is an evidence based program for youth suicide that trains student key leaders to strengthen social connectedness and healthy norms school-wide and is listed on the National Registry of Evidence Based Programs and Practices (NREPP).
214962597|NCT03697941|PROCEDURE|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
214962598|NCT03697941|PROCEDURE|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
214962599|NCT00540397|DRUG|Fuzhenghuayu Tablet, Huangqi Decoction Granule|
214962600|NCT03959046|BEHAVIORAL|GIST|The GIST intervention will train physicians in an alternative way of communicating with their patients.
214354188|NCT01953796|DRUG|clomiphene|For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
214354189|NCT04915794|OTHER|Simulation of preeclamptic pregnancy care|It is an important step in providing safe care to patients, as a learning environment is provided in which environmental risks are minimized with simulation applications. Simulation-based trainings are environments that allow each student to learn, equitable, based on adult learning principles, and open to different learning styles. In these environments, interests and needs are defined together by the learner and the educator. By keeping the experiences of the learner at the forefront, the opportunity is given to learn by doing and is supported with feedback.
214354190|NCT01146236|DEVICE|Sutures|Orthopedic surgical wounds closed with sutures
214354191|NCT01146236|DEVICE|Staples|Orthopedic surgical wounds closed with metallic staples
214354192|NCT03200522|OTHER|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
214354193|NCT03200522|OTHER|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
214354194|NCT06819670|DRUG|Prednisolone|active drug
214354195|NCT06819670|DRUG|Famotidine|active drug
214354196|NCT06819670|DRUG|Placebo|non-active drug
214354197|NCT03766971|BEHAVIORAL|7 days of Tobacco Cessation|Participants will be randomly assigned to 7 days of tobacco cessation.
214354198|NCT03766971|BEHAVIORAL|21 days of Tobacco Cessation|Participants will be randomly assigned to 21 days of tobacco cessation.
214354199|NCT03766971|DRUG|Cannabis|Participants will receive cannabis.
214354200|NCT06986525|PROCEDURE|CAF with PRF|Coronally advanced flap technique will be performed to reposition the gingival margin coronally. Platelet-rich fibrin (PRF) membranes will be placed over the exposed root surfaces and stabilized with sutures.
214354201|NCT06986525|PROCEDURE|Tunnel with PRF|A tunnel or subgingival pouch will be created using microsurgical instruments without vertical incisions. Platelet-rich fibrin (PRF) membranes will be inserted into the tunnel and the gingival tissue will be advanced coronally and sutured to cover the recession.
214354202|NCT00062933|PROCEDURE|Laparotomy|
214487096|NCT06750692|DEVICE|Robotic-assisted hand therapy|In the Robot Assisted Therapy group, a total of 20 sessions will be applied 5 days a week for 4 weeks using continuous passive range of motion, active assistive exercise and play therapy programs for hemiplegic upper extremities with AMADEO (Tyromotion Austria).
214962601|NCT02982889|DRUG|LIQ865A bupivacaine formulation|single subcutaneous injection in medial calf
214962602|NCT02982889|DRUG|LIQ865B bupivacaine formulation|single subcutaneous injection in medial calf
214962603|NCT02982889|DRUG|Diluent for LIQ865|Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
214962604|NCT02982889|DRUG|0.5% bupivacaine hydrochoride|single subcutaneous injection
214962605|NCT03787602|DRUG|KRT-232|KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
214962606|NCT03787602|DRUG|Avelumab|Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
214962607|NCT04217460|BEHAVIORAL|Intervention for fluency difficulty|Children are required to speak materials they hear on recordings. The materials are not words, but contain sound sequences that occur in their language and English.
214962608|NCT02843464|OTHER|reported remote ischemic preconditioning (RIPC)|Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
215079955|NCT00481325|DRUG|escitalopram|Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
215079956|NCT00481325|DRUG|placebo|Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
215079957|NCT03134365|OTHER|Mixed meal|Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
215079958|NCT03134365|OTHER|Combined meal|Combined meal.
215079959|NCT03342573|DRUG|Cosentyx|Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
214354203|NCT04657822|DRUG|Crizanlizumab|Concentrate for solution for infusion for Intravenous use
214354204|NCT05194410|BEHAVIORAL|First 3 months of virtual, team-based exercise|Participants will be randomized onto mixed teams of medical students, residents, fellows, and attendings and registered for the virtual, team-based exercise intervention on FitRankings.com. All exercise (including walking, biking, lifting, yoga, and 40+ exercises) will be tracked via user's smartwatches (ie Apple, Garmin), smartphone fitness apps (ie MapMyRun), or manual upload, converted into Metabolic Equivalent of a Task (MET) minutes, and displayed on online leaderboards. Group activities will be encouraged by awarding raffle tickets for prizes to those who submit pictures with their teammates.
214354205|NCT05194410|BEHAVIORAL|Second 3 months of virtual, team-based exercise|Same as above
214354206|NCT03207529|DRUG|Alpelisib|Given PO
214354207|NCT03207529|DRUG|Enzalutamide|Given PO
214354208|NCT05306327|DIAGNOSTIC_TEST|electroencephalography (EEG)|"1. brain cortical activity using full scalp~2. cerebral blood flow velocity~3. during the dying process following planned withdrawal of life sustaining measures (WLSM)"
214354209|NCT06669130|DEVICE|Xiangtong TM full degradation sinus drug stent system|use Xiangtong TM full degradation sinus drug stent system to deliver drugs into sinus
214354210|NCT06669130|DEVICE|nasopore|use nasopore to protect the post-operative sinus
214354211|NCT06669858|OTHER|manual therapy|"In first session 6 techniques were applied to favorise fluids circulation, respiratory mecanism end equilibration of pressions (all were external soft tissue techniques, without manipulation): on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on liver and spleen organ, on lumbar fasciae.~In second session 6 techniques were applied in order to improve quality and quantity of legs and pelvis mobility (all were external sof tissue techniques, without manipulation) : on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on pubic symphysis, on legs and pelvis and on lumbar fasciae"
214962609|NCT06274502|OTHER|YOLOv8|After image post-processing, the You Only Look Once (YOLO) version 8 was selected as the target algorithm model.
214354212|NCT06669858|OTHER|Sham|Wide ligth touch pressure applied with the 2 hand at day 2-4 and day 90
214354213|NCT06669260|PROCEDURE|TEThA technique|Patient in an orthostatic position, previously marked varicose veins will be punctured with a tracing adjacent to them, surrounding their edges. Applying an augmented reality device and Doppler ultrasound (Doppler USG), the marking will be complemented in the supine position. These punctures will in turn be carried out using the TEThA technique - endovenous thermoablation of tributary veins by means of transfixation - and will be done sequentially as they are treated one by one with endo- and perivenous thermoablation under generous tumescence with 0.08% lidocaine in saline solution. The laser used to treat the tributary veins will also be 1470 nm and will be fired as the fiber is removed at a speed of 1 mm/sec and power ranging from 5 to 7 watts.
214962610|NCT04059289|OTHER|Posterior chamber intraocular lens (IOL)|This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
214678901|NCT05055661|OTHER|Pharmaceutical Teleconsultation|The pharmacist will apply the teleconsultation according to the elaborated workflows and will follow in seven steps: scheduling the teleconsultation; pre-consultation, in which the pharmacist will make a checklist of the adequacy of the teleconsultation environment; presentation of the professional and the objectives of the teleconsultation to the patient; search for information about the patient and their pharmacotherapy; identification of problems related to pharmacotherapy; elaboration of a care plan and appointment for the re-consultation.
214354214|NCT06598306|DRUG|Tarlatamab|Administered by SC injection.
214354215|NCT05933148|DEVICE|Siemens 7T MRI|The active neurofeedback session will be done within the 7T MRI.
214354216|NCT05933148|DEVICE|Sham Neurofeedback|The sham Neurofeedback resembles the active condition but participants will not see their own brain activity and will instead view a past participant's active feedback from their same population group.
214354217|NCT00439907|PROCEDURE|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
214962611|NCT03784313|PROCEDURE|skin repair by axillary perforator flaps|"Perforators flaps (PF) of the axillary region for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa.~Perforated flap surgery does not involve any procedure or manipulation that may alter the biological characteristics and/or structural properties of the tissue (use autologue pur). A usual dressing is performed daily until complete healing."
214962612|NCT03784313|PROCEDURE|skin repair by secondary wound healing|Secondary intention wound healing (SIWH) for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa
214962613|NCT04033406|DRUG|VIR-2482|VIR-2482 given by intramuscular injection
214962614|NCT04033406|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by intramuscular injection
214962615|NCT01773603|DEVICE|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
214962616|NCT05034835|DEVICE|usual treatment with compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
214962617|NCT05034835|OTHER|usual treatment without compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
214962618|NCT06164938|DIAGNOSTIC_TEST|Diagnostic accuracy|The aim is to obtain a regional measure of brain glucose metabolism in each normal subject because this is a functional measure of brain activity.
214962619|NCT03335319|OTHER|Periodized Exercise Training Regime|MCT 1st: 20 min on an ergometer; at Anaerobic Threshold (AT) 1 or, if the AT could not be adequately determined, 50-60% of the Heart Rate Reserve (HRR), Borg Rating of Perceived Exertion (RPE) equivalent 9-11. MCT 2nd: 20 minutes; 60-70%HRR, RPE 12-13. HIIT 1st: 4 interval training periods of 2 minutes (AT2 intensity or 80-90%HRR, RPE 15-17) and 4 active pauses of 2 minutes (below AT 1 or 40-50%HRR, RPE 6-9) between interval training periods. HIIT 2nd: same intervals as in 1st HIIT different intensities: high intensity interval above AT2 intensity or \> 90%HRR, RPE 17-19 and active pauses at AT 1 or 50-60%HRR, RPE 9-11. Resistance training adaptation: 2 sets of 15-20 repetitions 50% 1RM; Hypertrophy: 2 sets 8-12 repetitions at 60% 1RM; Maximal Strength: 2 sets of 6-8 repetitions at 80% 1RM.
214962620|NCT03335319|OTHER|Non Periodized Exercise Training Regime|To ensure that total training loads were similar in both groups despite differences in intensity, it will be used the training impulses (TRIMP) method from Edwards for the aerobic component and the volume load method for the RT component. All sessions will include 10 minutes of warm up and cool down standardized for both groups. By design, the non periodized group involves an identical total training volume and time commitment but differed regarding metabolic stress induced by the linear periodized group. All patients will be monitored with a HR monitor during the execution of the exercise session in order to achieve the HR training. Blood pressure will be assessed before and after completing each session. If necessary, the blood pressure will be measured during the ET session.
214678902|NCT00016861|DRUG|irinotecan hydrochloride|
214962621|NCT00202501|DEVICE|Nasal CPAP (Continuous Positive Airway Pressure)|
214962622|NCT03591601|OTHER|Manual Therapy protocol|Treatment based on manual therapy with proven evidence.
214962623|NCT03591601|OTHER|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
215079960|NCT02196116|OTHER|PET|PET Scan with \[18F\]-Flutemetamol
214354218|NCT00439907|PROCEDURE|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
215079961|NCT02196116|OTHER|MRI|
215079962|NCT02196116|OTHER|neuropsychological tests|
214354219|NCT01951482|DRUG|Pemetrexed/Platinum|pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle for four to six cycles, followed by pemetrexed maintenance every 3 weeks.
215079963|NCT04841759|OTHER|Exercise|8 week exercise program, nutritional \& psychological consultation
215079964|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
214962624|NCT03591601|OTHER|Placebo control|Placebo treatment based on the placement of the hands on the head without intention to treat.
214962625|NCT00254059|PROCEDURE|Ambulatory diagnosis and titration with nasal CPAP using over night oxymetry and auto CPAP and vs conventional diagnosis and titration using polysomnography|
214962626|NCT04254081|DRUG|Buprenorphine 0.15 MG|Buprenorphine 0.15mg solution will be added to a 20mL 1% buffered lidocaine solution (paracervical block) which will be administered in the paracervical space prior to osmotic dilator insertion.
214962627|NCT04254081|DRUG|Lidocaine 1% Injectable Solution|20mL of 1% buffered lidocaine solution (paracervical block) will be administered in the paracervical space prior to osmotic dilator insertion.
214962628|NCT06480136|DRUG|SHR-A1921 injection and adebrelimab injection|The Treatment group receive SHR-A1921 injection combined with adebrelimab injection
214962629|NCT02210507|OTHER|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
214962630|NCT02210507|OTHER|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
214962631|NCT02210507|OTHER|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
214962632|NCT05174156|DRUG|Combination therapy|SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin
214962633|NCT00926341|DRUG|Pioglitazone|Tab. Pioglitazone-30 mg/day, oral, 24 weeks
214962634|NCT00926341|DRUG|Telmisartan|Tab. Telmisartan- 40 mg/day, oral, 24 weeks
214962635|NCT00816127|DRUG|Desmopressin|intranasal desmopressin (300μg)
214962636|NCT00816127|BIOLOGICAL|blood transfusion|fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
214962637|NCT01266824|DRUG|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
214962638|NCT05555277|OTHER|No interventions - retrospective data collection|The differences between the two diagnoses were investigated by using the scale results and EEG data in the patient files.
214962639|NCT01699334|BEHAVIORAL|Psychoeducational video|The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
214962640|NCT01699334|OTHER|Relaxation video|The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
214962641|NCT05604365|BEHAVIORAL|FearLess Intervention|8-12 weekly telehealth sessions one hour in length.The intervention includes psychotherapy techniques varying from relaxation response to self-regulation targeted to the specific fears of patients with glioma.
214962642|NCT05699512|BEHAVIORAL|Multiprofessional, tailored rehabilitation|Patients receive individual, tailored, multiprofessional rehabilitation
214962643|NCT01333423|DRUG|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
214962644|NCT01333423|DRUG|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
214962645|NCT00164138|PROCEDURE|Pelvic floor training group|pelvic floor training, electrotherapy, bladder retraining.
214962646|NCT01735318|DRUG|Lisinopril Tablets 40 mg|40 mg tablet once a day
214962647|NCT01735318|DRUG|Lisinopril|40 mg tablet once a day
214962648|NCT03165773|OTHER|Oatmeal|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
214962649|NCT03165773|OTHER|Corn grits|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
214962650|NCT06172231|PROCEDURE|Instrument Assisted Soft tissue mobilization|The treatment processes consist of Four phases: warm up (heat), Graston Technique®, passive stretching and cryotherapy.6\_10 long strokes on Hamstring and Rectus femoris by using G1 instrument .Brief bouts (30 - 60 s) of deeper and more specific. Frequency: 4 sessions in 4-week period. Duration: 15\_35 min each session.
215079965|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
215079966|NCT00246025|DRUG|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
214962651|NCT06172231|PROCEDURE|Conventional therapy|5 min moist Hot pack ,Patellar joint mobilizations and Tibiofemoral ,Maitland grades III and IV (5 oscillations in first week) ,PROMs of knee joint ( 5 reps) ,Quad sets ( 5 reps with 5 sec hold)Progression: 5 repetition of each exercise would be add in every week ,Frequency: 4 sessions in 4-week period Duration: 15\_ 35 min each session.
214962652|NCT03582384|DRUG|Tocofersolan|After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
214962653|NCT05104385|OTHER|Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines|Based on the Turkish Ministry of Health regulations, any research protocol involving use of any drug/vaccine needs to be presented in a clinical trial format, and is presented to the clinical research ethical boards accordingly. Otherwise, the study has no intervention (to the exposure status) involved. Selection, administration, number of doses applied and the period between vaccine doses are beyond the capacity the study team.
214962654|NCT00967577|DRUG|177Lu-J591|70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
214962655|NCT06435767|DRUG|Adjuvant chemotherapy|In the Cancer Hospital, postoperative chemotherapy regimens and doses were planned by oncologists, with adjustments made based on drug toxicities or tumor responses.
214962656|NCT00666107|BIOLOGICAL|Gardasil|Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6
214962657|NCT04533789|OTHER|selected physical therapy program|strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
214962658|NCT00738647|PROCEDURE|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
215079967|NCT00246025|DRUG|placebo|matching placebo capsule, once a day, oral administration
215079968|NCT03172806|DIAGNOSTIC_TEST|Polysomnography|To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
214354220|NCT01951482|DRUG|Bevacizumab and Pemetrexed/platinum|bevacizumab (7.5mg/kg, intravenously on day 1 of each 3-week cycle) plus pemetrexed-platinum chemotherapy (pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle) for four to six cycles, followed by bevacizumab plus pemetrexed maintenance every 3 weeks.
214487097|NCT03795311|DRUG|FOLFIRINOX Bevacizumab|"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~* Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~* Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~* Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."
214962659|NCT00126919|DEVICE|SonoPrep|
214962660|NCT00652912|DRUG|Clonazepam|ODT, 1 mg
214962661|NCT00652912|DRUG|Klonopin Wafers|ODT, 1 mg
214962662|NCT01558219|DRUG|cabacitaxel|Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
214962663|NCT05549583|DRUG|Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
214962664|NCT02859350|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
214962665|NCT02859350|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
215079969|NCT00571636|DRUG|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is \> 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
215079970|NCT00571636|DRUG|5% glucose solution|ev continuous infusion
215079971|NCT00343369|DRUG|asparaginase|
215079972|NCT00343369|DRUG|cyclophosphamide|
215079973|NCT00343369|DRUG|cytarabine|
215079974|NCT00343369|DRUG|daunorubicin hydrochloride|
215079975|NCT00343369|DRUG|dexamethasone|
215079976|NCT00343369|DRUG|doxorubicin hydrochloride|
215079977|NCT00343369|DRUG|mercaptopurine|
215079978|NCT00343369|DRUG|methotrexate|
215079979|NCT00343369|DRUG|pegaspargase|
215079980|NCT00343369|DRUG|prednisolone|
215079981|NCT00343369|DRUG|teniposide|
215079982|NCT00343369|DRUG|thioguanine|
214354221|NCT06669988|DEVICE|VR|VR - Immersive instruction using virtual reality.
214354222|NCT06669988|DEVICE|Video|Video - Educational content presented through video.
214354223|NCT06669988|DEVICE|written materials|Written Materials - Instruction using text and images.
214487098|NCT06748079|DRUG|TQC3721 inhalation powder|TQC3721 is a target inhibitor.
214487099|NCT06748079|DRUG|Placebo for TQC3721 inhalation powder|Placebo without drug substance.
214487100|NCT06741488|OTHER|no intervention|Exercise Adaptation Rating Scale
214487101|NCT06752408|DRUG|Aumolertinib|Aumolertinib will be administered orally at a dose of 110 mg per time, Q.D.
214962666|NCT02859350|OTHER|Normal Saline|0.9% Sodium chloride
214962667|NCT02859350|BIOLOGICAL|PfSPZ Challenge (for PfSPZ-CVac)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
214962668|NCT05598359|DIETARY_SUPPLEMENT|TA-65|TA-65 is a purified small molecule extracted from Astragalus root
214962669|NCT05598359|OTHER|Placebo|Inactive formulation
214962670|NCT03549598|DRUG|68Ga-DOTATATE PET/CT|5.4 mCi of 68Ga-DOTATATE will be administered by intravenous route.
214962671|NCT03549598|DRUG|18FDG PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 18FDG will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
215079983|NCT00343369|DRUG|vincristine sulfate|
215079984|NCT00343369|RADIATION|radiation therapy|
215079985|NCT02810301|OTHER|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
215079986|NCT02810301|OTHER|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
215079987|NCT00199316|DRUG|spinal morphine|
215079988|NCT01904916|PROCEDURE|Histological biopsy procedure|
215079989|NCT00909545|DRUG|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
215079990|NCT00909545|DRUG|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
215079991|NCT00909545|DRUG|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
215079992|NCT00909545|DRUG|Placebo|4 Placebo to Match (PTM) tablets once daily
215079993|NCT02974335|BEHAVIORAL|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
215079994|NCT00017589|BIOLOGICAL|oblimersen sodium|
215079995|NCT00017589|DRUG|gemtuzumab ozogamicin|
215079996|NCT03886337|DEVICE|Germicidal lighting|Germicidal ambient lighting
215079997|NCT03327376|DEVICE|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
214962672|NCT03549598|DRUG|13NH3 PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
214962673|NCT03987308|DRUG|Beinaglutide|Beinaglutide (continuous subcutaneous infusion)
214354224|NCT06997081|DRUG|Lenalidomide|Participants will receive 25mg of Lenalidomide orally on Days 2-21 of Cycle 1, then 25 mg by mouth on Days 1-21 of the remaining cycles.
214354225|NCT06997081|DRUG|Dexamethasone|Participants will receive 20mg of Dexamethasone orally on Days 1, 3, 8, and 15 of Cycle 1, then 4mg orally on Days 1 and 15 of Cycles 4-6.
214354226|NCT06997081|DRUG|Elranatamab|Participants will receive 12mg Elranatamab subcutaneous (SC) on Cycle 1; 32mg subcutaneous (SC) on Cycle 1 Day 3; 76mg subcutaneous (SC) on Cycle 1 Day 8 and Day 15. Then, participants will receive 76mg subcutaneous (SC) on Days 1 and 15 of Cycles 2-6. Lastly, participants will receive Elranatamab subcutaneous (SC) on Day 1 of the remaining cycles.
214354227|NCT06996561|DRUG|Nalbuphine Injection|Anaesthesia induction will be done with propofol (2 mg/kg) nalbuphine (0.1mg/kg) and atracurium (0.6mg/kg) intravenously. Maintenance of anaesthesia will be achieved with oxygen (O2), nitrous oxide (N2O) in 1:2 ratio and isoflurane (0.8-1%). Intermittent top up of the study drug 1-2 ml boluses will be administered if either the patient's HR or BP increased to 20 % above baseline and when other causes of tachycardia and hypertension are excluded. Timing of analgesia will be recorded. Pain will be assessed for 24 hours postoperatively using verbal rating scale (VRS) with 0 = no pain and 10 = worst pain. Sedation will be assessed as 0=no sedation, 1= mild sedation, (eye-opening on verbal commands), 2= moderate sedation (eye-opening on painful stimulus), 3= deep sedation (not waking up on pain). All patients will be prescribed paracetamol one gram IV six hourly and nalbuphine 1-2 mg IV infusion in the first 24 hours post operatively.
214354228|NCT06996561|GENETIC|Next Generation Sequencing|5ml of blood samples by venipuncture will be obtained from the first 70 patients half an hour before extubation at the time of muscle closure. These blood samples will be processed for DNA analysis. Only the 15 samples where pain persisted despite nalbuphine administration, with a pain score remaining above 4, continuous use of rescue analgesia, or any documented opioid side effects (such as nausea, vomiting, or sedation), or the need for additional analgesia within 24 hours, will be sent for NGS analysis. These samples will undergo whole exome sequencing via NGS, based on patient parameters and pain scores, after being categorized as responders or non-responders to nalbuphine
214354229|NCT06996561|GENETIC|whole exome sequencing|Only the 15 samples will be sent for NGS based on patient parameters and pain scores after being categorized as responders or non-responders to nalbuphine
214354230|NCT06667453|DRUG|PGN-EDODM1|Administered by intravenous (IV) infusion
214354231|NCT06667453|OTHER|Placebo|Administered by intravenous (IV) infusion
214487102|NCT06752408|DRUG|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
214962674|NCT03987308|DRUG|Insulin aspart|Insulin aspart (CSII)
214962675|NCT06235580|OTHER|Biological Samples|"For patients, different types of banked frozen or fresh biological samples will be used in this research:~* Blood~* Skin biopsy or other tissues (liver, muscle, brain, lung...)~* Urine~* Saliva~* Cerebrospinal fluid~* Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used."
214962676|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1
214962677|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1
215079998|NCT01753219|PROCEDURE|Onstep|
214487103|NCT06749756|DRUG|vitamin B6+ Vitamin B12 +vitamin C|In addition to the basic treatment of sepsis, intravenous injection of vitamin B6 300mg qd Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days.
214487104|NCT06749756|DRUG|vitamin B6+ Vitamin B12|In addition to the basic treatment of sepsis, vitamin B6 300mg qd and vitamin B12 0.5mg q6h were given intravenously for 4 days.
214487105|NCT06749756|DRUG|vitamin C|On the basis of the basic treatment of sepsis, intravenous vitamin C 50mg/kg q6h was given for 4 days.
214487106|NCT06749756|DRUG|0.9%Nacl|The same dose of placebo (0.9% sodium chloride solution) was administered on top of the sepsis base treatment for 4 days.
214487107|NCT06752343|DRUG|Photodynamic Therapy|Procedure: Photodynamic Therapy the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power de
214962678|NCT00807612|DRUG|Carboplatin|Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6
214962679|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1
214962680|NCT00807612|DRUG|Paclitaxel|Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
214962681|NCT01977768|BIOLOGICAL|V7|One pill of V7 once daily for 30 days together with standard of care TB drugs
214962682|NCT01977768|BIOLOGICAL|Placebo|
215079999|NCT01753219|PROCEDURE|Lichtenstein|
214354232|NCT06266416|BEHAVIORAL|IMARA for Black Male Caregivers and Girls Empowerment|IMAGE is delivered by trained Black female facilitators to improve girls' SRH outcomes, prevention HIV/STIs, and reduce sexual violence. Over the two days, some components of the curriculum are delivered separately to male caregivers and girls, covering parallel content, and other sections are delivered jointly in a single group. The curriculum, extensively tailored for the target population and pilot tested, addresses Black girls' sexual development, risk for sexual violence, female anatomy, body positivity, HIV/STI knowledge and attitudes, and condom use. IMAGE is designed to strengthen bonds and communication between male caregivers and girls by encouraging perspective-taking (i.e., reverse role play) and conflict resolution.
214354233|NCT06266416|BEHAVIORAL|Time-matched control program|FUEL will engage Black male caregivers and girls to promote good nutrition, exercise, and informed consumer behavior. Topics include the impact of media on body image, evaluating nutritional labels to make healthy food choices, eating balanced meals, establishing regular exercise routines, and how families and communities can support healthy behavior. FUEL includes a brief video about HIV/AIDS and other STIs but otherwise does not otherwise address sexual health. Like IMAGE, FUEL is delivered in groups of 6-8 dyads over two workshop days (\~10 hours total) in one weekend. Parts of the curriculum are delivered separately to girls and male caregivers covering parallel content and other components are delivered jointly.
214354234|NCT03760237|OTHER|observation only|No intervention, observational study only
214354235|NCT04439110|BIOLOGICAL|Trastuzumab Emtansine|Given IV
214354236|NCT04951336|DIETARY_SUPPLEMENT|FoTv|Fomitopsis Officinalis and Trametes Versicolor
214354237|NCT05244356|BEHAVIORAL|Health message exposure|Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
214354238|NCT00645398|DRUG|Pregabalin|Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
214354239|NCT00645398|DRUG|Pregabalin|Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
214354240|NCT00645398|DRUG|Pregabalin|Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
214354241|NCT00645398|DRUG|Placebo|Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
214678903|NCT05477966|OTHER|Medical records review|The clinical characteristics at the time of diagnosis of rifampin-susceptible pulmonary tuberculosis patients, the Xpert MTB/RIF assay Ct value, the tuberculosis activity score based on AI of the chest image, and treatment results will be collected retrospectively through medical records.
214962683|NCT01300247|DRUG|Fludarabine|Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m\^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
214962684|NCT01300247|DRUG|Obinutuzumab|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
214962685|NCT01300247|DRUG|Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m\^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
214962686|NCT01300247|DRUG|Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
214962687|NCT05819879|PROCEDURE|peri capsular nerve group block|The block will be administered under ultrasound guidance with low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease, at the level of anterior superior iliac spine. The scanning will be done with gradual caudad movement of the probe. After the anterior inferior iliac spine (AIIS) become visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of superior pubic ramus become visible. The psoas muscle with prominent tendon will be identified just above the pubic ramus. The target is the plane between these two structures. Aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a standard 25G Quincke needle will be introduced and 20 mL 0.125% bupivacaine with 4 mg dexamethasone was administered using ultrasound-guided out-of-plane technique.
215080000|NCT06896123|BEHAVIORAL|Dance Well: an artistic, multisensory dance intervention based on art and music|DW is specifically designed for people with early to mild severe PD and aims to de-liver multiple stimuli, including rhythmical auditory cues, proprioceptive and sensorimo-tor stimulation, balance training, and aerobic exercise, using carefully selected music to cue movement and promote relaxation. The components of DW are relatively simple and easy to be learned and performed for people with compromised mobility. The intervention is also enjoyable and engaging, as reported for other genres of dance
215080001|NCT06896123|BEHAVIORAL|Conventional motor therapy group|Conventional Motor Therapy consisted on 60-minute conventional physiotherapy, twice a week, for four weeks
215080002|NCT00427531|OTHER|physiologic testing|
215080003|NCT01108432|OTHER|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
215080004|NCT03032653|OTHER|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
215080005|NCT03032653|OTHER|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
215080006|NCT04060381|DRUG|Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine|Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
215080007|NCT02789670|OTHER|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
215080008|NCT05946291|OTHER|Pressure injury training|Pressure injury training with mulage application on a standardized patient
214678904|NCT01662973|OTHER|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1\*10E6 UC-MSC/kg body weight for 12 weeks.
214678905|NCT01662973|OTHER|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
214354242|NCT06670430|DEVICE|experimental group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive TENS and NMES for 30 minutes 3 days per week,for 10 weeks with medical treatment
214962688|NCT05819879|PROCEDURE|scaitico femoral block|. After draping the left inguinal region, the femoral nerve will be identified lateral to the femoral artery using a 5- to 13-MHz linear phased array transducer ). Under ultrasound guidance, a 25G Quincke needle will be introduced toward the femoral nerve parallel to the ultrasound beam, and 20 mL of a local anesthetic mixture 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be injected. The trajectory of the needle was adjusted to achieve even distribution of the local anesthetics around the femoral nerve. Then, the patient will be placed in the right lateral position with the left hip and knee joints flexed by 30° to 50°. Following the identification of the left sciatic nerve located in the intermuscular plane of the gluteus maximus and medius muscles between the ipsilateral ischial tuberosity and greater trochanter using a convex phased array transducer 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be placed near the sciatic nerve through the 22-ga Tuohy needle
214962689|NCT00080015|DRUG|Diflomotecan (BN80915)|
214962690|NCT01878695|DRUG|IV/oral n-acetylcysteine|
214962691|NCT05196425|GENETIC|Blood sampling|Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
214962692|NCT04819438|DRUG|Riluzole 50 mg orodispersible film|Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
214962693|NCT04819438|DRUG|Rilutek® 50 mg riluzole tablets|One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
215080009|NCT05946291|OTHER|Simulated Manneqquin training|Pressure injury training with mulage application on a simulated manneqquin
214354243|NCT06670430|DEVICE|control group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive placebo TENS and NMES for 30-min sessions, 3 days per week, for 10 weeks with medical treatment
214354244|NCT06670066|BEHAVIORAL|Let's Talk Birth Control|Let's Talk is an innovative, multi-level intervention addressing adolescents and providers that includes both in-person and online components and is feasible to implement in clinical settings. The three core components are: (1) a printed contraceptive decision aid (CDA) with a QR code linking to the Method Explorer (ME) page on Power to Decide's online birth control website, Bedsider; (2) the Bedsider ME, with information on the full range of contraceptive methods and a personalized method comparison feature; and (3) an online training for providers on Patient-centered Contraceptive Counseling (PCCC), including use of the CDA to support shared decision-making with adolescents.
214354245|NCT06670807|DIETARY_SUPPLEMENT|Probiotic Arm|Fifty of the participants will consume 1 capsule/day of the dietary supplement AB-MIND+CECT7481 for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the intervention period.
214962694|NCT06154226|DRUG|Pantoprazole|Subjects will receive pantoprazole (40 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on post operative day 1 (POD 1) for a total of 4 doses over 2 days.
214962695|NCT06154226|DRUG|Famotidine|Subjects will receive famotidine (20 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on POD 1 for a total of 4 doses over 2 days.
214962696|NCT05612217|OTHER|to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD|to estimate Sensitivity and Specificity of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD.
214962697|NCT03465709|DRUG|Pegcetacoplan|Study Drug
214962698|NCT00225186|DRUG|Visanne (SH T00660AA , BAY86-5258)|Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
214354246|NCT06670807|OTHER|Placebo|Fifty of the participants will consume 1 capsule/day of the PLACEBO for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the entire intervention period.
214354247|NCT06668974|OTHER|Mendelian Randomization|This study utilizes a bidirectional Mendelian randomization approach to analyze genetic data from individuals with allergic rhinitis and asthma. No active intervention is applied; genetic variants serve as instrumental variables to assess causal associations between the conditions.
214962699|NCT05565170|BEHAVIORAL|Structured ICT-assisted multimodal lifestyle intervention|The structured lifestyle intervention programme, partly tailored and personalised to individual needs, covers the following domains: physical activity, nutrition, cognitive activity, cardiovascular risk management, social interaction, sleep, and relaxation / stress management. The programme includes regular scheduled in-person sessions (group-based + individual) which are supported with independent digital activities in the LETHE App. The App has features such as e.g., a cognitive training programme, on-demand exercise videos, calendar to schedule activities, advice and educational material, group chat, and possibility to set and monitor goals and self-monitor risk factors such as e.g., blood pressure.
214962700|NCT05565170|BEHAVIORAL|Self-guided multimodal lifestyle intervention|Participants are advised to build their own healthy lifestyle programme based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits and through the simplified version of the LETHE app. The control group app does not include any structured / scheduled activities or personalised content.
215080010|NCT02885870|PROCEDURE|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
215080011|NCT02537262|DIETARY_SUPPLEMENT|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM\~MN) the day before the surgery and 200ml three hours before the surgery.
214354248|NCT07126860|BEHAVIORAL|Structured combined resistance and aerobic training|"The 12-week intervention phase comprises the initial 12 weeks of a home-based combined resistance and aerobic training protocol for the intervention arm. Training will commence 8 weeks (when medically cleared, a reduction to minimally 4 weeks is possible) after RP or completion of EBRT, or any time for PC patients undergoing systemic treatment. As part of their visit for baseline testing, participants will be familiarized with the online platform incorporating the training program, including the correct execution of the exercises. In addition, the online platform includes demonstration videos of all exercises.~Detailed information about the training program will be available for patients and investigators via a website and smartphone application. Additionally, participants will receive a printed document explaining the training program, the repetitions in reserve (RIR) scale (Helms et al., 2016), and the online tool/app for tracking."
214487108|NCT06752343|DRUG|Clobetasol|"The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.025 CLO for 8 days~Other Names:~topical steroid administration"
214962701|NCT05359952|BEHAVIORAL|Starting the Conversation|The Starting the Conversation intervention consists of a brief educational video and accompanying workbook with activities to help prepare patients to discuss sexual and menopausal types of health concerns effectively with gynecologic cancer providers, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback. In addition, participants receive a list of sexual and menopausal resources.
214962702|NCT05359952|BEHAVIORAL|Sexual and Menopausal Health Resources Only|A list of resources on sexual/menopausal health both within and outside the institution, including websites.
214962703|NCT03478085|OTHER|Oxygen guided exercise therapy|Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
214962704|NCT04791332|DRUG|JNJ-67953964|JNJ-67953964 capsule will be administered orally.
214962705|NCT04791332|DRUG|Placebo|Matching placebo will be administered orally.
214354249|NCT07126860|BEHAVIORAL|Standard of Care|Participants randomized to the SOC arm will also be informed about the benefits of exercise and motivated to engage in exercise under their own management (self-directed exercise). They will receive a booklet with general information and guidelines about physical activity in prostate cancer patients, but without any specific exercise prescriptions.
214354250|NCT07127640|OTHER|Exercise|An aerobic exercise session on a recumbent exercise bike with a 5-minute warm-up period, followed by a 40-minute cool-down period and ending with a 5-minute cool-down at decreasing speed.
214354251|NCT07127029|DEVICE|Petrolatum coating of fast-absorbing gut suture|6-0 fast absorbing gut suture was coated with sterile petrolatum and a single interrupted suture was placed into the skin of the deltoid
214354252|NCT07126847|DIAGNOSTIC_TEST|Renal Ultrasonography|To investigate the primary and secondary signs of stones with ultrasound and to additionally use the Stone criteria in patients with suspected nephrolithiasis.
214962706|NCT02258659|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214962707|NCT02258659|DRUG|carboplatin|Given IV
214962708|NCT02258659|RADIATION|radiation therapy|Undergo radiation therapy
214354253|NCT06670690|DRUG|Atenolol 50 MG|patients will be premedicated with atenolol (50mg)
214487109|NCT06752395|DIAGNOSTIC_TEST|Transbronchial lung biopsy with radial probe endobronchial ultrasound (Cryobiopsy centered)|When the lung nodule is visualized by bronchoscope using RP-EBUS, cryobiopsy is performed, followed by forceps biopsy.
214487110|NCT06752395|DIAGNOSTIC_TEST|Transbronchial lung biopsy with radial probe endobronchial ultrasound (Forceps biopsy centered)|When the lung nodule is visualized by bronchoscope using RP-EBUS, forceps biopsy is performed, followed by cryobiopsy.
214487111|NCT06753565|DRUG|Carnitine|"It is a nutritional supplement with trade name  Carnitol® in Egypt."
214962709|NCT02258659|DRUG|paclitaxel|Given IV
214487112|NCT06753565|DRUG|Disease-modifying anti-rheumatic drugs|They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .
214962710|NCT02258659|DRUG|fluorouracil|Given IV
214962711|NCT02258659|DRUG|hydroxyurea|Given PO
214962712|NCT02258659|DRUG|cisplatin|Given IV
214962713|NCT02258659|OTHER|laboratory biomarker analysis|Correlative studies
214962714|NCT02258659|PROCEDURE|quality-of-life assessment|Ancillary studies
214962715|NCT04437914|DIAGNOSTIC_TEST|Electrocardiogram diagnosis|Electrocardiographic diagnosis will be made in a double-blind manner by two specialists in cardiology and cardiac arrhythmias and the results will be compared between the groups studied.
214962716|NCT04892446|DRUG|Magrolimab|Administered IV
214962717|NCT04892446|DRUG|Daratumumab|Administered either SC or IV
214678906|NCT01784562|DRUG|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
214678907|NCT01519427|DRUG|Akt inhibitor MK2206|Given PO
214962718|NCT04892446|DRUG|Pomalidomide|Administered orally
214962719|NCT04892446|DRUG|Dexamethasone|Administered orally
214962720|NCT04892446|DRUG|Bortezomib|Administered either SC or IV
214962721|NCT04892446|DRUG|Carfilzomib|Administered IV
214962722|NCT00272844|DRUG|crystalline cholesterol oil-based suspension|200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
214962723|NCT06248307|DIETARY_SUPPLEMENT|Barrita experimental|Nutritional advice, as well as administration of protein bars.
214962724|NCT06248307|DIETARY_SUPPLEMENT|Barrita Placebo|Nutritional advice, as well as administration of placebo bars.
214962725|NCT04120909|DEVICE|Cardiac resynchronization therapy|Biventricular pacing according to current standards.
214962726|NCT04917354|DEVICE|Superb-Microvascular imaging|Device: Superb-Microvascular imaging Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
214962727|NCT00096187|DRUG|pemetrexed disodium|
214962728|NCT05709912|BEHAVIORAL|CARE Application|Self-administered, psychosocial mobile application comprised of 5 learning modules.
214354254|NCT06670690|DRUG|Propranolol Pill|patients will be premedicated with propranolol (10mg)
214354255|NCT06670690|DRUG|Ivabradine|patients will be premedicated with Ivabradine (5mg)
214962729|NCT05709912|BEHAVIORAL|Usual Care|Meeting with transplant social worker prior to HCT, consistent with standard-of-care.
214354256|NCT04797403|BEHAVIORAL|Stepped-care protocol adapted from the SPRINT intensive-treatment algorithm|The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
214962730|NCT01930916|DEVICE|INR capillary measurement with INRatio 2 device|INR capillary measurement with INRatio 2 device
214962731|NCT01930916|OTHER|antiphospholipid antibodies and lupus anticoagulant|Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
214962732|NCT03060291|BEHAVIORAL|FCU-Online, web/ mobile only|Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
214962733|NCT03060291|BEHAVIORAL|FCU-Online, web/ mobile + coach|"Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills."
214962734|NCT05495386|DEVICE|Hyposafe hypoglycaemia notification device (H02)|"The H02 device consists of two parts:~1. An implantable part which records the EEG signal and transmits the signal wirelessly to the external device.~2. The external device receiving signals and storing data from the implant."
214962735|NCT00247520|DRUG|topical nasal rEV131|
214962736|NCT00902759|OTHER|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
214962737|NCT00718094|DRUG|Polyphenon E®|Oral capsules
214962738|NCT00718094|DRUG|Placebo Oral Tablet|Oral tablet: placebo
214962739|NCT02983175|OTHER|ultrasound assessment of gastric content|"Achievement of gastric ultrasound (specific procedure) :~Gastric ultrasound is performed specifically for the study by a senior anesthetist physician in a patient placed supine, semi-sitting by an angle of 45 ° relative to the horizontal.~Standardised achievement of the antral ultrasound by the following method:~* First, a qualitative assessment of antral contents in 3 grades according to the Perlas method \[24\].~* Second, performing a quantitative analysis of antral contents calculating the CSA.~* Then, volume of gastric contents calculation as from the CSA."
214962740|NCT02364687|RADIATION|Computed tomography late enhancement imaging|
214962741|NCT01664702|DIETARY_SUPPLEMENT|Dairy Products|See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
214962742|NCT01664702|DIETARY_SUPPLEMENT|Dairy Servings|Continue baseline consumption of one or fewer servings of dairy per day
214354257|NCT05394103|DRUG|Q901|The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
214354258|NCT05394103|DRUG|KEYTRUDA® (pembrolizumab)|KEYTRUDA® (pembrolizumab) will be administered Q6W
214354259|NCT06045962|DEVICE|Ureteral stent|Used to open the ureter and help the kidney drain
214354260|NCT00127608|PROCEDURE|Collection of clinical samples|"The following samples were obtained from each subject:~* Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~* Papule swabs (PS) from four papules~* Crusts from two lesions~* One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique."
214962743|NCT05128591|DRUG|Rivaroxaban 18mg Oral Tablet|AD-109 (Rivaroxaban 18mg) Oral Tablet
214962744|NCT05128591|DRUG|Rivaroxaban 20 MG Oral Tablet|AD-1091 (Rivaroxaban 20mg) Oral Tablet
214354261|NCT00016133|BIOLOGICAL|BCG vaccine|
214962745|NCT05653947|PROCEDURE|Root canal instrumentation, 2.5% NaOCl irrigation|Root canal instrumentation, 2.5% NaOCl irrigation
214962746|NCT05398796|BIOLOGICAL|mRNA -1215|mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.
214962747|NCT05171270|OTHER|Questionnaire|PsAID questionnaire
214962748|NCT05870150|BIOLOGICAL|Salmonella Typhimurium|Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10\^3 CFU, 1-5x10\^4 CFU, 1-5x10\^5 CFU, 1-5x10\^6 CFU)
214962749|NCT00933985|DRUG|dexrazoxane hydrochloride|Given IV
214962750|NCT00933985|DRUG|doxorubicin hydrochloride|Given IV
214354262|NCT00016133|BIOLOGICAL|autologous tumor cell vaccine|
214354263|NCT00016133|DRUG|fluorouracil|
214354264|NCT00016133|DRUG|leucovorin calcium|
214354265|NCT00016133|PROCEDURE|adjuvant therapy|
214678908|NCT01519427|DRUG|selumetinib|Given PO
214678909|NCT01519427|OTHER|laboratory biomarker analysis|Correlative studies
214678910|NCT02595060|DRUG|inhaled molgramostim (rhGM-CSF)|
214962751|NCT00933985|DRUG|obatoclax mesylate|Given IV
214962752|NCT00933985|DRUG|liposomal vincristine sulfate|Given IV
214962753|NCT00933985|OTHER|pharmacological study|Correlative studies
214354266|NCT06507605|BIOLOGICAL|R21|R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.
214354267|NCT06507605|BIOLOGICAL|Pfs230D1-CRM197|Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.
214962754|NCT00933985|OTHER|laboratory biomarker analysis|Correlative studies
214962755|NCT03925181|BEHAVIORAL|Counselling Group|All sessions will be based off of SAMHSA's recovery curriculum but tailored to the participants recovering from the ICU and their caregivers. Throughout the 6-weeks, the sessions will be holistic, strengths-based, hopeful, respectful, relational, and subjective, while emphasizing social relationships, social contexts, and meaning and purpose.
214962756|NCT06114771|OTHER|strepsilis|Throat lozenge (strepsilis) was given to patients 30 minutes before the operation (the dissolution rate of the lozenge was proven to be 6-9 minutes).
214962757|NCT06114771|OTHER|Placebo|Sugar dragee in the same size and shape was given to 30 patients 30 minutes before the operation. In order not to cause any complications, sugar patients were sucked and told not to chew.
214962758|NCT02033278|DRUG|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
214962759|NCT02033278|DRUG|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
214962760|NCT01556932|DRUG|ABH gel|Given topically
214962761|NCT01556932|OTHER|placebo|Given topically
214962762|NCT06223308|DRUG|HB0028|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).
214962763|NCT06635252|DRUG|STA 4783|Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date
214962764|NCT06351553|PROCEDURE|Pulmonary vein isolation exclusively with radiofrequency|The QDOT (Biosense Webster, Inc.) or TactiFlex (Abbott S.E.) catheters will be used. The ablation will be controlled by temperature, with a limit of 42ºC and a power target of 30-40W. A high-power strategy (90 W/4 seconds) can be used on the posterior wall when the QDOT catheter is used.
214962765|NCT06351553|PROCEDURE|Pulmonary vein isolation exclusively with pulsed field ablation|The Sphere-9 catheter will be used (with biphasic and unipolar wave), with a duration per application of 5 seconds and a separation between lesions of 5-6mm. The target temperature increase will be at least 1.5ºC above the patient's basal temperature to mark the ablation as effective.
215080012|NCT02537262|DIETARY_SUPPLEMENT|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
215080013|NCT01804712|DRUG|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
214354268|NCT06507605|BIOLOGICAL|Pfs230D1-EPA|Recombinant Pfs230D1 conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA)
214354269|NCT06507605|OTHER|Matrix-M|Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.
214354270|NCT05245864|OTHER|blood flow restriction|Blood flow to the legs will be mostly restricted temporarily during physical therapy exercises for the initial several weeks of physical therapy.
214678911|NCT02595060|DRUG|inhaled placebo|formulated as the active substance without molgramostim
214962766|NCT06351553|PROCEDURE|Combined pulmonary vein isolation|"The Sphere-9 catheter will be used for both radiofrequency and pulsed field ablation. When using radiofrequency, the ablation will be temperature controlled, with a target temperature of 73ºC. The duration per application will be 5 seconds. Catheter irrigation during ablation will be 30ml/min, with a maximum current intensity of 3700mA, and a maximum current density of 13.6mA/mm2. The separation between lesions will be 7-8mm. Regarding pulsed field ablation, the characteristics will be those indicated in Pulmonary vein isolation exclusively with pulsed field ablation group."
214962767|NCT00502099|DRUG|Pegylated interferon alpha 2a|Injections: 180 ug once per week
214354271|NCT05245864|OTHER|physical therapy standard of care|the current standard of care after surgery for ACL repair.
214354272|NCT06680674|OTHER|Routine care for people with diabetes, with or without obesity, in the hospital setting|Routine care for people with diabetes, with or without obesity, in the hospital setting, including routine pharmacological treatment for diabetes and obesity.
214354273|NCT05501860|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
214354274|NCT05501860|DRUG|Placebo|Placebo Sterile Topical Ophthalmic Solution
214354275|NCT04640051|PROCEDURE|LAAO|LAAO by use of 3D in silico simulation by FEops HEARTguide as part of the pre-procedural assessment and device size selection
214962768|NCT00502099|DRUG|Ribavirin|Tablets, 1000-1200 daily
214962769|NCT00502099|DRUG|Pegylated interferon alpha 2 b plus ribavirin|Pegylated interferon alpha 2 b injections
214962770|NCT01882803|DRUG|Duvelisib|Phosphoinositide-3-kinase (PI3K) inhibitor
214962771|NCT06002659|BIOLOGICAL|CAR20(NAP)-T|Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP
214962772|NCT06002659|DRUG|Cyclophosphamide|pre-conditioning chemotherapy
215080014|NCT00129870|DRUG|oxaliplatin|
214962773|NCT06002659|DRUG|Fludarabine|pre-conditioning chemotherapy
214962774|NCT04525209|OTHER|No intervention|No intervention
215080015|NCT03933410|DRUG|KB195|KB195 is a novel glycan
215080016|NCT03444766|DRUG|Nivolumab|specified dose on specified days
215080017|NCT00867776|BEHAVIORAL|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
215080018|NCT01162174|DIETARY_SUPPLEMENT|Oligonol|
215080019|NCT01129037|OTHER|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased \< 10% in response to receding VL: SV is optimized, no further VL required.
215080020|NCT01022372|PROCEDURE|Endometrial biopsy|For all the groups
214354276|NCT06632041|DIAGNOSTIC_TEST|Complete blood count|Study haemtological disturbances in neonates with necrotizing enterocolities
214354277|NCT06632041|OTHER|Complete blood count|Haemtological disturbances in neonates with necrotizing enterocolities
214354278|NCT05705687|DRUG|BEP Protocol|anticancer therapy
214962775|NCT00560482|DRUG|ABR-215050, tasquinimod|Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
214962776|NCT00560482|DRUG|Placebo|Identical appearing gelatin capsules containing placebo
214962777|NCT00076401|DRUG|Motexafin gadolinium|
214962778|NCT01563913|DRUG|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
214962779|NCT01563913|DRUG|Placebo|Sugar Pill, taken for 1.5 years
214962780|NCT05552742|OTHER|Conservative rehabilitation|The conservative rehabilitation program includes a patient-specific conservative exercise program comprising exercises that strengthen the paralyzed side, increase joint range of motion and strengthen muscles, stretch spastic muscles, and ensure balance rehabilitation that enhances balance performance and coordination. The patients in both groups received conservative rehabilitation program for 8 weeks, 4 days a week for 1 h.
214962781|NCT05552742|DEVICE|Virtual Balance Training|Virtual balance training program using the Thera-Trainer Balo device was applied 4 times a week for a total of 8 weeks, and each session lasted for 20 min. The center of mass of each patient was determined using sensors and displayed on the screen. The patients were encouraged to move their mass by swiping in all directions via the apple picking game displayed on the screen
214962782|NCT05265832|PROCEDURE|Phacoemulsification|Endocapsular technique (Divide-and-conquer) and supracapsular technique (Subluxation) will be used equally.
214962783|NCT06265909|DEVICE|AmDTx|AmDTx (Mobio Interactive Pte Ltd, Singapore), is an advanced mobile health platform equipped with computer vision and AI to objectively quantify psychological stress and benchmarked ecological momentary assessments to subjectively measure stress, valence, and arousal. Asynchronous and on-demand psychotherapy available as audio files within AmDTx has been clinically validated across the mental illness severity spectrum. Psychotherapy within AmDTx primarily leverages meditation/mindfulness techniques to enhance relaxation, build stress resilience, improve focus and decision making, and influence behaviour and affect bias.
214962784|NCT02021110|DRUG|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
214962785|NCT00000809|BIOLOGICAL|Aluminum hydroxide|
214962786|NCT00000809|BIOLOGICAL|QS-21|
214962787|NCT00000809|BIOLOGICAL|MN rsgp120/HIV-1|
214962788|NCT04730401|BIOLOGICAL|Convalescent plasma from COVID-19 donors|Convalescent plasma from COVID-19 donors
214962789|NCT04730401|BIOLOGICAL|Placebo|200mL saline
214962790|NCT02044562|DIETARY_SUPPLEMENT|nitrate supplementation|A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
214962791|NCT02044562|DIETARY_SUPPLEMENT|Placebo|A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
214962792|NCT03243253|OTHER|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
214962793|NCT00705341|DRUG|fluticasone|Inhaled corticosteroid approved for treatment of asthma
214962794|NCT03942887|DRUG|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
214962795|NCT03942887|DRUG|endoxan|Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
214962796|NCT03942887|DRUG|Methylprednisolone|Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
214962797|NCT03942887|DRUG|Prednisolone|after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
214962798|NCT00417521|BEHAVIORAL|Family-Based Treatment|
214962799|NCT03070275|BIOLOGICAL|Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
215080021|NCT04373408|PROCEDURE|ACL repair without anterolateral repair|Surgical repair of the ACL using semitendinous autograft
214354279|NCT05705687|DRUG|Dose-dense regimen|T-BEP-Oxaliplatin followed by Cisplatin - Ifosfamide - Paclitaxel
214354280|NCT05705687|PROCEDURE|Early tumor resection or HD-CT|TIP protocol + early surgery or high-dose chemotherapy if surgery not feasible or metastatic disease
214354281|NCT07026942|BIOLOGICAL|Universal donor derived CD33 CAR-NK|Universal donor derived CD38KO CD33 CAR-NK manuctured on-site. The NK cells are derived from the peripheral blood of universal donors with desirable HLA/KIR types and CMV status, modified by CRISPR/Cas9 targeting the CD38 locus, using AAV6 vector to insert a CD33-targeted CAR gene into the CD38 locus, and expanded in number.
214354282|NCT06633640|COMBINATION_PRODUCT|Conventional flap with algae-based substitute (AlgOss) combined with collagen membrane.|The graft material will be prepared following the manufacturer instruction, transferred into a sterile cup than the mixture is condensed without overfilling in the intrabony defect to the level of the surrounding bony walls. The filled site will be than covered with collagen membrane.
214962800|NCT03070275|PROCEDURE|Two-stage surgical implant placement|Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
214962801|NCT00005083|PROCEDURE|conventional surgery|
215080022|NCT04373408|PROCEDURE|ACL repair with anterolateral repair|Surgical repair of the ACL using semitendinous autograft, and surgical repair of the ALL using an allograft (Arthrex, Extra-Articular Augmentation device)
215080023|NCT00612547|DRUG|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
214354283|NCT06025526|OTHER|aktivplan|"The aktivplan digital intervention consists of a digital planning calendar for regular heart-healthy physical activity Towards the end of rehabilitation phase II, health professionals introduce aktivplan and plan a personalised physical activity plan together with their patients using shared decision-making. The physical activity plan is devised for the time after discharge from cardiac rehabilitation.~In the aktivplan smatphone app, the patient can view their personalised physical activity plan, check off completed activities, enter additional unplanned activities, and open short videos with exercise instructions.~Additional functions of aktivplan include patient-centered goal-setting, automated messages to the patient (motivational messages and reminders), and the possibility for health professionals to monitor all their patients' adherence to the physical activity plan and to contact individual patients directly via the app."
214354284|NCT06025526|OTHER|Usual care|Usual care (standard of care) according to international and national cardiac rehabilitation guidelines.
214354285|NCT04936282|DRUG|Grafalon|When Borderline lesions are present in protocol biopsy, administer Grafalon ® 6 mg/kg/day in a single day. Then continue with the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day).
214354286|NCT04936282|DRUG|Normal Treatment|When Borderline lesions are present in protocol biopsy, administer the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)
214354287|NCT05467033|DRUG|Desmopressin|desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
214962802|NCT00005083|PROCEDURE|magnetic resonance imaging|
214354288|NCT05467033|DRUG|intravenous infusion NaCl|0,9% NaCl managed as intravenous infusion
214354289|NCT03555331|BEHAVIORAL|Child Safety Control Intervention|In the study period which spanned from early infancy through age 3 years, the child safety intervention group was given an educational program with messages focused on child and home safety, guided by the American Academy of Pediatrics and the Academy's guide for health supervision, Bright Futures. The observation-only study extension will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
214354290|NCT03555331|BEHAVIORAL|Responsive Parenting Intervention|During infancy, the Responsive Parenting group was given an educational program containing messages providing developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle aimed at preventing rapid weight gain in infancy and overweight at age 3 years. The new study period will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
214354291|NCT02546583|DRUG|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
214354292|NCT02546583|DRUG|IV Chlorothiazide|
214962803|NCT00005083|PROCEDURE|magnetic resonance spectroscopic imaging|
214354293|NCT04111445|DRUG|ADG116|IV infusion at Day 1 of each cycle
214354294|NCT06695156|BEHAVIORAL|Meditation|The objective of this study is to assess the safety, feasibility, and effects of the practice of the Transcendental Meditation technique in adults with migraines. This study will involve 30 male and female participants recruited from migraine treatment facilities and migraine support groups in the US. The study will span three months, with all participants practicing Transcendental Meditation (TM) while continuing their usual lifestyle and medication regimen. Pre-data will be collected through symptom analysis, headache patterns, and evaluation questionnaires. All potential subjects will use a migraine App for 30 days prior to inclusion in the study, both as a means of assessing migraine status and of ability to adhere to study protocols during the study. In addition, all subjects will take the PHQ-9 to screen for levels of depression that might impair participation in the study. All the subjects will receive TM instruction, followed by bi-weekly
214354295|NCT04146376|OTHER|Use of a postpartum diary and additional blood draws|"A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
214354296|NCT04146376|DRUG|VWF replacement therapy with Wilate|This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are \<100% in the third trimester of pregnancy
214354297|NCT04146376|DRUG|Tranexamic acid|This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
214354298|NCT04146376|OTHER|Use of a postpartum diary and additional blood draws.|"A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
214354299|NCT07127939|DIAGNOSTIC_TEST|AI-based Ocular Diagnosis Model for TCM Constitutions|AI-based Ocular Diagnosis Model for Identifying Traditional Chinese Medicine (TCM) Constitutions
214962804|NCT01625442|DRUG|Saffron tablet|Saffron tablets 100 mg
214962805|NCT01625442|DRUG|Barberry tablet|Barberry tablets 200 mg
214962806|NCT01625442|DRUG|Placebo|Placebo tablets received daily for 45 days
214962807|NCT06078644|OTHER|respiratory exercise diary|Patients in the intervention group will be asked to perform breathing exercises in the form of using a spirometer 10 times every hour during the preoperative period while they are awake for three days, starting from the first day after the surgery. Patients in this group will be given a breathing exercise diary.
214962808|NCT03887585|PROCEDURE|Achilles tendon lengthening|Achilles tendon lengthening by triple hemisection for Achilles tendon contracture
214962809|NCT00845273|DRUG|Pegaptanib sodium|"Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )."
214962810|NCT05777837|PROCEDURE|laparoscopic repair of cesarean scar niche|Intentional perforation of the niche will be done using uterine sound and excision of the fibrotic edges then suturing the uterine incision using 2-0 absorbable suture.
214962811|NCT05777837|PROCEDURE|Combined hysteroscopic and laparoscopic repair of cesarean scar niche|Hysteroscopic resection of the niche under laparoscopic guide will be done to avoid perforation of the niche. After completion of the hysteroscopic approach, laparoscopic plication of the niche without opening it will be done using multiple interrupted 2-0 absorbable suture.
214962812|NCT02412397|PROCEDURE|Total Shoulder Arthroplasty|
214354300|NCT07127458|DRUG|Adolescent PCOS group receiving oral contraceptives|Participants diagnosed with polycystic ovary syndrome (PCOS) during adolescence will receive a combined oral contraceptive (ethinylestradiol 30 µg + drospirenone 3 mg) once daily for six consecutive months. The intervention aims to regulate menstrual cycles, reduce hyperandrogenic symptoms, and evaluate changes in anxiety and depression scores over time.
214354301|NCT07128017|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (Internet-delivered)|A 4-week (30 days), unguided online adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program. The intervention consisted of six sequential modules delivered through a secure web platform, including guided mindfulness meditations, body scan, mindful movement, and cognitive-behavioral exercises. Participants received audio recordings, written materials, and reflective tasks, along with automated reminder emails. No therapist guidance was provided.
214962813|NCT05783947|DIAGNOSTIC_TEST|Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera|Sera and/or CSF samples are drawn from patients with a clinical suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome. Indirect immunofluorescence assays will be performed on commercial and in-house slides upon receipt in our center. In case of positive staining, additional tests such as cell-based assays, western-blots, ELISA or immunodots can be performed.
214962814|NCT00791700|DRUG|Maraviroc|Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
214962815|NCT05926843|PROCEDURE|Spinal cord stimulation surgery (device) and motor rehabilitation|The first part of the study will involve a preoperative evaluation. Participants' clinical history, neurological, neurophysiological and advanced brain/spine MRI examination will be assessed (Part 1). Subsequently, participants will undergo spinal cord stimulation surgery which involves the implantation of a medical device (Part 2). After the surgery, the research participants will be hospitalized at the Neurosurgery Unit (10 days) to monitor the incision site (Part 3). Thereafter, the patients will be moved (for at least 6 weeks) to the Rehabilitation Unit in order to identify appropriate stimulation parameters for inducing stepping and standing and for starting training. The combination of epidural stimulation with manual step/stand training will be thus evaluated (Part 4). Patients will be finally assessed by clinical evaluation, advanced MRI and neurophysiological examination to study the brain, spine and peripheral functions after six months (Part 5).
214962816|NCT06494592|BEHAVIORAL|Aerobic Exercise|Participants in the aerobic exercise intervention group will engage in a virtual aerobic exercise intervention three times a week for 12 weeks for a 30-minute session (5 minute warm up, 20 minutes of aerobic exercise, 5 minutes cooldown) and will receive information about the session prior to their appointment. Sessions have a goal of reaching at least 20 minutes of supervised exercise performed at 80% of the heart rate at symptom threshold.
215080024|NCT04504890|DEVICE|EYE-SYNC|Nystagmograph used to measure eye movement
215080025|NCT06534229|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine-needle aspiration|Endoscopic ultrasound-guided fine-needle aspiration for biopsy
214354302|NCT07128017|BEHAVIORAL|Progressive Muscle Relaxation (Internet-delivered)|A 4-week, unguided online progressive muscle relaxation (PMR) program adapted from Bernstein and Borkovec's protocol. The program included six sequential modules teaching systematic tensing and relaxing of major muscle groups, gradually reducing the number of groups until relaxation could be achieved through recall alone. Materials included audio recordings, written instructions, and automated reminder emails. No therapist guidance was provided.
214962817|NCT06494592|BEHAVIORAL|Balance Exercise|Participants in the balance exercise intervention group will participate in a staff-led virtual session three times a week for 12 weeks for a 30-minute session and will receive information about the session prior to their appointment. This group will focus on improving balance, with some additional work on flexibility and strength.
214962818|NCT05024656|OTHER|AmnioExcel Plus Amniotic Membrane|AmnioExcel® Plus will be applied weekly, in conjunction with SOC, if the ulcer remains open, or up to and including Week 11, whichever comes first.
214962819|NCT05024656|OTHER|Standard of Care|The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.
214962820|NCT05007626|OTHER|axial length and refractive error|Comparing the correlation between heterophoria and refraction, even after age adjustment.
214962821|NCT01472822|DIETARY_SUPPLEMENT|Omija extract.|Omija extract 1.2g/day for 12weeks
215080026|NCT01890395|OTHER|Blood draws|Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
215080027|NCT02274272|OTHER|ADR-1|two ADR-1 capsules, once daily, QD
215080028|NCT02274272|OTHER|GMNL-263|two GMNL-263 capsules, once daily, QD
215080029|NCT02274272|OTHER|placebo|two placebo capsules, once daily, QD
215080030|NCT02779907|OTHER|No Intervention|No interventions planned for this observational study
215080031|NCT01409083|DEVICE|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
215080032|NCT03524287|PROCEDURE|Robotic Assisted No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
214354303|NCT07128017|BEHAVIORAL|No Intervention - Waitlist Control|Participants in this arm received no active intervention during the 4-week waitlist period but completed all study assessments on the same schedule as intervention arms. After the waiting period, participants were offered the choice to take part in either the online MBCT or PMR program.
215080033|NCT00420810|DRUG|MK0928 / Duration of Treatment : 8 Weeks|
215080034|NCT04804631|DEVICE|Enteral feeding tubes|Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
215080035|NCT02281487|PROCEDURE|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
215080036|NCT02281487|PROCEDURE|Hysterectomy|standard hysterectomy
214354304|NCT07128004|DEVICE|tDCS|would provide direct current for 40 minutes in 20 minute interval at 2 mA
214354305|NCT07128004|DEVICE|sound therapy|would provide acoustic ripples along with tDCS
214354306|NCT06741449|PROCEDURE|keystone flap|facio-cutaneous flap used to cover the defect after removal of the disease
214354307|NCT06741449|PROCEDURE|lay open|after removal of the disease, the wound is left open to heal by granulation tissue
214354308|NCT06741202|BEHAVIORAL|Men's MST Group|see above
214354309|NCT06741202|BEHAVIORAL|Present-Centered Group Therapy|see above
214354310|NCT06511921|BIOLOGICAL|early biologic therapy|biologic therapy for perforated Crohn's disease in the early postoperative period
214354311|NCT06511921|BIOLOGICAL|late biologic therapy|no biologic therapy for perforated Crohn's disease up to 2 to3 months in the post operative period
214354312|NCT06713603|BEHAVIORAL|TAMI Coach|The investigators address the problems of intrinsic motivation, Evidence Based Practice (EBP) education, and referral tailoring using a digital-coaching intervention that 1) promotes readiness to change, 2) educates and builds confidence about EBP's, and 3) creates a tailored quit plan sensitive to social obstacles and needs.
214962822|NCT01472822|DIETARY_SUPPLEMENT|Placebo|Placebo 1.2g/day for 12weeks
214962823|NCT03426943|BIOLOGICAL|Arterial blood sampling|All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels
214962824|NCT03426943|BIOLOGICAL|Ultrafiltrate sampling|All patients will have ultrafiltrate sampling to assess cytokine levels
214962825|NCT03426943|DEVICE|CVVH using oXiris™ filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter
214962826|NCT03426943|DEVICE|CVVH using PrismafleX HF1400 filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter
214962827|NCT05767346|DRUG|Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)|Aficamten (CK-3773274) tablets administered orally
214962828|NCT05767346|DRUG|Placebo to match aficamten|Placebo for aficamten (CK-3773274) administered orally
214962829|NCT05767346|DRUG|Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)|Metoprolol succinate tablets administered orally
214962830|NCT05767346|DRUG|Placebo to match metoprolol succinate|Placebo for metoprolol succinate administered orally
214962831|NCT00205660|OTHER|Stayers|Participants remain on their current antipsychotic.
214354313|NCT07062042|BEHAVIORAL|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a short-term, trauma-focused intervention developed for individuals exposed to multiple traumatic events, including refugees and survivors of war and organized violence. It is grounded in principles of cognitive-behavioral therapy and testimonial therapy. NET helps adults reconstruct a coherent narrative of their life by integrating fragmented traumatic memories through structured exposure within a chronological autobiographical framework. Core components include lifeline construction, imaginal exposure to traumatic events, and reprocessing of emotional responses. The method emphasizes stabilization through therapeutic structure and is supported by evidence from randomized controlled trials showing reductions in PTSD symptoms. The approach is protocol-driven and applicable in low-resource settings under supervision, as outlined in the practice document.
214354314|NCT06873360|OTHER|Clinical interviews with patients and Usability interviews and glove testing.|"Clinical interviews with patients: These will be conducted by nursing staff with an approximate total of 50 patients during their treatment at the Hospital. Each interview will last 15 minutes. Under no circumstances will the patient be required to answer any question.~Usability interviews and glove testing: 10 patients selected from the previous interviews will test different gloves with various textures and levels of stiffness. Additionally, other questions will be asked focusing on refining the design. This evaluation will help determine the most suitable materials for the device's manufacturing, achieving a balance between comfort, discretion and functionality."
214354315|NCT06887036|DRUG|Methylene Blue|"Subjects will be initially treated with an initial dose of 200mg/day for 8 weeks at which point the investigators will assess the effect of the treatment.~Those patients that obtain a complete response will continue their treatment up to a total of 24 weeks with the same dose. Those who do not reach a complete response will be exposed to the next higher dose of 400mg/day for the following 8 weeks and the investigators will then again assess the effect of the treatment.~Those patients that obtain a complete response will continue their treatment up to a total of 24 weeks with the same dose. Those who do not reach a complete response will be exposed to the next higher dose of 600mg/day for the following 8 weeks and the investigators will then assess the effect of the treatment."
214354316|NCT06877715|OTHER|psychological and sensorial tests|children receive questionnaires and sensorial test
214487113|NCT06756061|DRUG|Prednisone + Jakavi(ruxolitinib)|"The experimental group will receive ruxolitinib 10 mg orally twice daily (BID) and prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease. (However, after the 48-week mark, participants in the ruxolitinib treatment group may continue to receive ruxolitinib for an additional maximum of 2 years, based on the investigator's judgment regarding the need for ongoing treatment. The total duration of ruxolitinib administration will not exceed 3 years.)"
214962832|NCT00205660|OTHER|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
214962833|NCT04873635|OTHER|Implant support prostheses|Implant support prostheses was provided to restore the missing teeth and tissues removed due to pathological jaw lesions
214962834|NCT03821766|DEVICE|Ballistocardiography and seismocardiography|SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
214962835|NCT05714540|DRUG|Ketamine Hydrochloride ,Magnesium sulphate and saline 0.9%|The Effect of Oropharyngeal Pack Soaked with Ketamine or Magnesium Sulphate on Post Operative Sore Throat after Nasal Surgeries
214962836|NCT03672344|DEVICE|Lookware TM|Lookware TM is a computer-based video game that requires the subject engage in social skills related exercises that include certain visual behaviors. These exercises combine techniques from applied behavior analysis (ABA) and use of gaze-contingent eye tracking technology during simulated social interactions with 3D animated characters to target certain social skills deficits in children with autism spectrum disorder (ASD). The game is delivered through a laptop computer, eye tracker, and game controller.
214962837|NCT03672344|DEVICE|Lookware TM Control Module|Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises. The game is delivered through a laptop computer, eye tracker, and game controller.
214962838|NCT03958110|DIAGNOSTIC_TEST|OCT A|OCT (Optical Coherence Tomography) and Retinophotography made at the beginning and end of the Rugby season.
214487114|NCT06756061|DRUG|Prednisone|"The control group will receive prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease."
214354318|NCT06140121|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
214487115|NCT06754605|BIOLOGICAL|SCTV02|Participants will receive a singe dose of SCTV02 on Day 0.
214487116|NCT06754605|BIOLOGICAL|Placebo|Participants will receive a singe dose of Placebo on Day 0.
214962839|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
214962840|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
214962841|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
214962842|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
214962843|NCT01720524|DRUG|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
214962844|NCT01720524|DRUG|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
214962845|NCT00996034|BIOLOGICAL|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
214962846|NCT00996034|RADIATION|[123I]5-IA-85380|up to 10 mCi of \[123I\]5-IA-85380, I.V. on each of two SPECT Scan days
214962847|NCT00996034|DRUG|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
214962848|NCT03508180|BEHAVIORAL|INTERVIONNAL|"Foot reflexology session (30 minutes) each course of chemotherapy (total 4 courses) during the 4 hours following the first 2 hours of injection + auto-massage done by the patient between each course.~During a session focused on the treatment of nausea / vomiting, the reflexologist will stimulate the reflex zones related to the digestive system in order to calm and stimulate all areas for deep relaxation of the patient."
214962849|NCT03508180|OTHER|CONTROL|None intervention.
214962850|NCT00670722|DRUG|insulin aspart|Intervention at the discretion of the physician
214962851|NCT00670722|DRUG|insulin detemir|Intervention at the discretion of the physician
214962852|NCT00670722|DRUG|biphasic insulin aspart 30|Intervention at the discretion of the physician
214962853|NCT01602497|DEVICE|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
214962854|NCT01602497|DEVICE|sham rTMS|Patients will undergo ten session of sham rTMS.
214962855|NCT02493452|DRUG|Plecanatide|
214962856|NCT02493452|DRUG|Placebo|
214962857|NCT02371902|DEVICE|MODULITH® SLK, STORZ MEDICAL AG, Switzerland|Three sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2, depending on the maximum tolerated pain of each patient. Analgesics or local anaesthetics were not administered before, during or after treatment.
215080037|NCT02281487|DEVICE|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
214354319|NCT06140121|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
214487117|NCT06755138|OTHER|Observational Assessment|This study includes the use of surface electromyography (sEMG), video analysis, and questionnaires to assess trunk compensation patterns and their relationship with scoliosis, functional, quality-of-life, and pain parameters
214487118|NCT06753643|OTHER|The IMPACTFrail programme|The IMPACTFrail programme
214487119|NCT06755892|DIETARY_SUPPLEMENT|ColMSM-HL|Participants will test continuous administration of investigational product for 16 weeks.
214487120|NCT06755892|DIETARY_SUPPLEMENT|Placebo syrup|Participants will test continuous administration of placebo product for 16 weeks.
214487121|NCT06755892|DIETARY_SUPPLEMENT|ColMSM-LH|Participants will test continuous administration of investigational product for 16 weeks.
214487122|NCT06755892|DIETARY_SUPPLEMENT|ColMSM-LL|Participants will test continuous administration of investigational product for 16 weeks.
214487123|NCT06755892|DIETARY_SUPPLEMENT|Col-L|Participants will test continuous administration of investigational product for 16 weeks.
215080038|NCT05105282|PROCEDURE|Two different blocks with same local anesthetic volume|Deep serratus anterior block and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
215080039|NCT03749096|DRUG|Intravenous Immunoglobulins, Human|Immunoglobulins are fractionated blood products made from pooled human plasma.
215080040|NCT03749096|DRUG|Placebos|Normal Saline
215080041|NCT03317093|DRUG|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
215080042|NCT03317093|OTHER|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
215080043|NCT01310179|GENETIC|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
215080044|NCT06241001|OTHER|eccentric streching|The player will lift up one leg from starting position so he stands on his to-be-trained leg. For performing eccentric exercises of the gastrocnemius muscles, the player will lower his heel until he will feel a slight stretch, while keeping his knee extended
214354320|NCT07074444|DRUG|Albendazole|Participants receive albendazole tablets orally at a total daily dose of 10 mg/kg for 7 consecutive days. The daily dose will be administered in two divided doses. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.
214962858|NCT02371902|DEVICE|Cryoultrasound™, Medisport S.r.l., Italy|Cryo-US therapy was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each. The treatment was performed in 3 weeks (4 daily sessions per week).
214962859|NCT03256357|BEHAVIORAL|Constraint-induced movement therapy|In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
214962860|NCT03256357|BEHAVIORAL|Action observation training|Action observation training consists of 15 sessions of 1 hour. Children watch 3 minute video clips of unimanual goal-directed actions followed by 3 minutes of execution of the actions.
214962861|NCT03256357|BEHAVIORAL|Placebo observation training|Placebo observation training consists of 15 sessions of 1 hour. Children perform the same actions as the AOT training after watching computer games without biological movements.
214962862|NCT00158262|DRUG|Propranolol|Propranolol short-acting or long-acting capsule
214962863|NCT00158262|DRUG|Placebo|Placebo-matching propranolol short-acting or long-acting capsule
214962864|NCT00527826|DRUG|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
215080045|NCT06241001|OTHER|IASTM|Specially designed tools are used to apply longitudinal pressure along muscle fibers, and treatment usually includes applying to more than the tissues in the isolated location of the pain
215080046|NCT04175522|DRUG|Immunoglobulin G|IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
215080047|NCT04913181|DIAGNOSTIC_TEST|Artificial intelligence sepsis prediction model|The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.
214354321|NCT07074444|DRUG|Tribendimidine|Patients receive tribendimidine enteric-coated tablets orally at 0.4 g once daily (QD) for 3 consecutive days.
214354322|NCT07074444|DRUG|praziquantel|Participants receive praziquantel tablets orally at 25 mg/kg per dose, three times daily (TID) for 2 consecutive days. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.
214487124|NCT06753929|DEVICE|wireless wearable thermal anisotropy measurement device|non-invasive device used for assessing CSF shunt flow via thermal anisotropy measurements in a routine outpatient clinic setting
214487125|NCT06755385|OTHER|Pleuropulmonary ultrasound|pleuropulmonary ultrasounds performed at D0, between D2 and D5 during hospitalization and at D-1 on discharge
214962865|NCT00527826|DRUG|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
214962866|NCT02332941|DRUG|Rituximab|The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
214962867|NCT00156026|PROCEDURE|loop electrosurgical excision procedure (LEEP)|1\. loop electrosurgical excision procedure
214962868|NCT03628378|DEVICE|Verasense|Ligamentous balancing device
214962869|NCT04769232|DEVICE|EG-760Z endoscope by Fujifilm|"Within a single endoscopic procedure under propofol sedation, images of the esophageal wall will be acquired and biopsies will be taken. All patients will be examined using the EG-760Z endoscope by Fujifilm.~In all patients as part of the clinical routine 4 biopsies of the proximal and 4 biopsies of the distal esophagus will be taken."
214962870|NCT00182741|DIETARY_SUPPLEMENT|calcitriol|
214962871|NCT00182741|DRUG|mitoxantrone hydrochloride|
214962872|NCT00182741|DRUG|prednisone|
214962873|NCT05463497|DRUG|Treatment A|JW0201: single administration, Tablet, Oral, BID for 5 days
214962874|NCT05463497|DRUG|Treatment B|C2103: single administration, Tablet, Oral, BID for 5 days
214962875|NCT05463497|DRUG|Treatment C|JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days
214962876|NCT05463497|DRUG|Treatment D|C2104 : single administration, Tablet, Oral, QD for 5 days
214962877|NCT05463497|DRUG|Treatment E|JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days
214962878|NCT02105285|DRUG|OPC-1085EL ophthalmic solution|
214962879|NCT02105285|DRUG|Carteolol long-acting ophthalmic solution|
214962880|NCT02383901|DRUG|Methotrexate|The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
214962881|NCT01779063|BEHAVIORAL|web based multimedia intervention|cognitive therapy based web intervention
214962882|NCT01779063|OTHER|educational booklet|patient education booklet
215080048|NCT00832130|DEVICE|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
215080049|NCT00832130|DEVICE|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
215080050|NCT02460783|OTHER|Boost (R) 5-2 diet|Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
215080051|NCT02460783|OTHER|Healthy Living Diet|Counseling and educational material on diet portion, consistency
214354323|NCT07075315|DRUG|Umbilical cord Mesenchymal stem cell|ucMSC 1 million/kg will be given once a week for 4 week . 250 ml normal saline will be infused 30 minutes prior to ucMSCs infusion. The fresh ucMSCs will then be infused through IV canula peripherally over 30 minutes followed by a further 250 ml normal saline over 20-30 minutes.
215080052|NCT04127357|PROCEDURE|1450 ppm fluoride toothpaste brushing x Resin sealing (FluroShield, Dentsply, Brazil).|"After randomization of the children, the selected molars were allocated through a randomized sequence list in 2 groups: A. Brushing with 1450 ppm fluoride toothpaste, donated by the researcher; B. Resin Sealing (FluroShield, Dentsply, Brazil).~The teeth included in the second group (group B) underwent a second randomization: B1. With absolute isolation; B2. With relative isolation. For the group with absolute isolation, topical anesthesia and local papillary infiltration were performed for subsequent staple placement. Relative isolation was performed with cotton rollers and moisture control suction. The sealant selected was the opaque fluroshield to facilitate visualization upon visual examination during reevaluations and was applied following the manufacturer's standards. The teeth were clinically and radiographically followed at 6 and 12 months and two sessions of motivation reinforcement were performed through video and brush change at 3 and 9 months."
214962883|NCT06152380|OTHER|Knee Care @Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
214962884|NCT04716374|OTHER|Tumor molecular profiling|Tumor tissue processing and all NGS genotyping were performed at the Laboratory of Molecular Oncology (Hellenic Foundation for Cancer Research / AUTH). Paraffin H\&E sections from the retrieved tissue blocks were centrally reviewed for tumor histology and tissue adequacy for DNA extraction and were marked for macrodissection along with tumor DNA content \[(former tumor cell content (TCC%)\] assessment. DNA was extracted from macrodissected tissue fragments with the QIAamp® DNA mini kit (Qiagen, Hilden, Germany), measured in a Qubit fluorometer (Thermo Fisher Scientific, Paisley, UK), and genotyped with NGS in an Ion Torrent Proton sequencer (Thermo Fisher Scientific) by using a previously published custom panel (Kotoula, Lakis et al. 2019). Following stringent variant quality filtering (Kotoula, Chatzopoulos et al. 2021), 500 tumors
214962885|NCT01421641|DRUG|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle
214962886|NCT01421641|DRUG|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
214962887|NCT01727817|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
214962888|NCT05221697|DEVICE|PRESAGE CARE|Participants in this arm will be followed by HCA and might benefit from Nurse health interventions
214962889|NCT01881607|BEHAVIORAL|RESPIRNET Program|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
214962890|NCT00883415|DRUG|Darbepoetin alfa|Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
214962891|NCT05289388|DIAGNOSTIC_TEST|Lactate/CRT index|index will be calculated as the product of multiplying the CRT and serum lactate
214962892|NCT04002726|OTHER|Inter-grader agreement (IGA) app|A smartphone-based app with images of conjunctivae for trachoma grading training purposes.
215080053|NCT06276452|BEHAVIORAL|Psychoeducation|Psychoeducation is the therapeutic management of illness through the increase of related knowledge, skills, and motivation.
215080054|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
215080055|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
214354324|NCT07075315|DRUG|Steroid|Prednisolone 40 mg once daily for 7 days as inpatients. After that Lille score will be calculated on day 7. Responders (Lille score \< 0.45) will be continued on steroids for a total of 4 weeks, followed by 2 weeks oftapering before stopping the therapy. In patients who were non responsive to steroids (Lille score \> 0.45) at day 7, steroids will be stopped at day 7 and will receive only SMT.
214354325|NCT07075315|OTHER|Standard Medical Treatment|All patients will receive the standard medical treatment.
214354326|NCT07079241|OTHER|Naloxone-responder: A volunteer first responder system connected to emergency dispatch service and alerting overdose and first aid educated volunteers with naloxone to suspected opioid overdoses|The model is a smartphone-based alert system with an app which is connected to dispatcher centers. Volunteer first responders will be alerted in addition to standard emergency medical service (like ambulance) to suspected opioid overdoses and also cardiac arrests. The aim is to see if volunteers equipped with naloxone and with up-do-date knowledge of overdose treatment and first aid can arrive and reverse the condition safely prior to emergency service arrival.
214678912|NCT02540174|PROCEDURE|integrated addiction treatment program|"At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program."
214354327|NCT06822998|DRUG|HF50|HF50 is a liposomal T-cell engager with an unique design based on the lipid bilayer. It was also named a T cell Redirecting Antibody Fragment-anchored Liposomes (TRAFsome). The liposomal surface carries anti-CD3ε and anti-HER2 antibody-conjugated lipid molecules, enabling T-cell redirection and activation at HER2-positive or HER2-low tumor sites. In addition, the liposome internal space contains a TLR7/8 agonist Resiquimod (R848), which has been shown to help modulate the myeloid cells in the tumor micro-environement to complement the immune activation effects.
214354328|NCT06573970|DRUG|Atomoxetine|Atomoxetine is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD), and executive dysfunction. Dispensing of blinded medication (40mg to 80mg ATX or placebo) will begin at randomization and will be dispensed at weeks 2, 4, 8, and 12. The initial dose of ATX is 40mg or placebo and will be given for one week, the dose will be titrated to 80mg if tolerated in the second week through week 12.
214354329|NCT06573970|DRUG|Placebo|placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
214354330|NCT07086482|COMBINATION_PRODUCT|Cyanoacrylate tissue adhesive|Cyanoacrylate tissue adhesive is a chemical synthetic and hybrid tissue sealant possessing strong, rapid acting adhesive properties and is often used in general surgery. Recently, cyanoacrylate tissue adhesive has been effectively introduced into dentistry to close wounds and stop ischemic areas from forming in periodontal aesthetic surgeries. As well as in exposed membranes to preserve the bone graft after guided bone regeneration, in post-extraction sockets, and to seal any surgical flap. This material has strong hemostatic, bacteriostatic, and sealing qualities.
214354331|NCT07086482|DEVICE|Collagen sponge|Collagen sponge is an organic polymer that promotes the development of blood clots, and it resorbs quickly and completely over time. Collagen sponge create a matrix at the bleeding site, encourage platelet activation and aggregation, and engage the extrinsic coagulation pathway. Thus, it can be utilized as the first choice for wound healing.
214354332|NCT07086742|DEVICE|Smart Mask V1 System|PPG-based sensors integrated into a PAP-compatible face mask to measure SpO2 and PR.
214354333|NCT07085754|BEHAVIORAL|Sleep Deprivation|Sleep deprivation for up to 24 hours with no naps or other sleep periods
214354334|NCT07085000|OTHER|No Intervention - Observational Assessment|No intervention is applied. Preoperative cognitive status (MoCA) and physical frailty (CFS) are assessed as part of observational data collection. Postoperative follow-up includes decision satisfaction and adherence evaluations.
214354335|NCT07084779|DEVICE|AI|"Following the completion of a pre-biopsy prostate MRI, the radiologist will interpret the MRI. Once interpreted by the radiologist alone, the radiologist will interpret the scan while aided by AI. A systematic biopsy in conjunction with radiologist-identified targets will be completed per standard of care, with the optional inclusion of up to 2 AI-detected targets.~When completing a biopsy per SOC, the prostate is divided into quadrants. In addition to noted targets, samples are taken systematically from each quadrant. If targets are detected by AI that were not identified by the physician when reviewing the MRI, these targets will be sampled. Sampling of these targets will not be in addition to the systematic sampling in each quadrant, but in place of up to two of the samples biopsied systematically"
214962893|NCT03894709|BEHAVIORAL|family-centered care model|Teaching and training family caregivers to enhancing their skills for providing care for hip-fractured older persons The content of teaching material provided including management of wound, nutritional and balanced diet, rehabilitation exercises, home environment and behavioral problems after a hip surgery
214962894|NCT04530929|DIETARY_SUPPLEMENT|SANPROBI BARRIER|Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
214962895|NCT04530929|DIETARY_SUPPLEMENT|PLACEBO|Competitors used placebo for three months at a dose of 2x2 capsules daily.
214962896|NCT05691413|OTHER|Other: Product X facial cleanser|Product X facial cleanser contain olive oil, virgin coconut oil, butylene glycol and hyaluronic acid
214962897|NCT03541148|DIETARY_SUPPLEMENT|Oncoxin-Viusid|Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.
214962898|NCT04691219|DIETARY_SUPPLEMENT|Mulberry leaves powder|Dried powder of mulberry leaves crude extract containing 12 mg of DNJ will be packed in a sealed packet with light and moisture protection. Participants will be instructed to mix 1 packet of the powder with a half glass (approximately 120 mL) of plain water and ingest thrice daily before meals. Additionally, they will be informed to rinse the glass with more water and drink to ensure that all of the powder will be taken.
214962899|NCT04691219|BEHAVIORAL|Diet control|Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
214962900|NCT01945346|DRUG|PRX167700|Oral capsule
214962901|NCT01945346|DRUG|Placebo|Oral capsule
214962902|NCT04538469|OTHER|COVID visitation restrictions|Visitation to patients in hospitals in Scotland was ceased due to the COVID 19 pandemic. Slow reintroduction of visitors has been introduced, however not to the pre COVID 19 levels. This study will examine the effects of these restrictions on patients in the cardiothoracic critical care unit that do not suffer from COVID 19.
214354336|NCT05763420|DEVICE|AH Plus Bioceramic Sealer|A bioactive, calcium silicate-based sealer will be used in combination with the core root canal filling material (gutta-percha). It's premixed and is dispensed in the root canal via a fine disposable syringe.
214354337|NCT05763420|DEVICE|AH Plus Sealer (resin-based)|A resin-based sealer will be used in combination with the core root canal material (gutta-percha). It consists of two pastes that are mixed together in equal amounts prior to application.
214354338|NCT06904079|OTHER|Gamified Digital Rehabilitation|The gamification intervention measures are as follows: Currently, the initial version of the community mental health rehabilitation interactive game mainly focuses on six dimensions of medication management, including the importance of taking medication, identifying and dealing with adverse reactions to antipsychotic drugs, learning self-management of medication, assessing the effectiveness of medication treatment, long-term management of medication treatment, and discussing issues related to medication effects with medical staff. Next, we will continue to design a series of games themed on symptom management and psychological rehabilitation, and implement game-based digital rehabilitation interventions for patients in the intervention group based on these games.
214354339|NCT06904079|BEHAVIORAL|Routine Care|Receive regular psychiatric medication treatment and regular community rehabilitation services, including regular follow-ups, rehabilitation guidance, and community education,etc.
214354340|NCT06888102|DRUG|Neoadjuvant Epigenetic Therapy|Participants will be assigned to receive one of the study interventions and will be monitored for safety and response. The duration of epigenetic therapy will be dependent on the treatment administered and will continue for the duration described in the cohort appendix for each respective combination, unless the participant: is no longer clinically benefiting (NLCB, as evidenced by symptomatic or radiographic disease progression and/or clinical deterioration); experiences any toxicity meeting specified discontinuation criteria (as described in the cohort appendix for each respective combination) or unacceptable toxicity in the best clinical discretion of the treating physician (i.e., Investigator discretion); reaches the maximum duration of study intervention; or withdraws consent.
214354341|NCT06668350|OTHER|Smoking outcomes|Participants will be assessed on several smoking outcomes including puffing behavior, subjective effects, and exhaled carbon monoxide
214354342|NCT07082283|PROCEDURE|Pacing Protocol for Pacing Group|"At four standardized time points (H0: arrival in the ICU, H6, H12, H24), a transient pacing sequence at 70, 80, and 90 bpm is conducted, with each rate applied for 10 minutes to allow stabilization, followed by recording of the hemodynamic profile and blood pressure, as follows:~* If the patient has a spontaneous rhythm between 50 and 69 bpm, measurements are taken at the spontaneous rate, then at 70 bpm, 80 bpm, and finally 90 bpm~* If the patient has a spontaneous rhythm between 70 and 79 bpm, measurements are taken at the spontaneous rate, then at 80 bpm, and finally at 90 bpm~* If the patient has a spontaneous rhythm between 80 and 89 bpm, measurements are taken at the spontaneous rate, then at 90 bpm~* If the patient has a spontaneous rhythm ≥ 90 bpm, measurements are taken at the spontaneous rate only"
214487126|NCT06738810|DIAGNOSTIC_TEST|Fibrotest-actitest/NASHtest|A blood sample will be collected from the patient in order to do Fibrotest-actitest/NASHtest and to calculate the NAFLD fibrosis score
214487127|NCT06763354|RADIATION|Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection|On the examination bed, the patient was placed in the lying truncated position, the perineum was disinfected with a towel, and a double-lumen urinary catheter was inserted via the perineum.Inject 50ml saline to clean the bladder once, open the drainage bag to drain.1mci SGC8 was dissolved in 50ml physiological saline. The drainage bag was clamped shut and 50ml of developer was injected into the bladder through the catheter, followed by 10ml of gas or saline (all developer in the ureter was injected into the bladder. The catheter was closed for 1 hour, during which time the patient was placed in the flat position, left lateral position, right lateral position, and supine position changing positions every 15 minutes.After 1 hour, the drainage bag was opened, the bladder was emptied with radioactive fluid, and the urine bag was replaced.
214962903|NCT03860298|DEVICE|NaviFUS System|Using NaviFUS System treatment for 10 minutes in drug resistant epilepsy. The site of the NaviFUS exposure is where the future surgery will be removed. Patients will concomitant use of anti-epileptic drugs (AEDs).
214962904|NCT01048853|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping with sentinel lymph node biopsy
214962905|NCT01048853|OTHER|Quality-of-Life Assessment|Ancillary studies
214962906|NCT01048853|PROCEDURE|Salpingo-Oophorectomy|Undergo hysterectomy with or without salpingo-oophorectomy
214962907|NCT01048853|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo lymphatic mapping with sentinel lymph node biopsy
214962908|NCT01048853|PROCEDURE|Therapeutic Conventional Surgery|Undergo hysterectomy with or without salpingo-oophorectomy
214962909|NCT04953143|BEHAVIORAL|LiverPal Intervention|"Inpatient longitudinal palliative care intervention~\- Patients will complete baseline assessments and will be followed by the palliative care clinicians delivering the LiverPal intervention during each of their hospitalizations over a 3 month period~LiverPal intervention domains include the following:~* Therapeutic relationship~* Symptom management~* Coping with illness~* Prognostic awareness and illness understanding~* Treatment decision-making~* End-of-life care"
214962910|NCT05505695|OTHER|Brace and Exercise Treatment|Schroth exercises, which are a specific exercise method for scoliosis, were given to the experimental group for 8 weeks, different from the control group.
214962911|NCT05505695|OTHER|Brace Treatment|Among the patients included in the study, those who wore braces but did not agree to exercise constituted the ''Brace Group'' of the study.
214962912|NCT05141318|OTHER|FROM-16 Questionnaire|A 16-item questionnaire to provide information about the impact of a patient's disease/condition the participants (family member of patient) quality of life
214962913|NCT05141318|OTHER|Semi-structured two-part interview|A telephone/video interview to provide additional context to the FROM-16 responses
214962914|NCT04268758|DEVICE|tulipon|Tulipon is a new kind of hygienic device, used to collect the secreted menses during the bleeding phase of the menstruation.
214962915|NCT03709147|DRUG|Metformin Hydrochloride|Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)
214354343|NCT07082283|PROCEDURE|Pacing Protocol for Non-pacing Group|"At H0, H6, H12, and H24, they will undergo transient pacing at 70, 80, and 90 bpm, following the same measurement protocol (10 minutes per rate), followed by recording of the hemodynamic profile and blood pressure, as follows:~* If the patient has a rhythm between 50 and 69 bpm, measurements will be taken at the spontaneous rate, then at 70 bpm, 80 bpm, and finally 90 bpm~* If the patient has a rhythm between 70 and 79 bpm, measurements will be taken at the spontaneous rate, then at 80 bpm, and finally at 90 bpm~* If the patient has a rhythm between 80 and 89 bpm, measurements will be taken at the spontaneous rate, then at 90 bpm~* If the patient has a rhythm ≥ 90 bpm, measurements will be taken at the spontaneous rate only~Outside the pacing periods at different rates, patients in the non-pacing group will remain on their spontaneous sinus rhythm."
214962916|NCT03709147|DRUG|Cisplatin|Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles
214354344|NCT05145361|DRUG|B001 injection|B001 injection 50mg/5mL Intravenous solution
214354345|NCT05145361|BIOLOGICAL|Placebo|Placebo 5mL Intravenous solution
214487128|NCT06771154|DRUG|Adebelimab Combined with Apatinib|"Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Apatinib, 250 mg, once daily (qd), orally (po). Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation."
214962917|NCT03709147|DRUG|Carboplatin|Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles
214962918|NCT03709147|DRUG|Pemetrexed|Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
214962919|NCT03709147|DIETARY_SUPPLEMENT|Fasting-mimicking diet|5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles
214962920|NCT03709147|DRUG|Pembrolizumab|Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
214487129|NCT06771154|DRUG|Adebelimab|"Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation."
214678913|NCT02540174|PROCEDURE|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~* At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~* At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
214678914|NCT02404831|OTHER|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
214678915|NCT02404831|OTHER|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
214962921|NCT05141929|BEHAVIORAL|web based education|In addition to routine care, web-based education was offered to pregnant women with Gestational Diabetes Mellitus.
214962922|NCT02264210|DRUG|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
214962923|NCT02585713|DRUG|Apixaban|Given PO
215080056|NCT00688246|OTHER|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture \[Lønning 2005\]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk \[Looker 2000\]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
215080057|NCT00688246|PROCEDURE|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
214354346|NCT07094386|PROCEDURE|External Oblique Intercostal Plain Block|The patient will be placed in the supine position. After sterilization of the skin, a high-frequency linear probe (6-13 MHz) will be placed obliquely medial to the anterior axillary line, the 6th and 7th ribs, skin, subcutaneous tissues, and external oblique muscle \[EOM\], intercostal muscles, pleura, and the lung will be identified. An 80 mm 22-gauge block needle (Stimuplex® D, BBraun, Germany) will be inserted in-plane to the US-probe in a craniocaudal direction directed under EOM. After confirmation of negative blood aspiration, 2-3 mL of normal saline will be injected for hydro-dissection to verify the correct needle tip placement then 30 mL of 0.25% bupivacaine will be injected between the EOM and intercostal muscles
214354347|NCT07094386|PROCEDURE|Quadratus Lumborum Block|Quadratus lumborum block will be performed. The patient will be placed in the lateral decubitus position After sterilization of the skin, a low frequency convex probe (5-8 MHz) will be positioned horizontally in the anterior axillary line half way between the subcostal margin and the iliac crest then will be advanced in the cranial direction to visualize the triple abdominal muscle layers and identifying the posterior border of the EO muscle (hook sign) with the underlying IO musclenforming a roof over the QL muscle. The QL muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. An 80 mm 22-gauge block needle will be inserted in-plane to the US-probe in an anterolateral to posteromedial direction. The needle tip will be placed between the middle layer of the thoracolumbar fascia and the QL muscle. After confirmation of negative blood aspiration, 30 mL of 0.25% bupivacaine will be injected.
214962924|NCT02585713|DRUG|Dalteparin|Given SC
214962925|NCT02585713|OTHER|Questionnaire Administration|Ancillary studies
214962926|NCT03160495|OTHER|All patients|All patients are scanned with PET/MR prior to surgery.
214962927|NCT00820287|PROCEDURE|Biopsy of testicular tumor|testicular biopsies performed through open surgery
214962928|NCT03956030|OTHER|Contraception Handout|Handout covering contraception options
214962929|NCT03956030|OTHER|Nutritional Handout|Handout covering nutrition
214962930|NCT04844008|DIETARY_SUPPLEMENT|Nanobubble drink|Commercially available sports drink
214962931|NCT04682379|DIAGNOSTIC_TEST|Proprioceptive assessment|"1. Trunk flexion-extension repositioning test~2. Trunk lateral-flexion repositioning test~3. Trunk axial-rotation repositioning test~4. Neck rotation repositioning test~5. Elbow flexion repositioning test~6. Knee extension repositioning test"
214962932|NCT02933398|PROCEDURE|Robotic Assisted Nephrectomy|Robotic (Davinci)
214962933|NCT02933398|PROCEDURE|Laparoscopic Assisted Nephrectomy|Regular Laparoscopic Technique.
214962934|NCT01409187|DRUG|Ipilimumab|Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
214962935|NCT01409187|DRUG|Interferon|5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
214962936|NCT01409187|DRUG|Interleukin-2 (Aldesleukin)|9 million IU/m\^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
214962937|NCT00441870|DRUG|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
214962938|NCT00441870|DRUG|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
214962939|NCT00597389|DRUG|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
214962940|NCT04910581|PROCEDURE|rTMS|Single 30-minutes session of 1Hz rTMS applied over the left laryngeal motor cortex
214962941|NCT04910581|PROCEDURE|Sham stimulation|Single 30-minutes session of sham stimulation applied over the left laryngeal motor cortex
214962942|NCT02764476|OTHER|Embodied Virtual Reality Therapy|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
214962943|NCT02764476|OTHER|Virtual reality|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
214962944|NCT03173456|DRUG|oxycodone/APAP|Oxycodone/acetaminophen 5 mg-325 mg oral tablet
214962945|NCT03173456|DRUG|hydrocodone/APAP|Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
214962946|NCT03173456|DRUG|codeine/APAP|Codeine/acetaminophen 30 mg-300mg oral tablet
214962947|NCT03173456|DRUG|400 ibuprofen/APAP|ibuprofen/acetaminophen 400 mg-1000mg oral tablet
214962948|NCT03173456|DRUG|800 ibuprofen/APAP|ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
214962949|NCT02450838|BIOLOGICAL|V180|Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
214962950|NCT02450838|BIOLOGICAL|Alhydrogel™|Aluminum hydroxide gel adjuvant
214962951|NCT02450838|BIOLOGICAL|Placebo|
214962952|NCT01028404|DRUG|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
214354348|NCT07094386|DRUG|Bupivacaine %0.25 (isobaric)|A single injection of 30 mg of 0.25 % bupivacaine will be administered as part of the External Oblique Intercostal Plain Block under ultrasound guidance, after confirming needle placement between the external oblique and intercostal muscles.
214354349|NCT07094386|DRUG|Bupivacaine %0.25 (isobaric)|A single injection of 30 mg of 0.25 % bupivacaine will be administered as part of the Quadratus Lumborum Block under ultrasound guidance, after confirming of correct needle placement and negative aspiration.
214354350|NCT06907615|DRUG|HLX43 DOSE 1 (2.0 mg/kg)|Dose 1; 2.0 mg/kg; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214354351|NCT06907615|DRUG|HLX43 DOSE 2 (2.5 mg/kg)|Dose 2; 2.5 mg/kg; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214354352|NCT07098260|BEHAVIORAL|DECIDE for MOM Provider Training|Participants will take an asynchronous online DECIDE for MOM provider training (approximately 3hours). DECIDE stands for Decide the problem; Explore the questions; Closed or open-ended questions; Identify the who, why, or how of the problem; Direct questions to your health care professional; Enjoy a shared solution. The 5 modules will cover shared decision-making, perspective-taking, patient activation, attributional errors, and being a responsive provider to perinatal individuals.
214962953|NCT01028404|DRUG|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
214962954|NCT01028404|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
214962955|NCT01028404|DRUG|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
214962956|NCT01028404|DRUG|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
214962957|NCT01028404|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
214962958|NCT03264612|BEHAVIORAL|Aerobic exercise|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
214962959|NCT01651975|DIETARY_SUPPLEMENT|Thickenup|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
214962960|NCT01651975|DIETARY_SUPPLEMENT|Thickenup Advance|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
214354353|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Two MSC infusions of 2.5x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
214354354|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose|Two MSC infusions of 5.0x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
214487130|NCT06765694|DRUG|Botulinum toxin injection|first injection was done under ultrasound control in the extensor carpi radialis brevis (ECRB). The second one if necessary was subordinated to clinical examination and focused in one or more of the following: ECRB, extensor digitorum communis, supinator.
214962961|NCT01050322|DRUG|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
214962962|NCT01050322|DRUG|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
214962963|NCT01050322|DRUG|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
214962964|NCT05075863|DRUG|Letrozole|Letrozole as 5mg from day 3 to 7 of menstrual cycle
214962965|NCT01733121|DRUG|NBI-98854|25 mg capsule
214962966|NCT01733121|DRUG|NBI-98854|50 mg capsule
214962967|NCT01733121|DRUG|Placebo|
214962968|NCT02297425|DRUG|PF-06459988|The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
214962969|NCT03340038|OTHER|Non-ICU Specialty ward|
214354355|NCT05579249|DRUG|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
214354356|NCT05579249|DRUG|Orlistat|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
214487131|NCT06772766|DRUG|9MW3011|Ascending IV doses administered per protocol
214487132|NCT06772766|DRUG|9MW3011 placebo|Ascending IV doses administered per protocol
214354357|NCT05579249|DRUG|Phentermine/Topiramate|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
214354358|NCT05579249|DRUG|Naltrexone/Bupropion|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
214354359|NCT05579249|DRUG|Liraglutide|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
214354360|NCT04133831|OTHER|Total Survival|"The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: \[(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)\] / \[number of patients alive on waitlist at start of year\]."
214354361|NCT04133831|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
214354362|NCT07103057|DEVICE|Viz HCM|Viz HCM is a Software as a Medical Device (SaMD) intended to receive 12-lead ECG recordings collected as part of a routine clinical assessment and analyze them in parallel to the standard of care. The device uses a machine learning based algorithm to analyze 12-lead ECGs and identify ECGs with suspected HCM.
214962970|NCT04736069|OTHER|Physical therapy program|In the physical therapy program, 20 minutes of hot pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS; 30 to 40 Hz), 6 minutes of ultrasound (US; 1 MHz, 1 to 1.5 Watt/cm2) therapy were applied to both groups. Both of the programs were supervised by physical therapists. A combined range of motion and strengthening exercises were given to both groups to be performed two times a day.
214962971|NCT02670421|BEHAVIORAL|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.
214962972|NCT02670421|BEHAVIORAL|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
214962973|NCT02670421|BEHAVIORAL|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
214962974|NCT05399147|OTHER|fiberoptic intubation classic technique|classic fiberoptic intubation
214962975|NCT05399147|OTHER|fiberoptic intubation tube 1st technique|tube 1st technique
214962976|NCT04671394|PROCEDURE|FMUD + DLIG|Full-Mouth Ultrasonic Debridement + Diode Laser and Indocyanine Green solution
215080058|NCT01646645|BIOLOGICAL|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
214354363|NCT05694559|BEHAVIORAL|Genetic Testing and Counseling|Participants will complete testing
214354364|NCT05694559|BEHAVIORAL|Screening Form|Participants will complete forms with demographics and history
214354365|NCT07108205|DEVICE|Paired reading analysis|Paired side be side evaluation Each reader will assess- Image Quality (IQ) \& Diagnostic Confidence Ratings will be recorded using a 5-point Likert scale
214354366|NCT07109700|DRUG|HDM1005 1|administered SC, QW, 20 weeks
214354367|NCT07109700|DRUG|HDM1005 2|administered SC, QW, 20 weeks
214354368|NCT07109700|DRUG|HDM1005 3|administered SC, QW, 20 weeks
214354369|NCT07109700|DRUG|HDM1005 4|administered SC, QW, 20 weeks
214354370|NCT07109700|DRUG|Placebo|administered SC, QW, 20 weeks
214354371|NCT07109700|DRUG|Dulaglutide 1.5 MG|administered SC, QW, 20 weeks
214354372|NCT07100392|DRUG|tauroursodeoxycholic acid (TUDCA)|TUDCA (250 mg, twice daily) will be administered orally until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214354373|NCT07100392|DRUG|Camrelizumab|Camrelizumab will be administered by IV, 200 mg on day 1 of each 14 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214354374|NCT07100392|DRUG|Regorafenib|Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214962977|NCT04671394|PROCEDURE|FMUD + ST|Full-Mouth Ultrasonic Debridement + Sham Treatment
214962978|NCT02247739|BIOLOGICAL|Recombinant human C1 inhibitor|
214962979|NCT02247739|OTHER|Placebo|
214962980|NCT06549738|DEVICE|Intermittent pneumatic compression therapy|Lympha Press Optimal Plus is an advanced intermittent pneumatic compression therapy device. It is FDA cleared (K170658) for the indication of lipedema as well as for other indications for use.
214962981|NCT03061188|OTHER|Laboratory Biomarker Analysis|Correlative studies
214962982|NCT03061188|BIOLOGICAL|Nivolumab|Given IV
215080059|NCT03158623|BIOLOGICAL|Platelet Rich Plasma|
214962983|NCT03061188|OTHER|Pharmacological Study|Correlative studies
214962984|NCT03061188|DRUG|Veliparib|Given PO
214962985|NCT01400724|DIETARY_SUPPLEMENT|Inofolic NRT|Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
214962986|NCT04351880|OTHER|Medically Tailored Meals|Compare 2 and 4 weeks of meal delivery
214962987|NCT01439984|DRUG|Clomipramine|Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
214962988|NCT04501952|DRUG|RDV|Administered as an intravenous infusion
214962989|NCT04501952|DRUG|Placebo to Match RDV|Administered as an intravenous infusion
214962990|NCT03025269|DRUG|Ocrelizumab|This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
214962991|NCT04649086|OTHER|Rehabilitation by Eccentric exercises|Participants will perform 24 exercises sessions (30 minutes) with cycloergometer in eccentric mode (while resisting against self-paced pedaling), inducing a greater muscular hypertrophy as compared with concentric mode, the mechanical stimulation being 3 to 4 times greater at the same level metabolic stimulation.
214962992|NCT04649086|OTHER|Rehabilitation by Concentric exercises|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
215080060|NCT03158623|BIOLOGICAL|Cellerate|
215080061|NCT03620552|DRUG|18F-S16|A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
215080062|NCT02279849|OTHER|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
214487133|NCT06773143|DRUG|Esketamine at low dose|After the induction of general anesthesia, patients in the esketamine group will receive a continuous infusion of esketamine (0.3 mg/kg/h) until the end of the operation.
214962993|NCT02308449|DRUG|Ferric carboxymaltose|Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride
214962994|NCT02308449|DRUG|Sodium chloride (placebo)|Infusion of 250 mL 0.9% sodium chloride
214962995|NCT00939614|DRUG|Lamotrigine|
214962996|NCT00573872|RADIATION|Radiosurgery|"Phase I: 20-25 Gy in 5 fractions~Phase II: 9-24 GY in 1 fraction"
214962997|NCT04442087|BIOLOGICAL|Serology SARS-CoV2|Collect serum for Serology SARS-CoV2 at inclusion
214962998|NCT04442087|BEHAVIORAL|Data collection|Collect clinical and demographic data, habitus, Lifestyle Counseling at inclusion
214962999|NCT05497765|DIETARY_SUPPLEMENT|Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza|Take 4 tablets with warm water twice a day
214963000|NCT05497765|DIETARY_SUPPLEMENT|Silibinin extract|Take 4 tablets with warm water twice a day
214963001|NCT05497765|DIETARY_SUPPLEMENT|Placebo|Take 4 tablets with warm water twice a day
214963002|NCT02548663|OTHER|Sport therapy|"Frequency: 60 min three times/week~1. 20 min: aerobic training on bicycle ergometer.~2. 20 min: strength training at 60% of maximal load.~3. 20 min: proprioception and stretching exercises."
214963003|NCT02548663|OTHER|Osteopathic treatment|Frequency: 60 min weekly
214963004|NCT04444765|OTHER|Collection of clinical and biological data during renal replacement therapy sessions|Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).
215080063|NCT02279849|OTHER|Pricing|The pricing incentives were used to help promote sales of healthier food items.
215080064|NCT02279849|OTHER|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
215080065|NCT02030080|BEHAVIORAL|Financial incentives|
214963005|NCT05358990|OTHER|Plain Language Recommendation (PLR)|New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
214963006|NCT05358990|OTHER|Standard Language Version (SLV)|Original recommendation as initially published by the guideline organization.
214963007|NCT00537186|DRUG|Iron oligosaccharide|
214963008|NCT01139346|DRUG|darinaparsin|dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
214963009|NCT00812032|DRUG|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
214963010|NCT00812032|DRUG|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
215080066|NCT02030080|BEHAVIORAL|Teams|
215080067|NCT02030080|BEHAVIORAL|Framing of feedback|
214487134|NCT06773143|OTHER|Normal Saline (0.9% NaCl)|After the patient's general anesthesia induction is completed, normal saline will be continuously infused until the end of the operation, and the infusion volume is the same as that of the esketamine group.
214487135|NCT06773260|DIAGNOSTIC_TEST|Liver and Spleen stiffness measurement.|The use of spleen stiffness measurement to reduce unnecessary upper digestive endoscopies has never been evaluated in this patient setting.
214963011|NCT03965520|BEHAVIORAL|exercise rehabilitation by near-infrared spectrometer|We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
214963012|NCT02080364|DRUG|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
214963013|NCT02080364|DRUG|Placebo|Placebo administered orally, once daily for 18 months
214963014|NCT00613379|DRUG|PRO 140|10 mg/kg PRO 140, one IV dose (N=10)
214963015|NCT00613379|DRUG|PRO 140|5 mg/kg PRO 140, one IV dose (N=10)
214963016|NCT00613379|DRUG|Placebo|PBO, one IV dose (N=10)
215080068|NCT02030080|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
215080069|NCT04053400|DRUG|Ketamine|
215080070|NCT01238770|DRUG|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
215080071|NCT03736993|OTHER|Additional blood sampling|Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
214963017|NCT03791762|PROCEDURE|WaveOne Gold|"WaveOne Gold was operated by an endomotor (VDW Gold, Munich, Germany) at WaveOne ALL setting."
214963018|NCT03791762|PROCEDURE|Reciproc Blue|"Reciproc Blue was operated by an endomotor (VDW Gold, Munich, Germany) at Reciproc ALL setting."
214963019|NCT03791762|PROCEDURE|ProTaper Next|ProTaper Next was operated by an endomotor (VDW Gold, Munich, Germany) with 16:1 contra angle at the settings suggested by the manufacturer (350 rpm, 3 Ncm).
214963020|NCT02609984|BIOLOGICAL|CMB305|A combination of LV305 administered intradermally (ID) and G305 administered intramuscularly (IM)
215080072|NCT02881112|DEVICE|Provant Therapy System|Treatment with the Provant Therapy System
215080073|NCT00712530|BIOLOGICAL|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
215080074|NCT00712530|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
215080075|NCT02374814|DRUG|Rabies vaccine|Compare dose schedule and route of administration
215080076|NCT02374814|DRUG|Placebo|Placebo
215080077|NCT01426984|DRUG|methylphenidate|a capsule containing 20 mg
215080078|NCT03717792|OTHER|no intervention|no intervention
215080079|NCT03292939|DIAGNOSTIC_TEST|A complete Doppler ﬂow assessment of the maternal and fetal circulation|A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
215080080|NCT00884039|DRUG|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
215080081|NCT00884039|DRUG|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
215080082|NCT02675192|OTHER|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
215080083|NCT02707081|DRUG|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
215080084|NCT02707081|DRUG|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
215080085|NCT02707081|DRUG|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
215080086|NCT02707081|DRUG|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
215080087|NCT06333743|PROCEDURE|laser ablation|Research has confirmed that laser ablation treatment of cervical HSIL is effective and feasible.
214963021|NCT02609984|BIOLOGICAL|atezolizumab|IV Infusion
214963022|NCT05476354|DRUG|Irbesartan/Amlodipine low|Irbesartan/Amlodipine low once daily for 8 weeks
214963023|NCT05476354|DRUG|Irbesartan/Amlodipine high|Irbesartan/Amlodipine high once daily for 8 weeks
214963024|NCT05476354|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
214963025|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F1|Febuxostat extended-release (XR) capsules formulation 1
215080088|NCT06333743|PROCEDURE|LEEP or Conization|The most common treatment for HSIL is LEEP or conization of the cervical lesion, but there are several perinatal complications involved in this surgery.
215080089|NCT02182908|OTHER|PET-Scan|PET-Scan
214354375|NCT07116278|DEVICE|QuantalX DELPHI-MD (TMS-EEG)|Direct Electro-Physiological Imaging medical device (DELPHI-MD), developed by QuantalX Neuroscience, is a neurophysiological assessment system which utilizes a specific TMS-EEG protocol that automatically analyzes specific features of this brain response to reproduce numerical output measures. DELPHI-MD has previously shown to differentiate different healthy age groups, mild dementia and Parkinson's Disease (PD) from age matched healthy control. In addition, DELPHI-MD measures are correlated to white matter microstructural differences in post stroke and TBI patients. This multimodal approach allows for the evaluation of several neurophysiological mechanisms such as cortical reactivity, excitation and inhibition in local and distal regions, effective connectivity, and neural plasticity, characterized as modifications that outlast the stimulation period. The investigators predict that Delphi-MD has the potential to identify features of brain function altered in pain syndromes.
214354376|NCT07121153|DRUG|NNC0487-0111 A|Participants will receive single dose (level 1, level 2, level 3) injection of NNC0487-0111 A subcutaneoulsy.
214354377|NCT07121153|DRUG|Placebo A|Participants will receive single dose (level 1, level 2, level 3) injection of placebo A subcutaneoulsy.
214487136|NCT06827431|DRUG|Ammoxetine|Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Ammoxetine and Sertraline.
214963026|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F2|Febuxostat XR capsules formulation 2
214963027|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F3|Febuxostat XR capsules formulation 3
215080090|NCT00280800|DEVICE|constant CPAP devices|different CPAP mode
215080091|NCT00280800|DEVICE|automatic CPAP devices|different CPAP mode
215080092|NCT00728520|DRUG|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
215080093|NCT00917072|BEHAVIORAL|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
215080094|NCT00917072|BEHAVIORAL|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
215080095|NCT00917072|BEHAVIORAL|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
215080096|NCT01175642|BEHAVIORAL|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
215080097|NCT01175642|BEHAVIORAL|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
215080098|NCT06190756|OTHER|Cardiovascular and Baroreflex stimulation by Tilting|Tilt of the patient at 4 angles (22°, 42°, 58° and 80°), the order is randomized for 3 angles (22°, 42°, 58°) while 80° will always be last.
215080099|NCT06190756|OTHER|Cardiovascular and Baroreflex stimulation by Lower Body Negative Pressure|The patient will undergo 4 level of LBNP (10Torr, 20Torr, 35Torr, 50Torr), the order is randomized for 3 intensities (10Torr, 20Torr, 35Torr) while 50Torr will always be last.
215080100|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
215080101|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
214487137|NCT06827431|DRUG|Ammoxetine|Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Sertraline.
214963028|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F4|Febuxostat XR capsules formulation 4
214963029|NCT00635544|OTHER|dietary treatment|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
214963030|NCT00635544|OTHER|dietary treatment|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
214963031|NCT03126461|RADIATION|SAbR|"For patients treated on the GRID A regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the GRID B regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose."
214963032|NCT03126461|DRUG|Ipilimumab|ipilimumab 3mg/kg IV q3wk x 4
214963033|NCT03126461|DRUG|Nivolumab|nivolumab 1 mg/kg IV q3wk x 4
215080102|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
215080103|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
215080104|NCT03390478|OTHER|Combined Intervention Group|Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
215080105|NCT00072293|PROCEDURE|Axillary lymph node dissection|Axillary lymph node dissection
215080106|NCT00072293|PROCEDURE|No axillary lymph node dissection|Therapeutic conventional surgery
215080107|NCT03454269|DIAGNOSTIC_TEST|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
215080108|NCT03378427|DRUG|Tedizolid Phosphate 200 MG [Sivextro]|Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
215080109|NCT05341895|OTHER|Kinesiotape|Taping
215080110|NCT04183855|DIETARY_SUPPLEMENT|Generation UCAN supplementation|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
215080111|NCT04183855|DIETARY_SUPPLEMENT|Mirexus PhytoSpherix supplementation|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
215080112|NCT04183855|BEHAVIORAL|satiety ratings|questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
215080113|NCT05797532|OTHER|breastfeeding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
215080114|NCT05797532|OTHER|skin to skin contact|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
215080115|NCT05797532|OTHER|swaddling and holding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
215080116|NCT02649374|BEHAVIORAL|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
215080117|NCT04209114|BIOLOGICAL|Nivolumab|Specified dose on specified days
215080118|NCT04209114|PROCEDURE|Radical cystectomy (RC)|Surgical removal of the bladder
215080119|NCT04209114|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
215080120|NCT04836416|OTHER|Observational|Observational
215080121|NCT01902563|OTHER|Osteopathic Manipulative Treatment|
214487138|NCT06827431|DRUG|Placebo|Drug: Placebo placebo to Ammoxetine hydrochlorid and Sertraline.
214487139|NCT06827431|DRUG|Sertraline|Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.
214487140|NCT06596733|DEVICE|Vit-A-Vision|Participants will apply Vit-A-Vision ointment on a daily basis, up to 3 times daily per eye, for at least 30 days.
214487141|NCT06746649|PROCEDURE|Combined training|12-week long time specific combined training 2 times a week
214487142|NCT06749587|DEVICE|TEOSYAL RHA® 1|"Product injection in infraorbital hollows~TEOSYAL RHA® 1 is a sterile, transparent, non-pyrogenic, viscoelastic gel made of Hyaluronic Acid (HA) of non-animal origin"
214963034|NCT01840592|DRUG|Sorafenib|
214963035|NCT01840592|DRUG|Doxorubicin|
214963036|NCT03404388|BEHAVIORAL|Balance Training|4 days of a challenging balance training task
214963037|NCT00921206|BIOLOGICAL|VAX102|1 ug i.m. compared to 2 ug s.c.
214963038|NCT05754671|OTHER|perceptual assessment of the recorded voice sample|perceptual assessment of the recorded voice samples
214963039|NCT05754671|OTHER|voice recording|voice recording
214963040|NCT03141515|DEVICE|Lung ultrasound|Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
214963041|NCT01758614|PROCEDURE|bypass surgery|all participants in this group will be performed EC-IC bypass surgery
214963042|NCT01758614|DRUG|Aspirin|all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
214963043|NCT01758614|DRUG|Clopidogrel|
214963044|NCT01210222|BIOLOGICAL|Trebananib|Given IV
214963045|NCT02102347|OTHER|exercise|
214963046|NCT02102347|OTHER|Phototherapy|
214963047|NCT04476498|PROCEDURE|Pull-PEG with Gastropexy|Additionally to a conventional pull-PEG a gastropexy will be performed.
214963048|NCT05201677|PROCEDURE|Supplement of perfusion fluid through the subiris suspensory ligament space from the lateral incision|After the capsule is filled with viscoelastic material, if the IOP is less than 10 mmHg, the investigators will supply the perfusion fluid through the subiris suspensory ligament space from the lateral incision.
214963049|NCT00421083|DRUG|tadalafil|
214963050|NCT02797860|DRUG|Rocuronium|comparison of onset time and duration of rocuronium using Train of Four watch
215080122|NCT04218838|DEVICE|CornerLoc SI Joint Stabilization Procedure|CornerLoc minimally invasive SI Joint Stabilization System
215080123|NCT04218838|DRUG|Intra-articular Sacroiliac Joint Steroid Injection|Standard of Care - Steroid injection into the sacroiliac joint
215080124|NCT02270762|OTHER|Rest in bed|
215080125|NCT02270762|OTHER|Passive verticalization|
215080126|NCT02270762|OTHER|Rest in bed|
215080127|NCT04393467|DEVICE|tSMS|tSMS delivered on bilateral motor cortex
215080128|NCT04393467|DEVICE|sham tSMS|sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
214487143|NCT06758349|OTHER|General questionnaire|Demographic, medical history, and musical activity data will be collected using a specifically designed questionnaire
215080129|NCT05440006|DRUG|Fuzuloparib|Fuzuloparib Capsules; 150mg; single dose per cycle.
215080130|NCT00901511|PROCEDURE|Baseline WLL|Scheduled bilateral WLL
215080131|NCT00901511|DRUG|Sargramostim|Inhaled GM-CSF
215080132|NCT00901511|PROCEDURE|Rescue WLL|Unscheduled bilateral WLL
215080133|NCT00596245|DRUG|MT400|MT 400, naproxen sodium 550mg
214487144|NCT06758349|OTHER|Pain Questionnaire|"Questionnaire that evaluate pain and functional limitation during last week, last six months e during the carrier.~The impact of painful symptoms on professional and non-professional activities , during the last week, will be assessed using the QuickDASH scale for the upper limb, the Modified Oswestry Low Back Disability Index for low back pain, and the Neck Disability Index questionnaire for cervico-dorsalgia"
214963051|NCT00973284|BIOLOGICAL|Norwalk VLP vaccine|Norwalk VLP vaccine dry powder
214963052|NCT00973284|BIOLOGICAL|mannitol and sucrose|Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder
214963053|NCT00973284|BIOLOGICAL|Norwalk virus|Norwalk virus solution
214963054|NCT03569826|OTHER|Observational; no intervention|Observational; no intervention
214963055|NCT01322087|DIETARY_SUPPLEMENT|Nutritional intervention|"The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.~All included patients received nutritional counseling and information about the new food concept by a clinical dietician.~Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient."
214963056|NCT02959333|BIOLOGICAL|hAEC|hAEC: human amniotic epithelial cells
214963057|NCT03997097|DRUG|Sildenafil|Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day
214963058|NCT03997097|DRUG|Placebos|Patients randomised in the group placebo in 3 oral doses of per day
215080134|NCT01824329|PROCEDURE|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
214963059|NCT00086450|PROCEDURE|Coronary Artery Bypass Graft|For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
215080135|NCT01824329|PROCEDURE|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
215080136|NCT05451173|RADIATION|Stereotactic body radiotherapy|An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.
215080137|NCT05451173|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.
215080138|NCT05451173|DRUG|Durvalumab|an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
215080139|NCT05480436|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
215080140|NCT05480436|BIOLOGICAL|COVID-19 vaccine|received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
215080141|NCT05480436|BIOLOGICAL|IIV4+PPV23|received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
215080142|NCT00624819|BIOLOGICAL|GSK1024805A|No vaccination in this trial
215080143|NCT00624819|BIOLOGICAL|Prevenar|No vaccination in this trial
215080144|NCT00624819|BIOLOGICAL|Infanrix hexa|No vaccination in this trial
215080145|NCT00624819|BIOLOGICAL|Havrix|No vaccination in this trial
215080146|NCT00624819|BIOLOGICAL|Varilrix|No vaccination in this trial
215080147|NCT03233763|PROCEDURE|Bone Marrow Aspirate|Diagnostic Bone Marrow aspirate
215080148|NCT00346489|DRUG|5-fluorouracil|
215080149|NCT00346489|DRUG|Mitomycin C|
214354378|NCT07127887|OTHER|KM Resource - AI|"The KM resource (an online resource sheet) was developed for the Public Health Agency of Canada about the prevention of post-covid condition (PCC). The resource presents recommendations that were developed by an international group according to standards for guideline development.~The resource has already been AI translated using ChatGPT 4.0 into French as well as six languages common to newcomers across Canada (Arabic, Punjabi, Ukrainian, Tagalog, Chinese, Spanish)."
214963060|NCT00086450|DEVICE|Percutaneous Coronary Intervention|"For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.~The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery."
214963061|NCT04978337|DRUG|Rilematovir|Rilematovir 250 mg will be administered orally.
214963062|NCT04978337|DRUG|Placebo|Placebo matching to rilematovir will be administered orally.
214354379|NCT07127887|OTHER|KM Resource - Professional|"The KM resource (an online resource sheet) was developed for the Public Health Agency of Canada about the prevention of post-covid condition (PCC). The resource presents recommendations that were developed by an international group according to standards for guideline development.~The resource has already been professionally translated into French as well as six languages common to newcomers across Canada (Arabic, Punjabi, Ukrainian, Tagalog, Chinese, Spanish)."
214678916|NCT04556331|BEHAVIORAL|Parenting programme (cognitive behavioural) aimed at reducing generational transmission of anxiety|'Psychoeducation' (psychologically informed information about the topic of transmitting anxiety) and cognitive-behavioural strategies aimed at reducing the transmission of anxiety from parent to young child. These will be shared with a group of maximum 8 remotely delivered, in a didactic format.
214678917|NCT00184912|DRUG|caffeine|
214678918|NCT00184912|DRUG|Technetium-TC99m-labeled Annexin A5|
214963063|NCT06155474|DIETARY_SUPPLEMENT|Prebiotic galacto-oligosaccharide (GOS) Powder|"Prebiotic GOS Powder is a galacto-oligosaccharide ingredient low in mono-sugars. Scientific studies have shown positive effects of oligosaccharides, among which galacto-oligosaccharides, on growth of bifidobacterial, stool consistency bowel function and transit time, support of natural defenses and mineral absorption.~The product mainly consists of 97% dry matter with 69% prebiotic GOS, 23% lactose and 5% glucose and galactose as monosaccharides. These prebiotics have β-(4) glycosidic linkages and have been proven as safe product"
214963064|NCT06155474|DIETARY_SUPPLEMENT|Starch Only|The Starch Solution is a low-fat diet.
214963065|NCT06155474|DIETARY_SUPPLEMENT|RUTF + Starch|ready-to-use therapeutic food and The Starch Solution is a low-fat diet.
214963066|NCT02497404|DRUG|5-Azacytidine|"Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,~-8 and -7. This will be administered on an outpatient basis if possible."
214963067|NCT02497404|DRUG|Fludarabine|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fludarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
214963068|NCT02497404|DRUG|Melphalan|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
214963069|NCT02497404|DRUG|Alemtuzumab|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 30 mg subcutaneously on Days -4 and -2 for unrelated donors, and Day -2 for related donors.
214963070|NCT02497404|RADIATION|Total Body Irradiation|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Total Body Irradiation (TBI) will be given at 2 doses of 200 cGy each on one day of the conditioning regimen (between days -6 and -3).
214963071|NCT01504672|OTHER|Medication review|"In the intervention, the pharmacist will evaluate:~* Is there an indication for the drug?~* Has the drug desired effect?~* Is the dose correct and dosing scheme correct?~* Side effects, contraindications, inappropriate drugs~* Interactions~* Treatment time~* Cost effectiveness~* Adherence to recommendation list~* Problems with handling the drugs (for example crushing of the tablets)~* Untreated indication~* Double medications~* Administration of drugs"
214963072|NCT01408901|BEHAVIORAL|Supervised Treadmill Exercise Therapy|Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
214963073|NCT01408901|OTHER|Health education sessions (Control)|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
214963074|NCT01408901|DRUG|granulocyte macrophage colony stimulating factor (GM-CSF)|The dose of GM-CSF will be 250 ug/M\^2 subcutaneously three times weekly for two weeks.
214963075|NCT00222638|DRUG|Influenza vaccination|
214963076|NCT00725907|BIOLOGICAL|PGRF|injection of 6cc into injured area
214963077|NCT00725907|BIOLOGICAL|placebo saline|injection of 6cc into injured area
214963078|NCT00606749|DRUG|KC706|300 mg once daily (QD) for 12 weeks.
215080150|NCT02880514|DEVICE|PROPEL Mini Sinus Implant|Sinus implant with 370 mcg of mometasone furoate released over 30 days
214354380|NCT07127237|DRUG|Bisacodyl 5 MG|On the day prior to the procedure, the group receiving bisacodyl will take 4 tablets (5 mg each) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.
214354381|NCT07127237|DRUG|Prucalopride 2mg|On the day prior to the procedure, the group receiving prucaloprida will take 1 tablet (2 mg) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.
214354382|NCT07127666|OTHER|Structured Agenda-Setting Tool|We are testing a novel clinical visit agenda-setting intervention developed through participatory research methods for the pediatric inpatient environment. This structured agenda-setting (SAS) intervention will be co-designed to include structured discussion topic areas with the option for patients (when appropriate) and their care partners to consider and indicate their priority topic areas and take notes before, during, and after a clinical visit.
214354383|NCT06945718|PROCEDURE|beyond D2 regional lymph node dissection|dissect the lymph nodes outside the extent of D2 LN region.
214963079|NCT03509181|BEHAVIORAL|I-Change|smartphone delivered word-sentence association task that encourages a healthier interpretive style
214963080|NCT03509181|BEHAVIORAL|Symptom Tracking|smartphone delivered self-monitoring of anxiety and depression symptoms
214963081|NCT06039137|DRUG|Cetirizine|Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine
214963082|NCT06039137|DRUG|Clemastine IV|Subjects were treated with paclitaxel premedication containing clemastine 2 mg IV
214963083|NCT04224532|PROCEDURE|Pneumoperitoneum Timing (Before Positioning)|Before Reverse Trendelenburg Position
214963084|NCT04224532|PROCEDURE|Pneumoperitoneum Timing (After Positioning)|After Reverse Trendelenburg Position
214963085|NCT01436227|OTHER|Laboratory Biomarker Analysis|Correlative studies
214963086|NCT01436227|DRUG|Pazopanib Hydrochloride|Given PO
214963087|NCT03465761|DEVICE|ExAblate|Bilateral side treatment of Essential Tremor
214963088|NCT03971591|BEHAVIORAL|Immediate Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
214963089|NCT06039319|OTHER|Physical activity|30 minute bout of moderate intensity physical activity performed on a treadmill
215080151|NCT02880514|PROCEDURE|Balloon Sinus Dilation Alone|
215080152|NCT05499338|PROCEDURE|Stretching program|The stretching programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. The final stretching position was that which generated a sensation of moderate-intense tightness in the muscles, but without exceeding the pain threshold. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
214354384|NCT06953076|DRUG|Relugolix/estradiol/norethisterone acetate|Oral therapy administered to patients with symptomatic uterine fibroids presenting with abnormal uterine bleeding
214354385|NCT04581525|DEVICE|transcranial direct current stimulation|
214354386|NCT04616508|BEHAVIORAL|motor control assessment|Basic science study of control of reaching movements
214354387|NCT04073602|DRUG|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
214354388|NCT06136390|OTHER|Oxytocin|Oxytocin nasal spray in combination with mindfulness based group therapy (MBGT).
214354389|NCT06136390|OTHER|Placebo|Placebo nasal spray in combination with mindfulness based group therapy (MBGT).
214354390|NCT04969523|PROCEDURE|lobectomy|Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
214354391|NCT01740674|OTHER|Electronic data collection|
214963090|NCT01860716|DRUG|Melatonin|Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
214963091|NCT01860716|DRUG|Placebo|
215080153|NCT02193035|OTHER|Microparticle levels|Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
214354392|NCT01704170|DEVICE|Kona Externally Focused Ultrasound Therapy|
214354393|NCT05800535|DRUG|Study of the adverse effects of long-term oncological treatments|Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
214678919|NCT00184912|PROCEDURE|ten minutes forearm ischemia|
214963092|NCT06117254|BEHAVIORAL|Communication Counseling|Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including general tips on environmental modification and communication repair strategies and personalized tips to help with patient-specific listening difficulties. This is consistent with current audiological standard of care.
215080154|NCT00622089|DRUG|DIO-902|150mg DIO-902 + 10mg atorvastatin
215080155|NCT00622089|DRUG|DIO-902|300mg dose once per day for 24 weeks
215080156|NCT00622089|DRUG|DIO-902|450mg dose once per day for 24 weeks
215080157|NCT02105493|DRUG|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
215080158|NCT02105493|DRUG|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
214354394|NCT05800535|BEHAVIORAL|Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients|Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
215080159|NCT02436668|DRUG|Ibrutinib|
215080160|NCT02436668|DRUG|Gemcitabine|
215080161|NCT02436668|DRUG|Nab-paclitaxel|
214354395|NCT04658303|DRUG|Pimonidazole|Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in-vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
214354396|NCT02811861|DRUG|Lenvatinib|
214354397|NCT02811861|DRUG|Everolimus|
214354398|NCT02811861|DRUG|Pembrolizumab|
214963093|NCT06117254|DEVICE|Hearing Aids|Hearing aids will be provided with amplification settings programmed specific to each participant's pure-tone hearing thresholds with subsequent adjustments based upon participant preferences. Standard noise cancelation and signal-to-noise ratio improvement strategies will be activated.
214963094|NCT06117254|DEVICE|Remote Microphones|Remote microphone systems will be provided for use with hearing aids.
214963095|NCT05190666|BEHAVIORAL|PACE Weight Loss program|12 month phone-based behavioral weight loss program
214963096|NCT05190666|BEHAVIORAL|Chronic Disease Self-Management|12 month phone-based chronic disease self-management program
214963097|NCT04686422|DEVICE|Tetric PowerFill|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the PowerCure system.
214963098|NCT04225013|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured
214963099|NCT04225013|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured
214963100|NCT06822101|BEHAVIORAL|Visual Training|Participants are asked to detect or discriminate visual stimuli.
214963101|NCT06234098|DRUG|AT-1965 Liposome Injection|AT-1965 Liposome Injection administered intravenously once weekly for the first 3 weeks (Days 1, 8 and 15) of a 4 week cycle.
214354399|NCT02811861|DRUG|Sunitinib|
214354400|NCT02394782|DEVICE|RebiSmart®2.0|Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
214354401|NCT02394782|DEVICE|MSdialog™|Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
214354402|NCT02925455|DEVICE|Contralaterally-controlled functional electrical stimulation|Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
214963102|NCT05854485|COMBINATION_PRODUCT|REACH robotic training and multi-muscle Functional Electrical Stimulation (FES) group|Participants in this group will receive multi-muscle FES during arm robotic training
214487145|NCT06758349|OTHER|Postural assessment without musical instrument in sitting position|Postural assessment without the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.
214963103|NCT05854485|COMBINATION_PRODUCT|Robot only group|Participants in this group will receive arm robotic training only
215000402|NCT07122258|DEVICE|CAROL NSCLC treatment Device|"Participants in this single-arm study will undergo treatment with the CAROL device for localized lung tumors (NSCLC ≤ 2 cm, cT1b). All participants will receive a single CAROL procedure using a conformable electrode, followed by surgical resection of the tumor.~The first 3 sentinel participants will receive a maximum dose of 0.3 mL of the conformable electrode. The next 4 participants will receive up to 2.0 mL. Safety and preliminary efficacy will be assessed through scheduled follow-up visits, including imaging, pulmonary function testing, laboratory assessments and pain monitoring.~Adverse events will be monitored throughout the study, with grading based on CTCAE v5.0, specifically focusing on Respiratory, thoracic, and mediastinal disorders. The study includes visits at screening, pre-procedure, post-procedure (24-36 hours), pre- and post-resection, and follow-up at approximately one and three months."
214354403|NCT02925455|DEVICE|Hand therapy video games|Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
214354404|NCT06209879|DRUG|SYSTANE™ Hydration Lubricant Eye Drops|SYSTANE™ Hydration Lubricant Eye Drops (Hyaluronic Acid \[HA\] 0.15%; Polyethylene Glycol 400 0.4%; Propylene Glycol 0.3%)1-2 drops 4 times a day) and 0.1% FML (1-2 drops 3 times a day) in both eyes for 12 week
214354405|NCT04912648|OTHER|Longitudinal follow up|Repeat follow up at 3,5 and 10 years
214354406|NCT02580708|DRUG|Rociletinib|
214354407|NCT02580708|DRUG|Trametinib|
214678920|NCT00184912|PROCEDURE|ischemic forearm exercise|
214963104|NCT05658172|DIAGNOSTIC_TEST|Determination of tumormarkers (CA27.29, CEA, CA125)|CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
214963105|NCT05658172|DIAGNOSTIC_TEST|Determination of CTC levels|CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
214963106|NCT05658172|DIAGNOSTIC_TEST|Determination of ctDNA levels|Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
214963107|NCT05658172|OTHER|Biobanking of blood samples|To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
214963108|NCT04387409|BIOLOGICAL|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
214963109|NCT04387409|BIOLOGICAL|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
214963110|NCT05101759|PROCEDURE|Comprehensive Geriatric Assessment|A systematic reassessment of geriatric parameters will be performed at 3 and 6 months post-inclusion.
214354408|NCT05645354|BEHAVIORAL|SmokefreeSGM|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of LGBTQ+ smokers.
214354409|NCT05645354|BEHAVIORAL|SmokefreeTXT|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of the general population
214963111|NCT06462898|DIETARY_SUPPLEMENT|Omega-3 Fortified Protein Smoothie|Omega-3 powder and protein supplementation.
214963112|NCT06462898|DIETARY_SUPPLEMENT|Non-Fortified Protein Smoothie|Protein without omega-3 powder supplementation.
214963113|NCT04504565|DIAGNOSTIC_TEST|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTc-3PRGD2
214963114|NCT05826340|BEHAVIORAL|Tailored progressive loading and return to sport|Participants will undergo a 5-stage progressive return to sport tool.
214963115|NCT05826340|BEHAVIORAL|Pain guided activity|Participants will be provided on information on how to guide activity based on pain response.
214963116|NCT02594917|PROCEDURE|Right Heart Catheterization|Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.
214963117|NCT02594917|OTHER|Blood draw|Test and control group will be asked to give 20 ml of blood samples
215080162|NCT04171596|BEHAVIORAL|Primary care coordination|"A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk."
215080163|NCT02526082|OTHER|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
215080164|NCT02826421|DEVICE|UltraSert Preloaded Delivery System|Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
214354410|NCT02380092|DEVICE|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
214354411|NCT06243146|OTHER|Titration of Inspired Oxygen|Titration of Inspired Oxygen During One-Lung Ventilation
214354412|NCT06635928|DEVICE|Bright light therapy|30min daily of 10.000 lux bright light therapy
214354413|NCT06635525|BIOLOGICAL|Influenza vaccination|Single-dose
214354414|NCT06635525|BIOLOGICAL|SARS-CoV-2 vaccine|Single-dose
214354415|NCT06533228|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)|Abbreviated magnetic resonance enterography (MRE) imaging to detect active inflammation in patient's with known Crohn's Disease.
214963118|NCT04293484|DEVICE|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
214963119|NCT04293484|DEVICE|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
214963120|NCT03608813|OTHER|Serum Metabolomics profiling|Untargeted serum metabolomics profiling
214963121|NCT03774888|PROCEDURE|Connective tissue graft at time of bone graft|following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
214963122|NCT03774888|PROCEDURE|Acellular Demal Matrix at time of bone graft|following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
215080165|NCT02826421|DEVICE|iTec Preloaded Delivery System|Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
215080166|NCT02826421|DEVICE|iSert Preloaded Delivery System|Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
215080167|NCT02826421|DEVICE|Monarch III D Manual IOL Delivery System|Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
214354416|NCT04537091|PROCEDURE|rESWT|rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
214354417|NCT04537091|PROCEDURE|PRP injection|PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
214354418|NCT03912259|DRUG|Dupilumab|"Pharmaceutical form: solution,~Route of administration: SC"
214354419|NCT03912259|DRUG|Placebo|"Pharmaceutical form: solution,~Route of administration: SC"
214963123|NCT03774888|PROCEDURE|No soft tissue grafting at time of bone graft|Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
214963124|NCT03003169|OTHER|Medical questionnaire|"* quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)~* Hospital Anxiety and Depression scale~* satisfaction care questionnaire (IN-PATSAT32)"
214963125|NCT05464420|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
214963126|NCT05464420|BIOLOGICAL|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
214963127|NCT01836146|DEVICE|EnligHTN™ Renal Artery Ablation Catheter|
214963128|NCT03101384|OTHER|Diagnostic error|There is no intervention in our study. Patient will be managed with usual care. We will divide patients in the 2 groups according to the presence of diagnostic error.
214963129|NCT01383018|DEVICE|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
214963130|NCT06038500|OTHER|Multicomponent intervention of resistance exercises, dancing sessions and nutritional education|The intervention consisted of two sets of ten repetitions of resistance exercises, the second month four sets of eight repetitions, and the third month four sets of fifteen repetitions. It was estimated that each session (dance + resistance exercise) generated a caloric expenditure of 270.85 calories corresponding to 4.5 and 3.5 METs per activity. The resistance exercises and the dance sessions began and with a warm-up and stretching session 10 min, followed by the resistance exercises 30 min and dancing practice 30 min. The session ended with a cooling down session 10 min. The nutritional education offered included weekly topics lasting 20 min, on basic concepts of nutrition and recommended diet for the maintenance of skeletal muscle mass. Reinforcement of the topics was carried out through triptychs that were provided throughout the 12 sessions.
214963131|NCT05828368|PROCEDURE|Non surgical periodontal therapy|"Scaling and root planing is a deep cleaning below the gumline used to treat gum disease.~Gum disease is caused by a sticky film of bacteria called plaque. Plaque is always forming on your teeth, but if they aren't cleaned well, the bacteria in plaque can cause your gums to become inflamed."
214354420|NCT03912259|DRUG|Emollient (moisturizer)|"Pharmaceutical form: cream,~Route of administration: topical use"
214963132|NCT00438204|BIOLOGICAL|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
214963133|NCT00438204|DRUG|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
215080168|NCT01325090|DRUG|BOTOX|A syringe of 1 ml contain 25 Allergan units.
215080169|NCT01325090|OTHER|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
215080170|NCT04821674|BIOLOGICAL|DS-5670a|DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
215080171|NCT04821674|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
215080172|NCT04899440|DEVICE|Water Flosser|A pressurized stream of water to reduce gingivitis and remove adherent plaque
214354421|NCT00007189|DRUG|Naproxen Sodium (Aleve)|
214354422|NCT00007189|DRUG|Celecoxib (Celebrex)|
214963134|NCT00438204|DRUG|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
214963135|NCT02077309|DRUG|Linagliptin|
214963136|NCT02077309|DRUG|Placebo|
214963137|NCT01158742|OTHER|Glomerular Filtration Rate with Iothalamate|used to determine kidney function
214963138|NCT01158742|OTHER|Glomerular Filtration Rate with Iohexol|used to determine kidney function
214963139|NCT02719002|DEVICE|spectral domain optical coherence tomography C-scan and multifocal electroretinogram|
214963140|NCT03383224|OTHER|genotype-guided therapy|treatment based on patient's CHRNA5 rs16969968 genotype
214963141|NCT03383224|DRUG|Nicotine patch|
214354423|NCT03496038|PROCEDURE|L-PRF|The use of the L-PRF as graft material for sinus augmentation procedure will be analysed
214354424|NCT03496038|PROCEDURE|DBBM|The use of bovine xenograft as graft material for sinus augmentation procedure will be analysed
214354425|NCT00064727|DRUG|Avandia (Rosiglitazone)|
214678921|NCT03632512|DIETARY_SUPPLEMENT|Hericium honey bolus|The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
214678922|NCT03632512|DIETARY_SUPPLEMENT|Placebo honey bolus|The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
214963142|NCT03383224|BEHAVIORAL|Smoking cessation counseling|
214963143|NCT03021317|DRUG|ACTHar|The patients will be given 80 Units subcutaneously of ACTHAR at the time of MS relapse daily for 10 days.
214963144|NCT00558987|BEHAVIORAL|Discipline Video|"1. The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~2. A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers."
214963145|NCT00558987|BEHAVIORAL|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
214963146|NCT04653259|OTHER|LYFE MD app|"LyfeMD app is a digital health platform for patients living with both Crohn's disease (CD) and Ulcerative colitis (UC). LyfeMD is meant to help people live and thrive while managing their inflammatory disease with holistic, easy-to-implement, evidence based lifestyle therapies. LyfeMD is one app with multiple features - ranging from customized diet using anti-inflammatory principles identified from recent research, exercise plans to mindfulness and stress reduction programs. It helps patients make therapeutic diet choices to treat inflammation and provides stress reduction strategies when they feel unwell. The LyfeMD app also supports patients to maintain remission even when they're feeling well with trusted resources designed to keep them symptom free.~In addition to delivering personalized and interactive support, the app uses behaviour science to help patients change their habits, improve their health and reduce the burden IBD places on their lives."
214963147|NCT03414229|DRUG|Epacadostat|100mg bid days 1-21
214963148|NCT03414229|DRUG|Pembrolizumab|200mg/dose Day 1, Q 3 weeks
214963149|NCT03576924|BEHAVIORAL|MICT|Individuals randomized to MICT will be asked to engage in only MICT 5 times/week for 30 min/session at 60-70% of heart rate max, consistent with physical activity guidelines of 150 min/week of moderate activity. Individuals are asked to engage in only MICT exercise during the 4-week supervised and unsupervised exercise sessions. During the supervised exercise the intensity will be based on the heart rate (HR) monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
215080173|NCT04899440|OTHER|Control|No Oral Irrigator Control
215080174|NCT02273635|DRUG|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
215080175|NCT02273635|DRUG|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
215080176|NCT02076360|BEHAVIORAL|Preoperative Video|Patients will watch preoperative instructional video
214354426|NCT00064727|DRUG|Avanclia (Rosiqlitazone)|
214354427|NCT00127075|DRUG|nomegestrol acetate|10 mg/day
214354428|NCT00127075|DRUG|estradiol|75 mcg, once a week
214354429|NCT00127075|DRUG|placebo|matching placebo treatments
214354430|NCT06219746|DIAGNOSTIC_TEST|PSMA-imaging|Subjects undergo additional imaging i.e. PSMA/SPECT/CT and PSMA/PET/CT
214487146|NCT06758349|OTHER|Postural assessment with the instrument in sitting position.|Postural assessment with the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.
214678923|NCT03894904|DRUG|Papaverine|0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose
214678924|NCT03894904|DRUG|Heparin|2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
214354431|NCT01549613|DRUG|Daptomycin|• Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.
214354432|NCT01549613|DRUG|Vancomycin|• Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
214354433|NCT04219748|BEHAVIORAL|Case Management|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes.~This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition.~The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system."
214678925|NCT03894904|DRUG|Rescue papaverine, as needed|If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
214678926|NCT03837756|DRUG|Saline|Placebo
214678927|NCT03837756|DRUG|Lefitolimod|A TLR9 agonist administered s.c. once weekly for 8 weeks.
214963150|NCT03576924|BEHAVIORAL|HIIT|Individuals randomized to HIIT will be asked to engage in only HIIT 5 times/week for 4 weeks. HIIT consists of 5 repeated vigorous intervals of 1-min duration at 80-90% of heart rate max interspersed with 1-min recovery periods. A 3-min warm-up and 2-min cool-down are also included, for a total session duration of 15 minutes. This matches the guidelines of 75 min of vigorous exercise per week. During the supervised exercise sessions, intensity will be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
214963151|NCT03576924|BEHAVIORAL|CHOICE|Participants will first be familiarized with HIIT and MICT in a randomized, counter-balanced order during supervised sessions 1 and 2, and will subsequently self-select the exercise type for the supervised and unsupervised exercise sessions. The HIIT and MICT protocols will match to the parallel imposed conditions. During the supervised exercise, intensity will also be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
214963152|NCT04533438|DEVICE|RhinAer Stylus|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session.
214963153|NCT04533438|DEVICE|Sham|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
214963154|NCT05443997|BEHAVIORAL|MIYCN capacity building|"* MIYCN knowledge, skills, and motivation of FLWs~* Supportive supervision~* Decentralized programmatic decision-making using data~* PRI member involvement~* Availability of THR~* IYCF knowledge and practices"
214963155|NCT04875780|BEHAVIORAL|Digital diabetes prevention app intervention|"16-week core program consisting of 16 online weekly interactive lessons on diet and physical activity for weight loss. After the completion of the core program, participant can proceed to the 36-week post-core phase. The post-core program provides 8 monthly lessons focusing on maintaining lifestyle habits and weight loss.~Participants will be guided to use the smartphone app for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 persons. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
214354434|NCT01541228|DEVICE|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.~Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval."
214354435|NCT01541228|PROCEDURE|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval."
214354436|NCT02216123|DRUG|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
214354437|NCT02216123|DRUG|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
214354438|NCT02216123|DRUG|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:~1. tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~2. tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
214354439|NCT02216123|DRUG|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
214487147|NCT06758089|DEVICE|Lens 1 (ocufilcon D)|15 minutes of daily wear
215080177|NCT03078790|DEVICE|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
215080178|NCT05326581|DEVICE|mri|The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
215080179|NCT02291757|DIETARY_SUPPLEMENT|NEM brand eggshell membrane|NEM 500 mg, once daily, p.o.
215080180|NCT02291757|DIETARY_SUPPLEMENT|Placebo|Placebo, 500 mg, once daily, p.o.
214487148|NCT06758089|DEVICE|Lens 2 (somofilcon A)|15 minutes of daily wear
214487149|NCT06758843|OTHER|measure the axial length, visual acuity, and refraction at follow-up of 6- and 12-month|the intervention is follow-up with parameters to measure and data to record
214487150|NCT06759090|DRUG|Metronomic capecitabine|Metronomic capecitabine: 650 mg/m2, twice daily, to be swallowed with water within 30 minutes after a meal;
215080181|NCT02141490|DRUG|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
215080182|NCT02141490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
214354440|NCT02216123|DRUG|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
214354441|NCT05734118|DEVICE|Perfusion assessment by means of the SPY-PHI camera|Minutes after injection of ICG, the intestinal perfusion can and will be assessed using the SPY-PHI camera by Stryker Endoscopy. The operative plan will not be changed based on the results of the perfusion assessment. Images will be recorded and evaluated postoperatively.
214963156|NCT04875780|BEHAVIORAL|Digital weight loss tracking app intervention|"All participants will be provided the same smartphone app as the intervention group for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 person. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
214354442|NCT02486926|OTHER|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
214354443|NCT02486926|DRUG|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
214354444|NCT02486926|DRUG|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
214354445|NCT02486926|DRUG|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
214354446|NCT02486926|DRUG|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
214354447|NCT04866316|OTHER|There is no active intervention as this is a service evaluation|There is no active intervention as this is a service evaluation
214354448|NCT04474626|DRUG|Isoquercetin|Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.
214354449|NCT04977050|DIAGNOSTIC_TEST|Quidel quickvue antigen test for COVID-19|rapid antigen test on nasal swab specimen for COVID-19
214354450|NCT03280758|BEHAVIORAL|Muscle Strengthening exercises|Participants will be required to participate in resistance training 3 hours per week.
214354451|NCT03025906|DRUG|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
214354452|NCT03025906|DRUG|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
214354453|NCT01605513|DRUG|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
214354454|NCT03162224|DRUG|MEDI0457|MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.
214354455|NCT03162224|DEVICE|CELLECTRA®5P device|MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.
214354456|NCT03162224|DRUG|Durvalumab|Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.
214487151|NCT06759090|DRUG|Camrelizumab|Camrelizumab: a PD-1 inhibitor, 200 mg, intravenous injection once every 2 weeks;
214487152|NCT06759090|DRUG|Apatinib Mesylate Tablets|Apatinib mesylate: a small molecule of tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) , 250mg, once daily, to be swallowed with water within 30 minutes after a meal.
214487153|NCT06759987|BEHAVIORAL|self-care behavior intervention|The intervention group received the self-care behavior intervention program based on the interaction model of health behavior
214487154|NCT06749275|DEVICE|5,000 ppm fluoride toothpaste|In group 1, toothbrushing with toothpaste of 5,000 ppm of fluoride twice per day for two minutes, after breakfast and before bedtime. Participants will be also instructed not to rinse with water after brushing and to only eliminate the excess of the dentifrice by spitting out. The amount of toothpaste to be used had to be about the size of a pea.
214354457|NCT02170987|DRUG|Dabigatran etexilate low|
214678928|NCT03837756|DRUG|3BNC117 and 10-1074|Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
214678929|NCT03242759|DRUG|nintedanib|Drug
214678930|NCT03242759|DRUG|pirfenidone|Drug
214963157|NCT04875780|BEHAVIORAL|Wait-list control (usual care)|Participants in the control group will be invited to have an annual review and blood test at baseline, 4 and 12 months and received general lifestyle advices from a registered nurse at a community clinic.
215000403|NCT07121803|OTHER|specialized food based on ice cream, order 1|Order of intervention: 1. ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose; 2: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin; 3: standard ice cream (12% fat)
214354458|NCT02170987|DRUG|Dabigatran etexilate high|
214354459|NCT02170987|DRUG|Moxifloxacin|
214354460|NCT02170987|DRUG|Placebo|
214354461|NCT00546585|BIOLOGICAL|Influenza A/H7N7 Vaccine|Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
214354462|NCT00546585|DRUG|Placebo|Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
214354463|NCT06096051|PROCEDURE|Use of fixed-dosed 4F-PCC|Determine if fixed-dose 4F-PCC is safe and effective in patients with DOAC-associated ICH when compared to weight-based dosing.
214354464|NCT05334498|OTHER|Motor dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed tossing and catching the ball, rehanging loops on hoops, buttoning and unbuttoning the shirts, holding the cup in water without the spilling and receiving with returning the water. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
214354465|NCT05334498|OTHER|Cognitive dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed sharp coloring, subtraction, counting, verbal analogical reasoning and backward spelling. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
214354466|NCT05964478|OTHER|Multi-component hand hygiene intervention in primary schools not connected to functional water supply system in Nigeria and Palestine|Each participating school receives: (i) Two Gravit'eau handwashing stations (http://www.graviteau.ch): these systems recycle on-site greywater and operate through gravity and a manual foot pump, and can be produced locally. (ii) Behavior change activities: Developed by a group of expert psychologists (http://www.ranasmosler.com/ranas), utilizing the risks, attitudes, norms, abilities, and self-regulation (RANAS) approach. (iii) WASH infrastructure rehabilitation and soap dispenser installation. (iv) Controlled chlorine monitoring: Equipment provided for monitoring chlorine concentration in water storage, with staff training. (v) Preventive maintenance: Trained circuit rider inspects infrastructure regularly under WASH committee supervision
214354467|NCT01118533|DEVICE|metal reusable blades MacIntosh|laryngoscope blades
214354468|NCT01118533|DEVICE|Single use plastic blades HEINE XP®|laryngoscope blades
214354469|NCT05191758|DIETARY_SUPPLEMENT|FPP supplement|Participants will take the supplements per randomization
214354470|NCT02077348|DRUG|Insulin withdrawal|Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.
214354471|NCT02077348|DRUG|Norditropin|0,4 mg of GH administered at 7.05 A.M. on the study day.
214354472|NCT02935491|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|"TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used"
214354473|NCT00002574|BIOLOGICAL|recombinant interferon alfa|
214354474|NCT00002574|DRUG|omacetaxine mepesuccinate|
214354475|NCT01104610|DEVICE|Breas Vivo 40|The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
214354476|NCT02795273|DRUG|Grass-SPIRE|
214354477|NCT02795273|DRUG|Placebo|
214678931|NCT06338059|OTHER|Vitamin B12 Level|Vitamin B12 Level Laboratory measurement of patient's vitamin B12 level in unit of pg/mL 25 OH Vitamin D Level Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
215080183|NCT04656041|DRUG|FOLFOX/ nal-IRI|"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1\) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2\) Oxaliplatin via IV, predetermined dosage per protocol~* 3\) Leucovorin via IV, predetermined dosage per protocol~* 4\) 5-Fluorouracil via IV, predetermined dosage per protocol"
215080184|NCT04656041|DRUG|Paclitaxel|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
214354478|NCT05079074|DIAGNOSTIC_TEST|ctDNA testing|ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.
214354479|NCT04681612|DIAGNOSTIC_TEST|MSNA|"Assessed via Muscle Microneurography during the first 14 days of the acute phase.~Indices: busts/min, busts/100bpm"
214354480|NCT04681612|DIAGNOSTIC_TEST|Heart Rate Variability|Assessed via 24hr ECG monitoring during the first 14 days of the acute phase. Indices: Time-domain, Frequency-domain, Non-linear
214354481|NCT04681612|DIAGNOSTIC_TEST|Blood Pressure Variability|Assessed via Ambulatory BPM during the first 14 days of the acute phase. Indices: SD, wSD, ARV, CV
214354482|NCT04681612|DIAGNOSTIC_TEST|CMR|Cardiac Magnetic Resonance during the first 14 days of the acute phase. Assessment of oedema, Late Gadolinium Enhancement ischaemic pattern. Assessment of cardiac function parameters
214354483|NCT04681612|DIAGNOSTIC_TEST|History, Lab, clinical and hemodynamic parameters|1\. Description of event, 2. Risk factors, 3. Medical history, 4. ECG parameters, 5. ECHO parameters, 6. Hemodynamic parameters of acute phase and hospitalization, 7. Coronary angiogram paraemeters, 7. Complete lab parameter assessment, 8. Thrombofilia assessment, 9. SF-12 QoL and Anxiety and Depression Scale (HADS) questionnaires
214354484|NCT06213948|DRUG|Mirtazapine 15 MG|"Mirtazapine~* Commercial name: Remeron® SolTab~* Pharmaceutical form: film-coated tablets (15 mg)"
214354485|NCT05055102|OTHER|Data collection|demographics co-morbidities risk factors operative, hospital and vascular follow-up data
214354486|NCT04585932|DRUG|Apalutamide|Given PO
214354487|NCT04585932|DRUG|Degarelix|Given SC
214354488|NCT04585932|DRUG|Leuprolide Acetate|Given IM
214354489|NCT04585932|OTHER|Quality-of-Life Assessment|Ancillary studies
214354490|NCT04585932|OTHER|Questionnaire Administration|Ancillary studies
214354491|NCT04585932|RADIATION|Radiation Therapy|Undergo RT
214354492|NCT06243705|DEVICE|Robot-Pet|The robot-pet makes sounds like a real cat and responds to touch and petting
214354493|NCT06243705|DEVICE|Virtual Reality Glasses|VR glasses allow you to see videos and films projected on the screen more realistic. With its filtering feature, it combines two different images in the brain and provides the perception of depth in the image and creates a 3D space environment
214678932|NCT05032833|DRUG|5-MeO-DMT|A single dose of 5-MeO-DMT will be administered intranasally
215080185|NCT04656041|DRUG|Carboplatin|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
214354494|NCT03546894|DRUG|Brigatinib|Brigatinib tablets.
214354495|NCT03546894|DRUG|Alectinib|Alectinib capsules.
214354496|NCT03546894|DRUG|Ceritinib|Ceritinib capsules.
214354497|NCT03546894|DRUG|Lorlatinib|Lorlatinib capsules.
215080186|NCT04656041|RADIATION|Proton Radiation Therapy|Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
214354498|NCT03546894|DRUG|Any FDA Approved ALK Inhibitors|FDA approved ALK inhibitors available for treatment.
214354499|NCT06141811|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
214354500|NCT06141811|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
214354501|NCT02204995|PROCEDURE|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
214354502|NCT02204995|PROCEDURE|Trapeziectomy|Trapeziectomy
214354503|NCT06050850|BEHAVIORAL|NOURISH-ALL|Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.
214354504|NCT04066114|BIOLOGICAL|lulizumab pegol|25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
214354505|NCT04066114|BIOLOGICAL|antithymocyte globulin (rabbit)|Study participants are administered four doses of rabbit anti-thymocyte globulin, total dose 6 mg/kg given in divided doses on the day of transplantation and days 1-3.
214963158|NCT03338504|DIAGNOSTIC_TEST|Invasive coronary angiography|Where patients are fit, coronary angiography will be performed via the femoral or radial artery with 6F arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, Minnesota) will be used to determine distal coronary pressure and the fractional flow reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) hyperaemia. Optical coherence tomography (OCT) will be performed in all three coronary vessels using a Dragonfly® coronary imaging catheter (Abbott Diagnostics, Abbott Park, Illinois) with pullback at 20 mm/s to identify features consistent with vulnerable plaque or recent plaque rupture.(16) If there is evidence of inducible myocardial ischaemia due to coronary artery stenosis, revascularisation with percutaneous coronary intervention may be considered if in the patients best interests.
214963159|NCT03338504|RADIATION|CT coronary angiography|CT coronary angiography will be performed using a 128 multidetector row CT. Patients with a heart rate exceeding 65 beats/min will receive oral beta-blockade 1 hour before computed tomography. Additional intravenous beta blockers will be given depending on heart rate at the time of imaging. All patients will receive sublingual glyceryl trinitrate (300 μg) immediately prior to dual cardiac and respiratory-gated computed tomography imaging of the coronary arteries. The investigators will quantify total plaque burden using CT calcium scoring. A bolus of 80-100 mL of contrast will be injected intravenously at 5 mL/s. An assessment of the functional consequences of coronary artery stenosis will be made using the computed tomography fractional flow reserve (CT-FFR) technique, using the HeartFlow platform.
214963160|NCT03338504|DIAGNOSTIC_TEST|Cardiac MRI|Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner. The MRI scan will consist of localisers, axial and coronal HASTE images, standard breath-held and ECG-gated cine sequences. Short-axis cine images will be obtained for the assessment of left ventricle function and volumes. Left ventricle volumes, mass and ejection fraction will be assessed using dedicated software and values indexed to body surface area. Breath-held, ECG-gated T2 mapping sequences of the myocardium will be performed in the short-axis as a marker of myocardial inflammation. T1-weighted imaging of the coronary arteries will be performed to look for evidence of recent intraplaque thrombus or haemorrhage. The late gadolinium enhancement and T2 mapping techniques will identify regions of new or old myocardial infarction as well as other patterns of injury. Where there are no contraindications, stress MRI will be performed using intravenous Regadenoson.
214963161|NCT06144203|BEHAVIORAL|Exercise|Participants will complete either a 30-minute bout of light-, moderate-, or high-intensity aerobic exercise at one of the visits.
214963162|NCT05279131|DRUG|Tirbanibulin ointment 1%|Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.
214963163|NCT01403571|DIETARY_SUPPLEMENT|Salba (Salvia hispanica L.)|30g/1000kcal/day over 24 wks
214963164|NCT01403571|DIETARY_SUPPLEMENT|Oat-based Control|Placebo: 36g/1000kcal/day over 24 weeks
215080187|NCT06305936|OTHER|Intervention with 100% plant-based diet|The intervention consists of three key components: 1) Educational materials (videos), 2) Participation in a cooking workshop introducing plant-based meals, complete with recipes, and 3) Daily delivery of plant-based dinner meals over a four-week period. The remaining meals during the period are modified by the participant to also adhere to a 100% plant-based composition.
215080188|NCT05966428|OTHER|Conventional Exercises|"This conventional exercises included stretching and strengthening, balance-coordination, mobility and range of motion exercises.~The control group received conventional therapy 3 days a week for 8 weeks. Each therapy session a day lasted 45 minutes in control group."
214354506|NCT04066114|DRUG|methylprednisolone|500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
214354507|NCT04066114|BIOLOGICAL|tocilizumab|8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
214354508|NCT04066114|DRUG|Prednisone|"Beginning on Day 3 post transplantation, taken orally: 60 mg daily~* Days 4 through 10: 30 mg daily~* Days 11 through 17: 20 mg daily~* Days 18 through 24: 10 mg daily~* After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol"
214354509|NCT04066114|DRUG|everolimus|Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
214354510|NCT04066114|BIOLOGICAL|belatacept|5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
214354511|NCT04066114|DRUG|mycophenolate mofetil|mycophenolate mofetil is started no later than one day after transplant at 1000mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do no tolerate everolimus can stay on or switch back to mycophenolate mofetil 1000 mg twice daily and remain in trial.
214354512|NCT04066114|DRUG|mycophenolic acid|mycophenolic acid is started no later than one day after transplant at 720mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do not tolerate everolimus can stay on or switch back to 720 mg twice daily of mycophenolic acid and remain in trial.
214354513|NCT00254982|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
214354514|NCT00728819|DEVICE|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
214354515|NCT00728819|DEVICE|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
214354516|NCT00223860|DRUG|Human chorionic gonadotropin (hCG)|
214354517|NCT00223860|DRUG|Luteinizing hormone releasing hormone (LHRH)|
214354518|NCT04100447|DRUG|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
214354519|NCT04110769|DIAGNOSTIC_TEST|next generation sequencing|the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.
214354520|NCT04110769|DIAGNOSTIC_TEST|following next generation sequencing|The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.
214354521|NCT03125304|OTHER|acupuncture|They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
214354522|NCT00982358|DRUG|Valsartan|
214354523|NCT00982358|OTHER|Placebo|
214354524|NCT03203369|BIOLOGICAL|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
214354525|NCT02998281|DEVICE|Threshold (IMT)|Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
214354526|NCT05795582|DEVICE|POPMETRE® (Axelife , France)|Measurement with 2 devices
214354527|NCT03195257|OTHER|GIP|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
214354528|NCT03195257|OTHER|GLP-1|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
214354529|NCT03195257|OTHER|Saline|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
214354530|NCT03886103|DRUG|14C labeled PXL770|Single administration
214354531|NCT03529474|OTHER|Psychology and Physiotherapy group|"Psychological program: 4 sessions,2 hours each,4 months~* Psychoeducation.Influence of psychological factors on chronic pain: modulators of pain experience. Biopsychosocial model of pain.~* Training techniques of psychological management of pain:Diaphragmatic Breathing and Progressive Muscle Relaxation to control vicious circle pain-tension-pain.~* Kinesiophobia. Rational regulation of the activity level:Cognitive therapy (management of irrational believes about pain) and Organisation of time and reinforcement activities.~Physiotherapy program:3 sessions per week,1 hour per session,4 months:~* Aerobic exercise:walking, cycling~* Warm-up: active ROM exercises of inferior and superior extremities (ISE)~* Progressive resistance training with elastic bands of ISE~* Stretching of ISE"
214354532|NCT03529474|OTHER|Placebo comparator: control group|Control group Normal daily activities Usual daily activities
214354533|NCT02931279|DEVICE|PASS OCT® Spinal System|Posterior osteosynthesis of the cervical and upper thoracic spine
214354534|NCT03117738|DRUG|AstroStem|Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
214354535|NCT03117738|OTHER|Placebo-Control|Saline with 30% auto-serum
214354536|NCT03845348|OTHER|TD03|Shampoo TD 3 days
214354537|NCT03845348|OTHER|TD07|Shampoo TD 7 days
214354538|NCT03845348|DRUG|Ketoconazole 2% Shampoo|Ketoconazole 2% Shampoo
214354539|NCT06354101|DRUG|Tirzepatide|Once-weekly subcutaneous injectable
214354540|NCT06354101|DRUG|Semaglutide|Once-weekly subcutaneous injectable
214354541|NCT01546896|DRUG|buspirone+alprazolam|day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg
214354542|NCT01546896|DRUG|alprazolam|0.5mg/d
214354543|NCT04099810|DIAGNOSTIC_TEST|three-dimensional echocardiography|"A focused echocardiographic exam will be performed. In details will be acquired:~* high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~* Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition."
214354544|NCT05319067|OTHER|Stool sampling|Stool sample taken at home 24 hours before hospital visit
214354545|NCT05314439|DRUG|ION904|ION904 will be administered by SC injection.
214354546|NCT05314439|DRUG|Placebo|Placebo will be administered by SC injection.
214354547|NCT02355808|BEHAVIORAL|Tailored Leaflet|
214354548|NCT02355808|BEHAVIORAL|GP visit|
214354549|NCT01564550|DRUG|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
214354550|NCT01564550|DRUG|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
214354551|NCT01564550|OTHER|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
214354552|NCT01564550|OTHER|no diet|The subjects will ingest a non-restricted diet prior to the study day.
214678933|NCT05032833|OTHER|Placebo|A single dose of placebo will be administered intranasally
214678934|NCT00259025|DRUG|lipid emulsion with a high content of n-3 fatty acids|
214354553|NCT00135148|PROCEDURE|Filling out a questionnaire on libido and possible partner relationship|
214354554|NCT00135148|PROCEDURE|Sex steroid analysis|
214487155|NCT06749275|DEVICE|22,600 ppm fluoride varnish|The application protocol of 5% fluoride varnish will be used together with the 1,450 ppm paste with the same protocol of the group 1: toothbrushing with toothpaste of 1.450 ppm of fluoride twice per day for two minutes, after breakfast and before bedtime. Participants will be also instructed not to rinse with water after brushing and to only eliminate the excess of the dentifrice by spitting out. The amount of toothpaste to be used had to be about the size of a pea.
214487156|NCT06749275|DEVICE|38% SDF|The application protocol of 38% SDF annually will be used together with the 1,450 ppm paste with the same protocol of the group 2: toothbrushing with toothpaste of 1.450 ppm of fluoride twice per day for two minutes, after breakfast and before bedtime. Participants will be also instructed not to rinse with water after brushing and to only eliminate the excess of the dentifrice by spitting out. The amount of toothpaste to be used had to be about the size of a pea.
214963165|NCT04350047|PROCEDURE|Radical nephrectomy with inferior vena cava thrombectomy without thoracotomy|The abdomen was accessed through a Makuuchi incision. After mobilization of the liver and assessment of the inferior vena cava infiltration (IVC), IVC was clamped below the level of the renal veins. In order to get access to the intrapericardial IVC, an incision was made through the tendon of the diaphragm and a clamp was placed first in the hepatoduodenal ligament (Pringle maneuver) and then in the endopericardial portion of the IVC, in that order. A longitudinal 3-4 cm incision was made incorporating the junction of IVC and right renal vein. After tumor removal thrombus was removed and a fine clamp was placed at the IVC just below the hepatocaval junction and immediate release of the clamping of the hepatoduodenal ligament. Total endopericardial clamp time was 4 minutes. Patients then underwent radical nephrectomy in a standard fashion with en bloc resection of the IVC thrombus.
214963166|NCT04949282|DRUG|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
214963167|NCT04949282|DEVICE|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
214963168|NCT04855331|PROCEDURE|Laparoscopic pancreatoduodenectomy|Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
214963169|NCT04855331|PROCEDURE|Open pancreatoduodenectomy|Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
214487157|NCT05934227|DRUG|Amoxicillin 500 milligrams capsules plus metronidazole 400 milligrams|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of amoxicillin (500 milligrams) + metronidazole (400 milligrams) three times a day for 7 days after SRP
215080189|NCT05966428|OTHER|Sensory Integration Therapy|"The Sensory Integration Therapy was applied to the intervention group in addition to the conventional exercise program. Sensory Integration Therapy included tactile, proprioceptive, and vestibular activities. The tactile sensory activities consisted of materials such as stepping stones, tactile box, brushing, fabric walking path. The vestibular sensory activities consisted of materials such as hammock swings, trampolines, rope nets, rock walls, river stones. Proprioceptive sensory activities consisted of materials such as weight bearing activities, heavy lifting, deep pressure, big ball activities, tug of war and ball pits.~The intervention group underwent each session 45 minute conventional therapy and 15 minutes SIT. The therapy program continued 3 days a week for 8 weeks in intervention group."
214487158|NCT05934227|OTHER|placebo|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of placebo containing corn starch capsules three times a day for 7 days after SRP
214487159|NCT06762262|COMBINATION_PRODUCT|Moderate-Intensity continuous training|refers to a type of aerobic exercise that involves maintaining a steady and moderate level of physical activity for an extended period. The exercise is performed at a consistent and moderate pace without significant fluctuations in intensity. MICT primarily targets the aerobic energy system, enhancing cardiovascular endurance and respiratory efficiency
215080190|NCT03234855|DEVICE|LMD|Physician uses LMD to measure defect during procedure.
215080191|NCT03457506|DIAGNOSTIC_TEST|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
215080192|NCT02938078|DEVICE|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
214354555|NCT03274843|OTHER|Activity of everyday life|Kitchen workshop
214354556|NCT01695967|PROCEDURE|turbinate cauterization|
214354557|NCT04004611|DRUG|Mirikizumab|Administered IV and SC
214354558|NCT05180760|BEHAVIORAL|Smartphone app use|Smartphone app use in the active arm
214354559|NCT05180760|BEHAVIORAL|Standard of care|Standard of care
214354560|NCT04826354|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin Versus Rosuvastatin plus Ezetimibe
214354561|NCT04826354|DRUG|Rosuvastatin|Rosuvastatin
214354562|NCT04420689|DRUG|Bevonescein|Bevonescein Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
214354563|NCT06382350|DEVICE|MiniMed 780 G|none, observational study
214354564|NCT02248792|DRUG|Methotrexate|
214354565|NCT02625103|PROCEDURE|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
214354566|NCT02625103|DRUG|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
214354567|NCT01575366|BEHAVIORAL|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
214354568|NCT06425354|DEVICE|Mechanical ventilation|Mechanical ventilatiom
214963170|NCT05320419|OTHER|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
214963171|NCT05320419|OTHER|Physiotherapy (PT group)|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
214963172|NCT01744158|OTHER|No intervention applicable|"Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:~* differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)~* measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording~* measurement of severity of spasticity using the modified Ashworth score~* description of presence of chorea or athetosis~* classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)~* classification of fine motor abilities using the manual ability classification system (MACS)~* collection of demographic data and associated medical history"
214963173|NCT06110598|DRUG|Capecitabine|Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
214963174|NCT00179803|PROCEDURE|Stem Cell Transplant|"Group A: recurrent medulloblastoma, recurrent germ cell tumor~* Cytoxan treatment~* Stem cell autologous harvest~Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET~* Carboplatin and Etoposide treatment~* Autologous stem cell harvest~The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to \>1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue."
214963175|NCT02497937|DRUG|GSK2798745|GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
214963176|NCT02497937|DRUG|Placebo|Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
214963177|NCT06553963|OTHER|Control group|The control group maintained their regular diet and training without additional nutritional support.
214963178|NCT06553963|OTHER|Experimental group|Biochemical Monitoring and Nutritional Support
214963179|NCT04088539|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date)
214963180|NCT04088539|BEHAVIORAL|Video-based health education|Educational videos on smoking and health will be developed to improve the knowledge of CSD smokers. The videos aim to raise their awareness on these important health topics and acquire effective cessation methods. The effectiveness of the educational videos will be evaluated by pre- and post-tests through a self-administered survey that assess the changes in knowledge related to smoking hazards, benefits of quitting, and methods to quit smoking.
214963181|NCT05297890|DRUG|Lorlatinib|Dosage Form: Lorlatinib tablet, Dosage: 25mg/tablet, Dosing Regimens: 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
214963182|NCT02980406|DIETARY_SUPPLEMENT|FODMAP|Fermentable oligo-, di- and monosaccharides and polyols are poorly absorbed carbohydrates that are known to cause symptoms in IBS patients.
214354569|NCT01621217|DRUG|Cetuximab|Will be given weekly intravenously during study treatment.
214354570|NCT01621217|DRUG|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
214354571|NCT01621217|DRUG|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
214354572|NCT01621217|RADIATION|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
214354573|NCT00089726|BIOLOGICAL|CG8123|
214354574|NCT00089726|DRUG|Cyclophosphamide|
214354575|NCT00441610|DRUG|Gimatecan|
214354576|NCT00682487|OTHER|Hair sampling for cortisol|Hair sampling for cortisol
214354577|NCT00682487|OTHER|Hair sampling for cortisol|Hair sampling for cortisol
214354578|NCT01055821|DRUG|pegylated interferon and ribavirin|48 weeks
214354579|NCT01055821|BIOLOGICAL|TG4040 + SOC|6 injections
214354580|NCT01055821|BIOLOGICAL|TG4040 + SOC|13 injections
214354581|NCT04049175|DRUG|Treatment A|Tablet of CHF 6532
214354582|NCT04049175|DRUG|Treatment B|Tablet of CHF 6532
214354583|NCT04049175|DRUG|Treatment C|Tablet of CHF 6532
214354584|NCT04049175|DRUG|Treatment D|Tablet of CHF 6532 placebo
214354585|NCT04315077|DIETARY_SUPPLEMENT|Oceanix®|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
214354586|NCT04315077|OTHER|Resistance Training|5 days of supervised and programmed whole-body resistance training.
214354587|NCT04729257|DEVICE|Philips IntelliSpace Cognition (ISC).|Philips ISC is a Class-II Medical Device in the US that aids in assessing cognition and helps inform the HealthCare Professional (HCP) to make a diagnosis and treatment plan. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
214354588|NCT04729257|DIAGNOSTIC_TEST|Paper-Pencil Tests.|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
214354589|NCT00712868|DRUG|Lactic acid|Once a day
214354590|NCT00515502|DRUG|GSK573719|250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
214354591|NCT00515502|DRUG|Tiotropium|strips of five capsules, each containing 18 μg administered via dry powder inhaler
214354592|NCT04720079|PROCEDURE|Subcutaneous infiltration of intercostobrachial nerve|Preoperative subcutaneous infiltration of intercostobrachial nerve with 10ml of 0.5% ropivacaine
214354593|NCT04720079|PROCEDURE|T2 paravertebral nerve block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of 0.5% ropivacaine
214354594|NCT00639873|DRUG|Artesunate|2 or 4 mg/kg/day for 7 days
214354595|NCT00639873|DRUG|quinine-doxycycline|quinine-doxycycline for 7 days
214354596|NCT03317002|DRUG|AZD5718|Oral dose of AZD5718 (tablet)
214963183|NCT02980406|DIETARY_SUPPLEMENT|Glucose (control)|Glucose is not a FODMAP.
214354597|NCT03317002|DRUG|AZD5718|Oral dose of AZD5718 (tablet)
214354598|NCT03317002|DRUG|Placebo|Matching placebo (tablet)
214354599|NCT03058211|DIAGNOSTIC_TEST|Echocardiography|Standard protocols
214354600|NCT03058211|DIAGNOSTIC_TEST|Cardiac Magnetic resonance|MRI with late gadolinium increase and T1 mapping
214354601|NCT03939377|OTHER|Questionnaire and treatment|EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
214354602|NCT05588726|BEHAVIORAL|Sleep Hygiene|Once weekly coaching calls with advice on sleep hygiene
214354603|NCT05588726|BEHAVIORAL|Mindfulness|Once weekly coaching calls with advice on mindfulness
214354604|NCT02645981|DRUG|Donafenib|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
214354605|NCT02645981|DRUG|Sorafenib|Control
214354606|NCT01945606|DRUG|Placebo (treatment 1)|Oral administration of placebo tablets
214354607|NCT01945606|DRUG|BAY1067197 (treatment 2)|Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
214354608|NCT02732938|DRUG|PF-04136309|PF-04136309 oral dosing
214354609|NCT02732938|DRUG|Nab-paclitaxel|Nab-paclitaxel IV dosing
214354610|NCT02732938|DRUG|Gemcitabine|Gemcitabine IV dosing
214354611|NCT05183971|OTHER|Proprioceptive Functional Analysis System|Proprioceptive testing and Physical Performance Tests
214354612|NCT00990223|DRUG|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
214354613|NCT00485290|BEHAVIORAL|meal (food intake)|600 kcal. (16% protein, 49%carbohydrate, 35% fatt)
214354614|NCT00636870|DRUG|Fexofenadine|
214354615|NCT03927950|DRUG|escitalopram|escitalopram 10-20mg per day 12 weeks
214354616|NCT03927950|DRUG|bupropion|bupropion 150-300mg per day 6 weeks
214354617|NCT03647501|DEVICE|Interbody cage (titanium)|Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.
214354618|NCT03647501|DEVICE|Interbody cage (PEEK)|Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
214354619|NCT00436657|DRUG|CHPP of Cisplatin|Starting dose of 100 mg/m\^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
214354620|NCT00436657|PROCEDURE|Abdominal Surgery|Surgical removal of abdominal tumors.
214354621|NCT04701398|OTHER|Multimodal prehabilitation|Exercise + nutritional supplementation + psychological advice
214354622|NCT03783182|DRUG|Betamethason Sodium Phosphate|Glucocorticoid
214354623|NCT03783182|DRUG|10% glucose solution|Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
214354624|NCT02462746|DIETARY_SUPPLEMENT|L-Cysteine|The trade name is New Root Herbal Inc.
214354625|NCT04530448|DRUG|Sodium bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
214354626|NCT04530448|OTHER|Standard of Care|Standard of Care treatment
214354627|NCT02592382|DIETARY_SUPPLEMENT|Xylitol spray|xylitol nasal spray will be administered to this arm three times daily for three months
214354628|NCT03214913|OTHER|Early Goal Directed Therapy|EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
214354629|NCT03214913|OTHER|Ruijin Strategy|"Ruijin Strategy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%\~35%."
214963184|NCT00671801|DRUG|Irinotecan|200 mg/m\^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
214963185|NCT00671801|DRUG|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
214354630|NCT02907021|DRUG|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
214354631|NCT03928080|DIAGNOSTIC_TEST|Bleeding on brushing|Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist
214354632|NCT01613248|DRUG|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
214354633|NCT01613248|DRUG|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
214354634|NCT01613248|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded."
214487160|NCT06788847|PROCEDURE|Ultrasound guided needle knife dissection|"This procedure involves a minimally invasive dissection of the fibrous cords in Dupuytren's Contracture using a needle knife guided by ultrasound imaging. Local anesthesia using 3-5 ml of 1% Lidocaine and 0.25% bupivacaine is administered for patient comfort. The technique aims to improve precision, minimize complications and reduce recurrence.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure."
214963186|NCT00735514|BEHAVIORAL|compliance monitoring|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
214963187|NCT00735514|OTHER|questionnaire administration|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
215000404|NCT07121803|OTHER|specialized food based on ice cream, order 2|"1. ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin;~2. ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose;~3. standard ice cream (12% fat)"
215000405|NCT07121803|OTHER|specialized food based on ice cream, order 3|"1. standard ice cream (12% fat)~2. ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose~3. ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin"
215000406|NCT07123155|DRUG|S-606001|S-606001 administered orally
215000407|NCT07123155|DRUG|Placebo|S-606001 matching placebo administered orally
215000408|NCT07123922|DIETARY_SUPPLEMENT|Silymarin|Participants received Silymarin 140 mg capsule orally thrice daily for 12 weeks
215000409|NCT07123922|DIETARY_SUPPLEMENT|Placebo|Participants received Silymarin placebo capsule thrice daily for 12 weeks
215000410|NCT07122466|DIAGNOSTIC_TEST|Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA)|ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.
215000411|NCT07122765|OTHER|Mixed Meal Feeding Challenge|Liquid flavored Ensure Plus Shake of varying caloric content based on individual daily estimated caloric need
215000412|NCT07123961|OTHER|High Driving Pressure Mechanical Ventilation|"A participant who is already invasively mechanically ventilated will be placed on Pressure Control Ventilation mode on an Evita V500 (Manufacturer: Dräger, Lübeck, Germany) ventilator if they are not already. The driving pressure will be set to 25 cmH2O (rate of pressure delivery). The Children's Hospital of Philadelphia (CHOP) PICU's standard of care regarding sedation, fluid management, ventilator weaning, and extubation readiness for invasively mechanically ventilated children will be adhered to for the duration of the study. An Enlight 2100 Electrical Impedance Tomography (EIT) Device (Manufacturer: Timpel) strap will be placed across the participant's chest up to four times throughout the study for a few hours to image the aeration in the lungs."
215000413|NCT07123961|OTHER|Low Driving Pressure Mechanical Ventilation|"A participant who is already invasively mechanically ventilated will be placed on Pressure Control Ventilation mode on an Evita V500 (Manufacturer: Lübeck, Germany) ventilator if they are not already. The driving pressure will be set to 15 cmH2O (rate of pressure delivery). CHOP PICU's standard of care regarding sedation, fluid management, ventilator weaning, and extubation readiness for invasively mechanically ventilated children will be adhered to for the duration of the study. An Enlight 2100 (EIT) Device (Manufacturer: Timpel) strap will be placed across the participant's chest up to four times throughout the study for a few hours to image the aeration in the lungs."
215000414|NCT07122999|DEVICE|Eustachi|A handheld device that delivers pulsed air through the nasal passage to facilitate opening of the eustachian tube. Participants in this group use the device twice daily for 5 weeks after tympanostomy tube extrusion.
215000415|NCT07123441|DRUG|Bevacizumab,Irinotecan liposome (II),5-FU/LV|Bevacizumab: 5 mg/kg, intravenous infusion, Day 1; Irinotecan liposome (II): 60 mg/m² (based on free base), intravenous infusion for at least 90 minutes, Day 1; 5-FU: 400 mg/m², intravenous bolus injection, Day 1; followed by 1200 mg/(m²·day) × 2 days of continuous intravenous infusion (total dose 2400 mg/m², infused over 46-48 hours); LV: 400 mg/m², intravenous infusion over 2 hours, Day 1; Q2w, continued until an event meeting the treatment discontinuation criteria occurs or the subject withdraws from the study.
215000416|NCT07124195|DRUG|Medroxyprogesterone acetate oral suspension|Medroxyprogesterone acetate oral suspension (Meishiya®) (administered from Day 1 to 21, 5 ml, once daily)
215080193|NCT02363374|DRUG|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
214678935|NCT06673108|DEVICE|SoLa Pelvic Therapy|SoLa Pelvic Therapy laser emits near-infrared (810-980 nm wavelength) energy to the vaginal tissues. The device treats at 5-8 W for 3-6 minutes and delivers a fluence of 3,000 and 5,000 J/cm2 through a sterile vaginal probe. Specific treatment time is calculated based on vaginal length. Based on a code input, the device can cycle between emitting laser energy or sham which is visible light without focused laser energy.
214678936|NCT06673355|OTHER|dental implant prosthesis|patients will receive frameworks made of high-performance polymer filled with nano zirconia and carbon
214678937|NCT06672783|PROCEDURE|echocardiogrphy|"Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening) o"
214678938|NCT06672744|OTHER|Exercise|Lumbar muscles (especially quadratus lumborum) and thoracolumbar fascia stretching exercises and strengthening exercises for the lumbar and abdominal muscles were described by the physiotherapist. Participants were asked to perform the exercises three times a day, five days a week
214678939|NCT06672744|OTHER|Myofascial release technique|Myofascial release technique was applied by the same researcher (YY) twice a week for four weeks.
214678940|NCT06672744|OTHER|Kinesiotaping|Kinesiotaping was performed by the same researcher (XX) for two sessions per week for four weeks with fascia correction technique
214678941|NCT06619990|BIOLOGICAL|XmAb942|Antibody
214678942|NCT06619990|DRUG|Placebo|Placebo
214678943|NCT06340555|OTHER|GUIA ATENCION MULTIDISCIPLINAR SANT BOI|Women with losses attended according to the multidisciplinary intervention proposed at the SJD Hospital de Sant Boi
214678944|NCT06340555|OTHER|USUAL CARE|Women with losses treated at the Hospital Comarcal del l'Alt Penedes.
214678945|NCT02133014|PROCEDURE|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
214678946|NCT02133014|DRUG|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
214678947|NCT00328263|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285 and Lactobacillus casei|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
214487161|NCT06765785|DIAGNOSTIC_TEST|CTCA|Screening CTCA will be performed in the experimental arm after 1:1 randomisation using sealed envelope technique
214487162|NCT06295952|DRUG|Pasireotide|Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.
214487163|NCT06295952|OTHER|SF-36 and HADS|Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.
214487164|NCT05495945|DEVICE|Low-intensity focused ultrasound pulsation (LIFUP)|LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.
214487165|NCT05495945|COMBINATION_PRODUCT|Functional Magnetic Resonance Imaging (fMRI) using Propofol|Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations
214487166|NCT05477589|DRUG|busulfan, cyclophosphamide and melphalan, BuCyMel|a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)
214487167|NCT05477589|DRUG|clofarabine, fludarabine and busulfan, CloFluBu|combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)
214487168|NCT05309577|BEHAVIORAL|Behavioral Self-Monitoring + Motivational Interviewing|Participants (n=20) will wear a iWatch to continuously measure their objective sleep-wake activity. The iWatch data sync to the new myRhythmWatch app, where participants will monitor their behavioral rhythm. Participants will also interact with a 'health coach' about their recorded behaviors weekly. This health coach will use motivational interviewing to enhance older adult caregivers' confidence and intrinsic motivation to engage in regular self-care.
214678948|NCT00328263|DIETARY_SUPPLEMENT|placebo|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
214678949|NCT02309710|DEVICE|ShangRing|ShangRing administered to males seeking medical male circumcision
214678950|NCT01690962|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
214678951|NCT01690962|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
214678952|NCT01123304|DRUG|MORAb028|1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
215080194|NCT02363374|RADIATION|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
215080195|NCT02363374|RADIATION|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
214487170|NCT06715501|DRUG|Cadonilimab|Cadonilimab is a PD-1/CTLA-4 bispecific antibody. The drug is administered at a fixed dose of 10mg/kg, intravenously (i.v.), on day 1, every 3 weeks (q3w), until disease progression or intolerable toxicity occurs, with a maximum treatment duration of 1 year.
214487171|NCT06715501|RADIATION|radiotherapy|GTV is defined as visible lesions (GTVp: primary lesion; GTVn: metastatic lymph nodes), CTVp is defined as 3cm above and below the primary lesion, with 0.5cm outward expansion around the periphery, and CTVn is defined as 0.5cm outward expansion of GTVn; PTVp is an outward expansion of 0.5cm for CTVp, and PTVn is an outward expansion of 0.5cm for CTVn. Radiotherapy dose: DT50.4Gy/28f, once daily, 5 times a week
214963188|NCT00735514|PROCEDURE|assessment of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
214963189|NCT00735514|PROCEDURE|management of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
214963190|NCT00735514|PROCEDURE|psychosocial assessment and care|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
214678953|NCT00221091|PROCEDURE|ventriculo-peritoneal shunt|
214963191|NCT04712864|BIOLOGICAL|LB1901|LB1901 - an autologous CD4-targeted CAR-T immunotherapy
214963192|NCT02145208|DEVICE|TIND System|An implant
214963193|NCT06050096|PROCEDURE|PCI|CTO patients treated by DCB
214963194|NCT02677597|DRUG|Cisplatin Combined With S-1|
214963195|NCT02677597|DRUG|Cisplatin Combined With Paclitaxel|
214963196|NCT05680077|DIAGNOSTIC_TEST|KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in both groups were collected and methylation tests were performed according to the kit instructions.
214963197|NCT02045186|OTHER|Assessment of Oral HPV Infection|"Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:~1. Polymerase chain reaction (PCR) for HPV DNA.~2. Fluorescent in-situ hybridization (FISH).~3. Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry."
214963198|NCT00256009|DRUG|Cytotec|
214963199|NCT01388712|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10\^8CFU).
214963200|NCT01388712|DIETARY_SUPPLEMENT|Placebo|Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
214963201|NCT00443157|BIOLOGICAL|Meningococcal B Vaccine NZ|
214963202|NCT06047223|DIAGNOSTIC_TEST|Magnetic resonanace imaging|Magnetic resonance imaging for measurement of diffustion tensor imaging
214963203|NCT03790865|DRUG|Livoletide|Daily subcutaneous injection
214963204|NCT03790865|DRUG|Placebo|Daily subcutaneous injection
214963205|NCT02273362|DRUG|Erlotinib|Given PO
214963206|NCT02273362|DRUG|Erlotinib Hydrochloride|Given PO
214963207|NCT02273362|OTHER|Laboratory Biomarker Analysis|Correlative studies
214963208|NCT02273362|OTHER|Quality-of-Life Assessment|Ancillary studies
214963209|NCT04540328|OTHER|Non-surgical periodontal treatment|
214963210|NCT06428032|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
214963211|NCT06428032|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
215000417|NCT07124195|COMBINATION_PRODUCT|high antiemetic regimen|Ondansetron Injection (administered on Day 1, 8 mg, once daily), Dexamethasone Tablets (administered on Day 1, 12 mg, once daily; administered from Day 2 to 4, 3.75 mg, twice daily), Fosaprepitant (administered on Day 1, 150 mg, once daily)
215000418|NCT07124195|COMBINATION_PRODUCT|moderate antiemetic regimen|Ondansetron Injection (administered on Day 1, 8 mg, once daily), Dexamethasone Tablets (administered on Day 1, 12 mg, once daily; administered from Day 2 to 4, 3.75 mg, twice daily)
215000419|NCT07125768|OTHER|Thermal Radiofrequency Neurolysis|Patients received C-arm guided neurolysis of superior medial \[SM\], superior lateral \[SL\], and inferior medial \[IM\] genicular nerves by thermal radiofrequency.
215000420|NCT07125768|OTHER|Alcoholic Neurolysis|Patients received C-arm guided injection of each of the three genicular nerves with 1 ml of a solution containing 70% alcohol in 0.25% lidocaine.
215000421|NCT07120776|DRUG|Camzyos (Mavacamten)|Camzyos (Mavacamten), a selective cardiac myosin inhibitor prescribed as part of routine care in patients with symptomatic HOCM. The study evaluates its effect on myocardial perfusion over a 12-month period using PET-CT imaging.
214354635|NCT03640260|BEHAVIORAL|breathing regulation with physical activity|The subjects will have education leaflets with breathing and oximetry level evaluation training.
214354636|NCT03496155|BEHAVIORAL|Build and Support Your Teen's Strengths|"This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach."
214354637|NCT02799966|DEVICE|Myndmove|20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.
214963212|NCT01973426|DEVICE|Isolated Orthosis for Thumb Actuation (IOTA)|In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
214963213|NCT02954549|DIETARY_SUPPLEMENT|Vitamin D3|As in Arms
214963214|NCT03340467|DEVICE|CGM patch|Patient receives four CGM patches.
214963215|NCT01672905|OTHER|laboratory biomarker analysis|
214963216|NCT00990509|DRUG|Albumin|Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
214963217|NCT00990509|DRUG|Placebo|Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
214963218|NCT00990509|PROCEDURE|Brain MRI with and without contrast|"All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~* Baseline~* 48 hours after enrollment(approximately Day 3)~* 96 hours after drug treatment begins (approximately Day 5)"
214963219|NCT00716768|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
214354638|NCT00353717|DRUG|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
214354639|NCT02212574|DRUG|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
214487172|NCT06715501|DRUG|carboplatin, paclitaxel|Induction chemotherapy: carboplatin 5AUC，q3w; Paclitaxel 135mg/m2,q3w. Simultaneous chemotherapy: 2AUC/W，total 5w; Paclitaxel 50mg/m2/w，total 5w
214487173|NCT06745687|DRUG|CM336|Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1 and cycle2. Then patients will be given 160mg every 2 weeks from cycle 3 to cycle 6. The dosing interval is adjusted according to the evaluation of efficacy every 6 cycles from cycle 7 to cycle 24.
214487174|NCT06739473|BEHAVIORAL|Movies|Participants will watch eight short movie clips, and the changes different emotions evoked by the clips will be studied using H2\[15O\]O PET/CT.
214487175|NCT06739473|BEHAVIORAL|Cold|Participants will be studied with H2\[15O\]O PET/CT while one of their legs will be exposed to cold to study the effects of cold stimulus on whole-body blood flow.
214487176|NCT06739473|DRUG|Hyperinsulinemic euglycemic clamp|Participants will be administered intravenous fast acting insulin (NovoRapid, Novo Nordisk, 1 mU/m2 body surface area/min) together with 20 % glucose to maintain normal glucose values (5.0 mmol/L) to study the effects of insulin on whole body blood flow with H2\[15O\]O PET/CT, and to assess tissue insulin-stimulated glucose uptake with \[18F\]FDG PET/CT.
214487177|NCT06739473|RADIATION|H2[15O]O PET/CT|H2\[15O\]O PET/CT, with a dose of 25-700 MB/bolus repeated 2-8 times per scan.
214487178|NCT06739473|RADIATION|[18F]FDG PET/CT|Whole-body \[18F\]FDG PET/CT scan to study tissue glucose uptake, dose 100 MBq
214487179|NCT06739473|DRUG|CEUS or Contrast enhanced Ultrasound|Contrast-enhanced ultrasound of left forearm muscles is performed during fasting and after 30-40 minutes of hyperinsulinemia
214487180|NCT06736912|DRUG|IN-114199 2.5mg or placebo|IN-114199 2.5mg or placebo (1 Tablet, QD)
214354640|NCT02212574|DRUG|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
214487181|NCT06736912|DRUG|IN-114199 10mg or placebo|IN-114199 10mg or placebo (1 Tablet, QD)
214487182|NCT06736912|DRUG|IN-114199 20mg or placebo|IN-114199 10mg or placebo (2 Tablets, QD)
214487183|NCT06736912|DRUG|IN-114199 40mg or placebo|IN-114199 10mg or placebo (4 Tablets, QD)
214487184|NCT06736912|DRUG|IN-114199 5mg or placebo|IN-114199 2.5mg or placebo (2 Tablets, QD)
214487185|NCT06758453|OTHER|Dietary Challenge|Ingestion of a high-fat, high-glucose meal to induce postprandial variations in bile acids and other metabolic markers.
214487186|NCT06759909|DRUG|Dapagliflozin (DAPA)|"We will record all baseline characteristics (Age, sex, BMI, HR and BP), AF type, EHRA class, previous use of ADD (B blockers, Class I, III AAD), previous CV, prior cerebrovascular stroke and Co-morbidities (HTN, DM, IHD, HF, Renal impairment, peripheral arterial disease, OSAS). CHADS2Vasc score and HAS-BLEED score will be calculated. Trans-thoracic echocardiograms will be performed within 4 weeks before the rhythm control attempts to determine LA diameter and volumes and left ventricular hypertrophy and functions (EF and E/'e).~After enrollment, the patients will be treated with dapagliflozin (10 mg/d) or placebo at the time of rhythm control strategy and will continue daily treatment at the same dose till the 9 month follow-up period."
214963220|NCT00716768|PROCEDURE|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
214963221|NCT02522793|OTHER|No intervention; this is an observational study|
214963222|NCT04993703|OTHER|Kinesiotaping|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, kinesiotaping and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.times per day 3sets of ten repetitions) will be applied.
214354641|NCT02212574|DRUG|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
214354642|NCT02212574|DRUG|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
214354643|NCT02212574|DRUG|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
214354644|NCT02212574|DRUG|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
214354645|NCT05758064|DRUG|Duphaston|10 mg tablet will be given twice
214354646|NCT05758064|DRUG|prolutex|subcutaneous injection daily
214354647|NCT03391674|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation through oral capsules after omeprazole pre-treatment
214354648|NCT05034003|DEVICE|Zirconia crown|Esthetic crowns for capping primary incisor with caries
214354649|NCT05034003|DEVICE|composite strip crown|Esthetic resin restoration for primary incisor with caries
214354650|NCT05403008|OTHER|Zirconomer improved|Zirconomer improved, is a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
214354651|NCT05199818|DRUG|Palonosetron HCl Buccal Film 0.5 mg|Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
214354652|NCT05199818|DRUG|IV Palonosetron 0.25 mg|IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
214963223|NCT04993703|OTHER|Night Splinting|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, night splinting and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
214963224|NCT04993703|OTHER|Control Group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
214963225|NCT03454451|DRUG|CPI-006|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.
214963226|NCT03454451|DRUG|CPI-006 + ciforadenant|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.
214963227|NCT03454451|DRUG|CPI-006 + pembrolizumab|Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.
214963228|NCT03454451|DRUG|CPI-006|Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.
214963229|NCT03454451|DRUG|CPI-006 + ciforadenant|Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.
214963230|NCT03454451|DRUG|CPI-006 + pembrolizumab|Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.
215080196|NCT02363374|DRUG|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
215080197|NCT02363374|PROCEDURE|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
214487187|NCT06759337|BEHAVIORAL|Stress Ball Group|Participants are given a colored silicone stress ball (5-7 cm diameter) 5 minutes before the procedure. During the procedure, they are instructed to squeeze the ball twice after counting to 10 and repeat this until the procedure is complete.
214963231|NCT04609449|PROCEDURE|Long biliopancreatic limb Roux-en-Y gastric bypass.|Long biliopancreatic limb Roux-en-Y gastric bypass.
215080198|NCT00127283|DRUG|eptacog alfa (activated)|
214354653|NCT03469323|DRUG|Succinylcholine|Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
214354654|NCT03469323|DRUG|Placebo|Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
214354655|NCT01433354|DRUG|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
214354656|NCT01016210|DRUG|Leuveris|IV
214354657|NCT01016210|DRUG|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
214354658|NCT04875481|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
214354659|NCT04875481|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
214354660|NCT01952496|OTHER|Assisted Standing Treatment Program|"Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of \~9 months.~Arm: Force-measuring platform"
214354661|NCT01512862|DRUG|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
214354662|NCT01512862|DRUG|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
214354663|NCT02639260|DRUG|N-acetyl D-mannosamine|dose escalation
214354664|NCT02898974|BEHAVIORAL|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
214354665|NCT01710176|DRUG|epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)|
214354666|NCT01710176|DRUG|gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)|
214354667|NCT01710176|DRUG|trabectedin 1.3 mg/m2|
215080199|NCT02496845|DRUG|VL#FIA3-30|Vasoactive dual treatment (MH30-01 \& IS045-01)
215080200|NCT01236092|OTHER|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
214963232|NCT04609449|PROCEDURE|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass
214354668|NCT01710176|DRUG|high-dose ifosfamide 14 g/m2, given in in 14 days|
214354669|NCT01710176|DRUG|etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)|
214354670|NCT01710176|DRUG|gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)|
214354671|NCT05098054|DRUG|Soticlestat|Soticlestat tablets.
214354672|NCT05999955|DRUG|Neomycin/ Dexameythasone/Xylometazoline|The active-control in the phase II study was a commercial form of nasal spray containing Dexamethasone/Neomycin/Xylometazoline. This formulation is approved by Vietnam's Ministry of Health as a treatment regime for rhinosinusitis. Dexamethasone sodium phosphate is fluoromethyl prednisolone, a synthetic glucocorticoid. Dexamethasone has the main effects of glucocorticoids as anti-inflammatory, antiallergic and immunosuppressant. Neomycin sulfate is an antibiotic belonging to the group of aminoglycosides that have a bactericidal mechanism due to inhibition of bacterial protein biosynthesis. In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatment
214354673|NCT05999955|COMBINATION_PRODUCT|Bacillus subtilis DSM32444|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/ PCBALA In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatmen.
214354674|NCT02571504|BEHAVIORAL|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
214354675|NCT00001430|PROCEDURE|PBSC|
214354676|NCT00001430|DRUG|IL-2|
214354677|NCT00001430|DRUG|EPOCH II|
214354678|NCT03905200|DIAGNOSTIC_TEST|3D-speckle tracking imaging|The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
214354679|NCT00175851|DRUG|Seletracetam (ucb 44212)|
214354680|NCT02015676|DRUG|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
214487188|NCT06759337|BEHAVIORAL|Hand-Holding Group|The researcher holds one of the participant's hands during catheter insertion and removal. The researcher's fingers are closed but not interlocked and placed gently on the participant's hand without additional movements or gloves.
214487189|NCT06751108|DRUG|Corticosteroids (CS)|Concomitant use of immune checkpoint inhibitors and corticosteroids
214487190|NCT06751108|DRUG|Immune Checkpoint Inhibitors|Non-concomitant use of corticosteroids
214963233|NCT04965337|DRUG|ASC42|ASC42 tablet administered orally
214963234|NCT04965337|DRUG|Placebo|Matching placebo administered orally
214963235|NCT04269824|BEHAVIORAL|Behavioral intervention package|"Community mobilization and commitment events~* Update factual beliefs~* Establish public commitment~* Update empirical expectations about toilet use~Audio announcements - Disseminate norms-related messages regarding toilet use and ownership~Group level~\- Facilitated sex-segregated group meetings to share information and action knowledge through increased social connections~Network-level social media messages - Transmit norms-related messages, and testimonials of adopters through influential social network members~Household-level Counseling visits~* Update empirical expectations of improved sanitation behaviors in their community~* Motivate improved sanitation practices~* Build capacity to achieve exclusive toilet use~Stickers/decals~\- Signal adoption of promoted behaviors to community members~Individual-level~* Update empirical expectations of improved behaviors among similar others~* Set goals, track progress and maintain improved behavior"
214963236|NCT03067259|OTHER|Exposure Group|Surgeries of high or low impact. They could be local , regional o general anesthesia; sedation or a combination of both.
214354681|NCT02015676|DRUG|paclitaxel|60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression
214354682|NCT02015676|DRUG|Myocet|40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
214354683|NCT01171326|DRUG|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
214354684|NCT01016769|DRUG|Temsirolimus + Weekly Paclitaxel + Carboplatin|"Temsirolimus Per dose escalation scheme Level 1 (15 mg) 2 (20 mg) Level 3 (25 mg) IVPB 30 minutes weekly (3 weeks on, 1 week off) days 1 and 8.~Paclitaxel 80 mg/m2 IVPB 1 hour weekly (2 weeks on, 1 week off) days 1 and 8. Carboplatin AUC 1.5 IVPB 30 minutes days 1 and 8. On Day 15 of each cycle, patients begin the rest week."
214354685|NCT02322671|DRUG|Reference Montelukast|It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
214487191|NCT06749743|DIAGNOSTIC_TEST|FASTER RCNN|train artificial intelligence models ( FASTER RCNN, YOLOY ) to detect dental caries , then test their accuracy
214487192|NCT06755151|DRUG|Fenofibrate|Fenofibrate 200mg
214487193|NCT06763614|BEHAVIORAL|Dog assisted therapy - animal interventions|Animal Assisted Therapy is when animals are used in goal directed treatment sessions. These goals are working emotionalaspects pf childres and adolescents with SAF
214963237|NCT02898636|OTHER|autopsy|At autopsy achieving adequate sampling of lesions and healthy skin
214963238|NCT05329350|DEVICE|muscular ventricular septal defects|intervention cardiology and structural heart disease, including transseptal puncture.
214963239|NCT06842576|BEHAVIORAL|Health Education Videos|Participants will be prompted to explore the 7 health education videos for up to 20 minutes.
214963240|NCT06842576|BEHAVIORAL|GotTransition.org Website|Participants will be prompted to explore the Gottransition.org website for up to 20 minutes
214963241|NCT02927574|DEVICE|DCB|
214963242|NCT02927574|DEVICE|POBA|
214354686|NCT02322671|DRUG|Test 1 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
214963243|NCT06613308|DRUG|Neoadjuvant immunotherapy combined with chemotherapy|The treatment regimen consisted of a PD-1/PD-L1 monoclonal antibody in combination with a platinum-containing two-agent standard chemotherapy regimen administered every three weeks. Following two to four cycles of therapy, patients who demonstrated no evidence of disease progression were eligible for surgical resection, which was performed within three to four weeks after the conclusion of the last neoadjuvant therapy. Consolidation with a PD-1/PD-L1 monoclonal antibody was initiated within three to eight weeks after surgery and continued every three weeks. The efficacy of the treatment was evaluated according to the irRECIST criteria. Chemotherapy regimens were selected based on tumour histology and investigator judgement. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.
214963244|NCT06613308|DRUG|Neoadjuvant chemotherapy|"A platinum-containing two-agent standard chemotherapy regimen was administered every three weeks. Following a two-to-four-cycle therapy, if the patients were evaluated without progressive disease, patients undergo surgical resection within three to four weeks of the final neoadjuvant treatment. Postoperative adjuvant chemotherapy is then conducted in accordance with the recommended regimen outlined in the 2022 edition of the CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer. The efficacy of the treatment was evaluated in accordance with the RECIST 1.1 criteria.~The chemotherapy regimens were selected based on the tumor histology and the judgement of the investigators, in accordance with the standard clinical practice. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments."
214963245|NCT01888952|DRUG|Prednisone|Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
214963246|NCT01888952|DRUG|Roflumilast|Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
214963247|NCT06612359|BEHAVIORAL|BOOST GAIT Program|In addition to usual care, participants will undergo additional therapy over a four-week period, with sessions occurring five times per week for one hour. The BOOST GAIT sessions will be conducted as group-based therapy with four patients and two physiotherapists present to oversee the performance of mobility-specific exercises, including sit-to-stand transfers, standing and stepping, and eventually walking.
214963248|NCT07016100|BEHAVIORAL|Contingency management|See arm description
214963249|NCT07016100|BEHAVIORAL|Cognitive behavioral therapy/ treatment as usual|See arm description
214963250|NCT07016919|OTHER|early enteral nutrition|Oral nutrition started within 6hours after paediatric open appendectomy
214963251|NCT07016919|OTHER|Conventional enteral nutrition|Oral nutrition started within 24hours after paediatric open appendectomy
214963252|NCT00865657|DRUG|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
214963253|NCT00865657|DRUG|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under non-fasting conditions
214963254|NCT01066871|DRUG|Sprifermin (AS902330) 10 mcg|Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
215080201|NCT05660902|OTHER|ROM Exercises|The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
214487195|NCT05198297|DEVICE|Hydrus Microstent|Minimally invasive glaucoma surgery device implanted into the Schlemm's canal of the eye to provide a natural outflow pathway for aqueous humor, leading to a reduction in intraocular pressure (IOP). The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
214487196|NCT05198297|PROCEDURE|Ophthalmic surgery|Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
214678954|NCT02081469|OTHER|TDF|To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
214354687|NCT02322671|DRUG|Test 2 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
214354688|NCT01426191|DRUG|xinzhijun|"durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)~1.5-3.0g,iv,bid or tid for 5-12 days;~Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days"
214487197|NCT04529616|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
214487198|NCT06779903|OTHER|the psychoeducation intervention program booklet|Psychoeducation Program was composed of nine basic topics (postpartum period and care, adaptation to the role of motherhood and mother-infant bonding, postpartum psychological changes, frequency, causes, symptoms of PPD, effects on mother, child and community health, diagnosis and treatment, preventive practices, social support and suggestions for coping, breast milk and breastfeeding, breast care and practices, nutrition and baby care).
214487199|NCT06779903|OTHER|routine care|routine care
214963255|NCT01066871|DRUG|Sprifermin (AS902330) 30 mcg|Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
214963256|NCT01066871|DRUG|Sprifermin (AS902330) 100 mcg|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
214963257|NCT01066871|OTHER|Placebo|Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
214354689|NCT02039037|DEVICE|Acupuncture|Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
214354690|NCT02039037|DEVICE|Electroacupuncture (device 585)|Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
214354691|NCT03788837|DRUG|ILOPROST|The patient will receive treatment with intravenous ILOPROST therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.
214963258|NCT05702099|DIAGNOSTIC_TEST|ultrasonography|By performing transvaginal or transabdominal ultrasonography on women, ovarian volume will be calculated and antral follicle will be counted.
214963259|NCT04162795|DRUG|Loratadine (Claritin, BAY76-2211)|Chewable tablet, oral, single dose
214354692|NCT03788837|DRUG|NaCl|The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
214354693|NCT02052505|PROCEDURE|Medication review|The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
214354694|NCT00004827|DRUG|docosahexaenoic acid|
214354695|NCT04161508|DRUG|Sugammadex Injection|injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery
214354696|NCT04161508|DRUG|Neostigmine Injection|injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
214354697|NCT02871648|DRUG|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
214354698|NCT02871648|DRUG|Fludrocortisone|Fludrocortisone 0.1 mg
214354699|NCT02871648|DRUG|Eplerenone|Epleronone 100 mg
214963260|NCT04171362|OTHER|Connective Tissue Massage|Connective tissue massage (CTM) is a manipulative technique that facilitates the diagnosis and treatment of a wide range of pathologies. Observation and subsequent manipulation of the skin and subcutaneous tissues can have a beneficial effect upon tissues remote from the area of treatment.
214963261|NCT04171362|OTHER|Education|Education patients were informed about migraine triggers, migraine prevention and coping strategies and exercise options. The exercises were demonstrated by the physiotherapist
214963262|NCT05373563|PROCEDURE|cesarean section women|The test will be applied to women who have had a cesarean section and the Turkish validity and reliability of the scale will be determined according to the answers given.
214963263|NCT03433300|DEVICE|Ottobock Kenevo/C-Leg|Microprocessor-controlled prosthetic knee
214354700|NCT02868060|DRUG|Romiplostim|
214354701|NCT04526366|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure device deployed for at least one night synchronously with polysomnography.
214354702|NCT04526366|DEVICE|Polysomnography|Polysomnography deployed for at least one night synchronously with Continuous Positive Airway Pressure.
214354703|NCT00439868|DRUG|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
214354704|NCT00439868|DRUG|placebo|Matching placebo tablets to WELLBUTRIN XL.
214354705|NCT02013622|DRUG|Brexpiprazole|Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
214354706|NCT04827511|OTHER|Refraction measurement with auto-ref-keratometer Canon|Refractive measurement and vitamin D level dosing
214487200|NCT06765174|DEVICE|Suction Drain placement (Example: Q-vac)|After thyroid surgery we pust drain at bed of surgery to monitor post operative bleeding.
214354707|NCT00432731|BIOLOGICAL|VARIVAX®|
214354708|NCT00432731|BIOLOGICAL|M-M-RTM II|
214487201|NCT06768021|BEHAVIORAL|Guided visualization and standardized pre-sedation instructions|One arm will receive standardized pre-sedation instructions, as well as one-minute guided visualization.
214487202|NCT06768021|BEHAVIORAL|Standardized pre-sedation instructions only|One arm will receive standardized pre-sedation instructions only.
214963264|NCT03433300|DEVICE|Ottobock 3R60/3R62|Nonmicroprocessor-controlled knee
214963265|NCT00821197|PROCEDURE|long-limb gastric bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
214963266|NCT00821197|PROCEDURE|distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
214963267|NCT01060423|DRUG|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
214963268|NCT01060423|DRUG|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
214354709|NCT05885672|BEHAVIORAL|Online psychoeducational lifestyle intervention|A webpage-baed intervention focused on lifestyle interventions that aim to reduce metabolic syndrome severity.
214354710|NCT01763931|DRUG|Digoxin|Digoxin once daily for 2 weeks prior to definitive breast surgery.
214487203|NCT06767371|PROCEDURE|Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.|Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.
214354711|NCT05668728|OTHER|Group 1: Peppering|Before injection we will palpate the muscles of trapezius, m. rhomboideus, m. levator scapula for finding painful trigger points, and we will mark the point. the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. The needle will be inserted and removed until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
214354712|NCT05668728|OTHER|group 2: spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapula will be identified and marked by palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the dry needle is inserted at each point found, it will be spinned counterclockwise and left. Waiting time for each patient will be limited to 15 minutes. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
214963269|NCT01060423|DEVICE|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
214963270|NCT06359262|OTHER|Hope@School|A digital platform aimed at promoting student mental health in schools
214354713|NCT05668728|OTHER|group 3: Peppering and spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapul will be identified and marked with palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the needle is inserted and removed, it will be spinned counterclockwise for 15 minutes in each patient until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program. With this method, dry needling will be applied to the patient 4 times a week, once a week.
214354714|NCT04650555|DRUG|BIO 300 Oral Powder|Amorphous solid dispersion of genistein milled into a powder
214354715|NCT00889538|DRUG|placebo|50 mL of 1/2 normal saline IV
214354716|NCT00889538|DRUG|glutathione|glutathione 600 mg IV
214354717|NCT00889538|DRUG|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
214963271|NCT06359262|OTHER|Treatment as usual|Regular student health care in schools
214963272|NCT00203658|DRUG|Tinzaparin sodium|
214963273|NCT00858806|DRUG|Imatinib|"Intermittent Imatinib administration.~* 1 week on / 1 week off for the 1st month(weeks 1-4)~* 2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~* 1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
214354718|NCT03765866|PROCEDURE|Thromboelastometry guided transfusion|Comparing resuscitation strategies with standard MTP v.s. ROTEM guided MTP
214354719|NCT03776955|DRUG|Carvedilol|Oral tablet
214354720|NCT02115555|BEHAVIORAL|HIT-aided approach|Subjects randomized to this approach will be using the HIT-aided monitor.
214354721|NCT02115555|BEHAVIORAL|Contracted conflict management system|Subjects randomized to this arm will be using the behavioral contracted conflict management system.
214963274|NCT04947410|DEVICE|CPAP or nasal dilators|CPAP = active comparator nasal dilators = placebo comparator
214963275|NCT03612466|DRUG|153Sm-DOTMP|For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 \& 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
214963276|NCT03612466|RADIATION|External beam radiotherapy.|The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)
214963277|NCT03612466|DRUG|Calcium Carbonate|Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
214963278|NCT03612466|DRUG|Mozobil|Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
214963279|NCT03612466|DRUG|Neupogen Injectable Product|Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
214963280|NCT04530838|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
214963281|NCT04530838|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
214963282|NCT00803712|DRUG|Cinacalcet|Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
214963283|NCT00803712|DRUG|Vitamin D|Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
214963284|NCT05581823|DRUG|Tavapadon|Oral tablets
214963285|NCT05581823|DRUG|Carbamazepine|Extended-release oral tablets
214963286|NCT05819372|PROCEDURE|Zygomaticomaxillary fracture repair|"A cone beam CT (CBCT) scan of the patient will be used to create a 3D scanned image of zygomaticomaxillary complex fracture (ZMC)~* 3D images will be introduced to finite element (FA) software to evaluate Stresses (MPa), Micromotion (microns), and Life time (cycle) For each model and determine which point of fixation is the best~* After application this point of fixation on the patient~* Finite element analysis will be done again to verify the previous results"
214963287|NCT00052078|DRUG|Sertraline (SRT)|Participants were treated with sertraline.
214963288|NCT00052078|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants received CBT.
214963289|NCT00052078|DRUG|Placebo|Participants were treated with a placebo pill.
214963290|NCT01834170|DRUG|Gemcitabine|"Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist"
215080202|NCT04352985|DEVICE|Toraymyxin PMX-20R (PMX Cartridge)|The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.
214354722|NCT02115555|BEHAVIORAL|HIT plus contracted conflict management|Subjects randomized to this arm will use both the HIT-aided approach and the behavioral contract conflict management system.
214354723|NCT03206346|DRUG|Ingavirin|Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
214354724|NCT03206346|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
214354725|NCT04307004|OTHER|Unattended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
214354726|NCT04307004|OTHER|Attended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
214354727|NCT04307004|OTHER|Ambulatory blood pressure monitoring|Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.
214354728|NCT04307004|OTHER|Home blood pressure monitoring|Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
214354729|NCT05043090|DRUG|savolitinib|Tablets : 3 × 200 mg tablets once daily
214354730|NCT05043090|DRUG|durvalumab|Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks
214354731|NCT05043090|DRUG|sunitinib|Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off
214354732|NCT06166225|BEHAVIORAL|Internet-based weight loss program|12-month, automated and behaviorally-based, Internet-delivered weight loss and weight loss maintenance program
214963291|NCT02672176|BEHAVIORAL|Usual Care|This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
214963292|NCT02672176|BEHAVIORAL|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
214963293|NCT04780815|OTHER|myBluTM Formulation 1|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs
214963294|NCT04780815|OTHER|myBluTM Formulation 2|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs
214963295|NCT02876796|DRUG|GS-0976|Capsule(s) administered orally
214354733|NCT06166225|BEHAVIORAL|Yoga|9-month Iyengar yoga program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12, and self-guided yoga practice recommendations.
214354734|NCT06166225|BEHAVIORAL|Health and Wellness|9-month health and wellness program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12.
214354735|NCT05523284|DIAGNOSTIC_TEST|SonoPODography|SonoPODography (SPG) is a novel ultrasound-guided technique whereby saline is injected through the cervix and flushed into the POD, creating an acoustic window for diagnosing superficial endometriosis.
214354736|NCT06523673|RADIATION|Stereotactic Body Radiotherapy|The dose of radiation therapy is determined by the radiologist based on the clinical parameters of the lesion, including tumor size and location. In most cases, radiotherapy fractionation regimens range from 27-30 Gy/3 Fractions or 30-50 Gy/5 Fractions, and appropriate radiotherapy doses covering 27-70 Gy/3-10 Fractions can also be selected by the radiologist based on radiation limitations of neighboring endangered organs.
214354737|NCT06523673|DRUG|second-line systemic therapy|a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen
214354738|NCT06292156|DEVICE|Theta treatment group|The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3consecutive weeks
214354739|NCT06292156|DEVICE|Alpha active control group|The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 10 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks
214354740|NCT06292156|DEVICE|Sham control group|Sham stimulation lasted 30 s (15 s of ramp- up and 15 s of ramp-down).
214354741|NCT06268574|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
214354742|NCT04373239|PROCEDURE|Assisted Reproductive Technology|Assisted reproductive technology includes IVF and IVF+ICSI.
214354743|NCT02988973|DRUG|roxadustat|Oral administration
214354744|NCT02988973|DRUG|DA|Subcutaneous administration
214354745|NCT05754450|DRUG|AVTX-803|L-fucose crystalline powder
214354746|NCT03817424|DRUG|VIB7734|Participants will receive VIB7734 via injection.
214354747|NCT03817424|DRUG|Placebo|Participants will receive placebo matching to VIB7734 via injection.
214963296|NCT02876796|DRUG|Placebo|Capsule(s) administered orally
215080203|NCT00263640|BIOLOGICAL|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
214963297|NCT02876796|OTHER|1-13C acetate|10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
214963298|NCT02876796|OTHER|Fructose solution|Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
214963299|NCT00018824|DRUG|NALTREXONE|
214963300|NCT00018824|DRUG|Placebo|
214963301|NCT05702580|PROCEDURE|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
214963302|NCT03565874|DEVICE|Heart rate variability biofeedback|Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
214963303|NCT00241007|DRUG|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
214963304|NCT06017401|PROCEDURE|Oblique Subcostal Transversus Abdominis Plane Block|The investigator will perform oblique subcostal transversus abdominis plane block to that patient group for postoperative analgesia
214963305|NCT06017401|PROCEDURE|Transmuscular Quadratus Lumborum Block|The investigator will perform transmuscular quadratus lumborum block to that patient group for postoperative analgesia
214963306|NCT05236907|DRUG|Melatonin|The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.
214963307|NCT05236907|OTHER|No intervention|No intervention was used.
214963308|NCT05236907|DRUG|Midazolam|7.5 mg of Midazolam orally.
214963309|NCT03241576|BEHAVIORAL|Small portion size provision|The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.
214963310|NCT03241576|BEHAVIORAL|Large portion size provision|The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
214963311|NCT00669318|BIOLOGICAL|alemtuzumab|
214963312|NCT00669318|BIOLOGICAL|rituximab|
214963313|NCT00669318|DRUG|pentostatin|
214963314|NCT00669318|DRUG|sargramostim|
214963315|NCT01701544|DEVICE|NBM DBS|Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
214963316|NCT01073163|DRUG|Bendamustine|Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.
215080204|NCT00263640|DRUG|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
215080205|NCT01125969|BEHAVIORAL|Incentives|Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
215080206|NCT01125969|BEHAVIORAL|Education|Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
214354748|NCT04737200|DIETARY_SUPPLEMENT|Time-of-day of enteral nutrition provision (daytime first)|Enteral nutrition (tube feeds) will be provided during the daytime followed by nighttime.
214963317|NCT01073163|DRUG|Rituximab|Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.
214963318|NCT05358899|DEVICE|accelerated theta burst stimulation|cTBS was administered at 80% of each participant's M1 area in a burst-firing pattern (3 pulses at 50 Hz) with a repetition frequency of 5 Hz (200 ms intervals). During each session, participants received 1800 pulses (120 s).
214963319|NCT05358899|DEVICE|Sham stimulation|Similar process with the accelerated theta burst stimulation with the coil 90 degrees tilted to the surface of the scalp, which could produce identical sound and vibration while avoiding real magnetic stimulation.
214963320|NCT05914818|DEVICE|EXPLORER V2|4 sessions of use of the exoskeleton, 1 in a laboratory of gait analysis and 3 in the home and the community of the participants
214963321|NCT01935986|DIETARY_SUPPLEMENT|probiotic|
214963322|NCT01935986|DIETARY_SUPPLEMENT|placebo|
214963323|NCT03272347|DRUG|Islatravir|Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
214963324|NCT03272347|DRUG|Placebo to Islatravir|Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
214963325|NCT03272347|DRUG|Doravirine|Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
214963326|NCT03272347|DRUG|Placebo to Doravirine|Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
214963327|NCT03272347|DRUG|Lamivudine|Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
214963328|NCT03272347|DRUG|Placebo to Lamivudine|Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
215080207|NCT01125969|BEHAVIORAL|Peer mentoring|Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
214354749|NCT04737200|DIETARY_SUPPLEMENT|Time-of-day of enteral nutrition provision (nighttime first)|Enteral nutrition (tube feeds) will be provided during the nighttime followed by daytime.
214963329|NCT03272347|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
214963330|NCT03272347|DRUG|Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks
214963331|NCT03272347|DRUG|Doravirine/Islatravir|Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
214963332|NCT01450514|DRUG|Pipamperone|15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
214354750|NCT03921515|OTHER|Blister induction|Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.
214354751|NCT03921515|OTHER|Skin Biopsies|The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
214963333|NCT01450514|DRUG|Placebo|matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
214963334|NCT01082679|DRUG|Methadone|daily for 12 months
214963335|NCT01082679|DRUG|buprenorphine (Suboxone)|daily for 12 months
214963336|NCT00578279|DRUG|dehydrated alcohol|subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
214963337|NCT03161041|PROCEDURE|Cytoreductive surgery combined with HIPEC|Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
214963338|NCT03161041|DRUG|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
214963339|NCT00753298|DEVICE|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
215080208|NCT02815436|OTHER|Telephone reminder|a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
215080209|NCT02815436|OTHER|SMS reminder|a one-way, SMS message sent from the centre to the screening participant's mobile phone
215080210|NCT00003787|BEHAVIORAL|educational/counseling intervention|
215080211|NCT00003787|BEHAVIORAL|therapeutic dietary intervention|
215080212|NCT03808363|OTHER|High Intensity Interval Training|Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
214354752|NCT06643351|OTHER|Standard Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-110mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 110 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
214354753|NCT06643351|OTHER|Liberalized Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-160mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 160 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
214354754|NCT06568705|RADIATION|Moderate hypofractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 43.5Gy in 15 fractions in patients who underwent breast conserving surgery or mastectomy.
214354755|NCT06568705|RADIATION|Ultrafractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 26Gy in 5 fractions in patients who underwent breast conserving surgery or mastectomy.
214354756|NCT05852015|BEHAVIORAL|Treatment-as-Usual (TAU)|TAU consists of weekly outpatient-based group therapy for substance use disorder
214354757|NCT05852015|BEHAVIORAL|Digital Mindfulness Treatment|The digital mindfulness-based treatment is a multimedia app-based program teaching mindfulness skills to facilitate recovery from substance use disorder
214963340|NCT00753298|DEVICE|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
214963341|NCT00921258|PROCEDURE|prostate biopsy|"patient of control group will have :~* 1 prostate biopsy 3 months after diagnostic biopsy~* 1 prostate biopsy each year during 2 years~* 1 prostate biopsy each 2 years during 8 years"
214963342|NCT06079996|OTHER|CAFFEINE GUM|Observing the effect of chewing gum on the performance of female softball players.
214963343|NCT01228656|DRUG|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
214963344|NCT01228656|DRUG|Mometasone furoate|Dermatologic ointment applied once a day
214963345|NCT04739592|DRUG|alendronate sodium vitamin D3 tablets|once per week for one year
215080213|NCT00002522|DRUG|cisplatin|
215080214|NCT00002522|DRUG|cyclophosphamide|
214963346|NCT04739592|DRUG|Placebo|once per week for one year
214963347|NCT04416919|OTHER|Assembled mask|Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
214963348|NCT05013502|DRUG|Empagliflozin 10 MG|empagliflozin 10mg PO once daily
215080215|NCT00002522|DRUG|etoposide|
214963349|NCT00405015|DRUG|rosiglitazone|Rosiglitazone 4 mg bidaily for 8 weeks
214963350|NCT01677182|DRUG|Ramelteon|Ramelteon tablets for sublingual administration
215080216|NCT00002522|PROCEDURE|autologous bone marrow transplantation|
215080217|NCT00002522|PROCEDURE|bone marrow ablation with stem cell support|
215080218|NCT00002522|PROCEDURE|peripheral blood stem cell transplantation|
215080219|NCT00002522|PROCEDURE|syngeneic bone marrow transplantation|
214963351|NCT01677182|DRUG|Placebo|Ramelteon placebo-matching tablets for sublingual administration
215080220|NCT00002522|RADIATION|radiation therapy|
215080221|NCT04531358|DEVICE|nasal spray|application of nasal spray
214354758|NCT05081128|DEVICE|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
214963352|NCT02706769|DRUG|Placebo|Study medication contains blinded placebo
214354759|NCT06459921|DRUG|SOX+Sintilimab|Patients would be allocated to the SOX+Sintilimab group.
214354760|NCT06459921|DRUG|FLOT+Sintilimab|Patients would be allocated to the FLOT+Sintilimab group.
214963353|NCT02706769|DRUG|Paracetamol|Study medication contains blinded paracetamol
214354761|NCT05403762|OTHER|ESENTA™ Skin Barrier Spray (ConvaTec, UK)|The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.
214354762|NCT05403762|OTHER|Hydrophobes Basisgel DAC|The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.
214354763|NCT06634641|BIOLOGICAL|blood test|Only carrying out additional immunological assays during blood tests before initiation of treatment, six months after initiation of treatment and then one year after initiation of treatment.
214963354|NCT05524766|DEVICE|BTL-785-7 Treatment|Treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
215080222|NCT04531358|OTHER|no treatment|no treatment
214354764|NCT06635317|DRUG|Aspirin|100 mg/day orally for 25 days
214354765|NCT06635317|DRUG|enoxaparin|40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
214354766|NCT04034030|DEVICE|Transcranial Magnetic Stimulation|"Each patient will receive a 10 minute treatment of one time stimulation of the Epileptogenic Cortical Area (ECA). The TRPMS cap will be worn over the previously fixed scalp EEG electrodes. The procedure during this treatment session will consist of positioning a device microstimulator component centered on an area of focal epileptiform discharges (identified with EEG electrode placement) with the patient relaxing in a chair.~The stimulus parameters used will be 120 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 10 min. . The investigators will measure the subject for adequate placement of the device prior to stimulation. Once the placement of the device is confirmed, the study technician administrating the treatment will turn on the device using the app downloaded on an electronic device connected by Bluetooth to the device."
214354767|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, patients receive clinically-optimized open loop DBS stimulation to the pallidum.
214354768|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation at random time points. These random stimulation times will in total equal the total amount of time of active movement.
214354769|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of contralateral limb movement (e.g. left brain stimulation during right leg/arm movement).
214354770|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of no movement for the contralateral limb (e.g. left brain stimulation while right leg/arm is not moving).
214487204|NCT06767371|PROCEDURE|Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.|Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.
214487205|NCT06767371|PROCEDURE|Teeth with irreversible pulpitis|Teeth with irreversible pulpitis to be treated with conventional root canal treatment
214963355|NCT00921635|PROCEDURE|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
214963356|NCT00921635|PROCEDURE|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
214963357|NCT05771454|PROCEDURE|Histopathological confirmation|After mastectomy, each specimen will be assessed histopathologically for the presence or absence of invasive focus of breast cancer.
214963358|NCT00995722|DRUG|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
214963359|NCT00995722|DRUG|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
214963360|NCT00492700|DRUG|rosiglitazone|
214963361|NCT02052427|DEVICE|Celution System|ADRCs processed by the Celution System for reintroduction into the myocardium
214963362|NCT02052427|DEVICE|Placebo|Physiological solution made of Lactated Ringers solution and a small amount (\<1mL) of autologous blood
214963363|NCT00351689|BEHAVIORAL|dietary supplement|
214963364|NCT03701542|DIAGNOSTIC_TEST|Microperymetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
214963365|NCT03701542|DIAGNOSTIC_TEST|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
215080223|NCT04370990|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
214963366|NCT05784376|BEHAVIORAL|Education-based|Nutrition education delivered via text messages through mobile applications (e.g. WhatsApp).
215080224|NCT01050374|DRUG|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
215080225|NCT01050374|DRUG|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
215080226|NCT04094142|DRUG|Acalabrutinib|"Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission."
214963367|NCT00762762|DRUG|Triclosan/copolymer/fluoride|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
214963368|NCT00762762|DRUG|Fluoride|Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
214354771|NCT05381974|DRUG|Psilocybin|Open-Label
214354772|NCT01293448|DEVICE|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
214354773|NCT02429882|DRUG|Brodalumab 210 mg|210 mg brodalumab will be administered subcutaneously
214354774|NCT02429882|DRUG|Placebo|Placebo will be administered subcutaneously
214354775|NCT04616157|BEHAVIORAL|ICBT-I|Cognitive-behavioral therapy for insomnia
214354776|NCT06343766|GENETIC|DNA collation and genotyping|"DNA collation and genotyping of specific genes ENAM rs3796703, AMBN rs4694075), TUFT1 rs78802584 and KLK4 rs2242670 through PCR and sequencing for various SNPs~Dental examinations by comparing dental covariates such as the number of DMF-T index, presence of biofilm, gingivitis, fluorosis, and detection of interproximal caries with caries progression."
214354777|NCT02081846|OTHER|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
214354778|NCT02081846|OTHER|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
214354779|NCT02657980|DEVICE|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
214354780|NCT02657980|DEVICE|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
214354781|NCT01952327|DEVICE|The pleurapump system|Implantation of the pleurapump system
214354782|NCT01211925|PROCEDURE|distal venous arterialisation|The investigators perform reverse revascularisation of the ischemic limb with arterial blood supply from patent in flow artery to the superficial dorsal venous arch.
214354783|NCT01211925|DRUG|Aspirin|100 mg per day continuous
214354784|NCT03850769|DRUG|nab-paclitaxel and S-1|Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 \< 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
214354785|NCT03782155|DRUG|glutamine supplementation|powder 14g
214963369|NCT06312384|PROCEDURE|3D Surgical Template on the Contour of Bone Augmentation, in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation|a two-piece tooth-supported surgical template will fabricated through 3D printing technology before surgery base on the digital simulation of bone graft contour.Sticky bone will placed into the defect under the guidance of the template to form customized sticky bone and will be covered with collagen membrane.
214963370|NCT06312384|PROCEDURE|conventional guided bone regeneration,in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation|The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane.
214354786|NCT03782155|DRUG|HMB|powder 3g
214354787|NCT03782155|DRUG|Placebo|powder 17g
214354788|NCT04019938|RADIATION|Dual-energy X-ray absorptiometry|Cystatin C is measured as a part of routine investigation at the time of admission.
214963371|NCT00366782|BIOLOGICAL|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50
214963372|NCT00366782|BIOLOGICAL|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10\^5 TCID50
214963373|NCT00366782|BIOLOGICAL|Placebo|Placebo for rB/HPIV3 vaccine
214963374|NCT02489448|DRUG|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
214963375|NCT02358265|DRUG|10 mg Rupatadine on demand|Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
214354789|NCT06535048|DRUG|Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons|"Entecavir: Participants will receive Entecavir 0.5 mg orally once daily for the duration of the study.~Tenofovir Disoproxil Fumarate (TDF): Participants will receive TDF 300 mg orally once daily for the duration of the study.~Tenofovir alafenamide fumarate (TAF): Participants will receive TAF 25 mg orally once daily for the duration of the study.~Interferon (IFN): Participants will receive IFN 180 µg subcutaneously once weekly for at least 12 weeks."
214354790|NCT04637412|OTHER|Menu label|Participants will be shown a sample of items from a restaurant menu, displayed with labels
214354791|NCT04089033|PROCEDURE|Pneumatic Retinopexy|The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.
214487206|NCT06307704|PROCEDURE|Lung Ultrasound - guided Stepwise PEEP|After endo-tracheal intubation; A PEEP of 4 cmH2O will be initially used till 5 min after pneumoperitoneum. Then The PEEP will be adjusted in a stepwise approach after performing bedside lung ultrasound. The PEEP will be increased by 2 cmH2O until no lung collapse is detected. Lung ultrasound will be repeated 5 min after every change in the PEEP with a maximal PEEP of 12 cmH2O.
214354792|NCT04089033|PROCEDURE|Pars Plana Vitrectomy|For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
214354793|NCT02576678|DRUG|Apremilast|
214354794|NCT03545854|PROCEDURE|Erector Spinae Plane Block|Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.
214354795|NCT01926756|PROCEDURE|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
214963376|NCT02358265|DRUG|10 mg Rupatadine|Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
214963377|NCT02358265|DRUG|20 mg Rupatadine|Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
214963378|NCT02358265|DRUG|10 mg Rupatadine on demand (sham updosing to 20 mg)|Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
214963379|NCT06473116|DRUG|Isoprenaline Only Product|Administration of intravenous isoprenaline of 600 mikrograms immediately after recognition of asystole in bystander-witnessed out-of-hospital cardiac arrest
214963380|NCT06172738|PROCEDURE|the left atrial appendage closure through surgery.|Surgical closure of the left atrial appendage during the set of an elective open heart surgery with the inclusion criteria fulfilled.
214963381|NCT00118989|DIETARY_SUPPLEMENT|Curcuminoids|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
214963382|NCT01580826|OTHER|pasteurization of mother's own milk|mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
214963383|NCT00391872|DRUG|Ticagrelor|Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
214963384|NCT00391872|DRUG|Clopidogrel|Clopidogrel 75 mg once daily dose (ODD)
214963385|NCT02010905|DRUG|Losartan|
214963386|NCT02010905|DRUG|Placebo|
215080227|NCT00866346|BIOLOGICAL|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
215080228|NCT01884558|DRUG|isavuconazole|oral
215080229|NCT01884558|DRUG|metformin|oral
215080230|NCT03647111|DRUG|Crizotinib|Crizotinib 250mg po bid
215080231|NCT02654288|OTHER|gemcitabine-based chemotherapy|
215080232|NCT00034229|DRUG|Felbamate|
215080233|NCT03698175|BEHAVIORAL|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
215080234|NCT03698175|BEHAVIORAL|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
214354796|NCT01926756|PROCEDURE|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
214354797|NCT00222651|DRUG|tenecteplase|
214354798|NCT02202473|DRUG|Lamivudine|
214354799|NCT02202473|DRUG|Lamivudine+Oxymatrine Capsules|
214354800|NCT03605095|DRUG|nitroglycerin|Vasodilatator solution is dropped on the gingiva.
214354801|NCT04879914|DIETARY_SUPPLEMENT|Butyrate|3 cps/die 300 mg/cps
214354802|NCT04879914|DIETARY_SUPPLEMENT|Placebo|3 cps/die 300 mg/cps
214354803|NCT00687648|DRUG|anastrozole|Given as previously prescribed
214354804|NCT00687648|DRUG|cyclophosphamide|Given by mouth
214354805|NCT00687648|DRUG|exemestane|Given as previously prescribed
214354806|NCT00687648|DRUG|letrozole|Given as previously prescribed
214354807|NCT00687648|DRUG|methotrexate|Given by mouth
214354808|NCT00687648|DRUG|prednisolone|Given by mouth
214963387|NCT04407039|DEVICE|PET/CT, H-MRS and MRI|Use imaging methods to get metabolic parameters.
214963388|NCT02484092|BIOLOGICAL|SPK-9001|A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
214963389|NCT05122624|OTHER|PredicTB score|"This is an easy-to-use clinical risk score designed to improve early management of tuberculosis in highly resource-constrained settings where same-day microbiological testing is unavailable. It consists of readily accessible demographic and clinical data and is scored from 1-10.~We will train clinic staff in eight clinics (four study clinics and four comparison clinics) on the Ugandan standard of care for the diagnosis and treatment of TB. In addition, in the four study clinics, we will provide training on the PredicTB score."
214963390|NCT00215644|DRUG|Matuzumab|Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
214963391|NCT00215644|DRUG|Epirubicin|Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
214963392|NCT00215644|DRUG|Cisplatin|Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
214963393|NCT00215644|DRUG|Capecitabine|Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
214963394|NCT02411279|OTHER|Equiped group with telemedicine systems|
214963395|NCT02335879|BIOLOGICAL|Gonal-F|
215080235|NCT00051467|GENETIC|TNFerade|
215080236|NCT00640640|DEVICE|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
215080237|NCT00640640|DRUG|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
214354809|NCT03863340|BEHAVIORAL|interruptions of work tasks|"During each activity two interruptions/breaks were selected randomly from a set of ten predetermined actions:~Active break types:~* Move shoulder and upper back~* Swing arms near the body~* Three slow but forceful elevations of the shoulders, a relaxation exercise based on the principles developed by Jacobson~* Stand up and stretch~* Slowly turn head in all possible directions.~Passive break types:~* Tell a couple of jokes~* Stand up and have a drink~* Relaxing the trapezius~* Questions on actual posture and feelings of comfort / discomfort.~* A short rest on the couch"
214354810|NCT00797654|BEHAVIORAL|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
214354811|NCT00797654|BEHAVIORAL|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
214354812|NCT00682734|DRUG|metoclopramide|metoclopramide 20 mg
214354813|NCT00682734|DRUG|metoclopramide|metoclopramide 40 mg
214354814|NCT00682734|DRUG|metoclopramide|metoclopramide 10 mg
214354815|NCT00682734|DRUG|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
214354816|NCT03310151|PROCEDURE|Imagined movements|Imagined wrist movements, 10-15 minutes, 4 times a day.
214354817|NCT02251990|DRUG|Grazoprevir/Elbasvir|FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.
214354818|NCT02251990|DRUG|Placebo|Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
214963396|NCT03170817|DIAGNOSTIC_TEST|Cardiac Perfusion Rest/Stress Digital PET/CT|"Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan.~These patients are given:~1. One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of \~20 minute duration.~2. A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart~3. One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of \~20 minute duration~Total patient time will take approximately up to 120 minutes."
214963397|NCT03170817|DRUG|N-13 ammonia|5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
214963398|NCT03170817|DRUG|Regadenoson|0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
214963399|NCT03981146|DRUG|Nivolumab|60 Minute IV Infusion
214487207|NCT06307704|PROCEDURE|Standard Ventilation Protocol|Volume-controlled ventilation (VCV) mode; with a tidal volume of 6 mL/kg of ideal weight, inspiratory : expiratory ratio 1: 2, PEEP 4 cmH2O, respiratory rate adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mm Hg, and inspired oxygen fraction of 50%.
214963400|NCT05332041|OTHER|Predicta Bioactive bulk fil composite restoration|Predicta Bioactive bulk fil resin composite restoration material
214963401|NCT00242411|DRUG|Budesonide/Formoterol Turbuhaler|
215080238|NCT00640640|DRUG|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
215080239|NCT04304885|DIAGNOSTIC_TEST|Sonication method|Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
215080240|NCT00434759|BEHAVIORAL|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
214354819|NCT03621644|RADIATION|Stereotactic MRI-guided On-table Adaptive Radiation Therapy|Radiation therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian or MRIdian Linac). The prescribed dose will be 50 Gray (Gy) in 5 fractions. Stereotactic body radiotherapy (SBRT) fractions will be delivered at least twice per week, and with at least 18 hours between fractions. Each participant will be aligned in the treatment system with MRI image-guidance. On-table adaptive re-planning will be used when clinically indicated. In all patients, real-time MRI imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam as necessary.
214354820|NCT01614665|DRUG|Tacrolimus|Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
214354821|NCT01614665|DRUG|Tacrolimus prolonged release|Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
214354822|NCT00002564|OTHER|educational intervention|
214354823|NCT00002564|PROCEDURE|therapeutic dietary intervention|
214354824|NCT06202521|DRUG|CX-4945 (SARS-CoV-2 domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
214963402|NCT00242411|DRUG|Conventional Best Asthma Therapy|
214963403|NCT01766531|DEVICE|body bioelectrical impedance|
214963404|NCT01672268|OTHER|cardiac computed tomography|cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
214963405|NCT00356161|DEVICE|interventionally implanted hepatic arterial port catheter|
214963406|NCT02861664|OTHER|Stannous fluoride (SnF2)|Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF
214963407|NCT02861664|OTHER|Sodium monofluorophosphate (SMFP)|Dentifrice containing 1400 ppm fluoride as SMFP
214963408|NCT01239394|DRUG|ofatumumab|Weekly infusion for 8 weeks
214963409|NCT01476267|DRUG|dalcetrapib|Single oral radiolabeled dose
214963410|NCT02229799|DRUG|Actilyse|
214963411|NCT01137487|PROCEDURE|monitoring of residual gastric volume|measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation
214963412|NCT01137487|PROCEDURE|not monitoring of residual gastric volume|no measurements of residual gastric volume
214963413|NCT00901615|DRUG|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
214963414|NCT01268657|BEHAVIORAL|Education|Learning about anxiety
214963415|NCT01268657|BEHAVIORAL|Relaxation Training|Learning skills to reduce tension
214963416|NCT01268657|BEHAVIORAL|Cognitive Restructuring|Learning skills needed to cope better with distressing thoughts
214963417|NCT01268657|BEHAVIORAL|Behavioral Activation|Learning to initiate healthy activity
214963418|NCT01268657|BEHAVIORAL|Exposure|Coaching in how to confront avoided thoughts, situations, and people)
214963419|NCT00905632|DRUG|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
214963420|NCT00905632|DRUG|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
214963421|NCT00905632|DRUG|Placebo + SOC|Placebo tid +SOC
214963422|NCT00905632|DRUG|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
215080241|NCT00434759|BEHAVIORAL|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
215080242|NCT04225091|DIETARY_SUPPLEMENT|Testing product|consume 1 bottle (50 mL) per day for 28 days
215080243|NCT04225091|DIETARY_SUPPLEMENT|Blank|consume 1 bottle (50 mL) per day for 28 days
215080244|NCT04298866|OTHER|Experimental Arm|"* 3T MRI, maximum 1H30 long duration, including diffusion tensor imaging, susceptibility weighted imaging, multiparametric acquisitions, without contrast perfusion acquisitions.~* 7T MRI, maximum 1H30 long duration, including contrast enhanced acquisitions~* Neuropsychological battery including chronometric measures obtained through a computer interface"
215080245|NCT01831440|BEHAVIORAL|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
215080246|NCT01831440|DRUG|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
215080247|NCT00002652|DRUG|suramin|
215080248|NCT00839865|DRUG|herb ointment|a kind of ointment made from herb
215080249|NCT00997425|DEVICE|Door cover/Floor cover|"Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.~Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door."
215080250|NCT00302016|DRUG|AMN107|
215080251|NCT06072716|DRUG|Chitosan|chitosan loaded with miconazole nanoparticles gel
215080252|NCT03871452|PROCEDURE|Ankaferd Blood Stopper in theTraumatic Bleeding|"ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses"
215080253|NCT05970094|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
215080254|NCT00002824|BIOLOGICAL|gene therapy|
214963423|NCT03832270|BEHAVIORAL|Parents InC|Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.
214963424|NCT03832270|BEHAVIORAL|Incredible Years|Also based on social learning theory but focus is not specifically on ADHD.
214963425|NCT06420037|DEVICE|Hearing aid feature adjustment (frequency compression) of the following hearing aids: Phonak Audéo Paradise/Lumity 70|Upon enrollment, each participant will be allocated to one of three research groups and participants will remain unaware of their group assignment. This groups will undergo a slight modification, namely frequency compression turned off, to the basic setting.
214963426|NCT06420037|DEVICE|Hearing aid feature adjustment (noise reduction) of the following hearing aids: Phonak Audéo Paradise/Lumity 70|Upon enrollment, each participant will be allocated to one of three research groups and participants will remain unaware of their group assignment. This groups will undergo a slight modification, namely noise reduction turned off, to the basic setting.
214354825|NCT06202521|DRUG|Placebo (SARS-CoV-2 domain)|The dosage and frequency is the same as active drug.
214354826|NCT06202521|DRUG|CX-4945 (Influenza virus domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
214354827|NCT06202521|DRUG|Placebo (Influenza virus domain)|The dosage and frequency is the same as active drug.
214354828|NCT05461625|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction
214354829|NCT05461625|OTHER|ALL anatomic|anatomic anterolateral ligament reconstruction
214354830|NCT05461625|OTHER|ALL tenodesis|anterolateral ligament teondesis
214354831|NCT04872764|OTHER|duration of hospitalization, mortality rate|duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.
214354832|NCT03265600|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.
214963427|NCT06420037|BEHAVIORAL|Cognitive screening and vision screening|The Dutch Montreal Cognitive Assessment will be assessed. The Snellen Eye Test will be used to screen for normal or corrected-to-normal vision.
214354833|NCT03265600|BEHAVIORAL|60-minute Introduction to Mindfulness|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
214963428|NCT06420037|BEHAVIORAL|Audiological Assessment|Three audiological tests are included: 1) Tympanometry to assess the middle ear status, 2) Pure-tone audiometry with headphone to evaluate the hearing thresholds, 3) Speech audiometry in free field to assess the ability to understand spoken sentences in quiet and in the presence of background noise.
214963429|NCT06420037|BEHAVIORAL|Questionnaires|"Three questionnaires are included:~1. The HAVICOP questionnaire to assess the hearing-related quality of life (Ceuleers, D., Baudonck, N., Keppler, H., Kestens, K., Dhooge, I., \& Degeest, S. (2023). Development of the hearing-related quality of life questionnaire for auditory-visual, cognitive and psychosocial functioning (hAVICOP). Journal of communication disorders, 101, 106291.)~2. the FAS (fatigue assessment scale) to assess how you usually feel~3. the EEAS (extended effort assessment scale) to assess how you experience listening in everyday life."
214963430|NCT06420037|BEHAVIORAL|Cognition|Four cognitive functions, important for speech understanding, will be assessed both audibly and visually: divided attention, working memory, processing speed, and cognitive flexibility and inhibition.
214963431|NCT06420037|OTHER|Real ear measurement|This test will give an objective assessment of the hearing aids' configuration.
214963432|NCT01278602|DRUG|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
214963433|NCT02793219|BIOLOGICAL|Sipuleucel-T|
214963434|NCT02793219|DRUG|Docetaxel|
214963435|NCT00938665|DEVICE|COGNISION™ System|30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
214963436|NCT01557673|DIETARY_SUPPLEMENT|NG bolus feeding over 5 min|Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
214963437|NCT01557673|DIETARY_SUPPLEMENT|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
214354834|NCT06454357|DRUG|B007|B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15
214487208|NCT06824389|OTHER|Consultation Model of large language model in Ophthalmology Clinics|Large language model completes the medical history collection and recommends examinations.
214963438|NCT02762435|OTHER|sham|light touch at established points on hand and wrist
214963439|NCT02762435|OTHER|control|no contact with the subject
214963440|NCT02762435|OTHER|acupressure|moderate pressure at established points on hand and wrist
214963441|NCT06326086|DRUG|Chemotherapy drug|Chemotherapy drug as prescribed by primary treating physician
214354835|NCT04282135|DIAGNOSTIC_TEST|MCC IMS|Diagnosis by MCC IMS
214354836|NCT03337529|OTHER|Vitamin C|200 mg Vitamin C will be given on daily basis for 8 weeks
214354837|NCT03337529|OTHER|Placebo|200 mg placebo will be given on daily basis for 8 weeks
214354838|NCT03575273|BEHAVIORAL|Sniffin' Sticks Odor Identification and Hedonic Scale|This task measures odor identification accuracy and perceived pleasantness of odors.
214354839|NCT03575273|BEHAVIORAL|Sucrose Taste Preference Assessment|This task measures participant ratings of sucrose preference.
214354840|NCT03575273|BEHAVIORAL|Food Preferences Task|Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).
214354841|NCT03575273|BEHAVIORAL|Progressive Ratio (PR) Task|In the PR task, the subject is required to make an increasing number of operant responses for each successive reward
214354842|NCT03575273|PROCEDURE|Clinical Electrophysiology|To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.
214354843|NCT03575273|DIETARY_SUPPLEMENT|Standardized Meal and Hunger and Satiety Ratings|Participants will receive a standardized meal and complete hunger and satiety ratings.
214487209|NCT06769607|DEVICE|Investigational algorithm|Investigational algorithm developed for the treatment of Obstructive Sleep Apnea.
214487210|NCT06769607|DEVICE|Control algorithm|Released algorithm intended for the treament of Obstructive Sleep Apnea
214963442|NCT06326086|DRUG|Targeted Agent|Targeted agents as prescribed by primary treating physician
214963443|NCT06326086|DRUG|Immunotherapy|Immunotherapy as prescribed by primary treating physician
214963444|NCT02778035|DEVICE|Dorsomedial prefrontal rTMS|Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval
214963445|NCT04617119|DEVICE|Threshold IMT device|10 breaths X 3 sets, two times a day for 2 weeks. starting intensity 10 % of pre-measured maximal inspiratory pressure.
214963446|NCT04617119|OTHER|Conventional physical therapy|daily
214963447|NCT01405495|PROCEDURE|MRI-based techniques (sMRI, fMRI, DTI, ASL)|no drugs include
214963448|NCT01467193|DIETARY_SUPPLEMENT|Fat diet|Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.
214963449|NCT01467193|OTHER|2h standardized aerobic exercise|Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours
214963450|NCT01229969|OTHER|Wii Fit Balance Games|Ski Slaloms and Table Tilt
214963451|NCT01229969|OTHER|NeuroCom EquiTest® System|Sensory Organization Test (SOT) and Limit of Stability (LOS).
214963452|NCT04349540|OTHER|no intervention|no intervention
214963453|NCT03822156|OTHER|Observation of AFB smear/culture|Observation of the patients from group for their AFB smear/culture results
214963454|NCT03782987|DRUG|BI 730357|0 mg BI 730357 tablet orally on Day 1
214354844|NCT00576069|DRUG|budesonide/formoterol|2 inhalations 2X/daily in treated arm/group. No placebo group
214354845|NCT00576069|DRUG|fluticasone/salmeterol|fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
214354846|NCT00576069|DRUG|mometasone/formoterol|"200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group"
214963455|NCT03782987|DRUG|Itraconazole|20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
214963456|NCT01666912|DRUG|Contraceptive implant|
214963457|NCT04626609|OTHER|Biopsy samples|Esophageal mucosal biopsies are collected during gastroscopy
214963458|NCT04626609|OTHER|Blood samples|Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes
214354847|NCT00576069|DRUG|Prednisone|0-15 mg daily as needed
214354848|NCT04176627|DEVICE|Lung ultrasound|One-time lung ultrasound study completed on peritoneal dialysis patients at monthly clinic visit
214354849|NCT02293538|DRUG|FID 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
214354850|NCT02293538|DRUG|Saline control eye drops (15 ml)|Saline eye drops (15 ml)
214354851|NCT02293538|DEVICE|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
214354852|NCT02218567|BEHAVIORAL|questionnaire qualilty of life|
214354853|NCT02218567|BEHAVIORAL|psychological interview|
214963459|NCT05118035|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which shows the risk prediction results for each patients. Moreover, the clinicians will recieve a short message when patients with a high risk ECG identified by AI.
214963460|NCT03290118|OTHER|Nutrition Rating System - Traffic Light|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.
214963461|NCT03290118|OTHER|Nutrition Rating System - Health Star|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.
214963462|NCT03290118|OTHER|Nutrition Rating System - Warning Label|"Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes."
214963463|NCT03290118|DEVICE|Smartphone application FoodFlip Device®|This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
214963464|NCT06158217|PROCEDURE|ultrasound combined with microbubbles|IBC tumors were treated with microbubbles (MBs) stimulated by ultrasound
214963465|NCT06082310|OTHER|Exercise|Two HIIT modalities
215080255|NCT00002824|DRUG|chemotherapy|
215080256|NCT00002824|DRUG|ganciclovir|
215080257|NCT00002824|PROCEDURE|conventional surgery|
215080258|NCT02751034|DEVICE|Neuramis® Deep Lidocaine|HA filler
215080259|NCT02751034|DEVICE|Restylane® PERLANE-L|HA filler
215080260|NCT02327936|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
214354854|NCT02218567|BEHAVIORAL|psychological tests|
214354855|NCT02218567|OTHER|Motor evaluation|
214354856|NCT02218567|BEHAVIORAL|Behavioral evaluation|
214354857|NCT02218567|BEHAVIORAL|cognitive tests|
214354858|NCT03576157|OTHER|Kilkari|Kilkari is an outbound service that delivers weekly, time-appropriate audio messages about pregnancy, childbirth, and childcare directly to families on their mobile phones, starting from the second trimester of pregnancy until the child is one-year-old.
214354859|NCT04401384|DRUG|Diclectin|Diclectin (combination of 10 mg doxylamine and 10 mg pyridoxine hydrochloride in a delayed release tablet) During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of Diclectin or placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
214354860|NCT04401384|DRUG|Diclectin placebo|Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
214678955|NCT03876340|OTHER|Treatment algorithm|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.
215080261|NCT02327936|DRUG|Oxybutynin XL|Administer medication to patients with overactive bladder
215080262|NCT00619346|DRUG|Placebo|Placebo tablets, BID X 14 days
215080263|NCT00619346|DRUG|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
214963466|NCT00610272|RADIATION|Radiotherapy|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
214354861|NCT04401384|DEVICE|Active acupuncture|Participants will receive active acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
214354862|NCT04401384|DEVICE|Sham acupuncture|Blunt-tipped placebo needles will be used. Participants will receive sham acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6). Then, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
214354863|NCT00965432|DRUG|STX107|Single dose of an oral suspension
214354864|NCT00430768|BIOLOGICAL|rAAV1-CB-hAAT|
214354865|NCT05172765|DEVICE|Transcutaneous Electrical Nerve Stimulation Device|Low-level, electrical stimulation of the outer ear (LLTS), using a transcutaneous electrical nerve stimulation (TENS) device.
214354866|NCT05447117|PROCEDURE|Micropulse laser|532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).
214354867|NCT05187676|DEVICE|Oxygen saturation measurement using the IPAM device|Skin oxygen saturation rate will be measured (%) using the non-contact optical device under evaluation called IPAM
214354868|NCT05187676|DEVICE|Transcutaneous oxygen partial pressure (TcPO2) using the PeriFlux6000 device|Skin TcPO2 will be measured (mmHg) using the reference device called PeriFlux6000
214354869|NCT01414387|PROCEDURE|Carotid filter|"Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott."
214963467|NCT00610272|RADIATION|Radiotherapy|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
214963468|NCT00610272|RADIATION|Radiotherapy|8 Gy in a single fraction; retreatments \> 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
214354870|NCT01414387|PROCEDURE|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
214354871|NCT00322348|DRUG|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
214354872|NCT00322348|DRUG|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
214354873|NCT00737126|DRUG|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
214354874|NCT00737126|DRUG|Placebo|Administration of an oral placebo pill
214963469|NCT00610272|RADIATION|Radiotherapy|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments \> 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
214963470|NCT02781818|DRUG|Triamcinolone Acetonide 10mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
214963471|NCT02781818|DRUG|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
214963472|NCT02781818|DRUG|Normal Saline|Normal saline 0.1 mL will be administered intralesionally at the selected site.
214963473|NCT05118620|DRUG|Active bupivacaine 0.375% PENG block|A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance
214963474|NCT05118620|DRUG|Placebo normal saline PENG block|A PENG block with normal saline and epinephrine will be administered using ultrasound-guidance
214354875|NCT03276351|DEVICE|Long-Stemmed with Hybrid Fixation|Long-stemmed revision implant with hybrid fixation for total knee arthroplasty
214354876|NCT03276351|DEVICE|Short-Stemmed with Augmented Fixation|Short-stemmed primary implant with augmented fixation for total knee arthroplasty
214354877|NCT03816748|DEVICE|High flow nasal cannula, HFNC|The HFNC used in this study can supply more than 40-60 L/min of oxygen flow, which is many times higher than the traditional nasal cannula. In addition, HFNC provides heating and moisturizing functions, so the patients 'nasal and oropharyngeal cavities do not dry out. This way, the patients can wear HFNC continuously for many days. Furthermore, when the patients close their mouths, HFNC can create a PEEP of 6-8 cmH2O, which helps with lung expansion after chest surgeries and lowers the risk of pneumonia related to lung collapses.
214354878|NCT05916690|DRUG|Electrochemotherapy with bleomycin or cisplatin|Combination of drug delivery platform (electroporation) and drug (bleomycin)
214354879|NCT01417299|DIETARY_SUPPLEMENT|RPh201|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
214354880|NCT01417299|DIETARY_SUPPLEMENT|saline|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
214963475|NCT03060226|DIAGNOSTIC_TEST|blood sample|Search of blood predictive marker (s)
214963476|NCT04127877|DEVICE|NICAS|Electric regional bio impedance device
215080264|NCT05622266|PROCEDURE|Pulpotomy|The patients who are randomly assigned to the experimental group receive pulpotomy.
214963477|NCT05171114|DIAGNOSTIC_TEST|Measurement of joint amplitudes|Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb
214354881|NCT01978613|DRUG|NNC0113-0987|Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.
214354882|NCT01978613|DRUG|placebo|Tablets for one-daily oral administration.
214963478|NCT03166501|DRUG|Lanicemine|Three 60 min parenteral infusions over a 5 day period
214354883|NCT04321538|DEVICE|Gocheck Kids|GoCheck Kids is a photoscreening device. It takes a special picture of the eyes that allows for detection of refractive error and eye misalignment.
214963479|NCT03166501|DRUG|Placebo|Three 60 min parenteral infusions over a 5 day period
214963480|NCT01439646|OTHER|it is a retrospective study, hence no active intervention|since it is an observational restrospective study hence no active intervention is planned
214963481|NCT04478565|OTHER|Indirect Calorimetry|"RMR was calculated by breath oxygen consumption (O2 in mL·min-1), minute by minute, using a portable device (Breezing®, Arizona, USA), and the Weir equation (1949), while participants remained in a sitting position for ≈15 to 20 minutes.~The anthropometric measurements were performed by certified level 3 anthropometrists following the guidelines of the International Society for the Advancement of Kinanthropometry, ISAK"
214963482|NCT01947842|DEVICE|Smartphone App Dosecast|The Dosecast app is configured to remind the patient to take their medication.
214963483|NCT00799084|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
214963484|NCT00799084|BEHAVIORAL|AVR|Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
214963485|NCT03464032|DRUG|BCD-135|Monoclonal anti-PD-L1 antibody
214963486|NCT00683488|BEHAVIORAL|Focus Group|Focus group using and collecting feedback on the CBT/CM intervention.
215080265|NCT05622266|PROCEDURE|Root Canal Therapy|The patients who are randomly assigned to the Active Comparator group receive root canal therapy.
214354884|NCT04321538|DEVICE|Welch Allyn Spot Vision Screener|The Welch Allyn Spot Vision Screener is a photoscreening device. It takes a special picture of the eyes that allows for the detection of refractive error and eye misalignment.
214354885|NCT04321538|DIAGNOSTIC_TEST|Physical Exam|Retinoscopy and an oculomotor testing will constitute the physical examination.
214354886|NCT03974542|BEHAVIORAL|telephone outreach|The navigator should make at least five (5) attempts to reach the participants on different days (at least one (1) attempt in weekend) and different time slots (at least one (1) attempt each in am, pm and evening). If the navigator only reached voice mail after the 1-month intervention period, a standard script will be read and a contact number will be provided.
214354887|NCT03568864|OTHER|Low nucleotide meal|The participants will consume a mixed meal (sandwich) containing a nucleotide depleted mycoprotein product (low in nucleotides)
214354888|NCT03568864|OTHER|High nucleotide meal|The participants will consume a mixed meal (sandwich) containing a non nucleotide depleted mycoprotein product (high in nucleotides)
214354889|NCT00232492|DRUG|Placebo males|Intravenous saline bolus (Placebo-control) males
214354890|NCT00232492|DRUG|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine iv bolus males
214354891|NCT00232492|DRUG|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine iv bolus males
214354892|NCT00232492|DRUG|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine iv bolus males
214678956|NCT03876340|OTHER|Current treatment|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
214678957|NCT03649776|OTHER|Mental Health First Aid|Mental Health First Aid (MHFA) is listed in the Substance Abuse and Mental Health Services Administration's National Registry of Evidence-based Programs and Practices. The program also teaches the common risk factors and warning signs of specific types of illnesses like anxiety, depression, substance use, bipolar disorder, eating disorders, and schizophrenia. Participants are introduced to local mental health resources, national organizations, support groups, and online tools for mental health and addictions treatment and support.
214354893|NCT00232492|DRUG|Placebo females|Intravenous saline bolus (Placebo-control) females
214354894|NCT00232492|DRUG|Ketamine 0,1 mg/kg females|0,1 mg/kg iv bolus ketamine females
214354895|NCT00232492|DRUG|Ketamine 0,3 mg/kg females|0,3 mg/kg iv bolus ketamine females
214354896|NCT00232492|DRUG|Ketamine 0,5 mg/kg females|0,5 mg/kg iv bolus ketamine females
214354897|NCT02566954|OTHER|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
214963487|NCT00683488|BEHAVIORAL|First Intervention Trial|"Intervention will comprise of approximately 15 weekly sessions.~* Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.~* Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.~* Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility."
214963488|NCT00683488|BEHAVIORAL|Intervention Trial 2|Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
214963489|NCT01594918|DRUG|Cabazitaxel|25 mg/m2 or 20 mg/m2, IV, once every 21 days
214963490|NCT01594918|DRUG|Mitoxantrone|4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
214354898|NCT05737810|OTHER|No treatment given|No treatment given
214963491|NCT01594918|DRUG|Prednisone|5 mg PO BID
215080266|NCT02436408|DRUG|Vismodegib|
214354899|NCT04208841|BEHAVIORAL|Person-Centered Care Quality Improvement Collaborative Sustain|Sustain improvements during QI collaborative focused on PCC
214354900|NCT04208841|BEHAVIORAL|Person-Centered Care Quality Improvement Collaborative Spread|Implement change package developed during QI Collaborative
214354901|NCT06135337|DEVICE|Thioderm Elate|Test Device
214354902|NCT06135337|DEVICE|Juvéderm Ultra 3|Active Comparator Device
214354903|NCT03776513|BEHAVIORAL|an MRI examination|The MRI examination implies the realization of an emotional associative memory task
214354904|NCT03993769|OTHER|A19010-F|A snus product
214354905|NCT03993769|OTHER|B19010-F|A snus product
214354906|NCT03805724|OTHER|Plaque Samples|After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.
214963492|NCT01594918|DRUG|Pegfilgrastim|6 mg, SC, once every 21 days
214963493|NCT01223404|DRUG|Placebo|Participants are administered a placebo patch and a placebo capsule
214963494|NCT01223404|DRUG|Nicotine|Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
214963495|NCT01223404|DRUG|Mecamylamine|Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
214963496|NCT04461548|BEHAVIORAL|Thinking, writing and imagining|All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.
214963497|NCT05136235|DIAGNOSTIC_TEST|Echocardiography|There will be screened for pulmonary hypertension by means of serial echocardiographies during the study period
214963498|NCT05136235|DIAGNOSTIC_TEST|NT-proBNP|At 36 weeks postmenstrual age there will be screened for pulmonary hypertension by means of an NT-proBNP measurement in a blood sample
214963499|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
214963500|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
214963501|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
214963502|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
214963503|NCT00707057|DRUG|Ibuprofen 600 mg Extended-Release Tablets|Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
214963504|NCT00707057|DRUG|Placebo|Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
214963505|NCT00176657|DRUG|HEMOBAG Assessment|
214963506|NCT01646840|DRUG|PF-04958242 capsule|Single dose of PF-04958242 0.35 mg oral capsule
214963507|NCT01646840|DRUG|PF-04958242 oral solution|Single dose of PF-04958242 0.35 mg oral solution
214354907|NCT05656950|PROCEDURE|Assessment|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
214354908|NCT01298128|DRUG|NuvaRing|NuvaRIng 21 days for IVF pre-treatment.
214354909|NCT01298128|DRUG|marvelon|marvelon 21 daily
214354910|NCT04802538|DEVICE|OstoRing®|Participants will use the OstoRing® along with their standard pouching equipment.
214963508|NCT04041596|DEVICE|Advanced Bionics' Acoustic Earhook|designed to deliver acoustic amplification through the modular attachment of the Naída CI Q90 AcoustiEarhook, while also delivering electrical stimulation along the full range of the implanted Advanced Bionics electrode.
214963509|NCT05535374|DEVICE|Feetme Connected Soles|Walk for 10 meters (and 30meters): - By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphonecollection of data by smartphone - By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers). If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.
214963510|NCT03380871|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
214963511|NCT03380871|BIOLOGICAL|Pembrolizumab|monoclonal antibody against PDL1
214963512|NCT03380871|OTHER|Adjuvant|immune adjuvant
214963513|NCT03380871|DRUG|Carboplatin|chemotherapy
214963514|NCT03380871|DRUG|Pemetrexed|chemotherapy
214354911|NCT01090453|BIOLOGICAL|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
214354912|NCT01090453|BIOLOGICAL|Prevenar 13®|3 co-administered doses
214354913|NCT01090453|BIOLOGICAL|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
214354914|NCT01090453|BIOLOGICAL|Menjugate®|3 co-administered doses
214354915|NCT01090453|BIOLOGICAL|Rotarix™|Oral, two doses
214354916|NCT04730050|DRUG|TT-01025-CL|Oral tablet
214354917|NCT03536806|DRUG|Saline 0.9%|Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.
214963515|NCT05186584|OTHER|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|"Group A will receive the 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set (total 75 oscillations) for AP mobilizations at most symptomatic segment, with 10 seconds rest between sets. Most symptomatic segment is that segment of cervical spine at which patient will feel greatest pain by palpation.~For AP mobilizations, patient will lye supine and therapist will stand by his head. Therapist will make broad contact with the thumb, at the costal process of the vertebrae to be mobilized and spread fingers around adjacent neck for stability. Shoulder will be positioned above the joint being treated. Gentle oscillatory Anteroposterior pressure will be performed by the therapist's arm and trunk."
214963516|NCT05186584|OTHER|MAITLAND'S LATERAL MOBILIZATION|Group B will receive the same sets (i.e. 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set) for lateral mobilizations at most symptomatic segment, with 10 sec rest between each set. For lateral mobilization, patient will lye supine and therapist will stand by his head. Therapist will place the anterolateral aspect 2nd metacarpophalangeal joint over the lateral aspect of transverse process of most symptomatic segment. Gentle lateral oscillations towards the asymptomatic side will be provided by the therapist.
214354918|NCT03536806|DRUG|Canrenone|Patients assigned to canrenone group will be administered canrenone in bolus of 200 mg diluted to 10 cm3 within 2-3 minutes in one dose. Drug administration will be stopped in case of serious adverse event. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
214354919|NCT04262544|BEHAVIORAL|iCardia4HF|Participants in the intervention group will receive the following main components in addition to usual care: 1) the Heart Failure Health Storylines mobile app which supports daily self-monitoring and management of vital signs and symptoms; 2) three connected health devices (Fitbit activity tracker, Withings Cardio Body weight scale and blood pressure monitor), and 3) a program of tailored text-messages targeting health beliefs, self-efficacy, and HF-knowledge.
214963517|NCT01688622|BEHAVIORAL|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
214963518|NCT03570775|DEVICE|Sleeping bag phototherapy|This device has a LED light emitter that incorporates one fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. The phototherapy sleeping bag is conceived with the aim of increasing the surface of phototherapy by means of a double exposure: ventral and dorsal, which allows the insertion of two phototherapy devices of 20x30 centimeters. The ventral and dorsal caps incorporate mesh optical fibers that are connected to the light emitter, in which the phototherapy time can be programmed. The fiber optic meshes are protected by a vinyl cover and a disposable lining for patient comfort and hygiene.
214963519|NCT03570775|DEVICE|Conventional phototherapy|This is a phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated. The device has a minimum height of 106 cm and a maximum of 152 cm, a depth of 64 cm and a width of 72 cm. The manufacturer recommends not using the lamp at distances of less than 50 cm because, although the heat radiation is minimal, this can influence distances less than 50 cm when the child is also exposed to infrared thermal radiation, typical of the servo cribs It is recommended to control temperature and eye protection due to the risk of ophthalmic injury from light, since the intensity of the light is concentrated in a single point.
214963520|NCT06407219|DEVICE|Robot Assisted Gait Training|The Trexo robotic gait trainer will be used to facilitate physical activity in people who cannot walk independently, either at all or without the use of assistive gait aids (ie. walkers or canes). Session length will be determined by the participant's perceived fatigue level (ie. the session will run until the participant feels they want to or need to stop), and will not exceed 1 hour of training time.
214963521|NCT01795794|DRUG|omeprazole|
214354920|NCT04262544|OTHER|Usual Care|Participants assigned to the control group will receive usual care and the same connected health devices (Fitbit activity tracker, Withings weight scale and blood pressure monitor) as patients in the intervention group, but without the heart failure health storylines mobile app and text-messaging program. Usual care includes patient education before hospital discharge, and follow-up visits at the outpatient HF clinic a week after discharge and monthly thereafter depending on the patient's condition. Patient education includes literacy-sensitive, education material about HF self-care developed by the Sheps Center for Health Services Research,and a 40-minute education session with an APN and a dietician to review and discuss the education material provided to the patient.
214354921|NCT00887497|PROCEDURE|Angioembolization|Angioembolization
214354922|NCT02495051|PROCEDURE|esophageal biopsies|
214354923|NCT01746004|DRUG|[^14C]-LY2157299|\[\^14C\]-LY2157299 monohydrate administered as oral solution
214354924|NCT06164717|BEHAVIORAL|Auditory feedback perturbation during speech|The intervention consists of manipulating real-time auditory feedback during speech production. In our lab, such feedback perturbations can be implemented with either a stand-alone digital vocal processor (a device commonly used by singers and the music industry) or with software-based signal processing routines (see Equipment section for details). Note that the study does not investigate the efficacy of these hardware or software methods to induce behavioral change in subjects' speech. Rather, the study addresses basic experimental questions regarding the general role of auditory feedback in the central nervous system's control of articulatory speech movements.
214354925|NCT06164717|BEHAVIORAL|Visual feedback perturbation during reaching|The intervention consists of manipulating real-time visual feedback during upper limb reaching movements. In our lab, such feedback perturbations can be implemented with a virtual reality display system.
214487211|NCT06768996|BEHAVIORAL|Synchronous Rhythm Production|The treatment group will take part in a dyad-based musical rhythm production activity facilitated by a trained musician. This activity will involve two rhythm conditions. The first condition requires tapping along to one pre-recorded audio track composed of an ensemble of Brazilian percussion instruments. The second condition requires tapping along with prerecorded audio tracks of rhythms progressively increasing in difficulty. Participants who indicate proficiency in learning to tap along in both conditions will be able to progress to more complex rhythms. All tapping data will be gathered through a Roland digital hand percussion controller.
214963522|NCT03880136|DRUG|CTP-543|Once daily dosing
214963523|NCT00121706|BEHAVIORAL|Condition A (see detailed summary)|
214963524|NCT00121706|BEHAVIORAL|Condition B (see detailed summary)|
214963525|NCT00121706|BEHAVIORAL|Condition C (see detailed summary)|
214963526|NCT03613714|OTHER|At-home Blood Pressure Monitoring|Participants will use over-the-counter digital monitor to measure blood pressure and pulse rate at home. Automatically averages the last 3 readings taken over 10 minutes.
214963527|NCT02089802|DRUG|Pazopanib|
214963528|NCT02380365|DEVICE|Electrocardiography|"Duration of intervention per patient/subject:~5 min, observation 6 months"
214963529|NCT01613261|DRUG|TAK-733 and alisertib|"TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle."
214354926|NCT06164717|OTHER|DBS stimulation ON/OFF|"Patients who have been previously implanted with a DBS stimulator for their clinical care will be tested in two speech motor learning tasks with the stimulation ON and with the stimulation OFF.~Note that (1) patients routinely turn the stimulation OFF and back ON (examples are, for some patients, to sleep, to save battery, etc), and (2) we are not in any way evaluating the stimulator itself or its clinical effectiveness but only whether or not two forms of speech motor learning (adaptation to auditory feedback perturbation and speech sequence learning) are affected differently by having the stimulation ON or OFF.~implant ON/OFF prior to participation in the speech auditory-motor learning tasks and speech sequence learning tasks. This intervention can be implemented by the subject themselves as all patients have a hand- held controlled that they use to switch stimulation ON/OFF."
214963530|NCT01773083|DRUG|unfractionated heparin|nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
214963531|NCT01773083|DRUG|placebo|Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
214963532|NCT05183334|DRUG|Sildenafil 50 mg|PD5I
214963533|NCT05183334|DRUG|Placebo|placebo
214963534|NCT05183334|DRUG|Tramadol Hydrochloride 100 MG|opiod
214963535|NCT00001577|PROCEDURE|double isolated limb perfusion with melphalan alone|
214963536|NCT04611542|BEHAVIORAL|Fathering In Recovery|Fathering In Recovery (FIR) will be designed to address the unique needs of fathers in treatment for opioid misuse. FIR integrates evidence-based parenting interventions that have well-documented positive outcomes on children, parents, and families, with innovative web-based mobile technology to maximize accessibility, fidelity, and consistency of intervention and support.
214963537|NCT02813928|GENETIC|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
214963538|NCT03094884|RADIATION|Pulsed Low Dose Radiation|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
214963539|NCT03094884|DRUG|Carboplatin|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
214963540|NCT03094884|DRUG|Paclitaxel|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
214963541|NCT00320242|DEVICE|1 mo baseline before visual cue|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
214354927|NCT00729833|DRUG|CP-751,871|CP-751,871 IV, every 3 weeks
214354928|NCT00729833|DRUG|Sunitinib|Sunitinib - daily dosing
214963542|NCT04424147|COMBINATION_PRODUCT|HVA Regimens as Salvage Treatment|venetoclax with a dose of 400mg per day for 14 days, combined with azacitidine (AZA) with a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days
214354929|NCT04250454|BEHAVIORAL|CONTRACT|"The intervention will consist of four elements:~1. Personal meeting - detailed information to the parents before the age of 15 weeks CA (1-3 days)~2. Home Activity Plan (HAP)~3. Home-based Feedback training~4. Electrical muscle stimulation~Combination of these elements has been chosen in order to ensure that optimal muscle growth is achieved through multi-modal stimulation of the motor and cognitive development of the child."
214354930|NCT00695669|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
214354931|NCT03102723|DRUG|Cangrelor|"1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~   Or~2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI."
214678958|NCT01201369|DEVICE|Coronary Stent Cypher|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
214963543|NCT02548377|PROCEDURE|Remote ischemic preconditioning|
214963544|NCT02548377|PROCEDURE|Sham|
214963545|NCT03202290|BEHAVIORAL|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)
214963546|NCT02076386|DRUG|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
214963547|NCT05468216|OTHER|MovIn-Lessons group|The MovIn-Lessons intervention will consist of infusing PA in math, English and natural sciences lessons in primary education. The movement will be integrated in the learning activities for at least 20 minutes per session, at different physical intensities.
214963548|NCT01668056|DRUG|Ovulation induction with choriogonadotropin alfa|Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
214354932|NCT05045625|DEVICE|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
214354933|NCT02938598|BEHAVIORAL|Maternal Depression Education and Care-Seeking Motivation|Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
214354934|NCT03598270|DRUG|Placebo|Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1
214354935|NCT03598270|DRUG|Carboplatin|Intravenous. Day 1
214354936|NCT03598270|DRUG|Paclitaxel|175 mg/m². Intravenous. Day 1
214354937|NCT03598270|DRUG|Niraparib|200 mg or 300 mg. Oral. From day 1 to 21
214354938|NCT03598270|DRUG|Gemcitabine|1000 mg/m². Intravenous. Day 1 and day 8.
214354939|NCT03598270|DRUG|Pegylated liposomal doxorubicin (PLD)|30 mg/m². Intravenous. Day 1
214354940|NCT03598270|DRUG|Atezolizumab|1200 mg. Intravenous. Day 1
214354941|NCT00349453|DRUG|Deferiprone (L1)|50-100 mg/kg body weight daily
214354942|NCT00349453|DRUG|Deferiprone (L1)|75 mg/kg body weight daily
214354943|NCT00349453|DRUG|Desferrioxamine|35-50 mg/kg body weight on 2 or more days per week
214354944|NCT00417079|DRUG|cabazitaxel (XRP6258) (RPR116258)|25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
214354945|NCT00417079|DRUG|mitoxantrone|12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
214354946|NCT00417079|DRUG|prednisone|10 mg daily administered by oral route
214354947|NCT04594161|DEVICE|Percutaneous Nephrostomy|A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis
214963549|NCT01668056|PROCEDURE|Aspiration of the dominant follicle|Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
214963550|NCT01668056|OTHER|Control|Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
214963551|NCT05409950|PROCEDURE|Immediate implant placement using socket shield technique|Evaluation of socket shield technique with immediate implant placement at the esthetic zone in comparison with the conventional immediate implant placement
214963552|NCT01131559|DRUG|Lisdexamfetamine|Oral; 20-70mg/day
214963553|NCT01131559|DRUG|Placebo control|Oral; 20-70mg/day
214963554|NCT05746169|OTHER|Health Questionnaires|A questionnaire with content developed and tested in the investigator's previous reproductive and cancer epidemiology studies as part of the NIH Environmental Influences on Child Health Outcomes (ECHO) consortium will be used to collect information on primary established and hypothesized risk factors for cancer and additional covariates.
214354948|NCT04594161|DEVICE|Double J catheter|A Double J catheter will be placed in patients with obstructive urolithiasis
214354949|NCT02512575|DRUG|AZD9567 Monohydrat|AZD9567 oral suspension 0.5 to 10 mg/ml
214354950|NCT02512575|DRUG|Placebo oral suspension/ Placebo capsule|Matching placebo
214354951|NCT02512575|DRUG|Prednisolone|Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
214354952|NCT05110092|BEHAVIORAL|leg resistance combined with breathing exercise training|The exercise group was provided breathing and leg resistance exercise manuals. The exercise involved 5 minutes of abdominal breathing in a relaxed sitting position, followed by 10 minutes of leg resistance training.
214354953|NCT01862705|OTHER|Thoracic spine manipulation|TSM thrust or non-thrust
214354954|NCT01696487|DIETARY_SUPPLEMENT|High oral Fructose challenge (150g per day for 28 days)|
214354955|NCT05068817|OTHER|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
214354956|NCT05068817|OTHER|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
214354957|NCT05068817|OTHER|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
214678959|NCT01201369|DEVICE|Coronary stent Xience|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
214354958|NCT05925127|BIOLOGICAL|NVX-CoV2373 (5μg)|Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg/mL and 100 μg adjuvant per mL, respectively
214354959|NCT05925127|BIOLOGICAL|NVX-CoV2601 (5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 50 µg Matrix-M adjuvant.
214354960|NCT05925127|BIOLOGICAL|NVX-CoV2601(5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 75 µg Matrix-M adjuvant.
214354961|NCT05925127|BIOLOGICAL|NVX-CoV2601 (35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 50 µg Matrix-M adjuvant.
214354962|NCT05925127|BIOLOGICAL|NVX-CoV2601(35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 75 µg Matrix-M adjuvant.
214354963|NCT05925127|BIOLOGICAL|NVX-CoV2601(50μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 50 µg of antigen with 100 µg Matrix-M adjuvant
214354964|NCT05925127|BIOLOGICAL|Bivalent BA.4/5|The bivalent BA.4/5 (or recommended mRNA vaccine at the time of the conduct of this study) Omicron subvariant/prototype licensed mRNA vaccine will be procured and stored per the manufacturer's instructions. For this vaccine group, treatment will be administered open label as a single IM injection
214678960|NCT00318201|DRUG|Erythromycin|
214354965|NCT00434382|DRUG|Sevoflurane|
214354966|NCT00434382|DRUG|Isoflurane|
214354967|NCT00434382|DRUG|Desflurane|
214354968|NCT00434382|DRUG|Propofol|
214354969|NCT00434382|DRUG|Fentanyl|
214354970|NCT00434382|DRUG|Sufentanil|
214354971|NCT00434382|DRUG|Alfentanil|
214354972|NCT00434382|DRUG|Remifentanil|
214354973|NCT00434382|DEVICE|Midlatency auditory evoked potentials|
214963555|NCT05746169|OTHER|Specimen sample collection|Collection of blood, urine, nails, hair, and saliva samples will be obtained during the participant encounters.
214963556|NCT03296969|PROCEDURE|cesarean section|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
214963557|NCT03296969|PROCEDURE|Rectus muscle approximation|aprroximation of the lower parts of rectus abdomius muscles during cesarean section
214963558|NCT05856253|PROCEDURE|Enhanced recovery program|Recvoery programs includes specific measures validated in multidisciplinary consultation, spread over the pre- intra- and postoperative period.
214963559|NCT03477292|DRUG|Duration of antibiotic|Duration of antibiotic for treatment of VAP
214963560|NCT02801825|PROCEDURE|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
214963561|NCT02801825|PROCEDURE|Real-time ultrasound-guided out-of-plane femoral artery cannulation.|Real-time ultrasound-guided out-of-plane femoral artery cannulation.
214354974|NCT05452057|BEHAVIORAL|Prehabilitation|"A Registered Kinesiologist will provide your exercise prescription during your first visit for the study. Your exercise sessions will consist of moderate-intensity cardiovascular (or aerobic) exercise, like brisk walking, for 30 minutes. You will also perform resistance exercises (weight lifting) for 30 minutes that will help strengthen your muscles with a focus on muscles that may be affected by your surgery. To complete your exercises, you will receive resistance bands, exercise ball, and exercise manual.~You will also meet with a Registered Dietician within a week of consent to receive information on healthy eating and you will receive protein to improve your nutritional health.~A consult with an expert in psychology to discuss ways to reduce your stress within a week of consent. Some strategies to help reduce your stress may include breathing exercises, being mindful, or other relaxation methods."
214354975|NCT04113122|DIAGNOSTIC_TEST|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
214354976|NCT04113122|DIAGNOSTIC_TEST|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
214354977|NCT03570619|DRUG|Nivolumab|"Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.~Patients in arm Metastatic CRPC will receive therapy with monotherapy nivolumab therapy at flat dose 480 mg IV every 4 weeks for up to 104 weeks of total therapy."
214354978|NCT03570619|DRUG|Ipilimumab|Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.
214963562|NCT06148103|DRUG|Patients who received Dexmedetomodine|1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
214963563|NCT06148103|DRUG|patients who received propofol-fentanyl|Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
214963564|NCT03145753|OTHER|HIV/HCV Education plus Testing|Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
214963565|NCT03145753|OTHER|HIV/HCV Education|Only education and support will be provided in this arm
214963566|NCT03113669|BEHAVIORAL|CBT-GSH|
214963567|NCT00102843|PROCEDURE|supplementation with folic acid and betaine|
214963568|NCT02915159|BIOLOGICAL|Abatacept|
214963569|NCT02915159|OTHER|Placebo|
214354979|NCT03154008|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.
214354980|NCT01750073|DRUG|Cyclophosphamide|Given IV
214678961|NCT00318201|DRUG|Diltiazem|
214678962|NCT01810991|DEVICE|Nd:YAG Laser|Nd:YAG 1440nm Laser
214354981|NCT01750073|DRUG|Doxorubicin Hydrochloride|Given IV
214354982|NCT01750073|OTHER|Laboratory Biomarker Analysis|Correlative studies
214354983|NCT01750073|DRUG|Paclitaxel|Given IV
214354984|NCT01750073|RADIATION|Radiation Therapy|Undergo RT
214354985|NCT01750073|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
214354986|NCT01750073|BIOLOGICAL|Trastuzumab|Given IV
214963570|NCT05407285|DRUG|cannabis 0 mg, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
214963571|NCT05407285|DRUG|Cannabis 20 mg,|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
214354987|NCT02457221|DRUG|Tacrolimus capsules|oral
214354988|NCT02457221|DRUG|Cyclophosphamide injections|intravenous injection
214354989|NCT02457221|DRUG|Prednisone|oral
214354990|NCT01022762|DRUG|repaglinide|Individually adjusted dose for 16 weeks
214354991|NCT01022762|DRUG|gliclazide|Individually adjusted dose for 16 weeks
214354992|NCT01302119|DRUG|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
214354993|NCT01302119|DRUG|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
214354994|NCT00679003|BEHAVIORAL|SLCBT|Social learning and cognitive behavioral therapy
214354995|NCT00679003|BEHAVIORAL|ES|Education and support (information about nutrition and gastrointestinal system)
214354996|NCT01244152|BEHAVIORAL|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
214354997|NCT01244152|BEHAVIORAL|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
214354998|NCT06427226|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg tab once daily given during the duration of AC cycles.
214354999|NCT02235493|BIOLOGICAL|Retrospective Case Only|
214355000|NCT05987683|PROCEDURE|Thread-Embedding Acupuncture, Sham Thread-Embedding Acupuncture|Thread-Embedding Acupuncture: using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread Sham Thread-Embedding Acupuncture: using a 29-gauge TEA needle but thread-removed, just needle alone
214355001|NCT06427772|PROCEDURE|bipolar hemiarthroplasty|bipolar hemiarthroplasty for neck femur fracture
214355002|NCT05875948|DRUG|R2R01|Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.
214355003|NCT05875948|DRUG|Terlipressin|"In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL).~In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin."
214355004|NCT05746845|BIOLOGICAL|Blood sample|"Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)"
214355005|NCT03049410|PROCEDURE|Intracorporeal Robot Assisted Radical Cystectomy|Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration
214355006|NCT03049410|PROCEDURE|Open Radical Cystectomy|Removal of bladder and adjacent organs
214355007|NCT02631798|DIETARY_SUPPLEMENT|Food grade dye mucosal staining|mucosal staining with food grade dye
214355008|NCT01191489|DEVICE|High Flow Conditioned Oxygen Therapy in High Risk Patients|OptiFlow system (R) with nasal cannula.
214355009|NCT01191489|DEVICE|Non-invasive mechanical ventilation|Bilevel pressure support through a facial mask
214355010|NCT01191489|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
214355011|NCT06647797|BEHAVIORAL|HOPE Clinical Communication Campaign|"* Patient-facing educational materials~* Provider counseling training and job aid"
214355012|NCT03463902|DEVICE|left IFG anodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
214355013|NCT03463902|DEVICE|left IFG cathodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
214355014|NCT03463902|DEVICE|left IPL anodal|Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
214355015|NCT03463902|DEVICE|left IPL cathodal|Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
214355016|NCT03463902|DEVICE|Placebo|Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
214355017|NCT03336619|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
214355018|NCT03336619|DRUG|Placebo|Placebo administered orally twice daily for five days
214355019|NCT02580565|OTHER|telephone interview|Clinical assessment for screening and a phone call for questionnaire administration
214355020|NCT01163370|DIETARY_SUPPLEMENT|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
214355021|NCT01163370|OTHER|exercise training|resistance training twice a week for 24 weeks
214355022|NCT01163370|OTHER|placebo (dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
215080267|NCT01300819|OTHER|Placebo|"Placebo patches of 2, 4, 6 \& 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
214963572|NCT05407285|DRUG|Cannabis 50 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
214963573|NCT05407285|DRUG|Cannabis 100 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
214963574|NCT05407285|DRUG|Cannabis 200 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
214963575|NCT06076031|BEHAVIORAL|Streaming Media|The aim of this study is to conduct a cross-over randomized clinical trial to compare the effects of with using streaming media (video and audio) on reducing pain medication use, anxiety, pain intensity, and factors related to pain during dressing changes for second-degree burn patients.
214963576|NCT01510964|BEHAVIORAL|prompt-sheet|"Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology."
214963577|NCT01510964|BEHAVIORAL|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
214963578|NCT03446209|DRUG|Tocilizumab Infusion RoAcemtra (EU)|Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks
214963579|NCT03446209|DRUG|0.9% physiological saline|"Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28."
214963580|NCT03005639|DRUG|Vemurafenib and Cobimetinib|All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
214963581|NCT05314829|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a phase-based evidence-based treatment method for children and adolescents between 6-18 years who experience posttraumatic stress symptoms following trauma exposure. Parents or other close caregivers receive parallel sessions. It is normally provided through 12-16 sessions.
214963582|NCT01761643|DEVICE|SoC + iTab|Text messaging reminders to improve adherence to PrEP
214963583|NCT01839071|PROCEDURE|biopsy|
214963584|NCT02821416|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
215080268|NCT01300819|DRUG|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
214963585|NCT02821416|OTHER|Placebo|Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
214963586|NCT03187184|DEVICE|OneOme RightMed®|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
214963587|NCT03903250|DIETARY_SUPPLEMENT|A-GPC|Taken orally in liquid form
214963588|NCT03903250|DIETARY_SUPPLEMENT|Sugar|Taken orally in liquid form
214963589|NCT00137787|DRUG|ciprofloxacin|
214963590|NCT00137787|DRUG|cefepime|
214963591|NCT01533402|BEHAVIORAL|therapist support|Weekly therapist support without CBT-interventions
214963592|NCT01533402|BEHAVIORAL|Internet-delivered CBT|Internet-delivered cognitive behavioural therapy with therapist support
214963593|NCT01666561|OTHER|Breakfast Test Cereal 1, Oat based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
214963594|NCT01666561|OTHER|Breakfast Test Cereal 2, Oat-based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
214963595|NCT01666561|OTHER|Ready-to-eat cereal|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
214963596|NCT01065571|DIETARY_SUPPLEMENT|carrageenan|The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
214963597|NCT01065571|OTHER|dietary intervention with no-carrageenan diet|The intervention will consist of the no-carrageenan diet.
214963598|NCT02244047|DRUG|Bifidobacterium breve|
215080269|NCT02649855|BIOLOGICAL|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
214355023|NCT06021301|OTHER|Platelet-Rich Fibrin and Microneedling|First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.
214355024|NCT05515432|DRUG|Single oral dose of BAY3283142 IR (immediate release) tablet|Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design
214355025|NCT00000744|DRUG|Fluconazole|
214355026|NCT04936022|OTHER|Isometric Exercise|Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
214355027|NCT04936022|BEHAVIORAL|Standard care lifestyle advice|Healthy lifestyle advice for hypertension, given by a healthcare professional.
214355028|NCT02488434|DEVICE|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
214355029|NCT00889213|PROCEDURE|Falciform patch and fibrin glue application|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
214355030|NCT00889213|PROCEDURE|standard pancreatic closure|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
214355031|NCT01022437|OTHER|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
214963599|NCT02244047|DRUG|Placebo (for Bifidobacterium breve)|
214963600|NCT03019029|OTHER|18-F Florbetapir PET/MR scan|18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
214963601|NCT00716807|DRUG|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
214963602|NCT00716807|DRUG|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
214355032|NCT02205944|OTHER|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg \& Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
214487212|NCT06768996|BEHAVIORAL|Solo Rhythm Production|Participants randomized to the control condition will complete the same rhythm conditions to the same recorded audio tracks described in the experimental condition. However, they will not interchange their tapping with their caregiver. They will participate in the rhythm task as a solo producer.
214963603|NCT00716807|DRUG|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
214963604|NCT00716807|DRUG|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
214963605|NCT00216528|DRUG|risperidone|
214963606|NCT00570336|DRUG|CTS-1027|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
215080270|NCT02649855|BIOLOGICAL|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
215080271|NCT02649855|DRUG|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
214963607|NCT00570336|OTHER|Placebo|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
214963608|NCT00652704|DRUG|Doxycycline monohydrate|Capsules, 100 mg, fed
214963609|NCT00652704|DRUG|Monodox|Capsules, 100 mg, fed
214963610|NCT00652704|DRUG|Doxycycline Monohydrate|Capsules, 100 mg, fasting
214963611|NCT01001520|DRUG|Tolcapone|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
214355033|NCT03341910|DRUG|DFD-03 Lotion, 0.1%|DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
214355034|NCT03341910|DRUG|Tazorac Cream, 0.1%|Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
214355035|NCT03341910|DRUG|DFD-03 Vehicle Lotion 0%|Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
214355036|NCT03341910|DRUG|Tazorac Vehicle Cream 0%|Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
214355037|NCT00001651|OTHER|[6,6-2H2]-glucose|\[6,6-2H2\]-glucose will be administered as a continuous IV infusion for one to five days.
214963612|NCT01001520|DRUG|Placebo|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
214963613|NCT03146338|OTHER|Magnesium-rich mineral water (Rozana)|intakes of 1.5 L by day
214963614|NCT02541422|DIETARY_SUPPLEMENT|N Acetyl Cysteine|
214963615|NCT02541422|OTHER|placebo|
214963616|NCT04272463|OTHER|No intervention|Patients currently in treatment with benralizumab as per approved indication and clinical practice
214963617|NCT05004792|OTHER|DermLoop Learn|DermLoop Learn is our AI-augmented digital educational platform with case training on a library of 18,000+ benign and malignant skin lesions, educational videos on the correlation between dermoscopy and histology, as well as written learning modules for the most common skin lesion diagnosis. The education platform will give the user feedback on the image-based case training in dermoscopic diagnostic accuracy and adjust the cases depending on the user's progression.
214963618|NCT00968955|DRUG|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
214963619|NCT00209950|DRUG|Gaboxadol|
214963620|NCT01967004|DEVICE|Morph|Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
214963621|NCT01351090|DRUG|Ketorolac tromethamine|10 mg Intranasal (2 x 100 uL of a 5% solution)
214963622|NCT01351090|DRUG|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution)
214963623|NCT01351090|DRUG|Placebo|Intranasal
214963624|NCT00209391|DRUG|Gadodiamide Injection|
215080272|NCT05215015|BIOLOGICAL|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
214355038|NCT04596254|OTHER|Pomegranate Juice|Collection of Mother's milk before and after juice consumption
214355039|NCT02724943|BEHAVIORAL|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
214355040|NCT02724943|BEHAVIORAL|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
214355041|NCT02724943|BEHAVIORAL|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
214355042|NCT02724943|BEHAVIORAL|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
214355043|NCT02724943|BEHAVIORAL|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
214963625|NCT04199377|PROCEDURE|HIP KNEE REPLACEMENT|HIP KNEE REPLACEMENT
214963626|NCT06542367|PROCEDURE|"Tympanoplasty performed under local anesthesia using fat graft and Tachosil."|"Under local anesthesia, subcutaneous fat from the neck will be harvested. After that trimming of the perforation edges, planting the fat graft medial to the tympanic membrane and placement of the Tachosil on top of the fat graft.~gelfoam is placed lateral to the tympanic membrane to fill the ear canal. follow-up will be held at 2, 4-6 and 12 months following the procedure, with audiometric and otological evaluation"
214963627|NCT04165356|PROCEDURE|Mouth-rinse with 0.12% clorhexidine|mouthwash with 0.12% chlorhexidine twice daily compared to isotonic bicarbonated solution twice daily for the prevention of any infection associated with mechanical ventilation in patients requiring endotracheal intubation in the intensive care unit of a third level hospital.
214963628|NCT04165356|PROCEDURE|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate|mouthwash with sotonic solution with 1.5% sodium bicarbonate twice daily for the prevention of any intection associated with mechanical ventilation
215080273|NCT05318612|PROCEDURE|Laser Interstitial Thermal Therapy (LITT)|LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
215080274|NCT05318612|PROCEDURE|Biopsy|A sample of tissue from the tumor is obtained to confirm the diagnosis.
215080275|NCT03509493|DIAGNOSTIC_TEST|FibriCheck|Digital health application
215080276|NCT01592019|DRUG|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
215080277|NCT01592019|DEVICE|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
215080278|NCT01592019|DRUG|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
214355044|NCT03065894|OTHER|Matched Physical Therapy Intervention|"Patients who are medium-risk will receive up to 6-8 physical therapy (PT) visits over a 3 month period that is guided by published evidence based practice guidelines. The PT treatment will be tailored to the physical findings and specific patient needs, and appropriate exercises, spinal mobilization/manipulation, strengthening/stretching as well as a home program will be given to improve patient pain and function and reduce disability.~Patients who are high-risk will receive the evidence based PT treatment as deemed necessary. In addition, the PT treatment will incorporate principles of psychologically informed practice to address psychosocial barriers (e.g., fear avoidance, anxiety, etc) that may be impeding disability reduction. This may include instruction on chronic pain rehabilitation techniques such as the use of: pacing in order to maintain or increase activity; graded activity principles in order to increase function; and pain education and understanding responses to pain."
214355045|NCT03065894|OTHER|Current Care in Family Medicine|Patient education, medication management
214355046|NCT04894253|BIOLOGICAL|SRAS-CoV-2 vaccination immunological response|"Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.~Intervention includes immunological analysis on additional volume of blood collected as part of routine care."
214355047|NCT00000129|PROCEDURE|Radial Keratotomy|
214963629|NCT06039072|DRUG|Patients with cardiac function recovered for more than one year and discontinued were in the discontinuation group.|Among the patients with perinatal cardiomyopathy who were included in the study, their heart function returned to normal in 1 year after receiving standardized treatment, and then after another 1 year of standardized treatment to respect the patients' individual wishes, fully inform the patients of the relevant information and potential risks, including the possibility of deterioration of heart function after discontinuation of the medication, and only after obtaining the patients' informed consent and signing the informed consent form could they be included in the discontinuation group, and the rest were in the non-discontinuation group.
214355048|NCT05518929|DRUG|Ciprofol|The sedation of gastrointestinal endoscopy with Ciprofol
214355049|NCT05518929|DRUG|Propofol|The sedation of gastrointestinal endoscopy with Propofol
214355050|NCT04604587|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807"
214963630|NCT02197585|PROCEDURE|Inguinal mesh hernioplasty|
214355051|NCT00744653|PROCEDURE|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
214355052|NCT01316926|DRUG|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
214355053|NCT01316926|DRUG|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
214355054|NCT03826667|DEVICE|Polyetheretherketone (PEEK) Shoulder Suture Anchors|"PEEK Suture Anchors, which include:~* HEALICOIL™ PK Preloaded Suture Anchors~* BIORAPTOR™ 2.3 PK Suture Anchors/BIORAPTOR™ Curved 2.3 PK Suture Anchors~* BIORAPTOR™ Knotless Suture Anchors~* MULTIFIX™ S Ultra Knotless Fixation System~* FOOTPRINT™ Ultra PK Suture Anchors~* TWINFIX™ Ultra PK Suture Anchors/TWINFIX™ Ultra Preloaded and with Needles~* SPEEDSCREW™ Knotless Fixation System~* SpeedLock Knotless Fixation Device"
214355055|NCT06427785|DRUG|Remimazolam besylate|Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
214963631|NCT05136079|PROCEDURE|Prophylactic lymphaticonvenous anastomosis|Prophylactic lymphaticovenous anastomosis is an immediate prophylactic approach whereby the lymphaticovenous anastomosis is performed at the time of nodal dissection utilizing fluorescing indocynanine green (ICG) and an operating microscope.
214963632|NCT03824717|DRUG|Dose of ropivacaine|Biased coin design up and down dose finding study of 0.5% ropivacaine to achieve a successful infraclavicular brachial plexus block
214963633|NCT02807831|BEHAVIORAL|Executive functions training|Daily training of executive functions via activities to develop auto-regulation, attention and memory.
214963634|NCT02807831|BEHAVIORAL|Language skills training|Daily training of language skills via activities to develop phonological awareness and vocabulary.
214963635|NCT02807831|OTHER|Regular school curriculum|Ministry of Education national school curriculum.
214963636|NCT06316596|PROCEDURE|Spinal Anesthesia|Near infrared spectroscopy , neonatal peripheral oxygen saturation measurements and hemodynamic data will be compared between groups
214963637|NCT06316596|PROCEDURE|Epidural Anesthesia|Near infrared spectroscopy , neonatal peripheral oxygen saturation measurements and hemodynamic data will be compared between groups
214355056|NCT03334123|OTHER|Functional training and cycling|"First 8 weeks: patients will perform 20 minutes of functional training before their dialysis procedure. The exercise program will be run by kinesiologists, who will also teach patients how to perform exercises on their own at home. During intradialysis cycling 3 times weekly participants will cycle on adapted ergometer. Participants will start with 10 - 15 minutes of cycling and then gradually increase time and intensity up to 45 minutes of duration.~Second phase of 8 weeks: participants will no longer perform functional training before dialysis but will be motivated, monitored and advised to perform functional exercise at home on non-dialysis days for 20-30 minutes and continue with cycling sessions during the dialysis procedures three times weekly."
214678963|NCT04670146|DIAGNOSTIC_TEST|ultrasound of the masseteric muscle|Ultrasound of the masseteric muscle to evaluate the thickness and rigidity of the masseteric muscle before and after oral cancer treatment. There will be no invasive investigation of the muscle.
214963638|NCT03000985|BEHAVIORAL|Psychoeducation|6 session psychoeducation program with the family caregiver of schizophrenics patients.
214963639|NCT00002182|DRUG|Megestrol acetate|
214963640|NCT06433843|BEHAVIORAL|Dialectical behavioral therapy for the treatment of posttraumatic stress disorder (DBT-PTSD)|12 weeks inpatient disorder specific psychotherapy
215080279|NCT01592019|DEVICE|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
214355057|NCT03334123|OTHER|Cycling|"First 8 weeks: cycling on an adapted ergometer during dialysis; starting with 10 - 15 minutes of cycling and then gradually increasing time and intensity up to 45 minutes of duration.~Second 8 weeks: continue with cycling at the target duration and intensity during dialysis."
214355058|NCT04313803|DEVICE|CGM|Dexcom CGM system
214355059|NCT01586143|DRUG|paracetamol|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
214355060|NCT01586143|DRUG|Placebo|
214355061|NCT03386123|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia|Continuous maintenance of sleep diary, cognitive behaviour therapy, including cognitive restructuring, and behavioural change focusing on sleep restriction and safety behaviours.
214963641|NCT06392152|DRUG|Focal Mass Drug Administration with Primaquine|"A population census was conducted in each village in August 2019 to record the demographic information and malaria histories of the villagers. Vulnerable groups such as pregnant women, breastfeeding mothers, and children under 7 years were excluded from PQ administration.~Both Group 1 \&2 underwent a preliminary clinical assessment to exclude individuals with G6PD deficiency and low hemoglobin levels.~Based on the WHO malaria treatment guidelines, a standard PQ regimen of 0.25 mg PQ base/kg body weight daily for 14 days was administered through directly observed treatment (DOT) to ensure drug intake and monitor potential adverse effects. The safety of each participant was monitored by follow-up blood testing using Hemocue's hemoglobin photometers to track changes in hemoglobin levels.~As per cross-over design, eligible individulas from Group-1 received PQ-MDA in year 1 and Group-2 received PR-MDA in the following year."
214963642|NCT05115539|OTHER|doppler US of portal vein, hepatic veins, intrarenal veins|"Hepatic Vein Doppler : To obtain the HV PW, a phased array transducer is used with cardiac pre-sets. ECG leads are placed to assist in the interpretation of HVD in sinus rhythm as well as atrial fibrillation. The middle hepatic vein is identified from mid-subcostal or lateral views during the end-expiratory phase of the patients respiratory cycle.~Portal vein Doppler: From a lateral costal or subcostal window, the portal vein is identified in the coronal plane using a phased-array transducer. The PV were considered abnormal if the pulsatilty index was greater than 30%. The portal pulsatility index was defined as: (VMax - VMin/VMax) \* 100%. Here, VMax is the maximal velocity and VMin is the minimal velocity during the cardiac cycle.~Intra-renal venous Doppler: From lateral costal window, the kidney is located in the coronal plane and a color flow box placed over the distal renal calyceal junction to cortex."
214963643|NCT06064058|DIETARY_SUPPLEMENT|Ghazwan program|6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction.
214963644|NCT06064058|DRUG|Standard management|Standard care with NSAIDs and acetaminophen for pain management
214355062|NCT03386123|BEHAVIORAL|Standard Audiological Care|Maintenance of sleep diary at key times. Psycho-education, provision of bedside sound generator.
214355063|NCT03386123|BEHAVIORAL|Sleep Support Group|Maintenance of sleep diary at key times. Social support focused on tinnitus and sleep problems.
214355064|NCT05323526|DIAGNOSTIC_TEST|Catquest-9SF questionnaire|Patients complete the questionnaire preoperatively and postoperatively.
214355065|NCT05323526|DIAGNOSTIC_TEST|Demographics and clinical parameters|The following clinical parameters are evaluated: age, gender, ocular and systemic comorbidities, educational level, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.
214355066|NCT04805723|PROCEDURE|VATS|"Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung."
214963645|NCT04694976|BIOLOGICAL|25-OH Vitamin D measure|As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.
214963646|NCT04420169|OTHER|Questionnaire|A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients
214963647|NCT01176786|OTHER|Culture Swabs, Rodac Plate Cultures|Culture swab is taken when breast tissue expander is removed and when breast implant is placed in breast pocket. Rodac Plate cultures are taken after the surgical procedure of the surgeons dominant palm, forearm of gown and subject's drape closest to the breast.
214963648|NCT03028675|OTHER|MRI Scan|MRI scans will consist of a 1-hour brain scan for both patients and controls.
214963649|NCT04491981|PROCEDURE|Encapsulated Glass Ionomer Cement|Repair of restorations in primary molars using Encapsulated High Viscosity Glass Ionomer (RIVA Self Cure - SDI). No local anesthesia will be used. A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with GIC (Glass Ionomer Cement).
214963650|NCT04491981|PROCEDURE|Composite resin|Repair of restorations in primary molars using composite resin (Filtek Bulk Fill- 3M ESPE.) No local anesthesia will be used.A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with CR (composite resin).
214963651|NCT00006114|DRUG|mitoxantrone hydrochloride|
214963652|NCT00006114|DRUG|vinorelbine tartrate|
214963653|NCT01369745|DRUG|Prednisolone|Prednisolone 2.7 mg daily
214963654|NCT01369745|DRUG|dipyridamole|dipyridamole 360 mg daily
214963655|NCT01369745|DRUG|Prednisone|Prednisone 5 mg daily
214355067|NCT04805723|PROCEDURE|Thoracotomy|Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
214963656|NCT01369745|DRUG|Z102|Prednisolone 2.7 mg plus dipyridamole 360 mg daily
214963657|NCT01369745|OTHER|placebo|
214355068|NCT02649868|PROCEDURE|Transarterial embolization (TAE)|Transarterial embolization
214355069|NCT02649868|DEVICE|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
214963658|NCT02861963|PROCEDURE|Experimental: RVOT reconstruction by femoral allogenic vein valve conduit|Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation
214355070|NCT00864448|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
214963659|NCT02861963|PROCEDURE|Systemic-to-pulmonary artery shunts|"Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side."
214963660|NCT03953521|DEVICE|intermittent Theta burst stimulation|Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
214963661|NCT00003205|DRUG|bryostatin 1|
214963662|NCT00878800|DRUG|PXD101|Administered in combination with doxorubicin (BelDox)
214963663|NCT00878800|DRUG|Doxorubicin|Administered in combination with PXD101 (BelDox)
214963664|NCT01080092|BEHAVIORAL|breathing technique|breathing technique as a stress management technique, reinforced by biofeedback
214963665|NCT01080092|BEHAVIORAL|behavioral strategies|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
214963666|NCT00613821|DRUG|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
215080280|NCT04347980|DRUG|Dexamethasone and Hydroxychloroquine|"Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before."
215080281|NCT04347980|DRUG|Hydroxychloroquine|Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
214355071|NCT00864448|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
214355072|NCT04537962|OTHER|Colgate Periogard® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash
214355073|NCT04537962|OTHER|Colgate Peroxyl® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash
214355074|NCT04537962|OTHER|Colgate Total® Mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Total® Mouthwash
214355075|NCT04537962|OTHER|Toothpaste with sodium monofluorophosphate|Patients will be submitted to brushing with toothpaste with sodium monofluorophosphate
214355076|NCT04537962|OTHER|Toothpaste with sodium fluoride and zinc|Patients will be submitted to brushing with toothpaste with sodium fluoride and zinc
214963667|NCT00613821|DRUG|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
214963668|NCT01252407|OTHER|transcutaneous electrical nerve stimulation|Application of low frequency (10-Hz) and high frequency (100-Hz) TENS, in two different days
214963669|NCT00292708|DRUG|Cefmetazole (drug)|
214963670|NCT06400901|OTHER|No interventions|No interventions were given to patients except for the deep brain stimulation surgery they originally planned to take
214963671|NCT04091737|BIOLOGICAL|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734|"* Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion~* Plerixafor to mobilize hematopoietic stem cells prior to each apheresis~* Single dose melphalan before administration of CSL200"
215080282|NCT00319475|PROCEDURE|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
215080283|NCT03796143|BEHAVIORAL|The Mindfulness and Acceptance Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
215080284|NCT03796143|BEHAVIORAL|The Cognitive Behavioral Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
215080285|NCT00938977|DEVICE|CPAP|Before and after effect of treatment with CPAP
215080286|NCT00938977|DEVICE|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
215080287|NCT05434013|BEHAVIORAL|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
214355077|NCT04537962|OTHER|Toothpaste with tin fluoride|Patients will be submitted to brushing with toothpaste with tin fluoride
214355078|NCT01055366|DRUG|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
214487213|NCT06768385|PROCEDURE|Transversus abdominis plane (TAP) block|: It was performed under USG guidance using 30 ml of 0.25% bupivacaine with an 80 mm insulated peripheral block needle. Local anaesthetic was applied between the upper fascia of the transversus abdominus muscle and the fascia of the internal oblique muscle at the midpoint of the distance between the costal margin and the iliac crest in the midaxillary line under USG imaging guidance.
214678964|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
214355079|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty combined with Pulmonary Artery Denervation|Participants in the intervention arm will undergo a combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN), as part of this phase 2/3 clinical trial. The trial aims to determine the optimal number of radiofrequency (RF) ablation points required for effective PADN based on pulmonary artery size or diameter. The BPA procedure addresses segmental and subsegmental thrombi masses through pulmonary artery dilation, while the PADN procedure involves the placement of a denervation catheter near the bifurcation of the main pulmonary artery. RF energy is selectively applied, and ablation points are determined based on individual patient characteristics and expected therapeutic effects. This unique approach seeks to customize the intervention to the patient's specific pulmonary anatomy, contributing to the overall effectiveness of the treatment strategy.
214355080|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty with Sham Pulmonary Artery Denervation|Participants receive Balloon Pulmonary Angioplasty (BPA) combined with a sham Pulmonary Artery Denervation (PADN) procedure. The sham PADN involves catheter placement mimicking the actual procedure without the application of radiofrequency energy
214355081|NCT00307827|DRUG|Visilizumab|Visilizumab administered intravenously once per day for two days
214355082|NCT05071157|BEHAVIORAL|echocardiography|"* speckle tracking echocardiography~* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)~* bioimpedance~* blood test for biological assays (metabolomic analysis)"
214355083|NCT02732925|DEVICE|Arm 2 Balloon Kyphoplasty|"Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy"
214355084|NCT02732925|PROCEDURE|Conservative Management|"Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~* Concomitant treatment with bisphosphonates~* Pain relief as required~* Systemic chemotherapy for Myeloma disease~* Bed rest~* Radiotherapy~* Physiotherapy"
214355085|NCT00679939|DRUG|Rosiglitazone|up to 8mg/day
214355086|NCT00679939|DRUG|Metformin|up to 2000mg/day
214355087|NCT04378348|BEHAVIORAL|Motivational Interview (MI)|The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey
214355088|NCT04378348|BEHAVIORAL|Participatory Group Activity|Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.
214487214|NCT06768385|PROCEDURE|thoracoabdominal nerve blockage with perichondrial approach (TAPA) block|Under USG guidance, 20 ml of 0.25% bupivacaine was administered between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue at the level of the 9th and 10th ribs (arcus costarum) in the midclavicular line with an 80 mm insulated peripheral block needle. Then, 10 ml of 0.25% bupivacaine was injected into the upper fascia of the costochondral tissue and the lower fascia of the external oblique muscle. The block was performed by following the needle path in the ultrasound image.
214487215|NCT06758336|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
214487216|NCT06750848|DRUG|Chidamide，Fulvestrant，angiogenesis inhibitors|chidamide，30mg，po. biw fulvestrant ，500mg， im., d1(c1d15), q4w angiogenesis inhibitors , according to the doctor's advice
214678965|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
214963672|NCT03972384|BEHAVIORAL|Post-ICU Problem Solving|"We have adapted the Cognitive Orientation to Daily Occupational Performance (CO-OP) as the Post-ICU Problem Solving intervention to be delivered in the home to patients following an illness that required an ICU stay. CO-OP is a form of meta-cognitive strategy training that teaches individuals to identify and prioritize problematic daily activities, identify barriers impeding performance, generate and evaluate strategies addressing these barriers, and generalize learning through practice. Thus, strategy training teaches skills that can be used to address disability in real-life activities, and is integral to personalized rehabilitation services. CO-OP has been adapted in numerous settings and most recently, it is being utilized successfully in patients with acquired cognitive dysfunction following acute stroke. This represents a useful intervention, tested in similar populations with minimal risk to the participants and potential for maximal benefit for this population."
214963673|NCT03363867|DRUG|Atezolizumab|840mg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion from Cycle 2 onwards.
214963674|NCT03363867|DRUG|Bevacizumab|5mg/kg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion.
214963675|NCT03363867|DRUG|Cobimetinib|60mg per day, every day for 21 days (i.e. Day 1 to Day 21 of each 28 day cycle)
214355089|NCT04378348|BEHAVIORAL|Control Condition|At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
214355090|NCT01357967|DRUG|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
214355091|NCT01357967|DRUG|Seroquel XR adjunctive|"Quetiapine group:~seroquel XR 50mg Day 1 --\> 50mg Day 2 --\> 150mg Day 3 --\> 150mg Day 4 --\> adjustment usually at hs but can be daytime"
214355092|NCT03317600|DEVICE|Lidocaine|Intervention is a nerve block with Lidocaine 2% with Adrenaline.
214355093|NCT03317600|DRUG|Placebo|"Intervention is a placebo nerve block with isotonic saline"
214487217|NCT06755749|BEHAVIORAL|Family Planning Education|"Stage 1 (Day 1, 10-15 min): The education content for Session 1 in the FP Education Booklet prepared by the researchers was provided to the participants using the face-to-face interview method. After making an appointment for Stage 2 (Day 3) to be carried out at the FHC, the first stage of the data collection process was complete.~Stage 2 (Day 3, 10-15 min): The education content for Session 2 in the FP Education Booklet was provided to the participants who arrived at the FHC on their predetermined appointment days using the face-to-face interview method. After making an appointment for Stage 3 (Day 7) to be carried out at the FHC, the second stage of the data collection process was complete.~Stage 3 (Day 7, 1-5 min): The data collection forms were administered again to the participants who arrived at the FHC on their appointment days assigned at Stage 2, and the data collection process was complete."
214963676|NCT05156996|DEVICE|Supersaturated O2 Therapy of the Therox Downstream System®|SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient's left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.
214963677|NCT05156996|PROCEDURE|PCI alone|Percutaneous Coronary Intervention for treatment of acute MI
214963678|NCT03868839|DRUG|Telmisartan Pill|telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
215080288|NCT05434013|BEHAVIORAL|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
214355094|NCT04364958|OTHER|A web based-Patient Decision Aid (PtDA) (shown on the computer)|Patient decision aids (PtDAs) are tools that assist patients in making health decisions, when there is uncertainty about treatment choice, incorporating their personal preferences and values about the available treatment options. This PtDA will include information about GAD symptoms, diagnosis, causes, and benefits and risks associated to psychological and pharmacological treatments for GAD (based on the Clinical Practice Guidelines-GAD). It will also include a values clarification exercise, in which patients will have to rate the importance attributed to the different aspects of treatments (e.g., mode of administration, benefits, risks, time to improvement, probability of relapse).
214355095|NCT04364958|OTHER|A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care.|Patients in the control group will receive a fact sheet (one page) with general information on mental health as a part of usual care provided by the Canary Islands Health Service.
214355096|NCT01680328|OTHER|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
214355097|NCT01680328|DRUG|sodium chloride 0.9% solution|Solution for injection.
214355098|NCT03977220|DRUG|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
214355099|NCT06503211|BIOLOGICAL|UTAA09 injection|The subjects, who sign the informed consent forms and been screeneinclusion/exclusion criteria, will be assigned into 3 x 108\~1 x 1010 CD19-CAR - γδT cells.
214487218|NCT06762028|DEVICE|SIMBA capsule|The small intestine microbiome aspiration (SIMBA) system is a single-use, ingestible passive capsule that allows for the non-invasive sampling of small intestinal contents. It is designed to open and adsorb intestinal content after having passed the acid stomach environment and to close mechanically before passing into the large bowel. It has distinct markers built in to allow radiographic tracking of its passage throughout the GI system.
214487219|NCT06758531|DIETARY_SUPPLEMENT|Instant coffee given as a drink|Commercially available instant coffee (3.6 g) will be provided in the form of a drink prepared with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
214963679|NCT02302846|DRUG|Ixazomib|4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
214963680|NCT00715299|BEHAVIORAL|locomotor training|Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
214355100|NCT05608629|DEVICE|Transcutaneous Non-Invasive Vagus Nerve Stimulation|The parasym is a system for delivering a fixed signal to stimulate the auricular branch of the vagus nerve. The device used is available without prescription in UK and EU. Similar devices have been used to treat migraine and one is in testing to be used for atrial fibrillation.
214355101|NCT03834064|BEHAVIORAL|Oral health promotion strategy|The proposed intervention is comprised of four components : (a) planned action including a behavioral contract Activity 1) with caregivers and action planning for oral health (Activity 2), (b) caregiver capacity building with didactic training (Activity 3), observational learning and caregiver practice (Activity 4); (c) environmental adaptations with location of oral health activities and reminder posters - physical environment (Activity 5) and administrative oral health support- (social environment (Activity 6); and (d) reinforcement with caregiver coaching (Activity 7).
214355102|NCT01702753|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
214355103|NCT01166633|DRUG|pitavastatin|pitavastatin 2mg per daily
214963681|NCT06312397|OTHER|Acupressure|"For the acupressure group, a total of three points will be applied: the heart meridian 7th point (HT7), the large intestine meridian 4th point (LI4), and the stomach meridian 36th point (ST36), which is deemed appropriate in the lower extremity The symmetry of the three selected different points will also be applied to the other extremity.~After coronary angiography, acupressure will be applied for a total of 15 minutes."
214963682|NCT06312397|OTHER|Sham acupressure|In the acupressure application applied to the sham group, parallel pressure will be applied to the bone area and points where the HT7, LI4, ST36 meridians do not pass.
214963683|NCT02790918|OTHER|6MWT|Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
214963684|NCT02790918|OTHER|Cardiovascular Magnetic Resonance Imaging (CMRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
214963685|NCT00171626|DRUG|Diclofenac Topical Sodium Gel 1%|
214963686|NCT02119078|OTHER|Acute Care of Elders focused geriatric care|Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
214963687|NCT06180434|RADIATION|proton therapy|Radiotherapy delivered with protons
214963688|NCT06180434|RADIATION|photon therapy|Radiotherapy delivered with photons
214963689|NCT00411450|BIOLOGICAL|Panitumumab|Administered by intravenous infusion
214963690|NCT00411450|DRUG|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
214963691|NCT05915273|OTHER|Computer Aided Design/ Computer Aided Manufacturing Retainers|Custom-bent fixed retainer wires from an in-office CAD/CAM system with FixR software and the BenderI machine (YOAT Corporation, Lynwood, WA). Dentaflex wires- round, 0.5mm in diameter, three-stranded Stainless Steel (Dentaurum GmbH \& Co., Ispringen, Germany)- were used for the CAD/CAM group
214963692|NCT05915273|OTHER|Lab-based Retainers|The lab group used the same type of wire as the CAD/CAM group but was manually bent by a lab technician
214963693|NCT05915273|OTHER|Chairside Retainers|The chairside group used three-stranded Stainless Steel, 0.974mm x 0.402 mm, flexible Ortho-FlexTech wires (Reliance, Itasca, IL)
214963694|NCT00872521|DRUG|PAD induction|"Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)"
214963695|NCT01301261|DRUG|sugammadex|Sugammadex 2 mg/kg when a two count of train of four appears
214963696|NCT01301261|DRUG|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
214963697|NCT01301261|DRUG|Sugammadex 16mg/kg|Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
214963698|NCT03556969|OTHER|Observation|no intervention
214963699|NCT03327389|DRUG|Dexmedetomidine|dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure.
214355104|NCT01166633|DRUG|atorvastatin|atorvastatin 10mg per daily
214355105|NCT00983073|DRUG|Tapentadol|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
214355106|NCT01453595|DRUG|BEZ235|"BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily"
214355107|NCT01373528|DRUG|Budesonide irrigation|A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
214355108|NCT00229333|DRUG|Escitalopram|
214355109|NCT03547089|DEVICE|Viveve®|A single treatment using Viveve® with 110 pulses administered to the vaginal introitus at 90 J/cm2
214355110|NCT02047838|OTHER|Anti-mullerian hormone (AMH) level dosage.|
214678966|NCT00765869|OTHER|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
214963700|NCT03327389|DRUG|placebo|0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
214963701|NCT04531748|DRUG|Toremifene|Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
214963702|NCT04531748|DRUG|Melatonin|Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
214355111|NCT02047838|OTHER|Follicle-stimulating hormone (FSH) level dosage.|
214355112|NCT02047838|OTHER|Antral follicle count (AFC).|
214355113|NCT06104475|OTHER|CT scan|A CT scan will be requested for every patient in addition to the chest X-ray
214355114|NCT01237639|OTHER|Red blood cell Transfusion|Transfusion of Red blood cells to based on daily complete blood count
214355115|NCT06015321|DRUG|Enzalutamide|enzalutamide 160 mg PO daily
214487220|NCT06758531|DIETARY_SUPPLEMENT|Coffee given in a tablet form|Commercially available instant coffee (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
214487221|NCT06758531|DIETARY_SUPPLEMENT|Control (placebo)|A caffeine and coffee free control (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
214963703|NCT04531748|OTHER|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions.
214963704|NCT03137277|PROCEDURE|screening colonoscopy|"Introduction and forwarding of the device up to caecum/terminal ileum. Then withdrawal and inspection of colonic wall. Biopsies and polypectomies if necessary. overall and diagnostic (only withdrawal) times being recorded separately.~Polyps are documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size (open forceps or snare for comparison) and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous) Polyps were then resected using biopsy forceps or cold snare (for polyps \< 5 mm), or conventional polypectomy according to local standards."
214963705|NCT00614874|DRUG|rosiglitazone|2mg, 4mg, 8mg
214963706|NCT04994561|DRUG|Study Drugs and Nutritional Supplements|"Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months."
214963707|NCT04135482|OTHER|colonic tissue biopsy|colonic tissue biospy of patients with severe crohn's disease using colonoscopy
214963708|NCT06434675|OTHER|No intervention done|No intervention done
214963709|NCT01468454|DRUG|18 F-DOPA|1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
215080289|NCT05434013|BEHAVIORAL|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
215080290|NCT00364052|DRUG|oral Valganciclovir vs oral Ganciclovir|
215080291|NCT01156168|GENETIC|DNA analysis|
215080292|NCT01156168|GENETIC|gene expression analysis|
215080293|NCT01156168|GENETIC|polymorphism analysis|
215080294|NCT01156168|GENETIC|protein expression analysis|
214355116|NCT03133975|DRUG|Vitamin D3 (Treatment)|Single high dose vitamin D3 in treatment of dyslipedemia
214355117|NCT03133975|OTHER|Mixed diet of carbohydrate and protein (Control)|Mixed diet of carbohydrate and protein
214355118|NCT04817280|OTHER|Ice Swimming|The intervention is not made in the course of a research study. Ice swimming has been introduced earlier by a given group. The group was made up of people who already swim in ice.
214355119|NCT04392765|DEVICE|eXciteOSA|eXciteOSA transoral neurostimulation device
214355120|NCT03722368|BEHAVIORAL|RCHC|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills.
214355121|NCT03722368|BEHAVIORAL|RCHC+|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills. This intervention group will also receive on-going support groups and one on one counseling as needed.
214355122|NCT03722368|OTHER|Waitlist control|This group will served as the control group and will receive treatment as usual until the end of the study. At the end of the study they will have the opportunity to take part in the RCHC or RCHC+
214355123|NCT00788996|BEHAVIORAL|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
214355124|NCT01133652|DEVICE|Veinviewer|Veinviewer machine
214487222|NCT06761040|OTHER|Intrinsic foot muscle training|"Technique In intrinsic foot muscle training, there are following exercises:~1. Toe spread out~2. First toe extension~3. Second to fifth toe extension The exercise would be performed in following positions 1. Sitting position for the first 2 weeks (3sec hold; 4 sets ×15 reps) 2. Standing position on the 3rd and 4th weeks (8sec hold; 4 sets × 8 reps) 3. One-leg standing position during the 5th and 6th week (20 sec hold;4 sets ×3 reps)"
215080295|NCT01156168|OTHER|immunohistochemistry staining method|
215080296|NCT01156168|OTHER|laboratory biomarker analysis|
215080297|NCT03118999|DIETARY_SUPPLEMENT|OM3-FFA|Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design
215080298|NCT03118999|DIETARY_SUPPLEMENT|OM3-MAG|Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design
215080299|NCT03118999|DIETARY_SUPPLEMENT|OM3-EE|Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
215080300|NCT03467984|BIOLOGICAL|LBVE|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
215080301|NCT03467984|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
215080302|NCT02491034|BEHAVIORAL|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
214963710|NCT00003494|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214963711|NCT00242697|PROCEDURE|spinal analgesia and anesthesia for coronary artery surgery|
215080303|NCT04367597|DEVICE|Home-based Neuromuscular Electrical Stimulation (NMES) therapy|A home-based NMES treatment applied by the subjects daily
215080304|NCT01406496|DRUG|insulin|Three different timings of insulin delivered by a pump
215080305|NCT03568955|DIAGNOSTIC_TEST|International Prolonged Grief Disorder Scale (IPGDS)|Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
215080306|NCT04184128|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
214963712|NCT00317746|DRUG|Citalopram|
214355125|NCT01133652|DEVICE|Ultrasound|Ultrasound
214355126|NCT01133652|OTHER|Conventional technique|Conventional IV placement by nurses
214963713|NCT00317746|DRUG|Placebos|
214963714|NCT02620787|DRUG|Tedizolid|
214963715|NCT02620787|PROCEDURE|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
214963716|NCT01918501|PROCEDURE|Blood testing|Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
214963717|NCT06011694|OTHER|MERCURY test, health questionnaires and annual routine physical exams|Each participant will undergo peripheral blood collection for MERCURY test, health questionnaires and annual routine physical exams once a year for three consecutive years, then followed up two additional years.
214963718|NCT06459713|DIAGNOSTIC_TEST|multiplex respiratory polymerase chain reaction test|According to our hospital policy, nasopharyngeal swab samples are collected by the clinicians and transported to the Clinical Microbiology Laboratory of the hospital in 10 minutes. The samples are analyzed in 2 hours and the samples were measured by Thermo Fisher / Applied Biosystems Quant Studio-5 for reverse transcription-polymerase chain reaction (RT-PCR) testing to detect multiplex respiratory agents
214963719|NCT05610488|DRUG|FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]|Intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits
214963720|NCT05821387|DRUG|Lucid-21-302|A small molecule inhibitor of hypercitrullination
214963721|NCT05821387|DRUG|Placebo|Product containing excipients with no active ingredients
214963722|NCT03744897|BEHAVIORAL|Hypnotic analgesia|Subjects will receive hypnotic analgesia during 20 minutes
214963723|NCT03744897|DEVICE|a-tDCS|Subjects will receive transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
214963724|NCT03744897|OTHER|Hypnotic analgesia + a-tDCS|Subjects will receive hypnotic analgesia associated to transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
214963725|NCT03744897|DEVICE|s-tDCS|Subjects will receive sham transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 0mA, 20 minutes
214963726|NCT05758896|DRUG|Isuzinaxib (APX-115)|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
214963727|NCT05758896|DRUG|Placebo|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
214355127|NCT02959996|DRUG|Liposomal bupivacaine|liposomal bupivacaine injection in the Pfannenstiel incision
214355128|NCT02959996|DRUG|Placebo|placebo injection in the Pfannenstiel incision
214355129|NCT02385344|DEVICE|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
214355130|NCT05734794|DRUG|Rituximab|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
214355131|NCT05734794|DRUG|Steroid|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
214355132|NCT00058838|DRUG|sumanirole|
214963728|NCT03722082|BEHAVIORAL|Enhancing Cognitive Reserve|The intervention is aimed at improving cognitive reserve in offsprings of patients diagnosed with schizophrenia or bipolar disorder. The program is composed of 12 sessions of 60 minutes and will be adapted according the three different age groups (6-12) (13-18) (18-25). Each group will include between 6-to-8 offsprings and conducted by 4 experienced neuropsychologists in both children and adults. The sessions are the following:
214963729|NCT03722082|BEHAVIORAL|Support intervention|The support group will schedule meetings with the participants in order to talk about their daily life with the possibility to talk about the difficulties they encounter.
214963730|NCT06171854|DRUG|Cabozantinib|cabozantinib in patients with refractory mCRC
214963731|NCT04583605|DEVICE|PREVENA|A negative pressure wound closure therapy is used after lymph node dissection
214355133|NCT02962908|BIOLOGICAL|FLU-v|Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH
215080307|NCT04103463|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
214355134|NCT02962908|BIOLOGICAL|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
214355135|NCT02962908|BIOLOGICAL|Saline|Subcutaneous injection in the upper arm with 0.5ml of saline
214355136|NCT02962908|BIOLOGICAL|Adjuvanted placebo|Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
214355137|NCT00002803|DRUG|cyclophosphamide|
214355138|NCT00002803|DRUG|doxorubicin hydrochloride|
214355139|NCT00002803|DRUG|vincristine sulfate|
214355140|NCT00002803|PROCEDURE|conventional surgery|
214355141|NCT01823848|DRUG|Sodium phosphate enema|Rectally administered medication to treat constipation
214355142|NCT01823848|DRUG|Normal saline enema|Rectally administered medication to treat constipation
214355143|NCT01823848|DRUG|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
214355144|NCT06064227|OTHER|training intervention|"In this experimental study, the subject matter and sessions of the educational intervention, the effect of which was tested, were prepared based on evidence on preventable risk factors through health behavior change. The educational intervention consists of the following topics:~Nutrition and physical exercise, chronic disease management and polypharmacy, anti-smoking and stress management, preventive health services, access to health screenings and immunization."
214355145|NCT03932604|DEVICE|Atrial sensing On mode|Single lead VDD-ICD programmed as atrial sensing On mode.
214355146|NCT05714189|OTHER|Low FODMAP diet|The Low FODMAP diet is an avoidance diet and consist of three phases. In the first phase, all nutrients high in FODMAPs (high-FODMAPS) are eliminated from the daily diet over a period of 2 to 6 weeks to calm down the bowel. The second phase consists of the addition of FODMAP challenges. During this phase the patient continues the Low FODMAP diet, but will reintroduce one high-FODMAP nutrient once every three days to see whether exposure to this high-FODMAP causes IBS symptoms. When this is not the case, the patient can continue eating this high-FODMAP group in their daily diet. In the third and final phase, the diet is fully personalized. This personalization is based on whether the patient tolerated the high-FODMAP nutrient or not during the FODMAP challenges. Only when the high-FODMAP nutrient is not tolerated, it is advised to permanently remove it from the daily diet.
214963732|NCT03929263|BEHAVIORAL|Real-time fMRI neurofeedback|Participants will attempt to regulate own and/or their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
214963733|NCT01200706|DRUG|Amoxicillin|amoxicillin 50mg/kg/day given in two different administration schemes
214963734|NCT06386380|OTHER|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012, Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS); translation, cultural adaptation, and validation were performed prior to its application.
214355147|NCT05714189|OTHER|Endometriosis diet|The endometriosis diet The endometriosis diet is a patient experience based, avoidance diet developed by women diagnosed with endometriosis. Therefore no specific recommendations exist regarding the application of the endometriosis diet. With the endometriosis diet, women avoid nutrients they noticed provoked or aggravated their endometriosis-related symptoms such as red meat, coffee, sugar, lactose and soy.
214355148|NCT06430450|DIAGNOSTIC_TEST|Clinical measurements and saliva samples collection|Clinical measurements will be taken from all patients and saliva samples will be collected for biochemical analysis.
214355149|NCT05210192|DRUG|Lidocaine Hydrochloride 1% Solution for Injection_#2|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
214963735|NCT06386380|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global status estimate. Each of the three individual measures is scored 0 to 10, for a total of 30
214963736|NCT06386380|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality.
214963737|NCT06386380|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
214963738|NCT06386380|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains seven items, divided into subscales with similar content.
214963739|NCT06386380|OTHER|Brief Resilient Coping Scale|The Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner.
215080308|NCT04103463|OTHER|Home exercise|Home exercise
214355150|NCT05210192|DRUG|Placebo|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
215080309|NCT03625232|DEVICE|CompuFlo® Epidural Computer Controlled System|"The CompuFlo® Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the HCP to perform epidural anesthesia and epidural injections using standard methods. Currently, HCPs rely on their subjective perception to feel a loss of resistance when inserting an epidural needle to identify the epidural space. The CompuFlo® Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
215080310|NCT03345719|DIAGNOSTIC_TEST|3D Cone-Beam Imaging|
214355151|NCT05768698|DIAGNOSTIC_TEST|Software algorithm|Validation of a software package based on an artificial intelligence algorithm for automated non-invasive estimation of LVFP against invasively measured ones by left and right heart catheterization
214355152|NCT01034124|DRUG|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
214355153|NCT04800874|DRUG|BBP-418|BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.
214355154|NCT05009849|OTHER|Yoga Exercises|The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
214355155|NCT02353923|DIETARY_SUPPLEMENT|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
214355156|NCT03007823|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
214355157|NCT05555394|OTHER|Basic Body Awareness Therapy|The intervention will be twice a week during 12 weeks. It lasts 90 min of movements of daily life, massage and self-reflections.
214963740|NCT06386380|GENETIC|Expression of CDKN2A /p16INK4a|CDKN2A/p16INK4a expression will be measured using the Taqman qPCR assay (TaqMan Universal Master Mix II, with UNG, Applied Biosystems, Foster City, USA) according to the manufacturer's specifications.
214963741|NCT06386380|OTHER|Immunophenotype of leukocyte subpopulations|CD4+ and CD8+ subpopulations will be analyzed. Blood samples will be analyzed by 8-color flow cytometry (Becton Dickinson Canto II cytometer) using fluorescently labeled antibodies from Biolegend Inc. (San Diego, USA).
214963742|NCT06386380|GENETIC|Telomere length|The rLTL will be estimated by quantitative monochromatic multiplex PCR (MM-qPCR). Integrated DNA Technologies, Inc. (IDT, Coralville, IA, USA) will synthesize the primers used for telomere measurements.
214963743|NCT06386380|OTHER|Cellular senescence|Expression of co-stimulatory molecules and surface receptors CD27- and CD28-
214963744|NCT06231134|DEVICE|Conventional surgery|an implant will be exposed using the conventional surgical exposure techniques with a tissue punch, the cover screw will be removed, and the healing abutment placed
214963745|NCT06231134|DEVICE|Diode laser 940 nm|implant will be uncovered using a diode laser (940nm) in contact type with a continuous mode at a power of 1.5 watts, the laser tip will be used in a circular motion to create a small opening which will be increased till large enough to expose and remove the cover screw and place the healing abutments.
214963746|NCT06231134|DEVICE|Electrosurgical|the monopolar electrosurgical device will be used in the same way as the laser tip with additional care avoiding contacting the implants during exposure.
214963747|NCT05051046|PROCEDURE|Colonoscopy under hypnosis|The hypnosis used will be of the Ericksonian type. Before the colonoscopy begins, the IDE puts the patient in a hypnotic situation.
214963748|NCT01885832|BIOLOGICAL|Autologous adipose tissue stromal vascular fraction|
214963749|NCT03869762|DRUG|Xgeva|Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer induced bone destruction.
214963750|NCT03869762|DRUG|Xtandi|"Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.~Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression."
214963751|NCT04094779|OTHER|Usual relation care|When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.
214355158|NCT05555394|OTHER|Stretching Exercise|It consists in stretching movements of whole body
214355159|NCT03820661|DEVICE|Ultrasound|High resolution ultrasound pre-operatively and intra-operatively
214355160|NCT06669065|DEVICE|extraoral versus intraoral scanning techniques|different data acquisition techniques for full-arch dental implants
214355161|NCT06669637|DEVICE|Ablation|Ablation procedure for Atrial Fibrillation
214355162|NCT06669390|DRUG|NG11-2|"NG11-2 dose level will vary from 0.92 mg/mL to 5.5 mg/mL during the dose escalation process. The NG11-2 is given as an oral rinse.~Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will rinse their mouth with 12.5 ml of NG11-2 for between 90 \& 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then expectorate the solution."
214355163|NCT06669598|OTHER|Whole Body Electromyostimulation|The ETG group underwent in two 20-minute training sessions per week (12 weeks), with 72 hours of rest between sessions. Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation. This stimu-lation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse dura-tion
214355164|NCT06669598|BEHAVIORAL|control group|The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
214355165|NCT05910736|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
214355166|NCT06613841|DRUG|Fluciclovine F18|To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET.
214355167|NCT06672718|DRUG|SPY002-091|Experimental
214355168|NCT06672718|OTHER|Placebo|Placebo
214355169|NCT05424068|BEHAVIORAL|In-person rehabilitaiton group|participants who have chosen to complete the study intervention by coming in for their 8 week education and exercise sessions.
214355170|NCT05424068|BEHAVIORAL|Virtual rehabilitation group|Participants who have chosen to complete the study virtually instead of in-person sessions.
214355171|NCT04754581|OTHER|Maximal ATP Production (ATPmax)|ATPmax will be measured in order to determine in vivo mitochondrial capacity. The magnetic resonance scans to measure mitochondrial energetics will also be performed.
214355172|NCT04754581|OTHER|Exercise Testing (VO2max)|Aerobic fitness level will be assessed while participant pedals on a stationary bicycle/walk on a treadmill. The volume of oxygen intake and carbon dioxide (CO2) production will be measured.
214355173|NCT04754581|PROCEDURE|Muscle Biopsy|Sample muscle cells from the left leg Vastus Lateralis (thigh) muscle.
214355174|NCT04754581|PROCEDURE|Adipose Tissue Biopsy|Sample fat tissue from the abdomen.
214355175|NCT04754581|OTHER|Hyperinsulinemic euglycemic clamp|Measurement of insulin sensitivity.
214355176|NCT04754581|OTHER|PET imaging|After an overnight fast, an intravenous catheter will be placed in each arm (one with arterial line for PET infusion, and the other for infusion of insulin, glucose, and 6,6 D2 glucose tracer. FDG-glucose will be injected followed by 90-minute PET scanning of the thigh.
214355177|NCT00651508|DRUG|KOS-1584|25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
214963752|NCT04094779|OTHER|"Flash activity breath of fresh air"|When a patient begins to agitate , he will be isolated from the group and the patient leave from the unit to walk outside with the caregiver.
214355178|NCT06669273|OTHER|CEST MRI sequence at 3T|"The MRI will be performed at the Clermont Ferrand University Hospital on the 3T research MRI on a Siemens MRI system (MAGNETOM VIDA, Siemens Healthcare, Erlangen, Germany), the emission of the radiofrequency pulses and the reception of the signal will be done using a coil dedicated to the abdo-pelvic region. The images will be analyzed by the radiologist.~MRI is non-irradiating medical imaging. It is practiced according to good practices and the recommendations of the French Society of Radiology.~* Acquisition of morphological T1, T2 sequences for the identification of areas of interest on the pelvic area.~* Acquisition of the CEST MRI sequence (acquisition time 5 min)~* Acquisition of functional sequences, DWI diffusion-weighted images and dynamic DCE sequence after injection of a single dose of non-linear gadolinum.~The imaging report will reveal the presence or absence of tumor lesions in the prostate and their location. Data will then be compared to the histopathological analysis."
214678967|NCT01861340|DRUG|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
214963753|NCT03045497|DRUG|Perflutren Lipid Microspheres|Given IV
214963754|NCT03045497|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
214963755|NCT03045497|DEVICE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
214963756|NCT05463861|DRUG|Lemborexant|Lemborexant tablet administered orally once daily.
214963757|NCT05463861|DRUG|Placebo|Placebo to match Lemborexant tablet administered orally once daily.
214963758|NCT04293705|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
214963759|NCT02498977|GENETIC|Biomarker|Real time polymerase chain reaction (PCR) gene expression measurement
214963760|NCT02498977|DRUG|Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine|Immunosuppression drugs as per protocol
214963761|NCT02815033|DRUG|Enzalutamide|
214963762|NCT02815033|PROCEDURE|11C or 18F-Choline PET/CT|
214963763|NCT02815033|PROCEDURE|Whole body MRI|
214963764|NCT02815033|PROCEDURE|Bone scan|
214963765|NCT06517745|PROCEDURE|Prone positioning|Prone positioning sessions: at least one session per day proning duration: 2 hours at least per session
214963766|NCT05684289|DRUG|BMS-986278|Specified dose on specified days
214963767|NCT05684289|DRUG|Sildenafil|Specified dose on specified days
214963768|NCT05684289|DRUG|Placebo|Specified dose on specified days
214963769|NCT02912221|OTHER|Incentive|Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
214963770|NCT00334087|BEHAVIORAL|feeding habits|
214355179|NCT06669078|DRUG|Nal-lRl+Oxaliplain+5- FU +PD 1|Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
214355180|NCT06669078|DRUG|Nal-lRl+Oxaliplain+5- FU|Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
214355181|NCT07002216|DRUG|Brentuximab Vedotin|Participants will receive 1.8 mg/kg of Brentuximab Vedotin intravenously (IV) for up to 30 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
214355182|NCT07002216|DRUG|Etoposide|Participants will receive 150 mg/m\^2 of Etoposide intravenously (IV) for up to 60 minutes on Days 1-3 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
214355183|NCT07002216|DRUG|Cyclophosphamide|Participants will receive 1250 mg/m\^2 of Cyclophosphamide intravenously (IV) for up to 60 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
214963771|NCT04227418|DEVICE|12 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
214963772|NCT04227418|DEVICE|6 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
214963773|NCT04227418|DEVICE|Hand held ECG monitoring|Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.
214355184|NCT07002216|DRUG|Doxorubicin|Participants will receive 40 mg/m\^2 of Doxorubicin intravenously (IV) for up to 30 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
214355185|NCT07002216|DRUG|Dacarbazine|Participants will receive 250 mg/m\^2 of Dacarbazine intravenously (IV) for up to 120 minutes on Days 2-3 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
214355186|NCT07002216|DRUG|Dexamethasone|Participants will self-administer 40 mg of Dexamethasone orally on Days 1-4 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
214355187|NCT00936390|DRUG|bicalutamide|Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
214355188|NCT00936390|DRUG|flutamide|Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
214355189|NCT00936390|DRUG|LHRH agonist (antagonist) therapy|LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
214355190|NCT00936390|RADIATION|Dose-Escalated Radiation Therapy|External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
214355191|NCT06091189|BEHAVIORAL|Relevant Trier Social Stressor Test (TSST)|The Relevant TSST condition is a behavioral intervention that catalyzes an internalized stress response in the presence of a relevant social identity.
214355192|NCT06091189|DRUG|Ethanol|The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.
214355193|NCT06091189|BEHAVIORAL|Placebo Trier Social Stressor Test (TSST)|The Placebo TSST is an established behavioral intervention that does not prompt significant stress responses.
214355194|NCT06091189|BEHAVIORAL|Placebo Beverage|Placebo drinks will not contain ethanol; Drinks given to participants in the placebo beverage condition will contain a mixer that does not contain ethanol.
214355195|NCT06091189|BEHAVIORAL|Irrelevant Trier Social Stressor Test (TSST)|The Irrelevant TSST condition is a behavioral intervention that functions as an alternative comparative condition, given no internalized stress response is expected in the presence of an irrelevant social identity.
214355196|NCT06670742|DEVICE|running|Running 10 kilometers on a treadmill
214355197|NCT07127952|DEVICE|Video Capillaroscopy|A non-invasive imaging technique used to assess capillary structure and morphology in the nailfold area, commonly used in evaluating microvascular changes associated with connective tissue diseases.
214355198|NCT07127718|BIOLOGICAL|Prophylactic Plasma Transfusion|ABO/Rh-type compatible fresh frozen plasma (FPP) units will be thawed to 37° prior to administration. Plasma transfusion will be administered intravenously, 1 unit for 4 hours every 12 hours. There will be two consecutive days for the transfusion for a total of 4 units.
214487223|NCT06761040|OTHER|hip abductor muscle training with intrinsic foot muscle training|"Hip abductor muscle training consists of the following two exercise~1. Resisted hip abduction 90° (2 sec hold; 3 sets × 10 reps)~2. Resisted hip abduction 45° (2 sec hold; 3 sets × 10 reps)~Standard treatment~* Shoe insoles (eight hours a day, medial longitudinal arch support,raised for by about 1.8 cm)~* Stretching of Hamstrings and Calf muscles (3 times for 30 seconds hold) Number of Sessions Per Week : 3 times Per week for 6 weeks"
214487224|NCT06771375|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|EMDR is a psychotherapeutic approach originally designed for individuals suffering from trauma and post-traumatic stress disorder (PTSD). It facilitates the processing of memories through a structured eight-phase treatment, involving the patient's focused attention on traumatic images, thoughts, and sensations while simultaneously engaging in bilateral stimulation, typically through guided eye movements. This process aims to reduce the emotional distress associated with aversive memories, promoting adaptive coping mechanisms and psychological healing. Recently, the indications for the method have been extended so that EMDR is also used for chronic pain and depressive disorders.
214487225|NCT06762418|DEVICE|RMR+SME|Patients will be asked to wear this removable appliance for 16 hours daily. The expansion screw is activated twice a week.
214963774|NCT03050177|DRUG|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
214963775|NCT03050177|DRUG|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
214963776|NCT04213391|DIETARY_SUPPLEMENT|sulforaphane|Sulforaphane take 2550mg once a day.
214963777|NCT04213391|DIETARY_SUPPLEMENT|Placebo|Placebo take 2550mg once a day.
214963778|NCT05033249|DIAGNOSTIC_TEST|Immature granulocyte count|Automatically calculated immature granulocyte count in white blood cell count
214963779|NCT05033249|DIAGNOSTIC_TEST|Immature granulocyte percentage|Automatically calculated immature granulocyte percentage in white blood cell count
214355199|NCT07127718|DEVICE|Hemoperfusion|The hemoperfusion (HP) procedure will follow the standard procedure of National Kidney and Transplant Institute (NKTI) using Jafron HA330 hemoperfusion cartridge. First, an internal jugular catheter is attached to the patient. Alternatively, an arteriovenous fistula or arteriovenous graft may be placed on the patient. The patient will then be hooked to a hemodialysis machine. Blood pump speed will be set to 150-200mL/min, and HP will last for 2 to 2.5 hours. Whole blood will flow through the sorbent HA330 cartridge and back to the patient. Anticoagulation is not necessary due to the short treatment time. Hemoperfusion will be repeated after 12-24 hours for at least three days.
214355200|NCT07127718|DEVICE|Extracorporeal Membrane Oxygenation|"A veno-venous ECMO (VV ECMO) will be applied by aseptically inserting a venous cannula into the femoral veins. The patients will be hooked to an ECMO machine. Patients without significant bleeding or vascular intervention will be managed with an activated clotting time set at 140-180 sec by 800-1000 U/h of heparin. Otherwise, heparin will be titrated to maintain a partial thromboplastin time of 60-80 sec.~ECMO settings are as follows:~* Mean blood pressure of \>60 mm~* SaO2 at \>90% with a flow of 3.5-4.5 L/min~* Hematocrit at \>35%~* Platelets \>50000-100000/mL~* Transfusions will be done when necessary~Criteria for weaning:~* ABG:~  * pH 7.35-7.45~ * PaO2 \>80 mm Hg~ * PCO2 \<45 mm Hg~* Under the following conditions:~  * Gas blender FiO2 of 0.21~ * Sweep gas of 0 L/min at an ECMO flow of 2 L/min~ * Ventilator mode (if applicable):~    * FiO2 of 0.6~   * Tidal volume of 6 mL/kg~   * PEEP of 8 cmH2O~   * RR of 12-16/min for VV ECMO or 3 L/min of O2 via nasal prong with awakening ECMO patients"
214355201|NCT07127718|OTHER|Conventional therapy|Conventional therapy for leptospirosis includes antibiotics, fluids, inotropes, renal replacement therapy, ventilator support, and other treatment that the attending physician deems necessary.
214487226|NCT06762418|DEVICE|BAIMT+RME|The elastics are worn 18 hours per day to achieve the sagittal correction. The RME appliance on the upper jaw is activated twice daily until the required expansion is achieved.
214963780|NCT05805683|DRUG|Calcitonin|patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
214963781|NCT05805683|DRUG|Placebo|patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
214963782|NCT06957990|OTHER|Music|Music of the participant's selected genre will be played through headphones according to the arm assigned.
214963783|NCT06308393|DRUG|RSS0393 ointment；Placebo|RSS0393 ointment；RSS0393 ointment placebo
214963784|NCT04854070|DEVICE|IVUS|IVUS-guided approach in patients with complex coronary lesions undergoing PCI
214963785|NCT04854070|DEVICE|Angio|Angio-guided approach in patients with complex coronary lesions undergoing PCI
214963786|NCT00525473|DRUG|Azathioprine|azathioprine usual dosage 100mg per day
214963787|NCT04783233|BIOLOGICAL|Chitosan succinamide|Chitogel will be tested for suitability as a packing material in tympanoplasty surgery.
214963788|NCT04783233|BIOLOGICAL|Gelfoam|Gelfoam is the current packing material for tympanoplasty surgery.
214963789|NCT00005032|BIOLOGICAL|oblimersen sodium|
214963790|NCT00005032|DRUG|paclitaxel|
214963791|NCT06218771|DRUG|TQB3454 Tablets|TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
214963792|NCT04701450|OTHER|digital consent|the patient's medical history is taken in a digital survey, information about the anaesthetic procedure is aided by video material
214963793|NCT02954328|DEVICE|tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
215080311|NCT02877654|PROCEDURE|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
215080312|NCT00671372|DRUG|FOLFIRI regimen|Intravenous repeating dose
215080313|NCT00671372|DRUG|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
215080314|NCT00671372|DRUG|cetuximab|Intravenous repeating dose
215080315|NCT00671372|DRUG|dulanermin|Intravenous repeating dose
214963794|NCT06382116|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
214963795|NCT06382116|DRUG|Pemetrexed+Cisplatin or Carboplatin|Administration by intravenous infusion for a cycle of 3 weeks.
215080316|NCT00671372|DRUG|irinotecan|Intravenous repeating dose
215080317|NCT04885322|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
215080318|NCT04423458|DEVICE|3D imaging|"The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes."
215080319|NCT01319721|PROCEDURE|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
215080320|NCT01319721|PROCEDURE|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
215080321|NCT01319721|PROCEDURE|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
215080322|NCT04688918|PROCEDURE|Retrolaminar block|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. A 50 mm 22-gauge needle will be inserted in an in-plane technique from cranial to caudal direction and will be advanced till hitting the laminae of fourth thoracic vertebrae and then we will try to inject the local anesthetic, if the resistance to injection is very high, hence we will withdraw the needle slowly and its tip will be kept in its position immediately after disappearance this high resistance. Bupivacaine 0.25%, 0.4mL/kg will be injected.
214963796|NCT04953741|DRUG|Fluticasone propionate inhaled aerosol|The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.
214963797|NCT04663165|PROCEDURE|Periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing. Elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device. Flap closure with non-resorbable sutures.
214963798|NCT04663165|PROCEDURE|Regenerative periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing combined with vertical bone defect of 4mm or more. After elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device, adjunctive treatment with EDTA gel applied to root surface for two minutes, followed by rinsing with saline solution. Finally, application of enamel matrix derivative on a blood free root surface, followed by flap closure with non-resorbable sutures.
214963799|NCT00232206|DRUG|Neoadjuvant Therapy with Cisplatin Plus Docetaxel|
214963800|NCT02090387|OTHER|ONS without AN777|2 servings a day
214963801|NCT02090387|OTHER|ONS containing AN777|2 servings a day
214963802|NCT03139136|DRUG|MBS2320|As described in the arm descriptions
214963803|NCT03139136|DRUG|Placebo|As described in the arm descriptions
214963804|NCT00871364|DRUG|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
214963805|NCT00871364|DRUG|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
214963806|NCT06066255|DRUG|Thymoglobulin Injectable Product|single intravenous injection of thymoglobulin
214963807|NCT02036684|BEHAVIORAL|Prehabilitation (PREHAB)|
214963808|NCT04569604|DIAGNOSTIC_TEST|MRI scans|Contrast-enhanced, magnetic resonance imaging (MRI) based method to detect disturbances in microvascular flow patterns in the human brain
214963809|NCT04569604|DIAGNOSTIC_TEST|Neuro cognitive tests|Standard neuropsychological test battery consists of validated tests to assess cognitive domains including verbal and visual memory, attention, language, visuospatial and executive functioning.
214963810|NCT04569604|DIAGNOSTIC_TEST|Questionnaires on Quality of Life|SF36v2, WHO-5 well-being index, HPQ28, Symptom questionnaire, and a general questionnaire on background information, medication and diet.
214963811|NCT04569604|DIAGNOSTIC_TEST|Blood samples|Markers of calcium homeostasis, inflammatory markers and hematology.
214963812|NCT04569604|DIAGNOSTIC_TEST|24 hr urine samples|24 hr urine content of calcium, phosphate, magnesium, and creatinine.
214355202|NCT04348604|BEHAVIORAL|Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA)|"Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA): CAE-AYA participants will have 4 core in-person sessions (45-60 minutes each) spaced about 1 week apart over a period of approximately 4 weeks and one booster in-person session approximately 4 weeks after completion of the 4 core sessions (total of up to 5 in-person sessions spaced out over 8 weeks). There will be one follow-up phone call with a study interventionist, approximately 6 weeks post-baseline (timed half-way between completion of the core sessions and the booster session). All AYAs assigned to the CAE-AYA arm will receive all 4 modules (Psychoeducation on BD Medications; Communication with Providers \& Caregivers; Medication Routines; and Targeting Risky Behavior via Modified Motivational Enhancement Therapy (MET)), with the content within each module being customized to developmental stage and behavioral experience."
214355203|NCT04348604|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Enhanced Treatment as Usual (ETAU): ETAU will consist of usual clinical care with prescribing clinicians and therapists, augmented by written materials specific to BD for AYAs and 6 follow-up telephone calls to briefly review the materials and be available for questions by social workers with mental health experience and at least some experience in working with AYA with BD. In order to ensure that there is not treatment contamination, different trained interventionists will be used for CAE and eTAU. Therapists will briefly review the materials and be available for questions during the phone calls. Materials will cover general self-management in BD. The calls will be relatively brief (maximum of 20-30 minutes).
214355204|NCT02097108|DRUG|Raltegravir|
214963813|NCT01384747|DRUG|Fimasartan|60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
214963814|NCT01384747|DRUG|Placebo|60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
214963815|NCT01466413|DEVICE|Tropoelastin|"Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼ needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43."
214963816|NCT01514110|DRUG|RAD001|Pharmacology of RAD001 as a combination partner for conventional agents.
214963817|NCT00868478|DRUG|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
214963818|NCT00402792|DRUG|Hydrocodone/Acetaminophen Extended-Release|1 tablet q 12 hours
214963819|NCT00402792|DRUG|Hydrocodone/Acetaminophen Extended Release|2 tablets q 12 hours
214963820|NCT00402792|DRUG|Placebo|2 tablets q 12 hours
214355205|NCT06615531|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
214355206|NCT06669910|OTHER|only assesment|only assesment
214355207|NCT06670729|OTHER|Quran listening|listening to quran recitation via head phone
214355208|NCT06670729|OTHER|silent headphones group|headphones were silent, patient do not listen to any thing
214355209|NCT05520138|DRUG|Enzalutamide|As provided in real-world setting
214355210|NCT05520138|DRUG|Abiraterone acetate|As provided in real-world setting
214355211|NCT06464835|DEVICE|Transcranial magnetic stimulation|The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.
214355212|NCT06628921|DRUG|Eptinezumab 100 or 300 mg ev|Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.
214355213|NCT02038673|DRUG|ASP5878|oral
214355214|NCT03829254|DRUG|NUC-7738|NUC-7738
214355215|NCT03829254|DRUG|Pembrolizumab|Pembrolizumab
214355216|NCT06535750|OTHER|Exercise|Participants were randomly divided into two treatment groups. There are 10 patients in each group. The patients in the control group received a standard treatment programme, while the patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. Treatment sessions for both groups lasted 50-55 minutes and were performed three days a week. Details of the study groups are given below.
214355217|NCT06904482|BIOLOGICAL|Haplo-Identical / Cord Blood Transplant|"Cord Blood Unit Selection Cord Blood Unit Selection should be consistent with published guidelines5 with the understanding that the goal cell dose is 1x105 CD34 cells/kg in this protocol. ABO matching and donor specific antibodies should be taken into account in the selection of the CB unit.~Haplo-Donor Selection Haplo-identical siblings and younger male donors are preferred. ABO matching, CMV compatibility, and donor specific antibodies should be taken into account in the selection of the donor."
214355218|NCT06144151|DEVICE|NeurOptics® NPi®-300 Pupillometer|The pupilometer is a non-invasive device which will be placed in front of your eyes, one at a time. It looks like a handheld spotlight or scanner, with a small plastic guide sticking out that will be placed against your cheek to help keep the device in place during the scan. It will not touch your eye. Both your left and right eyes will be measured with the device each time. Scanning with the pupilometer will take less than 5 minutes total for both eyes.
214355219|NCT07111364|OTHER|observational diagnostic model development|observational diagnostic model development
214963821|NCT03063736|DRUG|Entolimod|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
214355220|NCT06932406|OTHER|Self-management intervention|"This intervention will implement a self-management protocol. It will consist in 5 strategy levels: educational concepts and dynamics, cognitive behavioural tools and processes, therapeutic exercise of the orofacial region, guidelines and strategies for lifestyle modification and mindbody tools.~Several of the above 5 strategies will be employed in each session. Education will include TMD concepts, pain neurophysiology, contextualisation of pain in terms of perceived stress, anxiety and others. Exercises will aim to train motor control, strength and mobility. Cognitive behavioural tools will be used to modulate pain relationship through behaviour modification. Processes such as cognitive distraction, gradual exposure to movement or the scheduling of self-care activities will be used. Mindbody strategies such as relaxation exercises and pain acceptance will seek to reduce the patient's frustration with pain. Structured guidelines will be included to achieve desirable lifestyle changes."
214678968|NCT05129839|DEVICE|lightened and musical baby mobile|Before going to sleep in the infant's room in the intervention group, a lightened and musical baby mobile was used.
214963822|NCT03063736|BIOLOGICAL|Td Vaccine|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
215000422|NCT07125469|OTHER|The measurements taken from the CT scan will be used to determine the appropriate size for two types of theoretical Transcatheter Aortic Valve Replacement (TAVR) prostheses|"All patients with severe aortic stenosis (AS) who are scheduled for Surgical Aortic Valve Replacement (SAVR) with a bioprosthetic valve will undergo a pre-operative Computed Tomography (CT) scan. This CT scan will follow the pre-Transcatheter Aortic Valve Replacement (pre-TAVR) protocol and will focus only on imaging the aortic root, using a method called retrospective electrocardiogram (ECG) gating to capture detailed heart motion.~The measurements taken from the CT scan will be used to determine the appropriate size for two types of theoretical Transcatheter Aortic Valve Replacement (TAVR) prostheses:"
215080323|NCT04688918|PROCEDURE|paravertebral group|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The transverse process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vcostotransverse ligament, 0.4mL/kg will be injected
215080324|NCT00002650|DIETARY_SUPPLEMENT|folic acid|
214355221|NCT06932406|OTHER|Clinical Practice Guideline Intervention|"Following the guidelines, 5 sessions of education, cognitive behavioural tools, jaw exercises and manual therapy will be conducted.~The educational sessions will teach about TMD and basic pain concepts. A single type of cognitive behavioural tool will be employed. The aim will be to decrease bruxing and parafunctional activity during wakefulness. This will be done by training the jaw relaxation position, which will then be generalised to activities of daily living with the help of some conditioning through positive and negative reinforcement. Exercise activities will aim to train motor control, strength and mobility. Manual therapy will be carried out in the orofacial region by means of soft tissue techniques and joint mobilisation."
214355222|NCT00506493|DEVICE|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
214963823|NCT05203601|BIOLOGICAL|SIBP-03|"Stage 1:~Six dose groups of 2, 5, 10, 15, 20 and 40 mg/kg were planned. Dose increments began at 2 mg/kg using accelerated titration. In the first dose group, after the first patient was injected with Sibp-03, if the subject developed toxicity grade ≥2（CTCAE v5.0 standard）within 21 days of initial administration，then the subject increased to 3 and the study design method in this dose level convert to 3+3. If the subject didn't develop toxicity grade ≥2, then the study of the second and next dose group can be carried out using 3+3 incremental design.~Stage 2:~Cohort 1 included patients with advanced head and neck squamous cell carcinoma and cohort 2 included patients with breast cancer. According to the results of dose escalation stage and similar drug trials, 5mg/kg and 10mg/kg dose levels were selected to enter this phase. Each cohort will be extended to include 6-8 subjects to receive this product in combination with the standard treatment study."
214963824|NCT02738359|PROCEDURE|optical colonoscopy|optical colonoscopy
214963825|NCT02738359|PROCEDURE|colon capsule endoscopy|colon capsule endoscopy
215080325|NCT00461305|DRUG|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
215080326|NCT00461305|DRUG|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
214963826|NCT02738359|DIAGNOSTIC_TEST|fecal immunological test (FIT)|fecal immunological test (FIT)
214963827|NCT03961763|DIETARY_SUPPLEMENT|EPA+DHA|4 g/day EPA+DHA in tablets of 1g, 4 tablets daily, over 8 weeks (56 days)
214355223|NCT00506493|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
214355224|NCT04990401|BEHAVIORAL|Behavioral Activation Teletherapy|A total of 10 teletherapy sessions to be delivered over 12-14 weeks, designed to increase physical activity among depressed individuals.
214355225|NCT05981768|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
214355226|NCT00955357|DRUG|Lacosamide|"Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week"
214355227|NCT02110641|BEHAVIORAL|Weight Loss Counseling|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
214355228|NCT01297231|OTHER|MRI|"Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).~During Tamoxifen Treatment:~* Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.~* Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.~* Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated."
214487227|NCT06776978|DEVICE|Active treatment|Participants receive anodic tDCS using a battery-driven Eldith (neuroConn GmbH) Programmable Direct Current Stimulator with surface-soaked sponge electrodes (5×7 cm). A constant current of 2 mA is applied for 20 minutes per session. The stimulation targets the left frontal region (F5 of the extended International 10-20 EEG system), corresponding to Broca's area, while the reference electrode is placed over the contralateral frontopolar cortex. tDCS is performed for 10 daily sessions over two consecutive weeks (5 days per week).
214678969|NCT04430582|OTHER|Cognitive Assessment (not diagnostic)|Cognitive testing will assess premorbid intelligence, working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.
214963828|NCT03961763|OTHER|Placebo|4 g/day olive oil placebo in tablets of 1g, 4 tablets daily, over 8 weeks (56 days).
214963829|NCT01057667|DRUG|RO5024048|1000mg bid po, 24 weeks
214963830|NCT01057667|DRUG|Ribavirin [Copegus]|1000mg or 1200mg po daily
214963831|NCT01057667|DRUG|peginterferon alfa-2a [Pegasys]|180mcg sc weekly
214963832|NCT00516100|DRUG|bortezomib|MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.
214963833|NCT02412202|OTHER|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
215080327|NCT06289816|PROCEDURE|Minimally Invasive Surgery|Minimally Invasive Surgery : Laparoscopic partial splenectomy, cystectomy, and cyst deroofing.
214355229|NCT01760239|BEHAVIORAL|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
214355230|NCT05554068|DRUG|Shingrix|Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
214355231|NCT01387880|DRUG|Everolimus|"Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan."
214963834|NCT01502033|DEVICE|Transcranial Magnetic Stimulation|30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
214963835|NCT01664507|DRUG|conventional dose epinephrine|conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
214963836|NCT01664507|DRUG|low dose epinephrine|low dose epineprhine : 0.1mg/kg + 0.9% normal saline
214963837|NCT02018432|DRUG|Roflumilast escalation dosage|"This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.~Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks"
214963838|NCT02018432|DRUG|Roflumilast conventional dosage|Roflumilast 500 μg once daily for 12 weeks
215080328|NCT04545047|BIOLOGICAL|COVID-19 convalescent plasma|Convalescent plasma collected from individuals who have recovered from COVID-19
215080329|NCT04591925|DEVICE|Control Device insulin infusion devcie|Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula
215080330|NCT04591925|DEVICE|Investigative insulin infusion devcie|Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
214355232|NCT01387880|DRUG|Everolimus|1.66 mg per day up to 7½ mg per day
214963839|NCT05475899|DEVICE|Instrument assisted soft tissue mobilization|Application of IASTM on the plantar fascia with 10-15 strokes followed by stretching
214963840|NCT02834858|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells
214963841|NCT02834858|BIOLOGICAL|saline|
215080331|NCT03020017|OTHER|Laboratory Biomarker Analysis|Correlative studies
214963842|NCT02122315|OTHER|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles
214963843|NCT02122315|OTHER|Physical therapy|Best-evidence physical therapy intervention
214963844|NCT01266005|DRUG|Clevudine|30mg,QD
214963845|NCT01266005|DRUG|Entecavir|0.5mg QD
214963846|NCT03213392|DRUG|Anesthetic Agents|four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
214963847|NCT00672607|DRUG|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
214355233|NCT03709355|DRUG|Elpida®|Elpida® capsules, 20mg
214355234|NCT03709355|DRUG|Rifampin|Rifampin capsules, 150mg
214355235|NCT03709355|DRUG|Rifabutin|Rifabutin capsules, 150mg
214355236|NCT03709355|DRUG|Clarithromycin|Clarithromycin Film-coated tablets, 250mg
214355237|NCT03709355|DRUG|Omeprazole|Omeprazole Film-coated tablets 20mg
214355238|NCT03709355|DRUG|Atorvastatin|Atorvastatin Film-coated tablets, 80mg
214355239|NCT03709355|DRUG|Levonorgestrel+Ethinylestradiol|Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
214355240|NCT05382260|OTHER|Listening to music|After 5 minutes baseline, participants would listen to three kinds of music with 3 minutes washout and another 5 minutes baseline in the end, while EEG would record their cortical activity. And the order of the three kinds of music is random.
214355241|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
214355242|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
214678970|NCT04430582|DIAGNOSTIC_TEST|ECG|ECG will take place during screening visit.
214963848|NCT00672607|DRUG|Placebo|Placebo
214963849|NCT01808261|DRUG|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
214963850|NCT01808261|DRUG|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
214963851|NCT04294199|OTHER|Early Range of MOtion|Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
215080332|NCT03020017|OTHER|Pharmacological Study|Correlative studies
215080333|NCT03020017|DRUG|Targeted Molecular Therapy|Given NU-0129 IV
215080334|NCT05770024|OTHER|imaging tests|X-ray radiography (RX); computer tomography (CT); magnetic resonance (MR); positron emission tomography (PET); single photon emission computed tomography (SPECT)
215080335|NCT05953610|DRUG|Acetazolamide 500 MG QHS|Acetazolamide
215080336|NCT05953610|DRUG|Eszopiclone 3 mg QHS|Eszopiclone
215080337|NCT03527628|DRUG|Adriamycin|25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
215080338|NCT03527628|DRUG|Cyclophosphamide|400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
215080339|NCT03527628|DRUG|Vinblastine|6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
215080340|NCT03527628|DRUG|Dacarbazine|375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
214963852|NCT00178217|BEHAVIORAL|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
215080341|NCT03527628|DRUG|Brentuximab Vedotin|1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
215080342|NCT03527628|DRUG|ABVD|All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
215080343|NCT03612310|PROCEDURE|Skin biopsy/Urine Collection/Blood Sample Collection|"Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. Clinician will collect a 5-7mm section of skin, the area may be numbed beforehand and stitches may be used to close the wound when required. The wound will be dressed if deemed necessary by medical professional.~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or phlebotomost will use a disposable needle to remove a blood sample (normally 50ml but could be up to 320ml for adults).~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or other nominated member of the clinical team will provide a sterile urine collection vessel and direct the volunteer to a suitable private toilet area to provide the sample."
215080344|NCT02796872|DIETARY_SUPPLEMENT|GOS|GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
215080345|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 3%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
215080346|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 2%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
215080347|NCT02796872|DIETARY_SUPPLEMENT|Mother's breast milk|exclusively breastfed infants for at least 7 days prior to enrollment
215080348|NCT06023628|OTHER|Danish Helicopter Emergency Service|Patients with traumatic cardiac arrest assessed by the Danish HEMS
215080349|NCT04932213|DRUG|Tropicamide Ophthalmic|Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
215080350|NCT04744012|PROCEDURE|Modified Periostal Pocket Flap Technique|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
215080351|NCT04182061|BEHAVIORAL|The AMTE protocol|The AMTE program is an adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018) to be applied as an internet-based protocol. Like the UP-A, the program AMTE implements a set of core principles to address common factors underling youth anxiety and depressive symptoms. It includes the following 10 modules: (1) Understanding emotional problems and disorders, (2) Getting to know your emotions and behaviors, (3) Enjoy your positive activities, (4) Mindful emotion awareness, (5) Being flexible in your thinking, (6) Confronting physical sensations, (7) Situational emotion exposure, (8) How to regulate the emotional avoidance, (9) Respiratory relaxation training, and (10) Relapse prevention.
214355243|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
214355244|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
214355245|NCT01698684|DRUG|Placebo|One dose 15 minutes before attempting intercourse
214963853|NCT03128619|PROCEDURE|Biopsy of Breast|Undergo biopsy
214355246|NCT01698684|DRUG|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
214487228|NCT06776978|DEVICE|Sham Stimulation|Participants receive sham tDCS using a battery-driven Eldith (neuroConn GmbH) Programmable Direct Current Stimulator with surface-soaked sponge electrodes (5×7 cm). No therapeutic current is applied during the 20-minute session. The electrode placement mimics the active condition, targeting the left frontal region (F5 of the extended International 10-20 EEG system), corresponding to Broca's area, while the reference electrode is placed over the contralateral frontopolar cortex. Sham tDCS is performed for 10 daily sessions over two consecutive weeks (5 days per week).
214963854|NCT03128619|DRUG|Copanlisib|Given IV
214963855|NCT03128619|OTHER|Laboratory Biomarker Analysis|Correlative studies
214963856|NCT03128619|DRUG|Letrozole|Given PO
214963857|NCT03128619|DRUG|Palbociclib|Given PO
215080352|NCT04343014|DEVICE|Tongue Root Retractor|Fibroptic endutracheal intubation will be performed with tongue root retractor.
215080353|NCT04343014|DEVICE|Conventional Fibroscope|Fibroptic endutracheal intubation will be performed in conventional way.
214355247|NCT01698684|DRUG|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
214355248|NCT02681913|DRUG|Adenosine|This group receives intermittent warm blood cardioplegia enriched with adenosine
214355249|NCT00818857|BEHAVIORAL|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
214355250|NCT00818857|BEHAVIORAL|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
214963858|NCT03128619|OTHER|Pharmacological Study|Correlative studies
214963859|NCT05038449|DRUG|Colchicine Tablets|Colchicine Tablets (Each tablet contains colchicine 0.5mg)
214963860|NCT05038449|DRUG|Standard therapy|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)
214963861|NCT05034380|BEHAVIORAL|Acute exercise|All participants consumed a standardized, high carbohydrate meal (7 kcal/kg; 60% carbohydrate, 25% fat, 15% protein) and completed an exercise testing trial, expending a total of 650 kcal upon completion 4h later.
214355251|NCT01204801|DEVICE|Focused Microwave Thermotherapy|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
214355252|NCT01204801|DRUG|Chemotherapy (control)|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
214355253|NCT06034587|DIAGNOSTIC_TEST|multimodal ultrasound|An Aixplorer ultrasound machine (SuperSonic Imaging, Ltd, Aixen-Provence, France), equipped with AngioPLUS(AP) and shear wave elastography(SWE) functions, was used for all examinations using a 4-15MHz linear probe.AP function can detect microvessels of lesions,SWE can evaluate the stiffness of lesions and high frequency ultrasound can measure the thickness and volume of keloid.
214963862|NCT04832451|BEHAVIORAL|Interpersonal Relational Role Analysis|"Interpersonal Relational Role Analysis (IRRA) is a psychosocial group intervention that allows individuals to see the problems they experience in interpersonal relationships and interactions in the group environment and to be handled together with group members.~Similar to Yalom's interactional group therapy model, IRRA sessions comprise warm up, the stages of setting the agenda, working, evaluating, and getting feedback from observers, which are based on the 'here and now' principle. IRRA helps to safely examine the roles in which group members are stuck, in a group environment which is a small example of social life, and these roles are addressed in six steps."
214963863|NCT00941304|DRUG|Oxycodone|Single-dose of over-encapsulated oral 5-mg oxycodone capsule
214355254|NCT06034587|RADIATION|radioisotope applicator therapy|The radioisotope applicator therapy utilized 90Sr-90Y(0094SR814975) isotope, customized by the China Atomic Energy Research Institute. The element therapy instrument used had overall dimensions of 2.8cm x 2.8cm, with an effective treatment area of 2.0cm x 2.0cm. It delivered a radiation dose of 5.0Gy/h. Each patient received superficial radiation therapy through a single 90Sr source, administered in repeated doses. The isotope therapy instrument was customized to fit the exact size of the keloid, ensuring coverage the irradiation range extending 0.5cm beyond the keloid's edge. During treatment, the surface of the applicator was aligned with the irradiated area and directly contact the surface of the keloid tissue. The treatment was carried out low-dose irradiation method, over 5 sessions, with each session delivering a dose of 2Gy. Each irradiation lasted for 25min.
214355255|NCT05441085|DEVICE|programed intermittent epidural bolus interval 90 (EI90)|programed intermittent epidural bolus interval 90 (EI90) of 10 ml, 0.0625% bupivacaine plus 2 μg/mL fentanyl
214355256|NCT03663231|DEVICE|Biotene|Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase. 3 sprays, approximately 15 mL.
214355257|NCT03663231|DEVICE|Placebo|IND/IDE exempt device primarily water
214355258|NCT00033696|BIOLOGICAL|filgrastim|
214355259|NCT00033696|DRUG|carboplatin|
214355260|NCT00033696|DRUG|etoposide|
214963864|NCT00941304|DRUG|Buprenorphine|Single-dose of buprenorphine HCl buccal film
214963865|NCT00941304|DRUG|Placebo Film|Single-dose of placebo buccal film
214963866|NCT00941304|DRUG|Placebo Capsule|Single-dose of oral placebo capsule
214963867|NCT03293394|DEVICE|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
214355261|NCT00033696|DRUG|paclitaxel|
214355262|NCT00033696|DRUG|topotecan hydrochloride|
214355263|NCT00033696|RADIATION|radiation therapy|
214355264|NCT02635854|OTHER|Septic choc group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.
214963868|NCT03293394|DEVICE|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
214963869|NCT03648918|OTHER|Blood Collection|Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
215080354|NCT01376375|PROCEDURE|Acupuncture|
215080355|NCT03680872|DEVICE|Bidirectional Neural Bypass System|These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
214355265|NCT02635854|OTHER|Orthopedic surgery group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.
214355266|NCT00852631|DRUG|Quetiapine fumarate (Seroquel)|600mg Extended release tablet, oral, once daily
214678971|NCT02522481|DRUG|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
214963870|NCT04964167|COMBINATION_PRODUCT|Plant extract|Natural plant extract
214963871|NCT01861002|DRUG|Azacytidine|Dose assigned at study entry (75 mg/m2/day). Given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
214963872|NCT01861002|DRUG|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
214963873|NCT01861002|DRUG|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
214963874|NCT01861002|DRUG|Intrathecal (IT) Cytarabine|"Intrathecally to AML patients on day 1 of course 1 and 2.~* Omit on day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS disease, IT cytarabine can be given weekly until the CSF is clear. Two additional doses of IT cytarabine should be given weekly after the initial CSF clearing. It is permitted to change to intrathecal triple therapy (ITT) if persistent blasts are present in the CSF based on the treating physician's clinical judgment. Cytarabine dose defined by age:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age~ITT Dosing:~Age (yrs) - Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. \- 1.99 MTX: 8 mg, HC: 15 mg, ARAC: 30 mg~2. \- 2.99 MTX: 10 mg, HC: 25 mg, ARAC: 50 mg~   * 3 - MTX: 12 mg, HC: 35 mg, ARAC: 70 mg"
214355267|NCT02130310|BIOLOGICAL|CureXcell®|CureXcell® is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.
214355268|NCT02130310|OTHER|Placebo injection|Normal saline injected at each centimeter of ulcer bed
214355269|NCT03443960|DRUG|TNX-102 SL 5.6 mg|Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
214355270|NCT03443960|DRUG|Amrix 30 mg|Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.
214355271|NCT06395064|DRUG|Dimenhydrinate|Dimenhydrinate 50mg intravenously
214355272|NCT01603069|DRUG|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
214487229|NCT06776237|DIAGNOSTIC_TEST|PoCUS|Participants after getting recruited will be asked for an ultrasonography of the neck. It will take around 30 minutes. At home, participants will be asked to wear a portable sleep study device overnight, to perform home sleep study. Although these devices are noninvasive and safe, they are not routinely used as a standard of care in the pregnant patient population.
214963875|NCT01861002|DRUG|Intrathecal Methotrexate (IT MTX)|"* Intrathecally to patients with ALL on day 1 of course 1 and 2.~* Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. \- 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~2. \- 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~3. \- 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~   * 9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg"
214963876|NCT04004260|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
214963877|NCT04527042|DRUG|Rivaroxaban|It is determined by the clinician's routine clinical prescription.
214963878|NCT02279615|DRUG|Mirabegron|50mg of mirabegron per day will be given.
215080356|NCT01103063|DRUG|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
215080357|NCT01103063|DRUG|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
215080358|NCT03376685|BEHAVIORAL|Endurance Exercise Training (END)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week for 30 minutes (Week 1-2); 35 minutes (Weeks 3-4); or 40 minutes (Weeks 5-6) at 60% VO2 peak.
215080359|NCT03376685|BEHAVIORAL|Sprint Exercise Training (SIT)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 3 days a week involving a 3-minute warm-up, followed up 4 repetitions (Week 1-2); 5 repetitions (Weeks 3-4); or 6 (Weeks 5-6) repetitions of 30 seconds at a maximal intensity with 2 minutes' rest in between. Exercise will conclude with a 2-minute cool-down.
214963879|NCT02279615|DRUG|Tamsulosin|0.4mg of flomax per day.
214963880|NCT01765569|DRUG|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
214355273|NCT01603069|DRUG|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
214355274|NCT01603069|DRUG|Placebo|Placebo to AZD3241 BID
214355275|NCT02125201|DRUG|Fentanyl|A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
214355276|NCT04608370|BEHAVIORAL|Active tPBM session|In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
214355277|NCT04608370|BEHAVIORAL|Sham tPBM session|In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
214355278|NCT05278455|BEHAVIORAL|Lifestyle Medicine|A smartphone-delivered application with a series of lifestyle medicine components, including lifestyle psychoeducational, physical activity, dietary recommendations, stress management, sleep management, and motivation and goal-setting techniques.
214963881|NCT01765569|DRUG|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
214355279|NCT05602714|OTHER|Collection Data|
214355280|NCT01886924|BEHAVIORAL|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
215080360|NCT06242223|OTHER|Multimodal HIIT|multimodal HIIT protocol followed by sprinting followed by 2 minutes of rest, burpees with 3 minutes rest between sets and push ups 4-5 rep at 80-100% of HR max with a total of 20 minutes exercise per session a day 3 times a week followed by 6 weeks.
215080361|NCT06242223|OTHER|conventional HIIT|conve protocol with 4-5 repetitions of 40 seconds maximum running at 80-100% HR max followed by 20 seconds of walking for 20 minutes exercise per session 3 times a week followed by 6 weeks.
214963882|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
214963883|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
214963884|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
214963885|NCT04226014|PROCEDURE|Endoscopic ultrasound|Echo-endoscopy ultrasound is an examination that presents little risk. However, any medical act, exploration, intervention even conducted under conditions of competence and safety in accordance with current data of medicine and the regulations in force, conceals a risk of complications. In particular, esophageal perforations can occur. They are often favored by underlying lesions (tumor, diverticulum, anatomical variants ...). Other complications are possible such as cardiovascular, respiratory or infectious disorders, as with any anesthesia.
214963886|NCT05460858|DRUG|N-acetyl cysteine|One hundred and forty participants randomize in the intervention and placebo groups, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction. They will be received 1200 (2×600) mg of effervescent tablets of NAC or placebo daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles.
215080362|NCT05786339|DRUG|Tested Irbesartan Tablet|T
215080363|NCT05786339|DRUG|Reference Irbesartan Tablet|R
215080364|NCT02340182|DRUG|Vancomycin|250mg 3dd2
215080365|NCT02340182|DRUG|Ciprofloxacin|500mg 2dd1
215080366|NCT02340182|DRUG|Metronidazole|500mg 3dd1
215080367|NCT03115853|DRUG|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
215080368|NCT03115853|DRUG|Placebo|Placebo tablet for Aliskerin
215080369|NCT03115853|DRUG|HCTZ|HCTZ 25mg every day for 18 weeks
215080370|NCT03115853|DRUG|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
214487230|NCT06776991|BEHAVIORAL|Positive Affect Treatment - Behavioral (PAT-B)|8 therapy sessions conducted individually with a therapist. Focuses on improving reward processing to increase positive emotional experience. Specific techniques include psychoeducation on mood cycle and positive emotions, mood monitoring, behavioral activation, and imaginal recounting and savoring of behavioral activation events. Intervention includes between-session practice.
215080371|NCT00162461|DRUG|Phenytoin single dose (300 mg)|
214487231|NCT06776991|BEHAVIORAL|Relaxation Treatment|8 therapy sessions conducted individually with a therapist. Focuses on mindfulness and relaxation skills. Specific techniques include mindfulness approaches from dialectical behavior therapy, diaphragmatic breathing, and progressive muscle relaxation. Intervention includes between-session practice.
214502697|NCT03711084|DIETARY_SUPPLEMENT|Natural high potency sweetener from leaf extract|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
214963887|NCT05460858|DRUG|placebo|placebo
214963888|NCT00650338|DRUG|DE-104 ophthalmic solution, low concentration|Topical ocular application
214963889|NCT00650338|DRUG|DE-104 ophthalmic solution, medium concentration|Topical ocular application
214963890|NCT00650338|DRUG|DE-104 ophthalmic solution, high concentration|Topical ocular application
214963891|NCT00650338|DRUG|Placebo|placebo
214963892|NCT00650338|DRUG|0.005% latanoprost|Topical ocular application
215080372|NCT01649544|DEVICE|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
215080373|NCT01649544|DRUG|Amiodarone|
215080374|NCT06350487|DRUG|SGLT2 inhibitor|Enavogliflozin (0.3mg oral tablet once daily) will be administrated.
215080375|NCT05106712|DRUG|Vitamin D3|4000IU per day for around 12 weeks.
215080376|NCT05106712|DRUG|Clomiphene Citrate|"oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
214678972|NCT03340805|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
214963893|NCT03460873|PROCEDURE|holmium laser enucleation of the prostate|undergo holmium laser enucleation of the prostate
215080377|NCT05106712|DRUG|Letrozole|"oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
214355281|NCT01886924|BEHAVIORAL|Nutrition Control|Computer delivered nutrition education control condition
214355282|NCT03882333|OTHER|Acute exercise|30 min acute exercise (bicycle at stationary cycle)
214355283|NCT05152433|DEVICE|E-BRAiN therapy|The therapy system E-BRAiN is a purpose-built therapy system using a socially interactive humanoid robot and provides individualised therapy for arm rehabilitation based on the evidence-based therapies arm basis training, arm ability training, or mirror therapy for arm rehabilitation (paresis) or neurovisual training (neglect).
214355284|NCT05152433|BEHAVIORAL|Conventional therapy|Conventional therapy specifies the neurorehabilitation therapy as applied as regular treatment.
214355285|NCT01515410|DRUG|DM-1992|72.5mg carbidopa/230mg levodopa
214487232|NCT06776991|BEHAVIORAL|Exposure Therapy|8 therapy sessions conducted individually with a therapist using the inhibitory retrieval model of exposure therapy. Sessions are designed to include four exposures each (32 exposures total). Each exposure is a public speech delivered to an audience. Goal of this treatment is to reduce public speaking anxiety. Principles of exposure therapy that will be incorporated are maximizing prediction error, maintaining attention to the situation/stimuli that are perceived predictors of the feared outcome (e.g., social rejection), removing safety signals, variability, engaging in post-exposure rehearsal/consolidation, deepened extinction, and positive occasion setter extinction. Intervention does not include between-session practice.
214963894|NCT04963725|DRUG|Ustekinumab|No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
214487233|NCT06775353|DRUG|Dexamethasone eyedrop|Infants who developed stages of pretreatment-requiring severe ROP were usually given one eyedrop of dexamethasone daily until the ROP changes regressed.
214963895|NCT06585280|OTHER|No intervention|No intervention
214487234|NCT06776328|OTHER|Tools|In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of children and adolescents with suicidal thoughts/behavior.
214487235|NCT06776835|DIAGNOSTIC_TEST|Analysis of relative quantitative of small non-coding RNAs|Each participant was enrolled to assess the of relative quantitative of small non-coding RNAs
214963896|NCT05138055|OTHER|No intervention|No intervention
214963897|NCT00271219|DRUG|Methadone|daily oral dosing 20-140 mg
214963898|NCT00271219|DRUG|Buprenorphine|sl daily 2-32 mg
214355286|NCT01515410|DRUG|Sinemet IR|Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
214355287|NCT04452708|DEVICE|HFNC|HFNV vs NIV vs conventional nasal cannula
214355288|NCT05077787|OTHER|Massage therapy|Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.
214355289|NCT05077787|OTHER|Kinaesthetic stimulation|Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention
214355290|NCT00802568|BIOLOGICAL|anti-thymocyte globulin|
214963899|NCT06015230|BIOLOGICAL|low dose GR1603 in phase Ⅰb|6 subjects in GR1603 low dose，2 subjects in placebo
214963900|NCT06015230|BIOLOGICAL|high dose GR1603 in phaseⅠb|6 subjects in GR1603 high dose，2 subjects in placebo
214963901|NCT06015230|BIOLOGICAL|low dose GR1603 in phase Ⅱ|low dose GR1603 monthly
214963902|NCT06015230|BIOLOGICAL|high dose GR1603 in phase Ⅱ|high dose GR1603 monthly
215080378|NCT05106712|OTHER|placebo|participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
215080379|NCT05732584|OTHER|structured family voice stimulation|The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.
215080380|NCT05732584|OTHER|unstructured family voice stimulation|The unstructured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death.
215080381|NCT06348914|BEHAVIORAL|Knowledge assessment|survey on knowledge of a group of dental students regarding vital pulp therapy
214355291|NCT00802568|DRUG|busulfan|
214355292|NCT00802568|DRUG|fludarabine phosphate|
214355293|NCT00802568|PROCEDURE|allogeneic bone marrow transplantation|
214355294|NCT00802568|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
214355295|NCT03686852|OTHER|same medications but different dosages|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
214963903|NCT06015230|BIOLOGICAL|Placebo in phase Ⅱ|Placebo
214963904|NCT06342401|DIAGNOSTIC_TEST|ENCODE|A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.
214963905|NCT06329687|DRUG|Tyrvaya Nasal Pump|Tyrvaya Nasal Pump with Silicone Lubricant
214963906|NCT04704609|OTHER|Standard of Care Imaging|We are collecting imaging that is standard of care for uveitis patients
214963907|NCT04667715|DEVICE|Exablate BBBD|Blood brain barrier disruption using ExAblate Type 2 device using microbubble resonators
214963908|NCT03143270|DRUG|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
214963909|NCT03143270|DRUG|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
214963910|NCT05568797|BIOLOGICAL|RSVPreF3 OA vaccine|One dose of RSVPreF3 OA vaccine administered intramuscularly.
214963911|NCT05568797|BIOLOGICAL|FLU vaccine|One dose of FLU vaccine administered intramuscularly.
214963912|NCT05680142|DRUG|superficial cervical plexus block|The superficial cervical plexus block is applied as part of our routine protocol for postoperative pain control. Group sCPB will be administered from the C4 level by entering the posterior border of the sternocleidomastoid muscle from the right side of the neck.
214963913|NCT05680142|DRUG|cervical erector spinae plane block|The cervical erector spinae plane block is applied as part of our routine protocol for postoperative pain control. Group cESP is applied to the fascia between the semispinalis capitis muscle and the posterior scalene muscle of the C6 or C7 transverse process.
214963914|NCT03184129|DEVICE|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..
214963915|NCT03184129|DEVICE|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
214963916|NCT04178616|DIAGNOSTIC_TEST|olfactory testing with specific odorants (localisation and identification)|Olfactory testing : ETOC (European Test of Olfactory capabilities)
214963917|NCT03881202|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
214963918|NCT00679224|DRUG|ambrisentan|ambrisentan
214963919|NCT05284903|OTHER|Beamformer Benefit: Speech intelligibility and Listening effort|Confirm the improvement in terms of speech intelligibility (measured by OLSA, Oldenburg Sentence Test) and the reduction in terms of listening effort (measured by ACALES) of the I-BF (investigational Beamformer) compared to the R-BF (reference Beamformer), when speech is not coming from the front.
214963920|NCT05284903|OTHER|Speech Enhancer benefit: Speech intelligibility, Listening effort and Subjective Speech intelligibility|"Confirm the improvement in terms of speech intelligibility (measured by Oldenburg Sentence test) and the reduction in terms of listening effort (measured by ACALES) when the Speech Enhancer is on (SE ON) compared to Speech Enhancer is off (SE OFF) for distant speech or speech from adjacent room.~Confirm the improvement in terms of subjective level to follow a conversation in quiet when SE ON compared to SE OFF for distant speech or speech from adjacent room. Measured by a subjective assessment."
214963921|NCT05284903|OTHER|Hearing aid benefit: Speech intelligibility in noise (unaided vs aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) in noise with the investigational device (aided condition) compared to the unaided condition.
214963922|NCT05284903|OTHER|Hearing aid benefit: Speech intelligibility in noise (aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) with the Reference binaural beamformer compared to the fixed directional.
214963923|NCT05628857|DRUG|RC108|RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
214963924|NCT05341791|OTHER|Cartoon video describing study information notice|The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
215080382|NCT06348914|OTHER|Educational Material|An awareness lecture on vital pulp therapy will be given to a group of the students right after they answer the questionnaire for the first time.
215080383|NCT04506060|OTHER|serum withdrawal|Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.
214355296|NCT05227001|BIOLOGICAL|PF-07852352 Influenza saRNA 1|Intramuscular injection
214355297|NCT05227001|BIOLOGICAL|PF-07836391 Influenza saRNA|Intramuscular injection
214355298|NCT05227001|BIOLOGICAL|PF-07836394 Influenza saRNA|Intramuscular injection
214355299|NCT05227001|BIOLOGICAL|PF-07836395 Influenza saRNA|Intramuscular injection
214355300|NCT05227001|BIOLOGICAL|PF-07836396 Influenza saRNA|Intramuscular injection
214355301|NCT05227001|BIOLOGICAL|PF-07867246 Influenza saRNA|Intramuscular injection
214355302|NCT05227001|BIOLOGICAL|Placebo|Intramuscular injection
214355303|NCT05227001|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|Intramuscular injection
214355304|NCT05227001|BIOLOGICAL|PF-07871987 Influenza saRNA|Intramuscular injection
214355305|NCT05227001|BIOLOGICAL|PF-07914705 Influenza saRNA|Intramuscular injection
214355306|NCT05227001|BIOLOGICAL|PF-07915048 Influenza saRNA|Intramuscular injection
214963925|NCT05443074|OTHER|Face to face intervention group|"Participants of this group will participate in a one 15 minutes face to face session where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge urinary incontinence (UI)."
214963926|NCT05443074|OTHER|Remote intervention group|"Participants of this group will be referred to a room with a computer (inside the rehabilitation center) to participate in a one 15 minutes real time remote session, where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge UI."
214963927|NCT05443074|OTHER|Control group|Participants of this group will be assessed in the same time points of the participants of the two other groups. They will not receive any intervention or information about pelvic floor anatomy, functions and dysfunctions of the pelvic floor, however after the last assessment (20 days after) for ethical reasons they will receive the same intervention.
214963928|NCT05521113|BEHAVIORAL|Home Rehabilitation Monitoring System|The system consists of a small activity monitor worn on the wrist and a pulse oximeter worn on the finger while exercising. Simple exercises will be completed daily and the monitors will send information to a rehabilitation coach during a 12-week period.
214963929|NCT05521113|BEHAVIORAL|Health coaching calls|12 telephone-based health coaching calls over a 12-week period
214963930|NCT01135043|BEHAVIORAL|education by brochure|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
214963931|NCT01135043|BEHAVIORAL|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
214963932|NCT03538704|DRUG|Metformin|Metformin is given to patients 1-1.5g/d.
214963933|NCT00778349|DRUG|Metformin solution 100 mg/mL|
214963934|NCT02651337|DEVICE|Cerebrospinal Fluid (CSF) Drainage|Placement of Alivio in line flusher during CSF drainage
214355307|NCT04216108|DEVICE|Vitrectomy (23G gauge needle)|Vitrectomy surgery with 23G gauge needle technique
214355308|NCT04216108|DEVICE|Vitrectomy (27G gauge needle)|Vitrectomy surgery with 27G gauge needle technique
214355309|NCT06224738|BIOLOGICAL|human HER2-targeted CAR-M cells|The human anti-HER2 chimeric antigen receptor macrophages (anti-HER2 CAR-M cells) independently developed use adenoviral vector system to genetically engineer autologous macrophages to express CAR molecules containing single-chain antibodies, which specifically bind to the human HER2 antigen to recognize and kill tumor cells.
214355310|NCT00868439|DRUG|patiromer|Active investigational drug
214355311|NCT00868439|DRUG|placebo|placebo
214355312|NCT00650832|DRUG|TMC114; darunavir; Prezista|
214355313|NCT00344786|DRUG|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
214355314|NCT04769427|DEVICE|PDO max threads|To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale)
214355315|NCT01494831|BEHAVIORAL|TF-CBT|15 sessions of group-based, trauma-focused cognitive behavioral therapy
214355316|NCT04220164|OTHER|Education and inform the optimal threshold of LDL-C levels|Physicians educate patients and provide a clear information about optimal LDL-C value according to individual patient's condition according to current guidelines
214355317|NCT03215836|PROCEDURE|Bronchoscopy and Nasal Epithelium Brush Sampling|After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
214355318|NCT01139307|OTHER|cell culture procedure|
214355319|NCT01139307|OTHER|laboratory biomarker analysis|
214355320|NCT00520780|DRUG|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
214355321|NCT00520780|DRUG|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
214355322|NCT01189279|DRUG|bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
214355323|NCT01189279|DRUG|bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
214355324|NCT01189279|DRUG|bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
214355325|NCT00195910|DRUG|Morphine|0.1 mg/kg IV morphine
214355326|NCT00195910|DRUG|Hydromorphone|0.015 mg/kg IV hydromorphone
214355327|NCT00971048|DEVICE|HP828-101|Topical test article applied once daily
214487236|NCT06777186|OTHER|10 meter walk test|"The dual task skills of the individuals will be evaluated by adding motor and cognitive tasks to the 10-meter walk test. Tasks given to individuals~Single motor task (comfortable walking): The individual is asked to walk at normal speed, the time is recorded Motor-motor dual task: Both hands carry a half-full water bottle, time is recorded Motor-cognitive dual task (mental) : counts backwards from 10 by 1, time is recorded Motor - cognitive dual task (memory) : The individual is asked to say 3 words that were previously spoken. The time is recorded."
214487237|NCT06777186|OTHER|Functional Balance|It will be assessed with the TUG test. The TUG measures the time it takes for an individual to get up from a chair, walk a distance of 3 meters, turn around, walk back to the chair and sit down again after a ready, go signal.
214487238|NCT06777186|OTHER|Social Adaptation Assessment|Adaptive behavior will be assessed with the Vineland Adaptive Behavior Scales. It is a parent interview designed to assess functioning in daily life. \[35\]Specifically, adaptive behavior is assessed in four domains: Communication, Daily Living, Socialization and Motor skills. Vineland has reliability and current validity. It has been reported to be sensitive to the difficulties experienced by children with ASD
214487239|NCT06777186|OTHER|Motor skills and proficiency|The Bruininks-Oseretsky Motor Proficiency Test (BOT-2) assesses fine motor, hand coordination, body coordination, strength and agility between the ages of 4-21 years.There are 53 items in the BOT-2. In BOT-2, there are four motor domains including fine motor control, hand coordination, body coordination, strength and agility and a total of eight subtests related to these domains.
214963935|NCT02401035|DRUG|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
214355328|NCT00971048|DEVICE|Hydrogel/Hydrocolloid|Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
214355329|NCT06088264|DRUG|BMS-986322|Specified dose on specified days.
214487240|NCT06775314|DRUG|Cleanser|Cleanser consist of Triethyl citrate and Pyruvic acid, will be given to subjects to be applied every morning, evening and night in group 2
214487241|NCT06775314|DRUG|Combination cream|combination cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic acid will be given to subjects to be applied every morning, evening and night in group 2
214487242|NCT06775314|DRUG|spot cream|spot cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol, will be given to subjects to be applied every morning and evening in group 2
214487243|NCT06775314|DRUG|Adapalene 0,1% cream|adapalene 0.1% cream will be given to subjects to be applied every night in group 1 and 2
214487244|NCT06775314|DRUG|placebo cleanser|placebo cleanser will be given to subjects to be applied every morning, evening and night in group 1
214487245|NCT06775314|DRUG|placebo cream combination|placebo cream combination will be given to subjects to be applied every morning, evening and night in group 1
214487246|NCT06775314|DRUG|placebo spot cream|placebo spot cream will be given to subjects to be applied every morning and evening in group 1
214487247|NCT06769139|OTHER|Red blood cell exchange|Red blood cell exchange manual exchange and automatized exchange
214487248|NCT06768853|PROCEDURE|Lymph node dissection based on the guidelines|During surgery, mediastinal lymph nodes will be dissected based on the NCCN guidelines (2023) .
214487249|NCT06768853|PROCEDURE|Lymph node dissection based on the model|During surgery, lymph nodes will be dissected based on the predicted lymph node status by the model.
214963936|NCT04555707|DRUG|Apremilast 30mg|30mg PO BID started within 10 days of baseline
214355330|NCT00243204|DRUG|talabostat mesylate|
214355331|NCT00243204|DRUG|docetaxel|
214355332|NCT01250977|DRUG|Donepezil|
214355333|NCT01250977|DRUG|Placebo|
214355334|NCT04109703|DEVICE|High Level Pulsed Heat delivered by Generation 5 devices from Soovu Labs Inc.|The Soovu Labss Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are through a phone-based bluetooth connection. For this study the treatment algorithm used for subjects in this arm (experimental) used a temperature that was ramped from skin temperature to a peak temperature of 45° C and cycled for 30 minutes.
214487250|NCT06766669|OTHER|Shaping method activities combined with mirror therapy|This intervention involves the application of exercises consisting of shaping method activities accompanied by a mirror device. It is basically an intervention consisting of exercises that require manual dexterity.
214487251|NCT06767410|OTHER|Multidomain Intervention|The intervention is distinguished by its multidomain approach combining cognitive, social, and musical activities through choir participation, targeting holistic cognitive and emotional benefits, unlike active controls (general activities) and passive controls (no activities).
214963937|NCT04555707|DRUG|calcipotriene and betamethasone dipropionate|1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.
214963938|NCT00869128|DRUG|Circadin|2 mg prolonged-release melatonin
214963939|NCT00869128|DRUG|Placebo|
214963940|NCT05137002|DRUG|CIN-107|CIN-107 tablets by mouth once daily
214963941|NCT05137002|DRUG|Placebo|Placebo tablets by mouth once daily
214963942|NCT02400619|DEVICE|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
214355335|NCT04109703|DEVICE|Low Level (37 degrees C) delivered by the control device Generation 5 devices from Soovu Labs Inc.|The Soovu Labs Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are via a phone-based bluetooth connection. For this control arm of the study the treatment algorithm held a steady temperature of 37 degrees C for a 30 minute period.
214355336|NCT04850300|PROCEDURE|Total knee prosthesis with medial condylar stabilization|Surgery will be done of Total knee prosthesis with medial condylar stabilization
214355337|NCT04850300|PROCEDURE|Total knee prosthesis with central pivot stabilization|Surgery will be done of Total knee prosthesis with central pivot stabilization
214355338|NCT01015391|DRUG|T2|1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
214355339|NCT01015391|DRUG|Azathioprine|2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
214355340|NCT02412930|PROCEDURE|Ultrasound-guided Paravertebral Block|"paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.~After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion."
214355341|NCT02412930|DRUG|Group Tramadol|Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
214355342|NCT02412930|DRUG|Bupivacaine|
214355343|NCT02412930|DEVICE|Ultrasound|
214355344|NCT00606372|PROCEDURE|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
214355345|NCT03321396|DEVICE|sodium alginate mixed with calcium lactate|"The product is used in Endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. It's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as Gut Guarding Gel."
214355346|NCT01944501|PROCEDURE|Transcranial Magnetic Stimulation|TMS over the left temporoparietal cortex
214355347|NCT01944501|PROCEDURE|Transcranial Direct Current Stimulation|TDCS over the left temporoparietal cortex
214355348|NCT02167074|DEVICE|25G FNA needle|
214355349|NCT02167074|DEVICE|20G ProCore FNB needle|
214355350|NCT02540018|DEVICE|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|"Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied."
214355351|NCT02540018|DEVICE|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
214487252|NCT06767410|OTHER|General activities|Participants will carry out a series of physical, manual and/or intellectual activities (e.g., horticulture, physical activities, theatre, learning programs etc.) but not musical activities
214487253|NCT06768879|RADIATION|Ultrasound|To evaluate the different location of uterine fibroids in patient with disturbed menstrual cycle on ultrasound
214487254|NCT06769503|OTHER|aromatherapy|Lavender oil dropped on gauze will be smelled for approximately 3-5 minutes.
214487255|NCT06770205|OTHER|traditional physical therapy|hot pack and TENS for 10 minutes and massage that will as 3 sessions per week for 4 weeks.
214963943|NCT02400619|DRUG|Botulinum Toxin Type A|Botulinum toxin type A Botox
214963944|NCT02998996|BIOLOGICAL|15 µg HA/strain and 1% Endocine™|intranasal administration
214963945|NCT02998996|BIOLOGICAL|15 µg HA/strain and 2% Endocine™|intranasal administration
214355352|NCT01487811|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin)
214355353|NCT01973933|DRUG|Metformin and Pyrimethamine|
214678973|NCT03340805|DRUG|Normal saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
214355354|NCT04243317|BEHAVIORAL|Lifestyle & diet|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans.
214355355|NCT04243317|BEHAVIORAL|Lifestyle, diet & sleep|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans. The experimental group will additionally receive a sleep improvement program based on CBTi.
214355356|NCT02244866|DRUG|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
214355357|NCT02244866|DRUG|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
214963946|NCT02998996|BIOLOGICAL|15 µg HA/strain|intranasal administration
214963947|NCT02998996|BIOLOGICAL|intramuscular comparator|intramuscular administration
214963948|NCT02998996|BIOLOGICAL|intranasal comparator|intranasal administration
214963949|NCT02998996|BIOLOGICAL|Placebo, Saline|intranasal administration
214963950|NCT00848029|BIOLOGICAL|Monovalent inactivated influenza vaccine|Two doses of monovalent inactivated influenza adjuvanted vaccine
214963951|NCT05307679|DRUG|Basmisanil|Participants will receive oral basmisanil at age-appropriate dosages
214963952|NCT05307679|DRUG|Placebo|Participants will receive oral placebo
214963953|NCT04693078|DEVICE|AI polyp detection system based on deep learning|A Polyp detection system based on deep learning and artificial intelligence, which can alert the operator in real-time to the presence and location of polyps during a colonoscopy.
214963954|NCT00028626|DRUG|embolization therapy|
214963955|NCT01136564|DRUG|Zemplar|2 capsules of 1 microgram daily
214355358|NCT02750254|DRUG|Fludarabine|
214355359|NCT02750254|RADIATION|Fractionated total body irradiation|
214355360|NCT02750254|DRUG|Busulfan|
214355361|NCT02750254|DRUG|Cyclophosphamide|
214355362|NCT02750254|RADIATION|Single dose total body irradiation|
214355363|NCT02750254|DRUG|Melphalan|
214355364|NCT02750254|DRUG|Granulocyte-colony stimulating factor|
214355365|NCT02750254|PROCEDURE|Stem cell transplant|
214355366|NCT02750254|DRUG|Azacitidine|
214963956|NCT01136564|DRUG|Placebo|2 capsules daily
214963957|NCT02447913|BEHAVIORAL|Voucher|"Introduction of vouchers will improve uptake of family method as well as child immunization.~Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method"
214963958|NCT01118663|DRUG|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
214963959|NCT01118663|DRUG|Acetadote|Acetadote \[old formulation\] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
214963960|NCT00168155|DRUG|perioperative chemotherapy|
214963961|NCT03338283|OTHER|Electromassage|Electro-massage that will be performed by a specialist physiotherapist with more than 8 years of experience We use ENDOMED 482 (Enraf Nonius, Spain) for the elecro-massage. the current parameters are: frequency shift at 4000 Hz IFC, 100 Hz AMF in CV mode. We will gradually raise the current intensity until reaching a high level, but not so high as to cause pain or discomfort, nor evident muscle contraction, although a gentle vibration is allowed. The electro-massage was performed on the musculature of the shoulder and neck.
214963962|NCT03338283|OTHER|Conservatory treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
214963963|NCT02419391|BIOLOGICAL|MVA BN RSV|Liquid frozen suspension of MVA-mBN294B
214963964|NCT02419391|OTHER|Placebo|Tris Buffered Saline, sterile
214963965|NCT01566422|DRUG|Vancomycin powder|patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
214963966|NCT04663243|BEHAVIORAL|Thinking healthy Program sessions designed for antenatal period|Low line psychosocial intervention based on the principles of Cognitive Behavior Therapy (CBT), designed for non-specialist will be applied for expectant women experiencing depression during mid to late-pregnancy. It uses the core principles and strategies of the Thinking Healthy Program (THP). Four core sessions and two booster sessions will be applied, designed for antenatal period to prevent antenatal and post partum depression.
214963967|NCT02567175|DRUG|Domperidone|
214963968|NCT03046953|DRUG|Avelumab|anti-PDL1 antibody
215080384|NCT04853693|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
215080385|NCT04853693|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
214355367|NCT04024618|PROCEDURE|Parenteral Nutrition/Enteral Nutrition|Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
214355368|NCT03491865|BEHAVIORAL|REAL media Plus curriculum|REAL media Plus is a 7-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth smoking and vaping use.
214355369|NCT05346289|PROCEDURE|Elective surgery for intact AAA|Elective surgery including the following modalities: open repair, endovascular repair (EVAR), fenestrated end-vascular repair (FEVAR).
214963969|NCT05039125|RADIATION|ultrasonic cavitation|"* From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~* Part III: 3cm above the umbilicus to 2cm below the umbilicus~* After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~* The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~* The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~* After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months"
215080386|NCT04518852|COMBINATION_PRODUCT|TACE combined with sorafenib and PD-1 mAb|the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
215080387|NCT01437098|DEVICE|MDT-2111 CoreValve for TAVI|CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
215080388|NCT01187446|RADIATION|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
215080389|NCT01187446|DRUG|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
214355370|NCT03671668|OTHER|titanium bases using intra oral luting cement technique|comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction
214355371|NCT04799626|DRUG|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
214355372|NCT04447326|DRUG|Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy|Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles
214355373|NCT04447326|DRUG|IC＋CCRT|IC＋CCRT
214355374|NCT04020900|OTHER|Respiratory management|Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
214502698|NCT03711084|DIETARY_SUPPLEMENT|Glucose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
215080390|NCT02241330|DIETARY_SUPPLEMENT|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
215080391|NCT02241330|DIETARY_SUPPLEMENT|Fortification|Wheat flour is fortified before testmeal preparation
214355375|NCT00273312|DRUG|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
214963970|NCT06076122|DIETARY_SUPPLEMENT|Food supplement based on Salicornia extracts|Freshly Salicornia ramosissima plants were recollected. Its aerial part were left to dry and hydroalcoholic extracts were produced by the company Extractos Vegetales S.A. (EVESA) (Cadiz, Spain \[https://evesa.com/\]). The Salicornia extracts were encapsulated by BIO-DIS laboratories (Seville, Spain \[https://www.bio-dis.com/\]), experts in food supplements and certified for such procedures.
214963971|NCT06076122|DIETARY_SUPPLEMENT|Placebo|Placebo capsules physically equal to the Salicornia extracts capsules
214963972|NCT04039204|DRUG|Elagolix|This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET
214963973|NCT04039204|DRUG|Ortho Cyclen|Oral contraceptive prescribed by physician.
214963974|NCT00281723|DRUG|Pro-Pe adhesive tablet|
214963975|NCT02766036|DRUG|Propolis|Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses
214963976|NCT02766036|DRUG|Placebo|Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
214963977|NCT01199887|DRUG|IW001|IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
214963978|NCT01363284|DRUG|Duloxetine|First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
215080392|NCT02241330|DIETARY_SUPPLEMENT|Control|wheat flour is used as control comparator.
215080393|NCT03644914|BEHAVIORAL|10-week Reading Program|Intervention sessions will be carried out during the school day in a private school room. In each session, the investigator will work with the child individually to help him or her read better. Intervention will incorporate word recognition and phonetic decoding of words established as meeting 1st grade essential literacy standards. Learning techniques will involve games, play, movement, music, and breaks (i.e., the child is able to move about and associate words with color, video, and music. Three 5-minute breaks will be integrated into each 1-hour session to allow the child time to rest and process learned material). Intervention will also use each child's personal interests as a context around which sight words will be learned.
215080394|NCT03739957|DEVICE|BPCO Media Kit|Telemonitoring system for patients with COPD
214502699|NCT03711084|DIETARY_SUPPLEMENT|Sucrose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
214963979|NCT04594109|BEHAVIORAL|Tailored behavioral counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
214963980|NCT04594109|BEHAVIORAL|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
214963981|NCT01321632|DRUG|Zingiber officinalis|To start with subjects will be prescribed Zingiber officinalis in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
214963982|NCT01189461|DRUG|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
214963983|NCT04291118|PROCEDURE|Private system endoscopic sinus surgery|Patients that will undergo endoscopic sinus surgery though the private system. Beforehand they could of used medical management including, budesonide for their symptoms.
214963984|NCT04291118|PROCEDURE|Public system endoscopic sinus surgery|Patients that undergo endoscopic sinus surgery though the public system after waiting for at least 1 year. Beforehand they could of used medical management, including budesonide for their symptoms.
214355376|NCT01540851|BEHAVIORAL|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
214355377|NCT01540851|OTHER|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
214355378|NCT05138718|DIAGNOSTIC_TEST|18F-FDG PET/CT|Perform a 18F-FDG PET/CT to patients with history of myocardial infarction
215080395|NCT01206283|PROCEDURE|Modified Lund concept|"After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~* Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~* Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~* Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~* Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~* Control of ICP, which can be in majority of patients, kept at values below 15 mmHg."
215080396|NCT01206283|PROCEDURE|Cerebral perfusion pressure-targeted therapy|"* ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~* Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~* No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~* Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes \[Na, Cl and K\]);"
215080397|NCT02830607|DEVICE|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
215080398|NCT03417817|DEVICE|Bravo|wireless pH monitoring over 96 hours
215080399|NCT01037049|OTHER|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
215080400|NCT03141463|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
214963985|NCT04291118|DRUG|Budesonide|Patients will receive medical management for their symptoms that will consist of topical nasal steroid, budesonide and any other required medication for their disease.
214963986|NCT02716584|BEHAVIORAL|Physical exercise|Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
214355379|NCT02710799|OTHER|Teleconsultation|The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
214355380|NCT02710799|OTHER|Protocol|The informations provided in the referral list will be evaluated through the state's referrals protocols.
214963987|NCT02716584|BEHAVIORAL|Stretching exercise|Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
214963988|NCT03578133|DIAGNOSTIC_TEST|InBios® Active Melioidosis DetectTM-Lateral Flow Assay|Evaluation of a lateral flow assay for the detection of B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen from sputum
214963989|NCT01423929|DRUG|Oxygen|Fitting of Oxymask TM and treatment with 10 L O2/min
214963990|NCT01423929|DEVICE|Room air|Fitting of Oxymask TM
214963991|NCT05745545|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
214963992|NCT05745545|DRUG|Saline solution|One dose was administered by intramuscular injection, 0.5ml/vial
214963993|NCT05184387|OTHER|Blood samples|Collection of blood samples and completion of an electronic Diary (eDiary)
214963994|NCT06058273|BEHAVIORAL|Bruni® training|10 sessions (7 individual and 3 group) based on the Bruni method, which was born as a method for the artistic voice (rock, pop, gospel, R\&B, grunge, metal), acting and dubbing. It is a method based on the didactic desire to lead any artist to the ability to produce various types of noise, specifically generically supraglottic, predominantly arytenoid and falsechordal emissions, providing the perceptive, proprioceptive and praxis tools to safely emit and manage the many sounds generated from a supraglottic source
214963995|NCT05642104|DRUG|Neoadjuvant therapy|all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
214963996|NCT03466723|GENETIC|biomarker identification in Parkinson disease|circulating miRNAs profiling by NGS analysis functional miRNA characterization association of miRNA levels with genetic variants
214963997|NCT02924233|DRUG|Sym004|"Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).~Sym004 will be administered at different dose-levels via infusion Q2W"
214963998|NCT02924233|DRUG|Nivolumab|Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
214963999|NCT02938338|PROCEDURE|Bariatric surgery|Bariatric surgery, with an anticipated mean weight loss of 30 kg
214964000|NCT02555917|PROCEDURE|anterior cruciate ligament reconstruction|Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
214964001|NCT00023738|BIOLOGICAL|filgrastim|
214964002|NCT00023738|DRUG|dacarbazine|
214964003|NCT00023738|DRUG|doxorubicin hydrochloride|
214964004|NCT00023738|DRUG|ifosfamide|
214964005|NCT00023738|DRUG|semaxanib|
214964006|NCT00023738|PROCEDURE|conventional surgery|
214964007|NCT00023738|RADIATION|radiation therapy|
214964008|NCT04356287|BIOLOGICAL|UCMSC|Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.
214964009|NCT04356287|OTHER|Placebo|Each infusion will consist of 50 mL of PlasmaLyte A.
214964010|NCT03635762|BEHAVIORAL|Be In Charge|comparison of pre and post-program weight and calorie intake
214964011|NCT00585338|DEVICE|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
214964012|NCT00006390|BIOLOGICAL|alemtuzumab|
214964013|NCT00006390|BIOLOGICAL|filgrastim|
214964014|NCT00006390|DRUG|cyclophosphamide|
214964015|NCT00006390|PROCEDURE|peripheral blood stem cell transplantation|
214964016|NCT00006390|RADIATION|radiation therapy|
214964017|NCT02787122|BEHAVIORAL|CBT-E|Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy based on a manual. Interventions aim on patients' mood by implementing positive activities in their daily routine. Further, patients train to reduce worrying behavior. Social contacts are fostered as well. Later, patients are informed on emotions and train emotion regulation strategies. Finally, the focus of CBT-E is on self-acceptance.Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
214964018|NCT02787122|BEHAVIORAL|Treatment as Usual|Patients receive standardized treatment. After a waiting period of six month, patients receive CBT-E
214964019|NCT00229749|DRUG|AVI-4065 Injection|
215080401|NCT01551277|OTHER|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
215080402|NCT01551277|OTHER|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
215080403|NCT03730077|DRUG|18F-FMISO|18F-FMISO PET/CT
215080404|NCT00881764|PROCEDURE|Inguinal hernia surgery|Non-experimental procedure
215080405|NCT00881764|PROCEDURE|General anesthesia|Non-experimental procedure/treatment
215080406|NCT05264441|DEVICE|In-Check DIAL G16|Patients will inspire into an In-Check DIAL G16 device.
215080407|NCT05232968|OTHER|Long-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
215080408|NCT05232968|OTHER|Short-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
215080409|NCT03497091|OTHER|Enteral Formula|Enteral Feeding with an amino acid-based formula
215080410|NCT00496197|DRUG|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
215080411|NCT00496197|DRUG|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
215080412|NCT00496197|DRUG|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
214964020|NCT05355077|DRUG|JT001 200mg Bid|JT001 (VV116):200 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
214964021|NCT05355077|DRUG|JT001 400mg Bid|JT001 (VV116):400 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
214964022|NCT05355077|DRUG|JT001 600mg Bid|JT001 (VV116):600 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
214355381|NCT04781374|DRUG|Neratinib|Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
214964023|NCT02566499|DEVICE|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
214964024|NCT00048633|DRUG|Chemotherapy|
214964025|NCT06361186|DRUG|Proximod|Single and multiple-dose to establish the safety and PK profile
214964026|NCT06361186|DRUG|Placebo|Placebo controlled
214964027|NCT03112486|PROCEDURE|blood draw|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
214964028|NCT04457362|DIAGNOSTIC_TEST|Diagnostic Arthroscopy using the Arthrex NanoScope|"A diagnostic arthroscopy will be performed with the Arthrex NanoScope.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make an initial diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, ligament injury and determine the intended treatment."
214964029|NCT04457362|DIAGNOSTIC_TEST|Diagnostic Arthroscopy using standard arthroscopic instruments|"A diagnostic arthroscopy will be performed with the standard arthroscopic instruments.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make the final diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, and ligament injury and determine the final treatment."
214964030|NCT01712139|DRUG|Irbesartan and Hydrochlorothiazide|
214964031|NCT01712139|DRUG|Avalide|
214964032|NCT00758381|DRUG|Sorafenib 400 mg po bid, continuously|"NEXAVAR\*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010"
214355382|NCT00960466|BEHAVIORAL|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT\&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT\&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
214355383|NCT00960466|BEHAVIORAL|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
214355384|NCT01212367|BIOLOGICAL|SCH 721015|1.0 x 10e12 viral particles on Days 1 and 4
214355385|NCT01212367|BIOLOGICAL|SCH 721015|3.0 x 10e11 viral particles on Days 1 and 4
214355386|NCT02301312|DEVICE|POSS-PCU vascular graft|New vascular access graft
214355387|NCT01507220|DRUG|morphine sulfate|Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
214502700|NCT03711084|DIETARY_SUPPLEMENT|Maltodextrin|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
214964033|NCT00758381|DRUG|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
214964034|NCT01204086|DRUG|Venlafaxine|The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
214964035|NCT01204086|DRUG|Fluoxetine|The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
214964036|NCT04821843|DRUG|Platinum based chemotherapy|q1-3W according to physician's preference
214964037|NCT04821843|DRUG|Paclitaxel based chemotherapy|q1-3W according to physician's preference
214964038|NCT04821843|RADIATION|Radiotherpay|40-50Gy/1.8-2.2Gy/20-25f
214964039|NCT04821843|PROCEDURE|Surgery|Radical esophagectomy
214964040|NCT04821843|DRUG|Immunotherapy|Anti-PD-1/PD-L1 Antibody
215080413|NCT03179111|PROCEDURE|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
215080414|NCT01344538|DRUG|Ginger Root Extract (Pure Encapsulations)|2.0 g per day (10:1 extract)
215080415|NCT01344538|DIETARY_SUPPLEMENT|Placebo Capsule|2.0 g per day
215080416|NCT02763475|DRUG|cyclophosphamide|60mg/kg by vein on day -6
215080417|NCT02763475|DRUG|Fludarabine|25mg/m2 iv daily on day -5 to -1
214964041|NCT04821843|DRUG|5-FU Analog based chemotherpay|W1-5 qW or d1-14, q3W according to physician's preference
214964042|NCT04821843|DRUG|Nimotuzumab|200-400mg, d1,qW
214964043|NCT05955144|DEVICE|Picterus JP|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is placed.
214964044|NCT02951624|BEHAVIORAL|Control|Control intervention
214964045|NCT02951624|BEHAVIORAL|Breaker|Short breaks of physical activity
214964046|NCT02951624|BEHAVIORAL|Prolonger|longer breaks of physical activity
214964047|NCT02951624|BEHAVIORAL|Intermediate|Intermediate breaks of physical activity
214964048|NCT04839666|DRUG|Propofol|Perioperatively propofol administration
214964049|NCT00204061|BEHAVIORAL|Supportive management|The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.
214964050|NCT00204061|DRUG|Amisulpride|Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
214964051|NCT04693299|DIAGNOSTIC_TEST|colonoscopy|A colonoscopy scheduled within the normal pathway of care will be performed. No interventions will be performed.
215080418|NCT02763475|PROCEDURE|NK cell infusion|"* First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~* Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
215080419|NCT02763475|DRUG|IL-2|1x10\^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
215080420|NCT05452369|DRUG|Rhomboid intercostal plane block|\- 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
215080421|NCT05801393|RADIATION|CT, MRI|"HRCT with no IV contrast administration and bone algorithm. Intra thecal injection of contrast, then CT in prone position to obtain direct coronal cuts.~MR cisternography using a three dimensional constructive interference in steady state (3D-CISS) sequence."
215080422|NCT01655381|DRUG|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
215080423|NCT01574898|DRUG|V0474 - A mg|Single oral administration
215080424|NCT01574898|DRUG|V0474 - B mg|Single oral administration
215080425|NCT01574898|DRUG|V0474 - C mg|Single oral administration
215080426|NCT01574898|DRUG|V0018 - B mg|Single oral administration
215080427|NCT01574898|DRUG|Niquitin® Fresh Mint 4 mg|Single oral administration
215080428|NCT00973544|OTHER|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
215080429|NCT00320255|DRUG|Apixaban|Oral tablets administered once daily in 5-, 10-, or 20-mg dose
215080430|NCT00320255|DRUG|Placebo|Oral tablets administered once daily
215080431|NCT04201366|OTHER|No intervention|No intervention
214964052|NCT03017196|OTHER|My Life, My Healthcare Discussion Aid|The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
214964053|NCT06302049|DRUG|Esomeprazole|esomeprazole 20 mg once daily
214964054|NCT06302049|DRUG|Placebo|Placebo once daily
214964055|NCT02118779|BEHAVIORAL|Behavioural change intervention|The intervention is cognitive behaviour therapy (CBT). The CBT consists of six different modules. All patients will start with individual goal setting and psycho-education about the role of cognitive-behavioural variables in the disabilities patients' experience. The patient formulates his or her treatment goals in concrete terms and later on in the therapy the goals are realised step by step by the patient. The treatment is tailored to the patient's problems: which of the six modules a patient will receive is dependent on the scores on measures that have been collected at baseline assessment. Based on our previous experience with modular interventions we expect that most patients will receive less than four modules.
214964056|NCT05892250|BEHAVIORAL|Conventional physical therapy|Manual techniques and therapeutic exercise
215080432|NCT04748068|DEVICE|7-Fr Glidesheath Slender|The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
215080433|NCT04748068|DEVICE|Cordis 7-Fr radial sheath|Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
215080434|NCT05569057|DRUG|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
215080435|NCT00552630|DEVICE|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
214964057|NCT05892250|BEHAVIORAL|Conventional physical therapy + Dynamic Humeral Centering exercises|Manual techniques and therapeutic exercise and active dynamic humeral centering exercises
215080436|NCT00552630|DRUG|placebo|placebo with same characteristics as drug
215080437|NCT00043108|DRUG|carboplatin|
215080438|NCT00043108|DRUG|paclitaxel|
215080439|NCT00043108|PROCEDURE|conventional surgery|
215080440|NCT00043108|RADIATION|radiation therapy|
215080441|NCT02443493|DEVICE|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
215080442|NCT02443493|DEVICE|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
215080443|NCT02443493|RADIATION|radiotherapy|
215080444|NCT06185634|OTHER|Dietary intervention - Pasta at dinner|"The pasta at dinner nutritional intervention will consist, as the name suggests, in eating pasta at dinner for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
214355388|NCT01507220|DRUG|bupivacaine liposome extended-release injectable suspension|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
214964058|NCT01719991|OTHER|Nurse case management and self-management support|"Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.~Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease."
214964059|NCT05210439|DRUG|Short-treatment of any active antibiotic regimen|7 days of any active antibiotic treatment for BSI-PA
214964060|NCT05210439|DRUG|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment for BSI-PA
214964061|NCT02966821|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
214964062|NCT03142776|PROCEDURE|periodontal debridement|
214964063|NCT03142776|PROCEDURE|photodynamic therapy|
214964064|NCT03142776|DRUG|systemic clarithromycin|
214964065|NCT05198856|DRUG|Thalidomide Combined With Chemotherapy and Monotherapy|"Combined period：chemotherapy + T ：Thalidomide tablets: 100mg/d~Maintenance period: 100 mg/d, qn, orally. Sustained to disease progression or intolerable adverse reactions."
214964066|NCT00552214|DEVICE|Blood test|Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens
214964067|NCT06751719|OTHER|core stabilization exercises|"The core exercises would be held for 7 to 8 seconds, repeated 10 times, and rest for 3 seconds between repetitions and 1 minute rest between each exercise. These exercises will include:~1. Abdominal hollowing~2. Supine extension bridge~3. Partial Curls"
214964068|NCT06751719|OTHER|heat therapy|The heat therapy would be applied to the lumbar region for 10 minutes.
214964069|NCT06751719|OTHER|proprioceptive exercises|"The proprioceptive exercises will include rest for 3 seconds between repetitions and 1-minute rest between each exercise. These exercises will include:~1. One leg balance - 10 seconds hold time with 3 repetitions~2. Forward leg swings - 15 swings~3. Sideways leg swings - 15 swings"
214964070|NCT06751719|OTHER|calisthenic exercises|"The calisthenic exercises will include:~1. Abductor's leg raise for 10 repetitions~2. Prone leg extension for 10 repetitions~3. Alternate toe touch for 10 repetitions"
214964071|NCT06751719|OTHER|kinesthetic exercises|"The kinesthetic exercises will have 1 minute rest in between exercises. These exercises will include:~1. Toe walking for 20 meters distance~2. Heel walking for 20 meters distance"
214964072|NCT01406184|OTHER|Durham Connects|The program consists of 4-7 intervention contacts, including 1) a hospital birthing visit when a staff member schedules an initial home visit; 2) 1-3 nurse home visits between 3-12 weeks of infant age to provide physical assessments for infant and mother, intervention and education, assessment of family-specific needs, and connections to matched community resources, as needed, to provide longer-term support; 3) 1-2 nurse contacts with community service providers to facilitate successful connections; and 4) a telephone follow-up one month after case closure to review community connection outcomes. With family consent, letters from the program reporting on the visit are also provided to also connect families to maternal and infant healthcare providers for ongoing support.
214964073|NCT03519113|BIOLOGICAL|GC1102 80,000 IU|recombinant human hepatitis B immunoglobulin
214964074|NCT03519113|BIOLOGICAL|GC1102 100,000 IU|recombinant human hepatitis B immunoglobulin
214964075|NCT03519113|BIOLOGICAL|I.V HBIG|human anti-hepatitis B Immunoglobulin
214964076|NCT05962827|DIAGNOSTIC_TEST|lipoprotein (a)|dosage of lipoprotein (a)
214964077|NCT04611776|DRUG|Atezolizumab|Atezolizumab will be administered intravenously during the induction phase and the maintenance phase.
214964078|NCT04611776|DRUG|Placebo|Placebo will be administered intravenously during the induction phase and the maintenance phase.
214964079|NCT04611776|DRUG|Carboplatin|Carboplatin will be administered intravenously during the induction phase.
214964080|NCT04611776|DRUG|Cisplatin|Cisplatin will be administered intravenously during the induction phase.
214964081|NCT04611776|DRUG|Pemetrexed|Pemetrexed will be administered intravenously during the induction phase.
214964082|NCT04611776|DRUG|Gemcitabine|Gemcitabine will be administered intravenously during the induction phase.
214964083|NCT04611776|DRUG|Paclitaxel|Paclitaxel will be administered intravenously during the induction phase.
214964084|NCT02870764|DRUG|Dan-shen extract|A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
214964085|NCT02870764|DRUG|Placebo|200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
215080445|NCT06185634|OTHER|Dietary intervention - Pasta at lunch|"The pasta at lunch nutritional intervention will consist, as the name suggests, in eating pasta at lunch for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
215080446|NCT04979897|OTHER|Intensive care unit stay during the COVID-19 pandemic|Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open \[close\] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
215080447|NCT03839992|DIAGNOSTIC_TEST|spirometry|measure spirometry and lung CT
214964086|NCT02870764|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
214964087|NCT06023862|DRUG|Dostarlimab|Intravenous (IV) infusion
214964088|NCT06023862|DRUG|Bevacizumab|Intravenous (IV) infusion
214964089|NCT06023862|DRUG|Doxorubicin|Intravenous (IV) infusion
214964090|NCT06023862|DRUG|Gemcitabine|Intravenous (IV) infusion
214964091|NCT06023862|DRUG|Paclitaxel|Intravenous (IV) infusion
214355389|NCT03768167|PROCEDURE|Posterolateral corpectomy|Investigators' goal in this study is to report clinical series of 26 patients in Sohag university hospital with dorsolumbar metastatic lesions from different primaries treated by single-stage posterolateral circumferential corpectomy with reconstruction by a pyramesh titanium cage and account the degree of improvement regarding the pain.
214502701|NCT03711084|DIETARY_SUPPLEMENT|Water|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
214964092|NCT06023862|DRUG|Pegylated liposomal doxorubicin|Intravenous (IV) infusion
215080448|NCT03405935|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
215080449|NCT01761591|DEVICE|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
215080450|NCT01761591|DEVICE|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
215080451|NCT05036382|BEHAVIORAL|Steps data observation|Sending more step data from the experimental group that received the incentive message
215080452|NCT02198599|PROCEDURE|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
214964093|NCT05750563|DIETARY_SUPPLEMENT|diosmin and micronized flavonoids|the symptomatic treatment of haemorrhoids
214964094|NCT05750563|OTHER|Placebo|Use as comparator
214964095|NCT01940640|DIETARY_SUPPLEMENT|DHA|We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
214964096|NCT01940640|DIETARY_SUPPLEMENT|control|We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
214964097|NCT00331539|DEVICE|Cochlear Implant|
215080453|NCT03200639|OTHER|Combined training|The CT and CTc protocol (total length time \~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
214964098|NCT05259163|DEVICE|LFR-260 portable phoropter|Portable unit to evaluate visual refractive state of the patient
214964099|NCT05259163|DEVICE|Traditional phoropter (SOC)|Standard unit for evaluating visual refractive state of the patient
214964100|NCT06777329|BEHAVIORAL|10 days of dry immersion|The volunteers in this arm will be immersed up to the neck for 10 days in a specially designed bath filled with tap water.
214964101|NCT06777329|BEHAVIORAL|10 days of Head Down Bed Rest|The volunteers in this arm will spend 10 days in -6° head down bed rest.
214355390|NCT04230044|DRUG|Perampanel|Perampanel tablets.
214355391|NCT00937924|DRUG|Meperidine, Midazolam|
214355392|NCT00937924|DRUG|Diphenhydramine|
214355393|NCT00937924|DRUG|Promethazine|
214964102|NCT06294535|DEVICE|reconstruction of orbital walls|under GA, incision to access to orbital walls. Then insertion of prebent titanium mesh or customized titanium implant and fixation with miniscrews, examination of ocular motility using forced duction test followed by closure of flap.
214964103|NCT00913081|DIETARY_SUPPLEMENT|Quercetin|Quercetin 500, 1000, or 2000 mg PO one time
214964104|NCT00913081|DIETARY_SUPPLEMENT|Placebo|Placebo PO one time
214964105|NCT05753592|DRUG|Part 1; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
214964106|NCT05753592|DRUG|Part 2; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
214964107|NCT06259214|OTHER|15% HCl gel|Icon , DMG, Hamburg, Germany
214964108|NCT06259214|OTHER|H3PO4 gel|Scotchbond Etchant, 3M ESPE, St. Paul, MN, USA
214964109|NCT06259214|OTHER|Er:YAG laser|Fotona AT Fidelis III, Ljubljana, Slovenia
214964110|NCT01381926|DRUG|exenatide|exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
214964111|NCT01381926|DRUG|Saline|Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
214355394|NCT00315250|DRUG|[123I]β-CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
214355395|NCT04478968|OTHER|presence of AVF|Functioning AVF may have cardiotoxic potential
214355396|NCT00430794|DRUG|Spironolactone|
215080454|NCT03200639|OTHER|High intensity interval training with body weight|The HIITBW and HIITBWc protocol (total length time \~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (\<60% of HRmax or Borg Scale at \<5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
215080455|NCT05097508|DRUG|Atracurium Besylate|Anesthesia will be induced by atracurium (dose 0.5 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given
215080456|NCT05097508|DRUG|Rocuronium Bromide|Anesthesia will be induced by rocuronium (dose 0.6 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given.
214355397|NCT04910893|DEVICE|Cytokine Adsorption|Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.
214964112|NCT05095194|PROCEDURE|Cataract surgery with IOL implantation and with/without capsular tension ring implatation|Patients in this study will receive cataract surgery with IOL implantation and capsular tension ring implantation or cataract surgery with IOL implantation
215080457|NCT05097508|DEVICE|Entropy|No premedication will be given. After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system , starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
215080458|NCT05097508|DEVICE|train of four|After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system, starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
215080459|NCT00868218|BIOLOGICAL|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
215080460|NCT00929773|DEVICE|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
215080461|NCT00929773|DEVICE|Placebo laser|Inactive laser light.
215080462|NCT02781792|DRUG|Temozolomide|-Given standard of care
214355398|NCT04910893|OTHER|Standard of Care|Standard intensive care of patients suffering septic shock
214355399|NCT05909631|OTHER|Beetroot juice|250 ml of concentrated beetroot juice, were given to participants in the BJ groups .This was carried out in the morning, 30 minutes before breakfast, and on an empty stomach.
214964113|NCT04398602|BEHAVIORAL|behavior of the leader|A study investigator, expert in both PPH and simulation debriefing, not involved in the simulation, observed each scenario to record and check the team's technical skills according to the established 23 PPH key tasks. The behavioral scores were assigned by two independent observers, experts in communication and evaluation in simulation, who reviewed the videos of each simulation each simulation all participants were asked to complete a survey related to the leader and the team behaviors. Questions required a yes/no answer or an answer based on an ordinal scale (1=poor, 5=excellent).
214355400|NCT05909631|OTHER|placebo|250 ml of a placebo
214355401|NCT05909631|OTHER|Mediterranean diet alone (MeD)|Mediterranean diet alone (MeD)
214355402|NCT05909631|COMBINATION_PRODUCT|Mediterranean diet with beet juice (BJ+MeD)|Mediterranean diet with beet juice (BJ+MeD).
214964114|NCT04585490|DRUG|Durvalumab|Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)
214964115|NCT04585490|DRUG|Carboplatin|Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle
214355403|NCT06497452|DRUG|Glofitamab|Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling
214355404|NCT00224874|DRUG|Etanercept|Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].
214964116|NCT04585490|DRUG|Pemetrexed|500mg/m2 on Day 1 of every 21-day cycle
215080463|NCT02781792|OTHER|Functional Assessment of Cancer Therapy - Brain|"* 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire \[2\] that includes 27 items.~* Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~* The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia."
215080464|NCT02781792|OTHER|ActTrust Condor Instrument Watch|-Will be required to wear 24 hours per day and will only be removed at specified data collection time points
215080465|NCT03593135|DIETARY_SUPPLEMENT|Apple Cider Vinegar and tablet Tagipmet (Metformin + Sitagliptin group)|15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time, for 3 months and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
214355405|NCT00224874|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].
214355406|NCT00224874|DRUG|Denileukin Diftitox|Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].
214355407|NCT00224874|DRUG|Pentostatin|Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
214355408|NCT02519010|DRUG|Amlodipine/Valsartan|1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
214964117|NCT04585490|DRUG|Paclitaxel|175mg/m2 on Day 1 of every 21-day cycle
215080466|NCT03593135|OTHER|Water with Apple Cider vinegar flavor and tablet Tagipmet (Metformin + Sitagliptin group)|Flavor of apple cider vinegar in 200 ml water is added and given to have a placebo effect and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
215080467|NCT02699008|DRUG|Clopidogrel|Antiplatelet agent
215080468|NCT02699008|DRUG|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
215080469|NCT02172495|DRUG|Tiotropium bromide|Tiotropium bromide 18 micrograms
215080470|NCT03283969|OTHER|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
215080471|NCT03283969|OTHER|Isocaloric powder|Isocaloric powder
215080472|NCT01703117|DRUG|Riluzole|20-22 subjects between the ages of 60-85 will receive study drug.
215080473|NCT01703117|DRUG|Placebo|20-22 subjects between the ages of 60-85 will receive placebo
215080474|NCT05768204|DRUG|Prednisolone Acetate|The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.
214964118|NCT04585490|DRUG|Cisplatin|Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin
214964119|NCT04585490|DEVICE|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
214964120|NCT04585490|DRUG|Tremelimumab|not to exceed 75mg IV on Day 1 of every 21-day cycle
214964121|NCT06262633|DEVICE|Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation|Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism.
214964122|NCT00826410|DEVICE|Redon drain|subcutaneous suction drain after laparotomy for two days
214355409|NCT02519010|DRUG|Exforge|1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
214355410|NCT04991168|OTHER|Questionnaire|Two questionnaires used to assess the state of knowledge and practices in oral health. An oral assessment will be carried out for voluntary patients.
214355411|NCT03932851|OTHER|IVF-ET|HBV-infected pregnant women and non-HBV-infected pregnant women underwent IVF operation
214355412|NCT04940429|DEVICE|Neurofit|This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.
214355413|NCT04940429|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score|During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
214355414|NCT00056251|PROCEDURE|H&P; ECG; Blood tests; voiding diary; Cystoscopy|
214964123|NCT05820243|OTHER|Moderate Intensity Aerobic Exercise|Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).
214964124|NCT01932749|DEVICE|Transcranial Magnetic stimulation|
214502702|NCT05162716|DEVICE|Single-chamber pacemaker implantation with left bundle branch area pacing|A prepectoral single-chamber pacemaker is implanted with a 3830 (Medtronic) IS-1 pacing lead screwed via the right ventricle in the deep interventricular septum in order to capture the left Purkinje system on the left ventricular endocardial side.
214964125|NCT04090385|DEVICE|Transcranial Direct Current Stimulation|Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
214964126|NCT02090686|DEVICE|Pulsatile Cupping|"8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.~Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)"
214964127|NCT02090686|DEVICE|Minimal Cupping|8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
214964128|NCT02800005|DEVICE|AFA group (successive patients)|The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.
214964129|NCT02800005|OTHER|BMI group (successive patients)|The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
214964130|NCT03726073|DEVICE|Transcutaneous acupoint electrical acupoint stimulation(TEAS) and auricular acupressure|Bilaterally Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) will be used as the TEAS acupoints. Six acupoints (Shenmen, Point Zero, subcortex, heart, liver, and endocrine) located on ears will be used as the auricular acupressure points.
214964131|NCT03726073|OTHER|Usual care|Patients in this group only receive usual care developed by the study hospital
214964132|NCT06380205|DRUG|Povorcitinib|Povorcitinib will be administered at protocol defined dose.
214964133|NCT06380205|DRUG|Levonorgestrel/Ethinyl estradiol|Levonorgestrel/Ethinyl estradiol will be administered at protocol defined dose.
214964134|NCT00417157|DRUG|recombinant FSH (Puregon, Organon, The Netherlands)|
214964135|NCT00417157|DRUG|GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands)|
214964136|NCT00417157|DRUG|hCG (Pregnyl, Organon, The Netherlands)|
214964137|NCT05707390|DRUG|Mezigdomide|Specified dose on specified days
214964138|NCT02843815|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
214964139|NCT02843815|BIOLOGICAL|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
215080475|NCT05768204|OTHER|placebo|A placebo consistent in appearance with the prednisolone acetate.
215080476|NCT00683917|DRUG|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
215080477|NCT00683917|DRUG|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
215080478|NCT00683917|DRUG|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
215080479|NCT02583230|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
215080480|NCT06180330|OTHER|Aquatic baby class|The intervention will consist of exercises for infants. They will be in the water together with parents
214964140|NCT01680809|DEVICE|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
214964141|NCT01680809|DEVICE|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
214964142|NCT04232020|DIAGNOSTIC_TEST|Mismatch repair|MSI testing using Biocartis Idylla and MMR immunohistochemistry
214964143|NCT05787860|DRUG|Ruxolitinib 1.5% Cream|topical ruxolitinib 1.5% cream twice daily for 4 weeks
214502703|NCT03611075|OTHER|No Intervention|No interventions are administered in this study
214502704|NCT00196521|DEVICE|Tension-free vaginal tape obturator system|
214964144|NCT02404402|OTHER|LED|Low Level Light Therapy
214964145|NCT02404402|OTHER|sham LED|Inactive (sham) LED treatment
214964146|NCT01441869|DRUG|Onglyza (saxagliptin)|Oral tablets, 5 mg , single dose
214964147|NCT01441869|DRUG|Diabex|Extended release oral tablets, 1000 mg, single dose
214964148|NCT01441869|DRUG|5-mg saxagliptin/1000 mg metformin|Extended release fixed dose combination tablet, single dose
215080481|NCT01170598|OTHER|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
215080482|NCT00575432|RADIATION|diffusion MRI|diffusion MRI
215080483|NCT00575432|RADIATION|BOLD MRI|BOLD MRI
215080484|NCT00575432|OTHER|Clinical Outcome|Clinical outcome
215080485|NCT04251780|PROCEDURE|Surgical Treatment of Hyperaldosteronism|Surgery of an Aldosterone-producing adenoma
214964149|NCT01441869|DRUG|Diabex|Extended release oral tablets, 500 mg, single dose
214964150|NCT01441869|DRUG|5-mg saxagliptin/500 mg metformin|Extended release fixed dose combination tablet, single dose
214964151|NCT06247839|DRUG|Psilocybin|COMP360 (Brand name of psilocybin to be used)
214964152|NCT02201589|DEVICE|Endovascular repair with Valiant PS-IDE Stent Graft|Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
214964153|NCT04609423|DIETARY_SUPPLEMENT|Cod liver oil|5 ml of cod liver oil as a source of 10 ug of vitamin D and 1.2 g of long-chained n-3 polyunsaturated fatty acids (DHA 0,6g and EPA 0,4g) per day for 6 months x 1 time/day together with the first meal of the day. 5ml of Cod liver oil also contains 250ug vitamin A and 10 mg vitamin E.
214964154|NCT04609423|DIETARY_SUPPLEMENT|Corn oil (placebo)|5 ml of corn oil per day for 6 months x 1 time/day together with the first meal of the day
214964155|NCT02423811|DIETARY_SUPPLEMENT|Fursultiamine|Use of Fursultiamine in addition to CCRT
214964156|NCT05022459|DRUG|Emicizumab|Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A
214964157|NCT05022459|DRUG|FVIII|Patients in this group will be on standard of care FVIII prophylaxis for Hemophilia A
215080486|NCT04251780|DRUG|Drug treatment of Hyperaldosteronism|Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.
214964158|NCT01065558|DRUG|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
214964159|NCT01237288|DRUG|Z-521|
214964160|NCT06958393|DRUG|Dexmedetomidine|Continuous infusion at 0.5-1.0 μg/kg/h during surgery
214964161|NCT06958393|DRUG|Esketamine|Induction dose 0.3-0.5 mg/kg; maintenance 0.2-0.5 mg/kg/h; 0.02 mg/kg at closure; PCIA: 1.5 mg/kg in 100 mL saline
214964162|NCT06958393|DRUG|Esmolol|Maintenance 20-100 μg/kg/min during surgery
214964163|NCT06958393|DRUG|Sufentanil|0.3-0.5 μg/kg induction; 0.15 μg/kg at closure; 2 μg/kg in 100 mL for PCIA
214964164|NCT06958393|DRUG|Remifentanil|0.2-1.0 μg/kg/min maintenance
214964165|NCT05672316|BIOLOGICAL|Balstilimab|Given IV
214964166|NCT05672316|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214964167|NCT05672316|BIOLOGICAL|Botensilimab|Given IV
214964168|NCT05672316|PROCEDURE|Computed Tomography|Undergo CT
215080487|NCT03741803|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds after birth
215080488|NCT03741803|PROCEDURE|Early cord clamping|The umbilical cord will be clamped as soon as feasible after birth, usually within the initial 15 seconds after birth.
215080489|NCT05960305|OTHER|P1213416|Tobacco Flavor
215080490|NCT05960305|OTHER|P1213422|Tobacco Flavor
215080491|NCT05960305|OTHER|P1213716|Tobacco Flavor
214964169|NCT05672316|DRUG|Regorafenib|Given PO
214964170|NCT00832988|OTHER|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
214964171|NCT00519467|DRUG|Chlorproguanil-dapsone-artesunate (CDA)|
214964172|NCT05575739|DIAGNOSTIC_TEST|Measurement of oxidative stress levels (Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins )|Follicular fluid and serum were obtained within 1 hour of oocyte recovery. Considerable care was taken to pool follicular fluid uncontaminated with blood. The samples were processed by centrifuge and 1-mL aliquots stored ar -80ºC until assay. Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins were measured from follicular fluid and plasma according to manufacturer's protocol. This assay has been described as highly sensitive. Data were expressed as millimoles per liter from the reference curve.
214964173|NCT05178823|DRUG|Chlorhexidine mouthwash|Comparison of oral rinses
214964174|NCT03539276|BEHAVIORAL|Knowledge exchange|OptimaMed
214964175|NCT06428266|DEVICE|Bicanalicular intubation|Placement of the bicanalicular intubation set at each lacrimal point and fixed by means of its flaps at the level of the opening of the lacrimal sac.
214964176|NCT06428266|PROCEDURE|Closed dacryointubation|Placement of dacryointubation tube through the canaliculus until it reaches the medial wall of the lacrimal sac and then passed the nasolacrimal duct until it empties out at the level of the inferior meatus.
214964177|NCT01010737|BIOLOGICAL|Multimeric-001 250 mcg|Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
214964178|NCT01010737|BIOLOGICAL|Adjuvanted Multimeric-001 250mcg|Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
214964179|NCT01010737|BIOLOGICAL|Placebo|Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
214964180|NCT01010737|BIOLOGICAL|Adjuvant: Montonide isa 51 VG|Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
214964181|NCT01010737|BIOLOGICAL|Multimeric-001 500 mcg|Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
215080492|NCT05960305|OTHER|P1213722|Tobacco Flavor
215080493|NCT05960305|OTHER|P1211216|Menthol Flavor
215080494|NCT05960305|OTHER|P1211222|Menthol Flavor
215080495|NCT05960305|OTHER|P1213616|Menthol Flavor
215080496|NCT05960305|OTHER|P1213622|Menthol Flavor
215080497|NCT05960305|OTHER|P1213816|NTNM Flavor
215080498|NCT05960305|OTHER|P1213822|NTNM Flavor
215080499|NCT05960305|OTHER|P1211916|NTNM Flavor
215080500|NCT05960305|OTHER|P1211922|NTNM Flavor
215080501|NCT02119156|DRUG|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
214964182|NCT01010737|BIOLOGICAL|Adjuvanted Multimeric-001 500mcg|Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
215080502|NCT04108715|PROCEDURE|Erector spina plain block for mastectomy analgesia|After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
214964183|NCT01010737|BIOLOGICAL|TIV|Injection of the conventional flu vaccine: Vaxigrip to all study participants.
214964184|NCT04756622|DRUG|N acetyl cysteine|N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
214964185|NCT02100839|DRUG|AEM-28|Solution for injection
214964186|NCT02100839|DRUG|Normal Saline|0.9% saline for injection
214964187|NCT02343367|BEHAVIORAL|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
214964188|NCT02343367|OTHER|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
214964189|NCT02343367|BEHAVIORAL|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
214964190|NCT02343367|BEHAVIORAL|Text messages|regularly scheduled cell phone text messages for 12 months
214964191|NCT02343367|BEHAVIORAL|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
214964192|NCT02343367|BEHAVIORAL|Newsletters|12 monthly newsletters mailed to participant homes
214964193|NCT01087164|BEHAVIORAL|Compliance|Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
214964194|NCT01087164|BEHAVIORAL|Message sidedness|Parent will receive either a one-sided or two-sided message about the HPV vaccine
214964195|NCT03446092|BEHAVIORAL|Mindfulness for health|A course of mindfulness using the mindfulness for health programme.
214964196|NCT02653365|DEVICE|Non-invasive ventilation|Noninvasive ventilation (NIV) was performed with a noninvasive ventilator (BiPAP Synchrony®, Respironics Inc., Murrysville, PA, USA).
214964197|NCT04515836|DRUG|Olaparib|Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
214964198|NCT05181098|PROCEDURE|Robotic-guided spine surgery|The Mazor X Stealth Edition robotic platform will be used to guide posterior instrumentation during spine fusion surgery.
214964199|NCT00678847|DEVICE|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
214964200|NCT00678847|DEVICE|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
214964201|NCT03967860|DIAGNOSTIC_TEST|CT scan|Post surgical standard CT Scan as predictor of complication
214964202|NCT03440619|DEVICE|INVSENSOR00013|Investigational pulse oximeter device that will be placed on the subject's finger. This will be used as a spotcheck device
214964203|NCT03281746|PROCEDURE|Dental Procedure|Undergo dental examination
214964204|NCT03281746|OTHER|Educational Intervention (prevention education)|Receive prevention education
214964205|NCT03281746|OTHER|Interview|Ancillary studies
214964206|NCT03281746|OTHER|Survey Administration|Ancillary studies
214964207|NCT03281746|OTHER|Educational Intervention (one-on one education)|Receive one-on-one education
214964208|NCT03194178|OTHER|Pierre Robin sequence patients|"4 questionnaires will be completed by the patient :~* Kidscreen 52 (generic quality of life questionnaire)~* Voice Handicap Index : VHI-9i (specific quality of life questionnaire)~* Child Oral Health Impact Profile : COHIP (specific quality of life questionnaire)~* MDI-C (composite depression scale for minors)"
214964209|NCT04248946|OTHER|Transcranial direct current stimulation|tDCS alters neural excitability in a polarity-specific manner via a weak direct electric current delivered through electrodes placed on the scalp. There are 3 types of stimulation: anodal, cathodal, and sham. In anodal tDCS, the positive electrode is placed over the target brain area to increase neuronal excitability. In cathodal tDCS, the negative electrode is placed over the target brain area to decrease neuronal excitability. Sham tDCS emulates the physical sensations of active (anodal/cathodal) tDCS but current is only delivered for a short period of time and is not enough to cause any neuromodulations
214964210|NCT04955795|BEHAVIORAL|Alcohol Brief Intervention (BI)|The BI we will use was based on CETA's substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring change, goal setting, identifying the reasons, and skill building) including a 2-week alcohol timeline follow back assessment, which is completed by the therapist. BI will be provided by a trained research assistant who has completed consent, enrollment, and randomized procedures with the client.
214678974|NCT06123429|BEHAVIORAL|Mindfulness Based Stress reduction|"The MBSR course will consist of weekly sessions lasting two and a half hours, involving lecture, meditation, and self-reflection.~Mindfulness-Based Stress Reduction (MBSR) is a structured program designed to help individuals manage stress, increase self-awareness, and promote overall well-being. Developed by Dr. Jon Kabat-Zinn in the late 1970s, MBSR combines elements of mindfulness meditation and cognitive-behavioral techniques. MBSR is a comprehensive program that equips individuals with practical skills to better manage stress and enhance their mental and emotional well-being. Its emphasis on mindfulness, self-awareness, and the integration of these practices into daily life makes it a valuable resource for those seeking to reduce stress and improve their overall quality of life."
214964211|NCT04955795|BEHAVIORAL|Common Elements Treatment Approach (CETA) via Telemedicine|CETA consists of nine key elements (i.e. engagement and education; safety assessment and planning; psychoeducation/introduction; substance use reduction; behavioral activation; cognitive coping/restructuring; relaxation; exposure; and problem solving) that address common mental health problems such as trauma, PTSD, depression, and anxiety. Participants randomized to CETA will be assigned to a CETA provider (clinical psychology or social work graduate student or master's degree substance abuse counselor). Enrolled participants will be discussed at weekly supervision meetings. An individualized treatment plan will be designed for each participant including type and order of CETA modules. The counselor will contact the participant by phone to schedule CETA sessions and follow up any missed appointments. Counselors, who will also be given a unique ID# for documentation and analysis, will carry 3-10 active CETA cases at a time depending on their experience level.
214487256|NCT06770205|OTHER|kendall Exercise Group A|"The group B will receive Proprioceptive Neuromuscular Facilitation technique for stretching and rhythmic stabilization technique for strengthening. Proprioceptive Neuromuscular Facilitation (PNF) is a stretching technique utilized to improve muscle elasticity and has been shown to have a positive effect on active and passive range of motions. The PNF group performed the intervention for 30 minutes a day, six times a week, a total of 24 times. (13) In this group, two types of PNF techniques were given:~1. first is strengthening technique included rhythmic stabilization that is characterized by alternating isometric contractions against resistance, no motion intended to apply for the weak muscles of upper cross syndrome included deep neck flexors specifically lower trapezius and serratus anterior.~2. Second is stretching technique included contract relax that is resisted isotonic contractions of the restricting muscles (antagonists) followed by relaxation and movement"
214964212|NCT00844779|PROCEDURE|Bariatric surgery|Gastric bypass.
214964213|NCT00844779|PROCEDURE|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
214964214|NCT01427010|RADIATION|[18F]FDG-PET-voxel intensity-based IMRT|Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography (\[18F\]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
214678975|NCT00404768|DRUG|GSK221149A|6mg/h and 12 mg/h
214678976|NCT00404768|DRUG|Placebo|Matched Placebo to Drug
214678977|NCT01829789|BEHAVIORAL|Group Community Reinforcement Training for Parents|
214678978|NCT01829789|BEHAVIORAL|Individual Community Reinforcement Training for Parents|
214678979|NCT04446234|DRUG|Risperidone|Use medicine according to patients condition
214678980|NCT04446234|DRUG|Aripiprazole|Use medicine according to patients condition
214678981|NCT04446234|DRUG|Ziprasidone|Use medicine according to patients condition
214678982|NCT04446234|DRUG|Amisulpride|Use medicine according to patients condition
214678983|NCT04446234|DRUG|Quetiapine|Use medicine according to patients condition
214964215|NCT01058291|DRUG|KW-6500|Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
214964216|NCT01058291|DRUG|KW-6500 Placebo|Twelve weeks subcutaneous injection for the OFF state
214964217|NCT00703677|DRUG|Lithium|All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
214964218|NCT03103256|DRUG|YHP1701|PO, Once daily (QD), 8 weeks
214964219|NCT03103256|DRUG|YHR1703|PO, Once daily (QD), 8 weeks
214964220|NCT03103256|DRUG|YHR1704|PO, Once daily (QD), 8 weeks
214964221|NCT05201326|DRUG|Bevacizumab，Irinotecan and Re-radiotherapy|All patients with recurrent glioblastoma will accept irinotecan and bevacizumab combined with re-radiotherapy .
214964222|NCT04389528|OTHER|Neuromodulation by tDCS|The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
214964223|NCT05930171|PROCEDURE|Ultrasound guided L-ESPB and PENG block using Bupivacaine|Combined Lumbar Erector Spinae Plane Block and Pericapsular Nerve Group Block in Patients Undergoing Hip Surgeries
214964224|NCT05930171|DRUG|Postoperative conventional analgesia in form of Acetaminophen|Postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
214964225|NCT02809352|BIOLOGICAL|Human papillomavirus genotyping|
214678984|NCT01962636|DRUG|Fludarabine|25 mg/m\^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
214678985|NCT01962636|DRUG|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
214678986|NCT01962636|RADIATION|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
214678987|NCT01962636|DRUG|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
214964226|NCT03885323|DEVICE|RF utilizing powered toothbrush|RF utilizing Powered toothbrush
214964227|NCT03885323|DEVICE|Control placebo with no RF|Placebo control, with no RF
214964228|NCT05133583|OTHER|Laughter yoga|"The experimental group was interviewed in an online meeting prepared by a certified LY trainer.~She received LY exercises once a week (40 minutes per session) for 6 weeks (6 sessions). Each The meeting was organized with a maximum of 12 people."
214355415|NCT02607995|BEHAVIORAL|Behavioral standardized manual-based multidisciplinary routine care|Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
214964229|NCT01085422|DRUG|ABT-888|Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
215080503|NCT04108715|PROCEDURE|Deep serratus anterior plane block|After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
214964230|NCT01085422|DRUG|temozolomide|Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
214964231|NCT00940888|DEVICE|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
214964232|NCT05497297|DRUG|HSK7653 tablets|HSK7653, tablet, oral
214964233|NCT03688347|PROCEDURE|Nasal Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently inserted less than one inch into the anterior nare (nostril) until resistance is met at turbinate. Then it is rotated several times against nasal wall and repeated in other nostril using the same swab.
214964234|NCT03688347|PROCEDURE|Oral Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently rubbed along the inside of the participant's cheek for 5-10 seconds.
214964235|NCT03688347|OTHER|Stool Collection|A stool collection kit will be sent home with each participant. It will include instructions on how to collect the stool specimen and how to return the kit.
214964236|NCT03688347|GENETIC|Microbiome analysis|Study of microbial communities found in and on the human body.
214964237|NCT03688347|GENETIC|DNA Banking|Secure, long term storage of an individual's genetic material.
214964238|NCT03688347|PROCEDURE|Skin Swab|Gentle rubbing of the swab will be applied to the skin on the dorsal part of the hand.
214964239|NCT03923777|OTHER|Active Surveillance|Agreeing to postpone treatment while continuing with a CT scan surveillance regimen to follow tumor growth. SABR should be offered if either the tumor is \>3 cm in size or the VDT decreases to \<400 days.
214964240|NCT01535469|DRUG|Fluconazole|Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
214964241|NCT03215875|DRUG|Fed- 60mg ER Torsemide|60mg ER Torsemide will be given after high fat, high-calorie meal
214964242|NCT03215875|DRUG|Fasting- 60mg ER Torsemide|60mg ER Torsemide will be given after overnight fasting
214964243|NCT01963559|DRUG|Lidocaine/prilocaine 1g (topical administration)|Cutaneous blood flow measurement using laser Doppler
214964244|NCT04441788|DRUG|ION-827359|ION-827359 administered by oral inhalation
214964245|NCT04441788|DRUG|Placebo|Placebo administered by oral inhalation
214964246|NCT04441788|DRUG|ION-827359|ION-827359 administered by oral inhalation
214964247|NCT03003702|DEVICE|Nonin|
214964248|NCT02415192|DRUG|Levacalm|
214964249|NCT02415192|DRUG|Valsartan/amlodipine|
214964250|NCT01344694|OTHER|patient with liver fat|30 patient with liver fat
214964251|NCT01344694|OTHER|pts. with excess of visceral fat|pts. with excess of visceral fat
214964252|NCT01344694|OTHER|control|30 control subjects
214964253|NCT03547258|GENETIC|Clinical and Molecular data collection|Clinical and Molecular data collection at diagnosis, during treatment and at each relapse
214964254|NCT01196377|DRUG|Albuterol|Nebulized albuterol
215080504|NCT02017145|DRUG|Chloraprep|
214355416|NCT01638910|DRUG|EV/DNG (Qlaira, BAY86-5027)|Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
214355417|NCT06580132|DIETARY_SUPPLEMENT|Pectin|Pectin fibre (20g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
214964255|NCT03859648|DEVICE|BONEBRIDGE|Bone Conduction Implant
214964256|NCT03088228|DIAGNOSTIC_TEST|gingival crevicular fluid collection|
214964257|NCT03758768|OTHER|Blue light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
214964258|NCT03758768|OTHER|Full spectrum light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
214964259|NCT06321120|DRUG|variability-based lenvatinib regimen|Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. As per protocol, the daily dose was limited to match or remain below the patients' pre-enrollment dosage level. In the initial 4 weeks of the follow-up, participants followed a fixed standard regimen with the app serving as a reminder, allowing for an adaptation period. Subsequently, the algorithm-driven treatment plan was implemented for an additional 10 weeks.
214355418|NCT06580132|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin (10g) served as a control/ placebo to compare the effects observed with pectin.
214355419|NCT06009081|BEHAVIORAL|postural exercise|The exercises consisted of 4-way neck isometric exercises and stretching exercises for the activation of deep cervical flexors (chin tuck exercise) and combined with this exercise. This protocol consisted of protocols studied in similar studies.
214355420|NCT06009081|BEHAVIORAL|aerobic exercise|The walking program was carried out daily on a flat surface with a target of 7000 steps. This goal is based on the American College of Sports Medicine reports on the minimum recommended levels of physical activity required to achieve health benefits, which includes several design elements.
214355421|NCT05449951|OTHER|Dry needling|In dry needling filiform needle without a bore is used to mimic acupuncture t beyond the use of medicines. On the basis of purpose process and skill level it differs from acupuncture. DN is frequently used to treat pain caused by musculoskeletal structures, including as myofascial pain disorders
214355422|NCT05449951|OTHER|sustained stretching|sustained stretching is a treatment protocol in which muscle goes into a stretch position for period of time which reduce spasticity
214355423|NCT05591508|DIETARY_SUPPLEMENT|Ketogenic Diet|Ketogenic diet will be in the form of artificial powder which can be diluted and given through NG tube. It will be started at a ratio of 1:1 followed by daily increment (2:1,3:1 and 4:1) till a urine ketone of 2+ is seen
214355424|NCT03764332|DEVICE|Stabilometry|To evaluate the static balance of subjects when barefoot and when using three types of footwear with their eyes closed or open.
214355425|NCT05377580|DRUG|Period 1 IBI112 Placebo|Intravenous Injection
214355426|NCT05377580|DRUG|Period 2 IBI112 dose 3|Subcutaneous injections
214355427|NCT05377580|DRUG|Period 1 IBI112 dose 1|Intravenous Injection
214355428|NCT05377580|DRUG|Period 1 IBI112 dose 2|Intravenous Injection
214355429|NCT05377580|DRUG|Period 2 IBI112 dose 4|Intravenous Injection
214355430|NCT05377580|DRUG|Period 2 IBI112 Placebo|Subcutaneous injections
214355431|NCT05886270|OTHER|Housing Assessment/Safety Modifications|A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
214355432|NCT01191164|PROCEDURE|Partial Breast Irradiation Utilizing Permanent Breast Seed Implant|"Target Volumes: The surgical cavity will be assessed with US \& CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.~Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.~Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre."
214355433|NCT01961336|DRUG|Testosterone|10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
214355434|NCT06634576|DEVICE|Smooth pursuit neck torsion test|Used custom-made system to stimulate the procedure of smooth pursuit neck torsion test in the current study, the multiple axis motion platform can adjust the neck postures to three different neck motion planes, seven different neck postures.
214964260|NCT03313531|DIAGNOSTIC_TEST|Thrombin Generation Assay|Inter lab variation and level of agreement will be determined
214964261|NCT03313531|DRUG|Treatment with recombinant coagulation factor|To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
214964262|NCT03977987|DRUG|nucleos(t)ide analogue|Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
215080505|NCT04393272|DEVICE|Three dimensional sensor system designed for fall detection (Fearless)|Detection of falls in nursing home residents and acute geriatric hospital patiients
214355435|NCT05301751|DRUG|AG-73305|AG-73305 Ophthalmic Solution
214355436|NCT00814294|DRUG|placebo|placebo capsule,0 units, quater in die (QID) for 18 weeks
214355437|NCT00814294|DRUG|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)|Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.
214355438|NCT00814294|DRUG|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)|Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
214355439|NCT03314415|DEVICE|Aldebaraan Nao H25|The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.
214355440|NCT04588961|PROCEDURE|Trapeziectomy with suspensionplasty|Surgical removal of trapezium bone and ligamentoplasty of first metacarpal bone using abductor pollicis tendon
214355441|NCT04588961|PROCEDURE|Joint alloplasty|Surgical removal of degenerated joint surfaces nad replacement using modern designed prothesis
214355442|NCT05400434|BEHAVIORAL|Standard Parent-Child Interaction Therapy (PCIT)|PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
214355443|NCT05400434|BEHAVIORAL|Natural Helpers (NH)|Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
214964263|NCT01018745|DRUG|BMS-907351 (XL184)|Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
214964264|NCT06321185|PROCEDURE|Subcostal TAP block|"Subcostal TAP block will be applied after intubation and before surgery. A local anesthetic solution of 20 ml 0.25% bupivacaine for each side will be injected bilaterally between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
214355444|NCT04100200|DIETARY_SUPPLEMENT|Mixed berries|Strawberry and red raspberry
214355445|NCT04100200|DIETARY_SUPPLEMENT|FOS|Fructo-oligosaccharide
214355446|NCT04100200|DIETARY_SUPPLEMENT|Control|Placebo similar in color to mixed berry supplement without any polyphenols
214355447|NCT04100200|DIETARY_SUPPLEMENT|Combination|Mixed berry composite + FOS
214355448|NCT06116903|GENETIC|Blood sampling|Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
214355449|NCT04310592|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
214964265|NCT06321185|OTHER|Port site local anesthetic infiltration|"After intubation and before port placements, a solution of 20 ml 0.25% bupivacaine will be infiltrated into the laparoscopic port sites. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
215080506|NCT05732636|OTHER|Validation study|"The whole protocol is divided into two stages: Urdu Translation and validation. Following steps were involved.~1. First version (Forward Translation): Forward translation from the English to Urdu by two bilingual translators (Version 1)~2. Second Version: Three experts compared the original FADI with urdu version of FADI.~3. Backward translation: Version 2 was translated Back in English by an independent translator.~4. Third Version: was finalized after tracking differences in forward and backward translation.~5. Final Version: of Urdu FADI was used on Chronic Ankle Instability patients.~Foot and Ankle Disability Index(FADI) Urdu version was introduced and the patients were asked to fill FADI Urdu version. The questionnaire was filled again by the same participants after one week to assess the test retest reliability."
215080507|NCT02572232|DEVICE|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
215080508|NCT04421872|OTHER|receiving general anesthesia|patients receiving surgery under general anesthesia
214355450|NCT06511232|DRUG|Intraosseous Morphine|More recently, intraosseous infusion of analgesics and antibiotics has gained traction in the total joint arthroplasty literature. In knee arthroplasty patients, the combination of a spine and adductor canal block with an intraosseous infusion of morphine into the tibial tubercle prior to incision yielded lower pain in the immediate postoperative period and at 2 weeks, less pain medication use, and significantly better patient-reported outcomes while also reducing systemic opioid exposure in the early postoperative period compared to the spine and adductor block alone.3 No study to date in the available literature has evaluated the efficacy of intraosseous morphine infusion in managing acute postoperative pain in patients undergoing ACL reconstruction with bone-patellar tendon-bone autograft, so that is the intended evaluation point with this project.
214355451|NCT01753687|OTHER|Ocular scattering of the tear film|
214355452|NCT01753687|OTHER|Optical Coherence Tomography (OCT)|Tear film thickness as measured with OCT
214355453|NCT01753687|OTHER|Measurement of tear film osmolarity|
214355454|NCT03175133|OTHER|Strength exercise|Strengthening exercises performed with physical therapist.
215080509|NCT02361424|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
215080510|NCT02361424|DRUG|placebo|
214355455|NCT00908154|DRUG|Placebo|Tablets to match GSK1014802
214355456|NCT00908154|DRUG|GSK1014802|Sodium channel blocker
214355457|NCT00439205|DEVICE|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
214355458|NCT00439205|DEVICE|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
214355459|NCT04369560|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.
214355460|NCT04369560|DRUG|Gadobutrol intravesical administration (4mM)|A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
214355461|NCT04369560|DRUG|Ferumoxytol intravesical administration (5 mM)|An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
214355462|NCT04907253|DRUG|Quercetin|500 mg twice daily
214355463|NCT04907253|DRUG|Placebo|twice daily
214355464|NCT05966454|DRUG|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
214964266|NCT06321185|OTHER|No intervention or local anesthetic administration|"There will not be an intervention or local anesthetic administration. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
214964267|NCT05227443|PROCEDURE|Exercise aerobic training|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide only lower limbs training exercises.
214964268|NCT05227443|PROCEDURE|Upper, lower and breathing (ULB) exercise|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide lower and upper limbs training exercises as well as breathing exercises.
214964269|NCT04076436|OTHER|Drug: Intravenous fosfomycin|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 2, 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visit on day 2: Blood collection to fosfomycin levels calculation.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
214964270|NCT04076436|OTHER|Drug: Intravenous quinolone or beta-lactam|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
214964271|NCT03289013|OTHER|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
214964272|NCT03289013|OTHER|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
214964273|NCT03289013|OTHER|LT-2|Newly developed adhesive
214964274|NCT03289013|OTHER|LT-21|Newly developed adhesive
214964275|NCT03289013|OTHER|LT-25|Newly developed adhesive
214964276|NCT03289013|OTHER|33-20|Newly developed adhesive
214964277|NCT01563731|DRUG|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
215080514|NCT01760538|BEHAVIORAL|Exercise training|exercise training
215080515|NCT01760538|BEHAVIORAL|usual care|received usual medical care after heart transplantation
215080516|NCT00464061|DRUG|Volinanserin|oral administration
215080517|NCT00464061|DRUG|Placebo|oral administration
215080518|NCT00152711|DEVICE|nCPAP|
214355465|NCT05966454|DRUG|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
214355466|NCT05109091|DRUG|ATH434 dose level 1|ATH434 taken BID
214355467|NCT05109091|DRUG|ATH434 dose level 2|ATH434 taken BID
214964278|NCT02758288|OTHER|New Protocol - BK viremia or BK virus nephropathy|Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
215080519|NCT01431014|DRUG|"Dexamethasonelow-dose"|5mg
215080520|NCT01431014|DRUG|"Dexamethasonehigh-dose"|15 mg
215080521|NCT02705014|DRUG|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
215080522|NCT01810068|PROCEDURE|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
215080523|NCT01810068|PROCEDURE|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
215080524|NCT01810068|PROCEDURE|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
215080525|NCT01810068|PROCEDURE|Diagnostic cystoscopy|Cysto-urethroscopy
215080526|NCT01060436|DEVICE|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
215080527|NCT00580580|DRUG|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
215080528|NCT00580580|DRUG|Definity|intravenous injection at 0.05-0.20 mL
215080529|NCT00580580|DRUG|PESDA|intravenous injections dosage 0.05-0.20 mL
215080530|NCT02685748|DRUG|Aspirin|1000 mg pd in two doses
215080531|NCT02685748|DRUG|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
215080532|NCT02685748|DRUG|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
215080533|NCT00328653|DRUG|Cyclosporine NOVA22007 0.05%|
215080534|NCT00328653|DRUG|Cyclosporine NOVA22007 0.1%|
215080535|NCT00328653|DRUG|Vehicle|
215080536|NCT03009708|OTHER|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
214355468|NCT05109091|DRUG|Placebo|Placebo taken BID
215080537|NCT02510651|PROCEDURE|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
215080538|NCT04615975|DIETARY_SUPPLEMENT|Ketogenic diet with phytoextracts|Patients were provided with an individualized nutritional ketogenic plan during hospitalization
214964279|NCT02758288|OTHER|Standard Protocol - BK viremia or BK virus nephropathy|Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
214964280|NCT01700257|RADIATION|CT scan & Early CDT Lung test|
214964281|NCT01700257|OTHER|CT scan & Early CDT Lung test|
214964282|NCT05339815|DEVICE|SMR shoulder arthroplasty|Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres
214964283|NCT02809924|OTHER|Simulation-based just-in-time training|Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
214964284|NCT02809924|OTHER|Video training|Video describing endotracheal intubation
214964285|NCT05505383|OTHER|Exercise training|People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
214964286|NCT04099238|DRUG|Oral anticoagulant|Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
214964287|NCT04553614|BEHAVIORAL|Home-based HIIT|Home-based HIIT uses body-weight equipment free exercises. Participants complete all exercise in their own own at a time of their choosing. This potentially removes many of the barriers preventing at risk-individuals from engaging with the current exercise referral scheme, such as cost, time or intimidating gym environment.
214964288|NCT04553614|OTHER|Control|Usual exercise referral scheme procedure.
214964289|NCT03336814|DRUG|Terlipressin|Administration of terlipressine
214964290|NCT03336814|OTHER|Placebo|Administration of placebo
214964291|NCT01275989|OTHER|Ear acupuncture|
214964292|NCT02806856|DEVICE|tDCS neuroConn|Cathodal on M1
214964293|NCT02806856|DEVICE|Sham stimulation|Sham
214964294|NCT00640939|DRUG|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
214964295|NCT00640939|DRUG|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
214964296|NCT05733845|OTHER|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
214964297|NCT02212925|DRUG|BI 14332 CL|
214964298|NCT02212925|DRUG|Placebo|
214964299|NCT05376761|DRUG|Dexmedetomidine|The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
214964300|NCT01952418|DEVICE|Monitor size|"Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor."
215080539|NCT02898961|DRUG|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
214355469|NCT04066127|DEVICE|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
214355470|NCT04066127|DEVICE|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
214964301|NCT03763201|DIAGNOSTIC_TEST|measurement of GITR|serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
214964302|NCT00027547|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215080540|NCT03201692|DEVICE|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
214355471|NCT05036486|GENETIC|next-generation sequencing|Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis
214964303|NCT00027547|DRUG|cyclosporine|
214964304|NCT00027547|DRUG|cytarabine|
214964305|NCT00027547|DRUG|fludarabine phosphate|
214964306|NCT00027547|DRUG|methotrexate|
214964307|NCT00027547|DRUG|mycophenolate mofetil|
214964308|NCT00027547|PROCEDURE|allogeneic bone marrow transplantation|
214964309|NCT00027547|PROCEDURE|peripheral blood stem cell transplantation|
214964310|NCT00027547|RADIATION|radiation therapy|
214964311|NCT00256932|DRUG|alvimopan|0.5 mg
215080541|NCT03201692|DEVICE|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
215080542|NCT02703870|DEVICE|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
215080543|NCT02703870|DEVICE|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
215080544|NCT02703870|BEHAVIORAL|VRT|Vision restoration training, 10 sessions, 20 minutes
214964312|NCT00256932|DRUG|Placebo|
214964313|NCT04034212|OTHER|Singing for Lung Health group attendance|Singing for Lung Health is a group singing intervention designed for people with chronic lung diseases. Participants would attend weekly sessions lasting 1 hour.
215080545|NCT03445910|DRUG|Human chorionic gonadotropin|intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
215080546|NCT06363318|PROCEDURE|Laparoscopic appendicectomy|In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done
215080547|NCT00902993|DRUG|AZD1446|Solution, oral single and multiple dose
214355472|NCT05875181|DEVICE|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
214355473|NCT05875181|DEVICE|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
214355474|NCT06160947|OTHER|Usual Medical Care|In both the intervention and control arms of the study, usual medical care will be defined as any and all medical care provided to patients with chronic non-cancer back or neck pain at an Ontario CHC, including: primary care provider consultation visits, prescription medication (e.g., muscle relaxants, anti-inflammatories, anti-depressants, opioid and non-opioid analgesics), referral for diagnostic testing (e.g., lab work, imaging) or specialist consultation, as well as other co-interventions (e.g., visits with nurses, dieticians, social workers, or physiotherapists) as determined by their PCP. PCPs will also engage study participants in a formal effort to reduce their opioid use within the framework of each CHC's current opioid-reduction practices.
215080548|NCT00902993|DRUG|Placebo|Placebo
215080549|NCT05550038|DIAGNOSTIC_TEST|Compression ultrasound|Patients receive a 3-point compression ultrasound performed by the general practitioner to look for proximal deep vein thrombosis.
215080550|NCT02978963|BEHAVIORAL|Cognitive behavioral therapy|CBT focused on reducing intolerance of uncertainty
215080551|NCT02924714|OTHER|Discontinuation of imatinib|
215080552|NCT02536300|DRUG|Idelalisib|Idelalisib tablet administered orally
215080553|NCT03758313|OTHER|CO2 measurements|Distal etCO2, tcCO2 and paCO2 values will be recorded simultaneously in ventilated preterm infants. We will measure etCO2 in a distal position using a double lumen tube connected to an external side-stream capnometer.
215080554|NCT04348019|BEHAVIORAL|Fasting|Fasting was defined as no foods or caloric beverages.
215080555|NCT03050515|BIOLOGICAL|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
215080556|NCT00532571|DRUG|CoQ10|
215080557|NCT06605729|OTHER|e-learning|The content of this e-learning is based on most recent scientific knowledge and guidelines about the management of chronic pain and physical activity and on behavioral change. Four themes are presented: chronic pain, physical activity and chronic pain, specific populations and behavior change.
215080558|NCT06606015|DRUG|I.V Paracetamol.|Pharmacological thereby for hsPDA closure in the preterm neonates.
215080559|NCT06606015|DEVICE|Echocardiography.|It is routinely performed in neonates for PDA screening and detection of any other cardiac anomalies.
215080560|NCT06606015|DEVICE|Electrical Cardiometry|Non invasive hemodynamics monitoring
215080561|NCT06607081|COMBINATION_PRODUCT|Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention|The operative risk factors are multidisciplinary evaluated and the corresponded multimodal measures are used to optimize the whole condition of the elderly patient undergo spinal fusion surgery for his/her safty, early and fully recovery.
215080562|NCT04706273|DEVICE|GORE® VIABAHN® Endoprosthesis|Participants receiving the GORE® VIABAHN® Endoprosthesis
215080563|NCT03539289|BEHAVIORAL|MUFA Diet|Control of patient MUFA Diet
215080564|NCT03539289|BEHAVIORAL|SFA Diet|Control of patient SFA Diet
215080565|NCT02637427|BIOLOGICAL|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
215080566|NCT03745365|PROCEDURE|loop bipartition|A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
215080567|NCT01789983|BEHAVIORAL|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
215080568|NCT01789983|OTHER|Collect Blood, GA and Other Survey Tools|"* Geriatric Assessment (GA) (Version 5)~* Functional Assessment of Cancer Therapy-General (FACT)~* Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~* Outcome Expectations for Exercise (OEE) scale29~* Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~* Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~* Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
215080569|NCT01921374|BIOLOGICAL|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
214355475|NCT06160947|OTHER|Usual Medical Care + Chiropractic Care|Treatment sessions may include high-velocity, low-amplitude spinal manipulative therapy, as well as any or all of the following: spinal mobilization, soft-tissue massage/trigger point therapy, education and reassurance (e.g., pain management, ergonomic and activities of daily living recommendations), and home advice (e.g., icing, spinal stretching, core muscle strengthening, and cardiovascular exercises). As part of the intervention, chiropractic clinicians will engage PCPs in a collaborative effort to support opioid tapering. Consistent with current clinical practice guidelines, participants will be provided up to a maximum of 18 chiropractic visits during the active care period, although participants may continue with treatment after the 12-week period (e.g., one visit, every 2-4 weeks) to manage episodes of exacerbation/flare-up.
214355476|NCT01339585|DEVICE|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
214964314|NCT04362202|OTHER|Water-based Sequential Preparatory Approach|"The experimental training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises followed a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e., catching a ball thrown by the therapist).~The control aquatic therapy consists of water-based exercises, in line with suggestions of the Hydrotherapy Association of Chartered Physiotherapists Guidance on Good Practice in Hydrotherapy.~These consisted of warm-up exercises, stretching exercises for the lower limbs, recruitment exercises and walking exercises during each phase of gait (single stance, swing and double stance)."
214355477|NCT03855449|BEHAVIORAL|eDECIDE Web-based Intervention Group|"Will conduct 18 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention"
214964315|NCT03628859|BIOLOGICAL|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, everolimus, axitinib or cabozantinib \[in France only\], as per product SmPC or 1st line treatment with sunitinib or pazopanib or receiving 2nd or 3rd line of treatment with nivolumab)
214355478|NCT06506435|BEHAVIORAL|Two Dimensional (2D) Informational Video|A 30-minute informational video. The two dimensional (2D) video provides information about the radiotherapy process. Participants will receive this one-time intervention in-person, prior to treatment.
214355479|NCT06506435|BEHAVIORAL|First-Person Virtual Reality Video|A 30-minute virtual reality video, experienced through a headset, provides an immersive portrayal of the radiotherapy process from a first-person perspective. Participants will receive this one-time intervention in-person, prior to treatment.
214355480|NCT06506435|BEHAVIORAL|Third-Person Virtual Reality Video|A 30-minute virtual reality video, experienced through a headset, provides an immersive portrayal of the radiotherapy process from a third-person perspective. Participants will receive this one-time intervention in-person, prior to treatment.
214355481|NCT05157971|DRUG|Cyclophosphamide|Given IV
214355482|NCT05157971|DRUG|Cytarabine|Given SC, IV or IT
214355483|NCT05157971|DRUG|Daunorubicin Hydrochloride|Given IV
214355484|NCT05157971|DRUG|Mercaptopurine|Given PO
214355485|NCT05157971|DRUG|Methotrexate|Given IT
214355486|NCT05157971|DRUG|Pegaspargase|Given IM or IV
214355487|NCT05157971|DRUG|Prednisone|Given PO
214355488|NCT05157971|DRUG|Venetoclax|Given PO
214355489|NCT05157971|DRUG|Vincristine Sulfate|Given IV
214355490|NCT05631249|DRUG|Sotorasib 120Mg Tab|Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
214355491|NCT06952114|DRUG|Stem Cells Lenses|Each subject will wear Stem Cells Lenses for four consecutive days. After a 4-day treatment period, a 14-day follow-up observation period will be conducted to monitor for potential adverse events.
214355492|NCT04783155|DEVICE|POWERBreathe Plus®|Commercially available pressure-threshold device
214964316|NCT02586311|DRUG|CKD-330 16/5mg|Once a day, 8 weeks
214964317|NCT02586311|DRUG|Amlodipine 5mg Placebo|Once a day, 8 weeks
214964318|NCT02586311|DRUG|CKD-330 16/5mg Placebo|Once a day, 8 weeks
214964319|NCT02586311|DRUG|Amlodipine 5mg|Once a day, 8 weeks
214964320|NCT00678015|DRUG|Nordihydroguaiaretic Acid (NDGA)|NDGA 2000mg daily
214964321|NCT02377492|DRUG|Vasopressins|Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
214964322|NCT05017805|BIOLOGICAL|COVID-19 Vaccines|One dose (0.5 mL) of coronavirus vaccine was inoculated on day 0 and day 25±3, respectively.
214964323|NCT05681364|OTHER|metabonomics|profiles of metabolites in serum and exhale breath condensate (EBC) at baseline and after pulmonary rehabilitation
214355493|NCT04783155|OTHER|Cardiopulmonary rehabilitation post lung transplant|Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
214355494|NCT04808401|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
214355495|NCT06961812|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|"Next, the risk of falling will be assessed by a healthcare professional using a hetero-questionnaire and physical tests, as proposed in the algorithm for global recommendations (routine care).~These tests include a detailed characterisation of the history of falls, the Timed Up and Go, the Five Times Sit to Stand, the 4 m walking speed and the Short Physical Performance Battery."
214355496|NCT06961812|DIAGNOSTIC_TEST|Safe Self-Administered Questionnaire|"All people who agree to take part in the study will first complete the SAFE self-questionnaire (intervention).~the Self Assessment for Falls in the Elderly (SAFE), an auto-questionnaire that converts the binary items and performance tests of the 2022 World Guidelines for Falls Prevention and Management into visual analogue scales (100 mm each)."
214355497|NCT06962917|OTHER|Cross sectional study|This study is a cross-cultural study, not an intervention study. A total of 1,523 participants (484 from Germany, 548 from the United States, and 491 from Japan) were recruited.
214355498|NCT06961617|DRUG|LioCyx-M, HBV antigen-specific TCR-redirected T cells|Via intravenous (IV) infusion
214355499|NCT06962124|OTHER|serum sodium measurment|serum sodium measurment
214487257|NCT06773676|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
214487258|NCT06773676|DEVICE|Sham|The sham device is externally identical to active, emits the same guiding light and sound but does not emit the therapeutic near infrared invisible rays
214487259|NCT06778746|OTHER|no interventions|No interventions, this is an observational study
214964324|NCT02128659|BEHAVIORAL|SHE Project|Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
214355500|NCT06963086|BEHAVIORAL|Eating disorder prevention program (the Body Project)|The Body Project is an eating disorder prevention program for girls and young women aged 15-22 years old. The program will be delivered in groups of 8-10 youth by peer mentors, and in two formats: in-person and virtual. There are two versions of the program - one for high school aged individuals and one for university aged individuals. Participants will be divided into 4 cohorts: high school in-person, university in-person, high school-aged (15-18 years) virtual, and university-aged (19-22 years) virtual. The high school-aged program (in-person and virtual) consists of 4 weekly 1-hour sessions, and the university-aged program (in-person and virtual) consists of 2 weekly 2-hour sessions. Both versions cover similar content, and use a scripted intervention manual.
214355501|NCT06962319|DRUG|dihydroartemisinin-piperaquine (DP)|Weight-based dosing of 3 (\<60kg), 4 (6-80kg) or 5 (\>80 kg) 40/320 mg tablets of dihydroartemisinin-piperaquine given once daily for 3 days
214355502|NCT06962319|DRUG|Pyronaridine-artesunate (PA)|Weight-based dosing of 2 (24-\<45 kg), 3 (45-\<65kg), or 4 (\>=65 kg) 180/60 mg tablets of pyronaridine-artesunate, once daily for 3 days.
214355503|NCT06962319|DRUG|Artemether-lumefantrine|1 x 80/480 or 4 x 20/120 mg tablets of artemether-lumefantrine, given twice daily, approximately 8 hours apart for 3 days
214355504|NCT06962670|OTHER|Biomaterial collection|All subjects will be asked to provide biomaterial (blood or saliva) for bio marker screening and analysis. Additional biomaterial (breath, urin, stool) is optional.
214355505|NCT06962670|OTHER|BayPass mobile application|"All subjects will be asked to use the study-specific mobile application BayPass to complete questionnaires and provide results from screening examinations over a course of 12 months."
214355506|NCT06962813|PROCEDURE|Radiofrequency V Eraser|standar of care sclerotherapy
214964325|NCT01297543|BIOLOGICAL|human myeloid progenitor cells|Single intravenous injection/infusion
214964326|NCT01297543|DRUG|G-CSF|Background therapy
214964327|NCT01971567|DEVICE|HIRREM|
214964328|NCT03198429|BEHAVIORAL|Caring Dads|Caring Dads is a 15-week group intervention program for fathers, with an intensive intake and two additional individual sessions to set and monitor specific, individualized change goals. Major aspects of innovation in the Caring Dads program include: the use of a motivational approach to engage and retain men in intervention; consistent emphasis on the need to end violence against children's mothers alongside of improving fathering; program content addressing accountability for past abuse and a model of collaborative practice with child protection. The Caring Dads program was developed with a specific commitment to remain focused on the safety and well-being needs of children as a primary goal of intervention and with the recognition that children's safety and well-being is integrally connected to that of their mothers.
214964329|NCT03198429|BEHAVIORAL|Mothers in Mind|Mothers in Mind uses an attachment and trauma-informed psycho-educational process approach in 12 weekly sessions (10 of which are in group) with mothers. These sessions focus on raising awareness and validation about the experience of violence and the impact it has on mothering. Specifically, MIM increases mothers' awareness of the impact that exposure to family violence/trauma may have had on their infants and themselves as mothers, helps identify and promote positive parenting skills such as sensitivity and responsiveness to infant needs by increasing parental competence, helps promote emotional closeness and decreasing mothers' social isolation, increases mother and infant physical safety, and encourages positive attachment processes.
214964330|NCT02761590|OTHER|Circuit training protocol|The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
214964331|NCT03499106|DRUG|IW-1973|Oral Tablet
214964332|NCT03499106|DRUG|Itraconazole|Oral Capsule
214964333|NCT04472546|OTHER|in-vivo mesure|"* for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
214964334|NCT04472546|OTHER|Scotch|"* for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
214964335|NCT04472546|OTHER|Lipid index|"* for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face"
214355507|NCT06961656|OTHER|Intervention Group-Jigsaw IV technique|Wound care training with the Jigsaw IV technique method
214355508|NCT06961656|OTHER|Control Group-Traditional methods|Wound care training with traditional methods
214355509|NCT06962527|BEHAVIORAL|Uncertainty-focused single session intervention|Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60
214355510|NCT06962527|BEHAVIORAL|Maintaining a healthy lifestyle single session intervention|Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60
214355511|NCT06962748|DIAGNOSTIC_TEST|cerebral blood flow measurment|measuring CO using cerebral blood flow
214355512|NCT06962748|DIAGNOSTIC_TEST|TTE CO measurment|measuring CO using TTE
214355513|NCT06962748|DIAGNOSTIC_TEST|ETCO2|measure the average ETCO2 over 30 minutes period
214355514|NCT06962462|DRUG|Methyl Cellulose Placebo|Oral administration of inert methyl cellulose placebo tablets once daily for 3 months. Used as a comparator in healthy control participants to evaluate changes in Endothelin-1 and E-selectin serum levels.
214964336|NCT04472546|OTHER|Absorbant paper|"* for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead"
214964337|NCT04472546|OTHER|Hydratation Index|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
214964338|NCT04472546|OTHER|TransEpidermal Water Loss|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
214355515|NCT06962072|PROCEDURE|Surgical resection with or without radiotherapy and/or chemotherapy|The surgical resection of STS serves as the primary treatment, aiming to completely remove the tumor with a wide margin of surrounding healthy tissue to minimize the risk of recurrence. Radiotherapy and/or chemotherapy may be incorporated depending on the tumor's type, stage, and grade.
214355516|NCT06962423|OTHER|AI system|Participants will complete the research task with the AI system developed by out team to perform automated biomedical research.
214355517|NCT05596045|DRUG|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
214355518|NCT05596045|DRUG|Placebo|Participants will be randomized to receive placebo
214355519|NCT06962709|OTHER|Warmed lidocaine|Lidocaine warmed to 98 F
214964339|NCT00115206|DRUG|Neulasta® (pegfilgrastim)|
214964340|NCT00765739|OTHER|Neuromuscular electrical stimulation|neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
214964341|NCT00765739|OTHER|voluntary strengthening exercise|contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
214964342|NCT01562717|DRUG|Ibuprofen|3 times a day
214964343|NCT01562717|DRUG|Placebo|3 times a day
214964344|NCT03868189|OTHER|Electroneuromyography with ultrasound|Patients whose electroneuromyography examination will be performed using an ultrasound
215080570|NCT01921374|BIOLOGICAL|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
215080571|NCT01921374|BIOLOGICAL|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
214355520|NCT06962228|PROCEDURE|Anal fistula surgery|Anal fistula incision, anal fistula excision, anal fistula hanging
214355521|NCT06962371|DEVICE|cerebral embolic protection|Use of Transverse Medical Inc. Point-Guard CEP device.
214355522|NCT06962293|DEVICE|MAG-ESD assisted ESD|Flexible magnetic traction device would be used to assist the ESD procedure. Real time adjustment of traction could be achieved by controlling the EPM position and orientation anytime during the procedure.
214678988|NCT01962636|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
214964345|NCT03868189|OTHER|Electroneuromyography without ultrasound|Patients whose electroneuromyography examination will be performed without ultrasound (fake tracking)
214964346|NCT00929487|DEVICE|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
214964347|NCT00929487|OTHER|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
214964348|NCT00929487|DEVICE|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
214964349|NCT06260917|DIAGNOSTIC_TEST|position of urination|effect of position on uroflowmetry parameters
215080572|NCT01921374|BIOLOGICAL|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
214355523|NCT03644186|DRUG|Paclitaxel|Chemotherapy plus HER2 Blockade
214355524|NCT03644186|DRUG|Trastuzumab|Chemotherapy plus HER2 Blockade
214355525|NCT03644186|DRUG|Pertuzumab|Chemotherapy plus HER2 Blockade
214355526|NCT03644186|DRUG|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
214355527|NCT03644186|DRUG|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
214355528|NCT03644186|DRUG|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
214355529|NCT03644186|DRUG|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
215080573|NCT01921374|BIOLOGICAL|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
215080574|NCT04361604|BIOLOGICAL|Biological collection (patients co infected HIV Sras-CoV-2)|Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
215080575|NCT04361604|OTHER|Auto-questionnaires (patients co infected HIV Sras-CoV-2)|4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
214355530|NCT04897776|DEVICE|Central Thalamic Stimulation|Stimulation of the bilateral thalamic CL is a promising approach in human patients to improve conscious arousal. To restore conscious arousal by stimulation of the thalamic intralaminar CL it is necessary to provide bilateral stimulation, placing one lead in each thalamus. Bilateral thalamic CL stimulation was shown previously to improve human conscious arousal and is based on existing research in patients with disorders of consciousness.
214355531|NCT04897776|DEVICE|Hippocampal Stimulation|The hippocampus has been a target for brain stimulation for seizure reduction in epilepsy. While the efficacy of HC stimulation varies considerably among different studies, the surgical procedure and therapeutic electrical stimulation are well tolerated by patients, with few peri-operative complications being reported, and histopathologic analysis not revealing a difference between stimulated and non-stimulated hippocampal tissue (Han et al. 2014)
214355532|NCT05808101|OTHER|Neuro-QoL T-score determination|Neuro-Qol depression scale, using a T-score of 55 as a threshold
214355533|NCT05586230|DRUG|Pretomanid|Administered orally based on participant's weight
214355534|NCT05586230|DRUG|Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)|Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
214355535|NCT05392062|OTHER|Pathophysiology of gas exchange|Exploration of pathophysiology of gas exchange
214487260|NCT06777953|OTHER|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.
214964350|NCT03559283|DIAGNOSTIC_TEST|Walking and Record Cortical Activity|"The cortical activity of each patient is recorded by NIRS under the following conditions:~* Simple task : The patient walks on an electronic walking track (GAITRite system) over 10 meters. The data collected are the spatio-temporal parameters of walking.~* Cognitive task alone : two conditions of the n-back test (1-back and 2-back) to study neural activities related to working memory. The duration of realization will be 30 seconds by condition and we retain the number of errors realized.~* Double Task : Achievement of the motor task (10-meter walk) is performed at the same time as a weak cognitive task (1-back) and a high cognitive task (2-back). The spatio-temporal parameters and the number of errors are collected by the observer."
214964351|NCT05275465|DRUG|HH-006|Different dose levels of HH-006
214964352|NCT05275465|DRUG|Placebo|Different dose levels of placebo
214964353|NCT04423133|BEHAVIORAL|Online Family Literacy Program|Parent-child dyads will participate in 8 weekly online health-themed workshops that introduce language and literacy skills. Participants will also receive 2-3 text messages per week for the duration of the program and children's books.
214964354|NCT00075452|DRUG|gemcitabine hydrochloride|
214964355|NCT00075452|DRUG|oxaliplatin|
214964356|NCT02097511|DRUG|Sarpogrelate pretreatment|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days
214964357|NCT02097511|DRUG|Sarpogrelate|Sarpogrelate hydrochloride 100 mg three times a day
214964358|NCT02097511|DRUG|Metoprolol|Metoprolol Tartrate 100 mg once a day
214964359|NCT01409915|DRUG|Sagramostim|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
214964360|NCT01409915|DRUG|Saline -- placebo comparator|subcutaneous injection
214964361|NCT04826484|DRUG|Exparel 133 miligrams per 10 milliliter injection|Local wound infiltration with Exparel 133 miligrams per 10 milliliter injection
214964362|NCT04826484|DRUG|Bupivacaine Hydrochloride|Local wound infiltration with 0.25% bupivacaine.
214964363|NCT00511173|GENETIC|Warfarin Dose based on pharmacogenetics|Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
214964364|NCT02137148|DEVICE|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
214964365|NCT02250300|DRUG|MLN9708 (2.3 mg)|2.3 mg
214964366|NCT02250300|DRUG|MLN9708 (4.0 mg)|4.0 mg
214964367|NCT02250300|DRUG|MLN9708 (3.0 mg)|3.0 mg
214964368|NCT01745562|DRUG|Alprazolam 0.5 mg|Reference product
214964369|NCT01745562|DRUG|Alprazolam 0.5 mg|Test product
214964370|NCT02966132|BEHAVIORAL|iMD|Interactive video education delivered on a tablet computer
214964371|NCT02966132|BEHAVIORAL|NPA|
214964372|NCT00002125|DRUG|Foscarnet sodium|
214964373|NCT05646927|PROCEDURE|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by children preference
214964374|NCT05646927|PROCEDURE|Selection of parent(mother or father) according to randomization|The parent who will accompany the child during the perioperative period will be determined by randomization.
214964375|NCT00148044|PROCEDURE|Blood sampling for determination of uremic toxins|
214964376|NCT05630443|PROCEDURE|prone position|Ordinary ERAS treatment postoperatvely adding the prone position and voicetraining
214964377|NCT02603211|DEVICE|tactile imaging sensor or system made in our laboratory|This is a camera with elastomer tip and LED lights. It is a harmless device.
214964378|NCT04232644|DRUG|ADAIR 10mg IR capsules|manipulated ADAIR IR 3x10 mg capsules
214964379|NCT04232644|DRUG|Crushed d-amphetamine sulfate IR tablets|crushed d-amphetamine sulfate IR 6 x 5 mg tablets
214964380|NCT03939923|DRUG|Rocuronium|Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.
214964381|NCT03939923|DRUG|Neostigmine|Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)
215080576|NCT04361604|OTHER|Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)|Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
215080577|NCT02567682|DRUG|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
214964382|NCT03939923|DRUG|Glycopyrrolate|Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)
214964383|NCT03939923|DRUG|Sugammadex|Reversal with Sugammadex (2mg/kg)
214355536|NCT05698238|DRUG|CA9hu-1|Humanized monoclonal antibody to human carbonic anhydrase IX
214355537|NCT00310219|PROCEDURE|computed tomography|
214487261|NCT06777953|OTHER|Popliteal Sciatic Nerve Block|This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.
214964384|NCT01288365|BEHAVIORAL|Exercise training|Exercise training program for 3 months (two times a week).
214964385|NCT00758498|DRUG|armodafinil|50 mg/day orally, once daily in the morning for 3 days
214964386|NCT00758498|DRUG|armodafinil|150 mg/day orally, once daily in the morning for 3 days
214964387|NCT00758498|DRUG|placebo|placebo tablets, once daily in the morning for 3 days
214964388|NCT01229215|DRUG|FCFD4514S|Repeating intravitreal injection
214964389|NCT01229215|DRUG|sham|Repeating sham injection
214964390|NCT04214496|DEVICE|Sedline|Intraoperative EEG monitorization
214355538|NCT00310219|PROCEDURE|positron emission tomography|
214964391|NCT01516736|DRUG|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
214964392|NCT01516736|DRUG|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.
214964393|NCT05720195|DIAGNOSTIC_TEST|ALBI|Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC
214355539|NCT06211205|DEVICE|Customized 3D printed nostril retainer combined with lip taping|the infants will receive a customised nostril retainer appliance to enhance the nasal esthetics combined with lip tape to approximate the labial and alveolar segments
214964394|NCT00125060|DRUG|Simvastatin (20mg versus 80mg/day)|
214964395|NCT03671655|DEVICE|Drug-eluting stent|Drug eluting stent which are nitinol stent coated with Paclitaxel drug
214355540|NCT06211205|PROCEDURE|Lip taping|the infants will receive lip tape to approximate the labial and alveolar segments
214355541|NCT02034747|DRUG|Advagraf|oral
214964396|NCT03671655|DEVICE|Bare metal stent|Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
214487262|NCT06779539|DRUG|Ensartinib|Ensartinib 225 mg oral once daily 12 weeks
214487263|NCT06779422|BEHAVIORAL|Pai.ACT|The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors (see NCT06086951). The contents of Pai.ACT is underpinned by: (i) the core principles of Focused ACT, (ii) our validated Focused ACT protocol used in our ongoing Focused ACT trial (see NCT05803252), and (iii) our validated ACT protocols, established since 2019, that address psychological challenges specific to the Chinese parenting context (e.g., affiliate stigma, internalisation of external criticism, self-blame) through a 4-to-6 week of ACT.
214487264|NCT06779422|OTHER|Positive parenting advice|Positive parenting advice is recommended by the Child Assessment Services under the Department of Health, and videoconferencing session(s) led by another experienced counsellor for content revision. No access to AI chatbot/ACT modules will be granted.
214487265|NCT06778720|BEHAVIORAL|Music Therapy with over-the ear headphones|Eligible patients undergoing VATS procedure can have music therapy as an intervention to reduce pain levels after surgery and improve outcomes.
214355542|NCT02034747|DRUG|Corticosteroid|oral
214355543|NCT05642390|DEVICE|Breast implant|Patients operated for breast augmentation or reconstruction.
214487266|NCT05073510|DEVICE|BVE|Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
214487267|NCT06760702|DRUG|AUR109 200mg|AUR109 200mg (once daily)
215080578|NCT01724567|OTHER|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
215080579|NCT01724567|OTHER|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
214355544|NCT04235036|DRUG|Rituximab|Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).
214355545|NCT04235036|DRUG|Ibrutinib|Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
214355546|NCT05830942|BEHAVIORAL|Walking Exercise|aerobic walking exercise using complex (cognitively engaging) walking tasks
214355547|NCT05830942|DEVICE|Prefrontal Active tDCS|20 minutes of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
215080580|NCT01080768|DRUG|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
215080581|NCT01080768|DRUG|Amlodipine|Amlodipine 5 mg/day.
215080582|NCT01080768|DRUG|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
215080583|NCT01080768|DRUG|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
215080584|NCT03832114|DRUG|LNP023|Increasing doses of LNP023 up to 200 mg.
215080585|NCT01252550|DIETARY_SUPPLEMENT|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
215080586|NCT01252550|DIETARY_SUPPLEMENT|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
215080587|NCT00338273|DRUG|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
215080588|NCT00338273|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
215080589|NCT05528367|DRUG|Nab-PTX,S-1,Tirelizumab|"S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w."
215080590|NCT05528367|RADIATION|Chemoradiation|45-50Gy/25F
215080591|NCT02351687|DIETARY_SUPPLEMENT|Lipid Nutrient Supplement|
215080592|NCT02351687|DRUG|Sulfadoxine-pyrimethamine|
215080593|NCT02351687|DRUG|Albendazole|
214355548|NCT05830942|DEVICE|Prefrontal Sham tDCS|30 seconds of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
214355549|NCT03777098|DEVICE|Strepic® Device|The Strepic® device is a qualitative point-of-care diagnostic test for the detection of GAS pharyngitis. The test uses direct visualization of the pharynx with a light source of specified wavelengths, causing excitation of endogenous fluorophores that emit a characteristic colored light pattern. White light images may give additional diagnostic accuracy through use of an artificial intelligence analysis of a large set of images of GAS and non-GAS pharyngitis.
214355550|NCT01673932|BIOLOGICAL|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
214355551|NCT01673932|PROCEDURE|surgery|
214355552|NCT06309953|DRUG|Miebo|Miebo treatment
214355553|NCT04609891|DRUG|Avatrombopag|10×109/L\<PLT\<75×109/L, avatrombopag tablet 60 mg once a day for 5-10 days.
214355554|NCT06292455|OTHER|Elastic resistance training|six-weeks elastic resistance training of upper limb. Three days per week. volume per session would be 10 repetitions and three sets. 2 minute rest interval between each set.
214355555|NCT06292455|OTHER|Conventional Resistance Training|players follow their routine exercise protocol
214355556|NCT03282448|BEHAVIORAL|family therapy|The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus \& Miller, 2014).
214964397|NCT05225025|BEHAVIORAL|ROSE|"The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based intervention that has been proven to reduce cases of post-partum depression among low-income and racially and ethnically diverse women.~ROSE is administered to pregnant women in small group settings, typically in the same location that prenatal care is being provided (in this study, a hospital setting). It is divided into four 90-minute group sessions and teaches interpersonal psychotherapy-based skills that mitigate identified risk factors for PPD such as social support, stress management skills and communication.~ROSE curriculum will be implemented using groups in a continuous cycle, with patients entering into the intervention curriculum at the time of their enrollment and continuing through until all 4 total sessions have been accomplished."
214964398|NCT05225025|OTHER|Standard of Care|Usual hospital care with no behavioral intervention
214964399|NCT03782181|DEVICE|Whole body vibration platform|A neuromuscular treatment using a rotational whole body vibration platform.
214355557|NCT05597969|BEHAVIORAL|FoodCoach|The FoodCoach app displays transparent analysis and recommendations regarding participant's food purchases recorded on their loyalty cards. It tries to help participants understand why and how they should/can shop more healthily, motivating them to change their unhealthy food purchase behavior.
214964400|NCT06336317|BIOLOGICAL|Influenza vaccine|VaxigripTetra Suspension for injection, 0,5ml prefilled syringe ATC code: J07BB02
214964401|NCT06336317|BIOLOGICAL|Placebo|Sodium Chloride Solution for infusion, 9mg/ml ATC code: B05BB01
214964402|NCT06067867|OTHER|Data extraction from medical files|Data extraction from medical files
214964403|NCT03289988|OTHER|blood sampling|NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
214964404|NCT01587105|BEHAVIORAL|Comprehensive Case Management Service|When a child enrolls in the CCM program, the child's parent will work together with the CCM team at Seattle Children's to develop a shared care plan for their child. This plan will include all of the child's routine health care needs and information about what to do when the child gets sick. The parent will also have 24 hour access to an on-call CCM nurse.
214964405|NCT01416545|BEHAVIORAL|Educational program in cardiovascular prevention|a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
214964406|NCT01416545|BEHAVIORAL|Lifestyle counseling|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
214964407|NCT00848900|BEHAVIORAL|Outdoor activity|Adding 1 hour outdoor time into school curricula
214964408|NCT04284683|OTHER|DRINK - Water, Protein, Fat, Carbohydrate|Following exercise participants will consume a drink (with different composition in each visit) and than RMR will be evaluated.
214964409|NCT03559504|DRUG|Sevoflurane Inhal Soln|Anesthesia will be induced by sevoflurane inhalation only with a tight-fitting facemask and a 4-l airflow of 100% oxygen. Sevoflurane inhalation will be adjusted in all age groups to maintain 1.0 MAC concentration
214964410|NCT00689962|DEVICE|Linvatec 4.5 mm Smart Screw|Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
214964411|NCT00689962|DEVICE|Synthes 4.0 mm steel screw|Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
214487268|NCT06760702|DRUG|AUR109 300mg|AUR109 300mg once daily
215080594|NCT02351687|DRUG|Zinc|
215080595|NCT02351687|OTHER|Insecticide-treated bednet|
215080596|NCT00931723|DRUG|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
215080597|NCT00931723|DRUG|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
215080598|NCT00931723|DRUG|Placebo|Oral treatment twice daily.
215080599|NCT02115750|DRUG|Etanercept|Head-to-head comparison
215080600|NCT02115750|DRUG|CHS-0214|
214355558|NCT02068807|DIETARY_SUPPLEMENT|Lutein drops|After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
214355559|NCT02068807|DIETARY_SUPPLEMENT|Glucose drops|After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
214355560|NCT04954118|PROCEDURE|Internal jugular vein cannulation|The clinicians performed an internal jugular vein cannulation using personal protective equipment (PPE) or both of the aerosol box and PPE provide insertion of a central venous catheter in COVID-19 patients.
214355561|NCT02192502|DRUG|human albumin 5%|
214487269|NCT06760702|DRUG|AUR109 400mg|AUR109 400mg once daily
214355562|NCT02192502|DRUG|HES 130/0.4 (Voluven)|
214355563|NCT03390205|DIAGNOSTIC_TEST|Optical coherence tomography angiography under dark and light adaptation|Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
214487270|NCT06761807|PROCEDURE|Electrophysiology study of heart|"The procedure will be done comparatively for each patient; before the device placement and immediately after the procedure.~This will be done approaching the same sheath that is placed for ASD device closure (the right femoral vein).~Only one quadripolar EP catheter will be used, it will be placed in high right atrium then at His bundle.~The EP study will include:~Assessment of SAN function using cSNRT (through HRA pacing) Assessment of AH and HV intervals (through His bundle EGM) Assessment of antegrade AVN RP (refractory period) and AVN WP (Wenckebach point) through extra-stimuli and incremental atrial pacing.~Any inducible arrhythmia will be reported"
214487271|NCT06768970|DIETARY_SUPPLEMENT|CARDIO® salmon oil|CARDIO® is a natural salmon oil manufactured from the enzymatic hydrolysis of Norwegian Atlantic salmon. Salmon capsules contain a full spectrum omega- and non-omega marine fatty acids with naturally occurring astaxanthin.
214678989|NCT01962636|BIOLOGICAL|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
214964412|NCT02726789|DRUG|REP 2139-Ca|the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
214964413|NCT02726789|DRUG|pegylated interferon|immunotherapy
214964414|NCT02726789|DRUG|entecavir|local generic entecavir
214964415|NCT03106883|BEHAVIORAL|Affective training|3 sessions of active training using affective faces to modify the negative attention bias in depression
214964416|NCT03106883|BEHAVIORAL|Sham training|3 sessions of sham attention training using non-affective stimuli
214964417|NCT01510821|OTHER|Use of Maquet Vasoshield Pressure-limiting syringe on SVG|Use of Maquet Vasoshield Pressure-limiting syringe on SVG
214964418|NCT01510821|OTHER|Use of non-regulated syringe on SVG|Use of non-regulated syringe on SVG
214964419|NCT03365934|DEVICE|ADHESIVE BANDAGE #1|Bandage applied daily to wounded site for 14 days
214964420|NCT03365934|DEVICE|ADHESIVE BANDAGE #2|Bandage applied daily to wounded site for 14 days
214678990|NCT05836740|DRUG|Minocycline hydrochloride capsule|50 mg per capsule, containing 50mg of Minocycline Hydrochloride.
214964421|NCT03365934|DEVICE|ADHESIVE BANDAGE #3|Bandage applied daily to wounded site for 14 days
214964422|NCT03365934|DEVICE|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days
214355564|NCT02645734|DRUG|bevacizumab|1.25 mg of bevacizumab is injected
214355565|NCT02645734|DRUG|ziv-aflibercept 1.25 mg|1.25 mg of ziv-aflibercept is injected
214355566|NCT02645734|DRUG|ziv-aflibercept 2.5mg|2.5 mg of ziv-aflibercept is injected
214355567|NCT06302751|DEVICE|Care 4 Today ® (Johnson and Johnson) mobile app|Care 4 Today ® (Johnson and Johnson) mobile app will cover the perioperative period spanning through the preoperative assessment day (approximately -seven to -one from surgery) to 30 days after surgery and will monitor the adherence to preoperative and postoperative recommendations.
214964423|NCT03365934|OTHER|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
214964424|NCT03365934|OTHER|Wounded and No Bandage|This test site will be wounded but will not be treated with a bandage, serving as the positive control site.
214964425|NCT01781208|DEVICE|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
214964426|NCT01307891|DRUG|Abraxane alone|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
214964427|NCT01307891|DRUG|Abraxane + Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
215080601|NCT03054350|DRUG|Vadadustat|Daily oral dose
215080602|NCT03054350|DRUG|Placebo|Daily oral dose
215080603|NCT01218451|BIOLOGICAL|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
215080604|NCT01218451|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
215080605|NCT01218451|BIOLOGICAL|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
215080606|NCT04627623|DIAGNOSTIC_TEST|IgM and IgG antibodies assay|5 ml venous blood sample collection to assay IgM and IgM against COVID19
215080607|NCT05391425|OTHER|no intervention|no intervention planned, since it is an observational study
215080608|NCT01858805|PROCEDURE|esophagectomy|
215080609|NCT00769925|BEHAVIORAL|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
215080610|NCT00769925|BEHAVIORAL|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
215080611|NCT05850910|OTHER|Supine practice group|The practitioner's arm was placed in the mid-thoracic region from the opposite side of the individual's torso in the form of a half fist. In this position, the SPs coincide with the space in the middle of the half fist, while the TPs coincide with the fingertips and the thenar region. With the practitioner's other hand supporting the patient's elbows, a high-speed-low-amplitude thrust is applied from front to back.
214355568|NCT06338982|PROCEDURE|Interoperative wisdom tooth removal in conjunction with BSSO|The objective of the present randomized controlled trial is to assess the fracture pattern, condylar segment positioning, frequency of complications, and PROMs following BSSO with or without impacted mandibular third molars. this is illustrated by the fact that the test group had their wisdom teeth removed in connection with the sagittal split of the mandible (the BSSO surgery). Subsequently, all outcome measures are compared with the control group, who had their wisdom teeth removed 6 months prior their BSSO surgery.
214355569|NCT03883633|BEHAVIORAL|ReCODE Protocol|Functional medicine approach to address symptoms of Alzheimer's and cognitive decline
214355570|NCT01381692|DRUG|Bortezomib|Given IV or SC
214355571|NCT01381692|DRUG|Dexamethasone|Given PO
214355572|NCT01381692|OTHER|Laboratory Biomarker Analysis|Correlative studies
214355573|NCT01381692|OTHER|Quality-of-Life Assessment|Ancillary studies
214355574|NCT01381692|BIOLOGICAL|Rituximab|Given IV
214487272|NCT06781866|OTHER|Massage|A relaxation type of massage will be used as the main massage intervention in this study. This technique is designed to promote deep relaxation, reduce stress, and enhance overall well-being. It is characterized by the use of five primary techniques performed on the full body, including the palms and feet. Specifically, these techniques consist of effleurage (long, gliding strokes), petrissage (kneading and squeezing), tapotement (rhythmic tapping), friction (deep, circular rubbing), and vibration or shaking movements (Table 1). In addition to these, the technique also incorporates rhythmic movements and deep light pressure to enhance relaxation and alleviate tension. It is designed to promote relaxation, increase blood circulation, relieve muscle tension, improve flexibility and promote relaxation and reduce pain. The total duration of the Relaxation massage is 45 minutes.
214678991|NCT05836740|DRUG|Placebo capsules of Minocycline hydrochloride capsules|50 mg per capsule, containing 0mg of Minocycline Hydrochloride.
214678992|NCT02717689|OTHER|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
214964428|NCT03128450|BIOLOGICAL|human neural stem cell|human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel
214964429|NCT00527137|DRUG|darbepoetin alfa|Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
214964430|NCT00527137|DRUG|rHuEPO|same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
214964431|NCT00351585|DRUG|Vildagliptin|
214964432|NCT02937740|DRUG|NATESTO Testosterone Nasal Gel|"Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 \[Day 90\] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone."
214355575|NCT01381692|DRUG|Temsirolimus|Given IV
214355576|NCT02910622|OTHER|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
214964433|NCT04194489|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
214355577|NCT05850832|DRUG|Esmolol|loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
214355578|NCT05850832|DRUG|Magnesium sulfate|loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
214355579|NCT06508281|OTHER|experimental group|. Anatomy model videos prepared by the researchers for the experimental group students will be uploaded to Google Drive and sent via link. Students will be asked to log in from their computer or mobile phone and watch anatomy model videos whenever and wherever they want
214355580|NCT02683096|OTHER|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
214355581|NCT01869491|DRUG|Compound Sodium Alginate Double Action Chewable Tablets|2 tablets four times daily
214355582|NCT01869491|DRUG|Matching placebo tablets|2 tablets four times daily
214355583|NCT00493922|PROCEDURE|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
214355584|NCT00493922|PROCEDURE|Microscopy|Microscopy for diagnosis of malaria
214355585|NCT00493922|PROCEDURE|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
214355586|NCT03786029|DRUG|Acetaminophen|"Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
214355587|NCT03786029|DRUG|Placebo|"Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
214355588|NCT03786029|DRUG|Ibuprofen|"Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
214355589|NCT01435083|DRUG|Desmopressin|120 µg, oral lyophilisate, sublingual use
214355590|NCT05574660|DIETARY_SUPPLEMENT|High-Fat/High-Sugar (HF/HS) Diet|
214678993|NCT02463123|DEVICE|Indirect calorimetry|Resting energy expenditure will be studied using indirect calorimeter CCM Express (Medgraphics Inc, USA).
214678994|NCT04773041|PROCEDURE|Infinitome|All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.
214964434|NCT05118347|OTHER|Buteyko Breathing Technique|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. This helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
214964435|NCT01289548|DEVICE|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
214964436|NCT05242302|PROCEDURE|nerve transfer|the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.
214964437|NCT00490347|DEVICE|VentrAssist Left Ventricular Assist Device|
215080612|NCT05850910|OTHER|Prone application group|the practitioner positions the hypothenar part of his hands above the TPs in the mid-thoracic segment. From this point, a high-velocity-low-amplitude thrust is applied from the back to the front.
214678995|NCT01643915|BEHAVIORAL|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
214964438|NCT05191719|PROCEDURE|Botox injection|Comparator, current gold standard
215080613|NCT01133405|DRUG|LY2886721|Oral capsules
215080614|NCT01133405|DRUG|Placebo|Oral capsules
215080615|NCT06178536|PROCEDURE|Bone Consumption|The surgery will be done using a bone consumption protocol
214964439|NCT05191719|PROCEDURE|Neurotomy|Surgical procedure
215080616|NCT06178536|PROCEDURE|Bone expansion|implants will be placed after a bone expansion protocol
214355591|NCT05574660|DIETARY_SUPPLEMENT|Low-Fat/Low-Sugar (LF/LS) Diet|
214355592|NCT04237506|BEHAVIORAL|Targeted ballet dance|The one-hour ballet dance class will be provided twice per week for six weeks. The syllabi are adapted from the Joffrey Ballet Academy and Royal Academy of Dancing that are targeting grades primary to level 1 and typically developing kids at the age of 6 to 10 years old. PI will be the class instructor, and the class structure will follow the guidelines in 'Dance program for physical rehabilitation and participation in children with cerebral palsy' by Lopez-Ortiz et al.
214355593|NCT05891002|DEVICE|Cirq® Robotic Alignment Module Cranial|Robotic navigation for cranial biopsy procedure
214678996|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
214678997|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
214678998|NCT02924675|DRUG|Pregabalin|150mg daily in three doses during three weeks
214964440|NCT00002168|DRUG|Indinavir sulfate|
214964441|NCT00002168|DRUG|Lamivudine|
214964442|NCT00002168|DRUG|Stavudine|
214964443|NCT00002168|DRUG|Zidovudine|
214964444|NCT00002168|DRUG|Didanosine|
214964445|NCT01726062|BEHAVIORAL|Motivational Interviewing plus Incentives|"1. Two hospital-based, face-to-face MI+ sessions~2. Two home-based MI+ sessions~3. Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge"
214964446|NCT01726062|BEHAVIORAL|Conventional Care (CC)|Participants in this arm will receive brochures and a brief information meeting in the NICU.
214964447|NCT04300712|BEHAVIORAL|Questionnaires at the start and end of the school year|Interventions will be proposed to children identified in a worrisome situation. The Strengths and Difficulties. Questionnaire will be used by teachers to score these situations. The recognition process of mental health problem and need continue with responses. Responses are supporting a graduated response process in school and facilitating external support when needed (mental health services, community supports). Early intervention is one of all responses, which involve caregivers. Responses to worrisome situations aim to improve schooling conditions, to acknowledge mental health problems or condition and the health services need for children. To evaluate the intervention, the impact supplement of SDQ and the follow-up questions will be used by the teachers and the parents of children who benefit of the intervention. The interventions will be experimented during year 2020-21. Children might benefit of them from several weeks to one year, according to their need.
215080617|NCT04960878|DIETARY_SUPPLEMENT|Synbiotic|Synbiotics sachet mainly contained Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, and fructooligosaccharides.
214678999|NCT02924675|DRUG|Placebo|Three doses daily with lactose
214679000|NCT05534334|DRUG|Solu-Cortef|A vial sol. used for intra-mascular injection
214679001|NCT06270797|PROCEDURE|intubation for general anesthesia|routine intubation for general anesthesia
215080618|NCT04960878|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
215080619|NCT02673567|DRUG|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
215080620|NCT02673567|DRUG|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
215080621|NCT02673567|DRUG|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
215080622|NCT02673567|DRUG|Placebo|Matching Placebo
215080623|NCT05536089|DIAGNOSTIC_TEST|a multi-locus blood-based assay|Colorectal tumor-specific plasma ctDNA methylation markers detection
215080624|NCT05675267|OTHER|data collection|HEART score calculation
214355594|NCT05666453|BIOLOGICAL|LIV-GAMMA SN Inj.|LIV-GAMMA SN Inj. is administered at a dose of 0.6 g/kg/day from anhepatic phase to Day 2 post-operative to patients undergoing ABO-incompatible liver transplantation as an experimental group.
214355595|NCT05666453|OTHER|No intervention|None of investigational drugs are administered to patients.
214964448|NCT03897569|OTHER|frontal projection angle, ankle dorsiflexion|Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat
214355596|NCT01270347|DRUG|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
214355597|NCT01270347|DRUG|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
214355598|NCT04789668|DRUG|Bintrafusp Alfa|Given IV
214964449|NCT04683796|DRUG|100% Autologous platelet rich plasma|Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes containing 4 ml of 3.2% buffered citrate acid for anticoagulation. Tubes will be centrifuged at 350 g for 10 minutes at 20 C. The two upper layers of the centrifuged blood, the plasma and the superficial buffy coat, will be separated in a sterile manner under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
214487273|NCT06781866|OTHER|Sham (No Treatment)|The Sham massage (PLA) will be used as a control session, without applying the deeper techniques that characterize the Relaxation massage in order to eliminate the influence of the human touch sensation on the participant's skin. This massage consisted only of superficial oil application movements over the entire body, without any added pressure or deep muscle manipulation. Oil was used to facilitate smooth gliding, mimicking the sensation of a full massage, but without the intensity or techniques aimed at muscle tissue relaxation. The total duration of the sham massage is 45 minutes.
214964450|NCT04683796|DRUG|100% Autologous serum|Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes. The tubes will be left standing in an upright position for 1-2 hours to enable blood clot formation at room temperature (18-25 C). The tubes will be centrifuged at 3000 g for 30 minutes at 20 C. The supernatant serum will be aseptically transferred into a sterile syringe to enable filtration through a 0.2 µm pore size membrane filter under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
214964451|NCT05127564|DRUG|Diroximel fumarate|Administered as specified in the treatment arm
214964452|NCT00798941|BEHAVIORAL|mouth care|mouth spray, mouth swab, moisturizer
214964453|NCT00798941|BEHAVIORAL|pain intervention|music and massage
214964454|NCT02598739|OTHER|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
214964455|NCT02598739|OTHER|Waiting list for the exercises|
214964456|NCT01991964|OTHER|laryngeal ultrasound|
214964458|NCT01570140|BEHAVIORAL|Web portal|This study investigates the effects of the voluntarily use of a webportal and its educational content.
214487274|NCT06377124|BEHAVIORAL|3S intervention|"The 3S intervention includes information and support related to self-management of lung cancer, including~1. an individual 3S session at baseline,~2. 24-week messaging, telephone coaching and hotline services."
214487275|NCT06377124|BEHAVIORAL|GH information|"The GH information includes information related to general health, including~1. an individual GH session at baseline,~2. 24-week messaging, telephone coaching and hotline services."
214487276|NCT06892236|GENETIC|iPSC generation|Base editing
214487277|NCT06111885|DRUG|Indapamide 2.5 MG|1 indapamide 2.5 mg capsule per day for 28 days
214964459|NCT03642535|DRUG|ALA|In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
214964460|NCT03590171|DRUG|Bortezomib|Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.
214964461|NCT04853823|DRUG|PDC-APB|PDC-APB Intra-muscular Injection
214964462|NCT04853823|OTHER|Placebo|Vehicle
214964463|NCT03752476|PROCEDURE|number of Beta lactam class prescription for the same infection|Each number of Beta lactam prescription without interruption are compared
214964464|NCT01571141|DEVICE|Monogin|Gynaecological solution with polyhexamethylene biguanide, pH 4.0
214487278|NCT06111885|DRUG|Hydrochlorothiazide 50Mg|1 hydrochlorothiazide 50 mg capsule per day for 28 days
214355599|NCT04789668|DRUG|Pimasertib|Given PO
214355600|NCT04789668|OTHER|Quality-of-Life Assessment|Ancillary studies
214355601|NCT06461039|DRUG|NNC0487-0111 A|NNC0487-0111 A will be administered subcutaneously.
214355602|NCT06461039|DRUG|NNC0487-0111 C|NNC0487-0111 C will be taken orally.
214355603|NCT06461039|DRUG|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) will be taken orally.
214355604|NCT06461039|DRUG|Acetaminophen - 500 mg/15 ml|Acetaminophen - 500 mg/15 ml will be taken orally.
214355605|NCT04098133|OTHER|data collection for demographic data|data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
214355606|NCT04098133|OTHER|data collection for clinical data|data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
214355607|NCT04098133|OTHER|data collection for treatment data|data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
214355608|NCT04098133|OTHER|data collection for microbiological data|data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)
214355609|NCT05704634|DRUG|Cemiplimab|Given by Injection under the skin every 2 weeks
214355610|NCT05704634|DRUG|Kevzara (Sarilumab)|Given by IV (vein) over about 30 minutes every 3 weeks.
214355611|NCT01804452|OTHER|Observational Study|
214355612|NCT06283472|BEHAVIORAL|High-Intensity Cue|Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
214355613|NCT06283472|BEHAVIORAL|Low-Intensity Cue|Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
214355614|NCT04821778|RADIATION|Radiotherapy|50-66Gy/1.8-2.2Gy/25-30f
214355615|NCT04821778|DRUG|Platinum based chemotherapy|q1-3W according to physician's preference
214355616|NCT04821778|DRUG|Paclitaxel based chemotherapy|q1-3W according to physician's preference
214964465|NCT05377112|DRUG|SYNB8802v1|"SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites."
214355617|NCT04821778|DRUG|Immunotherapy|Anti-PD-1/PD-L1 Antibody
214355618|NCT04821778|DRUG|5-FU Analog based chemotherapy|W1-5 qW or d1-14, q3W according to physician's preference
215080625|NCT02737553|PROCEDURE|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
215080626|NCT02737553|PROCEDURE|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
215080627|NCT05768438|OTHER|Mulligan with upper limb movement|Group A subjects will receive mulligan mobilizations with upper limb movement of the involved side. The patient will be in a sitting position and the therapist will stand beside the patient. The therapist will place one thumb overlapped by the other on one of the selected cervical and then the therapist will push down the spinous process of that specific vertebrae, the pressure will be sustained and the patient will actively abduct his/her arm, assistance will be provided if needed. Initially it will start from 10 repetitions and 1 set which will further progress up to 2 or 3 sets as per patient's tolerance with 60 seconds rest in between each set.
214487279|NCT06111885|DRUG|Chlorthalidone 25mg|1 chlorthalidone 25 mg capsule per day for 28 days
214487280|NCT06844825|OTHER|Tele rehabilitation|The experimental group will receive the treatment remotely by ZOOM platform and phone call
214964466|NCT05377112|OTHER|Placebo|placebo powder will be aliquoted into high density polyethylene (HDPE) bottles and diluted in the same formulation buffer as SYNB8802v1 lyophilized powder. The placebo consists of corn starch and dyes to color match the placebo to the SYNB8802v1 powder for oral suspension
214355619|NCT04821778|DRUG|Nimotuzumab|200-400mg, d1,qW
214355620|NCT03842995|BEHAVIORAL|Genetic Counselor|Standard of Care
214355621|NCT03842995|BEHAVIORAL|Trained Healthcare Provider|Neonatologists and Neonatology Nurse Practitioners that receive training to deliver whole genome sequencing results
214355622|NCT04541134|DRUG|Pelubiprofen 45mg|Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)
214355623|NCT04541134|DRUG|Placebo|Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
214355624|NCT05804565|PROCEDURE|Bone Saw|The surgeon will use an oscillating microsaw to transect the metatarsal shaft
214487281|NCT06844825|OTHER|usual care only|in-person usual care provided by the physical therapist
214964467|NCT00260013|PROCEDURE|program of care delivery|
214964468|NCT02114619|DRUG|Low dose of I-131|We wil administer 100 micro currie of iodine per thyroid gram
214355625|NCT05804565|PROCEDURE|Bone Cutter|The surgeon will use a manual bone cutter to transect the metatarsal shaft
214355626|NCT02992262|DEVICE|Point of care ocular ultrasound|
214355627|NCT03239119|BIOLOGICAL|rE-4 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily
214355628|NCT03239119|BIOLOGICAL|rE-4 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily
214487282|NCT06754657|PROCEDURE|Continuous perineural infusion|infusion rate 4 ml/h, with 5 ml boluses (30-minute lockout). The PCA button disabled
214964469|NCT02114619|DRUG|Intermediate dose|We will administer 150 micro currie of iodine per thyroid gram
214964470|NCT02114619|DRUG|High dose|We will administer 200 micro currie of iodine per thyroid gram
214964471|NCT01851655|BEHAVIORAL|Plyometric Exercise|Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
215080628|NCT05768438|OTHER|McKenzie exercises with neural mobilizations|The subjects of Group B will receive McKenzie exercises. Initially, it will start with retraction exercises. The frequency of exercises will be 10 to 15 repetitions followed by three to four sets with one second hold. On the second or third day, the cervical extension will be added. While in the second week the same set of exercises will be administered with the patient in a sitting position combined with application of over pressure at the end range by therapist. In the third week, extension and retraction exercises will be performed along with traction which will be applied by the therapist. Finally, in the fourth week all retraction and lateral flexion then neck rotation and the last one retraction with neck flexion will be added. Neural mobilizations will be given to patients in group B in supine lying. From proximal to distal, 20 oscillations (1 oscillation/ 1 second)
214355629|NCT03239119|BIOLOGICAL|Placebo 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily
214964472|NCT00186342|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
214964473|NCT04576650|DEVICE|Summit System|Surgical implantation of the Summit system (consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities) for Safety and efficacy testing of the Medtronic Summit System.
214964474|NCT03151447|RADIATION|stereotactic body radiation therapy|"In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks."
214964475|NCT01737307|DRUG|Fluoride varnish|Fluoride Varnish (NaF 5%)
214964476|NCT01737307|OTHER|Oral Hygiene|Oral hygiene followed.
214964477|NCT01737307|DRUG|CPP-ACP|CPP-ACP paste was applied by patient, once daily.
214964478|NCT03018314|OTHER|Blood sample|Serum analysis
214964479|NCT01815658|DEVICE|Carbon fiber intramedullary nail (PEEK-CF)|Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
214964480|NCT04378686|OTHER|dialysis|treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis
214964481|NCT02288702|DEVICE|monitoring BIS in both groups|We will be monitoring BIS in both groups. A BIS monitor may be placed prior to induction or immmeditaely afterwards for monitoring BIS. All patients will receive general anesthesia. A standard inhalation induction agent such as sevoflurane and oxygen will be administered via face mask with or without an oral airway. An inhalation agent will be administered for the duration of the procedure. The MAC goal for inhalation agents will be 1. If the patient moves, the MAC goal will be increased to 1.5 and this change will be recorded.
214355630|NCT03239119|BIOLOGICAL|Placebo 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily
214355631|NCT03977519|PROCEDURE|MA|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used.Participants will receive manual acupuncture for 30 minutes each time.After acupuncture,we will twist the needles every 10 minutes for about 30 seconds.The patients will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
214355632|NCT03977519|PROCEDURE|TENS|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used.Participants will receive transcutaneous electric nerve stimulation for 30 minutes each time.They will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
214355633|NCT05121753|DIETARY_SUPPLEMENT|Survey investigating Infant formula feeding in newborns|A database will be created that allows individuals to register and enter information about the premature infant's feeding history and symptoms/ medical history.
214355634|NCT01606449|PROCEDURE|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
214355635|NCT04980053|OTHER|massage|Intervention group Control group
214355636|NCT00959517|DRUG|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
214355637|NCT00959517|DRUG|sulphadoxine-pyrimethamine (SP)|
214487283|NCT06754657|PROCEDURE|Single injection|infusion rate 0 ml/h, with 5 ml boluses (30-minute lockout). The PCA button will be enabled for rescue bolus administration
214487284|NCT06089551|DRUG|SmofKabiven|Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
214355638|NCT00959517|DRUG|Chloroquine (CQ)|
214487285|NCT06761417|DRUG|Mitoxantrone liposome|Mitoxantrone liposome: 16 mg/m\^2, d1; Each 21-day cycle was used for a total of 4-6 cycles.
214487286|NCT06761417|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2, d1-14, bid; Each 21-day cycle was used for a total of 4-6 cycles.
214964482|NCT00214617|DRUG|Rosuvastatin at 5 mg/day and 40 mg/day|
214964483|NCT01285661|DRUG|Sodium warfarin|Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
214964484|NCT02104076|DEVICE|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
215080629|NCT03109808|OTHER|e-health strategy|"* First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~* Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
215080630|NCT03109808|OTHER|Traditional Oral Hygiene Education|traditional oral hygiene education
215080631|NCT02654392|DIETARY_SUPPLEMENT|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
215080632|NCT02654392|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, \& Pumpkin oils) every day for 5 weeks
215080633|NCT00270088|DRUG|epoetin alfa|
215080634|NCT04971538|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
214355639|NCT00959517|DRUG|primaquine (PQ)|
214487287|NCT06761417|DRUG|Anlotinib|Anlotinib: according to patient weight: 8mg/ day in patients \<35kg; 10mg/ day for patients with 35kg≤ patient weight ≤50kg; 12mg/ day for patients \> 50kg; d1-14; Each 21-day cycle was used for a total of 4-6 cycles.
214487288|NCT06760871|OTHER|nebulised distilled water|After the surgery, the patients will be admitted to the ward and taken to the bed, and their care and treatment will be applied by the nurse. Afterwards, the researcher will apply cold vapour as an inhaler for 15 minutes. For this application, the stand to which the ultrasonic nebuliser device is connected will be positioned close to the patient's bed. 200 ml of distilled water will be placed in the liquid reservoir of the device. The patient will be given a comfortable position and the device will be adjusted so that the steam hose covers the patient's mouth and nose and the patient will be allowed to inhale the steam through the mouth and nose. After the electrical connection of the device is provided, the device will be started and cold steam application will begin. In the 1st hour, inhaler cold water vapour application will be performed for 15 minutes.
214964485|NCT04552561|BEHAVIORAL|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
214487289|NCT06737081|DRUG|SAL-0951 tablets 4mg|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
214487290|NCT06737081|DRUG|SAL-0951 tablets 5mg|initial phase：5mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
214355640|NCT03725644|BEHAVIORAL|parent-training program|Parents in the treatment group received the training program from the registered pediatric occupational therapist in six hours over three weeks. The occupational therapist provided suggestions and gave feedback. The parents were encouraged to interact with their children for at least 15 hours per week. Between the fourth and 14th weeks, the parents implemented the intervention programs at home and recorded the daily intensity. The occupational therapist met with the parents and children at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered and to practice the child-initiated activities.
214964486|NCT05704855|BEHAVIORAL|Combined Exercise + Behavioural Counselling|The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) sessions each week. Participants will also participate in bi-weekly, 45-60 minute, remotely-delivered, group-based behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.
214964487|NCT05704855|BEHAVIORAL|Active Control|The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
214964488|NCT02478515|DRUG|Ranibizumab|Intraviteal injection of 0.5mg ranibizumab
214964489|NCT01649882|PROCEDURE|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (\< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
214964490|NCT03062215|BEHAVIORAL|Space from Depression|Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
214964491|NCT03175614|OTHER|Intervention group|Smartphone with APP (EVIDENT III) and a Smartband for 3 months. Counseling on physical activity and nutrition
214964492|NCT03175614|OTHER|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
214964493|NCT00379561|DRUG|PSA-Activated PSA-PAH1|
214964494|NCT01546051|DRUG|BCI-838|BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
214964495|NCT01546051|DRUG|BCI-838|BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
214964496|NCT01546051|DRUG|BCI-1038, BCI-1206 & BCI-1283|Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
214964497|NCT01546051|DRUG|BCI-838|BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
214355641|NCT03725644|BEHAVIORAL|traditional program|Parents in the control group also conducted a 14-week program. They received six hours of training over three weeks.Between the fourth and 14th weeks, the parents implemented parent-led activities at home and recorded the daily intensity. The parents were encouraged to do activities with their children for at least 15 hours per week. The occupational therapist met with the parents at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered while practicing the parent-led activities.
214355642|NCT02102087|DEVICE|Initial Specimen Diversion Device (ISDD)|
214355643|NCT02102087|DEVICE|Lab standard practice (LSP)|
214355644|NCT02159833|OTHER|Intranasal challenge with active substance (food protein)|
214355645|NCT02159833|OTHER|Intranasal challenge with placebo|
214355646|NCT01856127|DRUG|Vilazodone|Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
215080635|NCT01683006|DRUG|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
215080636|NCT01683006|DRUG|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
215080639|NCT01238835|DEVICE|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
215080640|NCT00203112|DRUG|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
215080641|NCT00203112|DRUG|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
214355647|NCT01856127|DRUG|Sertraline|Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
214355648|NCT01972516|DRUG|Tivozanib|
214355649|NCT05821738|DRUG|Avapritinib|administered orally
215080642|NCT01774253|DRUG|Vismodegib|
215080643|NCT06163183|DEVICE|Edi catheter|
214355650|NCT03948568|COMBINATION_PRODUCT|Endocrine Therapy and Radiotherapy|Endocrine therapy and radiotherapy administered either concurrently or sequentially
215080644|NCT00554619|DRUG|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
215080645|NCT05415592|DEVICE|DePuy Synthes Radial Head Replacement System|DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.
214355651|NCT05258825|DRUG|Monoferric|A single intravenous dose of 1000 mg of Monoferric will be administered to a patient 3-4 weeks before anticipated surgery.
214355652|NCT01369862|BIOLOGICAL|GHB16L2|A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants
214355653|NCT01369862|BIOLOGICAL|Placebo|SPGNH buffer
214355654|NCT00596765|BEHAVIORAL|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
214355655|NCT01478568|DRUG|mirabegron|oral
214355656|NCT01478568|DRUG|desipramine|oral
214355657|NCT04051229|BEHAVIORAL|6-week exercise training program|Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
214355658|NCT04051229|BEHAVIORAL|Standardized isoenergetic high fat diet|Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
214355659|NCT04288908|OTHER|Cyberball experimental task|Cyberball is an experimental task in which participants have to pass a ball to two virtual players during 60 passes in total
214487291|NCT06772051|PROCEDURE|Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)|Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)
214487292|NCT06772051|PROCEDURE|Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)|Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)
214487293|NCT06772051|PROCEDURE|Resin composite restoration bonded using universal adhesive in self-etch mode|Resin composite restoration bonded using universal adhesive in self-etch mode
215080646|NCT02250807|DRUG|Simeprevir|Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
215080647|NCT02250807|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
215080648|NCT05897190|BIOLOGICAL|SARS-CoV-2 mRNA vaccine (RBMRNA-405)|Dose A
215080649|NCT05897190|BIOLOGICAL|CoronaVac®|Dose B
215080650|NCT00908648|PROCEDURE|Narrow Band Imaging|Narrow Band Imaging
215080651|NCT04073784|DRUG|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
215080652|NCT00481715|BEHAVIORAL|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
215080653|NCT00481715|BEHAVIORAL|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
215080654|NCT03641248|DRUG|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
214964498|NCT02812641|DRUG|BPF-CCRT (run-in)|Six patients will be enrolled in run-in phase. If \<= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If \> 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
214964499|NCT02812641|DRUG|BPF-CCRT (randomized)|Twenty-two patients will be planned to assign to the experimental arm
214964500|NCT02812641|DRUG|PF-CCRT (randomized)|Twenty-two patients will be planned to assign to the active control arm
214964501|NCT05390008|OTHER|Pelvic Floor Muscle Training|"In order to increase participants' PFM strength and endurance , PFMT was taught two days a week for 12 weeks. This training included two type of exercises that consisted of fast and slow PFM contractions.~Fast Contractions: This exercise was done in sitting position, While participants' arms were on thighs with their feet resting on the floor and sitting unsupported on the back of their seat. They were taught how to quickly contract and relax their PFM.~Slow Contractions: The practice position of this exercise was in sitting position as it happened in fast contraction. This training lasted for 12 weeks and it was divided into periods as 1-3 week, 4-6 week, 7-9 week, 10-12 week. In the forth coming weeks of this period, the number of exercise repetitions and the number of sets were increased."
214964502|NCT05390008|OTHER|Modified Pilates Exercise|"Before starting the 12-week practice protocol, the concept of stabilization was explained to the participants. Participants were taught how to control the core region by using the stabilizer device and the basic principles of pilates. The exercise program was planned that would last 50 minutes. This program was carried out as three-stage and these stages were warm-up phase, main exercise program and cool down phase. The allocated times for the warm-up phase was 10 minutes. The allocated time for the main exercise program was 30 minutes and active resting was done by performing breathing exercises in the 15th minute of the main exercise program. The allocated time for the cool down phase was 10 minutes. Each exercise was done as 10 repetitions then the next exercise was started.~The exercises of the second 6 weeks were performed by adding a red elastic exercise band at the beginner-intermediate level, which released 1.7 kg force with 100% stretching."
214964503|NCT02076204|BEHAVIORAL|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
214964504|NCT03952572|DRUG|Cyclophosphamide|750mg/m² ivgtt on day 1
214964505|NCT03952572|DRUG|pegylated liposomal doxorubicin|40mg/m² ivgtt on day 1
214964506|NCT03952572|DRUG|Vincristine|1.4mg/m²(Maximum 2 mg) ivgtt on day 1
214964507|NCT03952572|DRUG|Prednisone|Prednisone100mg/m² po on day1-5
214964508|NCT03952572|DRUG|Doxorubicin|50mg/m² ivgtt on day 1
214964509|NCT02458560|DEVICE|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
214964510|NCT00498680|DRUG|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
214964511|NCT00498680|DRUG|Sildenafil|100mg
214964512|NCT00498680|DRUG|Vardenafil|20mg
214964513|NCT00498680|DRUG|Sildenafil & Vardenafil|50mg \& 10 mg
214964514|NCT01667445|DRUG|Epimorph|Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
214964515|NCT01667445|DRUG|Spinal analgesia|Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
214964516|NCT03793569|BEHAVIORAL|Peer discussion group|Subjects in the intervention group will be asked to attend one peer group between four and eight weeks postpartum. Peer groups will be expected to last approximately one hour. Each peer group will include 5-10 new mothers. A facilitator will be present for these groups, but the hope is to have mothers discuss with each other their postpartum experience and activities of their newborn at home.
214964517|NCT01999647|PROCEDURE|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
214964518|NCT01999647|PROCEDURE|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
214964519|NCT01999647|PROCEDURE|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
214964520|NCT01999647|PROCEDURE|Patient-Controlled Postoperative Analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
214487294|NCT06776562|OTHER|Exercise|Education on activities of daily living will be provided. In addition, a program including muscle strengthening, neuromuscular control and flexibility exercises for lower extremity and trunk muscles will be performed. Exercise Program will be performed for 8 weeks, 2 sessions per week.
214964521|NCT01999647|DRUG|Ropivacaine|Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
214964522|NCT00977912|DIETARY_SUPPLEMENT|Probiotic supplementation|one capsule containing probiotics per day added to milk
214487295|NCT06776562|OTHER|Control|Education will be provided for activities of daily living. Individuals with dynamic knee valgus in the control group will not receive any intervention. Exercise program will be implemented after the end of the study.
214964523|NCT00977912|DIETARY_SUPPLEMENT|Milk containing placebo|one capsule containing placebo per day added to milk
214355660|NCT05291208|COMBINATION_PRODUCT|Combined tACS and Cognitive Training Program|The program contemplates 12 WM training sessions based on tasks of storage and manipulation of verbal and visuospatial information, with a frequency of twice a week during six weeks (total of 12 sessions). Patients will receive real electrical stimulation for 10 minutes during verbal working memory task. This includes 10s periods of phase-in and 10 s of phase-out and will be done in parallel with the cognitive intervention program in sessions 3, 4, 5, 6, 7, 8, 9, and 11. The electrical stimulation will be applied with two 3x1 arrays of electrodes. The central stimulation electrodes will be positioned in F3 and CP3 (10-20 system). The AC stimulation will be one mA from the baseline to the stimulation peak. The stimulation will have a gamma sine waveform (80Hz) over the positive phase of the theta oscillation (between 4 and 8 Hz, adjusted by each subject, Reinhart et al, 2019) phase-locked between arrays with impedances always under 10 kOhm.
214487296|NCT05154669|OTHER|Financial counseling|The goals of the financial counseling will be to: (1) screen and refer participants to financial benefits and empowerment programs; (2) help participants create and maintain a household budget to meet short- and long-term goals; and (3) help participants link smoking cessation to their budgeting goals.
214487297|NCT05154669|DRUG|Nicotine Replacement Therapy Agent - Patches|24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin. Nicotine patches are available in 3 dosages: 21 mg, 14mg, and 7mg. Patches will be adjusted based on withdrawal symptoms, urges, and comfort. After 4-6 weeks of abstinence, taper ever 2-4 weeks in 7-14 mg steps as tolerated.
214964524|NCT02380404|PROCEDURE|Implants-supported locators placement|Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
214964525|NCT05704400|DRUG|Rituximab Biosimilar ABP 798|Rituximab IV: the dose is standard for pediatric nephrotic syndrome; for dosage between 100 and 250 mg rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
214964526|NCT05704400|DRUG|Daratumumab|Daratumumab vials 20 mg 1 ml will be collected to reach the desired dose of 16 mg /Kg, the dose is standard recommend to treat myeloma; diluted in 1000 ml of normal saline and infused at the constant speed of 50 ml/h. This will be reduced in case of cutaneous allergic reactions
214964527|NCT01703390|DRUG|FOLFIRI + Cetuximab|
214964528|NCT01703390|DRUG|modifiedFOLFOX6 + Cetuximab|
214964529|NCT05200377|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
214964530|NCT00218478|BEHAVIORAL|Cue Desensitization|During the study session, both groups will be shown a nature video and will be asked to handle and smell various items; these will act as the neutral, non marijuana-related cues. Next, the participants will watch a video of individuals smoking marijuana and will be asked to handle and smell marijuana-related items; these will act as the marijuana-related cues.
214964531|NCT06086938|DEVICE|active cTBS combined with iTBS|"Daily TBS treatment consists of the following combination: active 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + active 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + active 600-pulse cTBS applied to the SFG in the unaffected hemisphere + active 600-pulses iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks."
214964532|NCT06086938|DEVICE|sham cTBS combined with iTBS|"Daily sham TBS treatment consists of the following combination: sham 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + sham 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + sham 600-pulse cTBS applied to the SFG in the unaffected hemisphere + 600-pulse sham iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of sham TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks."
214964533|NCT04745741|RADIATION|IB-positive group|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
215080655|NCT03641248|DRUG|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
214964534|NCT00230789|DRUG|Tolterodine ER 4 mg QD|
214964535|NCT00230789|BEHAVIORAL|OAB Patient Behavioral Training Material|
214964536|NCT03397121|DRUG|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
214964537|NCT03397121|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
214964538|NCT02738112|DEVICE|Encore System|Hyo-mandibular suspension
214964539|NCT05761418|DRUG|Dinoprostone|prostaglandin (PG) E2 analog
214964540|NCT05761418|DRUG|Misoprostol|prostaglandin (PG) E1 analog
215080656|NCT01230515|OTHER|Individual patient interview, focus group and structured survey|
215080657|NCT01230515|OTHER|interview, focus group and structured survey|
215080658|NCT01230515|OTHER|interview, focus group and structured survey|
215080659|NCT01230515|OTHER|interview, focus group and structured survey|
215080660|NCT03867565|OTHER|Nutritional intervention|Indirect calorimetry Weight development Nitrogen balance Food records Physical activity Nutritional risk screening and assessment Inflammatory response Wound healing as number of days from burn to no more need of dressing changes via health care facility Frequency of infections as the number, sort, dose, and length of antibiotic treatment(s) from burn to no more need of dressing changes via health care facility
215080661|NCT00096499|DRUG|ispinesib|Given IV
215080662|NCT00096499|OTHER|pharmacological study|Correlative studies
215080663|NCT00096499|OTHER|laboratory biomarker analysis|Correlative studies
214355661|NCT05291208|BEHAVIORAL|Traditional Cognitive Training Program|Participants will start a cognitive intervention program identical to the intervention group. Still, unlike the intervention group, they will receive placebo electrical stimulation, i.e., an electrical current will be applied for a short period at the beginning of the session (30 seconds), and then the stimulation will be stopped. This procedure induces a sensation in the skin similar to the real stimulation without generating a detectable impact on the brain state. They will be performed in parallel to the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10.
214487298|NCT05154669|DRUG|Nicotine Replacement Therapy Agent - Lozenges|"General Info 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin.~Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch, the idea is to taper the amount of lozenges used until you no longer need it. Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Comes in 4mg or 2mg. Initial dosing is 1-2 lozenges every 1-2 hours (minimum of 9/day). Taper as tolerated"
214487299|NCT05154669|DRUG|Nicotine Replacement Therapy Agent - Gum|Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Initial dosing is 1-2 pieces every 1-2 hours (10-12 pieces/day). Taper as tolerated
214487300|NCT06853158|BEHAVIORAL|Music therapy|Participants in the 2 experimental MT conditions (In person MT (InMT) or hybrid (inperson.virtual (HybMT) will receive 6 MT sessions over 6 weeks. Each MT session will last no longer than one hour. This 6-week treatment period may be extended to up to 8 weeks if a scheduling conflict prevents a participant from receiving the 6 MT sessions over 6 consecutive weeks.
214964541|NCT03939442|PROCEDURE|Sleeve gastrectomy with jejunoileal anastomosis|The sleeve gastrectomy was performed first, after using a sealer and divider device to dissect the omentum away from the greater gastric curvature from approximately 5 cm proximal to the pylorus up to the angle of His. Excision of the fundus and the body of the stomach was then performed with a laparoscopic linear stapler upon a 36 French orogastric tube (bougie). An isoperistaltic side-to-side anastomosis between the jejunum (at 50 cm distal to the Treitz ligament) and the distal ileum ( at 200 cm proximal to the ileocecal valve) was then created using the same linear stapler with a blue cartridge (3.5 mm). A soft Penrose drain was left at the subdiaphragmatic space, and the abdominal wound was closed.
214964542|NCT01089842|BEHAVIORAL|Health coaching|Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.
214964543|NCT01089842|OTHER|Usual care|Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
214964544|NCT05237115|DRUG|Clostridium butyricum capsule|Clostridium butyricum group: given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
214964545|NCT05237115|DRUG|esomeprazole|Esmeprazole 40mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
214964546|NCT05237115|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 40mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
214964547|NCT05237115|DRUG|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 40mg 1tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
214964548|NCT05237115|DRUG|Bacillus clotting|given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
214964549|NCT05237115|DRUG|Bismuth|given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
214964550|NCT01605864|DRUG|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
215080664|NCT04384601|DRUG|Chemotherapy|Perioperative chemotherapy will be administered according to description in two arms.
215080665|NCT01394224|DRUG|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
214964551|NCT03069235|BEHAVIORAL|Family member / peer support|supplemental individualized counselling
214964552|NCT03069235|BEHAVIORAL|Enhanced intervention with counselor support|"hands on EBF demonstrations"
214964553|NCT03069235|BEHAVIORAL|standard of care|one on one and in-group counselling
214964554|NCT00305227|DRUG|Lactin-V|
214964555|NCT00305227|DRUG|Placebo|
214964556|NCT05447143|OTHER|Fatigue Severity Scale|Evaluation for severity of fatigue
214964557|NCT05447143|OTHER|Berg Balance Test|Evaluation of balance
214964558|NCT05447143|OTHER|Time up and go- 25 steps walking test|Evaluation for walking
215080666|NCT01394224|DRUG|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
215080667|NCT02116114|OTHER|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
215080668|NCT00907803|DRUG|ST-246 400 mg|Capsules, 400 mg daily for 14 days
214355662|NCT06405373|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
214355663|NCT06405373|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
214355664|NCT06448871|DIAGNOSTIC_TEST|Ultrasound assessment of the right lower extremity muscles|Rectus femoris cross sectional area (RFCSA), RF muscle thickness, vastus lateralis (VL) muscle thickness, Gastrocnemius medialis (GM) muscle thickness, VL pennation angle (PA), and GM PA.
214355665|NCT06448871|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DXA) scan|skeletal muscle mass (SM), appendicular skeletal muscle mass index (ASMI), total lean body mass (LBM), total fat mass (BF), percentage fat mass, and fat mass index (FMI).
214355666|NCT01744028|DEVICE|Remote Patient Monitoring|Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
214355667|NCT01744028|OTHER|Usual care|Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
214355668|NCT01507870|PROCEDURE|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
214355669|NCT02025777|DEVICE|Capsule Endoscopy|
214355670|NCT03205995|BIOLOGICAL|OMS721|Intravenous loading dose followed by daily subcutaneous injections
214355671|NCT02195986|DRUG|Estradiol Vaginal Cream, 0.01%|Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
214355672|NCT02195986|DRUG|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
214964559|NCT05447143|OTHER|Multiple Sclerosis Quality of Life|Evaluation of quality of life
214487301|NCT06853158|OTHER|Health education|The content for the HybHE control was adapted from Project PEEP: Patients Empowered and Educated Providers. The Sickle Cell Community Consortium developed Project PEEP with a grant from Global Blood Therapeutics. Project PEEP addresses unmet needs directly identified and prioritized by a collective of patients with SCD, caregivers, and community-based organizations. The objective is to provide the tools and resources to improve communication and increase positive patient-provider interactions to receive quality, timely care. For the proposed study, we will use modules from the curriculum developed for patients living with SCD.
214964560|NCT05447143|OTHER|Brief International Cognitive Assessment for MS (BICAMS)|Evaluation of cognitive functions
214964561|NCT05447143|OTHER|Beck Depression and Anxiety Scale|Evaluation of depression and anxiety
214964562|NCT02632006|BIOLOGICAL|PIK-PD-1 cells|"DC cell suspension (1×10\*7 DC+ physiological saline~\+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10\*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
215080669|NCT00907803|DRUG|ST-246 600 mg|Capsules, 600 mg daily for 14 days
214964563|NCT02632006|BIOLOGICAL|DC-PMAT|"DC cell suspension (1×10\*7 DC+ physiological saline~\+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10\*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
214964564|NCT03407001|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
214964565|NCT03407001|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
214964566|NCT03407001|PROCEDURE|Ultrasound|Undergo non-contrast US
214964567|NCT05978518|DEVICE|CPM Device + Monitoring|Daily device use \& data monitoring leading to symptomology assessment and notification to provider.
214964568|NCT05978518|DRUG|CPM Device|Daily device use
214964569|NCT01781104|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
214964570|NCT01781104|DRUG|Placebo|Placebo delivered subcutaneously once daily for 14 days.
214964571|NCT03395626|DIETARY_SUPPLEMENT|ID-JPL934|probiotics
214964572|NCT03395626|DIETARY_SUPPLEMENT|Placebo|corn starch
214964573|NCT02851459|BEHAVIORAL|Baseline Survey|The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
215080670|NCT00907803|DRUG|Placebo|Capsules, once daily for 14 days
215080671|NCT03352557|DRUG|BIIB092|Administered as specified in treatment arm.
215080672|NCT03352557|DRUG|Placebo|Administered as specified in treatment arm.
215080673|NCT06279104|DRUG|physician's choice of chemotherapy|physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
215080674|NCT06279104|DRUG|immune checkpoint inhibitor based therapy|immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
214355673|NCT02195986|DRUG|Placebo Vaginal Cream|Placebo Vaginal Cream ( 1 x 2 g for 7 days)
214355674|NCT00884429|PROCEDURE|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
214355675|NCT00884429|PROCEDURE|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
214355676|NCT00884429|PROCEDURE|3-Airway suction|Airway suction
214355677|NCT01357798|DRUG|Botulinum toxin type A|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
214355678|NCT01357798|DRUG|0,9% saline|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
214355679|NCT01031147|OTHER|Examination|3D-TOF-MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
214355680|NCT03793985|DRUG|T|CKD-391 40/10mg
214964574|NCT02851459|BEHAVIORAL|Pre-intervention Survey|Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
214964575|NCT02851459|BEHAVIORAL|Morally Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.~Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized."
214964576|NCT02851459|BEHAVIORAL|Morally Non-Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.~Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized."
214964577|NCT02851459|BEHAVIORAL|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
214964578|NCT02851459|BEHAVIORAL|Post-Intervention Survey|Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
214964579|NCT01852123|DEVICE|High-sensitivity troponin I assay|
214964580|NCT02077686|BEHAVIORAL|Education - Diabetes and Travel|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible."
214964581|NCT00141414|DRUG|Pregabalin|
214964582|NCT04956471|OTHER|interview|A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.
214964583|NCT01751750|OTHER|Grape|16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
214964584|NCT04360460|OTHER|Immersive virtual reality + related functional translation into real-life|The experimental group will perform tasks in an immersive virtual reality setting designed to encourage functional task performance for 30 minutes. The patient will then be brought to a real-life setting and evaluated on similar task performances for an additional 30 minutes for a total of 60 minutes per day, 3 times a week for 2 weeks.
214964585|NCT04360460|OTHER|Immersive virtual reality + non-related translation into real-life|The control group will also be asked to perform tasks in an immersive VR setting for 30 minutes, however tasks will be unrelated to the tasks performed in the real-life setting in the following 30 minutes. The control group will also receive 60 minutes of therapy a day, 3 times a week, for 2 weeks.
214964586|NCT00338546|DRUG|Cocaine hydrochloride|
214964587|NCT00338546|DRUG|Dexmedetomidine|
214964588|NCT00338546|PROCEDURE|Microneurography|
214964589|NCT00338546|PROCEDURE|Laser doppler velocimetry|
214964590|NCT02635919|DEVICE|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
215080675|NCT03142555|BEHAVIORAL|Health talk plus intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
214355681|NCT03793985|DRUG|R|D086 and D337 co-administration
214355682|NCT02571218|DEVICE|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
214355683|NCT02571218|DEVICE|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
214355684|NCT04404712|DRUG|[11C]MK-3168|One PET scan involving administration of PET ligand \[11C\]MK-3168
214355685|NCT06961773|OTHER|Low energy availability|Participants follow 6 days of a low-energy availability diet. The kilocalories of each diet are prescribed individually based on their fat-free mass.
214355686|NCT06961773|OTHER|High energy availability|Participants follow 6 days of a high-energy availability diet. The kilocalories of each diet are prescribed individually based on their fat-free mass.
214355687|NCT06963073|OTHER|Diabetic DM|The intervention group will receive 45 minutes of diabetes education. Three telemonitoring sessions will be held 2 weeks, 1 month and 3 months after the education. During the monitoring, participants will be asked to monitor their blood sugar and HbA1C values, if any. Nothing will be done to the control group. The same monitoring will be held for the control group 3 months later.
214355688|NCT06961903|OTHER|physiotherapy programme|A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention.
214355689|NCT06961903|OTHER|Functional Taping|"A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention. In addition, the taping method applied in this study can be defined as a Function-Oriented Taping Application to Preserve Extension: Lumbar Extension Taping, which was specifically designed to maintain lumbar extension."
214355690|NCT06961903|OTHER|Manual Therapy|"A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention.Manual Therapy (MT), which literally means hands-on treatment, is an evidence-based therapeutic approach consisting of skilled hand movements and maneuvers applied to produce therapeutic effects and to treat musculoskeletal dysfunctions and pain. In addition to the standard program, manual therapy was also administered in this study."
214355691|NCT06961903|OTHER|Stereodynamic Interference Current|A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention.In addition, the stereodynamic interference current method was applied in this study. A 'Y' electrode was used during the application. Due to the rapid development of accommodation, the current intensity was frequently increased during the session. The average treatment duration was 15 minutes, and a frequency of 50-100 Hz was used to achieve analgesic effects.
214355692|NCT01716312|DRUG|Omalizumab|For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
214355693|NCT01306773|DRUG|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing \>= 1:160 of neutralizing antibody to Pandemic influenza A H1N1
214964591|NCT04328909|DEVICE|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
214964592|NCT04328909|OTHER|Control Group|Usual care - No E-Care app will be provided
214964593|NCT05089578|OTHER|focus interview|"The Information Form including descriptive characteristics of the individuals undergoing Covid-19, the semi-structured Interview Form, and the Complementary Therapy Use Form were used as the data collection tools. The Information Form consisted of 13 questions including socio-demographic and disease-related characteristics of individuals. In-depth interview method was used to collect data. Interviews were held by organizing video calls and online meeting programs on mobile phones both due to pandemic measures and in order to enable individuals to communicate comfortably. The time period in which the individuals felt most ready for the interview was determined and the data were collected during that time. During the interview, effective communication techniques were used, active listening was carried out and individuals were guided using question forms in accordance with the aim of the study. The interviews lasted for an average of 25-30 minutes."
214964594|NCT04085601|DRUG|APL-2|Complement (C3) Inhibitor
214964595|NCT01986803|DEVICE|Percutaneous Coronary Intervention|"Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point."
214964596|NCT04020653|DRUG|5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD|5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD
214964597|NCT04020653|DRUG|Sodium ferrous citrate (SFC) 472 mg QD|SFC 118 mg capsules will be given to the patients as 472 mg QD
214964598|NCT04020653|DRUG|Artemisinin-based combination (ACT)|Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.
214964599|NCT04020653|DRUG|Placebo|Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
214964600|NCT04020653|DRUG|5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID|5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID
214964601|NCT04020653|DRUG|Sodium ferrous citrate (SFC) 236 mg BID|SFC 118 mg capsules will be given to the patients as 236 mg BID
214964602|NCT00429832|DRUG|Ondansetron|
214964603|NCT00429832|DRUG|promethazine|
214964604|NCT06293274|PROCEDURE|Discharge training|What is motherhood blues? Why does it occur? What are its symptoms? How to deal with it? What is postpartum depression? What causes postpartum depression? Information is provided on this topic.
214964605|NCT04244617|BEHAVIORAL|iCBT with addition of peer-support|Peer-supporters and participants, as well as psychologists and participants, interact in the treatment program via asynchronous secure messages. Peer-supporters are able to give support and feedback on exercises. A reconciliation call via telephone is entered into the middle of the treatment and a follow-up call after completion of treatment conducted by the peer-support. The interaction between peer-supporters and participants is tracked by the psychologist.
214964606|NCT03492437|DRUG|Dabigatran Etexilate|Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.
214964607|NCT03492437|DRUG|Tepotinib|Participants received single oral dose of Tepotinib for 8 days in Treatment period 2.
214964608|NCT04559477|OTHER|Static extension endurance exercise|"Static extension endurance exercise were performed, 10 repetitions with 10 sec hold of each of exercises Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
214964609|NCT04559477|OTHER|Dynamic extension endurance exercise|"Dynamic extension endurance exercise with 10 repetitions of each of exercises which has been performed Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
214964610|NCT02418234|OTHER|mutation detection|
214964611|NCT02418234|OTHER|ARMS and ddPCR|
214964612|NCT02418234|GENETIC|ctDNA analysis|
214964613|NCT06132334|OTHER|Upper extremity aerobic exercise training|"Aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of aerobic exercise training will be applied at 50-80% of peak oxygen consumption or 60-80% of peak heart rate, dyspnea 3-4 points according to the Modified Borg Scale (MBS) or fatigue 4-6 points.~Blood sugar measurement will be performed before exercise training. Individuals with a blood sugar result of \>300 mg/dL will not be allowed to exercise that day."
214964614|NCT06132334|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
214964615|NCT04861844|BEHAVIORAL|mindfulness training|phone based mindfulness training on 4 consecutive days
214964616|NCT04861844|BEHAVIORAL|active listening|The active listening intervention script asks the participant to attend by relaxing their body and visualizing themself in various exotic locations and narratives described in the script; it also asks the participant to rate their attention level of various points. The active listening scripts were compiled from National Geographic article excerpts (taken from the public domain)
214964617|NCT04534517|DEVICE|JJV Investigational Multifocal Contact Lens|TEST Lens
214964618|NCT04534517|DEVICE|ACUVUE OASYS® with HYDRACLEAR® PLUS|The spherical test lens was used in the troubleshooting steps only for low ADD subjects who have reported a distance vision complaint.
215080676|NCT03142555|BEHAVIORAL|Health talk plus less intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
215080677|NCT05179083|OTHER|High-Impact Aerobic Exercise|Participants will be submitted to a 12-week high-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (80% of maximum) is reached, followed by 10 minutes of cool down.
215080678|NCT05179083|OTHER|Low-Impact Aerobic Exercise|Participants will be submitted to a 12-week low-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (40% of maximum) is reached, followed by 10 minutes of cool down.
215080679|NCT01212497|BEHAVIORAL|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
215080680|NCT06140381|PROCEDURE|Eccentric training|The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase
215080681|NCT06140381|PROCEDURE|Conventional therapy|3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation
215080682|NCT01719029|OTHER|Low-Carbohydrate/Higher Fat Diet|
215080683|NCT01719029|OTHER|High Carbohydrate/Low fat diet|
215080684|NCT06463704|OTHER|There is no intervention|There is no intervention
215080685|NCT02070393|RADIATION|Proton|14-24 Radiation treatments using Protons
215080686|NCT03510468|DRUG|Tenofovir alafenamide|Each tablet contains 25 mg of tenofovir alafenamide.
214964619|NCT04407676|OTHER|Summary PIS and Online Video Modules|Complex trial information presented in alternative and more accessible formats
215080687|NCT03510468|DRUG|Rifapentine|Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
215080688|NCT03510468|DRUG|Isoniazid (INH)|Each tablet is formulated as 100 or 300 mg of isoniazid.
215080689|NCT03510468|DIETARY_SUPPLEMENT|Pyridoxine|Each tablet contains 50 mg of pyridoxine
215080690|NCT02995083|DRUG|40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine|Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
215080691|NCT02995083|DRUG|Normal Saline 10 ml|Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
215080692|NCT02995083|DRUG|Air 10 ml|Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
215080693|NCT04911400|OTHER|Upper-lower clear plastic retainers + Class III elastics|Addition of Class III elastics to clear plastic retainers
215080694|NCT04911400|OTHER|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
215080695|NCT01654159|PROCEDURE|Monofocal IOL|Monofocal Intraocular lens will be implanted
215080696|NCT01654159|PROCEDURE|Multifocal IOL|Multifocal IOL will be implanted
215080697|NCT01654159|PROCEDURE|Toric IOL|Toric IOLS will be implanted
215080698|NCT04612842|BEHAVIORAL|Motivational Interviewing|The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
215080699|NCT04382625|DRUG|Hydroxychloroquine|Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.
215080700|NCT05426031|DRUG|Protamine fixed dose|250 mg of protamine intravenously (IV), one time use
215080701|NCT05426031|DRUG|Protamine ratio dose|1mg of protamine per 100 units of heparin given intravenously (IV), one time use
214964620|NCT00612911|OTHER|Cell therapy|bone marrow mononuclear cell
215080702|NCT02076269|OTHER|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
215080703|NCT02372552|DEVICE|CROMA|Microwave coagulation of small blood vessels
215080704|NCT02419131|BEHAVIORAL|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
215080705|NCT02419131|BEHAVIORAL|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
215080706|NCT02419131|BEHAVIORAL|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
215080707|NCT04419740|BEHAVIORAL|Mindfulness based psychological intervention|Women in the intervention group will have to use an application during 1 month. They will do meditation during 15 minutes each day.
214355694|NCT01306773|DRUG|Oral Oseltamivir alone|Oral Oseltamivir 75mg bid during ICU hospitalization
214355695|NCT02014714|DRUG|Morphine|Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
214964621|NCT01299350|OTHER|Nt-proBNP guided discharge|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops \>30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
214355696|NCT02014714|DRUG|Fentanyl|Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
214679002|NCT05782556|DEVICE|Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
214964622|NCT05515133|OTHER|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
214964623|NCT03363607|PROCEDURE|Digital indirect bonding|Indirect bonding of orthodontic attachments using digital 3D printed transfer tray
214964624|NCT03363607|PROCEDURE|Conventional indirect bonding|Indirect bonding of orthodontic attachments using thermoformed transfer tray
214355697|NCT00637221|DRUG|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
214964625|NCT03363607|PROCEDURE|Intraoral scanning|Intraoral Scanning of the bonded brackets
214964626|NCT03363607|PROCEDURE|Superimposition and evaluation|superimposition of the brackets' positions before and after bonding and evaluation of the transfer accuracy
214355698|NCT03104634|DRUG|Aclidinium bromide/formoterol fumarate dihydrate|Cross-over design with washout interval. Randomized order of active and placebo arm
214355699|NCT03104634|DRUG|Placebo|Placebo and delivery device matched to active intervention
214355700|NCT02715128|DEVICE|Transcranial direct current stimulation (tDCS)|non-invasive electric brain stimulation method
214355701|NCT06164626|PROCEDURE|Extraction|extraction: in all groups, extraction will be performed
214355702|NCT06164626|RADIATION|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
214355703|NCT06164626|BIOLOGICAL|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
214679003|NCT03339427|OTHER|vitamin D|different doses of vitamin D supplementation
214679004|NCT03339427|OTHER|control|control group
215080708|NCT05923294|PROCEDURE|Coronally advanced flap with connective tissue graft|In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area.
215080709|NCT05801757|DRUG|Remimazolam|Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
215080710|NCT05801757|DRUG|Propofol|propofol 2-3mg/kg/h
215080711|NCT06142513|OTHER|Assessment|Between December 2023 and June 204, 46 volunteer participants aged 18 years and older who met the inclusion criteria and were followed up at Istanbul University, Istanbul Faculty of Medicine, Department of Chest Diseases and Istanbul Faculty of Medicine, Department of Internal Medicine were included in the project. Participants' body composition, comorbidities, exercise capacity, peripheral muscle strength, sleep quality and quality of life were assessed.
215080712|NCT04677660|BIOLOGICAL|TAK-919|TAK-919 intramuscular injection
215080713|NCT04677660|BIOLOGICAL|Placebo|Placebo intramuscular injection
214964627|NCT03872843|DRUG|Norco 5milligram-325milligram Tablet|Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
214355704|NCT03335033|COMBINATION_PRODUCT|Contrast-enhanced ultrasound|Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.
214679005|NCT06257004|GENETIC|Saliva collection (screening of all participants)|All participants will give a salive sample (self-sampling kit) - selection of 25% extremes (UMC and AMC) participants for WGS and linkage analysis
214964628|NCT03872843|DRUG|Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED|Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
214964629|NCT00938353|DRUG|beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml|Single dose 1600 mcg/4 ml
214964630|NCT00938353|DRUG|Placebo solution for nebulisation 2 ml|single dose: 4 ml
214964631|NCT04828031|DRUG|Vitamin D|Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
214964632|NCT03100409|OTHER|Dietary modification|"Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).~Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.~1. No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.~2. Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.~3. Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day."
214964633|NCT04088162|DEVICE|Postoperative Negative Pressure Wound Therapy KCI NANOVA|
214964634|NCT02155192|DRUG|No Intervention|
214964635|NCT00823264|DRUG|Activated Charcoal|50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
214964636|NCT05133323|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm.
214964637|NCT05133323|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.
214964638|NCT00541567|DRUG|ibipinabant|oral, tablet, once daily
214964639|NCT00113295|DRUG|Continued Paroxetine CR|
214964640|NCT00113295|DRUG|Quetiapine|
214964641|NCT00113295|DRUG|Placebo|
214964642|NCT01714544|DRUG|Cloderm Cream|
214964643|NCT06474156|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional family therapy is a manualized,evidence-based, intensive intervention program with assessment and treatment modules focusing on four areas: (a) the individual adolescents' issues regarding substance use disorder, delinquency, and comorbid psychopathology, (b) the parents' child-rearing skills and personal functioning, (c) communication and relationship between adolescent and parent(s), and (d) interactions between family members and key social systems (Liddle, 2002).
214964644|NCT02697214|DEVICE|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device compared to ECG and Polar H7
215080714|NCT02053207|BEHAVIORAL|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
215080715|NCT00089986|DRUG|Intravenous GR270773- Phospholipid Emulsion|
215080716|NCT00089986|OTHER|Placebo|
215080717|NCT00522314|DEVICE|NIV and ACBT|
215080718|NCT00522314|OTHER|Active Cycle of Breathing Techniques|
215080719|NCT03207178|BIOLOGICAL|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
215080720|NCT02199951|DRUG|Dihydroartemisinin and piperaquine|Antimalarial
215080721|NCT03683654|OTHER|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
215080722|NCT01151111|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
215080723|NCT04695054|DEVICE|Buzzy device plus EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure
214964645|NCT02697214|DEVICE|Apple Watch|Apple Watch heart rate monitoring device compared to ECG and Polar H7
214964646|NCT02697214|DEVICE|Mio Fuse|Mio Fuse heart rate monitoring device compared to ECG and Polar H7
214964647|NCT02697214|DEVICE|Basis Peak|Basis Peak heart rate monitoring device compared to ECG and Polar H7
214964648|NCT03523195|BEHAVIORAL|Exercise Intervention|Complete exercise program
214964649|NCT03523195|OTHER|Informational Intervention|Receive written information on healthy exercise and diet recommendations
214964650|NCT03523195|OTHER|Laboratory Biomarker Analysis|Blood tests
214964651|NCT03523195|DEVICE|Monitoring Device|Wear Fitbit
214964652|NCT03523195|OTHER|Questionnaire Administration|Ancillary studies
214964653|NCT03523195|OTHER|Physical Performance Testing|Performance of physical tests
214355705|NCT03335033|DEVICE|Shear Wave Elastography|Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.
214355706|NCT03335033|DEVICE|Ultrasound Examination|A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.
214355707|NCT05027165|OTHER|Non-interventional|No intervention
214355708|NCT00062127|DRUG|irinotecan hydrochloride|Given IV
214355709|NCT00062127|DRUG|thalidomide|Given orally
214679006|NCT06257004|GENETIC|Bloodsampling|Based on the results of the WGS, a selection will be made of the 5% most extremes (UMC and AMC) participants for the iPSC-VSMC generation
214964654|NCT01179607|DRUG|M0002|
214964655|NCT01179607|DRUG|Placebo|
214964656|NCT02459197|BEHAVIORAL|Heat Pain Stimuli A|
214964657|NCT02459197|BEHAVIORAL|Heat Pain Stimuli B|
214964658|NCT02459197|BEHAVIORAL|Positive Video|
214964659|NCT02459197|BEHAVIORAL|Neutral Video|
214964660|NCT02459197|DRUG|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
215080724|NCT04695054|DRUG|Only EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure
215080725|NCT03995680|DRUG|Mebendazole|Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
214964661|NCT02459197|DRUG|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
215080726|NCT01906723|DEVICE|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
215080727|NCT02739529|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
215080728|NCT02281474|DRUG|Nilotinib|
215080729|NCT02334683|DEVICE|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
215080730|NCT02334683|DEVICE|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
214964662|NCT00041197|DRUG|imatinib mesylate|Given orally (PO)
215080731|NCT00364572|DRUG|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
215080732|NCT00364572|DRUG|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
215080733|NCT01069263|OTHER|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
215080734|NCT01069263|DRUG|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
214964663|NCT00041197|OTHER|placebo|Given PO
214964664|NCT00041197|OTHER|laboratory biomarker analysis|Correlative studies
215080735|NCT01023087|DRUG|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
215080736|NCT01023087|DRUG|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
215080737|NCT00916058|DRUG|Bendamustine|30 mg/m\^2 given on day 2 of melphalan
215080738|NCT00916058|DRUG|Melphalan|100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)
215080739|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 2nd day of melphalan
215080740|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 2nd day of melphalan
215080741|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 1st and 2nd day of melphalan
215080742|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 1st day of melphalan and 60 mg/m\^2 given on the 2nd day of melphalan
215080743|NCT00916058|DRUG|Bendamustine|125 mg/m\^2 given on the 1st day of melphalan and 100mg/m\^2 given on the 2nd day of melphalan
215080744|NCT06488612|PROCEDURE|Minced skin grafts for donor site|"After harvesting of STSG using watson's knife and coverage of the recipient site, the excess graft edges will be trimmed and together with any unused graft pieces will be collected in saline filled plate to prevent graft dissecation. Graft pieces will be placed over a rigid surface such as dorsum of a stainless steal jar or pot. Mincing of these small grafts will be done manually using large blade (no. 25) and sharp scissors. The resulting pasty graft mass composed of a large number of minced skin graft particles and a small amount of saline solution will be spread onto one half of the donor site using small dressing forceps.~Minced skin grafts will not be used on the other half (control side). The entire donor site will be covered with non-adherent absorbable dressing in the form of Vaseline gauze and sterilized cotton-filled dressing followed by elastic compression bandage."
214679007|NCT06512428|DRUG|simmitinib plus irinotecan liposome|simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks
214679008|NCT06512428|DRUG|irinotecan liposome|irinotecan liposome 70 mg/m\^2 every 2 weeks
214679009|NCT06512428|DRUG|irinotecan|irinotecan 180mg/m\^2 every 2 weeks
214964665|NCT05102071|DRUG|empagliflozin|empagliflozin
214964666|NCT05102071|DRUG|metformin|metformin
214964667|NCT05102071|DRUG|sulfonylurea|sulfonylurea
214964668|NCT00577772|DRUG|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
214964669|NCT00577772|DEVICE|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
214355710|NCT00062127|OTHER|pharmacological study|Correlative studies
214355711|NCT05086133|DEVICE|transcranial magnetic stimulation|transcranial magnetic stimulation with continuous theta burst pattern, 90% RMT, 50Hz within train and 5Hz train for 200 train and 40 second in total.
214355712|NCT05086133|DEVICE|sham stimulation|TMS coil vertical to the brain surface, with same protocol as cTBS
214355713|NCT00601926|BIOLOGICAL|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
214355714|NCT00558311|DRUG|Clazosentan|Intravenous clazosentan administered by continuous infusion at 5 mg/h
214355715|NCT00558311|DRUG|Placebo|Placebo administered by continuous infusion matching clazosentan administration
214355716|NCT04097457|BEHAVIORAL|"Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)"|"The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers"
214355717|NCT03369444|BIOLOGICAL|FLT180a|FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
214355718|NCT04490486|BIOLOGICAL|UCMSCs|100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.
214964670|NCT00577772|PROCEDURE|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
214964671|NCT02012400|OTHER|Exercise|The exercise group is given a 24-week individualized training program, including aerobic exercise, muscular training, relaxation exercises and stretching. Patients are asked to observe their asthma control daily and to mark in their diary asthma symptoms and activity limitations as well as duration, intensity and form of exercising on daily basis. They are also asked to perform PEF-measurements twice a day for one-week period every 4 weeks. The control group receives ordinary instructions.
214964672|NCT06484296|OTHER|Education|"Before the training, students in all groups will be provided to take the Pretest.~The students included in the training group will be trained on good and green health practices in the conference hall of the Faculty by expert researchers and the green transformation coordinator of the university who have a certificate of Conscious Awareness training. Three weeks after the training, all students will be given the Green Culture Scale Post-Test."
215080745|NCT04994782|BEHAVIORAL|GAME-EOL|The GAME-EOL involves Hello game booklets as well as meetings with an interventionist. Players (ICD recipient and their family member or friend dyad) take turns asking the questions in their booklet and providing their answers to the question. The gameplay continues until all questions are answered or the dyad wishes to stop. Following the completion of the game play, participants will be offered the opportunity to complete advance directives using the conversation guide and advance directive form included in the conversation guide that accompanies the questionnaire booklet.
215080746|NCT02125916|OTHER|oxygen therapy|
214355719|NCT04490486|OTHER|Placebo|Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion
214355720|NCT04148443|OTHER|Preoxygenation|participants will receive 3 minutes of preoxygenation before intubation
214355721|NCT04148443|OTHER|Preoxygenation (longer)|participants will receive 5 minutes of preoxygenation before intubation
214355722|NCT03581721|DEVICE|enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer|"The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group"
215080747|NCT00278902|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
215080748|NCT02178813|DRUG|Administration of minocycline|"Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o."
215080749|NCT04219319|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
215080750|NCT05517213|DRUG|Etoposide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
214355723|NCT03351374|OTHER|Software|multi-module system of web software tools
214355724|NCT00153777|DRUG|Cellulose Sulfate gel (6%)|
214355725|NCT01542918|DRUG|Lenalidomide|"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral"
214355726|NCT01542918|DRUG|Rituximab|"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"
214355727|NCT00785655|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
214355728|NCT01346748|DRUG|statin|Sinvastatin 80 mg per day - 21 days versus placebo
214964673|NCT00572455|DRUG|PF-04217329 - Lowest Dose|1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
214964674|NCT00572455|DRUG|PF-04217329 - Low Dose|1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
214964675|NCT00572455|DRUG|PF-04217329 - Middle Dose|1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
214355729|NCT01184287|DRUG|Ranpirnase|Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
214355730|NCT05947877|PROCEDURE|Non-pharmacological pain management strategies|Non-pharmacological pain management strategies
214355731|NCT02628210|OTHER|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
214355732|NCT03232970|OTHER|Full Plate Diet|12 weekly sessions on how to incorporate more fiber in the diet.
214355733|NCT00519181|DRUG|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
214355734|NCT02405520|BIOLOGICAL|low dosage HPV Vaccine|Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
214964676|NCT00572455|DRUG|PF-04217329 - High Middle Dose|1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
214355735|NCT02405520|BIOLOGICAL|medium dosage HPV Vaccine|Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
214355736|NCT02405520|BIOLOGICAL|high dosage HPV Vaccine|Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
214355737|NCT02405520|BIOLOGICAL|Aluminium Adjuvant|Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
214355738|NCT01993069|BEHAVIORAL|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
214355739|NCT01567618|DRUG|Docetaxel|"Docetaxel 50mg/m2 iv drip, repeat every two weeks;~Efficacy will be evaluated every three cycles."
214355740|NCT01567618|DRUG|Fluorouracil|Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
214355741|NCT03934398|DIAGNOSTIC_TEST|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
214355742|NCT03934398|DIAGNOSTIC_TEST|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.
214355743|NCT03934398|DIAGNOSTIC_TEST|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
214355744|NCT03934398|DIAGNOSTIC_TEST|Emotional/Behavioral Assessments|Participants and parents will fill out questionnaires for emotional/behavioral assessments
214679010|NCT04220047|PROCEDURE|Left Atrial Appendage Resection and Marshall Ligament Amputation|Left Atrial Appendage Resection and Marshall Ligament Amputation during the cardiac surgery
214964677|NCT00572455|DRUG|PF-04217329 - High Dose|1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
214964678|NCT00572455|DRUG|PF-4217329 - Highest Dose|1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
214964679|NCT00572455|DRUG|PF-04217329 - Vehicle|1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
214964680|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
214964681|NCT00572455|DRUG|PF-04217329 - Low Dose|Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
215080751|NCT05517213|DRUG|Cyclophosphamide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
214355745|NCT03146624|OTHER|attachment retained obturator|obturator which retained by attachment
214355746|NCT03146624|OTHER|clasp retained obturator|obturator which retained by clasp
214355747|NCT02937168|DRUG|Reslizumab|Reslizumab will be administered as per the dose and schedule specified in the arm.
214355748|NCT02937168|DRUG|Fludeoxyglucose F 18 (FDG)|FDG will be administered by IV infusion prior to each PET/CT scan.
214964682|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
214964683|NCT00572455|DRUG|PF-04217329 - Middle Dose|Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
214964684|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
214964685|NCT00572455|DRUG|PF-04217329 - High Dose|Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
215080752|NCT05121220|DEVICE|fixed retainer|bonded lingual mandibular fixed retainer on frontal teeth 33-43
214355749|NCT02937168|DRUG|Placebo|Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
214355750|NCT02491671|DEVICE|Hemopatch|
214355751|NCT02491671|PROCEDURE|standard preventive measures|
214355752|NCT05949723|DEVICE|Golf simulator device|The golf simulator can accurately predict the flight trajectory and landing point of the ball using high-speed moving object measurement technology, giving the user the impression that they are playing on a real golf course.
214355753|NCT02654626|DRUG|KBP-7072|Drug Intervention
214355754|NCT02654626|OTHER|Placebo|
214355755|NCT03392714|DRUG|R-B(O)AD|rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
214355756|NCT01398488|BEHAVIORAL|Patient education|Patient education by health care professional compared to education via tablet PC
214355757|NCT04166253|DRUG|Vitamin D|Alfacalcidol oral tablets once daily
214355758|NCT01342874|DIETARY_SUPPLEMENT|Inositol|inositol exposure in early GDM
214679011|NCT04207853|OTHER|whole body vibration em DM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
214964686|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
214964687|NCT00572455|DRUG|PF-04217329 - Low Dose|Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
215080753|NCT05121220|DEVICE|removable retainer|thermoplastic vacuum-formed removable mandibular retainer
214964688|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
214679012|NCT04207853|OTHER|"Vibration sham em DM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
214964689|NCT00572455|DRUG|PF-04217329 - Middle Dose|Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
214964690|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
214964691|NCT00572455|DRUG|PF-04217329 - High Dose|Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
214964692|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
214964693|NCT00572455|DRUG|PF-04217329 - Vehicle|Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
214964694|NCT06105606|DEVICE|AveCure Flexible Microwave Ablation Probe|Consists of a handheld, surgical device which delivers microwave energy from its microwave antenna. The flexible probe has a 3cm active microwave field that radiates from the tip.
214964695|NCT03627793|OTHER|resistance training|Moving muscles against loads with the purpose of increasing strength.
214964696|NCT00334412|DRUG|Ambisome|
214964697|NCT00334412|DRUG|caspofungin|
214964698|NCT00484471|DRUG|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
214964699|NCT00484471|DRUG|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
214964700|NCT00484471|DRUG|placebo|placebo to aripiprazole, 22 weeks
215080754|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
215080755|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma|Conventional melanoma educational intervention.
214964701|NCT04302207|BEHAVIORAL|De-implementation Strategy for Bronchiolitis|De-implementation strategy to reduce over-use of treatments for patients with bronchiolitis
214964702|NCT02955953|DRUG|LY2963016|Administered SC
214964703|NCT02453464|DRUG|Sevacizumab|escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
214964704|NCT02453464|DRUG|Irinotecan|Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
214964705|NCT02453464|DRUG|5-FU|5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
214964706|NCT02453464|DRUG|Leucovorin|Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
214964707|NCT01644097|DIETARY_SUPPLEMENT|Lactobacillus plantarum strain 299v|Given PO
214964708|NCT01644097|DIETARY_SUPPLEMENT|Lactobacillus acidophilus probiotic|Given PO
214964709|NCT01644097|DIETARY_SUPPLEMENT|placebo|Given PO
214964710|NCT01644097|OTHER|laboratory biomarker analysis|Correlative studies
214964711|NCT01644097|OTHER|questionnaire administration|Ancillary studies
214964712|NCT01644097|PROCEDURE|quality-of-life assessment|Ancillary studies
214964713|NCT01644097|DIETARY_SUPPLEMENT|Bifidobacterium lactis probiotic supplement|Given PO
214964714|NCT03310242|BEHAVIORAL|Sunlight Exposure|"* Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks~* Completing a Sun Diary after sunlight exposure"
214964715|NCT03310242|DIETARY_SUPPLEMENT|Vitamin D Supplementation|\- Supplementation of vitamin D3 500 IU/day for 8 weeks
214964716|NCT03310242|OTHER|Placebo|\- Intake of placebo for 8 weeks
214964717|NCT00117169|PROCEDURE|multi-detector helical computed tomography|
214964718|NCT00004244|BIOLOGICAL|recombinant interferon alfa|
214964719|NCT00004244|BIOLOGICAL|recombinant interleukin-12|
214964720|NCT00245024|DRUG|sulindac|
214964721|NCT00245024|OTHER|laboratory biomarker analysis|
214964722|NCT02824224|DRUG|Tamoxifen|10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
214964723|NCT02824224|DRUG|Placebo (for Tamoxifen)|Sugar pill manufactured to mimic the tamoxifen 10mg tablet
214964724|NCT06959667|OTHER|Observational study, no intervention|Observational study, no intervention
214964725|NCT04494269|DRUG|Tegoprazan 50mg|Oral administration once daily
214964726|NCT03846544|DRUG|Corifollitoropin alfa (CFA)-double pick up|In the study group, 225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with human chorionic gonadotropin (hCG) 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
215080756|NCT04174989|OTHER|Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)|ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.
215080757|NCT04174989|OTHER|Regular fresh-frozen plasma (not treated)|Regular fresh-frozen plasma (not treated)
215080758|NCT01185418|DRUG|risperidone|
215080759|NCT01185418|DRUG|aripiprazole|
215080760|NCT01185418|DRUG|haloperidol|
215080761|NCT01185418|DRUG|amisulpride|
214355759|NCT06443268|DIAGNOSTIC_TEST|questionnaire, hair samples, blood samples, clinical exam|The following parameters will be sequentially assessed in caregivers and patients (baseline, at 3 months and at 12 months): 1) quality of life / functioning will be determined through questionnaires (SF-36, EQ-5DL, ECOG (Eastern Cooperative Oncology Group) / Karnofsky, Barthel Index, ICIQ) 2) stress levels \& anxiety levels, caregiver burden will be assessed by the following questionnaires: Distress Thermometer, SBQ-G, GAD-7, PHQ-9, PSS-10, ZBI, PAC. Cortisol will be measured in hair to indicate stress within the past 3 months \[18\]. Fasting glucose, lipid profiles and HbA1c along with blood count, sodium, potassium, creatinine, TSH (thyroid-stimulating hormone) will be measured in routine blood samples from patients at the time of clinical checkups. Blood pressure, pulse and BMI will be determined during clinical visit in patients and additionally in caregivers.
214964727|NCT01912859|BEHAVIORAL|Nutrition/physical activity intervention|Nutrition/physical activity intervention
214964728|NCT01296854|OTHER|Spa therapy|3 weeks of spa therapy
214964729|NCT02047435|BEHAVIORAL|Information, event and workshops at a cartoon museum|"1. An event at the Storm P. Museum consisting of:~   * A guided tour at the museum~  * A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~  * The museum serves a refreshment and offer participants a season pass to the museum.~   And~2. Workshops at The Storm P. museum, for up to 12 months with approximately two workshops a months. In collaboration with the museum the participants create memory material for nursing home resident with dementia. The workshop will use narrative as a method to give participants a mutual relationship that is perceived as meaningful and rewarding for each participant and in the dialogues a mutual understanding is created. The museum staff facilitates the process of storytelling using events, significant stories and artistic works by Storm P., to encourage the participants, via the method known as narrative interview, to share similar stories from their life."
214964730|NCT02047435|BEHAVIORAL|Information and event at a cartoon museum|"1\. An event at the Storm P. Museum consisting of:~* A guided tour at the museum~* A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~* The museum serves a refreshment and offer participants a season pass to the museum."
214355760|NCT00535730|BIOLOGICAL|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
214355761|NCT00535730|BIOLOGICAL|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
214355762|NCT00535730|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
214964731|NCT00629031|DRUG|Paromomycin|11 mg/kg for 14 days
214964732|NCT00629031|DRUG|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
214964733|NCT02533583|DEVICE|pulse oximetry (PHILIPS intelliven MP5)|all newborn monitor pulse oximetry in left hand
214487302|NCT06702046|DEVICE|transcutaneous pulsed radiofrequency acupuncture|For the TCPRF acupuncture group, the investigators choose ST34 (Liangqiu), SP10 (Xuehai), GB34 (Yanglingquan), SP9 (Yinlingquan) around the affected knee. The TCPRF device is a wearable modality with innovative pulse radiofrequency technology aimed at alleviating symptomatic chronic pain, which revealed that UHF (500-kHz sine wave, 2-Hz frequency with a 25-ms pulse). It was attached to the electrode pad through magnetic attraction. A 500-KHz stimulus was delivered. The symmetric two-phase sine wave has a 2-Hz frequency witha 25-ms pulse width. The treatment has 15 min per time. Electrical stimulation is administered for 30 minutes each session, divided into two 15-minute phases. After the first 15 minutes, the treatment is paused and then restarted for an additional 15 minutes. The output peak current was 13.2 mA and the output peak voltage was 6.6 V at 500 Ω.
214487303|NCT06702046|DEVICE|Sham Comparison|same protocol will be done on the same acupoints, but the machine will be turn off interiorly. Therefore, although the machine still has lights and a vibrating sensation, it will not release PRF waves.
214487304|NCT04653740|PROCEDURE|specimen sample collection|"Before and during treatment, and at progression, collection of :~* Blood~* Exhaled air~* Saliva~* Sweat~* Tears~* Urine"
214487305|NCT06872983|PROCEDURE|cyanoacrylate tissue adhesive beside sutures|"A supracervical hysterectomy will be performed in the standard manner. Uterine amputation above the cervix will be performed with a monopolar needle or scissors. Concomitant adnexal surgery will be performed according to the presence of adnexa and the patient's request or medical indication.~In this study group, the implant is secured to the vaginal wall with cyanoacrylate tissue adhesive. Fixation of the implant to the cervix and promontory will be identical to the control group."
214487306|NCT06872983|PROCEDURE|Suture|A supracervical hysterectomy will be performed in the standard manner. Uterine amputation above the cervix will be performed with a monopolar needle or scissors. Concomitant adnexal surgery will be performed according to the presence of adnexa and the patient's request or medical indication. In this control group, the mesh will be fixed to the cervix with four non-absorbable sutures. In addition, the implant will be fixed to the anterior vaginal wall with four absorbable sutures and to the posterior vaginal wall with four absorbable sutures. The implant will be secured to the promontory with one non-absorbable suture.
214964734|NCT04054817|DEVICE|Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix|Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
214964735|NCT03180957|DRUG|Adalimumab|
214964736|NCT03180957|DRUG|Saline|
214964737|NCT02403583|BEHAVIORAL|Intervention- Home Visits|If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
214964738|NCT00346762|BEHAVIORAL|Education|HIV prevention education and risk reduction counselig
214964739|NCT03001947|OTHER|No intervention|Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
215080762|NCT01185418|DRUG|lactose|
215080763|NCT02762955|BIOLOGICAL|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
215080764|NCT02762955|BIOLOGICAL|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
215080765|NCT04953819|OTHER|Revascularization|Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease
214355763|NCT06470854|DRUG|Nebulized Dexmedetomidine|Nebulized Dexmedetomidine was prepared to provide 1 µg/kg and the calculated dose of DXM was diluted by 4-ml of 0.9% saline and was provided in the nebulizer to be nebulized in twice daily; i.e. every 12 hours for 72 hours
214964740|NCT01610856|DRUG|Polyethylene Glycol|4 Litres of polyethylene glycol bowel preparation solution
214964741|NCT01610856|DRUG|polyethylene glycol|Polyethylene glycol 4L given in two split doses of 2L each
214964742|NCT04037514|DRUG|Paracetamol|Intravenous paracetamol 15 mg/kg/6h
214964743|NCT04037514|DRUG|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
215080766|NCT04953819|OTHER|Medical therapy|Optimal medical therapy for coronary artery disease
215080767|NCT03964246|BEHAVIORAL|Compassion Meditation (CM) intervention|"10 weekly 90-minute sessions. Sessions 1-3 assist participants in basic mindfulness breathing practices; sessions 4-8 focus on personal analysis of factors underlying difficulties with compassion for self or others; sessions 9 and 10 review content and assist with relapse prevention.~\[These were planned as in-person groups but due to the COVID-19 social distancing requirements that started after initiation of cohort 1, the investigators had to retool the intervention for telehealth delivery.\]"
215080768|NCT03964246|OTHER|Healthy Aging Psychoeducation|"The investigators planned to administer a 10-week psychoeducational in-person group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent randomized controlled trial. This would include use of an existing library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity.~\[Unfortunately, with the switch to telehealth format necessitated by the COVID-19 social distancing requirements, the consensus of the investigators and staff was that these proved too be too dry/dull/academic to be a credible attention control in a telehealth format for the target population.\]"
214355764|NCT06470854|PROCEDURE|Bilateral greater occipital nerve block|The injection solution was prepared by mixing 2-ml of 2% lidocaine with 2-ml (8 mg) of dexamethasone. A line was drawn extending between the mastoid process and the external occipital protuberance, this line was divided as a medial third and lateral two-thirds to localize the occipital artery and the greater occipital nerve was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline and injection was performed bilaterally to achieve bilateral block.
214355765|NCT03734627|DRUG|Octreotide Acetate|50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
214355766|NCT03734627|DRUG|Saline Solution|Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
214355767|NCT03734627|DRUG|Paracetamol|Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
214355768|NCT03734627|DRUG|Sulfasalazine|1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
214355769|NCT03734627|DIAGNOSTIC_TEST|Duodenal biopsy|Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
214964744|NCT01773629|OTHER|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
214964745|NCT01773629|OTHER|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
214964746|NCT06492447|DRUG|Against HER 2-ADC Drug|Breast cancer subjects receiving anti-HER2-ADC drugs were treated with a 3-week treatment cycle lasting 6 cycles. Serum of patients before and after treatment was collected, and the changes of serum HER2 level before chemotherapy and after 2, 4 and 6 cycles of chemotherapy were dynamically monitored, and the relationship between HER2 level and the therapeutic effect of different targeted drugs was analyzed.
214964747|NCT00202020|DRUG|Cilostazol 200mg/day Oral|
214964748|NCT00202020|DRUG|Aspirin 100mg/day Oral|
214964749|NCT03579121|OTHER|Pharmacogenomic (PGx)|Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
214355770|NCT00303524|DRUG|Goserelin acetate|Injection 3.6 mg monthly
214355771|NCT00303524|DRUG|Goserelin acetate|injection 10.8 mg every 3 months
214355772|NCT02106299|DEVICE|Regen sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).
214355773|NCT02106299|DEVICE|tension-free vaginal tape-obturator(TVT-O)|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
214355774|NCT02739438|OTHER|Electronic cigarette use|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.
215080769|NCT06009887|BEHAVIORAL|Motivational Interview|Motivational interviewing is a collaborative speaking style to strengthen one's own motivation and commitment to change. Motivational interviewing is not a technique but a fundamental therapeutic style that does not try to make people change their behavior against their will. Proven to be effective in many areas of healthcare, motivational interviewing is widely used to help people resolve their indecision about change, explore their concerns, and set their own goals. The purpose of the motivational interviews conducted in the study is to increase the belief in normal and natural birth by enabling pregnant women to understand the factors that affect their low belief in normal birth, to take action for change and to believe in change, and to minimize the practices that cause medicalization of birth such as cesarean section by reducing medical birth beliefs.
215080770|NCT03403231|BEHAVIORAL|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
214355775|NCT02739438|OTHER|Cigarette use|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
214355776|NCT02739438|OTHER|Control group|Subjects with no history of prior conventional cigarette (\< 100 cigarettes lifetime) or electronic cigarette use.
214355777|NCT00862160|DEVICE|ROCsafeTM|using minimized perfusion circuit while CABG
214355778|NCT01279499|DRUG|Sevoflurane|Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR \> 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
214355779|NCT01279499|DRUG|Sevoflurane|Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
214355780|NCT01279499|DRUG|Propofol- Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR \> 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min"
214964750|NCT03579121|OTHER|Review results|Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
214964751|NCT01005017|PROCEDURE|Percutaneous Radiofrequent Lesioning|One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
214964752|NCT04257396|DEVICE|Carbon-Fibre Adjustable Reuseable Accessory (CARA)|Breast support device having a carbon-fibre breast cradle for supine patient positioning.
215080771|NCT06896942|OTHER|Autism Doula|The Autism Doula provides caregiver support, navigation with next steps for their child, connects families to resources and the Black autism community, and coordinates services to help alleviate caregiver stress (e.g., cleaning, cooking, respite care).
215080772|NCT06896942|OTHER|DDBP Family Navigation|A one-time consult with a DDBP family navigator via telehealth to come up with an action plan for next steps for the patient's care.
215080773|NCT04211987|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
215080774|NCT04211987|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
215080775|NCT03876015|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
215080776|NCT02943824|OTHER|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
215080777|NCT02943824|OTHER|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
215080778|NCT03921619|DEVICE|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
215080779|NCT01071200|DRUG|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
215080780|NCT01071200|DRUG|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
214355781|NCT01279499|DRUG|Propofol, Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR \> 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min"
214355782|NCT03556462|OTHER|Sleep Health Education|Parents and children receive sleep health education
214964753|NCT04152083|DRUG|Eptinezumab|Injection for IV administration
214964754|NCT04152083|DRUG|Placebo|Injection for IV administration
214964755|NCT06165198|DEVICE|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed-loop tACS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
214964756|NCT03792542|DRUG|Anlotinib|Anlotinib Hydrochloride ( 12mg, quaque die（QD）, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from adverse events(AEs), they can get declined dosage.
214487307|NCT06849154|BEHAVIORAL|REAL™ SEL Intervention Group|A structured intervention using virtual reality (VR) components to improve emotional regulation in early adolescents
214964757|NCT06958510|DEVICE|3D-Modified Anatomical-Mesh.|3D-Modified Anatomical-Mesh.
214964758|NCT06958510|DEVICE|conventional orbital rim miniplates and orbital mesh configuration|conventional orbital rim miniplates and orbital mesh configuration
215080781|NCT05718752|DIAGNOSTIC_TEST|Maximal incremental exercise test|Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value
215080782|NCT05718752|DIAGNOSTIC_TEST|30-min submaximal exercise test|A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery
215080783|NCT04895293|DRUG|RBM-007 Injectable Solution|Sterile solution
215080784|NCT04480190|DRUG|Gemcitabine|IV Gemcitabine 1000mg/m2 to be given on Days 1, Day 8 (Before Cisplatin); 3 week cycles
215080785|NCT04480190|DRUG|Cisplatin|IV Cisplatin 25mg/m2 to be given on Days 1, Day 8
214964759|NCT06054945|PROCEDURE|SIFIB (suprainguinal fascia iliaca block)|Ultrasound guided Suprainguinal Fascia Iliaca Block for Knee Arthroplasty Patients
214964760|NCT06054945|OTHER|IPACK (Interspace between the popliteal artery and capsule of the posterior knee )|Ultrasound guided IPACK (Interspace between the popliteal artery and capsule of the posterior knee ) Block for Knee Arthroplasty Patients
214393679|NCT04238403|BEHAVIORAL|Behavioral Parent Training (MATCH Protocol)|BPT. Behavioral Parent Training (BPT) is a well-established psychosocial intervention for the treatment for ADHD and related behavioral difficulties (e.g., oppositional problems). BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods (e.g., praise, effective communication, reward systems, time-out from positive reinforcement) to facilitate positive behaviors in their child (e.g., compliance) and reduce challenging behaviors (e.g., opposition). BPT comes in several manualized, commercially available manuals. The version of BPT that we will be utilizing is from the MATCH protocol (Chorpita and Weisz, 2009), which consists of 10 components, delivered with individual families, typically over the course of 10-16 weekly individual meetings (total meetings depends upon parent availability and acquisition of BPT skills).
214679013|NCT04207853|OTHER|whole body vibration em NDM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
214679014|NCT04207853|OTHER|"Vibration sham em NDM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
214679015|NCT02100657|DRUG|Plitidepsin|
214964761|NCT06054945|DEVICE|Patient controlled anagesia device|Those who were administered opioids with PCA as rescue analgesic in the postoperative analgesia plan on the selected dates will be included in the study.
214964762|NCT00215891|DRUG|PEG-Interferon a-2b + Ribavirin|
214964763|NCT06059937|OTHER|Patient with pre-eclampsia|Cardiovascular risk assessment by the general practitioner in the year following pre-eclampsia
214964764|NCT04870632|OTHER|Education|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.
214964765|NCT04870632|OTHER|Video-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by watching Youtube videos which were made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
214679016|NCT02100657|DRUG|Bortezomib|
214679017|NCT02100657|DRUG|Dexamethasone|
214964766|NCT04870632|OTHER|Booklet-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
214964767|NCT04512963|DRUG|Progerinin|100 mg/g nano-suspension for oral use
214964768|NCT04512963|DRUG|Placebo|A substance that has no therapeutic effect, used as a control in testing Progerinin
214964769|NCT06391359|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
214964770|NCT06391359|OTHER|Watchful waiting|Watchful waiting
214964771|NCT05084183|DEVICE|PermeaDerm®|Wound Management Device
214964772|NCT05084183|DEVICE|Mepilex Ag|Wound Dressing
215080786|NCT04480190|DRUG|Fluorouracil|Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT
215080787|NCT04480190|RADIATION|Short course ChemoRT|"Radiation Therapy:~Sim: All patients will undergo 4D-CT simulation with 3 hours fasting with or without IV contrast. Compression may be used depending on the tumor motion.~Radiation Target Volume: The gross tumor volume (GTV) will be defined on all relevant imaging datasets including diagnostic CT, MRI, MRCP and/or ERCP data. An iGTV will be generated using the 4D datasets. The clinical target volume (CTV) will include the entire iGTV as well as portal lymphatic and celiac nodal space for all patients with selective treatment of the SMA and pancreaticoduodenal depending on the tumor location. A 5 mm margin will be added to the CTV to generate the planning target volume (PTV).~Radiation Dose: The dose will be 30 Gy in 10 fractions (3 Gy per fraction) for all patients using either 3D Conformal or Intensity Modulated Radiation Therapy techniques."
214964773|NCT04366154|OTHER|Questionnaire|delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint
214964774|NCT00856999|DRUG|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
214679018|NCT00928616|DIETARY_SUPPLEMENT|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
214679019|NCT00928616|DIETARY_SUPPLEMENT|margarine (placebo)|non-sterol ester supplemented margarine
214679020|NCT03900559|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes."
214964775|NCT05010213|OTHER|Educational intervention|Educational intervention
214964776|NCT01427543|BEHAVIORAL|MILE intervention|Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
214964777|NCT06958133|OTHER|Standard Postoperative Rehabilitation|Standard rehabilitation protocol after surgical fixation of Weber type B ankle fractures without Kinesio taping.
214964778|NCT06958133|OTHER|Kinesio Taping|Kinesio taping applied over the surgical ankle to assist in reducing postoperative pain, swelling, and improving range of motion.
214964779|NCT00626652|DRUG|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
214355783|NCT04878562|BEHAVIORAL|I-COPE|The patient survey will be sent out via MyChart 3 days before the visit. It asks about current pain, goals, treatment history, treatment preferences, and health status. Alternatively, patients will be asked to compete a survey in clinic on paper or a tablet. The surveys will be identical, except screening for screening for depression and opioid use will depend on the availability of previous scores. Survey and the EHR will help auto-generate best practice advisories (BPAs) and a tailored smart set. The smartset is based on AGS and CDC guidelines for chronic pain and opioids. It shows which treatment options are not recommended based on the patient's history, comorbidities, and preferences. The smartset also includes links to decision aid and patient education tools. Personalized action plan will be created with pain rating and goal, treatment plan, and relevant tips and educational materials. Action plan will be clearly laid out using max 6 grade reading level, and simple graphics.
214964780|NCT06959433|DRUG|Lu-177 PSMA-617|Included patients will receive 4 cycles of 7.4GBq Lu-177 PSMa therapy every 6 weeks. If any toxicity develops after the first cycle, dose reduction will be performed for the other cycles. At 1. And 4. Cycles of therapy, whole body planar and SPECT/CT imaging will be performed at 4. And 24. Hours and any time at 4-7.days of injection. On these images , kindey, liver and salivary gland doses will be calculated. Mean tumor dose will also be calculated by measurinf the tumoral uptake. In the follow up, patients will be controlled at 9. And 24. Weeks and every 12 months then after.
214964781|NCT01341015|OTHER|Ultrasound|Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
214964782|NCT03557918|DRUG|Tremelimumab|"Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria."
214964783|NCT06959147|DRUG|High-Voltage Long-Duration Pulsed Radiofrequency plus Liposomal Bupivacaine group|High-Voltage Long-Duration Pulsed Radiofrequency Combined with Liposomal Bupivacaine Subcutaneous Block
214964784|NCT06959147|OTHER|High-Voltage Long-Duration Pulsed Radiofrequency|High-Voltage Long-Duration Pulsed Radiofrequency
214964785|NCT04164368|DRUG|Lenalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11
214964786|NCT03350490|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
214964787|NCT03350490|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
214964788|NCT01695382|BEHAVIORAL|Navigation|As per Arm description
215080788|NCT01527513|DRUG|Eslicarbazepine acetate (BIA 2-093)|Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
215080789|NCT01527513|DRUG|Placebo|Treatments will be administered by oral route, once-daily, in the evening.
214355784|NCT05525494|BEHAVIORAL|Text Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
214355785|NCT05525494|BEHAVIORAL|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
214393680|NCT00469365|BEHAVIORAL|pharmacist contact with the patient via telephone|
215080790|NCT04775927|OTHER|education|premarital education
215080791|NCT03279913|DEVICE|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
215080792|NCT03042377|OTHER|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
215080793|NCT03042377|DRUG|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
215080794|NCT03042377|DRUG|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid \& antibiotic paste and the cavity was filled with temporary restorative material.
214393681|NCT00469365|BEHAVIORAL|Pharmacist contact with the patient's physician via fax|
214393682|NCT00469365|BEHAVIORAL|Usual care|
214393683|NCT01594177|DRUG|Afatinib|20 mg daily for 17 weeks (first two weeks every second day).
214964789|NCT04575090|DRUG|Simvastatin|Simvastatin 40 mg daily.
214964790|NCT06958185|DEVICE|deep peripheral sensory stimulation|The proprioceptive stimulus will consist of intermittent mechanical pressure on the skin, localized at the neuromuscular motor points of the rectus femoris, vastus lateralis, and vastus medialis of the quadriceps. The tissue subjected to this precise pressure in areas of high neuromuscular innervation facilitates the stimulation of kinesthetic cortical sensitivity. The experimental group (EG) will be randomly and crosswise subdivided into two groups, so that both receive the intervention in two different modalities at two different times.
214964791|NCT06958965|OTHER|Resistance exercise training|The total duration of the training was 12 weeks, with a frequency of two sessions per week. Each session lasted approximately 90 to 120 minutes. The exercise intensity was set at 40-70% of the participants' one-repetition maximum (1RM), or adjusted based on the Modified Borg Rating of Perceived Exertion (RPE), targeting a moderate intensity level (approximately a score of 3).
214964792|NCT06959485|BIOLOGICAL|Oxygen Therapy|"1. To evaluate the effect of oxygen therapy (hyperbaric oxygen and oxygen by non- rebreather mask) and early morning air on proteinuria in patients with diabetic kidney disease.~2. To evaluate the effect of oxygen therapy (hyperbaric oxygen and oxygen by non- rebreather mask) and early morning air on glycated haemoglobin in patients with diabetic kidney disease.~3. Comparing the effects of oxygen therapy (hyperbaric oxygen and oxygen by non- rebreather mask), early morning air exposure, and standard care on kidney function"
214964793|NCT06958705|DRUG|Venetoclax combined with Ibrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using ibrutinib. After the completion of combination therapy, patients will stop both the ibrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and ibrutinib will continue for an additional 12 cycles. Venetoclax and ibrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Ibrutinib is intended to be admistratered orally 420mg once daily."
214964794|NCT06958705|DRUG|Venetoclax combined with Zanubrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using zanubrutinib. After the completion of combination therapy, patients will stop both the zanubrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and zanubrutinib will continue for an additional 12 cycles. Venetoclax and zanubrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Zanubrutinib is intended to be admistratered orally 160mg twice daily."
214964795|NCT06958705|DRUG|Venetoclax combined with Acalabrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using acalabrutinib. After the completion of combination therapy, patients will stop both the acalabrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and acalabrutinib will continue for an additional 12 cycles. Venetoclax and acalabrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Acalabrutinib is intended to be admistratered orally 100mg twice daily."
214964796|NCT06958705|DRUG|Venetoclax combined with Orelabrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using orelabrutinib. After the completion of combination therapy, patients will stop both the orelabrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and orelabrutinib will continue for an additional 12 cycles. Venetoclax and orelabrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Orelabrutinib is intended to be admistratered orally 150mg once daily."
214964797|NCT02465437|DRUG|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
214964798|NCT02465437|DRUG|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
214964799|NCT02465437|DRUG|Part B Open-Label Extension|JBT-101 20mg bid on Days 1-364
215080795|NCT03042377|DRUG|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
215080796|NCT01563120|DRUG|metformin|metformin up to 2550mg per day.
215080797|NCT01563120|DRUG|glybenclamide|glybenclamide up to 20mg per day.
215080798|NCT00159731|DRUG|Pregabalin|
215080799|NCT05425654|DRUG|Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide|The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
215080800|NCT06420362|OTHER|Blood Flow Restriction|"Before BFR training, a repetition maximal (1-RM) test will be determined by selecting a weight with which athletes can perform a maximum of 10 repetitions. The number of repetitions obtained here and the weight lifted will be written into the Brzycki formula, whose validity and reliability has been proven, and 1-TM will be calculated.~Brzycki formula; 1-TM = \[100 x (Weight Lifted) / \[(102.78 - 2.78 x (Number of Reps)\] The arterial occlusion pressure of the participants will be measured with a Doppler Ultrasound device by increasing the cuff to the point where the auscultatory pulse of the brachial artery ceases until occlusion occurs in the brachial artery. Then, 60% of this value will be calculated and BFR will be performed during the exercises."
215080801|NCT04465877|DRUG|JTT-662|Active drug tablets containing JTT-662
215080802|NCT04465877|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
215080803|NCT04873167|BEHAVIORAL|low fat|subjects subjected to a low-fat dietary regime
215080804|NCT04873167|BEHAVIORAL|mediterranean diet|subjects subjected to a mediterranean dietary regime
215080805|NCT03762616|DIAGNOSTIC_TEST|Micro-ultrasound targeted biopsy|Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
214964800|NCT02702362|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
214964801|NCT03128853|DEVICE|Rad-67 and DCI Mini Sensor|
214964802|NCT05680662|COMBINATION_PRODUCT|quercetin, EGCG, metformin , zinc|this intervention target many mechanisms at tumorigenesis, metastasis autophagy, apoptosis, interleukin 6, cathepsin L, and also epigenetic DNA methylation
214964803|NCT05999591|PROCEDURE|Intrauterine insemination|Transfer of sperm into the fallopian tube through a specialised cannula
214964804|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
214964805|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
214964806|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
214964807|NCT03403881|BEHAVIORAL|Physical activity promotion + TAU|"Pedometer:~Each patient will receive a pedometer with increasing weekly aims on number of steps during the trial.~The number of steps to be achieved starts on 4.000 and increases progressively until the end of the trial.~Behavioral strategy based on STD theory, and the assessment of barriers and facilitators of each patient.~All patients were receiving treatment as usual"
214964808|NCT03403881|BEHAVIORAL|Control|Weekly call on general health aspects + treatment as usual
214964809|NCT02104245|DRUG|Ciprofloxacin dispersion for inhalation|
214964810|NCT02104245|DRUG|Placebo|
214964811|NCT01874626|DRUG|Placebo|Placebo cream
214964812|NCT01874626|DRUG|SST-0225 Topical Ibuprofen Cream|SST-0225 Topical Ibuprofen Cream
214964813|NCT00001919|DRUG|Hypericum (LI-160)|
214964814|NCT00003483|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
214964815|NCT03967067|PROCEDURE|liver resection|Open or laparoscopic, major or minor hepatectomy performed using the clamp-crush technique and intermittent clamping of hepatic pedicle
214964816|NCT03938363|OTHER|Treadmill|Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
214964817|NCT03938363|DRUG|Botulinum Toxin injection|injection of Botulinum Toxin in the two groups of CD and BS
214964818|NCT03938363|DIAGNOSTIC_TEST|Severity scale of the disease|JRS for BS TWSTRS for CD
215080806|NCT03762616|DIAGNOSTIC_TEST|mpMRI targeted biopsy|Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
215080807|NCT01384331|DRUG|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
215080808|NCT04806490|DIAGNOSTIC_TEST|the diagnosis for Yin Deficiency Syndrome|The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome
215080809|NCT05553964|DIAGNOSTIC_TEST|In Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
215080810|NCT03054597|DEVICE|Circular light motion|Exercise with circular light motion
215080811|NCT03054597|DEVICE|Diagonal light motion|Exercise with diagonal light motion
215080812|NCT03054597|DEVICE|Peripheral light motion|Exercise with peripheral light motion
215080813|NCT03054597|PROCEDURE|Exercise|
214964819|NCT01706432|RADIATION|hyperfractionated radiation therapy|Undergo hypofractionated radiation therapy
214964820|NCT01706432|OTHER|laboratory biomarker analysis|Correlative studies
214964821|NCT01706432|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
214964822|NCT00994227|PROCEDURE|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
214964823|NCT05003284|DEVICE|acupressure wristband|acupressure after surgery
214964824|NCT05003284|DEVICE|placebo wristband|acupressure after surgery
214964825|NCT00939926|DRUG|Risperidone|
214964826|NCT00656175|DRUG|raltegravir|raltegravir
214964827|NCT05941624|DEVICE|Ha-330 Hemoperfusion Filter Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
214964828|NCT05941624|DEVICE|Conventional Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
214964829|NCT01818973|DRUG|Xeloda|po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
214964830|NCT01818973|DRUG|Oxaliplatin|iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
214964831|NCT01818973|DRUG|Bevacizumab|iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
214964832|NCT01818973|RADIATION|Radiation|Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
214964833|NCT01818973|PROCEDURE|surgery|Total Mesorectal Excision (TME)
214964834|NCT04967105|DEVICE|Near-infrared spectroscopy|Before the induction of anesthesia, NIRS sensors were placed on both sides of the flank area that overlies the kidney to monitor renal SO2, whose alteration trends over time during operation will be recorded and evaluated in later analysis.
214355786|NCT05525494|BEHAVIORAL|Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly by portal based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
214355787|NCT05525494|BEHAVIORAL|Portal Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
214964835|NCT05223816|DRUG|VG161|"Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections."
215080814|NCT02695823|DEVICE|Ultrasound|"Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days."
215080815|NCT00001155|DRUG|cyclophosphamide|
215080816|NCT04332939|OTHER|transcranial direct current stimulation|real tDCS sessions
214964836|NCT05223816|DRUG|Nivolumab Injection [Opdivo]|immunotherapy treatment
214964837|NCT04900649|OTHER|chest resistance exercise|lung function.
214964838|NCT04900649|OTHER|chest expansion exercises|thoracic excursion
214964839|NCT03086005|DRUG|Metformin|
214964840|NCT01014195|OTHER|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
214964841|NCT02344511|DRUG|Dalbavancin|Drug
214964842|NCT02344511|DRUG|cefazolin, nafcillin, oxacillin or vancomycin|Standard of Care
215080817|NCT04332939|OTHER|Physical exercise|Aerobic exercise and physical training combined with sham tDCS
215080818|NCT03332719|BIOLOGICAL|Etanercept|
214355788|NCT05525494|BEHAVIORAL|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
214355789|NCT00762320|DRUG|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
214355790|NCT00205283|DRUG|Nelfinavir|
214964843|NCT06043648|DEVICE|Endotracheal tube cuff pressure monitoring|The endotracheal tube cuff pressure was continuously monitored using a transducer from a standard invasive pressure monitoring device that is routinely used to measure arterial or central venous pressure.
214964844|NCT02723448|DRUG|aclarubicin|Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
214964845|NCT00594230|DRUG|Panobinostat|Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
214964846|NCT01789788|DRUG|Placebo|Matching placebo, multiple doses
214355791|NCT00003857|DRUG|tamoxifen citrate|
214355792|NCT00003857|PROCEDURE|adjuvant therapy|
214355793|NCT00003857|RADIATION|radiation therapy|
214964847|NCT01789788|DRUG|RO6811135|multiple ascending doses
214964848|NCT04847583|DRUG|Telacebec|Telacebec 100 mg tablet
214964849|NCT04847583|DRUG|COVID-19 Standard of care|The Standard of Care treatment and administration thereof will be determined by the Investigator
215080819|NCT03332719|DRUG|Methotrexate|
215080820|NCT05244460|DRUG|Droperidol Injectable Product|Treatment
215080821|NCT05244460|DRUG|Diphenhydramine|Treatment
215080822|NCT04962230|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
215080823|NCT04962230|DRUG|Carbamazepine|In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
215080824|NCT04962230|DRUG|PF 07321332/ritonavir|In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
215080825|NCT03576755|DRUG|Spironolactone 100mg|Spironolactone capsules will be prepared from USP grade powder at a dose of 100 mg.
215080826|NCT03576755|DRUG|Placebo oral capsule|Matching placebo capsules of the same color, mass, and appearance to the spironolactone capsules will be filled using microcrystalline cellulose powder.
215080827|NCT02529748|OTHER|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
215080828|NCT02529748|OTHER|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
215080829|NCT02529748|OTHER|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
215080830|NCT01530841|DEVICE|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
215080831|NCT01672658|DEVICE|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
214355794|NCT01355393|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
214355795|NCT01355393|BIOLOGICAL|sargramostim|Given ID
215080832|NCT01672658|OTHER|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
215080833|NCT05976503|DRUG|Tunodafil Hydrochloride Tablets|100mg Tunodafil Hydrochloride Tablets
214964850|NCT05501392|BEHAVIORAL|STEPS-PreK|Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).
215080834|NCT05976503|DRUG|Placebo|Placebo
215080835|NCT05976503|OTHER|Alcohol|0.5 g/kg alcohol
215080836|NCT06300918|OTHER|Time|Time point of injecting anti-VEGF drugs
215080837|NCT03958656|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
214964851|NCT03320174|DRUG|Tafenoquine|Tafenoquine 200mg
214964852|NCT03320174|OTHER|Placebo|Placebo
214964853|NCT01091870|DRUG|Placebo|Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.
214964854|NCT01091870|DRUG|Sildenafil Citrate, 25 mg, 3 times a day.|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
214964855|NCT01091870|DRUG|Sildenafil Citrate 50 mg, 3 times a day|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
214964856|NCT06198998|DEVICE|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides hemodynamics support for intraoperative protection during high-risk percutaneous coronary intervention.
214964857|NCT02805946|DRUG|posaconazole|iv versus oral
214964858|NCT03135509|DRUG|CC-220|CC-220 gelatin capsules
214964859|NCT01096381|OTHER|laboratory biomarker analysis|Blood collection
214964860|NCT01096381|OTHER|questionnaire administration|Survey regarding baseline health and activity level.
214964861|NCT00866112|OTHER|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
214964862|NCT00866112|OTHER|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
214964863|NCT03902470|PROCEDURE|Thoracic epidural anaesthesia video assisted thoracoscopic surgery|Patients in (TEA) group will pre-medicated using midazolam 3-4 mg (IV)and fentanyl 50 mcg (IV). Then An epidural catheter will be inserted between T3-T4 and T4-T5 . A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5%.
214964864|NCT01100632|DIETARY_SUPPLEMENT|Ginseng, vitamins, minerals|2 capsules per day
214964865|NCT01100632|OTHER|Placebo - Gelatin capsule|2 capsules per day
214964866|NCT03156257|BIOLOGICAL|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
214964867|NCT06467747|OTHER|Music|Music group: wear earphones to listen to music and receive standardized anesthesia protocol
214964868|NCT06467747|OTHER|Mute|Mute group: wear earphones without music and receive standardized anesthesia protocol
214964869|NCT02149264|DRUG|Testosterone gel (FE 999303)|
215080838|NCT03958656|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
214355796|NCT01355393|DRUG|rintatolimod|Given ID
214355797|NCT00037219|DRUG|Anidulafungin, VER002|
214964870|NCT06071117|DEVICE|Virtual Reality Glasses (VR)|Children allocated to this group will be distracted using VR glasses during dental treatment which is an individual headset that has earphones incorporated. Age-appropriate cartoons and movies will be shown to the children. The VR glasses will be then introduced to the children. The children will be given time to accommodate with the device before starting the procedure. The VR glasses will be applied during the dental examination and treatment.
214964871|NCT06071117|OTHER|White noise|"Wireless kids' headphones will be introduced to the children allocated to this group. They will be given some time to accommodate with the headphones. Then, the white noise will be played and children will be asked to concentrate on the music during the procedure.~White noise stimulus will be set at 70 decibels, within the normal conversation volume range and below what is considered harmful to hearing. The white noise of rain sound, managed with an iPhone application called Muse. The decibel level of white noise will be calibrated using a portable digital sound level meter"
214964872|NCT06071117|BEHAVIORAL|Basic behavior management techniques|Children allocated to this group will be managed by the basic behavior guidance techniques: (Tell-Show-Do). No adjunctive distraction tool will be used.
214964873|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2590066A|Intramuscular injection, two doses
214964874|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2592984A|Intramuscular injection, two doses
214964875|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340274A|Intramuscular injection, two doses
214964876|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340273A|Intramuscular injection, two doses
215080839|NCT03958656|DRUG|Rimiducid|0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
215080840|NCT03958656|BIOLOGICAL|Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 12.0x10\^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
215080841|NCT04698135|OTHER|Biological samples collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
215080842|NCT04698135|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
214355798|NCT01791933|DRUG|herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
214964877|NCT01236040|OTHER|Placebo|Intramuscular injection, two doses
214964878|NCT04329845|PROCEDURE|open splenectomy|open splenectomy for treatment of splenic injury
214964879|NCT04329845|PROCEDURE|laparoscopic splenectomy for splenic injury in trauma|laparoscopy as a technique for removal of the spleen in injury
214964880|NCT00697853|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
214964881|NCT00697853|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
214964882|NCT01243515|DEVICE|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
214964883|NCT01243515|PROCEDURE|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
214964884|NCT04036591|DIAGNOSTIC_TEST|Acute Bronchiolitis Severity Scale (ABSS)|All infants will be assessed using the Acute Bronchiolitis Severity Scale (ABSS) before and after being treated by experienced physiotherapists using the prolonged slow expiration technique and provoqued cough. Before the application of these techniques a retrograde rhinopharyngeal unclogging will be performed in order to clean the nasopharynx.
214964885|NCT04639362|DRUG|ibrutinib, venetoclax, obinutuzumab|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
214964886|NCT04639362|DRUG|ibrutinib, venetoclax|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
214964887|NCT01948921|DRUG|placebo|
214964888|NCT01948921|DRUG|Meperidine|
214964889|NCT03653845|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
214964890|NCT03653845|DRUG|Sequenced antihypertensvie drugs with titrated dosage|Patients will be treated with different antihypertensive drugs in two groups.
214964891|NCT01421992|DRUG|Methylphenidate|One Tablet of methylphenidate, 20 mg per day during 3 weeks
214964892|NCT01421992|DRUG|Placebo|one tablet placebo per day during 3 weeks
214964893|NCT03472521|DRUG|Gabapentin|Treatment with analgesic adjutant commonly used for post-operative pain, titrated to effect by chronic pain specialist compared to placebo titration.
214964894|NCT03472521|DRUG|Placebo|Placebo to match gabapentin
214964895|NCT00183508|BEHAVIORAL|Cognitive behavioral therapy|Participants will learn cognitive behavioral strategies for symptom reduction
214964896|NCT00183508|BEHAVIORAL|Psychoeducation|Participants will receive psychoeducation regarding common reactions to traumatic events
214355799|NCT01791933|PROCEDURE|Chuna manual therapy|A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion 1-2times a week for more than 2 months Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
214393684|NCT01594177|DRUG|Trastuzumab|First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
214964897|NCT03934840|DRUG|Cabazitaxel|20 mg/m2 Q 21 days
214393685|NCT01594177|DRUG|Paclitaxel|80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
214964898|NCT03934840|DRUG|Carboplatin|AUC 4 Q21 Days x 6 cycles with ADT
214964899|NCT03934840|DRUG|Abiraterone|1000 mg PO daily
214964900|NCT03934840|DRUG|Prednisone|5 mg PO daily on chemotherapy completion
214964901|NCT02284386|DRUG|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
214964902|NCT02284386|DRUG|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
214964903|NCT03634202|COMBINATION_PRODUCT|IMRT + oral chemotherapy|"It's a dose escalation of radiation (IMRT), during 5 to 7 weeks, 5 days per week.~Concomitantly, patient have oral chemotherapy (capecitabin)"
214964904|NCT03051347|OTHER|Itch Questionnaire and Interview|
214964905|NCT03051347|OTHER|Stigma Questionnaire and Interview|
214964906|NCT03051347|OTHER|Cognitive Interview and PROMIS Itch Questionnaire|
214964907|NCT05085470|BIOLOGICAL|Schistosoma mansoni infection|20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
214964908|NCT05085470|BIOLOGICAL|Placebo mock infection|Placebo mock infection with water
214964909|NCT01122459|OTHER|fluid administration|1.5mls/kg/hr fasting
214964910|NCT04918472|PROCEDURE|MCCE|Mangetically controlled capsule endoscopy will be performed
214964911|NCT03705286|DEVICE|EVAC-PU-ETT|Placement of a EVAC-PU-ETT in the setting of emergent intubation.
214964912|NCT03705286|DEVICE|PVC-ETT|Placement of a PVC-ETT in the setting of emergent intubation.
214964913|NCT02741232|DRUG|Lidocaine 1% with epinephrine 1/400000|
214964914|NCT02741232|OTHER|sham block|
214964915|NCT05395156|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Control group will receive TEAS on sham acupoint daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles Study group will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles
214964916|NCT03193229|BEHAVIORAL|MapTrek|The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.
214964917|NCT03193229|DEVICE|Fitbit|Fitbit
214964918|NCT03694223|OTHER|Health education delivery methods|
215080843|NCT04698135|OTHER|Medical/laboratory examinations|Blood pressure measurement, abdominal and thoracic physical examination, body composition through bioimpedance analysis and metabolic, cardiovascular and respiratory variables; OGTT 75gr for blood glucose and insulin at times 0, 30, 60, 90 and 120', and a nocturnal oximetry and subsequently, if necessary, overnight polysomnography for the diagnosis of obstructive sleep
215080844|NCT00599404|DRUG|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
214964919|NCT01401543|DRUG|LY2452473|Administered orally
214964920|NCT01401543|DRUG|Tadalafil|Administered orally
214355800|NCT01791933|PROCEDURE|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25 ) and other acupoints at physician's discretion, using a total of 10\~20 acupoints 1-2times a week for more than 2 months
214355801|NCT01791933|PROCEDURE|Bee-venom pharmacoacupuncture/pharmacoacupuncture|pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session 1-2times a week for more than 2 months
214355802|NCT04072159|BEHAVIORAL|Community Pharmacists Vaccinating Against Cancer|Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.
214355803|NCT06230289|PROCEDURE|Transabdominal plane block|Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (by using envelope selection method) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group B will receive a four-point TAP block, while no interventional procedures will be performed on patients in Group C.
214355804|NCT05956301|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through Nasal catheter
214355805|NCT05956301|DEVICE|High-flow nasal oxygen|High Flow Nasal Cannula will be administered
214355806|NCT05956301|DEVICE|Supraglottic jet oxygenation and ventilation|Nasal jet tube will be administered
214355807|NCT01177904|OTHER|Cease progsterone at 5|Cease administration of progsterone at first US at 5 weeks
214355808|NCT01177904|OTHER|control group: progesterone 8|Control group: progesterone until 8 weeks of pregnancy
214964921|NCT01401543|DRUG|LY900010|Administered orally
214964922|NCT04753333|BEHAVIORAL|Electromyography biofeedback (EMG-BF)|Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training with patellar taping
214964923|NCT04753333|BEHAVIORAL|Sham electromyography biofeedback (EMG-BF)|Participants in this group will receive Sham electromyography biofeedback (EMG-BF) guided strength training without patellar taping
214964924|NCT02308228|BEHAVIORAL|Progressive Resistance Training|Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
214964925|NCT02308228|DRUG|Metformin|Participants will be randomized to receive metformin in conjunction with their strength training program.
214964926|NCT06608017|DRUG|Chinese Herbal Medicine granules|Treatment group
214964927|NCT06608017|OTHER|Placebo|Placebo-controlled group
214964928|NCT05732558|PROCEDURE|8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system|The study is based on a comparison of the number of CT scans required for needle placement in bone biopsies (trunk area) performed with augmented reality navigation system (endosight) and without.
214964929|NCT03999749|DRUG|Ipilimumab|4 induction doses (during the 2 treatment cycles) at a dose of 1 mg/kg intravenously (IV) every 3 weeks, 4 times during the 12-week induction period, concurrent with nivolumab at 3 mg/kg administered at the same interval
215080845|NCT01767493|DRUG|[18F]Florbetapir PET imaging|\[18F\]Florbetapir and PET imaging
215080846|NCT00031746|DIETARY_SUPPLEMENT|soy protein isolate|25 mg daily
215080847|NCT00031746|DIETARY_SUPPLEMENT|casein proteins|25 mg daily
215080848|NCT01598753|DRUG|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
215080849|NCT01598753|DRUG|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
215080850|NCT01598753|BEHAVIORAL|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
215080851|NCT01598753|BEHAVIORAL|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
215080852|NCT03158012|BIOLOGICAL|Autologous Microbial Transplant|Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
215080853|NCT04346108|BIOLOGICAL|Immune Globulin Intravenous (IGIV)|Participants will receive IGIV infusion.
215080854|NCT04346108|BIOLOGICAL|Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)|Participants will receive IGSC, 20% SC infusion.
215080855|NCT03800589|PROCEDURE|phacoemulsification with implantation of the Ex-Press|The conjunctiva is dissected with the base in the limbus. A square scleral flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Mini seton was implanted at 12 o'clock according to the standard technique.
214355809|NCT03195192|OTHER|biomarker study|This is a biomarker study
214355810|NCT06475612|OTHER|Death|Mortality group.
214964930|NCT03999749|DRUG|Nivolumab|Nivolumab (3 mg/kg) will be administered IV on Days 1 and 22 of each 42-day induction treatment cycle. Nivolumab will continue to be administered IV at 240 mg flat dose every 2 weeks; i.e., at Days 1, 15, 29, 43, 57, and 71 of the 84-day treatment cycle for the first maintenance cycle until week 24, then nivolumab will be administered at 480 mg flat dose every 4 weeks to a maximum of 2 years
214964931|NCT03999749|DRUG|Tocilizumab|Administered intravenously for each 42-day induction treatment cycle. After 12 weeks of therapy, starting at Week 13, subjects enter the maintenance phase. Tocilizumab will be administered intravenously every 6 weeks during the first 84 day maintenance treatment cycle only at 4 mg/kg
214964932|NCT03378245|BEHAVIORAL|Behavioral modification and education on pharmacologic treatments.|Education and counseling of care-giving staff on behavioral modification strategies, as well as education about current standard of care best practices for pharmacologic interventions.
215080856|NCT03800589|PROCEDURE|deep sclerectomy, phacoemulsification, ExPress implantation|The conjunctiva is dissected with the base in the limbus. Superficial flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Deep scleral is dissected just below the trabeculo-Descemet membrane. The seton is implanted in the anterior chamber at the height of Schlemm's Canal.
215080857|NCT05126264|DRUG|Ibuprofen 400 mg|morning and afternoon
215080858|NCT05126264|DRUG|Ibuprofen 400 mg|morning, afternoon and night
215080859|NCT03598205|COMBINATION_PRODUCT|DIABEC plus intravitreal dexamethazone|Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)
214355811|NCT06475612|OTHER|Survival|Survival group.
214355812|NCT02846974|DEVICE|Pulse oximeter|A pulse oximeter will be used for calibration
214355813|NCT02305927|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum
214355814|NCT02305927|OTHER|Placebo|Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum
214355815|NCT00097331|DRUG|SB683699|
214355816|NCT01192438|PROCEDURE|Laser-based thermotherapy|MRI-guided transperineal placement of a laser probe into the prostate
214355817|NCT03943030|OTHER|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
214393686|NCT01594177|DRUG|Epirubicin|90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
214964933|NCT06671977|DRUG|DMT-Medium Dose|14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.
214964934|NCT06671977|DRUG|DMT-Low Dose|10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes
214964935|NCT06671977|DRUG|THC-Medium Dose|0.5 mg over 5 minutes and then 2 mg over and 55 minutes
214964936|NCT06671977|DRUG|THC-Low Dose|0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes
214964937|NCT06432478|DEVICE|3D-printed custom applicator|3D-printed custom applicator
214964938|NCT04776928|BEHAVIORAL|Push reports|"Surgeons in the experimental arm will receive provider-level push report notifications through an email displaying their personal prescribing performance compared to Michigan Opioid Prescribing Engagement Network (OPEN) prescribing guidelines and their de-identified peers.~The push report will also include a link to the secure MSQC data platform that displays more information about the case so the surgeon can further investigate prescribing information. The email will also contain contact information for the study team so as to help any surgeons troubleshoot, learn more, request to stop receiving reports, etc."
214964939|NCT06134661|DEVICE|cTBS (continuous Theta Burst Stimulation)|"Continuous Theta Burst Stimulation (cTBS) is an inhibitory stimulation protocol of the Transcranial Magnetic Stimulation (TMS) device that temporarily inhibits brain activation in a small targeted brain area.~The investigators apply the cTBS protocol 3 times daily at 100% of the resting motor threshold (RMT) for 1500 pulses per session."
214964940|NCT05521048|DRUG|Doxycycline Injection [Doxy]|Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
214964941|NCT00103285|RADIATION|3-Dimensional Conformal Radiation Therapy|Some patients undergo cranial radiotherapy
214964942|NCT00103285|DRUG|Cyclophosphamide|Given IV
214964943|NCT00103285|DRUG|Cytarabine|Given IV or SC
214964944|NCT00103285|DRUG|Dexamethasone|Given IV or PO
214964945|NCT00103285|DRUG|Doxorubicin Hydrochloride|Given IV or IT
214964946|NCT00103285|DRUG|Leucovorin Calcium|Given PO
214964947|NCT00103285|DRUG|Mercaptopurine|Given PO
214964948|NCT00103285|DRUG|Methotrexate|Given IM or IT
214964949|NCT00103285|DRUG|Pegaspargase|Given IM
214964950|NCT00103285|DRUG|Thioguanine|Given PO
214964951|NCT00103285|DRUG|Vincristine Sulfate|Given IV
214964952|NCT02150941|DEVICE|BioVac Direct Suction Device|The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.
214964953|NCT02150941|DEVICE|Standard Endoscopy Suction|Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
215080860|NCT00196586|DRUG|Interleukin 2|
215080861|NCT00196586|DRUG|pegylated interferon alpha 2a|
215080862|NCT00196586|DRUG|ribavirin|
215080863|NCT02788201|DRUG|75 approved agents|One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
215080864|NCT02788201|OTHER|COXEN|The CO eXpression ExtrapolatioN (COXEN) algorithm will be used to determine the next best therapy from among 75 Food and Drug Administration (FDA) approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
215080865|NCT02737644|OTHER|observation|This is an observational study
214355818|NCT05935345|BEHAVIORAL|Addressing NSSI in schools|During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
214355819|NCT05935345|OTHER|Control condition|Participating adolescents, parents, teachers and health care personnel receive no intervention during four months
214355820|NCT04039672|PROCEDURE|Skin biopsy|5mm skin metastasis or primary melanoma biopsy
214964954|NCT03031340|DRUG|Pregabalin|On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
214964955|NCT03031340|OTHER|placebo|placebo
214964956|NCT05502627|DRUG|0.25% lemon grass oil mouthwash|0.25% lemon grass oil mouth wash given twice daily for fourteen days to the patients of chronic periodontitis after scaling in experimental group and in control group only scaling was done.
214964957|NCT06725277|DRUG|Spravato|Intranasal esketamine
215080866|NCT01701479|DRUG|ch14.18/CHO|
215080867|NCT01701479|DRUG|Aldesleukin|
214355821|NCT05054608|OTHER|No intervention|Observational study. No intervention.
214355822|NCT00882947|DRUG|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
214355823|NCT03215797|DRUG|phenylephrine|phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
214355824|NCT03215797|DRUG|Norepinephrine|Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
214355825|NCT04084314|BIOLOGICAL|Erenumab|Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.
214964958|NCT06725277|DRUG|IV Ketamine|IV ketamine
215080868|NCT01701479|DRUG|Isotretinoin|
215080869|NCT00174681|DRUG|Insulin Glargine|
215080870|NCT00776464|DEVICE|Noveon laser|Two wavelenghts of light
215080871|NCT00612014|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
215080872|NCT00612014|DRUG|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
215080873|NCT00612014|DRUG|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
215080874|NCT00612014|DRUG|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
215080875|NCT00612014|DRUG|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
215080876|NCT00612014|DRUG|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
215080877|NCT04739618|DRUG|Keytruda Injectable Product|PD-1 inhibitor antibody
215080878|NCT04739618|DRUG|Yervoy Injectable Product|Anti-CTLA-4 antibody
215080879|NCT04739618|DRUG|GM-CSF|1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
215080880|NCT04739618|PROCEDURE|Non-ablative Cryosurgical freezing|To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
215080881|NCT01283906|DEVICE|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
215080882|NCT01283906|DEVICE|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
215080883|NCT02059759|DRUG|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
214355826|NCT06305338|OTHER|Optical Coherence Tomography|the study releated measurements will be performed: IOLMaster 700, Casia 2 and Pentacam HR.
214355827|NCT01055769|DRUG|Linezolid|"1. Linezolid OS 600 MG~2. Linezolid Tablet 600 MG"
214355828|NCT01055769|DRUG|Linezolid|"1. Linezolid Tablet 600 MG~2. Linezolid OS 600 MG"
214355829|NCT05576987|BEHAVIORAL|Education|Students selected for the experimental group will be trained by the researcher for school accidents prepared in line with the components of the Health Belief Model.The training program will be planned as 30 minutes per week for 4 weeks. Before the training and at the end of the training (at the end of the 4th week), the students will be applied personal information form and a behavior scale for safety precautions in school accidents.
214964959|NCT06337734|BEHAVIORAL|AI-Driven Lifestyle Coaching Program|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
215080884|NCT02059759|DRUG|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
215080885|NCT02059759|DRUG|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
215080886|NCT02944227|DRUG|Lucentis|Lucentis fixed-treatment arm
214964960|NCT02437994|BEHAVIORAL|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
214964961|NCT05438342|BIOLOGICAL|Autologous Adoptive immune cells|Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.
214964962|NCT05438342|DEVICE|Thermotron RF-8EX|Hyperthermia for 40-50 minutes
215080887|NCT02492360|PROCEDURE|Blood sample collection|Six tubes of blood will be collected during one blood draw.
215080888|NCT02492360|BEHAVIORAL|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
215080889|NCT05703620|DEVICE|Renal Denervation|All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels
215080890|NCT01219036|DRUG|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
215080891|NCT04829799|DRUG|1% preservative-free lidocaine|Instillation of intracameral lidocaine after initial paracentesis incision.
215080892|NCT04829799|DRUG|Phenylephrine 1.0%/ Ketorolac 0.3%|Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
215080893|NCT03132103|DIETARY_SUPPLEMENT|Oral Vitamin D3|
215080894|NCT03132103|DIETARY_SUPPLEMENT|Placebo Oral Vitamin D3|
215080895|NCT03132103|RADIATION|Solar simulated radiation (SSR)|
215080896|NCT03132103|RADIATION|Placebo SSR|
215080897|NCT04072367|DEVICE|NeVa Stent Retrievers|thrombus removal
214964963|NCT05438342|DRUG|Chemotherapy，checkpoint immunotherapy, targeted therapy|The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines
214964964|NCT03060369|DEVICE|CareGuide™ device|CareGuide™ is a minimal risk, non-invasive device that uses near-infrared spectroscopy to measure skeletal muscle oxygen saturation.
214964965|NCT03734523|COMBINATION_PRODUCT|Flourish Vaginal Care System|This is not technically an intervention. All women who enroll in the study will be those who have opted to use the Flourish Vaginal Care System. This system is comprised of a vaginal wash (Balance), an intravaginal moisturizing gel (Restore), and a vaginal probiotic supplement (BiopHresh). Balance will be used daily. Restore will be used every other day. BiopHresh will be used twice a week with Restore. All products will be started after the first visit and continue throughout the 6-month study.
215080898|NCT04072367|DEVICE|Solitaire Stent Retrievers|thrombus removal
215080899|NCT03692351|DEVICE|Uncemented acetabular cup with screw holes|
215080900|NCT03692351|DEVICE|Uncemented acetabular cup without screw holes|
215080901|NCT02159118|DEVICE|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
215080902|NCT02159118|DEVICE|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
215080903|NCT04686760|DRUG|Nitroglycerin|2 mg/ml solution of nitroglycerin used for nebulization four hourly
215080904|NCT05961176|DEVICE|Skiin pediatric band and Skiin biometric pod|Infants that meet the inclusion criteria will be equipped with a Skiin pediatric band appropriate for their chest size. Heart rate, respiratory rate, temperature, and electrocardiogram will be monitored from 2 to 12 hours through the Skiin pediatric band and a standard of care device (Phillips Intellivue MX750) commonly used in the CCCU at SickKids.
215080905|NCT00858260|GENETIC|blood sample|Searching for Klotho variants in DNA
215080906|NCT05979636|OTHER|Novamin containing toothpaste|children's teeth will be brushed using Novamin containing toothpaste.
215080907|NCT05979636|OTHER|Fluoride containing toothpaste|children's teeth will be brushed using Fluoride containing toothpaste.
215080908|NCT00386477|PROCEDURE|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
215080909|NCT02376101|PROCEDURE|Surgery less than 60 minutes|
215080910|NCT04349748|BEHAVIORAL|Health education, and regular HIV and STDs testing prompting service|Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
215080911|NCT04349748|BEHAVIORAL|Health status inquiry through app (partner notification)|The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
215080912|NCT02446418|DRUG|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
215080913|NCT02446418|DRUG|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
215080914|NCT02446418|DRUG|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
215080915|NCT02446418|DRUG|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
215080916|NCT02446418|DRUG|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
215080917|NCT02446418|DRUG|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
215080918|NCT03760757|DIETARY_SUPPLEMENT|ESPO-572®|ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
214393687|NCT01594177|DRUG|Cyclophosphamide|600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
214964966|NCT02953015|BEHAVIORAL|Manipulative articulatory (ART) and myofascial techniques|Three manipulative articulatory (ART) and myofascial techniques will be performed to improve cervical and thoracic spine joint mobility and reducing soft tissue stiffness in the cervico-thoracic spine. ART technique is a low velocity to high amplitude technique where each joint is carried through its full motion to increase range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier. Myofascial technique is directed at the muscle and fascia treatment. It engages continual palpatory feedback to achieve release of myofascial tissues. During each treatment session, each technique will be carried out for 10 minutes including 2 minutes of resting.
214964967|NCT02953015|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) of the upper trapezius muscle will be applied by a portable machine Master 932 (Elettronica Pagani SRL, Milan, Italy) that generates symmetric, bi-phasic rectangular pulses with 140μ sec duration. The current frequency will be set at 150 Hz and intensity will be increased up to patient's perception of paresthesia. The negative electrode will be placed on the active TrPs of the upper trapezius muscle and the positive one was on acromial tendon insertional site. The total duration of each application will be 20 minutes. Treatment frequency and duration will be the same of the EG treatment (1 session/week for 4 weeks). Each session will consist of 20 min of TENS and 10 min of resting in sitting position with the head lean on a pillow.
214964968|NCT02953015|DRUG|OnabotulinumtoxinA (Prophylaxis therapy)|Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
214964969|NCT03493438|OTHER|exercise|A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.
214964970|NCT00610181|PROCEDURE|MRI|MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
214964971|NCT04334525|BEHAVIORAL|Choice architecture + repeated exposure|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period.
214964972|NCT00437996|DRUG|Clonidine|
214964973|NCT00437996|DRUG|Levobupivacaine|
214964974|NCT00437996|DRUG|Sufentanil|
214964975|NCT03456843|DRUG|Antiandrogen Therapy|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
214964976|NCT03456843|DRUG|Docetaxel|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
214964977|NCT03456843|OTHER|Laboratory Biomarker Analysis|Correlative studies
214964978|NCT03456843|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214964979|NCT03456843|OTHER|Questionnaire Administration|Ancillary studies
214964980|NCT03456843|PROCEDURE|Radical Prostatectomy|Undergo cytoreductive radical prostatectomy
214964981|NCT02624947|BIOLOGICAL|RSV F vaccine with adjuvant|
214964982|NCT02624947|BIOLOGICAL|Formulation buffer|
214964983|NCT02604537|DRUG|betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone
214964984|NCT02604537|DRUG|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
214964985|NCT06952517|DRUG|Clascoterone Cream 1%|Clascoterone 1% cream
214964986|NCT04991792|OTHER|Intervention Group 1: Infant Formula with synbiotics|Infants will receive infant formula during the first 6 months of life
214964987|NCT04991792|OTHER|Intervention Group 2: Infant Formula with prebiotics|Infants will receive infant formula during the first 6 months of life
214964988|NCT04991792|OTHER|Control Group 1 and 2: Infant Formula without synbiotics|Infants will receive infant formula during the first 6 months of life
214964989|NCT06785090|DRUG|Bromfenac|Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) formulated as a 0.09% ophthalmic solution. It is administered to reduce inflammation and prevent cystoid macular edema (CME) following cataract surgery.
214964990|NCT06785090|DRUG|Moxifloxacin 0.5% ophthalmic solution|antibiotic, standard postoperative care regimen
214964991|NCT06785090|DRUG|Dexamethasone phosphate 0.1%|steroid, standard postoperative care regimen
214964992|NCT03187743|OTHER|Blood samples|"Blood samples at 3 visits :~V0 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis~V1 : - 5 mL in heparin tube / sample (2 to 5 samples) Pharmacokinetics + Pharmacogenetics + Gene Expression Analysis~V2 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis and - 5 mL in EDTA tube / DNA bank"
214964993|NCT04143659|BIOLOGICAL|levonorgestrel butanoate (LB) injection|"The initial formulation of the investigational product (IP) is LB Injectable Suspension at a concentration of 40 mg/2 mL (20 mg/mL). Each vial contains 2 mL at 20mg/mL for a total of 40 mg. This formulation will only be used for dosing groups A and B with the injections completed as 40 mg IM (2 mL) or 40 mg SQ (2 mL).~The second formulation of the investigational product (IP) is LB Injectable Suspension is a concentration of 140 mg/2 mL (70 mg/mL). Each vial contains 2 mL at 70 mg/mL for a total of 140 mg. This formulation will only be used for dosing groups B2, C, and D with the injections completed as 40 mg SQ (0.57 mL), 50 mg SQ (0.71 mL), and 60 mg SQ (0.86 mL)."
214964994|NCT04416997|PROCEDURE|Blood and serum samples|The blood and serum samples will taken from RA patients
214964995|NCT00378885|BEHAVIORAL|Cognitive-behavioral tailored intervention|
214964996|NCT06957977|PROCEDURE|Endoscopic Cryoballoon Ablation Treatment|ECAT: A cryoballoon with catheter is inserted along the endoscopic forceps channel, the balloon is placed on the surface of the tumor, and the balloon is dilated so that it fits snugly over the lesion. The freezing cycle is initiated and continued for 2-3 minutes, and then the balloon is rewarmed and frozen again for 2-3 minutes; the freeze-rewarm cycle is repeated twice. PD-1:The first PD-1 monoclonal antibody treatment in this study was given within 3 days before and after ECAT treatment, and subsequent treatment was given every three weeks according to the instructions.
215080919|NCT03760757|DIETARY_SUPPLEMENT|PCSO-524®|PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
215080920|NCT02116647|BEHAVIORAL|Psychoanalytic therapy|
215080921|NCT04829474|OTHER|Survey|It is a survey that the patient and doctor must complete.
214964997|NCT06957977|DRUG|PD1 Inhibitor|The first administration of the PD-1 monoclonal antibody is initiated when patients achieve a partial response (PR) following standard treatment. Subsequent administrations are given every three weeks according to the prescribing information.
214964998|NCT06099730|DEVICE|Pulsed Field Ablation (PFA)|PFA using Irreversible Electroporation (IRE) Ablation System
214964999|NCT01923675|OTHER|Spectacles with red-blocking tint|Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
215080922|NCT04381637|DEVICE|NIPE monitor|NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.
214965000|NCT01923675|OTHER|Spectacles with holographic diffuser and color neutral tint|Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
214679021|NCT02471248|DEVICE|Ankle Robot with Power Assistance|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded."
215080923|NCT04381637|PROCEDURE|Tetanic stimulations|"Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3."
215080924|NCT01716338|DRUG|Glyburide|
215080925|NCT01716338|DRUG|Placebo|
215080926|NCT04508751|OTHER|"3T Free-Breathing Fetal Magnetic Resonance Imaging"|Subject will have a one time MRI scan.
215080927|NCT02911740|OTHER|Urine LAM Ag test|TB diagnostic assay
214965001|NCT01923675|OTHER|Spectacles with holographic diffuser and red-blocking tint|Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
215080928|NCT05851872|PROCEDURE|Coronary angiogram|Being done per standard of care
215080929|NCT05851872|PROCEDURE|Right heart catheterization|Being done per standard of care
215080930|NCT02014480|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
215080931|NCT02014480|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
215080932|NCT02014480|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
215080933|NCT01758224|OTHER|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
215080934|NCT01758224|OTHER|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
215080935|NCT04384380|DRUG|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
215080936|NCT03114124|DEVICE|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
215080937|NCT03114124|DEVICE|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
215080938|NCT03836326|OTHER|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
215080939|NCT03836326|OTHER|Control|Routine care provided by health professionals in the NICU
215080940|NCT03836326|OTHER|Story telling attention refocusing intervention|A contact-free intervention where parents share stories with their infant for 10 minutes 3 times per week.
215080941|NCT04364607|DRUG|Neostigmine|Participants will receive 0.5 mg IM neostigmine
215080942|NCT04364607|DRUG|NaCl 0.9%|Participants will receive IM NaCl 0.9% as a placebo
215080943|NCT01420172|OTHER|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
215080944|NCT01575938|BEHAVIORAL|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
214965002|NCT01923675|OTHER|Spectacles with color neutral tint|Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
214965003|NCT01695005|DRUG|LY3039478|Administered orally
214965004|NCT01695005|DRUG|Prednisone|Administered orally
214965005|NCT03284034|DEVICE|CoolCurve|The right and left sides of the upper back fat will be randomly assigned to receive Cryolypolysis (CoolCurve + Advantage applicator) 35 minutes session, 3 sessions 30 days apart.
214965006|NCT03284034|DRUG|ATX-101|The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
214965007|NCT04206345|OTHER|exercise with blood flow restriction|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
214965008|NCT04206345|OTHER|exercise|Elbow bending exercises
214965009|NCT03783117|DEVICE|Magnetic field treatment|The MBPL device for clinical trials is made with modification of an electromagnet: A bore of 10cm diameter was made to go through the frame and poles. The device can produce a magnetic field close to 1.0 T inside the bore, which is along the axis direction. The trial for each subject takes about 20-30 minutes. To start with, the subject's blood pressure is measured first as the baseline. Afterwards, the subject places his/her right arm into the bore of the electromagnet for treatment while the blood pressure is monitored with the left arm. The magnetic treatment lasts about 15 minutes and will lower the subject's blood pressure. In order to see how long the effect lasts, the subject needs to return and measure the blood pressure again 24 hours after the treatment. The clinical trials are non-invasive. There is no medicine or surgery involved.
214965010|NCT02675764|OTHER|Vibration|peripheral vibration at the wrist skin at an imperceptible level
214965011|NCT02675764|OTHER|Placebo (for vibration)|No peripheral vibration at the wrist skin
214965012|NCT02675764|BEHAVIORAL|therapy|standardized hand therapy program
214965013|NCT00335517|DRUG|DepoDur|An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
214965014|NCT01162044|OTHER|Computer game|Playing with specially designed computer game while in emergency room
214965015|NCT00898430|GENETIC|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
214965016|NCT00898430|GENETIC|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
214965017|NCT00898430|GENETIC|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
214965018|NCT03720925|PROCEDURE|TDI treatment|The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
215080945|NCT01575938|BEHAVIORAL|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
215080946|NCT01865812|DRUG|Obeticholic Acid|All participants were treated with OCA (oral administration, 10 mg, once daily \[QD\]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
214355830|NCT04838899|RADIATION|Stereotactic Body Radiation Therapy (SABR)|SABR to oligoprogressive metastases while continuing abiraterone therapy
214355831|NCT05152680|DRUG|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
214355832|NCT06099626|OTHER|Different types of disease|Groups were observed according to disease type
214355833|NCT00000179|DRUG|Trazodone|
214965019|NCT05630482|BEHAVIORAL|Healthy Family Foundations|Healthy Family Foundations Curriculum
214965020|NCT05630482|OTHER|Standard of Care|Standard of Care
214965021|NCT05527795|OTHER|Frequency and duration of response to adjuvant immunotherapy according to clinical features|"* Frequency of relapse to adjuvant immunotherapy according to clinical features~* Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features"
214965022|NCT05527795|OTHER|Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features|Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features
214965023|NCT05527795|OTHER|Duration of relapse-free survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.
215080947|NCT01338610|BIOLOGICAL|ESBA105 ophthalmic solution|
215080948|NCT01338610|OTHER|ESBA105 vehicle|Inactive ingredients used as Run-In and placebo comparator
215080949|NCT02905617|DEVICE|Sientra 207 Silicone Gel Breast Implant|The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
215080950|NCT00188851|DRUG|therapeutic management strategy|
214355834|NCT00000179|DRUG|Haloperidol|
214965024|NCT05527795|OTHER|Duration of overall survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.
214965025|NCT05527795|OTHER|Overall response rate|Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.
214965026|NCT05527795|OTHER|Frequency of adverse events according to clinical features|Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features
214965027|NCT04643327|DRUG|Levetiracetam|Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.
214965028|NCT04643327|DRUG|Placebo|Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.
214965029|NCT02383069|OTHER|Intervention Group|Aerobic training
214965030|NCT02383069|OTHER|Control Group|Chest physiotherapy: Flutter and muscle stretching
214965031|NCT03082027|DIAGNOSTIC_TEST|ultrasonography|ultrasonography of median nerve
214965032|NCT02202798|DEVICE|Syringe device|
214965033|NCT00270101|DRUG|epoetin alfa|
214965034|NCT03569098|BIOLOGICAL|Botulinum toxin type A|Investigators will inject the reconstituted solution into foot muscles.
214965035|NCT03569098|DRUG|Placebo|Investigators will inject the reconstituted solution into foot muscles.
215080951|NCT00633230|DRUG|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
215080952|NCT00633230|OTHER|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
215080953|NCT01414205|DRUG|Obinutuzumab|Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
215080954|NCT01414205|DRUG|Corticosteroids|Participants were administered corticosteroids IV prior to the initial dose.
215080955|NCT00753805|DIETARY_SUPPLEMENT|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
215080956|NCT05249881|DRUG|Semaglutide Pen Injector|All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
214965036|NCT03450759|DRUG|AZD9977 Oral suspension (reference)|Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
214965037|NCT03450759|DRUG|AZD9977 capsule|Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
214965038|NCT03450759|DRUG|AZD9977 ER capsule (fastvrate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
214965039|NCT03450759|DRUG|AZD9977 ER capsule (Int. rate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
214965040|NCT04508686|DRUG|Capecitabine, camrelizumab|This is a single-arm study with all patients receiving these two drugs.
214965041|NCT01967680|PROCEDURE|Non-sedation for intubated, mechanically ventilated patients|
214965042|NCT01967680|PROCEDURE|Controlgroup, sedation with daily wake-up trial|
214965043|NCT00526448|DRUG|ribavirin|2000 mg/day
214965044|NCT00526448|DRUG|ribavirin|1000-1200 mg/day
214965045|NCT00526448|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
214965046|NCT00526448|DRUG|epoetin beta|epoetin beta 450 UI/week
214965047|NCT01697800|DRUG|Tadalafil|
215080957|NCT01854632|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
214355835|NCT01798329|DIETARY_SUPPLEMENT|probiotic VSL#3|"VSL#3 is a probiotic that reduces:~* urease faecal activity~* faecal pH~* inflammatory cytokine"
214355836|NCT00802074|DRUG|Raltegravir|400mg BID
214355837|NCT00802074|DRUG|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
214355838|NCT00802074|DRUG|Ritonavir|100 mg BID or QD
214355839|NCT01632748|DEVICE|Neurotech Vital Device|5 minute treatment
214965048|NCT01697800|DRUG|Placebo|
214965049|NCT00954122|DRUG|Quetiapine XR (Seroquel XR)|Tablet, oral, once daily
214965050|NCT06283953|BEHAVIORAL|Trach Plus|The Trach Plus program includes education, social support, and outreach to outpatient care team.
214355840|NCT01632748|DEVICE|Modified Neurotech Vital Device|5 minute stimulation
214355841|NCT00160433|DRUG|Asoprisnil|0.5 mg Tablet, oral Daily for 12 weeks
214355842|NCT00160433|DRUG|Asoprisnil|1.5 mg Tablet, oral Daily for 12 weeks
214965051|NCT06283953|BEHAVIORAL|Trach Me Home|The Trach Me Home discharge program includes caregiver education, skills training and case management.
214965052|NCT05911126|DRUG|Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet|Tablet form received prior to the procedure
214355843|NCT00160433|DRUG|Asoprisnil|5.0 mg Tablet, oral Daily for 12 weeks
214355844|NCT00160433|DRUG|Placebo|Tablet, oral Daily for 12 weeks
214965053|NCT02981199|PROCEDURE|stem cell transplantation|conditioning with chemotherapy \[VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)\], then stem cell transfusion
214965054|NCT04878068|DEVICE|Theram COVID-19 Rapid Antigen Test|The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19.
215080958|NCT01854632|BIOLOGICAL|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
214965055|NCT01030016|DRUG|atenolol|25 mg/day, twice a day for 6 weeks
214965056|NCT03438084|DIETARY_SUPPLEMENT|Interesterified fat|50 g fat provided as commercially available interesterified fat.
214965057|NCT03438084|DIETARY_SUPPLEMENT|Non- interesterified fat|50 g fat provided as commercially available non-interesterified fat.
214965058|NCT03438084|DIETARY_SUPPLEMENT|Rapeseed oil|50 g fat provided as commercially available rapeseed oil.
214965059|NCT03438084|DIETARY_SUPPLEMENT|Butter|50g fat provided as commercially available spreadable butter
214965060|NCT01563328|DRUG|DTG|50 mg q24h
214965061|NCT01563328|DRUG|BCV|800 mg q8h
214965062|NCT01563328|DRUG|TVR|750 mg q8h
215080959|NCT05238012|DRUG|Xuezhikang Capsule|Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
215080960|NCT05238012|DRUG|Atorvastatin Calcium Tablets|Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
214965063|NCT02049736|DRUG|Telbivudine|
214965064|NCT01569945|DRUG|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
214965065|NCT01569945|DRUG|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
214965066|NCT02511041|DRUG|N-Acetylglucosamine (GlcNAc)|N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- \<=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
214965067|NCT02511041|DRUG|Uridine|Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
214965068|NCT01684852|OTHER|Medical device, drug-like|
214965069|NCT00005916|DRUG|rV-PSA|
214965070|NCT00005916|DRUG|rF-PSA|
214965071|NCT00005916|DRUG|rV-B7.1|
215080961|NCT05910125|DRUG|Aspirin|See arm/group descriptions.
215080962|NCT05910125|DRUG|Clopidogrel|See arm/group descriptions.
215080963|NCT05910125|DRUG|Alteplase|See arm/group descriptions.
215080964|NCT02954419|OTHER|No intervention|No intervention
215080965|NCT05026372|BEHAVIORAL|Mindfulness Compassion (MC)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
215080966|NCT05026372|BEHAVIORAL|Mindfulness Gratitude (MG)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
215080967|NCT05026372|BEHAVIORAL|Mindfulness Value-Based Living (MV)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
215080968|NCT04189653|OTHER|Continuous Monitoring|Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
214355845|NCT04086420|BEHAVIORAL|Mindfulness|Received instructions to exercise at moderate intensity while listening to an audio-recorded mindfulness-based physical activity intervention
214965072|NCT04474561|OTHER|Reduced sulfur diet|A reduced sulfur diet includes reducing foods, food additives (e.g., carrageenan) and beverages high in sulfate/sulfur, limiting sulfur containing supplements, and consuming omega-3 fatty acid supplements to potentially help control overgrowth of sulfur-reducing bacteria in the colon. Omega-3 fatty acid intake for cardiovascular disease prevention should be around 500 mg/d23. After dietary assessment if patients are not meeting their required daily intake of 500 mg/d of Omega-3, the RD will recommend increased fish consumption to 200 g per week or 1 g/d of an Omega-3 supplement. This will ensure the daily recommended intake of 500 mg/d is being met to reduce the chances of a deficiency; however, a therapeutic dose for UC will not be recommended (i.e., \> 4 g/d18).
214965073|NCT03455712|BEHAVIORAL|Gestational Weight Gain Card|The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
214965074|NCT01000987|DRUG|varenicline|1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
214965075|NCT01000987|DRUG|placebo|placebo
214965076|NCT06394583|PROCEDURE|Lung ultrasound|We will perform a LU at birth to all infants, before the first dose of surfactant.
214965077|NCT05995834|OTHER|Research questions|"Stage 1: Secondary analysis of a previous international survey to identify items~Stage 2: Cognitive debriefing interviews with about 10 people living with iMCD to assess the content validity of the items~Stage 3: Completion of questionnaire to finalise scale~Stage 4a: Re-administering of follow-up questionnaire to Stage 3 patients to assess minimally important clinical difference. Test-retest will be calculated only in patients exhibiting no change.~Stage 4b: Qualitative interviews with a subset of participants from Stages and 4 to help with interpretation of meaningful difference from their perspective"
214965078|NCT02262650|DRUG|Telmisartan|
214965079|NCT02262650|DRUG|Clopidogrel|
214965080|NCT00416819|BIOLOGICAL|filgrastim|
214965081|NCT00416819|BIOLOGICAL|rituximab|
214965082|NCT00416819|DRUG|cytarabine|
214965083|NCT00416819|DRUG|etoposide phosphate|
214965084|NCT00416819|DRUG|leucovorin calcium|
214965085|NCT00416819|DRUG|methotrexate|
214965086|NCT00416819|DRUG|temozolomide|
214355846|NCT04086420|BEHAVIORAL|Heart-Rate|Given a heart rate monitor, told to exercise within the moderate intensity range (64-76% of estimated maximum heart rate)
214965087|NCT05119127|DEVICE|Alcon Vivity toric intra ocular lens|implanting vivity toric IOL to asses rotational stability. IOL is already FDA approved for implantation at time of cataract surger. Intervention is to assess rotational stability and visual outcome.
214965088|NCT04192721|BEHAVIORAL|Cognitive Behavioral Therapy-Based Group Counseling|"* Relaxation techniques~* Providing personal development books~* Sharing the factors affecting the situation defined as depression (brainstorming)~* Explaining the link between depressive symptoms, thoughts, feelings, and behaviors~* Explaining automatic thoughts~* Application of relaxation techniques; deep-breathing exercises~* Identifying alternative thoughts~* Explaining the correlation between alternative thoughts and mood~* Introduction of the Automatic-Thought Registration Form and distribution to students~* Describing the effects of depression on social interaction~* Explaining activities that could be done individually and with the group~* Distribution of the activity list to students~* Description of ways of coping with stress~* Determination of individual stressors and their effects~* Planning for the future: preventing depression~* Discussion of assumptions/expectations about life~* Homeworks related to session contents"
214965089|NCT00370773|DEVICE|Precision Spinal Cord Stimulation System|
214965090|NCT04081675|DEVICE|Ankle Foot Orthosis (AFO)|Thermoplastic orthotic device spanning the calf, ankle and foot.
214965091|NCT03934008|OTHER|MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE)|The MOTIVE tool incorporates the principles of motivational interviewing (MI) and provides a flowchart approach in which parental health beliefs have a corresponding MI-based strategy to further explore and/or address the hesitancy. The tool was developed from interviews with pediatricians and pediatric pharmacists, a review of the literature focusing on vaccine health beliefs, and the Parent Attitudes about Childhood Vaccines (PACV) Survey Tool. The tool was reviewed by multiple providers and feedback was provided on its usability in clinical practice when interacting with vaccine-hesitant parents and/or caregivers. The tool was then modified based on this feedback. Pediatric providers will complete four educational sessions on vaccine hesitancy, MI, and the use of the MOTIVE tool in clinical practice prior implementation.
214965092|NCT00409981|DEVICE|paclitaxel coated balloon catheter (device with drug)|
214965093|NCT00522548|DRUG|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
214965094|NCT00522548|DRUG|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
214965095|NCT03959007|OTHER|Aesthetic therapy sessions|Only for experimental arm at 3 times during hospitalization
214965096|NCT03959007|OTHER|Questionnaire|Both arm at 3 times during hospitalization
214965097|NCT03272243|PROCEDURE|short segment posterior spine fixation|
214965098|NCT03272243|PROCEDURE|long segment posterior spine fixation|
214965099|NCT00478270|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3
214965100|NCT02030262|PROCEDURE|Epiretinal membrane peeling with fluid-air exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
214965101|NCT02030262|PROCEDURE|Epiretinal membrane peeling with fluid-SF6 exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
215080969|NCT04123912|BEHAVIORAL|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
215080970|NCT04123912|BEHAVIORAL|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
215080971|NCT04155346|BEHAVIORAL|Exercise, nutritional optimization, and psychoeducation|Multimodal prehabilitation including exercise, nutrition, and stress-management delivered via a facility-based or home-based model
215080972|NCT03103672|PROCEDURE|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
215080973|NCT02046226|DEVICE|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
215080974|NCT01119833|DRUG|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
215080975|NCT01119833|DRUG|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
215080976|NCT03865667|DEVICE|PROFEMUR® Preserve Femoral Stem|Total Hip Total Hip Arthroscopy
215080977|NCT03905369|OTHER|Decision aid and SDM booster|The investigators develop the decision aid and SDM booster. The scope of the investigators of decision making combines the clinical and patient perspective. The decision aids are developed for patients with TC either newly diagnosed or patients with advanced disease, presently in the follow-up at the participating centers, covering the whole treatment trajectory of these patients (Figure 4). Three treatment decisions are considered: 1) the extent of thyroid resection, 2) the use of RAI, and 3) the initiation of TKIs.The SDM-booster is developed alongside the decision aids, as the SDM-booster (or values clarification exercise) is often a component developed together with a decision aid. The SDM-booster aims to shape patients' values regarding aspects of the decision and ensuing treatment preferences.
214355847|NCT03671837|OTHER|Oxygen|15 L/min O2
214355848|NCT03671837|OTHER|Air|15 L/min air
214355849|NCT04083248|BEHAVIORAL|Feasibility group|Same as arm description
214393688|NCT04438096|DRUG|100 mg|One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
214965102|NCT03851770|OTHER|Characterization of Vagus nerve stimulation|Characterization of Vagus nerve stimulation induced larynx evoked motor potential. Patients participating in the study will be asked to come to perform the experiment (duration maximum 1 hour) at the Neurophysiology Department of Saint Luc .
214965103|NCT04361799|DEVICE|CamAPS|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
214965104|NCT04361799|DRUG|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
214965105|NCT05722262|DRUG|K-001|K-877-ER and CSG452 combination tablet
214965106|NCT05722262|DRUG|K-877-ER|K-877-ER tablet
214965107|NCT05722262|DRUG|CSG452|CSG452 tablet
214965108|NCT01945879|DRUG|Enoxaparine|al patients received additional low molecular heparin, if the safety cohort of three patients received at least 4 weeks of combined treatment without severe side effects, recruitment were continued until a minimum of 15 patients completed at least 3 months of treatment.
214965109|NCT01151306|DRUG|Simvastatin|Simvastatin 20mg once daily (in the evening) for 6 weeks
214965110|NCT01151306|DRUG|Lactose tablet|One tablet taken each evening for 6 weeks
214965111|NCT04214574|DEVICE|Parasagittal oblique technique (Ultrasound)|the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.
214965112|NCT04214574|DEVICE|Paramedian tranverse technique (Ultrasound)|the transducer will be applied in the parasagittal plane, and after identification of the intervertebral level, the probe will be rotated 90 degrees into a transverse orientation and centered on the neuraxial midline in a way to align the beam with the interspinous and interlaminar space and thus to get a paramedian transverse interlaminar view. The needle will be inserted in plane from the lateral end of the ultrasound transducer with its tip directed towards the medial border of the articular process.
214965113|NCT03877146|BEHAVIORAL|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).
214965114|NCT01328639|OTHER|TeamCare Depression Intervention|The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.
214965115|NCT01328639|OTHER|Usual diabetes and depression care|Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.
214965116|NCT02121795|DRUG|FTC/TDF|200/300 mg FDC tablets administered orally once daily
214965117|NCT02121795|DRUG|F/TAF|Tablets administered orally once daily
214965118|NCT02121795|DRUG|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
214965119|NCT02121795|DRUG|FTC/TDF Placebo|Tablets administered orally once daily
214965120|NCT02121795|DRUG|F/TAF Placebo|Tablets administered orally once daily
214965121|NCT00849069|BIOLOGICAL|GSK2231395A|3 doses intramuscular injections
214355850|NCT01446458|DRUG|Modified FOLFIRINOX|Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
214393689|NCT04438096|DRUG|200 mg|Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks
214965122|NCT00849069|BIOLOGICAL|TwinrixTM|3 doses intramuscular injections
214965123|NCT05707416|DEVICE|gallium aluminum arsenide (Ga-Al-As) semiconductor diode laser (SMARTTM PRO, LASOTRONIX, Poland)|The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
214965124|NCT05707416|OTHER|group B|Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
214965125|NCT05544591|DRUG|611 Q2W|subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)
214965126|NCT05544591|DRUG|611 Q4W|subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)
214965127|NCT05544591|DRUG|Matching placebo|subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
214965128|NCT02379013|PROCEDURE|Volunteer with MRI|functional MRI
214965129|NCT01553565|PROCEDURE|Cold polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
214965130|NCT00346749|DRUG|Salmeterol|
214965131|NCT00346749|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
214393690|NCT04438096|DRUG|300 mg|Three 100 mg pills (QD) will be orally administered for 12 weeks
214393691|NCT04438096|DRUG|Placebo|Three placebo pills (QD) will be orally administered for 12 weeks
214965132|NCT00994110|DRUG|Pasireotide (SOM230)|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
214965133|NCT00994110|OTHER|placebo|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
215080978|NCT03905369|OTHER|Deliberation training|The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
215080979|NCT02470754|DEVICE|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
214965134|NCT06084702|OTHER|Rehydration with plain water|Plain water without calories, sweetener, or electolytes
214965135|NCT06084702|OTHER|Rehydration Drink|Roaring Water. An electrolyte drink with low Carbohydrate content
214355851|NCT01446458|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
214355852|NCT03936855|PROCEDURE|Direct composite resin|"For both groups: The teeth will have the enamel surface conditioned with 37% phosphoric acid. For the restorative procedure, the same adhesive system will be used~GROUP ACTIVE COMPARATOR~1. Insert resin-modified glass ionomer cement into the pulp chamber;~2. Complete the restoration by incremental technique using conventional composite resin in increments of 2mm;~EXPERIMENTAL GROUP~1. Insert Bulk Fill composite inside the pulp chamber to the height of 5 mm;~2. Complete the insertion of the Bulk Fill resin to the limit of the caval surface angle in the occlusal"
214965136|NCT04891666|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464|1 sachet SmartGuard® per day for 12 weeks
215080980|NCT02470754|DEVICE|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
215080981|NCT04679857|OTHER|TKA|Total Knee Arthroplasty
214355853|NCT02160587|DRUG|Chloraprep|ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
214393692|NCT00433576|DRUG|resveratrol|Given orally
214393693|NCT00433576|OTHER|pharmacological study|Correlative studies
214965137|NCT04891666|DIETARY_SUPPLEMENT|Placebo|1 sachet of placebo per day for 12 weeks
214965138|NCT05030116|DRUG|Shenqu Xiaoshi oral liquid|Shenqu Xiaoshi oral liquid
214965139|NCT05030116|DRUG|Domperidone suspension|Domperidone suspension
214965140|NCT00666211|OTHER|educational intervention|Participants will be educated on pain management.
214965141|NCT00666211|OTHER|Titrated pain management|Pain will be Monitored and Medication Titrated
214965142|NCT00666211|OTHER|questionnaire administration|Participants will be given questionnaires to complete.
214965143|NCT06029881|DEVICE|Movesense MD|This device can be attached to the skin (on the chest and center of mass) during sleep using a belt and adhesive electrodes.
214965144|NCT03457389|DRUG|Cabergoline|Cabergoline tablet
214965145|NCT02299440|OTHER|Baseline evaluation|Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
215080982|NCT02265419|DEVICE|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
215080983|NCT01166373|BEHAVIORAL|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
215080984|NCT01166373|PROCEDURE|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
215080985|NCT01166373|PROCEDURE|ULS|uterosacral ligament suspension to suspend the vaginal apex
215080986|NCT01166373|BEHAVIORAL|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
215080987|NCT01166373|OTHER|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
215080988|NCT02684812|DRUG|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
215080989|NCT01819129|DRUG|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
215080990|NCT01819129|DRUG|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
215080991|NCT01819129|DRUG|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
215080992|NCT00001250|DRUG|preoperative dose intense chemotherapy (FLAC/G-CSF)|
215080993|NCT01725230|DRUG|Fostamatinib|100-mg tablet
215080994|NCT01725230|DRUG|Rosuvastatin|20-mg tablet
215080995|NCT01725230|DRUG|Simvastatin|40-mg tablet
214965146|NCT02299440|DRUG|1st perfusion of ketamine|A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
215080996|NCT03812926|DEVICE|Compuflo assited procedure|number of needle entry required to identify the ligamentum flavum
215080997|NCT05670548|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
214355854|NCT02160587|DRUG|0.9% Physiological Saline|0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
214965147|NCT02299440|DRUG|1st perfusion of saline|A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
214965148|NCT02299440|OTHER|Follow-up between perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
214965149|NCT02299440|DRUG|2nd perfusion of ketamine|A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
214965150|NCT02299440|DRUG|2nd perfusion of saline|A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
214965151|NCT00163566|DRUG|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
214965152|NCT06436079|BEHAVIORAL|Intervention group|Patients who begin the first session in the hyperbaric chamber will receive a nursing educational intervention, with audiovisual support, about the operation of the chamber and aspects that must be taken into account once inside.
214965153|NCT05882929|OTHER|Watching Cartoons|The cartoon will be watched after the child comes to the service after the operation and the postoperative period is prepared (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.).
214965154|NCT05882929|OTHER|ball spin|ball squeezing will be applied after the child comes to the service after the operation and after the postoperative period preparation is made (taking the vital signs, dressing the clothes, controlling the bleeding, telling the feeding time, etc.).
214355855|NCT02160587|OTHER|ZuraPrep without IPA|ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
214965155|NCT03671876|DEVICE|Intervention plus therapy|Task oriented exercise plan to improve mobility for stroke patients
214965156|NCT02068638|PROCEDURE|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
214965157|NCT02068638|PROCEDURE|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
214965158|NCT02068638|PROCEDURE|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
215080998|NCT04740840|DRUG|Levamlodipine|According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
215080999|NCT04740840|DRUG|Amlodipine|According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
214355856|NCT04092374|PROCEDURE|Locking compression plates|Fixation of sternal fracture using locking compression mechanism
214355857|NCT06533943|OTHER|Exercise program|Each intervention session is divided into three different parts according to the specific aim such as warm-up (about 15 minutes) at the beginning, main exercises (about 30 minutes), and stretching and relaxation (about 15 minutes) at the end.
214965159|NCT02068638|PROCEDURE|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
214965160|NCT04088669|OTHER|Home-based Pulmonary Rehabilitation|Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.
214393694|NCT00433576|OTHER|laboratory biomarker analysis|Correlative studies
214355858|NCT05476939|DRUG|Everolimus|Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.
214355859|NCT05476939|DRUG|ONC201|Capsules of 125mg. The prescribed dose is 375mg/m², once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.
214355860|NCT05476939|RADIATION|Radiotherapy|"All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation."
214965161|NCT04088669|OTHER|Education and Recommendations|The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
214965162|NCT03791801|DRUG|Sugammadex|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
214355861|NCT06490146|OTHER|No intervention|this is an observational study
214965163|NCT03791801|DRUG|Neostigmine|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
214355862|NCT05504460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Treatments in the test group will lasts for 12 months, and symptomatic treatment will be provided based on the actual symptoms of the subjects. Subjects in the test group will be required to receive inhalation for at least 4 days every 7 days with at least 3780L inhaled every 7 days (It is recommended to inhale at least 540L per day; If the flow rate is 3L/min, it is recommended that the cumulative inhalation time should be at least 3 hours per day. If the flow rate is 1.5L/min, it is recommended that the cumulative inhalation time should be at least 6 hours per day).
214355863|NCT05504460|OTHER|basic treatment|supportive treatment determined by the investigator based on the condition of the patients
214355864|NCT01308216|PROCEDURE|low level laser therapy procedure|Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
214965164|NCT03791801|DRUG|Rocuronium|Both groups will receive rocuronium for paralysis during intubation
214965165|NCT03791801|DRUG|Glycopyrrolate|The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate
214965166|NCT06958874|PROCEDURE|Non-surgical periodontal therapy + sub-gingival air polishing|Participants receive a single session of non-surgical periodontal therapy (NSPT) using ultrasonic and manual instruments, combined with sub-gingival air polishing using erythritol powder. The treatment is applied to periodontal pockets with probing depth ≥ 4 mm in non-adjacent teeth.
214965167|NCT06958874|PROCEDURE|Non-surgical periodontal therapy alone|Participants receive a single session of non-surgical periodontal therapy (NSPT) using ultrasonic and manual instruments.
214965168|NCT03695146|BEHAVIORAL|Paced breathing|Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.
214965169|NCT03695146|BEHAVIORAL|Active relaxation|Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.
214965170|NCT06958991|DEVICE|Histolog Scanner|The clinical performance study is collecting data from the use of a CE mark product used within the scope of its intended purpose to intraoperatively visualize tissue specimen. The subjects are not submitted to invasive and burdensome procedures compared to the standard of care surgical practices and regular use of the CE mark product.
214965171|NCT03205293|BEHAVIORAL|Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren|
215081000|NCT01564095|DRUG|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
214965172|NCT02990403|DRUG|Aspirin|
214965173|NCT02990403|DRUG|Heparin|
214965174|NCT02990403|DRUG|Prednisone|
214355865|NCT04867577|DIAGNOSTIC_TEST|CT scan of lung and spine|Dual energy CT scan of thorax and spine
215081001|NCT01564095|DRUG|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
215081002|NCT06154941|PROCEDURE|Giomer Varnish|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession
215081003|NCT06154941|PROCEDURE|CPP-ACP varnish|CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. CPP-ACP Varnish delivers bioavailable calcium and phosphate ions to occlude dentinal tubules treating dentin hypersensitivity
215081004|NCT03436641|OTHER|No intervention|No intervention
214965175|NCT02990403|DRUG|Immunoglobulin|
214965176|NCT02990403|DRUG|Dydrogesterone|
214965177|NCT02683239|DRUG|Fasinumab|Participants will receive sub-cutaneous (SC) injections of fasinumab
214965178|NCT02683239|DRUG|Placebo|Participants will receive sub-cutaneous (SC) injections of matching placebo
214965179|NCT00320060|DRUG|Pyridorin (pyridoxamine dihydrochloride)|
214965180|NCT05094414|DRUG|Valacyclovir|oral valacyclovir 500 mg twice per day for 4 weeks
214965181|NCT05033925|DIETARY_SUPPLEMENT|FADA (active fraction of Ficus septica leaf) 800 mg/day|FADA is given twice a day (total dose of 800 per day per patient)
215081005|NCT04802239|OTHER|Medical hypnosis group|"Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~* State of calm at rest of 3 minutes.~* Hypnotic induction by catalepsy of the eyes guided by breathing.~* The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques."
214965182|NCT05033925|DIETARY_SUPPLEMENT|FADA (active fraction of Ficus septica leaf) 2000 mg/day|FADA is given twice a day (total dose of 2000 per day per patient)
214965183|NCT05033925|OTHER|Placebo capsule|Placebo capsule is given twice a day
214965184|NCT04797507|DRUG|SHR-1210 plus Anlotinib|SHR-1210: a novel anti-PD-1 antibody Anlotinib: a multi-kinase inhibitor
214965185|NCT03352492|PROCEDURE|Superior laser peripheral iridotomy|Iridotomy placement between 11:00 and 1:00 o'clock
214965186|NCT03352492|PROCEDURE|Temporal laser peripheral iridotomy|Iridotomy placement at 3:00 or 9:00 o'clock
214965187|NCT05948137|DIAGNOSTIC_TEST|F-18 FDOPA PET/CT|Nuclear medicine imaging modalities
214965188|NCT03015298|DEVICE|PET/MRI|The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
214965189|NCT03015298|DEVICE|PET/CT|At the next day of PET/MRI examination,A PET/CT examination will be performed.
214965190|NCT06959654|DIAGNOSTIC_TEST|ELISA test|ELISA test to evaulate serum oncostatin M and galactin 3 in two group of patientsL
215081006|NCT04802239|OTHER|calm wake group|healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
215081007|NCT01819558|BIOLOGICAL|recwt1-A10+AS01B|
215081008|NCT03651518|DRUG|Kineret|100 mg, once/day sc 6 months
215081009|NCT03651518|DRUG|Humira|40 mg/15 days sc 6 months
215081010|NCT03651518|DRUG|Stelara|45 mg/12 weeks sc, 6 months
215081011|NCT03651518|DRUG|Cosentyx|300mg sc every week for 1 month, then 300 mg/month sc for 5 months
215081012|NCT03651518|DRUG|Roactemra|480 mg/perf/4 weeks 6 months
214355866|NCT00670774|DRUG|Eculizumab|"* Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~* Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~* Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~* At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~* In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
214965191|NCT00287456|DEVICE|Insulin Pump|
214965192|NCT00287456|DRUG|Insulin|0
214965193|NCT00287456|PROCEDURE|Oral Glucose Tolerance Test|0
214965194|NCT00287456|PROCEDURE|Whole body Protein Turnover|0
214965195|NCT01401946|DRUG|soy isoflavones|
214965196|NCT01401946|DRUG|Placebo|
215081013|NCT03651518|DRUG|Rituximab|2 sessions of 1000 mg at inclusion and 15 days after inclusion
215081014|NCT05941000|BEHAVIORAL|Self-Monitoring of Behavior for Physical Activity|Self-Monitoring of Behavior for Physical Activity: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring the number of steps taken on the prior day relative to their baseline average number of steps.
214965197|NCT06959589|DRUG|IBI351, cetuximab β combined with FOLFIRI|"Cohort A - To evaluate the efficacy and safety of IBI351, cetuximab β combined with FOLFIRI as first-line treatment for metastatic colorectal cancer with KRAS G12C mutations; Twenty untreated patients with advanced colorectal cancer with KRAS G12C mutation are proposed to be enrolled and treated with the first-line IBI351+ cetuximab β injection +FOLFIRI regimen. The historical reference is expected to be around 40-50%, and it is expected to increase to around 75%. Therefore, among the 20 patients, if ≥15 patients achieve remission, it is considered that the efficacy of the trial protocol is statistically significant.~Cohort B - To evaluate the efficacy and safety of BI351 and cetuximab β as second-line treatment for metastatic colorectal cancer with KRAS G12C mutations.~It is proposed to enrolled 30 patients with advanced colorectal cancer with KRAS G12C mutation who have progressed after first-line treatment, and evaluate IBI351+ cetuximab β injection for second-line treatment. The hi"
214965198|NCT00629759|GENETIC|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
215081015|NCT05941000|BEHAVIORAL|Action Planning for Physical Activity|Action Planning for Physical Activity: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to walk an extra 1,000 steps relative to their baseline average step count.
215081016|NCT05941000|BEHAVIORAL|Self-Monitoring of Behavior for Mood|Self-Monitoring of Behavior for Mood: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring their mood on the prior day.
215081017|NCT05941000|BEHAVIORAL|Action Planning for Mood|Action Planning for Mood: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to improve their mood.
215081018|NCT02770976|DEVICE|Increasing and decreasing NAVA levels with 10-min intervals|
215081019|NCT03741946|PROCEDURE|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
215081020|NCT01296074|DRUG|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
215081021|NCT03009838|DRUG|Letrozole|oral tablets 2.5 mg
215081022|NCT03009838|PROCEDURE|ovarian drilling|laparoscopic electrocauterization
215081023|NCT02836873|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
215081024|NCT02836873|DRUG|Placebo|Placebo (inactive) tablet to match the active comparator
215081025|NCT04923646|OTHER|Primer|Mailed postcard notifying Veteran of upcoming FIT kit for annual CRC screening.
215081026|NCT03190265|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
215081027|NCT03190265|DRUG|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
214355867|NCT04273633|DEVICE|Monopolar 448 kilohertz radiofrequency stimulation|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant shoulder
214965199|NCT01967771|DRUG|DTG|DTG will be supplied as 50 mg tablet to be administered orally
214965200|NCT01967771|DRUG|CBZ|CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
215081028|NCT03190265|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
215081029|NCT03190265|DRUG|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
215081030|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
214355868|NCT04273633|DEVICE|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the dominant shoulder
214355869|NCT01808157|DRUG|CT327 ointment|
214355870|NCT01808157|DRUG|placebo|
214355871|NCT04744480|PROCEDURE|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
214355872|NCT02170168|OTHER|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
214355873|NCT02474927|DRUG|Carfilzomib|Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)
214355874|NCT01208454|DRUG|Isotretinoin|Given PO
214355875|NCT01208454|OTHER|Laboratory Biomarker Analysis|Correlative studies
214355876|NCT01208454|OTHER|Pharmacological Study|Correlative studies
214355877|NCT01208454|DRUG|Vorinostat|Given PO
214355878|NCT05887193|DEVICE|Biothesiometry|Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
214355879|NCT05887193|DEVICE|Near Infrared Spectroscopy|Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.
214355880|NCT05887193|DEVICE|Cycling on a home trainer|Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
215081031|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
215081032|NCT01071005|DRUG|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
214355881|NCT05887193|DEVICE|Bike Fitting|Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
214355882|NCT01763944|BEHAVIORAL|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
214965201|NCT01953042|BEHAVIORAL|Psychoeducation|4 educational sessions covering information on diagnosis, treatment, available resources and self care for OCD and OCD Spectrum Disorders
215081033|NCT01071005|DRUG|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
215081034|NCT02914548|DRUG|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
215081035|NCT02914548|DRUG|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
215081036|NCT00024661|DRUG|LErafAON|
215081037|NCT02540330|DRUG|Fulvestrant|
215081038|NCT00580125|DRUG|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
215081039|NCT00580125|OTHER|Placebo|Placebo, oral capsule, once daily for 21 days
214355883|NCT05146674|DRUG|Tadalafil 5mg|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
214355884|NCT04278053|DIETARY_SUPPLEMENT|inositol-stabilized arginine silicate|Participants were asked to complete the experimental protocol in a 2-hour fasted state. Each participant's brachial artery FMD was assessed twice during each trial, once before supplement ingestion, and again 60 minutes post-ingestion. Male participants were required to wait for a minimum of seven days between trials as a supplement washout period. Female participants reported for supplement trials outside of their follicular phase of the menstrual cycle so that results were not confounded by changes in serum estradiol, which can significantly attenuate flow-mediated dilation. Sixty minutes after supplement consumption, each participant was asked which supplement they thought they had consumed. Participants were also asked whether they experienced any adverse side effects.
214355885|NCT00509847|DRUG|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
215081040|NCT00580125|DRUG|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
215081041|NCT00580125|DRUG|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
215081042|NCT00580125|DRUG|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
215081043|NCT02214225|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
215081044|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
215081045|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
214965202|NCT06194162|DEVICE|Weighted blanket|"The intervention group will receive a weighted blanket classified as a medical device class 1 as an add on to usual treatment. Participants will be asked to choose one out of at least three different weighted blankets, each with different weight classes. The choice of weighted blanket is solely taken by the participant after having tried all five blankets.~Adherence to the weighted blanket intervention is defined as reported use 60 % of the intervention period.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
214965203|NCT06194162|DEVICE|Non-weighted blanket|"The control comparator will receive a sham intervention in the form of a non-weighted blanket as an add on to usual care. Participants will be asked to choose one out of two different sham blankets.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
214965204|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|Surgery -\> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
214965205|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
214965206|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|(Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
214965207|NCT04142671|OTHER|Individualised gait modification intervention|An individualised gait modification intervention to reduce knee joint loading. Knee joint loading will be presented in real-time during treadmill walking. A 10% reduction of each patients baseline knee loading will be used as a target threshold along with visualisation of the history of 5 previous steps. Patients are encouraged to determine their own gait modification strategy that is most efficient for them. Previous examples of gait modifications that mechanically reduce knee loading will be presented to them.
214965208|NCT05276206|DRUG|NSAID , NALUFIN , local anesthetic andTAP Block|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared"
214965209|NCT02363387|BEHAVIORAL|Incentives for Viral Suppression|Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
214965210|NCT02363387|BEHAVIORAL|Standard HIV Medical Care|The best HIV medical care available in each participant's medical clinic.
214965211|NCT02609386|BIOLOGICAL|IRX-2|Method of Administration: Administered for 10 days as subcutaneous bilateral injections in the upper neck.
214965212|NCT02609386|DRUG|Cyclophosphamide|Method of Administration: Cyclophosphamide is administered once by IV
214965213|NCT02609386|DRUG|Indomethacin|Method of Administration: Indomethacin is administered orally for 21 days.
215081046|NCT02648022|BEHAVIORAL|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
215081047|NCT04793997|BIOLOGICAL|Microbiome spray|Throat spray containing 3 beneficial lactobacilli strains
215081048|NCT04793997|BIOLOGICAL|Placebo spray|Throat spray
215081049|NCT02182440|BIOLOGICAL|recAP|One hour infusions once daily for three days
215081050|NCT02182440|OTHER|Placebo|1 hour IV infusion once daily for 3 days
215081051|NCT04159272|BEHAVIORAL|Mindfulness Training|"The programme consists of 8 90-min sessions held once a week for 8 consecutive weeks. Each session consists of guided experiential mindfulness exercises, sharing of experiences of these exercises, reflections in small groups, psycho-education, and review of home practices. An overview of the core elements in each session is given in Van der Gucht et al. (2017). The in-class MT programme will be supported with a mindfulness for adolescents smartphone application to support practice at home.~The curriculum is available in an open source platform. The training is supported by the use of homework assignments and audio material. The programme has already been piloted and reviewed in an expert group of mindfulness trainers and scientists working with youth in mental health care (Van der Gucht et al., 2017) and in refugee centres (Van der Gucht et al., 2019). The MT will be delivered by certified trainers (\>3 years of experience). During the trial they will receive regular supervision."
215081052|NCT04619446|DEVICE|Removable Twin Block|Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
214355886|NCT06119100|DIAGNOSTIC_TEST|Ultrasound characterization of stenotic lesion type|Target lesion type will be classified as restrictive, hyperplastic or mixed using high frequency Duplex ultrasound, before the angioplasty procedure and at 6 months follow up.
214965214|NCT02609386|DIETARY_SUPPLEMENT|Zinc-containing multivitamin|Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.
214965215|NCT02609386|DRUG|Omeprazole|Method of Administration: Omeprazole is administered orally for 21 days
214965216|NCT04131712|OTHER|Massage|A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
214965217|NCT04567004|OTHER|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
214965218|NCT04567004|OTHER|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
214965219|NCT04567004|OTHER|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
214965220|NCT04567004|OTHER|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
214965221|NCT04630782|DIAGNOSTIC_TEST|PET-MRI scan|Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.
214965222|NCT01240499|OTHER|Health-At-Every-Size (HAES)|"1. HAES group: 14 weekly sessions.~   Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~2. SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian \& psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study."
214965223|NCT04124380|BEHAVIORAL|Imaginal Exposure|Six 50 min, twice weekly video telehealth sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).
214965224|NCT04124380|BEHAVIORAL|Alcohol Skills Training|Six 50 min, twice weekly video telehealth sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.
214965225|NCT04124380|BEHAVIORAL|Supportive Telehealth|The supportive counseling intervention, modeled after Litz et al. (2007), will ask participants to self-monitor their experience of weekly symptoms and complete weekly online writing about daily non-trauma related concerns and hassles. Participants will talk with a therapist on the telephone twice per week.
214965226|NCT00809536|DRUG|Metformin|225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
214965227|NCT00809536|DRUG|Metformin|Single, oral, 500 mg of metformin immediate release
214965228|NCT00809536|DRUG|PD 0332334|500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
214965229|NCT00809536|DRUG|PD 0332334|Single, oral, 300 mg dose of PD 0332334 immediate release formulation
214965230|NCT01965314|OTHER|Simulation based training|In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device
215081053|NCT04619446|DEVICE|Fixed Functional , AdvanSync Appliance|AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
214355887|NCT02298192|DRUG|insulin degludec/liraglutide|For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
214355888|NCT00777725|DEVICE|FibroScan|Liver scan, similar to an ultrasound.
214355889|NCT06305572|DIAGNOSTIC_TEST|QFR|Patients suspected with CAD undergoing diagnostic coronary angiography with an indication for to perform invasive FFR were included. QFR was analyzed in an independent core laboratory (Uijeongbu Eulji Medical Center) using the software package QAngio XA 3D 2.1 (Medis Medical Imaging Systems, Leiden, the Netherlands).
214965231|NCT01965314|OTHER|Traditional training|Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
214965232|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
215081054|NCT03321903|DEVICE|Carlo Erba Ink Injection|Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
214965233|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).
214965234|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).
214965235|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.
214965236|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.
214965237|NCT06314360|OTHER|No intervention.|There is no intervention in this study.
214355890|NCT02909972|DRUG|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
214965238|NCT05409716|PROCEDURE|Compressive Elastic dressing for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, compressive elastic dressing, standardized as 13 threads gauze overlapped, opened, longitudinally pleated once and wrapped, making a 5-cm long cylinder, 1-cm in height, fixed with elastic crepe bandage was used to achieve hemostasis.
214965239|NCT05409716|PROCEDURE|Wristband TR band for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, hemostatic wristband TR BandR (Terumo Corporation, Tokyo, Japan) was utilized was used to achieve hemostasis.
214355891|NCT02909972|DRUG|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
214355892|NCT01371851|DRUG|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
215081055|NCT03321903|OTHER|EPR Oximetry Measurement|An oximetry measurement visit consists of \~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
215081056|NCT02889679|PROCEDURE|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
214355893|NCT02967627|DEVICE|Incisional Negative Pressure Wound Therapy (iNPWT)|Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.
214393695|NCT02693912|PROCEDURE|Bronchoscopy|Bronchoscopy will be implemented under sedation in both groups.
214965240|NCT01784276|BEHAVIORAL|Video|"Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player."
214965241|NCT05498597|DRUG|AMT-151|Administered intravenously
214965242|NCT02820077|DEVICE|Hemospray (Endoscopic treatment with hemostatic powder)|Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
214965243|NCT00198263|COMBINATION_PRODUCT|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
214965244|NCT02454348|DRUG|Vasopressin|Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
214965245|NCT02454348|DRUG|Norepinephrine|Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
214965246|NCT00873730|DRUG|etanercept|Etanercept 50 mg twice a week (BIW) for 12 weeks
214965247|NCT00873730|DRUG|etanercept/placebo|Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
214965248|NCT00196703|DRUG|memantine|
214965249|NCT00196703|PROCEDURE|constraint-induced language therapy|
214965250|NCT04330417|DEVICE|Robot-Assisted Hand Training|Perform activities of daily living, e.g., write sentences, turn cards, move small and big objects, simulated feeding, stack checkers, pour water, squeeze handles
214965251|NCT04330417|OTHER|Standard Hand Therapy|Stretching, Strengthening, Hand Functional Training
214965252|NCT00459771|DRUG|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
214965253|NCT00459771|DRUG|Placebo|Placebo, 32 mg, oral QD
214965254|NCT03413163|DRUG|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
214965255|NCT03413163|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
214965256|NCT00002692|DRUG|fluorouracil|
214965257|NCT00002692|DRUG|isolated perfusion|
214965258|NCT00002692|DRUG|leucovorin calcium|
214355894|NCT02967627|DEVICE|Sterile Gauze Dressing|In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
214355895|NCT00833638|DRUG|Placebo|One tablet orally daily
214355896|NCT00833638|DRUG|Tadalafil|Orally once daily
214355897|NCT00689650|DEVICE|1540 nm fractional laser|
214355898|NCT01692535|PROCEDURE|Intubation|Intubation with one of the six videolaryngoscopes
214355899|NCT06129669|DRUG|Indocyanine green|Administration of ICG during surgery and recording of the fluorescence video to perform data analyses
214355900|NCT03079752|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment of suspected problems at 12 and 24 months of age
214965259|NCT03112070|OTHER|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
214965260|NCT00815997|PROCEDURE|PCI (percutaneous coronary intervention)|PCI will be performed via the radial artery.
215081057|NCT02889679|PROCEDURE|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
214355901|NCT03079752|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
214965261|NCT03633253|OTHER|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
214965262|NCT06199427|DRUG|Cyclophosphamide|Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD
214965263|NCT06199427|DRUG|Ruxolitinib|Ruxolitinib 7 mg/m2 from day +5 after HSCT
214965264|NCT03464084|DRUG|placebo|Capsules containing microcrystalline cellulose
214965265|NCT03464084|DIETARY_SUPPLEMENT|melatonin|5 mg of melatonin per os.
214965266|NCT03464084|OTHER|bright light|room light will be bright
214965267|NCT03464084|OTHER|dim light|room light will be dim
214965268|NCT02299388|DRUG|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
214965269|NCT00103662|DRUG|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
214965270|NCT00103662|DRUG|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
214965271|NCT03446976|BIOLOGICAL|CT-P13 SC Auto-injector|Each subject may receive single dose by subcutaneous administration using Auto-Injector
214965272|NCT03446976|BIOLOGICAL|CT-P13 SC Pre-filled Syringe|Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
214965273|NCT02429102|DRUG|MT-8554|
214965274|NCT02429102|DRUG|Placebo|
214965275|NCT00006029|DRUG|gemcitabine hydrochloride|
214965276|NCT00006029|DRUG|pegylated liposomal doxorubicin hydrochloride|
215081058|NCT02889679|PROCEDURE|Standard polypectomy|Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
215081059|NCT01806025|OTHER|no intervention|
215081060|NCT06219837|DRUG|bupivacaine injection by ultrasound guided transversalis fascia plane block|With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.
215081061|NCT01166958|DRUG|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
214965277|NCT00006029|DRUG|vinorelbine tartrate|
215081062|NCT01166958|DRUG|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
215081063|NCT05617053|DEVICE|DAART|
215081064|NCT05617053|DEVICE|ATP/Supera stenting|
215081065|NCT02230761|DRUG|XOPH5 Ointment|
215081066|NCT02230761|DRUG|Placebo|
215081067|NCT04257175|BIOLOGICAL|CAR-T CD19|The CAR-T infusion will be given in IV infusion. The target dose is 1 X 106 positive CAR / kg T cells (range: 0.5-1.5X 106 CAR / kg positive T cells).
215081068|NCT01551290|DRUG|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
215081069|NCT01551290|DRUG|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
214393696|NCT04430335|BEHAVIORAL|Telephone interview|Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.
214355902|NCT03079752|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
214355903|NCT03079752|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
214355904|NCT03838042|DRUG|Nivolumab and Entinostat|Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
214355905|NCT04388020|DEVICE|Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
214355906|NCT04388020|DEVICE|Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
214355907|NCT04484467|DIETARY_SUPPLEMENT|Food Supplement With Standardized Menthol, Limonene, and Ginger|Components of Standart Zdorovya GASTRO: Peppermint oil (40% menthol, 1.5% limonene) - 240 mg, Ginger oil (14% gingerol) - 50 mg, olive oil - 440 mg, 1 capsule, 730 mg, once a day for 30 days
214355908|NCT04484467|OTHER|Placebo|Components of placebo Olive oil - 730 mg, 1 capsule, 730 mg, once a day for 30 days
214355909|NCT05205265|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
214355910|NCT02906150|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
214355911|NCT02906150|DRUG|SoC (chemotherapy and platinum agent)|Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
214355912|NCT01669122|DRUG|nicotine|4 mg nicotine lozenge experimental
214355913|NCT01308242|DRUG|Sevelamer Carbonate|Sevelamer 800 mg by mouth three times daily with meals for 3 months
214355914|NCT03386370|DEVICE|"Indigo Mechanical Thrombectomy System"|"Removal of acute clot (\< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra"
214355915|NCT00083018|GENETIC|cytogenetic analysis|
214355916|NCT00083018|GENETIC|proteomic profiling|
214965278|NCT00664118|PROCEDURE|Doula combined analgesia|Doula combined epidural analgesia in the latent phase of first stage of labor in primiparas
214965279|NCT00664118|PROCEDURE|Analgesia without doula|Epidural analgesia in the latent phase of first stage of labor without doula accompany in primiparas
214965280|NCT02741648|DEVICE|Near Infrared Spectroscopy|INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
215081070|NCT02168738|DRUG|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
215081071|NCT02168738|DRUG|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
215081072|NCT02168738|DRUG|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
214355917|NCT00083018|OTHER|cytology specimen collection procedure|
214355918|NCT00083018|OTHER|immunohistochemistry staining method|
214355919|NCT00083018|OTHER|laboratory biomarker analysis|
214355920|NCT00083018|PROCEDURE|breast duct lavage|
214355921|NCT00990691|DRUG|Administration of a high dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 50 mg ;~* From 26 to 35 kg : 75 mg ;~* From 36 to 45 kg : 100 mg ;~* \> 46 kg : 150 mg."
214965281|NCT04391179|DRUG|Dipyridamole 100 Milligram(mg)|Drug will be given for 14 days while in the hospital.
214965282|NCT04391179|DRUG|Placebo oral tablet|Placebo will be given for 14 days while in the hospital.
214965283|NCT00054223|PROCEDURE|psychosocial assessment and care|
214965284|NCT03925129|DEVICE|high frequency TENS treatment|Treatment with high frequency for minimum of 1 hour after misoprostol administration
214965285|NCT03925129|DEVICE|Sham TENS treatment|Treatment with sham TENS device for minimum of 1 hour after misoprostol administration
214965286|NCT01146015|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
214965287|NCT03334188|BEHAVIORAL|Patient engagement materials|The intervention is a brief, animated video designed to engage and activate patients around their HFrEF medication prescribing, as well as a HFrEF medication checklist.
214965288|NCT03334188|BEHAVIORAL|No Intervention--Usual Care|Control for intervention--patient receives care as usual from provider to contrast against intervention arm.
214965289|NCT01562652|DEVICE|AposTherapy (All Phases of Step-cycle {APOS} system, APOS-Medical and Sports Technologies Ltd. Herzliya, Israel)|
214965290|NCT04612985|DEVICE|XACT Robotic System|CT-guided Minimally Invasive Procedures e.g., Biopsies
214965291|NCT03373760|BIOLOGICAL|Durvalumab|Given IV
214965292|NCT03373760|OTHER|Laboratory Biomarker Analysis|Correlative studies
214965293|NCT03373760|BIOLOGICAL|Tremelimumab|Given IV
214355922|NCT00990691|DRUG|Administration of a low dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 25 mg ;~* From 26 to 35 kg : 50 mg ;~* From 36 to 45 kg : 75 mg ;~* \> 46 kg : 100 mg."
214355923|NCT00990691|DRUG|Administration of a placebo|Administration of a daily dose of placebo
214355924|NCT03543254|DRUG|BoNT-A|"90U BoNT-A, given in one treatment as 18 injections of 5u (0.2 ml) each, on specific preselected sites along the sutures of the skull.~First 100 U of Botox® is solved in 4 ml (cc) of isotone saline water (9 mg/ml), distributed in 4 syringes. This is half the usual concentration, allowing for better diffusion in order to reach the target structures."
214965294|NCT04218279|OTHER|Sleep Health Education|Intervention materials include 10 brief education modules that the target population will review/view on a secure study-specific website.
214965295|NCT01348685|OTHER|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
214965296|NCT01348685|OTHER|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
214965297|NCT01348685|OTHER|The effect of solid vs. liquid forms of whey protein on food intake|
214965298|NCT05950880|OTHER|High intensity shoulder exercise|Exercises that target the rotator cuff muscles using 90% of one repetition maximum only for 5 repetitions
214965299|NCT05950880|OTHER|Conventional physical therapy|Conventional physical therapy consisting of scapular stabilization exercises, posterior capsule stretch, and rotator cuff activation exercises
214965300|NCT04407702|OTHER|Hygiene Instructions|Two weeks prior to the onset of the study, the volunteers will undergo a wash-out period, in which they will only use oral hygiene products donated by the researchers. These products will be used through to the end of the study. The oral hygiene kit will contain a soft-bristle toothbrush (Professional Lab Series, Colgate Palmolive), fluoride toothpaste with no desensitizing agent (Elmex) and dental floss (Colgate). The participants will be extensively trained with regards to all procedures involved in the experiment.
214965301|NCT04407702|PROCEDURE|Sealant application|The teeth to be sealed will be isolated and 35% phosphoric acid will be applied for 20 seconds, followed by rinsing and drying the dental surfaces. A thin layer of PermaSeal will be applied to the tooth surface for 5 seconds and photopolymerized for 20 seconds. The occlusion will then be evaluated.
214965302|NCT04407702|RADIATION|Low-level Laser|Irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation. The power will be set to 100 mW; energy density will be 35 J/cm2 (considering a spot size of 0.028 cm2 of the equipment) and the dose will be 1 J per point. Irradiation will be performed on a cervical point, an apical point and a point precisely over the lesion, totaling a dose of 3 J. Treatment will be performed in three sessions with a 72-hour interval between sessions.
214965303|NCT03826537|OTHER|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin
214965304|NCT02616198|OTHER|EquiaFil G-coat|The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
214965305|NCT02616198|OTHER|EquiaFil Fuji Varnish|The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
214965306|NCT02616198|OTHER|Riva SC G-coat|The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
214965307|NCT02616198|OTHER|Riva SC Fuji Varnish|The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
215081073|NCT04486482|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
215081074|NCT04486482|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
215081075|NCT00405964|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
215081076|NCT00405964|DRUG|Placebo tablet|Placebo tablet, once daily for 12 weeks
214355925|NCT02389972|DRUG|Dasatinib|
214355926|NCT02283931|DEVICE|TTE / NICOM|
214355927|NCT00072267|DRUG|7-hydroxystaurosporine|
214355928|NCT00072267|DRUG|topotecan hydrochloride|
214355929|NCT01261338|DRUG|olestra|non-absorbable dietary fat
214355930|NCT01283412|DRUG|Placebo|Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
214355931|NCT01283412|DRUG|Dexmedetomidine|Dexmedetomidine 0.1\~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
214355932|NCT05545553|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
214355933|NCT05545553|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
214355934|NCT01295554|OTHER|NCE MRA and CE MRA|"Each patient will receive on the same day:~* NCE MRA~* CE MRA usually performed in the clinical routine~After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images."
214965308|NCT01710397|OTHER|Rapid ART initiation|Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
214965309|NCT02419599|OTHER|HE ONS|High energy density, low volume oral nutritional supplement (HE ONS) in addition to appropriate nutritional management
214965310|NCT02419599|OTHER|SE ONS|Standard energy density oral nutritional supplement (SE ONS) in addition to appropriate nutritional management
214965311|NCT05827692|BEHAVIORAL|Intervention group A|The forest bath sessions will be led by a specialized guide and will be conceived as a silent walk of about 3 km along a path and forest track with an average gradient of 3%, with three 10-minute stops (at the beginning, in the middle and at the end) to practice deep breathing and awareness of the 5 senses.
214965312|NCT04579432|OTHER|Education|With the training module prepared according to the ADDIE model, the intervention group will be trained on reproductive health and sexual health.
214965313|NCT00884260|DRUG|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
214965314|NCT02535650|DRUG|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
214965315|NCT01093586|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo transplantation
214965316|NCT01093586|OTHER|cytogenetic analysis|Correlative studies
214965317|NCT01093586|PROCEDURE|bone marrow aspiration|Correlative studies
214355935|NCT03195933|OTHER|Cortisol|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
214355936|NCT03195933|OTHER|Placebo|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
214355937|NCT04360733|OTHER|Blood draw|serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis
214355938|NCT04982900|DRUG|furmonertinib|AST2818 is an irreversible and highly selective EGFR inhibitor independently discovered and developed by Allist. It has the potential to become the best-in-class drug in the third-generation EGFR-TKIs. Data from the preclinical studies and the completed clinical studies show that AST2818 has the following advantages: 1) AST2818 has good target selectivity and tissue distribution specificity; 2) The objective response rate of AST2818 for the patients with locally advanced or metastatic NSCLC with EGFR T790M mutation is outstanding, reaching 74.1% in the key registration clinical study; 3) AST2818 has a good safety profile and is well-tolerated; 4) AST2818 and its active metabolites have a superior ability to penetrate the blood-brain barrier, and have a good therapeutic efficacy on brain metastases frequently seen in patients with NSCLC.
214355939|NCT04982900|DRUG|Placebo|The placebo has the same appearance, weight, and physical and chemical properties as the study drug, and is provided by the researcher to the subjects in control group.
214355940|NCT00234065|DRUG|Cilostazol|oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
214965318|NCT01093586|OTHER|fluorescence in situ hybridization|Correlative studies
214965319|NCT01093586|DRUG|busulfan|Given orally
214965320|NCT01093586|DRUG|cyclophosphamide|Given IV
214965321|NCT01093586|DRUG|anti-thymocyte globulin|Given IV
214965322|NCT01093586|DRUG|methylprednisolone|Given IV
214965323|NCT01093586|DRUG|cyclosporine|Given IV
214355941|NCT00234065|DRUG|Aspirin|oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
214355942|NCT04666168|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
214355943|NCT04666168|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
214355944|NCT04666168|PROCEDURE|Leukapheresis|Leukapheresis
214965324|NCT01093586|DRUG|mycophenolate mofetil|Given orally or IV
214965325|NCT01093586|OTHER|flow cytometry|Correlative studies
214965326|NCT01093586|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
214965327|NCT02949882|DIETARY_SUPPLEMENT|Yakult|Containing at least 6,5\*10\^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
214965328|NCT02949882|DIETARY_SUPPLEMENT|Dairy Peach Drink (AH Basic)|Commercially available dairy drink with peach flavour.
214965329|NCT01867320|DRUG|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
214965330|NCT01749046|DRUG|Remegal|Remegal 1500 mg for 12 weeks
214965331|NCT05873270|OTHER|Wrist and ankle acupuncture|Patients in the intervention arm started the wrist and ankle acupuncture treatment 1 day before the surgery. Take up and down 1,2 area as a needle point, use hua tuo brand sterile acupuncture needle (specification: 0.25mm 25mm), into the skin disinfection into the needle, keep 30 subcutaneous needle and skin, when the operator under the needle, patients without acid swelling, pain, close to the skin dermis, to about 1.5 inches, give tape fixed 24h, left under the skin, until postoperative 3 day.
214965332|NCT04263246|DIETARY_SUPPLEMENT|PhytoDyNAmic|PhytoDyNAmic (6 capsules per day)
214355945|NCT01544868|OTHER|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
214355946|NCT05983822|DEVICE|Technological Group|Specific rehabilitation for the recovery of hand function using the end-effector robot
214355947|NCT05983822|OTHER|Conventional Treatment|Conventional rehabilitation
214355948|NCT01521676|GENETIC|molecular alteration|research of molecular alteration
214355949|NCT02055131|DRUG|aspirin|
214355950|NCT00564122|DEVICE|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
214965333|NCT04263246|DIETARY_SUPPLEMENT|Inulin|Inulin (6 capsules per day)
214965334|NCT06117722|OTHER|Eplerenone torasemide in chronic heart failure|Heart Failure patients treated with eplerenone and torasemide
214965335|NCT01957423|DIETARY_SUPPLEMENT|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
214965336|NCT01957423|DIETARY_SUPPLEMENT|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
214965337|NCT01560026|PROCEDURE|surgery|endometrial cancer with or without oophorectomy
214965338|NCT00105989|DRUG|Duloxetine|
214965339|NCT00105989|DRUG|placebo|
214965340|NCT03442088|DRUG|Apremilast|Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
214965341|NCT05926141|BEHAVIORAL|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes). On any day during the week, the students will make a dish using groceries they received (1 hour).
214965342|NCT00817388|OTHER|No intervention|No intervention
214355951|NCT00564122|OTHER|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
214355952|NCT05374421|DEVICE|Erchonia® THL™|The Erchonia® THL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
214355953|NCT05374421|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
214355954|NCT05132699|DRUG|Cannabidiol (CBD) oral solution|An oral strawberry flavored liquid, taken as a 2.5ml (250mg) dose twice a day
214965343|NCT00357877|DRUG|10% w/v chlorhexidine acetate coating FDA IND #45466|Dental coating topically applied by dental professional supragingivally to the full dentition
215081077|NCT01932151|DRUG|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
215081078|NCT00257595|DRUG|Cetirizine Dry Syrup|
214355955|NCT05132699|DRUG|Placebo|An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
214355956|NCT05132699|BEHAVIORAL|Massed Prolonged Exposure (mPE)|mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.
214965344|NCT00357877|OTHER|Placebo|
214965345|NCT05678439|DIETARY_SUPPLEMENT|sesame extract|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
214965346|NCT05678439|OTHER|placebo|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
214679022|NCT02471248|DEVICE|Sham|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion."
214965347|NCT03301077|OTHER|2-phase epidemiological study (screening, interviews)|first phase is the screening phase, second phase is the interview phase
214965348|NCT00738855|OTHER|Oral Gastrografin|100 ml of the dye administered through a nasogastric tube
214965349|NCT00738855|OTHER|Nothing per os|A nasogastric tube
214965350|NCT03327285|BIOLOGICAL|C-CAR011|CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
214965351|NCT03147950|PROCEDURE|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
214965352|NCT03147950|PROCEDURE|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
214965353|NCT04668209|DRUG|Silmitasertib|Standard of care / best supportive care in combination with CX-4945 1000 mg administered orally, two times a day.
214965354|NCT01687634|BEHAVIORAL|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
214965355|NCT01687634|BEHAVIORAL|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
214965356|NCT01863290|OTHER|Primary care redesign|Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
214965357|NCT05618288|BEHAVIORAL|mobile Health Breastfeeding Counseling|a phone-based breastfeeding counseling intervention, delivered by labor and delivery nurses, nutritionists, and maternal and child health nurses.
214965358|NCT05618288|BEHAVIORAL|Standard of care breastfeeding counseling|The ongoing antenatal, delivery and postnatal breastfeeding and lactation counseling that is provided by the Naivasha sub-County Referral Hospital.
214965359|NCT03944213|DEVICE|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
214965360|NCT00534872|DRUG|SB-649868|10 mg
214965361|NCT02033044|OTHER|cognitive remediation|Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.
215081079|NCT03466619|DEVICE|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
215081080|NCT00717587|DRUG|motexafin gadolinium|
215081081|NCT00717587|DRUG|sunitinib malate|
215081082|NCT00717587|GENETIC|comparative genomic hybridization|
214965362|NCT02033044|OTHER|Psychoeducation|Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
214965363|NCT00767221|DRUG|Budesonide|8 mg PL-56 once daily for six months
214965364|NCT02710019|OTHER|Back to Reality Series Video Games|Back to Reality Series are a psycho-educational video games that provide information about psychosis and marijuana use from the perspective of 'Harry': a character who experiences problems with both issues. The aim is for players to learn how to detect some signs of psychosis and where to seek help for mental health and addictions problems.
214965365|NCT02710019|OTHER|Control Video Game|The control video game consists of digital puzzles and spelling game about pop culture. The control games does not have any content related to mental health and addictions problems
214965366|NCT05834218|OTHER|split body resistance training|"Split-group training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust) 3x12 repetitions for each exercise Day 2 ( Lat pulldown, Bench press, Cabled seated row)3x12 reps (Triceps press and biceps curls in cable (superset) Day 3 (Day 1 exercise repeated) Day 4 (Day 2 exercise repeated)"
214965367|NCT05834218|OTHER|full body resistance training|"Full body training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust, Lat pulldown, Bench press, Cabled seated) 3x12 reps for each exercise, (Triceps press and biceps curls in cable (superset) Day 2 (Repeat first day exercise)"
214965368|NCT00789620|DRUG|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
214965369|NCT00789620|DRUG|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
214965370|NCT02959216|OTHER|Aerobic Exercise|Participants will be given a prescription to exercise up to 90% of their threshold heart rate for symptom exacerbation. Heart rate threshold will be monitored weekly in order to increase exercise level accordingly.
214965371|NCT02959216|OTHER|Stretching Exercise|Participants will be given a prescription to complete a standardized stretching protocol.
215081083|NCT00717587|GENETIC|gene expression analysis|
215081084|NCT00717587|GENETIC|mutation analysis|
215081085|NCT00717587|GENETIC|polymorphism analysis|
215081086|NCT00717587|OTHER|immunohistochemistry staining method|
215081087|NCT00717587|OTHER|iodine I-124 girentuximab|
215081088|NCT00717587|OTHER|laboratory biomarker analysis|
215081089|NCT00717587|OTHER|pharmacological study|
215081090|NCT00717587|PROCEDURE|adjuvant therapy|
215081091|NCT00717587|PROCEDURE|neoadjuvant therapy|
215081092|NCT00717587|PROCEDURE|therapeutic conventional surgery|
214965372|NCT05929742|BEHAVIORAL|virtual reality training|The experimental group received five additional days of supervised VR training using a wireless sensor in a private room in the neurological care ward.
214679023|NCT04955145|DRUG|RUTA C 60|Rutin known as vitamin p or rotoside and C-retard is Ascorbic acid
214965373|NCT05929742|BEHAVIORAL|early rehabilitation|Five 60-minute sessions per week, was prescribed by a rehabilitation physician and performed by physical, occupational, and speech therapists from 3 to 6 days after admission.
214965374|NCT05258253|OTHER|High intensity aerobics|"London bridges (8mins) Jumping lunges(8mins) Mountain climbers(8mins) Quadruped bent knee hip extension (8mins)"
214679024|NCT04636008|DRUG|Sintilimab|Sintilimab+Hypofractionated radiotherapy
214965375|NCT05258253|OTHER|Pelvic clock exercises|Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
214965376|NCT00608751|RADIATION|IMRT|
214965377|NCT05323877|DEVICE|Test Device (PerQseal+)|Percutaneous arterial closure device
214965378|NCT03559543|DIETARY_SUPPLEMENT|Ocoxin-Viusid|"An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study."
214965379|NCT05128266|PROCEDURE|Endodontical Retreatment|"1. Linear canal Removal of the coronal dentine in order to create the space useful to an extractor to catch and remove the instrument. The preferred instrument to reach this aim is a .15 or .20 ultrasonic tip.~2. Curve canal When the instrument is broken inside a curve canal, it is not possible to create a circumferential space around the separated instrument without the risk of root perforation. Thus, the first step is the removal of the dentine of the external wall of the root canal. The second step is the removal of the dentine of the internal wall of the root canal. This selective removal of dentinal tissue unlocks thee separated instrument and determines its mobilization. Thus, the irrigation itself makes the instrument available for the removal.~After the removal of the broken instrument, root canal preparation was completed Canal filling was performed based on Schilder's technique."
214965380|NCT02311608|DRUG|Terlipressin|administered as a first-line medicine or as salvage
214965381|NCT02311608|DRUG|Usual Dose Somatostatin/Octreotide|administered as a first-line medicine or as salvage
214965382|NCT02311608|DRUG|High Dose Somatostatin/Octreotide|administered as salvage
214965383|NCT03735082|DRUG|Apatinib|apatinib 250mg,qd,d1-14,14day/cycle
214965384|NCT03735082|DRUG|Paclitaxel|paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
214965385|NCT03735082|DRUG|Carboplatin|carboplatin AUC=4,d1,14day/cycle;
214965386|NCT01718392|BEHAVIORAL|Training|
214965387|NCT03620149|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Denosumab 120 mg, SC, on day 1 of every 12-week cycle
214965388|NCT02988739|BIOLOGICAL|seasonal influenza vaccine|influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
214965389|NCT02988739|DEVICE|fractional Er:Yag laser|Fraction laser device to apply micorpores of defined depth and density into skin.
214965390|NCT05964985|DRUG|Normal saline|After the induction of anesthesia, normal saline is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
214965391|NCT05964985|DRUG|Ropivacaine|After the induction of anesthesia, 0.375% ropivacaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
214965392|NCT05964985|DRUG|Compound lidocaine|After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
214965393|NCT05964985|DRUG|Esketamine|After the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral quadratus lumborum block
214965394|NCT04883151|BEHAVIORAL|SOFUS pilot program|"The SOFUS pilot program consists of six pre-loss sessions (Program 1) and a further six post-loss sessions (Program 2), which are delivered over a 3-month period. Each session ranges from 1-1.5 hours. Sessions 1 and 6 includes the whole family, sessions 2 and 3 focus on the parents, while sessions 4 and 5 target the children (with parents if the child is \<10 years old).~SOFUS consists of three primary components: i) strengthening COMMUNICATION between parents and children, ii) NORMALIZATION of grief processes (pre and post-lost), and iii) EMOTION REGULATION strategies targeting motivational awareness and regulatory skills in grief management (pre and post-lost).~Families in Program 1 may be offered Program 2 if the child dies before the entire program has been delivered."
214965395|NCT03610074|OTHER|Mint Ice Cube|Application in patient's mouth of 3 mint ice cubes
214965396|NCT03610074|PROCEDURE|Blood test|Additional blood test 5 min after mint ice cubes application
214965397|NCT03610074|OTHER|Patient's questioning|Patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application
214965398|NCT05454995|OTHER|Vessel Restoration System (VRS)|Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
214679025|NCT04636008|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy
214679026|NCT04861961|PROCEDURE|DS vs. SADI-S vs. OAGBP|Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.
214965399|NCT03341845|DRUG|Axitinib|axitinib in combination with avelumab
214965400|NCT03341845|DRUG|Avelumab|axitinib in combination with avelumab
214965401|NCT05704205|DEVICE|NB-UVB phototherapy|Narrowband ultraviolet B irradiation 3 times a week
214965402|NCT05704205|COMBINATION_PRODUCT|Optimal topical therapy|A combination of detailed instructions about the disease and treatments by trained nurses, bathing and washing advices, adequate emollients use, avoidance of triggers (including possible and proven contact allergens), fingertip unit explanation for active topical therapy, and personalized topical therapy with different potency topical steroids, calcineurin inhibitors and tar ointments
214965403|NCT05748574|DIETARY_SUPPLEMENT|Sleep Well Sachet|Individuals will take 1 Sleep Well sachet daily over 2 weeks Exception: Two sachets are taken on days 4 and 17 upon acute assessment
214355957|NCT05977894|OTHER|Reduced Environmental Stimulation Therapy|"During floatation-REST (Reduced Environmental Stimulation Therapy), the participant enters a tank that is approximately 5 feet wide, 7 feet long and 5 feet high. The tank is filled with a 10 inch height of water containing enough Epsom salt (magnesium sulfate) to create body buoyancy. The water temperature is 93.5 degrees F, an approximate equivalent for normal skin temperature. Ear plugs are used to mitigate sound and the tank is without light illumination to prevent visual stimulation. The sessions are typically 60 minutes in duration. The individual is Floating-in Solitude, Darkness, Silence, and Thermal-Neutrality. This experience reduces external sensory nervous system input and creates an extraordinarily deep state of mental and physical relaxation."
214355958|NCT05548101|PROCEDURE|ICSI|Using the injecting pipet, one sperm will be isolated. Using the tip of the injecting pipet, the sperm tail will be broken by trapping it between the pipet and bottom of the dish. The sperm will be picked up in the pipet. The oocyte will be positioned so the polar body is at the 12 o'clock or 6 o'clock position. The sperm injecting pipet will be positioned at the 3 o'clock position of the oocyte. The injecting pipet will be advanced into the oocyte cytoplasm and the cytoplasm will be gently aspirated until the oocyte membrane breaks. The sperm will then be injected into the cytoplasm of the oocyte. The pipet will then be withdrawn from the oocyte.
214965404|NCT00028262|DRUG|Cystagon|
214965405|NCT02884739|OTHER|Data collection|
214965406|NCT01869777|PROCEDURE|bioelectric impedance analysis|Undergo bioelectric impedance analysis
214965407|NCT03866421|DIAGNOSTIC_TEST|MR spectroscopy of the liver|Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
214965408|NCT03866421|DIAGNOSTIC_TEST|Fibroscan of the liver|Transient Elastography for Measurement of liver fibrosis.
214965409|NCT03866421|DEVICE|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
214965410|NCT03866421|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|OGTT with incretin hormones. Measured for three hours.
214965411|NCT03866421|DIAGNOSTIC_TEST|Intra venous glucose infusion (IIGI)|This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.
214965412|NCT03866421|RADIATION|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
214965413|NCT03866421|BIOLOGICAL|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
214965414|NCT03866421|OTHER|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
214965415|NCT00018564|DRUG|treatments for essential tremor|
214965416|NCT01588158|DRUG|Acetaminophen|325 mg
214965417|NCT01588158|DRUG|Vicodin|Vicodin 5/325 mg
214965418|NCT05293522|COMBINATION_PRODUCT|NTX-001|2 solutions plus a delivery device; one time use surgical product
214965419|NCT04644120|DRUG|ABBV-47D11|Intravenous (IV) infusion.
214965420|NCT04644120|DRUG|Placebo for ABBV-47D11|Intravenous (IV) infusion.
214965421|NCT04644120|DRUG|ABBV-2B04|Intervenous (IV) Infusion
214965422|NCT04644120|DRUG|Placebo for ABBV-2B04|Intervenous (IV) Infusion
214965423|NCT00613366|DRUG|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
214965424|NCT00613366|DIETARY_SUPPLEMENT|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
214965425|NCT02966847|PROCEDURE|CBCT acquisition|Acquisitions are performed with the DynaCT function of a C-arm Artis Zeego System® device
214965426|NCT02966847|PROCEDURE|Anesthesia and surgery|The anesthesia and surgery will take place according clinical routine practice
214965427|NCT05208827|DRUG|Vitamin D3|Participants began to take medication at 12 weeks of gestation, and participants in the second trimester began to take medication at the time point of enrollment.The dosage is 2 tablets per day, taken orally for 12 weeks.The drug in the intervention group was fat-soluble vitamin D3, which was produced by Sinopril Holding Starfish Pharmaceutical (Xiamen) Co., LTD. Each tablet contained 800 units of vitamin D3, vegetable oil and starch as auxiliary material.
214965428|NCT05208827|DRUG|The placebo(not contain vitamin D)|Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
214965429|NCT04020536|DRUG|Antibiotics|Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
214965430|NCT02235181|DEVICE|Arabin Cervical Pessary|The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
214965431|NCT03583879|OTHER|Exoskeleton exercise|Functional exercise with a robotic exoskeleton
214965432|NCT03583879|OTHER|Standard exercise|Functional exercise without a robotic exoskeleton
214965433|NCT03583879|OTHER|No treatment|Wait-list control
214965434|NCT02392026|DRUG|Metronidazole Gel|Metronidazole Vaginal Gel 1.3% administered via applicator
214965435|NCT01146535|DRUG|Interferon-alpha|150 IU lozenges bid for 5 days
214965436|NCT01146535|DRUG|Oseltamivir|75 mg capsules bid for 5 days
214355962|NCT05440864|DRUG|Tremelimumab|Pre-operatively Tremelimumab will be administered first for 1 hour; the Durvalumab infusion (1hr) will start approximately 1 hour (maximum 2 hours) after the end of the Tremelimumab infusion. Post-operatively patients will receive Durvalumab Q4W to complete up to 12 months of treatment or a maximum of 11 cycles of adjuvant Durvalumab
214965437|NCT01146535|OTHER|maltose|200 mg maltose lozenges bid for 5 days
214965438|NCT00766597|DRUG|Vicriviroc|Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
214965439|NCT01992250|DEVICE|Visica 2 Treatment System|Cryoablation
214965440|NCT03285035|DEVICE|Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.|Upper endoscopy with cryotherapy using liquid nitrogen.
214965441|NCT01653145|OTHER|Diet A|Dietary
214965442|NCT01653145|OTHER|Diet B|Dietary
214965443|NCT01653145|OTHER|Diet C|Dietary
214965444|NCT02820870|BEHAVIORAL|Statin Decision Support Intervention|"The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline."
214965445|NCT02565602|OTHER|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
214965446|NCT02565602|OTHER|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
214965447|NCT02565602|DIETARY_SUPPLEMENT|Vitamin D|One tablet daily (400IU per tablet)
214965448|NCT03042351|DEVICE|Magic Kegel app|Pelvic floor muscles recover exercises with a specific device and Magic Kegel App
214965449|NCT02754518|DRUG|Entresto|
214965450|NCT00874315|OTHER|anti-thymocyte globulin|2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.
214965451|NCT00874315|DRUG|busulfan|0.8 mg/kg/dose for total of 8 doses.
214965452|NCT00874315|DRUG|cyclosporine|1.5 mg/kg/dose every 12 hours.
214355963|NCT00557115|OTHER|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
214355964|NCT00064805|BEHAVIORAL|Cognitive Therapy to Improve Reading|
214355965|NCT02899728|DRUG|Carboplatin|Given IV
214355966|NCT02899728|DRUG|Cediranib|Given PO
214355967|NCT02899728|DRUG|Cediranib Maleate|Given PO
214355968|NCT02899728|DRUG|Cisplatin|Given IV
214355969|NCT02899728|DRUG|Etoposide|Given IV
214355970|NCT02899728|DRUG|Olaparib|Given PO
214355971|NCT00501150|DRUG|linezolid|Linezolid is an antimicrobial with activity against MRSA that can be given orally.
214355972|NCT02448784|DRUG|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
214355973|NCT00208208|DRUG|Ziprasidone|
214355974|NCT02889991|OTHER|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
214355975|NCT02889991|OTHER|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
214965453|NCT00874315|DRUG|fludarabine phosphate|30 mg/m2/day for 5 days.
214965454|NCT00874315|DRUG|mycophenolate mofetil|15 mg/kg/dose every 8 hours
214965455|NCT00874315|DRUG|tacrolimus|0.03 mg/kg/day as continuous infusion or 12 hour divided doses
214965456|NCT00874315|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.
214965457|NCT02651844|DRUG|Mifepristone|"At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).~Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file."
214965458|NCT00459719|DRUG|Tacrolimus modified-release|oral
214965459|NCT00459719|DRUG|Prograf|oral
214965460|NCT03564769|BEHAVIORAL|Intervention Arm|Individuals randomized to the intervention group will receive skin cancer screening educational materials.
214965461|NCT03564769|OTHER|AAD SPOTmeⓇ skin cancer screening|All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.
214965462|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
214965463|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
214965464|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
214965465|NCT03317717|DRUG|Meditoxin|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
214965466|NCT03317717|DRUG|Botox|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
214965467|NCT00002034|DRUG|Zidovudine|
214965468|NCT00002034|DRUG|Ganciclovir|
214965469|NCT02044003|DEVICE|Innovasc Tack Intravascular Staple System (Tack)|Tack-It Dissection repair
214355976|NCT02889991|OTHER|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
214355977|NCT02889991|OTHER|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:~* To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~* Monitor longitudinally taut band, with index and middle fingers.~* Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~* Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~* Remove the bridles and perform hemostasis with cotton.~* We will give end to the technique placebo of dry needling."
214355978|NCT05652517|PROCEDURE|Vein of Marshall ethanol infusion|Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
214355979|NCT02157805|OTHER|beef meat|"Meat cooking conditions~1. st condition : beef meat cooked during 5 minutes at 55°C~2. nd condition : beef meat cooked during 30 minutes à 90°C"
214355980|NCT05214209|BEHAVIORAL|Digital health supported|Participants will be issued a fitness tracker, a Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (weekly bite-sized content over 4 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
214355981|NCT05214209|BEHAVIORAL|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
214355982|NCT03789721|OTHER|Medical Record Abstraction|Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
214355983|NCT03789721|OTHER|Biospecimen Sample Collection|Collect research samples, when feasible for those diagnosed with ALD.
214965470|NCT00311688|DRUG|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
214965471|NCT03318003|DEVICE|Auto-PAP|Women will be using the Auto-PAP device nightly from randomization to end of pregnancy
214965472|NCT04286620|DEVICE|LASIK|Correcting errors of refraction
214965473|NCT03943914|COMBINATION_PRODUCT|Preventive strategy|In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio \< 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate \< 25/min and SpO2 \> 92% under FiO2 \< 30% for at least 6 hours.
214965474|NCT03943914|COMBINATION_PRODUCT|Standard of care|In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 \> 92%. NIV is initiated only in patients having PaO2/FiO2 ratio \< 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.
214965475|NCT01608464|DRUG|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
214965476|NCT01608464|DRUG|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
215081093|NCT01397682|OTHER|blood sample collection|A blood sample will be drawn within 24 hours from admission for determination of biomarkers and genetic analyses
215081094|NCT06434129|DIAGNOSTIC_TEST|DTI|Diffusion MRI imaging
214965477|NCT01966887|GENETIC|MYDICAR-single intracoronary infusion|AAV1/Serca2a
214965478|NCT01966887|GENETIC|Placebo; single intracoronary infusion|single intracoronary infusion
214965479|NCT02051790|DRUG|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
214965480|NCT03844425|DEVICE|Conventional VFR|Conventional retainers
214965481|NCT03844425|DEVICE|VFR from SLA|SLA has better finishing compared to FDM but it is more expensive.
215081095|NCT01680692|DRUG|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
214965482|NCT03844425|DEVICE|VFR from FDM|FDM has poorer finishing compared to SLA but it is cheaper.
214965483|NCT02407873|OTHER|Non|
215081096|NCT01680692|DEVICE|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
215081097|NCT01680692|DEVICE|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
215081098|NCT03417362|OTHER|Animation|3 minute video describing and explaining early medical abortion, followed by questionnaire
214965484|NCT04019717|DRUG|AT-527|Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase
214965485|NCT04019717|DRUG|Daclatasvir|Inhibitor of HCV nonstructural protein 5A (NS5A)
214965486|NCT05036941|DEVICE|Acteev™ Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 1 will be supplied adequate number of Acteev™ N95 masks YQD8008 during 8-hour shift and Acteev™ fabric masks for community use.
214965487|NCT05036941|DEVICE|Comparison Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 2 will be supplied with adequate number of standard N95 masks during 8-hour shift and fabric mask for community use.
214355984|NCT05557942|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
214965488|NCT04089254|BEHAVIORAL|Inpatient Psychiatry|Inpatient hospitalization to treat and stabilize suicidal thoughts and behavior.
214965489|NCT04089254|BEHAVIORAL|Outpatient Crisis Intervention Clinic|Outpatient psychiatric clinic that provides crisis intervention to treat and stabilize suicidal thoughts and behavior.
214355985|NCT03808675|BEHAVIORAL|Aerobic walking|The investigators will use self-administered continuous walking exercise at a moderate intensity level, defined as 40-59% of heart rate reserve or 64-77% of heart rate at gas exchange threshold (HRGET) by ACSM as in the investigators' preliminary study (PMID: 24991037 PMCID: PMC4132568). The HRGET will be determined as the heart rate at VO2max during graded cycle ergometry. The total duration of the exercises will be 150 min/week per 2008 Physical Activity Guidelines for Americans and American Heart Association recommendations, conducted in three 50 min sessions. The aerobic walking intervention will take place outdoors (e.g., trails, sidewalks, parks) or indoors (e.g., track in a local gym or a mall) depending on the preferences of the subject and weather. Session duration will be 20 min the first week and will be advanced by 5 min per week over 6 weeks.
214965490|NCT03761485|OTHER|Use of Dentifrice Fluoride|Use of few of dentifrice on brushing during a year
214965491|NCT03444805|PROCEDURE|Autologous HSCT|1st AHSCT
214965492|NCT06355375|BEHAVIORAL|exercise in pregnancy|aerobic exercise
214965493|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
214965494|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
214965495|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
214965496|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
214965497|NCT02575196|DEVICE|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
214965498|NCT00417144|DRUG|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
214965499|NCT00417144|DRUG|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
214965500|NCT02274597|DEVICE|metraux epitympanic thermometer|accuracy of epitympanic temperature measurement in different environmental settings
214965501|NCT02004938|DEVICE|Sonosite Titan Ultrasound Machine|
214965502|NCT05503459|OTHER|Bicycle learning|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), bicycle learning (40 min), and cool-down (10 min). In the bicycle training activity, participants were asked to ride on a training bicycle with training wheels to gain better control of the bike in a gradual way. Participants then progressed from the training bicycle to a two-wheel bicycle. To keep participants on the learning curve, they were asked to ride through an obstacle course that was progressively more difficult to negotiate. The obstacles were designed by a focus group, which consisted of four physical education teachers from participating schools and one experienced cycling coach with more than five years of coaching experience.
214965503|NCT05503459|OTHER|Stationary cycling|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), stationary cycling (40 min), and cool-down (10 min). For stationary cycling activity, they were also asked every 10 mins during exercise to indicate their ratings of perceived exertion (target range: 3-5). Participants were positively reinforced verbally with compliments for their efforts in the training program and their daily improvements were visualized through graphs kept in the child's home.
214965504|NCT01617239|BIOLOGICAL|Virosomal influenza vaccine|"Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~* 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~* 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)"
214965505|NCT00760721|BEHAVIORAL|Educational Small Group Session|1 hour small group health-related discussion
214965506|NCT01716663|DEVICE|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
214965507|NCT01936363|DRUG|Pimasertib once daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
214965508|NCT01936363|DRUG|Pimasertib placebo|Placebo matching Pimasertib administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
214965509|NCT01936363|DRUG|SAR245409 placebo|Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
214965510|NCT01936363|DRUG|SAR245409|SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
215081099|NCT01537055|DRUG|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
215081100|NCT01537055|DRUG|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
215081101|NCT06225947|DRUG|Lemborexant 5 MG|The recommended dosage of Lemborexant(LEM) is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability.
214965511|NCT01936363|DRUG|Pimasertib twice daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
214965512|NCT02661230|DEVICE|COGNIPLUS|"Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest."
214965513|NCT01342575|PROCEDURE|Intra-operative exposure maneuvers|"* Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed~* Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.~* Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed~* Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed~* Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed"
214965514|NCT03049228|DIAGNOSTIC_TEST|31P-MRS scan and cardiac MRI scan|"31P-MRS measurement of the heart: Phosphorous magnetic resonance spectroscopy (31P-MRS) will be used for the determination of the energy status of the heart in vivo. The localization of phosphorus energy metabolites in the heart will be performed by one-dimensional spectroscopic imaging, resulting in spectra from slices through the heart of 1 cm thickness. The peaks of PCr and ATP will be fitted in order to calculate the ATP/PCr ratio.~The measurement of cardiac function is a standardised protocol. In the 4 chamber view setting a T1 mapping sequence will be performed for the detection of fibrosis. Hereafter patients will receive contrast for T2 mapping and late enhancement studies for determining extracellular volume and ischemia."
214965515|NCT03049228|DIAGNOSTIC_TEST|Atrial biopsy for high-resolution respirometry|Mitochondrial respiration rates are ex vivo measured in tissue homogenates under exposure of different substrates, stimulating different complexes of the electron transport chain of the mitochondria.
214965516|NCT03049228|DIAGNOSTIC_TEST|Blood analysis|To determine blood glucose metabolism and renal function.
214965517|NCT03049228|DIAGNOSTIC_TEST|Body composition|This device uses air displacement plethysmography for determining percent fat and fat-free mass in adults and children. The 5-minute test consists of measuring the subject's mass (weight) using a very accurate electronic scale, and volume, which is determined by sitting inside the BOD POD chamber. From these two measurements, the subject's body composition is calculated.
214965518|NCT03049228|DIAGNOSTIC_TEST|Indirect Calorimetry|As basal energy metabolism might be related to cardiac metabolism and mitochondrial function, and basal metabolic rate shows inter-individual variance, it is an important subject characteristic of the patients. Resting substrate oxidation rates are measured with indirect calorimetry for 30 minutes. A ventilated hood is connected to indirect calorimetry equipment, which measures concentrations of oxygen consumption and CO2 production. From these parameters, the respiratory quotient (RQ), as well as energy expenditure and substrate metabolism will be computed. During this measurement, every 10 minutes (so 4 times) one tube of blood (10ml) will be drawn for the analysis of lipid and glucose metabolites.
214965519|NCT05618015|PROCEDURE|Supervised progressive resistance training|Exercises were performed with cable resistance training machine
214965520|NCT05618015|PROCEDURE|Home-based progressive resistance training|In the first session, with the help of a physiotherapist, strengthening exercises were shown and taught to the patients. Two weeks after the beginning of the home-based PRT program, patients were called to check whether they were doing the exercises in the home program correctly. After the checking for exercise training, the patients were called by phone every two weeks for follow-up.
214965521|NCT01161576|BIOLOGICAL|AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies|The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10\^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.
215081102|NCT01001546|BEHAVIORAL|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
215081103|NCT01001546|BEHAVIORAL|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
215081104|NCT00287937|DRUG|vorinostat|Given orally
215081105|NCT00287937|DRUG|paclitaxel|Given IV
215081106|NCT00287937|DRUG|carboplatin|Given IV
215081107|NCT00287937|OTHER|laboratory biomarker analysis|Correlative studies
215081108|NCT00287937|OTHER|pharmacological study|Correlative studies
215081109|NCT01134926|DRUG|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
215081110|NCT00167180|PROCEDURE|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
215081111|NCT00167180|DRUG|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
215081112|NCT06235762|BEHAVIORAL|Nutritional Intervention|This clinical trial evaluate the effects of nutritional intervention (individualized and personalized for each patient) on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus
215081113|NCT00000630|BIOLOGICAL|HIVAC-1e|
215081114|NCT00000630|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214355986|NCT03808675|BEHAVIORAL|Usual care with PD specific health education|"In this study, patients will receive their usual medical treatment for motor and non-motor symptoms from their~primary neurologist. The investigators will use a streamlined form of PD specific health education prepared by the VA: My Parkinson's Story, which consists of a series of short videos prepared by the VA PADRECCs addressing various aspects of PD. These 6-12 minutes long videos are freely available on YouTube. The investigators can also provide them on a CD if subjects desire. They start with a patient testimony about the topic of the episode, followed by comments of experts in the field. The title of the episodes are: Early Parkinson's, Medications, Exercise, Memory, Visual Disturbances, Depression, Sleep, Speech and Swallowing, Impulsive Behaviors, Driving, Pain, Dyskinesias, Deep Brain Stimulation, Advanced Parkinson's Disease, Falls, The Caregiver, Hospitalization, Genetics, Environmental Exposure, Atypical Parkinsonism"
214355987|NCT06216002|DIAGNOSTIC_TEST|Train of four nerve stimulator|Patient receive nerve stimulation by TOF-scan equipment at recovery room after surgery.
214355988|NCT06218667|DRUG|Copanlisib|Dose level 1 (starting dose): 45 mg of copanlisib IV weekly x 3 weeks on/1 week off Dose level 2 (standard dose): 60 mg of copanlisib IV weekly x 3 weeks on/1 week off
214355989|NCT06218667|DRUG|Degarelix|Degarelix (GnRH antagonist): 240 mg loading dose sub-cutaneous once on C1D1; 80 mg maintenance dose on C2D1 and C3D1.
214355990|NCT06218667|PROCEDURE|Radical Prostatectomy|Standard treatment
214355991|NCT05083247|DRUG|mFOLFIRINOX or Gemcitabine nab-paclitaxel|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel
214355992|NCT05083247|RADIATION|Isotoxic High-Dose (iHD)-SBRT|Radiation therapy
214355993|NCT05083247|PROCEDURE|Surgery|Surgery
214355994|NCT02477618|DRUG|SAGE-547|
214355995|NCT02477618|DRUG|Placebo|Placebo
214355996|NCT03009526|DRUG|Sulfadoxine-pyrimethamine|500 mg sulfadoxine and 25 mg pyrimethamine
214965522|NCT01161576|BIOLOGICAL|AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies|The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10\^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
214965523|NCT03816553|DRUG|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).
214965524|NCT03816553|DRUG|Apatinib|Apatinib will be administered 250mg orally, once daily until progression.
214965525|NCT04552600|DRUG|Nuvastatic|Phase 1b Interventional, multi-centered, double-masked, randomized
214965526|NCT04552600|OTHER|Placebo|Phase 1b Interventional, multi-centered, double-masked, randomized
214965527|NCT04071782|DEVICE|Drug Coated Balloon|SELUTION DCB will be used during lower limb angioplasty for treatment of lesions that are TASC C and D, in patients with Critical Limb Ischemia
215081115|NCT04024215|DEVICE|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
215081116|NCT05789186|DRUG|CAVO aromatherapy patch at 3% concentration+Fluoxetine hydrochloride mimetic|CAVO aromatherapy patch at 3% concentration enhances neuroelectrical activity in the brain (especially in the prefrontal cortex), exerting an antidepressant effect.Fluoxetine hydrochloride mimetic without drug treatment effect.
215081117|NCT05789186|DRUG|Fluoxetine hydrochloride tablet+CAVO aromatherapy patch at 0.1% concentration|Fluoxetine hydrochloride tablet was widely used selective 5-HT reuptake inhibitor (SSRI) that selectively inhibits the 5-HT transporter, blocks the reuptake of 5-HT by the presynaptic membrane, and prolongs and increases the effects of 5-HT, resulting in antidepressant effects.CAVO aromatherapy patch at 0.1% concentration without drug treatment effect.
215081118|NCT05789186|DRUG|Fluoxetine hydrochloride mimetic+CAVO aromatherapy patch at 0.1% concentration|Placebo without drug treatment effect
214355997|NCT03009526|DRUG|dihydroartemisinin-piperaquine|40 mg dihydroartemisinin and 320 mg piperaquine
214355998|NCT03353818|BEHAVIORAL|Golf|A free golf course and free membership for one year in a golf club will be given to participants.
214965528|NCT03514719|DIAGNOSTIC_TEST|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-Avelumab PET scan
214965529|NCT03514719|DRUG|Avelumab|"Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent~Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging"
214355999|NCT03353818|BEHAVIORAL|No intervention|Patients acting as controls will not be restricted in any ways.
214356000|NCT00371891|PROCEDURE|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
214356001|NCT05283174|OTHER|Blood sampling to test drug level|To collect blood sample during acute stroke and measure NOAC concentration.
214356002|NCT03961165|DRUG|Butylscopolamine Bromide 20 MG/ML|1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
214356003|NCT03961165|DRUG|Sodium Chloride 9mg/mL|1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
214356004|NCT02723838|BIOLOGICAL|REOLYSIN®|3 cycles (each cycle = 21 days). Cohort 1: 3x10E10 TCID50 intratumoral via cystoscopy on Day 1 of each cycle. Cohort 2: 3x10E10 TCID50 intratumoral via cystoscopy on Day 2 of each cycle.
214356005|NCT02723838|DRUG|Gemcitabine|3 cycles (each cycle = 21 days). Cohort 1: 1000mg/m2 intravenously on Day 2 and Day 9 of Cycle 2 and Cycle 3. Cohort 2: 1000mg/m2 intravenously on Day 1 and Day 8 of each cycle.
214356006|NCT02723838|DRUG|Cisplatin|3 cycles (each cycle = 21 days). Cohort 1: 70 mg/m2 intravenously on Day 2 of Cycle 2 and Cycle 3. Cohort 2: 70 mg/m2 intravenously on Day 1 of each cycle.
214356007|NCT02680054|DRUG|Insulin, Asp(B28)-|This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
214356008|NCT04036175|DEVICE|High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen|Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2\>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2\>= 92%
214356009|NCT00148967|DEVICE|Implantable Cardioverter Defibrillator|
214356010|NCT05568888|DRUG|BE1116|4-Factor Prothrombin Complex administered by intravenous (IV) infusion
214356011|NCT05568888|DRUG|Placebo|Administered by IV infusion
214356012|NCT00003718|DRUG|temozolomide|
214356013|NCT04398277|BEHAVIORAL|Daily Coping Toolkit|"1. Emotion Labelling Activity: Participants rate 10 discrete negative and positive emotional words on a likert scale (0-4).~2. Expressive Writing and Self Distancing Activity: Participants respond to an open-ended prompt to write about their day in an open text box in response to the prompt: What was today like for you? After this is completed, they are prompted that if the experience was very challenging, to revisit that experience in their mind by taking a fly on the wall perspective (Kross \& Ayduk, 2016).~3. Positive Emotion Generation Activity (1 v. 2 prompts) Participants are prompted to take a deep breath and then respond to 1 (or 2) of 8 possible prompts in which they can generate positive emotions. In response to each, they are asked to describe their thoughts or memories in open-ended text box."
214356014|NCT06585969|DRUG|Trastuzumab deruxtecan (T-DXd)|Trastuzumab deruxtexan every three weeks
214356015|NCT06585969|DRUG|Ribociclib with ET|Ribociclib with endocrine therapy
214356016|NCT06585969|DRUG|Abemaciclib with ET|Abemaciclib with endocrine therapy
214356017|NCT01839734|DRUG|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
214965530|NCT03044847|OTHER|COPD group|The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
214965531|NCT02644278|DRUG|VX-984 120 mg + PLD 40 mg/m^2|Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m\^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
214965532|NCT02644278|DRUG|VX-984 240 mg + PLD 40 mg/m^2|Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
214356018|NCT06467006|OTHER|Use of IA for proximal humeral fracture prognosis|None (prognosis study)
214356019|NCT06100627|DRUG|AP301|Orally administered
214965533|NCT02644278|DRUG|VX-984 480 mg + PLD 40 mg/m^2|Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
214965534|NCT02644278|DRUG|VX-984 720 mg + PLD 40 mg/m^2|Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
214965535|NCT04488913|OTHER|RACE-IT Pathway|This care pathway includes the evaluation of suspected acute coronary syndrome with high-sensitivity troponin I testing and further prognostication as needed with a modified HEART score
214965536|NCT04488913|OTHER|Standard of Care|Standard of care protocol that uses the 99th percentile troponin values for evaluation of suspected acute coronary syndrome and further prognostication using the HEART score
214965537|NCT03019900|PROCEDURE|Red blood cells transfusions|The survey was designated to assess the practices of blood transfusion, specifically about the threshold and factors that can modify this threshold.
214356020|NCT05540522|BIOLOGICAL|Quadrivalent influenza modRNA vaccine|Quadrivalent influenza modRNA vaccine (single dose)
214965538|NCT04584515|DRUG|IMP4297 40 mg|IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297
214965539|NCT04584515|DRUG|IMP4297 100 mg|IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297
214965540|NCT00026247|PROCEDURE|pain therapy|
214965541|NCT00026247|PROCEDURE|radiofrequency ablation|
214965542|NCT04996966|BIOLOGICAL|human umbilical cord-derived mesenchymal stem cells|In the MSCs injection group, 1×10\^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
214965543|NCT04996966|OTHER|saline|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
214965544|NCT03545945|PROCEDURE|Additional office hysteroscopy|Patients in the study arm will undergo diagnostic office hysteroscopy where they look for any underlying polyp, fibroids or uterine anomaly in addition to endometrial biopsy.
214965545|NCT03545945|PROCEDURE|Endometrial biopsy|Patients randomized to endometrial biopsy only group will be prepped with betadine solution and local anesthesia in the form of lidocaine gel placed in the external cervical canal and biopsy will be performed using a Pipelle catheter.
214356021|NCT05540522|BIOLOGICAL|Quadrivalent influenza vaccine|Licensed quadrivalent influenza vaccine (single dose)
214356022|NCT02247505|DRUG|Harnal-D Cap. 0.2mg|
214356023|NCT02247505|DRUG|Cialis Tab. 5mg|
214393697|NCT04430335|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies.
214393698|NCT06403241|OTHER|2000 meter ergometer test|Rowers performed 2000m ergometer test.A 2,000-m time trial is a standard test used to assess performance in rowers.
214965546|NCT02993835|OTHER|Labeled iron salt Fe54|Fe salt enriched with Fe 54 isotopes
214965547|NCT02993835|OTHER|Labeled iron salt Fe57|Fe salt enriched with Fe 57 isotopes
214965548|NCT02993835|OTHER|Labeled iron salt Fe58|Fe salt enriched with Fe 58 isotopes
214965549|NCT05090202|DIAGNOSTIC_TEST|hbA1C|hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic
214965550|NCT04691128|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.
214965551|NCT04691128|DRUG|Propofol|After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
214965552|NCT00627562|DEVICE|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
214965553|NCT06069739|BEHAVIORAL|Guided physical activity|To achieve the European guidelines of 150 minutes by week of moderate intensity physical activity, participants randomized to the GPAG condition were prescribed three 60 minutes exercise sessions (five minutes of warm-up and five minutes of cool-down for a total of sixty minutes per session) per week for 12 weeks. Exercise consisted of brisk walking in urban and rural open spaces during which heart rate monitors were worn and participants were instructed to stay within their moderate intensity range. The incentives were different proposals for specific exercises to train the different musculoskeletal areas more comprehensively. Autonomous exercise was monitored offside the sessions through a series of weekly checkpoints.
214965554|NCT06069739|BEHAVIORAL|Standard physical activity|"Participants randomised to the SPAG performed their usual daily activities and continued with their daily routine.~Both conditions were matched for duration of physical activity. Participants in both conditions were required to attend three on-site sessions by week over 12 weeks that served as checkpoints. Moreover, both conditions were provided with brief healthy lifestyle counseling at baseline."
214965555|NCT02233699|DRUG|XEN-D0501|
214965556|NCT02233699|DRUG|Placebo|
214965557|NCT00372632|DRUG|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
214965558|NCT00372632|DRUG|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
214965559|NCT06369558|OTHER|PLYOMETRIC TRAINING|A 6 WEEK (3 TIMES A WEEK) CONSISTING OF JUMPING SINGLE LEG BRIDGE AND JUMPED SQUAT
214965560|NCT06369558|OTHER|CLASSIC PHYSIOTHERAPY PROGRAM|HOT PACKED ENTEFERANTIAL CURRENT THERAPY AND US THERAPY
214965561|NCT02597309|DRUG|Canagliflozin|
214965562|NCT05743153|BEHAVIORAL|Multimodal intervention program|"Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.~Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.~Psychological intervention: screening for psychological risk factors and if present, patients are referred to a psychologist for psychological support."
214965563|NCT00511810|DRUG|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
214965564|NCT00511810|DRUG|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
214965565|NCT02427841|DRUG|Fluorouracil|Given IV
214965566|NCT02427841|DRUG|Gemcitabine|Given IV
214965567|NCT02427841|RADIATION|Image Guided Radiation Therapy|Undergo IG-IMRT
214965568|NCT02427841|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
214965569|NCT02427841|OTHER|Laboratory Biomarker Analysis|Correlative studies
214965570|NCT02427841|DRUG|Nab-paclitaxel|Given IV
214965571|NCT02427841|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214965572|NCT01551966|DEVICE|Wireless esophageal capsule endoscopy ( PillCam Eso2)|"This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.~During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.~For to asses the tolerance, after they completed both exams, the patients will be asked to answer a comfort score questionnaire.~In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy."
214965573|NCT02896569|OTHER|Topical combination therapy|
214965574|NCT06249581|DRUG|AUX-001 40mg once-daily|AUX-001 (extended-release nicorandil) 40mg QD (once-daily)
214965575|NCT06273761|BEHAVIORAL|Medication Management Service (MMS)|Medication Management Service (MMS) is a service delivered by community pharmacists aiming at helping patients resolve their medication therapy problems (MTPs) by carrying out medication reconciliation, provision of education about their medication regimen, and also providing professional pharmacological advice to patients.
214965576|NCT05881655|DEVICE|Airdoc Red Lighting Device|A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.
214965577|NCT05881655|DEVICE|Special Spectacles to Control Myopia|Customer designed power and fitting to each subject for all the study periods.
214965578|NCT06363643|DEVICE|ELECTROSTIMULATION (ES)|ES will receive the electrostimulator directly at home and will do three weekly Tele supervised sessions of 30 minutes of indirect electrostimulation. The treatment will last 4 weeks.
214965579|NCT06363643|OTHER|EXERCISE (C)|C will perform three weekly Tele supervised sessions of exercise. The treatment will last 4 weeks.
214965580|NCT00130507|DRUG|Vinorelbine|
214965581|NCT00130507|DRUG|Capecitabine|
214965582|NCT00130507|DRUG|Trastuzumab|
214965583|NCT01425736|DRUG|Chemotherapy|Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
214965584|NCT01425736|DRUG|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );"
214965585|NCT03478371|DEVICE|tampon D|regular absorbency tampon
214356024|NCT06606470|BEHAVIORAL|All providers Better Communication Skills program' (ABCs) interprofessional provider education|The 'All providers: Better Communication Skills program' (ABCs) is a virtual, person-centred education curriculum for interprofessional health care providers. The ABCs program adopts a blended format (i.e., participants engage in both asynchronous online modules \[five\] and synchronous interactive workshops \[three\]) that has relevance to learners and clinicians at all levels of training and practice. The ABCs program focuses on four essential elements of being a skillful communicator: principles of effective communication, conversation structure, communication skills, and reflective practice. The program consists of virtual modules that provide any clinician with practical tools, tips, and strategies to implement when communicating with seriously ill patients and their families. Terminology is clarified and consistent, the complexities of conversations are simplified and the fundamental approach and structure can be applied to different contexts.
214965586|NCT03478371|DEVICE|tampon M|regular absorbency tampon
214965587|NCT03478371|DEVICE|tampon T|regular absorbency tampon
214356025|NCT05435612|DEVICE|cochlear implant|Patients enrolled in the study undergo the cochlear implant surgery.
214356026|NCT03881345|DRUG|Anticoagulants|anticoagulation according to the main diagnosis
214356027|NCT03881345|PROCEDURE|Open surgery|removal of blood clots with open surgery
214356028|NCT03881345|PROCEDURE|Thrombolysis|removal of blood clots with thrombolysis
214356029|NCT03881345|PROCEDURE|Venous stenting|elimination of vein obstruction by stenting
214356030|NCT06670326|BEHAVIORAL|Imagery Rescripting|Experimental: Baseline-Preparation-Imagery Rescripting-Post Treatment Each participant follows this sequence: (1) 5-9 weeks waitlist during which no treatment is offered; (2) 4 weekly preparatory sessions. During these sessions the rationale of ImRs will be explained in more detail and a list of painful (childhood) memories to be addressed with ImRs is to be compiled, based on any further input from the patient; and a case conceptualization is made; (3) 12 sessions (45-60 minutes) of ImRs will be offered to participating patients. The treatment for PAD will be based upon the protocol described by Arntz \& Weertman (1999); (4) After end of active treatment (ImRs) 4 weeks follow during which only weekly assessments are done.
214965588|NCT03478371|DEVICE|tampon V|regular absorbency tampon
214965589|NCT03861780|DRUG|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
214965590|NCT03861780|DRUG|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
214965591|NCT03861780|DRUG|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
214965592|NCT05855434|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy
214356031|NCT06669923|BEHAVIORAL|iSIPsmarter Program|web-based behavioral intervention to reduce sugary drink intake
214356032|NCT06669923|BEHAVIORAL|Patient Education|website with information about cancer screening and prevention (e.g. screening tests for seven types of cancer)
214356033|NCT06669468|OTHER|PFME|All patients were asked to mark the exercise at a daily home schedule. Patients who did not complete more than 20% of the list according to the daily home program were excluded from the study.
214356034|NCT06669468|OTHER|PFME + Anal ES|Anal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.
214965593|NCT02770911|PROCEDURE|"without Dog Ear group"|a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection
214965594|NCT02770911|PROCEDURE|"with Dog Ear group"|a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
214965595|NCT03153241|OTHER|No intervention|No intervention
214965596|NCT04167189|DRUG|Lidocaine gel|Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg
214965597|NCT00618826|DRUG|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
214965598|NCT00618826|DRUG|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
214356035|NCT06669468|OTHER|PFME + Perineal ES|Perineal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.
214356036|NCT03754803|OTHER|HIV symptom distress module (SDM) questionnaire|The SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
214356037|NCT03754803|OTHER|HIV treatment satisfaction questionnaire (TSQ)|The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.
214356038|NCT05239039|DRUG|spesolimab|spesolimab
214965599|NCT00618826|DRUG|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
214965600|NCT01509664|BEHAVIORAL|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
214965601|NCT02855567|DEVICE|Acupuncture needles|Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
214965602|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove inflammatory cytokines in peripheral blood.
214965603|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove lipids in peripheral blood.
214965604|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove toxic metal ions.
214965605|NCT05306847|DRUG|Sintilimab|Sintilimab will be given intravenously at a dose of 200mg every 21 days.
214965606|NCT05306847|DRUG|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
214965607|NCT03626701|DEVICE|RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.
214965608|NCT03626701|COMBINATION_PRODUCT|Mepilex® Ag Wound Dressing|Application of Mepilex® Ag Wound Dressing
214356039|NCT06670144|OTHER|Dietary pattern|(regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan; Mediterranean diet)
214356040|NCT06670144|OTHER|Alcohol intake|(Frequency and intake of beer, wine, sherry, and spirits were collected by asking the number of specified units (pints, glasses or measures) of each type of alcoholic beverage (beer or cider, wine, sherry or fortified wines, and spirits) per week.)
214356041|NCT06670144|OTHER|Fruit and vegetables intake|(Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire)
214356042|NCT06670144|OTHER|Tea consumption|(Intake of tea from food frequency questionnaire)
214356043|NCT06670144|OTHER|Coffee consumption|(Intake of caffeinated coffee and decaffeinated coffee from food frequency questionnaire)
214356044|NCT06670144|OTHER|Fish intake|(Intake of fish from food frequency questionnaire)
214356045|NCT06670144|OTHER|Meat intake|(Intake of red meat, processed meat, and poultry from food frequency questionnaire)
214356046|NCT06670144|OTHER|Vitamin D intake|(Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake)
214356047|NCT06670898|DRUG|[14C] NS-580|Oral suspension
214965609|NCT03626701|PROCEDURE|Conventional autografting (only when indicated)|When indicated, conventional autografting in accordance with Investigator's standard practice
214965610|NCT03289767|OTHER|Curved-tube|"Connecting both ends of the endotracheal tube (O shape) for 5-min and releasing it provides additional anterior angle temporarily."
214965611|NCT01095627|OTHER|Metacholine challenge|Exhaled breath analysis following metacholine challenge
214965612|NCT02734134|PROCEDURE|One-stage exchange joint replacement surgery|
214965613|NCT02734134|PROCEDURE|Two-stage exchange joint replacement surgery|
214965614|NCT03647566|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
214965615|NCT03647566|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
214965616|NCT03647566|DIAGNOSTIC_TEST|Aortic MRI|Aortic MRI to assess aortic morphology and contextualise PET scan
215081119|NCT02374658|BEHAVIORAL|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
215081120|NCT00003825|DRUG|pentosan polysulfate sodium|
214356048|NCT04201548|OTHER|Endurance Training|"These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980"
214356049|NCT04201548|OTHER|Long High Intensity Interval Training|"The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000"
214356050|NCT04201548|OTHER|Short High Intensity Interval Training|"The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050"
214356051|NCT03049046|DRUG|CC100|synthetic caffeic acid phenethylester
214356052|NCT03049046|DRUG|Placebos|Diluent
214965617|NCT00239473|DEVICE|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
214965618|NCT00239473|DEVICE|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
214965619|NCT03234803|OTHER|poly-amide|new denture base material
214965620|NCT03234803|OTHER|poly-methyl methacrylate|gold standard for denture base materials
214965621|NCT04428840|DEVICE|Self-measurement kiosk|Use of the self-measurement kiosk, with results forwarded to the triage nurse screens
214965622|NCT02602314|DRUG|Imatinib|
214965623|NCT02602314|DRUG|Nilotinib|
214965624|NCT00905424|DRUG|Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
214965625|NCT00905424|DRUG|Antidepressant + placebo|Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
214965626|NCT00426764|DRUG|Romidepsin|Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
214965627|NCT02412176|PROCEDURE|Pacing site - the implantation in the right ventricular (RV) apex|Pacing site - RV apex. The lead will be implanted in the RV apex.
214965628|NCT02412176|PROCEDURE|Pacing site - the implantation in the septum|Pacing site - septum. The lead will be implanted in the septum.
214965629|NCT06149572|PROCEDURE|lateral position procedure|Lateral positioning will be used as an intervention for spinal hypotension.
214965630|NCT06149572|PROCEDURE|sitting position porocedure|parturients will get spinal punctures in the sitting position
215081121|NCT00003825|PROCEDURE|quality-of-life assessment|
215081122|NCT01253265|DRUG|LY2439821|Administered subcutaneously
215081123|NCT01253265|DRUG|Placebo|Administered subcutaneously
215081124|NCT02156544|DRUG|CKD-519|
215081125|NCT02156544|DRUG|placebo|
215081126|NCT02333981|DEVICE|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
215081127|NCT02342379|DRUG|Bevacizumab|10mg/kg
215081128|NCT02342379|DRUG|TH-302|670mg/m2
214356053|NCT03216876|DRUG|Ursolic acid|Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
214356054|NCT02728388|DRUG|aminolevulinic acid|"Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements"
214965631|NCT05360407|OTHER|Using mobile information application about before and after surgery|"The mobile application had three sections: Information forum (I), Personal forum (notebook and reminder) (II) and Ask the Researcher (messaging) (III). The information forum (Figure 2) is a section that enables patients to access related articles, pictures, and videos. The personal forum is a section that allows patients to create their notes and use the necessary reminders. Ask the researcher section allows patients to communicate with the researcher via messages.~The participants could download the mobile application with the name Breast Cancer Surgery Information Guide from the Google Play Store and install it on their phones. Users who were authenticated by the researcher were able to access the content with an e-mail and password."
214356055|NCT02097979|BEHAVIORAL|Glaucoma Educational Intervention|
214965632|NCT06523049|DRUG|Vorolanib Tablets|Multi-targeted receptor tyrosine kinase inhibitor with potent inhibition of VEGFR2, KIT, PDGFR, FLT3 and RET, exerting anti-tumor effects mainly through inhibition of neovascularization.
214965633|NCT06523049|DRUG|Sintilimab Injection|Recombinant human-derived immunoglobulin G (IgG4)-type anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, by binding to PD-1 and blocking PD-1 binding to PD-L1 and PD-L2, disarms the immunosuppressive effect, activates T-cell function, and enhances T-cell immunosurveillance and killing ability against tumors to generate tumor immune response.
214965634|NCT05225389|DRUG|300 mg [C14] CT1812|Single dose of 300 mg CT1812 with microtracer dose of \[C14\]
214965635|NCT03695263|BEHAVIORAL|Choice of one of five behavioral interventions|All participants will choose one of the five intervention options.
214965636|NCT02074293|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
214356056|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, low dose
214356057|NCT00785408|DRUG|placebo|subcutaneous, twice daily, low dose
214965637|NCT02074293|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
214965638|NCT02074293|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
214965639|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
214965640|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox intramuscularly at Week 12, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
214965641|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
214965642|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
214965643|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
214356058|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, middle dose
214356059|NCT00785408|DRUG|placebo|subcutaneous, twice daily, middle dose
214965644|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
214965645|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
214965646|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
214965647|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
214965648|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
214356060|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, high dose
214356061|NCT00785408|DRUG|placebo|subcutaneous, twice daily, high dose
214356062|NCT04274452|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
214356063|NCT04274452|OTHER|Placebo|Intravenous infusion of placebo
214356064|NCT04560166|DRUG|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"* Irinotecan, solution for infusion (20 mg/mL)~* Temozolomide, capsules (5 mg, 20 mg and 100 mg)~* The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~* Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)"
214965649|NCT02074293|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
214356065|NCT04010071|DRUG|axitinib plus toripalimab|"Axitinib 5mg, twice a day, orally, 4 weeks a cycle. Dose reduction from 5mg twice a day to 3mg twice a day should be considered according to adverse events.~Toripalimab 240mg, every 3 weeks, intravenous infused, 6 weeks a cycle. Number of cycle: until disease progression or unacceptable toxicity events."
214356066|NCT05087082|OTHER|Virtual Hospital at Home - Home admission of epidemic patients|Admitting COVID-19 patients at home
214965650|NCT02074293|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
214965651|NCT04997876|OTHER|Biomarker analysis|Biomarkers from presurgical OCTs are assessed
214965652|NCT06028126|PROCEDURE|Intermittent Superficial Parasternal Intercostal Plane Block - Experimental|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.2% ropivacaine), intermittent boluses of 10 mL 0.2% ropivacaine per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
214965653|NCT06028126|PROCEDURE|Intermittent Superficial Parasternal Intercostal Plane Block - Sham|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.9% Saline), intermittent boluses of 10 mL 0.9% Saline per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
214965654|NCT05329857|DRUG|Metformin and Vildagliptin 1000/50 mg|50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
214965655|NCT03037515|DRUG|Tranexamic Acid|To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
214965656|NCT03804268|OTHER|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
214965657|NCT03804268|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
214965658|NCT05065294|DRUG|Psilocybin therapy|\- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring
214965659|NCT06156605|PROCEDURE|Sidelying lumbar manipulation|R sided lumbar manipulation
215081129|NCT00769717|BEHAVIORAL|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
214965660|NCT03158610|DRUG|Capecitabine|Oral fluorouracil
214356067|NCT06018792|DIAGNOSTIC_TEST|Molecular Culture|PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.
214965661|NCT02362893|OTHER|Direct Observed Therapy|Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
214965662|NCT05315648|PROCEDURE|anesthesia approach (general anesthesia or non-general anesthesia)|patients in group GA received general anesthesia followed with FNB. patients in group NGA received CSEA followed with FNB
214356068|NCT05009342|DEVICE|below-knee soft resin cast|Patients have soft resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
214356069|NCT05009342|DEVICE|Below-knee rigid resin cast|Patients have rigid resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
214356070|NCT04826601|OTHER|essential oils|A total of 40 cancer patients receiving chemotherapy will be recruited as participants in this study. Blood orange and rosewood will be chosen as the essential oils for aromatherapy in this study. Essential oils will be applied to all participants by inhalation for 30 minutes.
214965663|NCT00658892|BIOLOGICAL|B7-DC cross-linking antibody rHIgM12B7|
214965664|NCT00658892|OTHER|flow cytometry|
214965665|NCT00658892|OTHER|immunologic technique|
214965666|NCT00658892|OTHER|laboratory biomarker analysis|
214965667|NCT01635374|PROCEDURE|Per-Oral Endoscopic Esophagomyotomy|In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
214965668|NCT01737879|DRUG|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
214965669|NCT01737879|DRUG|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
214965670|NCT05524454|DEVICE|Novel CBCT Imaging|One or two CBCT images are acquired on the novel CBCT imaging system.
214965671|NCT01156805|OTHER|Educational program|The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
214965672|NCT02666001|DRUG|BMS-663068|BMS-663068
214965673|NCT02666001|DRUG|Methadone|Methadone
215081130|NCT00769717|BEHAVIORAL|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
214965674|NCT02666001|DRUG|Buprenorphine and Norbuprenorphine|Buprenorphine and Norbuprenorphine
214965675|NCT02574364|RADIATION|The application of abdomen CT|A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.
214965676|NCT02574364|OTHER|traditional incision|McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
214965677|NCT06067997|DIAGNOSTIC_TEST|pulmonary embolism diagnosis|"The diagnosis of pulmonary embolism will be made using the diagnostic algorithm suggested by the 2019 European guidelines . The pre-test clinical probability of pulmonary embolism will be defined based on the simplified Wells score. In patients with a low pre-test clinical probability and a D-dimer level below the threshold value the diagnosis of pulmonary embolism will be excluded. The D-dimer level will be measured using the quantitative assay routinely used in each participating center; the threshold value for a positive result compared to a negative result is 500 μg per milliliter for patients under 50 years of age. For each additional decade of age, the exclusion cutoff will increase by 100 μg per milliliter.~The criterion for the presence of pulmonary embolism is the detection of an intraluminal filling defect on CT."
214965678|NCT01843803|OTHER|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
215081131|NCT02863523|BEHAVIORAL|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
215081132|NCT02972541|DEVICE|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
215081133|NCT02972541|DEVICE|Stenting with immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
214965679|NCT01843803|OTHER|attention control|Patients will view a brief healthy living video on an iPad
215081134|NCT02321891|DEVICE|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
215081135|NCT04913701|OTHER|Observation group 1|Subjects will be followed with 3 swabs and serological test
214356071|NCT00998179|DEVICE|Acu-TENS|Application of Acu-TENS (with electrical output from the machine)
214356072|NCT00998179|DEVICE|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine)
214965680|NCT03311841|DRUG|Midazolam oral solution|Midazolam hydrochloride 10 μg (1 mL of 10 μg/mL oral solution), administered orally as part of a microdose cocktail
214965681|NCT03311841|DRUG|Dabigatran and pitavastatin oral solution|375/10 μg dabigatran etexilate and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail
214965682|NCT03311841|DRUG|Atorvastatin and rosuvastatin oral solution|100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
214356073|NCT06020222|DEVICE|cryotherapy|Both hands and feet received cryotherapy gloves and boots, and the frequency was once every three weeks. Each cycle was 90 minutes, and the cycle was performed 4 times.
214356074|NCT06020222|OTHER|education|Provide preventive CIPN education leaflets
214965683|NCT03311841|DRUG|Rifampin|Rifampin 600 mg single dose (two 300 mg capsules) administered orally
214965684|NCT03790852|DRUG|KSI-301|Intravitreal injection
214965685|NCT00985972|BEHAVIORAL|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
214965686|NCT05332314|DRUG|NSAIDs|The patients will be given NSAIDs with a reduced dose of the standard opioids treatment.
214965687|NCT00063804|DRUG|Ritonavir|
214965688|NCT00063804|DRUG|AMD070|
214965689|NCT01972412|BEHAVIORAL|telephone support|Telephone support for four months about healthy diet, physical activity and medication use.
214965690|NCT04734808|DIAGNOSTIC_TEST|Electroencephalography|Electroencephalography is an electrophysiological monitoring method to record electrical activity of the brain.
214965691|NCT04734808|DIAGNOSTIC_TEST|Electromyography|Electromyography is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles. We will use the hdEMG version.
214965692|NCT03048669|OTHER|Continuous quality improvement|A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
214965693|NCT05939245|PROCEDURE|Furosemide Injection|Continuous infusion of furosemide is administered starting at 2 mg/hour and can be titrated until the target urine output of 1-2 cc/kg/hour is achieved for 48 hours. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
214965694|NCT05939245|PROCEDURE|Placebo Injection|Continuous infusion of placebo fluid is administered at a rate of 2 mL/hour. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
214965695|NCT05719298|DEVICE|Respiratory interface|Application of the new interface and accessories and provision of non-invasive respiratory support through the device.
214965696|NCT04387461|BIOLOGICAL|CG0070|Engineered Oncolytic Adenovirus
214965697|NCT04387461|BIOLOGICAL|Pembrolizumab Injection|Immune checkpoint inhibitor, Monoclonal antibody
214965698|NCT04387461|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
214965699|NCT01324635|DRUG|Panobinostat|Given PO
214965700|NCT01324635|RADIATION|Stereotactic body radiation therapy|Undergo SBRT
214965701|NCT01324635|PROCEDURE|Quality-of-life assessment|Ancillary studies
214965702|NCT01324635|RADIATION|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
214965703|NCT05598749|DIETARY_SUPPLEMENT|Placebo|Arabic gum, sucrose and silicon dioxide mix
214965704|NCT05598749|DIETARY_SUPPLEMENT|Verum|Propolis dry extract ESIT12 and carriers (arabic gum, sucrose and silicon dioxide mix)
214965705|NCT04713930|DRUG|JNJ-61393215|JNJ-61393215 will be administered orally.
214965706|NCT04713930|DRUG|Placebo|Placebo will be administered orally.
214356075|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
214356076|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
214356077|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
214965707|NCT03339414|OTHER|collect blood|collect blood at different time point
214965708|NCT05264909|DEVICE|Multi-channel Transcranial direct current stimulation|A medical grade tDCS device will be use in this study (Star Stim TES, Neuroelectrics, Spain). The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
214965709|NCT06058611|OTHER|Cognitive stimulation|Cognitive stimulation through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
214965710|NCT06058611|OTHER|Stimulating leisure activities|"Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (\< 30 min, 30min-1 hour, 1-2 hours, \> 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life."
214356078|NCT02119260|DRUG|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
214356079|NCT02119260|DRUG|GSK2798745 suspension|Aqueous suspension of GSK2798745 (\>=0.5 mg)
214356080|NCT02119260|DRUG|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)
214356081|NCT02119260|DRUG|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
214356082|NCT02119260|DRUG|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
214356083|NCT02119260|DRUG|Placebo capsule|Matching white opaque placebo blend filled capsule
214356084|NCT02987075|OTHER|Compacting embryo transferring|transfer of 2 utilizable compacting embryos
214356085|NCT02987075|OTHER|Non- compacting embryo transferring|transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.
214965711|NCT04028063|DRUG|Balstilimab|Balstilimab (AGEN2034) is a human monoclonal antibody that targets programmed cell death 1 (PD-1). Engagement of PD-1 by its ligands, programmed death ligand (PD-L1) and PD-L2, leads to signal transduction that inhibits important aspects of T cell function including proliferation, cytokine production and cytolytic activity. Balstilimab (AGEN2034) potently inhibits PD-1 binding to PD- L1 and PD- L2 and is intended to reverse the immunosuppressive effects of this signaling pathway in the context of tumor immuno-surveillance by T cells. Balstilimab (AGEN2034) is intended for development as a treatment for advanced malignancies as a single agent or in combinations.
214965712|NCT04028063|DRUG|Zalifrelimab|Zalifrelimab (AGEN1884) is a fully human monoclonal immunoglobulin G1 κ subclass (IgG1κ) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152). Zalifrelimab (AGEN1884) is being developed as a monotherapy for cancer indications with potential for future development in combination with other immunotherapies.
214965713|NCT04028063|DRUG|Doxorubicin|Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.
214965714|NCT04028063|DRUG|Botensilimab|Botensilimab (AGEN1181) is a novel, human, fragment-crystallizable (Fc)-engineered immunoglobulin G1 (IgG1) anti-CTLA-4 antibody designed to exploit a novel mechanism by which increased Fc engagement enhances antigen-specific effector T cell responses.
214965715|NCT04677530|DRUG|JNJ-40411813|JNJ-40411813 will be administered orally.
214965716|NCT04677530|DRUG|Matching Placebo|Matching placebo will be administered orally.
214965717|NCT01693770|PROCEDURE|MRgFUS|Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
215081136|NCT04176120|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
215081137|NCT04176120|OTHER|Standard Care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
215081138|NCT02822131|DIETARY_SUPPLEMENT|sodium phosphate|
214965718|NCT06188325|DRUG|Eliglustat|Pharmaceutical form:Capsule-Route of administration:Oral
214965719|NCT04631237|OTHER|Observational, no intervention|No intervention involved
214965720|NCT02084017|DEVICE|Prevena (Negative Pressure Wound Therapy Device)|No other details required.
214965721|NCT02084017|DEVICE|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing|
214965722|NCT06387446|PROCEDURE|Valve transplant|Heart valves from an organ donor will be transplanted into recipient
215081139|NCT02822131|DRUG|sevelamer, sodium bicarbonate, sodium chloride|
214356086|NCT05213195|DRUG|NKG2D CAR-NK|NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.
214356087|NCT01738984|BEHAVIORAL|MomZing Web Program|Online web platform that is accessed via a television connected to internet
214356088|NCT01738984|BEHAVIORAL|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
214356089|NCT03230227|DRUG|Bupivacaine magnesium|bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
214356090|NCT03230227|DRUG|Bupivacaine only|bupivacaine 0.125% infusion in the presternum , for 48 hours
214356091|NCT03849274|COMBINATION_PRODUCT|Smart Scar Care Pad=Pressure Garment|Smart Scar Care Pad (SSCP) + conventional Pressure Garment in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
214356092|NCT03849274|DEVICE|Pressure Garment|Conventional Pressure Garment (PG) alone in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
214965723|NCT05980897|BEHAVIORAL|Naming treatment|"In this alternating treatment single-subject experimental design study, the investigators will alternate between two treatment conditions, i.e., two different types of stimulus items: those that are consistently reported as successful IS prior to treatment (sIS items) and those that are consistently reported as unsuccessful IS prior to treatment (uIS items). The treatment will be computerized to ensure consistency of presentation, timing, and cues across participants.~For each stimulus presentation, the treatment hierarchy will proceed as follows:~1. Name the picture independently~2. Name the picture with a written cue~3. Repeat the name of the picture~4. Name the picture after a 5 second delay Each participant will be trained on a set of 40 items chosen specifically for them based on initial/baseline testing."
214356093|NCT01592032|DRUG|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
214965724|NCT03875196|DEVICE|Pelvic Floor Muscle Training With Biofeedback|Biyofeedback: The Biyofeedback allows the patient to see the results of her behavior immediately By a perineometer device or electromyelography that is placed in the vagina, the patient sees how she hears the pelvic floor muscles, hears the sound or hears her voice, and detects how much she needs to contract.
214965725|NCT03875196|DEVICE|Extracorporeal Magnetic Innervation|Extracorporeal Magnetic Innervation: The patients are seated in a special chair connected to an external power unit and a magnetic field generator inside with their clothes on. In order to coincide the spreading magnetic field with pelvic floor muscles, the urethral and anal sphincters, the perineum of the patients should be placed in the center of the chair. In this way, the perineum tissues are stimulated by emitted magnetic field waves. Thus no electrical current passes through the device to the patient's body and the patient is exposed to only the magnetic current.
214965726|NCT05816668|DRUG|Tranexamic acid|Patients with prostate cancer and radical video laparoscopy prostatectomy indication will receive 1,0g of Tranexamic Acid solution IV in bolus 20 minutes before of anesthetic induction, followed by a maintenance hose of 1,0mg/kg/h of surgery.
214965727|NCT05816668|OTHER|Placebo|Patients randomized to placebo group will receive physiological saline and will undergo to the radical video laparoscopu prostatectomy normally
214965728|NCT02742363|OTHER|Collecting data|Collecting data from patient records
214965729|NCT03278366|BEHAVIORAL|Dancing|Participants in the intervention group will participate in daily dance activities with their teacher by following along with a video created by the dance researchers at Skidmore College. Teachers will be specifically asked to utilize the movement phrases just prior to administering any formal assessment activity within their classroom (tempo may be chosen at teacher's discretion). Furthermore, teachers may choose to utilize the dance phrases as 'brain breaks' at any point throughout their school day.
214965730|NCT02169843|DRUG|Sevoflurane|inhale Sevoflurane
214965731|NCT02169843|DRUG|Dexmedetomidine|intravenous pumping Dexmedetomidine 0.2µg/kg/h
214965732|NCT02169843|DRUG|Placebo(for Dexmedetomidine)|normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
214965733|NCT00164632|BEHAVIORAL|counselling, exercise, referrals (behavior)|
214965734|NCT00666159|DRUG|tacrolimus ointment|topical
214965735|NCT00666159|DRUG|pimecrolimus cream|topical
214965736|NCT01463800|BEHAVIORAL|Structured exercise training|12 weeks low level ambulatory structured exercise training
214965737|NCT03360019|DEVICE|Activlink insole|Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.
214965738|NCT03360019|OTHER|Activlink Phone Application|Smartphone tool used for monitoring location
214965739|NCT01681238|PROCEDURE|Protocol group 2|ensure SpO2≥ 92%, MAP 65-100 mmHg, HR \<100 bpm, Hb\> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
215081140|NCT01788579|BEHAVIORAL|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
215081141|NCT01788579|BEHAVIORAL|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
215081142|NCT02159378|OTHER|Fructosamines|
215081143|NCT05956808|DEVICE|Phonak Naida BTE hearing aid|Newest generation of ultra-power Phonak BTE hearing aids
215081144|NCT05956808|DEVICE|Phonak Naida legacy BTE hearing aid|Previous model/generation of the Naida BTE hearing aid
215081145|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
215081146|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
215081147|NCT02817347|DRUG|piperacillin 2% + tazobactam 0.25%|
215081148|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5%|
215081149|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0%|
215081150|NCT03271047|DRUG|binimetinib|Orally, twice daily.
214679027|NCT03700008|DIAGNOSTIC_TEST|Speech analysis tool|Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
215081151|NCT03271047|DRUG|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
215081152|NCT03271047|DRUG|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
215081153|NCT04014621|DEVICE|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
215081154|NCT02425800|OTHER|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
215081155|NCT02425800|OTHER|Laboratory Biomarker Analysis|Correlative studies
214356094|NCT01592032|DRUG|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
214965740|NCT01681238|PROCEDURE|Protocol group 1|The goal of this protocol is to ensure MAP\> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP \<8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
214965741|NCT00736294|DRUG|Ramipril|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
214965742|NCT00736294|DRUG|Placebo|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
214965743|NCT03253536|OTHER|observational|none (observational study)
214965744|NCT02496364|OTHER|Observational|
214965745|NCT02132143|RADIATION|intensity-modulated radiation|For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.
214965746|NCT02132143|RADIATION|intensity-modulated radiation|For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
214965747|NCT01462110|DEVICE|19416-154-1|0.15% ethyl lauroyl arginate HCl-containing mouthrinse
214965748|NCT01462110|DEVICE|W002194-0221P|5% hydroalcohol mouthrinse
214965749|NCT05207527|OTHER|cardiovascular exercise|Exercise that mainly stimulates the cardiovascular and respiratory systems.
214965750|NCT05207527|OTHER|Muscle strength|Exercise that primarily stimulates the musculoskeletal system.
214965751|NCT05207527|OTHER|Mixed|Exercise that stimulates the musculoskeletal, cardiovascular and respiratory systems.
215081156|NCT02753686|DRUG|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
214356095|NCT01592032|DRUG|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
214356096|NCT01592032|DRUG|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
214356097|NCT01592032|DRUG|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
214965752|NCT04337021|BEHAVIORAL|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
214965753|NCT03009227|PROCEDURE|Colonic resection with D2 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D2 lymph node dissection
214965754|NCT03009227|PROCEDURE|Colonic resection with D3 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D3 lymph node dissection
214965755|NCT02454751|DRUG|fentanyl|One time dose of 50mcg of fentanyl administered intranasally
214965756|NCT00100347|DRUG|PPI-2458|
214965757|NCT03883763|DRUG|bupivacaine S75:R25 plus 8% glucose|Spinal anesthesia, 20 mg
214965758|NCT03883763|DRUG|bupivacaine S50:R50 plus 8% glucose|Spinal anesthesia, 20 mg
214965759|NCT02377232|BEHAVIORAL|Decision Aid for Colon Cancer Screening|Paper decision aid describing different screening options for colon cancer
214965760|NCT02377232|BEHAVIORAL|Usual Care Outreach for Colon Cancer Screening|Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
214965761|NCT00065702|DRUG|Active liquid remedy|
214965762|NCT06024707|DRUG|Biological Drug|This intervention is part of regular treatment, subjects will be included if they get this treatment.
215081157|NCT02753686|DRUG|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
215081158|NCT02702531|DEVICE|FloShield Defogging and Cleaning System|
215081159|NCT05258084|BEHAVIORAL|sexual minority awareness training|sexual minority awareness training is planned as 4 interviews (1 interview per week) for a total of 4 hours. Gender and sexuality-related terminologies and concepts will be discussed in the 1st meeting. Expression of sexual identity and gender transition processes will be examined in the 2nd meeting. In the 3rd meeting, the determining factors in the inadequate utilization of health services by LGBT individuals will be discussed. In the 4th meeting, what can be done to create a safe and health-friendly environment for LGBT individuals and healthcare professionals will be discussed.
214356098|NCT02145221|OTHER|Music Therapy|
214356099|NCT05225623|BEHAVIORAL|BWLT|This group will attend 16 2-hour group-based weekly sessions in Small Changes BWLT in addition to their treatment at the Balfour Medical Clinic
214356100|NCT05225623|BEHAVIORAL|Waitlist Control for BWLT|This group will receive treatment as usual at the Balfour Medical Clinic and put on a waitlist for the Small Changes BWLT program
214356101|NCT02297568|DRUG|Calciferol|Comparison 25OHD levels between calciferol and placebo
214356102|NCT02297568|DRUG|placebo|
214356103|NCT00997087|DRUG|Flumazenil|Sublingual daily
214356104|NCT03786731|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
214356105|NCT05735067|OTHER|Blood sample collection|5 ml of blood samples were withdrawn from RRMS patients
214356106|NCT03877094|BEHAVIORAL|Nature virtual reality video|the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy
214356107|NCT03031691|DRUG|brontictuzumab|starting dose of 1.5mg/kg administered intravenously (IV)
214356108|NCT03031691|DRUG|trifluridine/tipiracil|
214356109|NCT03962387|OTHER|Not applicable(observational study)|Not applicable(observational study)
214356110|NCT00114868|DRUG|Vitamin A|
214356111|NCT05895032|OTHER|Exercise|12-week exercise intervention
214356112|NCT05895032|OTHER|Usual Care|usual care
214356113|NCT05518656|BEHAVIORAL|Experimental intervention|Daily lessons received by email to be completed the same day
214356114|NCT05518656|BEHAVIORAL|Comparison intervention|Daily lessons receive by email to be completed the same day
214356115|NCT02427126|DRUG|Apixaban|Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery
214356116|NCT02427126|DRUG|Aspirin|Acetylic Salicylic Acid 100mg o.d.; 12 Months
214356117|NCT03259633|DRUG|Selumetinib|open-label, single-arm, multicenter intermediate access protocol
214356118|NCT02526732|OTHER|individual training program|Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
214356119|NCT05420155|PROCEDURE|Surgical resection|Surgical treatment of hepatic hydatidic cyst
214356120|NCT00857207|BEHAVIORAL|Goal Management Training|Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
214356121|NCT03952858|OTHER|Telerehabilitation Group|The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.
214965763|NCT06305975|PROCEDURE|Blunt fascial abdominal entry|Blunt fascial entry technique description: a 5 mm incision is made in the umbilicus. Next, a curved Kelly forceps is used to open the fascia, and, if possible, the peritoneum. The Kelly forceps are then used to expand the opening to a 10 mm diameter. A 5 mm trocar is placed into the fascial hole and used to quickly insufflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
214965764|NCT06305975|PROCEDURE|Veress needle abdominal entry|Veress needle abdominal entry technique description: a 5 mm incision is made in the umbilicus. Next, a Veress needle is used to enter the peritoneal cavity and inflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
214965765|NCT03729791|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
214965766|NCT00964028|BIOLOGICAL|Infanrix™-IPV/Hib|Intramuscular, three doses
214965767|NCT03577314|OTHER|miscarriage|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
215081160|NCT05593276|BEHAVIORAL|Empower@Home|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
215081161|NCT02750865|BEHAVIORAL|Embodied Conversational Agent (ECA)|The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
215081162|NCT00110071|DRUG|fludarabine phosphate|Given IV
214356122|NCT01835457|DRUG|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects.
214356123|NCT01835457|BEHAVIORAL|Concentration/meditation|A self-taught concentration/meditation technique that Mr Wim Hof developed himself, characterized by cycles consisting of a few minutes of hyperventilation followed by breath holding for up to 1-2 minutes and deep concentration (mindset).
214356124|NCT00019916|BIOLOGICAL|aldesleukin|
214356125|NCT00019916|BIOLOGICAL|p53 peptide vaccine|
214356126|NCT00019916|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214356127|NCT01205594|DEVICE|ITPR|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
214356128|NCT01240174|BEHAVIORAL|Demonstration of near zero antibiotic prescribing for patients with acute bronchitis|A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
214356129|NCT00493818|DRUG|GSK690693|
214356130|NCT04592068|DEVICE|Retinal multi-diseases diagnosed by DL algorithm|DL algorithm automatically classify multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
214356131|NCT04592068|OTHER|Retinal multi-diseases diagnosed by expert panel|Expert panel classifies multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
214965768|NCT02385110|DRUG|Alemtuzumab|"Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks."
215081163|NCT00110071|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
215081164|NCT00110071|RADIATION|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
215081165|NCT00110071|OTHER|laboratory biomarker analysis|Correlative studies
215081166|NCT00110071|OTHER|flow cytometry|Correlative studies
214356132|NCT04461951|OTHER|Lifestyles (exposure)|no intervention
214356133|NCT02947126|DRUG|Hypertonic Saline|Inhaled 7% Hypertonic saline
215081167|NCT00110071|GENETIC|polymerase chain reaction|Correlative studies
215081168|NCT05497258|DEVICE|Artificial intelligence assistant system|The AI-assisted diagnosis system can provide the direction of disease diagnosis in real time and assist the doctor to give the final diagnosis
215081169|NCT02995226|OTHER|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
215081170|NCT02995226|OTHER|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
215081171|NCT00456066|DEVICE|Export Aspiration System|Patients scheduled for emergency angioplasty
215081172|NCT00495521|DRUG|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
214356134|NCT02947126|DRUG|Isotonic Saline|Inhaled 0.9% Isotonic saline
214356135|NCT02947126|DRUG|Indium-DTPA|Inhaled Indium 111 DTPA
214356136|NCT02947126|DRUG|Technetium Sulfur Colloid|Inhaled Technetium99m sulfur colloid
214356137|NCT02789280|BEHAVIORAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
214356138|NCT02789280|OTHER|Wait list|will receive the behavioral activation condition after one week of completing baseline assessment.
214679028|NCT03700008|DIAGNOSTIC_TEST|Conventional psychological measurements|Using well known and validated psychological measurements to identify the mental state of the participants.
214965769|NCT02385110|DRUG|Etoposide|"Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide."
214965770|NCT02385110|DRUG|Dexamethasone|"Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks."
215081173|NCT04254016|DIETARY_SUPPLEMENT|HIBISTEVER1|During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
215081174|NCT04927767|DEVICE|denture adhesive|Denture adhesive is a commercially available denture care product used to adhere a denture to the oral mucosa, in order to improve the retention and stability.
215081175|NCT00084019|DRUG|Atazanavir|
215081176|NCT00084019|DRUG|Ritonavir|
215081177|NCT01030185|DEVICE|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
215081178|NCT04424030|DIAGNOSTIC_TEST|Echocardiography|Standard echocardiography exam performed as part of clinical management.
215081179|NCT04424030|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Standard comprehensive cardiac MRI exam of the heart performed as part of clinical management.
215081180|NCT04424030|DIAGNOSTIC_TEST|Computed tomography (CT)|ECG-triggered, contrast-enhanced CT scan of the heart performed for research purposes in eligible study participants.
215081181|NCT05595018|OTHER|End user|Participants will provide their opinions in two rounds to reach consensus
215081182|NCT05595018|OTHER|Demand side- management|Participants will provide their opinions in two rounds to reach consensus
215081183|NCT05595018|OTHER|Supply side|Participants will provide their opinions in two rounds to reach consensus
215081184|NCT05595018|OTHER|Funder|Participants will provide their opinions in two rounds to reach consensus
215081185|NCT05595018|OTHER|Academia|Participants will provide their opinions in two rounds to reach consensus
215081186|NCT00612742|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
215081187|NCT00612742|DRUG|placebo gel|once daily transdermal placebo gel
215081188|NCT03693339|DRUG|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
214356139|NCT06263621|BEHAVIORAL|"Intervention Standard"|"The two cafes will offer entrees in two sizes, a smaller and larger size. In the intervention cafe, the smaller size will be labeled Standard during the intervention period, and Small during all other times. In the control cafe, the smaller size will always be labeled Small. The larger size will always be labeled Large for both cafes during the duration of the study."
214356140|NCT06248918|BEHAVIORAL|WATSOCPAP|Participants will receive an supervised and individualized exercise plan, activity tracker, and physical activity coaching program based Social Cognitive Theory. Participants will be administered strengthening and aerobic exercise program, structured and individualized according to the person's individual capacity and needs, under the supervision of a physiotherapist. The activity tracker will provide real-time activity information about daily steps, time spent with MVPA (minutes/day) and sedentary time. The nurse-led physical activity coaching program was planned according to the Social Cognitive Theory (SCT) components such as self-regulation, outcome expectation, social support and perceived environment. The interventions will continue with online and the 12-week program will be completed.
214356141|NCT01009931|DRUG|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
214356142|NCT01009931|DRUG|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
214356143|NCT01009931|DRUG|Choline magnesium trisalicylate|"Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles."
214965771|NCT02385110|DRUG|Methotrexate|Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
214356144|NCT01719835|DRUG|Cyclophosphamide|750mg/m2 IV every 21 days
215081189|NCT05027685|DEVICE|The Paradise Ultrasound Renal Denervation System|The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
215081190|NCT00607711|DRUG|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
215081191|NCT04592900|OTHER|balance exercising|selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
215081192|NCT05097300|OTHER|Suboccipital inhibition|The therapist will place his hands under the patient's head, making contact with the suboccipital muscles in the region of the posterior arch of the atlas, applying progressive and deep pressure. This pressure will be maintained for 10 minutes
215081193|NCT05097300|OTHER|Ischemic pressure|"Pressures will be made on the temporal, superior trapezius, masseter and sternocleidomastoid muscles. Physical therapist will apply gradual sustained finger pressure to the muscle's active trigger points for 5-15 seconds. The therapist will begin with light firm pressure and gradually increase the pressure until the patient feels a moderate but bearable level of pain (corresponding to a level 7 on a pain scale of 1 to 10 levels where 1 indicates no pain and 10 is excruciating pain). Pressure will remain at this level until pain levels decrease to level 3. The therapist will repeat this procedure approximately 3-4 times over a 90 second period."
214356145|NCT01719835|DRUG|Gemcitabine|1000mg/m2 IV Days 1, 8, 15 every 28 days
214356146|NCT01719835|DRUG|Doxorubicin|50mg/m2 IV every 21 days
214356147|NCT01719835|DRUG|Vincristine|1.4mg/m2 (max 2mg) IV every 21 days
214356148|NCT01719835|DRUG|Prednisolone|100mg PO Days 1-5 every 21 days
215081194|NCT05097300|OTHER|Passive stretching|Passive stretches will be applied to each muscle 2 times for 30 seconds, they will be performed slowly at the rate of the patient's normal breathing and checking that no compensations appear.
215081195|NCT05097300|OTHER|Diaphragmatic breathing exercice|To perform diaphragmatic breaths, there will first be an education on how to do them. The patient will lie supine, with the hips and knees semi-flexed. The therapist will ask you to place one hand on your chest and one on your abdomen. Successively, it will ask you to take a few deep breaths, inhaling through your nose for 2 seconds and exhaling through your mouth, with your lips pursed (almost closed) for 4 seconds, helping you to maintain the rhythm of your breath by counting out loud. The patient should note that during inspiration his hand on top of the chest does not rise (the chest remains still) and during expiration that his hand on top of the abdomen goes down (the abdomen sinks).
214356149|NCT01719835|DRUG|methylprednisolone|1000mg oral or IV Days 1-5 every 28 days
214356150|NCT01719835|DRUG|Cisplatin|100mg/m2 IV Day 15 every 28 days
214356151|NCT03204253|DRUG|rFSH + r-LH in combination|29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
214356152|NCT03204253|DRUG|rFSH alone|32 women who were stimulated with recombinant FSH alone
214356153|NCT04354467|DIAGNOSTIC_TEST|urine neutrophil gelatinase -associated lipocalin|urine biomarker is measured and batched procesessed
214356154|NCT03532074|DIAGNOSTIC_TEST|assessment of bowel symptoms before surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery
214356155|NCT03532074|DIAGNOSTIC_TEST|assessment of rectosigmoid during laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. A near-infrared camera-head (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
214356156|NCT03532074|DIAGNOSTIC_TEST|follow up and assessment of bowel symptoms after surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery
214965772|NCT02385110|BEHAVIORAL|Phone Call|If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
214965773|NCT02385110|DRUG|Tocilizumab|Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
215081196|NCT04021173|DRUG|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
215081197|NCT04021173|DRUG|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
214356157|NCT03532074|DIAGNOSTIC_TEST|assessment of rectosigmoid perfusion during robot-assisted laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. The robotic Firefly imaging system (daVinciXi surgical platform; Intuitive Surgical, Sunnyvale, CA) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
215081198|NCT06301750|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
215081199|NCT06301750|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
215081200|NCT06301750|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
215081201|NCT01415804|DEVICE|endoprosthesis|Thoracic aortic stentgraft
215081202|NCT02635139|BEHAVIORAL|Breakfast skipping|18h fasting period in the morning
215081203|NCT02635139|BEHAVIORAL|Dinner skipping|18h fasting period in the evening
215081204|NCT00004564|DRUG|Clopidogrel|
215081205|NCT00004564|DRUG|Atorvastatin|
215081206|NCT03584191|OTHER|No treatment given|Completion of a survey
215081207|NCT03981666|OTHER|Questionnaires|"To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~* Ad hoc questionnaire for demographics and medical data;~* Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~* Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion."
215081208|NCT04539522|BEHAVIORAL|Three-dimensionally corrective exercise for scoliosis|Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.
215081209|NCT04539522|BEHAVIORAL|Conventional exercise|Conventional exercise consists a series of spine exercises focusing on core strength training.
215081210|NCT05504304|PROCEDURE|open reduction and internal fixation plus primary subtalar arthrodesis|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
215081211|NCT05504304|PROCEDURE|conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
215081212|NCT03132519|DRUG|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
214356158|NCT03853668|BEHAVIORAL|exercise|control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks
214356159|NCT02319811|PROCEDURE|Cryopreserved meniscus transplants|Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
214356160|NCT03616548|DIAGNOSTIC_TEST|Endoscopic surveillance|Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
214965774|NCT02371876|DEVICE|ONYX PLUS Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
214965775|NCT04054726|DEVICE|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. Stimulation will be given for 20 mins.
214965776|NCT04054726|DEVICE|Sham Transcranial pulsed current stimulation (tPCS)|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. The electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
214965777|NCT04956939|DRUG|Low dose levodopa|Low frequency is defined as ≤ 3 LD doses a day
214965778|NCT04956939|DRUG|High dose levodopa|High frequency dosage is defined as ≥ 5 LD doses per day
214965779|NCT01002248|DRUG|Perifosine|Perifosine will be dosed as one 50 mg pill every day of each cycle.
214965780|NCT01002248|DRUG|Perifosine Placebo|Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
214965781|NCT01002248|DRUG|Bortezomib|Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
214965782|NCT01002248|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
214965783|NCT02076815|DRUG|Anagrelide retard|Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
214965784|NCT02076815|DRUG|Thromboreductin|Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
214965785|NCT00534638|BIOLOGICAL|Cervarix|Intramuscular injection, 3 doses
214965786|NCT00534638|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
214965787|NCT01768923|PROCEDURE|SDAI remission|SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score \[SDAI\] \<3.3)
214965788|NCT01768923|PROCEDURE|Minimal disease activity remission|Minimal disease activity group aims at minimal disease activity (DAS28\<2.6) (minimal disease activity group)
214965789|NCT04722107|DRUG|rAAV2/8-hCYP4V2|rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
214965790|NCT05998759|BIOLOGICAL|Telitacicept|subcutaneous telitacicept 160 mg weekly for 24 weeks.
214965791|NCT05998759|DRUG|Placebo|subcutaneous placebo weekly for 24 weeks.
214965792|NCT00103558|DRUG|Lumiliximab with FCR|Dose, schedule, and duration specified in protocol
214965793|NCT00452439|DRUG|Actonel (Risedronate)|35 mg (pill) by mouth weekly
214965794|NCT00452439|DIETARY_SUPPLEMENT|Calcium|500 mg by mouth twice a day for a total of 24 months.
214965795|NCT00452439|DIETARY_SUPPLEMENT|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
214965796|NCT02847325|DRUG|AC0058TA|50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
214965797|NCT02847325|DRUG|Placebo capsules|Placebo capsules
214965798|NCT04027088|DIETARY_SUPPLEMENT|Immunonutrition|It is a hypercaloric and hyperproteic dietary supplement formulated with immunonutrients: Arginin, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
214965799|NCT04027088|DIETARY_SUPPLEMENT|Standard|It is a hypercaloric and hyperproteic dietary supplement formulated without immunonutrients
214965800|NCT05133115|BEHAVIORAL|Fostering Resilience in Adolescents at Risk|"The FRAK training was developed according to ecological framework, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of FRAK were established based on The Individual \& Environmental Resilience Model (IERM). Previous to the intervention, a systematic review and a meta-analysis on Resilience Interventions were performed.~Students will follow a training consisting of six 55-minute sessions: (1) introducing resilience, (2) self-esteem, (3) emotional strategies regulation, (4) social skills, (5) solving problems (6) community resources, social and peers' support."
214393699|NCT05652764|OTHER|Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients|In this study, face-to-face patient education, giving patient education booklet, preparation of symptom management card, face-to-face and telephone counseling initiatives were planned to the experimental group.
214393700|NCT02438462|OTHER|Soluble Fibrin|Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
214965801|NCT01407016|DRUG|metronidazole IV 500 mg|On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
214393701|NCT03110328|DRUG|MK3475|anti-PD1 immunotherapy
214393702|NCT00519675|DRUG|alitretinoin|
214965802|NCT04956211|PROCEDURE|Periodontal therapy|Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
214965803|NCT02944175|DRUG|Sugammadex|At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
214965804|NCT02944175|DRUG|Neostigmine|At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
215081213|NCT04672525|DRUG|Rifabutin|2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
215081214|NCT04672525|DRUG|Rifampicin|10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
214356161|NCT04710810|OTHER|umbilical cord blood mononuclear stem cells|UCB samples (70-130 ml of initial volume) were aseptically drained in blood-collection bags with 35 mL of citrate phosphate dextrose (CPDA-1) anticoagulant. Red blood cell-depleted/plasma-reduced nucleated cells were isolated by sedimentation in dextran-40, resuspended in autologous plasma with 10% dimethylsulfoxide and 1% dextran-40, and aliquoted in 3.8 ml vials with target doses of 3.0±0.2 x 10⁶ cells per vial. Vials were cooled to -90⁰C, quarantined in the vapor phase of liquid nitrogen. Tested for HIV-1/2, hepatitis B and C, HTLV-1/2, HSV-1 and -2, CMV, syphilis, and sterility. Characterized by AB0/Rh, CD34/CD45-positive cell content. Before injection sample thaws in the water bath at +37⁰C and washes from an excess amount of DMSO in 40 mL of physiological saline containing 2.5% human serum albumin and 5% dextran-40. After centrifugation and supernatant withdrawal, the UCB resuspends in 40 ml of the same solution at a target dose of 250±10 x 10⁶ viable cells per sample.
214356162|NCT05786690|OTHER|Interventions|the temporospatial and kinematic gait characteristics
214356163|NCT00867438|PROCEDURE|Sigmoidoscopy|
214356164|NCT04928963|DIETARY_SUPPLEMENT|Prolon - FMD|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
214965805|NCT04808583|PROCEDURE|TLH with uterine artery ligation at its origin at the beginning of the operation|After insertion of the ports and surveying the abdomen as in the conventional method a window will be created in the broad ligament to enter the retroperitoneal space with exposure of the iliac vessel and identification of the internal iliac artery and its anterior branch which give rise to the uterine artery. Blunt dissection continues with identification of the paravesical and the pararectal spaces. The ureter is identified medially and the uterine artery laterally and dissection of the ureter away from the uterine artery will be done, followed by sealing the uterine artery 2 mm from its origin from the anterior branch of internal iliac artery
214965806|NCT04808583|PROCEDURE|conventional TLH with uterine artery ligation after the cornual pedicles|"Coagulation and section of round ligaments will be performed about 2 to 3 cm from the pelvic wall using blunt tip laparoscopic sealer LigaSure COVIDIEN (5mm-37cm) with average of sealing cycle of 2 to 4 seconds and 40 watts , followed by opening the anterior leaflet of the broad ligament to the vesico-uterine peritoneal reflection, coagulation and section of the infundibulo-pelvic ligament (total hysterectomy with bilateral adnexectomy) or of the uteroovarian ligament and the fallopian tubes (total hysterectomy). Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014).~Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides."
214965807|NCT03526042|DRUG|Losartan|Competitive blockade of AT1R-antibodies effect by binding to the angiotensin 1 receptor
214965808|NCT03526042|DRUG|Enalapril|Renin-angiotensin-aldosterone system (RAAS) blockade without any effect on AT1R-antibodies effect or concentration (control group)
214965809|NCT03052205|DRUG|IMO-2125|IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
214965810|NCT03574623|DEVICE|Electrical Stimulator|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).
214965811|NCT03574623|BEHAVIORAL|Occupational Therapy|Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
214965812|NCT01517308|DRUG|pegylated interferon alpha 2a + ribavirin|Comparison of different duration of drugs (48 weeks vs. 24 weeks)
215081215|NCT06508268|BEHAVIORAL|GAITRite walkway system OR 4-meter walking speed test|Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test
215081216|NCT06508268|BEHAVIORAL|Jamar hand dynamometer|Hand grip strength will be assessed by a Jamar hand dynamometer
215081217|NCT06508268|BEHAVIORAL|Picture description task|Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)
215081218|NCT06508268|BEHAVIORAL|Autobiographical semi-structured conversation|Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation
215081219|NCT06508268|BEHAVIORAL|Verbal fluency|The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency
214965813|NCT00058071|DRUG|amifostine trihydrate|
214965814|NCT03974802|DEVICE|somofilcon A contact lens|Contact Lens
214965815|NCT03974802|DEVICE|fanfilcon A contact lens|Contact Lens
214965816|NCT02524834|PROCEDURE|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
215081220|NCT04229212|DEVICE|hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)|In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System \[HAS\], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
215081221|NCT05945056|OTHER|Frog Leg Exercise|The patient lies supine with legs flexed, knees apart and the soles of the feet put together on couch. The physiotherapist stands at the side of the table, moves one arm between the legs to place the hand under the sacrum and cup it. The fingers spread to accommodate the spinous process of the fifth lumbar vertebra. The tips of the fingers contact and grasp the junction of the fifth lumbar vertebra and the base of the sacrum. This hand will give traction in a caudal direction throughout the procedure to move the sacral base posteriorly and the apex interiorly. patient is asked to take a deep breath and hold it, while at the same time they steadily slide the feet downward toward the end of the table.Then patient brings their legs back to the frog leg position, but as they do so the therapist maintains traction preventing the sacrum from moving cephalad. Procedure is repeated for a total of 8 repetitions.
214965817|NCT02524834|DEVICE|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
214356165|NCT03272633|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Receive IHC
214356166|NCT03272633|BIOLOGICAL|Irradiated Allogeneic Cells|Correlative studies
214356167|NCT03192605|OTHER|Blueberry|Blueberry - 150 grams wild blueberries (whole fruit)
214356168|NCT03192605|OTHER|Placebo|Placebo - matched for calories and fiber
214965818|NCT01550510|DRUG|Ascorbic Acid|3x a week for 9 weeks
214965819|NCT01550510|DRUG|Irinotecan|350mg/m2 once a week every 3 weeks
214965820|NCT03107182|DRUG|nab-paclitaxel|All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
214965821|NCT03107182|DRUG|Carboplatin|All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
214965822|NCT03107182|DRUG|Nivolumab|"All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses."
214965823|NCT03107182|DRUG|Cisplatin|Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
214356169|NCT05134181|DRUG|sacroiliac joint injection|"Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied"
214487308|NCT06769555|DRUG|CM-336 BCMA/CD3 bispecific antibody|Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1. For patients achieve hematological PR or better after 2 cycles, and hematological VGPR or better after 4 cycles, the treatment regimen will change to 160mg once every 2 weeks (Q2W).
214487309|NCT06844123|PROCEDURE|Robot-assisted keratoplasty|Feasibility pilot interventional study. Monocentric, one arm. Microsurgical robot will be used to perform penetrating keratoplasty. During the procedure, the corneal sutures will be performed using symani surgical system, that is a microsurgical robot controlled by a surgeon
214965824|NCT03107182|DRUG|Hydroxyurea|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
214965825|NCT03107182|DRUG|5-FU|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
214965826|NCT03107182|DRUG|Dexamethasone|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
214965827|NCT03107182|DRUG|Famotidine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
214965828|NCT03107182|DRUG|Diphenhydramine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
214965829|NCT03107182|DRUG|Paclitaxel|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
214965830|NCT03107182|PROCEDURE|Transoral robotic surgery (TORS)|Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
214965831|NCT03107182|RADIATION|Adjuvant RT|Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
214965832|NCT03107182|RADIATION|Chemoradiotherapy|"Patients who have low risk disease with \<50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and \<30% reduction of tumor, patients who have high risk disease and \<50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
214965833|NCT06147258|BEHAVIORAL|expressive writing|A typical session will begin with the teaching artist (i.e., writing coach) introducing a new writing theme. Participants will have at least 20 minutes to write, and each session will include post-writing reflections and sharing, an undirected supportive interaction among participants.
214965834|NCT03263715|DRUG|Tocilizumab Prefilled Syringe [Actemra]|Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
214487310|NCT06504966|DRUG|MAB-22|Single subcutaneous dose of 60 mg
214487311|NCT06504966|DRUG|Prolia®|Single subcutaneous dose of 60 mg
214965835|NCT03263715|DRUG|Placebos|Weekly administration of Placebo subcutaneous from Baseline to Week 16.
214356170|NCT04275466|PROCEDURE|necrotic cavity lavage|"1. At least two 30- to 36-Fr drainage tubes will be placed into each necrotic cavity. One of these drainage tubes will be used as the lavage tube; the other tube is designed for drainage.~2. Lavage will begin on the first day after debridement, and the relevant indices will be evaluated every 7 days to decide whether to continue the lavage.~3. 1200 mL of normal saline will be lavaged into each necrotic cavity every day at a speed of 200 mL/h for 3 hours each time and for a total of two times. The start times of lavage will be 08:00 and 20:00.~4. The lavage and drainage volumes of the first hour and second hour of each lavage session will be calculated. The lavage of the next hour will be stopped if the lavage volume minus the drainage volume is \>100 mL.~5. Lavage will be suspended if abdominal pain and distention occur, the maximum body temperature is \>38.5ºC, or the abdominal pressure is ≥15 mmHg during the lavage procedure."
214356171|NCT04222101|DIAGNOSTIC_TEST|Oral glucose tolerance test|measure insulin, glucose and FGF21 levels in response to oral glucose challenge
214965836|NCT03263715|DRUG|Glucocorticoids|Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
214965837|NCT05076877|DRUG|Lazertinib|Lazertinib tablets will be administered orally, alone or in combination with probe substrates.
214965838|NCT05076877|DRUG|Midazolam|Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.
214965839|NCT05076877|DRUG|Rosuvastatin|Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.
214356172|NCT04886024|OTHER|Advanced Glycation End Products (AGEs)|Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.
214356173|NCT03263754|BEHAVIORAL|Pocket Medic|10 short digital films utilising self-determination theory aiming to increase patient self-management
214356174|NCT03263754|BEHAVIORAL|Pulmonary Rehabilitation|PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach
214356175|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A1 in study phase 1|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
214356176|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A2 in study phase 1|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
214356177|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A1 in study phase 2|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
214356178|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A2 in study phase 2|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
214965840|NCT05076877|DRUG|Metformin|Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.
214965841|NCT05869071|DEVICE|Sensor analyzing software (own development)|A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
214965842|NCT05869071|DEVICE|Body plethysmograph|Body plethysmograph measures specific airway resistance
214965843|NCT03515863|GENETIC|DNA extraction and genetic characterization|Collection of blood samples for DNA extraction and genetic characterization using whole-genome sequencing, and for identification of cellular biomarkers using transcriptomics and mass cytometry.
215081222|NCT05945056|OTHER|Electrotherapy(Transcutaneous Electrical Nerve Stimulator)|TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.
214965844|NCT03515863|DEVICE|Orbit MRI examination|Orbit MRI examination is performed to confirm the diagnosis of TAO
214965845|NCT03515863|OTHER|Collection of life style data|Collection of life style data using quality of life questionnaire
214965846|NCT00535431|DRUG|AER 001|60 mg (in nebuliser), twice daily for 28 days
215081223|NCT05945056|OTHER|Exercise Therapy|Stretching of tight muscles(hip flexors and lower back extensors) Abdominal Curl-Ups and Bridging exercises.
215081224|NCT01181024|DRUG|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
215081225|NCT01181024|DRUG|RO5303253|Cohorts receiving single ascending doses
215081226|NCT01181024|DRUG|RO5303253|Single dose
214356179|NCT05380648|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty surgery will be performed by different orthopedist.
214356180|NCT01189968|DRUG|Demcizumab|The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.
214965847|NCT00535431|DRUG|placebo|Sterile saline nebulised, twice daily for 28 days
214965848|NCT02855775|OTHER|additional blood sample|blood sample every 3 weeks
214965849|NCT06212986|DEVICE|Promotion of mental training through mobile application Perform-UP Tennis|"Perform-UP Tennis is a sport specific mental training app that integrates breathing, relaxation and na-ture-based guided imagery exercises and aims to promote emotional well-being and the enhancement of mental skills. The app techniques are integrated into a single gradual path that involves increasingly complex breathing and relaxation exercises with increasing duration.~The intervention consists of eight weekly modules over a period of 8 weeks with progressive exercises."
215081227|NCT01181024|DRUG|RO5303253|Multiple doses
215081228|NCT03911752|OTHER|Semi-structured interviews|Semi-structured interviews were used to obtain the main data in this study.
214965850|NCT03251157|OTHER|Dietary intake of various nutrients, foods and biocompounds|Participants answered a self-administered FFQ, in which they reported the usual frequency of intake of a list of 250 food items
214965851|NCT03424798|DEVICE|Inspiwave|patients are monitored with the Inspiwave device. A low dose inert tracer gas is added to the inspred air
214965852|NCT01808274|DEVICE|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
214965853|NCT04572776|DRUG|Resiniferatoxin|Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.
214965854|NCT04572776|OTHER|Standard of Care|Standard of care for intractable pain with the exception of intra-thecal pump placement as determined by the investigator.
214965855|NCT03243825|RADIATION|combination group|chemotherapy (paclitaxel/cisplatinum) and brachytherapy
214965856|NCT03243825|DRUG|chemotherapy group|chemotherapy: (paclitaxel/cisplatinum)
214965857|NCT02799563|OTHER|Coach, Preselected number of cases|
214965858|NCT02799563|OTHER|Coach, Self-selected number of cases|
214965859|NCT02799563|OTHER|No coach, Preselected number of cases|
214965860|NCT02799563|OTHER|No coach, Self-selected number of cases|
214965861|NCT03414333|PROCEDURE|RYGB|RYGB is associated with a increase of circulating GLP-1 (up to ten-fold) especially in response to meal ingestion. This increased availability of GLP1 has been claimed to contribute to restoration of some of the beta-cell function.
215081229|NCT03911752|OTHER|Canadian Occupational Performance Measure|The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
215081230|NCT05720364|DRUG|TP-05 (lotilaner oral), fasted group|TP-05 (lotilaner oral), fasted group
214965862|NCT03414333|DRUG|GLP-1|GLP-1 is an hormone secreted by gut in response to nutrients ingestion.
214965863|NCT04487808|DRUG|Pecan|Unsalted raw pecans incorporated in snack and meal recipes as part of a dietary pattern
214965864|NCT04487808|OTHER|Average American Diet devoid of nuts|Diet mimicking usual American intake
214965865|NCT01601769|DEVICE|Vitom|Patients treated and diagnosed by vitom
215081231|NCT05720364|DRUG|TP-05 (lotilaner oral), high-fat group|TP-05 (lotilaner oral), high-fat group
214356181|NCT03035292|DIAGNOSTIC_TEST|Red-reflex assessment|The red reflex was examined in the standard manner using direct ophthalmoscope by medical student examiner
214356182|NCT03035292|DIAGNOSTIC_TEST|Infrared-reflex assessment|The infrared reflex was examined using a modified smart phone camera by a medical student examiner
214965866|NCT01601769|DEVICE|Colposcopy|"a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.~Patients treated by colposcopy"
214965867|NCT00388648|DRUG|mixture of amino and keto acids|
214965868|NCT04147247|DRUG|BI 905681|Infusion
214965869|NCT03788161|OTHER|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
214965870|NCT03788161|OTHER|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
214965871|NCT04591756|OTHER|Qualitative Fit Testing|Qualitative fit testing with denatonium benzoate
214965872|NCT01942876|BEHAVIORAL|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
214965873|NCT01942876|BEHAVIORAL|Health behavior maintenance|This attention-control arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
214965874|NCT00010751|PROCEDURE|Reiki|
214965875|NCT04533113|PROCEDURE|Carious tissue selective removal|Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration
214965876|NCT01901042|DIETARY_SUPPLEMENT|Symbiotic|Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
214965877|NCT01901042|DIETARY_SUPPLEMENT|Maltodextrin|Control patients will receive sachets containing maltodextrin
214965878|NCT00130689|DRUG|Cetuximab|
214965879|NCT03602716|DEVICE|HD-tDCS|HD-tDCS is going to be delivered at 1.5 mA intensity for 20 minutes once a day (+15 s fade-in and fade-out); sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. HD-tDCS will be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system.
215081232|NCT05720364|DRUG|TP-05 (lotilaner oral), low-fat group|TP-05 (lotilaner oral), low-fat group
215081233|NCT00869245|OTHER|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
215081234|NCT00869245|OTHER|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
215081235|NCT03194191|DEVICE|Acupuncture needles|The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
215081236|NCT00823212|DEVICE|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
215081237|NCT00823212|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS \[XIENCE V\] stent).
215081238|NCT00823212|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
214965880|NCT03602716|DEVICE|Sham HD-tDCS|HD-tDCS is going to be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system; sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. This group will have a 20-min-sham stimulation.
214965881|NCT05763810|OTHER|Erector Spinae Plane Block|Erector Spinae Plane Block
214965882|NCT05763810|OTHER|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
214965883|NCT00503347|DRUG|bavituximab|The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
214965884|NCT02809950|OTHER|oral carbohydrate beverage|oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively
214965885|NCT02809950|OTHER|control group|NPO from midnight of the day before surgery
214965886|NCT00528749|OTHER|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
214965887|NCT02487537|DIETARY_SUPPLEMENT|custom-made soft drink|
214965888|NCT00943397|DRUG|montelukast sodium|Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
214965889|NCT00943397|DRUG|Comparator: Usual Care|Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
214965890|NCT05238688|PROCEDURE|Thoracic Epidural Analgesia (TEA) group|Under full aseptic conditions while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine an 18-G Tuohy needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal . After negative response, 15 ml of 0.25% epidural bupivacine will be injected and the patient will be turned to the supine position.
214965891|NCT05238688|PROCEDURE|Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group|Thoracic Epidural Analgesia will be done at first. Then, the ultrasound probe will be placed longitudinally 2-3 cm lateral to the T2 spinous process in the sagittal line. The T2 spinous process will be identified by counting down anatomically from the vertebral prominens (C7), and the T2 transverse process will be visualized by counting down from the first rib via real-time ultrasound guidance. The erector spinae muscle will be visualized above the T2 transverse process. The needle will be inserted in a caudal cranial direction using the in-plane technique. A dose of 5 mL normal saline will be injected into the inter-fascial area between the erector spinae muscle and the transverse process for the correction of the injection site (hydro-dissection). After hydro-dissection, 15 mL of 0.25% bupivacaine will be injected here, and the linear spread of the solution will be visualized in the inter-fascial plane.
214965892|NCT06262971|DEVICE|Percutaneous coronary intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
214965893|NCT01499693|DRUG|Magnesium Pantoprazole 20 mg|oral dose, twice a day
214965894|NCT01499693|DRUG|Magnesium Pantoprazole 40 mg|oral dose, once a day (morning)
214965895|NCT01499693|DRUG|Placebo|"oral dose, once a day (night)~Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group)."
214965896|NCT04178408|OTHER|No intervention|No intervention
215081239|NCT00823212|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
214356183|NCT01241357|DEVICE|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
214356184|NCT02974790|PROCEDURE|Echocardiography|Two-dimensional imaging echocardiography
214356185|NCT01384708|DRUG|proflavine|1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
214356186|NCT04274907|DRUG|Venetoclax|Tablet: Oral
214356187|NCT04274907|DRUG|Pembrolizumab|Intravenous (IV) Infusion
214356188|NCT04352179|BEHAVIORAL|Virtual Education Simulation|"The simulations will be developed using Kognito's proprietary Conversation Platform.~In this pilot study, the simulations will be a bundle of four topic-based conversations with Linda, a virtual peer with a chronic disease. The four wellness topics are:~1. Fitness \& Nutrition~2. Smoking Cessation~3. Alcohol Use~4. Distress \& Anxiety"
214487312|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
214965897|NCT04878055|DRUG|Reparixin|2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
214965898|NCT04878055|OTHER|Placebo|Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).
214965899|NCT01865721|DRUG|Entonox|Entonox will be used according to the allocated method
214965900|NCT01827735|DRUG|Aldesleukin (Proleukin)|A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
214965901|NCT01968811|DEVICE|Avance Foam dressing kit|
215081240|NCT02753634|BEHAVIORAL|Square-stepping exercise|Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
215081241|NCT01759563|DEVICE|nasopharyngeal targeted brain cooling|
215081242|NCT02854124|PROCEDURE|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
214965902|NCT04658264|DIETARY_SUPPLEMENT|Wheat-Barley Composite flour|A combination of wheat and barley flour with 0.5% food grade xanthan gum as replacement for lost gluten, tested for sensory properties, nutrient profile, and rheology
214965903|NCT06358833|PROCEDURE|endodontic needle (EN)|the irrigation of root canals will be done with 2.5 % sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The tip of the needle will be pre-measured and positioned within 1 millimeter of the working length. No activation of the irrigant will be performed.
214965904|NCT06358833|PROCEDURE|Endodontic activation (EA)|the irrigation of root canals will be done with 2.5% sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The irrigant will be activated with ultrasonic energy using the Endo-1 Ultrasonic Endo Activator (Guilin Woodpecker, Guilin, China). The tip of the Endo-1 Ultrasonic Endo Activator device will be pre-measured and kept within 1 mm from the working length. The manufacturer's instructions regarding irrigant activation will be followed.
214965905|NCT02591641|DEVICE|Anti-shear mattress overlay|A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.
214965906|NCT02591641|OTHER|Standard of Care|Standard ambulance stretcher mattress
214965907|NCT05258734|OTHER|COVOS app|In this study, the patients in the experimental group will be followed up with the COVOS app and nursing interventions (videos, information messages) to manage their symptoms will be directed with the COVOS app.
214965908|NCT05258734|OTHER|Standard Care|In this study, the patients in the control group will not receive any intervention, the standard follow-up and health care provided by the family health center of the patients will continue.
214965909|NCT04574453|DEVICE|Iracross|Administration of max 2ml of Iracross at first visit
214965910|NCT04574453|DEVICE|Iraline|Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need
214965911|NCT00463918|DRUG|varenicline|
215081243|NCT03965884|OTHER|Physical therapy and rehabilitation|Physical therapy and rehabilitation
215081244|NCT00206882|DRUG|corticosteroids|
214965912|NCT00055445|DRUG|IdB 1016|
214965913|NCT02285075|DRUG|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T \> MIC of 8 and 16 mg/L).
214965914|NCT01254656|DRUG|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
214965915|NCT01254656|DRUG|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
214965916|NCT01254656|DRUG|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
215081245|NCT05791695|OTHER|Non Applicable|No study-specific interventions for this observational study.
215081246|NCT00560534|PROCEDURE|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
215081247|NCT05131776|DEVICE|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
215081248|NCT06439888|DRUG|all-trans retinoic acid|per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles
215081249|NCT06439888|RADIATION|Stereotactic Body Radiation Therapy|Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated
215081250|NCT00015860|DRUG|daunorubicin hydrochloride|
215081251|NCT00015860|DRUG|imatinib mesylate|
215081252|NCT00015860|DRUG|prednisone|
215081253|NCT00015860|DRUG|vincristine sulfate|
215081254|NCT01975519|DRUG|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
215081255|NCT01478230|DRUG|Nicotine|Nicotine 5 mg Inhaler
215081256|NCT01478230|DRUG|Nicotine|Nicotine 10 mg Inhaler
215081257|NCT05199376|DEVICE|Cryotherapy|The cryotherapy treatment lasts approximately 30 minutes during which two 10-minute freezing cycles are performed, separated by a reheating phase. During the freezing phases, the temperature is lowered below -40°C in the ablation zone, a temperature that is lethal for the cells.
215081258|NCT05063188|OTHER|Connective Tissue Massage|Connective tissue massage was started from lumbosacral region and continued lower thoracic, scapular, interscapular, and cervical regions, respectively.
215081259|NCT05063188|OTHER|clinical pilates exercises|Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
215081260|NCT05530044|BEHAVIORAL|Social diffusion intervention|training in communication skills
214356189|NCT02396654|OTHER|2D and 5D LB ultrasound comparison for fetal weight estimation|2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
214487313|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
215081261|NCT00003234|DRUG|vinorelbine tartrate|
215081262|NCT00003103|BIOLOGICAL|oblimersen sodium|
215081263|NCT00003103|DRUG|docetaxel|
215081264|NCT02509052|OTHER|Laboratory Biomarker Analysis|Correlative studies
215081265|NCT02509052|DRUG|Leflunomide|Given PO
215081266|NCT02509052|OTHER|Pharmacological Study|Correlative studies
215081267|NCT02472418|DRUG|DFN-15 Dose A (treatment A)|DFN-15 Dose A administered
215081268|NCT02472418|DRUG|DFN-15 Dose B (treatment B)|DFN-15 Dose B administered
215081269|NCT02472418|OTHER|Placebo (treatment C)|Placebo administered
215081270|NCT06276582|DEVICE|Screening for neonatal jaundice with a mobile health device|Picterus Jaundice Pro will be used to screen for neonatal jaundice by taking 6 photos of the newborns skin, where the Picterus calibration card is place.
215081271|NCT05326191|DIAGNOSTIC_TEST|Ultrasound|All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.
214965917|NCT01254656|DRUG|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
214356190|NCT06367205|DRUG|Goal-Directed Fluid Therapy (GDFT)|Norepinephrine will be administered intravenously at a rate of 0.06 µg/kg/min, followed by the implementation of fluid therapy guided by SVV until reaching our target. In instances where SVV ≤ 13%, indicative of adequate effective circulating blood volume, the fluid infusion rate will be adjusted to 1 ml/kg/h. Conversely, if SVV \> 13%, denoting inadequate effective circulating blood volume, a rapid infusion of 1 ml/kg of crystalloid fluid will be administered over 2 minutes, with subsequent observation of fluid reactivity after a further 2-minute interval. This process is reiterated until SVV ≤ 13% is attained. Should SVV \> 13% recurs during surgery, the aforementioned intervention is repeated.
214965918|NCT01254656|DRUG|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
214356191|NCT06367205|DRUG|Regular Fluid Therapy|Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary
214356192|NCT00214357|BEHAVIORAL|Mindfulness-based stress reduction|
214965919|NCT01254656|DRUG|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
214965920|NCT01014247|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Single dose of 400 mg
214965921|NCT01014247|DRUG|Placebo|Single dose of matching tablet
214356193|NCT05678764|DEVICE|Conversational Information Collection Tool|Conversational Information Collection Tool that facilitates the self-referral to talk therapy.
214356194|NCT01579591|OTHER|VSL#3|1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
214965922|NCT00137345|DRUG|sirolimus|
214356195|NCT01579591|OTHER|Placebo|1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
214356196|NCT05251051|BEHAVIORAL|pediatric physical therapy|Pediatric physical therapists will provide weekly home therapy using standard of care/best evidence procedures
214356197|NCT05251051|OTHER|Care Coordination|A navigator will be assigned who will assist families in obtaining Early Intervention services and other therapy services if needed
214356198|NCT04919265|OTHER|No intervention - mother-infant cohort study|There are no interventions because it is a mother-infant cohort study
214356199|NCT03675022|DRUG|Dupilumab|The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
214356200|NCT05703568|OTHER|virtual reality|14 elderly participants receive intervention protocol of group- based virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
214356201|NCT05703568|OTHER|Virtual reality|14 elderly participants receive intervention protocol of individual virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
214965923|NCT01678118|BEHAVIORAL|Patient Navigator|The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder \& to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs \& barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
214965924|NCT05352932|DIAGNOSTIC_TEST|pancreatic duct biopsy|"Enrolled patients will undergo a baseline assessment, including CP history, clinical symptoms, imaging tests, laboratory tests, etc.~Then, according to the clinical standard of diagnosis and treatment of chronic pancreatitis, ERCP (with or without Extracorporeal Shock Wave Lithotripsy (ESWL) / endoscopic lithotripsy) will be performed for patients with calculi; pancreatic stent or nasopancreatic stent will be placed for patients with pancreatic duct stenosis. During ERCP, the patient's pancreatic tissue will be biopsied and sent for pathological examination."
214965925|NCT05502952|DRUG|Pentoxifylline|Combined microneedling and topicalpentoxifylline vesrus intalesional pentoxifylline in Alopecia Areata patches in the same patient
214356202|NCT00974324|DRUG|endostar and CHOP|"endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone"
214356203|NCT00447057|DRUG|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
214356204|NCT00447057|DRUG|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
215081272|NCT04265508|OTHER|Assessment of hemostatic profile|To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
215081273|NCT01968291|BEHAVIORAL|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
215081274|NCT03861572|OTHER|Isokinetic eccentric training|Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
214356205|NCT00447057|DRUG|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
214965926|NCT00814138|DRUG|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
214356206|NCT00447057|DRUG|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
214356207|NCT05774366|DRUG|Remimazolam|General anesthesia was induced with 12 mg/kg/hr of intravenous remimazolam. When loss of consciousness was achieved, the infusion rate of remimazolam was reduced to 1mg/kg/hr for maintenance. At the end of surgery, 0.2 mg of flumazenil is administered.
214356208|NCT05774366|DRUG|Desflurane|Desflurane (1 minimum alveolar concentration (MAC) of end-tidal desflurane concentration) is used for the maintenance of general anesthesia. Induction of general anesthesia is achieved with 1-2 mg/kg of intravenous propofol bolus.
214356209|NCT00226330|DRUG|Tesaglitazar|(0.5 or 1 mg)
214356210|NCT00226330|DRUG|Pioglitazone|(15, 30 or 45 mg)
214356211|NCT00109291|DRUG|Placebo|
214356212|NCT00109291|DRUG|peginesatide|
214965927|NCT00814138|OTHER|Placebo|Weekly
214965928|NCT04993079|DEVICE|Clotild®|Use of Clotild® as neurovascular guidewire
214965929|NCT05364476|BEHAVIORAL|16 weeks digital intervention|"Participants will be enrolled into a 16-week program which consist of an online and offline support from health coaches and dietitian. Participants will be given diet and exercise recommendations and lesson plans on a weekly basis by the health coaches, and supported by the dietitian.~Participants will be required to log in their blood sugar levels, weight and steps daily using connected device, including glucometer, smart band and body fat weighing scale provided into the daily report card. They will also be required to manually record their meals and exercise daily in the daily report card provided upon enrollment into study. Reviews of log will be done on a weekly/biweekly interval by the health coaches."
214356213|NCT00440531|BIOLOGICAL|Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
214965930|NCT03235466|BEHAVIORAL|Voice Therapy|See Arm 1 \& 2
214356214|NCT00440531|BIOLOGICAL|Comparator: Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
214965931|NCT03235466|BEHAVIORAL|Voice Therapy and Heart Rate Variability Biofeedback|See Arm 2 \& 3
214965932|NCT03235466|BEHAVIORAL|Heart Rate Variability Biofeedback|See Arm 2 \& 3
214965933|NCT00116948|DEVICE|ReCap, Hip resurfacing system, Biomet|ReCap total hip arthroplasty inserted according to manufactures manual.
214965934|NCT05765357|DRUG|Trastuzumab for injection|Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
214965935|NCT05765357|DRUG|Herceptin|Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
214965936|NCT05636813|OTHER|Training|Patients are trained to use AT (2 sessions of 4 hours). Written langage skills, autonomy, the use are evaluated before and after training.
214965937|NCT06418113|RADIATION|hypofractionated stereotactic radiotherapy|conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period
214356215|NCT00440531|BIOLOGICAL|Comparator: ENGERIX-B™ (currently licensed product)|ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
214356216|NCT01229761|DRUG|cotrimoxazole prophylaxis|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
214356217|NCT01229761|DRUG|cotrimoxazole placebo|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
214356218|NCT01229761|BEHAVIORAL|exclusive breastfeeding until 6 months of age|Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
214356219|NCT01229761|BEHAVIORAL|breastfeeding for 12 months|Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
214965938|NCT06418113|PROCEDURE|Stereotactic biopsy|Stereotactic biopsy
214965939|NCT06418113|PROCEDURE|resection|supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring
214965940|NCT06418113|DRUG|Chemotherapy|4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months
215081275|NCT03861572|OTHER|Traditional eccentric training|Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
215081276|NCT02494089|OTHER|distress analysis|
215081277|NCT00010387|DRUG|cyclophosphamide|
215081278|NCT00010387|DRUG|filgrastim|
214356220|NCT01544322|DRUG|ME-344|"experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
214393703|NCT04253704|COMBINATION_PRODUCT|IDL lotion|IDL lotion is water-based (\> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
214356221|NCT05239130|DEVICE|Auralya|Auralya® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation. Auralya® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile glass syringe with a Luer adapter.
214356222|NCT02923804|DIETARY_SUPPLEMENT|Omega-3|3x 1g capsules taken daily for 6 months
214356223|NCT02923804|DIETARY_SUPPLEMENT|Olive oil|3x 1g capsules taken daily for 6 months
214356224|NCT03236298|DEVICE|CADD-Solis Ambulatory Infusion System|The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
214356225|NCT03509649|PROCEDURE|Cervical spine manipulation|High-velocity low-amplitude thrust joint manipulation to the cervical spine
214356226|NCT02265302|DRUG|BIIL 284 oral solution|
214356227|NCT02265302|DRUG|BIIL 284 wetability improved formulation (WIF) tablets|
214356228|NCT02265302|DRUG|Placebo|
214965941|NCT06418113|RADIATION|radiotherapy Stupp protocol|radiotherapy + TMZ concurrently after 4 weeks of resection surgery, as per usual protocol: Three-dimensional radiotherapy planning to deliver a total dose of 60 Gy, with a fractionation of 2 Gy/day, 5 days/week, encompassing a 1-2 cm margin around the contrast-enhancing region defined on T1 imaging or the entire abnormal volume defined on T2 or FLAIR imaging (Li et al., 2016) + TMZ at 75 mg/m2/day for 7 days/week, for 6 weeks during radiotherapy.
215081279|NCT04930549|DRUG|Dapagliflozin 10Mg Tab|Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
214356229|NCT04455789|PROCEDURE|routine lung protective, conventional mechanical ventilation|routine lung protective, conventional mechanical ventilation with stabil PEEP
214356230|NCT01928368|DRUG|AMG 282|Single dose either subcutaneously or intravenously on day 1.
215081280|NCT04930549|DRUG|Placebo|Patients receive placebo tablets once a day during 12 weeks
215081281|NCT04930549|PROCEDURE|impedance cardiography|impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
215081282|NCT04930549|PROCEDURE|Applanation tonometry|Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
214356231|NCT01928368|DRUG|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
214356232|NCT00083057|DRUG|gefitinib|
214356233|NCT00083057|DRUG|paclitaxel|
215081283|NCT04930549|PROCEDURE|post-ischemic hyperemia of forearm|An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
215081284|NCT04930549|PROCEDURE|haemodynamics parameters|haemodynamics parameters will be evaluated using automatic oscillometric recorder
215081285|NCT06396715|DEVICE|Transcranial direct current stimulation|tDCS is a type of non-invasive brain stimulation that in a standard paradigm, low intensity current (1-2 mA) is applied continuously through a battery connected to two 20 to 35 cm2 surface electrodes located on the scalp: an anode and a cathode. In the interhemispheric competition model, tDCS can serve as a means to increase ipsilesional cortical excitability through anodal stimulation, to decrease contralesional cortical excitability through cathodal stimulation, or to do both through a montage of bi-hemispheric electrodes.
215081286|NCT00760461|DRUG|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
214356234|NCT00083057|RADIATION|radiation therapy|
214965942|NCT06418113|DRUG|Chemotherapy Stupp Protocol|temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.
214356235|NCT02668081|PROCEDURE|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
214356236|NCT02668081|PROCEDURE|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
214356237|NCT02172755|DRUG|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
214356238|NCT02181803|DRUG|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg
214356239|NCT02181803|DRUG|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
214356240|NCT02181803|DRUG|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
214356241|NCT00508066|DRUG|Bupivacaine|Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours
214356242|NCT00508066|DRUG|Normal Saline|Normal Saline, 4ml/hour for 72 hours.
214356243|NCT03824379|DIETARY_SUPPLEMENT|Magnesium citrate|magnesium citrate equivalent 20-30 mmol elemental magnesium
214356244|NCT03824379|DRUG|Antidiabetic|insulin or oral hypoglycemics
214356245|NCT03278938|DRUG|bupropion|FDA approved drug for treating depression
214356246|NCT03278938|DRUG|citalopram|FDA approved treatment for depression
214356247|NCT01983748|BIOLOGICAL|Autologous Dendritic Cells loaded with autologous Tumor RNA|
214356248|NCT03162575|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal (2002)
214965943|NCT03038529|PROCEDURE|Classic postrolateral extraarticular percutaneous approach for O3 injection|Receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through the classic postrolateral extraarticular percutaneous approach
214356249|NCT05559034|BEHAVIORAL|Cognitive intervention|This is a cognitive intervention consisting in the repetition according to three blocks, of cognitive tasks (Stroop and N-back tasks) at variating workload levels (low, middle and high levels). Each cognitive task will be presented for each workload level during three minutes.
214356250|NCT03065868|DRUG|H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)|H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
214393704|NCT04253704|COMBINATION_PRODUCT|Control lotion|Control lotion is water-based (\> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
214393705|NCT04054895|DEVICE|Lead placed in the His-Purkinje system in order to achieve QRS shortening.|Physiologic pacing to achieve QRS shortening. If the patient has indication of stimulation (AV block), a backup lead will be implanted in the right ventricle. All patients will have a lead placed in the right atrium (except those that have permanent atrial fibrillation).
214965944|NCT03038529|PROCEDURE|Postrolateral transforaminal approach (Yess approach ) for O3 injection|Group B receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach ).
214965945|NCT01433419|DRUG|TAK-875|
214965946|NCT01433419|DRUG|TAK-875|
214965947|NCT02300623|DRUG|Antiretroviral therapy plus Interleukin-2|Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
214965948|NCT02300623|DRUG|Antiretroviral therapy alone|Standard antiretroviral therapy
214965949|NCT02534597|BEHAVIORAL|Promotores Training|
214965950|NCT02534597|BEHAVIORAL|Delayed Promotores training|
214965951|NCT02534597|BEHAVIORAL|Caregiver training|
214965952|NCT02534597|BEHAVIORAL|Delayed caregiver training|
214965953|NCT02534597|BEHAVIORAL|Materials support|
214965954|NCT02534597|BEHAVIORAL|Delayed materials support|
214965955|NCT02534597|BEHAVIORAL|Technical assistance|
214965956|NCT02534597|BEHAVIORAL|Delayed technical assistance|
214965957|NCT00027885|BIOLOGICAL|bevacizumab|Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
214965958|NCT00027885|DRUG|cyclophosphamide|Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
214965959|NCT00027885|DRUG|docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
214965960|NCT00027885|DRUG|doxorubicin hydrochloride|Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
214965961|NCT00027885|PROCEDURE|adjuvant therapy|"After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.~Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
214965962|NCT00027885|PROCEDURE|conventional surgery|After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
214965963|NCT00027885|PROCEDURE|neoadjuvant therapy|"Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.~Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
214965964|NCT00027885|RADIATION|radiation therapy|Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
214965965|NCT04678843|BEHAVIORAL|Virtual Family-Based Treatment|Treatment involving the youth/adolescent who has been diagnosed with anorexia nervosa and their family, delivered virtually via videoconferencing.
214965966|NCT01659840|RADIATION|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
214965967|NCT01659840|RADIATION|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
214965968|NCT05807971|DRUG|ATH-063|12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
214965969|NCT05807971|DRUG|Placebo|Identical capsule to the drug without the active ingredient.
214965970|NCT02372344|DRUG|AZD0585|Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
214965971|NCT03158961|PROCEDURE|Transoral endoscopic thyroidectomy vestibular approach|TOVETA is a new approach in surgery of thyroidectomy no longer open on the neck
214965972|NCT02664012|OTHER|Own Brand Menthol Cigarette|combustible menthol cigarette brand style smoked most frequently by subject
214965973|NCT02664012|OTHER|Electronic Menthol Cigarette #1|VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)
214965974|NCT02664012|OTHER|Electronic Menthol Cigarette #2|VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)
214965975|NCT02664012|OTHER|Electronic Menthol Cigarette #3|VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
214965976|NCT02664012|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
214965977|NCT01018758|DRUG|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
214965978|NCT06049446|DEVICE|Pintuition|Magnetic seed localization
214965979|NCT02879955|OTHER|Glucose + Fructose|Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
214965980|NCT02879955|OTHER|Sucrose|Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
214356251|NCT06469710|DEVICE|leukapheresis|Leukapheresis employs the density differential between leukocytes and other blood components to selectively separate leukocytes and return all other components of the blood to the patient. It can process multiple blood volumes in the body circulation, thereby enabling the concentration of nucleated cells to be significantly increased. The procedure is performed while maintaining no significant change in the patient's circulating blood volume, and it is a routine clinical procedure that is well tolerated and safe. CTC can be greatly enriched in a concentrated sample of leukocytes because it has a similar density to that of leukocytes and other nucleated cells. The density of CTCs is similar to that of nucleated cells, such as leukocytes, which enables their enrichment in single leukocyte concentrate samples.
214965981|NCT02879955|OTHER|Isomaltulose|Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
214965982|NCT02879955|OTHER|Sucrose + Acarbose|Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
214965983|NCT01116037|DEVICE|ATS 3f Aortic Bioprosthesis|Equine Pericardial Bioprosthesis for replacement of diseased valve
214965984|NCT02309970|DRUG|acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran|subject in this group will receive oral treatment with anti platelet drug
214965985|NCT02309970|DRUG|alteplase|subject in this group will receive intravenous tPA
214965986|NCT02309970|PROCEDURE|endovascular|
214965987|NCT00973583|DIETARY_SUPPLEMENT|vitamin D|vitamin D3 400 IU daily
215081287|NCT02156557|BIOLOGICAL|Colon KCC Heptapeptide|"* Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~* The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~* The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~* We will obtain copies of your endoscopy report and any pathology reports."
215081288|NCT02295215|OTHER|Exercise|Exercise Training for 4 months
215081289|NCT00620425|DRUG|Sumatriptan|injection
215081290|NCT01990430|BEHAVIORAL|Exercise Intervention|"Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer."
215081291|NCT00324428|PROCEDURE|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
214356252|NCT03676855|PROCEDURE|bladder dissection|Comparison between bladder dissection at the beginning of cesarean section For morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy
214356253|NCT01436825|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
214965988|NCT00973583|DIETARY_SUPPLEMENT|placebo|placebo
214965989|NCT03452462|DEVICE|Pacing|Programming of either Direct His Bundle pacing or biventricular pacing
214965990|NCT06169306|PROCEDURE|throat pack|Following endotracheal intubation, one saline soaked, throat pack will inserted into the hypopharynx under direct vision. The packs will record in writting on the anaesthesia safety form.
214965991|NCT02258217|DRUG|Acthar|Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
214965992|NCT02923583|BIOLOGICAL|M834|
214965993|NCT02923583|BIOLOGICAL|US-Sourced Orencia®|
214965994|NCT02923583|BIOLOGICAL|EU-Sourced Orencia®|
214965995|NCT03297229|BEHAVIORAL|Peer mentoring|Peers will be assigned to participants according to common socio-demographic characteristics. Each peer will be assigned up to 5 participants.
214965996|NCT03297229|BEHAVIORAL|Self-monitoring|"Along with providing patients with a BP monitor, a commitment contract will be signed, in which participants commit themselves to measure their blood pressure at home at least once a week during the 3 months of the intervention. Each participant will be given a form to weekly recording their blood pressure values."
214965997|NCT02266823|BEHAVIORAL|Social Cognitive Theory|The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
214965998|NCT04987463|DRUG|Vigabatrin|Vigabatrin in capsules administered orally, initially (between V1 and V2) once daily in the evening,and starting from V2 administered two times daily.
214965999|NCT04987463|DRUG|Rapamycin|Rapamycin in liquid administered orally, in the morning, every other day or daily depending on the patient's body weight. The starting dose of rapamycin will be calculated according to the body weight of the patient measured at V1.
214966000|NCT04987463|DRUG|Placebo|Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.
214966001|NCT04987463|DRUG|Placebo|Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
215081292|NCT01094314|OTHER|embryo culture medium|comparison between two types of embryo culture medium
214356254|NCT01180855|DRUG|Placebo|Placebo pill nightly for 42 nights.
214356255|NCT01180855|DRUG|Rozerem 8mg|Rozerem 8mg pill, nightly for 42 nights
214356256|NCT01180855|OTHER|Rozerem 8mg in combination with Multi Component Behavior Therapy|Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
214356257|NCT03151005|DRUG|Metformin-GLP-1 Receptor Agonist|metformin oral with exenatide/liraglutide subcutaneous injection.
214966002|NCT02770638|DEVICE|Scoop Stretcher|Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
214966003|NCT02770638|DEVICE|Long Back Spinal board|Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
214966004|NCT01142934|DEVICE|Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)|The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.
215081293|NCT03649373|PROCEDURE|Noergaard technique|The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
215081294|NCT01044212|DRUG|Docusate|Docusate 100mg BID
214966005|NCT01361750|PROCEDURE|gastric tube|the stomach will be cut into a narrowed tube-shape conduit
215081295|NCT01044212|DRUG|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
215081296|NCT06511557|DEVICE|Non immersive virtual reality ( xbox kinetic)|"Treatment starts with a gentle warm-up i.e. hot pack for 10 minutes and gentle stretching of Quadriceps, hamstrings and calves. Each game was performed for 10 minutes with 1 minute rest between games. 3 sessions Per Weeks for 8 weeks (45 Min per Session) were given. All the exergames target muscles like Hamstring, Quadriceps and calves to improve function of knee joint and reduce pain.~Baseline assessment was done at the start of the session and proper cool down and stretching will be performed at the end of each session to promote flexibility and reduce muscle soreness"
214356258|NCT03151005|DRUG|Metformin-Oral Contraceptive(OC)|metformin with Diane 35 oral intake.
214356259|NCT01263951|DRUG|Everolimus|One 5 mg. tablet daily.
214487314|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
215081297|NCT06511557|OTHER|Kinetic chain exercises|Session starts with a gentle warm-up i.e. Hot pack for 10 minutes and gentle stretching. Each exercise is performed in 2 sets, each set of 10 repetitions with 1min rest between sets. 3 sessions Per Weeks for 8 weeks (45 Min Per Session) were given .Kinetic chain exercises involve integrated movements that engage multiple joints and muscle groups \& focus on strengthening muscles like quadriceps, hamstrings, glutes, and calf muscles, improving joint stability, function, and reducing pain. Baseline assessment was done at the start of the session and proper cool down and stretching was performed at the end of each session to promote flexibility and reduce muscle soreness
215081298|NCT06036160|OTHER|Integrated care|Psychiatric follow-up, cognitive behavioral therapy, physical exercise, psychoeducation
215081299|NCT02495246|BIOLOGICAL|ChAd3-EBO-Z|
215081300|NCT02495246|BIOLOGICAL|Ad26.ZEBOV|
215081301|NCT02627547|BEHAVIORAL|Normal training|5-10 hours of endurance training each week
214356260|NCT01263951|DRUG|Sorafenib|200 mg. twice daily.
214356261|NCT05090709|OTHER|Spinal Mobilisation Intervention|30 minutes spinal mobilisations, rate = 0.37Hz, 22 beats per minute, force = less than grade 1, threshold of 80N, location = L1-L5.
214356262|NCT05090709|OTHER|General Massage|30 minutes manual touch with no specifications or recordings on rate, pressure or location of touch.
214356263|NCT01959451|DRUG|Prasugrel|see Arm description
214356264|NCT01959451|DRUG|Clopidogrel|see arm description
214356265|NCT03531047|PROCEDURE|Customised CXL|As for standard CXL, following mechanical removal of the corneal surface layer (epithelium), 0.1% riboflavin drops will be applied every 2 minutes for 10 minutes prior to ultraviolet A (UVA) irradiation - UVA power, distribution and timing as determined by analysis of Pentacam tomography scans. A bandage contact lens will be applied to encourage regrowth of the corneal surface and reduce post-operative pain.
214356266|NCT04855422|DIAGNOSTIC_TEST|Allosure|AlloSure Analysis For the AlloSure test, 10-20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) at ambient temperature in insulated packaging to minimize temperature fluctuation. The AlloSure test will be performed at the CareDx CLIA/CAP-accredited clinical laboratory. Samples will be tested, and results provided within 3 days of blood draw
214487315|NCT05470075|DRUG|Tramadol hydrochloride SR Tablets|Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
214487316|NCT05470075|DRUG|Placebos|Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
214679029|NCT01240811|DRUG|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
214679030|NCT01240811|DRUG|Levonorgestrel IUD|
214356267|NCT04855422|DIAGNOSTIC_TEST|AlloMap|AlloMap Kidney is intended to aid in the identification of SPK transplant recipients who have a low probability of rejection at the time in testing in conjunction with standard clinical assessment. For the AlloMap-Kidney test, approximately two tubes of blood will be obtained in PAXgene Blood RNA tubes and shipped to CareDx, Inc. (Brisbane, CA), where it will be tested.
214966006|NCT02447445|PROCEDURE|Grip strength assessment|Grip strength will be measured by the ward nurse using a Jamar dynamometer by asking the patient to squeeze with each hand twice, starting with the right hand using the standardised protocol The maximum GS measurement will be recorded. Patients who have low maximum GS values (men \< 27 kg and women \<16 kg) or those who are unable to perform the test will receive a care plan. The care plan will focus on review of dietary energy and protein intake and any need for oral nutritional supplements or dietetic review, and review of mobility with any need for physiotherapy review with regard to progressive resistance exercises to increase muscle strength.
214966007|NCT00488423|PROCEDURE|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test \& hyperglycemic clamp to assess insulin secretion \& sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp \& mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting \& specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass \& gastric banding.
214966008|NCT05775601|DRUG|18F-LY3950321|3 millicuries (±1 mCi)
214966009|NCT05775601|PROCEDURE|PET Scan|positron emission tomography (PET) scan
214966010|NCT03718390|DRUG|Formulation A|Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
214966011|NCT03718390|DRUG|Formulation B|Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
214966012|NCT03718390|DRUG|Formulation C|Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
214966013|NCT03718390|DRUG|Formulation D|Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
214966014|NCT03718390|DRUG|Formulation E|Placebo Capsule containing microcrystalline cellulose
214966015|NCT03718390|PROCEDURE|Endoscopy|Endoscopy at 2 hours post dosing
214356268|NCT01010594|BEHAVIORAL|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
214356269|NCT01010594|BEHAVIORAL|dietary treatment|A standard dietary treatment.
214356270|NCT04221997|DRUG|sertraline|Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)
214679031|NCT01240811|DRUG|Copper T380A IUD|
214966016|NCT03718390|PROCEDURE|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
214966017|NCT02532374|OTHER|Nicorette® inhalator|Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).
214966018|NCT02532374|OTHER|P3L|Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).
214966019|NCT02254772|BIOLOGICAL|Ipilimumab|A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
214356271|NCT03968913|DRUG|Anakinra injection|anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
214966020|NCT02254772|DRUG|SD-101|Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
214966021|NCT02254772|RADIATION|Radiation therapy|Undergo low-dose radiation therapy to 1 site of disease
214966022|NCT04288947|OTHER|Disrespect and Abuse in Maternity Care|Changing the culture of disrespect and abuse in maternity care
214966023|NCT05225558|DRUG|Delpazolid|BID, PO
214966024|NCT05225558|DRUG|Vancomycin|IV infusion per 2020 IDSA guideline
214966025|NCT05225558|DRUG|Placebo of Delpazolid|BID, PO
215081302|NCT02627547|BEHAVIORAL|De-training|No training
215081303|NCT06415981|DEVICE|Hypoglossal nerve and/or Ansa Cervicalis stimulation|Device stimulation of the hypoglossal nerve and/or Ansa Cervicalis
214966026|NCT05453110|BEHAVIORAL|Deadlift Form Education|The education will include information about the lumbar spine as it relates to a deadlift. The researchers will administer this education shortly prior to participants taking a strength test.
214966027|NCT03904420|OTHER|Clinical Education and Treatment Model|Patients will have self directed equipment education and standardized programming approaches
214966028|NCT03904420|OTHER|Traditional Model|Standard clinical practice and education
214356272|NCT03968913|PROCEDURE|sterile saline injection|5 milliliters of sterile saline will be injected into the knee joint
214393706|NCT04054895|DEVICE|Lead is placed in a tributary of the coronary sinus.|Biventricular Resynchronization Therapy is the use of a pacemaker with two endocardial leads placed in the right atrium and right ventricle. The third lead is placed in a tributary of the coronary sinus.
214393707|NCT02004860|DRUG|Protopic (R)|Protopic® 0.1% ointment - 2 applications per week for 6 months
214393708|NCT02004860|DRUG|Mycoster (R)|Mycoster 1% - 2 applications per week for 6 months
214393709|NCT00697021|DRUG|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
214393710|NCT00697021|DRUG|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
214393711|NCT02360774|DRUG|Canagliflozin|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
214393712|NCT02360774|DRUG|Placebo|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
214393713|NCT02139982|PROCEDURE|specific nerve block|specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
214393714|NCT02139982|DRUG|ropivacaine|Different concentration of ropivacaine
214487317|NCT06912477|DIAGNOSTIC_TEST|Hyperspectral imaging|"Hyperspectral imaging will be performed at study inclusion and will be repeated longitudinally every 1-2 days until delivery and on the first and second day after delivery. After a baseline measurement, a blood pressure cuff is inflated on the upper arm to 50 mmHg above the systolic blood pressure for 5 minutes, and then the hyperspectral imaging measurement is repeated.~Blood samples are collected at study inclusion and on the first and second day after delivery and are processed within the Department of Gynecology and Obstetrics of the Heidelberg University Hospital."
214966029|NCT03006562|DRUG|Subcutaneous Heparin|5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.
214966030|NCT00584584|DRUG|QAX576|
214487318|NCT06912477|DIAGNOSTIC_TEST|Further markers of endothelial dysfunction|"At study inclusion: 1. blood samples will be collected for the measurement of EASIX and cardiac/endothelial markers; 2. sublingual in vivo microscopy will be performed (requires about 20 minutes and can be compared to a sublingual temperature measurement); 3. Doppler ultrasound will be performed to evaluate uterine and ophthalmic arteries.~Blood samples will also be collected at the first and second day after delivery."
214966031|NCT00584584|DRUG|Placebo|
214966032|NCT00078013|DRUG|MCC-135|
214966033|NCT03583658|DRUG|ambroxol BIH1526|Pharmaceutical form: lozenges Route of administration: oromucosal
214966034|NCT03583658|DRUG|placebo|Pharmaceutical form: lozenges Route of administration: oromucosal
214966035|NCT05793749|BEHAVIORAL|Prophylactic lymphedema treatment|1\. perform manual lymphatic drainage twice a week after the start of radiotherapy for a total of 10 times, and wear lymphedema compression stockings after each manual lymphatic drainage, 2. teach patients how to care for their skin. 3. perform functional exercises for lymphedema of the lower extremities twice a day for 15 \~ 20 minutes each time. 4. follow up observation: before the start of radiotherapy, every Friday during radiotherapy, and every 3 months after the end of radiotherapy, the occurrence of lymphedema and related symptoms and quality of life were evaluated.
214966036|NCT00553488|DRUG|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
214966037|NCT00553488|DRUG|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
214966038|NCT02702089|PROCEDURE|Rectal cancer surgery|Rectal cancer resection
214679032|NCT04907006|DRUG|SY-004 capsule|After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule（80mg） orally with 240ml warm water. The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
214966039|NCT01042834|OTHER|Air pollution study on healthy volunteers.|"The subjects are examined three times:~* First the volunteers get used to equipments.~* Second and third the volunteers sleep in a pollution or purified air."
214966040|NCT02025192|DRUG|Tucatinib|Administered twice per day, orally.
214966041|NCT02025192|DRUG|Capecitabine|1000mg/m\^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.
214966042|NCT02025192|DRUG|Trastuzumab|Administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
214966043|NCT01734447|DRUG|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
214966044|NCT01734447|DRUG|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
214966045|NCT01734447|DRUG|somatropin|2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
214966046|NCT03576339|PROCEDURE|Free Gingival Graft|Free gingival graft removal from palate for socket preservation
214966047|NCT03576339|DEVICE|SHAM Electric stimulation|Simulation of electric stimulation protocol for 120 seconds once a day in five consecutive days. In Sham stimulation non current will be applied.
214966048|NCT03576339|DEVICE|Electric Stimulation|Local Electric Stimulation for 120 seconds once a day in five consecutive days.
214966049|NCT03280485|OTHER|no intervention|no intervention validation of guidelines via database
214966050|NCT03747393|BEHAVIORAL|DoD/VA CPG Core Set + PT|Participants randomized to receive the core set management class and physical therapy will be scheduled for their initial physical therapy evaluation approximately 1 week from their enrollment date. The purpose of the evaluation will be to identify relevant impairments that can be addressed during the physical therapy treatments. After this initial evaluation, the goal is for the patient to receive approximately 4 weeks of physical therapy (about 8-10 sessions in the clinic 2-3 times per week). Consistent with a pragmatic study we will not use placebos to blind patients or attempt to balance provider contact.
215081304|NCT00387738|BIOLOGICAL|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
214966051|NCT03747393|BEHAVIORAL|DoD/VA CPG Core Set|The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.
214966052|NCT06238024|DRUG|Tocilizumab|Single dose intravenous application
214966053|NCT06238024|DRUG|NaCl 0.9% 100ml|Single dose intravenous application
214966054|NCT03035565|BEHAVIORAL|Computerized Cognitive Training with Brain HQ|Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
215081305|NCT00387738|BIOLOGICAL|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
214966055|NCT03035565|BEHAVIORAL|Computerized Crossword Puzzles|Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
214966056|NCT03555487|DRUG|18F-choline PET|5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
214966057|NCT05704868|BEHAVIORAL|UniVRse + TAU|"UniVRse uses well-established evidence-basedcognitive behavioural therapy (CBT) techniques - specifically graded exposure - to reduce fear and worries about social situations. People work towards overcoming their anxiety in a step-by-step fashion, building up to the most feared situation. In the context of UniVRse, students will be presented with four university-based scenarios that our coproduction team identified as being the most anxiety-induing for students:~1. Attending a lecture;~2. Group work in a seminar;~3. Delivering a presentation;~4. Contributing to an online seminar.~The UniVRse programme has been designed with our co-production team comprised of tirst-generation students with social anxiety, CBT therapists, and a VR design company."
214966058|NCT00447772|BIOLOGICAL|Botulinum toxin type A|Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
214356273|NCT05240716|OTHER|FES program|8 weeks intervention. 3 sessions per week. Previous to the intervention, volunteers will familiarize with the electrical stimulation by receiving three trials of the stimuli. Electrical current intensity will be set for each volunteers, with the capacity of generating a muscle contraction without inducing discomfort in the volunteer. During the FES program, patient in standing position will perform a step, while electrical current stimulation will be applied to the skin over the tibial nerve on the contralateral of the stimulation side. The FES will be delivered during the paretic plantarflexor activation according to the gait cycle. The FES session will consist of 5-minutes stimulation blocks with breaks between blocks (total session time: 30 minutes). For safety reasons, a physical therapist will supervise all the FES intervention sessions.
214356274|NCT04651023|DIETARY_SUPPLEMENT|Nelumbo nucifera Leaf Extract|Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
214356275|NCT04786444|BIOLOGICAL|Biological Vaccine VLA1553|Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate
214966059|NCT04577989|OTHER|data collection|data collection for treatment strategies (cefepime vs. piperacillin/tazobactam vs. carbapenems) of infections caused by AmpC beta-lactamase producing Enterobacterales for the period January 1st , 2015 until July 31st , 2020.
214966060|NCT00716456|DRUG|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
214356276|NCT02403726|PROCEDURE|Operation|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
214356277|NCT02403726|PROCEDURE|Non-operative treatment|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
214356278|NCT03752229|DEVICE|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356279|NCT03752229|DEVICE|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356280|NCT03752229|DEVICE|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966061|NCT02177929|OTHER|adapted canoeing, hadbike and conventional physiotherapy|"The subjects adapted canoeing group will practice on the kayak and rowing exercises associating with ball.~The individuals in the group will handbike workouts outdoors and surpassing cirucuitos mounted with cones.~Individuals in the conventional physiotherapy group will make stretching and strengthening exercises."
215081306|NCT05734053|OTHER|Nilotinib|There was no treatment allocation. Patients administered Nilotinib by prescription could be enrolled.
214356281|NCT03752229|DEVICE|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356282|NCT03752229|DEVICE|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214679033|NCT00104494|DRUG|Zinc acetate (20mg/d)|Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
214679034|NCT04496791|DEVICE|RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
214679035|NCT00006360|DRUG|radioprotection|
214679036|NCT00006360|RADIATION|radiation therapy|
214679037|NCT06290830|BEHAVIORAL|Abdominal massage group|abdominal massage creates reflex and mechanical movement of the intestines by applying pressure to the rectum and changing intra-abdominal pressure.
214966062|NCT05861830|DRUG|The combination of Dalpiciclib with physician-selected endocrine therapy|"* Dalpiciclib: 150 mg, orally, once daily, on days 1-21, every 28 days (3 weeks on, 1 week off)~* Letrozole: 2.5 mg, orally, once daily (continuous), every 28 days OR Anastrozole: 1.0 mg, orally, once daily (continuous), every 28 days OR Exemestane: 25 mg, orally, once daily (continuous), every 28 days OR Fulvestrant: 500 mg, intramuscular injection on day 1/15 of the first cycle, then on day 1 of each subsequent cycle, every 28 days OR Tamoxifen: 10-20 mg, orally, twice daily (continuous), every 28 days~* Pre/perimenopausal women also require ovarian function suppression (OFS), which can be achieved through bilateral oophorectomy or the use of gonadotropin-releasing hormone (GnRH) analog drugs"
214966063|NCT05861830|DRUG|Chemotherapy selected by the physician|The chemotherapy regimen is chosen by the clinical physician and may include, but is not limited to, the following options: the combination of paclitaxel and capecitabine, the combination of paclitaxel and carboplatin, single-agent capecitabine, single-agent platinum drugs, and the combination of gemcitabine and platinum-based chemotherapy. Each treatment cycle consists of a 21-day duration.
214966064|NCT04651998|DIAGNOSTIC_TEST|MMSE, MoCA, functional near-infrared spectroscopy|MMSE and MoCA are used for cognitive test before carotid artery stent implant and 6 months later. Cerebral blood oxygenation is evaluated by functional near-infrared spectroscopy under the mental task before and after revascularization within one week, 6 months later respectively.
214966065|NCT01429467|DEVICE|Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)|Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
214966066|NCT04046068|PROCEDURE|ComfortSafe Care|In most cases, sevoflurane, an inhalation anesthetic, will be used in higher-than-traditional concentrations to replace opioids and provide safe control of vital signs along with amnesia and analgesia. Intravenous (IV) propofol, esmolol, and other beta-blockers can also be administered to prevent increases in BP and HR during surgery. At the time of wound closure, the ComfortSafe Pyramid derived Preemergence Analgesic Checklist guides the anesthesia and surgical teams through collaborative decisions for implementation of a multimodal analgesic plan. Local anesthetics, including liposomal bupivacaine, can then be injected and IV non-opioid analgesics administered allowing the patient to awaken comfortably from anesthesia. Standardized kits for liposomal bupivacaine administration will be utilized. If the patient does have pain, IV opioids can be administered to provide immediate relief without hesitation since the non-opioid analgesics have already been given.
214966067|NCT02137941|BEHAVIORAL|techniques to optimize potential (TOP)|The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
214966068|NCT02137941|BEHAVIORAL|heart coherence (HC)|The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
214966069|NCT01963702|DRUG|Docetaxol|
214966070|NCT01963702|DRUG|Oxaliplatin|
214966071|NCT01963702|DRUG|Capecitabine|
214966072|NCT03826017|DIETARY_SUPPLEMENT|Catechin high contain greentea extract|Catechin high contain greentea extract 260 mg/day for 12 weeks.
214966073|NCT03826017|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
214966074|NCT05947604|DRUG|Acoziborole|Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12
214966075|NCT05947604|DRUG|Midazolam|• Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21
214966076|NCT05947604|DRUG|Dextromethorphan|• Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14
214966077|NCT01971814|DRUG|Infliximab|All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.
214966078|NCT00710255|PROCEDURE|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
214966079|NCT02975401|PROCEDURE|rTAPP technique|robot-assisted rTAPP technique
214966080|NCT00572260|DRUG|daptomycin 6 mg/kg IV|daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
214966081|NCT00875563|DEVICE|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
214966082|NCT01178905|PROCEDURE|ultrashort heat inactivation|
214966083|NCT03404986|PROCEDURE|ureteroscopy|The patients will be subjected to rigid ureteroscopy
214966084|NCT03404986|RADIATION|Ultrasonography|The patients will be subjected to Ultrasonography
214966085|NCT02643641|BIOLOGICAL|BM32|BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
214966086|NCT02643641|BIOLOGICAL|Placebo|Placebo contains aluminum hydroxide only
214966087|NCT00147706|PROCEDURE|Tailored Healthmedia programs on EHR Patient Portal|
214966088|NCT02816294|BEHAVIORAL|Housing Prescription|
214679038|NCT06290830|BEHAVIORAL|Kegel Exercises group|Kegel exercises (also called pelvic floor exercises) have a functional connection with other core muscles and contribute to the synergistic effect of the abdominal and pelvic floor muscles
214679039|NCT06290830|BEHAVIORAL|Both abdominal massage and kegel exercises to gether|with both exercises are performed to accelerate the peristalsis movement by mechanical movements
214966089|NCT00920153|BIOLOGICAL|bleomycin sulfate|Given IV
214966090|NCT00920153|DRUG|ABVD regimen|Given IV
214966091|NCT00920153|DRUG|carmustine|Given IV
215081307|NCT01690546|DRUG|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
215081308|NCT01690546|DRUG|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
215081309|NCT01690546|DRUG|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
214966092|NCT00920153|DRUG|cisplatin|Given IV
214966093|NCT00920153|DRUG|cytarabine|Given IV
214966094|NCT00920153|DRUG|dacarbazine|Given IV
214966095|NCT00920153|DRUG|dexamethasone|Given orally
214966096|NCT00920153|DRUG|doxorubicin hydrochloride|Given IV
214966097|NCT00920153|DRUG|etoposide|Given IV
214679040|NCT00119301|DRUG|leucovorin calcium|
214966098|NCT00920153|DRUG|gemcitabine hydrochloride|Given IV
215081310|NCT00431886|PROCEDURE|64 multi-detector computed tomography|
215081311|NCT03076086|OTHER|Induced sputum procedure|induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
215081312|NCT01122342|DRUG|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
215081313|NCT03171246|DIETARY_SUPPLEMENT|Solid food-based intervention|Individually tailored energy content according to age/activity
215081314|NCT03282773|DEVICE|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
215081315|NCT03282773|DEVICE|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
215081316|NCT04710407|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
215081317|NCT00993109|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
215081318|NCT00993109|DRUG|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
215081319|NCT00673023|OTHER|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
215081320|NCT05990699|BEHAVIORAL|Mindfulness-Based Relapse Prevention program|"This program consists of eight sessions spanning across four weeks, each focusing on specific techniques and skills to aid in substance use disorder treatment. The first session emphasizes the correlation between the unconscious pilot and substance use, incorporating a corporeal examination technique to promote intentional concentration. The second session focuses on mindfulness to identify stimuli and observe accompanying sentiments, thoughts, and feelings. The third session introduces the ABSTEMIOUS space technique, urging patients to pause, observe their experiences, concentrate on breathing, broaden cognizance, and choose judicious responses in trying or hazardous situations. The remaining sessions address coping mechanisms for relapse risks, taking pragmatic action in high-risk situations, integrating healthy activities into life, and sustaining mindfulness practice through the development of a support network."
215081321|NCT04326725|DRUG|Plaquenil 200Mg Tablet|health workers under risk who took this medications
215081322|NCT05652231|DIAGNOSTIC_TEST|caries assessment|the child will examined for dental caries, caries prevalence, caries indices (def and DMF, or DMF)
214679041|NCT00119301|DRUG|methotrexate|
214679042|NCT00119301|DRUG|trimetrexate glucuronate|
214679043|NCT00092586|DRUG|MK0653, ezetimibe|
214966099|NCT00920153|DRUG|ifosfamide|Given IV
214966100|NCT00920153|DRUG|melphalan|Given IV
214966101|NCT00920153|DRUG|methylprednisolone|Given IV
214966102|NCT00920153|DRUG|mitoguazone|Given IV
214966103|NCT00920153|DRUG|vincristine sulfate|Given IV
214966104|NCT00920153|DRUG|vindesine|Given IV
214966105|NCT00920153|DRUG|vinorelbine tartrate|Given IV
214966106|NCT00920153|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
214966107|NCT00920153|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
214966108|NCT06405178|DRUG|Metformin|Insulin Sensitizer
214966109|NCT06405178|DRUG|Dapagliflozin|Sodium-Glucose Co-transporter-2
214966110|NCT06405178|DRUG|Dapagliflozin/Metformin|Anti diabetic drug
214966111|NCT06405178|DRUG|Letrozole|Aromataze inhibitor
214966112|NCT00060970|PROCEDURE|Physical Therapy|
214966113|NCT01730807|DEVICE|IntellaTip MiFi XP Catheter|Temperature controlled ablation catheter
214966114|NCT02945826|DRUG|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
214966115|NCT02945826|DEVICE|PET/MRI|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
214966116|NCT01339871|DRUG|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
214966117|NCT01339871|DRUG|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
214679044|NCT00092586|DRUG|Comparator: statins|
214966118|NCT05554029|DIAGNOSTIC_TEST|Coronaphobia|Coronophobia will be assessed with COVID-19-phobia scale.
214966119|NCT00827710|BEHAVIORAL|point of care patient report cards|gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
214966120|NCT00827710|BEHAVIORAL|Provider performance report card|Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
214966121|NCT00002610|BIOLOGICAL|dactinomycin|
214966122|NCT00002610|BIOLOGICAL|filgrastim|
214966123|NCT00002610|DRUG|carboplatin|
214966124|NCT00002610|DRUG|cyclophosphamide|
214966125|NCT00002610|DRUG|doxorubicin hydrochloride|
214966126|NCT00002610|DRUG|etoposide|
215081323|NCT02238431|DRUG|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
215081324|NCT02238431|DRUG|OCP|to schedule the start of the artificial cycle
214966127|NCT00002610|DRUG|vincristine sulfate|IV
214966128|NCT00002610|PROCEDURE|conventional surgery|
214966129|NCT00002610|RADIATION|radiation therapy|
214966130|NCT02266446|BEHAVIORAL|Attention & Interpretation Modification|
214966131|NCT06304571|DRUG|HC006|Specified dose on specified days
214966132|NCT05417412|BEHAVIORAL|Brief Behavioral Therapy|8-12 sessions of brief behavioral therapy administered by behavioral health / mental health staff at participating community health centers (CHCs)
215081325|NCT02238431|OTHER|Natural|to use the normal menstrual period to schedule treatment start
215081326|NCT00361699|DRUG|Statin|
215081327|NCT01991223|DRUG|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
215081328|NCT01991223|DRUG|NS infusion|Normal saline will be infused during surgery
214966133|NCT03236597|OTHER|Treadmill desk|A standing height desk with a treadmill attached.
214966134|NCT05438277|DRUG|Methylprednisolone (MPA)|injection into subacromial or glenohumeral space with MPA
214966135|NCT05438277|DRUG|Triamcinolone Acetonide (TA)|injection into subacromial or glenohumeral space with TA
214966136|NCT01217996|BEHAVIORAL|Computerized working memory training program (intervention)|A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention
214966137|NCT01217996|BEHAVIORAL|Computerized working memory training program (control)|Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
214966138|NCT02068937|DRUG|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day (1 tablet equivalent to 40 milligrams of furosemide)
214966139|NCT02068937|DRUG|Furosemide|This group received just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline.
214966140|NCT01841970|DEVICE|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
214966141|NCT03107910|BEHAVIORAL|Stigma and Structural Interventions|Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions
214966142|NCT03107910|BEHAVIORAL|Health Information Seeking|Seeking and evaluating online health information will be assessed.
215081329|NCT04503161|DEVICE|Duragen with Collagen Hydrodel and ASCs|Duragen combined with collagen hydrogel and patient's stem cells
215081330|NCT05266183|OTHER|Simultaneous Variety|3 different foods served
215081331|NCT05266183|OTHER|Single-Food|1 food served
215081332|NCT05266183|OTHER|Small Portion|Small meal portion size
215081333|NCT05266183|OTHER|Large Portion|Large meal portion size
215081334|NCT05370963|DRUG|Hylase versus dexmedtemodine|fluroscopic guided lumber epidural injection
215081335|NCT05517369|PROCEDURE|Hybrid ESD+|Injection of the Lift Up solution, followed by circumcision of the lesion using a snare tip or ESD knife. Using an additional working channel (AWC), the lesion is resected using a grasper and snare.
215081336|NCT01323270|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
215081337|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
215081338|NCT01323270|BIOLOGICAL|Saline|0.5 mL dose, given at 0, 2 and 6 months.
215081339|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
215081340|NCT03404804|DRUG|Amoxicillin|Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
215081341|NCT01269359|PROCEDURE|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
215081342|NCT03409211|DIETARY_SUPPLEMENT|PEVCO|All subjects will receive PEVCO for 6 more weeks.
215081343|NCT03409211|DIETARY_SUPPLEMENT|Dietary Supplement Capsules without Coconut Oil|All subjects will receive placebo (PBO) for 3 weeks
215081344|NCT06162546|OTHER|Registry|Registry Participation, providing data and clinical specimen
215081345|NCT00823745|DRUG|[14C]-PF-00868554|solution, single dose
215081346|NCT00711347|DEVICE|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
215081347|NCT00711347|DEVICE|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
214966143|NCT02592447|OTHER|Therapy for Targeted Therapy-related Fatigue (TTF)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
214966144|NCT02592447|OTHER|Wait-List Control Condition (WLC)|Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
214966145|NCT00132080|DRUG|Steroids|This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
214966146|NCT00750113|DRUG|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
214966147|NCT00750113|DRUG|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
214966148|NCT00750113|DRUG|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
214966149|NCT03692429|DRUG|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
214966150|NCT03692429|DRUG|FOLFOX|5-FU, leucovorin and oxaliplatin
214966151|NCT03692429|DRUG|FOLFIRI|5-FU, leucovorin and irinotecan
215081348|NCT01061047|DRUG|Ertapeneme|
215081349|NCT02360644|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
215081350|NCT03720665|COMBINATION_PRODUCT|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
215081351|NCT03556098|DRUG|glucose-dependent insulinotropic peptide|Infusion of GIP
215081352|NCT03556098|DRUG|Glucose-Dependent Insulin-Releasing Hormone[3-30]|Infusion of GIP antagonist GIP\[3-30\]
215081353|NCT03556098|DRUG|Saline Solution|Infusion of Saline
215081354|NCT03761394|DEVICE|Testing Devices|Pulsewatch system testing application on smartphone with smartwatch.
215081355|NCT03761394|DEVICE|Cardea Solo by Cardiac Insight|Gold-standard cardiac monitor for comparison of testing devices.
214966152|NCT03308240|BEHAVIORAL|Magic Therapy|As described in the arm description
214966153|NCT02652169|DRUG|PRF mixed with amikacin and teicoplanin|PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
214966154|NCT02652169|DRUG|PRF mixed with PHMB plus Macrogolol|PRF, mixed with Lavasorb is applied to the chronic ulcer
214966155|NCT02652169|DRUG|PRF plus normal saline|PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
215081356|NCT03761394|DEVICE|Kardia Mobile by AliveCor|Mobile ECG device for comparison of testing devices during the extended use period.
215081357|NCT04326244|DIAGNOSTIC_TEST|blood test|High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
215081358|NCT04326244|DIAGNOSTIC_TEST|genetic test|FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
215081359|NCT04326244|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Constitution in Chinese Medicine Questionnaire
215081360|NCT04326244|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale
215081361|NCT04326244|DIAGNOSTIC_TEST|cephalometry|Evaluation of craniofacial morphology in OSA patients
215081362|NCT04326244|DIAGNOSTIC_TEST|polysomnography|to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
215081363|NCT04069377|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
215081364|NCT04069377|OTHER|Manuel chest compressions by human efforts|In this way chest compressions will be handled by humans themselves.
215081365|NCT03112746|BEHAVIORAL|Cognitive Orientation to Daily Occupational Performance|In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
215081366|NCT01369082|DRUG|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
215081367|NCT06299982|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W (5 cycles)
214966156|NCT02652169|OTHER|Silver gauze|Acticoat 7 silver wound dressing is applied to the chronic ulcer
214966157|NCT03278496|BEHAVIORAL|Recovery Housing plus Counseling|Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.
214966158|NCT03278496|BEHAVIORAL|Usual Care Referral|Participants are referred to an outpatient program of their choosing with an appointment made for them.
215081368|NCT06299982|DRUG|608 Q4W|608 160 mg Q4W (3 cycles)
214966159|NCT03278496|BEHAVIORAL|Recovery Housing Only|Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
214966160|NCT00902655|DRUG|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
214966161|NCT05410678|DRUG|Renal stent|renal stent implantation in ectatic/aneurysmatic coronary arteries
214966162|NCT05926648|DEVICE|INVSENSOR00061|Noninvasive pulse oximetry and pulse rate device
214966163|NCT00261755|PROCEDURE|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
214966164|NCT00261755|OTHER|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
214966165|NCT00261755|OTHER|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
214966166|NCT05648903|OTHER|Total diet replacement|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly to 12 months. The TDR products will be provided to participants free of charge. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks but participants would have to self-fund these products.
214966167|NCT05648903|OTHER|Low-carbohydrate diet|Participants who choose this intervention will be supported to undertake a low-carbohydrate diet. During the first 12 weeks of the programme patients will be supported to consume below 100g carbohydrate per day, whilst being encouraged to increase protein, choose predominantly unsaturated fats alongside a high intake of non-starchy vegetables and low-carbohydrate fruits. After 12 weeks patients will be able to increase their carbohydrate intake up to 130g per day. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 100g carbohydrate for an additional 4 weeks.
214966168|NCT05648903|OTHER|Intermittent fasting 5:2|"Participants will have the option to follow a 5:2 dietary approach whereby calories are significantly reduced on two days of the week to 500 calories per day for women and 600 calories per day for men. The placement of the fasting days can vary each week, but there must be two fasting days in each seven-day period. After 12 weeks, patients will have the option of continuing with the 5:2 approach for further weight loss or adopting a 6:1 approach whereby patients would only fast on 1 day in each seven-day cycle for weight maintenance. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 5:2 approach for an additional 4 weeks."
214966169|NCT02849743|DRUG|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
214966170|NCT02849743|DRUG|Placebo (for Syntocinon)|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
214966171|NCT00594776|DEVICE|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
214966172|NCT04936503|DIAGNOSTIC_TEST|Resting electrocardiogram|An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
214966173|NCT04936503|DIAGNOSTIC_TEST|Stress test|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
215081369|NCT01070563|OTHER|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
214966174|NCT04936503|DIAGNOSTIC_TEST|Cardiac echocardiography|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
214966175|NCT04936503|DIAGNOSTIC_TEST|Cardiac rhythm monitoring|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
214966176|NCT04936503|OTHER|Questionnaire|To determine the rhythmic risk of athletes
214966177|NCT04936503|DEVICE|Injected Cardiac MRI|"High resolution MRIs is performed on 200 athletes :~* 100 athletes without rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)~* 100 athletes with rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)"
214966178|NCT04936503|BIOLOGICAL|Blood sampling for biobank|"For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage.~For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers)."
215081370|NCT00174174|DRUG|Modafinil|
215081371|NCT00823992|DRUG|placebo|sc once weekly
215081372|NCT00823992|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
215081373|NCT02636244|DRUG|SHAPE Gel|
215081374|NCT02147223|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
215081375|NCT02147223|DIETARY_SUPPLEMENT|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
215081376|NCT05357664|DEVICE|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
214356283|NCT03752229|DEVICE|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356284|NCT03752229|DEVICE|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356285|NCT03752229|DEVICE|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356286|NCT03752229|DEVICE|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966179|NCT05682417|DEVICE|Body Map Assessment Tool: MOVE Tool|"In VR, a spherical object approaches with linear trajectory the body of patients, it can be sent to 4 parts of the body (mid-arm/waist/hip/mid-thigh) both left and right side. Several conditions are presented, either the trajectory leads the object to touch the body, or it passes at ≠ distances from it. Patient is instructed to move only if he thinks the object will touch his body.~Procedure begins with a measurement taken on 3 body locations via the Move tool (shoulders/hips/thighs) to create an avatar allowing the tool to determine whether or not movement was necessary. Then, the movement of the patient is recorded. For each object/body distance, the software determines if dodging was necessary. The overestimation of the body schema corresponds to the average distance from which the patient considers that the object would have touched her body and performs a dodging movement, compared to her real morphological dimensions. This generates a body limit distortion % for each body area."
214966180|NCT05682417|OTHER|PAQ questionnaire|This questionnaire has been translated and validated (French version, Luminet et al., 2021). This is a self-reported measure of alexithymia in 24 items. It is designed to measure all the components of alexithymia for both negative and positive emotions. Five subscale scores and six composite scores can be obtained from the questionnaire, with high scores indicating higher levels of alexithymia.
214966181|NCT05682417|OTHER|F-DFlex questionnaire|This questionnaire (Detail and Flexibility Questionnaire, French version of Maria et al, 2020) assesses cognitive rigidity. This questionnaire assesses two frequently impaired cognitive dimensions in people with anorexia nervosa, central coherence and cognitive flexibility in daily functioning using 20 self-completed items.
214966182|NCT05682417|OTHER|BSQ questionnaire|"The Body Shape Questionnaire (BSQ, translated and validated in French by Rousseau et al., 2005) is a one-dimensional Anglo-Saxon self-questionnaire of 34 items that assesses concerns about body shape over the past four weeks. Responses are scored on a 6-point Likert scale. A score of 1 (never) means the problem is not present, up to a score of 6 (always) which means the problem is always present. The higher the score, the more the concern/dissatisfaction with one's body tends to be pathological."
214966183|NCT05682417|OTHER|Silhouette testing|Body overestimation is assessed by the computerized silhouette test (adapted from Gardner \& Brown, 2010, Van der Linder et al., 2017). Twenty-seven Body Mass Index silhouettes ranging from 11 to 40 are presented to participants in random order. For each silhouette presented, the participant answers whether or not the silhouette presented corresponds to her current silhouette. A body underestimation index is calculated as follows: Estimated figure average BMI - actual BMI.
214966184|NCT05682417|OTHER|Eating Disorder Inventory - 2|"Allows self-assessment of symptoms of eating disorders. It is composed of 91 questions grouped into 11 subscales that assess specific cognitive and behavioral dimensions: desire for thinness, bulimia, body dissatisfaction, feeling of inefficiency, perfectionism, interpersonal distrust, interoceptive sensitivity, fears relating to maturity, asceticism. , impulsiveness and social insecurity. For each item, participants can answer always, usually, often, sometimes, rarely or never. The score for each item is between 0 and 3. The subscale scores are calculated by simply adding all the item scores for each specific subscale. This questionnaire has demonstrated good internal consistency, test-retest reliability, and validity (Garner, 1991)"
214966185|NCT05682417|OTHER|EDEQ questionnaire|"Or Eating Disorders Examination - Questionnaire (Fairburn \& Beglin, 2008). This questionnaire assesses eating behaviors and concerns about weight and body shape, using 28 items focusing on these aspects over the past 28 days."
214966186|NCT05682417|OTHER|STAI questionnaire|The Spielberger Anxiety Scale (STAI) State and Trait. This questionnaire includes two distinct scales: one evaluating the current state of anxiety (STAI form Y-A: feelings of apprehension, tension, nervousness and worry that the subject feels at a precise precise moment) and the second evaluating the anxious personality trait (STAI form Y-B: feelings of apprehension, tension, nervousness, and worry that the subject usually feels). The Y version was developed in order to eliminate the items having appeal to depression compared to the initial form. Each scale has 20 items. This questionnaire has good psychometric qualities regarding validity, reproducibility and inter-individual sensitivity. It correlates well with other anxiety questionnaires in a literature review of anxiety questionnaires (Elwood, 2012).
215081377|NCT05357664|DEVICE|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
215081378|NCT00005764|DRUG|Lamivudine/Zidovudine|
214356287|NCT03752229|DEVICE|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356288|NCT03752229|DEVICE|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
215081379|NCT00005764|DRUG|Abacavir sulfate|
214356289|NCT03752229|DEVICE|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966187|NCT05682417|OTHER|BECK questionnaire|Beck Depression Inventory (Beck, 1987). The inventory is composed of items related to depressive symptoms as well as physical symptoms. This is a questionnaire that gives a quantitative estimate of the intensity of depression. Investigators will use the abbreviated version consisting of 13 items, each item comprising 4 sentences corresponding to 4 degrees of increasing intensity of a symptom on a scale of 0 to 3. The total score corresponds to the sum of the different items and makes it possible to judge the presence of depression and its intensity.
214966188|NCT00002293|DRUG|Nystatin|
214966189|NCT05865223|OTHER|Mckenzie exercise program|MacKenzie extension exercise program for cervical spine
214966190|NCT05865223|OTHER|Conventional Physical therapy|hot pack for 15 minutes will be given followed by joint mobilization,and home exercise program.
214966191|NCT04868669|BEHAVIORAL|In-home, intensive nutrition counseling|"* Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)~* The messages to be provided through the counseling will be contextualized~* Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation~* Counseling sessions will be conducted at the participant's place~* Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women~* Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session~* Sessions will be tailored according to each participant's need and progress"
214966192|NCT02635308|BEHAVIORAL|"Unilaterally Biased Resistance Training / MOVE"|High-intensity resistance training including: whole body movement patterns, unilaterally biased lower extremity strength training, task-oriented balance tasks
214966193|NCT02026765|DEVICE|traditional lens|A random eyes with traditional lens
214966194|NCT02026765|DEVICE|heparin surface modified aspheric lens|the other eye implant heparin surface modified aspheric lens
214966195|NCT02050334|DRUG|CC100|CC100 reconstituted in diluent
214966196|NCT02050334|DRUG|Placebo|Diluent. Amount to match CC100 dose.
214966197|NCT05831124|OTHER|Low dose multivalent pneumococcal conjugate vaccine formulation A|Biological
214966198|NCT05831124|OTHER|Low dose multivalent pneumococcal conjugate vaccine formulation B|Biological
214966199|NCT05831124|BIOLOGICAL|Low dose of multivalent pneumococcal conjugate vaccine control|low dose multivalent pneumococcal conjugate vaccine
214966200|NCT05831124|BIOLOGICAL|Standard dose multivalent pneumococcal conjugate vaccine control|multivalent pneumococcal conjugate vaccine
214966201|NCT04789525|OTHER|High-intensity aerobic training with high protein diet|High-intensity aerobic training was given with 50 to 70 % of the maximum heart rate. the intervention started with 10 mins of warm-up exercise through stretching of upper and lower limb muscles. Subsequent to stretching, the subjects were asked to do 30 mins of exercises; consisting of 20 mins on the treadmill and 10 mins of cycle ergometer at 50 to 70 % of MHR, then with 10 mins of cool down.
214966202|NCT02605759|DEVICE|CryoBalloon Focal Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
214966203|NCT05748964|PROCEDURE|Laparoscopic pyeloplasty|Twenty patients presented with ureteropelvic junction obstruction \[UPJO\] will be divided into two equal groups. The first was subjected to trans-peritoneal pyeloplasty while the second was subjected to retroperitoneal pyeloplasty.
214966204|NCT05814315|BEHAVIORAL|HOPE Intervention|Participants used the Health Checkins Platform for 12 weeks for emotional support and to obtain pain management tools
214966205|NCT05747859|OTHER|teletherapy|speech therapy remotely delivered
214966206|NCT01583413|PROCEDURE|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
214966207|NCT01983215|DEVICE|Prevena vac|
214966208|NCT06333730|PROCEDURE|inferior alveolar nerve block|After informed consent, the needle will be inserted into the muco-buccal fold adjacent to the mandibular molars and advanced it towards the mandibular foramen, aiming slightly anteriorly and superiorly. Aspirating to check for blood or resistance, the needle will be repositioned if either was present. Once the needle will be correctly positioned, the dental practitioner will slowly inject 1.8-1.9 mL of the anesthetic solution.
214356290|NCT03752229|DEVICE|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356291|NCT03752229|DEVICE|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966209|NCT06333730|PROCEDURE|mental nerve block|After informed consent, the needle will be inserted into the buccal fold between the lower premolars. Aspirating to check for blood or resistance. Once needle is correctly positioned, 0.6-0.9 ml of the anesthetic solution will be deposited.
214966210|NCT04518618|DRUG|Fentanyl|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
214966211|NCT04518618|DRUG|Naloxone|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
214966212|NCT04486508|DRUG|intermediate dose Enoxaparin/ unfractionated heparin|Intermediate dose anticoagulation according to creatinine clearance and weight
214966213|NCT04486508|DRUG|standard prophylactic dose Enoxaparin/ unfractionated heparin|Standard prophylaxis anticoagulation according to creatinine clearance and weight
214966214|NCT04486508|DRUG|Atorvastatin 20mg|Statin
214966215|NCT04486508|DRUG|Matched placebo|Matched placebo to atorvastatin 20 mg
214966216|NCT01290510|DEVICE|hyaluronic acid sodium salt|Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
214966217|NCT03509168|DRUG|Misoprostol Pfizer Brand|insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally
215081380|NCT00005764|DRUG|Lamivudine|
214356292|NCT03752229|DEVICE|Haemolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966218|NCT03509168|OTHER|Non-insertion of Misoprostol Pfizer Brand|participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.
214966219|NCT06107647|DEVICE|COVIDIEN WarmTouch|"COVIDIEN WarmTouch will be used as an active air blowing heater. Patients will be warmed starting from the beginning of anesthesia.~The INDITHERM Medical Alpha, which is a resistive heater, will be applied to patients starting at the beginning of anesthesia."
214356293|NCT03752229|DEVICE|Haemolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356294|NCT03752229|DEVICE|Haemolnace Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966220|NCT00532545|DRUG|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
214966221|NCT05201846|DEVICE|DIA:CONN G8 insulin pump|Subjects on continuous subcutaneous insulin infusion system with CGM
214966222|NCT05201846|OTHER|Multiple daily insulin injection|Subjects on multiple daily insulin injection with CGM
214966223|NCT01048541|DEVICE|Test Catheter - SpeediCath Compact Male|Compact catheter for intermittent catheterisation
214966224|NCT01048541|DEVICE|SpeediCath|Catheter for intermittent catheterisation
214356295|NCT03752229|DEVICE|Haemolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356296|NCT03752229|DEVICE|Haemolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356297|NCT03752229|DEVICE|Haemolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356298|NCT03752229|DEVICE|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966225|NCT00627497|PROCEDURE|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
214966226|NCT00627497|DEVICE|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
214966227|NCT00627497|DEVICE|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
214966228|NCT00627497|DEVICE|Fusion|Posterolateral Interbody Fusion
214966229|NCT03768778|PROCEDURE|Debridement and dural repair|
214966230|NCT01625871|DRUG|tablets artemether/lumefantrine|six doses of oral tablets of artemether/lumefantrine
215081381|NCT03000504|DEVICE|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
215081382|NCT03328169|BEHAVIORAL|Mindfulness-Based Therapy|Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.
215081383|NCT03328169|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
215081384|NCT01212211|OTHER|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
215081385|NCT04517786|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
215081386|NCT03424369|PROCEDURE|Tympanoplasty|Tympanoplasty
215081387|NCT00975104|DRUG|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
215081388|NCT00975104|DRUG|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
215081389|NCT00975104|DRUG|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
215081390|NCT00975104|DRUG|Placebo|Placebo IV QW
215081391|NCT00793429|DRUG|Prucalopride|
214356299|NCT03752229|DEVICE|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966231|NCT01372046|BEHAVIORAL|Booster Sessions|Provides onsite booster sessions for one year to the group after participating in standard care
214966232|NCT01372046|BEHAVIORAL|Training|memorandums, staff meetings
215081392|NCT00793429|OTHER|Placebo|
214356300|NCT03752229|DEVICE|ergoLance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356301|NCT03752229|DEVICE|ergoLance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356302|NCT03752229|DEVICE|ergoLance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356303|NCT03752229|DEVICE|Medlance (light blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966233|NCT04868019|DRUG|Fenofibrate Capsules|Solutions will be prepared in the required strengths and labeled accordingly. Group A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment
214356304|NCT03752229|DEVICE|Medlance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356305|NCT03752229|DEVICE|Medlance (dark blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356306|NCT03752229|DEVICE|Medlance (yellow)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966234|NCT01416077|OTHER|fluid optimisation|"Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised~1. Crystalloid infusion (2,5 ml/kg/t) throughout surgery~2. 3 ml/kg Volulyte (synthetic colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase \> 10% is observed. A new dose is given if SV decreases more than 10% from the last value.~3. If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI \> 2,5.~4. If despite CI \> 2,5 Mean Arterial Pressure \<65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65."
214966235|NCT00236691|DRUG|topiramate|
215081393|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-active|Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
215081394|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-sham|Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
215081395|NCT04911244|DIAGNOSTIC_TEST|bronchoalveolar lavage|endobronchial sampling through bronchoscopy
215081396|NCT02984150|DIETARY_SUPPLEMENT|dodecanoic acid|
215081397|NCT02984150|DIETARY_SUPPLEMENT|saline|
215081398|NCT05628506|DRUG|Potassium iodide|Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
215081399|NCT04199273|PROCEDURE|Magnetic stimulation|Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
215081400|NCT04199273|PROCEDURE|Electric stimulation|Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
215081401|NCT03394599|DEVICE|TheraTrainer + Motiview|TheraTrainer will be used in conjunction with Motiview.
215081402|NCT03394599|DEVICE|TheraTrainer Only|TheraTrainer will be used.
215081403|NCT05804513|DRUG|Placebo|s/c injection
215081404|NCT05804513|DRUG|Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector|s/c injection
215081405|NCT03473106|DEVICE|Pneumatic tourniquet use|Surgery requiring a pneumatic tourniquet on the thigh
215081406|NCT00521391|OTHER|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
215081407|NCT00165750|DRUG|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
215081408|NCT01643850|DRUG|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
215081409|NCT01643850|DRUG|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
215081410|NCT04274153|BIOLOGICAL|Gardasil9|Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
215081411|NCT00881153|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
215081412|NCT00881153|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
215081413|NCT03242772|DRUG|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.
215081414|NCT03242772|BEHAVIORAL|ESDM informed parent coaching|All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
214356307|NCT03752229|DEVICE|Medlance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356308|NCT03752229|DEVICE|Medlance (red)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356309|NCT03752229|DEVICE|Unistik 3 Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356310|NCT03752229|DEVICE|Unistik 3 Comfort|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356311|NCT03752229|DEVICE|Unistik Touch|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356312|NCT03752229|DEVICE|ReadyLance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356313|NCT03752229|DEVICE|ReadyLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356314|NCT03752229|DEVICE|AssureLance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356315|NCT03752229|DEVICE|AssureLance MicroFlow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356316|NCT03752229|DEVICE|Surgilance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356317|NCT03752229|DEVICE|Surgilance Lite (grey)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356318|NCT03752229|DEVICE|Surgilance Lite (purple)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356319|NCT03752229|DEVICE|SteriLance Lite2|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356320|NCT03752229|DEVICE|SensiLance (pink)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214679045|NCT02075502|BEHAVIORAL|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
214966236|NCT03578627|BEHAVIORAL|BioBehavioral Intervention|Psychological (stress and quality of life), behavioral (health behaviors and compliance), and biologic (neuroendocrine and immune) factors, and pathways by which health outcomes (e.g. disease endpoints-recurrence, disease free interval) might be affected.
215081415|NCT03242772|DRUG|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
214679046|NCT02075502|PROCEDURE|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
214966237|NCT06312865|DEVICE|Ophthalmic exam|include best corrected visual acuity and cycloplegic refraction data
215081416|NCT00043017|PROCEDURE|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
215081417|NCT00043017|RADIATION|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
215081418|NCT00529126|DRUG|SKY0402|SKY0402
214966238|NCT00325910|DRUG|Metformin|
214966239|NCT01848171|DRUG|L-thyroxine|
214966240|NCT03647306|BEHAVIORAL|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
214966241|NCT03647306|BEHAVIORAL|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
215081419|NCT00529126|DRUG|Bupivacaine HCl|Bupivacaine HCl
215081420|NCT03241823|DIAGNOSTIC_TEST|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
215081421|NCT03241823|DIAGNOSTIC_TEST|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
214966242|NCT03647306|BEHAVIORAL|Extended Overnight Fast|Provide subjects a regimented amount of calories at each meal.
214966243|NCT00922116|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
214966244|NCT00741312|BEHAVIORAL|Regular aerobic physical exercise|"Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.~The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises."
214966245|NCT00741312|BEHAVIORAL|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
214966246|NCT05015036|PROCEDURE|ERAS|Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
214966247|NCT05015036|PROCEDURE|Minimally invasive surgery|Classic Minimally invasive surgery of the lumbar spine
214966248|NCT03743766|DRUG|Relatlimab|Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.
214966249|NCT03743766|DRUG|Nivolumab|Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.
214966250|NCT03743766|DRUG|Relatlimab + Nivolumab|Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
214966251|NCT05179824|OTHER|Observation|No Intervention
214966252|NCT04607135|DEVICE|Acoustic radiation force impulse (ARFI)|"Sound waves are sent in a series and are expected to push on the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system"
214966253|NCT04607135|DEVICE|Ultrasound|Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen
214966254|NCT04195724|OTHER|mNGS for pathogen detection|mNGS for pathogen detection and metabonomics (ascites, fecal,venous blood from superior mesenteric vein, hepatic vein and peripheral vein, respectively)
214966255|NCT05288114|DEVICE|Signal Relief Patch|Eligible subjects will be provided a Signal Relief patch, the instructions for use, and patch placement materials (adhesive, athletic tape, or wrap as applicable for the location of the pain). Subjects will be instructed to use the patch daily for seven days. The patch must be worn constantly except when showing or swimming.
214966256|NCT02410408|DEVICE|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
214966257|NCT02410408|OTHER|information package|Information on PSC and RCA
214966258|NCT05490355|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves heating of periarticular nerves using continuous RFA (80-90C for 60-90 seconds) that results in electromodulation and denervation reducing pain. It can be done under fluoroscopy or CT guidance. CT guidance has additional benefit of better localization of the nerves, as opposed to simple bony landmarks used in fluoroscopy, since nerve branching variations are common and will be used in this study.
214966259|NCT05490355|PROCEDURE|Perineural Steroid Injection|Perineural Steroid Injections involve CT guided injection of Local Anesthetic and Steroid into a nerve root of the spine to provide ongoing pain relief.
214966260|NCT05268341|BEHAVIORAL|My Sentence Builder|computer-assisted treatment program for expressive grammar
214966261|NCT05465369|OTHER|giomer|injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster
214966262|NCT05465369|OTHER|high viscosity glass ionomer|High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
214966263|NCT06958549|PROCEDURE|Nerve block with Lidocain|Injection of Lidocaine (7mg/kg) with Epinephrine 1:100000 under Ultrasonographical guidance
214966264|NCT06958549|DRUG|pharmacological analgesics|Oral Paracetamol (500mg/6hr), IV Ketolac (15mg/6hr) and IV perfelgan (1gm/6hr)
214966265|NCT06958445|DRUG|Alginos Oral Suspension|containing: Sodium alginate 50mg/mL Sodium bicarbonate 26.7mg/mL Calcium carbonate 16mg/mL
214966266|NCT06843486|OTHER|Multicomponent Exercise|Training sessions will include aerobic, resistance, balance and flexibility exercises, following the American College of Sports Medicine (ACSM) guidelines for osteoporosis prevention.
215081422|NCT03241823|DIAGNOSTIC_TEST|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
215081423|NCT03241823|DIAGNOSTIC_TEST|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
215081424|NCT01598337|DRUG|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
215081425|NCT01598337|DRUG|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
215081426|NCT01598337|DRUG|Clopidogrel|75 mg orally started 6-8hours before surgery
215081427|NCT01598337|DRUG|Prasugrel|10 mg daily as per instructions of investigators
214356321|NCT03752229|DEVICE|SteriLance Press|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966267|NCT05722821|OTHER|Hypopressive intervention|"Hypopressive abdominal gymnastics is based on a basic level hypopressive exercise program that will be:~* A duration of 12 weeks with a frequency of 2 sessions a week and lasting 45 minutes each. Hypopressive abdominal exercises will be performed individually adapted to the capacity of the participant.~* There will be an initial anatomical training of the muscles involved in carrying out the exercise and practice in the respiratory technique for a duration of 15 minutes. Afterwards, hypopressive exercises will begin for 20-30 minutes, changing positions if possible."
214966268|NCT00913211|DEVICE|rTMS|600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
214966269|NCT00913211|PROCEDURE|Motor learning training|one hour of repeated finger tracking movements toward a changing target.
214966270|NCT00913211|PROCEDURE|rTMS and Tracking|Combination of rTMS and finger tracking
214966271|NCT00913211|DEVICE|Sham rTMS|Sham treatment of rTMS
214966272|NCT05519956|RADIATION|level Ib-covering IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
214966273|NCT05519956|RADIATION|level Ib-sparing IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
214966274|NCT02372994|OTHER|Loop|Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
214966275|NCT02431104|DEVICE|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
214966276|NCT01340729|DRUG|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
214966277|NCT05582629|DRUG|JT001|JT001 administered orally in tablet form every 12 hours for 5 days
214966278|NCT05582629|DRUG|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
215081428|NCT04694521|PROCEDURE|openSide to end colorectal anastomosis .|open Side to end colorectal anastomosis
214356322|NCT03752229|DEVICE|SensiLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356323|NCT03752229|DEVICE|mylife|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214966279|NCT02144038|DRUG|LGH447|pan-PIM inhibitor
214966280|NCT02144038|DRUG|BYL719|PI3K-alpha inhibitor
214966281|NCT04832256|DEVICE|Radical-7 Pulse CO-Oximeter|COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)
214966282|NCT00622102|BEHAVIORAL|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
214966283|NCT00622102|BEHAVIORAL|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
214966284|NCT01015716|BEHAVIORAL|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
214966285|NCT01015716|BEHAVIORAL|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
215081429|NCT04694521|PROCEDURE|open end end to end stapler anastomosis|open end to end stapler anastomosis
215081430|NCT02093429|DRUG|INCB047986|INCB047986 will be supplied as tablets.
215081431|NCT00502723|PROCEDURE|Radical retropubic prostatectomy|Radical retropubic prostatectomy
215081432|NCT00502723|PROCEDURE|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
215081433|NCT05082220|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
215081434|NCT03466138|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
215081435|NCT04312360|DRUG|therapeutic endoscopy with metronidazole and fosfomycin disodium|therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
214679047|NCT02075502|PROCEDURE|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
214966286|NCT05061147|DRUG|MAX-40279-01|"Drug: AZA AZA will be administered at 75 mg/m\^2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.~Other Name: Azacitidine~Drug: Max-40279-01 Max-40279-01 will be administered as a combination of multiple oral capsules containing 5 and 25 mg. An alternate combination of 35 mg, 50 mg and 60 mg Max-40279-01 twice a day may be utilized.~Other Name: NA"
214356324|NCT03752229|DEVICE|VeriFine|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356325|NCT03752229|DEVICE|Microdot|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
214356326|NCT02131272|DRUG|Insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
214356327|NCT02131272|DRUG|Insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
214356328|NCT02131272|BEHAVIORAL|Diet/exercise|Intervention will be performed through family based changes in eating and activity behaviours.
214356329|NCT05560672|OTHER|Human Umbilical Cord blood mononuclear cells|Intravenous infusion of cord blood mononuclear cells
214356330|NCT00605800|OTHER|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
214356331|NCT00605800|OTHER|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
214356332|NCT05188573|DEVICE|Early detection pancreatic cancer test|Blood collection and pancreatic cancer early detection testing with return of results
215081436|NCT06118541|BEHAVIORAL|Vestibular Rehabilitation therapy|"Vestibular rehabilitation exercises of 30 to 60 minutes twice a week for eight weeks~Vestibular rehabilitation exercise program:~1. Eye-Head Coordination exercise~2. Sitting balance exercises~3. Standing Static balance exercises~4. Standing Dynamic balance exercises~5. Ambulation exercises"
215081437|NCT03094650|DEVICE|MindMotion PRO|Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
214356333|NCT05188573|DEVICE|Early detection pancreatic cancer test and MRI Imaging|Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
214356334|NCT04195009|PROCEDURE|major surgery under opioid free anesthesia without regional anesthesia|measuring nociception in every patient but blinded for attending anesthesiologist
214356335|NCT02462876|DEVICE|GORE® VIABAHN® Endoprosthesis|Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.
214356336|NCT06204627|DEVICE|TDCS|Technique of non-invasive brain stimulation by direct current (TDCS) which involves the modulation of excitability and brain activity, capable of promoting reorganization of the cortical representation of the body schema or motor planning, and consequently, pain relief.
214356337|NCT06204627|DEVICE|Recognize (hand) - Laterality|This technique stimulates the ability to recognize hand images as right/left quicklPatients with chronic pain present delayed recognition of hand laterality, which is related to the duration of symptoms and the pain evoked by the execution of the movement. Thus, this technique can have beneficial effects in breaking the pain.
214356338|NCT06204627|OTHER|Sham TDCS|TDCS sham: The device remains inactive for 20 minutes.
214356339|NCT06204627|OTHER|Landscape recognition|Image recognition training that does not refer to right/left discrimination.
214393715|NCT01777243|DRUG|GSK2398852|Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg \[approximately equivalent to 0.1 mg/ kg\]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
214966287|NCT03701880|DRUG|Ivabradine|Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
214966288|NCT03701880|DRUG|Bisoprolol|Bisoprolol is beta-blocker
214966289|NCT06355661|DIETARY_SUPPLEMENT|ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
214966290|NCT06355661|DIETARY_SUPPLEMENT|MCC: 400 mg (± 10%) per Capsule|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
214966291|NCT00807885|DRUG|hylenex-facilitated subcutaneous Lactated Ringer's infusion|single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
214966292|NCT00062348|DRUG|boronophenylalanine-fructose complex|
214966293|NCT00062348|DRUG|sodium borocaptate|
214966294|NCT00062348|PROCEDURE|conventional surgery|
214966295|NCT04797988|DEVICE|eon® FR 1064 nm device|The subject will be treatment area - flanks, will be treated with the eon device.
214966296|NCT04909515|DRUG|Naxitamab|3.0 mg/kg/day = 9.0 mg/kg/cycle
214966297|NCT04909515|DRUG|GM-CSF|250 - 500 microgram/m2/day
215081438|NCT03783741|BEHAVIORAL|Questionnaire|Interview
215081439|NCT02434354|DRUG|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
214966298|NCT04909515|DRUG|Isotretinoin|160 mg/m2/day
214966299|NCT03521869|DEVICE|Compression bandage|Compression bandage placed after total knee replacement
214966300|NCT03521869|DEVICE|Gauze dressing|standard of care gauze dressing placed after total knee replacement
214966301|NCT01366313|DRUG|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
214966302|NCT01366313|DRUG|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
214966303|NCT01366313|DRUG|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
214966304|NCT05625724|DRUG|Aspirin|Experimental drug administrated orally
214966305|NCT05625724|DRUG|Placebo|Treatment for the control group
214966306|NCT00524251|DRUG|esomeprazole|
214966307|NCT02364388|DEVICE|Imagio IUS|Imagio diagnostic gray-scale ultrasound
214966308|NCT02364388|DEVICE|Imagio OA/US|Diagnostic opto-acoustic +gray-scale ultrasound
214966309|NCT00327717|DRUG|Zonisamide|Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
214966310|NCT00327717|DRUG|Placebo|Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
214966311|NCT03704831|OTHER|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block (Interspace between the Popliteal Artery and the Capsule of the posterior Knee)
214966312|NCT03704831|OTHER|Injection of local anesthetics during total knee arthroplasty by surgical infiltration|Injection of local anesthetics during total knee arthroplasty by surgical infiltration.
214966313|NCT02356952|BEHAVIORAL|Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
214966314|NCT02356952|BEHAVIORAL|Low Glycemic Index Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
214966315|NCT02356952|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
214966316|NCT04884347|DIETARY_SUPPLEMENT|Alline proMEN|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
214966317|NCT04884347|DIETARY_SUPPLEMENT|Placebo|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
214966318|NCT05682833|PROCEDURE|Non surgical periodontal therapy|Subgingival ultrasonic debridement + manual root planning
214966319|NCT04710875|DRUG|Na-lactate|intravenous
214966320|NCT04710875|DRUG|Sodium chloride|Intravenous
214966321|NCT00064415|DRUG|arformoterol|Arformoterol inhalation solution, 50 mcg QD
214966322|NCT00064415|DRUG|Salmeterol|Salmeterol MDI, 42 mcg BID
214966323|NCT05285787|DRUG|EPN-701 (Oral)|MK-7
214966324|NCT01509612|DRUG|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
214966325|NCT01509612|DRUG|Homeopathic Placebo globules|Homeopathic placebo globules every 2 to 3 months
214966326|NCT04827758|PROCEDURE|Screening and diagnostic tests for sarcopenia|"All of the following tests and questionnaires will be performed :~* SARC-F questionnaire,~* measurement of muscle strengh by a grip test,~* measurement of muscle mass by impedancemetry (ASM/size2),~* 4-meter walking speed test,~* Timed-Up and Go (TUG) test,~* ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires."
214966327|NCT02195973|DRUG|LDE225|After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
214966328|NCT02360280|DRUG|ketamine|sedative
214966329|NCT02360280|DRUG|midazolam|sedative
214966330|NCT03140163|RADIATION|ULD-CT|Siemens Healthcare SOMATOM FORCE Ultra Low Dose chest CT
214966331|NCT03140163|RADIATION|CXR|Conventional chest radiograph
214966332|NCT02472886|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214966333|NCT02472886|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214966334|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
214966335|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
214966336|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
214966337|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
214966338|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
214966339|NCT04058197|DRUG|Deferoxamine Product|Deferoxamine Intradermal Delivery Patch
214966340|NCT04058197|OTHER|Placebo|Placebo Patch
214966341|NCT05728333|DRUG|Tirofiban|Intravenous tirofiban before endovascular thrombectomy.
214966342|NCT05728333|DRUG|Alteplase|Intravenous alteplase before endovascular thrombectomy.
214966343|NCT00921583|DEVICE|Long-term examination|Follow-up dental implants 20 year in function
214966344|NCT03343743|OTHER|Oligomineral water|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C \<200 mg/L) for at least 12 months
214966345|NCT06101147|DRUG|Vitamin D3|These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.
214966346|NCT06101147|DRUG|Placebo Oral Tablet|These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group
214356340|NCT04320628|DEVICE|AnaSept®|AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.
214966347|NCT00826059|DEVICE|Active Sphenopalatine Ganglion (SPG) Stimulation|SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
214966348|NCT00826059|DEVICE|Sham Sphenopalatine Ganglion (SPG) Stimulation|Sham SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
214966349|NCT03662035|DRUG|Apatinib|"Apatinib~Patients with advanced pancreatic cancer after failure of first-line chemotherapy will receive Apatinib (500mg/d, orally) 30 minutes after meal with warm water.Take 21 days as a cycle, patients will receive this treatment until they have got disease progressed. Dose adjustment: with 3/4 level of adverse reactions, the dose should be lowered to 250 mg/d."
214966350|NCT03662035|DRUG|S-1|"S-1~Patients will receive S-1 (60mg/d for BSA\<1.25m2, 80mg/d for 1.25\<BSA\<1.5m2, and 100mg for BSA \>1.5m2, orally) twice a day, once after breakfast and once after dinner, for 14 days, 7 days for suspension and 21 days as one cycle."
214966351|NCT05857800|OTHER|Observation|Analysis of dynamic changes of lung cancer microenvironment in neoadjuvant therapy using bio-omics information collected in clinical trials.
214966352|NCT01539746|PROCEDURE|TAVI without BAV|Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
214966353|NCT01539746|PROCEDURE|TAVI standard procedure|TAVI standard procedure including BAV before valve deployment
214966354|NCT00098007|DRUG|Everolimus (Certican)|
214966355|NCT00704951|DRUG|Posaconazole or alternative fungal treatment|"Dosage of Posaconazole:~Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)"
214966356|NCT00627926|BIOLOGICAL|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
214966357|NCT00627926|DRUG|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
214966358|NCT00627926|DRUG|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg
214966359|NCT00627926|OTHER|Placebo|Telaprevir matching placebo
214966360|NCT02017093|DEVICE|Error Enhancement|Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
214966361|NCT02017093|DEVICE|control treatment|Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
214966362|NCT06289439|DIETARY_SUPPLEMENT|Green tea (Camellia sinensis) 1000 mg as extract|Two capsules per day; Each capsule includes Green Tea Leaf (Camellia sinensis) 5000 mg composed of 500 mg of green tea extract and 250 mg of polyphenols (epicatechin (EC), epigallocatechin (EGC), epicatechin gallato (ECG), and epigallocatechin gallato (EGCG))
214966363|NCT06289439|OTHER|Placebo|Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Green tea tablets to ensure blinding.
214966364|NCT04657263|OTHER|Vaccine coverage assessment|Vaccine coverage assessment
214966365|NCT05216835|DRUG|Sabestomig (AZD7789)|Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.
214966366|NCT05604404|OTHER|Supine|The patient will be positioned supine with head-of-bed at zero degrees.
214966367|NCT05604404|OTHER|Semi-Recumbent|The patient will be placed in a semi-recumbent position with head-of-bed at thirty degrees.
214966368|NCT05604404|OTHER|Semi-Recumbent with Legs Flexed|The patient will be placed in a semi- recumbent position with head-of-bed at thirty degrees and legs flexed.
214356341|NCT04320628|OTHER|NSS|NSS
214356342|NCT04417023|OTHER|B3 for NMD: Bench to Bedside and Back|Transformative discoveries leading to improved care in Neuromuscular Disease
214966369|NCT06378203|OTHER|tele-rehabilitation system with virtual reality Home Kit - Virtual Reality Rehabilitation System (VRRS KHYMEIA)|"A personalized exercise plan following macro-areas of objectives:~* maintenance of muscle lengths with selective and/or prolonged static stretching exercises;~* maintenance/improvement of muscle trophism with selective and/or postural and/or functional muscle recruitment exercises at moderate intensity (approximately 65%-70% of the maximum);~* maintenance of respiratory muscle weakness with thoracic and/or diaphragmatic breathing exercises combined with muscle exercise;~* endurance training with walking, cycle ergometer (to be used with both the upper and lower limbs) and treadmill at moderate intensity (approximately 65%-70% of the maximum).~Home treatment will mostly take place with the KHYMEIA tele-rehabilitation system."
214966370|NCT00056303|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.
214356343|NCT05986175|OTHER|Motor Imagery Training|The motor imagery training will be given with an audio recording containing 15 minutes of motor imagery training. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
214356344|NCT05986175|OTHER|Core Stabilization Exercises|Jeffreys' Core (body) Stabilization Exercises will be implemented. The protocol consists of exercises that progress gradually from the first level to the third level. The first level consists of static contraction training on a stable surface; the second level is dynamic training on stable surfaces; and the third level is dynamic and resistant training on an unstable surface. Each session is scheduled to last 45 minutes, with 5 minutes of heating and 5 minutes of cooling exercises. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
214356345|NCT01922115|DRUG|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
214356346|NCT01922115|DRUG|Placebo|
214356347|NCT05082038|DEVICE|Mandibular partial rehabilitation with IF Tapared implants|2 IF Tapared Implants (Group IF) on one side of the mandible
214356348|NCT05082038|DEVICE|Mandibular partial rehabilitation with CF Tapared implants|2 CF Tapared Implants (Group CF) on the other side of the mandible
214356349|NCT03191318|OTHER|ERAS pathway|ERAS pathway after laparoscopic sleeve gastrectomy
214356350|NCT03191318|OTHER|Standard pathway|Standard pathway after laparoscopic sleeve gastrectomy
214356351|NCT02552004|DEVICE|pCLE|Histological examination by pCLE technique preceding the frozen section
214356352|NCT02552004|DRUG|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
214356353|NCT05807451|PROCEDURE|High Tibial Osteotomy (Uniplanar and Biplanar )|High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques
214356354|NCT02203474|DRUG|Tiotropium HFA BAI 5 mcg|
214356355|NCT02203474|DRUG|Tiotropium 18 mcg Capsule|
214356356|NCT02203474|DRUG|Placebo|Placebo
214356357|NCT04917523|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cell), Inactivated|0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen
214966371|NCT00056303|BEHAVIORAL|Developmental Education for Families|Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
214966372|NCT03037346|OTHER|Questionnaire Administration|Complete questionnaires about MPOAD
214966373|NCT03037346|OTHER|Questionnaire Administration|Ancillary studies
214356358|NCT03464812|BEHAVIORAL|DSMES|It is primarily an educational intervention that is focused on assisting patients improve their management and coping with type 2 diabetes.
214356359|NCT06013644|DEVICE|Acupuncture needle|a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2
214356360|NCT06013644|DEVICE|Dry needle|a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes
214356361|NCT06013644|DRUG|Botox Injectable Product|each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
214966374|NCT03037346|OTHER|Video|Watch educational video
214966375|NCT05180019|DEVICE|SMD ( Self Monitoring Device)|Automated 3D ultrasound based follicullometry with SMD self-performed by the patient.
214966376|NCT05798156|DRUG|Glofitamab|Glofitamab is a fully humanized, engineered monoclonal bivalent antibody of the IgG1 isotype.
214966377|NCT05798156|DRUG|Rituximab|Rituximab is a genetically engineered chimeric mouse/human anti-CD20 monoclonal antibody
214356362|NCT02107118|BIOLOGICAL|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
214356363|NCT02107118|OTHER|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
214966378|NCT05798156|DRUG|Obinutuzumab|Obinutuzumab is a fully humanized, glycoengineered type II monoclonal antibody of the IgG1 isotype that binds to an epitope on CD20
214966379|NCT05798156|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is an antibody-drug-conjugate that contains a humanized IgG1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent (MMAE) linked through a protease-cleavable linker.
214966380|NCT01678664|DRUG|Everolimus|10 mg per day of everolimus during 24 months or until progression disease
214966381|NCT01678664|DEVICE|embolization|2 sessions embolization with spheric particles
214966382|NCT01678664|DRUG|Doxorubicin|2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
214966383|NCT01408719|DIETARY_SUPPLEMENT|Control|Minimal beta-glucan
214356364|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F1 Formulation|Modified release tablets for oral administration
214356365|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F2 Formulation|Modified release tablets for oral administration
214356366|NCT01786512|DRUG|Placebo|Modified release tablets matching to omecamtiv mecarbil
214356367|NCT01786512|DRUG|Omecamtiv Mecarbil Swellable Core Technology F2|Modified release tablets for oral administration
214356368|NCT03166618|DEVICE|Juvéderm® VOLUMA XC|Juvéderm® VOLUMA XC hyaluronic acid injectable gel
214966384|NCT01408719|DIETARY_SUPPLEMENT|3g LMW beta-glucan|3grams beta-glucan
214356369|NCT01954979|DRUG|Abatacept|The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
214356370|NCT04455672|DEVICE|splints|"* Scaning of the maxillary and mandibular cast in the centric relation.~* The CAD/ CAM splints will be designed using Exocad s.~* The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~* The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~* Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~* All patient will be asked to wear their spints during sleeping only.~* In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months ."
214356371|NCT01925950|DRUG|orBec|
214356372|NCT01925950|DRUG|Placebo|
214356373|NCT04546308|OTHER|Resistance exercise training|Eight weeks whole-body resistance exercise training (80%1 repetition maximal, 3 sessions per week) followed by a 4-week detraining intervention
214356374|NCT01795833|OTHER|Short text messages|In addition to structured education on healthy lifestyle provided at baseline, subjects in the arm will receive short text messages containing educational, motivational and supportive content on diet, physical activity, and smoking (if appropriate) during the study period. The content will be appropriate to the stage of the transtheoretical model of behavioural change that the subject is in. This will be assessed by questionnaire at each visit to clinic.
214356375|NCT00522158|DRUG|simvastatin|
214966385|NCT01408719|DIETARY_SUPPLEMENT|5g LMW beta-glucan|5 grams beta-glucan
214966386|NCT01408719|DIETARY_SUPPLEMENT|3g HMW beta-glucan|3 grams of high molecular weight beta-glucan
214966387|NCT01675388|OTHER|Hypothermia|Hypothermia to 33.5 deg C
215081440|NCT06453330|BIOLOGICAL|Horizontal platelet-rich fibrin (H-PRF)|Most commercially available centrifuges used for PRF production are fixed-angle systems designed primarily for pelleting samples to the bottom of tubes and are not particularly efficient at separating the cell layers effectively. Research has demonstrated that PRF produced using horizontal centrifugation (H-PRF) can lead to a higher concentration of platelets and leukocytes compared to PRF produced from fixed-angle centrifugation (LPRF). The resulting PRF from horizontal centrifugation is termed 'horizontal platelet-rich fibrin' (H-PRF). The H-PRF clot will be produced using a Bio-PRF horizontal centrifuge machine. This machine is CE marked and regularly used in the Dublin Dental University Hospital.
215081441|NCT00413920|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
215081442|NCT00413920|DRUG|Prednisone|Oral tablets
215081443|NCT00144768|DRUG|laronidase|dose of 0.58mg/kg body weight IV every week
215081444|NCT06301828|DRUG|Envafolimab Injection|Endostar+SBRT+Envafolimab Injection
215081445|NCT06301828|DRUG|Endostar|Endostar+SBRT+Envafolimab Injection
214356376|NCT00522158|DRUG|atorvastatin|
214356377|NCT05707533|PROCEDURE|TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique|The Transvaginal mesh procedure with Vaginal Adventitia Reserved and Anatomical Implant Technique for the treatment of POP. The Cefoxitin Injection Solution was used for Prophylactic antibiotics
214356378|NCT00605293|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv/month (starting dose)
214356379|NCT00605293|DRUG|Epoetin alfa|As prescribed
214679048|NCT05684159|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.
214966388|NCT02797678|DEVICE|Powersleep|Participants will receive 5 nights of stimulation
214966389|NCT02797678|DEVICE|Sham Powersleep|Participants will receive 5 nights of no stimulation
214966390|NCT02981914|DRUG|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
214966391|NCT03913871|BEHAVIORAL|Texts to support healthy eating|The intervention arm will receive tailored text messages to encourage healthy eating (increase consumption, fruits, vegetables and water; and a reduce intake of sugar sweetened beverages). Participants will receive an average of 1-2 messages per day for 4 weeks.
214966392|NCT03913871|BEHAVIORAL|Texts to support physical activity|The intervention arm will receive tailored text messages to support increased minutes of physical activity per day. Participants will receive an average of 1-2 messages per day for 4 weeks.
214966393|NCT04322669|DRUG|Pidotimod|Participants will be randomized in ratio of 1:1 to receive Pidotimod 400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
214966394|NCT04322669|DRUG|Placebo|Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
214356380|NCT04593433|OTHER|Museum virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 5 participants. They meet online one time per week for a 20 to 25 min of a visit tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
214966395|NCT01852513|DRUG|QNASL|
214966396|NCT01852513|DRUG|Placebo nasal spray|
214356381|NCT00950066|DRUG|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
214356382|NCT00950066|DRUG|Amlodipine|Oral administration of Amlodipine 5mg once a day
214966397|NCT05886088|DRUG|LID104|Experimental
214966398|NCT05886088|DRUG|Dapagliflozin|Active comparator
214966399|NCT05886088|DRUG|Linagliptin|Active comparator
214966400|NCT00200577|DRUG|TIL + IL2|Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
214966401|NCT00753675|DRUG|ZD6474, Vandetanib|300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214966402|NCT00753675|DRUG|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214966403|NCT00753675|DRUG|Gemcitabine|administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214966404|NCT00753675|DRUG|Placebo matching ZD6474|Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
214966405|NCT00203697|DRUG|minocycline|
214966406|NCT06415019|DRUG|Naproxen (BAYH006689)|BAYH006689 gel will be dispensed directly on the patch
214966407|NCT06415019|DRUG|Placebo Gel|Placebo gel will be dispensed directly on the patch
214356383|NCT00950066|DRUG|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
214356384|NCT00950066|DRUG|Placebo|Oral administration of a placebo once a day
214966408|NCT06415019|DRUG|A solution of 0.9% Saline|0.9% Saline will be dispensed directly on the patch.
214966409|NCT02017275|DEVICE|BuMA|This group will contain 1175 subjects.
214966410|NCT02017275|DEVICE|EXCEL|This group will contain 1175 subjects.
214966411|NCT00333710|BEHAVIORAL|Individual psychotherapy|Individual face-to-face contact with educational and goal setting components
214966412|NCT00333710|BEHAVIORAL|Telehealth Intervention|Individual telephone contact with educational and goal setting components
214966413|NCT04478162|OTHER|Supporting parents who have premature babies to be ready for discharge with the training given within the scope of FICare model.|At least 1 week of FICare training for parents At least 4 hours of training on FICare for health professionals Trainings will be held between 13:30 and 15:30 in a training room with heat, light and seating arrangement (for parents who are not able to participate in the training during the week, trainings will be held at the appropriate time interval on the weekend .) Premature baby dummy on oral care, eye care, nose care, ear care, skin care, bath, attired in clothes,/removal, safe sleeping baby, safe transport, kangaroo care (physical contact), non-invasive drug application will be shown and the parents also will be asked to implement,
214966414|NCT06392464|DEVICE|Clinical decision support system (software)|"Use of a clinical decision support system. Naevia Medical is clinical decision support software (CDSS) that, based on clinical input data (patient history, symptoms, complementary test data, etc.) from adult patients with heart disease, provides healthcare professionals with prioritized, justified, and referenced recommendations and knowledge-related suggestions related to diagnosis, prognosis, and/or treatment (recommended tests, medications, alerts, etc.)"
214356385|NCT04439526|DRUG|Guselkumab|Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study.
214966415|NCT03914274|DEVICE|Technical sock|Socks were of two types: technical socks, designed for high performance sports use (Lurbel brand, models Tierra and Set), and non-technical socks for everyday use. The socks had different composition: Tierra (50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra); Set (75% cotton, 17% polyamide, 8% lycra) and cotton (98% cotton, 2% elastane).
214356386|NCT02353650|DIETARY_SUPPLEMENT|Q10|
214356387|NCT02353650|DIETARY_SUPPLEMENT|placebo|
214966416|NCT02928523|DRUG|Autologous Fecal Microbiota Transplantation|
214966417|NCT04525040|DIETARY_SUPPLEMENT|ProbioKid®|Probiokid formulation includes three probiotic strains and fructooligosaccharides.
214966418|NCT04525040|OTHER|Pragmatic comparator|Standard of care as usual without a preventive intervention
214966419|NCT03162185|DRUG|Escitalopram|Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
214966420|NCT03162185|DRUG|Placebo|Control group participants (n = 30) will receive a placebo for 7 days.
214966421|NCT02729480|DEVICE|Halo Craniofacial Nerve Stimulator System|The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
214966422|NCT02686164|DRUG|Lenvatinib|Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
214356388|NCT01891916|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
214356389|NCT03068338|DEVICE|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
214356390|NCT03068338|DEVICE|Intermittent pneumatic compression|Conventional device used by hospitals
214356391|NCT05185310|PROCEDURE|Ablation|Ablation strategy during repeat AF ablation
214356392|NCT00381940|DRUG|ifosfamide|Given IV
214356393|NCT00381940|DRUG|bortezomib|Given IV
214356394|NCT00381940|DRUG|vinorelbine tartrate|Given IV
214356395|NCT00381940|BIOLOGICAL|filgrastim|Given IV or SC
214356396|NCT03154801|OTHER|Paramedical care|Paramedical early detection of sexual dysfunction and sexual health counseling
214356397|NCT00798720|DRUG|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
214356398|NCT00798720|DRUG|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
214966423|NCT02686164|DRUG|Midazolam|Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
214966424|NCT03283930|BEHAVIORAL|Active Attention Bias Modification Training|Computer-based attention bias modification training administered at weekly CBT session aimed at re-training attentional biases
214966425|NCT03283930|BEHAVIORAL|Placebo Attention Bias Modification Training|
214966426|NCT01829698|DRUG|tauroursodeoxycholic|Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
214966427|NCT01829698|DRUG|ursodeoxycholic acid|ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
214966428|NCT02487797|DRUG|Oxytocin|
214966429|NCT02487797|OTHER|Sodium Chloride 0.9%|
214966430|NCT01610869|DRUG|BIBF 1120|Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
214966431|NCT00805129|DRUG|Everolimus|Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
214966432|NCT00753129|PROCEDURE|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
214966433|NCT02590237|DEVICE|Ambu KingVision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
214966434|NCT02590237|DEVICE|Miller Direct Laryngoscopy|At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
214356399|NCT03137303|DEVICE|Spirometry at initial visit|Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.
214356400|NCT03137303|DRUG|Albuterol|The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
214356401|NCT03137303|DEVICE|Spirometry at 12-month follow-up|At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.
214356402|NCT05931692|DIAGNOSTIC_TEST|Virtual reality|Virtual environment that triggers fear of falling
214356403|NCT05931692|DIAGNOSTIC_TEST|Electroencephalogram|Detect brain waves in response to fear of falling
214966435|NCT03293017|DRUG|Diazepam 10 MG|If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
214966436|NCT03293017|DRUG|Baclofen 30mg|Baclofen 30 mg/day given over three gifts daily
214966437|NCT03293017|DRUG|Baclofen 60mg|Baclofen 60 mg/day given over three gifts daily
214966438|NCT02465164|DEVICE|Cook catheter|
214966439|NCT02465164|DRUG|Oxytocin|
214966440|NCT04258124|OTHER|Control motor intervention|The intervention through motor control will consist in the application of the protocol described by Hidalgo-Peréz et al. The objective of the application of the technique is to produce an increase in the strength of the deep cervical musculature. The exercises will be performed with the subject in different positions: supine, quadrupedic and standing position. The physiotherapist will be placed in standing position in front of the subject. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
214356404|NCT05931692|DIAGNOSTIC_TEST|Electromyography|Measures muscle activity and response to fear of falling
214356405|NCT05931692|DIAGNOSTIC_TEST|Motion Capture system|Measures postural and gait responses to fear of falling
214356406|NCT05931692|DIAGNOSTIC_TEST|Polar H10 Heart Sensor|Heart rate monitor
214356407|NCT05931692|DIAGNOSTIC_TEST|Inertial measurement Unite|Measure Postural sway
214679049|NCT06203548|BEHAVIORAL|Lifestyle modification programme|All patients will attend sessions weekly in the first 2 months and monthly in the remaining 4 months. The programme focuses on reducing caloric intake and increasing energy expenditure. At the first visit, the dietitian will perform a complete behavioural assessment including the patient's eating and lifestyle patterns, specific eating-related behaviours, knowledge, concerns and feelings. A target body weight will be set. During follow-up visits, the dietitian will review the patient's dietary pattern and provide recommendations. Each patient will be given an individualised meal plan. The dietary component and portion size are based on recommendations by the American Dietetic. The patients will be taught techniques to cope with at-risk situations such as parties and festival celebrations. In addition, the patients will be encouraged to have a combination of aerobic exercise and resistance training with intensity and frequency following the Physical Activity Guidelines.
214356408|NCT00986206|DIAGNOSTIC_TEST|Biomarker LPA and HE4|Non Interventional Trial
214966441|NCT03973541|BEHAVIORAL|Cognitive Behavioral Therapy with Exposure therapy|Treatment will be conducted for 10 consecutive weekly 60 min sessions. In the first two treatment conditions sessions are scheduled as follows: Session one: Building a therapeutic alliance and psycho-education about social anxiety and safety and avoidance behaviors. Session two to four: Cognitive restructuring. Session five to nine: Exposure in either in vivo or VR. Session 10: Relapse prevention. Sessions one to four and ten are identical in the two of three treatment arms.
214966442|NCT03973541|BEHAVIORAL|Relaxation Therapy|Relaxation Therapy
214966443|NCT03967041|DIAGNOSTIC_TEST|radiological defined sarcopenia|Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height
214966444|NCT02171117|PROCEDURE|microtransplantation|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
214966445|NCT02171117|BIOLOGICAL|HLA-mismatched donor peripheral stem cell infusion|
214966446|NCT04551664|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
214356409|NCT04110613|DIETARY_SUPPLEMENT|noFast: Start tube feeds within 1 hour of procedure|Earliest possible initiation of tube feeding after bedside PEG tube procedure.
214356410|NCT02852551|DRUG|PAT-1251|
214356411|NCT02852551|DRUG|Placebo|
214356412|NCT05682053|DIAGNOSTIC_TEST|Multiparametic MRI|patients will have a Multiparametric MRI
214356413|NCT02934490|DEVICE|Mesh|Meshes were made by Gynemech TM PS, (Johnson \& Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
214356414|NCT05959122|DIAGNOSTIC_TEST|CBC serum iron serum ferritin|"1. Fully automated blood cell counter (sysmex-Xs 800i) and AU 480-Chemistry auto-analyzer (Beckman Coulter Diagnostics-USA) was used for measurement of hemoglobin and serum iron levels~2. Chemiluminescence assay using an Abbott i2000SR analyser was used to measured serum ferritin"
214356415|NCT03604081|OTHER|CIMT|Intervention group will receive one hour of intense massed practice of lower extremity either in the form of shaping or task practice.
214356416|NCT03604081|OTHER|Conventional Physical Therapy|1 hour as per current standard of care that follows stroke clinical practice guideline.
214356417|NCT04530890|DIAGNOSTIC_TEST|Blood samples|Only blood samples at different times of treatment
214679050|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-L|Low dose: 2x1010 CFU/day
214966447|NCT04551664|PROCEDURE|Endovascular therapy|In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy (recommended with Solitaire、EMBOTRAP、Trevo or Reco revascularization device) or aspiration thrombectomy (recommended with Penumbra) will be recommended as the primary treatment.
214966448|NCT03821077|BIOLOGICAL|Allergen Immunotherapy (AIT)|Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation
214966449|NCT02499120|DRUG|palbociclib|Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
214966450|NCT02499120|DRUG|Cetuximab|Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
214966451|NCT02499120|DRUG|Placebo|"Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle."
214966452|NCT06538259|DEVICE|Transcranial direct current stimulation (tDCS)-anodal group|2mA/20mins/session; 2sessions/day,5days
214356418|NCT00689767|DEVICE|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
214356419|NCT00689767|DEVICE|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
214356420|NCT01556373|OTHER|NA : non interventional study|NA : non interventional study
214356421|NCT00717990|DRUG|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
214356422|NCT00717990|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
214356423|NCT00717990|DRUG|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
214356424|NCT03322969|DRUG|Paclitaxel/DDP|receiving the modified chemotherapy
214356425|NCT03322969|DRUG|XELOX/SOX|receiving the original chemotherapy
214356426|NCT05667220|DRUG|Sitagliptin|Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.
214966453|NCT06538259|DEVICE|Transcranial direct current stimulation (tDCS)-sham group|0mA/20mins/session; 2sessions/day,5days
214966454|NCT06442722|PROCEDURE|DDH with capsulorrhaphy|group will undergo capsulorrhaphy, a surgical procedure to tighten the hip capsule ,
214356427|NCT05667220|DRUG|Sitagliptin combined with Beidougen capsule|Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
214356428|NCT05550116|OTHER|Giomer|fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers
214356429|NCT05550116|OTHER|Two composite resin sealants|Unfilled composite resin sealants
214356430|NCT02566018|PROCEDURE|treatment/medical device|The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards
214356431|NCT02566018|PROCEDURE|standard|The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
214356432|NCT02642250|DRUG|Metronidazole|The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
214356433|NCT02642250|DRUG|Entoban|To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
214356434|NCT01440400|PROCEDURE|Ultrasound guided spinal anesthesia|Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
214356435|NCT02858050|DEVICE|Portal-724 MEMs Cap|
214356436|NCT05186870|OTHER|Outcome measures|Observational study
214487319|NCT05838924|OTHER|PHYSICAL ACTIVITY + VIRTUAL REALITY|"The VR therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 VR exercises of Back School by manipulating visual proprioceptive information during all lumbar movements. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
214966455|NCT06442722|PROCEDURE|DDH without capsulorrhaphy|group will not undergo capsulorrhaphy, a surgical procedure without tightness the hip capsule
214966456|NCT06111898|OTHER|No Intervention|No intervention
214966457|NCT01833585|BIOLOGICAL|Peripheral blood mononuclear cell|Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia
214966458|NCT02810275|DRUG|Folinic Acid|Folinic acid 5 mg, taking in the morning, daily, during four weeks
214966459|NCT02810275|DRUG|Placebo|Placebo capsule received 1 tablet, taking in the morning, during four weeks
214966460|NCT03134729|DRUG|Ropivacaine for Serratus Plane Block (SPB)|Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
214356437|NCT02943603|DRUG|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
214356438|NCT00478348|PROCEDURE|Prosthetic repair of abdominal incisional hernia|Rives-Stoppa repair of incisional hernia
214356439|NCT03663868|DIAGNOSTIC_TEST|CC-Test|Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells
214356440|NCT03210805|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acids Supplementation|28 days of a commercially available supplement. 4 capsules per day.
214966461|NCT00970645|PROCEDURE|Mediastinoscopy/thoracoscopy|Mediastinoscopy used to detect/stage lung cancer.
214966462|NCT00970645|PROCEDURE|EBUS/EUS|Minimal invasive technique to stage/detect lung cancer.
214966463|NCT02629744|DRUG|Etrolizumab|Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
214966464|NCT02629744|DEVICE|Prefilled Auto-injector (Rotaject)|Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
214356441|NCT00668954|DIETARY_SUPPLEMENT|Pomegranate Juice|Group A drinks 8 oz. pomegranate juice/day for 12 weeks
214356442|NCT00668954|DIETARY_SUPPLEMENT|Placebo Juice|Group B drinks 8 oz. placebo juice/day for 12 weeks
214356443|NCT03561090|DRUG|IW-3718|oral tablet
214356444|NCT03561090|DRUG|placebo|oral tablet
214356445|NCT03561090|DRUG|Standard-dose PPIs QD|background therapy
214966465|NCT02985112|DEVICE|FFR and IVUS-NIRS|
214966466|NCT06469450|DRUG|Atorvastatin|one 40 mg atorvastatin tablet once daily for 28 days
214966467|NCT03571724|OTHER|Non-Menthol Very Low Nicotine Cigarettes|King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco
214966468|NCT03571724|OTHER|Menthol Very Low Nicotine Cigarettes|King size menthol cigarettes containing 0.4mg nicotine /g tobacco
214966469|NCT03571724|OTHER|Subject's UB non-mentholated filtered cigarettes|King size non-menthol cigarettes
214966470|NCT03571724|OTHER|Subject's UB mentholated filtered cigarettes|King size menthol cigarettes
214966471|NCT03819413|DIAGNOSTIC_TEST|serum aquaporin 4 antibody (AQP-4-Ab)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum aquaporin 4 antibody (AQP-4-Ab) and serum myelin oligodendrocyte glycoprotein antibody (anti-MOG)
214966472|NCT03819413|DIAGNOSTIC_TEST|serum MOG antibody (anti-MOG)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum myelin oligodendrocyte glycoprotein antibody (anti-MOG) if they tested negative for serum aquaporin 4 antibody (AQP-4-Ab)
214966473|NCT03819413|DIAGNOSTIC_TEST|MRI brain, spine and orbit|All patients suspected to have NMOSD according to the recent diagnostic criteria will have MRI brain, spine and orbit with Gadolinium
214356446|NCT05455099|RADIATION|Carotid ultrasound examination 1|Participants will be assigned to obese group (body mass index 24.0-27.9 kg/m²). Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's explorer ultrasound system.
214966474|NCT03471832|DEVICE|stenfilcon A lens|contact lens
214356447|NCT05455099|RADIATION|Carotid ultrasound examination 2|Based on the inclusion criteria, 1200 overweight Han people（body mass index ≥28.0 kg/m²） and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
214356448|NCT04082546|PROCEDURE|Surgical unroofing of muscle-briged coronary artery|Medical therapy with beta-blockers or calcium-channels blockers
214356449|NCT00373399|DRUG|Inactive Marijuana (0% THC)|Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
214356450|NCT00373399|DRUG|Low THC marijuana (1.8 %THC)|Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
214679051|NCT04893746|DIETARY_SUPPLEMENT|Maltodextrin|0x1010 CFU/day
214966475|NCT03471832|DEVICE|narafilcon A lens|contact lens
214966476|NCT03666949|DRUG|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
214966477|NCT03666949|DRUG|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
214966478|NCT00343629|DRUG|sulindac|
214966479|NCT00343629|OTHER|pharmacological study|
214966480|NCT05382013|DRUG|Avatrombopag|Patients will receive treatment of oral avatrombopag 20mg per day for the first 5 days
214966481|NCT05382013|OTHER|Artificial Liver Support System|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
214966482|NCT05382013|OTHER|Comprehensive internal medical treatment.|Patients will receive comprehensive internal medical treatment.
214966483|NCT01476800|DRUG|YM178 OCAS|oral
214966484|NCT01476800|DRUG|Ketoconazole|oral
214966485|NCT03259256|PROCEDURE|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
214966486|NCT02320448|DRUG|PIPAC|
214356451|NCT00373399|DRUG|High THC marijuana (3.9% THC)|Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
214356452|NCT05225246|OTHER|Data collection on reasons for unplanned readmission to the University Hospital Basel within 30 days of leaving the hospital|Descriptive analysis of the reasons for unplanned readmissions after cardiac surgery and predictive factors for unplanned readmissions and validation of risk scores
214356453|NCT00962195|DIETARY_SUPPLEMENT|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
214356454|NCT05090579|PROCEDURE|Group I (BN10)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 1 mL of 10 mg of nalbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
214679052|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-H|High dose: 6x1010 CFU/day
214966487|NCT01060917|DEVICE|Non-invasive CGMS (continuous glucose monitoring system)|A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
214356455|NCT05090579|PROCEDURE|Active Comparator:Group ll (BN20)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 2 mL of 20 mg of nalbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
214966488|NCT01060917|PROCEDURE|Hyperglycemic and hypoglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
214966489|NCT01060917|DEVICE|Non-invasive CGMS (GlucoDay)|The minimally-invasive glucose sensor GlucoDay, was used as a control measure
214966490|NCT00843011|DRUG|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
214966491|NCT03833232|DEVICE|omentopexy with cyanoacrilate glue|apposition of omentum with cyanoacrilate glue on gastric section
214966492|NCT05929989|DIAGNOSTIC_TEST|ELISA TEST|ELISA TEST for cystatin D and fibrinogen like protein
214966493|NCT00613392|DIETARY_SUPPLEMENT|powdered antioxidant|one vial mixed with water every day orally or through enteral tube
214966494|NCT00613392|DIETARY_SUPPLEMENT|powdered cornstarch placebo|one vial mix with water and administer orally or via enteral tube
214966495|NCT02338401|DIETARY_SUPPLEMENT|Omega-3 Complete|Fish Oil Capsules
215081446|NCT00591968|DEVICE|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
215081447|NCT01824199|DRUG|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
215081448|NCT02152059|DRUG|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
214356456|NCT05090579|PROCEDURE|Active Comparator:Group lll (B)|patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
214356457|NCT04162769|DRUG|Etrasimod 1 mg|Etrasimod 1 mg tablet taken by mouth, once daily
214356458|NCT04162769|DRUG|Etrasimod 2 mg|Etrasimod 2 mg tablet taken by mouth, once daily.
214356459|NCT04162769|DRUG|Etrasimod matching placebo|Etrasimod matching placebo tablet by mouth, once daily.
214356460|NCT06579482|DRUG|Aesculus hippocastanum, and associations|combination product
214356461|NCT06578962|OTHER|Phase 1: short intensive treatment phase|During the treatment phase (phase 1), all subjects of the study applied the tested product RV3438G, thrice a week, for 2 weeks.
214356462|NCT06578962|OTHER|Phase 2 : Tested product RV3438G associated with gentle balancing shampoo|"During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the gentle balancing shampoo RD1089O was applied twice a week alternately with the RV3438G shampoo, for 8 weeks."
214356463|NCT06578962|OTHER|Phase 2 : Tested product RV3438G associated with neutral shampoo|"During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the neutral shampoo RD0057H was applied twice a week alternately with the RV3438G shampoo, for 8 weeks."
214356464|NCT06578962|OTHER|Phase 2 : neutral shampoo|"During maintenance phase (phase 2):~the neutral shampoo RD0057H was applied thrice a week for 8 weeks."
214966496|NCT02338401|DIETARY_SUPPLEMENT|Placebo Pill|Olive Oil Capsules
214966497|NCT00001013|DRUG|Trimetrexate glucuronate|
214966498|NCT00001013|DRUG|Pentamidine isethionate|
214966499|NCT00001013|DRUG|Sulfamethoxazole-Trimethoprim|
214356465|NCT06580288|DRUG|Finerenone|10mg or 20mg
214966500|NCT00001013|DRUG|Leucovorin calcium|
214966501|NCT05297461|OTHER|Medication review|Community pharmacy benchmarking guideline Pharmaceutical Services Division provides guidelines for medication review in community pharmacy settings in Malaysia
214966502|NCT02494895|DRUG|Ticagrelor monotherapy|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
214356466|NCT06580288|DRUG|Placebo|10mg or 20mg
214356467|NCT05728723|DEVICE|Android Application|Android Application for 3 months
214356468|NCT05728723|BEHAVIORAL|Pharmacy education|Pharmacy education in hypertensive patients
214356469|NCT03362567|OTHER|Sustained Natural Apophyseal Glides|Subjects in SNAGS group were treated with sustained natural apophyseal glides, twice weekly for six weeks
214356470|NCT03362567|OTHER|Mechanical Cervical Traction|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
214356471|NCT06431282|OTHER|CO2 laser + HA|Probands will be treated with a CO2 laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.
214679053|NCT01253512|DRUG|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
214356472|NCT06431282|OTHER|Thulium laser + HA|Probands will be treated with a thulium laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.
214966503|NCT02494895|DRUG|Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
214966504|NCT02709837|OTHER|Nutritional|
214966505|NCT06503978|COMBINATION_PRODUCT|MTP-101P|MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.
214966506|NCT06503978|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 14 Days"
214966507|NCT06503978|COMBINATION_PRODUCT|Miralax|Miralax is a common over-the-counter laxative and bowel cleanse
214966508|NCT06503978|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12 weeks"
214966509|NCT06503978|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12 weeks"
214966510|NCT06503978|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 14 days"
214356473|NCT04909242|DRUG|DZD9008|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.
214966511|NCT06180161|BEHAVIORAL|multidomain intervention|"Integrating exercise cognitive training with nutrition, chronic disease management, oral health, fall prevention, traffic safety, psychosocial well-being, and sleep to enhance the effectiveness of improving cognitive function in the elderly community."
214966512|NCT05680428|OTHER|early feeding|oral feeding within 12hours after stoma reversal
214966513|NCT05680428|PROCEDURE|conventional feeding|oral feeding after 48hours of NBM after stoma reversal
214966514|NCT03168451|BEHAVIORAL|Culturally Tailored Text Messages|Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
214966515|NCT03460626|DRUG|Lavender Oil|The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.
214966516|NCT03460626|OTHER|Placebo|an odorless oil without any therapeutic effect
214966517|NCT01074177|DRUG|BIBW 2992|Taken orally once a day
214966518|NCT00870467|BIOLOGICAL|Double-blind adalimumab|Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
215081449|NCT06346366|DEVICE|Bihormonal artificial pancreas (BIHAP) / closed loop|"The investigational device is a dual-hormonal fully closed loop system (BIHAP; industrial name AP® 5, Inreda Diabetic B.V.) which aims at optimally controlling plasma glucose levels. This BIHAP contains of two pumps for subcutaneous infusion of either insulin (Humalog, 3 ml pre-fill cartridge, Eli Lilly) or glucagon (GlucaGen, Novo Nordisk; 3.15 ml cartridge Accu-Chek Spirit, Roche) via an infusion set (Accu-Chek Insight Flex or AccuChek Flex Link, Roche), two subcutaneously placed glucose-sensors (Guardian, Medtronic) and an algorithm driving pump infusion rates based on the sensor input. Daily self-measurements of blood glucose (SMBGs; Accu-Chek Instant, Roche) are needed for calibration of the glucose sensors.~The BIHAP-system has to be worn continuously, except while showering."
215081450|NCT00110630|BEHAVIORAL|10-week smoking cessation group therapy combined with NicoDerm CQ|
215081451|NCT02138474|OTHER|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
214393716|NCT01777243|DRUG|GSK2315698|Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
215081452|NCT02138474|OTHER|Placebo|Unmedicated sucrose pillules
215081453|NCT03730961|DRUG|BMS-986231|Intravenous administration
215081454|NCT03730961|DRUG|Furosemide|Intravenous administration
215081455|NCT03730961|DRUG|Placebo|Intravenous administration
215081456|NCT05027490|OTHER|CANUT support|CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
214679054|NCT01253512|DRUG|Placebo|Intravenous
214679055|NCT03459131|DEVICE|Comfilcon A with Digital Zone Optics™ contact lenses|Silicone hydrogel spherical contact lenses with Digital Zone Optics™
214679056|NCT03459131|DEVICE|Comfilcon A contact lenses|Silicone hydrogel spherical contact lenses
214679057|NCT04703660|PROCEDURE|cervical mobilization|3 types of cervical mobilization at the level of C 5- 6
215081457|NCT05027490|OTHER|Anthropometric measures|These measures include weight, waist size, hip size and brachial circumference
214679058|NCT04628403|OTHER|massage|clinical interventions, of mechanophysiological origin for the treatment of symptoms corresponding to DOMS, after exercise
214679059|NCT04628403|DEVICE|lasertherapy|lasertherapy
214679060|NCT04628403|DEVICE|shock waves|shock waves
214356474|NCT04909242|DRUG|Placebo|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.
214966519|NCT00870467|DRUG|Double-blind Placebo|Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
215081458|NCT05027490|OTHER|Prehension strength measurement|Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
215081459|NCT05027490|BEHAVIORAL|QVA Questionnaire|Food quality of life questionnaire
215081460|NCT05027490|BEHAVIORAL|QLQ C30 Questionnaire|Quality of Life questionnaire Core 30
215081461|NCT05027490|BEHAVIORAL|Scratch & Snif Test|The Scratch \& Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
215081462|NCT05027490|BEHAVIORAL|Taste Strip Test|The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
215081463|NCT05027490|BEHAVIORAL|24 H feed back questionnaire|This questionnaire describes patient's food and drink intakes during the last 24 ours
215081464|NCT05027490|BEHAVIORAL|Condiment questionnaire|This questionnaire used to assess condiments consumption
215081465|NCT05027490|BEHAVIORAL|Tobacco questionnaire|This questionnaire used to assess tobacco consumption
214356475|NCT04909242|DRUG|DZD9008|In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.
215081466|NCT05027490|OTHER|Nutrition interview|This interview will be conducted by a dietician
215081467|NCT02203383|DEVICE|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
215081468|NCT02088619|BEHAVIORAL|Quality of Life Therapy (QOLT)|
214356476|NCT04909242|DRUG|DZD9008|Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).
214356477|NCT02178748|BIOLOGICAL|MVA85A|Single dose of 1x10\^8pfu MVA85A intramuscular vaccination
215081469|NCT02088619|BEHAVIORAL|Heart Healthy Education (HHE)|
215081470|NCT03130660|DEVICE|Ultrasonography|Ultrasound guidance for central line
215081471|NCT02615860|OTHER|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
214393717|NCT04117061|PROCEDURE|Observation|Patient after primary investigation is observed for 8-12 hours, (instead of being send directly to CT scan), after observation repeated clinical evaluation, laboratory tests and ultrasound examination are done , if final diagnosis stays unclear the patient is refered to CT scan.
214393718|NCT02929342|DRUG|Pitolisant|
214393719|NCT02929342|RADIATION|[14C]-Pitolisant|
214393720|NCT03477461|DRUG|terlipressin|a continuous infusion of terlipressin (0.4 mg/kg/h) was initiated
214966520|NCT00870467|BIOLOGICAL|Open-label Adalimumab|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
214966521|NCT00870467|BIOLOGICAL|Open-labelAdalimumabRescue|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
215081472|NCT02615860|PROCEDURE|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
215081473|NCT02728960|PROCEDURE|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
215081474|NCT02071420|BEHAVIORAL|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
215081475|NCT02071420|BEHAVIORAL|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
214966522|NCT05627050|DEVICE|An Online Augmented Reality (AR) Training Platform|The hardware system is based on camera depth sensor and combined with 3D human tracking technology and intelligent technology, to monitor, correct and record the user's whole body movements in real-time, and the users can follow the training program.
214356478|NCT04347551|OTHER|High velocity/low amplitude cervical spine manipulation|The participants will receive a single cervical spine rotary manipulation to the previously identified palpable cervical segmental fixation. During the performance of the manipulation, the supine participant will rest their arms at the sides of their body. Next, the index finger of the chiropractor's contact hand will be placed on the lamina of the restricted cervical segment. The chiropractor will then rotate the participant's head contralaterally until the barrier of the cervical segments volitional end range is reached. The chiropractor's other hand will be placed behind the participant's head to induce gentle neck rotation contralateral to the chiropractor's thrusting hand. The chiropractor will deliver a manual thrust, with the thrust vector directed towards the participant's opposite eye.
214356479|NCT02163733|DRUG|AZD9291 tablets|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
214356480|NCT02163733|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
214356481|NCT02163733|OTHER|Dietary Fasted|Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing
214356482|NCT02163733|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 80mg AZD9291 tablet
214356483|NCT02163733|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
214356484|NCT00275197|DRUG|Sertraline and Elzasonan Combination|
214356485|NCT00275197|DRUG|Sertraline|
214356486|NCT00275197|DRUG|Placebo|
214966523|NCT06092528|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed with Power Breathe®. Inspiratory muscle training will be given to the training group, starting from 50% of the MIP, and 2 sessions/day, 15 minutes/session. Patients will be asked to check breathing for 4-5 breaths after 8-10 consecutive breathing cycles. The patient will continue this cycle for 15 minutes.
214966524|NCT06092528|OTHER|Upper extremity aerobic exercise training|Upper extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 min/session using arm ergometer device accompanied by a physiotherapist. Aerobic exercise training workload will be 60-80% of maximal heart rate. In this study, the perception of dyspnea will be between 3-4, arm fatigue and general fatigue perception will be between 5-6, warm-up and cool-down periods will be 5 minutes, and pedaling speed will be 40-50 rev/min, according to MBS.
214966525|NCT06092528|OTHER|Lower extremity aerobic exercise training|Lower extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 minutes/session using the treadmill device, accompanied by a physiotherapist. Aerobic exercise training workload was set at 60-80% of maximal heart rate, dyspnea perception according to MBS was between 3-4, arm fatigue and general fatigue perception was between 5-6, and warm-up and cool-down periods were 5 minutes.
214966526|NCT06092528|OTHER|Resistant exercise training|Upper and lower additional limb strengthening training will be performed 3 days/week, 1 session/day, 10 repetitions/sessions from the first day by using bullion weights in the presence of a physiotherapist. The upper extremity strengthening program will consist of a progressive exercise program to strengthen the shoulder flexors and abductors, and the lower extremity strengthening program to strengthen the knee extensors. The training workload will be increased progressively. For strength training, the workload will be adjusted so that the perception of fatigue is between 4 and 6 according to MBS.
214966527|NCT06092528|OTHER|Thoracic expansion exercises|The control group will be asked to do thoracic expansion exercises seven days/week and 120 pieces/day for six weeks.
214966528|NCT00003925|DRUG|gemcitabine hydrochloride|
214966529|NCT00003925|DRUG|leucovorin calcium|
214966530|NCT00003925|DRUG|tegafur-uracil|
214966531|NCT03155555|OTHER|Measurement of aortic and carotid Doppler peak systolic velocity variation|Aortic peak systolic velocity variation to be measured by echocardiography from apical five chamber and suprasternal windows alongwith carotid peak systolic velocity variation by Doppler ultrasound simultaneously at intermittent time points intermittently.
214356487|NCT03633968|PROCEDURE|maxillary sinus lift|maxillary sinus floor elevation by using balloon through either small or large antrostomy without using graft material with simultaneous implant placement
214356488|NCT04552964|OTHER|Single arm|Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire
214356489|NCT00526266|BEHAVIORAL|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
214356490|NCT00526266|BEHAVIORAL|Diaphragmatic Breathing (DB)|"Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping."
214393721|NCT05195593|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
214966532|NCT02340143|OTHER|Control|Marketed partially hydrolyzed cow's milk protein infant formula
214966533|NCT02340143|OTHER|Investigational|Partially hydrolyzed cow's milk protein infant formula with a probiotic
214966534|NCT00992641|OTHER|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
214966535|NCT00992641|OTHER|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
214966536|NCT02106351|BIOLOGICAL|Botulinum toxin type A|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
214966537|NCT00524706|DRUG|S-1, oral Leucovorin, Oxaliplatin|
214966538|NCT02405767|OTHER|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
214966539|NCT00094523|DRUG|Fosamprenavir|Fosamprenavir
214966540|NCT00000256|DRUG|20% N2O|
214966541|NCT00000256|DRUG|40% N2O|
214966542|NCT00000256|DRUG|60% N2O|
214966543|NCT00000256|DRUG|80% N2O|
214966544|NCT00287209|DRUG|Amiodarone|
214966545|NCT02005237|BEHAVIORAL|Aerobic Exercise|3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
215081476|NCT02071420|BEHAVIORAL|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
214356491|NCT02633800|DRUG|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
215081477|NCT02071420|DEVICE|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
215081478|NCT02306863|DEVICE|vibrating chair|vibration provided via physioacoustic method
215081479|NCT02306863|DEVICE|sham treatment|simulated whole-body vibration
214356492|NCT02633800|DRUG|Cetuximab|Cetuximab 400 mg/mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
214356493|NCT02633800|DRUG|Cisplatin|Cisplatin at 100 mg/m\^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
214356494|NCT02633800|DRUG|Carboplatin|Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
214356495|NCT02633800|DRUG|Placebo|Placebo to match patritumab
214966546|NCT03876483|BEHAVIORAL|Virtual peer support group|Intervention package will consist of a WhatsApp group setup and organized by the study. Participants will be divided into 1-3 WhatsApp groups, each with 10-55 youth. Each group will be facilitated by a study staff member trained as a counselor. The facilitator will send weekly messages to the group. Messages from the facilitator will not contain overtly HIV-related language. These messages are intended to spark unstructured discussion among study participants, or with the facilitator, at any time through the WhatsApp group or individually. Subsequent messages from the study will answer participant questions or correct misinformation. Standard operating procedures (SOPs) will be developed for standardizing responses to the questions received so that study staff follow national guidelines and local practice standards to respond.
214966547|NCT02986347|PROCEDURE|Intravenous regional anesthesia (Bier)|Intravenous regional anesthesia (Bier Technique)
214966548|NCT02986347|PROCEDURE|Local anesthesia with adrenaline|local anesthesia with adrenaline without limber garroting (Lalonde Technique)
214356496|NCT04911790|BIOLOGICAL|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
214356497|NCT02176551|DRUG|Product 0405|Product 0405 will be administered topically twice daily for 28 days.
214356498|NCT02176551|DRUG|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
214356499|NCT05154279|DRUG|Terlipressin|intramyometrial terlipressin vs carbitocin vs saline as placebo
214356500|NCT01094925|DRUG|lactose|Single oral dose
214356501|NCT01094925|DRUG|Gabapentin 300mg|Single oral dose of 300mg gabapentin
214356502|NCT01094925|DRUG|Gabapentin 600mg|Single oral dose of 600mg gabapentin
214966549|NCT06477705|OTHER|FAM|Participants will perform a recreational Football Training session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
214966550|NCT01941199|DRUG|DA-1229|
214966551|NCT01941199|DRUG|metformin|
214966552|NCT01941199|DRUG|DA-1229 + metformin|
214356503|NCT03894852|DIAGNOSTIC_TEST|PCR and cytogenetics|detection of SRSF2 gene mutation and cytogenetic studies
214356504|NCT03979170|PROCEDURE|Lung tumor resection|lung tumor resection
214356505|NCT02486289|DRUG|Emeramide|Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
214356506|NCT02486289|DRUG|Placebo|NBMI Placebo
214356507|NCT02526654|DIAGNOSTIC_TEST|Heidelberg Edge Perimeter|HEP measures peripheral vision
214966553|NCT00683761|DRUG|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
215081480|NCT03410797|DEVICE|Inclusion of semi-occluded mask in voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
215081481|NCT01244581|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
215081482|NCT01244581|DRUG|Placebo|Placebo mixture in two daily doses for 7 days
215081483|NCT00274560|DRUG|Tiotropium|
215081484|NCT00274560|DRUG|Salmeterol|
215081485|NCT01854892|OTHER|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
215081486|NCT01854892|OTHER|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
215081487|NCT01854892|OTHER|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
215081488|NCT05709067|DIETARY_SUPPLEMENT|Probiotic|6 Billion CFU per day
215081489|NCT05709067|DIETARY_SUPPLEMENT|Placebo|0 CFU per day
215081490|NCT05211804|DRUG|Ophthalmic Drugs|Patients will receive the same treatment as if not a part of the project
214356508|NCT02526654|DIAGNOSTIC_TEST|Octopus Visual Field|OVF measures peripheral vision
214356509|NCT02526654|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT measures retinal nerve fiber layer thickness
214356510|NCT00002568|DRUG|cisplatin|
214356511|NCT00002568|DRUG|paclitaxel|
214356512|NCT00002568|PROCEDURE|conventional surgery|
214356513|NCT03137134|DRUG|Crizotinib|Crizotinib in a coated microsphere formulation
214356514|NCT03137134|DRUG|Esomeprazole|Proton pump inhibitor, esomeprazole
214356515|NCT00000392|DRUG|Peptide T|
214356516|NCT00000392|DRUG|Placebo|
214356517|NCT03006250|DRUG|Desflurane|Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
214356518|NCT03006250|DRUG|Sevoflurane|Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
214356519|NCT02438618|PROCEDURE|Surgery for Ponto bone anchored hearing aids|
214356520|NCT06372769|DIAGNOSTIC_TEST|electromyograph and kinesiograph|"The sEMG of the anterior temporalis (TA), masseter (MM), sternocleidomastoid (cervical group, CG), and digastric (DA) were recorded simultaneously with an sEMG device (K7/EMG, USA) using disposable silver/silver chloride bipolar surface electrodes.~First, sEMG was conducted on four pairs of muscles (TA, MM, CG, and DA) in the MPP, and subjects were guided to maintain the face and jaw as relaxed as possible. To determine the relative efficiency of muscle function, the second test was performed to measure the sEMG of TA and MM during the maximal biting force against natural dentition. In the third test, subjects were guided to clench three times to monitor early motor unit recruitment as they closed from rest through freeway space to initial tooth contact.~Kinesiographic recordings were performed using a kinesiograph (K7/Computerized Mandibular Scanning (CMS), USA) that measured the maximum mouth opening (MMO) and opening and closing velocities."
214356521|NCT06188572|OTHER|Michigan Neuropathy Screening Instrument|A two-step test consisting of symptom questionnaire and physical examination was used. The symptom questionnaire includes 15 questions about the legs and feet. Physical examination includes assessment of the appearance of the feet, Achilles reflex, thumb vibration and monofilament tests.
214356522|NCT06188572|OTHER|Numeric Pain Scale|"In this simple method, which is frequently used to measure pain intensity in the clinic and whose validity and reliability have been demonstrated, the participant is asked to mark a number on a 10 cm scale with numbers ranging from 0 (no pain) to 10 (unbearable pain) for the pain."
214356523|NCT06188572|OTHER|Mandibular Function Disorder Questionnaire|This valid and reliable scale evaluating mandibular dysfunction consists of two dimensions and 17 questions.A high total score obtained from the questionnaire indicates a high level of impairment in jaw function
214356524|NCT06188572|OTHER|Fonseca Anamnestic Index|This scale, which is valid and reliable as a TMJ disorder assessment tool, includes 10 questions. The presence of TMD is accepted in those with a score of 25.
214356525|NCT06188572|OTHER|Ferrans&Powers Quality of Life Index Diabetes Version|This index consists of two parts and a total of 68 items. A high score indicates a good quality of life.
214356526|NCT01848873|DRUG|Amlodipine|amlodipine 5mg daily
214356527|NCT01848873|DRUG|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
214356528|NCT01848873|DRUG|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
214356529|NCT06532214|DIAGNOSTIC_TEST|International Study Group for Liver Surgery (ISGLS)|According to the ISGLS criteria, the patient was judged to have liver failure and further analysis
214356530|NCT05510843|DRUG|THB001|100 mg capsules for oral administration
214356531|NCT05394870|OTHER|manual lymphatic drainage (massage)|Patients will begin treatment with manual lymphatic drainage in the affected extremity. In this context, while the patients are in the supine hook position, lymph drainage will be applied first to the neck and then to the abdomen. After the stimulation of the central lymph nodes, the lymph circulation will be increased by stimulating the axillary lymph nodes of the relevant region. First, the proximal part will be drained and it will be advanced towards the distal. Drainage will be repeated depending on the edema at the distal forearm-wrist level.
214356532|NCT05394870|OTHER|Splint treatment|The splint routinely given to patients diagnosed with mild to moderate carpal tunnel syndrome will be given to both groups in these patients
214356533|NCT02836808|BEHAVIORAL|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
214356534|NCT02836418|DRUG|ATYR1940|Concentrate for solution for infusion
214356535|NCT06311695|DEVICE|Contrast Enhanced Mammography|Contrast Enhanced Mammography
214356536|NCT02264028|DRUG|[14C]-DK-AH 269 CL, solution for infusion|
214356537|NCT02264028|DRUG|[14C]-DK-AH 269 CL, drinking solution|
214356538|NCT01087853|DRUG|Crystalloid|2 litres intravenous infusion in 60 minutes
214356539|NCT01087853|DRUG|Colloid|1 litre intravenous infusion over 30 minutes
214356540|NCT04522518|DEVICE|PmP-C App|"The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to."
214356541|NCT01835886|OTHER|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
214356542|NCT01936064|DIETARY_SUPPLEMENT|Jobelyn + Cyclophosphamide-Epirubicin6|Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6
214356543|NCT01936064|DRUG|Placebo + Cyclophosphamide - Epirubicin 6|Routine drugs for the treatment of breast cancer to be used with Placebo
214356544|NCT05457608|DEVICE|Lens A|monthly replacement multifocal silicone hydrogel contact lens 15 minutes of daily wear
214679061|NCT02219555|DRUG|Steroid Injection|volume and specific steroid drug will be based on the recommendation of the treating clinician
214679062|NCT02219555|PROCEDURE|Carpel Tunnel surgery|Standard of care carpel tunnel surgery
214966554|NCT01494012|RADIATION|stereotactic body radiation therapy|Undergo SBRT
214966555|NCT01494012|PROCEDURE|positron emission tomography|Undergo FDG-PET/CT
214966556|NCT01494012|PROCEDURE|computed tomography|Undergo FDG-PET/CT
214966557|NCT01494012|OTHER|questionnaire administration|Ancillary studies
214679063|NCT00162396|DRUG|Albuterol|
214966558|NCT01494012|DRUG|fludeoxyglucose F 18|Undergo FDG-PET/CT
214966559|NCT02574936|PROCEDURE|A new surgical technique|"Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.~A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used"
214966560|NCT01544647|OTHER|Usual spa protocol|In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
214966561|NCT01544647|OTHER|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
214966562|NCT04506723|PROCEDURE|Percutaneous Nephrolithotomy|PCNL will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
214966563|NCT04506723|PROCEDURE|Partial nephrectomy|Partial nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
214966564|NCT04506723|PROCEDURE|Radical nephrectomy|Nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
214966565|NCT02150252|DRUG|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
214966566|NCT00520039|PROCEDURE|osteopathic manipulative medicine (OMM)|At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
214966567|NCT03562858|PROCEDURE|Immediate dentin sealing protocol|Sealing of the dentin before impression taking directly after cavity preparation to prevent postoperative hypersensitivity during provisionalization and after cementation
214966568|NCT03562858|PROCEDURE|Delayed dentin sealing protocol|Sealing the dentin just prior to cementation
214966569|NCT05533489|OTHER|No intervention|No intervention This study is a retrospective descriptive study.
214966570|NCT01184612|BEHAVIORAL|Motivational Interviewing; MI|"MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client."
215081491|NCT03084913|OTHER|Plant- based, olive oil diet|used as part of daily diet, followed for 8 weeks
214356545|NCT05457608|DEVICE|Lens B|daily disposable multifocal silicone hydrogel contact lens 15 minutes of daily wear
214679064|NCT05855928|DIAGNOSTIC_TEST|Mime Therapy|electrical stimulation with the MIME therapy and protocol
214679065|NCT05855928|DIAGNOSTIC_TEST|PNF Technique|electrical stimulation with the PNF technique with the routine physical therapy
214679066|NCT04623190|BEHAVIORAL|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
214966571|NCT00244153|DRUG|intraarticular morphine|
214966572|NCT00244153|DRUG|intraarticular dexamethasone|
214966573|NCT05492513|BEHAVIORAL|Grade 1 CI Therapy +Sensory Components|All participants will receive Grade 1 CI Therapy + Sensory Components over a two-week period of time. The treatment intervention will include all CI Therapy treatment strategies including: 1) supervised motor training in the form of shaping with repeated trials and task practice for 1.5 hours per day for 5 weekdays for 2 weeks 2) a behavioral Transfer Package (TP) will be employed to aid carry-over of skills gained by the participant in the laboratory to the life situation 3) each participant will wear a mitt on the less-affected hand for most of their waking hours to encourage use of the more-affected hand 4) participants will be given home assignments to be carried out for at least 30 minutes each day. Sensory component strategies will be added to stimulate sensory input through the more-affected arm and hand as well as to train sensory discrimination skills.
214966574|NCT04140214|DRUG|Hypertonic saline|Nebulized hypertonic saline solution (6%)
214966575|NCT04140214|DRUG|Carbocysteine 750 MG|Carbocisteine tablet
215081492|NCT03084913|OTHER|Prostate Cancer Foundation diet|followed for 8 weeks
215081493|NCT02441140|PROCEDURE|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
215081494|NCT02441140|PROCEDURE|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
215081495|NCT02441140|PROCEDURE|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
215081496|NCT02441140|PROCEDURE|Blood collection|Intravenous blood collection will be drawn from an IV
214966576|NCT06241885|BEHAVIORAL|Intervention group I|Women in Intervention Group II will wear gynaecological shorts specially developed by the researchers before vaginal examination. These shorts will be made of disposable fabric and will be sewn by the researchers in four different sizes (S-M-L-XL) according to the weight of the women. The middle part of the shorts will be closed with a snap button, and the opening will be provided when the snap button is opened during vaginal examination. In addition, these shorts will be approximately knee-cap length for women.
214356546|NCT02884297|DRUG|Contrast agent: SonoVue®.|SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
214356547|NCT04319211|OTHER|Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.|The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
214356548|NCT06385808|DRUG|MTBF regimen|"The subjects will be treated with mitoxantrone hydrochloride liposome combined with thiotepa, busulfan and fludarabine as conditioning regimen prior to allo-HSCT.~Mitoxantrone hydrochloride liposome 24mg/m\^2 ivgtt d-7; Ctepide 5mg/kg ivgtt d-6\~-5; Busulfan 0.8mg/kg q6h ivgtt d-4\~-2; Fludarabine 50mg/m\^2 ivgtt d-4\~-2."
214356549|NCT02530307|DRUG|HT-3951|
214356550|NCT02530307|DRUG|Placebo|
214356551|NCT04091074|DRUG|Ticagrelor|Half of patients undergoing carotid stenting take ticagrelor+aspirin
214356552|NCT04091074|DRUG|Clopidogrel|Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin
214966577|NCT00223665|DRUG|Flutamide|Flutamide dosed at 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.
214966578|NCT00223665|DRUG|Leuprolide Acetate|Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.
214966579|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 1 + adjuvant / dose; Day 0 and Day 30
215081497|NCT02441140|PROCEDURE|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
214356553|NCT04091074|PROCEDURE|Carotid stenting|Patients with carotid stenosis will undergo carotid stenting
214356554|NCT06213766|DIAGNOSTIC_TEST|Cognitive assessment|"Group 1: Cognitively healthy subject:~After signing the consent form, during the only visit of the study, the investigator will administer to cognitively healthy subjects two cognitive screening tests to ensure that they meet the criteria for group 1. If performance on the cognitive scales prove to be borderline or below current standards (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15) for at least one of the 2 tests, the participant will prematurely end the study and may be offered an in-depth cognitive assessment as part of routine care.~Group 2: Patients suffering from Alzheimer's disease:~After signing the consent form, during the only visit of the study, the investigator will administer to patients the Montreal Cognitive Assessment to assess cognitive status."
214356555|NCT06213766|OTHER|Questionnaires|"For every participants (group 1 and 2):~During the only visit of the study and after the intervention 1, the participants will answer questionnaires about:~* Demographic data such as age, gender, weight, height, education level;~* Lifestyle habits such as usual mode of transport, sense of direction, use of GPS device, and video game practice;~* Quality of sleep over the previous month and the previous night;~* Cognitive reserve questionnaire from Rami et al., 2011;~* Concomitant treatment and comorbidities."
214356556|NCT06213766|DEVICE|Spatial navigation task with eye-tracking.|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1 and 2, the participants will complete the spatial navigation task with eye-tracking.~The participants will play the Sea Hero Quest video game and take on the role of the captain of a small boat that has to find its way through an aquatic environment. At the start of each level, the player is shown a map of the environment, with the boat's initial position and the buoys it must reach as quickly as possible in a set order. Once the map has been memorised, it disappears and the navigation begins.~Participants will play 6 levels of Sea Hero Quest (two training levels and four different navigation levels). This intervention will be proposed by a trained team member and participants will play on a digital tablet connected to an eye-tracker. The total duration of the task is 30 min (training phase + assessment sequences)."
214966580|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 2 + adjuvant / dose; Day 0 and Day 30
214966581|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 3 + adjuvant / dose; Day 0 and Day 30
214966582|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 3 / dose; Day 0 and Day 30
214966583|NCT01290419|BIOLOGICAL|Placebo|Placebo; Day 0 and Day 30
214966584|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 4 / dose; Day 0 and Day 30
214966585|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 4 + adjuvant / dose; Day 0 and Day 30
214966586|NCT04482088|BEHAVIORAL|Occupational Therapy in an Equine Environment|10 weeks of occupational therapy in an equine environment aimed at improving individual goals related to self-regulation, social communication, and play
214966587|NCT04482088|BEHAVIORAL|Occupational Therapy in a Clinic (OTC)|10 weeks of occupational therapy in a clinic aimed at improving individual goals related to self-regulation, social communication, and play
215081498|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
215081499|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
215081500|NCT03606447|DRUG|Uproleselan|\[14C\]-Uproleselan
214966588|NCT05263518|PROCEDURE|Cataract surgery with AcrySof IQ IOL implantation.|Patients in this study will receive cataract surgery with AcrySof IQ IOL implantation.
214966589|NCT05263518|PROCEDURE|Cataract surgery with TECNIS toric IOL implantation.|Patients in this study will receive cataract surgery with TECNIS toric IOL implantation.
214966590|NCT05176717|DRUG|QR-421a|RNA antisense oligonucleotide for intravitreal injection
214966591|NCT05176717|OTHER|Sham-procedure|Sham-procedure (no experimental drug administered)
214966592|NCT03284853|DRUG|Netarsudil/Latanoprost 0.02%/0.005%|Topical sterile ophthalmic solution
214966593|NCT03284853|DRUG|GANFORT®|Topical sterile ophthalmic solution
214966594|NCT03208608|DIAGNOSTIC_TEST|RBANS-H|The RBANS-H is a diagnostic cognitive test battery
214966595|NCT06283407|OTHER|ICF-based cross-country comparative analysis|ICF-based cross-country comparative analysis
214966596|NCT00534417|DRUG|capecitabine|Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight \< 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
214356557|NCT06213766|BIOLOGICAL|Blood sampling|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1, 2 and 3, a state-qualified nurse will take venous samples from 3 tubes of 4ml each.~These blood samples will be frozen and stored until the end of the study when they will be analysed:~* Sample 1: plasmatic Quanterix p-tau217 assay;~* Sample 2: apolipoprotein E genotyping;~* Sample 3: measurement of plasmatic creatinine levels. Neither the cognitively healthy subjects, nor the patients, nor the clinicians in charge of the patients included will be informed of the results of these biological assays (absence of clinical interest established at the present time of the APOE genotype and the p-tau217 protein level, absence of modification of the care pathway, in adequacy to the bioethics law of August 02, 2021. Creatinine level is used in this study as an adjustment variable to interpret the p-tau217 protein level and will not be used for clinical interpretation."
214356558|NCT02207920|BIOLOGICAL|AIDSVAX B/E Vaccine|600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
214356559|NCT02207920|BIOLOGICAL|DNA-HIV-PT123 Vaccine|4 mg/mL to be administered as 1 mL IM injection
214356560|NCT02207920|BIOLOGICAL|Placebo for DNA-HIV-PT123|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
214966597|NCT00534417|DRUG|fulvestrant|Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
214966598|NCT00765817|DRUG|placebo|subcutaneous injection, twice a day
214966599|NCT00765817|DRUG|exenatide|subcutaneous injection, twice a day, 10mcg
214966600|NCT04239352|DIAGNOSTIC_TEST|Pentraxin 3 ; new biomarker|"Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component."
214966601|NCT04239352|DIAGNOSTIC_TEST|Lipoprotein-associated phospholipase A2 ; new biomarker|Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.
214966602|NCT03905304|BIOLOGICAL|Medytoxin|Intramuscular injection up to 300U.
214966603|NCT03905304|BIOLOGICAL|Botox|Intramuscular injection up to 300U.
214966604|NCT02894814|BEHAVIORAL|One-Stop Dispensing|Use of own medication, review of the patient's medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
214966605|NCT02894814|BEHAVIORAL|One-Stop Dispensing and focused dialogue|Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
214966606|NCT04360369|DEVICE|IOP with Goldmann Applanation Tonometer|Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (\>16 to \<23 mmHg), or High IOP (\>23 mmHg).
214966607|NCT04360369|DEVICE|IOP with comparator ORA G3 and ic100 tonometers|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.
214966608|NCT04360369|DEVICE|IOP with Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer
214966609|NCT02429570|DRUG|Meclofenamate|
214966610|NCT01043133|BEHAVIORAL|social marketing-based medical education intervention|social-marketing based medical education intervention designed to influence medical student use of evidence-based templates. Led by physician instructor.
214966611|NCT03772834|BEHAVIORAL|Exercise Intervention|Undergo resistance training and walking
214966612|NCT03772834|DRUG|Methylphenidate|Given PO
214966613|NCT03772834|OTHER|Placebo|Given PO
214966614|NCT03772834|OTHER|Quality-of-Life Assessment|Ancillary studies
214966615|NCT03772834|OTHER|Questionnaire Administration|Ancillary studies
214966616|NCT03772834|OTHER|Stretching|Undergo stretching
214966617|NCT06607796|DRUG|Toluenesulfonamide (PTS) Intratumoral Injection|intratumoral injection of toluenesulfonamide(PTS) to oligo lesions
214966618|NCT06611566|BEHAVIORAL|VR-guided aerobic exercise|The intervention was 5 minutes of VR-guided aerobic exercise
214966619|NCT06611566|BEHAVIORAL|VR-guided mindfulness exercise|The intervention was 5 minutes of VR-guided mindfulness exercise
214966620|NCT06611566|BEHAVIORAL|TV-guided aerobic exercises|The intervention was 5 minutes of TV-guided aerobic exercises
214966621|NCT06611566|BEHAVIORAL|TV-guided mindfulness exercises|The intervention was 5 minutes of VR-guided mindfulness exercises
214966622|NCT06480786|DEVICE|Spinal cord stimulation|active spinal cord stimulation
214966623|NCT06480786|DEVICE|Sham stimulation|Sham stimulation
215081501|NCT00537667|DRUG|anakinra|anakinra
215081502|NCT00537667|DRUG|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
215081503|NCT05764304|DRUG|Sinomenine|Participants will receive one intra-articular injection every 4 months
215081504|NCT05764304|DRUG|Glucocorticoid|Participants will receive one intra-articular injection every 4 months
215081505|NCT03355560|DRUG|Nivolumab|Nivolumab 480 mg IV infusion
214356561|NCT02207920|BIOLOGICAL|Placebo for AIDSVAX B/E|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
214966624|NCT04460248|DRUG|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|"Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-21;~2. Lenalidomide, 25 mg qd, po, day 2-11;~3. Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years."
214966625|NCT00298883|DRUG|Myfortic|Myfortic 360mg PO BID for six weeks
214966626|NCT06730152|BEHAVIORAL|WeChat Intervention Based on the IMB Model|The intervention group would undergo a six-week intervention program. Researchers promoted a public WeChat account to the intervention group, and participants received the intervention by following the account. They automatically received pushed articles or videos, providing them with relevant knowledge about overcoming smartphone addiction. Furthermore, they would be motivated to quit their addiction through real-life cases of smartphone addiction etc., in addition to some practical skills of overcoming.
214966627|NCT03852823|DRUG|SG001|Phase Ia: Subjects will receive intravenous infusion of SG001 following a sequential dose escalation design (1mg/kg, 3mg/kg and 10mg/kg). Dose limited toxicity (DLT) will be observed within 21 days after the first administration, then subjects can continuously receive SG001 every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial. Phase Ib: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial.
214966628|NCT00255164|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
214966629|NCT00255164|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
214966630|NCT00255164|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
214966631|NCT02017626|BIOLOGICAL|mCyp c 1|2 patient groups with different doses of allergen.
214966632|NCT03369873|OTHER|Guidance Manual|The intervention group received of nursing orientation using a validated guidance manual about cardiac catheterization.
214966633|NCT06868316|OTHER|Walking|"Weeks 1-2, Sessions 1-4: The first condition will be walking with the speed self-selected based on a comfortable pace to walk for exercise as determined during the Baseline testing session. This speed will be held constant for the 10-minute walking portion prior to each condition but will be progressed for the remaining walking condition sessions (Sessions 2-4). The minimum speed will be limited to 1 mph."
214966634|NCT06868316|OTHER|Rucking|"Weeks 3-4, Session 5-8: The second condition will require participants to wear a standard rucksack equal to 20% of their body weight (minimum ruck weight: 15 pounds, maximum ruck weight: 45 pounds). The initial speed used during this condition will be self-selected based on a comfortable pace to walk for exercise carrying this weight as determined during the Baseline testing session."
214966635|NCT06868316|OTHER|Running|"Weeks 5-6, Sessions 9-12: The final condition is running. The self-selected running pace will be chosen as a pace that the participant can sustain for a leisure run for 20 minutes, as determined at the Baseline testing session. Participants will only run for the 15-minute condition period."
214966636|NCT05219968|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
214966637|NCT05219968|DRUG|Sham procedure control|Sham procedure control
214966638|NCT05219968|OTHER|Background Therapy|Daily Saline Irrigation
214966639|NCT05798481|DRUG|Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.|Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
214966640|NCT04157205|DIAGNOSTIC_TEST|Non-invasive ECG imaging - CardioInsight test|"1. Consent session~2. Fitting of ECGi vest and CT scan of the chest~3. Supervised exercise test and Valsalva maneuvre~4. Programmed stimulation via ICD (selected participants)~5. Blood tests - genetics"
214966641|NCT06445582|DIAGNOSTIC_TEST|[18F]SDM-8|synaptic vesicle glycoprotein 2 A（SV2A）PET tracer \[18F\]SDM-8
215081506|NCT01913028|DRUG|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
215081507|NCT01913028|DRUG|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
215081508|NCT04083313|DEVICE|Technique used for closing the appendiceal stump|In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
215081509|NCT02913001|OTHER|Low Glycemic Load Diet|Participants received a diet education on a low glycemic load diet.
215081510|NCT02913001|OTHER|Usual Eating Plan|Participants received a diet education to continue with their usual eating plan.
214356563|NCT06473896|DRUG|Ketalar|a dissociative anesthetic used medically for induction and maintenance of anesthesia
214356564|NCT06473896|DRUG|Dexmedetomidine|an agonist of α2-adrenergic receptors in certain parts of the brain used for sedation
214356565|NCT00245895|DRUG|Aranesp|Aranesp
214356566|NCT05394246|DRUG|FluoAB|Drug Injection: FluoAB (fluorescent-labeled IgG)
214356567|NCT06147895|BIOLOGICAL|CVI-HBV-002|Investigational Product
214356568|NCT05607693|DRUG|SHR3680 tablets|Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
214356569|NCT00454948|BEHAVIORAL|Home-based nutrition sessions and play group exercise|
214356570|NCT00454948|BEHAVIORAL|Group-based nutrition sessions and mail-out activities|
214356571|NCT01358968|DRUG|LY2603618|Administered intravenously as a 1-hour infusion.
214356572|NCT01358968|DRUG|Desipramine|Administered orally
214966642|NCT03888326|DEVICE|1x1 anodal tDCS|20 minutes of 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
214966643|NCT03888326|DEVICE|Sham tDCS|Sham 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
214966644|NCT03888326|BEHAVIORAL|Robotic Rehabilitation|10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
214966645|NCT03782805|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
214966646|NCT03782805|DIETARY_SUPPLEMENT|Placebo tablet|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
214966647|NCT04911491|DEVICE|IMST|Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
214966648|NCT04911491|DEVICE|Sham Training|Repeated inhalations against a low resistance will be performed using a handheld device.
215081511|NCT05293613|DEVICE|extracorporeal shock wave lithotripsy|shock wave transmited from the device through patient body towards the stone to disintegrate it
215081512|NCT02200419|OTHER|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
215081513|NCT05058105|DRUG|FL058 500mg and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
215081514|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
214356573|NCT01358968|DRUG|Pemetrexed|Administered intravenously as a 10-minute infusion.
214356574|NCT01358968|DRUG|Gemcitabine|Administered intravenously as a 30-minute infusion.
214356575|NCT01049048|DIETARY_SUPPLEMENT|Vitamin D3|2500 IU Vitamin D3
214356576|NCT01049048|DIETARY_SUPPLEMENT|Placebo|No (0 IU) vitamin D3 added to cookie.
214356577|NCT00728390|DRUG|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
214356578|NCT04892355|DEVICE|Root canal irrigation|Devices used during root canal irrigation
214966649|NCT02066597|DEVICE|Thrombectomy|Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
214966650|NCT04587336|BEHAVIORAL|Cognitive Interview|Examine the understanding and interpretation of diabetes distress and the Diabetes Distress Scale in Veterans with T2D.
214966651|NCT04587336|BEHAVIORAL|Baseline Survey|Examine the association of psychosocial factors (depression, PTSD), environmental factors (finances, support), self-management behaviors, and HbA1c with DD.
214966652|NCT04587336|BEHAVIORAL|Qualitative Interviews|Describe self-management challenges and preferred learning strategies to inform intervention components and delivery approach for Veterans with T2D.
214966653|NCT06950047|PROCEDURE|distal femoral osteotomies using the PediLoc® Locking Cannulated Blade Plate System|distal femoral osteotomies using the PediLoc® Locking Cannulated Blade Plate System
214966654|NCT06950047|PROCEDURE|distal femoral osteotomies using the 90°LCP-PCP|distal femoral osteotomies using the 90°LCP-PCP
215081515|NCT05058105|DRUG|FL058 1000mg（ IV 120min）|D1 qd;
215081516|NCT05058105|DRUG|FL058 Placebo （ IV 120min）|D1 qd;
215081517|NCT05058105|DRUG|Meropenem 1000 mg （ IV 120min）|D4 qd;
214356579|NCT06356064|DEVICE|Extracorporeal shock wave therapy|Radİal ESWT and focus ESWT
214356580|NCT02777151|DRUG|REGN3470-3471-3479|
214356581|NCT02777151|DRUG|Placebo|
214356582|NCT03630874|OTHER|Evaluate the impact of a prescription support tool|"From a systematic review of international guidelines (2012-2018), we developed a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy.~In the experimental group, the tool will be provided with an explanatory guide. Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (thanks to the tool) the right prescription of ATs by answering a multiple-choice question, with the number, type, duration and dosage of AT provided."
215081518|NCT05058105|DRUG|Meropenem Placebo （ IV 120min）|D4 qd;
215081519|NCT05058105|DRUG|FL058 1000mg and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
215081520|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
215081521|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
215081522|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
215081523|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
215081524|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
215081525|NCT05058105|DRUG|FL058 2000mg and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
215081526|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
215081527|NCT02280902|BIOLOGICAL|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
215081528|NCT04104919|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
215081529|NCT04104919|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
214356583|NCT00968682|BIOLOGICAL|trastuzumab|
214966655|NCT06949007|BEHAVIORAL|Yoga|Duration: 12 weeks; Class length: Three ∼75-minute classes per week. Two in-person/virtual (hybrid), one virtual only (MGB Zoom); Frequency: Three classes per week; Group size: 8-9 PPSP patients.
214966656|NCT06949007|BEHAVIORAL|Chronic Pain Health Education|Duration: 12 weeks (short videos and PowerPoint presentations); Class length: Interactive 15-30 minute education sessions delivered via video conference (i.e., MGB Zoom); Frequency: Three classes per week; Group size: 8-9 PPSP patients.
214966657|NCT06955156|DRUG|Trilaciclib|trilaciclib 240mg/m2 ivgtt d1 Q3w; anti-PD-1 antibody 200mg ivgtt d1 Q3w; Paclitaxel-albumin 250mg/m2 ivgtt d1 Q3w or 125mg/m2 ivgtt d1,d8 Q3w; carboplatin AUC=5 ivgtt d1 Q3w; Review every 2 cycles until the best efficacy or intolerable toxicity, usually 6-8 cycles;
214966658|NCT05570552|BEHAVIORAL|mHealth based behavioral change communication intervention|We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.
214966659|NCT02259205|OTHER|Enriched Yogurt|150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
214356584|NCT00968682|OTHER|laboratory biomarker analysis|
214966660|NCT02259205|OTHER|Plain Yogurt|150 g plain yogurt will be provided daily for 8 weeks
214356585|NCT00968682|PROCEDURE|assessment of therapy complications|
215081530|NCT03952117|DEVICE|transcranial direct current stimulation|tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
215081531|NCT03489967|OTHER|Induced-hypoglycemia test|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
215081532|NCT04005560|OTHER|no interventional study|no interventional study
215081533|NCT03663374|DRUG|Odelepan|Tablets, 125 mg
214356586|NCT06304259|DRUG|Saline|Submucosal infiltration injection of 1 mL cryo-treated saline maintained at a temperature of 2 to 5°C before the normal local anaesthetic routine
214356587|NCT06304259|DRUG|Saline|root canal treatment with final flush of cold saline maintained at a temperature of 2 to 5°C
214356588|NCT02821273|OTHER|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
214356589|NCT02821273|OTHER|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
214356590|NCT04832503|BEHAVIORAL|PROMPT- treatment|PROMPTs for Restructuring Oral Muscolar Phonetic Targets
215081534|NCT03663374|DRUG|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
215081535|NCT01810848|DEVICE|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
215081536|NCT01810848|OTHER|Control|Control is puncture of the skin at the site of the knee.
214356591|NCT04832503|BEHAVIORAL|LNSOM-treatment|Language Non-Speech Oral Motor Treatment
214356592|NCT02024906|DIETARY_SUPPLEMENT|soy protein isolate (SPI)|
214356593|NCT02024906|DIETARY_SUPPLEMENT|milk protein isolate (MPI)|
214356594|NCT01992380|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
214356595|NCT01992380|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection
214356596|NCT03438123|DEVICE|CZT SPECT imaging|Acquisition of SPECT (single photon emission computed tomography) imaging utilising a camera system with solid-state cadmium zinc telluride (CZT) detectors to visualise injected, or otherwise introduced, radioactivity in the human body.
214356597|NCT01413568|DRUG|POL6326|
214356598|NCT01413568|PROCEDURE|Leukapheresis|
214356599|NCT01413568|PROCEDURE|PBSC Transplant|
214356600|NCT05022680|BEHAVIORAL|mhealth|the peer-led intervention with mHealth technology (an application (APP) and Sports bracelet)
214356601|NCT03376581|PROCEDURE|Platelet rich plasma|Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.
214356602|NCT01420055|DRUG|fingolimod|
214356603|NCT03474341|DIAGNOSTIC_TEST|MRI|"* Anatomical (T2W) and functional MRI (DWI and DCE) at a 1.5T Siemens or Philips scanner~* DWI series: sagittal (sIVIM) and high-resolution transversal (HR tDWI)~* DCE serie: dynamic20~* In total, three MRI scan series (before, during, after nCRT)~* Measurements: i.a. change in apparent diffusion coefficient (ADC) or area-under-the-gadolinium-concentration time curve (AUC) within tumor delineation over time, radiological (qualitative) assessment of residual disease"
214393722|NCT03701009|PROCEDURE|CBD stone removal via lithotripsy|Hold saline irrigation just after X-ray demonstrated no stone residue, a Spyglass explored.
214393723|NCT03701009|PROCEDURE|Saline 50ml|If not clean, intermittent saline irrigation 50ml, and Spyglass explored second time.
215081537|NCT04442256|DRUG|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
215081538|NCT01185964|BIOLOGICAL|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
215081539|NCT01185964|DRUG|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
214356604|NCT03474341|DIAGNOSTIC_TEST|PET-CT|"* According to European Association of Nuclear Medicine (EANM) Research Ltd guidelines (EARL)~* In total one additional PET-CT (during nCRT) for study purposes. A PET-CT scan at diagnosis and after nCRT are included in the standard diagnostic work-up for esophageal cancer.~* Measurements: i.a. change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value) or Ktrans within tumor delineation over time"
214966661|NCT05801861|DEVICE|Active 10-Hz TMS to the parietal cortex|The active 10-Hz TMS group will receive 10hz TMS stimulation in the first TMS session, and single pulse TMS in the second TMS session. Participants in the active stimulation group will receive 10-Hz TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
214966662|NCT05801861|DEVICE|Active single pulse TMS to the parietal cortex|The active single pulse TMS group will receive single pulse TMS stimulation in the first and second TMS session. Participants in the active stimulation group will receive single pulse TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
214966663|NCT05801861|DEVICE|Sham 10-Hz TMS to the right parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214966664|NCT05801861|DEVICE|Sham single-pulse rTMS the rigt parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214966665|NCT02915172|DRUG|Lenvatinib|"Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1."
214966666|NCT02915172|DRUG|Capecitabine|Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
214966667|NCT05556460|DEVICE|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
214966668|NCT05556460|DRUG|Medical therapy|Subjects will continue to be managed on medical therapy, per physician discretion
214966669|NCT00186407|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
214966670|NCT03512353|DRUG|Dexamethasone|Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.
214966671|NCT03512353|DRUG|Carfilzomib|Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All
214966672|NCT00630799|DRUG|leuprolide acetate|17 mg i.m.
214966673|NCT01845597|PROCEDURE|MAKOplasty® medial UKA|A robot guided medial Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
214966674|NCT05927077|PROCEDURE|planned surgery for weight reduction|planned surgeries will be used to collect study material to determine chemical patterns in the study participants from the different geographical regions
214966675|NCT04403113|OTHER|Structured neck and trunk stabilization exercises|Intensive structured neck and trunk stabilization exercises based on Neurodevelopmental therapy method-Bobath concept principles. These exercises were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
214966676|NCT04403113|OTHER|Feeding and oral motor intervention strategies|Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
214966677|NCT04403113|OTHER|Caregiver training related to feeding|In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
214966678|NCT02581488|BIOLOGICAL|Santyl|
214966679|NCT02581488|OTHER|Product containing silver|Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer
214356605|NCT03474341|DIAGNOSTIC_TEST|Endoscopy|Additional endoscopy and/or endoscopic ultrasonography (EUS) with biopsies of the primary tumor site and other suspected lesions in the esophagus after completion of nCRT and prior to surgery
214393724|NCT03701009|PROCEDURE|Saline +50ml|If still have some stone fragments, intermittent saline irrigation another 50ml after the second Spyglass detection, Spyglass explored third time to evaluate stone clearance.
214966680|NCT01877668|DRUG|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
214966681|NCT01877668|DRUG|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
214966682|NCT01877668|DRUG|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
214966683|NCT01877668|DRUG|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
215081540|NCT00975819|DRUG|sirolimus|liquid dosing based on trough levels
215081541|NCT01920893|DRUG|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
215081542|NCT01920893|DRUG|Dupilumab|Solution for injection; Subcutaneous injection.
215081543|NCT01920893|DRUG|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
214393725|NCT00365495|PROCEDURE|Physical training (aerobic training)|
214966684|NCT01877668|DRUG|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
214966685|NCT01302418|DEVICE|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
214966686|NCT01810562|OTHER|Specific treatment in addition to standard stroke care|"Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.~Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.~Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.~Scrolling with spiked ball over the same area as brushing for two minutes evenly.~Firm pressure for two minutes evenly in the same area."
214966687|NCT00319709|DRUG|SR58611A|
214966688|NCT05681013|BEHAVIORAL|Laughter Therapy|The effect of the Laughter Therapy on nursing students
214966689|NCT00230334|DRUG|Gleevec|
214966690|NCT03157674|OTHER|Non-Interventional|Non-Interventional
214966691|NCT03685097|DIAGNOSTIC_TEST|Quantra System with the QPlus Cartridge|Point-of-care viscoelastic testing
214966692|NCT02508376|OTHER|AP10-602|AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
214966693|NCT02508376|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
214966694|NCT02508376|BIOLOGICAL|ID93|ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
214966695|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks|Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy
214966696|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks|Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks
214356606|NCT03474341|DIAGNOSTIC_TEST|Blood samples|"* Blood samples at three different time points (before, during and after nCRT) will be collected~* Blood will be collected in cell-free DNA collection tubes~* Purpose: isolation of ctDNA and subsequent mutation analysis by means of Next Generation Sequencing~* Measurements: the presence of, and changes in, ctDNA during nCRT"
214966697|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks|Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy
214966698|NCT04754646|DEVICE|Split-face injection of RHA® 4 with a cannula into a single NLF.|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).~The brand of cannula used for injection is up to the discretion of the Treating Investigator (TI), providing the cannula is registered for use by the US FDA."
214966699|NCT04754646|DEVICE|"Split-face injection of RHA® 4 with a needle (TSK 27G x ½) into the contralateral NLF."|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF)."
214966700|NCT01214889|BIOLOGICAL|PENTAXIM™: DTacP IPV//PRP~T combined vaccine|0.5 mL, intramuscular
214966701|NCT01214889|BIOLOGICAL|TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine|0.5 mL of each vaccine; intramuscular
214966702|NCT01828970|DRUG|Basal-bolus detemir-aspart insulin regimen|After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
214966703|NCT05121610|PROCEDURE|The procedures include PCI, CABG and HCR|The procedures include PCI, CABG and HCR
214966704|NCT06046677|OTHER|No intervention|No intervention
214966705|NCT00657800|BEHAVIORAL|Intensified inpatient diabetes education program (IDEP)|Assessment of educational needs and coordination of inpatient unit based education program by Certified Diabetes Educator (CDE)
214966706|NCT00377637|DRUG|Mycophenolate mofetil (MMF)|Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.
214966707|NCT00377637|DRUG|Cyclophosphamide|"Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m\^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m\^2. The target dose was 1.0 g/m\^2, but doses were titrated by 0.25 g/m\^2 increments to maintain nadir leukocyte count between 2500-4000/mm\^3."
215081544|NCT06027333|BEHAVIORAL|inpatient rehabilitation|This is an uncontrolled observational study on patients undergoing usual care in pulmonary rehabilitation and care
215081545|NCT04782245|DRUG|Dapagliflozin 10mg|The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
214966708|NCT00377637|DRUG|Azathioprine|2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
214966709|NCT00377637|DRUG|Placebo to Azathioprine|Placebo capsules matching Azathioprine taken orally once a day.
214966710|NCT00377637|DRUG|Placebo to Mycophenolate mofetil|Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
215081546|NCT04782245|DRUG|Placebo|Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
215081547|NCT02793596|OTHER|Obstetrical patients|Epidural waveform analysis as a confirmation of loss of Resistance
214356607|NCT05817695|DEVICE|Leadless pacemaker|To observe the effect of pacemaker implantation at different sites on cardiac synchronization and tricuspid regurgitation
214966711|NCT00377637|DRUG|Corticosteroid|Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
214966712|NCT04708158|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
214966713|NCT04708158|BIOLOGICAL|Placebo|Saline
215081548|NCT04290468|DEVICE|Dynamic ultrasound|"The ultrasound examination will be carried out blinded to the results of MRI using the Affiniti 70 ultrasound machine by Philips (USA) via a 5-12MHz linear transducer.~MRI was performed on a high field system (1.5 Tesla) magnet units (Philips Acheiva)."
215081549|NCT04897919|DRUG|Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet|Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
215081550|NCT04897919|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|Artemether-Lumefantrine is given as recommended by manufacturer
215081551|NCT01068782|DRUG|XL184|given orally as capsules
215081552|NCT04963530|PROCEDURE|Treatment with monolithic zirconia restorations|Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
215081553|NCT04963530|PROCEDURE|Treatment with lithium disilicate restorations|Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
215081554|NCT04963530|PROCEDURE|Treatment with metal ceramic restorations|Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
215081555|NCT04963530|PROCEDURE|No intervention|No intervention.
214356608|NCT04866550|OTHER|Data collection|Daily record of temperature, weight, heart rate, systolic blood pressure and oxygen saturation
214356609|NCT01463748|OTHER|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
214356610|NCT01463748|OTHER|Placebo|starch
214356611|NCT04871789|DIAGNOSTIC_TEST|Laboratory and instrumental examination|All patients will undergo a comprehensive examination to identify the consequences of COVID-19
214356612|NCT04292626|DIAGNOSTIC_TEST|SPECT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
214356613|NCT00181948|DRUG|atomoxetine (Strattera)|
215081556|NCT01933126|DRUG|HCG injection|
215081557|NCT01933126|DRUG|Placebo|
215081558|NCT01079013|DRUG|treosulfan|12 g/m2 x 3 days
215081559|NCT00236418|DRUG|topiramate|
214356614|NCT04678492|DRUG|Esomeprazole|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID
214356615|NCT04678492|DRUG|Amoxicillin|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID
214356616|NCT04678492|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
214356617|NCT04678492|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
214356618|NCT04678492|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
214356619|NCT04678492|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
214966714|NCT01842269|DRUG|Mycophenolate Mofetil 500mg|
214966715|NCT01842269|DRUG|Mycophenolate Mofetil 250mg|
215081560|NCT03919513|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
214356620|NCT06340620|DEVICE|Endoscopic ultrasound examination|Endoscopic ultrasound examination will be performed.
214966716|NCT00735345|DRUG|5-FU|750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
214966717|NCT00735345|DRUG|Cisplatin|15 mg/m2/d i.v. d1-5, d29-33
214966718|NCT00735345|DRUG|Taxotere|75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
214966719|NCT00735345|BIOLOGICAL|Cetuximab|Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
214966720|NCT00735345|RADIATION|Radiation during chemoradio-immunotherapy|39.6 Gy total dose
214966721|NCT04113291|OTHER|DASH Diet|12 Weeks of isocaloric DASH diet \<2300 mg Na/day using meals (lunch, dinner, snacks) prepared by the Wake Forest Clinical Research Metabolic Kitchen under the direction of a registered dietician (RD). Participants will prepare their own breakfast from a menu.The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
214966722|NCT04113291|OTHER|Usual diet|12 weeks usual diet \<2300 mg Na/day
215081561|NCT00661024|PROCEDURE|intraoperative RLN visualization|intraoperative RLN visualization
215081562|NCT00661024|PROCEDURE|intraoperative neuromonitoring of the RLN|IONM
215081563|NCT00244348|DRUG|Oxaliplatin (via HAI)|
214356621|NCT04870216|OTHER|Questionnaire regarding intimate protections habit.|Questionnaire regarding intimate protections habit.
214356622|NCT00386880|OTHER|Sounds|
214356623|NCT03430674|BEHAVIORAL|Exercise|Exercise, questionnaires and blood draws.
215081564|NCT00244348|DRUG|5 Fluorouracil (systemic)|
214356624|NCT00032695|DRUG|methionine|
214356625|NCT02313467|DRUG|Topical application of 1.5% Butenyl ALA|
214356626|NCT02313467|DRUG|Topical application of sham control|
214356627|NCT05437458|OTHER|Delirium (exposure)|No interventions.
214356628|NCT00408213|DRUG|mycophenolate mofetil [CellCept]|1g po bid
214356629|NCT00408213|DRUG|Placebo|po bid
214356630|NCT03545867|BEHAVIORAL|Seated control (CON)|Seated rest
214356631|NCT03545867|BEHAVIORAL|Moderate intensity continuous (MICT)|Arm cycling at a continuous power output
214356632|NCT03545867|BEHAVIORAL|High intensity interval training (HIIT)|Arm cycling at power outputs that vary between high and low intensity intervals
214356633|NCT03545867|BEHAVIORAL|Circuit resistance training (CRT)|Alternating between six upper extremity resistance maneuvers interspersed with low-resistance/high-speed arm cycling.
214356634|NCT03545867|OTHER|Liquid Meal|A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
214356635|NCT05684081|BEHAVIORAL|Digital payment|The proposed intervention is designed to support the implementation of polio campaigns through digital payments
214356636|NCT01616901|PROCEDURE|Spontaneous breathing trial|"5 spontaneous breathing trial will be tested by the patients in the same order :~* 7 cm H2O continuous positive airway pressure~* T piece~* 7 cmH2O of pressure support~* 0 cmH20 of pressure support~* 7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure."
214356637|NCT02294890|PROCEDURE|Total knee arthroplasty|
214966723|NCT06435975|OTHER|Physical Activity|Participants will perform a baseline +4000 steps/day for the duration of the study. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
214356638|NCT03876834|OTHER|respiratory training|Respiratory training was done by using threshold inspiratory muscle trainer(Respironics, New Jersey , USA, No.8373-0730)
214356639|NCT05350241|OTHER|Split-belt treadmill training|Participants in the split-belt walking group (experimental group) performed repeated split-belt treadmill training with an error-augmentation strategy (exaggeration of the initial step-length asymmetry) for 60 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics.
214356640|NCT05350241|OTHER|Standard physical therapy|Participants in the control group received the standard physical therapy program. Each session lasted for 60 minutes, repeated three times a week, over 12 consecutive weeks. The program consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
214356641|NCT00011505|DRUG|G-CSF|
214356642|NCT00011505|PROCEDURE|Leukapheresis|
214356643|NCT00676767|DIETARY_SUPPLEMENT|Resistant Starch Type 4|
214356644|NCT00676767|DIETARY_SUPPLEMENT|Dextrose|
214356645|NCT00676767|DIETARY_SUPPLEMENT|Puffed wheat|
214356646|NCT05782764|DRUG|To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).|immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
214356647|NCT00345982|DRUG|Serdolect|16 mg, 12 weeks
214356648|NCT00345982|DRUG|placebo|placebo
214356649|NCT00476476|DRUG|Erlotinib|Orally every day for about 4-6 weeks
214966724|NCT06435975|OTHER|Survey|Participants will complete a series of survey at multiple points throughout this study to assess quality of life issues. Questionnaires may be completed via paper forms with prepaid postage envelopes or using a REDCap online survey.
214966725|NCT06435975|BEHAVIORAL|Telehealth Lifestyle Coaching|Participants will meet with a health coach, the Principal Investigator, to review baseline bowel habits and symptoms as well as discuss physical activity and potential strategies to achieve this goal, on a weekly basis for 12 weeks.
214966726|NCT04179877|BEHAVIORAL|IPS|Occupational rehabilitation and support Integrated with clinical treatment
214966727|NCT01759953|OTHER|Game|InsuOnline game, on the web, in the player´s own time and rhythm
215081565|NCT01470690|DRUG|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
214356650|NCT04149405|PROCEDURE|Phase 1 periodontal therapy|Scaling and root planning with ultrasonic and hand instruments under local anesthesia.
214356651|NCT04149405|DRUG|Bisphosphonate therapy|Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
214356652|NCT00894231|DRUG|levocetirizine (Xyzal)|5mg po QD
214356653|NCT00894231|DRUG|placebo|sugar tablet
215081566|NCT01470690|DRUG|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
215081567|NCT03855813|OTHER|Intra rater reliability|Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
215081568|NCT03855813|OTHER|Inter rater reliability|Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
214356654|NCT01046305|BEHAVIORAL|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
214356655|NCT01046305|BEHAVIORAL|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
214356656|NCT01046305|BEHAVIORAL|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
214966728|NCT01759953|OTHER|Traditional CME|In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
214966729|NCT01914237|DEVICE|Castor Stent Graft|Endovascular Repair of Aortic Dissection
215081569|NCT00505037|DRUG|ASP1585|Oral
215081570|NCT00505037|DRUG|Placebo|Oral
215081571|NCT00505037|DRUG|Sevelamer hydrochloride|Oral
215081572|NCT05827562|DIAGNOSTIC_TEST|flow cytometry|"Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~1. CD3+CD4-CD8αα+~2. CD3+CD4-CD8α+CD8βlow~3. CD3+CD4-CD8α+CD8βhigh~4. CD3+CD4+CD8αβhigh~5. CD3+CD4+CD8αα+"
215081573|NCT01169688|OTHER|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
214356657|NCT05514353|DRUG|PBI-100 Topical Cream|PBI-100 Topical Cream in 1 of 3 dose levels
214356658|NCT05514353|DRUG|Vehicle Cream|The Vehicle Cream formulation contains the same excipients as the active cream
214356659|NCT00423176|DRUG|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
214356660|NCT00423176|DRUG|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
214356661|NCT00395902|DRUG|Sensipar after Post Transplant|
214356662|NCT04434989|RADIATION|Stereotactic Body Radiation Therapy|SBRT for perivascular HCC
214356663|NCT04434989|PROCEDURE|radiofrequency ablation|RFA for perivascular HCC
214356664|NCT02238262|DRUG|Telmisartan|
214356665|NCT02374905|DEVICE|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
214966730|NCT01507116|OTHER|No treatment given|Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
214966731|NCT02029131|BEHAVIORAL|Exercise|Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
214966732|NCT03319433|DEVICE|Perfusion Index|Use of non-invasive pulse oximeter to determine perfusion index
214966733|NCT03045653|DRUG|Tamoxifen Oral Product|Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
215081574|NCT02794844|DRUG|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
215081575|NCT00549029|GENETIC|DNA|withdraw 5\~10mL blood from vein only once during the whole design
215081576|NCT03005301|DEVICE|intelligent electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25\~40mm in length and 0.30\~0,38mm in diameter.Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes."
215081577|NCT03005301|DEVICE|Hwato electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.~Treatment time: each treatment time is 30 minutes."
214356666|NCT02374905|BEHAVIORAL|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
214356667|NCT06241274|OTHER|Moxibustion|Subjects received moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.
214356668|NCT06241274|OTHER|Symptomatic supportive treatment|Symptomatic supportive treatment.
214966734|NCT06465472|DRUG|Stiripentol Oral Capsule|The target dose of stiripentol will be 50 mg/kg/day with a maximum dose of 3,000 mg/day. Patients allocated to the Stiripentol group will receive this treatment during the first 6 months, and in continuation up to 12 months.
214966735|NCT06465472|DRUG|Placebo Oral Capsule|Placebo capsules will be administered for the first 6 months. Then patients will switch to stiripentol over the 6- to 12-month period.
214966736|NCT06465472|BIOLOGICAL|Urine samples collect|Collections of urine over 24 hours and the first urine in the morning (spot urines) will be carried out. Urine collections will be performed either during hospitalizations, or at home if appropriate conditions are met.
214356669|NCT01654549|DRUG|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
214356670|NCT05655754|DRUG|Methohexital|anesthesia during ECT
214356671|NCT05655754|DRUG|Ketofol|anesthesia during ECT
214356672|NCT03385928|DRUG|Tranexamic Acid|Investigational product given within 2 hours of symptom onset
214356673|NCT03385928|DRUG|Normal saline|Placebo given within 2 hours of symptom onset
214356674|NCT06018480|OTHER|Creatine Monohydrate|The supplementation is the intervention.
214356675|NCT06018480|OTHER|Maltodextrin (Placebo)|Placebo to Creatine Monohydrate
214356676|NCT05985187|DRUG|TQB2440 injection + Trastuzumab + Docetaxel|"TQB2440 injection is a biosimilar of Perjeta® (Pertuzumab injection) developed by Chia Tai Tianqing Pharmaceutical Group. Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
214356677|NCT05985187|DRUG|Perjeta + Trastuzumab + Docetaxel|"Perjeta® with the general name Pertuzumab injection, is a recombinant humanized monoclonal antibody targeting the extracellular second domain of human epidermal growth factor receptor 2 (HER2). Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
214356678|NCT03528070|DRUG|Tranilast|Subjects will be treated with tranilast
214966737|NCT06465472|BIOLOGICAL|Blood samples collect|Series of blood samples will be taken (serum pregnancy test, Primary Hyperoxaluria genetic characterization, clinical laboratory assessments, vitamin B6 dosage, plasma oxalate dosage, stiripentol pharmacokinetics)
214966738|NCT06465472|OTHER|Kidney imaging|Kidney imaging will be obtained. Renal ultrasounds will be compulsory for all patients.
214966739|NCT06465472|OTHER|Quality of Life questionnaires|"Kidney Disease Quality of Life Questionnaire : KDQOL-36 for patients ≥18 years of age at screening, and the Pediatric Quality of Life Inventory (PedsQL) including the generic and KF modules (parent and/or self-report versions) for patients \<18 years of age at screening.~EQ-5D: a standardized instrument consisting of a questionnaire and a visual analog scale pertaining to 5 dimensions. Scoring of the questionnaire is based on degrees of disability. Scoring of the visual analog scale is based on a visual scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better health status. The EQ-5D-5L questionnaire (will be utilized in patients ≥18 years of age at screening, and the EQ-5D-Y questionnaire will be utilized in patients \<18 years of age at screening, where available."
214966740|NCT01255072|PROCEDURE|Transcranial Magnetic Stimulation|20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
214966741|NCT01255072|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
214966742|NCT04571047|OTHER|Time to treatment|Treatment before or after 4 weeks after diagnosis
214966743|NCT06234540|PROCEDURE|PRP|a-PRP intrauterine instillation before frozen-thawed embryo transfer cycle
214966744|NCT06234540|OTHER|Standard treatment|Standard treatment
214966745|NCT04954521|DRUG|Anlotinib|This is an observational study
214966746|NCT06100796|COMBINATION_PRODUCT|Pembrolizumab|Immune check inhibitor with OHA
214966747|NCT01193946|DIETARY_SUPPLEMENT|dietary control|Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
214966748|NCT01111565|DRUG|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
214966749|NCT01111565|DRUG|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
214966750|NCT03049423|DEVICE|MRI scans|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
215081578|NCT05894538|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
214356679|NCT04357327|DIAGNOSTIC_TEST|rapid salivary test|a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay
214356680|NCT01353014|OTHER|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.
214356681|NCT01353014|OTHER|General dietary recommendations|This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
214356682|NCT00361543|DRUG|Raloxifene hydrochloride|120 mg per capsule (1 tablet daily)
214356683|NCT00361543|OTHER|Lactose Capsules|1 tablet daily for 12 weeks
215081579|NCT05894538|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
215081580|NCT03440918|OTHER|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
215081581|NCT03440918|OTHER|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
215081582|NCT02257177|DRUG|Inhaled TD139|DPI Galectin-3 inhibitor
214356684|NCT03382496|OTHER|Non-Interventional|Non-Interventional
214356685|NCT04913844|OTHER|Physical performance tests and observational assessments|There will be no interventions. Physical performance tests and observational assessments will be conducted.
214356686|NCT02738268|DEVICE|Low-level laser therapy|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment in combination with the standard skin care.
214356687|NCT02738268|DEVICE|sham laser|
214356688|NCT06580483|OTHER|amalgam restoration|An abutment tooth is restored on a side by amalgam plug
215081583|NCT02257177|DRUG|Placebo|DPI placebo
215081584|NCT00791401|DRUG|ER OROS Paliperidone|
214966751|NCT03049423|DIAGNOSTIC_TEST|MRI scans and general physical examination|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
214966752|NCT05026944|OTHER|Percussive massage and static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be treated with 5 minutes of percussive massage and 5 minutes of static stretching exercises. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
214966753|NCT05026944|OTHER|static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be managed with 5 minutes of static stretching exercises only. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
214966754|NCT02581683|DRUG|Magnesium Sulfate|Given via adductor canal block
214966755|NCT02581683|DRUG|Ropivacaine|Given via adductor canal block
214966756|NCT02581683|OTHER|Sham|Sham adductor canal block
214966757|NCT06959316|DEVICE|Hybrid closed loop insulin delivery system|Hybrid closed loop insulin delivery system is a system that uses a continuous glucose monitor (CGM) to send blood glucose values to an insulin pump that automatically provides insulin based on the blood glucose value and anticipated future level.
214966758|NCT00368108|DRUG|2 mg perampanel|2 mg perampanel
214966759|NCT00368108|DRUG|4 mg perampanel|4 mg perampanel
214966760|NCT00368108|DRUG|placebo comparator|placebo comparator
214966761|NCT06958952|DIETARY_SUPPLEMENT|Digestive Aid|one tablet daily for one month
214966762|NCT06958952|DIETARY_SUPPLEMENT|Placebo|Placebo
214966763|NCT02858635|OTHER|Clinical and neuropsychological assessment, Blood and saliva samples|Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
214966764|NCT00534027|DRUG|AMG 655|AMG 655 is a monoclonal antibody directed against TR-2.
214966765|NCT00534027|OTHER|AMG 655 placebo|Inactive dummy AMG 655 (to maintain blind)
214966766|NCT05208333|DRUG|Albenza 200Mg Tablet|"Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection"
214966767|NCT05662748|DEVICE|Transfemoral aortic valve replacement|aortic valve replacement
214966768|NCT00583908|DEVICE|senofilcon A|toric contact lens
214966769|NCT00583908|DEVICE|balafilcon A toric|toric contact lens
214966770|NCT00583908|DEVICE|lotrafilcon B toric|toric contact lens
214966771|NCT00583908|DEVICE|omafilcon A|toric contact lens
214966772|NCT02037815|DRUG|20% mannitol solution, 125 ml, IV infusion in 15 min|
214356689|NCT06580483|OTHER|nano-composite|An abutment tooth is restored on a side by nano-composite
214966773|NCT02037815|DRUG|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min|
214966774|NCT01253096|DRUG|Intratumoral injections of L19IL2|Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
214966775|NCT05270980|OTHER|Cohorting|"The cohorting strategy will result in pairing serology-positive staff with serology-negative residents and serology-negative staff and serology-positive residents to the degree that penetration of serologic presumed immunity allows this pairing to be positive. Any resident who refuses serology testing will be treated as if they are serology negative as the safest strategy for risk of unwanted exposure."
214966776|NCT02248064|DEVICE|Auto-titrating oxygen system|The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
214966777|NCT00890448|OTHER|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
214966778|NCT05952921|OTHER|Mouthwash|Concentration rinse with 0.05% HOCl
214356690|NCT02565043|DEVICE|RENASYS TOUCH Negative Pressure Wound Therapy System|RENASYS TOUCH NPWT System was administered to all participants.
214966779|NCT05952921|OTHER|Chlorhexidine|A high concentration of 0.2% CHX (7 days), followed by 0.012% CHX (14 days).
214966780|NCT04328025|OTHER|Peer-delivered HIV self-testing, STI self-sampling and PrEP|Peer delivery of combination HIV prevention interventions to transgender women.
215081585|NCT02081638|DRUG|Aspirin|Daily Asprin daily
215081586|NCT02081638|DRUG|Atorvastatin|Daily Atorvastatin Daily
215081587|NCT04397913|DRUG|Paracetamol|15 mg/kg, q6h
215081588|NCT04397913|DRUG|Ibuprofen|10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
215081589|NCT00297973|PROCEDURE|Blood pressure measurements|
215081590|NCT00297973|PROCEDURE|Blood samples|
215081591|NCT01056003|OTHER|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
215081592|NCT04369118|PROCEDURE|Conventional follow-up|Patients in this group benefit from conventional post-operative follow-up
215081593|NCT04369118|DEVICE|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.
215081594|NCT01389401|DRUG|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
215081595|NCT03419273|PROCEDURE|bariatric surgery|We are recruiting only those going through bariatric surgery
215081596|NCT05536492|PROCEDURE|A-PRF|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
215081597|NCT05536492|PROCEDURE|ALLOGRAFT|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
215081598|NCT02240823|OTHER|adipose derived stem cells|
214356691|NCT03999879|DIAGNOSTIC_TEST|Measure of OxPhos upregulation|OxPhos upregulation \[i.e., lower phosphocreatine (PCr)-to-ATP ratio levels\] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
214356692|NCT03999879|DIAGNOSTIC_TEST|lactate (measured with 1H-MRSI)|PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
214966781|NCT01252771|OTHER|PKM Algorithm|"The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.~If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.~The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet."
214966782|NCT03870334|DRUG|BT-11 880 mg|Oral once daily tablet
214966783|NCT03870334|DRUG|Placebo|Oral once daily tablet
214966784|NCT03967288|DRUG|Chloroprocaine Injection [Clorotekal]|1% chloroprocaine Hydrochloride Injection (50 mg/5 mL) for intrathecal use
214966785|NCT03967288|DRUG|Bupivacaine Hydrochloride 0.75% Injection Solution|0.75% bupivacaine Hydrochloride injection in 8.25% dextrose for intrathecal use
214966786|NCT00848757|BEHAVIORAL|Intensive Lifestyle Intervention|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
214966787|NCT02479659|OTHER|HIV testing commodity reinforcement|HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
215081599|NCT00799045|DRUG|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
215081600|NCT01693380|BIOLOGICAL|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:~* From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~* 9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
215081601|NCT01693380|BIOLOGICAL|Control vaccine|"Schoolchildren from 6 to 8 years of age:~\- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
215081602|NCT00198861|OTHER|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
215081603|NCT03356418|OTHER|WBV exercise group|The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
215081604|NCT03356418|OTHER|Sham WBV exercise group|The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
215081605|NCT01259076|PROCEDURE|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
215081606|NCT01259076|PROCEDURE|digital mammography|Undergo digital mammography at baseline and 1 year later.
215081607|NCT01259076|PROCEDURE|conventional surgery|Undergo gastric bypass surgery
215081608|NCT04401306|OTHER|Home-based self-regulated simulation training (SRST)|Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
215081609|NCT04401306|OTHER|Centralized instructor-regulated simulation training (IRST)|Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
214679067|NCT04623190|BEHAVIORAL|PREVENT tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
214679068|NCT03132805|BEHAVIORAL|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
214966788|NCT02479659|OTHER|Policy reinforcement meeting|District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.
214966789|NCT02479659|OTHER|Opt-out HIV testing for mothers and newborns|"Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:~* If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.~* If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner."
214966790|NCT02479659|OTHER|Operational support for service integration|The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.
214966791|NCT02479659|OTHER|Community sensitization|Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
214966792|NCT03472638|DEVICE|Dorsomedial prefrontal rTMS|Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.
214966793|NCT03534661|DRUG|Teduglutide + Normal Saline|Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion
214966794|NCT03534661|DRUG|Teduglutide + L-NMMA|Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
214966795|NCT03534661|DRUG|Placebo + L-NMMA|Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
214966796|NCT02415153|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214966797|NCT02415153|OTHER|Pharmacological Study|Correlative studies
214966798|NCT02415153|DRUG|Pomalidomide|Given PO
214966799|NCT01726075|DRUG|COLIRIOBCN070660|One drop per eye twice a day during 24 months
214966800|NCT01726075|DRUG|Placebo|One drop per eye twice a day during 24 months
214966801|NCT01726075|DRUG|Brimonidine|One drop per eye twice a day during 24 months
214966802|NCT04102293|PROCEDURE|NSK Endo motor Endomate|Rotary instrumenation used in pulp therapy
214966803|NCT04102293|PROCEDURE|manual K-files|manual instrumentation used in pulp therapy
215081610|NCT02985892|OTHER|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
214966804|NCT05022277|BEHAVIORAL|Low tech health SMS messages|Weekly health-related SMS messages are provided to adolescents.
214966805|NCT05022277|BEHAVIORAL|Low tech health Phone + SMS messages|Weekly health-related phone calls plus SMS messages are provided to adolescents.
214966806|NCT01769677|DRUG|90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
214966807|NCT03561896|RADIATION|IGRT|Image-Guided Radiation Therapy
214966808|NCT03561896|RADIATION|SRS|stereotactic radiation therapy
215081611|NCT02985892|OTHER|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
215081612|NCT05041595|DIAGNOSTIC_TEST|Lyme diagnostic assay|Serological and immunoresponse assay
215081613|NCT00391469|OTHER|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
214966809|NCT04064112|PROCEDURE|S-BLR|Surgery of slanted bilateral LR recession for CI-IXT patients
214966810|NCT04064112|PROCEDURE|C-BLR|Surgery of conventional bilateral lateral rectus recession for CI-IXT patients
214966811|NCT04986241|DRUG|Statin|Chronic use of statin prescribed previously by the assistant physician.
214966812|NCT04986241|OTHER|Physical activity|Physically active participants
214356693|NCT01257841|DRUG|Leptin administration|Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.
214966813|NCT04986241|OTHER|Sedentary|Physically inactive or sedentary participants.
214966814|NCT04007965|PROCEDURE|Pneumatic Posterior Capsulorhexis|Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.
214966815|NCT04616716|DRUG|FMTN|Single dose of FMTN after high-fat meal,low-fat meal and fast
214966816|NCT04870021|BIOLOGICAL|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs
214966817|NCT04870021|BEHAVIORAL|Short text messages and calls to parents for compliance to routine immunization schedule|After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
214356694|NCT01257841|BEHAVIORAL|Fasting|Complete fasting, save for water and multivitamin, for four days.
214356695|NCT05072080|BIOLOGICAL|CHIKV VLP/adjuvant|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
214356696|NCT05072080|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
214356697|NCT03960905|OTHER|Children with the usage of anti-infective drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
214356698|NCT04332796|DRUG|Chorhexidine scrub|Chorhexidine scrub was given to patients for 4 weeks
214356699|NCT04332796|DEVICE|ZnO-NPs socks|ZnO-NPs socks was given to patients for 4 weeks
214356700|NCT04332796|COMBINATION_PRODUCT|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks was given to patients for 4 weeks
214356701|NCT04335045|DRUG|Placebo|1\~8 Placebo capsule(s) corresponding to each PH100 dose
214966818|NCT04406922|PROCEDURE|Personalized cooling protocol|As an intervention, a personalized cooling protocol will be used in order to activate BAT and induce non-shivering thermogenesis. During the cooling procedure, subjects will be exposed to mild cold (approx. 14°C) for 150 min. Since the onset temperature of shivering shows a high interindividual variation, we will use a personal cooling protocol to ensure maximum non-shivering EE (and thus an equal maximum activation of BAT). The right temperature will be determined via a subjective method, e.g. to ask the subject if he or she experiences shivering. The time needed to achieve the right temperature is approximately 30-60 minutes. Then, the stable cooling period of 90 min is started. During this time the subject will be asked every 15 minutes whether he is experiencing shivering. If so, temperature will be increased with 2-3°C so that shivering just stops.
215081614|NCT00391469|DRUG|Rapid infusion of cold normal saline|
215081615|NCT01900106|DRUG|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
215081616|NCT01900106|DRUG|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
215081617|NCT03754582|DRUG|Perampanel|Oral tablets.
215081618|NCT03754582|DRUG|Perampanel|Intravenous infusion.
215081619|NCT02680574|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
215081620|NCT02680574|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
215081621|NCT05400902|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Sintilimab and Bevacizumab treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Sintilimab 200 mg ivdrip, Q3W; Bevacizumab 15 mg/kg ivdrip, Q3W"
215081622|NCT02847858|BEHAVIORAL|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
215081623|NCT00052312|DRUG|cisplatin|
215081624|NCT00052312|DRUG|doxorubicin hydrochloride|
215081625|NCT00052312|DRUG|paclitaxel|
215081626|NCT04026269|DRUG|MOAP|the new chemotherapy regimen for r/r cHL
215081627|NCT05326360|DRUG|Ramosetron Hydrochloride|we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
215081628|NCT03935555|DRUG|PU-H71|PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
215081629|NCT06298981|DEVICE|noninvasive and investigational NuraLogix AMC-SDK|The NuraLogix AMC-SDK is a noninvasive device that allows for real-time, remote measuring using facial recordings.
215081630|NCT00384982|PROCEDURE|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
215081631|NCT05149131|DRUG|ADT (Eligard®*) with or without treatment intensification|"Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix"
215081632|NCT03490604|DEVICE|wrist-worn accelerometer|accelerometer worn on the patient's wrist, changed every 15 ± 7 days for 6 months when the patient comes for a chemotherapy session
215081633|NCT03490604|OTHER|Auto-questionnaires|Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26
215081634|NCT01710735|PROCEDURE|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
215081635|NCT04167072|PROCEDURE|Stent removal|This is a procedural intervention in which the stent will be removed via endoscopy.
215081636|NCT02532712|DRUG|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
215081637|NCT02532712|DRUG|Placebo|Placebo with same shape and size
214356702|NCT04335045|DRUG|PH100 100mg|1 x 100 mg PH100 oral capsule
214356703|NCT04335045|DRUG|PH100 200mg|1 x 200 mg PH100 oral capsule
214356704|NCT04335045|DRUG|PH100 400mg|2 x 200 mg PH100 oral capsules
214356705|NCT04335045|DRUG|PH100 800mg|4 x 200 mg PH100 oral capsules
214356706|NCT04335045|DRUG|PH100 1200mg|6 x 200 mg PH100 oral capsules
214356707|NCT04335045|DRUG|PH100 1600mg|8 x 200 mg PH100 oral capsules
214356708|NCT05891821|DRUG|Balstilimab|An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody
214356709|NCT02633137|DRUG|Lenalidomide|
214356710|NCT02633137|DRUG|R-CHOP|"* Rituximab 375 mg/m\^2 IVPB with premedications Day 1~* Cyclophosphamide 750 mg/m\^2 IVPB Day 1~* Doxorubicin 50 mg/m\^2 IVP Day 1~* Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1~* Prednisone 100 mg PO Daily on Days 1-5 or 2-6"
214966819|NCT01129401|BEHAVIORAL|Stonewall Project|The Stonewall Project is an outpatient substance abuse treatment program for methamphetamine-using MSM that includes individual counseling, group counseling, and visits with a psychiatrists where indicated.
214966820|NCT04043429|BEHAVIORAL|Vision Restoration Training (VRT)|
214966821|NCT04043429|BEHAVIORAL|Vision Exploration Training (VET)|
214966822|NCT04553666|DRUG|Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)|800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
214966823|NCT02576262|PROCEDURE|TCT，HPV，colposcopic inspection|
215081638|NCT01584635|PROCEDURE|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
214356711|NCT02633137|DRUG|high-dose cytarabine (HIDAC)|
214356712|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 1.
214356713|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 2.
214356714|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m\^2 x 21 days) with group 3.
214356715|NCT02918110|DRUG|Misoprostol|Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
214966824|NCT01089127|DRUG|Indacaterol|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214966825|NCT01089127|DRUG|Salmeterol 50 μg|Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
214356716|NCT03827187|OTHER|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
214356717|NCT05554237|DRUG|Placebo|Placebo
214356718|NCT05554237|DRUG|PF-07612577|PF-07612577
214356719|NCT05554237|DRUG|PF-06264006|PF-06264006
214356720|NCT04224155|DEVICE|enVista MX60EFH trifocal intraocular lenses (IOLs)|enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally
214356721|NCT04224155|DEVICE|enVista MX60E monofocal intraocular lenses (IOLs)|enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally
214356722|NCT04531046|DRUG|axicabtagene ciloleucel|Patient-specific (autologous) product cryopreserved in cryostorage bag
214356723|NCT03541759|DRUG|Hydromorphone Hcl 4Mg Tab|Hydal retard 4Mg Tab 2 times after surgery as basic medication. Hydal retard 2.6Mg maximum 2 per 24h when NRS \> 5.
214356724|NCT03541759|DRUG|Piritramide 15mg s.c.|Dipidolor 15mg s.c. 2 times after surgery as basic medication. Dipidolor 7.5mg s.c. maximum 2 per 24h when NRS \> 5.
214356725|NCT06240442|OTHER|Fasted exercise|Bodyweight interval exercise performed 5 minutes before the start of a mixed-macronutrient breakfast meal
214356726|NCT06240442|OTHER|Fed exercise|Bodyweight interval exercise performed 10 minutes after the start of consuming a mixed-macronutrient breakfast meal
214356727|NCT02395042|DRUG|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
214966826|NCT01089127|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
214966827|NCT01089127|DRUG|Placebo to salmeterol|Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
214966828|NCT02622152|PROCEDURE|Right lateral position (2 hours)|Repositioning the patients for two-hours period on the right lateral position
214966829|NCT02622152|PROCEDURE|Left lateral position (30 minutes)|Repositioning the patients for 30 minutes period on the left lateral position
215081639|NCT03517995|DRUG|Sulforaphane Administration|1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
215081640|NCT03517995|OTHER|Placebo Administration|1 capsule (placebo) taken two times per day (2 capsules total).
214966830|NCT02622152|PROCEDURE|Supine position (30 minutes)|Repositioning the patients for 30 minutes period on the supine position
214966831|NCT02622152|PROCEDURE|Left lateral position (2 hours)|Repositioning the patients for two-hours period on the left lateral position
214966832|NCT02622152|PROCEDURE|Supine position (2 hours)|Repositioning the patients for two-hours period on supine position
214966833|NCT04110431|PROCEDURE|Left bundle branch pacing|Successful LBBP was defined as (1) LBBP lead is located at 1.5-2cm from His-bundle towards right ventricular apex; (2) Paced QRS morphology of right bundle branch delay(CRBBD) in lead V1; (3) Stimulus to the peak of R wave in V5 and V6 QRS wave, which represents left ventricular activation time(Stim-LVAT), is less than 100ms and constant at high and low output pacing; (4) Unipolar pacing threshold\<1.5V/0.5ms; (5) Recording P potential when narrow QRS escape rhythm or CRBBB escape rhythm(not essential).
214356728|NCT02395042|DRUG|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
214966834|NCT04110431|PROCEDURE|Biventricular pacing|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
214966835|NCT00958854|DRUG|cyclophosphamide|
214966836|NCT00958854|DRUG|fludarabine phosphate|
214966837|NCT00958854|DRUG|thalidomide|
214966838|NCT00958854|OTHER|laboratory biomarker analysis|
214966839|NCT03200548|BEHAVIORAL|Relaxing acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
215081641|NCT03517995|PROCEDURE|Standard of Care Surgery|The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
215081642|NCT02699151|DRUG|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
214356729|NCT03506958|PROCEDURE|Standard trauma care|In both groups, all procedures and management will be done according to the hospital's standard of care.
214356730|NCT03637205|PROCEDURE|ECLS insertion|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization
214356731|NCT03637205|OTHER|Revascularisation and optimal medical treatment|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
214356732|NCT04745611|DIAGNOSTIC_TEST|MRI|3T cranial MRI with T1-, and T2 weighted imaging, a FLAIR sequence, diffusion-weighted imaging and susceptibility-weighted sequence
214679069|NCT03132805|BEHAVIORAL|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
214966840|NCT03200548|BEHAVIORAL|Usual care|Negative control group. Participants are asked to carry on with their usual management practices and habits.
214966841|NCT03200548|BEHAVIORAL|Stimulating acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
215081643|NCT02699151|PROCEDURE|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
215081644|NCT02699151|OTHER|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
215081645|NCT01862835|DRUG|Degarelix|
214966842|NCT03200548|BEHAVIORAL|Sham acupressure plus usual care|Positive control group. Chosen pressure points are not known to be effective.
214966843|NCT03098680|DRUG|Albuterol Sulfate|see arm/group descriptions
214966844|NCT03098680|DRUG|Nicardipine Hydrochloride|see arm/group descriptions
214966845|NCT03098680|DRUG|Dobutamine Hydrochloride|see arm/group descriptions
215081646|NCT01862835|DRUG|Testosterone|
215081647|NCT01862835|DRUG|Anastrozole|
214966846|NCT03098680|DRUG|Phenylephrine Hydrochloride|see arm/group descriptions
214966847|NCT03098680|DRUG|Verapamil Hydrochloride|see arm/group descriptions
214966848|NCT03098680|DRUG|Phentolamine Mesylate|see arm/group descriptions
214966849|NCT03098680|DRUG|Placebo|see arm/group descriptions
214966850|NCT04010409|OTHER|no intervention|no intervention
214966851|NCT00059228|DRUG|17beta Estradiol|Alora 100 microgram per day by skin patch for 6 weeks.
215081648|NCT01862835|DRUG|Estrogen patch|
215081649|NCT03785587|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
215081650|NCT04526470|DRUG|Alpelisib|Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily
215081651|NCT04526470|DRUG|Paclitaxel|Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
215081652|NCT02867774|BEHAVIORAL|Physical Activity|"8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine."
215081653|NCT02844283|DRUG|Ad-HGF|
215081654|NCT02844283|OTHER|0.9% NaCl|
214966852|NCT00059228|DRUG|Placebos|Placebo skin patch for 6 weeks
214356733|NCT04745611|DIAGNOSTIC_TEST|Neuropsychological assessment|Montreal Cognitive Assessment (MoCA), Rey-Auditory Verbal Learning Test (RAVLT), Trail making A/B, Stroop, Digit Span Coding, Judgement of line orientation (JOLO), Boston Naming Task (BNT), Controlled Oral Word Associations Task (COWAT), Category Fuency, Test of Memory Malingering (TOMM)
214356734|NCT04745611|DIAGNOSTIC_TEST|Questionnaires Patient|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), NeNeSCo-Q (questionnaire created for this study, including common neurological symptoms), Checklist for post-IC cognitive complaints (CLC-IC self-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), PROMIS physical functioning short form, Items of Insomnia Severity Index (ISI) \& Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), Social Support List (SSL-12-I)
214356735|NCT04745611|DIAGNOSTIC_TEST|Questionnaires Family|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), Checklist for post-IC cognitive complaints (CLC-IC proxy-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), Social Support List (SSL-12-I), Caregiver Strain Index (CSI)
214356736|NCT02824133|DRUG|AZD4547|80 mg bd (per os)
214356737|NCT05597254|DIETARY_SUPPLEMENT|Probiotic with niacin and berry extract|1 capsule daily of probiotic with niacin supplementation for 8 weeks
214356738|NCT05597254|DIETARY_SUPPLEMENT|Probiotic without niacin and berry extract|1 capsule daily of probiotic without niacin supplementation for 8 weeks
214356739|NCT05597254|DIETARY_SUPPLEMENT|Placebo|1 capsule daily of placebo supplementation for 8 weeks
214356740|NCT01324271|DEVICE|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
214356741|NCT05130970|DRUG|Garadacimab|Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
214966853|NCT03151382|DRUG|Tandospirone Citrate|Tandospirone, 30-60 mg/d
214966854|NCT03151382|DRUG|Donepezil Hydrochloride|Donepezil, 10 mg/d
214966855|NCT03398694|PROCEDURE|Radiosurgery|"Stereotactic radiosurgery will be delivered on all patients utilizing gamma knife or linear accelerator based techniques as per RTOG-9005 dosing criteria (Section 11 Table 1) based on tumor diameter with the exception that the largest lesion diameter to be treated with 15 Gy will be 5 cm. All apparent, previously untreated brain metastases will be treated with radiosurgery at this time.~Radiosurgery will be performed 1-4 days prior to surgical resection. Vital signs and MRI Brain planning scan will be performed on the day of radiosurgery prior to the procedure."
214966856|NCT01033500|DRUG|Belatacept|Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
214966857|NCT03257436|DEVICE|CRT-D|Left Ventricular MultiSite Pacing
214966858|NCT03745053|DEVICE|Xlimus DES Implantation during coronary angioplasty|Xlimus DES Implantation during coronary angioplasty
214356742|NCT05130970|DRUG|Placebo|Participants received a matching placebo IV loading dose, followed by 3 SC doses.
214966859|NCT03745053|DEVICE|Synergy DES Implantation during coronary angioplasty|Synergy DES Implantation during coronary angioplasty
215081655|NCT00066469|BIOLOGICAL|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: \< 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: \< 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
215081656|NCT00066469|DRUG|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
215081657|NCT00066469|DRUG|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
215081658|NCT00066469|DRUG|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
215081659|NCT03287570|DEVICE|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
214356743|NCT04769037|DIETARY_SUPPLEMENT|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
214356744|NCT04769037|DIETARY_SUPPLEMENT|Placebo|Lactose identical in appearance and taste to the active supplement
214356745|NCT04620278|GENETIC|DNA or RNA Sequencing|Samples will be used for whole exome (DNA) or RNA sequencing
214393726|NCT04907487|DEVICE|MRI|"MRI of routine care includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~The sequences added by the research lasting 25 minutes are:~* SWI QSM 1.0iso 8 echoes (10 minutes)~* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)~* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)~* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)"
214393727|NCT05552729|DRUG|Vitamin D|The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
214966860|NCT04985045|OTHER|Evaluation|Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.
214966861|NCT01268852|DEVICE|Damon self ligating orthodontic bracket|Orthodontic treatment with Damon self ligating bracket
214966862|NCT01268852|DEVICE|Insignia self ligating orthodontic bracket|Orthodontic treatment with Insignia self ligating bracket
214966863|NCT02277327|BEHAVIORAL|Plans of Action and Care Transitions|"Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)"
214966864|NCT02277327|BEHAVIORAL|Routine Care|"Subjects randomized to the control group will continue to receive routine care within the medical home program"
214679070|NCT04646980|DIETARY_SUPPLEMENT|Biobran/MGN-3|Biobran/MGN3 is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as a food supplement. Biobran/MGN3 is manufactured by hydrolyzing rice bran with the enzymatic extract of medicinal Shiitake mushrooms. Enzyme hydrolysis of rice bran produces arabinoxylane, a hemi-cellulose compound, which constitutes the active ingredient of biobran/MGN3.
214679071|NCT04646980|OTHER|Placebo|Placebo, with same appearance and taste as Biobran/MGN-3, was given to control subjects at a dose of 500 mg everyday for 3 months
214679072|NCT03517748|DEVICE|DM05 eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
214966865|NCT00394186|DRUG|GW427353|
214966866|NCT00394186|DRUG|Placebo|
214966867|NCT03583008|BEHAVIORAL|Anticoagulation (AC) Intervention--Academic Detailing|One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.
215081660|NCT03287570|PROCEDURE|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
215081661|NCT03287570|OTHER|Usual care|The patients in this group maintain the usual treatment and self-care.
215081662|NCT01452295|DRUG|ELAD (Extracorporeal Liver Assist System)|ELAD (Extracorporeal Liver Assist System)
215081663|NCT03105648|OTHER|computerized cytomorphometry|use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
215081664|NCT01110798|OTHER|intraoperative complication management/prevention|
215081665|NCT01110798|PROCEDURE|assessment of therapy complications|
215081666|NCT01110798|PROCEDURE|gastrointestinal complications management/prevention|
215081667|NCT01110798|PROCEDURE|quality-of-life assessment|
215081668|NCT01110798|PROCEDURE|therapeutic conventional surgery|
215081669|NCT00334906|DRUG|memantine HCl|
215081670|NCT00711802|DRUG|Daptomycin|
215081671|NCT00711802|DRUG|Standard of Care (SOC)|
215081672|NCT00915655|DRUG|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
215081673|NCT00915655|DRUG|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
214966868|NCT03583008|BEHAVIORAL|Anticoagulation (AC) Intervention--Prescribing Practices|Education and support related to anticoagulant prescribing practices.
214966869|NCT02704312|RADIATION|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
215081674|NCT00915655|DRUG|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
215081675|NCT00915655|DRUG|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
215081676|NCT00915655|DRUG|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
215081677|NCT06200974|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate.
215081678|NCT00716378|BEHAVIORAL|Teen Passenger Presence|
215081679|NCT02351830|OTHER|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
215081680|NCT02351830|PROCEDURE|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
215081681|NCT02305849|DRUG|Peficitinib|oral tablet
215081682|NCT02305849|DRUG|Placebo|oral tablet
215081683|NCT02305849|DRUG|Methotrexate|Oral tablet/capsule
215081684|NCT04154319|BEHAVIORAL|HPV Vaccination|Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters
215081685|NCT04154319|BEHAVIORAL|Healthy Eating|Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
214966870|NCT02227277|DRUG|Peg-IFN-α2b|"Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL \> 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks."
214966871|NCT01305811|DEVICE|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
214966872|NCT06376487|DEVICE|Flow rate evaluation|Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.
215081686|NCT01913665|OTHER|B.lactis|
215081687|NCT01913665|OTHER|Inulin|
215081688|NCT01913665|OTHER|B.Lactis +Inulin|
215081689|NCT01913665|OTHER|Placebo|
215081690|NCT01241344|DRUG|Brincidofovir|"* Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
215081691|NCT01241344|OTHER|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
214356746|NCT05823259|OTHER|Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education|"A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased."
214356747|NCT05823259|OTHER|Standard Physical Therapy Care|A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
214356748|NCT06961526|PROCEDURE|Esophageal band ligation|upper endoscopy will be performed within 6 months before starting atezolizumab-bevacizumab therapy in HCC patients. Esophageal band ligation for small non-risky varices before starting atezolizumab-bevacizumab therapy. Endoscopy will be repeated 3, 5, 9, 12 months after atezolizumab-bevacizumab therapy
214356749|NCT06962436|DEVICE|Robotic bronchoscopy system|Utilization of a robotic bronchoscopy system for the biopsy of patients with peripheral pulmonary lesions suspected of malignancy
214356750|NCT06962436|DEVICE|Ultrathin bronchoscope combined with virtual bronchoscopic navigation|Utilization of ultrathin bronchoscope combined with virtual bronchoscopic navigation for the biopsy of patients with peripheral pulmonary lesions suspected of malignancy
214356751|NCT00126412|DRUG|123I-mIBG (meta-iodobenzylguanidine)|
214356752|NCT05111236|OTHER|Routine physical therapy|Rehabilitation strategies in management of children with spastic CP
214966873|NCT03301662|DIAGNOSTIC_TEST|chest and thumb- ECG|chest and thumb- ECG using the Coala Heart Monitor
214966874|NCT02339103|OTHER|Warmed IV fluids|1 Liter of warmed IV fluids at 42 degrees celsius
214966875|NCT02339103|OTHER|Warmed perfusion pads|Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
214966876|NCT03943498|DRUG|Fingolimod|Given PO daily for 4 weeks
215081692|NCT05493189|OTHER|Additional autonomous training sessions|The duration of the autonomous training will be 30 minutes, using a feedback CPR training simulator (eg Laerdal Little Anne QCPR).
214356753|NCT05111236|OTHER|Traditional massage|Rehabilitation strategies in management of children with spastic CP
214966877|NCT03943498|DRUG|Fingolimod Hydrochloride|Given PO
214966878|NCT03943498|OTHER|Questionnaire Administration|Ancillary studies
214966879|NCT03994978|PROCEDURE|elective sigmoidectomy|elective sigmoidectomy
214966880|NCT03064113|DRUG|Placebo|
214966881|NCT03064113|DRUG|TD-4208 700 μg|
214966882|NCT03064113|DRUG|TD-4208 350 μg|
214966883|NCT03064113|DRUG|Ipratropium 500 μg|
215081693|NCT02178046|DEVICE|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
215081694|NCT05472077|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop."
214966884|NCT03407417|OTHER|virtual technology|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Highly tailored patient reminders will be customized using all 12 constructs.
214966885|NCT02167438|DEVICE|Hem-Avert Perianal Stabilizer|
214966886|NCT05438979|DIETARY_SUPPLEMENT|Placebo|Placebo for comparison to CFB
214966887|NCT05438979|DIETARY_SUPPLEMENT|Calcium Fructoborate|216mg CFB
214966888|NCT03874013|DRUG|MOD-4023|"MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN.~MOD-4023 will be administered as a SC injection once weekly, using a delivery device."
214966889|NCT03874013|DRUG|Genotropin|"Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections.~A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated.~Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week)."
214966890|NCT04331691|DRUG|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
214966891|NCT04331691|DRUG|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
214966892|NCT02996721|BIOLOGICAL|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
214966893|NCT05143684|PROCEDURE|Left Lateral Uterine Displacement|a wooden wedge wrapped with cotton, to make it comfortable, and medical sheets with a measured angle of 15° under the right flank of the laying down patient
214966894|NCT00943657|BIOLOGICAL|Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]|Single intramuscular injection of vaccine
214966895|NCT05469126|DRUG|LY3502970|Administered orally.
214966896|NCT05469126|DRUG|Clarithromycin|Administered orally.
215081695|NCT05259761|OTHER|Unmanned ariel vehicle|Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)
214356754|NCT00402753|BEHAVIORAL|Ambulatory Physical Exercise Program|supervised exercise, 2 x / week
214356755|NCT02308748|DRUG|Dofetilide|"* 8 am: Placebo~* 12 pm (noon): 250 µg~* 5:30 pm: 250 µg"
214356756|NCT02308748|DRUG|Mexiletine|"* 8 am: weight x 4 mg/kg~* 12 pm (noon): Same as at 8 am~* 5:30 pm: Same as at 8 am"
215081696|NCT02410824|DEVICE|stenfilcon A toric lens|toric contact lens
214356757|NCT02308748|DRUG|Lidocaine|"* 9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~* 2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~* 7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes"
214356758|NCT02308748|DRUG|Moxifloxacin|"* 9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~* 2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~* 7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)"
214356759|NCT02308748|DRUG|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
214356760|NCT02308748|DRUG|Placebo|Placebo (#2 Gelcap or IV saline)
214356761|NCT06186752|BEHAVIORAL|MyIBD|MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.
214356762|NCT00435773|PROCEDURE|Single Leeching|
214356763|NCT00435773|PROCEDURE|Repeated Leeching after 4 weeks|
214356764|NCT00435773|PROCEDURE|Placebo Leeching|
214356765|NCT04879550|DIAGNOSTIC_TEST|Antithrombin III|Antithrombin III deficiency causes thrombosis. Is thrombosis in ECMO patients related to Antithrombin III deficiency? Groups with and without thrombosis will be separated and whether it is related to Antithrombin III deficiency will be evaluated.
214356766|NCT05814913|BEHAVIORAL|CaCBT for psychosis|The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms
214356767|NCT05814913|BEHAVIORAL|Culturally adapted Family Intervention (CulFI) for psychosis|CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.
214356768|NCT05256173|OTHER|Melatonin Tablets|Melatonin Tablets was given 3 tablets (6.21mg) daily at the beginning of bedtime at night for a total of 4 weeks.
214356769|NCT05256173|OTHER|Lactasin Tablets|The placebo group was given at the beginning of bedtime at night for a total of 4 weeks.
214356770|NCT05256173|DEVICE|transcutaneous vagus nerve stimulation|transcutaneous vagus nerve stimulation treatment, frequency 10Hz, stimulation site is the anterior wall of the left external auditory canal (tragus), used twice a day, each treatment for 30 minutes, a total of 4 weeks.
215081697|NCT02410824|DEVICE|etafilcon A toric lens|toric contact lens
214356771|NCT05256173|DEVICE|sham transcutaneous vagus nerve stimulation|In the sham stimulation group, the stimulation site was the left earlobe with a frequency of 10Hz, which was used twice a day for 30 minutes for a total of 4 weeks.
214356772|NCT00239174|DRUG|SR147778|
214356773|NCT02979262|BEHAVIORAL|Fathers for Change|
214966897|NCT04753294|DEVICE|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
214966898|NCT04753294|DEVICE|Avance Solo Adapt NPWT System|Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.
215081698|NCT05008757|OTHER|no drug|no intervention
215081699|NCT00392808|BIOLOGICAL|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
214966899|NCT00180089|DRUG|Budesonide|
215081700|NCT01476280|DRUG|palonosetron|0.075mg immediately before induction of anesthesia
215081701|NCT01476280|DRUG|Ramosetron|0.3mg immediately before induction of anesthesia
215081702|NCT01333995|BEHAVIORAL|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
215081703|NCT03177811|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
215081704|NCT03177811|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
215081705|NCT05675761|DRUG|Azorubine|Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
215081706|NCT01115335|PROCEDURE|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
215081707|NCT00136825|DRUG|N-Acetylcysteine|
214356774|NCT02979262|BEHAVIORAL|Parent Education|
214356775|NCT02388802|PROCEDURE|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
214966900|NCT06040814|BEHAVIORAL|Rehabilitation Training|12 week Rehabilitation Training course
214966901|NCT00380536|BEHAVIORAL|Peer-Led Health Education Class|Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
214966902|NCT02902835|BEHAVIORAL|BUP_FAST|Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)
214966903|NCT02902835|BEHAVIORAL|Referral to treatment|Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
214966904|NCT02481076|DEVICE|Flowtron Hydroven and Coban2 Lite|The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
214966905|NCT02481076|OTHER|Braun frame|The leg is elevated on a Braun frame
214966906|NCT02481076|DEVICE|compression bandage|application of flowtron hydroven boot and compression bandage
214966907|NCT06324877|DRUG|Nicotinamide riboside|Oral capsule Nicotinamide Riboside 25mg/kg/day divided into 3 equal doses
214966908|NCT02909010|DEVICE|BIS™ Brain Monitoring System|The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
214966909|NCT02909010|OTHER|RASS|control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
214966910|NCT03507855|OTHER|Reduced noise|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
214966911|NCT03507855|OTHER|Normal|No change in the normal operating room environment.
214966912|NCT01204203|DRUG|Zometa|Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.
214966913|NCT01460732|DEVICE|Blood Pressure Monitoring|Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
214966914|NCT03217292|PROCEDURE|Serratus Anterior Plane Block|
214966915|NCT03217292|DRUG|IV patient-controlled analgesia (PCA) tramadol|
214966916|NCT01484080|DRUG|BIBF + Paclitaxel|"Priming Period:~Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.~One week washout is planned before starting the treatment phase.~Treatment Phase:~Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days)."
214966917|NCT01484080|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
214966918|NCT06060496|DEVICE|Active cTBS|Two cTBS sessions (each session delivering 3600 pulses) separated by 50 minutes
214966919|NCT06060496|DEVICE|Sham cTBS|Two sham cTBS sessions (sham mimics the experimental session but does not deliver any electricity to the brain) separated by 50 minutes
214966920|NCT05532423|DRUG|Beetroot Juice - Active|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
214966921|NCT05532423|DRUG|beetroot juice - Placebo|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
214966922|NCT03990051|DRUG|Pro-ocular™ topical gel|Topical gel for forehead dermal application
214966923|NCT03990051|DRUG|Placebo topical gel|Topical gel for forehead dermal application
214966924|NCT06444503|OTHER|Biological samples|Blood and urine will be taken in larger quantity
214966925|NCT06444503|OTHER|Biological|Surgical residues may be preserved in the event of surgery carried out as part of the treatment.
214966926|NCT01411852|DRUG|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
214966927|NCT01411852|DRUG|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
214966928|NCT06010602|PROCEDURE|Quadratus lumborum block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
215081708|NCT00136825|DRUG|Placebo|
215081709|NCT02782325|BIOLOGICAL|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
215081710|NCT02782325|BIOLOGICAL|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
215081711|NCT03033563|PROCEDURE|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
215081712|NCT00407004|DEVICE|MARS (Molecular Adsorbents Recirculating System)|
215081713|NCT00407004|DEVICE|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
214966929|NCT06010602|PROCEDURE|İlioinguinal-İliohipogastric nerve block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
214966930|NCT00921661|DRUG|AVE0005 (aflibercept)|IV infusion
214356776|NCT02388802|PROCEDURE|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
214356777|NCT02388802|PROCEDURE|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
214356778|NCT02388802|DRUG|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
214966931|NCT01161810|OTHER|Routine post burn rehabilitation therapy|No testing outside of routine clinical rehabilitation will be performed
214356779|NCT02388802|PROCEDURE|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
214356780|NCT02388802|PROCEDURE|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
214356781|NCT03846830|DEVICE|Incremental Velocity Error (IVE)|A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.
214966932|NCT03861091|DRUG|risedronate|Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
214966933|NCT03861091|DRUG|Matching placebo|Dose not applicable, given once 7-21 days prior to initiation of SBRT
214356782|NCT03846830|BEHAVIORAL|Traditional Vestibular Rehabilitation (VPT)|Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.
214356783|NCT02445612|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
214966934|NCT04006470|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
214966935|NCT04006470|DRUG|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
214966936|NCT04006470|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
214966937|NCT01025102|DRUG|Naropin 0.1% cum sufentanil|20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
214966938|NCT01960465|DEVICE|Continuous positive airway pressure|A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
214966939|NCT00374348|DRUG|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
214966940|NCT02213315|DRUG|100mg Mavrilimumab|100mg Mavrilimumab
214966941|NCT02213315|DRUG|150mg mavrilimumab|150mg mavrilmumab
214966942|NCT02213315|OTHER|Placebo|Placebo
214966943|NCT05876884|DEVICE|Celsi Warmer Mattress|The hypothermic neonate will be placed on the Celsi Warmer mattress and a temperature probe will be placed on the neonate to monitor the temperature of the neonate for up to 24 hours of intervention time
214966944|NCT03093441|OTHER|Multimodal High-Intensity Interval Training Intervention|The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
214966945|NCT00503893|BEHAVIORAL|Questionnaire|Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.
214966946|NCT00503893|OTHER|Blood specimen|Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
214966947|NCT04919148|BEHAVIORAL|Heat risk and pro-environment behavior message|Eligible participants will be randomized to either a control condition to receive a standardized heat health warning or an intervention condition to receive a heat health warning plus figures depicting heat risk and pro-environment behavior via their preferred and accessible channel (WhatsApp, WeChat or the text message) each time when a Very Hot Weather Warning is issued by the Hong Kong Observatory.
214966948|NCT04773821|OTHER|Targeted biopsies|Prostate MpMRI at 12 month (after PCa focal treatment in standard care) and targeted biopsies in the presence of lesion(s) suggestive(s) of recurrence
214966949|NCT04714645|DEVICE|VR neglect training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. The training consists of 5 different VR tasks specifically designed for neglect training.
214966950|NCT04714645|DEVICE|VR control training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. This is a placebo training, where patients will also wear the HMD. Patients will be immersed in a virtual environment without a specific task.
214966951|NCT00889655|DRUG|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
214966952|NCT00889655|DRUG|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
214966953|NCT03126786|DRUG|IVT aflibercept|IVT aflibercept \[2 mg/0.05 mL\]
214966954|NCT03126786|DRUG|Sham SC|sham SC
214966955|NCT03126786|DRUG|SC CLS-TA|CLS-TA \[4 mg/100 μL\] SC injection
214966956|NCT05030532|BEHAVIORAL|EVERYbody Project|Brief behavioral group intervention (4 hours across two meetings)
214966957|NCT05030532|OTHER|Video + Expressive Writing|Brief video-based group intervention (4 hours across two meetings)
214966958|NCT00037063|DRUG|Thiamine hydrochloride|
214966959|NCT00037063|DRUG|Riboflavin|
214966960|NCT00037063|DRUG|Ascorbic acid|
214966961|NCT00037063|DRUG|Vitamin E|
214966962|NCT00991289|DRUG|Nitazoxanide (NTZ)|500 mg twice daily, taken orally with food
214966963|NCT00991289|DRUG|Pegylated interferon alfa-2a (PEG)|180 micrograms via subcutaneous injection once weekly
215081714|NCT02953236|PROCEDURE|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
215081715|NCT02953236|PROCEDURE|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
214356784|NCT05207813|DEVICE|Intracept Procedure|Intraosseous Basivertebral Nerve (BVN) Ablation
214356785|NCT03736434|BEHAVIORAL|Mindfulness and DASH Diet Education|"Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines."
214356786|NCT03736434|BEHAVIORAL|Education group|The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
214393728|NCT02173535|DEVICE|etafilcon test contact lens Variant AP|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
214966964|NCT00991289|DRUG|Ribavirin (RBV)|Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
214966965|NCT00379899|DRUG|cinacalcet|Low dose vitamin D with cinacalcet
214966966|NCT02404610|PROCEDURE|Moderate Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
214966967|NCT02404610|PROCEDURE|Deep Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
214966968|NCT02404610|DRUG|propofol|
214966969|NCT01701804|DRUG|Chuna herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
214966970|NCT01701804|PROCEDURE|Chuna manual therapy|A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
215081716|NCT02818036|DRUG|Naltrexone|
215081717|NCT02818036|DRUG|Placebo|
215081718|NCT03058666|DRUG|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
215081719|NCT03058666|DEVICE|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
214966971|NCT01701804|PROCEDURE|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10\~20 acupoints once a week for 16 weeks.
215081720|NCT03638869|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
215081721|NCT03638869|DRUG|Placebo|
215081722|NCT01038713|DEVICE|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
215081723|NCT02196415|DEVICE|Biplanar Radiography|standard biplanar radiography of the foot
214393729|NCT02173535|DEVICE|etafilcon test contact lens Variant JG|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
214966972|NCT01701804|PROCEDURE|Bee-venom pharmacoacupuncture|Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
214966973|NCT00013871|BIOLOGICAL|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
214966974|NCT00013871|BIOLOGICAL|Measles-Mumps-Rubella Vaccine (Live)|
214966975|NCT00013871|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
214966976|NCT00013871|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|
214966977|NCT00013871|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
214966978|NCT02235025|OTHER|Cardio-pulmonary exercise testing|
214966979|NCT04069676|OTHER|EEG|EEG, ECG and EDR record during a behavioral task
215081724|NCT02181101|DRUG|FEC-DocGemzar adjuvant chemotherapy|
215081725|NCT02181101|DRUG|FEC-Doc adjuvant chemotherapy|
215081726|NCT02181101|DRUG|Zoledronic acid i.v. 2 years|
215081727|NCT02181101|DRUG|Zoledronic acid i.v. 5 years|
215081728|NCT03983772|DIETARY_SUPPLEMENT|RS blend|The intervention is a proprietary resistant starch blend.
215081729|NCT03983772|OTHER|Placebo|The placebo is starch.
215081730|NCT01154283|DEVICE|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
215081731|NCT00031018|DRUG|Aricept|
215081732|NCT00031018|DRUG|IFN-alpha2A|
215081733|NCT03777917|DEVICE|Belotero Balance®|Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
215081734|NCT05302856|DIAGNOSTIC_TEST|Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)|Peripheric blood extraction
215081735|NCT00792532|PROCEDURE|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
214966980|NCT00532532|DRUG|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
214966981|NCT00532532|DRUG|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
215081736|NCT00792532|DEVICE|DBS electrodes|Deep brain stimulation (DBS) electrodes
215081737|NCT00042432|DRUG|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
215081738|NCT03000491|OTHER|No intervention|Variations in clinical practice as assessed by data relating to asthma extracted from patient electronic health records.
215081739|NCT02223416|DRUG|RGB-10|
215081740|NCT02223416|DRUG|Teriparatide|
215081741|NCT03700619|OTHER|BRIEF parental survey|estimate incidence of executive functions disorders in preterm children in 11 to 12 year old, born less than 34 weeks of gestation, with the BRIEF parental questionnaire. Effects are potentially important because this study could objectify an increase of risk of executive functions disorders f in preterm children in 11 to 12 year old, and identify associated risk factors. This work could eventually alert pediatrician to be careful at the executive functions and to propose adapted supportive cares.
215081742|NCT02262104|BEHAVIORAL|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
214966982|NCT00532532|DRUG|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
214966983|NCT01340755|PROCEDURE|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
214966984|NCT05923918|DRUG|PBK_M2101 2-Day|Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
214356787|NCT04956718|OTHER|Cold Pressor Test (CPT)|Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.
214356788|NCT04956718|OTHER|Placebo NaCl Nasal spray|placebo nasal spray containing NaCl solution
214356789|NCT05530135|OTHER|Exercise program|Exercise program
214356790|NCT05530135|OTHER|Cognitive behavioural therapy|Cognitive behavioural therapy
214356791|NCT05530135|OTHER|Standard clinical care|Standard clinical care
214356792|NCT04628689|OTHER|quadratus lumborum block by paraspinous sagittal shift approach|quadratus lumborum block by paraspinous sagittal shift approach
214966985|NCT05923918|DRUG|PBK_M2101 1-Day|Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
214966986|NCT05923918|DRUG|Oral Sulfate Tablet 2-Day|Subjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.
214966987|NCT04915560|DEVICE|Connected T-shirt|Ware of a connected T-shirt
214966988|NCT03585972|BEHAVIORAL|Frailty Prevention Program|4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.
214966989|NCT02716779|DRUG|Pegylated Interferon (PEG-IFN) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
214966990|NCT02716779|DRUG|Placebo|Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
214966991|NCT02716779|DRUG|Ribavirin|Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
215081743|NCT02262104|BEHAVIORAL|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
215081744|NCT01386268|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
214966992|NCT06324643|PROCEDURE|sensory motor integration training|one group treated by strengthening exercises , stretching ,and occupational therapy and other group treated by strengthening exercises , stretching ,and occupational therapy and sensory motor integration training
214966993|NCT00202098|PROCEDURE|Variable ventilation|"Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system."
214966994|NCT02931786|DRUG|propofol|propofol, midazolam and atropine administration via intravenous cannula.
214966995|NCT02931786|DRUG|Ketamine propofol mixture|Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
214966996|NCT00601315|DRUG|Clarithromycin|
215081745|NCT05908526|BEHAVIORAL|Baseline surveys, Cognitive testing and EMAs|Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
215081746|NCT05908526|DEVICE|Actiwatch|Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
215081747|NCT05908526|DRUG|suvorexant (or placebo)|FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
215081748|NCT05908526|OTHER|Placebo|An inactive substance that looks like the drug or treatment being tested.
215081749|NCT03129594|DIAGNOSTIC_TEST|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
214966997|NCT05205304|DRUG|D'Oxyva|The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
214356793|NCT05903417|DRUG|Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg|The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium chloride solution. t-PA and DNase are not mixed together in one syringe. In brief , both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.
214356794|NCT05903417|OTHER|Saline irrigation with 250 mls normal saline (over 1 hour)|subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
214966998|NCT04917614|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
214966999|NCT00107757|DRUG|GW685698X|
214967000|NCT06253533|BIOLOGICAL|ICVAX|ICVAX is a HIV therapeutic DNA drug developed by Immuno Cure Group based on the PD-1-Enhanced DNA Vaccine Technology platform. The unit dose strength is 2 mg in 1 mL. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
214967001|NCT06253533|OTHER|Placebo|Phosphate buffered saline of the same volume will be administered. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
214967002|NCT01674465|BIOLOGICAL|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m\^2 two-three hours prior to their standard of care biopsy
214356795|NCT04988308|DRUG|Bermekimab|Bermekimab will be administered subcutaneously.
214356796|NCT04988308|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
215081750|NCT00440856|BEHAVIORAL|Presentation of excised intervertebral disc fragments|
215081751|NCT01853072|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
215081752|NCT01853072|OTHER|Nepafenac vehicle|Inactive ingredients used as placebo comparator
214967003|NCT04110899|OTHER|Application of paratracheal force|An esophageal stethoscope is inserted into the upper esophagus under the application of different paratracheal force in anesthetized and paralyzed patients.
214967004|NCT03955159|DIETARY_SUPPLEMENT|Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
214967005|NCT03138577|DIAGNOSTIC_TEST|Ultrasound Imaging|"M-mode tracings of right diaphragm motion will be made and recorded by a skilled anesthesiologist. Patients will be examined in the supine position and scanned from a low intercostal or subcostal approach using the liver as an acoustic window. Patients will be asked to perform a voluntary sniff (VS) test, for which they will be asked to forcefully inhale through the nose in a sniffing position. The above measurement will be performed immediately preceding the brachial plexus blockade, and then at 15 minute and 30 minutes after block."
214967006|NCT03138577|DRUG|Supraclavicular Block|The patient will be positioned supine with the head turned to the contralateral side. The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine. The anesthesiologist can redirect the needle and perform additional injections for complete coverage of the brachial plexus. The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.
214967007|NCT03138577|OTHER|Bedside Negative Inspiratory Force Meter|A bedside negative inspiratory force (NIF) meter will be used to measure negative inspiratory force prior to the block and 30 minutes after the block.
214967008|NCT01051817|DRUG|AIN457|infusion 10 mg/Kg
215081753|NCT01853072|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
215081754|NCT01816906|DEVICE|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
215081755|NCT01816906|DEVICE|Footwear: MCP|One group of patients will receive footwear with MCP insoles
214356797|NCT04988308|DRUG|Placebo|Placebo will be administered subcutaneously.
214356798|NCT01168492|DRUG|ketamine|0.5mg/kg ketamine iv
214356799|NCT00866840|DRUG|riluzole|100 mg orally twice daily
214356800|NCT05404542|DRUG|Tavapadon|Oral tablets
214967009|NCT01051817|DRUG|Placebo|infusion
214967010|NCT01026948|DRUG|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
215081756|NCT01304810|BIOLOGICAL|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
215081757|NCT01304810|BIOLOGICAL|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
215081758|NCT05828472|DRUG|MY008211A tablets|MY008211A tablets, low/moderate/high dose orally, for 7 days
215081759|NCT05828472|DRUG|MY008211A tablets matched placebo|MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
215081760|NCT02585648|DEVICE|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
215081761|NCT02585648|DEVICE|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
215081762|NCT03283397|DRUG|EK-12|10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
215081763|NCT03283397|DRUG|INF beta-1a|Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
214967011|NCT01026948|DEVICE|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
214967012|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
214967013|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
214967014|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
214967015|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
214967016|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
214967017|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
214967018|NCT05205200|DRUG|SHR-1316|PD-L1 antibody
215081764|NCT04199364|DRUG|Poractant Alfa 80 mg/mL Intratracheal Suspension|Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.
215081765|NCT02544334|PROCEDURE|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
215081766|NCT02544334|OTHER|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
215081767|NCT02544334|OTHER|Saliva Collection|All participants will have a saliva collection.
215081768|NCT05995197|OTHER|action observation|cartoon observation
215081769|NCT01628861|DEVICE|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
215081770|NCT01628861|BEHAVIORAL|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
215081771|NCT00690170|DRUG|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
215081772|NCT00690170|DRUG|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
215081773|NCT00690170|DRUG|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
215081774|NCT00690170|DRUG|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
215081775|NCT03950713|BEHAVIORAL|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
215081776|NCT00746733|DRUG|Lisdexamfetamine Dimesylate|50mg capsule
215081777|NCT00746733|DRUG|Adderall XR (mixed salts amphetamine)|20mg capsule
215081778|NCT00206284|DRUG|AZD0865|
215081779|NCT04041427|DRUG|Albendazole Pill|Albendazole 400mg po
215081780|NCT04041427|OTHER|High fat content diet|High fat content diet
215081781|NCT04041427|OTHER|Moderate fat content die|Moderate fat content die
214356801|NCT06313762|DEVICE|Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet|They will experience in first person the two and a half minute graphic adventure, called Leia\&amp;amp;amp;amp;#39;s World, during the administration of the vaccines.
214356802|NCT06313762|BEHAVIORAL|Traditional Distractors|The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home, during the administration of the vaccines.
214967019|NCT05205200|DRUG|SHR6390|CDK4/6 inhibitor
214967020|NCT05205200|DRUG|Nab paclitaxel|Albumin bound paclitaxel
214967021|NCT05205200|DRUG|SERD|Fulvestrant
214967022|NCT05205200|DRUG|AI|aromatase inhibitor
214967023|NCT00701792|PROCEDURE|liver transplantation|liver transplantation
214967024|NCT00701792|OTHER|standard care for liver disease|"standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy."
214967025|NCT01951118|DRUG|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease. For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol. Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
215081782|NCT01527383|BIOLOGICAL|V212|V212 viral antigen for HZ
215081783|NCT01527383|BIOLOGICAL|Placebo|Placebo comparator to V212 vaccine
215081784|NCT03854292|PROCEDURE|Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.
215081785|NCT05221775|DRUG|Lenvatinib|XELOX regimen combined with GLS-010 and different doses of Lenvatinib
215081786|NCT02984059|GENETIC|Genomic DNA|blood draw
215081787|NCT02984059|GENETIC|RNA analysis|Mucosal Biopsy via colonoscopy
215081788|NCT02984059|GENETIC|Microbiome|Stool microbiome
215081789|NCT02984059|OTHER|Calprotectin|stool or blood analysis for calprotectin
215081790|NCT02984059|OTHER|Pain questionnaires|PSDS PCS-C/P PBI APPT
214679073|NCT03517748|DEVICE|Optive™ eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
215081791|NCT02984059|OTHER|Anxiety/Depression Questionnaires|RCADS-25 CSI-24 ARCS
214967026|NCT03155347|DRUG|Tocilizumab|Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
214967027|NCT03155347|DRUG|MTX|Participants will receive MTX stable doses at 10 to 25 mg orally.
214967028|NCT03155347|DRUG|Placebo Matched to MTX|Placebo matched to MTX.
214967029|NCT03155347|DRUG|Placebo Matched to Tocilizumab|Placebo matched to tocilizumab.
214967030|NCT05324553|PROCEDURE|Tissue Collection|Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
214967031|NCT05324553|DIAGNOSTIC_TEST|Blood Collection|Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional
214967032|NCT05324553|DIAGNOSTIC_TEST|Buccal Swab|Buccal swab may be requested, if necessary, to generate germline data.
214967033|NCT06336057|BEHAVIORAL|Mentalization|complete several questionnaires including the RFQ (reflective functioning questionnaire) and the MST (Mental states task) which are validated questionnaires about mentalization
214967034|NCT05312970|DRUG|Varithena®|Varithena® (polidocanol injectable foam) 1%
214967035|NCT05312970|DEVICE|FDA-approved Endothermal Ablation (ETA) systems|FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
214967036|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
214967037|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
215081792|NCT03412604|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
214967038|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
214967039|NCT00884078|OTHER|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
214967040|NCT01441128|DRUG|PF-02341066/PF-00299804|Combined PF-02341066 and PF-00299804
214967041|NCT01441128|DRUG|PF-02341066/PF-00299804|Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
214356803|NCT06313762|BIOLOGICAL|Triple Viral + Varicella Vaccine at 3 years of age|Administration of vaccines in 3-year-old children, as appropriate according to the vaccination schedule
214967042|NCT02529254|BEHAVIORAL|Video coaching session|A 30 minute video coaching session with a surgeon in witch the residaent and coach visualise the filmed anastomosis and where the surgeon gives constructive feedback.
214967043|NCT04819139|OTHER|Active Excersises|Active thumb exercises
215081793|NCT05300841|DRUG|dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt)|Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses
215081794|NCT05300841|DRUG|estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Shering, Germany)|will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
215081795|NCT05476432|PROCEDURE|HAIC|The microcatheter was advanced into the hepatic artery, and patients were transferred to the inpatient ward for drug infusion via the hepatic artery
215081796|NCT05476432|DRUG|FOLFOX 2d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
215081797|NCT05476432|DRUG|FOLFOX 1d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 23 hours
214967044|NCT04819139|OTHER|Reeducation ADL|Reeducation in the activities daily life
215081798|NCT05449275|OTHER|Faradic current|The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
214356804|NCT06313762|BIOLOGICAL|Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.|Administration of vaccines in 6-year-old children, as appropriate according to the vaccination schedule.
214393730|NCT02173535|DEVICE|etafilcon test contact lens Variant CS|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
214967045|NCT04819139|OTHER|Joint protection|Used of a thumb orthosis
214967046|NCT04819139|OTHER|Proprioception exercises|Specific proprioception exercises
214967047|NCT00443222|DRUG|Infliximab|
214967048|NCT00672633|DRUG|Lovaza|Lovaza , 4 grams/day orally for 6 months
215081799|NCT05449275|OTHER|Ankle foot orthosis|AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
214967049|NCT00672633|DRUG|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
214967050|NCT02824627|DRUG|Oxytocin|A growing body of data shows that intra-nasal administration of oxytocin has promise for treating a host of psychiatric disorders. Considerable data indicates that oxytocin reduces amygdala response to negative stimuli in patients with generalized anxiety disorder, borderline personality disorder, and post-traumatic stress disorder. Given that one of the potential underlying neurobiological mechanisms of irritability and emotional dysregulation in pediatric population with disruptive behavior and mood disorder is the hyperactivity of amygdala to negative emotional stimuli, and that oxytocin reduces this, it is critical to determine the extent to which this intervention improves irritability and emotional dysregulation in children and adolescents with disruptive behavior and mood disorders.
214967051|NCT02824627|DRUG|Placebo|Inactive substance administered in volume equivalent to volume administered in active treatment arm.
214967052|NCT06521190|DRUG|ACOU085 (bimokalner)|Transtympanic injection
214967053|NCT06521190|DRUG|Placebo|Transtympanic injection
215081800|NCT02242175|DEVICE|Glucose breath test (hydrogen breath test)|Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
215081801|NCT06126367|DIAGNOSTIC_TEST|Thrombotic assessment|"The Global Thrombosis Test (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~Thromboelastography is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Plasma will be stored for subsequent analysis of other thrombotic, fibrinolytic, inflammatory and coagulation markers as deemed appropriate.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
215081802|NCT06126367|DIAGNOSTIC_TEST|Measurement of Lp(a)|"Lp(a) will be measured by particle enhanced immunotubidimetricassay. Human lipoprotein (a) agglutinates with latex particles coated with anti-Lp(a) antibodies. The precipitate is determined turbidimetrically at 800 / 660 nm. The platform employed will be the Roche® Immunoassay Analyser (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim). Traceability: This method has been standardized against the IFCC (International Federation of Clinical Chemistry) reference material SRM2B for nmol/L.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
215081803|NCT00027586|DRUG|Imatinib mesylate (STI571)|400 mg twice a day orally
215081804|NCT02989844|DRUG|N-803|N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.
215081805|NCT02916225|BEHAVIORAL|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
215081806|NCT02916225|BEHAVIORAL|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
215081807|NCT02183129|DRUG|Diclofenac|
215081808|NCT02183129|DRUG|Meloxicam|
215081809|NCT04217161|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
215081810|NCT04630717|OTHER|Medical hypnosis session|"the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient"
215081811|NCT04630717|OTHER|control groupe|the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
215081812|NCT03302117|OTHER|Wood smoke exposure|Healthy volunteers will exposed to filtered air alternate with wood smoke generated from incomplete wood smoke combustion to assess the local and systemic effect of theses exposures
214356805|NCT03848533|DRUG|melatonin|"The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)"
214356806|NCT03848533|DRUG|metformin|"For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)"
214356807|NCT03848533|DRUG|Placebo|"The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)"
214356808|NCT01714128|DRUG|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
214967054|NCT05661695|DEVICE|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
214967055|NCT05716685|OTHER|Health coaching|The intervention consisted of transferring the knowledge acquired on health coaching by the nurses of the cardiology unit to their care activity with CHF patients. To this end, all the nurses in the cardiology unit received two training packages: 1) five theoretical and practical sessions on health coaching competencies, emotional intelligence, communication and support for CHF patients in the hospital setting; and 2) training sessions 7 months after the first training package to reinforce the theoretical and practical knowledge acquired in health coaching. During this period, debriefing was carried out to provide feedback on the health coaching process with patients.
214967056|NCT00778791|DRUG|metformin HC1 750 mg extended-release tablets|
214967057|NCT02797977|DRUG|SRA737, gemcitabine, cisplatin|
214967058|NCT02797977|DRUG|SRA737, gemcitabine|
214967059|NCT02235129|OTHER|breath-holding|
214967060|NCT02775097|DEVICE|OCT|OCT for all Arms
214967061|NCT01007370|PROCEDURE|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
214967062|NCT01007370|PROCEDURE|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
214967063|NCT00929344|DRUG|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
214967064|NCT00929344|DRUG|Duloxetine|40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
214967065|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
214967066|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
214967067|NCT00929344|DRUG|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
214967068|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
214967069|NCT00696735|PROCEDURE|chemotherapy|injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
214967070|NCT00696735|PROCEDURE|high dose therapy and autologous stem cell transplantation|VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
214967071|NCT02714010|DRUG|EGFR-TKI|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
214967072|NCT02714010|RADIATION|whole brain radiotherapy|30Gy/10F
214967073|NCT03452956|OTHER|None-Observation Only|No intervention-this is an observational study
214967074|NCT04293497|DIAGNOSTIC_TEST|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained using endoscopic ultrasound-guided fine needle aspiration. Three types of slides (direct smear, thinprep, surepath) are prepared for staining.~1. conventional cytology staining method~2. new cytology staining method using antibody of methionyl-tRNA synthetase 1"
214967075|NCT04213092|PROCEDURE|ERCP+LC|Patients in this group underwent a single setting ERCP and Laparoscopic cholecystectomy.
214967076|NCT04213092|PROCEDURE|OC+CBD|Patients in this group underwent a single setting open cholecystectomy and open CBD exploration.
214967077|NCT00473447|BEHAVIORAL|Modified Constraint-induced movement therapy|
214967078|NCT01853293|DRUG|Kudzu extract|
214356809|NCT06534398|DEVICE|Dental implant prosthesis with cantilever extension|A retrospective study on the radiographic and clinical findings of implant-supported dental prostheses with cantilever extensions in place and function for at least 10 years
214967079|NCT01853293|DRUG|Placebo|
214967080|NCT01853293|BEHAVIORAL|Medical Management|Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
214967081|NCT01689441|DRUG|Calcitriol|
214967082|NCT01689441|DRUG|Placebo|
214967083|NCT02477358|PROCEDURE|Left Tooth Platelet Rich Fibrin; Right Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy will be applied to the left tooth socket only. The right tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
214967084|NCT02477358|PROCEDURE|Right Tooth Platelet Rich Fibrin; Left Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy to the right tooth socket only. The left tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
214967085|NCT01115777|OTHER|Quality of Life surveys completed at specified timepoints|Quality of Life surveys (no treatment)
214967086|NCT00178516|OTHER|behavior, procedure|
214967087|NCT01481558|DEVICE|Transcranial direct current stimulation|tDCS 2 mA, dorsolateral pre-frontal cortex
214967088|NCT02741375|DEVICE|Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA)|All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
214967089|NCT00571662|DRUG|Pentostatin|4 mg/m\^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)
215081813|NCT01711229|DRUG|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
214356810|NCT02856464|OTHER|DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)|
214356811|NCT02856464|OTHER|DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice|
214356812|NCT05366777|DRUG|acetaminophen/ibuprofen fixed-dose combination|Intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (total 100 ml)
214356813|NCT05366777|DRUG|Saline|100 ml of normal saline
214356814|NCT03332368|OTHER|Traditional Chinese medicine|Chinese medicine has a long history of prevention and treatment of breast cancer, the effect is obvious. Chinese medicine its mechanism of action is from the whole, adjust the body yin and yang, blood, viscera function balance, emphasizing the combination of governance and external treatment of the combination of thinking, according to different clinical syndromes, using syndrome differentiation.
214356815|NCT02625623|DRUG|Avelumab|Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
214356816|NCT02625623|DRUG|Irinotecan|Irinotecan was administered at a dose of 150 mg/m \^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
214356817|NCT02625623|DRUG|Paclitaxel|Paclitaxel was administered at a dose of 80 mg/m\^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
214356818|NCT02625623|OTHER|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
214356819|NCT06349369|DEVICE|transcranial direct current stimulation|tDCS is a non-invasive neuromodulation technique that has gained attention for its potential to influence neural activity and address cognitive and functional deficits in individuals with schizophrenia. It involves applying a weak direct electrical current to the scalp, which can increase or decrease the excitability of underlying brain regions.
214356820|NCT01012869|DEVICE|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
214967090|NCT00571662|RADIATION|Total-body irradiation (TBI)|TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.
214967091|NCT00571662|DRUG|Cyclosporine A (CsA)|CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD
214967092|NCT00571662|DRUG|Mycophenolate Mofetil (MMF)|MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.
214967093|NCT00571662|DRUG|G-CSF|10 mcg/kg/day subcutaneously for at least 4 consecutive days.
214967094|NCT02568462|DEVICE|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
214967095|NCT01839916|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
214967096|NCT01839916|OTHER|laboratory biomarker analysis|Correlative studies
214967097|NCT05031377|BEHAVIORAL|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
214967098|NCT05031377|BEHAVIORAL|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.
214967099|NCT04102384|OTHER|e-PRO App|The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants. Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires.
215081814|NCT01711229|DRUG|oral acetaminophen|oral acetaminophen will be given preoperatively
215081815|NCT01107119|OTHER|integrated care pathway|communication and follow-up program for integrated care
214356821|NCT05585723|BEHAVIORAL|Questionnaires completion|Prospective, qualitative, observational, single-center study. 1) Two independent translations of the original questionnaires into French, 2) Back-translation of the consensus version into English by a professional bilingual translator 3) We will submit this final version to two opinion leaders in France. 4) Evaluation of the clarity, comprehension and acceptability of the translation of the questionnaire.
214356822|NCT02263404|DEVICE|Deep Brain Stimulation|DBS Implant Stimulation
214356823|NCT00115700|DRUG|Cyclophosphamide|1000 mg/m2 I.V. on day 1
214356824|NCT00115700|RADIATION|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
215081816|NCT01107119|OTHER|usual care|
215081817|NCT01287221|DRUG|Rifampicin|300 mg, 2 times daily
215081818|NCT01287221|DRUG|placebo|placebo
214356825|NCT00115700|DRUG|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
214356826|NCT00115700|DRUG|Prednisolone|50 mg/m2 orally daily for days 1 - 5
214356827|NCT00115700|DRUG|Rituximab|375 mg/m2 IV Infusion day 1
214356828|NCT04237662|PROCEDURE|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
214356829|NCT04237662|DEVICE|Enamel Matrix Derivative application|Enamel Matrix Derivative will be applied in the sites with at least 6 mm of pocket depths
214356830|NCT00808808|BIOLOGICAL|Choice of TIV or FluMist with baseline advertisement|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
214967100|NCT01815502|DIAGNOSTIC_TEST|Cardiac catheterization|All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.
215081819|NCT04041206|DEVICE|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated \[Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)\]. The acupoint microcirculation will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
215081820|NCT00930969|DEVICE|ICD|Subjects implanted with an ICD.
215081821|NCT01533467|DEVICE|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
215081822|NCT00657150|DRUG|Enoxaparin|40 mg once daily
215081823|NCT00657150|DRUG|Dabigatran etexilate|220 mg once daily
215081824|NCT03807297|DRUG|Injection dexmedetomidine|alpha 2 a agonist used for sedation, analgesia
215081825|NCT03807297|DRUG|Injection, Propofol, 10 Mg|non barbiturate type of intravenous anaesthetic drug
215081826|NCT03807297|OTHER|sevoflurane|inhalational anaesthetic agent
214356831|NCT00808808|OTHER|Choice of TIV or FluMist with enhanced advertisement and incentives|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
214356832|NCT00808808|BIOLOGICAL|Control - Usual care offering TIV only with baseline advertisement|A control arm of usual care offering TIV with baseline advertisement
214356833|NCT04405596|DRUG|Ambroxol Hydrochloride|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
214356834|NCT04405596|OTHER|Placebo|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
215081827|NCT03807297|OTHER|nitrous oxide|inhalational anaesthetic agent
215081828|NCT04194918|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Use the Flexiquit+ program
215081829|NCT04194918|OTHER|Text Message|Receive text messages
215081830|NCT04194918|OTHER|Handout|Receive handouts via email
215081831|NCT04194918|OTHER|Questionnaire Administration|Ancillary studies
215081832|NCT04194918|OTHER|Quality-of-Life Assessment|Ancillary studies
215081833|NCT04194918|OTHER|Survey Administration|Ancillary studies
215081834|NCT02966795|DRUG|Glecaprevir/Pibrentasvir|Fixed-dose combination tablets taken orally once a day.
215081835|NCT02416700|PROCEDURE|immediate implant surgery|Surgery of dental implants in one side of the mouth.
215081836|NCT02416700|DEVICE|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
214356835|NCT03591068|DRUG|Fluticasone Propionate|OPN-375 186 μg BID, Delivered via exhalation delivery system
214967101|NCT03492879|DEVICE|EIT Technology|Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage
214967102|NCT05681832|BEHAVIORAL|Intervention group|"The children in this group will participate in a 15-minute HIIT (High-intensity interval training) program twice a week for eight weeks. Motivational interviewing through presentations and Kahoot for the children and their parents will be done at the program's beginning, middle, and end.~The HIIT program will consist of 2.5 minutes of warm-up 12.5 exercises then a cool-down period of 5 minutes. The intensity of the exercise was increased based on each kid's performance and monitored during the sessions using a smartwatch."
214967103|NCT00999622|OTHER|laboratory biomarker analysis|
214967104|NCT00999622|OTHER|questionnaire administration|
215081837|NCT01960127|BEHAVIORAL|Aerobic Exercise|Aerobic exercise
215081838|NCT01960127|BEHAVIORAL|No Intervention|No Intervention
215081839|NCT00151034|DRUG|Trastuzumab|
215081840|NCT00151034|DRUG|Paclitaxel|
215081841|NCT00151034|DRUG|Carboplatin|
215081842|NCT00151034|DRUG|Gemcitabine|
215081843|NCT03121170|OTHER|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.
215081844|NCT03121170|OTHER|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
215081845|NCT03198364|BEHAVIORAL|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
215081846|NCT03198364|BEHAVIORAL|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
214967105|NCT00928850|PROCEDURE|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|"Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
214967106|NCT00928850|PROCEDURE|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|"Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
215081847|NCT06155734|DRUG|Fluorescence guided identification using indocyanine green|During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas
215081848|NCT05577364|DRUG|Selinexor|"Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen."
215081849|NCT05577364|DRUG|R-CHOP Protocol|"Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;"
215081850|NCT04941937|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
214356836|NCT01460329|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
214967107|NCT00928850|PROCEDURE|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
214967108|NCT00928850|PROCEDURE|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
214967109|NCT01330550|DIETARY_SUPPLEMENT|High fiber sugar free biscuit|Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
214967110|NCT03798548|BEHAVIORAL|Brief Bedside CBT|4 sessions of CBT including psychoeducation about TAVR and how mood can impact recovery in cardiac patients, discussion of patients' expectations and any concerns. Teaching and practice of cognitive restructuring and behavioral goal setting techniques for a healthy recovery.
214356837|NCT05216094|OTHER|smart phone App|stroke subjects completed tasks-oriented program demoed in the smart phone app with affected upper limb or bilateral arm movement for 12 weeks
214356838|NCT05216094|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program with smart phone app ,without task-oriented program demoed function, for 12 weeks
214356839|NCT04357626|OTHER|Inpatient Rehabilitation|Observational electronic records review study during inpatient rehabilitation
214967111|NCT04028791|OTHER|Exercise on ergocycle|The exercise includes 15 minutes of warm up, then participants will be asked to pedal as fast as possible for 6 seconds. The test of 6 seconds will be repeated twice or more with recovery each time
214967112|NCT04235504|OTHER|MDI|Subject continues their standard Multiple Daily Injections therapy with FGM or RT-CGM
214967113|NCT04235504|DEVICE|AHCL|"Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment."
214967114|NCT04544059|DRUG|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 \[capped at 2.0 mg\], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
215081851|NCT04941937|DRUG|Thalidomide|100mg/d, Po. on day1-28
215081852|NCT04941937|DRUG|Lenalidomide|PO,Lenalidomide 25mg once daily from D1-21
215081853|NCT04941937|DRUG|Pomalidomide|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
215081854|NCT04941937|DRUG|Dexamethasone|Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
215081855|NCT01046227|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
214356840|NCT04554875|DIAGNOSTIC_TEST|A scoring system|The scoring system was used to rate score patients.
214356841|NCT03578874|DRUG|Sorafenib|PO
214356842|NCT03578874|DRUG|Capecitabine|PO
214356843|NCT03578874|DRUG|Oxaliplatin|IV
214356844|NCT00493766|DRUG|LBH589|
214356845|NCT00615966|DRUG|Diannexin|single dose, 200 µg/kg IV
214356846|NCT00615966|DRUG|Placebo|Single dose, IV
214356847|NCT00615966|DRUG|Diannexin|Single dose, 400 µg/kg IV
214356848|NCT03923413|OTHER|Blood samples|Blood samples for MP evaluation
214356849|NCT03926091|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
214967115|NCT04069143|DIAGNOSTIC_TEST|18F-BMS-986327|Imaging Agent
214967116|NCT02587195|DRUG|Teriflunomide|
214967117|NCT03701412|RADIATION|MRI|MRI brain
214967118|NCT04715282|PROCEDURE|Epley maneuver|Epley maneuver
214967119|NCT02423083|DRUG|Guanabenz|
214967120|NCT05454020|DRUG|XG004|XG004 gel in two concentrations (5% and 10%) will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
214967121|NCT05454020|DRUG|Placebo|Placebo gel will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
214967122|NCT05365815|BEHAVIORAL|Melanated Group Midwifery Care|Racially concordant maternity care Group prenatal care Racially concordant nursing care coordination Postpartum doula support
214967123|NCT00069849|DRUG|ABT-089|
214967124|NCT00691288|DRUG|Omega Pure followed by placebo|Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
214967125|NCT00691288|DRUG|Placebo followed by Omega Pure|Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
214967126|NCT05429671|PROCEDURE|total knee arthroplasty|Participants will have total knee arthroplasty
214967127|NCT05429671|DRUG|Tobramycin|Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
214967128|NCT05429671|DRUG|Gentamicin|Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
214967129|NCT05429671|DEVICE|Antibiotic cement spacer|participants getting an antibiotic-loaded cement spacer during surgery comprised of vancomycin and tobramycin.
214967130|NCT00167518|DRUG|Triamcinolone acetate|
214967131|NCT00181883|DRUG|quetiapine|2.5 - 5.0mg/kg PO BID quetiapine
215081856|NCT03622437|BEHAVIORAL|Patient-led follow-up|"1. Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~2. The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~\- access to stoma care by specialist nurses"
215081857|NCT03622437|OTHER|Standard follow-up|"Patients with sphincter-preserving resection:~\- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~* outpatient visits at 3, 12 and 36 months~* access to stoma care by specialist nurses~All patients:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
215081858|NCT02649192|BIOLOGICAL|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
215081859|NCT02649192|DIETARY_SUPPLEMENT|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
215081860|NCT02649192|OTHER|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
215081861|NCT05212844|PROCEDURE|Musculoskeletal Physical Therapy|Therapeutic exercise and manual physical therapy based on the individual response to end range repeated movements.
215081862|NCT00836459|BEHAVIORAL|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
214967132|NCT05455151|PROCEDURE|Conservative therapy|Conservative therapy to which the patients were subjected was the effect of an electrical impulse
214967133|NCT05455151|BIOLOGICAL|PRP injection|This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium
214967134|NCT05455151|BIOLOGICAL|Injection of PRP after conservative therapy|This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium
214967135|NCT05455151|BIOLOGICAL|Injection of PRP with endometrial cells|This intervention consisted of injecting endometrial cells suspended in prp
214967136|NCT00101868|DEVICE|Discharge communication software|Computerized physician order entry software used by discharging physician
214967137|NCT00101868|OTHER|Usual care discharge process|Handwritten
214967138|NCT02188524|OTHER|Exercise|Tai Chi and Compensatory Stepping
214967139|NCT03924388|DEVICE|Epidural spinal cord stimulation|The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
214967140|NCT03924388|DEVICE|Trnascutaneous electrical spinal cord stimulation.|The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
214356850|NCT03926091|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
214393731|NCT02173535|DEVICE|etafilcon test contact lens Variant VC|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
214393732|NCT02173535|DEVICE|etafilcon test contact lens Variant LA|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
214393733|NCT03208400|BEHAVIORAL|virtual reality exposure|one-session exposure conveyed via virtual reality technology
214356851|NCT06161675|BEHAVIORAL|QuitAid|Participants will receive the QuitAid intervention, based on a medication adherence intervention, which addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician. Smokers not ready to quit will receive up to two sessions focused on using NRT to cut down cigarette use. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the full QuitAid intervention.
214356852|NCT06161675|BEHAVIORAL|SmokefreeTXT|All participants will receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment. For smokers not ready to quit, participants will receive two week-long pre-quit modules, Practice Quit and Daily Challenges. These modules will help the smoker become comfortable with not smoking for short periods of time and build skills before they attempt to quit. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the ready to quit treatment.
214356853|NCT06161675|DRUG|Nicotine Replacement Therapy Patch|All participants will receive up to 8 weeks of NRT in the form of patch. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
214356854|NCT06161675|DRUG|Nicotine lozenge|All participants will receive up to 8 weeks of NRT in the form of lozenge. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
214356855|NCT02352948|DRUG|MEDI4736 (durvalumab)|MEDI4736 (durvalumab) treatment by intravenous infusion
214356856|NCT02352948|DRUG|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
214356857|NCT02352948|DRUG|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
214967141|NCT02214030|DEVICE|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
214967142|NCT05405764|DIETARY_SUPPLEMENT|Porcine protein supplement|Porcine protein supplementation
214356858|NCT02352948|DRUG|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
214356859|NCT02352948|DRUG|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
214967143|NCT05405764|DIETARY_SUPPLEMENT|Control product maltodextrin supplement|Maltodextrin supplementation
214967144|NCT06376617|DEVICE|fibroptic bronchoscopy|take bal through fibrooptic bronchoscopy and send for stain and culcure
214967145|NCT02581033|DRUG|Nucleoside Analogue therapy|Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
215081863|NCT00836459|BEHAVIORAL|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
215081864|NCT03164083|BIOLOGICAL|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
214967148|NCT02708797|OTHER|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
214967149|NCT02708797|OTHER|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
214967150|NCT05643729|DRUG|Zofin|Intravenous Infusion (IV) of Zofin
214967151|NCT05643729|OTHER|Placebo|Intravenous Infusion of sterile saline
214967152|NCT01394341|DRUG|Liraglutide|Daily sc. injection, individual dosage
215081865|NCT03164083|BIOLOGICAL|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
215081866|NCT03561701|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
215081867|NCT03561701|DRUG|Placebo|matching placebo capsule
215081868|NCT01665989|BEHAVIORAL|Group Lifestyle Program|
215081869|NCT01665989|BEHAVIORAL|Usual Care|Visits with a dietitian at nutrition services at MGH
215081870|NCT05693051|OTHER|Prone position ventilation|Turning the patient prone for 16 hours
214967153|NCT05495529|PROCEDURE|Thermal Ablation|Data collection about complications, succes of the procedure, succes of complete treatement, recurrence, biologic pertubations.
214967154|NCT00069823|DRUG|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
214967155|NCT00069823|DRUG|Placebo proton pump inhibitor|Placebo proton pump inhibitor
214967156|NCT01739504|PROCEDURE|Liposuction with Local Anesthesia|Liposuction under tumescent anesthesia for adipose tissue harvesting.
215081871|NCT01243567|DRUG|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
215081872|NCT01243567|DRUG|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
215081873|NCT01672099|DIETARY_SUPPLEMENT|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
215081874|NCT01672099|DIETARY_SUPPLEMENT|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
214356860|NCT02352948|DRUG|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
214356861|NCT01694862|PROCEDURE|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
214356862|NCT01356017|DRUG|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
214967157|NCT01739504|BIOLOGICAL|Intra articular infusion of AD-SVF|"Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.~* AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.~* Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing."
214967158|NCT04261647|OTHER|kinesio-taping techniques.|
214967159|NCT04261647|OTHER|Pelvic floor exercise|
214967160|NCT04261647|OTHER|traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.|
214967161|NCT00086606|DRUG|Xolair (omalizumab)|
214967162|NCT02541409|DRUG|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
214967163|NCT02541409|DRUG|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
214967164|NCT02541409|DRUG|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
214967165|NCT01034228|OTHER|ORS + Isoleucine|ORS with Isolelucine for treatment of diarrhoeal in children
214967166|NCT01034228|OTHER|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
214967167|NCT00160264|DRUG|Lactulose, Vitamin D, Calcium|
215081875|NCT05896787|DRUG|AK104, nab-paclitaxel, carboplatin|AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
214356863|NCT01356017|DRUG|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
214356864|NCT00490646|DRUG|ixabepilone|"Ixabepilone 40 mg/m\^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
214967168|NCT04296578|DRUG|Abiraterone Acetate|Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.
214967169|NCT04296578|DRUG|Sodium Selenite|11 mg tablets
214967170|NCT04296578|DRUG|Prednisone|SOC prednisone 5 mg PO twice daily
215081876|NCT00824551|PROCEDURE|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
215081877|NCT00824551|OTHER|Standard care|Patient will undergo standard care
215081878|NCT00438854|DRUG|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
215081879|NCT01470833|PROCEDURE|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
215081880|NCT04575818|DRUG|GLPG4059 oral suspension|GLPG4059 for oral administration
214967171|NCT01727830|OTHER|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
214967172|NCT04633993|BEHAVIORAL|PCSMP|This study divided the patient-centered self-management manual for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
214967173|NCT03905941|DRUG|Metformin|Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.
215081881|NCT04575818|DRUG|Placebo|Placebo oral suspension
215081882|NCT04575818|DRUG|GLPG4059 tablet|GLPG4059 for oral administration
215081883|NCT01034618|DIETARY_SUPPLEMENT|Protein hydrolyzation|
215081884|NCT03542435|DRUG|SXC-2023|Oral capsule
215081885|NCT03542435|DRUG|Placebo|Placebo
214967174|NCT03905941|DRUG|Oral combined hormonal contraceptives|"Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause."
215081886|NCT00202033|BEHAVIORAL|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
214356865|NCT00490646|DRUG|docetaxel|Docetaxel 100 mg/m\^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
214356866|NCT00490646|DRUG|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
214356867|NCT02756767|OTHER|Survey|
214356868|NCT04879186|PROCEDURE|Peripheral endovascular angioplasty|Peripheral endovascular angioplasty - using endovascular techniques to treat peripheral artery occlusive lesions.
214356869|NCT01178086|DRUG|Rituximab|Rituximab IV
214967175|NCT02329327|BIOLOGICAL|Andexanet|There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
214967176|NCT03448523|BEHAVIORAL|Right To Play's Positive Child and Youth Development program|"1. Right To Play's Red Ball Child Play manual provided for 60 hours per annum for two years~2. Training of junior leaders~3. Related play-based activities such as sports days~4. Quarterly awareness sessions with community groups and parents~5. Summer camps for children~6. training of teachers on Right To Play's foundational resources, positive disciplining, and gender and child protection"
215081887|NCT03783611|BEHAVIORAL|MyPlan 2.0.|eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
215081888|NCT01668641|DRUG|GLPG0634|
215081889|NCT01668641|DRUG|Placebo|
215081890|NCT04076345|DIAGNOSTIC_TEST|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
215081891|NCT05615194|DRUG|Dexmedetomidine|0.6 mcg/kg in infusion over 10 minutes
215081892|NCT05615194|DRUG|Placebo|Volume equivalent in infusion over 10 minutes
215081893|NCT03251040|DEVICE|Autologous activated fibrin sealant|Application of fibrin sealant
215081894|NCT02388594|DRUG|ZFN Modified CD4+ T Cells|
215081895|NCT02388594|DRUG|Cyclophosphamide|
215081896|NCT02757794|OTHER|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
215081897|NCT02757794|OTHER|standard remediation|A speech therapy and / or academic support is realized.
215081898|NCT04218162|DRUG|Lasmiditan 50mg|Lasmiditan 50mg
215081899|NCT04218162|DRUG|Lasmiditan 100mg|Lasmiditan 100mg
215081900|NCT04218162|DRUG|Placebo|Placebo
215081901|NCT05566457|DRUG|Huangqi Guizhi Wuwu decoction (HGWD) infusion packs|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
215081902|NCT02547493|BIOLOGICAL|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
215081903|NCT02547493|BIOLOGICAL|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
215081904|NCT02547493|DRUG|Abatacept|Abatacept started on frst day
215081905|NCT03635034|DEVICE|Insert bladder catheter|Bladder catheter will be inserted according to randomization schema
215081906|NCT03635034|DEVICE|No catheter|Subjects will not receive a bladder catheter during the ablation procedure
215081907|NCT03198195|PROCEDURE|cyclophosphamide|on days +3，+4,using cyclophosphamide 50mg/kg
215081908|NCT03764917|OTHER|Time|Different detecting time
215081909|NCT04432493|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
214356870|NCT00236548|DRUG|risperidone|
214356871|NCT01592318|DRUG|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
214356872|NCT01592318|DRUG|danoprevir|Reference tablet, single oral dose
214356873|NCT01592318|DRUG|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
214356874|NCT01592318|DRUG|ritonavir|Reference tablet, single oral dose
214356875|NCT01384994|DRUG|Folic Acid|400 mg/m2, 2h infusion, d1, q2w
214356876|NCT01384994|DRUG|5-FU|400 mg/m2 bolus iv, d1, q2w
214356877|NCT01384994|DRUG|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
214356878|NCT01384994|DRUG|Oxaliplatin|85 mg/m2 d1, q2w
214356879|NCT01384994|DRUG|Panitumumab|6 mg/kg BW every 2 weeks
214356880|NCT01384994|DRUG|Panitumumab|Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
214356881|NCT01384994|DRUG|Folic Acid|400 mg/m2, 2-h infusion, d1, q2w
214967177|NCT03192124|DEVICE|Bactisure|"Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may be present in patient specimen (bacteria and fungi) and includes test for resistance factors to vancomycin and methicillin.~Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order to establish what type of bacterial and fungal species are present."
214967178|NCT04468724|BEHAVIORAL|MAKASI|"The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~* Listening and building trust~* Active referral to structures that answers sanitary and social needs~* Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons."
215081910|NCT04432493|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
214356882|NCT01384994|DRUG|5-FU|400 mg/m2 bolus iv, d1, q2w
214356883|NCT01384994|DRUG|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
214356884|NCT01384994|DRUG|Oxaliplatin|85 mg/m2 d1, q2w
214356885|NCT02768961|DRUG|sofosbuvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines"
214356886|NCT02768961|DRUG|ledipasvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines"
214967179|NCT05003869|PROCEDURE|Scar tissue is removed|The patients were divided into two groups according to whether the scar tissue was removed during TCRA operation: study group: resection of uterine scar tissue during TCRA operation;In the control group, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips using needle-like electrodes, and the scar tissue was not excised.
214967180|NCT00684164|DRUG|Conivaptan|20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
214967181|NCT00684164|OTHER|D5|Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
215081911|NCT00288457|DEVICE|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
215081912|NCT02668861|DRUG|Vitamin D|Vitamin D 4000IU/day for 8 weeks
214356887|NCT01840267|DEVICE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
214356888|NCT05602636|DRUG|bupivacaine, midazolam|Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
214356889|NCT01587534|DRUG|Norzyme|Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
214356890|NCT00988312|BIOLOGICAL|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
215081913|NCT02668861|DRUG|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
215081914|NCT02668861|OTHER|placebo|placebo for 8 weeks
214356891|NCT05598190|DEVICE|Pro-Yellow laser 577|4 session for cases with digtal photo before and after sessions
214356892|NCT04216810|OTHER|muscle strengthening exercises|segmental stabilization exercises
214356893|NCT04216810|OTHER|muscle strengthening exercises and dry cupping|segmental stabilization exercises and dry cupping
214356894|NCT02313428|DEVICE|Topical Oxygen Chamber for Extremities|Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
214356895|NCT05855980|PROCEDURE|Wound closure|Wound is closed or left open to heal secondarily after amputation.
215081915|NCT03655327|OTHER|reach to grasp a cup|reach to grasp a cup of different weights located at different heights of table
214356896|NCT00433784|DRUG|Clopidogrel|
214356897|NCT00433784|PROCEDURE|Blood sampling - platelet aggregation|
214356898|NCT00433784|PROCEDURE|Blood sampling - genotyping|
214356899|NCT01076569|OTHER|laboratory biomarker analysis|Correlative studies
214356900|NCT06383975|PROCEDURE|Pulsed field ablation with posterior wall isolation|Extended pulmonary vein isolation including posterior wall isolation using pulsed field ablation
214356901|NCT06383975|PROCEDURE|Radiofrequency ablation and vein of Marshall ethanolization|Radiofrequency pulmonary vein re-isolation (when necessary), vein of Marshall ethanol infusion with roof and mitral lines
214356902|NCT06814002|DIETARY_SUPPLEMENT|Meal with 400 kilocalories|Meal with 400 kilocalories
214356903|NCT06814002|DIETARY_SUPPLEMENT|Meal without calories|Meal without calories
214356904|NCT03829215|DEVICE|CAERVest cooling device|The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.
214356905|NCT05202561|BIOLOGICAL|RNA tumor vaccine|Subjects will receive single dose of RNA tumor vaccine injection on day 1, day 4, day 7, and day 14, each dose of 600 ng.
214967182|NCT05679245|DIAGNOSTIC_TEST|Assessment for exposure to psychological trauma and related symptoms|To be assessed for exposure to traumatic life events, post-traumatic stress disorder, trauma-related symptoms, dissociative symptoms, affective symptoms, and psychosocial functioning.
214967183|NCT06483906|DRUG|Venetoclax, Azacitidine and Homoharringtonine|Patients will receive the VAH regimen for the treatment of AML
214967184|NCT03560869|OTHER|Normal hydration|see description in 'arms'
214967185|NCT03560869|OTHER|Dehydration|see description in 'arms'
214967186|NCT01137097|PROCEDURE|Lateral sentinel lymph node biopsy|Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
214967187|NCT01801111|DRUG|Erlotinib|Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
214967188|NCT01801111|DRUG|Alectinib|Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
215081916|NCT00568113|DRUG|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
215081917|NCT00418587|DRUG|Cholecalciferol|800 IU oral daily
215081918|NCT00418587|DRUG|Cholecalciferol|2000 IU oral daily
215081919|NCT00418587|DRUG|Cholecalciferol|4000 IU oral daily
215081920|NCT01556776|DRUG|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
215081921|NCT01556776|DRUG|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
215081922|NCT00787137|DRUG|PG102|A single intravenous infusion
215081923|NCT00787137|DRUG|Placebo comparator|Phosphate-buffered saline
215081924|NCT03726515|BIOLOGICAL|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
214356906|NCT05202561|BIOLOGICAL|RNA tumor vaccine+Navuliumab|RNA tumor vaccine+Navuliumab Subjects will receive maintenance therapy with a PD-1 inhibitor in addition to monotherapy with the RNA tumor vaccine injection. Subjects received a single dose of RNA vaccine injection on day 1, day 4, day 7, and day 14, with each dose of 600 ng. Inhibitors, accept the Navuliumab on day 14, the recommended dose is 3 mg/kg, intravenous injection every 2 weeks.
214356907|NCT06491121|OTHER|Technology supported High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home, supported by a smartphone application
214679074|NCT04708392|DEVICE|Spinal Cord Stimulator|A spinal cord stimulator is a surgically implanted device that delivers an electrical signal to a patient's spinal cord to reduce the perception of pain
214967189|NCT00292253|DEVICE|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
214967190|NCT00292253|DEVICE|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
214356908|NCT06491121|OTHER|Moderate Intensity Training|patients will perform a 12-week MIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory continuous load, general resistance and core muscle training, all at moderate intensity. Phase 2 is a similar 12-week MIT program at home with an exercise program on paper.
214967191|NCT04710069|BEHAVIORAL|POINT|Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.
214967192|NCT04072250|PROCEDURE|hepatectomy|Hepatectomy for patients with recurrent intrahepatic cholanigocarcinoma
214967193|NCT04284826|PROCEDURE|Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture|
214967194|NCT04870957|BEHAVIORAL|PainGuide|A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.
214967195|NCT04870957|BEHAVIORAL|MBSR|"In this group (mindfulness-based stress reduction) participants will take part in 9 group sessions.~The groups sessions will be divided into 8 weekly 2-hour groups sessions and one 6-hour retreat. During the sessions participants will practice mindfulness exercises directed by the a MBSR therapist. Additionally, participants will also be asked to practice daily formal mindfulness at home using audio recordings of 30-45 minute guided meditation exercises. These audio recordings can be accessed online. The sessions may take place in-person or virtually."
214967196|NCT04870957|BEHAVIORAL|PT and exercise|"Participants will take part in 10 physical therapy visits over the course of 8 weeks. Participants will meet with the physical therapist twice a week for a 1-hour session for weeks 1 and 2 and then weekly for the remaining 6 weeks. The physical therapist will tailor a program to the participant's needs according to recommended PT practice guidelines that will include in-person treatment, home exercise prescription, and encouragement of progressive, low-intensity, submaximal fitness and endurance activities, such as walking.~Participants will be given a home program of exercises to be done daily and asked to engage in daily walking with a set goal based on the individual's capacity and current fitness level. Walking was selected as the aerobic exercise of focus for this treatment because it is recommended for patients with all levels of pain severity, is highly feasible to complete, and has shown effects on outcomes such as pain and disability."
214967197|NCT04870957|DEVICE|Self -administered acupressure|"A device called the AcuWand will be used to administer the self-acupressure intervention for approximately 30 minutes daily for 8 weeks. Participants will use a mobile application (app) called MeTime that will have daily instructions on how to use the AcuWand. Research staff will show participants how to use the AcuWand and MeTime app. In addition, participants will keep a daily log to track at-home acupressure sessions."
214967198|NCT04870957|DRUG|Duloxetine|For days 1-7, patients will take 30mg of duloxetine once a day, in the morning. Starting day 8, participants tolerating the medication will be escalated to 60mg once a day. They will also have the option of staying at 30mg, once a day or stopping the medication. At the end of the 8-week intervention period, participants will have the option to continue the medication commercially (non-study medication) under the care of their physician or taper off the medication. During the entire 8-week intervention, patients will be asked to keep a daily log of medication dosage, any missed doses, and any side-effects they may have experienced.
214356909|NCT06491121|OTHER|High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home with an exercise program on paper.
214356910|NCT05802745|OTHER|Reintubation|Patients requiring re-intubation for acute respiratory failure.
214356911|NCT06293235|OTHER|Lifestyle and metabolic indicators|Socio-demographics, health history, behavioural characteristics, environmental exposures, anthropometric measurements, body fat composition, metabolic and stress biomarkers, semen physical and molecular characteristics.
214356912|NCT01818323|OTHER|Intra-tumoral T4 immunotherapy|Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide. Cohort 7-8 patients receive T4 cells after lymphodepletion as above, combined with 4 doses of nivolumab.
214356913|NCT06925022|OTHER|Strength training session during Early Follicular Phase|"The strength training sessions follow guidelines and recent meta-analyses to optimize long-term outcomes. Participants will complete a standardized warm-up protocol consisting of 5 minutes on a stationary bike, lower limb mobility exercises, and 5 repetitions at 40% of their 1-RM on each machine before each strength training session. Subsequently, they will perform four exercises for the lower limbs, including bilateral leg press, unilateral leg extension, unilateral hip extension, and plantar flexion, using conventional weight machines (. Session intensity will be set at 70-75% of 1-RM, with a volume of 4 sets of 10 repetitions, leaving 1-2 reps in reserve (RIR), and with 120 seconds of rest between sets.~This phase occurs at the beginning of the menstrual cycle (days 2-5 after the onset of menstruation)."
214679075|NCT00665496|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg and 20 mg orally once a day as needed
214679076|NCT00665496|DRUG|Placebo|Matching Placebo
214967199|NCT04870957|DEVICE|Pro-Diary monitor|"Participants will wear during 5 separate 7-day home monitoring periods to assess physical activity (objectively measured via accelerometry), and ecological momentary assessment (EMA) of mental and physical symptoms. EMA will be collected during Weeks 1, 6, 15, 24 and 36."
214356914|NCT06925022|OTHER|Strength Training Protocol during Late Follicular Phase|The strength training sessions follow guidelines and recent meta-analyses to optimize long-term outcomes. Participants will complete a standardized warm-up protocol consisting of 5 minutes on a stationary bike, lower limb mobility exercises, and 5 repetitions at 40% of their 1-RM on each machine before each strength training session. Subsequently, they will perform four exercises for the lower limbs, including bilateral leg press, unilateral leg extension, unilateral hip extension, and plantar flexion, using conventional weight machines (. Session intensity will be set at 70-75% of 1-RM, with a volume of 4 sets of 10 repetitions, leaving 1-2 reps in reserve (RIR), and with 120 seconds of rest between sets. This phase occurs approximately between days 11-13 of the menstrual cycle.
214356915|NCT06925022|OTHER|Strength Training during Mid-Luteal Phase|The strength training sessions follow guidelines and recent meta-analyses to optimize long-term outcomes. Participants will complete a standardized warm-up protocol consisting of 5 minutes on a stationary bike, lower limb mobility exercises, and 5 repetitions at 40% of their 1-RM on each machine before each strength training session. Subsequently, they will perform four exercises for the lower limbs, including bilateral leg press, unilateral leg extension, unilateral hip extension, and plantar flexion, using conventional weight machines (. Session intensity will be set at 70-75% of 1-RM, with a volume of 4 sets of 10 repetitions, leaving 1-2 reps in reserve (RIR), and with 120 seconds of rest between sets. This phase occurs around days 19-28 of the menstrual cycle, following ovulation.
214356916|NCT05565430|OTHER|Acute Hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
214967200|NCT04804176|DEVICE|Ultra-low frequency repetitive transcranial magnetic stimulation|Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
214967201|NCT01210482|DRUG|Temsirolimus|The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30\~60 minutes. The dosage is to be appropriately reduced according to patients' status.
214967202|NCT06822387|BEHAVIORAL|Mindfulness-Based Intervention|Learning to BREATHE (L2B) is an evidence-based mindfulness curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
214967203|NCT06822387|BEHAVIORAL|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition education and 3) physical activity education. Parents set weekly goals to implement what they learned in each session at home with their family.
214967204|NCT06822387|BEHAVIORAL|Physical Activity|Focuses on using cardio and resistance training to improve cardiorespiratory health in youth.
214967205|NCT06822387|BEHAVIORAL|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education is based on the Learning to BREATHE curriculum.
214967206|NCT06822387|BEHAVIORAL|Preschool Curriculum|Preschool age children learn about and try new foods.
214967207|NCT06822387|BEHAVIORAL|Nutrition and Cooking Education|Nutrition education and hands-on cooking lessons for the whole family.
214967208|NCT06180148|DEVICE|Mechanical insufflator-exsufflator|"In the active comparator group a mechanical insufflator-exsufflator will be used in the postoperative period 6 and 24 hours after extubation as follows (coughing maneuver): application of inspiratory pressure of 40-70 cm of water (the minimum value to achieve a peak cough flow of 300 l/min) for 2 seconds with the subsequent creation of an expiratory vacuum of -40 cm of water within 2 seconds. During inhalation and exhalation, the patient will apply oscillations with a frequency of 10 Hz and an amplitude of 10 cm of water. A series of 10 such maneuvers will be used, with a pause of a few seconds to ensure patient comfort. The coughing maneuver will be performed through an oronasal mask tightly pressed to the face."
214967209|NCT02950038|DRUG|Ibrutinib|560 mg given by mouth daily in a 28 day cycle.
214967210|NCT02950038|DRUG|Nivolumab|3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
214967211|NCT02595112|OTHER|Staphylococcus aureus carriage|Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
214967212|NCT01223937|DRUG|Desmopressin|
214967213|NCT01223937|DRUG|Placebo|
215081925|NCT03726515|BIOLOGICAL|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
214967214|NCT03871985|PROCEDURE|Subglottic secretion lavage combined with aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion lavage combined with aspiration was performed every 4 hours: Underwent preoxygenation before cuff pressure checking, and was maintained between 30 and 35 cmH2O. After aspirating secretions from the mouth, nose, and airway, 2-5 mL distilled sterile water was instilled through the subglottic lumen, and then the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat lavage and aspiration until the irrigation fluid is clear. After washing, cuff pressure checking and was maintained between 25 and 30 cmH2O.
215081926|NCT03973463|BEHAVIORAL|Elastic knee joint movement|Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.
215081927|NCT03484832|DEVICE|Walter Ritter Ethyl Chloride Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
214967215|NCT03871985|PROCEDURE|Subglottic secretion aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion aspiration was performed every 4 hours:Underwent preoxygenation before cuff pressure checking ,and was maintained between 25 and 30 cmH2O. After aspirating secretions from the mouth, nose, and airway, the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat suction until the secretion is completely absorbed.
214967216|NCT05204914|DEVICE|Supra glottic airway devices|Using the device in save air way in patients under general anesthesia and the change in the tempromandibular joint will be evaluated
214967217|NCT02152215|PROCEDURE|Acellular dermal matrix membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
214967218|NCT02152215|PROCEDURE|Polylactic acid membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
214967219|NCT00831402|DIETARY_SUPPLEMENT|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
214967220|NCT00831402|DIETARY_SUPPLEMENT|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
214967221|NCT05308849|OTHER|Dosage of serum and peritoneal of the betalactam used for antibiotic treatment|"All patients will have antibiotherapy according to French recommendation.~Antibiotics recommended are:~cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d~Blood samples will be collected before surgery and after surgery (for all patients).~Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5.~Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method"
214967222|NCT03500926|DEVICE|total hip replacement - standard femoral stem|total hip replacement with standard femoral stem
215081928|NCT03484832|OTHER|Placebo Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
215081929|NCT03484832|OTHER|Placebo Cream|Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
215081930|NCT03484832|DRUG|EMLA Cream|Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
215081931|NCT05828420|OTHER|White noise|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
215081932|NCT05828420|OTHER|Heart sound|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
215081933|NCT05828420|OTHER|Music|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
215081934|NCT03815994|DEVICE|Neuromuscular Electrical Stimulation|This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
215081935|NCT04401956|OTHER|bread|Different types of bread
214356917|NCT05565430|OTHER|Chronic hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
215081936|NCT01628614|OTHER|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
215081937|NCT01669018|PROCEDURE|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
214356918|NCT05565430|DRUG|Effects of anticholinergic medication|Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.
214356919|NCT02725554|DEVICE|StimRelieve Halo System|The StimRelieve Halo System is intended as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic migraine as defined by the Third edition of the International Classification of headache disorders (ICDH-3). The system provides treatment by delivering small controlled electrical pulses to the occipital and supraorbital nerves, as it has been shown that for chronic migraine headaches the response to combined systems appears to be substantially better than occipital nerves stimulation alone.
214679077|NCT04254289|BEHAVIORAL|Usual Care|Usual care
214679078|NCT04254289|BEHAVIORAL|Home-based exercise program|Home-based program determined by exercise physiologist
214967223|NCT03500926|DEVICE|total hip replacement - short femoral stem|total hip replacement with short femoral stem
214967224|NCT02731170|BEHAVIORAL|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
214967225|NCT00142272|DRUG|Ciprofloxacin|
214967226|NCT05130645|DIAGNOSTIC_TEST|Mental Angle|In order to standardize and measure the mental angle, the projection of the mental will be accepted as the midline, the jaw structure will be transferred to the paper using the profile contour meter, and the angle between the angulus mandible and the mental will be measured and recorded with a digital protractor.
214967227|NCT00420719|DEVICE|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
214967228|NCT04516239|DEVICE|THA|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. For the THA, the standard techniques proposed by the manufacturer for insertion of the stem were followed. Neck sleeve adapters and three different prosthetic neck-shaft angles (125, 135, and 145) were available to adjust leg length and femoral offset with the large-diameter head THA system.
214967229|NCT04516239|DEVICE|HR|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. In the HR group, the capsulotomy was completed circumferentially, and the gluteus tendinous insertion on the femur was released in all men, but only when needed in women, to improve femur mobilization.
214967230|NCT00812942|PROCEDURE|colonoscopy|colonoscopy screening
214967231|NCT00812942|PROCEDURE|faecal test|faecal occult blood test for screening
215081938|NCT01669018|PROCEDURE|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
215081939|NCT04008511|DRUG|Regorafenib|Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.
215081940|NCT04008511|DRUG|Regorafenib|Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.
215081941|NCT04008511|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid po for 14 days.
215081942|NCT04008511|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, day 1, every 3 weeks
215081943|NCT02652416|DRUG|BI 1026706|oral administration
215081944|NCT02652416|DRUG|Placebo|placebo
215081945|NCT03825250|DRUG|Sodium Valproate|Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
215081946|NCT01609335|DRUG|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
214967232|NCT02058589|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
214967233|NCT02058589|DRUG|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
214967234|NCT03104608|OTHER|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.
215081947|NCT01609335|DRUG|C-11 PiB|One time intravenous administration of 10-20 mCi
215081948|NCT00787930|DRUG|Valproic Acid|Tablets, 250mg-3000mg
215081949|NCT02395055|DRUG|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
214679079|NCT05528003|PROCEDURE|Commercialized single-access port devices|Two kinds of commercialized single-access port devices were used.
214679080|NCT01520415|DRUG|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
214967235|NCT03104608|OTHER|Treatment as Usual|Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
214967236|NCT00765947|DRUG|Aliskiren|Aliskiren 150 or 300 mg
214967237|NCT00765947|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg
214967238|NCT00765947|DRUG|Amlodipine|Amlodipine 5 or 10 mg
215081950|NCT02395055|DRUG|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
215081951|NCT01869361|DRUG|Indomethacin|Study drug
215081952|NCT01869361|DRUG|Placebo|Control drug
215081953|NCT04942340|DRUG|Atipamezole & Caffeine|In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
215081954|NCT04942340|DRUG|Dexmedetomidine Hydrochloride & Saline|In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes
215081955|NCT03100721|BEHAVIORAL|PNE+Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
215081956|NCT03100721|PROCEDURE|Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques.
215081957|NCT01896271|DRUG|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
215081958|NCT01896271|RADIATION|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
215081959|NCT00758121|DEVICE|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
214967239|NCT01150253|DIETARY_SUPPLEMENT|L. paracasei fermented milk|
214356920|NCT06776614|PROCEDURE|Decompressive Craniectomy|"The DC will be performed through a standard trauma incision, a retro-auricular C-shape or a Kempe incision and execute a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. There are multiple techniques for DC. The elected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal DC will be considered. The removed bone flap may be stored in an abdominal pouch in the right or left upper abdominal quadrants or by freezing in a bone or blood bank freezer."
214356921|NCT06776614|PROCEDURE|Expansion Craniotomy|"The EC will be performed through a retro-auricular C-shape incision and executing a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. The expansion craniotomy will be finished with a cranioplasty using a full set of 3-5 Rialto plates for bone graft closure. The selected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal EC will be considered."
214356922|NCT04630730|DRUG|Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)|1 dose of VPM1002BC, live, 1-19.2 x 108 colony forming units (CFU) on day 1, 8 (+/- 1 day) and 15 (+/- 1 day)
214967240|NCT06542900|DEVICE|Deep Brain Stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (SCC, VC/VS, ALIC, ITP, NAc, LHb, MFB, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
214967241|NCT03205475|BEHAVIORAL|Alternate Coaching and Video Feedback Phase 1|Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)
214967242|NCT03205475|BEHAVIORAL|Weekly Coaching in Phase 1|Weekly coaching (live or telehealth)
214967243|NCT03205475|BEHAVIORAL|Weekly Coaching plus Intensive Refresher Course Phase 2|Continue weekly coaching with senior trainer and add one week intensive refresher course
214967244|NCT03205475|BEHAVIORAL|Weekly Coaching plus Peer Coaching Phase 2|Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity
214967245|NCT03205475|BEHAVIORAL|Video Feedback Only Phase 2|Receive video feedback and calls only
214967246|NCT02532283|DRUG|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
214967247|NCT02532283|DRUG|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
214967248|NCT02532283|DRUG|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
214967249|NCT02143024|BEHAVIORAL|Family-based depression intervention|The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.
214356923|NCT04630730|DRUG|Atezolizumab|Neoadjuvant immunotherapy with atezolizumab, 4 cycles 1200 mg fixed dose iv infusion on d1 q3w starting 4-16 weeks after date of surgery
214356924|NCT04630730|DRUG|Cisplatin|Neoadjuvant chemotherapy with cisplatin: 4 cycles 70mg/m2 iv infusion on d1 q3w (starting on d22)
214356925|NCT04630730|DRUG|Gemcitabine|Neoadjuvant chemotherapy with gemcitabine: 4 cycles 1000 mg/m2 iv infusion on d1 and d8 q3w (starting on d22)
214967250|NCT02143024|BEHAVIORAL|Usual care plus educational materials|Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
214967251|NCT01792102|DRUG|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m\^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m\^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16."
214967252|NCT01945944|DRUG|Hypertonic saline (3%)|3mL of HTS given via nebulizer every 6hrs
214967253|NCT01945944|DRUG|Placebo (0.9% saline)|3mL of normal saline given via nebulizer every 6hrs
214967254|NCT00526318|BIOLOGICAL|filgrastim|
214967255|NCT00526318|DRUG|carboplatin|
214967256|NCT00526318|DRUG|cisplatin|
214967257|NCT00526318|DRUG|cyclophosphamide|
214967258|NCT00526318|DRUG|dacarbazine|
214967259|NCT00526318|DRUG|doxorubicin hydrochloride|
214967260|NCT00526318|DRUG|etoposide phosphate|
214967261|NCT00526318|DRUG|ifosfamide|
214967262|NCT00526318|DRUG|isotretinoin|
214967263|NCT00526318|DRUG|melphalan|
214967264|NCT00526318|DRUG|topotecan hydrochloride|
214967265|NCT00526318|DRUG|vincristine sulfate|
214967266|NCT00526318|DRUG|vindesine|
214967267|NCT00526318|PROCEDURE|autologous hematopoietic stem cell transplantation|
214967268|NCT00526318|RADIATION|iobenguane I 131|
214967269|NCT00526318|RADIATION|radiation therapy|
214967270|NCT06813339|DRUG|UDP-003|The UDP-003 finished product is clear, colourless to yellow liquid that is intended to be a sterile solution for IV bolus push administration in sterile water at a concentration of 300 mg/mL.
214967271|NCT06813339|OTHER|Placebo|Placebo will be provided as a sterile clear, colourless solution formulated to match viscosity of the UDP-003 solution.
214967272|NCT03973398|PROCEDURE|Quadratus Lumborum block|ultrasound guided Quadratus Lumborum block for postoperative pain
215081960|NCT00712621|BEHAVIORAL|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
214967273|NCT06600919|OTHER|Preoperative Music Therapy Session|"Upon admission to the operating room:~Patients in the music therapy group will undergo a 20-minute music therapy session while lying on a stretcher in a designated room. This session will be conducted using the Music Care® application (https://www.music.care).~The sessions are standardized and divided into several phases, following a U-shaped sequence. The effect of this U-sequence is first achieved by a phase of reduced tempo, instrumental density, frequency, and sound volume , followed by a phase of reactivation .~Patients will be allowed to choose the musical style based on their preferences (influenced by their musical tastes and ethnicity). Given the ethnically diverse population of Réunion Island, a wide range of musical preferences is expected."
214967274|NCT01908309|DRUG|Iobitridol 350|
214967275|NCT01908309|DRUG|Iodixanol 320|
214967276|NCT02850549|OTHER|Procedure: physical therapy and Neck Pain Classification|Physical therapists treated patients in phase one as they usually do and in phase two were trained to follow a neck classification and matched intervention system.
214967277|NCT02578849|DRUG|L-DOPA|Patients and healthy controls are recruited to participate in \[11C\]yohimbine scans before and after L-DOPA challenge.
214967278|NCT05754541|DEVICE|WeFlow-Tribranch Aortic Arch Stent Graft System|Endovascular treament in patients with aortic arch dissection and aneurysm by WeFlow-Tribranch Aortic Arch Stent Graft System
214967279|NCT02711358|DRUG|indomethacin suppositories|The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
214967280|NCT02711358|DRUG|placebo|The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
214967281|NCT01545141|DRUG|Chemokin Modulatory Regimen (5 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
214967282|NCT01545141|DRUG|Chemokin Modulatory Regimen (10 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
214967283|NCT01545141|DRUG|Chemokin Modulatory Regimen (20 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
214967284|NCT04442477|DIETARY_SUPPLEMENT|Enriched Protein Fractions|Enriched protein fractions
214967285|NCT04442477|DIETARY_SUPPLEMENT|Protein Fraction|Protein fractions
214356926|NCT06231693|DRUG|Trastuzumab deruxtecan|Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting
214356927|NCT06938997|OTHER|Virtual clinical auditory hallucination solution combining AR/VR technology|"This study, titled Effectiveness of AR/VR-integrated OSCE on Psychiatric Nurses' Comprehensive Auditory Hallucination Care Ability: A Randomized Controlled Trial, involves both experimental and control groups watching videos. The control group views standard educational videos, while the experimental group uses AR/VR technology, virtual patient interaction platforms, and educational videos in a simulated clinical environment. Four scripts were developed: two for training and two for pre/post-testing. All scripts and OSCE checklists are researcher-developed, reviewed by experts, and pilot tested."
214356928|NCT06938997|OTHER|Auditory Hallucination Care Video|The videos include professional knowledge and skills related to auditory hallucinations.
214967286|NCT02385565|OTHER|high fat diet|high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
214356929|NCT06432166|DRUG|2-hydroxybenzylamine acetate|2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks
214356930|NCT06432166|OTHER|Placebo|Placebo taken three times per day for 16 weeks.
214356931|NCT05467176|DRUG|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
214356932|NCT01756950|BIOLOGICAL|2 mg/kg CR8020|administered as a single 2-hour intravenous infusion
214967287|NCT02385565|OTHER|normal fat diet|high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
214967288|NCT04794517|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
214967289|NCT04794517|OTHER|Placebo|Placebo one tablet/die will be administered orally for six-weeks.
214967290|NCT04608331|DRUG|Dexmedetomidine|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
214967291|NCT04608331|DRUG|Placebo|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
214967292|NCT04501055|BEHAVIORAL|perineal nerve block|An anesthesia method to block perineal nerve
214967293|NCT04501055|BEHAVIORAL|periprostatic block|An anesthesia method to block periprostate
214967294|NCT02213588|DIETARY_SUPPLEMENT|AOX blend|Antioxidant supplement
214967295|NCT02213588|DIETARY_SUPPLEMENT|Placebo|
215081961|NCT00712621|BEHAVIORAL|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
214356933|NCT01756950|BIOLOGICAL|5 mg/kg CR8020|administered as a single 2-hour intravenous infusion
214356934|NCT01756950|BIOLOGICAL|15 mg/kg CR8020|administered as a single 2-hour intravenous infusion
214356935|NCT01756950|BIOLOGICAL|30 mg/kg CR8020|administered as a single 2-hour intravenous infusion
214967296|NCT03932461|PROCEDURE|Vacuum assisted closure|The Vacuum assisted closure system consists of an abdominal dressing covering the intra abdominal viscera over the dressing there will be placed a blue sponge which will be covered by drape and connected to a vacuum pump.
214356936|NCT01756950|BIOLOGICAL|50 mg/kg CR8020|administered as a single 2-hour intravenous infusion
214356937|NCT01756950|BIOLOGICAL|Placebo|administered as a single 2-hour intravenous infusion
214679081|NCT01520415|DRUG|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
214356938|NCT02107209|PROCEDURE|Bronchoscopic Lung volume reduction|Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
214356939|NCT01990846|DRUG|Flufirvitide 3|
214967297|NCT03932461|PROCEDURE|"Relaparotomy on demand"|Abdomen is closed at the index operation after source of peritonitis is treated. Every 48-hours the patients are evaluated for the need of relaparotomy based on clinical and paraclinical parameters.
214967298|NCT04041921|PROCEDURE|Percutaneous coronary intervention|
214967299|NCT04041921|PROCEDURE|Coronary Artery Bypass Grafting|
214967300|NCT04041921|DRUG|Medical treatment|
214967301|NCT00042055|DRUG|CP-461|
214967302|NCT04435938|RADIATION|Stereotactic Body Radiotherapy (SBRT)|45 Gy in 5 fractions delivered once every 3-4 days
214967303|NCT04917705|OTHER|Collection of biological samples|Skin, muscle fiber and blood sampling
214967304|NCT04262193|DRUG|Suvorexant|In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.
214967305|NCT04262193|DRUG|Suvorexant Placebo|Suvorexant Placebo
214967306|NCT03809234|DRUG|Ondansetron 8mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
215081962|NCT05202821|DRUG|PRG Barrier Coat|3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
215081963|NCT05202821|DRUG|Fluoride varnish|First group will be receiving Fluoride varnish every 3 months
215081964|NCT05202821|DRUG|MI paste|Third group will be receiving MI paste
214356940|NCT01990846|DRUG|Placebo for Flufirvitide-3|
214356941|NCT06282679|DRUG|Botulinum Toxin Type A Injection [Botox]|you are asked to return to the hospital for follow-up at weeks 2, 4, 8, and 12
214356942|NCT04861857|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement
214356943|NCT04861857|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement
214356944|NCT04081467|OTHER|Bed rest|10-day of complete bed rest
214356945|NCT00235092|DEVICE|Cypher Sirolimus-Eluting Stent|
214356946|NCT00235092|DEVICE|Taxus Paclitaxel-Eluting Stent|
214967307|NCT03809234|DRUG|Ondansetron 16mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
214356947|NCT00375154|DEVICE|Noninvasive Positive-Pressure Ventilation (NPPV)|
214967308|NCT06342856|DRUG|co enzyme Q10 , L- Carnitine|Patient fulfilling inclusion criteria after obtaining consent will be randomized into four equal groups randomization will be computer based
214967309|NCT06508203|PROCEDURE|arthrocentesis with lactate ringer only|classical arthrocentesis with lactate ringer only (control group).
215081965|NCT03697499|COMBINATION_PRODUCT|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
215081966|NCT03697499|COMBINATION_PRODUCT|fish oil and sham exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
214356948|NCT02057874|DEVICE|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
214356949|NCT02057874|DRUG|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
214356950|NCT00432757|DRUG|Ketotifen with a Contact Lens (generic name not yet established)|
214356951|NCT06020092|PROCEDURE|Bone augmentation with I-BCP|The extraction socket will be filled after tooth extraction with I-BCP, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
214967310|NCT06508203|PROCEDURE|arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)|classical arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)
214967311|NCT05011578|RADIATION|Radiographic assessment|Radiographic assessment after at least 10 years after radiocapitellar surgical treatment
214967312|NCT02768688|OTHER|Brain connectivity and physiology|MRI to measure glymphactic flow during simulated natural sleep and again on return to wakefulness.
214967313|NCT02768688|DRUG|Dexmedetomidine|Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
214967314|NCT00263471|DRUG|7-methylxanthine|
214967315|NCT03271593|OTHER|No intervention|No intervention
214967316|NCT06587633|DEVICE|Endoscopic procedure|tSVFem injection + 3D scaffold placement
214356952|NCT06020092|PROCEDURE|Bone augmentation with BX|The extraction socket will be filled after tooth extraction with BX, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
214356953|NCT05390840|DRUG|MG-O-1002|MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye
214356954|NCT05390840|OTHER|Placebo|The placebo is 0.9% saline ocular administration 3 drops in study eye
214356955|NCT03464968|DRUG|Oxaliplatin,5FU, leucovorin|mFOLFOX
214356956|NCT03464968|DRUG|irinotecan,5FU, leucovorin|mFOLFIRI
214356957|NCT03910413|DIAGNOSTIC_TEST|Duel Energy CT|Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
214356958|NCT03676426|OTHER|Web platform for advance care planning/advance directive|Ourcarewishes (OCW) is a web-based platform to document advance care planning based at Penn. OCW contains more detailed content on preferences and values than a standard advance directive and allows electronic sharing with loved ones and transmission to the Penn EHR.
214967317|NCT03927859|OTHER|a mail letter, a phone call and a phone call plus mailed letter|"All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention."
214967318|NCT04177433|DRUG|Depo-Medrol Injectable Product|Corticosteroid
214967319|NCT04177433|DRUG|Saline|Placebo
214967320|NCT06609200|DEVICE|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
214967321|NCT00490971|DRUG|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
214967322|NCT00490971|DRUG|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
214967323|NCT00490971|DRUG|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
214967324|NCT06609291|BEHAVIORAL|Telematic Prenatal Psychological Intervention for Preventing Anxious Symptomatology|The psychological intervention will consist of 7 group sessions, conducted weekly, with a duration of approximately 60 minutes each, with the exception of the first and last ones, which will last an hour and a half, since they will carry out the presentation and evaluation of the intervention, respectively. In turn, the program will be divided into 3 modules. Module 1. Psychoeducation and awareness about perinatal mental health, which provides information on the prevalence of anxious symptoms in the perinatal stage and the consequences for mothers and babies. Module 2. Management of emotions and thoughts. It covers 3 sessions and aims to provide strategies to identify and restructure those thoughts that harm us, as well as recognize the behaviors and emotions that they generate. Module 3. Aimed at teaching how to solve problems effec-tively and communicate in the best possible way.
214967325|NCT06859983|BEHAVIORAL|progressive relaxation exercise|he researcher will provide approximately 45 minutes of information about relaxation exercises to the nurses. During the application of progressive relaxation exercises, the necessary precautions to be taken during and after the exercise will be explained to the nurses. In the study, a sound recording that includes the PRE will be uploaded to each nurse's phone. The relaxation exercises CD created by the Turkish Psychologists Association will be used for the sound recording. The first section of the CD, which is 10 minutes long, defines deep relaxation, its purpose, and the precautions to be taken during the exercise. The second 30-minute section explains the relaxation exercises with the sound of a stream and verbal instructions. The third 30-minute section contains only relaxation music without any verbal instructions. After the training, nurses will be given the sound recording in CD form. Nurses will be asked to perform the PRE according to the instructions. They will be instructed
214967326|NCT05908253|BEHAVIORAL|sham neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.
214967327|NCT05908253|BEHAVIORAL|nonadaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.
214967328|NCT05908253|BEHAVIORAL|adaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
214967329|NCT03552601|OTHER|traditional speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1000mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
214967330|NCT03552601|OTHER|faster speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1500mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
214967331|NCT06613295|RADIATION|SABR|SABR
214967332|NCT06613295|PROCEDURE|Separation surgery|Separation surgery
214967333|NCT06613282|DEVICE|Low Intensity Transcranial Magnetic Stimulation|"* Magnetic stimulation frequency range: 0.1 - 700 Hz.~* Amplitude of the magnetic field at a short distance from the magnetic coil: 1-5 milliTesla.~* Emitter coil dimensions: ⌀28×26 mm.~* Number of emitter coils: 32 coils.~* Covering the entire scalp of a human head with 32 coil emitters."
214967334|NCT06613282|DEVICE|Auditory and visual stimulation|"* Frequency range of light stimulation: 0.1 - 60 Hz.~* Audio stimulation frequency range: 20 - 2000 Hz.~* Sound level: 70 Decibel.~* The wavelength range of visual stimulation: red - 620 - 760 nm; green - 510 - 550 nm; blue - 450 - 480 nm.~* Illuminance: 300 - 350 lx."
214967335|NCT06612398|BEHAVIORAL|Preoperative preparation video|An animated video illustrating the story of a child's journey through the hospital facilities, including the anaesthesia induction, and the postoperative return home.
215081967|NCT03697499|COMBINATION_PRODUCT|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
214356959|NCT03676426|OTHER|Standard advance directive|Patients receive a paper copy of an advance directive used by social workers at Penn Medicine and are encouraged to complete on their own.
214356960|NCT03031587|OTHER|Additional MRI acquisition sequences|It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
214356961|NCT03031587|DEVICE|MRI|cardiac MRI
214967336|NCT06612411|DRUG|B. subtilis|2 capsules, 3 times a day, orally taken for one month
214967337|NCT06612411|DRUG|Dead B. subtilis|2 capsules, 3 times a day, orally taken for one month
214679082|NCT00710034|OTHER|Oral tobacco|Snus
214356962|NCT01624038|DRUG|Hydroxyurea ,Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
214967338|NCT05430685|DIETARY_SUPPLEMENT|Ashwagandha|Intervention and placebo group each received a bottle of 60 capsules. Subjects were instructed to take one capsule in the morning and 1 capsule in the evening. Intervention group was getting 350 mg ashwagandha root extract per capsule (or 700 mg per day). Each intervention capsule delivered 2.5 mg withanolides with equivalence of 2,700 mg dry herb.
214967339|NCT05430685|OTHER|Placebo|The Placebo group received the same type of bottle with similar looking capsules. Each person in the placebo group was instructed to take 1 capsule twice a day (2 capsules total). Capsules were filled with glycerin to the same weight as ashwagandha. Capsules were indistinguishable from each other.
215081968|NCT03697499|COMBINATION_PRODUCT|soy oil and sham exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
215081969|NCT01357135|DRUG|Metformin|
215081970|NCT01357135|DRUG|Sitagliptin|
215081971|NCT01357135|DRUG|Sulfonylurea|
215081972|NCT01357135|DRUG|Antihyperglycemic Medication|
215081973|NCT01049802|DEVICE|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
215081974|NCT00958464|PROCEDURE|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
215081975|NCT01367704|BEHAVIORAL|"Coaching Boys Into Men program"|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
214356963|NCT01624038|DRUG|hydroxyurea, blood transfusion|* Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
214356964|NCT03143114|PROCEDURE|Myomectomy|Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
214356965|NCT02646228|OTHER|molecular profiling, patient derived cells|"molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer."
214356966|NCT02159248|DRUG|Tolfenamic acid + gemcitabine + radiation|"Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day)."
214679083|NCT00710034|DRUG|Nicotine Gum|4 mg Nicotine gum
214967340|NCT00003832|DRUG|bromodeoxyuridine|Given IV
214967341|NCT00003832|PROCEDURE|conventional surgery|Undergo surgery
214967342|NCT00003832|OTHER|laboratory biomarker analysis|Correlative studies
214967343|NCT02253888|DRUG|TPV - Room condition|
214967344|NCT02253888|DRUG|TPV - Refrigerated conditions|
214967345|NCT02253888|DRUG|Ritonavir (RTV)|
214967346|NCT02643433|BIOLOGICAL|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
214967347|NCT02643433|BIOLOGICAL|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
215081976|NCT01656343|DRUG|Calcineurin inhibitors (CNI)|No Intervention
215081977|NCT01656343|DRUG|Belatacept|No Intervention
215081978|NCT00526110|DRUG|5-Fluorouracil|2.2 Gm/m\^2 IV over 48 hours on Day 1.
215081979|NCT00526110|DRUG|Docetaxel|20 mg/m\^2 IV over 60 minutes
215081980|NCT00526110|DRUG|Oxaliplatin|85 mg/m\^2 IV over 120 minutes on Day 1.
215081981|NCT04304911|BEHAVIORAL|Blended intervention (UP-APP)|Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP)
215081982|NCT04304911|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
215081983|NCT00043823|DRUG|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
215081984|NCT00043823|DRUG|Tarceva|100 mg By Mouth Daily for 3 Weeks
215081985|NCT04365543|BEHAVIORAL|Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia|Please see arm/group descriptions
215081986|NCT04365543|BEHAVIORAL|Psychoeducation and Relaxation Therapy (PRT)|Please see arm/group descriptions
215081987|NCT02193087|DRUG|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
215081988|NCT02193087|DRUG|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
215081989|NCT02193087|DRUG|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
215081990|NCT02193087|DRUG|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
215081991|NCT04096820|BIOLOGICAL|Uromune|2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
215081992|NCT04172961|DRUG|nanomicellular cyclosporine 0.09%|topical ophthalmic drop prior to elective surgery for eligible patients
215081993|NCT04172961|DRUG|Lifitegrast|topical ophthalmic drop prior to elective surgery for eligible patients
214967348|NCT04303416|DRUG|Albumin solution|plasma exchange with albumin, one per week for one month, then one per month for 5 months
214967349|NCT06611826|DRUG|GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy|The R-GEP regimen is as follows: Gemcitabine (G; 1.0 g/m2, d1, d8) in combination with recombinant human vascular endothelial growth factor (E; 150 mg, continuous intravenous infusion for 72 hours) and Carelizumab (P; 200 mg), administered every three weeks for a total of six cycles. During the 2nd-4th cycles, low-dose radiotherapy is administered to modulate the immune microenvironment (R: one course of radiotherapy per cycle: including booster fractions of 1 Gy\*3 times for the recurrent lesions, once a day, for three cycles). Approximately three weeks after the completion of the sixth cycle of GEP regimen (or the last cycle), high-dose fractionated radiotherapy (5-8 Gy\*5 times, once a day) is given to the recurrent lesions. Immune maintenance therapy continues until one year after treatment completion or disease progression.
214967350|NCT06611852|OTHER|Aerobic exercise|"Warm-up (5 minutes): Started with a 5-minute warm-up on the stationary bike at a low intensity to prepare the muscles for the workout.~Interval Training (15 minutes): Alternated between 1 minute of high-intensity cycling (pedaling at a faster pace with higher resistance) and 2 minutes of moderate-intensity cycling (steady pace with moderate resistance). This interval was repeated for a total of 15 minutes.~Hill Climbing (10 minutes): The resistance was increased on the stationary bike to simulate climbing a hill. Pedal at a slower pace but with higher resistance for 10 minutes to engage the muscles of legs and core.~Cool Down (5 minutes): The stationary cycling session was finished with a 5-minute cool down at a low intensity to gradually lower the heart rate and avoid fatigue."
214967351|NCT06611852|OTHER|electronic cupping therapy in addition to aerobic exercise|Four devices of electronic cupping therapy were equipped with 3.5-inch diameter cups (Becommend, model number: BE007, ASIN: B09PVF72RJ, China).
214967352|NCT06611852|OTHER|interferential therapy in addition to aerobic exercise|interferential current (Endomed 482, SN/29.382, Netherlands) was delivered by the following parameters: a carrier frequency of 5-kHz, a beat frequency of 80-160 Hz, and an intensity level below 33 mA. Four carbon rubber electrodes (8x12 cm) were used and fixed by a large abdominal strap with a wet spongy
214967353|NCT06611852|OTHER|interferential therapy, electronic cupping therapy in addition to aerobic exercises|interferential therapy, electronic cupping therapy in addition to aerobic exercises
214967354|NCT06611709|DEVICE|sham taping (non-elastic medical cloth tape)|sham taping
214967355|NCT06611709|DEVICE|Kinesiotaping: A standard 5-cm wide KinesioⓇ Tex Gold|A standard 5-cm wide KinesioⓇ Tex Gold
214967356|NCT06611709|OTHER|exercises|home-based exercises
215081994|NCT04289077|OTHER|Questionnaires|\- Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
215081995|NCT01336530|DRUG|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
215081996|NCT01336530|DRUG|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
215081997|NCT01336530|DRUG|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
214356967|NCT01770054|OTHER|obtention of a blood sample|a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
214356968|NCT02245932|DIETARY_SUPPLEMENT|Resveratrol|4 weeks of 150 mg resveratrol (2 times 75mg/day)
214356969|NCT02245932|DIETARY_SUPPLEMENT|Placebo|4 weeks of placebo supplementation (two doses per day)
214356970|NCT00240487|DRUG|Nitric Oxide|Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
214356971|NCT00240487|OTHER|No Intervention|Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.
214967357|NCT06612983|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument assisted soft tissue mobilization is a technique that is applied using specially designed tools/instruments to provide a mobilizing effect to soft tissues including the skin, fascia, muscles, and tendons by its various direct compressive stroke techniques on the gastroc/soleus complexes and Achilles tendons in the first session.
214967358|NCT06612983|OTHER|Walking Treatment|Movement itself should promote mobility so walking steadily for the same period of time as the IASTM had taken to complete is the sham treatment in second session.
214967359|NCT06612619|BEHAVIORAL|Dyad instruction|Rather than being instructed solo or one-on-one the trainees are instructed in pairs of two (dyad).
215081998|NCT01336530|OTHER|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
214356972|NCT05599802|BIOLOGICAL|SARS-CoV-2 variant mRNA vaccine low dose|50μg/dose
214356973|NCT05599802|BIOLOGICAL|SARS-CoV-2 variant mRNA vaccine high dose|100μg/dose
214356974|NCT03280173|DRUG|tafamidis|bioavailability study
214356975|NCT04529668|DRUG|vitamin D supplementation|vitamin D supplementation
214356976|NCT04529668|DRUG|usual therapy for nasal polyposis|steroids ( systemic and local )
214356977|NCT00487266|OTHER|Acupuncture|Acupuncture of low back and legs.
214356978|NCT03339674|BEHAVIORAL|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
214356979|NCT03339674|BEHAVIORAL|Cognitive Training|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
215081999|NCT00001399|DRUG|Transduced CD34+ Cells|
215082000|NCT04563234|BEHAVIORAL|COFLEX neurocognitive training|The COFLEX training group will then be provided with the cognitive training module and participants will be required to complete a targeted 30-minute daily training until the day of surgery, and then after the surgery, for a total of 6 weeks.
215082001|NCT04563234|BEHAVIORAL|Crossword puzzles|The control (crossword puzzles) group will be given a training module, where they can access crossword puzzles on the same platform, and can do puzzles whenever they desire over the 6-week time period.
214356980|NCT02800850|BEHAVIORAL|Bright Light|
214356981|NCT02800850|BEHAVIORAL|Placebo Light|
214967360|NCT06613113|DRUG|Fruquintinib|After receiving high and low dose radiotherapy on metastases, the enrolled patients will receive the combination of Fruquintinib and Adebrelimab. RECIST 1.1 standard was used for clinical tumor imaging evaluation every 6 weeks (±7 days). For complete response (CR) ,partial response (PR), or stable disease (SD), the enrolled patients will continue to receive the combination of Fruquintinib and Adebrelimab. Participants will receive the combination of Fruquintinib and Adebrelimab until disease progression or intolerable toxicity occurred.
214967361|NCT06613152|DRUG|HS-IT201 Injection|Adoptive transfer of 5x10\^9-4x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
214967362|NCT06613256|OTHER|Endothelial cell biopsy|Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis
214967363|NCT06611488|OTHER|No Intervention: Observational Cohort|No Intervention as the study is bservational Cohort
214967364|NCT03971409|BIOLOGICAL|Anti-OX40 Antibody PF-04518600|Given IV
214967365|NCT03971409|DRUG|Avelumab|Given IV
214967366|NCT03971409|DRUG|Binimetinib|Given PO
214967367|NCT03971409|BIOLOGICAL|Utomilumab|Given IV
214967368|NCT03971409|DRUG|Liposomal Doxorubicin|Given IV
214967369|NCT03971409|DRUG|Sacituzumab Govitecan|Given IV
214967370|NCT06504485|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
214967371|NCT00816777|PROCEDURE|Chemoembolization with irinotecan Bead|Intra arterial chemoembolization using Irinotecan Bead 100mg irinotecan per procedure in combination with irinotecan monotherapy 250mg/m2 alternating on a 3 weekly schedule
214967372|NCT00816777|DRUG|Irinotecan|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
214967373|NCT04376515|BEHAVIORAL|HOPE intervention|Online peer support community of peers trained in behavior change science
214967374|NCT05223322|BEHAVIORAL|Taking Charge during Treatment (TCT) Intervention|CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
214967375|NCT06332612|DRUG|Metformin Hydrochloride|Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.
214967376|NCT06332612|DRUG|betamethasone dipropionate|Group 1will recieve topical cream betamethasone thrice daily
214356982|NCT01367873|DRUG|Placebo|Oral, matching number of placebo capsule(s) with active arm
214356983|NCT01367873|DRUG|VIA-3196|Oral, capsule(s)
214356984|NCT05453825|BIOLOGICAL|navicixizumab+paclitaxel|navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly
214967377|NCT06332612|DRUG|Pentoxifylline|Group 1 will receive Pentoxifylline tablet 400 mg twice daily
214967378|NCT06612931|PROCEDURE|Dual-lumen catheter-guided mini-forceps biopsy is performed first|In ERCP procedures, catheter-guided mini-forceps biopsy is performed before biliary brush cytology.
214967379|NCT06612931|PROCEDURE|Biliary brush cytology with vacuum aspiration is performed first|In ERCP procedures, biliary brush cytology with vacuum aspiration is performed before dilation catheter-guided mini-forceps biopsy.
214967380|NCT01683604|OTHER|Observational study|
214967381|NCT06875843|BEHAVIORAL|Contingent responses|The adult systematically responds to more complex child vocalizations with more complex responses. When the child first vocalizes, the adult imitates that vocalization. The child's response determines the next adult response. If the child produces a vocalization within 3 seconds, the adult imitates the child, provides a linguistic map (i.e., puts the apparent meaning into words), and complies nonverbally with the child's apparent intent (e.g., giving item or action). If the child does not produce another vocalization within 3 seconds, the adult remains quiet until the child vocalizes again.
214356985|NCT05453825|BIOLOGICAL|navicixizumab+irinotecan|navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W
214356986|NCT05453825|BIOLOGICAL|navicixizumab monotherapy|navicixizumab 3 mg/kg Q2W
214356987|NCT04519840|OTHER|nill|nill
214356988|NCT00877643|OTHER|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
214356989|NCT00877643|OTHER|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
214356990|NCT01898468|PROCEDURE|Pericostal Closure Technique|
214967382|NCT06875843|BEHAVIORAL|Contingent responses plus vocal elicitation strategies|The adult follows the contingent responses condition protocol with the addition of using vocal toys (e.g., echo tubes, microphones that distort voices, and microphones that amplify voices) within exciting turn-taking activities/routines (e.g., blowing bubbles, balloons, and whoopee cushions). The vocal elicitation strategies emphasize the need to help children vocalize to initiate child-adult interactions. These strategies may be especially important for children who vocalize infrequently to benefit from other intervention aspects and enhance their spoken language skills. The vocal elicitation strategies are to be used when needed, rather than being obligatory for every adult-child interaction. If the child vocalizes without a vocal elicitation prompt, the adult still responds to the vocalization
214967383|NCT06875843|BEHAVIORAL|Non-contingent control|The adult provides non-contingent vocal responses based on audio recordings from prior contingent responses condition sessions transmitted via a wireless earpiece. Recordings from these yoked sessions control for number and type of adult vocalizations and minimize the degree of contingency between adult and child vocalizations in this condition.
215082002|NCT00572611|DRUG|[14C]-bilastine|Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only
215082003|NCT05062304|DRUG|Fluticasone Furoate-Vilanterol Trifenatate|Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.
215082004|NCT05062304|DRUG|Furoate-umeclidinium-vilanterol|Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.
215082005|NCT05123404|DIAGNOSTIC_TEST|multi parametric MRI|In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.
214356991|NCT01898468|PROCEDURE|Intracostal Closure Technique|
214356992|NCT06509126|DRUG|Panitumumab|Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion
214356993|NCT06509126|DRUG|Irinotecan|Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion
214356994|NCT06509126|DRUG|5-fluorouracil|Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2
214356995|NCT06509126|DRUG|L-folinic acid|Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion
214356996|NCT01073423|BEHAVIORAL|Music Therapy|1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.
214356997|NCT01073423|BEHAVIORAL|Yoga|1-hour yoga sessions administered in group format 3 times per week for 8 weeks
214356998|NCT03827954|OTHER|HeartMapp+CT|HeartMapp+CT is a mobile system that includes physiological modules that support self-monitoring and exercises that promote heart health, and computerized plasticity-based adaptive cognitive training modules that train participants to enhance cognitive functions and ultimately heart failure outcomes.
214356999|NCT05203926|PROCEDURE|MRI scan|Subjects will undergo T1 and STIR sequence MRI of sacroiliac joints (SIJ ) (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis. The study will utilize 3 Tesla with phased array coil to maximize signal to noise ratio for image quality. This is a single procedure, which takes about 60 minutes. 1 radiologists, blinded to all clinical information, will evaluate for presence of acute and structural lesions. Images will be scored for presence or absence of acute and/or structural lesions in a global manner.
214357000|NCT01702727|DEVICE|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
214357001|NCT01702727|DEVICE|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
214357002|NCT01702727|DEVICE|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
214357003|NCT05119894|DRUG|Brexpiprazole LAI: Dose 1|Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1
214357004|NCT05119894|DRUG|Brexpiprazole LAI: Dose 2|Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2
214357005|NCT05119894|DRUG|Brexpiprazole LAI: Dose 3|Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3
214357006|NCT05119894|DRUG|Brexpiprazole LAI: Dose 4|Cohort 4: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 4
214357007|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
214357008|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
214357009|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
214487320|NCT05838924|OTHER|PHYSICAL ACTIVITY|"The 8 therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 exercises of Back School without VR. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
215082006|NCT05123404|PROCEDURE|transurethral resection of bladder tumor|detection of degree of invasion to test accuracy of ViRADS score
215082007|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
215082008|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
214357010|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
214357011|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B2|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
214679084|NCT03466346|DRUG|Fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
215082009|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
214357012|NCT01499004|DRUG|tofacitinib (CP-690,550) immediate-release formulation|A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
214357013|NCT02002481|OTHER|transport|The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
214357014|NCT02224768|DRUG|Ipilimumab|
214357015|NCT00990834|DRUG|simvastatin|simvastatin 80 mg PO daily for one to eight months.
214357016|NCT03100617|BEHAVIORAL|Psychosocial caregiver intervention|Modified version of the REACH-VA intervention for family caregivers of persons with dementia. The intervention has several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
215082010|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
215082011|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
215082012|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
215082013|NCT01261130|BIOLOGICAL|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
214967384|NCT06465355|PROCEDURE|pharyngo-esophageal high-resolution manometry|The high resolution manometry (HRM) catheter will be inserted through the more patent nares and positioned such that it covers the pharynx and the esophagus. Affixed to the high resolution catheter will be a single lumen, end-hole catheter (length: 90 cm, outside diameter: 1.58 mm) wherein the end hole of the tube will be secured at a fixed pharyngeal site on the HRM catheter and the other end of the tube will be connected to a stopcock so that the tube may be either open or closed to atmospheric pressure. 3. Study subjects will be asked to swallow their ambient saliva ten times with the stopcock open and ten times with the stopcock closed. There is a 30 second interval between swallows.
214967385|NCT06612190|PROCEDURE|TMS|TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
214967386|NCT06612190|PROCEDURE|Control|The sham group will be given no real magnetic stimulation.
214967387|NCT06692296|BEHAVIORAL|Balance training over stabilometric platform|"The treatment using the stabilometric platform (a total of 20 sessions) generally includes an initial phase (approximately 5 minutes) of training and warm-up in monitor mode, during which the patient becomes familiar with the equipment. The patient then moves on to training library mode, which includes the following subcategories: (1) Stabilometric tracings in both static and dynamic phases (10 minutes); (2) Dexterity exercises in both static and dynamic phases (10 minutes); (3) Imbalance exercises in both static and dynamic phases (10 minutes).~The goal during this phase is to increase the patient's stability limits and provoke balance reactions through load shifts in all directions. The session concludes with 10 minutes of TecnoBody Exergames, which help to automate the functions learned within a more complex activity."
214967388|NCT06692296|BEHAVIORAL|Balance training by means of conventional rehabilitation|Conventional rehabilitation to improve balance includes an initial phase of tissue mobilization, particularly of the foot structures (approximately 5 minutes per foot), in order to prepare them for the subsequent activation phase. This is followed by a phase focused on activating the anti-gravity muscles and aligning the trunk within the chosen setting (10 minutes). The treatment continues with balance training, both static and dynamic, load transfers, and dual-task exercises using external references (15 minutes). The session concludes with functional exercises relevant to the patient's daily life context (10 minutes).
214967389|NCT04448275|OTHER|Neurodynamics Nerve flossing|"Neurodynamics Nerve flossing for femoral nerve that includes two techniques inform of:~slider technique and the second is the tensioner technique"
214967390|NCT04448275|OTHER|conventional selected exercise program|Ultrasound therapy The flexibility exercises for iliopsoas \& quadriceps The iliopsoas \& quadriceps muscles strength exercise
214967391|NCT06384742|BEHAVIORAL|Shift Worker Intervention for Sleep Health|SWISH, a multicomponent behavioral intervention based on cognitive behavioral therapy for insomnia that is individually administered via telehealth across nine approximately weekly sessions that range in length from 15-60 minutes
214967392|NCT07023276|OTHER|Neuromuscular Training|Coaches implemented neuromuscular training at the start of all warm-ups for practices and games. The neuromuscular training program was developed by sports medicine professionals at the home institution and the National Basketball Association and incorporates established principles of motor learning and performance training and has an added emphasis of being basketball-specific.
214967393|NCT06692959|DRUG|PD-1 vaccine IMU-201 (PD1-Vaxx)|Investigational Medicinal Product (IMP) PD1-Vaxx is supplied as lyophilized drug substance APi2568, which is a B-cell epitope (amino acids 92-110 from PD-1) linked to a promiscuous T-cell epitope (amino acid residues 288-302 from measles virus fusion protein) via a 4-amino acid linker (G-P-S-L). IMU-201 is combined with water for Injection (WFI) and is emulsified with Montanide ISA 51 VG adjuvant to produce PD1-Vaxx.
214967394|NCT06713668|DEVICE|Backup Pacing Rate Change|Patients will have backup pacing programmed to A (75 bpm) and B (100 bpm), randomizing to sequence of exposure A-B or B-A
214967395|NCT06880653|BEHAVIORAL|DREAM Adaptive Intervention|6-month physical activity program (Dose Response of Exercise for Arthritis Management (DREAM)) which includes monthly phone coaching, Walk With Ease Guidebook, behavioral lessons, and a Fitbit. Participants may receive additional contact (email, text, or phone) if they struggle to meet activity goal.
214967396|NCT04369833|DEVICE|continuous glucose monitoring system|wearing continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA)
214967397|NCT06549712|GENETIC|genetic determinants to develop respiratory failure|To identify the main common genetic determinants of severe COVID-19 by conducting a GWAS: in first phase we will compare SARS-CoV-2 positive patients with severe lung affection to healthy controls from the same geographic area, in order to provide initial data informing the research in the field in a timely fashion. This will be conducted in close collaboration with the University of Kiel COVID-19 genomic initiative. Later on, we will proceed to assess objectives 1 and 2 in the full cohort, including also infected controls who did not developed clinically significant symptoms
214357017|NCT01258608|DRUG|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
214357018|NCT01258608|DRUG|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
214357019|NCT01258608|DRUG|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
214357020|NCT00000779|BIOLOGICAL|Aluminum hydroxide|
214357021|NCT00000779|BIOLOGICAL|MF59|
214357022|NCT00000779|BIOLOGICAL|rgp120/HIV-1IIIB|
214357023|NCT00000779|BIOLOGICAL|rgp120/HIV-1MN|
214357024|NCT00000779|BIOLOGICAL|rgp120/HIV-1 SF-2|
214357025|NCT00000779|BIOLOGICAL|Env 2-3|
214967398|NCT06549712|GENETIC|genetic determinants to develop respiratory failure|To provide extensive genetic characterization of all patients managed at the Fondazione in order to facilitate other groups working on specific projects (e.g. on candidate genes such as SERPINA1 and ACE2 by the Intensive Care and Cardiology Units and other that may emerge from upcoming projects), in a large population and in a very timely fashion, and without incurring in any additional expenses for the Fondazione research network, and coordinate research efforts.
214967399|NCT06549712|GENETIC|genetic determinants to develop respiratory failure|"To provide a coordination to manage the collaboration with other research consortia in the field, e.g. the An anonymized GWAS to urgently query host genetic predisposition to severe COVID-19 (SARS-CoV-2 infection) lung disease, and the COVID-19 Host Genetic Initiative (https://www.covid19hg.org). Indeed, collaboration among large networks analyzing several thousand cases will be ultimately necessary to clarify the genetic basis of COVID-19 susceptibility, and large collaborative networks are essential instruments for conducting human genetic research."
214967400|NCT03862092|DIAGNOSTIC_TEST|Salivary VZV-DNA PCR|VZV-DNA PCR of saliva samples
214967401|NCT06544330|DRUG|SYNCAR-001|SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb
214967402|NCT06544330|DRUG|STK-009|STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
214967403|NCT02338115|DRUG|Paclitaxel 80mg/m2 weekly x 12 weeks|
214967404|NCT01814215|BEHAVIORAL|Keys to Healthy Family Child Care Homes|The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
214967405|NCT00004533|DRUG|Adeno-associated virus-CFTR vector|
214967406|NCT06236113|DRUG|Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution|administered at rate of 0.1 mg/kg/hr
214967407|NCT02185456|DRUG|750 mg metronidazole/ 200 mg miconazole vaginal suppository|The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
214967408|NCT02185456|DRUG|Standard of care|oral metronidazole 500 mg twice a day for 7 days
214967409|NCT02404129|OTHER|Turn 180 test|"The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor."
214967410|NCT03430856|DRUG|Insulin Tregopil|Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.
215082014|NCT01500369|OTHER|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
215082015|NCT01500369|OTHER|standard of care|Placebo Comparator
215082016|NCT03507959|OTHER|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
215082017|NCT03507959|OTHER|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
214679085|NCT03466346|BEHAVIORAL|Interpersonal Psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
215082018|NCT03507959|OTHER|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
215082019|NCT03507959|OTHER|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
215082020|NCT00806923|DRUG|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
215082021|NCT00806923|DRUG|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
215082022|NCT00806923|DRUG|Placebo|iv on day 1 of each 3 week cycle until disease progression
215082023|NCT00806923|DRUG|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
215082024|NCT00806923|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
214357026|NCT03044483|OTHER|Measurement of sublingual microcirculatory parameters|Measurement of the sublingual microcirculatory function using the CytoCam-IDF imaging device to establish the normal range for each age group noted.
214357027|NCT05670899|PROCEDURE|CAD PEEK frame-work|Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
214357028|NCT01437826|DRUG|antioxidants|tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
214357029|NCT01437826|DRUG|placebo|placebo had an identical appearance as intervention
214357030|NCT01140217|DRUG|Norethindrone Acetate|Norethindrone Acetate Transdermal Delivery System
215082025|NCT04030247|DRUG|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
215082026|NCT03223623|DEVICE|TMS|Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
215082027|NCT03223623|DEVICE|MRI|High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
215082028|NCT03223623|DEVICE|VASO Imaging|The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
215082029|NCT05017818|OTHER|Observational retrospective data|Non-intervention
214357031|NCT04757987|OTHER|Pain|As above
214357032|NCT05389579|DEVICE|electric blanket|"After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured the patients' blood pressure. Then, the electric blanket was operated at the warm level for the experimental group, and it was turned off and unplugged when their body temperature reached 36.0 °C."
214967411|NCT03430856|DRUG|Insulin Aspart|Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit
214967412|NCT01949142|DRUG|OTO-201|Single, intratympanic injection
214967413|NCT01949142|DRUG|Sham|Simulated single, intratympanic injection
214967414|NCT02086955|BEHAVIORAL|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention lasts five weeks. During a period of five weeks, the participants are provided with weekly skill training, and counseling sessions on foot care. Each participant receives a foot care kit with essential foot care material and a foot care diary.
214967415|NCT01900847|DRUG|Ketamine|0.3mg/kg ketamine
214967416|NCT01900847|DRUG|Morphine|Dosage of morphine determined by treating physician
214967417|NCT01900847|DRUG|placebo|saline of same volume as appropriate weight based dose of ketamine
215082030|NCT06013189|OTHER|Gas Flow Adjustment|Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
215082031|NCT03299543|DEVICE|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
214967418|NCT00962078|OTHER|continuous endurance training|at 60 percent of peak Watt
214967419|NCT00962078|OTHER|interval training|at 100 percent of peak Watt
214967420|NCT02002871|DEVICE|PSO-CT02 device|The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
214967421|NCT04437836|DRUG|Evaluation of high dose rifampicin in children|Evaluation of severity of adverse event from grade 1 to 5
215082032|NCT00509093|DRUG|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
214357033|NCT01532115|DRUG|BIA 9-1067|50 mg and 800 mg of BIA 9-1067 (single-dose)
214357034|NCT01532115|DRUG|Placebo|single-dose
214679086|NCT03041376|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
214967422|NCT00565604|DEVICE|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
214967423|NCT00834847|DRUG|pravastatin|40 mg tablet
215082033|NCT00509093|GENETIC|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
214967424|NCT00834847|DRUG|Pravachol®|40 mg Tablet
214967425|NCT03904810|BEHAVIORAL|Exercise intervention|HIIT groups performed 30-meter shuttle runs on a rooftop covered field whereas MICT group ran on a footpath with an overall flat and non-slippery road surface. All training sessions were preceded by a 5-minute self-pace warm-up jogging and ended with a 5-minute self-pace jogging or walking cool-down. Each session of MICT consisted of 30 minutes of continuous exercise at an intensity of 60% of heart rate reserve (HRR); \[i.e., (maximal HR - resting HR) × intensity + resting HR\]. For each HIIT session, the intensity was set at 90% HRR for high-intensity bouts, interspersed with active recovery at 70% HRR. All exercise sessions were supervised by qualified athletic coach or strength and conditioning coach.
214967426|NCT04833062|DIAGNOSTIC_TEST|Ultrasound|In women presenting for a routine antenatal appointment at 20 gestational weeks an ultrasound assessment will be carried out using the 3.5 MHz abdominal probe in order to assess foetal biometry and anatomy as per the guidelines. We will assess the utility of mid- and third trimester ultrasound parameters for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus.
214357035|NCT01532115|DRUG|moxifloxacin|400 mg moxifloxacin (single-dose)
214357036|NCT01726881|DEVICE|Thermal stimulation|"Stimulation using a Thermal Sensory Analyzer:~2001, Maddock ltd., Israel."
214357037|NCT01726881|DEVICE|Mechanical stimulation|Stimulation using Semmes-Weinstein-Monofilament Touch Test Sensory Evaluators
214357038|NCT01726881|DEVICE|Transcutaneous Electrical Nerve Stimulator (TENS)|A portable stimulator designed to Physical treatment of pain. TENS - Cedar rehab X2. Chattanooga group.USA.
214967427|NCT04833062|OTHER|Survey|"The maternal baseline characteristics are defined by maternal age at enrollment, parity, number of prenatal visits, some indicators of socioeconomic status and habits, family history of DM (first degree) and prepregnancy hypertension.~The prepregnancy body mass index (BMI; kg/m2) will be calculated using the self-reported prepregnancy maternal weight; the pregnancy weight gain (kg) will be calculated by the difference between final pregnancy weight and prepregnancy maternal weight and was classified according to the prepregnancy BMI."
214967428|NCT00003522|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214967429|NCT04536675|DRUG|Vilanterol and Umeclidinium Bromide|Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
214967430|NCT04536675|DRUG|Placebo|Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
214967431|NCT00540670|DRUG|E5555 50 mg|E5555 50 mg (tablet) taken orally, once a day.
214967432|NCT00540670|DRUG|E5555 100 mg|E5555 100 mg (tablet) taken orally, once a day.
214967433|NCT00540670|DRUG|E5555 200 mg|E5555 200 mg (tablet) taken orally, once a day.
214967434|NCT00540670|DRUG|Placebo|Placebo (tablet) taken orally, once a day.
214967435|NCT00523055|DRUG|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
214967436|NCT02523404|PROCEDURE|interventional therapy|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
214967437|NCT03442231|DEVICE|Journey UNI Unicompartmental Knee System|Lateral or medial knee compartment replacement
214967438|NCT01570842|OTHER|Anthropometric measurements|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
214967439|NCT01570842|PROCEDURE|Tissue samples|Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
214967440|NCT03831919|DEVICE|SYNC III|Hoya SYNC III design spectacle lenses
214967441|NCT03831919|DEVICE|single vision lenses|single vision spectacle lenses with no addition
214967442|NCT02155452|PROCEDURE|ALA|"Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation"
214967443|NCT04961697|BEHAVIORAL|Hospital diaries|Diaries will be used by family members, PICU staff or even the patient himself. They will take daily notes expressing feelings and thoughts and describing events that might help chronologically to better understand the course of disease and PICU stay. Photographs and other important PICU memories may also be used in the diary.
214967444|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
214967445|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
214967446|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
214967447|NCT03574038|DEVICE|Transcranial Direct Current Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
214967448|NCT03574038|OTHER|Sham Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.
214967449|NCT00674206|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
214967450|NCT00674206|DRUG|Oxaliplatin|Oxaliplatin 100mg/m\^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
214967451|NCT03054285|DRUG|Levetiracetam|Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
214967452|NCT04265261|DRUG|Placebo|Participants will receive oral placebo matched to RG7774
214967453|NCT04265261|DRUG|RG7774|Participants will receive oral RG7774
214967454|NCT02930681|DIETARY_SUPPLEMENT|Glucosanol 500mg|
214967455|NCT02930681|DIETARY_SUPPLEMENT|Placebo|
214967456|NCT05837546|OTHER|Animal-assisted intervention|presence of a dog, contact between dog and participant
214357039|NCT01235390|DIETARY_SUPPLEMENT|Walnuts|The consumption of assigned walnuts once a day during 4 weeks
214357040|NCT05885152|OTHER|Whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
214357041|NCT05638399|DRUG|Denosumab 60 mg/ml [Prolia]|60 mg subcutaneously per 6 month
214357042|NCT05638399|DRUG|Zoledronate|5mg, intravenous infusion once a year
214357043|NCT01835392|PROCEDURE|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
214357044|NCT01835392|OTHER|Control|Sham placement of blood pressure cuff without inflation
214967457|NCT05837546|OTHER|Factice dog intervention|presence of a factice dog, contact between factice dog and participant
214357045|NCT04098939|DIAGNOSTIC_TEST|Diaphragm evaluation|Ultrasound and radiographic evaluation of diaphragm function
214357046|NCT00908167|DRUG|Sorafenib|Please see detailed description.
214967458|NCT05837546|OTHER|Plant intervention|presence of a plant, contact between plant and participant
214967459|NCT04059341|DEVICE|Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)|Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
215082034|NCT00509093|GENETIC|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
215082035|NCT00509093|GENETIC|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
215082036|NCT00509093|OTHER|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
215082037|NCT00509093|PROCEDURE|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
215082038|NCT05240521|OTHER|ARM A|30 IBS-C patients will receive GA-AT0119 for 28 days, followed by a washout period of 28 days and Placebo for another 28 days
214967460|NCT00120341|DEVICE|Anodyne Therapy System|
214357047|NCT00908167|DRUG|Cytarabine|Please see Detailed Description.
214679087|NCT04082767|DRUG|Precedex|Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team
214967461|NCT02788318|OTHER|Brain samples|Collected in patients died
215082039|NCT05240521|OTHER|ARM B|30 IBS-C patients will receive Placebo for 28 days, followed by a washout period of 28 days and GA-AT0119 for another 28 days
214679088|NCT04082767|DRUG|Midazolam|Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team
214679089|NCT06534944|DRUG|Nicotinamide riboside|NR 1g daily for 4 weeks
214679090|NCT04393181|PROCEDURE|Heart transplantation 1|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with left ventricular dysfunction, defined as an ejection fraction less than 50% or regional hypokinesia.
215082040|NCT02408809|BEHAVIORAL|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
215082041|NCT02408809|BEHAVIORAL|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
214357048|NCT00908167|DRUG|Clofarabine|Please see Detailed Description.
214357049|NCT01252823|DEVICE|Implantation of ILR|Subcutaneous implantation of ILR under local anesthesia
214357050|NCT06423846|DRUG|Total intravenous anesthesia group|Patients in the TIVA group had anesthesia induced with propofol 2 mg/kg , fentanyl 1 ug/kg and maintained with propofol. 200 ug/kg/min, fentanyl 0.1ug/kg/min, dexmedetomidine 1 ug/kg/hour
214357051|NCT06423846|DRUG|sevoflurane group|For patients in the SEVO group, general anesthesia was induced with propofol 2 mg/kg, fentanyl 1 ug/kg and then maintained with sevoflurane in air and oxygen, dexmedetomidine 1 ug/kg/hour.
214357052|NCT00981981|DIETARY_SUPPLEMENT|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
214357053|NCT00981981|DIETARY_SUPPLEMENT|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
214967462|NCT02788318|OTHER|Skin samples|Collected in patients died
214357054|NCT00981981|DIETARY_SUPPLEMENT|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
214357055|NCT00981981|DIETARY_SUPPLEMENT|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
214357056|NCT00981981|DIETARY_SUPPLEMENT|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
214967463|NCT02360787|BEHAVIORAL|Energy restriction|
214967464|NCT02360787|BEHAVIORAL|Almonds (15% kcal/day)|
214967465|NCT06481943|DEVICE|Sponsor MCG device (CardiAQ)|Unshielded magnetocardiography device for measuring cardiac magnetic fields
214967466|NCT03202446|DRUG|1% Glycated Chitosan|
215082042|NCT06530888|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|Intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
215082043|NCT06530888|OTHER|Routine practice (r-PT)|Intervention planning as usual.
214967467|NCT03202446|DEVICE|Photothermal Laser|
214967468|NCT03202446|DRUG|Placebo|
214967469|NCT03202446|DRUG|Cyclophosphamide|
214967470|NCT03202446|DRUG|Standard of Care|
214967471|NCT02798107|DRUG|idarucizumab|drug
215082044|NCT06764771|DRUG|BMS-986488|Specified dose on specified days
214357057|NCT02943408|BEHAVIORAL|person-centered mental health intervention|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
215082045|NCT06764771|DRUG|Adagrasib|Specified dose on specified days
214967472|NCT06955650|DRUG|Imaging procedure to measure the distribution of a newly developed radiolabeled ligand for the oxytocin receptor|"13N-Oxytocin is a newly developed radiotracer designed to bind selectively to oxytocin receptors. It is labelled with nitrogen-13, a short-lived positron-emitting isotope, and is administered intranasally to facilitate direct access to the central nervous system via the nasal and trigeminal pathways. This radiotracer is investigational and is not intended to exert pharmacological effects. It is used solely for imaging purposes to assess the distribution and potential receptor binding sites of oxytocin in the human brain and the trigeminal nerve.~Following administration, PET imaging is conducted using a hybrid PET/MRI scanner. The imaging procedure enables visualisation of the biodistribution of 13N-Oxytocin in vivo. The PET scan protocol includes dynamic image acquisition to track tracer uptake over time and is used in conjunction with MRI for precise anatomical localisation."
214967473|NCT06955793|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
214357058|NCT02943408|BEHAVIORAL|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
214357059|NCT06380218|BEHAVIORAL|Nutrional and physical activity program|Nutritional prevention and physical activity workshops associated with a substitution of saturated and/or trans fatty acids by cis-unsaturated acids via the consumption of Primevère margarine to influence lifestyle habits, quality of life and improvement of the lipid profile of women with cardiovascular risk
214967474|NCT06955793|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
214357060|NCT01106833|DRUG|Sirolimus + calcineurin inhibitor + prednisone|"The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
214357061|NCT01106833|DRUG|Sirolimus + prednisone|"The target serum level for sirolimus is 3-12 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
214357062|NCT05582720|BEHAVIORAL|Conventional burger|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional burgers and will be asked to consume them twice weekly for 4 weeks. Conventional burgers will be produced by Hellenic Catering S.A. using standard procedures. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
214679091|NCT04393181|PROCEDURE|Heart transplantation 2|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with normal function, according to the recommendations from The International Society for Heart and Lung Transplantation (ISHLT).
214679092|NCT01315119|PROCEDURE|SPY Intra-Operative Angiography|Calculated per patient
214679093|NCT00500149|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
214679094|NCT00500149|DRUG|Placebo|Placebo
214967475|NCT04570709|OTHER|Palliative And supportive Care inTervention (PACT)|Using the Adaptive Leadership Framework for Chronic Illness as a guide. The nurse, occupational and physical therapists will meet with the patient and caregiver after the baseline assessment to discuss their Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals. Additionally, the occupational and physical therapists will provide the patient a PACT intervention binder. Regular phone calls or visits from a registered nurse, occupational therapists, and physical therapists for patients and caregivers in the intervention.
215082046|NCT06764771|DRUG|Cetuximab|Specified dose on specified days
215082047|NCT06764771|DRUG|Nivolumab|Specified dose on specified days
215082048|NCT01488292|BEHAVIORAL|RECAP social skills and reading program|weekly individual and group sessions
215082049|NCT06503380|OTHER|No intervenrion.|This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.
215082050|NCT02248207|DRUG|Pramipexole|
215082051|NCT03008135|OTHER|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
214679095|NCT00058578|DRUG|Cyclophosphamide|
215082052|NCT03008135|OTHER|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
215082053|NCT01731834|OTHER|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
215082054|NCT03209648|DRUG|Debio 1450|Debio 1450, 40 mg capsule.
214679096|NCT00058578|DRUG|Mesna|
215082055|NCT03209648|DRUG|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
215082056|NCT03705780|OTHER|the short OSAS scale|Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.
215082057|NCT03705780|DIAGNOSTIC_TEST|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
215082058|NCT02849782|DRUG|Fampridine|Oral intake of 10 mg twice daily
214967476|NCT02202369|OTHER|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
214967477|NCT02202369|OTHER|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
214967478|NCT03141190|BEHAVIORAL|Mindfulness Based Stress Reduction - modified|already described
214967479|NCT03141190|BEHAVIORAL|Active listening and reading|group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
214967480|NCT03983408|DIETARY_SUPPLEMENT|Korean Red Ginseng|Participants are provided with 2 Korean Red Ginseng extract tablets twice a day for total 24 weeks.
214967481|NCT03983408|DIETARY_SUPPLEMENT|Placebo|Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets. Participants are parovided with 2 placebo tablets twice a day for first 12 weeks, following Korean Red Ginseng extract tablets twice a day for another 12 weeks.
214967482|NCT05235932|PROCEDURE|Robotic radical total gastrectomy with D2 lymphadenectomy|Most surgical procedures are performed using the robot system.
214967483|NCT05235932|PROCEDURE|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|Without the robot system, Most surgical procedures are performed using laparoscopic equipment.
215082059|NCT04431713|DRUG|Exenatide Pen Injector [Bydureon]|Exenatide is a treatment licensed for use in Type 2 diabetes.
215082060|NCT02238314|DRUG|Tipranavir low dose|
214357063|NCT05582720|BEHAVIORAL|Vegan burger|Participants initially randomized to this intervention arm will be provided with a total of 8 vegan burgers and will be asked to consume them twice weekly for 4 weeks. Vegan burgers will be produced by Hellenic Catering S.A. using novel technologies. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
214357064|NCT05488392|PROCEDURE|Hypothermia with intrajugular cooling|Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.
214357065|NCT04376138|OTHER|BCI intervention|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
214357066|NCT04376138|OTHER|Conventional Therapy|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
214679097|NCT00058578|DRUG|G-CSF|
214679098|NCT00058578|PROCEDURE|Leukopheresis|
214967484|NCT01061697|DRUG|Pregabalin|At week 0, pregabalin 75mgbd will be given for 1 month. If visual analogue scale is not reduced by 50% after 1 month, pregabalin will be increased to 150mgbd for the second month
214967485|NCT00493012|DIETARY_SUPPLEMENT|vitamin D|6 drops of a vitamin D containing oil
214967486|NCT04545450|DRUG|dutasteride 5 mg/day|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
214967487|NCT04545450|DRUG|Testosterone Undecanoate|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
214967488|NCT02585453|DEVICE|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
214967489|NCT02585453|DEVICE|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
214967490|NCT02585453|DEVICE|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
214967491|NCT02962427|DRUG|Sphenopalatine ganglion Block|
214967492|NCT02962427|PROCEDURE|Epidural blood patch|
214967493|NCT03239678|DRUG|100% Oxygen|Conventional preoxygenation with 100% oxygen
214679099|NCT00058578|PROCEDURE|Total Body Irradiation|
215082061|NCT02238314|DRUG|Tipranavir high dose|
215082062|NCT02238314|DRUG|Ritonavir|
215082063|NCT02238314|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
215082064|NCT02238314|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
215082065|NCT04299919|PROCEDURE|Minimally invasive treatment|All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
215082066|NCT04299919|PROCEDURE|Hepatectomy|All hepatocellular carcinoma (HCC) patients received hepatectomy.
215082067|NCT02855957|OTHER|Free α-Hb pool analysis|
214679100|NCT06444737|DRUG|Intravenous ondansetron|Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia
215082068|NCT02110329|GENETIC|evaluation of the recurrence rate according to molecular analysis|
215082069|NCT05642143|DIAGNOSTIC_TEST|Dual Energy X-ray Absorbtiometry scan|Evaluation of body composition and bone mass density
215082070|NCT05642143|DIAGNOSTIC_TEST|High-resolution peripheral quantitative computed tomography|High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.
215082071|NCT05642143|DIAGNOSTIC_TEST|Microindentation|Measures Bone Material Strength Index (BMSi) of cortical bone.
215082072|NCT05642143|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
215082073|NCT05642143|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of sural nerve
214357067|NCT04000568|OTHER|Respiratory support: NAVA -NIV and PC-NIV|The infants enrolled will receive respiratory assistance by NAVA-NIV and PC-NIV in a randomized order
214357068|NCT01621126|DEVICE|Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)|Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
214357069|NCT00886340|BEHAVIORAL|Enhanced standard care|One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)
214357070|NCT00886340|BEHAVIORAL|Lifestyle counseling|Enhanced standard care Six appointments with nurse practitioner (20 minutes)
214357071|NCT02062359|BIOLOGICAL|Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|"Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.~On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes."
214357072|NCT02062359|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
214357073|NCT02062359|DRUG|Cyclophosphamide|On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
214967494|NCT03239678|DRUG|30% Oxygen|preoxygenation with 30% oxygen
214967495|NCT03239678|DRUG|21% Oxygen|preoxygenation with 21% oxygen
214967496|NCT03239678|DRUG|40% Oxygen|preoxygenation with 40% oxygen
214967497|NCT03239678|DRUG|60% Oxygen|preoxygenation with 60% oxygen
214967498|NCT03239678|DRUG|80% Oxygen|preoxygenation with 80% oxygen
214967499|NCT02037724|DIETARY_SUPPLEMENT|supplement containing 60 mg iron sulfate|control agent
215082074|NCT05642143|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score 31|A validated self-assessment questionnaire quantifying the severity and distribution of autonomic symptoms across six domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor functions) by scoring 31 clinically selected questions
215082075|NCT05642143|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
214679101|NCT06444737|DRUG|Intravenous normal saline|Intravenous normal saline 5 ml (control group) 5 min before spinal anesthesia
214967500|NCT02037724|DIETARY_SUPPLEMENT|iron rich food supplement (60 mg iron)|contains 60 mg of iron
214967501|NCT02037724|DIETARY_SUPPLEMENT|iron rich food supplement (10 mg iron)|contains 10 mg iron
215082076|NCT05642143|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
215082077|NCT05642143|DIAGNOSTIC_TEST|Assessment of cardiovascular autonomic neuropathy|Electrocardiographic recordings at rest and during cardiovascular autonomic reflex tests.
215082078|NCT05642143|DIAGNOSTIC_TEST|Handgrip strength|Evaluation of muscle strength
215082079|NCT05642143|DIAGNOSTIC_TEST|Force plate platform|Evaluation of balance while standing still
214357074|NCT02062359|DRUG|Fludarabine|On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
214357075|NCT03355417|OTHER|OT-SI|Occupational therapy using a sensory integration approach (OT-SI) 3x per week for 10 weeks. A typical session will be 1 hour (total of 3 hours per week).
214679102|NCT06516796|OTHER|No intervention|Patients were retrospectively screened.
214679103|NCT04747574|DRUG|EXO-CD24|The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
214967502|NCT02037724|DIETARY_SUPPLEMENT|supplement containing 10 mg iron sulfate|control agent
214967503|NCT00742794|OTHER|Observation|Observation of sting frequency
214967504|NCT03407313|DEVICE|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
214967505|NCT02667340|DIETARY_SUPPLEMENT|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game \& at halftime)
214967506|NCT02667340|OTHER|Placebo|0.7 g glucose per kg body mass in two ingestions (before game \& at halftime)
214967507|NCT03234036|DRUG|GSK2838232 100 mg tablet|It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
214967508|NCT03234036|DRUG|GSK2838232 50 mg capsule|It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
214967509|NCT03234036|DRUG|Ritonavir 100 mg tablets|It is a white film-coated ovaloid tablets.
214967510|NCT03234036|DRUG|Placebo for GSK2838232 tablets|It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
215082080|NCT05642143|DIAGNOSTIC_TEST|Biospecimen collection|Biochemistry including bone turnover markers, glycemic status, inflammation markers i.e
215082081|NCT05642143|DIAGNOSTIC_TEST|Isometric leg extension strength|Evaluation of muscle strength
215082082|NCT05642143|DIAGNOSTIC_TEST|Michigan Neuropathy Screening Instrument|MNSI is used to assess status of peripheral neuropathy. It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes.
215082083|NCT02441348|BEHAVIORAL|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
215082084|NCT05854576|PROCEDURE|vascular acess|AVF
215082085|NCT03287674|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
215082086|NCT03287674|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
214967511|NCT04363060|COMBINATION_PRODUCT|Azithromycin with amoxicillin/clavulanate|Patients will receive azithromycin 500 mg on day 1 followed by 250mg per day for the next four days with amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
214967512|NCT04363060|DRUG|amoxicillin/clavulanate|Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
214967513|NCT01913301|DRUG|Alagebrium|
214967514|NCT03983538|OTHER|Mathematical modeling to predict response to chemotherapy|Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.
214967515|NCT03221114|BEHAVIORAL|Positive Psychological Intervention|Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
214967516|NCT06959082|DRUG|VS-101|VS-101
214967517|NCT06959082|DRUG|Cisplatin|Cisplatin
214967518|NCT06959082|RADIATION|Radiation|Radiation
214967519|NCT00552695|DEVICE|Lidocaine tetracaine|Lidocaine 70 mg/tetracaine 70 mg
214967520|NCT00552695|DEVICE|Placebo|Placebo patch identical in appearance to Synera
214967521|NCT06959069|OTHER|Intermittent Fasting - Late feeding window|Intermittent fasting is an eating pattern that consists of alternating periods of fasting of varying duration with periods of eating. In the present study, all participants will follow a time-restricted feeding/eating (TRF/E) that restricts all dietary intake to an 8- hour daily eating window. There will be two different feeding periods. The first window will allow a feeding period from12 p.m. to 8 p.m. (late feeding window).
214967522|NCT06959069|OTHER|Intermittent Fasting - Early feeding window|Intermittent fasting is an eating pattern that consists of alternating periods of fasting of varying duration with periods of eating. In the present study, all participants will follow a time-restricted feeding/eating (TRF/E) that restricts all dietary intake to an 8- hour daily eating window. There will be two different feeding periods. The second window will allow a feeding period from 8 a.m. to 4 p.m (early feeding window).
214967523|NCT00408551|DRUG|floxuridine|Given IV
214967524|NCT00408551|DRUG|fluorouracil|Given IV
214967525|NCT00408551|DRUG|irinotecan hydrochloride|Given IV
214967526|NCT00408551|DRUG|leucovorin calcium|Given IV
214967527|NCT00408551|DRUG|oxaliplatin|Given IV
215082087|NCT03287674|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
215082088|NCT03287674|DRUG|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
214967528|NCT01569282|PROCEDURE|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
214967529|NCT01569282|PROCEDURE|Stent strategy|Biliary and/or enteral stents on demand
214967530|NCT00600093|DRUG|Amantadine|IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery
214357076|NCT04843033|DRUG|SH3809 tablet|Starting dose 2mg,oral administered once daily. If tolerated subsequent cohorts will test increasing doses (4mg,6mg,8mg,10mg,12mg) of SH3809.
214967531|NCT04214587|DIAGNOSTIC_TEST|tissue and blood sampling|only diagnostics will be peformed
214967532|NCT05827276|OTHER|Life story questionnaire|Participant will receive physical therapy treatment as usual using information from Life Story Questionnaire.
214967533|NCT00635921|DRUG|ziprasidone|Dose flexible from 40 to 200 mg/d during 12 weeks
214967534|NCT00635921|DRUG|Placebo|flexible doses from 40 to 200 mg/d during 12 weeks
214679104|NCT00353847|DEVICE|Acupuncture|
214967535|NCT04547140|BIOLOGICAL|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion 120 mg/kg
214967536|NCT04547140|DRUG|Placebo|Intravenous infusion
214967537|NCT04547140|DRUG|Standard Medical Treatment|SMT
214967538|NCT01819714|OTHER|Multi-sensory supportive care|"The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.~The impact of this multisensory strategy will be evaluated using a before-after design."
214967539|NCT06300502|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion.
215082089|NCT03287674|DRUG|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
214357077|NCT01949311|DRUG|Dupilumab|
214967540|NCT06300502|DRUG|Asclera|Injection into the cutaneous Neurofibromas lesion.
214967541|NCT06300502|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion.
214967542|NCT06300502|DEVICE|1064nm Nd:YAG Laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
214967543|NCT04613739|BEHAVIORAL|insurance navigation|Intervention subjects will be offered access to AAFA's chat bot and navigation services. The chat bot is an artificial intelligence-enabled interactive online tool that can answer clinical and insurance-related questions and provide information on coverage options and how to find lower-cost alternatives for asthma care. Intervention participants will be given a link to access the chat bot. They will also be provided with information about AAFA's insurance navigation program, how it can help with finding coverage and managing asthma costs, and how to access it within AAFA's asthma community platform. Subjects can access AAFA's community platform and join the private group where they can ask questions and share resources, with moderation by AAFA staff. They will be able to send private messages to an AAFA navigator who can provide support about insurance issues, access to asthma care, and assistance with asthma costs. The navigator will offer telephonic follow-up as needed.
215082090|NCT03287674|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
215082091|NCT03383783|DRUG|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
215082092|NCT03383783|DRUG|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
215082093|NCT03383783|DRUG|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
214967544|NCT00017641|DRUG|anti-thymocyte globulin|
214967545|NCT00017641|DRUG|cyclophosphamide|
214967546|NCT00017641|DRUG|filgrastim|
214967547|NCT00017641|PROCEDURE|CD34+ Peripheral Blood Stem Cell Reinfusion|
214967548|NCT05382546|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, polyolefin bag filled with 125 mL of NTM-001.
214967549|NCT03679559|OTHER|Best Practice|Continue usual physical activity
214967550|NCT03679559|BEHAVIORAL|Exercise Intervention (home walking program and resistance training)|Complete home-based walking program and resistance training
214967551|NCT03679559|BEHAVIORAL|Exercise Intervention (home-based Zumba program and resistance training)|Complete home-based Zumba program and resistance training
214967552|NCT03679559|BEHAVIORAL|Exercise Intervention (HIIT program and resistance training)|Complete HIIT program and resistance training
214967553|NCT03679559|OTHER|Informational Intervention|Watch video
214967554|NCT03679559|OTHER|Laboratory Biomarker Analysis|Correlative studies
214967555|NCT03679559|DEVICE|Monitoring Device|Wear Fitbit
214967556|NCT03679559|OTHER|Quality-of-Life Assessment|Ancillary studies
214967557|NCT03679559|OTHER|Questionnaire Administration|Ancillary studies
214967558|NCT00517608|DEVICE|Laparoscopic colectomy|
215082094|NCT03383783|DRUG|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
215082095|NCT00348907|DRUG|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
215082096|NCT00348907|DRUG|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
215082097|NCT03630744|OTHER|Fluid therapy|"* Analyze the type of fluid administered:~  * crystalloids:~    * Saline serum 0.9% ....... ml~   * Ringer Lactate ........ ml~   * Isofundin ® ........ ml~   * Plasmalyte® ... ... ml~   * Glucose Serum 5% ....... ml~   * Glucose serum 10% ........ ml~ * Glucosaline serum ........ ml~ * colloids:~    * Hydroxyethyl starch 130 / 0.4 ... ... ml~   * Hydroxyethyl alimdon 130 / 0.42 ... .... ml~   * Gelatins ... ....... ml~   * Albumin 5% .......... ml~ * Albumin 20% .......... ml.~* Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~* Analyze the form of administration:~  * Standard~ * Standard with dosimeters~ * on pump"
215082098|NCT00403780|DRUG|pregabalin|"Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily."
214967559|NCT03458377|OTHER|Educational telephone call|Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test.
214967560|NCT05853029|COMBINATION_PRODUCT|Combined shockwave therapy & conventional therapy , focused shockwave therapy& conventional therapy , conventional therapy|"The device used for management is from Storz-Medical company; Duolith-SD1 with focused and radial module.~\- Conventional therapy in the form of eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007)."
215082099|NCT00403780|DRUG|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
214967561|NCT00003537|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
214967562|NCT03221998|DRUG|IV paracetamol|100 gram paracetamol infusion for moderate pain management
214967563|NCT03221998|DRUG|IV saline (NaCl 0.9 %)|100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
214967564|NCT03209193|DRUG|Sevoflurane|Sevoflurane use as main anesthetic drug during the surgery
214967565|NCT03209193|DRUG|Desflurane|Desflurane use as main anesthetic drug during the surgery
214967566|NCT04221360|DRUG|CKD-375|Test drug, QD, PO
214967567|NCT04221360|DRUG|D390|Reference drug, QD, PO
214967568|NCT03131115|PROCEDURE|Lateral Crural Strut Graft|surgical technique as described
214967569|NCT03131115|PROCEDURE|Bone Anchored Suspension|Surgical technique as described
214967570|NCT00036088|DRUG|Olanzapine|
214967571|NCT04632277|OTHER|Water|Participants will receive a tab water
214967572|NCT04632277|DIETARY_SUPPLEMENT|Water with low Mg|Participants will receive Low Mg bottle water (50mg/l)
214967573|NCT04632277|DIETARY_SUPPLEMENT|Water with high Mg|Participants will receive High Mg bottle water (100mg/l)
214967574|NCT02403011|OTHER|soft tissue mobilization|soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle
214967575|NCT02403011|OTHER|home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
214967576|NCT04658979|OTHER|Pulmonary tele-rehabilitation|All the participant will by include in a tele-rehabilitation program who will be based on an 12-week intervention including therapeutic education and self-management sessions and training sessions, delivered through a videoconferencing application. All interventions will be under the supervision of a rehabilitation professional from the Pavillon de prévention des maladies cardiovasculaire (PPMC) and modeled according to the recommendations of the ATS/ERS.
214967577|NCT03019991|DRUG|Danoprevir|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
214967578|NCT03019991|DRUG|Ritonavir|Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
214967579|NCT03019991|DRUG|Placebo|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
214967580|NCT01407991|OTHER|enteral tube placement accuracy|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
214967581|NCT01407991|OTHER|NEM method for NG/OG tube placement|measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
214967582|NCT02196857|DRUG|Azacytidine|75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
214967583|NCT02196857|DRUG|Sorafenib|400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
214967584|NCT00712257|DEVICE|Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface|treatment for superficial femoral artery instent re-stenosis
214967585|NCT02336867|DEVICE|Closure clip (OTSC® Proctology)|
214967586|NCT00346957|DRUG|Anecortave acetate 30 mg|0.5ml administered onto the sclera once every six months for 24 months
214967587|NCT00346957|DRUG|Anecortave Acetate 15 mg|0.5ml administered onto the sclera once every six months for 24 months
214967588|NCT00346957|DRUG|Anecortave Acetate 3 mg|0.5ml administered onto the sclera once every six months for 24 months
214967589|NCT00346957|OTHER|Anecortave Acetate Vehicle|0.5ml administered onto the sclera once every six months for 24 months
214967590|NCT05235360|BEHAVIORAL|Episodic future thinking|Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.
214967591|NCT05235360|BEHAVIORAL|Positive affect imagery|Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.
214357078|NCT00201084|BEHAVIORAL|Uncertainty reduction|At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
214967592|NCT05235360|BEHAVIORAL|Action planning|Participants will listen to a guided thinking task directing them to think about the remainder of their week and when, where, and how they plan to attain their remaining activity for the week.
214967593|NCT05235360|BEHAVIORAL|High dose|Participants will listen to the audio-recording with the guided thinking tasks 5 times/week.
214967594|NCT05235360|BEHAVIORAL|Recent thinking|Participants will listen to a guided thinking task directing them to think about a regular habit or activity they completed in the past week and to imagine that activity in specific and vivid detail.
214967595|NCT05235360|BEHAVIORAL|Neutral imagery|Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).
214967596|NCT05235360|BEHAVIORAL|Low dose|Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.
214967597|NCT05983796|DIAGNOSTIC_TEST|18F-HER2 PET|18F-HER2 PET
214967598|NCT05337176|OTHER|app-coo application|"The Montreal Cognitive Assessment (MoCA) is a measure designed specifically for detecting mental cognitive impairment(MCI) APP-Coo-Balance-Test can assess the oscillation of the trunk in different static positions: Feet Together, On a Broad Base (medial malleoli 30 cm apart) , and during the gait Dynamic(Arcuria et al., 2020)."
215082100|NCT00049608|DIETARY_SUPPLEMENT|mistletoe extract|
215082101|NCT00049608|DRUG|gemcitabine hydrochloride|
214967599|NCT00270296|DRUG|Trizivir|300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
214967600|NCT00270296|DRUG|Lamivudine/Zidovudine|150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
214967601|NCT00270296|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
214967602|NCT00270296|DRUG|Nevirapine|200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
214967603|NCT06470490|BEHAVIORAL|psychoeducational|educational program
214967604|NCT06347367|OTHER|Group 1 (exercise and self-manual approaches targeting only the diaphragm muscles)|Both groups will receive the patient education before treatment. Diaphragmatic stretching technique, pectoral muscle relaxation, diaphragmatic mobilisation, thoracic mobilisation and diaphragmatic breathing. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
214967605|NCT06347367|OTHER|Group 2 (exercise and self-manual approaches targeting both diaphragm and core muscles)|İn addition to Group 1, patients in group 2 will receive, abdominal massage, abdominal mobilisation, stabilisation exercises and pelvic floor muscle training. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
214967606|NCT05922644|DEVICE|SCS|21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
214357079|NCT02939040|BEHAVIORAL|Positive Activities|"The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery."
214967607|NCT05922644|OTHER|Conventional|Routine brain resuscitation and rehabilitation awakening treatment.
214967608|NCT04279080|OTHER|low anterior resection syndrome evaluation|evaluation of postoperative functional bowel outcome
214967609|NCT02420535|BEHAVIORAL|Immediately Receive Tool|
214967610|NCT02420535|BEHAVIORAL|One Month Delay|
214967611|NCT02671851|DRUG|Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs with 20mL bupivacaine 0.375% at the level of T3-T4 as an adjunct to GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
214967612|NCT02671851|DRUG|IV metamizole sodium, paracetamol|Patients received only standardized GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
214967613|NCT03072667|DRUG|Omegaven|Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
214967614|NCT05946200|PROCEDURE|Low flow technique in general anesthesia|It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.
214967615|NCT00580957|DRUG|Blocked|Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
214967616|NCT00580957|DRUG|Intact|Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
214967617|NCT05897866|PROCEDURE|Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management|Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.
214967618|NCT00631059|OTHER|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
214967619|NCT04354415|PROCEDURE|Carpal tunnel or trigger finger release|Carpal tunnel or trigger finger release with and without the use of tourniquet
214967620|NCT05722717|GENETIC|Saliva collection at home|Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.
214967621|NCT00427141|DRUG|GSK580416|
214967622|NCT03249428|DEVICE|Improved Quality of Life of low-income Canadians that smoke tobacco and other substances|Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
214967623|NCT02942069|BEHAVIORAL|Blood glucose measured using CGM during standardized physical activity|Standardized exercise on bicycle at 70% of the participants work capacity for ½ hour.
214967624|NCT04245592|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of organic EVOO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
214967625|NCT04245592|DIETARY_SUPPLEMENT|Refined Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of ROO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
214967626|NCT00434772|DRUG|glucagon|
214967627|NCT05423457|BEHAVIORAL|Vegan diet|The participants were advised to eat foods in their original type.
214967628|NCT00735943|OTHER|No intervention|No intervention
214967629|NCT02464124|DRUG|Nitazoxanide|• Nitazoxanide dosing: 500 mg tablets twice daily
214967630|NCT02464124|DRUG|Lactulose|• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
214967631|NCT04033146|DEVICE|Ankle Exoskeleton Assistance|The investigators will use ankle-exoskeletons to modulate the amount of mechanical power generated by the user's ankle joint. That is, participants will walk in a robotic device that either (a) adds a spring or (b) a motor in parallel with their calf muscles to help them generate a stronger propulsive push-off that could reduce the effort of walking.
214967632|NCT01629550|PROCEDURE|skin disinfection prior catheter insertion|
214967633|NCT00275171|DRUG|Recombinant human thyrotropin (Thyrogen)|0.1 mg rhTSH administered intramuscularly
214967634|NCT00275171|DRUG|recombinant human TSH|0.1 mg rhTSH administered intramuscularly
214967635|NCT00275171|OTHER|isotonic saline = placebo|0.1 mg isotonic saline injected intramuscularly
214967636|NCT00500578|DRUG|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
214357080|NCT03449810|PROCEDURE|DSE plus MET group A|"The Dynamic stabilization exercises will consist of seven exercises, which are aimed to strengthen the lumbar stabilizing muscles. All seven dynamic stabilization exercises will be performed once and always in random order.~The procedure for MET involves voluntary contraction of the participant's muscle in a precisely controlled direction, at varying levels of intensity, against a distinctly executed counterforce applied by the therapist. In this type of therapy, a participant contracts muscles by pushing against resistance provided by the therapist. The therapist then assists the participant in stretching, strengthening and relaxing those muscles."
214357081|NCT03449810|PROCEDURE|DSE alone group B|The DSE in this arm is the same a described in group A, i.e. it involves seven exercises activities administered randomly at every session of the study intervention.
214967637|NCT00500578|DRUG|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
214967638|NCT02739217|DRUG|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily.
214967639|NCT02351401|BEHAVIORAL|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
214967640|NCT02548624|DEVICE|Zephyr BioPatch|"The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available.~The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station."
214967641|NCT01719380|DRUG|LGX818|
214967642|NCT01719380|DRUG|Cetuximab|
214967643|NCT01719380|DRUG|BYL719|
214967644|NCT02962310|DRUG|Torrent's Rosuvastatin Calcium Tablets 40 mg|oral, crossover
214967645|NCT02962310|DRUG|Crestor 40 mg Tablets of AstraZeneca LP, USA|oral, crossover
214967646|NCT05991011|OTHER|Immersive and Interactive Wall Exergames|This intervention will be performed using the Neo One device. It was chosen because of the variety and quality of the games offered which are accessible to older people. The target intensity of core workout will be moderate. Five to 7 five-minutes games will be selected from 19 games. A variety of materials will be used (e.g., basketball, rugby, handball ball, balloon, chair, hoop, rhythm ladder, tennis racket). The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity. Interventions will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Neo One device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants.
214967647|NCT05991011|OTHER|Complex Cognitive and Motor Activities program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving cooperation and opposition exercises inspired by team sports (basketball, volleyball, rugby) and individual sports (boxing, weight training), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants. The target intensity of body workout will be moderate. The first part will be focused on endurance and the second on muscle strengthening and coordination work in the form of circuit training. A variety of equipment will be used (e.g., tennis balls, basketballs, volleyballs, rugby balls, balloons, elastics, chairs, blocks). The number of partners and/or opponents will be changed regularly.
214967648|NCT05991011|OTHER|exergames program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, physically active (standing). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Nintendo Switch device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants. The games (Fitness Boxing 2, Switch Sport, Just Dance 2020, 2021, 2023, Let's Get Fit, Mario and Sonic at the Olympic Games Tokyo 2020, Instant Sport, Ring Fit, Zumba Burn It Up!) will be carried out in the form of circuit training, in pairs or groups of 4. The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity.
214967649|NCT05991011|OTHER|video games program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, while being inactive (sitting). The sessions will consist in one-hour single and multi-players games, using the Nintendo Switch device, in groups of 6 participants.
214967650|NCT05991011|OTHER|Bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this active comparator intervention, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike at about 50% of Heart Rate Reserve, and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
214967651|NCT05991011|OTHER|Video games + bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this experimental arm, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike (like BIKE program at about 50% of Heart Rate Reserve) and at the same time playing on a Nintendo Switch (like VG program), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
214357082|NCT03449810|PROCEDURE|Standard Physiotherapy treatment group C|In the control group, the participants will receive standard physiotherapy treatment offered for the management of chronic NSLBP patients in Nigeria. Therefore, individuals randomized to this therapeutic group will be treated with classical massage, therapeutic exercises and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region.
214357083|NCT02508467|DRUG|Fisogatinib (BLU-554)|
214357084|NCT02672254|RADIATION|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
214357085|NCT00559650|DRUG|Placebo|Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
214357086|NCT00559650|DRUG|Cinaciguat (BAY58-2667)|Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
214679105|NCT03557398|DEVICE|Hydeal-D vaginal pessaries|One vaginal application of Hydeal-D vaginal pessaries every 3 days to a total of 12 consecutive weeks.
214967652|NCT05194345|BEHAVIORAL|Autism Eats nutrition intervention|The Autism Eats intervention group will spend about 8.5 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, and a 60-minute exit interview). The Autism Eats intervention group EI provider will spend about 12 hours over 5 months (two 90-minutes training sessions, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, 10-minute fidelity checklist completion after each session, and a 60-minute exit interview).
214967653|NCT05194345|BEHAVIORAL|We Can! enhanced usual care|We Can! EUC control group will spend about 3 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, one 25-30 minute nutrition session, and a 60-minute exit interview). We Can! EUC control group EI provider will spend about 4.5 hours over 5 months (two 90-minutes training sessions, one 25-30 minutes session, 1-2-minute written material distribution at their 9 weekly EI sessions, and a 60-minute exit interview).
214967654|NCT00777868|DRUG|Low Strength IDP-108|Topical application once a day for 9 months
214967655|NCT00777868|DRUG|High Strength IDP-108|Topical application once a day for 9 months
214967656|NCT00777868|DRUG|High Strength IDP-108 under occlusion|Topical application once a day for 9 months
214967657|NCT00777868|DRUG|Vehicle|Topical application once a day for 9 months
214967658|NCT02842047|BEHAVIORAL|Stop, Breathe & Think™|online daily meditations delivered using smart phone or other computer based application
214967659|NCT02842047|BEHAVIORAL|End of Life Planning Videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.
214967660|NCT02842047|BEHAVIORAL|Caregiver wellness videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
215082102|NCT04677816|DRUG|Standard of Care Neoadjuvant Chemotherapy (NAC)|"Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician."
215082103|NCT04677816|DIETARY_SUPPLEMENT|Vitamin D3|Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
215082104|NCT04677816|OTHER|Drug Diary|Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
214357087|NCT03412682|DRUG|Budesonide (6 mg)|Budesonide (6 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
214357088|NCT03412682|DRUG|Budesonide (9 mg)|Budesonide (9 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
214357089|NCT03412682|DRUG|Mesalazine (3,600 mg)|Mesalazine (3,600 mg) administered once a day plus three mesalazine 400 mg three times a day, over an 8-week treatment period.
214393734|NCT04005547|BEHAVIORAL|Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder|Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication \*Bring your Trusted Adult\* Session 6 - Let's Talk About Growing Up
214393735|NCT02821520|DRUG|conbercept|At baseline conbercept injection is administered.And thereafter is administered based on re-treatment criteria from month 1 to 11.The PRN conbercept re-injection should be monthly.
214393736|NCT02821520|PROCEDURE|Initial PDT|At baseline PDT with verteporfin is administered initially.And thereafter PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
214393737|NCT02821520|PROCEDURE|Delayed PDT|PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
214393738|NCT02682498|DRUG|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
214967661|NCT00455169|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
214967662|NCT04601727|DIAGNOSTIC_TEST|16srRNA pyrosequencing analysis of microbiota of saliva and faeces|No intervention in this study
214967663|NCT04388410|BIOLOGICAL|convalescent plasma|Plasma obtained from volunteers who have recovered from SARS-Cov-2 infection. Two 200 ml infusions will be administered with 24-72 hours in between.
214967664|NCT02479555|DRUG|Dexamethasone sodium phosphate injection, USP, 4 mg/mL|"Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.~Investigational Drug will be administered via Bullfrog Micro-Infusion Device."
214967665|NCT02311829|OTHER|Telephone follow-up device|For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
214967666|NCT00887614|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
214357090|NCT03455374|DEVICE|Treatment with CSI atherectomy device|Following peripheral angiography, patients with significant SFA or below the knee artery disease (≥ 50%) or total occlusions (100%) will have a baseline OCT imaging of the target vessel and the lesion be treated with proper size CSI burr. Repeat OCT imaging will be performed after CSI. Drug eluting balloon angioplasty may be performed in discretion of the operator. If DEB is used, a final OCT imaging will be performed to assess lesion expansion and possible dissections. Balloon sizing will be based on 1:1 vessel ratio with the length covering from minimally diseased distal segment to minimally diseased proximal segment. We will try to avoid use of stents.
214357091|NCT02120027|DRUG|Ibodutant 10 mg|Oral tablet, to be given once daily.
214357092|NCT02120027|DRUG|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
214967667|NCT02874612|OTHER|Psychosocial Survey Questionnaires|Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
214967668|NCT01064414|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
214967669|NCT01064414|DRUG|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
214967670|NCT02708550|BEHAVIORAL|Participatory Organizational Intervention|
214967671|NCT02603198|DRUG|mepivacaine chloridrato epinephrine|local anesthesia for tooth removal
214967672|NCT02603198|DRUG|mepivacaine chloridrato levonordefrin|local anesthesia for tooth removal
214967673|NCT00995839|DRUG|continuous infusion of terlipressin|Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
214357093|NCT04106726|DRUG|Soolantra® Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
214357094|NCT04106726|DRUG|Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
214357095|NCT04106726|DRUG|Placebo for Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
214357096|NCT00875004|BIOLOGICAL|epoetin beta|
214357097|NCT00875004|DRUG|systemic chemotherapy|
214357098|NCT00875004|PROCEDURE|quality-of-life assessment|
214357099|NCT05549973|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
214357100|NCT02328833|OTHER|Experimental strategies of guidelines implementation|Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
214357101|NCT06495788|DEVICE|High-intensity laser therapy (HILT)|"* Pulsed high-intensity laser therapy (HILT) will be applied 3 sessions per week for 8 weeks with pulsed emission (1064 nm), very high peak power (3 kW), a short duration (120-150 ms), and low frequency (10-40 Hz).The probe is fixed vertically at 90° to the most painful points while the patients sit on a chair and wear safety eyewear.~* Conventional treatment ( 3 days per week for 8 weeks).: in the form of~* Hot pad: It will be used over the temporomandibular joint (TMJ) for 5 minutes at the beginning of each session.~* Ultrasound therapy (US): it will be applied over the TMJ with pulsed intensity of 1.0 W/cm2 at a 1MHz frequency for 5 min/session.~* TENS: one electrode is placed over the TMJ and the other just above the mandibular angle. it will be applied with a low frequency of 50 HZ, tolerable intensity for 15 minutes.~* Exercise therapy: anterior, medial and lateral glide of the mandible. Each glide will be done 10-15 repetitions, 5-6 times in a session, 10 minutes as a total."
214967674|NCT00995839|DRUG|Arginine vasopressin|Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
214967675|NCT00995839|DRUG|terlipressin bolus administration|intravenous terlipressin bolus administration at the dose of 0.5 mg
215082107|NCT00118352|BIOLOGICAL|alemtuzumab|Given IV
215082108|NCT00118352|RADIATION|total-body irradiation|Undergo low-dose TBI
215082109|NCT00118352|DRUG|fludarabine phosphate|Given IV
215082110|NCT00118352|DRUG|cyclosporine|Given PO or IV
215082111|NCT00118352|DRUG|mycophenolate mofetil|Given PO
215082112|NCT00118352|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
215082113|NCT00118352|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
215082114|NCT00118352|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
215082115|NCT00118352|OTHER|laboratory biomarker analysis|Correlative studies
215082116|NCT03282110|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
215082117|NCT03282110|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
215082118|NCT03282110|DRUG|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
214357102|NCT06495788|DEVICE|placebo high-intensity laser therapy|The same treatment procedure will be applied in the placebo group as in the experimental group, but the laser device is turned off during applications, in addition to the conventional treatment in the form of hot pad, US, TENS, and exercise therapy.
214357103|NCT02919800|BIOLOGICAL|MOD-5014|MOD-5014, a long-acting modified recombinant Factor VIIa
214357104|NCT02919800|OTHER|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
214357105|NCT02479568|DIETARY_SUPPLEMENT|Control|500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
214357106|NCT02479568|DIETARY_SUPPLEMENT|100% Florida OJ|500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
214357107|NCT02479568|DIETARY_SUPPLEMENT|100% Florida OJ-enriched|500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
214967676|NCT04381780|DIETARY_SUPPLEMENT|Recovery Factors|A unique porcine serum based polypeptide nutritional support
214967677|NCT04795063|PROCEDURE|Total Robotic Distal Gastrectomy|All the surgical procedures are performed using the robot system.
214967678|NCT04795063|PROCEDURE|Robotic-Assisted Distal Gastrectomy|After finishing the lymphadenectomy, the digestive tract reconstruction is performed extracorporal.
214967679|NCT00249873|DRUG|clopidogrel (SR25990C)|oral administration (tablets)
214967680|NCT00249873|DRUG|placebo|oral administration (tablets)
214967681|NCT05837273|DEVICE|Fully-immersive VR|For fully-immersive VR sets the highest level of immersion of VR technologies, presenting improvement in cognitive function in cognitive decline seniors. Fully immersive VR-based cognitive training also has a positive effect on psychological performance.
214967682|NCT05837273|BEHAVIORAL|Cognitive training|For the cognitive training, the therapy is a non-pharmacological approach, used for a series of standardized tasks to maintain or even increase person's cognitive function. The therapy can effectively improve multiple cognitive performance, such as: attention, reaction time (processing speed), working memory, and visual-spatial ability.
214967683|NCT04521556|PROCEDURE|Epidural anesthesia with light general anesthesia|"Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ml and fentanyl 8.3 μg/ml.~Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8."
214967684|NCT04521556|PROCEDURE|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
214967685|NCT04521556|PROCEDURE|General anesthesia|"Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1.~Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally."
214967686|NCT04521556|DRUG|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
214967687|NCT03865030|DEVICE|audiovestibular function|"Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.~tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.~otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.~Video head impulse test.~\- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness."
214967688|NCT01518803|DIETARY_SUPPLEMENT|Mediterranean-style breakfast|"The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight."
215082119|NCT00665756|PROCEDURE|second Trabeculectomy|second trabeculectomy with mitomycin-c
215082120|NCT00665756|PROCEDURE|Ahmed Implant|Ahmed silicone drainage device
215082121|NCT05600816|DEVICE|Pounce Venous Thrombectomy System|The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
214679106|NCT04138524|OTHER|SAFIR©|Early Supportive intervention for families of patients with acquired brain injuries.
214679107|NCT03357822|DRUG|Pegylated interferon|180ug Pegylated interferon is injected subcutaneously once a week
214967689|NCT01518803|DIETARY_SUPPLEMENT|Western-style breakfast|The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
215082122|NCT01224821|BIOLOGICAL|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
215082123|NCT01847105|OTHER|RevitaLens|Multi-purpose disinfecting solution
215082124|NCT01847105|OTHER|OptiFree PureMoist|Multi-purpose disinfecting solution
214967690|NCT05688865|OTHER|urinary markers|urinary marker testing
214967691|NCT00533819|OTHER|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
214967692|NCT02727738|DIETARY_SUPPLEMENT|Selenium|Selenium 80 mg bid for 90 days
215082125|NCT04337736|OTHER|Physical exercise|
215082126|NCT00136240|BEHAVIORAL|Computer Assisted Education for Behavior Change|
215082127|NCT05976022|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
214967693|NCT02727738|DRUG|Methimazole|Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values \<10 pg/ml, 10-15 pg/ml, \>15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
214967694|NCT04988204|BEHAVIORAL|Diabetes Prevention Program|The Diabetes Prevention Program is a 1 year validated program to prevent the development of type 2 diabetes. Participants with NAFLD will engage will work with a CDC certified DPP certified lifestyle coach and other participants in a group setting during the study focusing on lifestyle changes to achieve weight loss and improvement in NAFLD.
214967695|NCT01517633|DEVICE|BirthSign|When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
214967696|NCT03155711|PROCEDURE|HFNC group|Positive pressure plus supplemental oxygen through a high flow nasal oxygen device
214967697|NCT03155711|PROCEDURE|Standard group|Supplemental oxygen through venturi mask
214679108|NCT03357822|DRUG|Entecavir|0.5mg entecavir is orally taken every day
214679109|NCT03357822|DRUG|Tenofovir disoproxil fumarate|300mg tenofovir is orally taken every day
215082128|NCT02159222|PROCEDURE|Additional physical therapy|
215082129|NCT04465318|OTHER|E-cigarette (EC)|NJOY Daily E-cigarettes are self-contained and non-refillable. Each DAILY provides approximately 300 puffs, comparable to a full pack of cigarettes.
215082130|NCT04465318|OTHER|Nicotine Replacement Therapy (NRT)|Participants in the NRT arm will receive 21 mg nicotine patch (for those with CPD \>= 20) or 14 mg nicotine patch (for those with CPD \< 20) + 4 mg nicotine gum. CPD stands for Cigarettes Per Day.
215082131|NCT04465318|BEHAVIORAL|Smoking Harm Reduction Counseling Sessions|Counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects know to contribute to smoking among people with COPD (e.g., tips on dealing with depression)
215082132|NCT03082573|DRUG|H.P. Acthar gel|H.P. Acthar gel in treatment of Refractory RA
215082133|NCT00592540|PROCEDURE|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
215082134|NCT04133896|DIAGNOSTIC_TEST|IL-6, Clusterin, Irisin Level|Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
214967698|NCT03164447|BIOLOGICAL|UB-421|Monoclonal antibody by IV infusion
214967699|NCT03164447|DRUG|Optimized background therapy (OBT)|The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
215082135|NCT01340937|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
215082136|NCT01340937|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
214393739|NCT02682498|DRUG|Standard Preparation|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
214393740|NCT03064893|DEVICE|Alloderm|Reconstruction material
215082137|NCT01340937|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
215082138|NCT01340937|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
215082139|NCT01340937|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
215082140|NCT00819377|DRUG|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
215082141|NCT00819377|DRUG|Normal saline|5 ml normal saline by inhalation over 15 min
215082142|NCT01871155|DIETARY_SUPPLEMENT|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement"
215082143|NCT02638207|DRUG|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
214393741|NCT03064893|DEVICE|Dermacell|Reconstruction material
214679110|NCT01158534|DRUG|celecoxib|Given orally
214679111|NCT01158534|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously
214679112|NCT01158534|OTHER|polymerase chain reaction|Correlative studies
214679113|NCT01158534|OTHER|laboratory biomarker analysis|Correlative studies
214679114|NCT01158534|OTHER|reverse transcriptase-polymerase chain reaction|Correlative studies
214679115|NCT01158534|OTHER|immunologic technique|Correlative studies
214679116|NCT01158534|OTHER|immunohistochemistry staining method|Correlative studies
214679117|NCT01158534|OTHER|flow cytometry|Correlative studies
214967700|NCT02068911|DEVICE|Monitoring of ETCO2 and PTCO2|Concomitant monitoring of ETCO2 and PTCO2
214357108|NCT01002872|DRUG|Lanthanum Carbonate (Fosrenol)|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill three times a day (TID) Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus \<3.5mg/dL Reduce to 1 pill twice a day (BID). If Phosphorus \>5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is \<3.5mg/dL Reduce to 1 pill daily. If phosphorus \>5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus \<3.5mg/dL stop the drug If phosphorus is \>5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
214357109|NCT01002872|DRUG|placebo|Initial dose of placebo will be 1 pill three times a day
214357110|NCT00414817|BEHAVIORAL|Automated Phone-Based Refill Reminders|The BREATHE EASY Medication Reminder Program uses interactive voice recognition phone technology to offer timely reminders to patients to refill their ICS medication, educational messages about ICS, and may offer to transfer them to a refill line or to speak with a pharmacist if they have questions.
214357111|NCT02785341|OTHER|questionnaires every 6 weeks (T0, T1, T2, T3 and T4)|Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals
214357112|NCT02785341|OTHER|6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)|
214357113|NCT02785341|OTHER|leptin level with a blood test every 12 weeks (T0, T2 and T4)|blood sample
214967701|NCT03286218|DRUG|Lasmiditan|Administered orally
214967702|NCT03286218|DRUG|Alprazolam|Administered orally
214967703|NCT03286218|DRUG|Placebo|Administered orally
214967704|NCT06102720|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 0.5 mg per day during 14 days. Acetylsalicylic acid was used as an antiplatelet agent (300 mg on days 1 and continuing with 100 mg/day).
214967705|NCT06102720|DRUG|Clopidogrel|Dual antiplatelet therapy includes ASA (300 mg on days 1 and continuing with 100 mg/day) and clopidogrel (300 mg on days 1 and continuing with 75 mg/day).
214967706|NCT01979874|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months
214967707|NCT01979874|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
214967708|NCT02044757|BEHAVIORAL|SSB withdrawal|During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).
214967709|NCT02990013|DEVICE|Avenova|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
214967710|NCT02990013|DRUG|Povidone-iodine 5% solution|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
214357114|NCT03432923|DRUG|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
214967711|NCT02990013|DRUG|4% chlorhexidine|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
214967712|NCT02990013|DRUG|Isopropyl alcohol|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
214967713|NCT02931760|DEVICE|subcutaneous pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
214967714|NCT02931760|DEVICE|intramuscular pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
214967715|NCT04184557|BEHAVIORAL|Staying Calm in the OR|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) ir Mindfulness Self Compassion (MSC)."
214967716|NCT01493050|DRUG|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
214967717|NCT01493050|DRUG|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
215082144|NCT02813642|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
215082145|NCT02813642|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
215082146|NCT02813642|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by X-ray of the lateral abdominal aorta
215082147|NCT03661905|OTHER|Cognitive therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
214357115|NCT03432923|DRUG|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
214679118|NCT02929992|OTHER|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
214357116|NCT04963127|DIAGNOSTIC_TEST|Computed Tomography of the skeleton using a Dual-Energy-/Multi-Energy-/Spectral acquisition mode|CT acquisition using a Dual-Energy / Multi-Energy / Spectral acquisition mode
214357117|NCT04963127|DIAGNOSTIC_TEST|Computed Tomography of the skeleton using a conventional single-energy / non-spectral acquisition mode|CT acquisition using a standard single energy / non-spectral acquisition mode
214679119|NCT02929992|OTHER|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
214679120|NCT02929992|OTHER|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
214967718|NCT02896764|DEVICE|Cone-beam CT|
214967719|NCT01348139|DRUG|AZD3199|Inhaled via single inhaler device (SID)
214357118|NCT00476216|DRUG|Combination of Arixtra with chemotherapy|"Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 \& 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy."
214357119|NCT00640627|DRUG|Celecoxib|200 mg oral capsule once daily for 6 weeks
214357120|NCT00640627|DRUG|Placebo|Matched oral placebo for 6 weeks
214357121|NCT05049759|BEHAVIORAL|Confident, Active and Happy Youth|The three target goals of the intervention (confident, active and happy) link closely to the core symptoms of internalizing disorders. Thus, a core symptom of anxiety is a lack of confidence in one's ability to cope with a given fearful situation. The ensuing behavioral reaction is avoidance of the situation and/or enduring it with excessive discomfort. Similarly, a core symptom of a depressive disorder is lowered mood. Regarding both depression and anxiety, both disorders are associated with less physical activity, and low levels of physical activity conversely help maintain the disorders. As such, the aim is to alleviate symptoms and supplement ongoing treatment in CAMHS.
214357122|NCT05031364|BEHAVIORAL|Behavioral Interventions for Anxiety in Children with Autism (BIACA)|In the BIACA CBT program (e.g., Wood et al., 2020), clinicians work with families for 16 weekly sessions that include both the child and parent(s). In BIACA, anxiety, rigidity and inflexible routines, and irritability are all addressed using in vivo exposure therapy strategies during sessions as well as parent (and teacher) training to promote regulation across settings. ASD-related clinical needs that can impact mental health and emotion regulation such as friendship skills and social entry skills (e.g., joining games at school) are addressed with modeling, self-management, and parent- (or teacher-) implemented social coaching in daily settings. For youth with limited communication, therapy is adapted through the use of play-based representations of challenging situations and an emphasis on more action-oriented exposure therapy.
214357123|NCT05031364|BEHAVIORAL|Treatment-as-Usual Supplemented by Internet-Based Self-Instruction (MEYA)|Participating clinicians are expected to have varied training in numerous psychological therapy procedures (e.g., insight-oriented procedures, cognitive interventions, family therapy, etc.), any or all of which they may choose to implement with a participating child. These practices will be characterized through the Therapy Procedures Checklist (Weersing et al., 2002). Additionally, participating clinicians will be provided with information about self-instruction resources on CBT for children with autism, namely, the Modular Evidence-Based Practices for Youth with Autism (MEYA) website developed by our research group. MEYA is freely accessible to clinicians worldwide at meya.ucla.edu. MEYA incorporates treatment elements of both BIACA (Wood et al., 2020) and SEBASTIEN (Wood et al., 2021), which was designed to address additional autism-related clinical needs (e.g., reciprocal conversation). Clinicians in this arm will provide up to 16 therapy sessions.
214357124|NCT03638895|DEVICE|ECAL Indirect Calorimeter|The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).
214393742|NCT04192812|DRUG|PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
214679121|NCT02929992|OTHER|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
214679122|NCT04618692|OTHER|Surgical Loupes|Biliary reconstruction will be performed using surgical loupe
214679123|NCT04618692|OTHER|Microscope|Biliary reconstruction will be performed using microscope
214967720|NCT01348139|DRUG|AZD3199|Inhaled via Turbuhaler inhaler
214967721|NCT01348139|OTHER|AZD3199 Placebo|Inhaled via Turbuhaler inhaler and SID
214967722|NCT04008225|PROCEDURE|Bronchoalveolar lavage|
214967723|NCT01015326|OTHER|Questionnaire|Administered questionnaire
214967724|NCT01015326|OTHER|Questionnaire|Administered questionnaire
214967725|NCT02762084|DRUG|Patidegib|
214967726|NCT02762084|DRUG|Vehicle gel|
214967727|NCT01961414|DRUG|Aflibercept|Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
214967728|NCT02862145|DRUG|MRX34|Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
214967729|NCT02862145|DRUG|Dexamethasone|Premedication during the week of treatment
214967730|NCT03190824|DRUG|OBP-301|A novel, replication-competent Ad5 based adenoviral construct that incorporates a human telomerase reverse transcriptase gene (hTERT) promoter.
214967731|NCT03141112|PROCEDURE|renal replacement therapy|
214967732|NCT04702152|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be non-congruently related to the scenes in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
214967733|NCT03262077|DRUG|Methylene Blue|Irradiation with low-level laser for 1, 3, and 5 min
214967734|NCT03262077|DRUG|Methylene Blue Oral Product|Irradiation with low-level laser for 1, 3, and 5 min
214967735|NCT00037050|DRUG|Linezolid|
214967736|NCT00037050|DRUG|Vancomycin|
214967737|NCT00037050|DRUG|Oxacillin|
214967738|NCT00037050|DRUG|Dicloxacillin|
214967739|NCT00090727|DRUG|AQ4N|
214967740|NCT00857662|DEVICE|Onyx|Embolization
214967741|NCT00857662|DEVICE|TRUFILL|Embolization
214967742|NCT02869763|DIETARY_SUPPLEMENT|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
214967743|NCT02869763|DIETARY_SUPPLEMENT|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
214967744|NCT02869763|DIETARY_SUPPLEMENT|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
214967745|NCT01428843|DRUG|FERRISAT|A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
215082148|NCT03661905|BEHAVIORAL|Exposure and Response Prevention|Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
215082149|NCT05144880|OTHER|electroacupuncture|A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
215082150|NCT00731965|BIOLOGICAL|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
215082151|NCT02728414|DIETARY_SUPPLEMENT|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
215082152|NCT02728414|DIETARY_SUPPLEMENT|placebo|the patients in this arm will receive placebo intervention
215082153|NCT04297189|BEHAVIORAL|Coaching and health information intervention|8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
215082154|NCT05023616|OTHER|Real-time home CPR training|The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.
215082155|NCT05023616|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance."
215082156|NCT01768104|PROCEDURE|ESTD|"1. A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~2. Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~3. Dissection was done along the margin of the tumor.~4. After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~5. Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors… Endoscopy 2012; 44: 231-235)"
214967746|NCT01428843|DRUG|PLACEBO|A single infusion of Glucose 5% solution during inclusion visit
214967747|NCT03980262|BEHAVIORAL|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
214967748|NCT03980262|BEHAVIORAL|Money Smart|Money Smart is a financial literacy education program developed by the Federal Deposit Insurance Corporation (FDIC). Curricula are available for both adults and children.
214967749|NCT01164202|DRUG|sunitinib malate|placebo 3cps/days 4 weeks over 6 during 1 year
214967750|NCT01164202|DRUG|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
214967751|NCT01164202|PROCEDURE|transarterial chemoembolization|Chimioembolisation
214967752|NCT03248869|OTHER|Current Daily Survey|need description
214967753|NCT03248869|OTHER|Mobile Health App|Participants recruited, consented and enrolled via the AMHA and complete assessments using the app
214967754|NCT01001910|DRUG|Carboplatin|Given IV
214967755|NCT01001910|OTHER|Laboratory Biomarker Analysis|Correlative studies
214967756|NCT01001910|DRUG|Pemetrexed Disodium|Given IV
214967757|NCT02862080|DEVICE|cathode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
214967758|NCT02862080|DEVICE|Ekso|Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
214967759|NCT02862080|DEVICE|anode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
214967760|NCT02525016|BIOLOGICAL|Blood sampling|
214967761|NCT02525016|DRUG|Lidocaine|
214967762|NCT02938364|OTHER|Earplugs|Plastic earplugs on both ears
214967763|NCT02938364|OTHER|Acupressure|Sea Bands put on the wrists of the participant to apply pressure on P6 points
214967764|NCT02938364|OTHER|Placebo|Non pressure bands put on the wrists of the participant
214967765|NCT01619852|DRUG|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
214967766|NCT01619852|DRUG|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
214967767|NCT01464190|DRUG|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
214967768|NCT01464190|DRUG|Sevelamer carbonate|Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
214967769|NCT03787823|PROCEDURE|robotic Prostatectomy (RARP)|Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP
214967770|NCT00970489|DRUG|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
215082157|NCT01768104|PROCEDURE|VATS|"1. General anesthesia with double lumen intubation.~2. Three to four cameras or working ports are placed over the chest wall.~3. After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~4. The mass is exposed after the overlying muscle is split longitudinally.~5. The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~6. The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
215082158|NCT05860491|OTHER|dietary fiber|Retrospective analysis of the relationship between patient dietary fiber intake and hyperkalemia
215082159|NCT04789161|PROCEDURE|double kissing crush stenting|Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
215082160|NCT04789161|PROCEDURE|double kissing culotte stenting|Patients with true bifurcation lesion treating with double kissing culotte stenting technique
215082161|NCT04301180|DEVICE|Education food|The intervention consisted of the presentation of food education content while conducting an orchard with seasonal vegetables
215082162|NCT00681980|DRUG|Valproic acid|15 mg/kg/day
215082163|NCT00681980|DRUG|costicosteroids|metypredsolone 1 g/day
215082164|NCT00681980|DRUG|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
214967771|NCT00970489|DRUG|Placebo|Olive Oil capsules
215082165|NCT02469415|DRUG|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
215082166|NCT02469415|DRUG|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
215082167|NCT02469415|DRUG|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
215082168|NCT04475484|OTHER|Online questionnaire|"Parents will receive a link to an online questionnaire through computing services of Lyon's Academy. They have to give their consent to allow their child to participate in the study. Then, children can complete the online questionnaire.~The questionnaire starts with few explanations on the context of the study, and ends with psycho-education advices and what to do in the event of psychological distress."
215082169|NCT03384823|DRUG|EDP-938|Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).
215082170|NCT03384823|DRUG|Placebo|placebo to match EDP-938
215082171|NCT05396729|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
215082172|NCT00499655|DRUG|erlotinib hydrochloride|Given orally
215082173|NCT00499655|DRUG|celecoxib|Given orally
215082174|NCT00499655|OTHER|placebo|Given orally
214967772|NCT03415516|DEVICE|Gluma Universal|Adhesive systems
214967773|NCT03415516|DEVICE|All Bond Universal|Adhesive systems
214967774|NCT03415516|DRUG|Single Bond2|Adhesive systems
214967775|NCT02667925|DRUG|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
214967776|NCT02168491|DRUG|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
214357125|NCT03638895|BEHAVIORAL|Diet, exercise & behaviour modification therapy|Standard care (SC) - participants receive standard care (diet, exercise \& behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
214357126|NCT05759416|DRUG|Melatonin2%gel|Intra-pocket application of 2% Melatonin gel
214357127|NCT05759416|DRUG|PLACEBO|placebo intra-pocket application
214357128|NCT00868855|DRUG|Bradykinin|Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
214357129|NCT03078270|DRUG|botulinum toxin A|Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
214357130|NCT03078270|OTHER|Placebo|single treatment visit for 5 injections of normal saline
214967777|NCT02168491|DRUG|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
214967778|NCT04705012|OTHER|Submucosal supportive therapy|Increased frequency of submucosal cleaning using a rotating chitosan brush
214967779|NCT01096160|DRUG|MK-8226 BID, 1 mg|MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
214967780|NCT01096160|DRUG|MK-8266 BID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
214967781|NCT01096160|DRUG|MK-8266 TID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
214967782|NCT01096160|DRUG|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
214967783|NCT01096160|DRUG|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
214967784|NCT01096160|DRUG|Placebo BID (Panel A)|Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
214967785|NCT01096160|DRUG|Placebo BID (Panel B)|Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
214967786|NCT01096160|DRUG|Placebo TID (Panel C)|Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
214967787|NCT01096160|DRUG|Placebo TID (Panel D)|Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
214967788|NCT01096160|DRUG|Placebo TID (Panel E)|Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
214967789|NCT06164457|OTHER|ePROM Survey|The APPROACH ePROM survey consists of several well validated PROM instruments, including the Seattle Angina Questionnaire 7-item version,\[4\] the EuroQol EQ5D-5L,\[5\] the Medical Outcomes Study Social Support Scale (8 item version),\[6\] the Patient Health Questionnaire 2-item and 9-item (PHQ2/9) depression screening tools\[7\], and the Self-Care of Coronary Heart Disease Inventory (SC-CHDI-V3).\[8\]
214967790|NCT01536210|DRUG|YY-162|YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
214967791|NCT01536210|DRUG|Placebo|Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
215082175|NCT00499655|OTHER|laboratory biomarker analysis|Correlative studies
215082176|NCT00499655|OTHER|immunohistochemistry staining method|Correlative studies
215082177|NCT00499655|GENETIC|fluorescence in situ hybridization|Correlative studies
215082178|NCT00499655|GENETIC|mutation analysis|Correlative studies
215082179|NCT00499655|GENETIC|protein expression analysis|Correlative studies
215082180|NCT00499655|GENETIC|gene expression analysis|Correlative studies
214679124|NCT00521339|DRUG|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
214357131|NCT04648189|DRUG|Cetuximab|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
214357132|NCT00900068|OTHER|immunoenzyme technique|
214357133|NCT00900068|OTHER|laboratory biomarker analysis|
214357134|NCT00900068|OTHER|medical chart review|
214357135|NCT04133155|DRUG|nab paclitaxel plus gemcitabine|Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
214357136|NCT04487093|DRUG|neoantigen vaccine + EGFR-TKI|"Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks.~The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance."
214679125|NCT04503486|DIAGNOSTIC_TEST|handgrip strength|measure of handgrip strength using Jamar Dynamometer and a standardized protocol, strength expressed in kg
214967792|NCT05931536|OTHER|Dietary fibre|Habitual dietary consumption from a variety of foods will be assessed using 7-day food logs entered by the participant and assessed for accuracy by a dietitian.
214967793|NCT05660382|DRUG|Miconazole (2%) oil and mineral oil|Twice daily application, for 14 days.
214967794|NCT05660382|OTHER|Placebo|Twice daily application, for 14 days
214967795|NCT01610037|DRUG|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
214967796|NCT01610037|DRUG|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
214967797|NCT01610037|DRUG|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
214967798|NCT00715234|OTHER|Reminder/recall notices for vaccines|"1. Receive a generic letter reminding them to make an appointment to get vaccines.~2. Receive a computer-generated telephone message at 1 week post initial letter.~3. Receive a computer-generated telephone message at 2 months post initial letter.~4. Receive a letter at 3 months post initial letter."
214679126|NCT04503486|DIAGNOSTIC_TEST|quadriceps strength|maximal isometric quadriceps strength measured using a handheld dynamometer and a standardized protocol, strength expressed in Newton
214679127|NCT02372825|PROCEDURE|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
214967799|NCT01837251|DRUG|Carboplatin|
214967800|NCT01837251|DRUG|PLD|
214967801|NCT01837251|BIOLOGICAL|Bevacizumab|
214967802|NCT05375500|DEVICE|telemedicine digital therapeutic|digital therapeutics intervention for chronic pain utilizing coaching and virtual reality application
214967803|NCT03796312|BEHAVIORAL|Tub Bathing|The infant's face was washed and dried while still wrapped before being immersed. The water level in the tub was set at approximately 9-12 cm or deep enough to cover the baby's shoulders. A folded cloth towel was placed into the tub before bathing. The temperature of the bath water was controlled using a special water thermometer and adjusted to 37-38°C. The infant was held securely; the head and neck were supported on the researcher's forearm, and the shoulder was grasped using the researcher's thumb and finger. Cleaning was performed using a soft cloth and baby skin cleaner. The front and back areas were cleaned without turning the infant. The newborn was safely removed from the water and wrapped in a clean towel.
214967804|NCT03796312|BEHAVIORAL|Sponge Bathing|Sponge bathing is routine care of the clinic
214679128|NCT00648843|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fed
214967805|NCT02824835|PROCEDURE|biopsy during colonoscopy|sampling the lesion with forcept biopter
214967806|NCT03573596|DRUG|Dasatinib|CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
214967807|NCT00705757|DRUG|latanoprost|Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
214967808|NCT00705757|DRUG|bimatoprost|Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
214967809|NCT00705757|DRUG|travoprost|Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
214967810|NCT01644721|BIOLOGICAL|Early measles vaccine|Standard Edmonston-Zagreb measles vaccine
214967811|NCT04113941|DRUG|Neuronox|intradetrusor injection
214967812|NCT04113941|DRUG|Placebo|intradetrusor injection
214967813|NCT06336421|OTHER|Virtual Reality|"VR Box brand virtual reality glasses were used in primiparous pregnant women undergoing cesarean section.~During the cesarean section, the researcher showed the pregnant woman in the experimental group a video accompanied by music and baby pictures using virtual reality glasses for an average of 10 minutes."
214967814|NCT05321420|DRUG|Placebo|placebo
214967815|NCT05321420|DRUG|Pirfenidone|pirfenidone 801 mg TID
214967816|NCT05321420|DRUG|Deupirfenidone|Deupirfenidone
214967817|NCT02202304|DRUG|Chlorhexidine/Thymol varnish|This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
214967818|NCT00971477|OTHER|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
214967819|NCT00971477|OTHER|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
214967820|NCT00413543|OTHER|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
214967821|NCT03817944|OTHER|Warm Water|300 mL Warm Water per day for 8 weeks
214967822|NCT03817944|OTHER|Caffeinated Coffee|300 mL Caffeinated Coffee per day for 8 weeks
214967823|NCT03817944|OTHER|Decaffeinated Coffee|300 mL Decaffeinated Coffee per day for 8 weeks
214967824|NCT04758351|OTHER|Usual clinical practice|Based on European Respiratory Society guidelines on management for chronic cough.
214967825|NCT05377372|BEHAVIORAL|Breastfeeding support group|community-based breastfeeding support group aimed to increase exclusive breastfeeding success rates among Black women
214967826|NCT05377372|OTHER|Observation|Observe prospectively for breastfeeding initiation, duration and longitudinal health of child with sickle cell disease
214967827|NCT06047756|OTHER|Hippotherapy|Patient will perform different movement of the trunk while sitting on a horse.
214967828|NCT06047756|OTHER|Swiss Ball therapy|Patient will perform movements of trunk on swiss ball
214967829|NCT01698970|OTHER|1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)|1- 6 test products/day
214967830|NCT01698970|OTHER|2- excipients (150 mg) in capsule (control)|2- 6 control poducts/day
214967831|NCT02633969|DRUG|Indomethacin Capsules low dose|
214967832|NCT02633969|DRUG|Indomethacin Capsules high dose|
214967833|NCT03193047|DRUG|bempedoic acid 180mg|Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
214679129|NCT00648843|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fed
215082181|NCT04392921|DRUG|Amiodarone|"Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:~• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~* If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first)."
214967834|NCT03193047|OTHER|placebo|Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy
214967835|NCT03193047|DRUG|evolocumab|Monthly PCSK9i (evolocumab) background therapy
214679130|NCT02467907|DRUG|Bevacizumab|Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
214679131|NCT02467907|DRUG|Carboplatin|Administration of carboplatin at 5 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 every 3 weeks for at least 6 cycles
214679132|NCT02467907|DRUG|Paclitaxel|Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m\^2) on Day 1 every 3 weeks for at least 6 cycles
214679133|NCT02697461|OTHER|Intrinsic Foot Strengthening|"Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises."
214967836|NCT04715464|OTHER|review of surveillance cultures within the past year|"ASC results are reported as positive or negative based on the culture source. Antimicrobial susceptibility testing is performed but not reported; however, physicians may obtain susceptibility information for MDR GNB only if clinically indicated through the microbiology department.~1. Nasal swab for MRSA~2. Respiratory specimens~i. Sputum for MRSA, VRE, and Multi Drug Resistant gram-negative Bacteria (MDR GNB) (if not intubated but with productive cough) ii. Endotracheal aspirate for MRSA, VRE, and MDR GNB (if intubated) c. Drainage from any wounds for MRSA, VRE, and MDR GNB d. Rectal/ perianal swab for VRE, and MDR GNB e. Urine for MRSA, VRE, and MDR GNB (from patients catheterized prior to admission only)"
214967837|NCT03887182|DIAGNOSTIC_TEST|functional MRI|Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care
214967838|NCT03887182|DIAGNOSTIC_TEST|Automated Cortical Brainstem Auditory Evoked Potential|Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
214967839|NCT03887182|GENETIC|whole exome sequencing|A study of all the DNA-encoding exons of the child/parent from a sample taken as part of the usual care
214967840|NCT03887182|DIAGNOSTIC_TEST|Standard Cortical Brainstem Auditory Evoked Potential|Standard Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
214967841|NCT03887182|DIAGNOSTIC_TEST|multidisciplinary consultation|"multidisciplinary consultation is composed of:~* an ENT consultation and audiometry~* a speech therapy assessment~* a psychometric evaluation"
214967842|NCT05042752|PROCEDURE|CLINICAL ULTRASOUND|The intervention group will receive the standard care of treatment in AHF and the performance of CU.
214967843|NCT00467428|DRUG|NS2359|
214967844|NCT00467428|DRUG|Placebo|
214967845|NCT05643391|RADIATION|Radioembolization using Holmium-166|This technic consists of the intra-arterial infusion of smaller beads that are loaded with a radioactive isotope (yttrium-90), and it relies on the beta radiation emitted by the isotope to induce tumor necrosis, with a minor contribution from microembolization and without risk of ischemia of the remaining liver.
214967846|NCT01328938|BIOLOGICAL|GCPGC 3.6mg|Stage I:Single blinded
214967847|NCT01328938|BIOLOGICAL|GCPGC 6mg|Stage I: Single blinded;
214967848|NCT01328938|BIOLOGICAL|Neulasta (pegfilgrastim) 6mg|Stage II: Active comparator, double blinded
214967849|NCT01328938|BIOLOGICAL|GCPGC 6mg|Experimental: Stage II
214967850|NCT01942811|BEHAVIORAL|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
214967851|NCT06438887|DIETARY_SUPPLEMENT|Placebo|Corn-Starch Maltodextrin
214967852|NCT06438887|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine
214967853|NCT04642482|DIETARY_SUPPLEMENT|Synbiotic (Rillus)|Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.
214967854|NCT04642482|DRUG|Placebo|Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
214967855|NCT05489107|OTHER|Ziverel|Within a first flexible rectoscopy (Day 1) the product will be applied transanally. Then the patients will apply it as enemas twice daily for 7 days. On day 8 (after treatment completion), and on day 31 (after 23 days of no treatment) follow-up flexible rectoscopies will be performed.
214967856|NCT04724785|OTHER|only monitoring|monitoring the viraemia only
214967857|NCT04724785|OTHER|monitoring and regimen change if necessary|if those patients agree, the regimen will be changed.
214967858|NCT04724785|DRUG|regimen change|Based on ongoing one, regimen will be changed . The principle for adjusting anti-viral regimen is as follows: 1. The patients were treated with second-line drugs: changing ADV to ETV/TAF/TDF , changing LAM to TAF/TDF and changing LdT to TAF/TDF; 2. The patients were treated with ETV: adding or switching to TAF/TDF;3. TAF or ETV is recommended for patients with one or more TDF risk factors, such as \> 40 years old, patients with abnormal bone/kidney related indicators or patients with high risk of bone/kidney injuries.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】
214967859|NCT03743025|DRUG|Dulaglutide Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
214967860|NCT03743025|OTHER|Saline Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
214967861|NCT05262335|DRUG|Anlotinib + Oxaliplatin + Capecitabine|"1. Before 6 cycles, Anlotinib 12mg, po.qd, d1-14; Capecitabine 850 mg/m2, po. bid, d1-14; Oxaliplatin 130 mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
214967862|NCT05262335|DRUG|Anlotinib + Cisplatin + Paclitaxel/ Docetaxel|"1. Anlotinib 12mg, po.qd, d1-14; Cisplatin 60-75mg/m2, iv, d1/d1-d3; Paclitaxel 135mg/m2, iv (D1). or Docetaxel 75mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
214967863|NCT05262335|DRUG|Anlotinib + Standard first-line chemotherapy|"1. Anlotinib 12mg, po.qd, d1-14; Standard first-line chemotherapy determined by the researchers. The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
214967864|NCT00181675|DRUG|galantamine HBr|
214967865|NCT04753502|PROCEDURE|Laparoscopy|laparoscopic removal of pathologic appendix
214967866|NCT02413957|OTHER|Medication Reconciliation|Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
215082182|NCT04392921|DRUG|Placebo|"Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~* All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~  o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first)."
214357137|NCT04487093|DRUG|neoantigen vaccine + anti-angioge|neoantigen vaccine + anti-angioge
214357138|NCT02073695|PROCEDURE|Operative procedure to fix proximal humeral|Operative fixation by the shoulder team at Torbay Hospital
214967867|NCT02413957|OTHER|Pharmaceutical Care|Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
214967868|NCT02420119|OTHER|non interventional|
214967869|NCT02690012|OTHER|Magnesium Oxide|Magnesium Oxide
214967870|NCT02690012|OTHER|Magnesium Citrate|Magnesium Citrate
214967871|NCT03975257|DEVICE|Medical Device: Ectoin Lozenge|Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use
214967872|NCT00149396|DRUG|NV1020|NV1020 dose levels: 3x10\^6, 1x10\^7, 3x10\^7, and 1x10\^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
214967873|NCT03639246|DRUG|AVB-S6-500|AVB-S6-500 is experimental drug
214967874|NCT03639246|DRUG|Paclitaxel (Pac)|Paclitaxel is active comparator
214967875|NCT03639246|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD is active comparator
214967876|NCT03639246|OTHER|Placebo|Placebo comparator
214967877|NCT04001192|BEHAVIORAL|aerobic exercise program|The intervention is exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
214967878|NCT02236312|DRUG|Botulinum Toxin Type A|
214967879|NCT02236312|DRUG|Placebo|
214967880|NCT06522815|DEVICE|CART-I plus|"CART-I PLUS collects signals in two ways:~ECG: Utilizes the metal on the inner and outer sides as electrodes to detect subtle electrical changes resulting from the contraction and relaxation of the heart muscle.~PPG: Emits LED light into the blood vessels inside the finger and collects the signal reflected by the blood flow, thereby gathering data on the pulse and functional oxygen saturation (SpO2) of arterial hemoglobin.~In this clinical trial, PPG signals will be continuously collected during the polysomnography using the PPG method."
215082183|NCT06506799|OTHER|Training Given to Intensive Care Nurses on the Use of Physical Fixation|"Data will be collected with the 'Participant Information Form' and the 'Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale', prepared by the researcher in line with the literature and containing the demographic characteristics of the participants.~Intensive care nurses who will participate in the research will be asked to fill out the survey forms with individual consent.~Participant Information Form and Nurses' Knowledge, Attitude and Practice Levels Regarding Physical Restraint Scale will be used as pre-tests. After the pre-test, nurses will be given physical restraint training. The training content was created using the ADDIE model as reference. After the training, the Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale will be used as the final test."
215082184|NCT02986932|DEVICE|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
215082185|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
215082186|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
215082187|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10\^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
215082188|NCT00554658|DRUG|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
214357139|NCT02073695|DEVICE|Neutral Rotation Brace|Performed at the end of the surgical procedure at Torbay Hospital
214357140|NCT02073695|OTHER|Physiotherapy review|Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.
214357141|NCT02073695|OTHER|Functional outcome forms filled in|
214357142|NCT02073695|OTHER|Postal functional outcome scores|Sent to patient at 9 weeks post surgery
214967881|NCT06522815|DEVICE|Polysomnography|"In polysomnography, the following data are collected:~Electrocardiogram (ECG), Electroencephalogram (EEG), Electromyogram (EMG), Electrooculogram (EOG), Oxygen Saturation (SpO2) Respiratory Analysis, Body Position Monitoring"
214967882|NCT05756881|OTHER|Cosmetic product|Apply on the face twice a day
214967883|NCT03069534|DRUG|RhIL-2|RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy. rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.
214967884|NCT00306046|DRUG|Bisphosphonate treatment|
214967885|NCT03207191|DRUG|F16IL2|F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
214967886|NCT03207191|DRUG|BI 836858|BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours
215082189|NCT02372708|DRUG|dinitrophenyl(DNP)|
214357143|NCT02073695|OTHER|Post-operative Radiographs|Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital
214357144|NCT02415426|BEHAVIORAL|Metacognitive Training Program during mild to moderate depression|Diagnostic and therapeutical interventions are not part of this study. As part of this study, the change of cognitive and psychosocial achievement/behavior in patients with mild to moderate depression after taking part in the training program is being investigated. The training program seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). In addition, dysfunctional assumptions about one's thought processes, as well as dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are targeted (Lena Jelinek \& Steffen Moritz, http://clinical-neuropsychology.de/metacognitive\_training\_for\_depression.html).
214967887|NCT05437809|OTHER|Intake of nutritionally diverse ultra-processed foods|All participants will attend four food consumption assessment visits where, at each visit, they will be asked to consume a standardized snack portion of: 1) ultra-processed foods (UPFs) high in both fat and refined carbohydrates (UPF+FRC), 2) UPF high in fat (UPF+F), 3) UPF high in refined carbohydrates (white flour, sugar) (UPF+RC), or 4) minimally processed foods. The order of the four food consumption assessment visits will be randomized and counterbalanced across participants, who will each consume all the test snacks across the four appointments.
214967888|NCT01158937|DRUG|Meropenem Infusion|Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
214967889|NCT01308892|DIETARY_SUPPLEMENT|High flavanol chocolate|chocolate high in flavanols
214967890|NCT01308892|DIETARY_SUPPLEMENT|Low flavanol chocolate|chocolate low in flavanols
214967891|NCT01308892|DIETARY_SUPPLEMENT|High fat challenge|Milkshake with 95g fat
214967892|NCT02681458|OTHER|Direct Examination|It was an observational study and subjects received their routine treatment.
214967893|NCT00287521|DRUG|AL-37807 Ophthalmic Suspension, 1.0%|One drop in the study eye(s) once daily for 28 days
214967894|NCT00287521|DRUG|Latanoprost, 0.005% (Xalatan)|One drop in the study eye(s) once daily for 28 days
214967895|NCT00287521|OTHER|AL-37807 Vehicle|One drop in the study eye(s) once daily for 28 days
214967896|NCT00287521|DRUG|Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%|One drop in the study eye(s) once daily for 28 days
214967897|NCT04687904|BEHAVIORAL|Mindfulness meditation training|Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
214967898|NCT04687904|BEHAVIORAL|Therapeutic education|"Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.~The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.~No specific instructions will be given at the end of this interview."
214967899|NCT00186485|DEVICE|MagStim|The MagStim delivers low frequency 1Hz stimulation to the right frontal area of the brain
214967900|NCT00228839|DRUG|Infliximab|
214967901|NCT02533934|DRUG|Harvoni|Treatment of Hepatitis C with sofosbuvir based HCC therapy
214967902|NCT01954238|DRUG|GCC-4401C|"* Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion."
214967903|NCT01954238|DRUG|Rivaroxaban|Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
214967904|NCT01954238|DRUG|Placebo|GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
214967905|NCT00227539|DRUG|cisplatin|
214967906|NCT00227539|DRUG|pemetrexed disodium|
214967907|NCT00227539|PROCEDURE|adjuvant therapy|
214967908|NCT00227539|PROCEDURE|therapeutic conventional surgery|
214967909|NCT00227539|RADIATION|fludeoxyglucose F 18|
214967910|NCT02250339|OTHER|LAKU family program|Multi-systemic and multicomponent family-based intervention program
214967911|NCT02250339|OTHER|Etä-LAKU family program|Ecosystem-based intervention for families living in rural parts of Finland
214967912|NCT02250339|OTHER|Family therapy|Treatment as usual (TAU)
214967913|NCT03198858|PROCEDURE|CartoUnivu™|Ablation with Carto® 3 System and image integration module = IIM, CartoUnivu™
214967914|NCT03198858|PROCEDURE|Ablation with Carto® 3 System|usual Pulmonary vein isolation Ablation with Carto® 3 System only
214967915|NCT04780672|DRUG|Molixan|The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
214967916|NCT04780672|DRUG|Placebo|Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
214967917|NCT03307941|DRUG|Monalizumab|Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
215082190|NCT02372708|RADIATION|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
215082191|NCT04767178|DRUG|Ibuprofen (Sanofi, Istanbul, Turkey)|Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
215082192|NCT04767178|DRUG|Paracetamol (GlaxoSmithKline, Istanbul, Turkey)|Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
215082193|NCT05043519|DRUG|FAM-NP41|The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.
215082194|NCT00623545|DRUG|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
215082195|NCT01292564|DEVICE|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
215082196|NCT01292564|DEVICE|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
214967918|NCT03307941|DRUG|Oxaliplatin|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
214967919|NCT03307941|DRUG|5-Fluorouracil|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
214967920|NCT03307941|RADIATION|Metabolic|Radiation therapy must start the first day of FOLFOX chemotherapy. Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.
214967921|NCT03307941|OTHER|Metabolic|18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients. Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution
214967922|NCT03307941|PROCEDURE|Surgery|Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
214967923|NCT03215537|BEHAVIORAL|comprehensive intervention|preoperative and postoperative exercise program
214967924|NCT04693780|OTHER|Structured guide|Structured guide
214967925|NCT04693780|OTHER|List|List
214967926|NCT02900248|OTHER|Provider determined|Provider will treat patient as he/she feels best
214967927|NCT06367946|PROCEDURE|mechanical ventilation|Mechanical ventilation is machine-delivered flow of gases to both oxygenate and ventilate a patient who is unable to maintain physiological gas exchange.
214967928|NCT01922258|DRUG|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
214967929|NCT00673257|OTHER|pharmacological study|pharmacological studies
214967930|NCT00673257|PROCEDURE|dual x-ray absorptimetry|
214967931|NCT05855837|OTHER|Ready to Eat Cereal|Cereal products available in retail stores
214967932|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
214967933|NCT00299819|BIOLOGICAL|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
214967934|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
214967935|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
214967936|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
214967937|NCT04956510|OTHER|Evaluation|health status and quality of life were evaluated
214967938|NCT02183012|DRUG|Ibuprofen extrudate|
214967939|NCT02183012|DRUG|Ibuprofen lysinate|
214357145|NCT03872921|DRUG|norUrsodeoxycholic Acid|oral treatment
214967940|NCT02183012|DRUG|Ibuprofen|
214967941|NCT02638779|BIOLOGICAL|Blood sampling|Specific Blood sampling will be performed in patients and healthy volunteers
214967942|NCT04397874|DIAGNOSTIC_TEST|; Computerized cardiotocography (cCTG)|To estimate the correlation between the maternal perception of fetal movement and antepartum computerised cardiotocography parameters.
214967943|NCT04979091|DIAGNOSTIC_TEST|Sex Hormones|A panel of 13 hormones was measured in plasma samples of COVID-19 patients (total testosterone, free testosterone, dihydrotestosterone, androstenedione, 17-β-estradiol, estrone, sex hormone-binding globulin, thyroid-stimulating hormone, free triiodothyronine (T3), free thyroxine (T4), luteinizing hormone, follicle-stimulating hormone and cortisol).
214967944|NCT04552132|DEVICE|Multisonic vs Sonic activation of irrigants|Energy is input into the intracanal irrigants for activation in the hopes of increasing irrigant efficacy.
214967945|NCT03722706|OTHER|Educational handbook|The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.
214967946|NCT04846192|OTHER|Nutritional evaluation|Collecting existing data on pre operative nutritional status and outcomes after surgery
215082197|NCT00241098|DRUG|valsartan|
215082198|NCT05641428|DRUG|ARI-0001|Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
215082199|NCT05641428|DRUG|Axi-cel|Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
215082200|NCT05491070|DEVICE|Vascular closure device (Angio-Seal, Progilde)|In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI
214357146|NCT03531424|PROCEDURE|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
214357147|NCT03531424|PROCEDURE|Augmented-Reality CTA guided PCI|Augmented-Reality CTA guided PCI is coronary revascularization based on systematic use of CTA datasets displayed in augmented-reality glass plus coronary angiography.
214357148|NCT00383487|DRUG|Calcitriol|0.5 micrograms/kilogram q weekly
214357149|NCT00383487|DRUG|Naproxen-n-butyl nitrate|400 mg BID, oral
214393743|NCT04192812|DRUG|NO GnRHa|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
214393744|NCT02763540|PROCEDURE|Lung cryobiopsy|Transbronchial cryobiopsy
214393745|NCT03100565|DRUG|local lidocaine spray|The lidocaine spray will be introduced to the cervix just before the biopsy procedure
214393746|NCT03100565|OTHER|forced coughing|The patients will be asked to forced coughing during the biopsy procedure
214967947|NCT00920959|DRUG|FP 100mcg|Once-daily dosing
214967948|NCT00920959|DRUG|FSC 100/50mcg|Once-daily dosing
214967949|NCT00920959|DRUG|Placebo|Once-daily dosing
214967950|NCT02996916|DRUG|Olmesartan|10-40mg daily
214967951|NCT02996916|DRUG|Amlodipine|2.5-10mg daily
214357150|NCT01825629|OTHER|Multidisciplinary therapy|"Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.~Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.~Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks."
214967952|NCT03365661|BIOLOGICAL|ALT-803|A reduced intensity conditioning starts on Day -6, (CY/FLU/TBI/TLI) followed by infusion of a TCRα/β-deplete haploidentical graft on Day 0. Two doses of ALT-803 are given initially (early) 1 week apart to facilitate NK cell expansion. ALT-803 maintenance (late) for immune reconstitution begins at Day 42 and consists of 4 weekly doses, followed by 4 weeks off. Up to four 8 week treatment courses are permitted. No post-transplant GVHD prophylaxis is administered unless the final donor cell product contains \> 2 x 105 α/β T cells/kg recipient weight.
214967953|NCT05679453|DRUG|Lornoxicam 8 Mg Oral Tablet|Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
214967954|NCT05023538|OTHER|Cycling|Exercise on bicycle ergometer
215082201|NCT04126564|BEHAVIORAL|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.
215082202|NCT04126564|BEHAVIORAL|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
215082203|NCT01121445|DEVICE|NeilMed nose and sinus irrigation|Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
215082204|NCT00907530|DRUG|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
215082205|NCT00907530|DRUG|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
215082206|NCT02928302|OTHER|TVU CL screening|Transvaginal ultrasound cervical length screening
215082207|NCT03769818|DRUG|bupivacaine|Bilateral TAP block with 20 ml of 0.25% bupivacaine
215082208|NCT03769818|DRUG|dexamethasone|Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
215082209|NCT03769818|DRUG|placebo to dexamethasone|Bilateral TAP block with placebo to dexamethasone.
215082210|NCT03769818|DRUG|placebo to bupivacaine|Bilateral TAP block with placebo to bupivacaine.
215082211|NCT03500172|BEHAVIORAL|DTP|Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
215082212|NCT03500172|BEHAVIORAL|ICM|Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
215082213|NCT00136968|DRUG|Voriconazole|
215082214|NCT02682589|PROCEDURE|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
214967955|NCT06121440|OTHER|Listening to audiobook|Audiobook by children will be chosen by child psychologists. The books will be played to children via tablet computers. The researcher has a fairy tale therapy certificate. The audiobook listening will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. Audiobook will be listen to children only one day.
214967956|NCT06121440|OTHER|Playing musical-moving toy|Musical-moving toy by children will be chosen by child psychologists. The toy will be played to children by the researcher. Playing musical-moving toy will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. The toy will be played to children only one day.
214967957|NCT06478329|OTHER|Progressive Core Stabilization Exercise Training|The effects of 6 weeks progressive core stabilization exercise training on adolescent volleyball players' balance, strength and endurance
214967958|NCT03540732|OTHER|Indirect Calorimetry directed feeding.|Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)
214967959|NCT03540732|PROCEDURE|Cycle Ergometry|Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.
214967960|NCT00595543|DRUG|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
214967961|NCT00595543|DRUG|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
214967962|NCT00595543|DRUG|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
215082215|NCT02682589|PROCEDURE|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
215082216|NCT05825144|DEVICE|Robotic exoskeleton-assisted gait rehabilitation|Use a robotic exoskeleton for gait rehabilitation in addition to conventional rehabilitation
215082217|NCT05825144|OTHER|Conventional rehabilitation|Regular post-stroke rehabilitation
215082218|NCT04081961|DEVICE|Anamed OEM device; Air Next mobile spirometry device|Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
215082219|NCT01646619|DRUG|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%."
215082220|NCT01646619|DRUG|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
215082221|NCT02956759|PROCEDURE|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
214967963|NCT00512499|BEHAVIORAL|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
214967964|NCT00512499|BEHAVIORAL|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
214967965|NCT00512499|BEHAVIORAL|Intensive Intervention|"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"
214967966|NCT02256839|DEVICE|CST_001|
214967967|NCT01918917|DRUG|Levobupivacaine|intraarticular
214967968|NCT01918917|DRUG|Dexmedetomidine|intraarticular 1 ml (100 mcg)
214357151|NCT01825629|OTHER|Placebo|
214357152|NCT05741580|PROCEDURE|Evolution of symptoms|percentage of patients with improvement in their symptoms
214357153|NCT00002426|DRUG|Adefovir dipivoxil|
214967969|NCT01918917|DRUG|Morphine|intravenously, patient-controlled analgesia
214967970|NCT03930095|BEHAVIORAL|Acceptance-based Behavior Therapy|The protocol is widely based on Roemer and Orsillo (2007) acceptance model of GAD, using functional assessment, psychoeducation, mindfulness, commitment to valued behavior, and exposure techniques used in a willingness improvement verbal context.
214967971|NCT03930095|BEHAVIORAL|Non-directive Supportive Therapy|NDST consists in a form of therapeutic intervention from which all intervention principles pertaining to specific psychotherapeutic protocols are removed while maintaining the so-called common factors from different psychotherapy approaches. In other words, it is an unstructured therapy without specific psychological techniques other than those belonging to the basic interpersonal skills of the therapist, such as reflection, empathic listening, encouragement, and helping people to explore and express their experiences and emotions.
214967972|NCT03119948|DRUG|Placebo injection|"Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment"
214967973|NCT03119948|DRUG|Botulinum toxin injection|"Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
214967974|NCT03119948|DRUG|Placebo injection and botulinum toxin injection|"Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
214967975|NCT04928144|DRUG|SHJ - Low concentration|Topical ophthalmic
214967976|NCT04928144|DRUG|SHJ - Mid concentration|Topical ophthalmic
214967977|NCT04928144|DRUG|SHJ - High concentration|Topical ophthalmic
214967978|NCT04928144|DRUG|SHJ - Maximum tolerated|SHJ - Maximum tolerated
214967979|NCT01834456|OTHER|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
214357154|NCT05540925|PROCEDURE|Liver resection|"All patients underwent curative-intent resection for early-stage HCC (a solitary tumor nodule≤5 cm, or multiple nodules≤3, each≤3 cm).~We did not take any other intervention. We retrospectively analyzed the prognostic performance of patients with wide (≥1cm) or narrow (\<1cm) resection margin in different groups."
214357155|NCT00738946|DRUG|Intermittent preventive treatment with AQ+ SP|Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
214967980|NCT04964661|OTHER|Medical Imaging|MRI imaging
214967981|NCT00121719|DRUG|Lenvatinib|Lenvatinib tablets taken orally, once daily.
214967982|NCT01748019|DRUG|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
214967983|NCT01951417|DRUG|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
214967984|NCT01951417|OTHER|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
214967985|NCT01951417|OTHER|Foam Wash|Foam Wash (twice daily)
214967986|NCT06420817|BEHAVIORAL|Indian version of a 'Portfolio' diet|The participants will be required to follow the prescribed diet plan for 4 weeks
214967987|NCT06420817|BEHAVIORAL|Physical Activity|"The participants will be required to join for an hour of group online exercise program 3 days a week for 4 weeks~• (Exercise Duration = 180 minutes per week including cardio, strength training and flexibility)"
214967988|NCT06420817|BEHAVIORAL|Intermittent fasting|The participants will be required to do intermittent fasting for 12 hours daily for 4 weeks
214967989|NCT06420817|BEHAVIORAL|Monitoring of sleep and stress levels|The participants will be required to monitor their sleep and stress levels
214967990|NCT02664077|DRUG|Regorafenib|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
214967991|NCT02664077|DRUG|Placebo|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
214967992|NCT04577417|DRUG|ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate|Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
214967993|NCT01816178|BEHAVIORAL|communication training|Participants were instructed in the use of a voices output communication aid.
215082222|NCT03796754|BEHAVIORAL|YoBEKA|The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
215082223|NCT02557113|PROCEDURE|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
215082224|NCT02557113|PROCEDURE|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
215082225|NCT01752400|DRUG|AUY922|
215082226|NCT03518268|DRUG|Vivomixx|The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
215082227|NCT03518268|DRUG|Placebo|The intervention consists of 2 sachets a day of placebo, for 6 months
215082228|NCT00915668|DRUG|JNJ-31001074|
215082229|NCT06333522|DRUG|Losartan|Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
215082230|NCT06419179|DRUG|Durvalumab|1500 mg i.v. Q4W
215082231|NCT06419179|DRUG|Olaparib|300 mg BID orally
214967994|NCT01472445|DRUG|Vitamin D|
215082232|NCT05883254|DIAGNOSTIC_TEST|RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR|"Quantatative Real -Time PCR for quantification of PUM1;~* The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~* The method of total RNA extraction: TRIzol and TRIzol LS.~* The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~* cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels"
215082233|NCT00003847|DRUG|biricodar dicitrate|
215082234|NCT00003847|DRUG|doxorubicin hydrochloride|
214357156|NCT01834066|BIOLOGICAL|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
214967995|NCT00382785|BEHAVIORAL|moderated support|one 12-week online support group led by a professional healthcare provider
214967996|NCT00382785|BEHAVIORAL|peer-led|12-week online support in a peer-led format
214967997|NCT01649115|OTHER|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
214967998|NCT00649077|DRUG|Meloxicam Tablets 15 mg|15mg, single dose fasting
214967999|NCT00649077|DRUG|Mobic® Tablets 15 mg|15mg, single dose fasting
214968000|NCT02925858|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Normal saline infusion mimicking infusion rate of ketamine for a given weight
215082235|NCT00003847|DRUG|vincristine sulfate|
215082236|NCT06026995|DRUG|PEG-rhG-CSF|Subcutaneous injection with a fixed dose of 12 mg
215082237|NCT06026995|DRUG|RhG-CSF|Inject rhG-CSF 5-10 μg/kg subcutaneously every day
215082238|NCT04646161|DRUG|Misoprostol|misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
215082239|NCT04698785|DRUG|Treatment by regorafenib and best supportive care|"Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment"
215082240|NCT03287024|DEVICE|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
215082241|NCT05131399|DEVICE|Phase A1|Plastic standard ankle foot orthosis
215082242|NCT05131399|DEVICE|Phase B1|carbon medical device ankle foot orthosis
215082243|NCT05131399|DEVICE|Phase A2|Plastic standard ankle foot orthosis
215082244|NCT05131399|DEVICE|Phase B2|carbon medical device ankle foot orthosis
215082245|NCT06223789|DEVICE|Pulsed Field Ablation|Pulsed field ablation using the Volt PFA System
214968001|NCT02925858|DRUG|Ketamine Hydrochloride|Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
214968002|NCT01043978|BEHAVIORAL|Use of baby bottle nipple|Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
214968003|NCT01705977|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
214968004|NCT01705977|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
214968005|NCT01705977|OTHER|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
214968006|NCT03764514|DEVICE|Spinal Cord Stimulator|Permanent Implantation
214968007|NCT03999502|DEVICE|Endomina|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
214968008|NCT02156440|DIETARY_SUPPLEMENT|SierraSil Joint Formula 14|667 mg SierraSil® hydrothermal mineral complex
214968009|NCT02156440|DIETARY_SUPPLEMENT|Placebo|
214968010|NCT03310632|DRUG|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
214968011|NCT02288819|DEVICE|Weight monitoring|The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
214968012|NCT02288819|DRUG|Loop diuretic downtitration|"The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose \>40 mg furosemide OR \>1 mg bumetanide OR \>20 mg torsemide, the loop diuretic dose is halved."
214968013|NCT03708263|DEVICE|Excel V 532nm (KTP) green Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
215082246|NCT05705973|DEVICE|Ultimaster Nagomi™|The Ultimaster NagomiTM Sirolimus eluting coronary stent system with Rapid Exchange Balloon Delivery System consists of a balloon expandable intra-coronary L605 cobalt chromium (CoCr) stent with abluminal drug eluting coating, that consists of a blend of Sirolimus and Poly(D,L-lactide-co-caprolactone), pre-mounted onto a high pressure, semi-compliant balloon delivery catheter
214968014|NCT03708263|DEVICE|PHOTOLASE PLV 585 nm yellow laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
214968015|NCT06265337|DIETARY_SUPPLEMENT|Lactate|Lactate in an OGTT (300 mL lactate drink = 25 g D/L-lactate bound to Na) =LAC with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
214968016|NCT06265337|OTHER|Placebo|Placebo in an OGTT (300 mL salt water, NaCl) =CTR with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
214968017|NCT01972737|BIOLOGICAL|Ad5-hGCC-PADRE vaccine|A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
214968018|NCT05168995|DRUG|BDP/FF NEXThaler® 100/6 micrograms|"BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)"
214968019|NCT04736095|DIAGNOSTIC_TEST|3D Ultrasound|Doing 3D ultrasound for diagnosis of submucous myoma
214968020|NCT04736095|DIAGNOSTIC_TEST|Hysteroscopy|Doing hysteroscopy for diagnosis of submucous myoma
214968021|NCT02837302|DRUG|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
214968022|NCT06553404|DEVICE|Myoslow|The Myoslow spectacle lens is based on the Defocus Incorporated Multiple Segments (DIMS) mechanism of action. This lens provides the same optical image as the Defocusing Incorporated Soft Contact Lens (DISC) without the drawbacks inherent with contact lens fitting.
214968023|NCT06553404|DEVICE|Single Vision|Single vision glasses
214968024|NCT01537848|PROCEDURE|EUS guided transmural drainage|Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
214968025|NCT05222165|DRUG|Infigratinib|Hard gelatin capsules for oral use
214968026|NCT01131390|DEVICE|Ventilator setting changes|Ventilator settings will be changed every 3 minutes as described above, simultaneously measuring respiratory mechanics and patients' comfort.
214968027|NCT02571556|DRUG|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
214968028|NCT02732288|DIETARY_SUPPLEMENT|melatonin|After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
215082247|NCT02349607|DRUG|PF-05089771 300mg|PF-05089771 300 mg
215082248|NCT02349607|DRUG|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
215082249|NCT02349607|DRUG|Placebo|Placeco
215082250|NCT02349607|DRUG|pregabalin 300 mg|pregabalin 300 mg
215082251|NCT02349607|DRUG|ibuprofen 600 mg|ibuprofen 600 mg
215082252|NCT00562276|PROCEDURE|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
214968029|NCT01185470|DEVICE|Implantation of Morphine Sulfate delivering programmable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
214357157|NCT03099993|OTHER|Measurement of maximal forces of elbow pronosupination and flexion-extension|Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.
214968030|NCT00096538|DRUG|valganciclovir|
214968031|NCT04522557|DRUG|IFNα-2a|After mastectomy, it is used in the cavity of breast before conducting implantation.
214968032|NCT00598065|OTHER|PET/CT|Synchronized PET/CT Imaging
214968033|NCT01822210|DRUG|Botox|injection by gastroscopy (100 Allergen units)
214968034|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
214968035|NCT01938846|DRUG|exemestane|exemestane once daily
214357158|NCT00981890|DRUG|Sunitinib|Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
214357159|NCT02468401|PROCEDURE|Percutaneous coronary intervention|Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
214357160|NCT04905394|PROCEDURE|subchondroplasty|subchondroplasty is an innovative percutaneous procedure in which calcium phosphate, biocompatible material similar to the native bone apatite with osteoinductive properties, is injected inside BML areas. The purpose of subchondroplasty is the patient's symptoms relief, improving the mechanical strength of subchondral bone, stimulating bone remodeling to avoid bone sagging, and slow down the arthritic degenerative process to postpone arthroplasty.
214968036|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
214968037|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
214968038|NCT01938846|DRUG|paclitaxel|paclitaxel once weekly
214968039|NCT04568798|DEVICE|Sana Sham Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
214968040|NCT00563615|DRUG|Tegaserod|
214968041|NCT03603119|DRUG|Normal saline, Midazolam|2 cc normal saline i.v. after anaesthesia induction.2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery
214968042|NCT03603119|DRUG|Dexamethasone, ondansetron|8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
214968043|NCT00073450|DRUG|Farnesyl Protein Transferase Inhibitor|
214968044|NCT02260206|DRUG|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
214968045|NCT02324361|OTHER|Physical Activity|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
214968046|NCT02324361|BEHAVIORAL|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
214968047|NCT00823238|DRUG|ceftazidime and tobramycin|
214968048|NCT00823238|DRUG|inhaled tobramycin|
214968049|NCT03145103|DEVICE|CT ASPHINA 409|intraocular lens
214968050|NCT04575441|OTHER|Exercise with pilates ball|Pilates ball exercises are used to give various sensory stimulation and increase motor skills. Children usually enjoy these kind of exercises as there is ball in every movement.
214968051|NCT00384202|DRUG|Tacrolimus|Immunosuppression
214968052|NCT00353223|BEHAVIORAL|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
214357161|NCT01974167|DRUG|Eldecalcitol|Eldecalcitol 0.75 microgram once daily orally
214357162|NCT01974167|DRUG|Alfacalcidol|Alfacalcidol 1 microgram once daily orally
214968053|NCT00353223|BEHAVIORAL|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
214968054|NCT05150457|DRUG|BNA035|Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody
214968055|NCT02390089|DRUG|Capsaicin vapor|Single-breath and continuous inhalation paradigm to induce cough.
214968056|NCT02390089|OTHER|fog|Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
214968057|NCT02390089|RADIATION|Videofluoroscopic swallow evaluation|Fluoroscopic evaluation of oropharyngeal swallowing function.
214968058|NCT02390089|DEVICE|Nebulizer|A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
214968059|NCT01655095|DRUG|PEG|PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
214968060|NCT01655095|DRUG|Prucalopride|Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
214968061|NCT01655095|DRUG|Picosalax|One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
214968062|NCT01655095|DRUG|Bisacodyl|Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
214968063|NCT01655095|PROCEDURE|Colon capsule|The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
214968064|NCT01655095|PROCEDURE|Colonoscopy|At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
215082253|NCT01437644|DRUG|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
215082254|NCT04815122|RADIATION|SPECT TRODAT-1|The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical \[99mTC\] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.
215082255|NCT01035346|DRUG|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
214968065|NCT03097432|DRUG|ORALVAC COMPACT BÄUME|
214968066|NCT02958371|PROCEDURE|fMRI|
215082256|NCT01035346|DRUG|Placebo|Single dose of a placebo
215082257|NCT01974752|DRUG|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
215082258|NCT01974752|DRUG|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
215082259|NCT01974752|DRUG|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
215082260|NCT05669586|DRUG|Antitumor therapy guided by organoid drug sensitivity test|Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
214968067|NCT02958371|BEHAVIORAL|fruit-flavored drink ingestion|
215082261|NCT00690807|DRUG|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
215082262|NCT04754230|DRUG|Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)|Medication administered 15 minutes prior to end of surgery.
215082263|NCT01318278|DRUG|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
214357163|NCT01409148|BIOLOGICAL|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2mCi (1 mg)
214357164|NCT03228056|DIAGNOSTIC_TEST|pain intensity measured in VAS scale|Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
214357165|NCT00385580|DRUG|dasatinib|Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
214357166|NCT00385580|DRUG|dasatinib|Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
214502705|NCT05395234|BEHAVIORAL|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura \& McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction \& flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
214968068|NCT00291564|DEVICE|Cardiac Resynchronization Therapy Device|
214968069|NCT00039624|RADIATION|Brachytherapy|Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
214968070|NCT01377636|DRUG|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
214968071|NCT03030625|RADIATION|IGRT/VMAT focal therapy boost to DIL|Image-guided/VMAT focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer (PCa) of intermediate and high risk (criteria NCCN) eligible to receive radiotherapy
214968072|NCT02592941|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
214968073|NCT04988334|OTHER|Wait Control|usual activities
215082264|NCT01318278|DRUG|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
215082265|NCT04502264|DEVICE|Hand of Hope|A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
215082266|NCT04502264|DRUG|Botulinum toxin type A injection|A safe agent representing the gold standard treatment for focal spasticity.
215082267|NCT02654431|PROCEDURE|Breast Cancer patient|Samples
215082268|NCT02654431|PROCEDURE|Cancer patients|Samples
214357167|NCT04245280|DRUG|Ropivacaine 0.5% Injectable Solution|ropivacaine 0.5% with epinephrine 2.5 mcg/ml
214357168|NCT04245280|DRUG|Saline Solution|normal saline solution (NaCl 0.9%)
214357169|NCT03468556|DRUG|SNP-610|Subjects will take 2 tablets once a day orally for 12 weeks
214968074|NCT01388933|DRUG|TU-100|15g daily, orally as 5g three times daily for 8 consecutive weeks
214968075|NCT01388933|DRUG|Matching Placebo|15g as 5g three times daily, orally for 8 consecutive weeks
214968076|NCT00808067|DRUG|dabigatran dose 1|dabigatran high dose twice daily
214968077|NCT00808067|DRUG|dabigatran dose 2|dabigatran low dose twice daily
214968078|NCT01494805|BIOLOGICAL|rAAV.sFlt-1|1 x 10\^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
214968079|NCT01494805|BIOLOGICAL|rAAV.sFlt-1|1 x 10\^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
214968080|NCT01494805|OTHER|Control (ranibizumab alone)|Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
214968081|NCT00246584|DRUG|SPP100|
214968082|NCT03669601|DRUG|AZD6738|A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
214968083|NCT03669601|DRUG|Gemcitabine|Nucleoside metabolic inhibitor.
214968084|NCT00559143|OTHER|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
214968085|NCT00043277|DRUG|Angiomax (bivalirudin)|
214968086|NCT05291923|OTHER|no intervention|no intervention
214968087|NCT00309023|DRUG|BMS-663513|mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
214968088|NCT04969588|DIAGNOSTIC_TEST|Microsoft Azure Kinect Developer Kit|3D images and 3D joint coordinates are obtained.
214968089|NCT04969588|DIAGNOSTIC_TEST|Bioelectrical impedance analyzer|Fat mass, fat-free mass and percentage body fat in total body and body segments are estimated.
214487321|NCT06885684|BEHAVIORAL|Cognitive Control Training + Metacognition Coaching|Computer training is delivered in person by a coach. Training consists of four games; each requires multiple aspects of cognitive control. Training levels progress in difficulty by increasing the number of items or simultaneous dimensions, decreasing the available response time, requiring greater accuracy, or adjusting the proportion of distractors or their complexity. Parameters that influence the difficulty of each level and passing criteria are fixed, but children progress from level to level at their own pace. Training is accompanied by manualized metacognition coaching to provide strategies to meaningfully engage with the tasks, simplify the tasks, support sustained effort, emphasize key cognitive control skills needed, provide coping strategies to reduce frustration associated with challenging aspects of the games, and use guided conversations to highlight metacognition.
214968090|NCT04969588|DIAGNOSTIC_TEST|Dual Energy X-ray Absorptiometry|Skeletal length and body composition are estimated.
214968091|NCT05905432|DRUG|Vaccine AnAPN1|AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM\_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.
214968092|NCT04499833|PROCEDURE|liver transplant|liver transplant
214968093|NCT01901016|BEHAVIORAL|Jacobson progressive muscular relaxation|PMR involves learning to identify the tension in specific muscle groups by tightening and relaxing each muscle group. It includes three different exercises: 1) contraction-relaxation of 12 large muscle groups in the arms, legs, and trunk; 2) identification and relaxation of tensions without the need for movement or contractions; and 3) contraction-relaxation of 12 small muscle groups in the neck, eyes, and mouth
214357170|NCT03468556|DRUG|Placebo Oral Tablet|Subjects will take 2 tablets once a day orally for 12 weeks
214968094|NCT01901016|BEHAVIORAL|Schultz's autogenic training|AT is a relaxation technique that is based on body attitude, reduction of exterior stimulation, inner concentration, and mental repetition of verbal formulas \[28\]. These formulas are organized into six exercises: 1) heaviness; 2) warmth; 3) calm and regular heart function; 4) self-regulation of respiration; 5) warmth in the upper abdominal area; and 6) agreeable cooling of the forehead.
214968095|NCT02357056|OTHER|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
214968096|NCT02357056|OTHER|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
214968097|NCT02357056|OTHER|Virtual Reality|daVinci Surgical Skills simulation
214968098|NCT04929977|DEVICE|Wearable device with smart mobile phone|The wearable device will act as a sensor designed to identify critical parameters such as Kangaroo Mother Care adherence and temperature of the infant 24/7 and of the mother-infant pairs during these sessions.
214968099|NCT03228940|DRUG|RVX000222|oral, BID
214968100|NCT04825756|BEHAVIORAL|Manualized equine assisted therapy|This equine assisted therapy (EAT), which is delivered in a group setting, combines therapeutic horseback riding with cognitive behavioral strategies for anxiety. Each 45 minute session is delivered in a group format with up to four children between 6 and 17 years of age. Each session follows the same structure: (1) weekly review; (2) groom and connect; (3) warm-up period; (4) session activity; (5) cool down; (6) parent/caregiver psychoeducation, during which the instructor facilitates psychoeducation; and (7) homework instruction.
214968101|NCT02666833|DEVICE|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
214968102|NCT03389880|PROCEDURE|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
214968103|NCT03389880|PROCEDURE|Patellar denervation|circumpatellar electrocautery with monopolar coagulation diathermy
214357171|NCT05245929|DEVICE|Distalization|Distalizing the posterior maxillary segment
214357172|NCT04185805|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
214357173|NCT04185805|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
214357174|NCT00352482|DRUG|Sildenafil (50 mg)|
214357175|NCT00746122|PROCEDURE|Open repair|Standard treatment of emergency open surgery
214357176|NCT00746122|PROCEDURE|EVAR|Emergency endovascular aneurysm repair
214357177|NCT02539810|DEVICE|Renal artery Angioplasty plus stenting.|renal artery stenting
214487322|NCT06826716|DIETARY_SUPPLEMENT|Fenugreek (Trigonella foenum graecum)|"Dose: 600 mg/day Regimen:~One capsule (300 mg) to be taken twice a day 30 minutes post breakfast and dinner Route of administration: Oral"
214357178|NCT02539810|DRUG|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is \< 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
214357179|NCT02678130|DEVICE|InterFuse T|Transforaminal Lumbar Interbody fusion (TLIF)
214357180|NCT02678130|DEVICE|Standard of Care TLIF (Stryker AVS Unilif)|Transforaminal Lumbar Interbody Fusion (TLIF)
214357181|NCT03386903|DEVICE|Ture acupuncture|"Patients receive true acupuncture treatment by Zhoushi coordinated points at the Bai-hui (DU20), Shen-ting (DU24), bilateral Ben-shen (BG13), Shen-men (HT7), San-yin-jiao (SP6) with Deqi sensation. The needles are retained for 20 minutes in every course, three times per week and last for 3 months."
214968104|NCT05314777|PROCEDURE|Low dose ESWT application|Patients trained for low dose ESWT application.
214968105|NCT05314777|PROCEDURE|High dose ESWT application|Patients trained for high dose ESWT application.
214968106|NCT05314777|PROCEDURE|Sham ESWT|Patients trained for sham ESWT.
214357182|NCT03386903|DEVICE|Sham acupuncture|Patients receive sham acupuncture stimulation by non-acupoint points (superficial insertion, 0.2 cun, No needle sensation (de qi) is elicited) at the bilateral mid-point between Shuaigu(GB8) and Touwei(ST8), Touwei(ST8) and Yangbai(GB14), front tibia, the junction of biceps and triceps.
214487323|NCT06826716|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|"Dose: 600 mg/day Regimen:~One capsule (300 mg) to be taken twice a day 30 minutes post breakfast and dinner Route of administration: Oral"
214487324|NCT06762782|DRUG|Postoperative adjuvant lenvatinib|Follow the instructions and take lenvatinib 8 mg (body weight ≤ 60Kg) or 12 mg (body weight ≥ 60Kg) orally once a day.
214968107|NCT05314777|PROCEDURE|Exercise Training|Patients trained for exercise training.
214968108|NCT01514383|DEVICE|Cyanoacrylate (Octylseal )|surgical adhesive
214968109|NCT02584478|DRUG|AL3818|Taken daily from Day 8 to Day 21 (14 days),administered orally combination with one background chemotherapy in 21-day cycles.
214968110|NCT02584478|DRUG|Paclitaxel|"Weekly single agent Paclitaxel will be administered on Day 1, 8, and 15 of each 21-day cycle. Suggested dose: 80 mg/m\^2 intravenously or local standard.~Paclitaxel may also be administered once weekly with a 1-week break every 3 weeks in lieu of every week"
214968111|NCT02584478|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Single agent Pegylated Liposomal Doxorubicin (PLD) administered every 4 weeks on the following cycle days corresponding with AL3818 cycles until maximum cumulative dose per local standard reached.~Suggested dose: 40 mg/m\^2 intravenously or local standard"
214968112|NCT02584478|DRUG|Topotecan|Daily Topotecan on Days 1-5 of each 21-day cycle Suggested dose: 1.25 mg/m2 intravenously or local standard OR Weekly Topotecan with a 1 week break every 3 weeks. Suggested dose: 4 mg/m2 intravenously or local standard
214968113|NCT02584478|DRUG|Topotecan|Weekly Topotecan with a 1 week break every 3 weeks Suggested dose: 4 mg/m2 intravenously or local standard
214968114|NCT02584478|DRUG|Carboplatin|AUC 5/6 on Day 1 of each 21-Day cycles
214968115|NCT02584478|DRUG|Paclitaxel|175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle
214968116|NCT02584478|DRUG|AL3818|Taken daily from Day 8 to Day 21 (14 days). Administered orally.
214968117|NCT01999439|PROCEDURE|Eosinophilic Esophagitis with Dysphagia|"An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.~Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete."
214968118|NCT01999439|PROCEDURE|Eosinophilic Esophagitis with Dysphagia|Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
214968119|NCT04560959|DEVICE|tACS|tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes
214968120|NCT05947162|BEHAVIORAL|extinction training (nicotine cues)|extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
214968121|NCT05947162|BEHAVIORAL|extinction training (neutral cues)|extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
214968122|NCT05947162|BEHAVIORAL|Time-restricted smoking cessation|Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
214968123|NCT05947162|BEHAVIORAL|Time-restricted fasting|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.
214968124|NCT05947162|BEHAVIORAL|Time-restricted fasting with food supplemnet|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.
214968125|NCT05276102|OTHER|Emollient cream|Commercially available emollient cream
214968126|NCT02638987|PROCEDURE|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
214968127|NCT01167400|BEHAVIORAL|Cybercycling|exercising on a videogame-enhanced interactive 3D stationary bicycle for 3 months, 3-5x/wk
214968128|NCT01167400|BEHAVIORAL|Traditional exercise|exercising on a traditional stationary bike for 3 months, 3-5x/wk
215082269|NCT02281786|DRUG|Placebo|Matching placebo to RO6926496
215082270|NCT02281786|DRUG|RO6926496|single, ascending dose, intravenous administration
215082271|NCT03524690|DIETARY_SUPPLEMENT|Energy Balance|Energy Balance Sufficient food provided to maintain energy balance.
214357183|NCT06145243|OTHER|Home based exercise|Patients will be given a visual brochure with pictures explaining the exercises. Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the home exercise group will be checked by phone every week.
214357184|NCT06145243|OTHER|Video-based resistive exercise|A video recording of the exercises will be taken and given to the patients as a video recording.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the video-based exercise group will be checked by phone every week.
214357185|NCT06145243|OTHER|Supervised resistive exercise|Patients will perform their exercises under the supervision of a physiotherapist.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.
214487325|NCT06762782|OTHER|Supportive care measures|Adjuvant treatments such as antiviral, TACE, HAIC, radiotherapy, and systemic antitumor therapy can be used
214487326|NCT06673290|DRUG|Sirolimus (RAPAMUNE)|Use of different doses of the same drug
214968129|NCT06661460|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|The intervention is a therapist-guided, internet-delivered cognitive behavioral therapy (ICBT) program primarily based on exposure therapy, involving the gradual confrontation of feared situations and/or stimuli. Treatment is accessed through a smartphone, tablet or laptop/desktop device. The 12-week intervention is available in two different versions depending on the participant's age: one for 8-12-year-olds and one for 13-17-year-olds. Each version consists of separate logins to 12 modules (chapters) for the child/adolescent and 12 modules for the caregivers. Both the child/adolescent and caregiver have individual contact with a trained therapist over the internet platform. The therapist provides feedback, responds to questions and sends reminders to complete the next module if required. Communication is carried out via text messages in the platform, via telephone (if deemed justified) and through a scheduled telephone or videoconference call approximately 4-5 weeks into treatment.
214968130|NCT01575756|BIOLOGICAL|Octafibrin|Octafibrin was supplied as a powder for reconstitution with water for injection.
214968131|NCT01575756|BIOLOGICAL|Haemocomplettan® P or RiaSTAPTM|Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
214968132|NCT02049983|DEVICE|Use of Levita Magnetics Grasper|
214968133|NCT05298683|DRUG|Isatuximab|Intravenous (IV) infusion. Dose regimen: Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion on Days 1, 8, 15, and 22 in Cycle 1 and Days 1 and 15 in subsequent cycles. In patients with ≥VGPR who will be randomized to receive isatuximab once monthly from Cycle 7, isatuximab will be given on day 1 of each cycle.
214968134|NCT05298683|DRUG|Pomalidomide|Route of administration: Oral (PO). Dose regimen: Pomalidomide will be given at 4 mg orally (PO) will be given on Days 1-21 of each cycle.
214968135|NCT05298683|DRUG|Dexamethasone|Route of administration: PO or IV. Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV will be given on days 1, 8, 15, and 22 in each cycle.
214968136|NCT05298683|DRUG|Acetaminophen (paracetamol)|Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion
214968137|NCT05298683|DRUG|Ranitidine (or equivalent)|Route of administration: IV. Dose regimen: Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
214968138|NCT05298683|DRUG|Diphenhydramine (or equivalent)|Route of administration: IV. Dose regimen: Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
215082272|NCT03524690|DIETARY_SUPPLEMENT|Negative Energy Balance|Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
214487327|NCT03900845|DEVICE|Dynamic Air Exchange - Rising Edge Design (DAE-RED)|The DAE-RED suspension system expels perspiration to the prosthesis exterior using a hybrid battery-powered pump and a body-weight activated pump. To use the DAE-RED, subjects will be fit with a modified patellar tendon-bearing socket that fits over a custom liner and sock. Up to four air intake ports are located proximally on the liner, approximately 25 mm superior to the socket brim. These ports incorporate a microvalve that allows air to flow into the liner-skin interstitial space while still maintaining a vacuum suspension. Distally, the pin lock has a 3-mm hole along its longitudinal axis that allows perspiration to be expelled into a distal reservoir. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot with Unity pump and foot cover.
214502706|NCT00676091|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
214502707|NCT00676091|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
214502708|NCT03358433|OTHER|Exercise|
214968139|NCT00959283|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214968140|NCT00959283|OTHER|Pharmacological Study|Correlative studies
215082273|NCT05371080|BIOLOGICAL|HZ/su vaccine|No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)
214357186|NCT05074628|DRUG|Nitrofurantoin capsules|methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.
214357187|NCT03530930|DRUG|Comarum Palustre|Comarum Palustre tablets 500 mg BID, 1 month
214357188|NCT03393000|DRUG|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
214502709|NCT03160521|DRUG|Risperidone ISM 75 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
214502710|NCT03160521|DRUG|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
214968141|NCT05701254|PROCEDURE|Transilial bone biopsy|The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation. From one skin incision located \~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.
214968142|NCT06598137|PROCEDURE|Ex vivo confocal laser microscopy|Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations.
214968143|NCT06591793|BIOLOGICAL|AAVB-081|Single subretinal administration
214968144|NCT06612138|OTHER|pilates exercises|the patients will receive pilates exercises in the form of breathing exercises, chest lift, bridging, mermaid, swan, quadruped exercises
214968145|NCT06612138|OTHER|yoga exercises|"the patients will receive yoga in the form of Bhastrikā: rapid and powerful inhalations and exhalations by means of the force of the diaphragm, letting the air sound when exhaling, Nāḏī Śoḏhana: from Sanskrit, nadi means \&#39;to channel\&#39; and shodhana means \&#39;purify, cleanse\&#39;, o Hand position Mrigi mudra: It consists of flexing the index and ring fingers of the hand, o Breathing: Gently close the right nostril with the thumb, inhale fingers and exhale slowly through the right. Keeping your right nostril open, inhale, close it, and slowly open and exhale through the left. This is a cycle. Repeat 3-5 times and then release the hand mudra and return to normal breathing."
214357189|NCT03393000|OTHER|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
214968146|NCT06612138|OTHER|tai chi exercises|the patients will receive tai chi in the form of Commencing form, Repulse Monkey,Grasp Peacock's Tail,Move Hands like Moving Clouds (left side only), Fair Lady Works at Shuttles, Golden Cock Stands on One Leg (left and right),Brush Knees and Twist Steps, Closing form.
214968147|NCT06612138|OTHER|tradional physical therapy|Patients will receive traditional physiotherapy breathing, massage and relaxation exercises
214968148|NCT06404359|OTHER|Exercise|"There will be 2 weekly sessions of 50 minutes, always guided by a physiotherapist, with the following distribution:~1.- Warm-up: 15 minutes of global exercises of strength and resistance, focusing on the areas that are going to be worked as a priority in that session.~Strength training: 6 to 8 strength exercises of large muscle groups. The approximate duration will be 25 minutes.~3.- Cool down / cool down: Combination of breathing exercises and stretching, 10 minutes.~Monitoring with activity bracelets."
214968149|NCT06404359|OTHER|Physical activity recommendations|They will be provided with a physical activity plan to be followed on a weekly basis.
214968150|NCT00610779|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
214968151|NCT00610779|DIETARY_SUPPLEMENT|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
214968152|NCT06613373|DRUG|Dalpiciclib|Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.
214968153|NCT06613191|DRUG|Aspirin|Participant will be on aspirin alone or P2Y12 inhibitor alone
214968154|NCT06613191|DRUG|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|Participant will be taking either P2Y12 inhibitor at time of colonoscopy
214968155|NCT06612450|DEVICE|turbinate surgery|Turbinoplasty to decrease the turbinate size in cases with turbinate hypertrophy with mainly soft tissue component without sacrificing the mucosal function
214968156|NCT04495751|DIETARY_SUPPLEMENT|Muscadine grape extract|Four pills twice daily
214968157|NCT04495751|DRUG|Placebo|Four pills twice daily.
214968158|NCT04495751|OTHER|Quality of Life Assessment|Ancillary studies
214357190|NCT01773070|DRUG|ABT-450/ritonavir|ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.
214968159|NCT04495751|OTHER|Questionnaires|Ancillary studies
214968160|NCT04495751|OTHER|Participant Feedback|Ancillary studies
214968161|NCT03328442|PROCEDURE|VISTA Technique|VISTA with PRF membrane includes Treatment of recession class I and II using autologous PRF membrane
214968162|NCT03328442|PROCEDURE|modified coronally advanced flap|modified coronally advanced flap with PRF membrane for Treatment of recession class I and II
214968163|NCT00691652|BIOLOGICAL|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
214968164|NCT00691652|DRUG|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
215082274|NCT04744389|DEVICE|Hypothermic Machine Perfusion|The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
214357191|NCT01773070|DRUG|ABT-333|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
214357192|NCT01773070|DRUG|ABT-267|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
214357193|NCT02063334|DIETARY_SUPPLEMENT|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
214968165|NCT00691652|GENETIC|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
214357194|NCT02063334|DIETARY_SUPPLEMENT|Placebo|
214968166|NCT00691652|GENETIC|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
214968167|NCT00691652|GENETIC|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals \<\< 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
214968168|NCT00691652|GENETIC|polymerase chain reaction|
214968169|NCT00691652|OTHER|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
214968170|NCT00691652|OTHER|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
214968171|NCT05280613|BEHAVIORAL|Family Check-Up|See arm/group description
214968172|NCT05280613|BEHAVIORAL|Treatment as Usual|See arm/group description
214968173|NCT04817267|DEVICE|reSET-O app|The reSET-O app, a prescription digital therapeutic, provides cognitive behavioral therapy for opioid use disorder. The app provides psychoeducation related to opioid use, coping skills, and skills to avoid relapse.
214968174|NCT06866275|DRUG|KZ101|For active treatment with KZ101, a loading dose of 454 mg/m2 (salt-free) will be followed by a treatment dose of 363 mg/m2 (salt-free).
214968175|NCT06866275|DRUG|Placebo|Dosing in the placebo group will consist of a volume of normal saline equivalent to that given during the active treatment period for each participant.
214968176|NCT05182411|OTHER|assessment|Turkish version of Leg Activity Measure Rivearmead Mobility Index Nottingham Health Profile Functional Independence Measures
214968177|NCT06624787|DEVICE|Rapid Diagnostic Test|The Liverpool School of Tropical Medicine (LSTM) in collaboration with Global Access Diagnostics (GADx) have achieved the development of the first RDT to detect CCHF viral antigens with a sensitivity and specificity that exceeds the minimum recommendation in the WHO target product profile (TPP)of \>80% and \>90% for sensitivity and specificity respectively for minimal performance in pre-clinical studies. The RDT is not only faster providing a test result within 20 minutes, but is also substantially cheaper than RT-PCR, and simpler to perform. A predicted price per test of around $5, whereas the current price of the RT-PCR test ranges from $1,000 to $1,200 for 96 reactions. The RDT does not require refrigeration or require specialist personnel to undertake, and the only additional apparatus needed is a stopwatch to monitor running time.
214357195|NCT02940366|DRUG|Pitavastatin 4 mg orally daily|Pitavastatin 4 mg orally daily for 24months
214968178|NCT06450457|DEVICE|Polar H10 heart rate monitor|Heart rate will be monitored using a Polar H10 heart rate monitor, with the goal of reaching moderate to high intensity for 30 minutes during the one hour long therapy intervention.
214968179|NCT06450457|DEVICE|Therastride Treadmill System|Participants will be asked to walk on the Therastride Treadmill for 30 minutes.This treadmill can unweight patients so that the task of walking becomes easier. The body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study.
214968180|NCT06450457|DEVICE|VECTOR Bioness|Participants will be asked to walk using the VECTOR Bioness on a track outside the gym with a harness attached to an overhead sling system. This system can unweight patients so that the task of walking becomes easier. The body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study. This system allows for overground walking on a small indoor track as opposed to walking on a treadmill.
214968181|NCT06450457|OTHER|Physical therapy|Physical therapy will be administered by a physical therapist and will include overground walking, treadmill walking, stairs, and resisted walking.
215082275|NCT04744389|DEVICE|Normothermic Machine Perfusion|Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
214357196|NCT02940366|DRUG|Atorvastatin 20 mg orally daily|Atorvastatin 20 mg orally daily for 24months
214357197|NCT06043739|DRUG|Filgotinib|Commercially developed film-coated tablet administered orally
214357198|NCT06043739|DRUG|Filgotinib|Film-coated mini-tablets administered orally
214357199|NCT00484003|DRUG|Pimecrolimus cream 1%|
214357200|NCT01737957|DEVICE|Low-fluence PRP with 532nm green LASER|To administer low-fluence PRP in a single session for PDR
214357201|NCT01737957|DEVICE|Full-Fluence PRP with 532nm LASER|To administer full-fluence PRP in two sessions for PDR
214502711|NCT03160521|DRUG|Placebo of Risperidone ISM|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
214357202|NCT01562210|DRUG|Olaparib|"Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.~The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID."
214968182|NCT04589884|OTHER|Hyperspectral Imaging|Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.
214968183|NCT06612671|PROCEDURE|tumor wide excision|patients received properative or post-operative radiotherapy
214968184|NCT02595385|DEVICE|Cell Salvage|Reinfusion of shed blood during the operation
214968185|NCT02595385|PROCEDURE|Retrograde Autologous Prime|Removal of fluid from the bypass circuit
214968186|NCT06361706|BEHAVIORAL|VR-Enhanced Psychoeducational Program for Chronic Pain|Participants undergo eight weekly sessions that include VR to learn pain physiology, mindfulness, and self-management techniques. Each session is 90 minutes, with 15-20 minutes of VR activities designed to complement the educational content. Activities simulate pain management exercises and mindfulness meditation. The program, led by pain management and VR specialists, aims to improve pain management skills, emotional well-being, and quality of life.
214968187|NCT05736328|PROCEDURE|Traction|Postoperative lower extremity traction
214968188|NCT05632263|DIAGNOSTIC_TEST|EHMRGscore|validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
214968189|NCT04921592|OTHER|upper extremity stimulation|transcutaneous stimulation of the upper extremities
214968190|NCT06888570|OTHER|To evaluate fat liver content in the cases/controls population.|The studied population includes participants aged 5-22 years old with/without T21 Down Syndrome.
214968191|NCT04748965|DIAGNOSTIC_TEST|Digital Subtraction Angiography|Compare optical coherence tomography lesion sizing and characteristics compared to traditional digital subtraction angiography
214968192|NCT02252107|DRUG|decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
214968193|NCT04602156|PROCEDURE|Trocar percutaneous cholecystostomy|Percutaneous cholecystostomy using the one-step Trocar technique under US guidance. An 8Fr Trocar catheter will be inserted percutaneously within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
214968194|NCT04602156|PROCEDURE|Seldinger percutaneous cholecystostomy|Percutaneous cholecystostomy using the Seldinger technique under US guidance. Following percutaneous puncture of the gallbladder with an 18G needle under real-time US guidance, an 8Fr catheter will be inserted percutaneously over the wire within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
214357203|NCT01562210|DRUG|Cisplatin|6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
214357204|NCT01562210|RADIATION|Radiation|A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.
214357205|NCT01471054|DRUG|Ozurdex|"Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (\>10% decrease in central macular thickness with maintenance \[change in BCVA of \<=1 line\] or improvement of visual acuity \[increase of BCVA of \>1 line\]) ii. Interval since last Ozurdex implant should be \> 4 and \< 12 months. iii. The study eye must show definite evidence of recurrence of macular edema."
214357206|NCT01471054|DRUG|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
214357207|NCT01843192|DEVICE|Endocutter|
214968195|NCT01213446|BIOLOGICAL|Biostate|"PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.~Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition."
214968196|NCT04940156|DEVICE|Confirm Rx (Implantable Cardiac Monitor)|Confirm Rx implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
214968197|NCT04940156|DEVICE|Reveal LINQ (Implantable Cardiac Monitor)|Reveal LINQ implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
214968198|NCT05027815|BIOLOGICAL|Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells|cryopreserved cellular therapy product in cryostor CS5, for IV infusion
214968199|NCT02521597|DEVICE|Cellscope|The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images
215082276|NCT04017923|DIAGNOSTIC_TEST|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
214968200|NCT02521597|DEVICE|Traditional otoscope|Use of a regular otoscope
214968201|NCT04784507|PROCEDURE|En Bloc Resection|En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)
214968202|NCT04784507|PROCEDURE|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
214968203|NCT01307878|DRUG|chemotherapy ± targeted therapy|Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
215082277|NCT03837665|BIOLOGICAL|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
215082278|NCT05108025|DRUG|Topical Powder|Topical Powder mixed with diluent
215082279|NCT05108025|DRUG|Placebo Topical Powder|Placebo Topical Powder mixed with diluent
214357208|NCT02672787|BEHAVIORAL|ED-based behavioral intervention|Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
214357209|NCT02672787|BEHAVIORAL|ED usual care plus education|Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
214357210|NCT02269566|DRUG|HollisterStier|0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
214357211|NCT02269566|DRUG|Normal saline|0.1 ml of normal saline 3 injections into an inguinal lymph node
214357212|NCT01559844|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
214357213|NCT01559844|DRUG|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214357214|NCT04325438|OTHER|Pharmaceutical Care|"Pharmaceutical care interventions are categorised into 2 aspects:~1. Pharmacists' expertise aspect: medications review, identification and solution for the drug-related problem, adverse events, and other medication-related clinical problems. Therapeutic drug monitoring (TDM) is performed for any dose adjustment to the Rifampicin.~2. Motivational behavioral intervention to improve medication adherence (i.e. medications information and counseling to study participants)."
214357215|NCT04917133|BEHAVIORAL|Adapted Physical Activity program|classic 4-week rehabilitation program (standard care) + 6 APA workshops per week with collective care
214968204|NCT00523692|DRUG|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
214968205|NCT00523692|DRUG|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
214968206|NCT03470454|DRUG|Linagliptin Oral Tablet|Linagliptin for blood glucose control
214968207|NCT03770026|DRUG|clomiphene citrate|Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.
214968208|NCT03770026|DRUG|Saline cervical flushing|Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
214487328|NCT03900845|DEVICE|Perforated elastomeric liner|The unique element of this perforated elastomeric liner are small perforations (\~0.3 mm diameter), uniformly distributed on a 4 x 5 mm grid, but with no perforations on the distal umbrella, that allow perspiration to be exuded into the liner-socket interstitial space. To use the perforated elastomeric liner, subjects will be fit with a modified patellar tendon-bearing socket that fits over a sock and the perforated elastomeric liner with a pin lock. The sock, worn between the socket and the liner, is used to absorb perspiration that is transported through the perforations in the liner. When needed for residual limb volume control, additional socks will be donned and included in tare weighing. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot and cosmesis.
214968209|NCT03770026|BIOLOGICAL|Intrauterine Autologous platelet-rich plasma|Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.
214968210|NCT05758818|DRUG|Placebo|Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
214357216|NCT04917133|OTHER|Control|classic 4-week rehabilitation program (standard care)
214968211|NCT05758818|DRUG|Moxifloxacin (positive control)|Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2
214968212|NCT05758818|DRUG|Milademetan|"Participants will receive a single dose of Milademetan on Day 1 for part 1~Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2"
214968213|NCT04655326|BIOLOGICAL|Flore|personalized blend of GRAS approved probiotic strains, prebiotics, and botanicals
214357217|NCT00630110|DRUG|docetaxel|docetaxel (75 mg/m2)
214357218|NCT00630110|DRUG|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
214357219|NCT05113628|DIAGNOSTIC_TEST|methylene blue identification|"After ligation of the middle thyroid vein and the upper pole of the thyroid, the thyroid lobe was retracted medially and diluted methylene blue (0.5 ml methylene blue 2% was diluted by 5ml normal saline) was sprayed over the lower thyroid pole and the perilobar area. This area contains structures including recurrent laryngeal nerve, parathyroid glands, and inferior thyroid vessels which were observed After spraying.~The vocal cord mobility was assessed intraoperatively by the anesthesiologist at time of extubation. The serum calcium was measured on the 2nd postoperative day. There was no routine use of postoperative calcium supplementation. Hypocalcemia was defined when the serum calcium level was less than 8 mg/dl."
214357220|NCT00951041|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
214357221|NCT00951041|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
214357222|NCT01514448|DRUG|Everolimus (RAD001)|Everolimus was used as commercially available formulated tablets of 10 mg strength
214357223|NCT02881723|PROCEDURE|Surgery|
214968214|NCT02905045|DRUG|Ketoprofen|
214968215|NCT02905045|DRUG|placebo|
214968216|NCT04019145|DRUG|EverX Posterior|fiber reinforced bulk fill resin composite
214968217|NCT04019145|DRUG|Resins, Composite|incremental packing of Nanohybrid Resin composite
214357224|NCT02881723|RADIATION|Radio- chemotherapy|
214357225|NCT00107003|DRUG|lapatinib ditosylate|
214357226|NCT00107003|PROCEDURE|Adjuvant therapy|
214357227|NCT00107003|PROCEDURE|Conventional surgery|
214357228|NCT00107003|PROCEDURE|Neoadjuvant therapy|
214357229|NCT02314624|BEHAVIORAL|Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality|Evidence-based interventions for treating depression and concurrent problems
214357230|NCT02314624|BEHAVIORAL|Care-as-Usual Psychotherapy|Usual care psychotherapy for depression and concurrent problems
214357231|NCT00258258|DRUG|paricalcitol|
214357232|NCT00258258|DRUG|zoledronic acid|
215082280|NCT01636388|BIOLOGICAL|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
215082281|NCT02435680|DRUG|MCS110|taken by I.V
215082282|NCT02435680|DRUG|carboplatin|taken by I.V
215082283|NCT02435680|DRUG|gemcitabine|taken by I.V
215082284|NCT00648674|DEVICE|Apligraf|Applied at Day 0, possible re-application at Week 6
215082285|NCT06464744|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|Intermittent Theta burst stimulation will be delivered on the on the primary motor cortex using a figure-of-eight coil, supported by neuronavigation. The stimulation intensity will be set to 90% of the motor threshold
215082286|NCT06464744|PROCEDURE|Placebo stimulation using a placebo coil|The placebo coil looks identical to the active coil but it only delivers skin tingling and no active brain stimulation.
215082287|NCT00445848|BIOLOGICAL|bevacizumab|
214357233|NCT05668962|DRUG|Selpercatinib|Selpercatinib Oral, twice daily during initial treatment period (28 Days). A second course of selpercatinib if the participant is demonstrating clinical benefit to the initial course selpercatinib and deemed clinically appropriate by the treating investigator
214357234|NCT05668962|DRUG|Sodium Iodine I-131|I-131 NaI, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer
214357235|NCT05668962|DRUG|rhTSH|"RhTSH injection, dosage per protocol, timing per protocol during the initial treatment period per standard of care.~Participants may receive a second course of rhTSH if the participant is demonstrating clinical benefit to the initial course rhTSH and deemed clinically appropriate by the treating investigator."
214968218|NCT03677869|DEVICE|Intraocular gas (C3F8)|Intraocular gas (C3F8) injection
214357236|NCT05590780|OTHER|Clinical Attachment level|1-year
214968219|NCT01719159|DRUG|Rituximab|25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
214968220|NCT00330044|DRUG|Premetrexed (Alimta)|
214968221|NCT00330044|DRUG|Carboplatin|
214968222|NCT03877224|DRUG|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
214357237|NCT04945317|OTHER|ROSE (presence of cytotech) & liquid prep|Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
214968223|NCT03877224|OTHER|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
214968224|NCT05438966|OTHER|No intervention|No intervention
214968225|NCT02814617|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.68 g|Cordyceps sinensis mycelium culture extract 1.68 g
214968226|NCT02814617|DIETARY_SUPPLEMENT|Placebo|
214968227|NCT05483465|DRUG|Nicotinamide riboside|Oral NR, 1g/day per os for 8 weeks
214357238|NCT04945317|OTHER|NO-ROSE (absence of cytotech) & liquid prep|Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
214357239|NCT04945317|OTHER|ROSE (presence of cytotech) & tissue clot sample|Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
214968228|NCT05483465|DRUG|Placebo|Visually identical pill to NR, daily per os for 8 weeks
214968229|NCT00348465|PROCEDURE|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
214968230|NCT00673374|DEVICE|radio-opaque adhesive skin markers|The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
214968231|NCT03152266|OTHER|No intervention. Observational study|Follow up of the function of the hip after reduction of the impacted fragment which associated with acetabular fractures
214968232|NCT00816322|DIETARY_SUPPLEMENT|Omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
214968233|NCT00816322|DIETARY_SUPPLEMENT|Placebo|high oleic oil
214968234|NCT03285165|DRUG|0.2-0.7 mcg/kg/h dexmedetomedine infusion.|patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
215082288|NCT00445848|DRUG|erlotinib hydrochloride|
215082289|NCT02729610|DEVICE|double-lumen endotracheal tube (DLT group)|In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation
215082290|NCT02729610|DEVICE|endobronchial blocker (BB group)|In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
215082291|NCT00330928|DEVICE|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
215082292|NCT00330928|DEVICE|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
215082293|NCT03224871|DRUG|Intralesional IL-2|High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
215082294|NCT03224871|DRUG|Nivolumab|Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
215082295|NCT03224871|DRUG|Pembrolizumab|PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
214968235|NCT03285165|DRUG|10-70 mcg/kg/h propofol infusion.|Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.
214968236|NCT01494701|DRUG|nusinersen|Administered by intrathecal (IT) injection
214968237|NCT00496704|DRUG|capecitabine|
214968238|NCT00496704|DRUG|gemcitabine hydrochloride|
214968239|NCT00496704|DRUG|oxaliplatin|
214968240|NCT04019886|OTHER|Neurophysiological Facilitation of Respiration|Six neuro-facilitation techniques will be given to experimental group. Each technique will be given for 5 seconds hold with 5 repetitions and two sets.
214968241|NCT05167916|PROCEDURE|Outpatient check cytoscopy|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
214968242|NCT05167916|DIAGNOSTIC_TEST|Urine cytology|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
214968243|NCT02940236|OTHER|Ultrasound|Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
214968244|NCT04551235|OTHER|there are not any interventions in this study|there are not any interventions in this study
214968245|NCT03066037|PROCEDURE|regional-anaesthesiological infiltration|Patients with therapy refractory chronic pain are treated with local infiltration techniques using e.g. local anaesthetics, opioids or drug combinations. Targeted structures are e.g. Ganglion stellatum, Ganglion pterygopallatinum, Trigeminal nerve branches (V1-V3). Patients receive a context- sensitive number of blocks in a series of infiltrations depenting on their pain course.
214968246|NCT02278705|OTHER|Attention to BMI|Evidence (using electronic health record data) denoting provider attention to about high BMI.
214968247|NCT02278705|OTHER|Attention to high-BMI-related Medical Risk|Evidence (using electronic health record data) denoting provider attention to high-BMI-related medical risk, including from high blood pressure/hypertension, cholesterol/dyslipidemia, blood sugar/diabetes, liver enzymes/fatty liver, and low vitamin D/vitamin-D deficiency.
214968248|NCT02278705|OTHER|No attention to high BMI or high-BMI-related medical risk|Lack of evidence (using electronic health record data) denoting provider attention to high BMI or high-BMI-related medical risk.
214968249|NCT00933114|PROCEDURE|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
214968250|NCT01065298|BIOLOGICAL|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of \>40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
214968251|NCT03951545|PROCEDURE|First line total knee replacement for gonarthrosis .|Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).
215082296|NCT03224871|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
215082297|NCT02794987|DEVICE|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
215082298|NCT06394752|DEVICE|Visual Saline Infusion|Visual Saline Infusion (VSI) is a new intrauterine imaging procedure to identify uterine pathology. The VSI device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).
215082299|NCT06394752|DEVICE|Hydrosonography|Hydrosonography is an ultrasound based intrauterine imaging technique with sensitivity and specificity ranging from 90% to 100% for identifying uterine pathology. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus and using abdominal ultrasound to visualize the uterus.
214968252|NCT03099603|DRUG|HTD1801|A small molecular compound for the treatment of primary sclerosing cholangitis
214968253|NCT03836534|BEHAVIORAL|adherence to treatment of patients coming out of emergencies|Phone contact of patients within 48 hours of the consultation
214968254|NCT04420962|DIAGNOSTIC_TEST|Visual Acuity|Best corrected visual acuity utilizing the Snellen method
214357240|NCT04945317|OTHER|NO-ROSE (absence of cytotech) & tissue clot sample|Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
214357241|NCT01353352|OTHER|Clinical decision rule - clearing the c-spine|The goal of phase IV of the Canadian C-Spine Rule project is to evaluate the safety and potential impact of an active strategy to empower ED triage nurses to evaluate and clear the c-spine of very low-risk trauma patients.
214357242|NCT00380848|PROCEDURE|Hemodiafiltration|
214357243|NCT01620866|OTHER|Eye Movement Desensitization Reprocessing (EMDR)|EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
214357244|NCT03656601|DIAGNOSTIC_TEST|3D pelvic ultrasound|3D pelvic ultrasound by transperineal route
214357245|NCT05952180|DEVICE|Virtual reality and Cycloergometer|The session performed uses a standard cycloergometer, with the participant pedaling in a seated position with the lower limbs. A 43 inches TV screen is placed in front of the cycloergometer where the participant will watch a video of a walk through a natural environment on. The speed of the walk is linked to the pedaling speed so that the faster the participant pedals, the faster the video goes too. The session last 30 minutes in the participant's room.
214357246|NCT05952180|OTHER|Standard cycloergometer|the session uses usual cycloergometer with the participant pedaling in a seated position with the lower limbs. The session lats 30 minutes in the participant's room.
214357247|NCT03235167|DRUG|CpG DNA|CpG DNA concentrate
214357248|NCT03235167|PROCEDURE|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization (TACE) therapy for liver cancer
214357249|NCT03235167|DRUG|Placebo - Concentrate|CpG DNA vehicle
214357250|NCT06056375|BEHAVIORAL|Reclaiming Nature Intervention|The purpose of the community intervention is to prevent health disparities in Black, Latinx, Pilipinx, and Pacific Islander communities of San Francisco, California.
214968255|NCT05919485|PROCEDURE|tDCS|"0.06mA/cm2 from each electrode with total density of 0.054/cm2 for 20 minutes for 5 days a week, for 10 days and a total of 10 sessions in 14 days.~Brain area; DLPFC / LPC"
214968256|NCT03182790|BEHAVIORAL|Instant Messaging IM|Smokers can communicate with counsellors in real-time through instant messaging (social media). Our counsellors will trigger the conversation and invite the smokers to response after initial contact. Counsellors will keep contact with the smokers to offer help, positive encouragement, reflections and reminders about SC according to smokers' personal needs and to encourage them to seek SC services. Details of successfully booked SC appointment (e.g. SC services address, contact information, date, appointment number etc.) will be delivered to the smokers using IM. All smokers will receive a reminder-to-attend IM messages 1-3 days before the appointment date.
215082300|NCT05304143|OTHER|Virtual Immersive Reality Glasses|"The day of the examination, the patient will go to the MRI room and he will be fitted with virtual reality glasses compatible with the MRI equipment. The patient will visualize relaxing contents in open spaces with music and verbal instructions during all the procedure. The contents will be previously validated by the clinical psychologist of the center with experience in this regard.~During the test, the patient's heart rate will be monitored."
215082301|NCT05304143|OTHER|Conventional nurse support|Patients will be treated using the usual support technique to reduce anxiety in the Diagnostic Imaging service
215082302|NCT03028480|DRUG|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
214357251|NCT05719454|DEVICE|CNT testing|The effect of CNT on blood pressure will be obtained throughout the year long follow up period.
214357252|NCT01549431|DRUG|Panobinostat|"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~* Standard 3+3 design~* 3 out of 4 weeks"
214357253|NCT01549431|DRUG|Carfilzomib|"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~* Standard 3+3 design~* Days 1/2, 8/9 and 15/16 every 4 weeks"
215082303|NCT06980961|PROCEDURE|short-pulse ND: YAG 1064 laser|Nd: YAG 1064 nm short pulse laser (5 nanoseconds), 4 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Smart, a Q-Switch Laser produced by Medical San (Lajeado, RS, Brazil).
214357254|NCT01549431|DRUG|Dexamethasone|Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
214357255|NCT04040660|DRUG|NexoBrid|NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)
214357256|NCT06580691|PROCEDURE|Subcision plus Plasma gel injection Vs Subcision plus Cog PDO threads|"Plasma Gel: was injected into the scarred areas immediately after subcision. Thread Treatment: Cog PDO threads were inserted using a blunt-tipped cannula in a Z pattern within the scarred areas, filling the pockets created by subcision."
214968257|NCT03182790|BEHAVIORAL|Regular messages|Regular messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent to smokers after initial contact via social media.
214968258|NCT03182790|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
214487329|NCT03900845|DEVICE|As-prescribed prosthesis|The individual's as-prescribed suspension system is the prosthesis prescription that the patient and their clinical care team believes is the best prosthesis for their needs.
214357257|NCT06580262|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
214357258|NCT05193591|OTHER|Autoantibodies evaluation in lupus|"Biological analysis: anti-C1s, anti-HMGB1 and anti-C1q autoantibodies; C1s, HMGB1 and C1q proteins.~Purification of patients' autoantibodies (anti-C1s, anti-HMGB1and anti-C1q). Identification of the molecular targets recognized by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients' serum."
214357259|NCT02324218|OTHER|Data collection|Data extraction from CPRD database of UK.
214357260|NCT02507518|PROCEDURE|PET scan imaging|a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
214357261|NCT02489396|BEHAVIORAL|Nutrition facts automatically or not automatically displayed|"For two months nutrition information on the Rosie site will be displayed in a tab that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen healthiest, and fifteen least healthy items in six grocery categories; chips, cookies, cereal \& breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items."
214968259|NCT03182790|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
214968260|NCT03182790|BEHAVIORAL|Brief advice|Very brief, minimal and general smoking cessation advice
214968261|NCT03182790|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
214968262|NCT03182790|BEHAVIORAL|Placebo Messages|Placebo messages will be sent via smart phones (e.g. social media) to remind subjects to take follow-up calls before each follow-up time points.
214968263|NCT03182790|BEHAVIORAL|Warning Leaflet|The leaflet will include the information about the health risks of smoking.
214968264|NCT06936319|BEHAVIORAL|Best clinical practice plus CPM-biofeedback training|The CPM-biofeedback training consists of a baseline 2-minutes active standing and the following four different physical maneuver: leg crossing and muscle tensing, heel raises (10 tiptoeing per minute), squatting, unilateral handgrip (20 times per minute). All exercises will be performed under continuous heart rate and blood pressure monitoring to enable the study participants to gain feedbacks on the effect of the maneuvers on their own biosignals.
214968265|NCT06936319|OTHER|Best clinical practice|Recommendations about life-style and behavioural measures to mitigate POTS symptoms in daily life.
214968266|NCT06931977|DIETARY_SUPPLEMENT|Supplement system + copaiba softgels|"The supplement system consists of:~* dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets~* dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels~* dōTERRA PB Restore ProBiome Complex (PBR) capsules~Which will also be taken with:~• dōTERRA Copaiba Essential Oil (CEO) softgels~VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners.~EOM is a softgel containing fish oil and wild orange essential oil.~PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages.~CEO is a softgel containing Copaifera (copaiba) essential oil and extra virgin olive oil.~Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day."
214968267|NCT06931977|DIETARY_SUPPLEMENT|Supplement system + placebo softgels|"The supplement system consists of:~* dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets~* dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels~* dōTERRA PB Restore ProBiome Complex (PBR) capsules~Which will also be taken with:~• Olive oil placebo softgels~VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners.~EOM is a softgel containing fish oil and wild orange essential oil.~PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages.~The placebo is a softgel containing extra virgin olive oil.~Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day."
214968268|NCT00447902|DRUG|tipranavir|
214968269|NCT00447902|DRUG|ritonavir|
214968270|NCT02166359|DRUG|Extraneal (Icodextrin)|
214968271|NCT02166359|DRUG|Glucose solution|
214968272|NCT06948019|BIOLOGICAL|BFB-101 (AAV9-CBh-AP4B1)|The AAV9-CBh-AP4B1 biological drug product is an aqueous suspension of a gene transfer vector intended for CSF injection. It consists of replication deficient adeno-associated virus (AAV) vector with the AAV serotype 9 capsid enclosing a single stranded DNA with an expression cassette of AP4B1 driven by CBh promoter.
214968273|NCT06948032|DRUG|BLU-808|BLU-808 will be administered per schedule specified in the arm description.
214968274|NCT06948032|DRUG|Placebo|BLU-808 matching placebo will be administered per schedule specified in the arm description.
214968275|NCT06948032|DRUG|Midazolam|Midazolam will be administered per schedule specified in the arm description.
215082304|NCT06980961|PROCEDURE|ultra-short-pulse ND: YAG 1064 laser|Nd: YAG1064 nm ultra-short pulse laser (400 picoseconds), 2 to 10 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for 6 visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Premium, a picolaser produced by Medical San (Lajeado, RS, Brazil).
215082305|NCT06980961|DRUG|cold cream|The control vehicle is a cold cream, supplied by HERVA'S manipulation pharmacy. The composition of cold cream will be beeswax, acetyl palmitate, BHA, cetearyl alcohol, propylparaben, and water. This topical agent will be applied to patients daily throughout the treatment period. It is scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days.
215082306|NCT00723866|OTHER|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
215082307|NCT00723866|OTHER|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
215082308|NCT04839471|DRUG|BI-754091 plus afatinib|Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
214968276|NCT06948864|DRUG|Ferric Carboxymaltose (FCM)|Patients in the intervention group underwent surgery from 2020 to end-2022 and were managed according to the surgery prehabilitation protocol. Once the surgeon has included the patient on the SWL, they were evaluated and followed up by the prehabilitation nurse (no more than 72 hours in the case of cancer patients) together with the study internist. The protocol at this preoperative stage consists of a comprehensive biopsychosocial assessment and an analysis of lab and nutritional parameters, which are optimized using targeted treatment. One of the lab parameters analyzed was Hb. Study patients with Hb \< 13 g/dL received 500 mg, 1000 mg, 1500 mg or 2000 mg FCM, depending on their levels of Hb, ferritin, transferrin saturation index, and weight. The lab test was repeated immediately before surgery or 30 days after administration of FCM in order to determine whether Hb levels had improved with FCM therapy
214357262|NCT02489396|BEHAVIORAL|Nutrition facts in color|For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.
214357263|NCT02489396|BEHAVIORAL|Nutrition Facts Label in Larger Font|For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.
214393747|NCT03026569|OTHER|Orange juice (500 mL/d)|The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.
214393748|NCT01015261|PROCEDURE|Bone Marrow Transplantation|Allogenic Bone Marrow Transplantation
215082309|NCT01986309|DRUG|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
215082310|NCT01986309|DRUG|Normal saline|Sodium Chloride 0.9% infusion
215082311|NCT02677636|DRUG|MSRD-100|MSRD-100 is a topical gel.
215082312|NCT02677636|DRUG|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
215082313|NCT06069141|DRUG|Benzathine Penicillin G|Benzathine Penicillin G (2.4 MU intramuscularly once)
215082314|NCT06069141|DRUG|Doxycycline Capsule|doxycycline (100 mg orally twice daily for 7 days)
215082315|NCT03313284|PROCEDURE|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
215082316|NCT03313284|PROCEDURE|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
215082317|NCT03313284|PROCEDURE|Control|No intervention
215082318|NCT06585904|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.
214393749|NCT01015261|PROCEDURE|Chemotherapy|"1. Cyclophosphamide 1200 mg/m2 D15~2. Daunorubicin 45 mg/m2 D15-D18~3. Vincristine 1 mg/m2 D15, D22~4. Dexamethasone 24 mg/d D12-D28"
214393750|NCT04946305|OTHER|Lutathera|Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.
215082319|NCT06585904|OTHER|Exercise|The volunteer will perform moderate aerobic exercise for 10 consultative days on a cyclergometer.
215082320|NCT02337283|DRUG|BI 425809|Tablets
215082321|NCT02337283|DRUG|Placebo|Tablets
215082322|NCT06599983|OTHER|Educational program, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.|One day educational program, aiming at increase dental personnels attitude, knowledge and behaviour in regard to detect and report child abuse and neglect, and to treat patients with known and unknown history of child abuse and neglect.
215082323|NCT06605755|PROCEDURE|Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine|"The test vaccine in this study was Pentaxim®, a pentavalent vaccine produced by Sanofi Pasteur, France.This vaccine is a combination vaccine consisting of adsorbed acellular DTP and inactivated polio vaccine (DTaP-IPV) and Haemophilus influenzae type b conjugate vaccine (Hib).~1. Intervention group: 1 dose of experimental vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.~2. Control group: 1 dose of experimental vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age."
215082324|NCT03824275|DRUG|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
215082325|NCT05074888|DRUG|Prospekta|Oral administration.
215082326|NCT05074888|DRUG|Placebo|Oral administration.
215082327|NCT06604286|DRUG|In this group, patients received 8 mg IM dexamethasone injection into the masseter muscle after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the groups immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection in group 1 was made into the masseter muscle. injection; The margo anterior of the mandible was palpated and horizontally parallel to the occlusal level of the mandibular second molar tooth and 1 cm behind the margo anterior towards the mandibular ramus. Bone contact was not taken during the injection and the injection was made by taking negative aspiration.
215082328|NCT06604286|DRUG|8 mg IM dexamethasone injection into the pterygoid cavity after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the group immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection given to Group 2 was directed to the region between the margo anterior of the mandible and the raphe pterygomandibularis, 1 cm above the occlusal level of the mandibular 2nd molar tooth, and the direction of the syringe from the incisal top of the opposing mandibular canine tooth to this region, and then entering the pterygomandibular cavity.
215082329|NCT06592495|DRUG|Period 1|DWJ1589 or DWC202315
214357264|NCT02489396|BEHAVIORAL|Healthier Items First|For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
214357265|NCT05805592|BEHAVIORAL|Screen-to-Move-Program (STEP)|"It is planned as 6 sessions, 1 session per week for children and parents. The program will be introduced to children and parents under the call with Screen-to-Move-Program (STEP)."
214357266|NCT06109792|PROCEDURE|implant supported mandibular overdenture|In this crossover study, the patients received overdentures with two successive different pick-up techniques for the locator retentive caps; each technique was evaluated for patient satisfaction with blue and pink retentive inserts.
214357267|NCT02612987|BEHAVIORAL|Internet-based Cognitive Behaviour Therapy (iCBT)|
214357268|NCT00910923|DRUG|JNJ-38431055|
214357269|NCT04499573|DRUG|CD19/CD22 CAR-T|"The treatment plan will be based on stratification by the initial leukemia burden.~Patients with low disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days.~Patients will high disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days.~Based on interim analysis the following dosing approach will be implemented starting April 2021:~Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg"
214357270|NCT04274920|OTHER|Bioactive Glass|Bioactive glass was incorporated in resin composite and its adhesive
214357271|NCT04274920|OTHER|Light cured calcium hydroxide|Light cured calcium hydroxide
214393751|NCT03841344|DEVICE|MRI|Evaluation of the utility of candidate endpoints in PAH trials
214968277|NCT06950229|DRUG|Povidone-Iodine|Hundred (100) ml of 5% povidone iodine was poured into a sterilized bowl (galipot). Three pieces of gauze held with sponge holding forceps was dipped into the sterilized bowl containing 100mls of 5% povidone iodine and was allowed to be well soaked with 5% povidone iodine and thereafter used to swab the vulva in 360 degrees. one gram of ceftriaxone and 500mg of metronidazole was given prior to the procedure.
214968278|NCT06950229|DRUG|Normal Saline|Hundred (100) ml of Normal saline was poured into a sterilized bowl (galipot). Three pieces of gauze held with sponge holding forceps was dipped into the sterilized bowl containing 100mls of Normal Saline and was allowed to be well soaked with Normal saline and thereafter used to swab the vulva in 360 degrees. one gram of ceftriaxone and 500 mg of metronidazole was given prior to the procedure.
214968279|NCT06949683|BEHAVIORAL|Meal-Exercise|Breakfast intake before 22 minutes of brisk walking, followed by a lunch intake for another 75 minutes of observation period. The entire experiment lasted a total of 150 minutes.
214968280|NCT06949683|BEHAVIORAL|Exercise-Meal|22 minutes of brisk walking before breakfast intake, followed by 75 minutes of observational period. The entire experiment lasted a total of 150 minutes
214968281|NCT06956066|BIOLOGICAL|shotblocker|SHOTBLOCKER Shotblocker is a drug-free and non-invasive plastic device for all age groups that is placed during injection to press against the site of administration. It has standardized dimensions and is designed in a small, flat, horseshoe (U) shape with several blunt points on one surface in direct contact with the skin.
214968282|NCT06954935|OTHER|periorbital massage|An electronic eye massager (irest manufacturing company, China) will be applied. The massager has a vibration function and massages with a warm air bag.
214968283|NCT06956027|DIAGNOSTIC_TEST|Ultrasound assesment|Ultrasound image taken using MV-flow technique for measuring the distance skin-lesion and echogenicity measurement
214968284|NCT06956027|PROCEDURE|ROM measurement|Range Of Motion measurement of affected finger(s) where the ultrasound image will be taken from.
214968285|NCT06955390|DRUG|SHR-A2102+HRS-4642|A fixed dose was used for SHR-A2102,HRS-4642 can be dose adjusted.
214968286|NCT06954883|BEHAVIORAL|Augmented Reality Distraction|Participants in this group wore augmented reality (AR) goggles during local anesthesia administration and dental extraction. The AR system displayed interactive 3D animated videos (celestial bodies) to divert attention and reduce procedural pain and anxiety.
214968287|NCT06955559|DRUG|Magnesium sulfate|inhaled magnesium sulfate (MgSO4)
215082330|NCT06592495|DRUG|Period 2|DWJ1589 or DWC202315
215082331|NCT06592495|DRUG|Period 3|DWJ1589 or DWC202315
215082332|NCT06592495|DRUG|Period 4|DWJ1589 or DWC202315
215082333|NCT06605794|DEVICE|FreeFlow percutaneous atrial septal shunt|The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.
215082334|NCT06607367|DRUG|Ruxolitinib (JAKAVI®)|Initial starting dose will be 10mg BD
215082335|NCT06607367|DRUG|Eltrombopag (Revolade®)|Initial starting dose will be 50mg daily
214357272|NCT04731454|OTHER|Control Diet (CD)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. A sugar-sweetened juice drink was provided for consumption of one portion per day. Water, milk, coffee, tea and alcohol were consumed as usual.
214968288|NCT06955507|BEHAVIORAL|reflexology|Foot reflexology will be applied by the researcher Neziha BAYAZIT, who will receive training on this subject, in the quietest and most comfortable position possible. Foot reflexology will be applied by the researcher to the women in the experimental group. The researcher will receive training on foot reflexology before the study. In the clinic where the study will be conducted, the hours of foot reflexology application will be determined considering the analgesic treatment protocol applied. Accordingly, analgesic treatment is routinely applied to the women who will receive foot reflexology at the 4th hour according to hospital procedure. Foot reflexology will be applied by the researcher at least 1 hour before the analgesic treatment (3rd hour - 15th hour after birth). The same foot reflexology will be repeated 12 hours later at the 15th hour after the first foot reflexology is performed at the 3rd hour after birth. Each woman will be given an explanation before the application. Foot r
214968289|NCT06950255|DEVICE|Cane|"Individuals will receive a single-point cane, individually adjusted to maintain each individual's elbow at approximately 30 degrees of flexion. Participants will be instructed to use the device on dominant side or the side with less impairment. The training with the cane will be carried out by a trained physiotherapist. The training protocol will include gait training with the cane on different surfaces and speeds. At the beginning of each training session, individuals will have the opportunity to address any questions they may have about using a cane in their daily life context.~Individuals will be re-evaluated after the end of the training sessions. After revaluation, the canes will be left with participants who will be instructed as follows: Feel free to use the cane at any time as needed. Another diary will be provided for the participant to record the use of the device after the end of the intervention"
214968290|NCT06950255|OTHER|static stretching and health education|"The intervention for the control group will consist of 20 minutes of global static stretching and 20 minutes of guidance on general health care. The stretches will be performed in three sets of 30 seconds each, targeting different muscle groups. If a participant is unable to perform the self-stretches, the researchers responsible for implementing the intervention will provide assistance. The health education component will cover information on Parkinson's disease (PD) and fall prevention.~The intervention will be offered by the same physiotherapist responsible for training the experimental group. Individuals will be re-evaluated after the end of the training sessions. After revaluation, the participants will be instructed as follows: Feel free to continue stretching exercises and use the health information discussed as needed. Another diary will be provided for the participant to record the stretching exercises performed after the end of the intervention."
214968291|NCT06954896|DRUG|Bupivacain|The superior hypogastric plexus block (SHPB) was performed following uterine removal and closure of the vaginal cuff, but prior to trocar removal from the abdominal cavity. The promontory was identified under laparoscopic visualization. The posterior peritoneum overlying the promontory was gently grasped and elevated with an instrument to create a peritoneal tent. A needle was then inserted at the apex of the tent and advanced approximately 1 cm. At this point, a subperitoneal space was further expanded using a surgical instrument, and 30 ml of 0.25% bupivacaine was injected into the area
214968292|NCT06954896|DRUG|Dexketoprofen (KETAVEL 50 mg/2 ml)|In cases where the VAS score exceeded 3 in the postoperative period, it was deemed that the patient's analgesia was insufficient, prompting the intravenous administration of 50 mg of dexketoprofen sodium.
214968293|NCT06954896|DRUG|Intraperitoneal Bupivacaine spray|The peritoneal cavity and abdominal wall were treated with 30 milliliters of 0.25% bupivacaine, with a focus on areas involving the peritoneum in the lower abdominal region.
214968294|NCT06955767|OTHER|Blood will be drawn from 2 additional tubes of 5 ml each|Blood will be drawn from 2 additional tubes of 5 ml each
214968295|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，25mg|Usage and dosage: 25mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
215082336|NCT06607510|OTHER|Experimental HIIT|Subjects belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. This program is designed in a standardized warm-up: joint mobility exercises and neuromuscular activation (5 minutes). Main part os the training is design in treadmill walking exercise (28 minutes). Participants must complete four four-minute blocks at an intensity of 85-95% of peak heart rate.The initial starting speed is 5 km/h and adjust the intensity with incline increments of 2%. Between sets, a prescribed active rest period lasts three minutes, during which patients walk on the treadmill at an intensity of 60-70% of peak heart. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
215082337|NCT06607510|OTHER|Experimental HIFT|Subject belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. AMRAP will consist of a circuit of six global, functional exercises with external loads \[i) squat; ii) rowing; iii) dead weight; iv) chest press; v) step up; vi) farmer walk\]. Patients will perform 10 repetitions of each exercise and complete as many rounds as possible within the specified time. Between blocks, there will be a prescribed active rest period lasting three minutes, during which patients will walk on the treadmill at an intensity of 60-70% of peak heart rate. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
214357273|NCT04731454|OTHER|Healthy Nordic Diet (ND)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. Water, milk, coffee, tea and alcohol were consumed as usual.
214393752|NCT03317210|DRUG|iron sucrose (200 mg VENOFER®)|According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.
214357274|NCT05699330|DEVICE|Bilateral subgenual cingulate deep brain stimulation (SGC DBS)|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone. All patients will receive deep brain stimulation (DBS) targeting the subgenual cingulate (SGC) bilaterally. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
214357275|NCT00324870|DRUG|vorinostat|Given orally
214357276|NCT00324870|DRUG|bevacizumab|Given IV
214357277|NCT00725452|BIOLOGICAL|Infliximab|Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
214357278|NCT00620750|DRUG|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
214357279|NCT04710082|PROCEDURE|Photorefractive keratectomy (PRK)|Photorefractive keratectomy (PRK) is a surgical procedure used by ophthalmic surgeons to treat patients presented with refractive errors and involves corneal epithelial removal followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
214357280|NCT03817996|OTHER|Fluid challenge|250ml of saline in Responders (those who increased \>10% their cardiac output after a passive leg raising maneuver).
214357281|NCT04477187|DEVICE|Dermal Handpiece|Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
214357282|NCT02744222|BIOLOGICAL|BCD-054 180 mcg|180 mcg intramuscularly once every two weeks
214968296|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，50mg|Usage and dosage: 50mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
214968297|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，75mg|Usage and dosage: 75mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
214968298|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，100mg|Usage and dosage: 100mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
214968299|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，125mg|Usage and dosage: 125mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
214968300|NCT06955949|OTHER|Control Group|The control classes applied the drugs by doing home training with eccentric strengthening exercises with dumbbells (3 sets of 10 repetitions). They were asked to flex the wrist while the wrist was fully extended. Weights were given to strengthen the wrist extensor muscles with 0.5 kg in the first week, 1 kg in the second week and 1.5 kg in the third week. In addition, stretching exercises for the wrist extensor muscles (3 sets of 20 seconds) were performed and 20 seconds of rest were given between sets. After the exercises, we applied cold therapy for 15 minutes. All treatment types were treated by the same physiotherapist in accordance with the treatment protocols and treatment sessions were performed twice a week for 3 weeks. One session lasted between 35-45 minutes.
214968301|NCT06955949|OTHER|ESWT Group|Extracorporeal Shock Wave Therapy (ESWT) is palpated at the starting areas of the extensor carpi radialis brevis and longus muscles, at tender points, and placed at the bone-tendon junctions. This budget was set at 90 Hz, and the pulse rate was determined as 10 pulses:1500.
214968302|NCT06955949|OTHER|Mobilization movement group|Mobilization Technique (lateral glide) was recorded from the Mulligan method. Patients were placed in supine positions, height was recorded together and the application was done with a belt method. During this glide movement, the patient was asked to actively perform 3 sets of 10 repetitions of wrist extension. 15-20 seconds of rest was given between sets.
214968303|NCT06955949|OTHER|Combined MWM-ESWT|In addition to mobilization with movement and ESWT treatment, this group applied home training by doing eccentric exercises with dumbbells (3 sets of 10 repetitions). 15-20 seconds of rest was given between sets. In addition, stretching exercises (3 sets of 20 seconds) were performed to strengthen the wrist extensor muscles and 20 seconds of rest was given between sets. During the exercises, a position was given such that the elbow was in extension, the forearm was in pronation and the wrist was in ulnar deviation. We apply cold therapy for 15 minutes after the exercises.
214968304|NCT06955611|OTHER|Community based optometry with Virtual Review|Community based OCT imaging with optometrist and virtual review by ophthalmologist
214968305|NCT06955611|OTHER|Usual Care|Hospital eye services review conducted by an ophthalmologist
214968306|NCT06955000|DEVICE|traidmail|Patients in this group were instructed to sit on a stationary bicycle ergometer. The patients will be given explained the aerobic interval exercise training program and the intensity will be assessed using a modified Borg scale
214968307|NCT06955000|DEVICE|laser puncture therapy|This group's patients were all exposed to LLLT utilising Phyaction CL Phyaction, Bilzen, Belgium, which had the following specs: frequency 500 Hz, output 5-20 MW, wavelength 905 nm. For five minutes, a laser probe was applied to acupuncture sites
214968308|NCT06955533|DRUG|Double dose tamsulosin and solifenacin|Odd number
214968309|NCT06955533|DRUG|Single dose tamsulosin and solifenacin|Even number
214968310|NCT06955260|DRUG|Empagliflozin 10 mg|Participants will take 10 mg of empagliflozin once daily
214968311|NCT06955260|OTHER|Placebo|Participants will take 10 mg of placebo once daily
214968312|NCT06955182|OTHER|Dynamic hot spring hydrotherapy intervention|Under closed management, patients will receive 5 times a week, 20 minutes of routine rehabilitation and 20 minutes of hot spring water exercise each time: (1) 20 minutes of routine rehabilitation: including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); (2) 20 minute hot spring water balance walking function training
214357283|NCT02744222|BIOLOGICAL|Avonex®|30 mcg intramuscularly once a week
214357284|NCT02744222|BIOLOGICAL|BCD-054 240 mcg|240 mcg intramuscularly once every two weeks
214357285|NCT02744222|OTHER|Placebo|intramuscularly once a week (0,5 ml)
214487330|NCT06114069|PROCEDURE|implant supported maxillary fixed prosthesis|Maxillary fixed prosthesis according to all on four or all on six concept
214357286|NCT00002587|DRUG|paclitaxel|
214357287|NCT00002587|DRUG|topotecan hydrochloride|
214968313|NCT06955182|OTHER|Conventional rehabilitation intervention|Under closed management, patients will receive routine physical therapy for 40 minutes 5 times a week: 1) 20 minutes of routine rehabilitation, including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); 2) 20 minute land balance walking function training
214968314|NCT06402461|BEHAVIORAL|Mindfulness of the breath|A 10 minute, audio guided, mindfulness of the breath meditation of the sort used in mindfulness-based cognitive therapy
214968315|NCT06402461|BEHAVIORAL|Mindfulness of sounds|A 10 minute, audio guided, mindfulness of sounds meditation of the sort used in mindfulness-based cognitive therapy
214968316|NCT06402461|BEHAVIORAL|Audiobook control|Listening to a 10 minute extract from an audiobook
214968317|NCT04862260|DRUG|Cholesterol metabolism disruption|Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas
214357288|NCT03148470|DEVICE|Sham iTBS|Placebo stimulation for the iTBS group
214968318|NCT03082469|DEVICE|CytoSorb|Two consecutive 24h treatments with the CytoSorb-device
214968319|NCT01470703|DEVICE|ECMO (Quadrox®, Jostra®, Maquet®)|ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure \<25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level \<25 cm H2O and low pressure level ≥10 cm H2O
214968320|NCT01470703|OTHER|conventional care|Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 \<80% for \>6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
214968321|NCT00049725|DRUG|Daclizumab|
215082338|NCT06606912|OTHER|Skeletal muscle, subcutaneous fat and visceral fat area|CT-based measurement of skeletal muscle, subcutaneous fat and visceral fat areas at L1, L2, L3, L4 and L5 levels.
215082339|NCT06607887|DRUG|IV antibiotic|Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.
215082340|NCT06607887|DRUG|Oral antibiotic|Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
215082341|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 5|(Serving 1: 5 grams of creatine + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
215082342|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 3|(Serving 1: 3 grams of creatine + 5 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
215082343|NCT06606704|DIETARY_SUPPLEMENT|Creatine Intermittent 5|(Serving 1: 2.5 grams of creatine + 5.5 grams of placebo in the morning, Serving 2: 2.5 grams of creatine + 5.5 grams of placebo at least 6 hours after Serving 1).
215082344|NCT06606704|DIETARY_SUPPLEMENT|Placebo|(Serving: 8 grams of placebo in the morning; Servings 2: 8 grams of placebo at least 6 hours after Serving 1).
215082345|NCT06607562|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
215082346|NCT06607562|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
214357289|NCT03148470|DEVICE|Sham cTBS|Placebo stimulation for the cTBS group
214357290|NCT03148470|DEVICE|intermittent theta burst stimulation (iTBS)|Excitatory theta burst stimulation
214357291|NCT03148470|DEVICE|continuous theta burst stimulation (cTBS)|inhibitory theta burst stimulation
214357292|NCT02191696|DEVICE|IMED-4 recording|
214357293|NCT01402141|DIETARY_SUPPLEMENT|Chungkookjang|Chungkookjang(35g/say)for 12 weeks
214357294|NCT01402141|DIETARY_SUPPLEMENT|Placebo|Placebo(35g/day) for 12 weeks
214357295|NCT05506787|DRUG|Esketamine|Esketamine
214357296|NCT05506787|DRUG|Placebo|Placebo
214357297|NCT00713648|DRUG|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
214357298|NCT05047367|BEHAVIORAL|cross-sectional survey study|Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, Visual Analogue Scale and PainDETECT Questionnaire for pain, Pittsburgh Sleep Quality Scale and Epworth Sleepiness Scale for sleep quality
214357299|NCT06222515|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary record including fluid intake, urine amount, urgency and incontinence.
214357300|NCT03607929|PROCEDURE|optimal|Physiological Saline Solution
214357301|NCT03607929|PROCEDURE|variability|Other solutions
214357302|NCT05968001|DRUG|Obinutuzumab|obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
214357303|NCT00480103|DEVICE|in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil|
214357304|NCT06068855|DRUG|BOTOX|Intramuscular Injections
214357305|NCT06068855|DRUG|Placebo|Intramuscular Injections
214357306|NCT03603210|DEVICE|Drug coated balloon angioplasty|Drug coated balloons are semi compliant percutaneous coronary angioplasty balloons coated with a chemotherapeutic drug such as Paclitaxel used with an excipient which allows rapid absorption to vessel wall upon balloon expansion for 30-60s. This allows coronary angioplasty without any permanent or semi- permanent stent or scaffold provided there are no vessel threatening dissections or significant acute recoil.
214357307|NCT03212157|OTHER|Glucose infusion|Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.
214357308|NCT03212157|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.
214357309|NCT03212157|DIAGNOSTIC_TEST|FDG PET|FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
214357310|NCT00082173|DRUG|Moxifloxacin|400mg daily for 8 weeks
214968322|NCT05094375|DRUG|Vaginal Misoprostol 600 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~* Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
214968323|NCT05094375|DRUG|Vaginal Misoprostol 800 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
214968324|NCT00092924|DRUG|TRAIL-R1 mAb (TRM-1;HGS-ETR1)|
214968325|NCT04056949|DRUG|Paclitaxel/Albumin-Bound Paclitaxel|Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;
214968326|NCT04056949|DRUG|IBI308|IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
214968327|NCT04042584|PROCEDURE|Visio conference device evaluation (DVCM)|Standard neurological tele-evaluation (limited to 15minutes) remotely carried out by a first neurologist via a tablet (DVCM) and an operator. A second neurologist assist at the assessment without intervention next to the patient. Once the remote assessment is complet, the second neurologist ensure the continuation of standard patient care.
214968328|NCT00889629|DRUG|Doxercalciferol|Active group receives doxercalciferol (Hectorol) 1mcg
214968329|NCT00889629|DRUG|placebo|Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
214968330|NCT00889629|DRUG|25-OH Vitamin D3|All groups received cholecalciferol
214968331|NCT02772666|DEVICE|O-Glass|The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
214968332|NCT02772666|OTHER|Swinging Flashlight Test|The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
214968333|NCT01046864|DRUG|5-FU|IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
214968334|NCT01046864|DRUG|Leucovorin|IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
214968335|NCT01046864|DRUG|5-FU|IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
215082347|NCT06606418|OTHER|Acupuncture group|The patients in this group received acupuncture treatment 3 times a week for 4 weeks. Acupuncture points selection: bilateral Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), Shangqiu (SP5), Yin Bai (SP5), foot Qioyin (GB44), Li Dui (ST45). Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to skew 0.5\~0.8 inches at the back acupoint, 0.5\~0.8 inches at Shangqiu (SP5), 0.1 inches at Yin Bai (SP5), foot Qiaoyin (GB44) and Li Dui (ST45), and left the needle for 30 minutes to wait for qi.
214357311|NCT02771444|DEVICE|Tomo Assessment|A four-view tomosynthesis examination
214357312|NCT00644631|DRUG|sildenafil|sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
214357313|NCT00644631|DRUG|placebo|placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
214393753|NCT03317210|DRUG|recombinant human erythropoietin (10,000 U EPREX®)|According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.
214393754|NCT00165269|PROCEDURE|Mantle irradiation|Limited to above the diaphragm
214393755|NCT05931705|OTHER|questionnaire|questionnaire
214393756|NCT02263144|PROCEDURE|virtual chromo-endoscopy using FICE Fujifilm Technology|For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
214393757|NCT00018161|DRUG|Mecamylamine|
214393758|NCT00018161|DRUG|Nicotine Patch|
214393759|NCT00018161|BEHAVIORAL|Cigarette brand switching|
214487331|NCT03109873|RADIATION|External Beam Radiation Therapy|Undergo External Beam Radiation Therapy
214968336|NCT01046864|DRUG|Irinotecan|IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
214968337|NCT01046864|DRUG|Brivanib|Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
214968338|NCT01046864|DRUG|Brivanib|Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
214968339|NCT01046864|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
214968340|NCT03618901|OTHER|Rock Steady Boxing|Boxing programs as offered by the Rock Steady Boxing institution,
214968341|NCT03618901|OTHER|PD SAFEx|Progressive proprioception training.
214968342|NCT05006378|DIETARY_SUPPLEMENT|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
214968343|NCT05006378|DIETARY_SUPPLEMENT|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
214968344|NCT05006378|DIETARY_SUPPLEMENT|Placebo Capsule|"Placebo capsules consumed by subjects as described in Placebo Comparator study arms section."
214968345|NCT00687986|RADIATION|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
214968346|NCT00687986|PROCEDURE|primary surgery|an anatomical surgical resection with lymph node dissection
214968347|NCT00675987|DRUG|losartan|losartan 100 mg tablets 1 tab po QD
214968348|NCT00675987|DRUG|Placebo control|Placebo 1 po QD
214968349|NCT03714763|DRUG|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
214968350|NCT03714763|OTHER|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
214968351|NCT03885414|BEHAVIORAL|In-session Virtual Reality exposure therapy|A series of exposure exercises (speech exercises) in front of a virtual audience, focusing on promoting inhibitory learning, with audio-feedback.
214968352|NCT03885414|BEHAVIORAL|Internet-administered transition program|Four-module internet program with weekly therapist guidance, focusing on transitioning to in-vivo exposure in everyday settings.
214968353|NCT02359110|DRUG|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
214487332|NCT03109873|DRUG|Metformin Hydrochloride|Given orally
214487333|NCT03109873|OTHER|Placebo|Given orally
214487334|NCT06294678|PROCEDURE|Time of stem cell infusion|Randomization of patients according to the time of stem cell infusion
214502712|NCT05063045|BEHAVIORAL|smart-cloth assisted home nursing care|Older persons with dementia or hip fracture were asked to wear a smart vest, which contained a coin-size monitor in a hidden inner pocket. Sensors were installed in bedrooms and living areas to receive signals from the smart clothing. The home care nurses then gave feedback from the sensor signals to family caregivers.
214502713|NCT05481905|DRUG|ENX-101|Adjunctive treatment to current antiseizure medication
214502714|NCT02213146|DRUG|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
214502715|NCT02213146|DRUG|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
214502716|NCT02213146|DRUG|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
214502717|NCT02071043|DRUG|Capecitabine|Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3
214502718|NCT02071043|DRUG|Oxaliplatin|Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
214502719|NCT03608293|DIAGNOSTIC_TEST|Broncho Alveolar Lavages (BAL)|BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
214502720|NCT00533494|BEHAVIORAL|physician feedback (A)|Feedback information to physicians
214502721|NCT06264583|OTHER|HDV screening|1\. Analyze the rate of HDV-testing and evaluate the prevalence of HDV-infection by testing.
214968354|NCT02359110|OTHER|Placebo|Patient will receive placebo tab less than 1 hour before surgery
214968355|NCT01429662|BEHAVIORAL|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
214968356|NCT01429662|BEHAVIORAL|Lifestyle Education (LE)|Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
214968357|NCT02174107|RADIATION|External radiotherapy|The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1\*8 Gy; 5\*4 Gy and 10\*3 Gy
214968358|NCT02174107|PROCEDURE|Percutaneous vertebroplasty|
214968359|NCT04771013|BIOLOGICAL|Thymic peptides|250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.
214968360|NCT03941340|DRUG|[14]-AST2818|Volunteer will receive a single oral dose of 80 mg /100 u Ci \[14C\]-AST2818 as a solution on Day 1
214968361|NCT06520527|DIETARY_SUPPLEMENT|Andrographis paniculata|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
214357314|NCT04602130|OTHER|Control|"The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
214357315|NCT04602130|OTHER|Massage|"The researcher applied massage (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
214357316|NCT04602130|OTHER|Sponge Bathing|"The researcher applied sponge bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
214357317|NCT04602130|OTHER|Tub Bathing|"The researcher applied tub bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
214357318|NCT01733732|OTHER|SYSTANE® BALANCE Lubricant Eye Drops|
214357319|NCT01733732|OTHER|SYSTANE® Gel|
214968362|NCT06520527|BEHAVIORAL|Brisk Walking Exercise|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.
214968363|NCT06520527|OTHER|Combination|"Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.~Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days."
214357320|NCT05362890|DEVICE|DEVICE OPERATING UNDER THE CONTINOUS POSITIVE AIRWAY PRESSURE|The principle of operation is to prevent the closure and the narrowing of the structures of the upper respiratory tract by applying positive pressure. The device consists of a mask that protects the nose and/or mouth, a tube that connects the mask to the monitor and a monitor that blows air into the tube. A pressure in the range of 4 to 20 cm water is applied, depending on the individual needs of the patient to keep the airway open. The use is considered to be effective when the patient uses it continuously for at least 4 hours at bedtime. Today's modern devices have memory cards for storing data on the regularity and time of use of the device during the night and the efficiency of the device itself. For therapy to be considered effective, the number of apneas and hypopneas must be less than 5 per hour of sleep.
214968364|NCT01019161|DRUG|AZD1152|100mg Lyophile, 5mL Diluent IV infusion
214968365|NCT01019161|DRUG|C14 AZD1152|radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
214968366|NCT05909020|OTHER|No intervention.|No intervention.
214968367|NCT06129383|PROCEDURE|serratus anterior plane block and pectointercostal plane block in breast surgery|Serratus anterior plane block and pecto intercostal plane block will be performed as a single injection using 0.25% bupivacaine and with the same practitioner.
214968368|NCT05897749|OTHER|Brucea javanica oil emulsion injection|Drug: Brucea javanica oil emulsion injection Brucea javanica oil emulsion injection: intravenous drip, 30ml each time (add 250ml sterile physiological saline),once a day, 14 consecutive days as a cycle, at least 2 cycles completed. The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
214968369|NCT05897749|OTHER|The best supportive treatment|The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
214968370|NCT01403558|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
214968371|NCT02976610|DEVICE|Hemolysis Point-of-Care test|Hemolysis measurement of plasma using a point of care test to determine the hemolysis level in plasma
214968372|NCT06491355|DRUG|mfolfox6 and hlx04 regimen and Serplulimab|mfolfox6 and hlx04 regimen induction therapy followed by combined treatment with slulimumab in the experimental arm. In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
214968373|NCT06491355|DRUG|mfolfox6 and hlx04 regimen|In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
214968374|NCT01906242|OTHER|water|
214968375|NCT01906242|OTHER|sodium hypochlorite|
214968376|NCT01906242|OTHER|sodium bicarbonate|
214968377|NCT01906242|OTHER|chlorhexidine|
214968378|NCT00193414|DRUG|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
214968379|NCT00193414|DRUG|Gemcitabine|1500mg/m2, 30min IV
214968380|NCT05435469|OTHER|Questionnaires|Participants will be asked to respond to the demographic information sheet, Adolescent Self-Rating Life Events Check List, Coping Inventory For Stressful Situations, Social Skills Rating System, brief-symptom-inventory, and Wong and Law EI Scale.
214968381|NCT00563121|PROCEDURE|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
215082348|NCT06606418|OTHER|Sham acupuncture group|The patients in this group received sham acupuncture treatment 3 times a week for 4 weeks. Sham acupuncture points are selected at sham points close to the acupoints of the acupuncture group: 3 inches beside Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), 1 inches below Shangqiu (SP5), 0.1 inches behind the middle edge of the great toe, second toe and fourth toenail of the foot. Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to pierce the skin shallowly, and left the needle for 30 minutes.
214357321|NCT01578811|DRUG|Placebo|Dosage
214357322|NCT01578811|DRUG|SK-MS10|Dosage
214357323|NCT01578811|DRUG|SK-MS10|Dosage
214487335|NCT01761968|DRUG|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
214487336|NCT06046820|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
214357324|NCT00746590|DRUG|Prolarix (tretazicar co-administered with caricotamide)|Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
214357325|NCT00604526|RADIATION|High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds|"Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)\* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL~\*After 1 year, will follow up with doctor about every 6 months."
214357326|NCT05586568|DRUG|XZP-3621 tablet and itraconazole oral liquid (for Arm1)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.
214357327|NCT05586568|DRUG|XZP-3621 tablet and Rifampicin capsules (For Arm 2)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.
214357328|NCT05586568|DRUG|XZP-3621 tablet and esomeprazole tablet (For Arm3)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
214968382|NCT04561648|DRUG|Unfractionated Heparin|Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.
214968383|NCT01519817|BIOLOGICAL|GI-6301 (Yeast Brachyury Vaccine)|GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
214357329|NCT05283967|DIAGNOSTIC_TEST|urine colorimetric assay|Colorimetric assays will be performed for urine drug concentrations of rifampin, isoniazid and pyrazinamide from urine collected throughout one dosing interval. Assay results will experimental only and not used to change patient care.
214357330|NCT03222193|DEVICE|TRP|3 months of TRP tongue retraining
214357331|NCT01291498|DEVICE|High Intensity Focused Ultrasound|One or two HIFU sessions
214357332|NCT04342351|DRUG|sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs
214968384|NCT04228484|OTHER|Placebo|Placebo infusion
214968385|NCT04228484|OTHER|GIP receptor antagonization|GIP(3-30)NH2 infusion
214968386|NCT02881658|DIETARY_SUPPLEMENT|Plant sterols-enriched soya beverage provided by Vitasoy|the study product is a 2g plant sterols-enriched in 250ml soya beverage
214968387|NCT02881658|DIETARY_SUPPLEMENT|Soya beverage provided by Vitasoy|the placebo product is a 250 ml soya beverage
214968388|NCT01506856|DRUG|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
214968389|NCT01506856|DRUG|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
214968390|NCT05857722|BEHAVIORAL|Jóvenes Capibara|Jóvenes Capibara is a 10-session group intervention that was culturally adapted from the Youth Readiness Intervention, which was originally developed in Sierra Leone for conflict-affected youth. Jóvenes Capibara was adapted to the Colombian context using the ADAPT-ITT framework, which ensured that the intervention was relevant to the needs of Colombian and Venezuelan youth.
214968391|NCT00975377|PROCEDURE|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
214968392|NCT02999789|DEVICE|SmartInhaler with reminder function turned on|The SmartInhaler is a medication monitoring system that functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
214968393|NCT02999789|DEVICE|SmartInhaler|The SmartInhaler is a medication monitoring system manufactured by Adherium that also functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
214968394|NCT06077539|DRUG|Dexmedetomidine|a selective a-2 adrenoceptor agonist, has sedative, analgesic, and anxiolytic effects.
214968395|NCT06077539|DRUG|Ketamine|NMDA (N-methyl-D-aspartate) receptor antagonist
214968396|NCT06077539|DRUG|Magnesium|NMDA (N-methyl-D-aspartate) receptor antagonist
214968397|NCT06077539|OTHER|normal saline 0.9% NaCL|saline will be given as bolus over 10 min then will be infused as maintenance by the same rate of the other groups
214968398|NCT06225973|DRUG|TL-925|TL-925 is an eye drop.
214968399|NCT06225973|OTHER|Placebo|The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.
214357333|NCT04342351|DRUG|perindopril|Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur
214968400|NCT00191243|DRUG|Gemcitabine|"A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure"
214968401|NCT00191243|DRUG|docetaxel|"A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure"
214357334|NCT04342351|OTHER|Cardiopulmonary Exercise Test|All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.
214357335|NCT04342351|OTHER|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.
214357336|NCT01162681|DRUG|A-623|High dose given subcutaneously once a week for up to 52 weeks
214357337|NCT01162681|DRUG|A-623|Low dose given subcutaneously once a week for up to 52 weeks
214357338|NCT01162681|DRUG|A-623|High dose given subcutaneously once every 4 weeks for up to 52 weeks
214357339|NCT01162681|OTHER|Placebo Comparator|Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
214357340|NCT01738750|OTHER|Cost Information Included|
214357341|NCT02256215|DRUG|Vitamin D|
214357342|NCT05387824|DEVICE|Magnetic stimulation -Armchair type MS • NovaMag NT-60|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
214357343|NCT05387824|DEVICE|Electrical Stimulation- TTNS|TTNS were performed 2 days a week, for 30 min a day, for a total of 12 sessions for 6 weeks.
214968402|NCT06958692|DRUG|Dextromethorphan and Bupropion Sustained-Release Tablets|Oral dextromethorphan and bupropion sustained-release tablets, taken daily for 6 weeks.
214968403|NCT06958692|DRUG|Placebo|Oral placebo tablets, taken daily for 6 weeks.
214968404|NCT06959134|BEHAVIORAL|The intervention will be mainly focused on the lifestyle modification and medication adherence, and self monitoring at home|In the intervention arm, study participants will received health education mainly based on lifemodification changes which will include; eating healthy diet, adopting healthy physical exercise, smoking cessation , moderate alcohol consumption and stress amanagement), and will be taugh on medication adherence, but also on self monitoring of blood pressure for detecting the variation and react accordingly.
214968405|NCT04831034|DRUG|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
214968406|NCT01417468|BEHAVIORAL|CLSI, MI, CR|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
215082349|NCT06606457|BEHAVIORAL|Pain Acknowledgment Coping and Empowerment in CF (PACE CF)|The Pain Acknowledgment Coping and Empowerment in CF (PACE CF) program is a newly developed 3-session mind-body pain management intervention for adults with cystic fibrosis (CF), developed with CF community input. The sessions are delivered by the the CF care team psychologist. Each session will teach mind-body strategies to increase comfort and reduce the impact of pain on the participant\&#39;s life. These strategies include understanding pain in CF from a mind-body perspective, learning relaxation and mindfulness-based skills, identifying and practicing individualized cognitive and behavioral strategies that improve comfort and well-being, and discussing communication skills that empower people living with CF and pain. Participants will receive a workbook that will provide related education and resources and reinforce skill practice.
215082350|NCT06607159|OTHER|Implementation of healthy habits teaching protocol|Protocol for teaching healthy lifestyle habits, aimed at school-age children (initially between 1st and 4th grade of primary school), to be implemented transversally in schools. This protocol takes into account three levels of action: school, family and pupils. It includes materials in paper format and digital materials, that can be used both at school and at home.
215082351|NCT04926090|BEHAVIORAL|Emotional Support Plan - Clinician Guided (ESP-C)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-C is delivered by a clinician in 2 sessions.
215082352|NCT04926090|BEHAVIORAL|Emotional Support Plan - Self Guided (ESP-S)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-S is created by the participant on their own, with the support of self-guided materials.
215082353|NCT03078933|DEVICE|Standard of Care|Standard of Care arm which includes wound care, dressings and debridement.
215082354|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
215082355|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
215082356|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
215082357|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
214968407|NCT01417468|BEHAVIORAL|CLSI - Unknown|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
214357344|NCT05387824|BEHAVIORAL|Bladder Training|"Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.~BT, consisting of four stages, did not contain any PFMT programs in two groups."
214357345|NCT04741308|BEHAVIORAL|cognitive behavior therapy|The CBT intervention is a 8-times group-based intervention that meets 2-3 weeks.Each session will be performed during chemotherapy and will last for 60 min, including 45 min cognitive behavior therapy and 15 min relaxation training.Our CBT intervention is designed to be conducted in groups of 3 to 6 patients led by two group facilitators. Group leaders will: guide participants relaxation training, develop a supportive group environment, encourage emotional expression, assist participants develop a sense of self-confidence, identify maladaptive coping and encourage adaptive coping responses.
214357346|NCT03907319|DEVICE|SIS System|Software technology for visualization of anatomical structures in the brain
214357347|NCT00464815|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose
214357348|NCT00464815|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose
214357349|NCT04206189|DIETARY_SUPPLEMENT|carbohydrate group - carbohydrate (400ml)|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery according to the standard protocol.
214357350|NCT04139564|DEVICE|EaseVRx headset|EaseVRx is a virtual reality therapy intended to treat chronic pain
214357351|NCT04139564|DEVICE|Active control VR sham program|VR, 2d visual wildlife scenes similar to some EaseVRx content
215082358|NCT01155921|DRUG|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
214357352|NCT06102941|DEVICE|Cognitive Control Training (CT)|4 weeks of an at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes.
214357353|NCT05400343|PROCEDURE|Standard care (control group)|"Following 24 hours from admission to the ICU, the standard care will be continued according to conventional ICU protocols~The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment."
214968408|NCT00917826|DRUG|Arginine Butyrate|1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
214968409|NCT00917826|DRUG|Ganciclovir|5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)
214968410|NCT00917826|DRUG|Valganciclovir|900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
214968411|NCT02408848|OTHER|Observational|This is an observational study. There is no intervention.
214968412|NCT00994942|DRUG|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
214968413|NCT03600831|DRUG|Docetaxel plus cisplatin|cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks
214968414|NCT03600831|RADIATION|radiotherapy|radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)
214968415|NCT00197093|DRUG|SB773812|
215082359|NCT02279719|DRUG|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
215082360|NCT02279719|DRUG|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
215082361|NCT02279719|DRUG|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
215082362|NCT03099941|OTHER|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
215082363|NCT06605183|BEHAVIORAL|Community walking program using Nordic walking poles|This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to build up their step count to 10,000 steps per day. We do not anticipate that the weekly walk will get them to 10,000 steps but we will use that as a weekly event to drive behavioral change throughout the week.
215082364|NCT01012206|BEHAVIORAL|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
214357354|NCT05400343|PROCEDURE|US-guided ﬂuid management (active group)|Within 24 hours from admission to the ICU, IVC and lung sonography will be performed every other day and according to their measurements, the volume of fluid therapy will be adjusted.
214968416|NCT04102618|BIOLOGICAL|Pelareorep|4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
214968417|NCT04102618|DRUG|Letrozole|Oral dose of 2.5 mg/day starting on Day 3 for 13 days
214968418|NCT04102618|DRUG|Atezolizumab|1200 mg administered intravenously on Day 3
214968419|NCT04102618|DRUG|Trastuzumab|8mg/kg administered intravenously or 600mg subcutaneously on Day 3
214968420|NCT06034093|DEVICE|Real-time AI-assisted muscle ultrasound|RAIMUS software provides automatic segmentation and size measurement for the RFCSA
214968421|NCT05621447|DRUG|TAS-303, [14C]TAS-303|oral administration on day 1
214968422|NCT00904475|DRUG|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
215082365|NCT04333056|OTHER|Biometric measurement agreement|Patients scheduled for cataract surgery were measured with both ss-OCT devices. The following biometry parameters were compared: anterior keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and axial length (AL).
214968423|NCT00904475|DRUG|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
214968424|NCT00018317|BEHAVIORAL|low protein diet|
214968425|NCT00018317|BEHAVIORAL|resistance training|
214968426|NCT00018317|BEHAVIORAL|combination of diet control and exercise|
214393760|NCT01754779|DIETARY_SUPPLEMENT|Placebo|3 tablets twice daily of matching placebo during the placebo phase.
214393761|NCT01754779|DIETARY_SUPPLEMENT|Citric Acid|3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)
214393762|NCT01754779|DIETARY_SUPPLEMENT|Potassium Citrate|2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)
214393763|NCT04999358|BEHAVIORAL|Protein education|The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.
214393764|NCT04999358|BEHAVIORAL|Standard education|Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.
214393765|NCT03954158|DRUG|Crisaborole ointment 2%|BID regimen
215082366|NCT02630368|DRUG|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
215082367|NCT02630368|DRUG|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
214357355|NCT05400343|OTHER|Standard ICU Care|All patients will receive the usual care for 24 hours according to ICU policies. The main target is to maintain an adequate intravascular volume and good urine output. The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment. Lung sounds, heart rate, blood pressure, temperature, urine output, Lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values
215082368|NCT02630368|DRUG|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
215082369|NCT02630368|DRUG|Avelumab and JX-594 and Cyclophosphamide|"Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections ."
214968427|NCT06958497|DEVICE|Sphinkeeper™|The procedure was performed under spinal anesthesia, with the patients in lithotomy position. Ten 2-mm perianal skin incisions were made 1-2 cm from the anal margin (i.e., 0.5-1 cm from the intersphinteral sulcus), equidistant one each other, around the entire anal circumference, to allow implantation of 10 prostheses using a specifically designed delivery system (THD Sphinkeeeper Delivery System, THD Sp, Correggio, Italy). The introducer was placed through each skin incision in the intersphincteric space where the prostheses were delivered at a level below the puborectalis muscle. All of the steps were verified by palpation and direct vision using the Eisenhammer anal speculum. Patients were discharged on the same day and recommended to avoid any trauma or sexual practice during the first 48 hours after implantation. A 5-day course of antibiotics was also prescribed.
214968428|NCT05369143|OTHER|Chiropractic care|The mechanical properties of chiropractic adjustment have been investigated; and although the actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent68 and the duration of the thrust is always less than 200 milliseconds.
214968429|NCT05369143|OTHER|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
214968430|NCT05083663|DRUG|Hyaluronidase|using hyaluronidase as an additive to bupivacaine
214357356|NCT00249106|BIOLOGICAL|ADVAX|
214968431|NCT01344239|PROCEDURE|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
215082370|NCT03541187|BIOLOGICAL|German cockroach allergenic extract|Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
214357357|NCT05735873|OTHER|Low-energy diet|Twenty-one pre-made, low-energy meals delivered weekly to the subject for 12 weeks.
214357358|NCT01288482|DEVICE|AeroEclipse II breath-actuated nebulizer|The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
214357359|NCT01288482|DEVICE|English-Wright continuous-mode nebulizer|The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
214968432|NCT05116553|BEHAVIORAL|SDT|Standard 2 SDT (Self Determination Theory) psychological interviews.
214357360|NCT04104581|OTHER|Control Refined Grain Diet|Subjects will be fed the average American diet except it will be free of whole grains
214968433|NCT05116553|DEVICE|APP + CA|An APP with a CA (Conversational Agent).
214357361|NCT04104581|OTHER|Low Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain oats
215082371|NCT03541187|BIOLOGICAL|Placebo for German cockroach allergenic extract|Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
215082372|NCT06239441|DRUG|IL5/IL5R Antagonists|Treatment with IL5/IL5R antagonists for one year
215082373|NCT05173428|BEHAVIORAL|Smoking Cessation Program Based on Transtheoretic Model|Conducting motivational interviews based on the transtheoretic model according to the stages of change that individuals are in.
215082374|NCT01671501|BEHAVIORAL|Motivational Interviewing|
214357362|NCT04104581|OTHER|High Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain oats
214357363|NCT04104581|OTHER|Low Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain wheat
214393766|NCT03954158|DRUG|Vehicle|BID regimen
214393767|NCT03954158|DRUG|Crisaborole ointment 2%|QD regimen
214393768|NCT03954158|DRUG|Vehicle|QD regimen
214357364|NCT04104581|OTHER|High Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain wheat
214357365|NCT02593994|DEVICE|Onyx Drug Eluting Stent group|
214357366|NCT03709368|OTHER|Hardware|Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
214357367|NCT03709368|BEHAVIORAL|CLTS|CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch \& smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
214357368|NCT03709368|BEHAVIORAL|PHAST|PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
214357369|NCT03709368|BEHAVIORAL|RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
214357370|NCT03709368|BEHAVIORAL|mini-RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
214357371|NCT03709368|OTHER|Placebo poster|One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
214357372|NCT05832450|OTHER|Red cell concentrate transfusion|Perioperative data of patient undergoing elective brain tumor resection with requirements of red cell concentrate transfusion.
214393769|NCT00424853|DRUG|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
214968434|NCT02196298|DEVICE|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
214968435|NCT02196298|OTHER|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
214968436|NCT02070510|DRUG|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
214968437|NCT02070510|DRUG|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
214968438|NCT02070510|DRUG|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
214968439|NCT02070510|DRUG|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
214968440|NCT02589080|BEHAVIORAL|Non-invasive sensory feedback|"A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback."
215082375|NCT01671501|BEHAVIORAL|Email Feedback|
215082376|NCT01671501|OTHER|Usual Care|
215082377|NCT07040540|PROCEDURE|Intradermal methylene blue injection|All eligible patients will receive an intradermal injection of 5 mL of 1% methylene blue into the quadrant of the breast where the tumor is located or into the subareolar region prior to skin incision, as part of the standard sentinel lymph node mapping procedure during elective breast surgery. After injection, the site will be massaged for 10 minutes to facilitate lymphatic uptake. The procedure will be performed under general anesthesia, and all other aspects of perioperative care will follow standard clinical practice.
215082378|NCT00383643|DRUG|zolpidem tartrate|
215082379|NCT00383643|DRUG|sodium oxybate|
215082380|NCT00383643|DRUG|Matching Placebos|
215082381|NCT01369680|DRUG|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
214357373|NCT06485817|DRUG|Oxycodone|"3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
214357374|NCT06485817|DRUG|Placebo|"Pure saline was administered as the placebo condition.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
214968441|NCT02953496|DRUG|vonapanitase|Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
214968442|NCT05532384|BEHAVIORAL|Early resumption of oral intake|as above
214968443|NCT05532384|BEHAVIORAL|Late resumption of oral intake|as above
215082382|NCT03142399|DIETARY_SUPPLEMENT|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
215082383|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with carbohydrate counting|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the total grams of carbohydrates counted. This is the same as commercial hybrid closed-loop insulin therapy (standard treatment).
215082384|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with meal size estimation|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the qualitative amount of carbohydrates estimated (e.g., low-carb meal).
215082385|NCT06021158|COMBINATION_PRODUCT|Fully automated Lyumjev delivery system with meal detection|In this system, the patient does not initiate a Lyumjev insulin bolus at mealtime. An algorithm is used to detect a meal and administer a subsequent bolus, rather than requiring a carbohydrate count.
215082386|NCT02762630|DEVICE|Carestream Health Inc. weight bearing cone beam CT scanner|
215082387|NCT00429117|BEHAVIORAL|Survey|Internet survey lasting 30 to 40 minutes.
215082388|NCT00756184|DEVICE|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
215082389|NCT00756184|DEVICE|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
215082390|NCT01989780|DRUG|Paclitaxel|
215082391|NCT01989780|DRUG|Bevacizumab|
215082392|NCT01989780|DRUG|Letrozole|
215082393|NCT01989780|DRUG|Anastrozole|
215082394|NCT01989780|DRUG|Exemestane|
215082395|NCT01989780|DRUG|Fulvestrant|
215082396|NCT01989780|DRUG|Goserelin|
215082397|NCT01989780|DRUG|leuprorelin|
214968444|NCT00093483|BIOLOGICAL|filgrastim|Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.
215082398|NCT05254561|BIOLOGICAL|Intralesional antigen immunotherapy|Randomized double-blinded comparative effectiveness and safety clinical trial
215082399|NCT00380991|DRUG|lactoserum|
215082400|NCT00728247|PROCEDURE|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
215082401|NCT00336011|DEVICE|Magnetic resonance imaging|
215082402|NCT01641146|BEHAVIORAL|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
215082403|NCT01641146|BEHAVIORAL|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
215082404|NCT01519050|BEHAVIORAL|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
214968445|NCT00093483|DRUG|arsenic trioxide|IV over 1 hour on day 1
214968446|NCT00093483|DRUG|cytarabine|IV over 1 hour every 12 hours on days 1-6
214968447|NCT00093483|DRUG|idarubicin|IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).
214968448|NCT02958787|RADIATION|Radiation Therapy|Radiation Therapy Using MRI Based Treatment Planning
214968449|NCT01033630|DRUG|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
214357375|NCT06485817|BEHAVIORAL|Stress State Induction|"ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).~The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting."
214357376|NCT06485817|BEHAVIORAL|Control State Induction|Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.
214357377|NCT01164995|DRUG|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
214357378|NCT03549910|PROCEDURE|APRVplus protocol|Physiology-driven APRVplus protocol
214357379|NCT03549910|PROCEDURE|Low tidal volume ventilation|Low tidal volume lung protective ventilation
214357380|NCT04289818|OTHER|Health Coaching|Health Coaching as face to face with a coach
214968450|NCT01033630|DRUG|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
214968451|NCT01033630|DRUG|Placebo|Image-matched placebo, made with starch.
214968452|NCT03560011|DRUG|immunoglobulin IV|5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
214968453|NCT06010797|DEVICE|Showing Pre-treatment photographs of the patient|Extra-oral and intra-oral dental photographs of patients were taken before starting Orthodontic treatment. Experimental group were shown their photographs while control group were not shown their photographs.
214968454|NCT00099164|DRUG|17 alpha-hydroxyprogesterone caproate (17P)|Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.
214968455|NCT02946892|DRUG|Carvedilol|Carvedilol will be given for 12 weeks and then an exercise test will be performed
214968456|NCT02946892|DRUG|Placebo|Placebo will be given for 12 weeks and then an exercise test will be performed
214968457|NCT03795337|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
214968458|NCT00061841|BEHAVIORAL|exercise|
214968459|NCT00944346|DRUG|Metformin HCl|
214968460|NCT02381678|DEVICE|Perimount 2900/6900 Heart Valve|This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.
214968461|NCT00945412|DEVICE|Micropolysaccharide Hemospheres (Arista)|"MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.~No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect."
214357381|NCT03903133|DRUG|Vitamin E|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
214357382|NCT00990158|DRUG|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
214357383|NCT00990158|DRUG|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
214357384|NCT03411655|DEVICE|Ambu Aura GainTM|Time and success rate
214357385|NCT03411655|DEVICE|Ambu® Aura-ITM|Time and success rate
214357386|NCT00002153|DRUG|A-007|
214357387|NCT06451172|DRUG|ASO|Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.
214968462|NCT00945412|DEVICE|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
214968463|NCT03175926|DEVICE|placebo Diskus®|device will be given daily for one week, two puffs per day
214357388|NCT02541708|DRUG|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
214393770|NCT00424853|DRUG|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
214393771|NCT04412564|DRUG|TQ-B3101|TQ-B3101 is a ALK inhibitor.
214968464|NCT03175926|DEVICE|placebo Ellipta®|device will be given daily for one week, one puff per day
214968465|NCT03175926|DEVICE|Pulmicort® Turbuhaler®|device will be given daily for one week, two puffs per day
214968466|NCT01050946|BIOLOGICAL|Haploidentical/cord transplant|"Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~1. Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~2. Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion"
214968467|NCT04978324|BIOLOGICAL|leukocyte platelet rich fibrin (L-PRF)|Participants blood will be spun to obtain L-PRF strips and liquid L-PRF. Pockets will receive insertion of small L-PRF strips followed by liquid L-PRF injections to fill the 5-8mm pockets of the test side.
215082405|NCT03109028|BEHAVIORAL|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
215082406|NCT03109028|BEHAVIORAL|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
214968468|NCT04978324|PROCEDURE|Scaling and Root Planing|Scaling and root planing, which is the standard of care, will be performed on the control side using Cavitron and hand scalers on test and control sides under local anesthesia.
214968469|NCT04024605|DIETARY_SUPPLEMENT|Sunflower|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
214357389|NCT02541708|DRUG|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
214968470|NCT04024605|DIETARY_SUPPLEMENT|Rapeseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
214968471|NCT04024605|DIETARY_SUPPLEMENT|Flaxseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
214968472|NCT04024605|DIETARY_SUPPLEMENT|Lupin|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
214968473|NCT02757729|DRUG|PAC-14028 cream 0.1%|Topical application
214357390|NCT03298139|OTHER|3 levels of gravity (1G, 1.8G, 0G).|healthy volunteers will experience 3 levels of gravity (1G, 1.8G, 0G).
214968474|NCT02757729|DRUG|PAC-14028 cream 0.3%|Topical application
214968475|NCT02757729|DRUG|PAC-14028 cream 1.0%|Topical application
214357391|NCT03671096|OTHER|Intrastromal TCA Inlay|An intrastromal inlay that will be provided to correct the required hyperopic correction
214357392|NCT04092218|OTHER|Questionnaire|"Data will be obtained through a written questionnaire to determine the type of parenting style of parents or caregivers.~The collected data will be saved and tabulated on computer and finally statistically analysed."
214357393|NCT03583216|DIAGNOSTIC_TEST|Diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
214357394|NCT03583216|DIAGNOSTIC_TEST|Non-diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
214357395|NCT03434951|DRUG|Bupivacaine Hydrochloride, Spinal|Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia
214968476|NCT02757729|DRUG|PAC-14028 cream vehicle|Topical application
214968477|NCT03409536|DEVICE|SSEP monitoring|Participants will be monitored using the SSEP device both before and after induction of a brachial plexus block.
214357396|NCT03434951|DRUG|Morphine hydrochloride, Spinal|Intrathecally administered morphine 0,2mg (2mg/ml, 0,1ml)
214357397|NCT03434951|DRUG|Placebo - Concentrate|Intrathecally administered saline solution 0,9% 0,1ml to match morphine volume
214357398|NCT00249925|BEHAVIORAL|Home-Based Intervention|
214968478|NCT02972983|DRUG|Daptomycin|Adjuvant therapy for up to five days
214968479|NCT02972983|OTHER|Placebo|Placebo
214968480|NCT04559646|PROCEDURE|Pacemaker implantation|Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.
214968481|NCT04559646|DRUG|"Haemostatic solution Haemoblock application"|"Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
214968482|NCT04559646|DRUG|Saline solution application|Saline solution will be used after pocket formation during pacemaker implantation.
214968483|NCT04559646|DIAGNOSTIC_TEST|Ultrasound of pacemaker pocket|Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.
214357399|NCT00249925|BEHAVIORAL|Multi-component home-based intervention|
214393772|NCT02206152|DRUG|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
214393773|NCT02206152|DRUG|Placebo|
214393774|NCT00478608|DRUG|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
214968484|NCT04559646|DIAGNOSTIC_TEST|Blood sampling|Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.
214393775|NCT00004286|DRUG|immune globulin|
214968485|NCT04559646|DIAGNOSTIC_TEST|Echocardiography|Heart ultrasound examination for left ventricular ejection fraction measurement.
214393776|NCT00658697|DRUG|Docetaxel|Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
214393777|NCT00658697|DRUG|Bevacizumab|Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
215082407|NCT03109028|BEHAVIORAL|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
214968486|NCT01749410|BIOLOGICAL|onabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
214968487|NCT04194983|DIETARY_SUPPLEMENT|Fish oils and dairy fat|12-weeks, 3x per day
214968488|NCT04194983|DIETARY_SUPPLEMENT|Fish oils and plant fat|12-weeks, 3x per day
214968489|NCT05591157|DEVICE|CSF-3 watch, designed to monitor a user's heart rate based on ECG (electrocardiogram) and PPG (Photoplethysmograph) readings|The subjects will be connected to an ECG Holter, and an investigational Device will be placed simultaneously on the subject's wrist. All subjects in this phase will be asked to participate in a single continuous data recording measurement for seven (7) minutes
214968490|NCT02432885|DRUG|Enalapril|up to 20mg bid
214968491|NCT05448378|DIETARY_SUPPLEMENT|D-chiro-inositol|D-chiro-inositol 600 mg twice per day on an empty stomach for one month
214968492|NCT04685252|OTHER|(BL) NCC3001|Probiotic strain (BL) NCC3001 packed in stickpack, to be consumed daily.
214968493|NCT04685252|OTHER|Placebo|Matching placebo containing maltodextrin packed in stickpack, to be consumed daily.
214968494|NCT02090504|DRUG|Sodium Oxybate (SMO)|
214968495|NCT02090504|DRUG|Oxazepam|
215082408|NCT03109028|BEHAVIORAL|Empowerment-Groupintervention|"Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
215082409|NCT03109028|BEHAVIORAL|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
214968496|NCT00737100|DRUG|Placebo Respimat|patient to receive placebo matching active drug once daily
214968497|NCT00737100|DRUG|Tiotropium bromide 5 mcg|patient to recieve high dose tiotropium once daily
214968498|NCT00737100|DRUG|tiotropium bromide-low dose-2.5mcg|patient to receive low dose tiotropium once daily
214968499|NCT05713357|PROCEDURE|Catheter ablation|Endocardial catheter ablation
214968500|NCT03131284|BEHAVIORAL|Intensive education|"For each well visit within the first two years of their child's life, parents are provided with oral and written information on behaviors to adopt for their child to be protected from obesity: breast feeding, feeding on demand, responsive feeding, correct time of introduction of complementary feeding, portions shaped on the child's appetite, avoiding pressing the child to eat more and rewarding or punishing the child with food, avoiding added sugar and beverages other than milk and water, practicing active game with the child, alternating protein sources correctly and avoiding protein excess. Written menus examples and coloured photos of average portions are given for complementary feeding. Parents are also provided with information about health consequences of childhood obesity."
214968501|NCT01447407|BIOLOGICAL|NDV-3 vaccine with alum IM|One dose administered IM
214393778|NCT00658697|DRUG|ADT|Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
214968502|NCT01447407|BIOLOGICAL|NDV-3 vaccine without alum IM|One dose administered IM
214968503|NCT01447407|BIOLOGICAL|Placebo with alum IM|One dose administered ID
214968504|NCT01447407|BIOLOGICAL|NDV-3 vaccine without alum ID|One dose administered ID
214968505|NCT02571140|DRUG|Teriparatide|subcutaneous standard injection
214968506|NCT02571140|DRUG|Oral PTH (1-34)|Different optimization of API
214968507|NCT04240223|DRUG|Brilacidin|Brilacidin
214968508|NCT04240223|DRUG|Placebo|Placebo
214357400|NCT04386096|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
214357401|NCT04386096|OTHER|Mehealth for ADHD software with no medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician report card; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
214357402|NCT00345241|DRUG|Systane Ocular Drops (OTC)|
214357403|NCT00345241|DRUG|Placebo - Saline Drops|
214968509|NCT04240223|RADIATION|4Mq 99mTc-DTPA|4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
214968510|NCT01265394|DRUG|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
214968511|NCT00746226|BIOLOGICAL|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10\^9 CFU of a combination of L. acidophilus and B. lactis
214968512|NCT00746226|BIOLOGICAL|Placebo|"Microcrystalline cellulose~As capsule which could be opened"
214968513|NCT01908712|DRUG|Lamazym|ERT, i.v. infusions weekly
214968514|NCT00107562|BEHAVIORAL|Adolescent Safer Sex Social Network Intervention|
214968515|NCT03065491|DIETARY_SUPPLEMENT|Combined nutraceutical|Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
214968516|NCT03065491|OTHER|Placebo|Oral administration: 1 tablet per day
214968517|NCT00354965|DRUG|amoxicillin/clavulanate potassium|amoxicillin/clavulanate potassium
214968518|NCT01582113|DRUG|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
214968519|NCT01582113|OTHER|Microcrystalline Cellulose|Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
214357404|NCT01844804|BIOLOGICAL|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
214357405|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
214968520|NCT03860740|OTHER|Exercise|Exercise intervention adapted to maximum rate of oxygen consumption measured during incremental exercise (VO2level) of each patient, working between 60% to 100% VO2level. The activity will be walk-run in a treadmill. 10 sessions minimum
214968521|NCT03860740|OTHER|Stretching|Stretching and relaxing exercise during 30 minutes. Same number of sessions as intervention group
214968522|NCT03315845|OTHER|Palpation of bony landmarks for neuraxial anaesthesia.|"Manual palpation of anterior and posterior iliac crests; lumbar spinous processes; scapulae; and sacral cornua.~Ultrasound of neuraxial anatomy to assess depth to epidural space."
214968523|NCT04348708|GENETIC|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
214968524|NCT03131167|DRUG|SHP639 (n=60)|Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
214968525|NCT03131167|DRUG|Placebo Comparator (n=24)|Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
214968526|NCT01699048|PROCEDURE|Hybrid (MIDCAB+PCI)|Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
214968527|NCT01699048|PROCEDURE|PCI|Multi-vessel PCI with DES
214968528|NCT01699048|PROCEDURE|CABG|Coronary artery bypass graft (CABG) treatment
214968529|NCT00643201|DRUG|Enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
214968530|NCT00643201|DRUG|warfarin|tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
214357406|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
214357407|NCT03626948|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
214357408|NCT00517491|DRUG|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
214968531|NCT00643201|DRUG|Placebo for apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
214968532|NCT00643201|DRUG|Placebo for enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
214968533|NCT00643201|DRUG|Placebo for warfarin|tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
214968534|NCT00643201|DRUG|apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
214968535|NCT00165503|DRUG|Cisplatin|
214968536|NCT00165503|DRUG|Sodium Thiosulfate|
214968537|NCT00165503|DRUG|ALIMTA|
214968538|NCT02346708|DEVICE|Real TMS|real treatment
214968539|NCT02346708|DEVICE|Sham TMS|placebo treatment
214357409|NCT02025881|DRUG|Carboplatin + etoposide|"Carboplatin 160 mg/m\^2 Day 1 to day 5, as an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).~Etoposide 100 mg/m\^2 D ay 1 to day 5, as an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle."
214357410|NCT02025881|DRUG|Thiotepa|Thiotepa 200 mg/m² Day-3 to day-1, as an intravenously infusion over 1 hour dilution in 200 ml/m\^2 of 5% glucose saline or sodium chloride 9 mg/ml (0.9%).
214968540|NCT02085200|OTHER|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
214968541|NCT02085200|OTHER|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
214968542|NCT02976519|DRUG|BI 443651|twice daily
214968543|NCT02976519|DRUG|Placebo|twice daily
214968544|NCT04716972|OTHER|survey|Online survey
214968545|NCT04716972|OTHER|Interview|Interview
214968546|NCT04215562|COMBINATION_PRODUCT|rehabilitation|electro-therapy, heat therapy, massage and exercise therapy
214968547|NCT03728439|DEVICE|LED before|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules (J) per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
214968548|NCT03728439|DEVICE|LED interval|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
214968549|NCT03728439|DEVICE|LED after|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
214968550|NCT01908868|OTHER|EBUS-TBNA|Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
214968551|NCT01908868|OTHER|Conventional TBNA|Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
214968552|NCT01908868|OTHER|Endobronchial and transbronchial biopsy|Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
214968553|NCT03416270|DRUG|Ertugliflozin|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
214968554|NCT03416270|DRUG|Placebo|Placebo once daily for 12 weeks
214968555|NCT05419297|DRUG|Buprenorphine Buccal Film [Belbuca]|buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
214968556|NCT05419297|OTHER|Urine Drug Screening|Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance
214968557|NCT05419297|DEVICE|actigraph|Subjects will wear this device to monitor sleep and activity
214968558|NCT05419297|BEHAVIORAL|PROMIS 29|questionnaire will be administered once a week via e-dairy to monitor mood and sleep
214968559|NCT05419297|OTHER|sit to stand test|Subjects will complete this daily with specific instructions through the e-diary
214968560|NCT05419297|OTHER|numerical rating scale pain score|subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night
214968561|NCT05419297|BEHAVIORAL|patient global impression of function|subjects will be asked three questions once a day to assess their personal impression of functional status
214393779|NCT00658697|DRUG|Bicalutamide|Starting on day 84 orally once daily until hormone therapy is completed
214968562|NCT05419297|BEHAVIORAL|PROMIS - sleep|Subjects will answer 5 questions about sleep every morning via e-diary
214968563|NCT03069872|DIAGNOSTIC_TEST|Transvaginal ultrasound|Access to fast transvaginal ultrasound through general practice Develop and conduct training for general practicioners in the latest knowledge of ovarian cancer symptomatology
214968564|NCT04758013|PROCEDURE|Epidural injection through thoracic epidural catheter|The investigators inject drugs through a catheter inserted into the thoracic epidural space to control pain after surgery in patients undergoing gastric surgery by laparoscopy.
214968565|NCT04758013|PROCEDURE|Without epidural injection|The investigators don't epidural injection to find out the effect of only inter-abdominal pressure on intracranial pressure.
214968566|NCT02607501|DEVICE|Implant eCLIPs|Implant eCLIPs at target bifurcation aneurysm
214968567|NCT03984344|DEVICE|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
214968568|NCT03984344|DEVICE|Continuous Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
214968569|NCT03984344|DEVICE|Sham Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
214968570|NCT01781962|OTHER|No Treatment|No Treatment was given in this study.
214968571|NCT00928434|DRUG|Degarelix|Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.
214968572|NCT00928434|DRUG|Degarelix|Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).
214968573|NCT00928434|DRUG|Leuprolide|Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
215082410|NCT03109028|OTHER|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
214393780|NCT02080520|DIETARY_SUPPLEMENT|Nattokinase|
214393781|NCT02080520|OTHER|Placebo|
214968574|NCT05380245|DRUG|Voriconazole 200 mg x 2 Tablets|Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).
214968575|NCT05380245|DRUG|Clarithromycin 500 mg x 1Tablets|Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.
214968576|NCT03928054|OTHER|Kinesio Taping and therapeutic alliance|bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance
215082411|NCT03351816|PROCEDURE|Ablation of atrial fibrillation|Pulmonary vein isolation by radiofrequency or cryoablation.
214968577|NCT06410664|OTHER|72-hour HME exchange interval group|All patients in the experimental arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 72 hours. At the exchange point, both outlets of the HME filter will be swabbed.
214968578|NCT06410664|OTHER|24-hour HME exchange interval group|All patients in the control arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 24 hours. At the exchange point, both outlets of the HME filter will be swabbed.
214968579|NCT05767853|OTHER|Immune-phenotyping of tissue and peripheral blood myeloid compartment|"Peripheral blood sampling and bronchoalveolar lavage fluid collection based on the clinical indication at baseline (T0) and peripheral blood sample at the time of clinical worsening/improvement during the follow-up (T1). Moreover, after complete recovery and discharge from the hospital peripheral blood sampling in the outpatient clinical assessment will be performed (T2).~BALF and peripheral blood will be processed for immune-phenotyping of the myeloid compartment using single-cell RAN sequencing analysis."
214968580|NCT03263455|OTHER|Kinesio taping group|"The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 I-strips: the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching."
215082412|NCT03351816|PROCEDURE|Cardioversion|External electric shock delivery under general anesthesia.
215082413|NCT06357091|PROCEDURE|ACL reconstruction with Shark Screw ACL®|ACL reconstruction with the Shark Screw ACL®, Investigation of tunnel widening
215082414|NCT06357091|PROCEDURE|ACL reconstruction with biocomposite screw (Mecta)|ACL reconstruction with biocomposite screw (Mecta), Investigation of tunnel widening
215082415|NCT01638208|DRUG|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
215082416|NCT01375868|BIOLOGICAL|Silgard|vaccination with tetravalent antiviral vaccine
215082417|NCT02099162|DEVICE|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
215082418|NCT02088593|DEVICE|Simulated Dawn Light Box|per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
215082419|NCT02088593|BEHAVIORAL|Sleep Hygiene instructions|Sleep Hygiene instructions read aloud
215082420|NCT01613989|PROCEDURE|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
214357411|NCT02025881|DRUG|Cyclophosphamide + Busilvex|"Cyclophosphamide:~* Level 1 20 mg/kg/day~* Level 2 30 mg/kg/day~* Level 3 40 mg/kg/day~* Level 4 50 mg/kg/day~Busilvex:~\< 9 kgs 0.8 mg/kg/dose -\> 3.2 mg/kg/day; 9 à \< 16 kgs 0.96 mg/kg/dose -\> 3.84 mg/kg/day; 16 à 23 kgs 0.88 mg/kg/dose -\> 3.52 mg/kg/day; \> 23 à 34 kgs 0.76 mg/kg/dose -\> 3.04 mg/kg/day; \> 34 kgs -\> 0.64 mg/kg/dose."
214357412|NCT02025881|DRUG|Temozolimide + Irinotecan|"During 2 cycles of 21 days:~* Temozolomide: 100 mg/m\^2/day PO from Day 1 to Day 5;~* Irinotecan: 10 mg/m\^2/day IV from Day 1 to Day 5 + from Day 8 to Day 12"
214357413|NCT02025881|COMBINATION_PRODUCT|Etoposide + radiotherapy|"* Etoposide: 35 mg/m\^2/day PO during 21days~* Radiotherapy: 1.8 Gy/fraction/day (total dose: 54 Gy)"
214679134|NCT02697461|OTHER|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
214357414|NCT02025881|DRUG|Temozolomide|150 mg/m\^2/day PO during 5 days, during 6 cycles of 21 days
214357415|NCT00541515|DEVICE|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
214357416|NCT06273423|OTHER|OULA, Mind-body Physical Activity|Group dance fitness program with focus on the mind-body connection
214393782|NCT03875495|DRUG|Temferon|Genetically modified autologous HSPCs
214393783|NCT04418713|OTHER|active video-games|An intervention with active video-games to increase physical activity and improve body composition
214393784|NCT00486915|PROCEDURE|Left Atrial Appendage Ligation|
214357417|NCT06477575|DEVICE|neurocognitive therapy based on new technologies|"The cognitive neurorehabilitation program is based on gaming through the use of the Nintendo Switch device. The following games have been chosen: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder, since they are games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Hardware: Nintendo Switch Software: 60 in 1 game Games: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder. Therapy time: 30 minutes effective. Number of Sessions: 2 per week / Number of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito)."
214357418|NCT06477575|OTHER|conventional neurocognitive therapy|"The cognitive neurorehabilitation program for group active comparator is based on playing more conventional board games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Traditional games and token book. Games: Dobble, Lynx, Crazy cups, Jungle speed, animalea, ghost. Card: Stimulate and learn level 3 and 4. Therapy time: 30 minutes effective. No. of sessions: 2 per week / No. of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito)."
214357419|NCT00108095|DRUG|intravenous ondansetron|
214357420|NCT02376218|DRUG|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
214357421|NCT01260350|DRUG|SOF|Sofosbuvir (SOF) tablets administered orally once daily
214968581|NCT03263455|OTHER|Sham Taping|"Patients in the ST group, smaller I-strips of KinesioTape will be used and they will be applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the experimental group. Although the specific therapeutic elements of KinesioTaping (ie, longitudinal stretch, start and ending point tape application) will be removed"
214968582|NCT04702464|DRUG|Fedratinib|Fedratinib
214968583|NCT04702464|DRUG|Fluconazole|Fluconazole
214968584|NCT04549662|DIETARY_SUPPLEMENT|Active A|Powdered formula containing whey protein and arginine
214968585|NCT04549662|DIETARY_SUPPLEMENT|Active B|Powdered formula containing whey protein
214968586|NCT04549662|DIETARY_SUPPLEMENT|Lipid bolus|Omega-3 fatty acids
214968587|NCT04549662|DIETARY_SUPPLEMENT|Placebo oil|Control placebo oil that does not contain omega-3 fatty acids
214968588|NCT06331507|DEVICE|CMR patch|The Cardiac Magnetic Resonance (MR) patch is a sequence modification for enhancing the images in patients with devices (CIED) for assessing heart muscle scar. The Philips tested patch supports multiple cardiac MR imaging enhancements compiled from several individual patches generated by multiple Philips MR research collaborators for use on 1.5 Tesla Philips scanners.
214968589|NCT05224700|BEHAVIORAL|JAPI|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. All the activities are games with the following structure: an introduction with instructions and protagonist selection, followed by a practice exercise to ensure that the children understand what they have to do (the exercise is repeated until the child performs it correctly), and, finally, the activity itself (4 different activities with 5 tries each). The first 10 sessions jointly stimulate working memory and emotion knowledge (4 activities focused on each skill per session), while the 10 remaining sessions stimulate inhibitory control and the selection of prosocial behaviours. In the inhibitory control activities, they must suppress automatic stimuli and processes; in the emotion recognition activities, they must identify basic emotions; and in the selection of prosocial behaviours, they must choose an option to deal with a social problem.
214968590|NCT05224700|BEHAVIORAL|Painting group|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. They will play a tablet-based painting game that involves no cognitive, emotional, or social competence stimulation
214968591|NCT01687114|OTHER|cranberry juice|27% cranberry juice
214968592|NCT02281617|BEHAVIORAL|Smart-device apps as memory aids|Patients will be taught to use software running on smartphones and smart tablets to help compensate for memory difficulties
214968593|NCT02138565|PROCEDURE|Gastric by-pass surgery|
214968594|NCT06410716|DEVICE|Valve-regulated pleural drainage system|Patients using valve-regulated pleural drainage system (Ningbo Xinyue Medical Technology Co., Ltd., model AFG31-1) postoperatively.
214968595|NCT03276598|DRUG|Amlodipine|Treatment for four weeks. Dose: 5 mg o.d.
214968596|NCT03276598|DRUG|Bisoprolol|Treatment for four weeks. Dose: 5 mg o.d.
214968597|NCT03276598|DRUG|Hydrochlorothiazide|Treatment for four weeks. Dose: 25 mg o.d.
214357422|NCT01260350|DRUG|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
214357423|NCT01260350|DRUG|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
214357424|NCT01260350|DRUG|LDV|Ledipasvir (LDV) tablets administered orally once daily
214357425|NCT01260350|DRUG|GS-9669|GS-9669 tablets administered orally once daily
214357426|NCT01260350|DRUG|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
214357427|NCT01270451|OTHER|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
214357428|NCT01745432|DEVICE|ADBLOCK|Laparoscopic surgery
214968598|NCT03276598|DRUG|Losartan|Treatment for four weeks. Dose: 50 mg o.d.
214968599|NCT03276598|DRUG|Placebo|Treatment for four weeks. Dose: 1 tablet per day.
214968600|NCT02016768|PROCEDURE|decompressive cervical surgery|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
214968601|NCT00002223|DRUG|Indinavir sulfate|
214968602|NCT00002223|DRUG|Ritonavir|
214968603|NCT01278342|DRUG|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
214968604|NCT01278342|DRUG|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
214968605|NCT01278342|DRUG|cabergoline|"Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~1. st week: 0.25 mg twice a week (0.50 mg/week)~2. nd week: 0.50 mg/week twice a week (1 mg/week)~3. rd week: 0.50 mg four times a week (2 mg/week)~4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
214679135|NCT02060617|BEHAVIORAL|Patient Education|All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.
214968606|NCT05862493|DIAGNOSTIC_TEST|FOCUS echocardiography|Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs
214968607|NCT03210493|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
214968608|NCT04869592|BIOLOGICAL|low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
214968609|NCT04869592|BIOLOGICAL|high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
214968610|NCT04869592|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
214968611|NCT00171990|DRUG|Famciclovir|
214968612|NCT05946226|BIOLOGICAL|IMC002 injection|"three different IMC002 Doses will be escalated in 3+3 design"
214968613|NCT00224302|DRUG|Duloxetine|
214968614|NCT04968678|DIAGNOSTIC_TEST|P-wave duration measurement on 12 lead ECG with standard parameters|Hospital records will be used in order to obtain baseline characteristics and the most recent 12-lead ECG in sinus rhythm prior to ablation will be used to calculate PWD. Measurement of the PWD will be obtained at standard surface ECG recording settings of 25mm/s and 10mm/mV and measured accordingly to our previous protocol. In brief, all ECGs obtained will subsequently be anonymised and randomised by an Independent Clinical Investigator (ICI) before measured by the main clinical investigators blinded to initial results. If a dispute of the measurements arouse, consensus will be used to resolve it after consulting the Chief Investigator (CI) blinded to the results. Bland-Altman plots to minimise bias will be used
214968615|NCT05439421|BEHAVIORAL|Package/Advertisement With Claim|Waterpipe tobacco packages and digital marketing advertisement images with claim of interest as part of design
214968616|NCT05439421|BEHAVIORAL|Package/Advertisement Without Claim|Waterpipe tobacco packages and digital marketing advertisements shown without claim of interest as part of design
214968617|NCT06195436|BEHAVIORAL|Acceptance and Commitment Therapy for people with and without depression|Participants with and without depression will be assigned to two study groups; both groups will undergo Acceptance and Commitment Therapy based on the required guidelines for twelve weeks.
214968618|NCT01848574|OTHER|standardized multifaceted information procedure to improve patients' comprehension|
214968619|NCT02654639|DRUG|TAS-102|TAS-102 Twice a day by mouth day 1-5 and 8-12
214968620|NCT02654639|DRUG|Bevacizumab|Bevacizumab by intravenous infusion once every 14 days
214968621|NCT06223230|OTHER|Nutritional psychological interventions and vomit-free management|Nutritional psychological interventions and vomit-free management
214968622|NCT04253340|DIAGNOSTIC_TEST|Bone mineral analyser|high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12
214679136|NCT02060617|PROCEDURE|Manual therapy of the thoracolumbosacral spine and hips|Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.
214968623|NCT03606811|PROCEDURE|fluroscopic guided block|SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.
214968624|NCT03606811|PROCEDURE|double modality (ultrasound and fluroscopic) guided block|SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position. Then C-arm pictures will be checked (both P-A \& dead lateral)
214968625|NCT02348229|PROCEDURE|ERAS protocols|Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
214968626|NCT02348229|PROCEDURE|ERAS protocols|No bowel preparation
214968627|NCT02348229|PROCEDURE|ERAS protocols|No nasogastric placement; if used, remove on the 1st postoperative day
214968628|NCT02348229|PROCEDURE|ERAS protocols|Vasoactive drugs used if need be
215082421|NCT01613989|PROCEDURE|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
215082422|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
214679137|NCT02060617|PROCEDURE|Motor control exercises|Motor control exercises as determined by motor control impairments identified on clinical examination.
214968629|NCT02348229|PROCEDURE|ERAS protocols|Temperature management
214968630|NCT02348229|PROCEDURE|ERAS protocols|Intra-abdominal drains not to be used
214968631|NCT02348229|PROCEDURE|ERAS protocols|Intraperitoneal Ropivicaine infusion
214968632|NCT02348229|PROCEDURE|ERAS protocols|"On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.~Oral non-opioid analgesia/Drinking 0.5L liquid. Active mobilisation"
214968633|NCT02348229|PROCEDURE|ERAS protocols|On the 2nd postoperative day：Drains removed Oral diet was initiated
214968634|NCT02348229|PROCEDURE|ERAS protocols|3-4th postoperative day： Stop oral non opioid analgesia
214968635|NCT02348229|PROCEDURE|ERAS protocols|On the5-6th postoperative day Check discharge criteria
214968636|NCT02348229|PROCEDURE|conventional pathway group|No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
214968637|NCT02348229|PROCEDURE|conventional pathway group|Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
214968638|NCT02348229|PROCEDURE|conventional pathway group|1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
214968639|NCT02348229|PROCEDURE|conventional pathway group|2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
214679138|NCT02060617|PROCEDURE|Treatment-Based Classification intervention|Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
214968640|NCT02348229|PROCEDURE|conventional pathway group|3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
214968641|NCT02348229|PROCEDURE|conventional pathway group|"5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.~Drains removed"
214968642|NCT03154580|DRUG|N-acetyl cysteine|Participants will receive 4 capsules at 11:15am on each experimental session day.
214968643|NCT02996071|PROCEDURE|laparoscopic sleeve gastrectomy|a sleeve gastrectomy operation that is performed laparoscopically.
214968644|NCT03011866|DRUG|Wound topically irrigated with 500mg TXA|
214968645|NCT03011866|DRUG|1mg/kg/hr TXA intravenous infusion till the last suture|
214968646|NCT05481801|BIOLOGICAL|Covid-19 vaccination|"Correct Covid19 vaccination status was considered in the following situation:~Received at least two Covid-19 vaccine doses being the last in the last 6 months."
215082423|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
215082424|NCT01310400|BIOLOGICAL|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
215082425|NCT02345668|BEHAVIORAL|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
215082426|NCT02345668|DRUG|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
215082427|NCT02345668|BEHAVIORAL|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
215082428|NCT06061289|DIETARY_SUPPLEMENT|SP Detox Program|The production use and disposal of toxic chemicals and synthetic materials have increased the risk of exposure to health-threatening toxins. Causal relationships between toxic chemicals and diseases have been well established. However, many patients endure chronic symptoms that are associated with exposure to toxins before advanced stages of specific diseases are realized. Thus, there is a great demand for noninvasive laboratory tests that can provide timely assessment of chemical exposure and the capability of hepatic detoxification
215082429|NCT01468610|DRUG|desvenlafaxine|50-100 mg daily for 8 weeks
215082430|NCT04882644|BEHAVIORAL|Aerobic Exercise|The subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption three times per week for 60 min/session (including 5 min warm-up and 5 min cool down) with treadmills, ellipticals, and rowing machine. The subjects attend health education sessions (eg, general health knowledge of NAFLD and metabolic diseases, and elements of a healthy lifestyle) monthly in the 12 months.
214393785|NCT03570125|DIETARY_SUPPLEMENT|Prolon|The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS). In case the PROLON product will be unavailable at the time of the project we will design fasting mimicking diet without the usage of specifically designed commercial product
214679139|NCT00466128|DRUG|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
214679140|NCT04655495|DIETARY_SUPPLEMENT|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet
214679141|NCT05676320|DEVICE|V-Flex|Bone cement including Inossia Cement Softener. Treatment for vertebral compression fracture
214968647|NCT05481801|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~\- Received at least one Influenza vaccine dose in the last year."
214968648|NCT05481801|BIOLOGICAL|Pneumococal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year. One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years. One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
214968649|NCT05481801|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
214968650|NCT04214522|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
214679142|NCT05676320|DEVICE|V-Steady|Bone Cement alone
214968651|NCT00987168|DRUG|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
214968652|NCT03760224|OTHER|WhatsApp group|WhatsApp group will allow real-time group discussion for 8 weeks
214968653|NCT03760224|OTHER|SMS group|SMS group for 8 weeks
214357429|NCT06113627|OTHER|Resistance Therapeutic Exercise|"Strength exercises will be aimed at large muscle groups, such as the shoulder, chest, back and also muscle groups of the lower extremities. In the initial 2 weeks, intervention will start with low intensities of around 55-65% of 1RM, which allows to perform around 15-20 repetitions. The first week there will be performed 2 series, while in the second week it will be 3 series.~Moderate intensity in the 2nd week, corresponding to 65-75% of 1RM and allowing for around 8-12 repetitions. 3 series will be maintained throughout this period of time.In addition to the progressive change in intensity, throughout the intervention the load will be increased by 5-10% when the patient performs the exercise too easily or when they can perform more repetitions than estimated. Rest between sets will be 2-3 minutes."
214357430|NCT00249535|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
214357431|NCT06143826|OTHER|Progressive muscle relaxation exercises|Progressive muscle relaxation exercises involve contracting and relaxing 16 muscle groups in the body (hand, upper arm, forearm, forehead, nose, cheek, chin, neck, shoulder, chest, abdomen, waist, stomach, calf, hip, foot). During the exercise, the individual perceives the changes in the muscles during the contraction and relaxation of the muscles. Relaxation exercise is applied along with correct and deep breathing.
214968654|NCT05459909|DIETARY_SUPPLEMENT|Synbiotic supplementation|Daily supplementation of synbiotic
214357432|NCT05641558|DRUG|611 150mg|subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
214968655|NCT05459909|BEHAVIORAL|Dietary intervention|Increased fruits and vegetables consumption
214968656|NCT02256098|DEVICE|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
214968657|NCT02256098|DEVICE|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
214968658|NCT00021723|BIOLOGICAL|AN-1792 also known as AIP-001|
214968659|NCT04806022|OTHER|Fatigability assessment|Each participant will do both types of fatigue over 2 appointments spaced by 7 days so that the subject can recover from induced fatigue. The sequence of fatigue tasks will be randomized.
214968660|NCT02988011|PROCEDURE|Gastric by-pass surgery|Gastric by-pass surgery is expected to achieve a mean weight loss of 7-8kg in 4 weeks, which is similar weight-loss achieved in the other arm (low-caloric diet) during this time period.
214968661|NCT02988011|DIETARY_SUPPLEMENT|Low-caloric diet|Energy restricted diet with a total energy intake of 800-1200kcal/day
215082431|NCT01062841|BEHAVIORAL|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
215082432|NCT02426775|DRUG|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
215082433|NCT01702090|DRUG|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
215082434|NCT06105216|OTHER|Crossword and word search puzzles|Students in the intervention group received hard copies of the puzzles at the end of the laboratory practice.
215082435|NCT05186831|BEHAVIORAL|Texting|Patients will be asked to text their BP. They will receive an automated response to their texts.
214357433|NCT05641558|DRUG|611 300mg|subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
214357434|NCT05641558|DRUG|611 600mg|subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
214357435|NCT05641558|OTHER|Placebo|During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.
214357436|NCT04460118|PROCEDURE|Bristow surgery fixed by the screw|Bristow surgery fixed by the screw
214357437|NCT04460118|PROCEDURE|Bristow surgery fixed by the suture button|Bristow surgery fixed by the suture button
214357438|NCT02088268|OTHER|wound healing|wound healing
214357439|NCT03130400|PROCEDURE|Observational gait analysis procedure|All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
214357440|NCT01362738|PROCEDURE|RFCA of PV and extra-PV triggers|PVAI and isolation of extra PV triggers
214968662|NCT02773498|PROCEDURE|conventional TESE|usual procedure for sperm extraction
214968663|NCT02773498|PROCEDURE|Micro TESE|procedure of extraction is performed under the operating microscope
214968664|NCT00313846|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
214968665|NCT00313846|DRUG|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
214968666|NCT02276963|DRUG|Ublituximab|Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
214968667|NCT03049826|OTHER|Nutritional status|Body composition and nutrient status
214968668|NCT01462630|DRUG|pazopanib hydrochloride|Given PO
214968669|NCT01462630|OTHER|laboratory biomarker analysis|Correlative studies
214968670|NCT01462630|PROCEDURE|positron emission tomography|Correlative studies
214968671|NCT01462630|PROCEDURE|computed tomography|Correlative studies
214968672|NCT01462630|RADIATION|fludeoxyglucose F 18|Correlative studies
214679143|NCT05722899|OTHER|Football training|10-week progressive football training with small-sided games, 2x/week, 45min-1h sessions
214968673|NCT03943628|BEHAVIORAL|Familias Unidas|
214968674|NCT01809756|OTHER|Caphosol|Caphosol 4 times a day
214968675|NCT01102712|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
214968676|NCT03565354|DRUG|iron isomaltoside(Monofer®)|intravenous iron isomaltoside
214968677|NCT03936088|DEVICE|"Intervention -- Headspace mindfulness application"|"Patients will be provided with a pre-paid 12-week subscription to the mindfulness application, and provided an in-person demonstration on how to use it, and the subscription license code will be recorded for the purposes of tracking use after the conclusion of the study. The intervention group will be asked to use the mindfulness app 10 minutes per day/5 days per week. To standardize Pack usage across all participants, users will be asked to complete the Headspace Essentials, Pain Management, and Physical Health Session Packs."
214968678|NCT03936088|DEVICE|"Control -- My Water Balance application"|My Water Balance calculates an individual's recommended daily water requirements and assists users in tracking their daily fluid intake. The control group will be asked to log their water intake for the duration of the study, with requested use of 5 days per week to create an equal control. This application is free to download and use. There are options for in-app purchases and application upgrades, though users will be advised against doing so. Information logged in the application may be stored on a third party server; however, no application data will be extracted by the study team. Application use will be reported via weekly surveys, alone.
214968679|NCT01765296|DRUG|CG100649|2 mg capsule
215082436|NCT05186831|BEHAVIORAL|Online patient portal|Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
215082437|NCT05477173|BEHAVIORAL|The Strengths and Difficulties Questionnaire (SDQ) Parent Version Parent : It consists of 25 questionnaires used to screen for behavioral problems in children aged 4-17 years.|screen by using psychometric scales
215082438|NCT01218100|DRUG|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
215082439|NCT01218100|DRUG|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
214968680|NCT01765296|DRUG|Celecoxib|200 mg capsule
215082440|NCT01218100|DRUG|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
215082441|NCT01218100|DRUG|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
214968681|NCT01765296|DRUG|Placebo|Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
214968682|NCT01302405|DRUG|PRI-724|Dose escalation
214968683|NCT06314386|OTHER|Systems Analysis and Improvement Approach for TB (SAIA-TB)|The Systems Analysis and Improvement Approach for TB (SAIA-TB) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by clinic staff with support from study personnel in intervention clinics. Components of the intervention include TB cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally optimize TB screening, evaluation, diagnosis, TB preventive therapy and TB disease treatment initiation, successful treatment, and TB-free survival among the population at the intervention clinics.
214968684|NCT00707044|PROCEDURE|Control group (usual care)|control group, care as usual, 24 hours intensive care stay
214968685|NCT00707044|PROCEDURE|Short-Stay Intensive Care treatment (SSIC)|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
214968686|NCT06446934|DEVICE|CPAP|Initial CPAP titration and subsequent CPAP therapy for 12 weeks
214968687|NCT05934006|BIOLOGICAL|spot urine samples|No intervention, but measurement of urinary iodine concentration by 6 repeated spot urine samples
214968688|NCT04358016|DRUG|Terlipressin|Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
215082442|NCT01539343|DRUG|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
215082443|NCT06180681|BEHAVIORAL|Team-Enhanced Collaborative Life Skills Program|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
215082444|NCT06180681|BEHAVIORAL|Standard Collaborative Life Skills Program|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
215082445|NCT06349187|DIAGNOSTIC_TEST|Interview|Interviewing with using the Hall Emotional Intelligence test, the Maslach emotional burnout test, and the test for determining general and specialized digital competencies
214393786|NCT06049693|DRUG|Ferrous Gluconate 300 MG|Ferrous Gluconate 300 MG twice a day
214968689|NCT04358016|DRUG|Somatostatin|Somatostatin
214968690|NCT02541344|DEVICE|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
214968691|NCT02541344|DEVICE|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
214968692|NCT02541344|DEVICE|Placebo|"Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102."
214357441|NCT01362738|PROCEDURE|LAA isolation along with the conventional ablation strategy|PVAI + isolation of extra PV triggers + LAA isolation
214968693|NCT05370898|DRUG|Caltrate D|Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
214968694|NCT05370898|DRUG|Chinese medicine prescription|The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
214968695|NCT05370898|DRUG|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
214968696|NCT05122689|DIETARY_SUPPLEMENT|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
214357442|NCT05717868|OTHER|Kinesiology taping|5 cm wide and 0.5 mm thick waterproof, porous and adhesive tape will be applied to the posterior neck of the participants while sitting comfortably in a neutral position. The first tape (Y-strip) is placed over the posterior cervical extensor muscles with approximately 25% tension. The top strip will be placed perpendicular to the Y strip on the mid-cervical region. The participant's cervical spine is flexed to obtain tension in the posterior structures.
214968697|NCT05122689|DIETARY_SUPPLEMENT|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
214968698|NCT03933449|BIOLOGICAL|pembrolizumab|IV infusion
214968699|NCT03933449|DRUG|paclitaxel|IV infusion
214968700|NCT03933449|DRUG|docetaxel|IV infusion
214968701|NCT03933449|DRUG|irinotecan|IV infusion
214357443|NCT05717868|OTHER|Self-mobilization|The towel will be placed on the posterior arch of the fifth cervical vertebra and pulled horizontally across the face. The participant will be instructed to apply pressure to the towel and turn their head to the restricted side, then maintain the finishing interval for three seconds. The participant will be asked to apply extreme pressure in the bending position with towel support. The procedure should be painless and repeated 10 times.
214357444|NCT04644250|DRUG|Toripalimab|Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.
214357445|NCT04644250|DRUG|Paclitaxel liposome/Carboplatin|Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
214357446|NCT04644250|RADIATION|Intensity-modulated radiotherapy|A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.
214357447|NCT01099904|DRUG|RO5024048|multiple oral doses for 5 days
214357448|NCT04439422|BEHAVIORAL|Short ADHD Intervention|Short, intensive psychological intervention based on CBT and DBT practices
214357449|NCT04439422|OTHER|Self-help material with limited therapist support|Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
214357450|NCT04402866|DRUG|TD-0903|Study Drug to be administered by inhalation
214357451|NCT04402866|DRUG|Placebo|Placebo to be administered by inhalation
214357452|NCT03594669|OTHER|Intervention|Multi-modal sensorimotor training interventions, including vestibular, oculomotor, neuromotor, and postural control/ balance exercises.
214357453|NCT02621099|DEVICE|Hybrid optical-gamma imaging|Acquisition of images using the camera as additional steps to the standard SLNB procedures.
214357454|NCT05290350|OTHER|OSA|EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
214357455|NCT06225765|PROCEDURE|Transoral endoscopic thyroidectomy vestibular approach (TOETVA)|Remote access thyroid surgery
214357456|NCT06225765|PROCEDURE|Traditional Open Thyroidectomy|Open thyroidectomy via trans-cervical approach
214357457|NCT04477252|DEVICE|App-core|"Farmalarm App of the Inmovens group - Vall d´Hebrón Hospital will be used, adapted and updated by the main researcher. The App will have the rehabilitation option where the user can consult the description of the exercise and view a demonstration video so that it can be carried out correctly at home, independently or with help. The administrator therapist of the App has the permission to create users, contact them directly through chat or video-call and personalize the exercise program.~The exercises that will be carried out in this study phase, are described in previous studies by the author Rosa Cabanas et al. All possible exercises will be included in the administration platform, and according to of each user, the prescription of some exercises or others will be made."
214357458|NCT04477252|OTHER|Conventional physiotherapy|Conventional physiotherapy is considered neuromotor development therapy as the most frequently used therapy in the management of stroke patients and in the center where the study is performed.
214357459|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
214357460|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
214968702|NCT02376686|OTHER|Music intervention|Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
214968703|NCT06519916|BEHAVIORAL|Assessment of mental performance|There was no intervention, the mental performance was assessed
214968704|NCT02659943|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
214968705|NCT02659943|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
214968706|NCT02659943|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
214968707|NCT00345124|BEHAVIORAL|high sodium diet|250-350 mmol
214968708|NCT00345124|BEHAVIORAL|Low Sodium Diet|25-35 mmol
214968709|NCT01359930|OTHER|placebo|matching placebo
214968710|NCT01359930|DRUG|Naltrexone and Bupropion SR|25mg bid/day (NX) 200mg bid/day (BUP)
214357461|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
214357462|NCT06025474|DRUG|Vortioxetine 20Mg Tab|Encapsulated vortioxetine immediate release tablets, once daily
214357463|NCT06025474|DRUG|Paroxetine 20 Mg Oral Tablet|Encapsulated paroxetine tablets, once daily
214357464|NCT06025474|DRUG|Sertraline 50 MG|Encapsulated sertraline tablets, once daily
214968711|NCT03705702|OTHER|Education Program|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education, which will include information about the pathophysiology of asthma, medication and peak flow meter instructions, self-monitoring techniques, environmental control techniques and avoidance strategies. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active and maintain a healthy lifestyle.
215082446|NCT03112967|OTHER|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
215082447|NCT03112967|OTHER|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
215082448|NCT00004664|DRUG|megestrol|
215082449|NCT00004664|BEHAVIORAL|Exercise|
215082450|NCT05491941|OTHER|Sepsis Bundle|Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
215082451|NCT02887053|DEVICE|MRI|
215082452|NCT06413420|DRUG|Sunosi (solriamfetol)|Exposure to at least 1 dose of solriamfetol at any time during pregnancy.
215082453|NCT06413420|DRUG|Other prescription wake-promoting medications or stimulants|Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.
215082454|NCT06413420|OTHER|No treatment|No treatment
215082455|NCT04086537|DIAGNOSTIC_TEST|hepcidin levels and BMPR2 expression|Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
215082456|NCT01118520|DRUG|perindopril arginine|10mgs orally daily for the duration of the trial
215082457|NCT01118520|DRUG|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
215082458|NCT01118520|DRUG|placebo|one daily
215082459|NCT03088631|DRUG|Metformin|will receive metformin (1500 mg/day) starting with the commencement of oral contraceptive pills in the preceding cycle until the day of human chorionic gonadotropin triggering.
215082460|NCT03088631|OTHER|Placebo|will receive corn-flour placebo tablets (three tablets daily).
214357465|NCT06025474|DRUG|Citalopram 20mg|Encapsulated citalopram tablets, once daily
214357466|NCT06025474|DRUG|Escitalopram 10mg|Encapsulated escitalopram tablets, once daily
214357467|NCT06025474|DRUG|Duloxetine 60 MG|Encapsulated duloxetine tablets, once daily
214357468|NCT06025474|DRUG|Pregabalin 75mg|Encapsulated pregabalin tablets, once daily
214357469|NCT01814371|DRUG|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
214357470|NCT01814371|OTHER|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
214357471|NCT01814371|BEHAVIORAL|Hygiene Protocol|"Follow key hygiene tips:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors, brushes, or deodorant.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share."
214357472|NCT00006213|DRUG|BMS-214662|Given IV
214357473|NCT00006213|OTHER|pharmacological study|Correlative studies
215082461|NCT01279629|DRUG|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
215082462|NCT05234424|OTHER|THRIVE|During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.
215082463|NCT05671575|OTHER|Questionnaire about Epilepsy|After obtaining informed consent, a structured questionnaire will be administered to the accompanying relative. The questionnaire consists of 5 sections: participants socio-demographic characteristics, patient demographic and clinical characteristics, participants knowledge about epilepsy including sources of knowledge and management of an acute seizure, general attitudes, and behaviors towards the People with epilepsy, Stigma scale of epilepsy.\[14\], and Quality of life in epilepsy-10 inventory (QOLIE-10) as the main data collection tool as regard quality of life of patients with epilepsy.
215082464|NCT00145418|DRUG|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
215082465|NCT04217967|DRUG|Ixazomib|the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
215082466|NCT04217967|DRUG|Lenalidomide|the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
215082467|NCT04582435|DRUG|Insulin Icodec|Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
214357474|NCT00006213|OTHER|laboratory biomarker analysis|Correlative studies
214357475|NCT02794285|BIOLOGICAL|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
214357476|NCT02794285|DRUG|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
214357477|NCT06241248|DIAGNOSTIC_TEST|Rapid sepsis diagnostic test|The different stages of the OCEAN Dx whole blood bacterial identification test. Identification is carried out using 9 ml of whole blood taken at the patient's bedside, and is provided after comparing the DNA sequence of the bacteria with a database. The rapid sepsis diagnostic test developed by OCEAN Dx can identify the bacteria responsible for the infection in just 4 hours at present, and soon in 3 hours. Subject to future innovations, it will probably even be possible to obtain a positive result for the presence of bacteria in the patient's sample in just 2 hours.
214357478|NCT02346305|DEVICE|Non-invasive ventilation|Home NIV installation
214357479|NCT02486484|DRUG|ziv-aflibercept|zaltrap injection
214357480|NCT03692533|DIAGNOSTIC_TEST|Immunohistochemistry|"Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case."
214357481|NCT00696748|DRUG|Nebido (testosterone undecanoate)|Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
214357482|NCT00696748|DRUG|Placebo|Placebo 4 mL intramuscular
214357483|NCT00151307|DEVICE|INVOS cerebral oximeter|
214357484|NCT02362698|OTHER|electro-acupuncture|"13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.~HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour."
215082468|NCT04644796|DRUG|saline 0.9%|Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
215082469|NCT04644796|DRUG|Liposomal bupivacaine|Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
214357485|NCT02362698|OTHER|psychological intervention|Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
214357486|NCT06129773|PROCEDURE|antibiotic coated vicryl used for fascial closure|in this group fascial closure was done with antibiotic coated vicryl to compare with non coated vicryl after lapaprotomy in contaminated wounds
214357487|NCT01194960|DRUG|Docetaxel|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
214357488|NCT01194960|DRUG|TroVax|Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37
214357489|NCT02995772|DRUG|Aromatase Inhibitors (Arimidex)|Comparison of efficacy with chemotherapy
214357490|NCT02995772|DRUG|Tamoxifen|Comparison of efficacy with chemotherapy
214357491|NCT02995772|PROCEDURE|SOB|Comparison of efficacy with chemotherapy
214357492|NCT02995772|DRUG|FAC|Comparison of efficacy with hormonal therapy
215082470|NCT00000419|DRUG|Premarin and Provera|
214357493|NCT02995772|DRUG|Aromatase Inhibitors (Femara)|Comparison of efficacy with chemotherapy
214357494|NCT02995772|DRUG|Aromatase Inhibitors (Aromasin)|Comparison of efficacy with chemotherapy
214357495|NCT00733538|DRUG|zometa|patients receiving treatment during their follow-up
214357496|NCT04133233|DRUG|ILT101|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
214357497|NCT04133233|DRUG|Placebos|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
214357498|NCT00898885|PROCEDURE|oral biopsy|oral mucosa and salivary gland biopsy after bone marrow transplantation
215082471|NCT01070693|PROCEDURE|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
215082472|NCT01070693|DEVICE|Prolene Hernia System|Prolene Hernia System
215082473|NCT01070693|PROCEDURE|Lichtenstein technique|Lichtenstein technique
215082474|NCT02667223|BIOLOGICAL|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
215082475|NCT02667223|BIOLOGICAL|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
215082476|NCT02667223|BIOLOGICAL|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
215082477|NCT02667223|BIOLOGICAL|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
215082478|NCT02667223|BIOLOGICAL|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
215082479|NCT05016167|PROCEDURE|Replacement every 24 hours|"Processing Steps:~1. The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~3. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~4. The data were recorded."
214357499|NCT03048851|DEVICE|Low dosage SES group|The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
214357500|NCT03048851|DEVICE|High dosage SES group|The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
214357501|NCT03048851|DEVICE|VRCIT group|The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
214357502|NCT03048851|DEVICE|VRCIT+SES group|The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
214357503|NCT03048851|PROCEDURE|traditional rehabilitation program|The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
214357504|NCT01805492|BEHAVIORAL|Dr. Dean Ornish Program for Reversing Heart Disease|Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (\<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
214357505|NCT04460742|BEHAVIORAL|CAPABLE Transitions|The CAPABLE Transitions intervention group will receive an occupational therapy-led multidisciplinary in-home intervention in which the study occupational therapist (\<6 visits), registered nurse (\<5 visits), and handyman (\<2 visits) work with participants over 3-4 months. This intervention group also will receive home health agency care as usual services. CAPABLE Transitions in embedded within a home health agency and includes a care transitions emphasis.
214968712|NCT03705702|BEHAVIORAL|Behavioral intervention|The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting 40 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own PA data and the behavioural change stage, an individual action plan will be established with realistic goals to increase PA. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time. Techniques such as weekly goal-setting, motivational interviewing, activity tracker vibration instructions, self-management, positive reinforcement, relapse prevention and strategies to overcome barriers will be included.
214968713|NCT02463669|DEVICE|Point-of-care ultrasound|Enrolled patients will undergo POCUS of the spleen by the treating emergency physician (resident, fellow or attending). Canadian Emergency Ultrasound Society (CEUS) certified residents, fellows and attending physicians will conduct the bedside ultrasonography after receiving specific training for the purposes of this study. The spleen will be assessed using a curved 2-6 Megahertz (MHz) transducer with the participant in the supine position. The cranio-caudal splenic length will be measured and its maximum dimension will be recorded on the standardized study data sheet.
214357506|NCT04460742|BEHAVIORAL|Home Health Agency Care|Both the CAPABLE Transitions intervention and care as usual treatment arms will receive home health agency care as usual services, which can include nursing, health aide, medical social work, and occupational, physical, and speech therapy services. Home health agency clinicians will determine the types and duration of CHHA services that the study participants receive; these services will be completely independent from the research study.
214357507|NCT05356260|DEVICE|URincontrol4men|The intervention is built as an app
214357508|NCT05356260|OTHER|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
214357509|NCT03996473|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations
214968714|NCT02198196|BEHAVIORAL|Weight Talk-Mindfulness|
214968715|NCT01474850|PROCEDURE|lung recruitment maneuver|RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
214968716|NCT01576575|DRUG|Buprenorphine Control|Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
214968717|NCT01576575|DRUG|Buprenorphine + Rifampin|Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
214968718|NCT01576575|DRUG|Buprenorphine + Grapefruit juice|Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
214357510|NCT03996473|DRUG|Pembrolizumab|200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations
214357511|NCT06116591|BIOLOGICAL|mPnC candidate|monovalent pneumococcal conjugate candidate
214357512|NCT06116591|BIOLOGICAL|mPnC control|monovalent pneumococcal conjugate control
214357513|NCT01972841|DRUG|Solifenacin succinate|Oral tablet
214357514|NCT01972841|DRUG|Mirabegron|Oral tablet
214357515|NCT01972841|DRUG|Placebo to match solifenacin succinate|Oral tablet
214357516|NCT01972841|DRUG|Placebo to match mirabegron|Oral tablet
214968719|NCT01576575|DRUG|Buprenorphine + Ketoconazole|Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine
214968720|NCT01321034|DRUG|Niacin/Laropiprant|1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.
214968721|NCT03971331|DEVICE|PAC catheter and critical care ultrasound examination|Patients in study group were placed the PAC and performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately
215082480|NCT05016167|PROCEDURE|Replacement every 12 hours|"Processing Steps:~1. Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~3. The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~4. Monitored again.~5. Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~6. Immediately after drying, skin moisture was measured from the monitored areas.~7. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~8. The data were recorded."
214357517|NCT03696017|OTHER|Multi-domain assessment battery|Assessments of emotion regulation, neurocognitive performance, pain, sleep, and substance use. There is no therapeutic intervention; all participants are already independently in treatment for their substance use disorder and we are simply assessing them at baseline visit and 3-month follow-up.
214357518|NCT06962761|DRUG|Vit D|in this study we use a combination of vit d and probiotics
214357519|NCT03712891|DIETARY_SUPPLEMENT|Coffee|Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
214357520|NCT04461301|PROCEDURE|Multimodal Prehabilitation|A multimodal prehabilitation program (exercise, nutrition, anemia correction and smoking cessation).
214357521|NCT04969198|DRUG|Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)|Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
214357522|NCT05138419|OTHER|"CKD What You Need To Know Workbook System"|139 page Workbook including CKD Action Plan, Web-Based Resources, Interactive CKD Patient education material
214357523|NCT05138419|OTHER|CKD Action Plan|Goals based on international guidelines that can protect kidney function (1 knowledge and 10 action goals) Patient education material used separately for control arm.
214357524|NCT05138419|OTHER|CKD Web-based Resource List|CKD Patient education material used separately for control arm
214357525|NCT05138419|OTHER|Food Label reading exercise|CKD Patient education material used separately in all arms.
214357526|NCT03256162|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.
214357527|NCT03256162|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
214357528|NCT00508430|DRUG|ASP8825|oral
214357529|NCT00508430|DRUG|Placebo|oral
214357530|NCT06256133|PROCEDURE|Enhanced Recovery After Surgery protocol|Preoperative oral carbohydrate loading, Ultrasound-assisted thoracic epidural catheter placement, Intraoperative individualized goal-directed fluid therapy, Active warming techniques, The inspired fractional concentration of oxygen was maintained, Multimodal postoperative nausea and vomiting (PONV) prevention strategies, Anesthesia was maintained using a target-controlled infusion (TCI) of propofol and remifentanil, Scheduled administration of an intravenous (IV) or oral nonsteroidal anti-inflammatory drug (NSAID) (50 mg of dexketoprofen)
214968722|NCT05649670|OTHER|Mobile Stroke Unit deployment|Deployment of an MSU + conventional ambulance, allowing prehospital CT-scan imaging with intracranial CT angiography. This will allow prehospital intravenous thrombolysis and optimal triage (i.e. accurate identification of patients with large vessel occlusion, who are eligible for mechanical thrombectomy).
214968723|NCT05562245|OTHER|Motivational Interviewing-Based Breastfeeding Education|"Motivational interviewing is basically a directive and client-centered psychosocial intervention used to help individuals discover and analyze ambivalent emotions related to their health behaviors, to learn new skills and to improve their existing skills. One of the main guiding principles in motivational interviewing is self-support and empowerment. The interviews consist of one to four sessions lasting between 7.5-60 minutes.~A total of four motivational interviews will be held with the mothers in the experimental group."
214968724|NCT03400527|OTHER|Exercise|Participants will pedal on a stationary bicycle up to 25 minutes 2-3 times a week for 4 weeks at a self directed pace and intensity
215082481|NCT00637637|DRUG|indinavir sulfate|
215082482|NCT00637637|DRUG|ritonavir|
215082483|NCT00637637|RADIATION|radiation therapy|
215082484|NCT01089023|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
214968725|NCT01670864|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week \& 1-month will be made to the participants in this group.
214968726|NCT01670864|BEHAVIORAL|SMS intervention group|The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
214968727|NCT04270812|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)|"TranS-C adopts a modular approach to reversing the psychosocial, behavioral, and cognitive processes maintaining sleep problems via 4 cross-cutting modules (introduced in the first session and included in every session thereafter), 4 core modules and 7 optional modules. TranS-C typically involves 6-8 individual, weekly 50-minute sessions."
215082485|NCT00904618|PROCEDURE|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
215082486|NCT00904618|PROCEDURE|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
214968728|NCT05122611|OTHER|no intervention, imaging study only|Imaging study only
215082487|NCT00904618|DRUG|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
214357531|NCT04244032|BEHAVIORAL|Working Memory Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a working memory task designed to utilize individually-adapted difficulty levels.
214357532|NCT04244032|BEHAVIORAL|Inhibitory Control Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in an inhibitory control task designed to utilize individually-adapted difficulty levels.
214968729|NCT03531866|BEHAVIORAL|DigiKnowIt News|DigiKnowIt News is an online, interactive, multimedia web-based resource designed to educate youth about participating in clinical trials. Youth will learn general information about clinical trials, their rights in a clinical trial, the good and not so good of participating in clinical trials, communication with others during a clinical trial, and specific types of procedures used in clinical trials (i.e., needles, scans). DigiKnowIt News is web-based and youth can complete it at home, on their own time.
214968730|NCT06551896|DRUG|Pemigatinib|Pemigatinib and immune checkpoint inhibitors
214968731|NCT01723072|BIOLOGICAL|Omalizumab|Humanized monoclonal antibody against human IgE
214968732|NCT01723072|DRUG|Placebo|Placebo to omalizumab
214968733|NCT02785211|BEHAVIORAL|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
215082488|NCT00379782|OTHER|Navigation|Navigation and escourt
215082489|NCT03220581|BEHAVIORAL|Referral for care|referral for addictions support
215082490|NCT03220581|BEHAVIORAL|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
215082491|NCT01949623|OTHER|Anterior Chamber (AC) tap|Aqueous Samples will be collected for measurement of biomarkers
214357533|NCT04244032|BEHAVIORAL|Bias Modification Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a bias modification task designed to utilize individually-adapted difficulty levels.
214357534|NCT01904448|DEVICE|Auditory Brainstem Implantation in Children|
214357535|NCT02656797|DRUG|Topical Amphotericin-B 0.4% liposomal gel|Topical Amphotericin-B 0.4% liposomal gel
214357536|NCT01015989|OTHER|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
214357537|NCT01015989|OTHER|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
215082492|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
215082493|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
215082494|NCT01459640|DRUG|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
214357538|NCT05713617|BEHAVIORAL|PODER Familiar|Educational intervention designed to improve healthy behaviors of families of children with intellectual and developmental disabilities.
214357539|NCT05553808|DRUG|Docetaxel|Docetaxel was administered as IV infusion.
214357540|NCT05553808|DRUG|Feladilimab|Feladilimab was administered as IV infusion.
214357541|NCT01802372|BEHAVIORAL|WHO CVD risk assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
214357542|NCT01802372|BEHAVIORAL|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
214357543|NCT04492254|DRUG|Enoxaparin|The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
214357544|NCT02510495|PROCEDURE|"30 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
214357545|NCT02510495|PROCEDURE|"60 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
214968734|NCT03511703|DRUG|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, doubleblind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results lso showed good efficacy and safety.
214968735|NCT03511703|DRUG|Chemotherapy drugs+Iodized oil|Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion. First infusion of some chemotherapy drugs, the general infusion time should not be \<20 min. Then another part of the chemotherapeutic drugs and lipiodol were mixed into emulsions for embolization. The amount of lipiodol is generally 5-20 ml, not more than 30 ml.
214968736|NCT01418469|DIETARY_SUPPLEMENT|Caseinate|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
214968737|NCT01418469|DIETARY_SUPPLEMENT|Whey protein isolate|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
214968738|NCT01418469|DIETARY_SUPPLEMENT|Soy|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
214968739|NCT01418469|DIETARY_SUPPLEMENT|soy+BCAA|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
214968740|NCT04001088|DIETARY_SUPPLEMENT|Probiotic|Dosing regimen of one capsule daily for a maximum of 48 weeks.
214968741|NCT04001088|OTHER|Placebo|Dosing regimen of one capsule daily for a maximum of 48 weeks.
214357546|NCT02510495|PROCEDURE|"180 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
214357547|NCT02510495|PROCEDURE|"300 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
214357548|NCT01915134|DRUG|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
214487337|NCT06046820|DRUG|Control Arm (Conventional Therapy)|Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.
215082495|NCT01459640|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
215082496|NCT01980277|DRUG|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
215082497|NCT01396265|DRUG|Afatinib|single dose
215082498|NCT01396265|DRUG|Afatinib|single dose
215082499|NCT01396265|DRUG|Rifampicin|multiple doses
215082500|NCT01909180|DEVICE|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
214357549|NCT01915134|DRUG|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
214968742|NCT03362762|OTHER|Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:|The physician or the endocrinologist will see the patient during his consultation. The pharmacist will see the patient when he goes to the pharmacy for an insulin treatment. In each case, the patient will be informed about the study, about the medical data that will be collected anonymously. The date will be strictly confidential and under medical secrecy. Then the patient will meet the physician during another consultation at the University Hospital Center of Guadeloupe, in order to collect information's on a questionnaire. Otherwise, the physician can meet the patient at his home, in case he can't move to the University Hospital Center of Guadeloupe.
214968743|NCT02671253|PROCEDURE|Myomectomy|The patient series consists of consecutive patients scheduled for elective laparotomic, traditional laparoscopic or robotic assisted laparoscopic myomectomy. The surgical method is selected based on clinician´s preference.
214968744|NCT04664257|BEHAVIORAL|e-CBT|e-CBT will be administered with weekly modules. See arm/group descriptions for more information.
214968745|NCT03854721|DRUG|VAX014|Solution for intravesical infusion, 3.33x10\^10 rBMCs per vial
214968746|NCT03428100|DRUG|Baricitinib|Administered orally.
214357550|NCT03819491|DIETARY_SUPPLEMENT|COQUN ORAL FORMULATION|COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
214357551|NCT01597544|PROCEDURE|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
214357552|NCT00540280|RADIATION|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
214357553|NCT02672111|DRUG|CAM2038 q1w or q4w exposure to SL BPN/NX|
214968747|NCT03428100|DRUG|Placebo|Administered orally.
214968748|NCT03428100|DRUG|Topical corticosteroid|Administered as standard-of-care.
214968749|NCT01753882|DRUG|Lexapro|Agent + training vs Placebo + training
214968750|NCT01753882|DRUG|Placebo|Agent + training vs Placebo + training
214968751|NCT04556760|DRUG|AZD9567|Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.
214968752|NCT04556760|DRUG|Prednisolone|Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.
214968753|NCT04556760|OTHER|Placebo|Participants will receive placebo for 3 consecutive days of each treatment period in Cohort 3.
214968754|NCT03286920|DIETARY_SUPPLEMENT|Oral nutrition supplement|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
214968755|NCT03286920|DIETARY_SUPPLEMENT|Tube feeding nutrition supplement|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
214968756|NCT05673356|PROCEDURE|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB)|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients. QTB autografts will be harvested as described in the published technique: K. Malinowski, J. Paszkowski, M. Mostowy, A. Góralczyk, R.F. LaPrade, K. Hermanowicz, Quadriceps Tendon-Bone Full-Thickness Autograft: Reproducible and Easy Harvesting Technique Using Simple Surgical Tools, Arthrosc. Tech. 10 (2021) e1165-e1172. https://doi.org/10.1016/j.eats.2021.01.003. ACLR will be performed utilizing anteromedial technique with management of any accompanying intraarticular lesions.
214968757|NCT05116436|PROCEDURE|Blood sample|It will test the presence or absence of genetic mutations found in other cohorts in previous studies.
215082501|NCT04119622|DRUG|Toripalimab|toripalimab 240 mg d1; q3w, up to two cycles.
214357554|NCT02672111|DRUG|CAM2038 q1w or q4w new to BPN treatment|
214357555|NCT04686903|PROCEDURE|Epiduroscopy treatment|Device Epiduroscop, procedure mecahnical lysis, laser, radiofrequency + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline) Follow-up: before procedure, 6 months and 12 months after procedure
214968758|NCT05116436|PROCEDURE|Spine X-ray|To determine the scoliosis
214968759|NCT05399199|PROCEDURE|virtual reality distraction|study group patients will view VR scene for 6 minutes before puncture .It involves a soothing nature experience and calming background music. Patients in intervention group will not able to see the puncture procedure due to the VR glasses.
214968760|NCT02873767|DRUG|PR1|"* Active substance: UCB4019~* Route of Administration: subcutaneously"
214968761|NCT02873767|OTHER|PL1|"* Active substance: Placebo~* Concentration: 0.9 % saline~* Route of Administration: subcutaneously"
215082502|NCT04119622|DRUG|oxaliplatin|oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
215082503|NCT04119622|DRUG|capecitabine|apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
215082504|NCT01630551|DIETARY_SUPPLEMENT|Fishoil supplement|1 capsule per day
215082505|NCT01630551|DIETARY_SUPPLEMENT|Olive Oil|1 capsule per day
215082506|NCT04336371|DIAGNOSTIC_TEST|Self-administered questionnaires|Self-administered questionnaires by the patient will be given during visits in the following order:the self-administered questionnaires concerning the announcement consultation will be completed by the patient after consultation waiting room; self-questionnaires will be given in just before the operation waiting room (D0) just before the suture removal points (J10) and just before the follow-up visit (M3).
215082507|NCT02275117|BIOLOGICAL|ALD403|
215082508|NCT02275117|BIOLOGICAL|Placebo|
215082509|NCT02008513|BIOLOGICAL|AFFITOPE® AD02|
214357556|NCT04686903|PROCEDURE|Racz catheter epidural procedure|"Device Racz catheter, two procedures during clinical trial observation~* First procedure after enrolment into the study mechanical lysis and drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 6 months mechanical lysis + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)"
214357557|NCT04686903|PROCEDURE|Caudal epidural block|"Technique Caudal epidural block~Three procedures during clinical trial observation :~* First procedure after enrolment into the study drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 4 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)~* Third procedure after 8 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)"
214357558|NCT01909310|PROCEDURE|head extension|the lungs are ventilated with the patient´s head extended
214968762|NCT04564911|COMBINATION_PRODUCT|Flash Glucose Monitoring and Education|Participants will wear the flash glucose monitoring system, and receive an education package on how to self-manage their glucose levels. They will use the flash glucose monitoring system continuously for 6 weeks. From week 6 to week 24, the frequency of use of flash glucose monitoring will be reduced to one sensor every 4 weeks. They will receive education at weeks 0, 2, 8 and 16. They will also wear a blinded sensor for the last 2 weeks of the intervention period (week 25 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
214968763|NCT04564911|COMBINATION_PRODUCT|Capillary glucose monitoring and Education|Participants will use a capillary glucose meter and receive an education package on how to self-manage their glucose levels. Participants will be encouraged to test their blood glucose levels at least twice a day, but preferably 4 times daily: pre-meal and bedtime blood glucose levels. They will receive education at weeks 0, 2, 8 and 16. They will wear a blinded sensor again after the last 2 weeks of the intervention period (week 24 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
214968764|NCT03089463|DIAGNOSTIC_TEST|Observation|The primary objective is to employ the measurements of neuropathy, micro/macro-perfusion, and biomechanics of the foot mainly tissue stiffness and plantar pressure to determine the vulnerability of foot to mechanical trauma and ulceration. From the data collected it is proposed that a prognostic risk stratification system will be developed based on the range of parameters collected to identify those that are at highest risk of ulceration incident. Those that are classed as high risk are to be sub-stratified to increase the accuracy of the system in predicting ulceration. This will allow a patient-specific approach to be taken in the prevention of ulcers by providing adequate information to predict ulceration incident.
214968765|NCT06213987|DRUG|0.025% Tretinoin|Total duration of 8 weeks.
214968766|NCT06136468|BEHAVIORAL|Virtual coach|The virtual coch will be displayed to the participants using an optical see-through head-mounted display
215082510|NCT02008513|BIOLOGICAL|Placebo|
214357559|NCT01909310|PROCEDURE|neutral position|the lungs are ventilated with the patient´s head in neutral position
214357560|NCT01909310|PROCEDURE|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
214357561|NCT01839110|DRUG|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
214357562|NCT01839110|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks.
214357563|NCT04699279|DRUG|Rosuvastatin 10mg|Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
214357564|NCT00233077|BEHAVIORAL|Patient Assistance|Patients will be surveyed to assess their knowledge about cancer \& its treatment, experience with \& access to health care system, trust, depression, social support \& self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
214968767|NCT02979821|DRUG|Poziotinib|A cycle of study treatment is defined as 28 days.
214968768|NCT05340335|DRUG|Remimazolam|A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
214968769|NCT00400075|DRUG|azathioprine|
214968770|NCT00400075|DRUG|cyclophosphamide|
214968771|NCT04604834|OTHER|PFAT first|Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
214968772|NCT04604834|OTHER|APRP first|Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
215082511|NCT01045941|DRUG|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
214968773|NCT04633746|DIAGNOSTIC_TEST|measuring plasma Endostatin level|measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
214968774|NCT06391424|DIAGNOSTIC_TEST|Spontaneous Breathing Trial|Patients will undergo an SBT to determine whether they are ready for extubation.
215082512|NCT01045941|PROCEDURE|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
215082513|NCT05551013|DRUG|APG-157|"APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~* Progression post TMZ (will receive APG-157 only)~* Ongoing Optune (will receive concurrent Optune + APG-157)~* Progression post Optune (will receive APG-157 only)"
214357565|NCT00233077|BEHAVIORAL|Information only|Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
214357566|NCT04307823|OTHER|Treadmill training|"3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest\*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms"
214357567|NCT04307823|OTHER|Treadmill protocol and Respiratory training|"Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks"
214357568|NCT05790733|OTHER|Standard intubation|This involves the use of 5% Xylocaine nebulizer spray and a single-use cannula. The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia.
214357569|NCT05790733|OTHER|Hypnosis|"Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics.~As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products.~The installation of the NGS with hypnosis will be carried out according to the protocol set out in appendix 4."
214968775|NCT01047280|DIETARY_SUPPLEMENT|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
214968776|NCT01047280|DIETARY_SUPPLEMENT|Safflower oil|3.5 g/d of safflower oil
214968777|NCT01047280|DIETARY_SUPPLEMENT|G-c9, t11|3.5 g/day of c9, t11 CLA
214968778|NCT00954681|DRUG|quetiapine|Quetiapine treatment from 25 mg daily to 300 mg twice daily
214968779|NCT01954589|DRUG|ACT-462206 5 mg|
214968780|NCT01954589|DRUG|ACT-462206 25 mg|
214968781|NCT01954589|DRUG|ACT-462206 100mg|
214968782|NCT01954589|DRUG|ACT-462206 200mg|
214968783|NCT01954589|DRUG|ACT-462206 400mg|
214968784|NCT01954589|DRUG|ACT-462206 1000 mg|
214968785|NCT01954589|DRUG|ACT-462206 1500mg|
214968786|NCT01954589|DRUG|Almorexant 400mg|
214968787|NCT01954589|DRUG|Placebo|
214968788|NCT00222703|BEHAVIORAL|Smoking relapse prevention|
214357570|NCT00384228|DRUG|Nilotinib|
214357571|NCT03378167|BIOLOGICAL|MICROBIOTA|Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.
214357572|NCT03378167|BIOLOGICAL|PLACEBO|"Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist."
214968789|NCT04564001|DRUG|Infliximab|Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A
214968790|NCT04564001|DRUG|Tocilizumab|Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
214968791|NCT01877200|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
214968792|NCT01759706|BEHAVIORAL|Enhanced recovery after surgery protocol|ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
214968793|NCT01759706|PROCEDURE|Standard perioperative care|Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
214968794|NCT01759706|DRUG|PONV prophylaxis with Ondansetron + Dexamethasone|Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
214968795|NCT01759706|OTHER|Postoperative mobilization program|Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward
214968796|NCT01759706|DRUG|Epidural analgesia with naropin + sufentanil|Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
214968797|NCT01759706|DRUG|Pre-anesthetic medication with diazepam|Premedication before general anesthesia
214968798|NCT01759706|BEHAVIORAL|Preadmission counselling|Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.
214968799|NCT01759706|DRUG|Preoperative bowel preparation with sodium phosphate|Preoperative bowel preparation with oral assumption of sodium phosphate
214968800|NCT05528172|DRUG|Ripasudil|K-321 ophthalmic solution
214968801|NCT05528172|DRUG|Placebo|Placebo ophthalmic solution
214357573|NCT02046980|PROCEDURE|Gufoni|
214968802|NCT04307862|DRUG|ZEP-3Na 0.1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
214968803|NCT04307862|DRUG|ZEP-3Na 1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase, with optional 2 weeks of open label with ZEP-3Na 1%.
214968804|NCT04307862|DRUG|Placebo Vehicle only|he Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
214968805|NCT03172728|BEHAVIORAL|psycho-education pamphlet|psycho-education intervention, based on Cognitive Behavioral Therapy, that is easy to provide and feasible in standard perinatal care. It is intended to increase awareness of obsessive thoughts and to decrease anxiety and encourage treatment seeking.
214968806|NCT02303639|PROCEDURE|Radiofrequency catheter ablation|Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping
214968807|NCT02303639|DRUG|Antiarrhythmic drug therapy|Amiodarone (or sotalol) for prevention of VT/VF relapses
214968808|NCT05530772|DEVICE|Endoscopic necrosectomy|Initially, a tract is created between the stomach or duodenum with the walled-off pancreatic necrotic collection through placement of a stent. Then, the endosocpe is entered the necrotic cavity with CO2 insufflation, and the necrotic materials are removed with snare, grasper, or suctioning.
214968809|NCT03624491|OTHER|Esophageal pressure measurement guided ventilation|Use of esophageal pressure measurements to guide mechanical ventilation
214968810|NCT05772676|DRUG|Aprepitant|80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery
214968811|NCT05772676|OTHER|Placebo|Placebo + standard antiemetic regimen, once two hours before surgery
214968812|NCT05401994|PROCEDURE|screw retained arch bar|maxillomandibular fixation with bone screwed arch bar
215082514|NCT05839340|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.
215082515|NCT05839340|DEVICE|Assist Control Ventilation|ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.
214968813|NCT05401994|PROCEDURE|conventional Erich's Arch Bar|maxillomandibular fixation with conventional arch bar fixed to the teeth
214968814|NCT04592016|DRUG|Voltaren - Diclofenac sodium gel 1% (GSK, USA)|Topical application in dermal-sampling visit
214968815|NCT04592016|DRUG|Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)|Topical application in dermal-sampling visit
214968816|NCT04592016|DRUG|Diclofenac sodium gel 1% (Perrigo, USA)|Topical application in dermal-sampling visit
214968817|NCT04592016|DEVICE|Dermal open flow microperfusion - Pilot|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 24 hours post-dose.
214968818|NCT04592016|DEVICE|Dermal open flow microperfusion - Pivotal|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose.
214968819|NCT04592016|PROCEDURE|Blood sampling - Pilot|1 sample is taken pre-dose and 24 samples are taken post-dose.
214357574|NCT02046980|PROCEDURE|Vibration|
214357575|NCT02046980|PROCEDURE|Sham|
214968820|NCT04592016|PROCEDURE|Blood sampling - Pivotal|1 sample is taken pre-dose and 12 samples are taken post-dose.
214968821|NCT05728736|DRUG|Lemborexant 25 mg|Lemborexant 25mg will be taken nightly for two consecutive nights.
214968822|NCT05728736|DRUG|Placebo|Placebo will be taken nightly for two consecutive nights
214968823|NCT03335800|DEVICE|Apple Heart Study App|The Apple Heart Study app is a mobile medical app that analyzes pulse rate data. The app identifies episodes of irregular heart rhythms consistent with atrial fibrillation and other arrhythmias.
214968824|NCT00844090|DRUG|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
214968825|NCT03628651|OTHER|Blood Sample Collection|HCC subjects will have one blood sample collected.
214357576|NCT01367327|BEHAVIORAL|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
214968826|NCT03628651|OTHER|Blood Sample Collection|Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.
214357577|NCT01367327|BEHAVIORAL|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
214393787|NCT05641077|OTHER|Virtual Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via a virtual visit using videoconference technology at 6 weeks after the anticipated date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
214968827|NCT04976439|OTHER|co-occuring mutation|APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA
214968828|NCT05594147|DRUG|Non-TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
214968829|NCT05594147|DRUG|Other TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
214968830|NCT05594147|DRUG|Regorafenib (Stivarga, BAY73- 4506)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
214968831|NCT05594147|DRUG|Sorafenib (Nexavar, BAY43-9006)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
214968832|NCT02691546|OTHER|blood sample collection|
214968833|NCT02307227|DRUG|Trastuzumab|
214968834|NCT02307227|DRUG|Paclitaxel|
215082516|NCT03089879|BIOLOGICAL|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
215082517|NCT03592719|BEHAVIORAL|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
215082518|NCT03592719|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
215082519|NCT03421743|DRUG|Inhaled molgramostim|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
214357578|NCT01320046|OTHER|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|"Patients will undergo the following evaluation:~1. Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~2. Medical history.~3. Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~4. Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~5. Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours."
214357579|NCT01328574|DRUG|TRC105|15 mg/kg intravenously
214357580|NCT04508439|DRUG|Enoxaparin|Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
214357581|NCT01483924|DRUG|Apo805K1|Sequential parallel dose escalation.
214357582|NCT05378945|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
214357583|NCT05378945|DRUG|Placebo (vehicle)|Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
214357584|NCT03589898|DRUG|Gabapentin|Single dose of gabapentin 900 mg
214357585|NCT06060171|PROCEDURE|Aortic valve intervention|Surgical or transcatheter aortic valve intervention
214357586|NCT04093622|GENETIC|Genetically engineered NK cells|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered NK Cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
214357587|NCT01002326|BEHAVIORAL|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
214357588|NCT03160027|DEVICE|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
214968835|NCT02307227|DRUG|Epirubicin|
215082520|NCT03421743|DRUG|Antimycobacterial regimen|Multidrug NTM guideline-based antimycobacterial regimen
214968836|NCT02307227|DRUG|Docetaxel|
214968837|NCT03490617|DRUG|Vaginal misoprostol|To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
214968838|NCT03786107|DIAGNOSTIC_TEST|Almac HER-Seq Assay|whole blood sample analysis
214968839|NCT01666483|PROCEDURE|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
214968840|NCT01666483|PROCEDURE|Laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
214968841|NCT04283812|DEVICE|DBS Electrode Implantation using D1 Sterotactic System|Treatment intervention will consist of subjects undergoing Mayo Clinic standard deep brain stimulation surgery specific to their diagnosed neurological disorder consisting of implantation of stimulating electrodes using the D1 stereotactic system.
214968842|NCT04572828|PROCEDURE|Paracervical Block|Two-point (at 4 and 8 o'clock only) technique will be used for paracervical block for Group 1: Waiting 1 Minute After Paracervical Block and Group 2: Waiting 3 Minute After Paracervical Block. For these groups 10 ml 2% Prilocaine (VEM İlac, Tekirdag, Turkey) will be injected for each side approximately 10 mm into the cervical stroma at the cervico-vaginal junction with a 22- gauge hypodermic needle.
214968843|NCT04572828|DRUG|550 mg Naproxen Sodium 60 minutes before the procedure|550 mg Naproxen Sodium (Abdi Ibrahim, Turkey) will be given to participants in the Group 4, 60 minutes before the procedure.
214968844|NCT04572828|PROCEDURE|The capped needle|The capped needle model will be employed for Group 3: Control Group. After cervical and vaginal preparation with povidone iodine a capped needle will be touched the cervico-vaginal junction at 4 and 8 o'clock.
214968845|NCT03949595|OTHER|Data collection|
214968846|NCT02590666|PROCEDURE|Bipolar Polypectomy|Polyps resection with bipolar electrode
214968847|NCT02590666|PROCEDURE|Mechanical Polypectomy|Polyps resection with microscissors or graspers
214968848|NCT02590666|DEVICE|Bipolar electrode|Bipolar electrode used to performs polypectomy
214968849|NCT02590666|DEVICE|Microscissors or graspers|Mechanical instruments used to performs polypectomy
214968850|NCT02895269|BEHAVIORAL|Collaborative shared care|Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
214968851|NCT06169735|DRUG|Indocyanine green|ICG Administration: All enrolled patients with scheduled thyroidectomy or parathyroidectomy will receive a standard cervical incision that afford access to either side of neck. Following sufficient exposure of thyroid, 25 mg of indocyanine green (ICG), reconstituted in 10 ml of sterile water, will be administered intravenously. A dosage of 1 ml of this solution will be injected into a peripheral IV line, followed by a 5 ml flush of normal saline to ensure the propagation of the dye within the vascular compartment.
214968852|NCT06169735|DEVICE|SPY Portable Handheld Imaging|Fluorescent Imaging: Approximately 30 seconds post-administration, the parathyroid glands are expected to exhibit fluorescence under near-infrared imaging. The emitted fluorescence is anticipated to persist for approximately 20 minutes, allowing ample time for intraoperative evaluation of parathyroid viability and perfusion
214357589|NCT01386528|DRUG|nonacog beta pegol|The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
214357590|NCT00105638|BEHAVIORAL|educational program, by telephone|
214357591|NCT04797247|DRUG|lerodalcibep|PCSK9 inhibitor
214357592|NCT01716429|BEHAVIORAL|Vegan diet|Vegan dietary approaches for weight loss
214357593|NCT01716429|BEHAVIORAL|Low calorie diet|Reduced calorie diet for weight loss
214357594|NCT00536003|DRUG|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
214968853|NCT02990130|OTHER|Observational|
214968854|NCT06957951|OTHER|Conventional Physiotherapy|Application of hot packs, TENS (transcutaneous electrical nerve stimulation), therapeutic ultrasound, and posture/activity education for low back pain management.
214968855|NCT06957951|BEHAVIORAL|Core Stabilization Exercises|Supervised core stabilization exercises including planks, bird-dog, and pelvic bridging, targeting trunk muscle strength and stability.
214968856|NCT06957951|BEHAVIORAL|WBV-Supported Core Exercises|Core stabilization exercises performed on a whole-body vibration platform (30 Hz frequency, low amplitude \~2 mm) during exercise execution to enhance neuromuscular stimulation.
215082521|NCT02523131|DEVICE|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:~* Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
215082522|NCT02523131|DEVICE|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
214357595|NCT00536003|DRUG|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
214357596|NCT04947800|DEVICE|Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points
214357597|NCT04947800|DEVICE|Pulmonary rehabilitation program + Lv7/Gb26|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points
214487338|NCT04864145|DEVICE|Transcatheter Aortic Valve Implantation|The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.
214487339|NCT04864145|DRUG|Medical therapy|Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
214968857|NCT06483932|OTHER|Dried barberry|Subjects will ingest 10 grams of powdered seedless barberry on a daily basis, in conjunction with the low-calorie diet.
214968858|NCT06483932|OTHER|Low-calorie diet|Diet with 500 kcal subtracted from the daily energy requirement
214968859|NCT05237726|DRUG|Enoxaparin 40 mg q24 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
214357598|NCT00035529|DRUG|Placebo|Solution, i.v infusion, 0 mg, Days 1 \& 15 then monthly, 10 months.
214357599|NCT00035529|DRUG|BMS 188667 (Abatacept)|Vial, i.v infusion, 2mg/kg, Days 1 \& 15 then monthly, 10 months.
214968860|NCT05237726|DRUG|Enoxaparin 30 mg q12 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
214968861|NCT05237726|DRUG|Unfractionated heparin 5000 U q8 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
214968862|NCT02038179|DRUG|Allopurinol|Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.
214968863|NCT02038179|DRUG|Placebo|Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
214968864|NCT02899975|OTHER|Validation|Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
214968865|NCT02927054|OTHER|Sepsis Education|Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
214357600|NCT00035529|DRUG|BMS 188667 (Abatacept)|Vial, i.v infusion, 10 mg/kg, Days 1 \& 15 then monthly, 10 months.
214357601|NCT05034523|RADIATION|MRI Voxel based morphometry|Voxel based morphometry through analysis of 3D T1 weighted sequence to assess total intracranial volume. All participants were scanned on the 1.5Tesla MR scanner (Achieva, Philips Medical Systems, Best, NL) with a 16-channel head coil at the diagnostic radiology department.
214357602|NCT00901693|DRUG|AL-46383A Ophthalmic Solution|
214357603|NCT00901693|DRUG|AL-46383A Ophthalmic Solution Vehicle|
214357604|NCT01290432|DIETARY_SUPPLEMENT|Inofolic Plus|Inofolic Plus contains folic acid and myoinositol and melatonin
214357605|NCT00022256|DRUG|motexafin gadolinium|
214357606|NCT00022256|RADIATION|radiation therapy|
214357607|NCT01994954|OTHER|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
214357608|NCT00850473|DIAGNOSTIC_TEST|PET/CT|Patient will have one imaging modality - a Positron Emitting Tomography CT which includes F-18 FDG and heparin/intralipid infusion and Contrast Dye.
214357609|NCT01397838|DRUG|Pro-Bone|500 mg Capsules of Pro-Bone twice daily
214357610|NCT03516448|DRUG|Gan Fu Le Tablets|6 Tablets，tid,po
214357611|NCT03516448|DRUG|Tyroserleutide for injection|6mg/d, 5days,ivgtt
214357612|NCT03516448|DRUG|Placebo|0mg/d, 5days,ivgtt
214357613|NCT05305196|OTHER|Eccentric-focused exercises|"Three eccentric-focused exercises:~1. Shoulder external rotator eccentric contraction in shoulder abduction 90 degree~2. Shoulder external rotator eccentric contraction in shoulder abduction 0 degree~3. Shoulder abductor eccentric contraction in shoulder abduction 90 degree"
214357614|NCT05305196|OTHER|Stretching exercises|"1. Modified sleeper stretch~2. Modified cross-body stretch"
214357615|NCT05305196|OTHER|Hot pack|Hot pack application on shoulder region
214357616|NCT05305196|OTHER|Massage|Massage for upper trapezius
214357617|NCT02270333|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
214357618|NCT02270333|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
214357619|NCT00449176|DRUG|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
214357620|NCT00449176|DRUG|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
214357621|NCT00449176|DRUG|placebo|matching placebo twice daily for 15 weeks
214357622|NCT00528138|OTHER|Laboratory Test|CRP, white blood cell count, hepatic function tests
214357623|NCT02369094|OTHER|acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
214357624|NCT04597268|DRUG|Dexmedetomidine|intravenous dexmedetomidine 1 mic/kg
214357625|NCT04597268|DRUG|Ketamine|ketamine 1mg/kg
214968866|NCT02426008|OTHER|Growth Factors and Cytokine adding to embryo culture media|
214968867|NCT02426008|OTHER|No Intervention|Nothing to Add
214968868|NCT02221648|DRUG|Placebo|Subjects will be randomization to receive either the study drug or the placebo group.
214968869|NCT02221648|DRUG|AbobotulinumtoxinA Treatment|Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
214357626|NCT04597268|DRUG|Midazolam|midazolam 0.05 mg/kg
214357627|NCT00338065|BEHAVIORAL|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
214357628|NCT00338065|BEHAVIORAL|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
214357629|NCT02154763|DRUG|Ropivacaine|
214357630|NCT02154763|DRUG|Normal Saline|
214357631|NCT02901015|BEHAVIORAL|Assessment battery A|"Social cognition tests version A are administered to the patients"
214357632|NCT02901015|BEHAVIORAL|Assessment battery B|"Social cognition tests version B are administered to the patients"
214357633|NCT02920827|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
214487340|NCT06378619|DIAGNOSTIC_TEST|Tapping Test|For the administration of the tapping test, a computer application installed on a Tablet will be used. The test will be administered up to 3 times, with a 15-minute interval between each administration. Each tapping test trial will last 15 seconds. At the beginning of the session, the patient will perform 2 practice attempts.
214968870|NCT01820247|DRUG|enteral nutrition|
214968871|NCT01820247|DRUG|Tripterygium glycosides|
214357634|NCT02920827|COMBINATION_PRODUCT|Placebo vaginal ring|Placebo vaginal ring containing no dapivirine
214357635|NCT00837174|DRUG|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
214357636|NCT00526123|DEVICE|Symmetric Tip Catheter|Dialysis catheter
214968872|NCT00184938|DRUG|morphine|
214968873|NCT00184938|DRUG|naloxone|
214968874|NCT00184938|DRUG|Technetium-TC99m-labeled Annexin A5|
214968875|NCT00184938|PROCEDURE|forearm ischemic exercise|
214968876|NCT00184938|PROCEDURE|ten minute forearm ischemia|
214968877|NCT00953888|DRUG|AZD5069|Single dose of oral solution.
214968878|NCT00953888|DRUG|Placebo|Single dose of oral solution.
214968879|NCT06397430|DIETARY_SUPPLEMENT|parenteral nutrition supplements|parenteral nutrition
214357637|NCT00526123|DEVICE|Conventional Split-tip Catheter|Dialysis Catheter
214357638|NCT00649194|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fed
214357639|NCT00649194|DRUG|Aciphex® Tablets 20 mg|20mg, single dose fed
214357640|NCT00490893|DRUG|Detemir|
214357641|NCT06533033|DRUG|Rapid Release Capsules Melatoni|"Twenty-five will be given melatonin therapy in combination with the conventional treatment.~2 tablets,30 minutes before sleeping once daily for 8 weeks."
214357642|NCT06533033|DRUG|Triamcinolone Acetonide ointment, Kenacort-A orabase|"Twenty-five will be given topical corticosteroid applied twice to three times daily.~Topical antifungal will be applied three to four times daily. This conventional treatment will be given to the patients for 8 weeks"
214357643|NCT02045238|DRUG|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
214968880|NCT06397430|DIETARY_SUPPLEMENT|enteral nutrition supplements|enteral nutrition
214968881|NCT06397430|DIETARY_SUPPLEMENT|mixed nutrition supplements|mixed nutrition
214968882|NCT01168921|DRUG|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle
214968883|NCT02438189|DEVICE|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
214968884|NCT05430802|DRUG|Furmonertinib+cisplating/pemetrexed|Furmonertinib 80mg/d for 9 weeks and cisplating75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv in 21-day cycles for 3 cycles
214968885|NCT05074641|OTHER|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
214968886|NCT05074641|OTHER|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
214968887|NCT02937623|DEVICE|Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)|Experimental dissolvable polymer strip containing Novamin (15% weight by weight\[w/w\] calcium sodium phosphosilicate).
214968888|NCT00324974|DRUG|Lansoprazole microgranules suspension|"Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks."
214968889|NCT00324974|DRUG|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
214968890|NCT03489343|DRUG|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
214968891|NCT01388855|DRUG|Cholecalciferol|Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
214968892|NCT01388855|DRUG|Placebo|Pills made to look like vitamin D but have no medication in them
214968893|NCT02862964|OTHER|identify L4/L5|"* For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.~* The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.~* The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure"
215082523|NCT02969096|PROCEDURE|Targeted Cryoablation Therapy|A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
214357644|NCT02045238|RADIATION|Chest X-Ray|
214357645|NCT02045238|OTHER|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
214357646|NCT00088231|DRUG|Imatinib Mesylate (Gleevec)|"600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.~400 mg by mouth every day (for AMM) for a 28 day cycle."
214357647|NCT00088231|DRUG|PTK 787 (vatalanib)|"For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle."
214357648|NCT00220298|DRUG|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
214357649|NCT03651089|DRUG|SP16|subcutaneous injection of experimental anti-inflammatory drug
214357650|NCT03651089|DRUG|Placebos|subcutaneous injection of sterile saline
214357651|NCT01689064|PROCEDURE|Stamm Approach|
214357652|NCT01689064|PROCEDURE|Posterior Septectomy|
214357653|NCT04306198|DEVICE|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with lag screw as proximal fixation
214357654|NCT04306198|DEVICE|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a helical blade as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with helical blade as proximal fixation
214357655|NCT00253591|DRUG|cisplatin|
214357656|NCT00253591|DRUG|vinorelbine tartrate|
214357657|NCT00253591|RADIATION|radiation therapy|
214968894|NCT00394888|DEVICE|MRI|MRI of the spine.
214968895|NCT00394888|DEVICE|MRI of head and neck|MRI of head and C-spine
214968896|NCT00394888|OTHER|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
214968897|NCT00394888|OTHER|Cardiac examination|Complete cardiac examination
214968898|NCT00394888|DEVICE|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
214968899|NCT01526564|DRUG|Acetylcarnitine|Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or \>4 hours for 8 weeks
214968900|NCT01526564|DRUG|Placebo|3 t.i.d, two plates per time
214968901|NCT00116961|DRUG|Velcade|
214968902|NCT00116961|DRUG|Doxil|
214968903|NCT00116961|DRUG|Dexamethasone|
214968904|NCT00861666|BEHAVIORAL|Forgiveness-Based Writing|"Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task."
214357658|NCT02639130|DRUG|Exendin [9-39]|Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent
214968905|NCT03351543|BIOLOGICAL|microbial inoculate|volunteers will regularly receive microbial inoculate that they do not use orally
214968906|NCT05337865|OTHER|Aerobic exercise test.|Aerobic exercise test at a treadmill.
214968907|NCT04010292|BEHAVIORAL|Patient education card|Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
214968908|NCT03703778|PROCEDURE|Androgen deprivation therapy - bilateral orchidectomy|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
214968909|NCT03703778|DRUG|Androgen deprivation therapy - GnRH agonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
214968910|NCT03703778|DRUG|Androgen deprivation therapy - GnRH antagonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
214968911|NCT01921803|RADIATION|hypofractionation|
214968912|NCT01358292|PROCEDURE|Semi-extended Surgical Technique|Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
214968913|NCT01358292|PROCEDURE|Standard Surgical Technique|Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
214968914|NCT01166750|BEHAVIORAL|CD-ROM|"Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material."
214968915|NCT01166750|BEHAVIORAL|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
214968916|NCT04332068|DRUG|Oral ivermectin|Ivermectin (NT007) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.
214968917|NCT04332068|DRUG|Permethrin Cream|permethrin cream 5% (Pioletal® Plus) is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender.
214968918|NCT04332068|OTHER|Placebo tablet|placebo tablets are round, white, scored on one side. There are no active substances in the placebo tablets.
214968919|NCT04332068|OTHER|Placebo cream|A placebo cream is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender but lacking the permethrin agent.
214968920|NCT03812939|DRUG|Octreotide|Patients will receive 6-12 monthly injections every 28 (+/- 3) days.
214357659|NCT02639130|DRUG|Placebo|Placebo infusion as challenge agent
214357660|NCT03130751|BEHAVIORAL|Pocket Coach for AYA with Cancer|The Pocket Coach for AYA with Cancer is a psychosocial intervention to be delivered through a mobile platform. Intervention content is based on Mindfulness Based Stress Reduction (MBSR) and the Resilience in Illness Model \[Dr. Joan E. Haase et al\] and includes modules on relaxation, mindfulness, cognitions, and self-compassion.
214357661|NCT00290641|BIOLOGICAL|filgrastim|
215082524|NCT04284124|OTHER|Erector Spinae block|Patient in the prone position 20 min before induction of general anesthesia. Skin is sterilized by 10% povidone iodine. An US multifrequency convex probe (1-8 MHz) will be used for block. A 22G, 50-mm in length needle will be used and block will be performed at the T4 level of the spine using in-plane approach where a convex probe is placed 2-3 cm lateral to the spine using sagittal approach. Erector spinae muscle and the transverse processes are located and the needle will be inserted deep into the muscle. The needle is directed craniotomy-caudally. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic to monitor spread then 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic is monitored in both cranial and caudal directions
215082525|NCT03073018|DRUG|Fosinopril|oral administration, capsules
215082526|NCT03073018|DRUG|Pravastatin|oral administration, capsules
215082527|NCT03073018|DRUG|Fosinopril Placebo|oral administration, capsules
215082528|NCT03073018|DRUG|Pravastatin Placebo|oral administration, capsules
215082529|NCT01084980|DRUG|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
215082530|NCT05379062|BEHAVIORAL|Active Singing Group|The participants of the Active Singing Group take part in a weekly 45-minute singing activity in a group over a period of 3 months. In total the investigators expect 12 choir rehearsals. The rehearsals will take place between 2pm and 3.30pm in the church of the Wehrle-Diakonissen Private Clinic in Salzburg. The group will be led by a professional and experienced choir director.
214357662|NCT00290641|BIOLOGICAL|graft-versus-tumor induction therapy|
214968921|NCT06010212|DRUG|Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin|"Phase Ib: Patients with advanced ESCC will be enrolled in a 3+3 dose escalation fashion, with projected enrolment of between 9-18 patients to determine RP2D. Once the RP2D is confirmed, the study will proceed to phase II.~fruquintinib: 3 mg, 4 mg, or 5 mg qd p.o., 2 weeks and 1 week, every 3 weeks ( dose exploration phases were performed sequentially from the 4 mg group, refer to the study design section for specific protocols); Camrelizumab: 200 mg I.V D1, every 3 weeks for treatment cycles; Paclitaxel liposomes: 135 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles; Nidaplatin: 70 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles. Chemotherapy is used for up to 6 cycles, followed by maintenance therapy with fruquintinib + Camrelizumab until disease progression or intolerable toxicity.~Phase II: Up to a total of 30 patients with advanced ESCC will be enrolled."
214968922|NCT05499884|PROCEDURE|Endovaginal ultrasound|"Endovaginal ultrasound will be performed in the operating room by the radiology team to:~1. to confirm the operative indication for a rectal shaving ;~2. to confirm the complete removal of the lesion"
214968923|NCT02503241|PROCEDURE|PEEP INCREMENTAL|PEEP was progressively increased by steps of 2 cmH2O every 60 second until the end-expiratory transpulmonary pressure became positive between 0-2 cmH2O.
214968924|NCT02503241|PROCEDURE|PEEP DECREMENTAL|Lung recruitment maneuver (LRM) is a transitory and controlled increase in airway pressure to open collapsed alveoli. LRM is the first step of the PEEP DECREMENTAL method. After LRM, PEEP is systematically decreased, in small decrements, until the best respiratory system mechanics is identified.
215082531|NCT05379062|BEHAVIORAL|Receptive Music Group|The participants of the Receptive Music Group will individually listen to the already researched CD for Parkinson's patients (Bernatzky, Wendtner, Volc, 2012) at home at the same time on one weekday.
215082532|NCT00491660|BEHAVIORAL|supine positioning|
215082533|NCT00491660|BEHAVIORAL|lateral positioning|
215082534|NCT04835909|BEHAVIORAL|Modern board and card games group|Modern board and card games group
215082535|NCT04835909|BEHAVIORAL|Paper and pencil tasks group|Paper and pencil tasks group
215082536|NCT05124509|BIOLOGICAL|Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)|Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
215082537|NCT05124509|BIOLOGICAL|Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)|Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
215082538|NCT02825966|DEVICE|AUDICOR then LifeVest then AUDICOR|Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
215082539|NCT00532740|RADIATION|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
214357663|NCT00290641|DRUG|cyclophosphamide|
214357664|NCT00290641|DRUG|cyclosporine|
214357665|NCT00290641|DRUG|fludarabine phosphate|
214357666|NCT00290641|DRUG|mycophenolate mofetil|
214357667|NCT00290641|PROCEDURE|umbilical cord blood transplantation|
214357668|NCT00290641|RADIATION|radiation therapy|
214357669|NCT04183764|DRUG|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
214357670|NCT02958969|DRUG|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
215082540|NCT02345356|GENETIC|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
215082541|NCT02345356|OTHER|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
215082542|NCT01844011|OTHER|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
215082543|NCT00069524|DRUG|oyster mushroom|
215082544|NCT03608137|OTHER|Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships|To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
214357671|NCT05086367|OTHER|Diaphragmatic and pursed lip breathing|Breathing exercises were performed. Two breathing techniques were applied to the participants. Diaphragmatic and pursed lip breathing were intervened along with routine physical therapy.
214357672|NCT05086367|OTHER|Routine Physical Therapy|Routine physical therapy exercises were performed in which neck isometrics and neck range of motion exercises were performed
214357673|NCT04514848|DEVICE|INSTI Multiplex HIV-1/2 Syphilis AB test|For the detection of antibodies to syphilis and HIV
214357674|NCT04514848|DEVICE|Multiplo Rapid TP/HIV test|For the detection of antibodies to syphilis and HIV
214968925|NCT01585246|DRUG|Saw Palmetto|1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
214968926|NCT01585246|DRUG|soybean oil soft gel|placebo (soybean oil soft gel)
214968927|NCT01688323|OTHER|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
214968928|NCT00234026|DRUG|gemcitabine hydrochloride|
214968929|NCT00145769|DRUG|Short Course Adjuvent Chemotherapy|Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
214968930|NCT00145769|DRUG|Long Course Adjuvant Chemotherapy|Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
214968931|NCT00145769|RADIATION|Short Course Radiotherapy|25 Gy in 5 fractions over 5 days.
214968932|NCT00145769|RADIATION|Long Course Radiotherapy|50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
214968933|NCT00145769|DRUG|Concurrent Chemotherapy|5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
214968934|NCT00145769|PROCEDURE|Initial Surgery|Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
214968935|NCT00289094|DEVICE|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee System
214968936|NCT00289094|DEVICE|Total knee replacement|Fixed Cruciate Retaining Knee System
214968937|NCT02835859|OTHER|Dietary: saccharin|Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
214968938|NCT02835859|OTHER|Estimate glucose absorptions|Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
214968939|NCT03217552|DIAGNOSTIC_TEST|Mologic Biomarker Panel|In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
214968940|NCT00140062|DRUG|latanoprost 0.005% (Xalatan)|
215082545|NCT02504112|OTHER|there is no intervention|
215082546|NCT02700789|PROCEDURE|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
215082547|NCT00681564|PROCEDURE|One-Stage Full-Mouth Disinfection|"* Scaling and root planing, four quadrants in one session~* Tongue brushing with a 1% chlorhexidine gel (1 minute)~* Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~* Subgingival chlorhexidine (1%) irrigation in all pockets~* Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~* Basic oral hygiene instructions~* Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
215082548|NCT00681564|PROCEDURE|Periodontal care|"* Basic oral hygiene instructions~* Supragingival plaque removal"
214357675|NCT02363946|DRUG|ARC-AAT Injection|RNA interference-based, liver-targeted therapeutic
214968941|NCT02111174|DEVICE|Scrambler Therapy|
214968942|NCT02111174|DEVICE|Sham Therapy|
214357676|NCT02363946|OTHER|Placebo|0.9 % normal saline
214968943|NCT03551847|DRUG|Antibiotic|The intervention involves giving an infected patient antibiotics.
214968944|NCT03551847|DRUG|No antibiotics|The intervention involves not giving an infected patient antibiotics.
214968945|NCT03450577|PROCEDURE|PCI of bifurcation lesions|Different approaches for treatment of bifurcation coronary artery disease.
214968946|NCT06314334|DRUG|Sintilimab+Pegaspargase|"1. Sintilimab, 200mg intravenous drip, on day 1;~2. pegaspargase, 2000U/m\^2, capped at 3750U, intramuscular, day 1;"
214968947|NCT06314334|DRUG|P-GemOx|"1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular;~2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip;~3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip"
214357677|NCT02363946|DRUG|Diphenhydramine|Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
214357678|NCT03047200|BIOLOGICAL|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
214968948|NCT06314334|DRUG|GELAD|"1. gemcitabine 1.0g/m\^2 on day 1, intravenous drip;~2. etoposide 60mg/m\^2 on day 1-3, intravenous drip;~3. pegaspargase 2000U/m\^2, capped at 3750U on day 1,intramuscular;~4. dexamethasone 20mg on day 1-4, intravenous drip."
214968949|NCT06314334|RADIATION|IMRT|Intensity modulated radiotherapy (50-56Gy)
214968950|NCT02970955|PROCEDURE|Inoperable thoracic nodes metastases|The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues
214968951|NCT01246895|DEVICE|Microfracture with BST-CarGel|
214968952|NCT01246895|DEVICE|Microfracture without BST-CarGel|
214968953|NCT04838002|DEVICE|Extracorporeal shock wave|Focus and Radial types Extracorporeal shock wave therapy
214968954|NCT03733366|OTHER|Desk surface|The participants will test all 10 desk surfaces and will be randomly allocated to one of the desks each time.
215082549|NCT04151628|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent
215082550|NCT02615405|DIETARY_SUPPLEMENT|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 \& 2.
215082551|NCT02615405|DIETARY_SUPPLEMENT|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 \& 2.
215082552|NCT02615405|DIETARY_SUPPLEMENT|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
215082553|NCT03657563|OTHER|Positive psychological intervention|"Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available."
214968955|NCT04361422|DRUG|Isotretinoin Only Product in Oral Dose Form|assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
215082554|NCT05788588|DRUG|HR19006|An emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume, administered via a central venous line over a time period of approximately 15 hours per day.
214968956|NCT01209403|DRUG|Glucose-infusion|Continuous iv infusion of glucose
214968957|NCT01209403|DRUG|Glucose-insulin infusion|Continuous iv infusion of glucose and shortlasting
214968958|NCT04001010|DRUG|PPP011|1 capsule inhaled 3 times a day with a vaporizer device
214968959|NCT04001010|DRUG|Placebo|1 capsule inhaled 3 times a day with a vaporizer device
214968960|NCT00871234|DRUG|Etravirine|Two one-hundred mg tablets orally twice daily for four weeks
214968961|NCT02288104|DEVICE|needle based confocal endomicroscopy|real time imaging of living tissue at microscopic scale, through a needle.
214968962|NCT00970905|DRUG|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
214968963|NCT00970905|DRUG|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
214968964|NCT00687908|DRUG|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
214968965|NCT00687908|DRUG|Vehicle Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
214357679|NCT04453631|DEVICE|active tDCS|26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle.
214968966|NCT03380377|DRUG|Clazakizumab|Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
214968967|NCT00910845|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
214968968|NCT00910845|DRUG|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
214968969|NCT02600923|DRUG|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
214968970|NCT02600923|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
214968971|NCT01590901|DRUG|Probucol|250mg (1 tablet) bid. p.o for 14 consecutive days
214968972|NCT00792909|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
214357680|NCT04453631|DEVICE|sham tDCS|tDCS is controlled in this intervention: sham mode.
214968973|NCT00792909|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 2 doses
214968974|NCT03948152|OTHER|Standard of Care|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the sites standard of care.
214968975|NCT03948152|OTHER|Mask Advice Tool|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the mask advice tool.
214968976|NCT04865029|OTHER|Placebo injection and placebo pill|Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines
214968977|NCT04865029|DRUG|Estradiol Cypionate 5 mg/ml|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.
214968978|NCT04865029|DRUG|Progesterone 200 mg Oral Capsule|Standard of Care along with Progesterone 200mg by mouth daily for 5 days starting at admission.
214968979|NCT03281941|OTHER|Inhaled capsaicin cough challenge|
214968980|NCT04990115|OTHER|root canal shaping|root canal treatment
214968981|NCT05923710|PROCEDURE|Primary anterior cruciate ligament repair|Only arthroscopic primary anterior cruciate ligament repair was performed in patients with proximal anterior cruciate ligament tear.
214968982|NCT05923710|PROCEDURE|Primary anterior cruciate ligament repair and lateral extraarticular tenodesis (LET) with iliotibial band|In addition to primary anterior cruciate ligament repair, lateral extraarticular tenodesis was performed using the iliotibial band.
214968983|NCT04504110|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Patients with epithelial ovarian cancer who are scheduled for surgical intervention will undergo a comparative 68Ga-FAPI-04 and 18F-FDG PET/CT study before the surgery.
214968984|NCT02590991|OTHER|Prebiotics|To study the long term effect of supplementation in early life
214968985|NCT02590991|OTHER|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
214968986|NCT00128661|BIOLOGICAL|human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
214357681|NCT04453631|BEHAVIORAL|CBT-UP|15 psychotherapy sessions (1/week) following the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow et al. 2018.
214357682|NCT04453631|BEHAVIORAL|Psychoeducation|To control for the cognitive-behavioral intervention we will use psychoeducation materials.
214357683|NCT03905889|DRUG|Abemaciclib|Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
214357684|NCT03905889|DRUG|Sunitinib|Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
214357685|NCT04253743|OTHER|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households with children under age 5 incomes below 75% of the federal poverty level living in Clark County, Nevada received $40 in extra SNAP benefits per eligible child, and access to case management and nutrition education.
214357686|NCT06429254|OTHER|Experimental group|Life Scale will be administered as pre-tests to the EFT group. After the pre-tests, the first EFT session will be conducted. A second EFT session will take place 30 days later, followed by post-tests. During this period, affirmations will be provided as needed based on individual difficulties, perspectives, support systems, past traumas, and emotional blockages experienced by the woman. Each session is planned to last approximately 45 minutes to 1 hour.
214357687|NCT02211326|BEHAVIORAL|Genotype-guided dosing algorithm for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.
214357688|NCT02211326|BEHAVIORAL|Standard initiation dose for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
214357689|NCT01584622|DEVICE|CADence System|Non-invasive detection of \> or equal to 50% stenosis in any of the major coronary arteries.
214393788|NCT05641077|OTHER|Office Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via an in-office visit at 6 weeks after the planned date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
214393789|NCT05398497|DEVICE|Cryoablation|Cryoablation will be performed under ultrasound guidance.
214968987|NCT00128661|BIOLOGICAL|hepatitis A inactivated virus vaccine|Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
214393790|NCT02035215|DRUG|Atorvastatin 20mg|
214968988|NCT01836562|BIOLOGICAL|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
215082555|NCT05788588|DRUG|All-in-one parenteral nutrition|Trial participants are prescribed TPN by the attending physician, which will be administered via a central venous line over a time period of approximately 15 hours per day. The formulation is an emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume (nitrogen content, heat and liquid quantity as equal as HR19006).
215082556|NCT01698450|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
214393791|NCT02035215|DRUG|Omega-3-acids ethylesters 90 4g|
214393792|NCT02035215|OTHER|Placebo(Omega-3-acids ethylesters 90)|
214393793|NCT03263143|OTHER|Palliative Care|Palliative Care Consultation within 24 to 48 hours after admission
214393794|NCT00818909|OTHER|Systane|Systane prescription
214487341|NCT06378619|DIAGNOSTIC_TEST|Archimedes Spiral|For the administration of the Archimedean spiral, a computer application installed on a Tablet will be used. The Tablet screen will display a drawing of the spiral, serving as a reference for the participant. The test will be administered up to 3 times, with a 15-minute interval between each administration. At the beginning of the session, the patient will perform 2 practice attempts.
214487342|NCT06791577|DRUG|Carboxytherapy|Application of the intervention (CO2 Lift) in the area according to the protocol schedule
214487343|NCT06791577|OTHER|Placebo|Application of the placebo (Vaseline) in the area according to the protocol schedule
214487344|NCT06202560|DRUG|Tofacitinib 5 MG|Participants in the research will receive oral Tofacitinib medication with a dosage of 5 mg, twice a day, for 12 weeks. They will be scheduled to come for follow-up every 4 weeks throughout the 12-week period, and will continue to be followed up for 4 weeks after stopping the medication. The total duration of the research will be 16 weeks. The purpose is to evaluate the effectiveness and safety of the medication.
214487345|NCT05783934|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|"The PET/CT study will be performed using a dual time acquisition protocol consisting of an early acquisition and a late acquisition.~Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.~A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.~Early acquisition will last 30 minutes. Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake."
214487346|NCT06283147|BEHAVIORAL|Risk assessment and Management Programme - Knee Osteoarthritis|"(i) Arthritis education: Topics will cover the 21 key messages identified in International Consensus List of Essential Statements for Osteoarthritis What Do People With Knee or Hip Osteoarthritis Need to Know~(ii) Structured land-based exercise: We have selected strengthening, flexibility training (stretching), and aerobic exercise as our key components because they are most applicable in primary care settings.~(iii) Weight Management: Weight management will be offered for participants with a BMI ≥ 23 kg/m2.~(iv) Counselling support for psychosocial health: counselling support will be provided for those with mild to moderate anxiety and depression, insomnia and loneliness identified in the risk assessment.~(v) Dietary advice: Online dietary education for musculoskeletal health (with reference to local context) will be provided. The dietitian will also provide support regarding specific dietary advice on weight management."
214487347|NCT01805219|OTHER|GPS and accelerometer recording (s) during exercises|
214487348|NCT01688765|OTHER|Observational|
215082557|NCT03468816|DEVICE|Sensor activation (on DryMax Extra Soft)|Study profile of sensor activation
215082558|NCT00167596|DEVICE|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
215082559|NCT00167596|DEVICE|conventional|resuscitation will be based according to Surviving Sepsis Campaign
215082560|NCT04362371|DEVICE|Ainara|1 g at each administration
214968989|NCT01614015|BEHAVIORAL|Supervision|SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
214968990|NCT01614015|BEHAVIORAL|Observational Supervision|One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
215082561|NCT03738995|BIOLOGICAL|Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum|Administration of red cell or whole blood transfusion to parturients during pregnancy and up to 6 weeks postpartum
215082562|NCT00044681|DRUG|risperidone|
215082563|NCT05011214|DRUG|Sevoflurane|All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
215082564|NCT05011214|DRUG|Esketamine|All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
215082565|NCT03661788|DRUG|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
214357690|NCT04936152|OTHER|mime therapy using tablet PC mirror application|"After the baseline assessment, The patient in the experimental group will receive mirror therapy and mime therapy.~Exercises time period is 30 min/session~Mime Therapy Using Tablet PC:~Mirror therapy using tablet PC mirror application We will use a tablet PC mirror application that can convert images from right to left. In the mirror group, the mirror application was used during the exercise. Patients watched the tablet PC screen. The mirror application converts the image from right to left.~• Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present."
214357691|NCT04936152|OTHER|the control intervention including the mime therapy|After the baseline assessment, The patient in the experimental group will receive mime therapy Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present.
214357692|NCT06115733|DRUG|Fruquintinib、Capecitabine Tablets|"Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~3\) Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~4\) Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, as follows:~Phase II: Dose extension trial (n=47) :~The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression."
214968991|NCT02211378|OTHER|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
214968992|NCT02211378|OTHER|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
214357693|NCT02712034|BEHAVIORAL|MAT + A-CHESS|"Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~1. Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~2. The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~3. Advice on where to go for help and on how to make the best use of health and human services; and~4. A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~5. A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects)."
214357694|NCT02712034|OTHER|MAT|"Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care."
214357695|NCT01492075|DRUG|PCRA (Intermittent injection)|Intermittent injection of LA intraabdominally
214357696|NCT00262821|DRUG|cisplatin|Given IV
214357697|NCT00262821|DRUG|tirapazamine|Given IV
214357698|NCT05712590|OTHER|dietary habit|As it is observational study, women that follow three different dietary patterns will be inlcuded .
214968993|NCT02126215|PROCEDURE|MRI CO2 and O2 stress testing|Pre and post operatively
215082566|NCT03661788|DRUG|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
215082567|NCT06217523|OTHER|Pharmacogenomics-directed Hyperlipidaemia Management|Pharmacogenomics-directed Hyperlipidaemia Management
215082568|NCT00022685|BIOLOGICAL|epratuzumab|
215082569|NCT06127043|DRUG|Rosnilimab|PD-1 agonist antibody
214357699|NCT01509898|DEVICE|Water jet|use of water jet for a month
214357700|NCT03044379|DRUG|Dapivirine gel (0.05%)|MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.
214968994|NCT01518569|DRUG|ulinastatin|ulinastatin 5000 unit/kg iv before the initiation of CPB
214968995|NCT01518569|DRUG|placebo|placebo (the same amount of normal saline) iv before the initiation of CPB
214968996|NCT00954265|DRUG|10000 IU urinary HCG|ovulation triggering
214357701|NCT03044379|OTHER|Universal HEC placebo gel|
214357702|NCT01867151|DIETARY_SUPPLEMENT|Gluten Free Diet|
214357703|NCT01867151|DIETARY_SUPPLEMENT|Normal Diet|
214357704|NCT01988779|DRUG|oral levofloxacin|
214487349|NCT02324790|DEVICE|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
214968997|NCT00954265|DRUG|250 mcg recombinant HCG|ovulation triggering
214968998|NCT01488552|DRUG|Gemcitabine|1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
214968999|NCT01488552|DRUG|nab-paclitaxel|125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
214969000|NCT01488552|DRUG|FOLFIRINOX|"The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients)."
214969001|NCT01488552|GENETIC|Immunohistochemistry (IHC) Analysis|Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
215082570|NCT06127043|DRUG|Placebo|Administered via SC
214357705|NCT01988779|DRUG|nebulized levofloxacin|
214357706|NCT04504487|OTHER|Drain Removal|Abdominal drain placed during surgery removal
214969002|NCT01488552|DRUG|Metformin|Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
214357707|NCT02895087|OTHER|Diurnal Variation Group|This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).
214357708|NCT02895087|OTHER|External Stress Group|"2 visits will be required, each lasting approximately 2.5 hours in the afternoon.~At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.~At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit."
214357709|NCT04214704|DEVICE|Genteel lancing device|Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively
214969003|NCT01488552|DRUG|mFOLFIRI|5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
214969004|NCT03758157|DIAGNOSTIC_TEST|welloStationX|welloStationX is an automated electronic thermometer using an infrared sensor of the surface of the forehead to measure human body skin temperature to screen for fever.
214357710|NCT04214704|DEVICE|Conventional lancing device|Conventional lancing device
214357711|NCT06578923|DIAGNOSTIC_TEST|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
214357712|NCT06578923|BEHAVIORAL|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
214357713|NCT01041638|BIOLOGICAL|Aldesleukin|Given IV
214969005|NCT03758157|DIAGNOSTIC_TEST|SureTemp|SureTemp is an oral thermometer to measure human body skin temperature.
215082571|NCT03690492|OTHER|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
214357714|NCT01041638|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214357715|NCT01041638|BIOLOGICAL|Dinutuximab|Given IV
214357716|NCT01041638|DRUG|Isotretinoin|Given PO
214357717|NCT01041638|BIOLOGICAL|Sargramostim|Given IV or SC
214357718|NCT04930068|OTHER|low caloric diet|A low-calorie diet is a structured eating plan that restricts daily caloric intake, commonly for weight loss. Following a low-calorie diet typically means consuming around 1,200 to 1,500 calories per day, which creates a calorie deficit that can lead to weight loss. A low-calorie diet can be effective, but it requires a lot of discipline to work and be safe.
214357719|NCT00824226|DIETARY_SUPPLEMENT|magnesium|magnesium 350 mg tablets once a day for 3 weeks
214357720|NCT05223985|DEVICE|Depth Coagulation Electrode|SEEG and thermocoagulation
215082572|NCT01663428|OTHER|Sup-ER Splint|
215082573|NCT01663428|OTHER|Currently accepted treatment|
215082574|NCT04072679|DRUG|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
214357721|NCT02080468|DRUG|lomitapide|20 mg
214357722|NCT02080468|DRUG|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
214357723|NCT06387901|DRUG|Paclitaxel Chemotherapy|Participants will receive paclitaxel, a taxane chemotherapeutic agent used in the treatment of breast cancer. The administration involves an intravenous infusion of paclitaxel at a dosage of 80 mg/m². The treatment is scheduled once a week, continuing for a total duration of 12 weeks. This regimen is part of a (neo-)adjuvant therapy for female patients diagnosed with stage II or III breast cancer. The intervention aims to assess the pharmacokinetics of paclitaxel in relation to patient body composition and physical activity, evaluating its impact on dose-limiting toxicities and overall treatment efficacy.
214357724|NCT05964140|DRUG|Different post-operative antibiotic regimens following surgical treatment of mandible fractures|"The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control)."
214357725|NCT01938612|DRUG|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
214357726|NCT01938612|DRUG|tremelimumab|tremelimumab is administered by IV infusion every 4 weeks
214357727|NCT01922076|DRUG|Adavosertib|Given PO
214357728|NCT01922076|OTHER|Laboratory Biomarker Analysis|Correlative studies
214357729|NCT01922076|OTHER|Pharmacological Study|Correlative studies
214357730|NCT01922076|RADIATION|Radiation Therapy|Undergo radiation therapy
214357731|NCT05943457|DIETARY_SUPPLEMENT|Vitamin K2 or menaquinone-7|Vitamin K2 (MK7) 360 mcg/day orally once daily for 6 months
214357732|NCT05943457|OTHER|Placebo|Placebo pills will be administered orally once daily for 6 months
214357733|NCT00378989|BEHAVIORAL|Consultation at the occupational health services|Consultation at the occupational health services
214357734|NCT04311606|DRUG|Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of saline followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
214357735|NCT04311606|DRUG|Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
214357736|NCT04311606|DRUG|Sub-tenon injection of hyaluronidase (HA) alone|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) injection alone (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
214487350|NCT03771001|OTHER|Motivational Interviewing coaching and habit-building app|Coaches will use a manualized motivational interviewing approach and participants' wellness promoting changes will be supported via a habit building app that also delivers a micro-mindfulness program
214357737|NCT04853680|DEVICE|Anti-adhesion barrier (Collarbarrier)|Collagen derived anti-adhesion barrier
214487351|NCT06446492|OTHER|ViDEO explaining study|The research team will introduce themselves and ask the parents to watch an informational video explaining the ViDES study on an iPad while they stay in the room with the parents. After viewing the video, the team will answer any questions and provide written consent and enough time to decide whether to participate in the study. The research team will also provide a QR code that grants parents/guardians access to the video on their own device at any time. This allows them to pause, rewind, and revisit the information.
214487352|NCT06446492|OTHER|Usual Care|The research team will present a detailed explanation of the ViDES study, answer questions, provide written consent, and provide enough time to decide on participation or not in the study.
214487353|NCT06570616|DEVICE|CPAP (fixed mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
214487354|NCT06570616|DEVICE|APAP (automatic mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
214487355|NCT04140487|DRUG|Azacitidine|Given IV
214487356|NCT04140487|DRUG|Gilteritinib|Given PO
214357738|NCT04568135|OTHER|survey|survey
214357739|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
214357740|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
214357741|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
214357742|NCT05907382|DRUG|Placebo in Cohorts 1 to 5|oral once
214357743|NCT05907382|DRUG|Placebo in 2 Cohorts|oral once
214357744|NCT05808387|DIETARY_SUPPLEMENT|Resveratrol|Trans-resveratrol, 1000 mg daily for 90 days
214357745|NCT05808387|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 90 days
214487357|NCT04140487|DRUG|Venetoclax|Given PO
214357746|NCT01650753|DIETARY_SUPPLEMENT|Probiotic Powder|Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10\^10 cells/sachet)
214357747|NCT01650753|DIETARY_SUPPLEMENT|Placebo powder|powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
214357748|NCT06265428|DRUG|DB-1303/BNT323|Administered I.V.
214357749|NCT06265428|DRUG|T-DM1|Administered I.V.
214357750|NCT06128109|DEVICE|Thioderm Strong|Test Device
214357751|NCT06128109|DEVICE|Juvéderm VOLUMA Lidocaine|Comparator Device
214357752|NCT06545097|DRUG|Cebranopadol|Once a day for 2 days; once daily on Day1 (with Cebranopadol 200ug).
214357753|NCT06545097|DRUG|Cebranopadol|Once daily on Day 2 (with Cebranopadol 400 ug)
214357754|NCT06545097|DRUG|Placebo|Once daily for 2 days
214357755|NCT01390467|DRUG|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
214357756|NCT00676182|OTHER|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
214357757|NCT06071962|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
214357758|NCT06071962|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
214357759|NCT01247402|DEVICE|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
214357760|NCT01247402|DEVICE|standard balloon angioplasty|standard balloon angioplasty
214357761|NCT05017922|PROCEDURE|transarterial chemoembolization combined with endoscopic therapy|TACE: The tip of the catheter was advanced into tumor-feeding artery based on the tumor location and size. 5-Fu was injected. Then the chemolipiodolization was performed, using oxaliplatin, epirubicin and lipiodol. If stagnant flow did not realized, then injected pure lipiodol. If the tumor-feeding artery still cannot be completely embolized, several absorbable gelatin sponge particles would be injected. Endoscopic therapy: After the site of esophageal varices was identified by the gastroscopy, spiral ligation using the EVL device (COOK, MBL-6-F) was performed and ensure the varices were fully inhaled, 1-3 rubber bands were used totally. After EVL, water was sprayed to the ligation sites to check for bleeding. If gastric varices were found, EIS was performed using the 'sandwich method' of hypertonic glucose-tissue adhesive-normal saline. Make sure the needle entered the varieose vein before inject drugs, and repeated the injection if necessary.
214487358|NCT03705793|DRUG|Mometasone Furoate Nasal Irrigation|Participants will undergo an 8-week treatment course that includes nasal saline irrigation with mometasone powder and placebo nasal spray.
214487359|NCT03705793|DRUG|Mometasone Nasal Spray|Participants will undergo an 8-week treatment course that includes placebo saline irrigation with mometasone nasal spray.
214487360|NCT06158152|DIETARY_SUPPLEMENT|AM3 + Probiotic|Two capsules daily in the morning during 12 weeks. The capsule contains the mixture of AM3 Technology and probiotic SynBalance Metsyn.
214487361|NCT06158152|DIETARY_SUPPLEMENT|Placebo|Two capsules daily in the morning during 12 weeks. The capsule contains starch.
214487362|NCT06158152|DIETARY_SUPPLEMENT|AM3|Two capsules daily in the morning during 12 weeks. The capsule contains AM3 Technology.
214969006|NCT03292185|DRUG|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
214969007|NCT03292185|DRUG|insulin degludec|17 U Insulin Degludec, single dose administration under the skin in the thigh.
214969008|NCT03292185|DRUG|liraglutide|0.6 mg Liraglutide, single dose administration under the skin in the thigh
214969009|NCT01261390|BEHAVIORAL|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
214969010|NCT01261390|DEVICE|Sham PAP (Sham)|In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
214969011|NCT01261390|DEVICE|Active PAP with RT Support (Active-Beh)|In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
214969012|NCT01261390|DEVICE|Active PAP with Behavioral Modification (Active+Beh)|In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
214969013|NCT00642226|PROCEDURE|Grid Laser|ETDRS Grid Laser
214969014|NCT00642226|PROCEDURE|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
214969015|NCT00873717|OTHER|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
214969016|NCT00873717|OTHER|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
214487363|NCT06368310|DEVICE|INBRAIN Graphene Cortical Interface|Study device to be evaluated intra-operatively alongside standard of care neurophysiological monitoring.
214487364|NCT03027128|BIOLOGICAL|haNK™ for Infusion|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
214357762|NCT01677273|DIETARY_SUPPLEMENT|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
214487365|NCT03620058|BIOLOGICAL|CART22-65s cells|Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
214487366|NCT03620058|BIOLOGICAL|huCART19 Cells|Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB
214969017|NCT00873717|OTHER|Dentary + Nutrition|"trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat."
214357763|NCT01677273|DIETARY_SUPPLEMENT|Intact casein|30 g protein/supplement, 4 supplements/visit
214357764|NCT01677273|DIETARY_SUPPLEMENT|Intact whey protein|30 g protein/supplement, 4 supplements/visit
214357765|NCT01829438|BEHAVIORAL|Listening to fast music|
214357766|NCT01829438|BEHAVIORAL|Listening to preferred music|
214969018|NCT04906226|BEHAVIORAL|Self-foot massage|The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
214969019|NCT00643019|BEHAVIORAL|SAFE Behavioral Intervention|Group cognitive behavioral intervention sessions
214969020|NCT00643019|OTHER|Control|Individual Sexually Transmitted Infection Risk Reduction Counseling
214969021|NCT02721056|RADIATION|NBTXR3, IL or IA injection + SBRT|Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be 45 or 50 Gy, delivered as three fractions of 15 Gy or 5 fractions of 10 Gy each, over 5 to 15 days (45 or 50Gy, 15GyX3 or 10GyX5).
214969022|NCT04749095|DRUG|Erector spinae plane block|bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine
214969023|NCT04749095|DRUG|sham subcutaneous infiltration|bilateral ESP block will be injected with 20 ml of normal saline
214357767|NCT01829438|BEHAVIORAL|Listening to slow music|
214357768|NCT04039399|PROCEDURE|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).
214969024|NCT00407342|DRUG|Alefacept (drug)|alefaceptgiven iv
214969025|NCT00407342|PROCEDURE|Narrowband UVB phototherapy|
214969026|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 100μg/kg, subcutaneous injection, Once weekly.
214969027|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 120μg/kg, subcutaneous injection, Once weekly.
214969028|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
214969029|NCT04513171|DRUG|Norditropin®|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
214969030|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
214969031|NCT04513171|DRUG|Norditropin|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
214969032|NCT00977613|BEHAVIORAL|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
214969033|NCT01167348|PROCEDURE|auricular acupressure|Investigator will put a tape with a 0.5mmx0.5mm seed on the specific positions on the ear of participants of intervention group, and participants will be asked to press these specific positions 3 times a day.
214969034|NCT01535313|DEVICE|OnControl BM-Biopsy system|Bone marrow biopsy at posterior iliac crest
214969035|NCT06140433|DEVICE|VSC-MEDlib|VSC-MEDlib will be used for post-processing
214969036|NCT04132037|OTHER|data record|At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported
214969037|NCT05895045|BEHAVIORAL|Yoga|Restorative Vinyasa Yoga
214969038|NCT05341973|BEHAVIORAL|Education|Self-Management Program will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
214969039|NCT06158035|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214969040|NCT06158035|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
215082575|NCT04773561|DEVICE|Corneal tomography, optical coherence tomography and optical coherence tomography angiography|Ocular investigations were performed in one time during 30-36 weeks of gestational age. Due to avoidance of diurnal variation, all examinations were done between 10 am - 12 pm.
214357769|NCT04039399|PROCEDURE|Sham Ischemic Conditioning|There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
214357770|NCT02698124|DRUG|Decitabine|
214357771|NCT02877043|PROCEDURE|resection pulmonaire|
214357772|NCT01993225|DRUG|Androxal 12.5 mg/25 mg|
214357773|NCT01993225|DRUG|Placebo Capsules|
214357774|NCT01993225|DRUG|AndroGel 1.62%|
214357775|NCT01993225|DRUG|Placebo Gel|
214357776|NCT02001857|DRUG|1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.|at the end of surgery
214357777|NCT04375748|DIAGNOSTIC_TEST|Performing routine care (clinical and paraclinical tests)|ECG, standard biology and cardiology tests, and routine transthoracic echocardiography (TTE), MRI
214357778|NCT04375748|DIAGNOSTIC_TEST|Examinations for the research:|"Systematic research by polymerase chain reaction (PCR) for Covid-19 in the blood and in an oro-pharyngeal swab, in addition to the usual immunologic, bacteriological, viral and parasitic tests carried out as part of the routine care of all patients with suspected myocarditis.~A 30-days phone call follow-up (vital status) and a systematic 1-year follow-up will be realized (clinic, biology, ECG, TTE, +/- MRI)"
214357779|NCT04493216|DRUG|GSK3640254|GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.
214487367|NCT03713554|PROCEDURE|FNIRS Observational|In addition to completing an Informed Consent and survey questions, fNIRS Imaging and Electroencephalography (EEG) will take place will take place:The fNIRS imaging is experimental technology that has not been approved by the FDA. EEG is a noninvasive way to record electrical activity of the brain. The recording device is made up of electrodes that are fixed to a snug-fitting elastic cap. An MRI and EEG will follow the fNIRS procedure. The MRI will be performed before participants undergo fNIRS or EEG. The MRI will be done to show there are no lesions in the inner ear and therefore is a recruitment clearance tool.
214679144|NCT06440161|OTHER|Primary exposures were venous congestion defined by central venous pressure (CVP) and mean arterial pressure (MAP).|"After the induction of anaesthesia, a central venous or pulmonary artery catheter was positioned. Based on prior studies, thresholds for central venous pressure were set at 10, 12, 16, and 20 mm Hg. Venous congestion was quantified by time exceeding each CVP threshold and the area under the curve (AUC) surpassing each CVP threshold in mmHg × min. Assessments were limited to pre- and post-CPB periods, as the venous drainage cannulate generated negative CVP during CPB.~An arterial catheter was installed upon room admission. Continuous arterial blood pressure monitoring commenced after exposure to atmospheric pressure and calibration to zero. The MAP was determined using the formula: 2/3 × diastolic blood pressure + 1/3 × systolic blood pressure. Data were logged by automated software every minute. Established thresholds for MAP were 55, 65, and 75 mm Hg. Hypotension was quantified as (1) time under each MAP threshold in minutes and (2) the AUC below each MAP threshold in mmHg × min."
214357780|NCT04493216|DRUG|ABC/3TC|ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.
214487368|NCT06137976|PROCEDURE|Gastric decompression (oropharyngeal or nasopharyngeal gastric tube)|Placement of tube through the nose or mouth into the stomach for gastric decompression
214679145|NCT04586894|DIAGNOSTIC_TEST|Cardiac MRI|Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy
214679146|NCT04586894|DEVICE|Smart cloth|A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.
214679147|NCT04586894|OTHER|Biobanking|Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
214969041|NCT05288322|PROCEDURE|Mostafa Maged maneuver|"The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery . The Mostafa Maged technique is applied by :- (Description of the new Mostafa Maged technique) :-~1. First , placing our right hand to the posterior fornix of vaginal canal trying to cuddle the lower part of uterus compressing the anterior and posterior walls of the uterus .~2. Second , placing our left hand over the fundus of the uterus and the posterior wall of uterus from the abdominal part.~3. Third , by our two hands , trying to grasp the whole uterus by our two hands abdominally and vaginally against the symphysis pubis as if the uterus is cuddling the symphysis pubis bone and in this way , we try to get the anterior and posterior walls against each other and reducing the intra-cavitary space so we prevent the expansion of the uterus ."
214357781|NCT04493216|DRUG|FTC/TAF|FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
214357782|NCT04493216|DRUG|Dolutegravir|Dolutegravir was available as a 50 mg tablet to be administered via oral route.
214357783|NCT04493216|DRUG|Placebo|Placebo matching GSK3640254 was administered in the form of tablets via oral route.
214357784|NCT04899882|OTHER|KinHémo|Evaluation and cardiovascular training, combination of resistance and flexibility training
214357785|NCT00854633|DRUG|Talactoferrin|Enteral, 150 mg/kg twice per day
214487369|NCT06261814|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
214357786|NCT00854633|DRUG|Placebo|Oral, twice per day
214487370|NCT06261814|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
214487371|NCT06261814|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
214487372|NCT06261814|OTHER|Medical Chart Review|Ancillary studies
214679148|NCT03123354|DEVICE|O3 regional oximeter sensor|Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
214679149|NCT02969343|BEHAVIORAL|Patient Safety health information technology|Patient safety technology toolkits on hospital care units
214357787|NCT04203693|DRUG|Tildrakizumab|The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
214357788|NCT03202706|PROCEDURE|Samples of adipose tissue|Samples of visceral and subcutaneous adipose tissue collected during hernia surgery
214357789|NCT04857931|DRUG|Colchicine|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
214357790|NCT04857931|DRUG|Placebo|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
214679150|NCT01543464|DRUG|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
214679151|NCT06173492|PROCEDURE|Dental extraction|After local anesthesia (mepivacaine 2%), the tooth is extracted atraumatically with levers and forceps taking care to preserve the cortex. The roots of multi-rooted teeth are separated before extraction. The pocket epithelium and granulation tissue inside the socket are removed.
214679152|NCT06173492|DEVICE|Platelet Rich Fibrin|The clot obtained by centrifugation is made into PRF cylinders and inserted into the socket and compacted.
214357791|NCT03944525|DEVICE|High flow nasal cannula|Oxygen-therapy via HFNC
214357792|NCT03944525|DEVICE|Continuous positive airway pressure|Non-invasive CPAP ventilation
214357793|NCT06333054|DRUG|Pyrethrum Extract|Treatment with Goldgeist® Forte
214357794|NCT06333054|DEVICE|Silcap Shampoo|Treatment with Silcap Shampoo
214487373|NCT06547931|OTHER|Data collection and analysis|Retrospective collection of clinical and laboratory data relating to the definition of the nature of neutropenia
214357795|NCT03595579|DRUG|AXS-05|AXS-05 taken twice daily for 6 weeks.
214357796|NCT03595579|DRUG|Bupropion|Bupropion taken twice daily for 6 weeks.
214357797|NCT03977675|DRUG|Ketamine|Patients are assigned to one of three ketamine doses (0.3, 0.5, or 0.7 mg/kg) that will be administered intravenously.
214969042|NCT02882126|DRUG|Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
214357798|NCT04134156|PROCEDURE|sleeve gastrectomy|5-port sleeve gastrectomy
214357799|NCT04134156|PROCEDURE|one anastomosis gastric bypass|5-port one anastomosis gastric bypass
214969043|NCT01944748|BEHAVIORAL|Families Able To Resolve Situations (FARS)|Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
214969044|NCT01634503|GENETIC|GX-188E administered by electroporation|Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
214969045|NCT01676246|DRUG|100 mg flupirtine intravenous|Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
214357800|NCT02178605|PROCEDURE|Cervical arthrodesis with rhBMP-2|Cervical arthrodesis with rhBMP-2
214357801|NCT05211388|PROCEDURE|RFA controlled using echo decorrelation imaging|"The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion.~The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume.~To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points."
214357802|NCT05211388|PROCEDURE|RFA controlled using standard manufacturer-specified algorithms|The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.
214357803|NCT02606903|DRUG|BI 695501 prefilled syringe|
214357804|NCT02606903|DRUG|BI 695501 autoinjector|
214357805|NCT01633879|BEHAVIORAL|audio-CD parent education|audio CD stories in English and Spanish that support positive parenting practices
214357806|NCT01633879|BEHAVIORAL|health and success parent and school|Parenting education and school intervention
214357807|NCT03881306|DRUG|D-TACE|D-TACE with CalliSpheres-Oxaliplatin
214357808|NCT05228899|DRUG|Zofin|1mL of Zofin will be administered intravenously, containing 2-5 x 10\^11 particles/mL. Zofin will be diluted in 100 mL of sterile saline.
214357809|NCT05228899|OTHER|Placebo|1mL of Placebo (normal saline) will be diluted in 100 mL of sterile saline and administered intravenously.
214357810|NCT03764839|BEHAVIORAL|"Perioperative Digital Behavioral Pian Medicine My Surgical Success"|"The My Surgical Success website include 45 minutes of psychoeducation material developed and delivered by Beth Darnall, PhD. Viewers learn basic skills to improve regulation of pain-related distress. Treatment includes an app and a personalized plan for surgical success."
214357811|NCT02944136|BEHAVIORAL|enhanced usual care|usual care from health providers
214357812|NCT02944136|BEHAVIORAL|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
214357813|NCT01030861|DRUG|Teplizumab|intravenous infusions
214357814|NCT01030861|DRUG|Placebo infusion|Placebo for Teplizumab
214357815|NCT04286139|BEHAVIORAL|SHAPE|The SHAPE intervention provides information for carers, and maintains the dignity and autonomy of the person with dementia, supporting them in planning for the future with their family. The person with dementia attends an online 10 week facilitator lead group based course. It is designed to develop self-management skills in areas including decision-making, symptom management and social interaction. It also provides information on the disease process and the development of healthy behaviors in a supportive learning environment to prevent problems that are common in the later stages of the disease. The adjunctive e-learning platform for carers provides the same information that the person with dementia receives plus additional material and signposting to support them in their role. This will empower the whole family to support and enable more effective self-management by the person with dementia, and enhance their ability to plan ahead together and make key decisions jointly.
214357816|NCT04976738|DRUG|Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
214357817|NCT04339231|PROCEDURE|sphenopalatine ganglion block|"The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa."
214357818|NCT01925716|OTHER|Corn oil|corn oil 56 g/day for 21 days
214357819|NCT01925716|OTHER|Olive oil|olive oil 56 g /day for 21 days
214357820|NCT00158938|DEVICE|EASYTRAK 3 left ventricular pacing lead|
214357821|NCT05571631|OTHER|exercise|Arm ergometer will aplied as an aerobic exercise. Combination of balance training and arm ergometer exerise program will applied.
214357822|NCT01490996|DRUG|Oral complex C3 curcumin + chemotherapy|Daily oral capsule(s)
214357823|NCT01490996|DRUG|Chemotherapy only|Standard care chemotherapy
214969046|NCT01676246|DRUG|100 mg flupirtine per os|Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
214969047|NCT01676246|DRUG|400 mg flupirtine per os|Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
214357824|NCT04199858|BEHAVIORAL|Baseline pain stimulations|During baseline pain stimulations, a comparison block will include 6 high- and 2 moderate-pain stimulations.
214357825|NCT04199858|BEHAVIORAL|Conditioning|"During nocebo induction trials, the conditioned stimulus (i.e., a sham medical gel that can increase pain sensitivity, named TDA and contained in either a brown or a blue jar) is paired to unconditioned high-pain stimuli (nocebo trials). Lower 'baseline' pain is paired with no gel application (control trials)."
214357826|NCT04199858|BEHAVIORAL|Evocation|"During nocebo evocation, lower pain stimulations are administered both after the administration of the conditioned stimulus (i.e., a sham medical gel TDA) and the control stimulus (no medical gel), in order to evoke nocebo responses to the sham hyperalgesic medication."
214357827|NCT04199858|OTHER|Electroencephalography (EEG)|In the single group of participants, EEG recordings will be conducted during baseline, during a first resting-state of 5-minutes, during induction/evocation of nocebo responses, and during a second resting-state of 5-minutes.
214357828|NCT05245669|BIOLOGICAL|ENZ215|healthy volunteers receive ENZ215 (60mg) once
214969048|NCT01676246|PROCEDURE|induce delayed onset of muscle soreness (DOMS)|"The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from no pain to intolerable pain with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly."
214357829|NCT05245669|BIOLOGICAL|EU Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
214357830|NCT05245669|BIOLOGICAL|US Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
214357831|NCT03643952|DRUG|Daptomycin for Injection|Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.
214357832|NCT03886818|DEVICE|Standard dressings|Standard dressings will be used from surgery to wound healing
214487374|NCT06465420|BIOLOGICAL|Haemophilus influenzae type a (Hia) glycoconjugate vaccine|0.5 mL intramuscular injection, given on days 0 and 28
214969049|NCT01676246|PROCEDURE|electric pain measurement|"The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).~During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min."
214969050|NCT01345656|DRUG|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
214969051|NCT01345656|DRUG|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
214969052|NCT01345656|DRUG|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
214969053|NCT01345656|DRUG|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
214969054|NCT01345656|DRUG|Placebo|Placebo tablets for duration of 4 weeks
214969055|NCT01345656|DRUG|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
214357833|NCT03886818|DEVICE|PICO strategy|The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.
214357834|NCT01597050|DRUG|R932333|R393233 6% (60 mg/g), bid
214357835|NCT01597050|DRUG|Placebo|Placebo, bid
214357836|NCT03602170|BEHAVIORAL|High-Intensity Interval Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 20 minutes of exercise by completing 10 repetitions of 60 seconds of exercise at 90-95% maximal heart rate with 60 seconds of active rest between each repetition at 50-60% maximal heart rate.
214357837|NCT03602170|BEHAVIORAL|Moderate-Intensity Continuous Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 30 minutes of continuous exercise at 65-70% maximal heart rate.
214357838|NCT01936584|PROCEDURE|TAPP repair for inguinal hernias|
214357839|NCT01936584|PROCEDURE|TEP repair for inguinal hernia|
214357840|NCT01936584|OTHER|EuraHS-QoL questionnaire|questionnaire administration
214357841|NCT01936584|OTHER|Carolina Comfort Scale|questionnaire administration
214357842|NCT00483184|BIOLOGICAL|Veldona,|Very low dose oral natural human interferon alpha lozenges
214357843|NCT00558428|DRUG|fixed dose combination of telmisartan+amlodipine|
214357844|NCT00558428|DRUG|amlodipine|
214357845|NCT01375348|DRUG|Ultiva (remifentanil) or placebo|0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
214357846|NCT02308384|BEHAVIORAL|Intervention|CME, Start-package and status mail
214393795|NCT04315623|PROCEDURE|Regional citrate anticoagulation CRRT|Regional citrate anticoagulation Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
214393796|NCT04315623|PROCEDURE|No-anticoagulation CRRT|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
214393797|NCT04860154|DRUG|Hematoporphyrin|Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
214393798|NCT04789213|OTHER|Liver Transplantation|Liver Transplantation
214357847|NCT03229954|DRUG|iron isomaltoside (Monofer) intravenous infusion|"The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (\< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety."
214487375|NCT06165380|DRUG|Cardenilimab Combined With Chemotherapy|Cardenilimab Combined With Chemotherapy
214487376|NCT05282043|OTHER|Evaluation of Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults|Participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, O2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. In addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods.
214487377|NCT03094052|DRUG|Neratinib|Given orally (PO)
214487378|NCT03094052|BIOLOGICAL|Trastuzumab|Given Intravenously (IV)
214487379|NCT03094052|DRUG|Loperamide|Given PO
214487380|NCT03094052|DRUG|Crofelemer|Given PO
214969056|NCT00870454|DRUG|Pregabalin 300 mg/d|75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder
214969057|NCT00870454|DRUG|Carisbamate 800 mg/d|200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3
214969058|NCT00870454|DRUG|Carisbamate 1,200 mg/d|200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3
214969059|NCT00870454|DRUG|Placebo|Placebo capsules twice daily
214969060|NCT02864732|OTHER|Rehabilitation exercises|
214969061|NCT02864732|DEVICE|Electrical Stimulation|
214969062|NCT00308789|PROCEDURE|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
214969063|NCT00308789|PROCEDURE|CPAP|Continuous positive airway pressure
214487381|NCT03094052|DRUG|Diphenoxylate/Atropine|Allowed for participants experiencing refractory diarrhea
214969064|NCT02223351|DRUG|ASP2151|
214969065|NCT02223351|DRUG|ritonavir|
214357848|NCT03229954|DRUG|Ferrous sulfate(Feroba-YOU) per oral|160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
214357849|NCT04677972|DRUG|Ebselen|Glutathione peroxidase mimetic
214357850|NCT04677972|DRUG|Placebo|Matching placebo containing excipients
214357851|NCT02766530|OTHER|PETMR study|Use of PETMR study to evaluate the treatment response of breast cancer women
214357852|NCT02614716|DRUG|LY3090106|Administered SC
214487382|NCT05441280|DRUG|pimavanserin|pimavanserin 34mg PO at bedtime
214487383|NCT05441280|OTHER|Placebo|The placebo is a pill that looks like a study medication but has no medication in it
214487384|NCT00113360|DRUG|RAD001|Starting dose of 5 or 10 mg by mouth daily.
214487385|NCT00113360|DRUG|Octreotide Depot|30 mg injection into the muscle of either buttock once every 28 (±7) days.
214487386|NCT04173442|DRUG|dupilumab|Dupilumab cohort
214487387|NCT03831178|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
214487388|NCT03831178|DRUG|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
214487389|NCT05639309|DEVICE|near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics)|regional oxygen saturation measurement
214487390|NCT02454283|DRUG|Vanoxerine HCl|
214969066|NCT05293782|OTHER|Kinesitaping|Kinesiotaping - muscle facilitation technique
214969067|NCT04143191|DRUG|Sorafenib|Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.
214969068|NCT04143191|PROCEDURE|Transarterial chemoembolization|TACE including conventional TACE (cTACE) and DEB-TACE. Treatment choices are according to the specific condition of each patient and the experience of interventional radiologists.
214357853|NCT02614716|DRUG|Placebo|Administered SC
214357854|NCT03671005|BEHAVIORAL|Mindfulness-based group therapy|see above
214357855|NCT03671005|OTHER|Treatment as usual|see above
214487391|NCT02454283|DRUG|Placebo|
214679153|NCT05566197|DIETARY_SUPPLEMENT|Diet Nusantara|Diet Nusantara consists of 1700 kilocalories (or 500 kilocalories lower than basal energy expenditure) on first month and subsequent reduction for the following months (200 kilocalories). The participants should also limit the sodium intake not more than 2300 mg daily
214969069|NCT05005936|PROCEDURE|Ultrasonography|Undergo ABUS
214969070|NCT05005936|PROCEDURE|Ultrasonography|Undergo WBUS
214969071|NCT02590055|DRUG|gemcitabine/docetaxel combination|
214969072|NCT02665247|BEHAVIORAL|C-SIP|In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
214969073|NCT02665247|OTHER|Dream discussion|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
214969074|NCT02459522|OTHER|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
214357856|NCT06373757|OTHER|Nano-HAP/Chitosan hydrogel|The periodontal pockets more than or equal 3-5mm were isolated. Chitosan and nano-HAP hydrogel were prepared in the same steps that were mentioned in the methodology and then the prepared gel was applied to the test site of patients with the deepest probing pocket measurement once per week for 3 weeks. Periodontal dressing (Coe-pack) was to secure the hydrogel in place.
214487392|NCT04221503|DRUG|Niraparib|Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
214969075|NCT02102048|DRUG|Atazanavir|
214969076|NCT05957185|DIETARY_SUPPLEMENT|OPTIZIOME® P³ HYDROLYZER® - WHEY|One dose of P3 - WHEY will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
214969077|NCT05957185|OTHER|Placebo|One dose of placebo maltodextrain will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
214969078|NCT03049020|PROCEDURE|laparoscopic sacrocolpopexy|standard laparoscopic sacrocolpopexy for prolapse treatment
214969079|NCT04087837|DEVICE|bougie|The endotracheal tube is used in the bougie mode under the direct view of the electronic imaging laryngoscope.
214969080|NCT04087837|DEVICE|Nasogastric(NG) tube|The endotracheal tube is used in the NG tube mode under the direct view of the electronic imaging laryngoscope.
214969081|NCT02001701|PROCEDURE|Intravitreal Injection of sulfahexafluoride gas|After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
214969082|NCT00002424|DRUG|L-756423|
214969083|NCT00002424|DRUG|Indinavir sulfate|
214357857|NCT02242864|DRUG|Micardis®|
214357858|NCT02242864|DRUG|MicardisPlus®|
214357859|NCT01147224|DRUG|Alvesco|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
214487393|NCT04221503|DEVICE|Optune|"Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells."
214487394|NCT04221503|PROCEDURE|Planned surgical resection|Surgery of supratentorial glioblastoma (GBM).
214487395|NCT04861558|DRUG|5Fluorouracil|Injection of 250-850 mg/m2.
214487396|NCT04861558|DRUG|Irinotecan|Injection of 360 mg/m2
214487397|NCT04861558|DRUG|Oxaliplatin|Injection of 460 mg/m2
214969084|NCT00002424|DRUG|Lamivudine|
214969085|NCT00002424|DRUG|Stavudine|
214969086|NCT00374023|DRUG|Zinc, or Vitamin A or both|
214969087|NCT03880552|OTHER|Primigravid women with singleton pregnancy at 35th week over|Primigravid women with singleton pregnancy at 35th week over; only observational study will be done in this group and the data will be recorded.
214969088|NCT02665819|OTHER|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
214969089|NCT02564276|PROCEDURE|Sentinel lymph node biopsy|
214969090|NCT00036283|DRUG|Celecoxib|
214969091|NCT01893697|OTHER|HRCT scan in a specific postural position|HRCT Scan taken in supine and lateral position
214969092|NCT05278741|PROCEDURE|Surgery for unilateral breast reconstruction|"Before the surgery, patient will be completed two questionnaire DASH and BREAST-Q. Two tests will be performed (isokinetic test and EMG).~After the surgery, at one month : 2 Questionnaires (DASH / BREAST-Q) will be performed At three months, six months and 12 months: 2 questionnaires + two tests will be perfomed"
214969093|NCT04001803|DRUG|CAB LA+RPV LA|Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
214969094|NCT00908271|DRUG|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
214969095|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
214969096|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
214357860|NCT01130948|OTHER|altitude exposure|exposure to 490m, 1700m and 2590m
214357861|NCT05224050|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants will be provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
214487398|NCT02467270|DRUG|Ponatinib|Tablet, taken orally once daily.
214487399|NCT01086163|DRUG|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
214679154|NCT05566197|BEHAVIORAL|Nutrition Counseling|Nutrition counseling consists of the definition of balancing food, metabolic syndrome, exercise, and related health parameters.
214679155|NCT03903029|DRUG|Low-dose (10mg) rosuvastatin|Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
214679156|NCT02169635|PROCEDURE|macular buckle|macular buckle with a three-armed silicone capsule
214679157|NCT02485366|DRUG|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
214969097|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
214969098|NCT01750645|DRUG|Intradetrusor Injection of Type-A Botulinum Toxin|
214969099|NCT01750645|OTHER|Other interventions analyzed according to protocol|"* Placebo~* Different dosage of Type-A Botulinum Toxin injected~* Anticholinergic drugs"
214969100|NCT05799430|BEHAVIORAL|Multidisciplinary medication review|"FP communicate to the PCP patients recently discharged. The medication review process consists in 5 steps:~1. PCP perform a structured drug review based on information from health record and e-prescribing application. The drug review comprise the appraisal of potentially inappropriate medication based on lists of explicit criteria.~2. PCP communicates and discuss the results of medication review with GP and PCN, in a brief meeting face-to-face, with possible adaptation of the recommendations.~3. FP, PCN and PCP agree on a personalized therapeutic plan for the patient that includes actions to optimize the therapy.~4. FP and PCN share plan with the patient and/or carer with possible adaptation of the recommendations and agree about actions to be implemented.~5. FP and PCN communicate to PCP final agreement with patient and/or carer~6. FP and/or PCN follow-up implantation of agreed recommendations using standard health care procedures"
214969101|NCT05799430|BEHAVIORAL|Control group|Usual care by FP an PCN
214969102|NCT02447770|DIETARY_SUPPLEMENT|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
214969103|NCT02571764|OTHER|Nutritional Oats Cookie|
215082576|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
215082577|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
214969104|NCT00050635|DRUG|Sandostatin LAR Depot|
214969105|NCT02085746|OTHER|Defining Sexual Activity Questionnaire|
214969106|NCT03285945|DRUG|PET3|Prednisolone 60 mg daily for 3 days
214969107|NCT03285945|DRUG|PET10|Prednisolone 60 mg daily for 10 days
214969108|NCT01878318|DRUG|methotrexate|stable dose
214969109|NCT01878318|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 24 weeks
214969110|NCT04350645|DRUG|Tranexamic acid injection|1g slow bolus of tranexamic acid over 2 minutes
214969111|NCT04350645|DRUG|Normal Saline 0.9%|10mls normal saline 0.9% over 2 minutes
214357862|NCT05224050|BIOLOGICAL|Heart Rate Variability Biofeedback|Participants will be provided with seven individualized trainings in resonance breathing using biofeedback to help improve self-regulation.
214357863|NCT05224050|DRUG|Nicotine patch|All participants will be offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
214357864|NCT05422326|BIOLOGICAL|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)
214357865|NCT05422326|BIOLOGICAL|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination
214357866|NCT05422326|BIOLOGICAL|Placebo on Day 22|Saline placebo (sterile, 0.5 mL) given 3 weeks after the aH5N6c vaccination
214357867|NCT04960111|DEVICE|RSA|application of tantalium microsphere around knee prosthesis and RSA X-ray post operative to detect early mobilization in follow up.
214969112|NCT05547256|BIOLOGICAL|COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose|50μg/dose
214969113|NCT05547256|BIOLOGICAL|COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose|100μg/dose
214357868|NCT01292876|DEVICE|Extracellular Matrix|Extracellular Matrix
214969114|NCT05547256|DRUG|Placebo|Saline solution
214969115|NCT05404711|DEVICE|CGM|Participants will wear blinded Dexcom G6 Pro continuously for 10 days in their home environment. Two challenges will be completed at home: 1) glucose, using 1.75 g/kg (max 75g) glucose beverage provided by study team, and 2) mixed food, containing 50g carb as well as protein and fat content of participant's choice.
214357869|NCT04749030|OTHER|Faecal microbiota transplantation (FMT) capsules|The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (\~50 grams of original donor faeces).
214357870|NCT04749030|OTHER|Placebo capsules|The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
214357871|NCT04783467|BEHAVIORAL|Time Restricted Eating (TRE) Schedule|\[See arm/group descriptions\]
214969116|NCT01305707|DEVICE|C-ECT|"C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.~Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months."
215082578|NCT00003772|PROCEDURE|quality-of-life assessment|
215082579|NCT03386786|BEHAVIORAL|Health Partner|Health Partner is a combination of a mobile application and a web-based portal.
215082580|NCT03386786|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
214357872|NCT04238806|DRUG|Desflurane Inhalational agent|Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.
214357873|NCT01627327|DRUG|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
214969117|NCT01305707|DRUG|PHARMACOTHERAPY|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
214969118|NCT02841384|OTHER|taping patellar McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
214969119|NCT02841384|OTHER|Placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
214969120|NCT06272149|DRUG|VGN-R08b|VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.
214969121|NCT01383408|OTHER|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
215082581|NCT02139735|OTHER|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
215082582|NCT02139735|OTHER|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
215082583|NCT02139735|OTHER|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
215082584|NCT01009346|DRUG|RAD001|"Dose Level -1 2.5mg/day~Dose Level 1 5mg/day\*~Dose Level 2 10mg/day~MTD RAD001"
215082585|NCT01009346|DRUG|Cetuximab|250mg/m2/week
215082586|NCT01009346|DRUG|Cisplatin|40mg/m2 Day 1, 8 every 28 days
215082587|NCT01009346|DRUG|Carboplatin|"Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance."
215082588|NCT02330523|DEVICE|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
215082589|NCT02330523|DEVICE|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
214357874|NCT01627327|DRUG|tiotropium bromide 18mcg|inhalation powder
214357875|NCT04003168|DRUG|Human BCMA targeted T Cells Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
214357876|NCT01848080|BEHAVIORAL|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
215082590|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Immediately|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
214357877|NCT06124209|DRUG|TachoSil|TachoSil used in Vena Cava Inferior anastomosis during liver transplantation.
214357878|NCT02115594|DRUG|Fulvestrant|
214969122|NCT00498953|DRUG|carboplatin|
214969123|NCT00498953|DRUG|cisplatin|
214969124|NCT00498953|DRUG|docetaxel|
214969125|NCT00498953|DRUG|fluorouracil|
214357879|NCT02115594|DRUG|Entinostat|
214357880|NCT02115594|DRUG|Placebo|
214357881|NCT03435874|BIOLOGICAL|ChAd63 RH5|Vaccine
214357882|NCT03435874|BIOLOGICAL|MVA RH5|Vaccine
214357883|NCT03435874|BIOLOGICAL|Rabies Vaccine|Vaccine
214357884|NCT03731468|DRUG|local anesthetic|ultrasound guided superficial cervical block in thyroid surgery
214357885|NCT03731468|DRUG|Dexamethasone|dexamethasone will be added to ultrasound guided superficial cervical block in thyroid surgery
214357886|NCT03797768|BEHAVIORAL|Behavioural-FCHV Visit|Female Community Health Volunteer will visit selected households on average 3 times a year for providing health promotion messages on improving lung health status and avoiding risk factors to COPD.
214357887|NCT05156190|OTHER|bright classrooms with light level over 1000 lux|Grade 2 primary school students at the intervention groups will study in bright classrooms for three years and incidence of myopia will be compared with those in conventional classrooms
214969126|NCT00498953|DRUG|lapatinib ditosylate|
214969127|NCT00498953|GENETIC|cytogenetic analysis|
214969128|NCT00498953|GENETIC|fluorescence in situ hybridization|
214969129|NCT00498953|GENETIC|in situ hybridization|
214969130|NCT00498953|GENETIC|polymerase chain reaction|
214969131|NCT00498953|GENETIC|reverse transcriptase-polymerase chain reaction|
214357888|NCT01012830|DRUG|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
214357889|NCT04041960|OTHER|Transcranial magnetic stimulation (TMS)|The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
214357890|NCT05615298|RADIATION|Mammography|FFDM (Full-Field Digital mammography)
214357891|NCT01175850|DEVICE|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
214357892|NCT01175850|DEVICE|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
214357893|NCT04294966|DRUG|Dextrose|Administering dextrose to healthy volunteers for our placebo group
214487400|NCT05088421|DRUG|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days."
214487401|NCT05088421|DRUG|Placebo|SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
214487402|NCT04921488|DEVICE|screening colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
214487403|NCT01969916|DRUG|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
214969132|NCT00498953|OTHER|immunohistochemistry staining method|
214969133|NCT00498953|OTHER|laboratory biomarker analysis|
214969134|NCT00498953|PROCEDURE|conventional surgery|
214969135|NCT00498953|PROCEDURE|neoadjuvant therapy|
214969136|NCT00498953|RADIATION|fludeoxyglucose F 18|
214969137|NCT00498953|RADIATION|radiation therapy|
214969138|NCT00418028|DRUG|Capecitabine|
214969139|NCT05545137|DRUG|Pivmecillinam hydrochloride tablets|400mg tablet
214969140|NCT05545137|DRUG|Fosfomycin Tromethamine Granules|3g/pack
214969141|NCT04811807|DEVICE|Subthalamic Nucleaus Deep brain stimulation|In deep brain stimulation (DBS) therapy, a specific anatomical target in the brain is stimulated via surgically fixed electrodes. These electrodes release electrical currents of a specific voltage, wavelength, and frequency. They are connected via subcutaneous wires to a device called an implantable pulse generator (IPG) which is surgically fixed on chest wall, beneath the clavicle. After electrodes and IPG are successfully installed, a clinician will be able to adjust and modulate the stimulation via a remote device connected to the IPG to obtain a maximum potential benefit. Deep brain stimulation has been used in clinics to treat various neurologic diseases including neurodegenerative disorders, mainly movement disorders.
214969142|NCT01153607|DRUG|BAY1006578|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
214969143|NCT01153607|DRUG|BAY1006578|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
214969144|NCT01153607|DRUG|BAY1006578|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
214969145|NCT05914350|PROCEDURE|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
215082591|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Waitlisted|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
215082592|NCT00301548|DRUG|perioperative chemotherapy|
215082593|NCT03482284|OTHER|Dietary Intervention|Participants receive different monosaccharides for a defined number of days.
214487404|NCT06037252|DRUG|Tirzepatide|Administered SC
214487405|NCT06037252|DRUG|Placebo|Administered SC
214969146|NCT05914350|DRUG|methylprednisolone acetate and lidocaine|40 mg methylprednisolone acetate and 1 mL lidocaine
214969147|NCT05914350|DRUG|PRP and lidocaine|3 mL PRP and 1 mL lidocaine
214969148|NCT05914350|DRUG|medical ozone|10 ml of medical ozone
214969149|NCT01803659|DIETARY_SUPPLEMENT|b-carotene|
214969150|NCT01803659|DIETARY_SUPPLEMENT|retinyl palmitate|
214969151|NCT01803659|DIETARY_SUPPLEMENT|placebo|
214969152|NCT02346877|BEHAVIORAL|Personalized Patient Counselling|In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
214969153|NCT03054181|BIOLOGICAL|HyQvia|
214969154|NCT03827694|DIAGNOSTIC_TEST|Non-Invasive Testing for PIFI|galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq
214969155|NCT06373120|DEVICE|Microaxial flow pump|The microaxial flow pump (The CorVad percutaneous ventricular assist system device) is a microaxial rotary blood pump that expels blood from the left ventricle into the ascending aorta, thus unloading the left ventricle. The CorVad system device can be introduced through a femoral percutaneous approach (14Fr) and can deliver an output of up to 4-6 L/min.
215082594|NCT04171180|DRUG|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
215082595|NCT03419949|DRUG|oral lamotrigine 100 mg|Pain relief drug Lamotrigine inhibits the voltage-gated sodium and calcium channels. Inhibition of the voltage-gated sodium channel stabilizes the presynaptic neuronal membrane, thus preventing the release of excitatory neurotransmitters such as glutamate and inhibiting sustained repetitive neuronal firing
215082596|NCT03419949|DRUG|oral pregabalin 150 mg|Pain relief using drug Pregabalin is a structural analogue of the inhibitory neurotransmitter gama-aminobutyric acid (GABA), with anticonvulsant, antihyperalgesic, and anxiolytic properties
215082597|NCT06008769|BEHAVIORAL|12 Week Manualized Cognitive-Behavioral Therapy Intervention|The manualized intervention, Cognitive Behavioral Therapy for Opioid Use Disorder, was co-written and developed by the study PI, Dr. Lent (see Appendix). The manual consists of one module (Module 0) on assessment and 12 modules of CBT. This study will focus on delivery of Modules 1-12 that focus on several tenets of CBT, including skill development (cognitive restructuring, refusal skills, problem-solving, coping strategies), functional analysis (triggers, reinforcement) and utilizing the cognitive model.
214357894|NCT04294966|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
214969156|NCT06373120|DEVICE|VA-ECMO|Veno-arterial extracorporeal Membrane Oxygenation (VA-ECMO) is a device originally created to replace heart and lung function. Venous deoxygenated blood is mechanically suctioned from a large central vein through a venous cannula by a centrifugal pump. It is then oxygenated, warmed, and restored into systemic circulation through an arterial cannula.
215082598|NCT00267605|BEHAVIORAL|FHPADHD|Evidence-based psychological and behavioural distance intervention
215082599|NCT00267605|BEHAVIORAL|ADHD Standard Care|
215082600|NCT00310284|BEHAVIORAL|Computerized delivery of cognitive-behavioral treatment of insomnia|
215082601|NCT00310284|BEHAVIORAL|Self-help manual to improve insomnia symptoms|
215082602|NCT05923736|OTHER|Intima media thickness ultrasound|EIM is a non-invasive ultrasound technique in which an ultrasound-generating probe is conventionally placed opposite the right primary carotid artery. By distinguishing between an inner layer, consisting of the intima and media, and the outer layer, the adventitia, the intima-media thickness can be assessed.
215082603|NCT05923736|OTHER|hand ultrasound|Performed by the rheumatologist, to quantify the number of synovial thickenings in B mode and the number of synovitis in Doppler mode. The presence or absence of joint erosions on the metacarpophalangeal (MCP), proximal interphalangeal (PPI) or distal interphalangeal (DIP) joints.
215082604|NCT05923736|OTHER|EndoPAT™ 2000 system|It's a measurement that detects endothelial dysfunction in coronary arteries using reactive hyperemia.This examination will be carried out in accordance with the manufacturer's instructions by the Rheumatology Department nurse. The patient lies down for the duration of the examination (20 minutes). A probe is placed on the index finger of each hand and a cuff on the left arm. Recording begins with a 5-minute baseline period (at rest), followed by a 5-minute period of arm occlusion, and ends with a 5-minute period of return to normal.
214969157|NCT06597292|DEVICE|Vision improvement|Vision improvement for patients with refractive disorders (hyperopia and presbyopia)
215082605|NCT05923736|OTHER|X-ray absorptiometry (DXA)|This X-ray examination will be carried out on the Hologic device and the analyses by APEX 4.0 software. Two-photon X-ray absorptiometry (DXA) is a method commonly used to measure bone mineral density. It is based on a scan of the body by an X-ray beam at 2 different energy levels, which enables 3 compartments to be individualized: mineral mass, lean mass and fat mass. This low-radiation method (less than a conventional chest X-ray) is regarded as a benchmark for accurate measurement of both bone mineral density and the various body compartments. The examination lasts 10 minutes and is carried out by the department's electroradiology manipulators
215082606|NCT06031142|DEVICE|use wearable devices to monitoring fetal health conditions.|We used wearable devices and clinical cardiotocography (CTG) equipment to monitor pregnant women for 30 minutes to demonstrate the reliability of wearable devices.
215082607|NCT04429581|OTHER|Anthropometry|
215082608|NCT03067285|DRUG|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
215082609|NCT03067285|DRUG|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
215082610|NCT02928003|PROCEDURE|Lung surgery|Genetic analysis and questionnaires
214357895|NCT04294966|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
214357896|NCT04708444|DIAGNOSTIC_TEST|CD318|Flowcytometric marker
214357897|NCT06242626|OTHER|observation|analysis of clinical, laboratory and haemodynamics parameters
214357898|NCT00046358|DRUG|Lovostatin|
214357899|NCT00046358|DRUG|Ibuprofen|
214487406|NCT05779839|BEHAVIORAL|Algorithm|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be matched using an algorithm. They can then choose make a connection and maintain a connection for the duration of the study.
214487407|NCT05779839|BEHAVIORAL|Random Match|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be randomly matched. They can then choose make a connection and maintain a connection for the duration of the study.
214969158|NCT05773625|DEVICE|Just-In-Time Adaptive Intervention|Participants will be exposed to a new innovative app to test.
214969159|NCT02837393|PROCEDURE|Ureteral catheterization|During ureteral catheterization, urine samples will be obtain from each kidney
215082611|NCT05785260|BEHAVIORAL|ACT MINDFULNESS|"Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification."
214357900|NCT04432987|DRUG|Pulmozyme|"PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days"
214487408|NCT02932761|DRUG|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
214969160|NCT06657274|DEVICE|RICORDO-DTx|"Tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to digital therapeutics delivery model. Subjects assigned to the tele@cognitive group can access the app RICORDO-DTx through a tablet showing the prescribed rehabilitation activities to be performed.~Each cognitive exercise is structured into five levels of difficulty that adaptively increase (algorithm on both subject's performance and perceived difficulty). All data about patient progress and adherence will be collected with this digital solution and will be available to evaluate and monitor the results of rehabilitation."
214487409|NCT02932761|PROCEDURE|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
214487410|NCT05438992|DRUG|Bupivacaine 0.25% Preservative-Free Injectable Solution|local anesthetic drug injection for postoperative pain
214487411|NCT03311516|OTHER|New functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
214969161|NCT06657274|BEHAVIORAL|Home-based unstructured cognitive stimulation|Subjects assigned to the home-based unstructured cognitive stimulation will be requested to work on detailed activities for the same duration of the tele@cognitive intervention (3 sessions/week, 45 minutes/session). They will receive, from the therapist, an instructions booklet and a participant diary.
215082612|NCT03302455|BEHAVIORAL|eCBTI|The brief eCBTI contains a one-week core course: sleep hygiene education, sleep restriction, stimulus control, relaxation audios, cognitive components, information about sleeping pills, and a brief overview. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
215082613|NCT01316952|DRUG|Carvedilol immediate release only|All dosages of carvedilol immediate release
215082614|NCT01316952|DRUG|Carvedilol extended release only|All dosages of carvedilol extended release
214357901|NCT03546517|OTHER|Dry Needling|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
214357902|NCT03546517|OTHER|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
214357903|NCT05475054|PROCEDURE|Minimally invasive liver resection|A liver resection performed by minimally invasive (keyhole) surgery
214357904|NCT00083408|DRUG|Pamidronate|
214357905|NCT00083408|DRUG|Thalidomide|
214487412|NCT03311516|OTHER|functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
214487413|NCT04914403|BIOLOGICAL|UMC119-06-05|Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05
214487414|NCT00448552|DRUG|capecitabine|
214969162|NCT01779557|DRUG|Huaren Peritoneal Dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
214969163|NCT01779557|DRUG|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
214969164|NCT04972799|OTHER|injection of autologous fat at Day 0 and injection of saline at 6 months|injection into the intersphincter space
215082615|NCT01316952|DRUG|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
215082616|NCT01316952|DRUG|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
215082617|NCT01316952|DRUG|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
214357906|NCT05622669|OTHER|Observational|Sensed and lived experience data from all groups without a specific behavioural or drug intervention
214357907|NCT04184063|DRUG|NBMI|NBMI active treatment
214357908|NCT04184063|OTHER|Placebo|Placebo for comparison
214357909|NCT01851148|OTHER|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
214357910|NCT01851148|OTHER|sham treatment|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence"
214357911|NCT01851148|DRUG|triptans|administration of triptans drug treatment according to international guidelines
214357912|NCT04101305|DIAGNOSTIC_TEST|IsoPic|Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
214357913|NCT03270449|OTHER|Multidisciplinary intervention|10 week multidisciplinary education and exercise
214487415|NCT00448552|DRUG|oxaliplatin|
214487416|NCT03890848|BEHAVIORAL|Wechat application reminder intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
214487417|NCT03890848|BEHAVIORAL|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
214487418|NCT06539715|DIAGNOSTIC_TEST|Visual field assessment|Automated perimetry
214487419|NCT05220943|BEHAVIORAL|Video|This 5-minute video presents clips with voiceover narration summarizing and highlighting the key safety points in the Center for Surgical Innovation (CSI) location.
214357914|NCT01838798|OTHER|Baseline activities|Initial consent procedures and baseline data collection.
214357915|NCT01838798|OTHER|Clinical interview with a psychologist|"Clinical interview with a psychologist.~This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:~* An inventory of peritraumatic distress symptoms~* A questionnaire on peritraumatic dissociative experiences~* An assessment of related, potential impacts~* The HADS questionnaire"
214357916|NCT01838798|OTHER|Telephone interview 2 months after ICU discharge|"At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:~* Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ~* An assessment of psychological trauma~* An assessment of potential impacts"
214969165|NCT04972799|OTHER|injection of saline at Day 0 and injection of autologous fat at 6 months|injection into the intersphincter space
214969166|NCT04839718|BEHAVIORAL|ADAPT|The Achieving Depression and Anxiety Patient Centered Treatment (ADAPT) Program is a novel collaborative psychiatric care model that is designed to unburden PCPs and psychiatrists, increase access to quality specialty mental healthcare for Kaiser Permanente members, and improve patient depression and anxiety treatment outcomes by utilizing technology-driven appointments. This program uses principles of collaborative care, including patient-centered care, population-based care, evidence-based care, measurement-based treatment to target, and accountable care.
214969167|NCT06392035|OTHER|health education, web-based education|Data collection tools will be filled in by two study groups (experimental group, control group) and based on the pre-test results of both groups, Pender\&#39;s SGM-based breakfast training will be given only to the experimental group. No intervention will be made to the control group. In this study, a total of 6 sessions will be held for the experimental group for 6 weeks (one session per week), each lasting 40 minutes. In these sessions, web-based training will be given every week according to the components of the model and will be supported with written and visual brochures.
214969168|NCT00395993|DRUG|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
214357917|NCT01838798|OTHER|Clinical interview with a psychologist|"At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:~* assess cognitive functions~* evaluate clinical symptoms of depression~* assess quality of life~* assess symptoms of post traumatic stress"
215082618|NCT01316952|OTHER|No β-blocker|No β-blocker within the month prior to the index date
215082619|NCT05491746|DEVICE|Eye4|Patients will see if the device helps them see better at distance and near and if it improves their contrast sensitivity.
215082620|NCT05491746|OTHER|Placebo|This is the patient's best corrected vision with or without glasses/contact lenses
214357918|NCT02077179|BEHAVIORAL|HIP Program|"The entirety of the HIP Program is delivered through an interactive mobile website.~The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.~The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays."
214357919|NCT01982149|GENETIC|Group 1|Perform gene expression studies of airway epithelium to correlate findings in the gene expression of nasal bronchial epithelium
214357920|NCT01982149|GENETIC|Group 2|Correlate gene expression data from nasal and bronchial epithelium
214357921|NCT01982149|GENETIC|Group 3|Correlated nasal epithelial gene expression with the ultimate diagnosis (by biopsy or surgery)
214357922|NCT00745810|OTHER|Cardiopulmonary bypass|sequential changes of oxidative injuries before and after cardiopulmonary bypass
214357923|NCT03098134|BEHAVIORAL|Behavior Therapy|Virtual Reality and Video based Exposure Therapy
214487420|NCT04632394|DIAGNOSTIC_TEST|Generation of computational model from cardiac MRI.|Routine cardiac MRI scan results will be sent to Johns Hopkins University where a computer-generated model of the heart will be made, which will demonstrate predicted areas critical to VT generation and maintenance. This data will be sent back to St George's, and integrated with the standard VT ablation mapping software to allow comparison of its accuracy with standard mapping techniques.
214969169|NCT00395993|DRUG|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
214969170|NCT00971217|OTHER|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
215082621|NCT04054492|BIOLOGICAL|Sabin-IPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
215082622|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
215082623|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+Sabin-IPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
215082624|NCT06228638|OTHER|CognivAID (Sailuotong)|CognivAiD is 27.27 mg of panax ginseng standard extract, 27.27 mg of gingo biloba standard extract and 5.46 mg of crocus sativus standard extract which is equal to 60mg /capsule .CognivAiD is available at 60 mg /cap 2 caps twice a day.
215082625|NCT05295823|DEVICE|Butterfly portable ultrasound device with bladder ultrasound images|Point-of-care PVR measurement using existing ultrasound technology (3 consecutive measurements during the same encounter) the Butterfly portable ultrasound device with bladder ultrasound images
215082626|NCT05295823|DEVICE|Butterfly portable ultrasound device with abstract bladder images|Point-of-care PVR measurement using the Butterfly portable ultrasound device with abstract bladder images
215082627|NCT02044666|DEVICE|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
215082628|NCT02593812|BEHAVIORAL|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
214357924|NCT03098134|OTHER|Health Education|Video based health education covering common myths and false believes about dental surgeries
214679158|NCT02485366|PROCEDURE|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
214969171|NCT00971217|BEHAVIORAL|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
214969172|NCT00293553|PROCEDURE|Electronic Barostat|
214969173|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
214969174|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
214969175|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
214969176|NCT06525519|DRUG|ATLG|5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
214969177|NCT06525519|DRUG|ATLG|7.5mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
215082629|NCT04317326|PROCEDURE|"Lifestyle modifications group (Control)"|It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 \<55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.
215082630|NCT04317326|PROCEDURE|Automatic NIV|In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.
215082631|NCT04317326|PROCEDURE|CPAP treatment group|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.
215082632|NCT04317326|PROCEDURE|NIV treatment groups|In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
215082633|NCT01812356|DEVICE|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
215082634|NCT01812356|DEVICE|Cryomaze procedure using Argon|Cryomaze procedure using Argon
215082635|NCT04922931|PROCEDURE|scheduled surgery|Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia
215082636|NCT02031081|DRUG|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
214969178|NCT01984710|DEVICE|Medtronic Activa PC+S System|
214969179|NCT06473558|DEVICE|Biometrics (or AI Biomaker)|Patients will be asked to read a story and their facial expressions and audio cues will be recorded.
214969180|NCT05449444|DRUG|Masitinib 4.5 mg/kg/day|Masitinib 4.5 mg/kg/day
214969181|NCT05449444|DRUG|Placebo|Matching placebo
214969182|NCT05449444|OTHER|Best supportive care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.
214969183|NCT05449444|DRUG|Masitinib 6.0 mg/kg/day|Masitinib 6.0 mg/kg/day
214969184|NCT01212094|DRUG|Rituximab|
214969185|NCT01212094|OTHER|normal saline|normal saline
214969186|NCT01490892|DRUG|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
214969187|NCT03740204|DRUG|17-β estradiol transdermal patches with cyclic progesterone|17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
214969188|NCT03740204|DRUG|Placebo patch and pill|Placebo patch and pill
214357925|NCT02535273|DRUG|Dexmedetomidine|load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
214357926|NCT02535273|DRUG|Lidocaine|local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
214357927|NCT02535273|DRUG|Low-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
214679159|NCT05443958|OTHER||
214679160|NCT00348972|DRUG|Lantus® (insulin glargine)|
214679161|NCT00950690|DRUG|Xalatan 0.005% eye drops|ophthalmic solution dosed once daily for 3 months
214357928|NCT02535273|DRUG|Moderate-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
214357929|NCT02535273|DRUG|High-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
214357930|NCT02535273|DRUG|normal saline|Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
214357931|NCT06064396|OTHER|Gong's Mobilization|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Gong's Mobilization.
214969189|NCT00379405|DRUG|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
214357932|NCT06064396|OTHER|Stecco Fascial Therapy|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with stecco fascial therapy.
214357933|NCT04528069|DEVICE|ACRYSOF® IQ PanOptix® Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.
214357934|NCT04528069|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
214357935|NCT03673254|DEVICE|rotational atherectomy device|angioplasty with rotational atherectomy device on a nonselected population
214357936|NCT03966833|BEHAVIORAL|IPT-G|14 weeks of group-based interpersonal therapy (IPT-G)
214357937|NCT03966833|BEHAVIORAL|Unconditional Cash Transfer|Lump sum cash transfer
214357938|NCT02436265|DRUG|Dexamethasone|IV dexamethasone
214357939|NCT02436265|DRUG|Ropivacaine|Ropivacaine only
214969190|NCT00913601|DEVICE|Medtronic INTERSIM II - 3058|Medtronic INTERSIM II - 3058 Impuls Generator
214969191|NCT05985863|DRUG|standard medical treatment|standard medical treatment for ACLF
214969192|NCT05985863|DRUG|Placebo|5% human serum albumin in 0.9% saline (at week0, week1 and week2)
214969193|NCT05985863|DRUG|hUC-MSC|hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)
214969194|NCT05985863|DRUG|hUC-MSC_Prolonged|hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week4 and week5)
214969195|NCT02112695|OTHER|[11C]diprenorphine|3 micrograms \[11C\]diprenorphine - intravenous use - 1 time
214357940|NCT05955703|BEHAVIORAL|ppm based training|The training program based on the precede proceed model was applied to hemodialysis patients for 8 sessions. Eight sessions of training were given to the experimental group within the scope of the model, a booklet was developed in line with the trainings and posters were prepared.
214357941|NCT03584932|BEHAVIORAL|LINK2 Youth Services Navigation Intervention|There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
214969196|NCT05004090|DIAGNOSTIC_TEST|DNA methylation analysis|Genomic DNA will be extracted from 0.4 ml aliquots of each saliva sample using the kit manufacturer's suggested protocol, quantified with Qubit 2.0 (Invitrogen), and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed as described. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated and tabulated.
214357942|NCT03365024|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
214357943|NCT03365024|BEHAVIORAL|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform
214357944|NCT03901326|DIAGNOSTIC_TEST|CT-FFR assessment|When subjects are randomized to the CTA/CT-FFR arm, FFR based on the coronary CTA imaging will be measured. DEEPVESSEL FFR workstation is very dedicated software utilizing the original CTA imaging to meter simulated FFR values based on a machine learning algorithm. The first step is to extract a 3D coronary artery model and generate coronary centerlines which are similar to the routine reconstruction of coronary CTA. The centerlines are extracted using a minimal path extraction filter. Then a novel path-based deep learning model, referred to DEEPVESSEL FFR, is used to predict the simulated FFR values on the vascular centerlines. Deep learning algorithm is used to establish characteristic sample database of coronary hemodynamics characteristic parameters. When deep training model is proved to be valid, it is applied to a new lesion-specific measurement. Lesion-specific CT-FFR is defined as simulated FFR value at distance of 20mm away from the lesion of interest.
214357945|NCT02525874|DRUG|dimethyl fumarate|Initial oral dose for 7 days with maintenance dose thereafter
215082637|NCT02031081|DRUG|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
215082638|NCT06120595|DRUG|REBECCA-assisted intervention 1|The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).
215082639|NCT06120595|BEHAVIORAL|REBECCA-assisted intervention 2|The intervention will include dietary advice, to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH).
214357946|NCT04899830|DEVICE|Telepresence robot|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)
214357947|NCT00253968|DRUG|Eplivanserin|oral administration
214357948|NCT00253968|DRUG|placebo|oral administration
214357949|NCT06005805|DIETARY_SUPPLEMENT|Mastic gum|Mastic gum 3g/pack daily for 21 days
214357950|NCT06005805|BEHAVIORAL|Dietary modification|Adhere to the dietary recommendations for Korean dyspepsia patients
215082640|NCT06120595|OTHER|Standard follow-up|Standard follow-up
214357951|NCT04211038|DEVICE|inspiratory threshold load device|"Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV."
214357952|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro|
214357953|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro FreeD|
214357954|NCT05830955|OTHER|Lullaby group|The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
214357955|NCT05830955|OTHER|Breast milk group|The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
214357956|NCT05830955|OTHER|Control group|The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
214357957|NCT00006041|BIOLOGICAL|MUC1-KLH conjugate vaccine|
215082641|NCT01878110|BEHAVIORAL|COMB|
215082642|NCT02189499|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
215082643|NCT03990103|DRUG|S1|80-120 mg/day, PO, D1-14, every 21 days
215082644|NCT03990103|DRUG|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
215082645|NCT03990103|DRUG|Bevacizumab|200 mg, IP, D1, every 21 days
214357958|NCT00006041|BIOLOGICAL|MUC1-KLH vaccine/QS21|
214357959|NCT00006041|BIOLOGICAL|QS21|
214357960|NCT00446381|DRUG|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
214357961|NCT00446381|DRUG|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
214357962|NCT00961090|DRUG|Aminolevulinic Acid|20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
214357963|NCT05308173|PROCEDURE|Surgical Aortic Valve Replacement|Cardiac surgery under cardio-pulmonary bypass, via sternotomy or minimally invasive approach with the replacement of native valve with a biological or mechanic prosthesis.
214357964|NCT05308173|PROCEDURE|Transcutenous Aortic Valve Implantation|Transfemoral implantation of aortic bioprosthesis with one of the devices available in Poland.
214357965|NCT05368779|BEHAVIORAL|The internet-based psychosocial intervention|Participants were provided psychoeducation on intimate partner abuse, psychological trauma, Social Learning Theory, and Cognitive Behavioral Therapy methods. Intimate partner abuse and psychological trauma were discussed in the context of sociocultural factors. Cognitive Behavioral Therapy approaches were used to attempt to normalize intimate partner abuse, psychological trauma and their effects on participants. Participants were exposed to trauma gradually with record of sessions watching and imaginary exposure methods for reducing avoidance behaviours. Schemas, intermediate beliefs, and automatic thoughts of participants were studied using Cognitive Behavioral Therapy approaches and cognitive restructuring was fulfilled. The universality of mental pain, the meaning of life, the integrate trauma into life histories of participants, expectations for the future romantic relationships, and post traumatic growth were all discussed in accordance with the goals and values of participants.
214679162|NCT00711399|DEVICE|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
215082646|NCT03990103|DRUG|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
215082647|NCT01329614|BEHAVIORAL|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
215082648|NCT01329614|DRUG|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
215082649|NCT01329614|BEHAVIORAL|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
215082650|NCT01329614|BEHAVIORAL|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
215082651|NCT00453947|DEVICE|CPAP and Non Invasive Ventilation|
214357966|NCT05480150|DRUG|Escitalopram Oxalate Tablets|Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks
214357967|NCT05480150|DRUG|Quetiapine Fumarate Tablets|Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.
214357968|NCT05480150|DRUG|Lurasidone|Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.
214357969|NCT00297154|BEHAVIORAL|Lifestyle Modification (diet, exercise, and behavior)|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
214357970|NCT01692782|DRUG|SEP-225289|SEP-225289 4mg once daily
214357971|NCT01692782|DRUG|SEP-225289|SEP-225289 8mg once daily
214357972|NCT01692782|DRUG|Placebo|Placebo once daily
214357973|NCT00591474|DIETARY_SUPPLEMENT|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
214357974|NCT00591474|DIETARY_SUPPLEMENT|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
214679163|NCT06438913|DRUG|Tezepelumab|Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine suggested to be important in the initiation and continuation of airway inflammation.
214679164|NCT03601416|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
214679165|NCT03601416|DRUG|No Transplantation of Mesenchymal Stem Cell|Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
215082652|NCT01688843|DEVICE|INGEVITY lead|
215082653|NCT00248430|BIOLOGICAL|aldesleukin|
215082654|NCT00248430|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215082655|NCT00248430|DRUG|melphalan|
215082656|NCT00248430|PROCEDURE|bone marrow ablation with stem cell support|
215082657|NCT00248430|PROCEDURE|peripheral blood stem cell transplantation|
215082658|NCT02267330|PROCEDURE|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
215082659|NCT00469963|PROCEDURE|quality-of-life assessment|quality-of-life assessment
214357975|NCT02385305|DEVICE|Pressure support ventilation by anesthesia machine (Apollo, Dräger)|Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
214969197|NCT05004090|DIAGNOSTIC_TEST|Proteomics analysis|Urine samples are collected using non-invasive methods and are prepared according to a procedure preparatory to quantitative recovery of exosomes: once thawed and centrifuged at 17,000 x g for 10 min at 4°C, the recovered supernatants are separated and centrifuged at 200,000 x g for 1 hr at 4°C. Exosome pellets are separated, washed repeatedly and resuspended in buffer (NH4HCO3, 0.1 mM ph=7.8). Protein concentration is estimated with the SPNTM Protein Assay kit and each sample (50 ± 0.5 μg protein) is digested with trypsin using a 1:50 (w/w) enzyme/substrate ratio at 37 °C over night (o/w). A second tryptic digestion is performed with an enzyme:substrate ratio of 1:100 (w/w) for 4h. Digested samples, centrifuged at 13,000 × g for 10 min, are purified and concentrated using PepClean C-18 columns. The samples obtained are analyzed by reversed-phase liquid chromatography coupled to high-resolution mass spectrometry.
214969198|NCT05004090|DIAGNOSTIC_TEST|Still Face Paradigm|During an observational session, a short video recording of the mother-child interaction of approximately 10 minutes will be made in a semi-structured setting to assess the child's emotional regulation and social behavior. The interaction will be structured in 5 different phases according to the Still Face paradigm (Tronick et al., 1978): Play, Still#1, Reunion#1, Still#2, Reunion#2. Play: Mothers will be invited to interact with their babies for 10 minutes; Still: mothers will be asked to remain still while maintaining an unresponsive expressionless face and not to smile, touch, or talk to the child for 2 minutes (Still#1: 2 minutes; Still#2: 2 minutes); Reunion: mothers will be asked to resume the play activity with their own for an additional 2 minutes (Reunion#1: 2 minutes; Reunion#2: 2 minutes).
214969199|NCT00863915|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
214969200|NCT00863915|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
214969201|NCT03003910|BEHAVIORAL|Best Possible Self|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
214969202|NCT03003910|BEHAVIORAL|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
214969203|NCT06253377|DEVICE|Adsorption membrane filter Oxiris™|Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris™
214969204|NCT03541291|DEVICE|SMART-SYNC LM03|Doppler ultrasound cardiac gating device for fetal MRI application
214969205|NCT03650153|PROCEDURE|Trans-rectal MRI targeted Biopsy|Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.
214969206|NCT03650153|PROCEDURE|Trans-perineal MRI targeted Biopsy|Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
214969207|NCT01042340|OTHER|Calogen® - an energy dense oleic acid based formula|A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
214969208|NCT02991963|OTHER|Interview|A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
215082660|NCT00469963|RADIATION|yttrium Y 90 resin microspheres|radiation therapy
214357976|NCT03252587|DRUG|BMS-986165|Specified dose on specified days
214357977|NCT03252587|OTHER|Placebo|Specified dose on specified days
214357978|NCT06231173|OTHER|Visual Feedback Therapy and Conventional Therapy|In experimental group individuals will receive visual feedback therapy and Conventional rehabilitation therapy. In visual feedback therapy, bilateral method is used to receive the visual feedback from the mirror. This visual feedback therapy consists of the following parts as the patient is asked to follow the involved hand that did the mimicking while the non-involved side will be performing wrist flexion, wrist extension, ulnar deviation, radial deviation, supination, pronation, and closing hand and opening hand.In conventional therapy, Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the noninvolved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.
214357979|NCT06231173|OTHER|Conventional Therapy|In control group individuals will receive only conventional therapy. In conventional therapy, Patients are instructed to perform a sandbag and hand grip exercise with a resistive exercise for the non-involved side. At last, patients are instructed to perform a moving small object (ball of wool) and card flip operation to induce wrist and finger movements as functional activities. Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the non involved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. .This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.
214357980|NCT02846090|DRUG|Dexmedetomidine to reduce the IOP|Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
214357981|NCT05612074|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
214357982|NCT02869087|DEVICE|Akesys Prava Scaffold|Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
214679166|NCT02695485|PROCEDURE|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
214969209|NCT02991963|OTHER|Blood collection (Dried Blood Spot)|Dried Blood Spot
214969210|NCT02991963|OTHER|Blood Collection (Venous Blood collection)|Venous Blood collection
214969211|NCT02991963|OTHER|Blood Smear|Slide blood smear
214969212|NCT03180203|DEVICE|INTELLiVENT-ASV|"After ICU admission:~* The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.~* After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if \>10minutes PEEP:\<9cmH2O,FiO2:\<41%,VT/IBW\<5ml/kg and RSB:\<106l/l\*min.~Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate \>35b/min or increases \>100% since start of SBT, FiO2 \>50%, PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
214969213|NCT03180203|DEVICE|Conventional modes|"After ICU admission:~The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.~After three hours: manual SBT is required if \>10min PS\<11cmH2O,PEEP\<9cmH2O,FiO2\<41%.~Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate \>35b/min or increases \>100% since the start of SBT, saturation \<92% or the PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
214969214|NCT02277275|DIETARY_SUPPLEMENT|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
214969215|NCT02277275|DIETARY_SUPPLEMENT|Placebo|Placebo will be provided to the other two arms for six months
214969216|NCT02065401|DRUG|Deferitazole (disodium salt, granule)|Single oral dose of 1500 mg administered on Day 1
214969217|NCT02065401|DRUG|Deferitazole (disodium salt, tablet)|Single oral dose of 1500 mg administered on Day 1
214969218|NCT02065401|DRUG|Deferitazole (magnesium hydroxide salt)|Single oral dose of 2400 mg administered on Day 1
214969219|NCT01301300|DEVICE|Disinfecting Cap|Replace standard practice with using the disinfecting cap
214969220|NCT02467361|DRUG|BBI608|Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
214969221|NCT02467361|DRUG|Ipilimumab|Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
215082661|NCT02483130|DIETARY_SUPPLEMENT|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
215082662|NCT02483130|OTHER|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
215082663|NCT00541099|BIOLOGICAL|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
214357983|NCT04052204|DRUG|avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
214357984|NCT04052204|DRUG|Bempegaldesleukin|Investigational CD122-biased cytokine agonist
214357985|NCT04052204|DRUG|talazoparib|poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor
214357986|NCT04052204|DRUG|enzalutamide|androgen receptor inhibitor
214357987|NCT03602131|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
214357988|NCT03602131|DRUG|Cladribine|6 mg/m2 intravenously once daily for 5 days
214357989|NCT03602131|DRUG|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
214357990|NCT03602131|DRUG|Busulfan|3.2 mg/kg intravenously once daily for 4 days
214357991|NCT03602131|PROCEDURE|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
214357992|NCT00095225|DRUG|Avastin (bevacizumab)|
214357993|NCT00095225|DRUG|Tarceva (erlotinib HCl)|
214357994|NCT04928820|PROCEDURE|Computed Tomography|Undergo PET/CT
214357995|NCT04928820|OTHER|Gallium Ga 68 Gozetotide|Given IV
214357996|NCT04928820|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214969222|NCT02467361|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
214969223|NCT02467361|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
214969224|NCT02019550|DEVICE|Rebif Rebidose|Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
214969225|NCT02019550|DEVICE|Rebiject II|Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
214969226|NCT04161235|DEVICE|The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
215082664|NCT00541099|DRUG|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
215082665|NCT02525991|DEVICE|Staccato® Delivery System Loxapine (ADASUVE®)|one dose Loxapine Staccato 9.1 mg
214357997|NCT00268294|DEVICE|Cardiac Resynchronization Therapy|
214357998|NCT02161133|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
214357999|NCT02161133|BEHAVIORAL|Health Education|Health Education provides didactic information about Gulf War Illness
214358000|NCT03220490|BEHAVIORAL|5 minute interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
214358001|NCT03220490|BEHAVIORAL|no interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
214358002|NCT03220490|DRUG|IOP reduction of Brimonidine and Timolol with time interval|"In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop."
214358003|NCT03220490|DRUG|IOP reduction of Brimonidine and Timolol no time interval|"In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period."
214487421|NCT04632394|PROCEDURE|VT ablation|Routine VT ablation as described elsewhere in the literature. However, a brief period of extra time (\~30 minutes) will be spent analysing the areas of the heart which the MRI scan predicted as being important for generation of VT. We will study the effect of ablation of these areas (if indicated) on distant parts of the heart.
214487422|NCT03554889|BIOLOGICAL|NK Cell adaptive transfer|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
214487423|NCT03554889|DRUG|Nimotuzumab|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
214969227|NCT04264780|OTHER|Neuropsychological examination|Neuropsychological follow-up examination, including questionaires
214969228|NCT03834311|DEVICE|isokinetic strengthening|isokinetic upper extremity (forearm) strengthening for 4 weeks 3d/w
214969229|NCT03834311|OTHER|exercise band strengthening|upper extremity (forearm) strengthening with exercise band 4 weeks 3d/w
214969230|NCT02133391|OTHER|Centralized Reminder/Recall (R/R)|Method of increasing immunization delivery using reminder/recall techniques, which are implemented centrally.
214969231|NCT02133391|OTHER|Practice-based Reminder/Recall|Method of increasing immunization delivery using reminder/recall techniques, which are implemented at the practice level.
214969232|NCT04394598|DRUG|Dendrobium Huoshanense Granules|3g tid per day for 5weeks
214969233|NCT04394598|RADIATION|Pelvic Radiation|50Gy/25Fx
214969234|NCT04394598|DRUG|Capecitabine|625mg/m2 bid Monday-Friday per week
214969235|NCT04394598|DRUG|Irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
214969236|NCT04394598|OTHER|Placebo|3g tid per day for 5weeks
214969237|NCT01450319|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.
214358004|NCT04158050|DRUG|IL5 Antagonist or anti-IL5R-antibody or Omalizumab|mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma
214358005|NCT02557841|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
214358006|NCT02557841|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
214487424|NCT02438059|BEHAVIORAL|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
214969238|NCT01535677|DRUG|Dapagliflozin + Glucophage tablet fasted|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
214969239|NCT01535677|DRUG|Dapagliflozin/metformin IR FDC tablet fasted|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
214969240|NCT01535677|DRUG|Dapagliflozin + Glucophage tablet fed|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
214969241|NCT01535677|DRUG|Dapagliflozin/metformin IR FDC tablet fed|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
214969242|NCT02762448|DRUG|Daclatasvir+ Asunaprevir|HCV clearance and complete regression of NHL by ASV+ DCV
214487425|NCT00995631|PROCEDURE|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
214487426|NCT03426800|OTHER|Acupuncture and training|Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
214487427|NCT02297919|BEHAVIORAL|Effectiveness of Internet Based Obesity Control Programme|
214487428|NCT04852315|DIETARY_SUPPLEMENT|Caffeine|Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
214487429|NCT04852315|DIETARY_SUPPLEMENT|Placebo|Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
214487430|NCT01894074|BEHAVIORAL|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
214969243|NCT05299684|OTHER|EVALUATION|The level of addiction was assessed with the Smartphone Addiction Scale Short Form (SAS-SF). The posture of participants was evaluated by New York Posture Rating Chart (NYPRC), mostly usage smartphone posture, forward head and myofascial trigger points were questioned according to Simon and Travel criteria. Mann-Whitney U test Pearson's chi-squared test were used for analyzing the data.
214969244|NCT00823134|DEVICE|ApneaLink Plus|Device used to evaluate for the presence of obstructive, central or mixed apneas
214969245|NCT02192671|PROCEDURE|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
214969246|NCT02192671|PROCEDURE|Radiofrequency Ablation|
214969247|NCT01561937|DRUG|warfarin|After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
214969248|NCT01561937|DRUG|eptacog alfa (activated)|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
214969249|NCT01561937|DRUG|placebo|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
214358007|NCT02557841|DEVICE|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
214969250|NCT03463629|OTHER|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
214969251|NCT03463629|OTHER|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services
214358008|NCT04415450|BEHAVIORAL|Nutrition Education counseling|In the context of health education program, an educational intervention was developed by the research team based on a training module. The nutrition education contained introductory messages and focused on meanings of healthy diet, eating a variety of food, eating well with the locally available food, hazards of maternal malnutrition, important supplements to be taken during pregnancy, harmful substances to be avoided, and measures of alleviating common discomforts associated with nutrition during pregnancy. The training program was carried out in the form of counseling using printed materials and flip charts for pictorial representation. Self-reading of leaflets containing the core messages for every topic prepared in the native language of the participants was also employed as the women in the study had one each.
214358009|NCT04437784|PROCEDURE|Laparoscopic Trans-Abdominal Pre-Peritoneal|Laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
214969252|NCT04787367|PROCEDURE|TAP block|"An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine."
214969253|NCT00078403|DRUG|Peginterferon alfa-2a|180 mcg PEG-IFN subcutaneously
214969254|NCT00078403|DRUG|Ribavirin|One tablet or capsule containing ribavirin 200 mg
214969255|NCT05734820|DIAGNOSTIC_TEST|HD- colonoscopy|HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.
214969256|NCT05734820|DIAGNOSTIC_TEST|HD-colonoscopy assisted by AI|HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.
214969257|NCT02291029|DRUG|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
214969258|NCT02291029|DRUG|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
214969259|NCT02291029|DRUG|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
214969260|NCT02291029|DRUG|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
214969261|NCT02291029|DRUG|CFZ533 active -Cohort 3|multiple doses of CFZ533 s.c. injection
214358010|NCT04437784|PROCEDURE|Open pre-peritoneal repair|Open pre-peritoneal single mesh repair with suture fixation
214358011|NCT04437784|PROCEDURE|Bilateral Lichtenstein repair|Bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
214358012|NCT06580795|BEHAVIORAL|Student citizens' assembly|The intervention consists in participating in a deliberative mini-public, a student citizens' assembly whose mission is to to co-create a list of concrete proposals that would improve the access of USPN students to sustainable diets and physical activity
214487431|NCT01894074|BEHAVIORAL|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
214487432|NCT05353894|DRUG|GNS561 oral tablets and capsules|Two formulations and Two dosage will be compared
214487433|NCT05566067|OTHER|Survey|There will be no interventions for study participants. Participants will be asked to complete a survey.
214969262|NCT02291029|DRUG|CFZ533 active - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
214969263|NCT03036371|BEHAVIORAL|High Intensity Interval Exercise|6 week at-home aerobic exercise protocol
214969264|NCT05002166|OTHER|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.
214969265|NCT02558842|OTHER|Education Strategy|"Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.~During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.~During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit."
214969266|NCT06344715|BIOLOGICAL|SL-T10|A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants
214969267|NCT06344715|BIOLOGICAL|GX-I7|A T-cell growth factor
214969268|NCT06344715|BIOLOGICAL|Pembrolizumab|An immune check point inhibitor
214969269|NCT02410863|DRUG|Dabrafenib|150 mg twice daily
214969270|NCT02410863|DRUG|Trametinib|2 mg daily
214969271|NCT04575220|OTHER|12 weeks of bicycle exercise|Subjects will conduct monitored exercise, three sessions per week for 12 weeks.
214969272|NCT04265222|DEVICE|Hipcheck Software|Software
214969273|NCT04265222|OTHER|Conventional Fluoroscopy|Conventional Fluoroscopy
214969274|NCT04750018|OTHER|surgery|Patients were divided into surgery and no disease.
214969275|NCT03112694|OTHER|Data collection|This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.
215082666|NCT06344910|OTHER|Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies|"An algorithm will check if the patients if the patient has an age \>18 year and is treated at the cardiology department for HFrEF. The use of GDMT is determined using prescriptions data electronic health records (EHR). If the patient does not receive treatment for all 4 drug classes (ACE/ARB/ARNi, beta-blocker, MRA, SGLT2-inhibitor), an electronic alert will be displayed suggesting the clinician to prescribe additional medication when clinically indicated, including relevant recent laboratory results (renal function and electrolytes) and other relevant measures (LVEF, blood pressure and heart rate). The alert is linked to an order set to aid in the prescription of GDMT according to current guidelines.~Results will compared to a retrospective cohort (t=-12 to t=-6) months, and a silent mode cohort (t=-6 to t=0 months, in which a paired and a before and after analysis will be performed to evaluate the effect of the alert."
215082667|NCT05455008|BEHAVIORAL|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
215082668|NCT00432744|DRUG|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
215082669|NCT00432744|DRUG|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
215082670|NCT01256281|PROCEDURE|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
214358013|NCT02506842|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
214358014|NCT02506842|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
214358015|NCT02506842|DRUG|oxaliplatin|Patients receive oxaliplatin 85 mg/m\^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
214358016|NCT02506842|DRUG|folinic acid|Patients receive folinic acid 200 mg/m\^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
214358017|NCT02506842|DRUG|fluorouracil|Patients receive fluorouracil 2000 mg/m\^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
214358018|NCT03945188|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
214358019|NCT03945188|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
214358020|NCT05214833|BEHAVIORAL|Real Neurofeedback|During neurofeedback, the brain activity in response to a motor task is recorded in real-time and displayed back to the participants.
215082671|NCT00644618|DRUG|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
215082672|NCT00644618|OTHER|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
215082673|NCT02876497|OTHER|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
215082674|NCT00100295|DRUG|Hypericum perforatum|300 mg capsule taken three times a day
215082675|NCT00100295|OTHER|Placebo|300 mg given three times a day, containing rice protein powder
214358021|NCT05214833|BEHAVIORAL|Sham Neurofeedback|During sham neurofeedback, a signal which resembles the participant's brain activity is used instead of the actual brain activity.
214358022|NCT04833387|DRUG|PD-1 antibody|Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
214358023|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation A capsule with water and under fed condition
214358024|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation B capsule with water and under fed condition
214358025|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation C capsule with water and under fed condition
214358026|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation D capsule with water and under fed condition
214358027|NCT01552850|DRUG|Oxycodone|40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
214487434|NCT02988193|DEVICE|optima4BP Medication Management|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
214969276|NCT00303238|DRUG|Rose hips extract + blueberry/blackberry extract + resveravine|
214969277|NCT00303238|DRUG|Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract|
214969278|NCT00303238|DRUG|Rose hips extract + resveravine + Aframomum melegueta extract|
214969279|NCT01116947|OTHER|Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus|Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (\<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
214358028|NCT04233476|DRUG|99mTc-3PRGD2 injection|A diagnostic drug targeting integrin αvβ3, technetium-99m \[99mTc\] labeled hydrazinonicotinamide-PEG4-E\[PEG4-c(RGDfk)\]2 (99mTc-3PRGD2), will be intravenously injected to the participants for imaging of lung cancer and mapping lymph node metastasis via single photon emission computed tomography/ X-ray computed tomography (SPECT/CT) .
214358029|NCT03931148|DIAGNOSTIC_TEST|Geriatric Assesment with neuropsychological test more specific on decision making|The following tests will be made : MoCA, FAB, TMT, Stroop-Victoria, JAT
214358030|NCT03931148|DIAGNOSTIC_TEST|Functional RMI|With specific test of decision making (IGT) specially adapted to the population
214358031|NCT03931148|DIAGNOSTIC_TEST|High Resolution EEG|With specific test of decision making (BART) specially adapted to the population
214358032|NCT03931148|OTHER|Qualitative interview|Qualitative semi-directed interviews with participants, their caregivers and their geriatrician to analyse everyday life decision making ability.
214358033|NCT05030402|PROCEDURE|Maitland|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
214358034|NCT05030402|PROCEDURE|Tens, exercise, SW|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
214358035|NCT05030402|PROCEDURE|Conventional physiotherapy|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
214358036|NCT04896489|DRUG|Hydrocortisone 20 MG|Participants receive Hydrocortisone 20 MG
214358037|NCT04896489|OTHER|Placebo|Participants receive placebo
214358038|NCT01982240|DRUG|Plecanatide|Plecanatide tablets QD for 12 weeks
214358039|NCT01982240|DRUG|Placebo|Matching placebo tablets QD for 12 weeks
214969280|NCT05934916|DEVICE|CPAP ( Continuous positive airway pressure)|The enrolled eighty patients were simply randomized into two equal groups: Non-CPAP group and CPAP group using a computer-generated table of random numbers. The group allocation was concealed in sequentially numbered, sealed, and opaque envelopes. Patients were selected from isolation center in Mansoura University hospital,Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and CPAP group as in Non-CPAP group plus using CPAP.
214969281|NCT05934916|DEVICE|oxygen therapy|both groups will receive oxygen
214969282|NCT03423212|BEHAVIORAL|Just Do You|Just Do You is an intervention designed to keep young adults connected to their professional behavioral health treatments. It is a brief two-module engagement program that utilizes a hybrid provider team of a licensed clinician and peer to increase young adult engagement in adult outpatient day programs (i.e., New York State Personalized Recovery Oriented Services). The first session consists of the following components: 1) Welcome; Group Guidelines, Purpose, 2) Discuss Recovery Principles; Narrative of Role Model; 3) Video of Celebrity Service User and Discussion, and 4) Recovery Goals (and role of services in that). The second session consists of: 1) What are services \& how can they help? 2) Visual art exercise -- Cause of SMI and validation, 3) Maintaining my Medicaid Insurance, and 4) Discussion of Systemic Barriers.
214969283|NCT03423212|BEHAVIORAL|Active Control|The active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
214358040|NCT01982240|DRUG|Bisacodyl|Rescue medication
214358041|NCT03546881|PROCEDURE|fusion imaging guidance technology|Imaging fusion guidance overlay used during PAOD endovascular revascularisation
215082676|NCT00892606|DRUG|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
215082677|NCT00892606|DRUG|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
214358042|NCT03546881|PROCEDURE|2D X-ray screen|2D X-ray screen during PAOD endovascular revascularisation
214358043|NCT05019092|DIAGNOSTIC_TEST|Ultrasound examination of lower limb veins|Ultrasound examination will be performed by trained physicians using a commercially available ultrasound system and 5.0-15.0 MHz linear probe. The examinations consists of a comprehensive B-mode ultrasound protocol, from thigh to ankle, employing compression and color-Doppler at selected sites, according to the Consensus Conference of the Society of Radiologists in Ultrasound.
214358044|NCT04341116|DRUG|TJ003234|patients receive a single infusion
214358045|NCT04341116|DRUG|Placebo|patients receive a single infusion
214358046|NCT01845740|DRUG|milatuzumab|Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
214358047|NCT01845740|DRUG|Placebo|Placebo will be administered subcutaneously once weekly for 4 weeks.
214358048|NCT02194270|DRUG|Ambroxol hydrochloride - soft pastille|
214358049|NCT02194270|DRUG|Ambroxol hydrochloride - syrup - low dose|
214358050|NCT02194270|DRUG|Ambroxol hydrochloride - syrup - high dose|
214358051|NCT00363675|BEHAVIORAL|Functional hand tests|Chilren were tested after healed hand burns for functional ability.
214358052|NCT01803074|DRUG|BMS-955176|BMS-955176
214358053|NCT01803074|DRUG|Placebo matching with BMS-955176|Placebo matching with BMS-955176
214358054|NCT01803074|DRUG|Atazanavir|Atazanavir
214358055|NCT01803074|DRUG|Ritonavir|Ritonavir
214358056|NCT01803074|DRUG|Tenofovir|Tenofovir
214358057|NCT01803074|DRUG|Emtricitabine|Emtricitabine
214358058|NCT02006082|DEVICE|Telemedicine video-consultation (TVC)|All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
214358059|NCT06495619|BEHAVIORAL|treatment-as-usual|life style modification intervention for weight loss
214487435|NCT06030648|BIOLOGICAL|Mesenchymal stem cells (IV-MSC)|Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.
214358060|NCT06495619|BEHAVIORAL|combined TAU and guided self-help|combined TAU and guided self-help for improving eating behaviors
214358061|NCT06495619|BEHAVIORAL|combined TAU, GSH, and biofeedback|combined TAU, GSH, and biofeedback for improving eating behaviors and interoceptive awareness and arousal regulation
214358062|NCT02081573|BEHAVIORAL|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
214358063|NCT05772780|DEVICE|MP-3 microperimeter|Biofeedback stimulation two days a week
214969284|NCT04536714|BEHAVIORAL|Pythagorean Self-Awareness Intervention program|Stress management program of Pythagorean Self-Awareness Intervention (PSAI), which included eight sessions and lasted for eight weeks. On the first week, a personal session took place for measurements and training in the relaxation technique of diaphragmatic breathing. In the second week, patients attended a group session, in which they were adviced to follow specific directions for a healthy lifestyle, such as organized physical activity, adherence to the Mediterranean diet, creating a daily routine. In the third week, participants were introduced to the cognitive restructuring technique of (PSAI).In the following four group sessions, patients were trained on PSAI and the second relaxation technique, progressive muscular relaxation. In the last week, the final measurements were made. All sessions lasted for 120 minutes, except for the final one, which lasted for 60 minutes.
214969285|NCT03043742|DRUG|Bone Marrow Derived Autologous CD133+ Selected Cell Product|Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization
214969286|NCT00732927|DRUG|parnaparin|vials, 6.400 IU sc twice daily for 7 days, then once daily for a total of 3 months
214969287|NCT00732927|DRUG|aspirin|tablets, 100 mg for 3 months
214969288|NCT00368303|DRUG|Paroxetine CR|
214969289|NCT00368303|DRUG|Paroxetine IR|
214969290|NCT02194972|DRUG|Pectin|pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
214969291|NCT05240235|OTHER|Education, compression and exercise therapy|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home.
214358064|NCT05772780|DEVICE|MP-3 microperimeter|Biofeedback stimulation three days a week
214358065|NCT02683850|DIETARY_SUPPLEMENT|Omega-3 SPM™ softgel|This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.
214358066|NCT03121157|BEHAVIORAL|Multi-Component Technology Based Intervention|The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
214358067|NCT01445925|PROCEDURE|Pulmonary vein isolation (PVI)|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
214358068|NCT01445925|PROCEDURE|Pulmonary vein isolation + linear lesions|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
214358069|NCT01445925|DRUG|Pharmacological Substrate modification|at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
214358070|NCT05788757|DEVICE|Optetrak Total Knee System|Total Knee Arthroplasty using Exactech's Optetrak branded components.
214487436|NCT02299349|DRUG|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
214487437|NCT02299349|DRUG|concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL|Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
214487438|NCT00787969|BIOLOGICAL|rituximab|Give IV
214487439|NCT00787969|DRUG|cladribine|Give IV
214487440|NCT00787969|DRUG|temsirolimus|Give IV
214487441|NCT00787969|BIOLOGICAL|Filgrastim|Give SC
214487442|NCT00787969|BIOLOGICAL|Pegfilgrastim|
214487443|NCT04129164|DRUG|VIB4920|Intravenous Dose 1.
214487444|NCT04129164|DRUG|Placebo|Intravenous dose matched to VIB4920.
214969292|NCT05240235|OTHER|Education, compression and exercise therapy manual lymph drainage|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home. In addition, patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
214969293|NCT00877318|DEVICE|SCAD information system|Cardiac rehabilitation at home by telemedicine
214358071|NCT01508039|OTHER|Chitin Micro Particle|"The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)"
214969294|NCT02922153|DEVICE|Cryoanalgesia|AtriCure® cryoICE cryo-ablation system
214969295|NCT02922153|DRUG|Standard of Care|Institutional SOC for pain management will be followed.
214358072|NCT01919242|PROCEDURE|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
215082678|NCT05901805|OTHER|questionnaire application|"Participants will be asked to fill in the Occupational Sitting and Physical Activity Questionnaire adapted into Turkish. Correlation of the scale with the International Physical Activity Questionnaire-Short Form, VAS and YİBT-SF, Buss-Perry Aggression Scale will be tested. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
215082679|NCT02852941|DEVICE|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
215082680|NCT02852941|DEVICE|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
215082681|NCT02322294|DIETARY_SUPPLEMENT|Glucodia™|
215082682|NCT02322294|OTHER|Placebo|
215082683|NCT00974285|DRUG|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
215082684|NCT00974285|DRUG|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
214358073|NCT05449964|PROCEDURE|SCALING AND ROOT PLANING (SRP)in single sitting|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
214969296|NCT02935556|OTHER|no intervention|database and epigenetic study
214969297|NCT03429348|OTHER|Sauna Rehabilitation|Firefighters selected for sauna rehabilitation will spend time in a sauna
214969298|NCT05439746|DEVICE|Microlyte® Matrix|Microlyte® Matrix is indicated for the management of wounds and can be used over-the-counter for minor wounds such as abrasions and lacerations, minor cuts, and minor scalds and burns. Under the direction of a healthcare professional, Microlyte® Matrix may be used for more serious wounds such as partial and full thickness pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds. Microlyte® Matrix may be used over debrided and grafted partial thickness wounds.
214969299|NCT01461642|OTHER|Self management asthma plan indorsment.|Subjects adherence to asthma self management plan will be monitored through web-based support.
215082685|NCT04149860|DRUG|Lu AF87908|Lu AF87908 concentrate for solution for intravenous (IV) infusion
215082686|NCT04149860|DRUG|Placebo|Concentrate for solution for IV infusion
215082687|NCT03510351|DRUG|Ceftolozane-Tazobactam|Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
215082688|NCT02960646|DRUG|Cyclophosphamide|Given IV
215082689|NCT02960646|BIOLOGICAL|Filgrastim|Given SC
215082690|NCT02960646|DRUG|Fludarabine Phosphate|Given IV
215082691|NCT02960646|OTHER|Laboratory Biomarker Analysis|Correlative studies
215082692|NCT02960646|DRUG|Melphalan|Given IV
215082693|NCT02960646|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
215082694|NCT02960646|BIOLOGICAL|Rituximab|Given IV
215082695|NCT02960646|DRUG|Tacrolimus|Given IV or PO
215082696|NCT02960646|RADIATION|Total-Body Irradiation|Undergo TBI
215082697|NCT01183819|BEHAVIORAL|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
215082698|NCT01183819|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
215082699|NCT01183819|BEHAVIORAL|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
214358074|NCT05449964|PROCEDURE|SCALING AND ROOT PLANING (SRP)in two sittings|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
214358075|NCT02960100|OTHER|Informational Intervention|Receive standard HPV vaccine information (HPV VIS)
214358076|NCT02960100|OTHER|Media Intervention|Receive targeted HPV vaccine narrative-style video
214358077|NCT02960100|OTHER|Survey Administration|Ancillary studies
214358078|NCT01314274|DRUG|Bevacizumab|100mg intranasal submucosal bevacizumab in 10ml
214358079|NCT01314274|DRUG|NaCl|10ml of 0.9% NaCl intranasal submucosal
214358080|NCT02807558|DRUG|Tamibarotene|Administered as oral tablets
214358081|NCT02807558|DRUG|Azacitidine|Administered via intravenous (IV) or subcutaneous (SC) infusion
214358082|NCT02807558|DRUG|Daratumumab|Administered via IV infusion
214358083|NCT04079621|DRUG|primaquine|Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)
214358084|NCT02212704|OTHER|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
214358085|NCT02212704|OTHER|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
214358086|NCT02212704|OTHER|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
214358087|NCT05926180|DRUG|DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)|Patients will receive single oral doses of probe drugs alone and after at least 27 days of treatment with DZD9008, 300 mg, once daily, until a treatment discontinuation criterion is met. Each patient will receive a single oral dose of DZD9008 on Day 7, and DZD9008 once daily for 27 days from Day 9 to Day 35. Patients will also receive a single oral dose of 2 mg midazolam on Day 1 and Day 32, and oral dose of 10 mg rosuvastatin and 0.25 mg digoxin cocktail on Day 2, Day 7 and Day 33.
214358088|NCT04959370|DEVICE|internal fixation implantation of dynamic hip screw|Dynamic hip screws (DHS) are a femoral head-sparing orthopedic device used to treat femoral neck fractures.
214358089|NCT04959370|DEVICE|internal fixation implantation of cannulated compression screw|Cannulated Screw is designed to provide a minimally invasive method of anatomical fixation.
214969300|NCT05179304|PROCEDURE|Oncoplastic technique with a droplet-shaped glandular flap|"A droplet-shaped glandular flap (DSG) is in a shape of a water drop, with the pedicle at the top of the defect and the base underlying nipple-areolar complex (NAC). It runs from the outer upper quadrant to the center along a line parallel to the radial line. We harvest a DSG flap by dissociating the supplement mammary gland from the lateral of the defect after resection, developing deep to the pectoralis fascia, from the cusp at the defect and the round pore underlying nipple-areolar complex (NAC). The DSG flap was rotated inwards around the cusp, reaching the top of the defect. This tailored redistribution allowed the defects to be plugged with the lateral glandular flaps."
214969301|NCT05945238|OTHER|Thrower's Ten Exercise Program|T10 group were given thrower's ten exercises 3 times per week for 10 weeks, each exercise being 2x10 repetitions.
214969302|NCT01086670|OTHER|Physical Exercise|Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or over-training effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions. Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses.
215082700|NCT01183819|BEHAVIORAL|Control Games|Control games session 3 times a week for 12 weeks
214358090|NCT04575467|DRUG|CBL-514|CBL-514 will be administered via injection into the subcutaneous adipose layer.
214358091|NCT02967185|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis. Treatment components will include education about aging and sleep. It will also include instruction in techniques designed to: (a) promote good sleep habits, (b) restrict the use of the bed and bedroom to sleep and sleep-conducive activities, (c) modify bed and wake times to better match the participants sleep needs, and (d) promote relaxation. Daily home practice of these techniques will be encouraged. Participants will maintain logs of their home practice sessions and will continue to record their daily sleep habits throughout treatment.
214358092|NCT00456638|DRUG|Depodur|Depodur vs. traditional management
214358093|NCT00003298|DRUG|cisplatin|Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
214358094|NCT00003298|DRUG|fluorouracil|Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
214358095|NCT00003298|DRUG|leucovorin calcium|Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
214358096|NCT00003298|DRUG|paclitaxel|Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
214358097|NCT00003298|PROCEDURE|surgery|"The surgical procedure performed involved a radical subtotal or total gastrectomy.~A complete surgical resection was required"
214358098|NCT00003298|RADIATION|radiation therapy|Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
214358099|NCT05349344|OTHER|Aerobic circuit training|Aerobic Exercise Training, 3 times a week for 8 weeks, (Tuesday, Thursday \& Saturday, 24 sessions Total) 30 min each time, at 60-80 % of HR max (moderate intensity).
214358100|NCT05349344|OTHER|Outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
214358101|NCT01930370|DRUG|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
214358102|NCT01930370|DRUG|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
214358103|NCT05142267|DRUG|Placebo|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
214393799|NCT06294015|BIOLOGICAL|20% ASED + AT|Participants receive 20% Autologous Serum Eye Drops prepared by the hospital laboratory from the patients blood, diluted with sterile 0.9% sodium chloride to achieve the desired concentration. These drops are administered 6 times daily in one eye for two months. On top of this intervention is standard artificial tears therapy (Refresh Plus), applied four times daily.
214358104|NCT05142267|DRUG|Oxycodone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
214969303|NCT06080516|OTHER|Kettlebell exercise|Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch
214969304|NCT02692586|DEVICE|FlowTriever System|
214969305|NCT01693679|DRUG|Telbivudine, Lamivudine, Adefovir ,Enecavir|investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
214969306|NCT03709251|BEHAVIORAL|High Intensity Walking|Intense walking activity at an intensity of 70-80% of the maximum heart rate
214969307|NCT03709251|BEHAVIORAL|Casual Speed Walking|Moderate intensity (50-60% of Heart Rate maximum)
214969308|NCT06244732|PROCEDURE|Postoperative pain control|Postoperative analgesia after OR-AAA
214969309|NCT02752815|DRUG|Rituximab|
214969310|NCT02752815|DRUG|Cyclophosphamide|
214969311|NCT02752815|DRUG|Epirubicin|
214969312|NCT02752815|DRUG|Vincristine|
214969313|NCT02752815|DRUG|Prednisone|
214969314|NCT04421040|DEVICE|Biotronik Biomonitor 3 implant of device|The Biotronik Biomonitor 3 device will be implanted by the research team physician.
214969315|NCT04421040|DEVICE|Biotronik Biomonitor 3 explant of device|The Biotronik Biomonitor 3 device will be removed from the patient by the research team physician.
214969316|NCT03539107|PROCEDURE|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
214969317|NCT03539107|OTHER|spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
214969318|NCT03316586|DRUG|Nivolumab|Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
214969319|NCT03316586|DRUG|Cabozantinib|Cabozantinib may help to shrink or stabilize breast cancer
214393800|NCT06294015|DRUG|0.9% NS + AT|Participants in the placebo group receive eye drops consisting of sterile 0.9% sodium chloride solution, which serves as the placebo. The placebo solution is administered 6 times daily in one eye for two months. Alongside the placebo drops, participants continue with standard artificial tears therapy (Refresh Plus), applied four times daily throughout the study duration.
214393801|NCT00317174|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
214969320|NCT04135404|OTHER|health-related telephone surveys|The Behavioral Risk Factor Surveillance System (BRFSS) is a health-related telephone surveys that collect state data about United States residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services (Secondary-data analysis).
214969321|NCT03645642|DRUG|Midodrine|Midodrine 5 mg thrice daily
214969322|NCT03645642|BIOLOGICAL|Albumin|Albumin 20g/l
214393802|NCT06038812|DIAGNOSTIC_TEST|GCF sample collection|collecting GCF from deepest sites by paper points
214393803|NCT06038812|PROCEDURE|non-surgical periodontal treatment|performing scaling and root planning using ultrasonic device and manual curettes
214393804|NCT00005108|DRUG|Estradiol|
214969323|NCT03645642|DRUG|Diuretics|Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
214969324|NCT01396083|DRUG|Ranibizumab|
214969325|NCT01396083|DRUG|Dexamethasone implant and sham injections|
214969326|NCT02553824|DRUG|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
214969327|NCT02553824|DRUG|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
214969328|NCT03159936|BIOLOGICAL|Tofacitinib citrate|10 mg daily by mouth
214969329|NCT04993573|OTHER|Questionnaire|Questions about the impact of COVID-19 in their works
214969330|NCT04993573|OTHER|Individual interview|Discussion between the searcher and the participant about representations of COVID-19 and experiences about confinement.
214969331|NCT02806713|DRUG|Phenazopyridine|
214969332|NCT02806713|OTHER|no Phenazopyridine|Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided
214969333|NCT03485443|DRUG|%0.9 NaCl 10ml/kg|Fluid administration
214969334|NCT03485443|DRUG|%0.9 NaCl 20ml/kg|Fluid administration
214969335|NCT00524927|DRUG|Methoxyflurane|
214393805|NCT00005108|DRUG|Progesterone|
214393806|NCT05275751|DRUG|TRPA1-inhibitor|Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
214393807|NCT05275751|DRUG|TRPV1-inhibitor|Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid
214393808|NCT05275751|DRUG|TRPM3-inhibitor|Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid
214393809|NCT05275751|DRUG|Placebo|No pharmacological intervention
214393810|NCT05275751|DRUG|Chloride-channel inhibitor|Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid
214393811|NCT00850044|DRUG|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
214393812|NCT00850044|DRUG|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
214393813|NCT00850044|DRUG|placebo for ABT-450|capsules, QD, one dose
214393814|NCT00850044|DRUG|Placebo for ritonavir|capsules, QD, one dose
214358105|NCT05142267|DRUG|Naloxone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
214358106|NCT02219126|OTHER|Dietary intervention|
214358107|NCT05061251|DRUG|BAY 2402234|Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
214969336|NCT00524927|DRUG|Normal Saline|
214969337|NCT00735709|DRUG|Vortioxetine|Encapsulated immediate-release vortioxetine tablets
214969338|NCT00735709|DRUG|Placebo|Vortioxetine placebo-matching capsules
214969339|NCT05428956|PROCEDURE|Single Inhalation technique|Single maximal inhalation with breath hold technique
214969340|NCT05428956|PROCEDURE|Tidal inhalation technique|5 tidal breaths technique
214969341|NCT05175781|DRUG|Dexmedetomidine Hydrochloride|is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.
214969342|NCT05175781|DRUG|Ketamine Hydrochloride|Ketamine is an NMDA receptor antagoni
214969343|NCT05175781|DRUG|Placebo|Normal saline
214969344|NCT02492802|DRUG|posaconazole|collection plasma samples for measuring posaconazole drug concentration
214969345|NCT01165307|DRUG|Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
214969346|NCT01165307|DRUG|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
214969347|NCT01165307|DEVICE|NovaSure® Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
214358108|NCT00930293|BEHAVIORAL|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
214358109|NCT00930293|BEHAVIORAL|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
214358110|NCT00930293|DRUG|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
214358111|NCT01798550|DRUG|Enoxaparin|Twice daily dosing
214358112|NCT06171191|BEHAVIORAL|Move-ARound And Get Active|The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.
214358113|NCT03565887|DRUG|RVL-1201|RVL-1201 ophthalmic solution 0.1%
214358114|NCT03565887|OTHER|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
214358115|NCT00695643|DRUG|Mesalazine|3 g per day
214358116|NCT00695643|DRUG|Placebo|0 g per day
214358117|NCT05141669|DRUG|Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
214393815|NCT02508766|PROCEDURE|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
214969348|NCT06431464|OTHER|picosecond laser treatment + measurement with a multiphoton tomography system|Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
214969349|NCT06431464|OTHER|nanosecond laser treatment + measurement with a multiphoton tomography system|Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
214969350|NCT03569501|DIETARY_SUPPLEMENT|DHA|500 mg DHA tablets
214969351|NCT03569501|DIETARY_SUPPLEMENT|oat grains|90 mg oat, containing 4.05 mg β-glucan
214969352|NCT01126099|DRUG|Prazosin|4 mg capsules twice daily for 12 weeks
214969353|NCT01126099|DRUG|Placebo|Placebo capsules twice daily for 12 weeks
214969354|NCT02920190|DRUG|Liraglutide|1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months
214969355|NCT05466721|DEVICE|Hydrustoma C3|The participant will use the device for 14 days.
214969356|NCT05466721|DEVICE|Coloplast Alterna|The participant will use the device for 14 days.
214969357|NCT00311493|BIOLOGICAL|Tick-Borne Encephalitis vaccine|
214969358|NCT00015704|DRUG|Aldesleukin|
214969359|NCT03535961|DRUG|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
214969360|NCT00356447|DRUG|Estradiol/DRSP (Angeliq, BAY86-4891)|Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
214969361|NCT00356447|DRUG|Placebo|Same administration.
214969362|NCT02355717|OTHER|Observational Study|
214969363|NCT05667662|DRUG|Itraconazole Powder|Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)
214969364|NCT05667662|DRUG|Placebo|Capsules with 11.8 mg total powder (excipients only)
214969365|NCT00692380|RADIATION|Fractionated radiation therapy followed by chemotherapy|Increasing doses of radiation therapy
214969366|NCT02955875|BEHAVIORAL|Pharmaceutical care|Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
214487445|NCT03868930|BEHAVIORAL|STEP-Home|This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
214969367|NCT04531423|DRUG|SSRI + golimumab|Golimumab will be administered at the dose of 50mg every month during the acute phase.
214969368|NCT04531423|OTHER|SSRI + placebo|placebo
214969369|NCT05625685|OTHER|Quitbuddy|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD EMA/GPS smoking data collection. GPS guided NRT usage prompts, via hotspot algorithms, will be provided to participants in the Quitbuddy Arm. Participants will contribute four weeks of post-TQD EMA/GPS data to capture lapses and NRT use in real-time. Carbon Monoxide (CO) levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
214969370|NCT05625685|OTHER|Control|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD smoking data collection. Participants will contribute four weeks of post-TQD data to capture lapses and NRT use. CO levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
214969371|NCT05625685|OTHER|SDoH Augmentation|The SDoH intervention is based on the findhelp.org online platform, with customization to meet the specific needs of the study and communities being served: includes validated SDoH assessments, personalized social needs searching based on priorities, access to the most comprehensive social service database, and a streamlined closed loop referral system that integrates with workflows.
214969372|NCT05625685|OTHER|SDoH Control|No SDoH intervention
214969373|NCT04531124|OTHER|integrated management|establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients
214969374|NCT01116336|DRUG|Erlotinib|Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
214969375|NCT01116336|DIETARY_SUPPLEMENT|Green Tea Polyphenon E|Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
214969376|NCT03328481|PROCEDURE|Loss-of-resistance Quadratus lumborum block|"ِA blunted 22-G, 11 mm, short-bevel facet needle will be introduced in the paravertebral line at the level of L3 or L4, in 30-45 degree to the skin directing it laterally. Once the skin barrier is breached, the needle will be withdrawn back so that the tip lies just under the skin. The needle will be advanced through the posterior thoracolumbar fascia and a first fast pop sensation will be felt when the needle pierced it. With further advancement of the needle, a second deep pop will be felt after it pierces the middle thoracolumbar fascia. At this point, the needle will be in the plane of the quadratus lumborum block type II. After careful aspiration, the 30 mLs of local anaesthetic will be injected. The needle will be visualized by the ultrasound by another physician to ensure safety."
214969377|NCT03328481|PROCEDURE|Ultrasound-guided Quadratus lumborum block|A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 30 ml of local anesthetic (bupivacaine 0.25 %) will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
215082701|NCT05202665|PROCEDURE|ICON DMG Resin Infiltration (micro-invasive approach)|A plastic wedge located below the contact point to apart from the surface from adjacent tooth. A 15% HCl etching gel (Icon, DMG, Hamburg, Germany) was applied by syringe below the contact point for 120 s. After, the gel was washed off with air-water-spray for 30 s. The lesion was desiccated by air-blowing for 10 s, application of ethanol for 30 s and air-blowing again for 30 s. A resin infiltrant (Icon, DMG, Hamburg, Germany) was applied with another plastic holder during 3 min. Following the penetration, excess of material was removed by air blowing and flossing. The resin was light-cured for 40 s total from the buccal, occlusal, and lingual/palatal aspects. It was needed to reapplicate the resin infiltration for once because of infiltrating remaining porosities during 1 minute. Excess material removing process was again repeated and light cured for 40 s.
214969378|NCT03328481|PROCEDURE|General anesthesia|Patients will receive 2 mg of midazolam and 8 mg of dexamethasone IV; then, they will be transferred to the operating room to receive a standard general anesthetic. Perioperative monitoring will include ECG, non-invasive arterial blood pressure, and pulse oximetry (SpO2) and end-tidal carbon dioxide. Anesthesia will be induced by propofol 1.5-2.5 mg/kg, atracurium 0.5 mg/kg, and fentanyl 2 mcg/kg to facilitate the insertion of an endotracheal tube. Anesthesia will be maintained by isoflurane 1-2% end-tidal concentration to maintain systolic arterial blood pressure and heart rate within + 20% of the baseline values. Ventilation will be adjusted to maintain normocapnia.
214969379|NCT02396225|DRUG|Voriconazole|
214969380|NCT06958757|OTHER|Standard Exercise Therapy + Ankle Dorsiflexion Training|"The experimental group receives:~Standard Exercise Therapy (30 min/session, 3x/week for 8 weeks): Quadriceps eccentric exercises (e.g., slow step-downs), Hip abductor strengthening (e.g., side-lying leg lifts), and Neuromuscular control drills (e.g., single-leg balance on unstable surfaces).~Ankle Dorsiflexion Training (15 min/session, 3x/week for 8 weeks): Mobilization techniques (posterior glides of the talus), Resistance band exercises (dorsiflexion against elastic bands), Progressive Achilles tendon stretching (weight-bearing calf stretches).~Exercise progression (resistance/intensity) is adjusted biweekly based on functional assessments."
214969381|NCT06958757|OTHER|Standard Exercise Therapy Only|"Standard Exercise Therapy (30 min/session, 3x/week for 8 weeks): Quadriceps eccentric exercises (e.g., slow step-downs), Hip abductor strengthening (e.g., side-lying leg lifts), and Neuromuscular control drills (e.g., single-leg balance on unstable surfaces).~Exercise progression (resistance/intensity) is adjusted biweekly based on functional assessments."
214969382|NCT06958029|PROCEDURE|Cardiac surgery|Patients receiving general anesthesia for cardiac surgery
214358118|NCT05335317|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50% overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm (total handpiece length of 10 centimeter (cm), 20 treatment points along vagina), from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 100 milliseconds (ms), pause between packets of 50 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
214487446|NCT03868930|BEHAVIORAL|PCGT|The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
214969383|NCT02666989|DRUG|placebo|2 placebo pills twice a day
214969384|NCT06958601|OTHER|surgical procedure|Effectiveness of different surgical modalities in the treatment of thyroid cancer
214969385|NCT02537951|DEVICE|AFI microscope|measurement of AFI intensities following increasing nociceptive stimulus intensities
214969386|NCT02537951|DEVICE|negative control 1: lidocaine/prilocaine|measurement of AFI intensities following lidocaine/prilocaine cream
214969387|NCT02537951|DEVICE|negative control 2: 8% capsaicin|measurement of AFI intensities following 8% capsaicin patch
214969388|NCT02148393|PROCEDURE|Vitrification with subsequent-cycle embryo thawing/transfer|"The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).~In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation."
214969389|NCT02148393|PROCEDURE|Intensified luteal phase support for fresh embryo transfer|A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
214969390|NCT02148393|DRUG|Pregnyl®|1500 IU
214969391|NCT02148393|DRUG|Utrogestan®|200 mg tid
214969392|NCT02148393|DRUG|Progynova®|2 mg bid
214487447|NCT06199635|DEVICE|Self-Forming Magnetic Anastomosis Device and Delivery System|Self-Forming Magnetic Anastomosis Device to create a gastrointestinal anastomosis
214487448|NCT04416412|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
214487449|NCT04755439|PROCEDURE|DHCA|DHCA THE USE OF SEREBRAL PROTECTİON TECHNİQUE
214969393|NCT02148393|DEVICE|CryoBioSystem®|CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
214969394|NCT02697643|BEHAVIORAL|BHCDS-based recommendations|
214969395|NCT02697643|BEHAVIORAL|Non-tailored recommendations|
214969396|NCT06958224|GENETIC|Large and early multigene sequencing|"Part 1 sequential multi-gene sequencing (Simple NGS),~* Multi-gene DNA sequencing (43 genes panel corresponding to the most frequently targeted molecular alterations)~* And if no contributive:~Part 2: randomized study between two sequential approaches~\- Experimental arm: early Multi-gene DNA sequencing (638 genes panel) Multi-gene RNA sequencing (ARCHER panel)~1. MMR status in molecular biology~2. \- Tumour Mutational Burden~   * Control arm: after 1st line escape, according to Plan France Medecine Genomique 2025 In the Part 2, a new biopsy could be proposed if necessary"
214969397|NCT06959212|OTHER|Physiological recordings, Semi-structured interviews, Psychological scales|(Neuro)-physiological paradigms based on EEG, ECG, electrodermal activity, and respiratory activity recordings, and auditory and olfactive stimuli, to assess memory processes without the need to communicate ('no report' approach) in patients suffering from a Disorder of Consciousness and conscious controls. Semi-structured interviews and neuropsychological assessments (scales) in patients who have recovered from a Disorder of Consciousness and conscious controls to explore memories and subjective experience of the ICU
214358119|NCT05335317|DRUG|Topical hormone estriol|Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.
214358120|NCT05335317|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis (to include the participant in the study).
214358121|NCT05335317|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
214487450|NCT05825066|DRUG|Nab paclitaxel|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
214487451|NCT05825066|DRUG|Gemcitabine|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
214969398|NCT00521365|DRUG|Quetiapine 600mg|"300 mg quetiapine fumarate tablets for oral use.~Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day."
214969399|NCT00006193|BEHAVIORAL|diet|
214969400|NCT04839744|DRUG|TG103 produced by the modified manufacturing process|Drug: TG103 (a modified manufacturing process), 15mg, SC
214969401|NCT04839744|DRUG|TG103 produced by the original manufacturing process|Drug: TG103 (the original manufacturing process), 15mg, SC
214969402|NCT03627832|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
214358122|NCT05335317|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), immunocytochemical examination and cytology (to evaluate procedure efficiency).
214358123|NCT05335317|DIAGNOSTIC_TEST|Cervical oncocytology test.|Cervical smear for oncocytology test (to include the participant in the study).
214358124|NCT05335317|DIAGNOSTIC_TEST|Extended colposcopy|Extended colposcopy is performed under a microscope using a Lugol to determine external changes in the epithelium in order to determine atrophy and pathologies of the cervix and vaginal vault (dysplasia, erosion, cancer, etc.) (to include the participant in the study).
214969403|NCT03627832|BEHAVIORAL|Sleep Hygiene|All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
214969404|NCT04391257|DEVICE|geko™|Assess if cardiac pacemakers detect geko™ electrical output pulse.
214969405|NCT00624793|OTHER|Acupuncture|Standard Acup point protocol for treating nausea
214969406|NCT00624793|OTHER|Individualized Acup based on TCM diagnosis|Acup
214969407|NCT00624793|OTHER|Sham Acup|Sham Acup - Non-Active
214969408|NCT00169676|OTHER|observation|registry and database for surgery outcomes
214969409|NCT05888298|PROCEDURE|Greater occipital nerve radiofrequency|Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
214969410|NCT03477578|OTHER|freezers|neuropsychological evaluation
214969411|NCT03477578|OTHER|non freezers|neuropsychological evaluation
214358125|NCT05335317|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
214487452|NCT05825066|OTHER|Radiological Assessments|CT imaging of chest abdomen and pelvis will be performed every 8 weeks. MRI may be used.
214969412|NCT02390154|DRUG|roniciclib (BAY 1000394)|Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of \[14C\] roniciclib solution
214969413|NCT02390154|DRUG|roniciclib (BAY 1000394)|5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
214969414|NCT02729337|BEHAVIORAL|ITG (In This Together)|Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
214969415|NCT00999505|DRUG|Amantadine|Amantadine 200mg twice a day over 12 weeks
214969416|NCT00999505|DRUG|Placebo|Placebo capsules twice a day over 12 weeks
214969417|NCT03150082|DRUG|GR37547 tablet|"A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side."
214358126|NCT05335317|OTHER|King's Health Questionnaire|The King's Health Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
214969418|NCT03150082|DRUG|Ciprofloxacin reference tablet|"A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side."
214969419|NCT06959459|DEVICE|Intervention Group:Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.|Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.
214969420|NCT06959459|DEVICE|Control group: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.|Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.
214969421|NCT01718483|DRUG|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
214969422|NCT01718483|DRUG|Placebo|Administered once-daily, orally, for up to 12 weeks
214969423|NCT00275522|DRUG|Sirolimus|
214969424|NCT03049501|BEHAVIORAL|Caregiving condition|The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.
214969425|NCT03049501|BEHAVIORAL|Nutrition condition|The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
214969426|NCT02631005|OTHER|"Walk With Ease"|Six-week walking program
214969427|NCT06959615|DRUG|JAB-23E73|Administered orally
214969428|NCT06959615|DRUG|JAB-23E73|Administered orally
214969429|NCT02941315|DRUG|etiologic treatment,anti-myocardial remodeling|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
214969430|NCT02941315|DRUG|anti-myocardial remodeling|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
214969431|NCT02941315|DRUG|anti-myocardial remodeling,anti-acute heart failure|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
214969432|NCT02941315|DRUG|Etiological, anti-remodeling and symptom treatment|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
214969433|NCT04567940|BEHAVIORAL|ENRED@TE: Behavioural multicomponent intervention|Information and awareness activities; activities for the acquisition of skills; activities that help the elderly to attend spaces for leisure, participation and maintenance and/or improvement of their personal relationships.
214969434|NCT06958614|DRUG|Primary Prophylactic Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor|The experimental group received prophylactic PEG-rhG-CSF 48 hours after chemotherapy
214969435|NCT05731115|BIOLOGICAL|Experimental 23-valent Pneumococcal|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.
214969436|NCT02731378|DRUG|Erythropoietins (EPO)|A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
214969437|NCT02731378|DRUG|Aggressive iron dextran supplementation|Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
214969438|NCT02731378|DRUG|Erythropoietins (EPO)|Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
214969439|NCT02731378|DRUG|Sustained iron dextran supplementation|Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
214969440|NCT06958250|DEVICE|Novel Bite Block|Patients to utilize novel bite block during routine endoscopic procedures
214969441|NCT00927199|DIETARY_SUPPLEMENT|High-Oleic Canola Oil|Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
214969442|NCT00927199|DIETARY_SUPPLEMENT|High-Oleic Canola/Flaxseed Oil Blend|Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
214969443|NCT00927199|DIETARY_SUPPLEMENT|Western Dietary Control|Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
214969444|NCT06959498|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty
214358127|NCT05335317|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. pH (potential of hydrogen) will be investigated by test-lines paper (to evaluate procedure efficiency).
214358128|NCT05335317|DIAGNOSTIC_TEST|Ultrasound investigation|Ultrasound investigation with General Electric Voluson E8 Expert for assessing blood vessels (Doppler sonography) and vaginal wall thickness measurement (to evaluate procedure efficiency).
214969445|NCT04880668|DEVICE|Aerosol Box (Splashguard)|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
214969446|NCT03996668|OTHER|Thigh High Compression Stockings|Thigh high compression stockings will be placed after induction of anesthesia and intubation.
214358129|NCT05335317|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with IEASE device (to evaluate procedure efficiency).
214358130|NCT05335317|DIAGNOSTIC_TEST|Optical coherence tomography|Optical non-invasive method of investigation vaginal mucus morphological and functional condition.
214358131|NCT05335317|DIAGNOSTIC_TEST|Biopsy|Biopsy of the vaginal wall to assess the condition of the vaginal wall and compare the obtained data with the data of optical coherence tomography.
214358132|NCT05335317|DIAGNOSTIC_TEST|Femoflor screen|Femoflor screen for the study of vaginal microbiocenosis, specifically for the detection of the pathogens, opportunistic flora and normal flora and their qualitative and quantitative evaluation (to include the participant in the study).
214358133|NCT04216316|DRUG|Berzosertib|Given IV
214358134|NCT04216316|PROCEDURE|Biospecimen Collection|Correlative studies
214358135|NCT04216316|DRUG|Carboplatin|Given IV
214358136|NCT04216316|PROCEDURE|Computed Tomography|Undergo CT
214358137|NCT04216316|DRUG|Gemcitabine Hydrochloride|Given IV
214358138|NCT04216316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214358139|NCT04216316|BIOLOGICAL|Pembrolizumab|Given IV
214358140|NCT01329367|BEHAVIORAL|Control group|"Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
214358141|NCT01329367|BEHAVIORAL|Protein group|"Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
214358142|NCT01329367|BEHAVIORAL|Antioxidant group|"Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
214358143|NCT05978921|OTHER|Strength physical exercise programme|12 multi-joint strength exercises will be developed. Participants will be taught the rating scale of perceived exertion (RPE) based on the number of repetitions in reserve (RIR). Participants will be asked that during the performance of each of the exercises they must perceive an effort between 7-8 within the overall score of the scale (0-10; 0 = no effort at all and 10 = cannot perform one more repetition, i.e. maximal effort). When subjects perform the 12 repetitions with lower perceived exertion than the set effort in two consecutive sessions with full range of motion the training load will be increased by about 2-10% following the American College of Sports Medicine guidelines and reassessed using the RIR-based RPE. Patients in the usual treatment group will continue to participate in their existing rehabilitation programmes, but will not be included in the strength training programme.
214358144|NCT05978921|OTHER|Normal life|Normal life and carry out all the activities they have been doing previously.
214358145|NCT04881201|PROCEDURE|blood sample|blood sample
214358146|NCT05363566|DEVICE|airway divice|inserted airway device
214358147|NCT03632382|DIAGNOSTIC_TEST|3D acquisition of maxillofacial characteristics|A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
214358148|NCT01045746|DEVICE|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
214358149|NCT01045746|DEVICE|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
214358150|NCT06046274|BIOLOGICAL|Pembrolizumab|Pembrolizumab intravenous (IV) infusion
214487453|NCT05825066|DRUG|mFOLFIRINOX|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
214487454|NCT05816265|DRUG|IV Iron Infusion Group|Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
214358151|NCT06046274|BIOLOGICAL|Acasunlimab|Acasunlimab IV infusion
214358152|NCT04901858|DIAGNOSTIC_TEST|Aspiration of haemarthrosis and high definition MRI|Aspiration of haemarthrosis and high definition MRI
214358153|NCT03595644|RADIATION|SBRT+TKI|Received SBRT after three months after EGFR-TKI treatment
214358154|NCT03595644|DRUG|TKI|Received EGFR-TKI treatment
214358155|NCT00314197|BEHAVIORAL|Telephone Linked Care - Behavior Change Counseling System|
214358156|NCT00314197|BEHAVIORAL|Telephone-linked behavioral counseling|
214358157|NCT02265900|OTHER|Exercise|One type of exercise
214358158|NCT02265900|OTHER|Exercise|A different type of exercise
214358159|NCT03173040|DRUG|NiuBangZi pill or NiuBangZi pill placebo|For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
214358160|NCT00891267|DRUG|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
214358161|NCT00891267|DRUG|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
214358162|NCT00891267|DRUG|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
214358163|NCT06440148|BIOLOGICAL|SCLEROSTIN|Pathogenesis of mastocytosis bone disease
214358164|NCT02330718|OTHER|No intervention|
214358165|NCT06265077|DRUG|Placebo|Placebo
214358166|NCT06265077|DRUG|famotidine and loratadine|famotidine 20 mg once daily and loratadine 10 mg once daily
214358167|NCT02217930|DRUG|WCK 2349|
214358168|NCT02217930|DRUG|Placebo|
214358169|NCT02217930|DRUG|Moxifloxacin|
215082702|NCT05202665|PROCEDURE|ClinproTM White Varnish, 3M ESPE Fluoride Varnish (non-invasive approach)|Tooth surfaces were cleaned thoroughly and isolated with cotton rolls. According to the manufacturer's instructions, the unit dose packages were opened, and the contents were dispensed onto the application guide and mixed to avoid the separation of sodium fluoride components. A thin coat of varnish (ClinproTM White Varnish, 3M ESPE, USA) with 22600 ppm fluoride was applied to the tooth interface with a brush tip applicator and waited for 5 minutes. Aproximal areas were coated with dental floss. The patient was instructed not to rinse or apply suction immediately after application. Patients were advised to avoid eating hard and sticky foods or drinking hot beverages for the next 2 hours, to consume a soft diet immediately after 30 minutes and to avoid brushing and flossing for the rest of the day.
215082703|NCT02438956|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
214487455|NCT05290714|BEHAVIORAL|Mentalization-Based Treatment for Children (MBT-C)|MBT-C will involve 12 paralel individual sessions with the parents and children separately conducted by two different therapists.
214487456|NCT05290714|BEHAVIORAL|Parenting and Social Skills Group|Parenting/social skills groups will be co-led by two therapists and involve 12 group therapy sessions with the parents and their children separately (10 parents and children per group).
214487457|NCT05184088|DRUG|[18F]florbetaben|All enrolled patients will undergo \[18F\]florbetaben PET imaging.
215082704|NCT02438956|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
215082705|NCT02759315|DRUG|Uprifosbuvir 450 mg|450 mg administered as 3 x 150 mg oral tablets
215082706|NCT02759315|DRUG|Ruzasvir 60 mg|60 mg administered as 6 x 10 mg oral capsules
215082707|NCT00002465|DRUG|megestrol acetate|
215082708|NCT02048033|DEVICE|Regular endoscopy + endogastric suturing|Patients will get the usual endoscopy used for diagnosis. In addition, they will receive an endoscopic surgery using the APOLLO Endosuregery technique. The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
215082709|NCT02048033|DIAGNOSTIC_TEST|Regular endoscopy|Patients will get the usual endoscopy used for diagnosis.
215082710|NCT05703451|OTHER|laparoscopic surgery|"during laparoscopy Any adhesions will be noticed, the prevalence of adhesions will be calculated regarding the age, parity, previous history of miscarriage and past medical history.~The prevalence of adhesions will be calculated according to the indication of laparoscopy.~The prevalence of adhesions will be compared according to different items. Comparison between patients with no past surgical history and those who have past surgical history.~Comparison between patients who have history of ectopic pregnancy and those who have no history of ectopic pregnancy.~Comparison between patients with previous caesarean section and patients with previous other abdominopelvic surgery."
215082711|NCT02126566|DEVICE|Administration of light therapy - measurement of results before and after therapy|
215082712|NCT02102152|DRUG|Tobramycin|
214487458|NCT06960018|DEVICE|Ennovate® Cervical, open surgical technique|"Patients with need of posterior monosegmental and multisegmenta stabilization of the cervical and upper thoracic spine, because of~* Fractures~* Degenerative instability~* Post-trauma instability~* Tumors~* Degenerative cervical myelopathy due to multilevel subaxial spinal canal stenosis will be treated with Ennovate® Cervical system using an open surgical technique"
214358170|NCT02059967|DRUG|Paclitaxel|Given IV
214358171|NCT02059967|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
214358172|NCT02059967|DRUG|carboplatin|Given IV
214358173|NCT06481748|OTHER|Batman|"The investigators foresee several teams engaged throughout the day to ensure greater variability, each team will consist of three students for the experimental condition (Batman; pregnant girl, observer) and two students for the control condition (pregnant girl and observer), plus the presence in both cases of a member of the research team. The 'pregnant girl' will be properly prepared and equipped with a sponge prosthesis to simulate pregnancy. In addition, the subject dressed as Batman must be prepared to play the role in a natural and non-invasive manner. During this phase, the student observers collaborating in the study will carefully record the behavior of the passengers in the underground."
214358174|NCT05003089|DRUG|BAY1834845|Tablet, oral.
214487459|NCT06960018|DEVICE|Ennovate® Cervical, minimal invasive surgical technique|"Patients with need of posterior monosegmental and multisegmenta stabilization of the cervical and upper thoracic spine, because of~* Fractures~* Degenerative instability~* Post-trauma instability~* Tumors~* Degenerative cervical myelopathy due to multilevel subaxial spinal canal stenosis will be treated with Ennovate® Cervical system using a minimally invasive technique."
214358175|NCT05003089|DRUG|BAY1830839|Tablet, oral.
214969447|NCT04408664|DRUG|Sodium Cromoglycate|Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.
214969448|NCT04408664|DRUG|Placebo|Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
214969449|NCT03608605|DEVICE|MRI|magnetic resonance imaging with advanced sequences including tractography,volumetry and inversion recovery
214969450|NCT03535363|DRUG|Osimertinib|Drug: Osimertinib 80mg or 40mg
214969451|NCT06151808|DRUG|XTR006|All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan
214358176|NCT05003089|DRUG|Prednisolone|Tablet, oral.
214358177|NCT05003089|DRUG|Placebo|Tablet, oral.
214358178|NCT01568333|DRUG|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
214358179|NCT02774070|RADIATION|Plain X-ray|antero-posterior, lateral neutral, flexion, extension and open-mouth views
214358180|NCT02774070|RADIATION|Magnetic resonance imaging|Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences
214969452|NCT01884883|DEVICE|PROTEOR Internal unicompartmental knee brace|
214969453|NCT03587233|BEHAVIORAL|Physical assessment|Besides the demographic features of the participants, the interventions on physical assessment will be performed including weight in kilogram and height in meter; and weight and height will be combined to report body mass index in kg/m2. The waist circumference will be measured to understand the central fattening from costal margins or above umbilicus in cm. If it is measured above 95cm for men and 80cm for women is considered as higher than normal; if higher than 110cm for men and 88cm for women is considered as having risks for obesity, diabetes, cardiovascular diseases etc. Hand and pinch grip power will be assessed. It the elbow is in extension upper extremity power, and if it is flexed at 90 degree and forearm is supported on the table handgrip power is to assess.
214969454|NCT03587233|DEVICE|Analyses of body composition|The analyzes of body composition will be measured with bioelectrical impedance analysis method by a body composition analyzer.
214969455|NCT03587233|BEHAVIORAL|physical activity level assessment|The physical activity level will be assessed through the intervention titled with the Turkish version of the 'International Physical Activity Questionnaire-Short Form'. It consists of seven questions searching for the amount of walking and low, moderate and high intensity physical activities as total time in minutes per day and frequency in days per week. Sitting, as a sedentary behavior, will be evaluated separately. The scores will be achieved by the multiplication of the minutes, days and metabolic equivalent time values in a week, and over the last 7 days. Walking score and total weekly walking duration will be calculated as medium and vigorous; the physical activity level will be classified as low, moderate and high level activity.
214969456|NCT03943355|OTHER|Patient before cohort (2005-2010)|The NOM protocol with AE was recognized and accepted after our previous study reported in 2004.
214969457|NCT03943355|OTHER|Patient after cohort (2011-2016)|The protocol of NOM became more aggressively and strictly adhered to since 2011.
214969458|NCT03646942|RADIATION|low level laser therapy|low level laser therapy will be used in order to induce tooth movement. low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. Laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 Joules/each tooth.
214969459|NCT03646942|DEVICE|Lingual Orthodontics|Lingual braces will be used to conduct the orthodontic treatment of patients with moderate level of crowding on the upper dental arch.
214969460|NCT06828991|DRUG|Mosunetuzumab|Mosunetuzumab consolidation therapy will consist of 6 cycles of IV mosunetuzumab at the standard ramp-up dosing (Day 1 1mg, Day 8 2mg, D15 60mg, C2D1 60mg, and 30mg on day 1 of the subsequent 21-day cycles)
214969461|NCT03290430|BEHAVIORAL|Group Counseling|8 sessions over 4 weeks. Lasting 1-2 hours each
214969462|NCT03290430|BEHAVIORAL|Individual Counseling|8 in person sessions over 4 weeks. Lasting 30-45 minutes each
214969463|NCT03290430|BEHAVIORAL|Phone Counseling|8 phone sessions over 4 weeks. Lasting 30-45 minutes each
214969464|NCT03290430|BEHAVIORAL|Video Counseling|8 video call sessions over 4 weeks. Lasting 30-45 minutes each
215082713|NCT05792306|DEVICE|The novel electrolyzed water spray|The researcher use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
214358181|NCT01454583|DRUG|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
214358182|NCT01454583|DRUG|ACE-I/ARB|
214358183|NCT01454583|DRUG|No RAS-inhibition|
214358184|NCT04361929|DEVICE|Ultrasound|The following ultrasound measurements will be assessed: DS-HB, HMDR, TT, TT-S, TW, EW, ET, DS-E, and DS-V.
214969465|NCT03290430|BEHAVIORAL|Texting support|Texts with smoking cessation support throughout the program
214969466|NCT03290430|DRUG|Nicotine Replacement Therapy|Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
214969467|NCT04105608|DIETARY_SUPPLEMENT|High-fiber vegetarian meal|The intervention consisted in the administration of a high fiber vegetarian meal prepared by our research group staff.
214358185|NCT04434560|DRUG|Nivolumab|Nivolumab will be given at the FDA-approved dose of 3 mg/kg.
214358186|NCT04434560|DRUG|Ipilimumab|Ipilimumab will be given at the FDA-approved dose of 1 mg/kg.
214358187|NCT06174714|BEHAVIORAL|Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)|4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.
214358188|NCT06335134|DRUG|XW003 injection|Administered subcutaneously
214358189|NCT06335134|DRUG|Metformin|Administered orally
214358190|NCT06335134|DRUG|Warfarin|Administered orally
214358191|NCT06335134|DRUG|Rosuvastatin|Administered orally
214358192|NCT06335134|DRUG|Digoxin|Administered orally
214358193|NCT03046459|BIOLOGICAL|BNZ132-1-40|pegylated peptide inhibiting IL-2, IL-9 and IL-15
214358194|NCT05574569|BEHAVIORAL|Group 1: Play Therapy|Play therapy will be given to children having emotional and behavioral problems.
214358195|NCT05574569|BEHAVIORAL|Group 2: Mindful Parenting|Culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
214358196|NCT05574569|BEHAVIORAL|Group 3: (Combined Interventions of both Group 1 & 2)|Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
214358197|NCT01603264|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
214358198|NCT01603264|BIOLOGICAL|Herceptin|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
214358199|NCT01603264|BIOLOGICAL|Herceptin|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
214358200|NCT02656433|DEVICE|Transcranial Random Noise Stimulation|A special Helmet supply weak electrical currents in the head
214358201|NCT02656433|OTHER|Physiotherapy|Standard of care physiotherapy aimed to the motor impairment the subject presents
214358202|NCT03837912|BEHAVIORAL|Patient reported safety experiences fed back to PC providers|The intervention will involve three key stages: a) Measurement: Patients will be invited to complete the Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC) questionnaire using a tablet-computer. b) Feedback: Using a bespoke online tool, the information will be processed and presented to each centre in the form of a Feedback Report, which will offer comparisons with other centres along with a set of recommendations for addressing the problems identified. c) Action planning and change: centres will form an Action Planning Team, which will be responsible for analyzing the report, considering which area(s) should be improved, and developing, implementing and monitoring an action plan to address the safety problems identified.
214358203|NCT05758844|PROCEDURE|safe-line technique|Safe-line approach
214358204|NCT06063226|OTHER|Experimental|Orally administred probiotics with L. plantarum and L. rhamnosus
214358205|NCT06063226|OTHER|Negative control|Only routinary oral hygiene procedures
214358206|NCT06063226|OTHER|Positive control|Orally administred placebo without probiotics
214358207|NCT02677116|DRUG|Olaratumab|Olaratumab administered IV.
214358208|NCT02677116|DRUG|Doxorubicin|Doxorubicin administered IV.
214358209|NCT02677116|DRUG|Vincristine|Vincristine administered IV.
214358210|NCT02677116|DRUG|Irinotecan|Irinotecan administered IV.
214358211|NCT02677116|DRUG|Ifosfamide|Ifosfamide administered IV.
214969468|NCT04105608|DIETARY_SUPPLEMENT|Mediterranean-like meal|The intervention consisted in the administration of a Mediterranean-like meal prepared by our research group staff.
214969469|NCT00738634|BEHAVIORAL|Self-motivated physical activity|"Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles"
214358212|NCT04369092|OTHER|DYMUS|DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.
214358213|NCT02191553|BEHAVIORAL|Control group relaxation techniques|Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
214358214|NCT02191553|BEHAVIORAL|Loving-kindness meditation|Following Kristin Neff protocol
214358215|NCT02191553|BEHAVIORAL|Body scan|Body scan: Attention being directed with detailed awareness to every part of the body for a sustained period of time.
214358216|NCT02191553|BEHAVIORAL|Sitting practice|In the sitting exercise, participants are guided to pay attention to a certain range of still points, starting with attention to breathing. In this exercise attention is fully concentrated on a single object: the sensation attached to breathing. If the mind wanders or is distracted by an external stimulus, attention is gently returned to sensations derived from breathing.
214358217|NCT03182868|DEVICE|PAS Goggle|PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.
214358218|NCT03753061|DEVICE|Aspiration Catheter|Patients will be treated for mechanical recanalization with Aspiration Catheter within 8 hours after stroke onset plus standard medical management.
214358219|NCT03753061|DEVICE|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
214358220|NCT03122418|BEHAVIORAL|Personal Fitness Device|Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
214358221|NCT04632875|BEHAVIORAL|Loving-Kindness Meditation|Approximately 15-minute sessions are administered 6 days per week
214358222|NCT04632875|BEHAVIORAL|Relaxation Meditation|Approximately 15-minute sessions are administered 6 days per week
214358223|NCT01967732|OTHER|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
214358224|NCT01967732|OTHER|CC|Single use of subject's own conventional cigarette (CC)
214358225|NCT01967732|OTHER|NNS|Single administration of 1 mg of nicotine
214358226|NCT03342638|DRUG|Cyclophosphamide|Potent immunosuppressive agent; an alkylating agent
214358227|NCT03342638|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
214969470|NCT00738634|BEHAVIORAL|Nutrition|"Components:~1. Nutrition education booklet (Double-sided A4 page)~2. Nutrition motivation tips (single-sided A4 page)~3. Nutrition monitoring chart~4. Online presentation of common obstacles and ways to overcome these obstacles"
214358228|NCT03342638|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
214358229|NCT03342638|DRUG|Methylprednisolone|Steroid
214358230|NCT03342638|DRUG|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
214679167|NCT05738096|OTHER|TSEP + rhizotomy surgery|TGN patients recruited for this study will already be undergoing percutaneous rhizotomy surgery. TSEPs will be measured at baseline prior to surgery. During the rhizotomy procedure, an electrode or balloon is placed through a metal sheath to then damage the nerve. A stylet is introduced to clear tissue from the sheath in preparation for the electrode or balloon. Prior to the final insertion of the RF electrode where the gasserian ganglion will be damaged, we will place a standard stereotactic EEG electrode (SEEG). Following damaging the nerve (clinical procedure), we will record again to measure differences in the TSEPs following cell body damage. The Neuralynx system will be used to record the potentials at 40 KHz.
214679168|NCT05738096|OTHER|TSEPs recording only|TSEPS will also be recorded from healthy controls in a lab setting; all procedures for the healthy controls will be non-invasive.
214679169|NCT05074849|BEHAVIORAL|A 90-minute self-care education + bi-weekly 30-minute one-on-one follow-up phone discussion|A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Follow-up Care: A biweekly 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, addressing feedback and questions regarding the intervention and prevention of foot-related complications).
214969471|NCT00738634|BEHAVIORAL|Physical activity researcher contact|"Behavioral: Self-motivated physical activity~Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles"
214969472|NCT04993872|DRUG|Biktarvy Tab|Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
214358231|NCT03342638|BIOLOGICAL|IVIg|Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).
214358232|NCT03342638|BIOLOGICAL|Autologous Stem Cells|Infusion of participant's own stem cells
214358233|NCT03536000|DIAGNOSTIC_TEST|Fetal echocardiography using the aCMQ-Strain method|Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
214969473|NCT02976246|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|One tablet of vitamin K2 (MK7) 360 micrograms given once daily.
214969474|NCT02976246|OTHER|Placebo|One tablet of placebo given once daily.
214969475|NCT03893760|DIAGNOSTIC_TEST|Ventriculo-arterial coupling assessment (R-V/A)|R-V/A was achieved by computing the R-Elv/P-Ea ratio (Right ventricular elastance/Pulmonary arterial elastance). R-Elv was computed as PAPm / end-systolic area (ESA) of the right ventricle. P-Ea was obtained as (PAPm-PCWP)/ right ventricle stroke volume (R-SV).
214969476|NCT02777905|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
214969477|NCT02403804|DIETARY_SUPPLEMENT|Phosphatidylcholine|Phosphatidylcholine 3600 mg qam and 2700 mg qpm
214969478|NCT02403804|DIETARY_SUPPLEMENT|Betaine (588 mg qam and 412 mg qpm)|Betaine anhydrous 588 mg qam and 412 mg qpm
214969479|NCT02403804|DIETARY_SUPPLEMENT|Betaine (1000 mg BID)|Betaine anhydrous 1000 mg BID
214358234|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
214358235|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
214679170|NCT06001372|DRUG|Ketamine|"Ketamine, 0.5-1.2mg/kg, administered intramuscularly~* Doses can range 0.5-1.2 mg/kg. Starting dose for all participants will be 0.5mg/kg.~* Dose can be titrated up to maximum of 1.2 mg/kg or titrated down to 0.5 mg/kg based on response and clinical judgement.~* Dose will be administered by injecting into large muscle mass (eg, deltoid, gluteal muscle, thigh)"
214679171|NCT04913259|OTHER|Remote monitoring|Online remote monitoring tool during the care of patients over the age of 65 who are receiving medical treatment for cancer
214969480|NCT01554124|DRUG|Meropenem|"40 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
214969481|NCT05686655|OTHER|questionnaire about sleep quality in diabetic children|Pittsburgh sleep quality index
214969482|NCT02318888|PROCEDURE|Surgery|
214969483|NCT02318888|DRUG|Icodextrin|
214969484|NCT01051557|OTHER|Laboratory Biomarker Analysis|Correlative studies
214358236|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
214358237|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
214358238|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
214358239|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
214358240|NCT02216058|DEVICE|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
214358241|NCT03327987|BIOLOGICAL|standard of care influenza vaccine|The standard of care annual 2017-2018 influenza vaccine will be used for this study.
214358242|NCT00554970|DRUG|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
214358243|NCT00554970|DRUG|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
214358244|NCT00554970|DRUG|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
214358245|NCT00554970|DRUG|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
214358246|NCT03028974|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
214969485|NCT01051557|DRUG|Perifosine|Given PO
214969486|NCT01051557|DRUG|Temsirolimus|Given IV
214969487|NCT01051557|PROCEDURE|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
214358247|NCT03028974|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
214358248|NCT00935376|BEHAVIORAL|Sleep Education Program|Treatment as usual.
214358249|NCT00935376|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
214969488|NCT04724551|PROCEDURE|pancreatoduodenectomy (PD)|A pancreaticogastrostomy or -jejunostomy duct-to-mucosa was achieved according to the surgeon's preference and pancreatic texture.
214969489|NCT00293852|PROCEDURE|Outpatient clinic follow-up|
214969490|NCT04858308|DRUG|YYC506|YYC506
214969491|NCT04858308|DRUG|Control|Active control
214969492|NCT04858308|DRUG|YYC506 Placebo|Placebo
214969493|NCT04858308|DRUG|Control Placebo|Placebo
214969494|NCT03202420|OTHER|TOPS|Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
215082714|NCT05792306|DEVICE|The saline spray|The researcher use saline to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
215082715|NCT02714270|PROCEDURE|modified partograph|
215082716|NCT02714270|PROCEDURE|paperless partograph|
214358250|NCT00935376|BEHAVIORAL|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
214969495|NCT03808233|OTHER|ACTIVE mini|the ACTIVE-mini, is a non-invasive method of recording movement in an infant using a KINECT camera system. This camera is positioned over a resting infant and measures natural movement over a two minute time period.
214969496|NCT03723863|BEHAVIORAL|Occupational Therapy|Receive in-person occupational therapist-led work consultation
214969497|NCT04124770|OTHER|Movement|Re-positioning of neck
214358251|NCT02654808|DEVICE|AirSeal trocar|"The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes."
214969498|NCT04020029|OTHER|Mindset|Mindset Intervention will include watching three brief \~10-25 minute films
214969499|NCT04020029|OTHER|Reflection activities|Reflection activity include exercises to internalize the message
214969500|NCT03476421|PROCEDURE|Hepatic resection|Surgery of the liver; removal of a part of the liver
214969501|NCT04742504|BIOLOGICAL|BENRALIZUMAB|The decision of the patients treatment with benralizumab (Fasenra®, Astra Zeneca) included in the study will not come in any case influenced by their participation in the study but will be made in accordance with the clinical criteria established by the Asthma Multidisciplinary Unit (UMA).
214969502|NCT05865470|DRUG|Cannabis|smoked cannabis
214969503|NCT05865470|DRUG|Dronabinol|Oral delta-9-THC
214969504|NCT05865470|DRUG|Smoked Placebo|Placebo Cannabis
214969505|NCT05865470|DRUG|Oral Placebo|Oral Placebo
214969506|NCT00609544|DRUG|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
214969507|NCT03878823|DRUG|ODM-209|co-administered with glucocorticoid and mineralocorticoid, orally daily
214969508|NCT02760719|DRUG|nebulized 3% hypertonic solution|already described
214969509|NCT00360425|DRUG|ferumoxytol|
214969510|NCT00360425|DRUG|moxifloxacin|
214969511|NCT00360425|DRUG|placebo|
214969512|NCT04754815|DRUG|Pembrolizumab|PD-L1 inhibitor administered as an intravenous (IV) infusion.
214969513|NCT04754815|DRUG|Pemetrexed|Folate analog metabolic inhibitor administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
214969514|NCT04754815|DRUG|Paclitaxel|A novel antimicrotubular agent administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
214969515|NCT04754815|DRUG|Nab-paclitaxel|Microtubule inhibitor administered as an intravenous (IV) infusion indicated for the treatment of locally advanced or metastatic NSCLC
215082717|NCT04181580|DEVICE|Made-to-measure compression garment|Made-to-measure compression garment
215082718|NCT06146868|OTHER|Doing questionnaire|Participants will provide their opinions in a questionnaire
215082719|NCT06239090|DEVICE|Rehacor-T|During each session of bio/neurofeedback IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
215082720|NCT06239090|BEHAVIORAL|Sham Intervention|SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation and see only the scenarios
215082721|NCT02869412|OTHER|Computer-Assisted Intervention|Use BCG website
215082722|NCT02869412|OTHER|Computer-Assisted Intervention|Use passive website
215082723|NCT02869412|OTHER|Quality-of-Life Assessment|Ancillary studies
215082724|NCT02869412|OTHER|Questionnaire Administration|Ancillary studies
215082725|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
215082726|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
215082727|NCT02761694|DRUG|Vevorisertib|Administered as an oral dose every day or every other day.
215082728|NCT02761694|DRUG|Fulvestrant|Administered as an intramuscular (IM) injection.
215082729|NCT02761694|DRUG|Paclitaxel|Administered as an intravenous (IV) infusion.
215082730|NCT05841199|DIAGNOSTIC_TEST|Pressure and flow measurement during simulated VT|Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.
214969516|NCT04754815|OTHER|Laboratory Biomarker Analysis|Correlative studies
215082731|NCT01361932|OTHER|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
215082732|NCT02263456|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
215082733|NCT03840525|BEHAVIORAL|The Qigong Intervention|Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.
215082734|NCT03840525|BEHAVIORAL|Sham Qigong|This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
215082735|NCT03071991|PROCEDURE|study group|local anesthetic drug will be used
215082736|NCT03071991|PROCEDURE|control group|no local anesthetic drug will be used
215082737|NCT00989391|DRUG|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
215082738|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
215082739|NCT00989391|DRUG|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
214358252|NCT02654808|DEVICE|Standard trocar|"A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas."
214358253|NCT00450086|DRUG|Budesonide|9 mg per day
214487460|NCT05038215|BEHAVIORAL|adherence promotion techniques|The experimental group will receive adherence promotion techniques in addition to routine care, including 1-additional information tailored for the spouse/partner, persons living with the patient. 2- Educational material delivered at follow up appointments and by mail at intervals agreed upon by the patient and the clinician. 3- Electronic reminder/communication system established by patient and provider. 4-Follow up communication from the dental provider of the oral appliance to the primary care physician and with patient's approval, their general dentist. 5- After the 3 month follow up visits the patient will be provided with reports about their appliance wear per week. 6-Gift card delivery, $25, at 6 month follow up if a follow up with sleep physician is scheduled.
214969517|NCT04110314|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Gain-framed|Patients receive gain-framed reminder/recall messages via the patient portal to get an influenza vaccination.
214969518|NCT04110314|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Loss-framed|Patients receive loss-framed reminder/recall messages via the patient portal to get an influenza vaccination.
215082740|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
215082741|NCT00989391|DRUG|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
214358254|NCT00450086|DRUG|Mesalazine|3 g per day
214358255|NCT00450086|DRUG|Placebo|0 g per day
214487461|NCT05038215|PROCEDURE|Routine Care|The control group will receive routine care
214969519|NCT04110314|BEHAVIORAL|Pre-commitment prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
214969520|NCT03052881|DEVICE|Robot assisted surgery|The PRECEYES Surgical System is a robotically assistive device developed by PRECEYES Medical Robotics, a Dutch-based research group at the Technische Universiteit Eindhoven. It has been designed to enhance surgical precision, specifically for vitreoretinal eye surgery. The device provides accuracy beyond human capabilities of \<10μm in all directions (x, y, z planes). The surgeon is always in control of the instrument by manipulating the motion controller.
214969521|NCT01099358|DRUG|Cetuximab|Administered Intravenously
214969522|NCT01099358|DRUG|Cisplatin|Administered Intravenously
214969523|NCT01099358|DRUG|5 - Fluorouracil|Administered Intravenously
214969524|NCT03072290|DRUG|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)
214969525|NCT03072290|DRUG|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
214969526|NCT03746834|DEVICE|NASHA/Dx (Solesta®)|Perianal submucosal injection of 3-4 ml of NASHA/Dx
214969527|NCT04241770|OTHER|no intervention|no intervention
214969528|NCT05018702|DRUG|ARX788|1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
214969529|NCT03459716|OTHER|No intervention|No intervention
214969530|NCT04658797|DEVICE|somofilcon A Daily Disposable Contact Lens|Daily Disposable Contact Lens
214969531|NCT04658797|DEVICE|Single Vision Spectacle for Vision Correction|Single Vision Spectacle
214969532|NCT04658797|OTHER|Personal Facemask|Personal Facemask
214969533|NCT01178125|DRUG|DR-102|
214969534|NCT00122291|DRUG|Capecitabine|
214969535|NCT00122291|PROCEDURE|Pelvic radiation|
214969536|NCT05088499|GENETIC|DNA analysis|GWAS
214969537|NCT02948829|BIOLOGICAL|TDV|TDV SC injection.
214969538|NCT01004978|DRUG|Cisplatin|Undergo TACE
214969539|NCT01004978|PROCEDURE|Computed Tomography|Undergo CT scan
214969540|NCT01004978|DRUG|Doxorubicin Hydrochloride|Undergo TACE
214969541|NCT01004978|DRUG|Doxorubicin-Eluting Beads|Undergo TACE
214969542|NCT01004978|OTHER|Laboratory Biomarker Analysis|Correlative studies
214969543|NCT01004978|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214969544|NCT01004978|DRUG|Mitomycin|Undergo TACE
214969545|NCT01004978|OTHER|Pharmacological Study|Correlative studies
214969546|NCT01004978|OTHER|Placebo Administration|Given PO
214969547|NCT01004978|DRUG|Sorafenib Tosylate|Given PO
214969548|NCT04126044|DRUG|PF-06439535 (CN)|This is the test drug Pfizer biosimilar of bevacizumab-EU.
214969549|NCT04126044|DRUG|bevacizumab - EU|This is the reference drug bevacizumab sourced from EU
214969550|NCT05441228|DEVICE|Oculus Quest 2|Oculus Quest 2 is virtual reality headset with 2 hand control remotes. Beat Saber application will be used on Oculus Quest 2.
214969551|NCT05441228|DEVICE|Mirror therapy box|Mirror therapy is provided by mirror therapy box by placing it in sagittal plane of patient.
214969552|NCT00369915|DRUG|Scopolamine|
214969553|NCT00369915|DRUG|Scopolamine|
214969554|NCT01711983|DEVICE|GORE® CARDIOFORM Septal Occluder|Percutaneous Atrial Septal Defect Closure
214358256|NCT04728529|PROCEDURE|USSM protocol|"In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical and USCOM examination. If any improvement of clinical sign and normal SVI, CI, SVR, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by USCOM.~The therapeutic goal of USCOM: SVI 30-60 mL/m2, CI 3.3-6.0 L/minute/m2, and SVRI 800-1600 d.s/cm5/m2"
214358257|NCT04728529|PROCEDURE|ACCM protocol|In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical. If any improvement of clinical sign, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by clinical parameter.
214358258|NCT04279223|PROCEDURE|Laparoscopic cholecystectomy|Comparative study to investigate the effect of small-scale trocar use on the development of trocar site hernia in laparoscopic cholecystectomy
214487462|NCT06837805|OTHER|Iowa Produce Prescription Program (I-PPP)|The I-PPP intervention offers a produce prescription in the form of $30.00 per family member in a household every month to spend on fruit and vegetables. The dollars can be used at local retail partners, which are specific to each community. A mobile app has been developed for the I-PPP intervention participants. At the beginning of each month for six months, the app asks participants to complete a nutrition education module and a corresponding short quiz. After the participant completes the module, $30.00 per family member in the house will be loaded into the app for participants to use over the next month at local retail partners to buy fresh fruits and vegetables. Participants will have 30 days from the date of distribution to spend the funds before they expire.
214679172|NCT04144881|DIAGNOSTIC_TEST|coronary computed tomography|patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery
214969555|NCT02575417|BEHAVIORAL|Conversation Game|The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
214969556|NCT04473872|OTHER|respiratory rehabilitation|intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
214969557|NCT04350268|DEVICE|Wearable sensor|Wireless sensor
214969558|NCT04175132|DRUG|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg
214969559|NCT04175132|DRUG|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg
214969560|NCT02907567|DRUG|CT1812|Active study drug
214969561|NCT02907567|DRUG|Placebo|non-active study drug
214969562|NCT01276912|DRUG|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
214969563|NCT01276912|BEHAVIORAL|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
214969564|NCT01497548|DRUG|Methylphenidate|Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
214969565|NCT01497548|DRUG|Placebo|Placebo given on morning (0800) and noon (1200)daily
214969566|NCT04420728|COMBINATION_PRODUCT|Early auto-mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
214969567|NCT04420728|COMBINATION_PRODUCT|Delayed auto mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
214969568|NCT00268983|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
214969569|NCT00268983|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
214969570|NCT06203470|DRUG|Botulinum Toxin-A|Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.
214969571|NCT06203470|DRUG|Tacrolimus|topical Calcineurin inhibitor
214969572|NCT02147613|OTHER|High intensity interval training|3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
214969573|NCT02147613|OTHER|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
214969574|NCT01756989|DRUG|Thalidomide, etoposide, celecoxib|"Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day."
214969575|NCT05618314|DRUG|AT-527|single dose AT-527
214969576|NCT05618314|DRUG|AT-527|Single dose of AT-527 pre- and post-dialysis
214969577|NCT05618314|DRUG|AT-527 and Probenecid|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
214358259|NCT01292239|DRUG|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
214358260|NCT01292239|DRUG|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
214358261|NCT01292239|DRUG|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
214487463|NCT06837805|BEHAVIORAL|Produce Your Path Behavioral Nutrition Intervention (PYP)|The PYP Intervention is a six-month virtual behavioral intervention grounded in Self Determination Theory. The intervention aims to improve participants' competence, autonomy, and sense of relatedness through educational videos, recipes, and supplemental resources. Each monthly module contains several short videos, totaling around 15 minutes in length. The module topics include goal-setting, planning meals, preparing fruits and vegetables, reading nutrition labels, budgeting for healthier eating, and making healthier food swaps. The videos are tailored to represent a variety of cultures, ethnicities, and backgrounds, with diverse actors and recipes. Upon completion of each monthly module, a short quiz is administered to participants to measure self-efficacy related to the topic and prompt goal-setting. To further increase social support, an optional Facebook Group component allows participants to post questions, share goals and recipes, and answer prompts from the research team.
214487464|NCT06065501|BEHAVIORAL|PACE intervention|"The PACE intervention involves using Line (technological devices) to establish a collaborative group with patients. The researchers will regularly provide reminders to chronic kidney disease patients regarding the importance of nutrition and exercise. They will also provide information on how to adhere to nutritional and exercise regimens, offering praise for consistent performance."
214487465|NCT06065501|BEHAVIORAL|Usual care|Nurses provide routine education and consultation
214487466|NCT04740541|OTHER|Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies)|Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies to meet nutritional requirements, 5 levels of threonine intakes
214969578|NCT01586234|PROCEDURE|DSAEK with graft shaping and smoothing|"1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea (previously smoothed with a laser) will be inserted through the incision and placed against the endothelium of the host cornea."
214969579|NCT01586234|PROCEDURE|Standard DSAEK|"1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea will be inserted through the incision and placed against the endothelium of the host cornea."
214969580|NCT01854749|DRUG|S1 combined with cisplatin|
214969581|NCT03618446|OTHER|The presence of a pelvic fracture|
214969582|NCT04924634|DIAGNOSTIC_TEST|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
214969583|NCT01061541|BIOLOGICAL|Tritanrix™-HepB low thio /|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
214969584|NCT01061541|BIOLOGICAL|Hib 2.5|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
214969585|NCT01061541|BIOLOGICAL|Tritanrix™-HepB|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
214969586|NCT01061541|BIOLOGICAL|Hiberix™|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
214969587|NCT01061541|BIOLOGICAL|Unconjugated Hib vaccine (plain PRP)|One dose as intramuscular injection at 10 months of age
214969588|NCT00155714|DRUG|type-5 phosphodiesterase Inhibitor (Sildenafil)|
214969589|NCT00972959|DRUG|Bortezomib|1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
214969590|NCT00972959|DRUG|Zoledronic Acid|4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
214358262|NCT01292239|DRUG|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
214358263|NCT00113568|DRUG|Tranexamic acid tablets (XP12B)|Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
214969591|NCT00972959|DRUG|Dexamethasone|12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
214969592|NCT02365935|PROCEDURE|Group A adjuvant chemotherapy|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
214969593|NCT02365935|PROCEDURE|Group B adjuvant chemotherapy|In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
214969594|NCT02365935|DRUG|Cisplatin|
214969595|NCT02365935|DRUG|Paclitaxel|
214969596|NCT06175286|OTHER|POWERBreath Plus Medium Resistance training device|30 inspirations with the POWERBreath Plus Medium Resistance training device, twice per day for 5 weeks
214969597|NCT03135314|DIETARY_SUPPLEMENT|cocoa flavanol|7 days intake of cocoa flavanol supplement (naturex)
214358264|NCT05181163|DIAGNOSTIC_TEST|swab|Swabs from site of infection will be taken
214969598|NCT03135314|DIETARY_SUPPLEMENT|placebo|7 days of placebo intake
214969599|NCT03022591|OTHER|Management|management of twin pregnancies with a short cervix diagnosed between 16 0/7 WGA to 27 6/7 WGA.
214969600|NCT02917174|BEHAVIORAL|Mobile Asthma Management System|Patients in this group use a smartphone app in their asthma self-management.
214969601|NCT02917174|BEHAVIORAL|traditional Asthma Management System|Patients in this group use a printed asthma diary in their asthma self-management.
214969602|NCT01098084|DRUG|Decitabine|20mg/m2/day, one hour intravenous infusion, every day during 5 days
214969603|NCT01133548|DRUG|Testosterone Gel 1.62%|5 grams administered using an application Site Rotation
214358265|NCT03498833|OTHER|Test-retest reliability testing|Set of patient reported outcome measures
214358266|NCT00898469|GENETIC|polymorphism analysis|
214358267|NCT01489033|BIOLOGICAL|Subcutaneous immunotherapy with Phleum pratense pollen extract|Increasing doses up to a maximum dose of 500 TSU
214358268|NCT04687891|DIAGNOSTIC_TEST|transabdominal ultrasound and transvaginal ultrasound|Within a week before scheduled delivery,antepartum transabdominal and transvaginal ultrasound will be performed with moderately full bladder.
214358269|NCT06307587|PROCEDURE|dry needling|The vastus intermedius will be approached with DN from the lateral aspect and the pincer approach will be followed. The Hong fast-in and fast out technique with multiple rapid needle insertions will be performed following previous recommendations (Chou, et al., 2014). The control group will receive the rehabilitation program alone. A headless 0.25 × 25-mm needle (Stainless steel, Agupunt A1038P, 158 Caspe, Barcelona, Spain) will be used. The penetration depth will be varied according to the patient. Hemostasis will be performed for 1 minutes. DN will be performed medial to the sartorius muscle limit to avoid saphenous nerve adverse effects during DN (Henry et al., 2016).
214358270|NCT02057900|BIOLOGICAL|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
214358271|NCT00785369|DEVICE|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
214358272|NCT01410773|DEVICE|Ninja 2 Investigational Blood Glucose Monitoring System|The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
214969604|NCT01133548|DRUG|Testosterone Gel 1.62%|5 grams administered using an a combination of Application sites
214969605|NCT04590118|DRUG|it-hMSC|Single intravenous infusion of it-hMSC for ischemic stroke patients
214969606|NCT04590118|DRUG|Placebo|Single intravenous infusion of 1 ml/kg placebo
214969607|NCT04159467|OTHER|Pelvic Floor Muscle Training|4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The supervised 4 sets will be performed in 2 different positions (sitting and standing).
214969608|NCT04398940|DRUG|TQ-B3139|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
214969609|NCT03920085|DEVICE|OneTouch Verio|OneTouch Verio Blood Glucose Monitoring System.
214969610|NCT03920085|DEVICE|OneTouch Select Plus|OneTouch Select Plus Blood Glucose Monitoring System.
214969611|NCT03920085|DEVICE|OneTouch Ultra|OneTouch Ultra Blood Glucose Monitoring System.
214969612|NCT00178737|BEHAVIORAL|Electronic reminder message|
215082742|NCT00989391|DRUG|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
214358273|NCT01734304|BIOLOGICAL|DC vaccination for postremission therapy in AML|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
214358274|NCT00584727|DEVICE|senofilcon A toric contact lens|contact lens
214358275|NCT00584727|DEVICE|alphafilcon A toric|contact lens
214358276|NCT00584727|DEVICE|etafilcon A sphere|contact lens
214969613|NCT06254794|DEVICE|Blood flow restriction with Delfi Personalized Tourniquet System (PTS)|Standard of care physical therapy exercises with the use of the Delfi PTS cuff
214969614|NCT06254794|OTHER|Physical therapy|Standard of care physical therapy exercises
214969615|NCT03461198|DEVICE|Restylane® Silk|Restylane® Silk to a defined area of mid to low cheeks
214969616|NCT03921736|DRUG|Perindopril|4 mg/day p.o. for 12 months
214969617|NCT03921736|DRUG|Hydrochlorothiazide|hydrochlorothiazide 25 mg/day p.o. for 12 months
214969618|NCT03921736|DRUG|Estracomb TTS|Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months
214969619|NCT06057168|DRUG|Elucirem|Intravenous administration
214969620|NCT06057168|DRUG|Dotarem|Intravenous administration
214487467|NCT05889793|DRUG|Emetine Hydrochloride|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
214487468|NCT05889793|DRUG|Placebo|Participant takes a placebo for 10 consecutive days.
214969621|NCT03588130|DRUG|EscharEx (5% EX-02 formulation)|Active arm
214969622|NCT03588130|DRUG|Gel Vehicle|Control arm
214358277|NCT03942133|PROCEDURE|ultrasound-guided short-axis placement of catheter at the entrance of the adductor canal|Ultrasound probe is placed at the entrance of the adductor canal in short axis ，insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the entrance of the canal
214358278|NCT03942133|PROCEDURE|ultrasound-guided long-axis placement of catheter at the middle of the adductor canal|Ultrasound probe is placed at the middle of the adductor canal in long axis with the caphelad end of the probe aligned with the entrance of the canal. insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the middle of the canal
214358279|NCT01484548|BIOLOGICAL|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
214358280|NCT01484548|BIOLOGICAL|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
214358281|NCT01484548|BIOLOGICAL|LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
214358282|NCT02293044|DEVICE|Crest® Sensi-Stop™ Strips|
214358283|NCT05186948|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
214358284|NCT03273634|DRUG|Lansoprazole Pill|once daily at night time
214358285|NCT03273634|DRUG|Placebo|Placebo
214358286|NCT01789554|OTHER|MLS dispatch for bystander CPR|
214358287|NCT04085783|PROCEDURE|PRP|Platelet Rich Plasma
215082743|NCT03464422|BEHAVIORAL|ESTEEM conneCT|"The intervention adapts the ESTEEM (Pachankis et al, 2015) intervention to address the multiple-stigma stressors faced by MSM of color, including sexual orientation and racial stigma in a manualized, CBT-based intervention. Approximately thirty participants (divided between two cohorts) will complete ten group sessions will take place at regular times once per week over the course of three months. The groups will be closed, in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members."
215082744|NCT00739180|OTHER|Control|Standard care control (no exercise)
214358288|NCT01511848|DRUG|DFP (ferriprox) and deferasirox (ICL 670)|"Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670"
214487469|NCT06416085|DRUG|Psilocybin|Single high-dose (25mg) capsule of psilocybin taken orally in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy
214969623|NCT03588130|DRUG|Non-surgical standard of care (NSSOC)|Santyl (Enzymatic debridement) or commercially approved Hydrogel
214969624|NCT06474039|DRUG|Trelegy or Anoro|Both drugs delivered via Ellipta device and blinded package appearance
214969625|NCT06198920|PROCEDURE|Stenting of the superficial femoral artery|Submitted to stenting of the superficial femoral artery for stenosis or occlusion causing intermittent claudication or critical limb ischemia
214969626|NCT05017272|OTHER|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
214969627|NCT06581783|DRUG|Simethicone plus NAC|Drug simethicone plus N acetylcysteine will be given before endoscopy with different time intervals
215082745|NCT00739180|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
215082746|NCT00739180|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
214969628|NCT06412029|OTHER|Non-Interventional|Non-interventional study
214969629|NCT03607799|BEHAVIORAL|Dietary Intervention|Individualized diet advice will be developed for each participant by a dietitian familiar with South Asian foods.
214969630|NCT03607799|BEHAVIORAL|Control|Control group participants will be provided with PDFs, website links to encourage healthy eating, physical activity, and other lifestyle factors during pregnancy. They will also receive weekly text messages aimed at increasing walking.
214969631|NCT01487083|DRUG|Pomaglumetad methionil|Administered orally
214969632|NCT06958562|DIAGNOSTIC_TEST|No intervention administered. Standard care will be provided. Blood samples for lymphocyte count and CRP will be collected, and Syntax score will be calculated from angiography.|No intervention administered. Standard care will be provided. Blood samples for lymphocyte count and CRP will be collected, and Syntax score will be calculated from angiography.
215082747|NCT06044805|DRUG|Chloroquine|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
214487470|NCT05975554|DRUG|Interleukin-2 [IL-2]|5 sequential days of treatment (1.5MIU/day subcutaneously)
215082748|NCT06044805|DRUG|Primaquine|Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
215082749|NCT01370837|OTHER|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
215082750|NCT01370837|OTHER|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
214358289|NCT01511848|DRUG|DFP, DFO|"Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days"
214358290|NCT00377403|DRUG|Acetaminophen|"Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever"
214358291|NCT00377403|DRUG|Amoxicillin|"Intervention drug:~Dose: 500mg tid for 10 days"
214487471|NCT05975554|PROCEDURE|Standard care - Carotid Endarterectomy|Standard care for patients with carotid stenosis undergoing carotid endarterectomy
214502722|NCT02736851|OTHER|Home-based telemedicine group|"All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.~At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period."
214969633|NCT05711095|DIETARY_SUPPLEMENT|Fortified plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
214969634|NCT05711095|DIETARY_SUPPLEMENT|Plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
214969635|NCT05711095|DIETARY_SUPPLEMENT|Whey protein|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
214969636|NCT05179746|DEVICE|Implants are decontaminated with electrolytic cleaning|Implants are decontaminated with electrolytic cleaning
214358292|NCT00377403|DRUG|Dextromethorphan hydrobromide with guaifenesin|"Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough"
214358293|NCT00377403|DRUG|Guaifenesin|"Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions"
214358294|NCT00377403|DRUG|Pseudoephedrine Sustained Action|"Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion"
214358295|NCT00377403|DRUG|Saline spray (0.65%)|"Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion"
214969637|NCT05179746|DEVICE|Implants are decontaminated without electrolytic cleaning|Implants are decontaminated without electrolytic cleaning
214969638|NCT03191851|DEVICE|standard device|paracentesis using standard
214969639|NCT03191851|DEVICE|Melody Device|paracentesis using Melody Device
214969640|NCT03191851|DEVICE|Melody Device with Pump|paracentesis using Melody Device with Pump
215082751|NCT02590822|DIETARY_SUPPLEMENT|Cambridge Weight Plan|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
214358296|NCT06579651|DEVICE|Nailfold videocapillaroscopy (NVC)|Nailfold videocapillaroscopy (NVC) is the validated technique to assess SSc microvascular damage and is useful for the early diagnosis and follow-up of SSc micro- angiopathy.
214358297|NCT04756687|DRUG|Dimethyl fumarate|Administered as specified in the treatment arm.
214358298|NCT00627848|DRUG|rivastigmine|Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
214358299|NCT03451734|DRUG|antipsychotic medications|olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
214358300|NCT03451734|DRUG|adjunctive group|antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
214358301|NCT03451734|DRUG|metformin and lifestyle intervention|different dose metformin combines lifestyle intervention
214358302|NCT04513990|PROCEDURE|Biospecimen Collection|Undergo collection of nasopharyngeal, oral, saliva, and nasal samples
214358303|NCT04513990|OTHER|Questionnaire Administration|Demographic information, sample collection type preferences; clinical outcome information
214358304|NCT04762381|DRUG|Dexamethasone phosphate|24 mg dexamethasone infused peroperatively
214358305|NCT04762381|OTHER|Placebo|Saline
214969641|NCT01635829|DRUG|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
214969642|NCT01635829|DRUG|Phenytoin|Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
214969643|NCT01635829|DRUG|Carbamazepine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
214969644|NCT00321906|DRUG|azathioprine|azathioprine 2mg/kg
214358306|NCT06498765|OTHER|Pacifier Use|The newborns in the experimental group were given a pacifier, unlike the control group. The newborns were placed in a phototherapy incubator and each time they were placed in a phototherapy incubator, the newborns were given a pacifier for an average of 5 minutes. The researcher encouraged the babies to take the pacifier.
214358307|NCT02541890|BEHAVIORAL|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
214358308|NCT05884840|DIAGNOSTIC_TEST|HELENA|"The current CV risk screening program in based using the REGICOR risk function, which is integrated in the primary care electronic health record. This risk function predicts the probability within 10 years of developing a coronary event. Those who are categorized as high risk, obtaining a 10% of probability, are candidates of receiving lipid lowering drugs and recommendations on healthy life habits.~What this intervention suggests is that, besides the REGICOR estimation, the electronic health records will also incorporate a new CV risk function, REASON. The model predicts the risk of holding a pathologic ABI score, in people aged 50-74 years old who are apparently free of CV. Patients who obtain a score ≥ 7 will undergo a PAD screening program with ABI test. If the value of the test is ≤0.9, the REGICOR, physicians will recommend indications of the Health Catalan Institute's CV and lipid Guidelines to the patients."
214358309|NCT05008666|DRUG|Sintilimab|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
214358310|NCT05008666|DRUG|Chidamide|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
214502723|NCT01701401|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
214969645|NCT00321906|DRUG|sirolimus|sirolimus 2-4mg daily
214969646|NCT00516685|BIOLOGICAL|Recombinant Human rEGF-P64K/Montanide Vaccine|
214969647|NCT01018914|DRUG|Prograf|oral
214969648|NCT01018914|DRUG|Advagraf|oral
214969649|NCT01018914|DRUG|Myfortic|oral
214358311|NCT05008666|DRUG|Azacitidine|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
214358312|NCT05008666|DRUG|L-DEP|L-DEP
214358313|NCT00737165|BEHAVIORAL|Multimodal suicide prevention program|"A community intervention of multimodal suicide prevention program includes following components:~1. Building support networks for suicide prevention and mental health promotion in public health system~2. Primary prevention of suicide and suicide related behaviors~3. Secondary prevention of suicide and suicide related behaviors~4. Tertiary prevention; after care for suicide survivors~5. Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~6. Suicide prevention targeting for people with work-related problems"
214358314|NCT00737165|BEHAVIORAL|Suicide prevention program as usual|Usual suicide prevention program
214358315|NCT02275104|DEVICE|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
214358316|NCT02275104|DEVICE|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
214358317|NCT02275104|DEVICE|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
214358318|NCT02275104|DEVICE|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
214487472|NCT02885714|PROCEDURE|Placebo surgery and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated. Nothing is to be removed or excised and the use of any vapour or shaver device is not allowed. The presence of a full-thickness rotator cuff tear is verified. Altogether 3 to 5 small stab wounds are made in typical locations resembling locations of typical rotator cuff repair. The time spent in the operating theatre with patients in placebo group should resemble the time spent with patients in the active treatment group and hence give an impression of a rotator cuff repair.
214502724|NCT01701401|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214969650|NCT04380870|DIETARY_SUPPLEMENT|Chinese Herbal Medicine|Chinese Herbal Medicine (CHM) has been used in the prevention and treatment of epidemic diseases dating back to the Han, Ming and Qing Dynasties and extending al the way through modern times. CHM formulas may contain plant elements of root, seed, back, stem or leaf in addition to minerals and other natural substances. All herbs dispensed in this trial will be from Spring Wind Herb Company.
214969651|NCT01449292|DEVICE|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
214969652|NCT01449292|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
215082752|NCT02590822|OTHER|Supervised Exercise Sessions|"The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
215082753|NCT00041171|DRUG|Hypericum perforatum|
215082754|NCT00041171|DRUG|docetaxel|
215082755|NCT00041171|OTHER|placebo|
215082756|NCT04240093|BEHAVIORAL|Behavioral Activation (BA) Therapy|8 sessions of behavioral activation therapy
215082757|NCT04240093|BEHAVIORAL|Substance Abuse and Health Navigation Counseling|2 standard substance abuse and health navigation counseling
215082758|NCT04240093|OTHER|Medications for Opioid Use Disorder|Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
215082759|NCT05501613|DIAGNOSTIC_TEST|Multimodal Neuromonitoring|Invasive Multimodal Neuromonitoring
215082760|NCT03297489|PROCEDURE|Diagnostic Microscopy|Undergo observation via intravital microscopy
215082761|NCT03297489|DRUG|Fluorescein Sodium Injection|Given IV
215082762|NCT03297489|OTHER|Laboratory Biomarker Analysis|Correlative studies
215082763|NCT00886249|DEVICE|Acrysof IQ|Intraocular lens
215082764|NCT00886249|DEVICE|Acrysof Natural IOL|Intraocular Lens
214358319|NCT02275104|PROCEDURE|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
214358320|NCT01655290|OTHER|Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)|Other (Diagnostic)
214358321|NCT03602651|OTHER|Hamilton-anxiety scale (HAM-A)|Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)
214358322|NCT00970138|DRUG|apatinib tablet|"A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent"
214358323|NCT00999375|BEHAVIORAL|Education|
214358324|NCT00999375|BEHAVIORAL|Problem Solving|
214358325|NCT00999375|BEHAVIORAL|Social Learning|
214358326|NCT00999375|BEHAVIORAL|Behavior Modification|
214358327|NCT04739501|PROCEDURE|TACE|Trans-arterial chemoembolization in patients with hepatocellular carcinoma
214358328|NCT01687257|DRUG|SOF|SOF 400 mg tablet administered orally once daily
214358329|NCT01687257|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214358330|NCT06273098|BEHAVIORAL|Bladder Health Education|This will be a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies that are TBD (e.g. mobile technology bathroom passes).
214358331|NCT00003038|DRUG|doxorubicin hydrochloride|
214358332|NCT00003038|DRUG|suramin|
214358333|NCT00969501|DRUG|EUFLEXXA|2.5 mL of EUFLEXXA (per injection) x 3 injections
214358334|NCT00331747|DRUG|Glatiramer acetate|
214358335|NCT00219076|DRUG|aliskiren|
214358336|NCT00736645|DIETARY_SUPPLEMENT|selenomethionine|Given orally
214358337|NCT00736645|DRUG|finasteride|Given orally
214358338|NCT00736645|OTHER|placebo|Given orally
215082765|NCT01247935|OTHER|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
215082766|NCT01247935|OTHER|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
215082767|NCT01247935|OTHER|Control|Patients are monitored for pain and discomfort
214358339|NCT00700921|DRUG|Lovastatin|40mg po once daily
214358340|NCT00700921|DRUG|Placebo|One capsule, once daily
214358341|NCT00979836|DRUG|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
214358342|NCT01049126|OTHER|ChemoFx|Chemoresponse Marker Assay
214358343|NCT03565081|DEVICE|PWS elastic band training group|PWS participants received 9 sets exercises for the major muscle groups, over 24 weeks, three times a week, for a total of 72 sessions.
214358344|NCT01866228|OTHER|Consultation Recording|
214358345|NCT02955264|DIETARY_SUPPLEMENT|D-Galactose|D-Galactose is an oral powdered dietary supplement to be taken by mouth.
214358346|NCT00003214|DRUG|carboplatin|
214358347|NCT00003214|DRUG|cisplatin|
214358348|NCT00003214|DRUG|cyclophosphamide|
215082768|NCT04333602|DIAGNOSTIC_TEST|Urinary culture and treatment if asymptomatic bacteriuria is detected|Urinary culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. Based in the assigned group If we detect asymptomatic bacteriuria specific treatment will be instituted or No treatment.
214358349|NCT00003214|DRUG|doxorubicin hydrochloride|
214358350|NCT00003214|DRUG|in vitro sensitivity-directed chemotherapy|
214358351|NCT00003214|DRUG|paclitaxel|
214358352|NCT06132880|DRUG|Human Urinary Kallidinogenase|Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.
215082769|NCT05773261|DEVICE|MobilLINK TrabecuLINK cup|THA with MobilLINK TrabecuLINK cup and LCU stem
214358353|NCT06132880|OTHER|Clinical Routine Treatment|Conventional therapy of acute ischemic stroke after based on Chinese guidelines
214358354|NCT00047801|DRUG|TLK286 in combination with docetaxel|
214358355|NCT03547843|BEHAVIORAL|Group-based education|The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.
214358356|NCT03547843|BEHAVIORAL|Waiting list|No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.
214358357|NCT03547843|OTHER|Standard treatment|Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
214358358|NCT00881179|DRUG|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)|
214358359|NCT00881179|DRUG|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)|
214358360|NCT00295022|DRUG|Placebo|"* Pharmaceutical form: Over-encapsulated tablet~* Route of administration: Oral use"
214358361|NCT00295022|DRUG|Montelukast|"* Pharmaceutical form: Over-encapsulated tablet~* Concentration: 10 mg~* Route of administration: Oral use"
214358362|NCT00295022|DRUG|Levocetirizine|"* Pharmaceutical form: Over-encapsulated tablet~* Concentration: 5 mg~* Route of administration: Oral use"
214358363|NCT00734630|DRUG|nebivolol|"Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration"
214358364|NCT00734630|DRUG|Placebo|Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
214358365|NCT01652144|DRUG|AT7519M|
214358366|NCT01280279|OTHER|education for behavioral modification|a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
214358367|NCT03211286|DRUG|Tranexamic Acid|1 g of intravenous tranexamic acid in 100 mL of saline solution
214358368|NCT03211286|DRUG|Saline Solution|saline solution 100 mL intravenous
214358369|NCT04489043|OTHER|Exercise and healthy lifestyle recommendations|In the present study, renal transplant patients with proven prediabetes will do a planned exercise programme to test the impact of this treatment on the reversibility of prediabetes. Thus, the persistance of recurrency of prediabetes assessed by an Oral Glucose Tolerant Test (OGTT) at intermediate time points (3, 6 and 9 months) will be checked in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.
214358370|NCT05063838|OTHER|Pharmacogenomic optimisation of anaesthetic medications|Personalisation of anaesthetic plan based on pharmacogenomic results and international guidelines.
214358371|NCT00809887|DRUG|Micafungin lock therapy|
214358372|NCT04380922|OTHER|Periodontal screening|Periodontal data collection (PPD, REC, CAL)
214358373|NCT02568241|OTHER|Interferon Alfa-2b|High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
214358374|NCT04204629|DRUG|HIP1601 40mg|Single dosing of HIP1601 40mg, PO
214487473|NCT02885714|PROCEDURE|Rotator cuff repair and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated and the presence of a full-thickness rotator cuff tear is verified. The cuff tear is repaired to its anatomic location using suture anchors according to surgeon preference. . A biceps tenotomy or tenodesis may be performed according to surgeon preference if the biceps tendon is noted to be frayed, unstable or inflamed. An additional acromioplasty may be performed according to surgeon preference.
214487474|NCT03286114|DRUG|Pembrolizumab|200mg IV every 21 days
214487475|NCT06953661|PROCEDURE|Stellate ganglion block|Patients will receive a SGB
214358375|NCT04859504|DEVICE|transcranial alternating current stimulation (NE Starstim)|dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
214358376|NCT05502432|DEVICE|Active repetitive transcranial magnetic stimulation|Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation
214487476|NCT06953661|PROCEDURE|Sham injection of saline|Patients will receive a subcutaneous sham injection of saline
214487477|NCT06953661|DRUG|Ropivacaine|The SGB group will receive ropivacaine 0.5% 10ml
214487478|NCT06953661|DRUG|Normal saline|The control group will receive normal saline in the sham injection.
214487479|NCT06951438|DIAGNOSTIC_TEST|Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas|Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas
214487480|NCT02629497|DIETARY_SUPPLEMENT|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
214969653|NCT04835727|OTHER|Semi-vegetarian diet and increase fiber consumption|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
214969654|NCT01272908|DRUG|rituximab|1000 mg intravenously on Days 1 and 15
214969655|NCT02482142|DIETARY_SUPPLEMENT|Effect of phosphorus|Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
214969656|NCT05833126|DRUG|Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab|Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC
214969657|NCT00132288|BEHAVIORAL|Motivational support|Participants in the PALS program at SE Seattle Senior Center are assigned a volunteer phone buddy who uses motivational interviewing techniques during bi weekly or monthly phone calls to encourage the participant to become more physically active.
214969658|NCT00132288|BEHAVIORAL|PALS - Physical activity for lifetime success|Referral by a primary care provider to a community based support program to enhance uptake or maintenance of physical activity by the participants.
214358377|NCT05502432|DEVICE|Sham repetitive transcranial magnetic stimulation|Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation
214358378|NCT01634126|BEHAVIORAL|1 FIT kit|Patient receives 1 FIT
214358379|NCT01634126|BEHAVIORAL|2 FIT kit|Patient receives 2 FIT kits
214358380|NCT03742700|BEHAVIORAL|Cigarette smoking|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
214358381|NCT03742700|BEHAVIORAL|E-cigarette use|E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
214358382|NCT03742700|BEHAVIORAL|Simulation of the use of e-cigarette|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
214969659|NCT03899857|DRUG|Pembrolizumab|Pembrolizumab will be added to standard of care
214358383|NCT06497244|PROCEDURE|micro osteo-perforation|the patient will receive miniscrew micro osteo-perforation in one side every month with molar distalization and the other side the distalization without micro osteo-perforation
214358384|NCT02701712|RADIATION|Magnetic resonance - guided radiation therapy (MRgRT)|Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
214502725|NCT00933270|DEVICE|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
214969660|NCT02056418|DIETARY_SUPPLEMENT|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
214969661|NCT02056418|DRUG|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
214969662|NCT03162406|DIETARY_SUPPLEMENT|Vitamin D3|Oral supplementation 25000 IU once per week for 6 months
214969663|NCT03162406|DIETARY_SUPPLEMENT|Placebo|Oral supplementation once per week for 6 months
214969664|NCT04414852|DRUG|Apatinib Mesylate|All the subjects will be administrated with 250mg apatinib on day 1
214969665|NCT01158261|BIOLOGICAL|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
214969666|NCT03143101|BIOLOGICAL|FluMist trivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
214358385|NCT01766622|DRUG|[18F]-CP18|7mCi, IV (in the vein) at baseline
214358386|NCT01766622|PROCEDURE|PET/ CT|At baseline, Within 3 days after the initial Birinapant dose, A third \[18F\]-CP18 PET/CT will be obtained within 3 days following cycle 2, day 15 Birinapant therapy
214969667|NCT03143101|BIOLOGICAL|FluMist Quadrivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
214969668|NCT03143101|BIOLOGICAL|FluMist Quadrivalent (2017-2018)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
214969669|NCT05052853|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of prodromal schizophrenia .
214969670|NCT05052853|DRUG|Placebo Cap|Use of placebo as a comparator
214969671|NCT01493245|DRUG|JNS020QD|During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
214969672|NCT05986981|DRUG|Vaccine|"Dose-escalation trial, according to the classic 3+3 model, divided into three dose levels of 0.5 mg, 1.0 mg, 2.0 mg for enrollment, is expected to enroll a total of 9-18 subjects (0.5 mg dose group to be enrolled in 3-6 subjects, 1.0 mg dose group is proposed to be enrolled in 3-6 subjects, 2.0 mg dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects. dose group is proposed to include 3-6 subjects)."
214969673|NCT01912950|DEVICE|Prowave LX IPL|
214969674|NCT02373150|DRUG|Imeglimin|
214969675|NCT02373150|DRUG|Placebo|
214358387|NCT01181050|DRUG|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
214358388|NCT01181050|DRUG|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
214358389|NCT05381155|BEHAVIORAL|A single-session behavioral intervention composed of a brief evocation of the childbirth memory followed by a Tetris gameplay|"The intervention is composed of two tasks:~1. The childbirth narration task (8-10 min.): To trigger the malleability of the traumatic childbirth memory through memory reactivation, a psychologist will ask the participants to briefly narrate their childbirth and the moment associated with their most frequent or distressing CB-ITM. This intervention part will take place on the maternity ward to use this context as a reactivation cue.~2. The visuospatial task (3 min. practice + 20 min. gameplay): Participants will be instructed to engage in a Tetris gameplay for 20 minutes on a handheld gaming device (Nintendo 3DS), which is assumed to disrupt memory reconsolidation. This part of the intervention will take place in a neutral room."
214358390|NCT05695781|DRUG|BRM421 Ophthalmic Solution|A topical drop of BRM421 ophthalmic solution.
214358391|NCT05695781|DRUG|Vehicle|A topical drop of vehicle (minus active) ophthalmic solution.
214969676|NCT05028764|DIAGNOSTIC_TEST|Buccal Swabs, Blood Draws and Skin Punch Biopsy|Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers
214969677|NCT05357534|OTHER|Physical activity|Physical activity: 10 km run on a treadmill
214969678|NCT00201344|DRUG|Cisplatin,5-FU,Leucovorin|
214358392|NCT06962267|DRUG|TQB2916 Injection|A Phase II clinical study to evaluate the efficacy and safety of TQB2916 injection combined with gemcitabine and albumin-paclitaxel as first-line treatment for metastatic pancreatic cancer.
214358393|NCT06962267|DRUG|Chemotherapy|Chemotherapy is a systematic treatment.Chemotherapy drugs go into the body orally or intravenously, and they circulate throughout the body, and because of that, they can be used for advanced cancer, and they can also be effective against metastasized cancer cells.There are many chemotherapeutics, but the underlying mechanism is to kill fast growing cells.
214358394|NCT00403624|DRUG|OXALIPLATIN|
214358395|NCT01018394|DRUG|nicotine lozenges|4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.
214358396|NCT01018394|DRUG|tobacco-free snuff|Tobacco-free snuff used ad lib for a maximum of 12 weeks
214358397|NCT03240692|DEVICE|Accelerated theta-burst stimulation treatment|"All participants will receive intermittent theta-burst stimulation (iTBS) to the left dorsal lateral prefrontal cortex (L-DLPFC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered to L-DLPFC using the Magventure Magpro X100 and/or the NextStim TMS system."
214358398|NCT00683644|DRUG|Zinc|Zinc taken once daily
214358399|NCT00683644|DRUG|Placebo oral capsule|Placebo capsules taken once daily
214358400|NCT05901545|BIOLOGICAL|Panitumumab|Given by IV
214358401|NCT05901545|OTHER|Indium In 111 Panitumumab|Given by IV
214358402|NCT05901545|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214358403|NCT05901545|PROCEDURE|Computed Tomography|Undergo SPECT/CT
214358404|NCT05901545|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
214358405|NCT05901545|OTHER|Imaging agent|Receive local injection of optical dye
215082770|NCT05773261|DEVICE|Pinnacle Gription cup|THA with Pinnacle Gription cup and Coral stem
214358406|NCT05901545|PROCEDURE|Intraoperative Imaging|Undergo Intraoperative Imaging
214358407|NCT05901545|PROCEDURE|Near Infrared Imaging|Undergo Near Infrared Imaging
214358408|NCT05901545|PROCEDURE|Electrocardiography|Undergo Electrocardiography
214358409|NCT05901545|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214358410|NCT01027000|BIOLOGICAL|rituximab|
214358411|NCT01027000|DRUG|busulfan|
214358412|NCT01027000|DRUG|cyclophosphamide|
214358413|NCT01027000|DRUG|fludarabine phosphate|
214358414|NCT01027000|DRUG|methotrexate|
214358415|NCT01027000|DRUG|sirolimus|
214358416|NCT01027000|DRUG|tacrolimus|
214358417|NCT01027000|PROCEDURE|allogeneic stem cell transplant|
214358418|NCT04123067|DRUG|Pioglitazone 45 mg|45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
214969679|NCT01285869|OTHER|Multidimensional intervention|The patient will be cited 2 months after hospital discharge for a geriatric evaluation carried out by a geriatric nurse and an internist with geriatric training. The duration of the first visit is 45-60 minutes. The visit consists of: 1. Assessment of the pneumonia resolution, co-morbidities, aspiration risk, risk of multiresistant infections, and the immunization, functional and cognitive status. 2. An individualized intervention plan. The patient and family or caregiver will receive an educational intervention, a written report with the planned intervention and an educational leaflet. Those patients who require further assessment or follow up of the intervention will receive 1 or 2 more visits and all the patients will be cited one year after the first visit.
214969680|NCT02908152|DIETARY_SUPPLEMENT|curcumin|"1500 mg~1 capsule / day for 12 weeks"
214358419|NCT04123067|DRUG|Placebo oral tablet|placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
214358420|NCT04215042|DRUG|sodium chloride infusion|
214969681|NCT02908152|DIETARY_SUPPLEMENT|placebo|"1500 mg~1 capsule / day for 12 weeks"
214969682|NCT01518647|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
214969683|NCT04687410|DEVICE|ProControl, MediGlobe|standard 22G FNA needle
215082771|NCT03322501|BEHAVIORAL|Provider Advice, Framed Messaging|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
215082772|NCT00670176|BEHAVIORAL|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
215082773|NCT01403545|DRUG|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
215082774|NCT01403545|OTHER|Placebo|5% glucose infusion over 120 minutes
214358421|NCT06398327|PROCEDURE|PULPOTOMY TREATMENT|During pulpotomy treatment, a bleeding sample was taken from the pulp and levels of presepsin, IL-6 and IL-8, which are important inflammation markers, were determined. During the treatment, MTA, Neo MTA, Biodentine and ZOE groups were randomly selected and the remaining pulp tissue was covered. After pulpotomy treatment, the teeth were followed for one year. Treatment success was evaluated according to the material used in teeth with high levels of inflammation at the beginning.
214358422|NCT02485210|PROCEDURE|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
214358423|NCT01935817|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
214358424|NCT01935817|DRUG|Placebo|
214358425|NCT05260801|OTHER|Bright Lighting|The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.
214358426|NCT05260801|OTHER|Placebo Lighting|The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.
214358427|NCT00990639|DRUG|candesartan for hepatic fibrosis|"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"
214358428|NCT02437591|DRUG|fidaxomicin|oral
214969684|NCT04687410|DEVICE|TopGain, Medi-Globe|novel 22G crown-cut FNB needle
214969685|NCT05060575|OTHER|Education and Telephone Counceling|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
214969686|NCT01630135|DRUG|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
214969687|NCT01630135|DRUG|Placebo|Placebo, intranasal, 2 weeks
214969688|NCT02631317|BEHAVIORAL|Advance hospital notification by EMS|Advance hospital notification by EMS
214969689|NCT02631317|BEHAVIORAL|stroke team notification|stroke team notification
215082775|NCT02209402|BEHAVIORAL|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
214358429|NCT04101643|DRUG|evolocumab|Eligible patients receive subcutaneous injections of evolocumab 420 mg
214358430|NCT00127101|DRUG|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
214358431|NCT00127101|DRUG|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
214358432|NCT00843167|DIETARY_SUPPLEMENT|broccoli sprout extract|Given orally
214358433|NCT00843167|OTHER|placebo|Given orally
214358434|NCT01641250|DRUG|RO5429083|Multiple escalating doses
214358435|NCT01641250|DRUG|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
214358436|NCT02866565|DRUG|adipose-derived regenerative cells (ADRCs)|injection of the experimental treatment
214969690|NCT02631317|BEHAVIORAL|key performance indicators feedback form|"a key performance indicators real-time feedback form as continuing quality improvement"
215082776|NCT04317157|DIETARY_SUPPLEMENT|Caffeine|Specific dosage of caffeine for each participant (6 mg.kg-1).
215082777|NCT04317157|OTHER|Placebo|Placebo pill.
215082778|NCT01628367|PROCEDURE|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
214969691|NCT02631317|BEHAVIORAL|standard informed consent procedures|standard informed consent procedures with public poster of thrombolysis
214969692|NCT02631317|BEHAVIORAL|performance of thrombolysis at CT-room|performance of thrombolysis at CT-room or emergency room
214969693|NCT06223295|PROCEDURE|Focal therapy|"Focal therapy selectively treats a specific part of the prostate while preserving the rest of the gland in men with prostate cancer.~Focal therapy with ultrasound ablation (HIFU/TULSA) or irreversible electroporation (IRE) followed by an intensive MRI follow-up scheme at 12, 24, 36, 48 and 60 months, prostate biopsy at 12 months (and also when indicated) and PSA monitoring"
214969694|NCT06223295|PROCEDURE|Usual care|standard radical treatment; prostatectomy or radiotherapy with follow-up according international guidelines (PSA monitoring and imaging when indicated).
214487481|NCT02629497|DIETARY_SUPPLEMENT|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
214487482|NCT06460441|DIAGNOSTIC_TEST|SUNRISE© device|"The device under study is the Sunrise© sensor, a single-use Class IIa medical device with CE marking and ISO 13485 certification.~The system combines a mandibular movement sensor with an artificial intelligence program to collect and interpret data. It consists of a three-gram device that is placed on the chin using an adhesive. The sensor is linked to a (free) mobile app, enabling data to be sent to the Sunrise© company's secured platform at the end of the night, and results to be transmitted to the prescribing physician."
214487483|NCT05743387|OTHER|T2D care package|T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.
214487484|NCT05743387|OTHER|Referral to the responsible health facility|CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
215082779|NCT01628367|DEVICE|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
215082780|NCT01628367|BIOLOGICAL|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
215082781|NCT01628367|BIOLOGICAL|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
215082782|NCT01628367|BIOLOGICAL|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
214487485|NCT06191198|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
214487486|NCT06191198|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
214487487|NCT04299113|DRUG|Vinorelbine|Given IV
214487488|NCT04299113|DRUG|Mocetinostat|Given PO
214502726|NCT01000805|DRUG|Duloxetine|Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
214502727|NCT01000805|DRUG|Placebo|Participants received placebo QD, po for 8 weeks.
214502728|NCT00989196|BIOLOGICAL|Human-cl rhFVIII|50 IU/kg for PK dose
214969695|NCT06303206|DEVICE|Home Blood Pressure Telemonitoring (HBPT) + Case Management (CM)|"Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Case Management (CM) includes pharmacists reviewing BP data and providing counselling to participants based on their BP values."
214969696|NCT06129097|OTHER|Thyme honey mouthwash|"* Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse."
214969697|NCT03099577|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
214969698|NCT03099577|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
214358437|NCT06267053|DIAGNOSTIC_TEST|Direct digital radiography|All the participants had anterior posterior and lateral knee xray taken within 3 months of diagnosis
214358438|NCT06267053|DIAGNOSTIC_TEST|25-OH Vitamin D|All the participants had serum 25-OH Vitamin D levels measured from venous blood within 30 days of diagnosis
214969699|NCT03099577|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
214969700|NCT03099577|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
214969701|NCT03099577|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
214969702|NCT03099577|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
214969703|NCT03099577|RADIATION|radiochemotherapy 7|concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
214969704|NCT05259319|DRUG|Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]|Treatment given every 21 days during 24 months or until progression
214969705|NCT05259319|DRUG|Tiragolumab|Treatment given every 21 days during 24 months or until progression
214969706|NCT05259319|RADIATION|Stereotactic body radiation therapy (SBRT)|Radiothérapy is delivered as a hypofractionated schedule of 3 doses of 8Gy (idealy on Monday, Wednesday and Friday, or 3 sessions over a week, respecting at least 24 hours between each fraction)
214969707|NCT05921656|OTHER|Construction and evaluation of airway leakage risk model of patients with endotracheal tube|"1. Conduct statistical analysis on general information, respiratory data, tracheal catheter data, and cross-sectional area of the patient's airway to clarify the current status of airway leakage and related influencing factors.~2. Based on multivariate logistic regression, a line chart prediction model for predicting the risk of airway leakage in patients with tracheal catheters is constructed. The clinical efficacy of the prediction model is evaluated by using the area under the ROC curve, the Calibration scatter plot, and the DCA decision line, respectively, to assess its discrimination, calibration, and clinical practicality."
214969708|NCT02541864|DRUG|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
215082783|NCT01628367|DRUG|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
215082784|NCT00349258|DRUG|Leuprolide acetate|
214358439|NCT06267053|DIAGNOSTIC_TEST|Vitamin B12|All the participants had serum Vitamin B12 levels measured from venous blood within 30 days of diagnosis
214358440|NCT06267053|DIAGNOSTIC_TEST|Folic acid|All the participants had serum folic acid levels measured from venous blood within 30 days of diagnosis
214502729|NCT00989196|BIOLOGICAL|Kogenate FS|50 IU/kg for PK dose
215082785|NCT02839902|DRUG|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
215082786|NCT02839902|OTHER|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
214358441|NCT06579378|DEVICE|VSail 3D|"The CEREBRUM software with virtual sailing scenarios is made up of exercises of variable difficulty, designed to train different cognitive functions, in particular attention, memory, learning, cognitive estimates, working memory, executive functions, motor abilities and language. The different degrees of difficulty are designed to adapt to the user's functional diagnosis. The operator who conducts the intervention must adapt the difficulty level to the user's residual abilities, so that the exercises are neither too easy nor too complex. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback, and suggestions of practical homework related to the cognitive function trained during the session that the individual should try during daily life."
214358442|NCT06579378|OTHER|WEB-Health|The intervention includes a series of 3 webinars focused on active ageing promotion. In particular, each webinar will regard topics related to healthy lifestyle, such as physical activity in old age, effective communication, stress management, technologies and health. Each webinar will be conducted by a mental health professional, and it will be delivered in real-time in a group (plenary).
214358443|NCT01825213|DEVICE|Multispectral CT of the liver|Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
214358444|NCT01019876|DRUG|Fludarabine|
214358445|NCT01019876|DRUG|Cyclophosphamide|
215082787|NCT02698904|BEHAVIORAL|Guided Relaxation Technique|
215082788|NCT02698904|OTHER|Documentary Movie|
214969709|NCT02541864|DRUG|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
214969710|NCT00561938|PROCEDURE|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
214969711|NCT00561938|PROCEDURE|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
214969712|NCT02653911|OTHER|Acupuncture|Hwato Brand, Suzhou Medical Appliance Factory, China
214969713|NCT02653911|OTHER|Sham-acupuncture group|Hwato Brand, Suzhou Medical Appliance Factory, China
214969714|NCT01679392|DRUG|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
214969715|NCT03243305|DRUG|AMPHORA|non-hormonal contraceptive vaginal gel
214969716|NCT01155622|PROCEDURE|Endovascular Cooling|Infusion of \<8°C cold saline followed by the implantation of the Icy 9.3F 38-cm catheter (ZOLL Medical Corporation, Chelmsford, MA) placed in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). Cooling was set at a maximum rate with a target temperature of 32°C or 34°C according to randomization.
214969717|NCT04781296|DEVICE|CT with a photon-counting detector|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
214969718|NCT03130374|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
214969719|NCT01523145|BEHAVIORAL|Rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
214969720|NCT01523145|OTHER|Control Group|usual follow-up Standard follow-up at the participating heart center
214969721|NCT01519011|DRUG|oral azacitidine|oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
214969722|NCT01519011|DRUG|oral azacitidine|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
214969723|NCT05251116|DEVICE|FreeStyle Libre|FreeStyle Libre 2 continuous Glucose Monitoring System
214969724|NCT04718480|DRUG|Placebo|po placebo tablets
214969725|NCT04718480|DRUG|Fluvoxamine|po fluvoxamine tablets
214969726|NCT04977141|OTHER|Decisional Conflict Scale|Decisional Conflict Scale
214969727|NCT03964077|DIAGNOSTIC_TEST|Neurogenic Bladder Symptom Score Questionnaire|Neurogenic Bladder Symptom Score Questionnaire is a self-reported 24 item questionnaire.
214969728|NCT01655719|DRUG|Pioglitazone|
214969729|NCT03425318|DEVICE|CNAP|Application of CNAP in patients with ARDS
214969730|NCT00757393|DIETARY_SUPPLEMENT|Vitamin D + Calcium + Exercise program|Subjects is this arm of the study will receive a) a supplementation with vitamin D3, 1000 IU daily b) a dietary calcium intake set at DRI for age and a supplement used as needed to meet the requirement and c) a weight bearing exercise program appropriate for the underlying medical condition
214358446|NCT01019876|DRUG|Busulfan|
214969731|NCT00757393|DRUG|Vitamin D + Calcium + Exercise program + Humatrope|Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
214969732|NCT05171010|OTHER|no study-based therapeutic interventions|no study-based therapeutic interventions
214969733|NCT02993861|OTHER|Anti-epileptics|
215082789|NCT03009643|DRUG|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
215082790|NCT03009643|DEVICE|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
215082791|NCT03009643|DEVICE|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
215082792|NCT04596332|OTHER|no intervention measures|Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
215082793|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
215082794|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
215082795|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
215082796|NCT01376479|BIOLOGICAL|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
215082797|NCT01376479|BIOLOGICAL|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
215082798|NCT01376479|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
215082799|NCT02252809|DRUG|adalimumab|
215082800|NCT02252809|DRUG|methylprednisolone|
215082801|NCT02513823|DIETARY_SUPPLEMENT|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
215082802|NCT04766385|DRUG|KHK7791|oral administration
215082803|NCT03353922|DRUG|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
215082804|NCT03353922|DRUG|Placebo Oral Tablet|sugar pill
215082805|NCT04304170|DIETARY_SUPPLEMENT|VES002|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
215082806|NCT04304170|OTHER|Placebo|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
215082807|NCT00740714|DRUG|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
215082808|NCT00740714|DRUG|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
215082809|NCT03628638|OTHER|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
215082810|NCT03688555|DRUG|ACT-774312|ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
215082811|NCT03688555|DRUG|Placebo|Matching placebo hard gelatin capsules
215082812|NCT05204056|DRUG|iced normal saline|Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy
215082813|NCT05204056|DRUG|Tranexamic acid injection|20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
215082814|NCT05204056|OTHER|Cocktail (composing by Ropivacaine, Morphine and Epinephrine) perfusion|Cocktail was formulated during the operation by mixing Ropivacaine 150mg, Morphine 10mg and Epinephrine 1mg, then normal saline was used to dilute the mixture to 60ml. Then the cocktail mixture was applied for the joint cavity perfusion.
215082815|NCT06158230|DRUG|Pizotifen|Pizotifen will be given only at night time to avoid daytime somnolence. Starting dose will be 0.5mg then gradually increased to 1.5 mg
215082816|NCT06158230|DRUG|Amitriptyline-propranolol|"Amitriptyline will be given at bedtime only, starting at 10 mg daily and gradually increasing to 25 mg daily.~Propranolol will be started in 40 mg daily in divided doses, which gradually increases to 80 mg daily in divided doses"
215082817|NCT05732883|DRUG|Dexamethasone|Dexamethasone injection
215082818|NCT05732883|DRUG|Normal saline|Placebo
215082819|NCT00208520|DRUG|Carbamazepine|
215082820|NCT00208520|DRUG|Lamotrigine|
215082821|NCT00208520|DRUG|Levetiracetam|
215082822|NCT00346840|DRUG|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
214358447|NCT01019876|DRUG|Alemtuzumab|
214358448|NCT01019876|DRUG|Rabbit Anti-thymocyte Globulin|
214358449|NCT01019876|DRUG|Horse Anti-thymocyte Globulin|
214358450|NCT06543446|PROCEDURE|ICD implantation|Surgical implant of ICD device
214487489|NCT05512910|DRUG|Minocycline|200 mg minocycline orally or via feeding tube, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting. Considering the risk of difficulty in feeding tube before EVT, minocycline administered within one hours after EVT is acceptable.
214487490|NCT05993689|OTHER|BUNDLE|An integrated model of community-based doulas and clinical obstetric providers
215082823|NCT00346840|DRUG|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
215082824|NCT00346840|DRUG|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
215082825|NCT00346840|DRUG|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
215082826|NCT01735071|DRUG|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
214358451|NCT01565707|DRUG|Solifenacin Succinate Suspension|Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
214487491|NCT05993689|OTHER|Usual Care|Standard of care for pregnancy and pregnancy-related issues by the obstetric provider
214969734|NCT01715948|DEVICE|CROS hearing aid|Participants were randomly assigned to be fitted with the CROS hearing aid either at the end of the first visit or at the end of the second visit. They were given a 2-week trial with the CROS and asked to refrain from wearing their BAHD during that time. At the end of the first visit, four participants were fitted with the CROS hearing aid and were subsequently tested with this device on their second visit, at which time they were instructed to use the BAHD for the next 2 weeks. This protocol was reversed in the other four participants, with testing after each device experience. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
214969735|NCT01715948|DEVICE|Bone-anchored hearing device (BAHD)|All participants had received BAHD implantation prior to the study. They were randomly selected to continue wearing their BAHD for 2 weeks following the end of the first visit or the end of the second visit. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
214487492|NCT06643208|DRUG|TACE-HAIC, Envafolimab and Lenvatinib|TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib
214969736|NCT00625456|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10\^5 pfu/kg to 3 x 10\^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
214969737|NCT01693913|BEHAVIORAL|cognitive behavioral exercise and nutrition over|
214969738|NCT01693913|BEHAVIORAL|nutrition and exercise education|
214969739|NCT05609396|BEHAVIORAL|Behaviorally enhanced reminder letter|Behavioral interventions to increase FIT-based colorectal cancer screening uptake
215082827|NCT01735071|DRUG|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
215082828|NCT04979403|OTHER|Physiotherapy|Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
215082829|NCT06093178|BEHAVIORAL|Human coach-led digital health platform|This is an existing commercial digital platform developed by our technology partners (Empeal). The platform comes in the form of a smartphone app available via Android and Apple devices. Participants will communicate with their coach through the app via video, audio or text. Surveys are conducted on the app. Support content is also available through this app.
215082830|NCT00183963|DRUG|Tamoxifen|20mg
215082831|NCT00183963|DRUG|Fulvestrant|250mg
215082832|NCT00183963|DRUG|Fulvestrant|500 mg IM
215082833|NCT04671082|DRUG|Tolperisone Hydrochloride|TID
215082834|NCT04671082|DRUG|Placebo|TID
215082835|NCT03303898|PROCEDURE|Blood sampling|sampling of 7 blood tubes
215082836|NCT04206475|OTHER|rehabilitation|"the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes."
215082837|NCT04206475|OTHER|Intensive Memory-Focused Training Program (IM-FTP)|During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
215082838|NCT01955434|DRUG|Cyclophosphamide|Given PO
215082839|NCT01955434|OTHER|Laboratory Biomarker Analysis|Correlative studies
215082840|NCT01955434|OTHER|Pharmacological Study|Correlative studies
215082841|NCT01955434|OTHER|Quality-of-Life Assessment|Ancillary studies
215082842|NCT01955434|DRUG|Smac Mimetic LCL161|Given PO
215082843|NCT03426475|PROCEDURE|interprof ACT measures|Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
215082844|NCT02666456|OTHER|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
215082845|NCT03770494|DRUG|LY3405105|Administered orally.
214358452|NCT01565707|DRUG|Placebo|Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
215082846|NCT05445908|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
214358453|NCT01565707|BEHAVIORAL|Urotherapy|Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
214969740|NCT04928456|OTHER|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) involves a number of hands-on techniques that are meant to address somatic dysfunction in the body as a part of the osteopathic approach to treating patients. There will be five techniques in total used in the study treatment plan.
214969741|NCT05861414|BEHAVIORAL|EWM-T|"This paradigm was adapted from the n-back program described by Jaeggi et al. (2009) and comprised an affective dual n-back task consisting of a series of trials, each of which simultaneously presented a face (for 500 ms) on a 4 × 4 grid on a monitor. Intermediate interval 2500ms, during which, Participants press a button to determine if the current face or position is consistent with the first n. If the position is the same, press F; if the face is the same, press J; if the face and position are not the same, do not react.~The faces used in this training were selected from the Chinese Facial Emotional Picture System (CFAPS), and 12 faces (six male and six female) with fear, anger, disgust, and sadness were selected as n-back experimental materials."
215082847|NCT05445908|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
215082848|NCT00176176|DEVICE|EEG|
215082849|NCT00886119|DEVICE|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
215082850|NCT00886119|DEVICE|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
215082851|NCT02998047|DRUG|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.
215082852|NCT01339715|PROCEDURE|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
215082853|NCT01480609|DRUG|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
215082854|NCT00554398|DRUG|MK-0518 400mg twice a day|Raltegravir, MK-0518
215082855|NCT04042272|DIAGNOSTIC_TEST|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
215082856|NCT06480175|PROCEDURE|cervical plexus block|patients will receive cervical radiofrequency ablation on both sides then after 2 weeks they will be readmitted and will receive superficial cervical plexus block on one side only
215082857|NCT01367223|DIETARY_SUPPLEMENT|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
215082858|NCT01367223|DIETARY_SUPPLEMENT|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
215082859|NCT02743780|DRUG|MGV354 ophthalmic suspension|
215082860|NCT02743780|DRUG|MGV354 placebo|Inactive ingredients used as placebo comparator
215082861|NCT01294462|DRUG|Ticagrelor|90 mg, oral dose twice daily
215082862|NCT01294462|DRUG|Clopidogrel|75 mg, oral dose once daily
215082863|NCT01294462|DRUG|Acetylsalicylic acid ASA|Low Dose ASA
215082864|NCT06157320|DRUG|Shen-Fu|Within 24 hours of sepsis diagnosis, patients received a daily intravenous infusion of 100 ml of Shenfu Injection for a continuous duration of 7 days.
215082865|NCT06157320|DRUG|Norepinephrine (NE)，antibiotics，fluid resuscitation|empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine (NE)), which are employed to maintain mean arterial pressure above 65 mmHg and reduce the risk of fluid overload
215082866|NCT05282576|OTHER|NPF Group|Participants allocated to the experimental group completed until discharged, neurophysiological facilitation(NPF) techniques in addition to conventional physiotherapy.
215082867|NCT05282576|OTHER|Control Group|Critical ill patients was applied their conventional physiotherapy which includes chest physiotherapy and mobilization until discharged
214358454|NCT01765634|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) each week, four times for a cycle.
214358455|NCT01765634|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
214969742|NCT02411240|DEVICE|Air filtering|The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
214969743|NCT00646373|OTHER|Low Prime|The CPB circuit will be primed with mannitol (50 g of 20% solution) and crystalloid solution (Ringer's lactate) for a total volume of approximately 1200 ml.
214969744|NCT00624000|DRUG|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
214969745|NCT01005576|DRUG|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
214969746|NCT05231343|PROCEDURE|Dual Mini-fragment Plating|Patients randomized to dual mini-fragment plating will undergo clavicle fixation using any configuration of 2.0-mm, 2.4-mm and 2.7-mm limited contact dynamic compression (LC-DCP), locking compression (LCP) or reconstruction plates (i.e., 2.4-mm superior and 2.7-mm anteroinferior). One of the two plates used must be a LC-DCP or LCP plate. Surgeons will contour the mini-fragment plate intraoperatively to fit each patient's anatomy.
214969747|NCT05231343|PROCEDURE|Single Precontoured Plating|Patients randomized to a single plate construct will undergo fixation using an anatomically precontoured (superior or anterior-inferior) clavicle plate.
214969748|NCT00089518|DRUG|Valsartan|
214969749|NCT00055120|DRUG|Emtricitabine/tenofovir disoproxil fumarate|
214969750|NCT00055120|DRUG|Lopinavir/ritonavir|
214969751|NCT00055120|DRUG|Stavudine|
214969752|NCT02492893|OTHER|Hatha yoga|
214969753|NCT04432883|DEVICE|Active Comparator: Experimental: Active cathodal tDCS + language training|"Cathodal tDCS raises neuronal membrane potentials, leading to decreased probability of depolarization from incoming stimuli.~Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment."
214969754|NCT04432883|BEHAVIORAL|Sham Comparator: Placebo cathodal tDCS + Speech and language|Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment. .
214969755|NCT01129245|DRUG|Celebrex|400 mg PO daily intermittently based on hormone and ultrasound findings
215082868|NCT03002688|OTHER|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
214358456|NCT00048516|DRUG|paricalcitol capsule|
214969756|NCT01129245|DRUG|Placebo|Placebo identical to celecoxib
214969757|NCT06015971|DIETARY_SUPPLEMENT|omega-3|Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet
214969758|NCT06015971|DIETARY_SUPPLEMENT|Standard|Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet
214969759|NCT03644420|DIAGNOSTIC_TEST|Clinical evaluation|Functional scores for the pathological joint will be determined
215082869|NCT04253990|PROCEDURE|Precut EMR|"For treating of 10\~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
215082870|NCT04253990|PROCEDURE|Conventional MER|EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current.
215082871|NCT06375642|DRUG|Adebrelimab|Adebrelimab, Surufatinib and HAIC
214487493|NCT04353492|BIOLOGICAL|Ofatumumab|Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)
214487494|NCT05568355|BEHAVIORAL|GET2HOME Intervention|Intervention bundle designed to improve discharge effectiveness
214487495|NCT01198431|BEHAVIORAL|Sleep duration|Duration of sleep per night
214487496|NCT03694262|DRUG|Rucaparib|Rucaparib 600mg orally twice daily by continuous dosing
214487497|NCT03694262|DRUG|Bevacizumab|15mg/kg IV on day 1 of every cycle
214487498|NCT03694262|DRUG|Atezolizumab|1,200mg IV on day 1 of every cycle
214969760|NCT03644420|DIAGNOSTIC_TEST|Radiology|
214969761|NCT03644420|DIAGNOSTIC_TEST|Dynamic contrast-enhanced magnetic resonance imaging|Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.
214969762|NCT03644420|DIAGNOSTIC_TEST|Evaluation of histological status|Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
214969763|NCT01497067|DEVICE|ACRYSOF CACHET Phakic Lens (L-series)|Intraocular lens for the treatment of moderate to high myopia
214969764|NCT03130933|PROCEDURE|Lower third molar surgery|"All surgical procedures were performed under local anaesthesia (alveolar nerve block) with 2% lidocaine chloride. The full-thickness mucoperiosteal flap was raised using buccal approach, adequate osteotomy was done using micromotor handpiece and bur, and third molar removal was finished using elevating instruments in the appropriate direction. Removal of bone dust, granulation tissue and broken tooth fragments were done in order to wound toileting. Gentle, sterile saline irrigation was done on the end.~Primary closure of the surgical area was done using 3-0 silk sutures."
214969765|NCT03130933|DRUG|Amoxicillin 500 Mg|The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
214969766|NCT03130933|OTHER|Placebo|The control subgroups received a prophylactic single dose of placebo one hour prior the lower third molar surgery.
214969767|NCT01406314|DRUG|GSK2315698|Intravenous infusion for approximately 48hours followed by subcutaneous injection
215082872|NCT05513664|DRUG|Osimertinib|80 or 160 mg/qd
214358457|NCT04302350|PROCEDURE|nitrous oxide|During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.
214487499|NCT01401231|BEHAVIORAL|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
214487500|NCT01401231|OTHER|Usual care|Continued usual care (could include referral for medication or psychotherapy)
214487501|NCT01773993|DRUG|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
214487502|NCT05010746|DEVICE|Innovalve TMVR system|Innovalve TMVR system
214487503|NCT04664881|DEVICE|SmartHeart Device|A body-worn device that allows an individual to immediately transmit a 12-lead ECG from anywhere and anytime, using a smartphone application to a physician's office, hospital or monitoring center where designated on-call staff interpret the ECG and make recommendations.
214487504|NCT04153994|PROCEDURE|Erector Spinae Plane Blockade|The ESPB is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
214487505|NCT05817370|BEHAVIORAL|Enhanced Training on screening and treatment of HSIL (e-STH)|Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
214487506|NCT04400071|BEHAVIORAL|Active Music Engagement|Weekly 45-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
214969768|NCT03574077|BEHAVIORAL|Instant Messaging (IM)|Tailored automatic, fix- scheduled regular messages will be sent and counselors will interact with smokers in the intervention group through WhatsApp since initial contact and until 2-month after baseline. The interaction will follow the principle of Motivational Interviewing, which will focus on enabling change through the enhancement of intrinsic motivation and the exploration and resolution of ambivalence. Counsellors will identify discrepancies between participants' thought and their action, support their autonomy, be empathetic towards the participant, avoid confrontation, and adjust to resistance. Any smokers who do not use IM or refuse to receive IM messages will be contacted via SMS messages or telephone calls. For smokers who do not respond to regular messages, 3 additional prompt messages will be sent in the 1st month to initiate a conversation.
214969769|NCT03574077|BEHAVIORAL|AWARD advice|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
214969770|NCT03574077|BEHAVIORAL|NRT sampling|One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.
215082873|NCT04900948|DRUG|Pimecrolimus cream 1%|Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
215082874|NCT04900948|DRUG|cream 0.1% methylprednisolone aceponate|Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
215082875|NCT06107439|BIOLOGICAL|Bood and urine sampling|Bood and urine sampling
215082876|NCT01041300|DEVICE|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).~Total Duration of device: 15 minutes"
214358458|NCT01811550|OTHER|Glycemic Control|
214358459|NCT03024073|PROCEDURE|BB-Phaco|Phacoemulsification with bilateral bifocal lenses implantation
214358460|NCT03359980|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donors to the patients
214358461|NCT02768896|BEHAVIORAL|Baseline|Patients will walk naturally with EEG measuring brain waves
214969771|NCT03574077|BEHAVIORAL|Active referral|SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
214969772|NCT03574077|BEHAVIORAL|SMS messaging|All smokers will receive fix-schedule general messages on SC through short message service (SMS) since their initial participation until 2-month after baseline. These messages include: (a) brief health warning, (b) benefit of quitting, (c) methods to quit and to cope with craving, and (d) SC services and their effectiveness. General SC messages will be sent twice per week in the 1st month and once per week in the 2nd month after joining this study.
214969773|NCT03919123|OTHER|Evaluation of laparoscopic promontofixation|Evaluation of Functional Outcomes and Quality of Life After Laparoscopic Promontofixation (PFL). Unicentric Retrospective Cohort Study (PeSuLife)
214969774|NCT03742986|DRUG|Nivolumab 360mg|Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)
214358462|NCT02768896|BEHAVIORAL|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
214969775|NCT03742986|DRUG|Paclitaxel 80mg/m^2|Paclitaxel 80mg/m\^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)
215082877|NCT01041300|DEVICE|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).~Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).~Total Duration with Device: 2 hours and 30 minutes"
215082878|NCT02659553|PROCEDURE|steatosis|Liver Transplantation with graft steatosis
215082879|NCT03820453|DIETARY_SUPPLEMENT|Tribulus Terrestris|The experimental arm will receive a dietary supplement to increase the libido and sexual function
215082880|NCT03820453|OTHER|Placebo treatment|The control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics
215082881|NCT01140568|DRUG|nilotinib|400mg po (orally) BID (twice daily)
215082882|NCT01216943|DRUG|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
215082883|NCT01400243|DRUG|Nicotine|Nicotine patch 7mg
214969776|NCT03742986|DRUG|Doxorubicin 60mg/m^2|Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
214969777|NCT03742986|DRUG|Cyclophosphamide 600mg/m^2|Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)
215082884|NCT01400243|DRUG|Placebo Patch|Placebo patch
214969778|NCT03742986|DRUG|Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2|Paclitaxel 80mg/m\^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m\^2 on Day 1 of every 21 day cycle (Cycle 1-4)
214969779|NCT03742986|DRUG|Trastuzumab 8mg/kg and 6 mg/kg|Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4
214969780|NCT03742986|DRUG|Pertuzumab 840mg and 420mg|Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
214969781|NCT01598610|DEVICE|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
214969782|NCT05826210|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was performed in all patients with or without SO.
215082885|NCT05941338|DRUG|Tirelizumab ,+Carboplatin+albumin-bound paclitaxel|Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel
215082886|NCT01223898|DRUG|Tasigna|
215082887|NCT05615857|DEVICE|Use of Endocuff during colonoscopy|We will be adding the Endocuff device to the proximal end of the colonoscope, adding an additional tool to facilitate the visualization of the difficult-to-see mucosal areas as well as the rectum. There will be no need for retroflexion to evaluate the colon
215082888|NCT03400657|PROCEDURE|Multi-disciplinary Treatment|due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
214358463|NCT02768896|BEHAVIORAL|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
214358464|NCT02768896|BEHAVIORAL|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
214487507|NCT04400071|BEHAVIORAL|Audio Storybooks|Weekly 45-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
214487508|NCT02231749|BIOLOGICAL|Nivolumab|
214487509|NCT02231749|BIOLOGICAL|Ipilimumab|
214487510|NCT02231749|DRUG|Sunitinib|
214969783|NCT04346199|DRUG|Acalabrutinib|Acalabrutinib- administered orally
215082889|NCT06508606|DRUG|AK117|AK117: 45mg/kg (D1, IVGTT, Q3W maintained for one year or until progression or intolerable toxicity occurred
214358465|NCT06489613|DIAGNOSTIC_TEST|M protein detection by iMS-LC Assay|"iMS-LC Assay (intact M-protein Screening-Light Chain Assay) technology is a new method for the specific identification of M-proteins in peripheral blood, based on mass spectrometry recognition of intact clonal immunoglobulin light chains. Combined with AI algorithm models, M-proteins can be easily distinguished from the polyclonal background, enabling automated identification and quantitative analysis of M-proteins.~Previous studies have shown that the detection limit of the iMS-LC Assay is several times higher than that of IFE. Additionally, the iMS-LC Assay requires only 5 μL of peripheral blood serum for detection, offering advantages over traditional methods in terms of higher sensitivity, non-invasiveness, lower sample volume requirements, reduced detection costs, and higher throughput."
214358466|NCT02243033|DEVICE|MR-guided laser focal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
214358467|NCT00149058|DRUG|Erythropoietin|
214358468|NCT03487250|DEVICE|TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
214358469|NCT03516331|DRUG|FDL176 & FDL169 coadministration|CFTR corrector and potentiator
214358470|NCT03524040|DEVICE|SEB-250|Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
214969784|NCT00653367|PROCEDURE|Nerve section|Intercostal nerve is divided during surgery
214969785|NCT05447845|DIAGNOSTIC_TEST|Computerized visual acuity assessment program|Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program
214969786|NCT00228228|BIOLOGICAL|T cell vaccination|
214969787|NCT02921945|BIOLOGICAL|SCT800|recombinant human coagulation factor VIII
214969788|NCT05105191|DIAGNOSTIC_TEST|Roche Cobas® Liat Influenza A/B & RSV assay|Performance of a rapid molecular assay to diagnose influenza and RSV infections
214969789|NCT03812900|DRUG|Echinacea purpurea alcoholic extract|Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
215082890|NCT06508606|DRUG|anti-EGFR|anti-EGFR:initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred
214358471|NCT04074980|DIAGNOSTIC_TEST|Venous and Fingerstick blood draws|Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
215082891|NCT02279498|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
215082892|NCT02279498|DRUG|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
215082893|NCT01048866|DRUG|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
215082894|NCT01048866|DRUG|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
215082895|NCT01048866|DRUG|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
215082896|NCT04859244|DRUG|GS-441524|750 mg administered as a solution
215082897|NCT00377546|DRUG|Nepafenac|
214358472|NCT04074980|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to collect blood samples from subjects
214487511|NCT03582592|BEHAVIORAL|Fluid Distribution Timetable|It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
214969790|NCT00262652|DRUG|sodium pyruvate|
214969791|NCT02696395|DEVICE|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
214969792|NCT02696395|DEVICE|DePuy Corail® femoral stem + Deltamotion® acetabular component|
215082898|NCT00377546|DRUG|Ketorolac LS, Bromfenac|
215082899|NCT00219037|DRUG|aliskiren|
215082900|NCT00165542|OTHER|A PROTEIN level|
214969793|NCT05449171|OTHER|high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D|Patients will take an association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, from the first visit at the experimental center (within the 12th week of gestation) for 3 months.
214969794|NCT05397197|OTHER|Electroencephalography|experimental task, neuropsychological evaluation, clinical exam
215082901|NCT05110313|BIOLOGICAL|TILDRAKIZUMAB|"ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle."
215082902|NCT01779505|BIOLOGICAL|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
214358473|NCT00364429|DRUG|[123]I-CNS 1261|Study Drug
214358474|NCT00364429|DRUG|Lorazepam|Study Drug
214358475|NCT00364429|DRUG|Risperidone|Study Drug
214358476|NCT02012491|DRUG|Misoprostol|
214358477|NCT02012491|DRUG|Mifepristone|
214358478|NCT06447857|OTHER|Cardiac MRI|This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University. All patients underwent CMR.
214358479|NCT06078904|DRUG|Colchicine 0.5 MG|Colchicine 0.5 MG, one pill a day, oral intake
214358480|NCT06078904|DRUG|Colchicine 0.375 MG|Colchicine 0.375 MG, one pill a day, oral intake
214358481|NCT06078904|DRUG|Colchicine 0.25 MG|Colchicine 0.25 MG, one pill a day, oral intake
214358482|NCT06078904|DRUG|Placebo|Placebo, one pill a day, oral intake
214358483|NCT03762473|DRUG|Study Group|Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
214358484|NCT03762473|DRUG|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of \< 1 at month 1, and BK data available and month 2,3, 6,9,12.
214358485|NCT04144842|BIOLOGICAL|ATOR-1017|ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)
214487512|NCT05727332|BEHAVIORAL|Single-Sprint Training|A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
214969795|NCT00485069|DRUG|ROP|Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
215082903|NCT04150952|OTHER|HRV-based training|Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
214358486|NCT01542606|DEVICE|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
214487513|NCT03820544|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with SEMS placement
214487514|NCT03820544|OTHER|Standard of care|Undergo standard of care surgical resection
214487515|NCT03898596|DIAGNOSTIC_TEST|ECG|An ECG collects superficial readings of heart activity
214969796|NCT00485069|DRUG|ROP+L-Dopa|Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
214358487|NCT01821261|DEVICE|Mouth Rinse 19668-012|20 ml of experimental mouth rinse 19668-012 for 30 seconds, twice daily
214969797|NCT03805737|OTHER|Amulez and sunlight|Amulez and sun exposure for 2 hours
215082904|NCT04150952|OTHER|TRAD training|Traditional endurance training
214358488|NCT01821261|DRUG|Mouth Rinse 500347078842|10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
214358489|NCT01821261|DRUG|Toothpaste 035000513007|Approximately one inch of toothpaste 035000513007, twice daily
214487516|NCT04625023|OTHER|Observational|Retrospective cohorts and Prospective observation of standard clinical practice
214487517|NCT05541926|BEHAVIORAL|e-Connect|Implementation of the e-Connect system
214358490|NCT04364373|PROCEDURE|Left colon resection|"This procedure is performed for tumours in splenic flexure and proximal and descending colon.~Left colic artery is divided at its origin. Sigmoid arteries and superior rectal arteries are preserved. Inferior mesenteric vein is divided at the lower border of the pancreas. The colon is divided about 10 cm proximal and distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment a handsewn or stapler end-to-end or side-to-side colonic anastomosis is performed."
214358491|NCT04364373|PROCEDURE|Sigmoid colon resection|"This procedure is performed for tumours in sigmoid colon. Corresponding sigmoid arteries are divided at their origin. Left colic artery and superior rectal artery are preserved. Inferior mesenteric vein is divide close to the left colic artery. Proximal and distal margin compose 10 cm from the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph nodes dissection. After removal of the resected colonic segment a handsewn end-to-end or side-to-side or stapler colonic anastomosis is performed."
214487518|NCT06498258|OTHER|Pozitif Psikoterapi Denge Modeli Temelli Psikoeğitim|In this study, it can be said that adopting a loving, connected and balanced state of mind in the face of the difficulties experienced and responsibilities undertaken by caregivers will increase the joy, meaning and self-sufficiency in life and as a result, it can positively contribute to their level of well-being. All these results are important for caregivers to be able to recognise their own resources, to maintain their life balance, to develop a positive perspective towards themselves, to make subjective evaluations and to recognise their strengths.
214487519|NCT06550232|DRUG|Papaverine|Within 30-minutes prior to catheter insertion, women in the intervention group will receive IV-papaverine 80 mg in 100 ml 0.9% saline
214487520|NCT06550232|OTHER|placebo|I.V Sallne
214358492|NCT04364373|PROCEDURE|Distal sigmoid colon resection or anterior resection|"This procedure is performed for tumours in distal sigmoid colon or rectosigmoid junction. Superior rectal artery is divided below the origin of left colic artery. Left colic artery is preserved. Inferior mesenteric vein is divide close to the left colic artery. The colon is divided about 10 cm proximal and 5 cm distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment handsewn or stapler colo-rectal anastomosis is performed."
214358493|NCT01053182|PROCEDURE|Ivor-Lewis Esophagectomy|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
214358494|NCT01053182|PROCEDURE|Sweet Esophagectomy|Esophagectomy through Left Side Thoracotomy
214969798|NCT03805737|OTHER|Amulez and red light treatment|Amulez and red light treatment for 10 minutes
214969799|NCT01162616|DIETARY_SUPPLEMENT|labeled iron solutions|labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
214969800|NCT04009265|COMBINATION_PRODUCT|adjuvant treatment|adjuvant treatments include chemotherapy or chemoradiotherapy
214969801|NCT03227718|BEHAVIORAL|VOR and coordination measurements|measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
214969802|NCT03159598|DEVICE|Tissue Glu|Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
214969803|NCT03159598|DEVICE|Drain|Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
215082905|NCT03645304|DRUG|Ropivacaine|"Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .~Ropivacaine is local analgesics."
214358495|NCT00126438|DRUG|123I-mIBG (meta-iodobenzylguanidine)|Single Dose
214358496|NCT00000502|PROCEDURE|cardiopulmonary resuscitation|
214358497|NCT04824482|OTHER|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
214358498|NCT04824482|OTHER|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
214358499|NCT01420848|OTHER|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
214358500|NCT01420848|OTHER|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
214358501|NCT05737082|DRUG|HCP2201|Take 2 tablets once per period
214358502|NCT05737082|DRUG|RLD2205|Take 2 tablets once per period
214358503|NCT05737082|DRUG|RLD2206|Take 1 tablet once per period
214358504|NCT04470245|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI)|Our study will include healthy volunteers (to refine the scanning sequence) and patients undergoing surgery for CTS. Patients will be scanned before and after their operation using cutting-edge diffusion MRI techniques.
214358505|NCT05253872|OTHER|The MelaCare intervention|"The primary principles applied will be:~* Meta-cognitive strategies and normalization of emotions~* Self efficacy related to SSE and knowledge on when to seek a doctor for clinical examination~The intervention will include 4 components:~* An educational booklet~* Doctor consultation to ensure correct SSE skills and compliance to the protocol~* 3-5 sessions with a experienced and specially trained melanoma nurse~* Use of patients' answers from the Patient Reported Outcome 'Functional Assessment of Cancer Treatment - Melanoma' (FACT-M) at the nurse sessions to address current emotional and/or physical sequelae."
214358506|NCT03254680|DIETARY_SUPPLEMENT|Turmeric|Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
214358507|NCT05290558|DRUG|Bu Shen Yi Jing Pill|"Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
214358508|NCT05290558|DRUG|Placebo Drug|"Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
214358509|NCT06445491|OTHER|Control order|Participants will perform an initial baseline of tests, order of 1- 2- 3
214358510|NCT06445491|OTHER|Randomized sequence|the testing order will be randomized for follow up testing.
214969804|NCT03159598|OTHER|Questionnaires|Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
214487521|NCT06152809|BIOLOGICAL|Cytokine-Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
214358511|NCT03711773|OTHER|Group Physical Therapy Classes|Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
214969805|NCT03573635|DEVICE|Supratube|Aspiration of orotracheal secretions with supratube device
214969806|NCT03573635|OTHER|Reference|Usual aspiration with any other device
214969807|NCT06560684|DRUG|Oral F/TDF Pills|For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated RAI.
214969808|NCT06560684|DRUG|TFV rectal douche|For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated rectal anal intercourse (RAI).
214969809|NCT04891302|DRUG|Clevudine|Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
214969810|NCT04891302|DRUG|Placebo|Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
214969811|NCT03747705|OTHER|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (\>18) male and female with, intractable epilepsy, on stable doses of antiepileptic drugs (AEDs), will participate in a 4-week observation period during which no change in the drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window. Between 6:00-22:00 During the study, patients will fill a seizure diary daily.
214969812|NCT02989402|DRUG|Rivastigmine|15 cm\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day
214358512|NCT06021717|DRUG|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
214358513|NCT06021717|DRUG|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
214969813|NCT03066830|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
215082906|NCT03645304|DRUG|0.9% saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
214358514|NCT01389973|DRUG|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
214358515|NCT01389973|DRUG|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
214358516|NCT01389973|DRUG|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
214358517|NCT01389973|DRUG|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
214358518|NCT02198027|DRUG|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
214358519|NCT02198027|OTHER|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
214969814|NCT03066830|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
214969815|NCT03066830|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
214969816|NCT03066830|DRUG|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
214969817|NCT06201039|DRUG|0.5% Lidocaine Hydrochloride|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI block will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.
214969818|NCT06201039|DRUG|0.9% Normal Saline|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 72 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI placebo will start immediately at a speed of 4ml/h containing 0.9% normal saline + 1:400000 adrenaline.
215082907|NCT03645304|DEVICE|ON-Q Painbuster Silver Soaker|ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA)
214358520|NCT00375687|DRUG|Triptorelin|
214358521|NCT02421614|OTHER|high-protein low-carbohydrate diet with high olive oil|
214358522|NCT02421614|OTHER|high-protein low-carbohydrate diet with high sunflower oil|
214358523|NCT00786929|PROCEDURE|Catheter drainage|
214358524|NCT00786929|DRUG|Conservative treatment|
214358525|NCT00696254|BEHAVIORAL|Nerve excitability measurement|
214358526|NCT03375944|OTHER|Rehabilitation|"The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population."
214358527|NCT00428350|DRUG|Quetiapine Fumarate (Seroquel)|
215082908|NCT03913195|DRUG|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
214358528|NCT02626780|DEVICE|GID SVF-2|Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.
214358529|NCT03080129|DIETARY_SUPPLEMENT|Fresubin energy|dietary protein energy supplement
214358530|NCT03456700|DRUG|Auranofin|Given PO
214358531|NCT03456700|OTHER|Laboratory Biomarker Analysis|Correlative studies
215082909|NCT05901324|RADIATION|intensity-modulated radiotherapy (IMRT)|1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.
215082910|NCT01113034|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
214358532|NCT03456700|DRUG|Sirolimus|Given PO
214358533|NCT04154787|DRUG|LNP023|Investigation of LNP023
214487522|NCT06152809|BIOLOGICAL|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous (under the skin) injection per protocol.
214487523|NCT06152809|DRUG|Venetoclax|Selective inhibitor of BCL-2 protein, 10, 50, or 100 mg tablets, via orally per standard-of-care.
214487524|NCT02263274|DEVICE|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
214487525|NCT02828150|DIETARY_SUPPLEMENT|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure \[Harris-Benedict\] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI \>30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)
214969819|NCT05221970|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
215082911|NCT01113034|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
215082912|NCT03497364|DRUG|bupivacaine|0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173\~174cm, 1.65 ml for 170\~172cm, 1.6 ml for 168\~169cm, 1.55 ml for 165\~167cm, 1.5 ml for 163\~164cm, 1.45 ml for 160\~162cm, 1.4 ml for 158\~159cm, 1.35 ml for 155\~157cm, 1.3 ml for 153\~154cm, 1.25 ml for 150\~152cm, 1.2 ml for 148\~149cm)，1.15 ml for 145\~147cm).
214358534|NCT04154787|DRUG|Rituximab|Comparison of rituximab dose
214358535|NCT01437449|DRUG|Docetaxel|30 mg/m² by intravenous (IV) administration
214358536|NCT01437449|DRUG|Cisplatin|30 mg/m² by intravenous (IV) administration
214358537|NCT01437449|DRUG|Cetuximab|400 mg/m² by intravenous (IV) administration, thereafter 250 IV
214487526|NCT01380743|DRUG|duvoglustat|Single oral dose
214969820|NCT05221970|BEHAVIORAL|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
214969821|NCT05221970|BEHAVIORAL|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
214969822|NCT03714464|OTHER|Whole apples|350 of whole apples containing 49g of available carbohydrate with 173ml water
214969823|NCT03714464|OTHER|Apple puree|384g of apple puree containing 44g of available carbohydrates with 224 ml water
214969824|NCT03714464|OTHER|Apple Juice|338g apple juice containing 46g of available carbohydrate with 260 ml water
214969825|NCT01383434|PROCEDURE|Bone Marrow Transplant|Matched sibling, haploidentical or matched unrelated donor bone marrow transplant following chemotherapy
214969826|NCT00045799|DRUG|Omeprazole sodium bicarbonate immediate release PWD/FS|
215082913|NCT03497364|DRUG|ropivacaine|0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173\~174cm, 2.225 ml for 170\~172cm, 2.15 0ml for 168\~169cm, 2.075 ml for 165\~167cm, 2.000 ml for 163\~164cm, 1.925 ml for 160\~162cm, 1.850 ml for 158\~159cm, 1.775 ml for 155\~157cm, 1.700 ml for 153\~154cm, 1.625 ml for 150\~152cm, 1.55 0ml for 148\~149cm, 1.475 ml for 145\~147cm)
214358538|NCT01437449|DRUG|Carboplatin|Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration
214358539|NCT03880305|DIAGNOSTIC_TEST|complete blood count|complete blood count
214358540|NCT02703675|DEVICE|Excel Cryo Cooling Collar|Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.
214358541|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination A|Combined influenza and Pfizer-BioNTech COVID-19 Vaccine
214969827|NCT00045799|DRUG|Cimetidine IV|
215082914|NCT04631965|BEHAVIORAL|Transition support service|The hospital-wide transition support service provides systematic care coordination for young patients prior to the transfer of care
214358542|NCT06178991|BIOLOGICAL|Licensed influenza vaccine|Licensed influenza vaccine
214358543|NCT06178991|BIOLOGICAL|COVID-19 Vaccine|Pfizer-BioNTech COVID-19 vaccine
214487527|NCT01380743|DRUG|rhGAA|Single intravenous infusion
214487528|NCT06292767|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
214487529|NCT05781438|BEHAVIORAL|In-home standing and walking intervention|"Parents/legal guardians will be educated on and provided an activity booklet on intensive standing and walking play activities for their infant in a 9 by 9 foot body-weight support system (BWS). Activities include: squatting play at a couch or table, cruising along and between furniture, walking with a push toy or with one or two hands held, walking without support, and kicking and throwing a soft ball.~For 16 weeks, parents/legal guardians will be encouraged to implement the parent-led, intensive standing and walking intervention using BWS for at least 5 days/week for 30-60 min/day, with weekly telehealth calls and monthly home visits to coach parents in identifying key activities and progressing the program."
214969828|NCT00765856|DRUG|Oxymorphone ER|"Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications"
214487530|NCT05072093|BEHAVIORAL|PrEP discontinuation intervention|Men taking daily oral PrEP (Truvada) will receive a monthly screener through the mobile app. If answers to screener questions indicate a participant is at risk for PrEP discontinuation, then a peer navigator will deliver a motivational interviewing intervention and a clinician will consult with the participant. These efforts are intended to avert PrEP discontinuation.
214487531|NCT05072093|DRUG|Offering of on-demand oral PrEP|For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to take it immediately before/after a sexual encounter. It is hoped that this will serve as an alternative to daily oral PrEP use that is desirable for some people.
214487532|NCT05072093|DRUG|Offering of STI PEP|All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses. At a dosage of 200 mg to be taken in a single dose ideally within 24 hours of possible exposure (e.g. condomless anal sex) and no later than 72 hours after exposure. Participants will be dispensed enough pills to allow for up to 3 weekly doses of 200mg doxycycline (i.e. 6 pills/week) for 3 months (the interval between STI testing visits).
214969829|NCT02039778|RADIATION|Stem Cell Radiotherapy (ScRT) and Temozolomide|"Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin \& the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
214969830|NCT01715233|DRUG|Docetaxel|Modified Docetaxel 40mg/m2 on Day 1
214969831|NCT01715233|DRUG|Leucovorin|Leucovorin 400mg/m2 on Day 1
214969832|NCT01715233|DRUG|Fluorouracil|Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
214969833|NCT01715233|DRUG|Cisplatin|Cisplatin (or Carboplatin) 40mg/m2 on Day 3
215082915|NCT06006624|DRUG|Exparel 30 mL|30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block
215082916|NCT06006624|DRUG|0.5% bupivacaine|5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal
215082917|NCT06006624|DRUG|Dexamethasone|10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal
215082918|NCT06006624|DRUG|iPACK block|iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block
215082919|NCT01106508|DRUG|LEQ506|
215082920|NCT06331468|DRUG|Cisplatin|A total of two IV infusions of cisplatin will be administered on Day 1 and again on Day 8 +/- 1 day. Cisplatin starting dose is 40 mg/m2. Dose reduction is allowed (30 mg/m2) as needed for management of toxicities.
215082921|NCT06331468|RADIATION|intensity modulated radiation therapy (IMRT)|given once daily Monday-Thursday, four fractions per week for 2 weeks. The radiation dose is 4.56 Gy x 8 fractions.
214969834|NCT05380154|DRUG|Botulinum Toxin A type for injection (Botulax®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects
214969835|NCT05380154|DRUG|Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.
214969836|NCT01944436|DRUG|Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)|
214969837|NCT00000237|DRUG|Buprenorphine|
214969838|NCT02198846|DEVICE|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
215082922|NCT06331468|RADIATION|high-dose-rate (HDR) brachytherapy|administered 2x weekly (allow at least 72-hours window between sessions); weekdays only for 2 weeks. The radiation dose is 7 Gy x 4 fractions.
215082923|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 40 units
215082924|NCT05320393|DRUG|OnabotulinumtoxinA|One treatment of 20 units
215082925|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 20 units
215082926|NCT01179061|DRUG|Apelin|"Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.~Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.~Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine."
215082927|NCT01179061|DRUG|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
215082928|NCT05964335|DRUG|NAL ER|Oral tablets
215082929|NCT05964335|DRUG|Placebo|Oral tablets
215082930|NCT05964335|DRUG|NAL ER|Oral Tablets
214969839|NCT02198846|DRUG|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
214969840|NCT03505372|DEVICE|Contrast enhanced mammography|Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
215082931|NCT05964335|DRUG|NAL ER|Oral tablets
214969841|NCT03065647|DEVICE|Expedited Transport With Mechanical CPR|Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
215082932|NCT05693922|DEVICE|Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Delta-beta stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
215082933|NCT05693922|BEHAVIORAL|Single-session behavioral activation|"Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~* Treatment overview and rationale~* Tracking of daily activities~* Exploration of values~* Planning/scheduling activities"
215082934|NCT05693922|DEVICE|Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Active sham stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
215082935|NCT03383757|DEVICE|SpO2 Sensor application & blood draw|At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
215082936|NCT03187834|DRUG|Azithromycin|Children in this arm will receive Azithromycin once a day.
215082937|NCT03187834|DRUG|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
215082938|NCT03187834|DRUG|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
215082939|NCT03187834|DRUG|Placebo|Children in this arm will receive Placebo once a day.
215082940|NCT02857192|BIOLOGICAL|Blood samples|
215082941|NCT00650026|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
215082942|NCT03559699|DRUG|AG-348|"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
215082943|NCT01502150|OTHER|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
214969842|NCT06309667|DRUG|PG-102(MG12)|GLP-1 and GLP-2 fusion protein
214969843|NCT06309667|OTHER|Placebo|Placebo drug of PG-102(MG12)
214969844|NCT05601817|BEHAVIORAL|Vita|Vita is developed by this study team based on Attention Restoration Theory. The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.
214969845|NCT05601817|BEHAVIORAL|Com|Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity. The com intervention involves doing game-like training on a iPad.
214969846|NCT05601817|BEHAVIORAL|Vita+Com|Vita+Com intervention is a combination of both Vita and Com interventions. Participants will be asked to complete Vita first and then Com intervention.
214969847|NCT06171750|DRUG|tolododekin alfa|IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.
215082944|NCT01502150|OTHER|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
215082945|NCT03502304|BEHAVIORAL|Endurance training plus resistant training|CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
215082946|NCT01932255|PROCEDURE|prophylactic spinal tap|
215082947|NCT01932255|PROCEDURE|no prophylactic spinal tap|
215082948|NCT03353103|DRUG|Sodium fluoride F-18 PET imaging|prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
215082949|NCT04790812|DRUG|Celecoxib|Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
215082950|NCT04790812|DRUG|Acetaminophen|Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
215082951|NCT04790812|DRUG|Placebo|A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
215082952|NCT04699812|DEVICE|ELECTROCARDIOGRAM (ECG) PATCH WEAR|ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
214487533|NCT05072093|DRUG|Injectable PrEP|For men who are interested in injectable PrEP, they will be referred to local providers to access Apretude (Cabotegravir injection) every two months. In the study, their use of the medication will be monitored through monthly surveys during which they have the option to indicate interest in switching to oral PrEP.
214969848|NCT06171750|DRUG|Cemiplimab|Participants will receive four cycles of ANK-101 in combination with Cemiplimab. If there is no significant clinical deterioration as determined by the Investigator or unacceptable toxicity at Week 12, participants may receive an additional four cycles of the combination treatment. After stopping ANK-101 treatment, participants may stay on Cemiplimab monotherapy for an additional 24 weeks.
214969849|NCT05970965|PROCEDURE|Biological sampling|\- Saliva and blood sampling
214969850|NCT06009159|DEVICE|Transcutaneous Vagus Nerve Stimulation|30 minutes stimulation, twice per day for 4 weeks
214969851|NCT05995002|OTHER|Anthocyanin-rich diet|A weekly food plan aims to increase the consumption of anthocyanin-rich sources such as berries, black grapes (or currants), cherries, strawberries, pomegranates, and red onions.
214969852|NCT01821274|DRUG|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
214969853|NCT01821274|DRUG|Vehicle Cream|0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
214969854|NCT01821274|DRUG|0.1% solution o sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
214969855|NCT01821274|DRUG|Saline 0.9%|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
214969856|NCT02373423|OTHER|Advocacy|See above for description
214969857|NCT02943798|DRUG|etoposide plus carboplatin|etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
215082953|NCT05393414|DRUG|Opioid based protocol|Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
214969858|NCT02943798|DRUG|Paclitaxel plus carboplatin|Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
214969859|NCT02799017|OTHER|Intensive Phonology Treatment|Phonology based reading, writing, and naming therapy.
215082954|NCT05393414|DRUG|Opioid sparing protocol|Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
215082955|NCT05438602|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
215082956|NCT05438602|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
215082957|NCT05438602|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
215082958|NCT05438602|DRUG|Placebo for ritonavir|Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
215082959|NCT02036736|DRUG|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~* Sufentanil (0.15 mg / kg intravenously (IV))~* Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
215082960|NCT02036736|DRUG|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~* Sufentanil (0.15 mg / kg IV)~* Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
214969860|NCT02799017|OTHER|Intensive SFA Treatment|Semantic based reading, writing, and naming therapy.
215082961|NCT00348114|PROCEDURE|Transplantation of cultivated limbal epithelium|
214969861|NCT01553448|GENETIC|gene expression analysis|
214969862|NCT01553448|GENETIC|protein expression analysis|
214969863|NCT01553448|OTHER|enzyme-linked immunosorbent assay|
214969864|NCT01553448|OTHER|immunohistochemistry staining method|
214969865|NCT01553448|OTHER|laboratory biomarker analysis|
214969866|NCT01553448|OTHER|medical chart review|
214969867|NCT04872387|DRUG|BAY2586116|Nasal administration
214969868|NCT04872387|DRUG|Placebo|Matching placebo
214969869|NCT02529930|BIOLOGICAL|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
214969870|NCT05452915|DIAGNOSTIC_TEST|Neuropsychological (NPA)|"The neuropsychological assessment consists of following tests and questionnaires:~* Wechsler Adult Intelligence Scale (WAIS)-III: Digit-Symbol-Coding (Coding)~* WAIS-IV: Digit Span, Matrix reasoning~* Delis-Kaplan Executive Function Scale (D-KEFS): Color-Word Test, Word Fluency Test~* Ruff 2 \& 7~* MapCog Spectra~Questionnaires:~* EuroQoL five dimensions questionnaire (EQ5D)~* Hospital Anxiety and Depression Scale (HADS)~* Insomnia Severity Index (ISI)~* Multidimensional Fatigue Inventory-20 (MFI-20)~* Multidimensional Pain Inventory (MPI)~* Screening questions on physical activity~* Visual analogue scale on fatigue (VAS-f) before and after NPA~* Visual analogue scale on fatigue (VAS-f) and pain before and after the fMRI scanning.~* Pain level, experienced during the NPA, will be rated (0-10) at the end of the session"
214969871|NCT05452915|OTHER|Imaging|"Imaging (24 patients + 22 controls):~BOLD resting-state before and after 20-min vigilance task (e-prime). During the vigilance task, fMRI is performed.~Clinical protocol:~1. High-resolution T1-weighted.~2. High-resolution T2-weighted Scan (FLAIR)."
214969872|NCT05452915|DIAGNOSTIC_TEST|Inflammatory biomarkers|Blood samples from inflammatory biomarkers will be taken on 36 patients and 36 controls. Everyone who undergoes imaging will undergo blood tests.
214969873|NCT01963884|PROCEDURE|Tooth Extraction|Tooth from the maxillary anterior area extracted and alveolar socket remains intact
215082962|NCT01012752|BIOLOGICAL|modified allergen extract|subcutaneous injections
215082963|NCT01012752|BIOLOGICAL|Placebo|subcutaneous injections
214358544|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination B|Combined influenza and Pfizer-BioNTech COVID-19 vaccine
214358545|NCT06178991|BIOLOGICAL|Placebo|Saline Solution
214358546|NCT06178991|BIOLOGICAL|Investigational influenza vaccine|Investigational influenza vaccine
214358547|NCT06370598|BIOLOGICAL|TP-122A|Bacteriophage cocktail targeting Psa
214358548|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (10 ug group)|The participants took D2 10ug per day for a total of 4 weeks.
214358549|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (100 ug group)|The participants took D2 100ug per day for a total of 4 weeks.
214969874|NCT01963884|RADIATION|Cone-Beam technology evaluation|Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.
214969875|NCT01963884|OTHER|Measure Alveolar Socket Remodeling|In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
214969876|NCT01916460|PROCEDURE|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
214969877|NCT03300440|DIETARY_SUPPLEMENT|Probiotics and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
215082964|NCT02462408|PROCEDURE|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
215082965|NCT02462408|PROCEDURE|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
214358550|NCT03451838|DIAGNOSTIC_TEST|Ultrasound|Ultrasound will be done to every pregnant lady
214358551|NCT03451838|DIAGNOSTIC_TEST|HbA1c level in blood|a blood sample will be taken to measure HbA1c level
214969878|NCT03300440|DIETARY_SUPPLEMENT|Placebo and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
214969879|NCT04786691|OTHER|Addition of half and half to coffee|1 oz of half and half is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
215082966|NCT01930890|BIOLOGICAL|BIIB023|
215082967|NCT01930890|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
215082968|NCT01930890|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
214358552|NCT01367262|DRUG|LY2886721|Administered orally
214358553|NCT02049086|BEHAVIORAL|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
214358554|NCT02049086|BEHAVIORAL|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
214358555|NCT01204827|DEVICE|13C Methacetin Breath Test (BreathID)|
214358556|NCT02858895|DRUG|MDNA55|MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).
214358557|NCT06651073|OTHER|Observational|There is no intervention involved in the study. It is purely observational.
214358558|NCT06824480|BEHAVIORAL|debriefing group|Women who volunteered to participate in the study and met the participation criteria were informed about the study. The first session will be held face to face in the clinic for 40 minutes. Then, the second session will be held by phone within 4-6 weeks after birth, with a total of 2 meetings with each woman for approximately 40 minutes.
214358559|NCT06824480|BEHAVIORAL|control group|he women in the control group will be asked how the birth went within 12-24 hours after birth by the researcher as part of their routine care, but no detailed analysis or interpretation will be made.
214358560|NCT05602376|BEHAVIORAL|U=U testing messaging scripts|On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health
215082969|NCT02091284|DEVICE|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
214358561|NCT05602376|BEHAVIORAL|U=U adherence messaging scripts|After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
214969880|NCT04786691|OTHER|Addition of non-dairy creamer to coffee|1 oz of non-dairy creamer is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
214358562|NCT06600646|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopy will be performed in patients with refractory or unexplained chronic cough and healthy controls.
214358563|NCT03163758|DEVICE|real Repetitive Transcranial Magnetic Stimulation|The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
214358564|NCT03163758|DEVICE|sham Repetitive Transcranial Magnetic Stimulation|The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
214358565|NCT06322108|DRUG|Botensilimab + Balstilimab|Botensilimab is a fragment crystallizable (Fc)-engineered human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
214358566|NCT06331000|DRUG|elexacaftor-tezacaftor-ivacaftor treatment|Effect of one year elexacaftor-tezacaftor-ivacaftor treatment on glucose tolerance abnormalities in adult patients with cystic fibrosis
214358567|NCT06665763|OTHER|Sodium Lactate Solution|Infusion of sodium-lactate solution
214358568|NCT06665763|OTHER|Saline infusion (placebo)|NaCl solution
214358569|NCT06667921|DEVICE|Ultrasound|Ultrasound will be used to measure the hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), (HMDR) and (DSE).
214969881|NCT04786691|OTHER|Black|No Creamer
214969882|NCT01871077|DRUG|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
214969883|NCT03314883|DIAGNOSTIC_TEST|D-US ARF|Diaphragm ultrasound evaluation in acute hypoxic - hypercapnic respiratory failure (ARF) patients undergoing non invasive ventilation, with regard to thickening (%) and excursion (millimeters)
214969884|NCT04090346|DRUG|Fecal Microbiota Transplant|Fecal Microbiota Transplant (FMT) is a procedure to replace beneficial bacteria which has been killed or suppressed in the colon.
214358570|NCT02470546|DRUG|Metformin|Metformin 1000mg twice a day
214358571|NCT02470546|DRUG|Placebo|Placebo 1000mg twice a day
214358572|NCT06670612|OTHER|nature based music concert|It will be a resource for healthcare professionals to develop a behavior that will support patients in intensive care in relieving their pain and stabilizing their physiological parameters with nature-based music, and will contribute to the literature.
214358573|NCT06669481|OTHER|Semiquantitative 131I-MIBG Scintigraphy Assessment|Patients received thyroid blockade using solution of potassium iodide before the examination. After intravenous administration of 111 MBq of 131I-MIBG, whole body planar images were acquired at 24 hours (Day 1) and 48 hours (Day 2), respectively.
214358574|NCT06670820|DEVICE|Active rTMS|iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total10 sessions
214358575|NCT06670820|DEVICE|Sham rTMS|sham iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total 10 sessions
214487534|NCT06494605|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is an early naturalistic and behavioural intervention for children with initial signs of neurodivergence or on the autism spectrum between the ages of 12-48 months. This early intervention aims to increase the rates of development in several domains and to decrease the characteristics of autism conditions that hinder children's ability to learn from everyday experiences and interactions.
214487535|NCT05876078|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in ADHF patients
214487536|NCT05542082|DEVICE|CHILLS Procedure|Cryotherapy
214487537|NCT05708495|OTHER|posterior ilium mobilization|the therapist will mobilize the innominate on the affected side posteriorly
214487538|NCT05708495|OTHER|strengthening and stretching exercises|the participants will receive strengthening exercises on the hip and knee joint beside that they will receive stretching exercises
214487539|NCT05368467|COMBINATION_PRODUCT|The clinical course and disease management|The clinical course and disease management of pulmonary hypertension patients
214487540|NCT06448091|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|After consent and randomization into the immediate PGx testing, participants' results will (10-14 days after randomization) go into their EHR and be returned via a laminated results card
214969885|NCT03801642|DRUG|Dapagliflozin|10 mg oral tablets taken once daily for 12 weeks
214969886|NCT03801642|OTHER|Placebo|Placebo tablet (matched in size and color to active tablet) taken once daily for 12 weeks
214969887|NCT03183115|PROCEDURE|Radiofrequency ablation|HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare). Because the HALO 360 balloon catheter has been phased out since 2019, a new Barrx™ 360 Express catheter was used thereafter.
214969888|NCT03183115|DEVICE|Endoscopy|The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging
214969889|NCT03183115|DRUG|Lugol's Solution (1.5%)|Before the RFA intervention, the participants will received Lugol staining over the esophagus
214969890|NCT03822260|DIAGNOSTIC_TEST|Bezmialem VAkif Unv. Ethical board|If ıs any trials not convenient to Helsinki Agrement about Human research rules
214969891|NCT01119521|BIOLOGICAL|BCG strain Danish|Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10\^5 colony forming units (CFU) BCG.
214358576|NCT06670014|DEVICE|repeech|Participants in this group will use the repeech application for a period of 4 weeks, with recommended usage of 5 days per week for 30 to 60 minutes per session. A designated speech-language pathologist (SLP) will set individualized treatment goals and customize the content of the therapy sessions based on each participant's baseline assessment. The repeech intervention will be tailored to meet the specific needs of each participant to improve speech intelligibility and communication abilities.
214358577|NCT06670014|OTHER|Workbook|Participants in the control group will use a workbook provided by the sponsor for the treatment of dysarthria, due to the lack of a standardized care protocol for this condition. The recommended usage is the same as the treatment group: 5 days per week, for 30 to 60 minutes per session over a period of 4 weeks. After each self-treatment session, participants will record their activities on a checklist to monitor adherence and ensure compliance with the study protocol.
214487541|NCT05260047|BEHAVIORAL|IMANI|For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.
214487542|NCT05260047|BEHAVIORAL|Telehealth MAT|Describe what is the Telehealth MAT briefly
214487543|NCT05260047|BEHAVIORAL|Traditional MAT plus Referral and Linkage|Describe what he traditional MAT plus referral and linkage briefly
214487544|NCT06966154|DRUG|tislezumab|Tislelizumab will be administered intravenously at a fixed dose of 200 mg every 3 weeks (Q3W).
214487545|NCT06966154|DRUG|golidocitinib|"Golidocitinib: Dose-escalating oral regimens:~Dose level A: 150 mg every other day (QOD). Dose level B: 150 mg once daily (QD)."
214487546|NCT06966154|DRUG|Selinexor|Selinexor: Dose-escalating oral regimens: Dose A: 40 mg once weekly (QW) . Dose B: 60 mg QW for 2 consecutive weeks, followed by 1 week off.
214487547|NCT06965517|PROCEDURE|Maxillary implant supported overdenture , Digital jaw relation group|implant supported maxillary overdenture constructed using electronic facebow to record maxillo-mandibular relation.
214487548|NCT06965517|PROCEDURE|Maxillary implant supported overdenture , Static jaw relation group|implant supported maxillary overdenture constructed using the conventional jaw relation method.
214487549|NCT06505889|OTHER|Local anesthesia methods|Local pain control method before arterial blood sampling procedure
214358578|NCT06669689|DEVICE|operating position|In the Trendelenburg position, the operating table was tilted head down at an angle of 20-25°. In the Reverse Trendelenburg position, the operating table was tilted head up at an angle of 20-25°.
214358579|NCT06669689|DEVICE|pneumoperitoneum|Pneumoperitoneum was established with an intra-abdominal pressure of 10-15 mmHg.
214358580|NCT06670040|PROCEDURE|Transcranial Magnetic Stimulation|All TBS sessions will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds.
214487550|NCT01181154|DRUG|rituximab (Mabthera®)|1000 mg at day 1 and day 15
214487551|NCT01181154|DRUG|Placebo|equivalent volume total
214487552|NCT04868656|OTHER|Implementation Strategy: Foundational Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We propose that low intensity implementation support that promotes adapting STRIDE for context and provides tools for ongoing STRIDE evaluation (defined as foundational support), will be sufficient for some but not all hospitals to successfully incorporate STRIDE into routine practice.
214487553|NCT04868656|OTHER|Implementation Strategy: Enhanced Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We posit that monitoring hospitals' progress and adding, for hospitals with low adoption, higher intensity strategies (defined as Enhanced Support) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
214487554|NCT04909697|DRUG|Sivelestat sodium|4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days
214487555|NCT04909697|DRUG|Saline|50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days
214487556|NCT02656706|DRUG|Ipilumumab|
214487557|NCT02656706|DRUG|Nivolumab|
214487558|NCT05237908|DEVICE|Transforaminal Lumbar Interbody Fusion|Interbody Fusion means the operative immobilization or ankylosis of two or more vertebrae by fusion of the vertebral bodies with a short bone graft or often with diskectomy or laminectomy. (From Blauvelt and Nelson, A Manual of Orthopaedic Terminology, 5th ed, p236; Dorland, 28th ed
214969892|NCT01119521|DRUG|Isoniazid|United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].
214969893|NCT00201019|BEHAVIORAL|Physician-pharmacist collaborative intervention|Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
214969894|NCT01136252|DRUG|Adalimumab|Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
215082970|NCT01454349|DRUG|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
215082971|NCT01454349|DRUG|Placebo|Single intraprostatic injection of matching placebo
215082972|NCT01278407|DRUG|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
215082973|NCT01278407|DRUG|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
215082974|NCT01278407|DRUG|Donepezil matched placebo|
215082975|NCT05883943|DEVICE|Cook® Venous Valve System|The Cook® Venous Valve is a permanent prosthetic, bicuspid, one-way flow valve designed to be percutaneously implanted into the peripheral deep venous system. The Cook® Venous Valve Delivery System is used to percutaneously deliver the Cook® Venous Valve into the deep venous system.
215082976|NCT04427995|DEVICE|OMNI surgical system|GATT + viscodilation
214358581|NCT06670040|PROCEDURE|Transcranial Magnetic Stimulation Sham|We will use a robust sham technique that suitably replicates the sensory experience (auditory and peripheral activation) of active TBS with minimal intracranial activation. The Magstim Horizon™ sham coil will be utilized for treatment delivery. This sham coil is visually identical to the active coil and replicates the sounds and sensation of the magnetic stimulation. All sham treatment will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds
214358582|NCT04907942|OTHER|EMA + EMA and FACE Stress|1 wk of EMA (2 daily surveys per day delivered during waking hours to evaluate momentary affects) plus 2 weeks of EMA and FACE stress
214358583|NCT04907942|OTHER|EMA Alone|Three weeks of EMA consisting of 2 daily surveys per day delivered during waking hours to evaluate ecological momentary affects.
214358584|NCT06669962|DIAGNOSTIC_TEST|Study of coronary microcirculation and biomarkers of microvascular dysfunction|Patients with tako-tsubo syndrome will undergo to coronary angiography, ventriculography and assessment of physiological indexes of coronary circulation as per clinical practice
214358585|NCT03408717|OTHER|Questionnaires|Questionnaires including Pain catastrophizing scale (PCS), Central Sensitisation Inventory (CSI), Coping Strategies Questionnaire-Revised (CSQ-R), Brief Symptom Inventory-18 (BSI-18), Perceived Stress Scale (PSS), EQ-5D-3L and Eysenck Personality Questionnaire (EPQ) will be administered to the patient.
214358586|NCT03408717|OTHER|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
214358587|NCT03408717|OTHER|Pain threshold assessment|Pressure is applied 90 degree straight down force on the subject's right/left centre of the trapezius muscle using an algometer, with a speed of pressure \~ 1kgf/s. The above procedure is then repeated 3 times at each site (left/right) which is indicated on the pressure mark with each time having the reading recorded. When patient shows no response ≥ 6kgf, the threshold is recorded as 6kgf. The patient upon feeling pain will say stop or raise the hand to terminate the test. The mean value is obtained by averaging the readings and will then be recorded as the threshold estimate.
214487559|NCT05192057|DEVICE|Hypertonic Saline inhalation|Hypertonic Saline inhalation is thought to increase mucociliary clearance of the airways
214487560|NCT03725332|BEHAVIORAL|Telemedicine|Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance use counselor or perinatal nurse facilitator. Consultations will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
214969895|NCT06074783|BIOLOGICAL|Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)|50 x 106 allogeneic BM-derived MSCs formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under state of the art way of application that is ultrasound guidance which will ensure precise delivery of the BM derived MSCs at the site of injury or degeneration along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury or degeneration is not feasible.
214969896|NCT02105233|BIOLOGICAL|brain mimicking fluid|filled into the operation cavity during surgery for glioblastoma
214969897|NCT02141191|DRUG|inhaled hypertonic saline (7%)|Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
214969898|NCT04878120|DEVICE|Standard HCL System|Standard HCL system (USS Virginia)
214969899|NCT04878120|DEVICE|HCL System with Smart Bolus Calculator|HCL system (USS Virginia) with smart bolus calculator informed by insulin sensitivity
214969900|NCT04685928|DIAGNOSTIC_TEST|MRI and MRI-guided prostate biopsy|Multiparametric MRI prostates in the MRI arm will be performed using 1.5 or 3.0 Tesla scanner with a pelvic phased array coil and contrast injection. T2-weighted, diffusion weighted and dynamic contrast enhanced scans will be included and the reporting of MRI finding will be done according to PI-RADS (Prostate Imaging-Reporting and Data Systems) v2.1 recommendations. MRI-guided targeted biopsy will be performed by Urologists experienced in MRI-guided biopsy for men with PI-RADS score 3-5.
214969901|NCT04685928|DIAGNOSTIC_TEST|TP-arm Systematic biopsy|Transperineal 24-core biopsy using a free-hand technique under local anaesthesia will be performed under transrectal ultrasound guidance for men in this arm
214969902|NCT00908414|DRUG|TMC589337 40 mg|Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
214969903|NCT00908414|DRUG|TMC589337 100 mg|Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
214969904|NCT00908414|DRUG|TMC589337 200 mg|Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
214969905|NCT00908414|DRUG|TMC589337 400 mg|Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
214969906|NCT00908414|DRUG|TMC589354 40 mg|Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
214969907|NCT00908414|DRUG|TMC589354 100 mg|Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
214969908|NCT00908414|DRUG|TMC589354 200 mg|Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
214969909|NCT00908414|DRUG|TMC589354 400 mg|Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
214358588|NCT05780346|OTHER|TGNB-CARE (Connecting and Reflecting Experience)|12 session 60-minute mentalizing-focused parenting group with approximately 6 caregivers, facilitated by a mental health clinician
214358589|NCT06630871|DRUG|Distitamab Vedotin in combination with Tislelizumab|On the day after the initial TURBt procedure, use trastuzumab (200mg)+ Distitamab Vedotin (120mg \[≤ 60Kg\] or 2.0mg/Kg \[\>60Kg\]) every 3 weeks (Q3W). Simultaneously arrange for the patient to complete a second TURBt within 6 weeks, and continue to use 3 courses of Trastuzumab+Vediximab (Q3W) after surgery until the endpoint of 3-year follow-up
214358590|NCT05677087|BEHAVIORAL|PREPARE Nutrition Education Module|The Perinatal Remote Education for Pandemic Resilience (PREARE) program is a 6-week intensive program aimed at increasing maternal and infant dietary diversity as well as maternal health literacy. Modules that will be completed in the program include education on early initiation of breastfeeding, food groups and the benefits of a balanced diet, appropriate meal frequency for mother and infant, and appropriate sources of health information. Information on personal hygiene and COVID-19 hygiene protocols as well as danger signs during pregnancy are included in the module to improve maternal knowledge on safety protocols and pregnancy complications.
214358591|NCT03962894|DRUG|Prednisolone|During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
214358592|NCT06772155|PROCEDURE|Ventriculostomy|Involves inserting a catheter into the brain's ventricular system to drain cerebrospinal fluid (CSF) and reduce intracranial pressure (ICP). This is a common procedure performed in this type of patient. It can be performed by a frontal approach, using a standard point 10cm from the nasion and 3cm lateral to the midline in the skull. A burr hole is performed and then the catheter is inserted in the frontal horn of the ventricular system. Then the catheter is tunneled subcutaneously and connected to an external ventricular drain collection system that allows also ICP measurement.
214358593|NCT06772155|PROCEDURE|Ventriculostomy + Locking Device|Involves inserting a catheter into the brain's ventricular system to drain cerebrospinal fluid (CSF) and reduce intracranial pressure (ICP). This is an alternative procedure performed for this type of patient. It can be performed by a frontal approach, using a standard point 10cm from the nasion and 3cm lateral to the midline in the skull. A burr hole is performed and then the catheter is inserted in the frontal horn of the ventricular system. During the insertion, a locking device is attached and secured at the burr hole defect. Then the catheter is tunneled subcutaneously and connected to an external ventricular drain collection system that allows also ICP measurement.
214358594|NCT04894643|RADIATION|Proton Ions|According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
214358595|NCT04894643|DRUG|Nab-PACLitaxel|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes."
214358596|NCT04894643|DRUG|Gemcitabine|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel."
214969910|NCT00908414|DRUG|TMC589337 AA mg|Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
214969911|NCT00908414|DRUG|TMC589354 BB mg|Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
214969912|NCT00908414|DRUG|TMC589337 CC mg|Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
214969913|NCT00908414|DRUG|TMC589354 DD mg|Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
214969914|NCT00908414|DRUG|TMC589337 EE mg|Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
214969915|NCT00908414|DRUG|TMC589354 YY mg|Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
214358597|NCT04894643|DRUG|Capecitabine|Concomitant to proton-radiotherapy (on the same days, within week 14-19)
214358598|NCT04894643|PROCEDURE|Surgical resection of the pancreas (when feasible)|Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
214487561|NCT03725332|BEHAVIORAL|Group Care|Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator or substance use counselor, with a peer support specialist. Small group care meetings will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
214969916|NCT00908414|DRUG|TMC310911 300 mg|Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
214969917|NCT00908414|DRUG|TMC310911 600 mg|Participants will receive TMC310911 600 mg in Panel 7.
214969918|NCT00908414|DRUG|Placebo|Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
214969919|NCT04346160|DIAGNOSTIC_TEST|Schirmer Test I|Collection of tear fluid
214969920|NCT05943470|DRUG|Icodextrin Peritoneal Dialysis Solution|alternative day use of icodextrin comparing with daily use of icodextrin
214969921|NCT02012725|DRUG|Arm 1 MRI with gadolinium|Healthy volunteers will not receive gadolinium
214969922|NCT00992017|BIOLOGICAL|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
214969923|NCT06360965|DRUG|Improved warm meridians and relieve pain plaster|Starting from the 1st to 3rd day after the menstrual cycle is clean, apply it 6-8 hours before bedtime every day, with one day off. Apply 10 times per menstrual cycle as one course of treatment, with two consecutive courses of treatment.
214358599|NCT05477745|PROCEDURE|total knee arthroplasty|The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.
214358600|NCT05892328|OTHER|Watermelon Flesh Dose 1|1 cup watermelon flesh, \~152g, 7 days/week over a 4-week period
214358601|NCT05892328|OTHER|Watermelon Flesh Dose 2|2 cups watermelon flesh, \~304 g, 7 days/week over a 4-week period
214358602|NCT05892328|OTHER|Control|304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
214969924|NCT06360965|DRUG|Traditional warm meridians and relieve pain plaster|The treatment course is the same as the improved warm meridians and relieve pain plaster group.
214969925|NCT06360965|DRUG|Placebo plaster|The treatment course is the same as the improved warm meridians and relieve pain plaster group.
214969926|NCT05959967|BEHAVIORAL|Vestibular Rehabilitation Exercises|The VRE group will receive exercises aimed at improving gaze stability, postural control, and balance. This includes activities like gaze stabilization exercises, balance training on different surfaces, and walking with head movements.
214969927|NCT05959967|BEHAVIORAL|General Fitness Training|The GFT group will undertake exercises to enhance cardiovascular fitness, strength, and flexibility, such as light aerobic exercises, resistance training, and stretching. The exercise sessions will be 60 minutes in duration, consisting of a warm-up phase, the main exercise phase, and a cool-down phase.
214969928|NCT02864407|DRUG|Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)|The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
214969929|NCT04633681|DIETARY_SUPPLEMENT|Sweetener and sweetness enhancer consumption|Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
214969930|NCT02992119|BIOLOGICAL|RTS,S/AS01B Fractional dose|RTS,S/AS01B standard dose at Month 0 and Month 1 + RTS,S/AS01B fractional dose (1/5th dose) at Month 2.
214969931|NCT02992119|BIOLOGICAL|Double RTS,S/AS01E Fractional dose|A double dose of RTS,S/AS01E standard dose at Month 0 and Month 1 + a double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
214358603|NCT02277444|DRUG|Golimumab|Golimumab 80 mg/m\^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.
214358604|NCT02277444|DRUG|Methotrexate|Methotrexate BSA-based dose (10 to 30 mg/m\^2 per week for participants with BSA \<1.67 m\^2, or minimum of 15 mg/week for participants with BSA \>=1.67 m\^2) weekly at least through Week 28.
214358605|NCT00000279|DRUG|Clonidine|
214358606|NCT00246116|PROCEDURE|Functional Imaging of Treatment Effects|PET \& VQ Scans
214358607|NCT00815867|DRUG|epoetin beta (NeoRecormon ®)|"comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections"
214487562|NCT04783441|DEVICE|Dexcom G6|access to continuous glucose monitoring in the Dexcom G6 arm 24/7
214969932|NCT02992119|BIOLOGICAL|RTS,S/AS01E Standard dose|RTS,S/AS01E standard dose at Month 0, Month 1 and Month 2.
214969933|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Standard dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0, Month 1 and Month 2
214969934|NCT02992119|BIOLOGICAL|RTS,S/AS01E Fractional dose|RTS,S/AS01E standard dose at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
214969935|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Fractional dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2.
214358608|NCT03123146|BEHAVIORAL|Functional Behavior-Based Cognitive Behavioral Therapy|Fb-CBT involved nine 2-hour weekly sessions with three to four children in each group and two therapists. Therapy consisted of group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
214358609|NCT01074398|GENETIC|gene expression analysis|
214358610|NCT01074398|GENETIC|polymorphism analysis|
214358611|NCT01074398|GENETIC|protein expression analysis|
214358612|NCT01074398|OTHER|immunohistochemistry staining method|
214358613|NCT01074398|OTHER|laboratory biomarker analysis|
214487563|NCT04783441|DEVICE|Dexcom G6 blinded sensor|retrospective access to continuous glucose profile after 10 days of wear
214969936|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2
214969937|NCT01720316|DRUG|Glycine|Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
214969938|NCT01720316|DRUG|placebo|
214969939|NCT02721615|PROCEDURE|Insertion of intra spinal sub dural pressure monitor|
214358614|NCT01575353|DEVICE|Venturi mask|The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
214969940|NCT02721615|PROCEDURE|Insertion of sub dural microdialysis probe|
214969941|NCT02701725|DEVICE|CRI status|Measurement of CRI
214969942|NCT03620188|OTHER|Standard of care|Standard of care in PsA is outline in treatment guidelines as adjustment of therapy every 3 months until goals of treatment are being met. Goals of treatment are defined as remission or low disease activity.
214969943|NCT00029393|PROCEDURE|Hematopoietic Stem Cell Transplantation|
214969944|NCT00029393|DRUG|Immunosuppression|
214969945|NCT01827592|DRUG|Elobixibat 10 mg|Elobixibat 10 mg/day
214969946|NCT01827592|DRUG|Elobixibat 5 mg|Elobixibat 5 mg/day
214969947|NCT01827592|DRUG|Placebo|Placebo
215082977|NCT06258486|DRUG|ICG injection|Patient will have a green dye (ICG) injected into the lymph node to better visualize non-sealed leaks in order to pre-emptively seal any lymphatic leaks.
214358615|NCT01575353|DEVICE|Nasal high-flow|The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
214358616|NCT04257266|DEVICE|Ice Pack Cooling|5 ice packs (Cryo cooling pack or commercial ice pack) will be placed on the subject for 30 mins after exercise-induced hyperthermia
214969948|NCT05254899|DRUG|Anti-PD-1 monoclonal antibody|200mg iv on Day 1 of each 14-day cycle for 3 cycles in induction treatment; 200mg iv on Day 1,15, 29 during RT treatment
214969949|NCT05254899|DRUG|Pegaspargase|3000 U/m2 im on Day 2 of each 14-day cycle for 3 cycles in induction treatment
214969950|NCT05254899|DRUG|Gemcitabine|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
214969951|NCT05254899|DRUG|Oxaliplatin|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
215082978|NCT06258486|OTHER|Non-Injection/Control|No ICG injection
215082979|NCT06258486|PROCEDURE|Prostatectomy with pelvic lymph node dissection|Robotic assisted prostatectomy with pelvic lymph node dissection
215082980|NCT02241876|DRUG|N-acetylcysteine|
215082981|NCT00693641|OTHER|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
215082982|NCT00693641|OTHER|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
214358617|NCT00883506|DRUG|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
214358618|NCT00883506|DRUG|Lisinopril 40 mg Tablet under fasting conditions.|
214358619|NCT00883506|DRUG|Lisinopril 40 mg Tablet under fed conditions.|
214358620|NCT03878732|DIAGNOSTIC_TEST|Bindex measurement|One time bone density measurement with ultrasound device
214358621|NCT02464813|DRUG|Pregabalin|Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
214358622|NCT02464813|DRUG|Sugar pill|Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
214358623|NCT02464813|DRUG|Oxycodone|All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
214358624|NCT05182567|DRUG|GLS-5310 (Group 1)|GLS-5310 DNA plasmid vaccine
214358625|NCT05182567|DRUG|GLS-5310 (Group 2)|GLS-5310 DNA plasmid vaccine
214969952|NCT05254899|RADIATION|Involved site radiotherapy|Involved site radiotherapy according to the ILROG guideline with primary tumor dose of 50-56Gy 14-28 days after inductive therapy
214358626|NCT05182567|DRUG|GLS-5310 (Group 3)|GLS-5310 DNA plasmid vaccine
214358627|NCT05182567|DRUG|GLS-5310 (Group 4)|GLS-5310 DNA plasmid vaccine
214358628|NCT03426384|BEHAVIORAL|Mymee Program|A combination of digital therapeutics and telephonic health coaching is used to identify and test dietary, lifestyle, and environmental triggers in order to reduce symptoms of auto-immune disease.
214358629|NCT04171102|DEVICE|ProFlor Hernia implant|Inguinal hernia repair
214358630|NCT04918784|DEVICE|Restrata®|Restrata® is a sterile, single use device intended for use in local management of wounds. Restrata® is a soft, white, conformable, non-friable, absorbable matrix that provides a moist environment for the body's natural healing process to occur. Restrata® is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native extracellular matrix.
214358631|NCT04918784|DEVICE|Wound Dressing|Alginate or Foam wound dressing is intended to manage wounds.
214358632|NCT02773550|DRUG|Bortezomib|Low dose of bortezomib
214358633|NCT02773550|DRUG|Melphalan|
214358634|NCT02773550|DRUG|Prednisone|
214358635|NCT02219893|DRUG|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
214358636|NCT05662384|OTHER|No intervention is planned|Observational study, no intervention
214969953|NCT01146847|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish tight glycaemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mM)
215082983|NCT02534935|BIOLOGICAL|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
215082984|NCT02534935|BIOLOGICAL|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
215082985|NCT04666831|BEHAVIORAL|Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)|The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
215082986|NCT01460719|BIOLOGICAL|V212|V212 viral antigen for HZ
215082987|NCT06100094|OTHER|semi-structured qualitative interviews|"During the interview, a list of semi-open questions will be asked :~* What were your expectations/state of mind before the group?~* How would you describe your experience overall?~* If you had to describe the group how would you do it?~* Between two group sessions, how did it go for you?~* What do you think of the group ultimately?~Interviews will be carried out until data saturation.~Collection of socio-demographic data (age), medical history and criminal history in the patient's file"
215082988|NCT02253823|DRUG|EFV|
215082989|NCT02253823|DRUG|TPV/RTV - low dose|
215082990|NCT02253823|DRUG|TPV/RTV - high dose|
215082991|NCT06081413|PROCEDURE|bariatric surgery|bariatric surgeries - sleeve gastrectomy, roux-en-Y gastric bypass, one anastomosis gastric bypass, adjustable gastric band
214969954|NCT02493517|DRUG|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
214969955|NCT02493517|DRUG|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).
214969956|NCT03189355|PROCEDURE|Blood sampling|"* D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube~* D4 zonulin"
214969957|NCT03189355|PROCEDURE|Bioelectrical impedance vector analysis|"* D1~* D4"
214969958|NCT03189355|PROCEDURE|Muscular echography|"* D1~* D4"
214969959|NCT00507260|BEHAVIORAL|Food Record|A record of the amount and kind of food and drink you intake will be completed.
214969960|NCT00507260|OTHER|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
214969961|NCT02852421|PROCEDURE|Single injection paravertebral block|"The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections"
214969962|NCT02852421|PROCEDURE|Multiple injection paravertebral blocks|"Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
215082992|NCT05512702|DRUG|Tissue Plasminogen Activator, Alteplase|Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
215082993|NCT05512702|DRUG|Low-molecular weight heparin|Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
215082994|NCT00549185|DRUG|SAR3419|Intravenous infusion
215082995|NCT03093636|DEVICE|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
215082996|NCT03093636|OTHER|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
215082997|NCT01113346|DRUG|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
214358637|NCT06311279|PROCEDURE|Anterior resection of Rectal cancer|Anterior resection of cancer rectum and type of anastomosis (End to end or side to end)
214358638|NCT02160314|DEVICE|pessary|disposable, single-use pessary
214358639|NCT02160314|DEVICE|Absorbent pad|
214969963|NCT02983890|DRUG|Dicloxacillin|"Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
214969964|NCT02983890|DRUG|Placebos|"No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
214969965|NCT02047279|PROCEDURE|maze procedure|"The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases."
214969966|NCT02047279|PROCEDURE|mitral valve surgery|For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
214969967|NCT02047279|PROCEDURE|left atrial reduction|The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
215082998|NCT01113346|DRUG|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
215082999|NCT06410521|BEHAVIORAL|Exercise|Patients randomised to the intervention arm will undergo non-consecutive training sessions three times a week for a period of 12 weeks. The training session is divided into an aerobic and a resistance training component, with a 5-min warm-up (stretching exercises) and a 5-min cool-down (stretching and relaxing exercises). The cardiovascular component will comprise a progressive exercise duration from 30 to 40 minutes, an exercise intensity promoting moderate to severe claudication pain between 8-12 minutes, with rest time until the pain disappears, and a personalised load progression manipulated based on the claudication pain level, reaching a total of 60 minutes of walking per session. The resistance training component will comprise dynamic muscle contraction exercises (Leg extension, unilateral hip extension, and standing calf raise), with a load progression from 50% of 1-estimated one repetition maximum (e-RM) to 80% of 1-eRM.
215083000|NCT06410521|BEHAVIORAL|Usual care|Patients randomised to the active comparator arm will be advised about the importance of lifestyle modification (including general advice to increase walking but without specific recommendations about the exercise program) for a period of 12 weeks.
215083001|NCT00076336|DRUG|Telbivudine|600mg/day oral tablet for 104 weeks
215083002|NCT00076336|DRUG|Lamivudine|100mg/day oral tablet for 104 weeks
214358640|NCT01751126|DRUG|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
214969968|NCT01817075|PROCEDURE|Chlorhexidine Gluconate Skin Cleanser|Given CHG cleansing
214969969|NCT01817075|OTHER|Laboratory Biomarker Analysis|Correlative studies
214969970|NCT01817075|PROCEDURE|Mild Soap Skin Cleanser|Given control cleansing
214969971|NCT01817075|OTHER|Questionnaire Administration|Ancillary studies
214969972|NCT02154438|DRUG|Ketamine|ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
214969973|NCT03185286|DEVICE|3d-printed personalized metal implant|3d-printed personalized metal implant will be used in subtalar arthrodesis.
214969974|NCT03889249|DRUG|Tenecteplase|Stroke Thrombolytic
214969975|NCT03889249|DRUG|Alteplase|Stroke Thrombolytic
215083003|NCT00076336|DRUG|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
215083004|NCT02838901|DRUG|Beet it Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
215083005|NCT02838901|DRUG|Beet It Placebo Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
215083006|NCT01478841|DRUG|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
215083007|NCT01478841|DRUG|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
215083008|NCT02127034|DRUG|Mirabegron|oral
215083009|NCT02127034|DRUG|Solifenacin|oral
214358641|NCT01751126|DRUG|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
214358642|NCT02993445|OTHER|Alternate Nostril Breathing|
214358643|NCT02993445|DEVICE|Foot Reflexology|
214358644|NCT00061802|DRUG|risperidone, quetiapine|
214358645|NCT00137930|BIOLOGICAL|Live attenuated rotavirus vaccine|
214969976|NCT06173479|BEHAVIORAL|HeBSaPU|HeBSaPU training content explains the definition of pesticides, their way of entry into the body, and their health effects. Personal protective equipment, personal hygiene behaviors, and safe behaviors regarding the correct and safe use of pesticides were mentioned.
215083010|NCT02127034|DRUG|Digoxin|oral
215083011|NCT05394532|OTHER|Education|Common Education
214358646|NCT05538962|DIAGNOSTIC_TEST|Sensor skin|Skin sensor to detect inflammatory molecules in sweat
214358647|NCT02877511|DRUG|BAY987517|Applied liberally to the skin (Formulation: Y73-161
214358648|NCT02877511|DRUG|Sunscreen Lotion (Y65-110)|Applied liberally to the skin
214358649|NCT02422602|DRUG|Xarelto|Taking conventional charge
214358650|NCT02422602|OTHER|Experimental: Personalized information intervention|
214358651|NCT03151980|PROCEDURE|Hamam treated skin and sun exposure|Hamam is a skin treatment (soaping and scrubbing).
214358652|NCT03151980|OTHER|Untreated skin and sun exposure|Skin that will not receive Hamam.
214358653|NCT03578003|OTHER|Morning Bright Light Therapy|60 minutes of bright light therapy (10,000 lux) received within 90 minutes of waking
214358654|NCT01928420|DRUG|Drug: NIC5-15|A natural product, found in many foods and plants with mild insulin sensitizing effects
214358655|NCT01928420|DRUG|Placebo|Subjects with Alzheimer's Disease placebo comparator
215083012|NCT01164332|OTHER|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
214358656|NCT05877443|PROCEDURE|Open system|Oxygen delivered on open system, for example high flow nasal cannula or low flow oxygen by nasal cannula or face mask
214358657|NCT05877443|PROCEDURE|Non-invasive mechanical ventilation|Respiratory support by for example continues or bilevel positive airway pressure
214969977|NCT06593834|DRUG|bacillus coagulans combined with the best treatment options for preventing aGVHD|BAT means the best treatment options for preventing aGVHD
214969978|NCT06593834|DRUG|BAT|BAT
214969979|NCT03758599|PROCEDURE|Climbing|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
214969980|NCT03758599|PROCEDURE|Nordic Walking|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
214969981|NCT03758599|PROCEDURE|Social Contact|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
214969982|NCT05190874|DEVICE|Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
214969983|NCT04789382|DEVICE|LID018869+RepleniSH|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
214969984|NCT04789382|DEVICE|LID018869+Biotrue|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
214969985|NCT04789382|DEVICE|Biofinity+RepleniSH|Comfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
215083013|NCT04102553|DRUG|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
215083014|NCT04102553|DRUG|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
214358658|NCT05877443|PROCEDURE|Invasive mechanical ventilation|Respiratory support delivered through endotracheal tube or tracheostomy
214358659|NCT01245465|OTHER|Profermin|Medical Food (food for special medical purposes)
214358660|NCT00005801|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214358661|NCT00005801|PROCEDURE|peripheral blood stem cell transplantation|
214487564|NCT05810025|BEHAVIORAL|RealRisks|RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
214969986|NCT04789382|DEVICE|PV+Biotrue|Balafilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
214487565|NCT06277960|DEVICE|percutaneous intramyocardial septal radiofrequency ablation system|The device is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum.
214487566|NCT05035108|BIOLOGICAL|hiHep bioartificial liver therapy|HiHep cell bioartificial liver treatment was performed 48-72 hours after extensive hepatectomy. Temporary hemodialysis tube for large vein (jugular vein or femoral vein) is indwelled before treatment. Before treatment, prepare hiHeps-BAL in a biological safety cabinet that meets clinical standards, connect the corresponding tubing to the Jianfan DX-10 blood purification machine, and prefill with heparin saline. Half an hour before treatment, the patient was pre-heparinized (heparin about 600iu) and dexamethasone to prevent allergic reactions. The patient enters the ICU, the monitor is connected to the corresponding pipeline, the arterial pump 120-160ml/min, the slurry pump 30-40ml/min, the circulating pump 75-100ml/min, the duration is 4-6h.
214487567|NCT06559774|BEHAVIORAL|Hastiin Bidziil|Common Elements Treatment Approach (CETA) modified for cultural and gendered specific delivery for maximum community impact
214487568|NCT06559774|OTHER|Control condition - vehicle maintenance|Control condition was selected by the Community Research Council and includes five sessions on basic vehicle maintenance such as changing tire, checking fluid levels, and winterizing vehicles.
214487569|NCT04599010|OTHER|Dietary intervention|energy-restricted diet appropriate for resting metabolic rate using FFM as proxy
214487570|NCT03603730|DEVICE|taVNS|Active or inactive taVNS delivered to the external ear at a moderate, non-painful level.
214487571|NCT06964958|DRUG|177Lu-PSMA-617|A radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.
214487572|NCT05384873|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
214487573|NCT05384873|OTHER|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
214487574|NCT02340117|GENETIC|SGT-53|The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
214487575|NCT02340117|DRUG|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
214487576|NCT02340117|DRUG|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
214969987|NCT02126280|OTHER|In vitro estimation of individual reactivity of monocytes|Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
214969988|NCT04584814|DEVICE|No intervention|Basal analysis
214969989|NCT04584814|DEVICE|scare ventilator at 20|To set scare ventilator by 20 cycles per minute
214969990|NCT04584814|DEVICE|scare ventilator at 40|To set scare ventilator by 40 cycles per minute
214969991|NCT01851993|DRUG|Ondansetron|
214969992|NCT01851993|DRUG|Placebo|0.9% saline
215083015|NCT06198088|OTHER|PNF techniques|The patient in the experiment group will PNF techniques (hold relax) the participants who were assigned for post traumatic stiffness of the elbow with baseline treatment (heating pad), stretching applied for 30 sec then relaxation time 10 sec, 5 repetition were given in a session for 5 days a week for 4 weeks.
214358662|NCT00005801|RADIATION|radiation therapy|
214358663|NCT04837300|OTHER|Resisted Sprint Traininig|The Participants in this group had received plyometrics exercises; double leg jumping, drop jumping, hopping, bounding and hurdling.
214358664|NCT03672838|BEHAVIORAL|hand-held dynamometer|Strength of one weak muscle group and of the biceps of the dominant arm will be measured using a hand-held dynamometer. An average of three readings will be used as one observation. Three observations per patient will be obtained on one day with a minimum of 15 minute rest period between each observation.
214358665|NCT01757834|DEVICE|SWUS Elastography|
214358666|NCT02344043|DEVICE|Near infrared spectroscopy|This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
214969993|NCT06489561|BEHAVIORAL|Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system|Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried)
214358667|NCT00791206|PROCEDURE|Real preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
214969994|NCT02677415|OTHER|Intravenous anesthetics|
214969995|NCT02677415|OTHER|local anesthesia|
214969996|NCT02677415|OTHER|Controlled ventilation|
214969997|NCT02677415|OTHER|Spontaneous breathing|
214969998|NCT00419757|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
214969999|NCT00419757|DRUG|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
214970000|NCT05932758|PROCEDURE|Vacuum-assisted excisional biopsy|at least 4g of tissue sampled (excisional biopsy)
214970001|NCT05932758|PROCEDURE|Not excisional biopsy|biopsy with less than 4 g of tissue sampled
214970002|NCT00001057|DRUG|Zidovudine|
214970003|NCT00001057|DRUG|Didanosine|
214970004|NCT00480090|DRUG|Cytarabine|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
214970005|NCT02981030|DRUG|Mifepristone|Women seeking medical abortion will be offered the option to take mifepristone at home
215083016|NCT06198088|OTHER|Exercise therapy|exercise therapy range of motion, stretching and strengthening were applied with heating pad as baseline treatment. 5 repetition were given in a session for 5 days a week for 4 week.
215083017|NCT06350747|BEHAVIORAL|Face-to-Face Laughter Yoga Group|"In this study, each laughter yoga session lasted approximately 30-40 minutes and consisted of four parts: hand clapping and warm-up exercises, deep breathing exercises, playful games, and laughter exercises. According to Kataria (2011), the first three parts remained consistent across all sessions, while the laughter exercises in the fourth part varied (Kataria 2011). In the first session of each new group, participants were introduced to laughter yoga, its purpose, and objectives, with 10 minutes allocated to this introductory section. As a result, the first session for each group lasted 40 minutes, while the remaining sessions were 30 minutes each. The structure and duration of each session were as follows:~* Section 1: Hand Clapping and Warm-up Exercises - 5 minutes~* Section 2: Deep Breathing Exercises - 10 minutes~* Section 3: Playful Games - 5 minutes~* Section 4: Laughter Exercises - 10 minutes"
215083018|NCT06350747|BEHAVIORAL|Online Laughter Yoga Group|"In this study, each laughter yoga session lasted approximately 30-40 minutes and consisted of four parts: hand clapping and warm-up exercises, deep breathing exercises, playful games, and laughter exercises. According to Kataria (2011), the first three parts remained consistent across all sessions, while the laughter exercises in the fourth part varied (Kataria 2011). In the first session of each new group, participants were introduced to laughter yoga, its purpose, and objectives, with 10 minutes allocated to this introductory section. As a result, the first session for each group lasted 40 minutes, while the remaining sessions were 30 minutes each. The structure and duration of each session were as follows:~* Section 1: Hand Clapping and Warm-up Exercises - 5 minutes~* Section 2: Deep Breathing Exercises - 10 minutes~* Section 3: Playful Games - 5 minutes~* Section 4: Laughter Exercises - 10 minutes"
215083019|NCT06350747|OTHER|control group|Participants in the control group will not receive the laughter yoga intervention. They will continue with their usual daily routines and will only complete pre- and post-test assessments.
214358668|NCT00791206|PROCEDURE|Sham preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
214358669|NCT00817180|OTHER|Positive Expiratory Pressure (PEP)|Physiotherapy technique for airway clearance
214970006|NCT02981030|DRUG|Misoprostol|Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
214970007|NCT05988567|DIETARY_SUPPLEMENT|Placebo candy|consume 2 tablets per day
214970008|NCT05988567|DIETARY_SUPPLEMENT|melon and oil olive pressed candy|consume 2 tablets per day
214970009|NCT04222920|OTHER|Dose reduction to 2mg/L|Adalimumab dose reduction aiming drug concentration of 2mg/L
214970010|NCT04222920|OTHER|Dose reduction to 5mg/L|Adalimumab dose reduction aiming drug concentration of 5mg/L
214970011|NCT04222920|DRUG|Adalimumab|Adalimumab
214970012|NCT00327340|DRUG|custirsen (OGX-011)/mitoxantrone|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment."
214970013|NCT00327340|DRUG|custirsen (OGX-011)/docetaxel|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment."
214358670|NCT00817180|OTHER|High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System|Physiotherapy technique for airway clearance.
214358671|NCT00799292|DRUG|Vasopressin|20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
214970014|NCT01116921|DEVICE|Nasal continuous positive airway pressure (nCPAP)|nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.
214970015|NCT01116921|DEVICE|Laryngeal Mask Airway (LMA) to deliver surfactant|Laryngeal Mask Airway (LMA Unique-Size 1, The Laryngeal Mask Company Limited, San Diego, CA)
214970016|NCT01116921|DRUG|Surfactants, Pulmonary|Curosurf®, Chiesi USA, Inc., Cary, NC
214358672|NCT01477125|BEHAVIORAL|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
214358673|NCT04584034|DRUG|Salbutamol|Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate. Ventolin contains the propellant HFA 134a.
214358674|NCT04584034|DRUG|Placebo|The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
214970017|NCT04669431|OTHER|Xbox kinect Training|Xbox kinect 360, Tennis player, Joy riding, Rally ball. Tennis player in first 2 weeks, Joy riding in 3rd and 4th weeks, and all 3 games in 5th and 6th weeks 35 minute/3 days a week for 6 weeks with Conventional physical therapy, 25 minute
214970018|NCT04669431|OTHER|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living( eating, grooming, folding of towel, basket lifting, turn key into lock, reaching forward, sideways reach, ball grasping, picking up small blocks and lifting cane and pencil) 35 minute/3 days a week for 6 weeks
214970019|NCT06477744|BIOLOGICAL|Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_Low Dose|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -Low Dose : 7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
214970020|NCT06477744|BIOLOGICAL|Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_High Dose|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -High Dose : 1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
214970021|NCT02477592|PROCEDURE|individualized substrate modification|CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.
214970022|NCT02477592|PROCEDURE|stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
215083020|NCT00801476|PROCEDURE|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
215083021|NCT06076291|DRUG|SG1827|PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.
215083022|NCT03633279|DRUG|Branched chain amino acid|Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
215083023|NCT03633279|DRUG|Placebo|an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
214970023|NCT03144648|OTHER|lifestyle|Observational study
214970024|NCT03337815|DRUG|Treatment of MTX and TwHF placebo|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.
214970025|NCT03337815|DRUG|Treatment of TwHF and MTX placebo|Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
214970026|NCT05517629|OTHER|It is an observational cross-sectional study|It is an observational cross-sectional study
214970027|NCT00778596|DRUG|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
214358675|NCT04080804|DRUG|Nivolumab|A fully human anti-programmed death 1 (PD-1) monoclonal antibody checkpoint inhibitor, that blocks a signal that prevents activated T cells from attacking the cancer cells.
214358676|NCT04080804|DRUG|Relatlimab|A monoclonal antibody with anti-Lymphocyte-activation gene 3 (LAG-3) (immune checkpoint receptor protein found on the cell surface) activity.
214358677|NCT04080804|DRUG|Ipilimumab|A monoclonal anitibody that targets CTLA-4, a protein receptor, that down regulates the immune system.
214487577|NCT06461078|DRUG|Radotinib HCl|"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."
214487578|NCT05377528|DRUG|AGEN1571|A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.
214487579|NCT05377528|DRUG|Balstilimab|A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.
214358678|NCT04428879|DRUG|Topotecan Episcleral Plaque|Sustained Release Episcleral Topotecan Plaques (Chemoplaques) are glued to bare, dry sclera of the eye under conjunctiva and Tenon's capsule. A rolling six dose interpatient escalation schema will be employed. Chemoplaques with 0.6 mg and 0.9 mg of topotecan HCl formulation are available. Patients will receive 1 or 2 Chemoplaques per eye, to deliver 5 escalating doses: 0.6, 0.9, 1.2 \[2x0.6\], 1.5 \[0.6+0.9\] or 1.8 \[2x0.9\] mg. The prescribed dose will escalate or de-escalate by 0.3 mg at each level, and no patient will receive more than 1.8 mg of topotecan hydrochloride due to the physical limitations if the devices available. The planned removal is 42 days ± 7, unless dose limiting toxicity is observed, in which case the plaque is removed as soon as possible. The observation period for the purposes of dose-escalation will be 63 days (i.e. 21 days following Chemoplaque removal on day 42).
214358679|NCT06450132|DRUG|Atropine Ophthalmic|0.05% atropine ophthalmic solution
214358680|NCT06450132|DEVICE|MiSight 1-day disposable contact lenses|soft multifocal contact lenses
214358681|NCT05974449|DRUG|Vaginal Lactobacillus capsules|This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
214970028|NCT00778596|DRUG|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
214970029|NCT01460303|DEVICE|Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag|"OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
215083024|NCT02922842|DEVICE|Transcutaneous Electrical Nerve Stimulation|
214970030|NCT01460303|DEVICE|Transurethral catheter with leg bag|"Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
214970031|NCT00962312|DRUG|capecitabine|
214970032|NCT00962312|DRUG|lapatinib ditosylate|
214970033|NCT00241202|BEHAVIORAL|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
214970034|NCT03278821|BEHAVIORAL|Self Match|Video presentation of treatment option are shown to the patient whereafter the patient must choose between the five possible treatment options.
214358682|NCT06169514|OTHER|No intervention|No intervention
214358683|NCT02306070|DRUG|Metformin|metformin treatment + standard of care dietary and exercise advice
214358684|NCT02306070|DRUG|No metformin treatment|no metformin treatment + standard of care dietary and exercise advice
214970035|NCT03278821|BEHAVIORAL|Expert Match|Referral as usual to one of five possible treatment options. The referral is based on baseline data from the patient and by the means of an algorithm, used in daily clinical praxis.
214970036|NCT04958070|OTHER|MPS I|MPS I, symptoms of disease onset , ERT
214970037|NCT05660278|OTHER|Milk containing A1 and A2 beta-casein|Single dose of milk
214970038|NCT05660278|OTHER|Milk containing only A2 beta-casein|Single dose of milk
214970039|NCT01893112|BEHAVIORAL|Unity Workshop|The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training \& Education Center for health).
214970040|NCT01893112|BEHAVIORAL|Breast Cancer Screening|
214970041|NCT03662126|DRUG|KRT-232|KRT-232, administered by mouth
214970042|NCT03662126|DRUG|Best Available Therapy (BAT)|"Best available therapy options include:~1. hydroxyurea~2. chemotherapy or~3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed)."
214970043|NCT03403907|OTHER|Probiotic|twice a day for 4 months (Streptococcus thermophilus, Lactobacillus acidophilus, L.plantarum, L. paracasei, L. delbrueckii subs bulgaricus, Bifidobacterium breve, B.longus y B.infantis. y CD2).
214970044|NCT00347750|DRUG|Lopinavir pharmacokinetic/pharmacodynamic analysis|
214970045|NCT04230369|BEHAVIORAL|Exposure-based Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
215083025|NCT00413829|DRUG|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
215083026|NCT01963013|DEVICE|Non-returning catheter valve|
215083027|NCT01963013|DEVICE|Conventional urine bag|
215083028|NCT00266929|PROCEDURE|surgical|surgical treatment of odontoid fractures
215083029|NCT00266929|PROCEDURE|conservative treatment|conservative stabilization of fractures
214358685|NCT01394965|PROCEDURE|ECG electrodes|Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
214358686|NCT00265980|DRUG|Subcutaneous Placebo|Twice daily injections of saline in the same volume as will be used for leptin injections.
214358687|NCT00265980|DRUG|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
214358688|NCT01834105|DRUG|Liuwei Dihuang Pills|
214358689|NCT03348579|OTHER|Guidelines publication and application|Passing recommendations on using the guidelines in the intensive care units
214358690|NCT03348579|OTHER|Targeted experience feedback|"Targeted experience feedback: On top of the standard training, the centers receive an analysis of the evolution of the practices of their center and the future of their patients between phases 1 and 2, as well as these same values for the data set. The centers are then called to conduct a meeting to determine their priority improvement points based on this audi"
214358691|NCT05437133|DEVICE|Custom fabricated elbow extension orthosis|custom low temperature thermoplastic orthosis (Splint) holding the elbow in maximum extension at night
214358692|NCT05582564|OTHER|abstract vs concrete texts|The main experiment involved two groups of participants and two different articles about vaccine-related thrombosis taken from two Italian newspapers. One article used a more abstract descriptive style and language, while the other used a more anecdotical style and concrete language: each group read only one of these articles. Both articles are the same length and describe an episode of vaccine-related thrombosis. The abstract text uses a more formal and impersonal language, reporting more scientific considerations; the concrete text uses a more familiar and emotional style and provides a more anecdotical description of the case. Texts were also weighted according to a concreteness semantic vocabulary. French received translated versions.Two other groups were assigned categorization tasks; one was asked to complete a concrete categorization task and the other an abstract categorization task.
214487580|NCT05377528|DRUG|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
214970046|NCT04230369|OTHER|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
214970047|NCT01150630|DRUG|capecitabine|1250 mg/mq/day per os for 14 days every 14 days for 6 months
214970048|NCT01150630|DRUG|cisplatin|30 mg/mq every 14 days for 6 months
214970049|NCT01150630|DRUG|epirubicin|30 mg/mq every 14 days for 6 months
214970050|NCT01150630|DRUG|gemcitabine|ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
214358693|NCT06135103|DRUG|talfirastide|TXA127, a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II) is a sterile solution containing angiotensin (1-7) \[A(1-7)\], supplied in a 3 mL, single-use, stoppered vial.
214502730|NCT06106100|PROCEDURE|Antireflux mucosal ablation|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization
214970051|NCT03506438|BEHAVIORAL|Needs-focused mobile app|A mobile web app designed to assist both ICU clinicians in addressing patient/family needs and families in reporting their unmet needs.
214970052|NCT03506438|OTHER|Usual care|Usual ICU care as per the standards of the ICU attending
214970053|NCT05525351|DEVICE|Bispectral index (BIS) or Patient State Index (PSI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI). BIS is maintained between 40 - 60 and PSI between 25 - 50. The vital signs, BIS or PSI are recorded automatically and continuously through computerized software. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
214970054|NCT05525351|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Propofol is given via target control pump with typical target effect-site propofol concentration 1-5 ug/mL according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
214970055|NCT05525351|DRUG|Alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
214970056|NCT05525351|DRUG|Dexmedetomidine|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical Dexmedetomidine ranged from 0.5-1 ug/kg/hr according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
214358694|NCT06135103|DRUG|Placebo|Placebo is a sterile solution containing supplied in a 3 mL, single-use, stoppered vial.
214358695|NCT01816750|DEVICE|Cardiac GSI|A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
214358696|NCT01273233|BIOLOGICAL|Inactivated Enterovirus Type 71 Vaccine|A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
214358697|NCT01273233|OTHER|Placebo|Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
214970057|NCT01128296|DRUG|Hydroxychloroquine|Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
214358698|NCT04382105|OTHER|Observation of salivary IL-6 levels|Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
214358699|NCT02281799|DRUG|Azathioprine|"Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.~For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa."
214358700|NCT04381520|OTHER|Heat-sensitive moxibustion plus antihypertensive drugs|In this arm, patients will administer heat-sensitive moxibustion by themselves or by the help of their family after professional training. Patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
214358701|NCT04381520|DRUG|Antihypertensive drugs|In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
214358702|NCT05042778|OTHER|Auriculotherapy|A licensed acupuncturist (holder of civil liability insurance) with more than nine years of experience with this technique will apply auriculotherapy. Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used at the actives auricular points around the vagus nerve area.
214970058|NCT01128296|DRUG|Gemcitabine|Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
214970059|NCT05975814|DEVICE|dental implant|dental implants are placed as usual and require a healing abutment. Abutments can be straight or concave, both are equally available on the market.
214970060|NCT01317147|PROCEDURE|Roux-en-Y gastric bypass (RYGBP)|
214358703|NCT00698594|BIOLOGICAL|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
214358704|NCT00698594|BIOLOGICAL|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
214358705|NCT00698594|BIOLOGICAL|placebo|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
214358706|NCT02683564|DRUG|BOW015|monoclonal antibody against TNF-alpha
214970061|NCT01071174|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
214970062|NCT01071174|OTHER|Placebo|Vaginal Ring containing no drug substance
214970063|NCT02513004|DRUG|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
214970064|NCT02513004|DRUG|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
214970065|NCT00383201|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
214970066|NCT00345917|DEVICE|Retinal transplantation instrument|
214970067|NCT00345917|DEVICE|Fetal tissue.|
214970068|NCT03056521|OTHER|preoperative information about pain|It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
214358707|NCT02683564|DRUG|Remicade|monoclonal antibody against TNF-alpha
214358708|NCT05824065|DRUG|OMA102|1 mg
214358709|NCT05824065|DRUG|OMA102|2 mg
214358710|NCT05824065|DRUG|Placebo|OMA102 - Placebo
214358711|NCT05032209|OTHER|follow-up of children with severe asthma in adulthood|follow-up of children with severe asthma in adulthood
214502731|NCT06106100|PROCEDURE|Sham procedure|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed.
214502732|NCT00755144|DEVICE|LCS Knee|Cementless total knee arthroplasty with LCS Knee
214502733|NCT00755144|DEVICE|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
214970069|NCT04488445|BEHAVIORAL|Strength training|3 sets of 3 to 5 repetitions with 4 minutes of rest between sets. 90% load of 1 maximum repetition of a resistance exercise
214970070|NCT04488445|BEHAVIORAL|Stretch and balance training|3 sets of 3 exercises of stretching and balance of one minute each. One minute of resting time between sets.
214970071|NCT03060304|DRUG|Tamoxifen|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.
214970072|NCT03060304|DRUG|estradiol valerate|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
214970073|NCT01055015|DRUG|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
214970074|NCT01055015|DRUG|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
214970075|NCT04935203|BEHAVIORAL|Priming intervention|The priming manipulation will be embedded in one computerized experiment to test the effect of three priming interventions on people's emotional reaction and their subsequent sustainable food selection. The priming conditions include priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively. The cueing manipulation will be achieved by asking participants to complete a word-search exercise. Brief introduction will be provided to guide participants to choose words/statements that can indicate having a health and sustainable diet can have one of the three benefits: health benefits, environmental benefits or both benefits. The exercise will take \~2 min.
214970076|NCT04275258|OTHER|Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan|"PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed.~If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations.~If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation.~The collaborative pain care and opioid taper intervention ends at 20 weeks."
214970077|NCT06959056|DEVICE|cryo nerve block at T3-T8 intercostal nerves bilaterally|In order to obtain better analgesia at the level of the chest wall, where the chest is bilaterally opened for lung extraction and donor lung implantation, intraoperative cryo-ablation will be applied to the intercostal nerves at the bilateral intercostal spaces 3-8, 3cm lateral to the sympathetic chain, under direct visualization during surgery, as such covering 2 intercostal levels above as well as below the normal access of ICR 4 or 5. By providing analgesia to level 8, we will also cover the area of chest drains, which also tend to cause pain in the postoperative course, especially when patients start mobilizing at the ward. Each nerve bundle will be cooled to a temperature between -65 and -72 °C during 120 seconds by means of the CyroSphere v2 probe (AtriCure Inc; Mason, OH, USA) connected to the provided instrument tower (AtriCure CryoICE box) including a processor device measuring and regulating the N2O flow through the probe.
214970078|NCT04137809|DEVICE|AMBLE|Treadmill walking while wearing AMBLE device; three times a week for two weeks; 45-60 minutes per session.
214970079|NCT01851941|DRUG|mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
214970080|NCT06959576|OTHER|nanoparticles|Nanoparticles improve the dimensional stability of 3D printed denture base resin, so preventing instability of the denture over time
214970081|NCT06954324|PROCEDURE|Erector spinae plane block|This study aims to compare the effects of erector spinae plane block (ESPB) and systemic tramadol use as postoperative analgesia methods on the systemic immune-inflammatory index (SII) in patients undergoing breast cancer surgery.
214970082|NCT05203653|BEHAVIORAL|Resistance exercise only|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state.
214970083|NCT05203653|BEHAVIORAL|Resistance exercise plus cool down|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state followed by a 10-minute light aerobic cool down
214970084|NCT01818089|DEVICE|Lung sound analyzer|Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
214970085|NCT04553081|DRUG|Dual versus triple therapy in treatment of HIV-1 infection.|cfr arm description
214970086|NCT01831427|DRUG|Andecaliximab|Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
214970087|NCT01831427|DRUG|Placebo to match Andecaliximab|Placebo to match andecaliximab administered by IV infusion
214970088|NCT00536510|DRUG|laropiprant/niacin (MK0524A)|"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization"
214970089|NCT00536510|DRUG|Comparator: placebo|"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization."
214970090|NCT05869669|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
214970091|NCT05869669|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
214970092|NCT02169505|DRUG|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
214970093|NCT06122389|DRUG|SHR2554; Chidamide analog tablets|SHR2554 + Chidamide analog tablets
214502734|NCT00005974|DRUG|alvocidib|Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
214502735|NCT06855706|BEHAVIORAL|Behavioral Intervention|Receive personalized PA goals and positive feedback
214502736|NCT06855706|OTHER|Best Practice|Receive general PA counseling
214502737|NCT06855706|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214502738|NCT06855706|OTHER|Electronic Health Record Review|Ancillary studies
214970094|NCT06122389|DRUG|SHR2554 analog tablets; Chidamide|SHR2554 analog tablets + Chidamide
214970095|NCT02077998|RADIATION|carbon C 14 oxaliplatin|Given IV
214970096|NCT02077998|DRUG|oxaliplatin|Given IV
214970097|NCT02077998|OTHER|laboratory biomarker analysis|Correlative studies
214970098|NCT02043288|DRUG|NC-6004|"Study group (3 week/cycle):~NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1"
214970099|NCT02043288|DRUG|Gemcitabine|"Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15"
214970100|NCT02781987|OTHER|chronic pancreatitis|patients with chronic pancreatitis
214358712|NCT06105073|PROCEDURE|Pulmonary Rehabilitation Program|Consecutive patients who attend with a confirmed diagnosis of Systemic Sclerosis associated Interstitial Lung disease, at the Speciality Hospital from the Medical Center La Raza IMSS. The anxiety and depression questionnaire will be applied to them. Goldberg, as well as the SF-36 questionnaire to evaluate quality of life and the SySQ questionnaire to evaluate functionality, to include these data in the analysis, these questionnaires are validated in our population and have been widely used. All participants (T0) will undergo Forced Spirometry, Carbon Monoxide Diffusion Capacity and Cardiopulmonary Exercise Test. Then they will enter a supervised pulmonary rehabilitation program that consists of 36 sessions, which is equivalent to 12 weeks. At the end of this period (T1), again the respiratory function tests (spirometry, DLCO and Cardiopulmonary Exercise Test) as well as the Goldberg, SF-36 and SySq questionnaires.
214358713|NCT02586025|DRUG|FEC Chemotherapy|Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
214970101|NCT02824146|OTHER|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
215083030|NCT01981200|OTHER|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
215083031|NCT02285114|DRUG|F/TAF|F/TAF tablets administered orally once daily
215083032|NCT02285114|DRUG|3rd ARV agent|A 3rd antiretroviral (ARV) agent may include one of the following: allowed boosted 3rd ARV agents: lopinavir (LPV), atazanavir (ATV), darunavir (DRV); Allowed unboosted 3rd ARV agents: efavirenz (EFV), raltegravir (RAL), dolutegravir (DTG), or nevirapine (NVP)
215083033|NCT02285114|DRUG|Boosted PIs|Allowed boosted PIs: LPV, ATV, DRV.
214970102|NCT02174224|BEHAVIORAL|Brief Intervention|Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
214970103|NCT02174224|BEHAVIORAL|Case Management|Case management based on needs-assessment. Resource connection and mentoring.
214970104|NCT02174224|BEHAVIORAL|Standard Medical Care|This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
214970105|NCT02326272|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
214970106|NCT02326272|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
215083034|NCT03397134|DRUG|Placebo Oral Tablet|Placebo administered as a single dose once daily
215083035|NCT03397134|DRUG|Roluperidone 32 mg|Roluperidone administered as a single dose once daily
215083036|NCT03397134|DRUG|Roluperidone 64 mg|Roluperidone administered as a single dose once daily
215083037|NCT05904522|DIAGNOSTIC_TEST|biopsy|biopsy for histopathological examination
214358714|NCT02586025|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
214358715|NCT02586025|DRUG|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
214358716|NCT02586025|DRUG|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
214502739|NCT06855706|OTHER|Exercise Intervention|Participate in MVPA
214502740|NCT06855706|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit Sense 2 and CGM device
214502741|NCT06855706|OTHER|Questionnaire Administration|Ancillary studies
214970107|NCT01162889|DRUG|Placebo SC Injection|Single injection
214970108|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single intravenous infusion, 60 minute duration
214970109|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
214970110|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
214970111|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
214970112|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
215083038|NCT01156389|DRUG|Ritonavir and Pyramax|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
215083039|NCT01156389|DRUG|Pyramax|Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
214502742|NCT06855706|OTHER|Supportive Care|Receive ongoing support
215083040|NCT01538940|BIOLOGICAL|Intradermal vaccine|15ug
215083041|NCT01538940|BIOLOGICAL|Intramuscular vaccine|15ug
215083042|NCT03234348|DEVICE|Percutaneous coronary intervention|PCI + stent implantation
214358717|NCT02586025|DRUG|Placebo|Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
214502743|NCT04927494|BEHAVIORAL|Health is Wealth: A Cervical Health Program|Health is Wealth: A Cervical Health Program will be introduced in a one-time 2-hour educational session, participants will be given HPV self-sampling kits, and instructional sheet that visually depicts the steps for self-sampling. The program will be culturally tailored to increase self-efficacy and knowledge while simultaneously addressing perceived health beliefs associated with cervical cancer and barriers associated with cervical cancer screening and HPV self-sampling. Content will be delivered in a group format (about 10-15 participants) by lecture, demonstration, and interactive exercises.
214502744|NCT06016088|DRUG|RSP-1502|RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer. Each dose of RSP-1502 contains the active components tobramycin (300 mg) and CaEDTA in a 5 mL solution.
214970113|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single subcutaneous injection
214970114|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
214358718|NCT02586025|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
214970115|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
214970116|NCT01162889|DRUG|Placebo IV Infusion|Single intravenous infusion, 60 minute duration
214970117|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
214970118|NCT04126304|DRUG|Azithromycin|If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
214970119|NCT04126304|DRUG|non-macrolides antibiotics|If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
214970120|NCT04126304|DIAGNOSTIC_TEST|Mycoplasma detection|"1. common cold, acute bronchitis or post-infection cough :MPlgM colloidal gold detection;Pharyngeal swab MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection~2. community-acquired pneumonia:mycoplasma antigen antibody particle agglutination detection ;Sputum MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection"
214970121|NCT04126304|OTHER|Data collection|"1. Common cold:On enrollment, day 3 and day 7, scores were collected based on the Canadian acute respiratory diseases and influenza scale (CARIFS scale), success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~2. Acute bronchitis :on enrollment, day 3, and day 7, the Likert 7 subscale was used to score the cough severity questionnaire, collect the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~3. Post-infection cough:on the day after outpatient visit, day 3, day 7, and day 14, the cough severity questionnaire (Likert 7 subscale) was used to score the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate."
214970122|NCT04126304|OTHER|Data collection|Acquisition of children hospitalized time, heating time, mixed infection, drug (azithromycin, tetracycline, quinolone) dose and use time, pulmonary complication (pleural effusion, atelectasis, necrotizing pneumonia, interstitial pneumonia, occlusive bronchitis, occlusive bronchiolitis, lung, emphysema, lung abscess, bronchiectasis, transparent), pleural puncture/drainage, bronchoscope, oxygen time, into the ICU, mechanical ventilation time, surgery, and deaths and re-visit, hospitalization, surgery and death within 30 days after discharge
214970123|NCT05543538|OTHER|multimedia audio-visual program|Participants in the control group will receive teaching method with multimedia audio-visual material.
214970124|NCT05543538|OTHER|experiential learning programmes|Participants in the experimental group will receive teaching method with experiential learning.
214970125|NCT05543538|OTHER|teachers' personal demonstration|Participants in the experience group will receive teachers' personal demonstration.
214970126|NCT03099460|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
214970127|NCT03099460|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
214970128|NCT03099460|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
214358719|NCT06384586|DIETARY_SUPPLEMENT|Placebo shot|60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
214358720|NCT06384586|DIETARY_SUPPLEMENT|Functional energy shot|60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
214358721|NCT02541552|DRUG|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
214358722|NCT03493243|OTHER|Questionnaires|2-hour clinical observation
214358723|NCT04450537|BEHAVIORAL|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
214502745|NCT06016088|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution is 300 mg tobramycin in 5 mL solution.
214502746|NCT06151782|DIETARY_SUPPLEMENT|Wheat gluten 1000 mg|Nothing to add here
214502747|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 1000 mg|Nothing to add here
214502748|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 50 mg|Nothing to add here
214970129|NCT04784234|DIETARY_SUPPLEMENT|GlaucoCetin|GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
214970130|NCT04784234|OTHER|Placebo|The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
214970131|NCT03273959|OTHER|Exercise protocol|Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
214970132|NCT01676493|DRUG|Codeine|
214970134|NCT01513993|PROCEDURE|Telemonitoring for patients with Congestive Heart Failure|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms."
214970135|NCT05366595|DRUG|oral zinc sulfate|Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
214970136|NCT00000399|DRUG|Hormone replacement therapy|
214970137|NCT00000399|PROCEDURE|Strength training|
214970138|NCT00433550|DRUG|capecitabine|given orally
214970139|NCT00433550|DRUG|irinotecan hydrochloride|given IV
214970140|NCT00433550|DRUG|oxaliplatin|given IV
214970141|NCT01081782|DRUG|ONO-4641|0.15 mg once per day for 26 weeks
214970142|NCT01081782|DRUG|ONO-4641|0.1 mg once per day for 26 weeks
214502749|NCT06151782|DIETARY_SUPPLEMENT|Barley hydrolyzed gluten 50 mg|Nothing to add here
214970143|NCT01081782|DRUG|ONO-4641|0.05 mg once per day for 26 weeks
214970144|NCT01081782|DRUG|ONO-4641 placebo|Placebo once per day for 26 weeks
214970145|NCT02718872|BEHAVIORAL|Tobacco cessation online training|"The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the Brief Intervention for Smoking Cessation Training Program is composed of 4 modules."
214970146|NCT03920475|DRUG|Sertraline or venlafaxine|Patients were treated as needed with sertraline or venlafaxine following the official guidelines, starting with a dose of 25 mg/d or respectively 37,5 mg/day. The starting dose could be increased during the course of the treatment as clinically needed according to guide lines.
214970147|NCT03920475|DIAGNOSTIC_TEST|Immune parameters|Serum was taken before, during an after treatment for measurement of different immune parameters.
214970148|NCT05262816|OTHER|electroacupuncture|electroacupuncture at Sanyinjiao (SP6)
214502750|NCT06151782|DIETARY_SUPPLEMENT|Placebo slurry|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
214502751|NCT05882695|DRUG|SPG302|synthetic small molecule
214502752|NCT05882695|DRUG|Placebo|Placebo
214358724|NCT01981694|DRUG|PF-06649751|Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
214358725|NCT01981694|DRUG|PF-06649751|It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
214487581|NCT06978257|BEHAVIORAL|Digital positive affect intervention (PAI)|"The Positive Affect Intervention (PAI) is a fully digital, self-guided program uniquely designed to deliver weekly 30-minute online sessions focused on cultivating positive emotions, meaning, and engagement, alongside daily ecological momentary prompts delivered thrice daily over six weeks. Distinctively, the intervention seamlessly integrates multimedia content (e.g., brief weekly videos introducing each session's core principles), practical exercises, and in-the-moment reflection, aiming to reinforce positive affect skills in real time. Its structure not only emphasizes proactive skill application through digital reminders but also systematically assesses user engagement and perceived helpfulness via ecological momentary assessments and post-session feedback questionnaires.~Unlike conventional digital interventions that primarily focus on symptom reduction through passive content consumption, this PAI leverages continuous ecological momentary engagement via a dedicated mobile app, e"
214502753|NCT06602999|OTHER|Nutritional Intervention|Receive a booklet on nutrition and physical activity for cancer survivors
214502754|NCT06602999|OTHER|Instacart Voucher|Receive Instacart grocery delivery voucher
214502755|NCT06602999|BEHAVIORAL|Telephone-Based Intervention|Receive nutrition navigation phone calls
214970149|NCT02376504|BEHAVIORAL|Active workplace|This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.
214970150|NCT00468585|DRUG|Capecitabine|
214970151|NCT00468585|DRUG|Bevacizumab|
214970152|NCT02154139|DRUG|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
214970153|NCT02766348|DRUG|gemcitabine|gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
214970154|NCT02766348|BIOLOGICAL|DC-CTL|8×10\^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32
214970155|NCT02766348|DRUG|cisplatinum|cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
214970156|NCT03644771|DRUG|Acthar|4 treatment periods of 3 months each with 20 units biweekly, 40 units biweekly, and 80 units biweekly, with a tapering period to no drug for the fourth 3 month period. Then one year f/u.
215083043|NCT01752790|DRUG|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
215083044|NCT01752790|DRUG|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
215083045|NCT03523793|BEHAVIORAL|Clinical Practice Guideline Implementation|The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
215083046|NCT03523793|OTHER|Standard Care|Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
215083047|NCT05139199|BEHAVIORAL|Auricular Point Acupressure group|A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
214970157|NCT04238936|DIAGNOSTIC_TEST|Serum amyloid A values|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
214970158|NCT04238936|DIAGNOSTIC_TEST|Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
214970159|NCT01758497|PROCEDURE|Fascia iliaca compartment block|30 ml 0.5% ropivacaine, beneath the fascia iliaca
214970160|NCT01758497|PROCEDURE|Fascia Iliaca compartment block|30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
214970161|NCT03540862|DEVICE|maintenance negative pressure ventilation (Philips Respironics Lifecare NEV-100)|hospital-based NPV once every week as the maintenance program
214970162|NCT03212716|DRUG|Oseltamivir|150 mg twice a day during 10 days (ANSM guidelines for severe flu).
214358726|NCT06005766|BEHAVIORAL|Metacognitive Skills Training (MCT)|The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive\_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
214358727|NCT06005766|OTHER|Treatment as usual|Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
214358728|NCT00977353|DRUG|citalopram|20-60 mg/day, oral, for 6 weeks
214358729|NCT00977353|DRUG|sarcosine|500-1500 mg/day, oral, for 6 weeks
214358730|NCT01039051|BEHAVIORAL|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
214358731|NCT05338723|DRUG|Rosuvastatin 20mg|20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
214358732|NCT02538731|PROCEDURE|dilation-assisted stone extraction|
214358733|NCT02538731|DEVICE|Spyglass Guided Laser Lithotrips|
214358734|NCT01936480|DRUG|Moxifloxacin 400mg once time|
214358735|NCT01762150|DRUG|Sorafenib|Sorafenib 400mg BID by oral until progressed;
214358736|NCT01762150|DRUG|Gemcitabine|Gemcitabine: 1000mg/m2, administered by intravenous drip for 30\~60min on Day 1 and 8,for 4 cycles;
214358737|NCT01762150|DRUG|Cisplatin|Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
214358738|NCT04205630|DRUG|SYD985|SYD985 powder for concentrate for solution for infusion
214358739|NCT00173901|DRUG|ceftazidime|
214358740|NCT04526535|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound performed with a portable device with an 8 zones protocol within the first 24 hours after and ST-segment elevation acute myocardial infarction
214358741|NCT01785966|BEHAVIORAL|Daily checklist and clinician prompting|"Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items."
214358742|NCT00615043|PROCEDURE|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
214358743|NCT01918410|DEVICE|Contact Lens with alginic acid|Worn for 7 days, at least 8 hours a day
214358744|NCT01918410|DEVICE|Contact Lens without alginic acid|Worn for 7 days, at least 8 hours a day
214358745|NCT03386968|BEHAVIORAL|Active video gaming|"Children will visit Blythedale for 8 sessions, one 45-session visit per week, in place of one of the child's typical physical therapy sessions. During each session, children will play a video game on the X-Box Kinect system, using the games Kinect Adventures and Kinect Sports. The child will first play a Kinect Adventures game, which requires ambulating, ducking, and dodging one's way through an obstacle course."
214970163|NCT03212716|DRUG|Diltiazem|60 mgx3 per day during 10 days.
214970164|NCT03212716|DRUG|Placebos|Placebo of diltiazem
214970165|NCT05444790|DIAGNOSTIC_TEST|Rapid Diagnostic Test|The performance of two index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
214970166|NCT04036604|OTHER|Exercise|"Pelvic floor exercise programme include repetition of pelvic floor muscle contraction during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.~Pelvic floor education programme include pelvic floor anatomy, information about pelvic floor dysfunction and behavioral changes."
214358746|NCT03386968|BEHAVIORAL|Usual care physical therapy|Children will attend their usual care physical therapy appointments at Blythedale.
214358747|NCT05111795|DEVICE|Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres|SIRT work-up procedure and SIRT procedure
214358748|NCT00425048|PROCEDURE|wearing gloves|
214358749|NCT02054767|DRUG|Intervention: inferior alveolar nerve block injection|-22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
214970167|NCT00496340|DRUG|Pentostatin|"Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m\^2 on day -28. Patients may receive additional doses on days -21 \& -14 depending on cell counts.~Participant will receive pentostatin at a dose of 4 mg/m\^2 by intravenous infusion over 1-2 hours on days -4, -3."
214970168|NCT00496340|DRUG|Busulfan|"Pre-conditioning therapy:~Intravenous Busulfan (1st dose) at a dose of 200mg/m\^2 on day -4.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600."
214970169|NCT00496340|DRUG|Rituximab|"Pre-conditioning therapy:~Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m\^2 according to prescribing and institutional guidelines."
215083048|NCT00631150|DRUG|Levetiracetam (Keppra)|
214358750|NCT00473798|BEHAVIORAL|Questionnaire|Questionnaire
214358751|NCT03907124|DRUG|Genetically-guided treatment with FDA-approved psychotropic drugs|Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
214358752|NCT03907124|DRUG|Treatment as usual (TAU)|All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
214358753|NCT01081093|PROCEDURE|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
214487582|NCT06978257|BEHAVIORAL|Self-monitoring intervention|The self-monitoring intervention serves as an active comparator designed to isolate the effects of mood self-awareness without introducing therapeutic content. Participants in this arm receive daily prompts via the Qualtrics mEMA mobile app, three times per day over a six-week period, instructing them to track their mood and emotional states through brief ecological momentary assessments (EMAs). Unlike the digital positive affect intervention, this arm does not include psychoeducational material, skills training, or active enhancement strategies; instead, it focuses solely on routine self-monitoring to control for digital engagement and expectancy effects. This minimalist structure allows for a clean contrast between passive self-observation and active therapeutic engagement, enabling robust evaluation of the added value of the Positive Affect Intervention beyond self-monitoring alone
214487583|NCT06011629|DEVICE|Aquacel dressing|Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
214679173|NCT05305118|PROCEDURE|TSCS Mapping|"Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention."
214487585|NCT06982274|DRUG|Realgar-Indigo Naturalis Formulation|Oral Arsenic (Realgar-Indigo Naturalis Formulation) plus ATRA for low-intermediate risk APL pts, combined with daunorubicin for high-risk during induction
214487586|NCT06538779|DIAGNOSTIC_TEST|elastography,usg|Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.
214679174|NCT05305118|DEVICE|Transcutaneous spinal cord stimulation|"TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device)."
214679175|NCT06567106|OTHER|Ultrasound application|Apply ultrasound to the participant within a safe range.
214679176|NCT06567106|OTHER|No ultrasound application|No ultrasound application to the participant.
214487590|NCT06836453|DEVICE|Sweat stimulation and secretion quantification|"First session (50 minutes): a. Left arm: Iontophoresis using the Macroduct for the cholinergic and β-adrenergic stimulation (2 iontophoresis), then bubble test. b. right arm: Iontophoresis using the Macroduct for the cholinergic and β-adrenergic stimulation (2 iontophoresis), then evaporimetry.~Second session (50 minutes): a. Left arm: Iontophoresis using the Macroduct for the cholinergic and intradermal injection for the β-adrenergic stimulation, then bubble test. b. Right arm: Iontophoresis using the Macroduct for the cholinergic and intradermal injection for the β-adrenergic stimulation, then evaporimetry."
214487591|NCT05647265|BIOLOGICAL|Nivolumab|Given IV
215083049|NCT01309906|DEVICE|Investigational lens|Bausch \& Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.
214970170|NCT00496340|PROCEDURE|Allogeneic Hematopoietic Cell Transplant|Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
214970171|NCT03772808|DIETARY_SUPPLEMENT|Lycocomfort|Evaluate of the perceived efficacy of LycoComfort™ supplements in alleviating symptoms associated with lower urinary tract symptoms (LUTS) and general prostate discomfort over the duration of 12 weeks intervention
214970172|NCT06265090|OTHER|therapeutic exercises|Protocol of hemibridge with ball and balloon exercise Participants were given exercise called as hemibridge with ball and balloon exercise for 3 sessions over 3 days/week.
214358754|NCT04534231|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
214358755|NCT03388567|OTHER|Staff pharmacy whith intervention|Pharmacists who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
214358756|NCT04154202|OTHER|Bone Scan|Bone Scan: three-phase planar Bone Scan and a SPECT/CT \[perfusion, blood pool and SPECT/CT of the relevant region of interest (ROI), and a whole-body planar late bone scan\].
214487592|NCT05647265|BIOLOGICAL|Ipilimumab|Given IV
214487593|NCT05647265|PROCEDURE|Surgical Procedure|Undergo surgery
214487594|NCT05647265|PROCEDURE|Computed Tomography|undergo CT
214487595|NCT05647265|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214487596|NCT05647265|PROCEDURE|Positron Emission Tomography|Undergo PET
215083050|NCT01309906|DEVICE|Air Optix Aqua lens|Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
215083051|NCT01688947|DRUG|V116517 50-mg tablets|Taken orally twice daily
215083052|NCT01688947|DRUG|V116517 30-mg tablets|Taken orally twice daily
215083053|NCT01688947|DRUG|Pregabalin capsules|1-2 capsules taken orally twice daily
215083054|NCT01688947|DRUG|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
214358757|NCT02352558|DRUG|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
214358758|NCT02352558|DRUG|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
214358759|NCT02352558|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
214358760|NCT02352558|DRUG|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
214358761|NCT02352558|DRUG|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
214487597|NCT05811078|BEHAVIORAL|training sessions with peer interactive group|"Data were collected with data collection forms consisting of  Diabetes Adolescent Diagnosis Form, Diabetes Information Evaluation Form, Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes and Child's Attitude towards Own Disease Scale ."
214487598|NCT06781905|OTHER|Assessments of neuropsychiatric, neurocognitive and psychosocial alterations|Assessments will be conducted over two consecutive days. The first day will focus on the evaluation of neuropsychiatric and neurocognitive alterations. A comprehensive assessment involving various tools (clinical examination, individual interview, psychometric tests, standardized scales) will be carried out by a psychiatrist, a neuropsychologist, and a neurologist. The second day will be dedicated to psychosocial assessments by a team of social psychologists using a comprehensive qualitative and quantitative approach to quality of life. Quality of life will be understood as a subjective appreciation of the individual's place in their existence and three main dimensions will be explored: daily life management, social relationships, and self-image and self-esteem. The collected data will be subjected to a reflexive thematic analysis. The qualitative exploration of quality of life will be complemented by a quantitative assessment using a standardized tool (EORTC QLQ LC13).
214487599|NCT06996899|OTHER|Health Improvement Profile (HIP)|"The Health Improvement Profile (HIP) is a comprehensive physical assessment conducted by a trained clinician which aims to link evidence based interventions for flagged abnormal health parameters. There are 27 health parameters assessed such as weight, Body Mass Index (BMI), blood pressure, blood glucose, cholesterol levels, and waist circumference, alongside questions on lifestyle factors like smoking, diet, and physical activity, as well as medication use and its side effects.~Client participant will collaborate with their clinician in developing an individualised Health Improvement Profile which identifies suitable health behaviours interventions to improve physical health.~Health behaviours may be associated with diet, exercise, sleep, hygiene (including oral care) and mindfulness."
214487600|NCT06996899|OTHER|Clinician Health Improvement Profile user training|Clinician/staff participants will receive Health Improvement Profile user training on how to conduct the comprehensive physical assessments for 27 health parameters and how to link the evidence based actions to develop an individualised Health Improvement Profile for clients admitted to inpatient service. Training includes online videos simulating assessments and completing the Health Improvement Profile and face to face workshops.
214487601|NCT06996119|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214970173|NCT06265090|OTHER|exercises|"The second group received hemibridge with ball and balloon exercise in combination to core stability exercises.~Protocol of hemibridge with ball and balloon exercise The hemibridge with ball as well as balloon exercise was provided to the participants over the course of three sessions per week.~Instructions~1. supine-lying position, feet up against a wall, and bend your knees as well as hips to a 90° angle.~2. Insert a ball measuring between four and six inches in diameter in the space between your knees.~3. Put your left hand upon a balloon and your right arm above your head.~4. Tilt your pelvis to make sure your tailbone is just slightly elevated off the ground while you inhale with your nose and exhale using your mouth. Keep your low back as flat as possible on the mat. Dig your heels into the wall instead of pushing your feet flat.~5. drop your left knee till it is below the level of your right, without moving your feet. the activation of your left inner thigh muscle."
214970174|NCT00809445|BEHAVIORAL|On-site HIV rapid test and brief, prevention counseling|Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
214970175|NCT00809445|BEHAVIORAL|On- site HIV rapid test & information|Participants will be offered an on-site oral fluid HIV rapid test with basic info.
214970176|NCT00809445|BEHAVIORAL|Referral for off-site HIV testing|Participants will be offered a referral list of HIV testing agencies in the community.
214970177|NCT02490826|OTHER|Table-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation."
215083055|NCT06980792|PROCEDURE|Pancreatectomy and liver resection|Surgery for synchronous liver metastasis from PDAC with or without previous neoadjuvant chemotherapy
215083056|NCT06980792|DRUG|Chemotherapy|Chemotherapy alone in potentially resectable patients with PDAC and synchronous liver metastasis
215083057|NCT06979882|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
215083058|NCT06979882|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
214358762|NCT02073084|DRUG|K-877 Low Dose|K-877 Low Dose
214358763|NCT02073084|DRUG|Moxifloxacin|
214358764|NCT02073084|OTHER|Placebo|
214358765|NCT02073084|DRUG|K-877 High Dose|K-877 High Dose
214487602|NCT06996119|DRUG|Busulfan|Given IV
214487603|NCT06996119|PROCEDURE|Computed Tomography|Undergo chest CT
214487604|NCT06996119|DRUG|Cyclophosphamide|Given IV
214487605|NCT06996119|PROCEDURE|Echocardiography Test|Undergo ECHO
214970178|NCT02490826|OTHER|Tablet-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation."
214970179|NCT00821275|PROCEDURE|Interventional radiological or surgical management|Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
214970180|NCT06241911|DEVICE|transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation (tVNS) is a newly developed treatment for neuromodulation. It offers advantages such as being non-invasive, cost-effective, and not requiring battery changes, unlike invasive vagus nerve stimulation (iVNS). The auricular branch of the vagus nerve, which is the only afferent branch distributed on the surface of the human body, can be directly stimulated to produce effects similar to classic vagus nerve stimulation (VNS)
214970181|NCT03235037|DRUG|Levodopa|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
214970182|NCT00844402|DRUG|Atorvastatin|oral, 10 mg, daily, 48 weeks
214970183|NCT00676403|DRUG|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
214970184|NCT00676403|DRUG|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
214970185|NCT00676403|DRUG|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
214970186|NCT00676403|DRUG|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
214970187|NCT00676403|DRUG|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
214970188|NCT00676403|DRUG|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
214970189|NCT03747848|BEHAVIORAL|CBT group|Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity, changing poor sleeping hygiene habits, stress management, and encouraging utilization of social support.
214970190|NCT01831869|DRUG|L-thyroxine|
214970191|NCT03506048|DRUG|Lenvatinib|Given orally once daily continuously
214970192|NCT02911649|OTHER|Wearable Technology - Garmin Vivosmart|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
214970193|NCT02911649|OTHER|Online Educational Group|A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
214970194|NCT02911649|OTHER|Wearable Technology - FitBit Alta|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
214970195|NCT02911649|OTHER|Wearable Technology - Polar Loop 2|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
214358766|NCT01618162|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
214358767|NCT01618162|DRUG|placebo|Injected subcutaneously (under the skin) once daily.
214358768|NCT05829161|BEHAVIORAL|no intervention|no intervention
214358769|NCT02901457|OTHER|"The Healthy Body Image intervention"|Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
214358770|NCT01189916|PROCEDURE|Endoscopically assisted Appendectomy Surgery|Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
214358771|NCT05253248|DIETARY_SUPPLEMENT|OMIS|This is an open-label micronutrient supplementation trial in healthy adult volunteers. We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days.
214487606|NCT06996119|BIOLOGICAL|Emapalumab|Given IV
214487607|NCT06996119|DRUG|Fludarabine|Given IV
214487608|NCT06996119|PROCEDURE|Hematopoietic Cell Transplantation|Given infusion
214487609|NCT06996119|DRUG|Melphalan|Given IV
214487610|NCT06996119|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214487611|NCT06996119|DRUG|Mycophenolate Mofetil|Given IV or PO
214358772|NCT02693275|DEVICE|Quotient® System iPad Test|See arm/group description
214358773|NCT04124926|DRUG|Vonoprazan|Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
214358774|NCT04124926|DRUG|Lansoprazole|Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
214358775|NCT04618185|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI to study gut function and transit without the risk of exposure to ionising radiation.
214970196|NCT04822714|BEHAVIORAL|Mobile Career Competencies Intervention|Mobile career competencies intervention aim to enhance the career competencies (career behavioral action) among the participants
214970197|NCT06100536|BEHAVIORAL|Music-with-movement|The intervention group participants will receive 12 weekly music-with-movement interventions facilitated by trained staff in a community centre or a residential care home. The duration lasts 30 minutes to one hour. It can be carried out individually or with up to six persons in a group. The intervention will be supported by the standalone music-with-movement system.
214970198|NCT03648788|OTHER|NA (Observation study)|NA (Observation study)
214970199|NCT04987112|DRUG|CAN1012|CAN1012 IT injection (once every 4 weeks)
214970200|NCT02052986|OTHER|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
214358776|NCT04603534|OTHER|Aged Simulation Suit|The aged simulation suit (Sakamoto Model M716, Tokyo, Japan) will be worn by students. The simulation suit consist of a several items such as loads, a soft material band with Velcro, glasses, ear plugs, gloves, belts and a cane. All the items are need to simulate one's posture just like in elderly person. Small, medium and large sizes of suits are provided by the company thereby each suit is suitable for each student related to their wearing size. Prior to this study, a total of three sets of suits will be gathered. Then, each student will perform each pre-defined scenarios step by step after the suit is worn. During the activities no help or leading will be given to the students. However, one of the researchers will supervise the students during the activities so that to integrate a safe platform. In addition, each student will be informed that if he/she can terminate the activity whenever it is required.
214358777|NCT03725683|DEVICE|Increased caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
214358778|NCT03725683|DEVICE|matched caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
214358779|NCT02964416|DRUG|Injection Tramadol|
214358780|NCT02964416|OTHER|placebo|0.9% Normal saline in 10 ml syringe
214487612|NCT06996119|OTHER|Questionnaire Administration|Ancillary studies
214970201|NCT05191966|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|"S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
214358781|NCT00003260|DRUG|FOLFIRI regimen|
214358782|NCT00003260|DRUG|FOLFOX regimen|
214358783|NCT00003260|DRUG|fluorouracil|
214358784|NCT00003260|DRUG|irinotecan hydrochloride|
214358785|NCT00003260|DRUG|leucovorin calcium|
214970202|NCT05191966|PROCEDURE|Thoracic Paravertebral Block|"TPVB block will be performed 30 min. before general anesthesia. TPVB will be performed at T10 transverse process level, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the paravertebral space.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
214970203|NCT05719194|OTHER|Standard SBT|Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.
214970204|NCT05719194|OTHER|SBT with T-piece or PSV|"\- Risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.~If SBT failed : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.~\- No risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful."
214358786|NCT00003260|DRUG|oxaliplatin|
214358787|NCT01940042|BEHAVIORAL|CO2 was removed by means of trandelenburg positions|
214358788|NCT01587508|DRUG|meloxicam/cyclobenzaprine hydrochloride|two oral capsules a day during approximately 07 days
214358789|NCT01587508|DRUG|meloxicam - Movatec®|two oral tablet a day during approximately 07 days
214487613|NCT06996119|DRUG|Tacrolimus|Given IV or PO
214970205|NCT01039467|DEVICE|Medtronic Adapta Dual Chamber Pacemaker|Medtronic Adapta Dual Chamber Pacemaker
214970206|NCT02048722|DRUG|regorafenib|Given PO
215083059|NCT06979882|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
215083060|NCT06605573|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
215083061|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Placebo Product (PP)|1 spray (0 mg melatonin)
215083062|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Active Control (AC)|1 spray (1 mg melatonin)
215083063|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Test Product (TP)|1 spray (0.3 mg melatonin)
214358790|NCT01587508|DRUG|cyclobenzaprine - Miosan®|two oral tablet a day during approximately 07 days
214970207|NCT05696964|BEHAVIORAL|Motivational interviewing training enhanced with artificial intelligence|The training in motivational interviewing that medical residents will receive will make use of an artificial intelligence measurement tool, Real-time Assessment of Dialogue in Motivational Interviewing (ReadMI), that produces a spectrum of relevant MI metrics.
214970208|NCT04823780|DIETARY_SUPPLEMENT|nutrient solution|For the patients with esophageal and gastric varices after endoscopic treatment，start taking the nutrient solution at the fourth hour.
214970209|NCT04511897|DRUG|An'ningpai|An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
214970210|NCT04844216|DEVICE|STYLAGE® L Lidocaine|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
214970211|NCT04844216|DEVICE|Active control|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
214970212|NCT00766766|BEHAVIORAL|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
214970213|NCT00766766|BEHAVIORAL|Telephone Coaching Sessions|Telephone Coaching Sessions
214970214|NCT00766766|BEHAVIORAL|Physician Feedback Letter|Physician Feedback Letter
214970215|NCT01339039|DRUG|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
214970216|NCT01339039|DRUG|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
214970217|NCT01339039|DRUG|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
214970218|NCT01339039|DRUG|Plerixafor|Daily administration for 5-9 days prior to surgery
214970219|NCT01339039|PROCEDURE|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 \& 15).
214970220|NCT04335435|DIETARY_SUPPLEMENT|Oat Bran Consumption|Oat bran (120 g), single dose.
214358791|NCT03386279|DRUG|PF-04965842|one single dose of 600 mg by mouth
214970221|NCT00006077|DRUG|NS2330|
214970222|NCT00006077|DRUG|Levodopa and Domperidone|
214970223|NCT05714462|OTHER|meals consisting of primarily animal protein sources|an omnivorous diet
214970224|NCT05714462|OTHER|meals consisting of plant protein sources|an herbivorous diet
214970225|NCT00905996|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
214970226|NCT00905996|DRUG|Beta-blocker (propranolol)|
214970227|NCT03222908|BEHAVIORAL|Intervention1: Contract Agreement|Smoking Cessation Contract
214970228|NCT03222908|BEHAVIORAL|Intervention2: Implementation Intentions|Smoking Cessation Contract with worksheet for implementation intentions
214970229|NCT02733718|DEVICE|NIRS (near-infrared spectroscopy)|mesenteric oxygenisation measurement
214970230|NCT04076241|OTHER|Osteopathic manipulative treatment|The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures. Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration. Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
214970231|NCT04076241|OTHER|Yoga respiratory training|Nadishodhana pranayama (Alternate nostril breathing), Ujjayi pranayama (Psychic breath) and Bhramari pranayama (Humming bee breath) were used for the study. Nadishodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one. The patients performed 2 sets of 8 breathing cycles with a resting time of 2 minutes between the sets. Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis. The patients performed 2 sets of 10 breathing cycles per session with an inspiration:expiration phase as 1:2. Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils. The patients applied 2 sets of 10 breathing cycles per session with a respiration rate of 3-4/min.
214970232|NCT02884102|GENETIC|genetic sequencing|
214970233|NCT03672864|BEHAVIORAL|Intensive exercise|Intensive, child-initiated movement of the lower extremity: 1 hour/day, 4 days/week, 2 sessions delivered by a physical therapist, 2 delivered by a parent. All activities are play based, and exercise intensity is enhanced by small weights placed on the dorsum of the foot and the ankle of the affected limb. Intervention is delivered over 12 weeks for a target of 48 hours of training.
214970234|NCT02788721|DRUG|GLPG2451 single dose|GLPG2451 oral suspension, single ascending doses, daily
214970235|NCT02788721|DRUG|Placebo|Placebo, oral suspension, daily
214358792|NCT03386279|DRUG|Moxifloxacin|one single dose of 400 mg by mouth
214358793|NCT03386279|DRUG|Placebo|one single dose by mouth
214358794|NCT03871595|DRUG|BI 894416|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water.
214358795|NCT02694705|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
214358796|NCT02694705|DEVICE|Bag-Valve-Mask (BVM)|Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
214358797|NCT02694705|DEVICE|Non-rebreather Mask (NRM)|Preoxygenation provided by NRM, oxygen flow rate 15 l/min
214358798|NCT05640349|BIOLOGICAL|Positive blood culture|Positive blood culture recorded at the microbiology laboratory of University Hospital of Nic
214358799|NCT00911534|DRUG|rabeprazole sodium|One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
214358800|NCT00911534|DRUG|Placebo|One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
214358801|NCT06579716|OTHER|Traditional balance exercise|All patients in both group received a traditional balance exercise program, 3 sessions per week, for 6 weeks. Each session of exercise comprised 10 min of warm-up, 40min of balance exercise, and 5min of cool down. Warm-up included treadmill walking. Balance exercise comprised two sets of sit to stand, one leg stance, tandem stance and 30 squats. The first set of exercises was performed on a stable surface, whereas the second set of exercises was performed on an unstable surface by using Thera band stability trainer. Each set of each exercise was performed for 3 min, with 1-2 min of rest in between the exercises. Cool-down included deep breathing, abdominal breathing, and mild stretching.
214970236|NCT04569175|OTHER|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
214970237|NCT04760301|DRUG|local tranexamic acid injection|local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
214970238|NCT04760301|OTHER|local normal saline injection to cervix|local normal saline injection to the cervix- 20 ml saline
214970239|NCT02570386|PROCEDURE|Fresh embryo transfer|Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
214970240|NCT02570386|PROCEDURE|Frozen embryo transfer|Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
214970241|NCT02406456|OTHER|Neurofeedback|
214970242|NCT01870986|BIOLOGICAL|PF-06410293|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
214358802|NCT06579716|OTHER|Resistance exercise|All patients in both group received a resistance exercise program, 3 sessions per week, for 6 weeks. Each patient was seated in sitting position and the weight sandbags was applied at the dorsum of the foot. The resistance was set to be around 40%-60% of the 1RM. The patient performed the exercise for 3 bouts, every bout 10 repetitions. The one repetition maximum (1RM) was established prior to the training period using the following equation: 1 RM = Weight (kg) X (1 + {0.033 X number of repetitions)}.
214358803|NCT06579716|OTHER|Whole-body vibration (WBV)|Patients were asked to stand barefoot on the vibratory platform with an even distribution of weight on both feet and familiarized with WBV at a lesser frequency and amplitude. Then, they were asked to bend their knee 30º to the vertical; thereafter, to obtain a greater muscular response, WBV training was performed at a frequency of 30 Hz and an amplitude of 2mm. The exercise comprised five bouts of a 30-sec vibration with a 1-min elapse between the bouts.
214358804|NCT06579716|OTHER|Kineso tape|Kineso tape was applied to dorsiflexors 24 hours a day and was replaced every 5 days for patients who were taped in accordance with Kenzo Kase's Kinesio taping Manual. For taping, each patient's leg was placed in a relaxed position while he sat on a taping table. The skin was to be free of oils and lotions, to avoid anything that might limit the acrylic adhesive's ability to adhere to the skin. So, the subject's skin was cleaned with alcohol prior to tape application. For the Tibialis anterior, tape was measured from the muscle origin to the insertion while the muscle was stretched. The base of the tape was applied to the origin at the lateral condyle and superior 2/3 of anterolateral surface of tibia. Then the subject was asked to stretch the foot into plantar flexion and eversion; taping was then finished toward the insertion at the medial and plantar surface of medial cuneiform and base of the first metatarsal.
214358805|NCT02099474|OTHER|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
214358806|NCT04957537|BEHAVIORAL|semantic therapy and semantic re-education|"Patients will be followed over two periods Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks).~Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.~Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.~In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes)."
214358807|NCT03067038|DEVICE|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy with single port device
214358808|NCT03067038|DEVICE|Three port laparoscopic cholecystectomy|Laparoscopic cholecystectomy with three port
214487614|NCT06017115|DEVICE|Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)|Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
214487615|NCT06619847|DRUG|VX-993|Tablets for oral administration.
214487616|NCT06619847|DRUG|HB/APAP|Capsules for oral administration.
214970243|NCT01870986|BIOLOGICAL|Humira (adalimumab-EU)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
214970244|NCT01870986|BIOLOGICAL|Humira (adalimumab-US)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
214970245|NCT00669188|OTHER|Information absent|Information
214970246|NCT00669188|OTHER|Information|Information
214970247|NCT05720559|DRUG|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area
214970248|NCT05720559|DRUG|S1|Orally on d2-d15 at 20 mg three times daily
214970249|NCT05720559|DRUG|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
214487617|NCT06619847|DRUG|Placebo (matched to VX-993)|Placebo matched to VX-993 for oral administration.
214487618|NCT06619847|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
214487619|NCT06866093|OTHER|Lifestyle|Participants are asked to answer online survey questions about their anthropomethry, clinical conditions, socio-economical status, dietary habits, physical activity levels, quality of life, sleep quality and pshycological distress.
214487620|NCT01089101|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214487621|NCT01089101|DRUG|Selumetinib|Given PO
214487622|NCT06775028|OTHER|iABC platform use|The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment.
214487623|NCT06062420|DRUG|Dostarlimab|Dostarlimab will be administered.
214487624|NCT06062420|DRUG|Belrestotug|Belrestotug will be administered.
214487625|NCT06062420|DRUG|Nelistotug|Nelistotug will be administered.
214970250|NCT05720559|DRUG|Metronidazole|Metronidazole 0.4g/time, qd
214970251|NCT05720559|DRUG|Vitamin A|Vitamin A 25,000 units/time, qd
214970252|NCT05720559|DRUG|Folic acid|Folic acid 0.4 mg/time, qd
214487626|NCT06062420|DRUG|GSK4381562|GSK4381562 will be administered.
214487627|NCT06756321|BIOLOGICAL|anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells|"Each subject will be infused with single dose. A classic 3+3 dose escalation will be employed.~anti-CD19-CAR T-cells~Dose level 1：1x10\^5 CAR T cells/kg, Dose level 2：3x10\^5 CAR T cells/kg, Dose level 3：1x10\^6 CAR T cells/kg~anti-CD30-CAR T-cells~Dose level 1：3x10\^6 CAR T cells/kg, Dose level 2：6x10\^6 CAR T cells/kg, Dose level 3：1x10\^7 CAR T cells/kg~anti-CD20/CD30-CAR T-cells~Dose level 1：1x10\^6 CAR T cells/kg, Dose level 2：3x10\^6 CAR T cells/kg, Dose level 3：1x10\^7 CAR T cells/kg"
214487628|NCT06756321|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
214970253|NCT05720559|DRUG|Capecitabine|Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.
214970254|NCT04302402|DRUG|Rifaximin|Rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia
215083064|NCT06604780|BEHAVIORAL|Transitional discharge program|"For patients classified in the low-risk group, general measures would be applied. For patients in the medium-risk group, reinforced measures would be implemented. Lastly, for patients considered to be in the high-risk group, intensive case management measures would be applied, and if they meet the inclusion criteria, they would be included in the Post-Discharge Group Psychotherapeutic Intervention.~1. General measures~2. Reinforcement measures~3. Intensive measures~   * Intensive case management measures~  * Post-Discharge Psychotherapeutic Recovery Support Program: For application to patients at high risk of early readmission who meet the inclusion criteria. It consists of a multicomponent group psychotherapeutic intervention from a rehabilitative and recovery-oriented perspective. This intervention will be structured into 20 sessions, each lasting 90 minutes, held weekly in an open format."
214487629|NCT06756321|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
214487630|NCT07013929|DEVICE|Renal nerve stimulation|Renal nerve stimulation will be performed prior to and post renal denervation.
214970255|NCT04302402|DRUG|Placebo|Similar looking placebo
214487631|NCT06625970|DRUG|Darolutamide|Pharmaceutical form: 300 mg tablets Administration route: oral (PO) Posology: 600 mg twice daily (BID)
214970256|NCT02432339|DRUG|mycophenolate mofetil (MMF)|an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
214970257|NCT02432339|DRUG|Placebo|a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
214970258|NCT05209880|BEHAVIORAL|ED GOAL|The emergency department clinician-led, behavioral intervention (ED GOAL) is designed to engage seriously ill yet clinically stable older adults in the emergency department to address their values and preferences towards end-of-life care with their outpatient clinicians. The intervention consists of an interview to discuss participants' values and preferences for end-of-life care. The participants will receive coaching on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and outpatient clinicians. The participants' outpatient clinicians will also receive a summary of what participants disclosed via email or mailed letter.
214487632|NCT06625970|RADIATION|Stereotactic Body RadioTherapy (SBRT)|"Following randomization, patients will receive dose escalated intensity modulated radiotherapy (IMRT) using normo-fractionation or moderate hypo-fractionation including whole pelvic nodal radiotherapy (WPRT).~At study entry, each investigational site will be asked to choose one regimen (normo-fractionation or moderate hypo-fractionation) which will be applied for all patients included by the investigational site in the study.~SBRT, experimental treatment, will be used as a boost in Arms C \& D. The placement of 3 to 4 fiducial markers for stereotactic boost is mandatory.~SBRT will be applied only on Prostate: 2 times 10 Gy delivered to the prostate with a gap of one week between each SBRT fraction."
214487633|NCT06625970|DRUG|ADT (Standard of Care)|"Androgen Deprivation Therapy (ADT)~The ADT treatment will be chosen at the investigator's discretion, and will be administered according to local standard procedures for up to 2 years.~Patients who may have received ADT prior joining the study should have started the ADT treatment within a maximum of 6 weeks before randomization. Otherwise ADT will be started on Day 1 (or 14 days at the latest after the randomization)."
214970259|NCT00432900|RADIATION|[(11)C]PBR28|PET Ligand
214970260|NCT00405405|DRUG|Cisplatin|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
214970261|NCT00405405|DRUG|Docetaxel|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
214679177|NCT04917796|OTHER|Electroacupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
214970262|NCT00405405|DRUG|Bevacizumab|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
214970263|NCT00405405|DRUG|Erlotinib|"* Two cycles during neoadjuvant therapy (dose escalation)~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
214970264|NCT00405405|RADIATION|Radiotherapy|Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
214970265|NCT03983200|DEVICE|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min, bid
214970266|NCT03983200|DRUG|Mecobalamin|mecobalamine 0.5mg,tid
214970267|NCT06044818|DEVICE|Accexible|Speech Analysis
214970268|NCT01021397|DRUG|rHPIV3cp45|10\^5 TCID50 nasal drops
214970269|NCT01021397|DRUG|rHPIV3cp45 placebo|1X-L15 nasal drops
215083065|NCT03610139|DIETARY_SUPPLEMENT|Vitamin D3|At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
214358809|NCT04777045|DRUG|Diltiazem Hydrochloride|"Diltiazem hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). It is a white to off-white crystalline powder with a bitter taste. It is freely soluble in water, methanol and chloroform. It has a molecular weight of 450.98.~It provides its therapeutic effects by blocking the influx of calcium ions into vascular smooth and cardiac muscle cells during membrane depolarization. The decrease in intracellular calcium causes relaxation of smooth muscle cells and cardiac myocytes by inhibiting actin-myosin interactions. Vasodilation subsequently results in decreased peripheral vascular resistance. The antihypertensive effect of diltiazem in hypertensives is greater than in normotensives.~Diltiazem is registered for the treatment of hypertension, heart rate control in supraventricular tachycardia, chronic stable angina pectoris and angina pectoris resulting from coronary artery spasm."
214358810|NCT04777045|DRUG|Placebo|Matching placebo capsules, given QD per oral use. Placebo capsules will be used in the same manner with the same dose titration.
214358811|NCT06635967|DEVICE|frequency-specific rTMS|Patterned repetitive transcranial magnetic stimulation will be performed at specific frequencies and inter-train intervals
214358812|NCT06635967|DEVICE|1 Hz rTMS|Low-frequency rTMS will be performed at a frequency of 1Hz
214358813|NCT06636188|OTHER|Digi-Coach Chatbot|Participants will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer related concerns in the chatbot.
214358814|NCT06635707|DRUG|Urapidil|"1. Control systolic blood pressure within 130-140mmHg using urapidil and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, positioning of the body, and other means to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the use of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
214358815|NCT06635707|DRUG|Urapidil and Esmolol|"1. Utilize both urapidil and esmolol to control systolic blood pressure within 130-140mmHg and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, strategic positioning of the body, and other measures to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the administration of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
214970270|NCT05870306|PROCEDURE|pulmonary vein isolation and targeted radiofrequency ablation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins. Extra radiofrequency ablation will be performed on the targeted areas
214970271|NCT05870306|PROCEDURE|pulmonary vein isolation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins.
214970272|NCT05714501|DEVICE|Millipede System|Mechanical thrombectomy
214970273|NCT05293860|OTHER|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
214970274|NCT05293860|OTHER|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
214970275|NCT05766579|DEVICE|Elastic-compressive stockings|Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.
214970276|NCT05564598|BIOLOGICAL|CMV Cytotoxic T-Lymphocytes|Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.
215083066|NCT06658717|DIETARY_SUPPLEMENT|Investigational product (IP): Natural orange extract|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
215083067|NCT06658717|DIETARY_SUPPLEMENT|Group II: Placebo: Microcrystalline cellulose (MCC)|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
215083068|NCT06608706|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) for psychosis|EMDR aims to treat and process trauma by safely retrieving the trauma memories while taxing the working memory. EMDR targets trauma symptoms through memory reprocessing of traumatic memories, and consists of eight flexible phases: history taking/case conceptualization; preparation for memory reprocessing; assessment/identification of a target memory; desensitization/reprocessing; installation of positive cognition; body scan; closure; and re-evaluation. EMDR in the current trial has psychosis-specific adaptations including focus on psychoeducation, preparation for reprocessing and patient safety. Techniques targeting dissociation, psychotic symptoms and psychosis-related challenges are included.
215083069|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
214970277|NCT05564598|DRUG|Anti-viral Therapy|"All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months"
214970278|NCT06958796|DRUG|Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months|The interventional arm will receive Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months as (150 mg/kg) for 3 consecutive months (Days 0, 28 and 56 +/- 3 days). The non-interventional arm will not receive any intervention.
214970279|NCT06958627|DRUG|pyrotinib|Intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment.
214970280|NCT06958939|DRUG|Dose level 1 group|1.0 × 10e6/kg S103 CAR-T cells
214970281|NCT06958939|DRUG|Dose level 2 group|2.0 × 10e6/kg S103 CAR-T cells
214970282|NCT06958939|DRUG|Dose level 3 group|4.0 × 10e6/kg S103 CAR-T cells
214970283|NCT06958939|DRUG|Dose level 4 group|8.0 × 10e6/kg S103 CAR-T cells
215083070|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin and Sunlight exposure
215083071|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
214679178|NCT04917796|OTHER|Sham Acupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
214679179|NCT03336138|OTHER|AMA (Assistance for ambulatory patients)|telephone follow-up modality
214970284|NCT06958055|RADIATION|videofluroscopy evaluation of swallowing function|Videofluoroscopy swallowing evaluation was done using solid food bolus at three different oral conditions: Without dentures (WOD), with the conventional complete denture (CDs) and with mandibular implant retained overdenture (IODs).
215083072|NCT04371822|DRUG|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
215083073|NCT04371822|OTHER|placebo|No Intervention
215083074|NCT02270255|PROCEDURE|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
215083075|NCT02270255|DRUG|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
215083076|NCT02270255|PROCEDURE|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
215083077|NCT02270255|DRUG|1% Xylocaine|5ml of 1% Xylocaine
215083078|NCT06607926|DRUG|Thymosin Alpha 1|4.8 mg subcutaneous injection twice weekly over 12 weeks
215083079|NCT06607926|DRUG|Tislelizumab|200mg, IV, d1 of each 21-d cycle, four cycles
215083080|NCT06607926|DRUG|Platinum-doublet chemotherapy|Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.
215083081|NCT01442506|OTHER|biopsies|taking biopsies
215083082|NCT01442506|OTHER|biopsy|biopsy
215083083|NCT06605911|DRUG|topical triamcinolone acetonide|ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks
215083084|NCT06605911|DRUG|Topical Curcumin|Ten patients with OLP received topical curcumin four times per day for six weeks.
215083085|NCT06605911|DRUG|topical triamcinolone acetonide combiend with topical curcumin|Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.
215083086|NCT00101764|DRUG|Triamcinolone Acetonide|
215083087|NCT07040501|DEVICE|Chat GPT|On the date of appointment, participants will be given up to 30 minutes, to interact with a pre-prompted Chat GPT (Prostate Pathology Guide) using a Cleveland clinic device.
215083088|NCT07041944|OTHER|HEMImprove APP|"Experimental Group:~Use HEMImprove 1.0 mobile app at home for 30 minutes/session, 5 days/week, for 4 weeks. Exercises tailored progressively with avatar guidance.~Control Group:~Perform conventional home exercises guided by printed manual with instructions and images, matching frequency and duration of intervention group."
214970285|NCT06958471|BEHAVIORAL|Individualized Developmental Care Education Group|"An educational program will be implemented for the mothers in the intervention group throughout the hospitalization period of their premature infants, in line with the objectives of the study.~P1:Pretests for the mothers will be completed within the first three days of the infant's admission to the neonatal intensive care unit (NICU). Mothers will be given a brochure titled Your Premature Baby, prepared by the researcher, which includes information about the NICU and its staff, visiting hours/conditions, and breast milk expression times.~P2:Education will be provided on the characteristics, feeding, and care of premature infants.~P3:Mothers will receive training on environmental regulations (temperature, light, sound), kangaroo care,non-nutritive sucking, and parent-infant interaction. Each training session will be delivered each lasting no longer than 30-45 minutes.~P4:A final training session will be provided on home care for the premature infant."
214358816|NCT06635681|DRUG|combined chemotherapy|"Induction therapy(1 cycle):~Daunorubicin 60mg/m2/d d1-3 Cytarabine 100mg/m2/d d1-7 Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7 If the first course of treatment did not result in CR, patients with therapeutic target could be treated with targeted drugs, and the patients without targets would be treated with HAV regimen: Cytarabine 100mg/m2/d, d1-5, Homoharringtonine 2mg/m2 d1-5, Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7.~Consolidation therapy(3 cycles):~Cytarabine 2g/m2 q12h d1-3 Venetoclax 400mg d1-7 For patients with CBF and CEBPA dual mutations, the dose of cytarabine is 3g/m2.~Maintenance treatment(6 cycles):~Azacitidine 75mg/m2/d d1-5 Venetoclax 400mg d1-7~Allogeneic hematopoietic stem cell transplantation is recommended for high-risk groups and intermediate-risk with positive measurable residual disease."
214358817|NCT06191627|DIAGNOSTIC_TEST|Patch testing|Unlike many different dermatological diseases, a biopsy cannot easily distinguish ACD from irritant contact dermatitis or other forms of chronic dermatitis. Thus, the gold standard for diagnosis is patch testing. During patch testing, allergens are placed on the skin under occlusion using an aluminum disc and tape. When undergoing intensive testing for ACD, as many as 300 patches may be applied to a patient. Therefore, a large area of skin clear of rash is required, most often the back, but patches are frequently applied to the legs as well. Patches are applied by clinic patch technicians. They will proceed with their normal procedures, following the randomization to apply the patches to the appropriate location. Patches will be applied to the skin once, as is the normal standard of care. Patches are applied on day 1 and removed on day 3. Patients continue testing through day 5, though study elements will cease on day 3.
214970286|NCT06959628|DEVICE|Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets|To evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets for Cerebral Protection During Carotid Angioplasty
214970287|NCT04073303|BIOLOGICAL|Botulinum Toxin Type A|Day 1 Administration of bilateral intramuscular injections into the masseter
214970288|NCT04073303|OTHER|Placebo|Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
214970289|NCT05417568|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
214970290|NCT05417568|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
214970291|NCT04179279|DEVICE|Gili Biosensor System (Gili Pro Biosensor)|Non-contact monitoring of heart and respiratory rates using an optical device
214970292|NCT03327818|PROCEDURE|hysterectomy|
214970293|NCT03327818|PROCEDURE|uterine conservative study|
214358818|NCT00922285|OTHER|psychosocial support for caregiver|6 weekly 60 minute sessions
214358819|NCT00922285|OTHER|questionnaire administration|Evaluated at baseline, week 1 and week 6 of art therapy
214358820|NCT00922285|PROCEDURE|quality-of-life assessment|Evaluated at baseline, week 1 and week 6 of art therapy
214358821|NCT00922285|PROCEDURE|stress management therapy|6 weekly 60 minute sessions
214358822|NCT03152526|DEVICE|Interventions|CliniMACS® CD3 and CD19 Reagent System
214358823|NCT04823377|OTHER|Usual care|Patients receiving systemic anticancer treatment in their last days of life
214358824|NCT04823377|OTHER|Optimization of the medical decision|Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
214358825|NCT04867369|DRUG|Bupivacaine 20mL 0.5%|Interscalene nerve block with 20 mL 0.5% bupivacaine.
214358826|NCT04867369|DRUG|Bupivacaine 20mL 0.25%|Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
214970294|NCT01096953|BEHAVIORAL|Mental health care implemented by telepsychiatry|Care of 6-17 year-olds with ADHD
214970295|NCT01096953|BEHAVIORAL|Face-to-face care|Psychiatry provided for treatment of ADHD face-to-face in office
214970296|NCT00611585|DEVICE|Birmingham Hip Resurfacing|Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
214358827|NCT04867369|DRUG|Bupivacaine up to 15mL 0.25%|Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.
214358828|NCT06636877|DRUG|BR1019|One tablet administered alone
214358829|NCT06636877|DRUG|BR1019-2|One tablet administered alone
214358830|NCT06636877|DRUG|BR1019-3|One tablet administered alone
214358831|NCT05013450|DRUG|Dupilumab|three q3w cycles
214358832|NCT05013450|DRUG|PD-1/PD-L1 blockade|SOC immunotherapy with PD-1/PD-L1 blockade
214358833|NCT05013450|DRUG|Anakinra|100 mg daily injection for Three q3w cycles
214358834|NCT06540339|OTHER|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
214358835|NCT05732909|DIETARY_SUPPLEMENT|D-β-hydroxybutyrate/D 1,3 butanediol monoester|Ketone monoester
214358836|NCT04859764|DEVICE|Reparel knee sleeve|Unlabelled thermo-active knee sleeve that improves bloodflow to knee and decreased pain
214358837|NCT04859764|DRUG|Corticosteroid injection|intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)
214358838|NCT04859764|DEVICE|Placebo knee sleeve|unlabeled compression knee sleeve
214358839|NCT06099067|DRUG|Canagliflozin|Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication
215083089|NCT07041944|OTHER|exercises to upper limb|The patients will do the same exercises than the experimental group, without APP and using the same dosage
215083090|NCT07040670|PROCEDURE|Confocal laser endomicroscopy-assisted endobronchial ultrasound-guided transbronchial needle aspiration|First, use the EBUS needle to create a hole in the airway wall. Then, insert the CLE into the lymph node via this hole and detect the lymph node. When the specific pathological finding is detected by CLE, record the location. Finally, using the needle to perform EBUS-TBNA in the area under EBUS guidance.
215083091|NCT07040670|PROCEDURE|Endobronchial ultrsound-guided Mediastinal cryobiopsy|Using the cryoprobe to perform EBUS-TBMC three times per person.
214970297|NCT00001328|DRUG|Cytovene (Ganciclovir Sodium)|
214970298|NCT00001328|DEVICE|G1TKSVNa.53 Producer Cell Line|
214970299|NCT00507936|DRUG|ABT-894|ABT-894 1 mg capsule BID throughout treatment period
214970300|NCT00507936|DRUG|ABT-894|ABT-894 2 mg capsule BID throughout treatment period
214970301|NCT00507936|DRUG|ABT-894|ABT-894 4 mg capsule BID throughout treatment period
214970302|NCT00507936|DRUG|placebo|placebo capsule BID throughout the treatment period
214358840|NCT06099067|DRUG|DPP4 inhibitor|DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications
214358841|NCT06099067|DRUG|Liraglutide|Liraglutide dispensing claim is used as the Exposure drug in LEADER replication
214358842|NCT06099067|DRUG|Saxagliptin|Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
214358843|NCT06099067|DRUG|2nd generation Sulfonylurea|2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
214358844|NCT04435366|DRUG|Avacincaptad Pegol|Avacincaptad Pegol Intravitreal Injection
214358845|NCT04435366|DRUG|Sham|Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
214358846|NCT06069206|OTHER|T2Bacteria® Panel (direct-from-blood testing)|Providers will be prompted to order the T2Bacteria® Panel (direct-from-blood testing) and accompanying communications regarding panel results will be delivered.
214358847|NCT06069206|OTHER|Usual Care|Standard blood cultures.
214679180|NCT03851393|OTHER|Induction of cough with inhaled citric acid|perform artificially induced cough by inhalation of citric acid at various strengths
214679181|NCT03851393|PROCEDURE|Peptest™ analysis of saliva pepsin|collect patient saliva for analysis of pepsin levels
214679182|NCT03851393|DIAGNOSTIC_TEST|Peptest™|The Peptest™ lateral flow device
214970303|NCT00507936|DRUG|Duloxetine|Duloxetine 60 mg QD throughout treatment period
214970304|NCT06545903|DEVICE|LMA Supreme|The device is inserted and the manikin ventilated
214970305|NCT06545903|DEVICE|SLIPA|The device is inserted and the manikin ventilated
214970306|NCT06545903|DEVICE|I-gel|The device is inserted and the manikin ventilated
214970307|NCT06545903|DEVICE|AuraGain|The device is inserted and the manikin ventilated
214970308|NCT01898403|DRUG|Indocyanine green solution|Administered peri-tumoral and intradermally
214970309|NCT01898403|DRUG|Isosulfan blue (ISB)|Administered peri-tumoral and intradermally
214970310|NCT01898403|DIAGNOSTIC_TEST|Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)|
214970311|NCT06001697|BEHAVIORAL|Park prescription|The park prescription given by the patients care-provider includes information about the health benefits of spending time in nature and detailed information about the parks in the neighboring area. As well as access to a web-based platform called ParkRx which includes information and details about events in the parks in the study area. Together with information about the frequency and duration of visits to the parks.
214970312|NCT06001697|BEHAVIORAL|Regular health advice|Regular health advice relating to lifestyle factors that can decrease the risk of chronic disease and/or reducing the burden of an existing chronic disease. Areas included are diet, physical activity, sleep, stress and medications.
214970313|NCT00248469|BEHAVIORAL|In-school Sexual Health Education|
214970314|NCT00248469|BEHAVIORAL|Youth-friendly health services|
214970315|NCT00248469|BEHAVIORAL|Youth condom promotion & distribution|
214970316|NCT00248469|BEHAVIORAL|Community activities related to adolescent sexual health|
215083092|NCT00869050|DRUG|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
215083093|NCT00869050|DRUG|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
215083094|NCT02448979|PROCEDURE|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
214358848|NCT06079463|OTHER|progressive relaxation exercise|"Step 1: Take a comfortable position (sitting or lying down) and wear comfortable, non-tightening clothes.~Step 2: Try to relax with eyes closed, without focusing on thoughts, by focusing on your own body muscles.~Step 3: Right and left, respectively, hands, arms (triceps muscle), chest, abdomen, hips, legs (thigh muscles), feet and toes, neck, shoulder (scapula muscles) and muscle groups on the face (around the eyes, chin) and eyebrow muscles) by concentrating on contracting and relaxing these muscles.~Step 4: Focusing on the muscle groups of the whole body, contracting and relaxing.~Step 5: Opening the eyes slowly, trying to feel the feeling of comfort in the body (Turkish Psychologists Association Progressive Relaxation Exercises)."
214358849|NCT06551974|BEHAVIORAL|Guided self-help plus IPT|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours. Participants will also attend a weekly online forum with interactional materials, and an online interpersonal group session.
214358850|NCT06551974|BEHAVIORAL|Guided self-help|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours.
214358851|NCT06551974|BEHAVIORAL|TAU|The Treatment as Usual is the usual or routine care provided to participants in the outpatient setting.
214970317|NCT06038942|BEHAVIORAL|Formal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The formal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught formal mindfulness practices (e.g., sitting meditation, body scan, thought meditation, loving-kindness meditation) during the group sessions and will be asked to commit to practicing the strategies independently throughout the project period."
214970318|NCT06038942|BEHAVIORAL|Informal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The informal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught how to integrate informal mindfulness into their daily routine and will be guided through a series of demonstrations within the group sessions. Participants will be asked to commit to practicing informal mindfulness independently throughout the project period."
214970319|NCT03079167|DRUG|Epoetin Alfa|
214970320|NCT03079167|DRUG|Normal saline|
214970321|NCT03107208|DRUG|Glargine|A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
214970322|NCT03107208|DEVICE|Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)|All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
214970323|NCT04078711|DRUG|Losartan 100Mg Tab|100Mg Tab, qd, po, 6 months
214970324|NCT04078711|DRUG|Qianyangyuyin 20g Granule|20g, Granule, bid, po, 6 months
214970325|NCT04078711|DRUG|placebo|Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
214970326|NCT04804761|OTHER|Electroacupuncture|Needle insertion on bilateral LI4 HeGu and PC6 NeiGuan and ipsilateral ST6 JiaChe and ST7 XiaGuan (as shown in Table 1), using disposable sterile acupuncture needles (length 25 mm, diameter 0.25 mm; Seirin Corporation, Shizuoka, Japan)
214970327|NCT02511925|OTHER|Weekly poster of unit performance|Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals
214970328|NCT02511925|OTHER|Daily email of personal feedback|Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.
214970329|NCT02511925|OTHER|Active reminder from badge|The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
214970330|NCT01747356|DEVICE|Resolute stent treatment|A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
214970331|NCT03602703|DIAGNOSTIC_TEST|Flow cytometry and Western Blot analysis|Diagnostic tests
214970332|NCT00183118|BEHAVIORAL|Adapted Enhanced-RESPECT (HIV prevention intervention)|
214970333|NCT05739604|DIAGNOSTIC_TEST|Blood sample analysis|The concentrations of AAs and related compounds were determined by liquid chromatography/mass spectrometry (LC/MS)
214358852|NCT06962410|OTHER|Hybrid Closed-Loop Artificial Pancreas System|The pump was loaded with ultra-short-acting insulin (Manufacturer: Novo Nordisk A/S, Denmark; Approval Number: National Drug Approval No. J20050097; Specification: 3 mL: 300 U). The total daily insulin requirement was calculated at 0.2-0.4 U/(kg·d) based on the patient's weight. During operation, the system automatically adjusted the basal rate according to the blood glucose level. After the physician issued a large-dose order based on previous treatment experience and blood glucose conditions, the nurse manually entered the large-dose treatment instruction in the AAPS software.
214487634|NCT06625970|RADIATION|radiotherapy|"Following randomization, patients will receive dose escalated intensity modulated radiotherapy (IMRT) using normo-fractionation or moderate hypo-fractionation including whole pelvic nodal radiotherapy (WPRT).~Arm A and Arm B:~If Normo-fractionated radiotherapy: Pelvic nodes 46 Gy, seminal vesicles 46-54 Gy and prostate 78 Gy (39 fractions over 8 weeks).~If Hypo-fractionated radiotherapy: Pelvic nodes and seminal vesicles 44 Gy in 20 fractions; prostate 60 Gy delivered concomitantly in 20 fractions over 4 weeks.~Arm C and Arm D:~If Normo-fractionated radiotherapy: Pelvic nodes 46 Gy, seminal vesicles 46 Gy in 23 fractions over 4.5 weeks.~If Hypo-fractionated radiotherapy: Pelvic nodes and seminal vesicles 44 Gy in 20 fractions over 4 weeks."
214970334|NCT04189432|BIOLOGICAL|SCM-CGH|SCM-CGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
214970335|NCT04189432|OTHER|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
214970336|NCT05803694|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
214970337|NCT02377609|DRUG|Tacrolimus|oral
214970338|NCT05534568|OTHER|Parent-Child Assistance Program|Case managers work closely with mothers over the course of three years, meeting the mothers in their own homes when possible, to help them to set goals and take advantage of available resources.
214970339|NCT01360346|PROCEDURE|Enteral Sedation (EN)|Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
214970340|NCT01360346|PROCEDURE|Control group: Intravenous Sedation (IV)|Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
214970341|NCT06047639|DEVICE|Bone-anchored hearing implants|surgically placed hearing device
214970342|NCT04708080|PROCEDURE|thoracic epidural analgesia|A thoracic epidural catheter is routinely placed in patients undergoing open heart surgery in our hospital, at least 1 hour before heparin administration during the operation. After standard monitoring (ECG, SpO2, NIBP) is applied to the patients in the operating room, sedoanalgesia is provided with 1-3mg of midazolam and 50-100mcg of fentanyl. Then, by providing sterilization conditions, an epidural catheter is inserted through the T5-T6 interval with Tuohy needle. After confirming the location of the epidural catheter, 25mg / 10ml bupivacaine is administered as a bolus and then 3ml / hour bupivacaine infusion is started from the solution prepared as 3mg / ml and continues until the 48th postoperative hour. On the postoperative 2nd day, the catheter is removed 10-12 hours after LMWH administration and 2-4 hours after UFH, as recommended by the guidelines, paying attention to the anticoagulant administration times applied to the patients.
214970343|NCT02773095|OTHER|Novartis Access|Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
214970344|NCT05535608|DIETARY_SUPPLEMENT|SRW Cel System|Dietary supplement
214970345|NCT02899065|DIAGNOSTIC_TEST|Procalcitonin|Procalcitonin is a blood test used to differentiate between viral and bacterial infections. This test is expected to aid in determining the best course of treatment for patients enrolled into this arm.
215083095|NCT02448979|PROCEDURE|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
215083096|NCT06428916|PROCEDURE|tucking position during endotracheal suctioning|, the staff nurse will perform the endotracheal suctioning while the researcher will carried out the intervention
215083097|NCT06235359|DEVICE|intercostal tube|"A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand."
215083098|NCT01689714|DRUG|Tc 99m EC20|
214358853|NCT06961500|DRUG|Obinutuzumab|1000mg i.v., administered on Day 1/8/15 (D1/8/15) of Cycle 1 (C1), and D1 of C2-6
214487635|NCT05707351|BIOLOGICAL|Adynovate|Adynovate was injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (\<=) 5 minutes (maximum infusion rate, 10 milliliters per minute \[mL/min\]).
215083099|NCT04315688|DRUG|insulin degludec|Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
215083100|NCT03078283|OTHER|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
215083101|NCT02399280|BEHAVIORAL|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
215083102|NCT02399280|BEHAVIORAL|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
215083103|NCT05433038|DEVICE|skeletally anchored maxillary expander|used from day one and activated two times per day for two weeks
214358854|NCT06961500|DRUG|CHOP|a) Cyclophosphamide: 750 mg/m2 i.v. drip, administered on D1; b) Doxorubicin: 50 mg/m2 i.v. drip (or Epirubicin: 70mg/m2 i.v. drip), administered on D1; c) Vincristine: 1.4 mg/m2 i.v., administered on D1; d) Prednisone: 100mg/d po, administered on D1-5.
214358855|NCT06961500|DRUG|Bendamustine|90 mg/m2 i.v. drip, administered on D1-2.
214358856|NCT06962254|DRUG|Imatinib|"1. Imatinib is binding to the ATP-binding site of BCR-ABL, blocking its activity and preventing uncontrolled proliferation to target the BCR-ABL fusion protein in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It also inhibits PDGFR and c-KIT receptors, suppressing tumor growth and angiogenesis in gastrointestinal stromal tumors (GIST).~2. Preclinical studies have shown that imatinib combined with MEK inhibitors can suppress the growth of KRAS-mutated pancreatic adenocarcinoma."
214358857|NCT06962254|DRUG|Trametinib|Trametinib inhibits the MEK1 and MEK2 enzymes, preventing the downstream phosphorylation and activation of ERK1/2, which are crucial for the RAS-RAF-MEK-ERK signaling pathway. By blocking this pathway, trametinib reduces cell proliferation and induces apoptosis in tumor cells harboring pathway mutations.
214358858|NCT04054154|DEVICE|Shear Wave Elastography|Undergo shear wave elastography
214358859|NCT04054154|PROCEDURE|Tumor Interstitial Fluid Pressure Measurement|Undergo tumor pressure measurement
214358860|NCT06576362|PROCEDURE|Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy|Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy
214358861|NCT06574815|PROCEDURE|Early implant loading|Patients underwent definitive restoration at 6 weeks after implant surgery (early loading).
214487636|NCT07016269|DRUG|CnU capsule 500 mg(250mg 2 capsule)|According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.
214487637|NCT07016269|DRUG|CnU placebo capsule 500 mg(250mg 2 capsule)|According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.
214487638|NCT01996436|DRUG|Nicardipine|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
214487639|NCT01996436|DRUG|Verapamil|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
214487640|NCT01996436|DRUG|Nicardipine + Verapamil + Nitroglycerin|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
214970346|NCT02899065|OTHER|Pharmacist-Led Education|Pharmacists will interpret the results of the Roche Cobas Liat Flu/RSV assay and procalcitonin test (if available) and provide the treating physician with recommendations for antibiotic therapy based on these results.
214358862|NCT06574815|PROCEDURE|Delayed implant loading|Patients underwent definitive restoration at 6 months after implant surgery (delayed loading).
214358863|NCT06574815|PROCEDURE|GBR using an SIS membrane|An small intestine submucosa (SIS) membrane was used in the guided bone regeneration (GBR) surgery.
214358864|NCT06574815|PROCEDURE|GBR using an Bio-Gide membrane|An Bio-Gide membrane was used in the guided bone regeneration (GBR) surgery.
214358865|NCT05711641|DRUG|Lidocaine 10 MG/ML|Application of 10% topical lidocaine in the external auditory canal of tinnitus patients.
214358866|NCT05711641|DRUG|Distilled water|Application of distilled water in the external auditory canal of tinnitus patients.
214487643|NCT06688786|DRUG|neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy|Preoperative treatment with 4-6 cycles of mFOLFOX6 regimen combined with serplulimab
214487644|NCT07022782|OTHER|A nutritional intervention based on the principles of Mediterranean diet|The patients will consume meals three times (i.e., breakfast, lunch and dinner) per day for 90 days (i.e., three months) that are based on the principles of Mediterranean diet.
214487645|NCT06698003|DRUG|Mogamulizumab|Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses
214487646|NCT07026994|DRUG|Colchicine 0.5mg|Oral colchicine 0.5mg once per day combined with standard treatment
214487647|NCT07026994|DRUG|Matching placebo|Oral matching placebo once per day combined with standard treatment
214487648|NCT06710106|DIETARY_SUPPLEMENT|Prebiotic + hypocaloric diet|Study participants will add prebiotic formula in a natural yogurt every day to be consumed within a hypocaloric diet.
214487649|NCT06710106|DIETARY_SUPPLEMENT|Placebo + hypocaloric diet|Study participants will add placebo formula in a natural yogurt every day to be consumed within a hypocaloric diet.
214970347|NCT02554760|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device and CoolCore applicator with and without the Crown Cooling Insert will be used to perform the treatments.
214970348|NCT06009679|DRUG|Misoprostol 200mcg Tab|Patients in the intervention group with suspected postpartum RPOC will receive 600 micrograms of misoprostol up to 3 times following delivery and followed up by ultrasound and clinical examinations for 6-12 weeks post-partum
214970349|NCT02260219|PROCEDURE|Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2|Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
214970350|NCT05227118|DRUG|MK-8189|MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
214970351|NCT05227118|DRUG|Placebo|MK-8189 matching placebo administered orally QD
214970352|NCT02342392|DRUG|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
214970353|NCT04607902|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
214970354|NCT04607902|BEHAVIORAL|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
214970355|NCT04607902|BEHAVIORAL|Growth Mindset SSI|Online, 30-minute self-administered program for youth
214970356|NCT02689804|DRUG|LNG-EC|FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
214970357|NCT02689804|DRUG|UPA-EC|FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
214487650|NCT06881030|PROCEDURE|Noninvasive transcranial magnetic stimulation was administered six times daily|The motor threshold of 100% intensity, a TBS stimulus train for 2 seconds, including 10 times of 3 intrapascicular stimulation at 50 Hz and interapascicular stimulation at 5HZ, intervals of 10s, 60 repetitions, that is, a total of 1800 pulses per treatment, 6 treatments per day, 50 min apart, a total of 10800 pulses/day, continuous stimulation for 5 days.
214487651|NCT06881030|PROCEDURE|Noninvasive transcranial magnetic stimulation was administered 10 times daily|The motor threshold of 100% intensity, a TBS stimulus train stimulation for 2 seconds, including 10 times of 3 intrapascicular stimulation at 50 Hz and interapascicular stimulation at 5HZ, intervals of 10s, 60 repetitions, that is, a total of 1800 pulses per treatment, 10 treatments per day, intervals of 50 min, a total of 18000 pulses/day, continuous stimulation for 5 days.
214487652|NCT06881030|PROCEDURE|Sham|The appearance of the sham stimulation coil was consistent with that of the real stimulation coil, which could simulate the touch and sound of the scalp caused by the real stimulation. The treatment frequency, location, intensity and time of the sham stimulation group were the same as those of the real stimulation group.
214679183|NCT00722345|BEHAVIORAL|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
214970358|NCT01820897|DRUG|Fosfomycin-Trometamol|
214970359|NCT01820897|DRUG|Sulfamethoxazole trimethoprim|
214970360|NCT02565316|DRUG|Nepeta menthoides Boiss & Bohse freeze dried extract|
214970361|NCT02565316|DRUG|Sertraline|
214970362|NCT03773289|OTHER|No intervention|This is a retrospective, observational pharmacoepidemiological study using nationally collected data. There is no intervention.
214970363|NCT03390595|COMBINATION_PRODUCT|avelumab 10mg/kg with carboplatin/gemcitabine|"Dosage and schedule:~* Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:~  * Intravenously every 2 weeks for two cycles.~ * During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.~ * Intravenously every 2 weeks until progressive disease or intolerance.~* Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~  * Carboplatin 5AUC day +1.~ * Gemcitabine 1000mg/m2 day +1 and +8."
214970364|NCT03390595|COMBINATION_PRODUCT|carboplatin/gemcitabine alone|"•Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~* Carboplatin 5AUC day +1.~* Gemcitabine 1000mg/m2 day +1 and +8."
214970365|NCT01124318|DRUG|Lactofiltrum|Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
214970366|NCT01124318|DRUG|Placebo|Placebo 2 tablets 3 times a day before meals during 21 days
214970367|NCT04576728|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days.
214970368|NCT04576728|OTHER|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days.
214970369|NCT05897515|DIAGNOSTIC_TEST|LIAISON NES FLU A/B & COVID-19|The LIAISON® NES FLU A/B \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
215083104|NCT01426919|OTHER|Head CT scan and blood draw within 12 hours of injury|
215083105|NCT05846425|OTHER|Nose-breathing training|13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
215083106|NCT05846425|OTHER|Mouth-breathing training|13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
215083107|NCT05838053|PROCEDURE|Lobectomy with systemic lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
215083108|NCT05838053|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
215083109|NCT02089113|DRUG|Dexamethasone|
215083110|NCT02089113|PROCEDURE|Placebo Vehicle|
215083111|NCT01817673|DIETARY_SUPPLEMENT|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
215083112|NCT01817673|DIETARY_SUPPLEMENT|placebo|
215083113|NCT05042765|OTHER|self-reported entheogen use|self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
215083114|NCT03217084|DRUG|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
214358867|NCT04050683|PROCEDURE|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.
214358868|NCT04050683|PROCEDURE|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|"Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes."
214358869|NCT06731946|DEVICE|Flow diverting|Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.
214358870|NCT01795430|DRUG|etoposide|Given IV
214358871|NCT01795430|DRUG|ifosfamide|Given IV
214358872|NCT01795430|RADIATION|intensity-modulated radiation therapy|Undergo WB-MRI-guided IMRT
214358873|NCT01795430|DRUG|topotecan hydrochloride|Given IV
214970370|NCT04266899|DEVICE|Foot Drop Stimulator - Neuro Orthosis|The WalkAide system is a self-contained functional electrical stimulation device with a built-in tilt sensor and attaches with a cuff to the leg below the knee. The device stimulates the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
214970371|NCT04266899|DEVICE|Treadmill|Gait training on a treadmill
214970372|NCT01704807|DEVICE|foot orthotics|Experimental wore experimental orthotics throughout the study period as much of the day as possible.
214970373|NCT01704807|DEVICE|Sham foot orthotic|Control group wore sham insoles as much of the time as possible for the duration of the study period.
214970374|NCT02589470|OTHER|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
214970375|NCT00219947|OTHER|blood draw|"* T cell subset enumeration~* Serologic reactivity with HIV antigens~* Viral load assays by bDNA, PCR, or RT-PCR~* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~* HIV-1 Resistance Testing"
214970376|NCT04739033|BEHAVIORAL|VIVIR MEJOR EXPERIMENTAL|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
214970377|NCT02830412|OTHER|Postoperative nausea and vomiting (PONV) reminder|The postoperative nausea and vomiting (PONV) electronic reminder will be programmed to assess the patient risk for PONV according to the risk factors identified by Apfel and Koivuranta. The PONV risk assessment and current guidelines will be displayed electronically for patients randomized to receive the reminder.
214970378|NCT02417753|DRUG|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
214970379|NCT03638960|DRUG|Bupivacaine liposome|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either liposomal bupivacaine prior to the patient receiving surgery.
214970380|NCT03638960|DRUG|Bupivacaine Hydrochloride|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either plain bupivacaine prior to the patient receiving surgery.
214970381|NCT01660009|OTHER|Glycemic clamping|During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
214358874|NCT01795430|DRUG|busulfan|Given IV
214358875|NCT01795430|DRUG|melphalan|Given IV
214358876|NCT01795430|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell or bone marrow transplant
214358877|NCT01795430|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
214358878|NCT01795430|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow transplant
214358879|NCT04758637|BEHAVIORAL|Overdose Notification|We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
214358880|NCT04934423|DEVICE|Direct Current Transcranial Stimulation - tDCS|Active intervention
214358881|NCT04934423|DEVICE|Sham Intervention|Direct Current Transcranial Stimulation - Sham intervention
214358882|NCT05163574|DIETARY_SUPPLEMENT|High dose OIT|Patients will receive daily a high dose of peanut flour (300 mg peanut protein) mixed with well-tolerated fruit mousse.
214358883|NCT05163574|DIETARY_SUPPLEMENT|Low dose OIT|Patients will receive daily a low dose of peanut flour (150 mg peanut protein) mixed with well-tolerated fruit mousse.
214358884|NCT00998608|DRUG|risperidone|risperidone 4mg/d
214358885|NCT04512521|DRUG|Mepolizumab|Mepolizumab therapy
214358886|NCT02477111|DEVICE|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
214358887|NCT00989768|DRUG|Botulinum Toxin Type A (Dysport®)|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 5 units will be injected in the left or right forehead side."
214358888|NCT00989768|DRUG|Botulinum Toxin Type A/Botox®|2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
214970382|NCT03113968|PROCEDURE|electroconvulsive therapy (ECT)|ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.
214970383|NCT03113968|DRUG|Ketamine|Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
214970384|NCT04805671|DRUG|ADG20|Single dose of ADG20
214970385|NCT04805671|DRUG|Normal saline|Single dose of normal saline
214970386|NCT01387178|DRUG|fluticasone propionate/salmeterol 250µg/50µg (FSC)|Patient records with evidence of COPD and prescription claims for FSC
214970387|NCT01387178|DRUG|tiotropium bromide (TIO)|Patient records with evidence of COPD and prescription claims for TIO
214970388|NCT02550743|DRUG|BYL719|
214358889|NCT00989768|DRUG|Botulinum Toxin Type A/Dysport®|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox."
214970389|NCT02550743|DRUG|Capecitabine|
214970390|NCT02550743|RADIATION|Radiation|
214970391|NCT00251134|DRUG|Zodin (drug)|1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months
214970392|NCT00251134|DRUG|Olive oil (placebo)|1 gram olive oil daily for a period of 12 months
214970393|NCT02361034|DRUG|GRC 27864|
214970394|NCT02361034|DRUG|Placebo|
214358890|NCT00162370|DRUG|Perflutren Lipid Microsphere Injectable Suspension|Activated DEFINITY 10ug/kg by bolus injection
214358891|NCT02579252|BIOLOGICAL|AADvac1|
214358892|NCT02579252|DRUG|Placebo|
214358893|NCT03154216|BEHAVIORAL|Exercise|90 minutes of moderate-intensity walking exercise on a treadmill
214358894|NCT03154216|OTHER|Drink|Beverage to be consumed after exercise
214358895|NCT05431075|DRUG|Amoxicillin|Included in quadruple eradication medication.
214358896|NCT05431075|DRUG|Tetracycline tid|Included in quadruple eradication medication.
214358897|NCT05431075|DRUG|Tetracycline qid|Included in quadruple eradication medication.
214358898|NCT05431075|DRUG|Bismuth Potassium Citrate|Included in quadruple eradication medication.
214358899|NCT05431075|DRUG|Colloidal Bismuth Pectin|Included in quadruple eradication medication.
214358900|NCT05431075|DRUG|Esomeprazole 20mg|Included in quadruple eradication medication.
214358901|NCT02921997|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
214358902|NCT02921997|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
214358903|NCT02921997|BIOLOGICAL|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
214358904|NCT03488901|OTHER|chemoresistance signature|to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy
214358905|NCT03896035|BEHAVIORAL|Behavioral Intervention Group|The behavioral intervention is designed for older Veterans with cLBP and depression and will include 8 individual telephone sessions delivered by health coaches over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
214970395|NCT00657423|DRUG|Treated by endostar combined with docetaxel and cisplatin|recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
214970396|NCT00657423|DRUG|Treated by docetaxel and cisplatin|docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
214970397|NCT01028729|DRUG|Endostar|7.5mg/m2/day, iv, from day 1 to day 14
214970398|NCT01028729|DRUG|Gemcitabine-Cisplatin chemotherapy|Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
214358906|NCT04939129|DIAGNOSTIC_TEST|The research is terminated by calculating the percentage of PVI changes with SAB formed by LRM after fluid challenge.|Measurements will begin after a hemodynamically stable period in the supine position.Heart rate, central venous pressure, systolic, diastolic and mean arterial pressure, peripheral oxygen saturation, PVI and BIS baseline values (baseline 1) will be recorded.LRM will be automatically adjusted in the mechanical ventilator(30 cm H2O/30 seconds) and all hemodynamic parameters where the maximum change at the end of 30 seconds, will be recorded(after LRM), and the differences initial baseline values will be calculated and recorded as percentages.After the recording of the second values, the crystalloid infusion at 10ml/kg will be made to the patient through the peripheral venous line within 15minutes, new baseline values will be taken before the test(baseline 2).After fluid replacement, LRM will be repeated in the same way. The values after LRM(Fluid Challenge-FC) will be recorded and differences between basal 2 values will be calculated and recorded as percentages.
214970399|NCT02205372|DRUG|MT-3995|
214970400|NCT02205372|DRUG|Placebo|
214970401|NCT01657162|DRUG|Alendronate|Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.
214970402|NCT00901342|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
214970403|NCT03200353|DEVICE|system NATROX (device name)|system NATROX (device name) application on the wounds of lower limbs
214970404|NCT00300222|DRUG|NGX-4010|
214970405|NCT01148264|DRUG|olanzapine|1x10mg per day for three days
214970406|NCT01148264|DRUG|metoclopramide|3x10mg per day for three days
215083115|NCT03217084|DRUG|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
215083116|NCT02183337|DRUG|BI 1356|
214970407|NCT03560453|BEHAVIORAL|Project SEARCH Plus ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center (Daston et al., 2012). Students with developmental disabilities who participate in this model rotate through three 10-12 week internships within the business where they log approximately 720 hours of internship time learning marketable skills while receiving supported employment. They also get 180 hours of classroom time at the business for a total of approximately 900 hours embedded in the business setting. In addition to these important training components, Project SEARCH requires collaboration between multiple community partners to support students in attaining employment upon completion of the program. Collaborations include students with developmental disabilities and their family, a LEA, a local CRP, the state VR, and a host business.
215083117|NCT02183337|DRUG|BI 1356 + Pioglitazone|
215083118|NCT02183337|DRUG|Pioglitazone|
215083119|NCT02736266|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
214358907|NCT03492281|DRUG|vibegron|single daily oral dose of vibegron 75 mg for 12 weeks
214358908|NCT03492281|DRUG|Vibegron placebo|placebo to match vibegron (experimental drug)
214358909|NCT03492281|DRUG|Tolterodine Tartrate ER|single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
214358910|NCT03492281|DRUG|Tolterodine placebo|placebo to match tolterodine (active comparator)
214358911|NCT01506193|BIOLOGICAL|PriorixTetra™|One dose administered subcutaneously
214358912|NCT01506193|BIOLOGICAL|Meningitec|One dose administered intramuscularly
214358913|NCT03347968|BIOLOGICAL|MEDI0382|All participants will receive MEDI0382
214358914|NCT03347968|DRUG|Warfarin|All participants will receive Warfarin
214358915|NCT03347968|DRUG|Esmolol|All participants will receive Esmolol
214358916|NCT04100746|PROCEDURE|supramalleolar osteotomy|surgical intervention by using low tibial osteotomy
214358917|NCT05579353|OTHER|nothing|nothing
214970408|NCT03153046|DIETARY_SUPPLEMENT|prebiotics|Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
214970409|NCT03153046|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
214970410|NCT00614172|RADIATION|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
214970411|NCT03421379|DRUG|Glucagon Nasal Powder|Administered intranasally
214970412|NCT03421379|DRUG|Glucagon Hydrochloride Solution|Administered IM
214970413|NCT04038112|OTHER|psychological therapy Method of Levels (MOL)|Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
214358918|NCT02837627|OTHER|Tube feeding|During the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period.
214358919|NCT05441072|DEVICE|BulbiCam|"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."
214358920|NCT02243553|DRUG|Tipranavir capsule|
214970414|NCT01941784|OTHER|educational intervention|Undergo health education program
214970415|NCT01941784|OTHER|counseling intervention|Undergo health education program
214970416|NCT01941784|BEHAVIORAL|telephone-based intervention|Receive follow-up phone calls
214970417|NCT01941784|OTHER|questionnaire administration|Ancillary studies
214358921|NCT02243553|DRUG|Tipranavir solution|
214358922|NCT02243553|DRUG|Ritonavir capsule|
214358923|NCT02243553|DRUG|Caffeine|
214358924|NCT02243553|DRUG|Warfarin sodium|
214358925|NCT02243553|DRUG|Vitamin K|
214358926|NCT02243553|DRUG|Omeprazole|
214358927|NCT02243553|DRUG|Dextromethorphan hydrobromide|
214358928|NCT02243553|DRUG|Midazolam injection|
214358929|NCT02243553|DRUG|Midazolam oral solution|
214358930|NCT02243553|DRUG|Digoxin tablet|
214970418|NCT01941784|PROCEDURE|quality-of-life assessment|Ancillary studies
214970419|NCT06145503|DEVICE|Dance Intervention Group|The dance sessions, tailored to participants' preferences, were accompanied by music from the 80s and 90s. A dance instructor demonstrated each dance step, and the sessions comprised a 10-minute warm-up, 40 minutes of dancing, and a 10-minute cool-down. The complexity and intensity of the dance routines were adjusted based on individual abilities, functional variations, and capacity.
214970420|NCT05113680|BEHAVIORAL|compassion focused group|Based on compassion focused therapy (CFT) principles practices : soothing breathing rythm, compassionate-self, compassion for shame and self-criticism 12 sessions of 2h each
214358931|NCT02243553|DRUG|Digoxin injection|
214358932|NCT03343236|RADIATION|Radiotherapy|All patients will undergo radiotherapy or surgery, or combined modality treatment
214970421|NCT05113680|BEHAVIORAL|emotional competencies|Emotional competencies group focused on identification, comprehension, expression, regulation, utilization. practices : TCC, cognitive restructuring, and mindfulness 12 sessions of 2h each
214970422|NCT02782741|DRUG|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
214970423|NCT02782741|DRUG|Alglucosidase alfa (GZ419829)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
214970424|NCT04292210|DEVICE|Perisafe|A medical device simplifying the connection of tubing as well as breaking of the frangible which is done in a sterile environment with the help of levers and buttons.
214970425|NCT04157088|DRUG|Darolutamide (Nubeqa, BAY1841788)|600mg, twice daily
214970426|NCT04157088|DRUG|Enzalutamide|160mg, once daily
214970427|NCT01648062|BEHAVIORAL|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
214970428|NCT04374370|BIOLOGICAL|SARSCoV2 Convalescent Plasma|Provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.
214970429|NCT00802646|DRUG|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
214970430|NCT00802646|DRUG|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
214970431|NCT03468725|DRUG|XPF-008|Capsule filled with XEN1101
214970432|NCT03468725|DRUG|Microcrystalline Cellulose|Placebo capsule
214970433|NCT03663296|OTHER|Airway Ex App|30 minutes of self-directed learning and practice using the mobile application
214970434|NCT00035178|DRUG|Argatroban|
214970435|NCT06072118|DRUG|Adrenomedullin|Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.
214970436|NCT02421419|DRUG|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
214970437|NCT02421419|DRUG|Xylocaine|a local anesthetic agent
214970438|NCT02421419|DRUG|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
214358933|NCT04454866|DRUG|Single injection of penehyclidine|A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
214358934|NCT04454866|DRUG|Continuous infusion of penehyclidine|A dose of penehyclidine hydrochloride (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine hydrochloride (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
215083120|NCT05401045|BEHAVIORAL|Met exercises|Exercise plan: Each session of the self-designed MET exercise program was divided into 8 components: stretching exercises, chest expansion exercises, kicking exercises, lateral movement exercises, body rotation exercises, whole-body exercises, jumping exercises, and a cool down. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening. For patients with moderate fatigue and an RPFS score of 4 to 6 points, low-intensity exercise was recommended, i.e., patients could choose 1 to 4 metabolic equivalent exercises and repeat them twice; for patients with mild fatigue and an RPFS score of 1 to 3 points, moderate-intensity exercise was recommended, i.e., patients could choose to complete the entire set of metabolic equivalent exercises or 5 to 8 of the exercises and repeat them twice. The exercise frequency was 5 times per week.
215083121|NCT05333172|OTHER|Dual task exercises|Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
215083122|NCT00393302|PROCEDURE|HIV screening in pregnancy|
215083123|NCT06138444|DIETARY_SUPPLEMENT|Functional beverages from the submerged fermentation of Cordyceps militaris|The Cordyceps militaris submerged fermentation in fruit juice.
215083124|NCT06138444|OTHER|Fruit juice|Fruit juice is used as a placebo.
214358935|NCT04454866|DRUG|Placebo|A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
214358936|NCT01915615|OTHER|None - this is an observational study|None - this is an observational study
214358937|NCT00001020|BIOLOGICAL|rgp120/HIV-1IIIB|
214970439|NCT00726180|DRUG|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
214970440|NCT04824898|DRUG|Simvastatin|Statins are first known as drugs that decrease the cholesterol level by inhibiting hydroxy-methyl-glutaryl co-enzyme-A reductase as they improve the lipid profile and help in the treatment of many cardiac diseases and has a role in osteoblasts diffrentiation
214970441|NCT04824898|OTHER|injectable plasma rich fibrin|I- PRF is obtained by taking a blood sample from patients and then is centrifuged for three minutes at 3300 rpm, the I-PRF first will be in the form of liquid and then coagulate after few minutes from the injection
215083125|NCT03397888|DRUG|Betrixaban|80 mg capsule
215083126|NCT05176002|DRUG|Camrelizumab|Neoadjuvant Camrelizumab combined with radiotherapy
215083127|NCT06301724|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214358938|NCT00001020|BIOLOGICAL|rgp120/HIV-1MN|
214358939|NCT04789538|OTHER|monofocal lens|not applicable as patients are already implanted with the monofocal intraocular lens
214358940|NCT00743366|DRUG|Marijuana|0,6.2% THC
214358941|NCT00743366|DRUG|Quetiapine|200 mg/day
214358942|NCT00743366|DRUG|Placebo oral capsule|
214358943|NCT05946811|DRUG|Macitentan 10mg|Macitentan 10 mg oral once daily for 3 months. vs placebo
214358944|NCT04884438|BEHAVIORAL|Psychological intervention for the promotion of gratitude|"A brief intervention protocol has been developed for the promotion of gratitude. The protocol is manualized and the content will be explained to each participant in the videoconference sessions, and a copy of the manual will be given (or sent) to the patients at the end of the therapy sessions.~The structure and contents of the intervention are summarized below:~1. Psychoeducation about gratitude and its effects on health (both physical and psychological).~2. Gratitude towards life:~   1. Gratitude walk~  2. Three positive things~  3. Sharing gratitude~3. Social gratitude:~   1. Daily thanks to others~  2. Gratitude letter~  3. Proof of gratitude~4. Self-gratitude: this part includes an exercise aimed at fostering self-gratitude in three different areas:~   1. Gratitude for the things I do to take care of my physical health.~  2. Gratitude for what I do to take care of my mental health, my self-esteem and my personal development.~  3. Gratitude for what I do to take care of others."
214358945|NCT03206203|DRUG|Atezolizumab|Given by vein
214358946|NCT03206203|DRUG|Carboplatin|Given by vein
214358947|NCT03206203|OTHER|Laboratory Biomarker|Correlative study
214358948|NCT03206203|OTHER|Quality-of-Life Assessment|Ancillary studies
214358949|NCT02459873|BEHAVIORAL|Computer games to assess change in executive function skills|Children get access to computer games for 10 weeks for an hour each week.
214358950|NCT02478619|OTHER|IMT group|"Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.~They will also receive the routine physical therapy in the post operative period."
214358951|NCT02478619|OTHER|Control group|Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
214358952|NCT03548740|BIOLOGICAL|Human Papillomavirus|women with high-risk Human Papillomavirus or not
214970442|NCT02674139|DEVICE|Copper T 380A IUD|intrauterine contraceptive device T-shaped loaded with cupper
215083128|NCT06301724|DRUG|Lidocaine hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214358953|NCT03006523|PROCEDURE|Intrauterine insemination|IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
214970443|NCT00469222|PROCEDURE|hypofractionated external beam|
214970444|NCT04997603|OTHER|Accelerometer|Fitbit brand
214970445|NCT05398406|OTHER|TAP Block group|TAP Block: the US probe was placed on the imaginary line connecting the anterior superior iliac spine and the umbilicus. The ilioinguinal and iliohypogastric nerves in the fascia of the internal obliq and transverse abdominis muscles were visualized by US. A total of 40 ml of local anesthetic was infiltrated ESP Blok : a 100 mm 21G peripheral nerve block needle was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. 40 ml of the prepared solutions were injected PVB: In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made
214970446|NCT05398406|OTHER|Paravertebral block group|In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®, USA) was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made bilaterally in the form of 20+20 ml.
214970447|NCT05398406|OTHER|Erector spinae block group|In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
214970448|NCT06401824|DRUG|Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab|Sacituzumab govitecan 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression.
214970449|NCT00097214|DRUG|Carboplatin|AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.
215083129|NCT02626234|DRUG|INC280|
215083130|NCT02626234|DRUG|digoxin|
215083131|NCT02626234|DRUG|rosuvastatin|
215083132|NCT00585221|DRUG|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
215083133|NCT00585221|DRUG|Imatinib|Continue imatinib until progression.
215083134|NCT02027818|DRUG|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
215083135|NCT02494843|OTHER|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
215083136|NCT02494843|OTHER|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
215083137|NCT04848714|DRUG|ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL|Antivenin latrodectus (black widow) equine immune F(ab)2\] lyophilized powder for solution 10 mL for intravenous use \[parenteral formulation\]; hence, a single-dose fasting pharmacokinetic study is planned.
215083138|NCT05533203|BIOLOGICAL|Prodencel; an autologous dendritic cell therapeutic tumor vaccine|Subcutaneous injection, each injection point should not exceed 1ml.
214358954|NCT00030719|BIOLOGICAL|filgrastim|
214358955|NCT00030719|BIOLOGICAL|monoclonal antibody Ch14.18|
214358956|NCT00030719|DRUG|busulfan|
214358957|NCT00030719|DRUG|carboplatin|
214358958|NCT00030719|DRUG|cyclophosphamide|
214358959|NCT00030719|DRUG|etoposide|
214970450|NCT00097214|BIOLOGICAL|Cetuximab|400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.
214358960|NCT00030719|DRUG|isotretinoin|
214358961|NCT00030719|DRUG|melphalan|
214358962|NCT00030719|DRUG|vincristine sulfate|
214358963|NCT00030719|PROCEDURE|bone marrow ablation with stem cell support|
214358964|NCT00030719|PROCEDURE|conventional surgery|
214358965|NCT00030719|PROCEDURE|peripheral blood stem cell transplantation|
214358966|NCT00030719|RADIATION|radiation therapy|
214358967|NCT03963726|RADIATION|stereotactic radiotherapy|The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
214970451|NCT01051479|DRUG|C11-Choline|15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
214970452|NCT04549181|BEHAVIORAL|Phase II: Problem-Solving for Rural HF Dyads|Participants in the Intervention Group will be trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems collaboratively over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Dyadic problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this dyadic intervention is to move HF dyads toward a positive problem orientation and use of rational problem-solving strategies that support greater patient and family caregiver-contributed HF self-care.
214970453|NCT03224793|DRUG|BIIB059|Administered as specified in the treatment arm
214970454|NCT03224793|DRUG|Placebo|Administered as specified in the treatment arm
214970455|NCT06360523|DIAGNOSTIC_TEST|AI modal|The MRI image will be reviewed by radiologist and AI model(s) respectively. The urologist will combine the results of the two approaches to optimize the biopsy strategy which is expected to result in more accurate diagnosis.
214970456|NCT06360523|DIAGNOSTIC_TEST|Standard review|The MRI image will be reviewed by radiologist.
214970457|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Patients|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
214970458|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Caregiver|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
214970459|NCT01829958|DRUG|rituximab|
214970460|NCT01829958|DRUG|prednisone|
214970461|NCT01829958|BEHAVIORAL|Geriatric Assessment|
214970462|NCT03439267|COMBINATION_PRODUCT|Coronary Artery Calcium Screening and Statin Treatment|Will undergo coronary artery calcium screening and will receive statin treatment based on the cardiovascular risk algorithm.
214970463|NCT03439267|OTHER|Standard Treatment|Patients will be managed following the AHA/ACC guidelines for statin initiation and follow-up.
214970464|NCT04195061|PROCEDURE|Cardiopulmonary exercise test (CPET)|CPET studies will be performed in the Cardiovascular Performance Program exercise lab at MGH. Subjects will undergo CPET on an upright cycle ergometer with continual measurement of metabolic gas exchange via a commercially available metabolic cart as well as heart rate and blood pressure. Exercise will proceed according to a maximal effort clinical protocol. Subjects will then undergo a standardized 30-min work load on the upright cycle ergometer based on the results of the maximal effort clinical protocol.
214358968|NCT03963726|OTHER|microwave alabation|The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
214970465|NCT02040753|BEHAVIORAL|Intensive Lifestyle Intervention|Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
214970466|NCT04460872|DRUG|Testosterone Enanthate|Subjects receive testosterone (100 mg/week) by intramuscular injection
214970467|NCT04460872|BEHAVIORAL|Locomotor Training|Subjects receive locomotor training (4 sessions/week for 2-3 months)
214970468|NCT04739969|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Soterix Neural Navigator neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
214970469|NCT04739969|DEVICE|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214970470|NCT05566301|DRUG|Clopidogrel|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
215083139|NCT01389154|PROCEDURE|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
215083140|NCT02187523|DRUG|Hydrochlorothiazide|
215083141|NCT02187523|DRUG|Telmisartan|
215083142|NCT02187523|DRUG|Telmisartan/HCTZ FDC|
215083143|NCT06552481|DEVICE|NP-PWD|Application of NP-PWD device.
215083144|NCT06552481|DEVICE|Wound Vac|Application of wound vac device.
215083145|NCT06012279|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.
215083146|NCT03846531|DEVICE|Nano-Pulse Stimulation (NPS)|The Pulse generator delivers electrical pulses (nanosecond duration) that are applied directly to targeted lesion using sterile treatment tips with micro-needles.
214679184|NCT00722345|BEHAVIORAL|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current \& past activities; 2) reviewing the pros \& cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
214679185|NCT02065947|PROCEDURE|paravertebral block|catheter with 3-level-injection
214679186|NCT02065947|DRUG|fentanyl, propofol, atracurium|endotracheal intubation
214679187|NCT02065947|DRUG|lidocaine , adrenaline, ketamine bolus, midazolam|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
214679188|NCT02065947|DEVICE|catheter with 3-level-injection|
214679189|NCT02065947|DRUG|sevoflurane and 50% oxygen in air|
214970471|NCT05566301|DRUG|Ticagrelor|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
214970472|NCT06137248|DIETARY_SUPPLEMENT|Energy drink|Participants on this arm will consume an energy drink once daily in addition to their normal diet for 4 weeks.
214970473|NCT06558422|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined either to maintain fasting serum insulin levels (MH protocol) or to reduce fasting serum insulin levels by approximately 50% toward euinsulinemia (RE protocol).
214970474|NCT06558422|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
214358969|NCT05686057|DEVICE|percutanous coronary angiography with stenting|Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases. The severity of stenosis will be done by modified gensini score from angiogram. An sST2 ELIZA test will be done after withdrawal of the cases' samples.
214970475|NCT06558422|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
214970476|NCT06558422|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
214970477|NCT06558422|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
214970478|NCT06558422|DIAGNOSTIC_TEST|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
214970479|NCT06558422|DIAGNOSTIC_TEST|[1-13C1] sodium acetate|Stable isotope tracer administered to calculate de novo lipogenesis during pancreatic clamp.
214970480|NCT06558422|DIETARY_SUPPLEMENT|Nestle BOOST Plus|"Nutritional supplement will be administered to provide standardized mixed meals prior to the pancreatic clamp."
214970481|NCT06558422|DIETARY_SUPPLEMENT|KIND Bar|Energy bar snack will be administered the evening before the pancreatic clamp.
214970482|NCT06558422|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
214970483|NCT06558422|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
214970484|NCT03377270|BEHAVIORAL|Respiratory Swallow Training|Training in the Optimal Respiratory Swallow Pattern and Lung Volume at Swallow Initiation
214970485|NCT05067790|DRUG|Nusinersen|Administered as specified in the treatment arm
214970486|NCT05132504|DRUG|Pembrolizumab|Pembrolizumab will be initiated starting with the Cycle 2 Day 1 and will be administered every 6 weeks with a max amount of 9 cycles throughout the study.
214970487|NCT05132504|DRUG|Folfirinox|Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil) chemotherapy treatment. Each cycle is 14 days; a total of six cycles will be administered. Patients will receive growth factor support at the discretion of treating physician.
214970488|NCT00120705|DRUG|darbepoetin alfa|
214970489|NCT00196105|DEVICE|6 mm Nitinol Zilver Stent|
214970490|NCT00196105|DEVICE|10 mm Nitinol Zilver Stent|
214970491|NCT00196105|DEVICE|10 mm Stainless Steel Wallstent|
214970492|NCT04968093|BEHAVIORAL|Mindfulness-based therapy.|"Educational. Patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. Patients will be encouraged to restrict use of acute medications to headaches and to engage in regular physical activity, avoiding skipping meals, remain well hydrated, maintain a regular sleep.~Mindfulness therapy. The intervention is delivered in small groups and consisted of 7 weekly group sessions. It was aimed to teach and make direct practice with skills intended to enhance sustained, non-judgmental present moment awareness. Each session was conducted by a neurologist and a psychologist. To patients were asked to close their eyes and focus their attention on the breathing so that they can concentrate on the present moment and on all the sensations. Intervention's main topics: posture education; breath use and control; guided body scan; work with sounds; tension release; guided imagery; decentralization of thoughts."
214970493|NCT01328470|DRUG|Clopidogrel, cilostazol|Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
214970494|NCT04863872|OTHER|Proactive Care Management|Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
215083147|NCT03276052|DRUG|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
215083148|NCT01994863|DEVICE|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
215083149|NCT01994863|DEVICE|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
215083150|NCT06216782|OTHER|Non-intervention|Non-intervention
215083151|NCT05278364|DRUG|SY-5007|a RET selective Inhibitor
215083152|NCT06184464|OTHER|ACETATE LEUPRELINE|USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
215083153|NCT01363180|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
215083154|NCT01363180|OTHER|No stress condition|
215083155|NCT01982006|PROCEDURE|Cataract surgery with Phacoemulsification|"Each patients randomized in the phaco arm will undergo a conventional cataract surgery.~Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.~Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center."
215083156|NCT01982006|DEVICE|Femtosecond laser-assisted cataract surgery|"Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.~Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.~Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm"
215083157|NCT01082510|DRUG|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
214970495|NCT04863872|BEHAVIORAL|MyHC-T2D education program|Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
214970496|NCT05866393|BEHAVIORAL|Clean Hands Accessible and Manageable for Patients|Use of a patient-smart hand sanitation dispenser that provides reminders that are non-beeping reminders.
214970497|NCT06240481|DRUG|Test Regimen|toothpaste \& mouthwash
214487653|NCT06881225|OTHER|Using DCE-MRI, fMRI, and DSI, establish a longitudinal brain functional and structural imaging database for three groups of nasopharyngeal carcinoma patients before and 18 months after radiotherapy.|"1. Resting-state fMRI:~   Use the Gradient Echo Echo Planar Imaging (GRE-EPI) sequence with the following parameters: repetition time (TR) = 2000 ms, echo time (TE) = 30 ms, flip angle (FA) = 90°, slice thickness = 3.0 mm, slice spacing = 0.8 mm, field of view (FOV) = 240 mm × 240 mm, matrix = 128 × 128, in-plane resolution = 64 × 64, 39 axial slices scanned, 240 dynamic scans.~2. DSI:~   Use diffusion-sensitive imaging (DSI) with 64 diffusion directions, b-values of 0 and 1000 s/mm², TR = 3000 ms, TE = 64 ms, number of excitations (NEX) = 1, matrix = 112 × 112, FOV = 224 mm × 224 mm, slice thickness = 2 mm, no spacing between slices, full brain coverage, and 75 slices scanned.~3. Three-dimensional brain structural MRI:~Sagittal data acquisition is performed with the following parameters: TR = 8.16 ms, TE = 3.18 ms, inversion time (TI) = 800 ms, flip angle (FA) = 8°, matrix = 256 × 256, FOV = 256 mm × 256 mm, voxel size = 1 mm × 1 mm × 1 mm, and 176 slices scanned."
214487654|NCT06881589|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
214487655|NCT07039890|DRUG|Empagliflozin + Linagliptin filmcoated tablets|Empagliflozin + Linagliptin 10 mg/5 mg filmcoated tablets
214487656|NCT07039890|DRUG|Glyxambi film-coated tablets|Glyxambi 10 mg/5 mg film-coated tablets
214487657|NCT07039435|OTHER|Alternative Frequency Mapping|Patients will have their speech processors programmed with four maps, three of which use a higher low-frequency cutoff than the default map (313 Hz, 438 Hz, 563 Hz, compared to the default map that has a low-frequency cutoff of 188 Hz).
214487658|NCT06688071|DIAGNOSTIC_TEST|Single Group Assignment|68Ga-DOTA/NOTA-FAPI-04 Each subject receive a single intravenous injection of 68Ga/18F-FAPI, and undergo PET/CT imaging within the specificed time.
214487659|NCT07037810|DEVICE|iBolus|MDI+ FreeStyle Libre 2 +iBolus
214487660|NCT07037810|OTHER|Carb counting|MDI+FreeStyle Libre 2+ Carbcounting
214487661|NCT07039812|DEVICE|Virtual Reality Headset|During the dressing change, nature-themed videos will be shown through a virtual reality headset that immerses the user in a 360-degree, three-dimensional virtual environment.
214970498|NCT06240481|DRUG|Control Regimen|toothpaste
215083158|NCT01082510|DRUG|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
215083159|NCT05577832|PROCEDURE|Helfer Skin Tap Technique|In a single-group design, 3 technique injections will be administered to the patients, to be randomized. The HST technique will be applied to patients in any one of 1days in a randomized fashion.
215083160|NCT05577832|PROCEDURE|ShotBlocker Technique|In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The ShotBlocker technique will be applied to patients in any one of 1 weeks(3 days) in a randomized manner.
214487662|NCT07039812|DEVICE|Eye Mask|A soft, adjustable, 3D-structured eye mask (Poblex brand) will be applied during the dressing procedure.
214970499|NCT04058028|DRUG|Rozibafusp Alfa|Rozibafusp Alfa will be presented in 5 mL glass vial
214970500|NCT04058028|DRUG|Placebo for Rozibafusp Alfa|Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
214970501|NCT04680533|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Quell TENS device. The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
214970502|NCT00980824|BEHAVIORAL|Cognitive behavioural therapy|Six sessions brief CBT.
214970503|NCT00980824|OTHER|Standard treatment|Referral to NHS services appropriate to patient's needs
214970504|NCT03666416|BEHAVIORAL|Sprint Interval Training|Participants will attend two experimental appointments, during which they will complete two identical executive functioning tasks (i.e., sustained attention, working memory). During one appointment, participants will receive the sprint interval training manipulation prior to completing the tasks.
214970505|NCT04848636|DIAGNOSTIC_TEST|Cardiac Sodium and Proton MRI|Sodium-23 MRI of the Heart Proton MRI of the Heart
214970506|NCT04871152|DRUG|OnabotulinumtoxinA|To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.
214970507|NCT03552991|DRUG|Agiocur Pregranules|6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout
214970508|NCT06556719|BEHAVIORAL|Hoosier Sport Re-Social|Hoosier Sport Re-Social is a 6-week school-based intervention designed to reduce cardiovascular disease risk in rural children. It includes twice-weekly physical activity sessions during PE classes and weekly social media literacy training in health classes, promoting healthier physical and digital behaviors.
214970509|NCT03751475|OTHER|Nutritional Strategy - OptiMA|"All children with a MUAC\<125mm or oedema will be treated with the same RUTF, according to a new dosage table based on the evolution of MUAC and weight during recovery (RUTF dosage prescribed is gradually reduced as weight and MUAC increase).~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet discharge criteria, and then a bimonthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
214970510|NCT03751475|OTHER|Effective nutritional standard strategy|"Children presenting with MUAC\<115 or WHZ\<-3 or nutritional oedema, will be treated with RUTF, according to the usual dosage table based on weight at each visit.~All children (whether eligible for RUTF or not) will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated). Children not eligible for RUTF at randomization will benefit from this same monthly community-based follow-up."
214970511|NCT05694806|OTHER|analysis of thoracic scans|analysis of thoracic scans realised in standard care
214970512|NCT05750264|DRUG|Ibuprofen|800 mg of IV ibuprofen
214970513|NCT04443647|DRUG|Oxytocin|Syntocinon nasal spray
214970514|NCT04443647|DRUG|Placebo|Placebo nasal spray
214970515|NCT04262011|PROCEDURE|immediate treatment|Patients allocated to the immediate treatment group will receive full mouth treatment, and will use 0.12% chlorhexidine mouthwash, every 12 hours for a week, and will receive oral hygiene instructions throughout the follow-up period. Patients will be evaluated at the beginning, at 3 and 6 months.
214970516|NCT04262011|PROCEDURE|postponed treatment|Patients allocated to the late treatment group will be assessed at baseline, 3 and 6 months. After the end of the follow-up period, they will receive non-surgical periodontal treatment performed in four sessions.
214970517|NCT00970021|DIETARY_SUPPLEMENT|Intake of 60 ml placebo daily in addition to chemotherapy|The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.
214970518|NCT00970021|DIETARY_SUPPLEMENT|Intake of 60 ml agaricus daily in addition to chemotherapy|The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
214970519|NCT05782803|BEHAVIORAL|Exercises Group|A Pressure Biofeedback Device will be used in CCF training to increase awareness and focus on the desired muscle. After the person is brought to the hook position, the pressurized biofeedback device will be placed in the middle position between the craniocervical and cervical vertebrae or horizontally so that the protrusion between the earlobe and the chin is removed. It is inflated to a standard 20 mmHg to ensure surface-to-longitudinal contact. Participants are taught the correct craniocervical flexion movement without first working the superficial muscles. The patient is then asked to look with their eyes slightly toward the chest cavity. During the exercises, starting from 20 mmHg and increasing by 2 mmHg, the desired level of 30 mmHg will be reached. At each level, the movement is continued for 10 seconds, resting for 3-5 seconds, 10 repetitions are required. If the same level is maintained for 10 seconds and 10 repetitions, the next level is passed.
214970520|NCT02105194|DRUG|Hyperbaric oxygen therapy|total body exposure to greater than atmospheric pressure oxygen
214970521|NCT00397605|DRUG|Synthetic cannabinoids (1:1 ratio of THC % CBD)|Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
214970522|NCT01326247|OTHER|thermal waters nasal irrigation|"The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution."
215083161|NCT05577832|PROCEDURE|Standard Technique|Standard Technique In a single-group design, 3 technique injections will be administered to the patients, 1 technique per days, to be randomized. The standard technique will be applied to patients in any one of 1 weeks in a randomized fashion.
214970523|NCT00888888|PROCEDURE|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
214970524|NCT01121939|DRUG|Bevacizumab|"15 mg/kg IV Day 1. The first dose should be administered over~90 minutes. If no adverse reactions occur after the initial dose, the second dose should~be administered over a minimum of 60 minutes. If no adverse reactions occur after the~second dose, all subsequent doses should be administered over a minimum of 30~minutes. Bevacizumab will be infused prior to pertuzumab."
215083162|NCT05462977|BEHAVIORAL|Group exercise program|Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
214358972|NCT05105295|BIOLOGICAL|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
214970525|NCT01121939|DRUG|Pertuzumab|"840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.~If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later."
214970526|NCT01121939|DRUG|Sandostatin LAR® Depot|30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
214970527|NCT05438238|DEVICE|Oncomfort|Virtual Reality
214970528|NCT03513679|PROCEDURE|Surgical intervention|Surgery to decompress the spinal cord, either with or without concurrent fusion
214970529|NCT03256019|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
214970530|NCT02298426|BEHAVIORAL|Health Management|We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
214970531|NCT02298426|BEHAVIORAL|General Management|We provide general information about health. Information is provided through telephones and materials.
214970532|NCT02298426|OTHER|Placebo|We use placebo to replace the health product.
214970533|NCT02298426|DIETARY_SUPPLEMENT|SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®|We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
214970534|NCT01211756|DRUG|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
214970535|NCT01211756|DRUG|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
214970536|NCT02811315|OTHER|Observational. Non interventional study|Observational. Non interventional study
214970537|NCT01877161|DEVICE|Repetitive magnetic stimulation to superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
214970538|NCT01877161|DEVICE|Repetitive magnetic stimulation to middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
214970539|NCT01877161|DEVICE|Repetitive magnetic stimulation (Sham)|Repetitive magnetic stimulation (Sham)
214970540|NCT04226781|DIAGNOSTIC_TEST|Hyperspectral-Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
214970541|NCT04226781|DIAGNOSTIC_TEST|Indocyaningreen-Fluorescence imaging|Photos were taken with the Fluorescence camera after injection of the indocyaningreen-dye of the gastrointestinal anastomosis
214970542|NCT06325891|DIAGNOSTIC_TEST|Gastric mucosal brushing|Gastric mucosal brushing will be performed at body of stomach in control group and non-tumorous area of body in gastric cancer group. If gastric body area could not feasible (eg. tumor involvement), then gastric antrum and more proximal part of body will be sampling.
214970543|NCT06325891|DIAGNOSTIC_TEST|Gastric mucosal biopsy|Gastric mucosal biopsy will be performed at the area within 2 cm. from brushing site.
214970544|NCT01735149|DIETARY_SUPPLEMENT|Kochujang Pills|Kochujang Pills (34.5g/day)
214358973|NCT06187753|DIAGNOSTIC_TEST|Sensory Profile|The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.
214358974|NCT01107184|PROCEDURE|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
214358975|NCT01107184|PROCEDURE|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
214358976|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR and PVI|
214970545|NCT01735149|DIETARY_SUPPLEMENT|Placebo|Placebo (34.5g/day)
214970546|NCT03923153|DEVICE|Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
214970547|NCT03923153|DEVICE|Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
214358977|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR|
214358978|NCT05888636|OTHER|ChIP-seq, NGS, ATAC-seq|Bone narrow sampling
214487663|NCT07038811|DEVICE|Tät®II|"The Tät®II app offers a treatment program for women with urge or mixed urinary incontinence. The program includes information on the pelvic floor, urinary incontinence, and factors affecting incontinence; a bladder training program; a pelvic floor muscle training program; and incontinence-related psychoeducation. The app also contains helpful functions, the ability to create reminders, visualization of each training level, a statistics function regarding the number of exercises performed, and feedback on changes in the level of bother due to urinary incontinence during treatment.~The Tät®II app is available for download on Google Play and the App Store. Users need a one-time code to access the app, which is provided by the research team after they are included in the study. The app is self-instructive and can be used anywhere; no formal education is necessary. There is no option to communicate through the app."
214487664|NCT07039877|DRUG|Venetoclax low dose with itraconazole|We will add venetoclax in low dose (100 mg) with itraconazole to the pediatric inspired regimen TACL to enchance the complete response rate
214487665|NCT07039695|PROCEDURE|Volar buttress plate|Patients will be treated by a volar buttress plate.
214487666|NCT07039695|PROCEDURE|Herbert screw|Patients will be treated by Herbert screw.
214487667|NCT07040072|COMBINATION_PRODUCT|Stapokibart and Finotonlimab|"Receive the combination of Stapokibart and Finotonlimab in cycles 1-3, and maintain treatment with Finotonlimab in subsequent cycles.~Stapokibart, 600mg for the first cycle, 300mg for the second and third cycles, administered subcutaneously every 3 weeks, for a total of 3 doses of Stapokibart; Finotonlimab 200mg, administered intravenously every 3 weeks until confirmed disease progression occurs according to the RECIST 1.1 imaging criteria (if the researcher determines that the subject can benefit from continuing PD-1 drug treatment, and the subject can tolerate the study treatment and agree, PD-1 drug can be continued and recorded in the study records), unacceptable toxic side effects, initiation of new anti-tumor treatment, withdrawal from the study or death (whichever occurs first), or reaching a maximum treatment period of 2 years."
214487668|NCT07038213|GENETIC|glycation genes|glycation genes
214487669|NCT07038213|DIAGNOSTIC_TEST|beta 2 microglobulin|b2m
214487670|NCT07040020|PROCEDURE|Underwater ESD (U-ESD)|Underwater ESD (U-ESD): after filling the lumen with saline and sucking all the air, initial submucosal injection of saline and methylene blue is performed; subsequent mucosal incision with ESD knife all around the lesion and submucosal dissection deep in the submucosal layer leading to an en bloc resection is carried out
214970548|NCT01691378|OTHER|Window to Hope|Psychotherapy - Group
214358979|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
214358980|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
214970549|NCT01691378|OTHER|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
214970550|NCT03438201|DIETARY_SUPPLEMENT|Intervention|Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day
214970551|NCT03438201|DIETARY_SUPPLEMENT|Control|Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day
214970552|NCT03298997|PROCEDURE|Ligation and Hemorrhoidopexy|"Identification through palpation and ligation of the hemorrhoidal nodules (3rd, 7th, 11th hour), using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to pudendal nerve block."
214358981|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
214358982|NCT02166008|DRUG|Repamipide|
214358983|NCT02166008|DRUG|Placebo|
214970553|NCT03298997|PROCEDURE|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"Ultrasound guided identification and ligation of the hemorrhoidal arteries, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to spinal anesthesia."
214970554|NCT04423640|OTHER|Active COVID-19 disease|Adult patients admitted to the UMAE Specialty Hospital of CMN SXXI with a diagnosis of COVID-19. The diagnosis must be corroborated by the RT-PCR test.
214358984|NCT01235208|OTHER|"The Dr. Fedon Lindbergs Vektcoach Treatment"|Diet and lifestyle treatment
214358985|NCT01152580|DIETARY_SUPPLEMENT|melatonin|3mg p.o. at bedtime daily
214358986|NCT01152580|DIETARY_SUPPLEMENT|sugar pill|lactose p.o. at bedtime daily
214358987|NCT01437748|DRUG|Indacaterol maleate|Dry powder, 300 mcg, only one inhalation with 24 hours duration
214358988|NCT01437748|DRUG|Tiotropium bromide|Dry powder, 18 mcg, only one inhalation with 24 hours duration
214358989|NCT04973865|OTHER|Validation & reliability|Translated version of IPAQ(SF) validation \& Reliability
214358990|NCT01570829|DRUG|Dietressa|Oral administration.
214358991|NCT01570829|DRUG|Placebo|Oral administration.
214358992|NCT03950765|BEHAVIORAL|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
214358993|NCT05594979|DIETARY_SUPPLEMENT|TOTUM-070|2.5-g dose of TOTUM-070 diet supplement; Four capsules per day to consume orally in two intakes
215083163|NCT06482320|DIAGNOSTIC_TEST|Recording EKG traces on the smartwatch|Upon enrollment, patients are associated with a progressive identification number (ID). They will then be instructed to record a baseline single-lead EKG (EKG 0) to be sent to a dedicated email address. The sender's email address will be recorded and associated with the ID. The main clinical and demographic data will also be collected. Within 30 days of the enlistment date, a 24-hour EKG Holter will be performed. From the date of enlistment and for the following three months, before, after and during the execution of the 24-hour EKG Holter, enrolled patients can send single-lead EKGs (recorder throug the smartwatch) in case of palpitation. The report of the single-lead EKGs will be communicated electively via e-mail (in response to the email sent by the patient and containing the trace in question) in the following days. In case of diagnostic and/or therapeutic measures to be implemented following the reporting of the trace, doctors will take care of it.
214970555|NCT04338477|DRUG|Nephrosolid tablets|Adminstration of drug
214970556|NCT03174015|BEHAVIORAL|Bauleni Secret|The intervention will invite enrolled landlords to a series of meetings in which various mechanisms will be used, each designed to increase their likelihood of improving the toilet(s) on their plot. These meetings will be the main vehicle for a status-building campaign associated with increasing wealth by improving plot sanitation, understanding tenants' implicit demand, understanding the processes by which toilets can be improved, and a competition rewarding landlords that make the greatest improvements to the improvement of their toilet(s).
214358994|NCT03424824|DRUG|BP1.3656 low dose|Tablet, once daily oral administration at the low dose
214970557|NCT00331565|PROCEDURE|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
215083164|NCT01402076|DRUG|Tasimelteon|20mg daily dosing, Days 4-20
215083165|NCT01402076|DRUG|Rosiglitazone|4mg, single dose, Days 3 and 20
215083166|NCT01402076|DRUG|Midazolam|10mg, single dose, Days 1 and 18
215083167|NCT02202512|DRUG|Placebo|tablets
215083168|NCT02202512|DRUG|Cimetidine|
215083169|NCT02202512|DRUG|Placebo|tablets
215083170|NCT02202512|DRUG|Placebo|tablets
215083171|NCT02202512|DRUG|BI 1060469 high dose|tablets
215083172|NCT02202512|DRUG|BI 1060469 low dose|tablets
215083173|NCT02202512|DRUG|Naproxen|
215083174|NCT02202512|DRUG|BI 1021958|tablets
215083175|NCT04617418|BEHAVIORAL|Change in touchscreen interactions|The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions
215083176|NCT03060512|DRUG|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
215083177|NCT03060512|DRUG|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
215083178|NCT03946124|DRUG|Fesoterodine|Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.
215083179|NCT00302276|DRUG|Metobes-compound|
215083180|NCT02792491|DRUG|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
215083181|NCT02163720|DRUG|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
215083182|NCT05516784|DRUG|Clopidogrel|Comparison of platelet reactivity between clopidogrel and ticagrelor
214970558|NCT04793984|DEVICE|Carragelose|inhalation 3 times a day
214970559|NCT04793984|DEVICE|NaCl|inhalation 3 times a day
214970560|NCT00109746|DIETARY_SUPPLEMENT|chromium picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
215083183|NCT05516784|DRUG|Ticagrelor|Comparison of platelet reactivity between clopidogrel and ticagrelor
215083184|NCT01882049|DEVICE|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
215083185|NCT02370004|PROCEDURE|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
215083186|NCT04765423|DEVICE|[F-18] NaF PET/CT|Radiotracer F-18 NaF used on the PET/CT imaging
215083187|NCT04765423|DEVICE|[F-18] fluciclovine PET/CT|F-18 fluciclovine (Axumin ®) used on the PET/CT camera
215083188|NCT02793830|OTHER|Daily reminders of taking medications|Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
214358995|NCT03424824|DRUG|BP1.3656 intermediate dose|Tablet, once daily oral administration at the intermediate dose
214358996|NCT03424824|DRUG|Placebo|Tablet, once daily oral administration
214358997|NCT03424824|DRUG|BP1.3656 high dose|Tablet, once daily oral administration at the high dose
214358998|NCT02073396|DIAGNOSTIC_TEST|Blood test|Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
214358999|NCT03364751|OTHER|IQOS|Patients will switch from cigarette smoking to ad libitum IQOS use.
214970561|NCT01001312|OTHER|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
214970562|NCT01001312|OTHER|Clinical volume status assessment|Volume assessment based on history and physical examination
214970563|NCT02975817|OTHER|Hibler's|Passive body heat retention using multiple-layer tight wrapping of patient
214970564|NCT02975817|OTHER|Warm Air|Active, convective warming of patient using warm air blanket
214970565|NCT05651386|OTHER|Diet|No blinded, no controlled intervention.
214359000|NCT03364751|OTHER|Cigarette|Patients will continue to smoke cigarettes ad libitum.
214487671|NCT07040020|OTHER|Conventional ESD (C-ESD)|Conventional ESD (C-ESD): under CO2 insufflation, initial submucosal injection of saline and methylene blue is performed; subsequent mucosal incision with ESD knife all around the lesion and submucosal dissection deep in the submucosal layer leading to an en bloc resection is carried out.
214487672|NCT07038850|OTHER|Multimodal nurse training about nurse driven sedation-analgesia protocol|"The training program for nursing staff in the use of the sedation-analgesia protocol includes 3 stages:~1. Initial training: e-learning module to be validated~2. Feedback session: sessions in small groups of 5 to 6 participants, led by a nurse trainer, allowing interprofessional transmission (questions/answers and critical analyzes of sedation collection sheets).~3. Bedside rehearsal: individual practice of the sedation-analgesia protocol at the patient's bedside under the supervision of a doctor or nurse trainer."
214487673|NCT07037836|DRUG|Inhaled Treprostinil (Tyvaso Nebulizer)|Participants will receive inhaled Treprostinil (Tyvaso nebulizer), 6 µg per breath, administered four times daily for 4 weeks. The starting dose will be 3 breaths per session. The dose will increase by 1 breath per session each week, as tolerated, to a target of 6 breaths per session by week 4. If adverse effects occur, participants will remain at the highest tolerated dose. The drug will be administered using the Tyvaso inhalation system provided by United Therapeutics. No changes to baseline COPD maintenance medications are allowed during the treatment period. Participants will be monitored for safety throughout the study.
214970566|NCT02849080|DRUG|semaglutide|Oral administration once-daily.
214970567|NCT02849080|DRUG|sitagliptin|Oral administration once-daily.
214970568|NCT05292885|DIAGNOSTIC_TEST|Gadopentetate Dimeglumine Injection|Patients with liver fibrosis after liver transplantation receive multi-parameter magnetic resonance scanning, percutaneous liver biopsy (or FibroScan).
214970569|NCT01264809|BEHAVIORAL|Specific consultation for physical activity counseling|Specific consultation
214970570|NCT01264809|BEHAVIORAL|Consultation for physical activity counseling|Specific consultation
214970571|NCT04288934|BIOLOGICAL|Collection and expansion of BM-MSC|MSCs collection from patients owns marrow using a volume of 20 ml of bone marrow obtained from iliac crest of SCI patients under local anesthesia. Manipulations of blood and bone marrow are to be done according to Good Laboratory Practice (GLP) using the gradient sedimentation method.
214970572|NCT04288934|DIAGNOSTIC_TEST|VI-SCI evaluation and patients' follow up|"* At 6, and 12 months post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline.~* The (ASIA)/(ISNCSCI) score will be repeated every 3 months to evaluate any motor or neurological changes~* The Spinal Cord Independence Measure (SCIM III) score will be repeated every 3 months to evaluate the effect on daily activities.~* Blood samples will be withdrawn from patients at 3 months interval for biomarkers detection."
214970573|NCT02057263|DRUG|Alendronate|Participants will receive 4 doses of alendronate during the course of the study.
214970574|NCT02057263|DRUG|Hepatitis B Vaccine|Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.
214970575|NCT02057263|DRUG|Placebo|Participants will receive 4 doses of placebo during the course of the study.
214970576|NCT05200585|BEHAVIORAL|Healthy Liver/Hígado Sano program|The program will last 4-6 months and include 16 sessions, each 30-60 minutes long, that focus on self-management strategies for dietary changes and physical activity and is meant to be delivered in 4-6 months. The 16 sessions are as follows: 1) Introduction to the program, 2) Get Active, 3) Track Your Activity, 4) Eat Well, 5) Track Your Food, 6) Get More Active, 7) Burn More Calories Than You Take In, 8) Shop and Cook, 9) Manage Stress, 10) Find Time for Fitness, 11) Cope with Triggers, 12) Keep Your Heart Healthy, 13) Take Charge of Your Thoughts, 14) Get Support, 15) Eat Well Away from Home, and 16) Staying Motivated
214970577|NCT05200585|BEHAVIORAL|Usual standard of care|Participants will receive ongoing monitoring of condition at the clinic per standard of care and a short informational pamphlet
215083189|NCT02793830|OTHER|Educational materials|Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (\< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
215083190|NCT01205802|PROCEDURE|MHV reconstruction|MHV reconstruction with PTFE or homograft
215083191|NCT00390117|DRUG|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
214359001|NCT00323596|BEHAVIORAL|physical activity program of strength and balance retraining|
214359002|NCT05289726|DRUG|Traditional chinese medicine TDX105|Experimental group Traditional chinese medicine TDX105
214359003|NCT05289726|DRUG|Placebo|he control group received placebo granules mixed with dextrin and food coloring
214359004|NCT01937052|OTHER|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
214359005|NCT01937052|BEHAVIORAL|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
214359006|NCT01475968|OTHER|Ultrafine Air Pollution Particulate Matter|Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
214359007|NCT01475968|OTHER|Filtered Air|Filtered Air
214359008|NCT02496624|OTHER|Cone Beam CT localization and placement of microcoil|Cone Beam CT localization and placement of microcoil
214359009|NCT02636634|OTHER|imaging|
215083192|NCT00390117|OTHER|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
215083193|NCT04059523|DRUG|S6G5T-3|once daily
215083194|NCT04059523|DRUG|Retin-A® 0.1% Cream|once daily
214359010|NCT00715546|PROCEDURE|autologous transplantation of liposuction material enriched with adipose-derived stem cells|Lipoinjection enriched with adipose-derived stem-cells.
214359011|NCT06449833|DRUG|Henagliflozein and Metformin|The experimental group will be treated with 10mg Henagliflozein and Metformin.
214359012|NCT06449833|DRUG|Linagliptin and Metformin|The control group will be treated with 5mg Linagliptin and Metformin.
214970578|NCT02899247|PROCEDURE|Surface sealant|"Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~* The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA)."
214970579|NCT02899247|PROCEDURE|No surface sealant|"Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA)."
214970580|NCT02267915|DRUG|subcutaneous Rituximab|MabThera 1400 mg solution for subcutaneous injection
214970581|NCT06128421|DIETARY_SUPPLEMENT|Individual nutritional support|Nutritional products and route（oral, parenteral）is possible to reach goals
214970582|NCT03472911|OTHER|minimum effective volume|The determination of MEV50 and its 95% confidence interval (CI) was based on the staircase up-and-down method by Dixon and Massey.
214970583|NCT01819727|DRUG|BMN 165|After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.
214970584|NCT01836068|DRUG|Enfuvirtide|Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
214970585|NCT01104883|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
214970586|NCT01104883|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
214359013|NCT04468438|DIAGNOSTIC_TEST|serum estrogen and urinary albumin creatinine ratio|serum estrogen and urinary albumin creatinine ratio
214359014|NCT00413387|DRUG|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
214359015|NCT00413387|DRUG|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
214359016|NCT04396067|DRUG|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
214359017|NCT04396067|DRUG|Aerosolized All trans retinoic acid|The infected patients will receive Aerosolized All trans retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled all trans retinoic acid therapy for 14 days
214359018|NCT04396067|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
214359019|NCT04654338|RADIATION|SABR + HDR|One SABR treatment + one HDR brachytherapy treatment
214359020|NCT02829853|GENETIC|Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING|Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo \& HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
214359021|NCT00362518|DIETARY_SUPPLEMENT|Study Arm A|Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.
214359022|NCT00362518|DIETARY_SUPPLEMENT|Study Arm B|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).
214359023|NCT00362518|DIETARY_SUPPLEMENT|Study Arm C|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).
214359024|NCT00362518|DIETARY_SUPPLEMENT|Study Arm D|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
214970587|NCT00387322|DRUG|erlotinib hydrochloride|Given orally
214970588|NCT00387322|DRUG|pemetrexed disodium|Given IV
214970589|NCT02340377|DEVICE|ELITE 3 HQ|The pill is about the size of a multivitamin, is coated with special medical plastic, and is easy to swallow. The pill sends radio signals to a small recording device that participants wear that send a signal to a monitor and records the participant's internal body temperature. The pill will exit the participant's body in one of his/her bowel movements approximately 1-5 days after ingestion. Pills are not reused.
214970590|NCT01542138|DRUG|Desonide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
214970591|NCT01542138|DRUG|Niacinamide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
214970592|NCT01542138|DRUG|Placebo|Humectant placebo cream
214970593|NCT00713271|DRUG|AZD3199|"Low dose~Dry powder for inhalation, o.d., 1+12 days"
214970594|NCT00713271|DRUG|Placebo|
214970595|NCT00713271|DRUG|AZD3199|"intermediate dose~Dry powder for inhalation, o.d., 1+12 days"
214970596|NCT00713271|DRUG|AZD3199|"high dose~Dry powder for inhalation, o.d., 1+12 days"
214970597|NCT04030741|DRUG|Meronem and flagyl|meronem and flagy
214970598|NCT04030741|PROCEDURE|Appendectomy|Appendectomy as treatment for acute appendicitis
214970599|NCT03334357|OTHER|PAR|
214970600|NCT03334357|OTHER|HIIT|
214970601|NCT03334357|OTHER|WB-EMS|
214970602|NCT06197308|DRUG|oral vancomycin and oral amoxicillin|In this study, PSC patients will receive an antibiotic preconditioning regimen of oral vancomycin (500 mg liquid twice a day) for 28 days and oral amoxicillin (1000 mg twice a day) for 7 days (during the last 7 days of the oral vancomycin). Following vancomycin and amoxicillin, encapsulated, freeze-dried microbiota preparation (MTP-101C) will be administered - dosed at ≥ 5 x 10\^11 bacteria (five capsules) daily for 3 days followed by ≥ 2 x 10\^11 bacteria (two capsules) for 11 days - for a total of 14 days of MTP-101C; total of 37 capsules.
214970603|NCT01664676|DRUG|Liraglutide|
214970604|NCT01664676|DRUG|Placebo-liraglutide|
214970605|NCT01189877|PROCEDURE|Eppendorf hypoximeter|Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
214970606|NCT00446017|DRUG|adrenaline|
214970607|NCT00446017|DRUG|milrinone|
214970608|NCT03356600|COMBINATION_PRODUCT|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy"
214970609|NCT02155985|DRUG|Aspirin|Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
214970610|NCT02155985|DRUG|Placebo|Placebo for aspirin
214970611|NCT01602796|BEHAVIORAL|School intervention|The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
214970612|NCT02998151|DRUG|Acamprosate|two 666mg pills
214970613|NCT02998151|DRUG|Lovastatin|two 20mg pills
214970614|NCT02998151|DRUG|Minocycline|two 135mg pills
214970615|NCT02998151|DRUG|Placebo|placebo pill
214970616|NCT02998151|DRUG|Baclofen|one 30mg pill
214970617|NCT03110133|DRUG|Full Spectrum Microbiota|Orally administered donor derived microbiota
214970618|NCT03110133|DRUG|Placebo|Placebo for CP101
214970619|NCT03995888|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
214359025|NCT04067466|DIETARY_SUPPLEMENT|Fiber product|Fiber product with inulin, maltodextrin, gum guar and plum powder.
214359026|NCT04067466|DIETARY_SUPPLEMENT|Control product|Placebo product with maltodextrin and plum powder
214970620|NCT02573259|DRUG|PF-06801591|IV every 21 days (Part 1)
214359027|NCT01964170|DRUG|degarelix|subcutaneous
214359028|NCT01964170|DRUG|Goserelin|subcutaneous
214970621|NCT02573259|DRUG|PF-06801591|300 mg SC every 28 days (Part 1 and 2)
214970622|NCT04750057|DRUG|Anifrolumab|Multi-centre, open-label, early access program (EAP) designed to provide access to intravenous (IV) treatment regimen of 300 mg anifrolumab (MEDI-546) every 4 weeks (Q4W) for eligible patients with moderate-to-severe active SLE while receiving standard therapy.
214970623|NCT00751140|PROCEDURE|Lymph Node Dissection|The lymph nodes will be sent to pathology for review.
214970624|NCT05347810|OTHER|Application of repetitive forces mimicking exoskeleton use|The investigational treatment consists of applying a predefined set of continuous and repetitive forces to the participant's thigh. It is applied using a custom device that has been designed specifically for this study. The forces to be applied are based on forces measured during exoskeleton use and will not exceed pain pressure thresholds reported in literature. The participants will hold an enabling switch at all times which they can activate to release the force exerted to their thigh. Alternatively, the experimenter can activate an emergency switch if the situation seems unsafe.
214970625|NCT02316639|OTHER|Neuromuscular Training|The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
214970626|NCT02413632|OTHER|creation of a STIs score risk|4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)
214970627|NCT02413632|OTHER|validation of a STIs score risk|DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
214970628|NCT00168571|BIOLOGICAL|Measles vaccine|
214970629|NCT04273516|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily
214359029|NCT06486467|OTHER|Fluid challenge (cristalloids) OR passive leg raising|"Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition"
214359030|NCT05371184|DRUG|L-Glutamine, Oral Powder for Reconstitution|Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care
214359031|NCT05371184|OTHER|Standard of care|Hydroxyurea 15-25 mg per kg per day and/ or blood transfusion therapy
214970630|NCT04273516|DRUG|Rivaroxaban placebo tablets|Placebo tablets add to ASA 80 mg daily that is standard treatment
214359032|NCT02557152|DEVICE|GentleWave System Treatment|
214487674|NCT06875076|DRUG|Ivonescimab Combined With Chemotherapy|ivonescimab 20mg/kg combined with pemetrexed 500mg/m²/gemcitabine 1000mg/m²/vinorelbine 25mg/m² every 21 days for 4 cycles followed by a maintenance phase (ivonescimab monotherapy 20mg/kg every 21 days until disease progression, intolerance, or up to 2 years)
214970631|NCT03588858|OTHER|structured interview questionnaires|"* Module (1): Socio-demographic characteristics~* Module (2) :Occupational history~* Module (3): Presence of work related injuries and diseases by history and observation.~* Module (4): Food frequency questionnaires (FFQ) during the past week.~* Module (5): Mental health screening: Self-reporting questionnaire 20 questions for assessment of mental health status of children."
214970632|NCT04776577|DEVICE|Wirecath@ and Abbott PressureWire® (20 patients)|Simultaneous FFR measurements with Wirecath@ and Abbott PressureWire®
214359033|NCT04270214|DRUG|Dysport Injectable Product|Dysport injections optimized using kinematics
214359034|NCT03809481|DRUG|Danaparoid Sodium|inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
214970633|NCT04776577|DEVICE|Wirecath® (20 patients)|FFR measurement with Wirecath® only
214970634|NCT04776577|DEVICE|Coronary flow reserve|Pressure derived CFR with Wirecath®, Thermodilution CFR with Abbott PressureWire®, Absolut flow CFR with Abbott PressureWire® and Hexacath Rayflow catheter®, Non-invasive echo derived CFR
214970635|NCT03629769|DRUG|Proxelan|Administration of one suppository of proxelan once a day for 30 days
214970636|NCT05343299|COMBINATION_PRODUCT|Ambulatory surgery under Lidocaine alone|In this conventional procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 10 to 20 mL, i.e. a total of 50 to 200 mg of lidocaine.
214970637|NCT05343299|COMBINATION_PRODUCT|Ambulatory surgery under a combination of Lidocaine and Ropivacaine|In this experimental procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 18 mL + ropivacaine 7.5 mg/mL 2 mL or 15 mg. For a total of 20 mL: lidocaine 9mg/mL, ropivacaine 0.75 mg/mL, adrenaline 0.005 mg/mL
214970638|NCT05002504|DIAGNOSTIC_TEST|A series of questions were asked to the children's parents in a virtual questionnaire|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children
214970639|NCT05002504|DIAGNOSTIC_TEST|"neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI)"|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
214970640|NCT05002504|PROCEDURE|Therapy sessions|Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
214970641|NCT02472262|DIETARY_SUPPLEMENT|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
214970642|NCT02472262|DIETARY_SUPPLEMENT|Corn soy flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
214970643|NCT02472262|DIETARY_SUPPLEMENT|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
214970644|NCT04621058|DRUG|Vitamin D|In case of Vitamin D levels \<30 or 40ng/ml patients will take vitamin D supplements.
214970645|NCT04621058|DRUG|PLACEBO|Placebo capsules exactly the same as the above, but without the active component.
214487675|NCT05023382|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection
214487676|NCT07038837|OTHER|"Synchronised arm (intervention)"|Vaccines received together with CPS
214487677|NCT06884865|BIOLOGICAL|Enekinragene Inzadenovec (PCRX-201)|Enekinragene Inzadenovec (PCRX-201) injection
214487678|NCT06884865|BIOLOGICAL|Placebo|Placebo injection
214487679|NCT06882863|BEHAVIORAL|Motivational interviewing|"This intervention consists of a single nurse-led motivational interview aimed at reducing sedentary behavior in patients with severe COPD. The session, conducted in the patient's home, lasts approximately 60 minutes and focuses on identifying personal barriers, exploring motivation, and setting small, realistic goals to reduce sedentary time.~Unlike traditional pulmonary rehabilitation, this intervention does not involve structured exercise but instead uses motivational interviewing (MI) techniques to encourage gradual behavior change in daily routines. Before the intervention, patients wear an accelerometer for seven days to objectively measure baseline sedentary time. The study assesses feasibility, patient engagement, and adherence to determine whether the approach is suitable for a larger randomized controlled trial (RCT)."
214487680|NCT06883513|OTHER|Osteopathic Manipulative Therapy Long-COVID protocol|"1. Rib Raising~2. Suboccipital Release~3. Thoracic Inlet Release~4. Miller Pump~5. Pedal Pump~6. Suboccipital Release~7. Cranial Sequence of Sinus Effleurage followed by indirect force within vault hold"
214970646|NCT05936814|PROCEDURE|total knee arthroplasty|cemented bicondylar PCL substituting total knee replacement
215083195|NCT04999865|OTHER|4-part educational program to build patient-engagement methodology capacity|We created four online training sessions. Our first training for patients/caregivers only (Research 101) was an exception, however, in which we produced a 25-minute asynchronous, self-directed learning seminar intended to be viewed before the subsequent interactive PCOR sessions. Of the three following synchronous interactive training sessions, two included both learner working groups (patients/caregivers and researchers/providers) together (PCOR 101 and PCOR Team Dynamics) and one session (PCOR Study Design) was for researchers/healthcare providers only.
215083196|NCT01188148|DRUG|Memantine|5 mg per day of memantine
215083197|NCT01188148|DRUG|Placebo|
215083198|NCT03289832|DIETARY_SUPPLEMENT|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
215083199|NCT03289832|DIETARY_SUPPLEMENT|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
215083200|NCT00800319|DRUG|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
215083201|NCT00800319|DRUG|Placebo|Volume matched placebo; oral solution; single dose
215083202|NCT02393846|DRUG|Ketoprofen gel|Topical ketoprofen as used in gel form.
215083203|NCT02393846|DRUG|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
215083204|NCT02728544|OTHER|exercise and blood tests|At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
215083205|NCT05980364|OTHER|Technology-based training structured according to the Health Promotion Model|Experimental group: A video recording was created with a total of 6 zoom applications to be shared with the patients. The content of the video recordings consists of a presentation accompanied by a slide show with open-ended questions prepared by considering the basic concepts of the trainings and the Health Promotion Model. Video recordings, each of which lasted approximately 15-25 minutes, were shared with patients once a week for a total of 6 weeks via WhatsApp. After each video, patients were given three days to watch the video recordings and create their own responses. After this three-day period, the researcher called the patients with whom he shared the content and gave counseling for 10-15 minutes and received feedback. Follow-up was done in the second 6-week period. During the monitoring process, two reminder interviews were made over the phone, with an interval of 2 weeks, for reminder and counseling, and the post-test data were collected at the end of the monitoring period.
214487681|NCT06883513|OTHER|Osteopathic Manipulative Therapy NOT Long-COVID treatment protocol|"1. Bilateral Trapezius Direct Myofascial Release~2. Still's technique of the First rib Bilaterally:~3. Hamstring Muscle Energy"
214487682|NCT06719063|OTHER|Multisensory Virtual Reality|"The VirtySens® multisensory travel capsule is an immersive virtual reality technique. This total immersion occurs through the simultaneous stimulation of four of the five senses.~Session duration: 45 minutes, with 15 minutes dedicated to the protocol administration. The remaining 30 minutes will be used to welcome the patient, explain the content of the session, and review the session's outcome, particularly to assess tolerance (Simulator Sickness Questionnaire (SSQ) completed at the start of each week after the first VirtySens® session). The sessions will take place in the morning to prevent the session from being disrupted by fatigue related to the rehabilitation day."
214487683|NCT07037979|OTHER|Not applicable- observational study|non-applicable
214679190|NCT01320579|DRUG|Cis-UCA 2.5% emulsion cream|2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
214970647|NCT05940415|BEHAVIORAL|active surveillance|active surveillance without prostate biopsy
214970648|NCT00538941|DIETARY_SUPPLEMENT|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
214970649|NCT00538941|DIETARY_SUPPLEMENT|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
215083206|NCT02488213|OTHER|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
214970650|NCT04743089|DEVICE|ERCP using SpyGlass™ DS Direct Visualization System|Lithotripsy and stone removal will be performed using ERCP and Spyglass system to patients with IHD/EHD stone, which is difficult to remove through conventional ERCP. The SpyGlass™ DS Direct Visualization System will be applied directly into the bile duct via the working channel of the duodenoscope. Under the high-resolution digital imaging, lithotripsy such as EHL could be done.
214970651|NCT04743089|OTHER|PTCS|A historical cohort of patients who underwent PTCS to remove bile duct stones which is difficult to treat by ERCP.
214970652|NCT00914225|OTHER|Bednets and Water Purification|Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
215083207|NCT02488213|OTHER|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
215083208|NCT04152330|OTHER|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
215083209|NCT00919867|DRUG|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
215083210|NCT00919867|DRUG|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
215083211|NCT00919867|DRUG|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
215083212|NCT00004174|BIOLOGICAL|filgrastim|
215083213|NCT00004174|DRUG|cyclophosphamide|
215083214|NCT00004174|DRUG|paclitaxel|
215083215|NCT00004174|DRUG|thiotepa|
215083216|NCT00004174|PROCEDURE|peripheral blood stem cell transplantation|
215083217|NCT00004174|RADIATION|radiation therapy|
214359035|NCT03809481|DRUG|Argatroban|Synthetic direct thrombin inhibitor
214359036|NCT06141148|DIAGNOSTIC_TEST|sputum analysis|sputum analysis to diagnose tuberculosis
214359037|NCT06141148|DIAGNOSTIC_TEST|lymph node biobsy|to diagnose tuberculous lymphadenitis
214359038|NCT03222648|OTHER|Structured Responsive Exercise Training|Twice weekly, 8 week structured responsive exercise training programme. Protocol used the same as that used in previous EMPOWER Trial (Loughney et al. 2016)
214970653|NCT03718429|DRUG|Rivaroxaban 2.5 mg Tablet|PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.
214970654|NCT02249104|DRUG|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Topical AV therapy
214970655|NCT02249104|OTHER|Cetaphil Acne Regimen|Cleanse, Moisturize, and Protect
214359039|NCT03222648|OTHER|Usual Care|Continuation of usual care
214359040|NCT05717634|DIAGNOSTIC_TEST|Hysteroscopy|Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
214359041|NCT03215732|DIAGNOSTIC_TEST|HBV testing with dried blood spots (DBS) technique|Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper).
214359042|NCT04299672|PROCEDURE|Postural reconstruction|Interventions are described in group descriptions
214359043|NCT01632605|DRUG|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
214359044|NCT05755308|PROCEDURE|Autologous FMT|Autologous faecal microbiota transplantation by colonoscopy.
214359045|NCT05755308|PROCEDURE|Placebo FMT|Placebo FMT will consist of 250 mL water. Placebo infusions will be delivered by colonoscopy.
214359046|NCT01625221|DEVICE|Magnetic Anal Sphincter|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
214970656|NCT03279809|DRUG|Aspirin|Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
214970657|NCT03279809|DRUG|Placebo|Case with placebo medication for 6 months after stenting
214970658|NCT05254340|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent irritable bowel syndrome. Inulin is being used to study an individual's ability to ferment dietary fiber.
214970659|NCT03516565|OTHER|Saliva collection|
214970660|NCT03516565|OTHER|GCF collection|
214970661|NCT04632225|BIOLOGICAL|Engensis|Lyophilized biologic to be reconstituted containing Engensis
214970662|NCT04632225|OTHER|Placebo|Injectable liquid
214359047|NCT04180618|OTHER|Personal health wallet service for emergency situation|Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
214970663|NCT04305028|DRUG|Rivaroxaban|Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet
214970664|NCT04305028|DRUG|Aspirin|Aspirin 75-100 mg once daily, tablet
214970665|NCT00887705|BEHAVIORAL|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
214970666|NCT00325819|DRUG|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
214970667|NCT00325819|OTHER|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
214970668|NCT03625739|DRUG|anti-tuberculosis drug|The intervention drugs are prescribed by treating caregiver
214970669|NCT00090909|DRUG|cisplatin|
214970670|NCT00090909|DRUG|dexamethasone|
214970671|NCT00090909|DRUG|gemcitabine hydrochloride|
214359048|NCT06496633|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation|PIMSRA procedure represents a significant breakthrough in the treatment of HOCM patients, as it uses a unique transmyocardial approach to directly and precisely insert a radiofrequency electrode needle into the hypertrophied IVS for targeted ablation
214359049|NCT03541070|DEVICE|Kinesiology tape|Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
214359050|NCT05163366|DRUG|GROUP A|Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.
214359051|NCT05163366|DRUG|GROUP B|The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
214359052|NCT00001587|PROCEDURE|Isolated hepatic portal and arterial perfusion|
214359053|NCT00001587|DRUG|Melphalan|
214359054|NCT02275065|DRUG|Bictegravir|Bictegravir tablet(s) administered orally once daily
214359055|NCT02275065|DRUG|Placebo|Placebo to match bictegravir administered orally once daily
214359056|NCT01473667|PROCEDURE|Superficial Cervical Plexus Block (SCP) block|SCP block using 10-15ml of 1% Ropivacaine
214359057|NCT01473667|PROCEDURE|Local site infiltration|Local site infiltration using 2% lidocaine
214679191|NCT01320579|DRUG|Cis-UCA 5% emulsion cream|5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
214970672|NCT04264845|OTHER|Provider Focus|The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
214970673|NCT04264845|OTHER|Patient Interview|A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
214970674|NCT04264845|OTHER|PROs/Clinical Data Integration|A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
214970675|NCT02021214|DRUG|Methylphenidate|
214970676|NCT02021214|DRUG|Placebo|
214970677|NCT06236321|OTHER|Fast Field Cycling MRI scan|Three scans to be done over the period of cancer treatment
214970678|NCT06236321|OTHER|Provision of saliva and faecal samples|Three times over the period of cancer treatment
214970679|NCT00508911|DRUG|GW876008|GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
214970680|NCT00508911|DRUG|COC|COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
214970681|NCT06612567|DIAGNOSTIC_TEST|PET/CT|is an imaging test that can help reveal the metabolic or biochemical function of your tissues and organs. The PET scan uses a radioactive drug called a tracer to show both typical and atypical metabolic activity. A PET scan can often detect the atypical metabolism of the tracer in diseases before the disease shows up on other imaging tests, such as computerized tomography (CT) and magnetic resonance imaging (MRI).
214970682|NCT05130034|BEHAVIORAL|Home-based pulmonary rehabilitation|Home-based tablet-assisted pulmonary rehabilitation with monitoring technology and telephonic health coach calls using motivational interviewing techniques
214970683|NCT06612593|DRUG|Cilostazol|2 tablets of 50 mg cilostazol will be received for 4 weeks, then the does will be 2 tablets of 100 mg cilostazol twice daily for 20 weeks
214970684|NCT06612593|DRUG|Placebo|The patient will receive 2 tablets twice daily
214359058|NCT03213158|DRUG|Ixazomib Oral Capsule|Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.
214487684|NCT07039968|RADIATION|Spine Stereotactic Radiosurgery (SSRS)|A non-invasive procedure that uses highly focused, high-energy radiation beams to precisely target metastatic tumors in the spine. The procedure is delivered using advanced techniques like Intensity Modulated Radiotherapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT/RapidArc), which allow the radiation dose to conform tightly to the shape of the tumor. This approach maximizes the dose to the cancer while carefully sparing surrounding healthy tissues, especially the critical spinal cord. The entire course of treatment is delivered in a single session, guided by on-board imaging to ensure sub-millimeter accuracy.
214487685|NCT07030855|COMBINATION_PRODUCT|Elixirium thymi compositum (FoNo VIII.)|During the study, the dosage is for children and adolescents as follows: 6 ml three times a day for 6-9 years, 8 ml three times a day for 9-15 years, and 10 ml three times a day for 15-17 years.
214487686|NCT07030855|COMBINATION_PRODUCT|Elixirium thymi compositum (FoNo VIII.) placebo|During the study, the dosage is for children and adolescents as follows: 6 ml three times a day for 6-9 years, 8 ml three times a day for 9-15 years, and 10 ml three times a day for 15-17 years.
214970685|NCT06612593|DRUG|Standard treatment|It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.
214970686|NCT06611670|DEVICE|Cataract surgery with Active Sentry|Surgical instrument that detects changes in intraocular pressure and allows rapid feedback to stabilize pressure during cataract surgery.
214970687|NCT06611670|PROCEDURE|Traditional cataract surgery|Cataract surgery performed with high intraocular pressures
215083218|NCT00132795|BEHAVIORAL|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
215083219|NCT00132795|BEHAVIORAL|control group|standard care (no added treatment)
215083220|NCT04270162|DEVICE|Respiratory muscle training 1|"For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups."
215083221|NCT04270162|OTHER|Respiratory muscle training 2|"Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups."
215083222|NCT04270162|OTHER|Respiratory muscle training 3|The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
214487687|NCT06706544|DRUG|Ozone therapy|Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
214487688|NCT06706544|DRUG|Oxygen (placebo)|Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
214487689|NCT07038590|OTHER|exergame program with virtual reality|Participants who attend a patient association will add to their usual therapies or virtual exercise program to be developed 2 days a week for 3 months.
214487690|NCT07038590|OTHER|usual treatment patient association|Common therapies in patient associations: memory workshops, relaxation, and occupational therapy
214487691|NCT07038798|DEVICE|Brainsway H1-Coil Deep TMS System|Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H1-coil.
215083223|NCT00315770|PROCEDURE|weight loss diets for young adults|
215083224|NCT00004480|DRUG|botulinum toxin type A|
215083225|NCT04947878|OTHER|Prompt list|The patients in the intervention group will review a prompt list before their visit.
215083226|NCT00668018|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
215083227|NCT01355263|DRUG|iron and vitamin a|
215083228|NCT01053559|DRUG|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
214359059|NCT05717556|PROCEDURE|Internal Jugular Vein Catheterization|Inserting a cannula into the internal jugular vein
214359060|NCT00276640|DRUG|vincristine, carboplatin|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21"
214359061|NCT00276640|DRUG|vincristine, carboplatin, etoposide|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21~etoposide: 100 mg/m² i.v., week 1,4,7,10"
214359062|NCT00276640|RADIATION|radiation therapy|"intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks~spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks"
214359063|NCT00202202|PROCEDURE|consultation format|
214359064|NCT04508595|DIAGNOSTIC_TEST|RestEaze|Wearable band to detect leg movements of sleep
214359065|NCT03169387|BEHAVIORAL|Virtual Reality|For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
214359066|NCT03169387|BEHAVIORAL|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
214359067|NCT00914329|DRUG|Gelsemium Sempervirens|5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
214359068|NCT00914329|DRUG|Gelsemium Sempervirens|15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
214970688|NCT06611449|OTHER|The minimal flow anesthesia with sevoflurane group|"In the minimal flow group, anesthesia will be maintained with minimal fresh gas flow (0.3-0.5 L/min). The effect of minimal flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery."
214970689|NCT06611449|OTHER|The high flow anesthesia with sevoflurane group|"Maintenance of anesthesia in the high flow group will be provided with a high fresh gas flow (4 L/min). The effect of high flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery."
215083229|NCT04524559|OTHER|conventional physical therapy training|"The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity."
215083230|NCT04524559|OTHER|oral motor training.|"Children in the experimental group received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time.~The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol. The utmost aims of the protocol were to decrease hypersensitivity of oral structures, increase jaws movement, and reinforce muscle strength, improve tongue movement and enhance oral motor organization"
215083231|NCT02102126|PROCEDURE|Renal denervation|
215083232|NCT04695002|BEHAVIORAL|MIRA|Based on the initial assessment, the citizen and professional agree what outcomes the citizen should report in MIRA. This could be pain, mood, sleep quality, energy level, dependent on the priorities of the citizen. Similarly, different activities are reported, e.g. exercise, social activities, prolonged sitting or work-related tasks. The citizen and the professional agree how often the citizen reports the outcomes and tasks, and the citizen is notified by the MIRA-app when it's time for reporting. The data will be visualized in a graph for the professional in the back-end of the system, making it possible for the citizen and the professional to view the same, real-time reported data. This provides the base for discussing and adjusting the course of rehabilitation as symptoms change over time. At the same time, this increases the citizen's knowledge of how symptoms, mood, sleep and activities all interact, thereby giving them the tools better cope with their health condition.
215083233|NCT04695002|BEHAVIORAL|Control|Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
214359069|NCT00914329|DRUG|Placebo|placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
214359070|NCT02763800|DRUG|BIA 3-202|BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
214487692|NCT07038798|DEVICE|Brainsway H4-Coil Deep TMS System|Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H4-coil.
214487693|NCT07038798|DEVICE|Brainsway H7-Coil Deep TMS System|Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H7-coil.
214970690|NCT07000682|BIOLOGICAL|UTAA91 injection|CAR-modified gamma delta T cells
214359071|NCT02763800|DRUG|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
214359072|NCT04791501|DEVICE|Mechanical ventilation|Ventilatory support
214487694|NCT03734809|DRUG|Pembrolizumab|200mg every 3 weeks infusion
214487695|NCT06888596|BEHAVIORAL|Exercise|Exercise using cycle ergometer
214487696|NCT06887205|PROCEDURE|Lymphovenous bypass (LVB)|At the time of axillary lymph node dissection (ALND) or inguinal lymph node dissection (ILND) in the melanoma patient population.
214487697|NCT06887933|DRUG|Niraparib|Niraparib will be administered.
214487698|NCT06731530|DEVICE|Pentacam-AXL|Pentacam-AXL (Oculus, Wetzlar, Germany)
214487699|NCT06731530|DEVICE|HD Analyzer|HD Analyzer (Visiometrics, Terassa, Spain, Keeler)
214970691|NCT05212168|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
214970692|NCT05212168|OTHER|Placebo Tablets|Oral tablets similar in appearance and number to active vaccine tablets
214970693|NCT05212168|BIOLOGICAL|Norovirus GI.1 Norwalk Virus Inoculum|Norwalk Virus Inoculum Lot 01-09NV
214970694|NCT06865872|OTHER|Direct Sexual Communication|Participants assigned to receive direct communication about their sexual preferences from their partner.
214970695|NCT06865872|OTHER|Indirect Sexual Communication|Participants assigned to receive indirect communication about their sexual preferences from their partner.
214970696|NCT06865872|DRUG|Alcohol (Ethanol)|Participants assigned to moderate alcohol dose condition (target BrAC .10%) with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) approved alcohol administration procedures.
214970697|NCT06865872|OTHER|No-Alcohol Control|Participants assigned to a no-alcohol control beverage.
214970698|NCT05442697|DEVICE|PEMF treatment|Patient will receive a PEMF treatment. The involved leg will be exposed to PEMF for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of PEMF exposure in total.
214970699|NCT05442697|DEVICE|Placebo treatment|Patient will receive a placebo treatment. The involved leg will be exposed to placebo treatment for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of placebo exposure in total.
214970700|NCT06589648|OTHER|mandala painting|Mandala coloring creates a relaxing effect on individuals because it starts with a pattern that develops like a flower around a point; it allows the individual to stay in the moment, to get away from stress, anxiety and worries, and it relaxes the mind.
214970701|NCT03811821|BEHAVIORAL|Biofeedback|The participant will learn how to improve strength and rectal sensation during five (5) - six (6) visits each lasting 60 minutes.
214970702|NCT03811821|DEVICE|Injection|The participant will have a bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
214970703|NCT06453733|DEVICE|Crainio|Crainio device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the sensor detect the backscattered light, which is modulated by pulsation of the cerebral arteries. A control unit processes the backscattered light (called the photoplethysmogram, PPG) and transmits it to a computer device to train ML models that will estimate ICP offline.
214970704|NCT02794298|DEVICE|Transcranial direct current stimulation (tDCS)|
214970705|NCT02794298|DEVICE|sham-tDCS|
214970706|NCT00087100|DRUG|pemetrexed disodium|
214970707|NCT05748366|PROCEDURE|Serratus Anterior Plane Block (SAPB)|The ultrasound-guided serratus anterior plane block (SAPB) will be performed in a manner previously described in published medical literature. Patients will be consented and monitored. Bupivacaine 0.5% (5 mg/ml) diluted to 30-40 ml will be used in a dose not to exceed 2 mg/kg. The serratus anterior fascial plane will be identified in the 4th/5th intercostal space. The needle will be advanced under real-time ultrasound guidance targeting the superficial serratus anterior fascial plane. The procedure assistant will inject small volumes to hydrodissect the muscle bellies evenly under direct visualization, indicating local anesthetic spread within the fascial plane. Anesthetic will then be injected in 5 ml increments and the needle will be removed. Patient will be continuously monitored on telemetry and pulse-oximetry. Reassessment of the patient will continue for 30 minutes to monitor for signs of local anesthetic systemic toxicity.
214970708|NCT05748366|DRUG|Standard Analgesic Medications|Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
214970709|NCT06083376|OTHER|Spinal Stabilization Exercise|Spinal stability exercises are commonly used isometric and isotonic exercises. A spinal stabilization exercise training program will be applied to the exercise group participants using the telerehabilitation method (simultaneous connection) 3 days a week for 8 weeks and a total of 24 sessions.
214970710|NCT06083376|OTHER|physical activity counseling|Control group participants will first be given initial evaluations and verbal physical activity recommendations will be given. Patients will be contacted by phone at the 2nd, 4th and 6th weeks and reminded about the importance of physical activity.
214970711|NCT06082726|DIETARY_SUPPLEMENT|SCFA|Participants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours.
214970712|NCT03574974|DEVICE|Experimental Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators believe that this feedback may help participants learn to control their PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
214970713|NCT03574974|DEVICE|Control Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators do not believe this feedback can help participants' PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
214970714|NCT07035340|OTHER|inspiratory muscle training|inspiratory muscle traning MIP%40-60
214970715|NCT07035340|OTHER|standart care|standart care
214970716|NCT06729528|DIAGNOSTIC_TEST|The PePCI and ManTIS scores|The PePCI and ManTIS scores have been developed to predict the indication for whole-body CT in pediatric cases presenting to the emergency department with trauma. These scores help reduce unnecessary radiation exposure in pediatric trauma cases.
214970717|NCT00564941|DRUG|deferasirox|
214970718|NCT05275933|OTHER|TCM intervention|Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
214487700|NCT06731530|DEVICE|Corvis ST|Corvis ST (Oculus, Germany)
214487701|NCT06731530|DEVICE|OCT-A Angiovue|OCT-A Angiovue (Optovue, Inc., Fremont, California, USA)
214970719|NCT05275933|OTHER|Placebo intervention|Placebo Capsules (PC) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
214970720|NCT06524154|BEHAVIORAL|positive reinforcement|normal treatment with with praising the child with encouraging words and pleasing smiles.
214970721|NCT06524154|BEHAVIORAL|rewarding|normal treatment with giving simple gifts like stickers at the end of the procedure.
214970722|NCT06524154|BEHAVIORAL|contingent escape|normal treatment with giving some rest of the procedure while the child on the chair.
214970723|NCT02194894|DRUG|Acetaminophen|acetaminophen will be given for patient for both arms for 14 days
214970724|NCT03206827|OTHER|70% animal, 30% plant proteins in diet|Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).
214970725|NCT03206827|OTHER|50% animal, 50% plant proteins in diet|Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
214970726|NCT03206827|OTHER|30% animal, 70% plant proteins in diet|Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
214970727|NCT01502488|PROCEDURE|Fat Harvesting and Stem Cell Injection|Cells will be harvested through a local liposuction and injected via IV delivery
214970728|NCT03013192|OTHER|Text message reminder|Patients will receive automated text message reminders regarding their physical therapy
214970729|NCT04888494|DEVICE|Transcranial Magnetic Stimulation|For the brain stimulation the investigators will use Repetitive Transcranial Magnetic stimulation (rTMS). Different stimulation conditions (hippocampal or sham) will be delivered in each round of stimulation (5 days). Repetitive TMS will be applied at 100% resting motor threshold intensity, 20 Hz pulse trains separated by 28-s inter-train intervals (\~20 minutes for the entire daily stimulation session). Stimulation parameters will be identical in both groups
214359073|NCT01777854|DRUG|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients \>20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
214970730|NCT04888494|DEVICE|Sham rTMS|Sham rTMS
214970731|NCT03921476|OTHER|Online survey|Online survey completion through Northwestern's REDCap
214970732|NCT03945071|DEVICE|Punctal plug|Punctal plug will be given to subjects after intravitreal injection in half of the study subjects
214970733|NCT06404255|BEHAVIORAL|Stress management training|Stress management training
214970734|NCT01039779|BEHAVIORAL|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
214970735|NCT04385979|OTHER|Gel|containing herbal Curcumin or NanoCurcumin
214970736|NCT01475344|DRUG|Human Fibrinogen Concentrate|"intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
214970737|NCT01475344|DRUG|Placebo|"intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
214970738|NCT03563898|OTHER|Sweating with Portable Sauna Bath|Patients will be subjected daily for 30 minutes to the Portable Sauna Care steam bath (45 degree C temperature). The patient will decide if the time and / or temperature of the Sauna Bath is reduced to Tolerance. Before being subjected to the sauna bath, blood pressure will be taken 10 minutes prior. Weigh the patient with a Scale. You will be informed of the symptoms that may occur during the bath, and if present, you will let the health staff know that you will be present at all times during the bathing period, which will have a SURVEILLANCE TABLE which It will be filled during the intervention where they are monitored and comply with the stipulated norms as well as notes for adverse effects. After the completion of the bath, there will be a space of 15 minutes for the patient to dry the skin and the bathing suit with a towel. After 15 minutes, the patient will be weighed and the blood pressure will be taken again.
214970739|NCT00304460|BIOLOGICAL|aldesleukin|
214970740|NCT02506062|DEVICE|Manual blood pressure cuff inflation over brachial artery|A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
215083234|NCT06464900|BEHAVIORAL|Routine Care|Provide patients with regular medication guidance, dietary guidance, exercise guidance and knowledge about diabetes mellitus and hypoglycaemia; test and record blood glucose regularly every day; answer patients' clinical questions and provide psychological support in a timely manner.
214487702|NCT06731530|DEVICE|IOLMaster V.5.4|IOLMaster V.5.4 (Carl Zeiss., Meditec)
214487703|NCT06731530|DEVICE|Topcon SP-1P|Topcon SP-1P (Topcon Medical Inc., Tokyo, Japan)
214359074|NCT01560039|DEVICE|TMS|Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
214359075|NCT01560039|OTHER|Neurofeedback|EEG neurofeedback based on the primary motor cortex
214359076|NCT01560039|OTHER|Sham neurofeedback|Sham EEG neurofeedback
214487704|NCT06731530|OTHER|BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus examination|BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus Examination
214970741|NCT00273598|PROCEDURE|Moss Miami Spine Instrumentation System|
214970742|NCT00273598|PROCEDURE|Universal Spine Instrumentation System|
214970743|NCT00433433|DRUG|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
214970744|NCT00433433|DRUG|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes\>1.0x109/l
214970745|NCT00433433|RADIATION|IN-RT 30 Gy (+ boost 6 Gy residual)|
214970746|NCT00433433|PROCEDURE|FDG-PET scan|
214970747|NCT04367662|PROCEDURE|blood sampling|blood sampling in hospitalized patient for COVID-19 infection
214970748|NCT01438138|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214970749|NCT00616746|DRUG|Nicotine|1.0 microg/kg/min IV x 10 minutes
214970750|NCT00616746|DRUG|Ethanol|IV
214970751|NCT00933504|DRUG|LACTIC ACID(ND)|Treatment duration: 6 weeks.
214970752|NCT06765954|DRUG|N-803 (IL-15 Superagonist)|Administered subcutaneously (SC) both before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.
214970753|NCT06765954|DRUG|ETBX-071 (PSA-based Oncolytic Virus)|Administered subcutaneously (SC) before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.
214970754|NCT06765954|DRUG|M-CENK (Activated NK Cells)|Administered intravenously (IV) before and after radiation therapy, also with variations in the timing and dosing across different cohorts.
214970755|NCT06765954|RADIATION|External Beam Radiation Therapy (EBRT)|This is a standard treatment administered to all participants. The specific dose and schedule (40 Gy in 5 fractions over 2 weeks or up to 9 weeks) are determined by the investigator based on clinical judgment.
214970756|NCT06765954|RADIATION|Androgen Deprivation Therapy (ADT)|May be used in conjunction with the other therapies. The specific type and duration of ADT are at the investigator's discretion, and it may be initiated up to 6 months after the completion of radiotherapy. This treatment is not part of the experimental treatment regimen.
214970757|NCT06765954|RADIATION|Post-radiation immunotherapy|The post-radiation immunotherapy phase in the ResQ110B-PROS study involves the continued administration of N-803, ETBX-071, and M-CENK, but with a specific schedule and after the completion of radiation therapy.
214970758|NCT07073300|DEVICE|Endoscopy|Upper Endoscopy and colonoscopy will be used
214970759|NCT06732180|DRUG|GT-02287|Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent
214970760|NCT07073508|OTHER|Renal Artery Duplex|Renal artery duplex will be performed to all patients in terms of renal resistivity index (RRI).
214970761|NCT07072546|PROCEDURE|free gingival graft + gelatin sponge|Free gingival graft surgery and application of gelatin sponge to the palatal wound
214970762|NCT07072546|PROCEDURE|free gingival graft + chitosan|free gingival graft surgery and application of chitosan to the palatal wound
214970763|NCT07072546|PROCEDURE|free gingival graft + chitosan and i-PRF|free gingival graft surgery and application of chitosan and i-PRF to the palatal wound
214970764|NCT07068230|DRUG|Ondansetron 8mg|Ondansetron 8 mg IV Administered 5 minutes before spinal anesthesia
214359077|NCT02652481|DEVICE|ImageReady MR Conditional Defibrillation System|"ImageReady MR Conditional Defibrillation System Components:~Device Name Device Model Number Pulse Generators Phase I and II Phase II Only \* CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD\* AUTOGEN EL ICD\* AUTOGEN X4 CRT-D\* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI\* Suture Sleeve for INGEVITY MRI\* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)\* Suture Sleeve for RELIANCE 4-FRONT leads\*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads~\* May only be used internationally outside the US"
214970765|NCT07068230|DRUG|Dexamethasone|Dexamethasone 8 mg IV Administered 5 minutes before spinal anesthesia
214970766|NCT07068230|DRUG|Saline|5ml normal saline Administered 5 minutes before spinal anesthesia
214970767|NCT07073027|OTHER|2D video on smartphone|2D video with audio viewed on smartphone
214970768|NCT07073027|OTHER|360 video on smartphone|360 video with audio viewed on smartphone (not in virtual reality)
214970769|NCT07073027|OTHER|360 video on smartphone inserted into VR cardboard headset|360 video with audio in virtual reality
214970770|NCT07072507|BEHAVIORAL|Chilbirth Education|Participants divided into training groups will receive training on pregnancy, birth, breastfeeding, preparation for parenthood, and baby care in groups of 6-8 people, 2 hours a week for five weeks.
214970771|NCT07072559|OTHER|dental simulation game|At the first visit children will play on any procedure in dental simulation game, after that the child will be shown two animals, after which they virtually do a root canal procedure. Tasks include performing a dental X-ray, anesthetizing the tooth using a syringe, drilling decayed cavity and start pulp treatment, rinsing, pulp treatment and filling the tooth, applying light cure and finally polishing the teeth. The second visit for pulpotomy procedure will be scheduled two days after first visit. Children will be managed using the TSD (Tell-Show-Do) technique.
214970772|NCT07072559|OTHER|tell show do|"For the control group (group 1) TSD (Tell-Show-Do) technique group, children will be managed with a verbal explanation and a friendly, non-threatening demonstration of the upcoming dental treatment. The do phase involved carrying out the dental procedure as per the prior explanation and demonstration"
214359078|NCT01803308|DRUG|SB9200|Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.
214359079|NCT01803308|DRUG|SB9200|Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
214359080|NCT01803308|DRUG|Placebo|Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
214359081|NCT05140928|OTHER|Dadiah Pudding|Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy
214970773|NCT07072078|BEHAVIORAL|Video-based Communication|Participants received structured video-based communication sessions with their family members using the WhatsApp platform. The intervention was delivered once daily for three consecutive days, with each session lasting between 5 and 20 minutes. Communication was guided to include emotional support, positive conversations, and future-oriented discussion. The sessions were facilitated by nurses who ensured clinical stability, technical setup, and emotional readiness of the patient. This intervention aimed to reduce emotional and social loneliness among ICU patients and was integrated into standard intensive care routines without disrupting medical care.
214359082|NCT05140928|OTHER|Pudding without Dadiah|Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy
214359083|NCT00811876|OTHER|Data Collection on Depo-Eligard exposure|Retrospective, Non-interventional
214359084|NCT02379182|BEHAVIORAL|standard clinical care|adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
214487705|NCT04878445|PROCEDURE|Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.|Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.
214970774|NCT05732831|DRUG|TNG462|TNG462, a selective PRMT5 inhibitor, will be administered orally
214970775|NCT05732831|DRUG|Pembrolizumab|An anti PD-1 antibody, will be administered intravenously
214970776|NCT03466632|DRUG|Propofol|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.
214970777|NCT03466632|DRUG|Dexmedetomidine|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
214970778|NCT02430558|BIOLOGICAL|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
214970779|NCT01466361|DRUG|Nicotine lower dose|lower dose nicotine lozenge
214970780|NCT01466361|DRUG|Nicotine higher dose|higher dose nicotine lozenge
214970781|NCT01466361|DRUG|Placebo|placebo
214970782|NCT05696353|COMBINATION_PRODUCT|In-vehicle Device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smart phone app (downloaded on the teen's smart phone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data via the smart phone app and study website; and 3) A customized biweekly driving summary report via study website.
214970783|NCT05696353|BEHAVIORAL|Expert-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a traffic safety communication specialist to parents in the Feedback and Expert-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
214970784|NCT05696353|BEHAVIORAL|Peer-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a peer trainer who is a parent of teen with traffic citation and has participated in the Feedback and Peer-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
214970785|NCT02302274|DRUG|flecainide iv|infusion over 10 min
214970786|NCT01271647|DRUG|Yin and Yang tonic granules|Yin and Yang tonic granules,18g per time,two times per day,six months
214970787|NCT01271647|DRUG|placebo|granules,18g per time,two times per day,six months
214970788|NCT02728232|PROCEDURE|internal iliac artery ligation|
214970789|NCT02728232|PROCEDURE|Cesarean Hysterectomy|
214970790|NCT01805661|PROCEDURE|Canal Block and Capsular Injection|Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.
214970791|NCT01805661|PROCEDURE|Femoral with Tibial Nerve Block|Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
214970792|NCT00059553|BEHAVIORAL|Locomotor treadmill training with body weight support|
214487706|NCT06731868|DRUG|LPM3770164 sustained release tablet 5 mg|LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks
214487707|NCT06731868|DRUG|LPM3770164 sustained release tablet 10 mg|LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.
214487708|NCT06731868|DRUG|LPM3770164 sustained release tablet 20 mg|LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.
214487709|NCT06731868|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.
214970793|NCT03167203|BIOLOGICAL|Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells|Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
214970794|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
214970795|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
214970796|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
214970797|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
214359085|NCT02379182|DEVICE|transcutaneous electrical stimulation at sensory level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
214359086|NCT02379182|DEVICE|transcutaneous electrical stimulation at motor level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
214359087|NCT02605629|OTHER|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
214359088|NCT02605629|OTHER|Placebo|The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
214359089|NCT04684121|DRUG|Granexin® gel (200 μM)|Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
214359090|NCT04684121|DRUG|Vehicle gel|Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
214359091|NCT00710138|DIETARY_SUPPLEMENT|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
214359092|NCT03260166|DRUG|nicotinamide|Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
214970798|NCT02564367|DRUG|S-1|"18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m\^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m\^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m\^2 BSA, D1-14, q 3 wks"
214970799|NCT00004558|BEHAVIORAL|dietary n-3 polyunsaturated fatty acids|
214970800|NCT03556995|OTHER|bariatric surgery patients|
214970801|NCT04588974|DEVICE|magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images|The patient will undergo both diagnostic tests within two days, a magnetic-assisted capsule endoscope system first and then conventional EGD will be carried on at least 4 hours afterward.
214970802|NCT01095172|DRUG|Rituximab|375mg/m\^2, single dose given 2-4 weeks prior to transplantation
214359093|NCT05029765|DIETARY_SUPPLEMENT|Mediterranean diet|"Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates"
214359094|NCT05029765|DIETARY_SUPPLEMENT|Healthy diet (WHO recommendations)|Recommendations according to WHO
214359095|NCT05029765|DIETARY_SUPPLEMENT|Placebo|Placebo
214359096|NCT05029765|DIETARY_SUPPLEMENT|Biopolis-MIX42|Biopolis-MIX42: a capsule containing 10\^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
214359097|NCT04126408|DEVICE|gammaCore|The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.
214970803|NCT01095172|DRUG|Tacrolimus|dose calculated to give levels of 3-7ng/ml
214970804|NCT01095172|DRUG|Mycophenylate mofetil|Mycophenylate mofetil 2g/day in divided doses
214970805|NCT01095172|DRUG|Hydrocortisone|100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
214970806|NCT01095172|DRUG|Prednisolone|Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
214970807|NCT01095172|DRUG|Prednisolone|Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
214970808|NCT01738945|DRUG|Amlodipine|10 mg/day for 12 weeks
214970809|NCT06469957|OTHER|Questionnaires and data collection sheet|Questionnaires
214359098|NCT01922492|PROCEDURE|Autologous islet transplantation|"Islet was isolated from the normal part of resected pancreas with modified Ricordi method.~After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization."
214970810|NCT00611806|DIETARY_SUPPLEMENT|Folic Acid|Folic acid 2mg po daily
214970811|NCT00611806|DIETARY_SUPPLEMENT|B12|B12 400 micrograms po daily
214970812|NCT00611806|OTHER|Placebo|1 capsule po daily
214970813|NCT05108766|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
214970814|NCT05108766|DRUG|Placebo|Matching placebo to tildrakizumab administered SC
214970815|NCT01023607|DRUG|Atorvastatin|Atorvastatin 20mg/day
214970816|NCT01023607|DRUG|Atorvastatin|Atorvastatin, 60mg/day
214970817|NCT01023607|DRUG|Rosuvastatin|Rosuvastatin,10mg/day
215083235|NCT06464900|BEHAVIORAL|Based on BCW Theory of Health Education|BCW theory was applied to analyse behaviour and develop interventions in terms of capability, motivation and opportunity. Capability: Intensive daily management of diabetes through intervention functions (education, training, persuasion, modelling) to change attitudes and habits, understand the negative consequences of fear of hypoglycaemia, improve hypoglycaemia awareness and self-regulation skills. Opportunity: Through the intervention function (education, training, realization) to improve the awareness of hypoglycemia awareness, timely detection of hypoglycemia. In the event of a hypoglycaemic event patients know how to deal with it. Motivation: Through intervention functions (environmental reconstruction, realisation) that take full account of external factors and their own opportunities. Glucose management through microsoft platforms, on-site teaching and coaching by specialist nurses to create opportunities for patients who can change excessive/avoidant behaviours.
215083236|NCT01413620|DRUG|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
215083237|NCT02386891|OTHER|Thermal Environment|
215083238|NCT00454753|DRUG|Dasatinib|
215083239|NCT02211118|DRUG|Intranasal dexemdetomidine (IN-DEX)|
215083240|NCT04061954|BEHAVIORAL|Comprehensive family intervention including individual sessions of FORNET|"Families in the intervention group received:~1. Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~2. Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~3. Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~4. Parents receive training regarding agriculture and micro credit projects, and financial assistance~5. One child per family receives a social skill training group preparing them for returning to school~6. Access to schools and school material~7. If needed medical assistance is provided~8. If needed legal assistance is provided"
215083241|NCT05256784|COMBINATION_PRODUCT|Natural probiotics|Two of the group members use daily Allium Sativum - garlic, one use Natural honey, and 1 Yogurt. It is verifying the immunity of the organism after 40 days of using natural probitotics.
215083242|NCT02069730|DRUG|Selinexor|"If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE)."
215083243|NCT02069730|DRUG|EGFR or HER2 Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor"
215083244|NCT02069730|DRUG|FGFR Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor"
215083245|NCT02069730|DRUG|C-KIT Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor"
215083246|NCT02069730|DRUG|Anti-androgen|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens"
214970818|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
214970819|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
214970820|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
214359099|NCT01922492|DRUG|Oral anti-diabetic drugs|"* Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~* Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose."
214970821|NCT00664352|DRUG|Mannose-6-Phophate (Juvidex)|"* 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
215083247|NCT02069730|DRUG|NOTCH Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor"
215083248|NCT02069730|DRUG|MEK or PI3K Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor"
215083249|NCT03068416|BIOLOGICAL|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
214970822|NCT00664352|DRUG|Placebo|"* 100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site."
214970823|NCT02317991|DRUG|nab-paclitaxel|nab-paclitaxel 125 mg/m\^2 IV
214970824|NCT02317991|BIOLOGICAL|ramucirumab|Ramucirumab 8 mg/kg IV
214970825|NCT01814410|DRUG|Intravenous ethanol placebo plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
214970826|NCT01814410|DRUG|intravenous ethanol 40mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
214970827|NCT01814410|DRUG|intravenous ethanol 100mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
214359100|NCT05012800|BIOLOGICAL|COVID-19 Vaccine|Coronavirus vaccine was inoculated on day 0 and day 21, respectively.
214970828|NCT04884100|OTHER|Validating and improving PPG-based algorithms|Our project aims at validating and improving PPG-based algorithms that were previously developed during the time course of a preceding study mini-Holter, accepted by the CER-VD in 2015. The developed features might help improve our understanding of the physio-pathological expression of cardiac arrhythmias. Indeed, current evidence demonstrates that PPG signals contain rich information on diverse cardiovascular mechanisms and properties
214970829|NCT02676557|DEVICE|Exposed to the high pressure during the surgery|
214970830|NCT01921517|DEVICE|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
214970831|NCT01921517|DEVICE|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
214970832|NCT00305669|BIOLOGICAL|sargramostim|
214970833|NCT00305669|OTHER|immunohistochemistry staining method|
214970834|NCT00305669|OTHER|immunological diagnostic method|
214970835|NCT00305669|OTHER|laboratory biomarker analysis|
214970836|NCT00305669|PROCEDURE|conventional surgery|
214970837|NCT00305669|PROCEDURE|neoadjuvant therapy|
214359101|NCT01931280|BEHAVIORAL|Lifestyle Counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
214359102|NCT02982005|DRUG|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 62.
214359103|NCT02982005|DRUG|Placebo|Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
214970838|NCT02402946|BEHAVIORAL|Biofeedback|
214970839|NCT02402946|DRUG|Placebo|
214970840|NCT04378712|DEVICE|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
215083250|NCT03097575|DRUG|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
214359104|NCT04667312|DRUG|Durvalumab|Durvalumab
214970841|NCT04378712|OTHER|Standard-of-care|Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission
214970842|NCT00616551|DRUG|C2L-OCT-01 PR, 30 mg|Administered by deep IM injection (gluteus) on days 1 and 42
215083251|NCT03097575|DEVICE|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
214970843|NCT00616551|DRUG|Octreotide acetate prolonged release, 30 mg|Administered by deep IM (gluteus) on Days 1, 28 and 56
214970844|NCT02751112|BIOLOGICAL|Predictor' kit|Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
214970845|NCT03643718|PROCEDURE|Emergency General Surgery|Emergency General Surgery and Trauma operative/non operative management
214970846|NCT00775762|DRUG|aspirin|Aspirin (75-100 mg)die for three months
214970847|NCT00775762|DRUG|clopidogrel|Clopidogrel (75mg) die for three months
214970848|NCT00775762|DRUG|clopidogrel plus aspirin|clopidogrel 75 mg die plus aspirin 75-100 mg for three months
214970849|NCT00334789|DRUG|Belinostat|Given IV
214970850|NCT00334789|DRUG|Isotretinoin|Given orally
214970851|NCT00334789|OTHER|Pharmacological Study|Correlative studies
214970852|NCT03275207|DRUG|saline|an equal volume of saline
214970853|NCT03275207|DRUG|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
214970854|NCT03361462|BEHAVIORAL|Joyful Adventure Day|"Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session."
214970855|NCT04727957|OTHER|Diagnostic and prognostic models for VA-LRTIs|Diagnostic and prognostic models for VA-LRTIs
214970856|NCT06109389|DRUG|Lidocaine IV|LIDOCAINE INFUSION STARTED 3 MG PER KG FOR 2 SUCCESSIVE WEEKS ,THEN 4 MG PER KG FOR ANOTHER 2 WEEKS .ONCE WEEKLY,other group saline infusion once weekly for 4 successive weeks
214970857|NCT03903263|DIAGNOSTIC_TEST|survey on sleep disorders|self-administered patient questionnaire regarding the different aspects of sleep disorders in patients with dermatologic diseases
214970858|NCT02861508|OTHER|Point-of-care ultrasound|
214970859|NCT02861508|OTHER|Usual care|
214970860|NCT02630862|DRUG|Aspirin|Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk
214970861|NCT02630862|DRUG|aspirin plus dipyridamole|the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
214970862|NCT04211350|DEVICE|NightBalance Sleep Position Trainer (SPT)|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
214970863|NCT04211350|DEVICE|Automatic Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
214970864|NCT02178904|PROCEDURE|CT and stress test|Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
214970865|NCT05988762|OTHER|Supramaximal Walkout|Walkout set performed at 110% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
214970866|NCT05988762|OTHER|Submaximal Walkout|Walkout set performed at 30% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
214970867|NCT01437618|DRUG|FOLFOXIRI plus bevacizumab|"* BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by~* IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by~* 5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks"
214970868|NCT04810988|BEHAVIORAL|Unified Protocol|The Unified Protocol is an empirically supported, transdiagnostic treatment for emotion disorders based on principles of cognitive behavioral therapy. Treatment focuses on increasing awareness of maladaptive thoughts and behaviors and decreasing avoidance of emotions and physiological sensations. Module 1 is focused on increasing motivation, readiness and self-efficacy for change. Module 2 focuses on increasing understanding and awareness of emotions. Module 3 is focused on further expanding awareness of emotions. Module 4 focuses on the role of thoughts in emotional disorders. Module 5 is focused on the role of behaviors in emotional disorders. Module 6 focuses on the role of physical sensations in emotional disorders. Module 7 focuses on exposure to interoceptive and situational triggers for emotions. Module 8 is focused on maintenance of treatment progress and relapse prevention.
214970869|NCT04810988|BEHAVIORAL|Therapist Support|4 video calls with study therapists
214970870|NCT04066933|COMBINATION_PRODUCT|A2M enriched plasma|Plasma enriched for alpha2macroglobulin (A2M-PPP) was produced by a centrifugation and filtration process developed by Cytonics Corporation. Initially, 7 milliliters of Anticoagulant Citrate Dextrose Solution A, ubiquitous surface protein (USP) was drawn into a 60 cc syringe and then an additional 38 cc of autologous blood was drawn up through an antecubital vein. Two syringes were prepared in this manner and then centrifuged at 4000 rpm (1280G) for 4 minutes. The supernatant plasma fraction was then transferred to a roller pump system that circulates the fluid through a proprietary filter having a high molecular weight cutoff designed to trap larger molecules including alpha 2 macroglobulin (720 kDa).
214970871|NCT01325350|DRUG|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
214970872|NCT01325350|DRUG|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
214970873|NCT01325350|DRUG|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
214970874|NCT01325350|DRUG|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
214970875|NCT01325350|DRUG|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
214970876|NCT00505050|OTHER|Disease Program Management|"This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.~After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms."
214970877|NCT00006877|DRUG|temozolomide|
214970878|NCT03852589|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. PLMA will inserted by anesthesiologist with C-MAC videolaryngoscope.
214970879|NCT03852589|DEVICE|Blind|PLMA will inserted by anesthesiologist with digital finger.
214970880|NCT02614989|PROCEDURE|MRI guided focused ultrasound thalamotomy|MRI guided focused ultrasound thalamotomy
214970881|NCT05355467|DRUG|Tenofovir disoproxil fumarate|Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.
214970882|NCT05355467|OTHER|Historical Data|Historical Data
214970883|NCT00105612|DEVICE|Memory and Organizational Aid|
214970884|NCT00105612|BEHAVIORAL|Standard Informed Consent Process|The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home
214970885|NCT00811694|OTHER|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
214970886|NCT01980433|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Inhibitory 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
214970887|NCT01980433|OTHER|pre and post-rTMS electroencephalogram|to verify the absence of infraclinical seizures
214970888|NCT01980433|OTHER|WCRS|Writer's cramp rating scale
214970889|NCT01980433|OTHER|handwriting scale DPRE|handwriting in development and being evaluated by the NRC Wilson
215083252|NCT01074333|DRUG|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
215083253|NCT01943838|DRUG|SAR245408|Pharmaceutical form: tablet Route of administration: oral
215083254|NCT04612660|BEHAVIORAL|Education on cervical cancer prevetnion|Motivational group education by trained bilingual community health educators (CHEs) on cervical cancer prevention
215083255|NCT04612660|BEHAVIORAL|Dynamic group interaction|Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
215083256|NCT04612660|BEHAVIORAL|Physician engagement|Engaging community bilingual physicians in cervical cancer screening and referral;
215083257|NCT04612660|BEHAVIORAL|Patient Navigation|Patient navigation assistance will be provided to participants who tested HPV positive for further diagnostic testing and treatment.
215083258|NCT04612660|BEHAVIORAL|General Health Education|general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
215083259|NCT01059253|OTHER|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
215083260|NCT00225589|DRUG|Rosuvastatin calcium|
214970890|NCT01980433|OTHER|visual analog scale of discomfort writing and parameters collected on touchpad|
214970891|NCT02601079|DEVICE|Endodrill Biopsy|Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
214970892|NCT02601079|DEVICE|Conventional Biopsy forceps|Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
214970893|NCT00734292|DRUG|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 2 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 3 Treatment Regimen C: placebo~SKP placebo; (two actuations)"
214970894|NCT00734292|OTHER|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 2 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 3 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)"
214970895|NCT00734292|OTHER|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 2 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 3 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)"
214970896|NCT05677711|DEVICE|ultimaster|Subjects who received Ultimaster stent will be included.
214970897|NCT01716806|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
214970898|NCT01716806|DRUG|bendamustine|70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
214970899|NCT01716806|DRUG|dacarbazine|375 mg/m\^2 every 3 weeks by IV infusion
214970900|NCT01716806|DRUG|nivolumab|3 mg/kg every 3 weeks by IV infusion
215083261|NCT03885570|PROCEDURE|Mitral valve replacement|Blood transfusion
215083262|NCT00182767|DRUG|ixabepilone|Given IV
215083263|NCT00182767|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
215083264|NCT01463930|BEHAVIORAL|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
215083265|NCT01463930|BEHAVIORAL|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
215083266|NCT03135444|BEHAVIORAL|PSA TOOL|Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
215083267|NCT03135444|BEHAVIORAL|Revised PSA TOOL|Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
214970901|NCT00956839|DRUG|Vitamin D3 (Cholecalciferol)|"Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months"
214970902|NCT02597777|OTHER|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
214970903|NCT02597777|OTHER|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
214970904|NCT00508950|PROCEDURE|Large volume blood draw|Large volume blood draw
214970905|NCT00831116|DEVICE|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
214970906|NCT03894839|OTHER|glutaraldehyde disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
214970907|NCT03894839|OTHER|Chlorhexidine gluconate disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
214970908|NCT03894839|OTHER|Sodium hypochlorite disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
214970909|NCT03894839|OTHER|glutaraldehyde disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
214970910|NCT03894839|OTHER|Chlorhexidine gluconate disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
215083268|NCT03135444|BEHAVIORAL|Informal Interview|Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
215083269|NCT02929901|DIETARY_SUPPLEMENT|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
215083270|NCT02929901|DIETARY_SUPPLEMENT|caffeine|caffeine plus placebo
214970911|NCT03894839|OTHER|Sodium hypochlorite disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
214970912|NCT02277483|DRUG|LAIS®|10 X 1,000 / twice a week
214970913|NCT03527277|OTHER|Naturally-sweetened orange juice|Commercially-available ready-to-serve refrigerated orange juice
214970914|NCT03527277|OTHER|Sugar-sweetened beverage|Sugar-sweetened water flavored with Kool-Aid (TM)
214970915|NCT06141785|OTHER|Nutritional intervention|An individually targeted nutritional intervention, and a simple home-based physical exercise program. The Nutritional intervention will be delivered by a clinical dietitian, from treatment initiation and throughout the treatment trajectory
214970916|NCT02527629|OTHER|Decellularized human heart valves|Decellularized human aortic heart valves
214970917|NCT00270452|DRUG|WT1 and PR1 Peptide Vaccine|
214970918|NCT04155463|OTHER|Organic Diet|Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.
214359105|NCT01551199|BEHAVIORAL|Multiple Channel Exposure Therapy- Veterans|Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
214359106|NCT01185444|PROCEDURE|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
214970919|NCT04155463|OTHER|Conventional Diet|Participants receive one week of conventionally grown (non-organic) food.
214970920|NCT05868317|DRUG|Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan)|"Induction chemotherapy with six cycles of modified 5 fluorouracil,oxaliplatin and irinotecan followed by short course radiotherapy (RT) (5x5 Gy), then two cycles of 5 fluorouracil and oxaliplatin based chemotherapy and surgery will be performed 6 to 8 weeks after completion of RT.~After surgery , continuation of chemotherapy with 4 cycles of 5 fluorouracil and oxaliplatin regardless of pathological response"
214970921|NCT05868317|RADIATION|Radiotherapy|Short Course Radiotherapy
214970922|NCT03070795|PROCEDURE|early feeding|start oral sips four hours after cesarean section
214970923|NCT03070795|PROCEDURE|delayed feeding|start oral feeding on post operation day 1 (\>12hours) after surgery
214970924|NCT04232930|OTHER|Music|Four types of music will be provided, including pop, classical, jazz or spa music which are prepared by the study team. They contain instrumental songs only without vocal.
215083271|NCT02929901|DIETARY_SUPPLEMENT|chlorogenic acid|chlorogenic acid plus placebo
215083272|NCT02929901|DIETARY_SUPPLEMENT|placebo|placebo plus placebo
215083273|NCT02516826|DRUG|Rosuvastatin|
215083274|NCT02516826|DRUG|Olmesartan|
215083275|NCT02516826|DRUG|Combination|Rosuvastatin/Olmesartan(Combination)
215083276|NCT02516826|DRUG|Placebo of Rosuvastatin|
215083277|NCT02516826|DRUG|Placebo of Olmesartan|
215083278|NCT02516826|DRUG|Placebo of Rosuvastatin/Olmesartan(Combination)|
214359107|NCT01185444|PROCEDURE|Hyalgan|The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
214359108|NCT01408355|DRUG|PF-06273588|Intravenous, 50 microgram, single dose
214359109|NCT01408355|DRUG|PF-06273588|Oral solution, 50 microgram, single dose
214359110|NCT02624362|BEHAVIORAL|Therapeutic Suggestion|suggestions about potential beneficial effects of the odor are given
214359111|NCT02624362|BEHAVIORAL|Asthmogenic Suggestion|suggestions about potential negative effects of the odor are given
214359112|NCT02624362|OTHER|Phenylethyl Alcohol odor|Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
214359113|NCT05204225|OTHER|Tablet Application|Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions. The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation. Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks. Also, ReHand app includes a prescription and monitoring web-based system for professionals. Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.
214970925|NCT01491022|DRUG|Ampyra first, then Placebo|10 mg po bid for 4 weeks followed by placebo 4 weeks.
214970926|NCT01491022|DRUG|placebo first, then Ampyra|placebo
214970927|NCT01065753|BEHAVIORAL|Lifestyle Counseling|Diet control with exercise
214970928|NCT00032448|PROCEDURE|Standardized tension-free herniorrhaphy with prosthesis|Compare the effect of two typs of operative treatment of inguinal hernia.
214970929|NCT06506201|DEVICE|Velys hip navigation|Computer assisted surgery
214970930|NCT06506201|PROCEDURE|Standard of care|surgery without navigation
214970931|NCT03790410|OTHER|Complex pulmonary rehabilitation|Complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.
214970932|NCT03790410|OTHER|Inspiratory muscle training|The training program contains strengthening exercises on the diaphragm muscle.
214970933|NCT03729050|BEHAVIORAL|Rehabilitation Coordinator in Specialist Psychiatry|Rehabilitation Coordinator service in Specialist Psychiatry
214970934|NCT05633433|DRUG|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
214970935|NCT05633433|DRUG|Placebo|Placebo
214970936|NCT02597517|DEVICE|Digital chromoendoscopy and magnification|After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
214970937|NCT01095497|BIOLOGICAL|CINRYZE|C1 esterase inhibitor (human)
214970938|NCT01712828|DRUG|Lenalidomide|25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
214970939|NCT01712828|DRUG|Quinidine|300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
214970940|NCT01712828|DRUG|Temsirolimus|25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
214970941|NCT01712828|DRUG|Diphenhydramine|Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
214970942|NCT02092753|OTHER|Standard diet (SD)|Nutrition intervention following the recommendations of the germans society for nutrition (DGE)
214970943|NCT02092753|OTHER|Experimental 1: Ketogenic diet (KD).|Nutritional intervention: recommendations to follow a ketogenic diet
214970944|NCT02092753|OTHER|"Experimental 2: Low glycämic and insulinemic diet (LOGI)"|"Nutritional intervention: patients were instructed to follow the LOGI diet regimen"
214970945|NCT01914393|DRUG|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
214970946|NCT06251271|DEVICE|Point-of-Care Ultrasound|Patients will undergo routine point-of-care ultrasound scans as part of the diagnostic process. The collected sonographic data and PFT results will assess point-of-care ultrasound's accuracy in diagnosing OLDs within the natural clinical setting.
214970947|NCT00228163|DRUG|teriflunomide (HMR1726)|tablet, oral administration once daily.
214970948|NCT00243009|DRUG|cyclosporine|
214970949|NCT00243009|DRUG|fludarabine phosphate|
214970950|NCT00243009|DRUG|mycophenolate mofetil|
214970951|NCT00243009|PROCEDURE|allogeneic bone marrow transplantation|
214970952|NCT00243009|PROCEDURE|peripheral blood stem cell transplantation|
214970953|NCT00243009|RADIATION|radiation therapy|
214970954|NCT04021966|PROCEDURE|Vaginal laser application|"One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa."
214970955|NCT00434031|DRUG|docetaxel|
214970956|NCT00434031|DRUG|cyclophosphamide|
214970957|NCT00434031|DRUG|trastuzumab|
214970958|NCT00434031|DRUG|liposomal doxorubicin|
214970959|NCT01063855|DRUG|Placebo|Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
214970960|NCT01063855|DRUG|Dapoxetine|30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
214970961|NCT01063855|DRUG|PDE5I (phosphodiesterase-5 inhibitor)|Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
215083279|NCT04677426|DRUG|Hyperpolarized Xe129|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
215083280|NCT06524557|DIAGNOSTIC_TEST|with chronic liver disease|patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease
215083281|NCT00810485|DRUG|ADX10059|oral administration
214970962|NCT05726435|DIETARY_SUPPLEMENT|Soluble dietary fiber with prebiotic properties|14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. The Nutriose group in this particular intervention contains 7 randomy selected players.
214970963|NCT05726435|DIETARY_SUPPLEMENT|Placebo|"14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. This second (Placebo) group also consists of the 7 players and receives Maltodextrin supplementation. Since the study type is double-blind, neither the participants (players) nor the person handing out the supplementation know the exact nature of fiber substance being handed during the entire duration of the trial. Independent statistician is handling the randomization of both interventions."
214970964|NCT02472730|DEVICE|Distal Attachment Cap|Colonoscopies are performed under the supervision of board certified attending gastroenterologists experienced in colonoscopy. Attending physicians will provide assistance at their discretion or at the request of the trainee. All close examinations for polyps will be carried out on withdrawal of the colonoscope.
214970965|NCT02484144|OTHER|modern information|information by video for coronarography
214970966|NCT02484144|OTHER|usual information|usual information for coronarography
214970967|NCT02976311|PROCEDURE|cesarean section(C/S) via the modified Misgav-Ladach technique|the first consecutive 44 patients underwent C/S via the modified Misgav-Ladach technique
214970968|NCT02976311|PROCEDURE|cesarean section via the Pfannenstiel-Kerr technique|the second consecutive 44 patients underwent C/S via the Pfannenstiel-Kerr technique
214970969|NCT02163395|DEVICE|FullCeram implant|FullCeram implantation
214970970|NCT05619666|PROCEDURE|Acute rehabilitation program|Patients included in the study started the rehabilitation program when they were hemodynamic stable, when it was determined that it was safe for patients. Until discharge from the hospital, a re-evaluation of neuromuscular and respiratory function was performed.
214970971|NCT04078620|DIAGNOSTIC_TEST|Survey for drug drug interactions on medscape and lexicomp applications|Survey for drug drug interactions on Medscape and Lexicomp interaction checker applications
214970972|NCT04348526|PROCEDURE|Corticision|Surgical intervention is going to be used in the interdental areas between the lower anterior teeth to accelerate tooth movement. Three incisions are going to be made
214970973|NCT04348526|PROCEDURE|Traditional orthodontic treatment|No surgical intervention will be used, just normal orthodontic sequence of procedures.
214970974|NCT01195779|BIOLOGICAL|GSK Bio's influenza vaccine GSK2584786A, different formulations|Intramuscular injections
214970975|NCT01195779|BIOLOGICAL|GSK Bio's influenza vaccine GSK2321138A|Intramuscular injections
214970976|NCT01195779|BIOLOGICAL|Fluarix™|Intramuscular injections
214970977|NCT05020041|BEHAVIORAL|Physical activity|"The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers, given that they are fundamental for the development of habits in the school stage; besides, painted games will be implemented in the school playground.~The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers or manipulation of objects in order to maintain COVID-19 sanitary and safety protocols. The psychomotor circuit includes a line circuit, a jumping sequence game, and a letter spiral. All the games will be implemented in a space within the educational establishment to which the students will have access during recess. The game designs involve activities to develop motor patterns such as jumping with different supports, running, and dynamic balance."
214970978|NCT06321822|DIAGNOSTIC_TEST|Whole exome sequencing (WES)|Patient selected for genetic study will undergo blood sample collection for DNA estraction, biobank storage and WES study
214359114|NCT05204225|OTHER|Conventional Treatment|Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions. This intervention is the conventional approach usually delivered in their respective centres. Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
214359115|NCT01239030|DRUG|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
214970979|NCT01541709|DRUG|imatinib|The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
214970980|NCT05324319|DRUG|Ad26COVS1|Heterologous vaccination
214970981|NCT05324319|DRUG|ChAdOx1 SARS2 Vaccine|Heterologous vaccination
214970982|NCT05324319|DRUG|BNT162B2|Homologous vaccination
214970983|NCT05324319|DRUG|mRNA-1273|Homologous vaccination
214970984|NCT01401595|DRUG|escitalopram oxalate|The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
214359116|NCT01239030|DRUG|Placebo|Placebo capsules
214359117|NCT04569630|OTHER|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.
214359118|NCT03433989|DIAGNOSTIC_TEST|telephone interview|questionnaire PDEQ et IES-R
214359119|NCT01925833|PROCEDURE|Both insertion and withdrawal|inspection and polypectomy during both insertion and withdrawal of colonoscopy
214970985|NCT02850094|BEHAVIORAL|Financial Bonuses|Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
214970986|NCT01950299|DRUG|Anakinra 100 mg|Anakinra 100 mg starting immediately and then every 24 hours
214970987|NCT01950299|DRUG|Anakinra 100 mg|Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
214970988|NCT01950299|DRUG|Placebo|Placebo 0.67 ml injections twice daily
214970989|NCT01389739|OTHER|Multi-faceted intervention to improve continuity of care|Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
214970990|NCT04995913|OTHER|Online cognitive behavioral therapy|The intervention includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy. Participants will learn and practice a variety of the cognitive behavioral skills to cope with their social anxiety. The functions of the EASE Online Program include animation briefing and debriefing, case demonstration videos, assignment and feedback, forum, internal messaging, reminder, online assessment, online booking and progress checking. The duration of the intervention is 14 weeks.
214359120|NCT01925833|PROCEDURE|Only withdrawal|inspection and polypectomy during only withdrawal of colonoscopy
214359121|NCT04733287|OTHER|High Intensity Interval Training of the Knee Extensors|"Subjects will perform intense, single leg knee extension exercise 3 times a week for 6 weeks. Specifically, subjects will be seated in a custom knee extension ergometer and perform single leg, dynamic knee extension (similar to single leg cycling) as they perform the exercise. After a 6 minute warm-up at \~20% of that leg's maximum aerobic power (determined during a graded exercise test of single leg knee extension), subjects will perform 4 bouts of 4 minutes at \~80% of maximum aerobic power. Recovery of 4 minutes at \~40% will occur between each bout of exercise. A cool down will be provided at the end of exercise. In total, subjects will perform 40 minutes of single leg knee extension exercise, 3 times a week for 6 weeks.~Maximum aerobic power (determined by a graded exercise test) will be determined again at 3 weeks to appropriately adjust the training intensity."
214970991|NCT06550843|PROCEDURE|mesentery-guided division|In the Mes-G group, all surgeries were performed by one surgeon team (J.K.) from January 2013 using the following strategy for the proximal division site: the diseased bowel and para-intestinal mesentery were carefully compared by palpation and translucent observation through a shadowless lamp. The comparison was conducted from the diseased bowel towards the normal-appearing region upstream, to identify a point where the hypertrophied mesentery transitioned into normal thickness and softness and became translucent as observed through the shadowless lamp.
214970992|NCT06958770|DIAGNOSTIC_TEST|Electrical impedance tomography|"* Electrical impedance tomography (EIT)：Assessing pulmonary function in chronic lung diseases.~* Lung ultrasound：Assessing diaphragm atrophy in mechanically ventilated patients.~* Esophageal pressure：The work of breathing, or the energy required by respiratory muscles to meet ventilatory demands, can be directly evaluated by esophageal pressure~* Oxygen consumption：Indirectly evaluated by measuring oxygen consumption (V̇O2) during mechanical ventilation The oxygen cost of breathing, reflected the increase in V̇O2 when transitioning from mechanical ventilation to spontaneous breathing, has been shown to predict weaning outcomes."
214970993|NCT01960101|OTHER|LactoXeros|
214970994|NCT01960101|DEVICE|Aequasyal|
214970995|NCT06958575|PROCEDURE|Septal extension graft|Septal extension graft will be used. The triangle-shaped cartilage graft prepared from the septal cartilage is placed into one or bothsides of the caudal septum reciprocally according to its structure and curvature and sutured with horizontal mattress sutures. After graft stabilization, two insulin needles are passed through the medial crura and the graft to determine its level of placement. After the rotation and nasal projection are adjusted, the medial crura are sutured to the septal graft.
214970996|NCT06958575|PROCEDURE|Columellar strut|Columellar strut graft will be used. A strut graft 1012 mm long is placed into a web created between the two medial crura and stabilized by sutures placed between the graft and medial crura.
214970997|NCT05402956|BEHAVIORAL|Aerobic exercise|Moderate aerobic exercise training
214970998|NCT06958588|DEVICE|Experimental: Hyperslim|The PEMF will be carried out using the Hyperslim® device. The Hyperslim® device is produced by Medical San (Lageado, RS, Brazil).
214970999|NCT06958588|DEVICE|Active Comparator #1|The intermittent pneumatic compression group will use the devices Covidien Kendall SCD 700® (Cardinal Health) or Doctor Life 2600® (Venosan).
214971000|NCT03462810|DRUG|cabotegravir, CAB|open label investigational product
214971001|NCT06958809|DIAGNOSTIC_TEST|Echography|An exhaustive echography will be performed to determine fluid responsiveness (using a passive leg raising test and cardiac output measurement by left ventricular outflow tract velocity time integral)
214971002|NCT06957925|BEHAVIORAL|educational|Teachers were provided with a manual that could be implemented in a flexible way adapted to the local context of the school consisting of six sessions. The manual assisted teachers to prepare students for success in understanding what is a good mental health (session 1), how to optimize and maintain good mental health, with a particular focus on being mentally, spiritually, socially and physically active including coping with stressors via breathing exercises and progressive muscle relaxation techniques (session 2), physical activity participation (session 3) and sleep hygiene measures (session 4), the importance of belongingness and commitment (session 5), and how to seek support including peer support, community engagement and existing local services (session 6). The first 6 sessions were facilitated by the teacher, and the next 6 by peers.
214971003|NCT01959113|BIOLOGICAL|Autologous Microbiome Transplant|
214359122|NCT04733287|OTHER|Muscle Heat Therapy|Subjects will receive muscle heat therapy on the knee extensor muscles (short-wave diathermy) for 120 minutes for each visit. Specifically, subjects will lie supine while short-wave diathermy units (Megapulse II) will be placed on the quadriceps femoris and turned on to 800 pulses per second with a pulse duration of 400 microseconds. Our previous research (e.g. Hafen et al 2018- Repeated exposure to heat stress...) has indicated that this treatment raises muscle temperature to \~39C, a similar temperature induced by exercise.
214971004|NCT01959113|OTHER|Placebo Arm|
214971005|NCT00477763|DRUG|Restasis, Refresh Endura|"1. Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~2. Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening"
214971006|NCT00510341|BEHAVIORAL|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
214971007|NCT05137717|DRUG|Maribavir|Maribavir tablets
214971008|NCT02035553|DRUG|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
214971009|NCT02035553|DRUG|Placebo|Placebo, two tablets, once daily by mouth
214971010|NCT02619617|DRUG|SOM230|The study evaluated SOM230 vs Placebo
214971011|NCT02619617|DRUG|Placebo|The study evaluated SOM230 vs Placebo
214971012|NCT01854697|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
214359123|NCT04733287|OTHER|Muscle Disuse|Subjects will undergo 2 weeks of limb immobilization (a model of muscle disuse). Specifically, a knee brace will be placed on one of the subjects' legs and bent to a flexion of 60 degrees to prevent the foot from touching the ground while standing. Subjects will given a pair of crutches and asked to ambulate on crutches for 2 weeks, avoiding bearing any weight with the immobilized leg.
214359124|NCT04733287|OTHER|Sham Heat Therapy|Specifically, subjects randomly assigned to the sham group will receive the same treatment as the heat group (same number of visits and set up with the heating units applied to leg for 2 hours each visit) except, unbeknownst to either group, the heating units will never be turned on for the sham group.
214359125|NCT05412641|OTHER|Intervention - Responsible Fatherhood Programming|Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management.
214359126|NCT05668533|DIAGNOSTIC_TEST|Interscalene versus PENG Block|"1. Interscalene group: Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).~2. PENG Block: Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg)."
214359127|NCT02119507|DEVICE|Curodont Repair|Single application on Day 0
214359128|NCT02119507|OTHER|No treatment - control|
214359129|NCT04459390|DIAGNOSTIC_TEST|realtime PCR|Detection of SARS-CoV-2 genes by realtime PCR
214487710|NCT06715553|BEHAVIORAL|BALANCE Program (Body, Art, Learning, Activities, Nutrition, Creativity, and Education)|"Six types of intervention will be done on the patients as follows:~* Psychoeducational intervention program~* Art therapy program~* Bibliotherapy program~* Nutrition program~* Sport activity~* Ping Pong activity"
214487711|NCT05188079|DIETARY_SUPPLEMENT|Beetroot juice|high nitrate supplement
214487712|NCT05188079|DIETARY_SUPPLEMENT|Placebo drink|placebo
214487713|NCT05693363|DEVICE|AURA10 Specimen Imager|High-resolution specimen imaging using the AURA10 PET-CT specimen imager during thoracic surgery.
214487714|NCT06735677|BEHAVIORAL|sexual health education|These sessions covered reproductive health, sexual activity during pregnancy and the postpartum period, personal and sexual hygiene, domestic violence during pregnancy, and misconceptions about pregnancy.
214971013|NCT01854697|DRUG|Ribavirin|Tablet
214971014|NCT01854697|DRUG|Telaprevir|Film-coated tablet
214971015|NCT01854697|DRUG|Pegylated Interferon alpha 2-a (PegIFN)|Pre-filled syringe
214971016|NCT03414853|DIAGNOSTIC_TEST|Free text prediction algorithm for appendicitis|A free-text prediction software that predicts the probability of acute appendicitis
214971017|NCT02749162|DRUG|Dexamethasone phosphate|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
214971018|NCT02749162|DRUG|Paracetamol|After the block regression, at the first analgetic request the patients received the analgesia protocol
214971019|NCT02749162|DRUG|Morphine|After the block regression, at the first analgetic request the patients received the analgesia protocol
214971020|NCT02749162|DRUG|Lidocaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
214971021|NCT02749162|DRUG|Ropivacaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
214487715|NCT06541834|DEVICE|Retinal imaging|Data of retinal imaging were acquired using Spectralis (Heidelberg, Germany) and California (Optos, UK).
214971022|NCT01904110|DRUG|Risedronate/Cholecalciferol combination(montly)|once a month
214971023|NCT01904110|DRUG|Risedronate/Cholecalciferol combination(weekly)|once a week
214971024|NCT05078203|BEHAVIORAL|Exercise|36 minutes of Exercise
214971025|NCT02104661|DRUG|Oxcarbazepine|Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
214971026|NCT02104661|DRUG|Placebo|Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
214971027|NCT01943487|DRUG|EC905|Oral
214971028|NCT01943487|DRUG|verapamil|Oral
214971029|NCT05534139|DIAGNOSTIC_TEST|7T MRI-scan|MRI-scanning of the brain using a 7T-MRI scanner
214971030|NCT05534139|DIAGNOSTIC_TEST|CSF collection via lumbar puncture|CSF is collected by doing a lumbar puncture
214971031|NCT05534139|DIAGNOSTIC_TEST|Blood withdrawal|Blood is collected by doing a blood withdrawal
214971032|NCT05534139|DIAGNOSTIC_TEST|Clinical measures|UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments
214971033|NCT00475137|DRUG|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
214971034|NCT00475137|DRUG|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
214359130|NCT02316964|DRUG|decitabine|20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
214971035|NCT03713684|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214359131|NCT02316964|BIOLOGICAL|natural killer cell therapy|Undergo infusion of allogeneic NK cells on day 0
214359132|NCT02316964|BIOLOGICAL|aldesleukin|Given SC
214359133|NCT02316964|OTHER|laboratory biomarker analysis|Correlative studies
214359134|NCT06457828|PROCEDURE|Non-corticosteroid injection|no infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
214971036|NCT03713684|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214971037|NCT03713684|DRUG|Background therapy|Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
214971038|NCT05656170|PROCEDURE|Stellate ganglion block|"Ultrasound will be utilized to identify anatomic landmarks and prepare for the stellate ganglion block. Skin will be prepped with chloraprep. The C6 level is identified. The Chassaignac tubercle (the anterior tubercle of the C6 vertebral body) is then identified. Placement of the ultrasound transducer helps retract the carotid sheath and sternocleidomastoid muscle laterally. Pressure is applied with the ultrasound transducer to reduce the distance between the skin and tubercle.~The needle is inserted towards to the Chassaignac tubercle after contact it is redirected towards the body of C6. The needle is then withdrawn 1-2 mm to bring it out of the longus colli muscle while still staying within the prevertebral fascia. After negative aspiration, 1-2 mL of local anesthetic (or normal saline in the placebo group) is injected, and spread can be visualized with ultrasound. Once confirming that the injection was subfascial, the remaining local anesthetic can be given (10 mL in total)."
214971039|NCT05656170|DRUG|Bupivacain|The intervention group will receive bupivacaine injection guided by ultrasound at the location of the stellate ganglion.
214971040|NCT05656170|DRUG|Saline|The control group will receive a normal saline injection guided by ultrasound at the location of the stellate ganglion.
214971041|NCT01803087|DRUG|Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1|
214971042|NCT01803087|DRUG|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).|
214971043|NCT01803087|DRUG|BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)|
214971044|NCT01803087|DRUG|CHF 1535 100/6 pMDI (Foster®) (CTR)|
214971045|NCT04542980|DIAGNOSTIC_TEST|SARS-CoV2 Autoantibody detection|Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2
214971046|NCT04637243|OTHER|Treatment of Benign or Malignant Liver and Bile Duct Diseases|Available treatment of Benign or Malignant Liver and Bile Duct Diseases
214971047|NCT03572673|DEVICE|Flexima 3S|Flexima 3S (2-piece appliance) with drainable pouch
214971048|NCT03572673|DEVICE|New 2-piece ostomy appliance|New 2-piece ostomy appliance with drainable pouch
214971049|NCT03564990|OTHER|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
214971050|NCT03564990|OTHER|conventional approach|conventional follow-up
214971051|NCT05150431|DRUG|Parecoxib|Parecoxib 40mg will be administered to the experimental group if the patient has no contraindication.
214971052|NCT05150431|DRUG|Placebo|This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
214971053|NCT01611623|DRUG|SNX-5422|Tablets dose every other day; dose escalation based on safety
214971054|NCT03660748|BIOLOGICAL|MET-2|Ingestion of a novel human microbiome preparation
214971055|NCT02185417|DRUG|Hydrochlorothiazide (HCTZ)|Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
214971056|NCT02185417|DRUG|Chlorthalidone (CTD)|Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
214359135|NCT06457828|DRUG|Corticosteroid injection|infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
214359136|NCT03655769|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
214359137|NCT03655769|DEVICE|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
214359138|NCT04136886|DRUG|Cisplatin|cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction
214971057|NCT04653831|DRUG|Pirfenidone|Treatment with Pirfenidone as mentioned in the experimental arm description.
214971058|NCT04653831|OTHER|Standard of care|Treatment with SoC as mentioned in the control arm description.
214971059|NCT03533231|COMBINATION_PRODUCT|Canal Disinfection Triple Antibiotic Paste (TAP)|"Patients were treated as follows: Caries was excavated; access cavity was prepared. The rubber dam was then applied and working length was determined. Canal space was irrigated using 40 cc of NaOCl 2.6% solution and final flush of saline. Canal space was dried using paper points. One cc of the prepared paste was injected into the canals using a sterile plastic syringe with 20 gauge needle. The access cavity was then sealed using temporary restoration. After the 3 weeks, anesthesia without vasoconstrictor was administrated. The antibiotic paste was removed and the canal was irrigated using a sterile saline and dried using paper points. Sterile hand file size #25 was introduced into the root canal beyond the working length to induce bleeding. The bleeding was allowed to reach a 3-mm level below the cemento-enamel junction. MTA was used to seal the root canal at the cervical level. After one week, adhesive composite resin was used to seal the access cavity."
214971060|NCT03533231|COMBINATION_PRODUCT|Ciprofloxacin + Propolis Paste|
214359139|NCT04136886|RADIATION|IMRT|Radiation: IMRT IMRT is to give 60Gy in 27 fraction
214359140|NCT00369330|DEVICE|external electrical cardioversion|
214359141|NCT03084666|DEVICE|Zimmer ATS tourniquet system|The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
214359142|NCT01201057|DRUG|0.5% SPL7013 Gel|Vaginal gel
214971061|NCT03533231|COMBINATION_PRODUCT|Ciprofloxacin + Metronidazole Paste|
214971062|NCT03533231|COMBINATION_PRODUCT|Propolis + Metronidazole paste|
214971063|NCT02361112|DRUG|pyrotinib combined with capecitabine|
214971064|NCT05093556|BEHAVIORAL|iCHART - Interactive CBT for Headache And Relaxation Training|IVR based cognitive behavioral therapy for headache
214971065|NCT03721224|DIAGNOSTIC_TEST|Kiddie Schedule for Affective Disorders and Schizophrenia|Both of the clinical and control group will be evaluated via Psychiatric semi-structured interview
214971066|NCT01819675|DEVICE|Low frequency rTMS|
214971067|NCT01819675|DEVICE|High frequency rTMS|
214971068|NCT01819675|DEVICE|Sham rTMS|
214971069|NCT00524524|DRUG|ARQ 501|Weekly IV Infusion; 450 mg/m2
214971070|NCT02595502|DEVICE|JJVC Marketed Contact Lens (Test)|
214971071|NCT02595502|DEVICE|Competitor Marketed Contact Lens (Control)|
214971072|NCT00974311|DRUG|Enzalutamide|MDV3100, 160 mg orally per day
214971073|NCT00974311|DRUG|Placebo|Placebo comparator
214359143|NCT01201057|DRUG|1.0% SPL7013 Gel|Vaginal gel
214971074|NCT00763997|DRUG|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
214359144|NCT01201057|DRUG|3.0% SPL7013 Gel|Vaginal gel
214359145|NCT01201057|OTHER|Placebo Gel|Vaginal gel
214359146|NCT00010179|DRUG|lurtotecan liposome|
214359147|NCT06275152|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
214359148|NCT06275152|DEVICE|Sham Remote Ischemic Conditioning|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
214971075|NCT00763997|DRUG|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
214971076|NCT00763997|DRUG|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
214971077|NCT00763997|DRUG|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
214971078|NCT00763997|DRUG|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
214971079|NCT00763997|OTHER|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
214971080|NCT01158560|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D3)|oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks
214971081|NCT01158560|BEHAVIORAL|Gargling|gargling with tap water, twice daily
214971082|NCT01158560|DIETARY_SUPPLEMENT|Placebo|matched placebo for active vitamin D
214971083|NCT05508373|BIOLOGICAL|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
214971084|NCT04121338|PROCEDURE|Celiac ganglion block|The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home
214359149|NCT04259086|DRUG|DaxibotulinumtoxinA for injection|Intramuscular injection
214359150|NCT06230003|DRUG|Ropivacaine|Ultrasound guided ESP block either with the local anesthetic of 0.5% of Ropivicane 20 mL bilaterally (intervention group) or normal saline (control group) before surgery which will take 5-10 minutes in a 1:1 ratio.
214359151|NCT06230003|DRUG|normal saline|Ultrasound guided bilateral ESP block either with normal saline
214359152|NCT05318794|DRUG|Doxorubicin and Cisplatin|Pressurised intraperitoneal aerosol chemotherapy
214359153|NCT01850979|DRUG|Tacrolimus|tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
214359154|NCT01850979|DRUG|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
214359155|NCT06005233|DEVICE|Smartwatch|Smartwatch with PPG- and 1-lead ECG derived analysis of cardiac arrhythmia. Analysis will be performed centrally at the Cardiology Core Lab at the Klinikum Rechts der Isar.
214971085|NCT04121338|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
214971086|NCT00549796|OTHER|Percutaneous coronary intervention (PCI)|Patients undergo routine, clinically indicated PCI
215083282|NCT00810485|DRUG|ADX10059|oral administration
215083283|NCT00810485|DRUG|ADX10059|oral administration
215083284|NCT00810485|DRUG|ADX10059 Matching Placebo|oral administration
215083285|NCT02408081|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
215083286|NCT02498067|BEHAVIORAL|rPlan dual protection waiting room app intervention|
215083287|NCT01636505|DRUG|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
215083288|NCT01636505|DRUG|gnrh agonist (suprefact)|suprefact 5.5 ml
214359156|NCT06568562|DRUG|XL092|XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle.
214359157|NCT06112756|DRUG|Elinzanetant|Oral
214359158|NCT06112756|OTHER|Placebo|Oral
214359159|NCT00554879|PROCEDURE|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
214679192|NCT01320579|DRUG|Placebo for cis-UCA emulsion cream|The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
214971087|NCT03193632|DIAGNOSTIC_TEST|US Muscle layer thickness (MLT) estimation|"Three measurements will be made at each of three sites; mid-upper arm, forearm and thigh anteriorly and the mean value will be calculated. Measurement sites will be marked with indelible ink to ensure day-to-day consistency.~1. Thigh: MLT of the quadriceps femoris muscle (M. Vastus intermedius and M. rectus femoris) will be assessed bilaterally~2. Mid-upper arm: Muscle layer thickness will be measured over the biceps,midway between the tip of the acromion and the tip of the olecranon~3. Forearm: A point midway between the antecubital skin crease and the ulnar styloid was marked and muscle thickness down to the interosseus membrane"
214971088|NCT03193632|DIAGNOSTIC_TEST|REE estimation by indirect calorimetry|REE will be calculated using indirect calorimetry via metabolic module on General Electric ventilator (Engstrom Carestation and Carescape R860, GE Health care, USA) All indirect calorimetric measurements will be done using standardized technique. Gas calibration will be performed before each measurement, and the measurements will last for at least 30 minutes. Measurements will be taken with the patient lying supine and ventilator settings left unchanged for at least 60 minutes ahead of indirect calorimetry. The REE will be calculated during the first 24 hours of admission to ICU.
214971089|NCT01853787|DRUG|Formoterol Fumarate|Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
214971090|NCT01853787|DRUG|Salmeterol|Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
214971091|NCT04152681|DRUG|Apatinib|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
214971092|NCT01639612|BIOLOGICAL|ALD-451|ALD-451 iv
215083289|NCT03723174|BEHAVIORAL|Oral Health Educational Program|proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
215083290|NCT04175457|OTHER|e-cigarette|E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
214359160|NCT00554879|PROCEDURE|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
214359161|NCT02804568|DRUG|ALKS 3831|Oral capsule, daily administration
214359162|NCT01176487|OTHER|questionnaire administration|
214359163|NCT01176487|PROCEDURE|quality-of-life assessment|
214971093|NCT02818855|PROCEDURE|Coronally advanced flap (CAF)|"The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner."
214971094|NCT02818855|DRUG|Collagen Matrix|A new collagen membrane
215083291|NCT04750694|BEHAVIORAL|Resistance training|A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
215083292|NCT00747344|DRUG|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
214359164|NCT01176487|RADIATION|3-dimensional conformal radiation therapy|
214359165|NCT01176487|RADIATION|palliative radiation therapy|
214359166|NCT01176487|RADIATION|whole-brain radiation therapy|
214359167|NCT05599828|DRUG|AMG 510|Oral Tablet
214359168|NCT05599828|DRUG|Omeprazole|Capsule
214359169|NCT05599828|DRUG|Famotidine|Tablet
214359170|NCT04389450|BIOLOGICAL|PLX-PAD|PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells
214359171|NCT04389450|BIOLOGICAL|Placebo|Placebo solution for injection
214359172|NCT06504615|DRUG|nivolumab + chemotherapy|As prescribed by the treating clinician, as per product label
214359173|NCT03085485|DRUG|Ivacaftor 150 MG|Ivacaftor is a CFTR potentiator
214359174|NCT03085485|DRUG|Placebo|placebo pills
214359175|NCT04571398|OTHER|ApricityRx mobile application|AE detection and monitoring software
214359176|NCT04986176|DRUG|HC-1119|oral
214359177|NCT04986176|DRUG|Placebo|oral
214359178|NCT06221566|OTHER|Muscle Energy Technique|"Muscle energy technique (MET) for upper trapezius and levetor scapulae muscle of neck with 7 to 10 second hold, 3 to 5 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
214971095|NCT02818855|PROCEDURE|Subepithelial connective tissue graft|Connective tissue graft
214971096|NCT00412841|DRUG|Atorvastatin|Atorvastatin 40mg vs placebo 40mg daily
214971097|NCT00412841|PROCEDURE|MRI, Venipuncture|MRIs done baseline, four and nine months
214971098|NCT00412841|DRUG|Placebo|Tablets identical to atorvastatin 40mg
214971099|NCT02541331|BIOLOGICAL|ISMIGEN|Tablets of 30 billion organisms/mg - Sublingual use 1 tablet per day over 10 days for 3 successive months.
214971100|NCT02541331|BIOLOGICAL|PLACEBO|Matched tablets without any active substance.
214971101|NCT05556148|DRUG|Otrivine Congestion Relief|0.1% Nasal Spray (Xylometazoline Hydrochloride)
214971102|NCT00144677|DRUG|sirolimus|
214971103|NCT00144677|DRUG|tacrolimus|
215083293|NCT00747344|DRUG|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
214359179|NCT06221566|OTHER|Stretching Exercises|"Stretching exercises program for upper trapezius and levetor scapulae muscle of neck with 10 second hold, 15 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
214971104|NCT06150300|BEHAVIORAL|Pulmonary rehab program|Exercise videos, breathing exercises, and educational messages delivered virtually
214971105|NCT06150300|BEHAVIORAL|Placebo|Breathing exercises and educational messages
214971106|NCT03158207|DEVICE|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
214971107|NCT03158207|OTHER|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales). Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication.
214971108|NCT02885038|OTHER|Platelet concentrate transfusion|
214971109|NCT00458003|DRUG|Ephedrine|Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
214971110|NCT00458003|DRUG|Phenylephrine|Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
214971111|NCT02016443|DRUG|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
214971112|NCT02016443|DRUG|Placebo|Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
215083294|NCT00747344|DRUG|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
214359180|NCT01710072|DRUG|aspirin|
214359181|NCT01662882|DRUG|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
214359182|NCT01775904|DRUG|LY2886721 in a Capsule|Administered orally.
214359183|NCT01775904|DRUG|LY2886721 in an orally disintegrating tablet (ODT)|Administered orally.
214359184|NCT00518115|DRUG|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
214359185|NCT04891419|DEVICE|JUVÉDERM® VOLUMA® with Lidocaine|JUVÉDERM® VOLUMA® with Lidocaine injectable gel
214971113|NCT00003740|BIOLOGICAL|trastuzumab|
214971114|NCT06344975|BIOLOGICAL|STR-V003/Placebo|IM
214971115|NCT03136718|OTHER|Mobile-enabled RLOs (mRLOs)|A theoretically-driven, personalised educational intervention delivered through mobile technologies based on the C2Hear (https://www.youtube.com/C2HearOnline) RLOs. The mRLO intervention will include shorter 'bite-sized' RLOs suitable for mobile technologies. This will allow a unique dynamic tailoring approach, whereby relevant mRLOs will be provided based on the user's responses to a self-evaluation filter aid, which will enable individualised, tailored learning.
214971116|NCT00189163|DRUG|Pioglitazone|30 mg, taken orally, once per day, for 48 weeks
214971117|NCT00189163|DRUG|Placebo Oral Tablet|Sugar Pill, taken orally, once per day, for 48 weeks
214971118|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
215083295|NCT00747344|DRUG|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
215083296|NCT04382521|BEHAVIORAL|Text Message Intervention|Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
215083297|NCT01659281|DRUG|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
214359186|NCT05426551|OTHER|Dual isotope method|The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.
214359187|NCT04091139|BEHAVIORAL|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
214359188|NCT04091139|BEHAVIORAL|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
214679193|NCT01320579|DRUG|Protopic® 0.1% ointment|0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
214971119|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
214971120|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
214971121|NCT01951144|DRUG|PF-06372865 or Placebo or Lorazepam|Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
214971122|NCT03006536|DEVICE|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
214971123|NCT04426942|OTHER|survey|survey on sexuality during pregnancy
214971124|NCT05235152|OTHER|Usual individual physiotherapy care|"Usual and individual physiotherapy care guidelines were developed through a round-table discussion involving experts in musculoskeletal health. From the round-table discussion, the consensus as reflecting best-practices for the rehabilitation of musculoskeletal rehabilitation supported an active exercise rehabilitation approach which includes strengthening and neuromuscular training exercises. Furthermore, the following treatments are considered in addition to active exercises:~* Range of motion: active, active-assisted, passive, repeated movements (Mulligan or McKenzie);~* Stretching / manual therapy: mobilizations, manipulation, neural mobility, active release therapy;~* Individual proprioceptive training."
214971125|NCT05235152|OTHER|Group-supervised physiotherapy training programs|Three group-supervised physiotherapy training programs (The lumbar, the upper extremity and the lower extremity training programs) were developed for military members with musculoskeletal conditions. They are composed of stations that each include several exercises of varying levels of difficulty. Group size will vary between 5 to 20 participants for one physiotherapist, and each military member performs his/her own exercises. During a typical session, the participant and therapist will choose one exercise to perform per station according to two main criteria: severity of the condition and the ability to perform the exercises optimally. The level of supervision is adapted to the participant's needs and performance. Progression in the programs leads to the execution of exercises that simulate functional and occupational tasks.
215083298|NCT01659281|DRUG|Artesunate|4 mg/kg/day for 3 days
215083299|NCT01659281|DRUG|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
215083300|NCT01659281|DRUG|Mefloquine|8 mg/kg daily for 3 days
214359189|NCT01428648|BEHAVIORAL|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
215083301|NCT01484834|BEHAVIORAL|Exercise and Education|"Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors"
215083302|NCT01484834|BEHAVIORAL|Exercise|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
215083303|NCT01484834|BEHAVIORAL|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
215083304|NCT01484834|OTHER|Control Company|No intervention was applied for the participants of this group
215083305|NCT01329796|DRUG|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
215083306|NCT01329796|DRUG|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
214359190|NCT06360939|RADIATION|SBRT|Delivery of 25Gy in a single dose fraction to target area within 6 weeks of randomization
214359191|NCT06360939|PROCEDURE|CA|CA (endocardial and/or epicardial at operator discretion) within 6 weeks of randomization.
214359192|NCT04866173|OTHER|Dog|Subjection to standardised stress situations in the presence of a dog and a person
214359193|NCT04866173|OTHER|No Dog|Subjection to standardised stress situations in the presence of a person
214359194|NCT00127244|PROCEDURE|Periodontal Treatment|
214359195|NCT03712644|DEVICE|FFR-guided coronary revascularization|Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.
215094406|NCT04713332|DIETARY_SUPPLEMENT|Vitamin E|Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.
214359196|NCT04443140|DIAGNOSTIC_TEST|PCR, lung ultrasound|PCR for Covid-19
214679194|NCT01518582|DEVICE|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
214679195|NCT02393651|DEVICE|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
214679196|NCT06023238|PROCEDURE|Treatment of Chronic TKA PJI|Patients will all undergo standard of care treatment for a chronic total knee arthroplasty prosthetic joint infection.
214359197|NCT01845675|DRUG|temozolomide or dacarbazine-based chemotherapy, endostatin|
214971126|NCT01040949|BEHAVIORAL|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
214971127|NCT01040949|BEHAVIORAL|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
214971128|NCT03353324|DRUG|intravitreal injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness, if in month four or more the CMT is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeatet and follow up in this manner is continued until 9 months.
214971129|NCT03353324|RADIATION|intravitreal injection of bevacizumab+ targeted laser|"patients in this group undergone laser photocoagulation of retinal non perfused areas based on FAG wide field imaging .~After 9 month follow up the outcomes such as Vusal acuity, Central macular thickness, intraocular pressure, neovascular formation are compared"
214971130|NCT01139996|DRUG|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
214971131|NCT01139996|DRUG|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
214971132|NCT05934474|BIOLOGICAL|Peripheral venipuncture blood sampling, as part of standard care procedures|Collection of 36 mL of blood
214971133|NCT05934474|OTHER|Interview with a psychiatrist|Research project data collection
215083307|NCT03326557|PROCEDURE|Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery|Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
214359198|NCT05462665|BEHAVIORAL|theory training|theory training
214679197|NCT03527446|BEHAVIORAL|Sprint Interval Training|The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.
214359199|NCT05462665|BEHAVIORAL|theory and simulation training|theory and simulation training
214359200|NCT02234869|DRUG|Interferon Beta|Subcutaneous injection
214359201|NCT02234869|DRUG|BIIB017 (Peginterferon beta-1a)|Single-use, disposable, prefilled pen for subcutaneous injection
214359202|NCT05243758|DEVICE|Group video fiberscope of experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopyvideo fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
214359203|NCT05243758|DEVICE|Group video laryngoscope of experienced practitioner|Intubation Pending Difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.
214679198|NCT03975972|OTHER|Occupational Therapy Based Literacy Intervention|Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
214971134|NCT04595006|OTHER|Cold Stimulation (CS)|Subject wear cooling vest to stay cool
214971135|NCT04595006|OTHER|Browning Nutraceutical (BN)|Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root
214971136|NCT04595006|OTHER|Cold Stimulation and Browning Nutraceutical (CSBN)|Subject wear a cooling vest and consume 2000mg of curcumin
214971137|NCT04746469|BEHAVIORAL|Delayed automated phone call|Cipher provides automated phone calls to patients; in this case the script for Cipher was modified to provide patients a reminder to return FIT kits, allow patients to request a new kit in case they need a replacement, and to allow patients to provide information if they already completed CRC screening
214971138|NCT03143361|PROCEDURE|Aortic valve replacement|All surgical procedures used for both traditional and mini-invasive aortic valve replacement, as well as transcatheter valve implantation.
214971139|NCT04176939|BIOLOGICAL|HZ/su vaccine (GSK1437173A)|2 intramuscular (IM) revaccination doses of the HZ/su vaccine administered - first dose at Month 24 and second dose at Month 25.
214971140|NCT04623866|DRUG|Huaiqinhuang|Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
214971141|NCT04623866|DRUG|valsartan|Valsartan granules 80mg/1.73m2 based qd 24 weeks
214971142|NCT03520452|OTHER|Green coffee extract|Reconstituted in water and given to subjects
214971143|NCT03520452|OTHER|Placebo|Placebo
214971144|NCT02977793|DEVICE|Tomey EM-4000 Specular Microscope|
214971145|NCT02977793|DEVICE|Konan CellChek XL Specular Microscope|
215083308|NCT02683486|DEVICE|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
215083309|NCT02683486|DEVICE|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
215083310|NCT00765882|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
215083311|NCT00765882|DRUG|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
215083312|NCT00765882|DRUG|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
215083313|NCT01117506|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
215083314|NCT02337530|DRUG|Selumetinib|
215083315|NCT02337530|DRUG|Pemetrexed|
215083316|NCT02337530|DRUG|Cisplatin|
215083317|NCT02337530|DRUG|Carboplatin|
214679199|NCT04385797|OTHER|Telephone interview|Sociodemographic data. Clinical data. PMCI/MD quality of life, cognition, depression, technophilia and perceived stress and caregiver quality of life and burden assessments.
215083318|NCT00002454|BIOLOGICAL|autologous tumor cell vaccine|
215083319|NCT04051385|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
214679200|NCT00103194|DRUG|lapatinib ditosylate|Given PO
214679201|NCT00103194|OTHER|laboratory biomarker analysis|Correlative studies
214971146|NCT00570375|DRUG|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
214971147|NCT02697071|DRUG|Ketamine|Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
214971148|NCT02697071|DRUG|Normal Saline|Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
214971149|NCT04503317|DEVICE|active acupuncture low level laser in addition to nasal laser irradiation|laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. applied on specific acupuncture points ( acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time with treadmill aerobic exercise, once per day, 3 times per week for three months
214971150|NCT04503317|OTHER|treadmill exercise|aerobic exercise once per day, 3 times per week for three months
215083320|NCT04051385|OTHER|Gingival crevicular fluid and serum collection|GCF with filter paper using the intracrevicular method and serum collection
215083321|NCT02231762|DRUG|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
215083322|NCT02231762|DRUG|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
215083323|NCT01757561|PROCEDURE|propofol|use total intravenous anesthesia with propofol
215083324|NCT01757561|PROCEDURE|sevoflurane|use inhalation anesthesia with sevoflurane
215083325|NCT01404013|DRUG|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
215083326|NCT01404013|DRUG|Montelukast|Montelukast 10mg ,every night, for 8 weeks
215083327|NCT01404013|DRUG|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
214971151|NCT01529606|OTHER|Composite restoration and tooth cleaning|Standard preventive treatment will be repeated on semi-annual (6-month) recall visits. All composite restorations will be placed according to the manufacturer's instruction.
215083328|NCT06306690|DIAGNOSTIC_TEST|OCT, OCT angiography, flicker ERG and Ultra Wide Field retinography and autofluorescence.|"the best visual acuity will be evaluated using decimal tables and then converted to logMar.~Ocular fundus examination will be evaluated following pharmacological mydriasis with Tropicamide 1%.~OCT will be essential to quantify the central macular thickness and the thickness of the RPE.~OCT angiography is a non-invasive method to assess the presence or absence of neovascular membrane and macular flow density.~Color and ultra wide field autofluorescence images of the retina will be performed with Zeiss Clarus retinography to search for signs that identify different types of RP and predict their activity and evolution.~Electroretinogram flicker (ERG) is a common measure of cone pathway function that is used to study the normal visual system and that of patients with inherited and acquired retinal dysfunction Measurements will be performed using an electrophysiological recording system (CSO). Intermittent stimuli are presented using a Ganzfeld dome (CSO)."
215083329|NCT04920721|OTHER|no intervention|no intervention descriptiv study
215083330|NCT05384535|DIAGNOSTIC_TEST|Bi-parametric MRI|When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI
215083331|NCT02165956|DIETARY_SUPPLEMENT|New Infant Cereal|New Infant Cereal
215083332|NCT02165956|DIETARY_SUPPLEMENT|Standard Infant Cereal|Standard Infant Cereal
215083333|NCT00212199|DRUG|orlistat|
215083334|NCT00212199|BEHAVIORAL|Brief cognitive behavioral counseling|
215083335|NCT00135928|DRUG|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
215083336|NCT02973542|DRUG|Ethosuximide|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
215083337|NCT02973542|OTHER|Placebo|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
215083338|NCT02545114|DRUG|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
215083339|NCT04547114|DIAGNOSTIC_TEST|Multicapillary column coupled ion mobility spectrometry|sampling of nasal air via a foam cuffed oxygen catheter
215083340|NCT03445728|DRUG|Nicorandil|After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h
215083341|NCT03445728|OTHER|Placebo|After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h
215083342|NCT01799239|DEVICE|Test product|The test product consists of an adhesive with a new top film
214971152|NCT01529606|PROCEDURE|Plasma treatment|plasma treatment after preparation and for caries prevention
214487716|NCT06541054|OTHER|WARM SOCKS|One hour before the operation,warm socks will be put on the experimental group,body temperature,heart rate,blood pressure,SPO2 will be measured and recorded every fifteen minutes.During the surgery,body temperature,heart rate,blood pressure,SPO2 value, drainage amount will be measured and recorded every fifteen minutes.The patient will be transferred to the postoperative care unit with warm socks and will stay on his feet in the postoperative care unit.Body temperature, heart rate,blood pressure,SPO2 values will be recorded every fifteen minutes.He will be transferred from the postoperative care unit to the clinic with socks.will stay. After transferring to the bed,body temperature,heart rate, arterial blood pressure, SPO2 will be recorded every fifteen minutes for a total of 180minutes.Chills,chills and the total drainage amount for 24hours will be recorded in the same section.
215083343|NCT01799239|DEVICE|SenSura|SenSura is the CE-marked and commercially available comparator product
214679202|NCT03071224|DRUG|[18F] MNI-946|Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.
215083344|NCT01107600|PROCEDURE|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
214971153|NCT05291624|DIAGNOSTIC_TEST|AAGL Endometriosis Classification score - ULTRASOUND|At baseline, ultrasonographic evaluation of patients by following AAGL Endometriosis Classification
214487717|NCT06733298|DRUG|[ 14C]-labeled RO7269162|Participants will receive one oral dose of \[14C\]-labeled RO7269162.
214971154|NCT05291624|DIAGNOSTIC_TEST|AAGL Endometriosis Classification score - SURGERY|Within 1 month from enrollment, surgical evaluation of patients by following AAGL Endometriosis Classification
214971155|NCT04263259|BEHAVIORAL|Attentional Bias Modification|Mobile-Delivered Cognitive Retraining Intervention
214971156|NCT01210794|PROCEDURE||The influence of different food components on zinc absorption in young adults consuming zinc fortified porridges prepared from maize, beans and sorghum
214971157|NCT03511677|DEVICE|Insole|Customized insole
214971158|NCT03511677|DEVICE|Placebo Insole|Placebo flat insole
214971159|NCT02844166|OTHER|viscoelastic surface support|Patients will be placed in an ICU bed with viscoelastic surface support
214971160|NCT02844166|OTHER|pyramidal foam surface support|Patients will be placed in an ICU bed with pyramidal foam surface support
214971161|NCT01341496|BIOLOGICAL|Epigenetically Modified Autologous Tumor|5x 10\^7 autologous tumor cells emulsified in 0.5 mL ISCOMATRIX adjuvant will be administered IM every 4 weeks for 6 months
215083345|NCT00741494|DEVICE|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
215083346|NCT02917213|OTHER|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
215083347|NCT02917213|OTHER|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
215083348|NCT02917213|OTHER|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
215083349|NCT02917213|OTHER|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
214487718|NCT06741267|DEVICE|RBS|physicians control RBS
214487719|NCT06741267|DEVICE|AB|physician control automatic bronchoscopy
214971162|NCT01341496|DRUG|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
214971163|NCT01341496|DRUG|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
214971164|NCT05943366|DEVICE|Keep-on-Keep-Up Nutrition (KOKU-Nut)|Keep-on-Keep-Up (KOKU) is a free, tablet-based strength and balance exercise application that was soft launched in 2020 (https://kokuhealth.com/). KOKU is approved by the National Health Service (NHS) and Organisation for the Review of Care and Health Apps (ORCHA) as a lifestyle app and has been viewed positively by older adults after 6 weeks of independent use. KOKU-Nut is the latest development of this interactive platform and includes nutritional games based on the UK dietary guidelines to nudge older adults to improve their diet with a specific focus on protein, fibre and fluid.
214971165|NCT01285843|PROCEDURE|Anterior Minimally Invasive Approach (AMIS)|
214971166|NCT02955303|OTHER|TECH: Tablet Enhancement of Cognition and Health|cognitive training using touchscreen tablet gaming applications
214971167|NCT03352076|DRUG|Vaginal Danazol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
214971168|NCT03352076|DRUG|Oral Danatrol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
214971169|NCT01631448|BIOLOGICAL|Fibrin Glue|The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
214359204|NCT05243758|DEVICE|Group video fiberscope of less experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopy video fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
214359205|NCT05243758|DEVICE|Group video laryngoscope of less experienced practitioner|Entubation pending difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.Storz DCI Video Laryngoscope (Karl Storz GmbH \&Co. KG, Tuttlingen, Germany)
214359206|NCT02848248|DRUG|SGN-CD123A|Intravenous infusion in 3-week cycles
214971170|NCT01746862|DRUG|Saizen®|Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone \[r-hGH\]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
214971171|NCT01746862|DRUG|Saizen®|Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
214487720|NCT06741267|DEVICE|ENB|physicians control electromagnetic bronchoscopy
214487721|NCT06883617|DEVICE|Neuro stimulator Implant|Neuro Stimulator for treating sleep disordered breathing
214679203|NCT03071224|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.
214971172|NCT04693793|OTHER|Education Materials and Janssen Test|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations."
215083350|NCT02917213|PROCEDURE|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
215083351|NCT02917213|OTHER|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
215083352|NCT02917213|OTHER|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
215083353|NCT02085096|BEHAVIORAL|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
215083354|NCT03043495|PROCEDURE|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
214359207|NCT00827918|DRUG|MK-8998|MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
214359208|NCT00827918|DRUG|Comparator: Olanzapine|Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
214359209|NCT00827918|DRUG|Comparator: Placebo|Placebo tablets matching olanzapine tablets and MK-8998 capsules
214359210|NCT05704075|PROCEDURE|Transverse Tibial Transport (TTT)|Transverse tibial transport is a novel adaptation of concepts used in distraction histogenesis. The most common use of this surgical principle is in bone lengthening surgery, which is a well-established surgical procedure by applying an external fixator to the bone, creating a corticotomy, and gradually lengthening the bone at the optimal rate of 0.5mm/12hrs. The biological mechanisms of distraction histogenesis involve activating signalling pathways such as cytokines Interleukin 1 and Interleukin 6, pro-inflammatory markers TNF alpha, pro-osteogenic TGF-beta, BMPs and pro-angiogenic factors VEGF and angiopoietin . TTT utilises the concept of distraction histiogenesis, but distraction is performed in the transverse plane instead of a longitudinal distraction. In addition, the period of distraction is coupled with a corresponding compression period and ultimately results in no net change in limb length.
214971173|NCT04621721|BEHAVIORAL|Gait/balance & resistive exercise|Walking forward and back, walking with head motion, static standing, Standing Partial Tandem, Tandem Standing heel to toe, Standing with head turns Single leg stance and March in place. Resistance exercises include: calf raises, lunges, supine leg curls and extensions.
214971174|NCT03713099|DEVICE|Microwave ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound (EBUS) to confirm disease staging.
215083355|NCT03043495|DRUG|Dexamethasone|Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs
215083356|NCT05725460|PROCEDURE|dextrose 5% median nerve hydrodissection|planned to be a good alternative to steroid hydrodissection
215083357|NCT02594098|DRUG|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
215083358|NCT02594098|DRUG|Placebo|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
214359211|NCT05704075|PROCEDURE|Conventional|Dressing + Negative Pressure Wound Therapy
214359212|NCT05283317|BIOLOGICAL|Mesenchymal stem cells|Standard therapy of sepsis as suggested in the guidelines were given to all patients and additionally MSCs treatment was applied to the patients in the study group.
214359213|NCT02959489|BEHAVIORAL|Alzheimer's Disease Risk Disclosure|Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
214359214|NCT02959489|BEHAVIORAL|Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure|"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."
214359215|NCT03623087|DRUG|Cisplatin|SIMPLE
214359216|NCT03623087|DRUG|Gemcitabine|SIMPLE
214359217|NCT03623087|DRUG|Etoposide (VP-16)|SIMPLE
214359218|NCT03623087|DEVICE|Ifosfamide|SIMPLE
214359219|NCT03623087|DRUG|Dexamethasone|SIMPLE
214359220|NCT03623087|DRUG|L-asparaginase|SIMPLE
214487722|NCT06883643|BEHAVIORAL|Differentiated service delivery approach (DSD) in TB treatment and prevention.|Although DSD models have been widely adopted in HIV programs, DSD is a relatively new approach for TB programs because of an historical reliance on directly observed therapy (DOT) (6). DSD provides opportunities to improve health outcomes and reduce the burden of seeking care for people diagnosed with TB.
214487723|NCT06886191|DEVICE|RenalGuard Therapy|Fluid management system, which weighs urine and controls intravenous administration of crystalloid solution.
214487724|NCT06887894|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy, plaque histological analysis and miRNA expression
214971175|NCT05313724|OTHER|Mind-Body Online Therapy|There are 8 different modules (e.g. relaxation, mindfulness, stress management, disease management, nutrition and exercise behavior) with a mind-body focus available for the patients to independently (time, location) work on.
214971176|NCT03087864|DRUG|Atezolizumab|Atezolizumab 1200 mg i.v. day 1-22-43-64-85
214971177|NCT03087864|DRUG|Carboplatin|Chemotherapy
214971178|NCT03087864|DRUG|Paclitaxel|Chemotherapy
214971179|NCT03087864|RADIATION|Radiotherapy 23 x 1.8 Gy|Radiotherapy
214971180|NCT06076785|DEVICE|OdySight|At home measurements of visual acuity through a mobile app.
214971181|NCT02136537|DEVICE|Bilateral NMES legs|Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
214971182|NCT02136537|OTHER|Best medical therapy|Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
214971183|NCT04742673|DRUG|Guanfacine|Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
214971184|NCT04742673|DRUG|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
214971185|NCT05485311|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
214971186|NCT02327234|DRUG|ibuprofen|2x 200mg ibuprofen, single dose, blinded in 00 capsules
214971187|NCT02327234|DRUG|Placebo|lactose filled 00 capsules to match appearance of ibuprofen intervention
214359221|NCT00115115|DRUG|Dopamine infusion to brain dead organ donors|Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
214359222|NCT01761097|DEVICE|Endocuff attachment|Endocuff
214359223|NCT05789043|DRUG|camrelizumab+apatinib+TMZ|camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
214359224|NCT05789043|DRUG|camrelizumab+apatinib|camrelizumab 200mg，q2w+apatinib 250mg qd
214359225|NCT05789043|DRUG|camrelizumab|camrelizumab 200mg，q2w
214359226|NCT03030222|DRUG|Empagliflozin 10 mg Tab|Empagliflozin 10 mg Tab
214359227|NCT03030222|DRUG|Placebo Oral Tablet|Empagliflozin matching placebo
214359228|NCT04231812|DEVICE|Laparoscopic Tissue Morcellation working space (bag)|"The LapBox is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy"
214359229|NCT00325611|BEHAVIORAL|Multidisciplinary palliative care team met with patient|
214487725|NCT06737445|PROCEDURE|Radiofrequency ablation alone|RTL was performed as a single session using the radiofrequency ablation device (NeuroTherm JK4A; NeuroTherm Ltd, Croydon, London, England).
214487726|NCT06737445|PROCEDURE|Cortisone Injection|An injection of 1 ml of betamethasone 40 mg/ml and 2 ml of bupivacaine 5 mg/ml was performed.
214971188|NCT02114021|DRUG|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
214971189|NCT02114021|DRUG|lidocaine jelly|the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
214971190|NCT02114021|DRUG|distilled water|The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
214971191|NCT04552197|DRUG|JNJ-64251330|JNJ-64251330 tablet will be administered orally.
214971192|NCT04552197|DRUG|Tofacitinib|Tofacitinib tablets will be administered orally.
214359230|NCT05060328|OTHER|Medical Device Usage and Evaluation|"Use Google Translate Conversation Mode translation application."
214359231|NCT05060328|OTHER|Survey Administration|Complete survey
214359232|NCT02806375|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
214359233|NCT02806375|DRUG|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
214359234|NCT02806375|DRUG|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
214971193|NCT02151721|DRUG|Vorinostat, gefitinib|Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
214971194|NCT03668106|PROCEDURE|sperm processing method|different sperm processing method for selcting most proper sperm for ICSI
214971195|NCT01613924|DEVICE|Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
214359235|NCT02806375|DRUG|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
214971196|NCT01613924|DEVICE|Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
215083361|NCT03752268|BEHAVIORAL|Enhancing Cancer Pain Management|Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
215083362|NCT04796688|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
215083363|NCT03029078|DRUG|fecal microbiota transplant|We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
214359236|NCT02806375|DRUG|Ruxolitinib|Days -8 through -2 15 mg tid
214359237|NCT02806375|DRUG|Ruxolitinib|Days +5 through +100: 7.5 mg bid
215083364|NCT02606435|PROCEDURE|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
214487727|NCT06737445|OTHER|Extracorporeal shock wave therapy|Patients underwent 3 ESWT sessions applied to the plantar heel area, once a week with the same ESWT dose (15 Hz, 2000 pulse, 4.0 bar energy density) using a BTL-5000 SWT device (BTL Industries, USA).
214487728|NCT06737289|PROCEDURE|Surgical Guide|Placing extralarge implats for rahabilitation atrophic maxilla
214359238|NCT03479320|DRUG|Lidocaine|Postoperative analgesic effects will be compared between lidocaine and normal saline group
214359239|NCT03479320|DRUG|Placebo|Postoperative anlagesic requirements will be calculated and compared with experimental group
214359240|NCT03088826|DRUG|Morphine Sulfate|15mg PO morphine sulfate
214359241|NCT03088826|DRUG|Oxycodone|10mg Oxycodone
214487729|NCT06739876|BEHAVIORAL|Wearable device-based intervention (with motivational support via social media)|The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity. Motivational support will be provided via an online community created using LINE platform. The platform serve for the following purposes: a) providing psychoeduation prior to the intervention; b) providing a place for participants to motivate and encourage each other; c) provide health knowledge to participants weekly, to motivate behavioral change; d) encouraging participants to upload their daily step count to the community page to motivate each other's progress; e) based on participant's performance, research assistants will provide tailored support using Line stickers designed for the present intervention; f) research assistants will monitor participants' step counts and provide prizes (vouchers) for those who had the most step counts and made the most improvements.
214487730|NCT06739876|BEHAVIORAL|Wearable device-based intervention (without support)|The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity.
214487731|NCT06741241|BEHAVIORAL|eHealth Promotora|Intervention participants attend an eHealth promotora-delivered educational session. Activities include an icebreaker, the completion of a baseline survey, an introduction to cervical cancer using a video and slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore possible barriers and solutions to health care access. Main topics included in the slide presentation are: female anatomy; cervical cancer etiology and disease progression by stage; cancer prevention including diet, exercise, safe sex, cancer screening; human papillomavirus (HPV) vaccine recommendations; Pap test preparations, procedure, screening interval; and information about where to receive a Pap test and seek more information about cervical cancer.
214359242|NCT03088826|DRUG|Acetaminophen|650 mg Acetaminophen
214359243|NCT03973008|RADIATION|Adjuvant Chemoradiotherapy|DT 45Gy/25F/5W, using IMRT technology, synchronous tegio single drug chemotherapy
214359244|NCT03973008|DRUG|Adjuvant Chemotherapy|Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days
214971197|NCT01879293|DRUG|Metformin|
214971198|NCT01879293|DRUG|placebo|
214971199|NCT05799846|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention
214971200|NCT05799846|BEHAVIORAL|PREVENT Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on preventing future negative consequences of obesity
215083365|NCT02606435|DEVICE|thrombus aspiration|thrombus aspiration with export catheter
215083366|NCT01618383|OTHER|colonoscopy or rectosigmoidoscopy|Usual procedure
215083367|NCT02032693|DIETARY_SUPPLEMENT|Everycell™|
215083368|NCT02032693|OTHER|Placebo|
214359245|NCT06109987|OTHER|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
214359246|NCT03282318|DRUG|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
214359247|NCT03282318|DRUG|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
214359248|NCT05934513|DRUG|GFH009|patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
214359249|NCT03058588|GENETIC|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
214971201|NCT05799846|BEHAVIORAL|PROMOTE Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on promoting future benefits of maintaining a healthy weight
214359250|NCT04556578|PROCEDURE|High-flow extracorporeal CO2 removal|Applying of a CO2 removal using an extracorporeal circulation with a flow of 2-3.5L/min in order to reduce the aggression induced by the mechanical ventilation.
214359251|NCT06052410|OTHER|Early Intervention|Based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children at risk of developmental delay between 24-36 months, activity-based training is aimed at the development of sensory and cognitive skills in addition to the training of motor skills, which are intensively discussed in the content of the approach. Individualized early occupational therapy intervention including strategies was implemented.
214487732|NCT06741241|BEHAVIORAL|eHealth Healthy Nutrition|Control group participants attend an eHealth educational session on healthy nutrition. Activities include an icebreaker, the completion of a baseline survey, an introduction to healthy eating using a video and a slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore benefits and challenges to healthy eating.
214971202|NCT04222816|DRUG|Lithium Carbonate|Lithium carbonate 800-900 mg orally daily for 12 weeks
214487733|NCT06737549|DRUG|Nerver growth factor (NGF) injection|The 20ug mouse nerve growth factor (NO. S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd., Wuhan, China. mNGF will be dissolved in 2 ml of sterile water for injection and then injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
214487734|NCT06737549|DRUG|Placebo injection|Patients will receive 2ml volume of physiological saline (PS) injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
214487735|NCT06737549|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of patient can tolerate, targeting a current strength of 3.0mA, for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks."
214487736|NCT06737549|DEVICE|Acupuncture intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are connected to an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) without closed circuit, with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks."
214971203|NCT04222816|DRUG|Sodium chloride|Sodium chloride 1gm daily per orally for 12 weeks
214487737|NCT06739343|PROCEDURE|PHACO-Trabeculectomy|Phaco-Trabeculectomy is a combined surgical procedure that integrates phacoemulsification, a modern cataract extraction technique using ultrasound, with trabeculectomy, a glaucoma filtration surgery. This intervention is distinguished by its precision, minimal incision size, and suitability for patients with coexisting cataract and glaucoma. Phacoemulsification efficiently emulsifies and aspirates the cataract through a small incision, while trabeculectomy creates a filtration bleb to lower intraocular pressure (IOP). This combination allows for simultaneous management of both conditions, particularly in cases where phacoemulsification is preferred for cataract extraction.
214971204|NCT03286764|OTHER|Peppermint Oil|
214971205|NCT03286764|OTHER|Distilled water|Distilled water spray as a placebo during Colonoscopy
214971206|NCT01900444|BIOLOGICAL|IMOJEV|0.5 mL, Subcutaneous
215083369|NCT03289221|DIAGNOSTIC_TEST|Anal Manometry|"A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.~Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry."
215083370|NCT06078111|BEHAVIORAL|Prism 10 + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with 10 degrees of visual field deviation
214971207|NCT05033626|PROCEDURE|Simultaneous thyroidectomy and hyoid suspension|Under endotracheal anesthesia, a horizontal skin incision up to 50 mm long is made at the level of the upper thyroid cartilage, the skin and subcutaneous fat are dissected. The sternohyoid and sternothyroid muscles are retracted. An audit of the thyroid gland is performed. Step by step, using the ultrasonic dissector, the sections of the gland necessary for resection are separated, ligated and transected. Using microsurgical techniques, neurolysis of the recurrent laryngeal nerves is performed. The quality control of the return of the laryngeal nerves is ensured to the required extent using the neuromonitoring apparatus.
214971208|NCT05033626|PROCEDURE|Thyroidectomy|The hyoid bone is mobilized in the anterocaudal direction and is fixed to the thyroid cartilage with four permanent non-absorbable sutures. If sufficient mobilization does not occur during the operation, the tendon of the stylohyoid muscle is dissected. Surgical drainage is installed 24 hours after surgery.
214971209|NCT00096213|PROCEDURE|conventional surgery|surgery
215083371|NCT06078111|BEHAVIORAL|Neutral Prism + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with no visual field deviation
215083372|NCT00723346|BIOLOGICAL|GRASPA|50 UI/Kg
215083373|NCT00723346|BIOLOGICAL|GRASPA|100 UI/Kg
215083374|NCT00723346|BIOLOGICAL|GRASPA|150 UI/Kg
215083375|NCT00723346|DRUG|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
215083376|NCT00940095|DRUG|Clazosentan 5 m/h|Continuous intravenous infusion of clazosentan (5 mg/h)
215083377|NCT00940095|DRUG|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
215083378|NCT00940095|DRUG|Placebo|Continuous intravenous infusion of placebo-matching clazosentan
214359252|NCT06052410|OTHER|Home Programme|For the control group, evaluation tests were first applied to the babies selected by simple random sampling method. An individualized home program was given according to the evaluation results. Home programs include activities for every skill area and were prepared together with the parents, taking into account the criteria suggested for the success of the home program. Based on these criteria, it was checked whether the family had received another home program, and while preparing the program, care was taken not to overload the parents, importance was given to the family's willingness to receive the home program, activities and goals were decided in cooperation with the parent, thus facilitating the applicability of the activities in daily life, ensuring that the number of activities was 6. Care was taken to ensure that the activity was not too much, the parent was given the necessary time to implement the program, and a phone call was made to the parent every 3 weeks.
214359253|NCT05101239|DEVICE|MRI imaging exam|3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)
214359254|NCT04365660|DRUG|18-F FTC 146|Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
214359255|NCT04259268|OTHER|Quality of preoperative information register|Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)
214359256|NCT04259268|OTHER|Suitability of information contained in the informed consent|Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)
214487738|NCT06739343|PROCEDURE|MSICS-Trabeculectomy|Manual Small Incision Cataract Surgery (MSICS) with Trabeculectomy is a cost-effective, combined surgical approach involving a manual technique for cataract removal alongside glaucoma filtration surgery. MSICS utilizes a larger incision than phacoemulsification, allowing for the manual extraction of the cataract nucleus. This procedure is particularly advantageous in resource-limited settings where phacoemulsification equipment may not be available. The trabeculectomy component is the same as in the PHACO-Trabeculectomy intervention, providing effective IOP reduction through the creation of a filtration bleb.
214487739|NCT06040359|OTHER|The Thriving Mamas programme|Enhanced antenatal course plus usual perinatal care
214487740|NCT06040359|OTHER|Usual care|Usual perinatal care
214971210|NCT01726166|PROCEDURE|Suprapubic Aspiration|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
214971211|NCT01726166|PROCEDURE|Urinary Catheterization|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
214971212|NCT03423043|RADIATION|Low Dose CT Scan of the Wrist|A low dose CT scan will be obtained in patients with a distal radius fracture of the wrist.
214971213|NCT03434639|DIAGNOSTIC_TEST|Spectroscopic gut permeability test|"The spectroscopic gut permeability test first involves patients receiving an oral dose of one or more fluorescent dyes. A wearable sensor will then be attached to the patients' skin and this will be used to monitor the leakage of the fluorescent dyes from the intestine into the blood stream in a non-invasive manner. In this way, a measure of the permeability of the intestine will be obtained.~Note that patients in Group 1 (ophthalmology patients) will not receive oral doses of contrast agents. Instead, the wearable sensor will simply be used to detect the presence of fluorescent dyes that were administered intravenously as part of planned ophthalmic procedures.~Complete details of the spectroscopic gut permeability test can be found in the attached protocol."
214971214|NCT05606601|BEHAVIORAL|Minder|"There are four main components of the Minder app: The Chatbot, Services, Community, and Peer Coaching components. The Services component asks participants to complete a series of questions on various mental health, substance use, and general life issues. It then recommends community and on-campus resources based on their current needs. The Community component of the app matches individuals with groups (e.g., student clubs) and events at the university or in the broader community that they may be interested in. The Chatbot component of the app contains pre-formatted conversational scripts that users engage with via a chatbot and videos designed to teach evidence-based skills (e.g., cognitive strategies to manage anxiety) that can be applied to everyday life. To support use of the app, all users in the intervention group will be offered access to trained peer coaches to help users navigate the different app components and provide non-clinical peer support."
214971215|NCT05509361|BIOLOGICAL|AK101 injection SC|AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.
214971216|NCT04074265|DRUG|Ropivacaine injection|Injection containing a mix of the above medications will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
214971217|NCT04074265|DRUG|normal saline|Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
214971218|NCT02991365|OTHER|nasal insulin|
214971219|NCT02991365|OTHER|placebo spray|
214971220|NCT02233530|BEHAVIORAL|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
215083379|NCT04124458|DEVICE|Radiofrequency ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
214359257|NCT00497302|BEHAVIORAL|RBT|Contingency management and behavioral counseling including motivational interviewing
214359258|NCT00497302|BEHAVIORAL|usual care|receives usual comprehensive care at Center for Addiction and Pregnancy
214359259|NCT00734227|PROCEDURE|Emergency portacaval shunt|
214359260|NCT00734227|OTHER|Emergency TIPS|
215083380|NCT04975737|BIOLOGICAL|GamTBvac|The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)
215083381|NCT04975737|BIOLOGICAL|Placebo|Placebo for subcutaneous administration
215083382|NCT00061074|DRUG|Nicotrol|
215083383|NCT01740479|PROCEDURE|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
215083384|NCT00701142|BIOLOGICAL|Haemocomplettan® P|Single intravenous infusion
215083385|NCT00701142|BIOLOGICAL|Saline solution|Single intravenous infusion
214359261|NCT03013114|DRUG|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
214359262|NCT02118220|OTHER|Concussion Questionnaire|
214359263|NCT04994457|DEVICE|Virtual Reality Visual Field|A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses
214359264|NCT04994457|DIAGNOSTIC_TEST|Standard Automated Perimetry|Standard of care perimeter
214359265|NCT04659655|PROCEDURE|automated annular suturing|RAM® Automated Suturing Technology. The RAM® DEVICE and SEW-EASY® DEVICE are automated suturing devices indicated for use in the approximation of soft tissue and prosthetic materials when used in conjunction with RAM® COR-SUTURE® QUICK LOAD® surgical suture. Devices will be used for the approximation of respective replacement valves during surgical aortic or mitral valve replacement as described in the study protocol. Cases may include use of the RAM® RING/RAM® RACK devices for suture management and the Aortic Root Retractor (ARR) with delivery device.
214359266|NCT03584451|BEHAVIORAL|rehabilitation sport|rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
214359267|NCT03306212|DRUG|Botulinum toxin A|
214359268|NCT03306212|OTHER|Occupational Therapy|
214359269|NCT03306212|OTHER|Intermittent serial casting|
214359270|NCT03694639|OTHER|ganglion impar block|CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected
214971221|NCT03744442|PROCEDURE|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
214971222|NCT03744442|PROCEDURE|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
214971223|NCT03744442|PROCEDURE|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
214971224|NCT03694379|OTHER|Apneic oxygenation during endotracheal intubation|Providing oxygenation through nasal cannula during the apneic phase of endotracheal intubation.
214971225|NCT00072384|DRUG|liposomal vincristine sulfate|Given IV
214971226|NCT00072384|PROCEDURE|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
214971227|NCT00072384|PROCEDURE|laser surgery|Surgery using a laser (instead of a scalpel) to cut tissue
214971228|NCT00072384|DRUG|carboplatin|Given IV
214971229|NCT00072384|DRUG|etoposide|Given IV
214971230|NCT00072384|BIOLOGICAL|filgrastim|Given subcutaneously
214971231|NCT01825200|BIOLOGICAL|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
214971232|NCT01825200|BIOLOGICAL|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
214971233|NCT01558934|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
214971234|NCT04507152|OTHER|Blood flow restriction resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The experimental group will execute the training with blood flow restriction.
214971235|NCT04507152|OTHER|Resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The control group will execute the training without blood flow restriction.
214971236|NCT01207947|DRUG|Vardenafil (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
214971237|NCT00065299|BEHAVIORAL|Restricted phenylalanine diet|
214971238|NCT06402019|DRUG|Dexmedetomidine in 0.9 % NaCl 20 Mcg/5 mL (4 Mcg/mL) INTRAVEN SYRINGE (ML)|Group went under multiple sessions of Dexmedetomidine infusion for 10 sessions; The infusion was provided under non-invasive monitoring for heart rate (HR) and mean arterial pressure (MAP). The infusion rate was adjusted to maintain HR in range of 60-80 beats/min and MAP in range of 65-75 mmHg.
214971239|NCT06402019|DRUG|normal saline|Group went under multiple sessions of normal saline injection.
214971240|NCT02810782|DRUG|Phenobarbital|Phenobarbital per os
214971241|NCT02810782|DRUG|Chlorpromazine|Chlorpromazine per os
214971242|NCT02810782|DRUG|Morphine|Morphine per os
214971243|NCT03460041|DRUG|Magnesium Sulfate|caudal magnesium sulphate added to bupivacaine for pain management
214971244|NCT03460041|DRUG|Dexmetedomedine|Caudal dexmetedomedine added to bupivacaine for pain management
214971245|NCT03460041|DRUG|Bupivacaine|Caudal bupivacaine for pain management
214679204|NCT05348187|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|The primary objective is to utilize a clinical trial assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 2 of Amgen clinical trial, in order to identify patients (with NSCLC and CRC) with KRAS G12C mutation positive tumors
214679205|NCT03313505|BIOLOGICAL|S100B protein dosage|S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
214971246|NCT00490035|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
214971247|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
214971248|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
214971249|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
214971250|NCT05862935|OTHER|Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2|20-30 min/session, 3 times/week for 4 weeks. After a 5-min warm-up, participants perform a moderate-intensity functional training program. This program is designed in circuit mode consisting of 6 global functional exercises: i) sit and stand, ii) forward lunges, iii) chest press, iv) high row, v) lateral shoulder raises and vi) heel raises. Participants must complete the highest number of repetitions and/or rounds as possible (AMRAP) in 15-min without a designated rest.
214971251|NCT05862935|OTHER|Supervised Physical Activity: Phase 1|40-60 min/session, 3 times/week for 12 weeks. After a 5-min warm-up, participants performed 6 global functional exercises: i) sit-to-stand; ii) chest press, iii) forward lunges; iv) unilateral shoulder raises; v) unilateral row; and vi) heel raises. The initial volume is 2 sets and 8 repetitions and it will progressively increase until 3 sets and 12 repetitions.
214971252|NCT06295432|DRUG|DZD9008+AZD4205|Daily dose of DZD9008+AZD4205 until intolerant, disease progression or patient decision. Starting dose of DZD9008 is 200mg once daily and starting dose of AZD4205 is 75mg once daily orally used. If tolerated, subsequent cohorts will evaluate increasing doses of the combination therapy.
214971253|NCT03519009|BEHAVIORAL|IPS Plus Abstinence-Contingent Wage Supplement|Participants are offered abstinence-contingent wage supplements if they obtain and maintain competitive employment. The wage supplements are designed to promote employment while reinforcing drug abstinence. To help participants obtain and maintain competitive employment, participants will receive Individual Placement and Support (IPS) supported employment. IPS is a supported employment intervention that has been proven effective in promoting employment in adults with severe mental illness. To promote employment and prevent relapse to drug use, participants will receive IPS Plus Abstinence-Contingent Wage Supplements.
214971254|NCT06058390|DRUG|Bepirovirsen|Bepirovirsen will be administered.
214971255|NCT02065180|DIETARY_SUPPLEMENT|commercially available nutrition supplement|the food supplement contains red rice yeast and olive extract
214971256|NCT02065180|DIETARY_SUPPLEMENT|placebo|
214971257|NCT05686577|OTHER|no intervention|no intervention
214971258|NCT03877744|BEHAVIORAL|interactive virtual presence|parents will install car seat through remote guidance via interactive virtual presence
214971259|NCT03877744|BEHAVIORAL|live technician|parents will install car seat through guidance from a live certified technician who is present
214971260|NCT04818073|DEVICE|New FINGER|New FINGER exoskeleton is a robotic device that can provide assistance and resistance to thumb and finger movement
214971261|NCT02509377|PROCEDURE|Open Fetal Repair of Myelomeningocele|Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
214971262|NCT04577508|BEHAVIORAL|Functional Remediation|Functional Remediation is a manualized, group-based psychosocial intervention built on a neurocognitive-behavioural approach, involving modeling techniques, role-playing tasks, self-instruction, positive reinforcement and metacognitive cues (Vieta E et al, Cambridge University Press, 2014). It consists of 21 90-min weekly sessions, in which a trained therapist and co-therapist work with 10-12 patients: the first 3 sessions are dedicated to psychoeducation on neurocognitive deficits; then 13 sessions of neurocognitive training sequentially target attention, memory and executive functions domains, comprising exercises carried out individually, in pairs or in small groups; the last 5 sessions focus on skills training (communication, interpersonal relationships, autonomy, stress management). Content of the sessions involves ecological tasks adapted to real-world situations, and to-be-performed in two contexts (clinical and daily). Homework is assigned, collected and discussed each time.
214971263|NCT04577508|OTHER|Treatment as usual|Standard care for bipolar disorders according to good clinical practice, including drug therapy and individual case management.
215083386|NCT03114436|OTHER|Observational Data Collection|All aspects of deceased donor care in the ICU.
214679206|NCT03313505|OTHER|Brain CT scan|No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
214971264|NCT06556173|DRUG|VTX3232|Dose A
214971265|NCT03836027|OTHER|No intervention|No intervention
214971266|NCT01439113|PROCEDURE|Ultrasound guided IV placement|The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
214971267|NCT04334759|DRUG|Durvalumab|Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks
214971268|NCT04334759|DRUG|Standard Chemotherapy|Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation
214679207|NCT02298270|BEHAVIORAL|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
214679208|NCT03735095|DRUG|Porfimer Sodium|Given IV
214971269|NCT04334759|DRUG|Ipilimumab and Nivolumab|Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years
214971270|NCT03301402|DEVICE|Air purifier|Air purifier with filter at automatic mode on all time
214971271|NCT03413514|DRUG|NACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0\<n\<8)
215083387|NCT05325216|PROCEDURE|POPRC+OIN|Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
215083388|NCT05325216|PROCEDURE|SRC+OIN|Standard radical cystectomy with orthotopic ileal neobladder
215083389|NCT00033540|DRUG|capecitabine|650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
215083390|NCT00033540|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
215083391|NCT03897946|BIOLOGICAL|Birth dose hepatitis B vaccine|Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
215083392|NCT03366103|BIOLOGICAL|Navitoclax|Given PO
215083393|NCT03366103|DRUG|Vistusertib|Given PO
215083394|NCT01110837|OTHER|Allergen|Allergen nasal challenge
215083395|NCT01110837|OTHER|Placebo challenge|Placebo nasal challenge
215083396|NCT03670329|DEVICE|URGO2875|Dressing
214359271|NCT04464928|OTHER|Facebook Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Facebook Ads when triggered by user characteristics indicating elevated risk of female urinary incontinence.
215083397|NCT04231214|DRUG|Olodaterol-Tiotropium|5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
215083398|NCT01036529|DEVICE|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
215083399|NCT01036529|PROCEDURE|Back Surgery|Different types of back surgery may be performed
215083400|NCT01497821|DRUG|AMG 172|AMG 172 is an antibody drug conjugate
215083401|NCT01340781|PROCEDURE|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
215083402|NCT00456976|DRUG|Selegiline|
215083403|NCT03696082|BEHAVIORAL|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
215083404|NCT03696082|BEHAVIORAL|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
214359272|NCT04464928|OTHER|Google Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Google Ads when triggered by keywords relevant to female urinary incontinence.
214359273|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 20 µg/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 µg/1.0 mL
214359274|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 40 µg/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 µg/1.0 mL
214971272|NCT03413514|PROCEDURE|SDM|Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making
214971273|NCT03413514|PROCEDURE|Surgery|Radical surgery with D2 lymph node dissection
214971274|NCT03413514|DRUG|ACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0\<n\<8)
214359275|NCT00313404|BIOLOGICAL|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
214359276|NCT05175755|OTHER|Patients|The procedure involves taking a total of 12 ml of blood.
214359277|NCT00435604|DRUG|Hylenex|
214359278|NCT04408573|OTHER|Cycling deep brain stimulation|Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF
214971275|NCT03413514|OTHER|Questionnaire|MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy
214359279|NCT06085248|DEVICE|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
215083405|NCT03696082|BEHAVIORAL|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
215083406|NCT03696082|BEHAVIORAL|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
215083407|NCT04287088|DIAGNOSTIC_TEST|A shared decision making|Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
215083408|NCT03653468|BEHAVIORAL|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
215083409|NCT00819494|PROCEDURE|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
215083410|NCT02595697|BEHAVIORAL|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
215083411|NCT00000916|DRUG|Indinavir sulfate|
215083412|NCT00000916|DRUG|Lamivudine/Zidovudine|
215083413|NCT00000916|DRUG|Hydroxyurea|
215083414|NCT00000916|DRUG|Lamivudine|
214971276|NCT04261140|OTHER|EQUIA Forte Fil|"Apply cavity conditioner (20% polyacrylic acid) 10 s on enamel and dentine, rinse Mix 10 s and apply bulk-fill Apply EQUIA coat and light cure for 20 s~unit"
214971277|NCT04261140|OTHER|Clearfil Majesty Esthetic|Apply in 2-mm increment, light cure for 20 s
214971278|NCT04261140|OTHER|NexComp Flow|Apply in 2-mm increment light cure for 20 s
214971279|NCT04261140|OTHER|3M Espe Bulk-fill|Apply in single increment up to 4 mm; light curing for 20 s
214971280|NCT05864950|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
214971281|NCT05257551|OTHER|Observation|No intervention
214971282|NCT06958289|DEVICE|Cryoneurolysis|Each participant will receive cryoneurolysis which involves the application of extreme cold directly to, or near targeted nerves under ultrasound guidance. This cold causes axonotmesis to occur, thereby completely preventing the treated nerve from propagating any signal. Cryoneurolysis produces an effect called Wallerian degeneration, where the treated nerve's axon is destroyed but the epineurium and perineurium are left intact. Therefore, the axon can regenerate, following the same path as prior to treatment.
214971283|NCT06958640|BEHAVIORAL|Lifestyle interventions|"Dietary intervention: 30kcal energy intake per kilogram of body weight per day, increase vegetable intake, control sugar and alcohol intake, encourage overweight and obese people to lose weight, lose 0.5-1kg per month until the weight reaches the target.~Exercise intervention: Appropriate physical activity in spare time, 30-40 minutes per day, 5 times a week."
214971284|NCT06095089|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
214971285|NCT06095089|DRUG|JNJ-87189401|JNJ-87189401 will be administered.
214971286|NCT06849466|DRUG|Dexmedetomidine|Dexmedetomidine Hydrochloride Nasal Spray Dexmedetomidine is a selective alpha-2 adrenergic agonist primarily used for its sedative, anxiolytic, and analgesic effects. It works by inhibiting the release of norepinephrine in the central nervous system, leading to sedation, decreased anxiety, and reduced pain sensitivity. When used intranasally, it can offer an effective, non-invasive method for sedating patients and improving sleep quality, particularly in perioperative settings.
214971287|NCT06849466|DRUG|Saline solution|The saline solution will be used as a placebo, and the same device will be employed for intranasal administration.
214971288|NCT04399369|DEVICE|SDF|38% silver diamine fluoride solution
214971289|NCT04399369|DEVICE|NaF|5% sodium fluoride varnish
214971290|NCT03456817|DRUG|Treatment Arm - high dose ATG|Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 \& -2, ATG will be infused after fludarabine \& busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 \& over at least 4 hrs on days -3, -2, -1 \& 0. Dose is based on actual body wt, \& rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in \>5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 \& 10 mg/m2 on days +3, +6 \& +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.
214971291|NCT03456817|DRUG|Control Arm - standard of care|The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
214971292|NCT06090357|OTHER|Plantar pressure|Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.
214971293|NCT03361306|DRUG|Elotuzumab|Experimental
215083415|NCT00000916|DRUG|Stavudine|
215083416|NCT00000916|DRUG|Zidovudine|
215083417|NCT00000916|DRUG|Didanosine|
214971294|NCT05498428|DRUG|Amivantamab|Amivantamab will be administered subcutaneously by manual injection.
215083418|NCT01945775|DRUG|talazoparib|Until progression or unacceptable toxicity develops
214359280|NCT06085248|BEHAVIORAL|Active walking|walking without RAS cue
214359281|NCT03234426|OTHER|Perturbation|Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
214359282|NCT03234426|OTHER|Conventional Physiotherapy Treatment|Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
214359283|NCT05153980|DEVICE|Warm-up + Blood Flow Restriction cuff (smart-cuff pro device, acting as pressurized tourniquet)|Blood Flow Restriction
214971295|NCT05498428|DRUG|Lazertinib|Lazertinib will be administered as an oral tablet.
214971296|NCT05498428|DRUG|Carboplatin|Carboplatin will be administrated by IV infusion.
215083419|NCT01945775|DRUG|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
215083420|NCT05482581|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,awareness of e-cigarettes sheet;,willingness to use e-cigarettes sheet, knowledge, attitudes and cognitions related to e-cigarettes sheet, awareness of new regulations on e-cigarette control sheet.
215083421|NCT04411537|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
214359284|NCT05153980|OTHER|Warm-up|Warm-up without any special intervention (no Blood Flow Restriction)
214359285|NCT03278418|PROCEDURE|Tricuspid Valve Repair|It will be performed according to the surgeon preference
214971297|NCT05498428|DRUG|Pemetrexed|Pemetrexed will be administered by IV infusion.
214971298|NCT05498428|DRUG|Direct Oral Anticoagulant (DOAC)|DOAC will be administered orally.
215083422|NCT04411537|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
214359286|NCT03278418|PROCEDURE|Left-sided valve surgery|It will be performed according to the surgeon preference
214359287|NCT03283904|OTHER|Multicomponent physical activity intervention|School-based multicomponent intervention
214359288|NCT00450411|RADIATION|125-Iodine|Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
214971299|NCT05498428|DRUG|Low Molecular Weight Heparin (LMWH)|LMWH will be administered subcutaneously.
214971300|NCT06962007|DRUG|Sugammadex 1 mg/kg Group|Participants receive 1 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
214971301|NCT06962007|DRUG|Sugammadex 2 mg/kg Group|Participants receive 2 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
214971302|NCT06962007|DRUG|Sugammadex 4 mg/kg Group|Participants receive 4 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
214971303|NCT06962007|DRUG|Pyridostigmine/Glycopyrrolate Group|Participants receive pyridostigmine 0.2 mg/kg and glycopyrrolate 0.01 mg/kg intravenously for reversal of rocuronium-induced neuromuscular blockade.
214971304|NCT05538871|DIAGNOSTIC_TEST|Survey + Physical exam|"Survey:~Demographic data Pain Oswestry disability index International Physical Activity Questionnaire Scoliosis Research Society (SRS-22r) Spinal appearance questionnaire Fear Avoidance and Beliefs Questionnaire Short Orebro musculoskeletal pain questionnaire Work Ability Index~Physical exam:~Repeated movements (MDT) Posture ROM Neuro Updated treatment based classification tests Pathoanatomical classification tests"
214971305|NCT05573451|DIAGNOSTIC_TEST|ultrasound - transvaginal/transrectal + transabdominal|Each patient undergoes at least ultrasound examination and PET-CT.
214971306|NCT06361537|DRUG|OCTA-C1-INH|OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
214971307|NCT06361537|OTHER|Placebo|0.1 mL/kg BW 0.9% sodium chloride injection
214971308|NCT05240014|DEVICE|Modular powered orthosis|This study will investigate modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. The central hypothesis is that high-torque, low-inertia motor systems controlled with energetic objectives will enable modular powered orthoses to partially assist the joints. High-torque electric motors combined with minimal transmissions can be freely rotated (i.e., backdriven) by human joints, allowing the use of an emerging torque control method called energy shaping to reduce the perceived weight/inertia of the body during any motion. By mounting these modular actuators to commercial orthoses, this technology will be easily prescribed/configured by clinicians.
214971309|NCT06438744|PROCEDURE|Thread embedding acupuncture (TEA) + standard therapy|"* TEA : one-time TEA using 30 gauge TEA needle with 30 mm polydioxanone thread at CV3 through CV4, SP6 and ST36 bilaterally~* Standard therapy : 2 mg dienogest daily for 8 weeks after TEA"
214971310|NCT05542199|OTHER|Multicomponent nutrition supplement (MCNS)|Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
214971311|NCT05542199|BEHAVIORAL|Behavioral weight loss program|Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
214971312|NCT04758806|BIOLOGICAL|Fecal microbial transplantation|Procured faeces procured from unrelated donor
214971313|NCT02532335|DRUG|Obeticholic acid|active drug
214971314|NCT02532335|DRUG|Obeticholic acid placebo|matching placebo
214679209|NCT03735095|PROCEDURE|Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy|Undergo EBUS-TBN guided I-PDT
214679210|NCT05346393|PROCEDURE|TIPS|A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver
214971315|NCT03437694|OTHER|Medication optimization intervention|Pharmacists will engage participants in medication therapy management either with access to the medical records (intervention) or without access (control).
214971316|NCT06187337|DEVICE|Maxillary expansion device|The maxillary expansion device is a orthodontic appliance that is used to expand the maxilla in children.
214971318|NCT02871609|OTHER|Stent examination, urinary analysis, USSQ questionnaire|
214971319|NCT05688215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214971320|NCT05688215|PROCEDURE|Computed Tomography|Undergo a CT scan
214971321|NCT05688215|PROCEDURE|Core Biopsy|Undergo core biopsy
214971322|NCT05688215|DRUG|Fluorouracil|Given IV
214359289|NCT00450411|RADIATION|103-palladium|Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
214359290|NCT00688818|DRUG|Quetiapine|Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
214359291|NCT00688818|DRUG|Placebo|Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
214971323|NCT05688215|DRUG|Irinotecan|Given IV
214971324|NCT05688215|DRUG|Leucovorin|Given IV
214971325|NCT05688215|DRUG|Leucovorin Calcium|Given IV
214487741|NCT06793176|DIAGNOSTIC_TEST|Video capture|A 20-second video capture of head-neck movements at high frame rates is conducted for all participants to obtain high-resolution images. The captured videos are analyzed using an algorithm based on Vibraimage technology to infer whether the participants have depression.
214487742|NCT06736184|DRUG|Sodium Zirconium Cyclosilicate (SZC)|5g/meal\*3meals/day
214487743|NCT06735118|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy
214487744|NCT06735430|DRUG|Ciprofol|Ciprofol for anesthesia induction (0.5mg / kg) and anesthesia maintenance (1-2.5mg/ (kg·h))
214487745|NCT06735430|DRUG|Propofol|Propofol for anesthesia induction (2mg / kg) and maintenance of anesthesia (4-10 mg / (kg·h))
214359292|NCT00912548|DRUG|goserelin|"1. Zoladex™ administration:~   Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~2. Sequence of administration Zoladex depot:~   The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~3. Dosage:~   Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~4. Storage instructions for Zoladex™ Zoladex™ is kept a room temperature."
214359293|NCT00912548|DRUG|tamoxifen|"1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light."
214359294|NCT03249519|RADIATION|Radiation|50.4 Gy
214359295|NCT03249519|RADIATION|brachytherapy|35-40 Gy
214359296|NCT03249519|DRUG|Cisplatin|weekly 40 mg/m\^2 (6cycles)
214359297|NCT03249519|OTHER|Hyperthermia|10 times
214487746|NCT07039851|OTHER|Experimental|"Each session in the experimental group includes four phases:~1. Warm-up (10 min): Students engage in ice-breakers and movement activities to relax and prepare mentally and physically.~2. Games \& Activities (30 min): Drama and game-based tasks related to nature and recycling promote experiential learning and teamwork.~3. Improvisation (30 min): Students take part in role-plays and skits (e.g., acting as a tree or a recycled item) to build empathy and deepen their connection to environmental themes.~4. Evaluation (20 min): Students reflect on their learning, share feelings, and receive feedback. Facilitators summarize key points and reinforce the session's goals."
214359298|NCT02430194|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
214359299|NCT02430194|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
214359300|NCT02430194|DRUG|Pegylated interferon-alfa-2a|immunomodulator
214487747|NCT06892431|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome Injection 20mg/m2, or 16mg/m2, intravenous drip, Q4W.
214487748|NCT06892431|DRUG|JMT101 injection|JMT101 Injection 6 mg/kg, intravenous drip,
214487749|NCT06892431|DRUG|Capecitabine|The dosage of capecitabine is 1000 mg/m2, taken orally twice daily, administered on D1-14 (Days 1-14) of each cycle, with every 3 weeks as one cycle (Q3W);
214971326|NCT05688215|DRUG|Oxaliplatin|Given IV
214487750|NCT06892431|DRUG|Docetaxel injection|The dosage of docetaxel is 75 mg/m2, administered via intravenous drip on D1 of each cycle, Q3W.
214487751|NCT06892431|DRUG|Gemcitabine hydrochloride for injection|The dosage of gemcitabine is 1000 mg/m2, administered via intravenous drip on D1 and D8 (Day 1 and Day 8) of each cycle, Q3W;
214487752|NCT06891404|OTHER|Nurse-Led Health Belief Model-Based Education|"Topic of the Training:~Importance of Genital Hygiene Behaviors Definition of Urinary Tract Infection (UTI) Complications that may arise if left untreated Effects on daily life Proper toilet hygiene Selection and cleaning of underwear Menstrual hygiene Importance of sexual hygiene Common Misconceptions About Genital Hygiene Behaviors"
214971327|NCT05688215|DRUG|Quemliclustat|Given intravenously (IV)
214971328|NCT05688215|DRUG|Zimberelimab|Given IV
214971329|NCT00333489|DRUG|valsartan|
215083423|NCT04411537|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
214359301|NCT02137369|DRUG|Selective serotonin re-uptake inhibitor|Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks
214359302|NCT02137369|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
214487753|NCT06744790|DEVICE|Linshom Continuous Predictive Respiratory Monitoring|Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
214487754|NCT06739863|OTHER|healthcare waste management|"To evaluate and compare the healthcare waste management practices in primary and secondary hospital Mianwali.~Focuses on assessing the current methods of waste disposal, segregation, treatment, and overall management in healthcare settings at two different levels of care: primary and secondary hospitals."
214487755|NCT06893874|OTHER|Preventive migraine treatment|Participants will be observed while receiving treatment-as-usual for their migraine by their treating physician
214487756|NCT05795881|OTHER|Cyclic daytime enteral nutrition|The allocated feeding schedule is followed from the start of enteral nutrition after ICU admission until discharge from the ICU.
214971330|NCT04817332|DRUG|Brensocatib|Selective, competitive, and reversible inhibitor of DPP1
214971331|NCT04817332|DRUG|Placebo|Matched placebo
214359303|NCT02137369|OTHER|Combination treatment (SSRI + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
214359304|NCT03105310|DRUG|Pegylated interferon alfa|Pegylated interferon alfa
214359305|NCT03105310|DRUG|Ezetimibe|Ezetimibe
214359306|NCT00781976|DRUG|AZD7295|700mg per day maximum
214359307|NCT00781976|DRUG|Placebo|matched placebo
214359308|NCT03298646|DRUG|Lidocaine Hydrochloride|10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
214359309|NCT03298646|DRUG|Diclofenac|100 mg Diclofenac oral tablet one hour before the procedure.
214971332|NCT05200273|DRUG|AK114|AK114 administered by subcutaneous injection
214971333|NCT04390646|DRUG|GnRH, gonadorelin acetate|Drug administered by a subcutaneous pump
214971334|NCT04390646|DRUG|0.9% NaCl|Drug administered by a subcutaneous pump
215083424|NCT04411537|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
215083425|NCT05837949|BEHAVIORAL|MS FIT: Falls Insight Track|Participants will respond to a set of surveys every two weeks to increase communication on falls with their clinician.
215083426|NCT00002239|DRUG|Enfuvirtide|
215083427|NCT00002239|DRUG|Ritonavir|
215083428|NCT00002239|DRUG|Abacavir sulfate|
215083429|NCT00002239|DRUG|Amprenavir|
215083430|NCT00002239|DRUG|Efavirenz|
215083431|NCT05315375|DEVICE|corpectomy|vertebral corpectomy using expandable cage
215083432|NCT02066506|OTHER|asymptomatic group|2 visits with MRI
215083433|NCT02066506|OTHER|symptomatic group|2 visits with MRI
214487757|NCT06798428|DEVICE|group A will receive ultrasound phonophoresis (Glucosamine, Chondroitin and Some Herbs Extract )|Group (A)will have GL, CH and natural herbs phonophoresis .Ultrasound parameters are 1 W/cm for intensity, 1 MHz for frequency and 5 min continuous mode then 5 min pulsed mode. The device that will be used is medserve, England (the head of the device is 5cm).
214971335|NCT03307928|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test Protocol|The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.
214971336|NCT03307928|DIAGNOSTIC_TEST|Polysomnography Assessment|The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
214971337|NCT00203515|DEVICE|Standard Latex Foley Catheter|
214971338|NCT00203515|DEVICE|Silver Coated Latex Foley Catheter|
214971339|NCT04987866|DEVICE|vibration device , Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China|The vibration device is a reusable, handheld device with a battery-powered motor and a vibration frequency of approximately 6000 times per minute (Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China)
214971340|NCT01368263|DRUG|goserelin acetate|Given SC
214971341|NCT01368263|DRUG|letrozole|Given PO
214971342|NCT01368263|DRUG|anastrozole|Given PO
214487758|NCT06798428|DEVICE|Group B will receive ultrasound with topical gel , same parameter as group A|Ultrasound parameters are 1 W/cm for intensity, 1 MHz for frequency and 5 min continuous mode then 5 min pulsed mode. The device that will be used is medserve, England (the head of the device is 5cm). Topical gel with no drugs
214487759|NCT06798428|DEVICE|Group C sham ultrasound for massage - 5 minutes|sham ultrasound for massage - 5 minutes
214487760|NCT06789016|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
214487761|NCT06789016|DRUG|0.9%NaCl|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
214487762|NCT03876951|DIAGNOSTIC_TEST|Vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery.
214487763|NCT02951052|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
214971343|NCT01368263|DRUG|chemotherapy|Standard chemotherapy
214971344|NCT01368263|PROCEDURE|Surgery|
214971345|NCT05793281|OTHER|No Drug|Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
214971346|NCT03095807|DRUG|NNC9204-1706 A|Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
214971347|NCT03095807|DRUG|Placebo|Administered subcutaneously (s.c., under the skin)
214971348|NCT06215742|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
214971349|NCT06215742|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214971350|NCT01724827|DEVICE|ceramic (Empress CAD, Ivoclar Vivadent)|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
214971351|NCT01724827|DEVICE|composite (Lava Ultimate, 3M Espe)|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
215083434|NCT05581095|BEHAVIORAL|Mindful Eating Self-Help Program|10-week exposure to mindful eating principles and practices outlined in the Eat What You Love, Love What You Eat for Binge Eating book
215083435|NCT05581095|BEHAVIORAL|Mindful Eating Smartphone Application (Am I Hungry? Virtual Coach)|10-week exposure to using a mindful eating mobile phone application daily.
215083436|NCT02876328|BIOLOGICAL|Ad26.ZEBOV|0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
215083437|NCT02876328|BIOLOGICAL|MVA-BN-Filo|0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
215083438|NCT02876328|BIOLOGICAL|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
215083439|NCT02876328|BIOLOGICAL|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
215083440|NCT02876328|BIOLOGICAL|rVSV boost|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
214359310|NCT06059495|DRUG|Dostarlimab|"After inclusion: dostarlimab 500mg IV 30min q3w (± 2-3 days) for 4 cycles (C1-C4)~Then:~At wk12 • If cCR: dostarlimab 1000mg q6w for 2 cycles (C5-C6)~• If downstaging at UGI endoscopy, and no disease progression (PD)/or mets on TAP-CT, \<3 biopsies with tumor cells: dostarlimab 500mg q3w for 4 cycles (C5-C8)~• If loco/loco-regional PD on TAP-CT, macroscopic tumor on UGI endoscopy, no distant mets, and \>2 positive biopsies at wk12 followed by surgery and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 6 cycles (C5-C10)~At 24wk~• If cCR at 12 and 24 wks: dostarlimab 1000mg q6w for 4 cycles (C7-C10)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with \<3 biopsies with tumor cells at wk12 and cCR: dostarlimab 1000mg q6w for 4 cycles (C9-C12)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with and no cCR, surgery will be proposed and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 4 cycles (C9-C12)"
214359311|NCT06303050|OTHER|Mental Imagery with task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The experimental group will receive 20 minutes of MI training followed by 25 minutes of TOT for a total of 45 minutes, 5 days per week for 6 weeks. During each 45 minutes of session, the participants will perform warm-up exercise for 5 minutes to prepare the body for functional task and to improve overall performance. Regular breaks will give to the participants to avoid overexertion and fatigue during 45 minutes of continues practice. The 2 minutes rest period will provide to the partici-pants during each practice session
214359312|NCT06303050|OTHER|Task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The control group will receive the Task oriented training for 25-30 minutes, 05 days a week for 06 weeks consisting of Warm up Period, Task oriented training In standing, forward stepping and sideward stepping, reaching in standing, Transition from sit to stand, Walk then back to sit, Walk with even steps, Walk with carrying objects.
214359313|NCT05188001|OTHER|Not an Interventional Study|Not an interventional Study
214359314|NCT01188434|BEHAVIORAL|ITSAN|integrated behavioral intervention for substance abuse, parenting skills, and basic needs
214359315|NCT01188434|BEHAVIORAL|Services as Usual|Services as usual referred by child welfare
214359316|NCT04184791|DEVICE|Deep Brain Stimulation|Each DBS electrode contact will be reprogrammed in 60hz and High Frequency Stimulation (180hz) in the Levodopa ON (medicated) and OFF (unmedicated) conditions.
214359317|NCT04847869|DEVICE|Ellex Integre NIR laser|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
214359318|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
214359319|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
214359320|NCT01639885|BIOLOGICAL|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
214679211|NCT05346393|DRUG|Standard of Care|Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
214679212|NCT05925114|DRUG|S-309309|Administered as oral capsules
215083441|NCT01922375|DRUG|Naftopidil|
215083442|NCT03908827|BIOLOGICAL|Bone Mineral Aspirate Concentrate (BMAC)|A single BMAC injection will be performed into the arthritic joint
215083443|NCT06279702|OTHER|SERIOUS GAME|Students will play serious game that about first aid.
215083444|NCT06279702|OTHER|COMICS|students will learn comics that about first aid.
215083445|NCT00645905|DRUG|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
214971352|NCT03460678|DRUG|Pemetrexed|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects
214971353|NCT03460678|DRUG|Erlotinib|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
214971354|NCT06148870|DEVICE|Myopia Control Lens-1 (MCL1)|The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.
214971355|NCT06148870|DEVICE|Myopia Control Lens-2 (MCL2)|The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.
214971356|NCT01982695|DRUG|Losartan|
214971357|NCT01982695|DRUG|Lisinopril|
214971358|NCT04754997|OTHER|Traditional exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. The lower extremity range of motion exercise and strengthening exercises will be applied on the mat 10 repetition. The number of repetitions and type of exercises will be changed every 3 weeks.
214971359|NCT04754997|OTHER|Specific exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. Exercise training consists of lower extremity closed kinetic chain exercises and core exercises. The type of exercise changes every 3 weeks.
214971360|NCT03781466|PROCEDURE|Cervical cerclage|Cervical cerclage indicated by short cervix ≤25mm
214971361|NCT03781466|DRUG|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
214971362|NCT05656300|DIAGNOSTIC_TEST|MRI scan using USPIO particles|Diagnostic imaging
214971363|NCT02614638|OTHER|One month of department-wide observation|A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.
214971364|NCT02614638|OTHER|Pharm Tech participates in department|Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
214971365|NCT02686853|DRUG|Liposomal amphotericin B|
214971366|NCT05180045|BEHAVIORAL|LINKED-BP Program|The intervention arm will include training on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. Patients will be trained to measure their BP in the morning and evening for 7 days. Patients enter data using Bluetooth device transmission or manual entry. Guidance is provided on accurate BP measurement. The app stores and securely relays data to the cloud. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal. Other components of usual care at the practices may include dietary counseling, on-site clinical pharmacists, social workers, case managers as needed for BP follow up, and assistance with medications and appointments as needed. The intervention period for each study participant is 12 months.
214971367|NCT04795466|BIOLOGICAL|Canakinumab|Biological subcutaneous injection
214971368|NCT04795466|OTHER|Placebo|Matching placebo subcutaneous injection
214971369|NCT05635045|DRUG|I 124-Evuzamitide|Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
214971370|NCT04692493|DRUG|targeted synthetic DMARD class|Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
214971371|NCT04692493|DRUG|non-TNFi-biologic class|Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
214971372|NCT05776303|BEHAVIORAL|Good Bowls|Healthy, frozen subsidized meals are made conveniently available on worksites.
214971373|NCT05776303|BEHAVIORAL|Good Bowls + App Nudges|"Healthy, frozen subsidized meals are made conveniently available on worksites.~Additionally, Bluetooth enabled beacons will be set up at each worksite that will send location specific messages to an individual's Smartphone via an App. These messages will include nutritional information, tips, and behavioral nudges."
214971374|NCT06314503|DEVICE|WEAKID|"Six treatments over the course of two weeks with the WEAKID system:~* Week 1 (without the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment~* Week 2 (with the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment"
214971375|NCT05316142|PROCEDURE|AGV with intraoperation MMC and postoperative BSS|This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world
214971376|NCT05316142|PROCEDURE|AGV with intraoperation MMC and post operation 5FU|This method will use Ahmad FP7 model valve shunt (New World Medical, LA). First, 5FU at a dose of 0.04% is placed in the shunt plate for two minutes and then rinsed.
214971377|NCT05608018|OTHER|Intervention Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with all features turned on.
214971378|NCT05608018|OTHER|Intervention non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with all features turned on.
214971379|NCT05608018|OTHER|Control Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with some features turned off.
214971380|NCT05608018|OTHER|Control non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with some features turned off.
214971381|NCT03832361|DRUG|IMGN853|IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
214971382|NCT03796936|BEHAVIORAL|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy|a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)
214359321|NCT01190592|OTHER|Resistance Training with Milk Supplementation in Adolescents|"On resistance training days, the RT+ milk group will receive milk (280kcals) immediately following exercise and milk at another time during the day. The RT+ juice group will receive fruit juice immediately following resistance exercise and juice again another time during the day. The RT+ water group will receive water following resistance exercise and water at another time during the day.~On non training days, students in the RT+ milk group will receive milk. Students in the RT+ juice group will receive juice. The RT+ water group will receive water during the school day. On non-RT days, the total volume of milk, juice, or water will be split into two administration times during the school day."
214359322|NCT01918735|DRUG|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
214359323|NCT01918735|DRUG|GWP42006|"Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects."
214359324|NCT01297959|DRUG|E-101 Solution 300 GU/ml|8 mL of E-101 Solution
214359325|NCT01297959|DRUG|Saline solution|Saline solution matched to E-101
214359326|NCT02243943|DRUG|Sugammadex|
214359327|NCT02243943|DRUG|Neostigmine|
214359328|NCT02483169|DRUG|cilostazol|Cilostazol 100mg bid
214359329|NCT02483169|DRUG|Probucol|Probucol 250mg bid
214971383|NCT05493761|DRUG|Denosumab|60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
214971384|NCT05493761|DRUG|Alendronate Sodium|70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
214971385|NCT00764569|DEVICE|Fluorescence/Elastic Scattering Spectroscopy|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
214971386|NCT03270033|DRUG|Dexamethasone|0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
214971387|NCT03270033|DRUG|Dexmedetomidine|0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
214971388|NCT00242047|BIOLOGICAL|Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).|
214971389|NCT02778152|DEVICE|Laser depilation|Laser depilation of natal cleft (pilonidal region)
214971390|NCT04351165|DRUG|IMP4297|IMP4297 10mg/capsule; IMP4297 20mg/capsule;
214971391|NCT01451918|DRUG|Resveratrol|500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
214971392|NCT00437164|DRUG|Insulin|
215083446|NCT00645905|DRUG|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
214971393|NCT00437164|DRUG|Oral GW677954 Capsules (15 mg)|
214971394|NCT04986774|PROCEDURE|Rescue intracranial stenting|Rescue Intracranial Stenting in Acute Ischemic Stroke caused by intracranial large vessel occlusion
215083447|NCT01697150|DEVICE|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
214359330|NCT02483169|DRUG|Aspirin|Aspirin 100mg qd
214359331|NCT02483169|DRUG|placebo of cilostazol|same shape and size of active cilostazol
214359332|NCT02483169|DRUG|Placebo of aspirin|same size and shape of active aspirin 100mg
214359333|NCT02483169|DEVICE|Intima-medial thickness|ultrasound measured IMT of both common carotid arteries
214359334|NCT02950246|PROCEDURE|perineural catheterization implementation|Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
214359335|NCT02950246|DRUG|2% alcoholic chlorhexidine|
214359336|NCT02950246|DRUG|povidon iodine|
214359337|NCT01667432|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
214359338|NCT02464189|OTHER|Q-Kap|
214359339|NCT03662204|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
214359340|NCT03526822|BIOLOGICAL|Blood sample|Five blood sample in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma
214359341|NCT03526822|BIOLOGICAL|Tumor sample|One tumor sample in operative period
214487764|NCT02951052|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"
214679213|NCT05925114|DRUG|Placebo|Administered as an oral capsule that looks identical to S-309309 capsule
214679214|NCT05307289|OTHER|Biposy|Biopsy at inclusion visit and at disease progression if applicable
214971395|NCT03565757|BEHAVIORAL|SMART intervention|All participants will attend a 90-minute SMART small group session. This session provides education on the stress response and the principles of gratitude, compassion, mindful presence, and resilient mindset. In addition to the class, there will be follow-up online and written resources.
214971396|NCT01218542|RADIATION|Volumetric modulated arc therapy|Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
214971397|NCT06278948|OTHER|Group TP|Application full face, twice daily, in the morning and at bedtime for 4 months
214971398|NCT06278948|DRUG|Group CYS|Application short contact, of thin layer once daily at bedtime for 4 months
214971399|NCT01475903|PROCEDURE|Longitudinal sleeve gastrectomy|The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
214971400|NCT01493895|DEVICE|standard hoem treatment|"All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method."
214971401|NCT01493895|DEVICE|LLLT-808 B-cure laser machine|"From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.~All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.~The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards."
214971402|NCT05044429|DRUG|Intravenous Lidocaine|Patient will receive intravenous lidocaine 1.0-1.5 mg/kg/hour for 48 hours post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
214971403|NCT05044429|DRUG|Transversus abdominis plane (TAP) block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through transversus abdominis plane (TAP) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
214971404|NCT05044429|DRUG|Quadratus Lumborum (QL) Block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through quadratus lumborum (QL) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
214971405|NCT01062893|OTHER|Sterile normal saline 0 mls|at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
214971406|NCT01062893|OTHER|15 mls sterile normal saline|After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
214971407|NCT02131064|DRUG|Carboplatin|Carboplatin IV infusion at a dose to achieve an AUC of 6 mg\*min/mL q3w
214971408|NCT02131064|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV infusion q3w
214359342|NCT01348867|OTHER|Structured care led by a nurse consultant|"For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit."
214359343|NCT02339831|DEVICE|CAMOPED|Camoped given after surgery
214359344|NCT02339831|DEVICE|CPM passive motion device|passive motion device given after surgery
214359345|NCT02077166|DRUG|Ibrutinib|
214359346|NCT02077166|DRUG|Lenalidomide|
214359347|NCT02077166|DRUG|Rituximab|
214359348|NCT05415735|BEHAVIORAL|Stress Management and Resiliency Training Program|This is a multimodal mind-body program designed to teach participants a variety of different strategies to reduce their physiologic stress response.
214359349|NCT03519854|DRUG|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
214359350|NCT03519854|DRUG|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.
214359351|NCT03519854|DRUG|Esmeron®|Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
214487765|NCT02951052|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
214679215|NCT02324530|DEVICE|Continuous positive airway pressure (CPAP)|CT simulation with and without CPAP
214971409|NCT02131064|DRUG|Pertuzumab|Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
214971410|NCT02131064|DRUG|Trastuzumab|Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
214359352|NCT03356925|DIAGNOSTIC_TEST|Xpert Ultra Point of Care testing|The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
214359353|NCT01667601|OTHER|Routine Care|Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
214359354|NCT01667601|BEHAVIORAL|Mindfulness-based program|The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
214971411|NCT02131064|DRUG|Trastuzumab Emtansine|Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
214971412|NCT05664308|OTHER|Clinical follow-up (ECG)|Clinical follow-up with a consultation at the University Hospital at 3, 6, and 12 months, with an ECG at each visit.
214487766|NCT02951052|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
214487767|NCT02951052|DRUG|2 NRTIs plus an INI, NNRTI, or PI|"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~* INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~* NNRTI (either the initial or second cART regimen)~* Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)"
214487768|NCT05759923|DRUG|OATD-02|Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
214359355|NCT01667601|BEHAVIORAL|Psychoeducation group|A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
214359356|NCT04881006|DRUG|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
214359357|NCT04881006|DRUG|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
214359358|NCT01229540|GENETIC|genetic analyzer|
214359359|NCT05433870|OTHER|Whether the PE or E patient combined with PRES|According to the Diagnostic criteria of PRES, all the patients grouped into two groups.
214359360|NCT03157609|DEVICE|Thermometry|Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
214359361|NCT05744648|PROCEDURE|Composite resin restoration using Titania nanoparticle reinforced bonding agent|Each group will receive Composite resin restoration for Class-I and Class-II carious lesion. In group A, titania nanoparticle reinforced bonding agent will be used
214359362|NCT05744648|PROCEDURE|Composite resin restoration without Titania nanoparticle incorporated bonding agent|Composite resin restoration without Titania nanoparticle incorporated bonding agent
214359363|NCT02603081|DRUG|SPI-1005|Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
214359364|NCT04014764|OTHER|This is a non-interventional study|N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
214487769|NCT06831266|OTHER|High Intensity Interval Training (HIIT)|"1 minute interval, 1 minute active recovery~5 minutes warm-up - 3 minutes cool-down will be done at 60% of peak heart rate.~Weeks 1-2: Loading at an intensity of 85% of peak heart rate, active recovery at an intensity of 60% of peak heart rate 4x1~Weeks 2-7: Loading at an intensity of 90% of peak heart rate, active recovery at an intensity of 60% of peak heart rate 6x1~Weeks 8-12: Loading at an intensity of 90% of peak heart rate, active recovery at an intensity of 60% of peak heart rate 8x1"
214679216|NCT01996319|DRUG|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
214679217|NCT01996319|DRUG|Placebo|Placebo once a day via Breezhaler® device
214971413|NCT05664308|OTHER|Ongoing monitoring|"Once operated, patients will be monitored remotely via a computerized data transfer routine anonymized by the WITHINGS software, based on the data from the watch.~It's contractually agreed with WITHINGS that the transmissions will be scheduled and transmitted weekly to the center."
214971414|NCT04086810|DRUG|DCCR|Once daily oral administration
215083448|NCT00298493|PROCEDURE|Sedation management strategy|
215083449|NCT03849690|DRUG|TAK-906|TAK-906 capsules.
215083450|NCT03849690|DRUG|Esomeprazole|Esomeprazole capsules.
215083451|NCT02726191|BEHAVIORAL|Spatial Match Exercise|
215083452|NCT02726191|BEHAVIORAL|Temporal Sequence Reconstruction Exercise|
214359365|NCT04447170|PROCEDURE|Simple repair or Graham technique|Simple suture with or without omental protective patch
214359366|NCT05566223|DRUG|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
214359367|NCT05566223|DRUG|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
214359368|NCT05566223|BIOLOGICAL|CISH Inactivated TIL|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
214359369|NCT05566223|DRUG|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
214359370|NCT05566223|DRUG|Pembrolizumab|Administered as maintenance therapy in some patients starting at first follow-up (400 mg/dose starting Day 28 /Week 4 then every 6 weeks thereafter until disease progression, unacceptable toxicity, or up to 24 months)
214359371|NCT04341506|DEVICE|Non-contact ECG|A non-contact ECG will be used to detect a patient cardiac electrical activity.
214359372|NCT01299948|DRUG|Prednisolone|5 mg prednisolone orally per day
214359373|NCT01567384|DRUG|OSI-906 and Pemetrexed|"Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1."
214359374|NCT01015157|PROCEDURE|Roux-en-Y laparoscopic gastric bypass for morbid obesity|Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
214359375|NCT02320565|PROCEDURE|3D Laparoscopy|3D Laparoscopy approach
214359376|NCT02320565|PROCEDURE|Standard Laparoscopy|Standard laparoscopy approach
214359377|NCT02271958|DRUG|Mifepristone|
214359378|NCT02271958|DRUG|PLACEBO|
214359379|NCT06286150|PROCEDURE|Surgical robot system|SHURUI Single-port surgical robot system
214359380|NCT01760096|DRUG|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
214359381|NCT01760096|DRUG|cyclosporin A+Glucocorticoids|cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
214487770|NCT06831266|OTHER|Moderate Intensity Continuous Training (MICT)|"5 minutes warm-up - 3 minutes cool-down will be done at 60% of peak heart rate.~Weeks 1-2: Loading at 65% of peak heart rate intensity (22 minute)~Weeks 2-7: Loading at 75% of peak heart rate intensity (30 minute)~Weeks 8-12: Loading at 75% of peak heart rate intensity (38 minute)"
214487771|NCT04227600|DRUG|JR-171 (lepunafusp alfa)|IV infusion
214487772|NCT05188664|DRUG|LM-302|LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。
214487773|NCT05188664|DRUG|Toripalimab|Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
214487774|NCT06172283|OTHER|Intermittent Fasting|Dietary intervention
214487775|NCT05739435|DRUG|ESK-001|Oral tablet
214487776|NCT06844201|DRUG|Ephedrine|Received ephedrine the same day of surgery.
214487777|NCT06844201|DRUG|Norepinephrine|Received norepinephrine the same day of surgery.
214487778|NCT06846827|OTHER|Oyster mushroom|Sachet containing the equivalent of 1 serving (9.39g) of dried ergothioneine-rich Pleurotus oyster mushrooms
214487779|NCT06846827|OTHER|Maltodextrin|Sachet containing 6.67g of maltodextrin
214487780|NCT05229341|PROCEDURE|Diagnostic Procedure|Analysis via DDMS-2
214971415|NCT05292261|OTHER|Recreational team handball|Two to three weekly sessions of recreational team handball training for 36 weeks. Each 60-min session started with a standardised warm-up (including running, coordination, strength, flexibility, and balance exercises) followed by three 15-min periods of recreational team handball matches, interspersed by 2-min breaks, played as small-sided games (4v4, 5v5 or 6v6). The training sessions were performed on an indoor team handball court (40x20 m) adjusted to result in 34-36 m2 per player. During the matches, the participants rotated positions every 3 min in a random order, including the goalkeeper and no exclusions or substitutions were applied.
214971416|NCT05157880|BEHAVIORAL|Recovering Together|In the skills-based intervention group, sessions focus on developing skills to cope and manage ANI related stressors. The intervention will be tailored consistent with AHA recommendations for ANI skills-based interventions and will include 2 general and 4 specific modules. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered, in person if possible, within the NICU, or through live video using Zoom if patients leave the hospital before sessions occur, and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom.
214971417|NCT05157880|BEHAVIORAL|Recovering Together|Those in the educational program will receive general health information that mimics the skills-based intervention, but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. There will also be 6 sessions, 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits following discharge. The educational program group will not have the opportunity to specify which modules they would like to take; the modules will be predetermined. All participants will receive medical care as determined by their medical team.
215083453|NCT02726191|BEHAVIORAL|Token Task Exercise|
215083454|NCT02726191|BEHAVIORAL|Story Recall Exercise|
215083455|NCT02726191|BEHAVIORAL|Sample-Match (Within Modality) Exercise|
215083456|NCT02726191|BEHAVIORAL|Pair-Match (Across-Modality) Exercise|
214359382|NCT01760096|DRUG|Glucocorticoids|Glucocorticoids0.25mg/kg every day(prednisone)
214359383|NCT05445648|DRUG|Tislelizumab Injection|After patient recruitment, every patient first receives a regimen of tislelizumab injection 200 mg every time , q3w, 4 times in total. Then all patients, if operable, undergo TURBT. The first day after TURBT, patients again start to receives a regimen of tislelizumab Injection 200 mg every time , q3w, 4 times in total. Meanwhile, on the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
214359384|NCT05445648|PROCEDURE|Transurethral resection of bladder tumor|After the initial tislelizumab injection regimen, patients undergo clinical assessment and receive transurethral resection of bladder tumor if operable.
214487781|NCT05229341|OTHER|Electronic Health Record Review|Review of medical records
214487782|NCT05229341|PROCEDURE|Needle Biopsy|Undergo needle biopsy
214487783|NCT01839747|PROCEDURE|PET-MRI|Imaging
214679218|NCT03108755|DRUG|ASP7713|oral
215083457|NCT02726191|BEHAVIORAL|Triad-FiguresExercise|
215083458|NCT02726191|BEHAVIORAL|Monster Garden Exercise|
215083459|NCT02726191|BEHAVIORAL|Memory Match Exercise|
214487784|NCT01839747|PROCEDURE|PET-CT|Imaging
214487785|NCT04277637|DRUG|Sonrotoclax|Film-coated tablets administered once daily at a dose as specified in the treatment arm
214487786|NCT04277637|DRUG|Zanubrutinib|320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
214487787|NCT04277637|DRUG|Obinutuzumab|Given as an intravenous infusion administered per label.
214487788|NCT06747559|DRUG|Vitamin D|Vitamin D oral supplementation
214487789|NCT06746545|DRUG|Fruquintinib+S-1|Fruquintinib: 5 mg, oral, once daily，2w/1w；Q3W S-1：40-60 mg (dosed according to body surface area), oral，2w/1w；Q3W
214487790|NCT05328401|DEVICE|Verum laser acupuncture|Applied verum laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
214487791|NCT05328401|DEVICE|Sham laser acupuncture|Applied sham laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
214487792|NCT06819527|OTHER|Medication reconciliation service|Patients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions.
214679219|NCT03108755|DRUG|Placebo|oral
214679220|NCT00915811|DRUG|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
214679221|NCT00915811|DRUG|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
214359385|NCT05445648|RADIATION|Adjuvant radiotherapy|On the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
214971418|NCT06431529|BIOLOGICAL|tumor neoantigen specific T cell|Isolate the patient's autologous monocytes, induce and culture them into tumor antigen presenting cells in vitro, and then phagocytose tumor tissue cells obtained from biopsy or surgery to present tumor neoantigens to autologous T cells. The final product For tumor neoantigen specific T cells (NeoT).
214359386|NCT04253327|OTHER|questionnaire|"Patients will be contacted by their physician during regular follow-up in the out-patient clinic or contacted by phone.~The questionnaires will be filled in at the UZBrussel, Laarbeeklaan 101, 1090 Brussels or at the patients home.~Filled-in questionnaires can be hand off immediately at the physician or send by post or email.."
214359387|NCT02741401|OTHER|Usual post-operative care|Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
214359388|NCT02741401|OTHER|Hand-foot massage|Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
214359389|NCT02393872|BEHAVIORAL|Feel4Diabetes-intervention|Community-based intervention.
214359390|NCT03153579|DRUG|LSD|"Lysergic Acid Diethylamide~200ug per os, single dose"
214971419|NCT03287076|DRUG|Exenatide Injection|5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
215083460|NCT02726191|BEHAVIORAL|Memory Matrix Exercise|
214359391|NCT03153579|DRUG|Placebo|Capsules containing mannitol looking identical to LSD
214359392|NCT01944865|OTHER|Interval Training|The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
214359393|NCT01944865|OTHER|Intermittent Training|The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
214359394|NCT02479230|BIOLOGICAL|tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Given ID
214679222|NCT00915811|DRUG|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
215083461|NCT02726191|BEHAVIORAL|Familiar Faces Exercises|
214359395|NCT02479230|DRUG|gemcitabine hydrochloride|Given IV
214971420|NCT04464291|OTHER|Detection of Streptococcus pneumoniae strains|There will be detection of Streptococcus pneumoniae, serotype identification, susceptibility tests for penicillin, erythromycin, azithromycin, tetracycline, ciprofloxacin, levofloxacin, moxifloxacin and vancomycin
214971421|NCT03086629|OTHER|Patient Concerns Inventory|
214971422|NCT03086629|OTHER|No Patient Concerns Inventory|
214971423|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.5 mg, single dose, injection
214359396|NCT01779726|RADIATION|CT scan before chest physician|Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician
214359397|NCT01779726|RADIATION|Usual diagnostic workup|Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
214359398|NCT04740489|BEHAVIORAL|Phase 3 Cardiac rehabilitation|Phase 3 CR is a comprehensive outpatient programme, considered the core rehabilitation phase, in which participants receive structured exercise, health education, risk factor modification and psychological support. Upon discharge from clinically supervised phase 3 CR participants are generally signposted to long-term community-based exercise classes (phase 4). The current study will take place within a core phase 3 CR programme in the UK.
214971424|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.75 mg, single dose, injection
214971425|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.1 mg, Single dose, injection
214971426|NCT00672568|DRUG|Placebo|Solution, single dose, injection
215083462|NCT02726191|BEHAVIORAL|Lost in Migration Exercise|
215083463|NCT02726191|BEHAVIORAL|Playing Koi Exercise|
215083464|NCT02159677|DEVICE|EIM Measurements|
215083465|NCT02358655|OTHER|Retrospective review of OAC prescription|
215083466|NCT02358655|OTHER|Prescription of OAC in ED|
215083467|NCT02358655|OTHER|Community AF clinic|
215083468|NCT02302183|DEVICE|FreeO2 v2.0 automatic adjustment|
215083469|NCT02302183|DEVICE|FreeO2 v2.0 data collecting|
215083470|NCT04353219|DEVICE|compression stocking|participants will continue their training program as prepared by their coach with compression stocking
215083471|NCT04353219|OTHER|control|participants will continue their training program as prepared by their coach without compression stocking
215083472|NCT04956055|OTHER|Reflexology|The patient will be kept in a lying position. First, the patient will be given four minutes of hand reflexology on each hand with warming and stimulation techniques.Reflexology will be applied to the left hand with the thumb of the right hand, the thumb of the left hand and the special points in the right hand. It will be applied to the fingers, palm, back of the hand, and finally the wrists, respectively, starting with the fingertips and using special reflexology techniques (a total of six minutes for each hand separately). By sending a moderate stimulus, a total of 20 minutes of reflexology session will continue.Since the patient reveals and uses his own internal energy at the end of the session, nobody should talk to the patient until five minutes after the procedure. Survey questions and vital signs would be examined five minutes after the session and the research with the participant would end.
215083473|NCT01281098|PROCEDURE|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
215083474|NCT01281098|DRUG|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
215083475|NCT00005013|DRUG|Sertraline|
215083476|NCT00005013|DRUG|Hypericum perforatum (St. John's wort)|
215083477|NCT01787318|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
214359399|NCT04462666|DRUG|Huzhang granule|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
214359400|NCT04462666|DRUG|Etoricoxib|take one capsule per day in the morning, at approximately 30 minutes after the meal.
214971427|NCT02269839|DEVICE|rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
214971428|NCT05354518|BEHAVIORAL|gestational diabetes management of midwifery students|Gestational diabetes management of midwifery students with a simulator
214971429|NCT06175208|BEHAVIORAL|Emotional Freedom Techniques|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
214359401|NCT04462666|DRUG|Huzhang granule Placebo|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
214359402|NCT04462666|DRUG|Etoricoxib Placebo|take one capsule per day in the morning, at approximately 30 minutes after the meal.
214359403|NCT03533712|DIETARY_SUPPLEMENT|Fortified balanced energy-protein (BEP) supplement|"The product contains the following target nutrients:~* Total energy: 250-500 kcal per daily serving~* Fat content: 10-60% of energy intake~* Protein content: 16 g (range 14-18 g) with a Digestible Indispensable Amino Acid Score (DIAAS) of ≥ 0.9~* Carbohydrate (CHO) Content: no specific recommendations, relative to fat and protein content.~* Trans Fats: \<1% energy intake Micronutrients include the following: A, D, E, K, B1 (thiamin), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), B9 (folate), B12 and C; minerals: iron, zinc, iodine, calcium, phosphorous, copper, and selenium.~The final composition of macro en micronutrients will be available after the acceptability testing (phase 1) and will be determined by 1) the product type and 2) the preferred taste."
214359404|NCT03533712|DIETARY_SUPPLEMENT|Fe and folic acid supplement|Routine iron and folic acid supplementation.
214359405|NCT03372122|DRUG|Chlorhexidine Gluconate|A cloth to cleanse and disinfect the skin
214359406|NCT03372122|COMBINATION_PRODUCT|HUBS with Hibiclens|A dry cloth to be used in combination with water and antimicrobial soap to cleanse and disinfect the skin
214359407|NCT02813070|DRUG|[18F] Flutemetamol|PET brain imaging and Magnetic resonance brain imaging
214359408|NCT00818753|DRUG|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
214359409|NCT00818753|DRUG|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
214359410|NCT00818753|DRUG|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
214359411|NCT03195010|BIOLOGICAL|Platelet Transfusion|Undergo lower dose platelet transfusion
214971430|NCT06175208|BEHAVIORAL|Mindfulness Meditation|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
214971431|NCT00810069|DRUG|Duloxetine Hydrochloride|Flexible dose of 60 or 120 mg daily
214971432|NCT00810069|DRUG|Escitalopram|10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
214971433|NCT04998890|OTHER|adventure-based cognitive behavioral intervention|"The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course entailed Improving Mental Health for University Success in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues."
214971434|NCT04893551|BIOLOGICAL|Tilvestamab|Tilvestamab will be administered as IV infusion.
215083478|NCT01787318|DEVICE|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
215083479|NCT04437719|OTHER|Obvio-19 app|"As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.~Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months.~To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months.~To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months."
214359412|NCT03195010|BIOLOGICAL|Platelet Transfusion|Undergo higher dose platelet transfusion
214359413|NCT01284465|BEHAVIORAL|Education and patient liaison combination|Group education sessions with Patient liaison using ecological momentary assessment principles
214359414|NCT01284465|BEHAVIORAL|Control group|Group education sessions at baseline, 3 and 6 months
214359415|NCT03710915|DRUG|HG146|HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.
214359416|NCT05450965|DRUG|Onvansertib|Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.
214487793|NCT06866301|BEHAVIORAL|Progressive Resistance Exercise|The exercise program will have a duration of 10 weeks. It will be divided in two phases: conditioning phase and training phase. During the conditioning phase (2-3 weeks), participants will learn exercise techniques, work on their interoceptive awareness and perform same exercises at a lower intensity to prepare the muscles for the next phase. In the training phase, the intensity will be moderate starting at approximately 60% of capacity, with a frequency of three days per week and continuous adjustment (progression) based on the participant's improvements. Each session will include a warm-up and cool-down of approximately 10 minutes. The central part of the session will be in the form of a circuit and will include 6 large muscle group exercises using a combination of machine exercises following the PPL (push, pull and legs) model and 3 core strengthening exercises.
214359417|NCT05411458|OTHER|Aerobic and Relaxation Exercises|"12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~Aerobic exercise (AE) program:The aerobic training program was applied as walking for 40 minutes in the open air. The Rating of Perceived Exertion (RPE) Borg Scale (6-20) was used to determine the walking pace, and they were asked to walk according to the light (11-12) level according to the Borg scale.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
214359418|NCT05295498|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
214971435|NCT03675360|BEHAVIORAL|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target \<40 g net carbohydrates per day for first 3 months; \<60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
214487794|NCT05848791|OTHER|Exercise exposure|Participants are exposed to three different air quality environments in central London, chosen to maximise differences in nontailpipe air pollution. Participants will cycle at 60% of estimated maximum vo2 on static bikes for six 15 minute bouts with 15 minutes rest between bouts.
214971436|NCT00785161|DEVICE|Penumbra System|Mechanical Thrombectomy in acute stroke
214971437|NCT03242941|PROCEDURE|Pulmonary vein ablation|After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
214971438|NCT02915146|RADIATION|combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy|NB-UVB combined with UVA1
214971439|NCT03031717|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
214971440|NCT06524986|BEHAVIORAL|Self-efficacy promoting program using computer game|The self-efficacy promotion program, inspired by Bandura's principles (1997, 2001) and employing computer games, extends across 5 weeks with 30-minute sessions conducted 10 minutes. Activities include: 1) Enactive Mastery Experiences 2) Modeling 3) Verbal Persuasion 4) Physiological and Affective States Assessment
214971441|NCT06524986|BEHAVIORAL|Standard nursing care|The control group received standard nursing care, which included providing dietary recommendations for pediatric patients. The recommended daily intake consisted of 0.8 grams of protein per kilogram of the child's weight, low-sodium foods, and low-fat options. This personalized guidance was communicated through informational brochures.
214971442|NCT00971867|DRUG|Paclitaxel|Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
214971443|NCT04799925|DRUG|Febuxostat|uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
214971444|NCT05532215|DRUG|Misoprostol|The misoprostol tablets to be used in the study will be of the same brand and batch
214971445|NCT05532215|DRUG|Oxytocin|The oxytocin ampoules to be used in the study will be of the same brand and batch
214971446|NCT04619784|OTHER|Pilates Exercises|Patients will receive 12 sessions of pilates.
214971447|NCT04619784|OTHER|control|Their routine medical treatments were continued
214971448|NCT01244074|BEHAVIORAL|biofeedback training|
214971449|NCT00217035|DIETARY_SUPPLEMENT|TPN or TPN enriched with glutamine|Each patient undergoes two nutritional support periods either with or without Glutamine supplementation.
214971450|NCT05774561|DIAGNOSTIC_TEST|Arm A - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.
214971451|NCT05774561|DIAGNOSTIC_TEST|Arm B - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.
214971452|NCT04767373|BIOLOGICAL|Clesrovimab|Clesrovimab solution
214971453|NCT04767373|DRUG|Placebo|Placebo (0.9% sodium chloride \[NaCL\]) solution
214971454|NCT04959448|DRUG|DUPIXENT®|No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.
214971455|NCT00367003|DEVICE|Deep Brain Stimulation|The deep brain stimulation system (consisting of a lead, extension wire, and implanted pulse generator) will be surgically implanted to stimulate the targeted area of the brain. Stimulation will be turned off for 4 weeks following implantation, then participants will use brain stimulation for 6 months. Participants will also take part in Behavioral Activation therapy during the 6 months of active stimulation. Participants will be followed for 10 years, or until the DBS device has been FDA approved, with adjustments made to the stimulator and medications as necessary.
214971456|NCT02983045|DRUG|Dose Escalation Doublet: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels.
215083480|NCT03308045|BIOLOGICAL|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
215083481|NCT04094233|DIETARY_SUPPLEMENT|Beetroot extract|Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
215083482|NCT04094233|OTHER|Placebo|Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
215083483|NCT03288194|BEHAVIORAL|Problem-Solving Treatment|
215083484|NCT03288194|BEHAVIORAL|Time Management|
215083485|NCT02579694|DEVICE|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
214359419|NCT05295498|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
214359420|NCT06713863|OTHER|BEtter AT LEarning (BEATLE)- Digital Care Pathway|"BEATLE is a digital care pathway consisting of ten episodes resembling an online course. The episodes are designed to be multimodal and immersive, incorporating text, recorded voice, pictures, cartoons, videos and peer support through given examples and case stories. Participants are encouraged to access BEATLE through a web browser on a computer, although it is also accessible through a mobile application. Participants have control over the pace of completing the BEATLE, but there must be a minimum five-day break between episodes. In other words, it is possible to complete the BEATLE in seven weeks.~All participants are referred to the BEATLE by a neuropsychologist and are strongly authenticated in the healthvillage.fi online platform. Each participant is assigned a designated neuropsychologist who tracks their progress in the BEATLE and to whom messages and questions can be sent by the participant."
214359421|NCT03415620|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlist of different music genres. Music listening session will be given for 30 minutes before, during and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
214359422|NCT06730542|DRUG|Zanubrutinib|Zanubrutinib capsules will be self-administered orally by participants at a starting dose of 160 mg twice a day (BID) or 320 mg once a day (QD)\* at the beginning of Cycle 2 of Pola-R-CHP therapy.
214359423|NCT06730542|DRUG|Methotrexate|Participants will receive Methotrexate as per standard of care (SOC).
214359424|NCT06730542|DRUG|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin as per standard of care (SOC).
214359425|NCT06730542|DRUG|Rituximab|Participants will receive Rituximab as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
215083486|NCT03515941|DRUG|Oxaliplatin|130 mg/m2 by IV (Arm 1)
214359426|NCT06730542|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
214359427|NCT06730542|DRUG|Doxorubicin|Participants will receive Doxorubicin as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
214359428|NCT06730542|DRUG|Prednisone|Participants will receive Prednisone as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
214359429|NCT06732817|DEVICE|Active rTMS was administered using a transcranial magnetic stimulator (Rapid2; MagStim).|Active rTMS was sequentially administered over the left DLPFC and left TPJ sites one hour apart, for 3 weeks (21 consecutive days), using a transcranial magnetic stimulator (Rapid2; MagStim) with a 70-mm air-cooled figure-of-eight coil. Stimulation at 20 Hz (2 seconds on, 28 seconds off) was applied over the left DLPFC with an intensity set at 100% of the individual resting motor threshold (RMT), delivering a total of 1,600 pulses daily. Continuous theta burst stimulation (cTBS) was applied over the left TPJ at either 100% of the individual RMT or at the highest intensity that the stimulator could deliver for this protocol (50% of maximum output). Three daily sessions of cTBS were administered, separated by two 15-minute breaks, delivering a total of 1,800 pulses daily. The coil was navigated in real-time using a frameless neuro-navigation system (Brainsight; Rogue Research, Montreal, Quebec, Canada).
214359430|NCT06732232|DRUG|CD19/CD20/BCMA CAR-T|CD19/CD20/BCMA CAR T therapy
214359431|NCT05622305|BEHAVIORAL|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
214359432|NCT05986578|DEVICE|TMS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dmPFC, approximately 25% of the nasion-inion distance or Talairah coordinates X 0 Y+60 Z+60 will be measured. The first session will begin with the acquisition of the resting motor threshold (rMT) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last \~3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
214359433|NCT05986578|DEVICE|TMS to dlPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dlPFC, position F3 will be measured, using probabilistic EEG placement. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last 3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
214487795|NCT06742086|DRUG|Venetoclax|Oral Tablet
214487796|NCT06742021|DIAGNOSTIC_TEST|Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer|Chest MRI scans outside of the standard treatment protocol
214487797|NCT06741878|BEHAVIORAL|Exercise|Involves participants engaging in physical training group sessions in light-to-moderate intensity.
215083487|NCT03515941|DRUG|Capecitabine|625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
215083488|NCT03515941|DRUG|Leucovorin|400 mg/m2 by IV (Arm 1 \& Arm 2)
215083489|NCT03515941|DRUG|5-fluorouracil|400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
215083490|NCT03515941|RADIATION|radiation|45 Gy in 1.8 Gy/fraction
215083491|NCT01152515|DRUG|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
214359434|NCT05986578|DEVICE|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 3 sessions with a 15-20 min interval between sessions.
214359435|NCT06951789|OTHER|Molecular hydrogen|Hydrogen gas, purity \>99.9%, flow rate 600 ml/min (two generators 300 ml/min each).
214359436|NCT06951789|OTHER|Placebo|Ambient air, flow rate 600 ml/min (two pumps 300 ml/min each).
214359437|NCT01530217|DRUG|Ibuprofen.|Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
214359438|NCT05952635|PROCEDURE|Tip bendable suction ureteral access sheath|Patient use tip bendable suction ureteral access sheath during flexible ureteroscopy to see if flexible ureteroscopy with S-UAS offers the better treatment outcomes in terms of clinical effectiveness and post-operative complications.
214359439|NCT05682092|DIETARY_SUPPLEMENT|WonderLab Collagen Tripeptide Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
214359440|NCT05682092|DIETARY_SUPPLEMENT|Ordinary Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
214359441|NCT04296695|DRUG|B/F/TAF|randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV
214359442|NCT04296695|DRUG|TDF/3TC/EFV|TDF/3TC/EFV
214487798|NCT06741878|BEHAVIORAL|Psychosocial|Involves participants engaging in selected board and card games which require cognitive and socialization skills to play in a group setting of 2-4 people.
214487799|NCT06741878|BEHAVIORAL|Nutritional|Involves participants attending dietary classes taught by a certified dietitian, including individualized consultation.
214679223|NCT00915811|PROCEDURE|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
214679224|NCT05834959|OTHER|An Educational and Training Program|Education and practical training program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury
214679225|NCT06804031|BEHAVIORAL|Nutrition and exercise education|Nutrition and exercise training was created as a result of literature review, and expert opinions (Public Health Nursing, Pediatric Nursing, Physical Therapy and Rehabilitation, Nutrition and Dietetics) were taken for the training content and finalized. The training program consists of six sessions. It is planned to have one session per week and each session will last 30-45 minutes on average. The times when the students are available will be determined by discussing with the school administration in advance. Computers and barcovisions in schools will be utilized for the training of students. Trainings will be conducted through verbal expression, power point presentations, brainstorming, exercises, games, written and visual materials, video screenings and question-answer methods. Adolescents will be given bookmarks, magnets and brochures prepared to prevent obesity.
214679226|NCT05920096|OTHER|Diabetes specialist nurse-led multi-component smoking cessation intervention|"Aims to:~* inform participants on the association between smoking and diabetic complications;~* motivate and encourage smokers to quit;~* support participants in using the appropriate behavioural skills to quit smoking and avoid relapse.~In the first session, the participants will be supported to set a Target Quit Date (TQD) within two weeks. Participants will be followed up within a week (or two weeks max.) from their TQD. Those who report having not smoked (for ≥24 hours from the time of assessment) will be provided with a final follow-up session within five weeks from their set TQD (three sessions in total). Conversely, those who report still smoking will be encouraged to set another TQD and will be seen again in one (or two weeks max.) and five weeks from their new TQD (four sessions in total). The participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) nicotine patch and/or spray to use for a few days prior to their TQD and on quitting."
214679227|NCT05920096|BEHAVIORAL|Health Promotion and Disease Prevention Directorate's one-to-one smoking cessation service (standard care)|A behavioral smoking cessation intervention based on motivational interviewing and delivered by trained tobacco cessation facilitators within community health centres. Participants will be provided with 20-minute counseling sessions based on their needs.
214487800|NCT06735040|OTHER|Photobiomodulation Therapy|Before each treatment session, the borders of the thyroid gland were marked with ultrasound by an endocrinology specialist. Eight target points (superior, mediolateral, inferior borders of the right and left thyroid lobes, right and left side of the isthmus) were demarked with a surgical pen. PMBT was applied to the marked areas on the thyroid gland, which were approximately 1 cm apart from each other.
214679228|NCT03229746|DRUG|Hydroxychloroquine|200mg twice daily orally for at least 12 weeks
214679229|NCT03229746|DRUG|vincristine|1mg intravenous weekly for 4 weeks
214679230|NCT03229746|DRUG|azathioprine|dose 100mg daily for at least 3 weeks
214359443|NCT01712009|DRUG|Naproxen|
214359444|NCT01712009|DRUG|Loratadine|
214359445|NCT01712009|BIOLOGICAL|Pegfilgrastim|Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
214359446|NCT01712009|DRUG|Chemotherapy|The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
214359447|NCT02685722|BIOLOGICAL|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.
214359448|NCT02685722|OTHER|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
214359449|NCT05668169|OTHER|Family-centered support program for caregivers of stroke survivors|Once participants joined the family-centered support group, participants received 90-minute interventions, including an introduction to stroke and rehabilitation education, problem-solving skills training, and long-term care information. Investigators also invited participants to join the instant messaging application-based 24-h peer-support group for caregivers. On the second and fourth days after receiving the interventions, the researcher visited the participants to review and practice the content provided on the first day; each session was 30 to 40 minutes long. The researcher contacted the participants one week after participants joined the study to discuss their care difficulties or experiences and did so three times biweekly thereafter via the instant messaging application.
214487801|NCT06735040|OTHER|Sham|In the sham PMBT group, the probe was placed similarly to the treatment group. The screen of the laser device was active; however, the energy was set to 0 J and the power to 0 Mw, and the same procedures were also performed.
214487802|NCT06883448|COMBINATION_PRODUCT|Home monitoring care|Patients in the home monitoring group will receive a home spirometer, pulse oximetry meter, and access to a smartphone or tablet app, where they can perform home based measurements weekly and complete PROMs. Furthermore, this app includes disease specific information and allows for direct communication with the hospital via eConsultation. In the home monitoring group, half of the outpatient clinic visits will alternately be replaced by remote visits via video consultation.
214487803|NCT06889922|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Coil
214971457|NCT02983045|DRUG|Dose Expansion Doublet: Combination of NKTR-214 + nivolumab|Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
214971458|NCT02983045|DRUG|Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.
214971459|NCT02983045|DRUG|Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
214971460|NCT02186977|DEVICE|VAX-ID|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
214971461|NCT02186977|DRUG|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
214487804|NCT06889922|DEVICE|Transcranial Magnetic Stimulation Sham|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Sham Coil
214487805|NCT05466799|DRUG|FOLFIRINOX chemotherapy|Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer
214487806|NCT05466799|DEVICE|OncoSil™|Implantation of OncoSil 32P microparticles into the Pancreatic Tumour under EUS guidance
214487807|NCT06892964|GENETIC|Genetic profiling of all eligible patients|Performed genetic profiling in DNA extracted from fresh tissue or FFPE in all patients affected by lymphatic malformation recruited
214487808|NCT06895356|DRUG|Tavapadon|Oral: Tablet
214487809|NCT00866021|DRUG|Lopinavir/ritonavir|NRTI sparing-regimen
214487810|NCT00866021|DRUG|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
214679231|NCT00677027|OTHER|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
214971462|NCT02186977|DRUG|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
214971463|NCT02658669|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
214971464|NCT02658669|BEHAVIORAL|Sleep Education|Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
214971465|NCT02732392|PROCEDURE|standard lymphadenectomy|
214971466|NCT02732392|PROCEDURE|lymphadenectomy radio-isotope method|
214971467|NCT02932800|PROCEDURE|"Fixation with ballerina technique and flip"|
214487811|NCT02817659|DRUG|Glucagon|Glucagon infusion
214487812|NCT06759311|OTHER|ART|The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin
214679232|NCT00677027|OTHER|placebo|Placebo
214679233|NCT03253406|BEHAVIORAL|Polar M400 + Facebook Group (PM400+FG)|Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
214971468|NCT02932800|PROCEDURE|Habitual Fixation|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture
214971469|NCT02932800|OTHER|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture|
214971470|NCT01396889|DRUG|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
214971471|NCT01396889|DRUG|Placebo|Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
214971472|NCT03132090|DIAGNOSTIC_TEST|PET/MR (Biograph mMR)|The combination of PET and MRI allows for evaluation of metabolic, functional and morphological parameters such as glucose metabolism, perfusion, diffusion restriction or size in one examination. Due to the combination of MRI and PET in one scanner it is possible to align the acquired PET and MR datasets with high precision
214359450|NCT01912924|DEVICE|Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery
214971473|NCT00419042|DRUG|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
215083492|NCT04643119|DEVICE|Medial Congruent Insert|The Medial Congruent Bearing (MC Bearing) design was introduced in 2016 for use with the Zimmer-Persona Cruciate-Retaining Femur: the design facilitates greater stability through increased anterior lip height compared to the original Cruciate Retaining Bearing (CR Bearing), allowing for greater anterior constraint and subluxation resistance that aids in full extension and deep flexion. Furthermore, the MC Bearing has been suggested for use in patients presenting with more complicated surgical histories (e.g prior high tibial osteotomies or patellectomies), whereas the original CR Bearing is strictly suggested for use only in patients undergoing knee surgery for the first time, where the posterior cruciate ligament may still be intact.
215083493|NCT04643119|DEVICE|Cruciate-Retaining Insert|The Cruciate-Retaining Bearing (CR Bearing) design was launched together with the use of the Cruciate-Retaining Femoral Components (CR Femur) of the Zimmer-Biomet Persona® Total Knee system. The design not only stabilises the knee through medial conformity and anterior constraint, but also allows for freer and more natural deep flexion through freer movement of the lateral condyle.
215083494|NCT00334282|DRUG|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
214359451|NCT00654719|DIETARY_SUPPLEMENT|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
214359452|NCT00654719|DIETARY_SUPPLEMENT|Placebo|Nutritional supplementation containing only 12 kcal/day
214359453|NCT04979559|DEVICE|Mobile health apps|Mobile health application intervention including screening and early intervention such as diet and physical activity suggestion
214359454|NCT04979559|OTHER|Standard care|Regular practice for screening and early intervention for prediabetes patient in primary health cares setting
215083495|NCT00334282|DRUG|placebo|matching placebo (800 mg tablet) once daily
215083496|NCT00468845|DRUG|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
214359455|NCT04246983|DIAGNOSTIC_TEST|Opportunistic infection Ultrasound (OpUS) screening|this point-of-care ultrasound protocol will include lung ultrasound, assessment of pericardial and pleural effusions, ascites, abdominal lymphadenopathy and splenic micro abscesses, as well as a focused ultrasound of liver and kidneys.
214359456|NCT00739375|PROCEDURE|Primary arterio-venous vascular access creation|Primary arterio-venous vascular access creation, ECHO with pulmonary artery pressure measurements, Assessment of blood NO metabolite levels
214359457|NCT02657616|DRUG|vitamin-k-antagonists|
214359458|NCT02657616|DRUG|Novel oral anticoagulants|
214971474|NCT00419042|DRUG|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein-called intravenous infusion (IV). This will take about 30 minutes
214971475|NCT05391997|OTHER|Modified Cervical and Shoulder Retraction exercises|11 patients will receive cervical traction and modified cervical and shoulder retraction exercises (10 to 12 repetitions). The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days.
214971476|NCT05391997|OTHER|Cervical Extension Traction exercises|11 patients will receive cervical traction force for 10 seconds and extend the cervical spine. The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days
214971477|NCT03752879|PROCEDURE|Fundal Pressure|Fundal Pressure to assist the vaginal delivery to shorten the second stage of labor
215083497|NCT00468845|DRUG|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
215083498|NCT00468845|DRUG|matched placebo|matched placebo
215083499|NCT00029458|DRUG|Clozapine|
215083500|NCT04976218|BIOLOGICAL|TGFβR-KO CAR-EGFR T Cells|Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10\^5/kg, dose 2 will be 1×10\^6/kg，and dose 3 will be 1×10\^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10\^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
215083501|NCT05864131|BEHAVIORAL|Lying|After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.
215083502|NCT05864131|BEHAVIORAL|Holding|Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
215083503|NCT01812369|DRUG|GEMCITABINE CISPLATINE|
215083504|NCT01812369|DRUG|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
214359459|NCT02093767|DIETARY_SUPPLEMENT|Synergy1|The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).
214359460|NCT03297515|DIETARY_SUPPLEMENT|Madeos|Arm 1: Omega 3
214359461|NCT03297515|DIETARY_SUPPLEMENT|Placebo|Arm 2 : Placebo
214359462|NCT00593567|DRUG|gentamicin-collagen sponge|Inserted daily into open ulcer
214359463|NCT00593567|DRUG|Levofloxacin|750mg oral levofloxacin daily
215083505|NCT03350139|DEVICE|gamma knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
215083506|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy|The experimenter gives the subject psychoeducation about emotional regulation and distraction strategy with the help of a conversation and a presentation.
214359464|NCT01946542|DRUG|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
214971478|NCT03389100|DRUG|18F-MK6240 injection|Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
214971479|NCT03727841|DRUG|Marizomib|0.8mg/m(2) intravenous (IV) on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.
214971480|NCT01601496|DEVICE|FUSION Vascular Graft|All subjects who received the FUSION Vascular Graft at the baseline implant procedure.
214971481|NCT04771078|BIOLOGICAL|Nonconforming idecabtagene vicleucel|Nonconforming idecabtagene vicleucel is to be administered to participants after lymphodepleting chemotherapy
214971482|NCT04211012|DRUG|Toripalimab plus Nab-Paclitaxel +/- cisplatin|"Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin"
214971483|NCT01406119|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
214971484|NCT06117696|OTHER|Animated video|delivery of written and oral information, supported by animated videos.
214971485|NCT06218615|OTHER|Educational Intervention (Video)|Watch video
214971486|NCT06218615|OTHER|Survey Administration|Answer survey questions
214971487|NCT02240017|DRUG|Carboplatin|Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
214971488|NCT02240017|DRUG|Fractionated Cisplatin|Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
214971489|NCT02240017|DRUG|Gemcitabine|Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
214971490|NCT02078193|DRUG|Belatacept|Patients will be converted from their MMF to Belatacept
215083507|NCT06197464|DEVICE|Using the FLOAT app on a virtual reality device|The subject should wear the VR device, and use the FLOAT application.
215083508|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy + Application|psychoeducation on emotional regulation and distraction strategy + Application
214359465|NCT01946542|OTHER|placebo|
214359466|NCT01826240|BEHAVIORAL|MBCT+SPI|Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
214359467|NCT00590902|DRUG|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
214971491|NCT03764280|OTHER|Multiple Daily Injections: Slow acting insulin and Rapid acting insulin|Multiple daily injections (MDI) therapy involves four or more daily insulin injections. Once or twice daily, a long acting insulin is injected as a basal dose. These long acting insulins are designed to dissipate slowly and evenly into the bloodstream for 24 to 36 hours following injection. This basal injection aims to mimic the physiological healthy basal insulin released from a healthy pancreas all day. Furthermore, multiple insulin bolus doses are injected at every meal each day using rapid or short acting insulin. These injections are administered before meals and are calculated using patients' ICRs and meal carbohydrate quantities.
214971492|NCT01569126|DRUG|LY110140|Administered orally as capsules
214971493|NCT01569126|DRUG|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
215083509|NCT06105658|BIOLOGICAL|Unrelated umbilical cord blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
215083510|NCT06105658|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
215083511|NCT06105658|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
214359468|NCT06154343|DRUG|GQ1005|an antibody drug conjugate
214359469|NCT03664479|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
214359470|NCT01037855|OTHER|Non-intervention observational study|Non-intervention observational study
214971494|NCT04175275|OTHER|Interview patient|Interview patient without scoring about the reasons for the implant, the complications, the reasons for abandonment, the evaluation of the satisfaction
215083512|NCT06105658|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
215083513|NCT01689350|GENETIC|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
215083514|NCT03759964|DRUG|Ferric carboxymaltose|1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
215083515|NCT03759964|DRUG|Placebo|100 mL of IV isotonic serum saline at day 1 following surgery
215083516|NCT05616884|PROCEDURE|Cementless fixation|Three dimensional printed porous metal, a biomaterial with morphological and mechanical properties that resemble those of native trabecular bone, is now being used for fixation of the tibial component in unicondylar knee arthroplasty. This can reliably achieve osseointegration into the tibia and could lead to a lower risk of aseptic loosening which is the leading cause of revision in partial knee replacements.
215083517|NCT00985907|DRUG|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
215083518|NCT00134732|BIOLOGICAL|Live attenuated human rotavirus vaccine|
215083519|NCT02823132|BIOLOGICAL|blood sample|
215083520|NCT02076399|DRUG|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
214359471|NCT01253525|BIOLOGICAL|Ramucirumab (IMC-1121B )|8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
214359472|NCT01253525|DRUG|Paclitaxel|80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
214359473|NCT00785291|BIOLOGICAL|Bevacizumab|Given IV
214971495|NCT04238377|PROCEDURE|Stellate Ganglion Block|"Using US with a linear array transduce, subfascial-C6- Stellate Ganglion Block. Patients will be supine with the neck slightly hyper- extended. After aseptic preparation of the skin, the transducer is placed on the neck to enable cross sectional visualization of anatomical structures at the level of C6. The carotid artery, internal jugular vein, thyroid gland, trachea, longus colli covered with the prevertebral fascia, root of C6, and transverse process of C6 are all visualized. The transducer will then gently be pressed between the carotid artery and trachea to retract the carotid artery laterally and to position the transducer close to the longus colli.~A 1.0-inch, 25-gauge long-bevel needle were paratracheal inserted toward the middle of the longus colli. The endpoint for injection were the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in the longus colli. After negative aspiration, 5 mL of 0.5% bupivacaine was injected"
214971496|NCT04238377|DRUG|Multimodal Analgesia|Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
215083521|NCT02076399|DRUG|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
215083522|NCT05363761|COMBINATION_PRODUCT|Neurotronic Infusion Catheter|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
215083523|NCT01449110|DIETARY_SUPPLEMENT|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:~1. capsule/day of placebo (350 mg maltodextrin) for 6 months~2. capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
215083524|NCT01449110|DIETARY_SUPPLEMENT|Placebo in secondary prevention|"12 months follow-up:~1. capsule/day (350 mg maltodextrin) for 6 months~2. capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
215083525|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in primary prevention (PP)|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
215083526|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in SP|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
215083527|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
214359474|NCT00785291|DRUG|Ixabepilone|Given IV
214359475|NCT00785291|OTHER|Laboratory Biomarker Analysis|Correlative studies
214359476|NCT00785291|DRUG|Nab-paclitaxel|Given IV
214359477|NCT00785291|DRUG|Paclitaxel|Given IV
214359478|NCT00785291|OTHER|Questionnaire Administration|Ancillary studies
214359479|NCT05864664|PROCEDURE|Wide awake local anaesthesia no tourniquet technique|"Patient awake with no form of sedation or analgesia~* A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution~* Injection is performed around incision site - superficial to deep including periosteum~* Incision is performed in the normal fashion~* Plate and screws are removed and incision is closed"
214359480|NCT03110341|DRUG|Erythropoietin|rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
214359481|NCT03110341|DRUG|Normal saline|placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
214359482|NCT05543291|BEHAVIORAL|renal function|levels of eGFR
214359483|NCT04967768|OTHER|Questionnaire about impact of the COVID-19 pandemic on orthopaedic resident training|Answers were collected for the effects of the COVID-19 pandemic on the real-life experiences of orthopaedic residents
214359484|NCT00844857|DRUG|Olanzapine Fluoxetine Combination (OFC)|OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
214359485|NCT00844857|DRUG|Placebo|Orally, once daily in the evening for 8 weeks.
214359486|NCT06064084|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test 50g
214359487|NCT06064084|OTHER|Intravenous isoglycaemic glucose clamp|Intravenous isoglycaemic glucose clamp
214359488|NCT06064084|OTHER|Liquid Mixed meal test|Liquid Mixed meal test 520 kcal
214359489|NCT00570674|DRUG|Abraxane|
214359490|NCT00570674|DRUG|Erbitux|
214359491|NCT00570674|DRUG|Carboplatin|
214359492|NCT00570674|RADIATION|Intensity Modulated Radiation Therapy|
214359493|NCT05144932|DEVICE|Stroke Alarm|The patients are in this clinical trial instructed to use the device continuously for 1 month.
214359494|NCT05183022|DEVICE|Total30 Sphere Contact Lenses|Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.
214359495|NCT03103243|BEHAVIORAL|Mindfulness Based Group Sessions|In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
214359496|NCT03519750|DRUG|Melatonin 25 mg|24-48 hour monitoring of plasma melatonin as well as adverse events.
214359497|NCT00244790|BEHAVIORAL|Diet|crossover low vs high protein diet before and after weight loss
214487813|NCT06759311|OTHER|Brix 3000|Brix 3000 gel will be applied to the caries lesion using a spoon excavator\*\* leaving gel according to the manufacturer's instructions. After 2 minutes, the gel will turn from translucent green colour to cloudy after the gel removal.
214487814|NCT06759311|OTHER|Carie Move|Carie-Move gel will be applied to the caries lesion according to the manufacturer's instructions at second visit in the same child. After 30 second the gel will be removed.
214679234|NCT03253406|BEHAVIORAL|Facebook Only Group (FG)|Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
214971497|NCT00729716|BIOLOGICAL|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
214971498|NCT00729716|PROCEDURE|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
214971499|NCT05621044|BEHAVIORAL|FitBrothers smartphone active app|The FitBrothers smartphone active app is designed to assist African American men with adopting and maintaining PA. The app will be developed with significant input from African American men and contain self-monitoring, goal setting, reward, and educational components. The app will include additional elements including PA adoption strategies, competitions, incentives, health information, and greater compatibility with activity monitoring devices. The intervention is based on the Social Cognitive and Self-Determination theories and is culturally tailored.
214971500|NCT05621044|BEHAVIORAL|Nike Training Club|The app is designed to increase fitness in users through a variety of mechanisms. Users are able to track and monitor their physical activity level, set goals, engage in competitions, and upload activity data from a wearable. They will also be provided with preset workouts, receive guidance from an expert, and receive personalized plans that automatically adapt to user behavior.
214971501|NCT03603522|DIETARY_SUPPLEMENT|BioGaia-DSM17938|2mL per day (1x10\^9 CFU) per day taken orally for 28 days
215083528|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
214359498|NCT02979639|BIOLOGICAL|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
214971502|NCT03603522|OTHER|Placebo Comparator: Placebo Control|2mL per day of placebo formulation taken orally for 28 days
214971503|NCT02245165|BIOLOGICAL|L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV|
214971504|NCT02245165|BIOLOGICAL|saline|
214971505|NCT03740269|OTHER|oral health educational program|poster education about the important of oral health status, different brushing technique, different tooth paste, the balanced diet, changes occur to their mouth during the puberty period
214971506|NCT05399797|OTHER|Educational training|Pharmacists in the intervention group will given detailed online educational training on how to recognize and manage acute uncomplicated urinary tract infections in adults.
214971507|NCT05507892|DRUG|canagliflozin|Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is a used to treat type 2 diabetes. Canagliflozin lowers blood sugars by causing the kidneys to excrete more glucose in the urine.
214971508|NCT05507892|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure renal plasma flow (RPF) PAH (Basic Pharma, Geleen, Netherlands) has been used to measure RPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
214971509|NCT02208544|PROCEDURE|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
214359499|NCT01760889|DRUG|SPD489 low dose range (40mg, 80mg, and 100mg)|"Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once-daily for 4 weeks; then,~* 100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;~* if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks"
214971510|NCT02208544|DEVICE|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
215083529|NCT03594916|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
214359500|NCT01760889|DRUG|SPD489 high dose range (120mg, 140mg and 160mg)|"Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once daily for 1 week; then~* 120 mg capsule once-daily for 1 week, then,~* 140 mg capsule once-daily for 2 weeks, then~* 160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;~* if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks"
214487815|NCT06759311|OTHER|Smart Bur|Removal of carious dentin will be carried out employing smart bur II mounted on a low-speed handpiece without water spray. Caries removal will be proceeded until the smart bur II becomes dull after repeated contact with healthy dentin (21) (figure 3)
214679235|NCT03781193|OTHER|Questionnaires administration|Psychological and quality of life questionnaires
214679236|NCT03781193|OTHER|Five Facet Mindfulness Questionnaire (FFMQ)|FFMQ is a 39-item measure consisting of five subscales (observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience).
214359501|NCT01760889|DRUG|Placebo|One capsule a day for 26 weeks
214971511|NCT02208544|RADIATION|FDG-PET/CT|Head and Neck FDG-PET/CT
214971512|NCT03502499|DRUG|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
214971513|NCT03502499|DRUG|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
214971514|NCT01575171|BEHAVIORAL|Nudge|"Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
214971515|NCT01442662|DRUG|pazopanib + gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
214971516|NCT04808934|DRUG|Apixaban|Adults receiving apixaban
214971517|NCT04808934|DRUG|dabigatran|Adults receiving dabigatran
214971518|NCT04808934|DRUG|rivaroxaban|Adults receiving rivaroxaban
214971519|NCT04808934|DRUG|VKAs|Adults receiving VKA
214971520|NCT00002295|DRUG|Inosine pranobex|
214971521|NCT03771963|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV SC injection.
215083530|NCT03594916|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
215083531|NCT00085254|DRUG|cilengitide|Given IV
215083532|NCT00085254|DRUG|temozolomide|Given orally
215083533|NCT00085254|RADIATION|radiation therapy|Undergo radiotherapy
214359502|NCT03640702|OTHER|Protocol change|To examine the effect of prolonging the second stage of labor on the rate of cesarean delivery, maternal and neonatal outcomes
214359503|NCT03176420|PROCEDURE|angioplasty and stenting of occluded cervical ICA|The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
214359504|NCT04050865|DRUG|Dexamethasone, 0.4mg|Ophthalmic Insert
214359505|NCT04050865|DEVICE|Placebo plug with no drug|Ophthalmic Insert
214971522|NCT05201612|DRUG|Olaparib|Olaparib 300 mg, orally (po), twice a day (BID) continuously
214971523|NCT05201612|DRUG|Pembrolizumab|Pembrolizumab 200 mg, intravenously (IV), every 21 days. Max 2 years (i.e. 35 cycles)
214971524|NCT01057836|BEHAVIORAL|Neck endurance training|
214971525|NCT01057836|BEHAVIORAL|Stretching|
214971526|NCT03171597|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
214971527|NCT03171597|DRUG|Lipid Regulating Drugs|Mainly including statins
214971528|NCT03171597|DRUG|Coronary Vasodilator|Mainly including nitrates
214971529|NCT03171597|DRUG|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
214971530|NCT03171597|DRUG|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
214971531|NCT03171597|DRUG|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
214971532|NCT05857410|DRUG|Dexmetomidine|Dexmetomidine (H20183219) 0.4μg / (kg·min)；
215083534|NCT00085254|OTHER|laboratory biomarker analysis|Correlative studies
215083535|NCT00085254|OTHER|pharmacological study|Correlative studies
214971533|NCT05857410|DEVICE|Lower limb heating blanket|Beijing Maikang Medical Device Co., Ltd., Model: Warm-1-1.
214971534|NCT05970380|OTHER|Erector spinae plane block|Local anesthetic solution (40 mL 0.25% bupivacaine totally) will be given bilaterally between the processus transversalis of the fractured vertebra and the erector spinae muscle under ultrasound imaging by an anesthesiologist.
214971535|NCT05970380|OTHER|Local anesthesia|Local anesthetic solution (20 mL 0.25% bupivacaine) will be given extrapedicular part of the fractured vertebra by the surgeon.
214971536|NCT03625596|DIETARY_SUPPLEMENT|L-Arginine|Acute intervention (3 hours)
214971537|NCT03625596|DIETARY_SUPPLEMENT|Nitrate / Nitrite|Acute intervention (3 hours)
214971538|NCT03625596|DIETARY_SUPPLEMENT|Placebo|Acute intervention (3 hours)
214971539|NCT06484283|OTHER|Meditation|Guided meditation will be applied within the scope of the study. A guided meditation video prepared by a Yoga Alliance-certified researcher will be used for this intervention. Guided meditation aims to ensure being in the moment (here and now) with the help of breathing. Meditation practice will take participants 10 minutes.
214971540|NCT04659148|PROCEDURE|Total proctocolectomy|Total proctocolectomy: surgical removal of the colon, rectum, and anus
214971541|NCT01275443|DRUG|300mg TMC278LA|300mg TMC278LA intramuscular injection
214971542|NCT01275443|DRUG|150mg TMC278LA|150mg TMC278LA intramuscular injection
214971543|NCT01275443|DRUG|1200mg TMC278LA|1200mg TMC278LA intramuscular injection
215083536|NCT01811576|DRUG|TV-1106|
215083537|NCT01811576|DRUG|Recombinant human growth hormone|Subcutaneous once daily
215083538|NCT00976378|DRUG|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
215083539|NCT00976378|DRUG|NOX-A12|single IV dose, at efficacious dose level
214359506|NCT05699733|DEVICE|mechanical traction for knee joint|All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions
214359507|NCT04378322|BEHAVIORAL|Nutrition and food purchasing tool + telenutrition|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks) and schedule appointments with a registered dietitian.
214359508|NCT04378322|BEHAVIORAL|Nutrition and food purchasing tool|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks).
214359509|NCT04378322|BEHAVIORAL|Nutrition education tool|Participants will be asked to review nutrition education materials online.
214359510|NCT01466985|DRUG|Doravirine|Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
214359511|NCT01466985|DRUG|Placebo|Placebo tablets once daily for 7 days.
214359512|NCT05616962|DIETARY_SUPPLEMENT|Diosmiplex|diosmin glycoside in combination with alkaline granules known as alka4-complex
214359513|NCT02330432|BIOLOGICAL|Mycobacterium w|Single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
214359514|NCT02330432|OTHER|Best standard care|Antibiotics as early as possible; Norepinephrine \> vasopressin \> epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
214359515|NCT04924283|BEHAVIORAL|Tetris and Assessments|Participants will complete assessments on their phone to rate cravings for alcohol. Participants will complete a visual cognitive interference task (i.e., play Tetris on their phone) after endorsing a alcohol craving, and then re-rate craving after the task.
214359516|NCT04924283|OTHER|Assessment Only|Participants will complete assessments on their phone to rate cravings for alcohol.
214359517|NCT00225654|DEVICE|coronary stent|
214359518|NCT03500614|BEHAVIORAL|Air cleaner use method 1|All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.
214971544|NCT01275443|DRUG|600mg TMC278LA|600mg TMC278LA intramuscular injection
214487816|NCT02817958|DRUG|Chemotherapy TIP|Paclitaxel, ifosfamide, and cisplatin
214971545|NCT01858038|DEVICE|Fraxel Repair - Fractional Laser treatment|An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
215083540|NCT03177447|BEHAVIORAL|ENABLE CHF-PC|An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
215083541|NCT06184841|DRUG|HAIC combined with intravenous PD-1|Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
215083542|NCT04091984|DIAGNOSTIC_TEST|Prospera|No Interventions, this is an observational study.
215083543|NCT03594149|DRUG|Levofloxacin|Levofloxacin 500 mg/d p.o.
214487817|NCT06760468|OTHER|Control|Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the control group. Participants in the control group will undergo an 8-week placebo supplementation intervention. The placebo has a similar appearance and taste to the probiotic powder but does not contain active probiotic ingredients. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the placebo once a day at the same time to ensure the consistency and standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise capacity tests and blood sample collections will be conducted again. Comparing exercise performance and biochemical markers before and after t
214971546|NCT00002029|DRUG|Fat Emulsion 2%|
215083544|NCT05750810|OTHER|Severe exacerbation frequency|A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
215083545|NCT06247228|BEHAVIORAL|Click2Move|One year multicomponent intervention including a wearable, and a mobile phone application downloaded in the own mobile phone. Participants will have activity tracking and app provision, sedentary reminders, cooperative challenges, organisational support and motivational messages, educational material, self-monitoring, feedback provision, demonstration videos and strategies.
215083546|NCT01983280|OTHER|Healing Touch|
214359519|NCT03500614|BEHAVIORAL|Air cleaner use method 2|All interventions in the second cohort will start from the beginning to the end of smog episodes.
214679237|NCT03781193|OTHER|Langer Mindfulness Scale (LMS)|The LMS Tis a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
214971547|NCT00002029|DRUG|Fat Emulsion 20%|
214971548|NCT03414944|RADIATION|SMART-Brain|"Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10 fractions/2 weeks.~OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy."
215083547|NCT06349135|PROCEDURE|Open Reduction & Internal Fixation|Open Reduction \& Internal Fixation of Mandibular fracture either through intraoral or extraoral approaches.
215083548|NCT03503292|DRUG|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
214971549|NCT05199922|DRUG|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 40 ml (20 ml for each side) of %0,25 bupivacaine.
214971550|NCT01309412|DRUG|Siltuximab|5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
215083549|NCT03503292|DRUG|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
215083550|NCT01540409|DRUG|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
215083551|NCT02930408|PROCEDURE|electrocardiogram|
215083552|NCT02930408|PROCEDURE|Echocardiography|
215083553|NCT00004437|DEVICE|Multichannel Auditory Brain Stem Implant|
215083554|NCT04342689|DRUG|Dietary Supplement containing resistant starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
215083555|NCT04342689|DIETARY_SUPPLEMENT|Placebo Starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
215083556|NCT01460407|DRUG|LY2216684|Administered orally
215083557|NCT01460407|DRUG|Clarithromycin|Administered orally
215083558|NCT00902421|DRUG|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
215083559|NCT00902421|DRUG|Antimuscarinics|Antimuscarinics for 3 months
214359520|NCT05104528|DEVICE|OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3|Based on its precedent electrical impedance. 4 electrodes are placed on the patient: 2 on the left of the neck and the other 2 on the left lower chest . A low magnitude (2 mA), high frequency (30-100 KHz) alternating electrical current (AC) of constant amplitude is applied through the outer electrodes, and the resulting voltage is received by the inner electrodes. The ratio of the detected voltage to the applied current is the bio-impedance. The principle on which this is based is that during systole, red blood cells flow in a parallel manner, which allows the electrical current to flow easily thereby improving the electrical velocity and decreasing impedance. While during diastole, RBCs are randomly arranged, consequently hindering the electrical current (increased impedance) and decreasing electrical velocimetry. The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other parameters.
214359521|NCT05104528|DEVICE|Fujifilm Sonosite M-Turbo C Ultrasound system|A low-frequency phased array transducer (3.5-5 MHz) will be used to assess the IVC, which lies in the retroperitoneum, to the right of aorta. At or near the junction with the hepatic veins, we will measure the IVC diameter. To properly visualise the IVC, the probe will be inserted in the subxiphoid 4-chamber position with the probe marker oriented vertically to find the right ventricle and atrium. We will see the convergence of the IVC with the right atrium as the probe is progressively aimed towards the spine. We will then follow the IVC inferiorly, to detect the meeting of the hepatic veins with the IVC. M-mode Doppler sonography of the IVC will be used to graphically document the absolute size and dynamic changes in the calibre of the vessel during inspiration and expiration. After the visualisation of the IVC, we will freeze the US screen, and using the caliper function on the US machine, maximum and minimum diameters of the IVC will be documented.
214359522|NCT05256108|DRUG|Oxycodone 40 mg|Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
214971551|NCT05217602|BEHAVIORAL|AC+ARwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+ARwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+ARwdC group will be offered incentives for using their anchoring plan during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
215083560|NCT06355115|DRUG|Cefazolin 1000 MG Injection|Cefazolin 1000 mg given intravenously
215083561|NCT02801721|OTHER|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
215083562|NCT05785507|OTHER|PriskA tool|PriskA tool is an algorithm that generates a risk score of having PCOS.
215083563|NCT03035773|BEHAVIORAL|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
215083564|NCT03035773|BEHAVIORAL|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
215083565|NCT03035773|BEHAVIORAL|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
215083566|NCT02295007|BEHAVIORAL|text message|
214359523|NCT05256108|DRUG|Tramadol 600 mg|Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
214359524|NCT05256108|DRUG|Placebo|Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
214359525|NCT05256108|DRUG|Cebranopadol 600 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
214971552|NCT05217602|BEHAVIORAL|AC+RwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+RwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+RwdC group will be offered incentives for meditating during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
214359526|NCT05256108|DRUG|Cebranopadol 1000 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
214359527|NCT01459432|OTHER|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
214359528|NCT01452633|DRUG|0.25% bupivicaine will be injected at the study port site prior to incision|Injection will precede the incision
214359529|NCT01452633|DRUG|Saline will be injected at the study port site prior to incision|Injection will precede incision
214359530|NCT01452633|DRUG|Saline will be in injected into the port site prior to closure|Saline will be injected into the port site prior to the closure without any preincisional intervention
214359531|NCT01452633|DRUG|0.25% bupivicaine will be injected into the port site prior to closure|0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
214359532|NCT00175825|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
214359533|NCT00175825|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
214359534|NCT00608582|DEVICE|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
214359535|NCT01263808|DRUG|Indacaterol 150 µg|Once daily (QD) via single-dose dry powder inhaler (SDDPI)
214359536|NCT01263808|DRUG|Indacaterol 300 µg|QD via SDDPI
214971553|NCT05217602|BEHAVIORAL|Usual Calm Control (UC)|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the UC group will watch a video with information about the study and how to create an anchoring plan for their meditation habit. Participants in the UC group will be offered incentives for completing the baseline, post-intervention, and follow-up surveys.
214971554|NCT04519983|DRUG|Aumolertinib Oral Tablet|Aumolertinib 110 mg p.o. qd+ SRT(32Gy/4fx)
214971555|NCT00263198|DRUG|PTK787/ZK222584|
214971556|NCT00263198|DRUG|Letrozole|
214971557|NCT00791219|DRUG|SUBA-itraconazole|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
214971558|NCT00791219|DRUG|Itraconazole|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
214971559|NCT00791219|DRUG|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
214971560|NCT03050827|DRUG|3% oxybutynin|Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
214971561|NCT03050827|DRUG|Placebo|Non-active placebo for 3% oxybutynin
214971562|NCT04449289|DRUG|Intravenous lidocaine|Intraoperatively and postoperatively a standard intravenous infusion of lidocaine will be used for analgesia
214971563|NCT04449289|DRUG|Epidural ropivacaine|Intraoperatively and postoperatively an epidural infusion of ropivacaine will be used for analgesia
215083567|NCT05579873|PROCEDURE|Clavicle plating|VariAx 2.0mm + 2.4 or 2.7mm vs any other single plate
215083568|NCT00103519|DRUG|DITPA (3,5-diiodothyropropionic acid)|
214359537|NCT01263808|DRUG|Indacaterol 600 µg|QD via SDDPI
214359538|NCT01263808|DRUG|Placebo|QD via SDDPI
214359539|NCT01263808|DRUG|Placebo/moxifloxacin|Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
214679238|NCT03781193|OTHER|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
214679239|NCT03781193|OTHER|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
214679240|NCT03781193|OTHER|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
215083569|NCT00103519|DRUG|Placebo|Placebo
215083570|NCT00702455|BEHAVIORAL|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
214359540|NCT04959058|DEVICE|Volunteer|An ultrasound machine will be used to calculate the elastographic value of the brachial plexus in three different positions.
214359541|NCT01393782|DRUG|Angiotensin II|All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
214359542|NCT00379522|DRUG|Vasopressin|10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
214971564|NCT04224025|OTHER|exercise and respiratory therapy|three weeks in-Hospital exercise Rehabilitation program with continuation at home (total 15 weeks).
214971565|NCT00952315|DEVICE|Cyberwand|Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
214971566|NCT00952315|DEVICE|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
215083571|NCT00702455|BEHAVIORAL|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
215083572|NCT04911907|DRUG|utidelone injection|Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
215083573|NCT00462735|DRUG|Cetuximab|250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
215083574|NCT00462735|DRUG|Hydroxyurea|500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
214359543|NCT00379522|DRUG|Saline placebo|Placebo for arginine vasopressin
214971567|NCT00952315|DEVICE|Lithoclast Select|Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
214971568|NCT05930314|DRUG|CNCT19 cell injection|"Leukapheresis and manufacturing of CNCT19: enrolled subjects will undergo a leukapheresis to target a yield of \> 1x 10\^9 mononuclear cells~* Lymphodepleting chemotherapy i. Fludarabine 25 to 30 mg/m2, once daily for 3 days ii. Cyclophosphamide 500 mg/m2, once daily for 3 days~* CNCT19 administration i. 0.25 to 0.5 x 10\^8 CAR-positive viable T cells"
214971569|NCT05062746|OTHER|Matrix-Rhythm Therapy|One session Matrix-Rhythm Therapy will be applied to affected body parts.
214971570|NCT05062746|OTHER|Conventional physiotherapy and rehabilitation|Hemiparetics wil receive one session conventional physiotherapy and rehabilitation.
214971571|NCT02258594|OTHER|Web-Based Patient Centered Toolkit (PCTK)|"The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via patient-facing tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The provider-facing PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the patient thread; and 5) discussing patient's plan of care with other providers via the provider thread."
214971572|NCT02258594|BEHAVIORAL|The Patient-SatisfActive® Model|The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
214971573|NCT03176719|OTHER|Venipuncture|"1. Full blood count and leukocyte differentiation.~2. Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30)~3. Detection of anemia, thallasemia and sickle cell anemia (XN-20)~4. Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA)~5. Circulating cytokines and inflammatory markers (ELIZA)~6. DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.~7. pan-Salmonella PCR~8. Gametocyte PCR"
214971574|NCT02103660|DRUG|Depo-Medroxyprogesterone Acetate|150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
214971575|NCT02103660|DRUG|Progestin Contraceptive (Jadelle)|2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
214971576|NCT03588897|DIETARY_SUPPLEMENT|Nutridrink Multi Fibre|Dietary supplementation of 300 kcal for 14 days
215083575|NCT00462735|DRUG|Fluorouracil|continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
215083576|NCT00462735|PROCEDURE|radiotherapy|"Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients."
215083577|NCT04868487|OTHER|Health Literacy Education|Health literacy education, consisting of four sessions, was given to the intervention group.
214359544|NCT00433901|BEHAVIORAL|Targeted parental instruction for positive lifestyle change with follow-up calls.|
214359545|NCT00587327|DRUG|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
215083578|NCT00378937|DRUG|acetaminophen|
215083579|NCT00378937|DRUG|codeine phosphate|
215083580|NCT00378937|DRUG|dextropropoxyphene hydrochloride|
215083581|NCT00378937|DRUG|morphine sulfate|
214971577|NCT06612801|BEHAVIORAL|The REThink Game|REThink is an online therapeutic game designed to improve the emotional well-being of young people, based on the principles of Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who leads players through seven levels, each dedicated to teaching a particular emotional regulation skill. Each level consists of three sub-levels that gradually become more challenging. REThink can be utilized as a standalone intervention, as a complement to self-help psychotherapeutic methods, or for focused skills training in emotional regulation. Each level trains a specific emoion-regulation skills such as emotion recognition, relaxation, cognitive change, problem solving, compassion and self-compassion.
214971578|NCT06553482|OTHER|FatMAx training intervention|FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them
214971579|NCT06553482|OTHER|FatMax and physical endurance exercise intervention|FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them, with muscular endurance exercise
214971580|NCT06553482|OTHER|Control|No intervention pf physical activity
214971581|NCT04235166|OTHER|Current risk scores|Current risk scores for assessing the prognosis of acute upper gastrointestinal bleeding in cirrhosis were used.
214971582|NCT04235166|OTHER|New risk scores|New risk scores for assessing the progress of acute upper gastrointestinal bleeding in cirrhosis was used.
214971583|NCT01599169|DIETARY_SUPPLEMENT|Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)|2 tablets/day after breakfast during 12 weeks
214971584|NCT01599169|DIETARY_SUPPLEMENT|B-Back® placebo (without active compounds)|2 tablets/day after breakfast during 12 weeks
214971585|NCT07073833|DRUG|IBR900 cell injection|NK cells
214971586|NCT07073833|DRUG|rituximab|CD20 antibody
214971587|NCT07072676|DEVICE|Assistive gait devices combined with physiotherapy|During the intervenation week, the patient undergoes 12 hours/week of gait training, fall prevention, balance group and physiotherapy as part of their inpatient rehabilitation programme. The individual sessions last 30 minutes each.
214971588|NCT06882096|DRUG|Nicotinamide Mononucleotide (NMN)|Nicotinamide Mononucleotide (NMN)
214971589|NCT06882096|DRUG|Nicotinamide (NAM)|Nicotinamide (NAM)
214971590|NCT04999904|OTHER|Uneven Treadmill Intervention|Progressive proprioceptive training on the uneven treadmill with up to twelve training sessions. Subjects will be advanced through activities with progression pragmatically assessed by the physical therapists for the benefit and tolerance of the individual subject. Activities may include: slow walking, fast walking, inclined/declined walking, head turning, vision obstruction, dual task walking, fatigued walking, load carriage. Standard of care physical therapy is still provided.
214971591|NCT04999904|OTHER|Standard of Care Physical Therapy|Standard of Care Physical Therapy
214971592|NCT02110251|BEHAVIORAL|Supervised Exercise Therapy|
214971593|NCT06214884|BEHAVIORAL|Mindfulness for All|"Experimental:~The MFA will take place in a group setting with 10-15 participants per cluster. Due to participants' convenience, the delivery mode of each intervention session would be conducted online. At the end of session, they will be provided the task and supplementary materials (e-book, short audio, and video) to be apply after the session. The modules will be delivered by two trainees. Both trainees have received the certificates from the mindfulness-based strategic awareness training course. Participants in the intervention group will be joining the modules for 5 sessions weekly for 60-minute/session. Details on the modules can be referred in the Supplement material."
214971594|NCT06253702|DRUG|Indomethacin|to inhibit cyclooxygenase (COX)
214971595|NCT06253702|DRUG|Placebo|Placebo
214971596|NCT06253702|DRUG|Orilissa|to suppress hormones 200mg dose 2x per day (all participants)
214971597|NCT06253702|DRUG|Testosterone gel|50 mg each morning for add back phase (male participants)
214679241|NCT03781193|OTHER|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
214971598|NCT06253702|DRUG|Anastrozole|1mg/day in men to prevent conversion of testosterone to estradiol
214971599|NCT06253702|DRUG|Estradiol|Women will receive oral estradiol 2mg/daily
214971600|NCT06440525|DRUG|RSLV-132|Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
214971601|NCT06440525|DRUG|Placebo|0.9% sodium chloride solution
214971602|NCT02358031|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 35 cycles (up to \~2 years).
214971603|NCT02358031|DRUG|Cisplatin|Cisplatin 100 mg/m\^2 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
214971604|NCT02358031|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
214971605|NCT02358031|DRUG|5-FU|5-FU 1000 mg/m\^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
214971606|NCT02358031|BIOLOGICAL|Cetuximab|Cetuximab on Day 1 at a dose of 400 mg/m\^2 IV, and then 250 mg/m\^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity
214971607|NCT05962398|GENETIC|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).
214971608|NCT06050642|OTHER|enhanced care model provided by Timkl, a home support provider|A new type of care provided by timkl, a home support provider, involving nurses and the dispensing pharmacist. This approach combines the current tasks of the service provider's nurses with closer monitoring by the pharmacist, thanks to more frequent contacts and a holistic view of the patient.
214971609|NCT05048836|OTHER|Food Subsidy, 6 months|Food subsidy for 6 months
214971610|NCT05048836|OTHER|Food Subsidy, 12 months|Food subsidy for 12 months
214679242|NCT03781193|OTHER|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
214971611|NCT05048836|BEHAVIORAL|Lifestyle Support, 6 months|lifestyle support intervention delivered by community health workers for 6 months
214971612|NCT05048836|BEHAVIORAL|Lifestyle Support, 12 months|lifestyle support intervention delivered by community health workers for 6 months
214971613|NCT05048836|OTHER|Food Delivery, 6 months|Twice monthly delivery of healthy food for 6 months
214971614|NCT05048836|OTHER|Food Delivery, 12 months|Twice monthly delivery of healthy food for 12 months
215083582|NCT00378937|DRUG|oxycodone hydrochloride|
214359546|NCT00587327|DRUG|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
214359547|NCT00587327|DRUG|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
214359548|NCT04573465|BEHAVIORAL|Phone Coaching|Participants receiving phone coaching receive one 10-15 minute phone call each week from their randomly assigned peer-support coach. During coaching calls, the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed, asking what the participant liked/disliked about the modules, etc.).
214679243|NCT03781193|OTHER|Toronto Alexithymia Scale (TAS)|The TSA is a 20-item scale that evaluates the three components of alexithymia: difficulty to identify feelings and distinguish between feelings and bodily sensations of emotional arousal difficulty, describing feelings to others, and a cognitive style that is literal, utilitarian, and externally oriented.
214971615|NCT05960240|DRUG|AB-101|AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.
214971616|NCT05960240|DRUG|Placebo|A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.
214971617|NCT05960240|DRUG|Nucleos(t)ide Analogue|Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
214971618|NCT06539988|BEHAVIORAL|Clinician Coaching Sessions|PCPs will receive interactive coaching sessions from a Clinician Coach 2 months into the intervention period and again at 4 months into the intervention period.
214971619|NCT06539988|OTHER|Personalized text messages to patients|Drawing upon a library of messages that have previously been developed and refined, Veterans will receive 6 months of optimized text messages. The frequency of text messages will be determined based on feedback from Veterans in earlier phases of the research.
214971620|NCT06243068|BEHAVIORAL|Educate and Engage|Nephrology practices implement a bundle in which they will encourage their patients to a) participate in a kidney disease education program providing a balanced presentation of all options including ATPs, b) use evidence-based patient decision aids that include ATPs, and c) engage in shared decision-making with staff who have been trained in communication skills and best practices.
214971621|NCT06243068|BEHAVIORAL|Educate and Engage Plus Kidney Supportive Care Program|"In addition to bundle described under Educate and Engage, nephrology practices offer a systematic program integrating primary palliative care to support patients and their families who choose any ATP. The program closely follows patients and their families on ATP with care coordination, symptom management, advance care planning, and psychosocial support to supplement usual care from their nephrologist."
214971622|NCT06955754|DRUG|BI 764198, formulation 1|BI 764198, formulation 1
214971623|NCT06955754|DRUG|BI 764198, formulation 2|BI 764198, formulation 2
214971624|NCT06955754|DRUG|BI 764198, formulation 3|BI 764198, formulation 3
214971625|NCT05074329|DEVICE|Moventis PNS|Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
214971626|NCT00978952|DEVICE|Large Diameter Advanta™ V12 Covered Stent|Stent placement
214971627|NCT02114138|PROCEDURE|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
214971628|NCT02114138|DIAGNOSTIC_TEST|urine collection|urine collection will be performed on both the control group and hospitalized participants
214971629|NCT05664581|DEVICE|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
214971630|NCT06189755|DEVICE|Positive Airway Pressure|Case participants will use Positive Airway Pressure (PAP) treatment as part of routine clinical care.
214971631|NCT00116181|DRUG|Etanercept|"All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24."
214971632|NCT06959277|DEVICE|Walkasins|Walkasins® is an external, lower limb sensory prosthesis intended to replace part of the nerve function used for detection and signaling of foot pressure sensation during standing and walking activities. Walkasins consist of two parts for each leg: the Haptic Module and the Receptor Sole. The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
214971633|NCT06959277|OTHER|Fall Prevention Training|"Participants will watch 6 Steps to Prevent a Fall, a short (2 minute) educational video from the National Council on Aging, which describes simple steps to reduce fall risk. To improve their access to the education provided, participants will also receive three handouts, produced by the Center for Disease Control and Prevention (CDC) STEADI initiative (Stopping Elderly Accidents, Deaths, and Injuries), to review after the study visit. The STEADI Initiative is a coordinated approach for healthcare providers to implement the American and British Geriatrics Societies' Clinical Practice Guideline for fall prevention (https://www.cdc.gov/steadi/index.html)."
215083583|NCT00378937|PROCEDURE|management of therapy complications|
215083584|NCT00378937|PROCEDURE|quality-of-life assessment|
214359549|NCT04573465|BEHAVIORAL|Text Message Coaching|Participants receiving text message coaching receive text messages on a weekly basis from their randomly assigned peer-support coach. Text messages from the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed).
214679244|NCT00179920|DRUG|Carboplatin|
214679245|NCT00179920|DRUG|VP-16|
214679246|NCT00179920|PROCEDURE|Local Surgery|
214679247|NCT00179920|PROCEDURE|Cryotherapy|
214679248|NCT00179920|PROCEDURE|Laser hyperthermia|
214679249|NCT03660371|PROCEDURE|PPV/MP|Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
214359550|NCT04573465|BEHAVIORAL|ACT Guide|ACT Guide is an online self-help program based on acceptance and commitment therapy (ACT), targeting acceptance, mindfulness, and values-based processes. It is intended to be used for 20 to 40 minutes at time, a few times a week. While using ACT Guide, participants will read about concepts relevant to ACT and engage in guided experiential exercises, with additional exercises being assigned to be completed in between sessions as homework.
214359551|NCT03064516|PROCEDURE|Endocrown|In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.
214971634|NCT05943951|PROCEDURE|Right hemicolectomy|It begins with a thorough laparoscopic inspection of the abdomen for evidence of metastatic disease and to confirm the location of the tumor. Usually is performed dissection using a medial-to-lateral approach. A lateral or inferior approach can also be used depending on the anatomy. The vascular dissection may begin at the ileocolic pedicle or over the superiore mesenteric vein. After completing the medial-to-lateral dissection, the sourgeons return to the ileocolic pedicle to begin vascular dissection. Whether a D2 (until encountering the right branch of the middle colic) or D3 dissection (until the root of ileocolic artery and vein) is performed depends upon the tumor stage. For an intracorporeal anastomosis, the bowel is transected proximally and distally using a linear stapler. The terminal ileum is positioned along the transverse colon in an isoperistaltic fashion. After that a colotomy and an enterotomy are made on the antimesenteric edge of the colon and small bowel respectively
214971635|NCT05541939|DRUG|Mizagliflozin|Encapsulated or Liquid Formulation
214971636|NCT03101150|DRUG|400 IU Vitamin D3|Antenatal multivitamin
214971637|NCT03101150|DRUG|4000 IU Vitamin D3|4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily
214971638|NCT04355364|DRUG|Dornase Alfa Inhalation Solution [Pulmozyme]|Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days
214971639|NCT04355364|PROCEDURE|standard procedure|Patients will receive the usual care in accordance with good practice.
214971640|NCT03323593|DRUG|Dexmedetomidine|blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.
214971641|NCT03627325|OTHER|Patients who are scheduled for any surgical procedure|looking for correlation for estimating the complications between the anesthesiologists and the computerized method.
214971642|NCT03594929|DEVICE|Active RIC|
214971643|NCT03594929|DEVICE|Sham Control|
214971644|NCT03163446|BIOLOGICAL|CF-301|CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion
214971645|NCT03163446|DRUG|Placebo|Placebo, given as a single 2 hour iv infusion
214971646|NCT05900375|BEHAVIORAL|Parent Decision Aid|A paper parent decision aid in color will be provided to all patients at the time of their appointment and will aid in discussion with health care professionals.
214971647|NCT02365662|DRUG|ABBV-221|ABBV-221 will be given either every 3 weeks or 2 weeks on, 1 week off or weekly dosing by intravenous infusion approximately over 30 minutes to 3 hours. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
214971648|NCT01317641|DRUG|ODM-201|ODM-201 administered orally daily
214971649|NCT00350441|DRUG|Sildenafil Citrate|
214359552|NCT03064516|PROCEDURE|Onlay and fiber pin|In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
214359553|NCT03251625|DRUG|Probiotic Formula Capsule|
214971650|NCT00563290|DRUG|dasatinib|Given PO
214971651|NCT00563290|OTHER|laboratory biomarker analysis|Correlative studies
214971652|NCT01228591|DEVICE|Acuvue Advance Plus|Silicone hydrogel contact lens.
214971653|NCT01228591|DEVICE|Acuvue Advance|Silicone hydrogel contact lens
214971654|NCT03159403|DRUG|Oritavancin|This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
214971655|NCT01121471|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid (CLA)|6.4 g CLA/day, capsule form, for 16 week arms
214971656|NCT01121471|DIETARY_SUPPLEMENT|Safflower OIl|8.0g/day safflower oil
214971657|NCT00944918|DRUG|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
214971658|NCT00944918|DRUG|anastrozole|Tablet, oral, once daily until disease progression.
214971659|NCT00944918|DRUG|exemestane|Tablet, oral, once daily until disease progression.
214971660|NCT00199953|DRUG|Rabeprazole 20 mg twice a day for 90-day period treatment|
214971661|NCT00010140|DRUG|docetaxel|
214971662|NCT00010140|DRUG|epirubicin hydrochloride|
214971663|NCT00010140|DRUG|tamoxifen citrate|
214971664|NCT00010140|PROCEDURE|adjuvant therapy|
214971665|NCT04333004|DRUG|Pembrolizumab Combined With Chemotherapy|Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
214971666|NCT01505920|PROCEDURE|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
214971667|NCT01505920|PROCEDURE|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
214971668|NCT06365905|OTHER|Non-Interventional Study|Non-Interventional Study
214971669|NCT01356095|OTHER|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
214359554|NCT02668523|DEVICE|Raindrop Near Vision Inlay|To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
214359555|NCT00160680|DRUG|Levocetirizine|"* Pharmaceutical form: Tablet~* Concentration: 5 mg~* Route of administration: Oral use"
214359556|NCT04244890|DEVICE|Uninterrupted CPAP for the first hours of life|Directly at birth the infant will be supported with PPV with PEEP as needed, followed by nasal CPAP. Support will be provided with a single device for up to four hours.
214679250|NCT03660371|PROCEDURE|PPV without MP|No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
214359557|NCT03697902|DIAGNOSTIC_TEST|Ultrasonographic Measurement on Fetal cisterna magna length|"The length measurement on the fetal cisterna magna (CM) with an angle of 0° between the transducer and the axial cerebellar plane of the fetal head (midline structures will be perpendicular to the ultrasound beam). After that, CM will be measured again after moving the transducer approximately 30° towards the fetal occiput.~Measurements will be performed on the axial cerebellar plane using internal landmarks including the cavum septi pellucidi, thalamus, third ventricle, cerebral peduncles and cerebellar hemispheres.The anteroposterior measurement will be made between the posterior border of the cerebellar vermis and the internal face of the occipital bone.~All the ultrasonography examinations were performed abdominally, using 3-5 megahertz (MHz) transducers."
214359558|NCT02126501|OTHER|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
214359559|NCT02686580|BIOLOGICAL|Collagen paste|Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
214359560|NCT02577666|BEHAVIORAL|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
214971670|NCT01356095|OTHER|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
214971671|NCT04603352|OTHER|Hip Helpers home program|Home program: Infants will wear Hip Helpers 30 minutes, twice per day.
214971672|NCT06241118|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
214971673|NCT06241118|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
214971674|NCT06241118|DRUG|Topical corticosteroids|Pharmaceutical form: Various Topical formulation Route of administration: Topical
214971675|NCT06241118|DRUG|Topical tacrolimus or pimecrolimus|Pharmaceutical form: Various Topical formulation Route of administration: Topical
214971676|NCT04792320|DIETARY_SUPPLEMENT|Active bamboo charcoal|4g particle
215083585|NCT04126265|DEVICE|Artificial intelligence assisted colonoscopy|The colonoscopy is connected to the real-time polyp detection system. If the polyp is detected by enteroscopy, the alarm will be given.
214971677|NCT04792320|DIETARY_SUPPLEMENT|probiotics|0.8g powder
214971678|NCT01505777|DRUG|Probiotics (Medirac)|10/mosapride 10mg three times a day, P.O. 4week
214971679|NCT01505777|DRUG|Probiotics (Medirac)|15/mosapride 10mg three times a day, P.O. 4week
215083586|NCT00844805|DRUG|Infliximab|
215083587|NCT00844805|DRUG|Placebo|
215083588|NCT00844805|DRUG|Naproxen|
214971680|NCT01505777|DRUG|Probiotics (Medirac)|15/mosapride 15mg three times a day, P.O. 4week
214971681|NCT01505777|DRUG|Probiotics (Medirac)|30/mosapride 15mg three times a day, P.O. 4week
214971682|NCT01505777|DRUG|Probiotics (Medirac) placebo/mosapride placebo|three times a day, P.O. 4week
214971683|NCT02898857|OTHER|biopsies|The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
215083589|NCT00567918|DRUG|FK506|Ophthalmic suspension
215083590|NCT04110470|DIAGNOSTIC_TEST|X-ray|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
215083591|NCT04110470|DIAGNOSTIC_TEST|No-Xray|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
215083592|NCT04315636|DRUG|Surfactant nebulisation|200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
215083593|NCT01287377|BEHAVIORAL|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
215083594|NCT01287377|DRUG|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
215083595|NCT04006990|BEHAVIORAL|Provision of recliner chairs and encouragement to get out of bed|Provision of recliner chairs and encouragement to get out of bed
214971684|NCT00269945|DRUG|epoetin alfa|
215083596|NCT00146185|DRUG|ALGRX 3268|
215083597|NCT06375785|OTHER|Otago-based (slow rhythmic) exercise group|"Slow Rhythmic Exercises (Otago based) A.Strength training~1. Knee flexion and extension~2. Ankle dorsiflexion and plantar flexion~3. Toes flexion and extension~4. Hip abduction and adduction B. Balance training~1\. Stepping backwards, walking and turning 2.Side walking 3. Octet walking 4.Tandem walking 5. Standing up from a sitting position"
215083598|NCT06375785|OTHER|LSVT BIG-based (large amplitude) exercise group|"Large Amplitude Exercises (based on LSVT-BIG)~1. Bending towards the floor and rising towards the ceiling (opening) while sitting~2. While sitting, turn to the right and left with the body and reach out~3. Sit down~4. Step forward~5. Sidestepping~6. Stepping back~7. Step forward and extend arm towards the ceiling~8. Step sideways and extend arm towards the ceiling~9. Walking with big steps~10. Turning from right to left and left to right while walking"
215083599|NCT05280327|OTHER|Virtual Reality Application|The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
214971685|NCT05748132|PROCEDURE|combined conventional and pulsed RF|"1. the classic Hartle technique is used to reach the Gasserian ganglion~2. Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~3. After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~   * Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~  * Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~4. Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given"
214971686|NCT01973686|BEHAVIORAL|Physical activity|
215083600|NCT03618628|DEVICE|Carbon Fiber Off Loading Orthosis (CFO)|A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
215083601|NCT04150731|RADIATION|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
215083602|NCT03299231|DEVICE|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
215083603|NCT03299231|DEVICE|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
215083604|NCT01587638|DRUG|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
215083605|NCT01587638|DRUG|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
215083606|NCT03998748|OTHER|Sham Genetic Feedback|Participants will be told either that they have or do not have a genetic predisposition to developing depression.
215083607|NCT05067920|DIAGNOSTIC_TEST|Levels of SARS-COV-2 antibodies|Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)
215083608|NCT05067920|DIAGNOSTIC_TEST|rRT-PCR SARS-Cov-2|Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th
215083609|NCT05067920|DIAGNOSTIC_TEST|Hematological and immunological biomarkers|Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.
215083610|NCT05067920|DIAGNOSTIC_TEST|Mitochondrial DNA|One time quantification mitochondrial DNA haplogroup.
215083611|NCT05067920|DIAGNOSTIC_TEST|SARS-CoV-2 Viral Culturing|Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.
215083612|NCT05067920|DIAGNOSTIC_TEST|Sequencing COVID-19|Sequencing viral protein spike (S) COVID-19 related to CT value below 15.
215083613|NCT00763906|DEVICE|norepinephrine infused at the clinician's discretion|
215083614|NCT00763906|DEVICE|norepinephrine infused under computerized fuzzy logic control|
215083615|NCT05093920|DRUG|Doxorubicin-Eluting Beads|"* The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~* After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter."
215083616|NCT03094286|DRUG|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
215083617|NCT05750433|DIETARY_SUPPLEMENT|PreforPro+B. subtilis DE111 probiotics|PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.
215083618|NCT05750433|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is rice based powder which was used as placebo.
214971687|NCT04818944|DRUG|Tirofiban Hydrochloride|Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV
214971688|NCT04818944|DRUG|Placebo|Saline will be dosed for 24 hours post MT via continuous IV
215083619|NCT05750433|DIETARY_SUPPLEMENT|B. subtilis DE111|Bacillus subtilis probiotics.
215083620|NCT00237380|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
215083621|NCT01741532|DRUG|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
215083622|NCT01741532|DRUG|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
215083623|NCT00168077|DRUG|Prothrombin Complex Concentrate|
214971689|NCT05447273|DIAGNOSTIC_TEST|Multi-parametric, functional magnetic resonance imaging (MRI)|Multi-parametric, functional magnetic resonance imaging (MRI) will be performed in all included patients prior to surgery.
214971690|NCT01997034|BEHAVIORAL|Intensive Lifestyle Intervention|The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
215083624|NCT03395730|DRUG|Intraumbilical vein injection oxytocin|intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
215083625|NCT03395730|PROCEDURE|placental cord drainage|placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
215083626|NCT03395730|PROCEDURE|Expectant managment of 3rd stage of labour|Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
215083627|NCT00475865|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
214359561|NCT02577666|BEHAVIORAL|Housing Only|receives 3 months of project supported rental assistance
214359562|NCT02577666|BEHAVIORAL|Treatment as Usual|receives services as normally offered within the community
214359563|NCT02187913|DIETARY_SUPPLEMENT|Resistant starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
214359564|NCT03086304|DEVICE|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation is same to the traditional Chinese medicine acupuncture treatment,treat diseases by stimulate different acupuncture points.
214359565|NCT03086304|DEVICE|no transcutaneous acupoint electrical stimulation|the choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation.
214359566|NCT01777659|DEVICE|Transcutaneous electrical nerve stimulation|Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
214359567|NCT03484975|DEVICE|Observation group|Collect coronary images with a hybrid IVUS OCT system.
214359568|NCT05461976|BEHAVIORAL|Home-based self-management exercise program|Session 1 will includes education about stroke. Session 2 will includes feedback on behaviour performance on initial measurement outcomes, health consequences of the physical inactivity, answering an exercise preferences questionnaire, generation of a list of goals, delivering a smartband and a diary to self-monitoring. Session 3 will includes reviewing of goals and strategies to self-monitoring, encouragement, rising barriers to exercise and potential solutions to them, development of a weekly schedule physical exercise, implementation of the physical exercise session with participant and delivering a paper-exercise guide. Session 4 will includes reviewing of goals and weekly schedule physical exercise, encouragement, problem solving/coping planning, reviewing strategies to self-monitoring and showing to participant a video with another stroke survivors which are physically active. Sessions 5 and 6 will be the same as session 4 with exception of vicarious reinforcement.
214359569|NCT02443948|OTHER|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
214359570|NCT01313702|DRUG|polipillV1|polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
214359571|NCT01313702|DRUG|polipillV2|Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
214359572|NCT01313702|DRUG|usual care|the drugs used in clinical practice, defined by physician
214359573|NCT02348450|DRUG|Irinotecan|40mg
214359574|NCT02348450|DRUG|Etoposide|5ml：0.1g
214679251|NCT01780558|OTHER|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
214971691|NCT04454008|BEHAVIORAL|executive function family training|Intervention programs include executive function training for children with ADHD and parenting guidance for parents
214971692|NCT04454008|BEHAVIORAL|treat as usual|Outpatient routine health education, behavioral guidance and family support
214359575|NCT02348450|DRUG|Cisplatin|6ml：30mg
214359576|NCT01808950|DRUG|0.06% Resiquimod Gel - A|single 60mg dose
214971693|NCT02938572|DRUG|NNC0143-0406|Administered subcutaneously (s.c. under the skin)
214359577|NCT01808950|DRUG|0.06% Resiquimod Gel - B|single 100mg dose
214359578|NCT01808950|DRUG|0.06% Resiquimod Gel - C|shave biopsy of BCC followed by single 100mg dose
214359579|NCT01459510|BEHAVIORAL|Play Nicely Program|Multi media educational intervention
214359580|NCT00142779|DRUG|Fluoxetine|
214359581|NCT02897713|OTHER|intensive enteral nutrition|After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.
214359582|NCT02897713|OTHER|routine enteral nutrition|Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
214359583|NCT04323813|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
214359584|NCT00985725|DRUG|SPD489 (Lisdexamfetamine dimesylate)|Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
214359585|NCT00985725|DRUG|Matching placebo|oral, once daily
214971694|NCT02938572|DRUG|Insulin Aspart|Administered subcutaneously (s.c. under the skin)
214971695|NCT03856372|RADIATION|Hypofractionated|daily fractions, five fractions per week.
214971696|NCT03856372|RADIATION|Conventional|daily fractions, five fractions per week.
215083628|NCT00475865|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
214359586|NCT05182879|DIAGNOSTIC_TEST|Assessement with GERONTOPOLE scale|"The practitionner assesses the frailty of the elderly outpatient with the GERONTOPOLE scale and compares it with the évaluation gériatrique standardisée (GDS)"
214359587|NCT05276830|DRUG|BXCL501|Sublingual film containing 40 Micrograms BXCL501
214359588|NCT05276830|DRUG|BXCL501|Sublingual film containing 60 Micrograms BXCL501
214679252|NCT01780558|DRUG|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
214679253|NCT04015297|DIAGNOSTIC_TEST|raman analysis|negative or pozitive
214971697|NCT03041389|BEHAVIORAL|CCBT-I Group|Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
214971698|NCT03041389|BEHAVIORAL|Control Group|Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
214971699|NCT00036764|DRUG|ixabepilone|Given IV
214359589|NCT05276830|DRUG|Placebo film|Matching Sublingual Placebo film
214359590|NCT05530213|DEVICE|3D gait analysis on the GRAIL|3D gait anlysis performed on an instrumented treadmill (GRAIL, Motek Medical)
214359591|NCT05530213|OTHER|Weight and height|The subject's body weight and height will be assessed
214359592|NCT04962555|PROCEDURE|Meniscus Suture|Patients with knee joint meniscus injury undergoing meniscus suture
214359593|NCT04962555|PROCEDURE|Partial meniscus resection|Patients with knee joint meniscus injury undergoing partial meniscus resection
214359594|NCT04962555|PROCEDURE|Subtotal meniscus resection|Patients with knee joint meniscus injury undergoing subtotal meniscus resection
214359595|NCT04962555|PROCEDURE|Complete meniscectomy|Patients with knee joint meniscus injury undergoing complete meniscectomy
214359596|NCT02942602|DRUG|Atorvastatin 20 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
214359597|NCT02942602|DRUG|Cholestyramine 8 g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
214359598|NCT02942602|DRUG|Omega-3 2g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
214359599|NCT02942602|DRUG|Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
214359600|NCT02942602|BEHAVIORAL|Lifestyle modification|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
214359601|NCT01104194|DIETARY_SUPPLEMENT|omega-3 fatty acids supplements (fish oil)|1.74g eicosapentaenoic acid (EPA) and 0.25g docosahexaenoic acid (DHA)
214359602|NCT01104194|DIETARY_SUPPLEMENT|Placebo|softgel capsules (identical in appearance to fish oil capsules) containing olive oil. 3 capsules/day, 4 weeks
214679254|NCT06330948|DIETARY_SUPPLEMENT|SugarCut® Unripe Guava Fruit Extract|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the SugarCut® Guava Extract group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
214359603|NCT06525324|PROCEDURE|Immediate implant surgery with T-PRF and xenograft|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with T-PRF and xenograft will be placed according to the standard protocol.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
214359604|NCT06525324|PROCEDURE|Immediate implant surgery with PRF and xenograft|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with PRF and xenograft will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures"
214359605|NCT03048344|DRUG|ORH-2014|ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
214359606|NCT03048344|DRUG|ORH-2014|ORH-2014 capsule at recommended dose orally.
214359607|NCT00259532|PROCEDURE|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
214679255|NCT06330948|DIETARY_SUPPLEMENT|Placebo group|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the placebo group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
214971700|NCT00036764|OTHER|pharmacogenomic studies|Correlative studies
214971701|NCT00036764|OTHER|laboratory biomarker analysis|Correlative studies
214359608|NCT03235505|DRUG|Nicotine|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
214359609|NCT03235505|DRUG|Varenicline Tartrate|Varenicline + Innokin Endura T20S electronic inhaler but without any nicotine content + MI
214359610|NCT03235505|BEHAVIORAL|Motivational Interview|Placebo-varenicline + Innokin ENdura T20S electronic inhaler but without any nicotine content +MI
214359611|NCT05941754|DIETARY_SUPPLEMENT|omega-3|supplement in the market
214359612|NCT05941754|DIETARY_SUPPLEMENT|placebo|corn oil
214359613|NCT02465281|OTHER|Device: 3T scanner with MRI-compatible robot|
214359614|NCT02450331|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg).
214359615|NCT05263752|DEVICE|ERCP with NvisionVLE® Imaging Low Profile System|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with NvisionVLE® Imaging Low Profile System
214359616|NCT04326270|DEVICE|Nasal interface|Randomized to initial interface of nCPAP prongs or infant cannula
214359617|NCT01410474|BIOLOGICAL|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
214359618|NCT06457074|DRUG|Finerenone Oral Tablet|Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
214971702|NCT04318704|DRUG|Ifenprodil|Ifenprodil 20 mg TID
214971703|NCT03533218|DEVICE|Point of care Ultrasound machine|"POCUS methods of assessing ETT location offer an alternative that is time saving and thereby of critical importance in the neonatal time-is-brain scenario. Recently the government of Pakistan began upgrading health facilities and ensuring placement of essential equipment required to provide competent medical care, which may include provision of ultrasound machines to areas where there is established benefits to their use. Presence of trained staff and provision of portable ultrasound machine with short start-up time can save newborn lives(12).POCUS method empowers health care providers to read and interpret images in real time thereby saving critical time and need for specialized human resources (radiologists)."
214359619|NCT06457074|DRUG|Spironolactone Oral Tablet|Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
214359620|NCT04525495|DRUG|Dopamine|Dopamine treatment
214359621|NCT03823781|DRUG|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo.
214679256|NCT00591227|DRUG|insulin aspart|"insulin aspart: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
214679257|NCT00591227|DRUG|insulin detemir|"insulin detemir: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
214679258|NCT00130208|DRUG|Sulodexide|100 mg sulodexide gelcaps
214971704|NCT03328234|RADIATION|SIB-IMRT|Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
214971705|NCT03328234|DRUG|Paclitaxel|45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
214971706|NCT03328234|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
214971707|NCT03328234|DRUG|Paclitaxel|135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
214971708|NCT03328234|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
214971709|NCT03328234|OTHER|Involved Field Irradiation (IFI)|CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
214971710|NCT01256528|PROCEDURE|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
214359622|NCT03823781|DRUG|Normal saline|The study intervention is an intravenous infusion of milrinone or placebo.
214359623|NCT00002974|DRUG|carboplatin|
214359624|NCT00002974|DRUG|etoposide|
214359625|NCT00002974|DRUG|ifosfamide|
214359626|NCT00002974|PROCEDURE|hyperthermia treatment|
214359627|NCT06185257|DEVICE|EEG|"Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~* Patients in remission~* Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured"
214679259|NCT00130208|DRUG|Placebo|0 mg gelcap
214679260|NCT03017586|DEVICE|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
214359628|NCT03346720|OTHER|Semi-structured interviews|These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.
214679261|NCT06570902|DEVICE|WCD|An FDA-approved, CE marked WCD will be prescribed for up to 3 months of use after hospital discharge, with the option for longer use under physician discretion
214679262|NCT03132246|DIAGNOSTIC_TEST|Blood draws|The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
214971711|NCT01298700|DRUG|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
214971712|NCT01298700|DRUG|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
214971713|NCT05257317|OTHER|Osteopathic Medicine|"Where compression and traction movements will be carried out on these structures.~Technique called CV4, applied on the occipital, and Technique called asynchronous rolling of the temporal bones."
214971714|NCT05257317|OTHER|Placebo therapy|Circular movements will be induced in a frontal and parietal bones
214971715|NCT01897337|DRUG|Aprepitant|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room. (Before patient get in the operating room)And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
214971716|NCT01897337|DRUG|placebo|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
214971717|NCT00129441|DRUG|Merck L-830982|The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
214971718|NCT00129441|DRUG|Placebo|Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
214971719|NCT01053156|DRUG|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
214971720|NCT01053156|DRUG|Placebo|Placebo will be given daily for 3 months.
214971721|NCT00667329|DRUG|2CdA|1.5 mg/m\^2 subcutaneous injection three times daily x 7 days.
214971722|NCT00667329|DRUG|Cyclophosphamide|40 mg/m\^2 PO twice daily x 7 days.
214971723|NCT00667329|DRUG|Rituximab|375 mg/m\^2 IV once weekly x 4 weeks.
215083629|NCT00475865|DRUG|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
214359629|NCT03346720|OTHER|Focus group discussions (FGDs)|These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.
214971724|NCT01725633|BEHAVIORAL|Progressive Stretching Group|Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
214971725|NCT01725633|BEHAVIORAL|Nonlinear Aerobic Training|Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
214971726|NCT01725633|OTHER|Blood draw|At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
214971727|NCT01725633|OTHER|Cardiopulmonary Exercise Testing (CPET)|At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
214971728|NCT01690507|DRUG|Decitabine|20 mg/m²/day for 5 days
214971729|NCT01690507|DRUG|Cytarabine|
214971730|NCT01690507|DRUG|aclacinomycin|
214971731|NCT01690507|DRUG|Granulocyte colony-stimulating factor|
214971732|NCT01690507|OTHER|HLA haploidentical mononuclear cells infusion|
214971733|NCT04321928|BEHAVIORAL|Personalized health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.
214971734|NCT04321928|BEHAVIORAL|General health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.
214971735|NCT03756948|OTHER|Usual Care|Treatment of Coagulation Disorders Using Standard Coagulation Tests and Blood Components
214971736|NCT03756948|OTHER|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates|Thromboelastometry-Guided Treatment of Coagulation Disorders Using Synthetic Factor Concentrates
214971737|NCT03008811|PROCEDURE|Pulmonary vein isolation with cryoballoon catheter.|Device: Arctic Front Advance™ cardiac cryoablation catheter system.
214971738|NCT03008811|PROCEDURE|Pulmonary vein isolation with radiofrequency ablation.|Device: TactiCath™ Quartz irrigated ablation catheter (St. Jude Medical) with aid of 3-D mapping system (EnSite Precision, St. Jude Medical).
214971739|NCT03904823|DRUG|famitinib po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
214971740|NCT03904823|DRUG|HS-10296 po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
214971741|NCT05468255|OTHER|removal of exercise|Subjects will stop doing their normal exercise routines for 3 or 5 days and then subjects will resume doing their normal exercise routines for 3 days.
214971742|NCT03308422|BEHAVIORAL|parental representations|parental representations of the impact of the use of screens on their preschool children health and development
214971743|NCT05471011|OTHER|Blood and nasal swab sampling|Blood and nasal swab sampling
214971744|NCT00913549|DRUG|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|
214359630|NCT03232983|DRUG|LY900014 (SC)|Administered SC
214359631|NCT03232983|DRUG|LY900014 (IV)|Administered IV
214971745|NCT00913549|DRUG|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)|
214971746|NCT02179125|DEVICE|RePneu Lung Volume Reduction Coil System|Bronchoscopic lung volume reduction treatment with Coils.
214971747|NCT06106230|COMBINATION_PRODUCT|Bee venom phonophoresis|Bee venom gel preparation with low freq ultrasound Bee venom solution (100 mg/mL) that was prepared and preserved at the correct temperature was purchased from the Egyptian Organization for Biological Products \& Vaccines (Vacsera). The solution was a mix of a crude form of BV dissolved in sterile normal saline with a concentration ratio of 1:1 vol/vol. Then, the BV gel was prepared at the laboratories of the Faculty of Pharmacy, Modern University, Cairo, Egypt, by dissolving the previous mixture in 10% propylene glycol, followed by the addition of 0.01% butylparaben. To make bee venom gel, the resulting mixture was mixed with the matrix. The BV gel had a homogeneous and translucent appearance and a pH of 7.53. There was no discoloration, phase separation, or off-putting odor. Stratification was not observed after 30 min of centrifugation at 2,500 rpm at 25◦C, used with low frequency ultrasound Device: low intensity ultrasound
214359632|NCT02230202|OTHER|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
214359633|NCT02230202|OTHER|single blood draw|single blood draw of approximately 45 mL.
214359634|NCT03820856|PROCEDURE|acupuncture plus fire needle therapy|The protocol used in this group was the same as that used in the acupuncture alone group except that fire needle therapy was added. The treatments were administered twice weekly for 6 weeks. Fire needle therapy was performed as follows: an acupuncture needle made of tungsten was heated until red-hot over a lighter and then inserted into the two Ah shi points (the tender points on the common extensor tendon, specifically extensor carpi radialis). The red-hot needle was inserted rapidly into the Ah shi point (approximately 5-8 fen deep, 1 cun = 10 fen) for approximately half a second and then removed. Pressure was then applied to the needle hole using a sterilized dry cotton ball.
214359635|NCT03820856|PROCEDURE|acupuncture|We selected acupoints that have often been recommended for the treatment of lateral epicondylitis. Triple needling was performed at the Ah shi point, i.e., the 1-2-cm area encompassing the most painful spot on the humeral epicondyle. We also manipulated acupuncture needles in the following areas: LI10 (Shousanli), LI11 (Quchi), LI12 (Zhouliao) and LU5 (Chize). The treatments were administered twice weekly for 6 weeks.
214359636|NCT05439798|DRUG|Ondansetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
214359637|NCT05439798|DRUG|Palonosetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
214359638|NCT05439798|DRUG|Dexamethasone|Dexamethasone
214359639|NCT02022579|PROCEDURE|DCE-MRI and DWI|DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
214359640|NCT00405626|DRUG|Bellis Perenis ,Arnica montana|
214971748|NCT03984708|OTHER|Samples|Blood sample, skin biopsy
214971749|NCT03984708|OTHER|Indirect calorimetry|Measurement of energy expenditure by indirect calorimetry
214359641|NCT03346226|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg，adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery
214359642|NCT03346226|DRUG|Propofol|Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts，adjust the propofol's dose to keep BIS between 70-80 before the end of surgery
214359643|NCT00778583|DRUG|Nitrofurantoin 100 mg capsules|
214359644|NCT00906841|DRUG|90Y-DOTA-hLL2|Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
214359645|NCT04480294|DRUG|HRS5091|"Single dose in group 1-5~Multiple doses in group 6-9"
214487818|NCT06760468|DIETARY_SUPPLEMENT|Experimental Group|"Experimental:~Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the experimental group. Participants in the experimental group will undergo an 8-week probiotic powder supplementation intervention. The dosage of the probiotic powder is set at 1x10\^9 CFU/kg·bw·d, which means ingesting 10 billion CFU (Colony-Forming Units) of probiotics per kilogram of body weight per day. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the probiotic powder once a day at the same time to ensure the consistency of the dosage and the standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise ca"
214487819|NCT06758830|RADIATION|Radiation Therapy|Radiation therapy (RT) is administered at a dose of 2 Gy per day for a total dose of 50 Gy delivered to the pelvis. This is done throughout 5 to 6 weeks.
214359646|NCT03360708|OTHER|Laboratory Biomarker Analysis|Correlative studies
214359647|NCT03360708|BIOLOGICAL|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
214359648|NCT03046212|DEVICE|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
214487820|NCT06758830|DRUG|Chemoradiotherapy|"Capecitabine: 825 mg/m² twice daily, prescribed 1-5 days per week, for 5 weeks during RT.~Or Bolus 5-FU regimen: 5-fluorouracil (5-FU) 400 mg/m2/day intravenously, administered on days 1-4 and 33-35. Calcium folinate (folinic acid) 20 mg/m2/day intravenously on days 1-4 and 33-35."
214971750|NCT03984708|OTHER|Electrical bioimpedance|Measurement of electrical bioimpedance
214971751|NCT04657939|DRUG|Liraglutide|Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks.
214971752|NCT04657939|DRUG|Pioglitazone|Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.
214971753|NCT00643760|DRUG|Placebo|placebo
214971754|NCT00643760|DRUG|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
214971755|NCT00643760|DRUG|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
214971756|NCT00643760|DRUG|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
214971757|NCT00643760|DRUG|Pregabalin|pregabalin 300mg/day
214971758|NCT03934216|DRUG|BMS-986165|Specified Dose on Specified Days
215083630|NCT01568372|OTHER|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
214359649|NCT03046212|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
214359650|NCT06131866|OTHER|Psychoeducation based on Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
214359651|NCT01509729|PROCEDURE|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
214971759|NCT03934216|OTHER|Placebo|Specified Dose on Specified Days
214971760|NCT03916666|PROCEDURE|Epiduroscopy|Endoscopic intervention
215083631|NCT00914563|DEVICE|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
215083632|NCT00914563|OTHER|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
214971761|NCT02084524|PROCEDURE|Malnutrition screening and perioperative nutritional support|"* Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines"
214971762|NCT06957964|OTHER|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy is an intervention in which a suction is applied at applied thus creating a negative pressure which not only removes any exudate but also aids in formation of granulation tissue. NPWT is provided along with empirical prophylactic antibiotics
214971763|NCT06957964|DRUG|Standard Antibiotic Treatment|According to hospital antibiogram, empirical antibiotics are given prophylactically
214971764|NCT06958146|DRUG|oral azithromycin|we will be administering single-dose oral azithromycin to ladies who go into labor and have no risk factors for sepsis, as there is increased risk of postpartum sepsis in both mother and neonate after normal vaginal delivery in low-income and middle-income countries
214971765|NCT06958146|OTHER|no azithromycin|participants in this arm will be given only standard labor care and no oral azithromycin
214971766|NCT06958172|OTHER|Exercise|Study Group received core stabilization, thoracic mobility and hip mobility exercises
214971767|NCT03675646|DRUG|Morphine|Intrathecal injection of 250 mcg preservative-free morphine before surgery
214971768|NCT05588531|DRUG|Group 1:YK-1169|YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
214971769|NCT05588531|DRUG|Group 2:YK-1169/Placebo Injection|YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
214971770|NCT05588531|DRUG|Group 3:YK-1169/Placebo|On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
214971771|NCT05588531|DRUG|Group 4:YK-1169/Placebo|On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
214971772|NCT05588531|DRUG|Group 5:YK-1169/Placebo Injection|YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
214971773|NCT05588531|DRUG|Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injection|YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
214971774|NCT05043740|DRUG|Repatha or Praluent|Evolocumab (Repatha®) 140 mg or Alirocumab (Praluent) 75mg every two weeks, first subcutaneous injection at the time of randomization, followings during 12 months
214971775|NCT03884010|OTHER|No intervention|Cross-sectional
214971776|NCT06958887|OTHER|Betwixt app intervention|Narrative gaming smartphone app
214971777|NCT02505958|OTHER|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing \~ 6000 Kcal/24 h.
214971778|NCT02505958|OTHER|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (\~333 calories each) totaling \~ 1,000 calories/24 hours.
214971779|NCT01166256|DEVICE|Non-invasive ventilation|Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 \>92% or PaO2 \>65 mmHg.
214971780|NCT01166256|DEVICE|High flow nasal cannula system|High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 \>92% or PaO2 \>65 mmHg.
214971781|NCT03566277|BEHAVIORAL|Self-monitoring|Participants will have access to a wrist-worn activity monitor and have a daily step goal
214971782|NCT03566277|BEHAVIORAL|Incentives|Participants will have a deposit contract, wherein they will lose money if a goal is not reached, or double their money if a goal is reached
214971783|NCT03566277|BEHAVIORAL|Feedback|Participants will receive text message feedback each day about progress towards their goal
214359652|NCT01509729|PROCEDURE|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
214971784|NCT03041662|DIAGNOSTIC_TEST|MR/MRCP|MR/MRCP
214971785|NCT02347709|PROCEDURE|Diabetic Foot Ulcer Biopsy|Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.
214971786|NCT02347709|OTHER|Survey|Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.
214971787|NCT02347709|OTHER|Comprehensive Neuropathy Assessment|Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.
214971788|NCT02347709|OTHER|Wound Photography|Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
214971789|NCT02787499|PROCEDURE|HIV-1 RNA Resistance Testing|Perform drug resistance on enrollment to guide management of virologic failure
214971790|NCT05433610|DEVICE|Non-invasive Ventilation|Exercise capacity testing using the device
214971791|NCT06122350|BEHAVIORAL|Earthquake preparedness training|Mothers with physically disabled children will be trained on what to do before, during and after an earthquake within the scope of earthquake preparedness training.
214971792|NCT00048035|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of iv administration
214971793|NCT05906147|OTHER|Regular follow-up|Follow-up of the population was conducted to track the incidence of fractures
214971794|NCT01825304|DEVICE|titrated setting peep|titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
215083633|NCT04424056|DRUG|Anakinra +/- Ruxolitinib (stages 2b/3)|administration of Anakinra +/- ruxolitinib, depending of evolution
214359653|NCT02261493|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
214359654|NCT02261493|DRUG|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
214359655|NCT02965950|DRUG|Cyclophosphamide|I.v. infusion
214359656|NCT00530855|DRUG|Lacosamide|50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
214359657|NCT00815295|DRUG|Sorafenib|Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
214359658|NCT00815295|DRUG|Cetuximab|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
214359659|NCT03972111|DRUG|TPOXX 200Mg Capsule|TPOXX 600 mg (three 200 mg.) capsules twice daily for 14 days
214359660|NCT02816151|DRUG|full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
214359661|NCT02816151|DRUG|half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
214971795|NCT02930057|DRUG|Celestone|all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
214359662|NCT05156918|OTHER|Exercise|Participants will rotate between three exercise machines (randomly assigned rotation order at outset): A Concept C2 rowing machine, a stationary bicycle, and a treadmill. Study participants will use a different machine each day so that they are using each of the three exercise machines once per week. Two treadmills, two bikes, and two rowers are available during each exercise session. Participants will be randomly assigned to one of three machine orders: treadmill-rower-bike, rower-bike-treadmill, or bike-treadmill-rower. We will employ a percent of heart rate protocol as an exercise intensity measure (77-93% of age-adjusted maximum heart rate) rather than a less well-defined maximal effort protocol or rating of perceived exertion scale. For the purposes of this exercise protocol high intensity exercise will be defined as 77-93% of age adjusted maximum heart rate.
214971796|NCT02930057|PROCEDURE|pulsed radiofrequency treatment|all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
214971797|NCT02930057|DRUG|Control|all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
214971798|NCT01045005|OTHER|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
214971799|NCT01045005|OTHER|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
214971800|NCT02246738|OTHER|Blood Collection|
214971801|NCT04601168|DEVICE|kneeSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
214971802|NCT03072095|BEHAVIORAL|Text-only|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.
214971803|NCT03072095|BEHAVIORAL|Text + Lottery|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
214971804|NCT02895685|OTHER|Dyad training|Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
214359663|NCT05156918|OTHER|Non Exercise|There are no modifications to regular diet or exercise habits for 30 days.
214359664|NCT02692326|PROCEDURE|Cyclic parenteral nutrition|Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies \< 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
214971805|NCT02735980|DRUG|Prexasertib|Administered IV
214359665|NCT05450315|BEHAVIORAL|Stride to Survive:An Exercise Guide for Young Adult Cancer Survivors|
214359666|NCT05450315|BEHAVIORAL|Canadian Physical Activity Guidelines|
214487821|NCT06758830|DRUG|Consolidation Chemotherapy|"XELOX: Oxaliplatin 130 mg/m² (day 1) + capecitabine 1000 mg/m² (days 1-14), every 3 weeks for 4 cycles.~Or FOLFOX: Oxaliplatin - 85 mg/m2 intravenously (2-hour infusion), drip for 1 day. Calcium folinate (folinic acid) - 400 mg/m2/d. intravenously (2-hour infusion), started on day 1. F(5-fluorouracil) - 400 mg/m2/d. intravenously (bolus), started on day 1. Repeat every 2 weeks for 6 times."
214487822|NCT06758830|PROCEDURE|Surgery|Transabdominal Resection: Abdominoperineal resection, low anterior resection, or coloanal anastomosis using total mesorectal excision.
214971806|NCT00509899|DRUG|Ruxolitinib|5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
214971807|NCT05192317|DEVICE|Sollievo Fisiolax|Class IIb Medical Device
214971808|NCT05192317|OTHER|Sollievo Fisiolax Placebo|Placebo
214971809|NCT05492149|OTHER|Performance follow-up|Diary performance during rehabilitation will be collected and a CAT questionnaire will be completed by the patient.
214971810|NCT02335255|DRUG|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
214971811|NCT02335255|DRUG|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
214359667|NCT05853679|DEVICE|Lumoral Treatment|The device will be used 5 to 7 times per week according to the manufacturer's instructions.
214359668|NCT05853679|OTHER|Standard oral hygiene instructions according to the Finnish Dental Association|Participants will be instructed to clean their teeth twice per day by an electric toothbrush, an interdental brush, and flossing.
214359669|NCT01137474|DRUG|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
214359670|NCT01137474|DRUG|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
214359671|NCT03540654|OTHER|Budget impact|Budget impact, using a probabilistic markov model, of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with current practice (treatment during entire life), from the healthcare system point of view
214487823|NCT06758830|OTHER|Part two|Standard treatment protocols and follow-up procedures are implemented in clinical practice.
214487824|NCT06758830|OTHER|Adjuvant treatment|If indicated, adjuvant therapy will be administered as usual in clinical practice.
214487825|NCT06761573|DEVICE|Bilateral Bispetral Index Monitor will be applied on forehead of our patients, before surgery begins|In patients undergoing surgery and general anesthesia, the investigators want to examine -using bilateral BIS monitor- synthetic electroencephalographic differences between the two cerebral hemispheres (ASYM) to evaluate any correlation with the development of POD and POCD in the post-operative period.
214487826|NCT06789354|OTHER|Questionnaire and Physical Exam|All assessments were carried out face-to-face with the same physiotherapist.
214487827|NCT06794593|DRUG|Camostat Mesylate|Oral Camostat Mesylate 200 mg x 3 daily for 4 days.
214487828|NCT06797154|BEHAVIORAL|StrokeWear Motor and Behavioral Intervention|The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.
214487829|NCT06797154|OTHER|Usual Care + Sham|The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
214971812|NCT02335255|DRUG|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
214971813|NCT00179595|BEHAVIORAL|relaxation response- meditation|
214971814|NCT02501746|OTHER|Usual Clinical Care|Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
214971815|NCT02501746|OTHER|Group Medical Visits|"The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute breakout time. The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic."
214971816|NCT02501746|OTHER|Microfinance Groups|The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
214971817|NCT00002192|DRUG|Rifapentine|
214971818|NCT00002192|DRUG|Ethambutol hydrochloride|
214971819|NCT00002192|DRUG|Clarithromycin|
214487830|NCT05684705|DRUG|BV100|Intravenous infusion
214487831|NCT06772012|OTHER|Low-Level Laser Therapy (LLLT)|"* Frequency: LLLT was administered 3 times per week.~* Duration: Each session lasted approximately 15-20 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.(50)"
214487832|NCT06772012|OTHER|Orofacial Physical Therapy|"* Frequency: Orofacial physical therapy sessions were conducted 3 times per week.~* Duration: Each session lasted around 30-40 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.~* Components:~  * Manual Therapy: Included techniques such as joint mobilization, soft tissue manipulation, and muscle stretching.~ * Therapeutic Exercises: Focused on strengthening, coordination, and improving mobility of the masticatory muscles.~ * Postural Training: Addressed poor posture and cervical muscle spasm.(50)"
214971820|NCT00002192|DRUG|Azithromycin|
214971821|NCT03186144|GENETIC|Blodd punction for genetic analysis|
214971822|NCT00713843|OTHER|Manual Therapy Utrecht|Manual Therapy (6 weeks).
214971823|NCT00713843|OTHER|Physical Therapy|Physical Therapy (six weeks).
214359672|NCT06335433|OTHER|Exercise Training (Isometric Handgrip Exercise)|Participants allocated to the exercise groups will complete 6 weeks of isometric handgrip exercise training (IHGT) using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong) for either 2 or 4 sessions per week. Each exercise session will consist of 4 x 2-minute isometric contractions at 30% MVC with 1 minute rest periods between contractions. The first bout will be performed on the dominant arm and then the arm will be alternated for each subsequent two-minute bout. Participants will be instructed to try keep the contraction tension as close as possible to the set tension of 30% MVC using visual feedback from the dynamometer's electronic display.
214359673|NCT03833882|DEVICE|MAF1217|The study population will have to self-administer the study treatment in a TID posology.
214359674|NCT03833882|OTHER|Cationorm|The study population will have to self-administer the study treatment in a TID posology.
214971824|NCT00976326|DRUG|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
214359675|NCT00498719|BEHAVIORAL|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
214971825|NCT03273920|PROCEDURE|Robotic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
214971826|NCT03273920|PROCEDURE|Laparoscopic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
214971827|NCT03426410|OTHER|Survey|Electronic survey containing a questionnaire regarding knowledge and use of national guidelines of low back pain rehabilitation, type and frequency of cross sectional communication, attitudes and beliefs about back pain and two patient vignettes.
214971828|NCT03677115|DRUG|Dexmedetomidine|combination of ropivacaine and dexmedetomidine 20 ug every time
214971829|NCT04777981|DIETARY_SUPPLEMENT|CBDRA60 supplement|CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans \[15, 16\]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,
214971830|NCT04777981|DIETARY_SUPPLEMENT|Placebo|Placebo
214359676|NCT00498719|OTHER|Control Group|Standard educational support.
214971831|NCT00114985|DEVICE|Prostate Immobilization Device|Device placed during radiation treatment
214971832|NCT05343663|BEHAVIORAL|Education|Self-Management Program Conducted with Tele-Nursing will increase Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients.
214971833|NCT01407809|DEVICE|Venous Sinus Stenting|Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
214971834|NCT00003713|DRUG|intoplicine|
214971835|NCT04767113|DRUG|Heparin sodium|"For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol."
214971836|NCT04767113|DRUG|Normal saline|For infants enrolled, normal saline was infused at the corresponding speed.
214971837|NCT02975180|DEVICE|FES|The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.
214971838|NCT02975180|BEHAVIORAL|Conventional|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
214971839|NCT04096846|DIAGNOSTIC_TEST|laboratory investigation|detection of serum level of methotrexate and serum level of vitamin D
214971840|NCT02437760|OTHER|serum and pleural effusion CA-125 level|"serum and pleural effusion(if exist) CA-125 are collected:~* at time of diagnosis~* every 3 month during treatment~* stop at the progression or after 12 months"
214971841|NCT04073719|DIETARY_SUPPLEMENT|Apple Cider Vinegar|Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.
214359677|NCT02219048|DRUG|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
214487833|NCT06752837|DEVICE|Tornado rotary system|In arm one, stainless steel tornado files works by high-speed rotation that influences the fluid dynamics within the canal and improves irrigation efficiency. Canals are finished with a file having a 4% taper and an apical diameter of 0.25 mm.
214971842|NCT04073719|DIETARY_SUPPLEMENT|Other Beverage|To what degree do other high citrate beverages impact urinary citrate output.
214971843|NCT05882500|OTHER|No intervention, observation|
215083634|NCT04424056|DRUG|Anakinra and Ruxolitinib (Advanced stage 3)|administration of Anakinra and ruxolitinib
214359678|NCT02219048|DRUG|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
214359679|NCT02769286|DRUG|Osimertinib|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
214359680|NCT02521090|BIOLOGICAL|EGFRBi-Armed Autologous T Cells|Given IT and IV
214359681|NCT02521090|OTHER|Laboratory Biomarker Analysis|Correlative studies
214359682|NCT04592445|DEVICE|Satera GSN Ablation|The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .
214359683|NCT04592445|DEVICE|Sham Control|The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (\~30 minutes).
214359684|NCT04983550|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w
214359685|NCT04983550|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w
214359686|NCT00003006|GENETIC|reverse transcriptase-polymerase chain reaction|
214359687|NCT00003006|OTHER|immunohistochemistry staining method|
214359688|NCT00571454|BEHAVIORAL|telephone depression care management|"1 call per week for first 4 weeks~1 call every other week for next 8 weeks"
214359689|NCT05895266|DRUG|ABBV-903|Oral Tablet
214359690|NCT05895266|DRUG|Midazolam|Oral Liquid
214359691|NCT05995028|BIOLOGICAL|Universal CD7-specific CAR gene-engineered T cells|Infusion of 4SCAR7U T cells
214359692|NCT02825082|PROCEDURE|Abdominal emergency surgery|all abdominal emergency surgery procedures
214359693|NCT04150003|BEHAVIORAL|Pulmonary Rehabilitation program|Structured rehabilitation program of directed exercises
214359694|NCT04150003|OTHER|Usual care|Usual care for patients who had suffered a Pulmonary Embolism
214487834|NCT06752837|DEVICE|WaveOne rotary system|In arm two, WaveOne system is a single reciprocating file system with a heat-treated NiTi Memory Wire (M Wire).It has a taper of 0.08 in apical 3 mm, with a tip diameter of 0.25 mm. in a torque control endodontic handpiece (X smart plus with reciprocation mode)
214971844|NCT05074875|OTHER|Questionnaires and Patient Reported Outcomes (PROs)|"* EuroQol 5 Dimensional Quality of Life Questionnaire (EQ-5D).~* St. George's Respiratory Questionnaire (SGRQ)~* Impact of Events Scale Revised (IES-R)~* Generalized Anxiety Disorder 7-Item (GAD-7)~* Patient Health Questionnaire (PHQ-9)"
214971845|NCT05074875|DIAGNOSTIC_TEST|Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)|If required by the local site's COVID-19 guidelines, subjects should have the COVID-19 RT-PCR Nasal Swab collected at the beginning of the visit or within 5 days prior to the scheduled visit.
214971846|NCT05074875|GENETIC|Blood Samples for Biomarkers|Venous blood will be collected using pre-labeled tubes.
214971847|NCT05074875|DIAGNOSTIC_TEST|High Resolution Computed Tomography|Subjects will have HRCTs at Visits 1, 2, 3, and 4. Inpatient HRCT scans will be collected during the baseline visit (V0 or V1)
214971848|NCT05074875|DIAGNOSTIC_TEST|Physical Exam and Vital Signs|"A complete physical exam, including height, weight, general appearance, neck, lungs, cardiovascular system, abdomen, extremities, and skin will be performed at Visit 1.A brief physical exam will be completed at subsequent visits, including weight, general appearance, lungs, cardiovascular symptoms, extremities, and other body systems pertinent to the participants health status, at the discretion of the investigator.~Blood pressure, heart rate, and oxygen saturation will be collected at all visits, prior to blood draws and after subjects have rested."
214971849|NCT05074875|DIAGNOSTIC_TEST|Medical Research Council Sum Score|The Medical Research Council Sum Score (MRC-SS) is used globally to detect peripheral muscle strength and to help diagnose ICU-acquired muscle weakness. The MRC-SS ranging from 0 (complete paralysis) to 60 (normal).
214971850|NCT05074875|DIAGNOSTIC_TEST|Hand Grip Strength|Each subject will have hand grip strength measured at each visit. This is being done in order to assess the maximum isometric strength of hand and forearm muscles.
214487835|NCT06752837|DEVICE|OneShape rotary system|In arm three, OneShape system utilizes a conventional, continuous rotational motion. It has asymmetric cross-sectional geometry, and traveling waves of motion that are produced along the file's active region. It has a single constant taper of 0.06 and a tip size of 25 with distinct cross-sectional designs along the whole length of the working parts
215083635|NCT04424056|DRUG|Tocilizumab +/- ruxolitinib (stages 2b/3)|administration of Tocilizumab +/- ruxolitinib, depending of evolution
215083636|NCT04424056|DRUG|Tocilizumab and Ruxolitinib (Advanced stage 3)|administration of Tocilizumab and Ruxolitinib
214487836|NCT06752837|DEVICE|Cone beam computed tomography|A post-operative CBCT image was obtained and compared to the pre-operative one to assess the impact of canal preparation of each file on the periapical lesion.
214487837|NCT06841120|DEVICE|Actual laser application|At approximately 45 minutes into the treatment session, subjects in the laser group received irradiation from a 4 W power, 810 nm diode laser (Fox; ARC Laser, GmbH, Nürnberg, Germany). The laser was operated in continuous mode, delivering 12-second shots per point using a therapy head with a point size of 0.38 cm². Each point received 6.3 J/cm² of laser energy, resulting in a total energy density of 37.8 J/cm² across 6 points.
214359695|NCT04794803|DRUG|Reparixin|Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.
214487838|NCT06841120|DEVICE|Sham laser application|Sham laser was applied symbolically as a diffused closed laser (targeted beam) at the same distance and simultaneously. Evaluations after laser irradiation were conducted by a responsible specialist physician who was not involved in performing the treatment procedures.
214359696|NCT04794803|DRUG|Standard of care|Standard of care
214359697|NCT02923843|OTHER|Comprehensive Geriatric Assessment|The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
214359698|NCT06165783|OTHER|Therapeutic Exercises and Ultrasound|describe the rationale and methodology for evaluating the effect of using therapeutic exercises and ultrasound in the rehabilitation of partially injured hamstring muscles
214359699|NCT05300425|OTHER|Blood sample collection|Blood sample collection (at baseline and approximately two years after baseline). Enzyme-linked immunosorbent assays will be used to screen for IgG and IgM antibodies directed against the three pathogens (Leptospirosis, Tularemia, Hepatitis E).
214359700|NCT05300425|OTHER|Data collection|Data collection on sociodemographic questions e.g. profession, leisure activities, animal contact
214359701|NCT05971719|DIAGNOSTIC_TEST|Air Leaks: Aerosol glycerine System|A range of different leak will be done with different needle sizes on the lung. Perform localization on staple lines used surgically during pulmonary surgeries, as they are known to not consistently give an airtight closure. The lung will be put in the ex-vivo model and ask for a surgeon to localize the leaks with our system. The needle incisions will be repeat on another lung and ask the same surgeon to localize the leaks with the submersion test. To perform the submersion test the surgeon will have to submerge the lung in saline solution and to check the presence of air bubbles. The lung is inflated to pressures of 20 to 40 cm H209. The precision of both systems will be compared by the minimal incision the minimal incision the surgeon was able to localize.
214359702|NCT04475549|DRUG|IW-6463 Tablets|IW-6463 tablets administered orally (daily)
214487839|NCT05197309|DIETARY_SUPPLEMENT|Metabolic Diet|Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.
214487840|NCT06842719|PROCEDURE|on-site housing counseling|on-site housing counseling by a certified housing counseling expert
214971851|NCT05074875|DIAGNOSTIC_TEST|Spirometry|Spirometry will be assessed at Visits 1, 2, 3 and 4. Each site will use its own spirometry machine. Each subject should use the same machine at each visit and conduct measurements at approximately the same time. Before any testing, the maneuver should be demonstrated to the subject. The spirometry should be reviewed by the investigator.
214971852|NCT05074875|DIAGNOSTIC_TEST|Diffusing Capacity of Carbon Monoxide|The site will use its own DLCO equipment for measurements at Visits, 1, 2, 3, and 4. The Single-breath DLCO maneuver will be carried out in accordance with the 2017 American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Subjects should use the same device at approximately that same time at each visit. The maneuver should be demonstrated to the subject prior to the test.
214971853|NCT05074875|DIAGNOSTIC_TEST|6 Minute Walk Test|"The 6 Minute Walk Test (6MWT) will assess exercise capacity and tolerance. 6MWTs will be conducted at Visits 1, 2, 3, and 4.~The procedure of the 6MWT should be explained and demonstrated to the subject prior to the start of the test."
214971854|NCT05074875|DIAGNOSTIC_TEST|Sit to Stand (STS) Measurement|The STS will be conducted at Visits 1, 2, 3, and 4 to assess the physical functioning of the adult participants.
214971855|NCT03566095|BEHAVIORAL|Coaching and Voices for Food Kit|Community Coaching and Voices for Food Kit
214971856|NCT03566095|BEHAVIORAL|Voices for Food Kit|Voices for Food Kit
214971857|NCT00905242|DRUG|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
214971858|NCT06165432|DRUG|Topical Benzocaine|Benzocaine topical anesthetic gel will be used a pre-injection anesthetic on one half of the palate before giving greater palatine nerve block
214971859|NCT06165432|OTHER|Topical ice|For the other half of the palate topical ice would be used before greater palatine nerve block
214971860|NCT03266900|PROCEDURE|re-TURBT|2nd bladder biopsy within 4-6 weeks of initial biopsy
214971861|NCT03266900|DRUG|6 weeks BCG instillation|standard 6 weeks of BCG induction
214971862|NCT05181150|OTHER|Meal test|Ingestion of an oral liquid meal (nutridrink), 200 mL.
214971863|NCT05181150|OTHER|GIP|Subcutaneous GIP injection.
214971864|NCT05181150|OTHER|GLP-2|Subcutaneous GLP-2 injection.
214971865|NCT05181150|OTHER|GIP + GLP-2|Subcutaneous GIP + GLP-2 injection.
214971866|NCT05181150|OTHER|Placebo|Subcutaneous saline injection.
214971867|NCT03387605|DRUG|Ivabradine|ivabradine or placebo given orally 2 times daily for 72 hours
214359703|NCT00109616|BEHAVIORAL|Newborn skin cleansing with 0.25% chlorhexidine solution|
214359704|NCT00109616|BEHAVIORAL|Cleansing of umbilical cord with soap and water solution|
214487841|NCT06865963|GENETIC|vulvar biopsy and blood semples|Collection of different types of specimen from VBD patients and healthy controls: mRNA, protein, cells, blood
214487842|NCT06884111|DRUG|EE001，70-105ml per day by IV|EE001 is a brand-new testing agent for human studies, it is the first time in human being
214487843|NCT06881537|DRUG|Capecitabine|Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 4 cycles
214487844|NCT06881537|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 130mg / m² on Day 1 every 3 weeks for 4 cycles
214487845|NCT06881537|DRUG|Bevacizumab|Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 4 cycles
214487846|NCT06881537|DRUG|Tislelizumab|Tislelizumab is given intravenously at 200 mg on day 1 every 3 weeks for 4 cycles
214359705|NCT00109616|BEHAVIORAL|Cleansing of umbilical cord with 4% chlorhexidine|
214359706|NCT00146575|DEVICE|Sirolimus-eluting stent (Cypher)|patients have been implanted a Cypher stent
214359707|NCT00146575|DEVICE|Paclitaxel-eluting stent (Taxus)|patients have been implanted a Taxus stent
214359708|NCT04262362|PROCEDURE|Root canal treatment|Incidence of pain that may occur due to sodium hypochlorite extrusion
214359709|NCT00606775|DRUG|Carvedilol|2.5-5mg/day
214971868|NCT03387605|DRUG|Placebo|matching placebo given 2 times daily for 72 hours
214971869|NCT05695742|OTHER|Active Smoking|Being active smoker
214971870|NCT05695742|OTHER|Passive smoker|Being exposed to secondhand smoke
214971871|NCT05695742|OTHER|Non-smoker|Not being an active or passive smoker.
214971872|NCT01167569|DRUG|Ascorbic Acid|Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
214971873|NCT01167569|OTHER|5 % Dextrose Water or Normal Saline|100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
214971874|NCT02501824|OTHER|anthroposophic therapeutic speech|anthroposophic therapeutic speech
214971875|NCT02306889|DRUG|Fenofibrate|130mg Capsules
214971876|NCT02306889|DRUG|ANTARA® (fenofibrate)|130mg Capsules
215083637|NCT04424056|OTHER|Standard of care|Treatment with drugs or procedures in routine clinical practice
214359710|NCT00877331|BEHAVIORAL|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
214487847|NCT06886568|PROCEDURE|Ultrasound-guided ganglion impar block|The procedure will be performed under sterile conditions and continuous monitoring. Using an ultrasound device with a 10-12 MHz linear probe, a 22G spinal needle will be advanced into the sacrococcygeal joint space using the out-of-plane technique. After confirming loss of resistance with a syringe containing normal saline as the needle exits the capsule anterior to the joint, approximately 1 mL of contrast medium will be injected. Anteroposterior (AP) and lateral fluoroscopic images will be obtained to verify the spread of the contrast agent. Once adequate contrast distribution is confirmed anterior to the coccyx on the lateral view, a mixture of dexamethasone and bupivacaine will be injected to complete the block. Procedures that cannot be completed or successfully visualized under ultrasound guidance will be finalized under fluoroscopic guidance.
214487848|NCT06883656|DRUG|SAL067|Fasting oral test drug 12mg
214971877|NCT04100928|OTHER|dental students|WEMWBS and a questionnaire included demographic details and social background, lifestyle behaviors was applied to the participants.
214971878|NCT04802499|PROCEDURE|Turkish Reliability and Validity of TESS|Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed
214971879|NCT04101292|OTHER|Characterization of tumor tissue by fluorescence|"* HSI Imaging of the resected specimen, from the serum and the mucous side~* FF-OCT imaging of the tumor and the healthy tissue biopsies~* Local application of Bevacizumab-IRDye800CW and visualization with the Surgvision Explorer system~* Standard anti-VEGF Immunohistochemistry and pathology"
214971880|NCT04872088|BEHAVIORAL|Strengthened SBCC|Social and Behavioral Change Communication related to prenatal, postnatal, IYCF practices as well as on the care of young children at several specific ages, hygiene, and health will be delivered during monthly home visits by pairs of NASG members.
214971881|NCT04872088|DIETARY_SUPPLEMENT|Preventive nutritional supplement|"Monthly delivery by NAGS pairs of a nutritional supplement: SQ-LNS, at a dose of 28 bags of 20g per month per beneficiary child. The nutritional supplement is limited to :~\- \[6-17\]months old children diagnosed as non-wasted (MUAC\>=125mm)"
214971882|NCT04872088|BEHAVIORAL|Family MUAC|"MUAC screening of children 6 to 59 months of age by family members will be introduced. This will involve distributing Shakir MUAC tapes to all intervention households and training mothers/guardians, or any other family member expressing an interest, in the screening of wasting with the MUAC criterion.~The training will be carried out by the members of the NASGs and during each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary. They will also explain the procedure to be followed if the child is diagnosed as wasted by a family."
214359711|NCT03683485|PROCEDURE|long duration EPBD|An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.
214359712|NCT03683485|PROCEDURE|EST|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
214359713|NCT01698294|OTHER|Clinical Observation|Participants maintain usual diet and undergo clinical observation
214359714|NCT01698294|DIETARY_SUPPLEMENT|Flaxseed|Given PO
214487849|NCT06744556|DRUG|daunorubicin|Used in combination with cytarabine and venetoclax for induction therapy in DAV.
214487850|NCT06744556|DRUG|Venetoclax|Used in combination with cytarabine and daunorubicin for induction therapy in DAV.
214487851|NCT06744556|DRUG|cytarabine|Used in combination with venetoclax and daunorubicin for induction therapy in DAV or used by intermediate does for consolidation therapy.
214971883|NCT04872088|BEHAVIORAL|Active screening by NASGs|"Monthly screening by the NASG members of the children they follow, using the MUAC.~Referral to the health center of \[6-17\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled."
214971884|NCT04872088|BEHAVIORAL|Intensified followup of children with wasting referred to and enrolled in CMAM treatment|NASG members will conduct biweekly follow-up visits in the households of children with wasting referred to and enrolled in CMAM treatment programs to ensure adherence to the outpatient treatment schedule.
214971885|NCT04872088|BEHAVIORAL|Relapse prevention|NASG members will conduct biweekly home visits to monitor the nutritional status of children aged 9 to 17 months who were discharged from CMAM treatment after recovery. NASGs members will provide additional counseling to prevent relapse and screen these children for wasting to detect possible relapse.
214971886|NCT04872088|BEHAVIORAL|Cooking demonstrations|NASGs members will also be supported by the IRAM project in the organization of cooking demonstrations with nutrient-rich foods in the community, during which passive screening of children will be carried out.
214971887|NCT02130999|DRUG|tasimelteon 20 mg capsule|
214971888|NCT02130999|DRUG|tasimelteon 2 mg I.V.|
214359715|NCT01698294|OTHER|Laboratory Biomarker Analysis|Correlative studies
214359716|NCT01698294|OTHER|Questionnaire Administration|Ancillary studies
214487852|NCT06744556|DRUG|azacitidine|Used in combination with venetoclax for maintenance therapy.
214487853|NCT06744556|DRUG|Homoharringtonine|Used in combination with cytarabine and venetoclax for induction therapy in HAV.
214487854|NCT06744556|DRUG|Idarubicin|Used in combination with cytarabine and venetoclax for induction therapy in IAV.
214487855|NCT06765772|PROCEDURE|Erector spinae plane block|the patient will recieve ultrasound guided erector spinae plane blockbe. A 20-gauge needle will be placed between the erector spinae muscle and the thoracic transverse processes at the level of T10 using an 'in plane' technique, 20 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.
214359717|NCT04040751|BEHAVIORAL|CARE-CITE|The primary CARE-CITE components will be education via web platform. Carepartners complete 6 online CARE-CITE modules (15-30-minute sessions each). The modules include demonstration videos and instructive content covering following areas: principles of functional task practice (i.e., activities of daily living such as eating, grooming, or leisure/vocational activities), adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity (i.e., increasing numbers of practice repetitions or weight of objects lifted). Underpinning the content is the concept of autonomy support, with examples of fostering empathy, problem solving, instruction in the use of non-controlling language with role playing situations and the importance of creating choice in activities.
214971889|NCT00697320|DRUG|eptacog alfa (activated)|"A NON INTERVENTIONAL OBSERVATIONAL STUDY:~Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation"
214971890|NCT02087774|BEHAVIORAL|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
214971891|NCT00371735|DRUG|chlorproguanil-dapsone-artesunate|
214971892|NCT00371735|DRUG|chlorproguanil-dapsone|
214971893|NCT05081388|DRUG|REGN14256|Sub-cutaneous (SC) single dose
214971894|NCT05081388|DRUG|imdevimab|SC single dose
214971895|NCT05081388|DRUG|casirivimab + imdevimab|SC single dose
214359718|NCT04040751|BEHAVIORAL|Standard of care|The carepartner will receive a support brochure with general caregiving information including website resources to mimic web interaction of intervention group (e.g., stroke caregiver resource site).
214359719|NCT04118530|OTHER|HSCT Patients|Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
214487856|NCT06765772|PROCEDURE|Rectus sheath block|the patient will recieve ultrasound guided rectus sheath block. An 18-gauge needle will be introduced- in plane- just below the costal margin at an angle of approximately 45 degrees to the skin between the rectus abdominis muscle and posterior rectus sheath. 10 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.
214679263|NCT04016493|PROCEDURE|Connective tissue graft|The patient received 600 mg of ibuprofen (paracetamol 1 g in case of allergy) prior to surgery, and chlorhexidine mouthwash 0.2% was provided for 2 min. Patients received local anaesthesia at the donor and recession sites (articaine hydrochloride 7200 mg/1.8 ml, adrenalin 1800 mcg/1.8 ml). CTG harvesting was performed prior to the preparation of the reception site to avoid any bias. The graft dimension was calculated according to the recession dimensions; a minimum of 3 mm of the graft was submerged mesially, distally and apically. The CTG was harvested from the palate with single edge incision and sutured with 4.0 silk. The patient was subsequently assigned randomly to the control (CAF+CTG) or the test group (TUN+CTG).
214971896|NCT05081388|DRUG|Placebo|SC single dose
214971897|NCT04581434|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged Exposure Therapy is an individually-delivered treatment for PTSD that includes in vivo exposure to trauma reminders and imaginal exposure to the trauma memory delivered in 90-minute weekly sessions.
214971898|NCT04581434|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an individually-delivered treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to the trauma, with an optional written trauma account during weekly 60-minute sessions
214971899|NCT04581434|BEHAVIORAL|Present Centered Therapy|"Present Centered Therapy is an individually-delivered treatment for PTSD that focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to current life difficulties and stress identified by patients, and emotional support and validation"
214971900|NCT00255619|DEVICE|Baxter's UltraBag® and FMC Andy·Disc®|
214971901|NCT03677635|BEHAVIORAL|Guided Autobiographical Memory Recall|Participants are asked to recall positive autobiographical memories with the assistance of prompts to promote specificity, generalisability and links to the future. The participants will also view a 5min psychoeducation video on the subject of memory specificity and motivation.
214971902|NCT03478709|OTHER|volume expansion|Volume expansion when the patient has a dependent preload evaluated by a positive leg lever test (variation of more than 10% of the VES). It corresponds to the intravenous administration of 500 ml of Ringer lactate over 10 min.
214971903|NCT03478709|OTHER|norepinephrine|Vasopressor agent when the patient has persistent arterial hypotension related to postoperative vasoplegia syndrome. Norepinephrine is administered during persistent hypotension (MAP \<60mmHg) despite volume expansion. It corresponds to continuous intravenous norepinephrine administration to obtain a MAP of more than 70 mmHg
214971904|NCT04092738|BEHAVIORAL|Walk@WorkApp-Diab|The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones
214971905|NCT00597818|DRUG|Cobiprostone|18 mcg cobiprostone capsules for oral administration
214971906|NCT00597818|DRUG|Placebo|Matching placebo capsules for oral administration
214971907|NCT00597818|DRUG|Non-steroidal anti-inflammatory drug|Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.
214971908|NCT03250689|DRUG|Danirixin|Danirixin will be available as 35 mg oval shaped, white film coated HBr embossed tablets.
214971909|NCT03250689|DRUG|Placebo|Placebo will be available as oval shaped, white film coated tablets.
214971910|NCT03250689|DRUG|Rescue medication|Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
214971911|NCT03250689|DRUG|Inhaled COPD maintenance medication|Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist \[LAMA\], long-acting beta-agonist \[LABA\]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
214971912|NCT02157519|OTHER|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
214971913|NCT01656395|DRUG|MK-1029|MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
214971914|NCT01656395|DRUG|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
214971915|NCT01656395|DRUG|Placebo|Parts I-II: Participants will receive Placebo tablets QD
214971916|NCT03075267|DRUG|PT010 (BGF MDI) 320/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
214971917|NCT03075267|DRUG|PT010 (BGF MDI) 160/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
215083638|NCT05044104|DEVICE|Consumer-facing wearable smart watch|Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
214359720|NCT04737460|GENETIC|AAV9/CLN7|Enrollees will receive gene therapy via a viral vector
214359721|NCT06297486|GENETIC|SPK-8011|Participants will receive a single dose of SPK-8011, administered by intravenous (IV) infusion, on Day 1.
214359722|NCT00006136|DRUG|arginine butyrate|
214359723|NCT00006136|DRUG|epoetin alfa|
214359724|NCT00465413|DEVICE|Small volume spacer and/or Rinsing the mouth with water|
214679264|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
214359725|NCT00000602|DRUG|hydroxyurea|
214359726|NCT06530862|OTHER|ESWT+stretching exercises|Participants in this group will receive ESWT treatment
214679265|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
214971918|NCT03075267|DRUG|PT003 (GFF MDI) 14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
214971919|NCT00523913|DRUG|rosiglitazone|
214971920|NCT02314858|BEHAVIORAL|Brief Personalized Video (BPV)|The BPV group will view a portion of their own sleep study that took place during their overnight sleep study.
214971921|NCT02314858|BEHAVIORAL|Non-Personalized Video (NPV)|The NPV group will see a stock video of someone with OSA.
214971922|NCT02314858|BEHAVIORAL|Treatment as Usual (TAU)|The TAU group will not watch a video.
214971923|NCT00850369|OTHER|RBC transfusion|Study subjects will receive monthly transfusions with 2 units of red blood cells
214971924|NCT04319393|BEHAVIORAL|Cognitive Behavioral Therapy|"The CBT intervention was carried out through six two-hour sessions over a month. The intervention group was divided into three subgroups of 18 to 19 nurses each. It was required for each subgroup to attend two CBT sessions to complete the intervention.~The CB therapist followed the same structure in the delivery of each CBT session. The CBT session was delivered in five modules: generating objectives and outcomes, enhancing self-esteem and interpersonal relationships, changing beliefs regarding symbolic mortality, and changing attitudes regarding death anxiety. The first session began with highlighting the objectives of the CBT. Then, a detailed presentation of the intervention modules was provided to the nurses with integration of CBT exercises, including cognitive restructuring, graded exposure, mindfulness meditation, interpersonal skills training, and activity scheduling"
215083639|NCT03918226|PROCEDURE|exploratory laparotomy|Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
215083640|NCT03189654|DEVICE|Non-invasive ventilation|Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
215083641|NCT01048294|DEVICE|Original Energy Light,|9000 lux, 30 minutes in the morning
215083642|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 20 minutes in the morning
215083643|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 30 minutes in the morning
214359727|NCT06530862|OTHER|Dry needling+stretching exercises|Participants in this group will receive Dry needling treatment
214359728|NCT03624504|DEVICE|Micra Transcatheter Pacing System (TPS)|Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements
214359729|NCT03341390|DRUG|Aspirin|1 x 325 mg tablet of aspirin administered once daily
214359730|NCT03341390|DRUG|BMS-986177|200 mg of BMS-986177 administered twice daily
214359731|NCT03341390|DRUG|Placebo|200 mg of Placebo administered twice daily
214359732|NCT02526264|OTHER|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
215083644|NCT01488214|OTHER|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
214359733|NCT06066060|DRUG|JMKX000623|JMKX000623, administered orally ;
214359734|NCT06066060|DRUG|Metformin|Metformin,administered orally
214971925|NCT06160089|OTHER|Isoinertial training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (inertial). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
214971926|NCT06160089|OTHER|Gravitational training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (gravitational). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
214971927|NCT03625726|BIOLOGICAL|Thrombin generation assay (in vitro)|One blood sample.
214971928|NCT02360514|DRUG|Hantavax injection|Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
214971929|NCT04936516|DEVICE|Endotracheal intubation|Endotracheal intubation using either McGrath or C-MAC video laryngoscopy
214971930|NCT05563337|PROCEDURE|Arteriography and renal denervation|Diagnostic renal Arteriography - Randomization - Renal denervation
214971931|NCT05563337|PROCEDURE|Arteriography without renal denervation|Diagnostic renal Arteriography - Randomization
214971932|NCT02895035|DRUG|Phenylephrine-ketorolac|Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
214971933|NCT02895035|DRUG|Epinephrine|Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
214971934|NCT00967304|OTHER|"Application of theMen continue and HER DOO2 rule"|"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."
214971935|NCT00908765|BEHAVIORAL|Exercise|"1. High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~2. Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks"
214971936|NCT00661089|DRUG|Botulinum Toxin Type A - OnabotulinumtoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
214971937|NCT00661089|DRUG|Placebo (Saline)|Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
214971938|NCT01500798|DRUG|20 mg bardoxolone methyl|20 mg, oral, once daily
214971939|NCT01500798|DRUG|Placebo|Oral, once daily
214971940|NCT01187732|DEVICE|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
214971941|NCT02979964|BEHAVIORAL|Audit and Feedback|
214359735|NCT04822220|OTHER|Fatigue Self-management Programme|Fatigue Self-management Programme
214679266|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
215083645|NCT02445937|BEHAVIORAL|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
214359736|NCT04298593|DEVICE|Cardiostat|This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
214359737|NCT00611143|DRUG|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
214359738|NCT01183676|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg Tablet, under fed conditions
214359739|NCT01183676|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 x 500 mg Tablet, under fed conditions
214359740|NCT03479372|DRUG|PAN-90806 Ophthalmic Suspension|PAN-90806 provided in single-use dropper bottles for topical ocular administration
214359741|NCT02862457|DRUG|Epacadostat 25 mg|Oral administration
214359742|NCT02862457|DRUG|Epacadostat 100 mg|Oral administration
214679267|NCT00589472|DRUG|Bicalutamide|Given PO
214359743|NCT02862457|BIOLOGICAL|pembrolizumab 200 mg|Intravenous (IV) infusion
214359744|NCT02862457|DRUG|Cisplatin 75 mg/m^2|IV infusion
214359745|NCT02862457|DRUG|Carboplatin Area Under the Curve (AUC) 5|IV infusion
215083646|NCT04852510|DRUG|Metformin Versus a combination of Metformin and Thymoquinone (TQ)|Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
214679268|NCT00589472|DRUG|Goserelin Acetate|Given SC
214679269|NCT00589472|OTHER|Laboratory Biomarker Analysis|Correlative studies
214971942|NCT04228224|DEVICE|Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain)|The H3 is a powered lower extremity exoskeleton with actuated at hips, knees and ankles joints. A novel control software has been design and implemented in this device, which allows selective joint movement and recording of data from each rehabilitation session.
214971943|NCT04228224|BEHAVIORAL|Conventional gait rehabilitation|Conventional gait rehabilitation consist in walking and other applicable lower limb exercises performed by participants with assistance of a physical therapist.
214971944|NCT00621790|DRUG|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
214971945|NCT00621790|DRUG|placebo|placebo
215083647|NCT05995041|BIOLOGICAL|CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells|Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
215083648|NCT02032641|DEVICE|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
215083649|NCT00174538|DRUG|Codeine (30 mg)|
215083650|NCT03051984|DEVICE|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (\~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
214359746|NCT02862457|DRUG|Pemetrexed 500 mg/m^2|IV infusion
214359747|NCT02862457|DRUG|Paclitaxel 200 mg/m^2|IV infusion
214359748|NCT02862457|DRUG|Carboplatin AUC 6|IV infusion
214359749|NCT01782066|BIOLOGICAL|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
214359750|NCT01388816|DRUG|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
214359751|NCT04749719|DEVICE|remotely supervised transcranial direct current stimulation|Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.
214679270|NCT00589472|DRUG|Leuprolide Acetate|Given IM
214679271|NCT00589472|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical prostatectomy
214971946|NCT00274742|BIOLOGICAL|Blinatumomab (MT103)|Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion
214971947|NCT05296707|OTHER|Inspiratory muscle training|"The MIP/MEP value of the group that will receive inspiratory muscle training was determined and Threshold IMT training was given with 30%.~In the training, the subjects were asked to sit in a relaxed position with their upper chest and shoulders relaxed.~After the nose clip was attached, the children were asked to inhale and exhale by tightly closing the mouthpiece of the instrument with their lips.~A 30-minute training session was carried out for 6 weeks, with 10-15 repetitive breathing apparatus and 5-10 seconds rest breaks every day."
214971948|NCT05296707|OTHER|Used routine medicine|After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.
214971949|NCT05296707|OTHER|Control group|A healthy child compatible with the age and sex of the patient group was evaluated once.
214971950|NCT04712292|PROCEDURE|Surgical procedure for confirmed or suspected colorectal cancer|"Surgical procedure for cancer may include:~* any radical surgery (right or left hemicolectomy, rectal resection, abdomino-perineal resection, total colectomy, proctocolectomy, and others depending on the tumor site and other tumor characteristics),~* surgery for radicalization of cancer polyps previously removed endoscopically~* surgery for excision of large polyps which are not removable endoscopically~* staging surgery (laparoscopy or laparotomy), in case of advanced-non operable cancer~* palliative surgery (defined as any surgery with no curative intent)"
214359752|NCT04752423|OTHER|Pre operative assessment|"Anxiety assessment : Numeric rating scale (patient and caregiver), APAIS scale (patient), Covi Scale (Caregiver)~Verbalization : anesthesia-related concerns (expressed by patient and considered by caregiver)"
214359753|NCT04013711|DIAGNOSTIC_TEST|Thermography|Thermograms will be acquired of both treated and non-treated cancer site for comparison.
214359754|NCT00507000|DRUG|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
214679272|NCT00589472|DRUG|Vorinostat|Given PO
214971951|NCT03064711|DIAGNOSTIC_TEST|Electronyugraphy|Surface electromyography (sEMG) recorded diaphragmatic muscle activity during rest and while performing maximal voluntary ventilation
214359755|NCT00507000|DRUG|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
214971952|NCT02786992|DRUG|Misoprostol|
214971953|NCT02786992|DRUG|Oxytocin|
214971954|NCT02786992|DRUG|Carbetocin|
214971955|NCT02786992|DRUG|Placebo|
214359756|NCT02859792|DRUG|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
214359757|NCT02859792|DRUG|Placebo|placebo capsules 25 or 50 mg
214359758|NCT02859792|BIOLOGICAL|Blood Samples|v1;v2;v3;v4
214487857|NCT06745115|DIAGNOSTIC_TEST|Blood fluorescence metabolite analyzer|This study does not involve Intervention. The fluorescence intensity quantified by the blood fluorescence metabolite analyzer does not affect or interfere with clinical diagnosis and treatment. In both the early and late stages of sepsis, a significant increase in inflammatory free radicals changes the optical properties of the patient's blood, distinguishing it from that of healthy individuals. To explore this phenomenon, 10 cc of fasting blood is drawn from patients who pass our screening criteria. This sample is then centrifuged in accordance with our detailed standard operating procedures to ready it for analysis. Subsequently, the fluorescence intensity of the blood is measured quantitatively using a precisely calibrated blood fluorometer, which is specifically designed to detect subtle variations indicative of both early and late sepsis. This entire process is executed under stringent quality control protocols to ensure the reliability and accuracy of the results.
214487858|NCT06766812|DEVICE|epidural set|The epidural space will be identified at either the L3-L4 or L4-L5 interspace using the loss of resistance technique with an 18 Gauge Epidural needle.A test dose of 3 mL of 2% lidocaine with epinephrine will be administered to each participant to rule out intravascular or intrathecal placement of the catheter. This ensures the proper placement of the catheter before the full dose of analgesia is administered.Following the test dose, an initial bolus of 8 mL of 0.25% bupivacaine combined with 2 μg/mL fentanyl will be administered to provide effective labor analgesia. Subsequently, maintenance Dose 0.125% 2 ml/0.5 hr
214487859|NCT06765512|OTHER|use of deep learning and automated machine learning to diagnose and classify adenomyosis|Vertex AI Vision V1 software will be used as an automated machine learning tool and Pytorch 2.5 as deep learning framework. The complete set of reviewed, formatted and labelled images will be uploaded and split manually into two different datasets in 9:1 ratio; 90% of the selected images will be used as training dataset (training + validation) and 10% as test dataset.
214487860|NCT06885463|PROCEDURE|platelets rich plasma combined with PDO threads|"1. Injections of platelets-rich plasma in the Anterior Vaginal Wall.~2. PDO thread placement in the paraurethral, lateral urethrovaginal, and suburethral areas"
214971956|NCT01575080|DEVICE|Contour TS Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
214971957|NCT00617552|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
214971958|NCT00617552|DRUG|TZP-101|20 micrograms/kg IV 2ml/minute for 30 minutes
214971959|NCT00617552|DRUG|TZP-101|40 micrograms/kg IV 2 ml/minute for 30 minutes
214971960|NCT00617552|DRUG|TZP-101|80 micrograms/kg IV 2ml/minute for 30 minutes
214971961|NCT00617552|DRUG|TZP-101|160 micrograms/kg IV 2ml/minute over 30 minutes
214971962|NCT00617552|DRUG|TZP-101|320 micrograms/kg IV 2ml/minute for 30 minutes
214971963|NCT00617552|DRUG|TZP-101|480 micrograms/kg IV 2ml/minute over 30 minutes
214971964|NCT00617552|DRUG|TZP-101|600 micrograms/kg IV 2ml/minute for 30 minutes
214971965|NCT02163161|DRUG|PF-04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
214971966|NCT02163161|DRUG|PF-04965842|Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
214971967|NCT02163161|DRUG|PF- 04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
214971968|NCT03927092|OTHER|Multiple Sclerosis Knowledge Questionnaire|A 25-item self-administered questionnaire
214971969|NCT05394948|DIETARY_SUPPLEMENT|Dietary recommendations including experimental nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the experimental nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
214971970|NCT05394948|DIETARY_SUPPLEMENT|Dietary recommendations including control nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the control nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
214971971|NCT00157339|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 12 months
214971972|NCT00157339|DRUG|injected insulin|patient specific dose, injected, before meals, 12 months.
214971973|NCT01720641|BEHAVIORAL|Internet|Referral and user instructions for Peru section of www.inspot.org partner notification website
214971974|NCT01720641|BEHAVIORAL|Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources.
214971975|NCT01720641|BEHAVIORAL|Internet and Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources; Referral and user instructions for Peru section of www.inspot.org partner notification website.
214971976|NCT03043456|DEVICE|Thermoplastic complete denture|A device used to substitute the teeth for edentulous patients made of thermoplastic resin
214971977|NCT03043456|DEVICE|Conventional acrylic resin complete denture|A device used to substitute the teeth for edentulous patients made of acrylic resin
214971978|NCT02256696|DRUG|PA-824|200 mg QD
214971979|NCT02256696|DRUG|Rifampin|600 mg QD
214971980|NCT02256696|DRUG|Rifabutin|300 mg QD
214359759|NCT05590819|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|5 hertz(Hz), 1000 pulses, 90% RMT stimulation; 15 minutes per session; for a total of 10 sessions
214359760|NCT05590819|DEVICE|Intermittent Theta-burst Stimulation(iTBS)|3 pulses of stimulation delivered at 50 Hz and repeated at 5 Hz; 2s train of TBS with repetitive interval of every 10s, 70% RMT; 600 pulses in total; 15 minutes per session; for a total of 10 sessions
214359761|NCT05590819|DEVICE|Sham stimulation|Set-up the coil without true stimulation; 15 minutes per session; for a total of 10 sessions
214359762|NCT04070924|OTHER|Bandaid|Bandaid dressing
214971981|NCT02256696|DRUG|Pyrazinamide|25mg/kg QD
214971982|NCT02256696|DRUG|Ethambutol|15mg/kg QD
214971983|NCT02256696|DRUG|Isoniazid|300 mg QD
214971984|NCT02572453|DRUG|Onalespib|Given IV
214971985|NCT05074966|DRUG|Experimental: mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
214971986|NCT05074966|DRUG|Active Comparator: FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Oxaliplatin 85 mg/m2, IV d1; Leucovorin 400 mg/m2 IV d1; 5-FU 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion; q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
214971987|NCT05075278|BEHAVIORAL|Survey|A survey will be completed by the participants at the conclusion of each day.
214971988|NCT06962098|DRUG|Isuzinaxib|Oral dosing regimen once daily
214971989|NCT06962098|DRUG|Placebo|Oral dosing regimen once daily
214971990|NCT04144322|DEVICE|Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition|Placement of a short implant
214971991|NCT04144322|DEVICE|Zimmer T3 with Discrete Crystalline Deposition Ex Hex Parallel Walled implants|Placement of a long implant with sinus lift and bone graft
214971992|NCT05692401|BEHAVIORAL|Nutrition and Exercise Instruction|Eating and exercise patterns. Educational handouts and instructions will be provided, which are intended as a guide for subjects in intervention group. Subjects will also be given a Patient Diary to complete their daily meal intake and physical exercises. Use of and return of the diary is optional but encouraged. It has been found that use of a patient diary to record food intake keeps one from eating more than they planned and can be a useful tool in weight control.
214971993|NCT05046015|OTHER|10% Urea foot lotion|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
215083651|NCT03230812|DRUG|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
215083652|NCT06242639|OTHER|Clinical examination|clinic and radiographic evaluation
215083653|NCT01453946|DRUG|Entocort|Entocort capsules, taken orally, 6 mg daily.
214971994|NCT05046015|OTHER|10% Urea foot ointment|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 ointment10% Urea once daily in the evening by themselves."
214971995|NCT02263053|PROCEDURE|POSTERIOR MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
214971996|NCT02263053|PROCEDURE|CAUDAL MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
215083654|NCT00363727|DRUG|ropinirole controlled-release (REQUIP CR) for RLS|
214359763|NCT04070924|OTHER|Conventional bulky soft tissue dressing|Conventional bulky soft tissue dressing
214487861|NCT06763380|DIAGNOSTIC_TEST|Ultrasound|Detection of uterine abnormalities in patients who are infertile buy using Ultrasound
214971997|NCT03580161|OTHER|18-F FDG PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
214971998|NCT03580161|OTHER|Ga-68 PSMA PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
214971999|NCT03580161|OTHER|68-Ga Dotatate PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
214972000|NCT03580161|OTHER|99mTc Pertechnetate Thyroid dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
215083655|NCT02549222|OTHER|Standard of Care|
215083656|NCT03934970|DIAGNOSTIC_TEST|Diffusion tensor imaging of peripheral nerves|All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.
215083657|NCT03155334|OTHER|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~* individual reading of the text;~* individual questionnaire for a quantitative and qualitative evaluation;~* a brief semi-structured interview to each participant;~* a text revision to address any problems identified from participant feedback."
215083658|NCT04864626|OTHER|semi-standardized interview|annual collection of the number of consultations and hospitalizations at the center, as well as the number of treatments
215083659|NCT04864626|OTHER|care experience questionary|questionary with 12 questions to rate the quality of the telephone reception and your feelings during the interview
215083660|NCT04794647|OTHER|Cervical mobilization|A kind of manual therapy tecnique applied to the cervical region
214359764|NCT02257268|BEHAVIORAL|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
214487862|NCT06763380|DIAGNOSTIC_TEST|ultrasound then hysterosalpingography|If uterine abnormality could not diagnosed with ultrasound then hysterosalpingography would be performed
214487863|NCT06763601|PROCEDURE|SSMP, Isometric exercise, eccentric exercise, heavy slow resistance , functional program|In this group the patients will be given symptom modification procedure in the first phase followed by isometric exercises in second phase, eccentrics and HSR in third phase and functional program in fourth phase
214487864|NCT06763601|PROCEDURE|MWM,Isometric exercise, eccentric exercise, heavy slow resistance , functional program|in this mobilization with movement in first phase will be given followed by isometrics, eccentrics and heavy slow resistance exercise and finally the functional program
214487865|NCT06763601|PROCEDURE|sham mobilization|Sham mobilization followed by isometrics, eccentric training and heavy resistance training and finally the functional program .
214487866|NCT06742632|BEHAVIORAL|Symptoms checklist-90|The Symptom Checklist-90 (SCL90) is a 90-item questionnaire used to assess psychological problems. The Symptom Checklist-90-Revised (SCL90R) is the revised version of the questionnaire.
214487867|NCT06735196|DEVICE|sampling capsule endoscopy|Healthy volunteers swallowed SCEs to collect intestinal fluids in different intestinal areas. When SCEs excreted, the fluids inside SCEs would be collected for microbiome and metabolome analysis.
214487868|NCT06740682|BEHAVIORAL|Podcast olumlu doğum hikayeler|"ositive birth stories were listened to by women who gave birth in the hospital included in the study and created with their permission. The podcast recording was done in a single session. These positive birth stories were expertly reviewed by 3 obstetricians and 3 academics. Each podcast content is 10 to 20 minutes (Cai et al., 2023). A WhatsApp reminder msg will be sent so that the stories are not forgotten.~In addition, the pregnant woman will be contacted by phone and trained to listen (Cai et al., 2023).~Participants will be allowed to listen to the podcasts as much as they want (Cai et al., 2023). After listening to each story, their feedback will be received and the participants' doubts will be clarified. (Cai et al., 2023; Çankaya and Şimşek, 2021; Mousavi et al., 2022).~Based on multimedia principles, podcast positive birth experiences will be prepared (Clark and Mayer, 2023). Week 24, Week 30-32, Week 36-38 First story"
214487869|NCT06763393|RADIATION|Ultrasound|To determine the correlation between adnexal masses and endometrial thickness measured with ultrasound in adults women.
214487870|NCT06764628|DRUG|SHR-4375|SHR-4375 injection
214487871|NCT06835764|BEHAVIORAL|NOVELA|The family caregivers that consent to participate will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the telenovela video (one of four episodes, each 3-6 mins) twice per week over the course of 4 hospice telehealth visits (one episode per visit). All four visits will use telehealth via video-conferencing. The number of visits is based on the number of videos which content is prioritized based on previous work. The interventionist will introduce the purpose and topic of the video, facilitate video viewing and then elicit clarifying questions and reinforce main message.
214487872|NCT06792682|BIOLOGICAL|Dose escalation|"Three dose groups are preset. The doses are 2.0×10\^6/kg/time, 3.5×10\^6/kg/time and 5.0×10\^6/kg/ time respectively, in accordance with the 3+3 dose escalation principle, and proceed in turn.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals."
214487873|NCT06792682|BIOLOGICAL|Dose extension|"According to the safety data of dose escalation stage, one dose group is selected for extension.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals."
214972001|NCT03580161|OTHER|99mTc DMSA(III) Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
214972002|NCT03580161|OTHER|99mTc MAG3 Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
214972003|NCT03580161|OTHER|99mTc MDP/HDP Bone dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
214972004|NCT02212119|DRUG|Botulinum Toxin|
214972005|NCT02212119|DRUG|Saline|
214972006|NCT02652637|DRUG|neomycin, metronidazole, polyethylene glycol (PEG)|
214972007|NCT02104024|OTHER|Contrast Enhanced Ultrasound Scanning|
214972008|NCT01056393|DRUG|ibalizumab 800mg Q2Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
214972009|NCT01056393|DRUG|ibalizumab 2000mg Q4Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
214972010|NCT02389660|BEHAVIORAL|Blended Cognitive Behavioural Therapy (CBT)|
214972011|NCT02389660|BEHAVIORAL|Treatment as usual|
214359765|NCT03018405|BIOLOGICAL|NKR-2 cells|"In cohorts 1-6, the schedule of administration will be 3 NKR-2 doses administered with a 2-week interval. In absence of progressive disease at the first tumor assessment following NKR-2 administration (on Visit D29 for hematological tumors or on Visit D57 for solid tumors), and according to product availability, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval, at a dose of 1x109 NKR-2 cells per injection, or at the same dose of cycle 1 if it was below 1x109 NKR-2 cells.~Patients in cohorts 8-9 (solid arm) and 10-11 (hematological arm) of first segment will receive 3 treatment doses at 1x109 NKR-2 (cohorts 8 and 10) or 3x109 NKR-2 (cohorts 9 and 11) per injection, with a 1-week interval between each dose. A second cycle of three NKR-2 injections at the same dose as in 1st cycle will be administered 2 weeks after the third NKR-2 injection, and with a 2-week interval between each dose."
214359766|NCT00951483|DRUG|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
214359767|NCT03291574|PROCEDURE|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
214359768|NCT03291574|PROCEDURE|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
214487874|NCT06837818|DRUG|Dexmedetomidine|The first patient was started on dexmedetomidine Cp 0.4 ng/ml, 2 minutes before the procedure, and the up and down method was used, with the Cp of dexmedetomidine adjusted to 0.05 ng/ml each time. The analgesia nociception index (ANI) during skull pin fixation is lower than (\<) 30 and the heart rate (HR) and arterial blood pressure (ABP) exceed (\>) 20% of the baseline (or the HR is \>100 bpm and the ABP is \>180/100 mmHg), indicating insufficient analgesia or hemodynamics (failure). If the patient is failure for the procedure, increase the Cp by 0.05 ng/ml for the next patient; the ANI is higher than or equal to (≥30) and the HR and ABP do not exceed 20% of the baseline or the HR is ≤100 bpm and the ABP is ≤180 /100 mmHg) indicates that the analgesia and hemodynamic stability are acceptable (success), and the next patient will be adjusted downward by 0.05 ng/ml.
214487875|NCT05545280|DRUG|Neostigmine with glycopyrrolate|Administration by intravenous infusion
214487876|NCT05545280|DRUG|Sugammadex|Administration by intravenous infusion
214487877|NCT05784883|DIAGNOSTIC_TEST|Echocardiography|A comprehensive 2- and 3-dimensional transthoracic echocardiography (TTE) assessment of the tricuspid valve and right side of the heart at baseline.
214487878|NCT06755580|PROCEDURE|spinopelvic fixation|open and minimally invasive spinopelvic fixation for unstable or dislocated high-energy sacral fractures
214487879|NCT06794294|BIOLOGICAL|Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell|"Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Low dose: 1x10⁷ cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10⁷ cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator"
214487880|NCT06760988|DIETARY_SUPPLEMENT|CL22205|Experimental Dose: 200 mg, Mode: Oral, once daily after breakfast Duration: 135 days
214487881|NCT06760988|OTHER|Placebo|Mode: Oral, once daily after breakfast Duration: 135 days
214487882|NCT06761378|PROCEDURE|Renal stent|Renal stent before flexible uretroscopy
214487883|NCT06761378|DEVICE|Flexible uretroscopy|Renal stent for 2 weeks prior flexible uretroscopy
214487884|NCT06855940|OTHER|Bleaching Agents|whitening agent containing fluoride and 40% hydrogen peroxide
214972012|NCT02732808|DRUG|Ovulation stimulation|"Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection."
215083661|NCT04794647|OTHER|Placebo mobilization|It was applied to the randomly selected cervical faset without any pushing or pulling in the same position and the same grip with cervical mobilization.
215083662|NCT01776671|DRUG|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
214359769|NCT01206998|DRUG|Vaginal progesterone gel|Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
215083663|NCT00858897|OTHER|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-\[3,3-2H2\]cysteine
215083664|NCT00858897|DRUG|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
215083665|NCT03158272|BIOLOGICAL|Cabiralizumab|Specified dose on specified days
214359770|NCT01206998|DRUG|Placebo vaginal gel|Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
214359771|NCT06580236|DRUG|B11-FC|Infusion
214359772|NCT06580236|DRUG|Botulinum neurotoxin type A|Infusion
214359773|NCT06580236|OTHER|Placebo|Infusion
214359774|NCT02414542|DEVICE|MINIMA stem|
214359775|NCT02219022|OTHER|Control group|
214359776|NCT02219022|OTHER|Experimental group|
214359777|NCT02560948|BIOLOGICAL|Placebo solution|4 x 2 injections over 21 days
214359778|NCT02560948|BIOLOGICAL|gpASIT+TM|4 x 2 injections over 21 days
214359779|NCT03015402|DRUG|Sodium Nitrite|40 mg PO (by mouth) TID (three times each day) for 10 weeks
215083666|NCT03158272|BIOLOGICAL|Nivolumab|Specified dose on specified days
214359780|NCT03015402|DRUG|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 10 weeks
214359781|NCT05072873|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
214359782|NCT05072873|OTHER|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
214487885|NCT06855940|OTHER|Bleaching Agents|whitening agent containing calcium and 35% hydrogen peroxide
214972013|NCT05083910|DRUG|I.V Oxytocin administration|Group I: Oxytocin( the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord). Group II:oxytocin plus intrauterine misoprostol (the oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity. Group III:100-mg carbetocin was intravenously administered immediately after birth of the baby.
214972014|NCT05430425|OTHER|respiratory safety|Which of the 3 lma selection methods is effective in ensuring respiratory safety?
214972015|NCT00543114|DRUG|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
214972016|NCT00543114|DRUG|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
214972017|NCT00543114|DRUG|Rituximab|Given intravenously on Day 1 of each 28 day cycle
214972018|NCT04453761|DRUG|Neurobion|Intravenous Thiamine 2 mg/kg in Neurobion injection
214972019|NCT04453761|DRUG|Placebo|Intravenous NaCl0.9%
214972020|NCT03984084|OTHER|no intervention|no intervention
214972021|NCT02047370|OTHER|Diaphragm stretching|The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.
214359783|NCT04606355|DIAGNOSTIC_TEST|Visual Acuity|autostereoscopic, monocular dynamic force choice test
214359784|NCT04606355|DIAGNOSTIC_TEST|stereopsis|autostereoscopic dynamic forced-choice depth perception test
214972022|NCT02047370|OTHER|Placebo|The same therapist, patient position and duration of the technique, but using disconnected ultrasound
214972023|NCT06268834|DIAGNOSTIC_TEST|Blood for zonulin level was drawn from the group.|Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.
214972024|NCT06518733|OTHER|appliance type|different types of appliances: labial fixed appliances only, fixed retainers, palatal appliances and miniscrews
214972025|NCT05493293|DRUG|NBI-921352|Tablets for oral administration
214972026|NCT01598805|BEHAVIORAL|electronic alerts|An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
214972027|NCT02435303|DRUG|Sildenafil|
214972028|NCT02435303|DRUG|Placebo|
214972029|NCT04547777|DRUG|D2C7-IT|D2C7-IT intratumoral infusion
214972030|NCT04547777|DRUG|2141-V11|2141-11 intratumoral infusion
214972031|NCT06319794|DRUG|Bimiralisib|Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 2 weeks
214359785|NCT04606355|DIAGNOSTIC_TEST|Color vision|autostereoscopic forced choice monocular or binocular color vision tests
214972032|NCT06319794|DRUG|Bimiralisib|Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 4 weeks
214359786|NCT06102265|PROCEDURE|sterilization|the use of sterilization methods and the reuse of gowns
214972033|NCT05936151|DRUG|Retatrutide|Administered SC
214972034|NCT05936151|DRUG|Placebo|Administered SC
214972035|NCT06328738|DRUG|ELVN-002|capsule
214972036|NCT06328738|DRUG|Trastuzumab|intravenous
214972037|NCT06328738|DRUG|5-Fluorouracil|intravenous
214972038|NCT06328738|DRUG|Oxaliplatin|intravenous
214972039|NCT06328738|DRUG|Capecitabine|capsule
214972040|NCT06328738|DRUG|Eribulin|intravenous
214359787|NCT01813474|DRUG|olaparib|tablet oral
214359788|NCT00312793|DEVICE|stimulation of the quadriceps muscle with Myospare|
214359789|NCT04775914|PROCEDURE|PCI + Ischemic conditioning|IPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.
214359790|NCT04775914|PROCEDURE|Stent with ultrasound|IVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.
214359791|NCT02186210|DEVICE|prewarming|recovery slope StO2
214359792|NCT02335073|OTHER|Venous blood|
214359793|NCT04169308|DRUG|Restylane-L® Filler injection|Restylane-L® Filler injection into the soft tissue of the nose
214359794|NCT04605796|COMBINATION_PRODUCT|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
214487886|NCT06855940|OTHER|Bleaching Agents|whitening agent containing hydroxyapatite and 18% hydrogen peroxide
214972041|NCT06328738|DRUG|paclitaxel|intravenous
214972042|NCT06328738|DRUG|Leucovorin|intravenous
214972043|NCT03429790|COMBINATION_PRODUCT|intra-operative cell salvage|intra-operative cell salvage collects the patient's blood lost during an operation, processes it and returns it to their own circulation.
214972044|NCT03429790|COMBINATION_PRODUCT|allogeneic blood transfusion|transfuse allogeneic blood to patients if blood transfusion is needed.
214359795|NCT05361226|OTHER|Accuracy measurement|"Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters."
214972045|NCT04938960|DIAGNOSTIC_TEST|blood draw|blood will be drawn at pre-operation, between 2 weeks and 3 months, between 3-11 months (optional; we will collect a sample if the patient returns to Mayo Clinic for any other non-study related visit), and between 12-18 months post-operatively.
214972046|NCT06247696|OTHER|Herbal Pillows|Pillows containing herbs
214359796|NCT04576468|PROCEDURE|Open flap debridement|Surgical intevention
214359797|NCT04576468|PROCEDURE|perforated membrane|surgical intervention
214359798|NCT04576468|PROCEDURE|leucocyte - platelet rich fibrin|surgical intervention
214359799|NCT01121068|OTHER|Blood samplings|About 3.5ml of blood will be drawn from the participants monthly.
214487887|NCT06769958|BEHAVIORAL|Reflexology|Reflexology application
214487888|NCT06891690|OTHER|tDSC stimulation|tDCA stimulation not exceeding 2 mA
214487889|NCT06893913|BEHAVIORAL|pyramidal training plus intermittent fasting|"twenty obese patients with dryness of eye, obesity, (prediabetes), and psoriasis will receive intermittent fasting consisted of eating ad libitum for 5 days and then will restrict calories ('fasting') for two days weekly, for 12 weeks. On the fasting days, participants will restrict calories to a maximum of 600 kcal/day for females and 650 kcal/day for males.~The dietary intervention will be based on the 5:2 fasting diet. Subjects will be asked to consume a total of allowed calories in a window of 6 hours or less from 8:00 am till 2:00 pm, twice per week on 2 non-consecutive days.~also this group will receive a pyramidal training nearly 60 minutes (nearly two rounds of 21 minutes of running on treadmill will be separated with 10 min of rest between the two rounds. Also, warming (4 min before start of pyrimidal trianing) and cooling (4 minu after pyramidal training) will be done through gentle stretching. the exercise will be applied 3 times weekly for 12 weeks"
214972047|NCT02691390|DEVICE|Active dTMS|dTMS to ACC
214972048|NCT02691390|DEVICE|Sham dTMS|SHAM - no stimulation
214972049|NCT03003247|DRUG|IDP-120 Gel|IDP-120 Gel is a combination product
214972050|NCT03003247|DRUG|IDP 120 Component A Gel|Monad of Component A
214972051|NCT03003247|DRUG|IDP 120 Component B Gel|Monad of Component B
214972052|NCT03003247|DRUG|IDP 120 Vehicle Gel|Vehicle
214972053|NCT03488797|BEHAVIORAL|Supervised web- and home-based exercise intervention|"* The intervention group gets access to a training platform. Every week, 3 training videos of 20 minutes each will be released on that platform with the aim to perform those during the ongoing week.~* Each exercise session is arranged in a video session with child friendly instructions and executions for the different exercises. The videos serve as a virtual training partner and exercise will be performed simultaneously while watching the video~* The overall training volume is 72 session calculated from 3 sessions per week over a duration of 24 weeks (6 month)"
214972054|NCT00472745|BEHAVIORAL|Weight Loss|Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months
214972055|NCT00472745|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 months
214972056|NCT04535999|DRUG|Secukinumab Auto-Injector|300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
214972057|NCT00781053|DRUG|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
214972058|NCT05657366|PROCEDURE|Peritoneal lavage|Continuous abdominal flushing with normal saline
214972059|NCT01372631|DEVICE|miniature spectral imaging system|Use of miniature spectral imaging system
214972060|NCT01372631|DEVICE|Bench-top optical spectrometer|Use of bench-top optical spectrometer
214972061|NCT01372631|DEVICE|High resolution microendoscope|Use of high resolution microendoscope
214972062|NCT01431339|DRUG|IV Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
214972063|NCT01431339|DRUG|Vancomycin/Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
214972064|NCT03003442|DIETARY_SUPPLEMENT|Supradyn® Energy 3RDA|Multivitamin/mineral containing co-Q10
214972065|NCT03003442|DIETARY_SUPPLEMENT|Placebo|Placebo
214972066|NCT06387758|BEHAVIORAL|Low systemic strength training|Low systemic strength training. Youth will complete exercise training for 45 minutes. Eight specific exercises will be performed to target all major muscle groups: calf raises, handgrip, squats, seated row, chest press, plank, low bac extension, and crunches (Table 1). Each exercise involves contractions with moderate load but with an extended duration of up to five minutes.16,17 During each exercise session, youth will have a 5-minute warm up, 5-minute cool down, and be allowed to take rest breaks as needed (minimum 30 seconds). Youth will initially progress by decreasing the number of rest periods and then increasing load. Youth will be provided a 2 lb medicine ball, resistance weight bands, Thera Putty, and a Yoga mat for home exercises. Youth will keep this home exercise equipment.
214972067|NCT06387758|BEHAVIORAL|Moderate systemic exercise|Youth assigned to the moderate systemic exercise load group will perform whole-body aerobic exercise at 40-59% of heart rate reserve (HRR) for 45 minutes.76,111 Youth will complete moderate systemic aerobic exercise by walking at a brisk pace and swinging their arms as they walk. Exercise personnel will supervise a 5-minute warm up and 5-minute cool down via videoconferencing and remain on the phone with youth at all times during the walking exercise session. Youth will exercise until the prescribed duration is achieved or until fatigue at which point they will either reduce the intensity or stop until they recover. All training intensities will be based around HRR so it is individualized (not exceeding 59% of HRR). Youth unable to meet the initial training requirements will be slowly progressed over the 8 weeks.
214359800|NCT01995461|DRUG|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
214359801|NCT03434938|BEHAVIORAL|Motivational interviewing|"MI sessions' goals will to obtain patients' collaboration, creating a shared tailored approach to complement the individual geriatric rehabilitation plan, and reinforcing engagement and adherence at 3 months.~All 20-minutes sessions will follow the logical sequence of MI by Rollnick and Millner (engaging, focusing, evoking and planning) in a semi-structured format to ensure homogeneity. Content will include: 1) Creating engagement with patients by exploring their preferences, values, goals, and their knowledge and expectations about rehabilitation and recovery, 2) enhancing motivation by evoking patients' strengths and abilities, 3) follow-up and reinforcement, and 4) adapting the plan to the improved abilities and to home setting after discharge."
214359802|NCT01684748|DRUG|Olmesartan medoxomil|Crossover intervention comparing antihypertensive medication to no drug intervention.
214487890|NCT06893913|BEHAVIORAL|intermittent fasting|"twenty obese patients with dryness of eye, obesity, (prediabetes), and psoriasis will receive intermittent fasting consisted of eating ad libitum for 5 days and then will restrict calories ('fasting') for two days weekly, for 12 weeks. On the fasting days, participants will restrict calories to a maximum of 600 kcal/day for females and 650 kcal/day for males.~The dietary intervention will be based on the 5:2 fasting diet. Subjects will be asked to consume a total of allowed calories in a window of 6 hours or less from 8:00 am till 2:00 pm, twice per week on 2 non-consecutive days."
214972068|NCT03166787|OTHER|Charcoal hookah|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.
214972069|NCT03166787|OTHER|E-coal hookah|"The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each."
214487891|NCT06749015|OTHER|Non interventional study|Non interventional study
214487892|NCT06748885|DEVICE|Mpact 3D Metal Monolith|THA with Mpact 3D Metal Monolith
214487893|NCT06746493|OTHER|Rehabilitation|People after a stroke participated in a standard rehabilitation process carried out at the neurological rehabilitation department.
214487894|NCT06897410|OTHER|Interdisciplinary Program for Post-Hospitalization / Hospital at home Management and Long-Term Outcomes in Older Adults with Chronic Cardiorespiratory Condition|"Intervention Phase 1: Feasibility Assessment Duration: January 7, 2025 - January 11, 2025 Participants: 10-15 patients~Description:~All involved services will be available to address and resolve potential issues.~The objective is to assess the feasibility of the program, ensuring that the intervention can be implemented as planned and identifying any practical or logistical challenges.~Phases 2 \& 3: Comprehensive Intervention Duration: January 12, 2025 - June 30, 2025 Participants: 200 patients~Description:~Full-scale implementation of the intervention. Includes interdisciplinary care, home follow-ups, therapeutic optimization, functional rehabilitation, health education, and psychosocial support.~Phase 4: Long-Term Follow-Up Duration: April 7, 2025 - June 30, 2026 Participants: 200 patients~Description:~Follow-up assessments at 3, 6, 9, and 12 months post-intervention. Evaluates hospital readmissi"
214487895|NCT06742424|DRUG|PD-L1 antibody|1200mg intravenously every 3 weeks
214487896|NCT06742424|DRUG|Bevacizumab|15mg/kg intravenously every 3 weeks
214487897|NCT06742424|PROCEDURE|HAIC-FOLFOX|Oxaliplatin 130 mg/m² via hepatic arterial infusion over 3 hours Leucovorin 400 mg/m² via hepatic arterial infusion over 2 hours Fluorouracil 400 mg/m² bolus via hepatic arterial infusion at hour 5, followed by 2400 mg/m² continuous hepatic arterial infusion over 46 hours HAIC treatment repeats every 3 weeks for up to 6 cycles
214487898|NCT06739720|DRUG|LingZhi capsule|Lingzhi-containg capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm CO LTD containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black sesame extract
214972070|NCT03166787|OTHER|Cigarette|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).
214487899|NCT06748794|DIAGNOSTIC_TEST|group 1|A comparative analysis was conducted to assess sensory and motor block characteristics, postoperative analgesia duration, maternal hemodynamic stability, and neonatal outcomes. Results demonstrated that intrathecal midazolam significantly prolonged postoperative analgesia and reduced analgesic requirements while maintaining hemodynamic stability and maternal-neonatal safety. This combination provides a potential enhancement to spinal anesthesia techniques, improving maternal comfort and overall perioperative outcomes in obstetric patients.
214487900|NCT06744361|DRUG|esketamine hydrochloride|Prehospital intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine
214487901|NCT06744361|DRUG|propofol|Prehospital intravenous or intraosseous bolus administration at a minimum dose of 0.25 mg/kg propofol
214972071|NCT03166787|DRUG|Carbon Monoxide inhalation|A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.
214972072|NCT03166787|OTHER|Room Air inhalation|A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.
214359803|NCT05117138|BIOLOGICAL|AMT-116 CAR-T cells|"1. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced non-small cell lung carcinoma (NSCLC) enrolled.~2. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced head and neck Squamous Cell Carcinoma (HNSCC) enrolled."
214972073|NCT03166787|DRUG|vitamin C|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .
214972074|NCT03166787|DRUG|tadalafil|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
214972075|NCT01205347|DRUG|Simvastatin 80mg|Simvastatin 80mg once a day
214972076|NCT01205347|DRUG|Simvastatin 10mg|Simvastatin 10mg once a day
214972077|NCT00385918|DEVICE|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
214972078|NCT00385918|OTHER|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
214972079|NCT03923881|DEVICE|MSOT Acuity Echo|Optoacoustic imaging with the MSOT Acuity Echo
214972080|NCT03094585|OTHER|Written and oral information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
214972081|NCT03094585|OTHER|Written information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
214972082|NCT00000962|DRUG|Nevirapine|
214972083|NCT06328257|BEHAVIORAL|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
215083667|NCT05762861|OTHER|Experimental|Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
214359804|NCT05117138|BIOLOGICAL|AMT-253 CAR-T cells|"1.The classic 3 + 3 dose escalation will be applied to 9 selected subjects with moderate or far advanced melanoma by intravenous drip.~2.3 \~ 6 patients with intermediate and advanced melanoma will be injected intratumorally at a dose of ≤ 1 × 10\^8 cells.~3.3 \~ 6 patients with operable advanced melanoma will be treated with postoperative adjuvant treatment at a dose of ≤ 1 × 10\^8 cells ≤ intravenous drip on Day 1 of each 42 days cycle (8 cycle maximum)."
214359805|NCT01826812|OTHER|30 minutes sustained reading|The participants will be given a text to read silently in 30 minutes.
214359806|NCT01826812|OTHER|Dry eye exam|Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
214487902|NCT06745245|DIETARY_SUPPLEMENT|Nutritional counseling and supplementation with a gelatin with prebiotic fiber and probiotic microorganisms|One serving (15 g) of symbiotic gelatin
214487903|NCT06745609|OTHER|Prehabilitation|"Pre-KiT prehabilitation consists of~1. A geriatric guided assessment with relevant interventions. The assessment will include cognitive evaluation, screening for depression, functional assessment, as well as evaluation of nutritional risk, assessment of past and current diseases, and a thorough review of the patient's medication list focusing on drug interactions. It will also include social history and standard laboratory results,~2. Physical activity. A four week home exercise program, adjusted to the participants physical abilities.~3. Assisted smoking cessation"
214487904|NCT06739759|DRUG|Antagonist protocol for IVF|antagonist protocol with triggering by Decapeptyl
214487905|NCT06739759|DRUG|Modified Agonist protocol for IVF with additive treatments as HCQ|giving additive drugs to agonist protocolas HCQ
214972084|NCT01935024|OTHER|Personalized Exercise Regimen|All exercise regimens include a stationary bicycle.
214972085|NCT00916552|DRUG|Erythropoietin|40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
214972086|NCT01634646|DIETARY_SUPPLEMENT|Lyzme5|"Dietary Supplement (or placebo):~Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).~Week one:~A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;~Week two:~Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;~Week three through the end of the study:~Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day."
214972087|NCT01775007|DEVICE|Brillouin Ocular Analyser|Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
214972088|NCT02709148|DEVICE|Activa PC+S|DBS
214972089|NCT01878903|OTHER|Electronic VAS|Post-opearive pain patients will be assessed using electional VAS and verbal NRS
214972090|NCT01676701|DRUG|Tabalumab Auto-Injector|Administered SC by auto-injector
214972091|NCT01676701|DRUG|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
214972092|NCT02197390|BEHAVIORAL|Family wellness workshops|Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.
214972093|NCT02197390|BEHAVIORAL|Obesity chronic care model|
214972094|NCT02197390|BEHAVIORAL|Physical activity, healthy eating, water drinking, healthy sleep promotion|
214972095|NCT02197390|BEHAVIORAL|Environment, policy, systems changes in clinic setting only|
214972096|NCT02197390|BEHAVIORAL|No intervention|No intervention.
214972097|NCT02197390|BEHAVIORAL|Environment, policy, and systems changes in schools, early child care education & recreation|
214972098|NCT06521047|OTHER|NA - Observational study|Observational study, data collection only.
215083668|NCT04947631|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
215083669|NCT04947631|DRUG|Dutasteride|Dutasteride 0.5 mg once daily for 48 weeks
215083670|NCT04947631|DRUG|Tadalafil|Tadalafil 5 mg once daily for 48 weeks
214359807|NCT00712361|DEVICE|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
214359808|NCT04873648|BEHAVIORAL|caloric reduced -intermitted fasting diet|obese women with food addiction and binge eating follow intermittent calorie restriction diet ( time-restricted eating - typically 16 -hour fasting and 8-hour eating)
214359809|NCT04873648|BEHAVIORAL|Daily calorie restriction|obese women with food addiction and binge eating disorder follow a Daily calorie restriction diet
214679273|NCT06297460|BEHAVIORAL|Systems Training for Emotional Predictability & Problem Solving (STEPPS)|STEPPS is based on a cognitive-behavioral and skills training approach divided into three major components. The first component (sessions: 1-2) teaches participants to replace misconceptions about the presented issues with greater awareness of thoughts, feelings, and behaviors that characterize them. It also helps them identify their own thought patterns driving their behaviors. The second (sessions 3-12) teaches skills to more effectively manage the cognitive and emotional effects of the issues, such as distancing, communication, challenging, distraction, and problem-solving. The third component (sessions 13-19) teaches behavioral skills where participants are encouraged to master habits of healthy eating, sleep hygiene, regular exercise, leisure activities, health monitoring, self-harm prevention, and interpersonal effectiveness. The therapeutic objectives of the three blocks are awareness of illness (1), emotional regulation (2), and behavioral regulation (3).
214972099|NCT03635697|BEHAVIORAL|Mindfulness Auditory Intervention|This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
214972100|NCT04406714|BEHAVIORAL|Trial Mailed FIT Intervention - Age Group 50-75|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
215083671|NCT04947631|DRUG|DKF-313 placebo|Once daily for 48 weeks
215083672|NCT04947631|DRUG|Dutasteride placebo|Once daily for 48 weeks
215083673|NCT04947631|DRUG|Tadalafil placebo|Once daily for 48 weeks
214972101|NCT04406714|BEHAVIORAL|Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49|"Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an enhanced envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The enhanced envelope is a yellow padded envelope with a USPS tracking label and sticker message: Important information from your doctor. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call."
215083674|NCT01822535|DRUG|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
215083675|NCT00420173|PROCEDURE|Laboratory analysis|blood withdrawal
214359810|NCT04873648|BEHAVIORAL|Control group|obese women without food addiction and binge eating disorder follow a Daily calorie restriction diet
214359811|NCT00466518|DRUG|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
214359812|NCT04901650|DIAGNOSTIC_TEST|Survey|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
215083676|NCT01071356|BEHAVIORAL|Intensive MI|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
215083677|NCT01071356|BEHAVIORAL|Single session MI|Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
215083678|NCT02278614|DRUG|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
215083679|NCT02278614|DRUG|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
215083680|NCT03453866|PROCEDURE|Warmed Arthroscopic Fluids|Warmed Arthroscopic Fluids
215083681|NCT03453866|PROCEDURE|Room Temperature Arthroscopic Fluids|Room Temperature Arthroscopic Fluids
215083682|NCT04919460|OTHER|clinical observation combined with pathological biopsy|Inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
215083683|NCT04919460|OTHER|Clinical observation, in vivo staining (reagent: toluidine blue) combined with pathological biopsy|(2) Inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
215083684|NCT03430505|DEVICE|Bilevel|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
215083685|NCT03430505|DRUG|Albuterol|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
215083686|NCT04943692|DRUG|Metformin glycinate|1050 mg, tablets Administered orally, twice a day, for 12 months.
215083687|NCT04943692|DRUG|Metformin Hydrochloride|850 mg, tablets. Administered orally, twice a day, for 12 months.
215083688|NCT03190694|DRUG|Dapagliflozin 10mg|Tablet
214487906|NCT06753474|BIOLOGICAL|Influenza Virus influenza A H3N2 strain|"Live Influenza Virus RG-A/Texas/71/2017 (H3N2). It is a cell-grown, reverse genetics-derived influenza A virus manufactured to conduct clinical trials that involve controlled human infection with influenza A virus. This influenza human challenge virus was produced for the National Institute of Allergy and Infectious Diseases (NIAID).~The final Drug Product Live Influenza Virus RG-A/Texas/71/2017 (H3N2) (Lot #1507-232149) vial contains 1.86 X 106 median tissue culture infectious doses (TCID50)/mL formulated in 1X sucrose-phosphate-glutamate (SPG; 7.4% sucrose, 3.8 mM KH2PO4, 7.2 mM K2HPO4, 5.4 mM L-glutamic acid) in Ex-Cellä 293 serum-free medium (Sigma-Aldrich). It is susceptible to the FDA-approved neuraminidase (NA) inhibitors (NAI) oseltamivir phosphate, zanamivir, and peramivir, and the polymerase acidic (PA) inhibitor (PAI) baloxavir marboxil.x"
214487907|NCT06757153|DRUG|NRG-103|NRG-103 is an oncolytic virus, which can kill GBM cells via three manners.
214487908|NCT06754384|BIOLOGICAL|Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)|Low-dose tetravalent inactivated enterovirus vaccine (Vero cell) )(only for phase Ⅰ）
215083689|NCT03048591|DEVICE|electroacupuncture|Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
215083690|NCT03582813|BEHAVIORAL|Self-directed care|Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system
215083691|NCT03582813|BEHAVIORAL|Services as usual|Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
215083692|NCT03399357|BIOLOGICAL|Influenza Vaccine|Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
215083693|NCT03164850|DEVICE|Laparoscopic Tactile Imaging|Provides Tactile feedback during laparoscopic surgery
215083694|NCT03745183|OTHER|Senna alata leaf decoction|"Preparation of the akapulko decoction~1. Remove the leaflets from the rachis of a mature leaf.~2. Wash the mature leaflets thoroughly to remove dust, dirt and debris.~3. In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~4. Cook the leaves and bring to a rolling boil.~5. When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~6. Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~7. Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko."
214972102|NCT04406714|BEHAVIORAL|Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in plain envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The plain envelope is a white envelope without a USPS tracking label or sticker message. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
214972103|NCT06452771|DRUG|ALN-ANG3|Administered subcutaneous (SC) injection
215083695|NCT00225342|DRUG|Rosiglitazone|
214359813|NCT03185533|BEHAVIORAL|Quality improvement (QI) interventions|"1\. The ED admissions exhibited prolonged length of stay.~2\. The Interventions for Reducing Medical Decision Time:~1. The ED director created QI education sessions and reported monthly QI outcomes.~2. The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~3. The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3\. The Interventions for Reducing Boarding Time~1. The ED patients could be admitted before 8 a.m. if the bed was vacant.~2. The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~3. Monthly QI outcomes were reported in the hospital affairs meeting."
214487909|NCT06754384|BIOLOGICAL|Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)|Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
214359814|NCT05435274|DRUG|HS-10376|HS-10376 will be administered orally once daily in a continuous regimen
214359815|NCT01955954|DEVICE|Canary Breathing System|The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of abnormal breathing patterns.
214487910|NCT06754384|BIOLOGICAL|High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )|High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
214487911|NCT06754384|BIOLOGICAL|EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）|EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）
214487912|NCT06754384|BIOLOGICAL|placebo (for ages 6-12 years)|placebo (for ages 6-12 years)
214972104|NCT06452771|DRUG|Placebo (PB)|Administered SC injection
214359816|NCT00134979|DRUG|Formoterol|
214972105|NCT06483061|DRUG|Ferumoxytol|Ferumoxytol will be injected to enhance MRI images
214972106|NCT03913819|DRUG|First line treatment: oral NSAID and anticholinergic agents|oral NSAID and anticholinergic agents
215083696|NCT00225342|DRUG|Gliclazide (Comparison drug)|
215083697|NCT04765644|DRUG|Celecoxib|Two 200 mg capsules per day (400 mg/day) for 7 days
215083698|NCT04765644|OTHER|Placebo|2 capsules/day for 7 days
215083699|NCT04765644|OTHER|L-arginine + placebo|L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
215083700|NCT04765644|OTHER|L-arginine + celecoxib|L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
215083701|NCT05154760|OTHER|Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises|An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
215083702|NCT04454593|OTHER|no intervention|This is an observation study,with no intervention
215083703|NCT05873036|DIAGNOSTIC_TEST|Aerobic Training|Aerobic Training to Improve Functional Ability After Breast Cancer Surgery
215083704|NCT05873036|DIAGNOSTIC_TEST|Progressive Resistance Training|Progressive Resistance Training to Improve Functional Ability After Breast Cancer Surgery
215083705|NCT05042960|OTHER|Brightness|Changing the colors or brightness on the device (computer screen) for one month
215083706|NCT00795912|DRUG|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
214487913|NCT06764550|OTHER|This is an observational study, participants are not assigned an intervention as part of the study.|This is an observational study, participants are not assigned an intervention as part of the study.
214972107|NCT03913819|DRUG|Second line treatment: additional treatment for pain control|Gabapentin, tramadol, Lyrica
214972108|NCT03913819|DRUG|Third line treatment: A course of intravesical hyaluronate will be given.|A course of intravesical hyaluronate will be given.
214972109|NCT03913819|PROCEDURE|Fourth line treatment: surgical intervention|Consideration of hydrodistention and augmentation cystoplasty
214972110|NCT06334133|DRUG|Cadisegliatin 800 mg QD|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
214972111|NCT06334133|DRUG|Cadisegliatin 800 mg BID|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
214972112|NCT06334133|DRUG|Placebo|Placebo (insulin alone)
214972113|NCT05918406|COMBINATION_PRODUCT|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
214972114|NCT05078983|DIAGNOSTIC_TEST|CGA-FI (COMPREHENSIVE GERIATRIC ASSESMENT - FRAILITY INDEX)|GERIATRIC ASSESMENT TEST
214972115|NCT00965133|OTHER|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
214972116|NCT03064048|DIETARY_SUPPLEMENT|Neo-ASA|Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
214972117|NCT03064048|DIETARY_SUPPLEMENT|Placebo|Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
214972118|NCT01307059|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
214972119|NCT05117112|DIETARY_SUPPLEMENT|XS Muscle Multiplier|Distributed by Amway; this product is a powder, sold in a 6.8 ounce (192g) container.
214972120|NCT04884646|OTHER|VR with Routine physical therapy and Virtual reality|VR group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
214972121|NCT04884646|OTHER|Motor Imagery with Routine physical therapy|MI group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
214972122|NCT04884646|OTHER|Routine physical therapy|Group A will be given routine physical therapy in 40-min sessions and 20 min of walking and cycling with a short period of rest, every alternate day (3 days per week) for 12 weeks
214972123|NCT00550797|BIOLOGICAL|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
214972124|NCT00550797|BIOLOGICAL|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
214972125|NCT02155699|BEHAVIORAL|Exercise 1|65% of VO2max and 2 sessions per week
214972126|NCT02155699|BEHAVIORAL|Exercise 2|85% intensity and 3 sessions per peek
214972127|NCT04554602|DIAGNOSTIC_TEST|Fusion ultrasound|Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.
214972128|NCT02227784|DRUG|Evacetrapib|Administered orally
214972129|NCT02227784|DRUG|Atorvastatin|Administered orally
214972130|NCT02227784|DRUG|Ezetimibe|Administered orally
214972131|NCT02227784|DRUG|Placebo|Administered orally
214972132|NCT02992028|DRUG|Intravenous Nutrition (Vitamins) injection|
214972133|NCT02992028|DRUG|Intravenous Saline injection|
214972134|NCT01320241|DEVICE|self-expandable 125I radioactive seeds-loaded-stent|Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.
214972135|NCT01320241|DEVICE|self-expandable biliary nitinol alloys stent|Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.
214972136|NCT05982106|DRUG|TQ05105 Tablets|TQ05105 tablet is a novel JAK2 inhibitor.
214972137|NCT04998864|DEVICE|Magnetic Resonance guided Focused ultrasound (MRgFUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
214972138|NCT05029687|BEHAVIORAL|Youth-Led Hypertension Education Digital Intervention|The intervention is a youth-led HTN education digital intervention, which will be comprised of a 6-week playlist of one module per week comprising the playlist. Youth will learn from the module and will teach the adult in their dyad about hypertension education in each week's themed module.
214972139|NCT01136577|DEVICE|Phototherapy|Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
214972140|NCT03087734|DEVICE|Implantation of new model of bar with oblique stabilizers|Implantation of new model of bar with oblique stabilizers
214972141|NCT03087734|DEVICE|Implantation of regular bar with perpendicular stabilizers|Implantation of regular bar with perpendicular stabilizers
214972142|NCT00653393|DRUG|Tranylcypromine|Tablets, 10 mg, single-dose
214972143|NCT00653393|DRUG|Parnate|Tablets, 10 mg, single-dose
214972144|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.
214972145|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
214972146|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
214972147|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
214972148|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
214972149|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
214972150|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
214972151|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
214972152|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
214487914|NCT06762301|BEHAVIORAL|sexual education and counseling|After the initial evaluation, pregnant women who will be included in the study group will be given an appointment for 1 week later, they will be asked to come with their partners and couples will be given sexual education and counseling in line with the PLISSIT model. After the initial evaluation, couples will be interviewed in the 1st, 2nd and 3rd trimesters, their sexuality since the previous evaluation according to the PLISSIT model, their problems, if any, will be discussed and short counseling will be given if necessary. In the first 4 weeks after delivery, couples in the study group will receive sexual education and counseling for the postpartum period in line with the PLISSIT model. They will be interviewed at the 3rd and 6th month after delivery and their postpartum sexuality and problems, if any, will be discussed and the sexual functions of the couples for the last 4 weeks will be evaluated.
214487915|NCT06762301|OTHER|Routine clinical care|Control Group
214359817|NCT02426788|BEHAVIORAL|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
214359818|NCT01383733|DRUG|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
214359819|NCT03372200|DRUG|FYU-981|Oral daily dosing for 14 weeks
214359820|NCT03372200|DRUG|Febuxostat|Oral daily dosing for 14 weeks
214487916|NCT06763900|DEVICE|Skeletal anchorage and intermaxillary elastic assisted maxillary protraction|maxillary protraction with corticotomy-assisted different miniplate and intermaxillary elastic applications after growth spurt in patients with skeletal Class III malocclusion
214487917|NCT06764914|OTHER|integrative and complementary medicine|Treatment with integrative and complementary methods for both, inpatients and outpatients, includes conventional therapy, integrative methods and ordinal therapy/MBM, which are individually designed for each patient. Similar to a shedule, with therapy units from the following areas: hydrotherapy/thermotherapy, exercise therapy, physiotherapy, nutritional therapy and bodywork therapy, supplemented as required by phytotherapeutic and other therapies, such as acupuncture, neural therapy and cupping. After inpatient treatment, patients can receive up to 10 additional outpatient treatments at our TCM outpatient clinic. There is also a 10-week programme for day patients. This focuses on ordinal therapy to achieve sustainable, balanced lifestyle changes. This includes classic acupuncture and drainage techniques such as Gua Sha (connective tissue massage in TCM) or cupping, as well as neural therapy, electro-acupuncture and others. Daily medical visits and self-care advice are also included.
214487918|NCT06773221|DRUG|Chiglitazar 64mg|Chiglitazar 64mg, oral, qd, for 72 weeks
214487919|NCT06773221|DRUG|Placebo|Placebo, oral, qd, for 72 weeks
214487920|NCT06779253|DRUG|pimicotinib capsules|the effect of multiple oral doses of pimicotinib (50 mg QD) on the pharmacokinetics of fexofenadine (P-gp sensitive substrate), rosuvastatin (BCRP sensitive substrate) and metformin (MATE1 sensitive substrate). Fexofenadine and rosuvastatin will be administered together as a cocktail, and metformin will be given via staggered dosing from the cocktail drugs administration
214487921|NCT06781138|DEVICE|Conventional stabilization splint|conventional versus 3D designed and printed stabilization splints
214487922|NCT06781138|DEVICE|3D designed and printed stabilization splints|Conventional versus 3D designed and printed stabilization splints
214679274|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation using surgical guide|The surgical procedure begins with securing a prefabricated guide firmly to the surgical site. Implant positions are marked, and after guide removal, a crestal incision is made 1 mm palatal to the marked point, extending with sulcular and vertical incisions. A full-thickness mucoperiosteal flap is reflected to expose the maxillary sinus and alveolar crest. After readapting the surgical guide to the bone, implant positions are marked, and cutting edges are tracked. The lateral window is formed by extending and connecting mesial and distal borders, created using piezotome. The sinus membrane is carefully reflected and elevated with a surgical curette to avoid iatrogenic perforation. Implant fixtures are then placed using the identical surgical guide, followed by graft material placement beneath the elevated sinus membrane. If the bony plate is preserved, the lateral window is covered with the plate.
214679275|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation without surgical guide|The sinus's lateral wall is exposed through a crestal incision and a mucoperiosteal flap. A bony window is created, and upon its removability, the sinus floor is carefully elevated using sinus elevation curettes, taking care to avoid membrane perforation. In cases of perforation, a resorbable collagen membrane is applied to cover the hole. Implant osteotomies are then completed following the standard sequential placement protocol. Graft material, mixed with normal saline, is gently packed into the sinus to fill the cavity with bone substitute material and achieve the desired bone height. Finally, a resorbable membrane is placed on the outer surface of the window, and the flap is sutured for primary closure.
214679276|NCT00553059|DRUG|dexamethasone|10 mg IV 30 minutes prior to administration of chemotherapy
214679277|NCT00553059|DRUG|dronabinol|5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
214679278|NCT00553059|DRUG|palonosetron hydrochloride|0.25 mg IV 30 minutes prior to administration of chemotherapy
214679279|NCT00553059|OTHER|placebo|1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
214679280|NCT03462004|BIOLOGICAL|HPIV3/ΔHNF/EbovZ GP vaccine|Administered intranasally
214359821|NCT01509222|BEHAVIORAL|Personalized nutrition counseling|
214359822|NCT03356379|DIAGNOSTIC_TEST|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves
214359823|NCT00156793|PROCEDURE|AI-700 contrast-enhanced echocardiography|
214359824|NCT00417352|DEVICE|Brace|
214679281|NCT03462004|BIOLOGICAL|Placebo|Administered intranasally
214679282|NCT06517030|PROCEDURE|Tooth Extraction|After local anaesthesia, a buccal split-full-split-thickness envelope flap will be elevated, and the tooth will be extracted a-traumatically.
214972153|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
214359825|NCT00417352|DEVICE|Added mass|
214487923|NCT06779955|BEHAVIORAL|foot massage application|The characteristics of Massage Manipulations are an important feature in planning. Since the purpose of the massage is to rest, calm and relax, Effleurage (Stroke), Petrisage (Kneading) and Friction (Circular Rubbing) techniques that support circulation and have a loosening effect on the tissues have been chosen.A massage will be given to both feet for a total of 16 minutes, 8 minutes for each foot.The person receiving the massage will be lying down comfortably in a supine position, supported by pillows under the head and lower legs.Foot massage will be applied once to patients in the supine position at the first hour after their admission to the coronary intensive care unit following transfemoral angiography.
214487924|NCT06768775|DIETARY_SUPPLEMENT|Pastured Livestock Diet|Participants will consume a diet consisting of animal-source foods (chicken, beef, pork, and eggs) from regenerative/pastured farming practices. Foods will be provided weekly in specific quantities for a 16-week intervention. Adherence will be monitored through dietary logs and ASA24 dietary assessments.
214487925|NCT06768775|DIETARY_SUPPLEMENT|Conventional Livestock Diet|Participants will consume a diet consisting of animal-source foods (chicken, ground, pork, and eggs) from conventional farming practices. Foods will be provided weekly in specific quantities for a 16-week intervention. Adherence will be monitored through dietary logs and ASA24 dietary assessments.
214487926|NCT06766110|OTHER|Assessment|31 volunteer participants who were followed up at the Department of Chest Diseases, Istanbul University, Istanbul Faculty of Medicine and met the inclusion criteria were included in the study. Participants' body composition, upper extremity functional exercise capacity, grip strength, and activities of daily living were evaluated.
214487927|NCT06766123|PROCEDURE|CABG|All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities
214487928|NCT06758193|OTHER|No intervention was applied in this study.|No intervention was applied in this study.
214487929|NCT06756711|DIETARY_SUPPLEMENT|A combination of apitherapy and plant extracts|This combination contains the active comparator
214487930|NCT06756711|COMBINATION_PRODUCT|Placebo Combination|A combination containing inert substances - placebo
214487931|NCT06751017|DRUG|S-892216|S-892216 will be administered orally as a tablet.
214487932|NCT06751017|DRUG|Carbamazepine|Carbamazepine will be administered orally as a tablet.
214487933|NCT06752967|OTHER|High protein liquid test meal|High protein liquid test meal consisting of whey protein, water and sugar-free coadial mix for flavour.
214487934|NCT06752967|OTHER|High carbohydrate liquid test meal|High carbohydrate liquid test meal consisting of sucrose, water and sugar-free coadial mix for flavour.
214487935|NCT06750211|OTHER|METs|"* Hot pack for 10 minutes.~* Neck isometrics with 10 second hold.~* Each series of neck isometrics strengthening exercises had three movements including cervical flexion, cervical extension and cervical side flexion.~* Muscle energy technique protocol: The individual was in a position of supine. The therapist was at the edge of bed, near the participants head. the therapist positioned the joint at the point of beginning range of motion resistance when performing a given movement. When the therapist felt restriction, positioned the cervical spine in that region and apply the resistive force. Patient was instructed to contract isometrically for five seconds without exceeding the therapist force. thereafter, therapist counterforce gradually reduced and patient was asked to relaxed. Therapist move the joint into new point of barrier and same protocol repeated three times.~Patient came thrice per week for a total of 4 weeks."
214487936|NCT06750211|OTHER|MCTE along with METs|"▪ Hot pack for 10 minutes.~* Neck isometrics with 10 second hold.~* Each series of neck isometrics strengthening exercises had three movements including cervical flexion, cervical extension and cervical side flexion.~* After it was treated with motor control therapeutic exercises together with muscle energy technique. Motor control therapeutic exercises included cranio-cervical flexor exercises, cranio-cervical extensor exercises, co contraction of flexor and extensor and synergy exercise for strengthening deep neck flexor. Exercises were performed in three sets with 10 repetitions with an approximate duration of 10 to 20 minutes. They were advised to perform at home once in a day, five times in a week for a duration of 4 weeks.~All exercises were performed three times per week for total of 4 weeks."
214487937|NCT06756594|DRUG|Dexmedetomidine-Propofol|efficacy of sedation with Dexmedetomidine-Propofol combination in the upper or lower gastrointestinal system endoscopy.
214487938|NCT06756594|DRUG|Ketamine-Propofol|efficacy of sedation with Ketamine-Propofol combination in the upper or lower gastrointestinal system endoscopy.
214972154|NCT04999761|DRUG|TAS-115|TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
214487939|NCT05652673|DRUG|nivolumab|Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma
214487940|NCT06898385|BIOLOGICAL|IX001 TCR-T injection|IX001 TCR-T injection will be administered intravenously after lymphodepletion.
214487941|NCT06898385|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
214487942|NCT06898385|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
214487943|NCT04789044|DRUG|NTX-001|• PEG fusion is the application of a polyethylene glycol (PEG) using a combination of sequenced reagents to a freshly performed nerve coaptation, or neurorrhaphy, to allow the axonal membranes of the proximal and distal axonal stumps to fuse back together and re-establish full axonal continuity.
214972155|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
214972156|NCT04999761|DRUG|TAS-115|TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
214359826|NCT05959993|BEHAVIORAL|Human Care Model Based Nursing Interventions|The interviews scheduled for the intervention group were organized in accordance with the sub-dimensions of the PAIS-SR scale, and the content of each interview was informed by the 10 improvement processes of HCT.
214359827|NCT01732068|DRUG|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
214359828|NCT01732068|DRUG|Corifollitropin alfa|Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
214359829|NCT01732068|DRUG|hpHMG|300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
214359830|NCT04763057|DRUG|NeoPUTTY MTA|NeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing
214972157|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
214679283|NCT06517030|PROCEDURE|Immediate Implant Placement|After providing that the extraction socket will meet the inclusion criteria, an implant will be immediately inserted with 1 mm of its transmucosal portion positioned under the interproximal bone crest.
214972158|NCT04999761|DRUG|TAS-102|TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
214679284|NCT06517030|PROCEDURE|Socket reconstruction with DBBB+HA|The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral with hyaluronic acid (DBBM+HA).
214972159|NCT04999761|DRUG|Ramucirumab|Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.
214972160|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
214972161|NCT04999761|DRUG|TAS-102|TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
214972162|NCT04999761|DRUG|Bevacizumab|Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.
214972163|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
214972164|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
214359831|NCT04763057|DRUG|calcium hydroxide|Calcium hydroxide the gold standard for IPT
214359832|NCT02671032|DEVICE|Nucleus CI532 cochlear implant|
214359833|NCT01744652|DRUG|Crizotinib|"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
214359834|NCT01744652|DRUG|Dasatinib|"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."
214359835|NCT05321680|OTHER|Treatment withdrawal|Tapering or suspension of antidementia drugs
214359836|NCT01538732|DRUG|alitretinoin|30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
214359837|NCT00540124|DRUG|Tadalafil|5 mg once a day
214359838|NCT00540124|DRUG|Placebo|once a day
214359839|NCT00540124|DRUG|Tamsulosin|0.2 mg once a day
214359840|NCT01403896|DRUG|Plerixafor (Mozobil)|They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
214359841|NCT01403896|DRUG|Plerixafor + G-CSF|They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
214359842|NCT01245010|OTHER|Water|Water and education will be provided
214359843|NCT01245010|OTHER|Education|Education
214359844|NCT05637840|OTHER|Urine sample|Collection of 36-84 urine samples over a 14 consecutive day period.
214359845|NCT05637840|OTHER|Sleep restriction|Participants will be asked to limit their sleep to 4 hours within a 24-hour period for 2 days in a row.
214679285|NCT06517030|PROCEDURE|Socket reconstruction with DBBB|The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral (DBBM).
214972165|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
214359846|NCT00384904|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.
214359847|NCT00384904|DRUG|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.
214359848|NCT00384904|DRUG|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
214359849|NCT00384904|DRUG|Atazanavir/Ritonavir|Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.
214359850|NCT00384904|DRUG|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.
214359851|NCT00384904|DRUG|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
214359852|NCT01921296|DRUG|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
214359853|NCT00331643|DRUG|ixabepilone|Given IV
214972166|NCT04999761|DRUG|Fluorouracil|Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.
214972167|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.
214972168|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
214972169|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
215083707|NCT02366767|DEVICE|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
215083708|NCT02366767|DEVICE|Control|Threshold suspend
215083709|NCT01806649|DRUG|BKM120|
214972170|NCT04999761|DRUG|AB154|AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
215083710|NCT00579995|DRUG|Oral N-Acetylcysteine|600 milligrams (mg)
215083711|NCT00579995|DRUG|Sodium Bicarbonate|3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
215083712|NCT01389349|OTHER|Acupuncture|Battlefield acupuncture protocol
215083713|NCT01389349|OTHER|Sham Control|Sham control acupuncture
214972171|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
214359854|NCT00796302|DRUG|Methylphenidate HCl|"For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily."
214487944|NCT06774079|DRUG|Tirzepatide|Patients in this arm will receive tirzepatide starting at 2.5 mg subcutaneous (SC) weekly for 4 weeks, then increase to 5 mg SC weekly for 4 weeks and then 7.5 mg SC weekly for the last 4 weeks of the intervention period. Place of injection includes abdomen, thigh, or upper arm.
214487945|NCT06774079|BEHAVIORAL|Mediterranean diet|The diet is comprised of a content of 25-30 grams of fiber per day (from fruits, vegetables, whole grains) that is low in animal protein and minimally processing of foods The diet arm will receive dietary guidance from our dietician on weekly 30-minute guided sessions. Participants will be encouraged to adhere to the diet for up to three meals per day for the duration of the study.
215083714|NCT03199521|OTHER|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)|Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
215083715|NCT05623215|RADIATION|Radiographs of the knee for radiostereometric analysis (RSA)|RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.
215083716|NCT02558400|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
215083717|NCT02558400|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
215083718|NCT02558400|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
215083719|NCT00973882|DRUG|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
215083720|NCT00973882|DRUG|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
215083721|NCT03130426|DRUG|iGlarLixi|Dose is titrated to achieve fasting normoglycemia
215083722|NCT03130426|DRUG|Insulin Glargine|In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
215083723|NCT03130426|DRUG|Metformin|Dose is titrated to 2000 mg daily or maximal tolerated dose
215083724|NCT03130426|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
215083725|NCT05126160|DIAGNOSTIC_TEST|Immune Score Based Radiomics|To establish an immune score based radiomic staging system for nasopharyngeal carcinoma
215083726|NCT04561323|DIAGNOSTIC_TEST|Dual-energy CT|"Patients suspected of acute bowel ischemia will be scanned in the dual-energy CT scanner.~The abdominal imaging protocols are predetermined by the Department of Diagnostic Radiology, Righospitalet, Denmark."
215083727|NCT02230683|DRUG|IDN-6556|25 mg BID
215083728|NCT03464357|RADIATION|fMRI|"The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately."
215083729|NCT02302235|OTHER|Ketogenic Diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction.
215083730|NCT02302235|OTHER|Standardized Diet|Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
214487946|NCT06830902|DEVICE|Regular Double J stent|Regular Double J stent
214487947|NCT06830902|DEVICE|Comfi J stent|Comfi J stent
214487948|NCT06771856|BEHAVIORAL|Standard Care CBTi|Standard Care CBTi will take 10 weeks, during which the participant will receive 5 online les-sons and 3 online face-to-face talks with the therapist. The construction of the online intervention was based on self-help materials, research of the literature, and patient interviews. It consists of 5 online les-sons and incorporates elements commonly used in face-to-face CBTi. The 5 online lessons, one introduced every second week, cover the following topics: Education, stimulus control, sleep restriction, relaxation, cognitions. The intervention is supported by online coaching, with feedback aimed at reviewing exercis-es, clarifying information, and motivating patients to continue the course and make necessary behavioral changes.
215083731|NCT00260065|DRUG|Decitabine|20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
215083732|NCT01986959|PROCEDURE|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
215083733|NCT01986959|PROCEDURE|Without Periodontal dressing|The dressing was not inserted.
215083734|NCT04689971|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
215083735|NCT04689971|DRUG|Vitamin B combination|Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
215083736|NCT05265507|DRUG|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
215083737|NCT05265507|DRUG|Ondansetron|Glycopyrronium (4mg) was intravenously given at the ending of the surgery.
215083738|NCT04068519|DRUG|Tislelizumab|Administered intravenously
215083739|NCT04559022|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
214487949|NCT06771856|BEHAVIORAL|Stepped Care CBTi|"The stepped care approach in CBTi entails a two-step approach. Participants in this group all receive an initial entry level session of 1 hour delivered by a trained physiotherapist. Step 1: The entry level in this stepped care approach will imply a single, 1-hour long session, administered by a physiotherapist. This single session will cover: 1) education on sleep, sleep pressure, circadian rhythms; 2) introducing entry-level CBT-i principles (e.g., optimizing sleep environment, pre-bedtime food and beverage consumption) 3) pinpointing 2 to 3 of the most relevant strategies for the participant; and 4) creating an action plan for consistent implementation of these strategies over the next month. One month after 'Step 1' the participants' score on the Insomnia Severity Index (T1) will guide further decision making. Those with ISI scores \<12 will enter the follow-up phase immediately. Those with ISI scores ≥12 after step 1 will be referred to standard care CBTi."
214487950|NCT06828211|DIETARY_SUPPLEMENT|Trans-resveratrol extract from Polygonum Cuspidatum|Trans-resveratrol extract from Polygonum Cuspidatum
214487951|NCT06828211|OTHER|Placebo|Placebo
214487952|NCT06775041|DRUG|Progerinin|Dosing will be determined based on body weight. Dosing ranges from 500mg to 1500mg daily. Progerinin is available in sachets of 250 mg or 350 mg for oral use.
214487953|NCT06775041|DRUG|Lonafarnib|Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.
214487954|NCT06770088|DRUG|vnacicizumab|Vunakizumab 120 mg subcutaneous injection at baseline and week2, week4, then every other 4 weeks.
214487955|NCT06773078|OTHER|High intake group|Intake of a breakfast containing the foods of interest avocado (80gr), corn tortilla (60 gr), nopal (200 gr), guava (108 gr), mango (100 gr), amaranth (14 gr).
214487956|NCT06773078|OTHER|Average intake group|Intake of a breakfast containing the foods of interest avocado (40gr), corn tortilla (30 gr), nopal (100 gr), guava (54 gr), mango (50 gr), amaranth (7 gr).
214487957|NCT06770816|OTHER|Echocardiography|HR, MAP, SBP and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Changes in LV systolic function will be assessed with three parameters: fractional shortening (FS), ejection fraction (EF) using the Simpson method and S' wave of tissue Doppler imaging (TDI) of the mitral annulus (average of values at the medial and lateral annulus). LV diastolic function will be assessed with three parameters and interpreted according to the European Association of Cardiovascular Imaging guidelines. Pulsed wave (PW) Doppler of trans-mitral flow will be used to obtain the ratio between early (e) and late (atrial, a) waves. A PW Doppler between the LV outflow tract and the mitral valve will be performed to estimate the iso-volumetric relaxation time IVRT. TDI will be used to investigate myocardial relaxation at the mitral annular level (ear
214972172|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
214359855|NCT00796302|DRUG|Risperidone|"For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day."
214359856|NCT00796302|BEHAVIORAL|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
214972173|NCT04999761|DRUG|Fluorouracil|Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.
214972174|NCT04999761|DRUG|Carboplatin|Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.
214972175|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.
214972176|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
214359857|NCT00796302|DRUG|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
214359858|NCT00775710|DEVICE|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
214359859|NCT01207102|DRUG|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
214487958|NCT06770946|OTHER|Amniotic Membrane Application|"Amniotic Membrane Application:~This intervention involves the application of an amniotic membrane harvested intraoperatively from the fetal side of the placenta during cesarean delivery. The membrane is placed directly on the incision site before surgical closure to promote wound healing and reduce complications such as infection, dehiscence, and scarring. The membrane is removed 24 hours postoperatively, and standard wound care is continued thereafter."
214487959|NCT06771258|OTHER|Red Light (PDT)|Red LED light
214972177|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
214972178|NCT04999761|DRUG|AB154|AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
214972179|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
214972180|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
214972181|NCT04999761|DRUG|Carboplatin|Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.
214972182|NCT04999761|DRUG|nab-Paclitaxel|Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
214972183|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
214972184|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
214972185|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.
214359860|NCT01207102|DRUG|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
214359861|NCT03076255|PROCEDURE|Computed Tomography|Undergo CT simulation
214359862|NCT03076255|DEVICE|Medical Device|Given thermoplastic mask
214359863|NCT03076255|DEVICE|Medical Device|Given MID
214359864|NCT03076255|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT imaging
214359865|NCT05697094|BEHAVIORAL|Meditation to Remove Stress and Create A Proper System in Mind|Meditation to Remove Stress and Create A Proper System in Mind is a guided meditation.
214359866|NCT04629703|DRUG|Fostamatinib|Fostamatinib (150 mg twice daily) for 14 days and Standard of Care
214487960|NCT06770426|DRUG|carbogen with or without phenyleprhine|Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes. All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
214487961|NCT06770426|DRUG|phenylephrine|All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
214487962|NCT06772337|BEHAVIORAL|digital cardiac rehabilitation|Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.
214972186|NCT04999761|DRUG|Gemcitabine|Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.
214972187|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
214359867|NCT04629703|DRUG|Placebo|Placebo (twice daily) for 14 days and Standard of Care
214359868|NCT03278262|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
214359869|NCT06200454|DEVICE|neuromuscular ultrasound of cranial nerves|neuromuscular ultrasound of cranial nerves.
214359870|NCT03407599|DRUG|Faster aspart|An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.
214359871|NCT03407599|DRUG|Insulin aspart (NovoRapid®)|An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.
214679286|NCT06517030|PROCEDURE|CTG placement|Once the appropriate healing abutments will be installed, a CTG will be utilized as a barrier membrane. Then, the buccal flap will be coronally advanced and will be adapted to the healing abutment.
214972188|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
214972189|NCT04999761|DRUG|nab-Paclitaxel|Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
214972190|NCT04999761|DRUG|Gemcitabine|Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
214972191|NCT03851848|OTHER|Joint mobilization (JM)|Joint mobilization (JM) is a manual therapy to move the joint in a desired direction. It is commonly used for improving the joints' ROM and pain intensity, and to overcome joint restriction.
214359872|NCT00474695|DRUG|Lucentis|0.05 mg intravitreal injection
214359873|NCT02782338|DRUG|Voltaren ophtha 0.1%|All study patients will be treated with Voltaren ophtha 0.1% after cataract surgery
214359874|NCT02330133|BEHAVIORAL|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
214359875|NCT02330133|BEHAVIORAL|Online sexual health content|Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections
214972192|NCT03851848|OTHER|Myofascial release (MFR)|Myofascial release (MFR) is a technique in which a slow, sustained pressure is applied to the restricted soft tissue in order to restore optimal length, reduce pain and improve function.
214972193|NCT01794962|OTHER|Cognitive functional therapy|The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
214972194|NCT01794962|OTHER|manual therapy and exercises|Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
214972195|NCT05555238|DRUG|single arm, single group(No interventional)|(Newvast® Tab, 10 to 80 mg daily administered per the locally approved product information)
215083740|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in experimental group will receive stimulation of DBS system within 1 month after surgery.
214359876|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
214359877|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
214359878|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
214359879|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
214359880|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
214359881|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
214359882|NCT00406003|DRUG|Paroxetine controlled release tablet|Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
214359883|NCT05161299|PROCEDURE|Surgery (across all specialities)|Surgery performed by a surgeon in an operating theatre during the patient inclusion period
214359884|NCT02060851|OTHER|standard PN|Group 1: a control group who received standard PN
214359885|NCT02060851|DRUG|Vifor|iron sucrose, 200 μg/kg per day, was given everyday with PN,
214359886|NCT02060851|DRUG|Vifor and EPO|EPO, 400U/kg, was given twice a week (Monday and Friday). IS, 200 μg/kg per day, was given everyday with PN, and the dose was continued until 2 weeks after birth
214972196|NCT02108977|OTHER|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
214972197|NCT02108977|OTHER|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
214359887|NCT05094531|OTHER|Primary prevention programm|This programm aims to adress three dimensions : (i) biophysiology (flexibility of the autonomic nervous system), (ii) psychology (flexibility of coping strategies, sens of mission) and (iii) the social (stigmatization, seeking health care).
214359888|NCT03792126|OTHER|Implicit Learning Approach|"All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA."
214359889|NCT06226246|BEHAVIORAL|HEROS VR CPR training program|HEROS VR training program which combined video training and VR session
214359890|NCT06226246|BEHAVIORAL|Conventional HEROS CPR training program|Conventional HEROS training program using video learning
214359891|NCT02300220|DRUG|Ciprofloxacin|500 mg, twice daily for 1 week (oral)
214359892|NCT02300220|DRUG|Placebo|One capsule, twice daily for 1 week
214359893|NCT04322682|DRUG|Colchicine|Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
214359894|NCT04322682|DRUG|Placebo oral tablet|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
214359895|NCT00173108|BEHAVIORAL|clinic-based intervention program and home-based intervention program|The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
214359896|NCT00349089|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
214359897|NCT00349089|DRUG|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
214359898|NCT00349089|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
214359899|NCT01835951|OTHER|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
214487963|NCT06772337|BEHAVIORAL|Regular Treatment|Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Out-of-hospital cardiac rehabilitation: Receiving conventional treatment and secondary prevention drugs recommended by current guidelines, nutritional diet and lifestyle guidance, and establishing a WeChat group as a postoperative follow-up contact method.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.
214359900|NCT01835951|OTHER|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
214359901|NCT03119467|DRUG|RP4010|Escalating doses starting at 25 mg
214359902|NCT02455648|PROCEDURE|ESD/EMR plus Cell Sheet|"Patients receive ESD/EMR plus CellSheet:~Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) that are inserted 2 weeks later on the occasion of the ESD or EMR"
214359903|NCT02455648|PROCEDURE|ESD/EMR|"only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) but NOT used for insertion in the patient during/after ESD/EMR two weeks later"
214359904|NCT00009828|DRUG|leucovorin calcium|
214359905|NCT00009828|DRUG|paclitaxel|
214359906|NCT00009828|DRUG|tegafur-uracil|
214972198|NCT02787577|BEHAVIORAL|Sleep Lengthening|Behaviour change techniques targeting sleep hygiene
214359907|NCT02238379|DRUG|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
214359908|NCT02238379|OTHER|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
214972199|NCT02081378|DRUG|Asciminib (ABL001)|Asciminib was be administered orally in a dose escalation schedule.
214972200|NCT02081378|DRUG|Nilotinib|Asciminib and Nilotinib was administered orally in CML patients
214972201|NCT02081378|DRUG|Imatinib|Asciminib and imatinib was administered orally in CML patients
214972202|NCT02081378|DRUG|Dasatinib|Asciminib and dasatinib was administered orally in CML patients
214972203|NCT05446961|DIETARY_SUPPLEMENT|LCLT : 68% elemental L-carnitine and 32 % Tartric acid|3 g orally capsules
214972204|NCT05446961|DRUG|Placebo|orally capsules
214972205|NCT02988700|DRUG|Intrathecal hyperbaric bupivacaine 0.25mg/kg 0.5%|The lumber puncture will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
214972206|NCT02988700|DRUG|caudal plain bupivacaine 2.5mg/kg 0.25%|"The sacral hiatus between the sacral conru will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
214972207|NCT00101244|DRUG|ispinesib|Given IV
214487964|NCT06759610|DRUG|Tetracyclin|to evaluate the effect of tetracycline socked pack on acceleration of healing during marsupialization as a primary treatment for locally invasive lesions.
214359909|NCT00441090|DRUG|Placebo|Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
215083741|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in control group will receive stimulation of DBS system at 3 months after surgery.
215083742|NCT01310959|OTHER|Database|Database
215083743|NCT04886947|PROCEDURE|stem cell transplantation|After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
214359910|NCT00441090|DRUG|Avatrombopag tablets|Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
214679287|NCT01863264|OTHER|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
214679288|NCT06553924|DRUG|Macitentan and Tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
214679289|NCT06553924|DRUG|PrOpsynvi® macitentan and tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
214359911|NCT02089256|DRUG|Liraglutide|"Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection)."
214359912|NCT00410033|DRUG|soluble human insulin|
214359913|NCT00410033|DRUG|isophane human insulin|
214359914|NCT00410033|DRUG|insulin aspart|
214359915|NCT06170541|DEVICE|Aquilion Precision|Ultra-High Resolution CT (UHR CT) capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today's CT technology, with an all-new detector as well as tube, gantry and reconstruction technologies.
214359916|NCT06170541|DEVICE|Conventional Computed Tomography|Conventional reconstruction Computed Tomography (CT) represents a pivotal approach in medical imaging.
214359917|NCT06205667|PROCEDURE|Computer Guided Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ through custom guided template planned in a manner inspired by earphone design to get support from the tragus.
214487965|NCT06776588|PROCEDURE|Microwave ablation combined with biopsy|CT thin-layer scanning 3D reconstruction is used, and AI and fragment omics technology are used to evaluate the risk of malignant transformation of pulmonary nodules. Microwave ablation of pulmonary nodules is combined with intraoperative rapid pathology technology to determine the nature of punctured tissue and the degree of ablation, and to explore the optimal ablation time and ablation power.
214972208|NCT00101244|OTHER|laboratory biomarker analysis|Correlative studies
214972209|NCT00101244|OTHER|pharmacological study|Correlative studies
214972210|NCT04155866|OTHER|Measurement of muscle activation.|Measurement of lower-limb muscle activation during walking for healthy participants.
214972211|NCT00909064|DRUG|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
214359918|NCT06205667|PROCEDURE|Conventional Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ using conventional method anatomical landmark determination
214359919|NCT01441102|DRUG|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
214359920|NCT04893486|DRUG|PTX-022|QTORIN 3.9 % Sirolimus Topical Gel
214359921|NCT04893486|DRUG|Vehicle comparator|Vehicle comparator topical gel
214359922|NCT03746366|RADIATION|[C-11]|Radiolabel
214359923|NCT03746366|DRUG|Pittsburgh Compound B|Tracer
214359924|NCT00005057|BIOLOGICAL|adenovirus RSV-TK|
214359925|NCT00005057|DRUG|ganciclovir|
214359926|NCT00605280|DRUG|Standard of Care|Clinicians decision to use optional laser therapy.
214359927|NCT00605280|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
214359928|NCT04663048|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
214359929|NCT03152253|BEHAVIORAL|Text My Quit (TMQ)|Text messages designed to aid smoking cessation
214359930|NCT03152253|BEHAVIORAL|Peer Support|A group chat room for peer support
214359931|NCT03152253|OTHER|Motivational Messages|Generic motivational messages not related to smoking cessation
214359932|NCT02234674|OTHER|Current intensive CDP|"Standard Intensive CDP including~* manual lymph drainage,~* pressotherapy and~* bandaging"
214972212|NCT04203641|BIOLOGICAL|L-DOS47|A treatment cycle will be 28 days, with patients receiving L-DOS47 on Days 1, 8, 15, and 22.
214972213|NCT04203641|DRUG|Doxorubicin|A treatment cycle will be 28 days, with patients receiving doxorubicin on Days 2, 9, 16 and 23
214972214|NCT04503967|DRUG|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line Treatment of Gastric and Esophageal Cancer patients
214972215|NCT04764188|DRUG|Alectinib|Participants will receive alectinib in accordance with local clinical practice and local labeling.
214972216|NCT04751383|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214972217|NCT04751383|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214972218|NCT04751383|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214972219|NCT04751383|PROCEDURE|Computed Tomography|Undergo CT
214972220|NCT04751383|BIOLOGICAL|Dinutuximab|Given IV
214972221|NCT04751383|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214972222|NCT04751383|BIOLOGICAL|Magrolimab|Given IV
214972223|NCT04751383|PROCEDURE|Resection|Undergo surgical resection
214359933|NCT02234674|OTHER|intensive CDP where Stendo pulsating suit replaces pressotherapy|The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
214359934|NCT05729763|OTHER|3D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 3D images
214359935|NCT05729763|OTHER|2D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 2D images
214487966|NCT06779240|OTHER|Quality of life questionnaires|The clinical protocols at our institute involve the regular and continuous evaluation of the quality of life in patients undergoing treatment and monitoring for scoliosis and other vertebral deformities. To this end, the SRS-22 (Scoliosis Research Society) questionnaire and the ODI (Oswestry Disability Index) questionnaire are employed, along with other measures such as the COMI (Core Outcome Measure Index) and ISYQoL (Italian Spine Youth Quality of Life) and administrated to every patients
214359936|NCT02466022|DRUG|Dexmedetomidine|Bolus dose prior to spinal anesthetic
214359937|NCT02466022|DRUG|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
214359938|NCT02466022|DRUG|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
214359939|NCT02466022|DRUG|Fentanyl|Intrathecal Fentanyl 10ug
214359940|NCT02466022|DRUG|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
214359941|NCT03417167|OTHER|US-guided synovial biopsy|Needle Synovial biopsy performed using a Tru-cut® device.
214359942|NCT05258110|DRUG|midazolam|midazolam
214359943|NCT05258110|DRUG|BI 425809|BI 425809
214359944|NCT05050201|DEVICE|Sleepio|Digital CBT application for insomnia
214359945|NCT02961465|DEVICE|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
214487967|NCT06787391|PROCEDURE|Neurotization of Spinal Accessory Nerve To Supra-Scapular in children with OBPP with deficiency of Shoulder External Rotation|Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve in children with OBPP presented with deficiency of Shoulder External Rotation.
214972224|NCT06152185|BEHAVIORAL|Mindfulness Training|The mindfulness intervention includes 28 daily 20-minute audio lessons plus brief daily practice prompts. The first 14 lessons train techniques for developing foundational mindfulness skills through didactics and guided practice; the second 14 lessons review these techniques through guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts delivered 3 times daily encourage participants to practice brief moments of mindful awareness.
214972225|NCT06152185|BEHAVIORAL|Enhanced Usual Care|Participants in the EUC condition will have no study requirements during the 4-week intervention period, but they will receive a list of stress management resources upon randomization (websites, books, health tracking apps, and mental health services) with no additional intervention support.
214972226|NCT04788277|PROCEDURE|Biospecimen Collection|Undergo collection of urine samples
214972227|NCT06139354|BEHAVIORAL|decision aid|"A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - I want to do everything I can to prevent HIV, privacy - I don't want others to know about the exposure, or cost - I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making."
214972228|NCT05468463|BEHAVIORAL|Living Donor Navigator Program|The investigators have developed a 4-session educational program that simultaneously addresses potential donor concerns with the evaluation/donation process and provides advocacy training to transplant candidates and their advocates.
214972229|NCT05234177|OTHER|Observation|No intervention
214972230|NCT06466161|DEVICE|Upper Arm Cylindrical Blood Pressure Cuff|In Group 1, the upper arm cylindrical cuff is inflated first, followed by inflation of the forearm conical cuff.
214972231|NCT06466161|DEVICE|Forearm Conical Blood Pressure Cuff|In Group 2, the forearm conical cuff is inflated first, followed by inflation of the upper arm cylindrical cuff.
214972232|NCT06327490|PROCEDURE|ICG-guided manual lymphatic drainage|Participants will perform manual lymphatic drainage on their affected arm using ICG lymphography images of the lymphatic pathway in their affected arm as guidance once daily for 2 years post-surgery.
214972233|NCT06327490|PROCEDURE|Traditional manual lymphatic drainage|Participants will perform manual lymphatic drainage on their affected arm using traditional technique once daily for 2 years post-surgery.
215083744|NCT00029757|DRUG|Estrogen|
215083745|NCT03463395|DEVICE|Reza band|Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
215083746|NCT04911179|OTHER|Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.|"The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant."
214359946|NCT02119351|DEVICE|ViaValve™ Safety IV Catheter|Safety peripheral IV catheter with a blood control feature
214359947|NCT02119351|DEVICE|ProtectIV® Plus Safety IV Catheter|Safety peripheral IV catheter with no blood control feature
214359948|NCT04183270|OTHER|Questionnaires|The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.
214359949|NCT03609762|BEHAVIORAL|EQ-5D-5L HRQOL results be available to the attending doctor|all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
214359950|NCT02291614|DRUG|AMG 211|continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days
214359951|NCT05832138|BEHAVIORAL|ONLOOP program|Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
214359952|NCT06291168|OTHER|Chiropractic Manipulation (HVLA - High Velocity Low Amplitude)|"Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.~After determining that the movement disorder of the sacroiliac joints of the participant is caused by the impaired movement of the ilium in the posterior and inferior direction or the impaired movement of the ilium in the anterior and superior direction, the participant will be asked to take a side lying position.HVLA spinal manipulation was performed for less than one second from posterior to anterior, inferior to superior and medial to lateral directions."
214487968|NCT06787391|PROCEDURE|Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve|Just to assess clinical outcomes after Neurotization of spinal accessory nerve to Supra-Scapular Nerve in patients with deficiency of Shoulder External Rotation
214487969|NCT06847347|BEHAVIORAL|More Than Words®|More Than Words® (MTW) is a 13-week parent-implemented program designed to enhance communication, play development, and parent-child interaction for children under 4 years of age who have autism or social communication challenges. MTW is delivered by speech-language pathologists (SLPs) certified by The Hanen Centre, a global not-for-profit organization based in Toronto. MTW is delivered virtually in this trial. The program an orientation session, an individual pre-program consultation appointment, 8 x 2½ hour group training sessions (with 6-8 parents per group), and 3 individual video feedback sessions. During video feedback, the parent demonstrates use of communication facilitation strategies with their child, while the SLP records the interactions. The parent and SLP then review the videos together, analyze use of the strategies and how the child responded, and formulate plans to foster development of new skills.
214487970|NCT06839326|BIOLOGICAL|Autologous Conditioned Serum, Genesis Biyomedikal, Sanakin®-Acrs produce|Arthrocentesis and 1ml ACS injection will be performed twice in total, two weeks apart.
214487971|NCT06839326|BIOLOGICAL|Platelet Rich Plasma|Arthrocentesis and 1ml PRP injection will be performed twice in total, two weeks apart.
214487972|NCT06839326|OTHER|Control Group/ Only Arthrocentesis|Arthrocentesis will be performed twice in total, two weeks apart.
214487973|NCT06810414|BEHAVIORAL|Food and alcohol disturbance expectancy challenge|The intervention will focus on strengthening negative FAD expectancies and weakening positive FAD expectancies.
214487974|NCT06815900|OTHER|one group .observational study|observational study of this group
214487975|NCT06772727|DRUG|Lidocaine|After preoxygenation with 100% oxygen for 3 minutes, the study drug (lidocaine) will be administered. Patients will receive 1 mg/kg lidocaine of 10 mg/mL lidocaine solution (prepared by diluting 5 mL of lidocaine 20% in saline to a total volume of 10 mL)
214487976|NCT06772727|DRUG|Fentanyl|After preoxygenation with 100% oxygen for 3 minutes, the study drug (fentanyl) will be administered. Patients will receive 1 mcg/kg fentanyl of 10 mcg/mL fentanyl solution (prepared by diluting 100 mcg fentanyl in saline to a total volume of 10 mL).
214487977|NCT06772727|DRUG|Propofol|After administration of the study drug, all patients will receive 2 mg/kg propofol intravenously
214487978|NCT06772727|DRUG|Succinyl choline|After loss of consciousness, 1 mg/kg succinyl choline will be administered over 5 seconds, and tracheal intubation will be done through direct laryngoscopy after 60 seconds.
214487979|NCT06762327|DRUG|Ensartinib|ensartinib 225mg ,PO,QD,until disease progression or intolerable toxicity
214679290|NCT00117338|DRUG|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
214679291|NCT00117338|DRUG|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
214972234|NCT06327490|DRUG|Indocyanine green|All participants will be injected with indocyanine green for lymphatic mapping of the affected upper extremity, however this mapping will only be used to guide manual lymphatic drainage for participants on the ICG-guided manual lymphatic drainage arm.
214972235|NCT05582343|BEHAVIORAL|MINDBODYSTRONG™|"Digitalized MINDBODYSTRONG™ is designed for self-paced weekly use via an online platform.~MINDBODYSTRONG© Session Content~1. Thinking, feeling, \& behaving, The ABCs of CBT, Mindfulness Skills Building: Positive self-talk/The ABCs~2. Self-esteem \& positive self-talk, Intentional gratitude, Managing change Skills building: Self-esteem \& positive self-talk~3. Stress, Healthy coping, Abdominal breathing Skills Building: Managing stress~4. Problem solving, Setting goals, Steps to problem solving Skills building: Strategies to overcoming barriers~5. Dealing w/ emotions in healthy ways, Using guided imagery, Coping strategies, Effective communication Skills building: Dealing with emotions~6. Coping w/ stressful situations/valuable sleep Skills building: Coping w/ stressful situations~7. Distress tolerance \& added emotional regulation skills Skills bulding: RAIN practice, Self-love skill, Distracting using ACCEPTS~8. Putting it all together for a healthy YOU!"
214972236|NCT05276778|DIAGNOSTIC_TEST|Diabetic Retinopathy Screening|Screenings are performed in the diabetes consultation in general practice
215083747|NCT00758589|DRUG|AZD1981|Oral tablet, 50 mg twice daily
215083748|NCT00758589|DRUG|AZD1981|Oral tablet, 400 mg twice daily
214679292|NCT01723501|DRUG|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
214679293|NCT01723501|DRUG|sterile water|Sterile water wipes (placebo)
214972237|NCT05589753|OTHER|Hyperoxia|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure.
214972238|NCT05589753|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
215083749|NCT00758589|DRUG|AZD1981|Oral tablet, 1000 mg twice daily
215083750|NCT00758589|DRUG|Placebo|
215083751|NCT01054521|PROCEDURE|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
215083752|NCT01054521|DEVICE|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
215083753|NCT00005048|DRUG|estramustine phosphate sodium|
215083754|NCT00005048|DRUG|paclitaxel|
215083755|NCT06547060|OTHER|Exercise leggings|The participants will wear two types of leggings (i.e., control leggings vs. leggings with shortened resistance bands) while performing the same exercise on two different days, respectively.
215083756|NCT02088567|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty, per the usual practice of the physician.
214679294|NCT04310137|BEHAVIORAL|Therapist-Directed Re-loading|Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
214679295|NCT03469245|OTHER|numerical simulation|After patients have been treated by fenestrated endovascular of society Vascutek data will be collected by society Vascutek and send to Predisurge society. They will perform numerical simulation and compare with the method of Vascutek.
214972239|NCT03834506|BIOLOGICAL|Pembrolizumab|IV infusion
214972240|NCT03834506|DRUG|Docetaxel|IV infusion
214972241|NCT03834506|DRUG|Prednisone|Oral tablets
214972242|NCT03834506|DRUG|Placebo|IV infusion
214972243|NCT03834506|DRUG|Dexamethasone|Oral tablets
214972244|NCT05930678|PROCEDURE|No ventilation with face mask|During the period of apnea (in general anesthesia), the patient did not help with face mask
214972245|NCT05930678|PROCEDURE|Ventilation with face mask|During the pperiod of apnea (in general anesthesia), the patient did help with face mask
214972246|NCT06576323|BEHAVIORAL|An implementation model for co-located Medications for Opioid Use Disorder (MOUD) prescription in the NICU|We will use implementation mapping to develop a suite of implementation strategies to deliver evidence-based MOUD prescription to mothers attending the bedside of their infants hospitalized in the NICU. The intervention itself is buprenorphine induction and treatment, however the model for delivery is not yet developed, consistent with the need for results from Aim 1 to inform the approach used to develop the implementation model in Aim 2.
214972247|NCT04420702|DEVICE|MRI with DBSI analysis|-The procedure will take approximately 1 hour of the participant's time
214972248|NCT00816114|OTHER|Chart Review|Investigator review of MDACC CML patient charts.
214972249|NCT06411821|DRUG|Ulixertinib|300 mg twice daily, for every 28-day cycle.
214972250|NCT06574568|DRUG|YKST02|BCMA-CD3 bispecific antibody
214972251|NCT05456724|DRUG|TO-O-1001|TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye
214972252|NCT05456724|OTHER|Placebo|The placebo is of same visual appearance and identical formulation as TO-O-1001, except the active component TO-168 ocular administration only one drop in one eye
214972253|NCT04333212|DEVICE|DR. Chip HPV genotyping IVD kit|HPV typing by gene chip
214972254|NCT02300870|DRUG|Optison|Echocardiogram with IV contrast
214972255|NCT00061178|DRUG|rhuMAb VEGF (Bevacizumab)|
214972256|NCT04381078|OTHER|ACE - AudioVisual Guide|Audiovisual guide to Alveolar Bone Graft Procedure, Pre-surgical orthodontics and post-operative care
215083757|NCT02088567|OTHER|Application of dHACM|Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
215083758|NCT00238368|BIOLOGICAL|filgrastim|
215083759|NCT00238368|BIOLOGICAL|rituximab|
215083760|NCT00238368|DRUG|busulfan|
214972257|NCT00477802|BIOLOGICAL|Botulinum Toxin Type A|Injected once during the course of the study.
214972258|NCT00477802|BIOLOGICAL|Placebo|Injected once during the course of the study.
214972259|NCT05780138|BEHAVIORAL|Parents Taking Action|Educational intervention designed to provide caregivers of children with autism information about autism, and strategies to advocate and support their child's development.
214972260|NCT02788643|BIOLOGICAL|biological fluids (serum, bronchoalveolar lavage and pulmonary aspiration) and bronchial biopsies collection|
214972261|NCT04577794|DRUG|GLPG3970|GLPG3970 powder and solvent for oral solution reconstituted prior to use.
215083761|NCT00238368|DRUG|cisplatin|
215083762|NCT00238368|DRUG|cyclophosphamide|
215083763|NCT00238368|DRUG|cytarabine|
215083764|NCT00238368|DRUG|doxorubicin hydrochloride|
215083765|NCT00238368|DRUG|etoposide|
215083766|NCT00238368|DRUG|methylprednisolone|
215083767|NCT00238368|DRUG|prednisone|
215083768|NCT00238368|DRUG|vincristine sulfate|
215083769|NCT00238368|PROCEDURE|autologous bone marrow transplantation|
215083770|NCT00238368|PROCEDURE|peripheral blood stem cell transplantation|
215083771|NCT00238368|PROCEDURE|positron emission tomography|
215083772|NCT00238368|RADIATION|fludeoxyglucose F 18|
215083773|NCT00238368|RADIATION|radiation therapy|
215083774|NCT06264297|PROCEDURE|Radiofrequency|Pulsed radiofrequency (PRF) is a nonablative pain treatment that uses radiofrequency current in short high-voltage bursts, resulting in interruption of nociceptive afferent pathways. This study aims to show how the variation in radiofrequency voltage applied to the dorsal root ganglion (DRG) affects the treatment of neuropathic pain.
215083775|NCT01243827|DRUG|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.
215083776|NCT01243827|DRUG|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
215083777|NCT00053807|BIOLOGICAL|aldesleukin|
214359953|NCT06291168|OTHER|Yoga-Based Exercise Program|"Yoga treatment includes exercise, respiration, balance and coordination, and stretching and will be performed by a physiotherapist with yoga certification. Patients will be evaluated before treatment, two weeks later, after treatment (at the end of the 8th week) and at the end of the 12th week after treatment (control).~Yoga exercises will be practiced with the classical yoga program, divided into groups of 3-4 people, for 8 weeks, 2 days a week, 60 minutes a day.~It will be applied as a yoga session program including breathing and warm-up exercises, suyanamaskar, various relaxation techniques and asanas."
214359954|NCT06291168|OTHER|Conventional Exercises|Spinal stabilization exercises for the lumbar region will be given in 3 phases following the protocol given to the chiropractic manipulation group. The exercises will be performed two days a week with a physiotherapist. In order to facilitate the memorization and follow-up of the exercises, short videos will be made to facilitate compliance with the exercises by showing the exercises and methods of prevention of low back pain. Individuals will be called to the hospital two days a week for 8 weeks.
214359955|NCT04010994|PROCEDURE|Transorbital electrical stimulation|Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
214359956|NCT03577210|PROCEDURE|augmentation genioplasty|augmentation genioplasty with patient-specific PEEK implant
214359957|NCT01662310|DRUG|Paliperidone|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
214359958|NCT01662310|DRUG|Placebo|Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
214359959|NCT03051503|DRUG|The Transdermal Therapeutic System-Fentanyl (TTS-F)|(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
214359960|NCT03051503|DEVICE|Intravenous patient-controlled analgesia (PCA) morphine|IV PCA morphine for pain in the postoperative period.
214359961|NCT02462707|DRUG|PF-03084014|gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
214359962|NCT00683826|DIETARY_SUPPLEMENT|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
214359963|NCT00683826|OTHER|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
214359964|NCT00683826|DIETARY_SUPPLEMENT|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
214359965|NCT05085587|DRUG|Test|2 inhalations of Test and Reference product in each study period
214359966|NCT05085587|DRUG|Reference|2 inhalations of Test and Reference product in each study period
214359967|NCT01619202|BEHAVIORAL|Risk Anticipation -Perception Training|Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
214359968|NCT00994838|OTHER|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
214359969|NCT01302847|DRUG|DTG film-coated tablets|DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
214972262|NCT04577794|DRUG|Placebo|Placebo powder and solvent for oral solution reconstituted prior to use.
214972263|NCT03002636|PROCEDURE|anesthesia|Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
214972264|NCT05460299|COMBINATION_PRODUCT|Telko plus conventional physical therapy (CPT)|All patients underwent about 15-minute CPT sessions 3 days a week for 4 weeks. The CPT intervention program consisted of closed kinetic chain exercises (squatting, hip bridge, lunge, and toe standing), 3 sets, 10 repetitions each and gait training (walking forward, backward, sidewalk, and between obstacles). Short breaks (1-5 minutes) were provided, depending on the patient tolerance. Before treatment, the skilled physical therapist was instructed about the duration, frequency, and content of therapy. The patients in the experimental group received additional lower extremities closed kinetic chain training using the Telko device. The participants train on Telko for 15 minutes using moderate resistance, 3 days a week for 4 weeks.
215083778|NCT00053807|BIOLOGICAL|recombinant interferon alfa|
214972265|NCT03328247|OTHER|ASICA digital app|Participants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only. The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.
214359970|NCT01302847|DRUG|DTG granules for suspension|DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
214359971|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
214359972|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
214359973|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets."
214359974|NCT06134349|OTHER|Lithium MR imaging|After obtaining written informed consent and within four weeks of reaching a stable therapeutic serum lithium concentration, lithium MR imaging will be performed using a 7 Tesla MR system (Achieva, Philips Medical Systems, Eindhoven, The Netherlands) with a dual-tuned 7Li/1H volume head coil (RAPID Biomedical GmbH, Rimpar, Germany). Various approaches, including whole-brain, voxel-wise, parcellation, mean, and regions of interest, will be applied to measure lithium concentrations.
214359975|NCT06534567|OTHER|Mediterranean Diet|Mediterranean diet adherence
214359976|NCT06534567|OTHER|Physical activity|Physical activity level
214359977|NCT02342067|DRUG|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
214359978|NCT02342067|DRUG|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
214359979|NCT06239168|DIETARY_SUPPLEMENT|Citrus extract|As described in experimental arm
214359980|NCT06239168|DIETARY_SUPPLEMENT|Maltodextrin|As described in comparator arm
214359981|NCT00297752|DRUG|ceriumnitrate silversulfadiazine (flammacerium)|treatment of patients with facial burns with CE-SSD
214679296|NCT03968367|PROCEDURE|Magnetic activated sperm sorting|MACS is a technique which allows the spermatozoa with the best characteristics to be selected for use in assisted reproduction treatments. This technique removes apoptotic spermatozoa - those which will die without achieving fertilisation - and selects the healthy ones, thus increasing the possibility of pregnancy.
214972266|NCT01628848|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
214972267|NCT01628848|DRUG|Placebo|Placebo transdermal patch
214972268|NCT03513263|PROCEDURE|Scaling and polishing|An electronic scaler will be used to clean the gums
214972269|NCT03513263|OTHER|oral hygiene instructions|It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning
214972270|NCT03163407|DRUG|Norepinephrine|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
214972271|NCT03163407|DRUG|Ephedrine|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
214972272|NCT02819570|DRUG|I.V cefuroxime 750 mg*3/d for 2 days|
214972273|NCT02819570|DRUG|I.V ampicillin 2 gram x4/d for 2 days|
214972274|NCT02819570|DRUG|P.O cefuroxime 500 mgx2/d for 5 days|
214972275|NCT02819570|DRUG|P.O roxithromycin 150 mg*2/d for 7 days|
214972276|NCT02819570|DRUG|P.O moxypen 500 mgx3/d for 5 days|
214972277|NCT00003471|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a recurrent/progressive low grade astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214972278|NCT04611100|DEVICE|ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)|Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent
214972279|NCT05251272|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
214972280|NCT00018642|DRUG|quetiapine|
214972281|NCT00018642|DRUG|haloperidol decanoate|
214972282|NCT01681758|OTHER|IV fluid according to PPV|intravenous fluids
214972283|NCT01681758|OTHER|fluids according to standard care|
214972284|NCT00463736|DRUG|Magnesium sulfate|
214972285|NCT02104895|RADIATION|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
214972286|NCT02104895|RADIATION|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
214972287|NCT04253158|BEHAVIORAL|Educational standard|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs.
214972288|NCT04253158|BEHAVIORAL|Educational standard and Harm prevention|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs increasing intentions to use harm prevention strategies.
214972289|NCT04253158|BEHAVIORAL|Educational standard and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and shifting alcohol-related expectancies.
214972290|NCT04253158|BEHAVIORAL|Expectancies and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and shifting alcohol-related expectancies.
215083779|NCT00053807|DRUG|fluorouracil|
215083780|NCT00053807|PROCEDURE|adjuvant therapy|
214359982|NCT00297752|DRUG|silversulfadiazine (flammazine)|treatment of patients with facial burns with SSD
214359983|NCT00374322|DRUG|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
214359984|NCT00374322|OTHER|placebo|6 tablets daily for 12 months
214359985|NCT04750746|OTHER|Control group|Conventional Therapy Passive ROM and/or AROM exercises Muscle strengthening; Therapeutics stretching of the shoulder, the elbow, the wrist, and the fingers. Activities of daily living training, including eating, grooming, dressing, toileting, and transfer
214359986|NCT04750746|OTHER|Experimental Group|Interventional therapy Xbox Kinect (Xbox 360, Microsoft,) For training, programs such as Boxing and Bowling in the Kinect sports pack and Rally Ball, 20,000 Leaks, and Space Pop in the Kinect adventure pack, all of which required the use of the upper extremities, will be selected
214359987|NCT03969719|DRUG|Placebo|Placebo
214359988|NCT03969719|DRUG|PF-06835919|150 mg once daily
214359989|NCT03969719|DRUG|PF-06835919|300 mg once daily
214487980|NCT06741501|PROCEDURE|"C Single Flap Plasty Reconstruction"|"1\. C-shaped flap creation: A 3.0 cm wide by 3.5 cm high C-shaped flap is marked on the anterior gastric wall, 1.5-2.5 cm distal to the stomach transection line. The flap is created by carefully separating the submucosa from the muscular propria using an electric scalpel, forming a left-opening flap. This flap will later be used to cover the anastomotic site. 2. Esophagogastric anastomosis: The esophagus and stomach are anastomosed intracorporeally. After continuous suturing of the posterior esophageal wall to the remnant stomach, the common opening between the esophagus and the stomach is closed. 3. Flap coverage: After anastomosis, the C-shaped flap is sutured over the anastomotic site, reinforcing it by covering both the esophageal stump and the gastric window, which helps prevent complications like leakage or reflux."
214972291|NCT04253158|BEHAVIORAL|Educational standard and Normative perceptions|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and correcting erroneous norms about alcohol use.
214487981|NCT06741501|PROCEDURE|Normal Reconstruction|1\. Preparation of the Remnant Stomach and Esophagus: After the resection of the proximal stomach, the remaining stomach is prepared for direct anastomosis with the esophagus. The esophageal stump and gastric stump are aligned, typically without additional modifications to the gastric wall. 2. End-to-End or End-to-Side Anastomosis: The esophagus is directly connected to the remnant stomach, either in an end-to-end or end-to-side fashion, using a stapler or manual suturing techniques.
214972292|NCT04253158|BEHAVIORAL|Normative perceptions and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and increasing intentions to harm prevention strategies.
214972293|NCT04253158|BEHAVIORAL|Educational standard, Normative Perceptions, and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs, correcting erroneous norms about alcohol use, and shifting alcohol-related expectancies.
214972294|NCT04253158|BEHAVIORAL|Normative perceptions, Expectancies, and Harm Prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use, shifting alcohol-related expectancies, and increasing intentions to use harm prevention strategies.
214972295|NCT01241422|DRUG|JNJ 40929837|On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.
214972296|NCT01241422|DRUG|Placebo|On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
214972297|NCT01241422|DRUG|Montelukast|On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
214972298|NCT06519838|OTHER|Local anesthesia solution at room temperature|The local anesthesia cartridge is used at room temperature (average of 21 °C)
214972299|NCT06519838|OTHER|Local anesthesia solution pre-warmed to 37°C|"About 150 ml of water at 21°C is added to the heating compartment of the heating device. The Local anesthesia cartridge is placed at the bottom of the heating compartment. The device is plugged in and the control gauge is set at the Express milk warming setting for contents up to 180ml/6oz mark. The contents would reach 37°C at 120 seconds."
214972300|NCT06519838|OTHER|Local anesthesia solution pre-warmed to 40°C|"About 150 ml of water at 21°C is added to the heating compartment of the heating device. The Local anesthesia cartridge is placed at the bottom of the heating compartment. The device is plugged in and the control gauge is set at the Express milk warming setting for contents up to 180ml/6oz mark. The contents would reach 40°C at 130 seconds."
214972301|NCT06519838|OTHER|Maxillary infiltration technique|A 30 gauge short needle is oriented so that the bevel is facing the bone. The syringe is held parallel to the long axis of the tooth and the needle is inserted into the height of the mucobuccal fold over the offending tooth. The needle is advanced to a depth of 1 millimeter into the tissues. Aspiration is done, and once it is negative then 0.6 ml (nearly one third of the cartridge) of the anesthetic solution is injected slowly without permitting the tissues to balloon.
214359990|NCT00726726|DRUG|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
214487982|NCT06887114|OTHER|Experimental Group (Mulligan Mobilization + Conventional Therapy)|Mulligan Sustained Natural Apophyseal Glides (SNAGs) applied to the lumbar spine, combined with conventional rehabilitation exercises (neuromuscular training, stretching, strengthening, and balance exercises).
214487983|NCT06887114|OTHER|(Conventional Therapy Only)|Neuromuscular training, stretching, strengthening, balance exercises, and gait training performed without Mulligan mobilization.
214487984|NCT06888791|PROCEDURE|US-guided Hydro Dissection|All procedures are performed under sterile conditions. The patient is seated in a sitting position with the physician behind the patient, the shoulder joint and the surrounding area is cleaned extensively with 10% povidone iodine. The probe is placed in the posterior lateral region of the shoulder, below the level of the scapular spine. The posterior labrum is observed as a triangular hyperechoic structure extending from the glenoid to the humeral head. A 22 G spinal needle is inserted approximately 1 cm medial to the probe along the axis of the spina scapula and 8 mg (2 mL) dexamethasone, 80 mg (4 mL) 2% lidocaine, 14 mL 0.9% saline is slowly injected into the joint in a total of 20 mL into the glenohumeral region. For suprascapular nerve block, 2 ml 0.5% bupivacaine + 2 ml 0.9% saline is administered. Patients are followed up in the recovery unit for 30 minutes after the procedure.
214487985|NCT06888791|PROCEDURE|Fluoroscopy-guided Hydro Dissection|The patient is placed on the scope table in supine position and the shoulder joint is cleaned with 10% povidone iodine. The acromioclavicular joint and the glenohumeral joint are visualized using C-arm fluoroscopy with anteroposterior view. The acromioclavicular joint is marked as the entry point to the shoulder joint. After the skin and subcutaneous tissue is anesthetized with 1 cc 2% lidocaine with a 27 G needle, a 22 G spinal needle is inserted through the acromioclavicular joint and the needle is directed towards the glenohumeral joint. With 1 ml of contrast medium, the localization of the needle is confirmed. After appropriate spread of contrast agent, 8 mg (2 mL) dexamethasone, 80 mg (4 mL) 2% lidocaine, 14 mL 0.9% saline are administered into the joint in a total of 20 mL. For US-guided suprascapular nerve block, 2 ml 0.5% bupivacaine + 2 ml 0.9% saline is administered. Patients are followed up in the recovery unit for 30 minutes after the procedure.
214487986|NCT06760442|PROCEDURE|Subcrestal implant placement|Delayed implant placement 2 mm subcrestally in missing mandibular posterior site.
214487987|NCT06760442|PROCEDURE|Crestal implant placement|Delayed implant placement equicrestally in missing mandibular posterior site.
214972302|NCT06519838|OTHER|Inferior alveolar nerve block technique|While the mouth is opened as wide as possible, the index finger palpates the external oblique ridge reaching the Coronoid notch. A 27-gauge long dental needle will be used for injection. The needle will be directed between the two primary molars on the opposing side of the arch, penetrating the tissues at the point halfway between coronoid notch and the pterygomandibular raphe at the occlusal plane level or slightly lower.The needle is withdrawn 2mm to aspirate. Once negative aspiration is checked, the remainder of the solution is deposited slowly. Approximately 1.0 mL of LA will be delivered near the inferior alveolar nerve. The average depth of insertion is about 15mm, which is nearly two-thirds the needle length.
214359991|NCT00726726|DRUG|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
214359992|NCT00726726|DRUG|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
214359993|NCT05918926|BEHAVIORAL|Exercise|Individualised remote exercise intervention
214359994|NCT02644187|DEVICE|BF-RhodoLED|Infrared light, with total dose of 37J/cm2.
214972303|NCT03825822|BEHAVIORAL|ImPaC Resource Intervention (INT)|"A Change Team will lead the implementation process of the ImPaC Resource using the steps:~Step 1: Complete a checklist to ensure its members can commit to responsibilities.~Step 2: Reflect on the unit's readiness for change.~Step 3: Perform an audit on 10 to 15 medical charts.~Step 4: Identify a practice change based on audit results (pain assessment or pain treatment). Develop an aim statement for the practice change.~Step 5: Select the KT strategies and plan the implementation.~Step 6: Perform an audit on 10 to 15 medical charts.~Step 7: Examine the effectiveness of the implementation and decide on the aim and KT strategies for the next cycle of change."
214972304|NCT03825822|OTHER|Standard Practice (SP)|The SP arm will continue as usual with their standard pain practices and will be offered the intervention 6 months after randomization and completion of data collection.
214972305|NCT02404051|DRUG|Everolimus|10 mg daily tablets
214972306|NCT02404051|DRUG|Exemestane|25 mg daily tablets
214972307|NCT02404051|DRUG|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
214972308|NCT04148547|DEVICE|Sooma transcranial direct current stimulation device|This group received brain training through transcranial direct current for 20 minutes.
214972309|NCT04148547|DEVICE|Placebo Sooma transcranial direct current stimulation device|This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
214972310|NCT02755506|DEVICE|endobronchial ultrasound elastography|Before endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), patients will undergo the examination of endobronchial ultrasound elastography
214972311|NCT01863615|DRUG|Isotretinoin 40 mg|Roaccutan 2 capsules of 20 mg; reference drug
214972312|NCT01863615|DRUG|Isotretinoin 40 mg|Oratane 2 capsules of 20 mg; test drug
214359995|NCT02644187|DEVICE|Aktilite CL128|Infrared light, with total dose of 37J/cm2.
214359996|NCT02644187|DRUG|BF200-ALA/5-aminolevulinic acid|Prodrug applied to whole treatment area previous to illumination with either light source.
214359997|NCT03580733|DRUG|caspofungin antifungal therapy|caspofungin
214359998|NCT03580733|OTHER|placebo|placebo
214359999|NCT04999813|COMBINATION_PRODUCT|Comprehensive intensive intervention|"* Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~  * Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~    * Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~      * Weight loss guidance."
214360000|NCT02058615|BEHAVIORAL|Male Spouse Transition Toolkit|
214360001|NCT03686046|OTHER|Exploratory use|Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
214360002|NCT01417026|DRUG|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
214360003|NCT04674124|BEHAVIORAL|Brief Online Mindfulness Intervention|A nine-week mindfulness course compromising of 9x weekly 15 minute group sessions which will be on an online platform and daily micro meditations for participants to undertake.
214360004|NCT02130193|DRUG|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
214360005|NCT02130193|DRUG|Placebo|Subjects will receive danirixin matching placebo
214487988|NCT06809647|DEVICE|Glaucoma surgery|This is an implant-free, minimally invasive glaucoma surgery
214487989|NCT06844344|DIAGNOSTIC_TEST|forceps biopsies|5 forceps biopsies
214487990|NCT06844344|DIAGNOSTIC_TEST|Cryo biosies|5 cryo biopsies
214487991|NCT06841549|OTHER|FAPI|FAPI is a new method to find the myocardial fibrosis under some conditions, like myocardial infarction or cardiac myopathy.
214487992|NCT06779877|PROCEDURE|Percutaneous dilatational tracheostomy|Percutaneous dilatational tracheostomy
214487993|NCT06779877|DIAGNOSTIC_TEST|The optic nerve sheath diameter measurement method by ultrasonography|The optic nerve sheath diameter measurement method by ultrasonography-Determine intracranial pressure.
214487994|NCT06844708|BIOLOGICAL|CMTS0929|China Microbiota Transplantation System 0929 (CMTS0929) is defined as suspension from washed microbiota.
214487995|NCT06746038|DEVICE|Extended Wear Hearing Aid|Extended wear hearing aid means that the device is worn 24 hours per day, 7 days a week for months at a time. However, this study will only fit devices on participants for one testing session lasting 2 hours.
214487996|NCT03891758|BIOLOGICAL|DPT-IPV-Hib|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
214487997|NCT03891758|BIOLOGICAL|Hib vaccine|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
214487998|NCT03891758|BIOLOGICAL|DPT-IPV|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
214360006|NCT01421576|DIETARY_SUPPLEMENT|High fat meal|offer high fat-meal in the morning before drug intake.
214360007|NCT03494387|DRUG|Oxygen|80% versus 30% inspiratory oxygen concentration
214360008|NCT03494387|DRUG|Antioxidants|Antioxidants versus placebo
214360009|NCT01525732|PROCEDURE|Per Oral Endoscopic Myotomy|
214360010|NCT01936025|DRUG|Dextromethorphan|
214487999|NCT01643954|PROCEDURE|robotic radical prostatectomy|robotic assisted surgery
214488000|NCT05990062|DEVICE|K-Socket-Harness|"A transradial socket and harness design that offers a hybrid polymer and textile-based design derived from advanced athletic shoe technology. The KSH integrated socket, frame, and wrist, the variable compliance prosthetic socket with breathable matrix, creates a dynamic and secure attachment with a combination of two lacing systems. The lacing systems lengthen and shorten six flexible hinges at the elbow, maintaining a secure attachment throughout the range of motion and accounting for volume changes in the soft tissue of the elbow that would otherwise restrict range of motion or cause the socket to separate from the residual limb."
214488001|NCT06225297|COMBINATION_PRODUCT|Intervention package|Intervention package will include vector control through meganets (multiple insecticide-treated mosquito nets sewn together), seasonal malaria chemoprevention (SMC) extended to all ages using DHA-PQ, and behavior change communication.
214488002|NCT06890195|PROCEDURE|dialysate cooling|patients will be subjected to individualized cool dialysate (dialysate temperature 0.5 °C lower than core body temperature)
214488003|NCT06890195|PROCEDURE|standard dialysate temperature|patients will be subjected to standard dialysate temperature (dialysate temperature of 37 °C).
214488004|NCT06881017|DRUG|Trastuzumab|iv，d1
214488005|NCT06881017|DRUG|Adebrelimab|iv，d1，q3w
214488006|NCT06881017|DRUG|Apatinib|po，qd，d1-21，q3w
214488007|NCT06881017|DRUG|S-1|po，bid，d1-14，q3w
214360011|NCT01936025|DRUG|Sitagliptin|
214360012|NCT01936025|DRUG|Placebo|
214488008|NCT06881017|DRUG|Capecitabine|po，bid，d1-14
214488009|NCT06881017|DRUG|Oxaliplatin|iv，d1，q3w
214488010|NCT06881017|DRUG|zolbetuximab|iv，d1
214488011|NCT06881017|DRUG|SHR-A1811|iv，d1 ，q3w
214488012|NCT06881017|DRUG|SHR-A1904|iv，d1 ，q3w
214488013|NCT06881017|DRUG|SHR-1701|iv，d1 ，q3w
214488014|NCT06750068|OTHER|3D printed space maintainer|Digitally fabricated #d printed space maintainer
214488015|NCT06750068|OTHER|Conventional space maintainer|Stainless steel space maintains
214488016|NCT06833749|DRUG|KBP-336|KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.
214488017|NCT06833749|DRUG|Placebo|Placebo to match KBP-336
214488018|NCT06832995|DRUG|IV morphine administered during the PACU stay|IV morphine administered during the PACU stay
214488019|NCT06795984|OTHER|Establishing the correlation between KIR AA and KIR non-AA and CD56 endometrial cells and IVF succes|The analysis aimed to compare CD56 levels between patients with the KIR AA genotype and those without. A multiple linear regression model was used to determine the predictive value of CD56+ levels, KIR genotype, and age on the number of blastocysts.
214679297|NCT06316661|DIAGNOSTIC_TEST|stress perfusion cardiac magnetic resonance|stress perfusion cardiac magnetic resonance according to guidelines, with quantitative evaluation for microvascular dysfunction assessment
214679298|NCT06316661|DIAGNOSTIC_TEST|cardiopulmonary exercise test|bike exercise with ECG and non invasive respiratory gas exchange monitoring
214360013|NCT04682496|PROCEDURE|Intratendon vascularization|Ultrasonic exploration by power-Doppler of the intratratendon vascularization, making longitudinal cuts of the patellar tendon and with previously pre-established Doppler optimization parameters for all patients. The optimization parameters of the power-Doppler signal will be set at a Doppler frequency of 6.7 MHz, pulse repetition frequency (PRF) of 0.7 kHz. The lowest wall filter and a standardized gain just below the level that produces random noise will be applied. This examination will be repeated several times with different probe pressures, which will be quantitatively adjusted through the force sensor and maintained with the articulated arm. A 4-second static video will be recorded of the longitudinal section that presents a higher Doppler signal in each of the scans at different probe pressures.
214360014|NCT02127424|PROCEDURE|Nurse-driven HIV targeted screening|
214972313|NCT04522648|OTHER|Prospective surveillance|A participant with an increase from pre-surgery in total arm volume of ≥6% by self-measurement, or symptoms of BCRL ≥2 NRS will receive an assessment by a lymphedema therapist. At this appointment, participants will receive a physical examination of the arm along with a BIS measurement. A participant is considered having subclinical BCRL if an increase in lymphedema index (L-DEX) ≥7 from pre-surgery measured by BIS is identified. A fitted compression garment and gauntlet is then provided, free of charge, for daily wear 10 hours/day for four weeks along with a recommendation to use the arm for daily activities and maintain regular physical activity. Following the four-week compression period, participants will be re-measured using BIS to evaluate response. Participants who do not respond to compression will receive CDT delivered by the lymphedema therapist.
214972314|NCT00569452|DEVICE|Accu-Chek Spirit Insulin Pump|One basal rate
214972315|NCT00569452|DEVICE|Accu-Chek Spirit Insulin Pump|Multiple basal rates
214360015|NCT02127424|PROCEDURE|Current practice|
214360016|NCT01212770|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
214360017|NCT01212770|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
214360018|NCT01212770|DRUG|Placebo|
214972316|NCT00260260|DRUG|Oxycodone|
214972317|NCT03311945|DRUG|Raltegravir|Raltegravir (1200 mg QD)
214972318|NCT03311945|DRUG|Lamivudine|Lamivudine (300 mg QD)
214972319|NCT01107925|DRUG|prasugrel|Administered orally, daily for 12 days
214972320|NCT01107925|DRUG|clopidogrel|Administered orally, daily for 12 days
214972321|NCT01960166|BEHAVIORAL|Active Distraction|iPad will be used as active distraction
214972322|NCT01960166|BEHAVIORAL|Passive Distraction|child will watch TV as passive distraction
214972323|NCT01078142|DRUG|Temsirolimus, Rituximab, Bendamustin|"Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)"
214972324|NCT02916134|PROCEDURE|Laparoscopic +/- Open Appendicectomy|Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
214972325|NCT02916134|DRUG|Antibiotic treatment|"Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics."
214972326|NCT04877990|DRUG|Deucravacitinib|Specified dose on specified days
214972327|NCT01007604|DEVICE|Peristaltic pulse PCD|Daily use for two hours
214360019|NCT03717961|DRUG|BOTOX® solution|Botox solution + Saline serum + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
214360020|NCT03717961|DRUG|Placebo group|Placebo + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
214360021|NCT04440566|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
214360022|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 1|To be eaten instead of regular snacks twice a day for 4 weeks.
214360023|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 2|To be eaten instead of regular snacks twice a day for 4 weeks.
214360024|NCT03581812|DIETARY_SUPPLEMENT|Control snack|To be eaten instead of regular snacks twice a day for 4 weeks.
214360025|NCT02019368|DIETARY_SUPPLEMENT|Placebo|
214360026|NCT02019368|DIETARY_SUPPLEMENT|Aged garlic extract|
214360027|NCT01248338|DRUG|metoprolol succinate|once daily 50 or 100 mg for one year
214360028|NCT01248338|DRUG|Nebivolol|once daily 5 mg capsule for one year
214360029|NCT00277667|DRUG|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
214360030|NCT05449834|DRUG|Fibrinogen Concentrate|3g Fibrinogen Concentrate
214972328|NCT01007604|OTHER|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
214972329|NCT02693457|PROCEDURE|Drain|One randomized knee will be assigned to receive an intra-articular drain procedure following bilateral total knee arthroplasty. The drain will be removed 24 hours post-operatively. The patient will be blinded to fluid output from intra-articular drain.
214972330|NCT02693457|PROCEDURE|No Drain|The contralateral knee will be assigned to a placebo drain procedure following bilateral total knee arthroplasty. This will blind the patient as to which knee contains the functioning intra-articular drain. A non-suction/ non-functional subcutaneous drain will act as the placebo drain. This drain will not output any fluid and will also be removed 24 hours after post-operatively.
214972331|NCT00894088|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
214972332|NCT03649893|DEVICE|Active Office|Active Office intervention includes sit-to-stand desk, bike desk, seddle chair, and active breaks.
214972333|NCT01361828|PROCEDURE|Electrophysiology|Visual Evoked Potential and Elctroretinogram
214972334|NCT05291130|DEVICE|Plasmafit® Vitelene® Vitamin E|Plasmafit® Acetabular Cup System with an insert Aesculap ® Vitelene ® Vitamin E Stabilized Highly Crosslinked Polyethylene and BIOLOX delta Ceramic Femoral Head or ISODUR® Metal Femoral Heads
214972335|NCT05816382|DRUG|TAK-861|TAK-861 tablets
214972336|NCT05987826|DRUG|Furmonertinib|Furmonertinib 80mg QD oral 8 weeks.
214360031|NCT05449834|OTHER|Cryoprecipitate|10U WB or 4U Apheresis Cryoprecipitate
214360032|NCT02069444|PROCEDURE|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
215083781|NCT02517632|BEHAVIORAL|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
214488020|NCT06930092|PROCEDURE|Physiology-and imaging-guided PCI|"The criteria for performing revascularization are as follows~1. Lesions with ≥50% diameter stenosis and FFR ≤ 0.80, or lesions with severe stenosis (\>90%)~2. In vessels meeting the above criteria, IVUS findings consistent with either:~   * Minimum lumen area (MLA) ≤ 3 mm²~  * 3 mm² \< MLA ≤ 4 mm² and plaque burden \>70%~For all target vessels and lesions identified for intervention, optimal revascularization should be pursued. The criteria for optimal revascularization are as follows, and operators are encouraged to achieve them:~1. Post-PCI FFR \> 0.86 in all treated vessels is recommended, with a minimum threshold of post-PCI FFR \> 0.80 to achieve functional complete revascularization.~2. Post-PCI ΔFFR (defined as \[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05 is recommended.~3. On IVUS, achieving a minimum stent area (MSA) \> 5.5 mm² and MSA/average reference lumen \> 80% is recommended."
214488021|NCT06930092|DRUG|Optimal medical treatment|All study participants will receive guideline-directed medical therapy. Even for patients assigned to the optimal medical therapy group, revascularization may be performed during follow-up if clinically indicated. If such a decision is made prior to the primary endpoint assessment, a gadolinium-enhanced cardiac MRI will be performed at the time of consideration to reassess myocardial viability.
214488022|NCT06308029|BEHAVIORAL|eHealth self-management support program|This web-based eHealth program consists of two parts. First participants will complete a pain science education program. After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part. The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle. The eHealth program will be accessible from any digital device (laptop, tablet, smartphone) after receiving a personal login code provided by the researcher. Participants go through the eHealth program independently at their own pace. It is recommended to do this in 8-12 weeks.
214488023|NCT06308029|BEHAVIORAL|Face-to-face rehabilitation program|The face-to-face rehabilitation program combines pain science education with an active behavioral approach. First, 2-3 individual face-to-face sessions are organized with a physical therapist to provide pain science education. The content of this pain science education program is the same as for the eHealth program. Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle. The educational information will be presented verbally and written. After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions. It is recommend to organise the in total 9 face-to-face sessions within a periode of 8-12 weeks.
214488024|NCT00650078|DRUG|MR prednisone|1 x 5 mg daily
214488025|NCT00650078|DRUG|Placebo|1x daily
214488026|NCT05672017|BEHAVIORAL|Dietary Instructions|Dietary Instructions
214488027|NCT06873542|DRUG|DC05F01|DC05F01 capsule
214488028|NCT04678427|OTHER|6 Minute Walk Functional Test|Complete 6-minute walk test
214488029|NCT04678427|BEHAVIORAL|Behavioral Intervention|Participate in walking and other activities
214972337|NCT00404209|PROCEDURE|Vitrectomy|pressurized 23GA vitrectomy with a 3D system
214972338|NCT01619878|DRUG|Artemether-lumefantrine (COA566)|One dispersible tablet taken orally twice a day during 3 days.
214972339|NCT00298064|GENETIC|Tissue Repository|
214972340|NCT03248648|DRUG|Neostigmine|patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
214972341|NCT03248648|DRUG|ketamine|patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
214360033|NCT02069444|PROCEDURE|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
214360034|NCT02495272|DRUG|Oxytocin|Oxytocin 10IU Administered intramuscularly.
214972342|NCT03839394|BEHAVIORAL|Telephone|A series of educational pamphlets on CVD risk reduction plus a telephone-based CVD risk reduction curriculum will be administered by Clinic-Based Case Managers (CCMs). Six modules will be given over 24 weeks in a rotating fashion on topics relevant to CVD risk. Subjects will be given the pamphlets every 2 weeks corresponding with the first time they receive the telephone - based module.
214972343|NCT03839394|OTHER|Educational pamphlets|A series of 6 handouts will be given to controls once monthly over 6 months on the same topics presented in the telephone modules. Educational packets will be primarily drawn from free printed material available at www.learningaboutdiabetes.org and the American Heart Association website.
214972344|NCT00667485|DRUG|Rapamycin (liquid)|Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
214360035|NCT02393794|DRUG|Romidepsin|Histone deacetylase inhibitor
214972345|NCT00667485|DRUG|Bevacizumab|Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
214360036|NCT02393794|DRUG|Cisplatin|Platinum compound
214360037|NCT02393794|DRUG|Nivolumab|Monoclonal antibody, checkpoint inhibitor
214360038|NCT03381495|DRUG|Ropivacaine Hydrochloride, Sufentanil|In this research one group will receive epidural analgesia(Ropivacaine Hydrochloride, Sufentanil), data will be collected and analyzed between this group and non-epidural analgesia group.
214360039|NCT05378633|RADIATION|SRS|Stereotactic Radiotherapy (SRS)
214360040|NCT05378633|RADIATION|Whole Brain Radiotherapy|Whole Brain Radiotherapy (WBRT)
214488030|NCT04678427|OTHER|Survey Administration|Complete survey
214972346|NCT00667485|DRUG|Rapamycin (Tablets)|Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
214360041|NCT06009341|OTHER|Rehabilitation|The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given. In addition, the intervention group will be taught the training program and applications.
214360042|NCT05245344|PROCEDURE|Peripheral blood withdrawal|25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers.
215083782|NCT02517632|BEHAVIORAL|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
214360043|NCT01923155|PROCEDURE|Colonoscopy|
214360044|NCT00829387|BEHAVIORAL|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
214360045|NCT00829387|BEHAVIORAL|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
214360046|NCT03036163|DRUG|PBTZ169 - 40 mg|40 mg of PBTZ169 (1 capsule) orally once in fasting state
214360047|NCT03036163|DRUG|PBTZ169 - 80 mg|80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
215083783|NCT04379115|DEVICE|Active Comparator: Active tDCS + Active TUS|"Device: Active comparator device: Active transcranial Direct Current Stimulation (tDCS). Subjects will receive 20 minutes of active tDCS. During each Active stimulation session, stimulation will be applied for the full 20 minutes.~Device: Active comparator device: Active Transcranial Ultrasound (TUS). Subjects will receive 20 minutes of active Transcranial Ultrasound (TUS). During active stimulation the (TUS) will be active for the full 20 minutes."
215083784|NCT04379115|DEVICE|Sham Comparator: Sham tDCS + Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of sham tDCS. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of sham TUS. During sham stimulation the ultrasound will not be active for the full 20 minutes."
215083785|NCT05951959|DRUG|Acalabrutinib|Investigational Product
215083786|NCT05951959|DRUG|Venetoclax|Investigator Product
214360048|NCT03036163|DRUG|PBTZ169 - 160 mg|160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
214360049|NCT03036163|DRUG|PBTZ169 - 320 mg|320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
214360050|NCT03036163|DRUG|PBTZ169 - 640 mg|640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
214360051|NCT03036163|DRUG|PBTZ169 - 320 mg (multiple administration)|320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
214360052|NCT03036163|DRUG|PBTZ169 - 640 mg (multiple administration)|640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
214360053|NCT05189730|DRUG|Tirelizumab|Two cycles of Tirelizumab (200mg administered as an intravenous infusion over 30 minutes per 3 weeks), D1.
214972347|NCT00338403|PROCEDURE|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
214972348|NCT01137513|DEVICE|Observational Measurement of T-wave Alternans|Measurement is similar to typical EKG
214972349|NCT01137513|DEVICE|T-wave Alternans|T-Wave Alternans will be measured in an observational fashion
214972350|NCT04970121|DRUG|Duloxetine|"Duloxetine, tablets, 20mg as starting dose and up to 60mg as maximum dose, once daily.~Taxanes is used according to manual instruction and patient condition."
214972351|NCT03113565|BEHAVIORAL|Count daily number of footsteps.|Using a connected electronic wristband to mainly quantify daily number of footsteps.
214972352|NCT01976481|DEVICE|sunbed exposure|exposure to sunbed ultraviolet radiation
214972353|NCT06439108|PROCEDURE|single symphyseal plating in management of vertically unsable open book pelvic ring injuries|open book pelvic ring injuries can be managed via the two techniques.
214972354|NCT02264808|OTHER|Developmental Outcomes|A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
214972355|NCT01219712|PROCEDURE|Colloids, dobutamin, levosimendan|": The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.~* Hb would be optimized to \> 90 g/l~* SaO2 \> 96%~* Stroke volume index (SVI) \> 30~* Heart rate should ideally be \< 80~Stroke volume index (SVI) \> 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is \< 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal"
214972356|NCT04241549|DRUG|Cusatuzumab|Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
214972357|NCT04241549|DRUG|Azacitidine|Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.
214972358|NCT01733745|OTHER|SYSTANE® Lid Wipes|Pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes
214972359|NCT01733745|OTHER|SYSTANE® BALANCE|Lubricant Eye Drops
214360054|NCT05189730|DRUG|Paclitaxel|Two cycles of paclitaxel (135mg/m2 administered as an intravenous infusion per 3 weeks), D1.
214360055|NCT05189730|DRUG|Carboplatin|Two cycles of carboplatin(AUC=5 administered as an intravenous infusion per 3 weeks) D1.
214360056|NCT05189730|RADIATION|Neoadiuvant radiotherapy|Simultaneous radiotherapy would be consecutively performed for 4 weeks with the total dose of 40Gy (40Gy/ 4W /20F), D1.
214360057|NCT02668224|DEVICE|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
214360058|NCT02668224|OTHER|Usual activities|The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
214360059|NCT00796081|DRUG|ER OROS paliperidone, paliperidone ER|
214360060|NCT06089811|DIETARY_SUPPLEMENT|Prebiotic|Group 1 (prebiotic and placebo L-tryptophan): prebiotic (oligofructose, Orafti®P95, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day)
214360061|NCT06089811|DIETARY_SUPPLEMENT|L-Tryptophan|Group 2 (placebo prebiotic and L-tryptophan): L-tryptophan (3g/day) and placebo prebiotic (microcrystalline cellulose, 20g/day)
214488031|NCT04678427|BEHAVIORAL|Timed Get Up and Go Test|Complete timed get up and go test
214972360|NCT01733745|DIETARY_SUPPLEMENT|SYSTANE® Vitamins|
214360062|NCT06089811|DIETARY_SUPPLEMENT|Placebo|Group 3 (placebo prebiotic and placebo L-tryptophan): placebo prebiotic (microcrystalline cellulose, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day).
214360063|NCT05257096|BEHAVIORAL|Medical clown|The medical clown will meet the children in the waiting room for 15-30 minutes and will accompany them through the whole investigation, up to one hour.
214360064|NCT00707031|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
214360065|NCT00707031|DEVICE|Pen auto-injector|
214360066|NCT00707031|DRUG|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
214360067|NCT00707031|DEVICE|Prefilled pen injector|
214360068|NCT00707031|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
214360069|NCT00182754|DRUG|octreotide acetate|Given subcutaneously
214488032|NCT06225648|OTHER|threonine|There are 7 different threonine test levels ranging from 5 to 45 mg of threonine per kilogram body weight per day.
214488033|NCT02107573|PROCEDURE|Rotator Cuff Repair without Suprascapular Nerve decompression|Traditional rotator cuff repair without Suprascapular nerve decompression
214488034|NCT02107573|PROCEDURE|Rotator Cuff Repair with Suprascapular Nerve decompression|Traditional rotator cuff repair with Suprascapular nerve decompression
214488035|NCT06905405|DIAGNOSTIC_TEST|Advanced imaging|Cardiac MRI scan Transthoracic ECHO
214488036|NCT06905405|DRUG|SGLT-2 inhibitor|SGLT-2 inhibitor
214488037|NCT06892366|BEHAVIORAL|Home-Based Aerobic Exercise Program|Aerobic Exercise (AE) Group This intervention consists of a home-based aerobic exercise program emphasizing moderate-intensity walking, tailored to 40-60% of peak VO2 or Borg Scale 4-6 for those on beta blockers. Distinctive features include real-time session supervision via video conferencing and heart rate monitoring with a smart wristband. This approach ensures remote guidance, personalized intensity, and participant safety throughout the 8-week program.
214488038|NCT06892366|BEHAVIORAL|Home-Based Aerobic and Resistance Exercise (ARE) Group|Participants engaged in a combined home-based aerobic and resistance exercise program. Aerobic sessions followed the same protocol as the AE group (3 days/week). Resistance training was performed 2 additional days per week using elastic resistance bands set at 40-50% of one-repetition maximum (1RM). Resistance exercises targeted major muscle groups, with each session consisting of 3 sets of 10 repetitions, and 1-3 minutes of rest between sets. All sessions were monitored and supervised remotely.
214488039|NCT02650622|PROCEDURE|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
214488040|NCT04794114|DEVICE|experimental ankle foot orthosis|On the basis of an accurate kinetic and kinematic analysis, a customized orthosis in thermoplastic material with carbon inserts will be created that will make the brace more elastic and facilitate the child's motor activities.
214488041|NCT04794114|DEVICE|traditional ankle foot orthosis|The normal afos in thermoplastic material, while guaranteeing an ankle joint stability, make the joint more rigid and reduce the elasticity of movement especially during running, jumping and sprinting.
214360070|NCT00182754|OTHER|placebo|Given subcutaneously
214360071|NCT01458197|DRUG|Tarafenacin 0.2 mg|Capsule, qd, 12 weeks
214360072|NCT01458197|DRUG|Placebo|Capsule, qd, 12 weeks
214360073|NCT01458197|DRUG|Tarafenacin 0.4 mg|Capsule, qd, 12 weeks
214972361|NCT01733745|OTHER|Microfiber towels (as warm compresses, with or without saline eye drops)|
214972362|NCT04039724|DRUG|HCP0605 + HGP0816|
215083787|NCT05951959|DRUG|Rituximab|Investigator Product
214360074|NCT01763710|DRUG|Paclitaxel 80 mg/m2|Paclitaxel 80 mg/m2 days 1, 8 and 15
214360075|NCT01763710|DRUG|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
214360076|NCT01763710|DRUG|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
214360077|NCT01763710|DRUG|Nab-paclitaxel 150 mg/m2 days 1 and 15|Nab-paclitaxel 150 mg/m2 days 1 and 15
214360078|NCT05777226|DRUG|Epalrestat|Patients in the treatment group are intervened with Epalrestat tablets.
214488042|NCT06752122|DRUG|Placebo (in SAD)|Inhalation once daily in the SAD part
214360079|NCT02297022|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
214488043|NCT06752122|DRUG|RCS-21 (in SAD)|Inhalation once daily in the SAD part
215083788|NCT02525614|DEVICE|Triathlon Standard Keel|Implantation of Knee Prosthesis
215083789|NCT02525614|DEVICE|Triathlon Short Keel|Implantation of Knee Prosthesis
214360080|NCT02535104|DRUG|Ranpirnase|Topical application by subject
214360081|NCT02535104|DRUG|Vehicle|Vehicle control
214360082|NCT00236873|DRUG|topiramate|
214360083|NCT01232608|BEHAVIORAL|Exercise|12 months of exercise training
214360084|NCT01054768|DRUG|alpha-lipoic acid and acetyl-L-carnitine|none to report
214488044|NCT06752122|DRUG|Placebo (MAD)|Inhalation once daily for seven days in the MAD part
214488045|NCT06752122|DRUG|RCS-21 (in MAD)|Inhalation once daily for seven days in the MAD part
214488046|NCT06771609|DRUG|Adebry single antibody + VEX metronomic chemotherapy + radiotherapy|1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
214972363|NCT04039724|DRUG|HCP1305|
214972364|NCT05016375|OTHER|Interview|Interview with individuals with T2DM
214972365|NCT04201236|OTHER|respiratory muscle strengthening exercise|These exercises strengthen locally inspiratory muscles. IMT can be done with threshold loaded devices.
214972366|NCT04201236|OTHER|oropharyngeal muscles strengthening exercise|These exercises strengthen locally oropharyngeal muscles. Oropharyngeal exercise can be done with some facial movements .
214972367|NCT05348044|OTHER|Res-ET intervention|Remote IMST delivery on Resilience
214972368|NCT03635827|COMBINATION_PRODUCT|NBTX-001 Xenon Inhaler|The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
214360085|NCT01054768|DRUG|Control|none to report
214360086|NCT04786158|DRUG|Apomorphine|Reporting the effects of subcutaneous apomorphine on pain and on quality of life
214360087|NCT02122133|DEVICE|PC 400|
214360088|NCT06011590|OTHER|No intervention.|No intervention.
214679299|NCT03453749|DIETARY_SUPPLEMENT|Salovum|Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
214972369|NCT03635827|COMBINATION_PRODUCT|Placebo|The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
214972370|NCT05932771|DIETARY_SUPPLEMENT|Experimental: Consumption of three different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
214972371|NCT05932771|DIETARY_SUPPLEMENT|Experimental: Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams maltodextrin was used in 0 grams HC. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
214972372|NCT02426034|DRUG|ApatinibTablets|Apatinib Tablets, recommended dose of 850mg
214972373|NCT03916445|OTHER|Connor Davidson Resilience Scale (CD-RISC 10)|questionnaires about resilience (Connor Davidson Resilience Scale(CD-RISC 10)) and quality of life (EQ-5D-5L)
214972374|NCT02895295|BEHAVIORAL|Expert Recommendation|Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
214972375|NCT02895295|BEHAVIORAL|Individual Analysis|Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
214972376|NCT02895295|BEHAVIORAL|Usual Care|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
214972377|NCT01367249|DRUG|Bromfenac Ophthalmic Solution|Sterile ophthalmic solution
214972378|NCT01367249|DRUG|Placebo|Sterile ophthalmic solution
214972379|NCT04147143|OTHER|Documentation|Retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.
214972380|NCT03739424|OTHER|Whole egg powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole egg powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
214972381|NCT03739424|OTHER|Whole milk powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole milk powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
214972382|NCT03739424|OTHER|Gelatin food product|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with gelatin. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
214972383|NCT01624285|DRUG|sorafenib tosylate|Given PO
214972384|NCT01624285|OTHER|placebo|Given PO
214972385|NCT01624285|OTHER|laboratory biomarker analysis|Correlative studies
214972386|NCT00060606|PROCEDURE|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
214972387|NCT00060606|PROCEDURE|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
214972388|NCT06610643|DRUG|combination therapy|A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir
214972389|NCT06610643|DRUG|SOC|Standard of care
214972390|NCT06824415|DEVICE|TMS|Transcranial magnetic stimulation (TMS) applies magnetic pulses to stimulate nerve cells in the brain.
214360089|NCT02575885|OTHER|Electronic Cigarette|Receive different type of ENDS product at each visit
214360090|NCT02575885|OTHER|Electronic Cigarette|Receive BLU e-cigarette ENDS product
214360091|NCT02575885|OTHER|Laboratory Biomarker Analysis|Correlative studies
214360092|NCT02575885|OTHER|Pharmacological Study|Correlative studies
214360093|NCT02575885|OTHER|Questionnaire Administration|Ancillary studies
214360094|NCT02471651|DRUG|Dexamethasone intravitreal implant (0.7 mg)|Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).
214360095|NCT02471651|DRUG|Intravitreal anti-VEGF injection|This injection may be ranibizumab, bevacizumab, or aflibercept.
215083790|NCT02571660|DRUG|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
215083791|NCT02571660|DRUG|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
214360096|NCT02747238|DEVICE|Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
214360097|NCT02747238|PROCEDURE|No ultrasound|Palpation of anatomical landmarks is used for placement of labor analgesia
214488047|NCT06771609|DRUG|debry single antibody + VEX metronomic chemotherapy|1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
214488048|NCT05517902|BIOLOGICAL|StrataGraft|StrataGraft® Construct
214488049|NCT00349830|PROCEDURE|blood draw|
214488050|NCT05315427|OTHER|one music therapy session|Edmonton Symptom Assessment System (ESAS) scale (before and after music therapy session), Numerical pain scale (before and after music therapy session)
214488051|NCT06035276|OTHER|Exposure to clean air|"Subjects will be exposed to filtered indoor air (clean air) for 4 hours in the Fraunhofer Environmental Exposure Chamber. The chamber can accommodate up to 18 subjects, is ventilated by HEPA-filtered and conditioned air, ensuring a constant humidity (40 ± 10%), temperature (22 ± 2°C), and airflow (1500 ± 100 m3/hr). During exposure they will perform an intermittent bicycle ergometer activity at 50 W for 10 minutes alternating with 20 minutes rest."
214488052|NCT06035276|OTHER|Exposure to urban air|"Subjects will be brought to a traffic dense urban region (urban air) with high traffic density and increased levels of particulate matter and vehicle emissions. Subjects will stay in this area for 4 hours. During exposure, all subjects will walk together with study staff. Rest periods are only allowed outside. Intervals of activity and rest will be similar to the clean air regimen."
214488053|NCT06833060|DEVICE|Selective Laser Trabeculoplasty|Treatment of Glaucoma or Ocular Hypertension participants using Transscleral Selective Laser Trabeculoplasty
214488054|NCT06756893|PROCEDURE|Dorsal Root Ganglion Pulsed Radiofrequency|"Using C-arm fluoroscopy, a 22G, 10 cm RF needle with a 5 mm active tip will be directed from lateral to medial towards the vertebral foramen. Once the needle reaches the lateral edge of the pedicle shadow, the C-arm will be adjusted to a lateral view to confirm that the needle is located at the craniodorsal portion of the intervertebral foramen. Sensory stimulation will be delivered through the RF generator at 50 Hz, and paresthesia will be sought in the corresponding dermatome at values between 0.4-0.8 mA.~After achieving paresthesia, motor stimulation at 2 Hz will be applied, and the location near the DRG will be confirmed if motor stimulation is not elicited at values less than 1.5 times the sensory threshold. Pulsed RF will then be applied for 4 minutes at a setting of 45 V, 20 ms pulse width, and 2 Hz frequency. Following the application, needle will be directed slightly anterior and after appropriate contrast flow, dexamethasone will be injected."
214488055|NCT07040046|DRUG|HS-10542|"1. SAD：HS-10542 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1.~2. Food Effect \[FE\] study：HS-10542 capsule (in one predefined dose cohort ) will be administered orally once on Day 15."
214488056|NCT07040046|DRUG|HS-10542 Placebo|SAD：HS-10542 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1
214972391|NCT04821830|DRUG|carbidopa/levodopa, as prescribed by treating physician|"There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR)."
214972392|NCT06611865|PROCEDURE|Intraligamentary anaesthesia|Injection of anesthetic solution into the intraligamentary space along the long axis of a tooth root using a pressure syringe.
214972393|NCT06611865|PROCEDURE|Inferior alveolar nerve block|Anaesthetic injection into the pterygomandibular space to block the Inferior alveolar nerve at the mandibular foramen point.
214360098|NCT02747238|PROCEDURE|Epidural infusion|An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
214360099|NCT03758170|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
214360100|NCT02568748|BIOLOGICAL|CIK|Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.
214360101|NCT02568748|PROCEDURE|TACE|Trans-arterial chemoembolization
214488057|NCT07040046|DRUG|HS-10542|MAD：HS-10542 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 10.
214488058|NCT07040046|DRUG|HS-10542 Placebo|MAD：HS-10542 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 10.
214972394|NCT06611904|DRUG|Dulaglutide|Combined treatment with dulaglutide and dapagliflozin
215083792|NCT00238784|DRUG|Budesonide/formoterol Turbuhaler|
214360102|NCT05069090|BEHAVIORAL|Lockdown and other social distancing measures|During the study period, the Chilean Ministry of Health established a five-step process for social distancing measures. These ranged from full lockdown (step 1) to almost no restrictions (step 5). Even under full lockdown, citizens were able to obtain permits for essential activities. Citizens had a maximum of two permits per week and were obtained in a virtual station of the Chilean Police Force (Carabineros de Chile).
214360103|NCT00815282|OTHER|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
214360104|NCT05665933|BEHAVIORAL|ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION|Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
214360105|NCT01944904|DIETARY_SUPPLEMENT|Sugar Pill|The placebo is identical in appearance to the XOS and contains 505mg maltodextrin
214360106|NCT01944904|DIETARY_SUPPLEMENT|XOS 2.8|2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
214360107|NCT01571505|BIOLOGICAL|IPV vaccination|Randomized IPV or OPV to children aged at 39weeks.
214972395|NCT06611904|DRUG|DPP-4 Inhibitors|DPP-4i treatment as an add-on to metformin
214972396|NCT06612489|DEVICE|biofeedback based dynamic-difficulty game|A biofeedback based dynamic-difficulty serious game rooted in distraction therapy.
214972397|NCT06612489|DEVICE|fixed difficulty game|A fixed difficulty serious game rooted in distraction therapy.
214972398|NCT06612476|DRUG|Interleukin 6-guided antibiotic therapy|In Interleukin-6 group, antibiotic prescription decisions will made according to the results of IL-6.
214972399|NCT06612476|DRUG|GOLD-guided antibiotic therapy|In guideline group, antibiotic prescription decisions will made according to the recommendations of GOLD guideline.
214360108|NCT02085252|DRUG|Leuprorelin|Solution for injection
214360109|NCT02085252|DRUG|Bicalutamide|Bicalutamide tablets
214360110|NCT03606330|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics.~* Intracoronary imaging techniques: IVUS and OCT."
214360111|NCT03606330|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
214360112|NCT00951275|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 months
214360113|NCT00951275|DRUG|Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)|As prescribed
214360114|NCT01460940|DRUG|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
214360115|NCT01460940|DRUG|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
214360116|NCT04477928|DIAGNOSTIC_TEST|Sera and whole blood sampling|"* Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry.~* 2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies~* 5 years old: T1D and celiac autoantibodies~* 9-16 year old: one-time T1D and celiac autoantibodies~* Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies"
214360117|NCT04477928|DIAGNOSTIC_TEST|Differential Gene Expression (DGE)|Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
214360118|NCT02767258|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
214360119|NCT02767258|DEVICE|VIDISIC® GEL|Carbomer based gel, used in the treatment of dry eye.
214360120|NCT06323733|OTHER|Exercise Intervention|The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France. Each session will last 1 hour under the supervision of physiotherapists. Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of
214360121|NCT04575636|DIAGNOSTIC_TEST|Magnetic Resonance Lymphography|Magnetic Resonance Lymphography using Siemens 3T MRI unit and Gadobutrol as a contrast agent to visualize the lymphatic system
214360122|NCT04405518|DRUG|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.
214360123|NCT01254123|DRUG|Exenatide infusion|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the Exenatide group will immediately be treated be with Exenatide iv, 5ug bolus in 30 minutes, followed by a continuous Exenatide infusion of 20ug/ 24 hours.~Exenatide preparation: Byetta injection pens containing 1,2 ml (concentration 0,25 mg/ml; 60 doses of 5 μg) will be obtained. 3 doses (15 μg) will be diluted in 49 ml saline and 1 ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml containing 15 μg exenatide (or 300 ng exenatide / ml). A 50cc syringe will be placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
214360124|NCT01254123|DRUG|Placebo infusion.|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.~Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
214360125|NCT02446301|DRUG|Bain®|Nalbuphine HCl 20mg, IM injection
214972400|NCT06611462|BEHAVIORAL|Prehabilitation (the STRONG programme)|Participants screened positive for one or more SNAP factors and randomised to the intervention group will receive an individualised plan for prehabilitation of their specific SNAP factors.
214972401|NCT06612775|DRUG|Test drug CB03-154 5mg group|CB03-154 tablet (5mg/tablet) once daily.
214360126|NCT02446301|DRUG|SDE|Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
214360127|NCT03295890|PROCEDURE|Dry Needing|Dry Needling
214360128|NCT01826864|BIOLOGICAL|sargramostim|Given SC
214360129|NCT01826864|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
214360130|NCT01826864|OTHER|laboratory biomarker analysis|Correlative studies
214360131|NCT01826864|OTHER|hypertonic saline|Given SC
214972402|NCT06612775|DRUG|Test drug CB03-154 10mg group|Two CB03-154 tablets (5mg/tablet) once daily.
214972403|NCT06612775|DRUG|Test drug CB03-154 20mg group|Four CB03-154 tablets (5mg/tablet) once daily.
214972404|NCT06612775|DRUG|Placebo group|Four Placebo tablets once daily.
214972405|NCT06612528|DEVICE|tDCS|"The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle."
214360132|NCT05483504|DRUG|F61 injection|Colorless or slightly yellow liquid, may be slightly opalescent
214360133|NCT05483504|DRUG|F61 Placebo|Colorless or slightly yellow liquid, may be slightly opalescent
214360134|NCT06294496|PROCEDURE|CEA/CAS|carotid endarterectomy (CEA) and carotid artery stenting (CAS)
214488059|NCT06736080|DRUG|MUNC-CD34|"* Dosage: ≥ 2 x10e6 CD34/kg after thawing, dose limit: 20x10e6 CD34+ cells/kg~* Route of administration: intravenous, on D0"
214488060|NCT06736080|DRUG|MUNC-T3|"* Dosage: \[1.10e4; 5.10e6\] T-CD3+/kg after thawing,~* Route of administration: intravenous, on D14 post-GT +/- D28 In case of persistent circulating T-cell after the HLH remission at inclusion, the MUNC-CD34 will be completed by MUNC-T3 infusion"
214488061|NCT06855927|OTHER|Guided Imagery|Guided imagery is a potential healing technique that aims to help individuals mentally visualize positive physical and psychological states.
214488062|NCT04705896|BIOLOGICAL|20-25% Albumin fluid (100 mL)|"Participants will be randomized to receive albumin (20-25%) during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (i.e. for SLED sessions, at 0 and 4 hours; for IHD sessions, at 0 and 2 hours)."
214488063|NCT04705896|OTHER|0.9% Normal Saline (100 mL)|"Participants will be randomized to receive normal saline 100 mL boluses during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (e.g. for 8 hour SLED sessions, at 0 and 4 hours; for 4 hour IHD sessions, at 0 and 2 hours; for CRRT, after starting/randomization then every 12 hours while continuing on CRRT)."
214488064|NCT06939088|DRUG|Tirzepatide|Once weekly injections s.c. with tirzepatide (Mounjaro(R))
214488065|NCT06939088|DRUG|Placebo|Once weekly injections s.c. with placebo (BD Posiflush)
214488066|NCT06946654|PROCEDURE|Geriatric Assessment|This is a study held in all patients undergoing allogenic hematopoietic stem cell transplantation. Pre-transplant assessment: (1)Patients-related assessment: (a) Age; (b) Functional status (BADL score; IADL score; KPS score; ECOG PS score); (c) Comorbidities (HCT-CI score); (d) Nutritional Status (Body weight; BMI; NRS-2002; MNA-SF; MUST); (e) Psychological Status (SF36-MCS; GDS; PHQ-9; GAD-7); (f) Cognitive Function (MMSE; BMOC); (g) Social Support Level (MOS-SSS; MSPSS); (h) Total Number of Medications Used. (2) Disease-Related Factors Assessment: Primary Disease Diagnosis; ELN Risk Stratification (assessed only for AML patients); Disease Status. (3) Donor-Related Factors Assessment: Donor Age; Donor Sex; Donor-Recipient Blood Type Compatibility; Donor Type; DSA. (4) Treatment-Related Factors Assessment: Conditioning Regimen; GVHD Prophylaxis Regimen; Graft Type.
214360135|NCT00100685|DRUG|Volociximab (anti-α5β1 integrin monoclonal antibody)|Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
214360136|NCT04359472|DEVICE|Application of Autologous Amniotic Fluid|Collection and reapplication of amniotic fluid at wound layers during a cesarean section.
214360137|NCT05748548|OTHER|Thoracic kyphosis- Lumbal Lordosis angle measurement|In order to determine the kyphosis, the degrees determined by measuring the spinous processes of the T12 T1, T2 and L1 vertebrae with an inclinometer while the individuals are standing will be collected. In order to determine the degree of lumbar lordosis, the measurement between the spinous processes of the T12L1 and S2S3 vertebrae will be made and the degree of lordosis will be determined by adding the degrees found. While the reference values for thoracic kyphosis are 20-45 degrees, this value is 20-40 degrees for lordosis. These measurements will be made with an inclinometer. Measurements will be repeated 3 times and the results will be recorded by taking the average of the measurements.
214360138|NCT05748548|OTHER|Back Muscle Endurance Test - Sorenson Test|The endurance of the back muscles will be evaluated with the Biering Sorensen Test (Static Back Endurance Test).
214972406|NCT06612528|DEVICE|Flexible tube in water|"The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy."
214972407|NCT06612385|DEVICE|platelet indices|Significance of platelet indices and ratios in different degrees of burn
214972408|NCT06999980|DRUG|Ipilimumab 3mg/kg and nivolumab 1mg/kg|Neoadjuvant for 2 doses on days 1 and 22
214972409|NCT06999980|DRUG|Nivolumab 480mg and relatlimab 160mg and ipilimumab 1mg/kg|Neoadjuvant for 2 doses at days 1 and 29
214972410|NCT06999980|DRUG|Nivolumab 480mg and relatlimab 160mg|Neoadjuvant for 2 doses on days 1 and 29
214972411|NCT04853043|DRUG|Cetuximab|Cetuximab will be administered every 2 weeks (14 days). The initial dose of 500 mg/m2 is to be administered by IV infusion over 120 minutes on the first day of the treatment. In the absence of infusion reactions, subsequent doses are to be administered over 60 minutes biweekly. Each cycle will be defined as 14 days of treatment.
214972412|NCT07003984|BIOLOGICAL|CHIKV VLP vaccine|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%
214972413|NCT07003984|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
214972414|NCT00593450|DRUG|ranibizumab|• 0.5 mg (0.05 mL)intravitreal injection
214972415|NCT00593450|DRUG|bevacizumab|• 1.25 mg (0.05 mL)intravitreal injection
214972416|NCT07006896|DEVICE|Foley balloon|Foley balloon for induction of labor
214972417|NCT07006896|DRUG|Oxytocin|Pitocin for induction of labor
214972418|NCT00994747|OTHER|Nutramigen (Flavor and Type of Infant Formula)|Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life
214972419|NCT00994747|OTHER|Enfamil, milk-based formula|Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
214972420|NCT06695507|DRUG|Ruxolitinib|Participants will receive ruxolitinib for 6 months.
214488070|NCT06953622|DRUG|Conservative treatment|Receive no antipaletet drug treatment and surgery
214488071|NCT06953622|DRUG|Antipaletet drug|Use of antipaletet drugs.
214488072|NCT06953622|PROCEDURE|Patent Foramen Ovale Closure|Receive the surgery of Patent Foramen Ovale
214488073|NCT02911064|BEHAVIORAL|Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
214488074|NCT01513122|DRUG|Lopinavir / ritonavir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
214488075|NCT01513122|DRUG|2-3N(t)RTI|
214488076|NCT01513122|DRUG|raltegravir|raltegravir 400mg 1 tablet twice daily.
214488077|NCT05604963|PROCEDURE|Total Thyroidectomy|Total Thyroidectomy - surgical removal of entire thyroid gland
214972421|NCT05443451|DEVICE|3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH|The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.
214972422|NCT06882031|DRUG|Treatment A: Arsenic Trioxide (ATO) Intravenous|0.15 mg/kg 2-hour IV infusion of ATO administered under fasted state in single dose
214360139|NCT05748548|OTHER|Surface EMG activation|We will try to find out which of the exercises such as pressing back the back, waist extension on the balance ball, lumbar extension while in the active prone position, Superman exercises have better lumbar extensor muscle activations.Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
214360140|NCT03502382|DIAGNOSTIC_TEST|x-ray|Radiological: standing antero-posterior full-length digital images of the lower extremities
214360141|NCT04567108|BEHAVIORAL|Maintain usual SSBs|Instruction/guidelines to maintain baseline intake of SSBs (months 0-6); then switch to water only (months 6-12)
214360142|NCT04567108|BEHAVIORAL|Substitute to non-SSBs|Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)
214360143|NCT04567108|BEHAVIORAL|Study app|Engage with a motivational mobile app to track beverage intake and complete study data collection
214360144|NCT04567108|BEHAVIORAL|Beverage delivery|Select from approved beverages for a monthly at-home delivery (months 0-6)
214360145|NCT05874765|DIAGNOSTIC_TEST|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5)|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5) , will be used to diagnose and classify the Tics among all included patients
214360146|NCT01767558|OTHER|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
214360147|NCT01464541|PROCEDURE|operative fracture size vs CT fracture size|comparing actual intraoperative fracture size to the CT fracture size
214360148|NCT01464541|PROCEDURE|orbital fracture intraoperative measurement|comparing intraoperative fracture size to the CT orbital fracture size
214360149|NCT02341430|DEVICE|Symbotex™ Composite Mesh|Repair of a Grade I or II ventral hernia according to VHWG classification system with Symbotex™ Composite Mesh
214360150|NCT04636970|OTHER|Home training program|Subjects randomized to the IG will participate at home training program that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after.
214360151|NCT03735264|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
214360152|NCT01417689|OTHER|Encouragement to attempt eye drop instillation with a specific technique|Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
214360153|NCT02128464|PROCEDURE|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
214360154|NCT02128464|PROCEDURE|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
214488078|NCT05604963|PROCEDURE|Hemithyroidectomy|Hemithyroidectomy - surgical removal of partial thyroid gland
214360155|NCT01112579|DEVICE|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
214360156|NCT01112579|DEVICE|Medtronic PrimeADVANCED Neurostimulator|Medical management
214360157|NCT01735890|DRUG|CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg|single dose
214360158|NCT01385072|BIOLOGICAL|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
214360159|NCT03778879|DRUG|CCX872-B|CCX872-B concurrent with stereotactic body radiation therapy for pancreatic adenocarcinoma.
214488079|NCT03133988|BIOLOGICAL|Margetuximab|anti-HER2 monoclonal antibody
214360160|NCT00282022|DRUG|laromustine|
214972423|NCT06882031|DRUG|Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state|0.15 mg/kg SDK001 administered orally under fasted state in single dose
214972424|NCT06882031|DRUG|Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state|0.15 mg/kg SDK001 administered orally under fed state (high fat breakfast) in single dose
214972425|NCT06882031|DRUG|Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate|0.15 mg/kg SDK001 administered orally with calcium carbonate in tablet form (1g) under fasted state in single dose
214972426|NCT06706232|DRUG|Psilocybin|Two sequential administrations of 25 mg psilocybin, 4 weeks apart.
214972427|NCT06706232|BEHAVIORAL|Therapeutic Support|"Five preparatory in-person psychotherapy sessions will be offered before the first administration session during weeks 1, 2, 3, 4, and 5. The optional second administration session will be preceded by a shorter 60 min preparatory session the day before.~Each administration session will be followed by 3 integration sessions and will adopt a Mindfulness-based CBT approach (M-CBT), in which a therapist will help the participant to process their experience and how to translate this into actual changes in everyday life.~If participants prefer more psychological support after the second administration session, they will be offered additional, optional therapy sessions for the duration of the trial regardless if they opted for a second administration session or not."
214972428|NCT00960804|BIOLOGICAL|Tanezumab|IV, 5 mg dose, q 8 weeks, for up to 80 weeks
214360161|NCT05738993|DRUG|BCD-178|A single intravenous (IV) infusion at a dose of 420 mg
214360162|NCT05738993|DRUG|Perjeta|A single intravenous (IV) infusion at a dose of 420 mg
214360163|NCT04062357|DRUG|Lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
214360164|NCT04062357|OTHER|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
214360165|NCT04133727|BEHAVIORAL|Use of an ageing suit|The simulation suit consists of a pair glasses which simulates narrowing of visual field; a pair of gloves ; a vest ; elbow and knee wraps and sand bags worn on the wrists and ankles
214360166|NCT04133727|OTHER|Polypharmacy workshop|Participants will conduct a full medication review for older adults within 1 hour and develop a medication list which can be used for counselling of older adults
214360167|NCT01963325|DRUG|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, \<1.25 m2: 80mg/day, 1.25\~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
214360168|NCT03565445|DRUG|ASP1948|Intravenously (IV)
214360169|NCT03565445|DRUG|nivolumab|Intravenously (IV)
214360170|NCT03565445|DRUG|pembrolizumab|Intravenously (IV)
214360171|NCT04770025|DEVICE|High-density transcranial alternating current stimulation|High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range
214360172|NCT04770025|DEVICE|Sham stimulation|High-density electrode configuration with sham stimulation
214360173|NCT04770025|BEHAVIORAL|Motivational interviewing|Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
214360174|NCT06440915|OTHER|Theraputic drug monitoring|High Performance Liquid Chromatography (HPLC) is used to determine the plasma concentrations of isavuconazole
214360175|NCT06440915|DRUG|Isavuconazole|Isavuconazole
214360176|NCT02504658|BEHAVIORAL|Lifestyle text messages|"Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website."
214360177|NCT02504658|BEHAVIORAL|Attention Control Group|"Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over."
214360178|NCT02289391|DRUG|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
214360179|NCT02289391|DRUG|Anesthesia maintenance|"* Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60."
214360180|NCT02289391|DRUG|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
214360181|NCT06332885|DEVICE|Zephyr Endobronchial Valve|Zephyr Valve provides an alternative technique to achieve bronchoscopic lung volume reduction (BLVR) using a minimally invasive approach. Zephyr Valve is a tiny unidirectional valve. During BLVR, multiple valves are placed to occlude a hyperinflated lobe of the lungs, allowing air to escape while blocking airflow into the treated lobe. This is intended to result in a reduction in lung volume and hyperinflation in the targeted area. Consequently, the remaining lobes can expand more fully, the overall lung works more efficiently, with resultant improvement in overall lung function in patients with hyperinflation associated with severe emphysema.
214360182|NCT02357251|OTHER|Enhanced recovery protocol|
214360183|NCT04304833|OTHER|Provider-Based Care Model Arm|The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.
214972429|NCT00960804|BIOLOGICAL|Tanezumab|IV, 10 mg dose, q 8 weeks, for up to 80 weeks
214972430|NCT00960804|OTHER|Placebo|IV, q 8 weeks, for up to 80 weeks
215083793|NCT04627181|DRUG|Ferric carboxymaltose|Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
214360184|NCT04304833|BEHAVIORAL|mHealth Model Arm|The PI will provide each patient with weight scale, blood pressure cuff, \& pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
214488080|NCT04978129|BEHAVIORAL|Online and Text Messaging Intervention|The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
214488081|NCT05933057|DRUG|Givinostat|Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
214488082|NCT05933057|DRUG|Placebo|Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
214488083|NCT05062291|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target Lesion Primary Patency (TLPP)
214488084|NCT06562673|DRUG|intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar)|After insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under local anesthesia, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
214488085|NCT05795153|DRUG|LOU064|One film-coated tablet (25 mg) was to be taken in the morning and evening, respectively, with a 12-hour interval at approximately the same time everyday.
214488086|NCT01614405|DRUG|TDF/FTC/LPV/r|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
214488087|NCT01614405|DRUG|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.
214488088|NCT05006989|OTHER|Blueberry Powder|Administered one packet per day (10 grams/packet) and participants consume up to 10 grams per day.
214488089|NCT05006989|OTHER|Placebo Powder|Administered one packet per day (10 grams/packet) and participants consume up to 10 grams per day.
214972431|NCT01635621|DRUG|Olokizumab (OKZ)|"Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~* OKZ 120 mg every 2 weeks~* OKZ 240 mg every 2 weeks~* OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0."
214972432|NCT01635621|DRUG|Placebo|Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
214360185|NCT02878473|PROCEDURE|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
214360186|NCT06647550|DRUG|HD-6277 100mg|PO, QD
214360187|NCT06647550|DRUG|HD-6277 50mg|PO, QD
214360188|NCT06647550|DRUG|HD-6277 25mg|PO, QD
214360189|NCT06647550|DRUG|Placebo|PO, QD
214360190|NCT03253224|DRUG|Magnesium Sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.
214360191|NCT03253224|DRUG|Normal saline|Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
214360192|NCT01951625|DRUG|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
214360193|NCT01951625|DRUG|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
214360194|NCT01951625|DRUG|Placebo|
214360195|NCT06483750|DEVICE|Systane iLux Treatment|The Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.
214360196|NCT00778765|DRUG|400 mg Gabapentin Capsules|
214360197|NCT05815329|OTHER|cognitive training|After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered to half of the outpatients included in this research by means of technological devices (Neurotablet). A neuropsychologist will supervise the cognitive training offline (about 30 minutes per 5 days, 8 weeks) and through a face-to-face 1 hour-session each week per each outpatient.
214360198|NCT04866017|DRUG|Tislelizumab|200 mg intravenously every three weeks
214360199|NCT04866017|DRUG|Durvalumab|10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
214360200|NCT04866017|DRUG|Ociperlimab|900 milligrams (mg) intravenously every three weeks
214360201|NCT04866017|DRUG|Chemotherapy|"The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options:~* Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days.~* Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously.~* Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~* Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~The pemetrexed plus platinum regimen was only for participants with non-squamous histology."
214360202|NCT04866017|RADIATION|Radiotherapy|All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.
214360203|NCT01475136|DRUG|LY2140023|
215083794|NCT04627181|DRUG|Hydroxycobalamin|Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
215083795|NCT04627181|DRUG|Placebo|Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
215083796|NCT04627181|DRUG|Placebo|Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
215083797|NCT03406416|DEVICE|44Ch Bionic Eye Device|Prototype wide view suprachoroidal retinal prosthesis
215083798|NCT05932264|DRUG|Apatinib + Fluzoparib|Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid
214972433|NCT00651300|DRUG|Parecoxib/Valdecoxib|A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
215083799|NCT05932264|DRUG|Apatinib + Fluzoparib + Adebrelimab|Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]
214972434|NCT00651300|DRUG|Placebo|A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
214972435|NCT02248168|DRUG|Pramipexole|
214972436|NCT01296139|DRUG|Ferumoxytol|All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2\*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
214972437|NCT00490919|DRUG|Buprenorphine transdermal system|Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
214972438|NCT00490919|DRUG|Placebo|transdermal system (placebo) worn for 7 days
214972439|NCT00428480|BEHAVIORAL|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
214972440|NCT00428480|BEHAVIORAL|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
214972441|NCT00005743|BEHAVIORAL|exercise|
214972442|NCT00005743|BEHAVIORAL|weight loss|
214972443|NCT02176369|DRUG|Vinorelbine|Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
214972444|NCT01014598|DRUG|Cisplatin|Given intra-arterially via isolated lung suffusion
214972445|NCT01014598|OTHER|Pharmacological Study|Correlative studies
214972446|NCT02193204|BEHAVIORAL|Personal Stress Imagery|"The stress imagery script will be based on participants' description of a recent personal event experienced as most stressful, and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions."
214972447|NCT02193204|BEHAVIORAL|Neutral Imagery|The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
214972448|NCT03981016|OTHER|Biological collection|"* blood samples collected at different times : Before surgery and during the post-operative visit and~* frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
214972449|NCT03896750|DRUG|PA-824|PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
214972450|NCT07063706|OTHER|Pharmaceutical Care|Participants in the intervention group received pharmaceutical care
214972451|NCT07065643|OTHER|Phase 1 - Maintenance Diet|3d maintenance diet (MT, fixed macronutrient composition of 15% protein, 30% fat and 55% CHO), fed to energy requirements (1.3 X RMR)
215083800|NCT05216003|BEHAVIORAL|PATH4YOU|PATH4YOU offers patient-center, comprehensive, contraceptive counseling; pregnancy planning; and same to next day access to birth control. This clinical care program will reduce obstacles to contraception in Indiana and enables access to healthy pregnancy planning conversations.
215083801|NCT04735198|PROCEDURE|Primary tumor surgery|Large bowel resection.
215083802|NCT04735198|PROCEDURE|Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy|Large bowel resection combined and cholecystectomy.
215083803|NCT03542916|DRUG|CJ-40001 60ug|CJ-40001 60ug SC, IV injection
215083804|NCT03542916|DRUG|NESP 60ug|NESP 60ug SC, IV injection
215083805|NCT06507514|COMBINATION_PRODUCT|"blinatumomab and auto-HSCT sandwich  strategy"|The patients received sequential infusion of blinatumomab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after infusion. Following successful stem cell collection, autologous stem cell transplantation was conducted. Starting from the third month after autologous stem cell transplantation, the second maintenance treatment with brentuximab vedotin was administered, with one cycle every three months, for a total of four cycles. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
215083806|NCT03852979|DRUG|Paclitaxel|weekly paclitaxel 80 mg/m2 for 12 weeks
215083807|NCT03852979|DRUG|Carboplatin|weekly carboplatin AUC=2 for 12 weeks
215083808|NCT03852979|PROCEDURE|conisation|if tumor is reduced to \<2 cm, patients will be treated with a conisation
215083809|NCT06008899|PROCEDURE|US assisted caudal epidural pulsed radiofrequency|patients will receive US assisted caudal epidural pulsed radiofrequency and followed up to 8 weeks
214360204|NCT06693479|DEVICE|Shoulder watch load (SWL) feedback|During week 2 and 3 after randomization, the experimental group will undergo the intervention using the SWL, designed to monitor workers' physical work demands. During this time, the SWL will provide real-time feedback based on parameters set via Ergowatchapp. A workplace visit by a physiotherapist will be conducted to establish and adjust the feedback thresholds in week 2, after the education intervention. If necessary, a second remote meeting will take place in week 3 to explain how participants can modify the thresholds themselves. The initial feedback thresholds will be set based on the physical work demands measured during week 1 and will be adjusted after one week of feedback use. These thresholds will be collaboratively determined by a physiotherapist and the workers. Only the experimental group will receive feedback from the SWL during the study period.
214360205|NCT06693479|OTHER|Education|Participants will receive an education intervention delivered by a physiotherapist. This intervention will take place preferentially at the participants' workplace at the end of the 2nd week post-randomization. The session will last 30 to 45 minutes, and involve personalized, patient-centered education on their condition. The physiotherapist will use open-ended questions to encourage participants to express their goals and address specific concerns related to their shoulder condition. Given the expected diversity in physical constraints (manual vs. non-manual workers) and individual challenges, the session will be tailored to each worker needs. At the end of the session, workers will receive a booklet summarizing key points, including: understanding shoulder anatomy, function and pain, managing shoulder pain, enhancing movement variability, adjusting work environment, and considering factors such as sleep, stress, coping mechanisms, and psychological factors on pain.
214360206|NCT06262620|PROCEDURE|EBUS-TBNA|A 22G biopsy needle was insert into the lesion through tracheal-bronchial wall under real-time EBUS guided by bronchoscopist. Needle punctures were performed by using the jabbing method. Once it is confirmed that the puncture needle is within the target lesion, the puncture needle is moved back and forth while suction (An empty 50 ml syringe was connected to the port at the end of the puncture needle and aspirated to 20 ml maintained for 20 seconds.) is applied. Each lymph node was operated 5 times.
214488090|NCT05237466|BEHAVIORAL|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
214488091|NCT05237466|BEHAVIORAL|Sorting Practice|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
214488092|NCT05576207|DIETARY_SUPPLEMENT|Balanced energy and protein supplement for pregnant women|A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.
214972452|NCT07065643|OTHER|Phase 2 - Weight loss diet|6 week calorie restricted high protein diet (CR, fixed macronutrient composition as 30% protein, 35% fat and 35% CHO) fed to energy requirements \[0.8 X Resting Metabolic Rate (RMR)\], with stepwise reduction of 100kcal/d at week 3 and 5
214972453|NCT07069348|OTHER|No intervention|There is no treatment or intervention administered to the patients
214972454|NCT07066501|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor or defusion training.
214972455|NCT07064902|DRUG|Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）|Ivonescimab (AK112) is a novel PD-1/VEGF bispecific antibody designed to simultaneously block PD-1-mediated immune evasion and inhibit VEGF-driven angiogenesis. In this study, ivonescimab is administered intravenously at a dose of 10 mg/kg every 3 weeks, starting on Day 1 of induction chemotherapy (3 cycles), followed by concurrent chemoradiotherapy (no ivonescimab), and then continued as adjuvant monotherapy for 9 additional cycles.
214972456|NCT07066566|DEVICE|Asymmetric nasal cannula - DUET|DUET asymmetric nasal high flow interface that fits best to patients' nostrils (size: one nostril of the patient should be fully occluded) Patients will be crossed - over between the 2 interventions
214972457|NCT07066566|DEVICE|Conventional nasal high flow cannula|Well - established conventional nasal high flow cannula (size: medium) Patients will be cross - over between the 2 interventions
214972458|NCT07072208|DRUG|Induction therapy-Pro regimen|"Pro regimen induction(21days per cycle\*1 cycle)~* Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle~* Rituximab 100mg per vial 375mg/m2, intravenous drip, Day 1 of each cycle~* Orelabrutinib 50mg per tablet 150mg orally per day from Days 1 to 21 of each cycle"
214972459|NCT07072208|DRUG|Consolidation therapy-Pro-pola regimen|Pro-pola regimen consolidation(21days per cycle\*6 cycle) -Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle -Rituximab 100mg per vial 375mg/m2, intravenous drip, Day 1 of each cycle -Orelabrutinib 50mg per tablet 150mg orally per day from Days 1 to 21 of each cycle -Polatuzumab vedotin 30mg per vial 1.8 mg/kg, intravenous drip, Day 1 of each cycle
214972460|NCT07072364|BEHAVIORAL|Video on uterine fibroids|Patients will be sent a link to a 5 minute video on uterine fibroids including their diagnosis, symptoms and treatment options prior to their scheduled appointment.
214972461|NCT07072572|DRUG|Lower albumin dosage|A fixed dose of 35 grams of albumin on they one and day two.
214972462|NCT07073768|DRUG|Trelagliptin 100 mg|Trelagliptin will be administered as oral tablets at a dose of 100 mg once weekly for 3 months. Participants will continue background metformin therapy as prescribed. Trelagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and differs from daily DPP-4 inhibitors due to its longer duration of action, allowing weekly dosing.
214488093|NCT05576207|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement for pregnant women|"Prenatal supplements containing vitamins and minerals - also called multiple micronutrient supplements will be used in the control group."
214488094|NCT06243575|DRUG|Multimodal Intraosseous Femoral Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal
214488095|NCT06243575|DRUG|Multimodal Intraosseous Tibial Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
214488096|NCT05247164|PROCEDURE|EUS-guided Portal Vein sampling|"Transgastric and Transhepatic Fine Needle Aspiration of a branch of the Portal Vein under EUS guidance.~A paired peripheral sample will be acquired."
214488097|NCT02905357|DEVICE|OCT|Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
215083810|NCT04599166|BEHAVIORAL|Who Would You Choose: Serious Fun|"Who Would You Choose: Serious Fun is a conversation activity that prompts players (using scenarios and metaphors) to choose a spokesperson whose qualities are best suited to the role. At the end of the activity, players identify a real-life spokesperson based on the qualities considered during gameplay."
215083811|NCT03289169|DRUG|MEDITOXIN®|20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
215083812|NCT06980402|PROCEDURE|Early post-surgical discharge with post-surgical home based monitoring|The SKH@home program, is a post-discharge monitoring program, which allows stable post-surgical patients to be discharged earlier from hospital while providing regular post-discharge monitoring at the patient's own home, either through home visits and patient assessment, or telemonitoring of patients.
215083813|NCT06980402|PROCEDURE|Standard inpatient care until deemed suitable for discharge|Patients will receive standard postoperative management in the acute hospital until they are deemed fit for discharge by their primary surgeon
214360207|NCT06262620|PROCEDURE|EBUS-TBMC via a tunnel|First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Bronchus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
214360208|NCT06262620|PROCEDURE|EBUS-TBFB via a tunnel|Firstly, a tunnel to reach the lymph node is established by making use of a puncture dilation catheter, and a 1.5mm biopsy forceps is pushed into the lymph node through the working channel of the ultrasound bronchoscope. After entering the lymph node, the biopsy forceps were opened proximally to the lymph node, the biopsy forceps were advanced, and then the biopsy forceps were closed distally to the lymph node for each specimen. Each lymph node was operated 5 times.
214360209|NCT06723951|OTHER|QUALAS survey|Participants will be asked to complete the surveys at one (controls) and two (patients) timepoints.
214360210|NCT06733779|OTHER|observation|cross-sectional study
214360211|NCT06733727|DRUG|Letrozole|Letrozole pre-treatment in addition to misoprostol as medical management for silent miscarriage
214360212|NCT06733727|DRUG|Mifepristone|Mifepristone pre-treatment in addition to misoprostol as medical management for silent miscarriage
214488098|NCT02905357|OTHER|CMR|Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).
214488099|NCT06297551|DIAGNOSTIC_TEST|Quantification of blood cells positive for CLL1 and CD45RA surface markers by flow cytometry|During induction therapy for AML, researchers will measure the relative percentage of hematopoietic stem cells (defined by markers CD34+/CD38-) that test positive for CLL1 and CD45RA surface markers in the blood of participants on day 3, 5 and 7 days of systemic therapy. The variation of blood cells positivity for these markers, will be correlated with treatment outcome (complete response, partial response, no response), as determined by a bone marrow biopsy done approximately 4 weeks after induction chemotherapy.
214488100|NCT02734069|DRUG|Carboplatin|Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.
214488101|NCT05207033|OTHER|Regulated ad condition|This intervention will determine if restriction of appealing features in e-cigarette ads deter young adults from trying the product.
214488102|NCT05207033|OTHER|Unregulated ad condition|This intervention will determine if unrestricted appealing features in e-cigarette ads deter young adults from trying the product.
214679300|NCT02599467|OTHER|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
214679301|NCT01278628|OTHER|exercise training|exercise class once a year
214679302|NCT01648608|DRUG|Exemestane|Exemestane for neoadjuvant chemotherapy
214972463|NCT07073768|DRUG|Sitagliptin 100mg OD|Sitagliptin will be administered as oral tablets at a dose of 100 mg once daily for 3 months. Participants will continue background metformin therapy as prescribed. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and requires daily dosing.
214972464|NCT07073612|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing (CPET)|CPET will be performed on a cycle ergometer using a ramp protocol designed to achieve an exercise time of 8-12 min. The entire procedure duration is approximately 60 min. CPET will be completed 6 months to 1 day before the cardiac catheterization and will be repeated 3-6 months following cardiac catheterization.
214972465|NCT07073612|DIAGNOSTIC_TEST|Shear Wave Elastography Scan|The study lasts approximately 20 minutes. Shear Wave Elastography will be completed 6 months to 1 day before the cardiac catheterization. The Scan will be repeated 2-4 weeks following cardiac catheterization, and 3-6 months following cardiac catheterization.
215083814|NCT06607848|DEVICE|Low-Add EDOF IOL|Acunex Vario AN6V
215083815|NCT06607848|DEVICE|EDOF IOL|PureSee EDOF IOL
215083816|NCT06608836|OTHER|an ice massage|an ice massage
214360213|NCT06732219|BEHAVIORAL|Functional Communication Training|Functional Communication Training (FCT) focuses on teaching an appropriate functional communicative response (FCR) to access the reinforcer maintaining severe problem behavior (SPB). This procedure involves selecting an appropriate topography for the FCR (e.g., touching a card, exchanging a picture) and using a backward chaining approach. The training will progress from full physical prompts to partial prompts and eventually to independent, unprompted responses, all within a trial-based format.
214360214|NCT06732219|BEHAVIORAL|Extinction-Correlated Stimuli|A distinct extinction-correlated stimulus (e.g., a laminated picture card) will be used in all treatment sessions where severe problem behavior (SPB) is subject to extinction contingencies. This stimulus will also be present during relapse challenges (described below). The selection of the stimulus will be individualized for each participant to ensure it has no prior association with treatment-related contexts, minimizing the influence of pre-existing learning histories.
214360215|NCT06732219|BEHAVIORAL|Caregiver Fading|"Behavioral Skills Training (BST) will be used to teach caregivers to (1) implement the behavioral intervention package (i.e., differential reinforcement of alternative behavior with extinction) in a controlled setting with confederates and (2) transition into behavioral sessions with the participant while gradually phasing out the clinical therapist.~Caregivers will begin by implementing mastered intervention components alongside the therapist during sessions with the participant, where the therapist will provide in-situ feedback. Once the caregiver demonstrates at least 80% treatment integrity across two consecutive sessions, the therapist will systematically increase their distance by 3 meters each session (maintaining at least 80% integrity) until they are fully removed from the treatment area."
214360216|NCT06732219|BEHAVIORAL|Structured-Probe Schedule Thinning|"Once a clinically significant decrease in severe problem behavior (SPB) is achieved (defined as an 80% reduction from the baseline mean rate), schedule thinning will be implemented. This process involves reducing the density of reinforcement by introducing a multiple schedule with alternating periods where reinforcement for the functional communication response (FCR) is available and unavailable.~Schedule thinning will begin immediately at the terminal schedule, with an 80% reduction in reinforcer density from treatment. Specifically, the FCR will be placed on extinction for 540 seconds and reinforced for 60 seconds during each session. This schedule was selected based on prior analyses of effective reductions in reinforcer density. If the treatment effect remains strong (defined as maintaining at least an 80% reduction in SPB relative to baseline), schedule thinning will proceed at this step until three consecutive sessions show consistent results."
214360217|NCT06732219|BEHAVIORAL|Multiple-Context Generalization Training|In multiple-context training, treatment will be implemented at the terminal schedule (i.e., after completing schedule thinning) in new contexts, including unique locations and with different individuals, distinct from the setting used during the initial treatment phase.
214360218|NCT06731920|DIAGNOSTIC_TEST|cervical medial branch block|ultrasound-guided cervical medial branch block with fluoroscopic control and digital subtraction angiography
214360219|NCT04506970|DIAGNOSTIC_TEST|Comprehensive Doppler Ultrasound of the Placenta|Ultrasound measures to be collected include uterine artery (UtA) and umbilical artery (UA), systolic/diastolic (S/D) ratio, resistance index (RI), pulsatility index (PI) and presence of early diastolic notch.
214360220|NCT04506970|OTHER|Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)|In addition, a Verasonics ultrasound scanner will be used for ultra-sensitive Doppler imaging. Data will be collected on vessel density, periphery-to-center vessel density ratio (VDR) and microvessel morphology.
214360221|NCT06732336|DIAGNOSTIC_TEST|89Zr-trastuzumab|Patients will receive an intravenous dose of 0.5 MBq/kg (max 60 MBq) of 89Zr-trastuzumab in order to perform a PET imaging session 3-6 days later.
214488103|NCT01496651|PROCEDURE|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.~There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
214488104|NCT01496651|PROCEDURE|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
215083817|NCT06608836|OTHER|the cold spray|the cold spray
214488105|NCT04644029|DRUG|Islatravir|Oral 60 mg tablet administered once monthly during Part 1.
214488106|NCT04644029|DRUG|Placebo to FTC/TDF|0 mg tablet administered once daily during Part 1.
214488107|NCT04644029|DRUG|FTC/TDF|Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
214488108|NCT04644029|DRUG|Placebo to ISL|0 mg tablet administered orally once monthly in Part 1.
214679303|NCT05827146|DRUG|Hepalatide|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
214679304|NCT05827146|DRUG|Hepalatide Placebo|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
214679305|NCT01497314|OTHER|Low Lactose Infant Formula|Low Lactose Infant Formula
215083818|NCT01777542|DRUG|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
215083819|NCT01777542|DRUG|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
215083820|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
215083821|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
214360222|NCT06732024|PROCEDURE|Vaccum assisted closure|close skin and SC tissue by vaccum device
214679306|NCT06203145|DRUG|Bortezomib|A reduction in serum FLCs level of more than 80% by day 14 of BCD is defined BCD-AutoHSCT group; A reduction in serum FLCs level of less than 80% by day 14 of BCD is defined BCD-KPD-AutoHSCT group.
214360223|NCT06732024|PROCEDURE|primary wound closure|close skin and SC tissue by primary closure
214972466|NCT07072338|BEHAVIORAL|Stress management training|The stress management training is the WHO SH+ (Self-Help Plus) program, a low-intensity, group-based intervention developed by the World Health Organization to improve stress management and psychological flexibility. It combines pre-recorded audio sessions with an illustrated self-help guide and is based on Acceptance and Commitment Therapy (ACT). The program is delivered over five sessions and supported by a digital platform for at-home practice.
214972467|NCT07072338|BEHAVIORAL|Multidomain cognitive training|The multidomain cognitive training is a low-intensity, group-based intervention aimed at sustainably improving a healthy lifestyle, which in turn supports brain health and cognitive functioning. It combines pre-recorded audio sessions with an illustrated self-help guide and provides knowledge about aging and how to enhance three key lifestyle factors-social engagement, physical activity, and cognitive stimulation. The training uses metacognitive strategies and monitoring tools to help participants sustainably integrate these behaviors into their daily lives. The program is delivered over five sessions and supported by a digital platform for at-home practice.
214972468|NCT07072338|BEHAVIORAL|Social activities|The social activity intervention consists of a podcast discussion group in which participants listen to short podcasts on aging-related topics during each group session. Topics include driving (Session 1), intergenerational relationships (Session 2), technology (Session 3), the transition to retirement (Session 4), and travel (Session 5). These themes are deliberately chosen to be neutral and are not directly related to the techniques or content used to enhance well-being or cognitive functioning in the SH+ or COG interventions. The program is delivered over five sessions.
215083822|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
215083823|NCT00953524|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
215083824|NCT02867618|DRUG|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
215083825|NCT02867618|DRUG|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
215083826|NCT03065101|DEVICE|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
215083827|NCT03065101|OTHER|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
215083828|NCT03065101|DEVICE|Sliding Hip Screw|Sliding Hip Screw
214360224|NCT03355326|DRUG|Glycerin Suppository|Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.
214360225|NCT06359769|BEHAVIORAL|Group Cognitive Evolutionary Therapy|In-person therapy group. Delivery method: in-person groups. Number of sessions: 2. Duration of each session: 8 hours. Topics to be covered in the sessions are informed by the answers to the Fitness Evaluation Scale, following an adapted protocol of Cognitive Therapy for Depression.
214360226|NCT06535061|OTHER|white noise|The experimental group was exposed to a white noise sound combined from 4 different sounds: ultrasound heartbeat sound, wave sound, vacuum cleaner sound and hair removal machine sound at 50 dBSPL 5 minutes before the procedure. The experimental group was exposed to white noise for a total of 15 minutes before, during and after the procedure. At the same time, the newborn in the experimental group I was given a pacifier.
214360227|NCT06831864|DRUG|HFrEF Polypill|"The heart failure with reduced ejection fraction (HFrEF) polypill will include 4 guideline recommended medications used to treat HFrEF patients. The dose of initiation and titration will be at the investigator's discretion.~HFrEF polypill strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 3: bisoprolol 10 mg + losartan 100 + eplerenone 50 mg + dapagliflozin 10 mg"
214360228|NCT06831864|OTHER|Comparator Arm|Participants in the comparator control group will receive usual care by their healthcare providers. Providers will be encouraged to treat all participants according to international and local clinical practice guidelines.
214360229|NCT06902571|DEVICE|Intermittent theta burst stimulation (iTBS)|600 pulses (3 pulses × 10 bursts × 20 trains = 600 pulses) will be delivered each session with reference to a 3-minute protocol developed by Huang, et al. (2005). Before, during and after iTBS, both fNIRS and fMRI measurements will be conducted simultaneously.
214360230|NCT06495710|OTHER|Blood pressure treatment algorithm|Single or combination antihypertensive therapy as needed: 1) amlodipine (2.5-10 mg), 2) telmisartan (20-80 mg) or losartan (25-100 mg), 3) chlorthalidone (6.25-25 mg), or 4) spironolactone (12.5-50 mg). a two-drug regimen with either amlodipine + chlorthalidone or telmisartan + chlorthalidone will be initiated following randomization. If a diuretic is contraindicated, amlodipine + telmisartan will be initiated. For those over 75 years, either amlodipine or telmisartan will be initiated at baseline if SBP is \<140 mmHg. In the standard treatment group (SBP goal of \< 140 mmHg), participants will either be prescribed amlodipine or telmisartan/losartan as initial therapy. If \>3 medications are necessary to reach the intensive goal and no first line options remain, potassium sparing diuretics or direct vasodilators will be considered.
214679307|NCT05275218|PROCEDURE|Implementation of the KDIGO bundle)|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"
214488109|NCT05040841|BEHAVIORAL|M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result|"Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the Risk of Treatment Failure (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1."
214972469|NCT07072065|DRUG|protein purified derivative|tuberculin purified protein derivative with dose 5 tuberculin unit
214972470|NCT07073534|DRUG|SHR-1501, Adebrelimab|the combination of SHR-1501 and Adebrelimab
214972471|NCT07072117|DRUG|Intranasal Dexmedetomidine as a Premedication for Prevention of Anxiety & Respiratory Complications|Intranasal Dexmedetomidine as a Premedication for Prevention of Anxiety and Respiratory Complications in Children Undergoing Adenotonsillectomy
214972472|NCT07072117|DRUG|Intranasal Ketamine as a Premedication for Prevention of Anxiety and Respiratory Complications|Intranasal Ketamine as a Premedication for Prevention of Anxiety and Respiratory Complications in Children Undergoing Adenotonsillectomy
214972473|NCT07072117|DRUG|Intranasal Midazolam as a Premedication for Prevention of Anxiety and Respiratory Complications|Intranasal Midazolam as a Premedication for Prevention of Anxiety and Respiratory Complications in Children Undergoing Adenotonsillectomy
214972474|NCT07072351|RADIATION|hypofractionated radiotherapy|In Phase Ib, HFRT will be administered at one of three dose levels: 3 Gy × 5 fractions, 4 Gy × 5 fractions, or 5 Gy × 5 fractions. The recommended dose determined in Phase Ib will be used in Phase II (delivered as 5 fractions).
214972475|NCT07072351|DRUG|SOX Chemotherapy|SOX chemotherapy regimen: Oxaliplatin 130 mg/m² administered by intravenous infusion on Day 1; S-1 administered orally for 14 consecutive days followed by a 7-day rest period. The dosage of S-1 is based on body surface area (BSA): 40 mg twice daily for BSA ≤1.5 m², 50 mg twice daily for BSA between 1.5-1.6 m², and 60 mg twice daily for BSA ≥1.6 m². Each cycle is repeated every 3 weeks.
214360231|NCT03303612|DEVICE|Pacemaker implant|Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
214972476|NCT07072351|DRUG|PD-1 inhibitor|Sintilimab 200 mg administered by intravenous infusion on Day 1 of each 3-week cycle.
214972477|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 50 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
214360232|NCT03303612|DEVICE|Transcutaneous cardiac monitor|"Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include:~Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval \>5 sec; Third-degree AV block or Mobitz 2 AV block;"
214360233|NCT06914167|BEHAVIORAL|Slow Breathing Exercises|Participants will perform slow breathing (6 breaths/min) for 3 minutes daily before bedtime
214360234|NCT06914167|BEHAVIORAL|Lavender Essential Oil Inhalation|inhalation of 3 drops of lavender essential oil on a towel,
214360235|NCT06914167|BEHAVIORAL|linalyl acetate essential oil Inhalation|inhalation of 3 drops of linalyl acetate essential oil on a towel.
214360236|NCT06914167|BEHAVIORAL|linalool essential oil Inhalation|inhalation of 3 drops of linalool essential oil on a towel.
214360237|NCT06931262|DRUG|Dichloroacetate (DCA)|Study medication DCA is an oral solution mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL) Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens: EGT carriers will receive 12 mg/kg/12hr DCA. EGT non-carriers will receive 6 mg/kg/12 hr DCA.
214360238|NCT05665699|DRUG|D-0120|increasing dose of D-0120
214488110|NCT05040841|BEHAVIORAL|M2/PRM: Immediate outreach to subject after a missed pharmacy refill|The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
214972478|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 100 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
214972479|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 200 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
214972480|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 400 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
214972481|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 400 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly) and carboplatin/paclitaxel (3-weekly)
214972482|NCT07072637|DIAGNOSTIC_TEST|Neurological function assessment|Neurological evaluations including neurological examination (NE), nerve conduction study (NCS), quantitative sensory testing (QST), autonomic function testing (AFT), and the Toronto Clinical Neuropathy Score (TCNS) questionnaire. Assessments will be conducted at baseline and every three months until six months after completion of EV treatment.
214360239|NCT05665699|DRUG|Allopurinol|standard dosing
214360240|NCT06952712|DRUG|Aspirin 100mg|Aspirin 100mg qn was started from 12-16 weeks of gestation and discontinued from 36+0-36+6 weeks of gestation
214488111|NCT05040841|BEHAVIORAL|M3/EAM: Immediate outreach to subject after EAM-identified missed doses|The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
214488112|NCT05040841|BEHAVIORAL|S1/Text: Weekly check-in texts|"Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent."
214488113|NCT05040841|BEHAVIORAL|S2/Peer: Enhanced peer group support|"Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks."
214488114|NCT06173466|DRUG|Liposomal bupivacaine|Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
214488115|NCT06173466|DRUG|Bupivacaine Hydrochloride combined with dexamethasone|Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
214488116|NCT06579807|BEHAVIORAL|Exercise training|The multimodal supervised exercise program will include aerobic, resistance, and flexibility exercises. The training program will last 12 weeks, performed in 3 weekly sessions lasting 60 minutes each. Aerobic exercise, lasting between 20-30 minutes, will be conducted on a treadmill or stationary bike at an intensity ranging from 75-85% of the maximal heart rate (HR), based on the cardiopulmonary exercise testing. Resistance training, lasting 30 minutes, will include 8 to 10 exercises performed in 3 sets of 10 to 12 maximum repetitions with 1-minute intervals, targeting major muscle groups of the upper and lower limbs, with loads corresponding to 80-90% of the 10-repetitions maximum (RM).
214488117|NCT05661955|DRUG|BGB-A445|administered intravenously
214488118|NCT05661955|DRUG|Tislelizumab|administered intravenously
214488119|NCT05880004|BEHAVIORAL|Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications|The primary intervention is a mobile application (app) which supports food pantries to recruit, train and schedule volunteers; provide a safe, remote form of client choice; and provides a means of sharing real-time status information with clients, pantries, food banks, and emergency operation centers. Following formative work, user centered design, and usability testing, the SAFPAS app will be implemented in three stages, where each stage introduces new features. Pantry clients will be encouraged to download the app and learn its key features at the end of baseline data collection. During the first weeks of each stage, training of participating food pantry directors/staff and Maryland Food Bank (MFB) staff will take place - focusing on use of any new features. Initial training will be follow up by proficiency testing.
214972483|NCT07072845|BEHAVIORAL|Enhanced Brief Cognitive Behavioral Therapy (E-BCBT) for Suicidal Inpatients|"E-BCBT is a brief, structured cognitive behavioral therapy designed for psychiatric inpatients at risk of suicide. The primary goals are to reduce the risk of suicide attempts after discharge, improve problem-solving and coping with recent stressors related to suicidal crises, and help patients shift from maladaptive suicidal modes to more adaptive cognitive and behavioral patterns. The intervention consists of five individual sessions (approximately 50-60 minutes each) delivered during hospitalization. It includes two sessions on crisis management, two sessions on cognitive and behavioral strategies, and one relapse prevention session. Each session incorporates psychoeducation, skill-building, and worksheet-based self-practice to enhance self-regulation and promote continued use after discharge."
214972484|NCT07072845|OTHER|Treatment as Usual (TAU)|TAU is based on a short-term inpatient stabilization model and includes 24-hour multidisciplinary care provided by the psychiatric ward. Individualized treatment may involve pharmacotherapy, occupational therapy, and supportive psychotherapy, depending on patient needs and hospital protocols.
214972485|NCT07073014|DRUG|Vosoritide|Open-label administration of vosoritide using weight-band dosing
214972486|NCT06602414|PROCEDURE|Conservative treatment|Conservative treatment instead of surgical repair
214972487|NCT03629288|OTHER|Lactose tab|Tablet containing lactose Procedure: Periodontal treatment Scaling and root planning
214360241|NCT06952712|DRUG|Aspirin 150mg|Aspirin 150mg qn was started from 12-16 weeks of gestation and discontinued from 36+0-36+6 weeks of gestation
214679308|NCT02369978|DRUG|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
214972488|NCT03629288|DRUG|Azithromycin|Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
214972489|NCT05509400|DRUG|Rimegepant|DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)
214972490|NCT05509400|DRUG|Placebo|DB Phase: matching placebo
214972491|NCT05509400|DRUG|Rimegepant|OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
214972492|NCT00431093|DRUG|tibolone|uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
214360242|NCT06225167|BEHAVIORAL|To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.|"To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.~To compare the incidence of overt GI bleeds (defined as hematemesis, bloody nasogastric tube aspirate, or melena) between patients who were on stress ulcer prophylaxis versus patients whose acid suppression therapy was discontinued through the stress ulcer prophylaxis minimization protocol."
214360243|NCT03553004|DRUG|Niraparib Treatment|Niraparib treatment by mouth (oral)
214972493|NCT00431093|DRUG|low-dose estradiol/noresterone|"Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time)."
214972494|NCT05042817|DRUG|100 mcg morphine|The effect of intrathecal morphine on vesical function and the need for bladder re-catheterization after a cesarean delivery
214488120|NCT05384847|DRUG|Thyroid hormone T3|Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.
214360244|NCT01965405|DRUG|Bupropion|Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
214360245|NCT01965405|BEHAVIORAL|Brief Counseling|Participants are provided with brief counseling for smoking cessation.
214360246|NCT01965405|BEHAVIORAL|High-magnitude prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
214360247|NCT01965405|BEHAVIORAL|Monitored support to quit smoking|Brief supportive sessions and monitoring of smoking cessation efforts.
214360248|NCT01965405|BEHAVIORAL|No additional treatment|No additional treatment will be given.
214360249|NCT01965405|BEHAVIORAL|Prize contingency management for abstinence|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
214360250|NCT01965405|BEHAVIORAL|Low intensity prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
214360251|NCT03811184|DIAGNOSTIC_TEST|MemScreen|Neuropsychological test on smartphone or digital tablet, on self assesment.
214360252|NCT04209816|DIAGNOSTIC_TEST|Lipoprotein kinetics|Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.
214360253|NCT01635608|DRUG|Acetaminophen|administration of 500 mg paracetamol
214360254|NCT01635608|DRUG|Talinolol|administration of 50 mg talinolol
214488121|NCT05384847|OTHER|Control Group|The control group will have testing and study procedures as per protocol but will not be admitted to the General Clinical Research Center (GCRC) and will not receive the study medication. After completion of phase I, participants will be permitted to enroll in Phase II.
214488122|NCT04310449|PROCEDURE|Connective tissue graft and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Connective tissue grafts from the hard palate will be placed at the implant sites in a supraperiosteal partial dissection prepared at the buccal aspect. Sutures will be used to stabilize the graft, followed by customized healing abutment. Flowable composite will be injected at the gingival margin level to adapt to the sandblasted abutment, taking the shape of the socket at the marginal gingiva. Buccal groove will be made after the polymerization of this material for easier application. The abutments will be removed for final configurations of the apical part mimicking the emergence profile of the extracted tooth and finishing with laboratory discs and burs. The custom healing screw will be screwed to the implant.
214488123|NCT04310449|PROCEDURE|Dual zone concept and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Followed by bone grafting following dual zone concept and customized healing abutment.
214360255|NCT01635608|DRUG|Amoxicillin|administration of 500 mg amoxicillin
214360256|NCT01635608|OTHER|non-caloric water|administration of 240 ml water
214360257|NCT01635608|OTHER|caloric water|administration of 240 ml caloric water (containing 25.5 g sucrose)
214360258|NCT06444906|DEVICE|Dermacyte Matrix|The appropriate square centimeters of Dermacyte Matrix is applied directly to the target DFU that is free of debris and necrotic tissue. The Dermacyte Matrix will be applied at weekly intervals or for up to 10 applications.
214488124|NCT04967118|BEHAVIORAL|Skin-to-skin contact|Diaper clad baby will be placed ventral position on bare chest of mother 30 minute prior to the heel lance
214488125|NCT04967118|BEHAVIORAL|Mother's heartbeats as sound and vibration|The mother's heartbeat will be recorded and the heartbeat sounds will be saved to the platform. The platform will be placed under the infant's mattress and the heartbeat will be started 30 minute prior to the heel lance.
214488126|NCT04967118|DRUG|30% oral glucose|The infant will be given 30% oral glucose solution 2 minutes before the injection
214488127|NCT01308684|DRUG|RO5323441 + bevacizumab [Avastin]|Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
214488128|NCT01308684|DRUG|bevacizumab [Avastin]|Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
214488129|NCT00327561|PROCEDURE|Intensive periodontal therapy|
214488130|NCT00327561|PROCEDURE|Community based periodontal therapy|
214488131|NCT00739908|DRUG|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
214488132|NCT00739908|DRUG|Placebo|Six capsules administered three times a day for six weeks.
214488133|NCT01440933|DRUG|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
214972495|NCT05042817|DRUG|0.9% NaCl|NaCl 0.9%
214972496|NCT05042817|DRUG|50 mg prilocaine + 2.5 mcg sufentanil|50 mg prilocaine + 2.5 mcg sufentanil
214360259|NCT06444906|OTHER|Standard of Care (SOC)|SOC therapy will consist of debridement of nonviable tissue, saline-moistened non-occlusive dressing, weight off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated at weekly intervals or for up to 10 applications.
214360260|NCT03921125|DEVICE|Massimo for Pleth variability index|To assess fluid response
214360261|NCT05040555|COMBINATION_PRODUCT|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1\~5.
214360262|NCT00003508|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214360263|NCT02142647|BEHAVIORAL|a high-protein complementary diet with meat|infants will consume a high-protein complementary diet with protein mainly from meat
214360264|NCT02142647|BEHAVIORAL|a high-protein complementary diet with dairy|infants will consume a high-protein complementary diet with protein mainly from dairy
214360265|NCT05228548|OTHER|Perioperative blood transfusion|Perioperative blood transfusion
214360266|NCT01925664|BEHAVIORAL|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
214360267|NCT03113292|OTHER|Pilates|"The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.~."
214360268|NCT03113292|OTHER|Home Exercises|The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
214360269|NCT03217448|DRUG|Dabigatran etexilate|Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
214360270|NCT03217448|DRUG|Warfarin|Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
214360271|NCT01834885|DRUG|QVA149|QVA149 via inhaler twice a day
214488134|NCT01440933|DRUG|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
214488135|NCT01334489|DEVICE|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
214488136|NCT01461759|DRUG|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
214488137|NCT01461759|DRUG|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
214488138|NCT01646450|DRUG|Icotinib|Icotinib: 125mg, oral administration, three times per day.
214488139|NCT04347733|DRUG|Triamcinolone Acetonide 40mg/mL|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
214488140|NCT04347733|DRUG|Hyaluronidase Injection|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
214360272|NCT01834885|DRUG|fluticasone/salmeterol|fluticasone/slameterol via inhaler twice a day
214360273|NCT00388310|PROCEDURE|Culture|Culture
214360274|NCT04498130|BEHAVIORAL|12-Week Home Exercise Group|12 week home-based program consisting of: weekly Zoom group chats; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page
214360275|NCT04498130|BEHAVIORAL|Education Comparison Group|12 week home-based program consisting of: weekly check-in phone calls; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page.
214360276|NCT03625401|DRUG|AD-35 60mg group|AD-35 60mg QD
214360277|NCT03625401|DRUG|Placebo group|Placebo: 3 placebo of AD-35 30mg tablets
214360278|NCT01377480|DRUG|Posaconazole|POS 40 mg/mL oral suspension
214360279|NCT01377480|DRUG|Placebo for posaconazole|Placebo oral suspension
214488141|NCT02972788|DRUG|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
214488142|NCT02972788|OTHER|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
214488143|NCT03778541|DRUG|Temozolomide|75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
214360280|NCT01377480|DRUG|Benznidazole|BNZ 100 mg oral tablet
214488144|NCT03778541|RADIATION|hypofractionated radiotherapy|the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
214488145|NCT01921075|OTHER|normal dietary behavior|normal dietary behavior during examination days
214488146|NCT01921075|OTHER|Magnetic resonance spectroscopy|Non-invasive diagnostic procedure
214488147|NCT02996136|DEVICE|Flu Symptoms|Flu Symptoms
214360281|NCT06463444|DRUG|HAIC + Tislelizumab +lenvatinib|"All patients were treated with HAIC combined with tislelizumab and lenvatinib.~1. HAIC was adopted of the FOFOLX 6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days.~2. Lenvatinib was started before HAIC treatment, discontinued during HAIC treatment, Oral 8 mg or 12mg once a day depending body weight.~3. First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later."
214488148|NCT02020694|DRUG|Vitamin D|
214488149|NCT02020694|DRUG|Placebo (for vitamin D)|
214488150|NCT06510608|DIAGNOSTIC_TEST|Biochemical analysis of saliva sample|It is the examination of saliva samples taken with biochemical methods. In this way, the substances in its content and the concentration of cytokines are analyzed.
214488151|NCT01476241|PROCEDURE|PEG tube placement|Percutaneous endoscopic gastrostomy
214488152|NCT05036837|DRUG|OZOPROMAF_SEQ1|"OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ."
214488153|NCT02254720|DRUG|BEA 2180 BR solution for infusion|
214488154|NCT02254720|DRUG|Placebo|Intravenous infusion
214488155|NCT02254720|DRUG|BEA 2180 BR solution for inhalation|
214488156|NCT02254720|DEVICE|Respimat®|
214488157|NCT02559349|OTHER|Stool Collection|
214488158|NCT06307743|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
214972497|NCT05042817|PROCEDURE|bilateral transverse abdominal plane block|20 mL of ropicavaine 0.375% on each side
214972498|NCT02490774|DRUG|BAY1007626|Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
214972499|NCT02490774|DRUG|Jaydess|Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
214972500|NCT02490774|DRUG|Mirena|Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
214972501|NCT00090896|BIOLOGICAL|maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody|
214972502|NCT05702437|OTHER|assessment of cognitive performance|evaluation of the cognitive and physical performance of the participants by two separate researchers at the same time
214972503|NCT05852314|BEHAVIORAL|Culturally Adapted Manual Assisted Therapy (CMAP-SI)|C-MAP has been adapted from a self-help guide called Life After Self-Harm based on the principles of CBT. It is a brief problem-solving therapy comprising have 4 sessions weekly and then 4 fortnightly and last about 50 minutes each. The manual has been translated to Urdu giving special consideration to cultural adaptation of phrases and concepts to reflect Pakistani culture. Additionally, culturally appropriate case scenarios were incorporated and a consensual view to addressing cultural factors such as gender role, family conflicts and financial difficulties was taken. The culturally adapted intervention consists of the following components: evaluation of self-harm attempt, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships, and relapse prevention strategies. Participants will receive sessions according to adapted CMAP-SI manual.
214972504|NCT01823471|OTHER|The use of I-scan in the detection of polyps in HNPCC|Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
214488159|NCT00355888|DRUG|MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
214488160|NCT00367653|DRUG|Azithromycin plus Chloroquine|Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
214488161|NCT00367653|DRUG|Mefloquine|Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
214488162|NCT05222646|DRUG|Metoclopramide|Will receive single dose of 10mg of Metoclopramide intramuscularly
214360282|NCT05024851|OTHER|Questionnaires|Evaluation of the Psychogenic and Neurogenic Components using questionnaires
214360283|NCT02837640|DRUG|levodopa-carbidopa|sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
214360284|NCT04536311|PROCEDURE|internal fixation of mulitiple rib fracture|The dislocated rib fracture was anatomically reduced, and then fixed with appropriate equipment to prevent the fracture from being displaced again
214488163|NCT00047190|DRUG|tipifarnib|Given PO
214488164|NCT00047190|OTHER|laboratory biomarker analysis|Correlative studies
214488165|NCT01534546|DRUG|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1\~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
214488166|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
214972505|NCT02787304|DRUG|SHP626|5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
214972506|NCT02787304|DRUG|Placebo|Matching placebo
214972507|NCT03561454|DEVICE|IORT|Intra-Operative Radiation Therapy
214972508|NCT04579809|PROCEDURE|4 strand technique|4 strand technique reapir of tendin flexor injury
214360285|NCT00871689|BIOLOGICAL|aldesleukin|IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
214360286|NCT00871689|DRUG|cyclophosphamide|60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
214360287|NCT00871689|DRUG|fludarabine phosphate|25 mg/m\^2 intravenously (IV) over 1 hour on days -7 through -5.
214360288|NCT00871689|PROCEDURE|umbilical cord blood transplantation|On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units
214360289|NCT00871689|RADIATION|total-body irradiation|administered on days -5 through -2; 330 cGy daily
214360290|NCT03940599|DEVICE|step counter|Fitbit
214360291|NCT03940599|DEVICE|weight scale|BodyTrace weight scale
214360292|NCT03940599|DEVICE|step counter with screen covered|Fitbit with screen covered
214360293|NCT01127880|DRUG|Ancef or Clindamycin|1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
214360294|NCT01127880|DRUG|Placebo|.9% Normal Saline as a placebo
214360295|NCT05634239|BEHAVIORAL|Health Education|"Interview, clinical examination and health education conducted by the clinic nurse.~Appointment with the physiotherapist including the assessment of physical functioning, use of assistive mobility devices, and amount of help needed in activities of daily living."
214360296|NCT05592054|PROCEDURE|Balloon guide catheters (BGCs)|MT procedure with Balloon guide catheters (BGCs)
214360297|NCT05592054|PROCEDURE|Standard guide catheter|MT procedure with standard guide catheter
214360298|NCT02244905|BEHAVIORAL|Positive Deviance|The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
214360299|NCT02244905|OTHER|Standard-of-Care Infection Control approach|Standard-of-Care Infection Control approach
214360300|NCT03576768|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
214360301|NCT03576768|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
214360302|NCT03576768|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
214488167|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
214972509|NCT02745652|DEVICE|pulsed electromagnetic field|it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
214972510|NCT02745652|DEVICE|Therapeutic ultrasound|Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
214972511|NCT04938076|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation on motor cortex
214972512|NCT04938076|DEVICE|sham control|sham control
214972513|NCT01810224|PROCEDURE|Surgical revascularization|The final intervention (surgical revascularization) will be the same for both arms.
214972514|NCT00991081|BEHAVIORAL|Counseling|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~1. One week prior to the target quit date (TQD)~2. Two weeks post-TQD~3. Four weeks post-TQD"
214972515|NCT00991081|BEHAVIORAL|Self-help guide|A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
214972516|NCT00991081|DRUG|Pharmacotherapy|"8-week course of genetically-tailored pharmacotherapy~* Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~* Participants with the A2 allele (CC) were assigned to receive bupropion"
214972517|NCT00991081|BEHAVIORAL|Genetic feedback, verbal|During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
214972518|NCT00991081|BEHAVIORAL|Genetic feedback, printed|After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
214972519|NCT01786057|PROCEDURE|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
214488168|NCT03875313|DRUG|CB-839|CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
214488169|NCT03875313|DRUG|Talazoparib|Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
214972520|NCT01786057|PROCEDURE|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
214972521|NCT01051921|DRUG|CTS-1027|CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
214972522|NCT01051921|DRUG|Pegylated interferon|Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
214972523|NCT01051921|DRUG|Ribavirin|Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
214972524|NCT01638715|DRUG|Remicade|\- Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
214972525|NCT01638715|DRUG|Orencia|\- Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: \<60 kg Body weight (BW): 500 mg; \>60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.
214972526|NCT01638715|DRUG|Ro-Actemra|\- Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
214972527|NCT01638715|DRUG|Mabthera|"\- Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.~Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©)."
214972528|NCT03103191|DIAGNOSTIC_TEST|KL-6 levels|Measure of KL-6 in serum
214972529|NCT01796028|DRUG|METFORMIN|
214972530|NCT01796028|DRUG|Placebo|
214972531|NCT01796028|DRUG|TAXOTERE®|
214972532|NCT02100280|DRUG|deep block|sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
214972533|NCT02507791|OTHER|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
214360303|NCT03576768|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
214360304|NCT02342522|DEVICE|Remote ischemic conditioning|An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total.
214360305|NCT02342522|DEVICE|Control|An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
214488170|NCT04121546|BEHAVIORAL|Telecare Intervention|Patients will meet with a care coordinator to discuss current opioid use pattern and potential reduction strategies. Participants will fill out baseline measures. A 6 week positive psychology intervention will also be introduced in which patients will practice different techniques each week over 6 weeks, and will then practice incorporating a single technique into daily practice for the remaining 6 weeks. During the first 6 weeks, patients will have weekly check in meetings with a care manager to report on any withdrawal symptoms. These meetings will space to ever other week during the remaining 6 weeks. Possible treatment adjustments will be discussed between the care coordinator and primary investigator at weekly meetings. At the completion of the 12 week study, patients will complete outcome measures.
214488171|NCT06295341|DRUG|Recombinant human growth hormone (only for children with growth hormone deficiency)|6 months of therapy with recombinant DNA GH (at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
214488172|NCT01864538|DRUG|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
214488173|NCT04963088|DRUG|BGB-A317|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason
214488174|NCT04963088|DRUG|Anlotinib|oral administration daily d1-d14, q3w;
214488175|NCT04963088|DRUG|Oxaliplatin|30 mg/m² IV on Day 1 during each 21-day cycle. during each 21-day cycle
214972534|NCT03937115|DEVICE|Active tDCS|2 active tDCS sessions (20 min each, 2 mA) applied to the dlPFC and right motor cortex
214972535|NCT03937115|DEVICE|Sham tDCS|1 sham tDCS session (20 min, 0 mA) applied to the dlPFC
214972536|NCT03937115|DEVICE|Active tDCS|10 tDCS sessions (2 sessions/day for 5 days, 20 mA, 20 min each) applied to the dlPFC
214972537|NCT03937115|DEVICE|Sham tDCS|10 tDCS sessions (2 sessions/day for 5 days, 0 mA, 20 min each) applied to the dlPFC
214972538|NCT06455657|OTHER|breast cancer education|Questionnaires and scales will be administered to the participants as a pre-test. Breast cancer education will be provided in groups and their feedback will be received. Reminder training will be repeated 1 month after the training. The survey and scales will be administered to the participants as a posttest 1 month after the second training.
214972539|NCT04265521|DEVICE|Biocool Footcare|BioCool Footcare is a footbath containing granulate of sodium percarbonate that will in this study be used for treatment of foot fungus, heel cracks, calluses and/or dry feet.
214972540|NCT02843009|BEHAVIORAL|Resistance Exercise Training|Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl
214972541|NCT02843009|DIETARY_SUPPLEMENT|Supplementation|Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
214488176|NCT04963088|DRUG|Capecitabine|1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
214488177|NCT05870254|OTHER|ExeRVIEM Program|Virtual exercise based program
214972542|NCT06338306|DRUG|Tacrolimus（FK506）|Prograf
214972543|NCT03110354|DRUG|DS-3201b|DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
214972544|NCT05761353|DEVICE|Endermologie|"Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.~Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.~-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
214360306|NCT03888339|PROCEDURE|Commercially available high abutments placement|Patients will be randomly selected for the commercially available high abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, conventional high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
214360307|NCT03888339|PROCEDURE|Modified shape abutments|Patients will be randomly selected for the modified shape abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, modified high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
214360308|NCT02489955|DRUG|Amikacin|
214360309|NCT02489955|DRUG|Tobramycin|
214360310|NCT02489955|DRUG|Colomycin|
214360311|NCT06526403|DEVICE|Zero-fluoroscopy ASD closure|Percutaneous ASD closure without fluoroscopy was performed in secundum-type oval-shaped ASD
214360312|NCT00238030|DRUG|L-thryoxine|2 mcg/kg iv or 2 mcg/kg po at time of enrollment
214360313|NCT00238030|DRUG|iv thryoxine|thyroxine 2 mcg/kg iv
214360314|NCT00915031|DEVICE|UroCool|Hypothermia Endorectal Device
214488178|NCT05870254|OTHER|Usual center program|Usual center cares
214488179|NCT05785754|DRUG|DCSZ11|A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
214488180|NCT05785754|DRUG|Pembrolizumab|Pembrolizumab injection
214488181|NCT05785754|DRUG|Doxorubicin|1b SOC Cohort 1: Doxorubicin combination in soft tissue sarcoma
214488182|NCT05785754|DRUG|Tebentafusp|1b SOC Cohort 2: Tebentafusp combination in uveal melanoma
214488183|NCT05504135|DIAGNOSTIC_TEST|Pharmacogenomics Testing|To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
214488184|NCT04838717|DRUG|BPG|intramuscular injection of 2.4 million units
214488185|NCT04838717|DRUG|Doxycycline|Oral: at a dose of 100 mg bid for 14 days
214488186|NCT06467136|BEHAVIORAL|Sound production treatment|Evidence based treatment for apraxia of speech, developed by Julie Wambaugh.
214488187|NCT06467136|BEHAVIORAL|Motor Imagery Practice|Practice of target items using motor imagery during home practice
214488188|NCT06203990|BEHAVIORAL|Barre exercise|Group barre exercise class
214488189|NCT04697784|DEVICE|TREO Abdominal Stent-Graft System|The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.
214360315|NCT03924479|DEVICE|PowerBreathe (Breathing muscle training)|The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
214488190|NCT05508867|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
214488191|NCT05508867|DRUG|bendamustine|IV infusion
214488192|NCT05508867|DRUG|gemcitabine|IV infusion
214488193|NCT04430075|DEVICE|Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System|Transcatheter Valve Repair with Edwards PASCAL and PASCAL Precision System
214488194|NCT06951750|OTHER|Reflexology|The participants will receive two minutes of specific reflexology on each point of the uterus, pituitary, and solar plexus in the form of rotational pressures. This will be performed in the first hour post-partum and will be repeated in the second hour post-partum
214488195|NCT06951750|OTHER|placebo reflexology|The participants will receive rotational pressures on a neutral point on the lateral side of the heel (placebo point) for six minutes. This will be performed in the first hour post-partum and will be repeated in the second hour post-partum
214488196|NCT06951750|OTHER|general foot massage|The participants will receive a general massage on each foot for four minutes. This will be performed in the first hour post-partum and will be repeated in the second hour post-partum
214488197|NCT04285671|BIOLOGICAL|Necitumumab|Given IV
214360316|NCT04274270|DRUG|Endostar|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
214488198|NCT04285671|DRUG|Osimertinib|Given PO
214488199|NCT04285671|OTHER|Quality-of-Life Assessment|Ancillary studies
214488200|NCT04285671|OTHER|Questionnaire Administration|Ancillary studies
214488201|NCT04285671|BIOLOGICAL|Trastuzumab|Given IV
214488202|NCT01046825|DRUG|COPAD|"Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
214488203|NCT01046825|DRUG|COP, COPD M3, CYM|"GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
214679309|NCT02369978|DRUG|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
214679310|NCT02369978|DRUG|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
214488204|NCT01046825|DRUG|COP, COPADM8, CYVE|"Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
214488205|NCT05864612|BEHAVIORAL|Screening Questionnaires|Standard care screening questionnaires on anxiety and depression
214360317|NCT04821479|BIOLOGICAL|Mesenchymal stem cells (MSC)|Intrathecal injections of autologous bone marrow derived mesenchymal stem cells
214360318|NCT02273284|DEVICE|Buzzy|The Buzzy will be applied for 30 seconds over the area that is going to be injected, then during the actual injection the Buzzy will be moved rostrally and continuously used during the injection. When the injection is completed the Buzzy is positioned in the same way over the next injection site.
214972545|NCT05761353|DEVICE|Negative pressure therapy|"Group B will receive negative pressure therapy with~* Pressure: 20-250 mmHg.~* Total treatment period: 6weeks~* A number of sessions: 3sessions/ week. Time of application : 30 min~* In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
214360319|NCT05307380|DIAGNOSTIC_TEST|"functional pain scale"|French translation of the Defence and Veterans Pain Rating Scale (DVPRS)
214360320|NCT04604002|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
214360321|NCT04604002|DEVICE|Color Fundus Photography|Non-contact white light photography
214360322|NCT04604002|DEVICE|Optical Coherence Tomography|A non-contact test that uses light waves to take cross-sectional pictures of the retina
214488206|NCT05598151|DRUG|HM97662|To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of HM97662 in solid tumors
214488207|NCT03304418|DRUG|Radium Ra 223 Dichloride|Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
214679311|NCT05360732|DRUG|FOLFIRINOX|Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
214679312|NCT03887637|DRUG|DAAs|Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.
214972546|NCT04101383|DRUG|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
214972547|NCT04101383|DRUG|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
214972548|NCT00379834|DRUG|Cosopt|Cosopt twice daily in both eyes
214972549|NCT03984396|OTHER|Educational Materials - Patient & Clinician|deprescribing information for patient \& clinician
214972550|NCT05415189|OTHER|Not relevant|This is a non-intervention cohort study
214972551|NCT02233218|DRUG|Telmisartan|
214972552|NCT02233218|DRUG|Amlodipine|
214972553|NCT02233218|DRUG|Rosuvastatin|
214972554|NCT05700734|DRUG|MK-8510|Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
215083829|NCT06601933|OTHER|Cognitive Training|"Participants (n=240) will be randomized to high dose crosswords, low dose crosswords, and health education at 1:1:1 ratio, stratified by site, age (\< 70 and 70 years), and MCI status (early MCI and late MCI). In the two crossword puzzles conditions, after initial training to use the web-based platform, the participant will be assigned to do 12 weeks of crossword puzzles four times per week or 12 weeks of crossword puzzles once per week at home. After these 12 weeks, booster sessions will be either four or one 30-minute session(s) completed over 1 week. These booster sessions will occur at weeks 20, 32, 42, 52, 64, and 78. In-person assessments will occur at 0, 12, 32, 52, 78 weeks with one crossword puzzle session, which will count toward the booster session.~Health education will involve reading chapters in a book on common illnesses and lifestyle, and a research staff member will review these chapters at the same assessment intervals as the crossword puzzles conditions."
215083830|NCT04145674|DRUG|D-methadone|Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days
214972555|NCT02907242|OTHER|Revealment|Cerebroplacental ratio revealment
214972556|NCT01595373|DRUG|Acyl ghrelin|Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
214972557|NCT01595373|DRUG|Placebo (Ringer acetate)|Ringer acetate 2 microliter/min for 300 minutes
214360323|NCT05202925|OTHER|Musical Training Program|a weekly 45-minute lesson, one-to-one musical training
214972558|NCT04577638|COMBINATION_PRODUCT|Nivolumab and Intensity Modulated Radiotherapy (IMRT)|"Every included patient will receive the experimental treatment regimen as follows:~* Combination of IMRT 66 Gray (Gy)/24 fractions of 2.75 Gy) and immunotherapy with 3 doses of nivolumab, 240 mg (1th, 3th and 5th week of IMRT) during 5 weeks~* Maintenance treatment by nivolumab 240 mg (Q2W) during 6 months, or until progression and severe toxicity leading to definitive treatment interruption."
214972559|NCT03504215|OTHER|Exercise Intervention|Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
214972560|NCT00115310|DRUG|NGX-4010|
214972561|NCT03909048|BEHAVIORAL|Interactive - Psychoeducation|Individuals will receive interactive psychoeducation in the lab over the course of a week period. Each session will take approximately 30 minutes.
214360324|NCT01986881|DRUG|Ertugliflozin|Oral, once daily, for up to approximately 6 years
214360325|NCT01986881|DRUG|Placebo|Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
214360326|NCT01986881|DRUG|Glycemic Rescue|Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea \[SU\], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
214488208|NCT03304418|RADIATION|Radiation|"All external beam radiations oligometastatic sites will commence after cycle 1 of Radium-223 but prior to cycle 2 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.~Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:~* Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)~* Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)~* Five fractions: 30 Gy total at 6Gy per fraction (SBRT).When using five fractions, can reduce to 25 Gy total at 5 Gy per fraction (SBRT) or to a minimum of 20 Gy total at 4 Gy per fraction (SBRT), per treating investigator.~* Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)"
214488209|NCT06066242|OTHER|Different induction chemotherapy regimens|azacitidine combined with venetoclax or chemotherapy with or without venetoclax
214488210|NCT06638372|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
214679313|NCT02754778|BEHAVIORAL|conditional workout|6 month of regular conditional workout 1-3 times a weak
214972562|NCT03909048|BEHAVIORAL|Non-interactive Psychoeducation|Individuals will receive non-interactive psychoeducation over the course of a week period. Each session will take approximately 30 minutes.
214972563|NCT02864069|BEHAVIORAL|Walking Intervention|The walking intervention will begin following baseline assessments and will be continued for 12 weeks. Participants will be given a pedometer to use daily and log their daily steps, with an identified goal of increasing step counts by 3000 steps a day over the course of the intervention. After obtaining a week long baseline step count, individuals in the intervention group will progressively increase their step counts by 100 steps daily each week for the first three weeks, by 200 steps daily for weeks four through six, by 300 steps daily for weeks seven through nine, and by 400 steps daily for weeks ten through twelve. Mean baseline step counts for sedentary older adults in our pilot work were 4150 per day; therefore, most participants will almost double their daily activity by the end of the intervention.
214360327|NCT05261893|OTHER|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|It creates tension in the spine and stretch the fascia and is a myofascial stretch technique and manual physical therapy tool
214360328|NCT05261893|OTHER|Post Facilitation Stretching|Post Facilitation Stretching effectively decreases hamstring muscle tightness while also increasing popliteal angle range. Post-facilitation exercise can help to relieve knee pain. It effectively raises ROM or aligns collagen fibers due to the muscle contraction performed immediately before stretching.
214360329|NCT02709668|DIETARY_SUPPLEMENT|Enlyte|gel cap of reduced B vitamins
214360330|NCT02709668|OTHER|placebo|identical to Enlyte
214360331|NCT04159974|DRUG|Durvalumab 50 MG/ML|IV Infusion
214360332|NCT04159974|DRUG|Tremelimumab|IV Infusion, Combination with Durvalumab
214360333|NCT01331057|OTHER|NEEL test|An assessment for children in French with items extracted from the NEEL test
214972564|NCT02864069|BEHAVIORAL|Cognitive Training Intervention|In the CT condition, participants will use Brain HQ, a computer cognitive training program (Posit Science Corporation, San Francisco, CA), shown to be well tolerated by older adults with positive short- and long-term cognitive outcomes. Participants will use the program 60 minutes/day, 5 days/week for 12 weeks. If participants do not have a home computer/internet access, they can complete the modules at another location such as a public library, senior center, or at the MARC, but training will still be self-directed.
214972565|NCT02864069|BEHAVIORAL|Combined Intervention|The combined condition will concurrently follow both the walking and the CT programs as described above.
214972566|NCT01775670|DEVICE|Off-the-shelf splint|Subjects will use an off-the-shelf splint
214972567|NCT01775670|DEVICE|OT Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
214972568|NCT02027233|OTHER|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses (VRS, SARS-CoV-2 and others).
214972569|NCT04192149|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
214972570|NCT02794129|OTHER|Functional Magnetic Resonance Imaging|
214972571|NCT04383301|PROCEDURE|Intracorneal ring segment implantaion as the first stage|Intracorneal ring segment (ICRS)
214972572|NCT04383301|PROCEDURE|ACXL and wafe front guieded TPRK as the second stage|Accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
214972573|NCT01455870|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
214972574|NCT01455870|DRUG|sitagliptin|oral sitagliptin 100 mg/day
214972575|NCT05555498|DEVICE|Virtual Reality glasses|The intervention used are Virtual Reality glasses. The VR-glasses used are designed by SyncVR medical (Utrecht, the Netherlands), and are applicable specifically for medical use. By distracting the patients' cognition from the procedure, using images and sounds, the patient hopefully experiences less pain and anxiety. Women can choose between relaxation excersises and nature films
215083831|NCT04145674|OTHER|Placebo|Patients will take one tablet of placebo once daily at 6 pm over a period of 30 days
215083832|NCT04957992|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
215083833|NCT04957992|OTHER|Control Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
215083834|NCT04957992|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
214972576|NCT01001429|DRUG|Dexmedetomidine infusion|bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug
214972577|NCT01001429|DRUG|propofol|propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
214972578|NCT03425669|DEVICE|Stochastic Vestibular Stimulation|Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
214360334|NCT01331057|OTHER|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
214488211|NCT05933551|OTHER|Z Technique Training|Training on Z technique will be given on the planned day, time and place. The education is planned to be given at Tarsus University. The training content will be presented to the participants as a powerpoint presentation (30 min), laboratory practice (15 min) and question-answer (15 min).
214488212|NCT05154201|DRUG|ORIN1001|Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
214972579|NCT03425669|DEVICE|Sham stimulation|Patients will receive sham stimulation in place of active vestibular stimulation.
214972580|NCT03425669|DRUG|Active medication|Patients will be examined with and without medication.
214972581|NCT04622917|DRUG|MethylPREDNISolone 40 Mg/mL Injectable Suspension|intramuscular injection
214972582|NCT04622917|DRUG|NaCl 9 MG/ML Injectable Solution|Intramuscular injection
214972583|NCT02880254|DEVICE|Kurbo|health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
214972584|NCT02880254|DEVICE|Personal Health Coach|weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
214488213|NCT05143619|OTHER|Survey Administration|Complete surveys
214972585|NCT01348126|DRUG|Docetaxel|75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion
214972586|NCT01348126|DRUG|Combination of ganetespib and docetaxel|Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
214360335|NCT01331057|OTHER|Interview|For parents of children include in the study: A semi -structured interview
214972587|NCT04643132|DRUG|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
214972588|NCT04643132|DRUG|S-ketamine (low-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
214972589|NCT04643132|DRUG|S-ketamine (high-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
214972590|NCT02627079|OTHER|Daily SMS text messaging|
214972591|NCT01092013|BEHAVIORAL|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
214972592|NCT01092013|BEHAVIORAL|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
214972593|NCT01092013|BEHAVIORAL|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
214972594|NCT01838239|DIETARY_SUPPLEMENT|Fish Oil|Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
215083835|NCT04957992|OTHER|Experimental Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
215083836|NCT04957992|OTHER|Human Milk|Ad libitum or as instructed by HCP
214360336|NCT03160989|OTHER|physical exercises|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
214360337|NCT01741376|DRUG|Progesterone|Progesterone 200 mg twice daily
214360338|NCT01741376|DRUG|Placebo|
214360339|NCT00290862|DEVICE|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
214488214|NCT01957332|PROCEDURE|Molecular imaging|On the day of FES-injection\&scan or the day after FES-injection, 89Zr-trastuzumab (\~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
214488215|NCT01957332|PROCEDURE|Molecular imaging|All patients receive 18F-FES (\~200MBq) injection followed by a FES-PET.
214488216|NCT03913117|BIOLOGICAL|pNGVL4aCRTE6E7L2|Naked pNGVL4aCRTE6E7L2 DNA plasmid
214488217|NCT03913117|BIOLOGICAL|TA-CIN|TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
214488218|NCT06643715|DEVICE|PANDA PLUS|Using the PANDA PLUS model to assist in image interpretation, radiologists are provided with the model's output classification-non-PDAC, PDAC, or normal-alongside the initial CT image assessment. The radiologists then integrate the information from both the PANDA PLUS output and the original image interpretation to formulate the final report.
214488219|NCT06644183|DRUG|Roginolisib|Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.
214488220|NCT06644183|DRUG|Venetoclax|B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.
214488221|NCT06644183|DRUG|Rituximab|Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.
214488222|NCT06643117|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
214488223|NCT06643117|BIOLOGICAL|FYB206|Open-label treatment with FYB206 combined with chemotherapy (Cycles 18-34) to assure treatment continuation for trial patients up to a total of 2 years (a total of 34 treatment cycles)
214972595|NCT01621386|DRUG|Montelukast|Administered orally as a single daily 10 mg dose for 2 weeks
214972596|NCT01621386|DRUG|Prednisone|Administered orally as a single daily 20 mg dose for 2 weeks
215083837|NCT04957992|OTHER|Human Milk Supplemental Formula|Ad libitum if consuming supplemented formula; feeding period up to 12 months of age
214488224|NCT06643117|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
214488225|NCT04580771|DRUG|Cisplatin|Given IV
214488226|NCT04580771|BIOLOGICAL|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
214488227|NCT04580771|RADIATION|Radiation Therapy|Undergo radiation therapy
214488228|NCT00050063|BIOLOGICAL|Therapeutic vaccinations from A5058s|Participants will receive assigned interventions assigned in study A5058s.
214488229|NCT02075554|DEVICE|CALIBER|Expandable interbody spacer
214488230|NCT06180460|BEHAVIORAL|CALM|The CALM intervention is a supportive-expressive therapy that is administered by CALM trained clinicians in a particular style.
214488231|NCT06180460|BEHAVIORAL|Treatment as usual|Treatment as usual includes a list of local / national resources (e.g., psychologist, social worker, or other mental health providers) if an individual chooses to seek treatment for the distress they are experiencing.
214488232|NCT06091267|DRUG|IV Decitabine|The subjects will receive decitabine 20 mg/m\^2 IV daily × 5 days in 28-day cycles.
214972597|NCT05874232|BEHAVIORAL|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a weekly webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
214972598|NCT04882696|OTHER|Non-slip socks|Patients will wear non-slip socks during their hospitalization
215083838|NCT04957992|OTHER|Human Milk Toddler Drink|\~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
214360340|NCT04649866|DIAGNOSTIC_TEST|plethysmography|"Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~* SNP 0.8, 1.6 and 3.2 mcg/min~* ACh 7.5, 15 and 30 mcg/min~* Normal saline"
214360341|NCT04333420|DRUG|IFX-1 + BSC|Phase II study part: IFX-1 + BSC
214360342|NCT04333420|DRUG|BSC|Phase II study part: BSC
214360343|NCT04333420|DRUG|IFX-1 + SOC|Phase III study part: IFX-1 + SOC
214360344|NCT04333420|DRUG|Placebo + SOC|Phase III study part: Placebo + SOC
214360345|NCT03664466|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin capsules 12 mg twice daily
214360346|NCT03664466|OTHER|Placebo|placebo capsules twice daily
214360347|NCT06550336|DRUG|Chidamide|20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25.Each 4-week period constitutes one treatment cycle.
214360348|NCT03672773|DRUG|Talazoparib|Given PO
214360349|NCT03672773|DRUG|Temozolomide|Given PO
214360350|NCT06052696|DRUG|Gardasil 9 Suspension for Injection|"After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
214360351|NCT06052696|DRUG|Placebo|"After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
214488233|NCT06091267|DRUG|Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles.
214488234|NCT06091267|DRUG|only Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles, until disease progression, unacceptable toxicity, or the subject/investigator decides that the subject should discontinue treatment or withdraw from the trial.
214488235|NCT02320370|DEVICE|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
214488236|NCT03124017|OTHER|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart|
214488237|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
214488238|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
214488239|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
214488240|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
214488241|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
214488242|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
214488243|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
214488244|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
214488245|NCT00624442|DRUG|Placebo|IV infusion for 2 hours
214488246|NCT00624442|DRUG|Placebo|IV infusion for 24 hours
214488247|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
214488248|NCT00624442|DRUG|Placebo|IV infusion for 72 hours
214360352|NCT02922348|DRUG|Hormone Replacement Therapy|Hormone replacement therapy as indicated in Arm 1
214360353|NCT02922348|DRUG|Combined Oral Contraceptives|Combined oral contraceptives as indicated in Arm 2
214360354|NCT03362333|OTHER|Exercise|Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.
214360355|NCT03362333|OTHER|Pain neuroscience education|Pain neuroscience education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
214360356|NCT04179175|DRUG|secukinumab|secukinumab 300mg every 2 weeks
214360357|NCT04179175|DRUG|secukinumab|secukinumab 300mg every 4 weeks
214360358|NCT00610116|DEVICE|Electronic Repositioning|Change of pacing vectors for CRT pacing
214360359|NCT02792361|PROCEDURE|Standard Suction Drain|The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
214360360|NCT05819814|GENETIC|Disclosure of high polygenic risk result for coronary artery disease|The disclosure of a high polygenic risk result for coronary artery disease involves a clinical report coupled with a virtual meeting with a genetic counselor.
214360361|NCT00392405|DRUG|3 amps of sodium bicarbonate mixed in one liter of D5W|
214360362|NCT02801994|DEVICE|PAV, Puritan Bennett 980 ventilator|The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
214360363|NCT02776332|PROCEDURE|Manual Expression of Breastmilk|Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
214360364|NCT01746693|DEVICE|Dynamic Vessel Analyzer|retinal vessel diameter, retinal oxygen saturation
214360365|NCT01746693|OTHER|Laser Doppler Velocimetry|retinal blood flow velocity, retinal blood flow
214360366|NCT01746693|DEVICE|7-Tesla MRI|High resolution functional and anatomical imaging of the visual pathway
214972599|NCT02189668|DRUG|Antibiotics only (Zosyn then Augmentin)|Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
214972600|NCT03979066|DRUG|Atezolizumab|840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
214972601|NCT03979066|DRUG|PEGPH20|PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
214972602|NCT00104936|PROCEDURE|adjuvant therapy|
215094407|NCT04713332|DIETARY_SUPPLEMENT|Hydrogen rich water|Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
214972603|NCT00104936|RADIATION|radiation therapy|
214972604|NCT00104936|RADIATION|stereotactic radiosurgery|
214972605|NCT03732027|PROCEDURE|Surgical Transversus Abdominis Plane Block|At the end of operation and after hemostasis, 20 ml of 0.25% bupivacaine will be injected intra-abdominally into the Transversus Abdominis plane at the midpoint of the line connecting the crista iliaca and inferior costal margin and at two locations in the lateral abdominal wall at 3-4 cm inferior to the previous midline injection. The same procedure will be repeated on the opposite side using an identical amount of local anesthetic.
214360367|NCT01746693|OTHER|Pattern electroretinography|inner retinal function
214360368|NCT01746693|OTHER|Fourier domain optical coherence tomography|Blood flow in retina.
214360369|NCT04007458|BEHAVIORAL|Letter|MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.
214360370|NCT04007458|BEHAVIORAL|Community Health Worker Phone Call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
214360371|NCT02525848|DRUG|dexamethasone|dexamethasone 8 mg iv 2 minutes before induction of anesthesia
214360372|NCT02525848|DRUG|Gabapentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
214360373|NCT02525848|DRUG|Aprepitant|oral aprepitan 80mg 1 hour before induction of anesthesia.
214360374|NCT01533701|OTHER|Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling|Fetal blood sampling is conducted when a non reassuring cardiotocographic pattern occurs to detect fetal hypoxia during labor. Amniotic fluid, maternal blood is sampled in cases of fetal blood sampling. Umbilical cord blood sampling is conducted at delivery.
214360375|NCT04163887|PROCEDURE|hepatectomy|Resection colorectal liver metastases using a laparoscopic approach or an open approach.
214360376|NCT03771014|OTHER|Early mobility|This progressive mobility pathway commenced with passive cycling within 48 hours of intubation and ventilation and progressing through assisted cycling, active cycling, bed exercises, sitting, mobilising out of bed to walking
214360377|NCT02699502|OTHER|matching an appropriate drug therapy to patients with osteoporotic hip fractures|The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician
214360378|NCT04573621|PROCEDURE|Pelvic drain|A pelvic drain is placed
214360379|NCT04573621|OTHER|No pelvic drain is placed|A pelvic drain is not placed
214972606|NCT03732027|PROCEDURE|Surgical Rectus Sheath Block|At the end of operation and after hemostasis,20 ml 0.25% bupivacaine will be administered slowly under direct vision after careful aspiration to the rectus sheath space which is present inbetween rectus abdominis muscle and the posterior layer of its sheath at the upper pole of the midline incision by time of closure of the anterior abdominal wall. The procedure will be repeated on the opposite side.
214972607|NCT01549145|DEVICE|Nimbus Multifunctional Stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
214360380|NCT06221202|OTHER|Stories in the Moment Dance Program - Online|Stories in the Moment is a co-creative dance, movement and storytelling program for persons living with dementia and care partners.
214360381|NCT00744770|DRUG|TMC278|
214360382|NCT00006155|DRUG|SU5416 and carboplatin|
214360383|NCT00644462|DEVICE|PulmoTrack® 2010 with WIM-PC™ Technologies|wheeze detection during dynamic bronchial situations in infants
214360384|NCT03111056|BEHAVIORAL|Alc-ERDT|Web-based cognitive behavioral skills-based alcohol intervention that incorporates emotion regulation and distress tolerance skills
214360385|NCT02729181|DEVICE|DRX9000|
214360386|NCT03428425|DRUG|paclitaxel apatinib S-1|"HIPEC: 43℃, 60min. the drug is paclitaxel : 70mg/m2 d1 d3 d5, The interval is not less than 24h , A total of three times.~apatinib：500mg qd po, 28 days is a cycle.preoperative 2 cycles, 2 cycles after surgery.~S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery"
214360387|NCT04177680|DRUG|Omega 3 pentaenoic acid|Encapsulated omega-3 pentaenoic acid
214360388|NCT04177680|DRUG|icosapent ethyl|Encapsulated omega-3 acid ethyl esters
214360389|NCT03364322|OTHER|Observation|Observation
214360390|NCT04499807|OTHER|AFib detection with wearable smart watch|Patients will transmit two rhythm strips every day through both the devices and additional transmission whenever they have symptoms (palpitations, skipped beats, shortness of breath and chest pain). The transmitted rhythm strips are de-identified and analyzed after assigning a unique ID for research purposes.
214360391|NCT01830114|BEHAVIORAL|Web app|The Checkup and Choices web application
214360392|NCT00178425|PROCEDURE|Serial blood sampling as described in protocol|
214972608|NCT01053741|BIOLOGICAL|Radiolabeled autologous seminal fluid|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
214972609|NCT01053741|BIOLOGICAL|Radiolabeled Normosol-R|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
214360393|NCT00178425|PROCEDURE|Estimation of Creatinine Clearance at regular intervals|
214360394|NCT03642925|DIETARY_SUPPLEMENT|Meal replacement diet|Obese subjects were requested to replace two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks with one regular meal and make sure the daily target calorie limit should be less than 1500 kcal/day for men and 1200 kcal/day for women.
214360395|NCT04768400|DRUG|Arm I (MEP)|Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
214360396|NCT05769985|OTHER|Caregiver's responses and patient satisfaction|Interaction between caregivers' responses and patient satisfaction about those responses
214360397|NCT03801785|OTHER|Pacifier|The pacifiers used in this clinical trial have the same shape and material. They are produced by Artsana S.P.A. for soothing children. As such, the FDA has no jurisdictions over pacifiers (US FDA regulations May 15, 2012 https://www.fdaimports.com/blog/pacifiers-fda-change-abi-system/) because they are not medical devices intended for teething.
214360398|NCT01047592|DRUG|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
214360399|NCT01047592|DRUG|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
214360400|NCT01047592|DRUG|placebo|placebo,oral, for 12 weeks
214360401|NCT05796856|DEVICE|repeated low level light device (Eyerising [Suzhou Xuanjia Optoelectronics Technology)|crossover device (repeated low level light device with wavelength of 810/650 nm- alternate to first group) Cross over arms after one month of use and one month of washout period.
214360402|NCT04149925|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
214360403|NCT04149925|DEVICE|Echelon Flex Powered Stapler|Surgery with Echelon Flex Powered Stapler
214360404|NCT01175525|DRUG|CROMOLYN|Cromolyn 200mg (dissolved in water) given 4 times a day
214360405|NCT01175525|DRUG|sugar pill|sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
214360406|NCT03104764|DEVICE|Scalpel|Labial frenulum removed by scalpel
214360407|NCT03104764|DEVICE|Er:YAG laser|Labial frenulum removed by Er:YAG laser
214360408|NCT03254082|OTHER|Glycemic response of F-1000|The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.
214360409|NCT03254082|OTHER|Glycemic response to sumac sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.
214360410|NCT03254082|OTHER|Glycemic response to MMR sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.
214360411|NCT03254082|OTHER|Glycemic response to wheat flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.
214360412|NCT03254082|OTHER|Glycemic response to sucrose|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
214360413|NCT02478411|PROCEDURE|Cycle ergometer physiotherapy|15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
214360414|NCT02478411|PROCEDURE|Conventional physiotherapy|30 minutes of conventional physiotherapy
214972610|NCT04881643|BEHAVIORAL|Trauma-focused cognitive behavioural therapy via a digital support|A blended treatment approach to PTSD, blending internet-based CBT with face-to-face sessions with a therapist
214972611|NCT02063672|DEVICE|Lutonix DCB|
214360415|NCT05129319|DRUG|prabotulinumtoxinA|Injection of glabellar rhytids
214360416|NCT00642512|DRUG|dronabinol|10 - 20 mg
214360417|NCT00642512|DRUG|ondansetron|8 - 16 mg
214360418|NCT00642512|DRUG|dronabinol/ondansetron|10 - 20 mg/8 - 16 mg
214360419|NCT00642512|DRUG|placebo|placebo
214360420|NCT05721131|DEVICE|NC° Thermometer (Gen 3)|The NC° Thermometer (Gen3) is used orally for the intermittent measurement and monitoring of human body temperature. The device can be used by adults and children over the age of 5 years old.
214360421|NCT00004122|BIOLOGICAL|BCG vaccine|
214360422|NCT00004122|BIOLOGICAL|recombinant interferon alfa|
214360423|NCT02030015|DRUG|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
214360424|NCT02030015|OTHER|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
214360425|NCT00365391|BIOLOGICAL|bevacizumab|Given IV, 10 mg/kg, days 1 and 15 in every cycle
214360426|NCT00365391|DRUG|erlotinib hydrochloride|Given orally, 150 mg, every day during each cycle.
214360427|NCT00608010|PROCEDURE|Vitrification|Embryos were vitrified according to a previously described technique
214360428|NCT00608010|PROCEDURE|Slow freezing|Embryos were frozen with slow freezing technique
214360429|NCT01429129|DRUG|Nicotine replacement therapy|Nicotine transdermal patches as per product monograph
214360430|NCT04888390|BEHAVIORAL|Muti-model exercise intervention|The Muti-model exercise intervention include aerobic exercise training by ergometer or treadmill, resistance exercise by using elastic band and flexibility exercise by active stretch. The total training program takes for 60 minutes, 2-3 times per week for 3 months.
214360431|NCT04888390|BEHAVIORAL|Disease and exercise suggestion|The participants will be provided by educational program about heart failure self-care and home-based exercise approach.
214972612|NCT02063672|DEVICE|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
214972613|NCT04131920|DEVICE|handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform|Patients receive training by the physical therapist to operate a handheld ultrasound (HHUS) including proper probe placement. Subjects will be tested on their knowledge at the HTC to demonstrate proficiency, and will then repeat the testing at home via tele-ultrasound.
214360432|NCT04130516|DRUG|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
214360433|NCT04130516|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|pembrolizumab- anti-PD-1 antibody
214360434|NCT02070055|OTHER|No intervention|
214360435|NCT01406626|BEHAVIORAL|Peer Navigator|Peer navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
214360436|NCT03199222|DEVICE|Prosthetic smart socket technology with patient prompting|The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
214360437|NCT00745745|DEVICE|Device Implantation|ICD lead implantation
214360438|NCT03014674|BIOLOGICAL|Lyophilized mepolizumab|Mepolizumab will be provided as white, uniform, lyophilized cake in vials with unit dose strength of 100 mg/vial for reconstitution in 1.2 mL sterile water for injection (SWFI). Following reconstitution it forms a clear to opalescent, colorless to pale yellow solution for SC injection.
214360439|NCT03014674|BIOLOGICAL|Liquid mepolizumab|Mepolizumab will be provided as a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled autoinjector or safety syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose ethylenediaminetetraacetic acid and polysorbate 80.
214360440|NCT03014674|DEVICE|Prefilled autoinjector|Single use, disposable autoinjector will be assembled with the prefilled syringe containing the drug product. It will enable automatic delivery of the drug product under the power of a spring mechanism following activation of the device. Start and end of injection clicks will inform the user of correct use. A plastic needle will cover shield the needle before and after injection to minimize the potential for needle stick injuries.
214360441|NCT03014674|DEVICE|Prefilled Safety Syringe|Single use, disposable safety syringe with a retracting needle guard and locking system.
214360442|NCT01096992|DRUG|Bendamustine|"Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)"
214360443|NCT01096992|DRUG|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
214360444|NCT01096992|DRUG|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
214360445|NCT05164575|BEHAVIORAL|progressive resistance exercise|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
214360446|NCT05164575|BEHAVIORAL|self-management strategies|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
214360447|NCT04167501|OTHER|biological sample analysis|HPV Prevalence analysis
214360448|NCT03834233|DRUG|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
214360449|NCT03382964|BIOLOGICAL|VLA1553|I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
214360450|NCT04047043|DIAGNOSTIC_TEST|serum taurine|blood sample for serum taurine level
214360451|NCT01093118|DRUG|TMI-358|Micro implant monthly x 3
214360452|NCT01093118|DRUG|MMI-467|Micro implant monthly x 3
214360453|NCT04336735|OTHER|immunization app|A transplant specific immunization app will be trialed that 1) provides vaccine information and education, 2) stores vaccine records and 3) provides reminders when vaccines are due
214488249|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
214488250|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
214972614|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure GPx activity|Routine blood draw to measure levels of blood markers.
214972615|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure SOD activity|Routine blood draw to measure levels of blood markers.
214488251|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
214488252|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
214488253|NCT03462485|OTHER|Golf|Eight weeks of twice-daily golf training
214488254|NCT04263610|DRUG|Dimethyl fumarate (DMF) standard scheme|Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.
214488255|NCT04263610|DRUG|Dimethyl fumarate (DMF) simplified scheme|Participants will receive DMF gastro-resistant tablet orally at a dose of 60, 120, 180, 240, 360 mg daily in Week 1, Week 2, Week 3, Week 4, Week 5 respectively, and 480 mg daily from Week 6 to Week 8. If a PASI is greater than or equal to (\>=) 30% at Week 8, no dose increase will be done and if PASI is less than (\<) 30% at Week 8, participants will receive 600 mg daily in Week 9 and 720 mg from the Week 10 onwards.
214488256|NCT04263610|DRUG|Tildrakizumab|Participants who achieve PASI less than (\<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg \[(as per the Summary of Product Characteristics (SmPC)\] at Weeks 16, 20 and 32 up to Week 40.
214972616|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure Lp(a) levels|Routine blood draw to measure levels of blood markers.
214972617|NCT04790695|DRUG|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
214972618|NCT03143257|DEVICE|Sophono Bone Conduction Hearing Systems|"The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of Bone Conduction (BC) of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear."
214360454|NCT00047476|DRUG|dexmethylphenidate(d-mph)|
214360455|NCT05603468|DRUG|platelet rich plasma|Platelet rich plasma group: after the surgery of rotator arthroscopic rotator cuff repair, 3ml PRP (LongTai Biological Company) was injected into the rotator cuff tear under the rotator arthroscope for a time. PRP production process: before anesthesia, 20ml arterial blood was drawn and injected into the PRP tube. The blood was fully oscillated in the tube, and then placed in a centrifuge with 1500g for 9min to remove excess plasma and make 5ml PRP. 3ml is used for injection and 2ml is used for quality control.
214360456|NCT05603468|DRUG|Corticosteroid|Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
214360457|NCT05603468|DRUG|Normal saline|Normal saline
214360458|NCT02594748|BEHAVIORAL|Self-management education|The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .
214360459|NCT02594748|BEHAVIORAL|Routine care|They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
214488257|NCT00167765|DRUG|Abciximab|
214488258|NCT02574611|DRUG|Neostigmine|
214488259|NCT02574611|DRUG|Glycopyrrolate|
214488260|NCT02574611|OTHER|Saline (Placebo)|
214488261|NCT02574611|DEVICE|High Resolution Colonic Manometry|
214488262|NCT00127387|DRUG|Enbrel|
214488263|NCT03618758|DRUG|Paclitaxel|"Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum~Phase 2: Intraperitoneal Paclitaxel with recommended dose"
214488264|NCT03618758|DRUG|mFOLFOX6 regimen|Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
214488265|NCT03568409|DEVICE|ABO-GLYC|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
214488266|NCT03568409|OTHER|ABO-GLYC Placebo|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
214679314|NCT06521008|DRUG|anti muscarinic drugs|a selective anti muscarinic drugs (5-10mg) once per day for 12 weeks.
214972619|NCT02536937|DRUG|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
214972620|NCT00933725|OTHER|TCM intervention|"Drug: Particle of compound Chinese herbs(produced by San\_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~One tablet placebo of Tibolone (provided by San\_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.~Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months."
214360460|NCT00155389|DRUG|Helicobacter pylori eradication|"For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.~The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013."
214360461|NCT06443619|PROCEDURE|unilateral USG-deep SAPB with glucose|patients will receive unilateral USG-deep SAPB ; 15 ml 0.5 % isobaric bupivacaine with addition of 15ml glucose 10% to (30 ml total volume).
214972621|NCT00933725|OTHER|Western intervention|"Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San\_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months."
214360462|NCT06443619|PROCEDURE|unilateral USG-deep SAPB without glucose|will receive unilateral USG-deep SAPB; 15ml 0.5% isobaric bupivacaine to be diluted with 15ml isotonic saline0.9% (30 ml total volume).
214360463|NCT05446324|DRUG|Gallium-68-tilmanocept|All participants receive a cervical injection with 10 MBq 68Ga-tilmanocept in an outpatient setting (at least one week) before surgery. Within 30-90 minutes post-injection a PET with contrast enhanced CT is performed (PET/CT). Data (i.e. detection rate) from the imaging modalities are collected.
214488267|NCT02757898|DRUG|Biotin-Labeled Red Blood Cells (RBCs)|"500 mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.~For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.~For participants 3 through 8, the RBCs will be stored at 2-6 C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.~Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs."
214488268|NCT06632158|BEHAVIORAL|MindBoba|MindBoba is a smartphone app that uses strategies based on Problem-Solving Therapy to help decrease stress and anxiety, and teach new skills.
214488269|NCT06632158|BEHAVIORAL|Mindshift CBT|MindShift® CBT uses strategies based on Cognitive Behavioural Therapy (CBT) to help participants learn to relax and be mindful, develop more effective ways of thinking, and use active steps to take charge of their anxiety.
214488270|NCT02994667|DEVICE|Permanent Pacemaker Placement|
214488271|NCT01316107|DRUG|ipragliflozin|oral
214488272|NCT01316107|DRUG|nateglinide|oral
214488273|NCT02401711|BEHAVIORAL|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
214488274|NCT02401711|BEHAVIORAL|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
214488275|NCT02401711|BEHAVIORAL|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
214488276|NCT05175794|DIAGNOSTIC_TEST|Xpert® MTB/XDR|The Xpert MTB/XDR Assay, performed on the GeneXpert Instrument Systems, is a nested real-time polymerase chain reaction(PCR) in vitro diagnostic test for the detection of extensively drug resistant (XDR) Mycobacterium tuberculosis (MTB) complex DNA in unprocessed sputum samples or concentrated sediments prepared from sputum. In specimens where MTB is detected, the Xpert MTB/XDR Assay can also detect isoniazid (INH) resistance associated mutations in the katG and fabG1 genes, oxyRahpC intergenic region and inhA promoter; ethionamide (ETH) resistance associated with inhA promoter mutations only; fluoroquinolone (FLQ) resistance associated mutations in the gyrA and gyrB quinolone resistance determining regions (QRDR); and second line injectable drug (SLID) associated mutations in the rrs gene and the eis promoter region.
214488277|NCT04993677|DRUG|SEA-CD40|Given into the vein (IV; intravenously); schedule is cohort-specific
214488278|NCT04993677|DRUG|pembrolizumab (KEYTRUDA®)|Given by IV; schedule is cohort-specific.
214488279|NCT04993677|DRUG|pemetrexed|Given by IV on Day 1 of each 21-day cycle.
214488280|NCT04993677|DRUG|carboplatin|Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.
214972622|NCT00236002|DRUG|Alendronate|Alendronate 70mgm once a week for one year
214972623|NCT02244983|OTHER|Patients History|History taking and drawing of a blood sample
214972624|NCT00843141|BEHAVIORAL|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
214972625|NCT00843141|BEHAVIORAL|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
214972626|NCT00619827|DRUG|300 IR grass pollen allergen extract tablet|300 IR grass pollen allergen extract tablet once daily during four months
214972627|NCT00619827|DRUG|Placebo tablet|Placebo tablet once daily during four months
214360464|NCT06162650|RADIATION|Short-course radiotherapy|Short-course radiotherapy, 5×5 Gy.
214360465|NCT06162650|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
214488281|NCT03462147|DEVICE|Spinal cord stimulation|Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
214488282|NCT04899778|DRUG|Oral Contraceptive Pill, norethindrn a-e estradiol-iron|tablet
214972628|NCT02696824|BEHAVIORAL|Cognitive Behavioral Therapy for Adherence and Depression|"This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach."
214360466|NCT00059644|DRUG|Ecraprost in lipid emulsion|
214360467|NCT03774901|DRUG|Avelumab|intravenous 10 mg/kg every 2 weeks
214360468|NCT04250727|DEVICE|ZYN|30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.
214360469|NCT04358172|OTHER|'Oral and Denture Guide' mobile application|'Oral and Denture Guide' mobile application provides evidence-based information about cleaning aids and material for dentures, denture care and oral hygiene instructions.
214360470|NCT05005780|DEVICE|Negative peak triggered 100 Hz triplet burst TMS|MagVenture MagPro X100: Ipsilesional negative peak triggered 100 Hz triplet burst TMS.
214360471|NCT05005780|DEVICE|1 Hz rTMS|MagVenture MagPro X100: Contralesional 1 Hz rTMS.
214360472|NCT05745142|DRUG|Sunitinib|as provided in real world practice
214360473|NCT06096493|PROCEDURE|curative surgery for cancer rectum|Curative surgery for cancer rectum.
214360474|NCT05656599|DRUG|Letermovir|Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
214360475|NCT02784483|DRUG|Atezolizumab (1200mg via IV infusion)|Patients will get atezolizumab every 21 days for up to 1 year
214360476|NCT00002411|DRUG|Nelfinavir mesylate|
214360477|NCT00002411|DRUG|Lamivudine|
214360478|NCT00002411|DRUG|Stavudine|
214360479|NCT00002411|DRUG|Zidovudine|
214488283|NCT05799053|DRUG|Small intestinal release peppermint oil|Tempocol®, a gastric acid resistant (enteric-coated) capsule containing 182mg of Menthae Piperitae Aetheroleum (peppermint oil), is currently registered as an over the counter prescription drug on the Dutch market for treatment of abdominal pain, discomfort or flatulence.
214488284|NCT05799053|DRUG|Peppermint sweets|Wilhelmina® peppermints contain 9.2 mg of Menthae Piperitae Aetheroleum (peppermint oil), and 18.4 Kcal per mint and are to be taken orally.
214488285|NCT05799053|DRUG|Placebo|Capsule containing microcrystalline cellulose
214488286|NCT06798467|OTHER|Endodontic sealer|endodontic sealer is a material used in root canal therapy to fill the microscopic spaces between the root canal filling material (typically gutta-percha) and the walls of the root canal. Its primary function is to create a tight seal that prevents the ingress of bacteria and fluids into the root canal system, helping to prevent reinfection and promoting the healing of periapical tissues. Endodontic sealers also help to ensure that the root canal filling reaches all parts of the canal, especially in complex or irregularly shaped anatomies.
214488287|NCT06798467|OTHER|post obturation pain|Unpleasant sensation of any degree of pain after root canal treatment.
214488288|NCT06014528|DRUG|IN10018|100mg QD orally (PO)
214488289|NCT06014528|DRUG|Placebo of IN10018|100mg QD orally (PO)
214488290|NCT06014528|DRUG|Pegylated Liposomal Doxorubicin|40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
214488291|NCT06414434|DRUG|BTX-A51|Multi-kinase inhibitor, 1.0 mg, 2.0 mg, and 7.0 mg immediate-release capsules, taken orally per protocol.
214488292|NCT00149591|PROCEDURE|coronary balloon-angioplasty with stenting|
214488293|NCT04900675|OTHER|Bright light intervention|Exposure with 5,000 lux at eye level for one hour and a Correlated Color Temperature of 5,300 Kelvin every morning for three weeks.
214488294|NCT04900675|OTHER|Reddish placebo light|Exposure with 50 lux at eye level for one hour and a Correlated Color Temperature of 2,200 Kelvin every morning for three weeks.
214360480|NCT00002411|DRUG|Didanosine|
214972629|NCT03301389|OTHER|Cardiac magnetic resonance imaging|The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
214972630|NCT00004246|DRUG|Fludarabine Phosphate|IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
214972631|NCT00004246|RADIATION|Radiation Therapy (RT)|Days 1-5 for 7 weeks
214972632|NCT03795480|BEHAVIORAL|MOOD|MOOD is an online self-help program targeted on depressive symptoms. The program consists of nine modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention. All modules are based on principles of cognitive behavioral therapy (CBT) and include elements of mindfulness-based and metacognitive techniques. The modules contain interactive exercises which are aimed at incorporating the participant's experiences into the program and increasing identification of the participant with the presented material. Participants are free to work through the different modules in their own speed and way, however, it is recommended to work on one to two modules per week.
214360481|NCT01911403|PROCEDURE|Manual compression|Closure procedure by Manual compression
214488295|NCT06242366|BEHAVIORAL|Intervention group|"Intervention 2 phases Phases 1) In-hospital period (4 times and 30-60 mins/times) intervention includes Stroke education, Rehabilitation, environmental management, and complication prevention. Intervention participants will receive a booklet (choose between hard copy or electronic copy) self-care for stroke patients, Rehabilitation clip, and Self-care record form.~Phases 2) after hospital discharge 5 times (first times within 24 hours after hospital discharge) and (second-fifth time: 1 time/weekly)15-30 mins/times by Line Application for repeat and following education, rehabilitation complication prevention and finding limit to self-care management."
214360482|NCT01911403|DEVICE|Angio-Seal|Closure procedure by angio-Seal
214488296|NCT01318694|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
214488297|NCT01318694|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
214488298|NCT01318694|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
214360483|NCT03722927|DRUG|Bupivacaine|While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
214488299|NCT01318694|DRUG|ALV Placebo|ALV placebo soft gel capsules administered orally
214488300|NCT04959669|OTHER|DeSSBack|The DeSSBack (Decision Support System for Low Back Pain) is a decision support tool developed in the University of Malaya Medical Centre's (UMMC) electronic medical record system by adopting and re-packaging the STaRT system to suit the local context. It stratifies patients with low back pain to low, medium or high risk, which are then managed differently. The DeSSBack has also been incorporated the local clinical practice guidelines and feedback from local experts.
214972633|NCT03632564|DEVICE|REVIVIEW dichoptic audio-visual stimulation|REVIVIEW dichoptic audio-visual stimulation using video goggles
214360484|NCT03722927|DRUG|Liposomal Bupivacaine|While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
214360485|NCT01605929|PROCEDURE|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
215083839|NCT06684977|BEHAVIORAL|360 Video|360° Video consists of video recordings, made with a camera to simultaneously capture and combine scenes in a 360 degrees perspective such as Instant Google Street View Instant Google Street View (instantstreetview.com). When uploaded to a VR headset, 360° videos may provide a more cost-effective method for rapidly creating virtual environments in which users can experience a sense of immersion and the viewer can control and change the viewing angle at any stage through head movement. While photorealism may be superior, this option is known to be less interactive as the viewer can't move or walk around within the virtual space. In addition, the landscape and imagery may have been changed or developed meaning the recordings captured do not match the traumatic memory. Despite these limitations, the use of 360° video has been trialled in clinical mental health settings showing positive outcomes for both user and clinician.
214360486|NCT02200718|BIOLOGICAL|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
214360487|NCT02200718|BIOLOGICAL|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
214360488|NCT00444808|DRUG|Intranasal calcitonin|
214360489|NCT04125368|BEHAVIORAL|Health Facility Interventions|"1. Intensified counselling on dietary diversity and increased meal frequency during pregnancy.~2. Strengthened government distribution of IFA supplies with counseling about its importance, managing side effects, and reminder about subsequent supplies.~3. Weight-gain monitoring with messaging to mothers about healthy diet and adequate rest; excess weight gain as a danger sign.~4. Intensified counseling on importance, benefits, and how-tos of early initiation of breastfeeding and exclusive breastfeeding."
214360490|NCT04125368|BEHAVIORAL|Community Interventions|"1. Home visits to pregnant women by HEWs to discuss maternal nutrition (dietary diversity, adequate food intake, IFA supplementation, and weight gain), early breastfeeding practices, provide ANC and Pregnant Women Conference referrals, and engage husbands.~2. HEWs use A\&T intervention tools (e.g. posters and maternal nutrition follow-up card) at Pregnant Women Conferences/ Mother Support Groups to reinforce maternal nutrition messages, encourage ANC attendance, distribute IFA tablets, measure and track weight gain, promote early breastfeeding practices, and encourage husband participation.~3. HEWs and community volunteers (Women's Development Army (WDA), imams, etc.) deliver maternal nutrition messages and encourage ANC visits at kebele and community meetings."
214360491|NCT04125368|BEHAVIORAL|Health System Interventions|"1. Trainings on the maternal nutrition interventions for health center heads, nurse-midwives, HEWs, community volunteers (WDA, imams, etc.), woreda health officers, and other key actors.~2. Supportive supervision of maternal nutrition activities conducted by woreda nutrition officers, woreda health officers, TDA or A\&T."
214360492|NCT05843916|DRUG|Recombinant human alpha galactosidase A (agalsidase beta)|All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks
214488301|NCT05513742|DRUG|CTX-009|IV infusion administered on day 1 and 15 of every 28-day cycle
214488302|NCT05672251|PROCEDURE|Biopsy|Undergo biopsy
214488303|NCT05672251|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214488304|NCT05672251|PROCEDURE|Computed Tomography|Undergo PET/CT
214488305|NCT05672251|BIOLOGICAL|Loncastuximab Tesirine|Given IV
214488306|NCT05672251|BIOLOGICAL|Mosunetuzumab|Given IV
214488307|NCT05672251|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214488308|NCT00004361|DRUG|calcium gluconate|
214972634|NCT06379243|PROCEDURE|PVP/PKP|PVP or PKP surgery in patients with osteoporotic vertebral compression fractures
214972635|NCT02112942|DRUG|IDX21459|
214972636|NCT02112942|DRUG|Matching Placebo|
214972637|NCT05971771|OTHER|Placebo|Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed
214488309|NCT00004361|DRUG|sodium citrate|
214972638|NCT05971771|DIETARY_SUPPLEMENT|Treatment|14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed
214972639|NCT03087305|DIAGNOSTIC_TEST|Supraclavicular lymph node ultrasound|Patients will have supraclavicular lymph node assessed prior to EBUS-TBNA
214360493|NCT05843916|DRUG|Recombinant human alpha-galactosidase A (agalsidase beta)|All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks
214360494|NCT00863252|DRUG|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
214360495|NCT00863252|DRUG|angiotensin blockade|Continuation of angiotensin blockade
214360496|NCT03281148|DEVICE|Computer guided implant insertion group|Implants will be immediately inserted in fresh extraction sockets using CAD/CAM guides
214360497|NCT03281148|DEVICE|Free hand implant insertion group|Implants will be immediately inserted in fresh extraction sockets using free hand technique
214488310|NCT05682144|BIOLOGICAL|Autologous Plasmablasts (B cells)|Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
214488311|NCT05630508|BEHAVIORAL|interactive Mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
214488312|NCT05630508|OTHER|Sham|Receiving standard care, LIVEN educational material and access to the application
214488313|NCT00003222|BIOLOGICAL|aldesleukin|Systemic subcutaneous delivery of low-dose IL-2.
214488314|NCT00003222|BIOLOGICAL|gp100 antigen|
214360498|NCT03224182|DRUG|Qapzola|Qapzola administered by the intravesical route.
214488315|NCT00003222|BIOLOGICAL|incomplete Freund's adjuvant|
214488316|NCT00003222|BIOLOGICAL|sargramostim|
214488317|NCT00003222|BIOLOGICAL|tetanus peptide melanoma vaccine|
214488318|NCT00003222|BIOLOGICAL|tyrosinase peptide|
214488319|NCT04736485|DRUG|perioperative treatment|FLOT + Spartalizumab
214488321|NCT03011671|DRUG|Acetazolamide|ACZ will be given at an initial dose of 250 mg twice a day (BID) and then escalated to 500 mg BID after 1 week. ACZ will be given on days 1-21 of each cycle.
214972640|NCT03844659|OTHER|"Song Weightless by Marconi Union"|"Patients will be randomized to the intervention group (the song Weightless by Marconi Union will be playing) during subjects labor epidural placement. The intervention in this study is solely the addition of music."
214972641|NCT03844659|OTHER|No Song|No song will be played during subjects labor epidural placement.
214972642|NCT00104052|BIOLOGICAL|peginterferon alfa-2b (PEG2b) (SCH 54031)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
214972643|NCT00104052|DRUG|ribavirin (SCH 18908)|15 mg/kg/day for up to 48 weeks
214972644|NCT01241474|DIETARY_SUPPLEMENT|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
214972645|NCT01241474|DIETARY_SUPPLEMENT|Maize (corn) oil|6 x 1g capsules per day for 9 months
214360499|NCT03224182|DRUG|Placebo|Qapzole-matching placebo administered by the intravesical route.
214360500|NCT02822222|DRUG|Magnesium citrate, tribasic anhydrous soft gelatin capsule|110 mg elemental magnesium/capsule
214488322|NCT03011671|DRUG|Temozolomide|For cycle 1 of the maintenance phase, TMZ will administered at 150 mg/m2 on days 1- 5 followed by 23 days with no drug. For cycles 2- 6, TMZ can be increased to 200 mg/m2 at the discretion of the treating investigator.
214488323|NCT06564909|DRUG|L-Carnitine|L-Carnitine 5 g intravenous administered as slow IV push over 2-3 minutes (L-Carnitine 1 gm / 5 mL Injection®, MEPACO, Egypt) and Carnitol 500 mg® Oral, Global Napi, Egypt)
214488324|NCT06564909|DRUG|The standard care for the management of myocardial infarction post PCI|include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
214488325|NCT05572970|DRUG|Balstilimab|An anti-programmed death 1 (PD-1) monoclonal antibody.
214488326|NCT05572970|DRUG|Zalifrelimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
214972646|NCT04065490|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System
214972647|NCT04065490|DEVICE|Valeda Sham treatment|The sham mode of the Valeda Light Delivery System.
214972648|NCT01195649|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients under daily life treatment according to local drug information
214972649|NCT02536872|OTHER|None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied|
214972650|NCT04500574|DRUG|Latanoprost eluting contact lens|The latanoprost-contact lens will be worn in one eye for one week.
214972651|NCT04500574|DRUG|Topical Latanoprost|A commercial contact lens with no drug will be worn in one eye for one week.
214972652|NCT03850717|DEVICE|acupuncture|insert in filiform needles into skin and other soft tissue to treat the illness or disorders
214972653|NCT03080740|DRUG|Clindamycin palmitate hydrochloride dispersible tablet|300mg, oral after meal, twice daily, a total of 7days
214972654|NCT03080740|DRUG|Metronidazole Tablet|400mg, oral after meal , twice daily, a total of 7days
214972655|NCT06253936|OTHER|Magnetic Resonance Venography|Detect the anatomical variants of dural sinuses by Magnetic Resonance Venography
214360501|NCT02822222|DRUG|Placebo soft gelatin capsule|0 mg elemental magnesium/capsule
214972656|NCT02498678|PROCEDURE|Tetanus|tetanic electric stimulation
214972657|NCT03610893|DRUG|Dexamethasone|Dexamethasone as perineural local anesthetic adjuvant
214972658|NCT03610893|DRUG|Dexmedetomidine|Dexmedetomidine as perineural local anesthetic adjuvant
214972659|NCT04135547|DEVICE|intra-osseous access vs. intra-venous access|EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures
214360502|NCT04279314|DRUG|Trofinetide|Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
214972660|NCT03186313|DRUG|Dactavira Plus|1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
214360503|NCT03665610|DRUG|ozanimod|ozanimod
214360504|NCT01248273|BIOLOGICAL|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
214360505|NCT02481310|DRUG|Cyclophosphamide|Given IV
214360506|NCT02481310|DRUG|Cytarabine|Given IT or intraventricularly
214360507|NCT02481310|DRUG|Doxorubicin Hydrochloride|Given IV
214360508|NCT02481310|DRUG|Etoposide|Given IV
214360509|NCT02481310|DRUG|Ixazomib Citrate|Given PO
214360510|NCT02481310|OTHER|Laboratory Biomarker Analysis|Correlative studies
214360511|NCT02481310|DRUG|Methotrexate|Given IT or intraventricularly
214360512|NCT02481310|DRUG|Prednisone|Given PO
214360513|NCT02481310|BIOLOGICAL|Rituximab|Given IV
214360514|NCT02481310|DRUG|Therapeutic Hydrocortisone|Given IT or intraventricularly
214360515|NCT02481310|DRUG|Vincristine Sulfate|Given IV
214360516|NCT06449040|DRUG|Liposomal amphotericin B (AmBisome®)|Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved
214360517|NCT01958632|PROCEDURE|Nerve reconstruction|
214360518|NCT05407454|OTHER|Questionnaire|The original form of the Diabetes Quality of Life-Brief Clinical Inventory was first developed in 1999 to establish a valid and reliable form of diabetes-specific quality of life. Inventory items were developed to address the issues that have the greatest impact on assessing patient self-care behaviors and satisfaction with diabetes care. Items are ranked on a 5-point Likert scale and are in two general formats. One format includes satisfaction with treatment and quality of life and is scored from 1 (very satisfied) to 5 (not very satisfied). The second format includes the frequency of adverse effects of diabetes itself or diabetes treatment and offers response options from 1 (never) to 5 (always). Therefore, higher scores on the DQL-BCI items and subscales include negative values indicating problem frequency or dissatisfaction. In order to use the DQL scale more efficiently in clinics, Burroughs et al. organized the 15-item DQL-BCI in 2004.
214360519|NCT02675387|DEVICE|Buzzy|Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
214360520|NCT02675387|DRUG|2%Lidocaine|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
214360521|NCT00833560|DRUG|Cyclophosphamide|In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
214360522|NCT00833560|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
214360523|NCT00833560|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
214360524|NCT00004070|BIOLOGICAL|IL-12|
214360525|NCT06111651|BEHAVIORAL|Parenting Intervention|parent training program with an added emphasis on ethnic-racial socialization and healthy lifestyle behaviors
214360526|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
214360527|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
214360528|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
214360529|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
214360530|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
214972661|NCT03186313|DRUG|Sofosbuvir + Daclatasvir + Ribavirin|Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg \& Ribavirin 800 mg for 12 weeks.
214972662|NCT03186313|DRUG|Dactavira|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
214972663|NCT03186313|DRUG|Sofosbuvir + Daclatasvir|Daily dose Sofosbuvir 400 mg \& Daclatasvir 60 mg for 12 weeks
214360531|NCT00643916|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to \<6 years of age)
214360532|NCT00708240|DRUG|Escitalopram|Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
214360533|NCT03971682|BEHAVIORAL|PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP program is a structured individualized program for detained youth based on Compassion Focused Therapy, aimed to develop a compassionate motivation in these youth.~Treatment As Usual Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation."
214360534|NCT03971682|OTHER|Treatment As Usual - TAU|Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
214360535|NCT05047055|DRUG|Isoniazid|Intensive Phase for 2 months and Continuation phase for 2 months dose: 75 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
214360536|NCT05047055|DRUG|Rifampicin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 150 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
214972664|NCT00122434|DRUG|BEA 2180 BR|
214972665|NCT00122434|DRUG|tiotropium|
214972666|NCT03819517|DRUG|Resveratrol|Over the counter supplementation
214360537|NCT05047055|DRUG|Pyrazinamide|Intensive Phase for 2 months only dose: 400 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
214360538|NCT05047055|DRUG|Ethambutol|Intensive Phase for 2 months and Continuation phase for 2 months dose: 275 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
214679315|NCT06521008|OTHER|Instructions including bladder training|The program teaches women skills and strategies to prevent incontinence, including bladder irritants like caffeine and discussing bowel habits to prevent constipation. It also teaches them how to respond adaptively to urgency, such as pause, sit down, relax, and contract pelvic muscles to diminish urgency and prevent urine loss. Once urgency subsides, they can proceed to the toilet at a normal pace. The program emphasizes the importance of educating patients about bladder irritants and bowel habits.
214972667|NCT03819517|OTHER|Placebo|Empty white colored soft vegetarian capsule
214972668|NCT05985746|OTHER|Augmented reality group|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a 20 minutes tutorial to introduce the HoloLens 2 and the TEACHANATOMY learning platform.~* Study session: The study session consists of three learning blocks of approximately 20 minutes each, plus a repetition block to assess the acquired knowledge. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
214360539|NCT05047055|DRUG|Moxifloxacin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 400 mg for 30 to 64 yrs AND 600 mg for 65 and above years of age.
214360540|NCT01791725|DRUG|ELND005|
214360541|NCT01791725|DRUG|Placebo|
214972669|NCT05985746|OTHER|Traditional learning group|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a presentation to introduce the study session.~* Study session: The study session consists of the learning resources most used by students: specific sections from four different neuroanatomy books, access to two websites, two 3D videos, and two online learning programs. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
214972670|NCT01932489|PROCEDURE|Biopsy of a metastatic lesion.|
214972671|NCT04854239|PROCEDURE|Half-guided implant placement|The surgery was performed under local anaesthesia in both groups, half-guided implant placement was carried out based on randomization.
214972672|NCT00005868|DRUG|cisplatin|
214972673|NCT00005868|DRUG|docetaxel|
214972674|NCT02507570|DRUG|Enzalutamide|used concomitantly
214972675|NCT02507570|RADIATION|Radium ra 223 dichloride|
214972676|NCT04789304|DRUG|BI 1595043|BI 1595043
214972677|NCT04789304|DRUG|Placebo|Placebo
214972678|NCT04789304|DRUG|Midazolam|Midazolam
214972679|NCT03159585|DRUG|TAEST16001|After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
214972680|NCT06958913|DRUG|Propofol group|In group P, 0.125 cc/kg saline infusion was administered in 10 minutes. Fentanyl was administered at a dose of 3 mcg/kg at 5 minutes of this application. Then propofol was administered until the eyelash reflex disappeared and the BIS value was 40. 0.6 mg/kg rocuronium was administered to facilitate intubation. All patients received 8 mg dexamethasone and lidocaine at a dose of 1 mg/kg.
214972681|NCT06958913|DRUG|Dexmedetomidine|In group DP, dexmedetomidine at a dose of 0.5 mck/kg was administered over 10 minutes. At the 5th minute of this infusion, fentanyl was administered at a dose of 3 mcg/kg. Propofol was added until the BIS value was 40. The patients received 0.6 mg/kg rocuronium, 8 mg dexamethasone, and 1 mg/kg lidocaine.
214972682|NCT03208816|BEHAVIORAL|symptom management program for chemotherapy patients|Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
214972683|NCT00927875|DRUG|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
214972684|NCT00927875|DRUG|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
214360542|NCT05715996|DEVICE|mixed reality guided localization|In this study, MR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
214679316|NCT06521008|OTHER|pelvic floor muscle training (PFMT)|The training program teaches bladder control through contracting the striated skeletal pelvic floor muscles (PFM). The women are instructed to empty their bladder, lie in a lithotomy position, and tighten their pelvic floor muscles. The duration of contraction and repetitions is gradually increased, totaling 20-30 minutes. The program is 3 sessions per week under supervision for 12 weeks, and each woman is instructed to perform exercises at home until they can do 300 contractions per day.
214360543|NCT05545982|PROCEDURE|Video laryngoscope with Miller approach|Miller approach indicates lifting epiglottis during laryngoscopy, which is the way of using Miller laryngoscope
214360544|NCT00512148|DEVICE|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
214360545|NCT01686789|DRUG|Pegylated interferon alpha-2a|
214360546|NCT03523468|PROCEDURE|uniportal sleeve lobectomy|central lung cancer sleeve resection performed by uniportal VATS
214360547|NCT03523468|PROCEDURE|open sleeve lobectomy|central lung cancer sleeve resection performed by open chest
214972685|NCT00927875|DRUG|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, \& 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
214972686|NCT03551795|BIOLOGICAL|Infusion of iNKT cells|The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) in one course of treatment.
215083840|NCT06684977|BEHAVIORAL|VR Photoscan|VR Photoscan creates immersive virtual environments by transforming real-world imagery into detailed 3D models. Using high-resolution images captured from a smartphone, these images are processed in 3D graphics software to sculpt realistic virtual scenes. The resulting 3D models are imported into a game engine, adding VR functionality, allowing users to navigate freely with six degrees of freedom. Interactive content, such as animated cars and people, can be added in real-time, while menu systems guide users through the experience. Environmental factors like lighting, weather, and time of day can be adjusted to simulate real conditions. Spatial 360° audio enhances immersion, providing sounds from various directions. This VR environment creation process is efficient and cost-effective, requiring no specialised equipment, and ensuring high-quality immersive experiences at minimal production time and cost.
214360548|NCT06413836|DEVICE|aPDT|Mechanized endodontic treatment using an endodontic rotatory device (DENTSPLY) will be used to prepare the root canals. Following, it will be applied the methylene blue solution in surfactant medium and after 1 minute a diode laser equipment (DMC THERAPY/EC, Sao Carlos, Brazil) will be used to shine light at a wavelength of 660nm, 100 mW (miliWatts) and irradiation time of 3 min. CaOH (calcium hydroxide) paste will be applied at the root canals canals as a long-term dressing for endodontic treatment..
214360549|NCT06413836|PROCEDURE|Endodontic treatment|Mechanized endodontic treatment using an endodontic rotatory device (DENTSPLY) will be used to prepare the root canals. Following, it will be applied the methylene blue solution in surfactant medium and after 1 minute a diode laser equipment (DMC, THERAPY/EC, Sao Carlos, Brazil) will be used with an aluminium foil at the tip of the equipment to block light and use during 3 min as study group. CaOH (calcium hydroxide) will be applied at the root canals as a long-term dressing for endodontic treatment.
214360550|NCT00221442|DRUG|Zonegran|zonegran (zonisamide)
214360551|NCT00221442|DRUG|sugar pill|fake pill
214360552|NCT03105674|DRUG|Multi-drug local anesthetics (Combination)|"1. Ropivacaine 0.5% - 30 ml~2. Ketorolac 30mg/ml - 1 ml~3. Kenalog 10 mg/ml - 5 ml~4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
214360553|NCT03105674|DRUG|Standard local anesthetics (Combination)|Marcaine and Lidocaine
214360554|NCT02904408|BEHAVIORAL|psychotherapy|Group psychotherapy
214360555|NCT00822133|DRUG|lidocaine|lidocaine 5%
214360556|NCT00822133|DRUG|ketamine|ketamine cream
214360557|NCT00822133|DRUG|non-active drug cream|will be put on the skin
214360558|NCT05527379|DEVICE|Virtual reality|"When the patient is ready to have the CIP procedure the tablet will be presented to him so that he can view and choose the immersive film that suits him best.~Before fitting the virtual reality helmet and the start of the film, the patient's anxiety will be evaluated by ENS on a scale of 0 to 10 . The patient's anxiety will also be evaluated at the end of the procedure.~The patient will be contacted by telephone by an investigator between D+1 and D+5 in order to reassess and remotely from the pose, his memorization of the gesture and to look for adverse events."
214360559|NCT02926248|DRUG|Colchicine|Colchicine is an anti-fibrotic and anti-inflammatory drug
214360560|NCT02926248|OTHER|Placebo|
214360561|NCT01223157|BIOLOGICAL|Biological data|Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.
214360562|NCT03705208|OTHER|Youth First Curriculum|A 25 session emotional resilience and health curriculum designed for 7th and 8th grade students.
214360563|NCT05482048|OTHER|Exercise as Airway Clearance Therapy (ExACT)|"Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET). The undertaking of ExACT at least once per day is expected.~Written and verbal instruction will be provided on the type, duration, frequency and intensity of exercise that is considered adequate replacement for routine chest physiotherapy. A compendium of allowable activity types, and the required times at different intensities that are considered to replace chest physiotherapy for ACT The research team will support exercise advice in line with standard care if subjects request this. The trial has no other changes to CF care. All medications, nutritional support and other treatments continue."
214360564|NCT06580535|OTHER|blood sample|Blood sample taking from patient for tissue culture
214679317|NCT06521008|OTHER|abdominal exercise|Women will engage in transverse abdominis exercises, focusing on drawing the lower abdominal wall towards the spine and pressing the lumbar region downward, repeated for 15 minutes per session, three times per week.
214972687|NCT03041441|DEVICE|MRI algorithm|MRI sequences have been developed that may be able to estimate intracranial pressure in a non-invasive fashion
214972688|NCT03041441|PROCEDURE|Lumbar puncture|Lumbar puncture according to the standard-of-care treatment plan.
214972689|NCT03041441|PROCEDURE|Epidural patching|Epidural patching will be performed to the standard-of -care treatment plan
214972690|NCT04353726|OTHER|Weight management|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
214972691|NCT00239720|DRUG|hOKT3gamma1(Ala-Ala)|Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle
214972692|NCT00239720|DRUG|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
214972693|NCT00807066|DRUG|Gefitinib|Gefitinib 250 mg/day
214972694|NCT00807066|DRUG|Platinum|Platinum based chemotherapy with cycles every 21 days
214972695|NCT03577249|DRUG|Dialysis Solutions|Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
214360565|NCT01444157|OTHER|Palliative homecare nursing|The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
214360566|NCT00780858|DRUG|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
214360567|NCT05065489|OTHER|No intervention|No intervention
214360568|NCT00677833|DRUG|Azithromycin plus Chloroquine|Combination of Azithromycin plus Chloroquine Azithromycin (\~30 mg/kg) + chloroquine (\~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
214360569|NCT00677833|DRUG|Artemether-lumefantrine|Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
214360570|NCT02975570|DRUG|Delamanid|Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
214360571|NCT02975570|DRUG|Linezolid|Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
214360572|NCT02975570|DRUG|Levofloxacin|Levoflaxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
214360573|NCT02975570|DRUG|Pyrazinamide|Pyrazinamide is a medication used in combination with other drugs such as isoniazid and rifampicin in the treatment of Mycobacterium tuberculosis.
214488327|NCT06189807|BEHAVIORAL|Decision aid|Enrolled participants will be sent the novel educational decision aid about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment, study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.
214488328|NCT06189807|OTHER|Standard handout|Enrolled participants will be sent the standard information about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment, the participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.
214488329|NCT06561009|DRUG|Anti-BAFFR CART|Anti-BAFFR CART
214488330|NCT05904054|BIOLOGICAL|SARS-CoV-2 DNA Vaccine (ICCOV)|The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.
214488331|NCT04782830|DEVICE|Accelerometer|A uniaxial accelerometer-based activity monitor (ActivpalTM) will be worn by participants on one of the thighs during the 7 days of the placebo and treatment periods.
214488332|NCT04782830|DRUG|placebo pill|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
214488333|NCT04782830|DRUG|Midodrine or atomoxetine pill|Either midodrine or atomoxetine at their regular dose.
214488334|NCT06435845|DRUG|Anti-(integrin beta-3) human monoclonal antibody|human monoclonal anti-human platelet antigen (HPA)-1a immunoglobulin G antibody
214360574|NCT02975570|DRUG|WHO MDR-TB regimen|The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
214360575|NCT00004549|PROCEDURE|Magnetic resonance imaging|
214360576|NCT00811343|BIOLOGICAL|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
214360577|NCT03948750|PROCEDURE|Aqueous humour sampling|Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting
214360578|NCT02978755|DRUG|GM102|GM102 escalating doses (phase1)
214360579|NCT02978755|DRUG|GM102 escalating doses|GM102 escalating doses combined with paclitaxel and carboplatin
214360580|NCT02978755|DRUG|GM102|GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)
214360581|NCT05805995|PROCEDURE|vertebral derotation|"* Incentive spirometer (Mediciser): Used for breathing exercises.~* Cycle ergometer ( Mijnhardt , St. Paul, MN): Used for lower limb exercise."
214360582|NCT04575168|DIAGNOSTIC_TEST|Spartan COVID-19 Test|A nasopharyngeal sample analyzed on the Spartan COVID-19 System.
214360583|NCT05072457|DEVICE|Roger On microphone|Roger On microphone transmitter which is used with Roger receivers and Audeo P hearing aids
214360584|NCT05072457|DEVICE|Roger Select microphone|Roger Select microphone transmitter which is used with Roger receivers and Audeo P hearing aids
214360585|NCT03852563|DRUG|BAY207543 (Bepanthol)|Product is applied to one hemiface.
214360586|NCT03852563|OTHER|Semisolid vaseline|Product is applied to one hemiface.
214360587|NCT03075579|DRUG|Medication Other|medication of atomoxetine
214360588|NCT03075579|DEVICE|motor measurement and saliva collection|motor measurement by actometer and saliva collection for measurement of saliva cortisol and saliva alpha amylase
214360589|NCT02001194|BEHAVIORAL|Individual Incentives|
214360590|NCT02001194|BEHAVIORAL|Team Incentives|
214360591|NCT02001194|BEHAVIORAL|Individual plus Team Incentives|
214360592|NCT00184548|DRUG|eptacog alfa (activated)|"Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours."
214360593|NCT00184548|DRUG|placebo|placebo
214360594|NCT02037048|DRUG|oxaliplatin|Given IV
214360595|NCT02037048|DRUG|leucovorin calcium|Given IV
214360596|NCT02037048|DRUG|fluorouracil|Given IV
214360597|NCT02037048|PROCEDURE|therapeutic conventional surgery|Undergo therapeutic conventional surgery
214488335|NCT03248492|DRUG|DS-8201a|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
214488336|NCT06466330|DEVICE|microparticles|inert microparticles
214488337|NCT06466330|PROCEDURE|embolization|Injection of inert microparticles in neovessels using a microcatheter
214488338|NCT06466330|PROCEDURE|sham embolization|injection of saline solution
214360598|NCT02037048|RADIATION|radiation therapy|Undergo radiation therapy
214360599|NCT02037048|DRUG|carboplatin|Given IV
214360600|NCT02037048|DRUG|paclitaxel|Given IV
214360601|NCT01579604|PROCEDURE|Nerve reconstruction|Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
214360602|NCT02606279|DRUG|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
214488339|NCT05877898|BEHAVIORAL|CHW Education|Participants will be invited to meet with the CHW to learn about eating healthier to reduce blood pressure and enhance quantity and quality of life.
214488340|NCT05877898|BEHAVIORAL|CHW Education and Navigation|Participants will be invited to complete all the CHW education arm material and be offered a menu of optional services for personalization including: (1) transportation to the grocery store (weekly for 4 weeks), (2) culturally adapted hypertension-tailored cooking recipes, (3) a virtual cooking class with food delivered to their door led by community partner, (4) access to UF IFAS's online library of healthy food cooking videos, and (5) in-store education on food labels, grocery shopping, and food resource management skills through the Cooking Matters at the Store curricula.
214488341|NCT06160102|OTHER|Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities|"Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project.~Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework.~Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation."
214488342|NCT06552091|OTHER|self-hypnosis sessions|3 self-hypnosis sessions over 3 weeks, one session per week to be practiced daily
214360603|NCT02606279|OTHER|Placebo|
214360604|NCT02925910|DEVICE|Shock absorbing wheelchair|2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
214360605|NCT02690974|DRUG|LCZ696 (sacubitril/valsartan)|All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
214360606|NCT01091155|DEVICE|ColonRing (Colorectal anastomosis)|Creation of a colorectal compression anastomosis
214360607|NCT03791164|BEHAVIORAL|The Pain Toolkit|the Pain Toolkit is a leaflet that encourages self management techniques for patients with chronic pain
214360608|NCT03791164|BEHAVIORAL|the Back Book|The Back Book is a patient information leaflet that offers information and advice about back pain
214360609|NCT05025657|BEHAVIORAL|ALLY|ALLY is a universal, school-based prevention program that takes place during the school day with individual students over 6 weeks.
214360610|NCT01355588|DRUG|Ketorolac Tromethamine|30 mg Ketorolac Tromethamine intranasal (IN)
214360611|NCT01355588|DRUG|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
214360612|NCT01355588|DRUG|Ketorolac Tromethamine with 5% Lidocaine HCl|30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
214360613|NCT01355588|DRUG|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
214360614|NCT00678314|DRUG|Ropivacaine 0.2%|10 ml
214360615|NCT00678314|DRUG|Ropivacaine 0.75%|3 ml
214360616|NCT00678314|DRUG|Normal saline|10 ml
214360617|NCT00002481|DRUG|cisplatin|
214360618|NCT00002481|DRUG|cyclophosphamide|
214360619|NCT00002481|DRUG|cytarabine|
214360620|NCT00002481|DRUG|dexamethasone|
214360621|NCT00002481|DRUG|etoposide|
214360622|NCT00002481|PROCEDURE|autologous bone marrow transplantation|
214360623|NCT00002481|RADIATION|radiation therapy|
214360624|NCT02184611|DRUG|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
214679318|NCT06521008|OTHER|Diaphragmatic Training|The therapist will instruct each woman to lie on her back with knees bent, place one hand on her upper chest and the other on her belly. They will breathe in slowly, tighten abdominal muscles, and exhale through pursed lips. Expiration should be relaxed and lightly controlled, and not forceful. Expiration should not be prolonged, and the woman should not initiate inspiration with accessory muscles or upper chest. The session will be repeated 3-4 times, lasting 5-10 minutes, and repeated three times per week for 12 weeks.
215083841|NCT06684977|BEHAVIORAL|Standard TF-CBT|Ehlers and Clark's model follows the general style of reliving (recommended by NICE) suggested by Foa and Rothbaum with some fluidity and in vivo exposure (i.e., trauma site visit). During the treatment process of reliving, clients are asked to close their eyes and intentionally recall the traumatic memories, i.e., relive the trauma in their mind in detail and narrate their experience in present tense, including recalling images, sensory experiences, thoughts, and feelings. VR-based PTSD treatments can promote emotional engagement and the process of trauma via providing visual, auditory, and haptic sensory cues.
214360625|NCT02184611|DRUG|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
214360626|NCT03201016|DIAGNOSTIC_TEST|Bone densitometry|Procollagen Type I Propeptides, alkaline phosphatase, Crosslinked Telopeptides of Type I Collagen
214360627|NCT06150651|OTHER|CAR T-cell therapy|1x10\^6 cells/kg CD-19 CAR-T cells
214360628|NCT01900938|PROCEDURE|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
214360629|NCT01900938|PROCEDURE|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
214360630|NCT01900938|DRUG|Midazolam|
214360631|NCT01900938|DRUG|Propofol|
214360632|NCT06202833|DEVICE|Acupuncture with regulating immunity as the core of treatment|The patient was supine, the acupuncture points were disinfected with 75% ethanol, and the acupuncture points on the head and neck were first acupuncture, and then the acupuncture points on the abdomen and limbs. baihui: When the 1.5 inch millimeter needle is needled, the tip of the needle and the acupoint are at a 15-30 ° Angle, and the needle is about 1 inch flat along the subcutaneous area. The twisting speed is about 200 times per minute, and the stitches are once every 15 minutes, and each stitch is about 30 seconds. zhongwan, tianshu: 1.5 inch needle straight puncture 1 inch, small amplitude lifting and twisting. guanyuan, qihai: 1.5 inch millimeter needle downward oblique puncture 1 inch, small amplitude lifting and twisting. The above acupoints were measured by obtaining qi, and the needles were retained for 30min, once a day.5 days a week for 4 weeks.Twenty days in total.
214360633|NCT06202833|DEVICE|Needles that are not on acupoints|In this group, acupuncture treatment was performed at 1cm side of the selected points of the Tongyuan acupoint acupuncture group.The piercing Angle is the same as the test group, only piercing, not twisting.Once a day, 5 days a week for 4 weeks.Twenty days in total.
214360634|NCT00522301|DRUG|sorafenib tosylate|
214360635|NCT00522301|OTHER|immunoenzyme technique|
214360636|NCT00522301|OTHER|immunohistochemistry staining method|
214360637|NCT00522301|OTHER|laboratory biomarker analysis|
214360638|NCT00522301|OTHER|pharmacological study|
214360639|NCT04646655|DRUG|Enoxaparin|subcutaneous injections
214360640|NCT01666951|DRUG|LCP-Tacro tablets|Tacrolimus
214360641|NCT01666951|DRUG|Prograf|Tacrolimus
214360642|NCT00772785|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
214360643|NCT04613908|DEVICE|neuro muscular electro stimulation|We used a commercial equipment of electro stimulation with a pulse width of 300 micro seconds, a frequency of 50 Hz, with symmetrical balanced biphasic rectangular wave and with an intensity of up to 80 milliampere.
214360644|NCT04613908|OTHER|Early Mobilization protocol|"The protocol consisted in applying a specific treatment based on different levels of treatment to each subject. Admission to them was carried out according to the maximum capacity of each subject, the conditions of each level being the following:~* Level 1: MRC (shoulder) \<3 + MRC \<3 (hip).~* Level 2: MRC (shoulder) ≥ 3 + MRC (hip) \<3.~* Level 3: MRC (shoulder) ≥ 3 + MRC (hip) ≥ 3 + sitting on the edge of the bed without assistance (minimum 15 minutes).~* Level 4: Standing without assistance and walking with or without assistance."
214360645|NCT04613908|OTHER|standard care or usual rehabilitation|routine, non-protocolized rehabilitation treatment performed by the physiotherapist assigned to intensive care
214360646|NCT06083025|DEVICE|CleaRing|The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate. The device is implanted into the capsular bag after the extraction of the crystalline lens and prior to implantation of the IOL. The device is manufactured by Hanita Lenses from a hydrophilic acrylic co-polymer which is being used for the production of Intra-ocular lenses.
214360647|NCT02885987|DEVICE|AmplifEYE|AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
214488343|NCT06337474|DRUG|anti-CD19 CAR NK cells (KN5501)|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3. Doses of 9×10\^9 cells, 13.5×10\^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the dose-escalation strategy
214679319|NCT01313104|PROCEDURE|colposcopy|Undergo colposcopy
214488344|NCT02224729|DRUG|Bendamustine hydrochloride|Given IV
214488345|NCT02224729|DRUG|Bortezomib|Given SC
214488346|NCT02224729|DRUG|Dexamethasone|Given PO
214488347|NCT03767335|DRUG|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle
214488348|NCT03767335|DRUG|Trastuzumab|Trastuzumab solution for infusion administered weekly via IV
214360648|NCT06221189|BEHAVIORAL|ACT-CSP|The ACT treatment will consist of three 45 to 60-min weekly sessions to be delivered to the caregiver in an individual format via online videoconferencing application e.g. ZOOM or WhatsApp within 3 weeks. The ACT-CSP can be delivered via face-to-face on request. Each session has a specific content with pre-planned materials and mindfulness exercises and metaphors. Psychological-based homework will be assigned at the end of each session. The components of ACT process will be emphasized in the intervention programme, which include perspective taking, self-as-context and defusion (i.e. recognizing worry thoughts as thoughts only), identifying values and acceptance of present-moment experience with respect to the values, and committed action.
214360649|NCT06078605|OTHER|Nicotinamide(Mitovita)|Nicotinamide(VitaminB3)
214360650|NCT06078605|OTHER|Placebo|Placebo
214360651|NCT05339048|GENETIC|Genetic risk variants|Exposure: Genetic predisposition to complex diseases.
214488349|NCT03767335|DRUG|Fulvestrant|Fulvestrant solution for injection administered monthly via IM (only for HR-positive postmenopausal women)
214488350|NCT05740241|OTHER|Elderly|A group of participants with physical activity (protocolized)
214488351|NCT03705390|DRUG|ILB®|Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks
214488352|NCT06648135|PROCEDURE|Immediate implants with bone grafts|Immediate implants with bone grafts
214488353|NCT06648135|PROCEDURE|Immediate implant placed without bone grafts or any grafting substitutes in the labial gap|Immediate implant placed without bone grafts or any grafting substitutes in the labial gap
214488354|NCT05327270|DRUG|Nivolumab|Given by IT
214488355|NCT04832100|DRUG|Pregabalin 150mg, imipramine 25mg|Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
214488356|NCT05345561|OTHER|Clinical data collection|Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
214488357|NCT03510104|DRUG|MRX-2843|MRX-2843 capsules
214360652|NCT05339048|OTHER|Diet|Exposure: dietary intake of unhealthy foods known to be associated with higher prevalence of respiratory and cardiovascular diseases.
214360653|NCT05339048|BEHAVIORAL|Physical activity|Exposure: frequency of moderated or intense physical activity, and daily exposure to sedentary behavior.
214488358|NCT06106191|BEHAVIORAL|Mindfulness meditation|Ordinary activities like breathing, eating, and walking are turned into a meditation by creating greater awareness of the moment-to-moment sensations, emotions, thoughts and behaviors that arise during these activities.
214488359|NCT06106191|OTHER|Perspectives on pain|Understanding pain from a mind-body perspective and viewing pain as a stressor on physical sensations, thoughts, emotions, and behavior.
214488360|NCT06106191|OTHER|Discussion|Discussion on patients' use of mindfulness to work with pain and pain-themed meditations.
214488361|NCT05116462|DRUG|Pemetrexed|500 mg/m2 D1 IV Q3W
214488362|NCT05116462|DRUG|Carboplatin|AUC 5 or 6 mg/ml/min D1 IV Q3W
214360654|NCT05339048|OTHER|Socio-economic conditions|Exposure: socio-economic vulnerability indexes associated with higher prevalence of respiratory and cardiovascular diseases (including household conditions, accessibility to health care services, among others).
214360655|NCT04272580|DRUG|Control group|No preload was given before spinal anesthesia.
214488363|NCT05116462|DRUG|Paclitaxel|175 or 200 mg/m2 D1 IV Q3W
214488364|NCT05116462|DRUG|Sintilimab|200 mg D1 IV Q3W
214488365|NCT05116462|DRUG|Cisplatin|75 mg/m2 D1 IV Q3W
214488366|NCT05116462|DRUG|Nab paclitaxel|100 mg/m2 D1, 8, 15 IV Q3W
214360656|NCT04272580|DRUG|4 ml/kg group.|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
214360657|NCT04272580|DRUG|8 ml/kg group.|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
214360658|NCT04272580|DRUG|12 ml/kg group.|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
214360659|NCT02430402|OTHER|Rehabilitation in warm climate|
214360660|NCT02366910|DEVICE|omafilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
214360661|NCT02366910|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
214488367|NCT05116462|DRUG|Placebo|20 ml D1 IV Q3W
214488368|NCT06269432|DRUG|Precision Antiplatelet Therapy Trial Group|Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.
214488369|NCT06269432|DRUG|Traditional Antiplatelet Therapy Control Group|No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.
214488370|NCT05386615|DEVICE|Body System - Functional|MR-Guided Focused Ultrasound
214488371|NCT06549296|DRUG|RD06-04 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
214488372|NCT03725670|GENETIC|Intrathecal and intravenous LV gene therapy|Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 transduction units/ml which carry a normal ARSA gene
214488373|NCT05988957|OTHER|Semi-structured interviews using an IRB-approved interview guide|A single, semi-structured interview will be conducted using an IRB-approved interview guide. The interviews will be approximately 30 minutes total.
214488374|NCT04732962|DEVICE|AposHealth|"AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately."
214360662|NCT01792479|DRUG|BIND-014|
214488375|NCT04732962|PROCEDURE|Total Knee Replacement (TKR)|A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
214488376|NCT02055534|OTHER|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
214488377|NCT02055534|OTHER|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
214488378|NCT04495621|DRUG|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle.
214488379|NCT04495621|DRUG|Cetuximab|Cetuximab solution for infusion administered weekly via intravenous infusion.
214488380|NCT06199986|BEHAVIORAL|ADT Order Check Attestation (Or)|Clinical reminder order check in electronic health record
214488381|NCT06199986|BEHAVIORAL|Provider Script (Sc)|Provider script added to progress note in electronic health record
214488382|NCT04932525|PROCEDURE|Biopsy|Blood and tumor samples for Genetic Profiling research
214488383|NCT04967131|OTHER|PNF exercises|PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
215083842|NCT06689735|OTHER|schroth exercises|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
214360663|NCT03331718|DRUG|PGA felt reinforcement|During pancreaticojejunostomy, 1) a 0.3 mm thick PGA felt (Neoveil®, Gunze, Japan) is pasted on the ventral side and the dorsal side of pancreatic parenchyma, through which suture between pancreatic parenchyma and jejunum is performed. 2) Before abdominal closure (after completion of all reconstruction, after washing in the abdominal cavity), a 0.15 mm thick PGA felt is further covered around the anastomotic site and fibrin glue is sprayed.
214360664|NCT01907191|DRUG|liposomal bupivacaine|(Ultrasound guided injection of liposomal bupivacaine) for patients undergoing hip arthroscopy
214488384|NCT03553810|DRUG|Entresto|Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
214488385|NCT03553810|DRUG|Valsartan|Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
214488386|NCT02834884|GENETIC|RP-1828 IMMUcan|WES, lcWGS and RNAseq, multiplex IF and IMC
214488387|NCT02834884|GENETIC|RP-1759 AYA/TYA|WES, RNAseq and EPIC array
214488388|NCT02834884|GENETIC|RP-1843 Arcagen|NGS panel
214488389|NCT02834884|GENETIC|RP-1920 BioRadon|NGS panel
214488390|NCT06295354|OTHER|No intervention, we just study 'aging'|No intervention, we just study 'aging'
214488391|NCT05089084|DRUG|Plozasiran|ARO-APOC3 injection
214488392|NCT05089084|DRUG|Placebo|sterile normal saline (0.9% NaCl)
214488393|NCT06598371|DRUG|Cyclophosphamide|Given by IV
214488394|NCT06598371|DRUG|Fludarabine|Given by IV
214488395|NCT06598371|DRUG|KSQ-004EX|Given by IV
214488396|NCT06598371|DRUG|Interleukin-2|Given by IV
214488397|NCT03766126|BIOLOGICAL|CART123 cells; cyclophosphamide; fludarabine|"CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2.~The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10\^6 CART123 cells/kg for Cohort 1a, 5x10\^6 CART123 cells/kg for Cohort 1b, or 2x10\^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10\^5 CART123 cells/kg."
214488400|NCT06559462|OTHER|Focus Group|Open-ended group discussion of potential nudges to elicit constructive feedback on nudge development.
214488401|NCT06559462|OTHER|Discrete Choice|Survey involving choice between two potential nudges to elicit feedback on which nudge version is considered superior.
214488402|NCT05352022|BEHAVIORAL|Monthly Unconditional Financial Incentive|No requirements will be placed on how or where funds will be spent.
214488403|NCT05352022|BEHAVIORAL|Weekly Food Purchasing Financial Incentive|Incentive for healthy food purchases
214488404|NCT05352022|BEHAVIORAL|Glycemic Control Financial Incentive|Incentive for absolute drop in HbA1c
214488405|NCT05352022|BEHAVIORAL|Diabetes Education|mailed education information
214488406|NCT06315933|PROCEDURE|General anesthesia|General anesthesia including inhaled and intravenous
214679320|NCT01313104|OTHER|cervical Papanicolaou test|Undergo cervical Pap smear
214679321|NCT01313104|PROCEDURE|screening method|Undergo anal Pap smear
214679322|NCT01313104|PROCEDURE|screening method|Undergo high resolution anoscopy
214488410|NCT05150145|RADIATION|Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.|Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .
214488411|NCT06839001|PROCEDURE|cryoablation|"Two devices can be used to perform cryoablation: Cryocare® and ProSense IceCure®:~* Cryocare® - This procedure utilizes two types of gases: argon gas for freezing and helium gas for thawing.~* ProSense IceCure® - This procedure uses extremely low temperatures generated by liquid nitrogen (LN2) to freeze and destroy the target tissue, without the need for an additional gas."
214488412|NCT06839001|PROCEDURE|Breast Surgery (Lumpectomy or Mastectomy)|Surgery can be performed as lumpectomy or mastectomy and axillary surgery, preferably sentinel lymph node biopsy.
214488413|NCT05579626|DRUG|high-intensity statin arm|•high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily
214488414|NCT05579626|DRUG|low-intensity statin plus ezetimibe|•low-intensity statin plus ezetimibe strategy (experimental arm): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
214488415|NCT02944487|DRUG|Lucerastat|Hard gelatin capsule for oral administration containing lucerastat
214488416|NCT02944487|DRUG|Placebo|Matching placebo capsules
214488417|NCT05118919|BIOLOGICAL|BGP-014|Oral capsule containing lyophilised Lactobacillus reuteri
214488418|NCT05118919|BIOLOGICAL|Placebo|Oral capsule
214488419|NCT04757753|DEVICE|ready-to-use root canal sealer: PA1704|The participant will be treated with the ready-to-use root canal sealer (PA1704) in combination with gutta percha.
214488420|NCT04757753|DEVICE|root canal sealer: BioRoot™ RCS|The participant will be treated with BioRoot™ RCS sealer in combination with gutta percha.
214488421|NCT06965218|DIAGNOSTIC_TEST|Trans thoracic echo doppler|Aortic valve sclerosis severity study be transthoracic echo doppler
214488422|NCT06964906|PROCEDURE|HIFU|HIFU therapy is administered to the targeted breast lesion site.
214360665|NCT01907191|DRUG|Bupivacaine|(around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy
214488423|NCT06964906|DRUG|Toripalimab|240 mg, IV infusion, Q3W
214488424|NCT06964906|DRUG|nab-Paclitaxel (nab-P)|125 mg/m2, IV infusion, QW
214488425|NCT06964906|DRUG|Epirubicin (E)|90 mg/m2, IV infusion, Q3W
214488426|NCT06964906|DRUG|Cyclophosphamide (C)|600 mg/m2, IV infusion, Q3W
214488427|NCT06964971|DRUG|Luspatercept|The recommended starting dose of luspatercept is 1.5 mg/kg administered subcutaneously (SC) once every 3 weeks. Treatment response should be evaluated and dosage adjusted after at least 3 treatment cycles (9 weeks).
214488428|NCT06964971|DRUG|Luspatercept combine with Deferasirox|"The recommended starting dose of luspatercept is 1.5 mg/kg administered subcutaneously (SC) once every 3 weeks. Treatment response should be evaluated and dosage adjusted after at least 3 treatment cycles (9 weeks).~For patient with platelet counts \< 50×10⁹/L:~Deferasirox dosage: 8-10 mg/kg/day, orally.~For platelet counts ≥ 50×10⁹/L:~Deferasirox dosage: 20 mg/kg/day, orally. Discontinue deferasirox if serum ferritin drops below 500 μg/L."
214488429|NCT06965647|BEHAVIORAL|Partner-Conducted Fetal Heart Sound Measurement|Expectant fathers in the intervention group were trained in basic Leopold maneuvers and fetal heart sound measurement using a Doppler device. Under the supervision of a midwife, fathers located the fetus's back, applied gel, and measured the heart sound during prenatal visits at 28-32 and 33-38 weeks of gestation.
214488430|NCT06965062|PROCEDURE|Deep cervical lymph node to venous bypass (DCLNV-BP)|Participants will under bilateral deep cervical lymph node to venous bypass procedure under general anaesthesia.
214488431|NCT06965673|BEHAVIORAL|Visual exploration training|Visual exploration of natural scenes guided by closed-loop auditory biofeedback through eye-tracking
214488432|NCT06965673|BEHAVIORAL|Standard neuropsychological rehabilitation|Standard rehabilitation delivered at the IRCCS San Camillo hospital
214679323|NCT05828238|DRUG|[18F]SF-DEVD-2|Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
214679324|NCT05828238|DRUG|[18F]-FDG|Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
214972696|NCT01503554|BEHAVIORAL|Combined Social Worker and Pharmacist Program|"Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.~Pharmacist will be available to patients should they have any medication-related questions post-discharge"
214360666|NCT05527366|OTHER|Vagus stimulation|The Vagus Stimulation Group received auricular vagus stimulation for a total of 15 sessions of 25 minutes 5 days a week. The patients were applied with vagustim device consisting of TENS device with electrodes placed bilaterally in the outer ear with headphones that can be selected according to ear size. During the application, the gel was used to avoid causing any damage and to ensure conductivity. It is placed so that tragus and konkaya are facing. The pulse duration of the TENS device is less than 500 microseconds, the frequency is 10 Herzt, the module was applied in TENS mode and in the form of a biphasic asymmetric wave.
214488433|NCT06965491|DIETARY_SUPPLEMENT|Placebo Supplement|"Placebo supplement:~Oral supplement containing: 16.4 grams of medium chained triglycerides, 1mM or sucrose octaacetate and water"
214488434|NCT06965491|DIETARY_SUPPLEMENT|Ketone ester supplement|Ketone ester supplement Oral supplement containing: 25 grams of pure (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate ketone monoester drink
214488435|NCT06965127|DEVICE|NNP-LE|Networked NeuroProsthesis - Lower Extremity Configuration (NNP-LE) measuring physiologic command signals and delivering neural stimulation to intramuscular and nerve cuff electrodes for trunk and leg muscle assistance.
214488436|NCT06966310|OTHER|Prone position|depending on tolerance, the objective is to spend as much time as possible, up to 16h and beyond, in prone position per period of 24 hours. For each session the patients will be encouraged to stay as long as possible in the prone position (i.e. ideally 4-8 hours each session).
214488437|NCT06965075|BEHAVIORAL|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
214488438|NCT06965270|BEHAVIORAL|Standardized clinical intervention|"This manualized intervention consists of 8 sessions of evidence-based treatments for substance abuse and mental health problems.~Session 1: Introduction, Psychoeducation, Assessment and Safety: Introduces what the patient's clinical assessment suggests about strengths and needs.~Session 2: Relaxation, Mindfulness and cognitive distortions in CBT. Session 3: Getting started in Cognitive Restructuring (CR): thought challenge and action plan.~Session 4: Craving management practice: includes challenging and replacing thoughts that lead to drug and alcohol use.~Session 5: CR practice exercises and motivation: introduction to risk behaviors and triggers for drug and alcohol use. Relapse prevention.~Session 6: Assertiveness and refusal techniques. Session 7: Problem solving, practice and reinforcement: CR skills, relaxation and relapse prevention applied in current circumstances.~Session 8: Care plan and end of program."
214972697|NCT01503554|BEHAVIORAL|No Intervention: Usual Care|Patient receives usual care upon discharge from the hospital.
214360667|NCT05527366|OTHER|Consevative treatment|A total of 15 sessions 5 days a week, 20 minutes of hotpack, 20 minutes of TENS, 5 minutes of 1,3 watt/cm2 ultrasound consisting of a total of 25 minutes of treatment was applied to the neck area.
214360668|NCT01843426|DRUG|Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
214360669|NCT02623322|DRUG|MHAA4549A|MHAA4549A will be administered as a single dose by IV administration.
214488439|NCT06965270|BEHAVIORAL|Internet/App intervention|"Using an already developed Internet/App platform (MeMind), patients will have access to the same therapeutic components as in the standardized intervention arm, arranged in sessions by modules.~Components will be released weekly and reminded via push notifications. Patients will also receive two counseling calls at weeks 1 and 8 to help with technical issues and review problems with the program modules."
214488440|NCT06965270|BEHAVIORAL|Treatment as usual|Patient will recieve the usual intervention provided by the Health system
214488441|NCT01313559|DRUG|Pasireotide|Given IM
214972698|NCT06159504|DRUG|sofosbuvir/velpatasvir (SOF/VEL)|400mg of SOF and 100mg of VEL self administered daily as a tablet.
214972699|NCT06159504|DIAGNOSTIC_TEST|Shortened read time of rapid diagnostic test for hepatitis C virus.|Administered once during hepatitis C testing. Test is read after 5 minutes rather than its usual time of 20 minutes.
214972700|NCT00215917|DRUG|D-serine 2100 mg daily|
214360670|NCT02623322|DRUG|Placebo|Placebo will be administered as a single dose by IV administration.
214360671|NCT01196455|DRUG|Capecitabine and Mitomycin C|"* Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks~* Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks"
214360672|NCT06335264|DEVICE|Watch HOP|A multisensorial wearable smartwatch that measures actigraphy (motion), skin temperature, heart rate variability (PPG), electrodermal activity, and voice (via App)
214360673|NCT01278355|DEVICE|Ear acupuncture|Ear acupuncture
214488442|NCT01313559|DRUG|Everolimus|Given PO
214488443|NCT01313559|OTHER|Laboratory biomarker analysis|Correlative studies
214488444|NCT04899739|DIAGNOSTIC_TEST|Echoendoscopy|Peripancreatic lymph nodes and at a distance from the pancreas assessment by endoscopic ultrasound, elastography an doppler to record their anatomical location and characteristics. All lymph nodes suspected of metastatic disease will be marked with sterile black ink.
214488445|NCT02514915|RADIATION|Stereotactic Radiosurgery|Radiation therapy
214488446|NCT06966102|DRUG|Lidocaine group|25ml of lidocaine hydrochloride 2% will be added to 25 ml of standard saline 0.9% solution in a 50ml syringe to be infused via a syringe pump. The resultant concentration will be 10mg/ml. According to the calculated study drug dose, each patient will receive 0.2ml/kg/h
214488447|NCT06966102|DRUG|Magnesium group|a 50ml syringe will be filled with magnesium sulfate solution (100mg/ml) to be infused via a syringe pump. According to the calculated study drug dose, each patient will receive 0.2ml/kg/h
214488448|NCT06966102|DRUG|Control group|a 50ml syringe will be filled with a standard saline 0.9% solution to be infused via a syringe pump. Each patient will receive 0.2ml/kg/h
214488449|NCT06823661|DEVICE|transcutaneous electrical nerve stimulation (TENS)|"A TENS 3000-unit, which is FDA and health Canada approved (Licence No.: 95655) and operated by a small 9V block battery will be used. Potential participants will receive a detailed written explanation of the TES protocol and a brief demonstration of how it works, including the feeling produced by the skin stimulator. Patient-specific TES thresholds will be determined after informed written consent for study participation is obtained. Surface electrode pads will be placed on the ventral surface of the forearm, and 1-Hz pulses will be gradually administered with an increase in current. Patients will be asked to report when they first feel the stimulation and when it becomes annoying. The milliamp current associated with these two levels of stimulation will be recorded on the participant's baseline data collection form. The annoying thresholds for all study participants will be used to deliver stimuli in response to respiratory depression in the PACU."
214488450|NCT05719883|DEVICE|Maurora® Sirolimus Eluting Stent System|The Maurora® for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
214488451|NCT05719883|DEVICE|APOLLO™ Intracranial Stent System|The Apollo stent system comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
214488452|NCT05546567|DIETARY_SUPPLEMENT|Nicotinamide Riboside|1200mg x1 Nicotinamide Riboside
214488453|NCT06462027|DRUG|Packed Red Blood Cells (1 unit)|500 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
214488454|NCT06462027|DRUG|Packed Red Blood Cells (2 units)|1000 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
214972701|NCT00464022|DEVICE|Carbon dioxide|
214972702|NCT04339049|DRUG|lidocaine spray|four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
214972703|NCT04339049|DRUG|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
214972704|NCT04339049|DRUG|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
214972705|NCT03259958|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
214972706|NCT03259958|DRUG|Aricept|Aricept Tablet
214972707|NCT06472947|DEVICE|ULM and MSOT|transplanted kidney will be examined non-invasively with ULM and MSOT
214972708|NCT00710931|DEVICE|AcrySof ReSTOR Aspheric IOL model SN6AD1|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL) following cataract removal.
214972709|NCT01484951|DRUG|Brinzolamide 1% and timolol 0.5% fixed combination eye drops|
214972710|NCT01591798|PROCEDURE|Robotic surgery|Robotic assisted rectal resection
214360674|NCT03563716|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
214360675|NCT03563716|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
214360676|NCT03563716|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
214972711|NCT01591798|PROCEDURE|Laparoscopic surgery|Laparoscopic assisted rectal resection
214972712|NCT05319717|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food with heat stabilized rice bran|Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
214972713|NCT05319717|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (no rice bran)|Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
214360677|NCT01828580|DEVICE|active laparoscope positioner (AutoLap)|
214360678|NCT06459947|PROCEDURE|Free gingival graft procedure|The palatal area is anesthetized using local anesthesia. The free gingival graft (FGG) is taken from the donor site with a scalpel.
214360679|NCT05595668|BEHAVIORAL|Prism Adaptation - 15-degree prism goggles|Patients in the experimental condition will wear prism goggles while completing an iPad-administered aiming task. The prisms will shift the patients' vision 15 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out for ten sessions for 15 minutes a day, over the span of two weeks.
214360680|NCT05595668|OTHER|Prism Adaptation - 5-degree prism goggles|5-degree goggles are worn instead of the 15-degree prism goggles, while completing the same tasks as those assigned to the 15-degree condition.
214360681|NCT00005041|DRUG|tipifarnib|
214360682|NCT03326505|BIOLOGICAL|Umbilical cord derived Mesenchymal Stem Cells|Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients
214360683|NCT03326505|OTHER|Supervised physical therapy|A combined physical therapy program of Balance, strengthening and endurance exercises
214360684|NCT04796441|BIOLOGICAL|CAR-γδT|Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
214360685|NCT02331381|DEVICE|Magnetic resonance imaging|
214360686|NCT03775200|DRUG|Psilocybin|Dose-finding
214360687|NCT06385743|OTHER|Neuromuscular Training-based Exercise Program|Neuromuscular training has been accepted as an effective treatment modality to improve the neurophysiological states of the joints for coordinated work. In addition to shoulder strength, stabilization and kinetic chain exercises, this program includes internal and external focus (sound, touch, light, dual task, etc.), sport-specific exercises and plyometric exercises (speed, agility). All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks.
214360688|NCT06385743|OTHER|''Thrower's Ten'' Exercise Program|"''Thrower's Ten'' Exercise Program includes 10 different shoulder strengthening and shoulder stabilization exercises in a diagonal pattern. Advanced Thrower's Ten exercises that include kinetic chain exercises (covering more than one joint) in addition to shoulder exercises planned to be used in the late stages of rehabilitation into the program, progression is considered after the 3rd week will be added. All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks."
214360689|NCT05100290|DIAGNOSTIC_TEST|Hyperventilation Provocation Test (HPTest)|"During the HPTest, the subject is comfortably seated in a chair with armrests and breathes in a mouthpiece with a salivary collector and a nasal clamp. Parameters of ventilation and gas exchange are analyzed via an Oxycon ProTM (SN808008) with TripleV-Volume Sensor digital(Jaeger).~The HPTest begins with a 3-minutes adaptation phase during which the patient is asked to breathe normally. During the 3-minutes of voluntary hyperventilation phase, the patient is asked to increase his tidal volume and support a breath rate of at least 30/min in order to reduce his PETCO2 by at least 50%. During the recovery phase of the HPTest, the patient is invited to regain a natural breathing for 5 minutes, without guidance on tidal volume or breath rate."
214360690|NCT01568099|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
214360691|NCT01568099|OTHER|Control|Untreated control
214360692|NCT04586725|OTHER|Encouragement a one minute intervals|Patients will perform the six exercise tests with encouragement at one minute intervals
214360693|NCT04586725|OTHER|Encouragement a two minute intervals|Patients will perform the six exercise tests with encouragement at two minute intervals
214360694|NCT00003125|BIOLOGICAL|ALVAC-CEA vaccine|
214972714|NCT03915834|DEVICE|Endovascular treatment|Mechanical thrombectomy and/or Aspiration
214972715|NCT02600117|DRUG|Tenofovir disoproxil fumarate|300 mg, oral, once a day
214972716|NCT01608165|PROCEDURE|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
214972717|NCT01608165|PROCEDURE|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
214972718|NCT01608165|PROCEDURE|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
215083843|NCT06689735|OTHER|pilates exercises|The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively.
214972719|NCT02948712|BEHAVIORAL|Distress Screening Thermometer|Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
214360695|NCT00003125|BIOLOGICAL|aldesleukin|
214360696|NCT00003125|BIOLOGICAL|sargramostim|
214360697|NCT00003125|BIOLOGICAL|vaccinia-CEA vaccine|
214679325|NCT05447377|BIOLOGICAL|SII Yellow Fever Vaccine|"SII YF vaccine:~Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-213 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 5 mg of sorbitol per dose."
214679326|NCT05447377|BIOLOGICAL|STAMARIL®|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL® is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-204 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 8 mg of sorbitol (E420) per dose."
214679327|NCT03002389|DRUG|Anoro Ellipta|inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
214679328|NCT03002389|DRUG|Arnuity Ellipta|inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
214679329|NCT02805907|DRUG|Calcifediol|
214679330|NCT02805907|DRUG|Placebo|
214972720|NCT02948712|BEHAVIORAL|NCCN Guidelines: Distress management|Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
214972721|NCT02737267|BEHAVIORAL|Moderately high protein diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction."
214972722|NCT02737267|BEHAVIORAL|Low fat diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat"
214360698|NCT04605978|DRUG|S95011 concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
214360699|NCT04605978|DRUG|Placebo concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
214360700|NCT02660723|OTHER|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
214360701|NCT05562479|BIOLOGICAL|Sars Cov 2 infection|Donors recovered from Sars Cov 2 Infection
214360702|NCT05562479|BIOLOGICAL|Sars Cov 2 vaccination|Egg Donors vaccinated
214360703|NCT03019354|DEVICE|high-flow nasal oxygen|Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.
214360704|NCT03019354|DEVICE|Oxygen mask|Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
214360705|NCT06413251|OTHER|Boxing Training|The boxing training intervention will consist of three exercise sessions per week on nonconsecutive days for six weeks. Participants will be instructed to complete 10 rounds of three minutes with a one-minute resting period interspersed. Four rounds will consist of heavy bag punching (e.g. straight, jab, hook) at 60% VO2max and three rounds at 90-95% VO2max, while the remaining 3 rounds will be focused on mitt work at 60% VO2max.
214360706|NCT06413251|OTHER|Control flexibility|The control group will perform three days per week 10 minutes of dynamic articular movement, five minutes of uni pedal stance, and five minutes of stretching of the upper limbs for six weeks.
214360707|NCT02834156|OTHER|LP in a seated position then LP in a lying position|
214360708|NCT02834156|OTHER|LP in a lying position then LP in a seated position|
214360709|NCT02003079|BEHAVIORAL|Cystic Fibrosis Questionnaire (Revised) for Teens/Adults|
214360710|NCT03813238|DRUG|TEV-50717|Dosage ranging from 6 mg to 48 mg.
214360711|NCT03813238|DRUG|Placebo|Dosage ranging from 6 mg to 48 mg.
214360712|NCT02484157|DEVICE|Hemochron|Activated coagulation time was checked serially by Hemochron Jr.
214360713|NCT02484157|DEVICE|ACT Plus|Activated coagulation time was checked serially by ACT Plus.
214360714|NCT02583425|DRUG|DFN-11 Injection|
214360715|NCT06956963|OTHER|Partial Sleep Deprivation|30% reduction in habitual time in bed
214360716|NCT03037632|BEHAVIORAL|Family Heart Talk Booklet|
214488455|NCT06462027|OTHER|Saline|Control subjects will receive 500mL of normal saline intravenously.
214488456|NCT05086393|DRUG|Duloxetine|Patients will be randomized to receive Duloxetine or a placebo.
214488457|NCT05086393|DRUG|Placebos|Patients will be randomized to receive Duloxetine or a placebo.
214488458|NCT06965244|DRUG|Lenalidomide|Lenalidomide with oral dose of 5 mg/day during 16 weeks associated with low-dose aspirin of 100 mg/day except for patients already receiving anticoagulant therapy
214360717|NCT06788184|DEVICE|Virtual Reality (VR) Game for Auditory Processing|"The Virtual Reality (VR) Game is a novel auditory rehabilitation tool designed to enhance central auditory processing skills in children with cochlear implants. This intervention features a restaurant simulation environment where participants perform auditory tasks such as identifying verbal orders, recognizing speech in noisy environments, and matching auditory cues to visual inputs.~Dosage Form: Virtual reality sessions conducted through a VR headset (Oculus Meta Quest 3).~Frequency: Once per week. Duration per Session: 30 minutes per session. Total Duration: Four weeks (4 sessions). Complexity Levels: Tasks increase in complexity over time, starting with simple auditory cues in quiet environments and progressing to more challenging scenarios involving background noise and multitasking.~The VR game is specifically designed to replicate real-world auditory challenges in a controlled and engaging virtual environment, providing participants with tailored tasks to improve auditory atten"
214360718|NCT06788184|BEHAVIORAL|Traditional Auditory Rehabilitation|"Name: Traditional Auditory Rehabilitation~Description:~Participants will continue the standard auditory rehabilitation program they currently receive at their registered rehabilitation center and will focus on improving auditory processing skills. This program includes:~Session Length: 30 minutes per session Frequency: Once a week Total Duration: 4 weeks (4 sessions total)~Components:~Improve speech understanding in noise"
214360719|NCT06958315|OTHER|Inclisiran|This is an observational study, there is no treatment allocation.
214360720|NCT00292435|DRUG|Read vine leaf extract (AS 195)|
214360721|NCT02623465|DRUG|Insulin Lispro|Administered subcutaneously (SC)
214360722|NCT05686239|DRUG|RL-007 (Inidascamine)|investigational study drug
214360723|NCT05686239|DRUG|Placebo|placebo capsules matching the appearance and size of the active drug
214360724|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1|Participants wear a VR headset which plays VR content/material pre- endoscopy only.
214360725|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1&2|Participants wear a VR headset which plays VR content/material pre- endoscopy and during endoscopy.
214360726|NCT00005855|DRUG|carmustine|
214360727|NCT00005855|DRUG|efaproxiral|
214360728|NCT04467385|OTHER|VR training + Sensory Integration therapy + conventional therapy|"After the baseline assessment,~* Coconut ShootersVR - 5 min/day~* Ninja flipVR - 5 min/day.~* Sensory integration training include Exercises on BOSU ball and mini-trampoline. It will involve:~* Passive bouncing with child standing with his/her feet shoulder width apart for 2.5 and 2.5 minutes on both.~* Active bouncing (the child bounces and therapist will control the rate) for 2.5 and 2.5 minutes on both.~* Mini-squat exercises with feet apart and feet together for 2.5 and 2.5 minutes on both.~* Conventional exercises include:~  * passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
214488459|NCT06965244|DRUG|Methotrexate (MTX)|Methotrexate oral dose of 15 mg per week for individuals \< 80 kg, and a dose of 20mg per week for those over 80 kg, along with an equal dose of folic acid supplementation given 48 hours after each dose
214488460|NCT05563649|BEHAVIORAL|Online Guided Self-Help-Family-based Treatment|GSH-FBT consists of 10 20-minute sessions for parents only over 9 months. Sessions follow an online curriculum of 65 short videos: 62 with an expert clinician instructing parents on the principles of FBT, and 3 reflections from an adolescent who recovered from AN and completed FBT. Each lecture series contains an introduction orienting the viewer to the videos, 5-9 short videos (\< 7 minutes each), and assigned reading from the parent education manual Help Your Teenager Beat an Eating Disorder. Three lectures include additional resources for parents (e.g., Academy of Eating Disorder (AED) Medical Management Guidelines). Homework assignments are included with some lectures (e.g., strategies to help the child eat during meals, practice making calorically dense meals). In line with GSH approaches, coach-therapists direct parents, to watch or re-watch specific video content contained in the online learning material related to their questions rather than direct behavioral change.
214488461|NCT05563649|BEHAVIORAL|FBT via Videoconferencing|15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
214488462|NCT04207086|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
214488463|NCT04207086|DRUG|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).
214972723|NCT03194009|DRUG|Metformin|The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations
214972724|NCT03194009|BEHAVIORAL|Lifestyle intervention|The patient will received recommendations to modify their diet and increase their physical activity every three months towards prevention of diabetes
214972725|NCT03117504|OTHER|questionnaire|a questionnaire is given to each woman to determine the urinary incontinence and it's impact on quality of life.
214972726|NCT03166020|OTHER|Rehabilitation|An occupational therapist will be required only for patient installation in front of the table.
214972727|NCT00000795|BIOLOGICAL|HIV-1 Peptide Immunogen, Multivalent|
214972728|NCT00000687|DRUG|Interferon alfa-2a|
214972729|NCT00000687|DRUG|Zidovudine|
214972730|NCT03021811|DEVICE|KLOX LumiHeal BioPhotonic System|Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
214972731|NCT02292459|DRUG|Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|
214972732|NCT02292459|DRUG|Polyethylene Glycol 4000 Powder for Solution (PEG 4000)|
214972733|NCT05597995|DRUG|Sodium Tetradecyl Sulfate|subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
214488464|NCT04590235|DRUG|Selumetinib|"All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m\^2. After a washout period of 2 days, oral selumetinib 25 mg/m\^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first.~10 mg and 25 mg capsules strengths available."
214488465|NCT04091126|DRUG|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as intravenous infusion.
214488466|NCT04091126|DRUG|Bortezomib|Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.
214488467|NCT04091126|DRUG|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
214360729|NCT04467385|OTHER|VR training + conventional therapy|"After the baseline assessment,~* The Your Shape: Fitness Evolved 2012TM game is selected for VR training (walking and walking with obstacles) for 8 min~* Coconut ShootersVR - 8 min/day~* Ninja flipVR - 8 min/day~* Conventional Therapy - 20 min per day~  * Passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest 3-5 times for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
214360730|NCT04460144|DIAGNOSTIC_TEST|Mass spectrometry|Proteomic analysis
214360731|NCT04477642|DRUG|Abatacept|10mg/kg intravenously administered on Day 1
214360732|NCT02035800|DRUG|Adalimumab|Patient will received medication as standard of care
214360733|NCT03731273|BEHAVIORAL|portion size|"Smaller than normal portion size - the intervention is the meal size perceived as 'smaller than normal' that participants are provided with during a lunchtime session in the laboratory.~'Small-normal' portion size - the intervention is the meal size perceived as 'small normal' that participants are provided with during a lunchtime session in the laboratory.~'Large normal' portion size - the intervention is the meal size perceived as 'large normal' that participants are provided with during a lunchtime session in the laboratory."
214360734|NCT02073799|PROCEDURE|Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)|
214360735|NCT02823951|DRUG|Rebif|
214488468|NCT04091126|DRUG|Dexamethasone|Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
214488469|NCT06149156|BEHAVIORAL|Healthy Minds Program App|The four-week intervention comprises two introductory lessons and guided meditations followed by one week of content for each pillar of well-being. Each week includes two brief lessons (5-7 minutes) with education on the scientific research behind the practices, as well as examples of how to strengthen the skills of each pillar in daily life, along with three guided meditations for which the participant can select the practice length (5-30 minutes).
214488470|NCT06149156|BEHAVIORAL|Well-being Resources|List of well-being resources that comprises of online video links and books
214488471|NCT04262206|DRUG|Atorvastatin 40 Mg Oral Tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
214488472|NCT04262206|DRUG|Placebo oral tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
214360736|NCT02823951|DRUG|Tecfidera|
214360737|NCT05271864|DEVICE|Apple Watch|Apple Watch
214360738|NCT01404520|OTHER|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
214488473|NCT03567876|DRUG|Venetoclax|Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
214488474|NCT06367933|PROCEDURE|mini-invasive spine surgery|spine deformity correction using a mini-invasive technique
214488475|NCT04221035|DRUG|Vincristine|1.5 mg/m2 (max dose 2 mg)
214488476|NCT04221035|DRUG|Carboplatin|750 mg/m2
214360739|NCT04052672|OTHER|Exercise and Nutritional Supplement|The intervention consists of exercise (a combination of supervised and in home) as well as a nutritional supplement (a combination of whey protein and creatine).
214360740|NCT02231827|OTHER|Gait analysis|Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
214360741|NCT03646799|DRUG|CKD-387|test drug
214360742|NCT03646799|DRUG|D484|reference drug
214360743|NCT01460550|PROCEDURE|Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
214488477|NCT04221035|DRUG|Etoposide|175 mg/m2
214488478|NCT04221035|DRUG|Vindesine|3 mg/m2/day (max dose 6 mg)
214488479|NCT04221035|DRUG|Dacarbazine|200 mg/m2/day
214488480|NCT04221035|DRUG|Ifosfamide|1500 mg/m2/day
214488481|NCT04221035|DRUG|Doxorubicin|30 mg/m2/dose
214488482|NCT04221035|DRUG|Busulfan|\< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses
214488483|NCT04221035|DRUG|Melphalan|140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose
214488484|NCT04221035|DRUG|Thiotepa|300 mg/m2/day over 2 hours
214488485|NCT04221035|RADIATION|Radiotherapy|21.6 Gy 21.6 Gy + boost de 14.4 Gy
214488486|NCT04221035|DRUG|Dinutuximab Beta|Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day
214488487|NCT04221035|DRUG|Cisplatin|80 mg/m2/24h
214488488|NCT04221035|DRUG|Temozolomide 100 MG|100 mg/m²/Day
214488489|NCT04221035|DRUG|Irinotecan|50 mg/m²/jour de J0 à J4
214488490|NCT04221035|DRUG|Cyclophosphamid|Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.
214488493|NCT06186869|BEHAVIORAL|Aerobic Exercise and diet intervention|subjects randomized and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform moderate-intensity aerobic exercises
214972734|NCT04797208|DEVICE|Real-Time CGM|Participants will be wearing a real-time continuous glucose sensor which will enable their glucose levels to be remotely monitored. High and Low glucose alerts will also be available.
214972735|NCT04797208|DEVICE|Capillary blood glucose testing with masked CGM|Participants will have their glucose monitored in hospital in the conventional manner using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted for data collection only.
214972736|NCT05687097|DEVICE|Home-based sleep screening test or hospital-unattended sleep screening test|ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.
214360744|NCT01460550|PROCEDURE|Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
214360745|NCT02139722|BEHAVIORAL|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
214488494|NCT06186869|BEHAVIORAL|Hiit and diet intervention|subjects randomised and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform high-intensity interval exercises in the gym
214488495|NCT06186869|BEHAVIORAL|Diet|subjects randomised and assigned to this intervention group will follow the low-glycaemic index Mediterranean diet
214488496|NCT05617638|BEHAVIORAL|Intervention|Participants will watch nature images in virtual reality from the e-Natureza VR Database for 20 minutes for 2 consecutive days.
214488497|NCT01187199|DRUG|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
214488498|NCT01187199|DRUG|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
214488499|NCT01187199|DRUG|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
214488500|NCT01187199|DRUG|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
214488501|NCT01187199|DRUG|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
214488502|NCT03910218|BEHAVIORAL|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
214488503|NCT03910218|BEHAVIORAL|Usual Care|Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
214488504|NCT04370509|DRUG|Axitinib (VEGF-TKI)|Given PO
214488505|NCT04370509|PROCEDURE|Cytoreductive Nephrectomy (CN)|Undergo CN
214488506|NCT04370509|PROCEDURE|Metastasectomy (MET)|Undergo MET
214488507|NCT04370509|BIOLOGICAL|Pembrolizumab|Given IV
214972737|NCT05687097|DEVICE|Cardiovascular beat-to-beat monitoring|CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.
214360746|NCT03318523|DRUG|Placebo|Administered as specified in the treatment arm
214360747|NCT03318523|DRUG|BIIB054|Administered as specified in the treatment arm.
214360748|NCT05632146|PROCEDURE|Continuous suturing|In continuous closure, each bite will be taken 2 cm from the cut edge of linea alba and successive bites taken 1 cm from each other in continuous fashion followed by gentle approximation of the wound
214488508|NCT05356169|DRUG|with or without venetoclax|Bcl-2 inhibitor
214488509|NCT06144073|BEHAVIORAL|Intervention (Mandala art therapy) group|Personal Information Form, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied to the students in both groups before mandala art therapy. The students in the experimental group will be given mandala activity by the researcher two days a week for 12 weeks/total 24 times. Three months after the first interview, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be administered as a post-test. One month after the end of the study, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied again as follow-up evaluation.
214488510|NCT06130722|DRUG|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
214488511|NCT06648278|BEHAVIORAL|Patient Navigation Program|Online health tool
214488512|NCT06648278|OTHER|Quality-of-Life (QOL) Assessment|Online surveys to assess QOL
214488513|NCT06648278|OTHER|Survey Administration|Ancillary studies
214488514|NCT02612454|DRUG|Dupilumab|Weight-tiered dosing administered subcutaneous (SC)
214488515|NCT06476717|PROCEDURE|Biopsy|Kidney allograft biopsy
214972738|NCT05687097|DEVICE|ECG monitoring|Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.
214360749|NCT05632146|PROCEDURE|Interrupted X suturing|In interrupted X closure, large bite will be taken outside-in, 2 cm from the cut edge of linea alba and the needle emerged on the other side from inside out diagonally 2 cm from the edge and 4 cm below the first bite and this strand will be crossed and continued outside-in, diagonally at 90 degree to the first diagonal. The two ends will be tied just tight enough to approximate the edges of linea alba.
214360750|NCT03581981|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|Brief version of Prolonged Exposure (PE) provided in 30 minute sessions in primary care (PC)
214360751|NCT03581981|BEHAVIORAL|Treatment as Usual|Veterans assigned to Primary Care (PC) Mental Health Integration (PCMHI)-Treatment as Usual (TAU) will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
214360752|NCT02080871|DEVICE|Stenting of the Common and/or External Iliac Arteries|Balloon expandable stenting of iliac occlusive disease.
214360753|NCT05201573|OTHER|Observational|This is an observational study of long term follow up data for patients who previously received the DIAM implant
214360754|NCT02696655|BEHAVIORAL|Behavioural intervention|Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
214360755|NCT04150679|PROCEDURE|duodenojejunostomy access loop|ROUX en Y hepaticojejunostomy with duodenojejunal anastomosis as permanent access
214360756|NCT04150679|PROCEDURE|hepaticojejunostomy without access loop|ROUX en Y hepaticojejunostomy without access loop
214360757|NCT06106386|OTHER|cryotherapy|Cooling of irrigation
214360758|NCT00234052|BIOLOGICAL|bevacizumab|5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
214360759|NCT00234052|DRUG|carboplatin|Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
214488516|NCT06476717|DIAGNOSTIC_TEST|Blood Biomarkers - cfDNA|dd-cfDNA
214972739|NCT04052646|OTHER|Medical condition: Subarachnoid hemorrhage|We identify patients with the condition of interest and retrospectively collect data on them.
214972740|NCT04685993|DRUG|LPCN 1144|Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).
214360760|NCT00234052|DRUG|pemetrexed|Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
214360761|NCT04481295|OTHER|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
214360762|NCT04481295|OTHER|Low SpO2|Low SpO2
214972741|NCT01480388|DRUG|Placebo/JNJ-39758979 (300 mg/d)|Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
214360763|NCT06579066|DRUG|Probiotic Blend Capsule|Patients will administer (probiotics) Linex® one capsule daily orally along with the standard care of therapy for duration of 4 weeks.
214360764|NCT06579066|DRUG|Activated Charcoal|Patients will administer (activated charcoal) Charclone® 1000MG Tablet three times daily orally along with the standard care of therapy for duration of 4 weeks.
214972742|NCT01480388|DRUG|JNJ-39758979 (10 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
214972743|NCT01480388|DRUG|JNJ-39758979 (30 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
214972744|NCT01480388|DRUG|JNJ-39758979 (100 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
214972745|NCT01480388|DRUG|JNJ-39758979 (300 mg)|Form = tablet, route = oral adminstration once daily for 48 weeks
214972746|NCT04776408|DEVICE|Lung recruitment combined inhaled Nitric oxide|Ventilator combined inhaled Nitric oxide and Electrical Impedance Tomography monitor the V/Q mismatch
214972747|NCT04776408|DEVICE|Lung recruitment|Ventilator and Electrical Impedance Tomography monitor the V/Q mismatch
214360765|NCT06579222|OTHER|Primary Care Rheumatology Family Physician Consultation|The participant will be booked with a primary care rheumatology family physician for rheumatoid arthritis comorbidity screening. They will complete weight, height, blood pressure measurement, assess for risk factors for dyslipidemia, type 2 diabetes, hypertension, bone mineral density loss and vaccine preventable infectious diseases.
214360766|NCT00254033|DRUG|Dextroamphetamine|
214360767|NCT00254033|DRUG|Methylphenidate|
214360768|NCT02428296|DRUG|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
214488517|NCT06476717|DRUG|Antirejection therapy|Patients will receive standard antirejection therapy according to center protocol.
214488518|NCT04503265|DRUG|AMXI-5001:Dose Escalation Phase I|Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
214972748|NCT02507492|DRUG|RM-493|
214360769|NCT04406948|DRUG|MGCND00EP1|Patients will take cannabis oil during the study
214972749|NCT06018805|OTHER|BMI≥30; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration ( in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
214972750|NCT06018805|OTHER|BMI:18,5-24,9; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
214972751|NCT02416232|DRUG|Trametinib|Trametinib will be provided as tablets containing 0.5 milligram (mg) or 2.0 mg of trametinib parent (present as the DMSO solvate). The starting dose of trametinib will be administered orally 2.0 mg, once daily (QD)
214360770|NCT04406948|DRUG|Placebo|Patient will take carrier oil during the study
214360771|NCT04406948|DIAGNOSTIC_TEST|ECG|"A standard 12-lead ECG will be recorded using digital ECG recording equipment provided to the investigational site. The ECG has to be performed prior to laboratory samplings at time points indicated in the Schedule of Assessments.~The ECG recording will be reviewed by investigator and case of need consultation with cardiologist will be performed. The investigator has the final decision on the clinical significance of the ECG results."
214360772|NCT04406948|DIAGNOSTIC_TEST|EEG|An EEG is an electrophysiological monitoring method that records the electrical activity and measures voltage fluctuations resulting from ionic current within the neurons of the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time.
214360773|NCT04406948|DIAGNOSTIC_TEST|Blood and urine collection|safety blood tests - hematology\\blood count and biochemistry standard blood tests urinalysis - urine test analysis
214360774|NCT02723864|DRUG|Veliparib + VX-970 + Cisplatin|Ataxia-telangiectasia-related (ATR) protein kinase is central to the deoxyribonucleic acid (DNA) damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. Poly (ADP-ribose) polymerase (PARP) plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor M6620 (VX-970) synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a breast cancer gene (BRCA) null phenotype, and potentiation of the antitumor activity of cisplatin.
214488519|NCT04503265|DRUG|AMXI-5001:Dose Expansion Phase II|Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
214488520|NCT05247424|DRUG|Unfractionated heparin|Unfractionated heparin at dose of 100 IU /kg body weight
214488521|NCT06047132|DIAGNOSTIC_TEST|Salivaru biomarkers|C-reactive protein (CRP), triggering receptor expressed on myeloid cells-1 (TREM-1), interleukin (IL)-1beta, metalloproteinase (MMP)-8, IL-10, IL-6, monocyte chemoattractant protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Alpha (MIP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), Tumor Necrosis Factor-Alpha (TNF-alpha)
214488522|NCT04875871|RADIATION|Particle radiotherapy|Partial radiotherapy targeting the hypoxic tumor segment
214488523|NCT04875871|DIAGNOSTIC_TEST|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
214488524|NCT04875871|DIAGNOSTIC_TEST|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
214488525|NCT04875871|DIAGNOSTIC_TEST|Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|For the definition of the hypoxic tumor segment in treatment planning.
214972752|NCT02416232|DRUG|Dabrafenib|Dabrafenib is commercially available as capsules containing 50 mg or 75 mg as free base (present as the mesylate salt). Dabrafenib will be administered orally 150 mg, twice daily (BID).
214972753|NCT00166868|DRUG|Lactobacillus casei rhamnosus (Lcr35)|
214972754|NCT00166868|DRUG|Neomycin|
214972755|NCT03175796|BEHAVIORAL|Infant Mental Health-Home Visiting|Behavioral intervention aimed to increase parental competencies and promote mental health and sensitive caregiving.
214972756|NCT04839172|DIAGNOSTIC_TEST|Dual-energy X-ray Absorptiometry (DXA) scan|Longitudinal changes in body composition are examined over four consecutive seasons (2017-2018, 2018-2019, 2019-2020, 2020-2021), four times per season in the following stages: start-preseason, start-season, mid-season and end-season.
214972757|NCT00527280|PROCEDURE|Feasibility ot face transplantation|Feasibility ot face transplantation
214972758|NCT02539992|DEVICE|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
214972759|NCT02539992|DEVICE|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
214972760|NCT02539992|DEVICE|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
214972761|NCT03900208|DIAGNOSTIC_TEST|Hystological analysis of ventricular tissue|Sections (4μm thick) will be stained with hematoxylin and eosin stain (H\&E) for diagnosis. After diagnosis, sections of the representative heart tissue will be stained with a PicroSirius Red/Fast Green for fibrosis evaluation. All stained samples will be examined under digital and light microscope. Beside the location of adipose/fibrous tissue in the right or left ventricles and in the septum, seven high magnification fields (40x) will be evaluated in five regions of the myocardium.
214972762|NCT00917124|DEVICE|INVOS|"Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.~None of the interventions are outside the range of good clinical practice."
214972763|NCT05055726|DRUG|Benzydamine Hydrochloride 0.15% w/v oromucosal solution|Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A.
214972764|NCT02584283|PROCEDURE|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
214972765|NCT02584283|DEVICE|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
214972766|NCT02584283|PROCEDURE|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
214972767|NCT02584283|DRUG|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
214972768|NCT04387123|PROCEDURE|Vaginoscopy|Vaginoscopic examination and possible operative endoscopic management
214488526|NCT04875871|DIAGNOSTIC_TEST|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For follow-up radiological tumor assessment.
214972769|NCT02789501|DEVICE|4% citrate lock solution regimen|(CitraFlow™ 4%, MedXL, Montreal, Canada) will be injected in each of the 2 lumens of the tunneled catheters after each dialysis session (2ml/lumen, 3x/week).
214972770|NCT02789501|DEVICE|TauroLock lock solution regimen|After the first two dialysis sessions of the week (before the short intervals) 2 ml of TauroLock™-Hep500 containing 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin will be injected into each of the two lumens of the tunneled catheter. After the third dialysis of the week, thus before the long interval, 2 ml of TauroLock™-U25.000 which contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase will be applied into each lumen.
214972771|NCT01240096|DRUG|Mirtazapine|Mirtazapine 15 mg daily
214972772|NCT01768780|DEVICE|the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine|"The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.~A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.~For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle."
214972773|NCT04861142|DRUG|Anti-osteoporotic medication( alendronate or denosumab)|Initiation of anti-osteoporotic medication (alendronate or denosumab)
214972774|NCT00115778|DRUG|IVIG|10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks
214972775|NCT00115778|OTHER|Placebo|0.1% Albumin in an equal volume to the investigational product
214972776|NCT04126434|DEVICE|mask|facemask
214972777|NCT02412124|PROCEDURE|Supportive Care|Complete W2W mentoring program
214488527|NCT04875871|DIAGNOSTIC_TEST|Blood sampling|Evaluation before treatment-start, during treatment and follow-up period.
214488528|NCT04906096|DRUG|PAXALISIB|Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol
214360775|NCT00112268|BEHAVIORAL|QuitLink (office support system for quit line referral)|
214972778|NCT02412124|OTHER|Quality-of-Life Assessment|Complete the FACT-G
214972779|NCT02412124|OTHER|Questionnaire Administration|Complete the W2W Patient Survey
215083844|NCT06037265|DEVICE|PAVmed PortIO™ Intraosseous Infusion System|The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
214972780|NCT03007303|DRUG|Atypical Antipsychotic|Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
214972781|NCT03007303|OTHER|atypical antipsychotic combined with MECT|The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
214360776|NCT03355638|DRUG|Aflibercept Injection [Eylea]|patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
214360777|NCT03355638|DRUG|Pranoprofen Eyedrops|Patients were given a bottle of eyedrops for self-administration of 0.1% pranoprofen (Pranoflog, Sifi SpA, Aci Sant'Antonio, CT, Italy). Pranoprofen dosage was 1 drop in the study eye, 3 times a day, over the 12-month study period
214360778|NCT03355638|DRUG|Omega-3 Supplementation|Ppatients were given daily tablets of Omega-3 supplementation provided free of charge by the company (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
214360779|NCT03840590|DEVICE|CSK AI system|CSK system is equipped with the endoscopic mainframe and alarms the examiners when suspect lesions appear.
214360780|NCT03840590|DEVICE|Standard Colonoscopy|This is the routine examination in nowadays clinical practice. Both the equipment and the procedure are as usual as clinical routine.
214360781|NCT05617690|DRUG|Cyclopol|Cyclopol 0.4mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. Anesthesia maintenance strategy is cyclopol 0.8-2.4 mg/kg/h and remifentanil 0.15 - 0.2 μg/kg/h
214360782|NCT05617690|DRUG|Propofol|Propofol 1-3mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. The anesthesia maintenance strategy is propofol 4-8mg/kg/h and remifentanil 0.15 - 0.2 μ g/kg/h
214360783|NCT00402181|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.
214360784|NCT00402181|DRUG|Dexamethasone|Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
214360785|NCT05807243|OTHER|Dietary intervention for healthy weight loss|Balanced and varied dietary plan adjusted to each participant's needs, with an approximate reduction of 500 Kcal from their total metabolic expenditure. The diet will be followed by the subjects during the 4 weeks of the study.
214360786|NCT00828984|DRUG|macrogol 3350-based oral osmotic laxative|Given PO
214360787|NCT00828984|OTHER|Placebo|Given PO
215083845|NCT00947414|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
214360788|NCT00828984|OTHER|Laboratory Biomarker Analysis|Correlative studies
214360789|NCT00446810|DRUG|Benfotiamine|
214360790|NCT00446810|DRUG|Placebo|
214360791|NCT05904951|DEVICE|INVADER™ PTCA Balloon Dilatation Catheter|INVADER™ PTCA Balloon Dilatation Catheter is a single use, EO sterilized, monorail rapid exchange (RX) coronary angioplasty balloon dilatation catheter. The INVADER™ PTCA has been designed to dilate the stenotic atherosclerotic lesions in coronary arteries or bypass grafts. The INVADER™ PTCA is an interventional, non-surgical device, and considered minimally invasive.
214360792|NCT04232514|DRUG|HEC74647|Administered HEC74647 200 mg orally once daily in fed state
214360793|NCT04232514|DRUG|HEC110114|Administered HEC110114 800 mg orally once daily in fed state
214360794|NCT02710279|BEHAVIORAL|Trier Social Stress Test (TSST)|"For the TSST the participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days."
214360795|NCT02710279|DEVICE|smartphone|
215083846|NCT00947414|DEVICE|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
214360796|NCT01210833|DEVICE|HandTutor System|Computerized system designed to evaluate and rehabilitate hand function. It is composed of a glove with special sensors detecting the movements of the wrist and the fingers, with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns.
214972782|NCT04428385|OTHER|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
214360797|NCT04043923|DRUG|Norketotifen|Oral capsule
214360798|NCT04043923|DRUG|Placebo|Oral capsule
214360799|NCT01543243|DEVICE|Stochastic resonance whole-body vibration A|"Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1."
214972783|NCT04428385|OTHER|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
215083847|NCT02299570|BIOLOGICAL|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
215083848|NCT02299570|OTHER|Placebo|A suspension of saline and cryoprotectant
214360800|NCT01543243|DEVICE|Stochastic resonance whole-body vibration B|"Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4."
214360801|NCT02340741|PROCEDURE|conventional prophylaxis of aeroembolism|167 patients will be enrolled. Will perform standard way of aeroembolism prevention
214488529|NCT02887950|OTHER|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
214488530|NCT02887950|DIETARY_SUPPLEMENT|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
214488531|NCT02887950|DIETARY_SUPPLEMENT|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
214488532|NCT06732505|DRUG|[225Ac]Ac-DOTATATE|"The dose escalation phase will be divided into two cohorts: patients who had previously received 177Lu-PRRT will be enrolled in cohort 1, and patients who had not received 177Lu-PRRT will be enrolled in cohort 2. Dose escalation was performed independently in the two cohorts. DL1 will be administered as a dose of 90kBq/kg per cycle, and DL2 will be administered as a single dose of 120kBq/kg per cycle.Every patient will receive one \[225Ac\]Ac-DOTATATE infusion every 8 weeks for up to 4 cycles.~The dose expansion phase will be divided into 3 cohorts based on Ki-67 index."
214488533|NCT06112847|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214360802|NCT02340741|PROCEDURE|conventional prophylaxis plus CO2 insufflation|167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide
214360803|NCT02340741|PROCEDURE|cardiac surgery with opening of heart chambers|Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
214360804|NCT04465357|DRUG|Erenumab-Aooe 140 MG/ML [Aimovig]|140 mg/mL administered subcutaneously
214488534|NCT06112847|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214488535|NCT06112847|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214488536|NCT06112847|OTHER|Electronic Health Record Review|Ancillary studies
214488537|NCT06112847|BIOLOGICAL|Epcoritamab|Given SC
214488538|NCT06112847|DRUG|Lenalidomide|Given PO
214488539|NCT06112847|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214488540|NCT06112847|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214488541|NCT03560908|DRUG|Dasatinib|Dasatinib 70mg twice a day will be administered orally for 2 weeks along with re-induction chemotherapy from day 1 of chemotherapy. Recommended re-induction regimens include (1)FLAG: Fludarabine 30mg/m2/d,d1-5;cytarabine 1g-2g/m2/d,d1-5;±G-CSF;(2)IA/DA:idarubicin 8-12mg/m2/d,d1-3 or daunorubicin 45-60mg/m2/d，d1-3;cytarabine 100-200mg/m2/d，d1-7;(3)CAG:Aclarubicin 20mg/d,d1-4；cytarabine 15mg/m2/Q12h,d1-14; ±G-CSF.The chemotherapy regimen is not limited to recommended regimens. Patients will be recommended to receive allogeneic hematopoietic stem cell transplantation (HSCT) once complete remission is achieved. Otherwise, they will continue the consolidation chemotherapy.
214360805|NCT02538185|DEVICE|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
214360806|NCT02538185|DEVICE|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
214488542|NCT06467019|OTHER|Informative Session|The intervention consists of implementing an interactive exhibition on the risks of chronic benzodiazepine treatment in the waiting room of a primary care center. Additionally, the health professionals at the center will receive a single informative session on the same topic.
214972784|NCT00528424|BIOLOGICAL|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
214972785|NCT02515630|DRUG|MMB|Momelotinib (MMB) tablet administered orally once daily
214972786|NCT06086990|DEVICE|Contigo Application|Contigo, a smartphone app, focuses on two main goals: monitoring cancer patients for early signs of drug toxicity and offering educational content to empower them in managing clinical challenges linked to their diagnosis and treatment. Monitoring involves patients inputting experiences via oncology-related questionnaires, with weekly checks for chemotherapy toxicity using a validated questionnaire (PRO-CTCAE). Severe cases trigger alerts, while milder ones receive educational guidance. Data collected is shared with healthcare providers. Educational content, backed by scientific evidence and expert collaboration, covers cancer-specific topics and healthcare processes to enhance patients' self-awareness and self-care practices.
214972787|NCT03690713|DIAGNOSTIC_TEST|Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance|The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × (\[1.35 × Pd/Pa\] - 0.32).
214972788|NCT03899727|DEVICE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study
214972789|NCT05648799|DRUG|GP30341 capsules 200 mg|orall take of capsules twice a day
214972790|NCT05648799|DRUG|Standard therapy|Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
214972791|NCT00483652|DRUG|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
214360807|NCT02538185|DEVICE|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
214488543|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Once the intra-cuff pressure is measured and recorded, the cuff will be deflated by drawing the air 0.5ml per step with each step lasting 3 breaths until a leak, in which a 10% reduction in expiratory volume over the inspiratory tidal volume, is detected.Cuff will then be reinflated until the expiratory tidal volume reaches the inspiratory tidal volume and the discrepancy between the inspiratory and expiratory tidal volume is less than 10 percent. If the intra-cuff pressure applied by the anesthesia care team is inadequate and the discrepancy between the inspiratory and expiratory tidal volume is 10% or greater, the cuff will be further inflated with air 0.5ml per step with each step lasting 3 breaths until it reaches Pcr. This Pcr will be maintained during the entire anesthesia time until extubation.During the course of surgery, if any leak is detected, the cuff will be re-inflated by 0.5ml of air until the leak is not detectable.
214488544|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Pcr is obtained just as it is done in the intervention group. The cuff will then be reinsufflated to the actual cuff pressure the care team initially chose. The care team will be blinded to the measured critical cuff pressures and hence will maintain the usual level of intracuff pressure in the control group during the entire anesthesia time.
214488545|NCT06647277|COMBINATION_PRODUCT|Fecal Microbiota Transplant|Fecal Microbiota Transplant
214488546|NCT01135433|DRUG|ipragliflozin|oral
214488547|NCT01135433|DRUG|Placebo|oral
214488548|NCT01135433|DRUG|metformin|oral
214488549|NCT06651554|BEHAVIORAL|Digital Platform Intervention|Key features of the digital platform include mental health self-help tools, a customizable safety plan, links to online counseling services, and gamification elements. Youth will be able to access the digital platform as often as they like during their assigned 3-month intervention period.
214488550|NCT06469190|BIOLOGICAL|anti-CD19 CAR NK cells|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
214488551|NCT06841406|DRUG|budesonide|During an 8-week treatment period, patients will receive 9 mg of Budesonide daily, administered orally in enteric-coated capsules. Following this period, participants will undergo a gradual dose reduction to minimize the risk of adrenal insufficiency: 6 mg daily for 2 weeks, followed by 3 mg daily for another 2 weeks before discontinuing treatment.
214488552|NCT06841406|DRUG|Mannitol|During an 8-week treatment period, patients will receive 9 mg of Mannitol daily, administered orally in enteric-coated capsules as placebo control. Following this period, participants will undergo a gradual dose reduction as is the case in the experimental group: 6 mg daily for 2 weeks, followed by 3 mg daily for another 2 weeks before discontinuing treatment.
214488553|NCT02752685|DRUG|Pembrolizumab|
214488554|NCT02752685|DRUG|Nab-Paclitaxel|
214488555|NCT06827249|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 90 mcg, on the basis of conventional treatments such as asthma control, oxygen inhalation, and fluid replacement, nebulized inhalation using air compression or oxygen-driven methods is administered on days 1, 3, and 5, once a day.
214488556|NCT06827249|DRUG|Recombinant Human Interferon α2b|Recombinant Human Interferon alpha 2b, at a dose of 100,000 IU/kg, based on the conventional treatments such as asthma control, oxygen inhalation, and fluid replacement, will be administered via nebulized inhalation using air compression or oxygen-driven methods from day 1 to day 5, twice daily.
214488557|NCT06988020|DEVICE|MRI|Whole body MRI including ZTE sequences
214488558|NCT06825195|OTHER|isokinetic muscle strength measurement|Wrist isokinetic eccentric flexor and extensor peak Torque and fatigue will be measured at the angular velocity of 180°/s
214488559|NCT06825195|OTHER|Minimum pinch force measurement|the minimum fingertip pinch force required to hold a constant weight will be measured
214488560|NCT06611293|DIAGNOSTIC_TEST|Breath test|"Participants will perform breath testing in Primary care followed by Secondary care on Day 1. At each location, participants will be asked to perform three breath tests (15 minutes apart). The environmental air will also be sampled.~This entire process will be repeated in the reverse order (i.e. breath testing in Secondary care followed by Primary care on Day 2).~Participants will be asked to maintain a clear fluid diet for a minimum of six hours prior to breath collection on both Day 1 and Day 2 of sampling."
214488561|NCT06788405|OTHER|hand hygiene theoretical training with a hand hygiene virtual reality simulation application|After giving 360 hours of hand hygiene theoretical training to the participants in the experimental group, a hand hygiene virtual reality simulation application will be performed.
214972792|NCT00483652|DRUG|Placebo|placebo (sugar pill)
214972793|NCT03540693|PROCEDURE|RYGB|RYGB-weight loss surgery
214972794|NCT03540693|PROCEDURE|SG|SG- weight loss surgery
214972795|NCT03540693|PROCEDURE|LAGB|LAGB- weight loss surgery
214972796|NCT02168959|DRUG|bupivacaine|This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
214972797|NCT02548936|DRUG|Ezetimibe+Simvastatin Drug Combination|The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
214972798|NCT03255369|OTHER|Child exposed Zika virus proved|There will be applied Bayley Teste 3rd edition
215083849|NCT07033949|DEVICE|Green light glasses|Exposure to green light for 30 minutes
215083850|NCT07033949|DEVICE|Transparent light exposure|Exposure to transparent light for 30 minutes
215083851|NCT07041866|DIETARY_SUPPLEMENT|Fortified Biscuit with Local Iron-Rich Ingredients|Participants consumed one fortified biscuit per day, five days a week (school days), for a period of three months. The biscuit was formulated using wheat flour, millet, maize, peanut paste, sugar, and was filled with a blend of Moringa oleifera, Hibiscus sabdariffa, Adansonia digitata, and Detarium senegalense-all selected for their high iron and vitamin C content. The iron content was approximately 4 mg per 100 g.
214360808|NCT02538185|DRUG|Vaccin rabique Pasteur®|
214360809|NCT02538185|DRUG|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
214360810|NCT01040858|BEHAVIORAL|Cognitive Strategy Training|Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
214360811|NCT01040858|OTHER|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
214360812|NCT03656705|BIOLOGICAL|CCCR-NK92 cells|CCCR-NK92 cells will be administered intravenously over 1h. The starting dose of CCCR-NK92 cells will be 1×10e7-1×10e8,twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
214488562|NCT06788405|OTHER|hand hygiene theoretical training|Participants in the control group will receive only 360 hours of hand hygiene theoretical training. Participants in this group will not be given hand hygiene virtual reality simulation application.
214488563|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
214488564|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
214488565|NCT02051257|OTHER|Laboratory Biomarker Analysis|Correlative studies
214972799|NCT05673447|BIOLOGICAL|anti-CD19 CAR NK cells|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Doses of 6×10\^8, 1×10\^9, 1.5×10\^9 Anti-CD19 CAR NK cells will infused in each group using the 3 + 3 dose-escalation strategy."
214972800|NCT03326440|OTHER|VERT system|3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
214972801|NCT02089477|OTHER|Support group|"The participants in the intervention group receives the intervention and support consisting of:~1. Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~2. SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
214972802|NCT00926250|DIETARY_SUPPLEMENT|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
214972803|NCT00926250|DIETARY_SUPPLEMENT|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
214972804|NCT00663650|PROCEDURE|Permanent Section Control|After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
214972805|NCT00663650|PROCEDURE|Frozen Section Control|After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
214972806|NCT05558319|DRUG|Bortezomib|Bortezomib
214972807|NCT05558319|DRUG|Isatuximab|Isatuximab
214972808|NCT05558319|DRUG|Iberdomide|Iberdomide
214972809|NCT05558319|DRUG|Lenalidomide|Lenalidomide
214972810|NCT05558319|DRUG|Dexamethasone|Dexamethasone
214972811|NCT02904746|BEHAVIORAL|Make It!|The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
214972812|NCT05380765|BEHAVIORAL|Native PATHS|A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
214360813|NCT01787448|DRUG|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
214360814|NCT01787448|DRUG|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
214488566|NCT06988579|OTHER|AI|An integrated AI-human collaborative workflow for lung cancer screening interpretation
214488567|NCT03124277|DIETARY_SUPPLEMENT|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
214488568|NCT03124277|OTHER|Control Group|Best local diet
214488569|NCT06991712|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks
214488570|NCT06991712|DIETARY_SUPPLEMENT|Nicotinamide|Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks
214488571|NCT06991712|DIETARY_SUPPLEMENT|Nicotinamide Mononucleotide|Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks
214488572|NCT06991712|DIETARY_SUPPLEMENT|Nicotinic Acid|Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks
214488573|NCT06991712|OTHER|Placebo (Corn Starch)|Oral supplementation of 300mg Placebo daily for 2 weeks
214488574|NCT06991712|OTHER|Placebo (Corn Starch)|Oral supplementation of 300mg Placebo daily for 2 weeks
214972813|NCT00120692|DRUG|Darbepoetin Alfa|
214972814|NCT00120692|DRUG|Recombinant Human Erythropoietin|
214972815|NCT05959265|BEHAVIORAL|exercise|Patients in the treatment group will undergo a 12-week intervention consisting of three 30-minute walking exercises per week during their standard cancer treatment. A personalized walking plan using fitness trackers will be provided to record each patient's daily average heart rate, step count, and additional steps and heart rate during the three 30-minute walking exercises per week to assess their activity levels. Weekly collaborations between the principal investigator and each participant will be conducted to assess step-related parameters.
215083852|NCT07041866|DIETARY_SUPPLEMENT|Non-Fortified Biscuit|Participants received a placebo biscuit daily for the same period and frequency as the intervention group. The placebo biscuit was visually and texturally identical to the fortified biscuit but did not contain the micronutrient-rich filling.
215083853|NCT07041957|OTHER|Individualized flow-controlled ventilation strategy|"1. Compliance-guided PEEP trial: An incremental PEEP trial from 5 to 15 cmH2O in 2 cmH2O steps with a constant driving pressure (ΔP) will be performed. At the first PEEP level, the tidal volume is set to 6-8 ml/kg PBW. The best PEEP level is defined as the one with the highest dynamic compliance. Participants are ventilated with this PEEP level + 1-2 cmH2O for a reduction of lung de-recruitment and atelectrauma.~2. Compliance-guided driving pressure (ΔP) trial: In the FCV group, an additional incremental ΔP trial in 1 cmH2O steps is initiated after the PEEP trial. This trial evaluates if the tidal volume increases (over-)proportional to the dynamic compliance on the previous ΔP level when the ΔP is increased by 1 cmH2O. In the FCV group, participants are ventilated with a ΔP consistent with the highest dynamic compliance ± 1-2 cmH2O. The compliance-guided PEEP and ΔP trials are repeated every 8 hours in order to account for changes in overall lung compliance."
214360815|NCT01787448|DRUG|Sodium lauryl sulfate 0.1%|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
214360816|NCT01787448|DRUG|Sodium chloride solution 0.9% (saline)|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
214972816|NCT04282174|DEVICE|CliniMACS|allogeneic Human leukocyte antigen-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system
214972817|NCT04282174|PROCEDURE|Bone Marrow Transplant|Bone Marrow Transplant will come from either an HLA matched related sibling or HLA un-related donor
214972818|NCT04282174|DRUG|Hyperfractionated Total Body Irradiation|Hyperfractionated Total Body Irradiation is administered at a dose rate of \< 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).
214972819|NCT04282174|DRUG|Thiotepa|Thiotepa: 5mg/kg/day IV over approximately 4 hr. daily x 2 (Day -5 and Day -4). If scheduling of transplant harvests requires, the dose of Thiotepa may be administered as a single dose of 10mg/kg/day x 1.
214972820|NCT04282174|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is \> 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.
214972821|NCT04282174|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified
214972822|NCT04282174|DRUG|Melphalan|Melphalan 70mg/m2/day x 2 days IV over 30 minutes. Dose should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight per MCI standard of care guidelines. Melphalan will be administered on Days - 7 and -6 for multiple myeloma patients.
214972823|NCT04282174|DRUG|Fludarabine|"Fludarabine 25mg/m2/days x 5 days IV over 30 minutes. Fludarabine may be adjusted in the case of renal toxicity.~In select cases in which the peripheral blood stem cells must be harvested a day later than requested due to a scheduling issue with the donor or Stem Cell Processing Laboratory."
214972824|NCT04366245|BIOLOGICAL|Hyperimmune plasma|PLASMA OF CONVALESCENT COVID-19
214972825|NCT04366245|DRUG|Standard of care for SARS-CoV-2 infection|Standard of care for SARS-CoV-2 infection
214972826|NCT01703494|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
214972827|NCT01703494|BIOLOGICAL|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
214360817|NCT04051164|OTHER|Progressive Muscle Relaxation Technique|"PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week."
214488575|NCT06587568|BEHAVIORAL|Mobile chat messaging|A trained counsellor will interact with a participant individually and provide personalised alcohol reduction information and advice via a mobile instant messaging app in real time for 3 months from randomisation.
214488576|NCT06587568|BEHAVIORAL|Screening, brief intervention and referral to treatment|Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet
214488577|NCT06997432|PROCEDURE|Double-blind placebo-controlled oral challenge test (DBPCFC)|Group 1. To evaluate MTD, DBPCFC will be done with peach with skin and/or peach juice as described. The patient will remain under observation for at least 2 hours.
214488578|NCT06997432|OTHER|Dietary intervention|Group 2. Patients will take for one year, MTD of fresh peach or peach juice with a frequency of 3 times/week.
214488579|NCT06997328|OTHER|Implementation of the '5 Rs to Rescue'|Quality improvement intervention increases surveillance for patients at risk of 'failure to rescue' after surgery
214972828|NCT02071459|DRUG|L-Threo DOPS|initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
214972829|NCT02071459|DRUG|placebo|initial period (4 weeks) followed by 8 weeks
214972830|NCT01477762|DRUG|Dexamethasone|One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.
214972831|NCT01477762|DRUG|Placebo|One placebo tablet will be taken ten hours prior to completing study assessments.
214972832|NCT04414007|BEHAVIORAL|Internet+ home-based cardiac rehabilitation|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
214488580|NCT06997211|BEHAVIORAL|EFT|The EFT session will be conducted mutually with the practitioner. The average duration of the session is planned to be 40-45 minutes.
214488581|NCT06996457|DEVICE|VR|The use of a virtual reality (VR) headset to present videos with nature imagery and natural sounds (music)
214488582|NCT06996522|PROCEDURE|underwater endoscopic mucosal resection|The Pedunculated colorectal polyps less than 10mm in size in this group will be treated by UEMR
214488583|NCT06996522|PROCEDURE|Hot snare polypectomy|The Pedunculated colorectal polyps less than 10mm in size in this group will be treated by HSP
214488584|NCT06996340|OTHER|White noise group|The woman who was taken to the gynecological table for invirto fertilization will be made to listen to white noise (rain and waterfall sound) with a Bluetooth headset at a range of 75-85 decibels during the procedure. Because, it covers all sound ranges that people can hear within the range of 75-85 decibels (Cho and Hwang, 2021; Lin et al, 2018).
214488585|NCT06996340|OTHER|routine care|routine care
214488586|NCT06997055|DRUG|Ustekinumab 45 mg|biosimilar
214488587|NCT06997055|DRUG|Ustekinumab 90 mg|biosimilar
214488588|NCT06996704|DRUG|AK0610 Injection solution|Active Substance: AK0610 Pharmaceutical Form: Injection solution Route of Administration: Intramuscular injection or intravenous injection.
214488589|NCT06996704|DRUG|Placebo|Active Substance: Placebo Pharmaceutical Form: Injection Route of Administration: Intramuscular injection or intravenous injection
214488590|NCT06996171|DRUG|Magnesium glycinate|Tab Magnesium glycinate 500mg will be given to one group for treatment of primary insomnia
214488591|NCT06996171|DRUG|Melatonin|Tab Melatonin 10mg will be given to the other group for treatment of primary insomnia
214488592|NCT06997783|OTHER|warm up|"1. Standard Warm-Up (SWU):~   This condition will involve a typical judo-specific warm-up protocol lasting approximately 25 minutes.~2. Moderate-Load PAPE Warm-Up (80% of 6RM):~   This experimental warm-up condition will consist of the same initial exercises as the SWU, followed by the addition of a moderate-load squat-based PAPE protocol.~3. Maximal-Load PAPE Warm-Up (100% of 1RM):~This condition will also begin with the same general and judo-specific exercises as the SWU, followed by a high-intensity PAPE protocol: 1-2 sets of a single repetition of back squats at 100% of the participant's 1-repetition maximum (1RM)."
214488593|NCT05663723|DEVICE|Intervention group with the IV and V LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
214488594|NCT05663723|DEVICE|Intervention group with the IV, V and Violet LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
214488595|NCT05663723|DEVICE|Control group with LED board without emitting light|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
214488596|NCT06996613|PROCEDURE|Upper endoscopy|It's a diagnostic endoscope to show the cause of upper Git bleeding
214972833|NCT04414007|BEHAVIORAL|Conventional rehabilitation|We provide patients with cardiac rehabilitation manuals and exercise logs. 4 weeks after ablation，Patients have CPET.Their exercise prescription was made according to CPET .The patients have rehabilitation training at home and recorded their exercise data including exercise time、type、frequency and average heart rate.
214972834|NCT01622556|DRUG|Fludarabine|35 mg/m2 IV/day x 5 days
214972835|NCT01622556|DRUG|Busulfan|.8 mg/kg IV Q6h x 8 doses
214972836|NCT01622556|DRUG|Thymoglobulin|1.5 mg/kg/day x 3 days
214972837|NCT01622556|RADIATION|Total Body Irradiation|150 cGy for 2 days
214972838|NCT01622556|BIOLOGICAL|Umbilical Cord Blood|Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
214488597|NCT06997224|OTHER|triflow application|After we have exhaled, we will try to hold the balls up as long as possible by pulling them inward with all our strength. After repeating this five times, we will turn them over.
214972839|NCT02151357|DRUG|DCBCI0901|DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
214972840|NCT03468842|BIOLOGICAL|Probiotic|Already described
214972841|NCT03468842|BIOLOGICAL|Placebo|Placebo
214972842|NCT00473655|DRUG|rosuvastatin|10mg or 20mg
214972843|NCT04979481|BEHAVIORAL|BRAVE|The BRAVE campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The role model videos (1-3 minutes each) featured relatable characters experiencing and addressing violent behavior, alcohol misuse, and suicidality (through the eyes of a perpetrator, an intimate partner violence survivor, and a peer bystander), intended to demonstrated important coping and help-seeking skills.
214972844|NCT04979481|BEHAVIORAL|STEM|The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The series promoted STEM career pathways and highlighted Native professionals in Science, Technology, Engineering, Math, and Medical careers.
215083854|NCT07041957|OTHER|Pressure-controlled ventilation strategy via the application of Biphasic Positive Airway Pressure ventilation|"1. Compliance-guided PEEP trial: An incremental PEEP trial from 5 to 15 cmH2O in 2 cmH2O steps with a constant driving pressure (ΔP)will be performed. At the first PEEP level, the tidal volume is set to 6-8 ml/kg PBW. The best PEEP level is defined as the one with the highest dynamic compliance. Participants are ventilated with this PEEP level + 1-2 cmH2O for a reduction of lung de-recruitment and atelectrauma.~2. The driving pressure (ΔP) is set to achieve a tidal volume of 6-8 ml/kg predicted body weight.~The compliance-guided PEEP trial is repeated every 8 hours in order to account for changes in overall lung compliance."
215083855|NCT07040852|BEHAVIORAL|Mental Health Literacy Promotion Intervention Program|10 sessions, 90 minutes each, weekly. A face-to-face group treatment for Chronic Pain that focuses on enhancing individuals' understanding of mental health issues, promoting help-seeking behaviors, and reducing stigma associated with mental illness. Intervention includes group discussions, audio-visual material and written material.
215083856|NCT07042009|OTHER|Nutritional resources|The participants will be provided with the nutritional resources only.
215083857|NCT07042009|OTHER|Milk docosahexaenoic acid levels|The participants will be provided with information on the levels of docosahexaenoic acid in their breast milk.
215083858|NCT07041541|PROCEDURE|Esthetic Crown Lengthening|Conventional Esthetic Crown Lengthening
215083859|NCT07041541|PROCEDURE|Esthetic Crown Lengthening using GingivalStat approach|Esthetic Crown Lengthening using GingivalStat approach (composite stops)
214360818|NCT04051164|OTHER|Conventional treatment|Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
214488598|NCT06997822|BEHAVIORAL|LINE Bot-Based Remote Care Combined with In-Person Post-ICU Clinic|"Participants in this group will receive the I-CARE intervention, which includes two components: (1) a LINE Bot-based remote care system providing scheduled health education, functional assessments, and reminders tailored to ICU survivors, and (2) structured in-person visits to a post-ICU recovery clinic, where multidisciplinary professionals provide follow-up assessments and individualized rehabilitation guidance. The LINE Bot also features an interactive module (Thanks to Nurses) that allows patients to send messages, images, or audio clips to their ICU care team, with optional reciprocal feedback. The intervention will be delivered for up to 6 months following hospital discharge."
214972845|NCT02617615|DRUG|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
214972846|NCT02617615|DRUG|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
214972847|NCT01635660|DEVICE|Intubation|Tracheal Intubation with the assigned video laryngoscope
215083860|NCT07032675|DEVICE|Low-temperature radio-frequency reshaping of autologous cartilage nasal and/or auricular cartilage|The device settings will be set per the manufacturer's instructions: temperature = 60° C, power = 4 W, treatment time = 18 seconds, and cooldown = 12 seconds. For curved-to-straight (CTS) samples (natively curved cartilage to be remolded to be flat), the cartilage specimens will be placed on a blue towel on a flat surface with the transmission medium over top and treated. For straight-to-curved (STC) samples (natively flat cartilage to be remolded to be curved), cartilage specimens will be placed along the inner surface of various shallow, plastic, cylindrical objects with the transmission medium over top and treated. Various device settings may be tested for reshaping efficacy.
215083861|NCT07040189|OTHER|Gustabor server|AI based web platform providing individual lifestyle tips and recipe recommendations based on the patient's individual data and taste disorder
215083862|NCT07040345|OTHER|Annurca apple oleolite|3 mg twice daily for 28 days
215083863|NCT07040345|OTHER|Placebo|3 mg twice daily for 28 days
215083864|NCT07040176|PROCEDURE|Upper molar distalization|This study aims to compare upper molar distalization movement achieved with a non-compliance miniscrew implant supported appliance (AMDA®) with distalization of upper molars achieved with clear aligners (Spark®) supported by Class II elastics.
215083867|NCT07040683|DEVICE|Negative Pressure Wound Therapy (NPWT)|Negative pressure wound therapy (NPWT) applied over the split-thickness skin graft on the lower leg after tumour excision. A protective silicone interface layer will be used, with continuous negative pressure of -125 mmHg applied until postoperative day 5, unless earlier change is clinically indicated.
214360819|NCT02548455|DEVICE|Quartet 1457Q LV Lead|
214360820|NCT05872373|BEHAVIORAL|Snakebite prevention and first aid|The study will offer a communication strategy to develop an effective narrative by using a mix-media campaign, where IEC materials would be chiefly localized.
214360821|NCT03021356|DEVICE|Aortic xenograft|After randomization, the aortic xenograft is implanted in the standard fashion
214488599|NCT06997809|OTHER|pathway care|"Group for whom the test results will be used to determine the management strategy. If one of the tests performed before randomization is positive an algological consultation before surgery will be performed with an adapted treatment. Then surgical treatment as planned.~If all tests are negative, surgical treatment is performed. The dedicated algology consultation must be done with an experienced practitioner different from the one who will perform the surgery. A rapid algological treatment circuit must be put in place to maintain the surgery date set.~Group without using the results of test for associated pain components. Standard surgical treatment as planned through dedicated staff on endometriosis treatment."
214488600|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（4 hours）|The 4-hour group treatment session lasts 4 hours (±15 minutes). In the HBAL mode of the combined bioartificial liver device QH-1A, blood is initially filtered to separate the plasma, which is then pumped into a bioreactor. In this study, this bioreactor is uniquely filled with immortalized mesenchymal stem cells (PT-MSCs) optimized for blood purification. These cells are cultured to adhere to the outer surface of hollow fibers within the bioreactor, creating a stable and efficient living interface that continuously secretes bioactive factors such as exosomes.After passing through the bioreactor, the plasma is re-filtered and then returned to the patient's circulation via a dedicated pump.
214972848|NCT01991353|PROCEDURE|With PRP|Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.
214972849|NCT01991353|PROCEDURE|Without PRP|Standard of care meniscal repair without augmentation.
214360822|NCT04818580|PROCEDURE|Progressive Tension Sutures|In each patient, one side of the chest will receive progressive tension sutures inside the mastectomy pocket, from pectoral fascia to underside of mastectomy flap. 2-0 Vicryl about 15-20 sutures per chest. Both sides will receive bilateral drains (standard of care)
214360823|NCT05836493|PROCEDURE|Ring annuloplasty|A prosthetic ring is implanted to treat tricuspid regurgitation
214360824|NCT05836493|PROCEDURE|Suture procedure|Suture techniques such as Kay or De Vega are used to reduce tricuspid annulus in order to treat tricuspid regurgitation
214360825|NCT03978234|DRUG|AbobotulinumtoxinA 300 UNT|AbobotulinumtoxinA 300 UNT
214360826|NCT04315168|DEVICE|FRED and FRED JR|Intracranial aneurysm treatment
214360827|NCT01335204|DRUG|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
214360828|NCT04496180|DEVICE|Closed incision negative pressure therapy versus standard dressing after emergency abdominal laparotomies|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply the PREVENA just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
214360829|NCT02144064|DRUG|Heparin|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
214360830|NCT03886532|OTHER|Medical Marijuana|registry and blood samples
214360831|NCT03637946|OTHER|Device: SHOFU beautifil II LS|Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were used following manufacturer's instructions
214360832|NCT04880564|DRUG|CN1, 0.5mg/kg and CN401, 400mg|CN1(0.5mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(400mg) will be administered orally twice daily.
214360833|NCT04880564|DRUG|CN1, 1mg/kg and CN401, 600mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(600mg) will be administered orally twice daily.
214360834|NCT04880564|DRUG|CN1, 1mg/kg and CN401, 800mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
214360835|NCT04880564|DRUG|CN1, 3mg/kg and CN401, 800mg|CN1(3mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
214360836|NCT04880564|DRUG|CN1, 10mg/kg and CN401, 800mg|CN1(10mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
214360837|NCT00104169|DRUG|Epoetin Alfa|
214360838|NCT06381089|DEVICE|Robotic Rehabilitation|Lokomat is an exoskeleton type robotic walking device that can support both extremities symmetrically.
214360839|NCT06381089|DEVICE|Transcutaneous Auricular Vagal Nerve Stimulation|Vagus nerve stimulation is defined as any technique that stimulates the vagus nerve in our body.
214360840|NCT00141427|DRUG|Pregabalin|
214360841|NCT00108602|DRUG|acetazolamide|
214360842|NCT00831779|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, once daily, 12 weeks
214360843|NCT00831779|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks
214360844|NCT00372281|DRUG|Cliavist|Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight \> 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
214360845|NCT04269499|DEVICE|QuiremSpheres®|Radioembolization with QuiremSpheres® under MR imaging
214972850|NCT03467074|BIOLOGICAL|influenza A/B vaccine|Regardless of the study enrollment, a two-time influenza vaccination at the start of the flu season is recommended every 4 weeks for all patients after stem cell transplantation. The vaccine is a trivalent inactivated non-adjuvanted influenza virus vaccine containing two influenza A viruses: pandemic H1N1, and H3N2, and an influenza B virus
214972851|NCT00109863|BIOLOGICAL|hu14.18-IL2 fusion protein|
214488601|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（6 hours）|After the three subjects in the 4-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 6-hour group.The 6-hour group treatment session lasts 6 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.
214488602|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（8 hours）|After the three subjects in the 6-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 8-hour group. The 8-hour group treatment session lasts 8 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.
214360846|NCT02235350|OTHER|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
214360847|NCT02235350|OTHER|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
214360848|NCT05108792|OTHER|NO INTERVENTION|observational study, no intervention performed
214488603|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（Multiple-treatment）|Subjects in the multiple-treatment group will receive 2-3 sessions of bioartificial liver treatment; the number of sessions will be determined by the investigators based on the subjects' clinical needs. The treatment duration for each session will be set as the maximum tolerable period, as confirmed by the Safety Evaluation Committee based on 28-day safety observations from the 4-hour, 6-hour, and 8-hour groups. Each treatment session is administered following the procedure applied to patients in the group with the optimal tolerability duration.
214488604|NCT06997679|DIAGNOSTIC_TEST|Patients receiving CPM|Group A was treated with Continuous Passive Motion for 30-45 minutes for 2 sessions per day for 8 weeks. CPM can be initiated in the immediate post-operative period, typically within 24-48 hours after surgery. Range of motion will be 0-90 degrees of flexion, with a gradual increase in range over time. Speed is 1-2 cycles per minute. Therapist will Monitor patients for pain and discomfort during CPM, and adjust the protocol as needed. Therapist will Monitor patients range of motion and adjust the CPM protocol to ensure optimal progress. Therapist will monitor patients' knee functions and adjusts the CMP protocol to ensure optimal progress
214488605|NCT06997679|COMBINATION_PRODUCT|Patients receiving intermittent compression|Group B was treated with Intermittent Compression Therapy for 30-45 minutes for 2 sessions (morning and evening) per day for 8 weeks. Therapist stand beside the patient .IC therapy initiated in the immediate post-operative period, typically within 24-48 hours after surgery .Pressure of device between 30-40 mmHg and Cycle time is 10-30 seconds inflation, 10-30 seconds deflation. Therapist will Monitor patients for pain and discomfort during IC therapy, and adjust the protocol as needed. Therapist will Monitor patients' swelling and edema, and adjust the IC therapy protocol to ensure optimal progress. Therapist will Monitor patients' knees functions and adjust the IC therapy protocol to ensure optimal progress.
214488606|NCT06997302|OTHER|Nutritional Supplement|Dietary nutrition guidance.
214488607|NCT06499506|PROCEDURE|Below knee amputation|trans tibial amputation one hand breadth below tibial tuberosity
214488608|NCT06322433|DIAGNOSTIC_TEST|no drugs used for this study|tomographic, angiographic and clinical follow up
214488609|NCT03201939|DRUG|Lisinopril|ACE-inhibitor (lisinopril)(intervention arm
214488610|NCT03201939|OTHER|Placebo Oral Tablet|Comparator placebo (control arm)
214488611|NCT07030426|DRUG|Vaginal Estrogen - Twice Weekly|Twice weekly for six weeks following pelvic organ prolapse repair surgery. 0.5 grams of cream per vagina at bedtime .
214488612|NCT07030426|DRUG|Vaginal Estrogen - Daily|Daily for six weeks following pelvic organ prolapse repair surgery. 0.5 grams of cream per vagina at bedtime.
214972852|NCT03391752|COMBINATION_PRODUCT|Integrated Nutrition Pathway for Acute Care|algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement
214972853|NCT05567081|DRUG|Triamcinolone Acetonide 40mg/mL|Deep perineural injection with 1cm corticosteroid mixed with 1ml lidocaine hydrochloride.
214972854|NCT05567081|DRUG|PRP|Deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve.
214972855|NCT04942262|DRUG|denture adhesive (Polident®, GlaxoSmithKline, Ireland)|cream-type denture adhesive available as an over-the-counter product in Thailand
214972856|NCT00789503|DIETARY_SUPPLEMENT|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
214972857|NCT06515756|OTHER|Post operative pain assessment after root canal treatment|the sealer was administered to the root canal using the initial paper point and then uniformly distributed using a second paper point before removing any excess sealer with a third paper point. Once the sealer was applied, a single tapered gutta-percha cone was adjusted to fit the root canal. The coronal access cavities were restored with a composite resin material
214972858|NCT00000867|DRUG|Memantine|
214972859|NCT00247468|PROCEDURE|Strict Glucose Control|
214360849|NCT00713440|OTHER|Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.~Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.~Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days"
214360850|NCT02425332|DEVICE|Lokomat gait trainer|
214360851|NCT02436330|BEHAVIORAL|Exergaming|"6 months of weight management programming consisting of 10 weekly sessions:1 hour of session was spent exergaming, which included active video game play and traditional group exercises. Some examples include: Dance, Dance, Revolution, Exerbike, Treadwall, Yoga, Spin class, etc."
214972860|NCT02809365|DEVICE|FreeStyle Libre|Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections
214360852|NCT02436330|BEHAVIORAL|Didactic health teaching|6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.
214360853|NCT00174525|DRUG|AAB-001|
214360854|NCT00096694|DEVICE|Levonorgestrel-releasing intrauterine device (IUD)|
214972861|NCT02809365|DEVICE|personal glucometer|Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
214972862|NCT03846401|DEVICE|fiberoptic bronchoscopy|"Will be performed according to British Thoracic Society guidelines 2013.~-Microbiological methods The specimen (tracheal aspirate \& BAL) will be collected under aseptic conditions in a sterile container and immediately sent to the laboratory for microbiological analyses.~Samples will be apply for:~1. Direct smear by Gram stain and ZeihlNelseen stain~2. Samples culturedinBact/alert bottle(BioMérieux, France).~3. Isolation of causative organism from positive cases by:~   Subculture on MacConkey , blood , chocolate agar , Sabouroud's agar and Lowenstien Jensen media.~4. Identification of isolated organism and drug sensitivity test by Automated Vitek2 Compact(BioMérieux, France).~5. Multiplex PCR for detection of Respiratory viruses in lower respiratory tract"
214972863|NCT02528474|DEVICE|balloon angioplasty with Pantera Lux|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
214972864|NCT02528474|DEVICE|balloon angioplasty with SeQuent Please|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
214972865|NCT04541563|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator Device|Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
214972866|NCT02219685|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214972867|NCT02219685|DRUG|Placebo|Tablet administered orally once daily
214972868|NCT02228005|DRUG|Sertraline|Protocolized titration from 50 to max 200mg based on response and tolerance.
214972869|NCT00001989|DRUG|Trichosanthin|
214972870|NCT00001989|DRUG|Zidovudine|
214972871|NCT06389981|OTHER|Veterans peer connect Program|To assess outcomes of the Peer-led program, the study team will collect information from Veteran pilot test participants via surveys and data abstraction on healthcare utilization (Lung cancer screening completion, tobacco treatment) from the Veterans Affairs Corporate Data Warehouse. Survey data will be collected at 3 timepoints: baseline, post-Peer-led orientation, and 3-months post-enrollment. Healthcare utilization data will be abstracted from the corporate data warehouse to reflect the 3-month post-enrollment timepoint. Finally, interviews will be conducted with a subset of participants.
214972872|NCT01848106|DRUG|pegnivacogin/anivamersen|
214972873|NCT01848106|DRUG|Bivalirudin|
214972874|NCT04723459|OTHER|ivermectin impregnated mask|mask with ivermectin nano solution
214972875|NCT02979782|PROCEDURE|Endo-CABG|minimal invasive cardiac intervention
214972876|NCT02979782|PROCEDURE|PCI|stenting procedure
214972877|NCT05732376|BEHAVIORAL|Nasopharyngoscopic Velopharyngeal Training with 3D Printed Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the 3D printed endoscopy training model. Participants will receive hands-on training on the 3D printed endoscopy training model, under the guidance of the principal investigator."
214972878|NCT05732376|BEHAVIORAL|Nasopharyngoscopic Velopharyngeal Training with Ready-Made Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the ready-made endoscopy training model. Participants will receive hands-on training on the ready-made endoscopy training model, under the guidance of the principal investigator."
214972879|NCT00818584|DRUG|Micafungin|IV Administration
214488613|NCT07035626|DRUG|Spermidine|As a member of the polyamine family, spermidine is a trivalent cationic compound found in eukaryotic cells. It interacts with polyanions such as nucleic acids, proteins, and ATP through electrostatic binding, thereby maintaining genomic DNA stability, regulating gene transcription and translation, and modulating autophagy, apoptosis, oxidative stress, angiogenesis, and intercellular communication. Spermidine is indispensable for cell division and proliferation.
214488614|NCT07035626|DRUG|Spermidine simulants|Patients in control group were treated with Spermidine simulants, and its use method and use time are the same as intervention group.
214488615|NCT07038681|OTHER|Mediterranean Diet Intervention Group|In the same way as the control group, the intervention group receives standard nutritional care from the hospital nutritionist, since all the pregnant women have at least one of the following risk factors: obesity, diabetes or hypertension, nutritional - standard-care procedure in the Portuguese National Health System.
214488616|NCT07038681|OTHER|Control Group (Standard Hospital Dietary Care)|The control group will receive standard care from the nutritionist in the hospital.
214488617|NCT07039409|BEHAVIORAL|Acupressure|Patients will receive three 1-hour sessions of training at home within 3 days by Community Psychiatric Nurse (CPN), who was trained by an experienced TCM practitioner. They will learn acupressure. After the training, they will be assessed by the CPN to ensure that they are able to identify the acupoint based on reports of a sensation of obtaining 'Qi' when using the Point Locator device. They will then apply constant pressure for approximately 1 minute on each acupoint using the Acupen, as indicated by a marking in red by themselves. To ensure treatment compliance, the participants will apply this intervention once per day for 10 days. During the 10-day intervention period, and the patient should sign in on WhatsApp every day. If the patient is unable to use WhatsApp, the print edition of diary will be provided and supervision will be performed by short message and home visit during the 1st day, 5th day and 10th day of the intervention period.
214488618|NCT07039019|DRUG|Corticosteroid|Patients take 40 mg of prednisone daily for 4 weeks to help reduce inflammation.
214488619|NCT07039019|OTHER|No Corticosteroid|Patients do not take corticosteroid.
214488620|NCT07039747|DRUG|treatment with DIELEN® Protect|treatment with DIELEN® Protect for 8 weeks at a dose of 5 grams, 3x a day
214488621|NCT07039747|DRUG|treatment with placebo of DIELEN® Protect|treatment with placebo of DIELEN® Protect for 8 weeks at a dose of 5 grams, 3x a day
214488622|NCT05846789|DRUG|SOC Chemotherapy|SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
214488623|NCT05846789|DRUG|Tocilizumab|Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
214488624|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (Zepbound) placebo"
214488625|NCT06732245|DRUG|Tirzepatide|"Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound NA-931 Placebo (oral, daily)"
214488626|NCT06732245|DRUG|Tirzepatide|"Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist~• Other Names:~* Mounjaro~* Zepbound~NA-931 Placebo (oral, daily)"
215083868|NCT07040683|OTHER|Traditional Dressing|Traditional dressing applied over the split-thickness skin graft on the lower leg after tumour excision. The dressing consists of one or more layers of foam dressing applied on top, which may or may not be fixed with sutures according to surgeon preference, and an elastic bandage applied over the foam to provide gentle, even compression and immobilisation of the graft. The dressing will remain undisturbed until postoperative day 5 unless earlier change is clinically indicated.
215083869|NCT04528615|BEHAVIORAL|CCK In-Person Sessions|This group attended eight weeks of nutrition education-focused experiential learning.
214488627|NCT06732245|DRUG|NA-931|"NA-931, an oral, daily~• A quadruple receptor agonist"
214488628|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
214488629|NCT06732245|DRUG|NA-931|"NA-931 (oral daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
214488630|NCT06732245|DRUG|NA-931 150 mg + no Tirzepatide|NA-931 150 mg + no Tirzepatide
214488631|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
214488632|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
214488633|NCT06738667|OTHER|Acupuncture|Patients in the acupuncture group will receive treatment at specified acupoints, performed by acupuncturists with at least five years of experience. The acupoints include bilateral Hegu (LI4), Yanglingquan (GB34), and affected-side Jiache (ST6), Xiaguan (ST7), and Tinggong (SI19). Participants will lie supine, and the skin will be sterilized. Sterile stainless-steel needles (0.25 mm diameter, 40 mm length) will be inserted using a guide device and a self-adhesive pad. Needles will be manipulated for at least 10 seconds to induce Deqi. Participants will receive 30 minutes of acupuncture for twelve sessions (3 per week for 4 weeks).
214488634|NCT06738667|OTHER|Sham treatment|The Park Sham device will be used for the sham acupuncture group. To maintain blinding, the acupuncture ritual will be identical in both groups, with the following exceptions: patients in the sham group will receive noninvasive acupuncture at the same acupoints as the acupuncture group. Sham needles, which resemble real needles but are blunt and slide within their handles, will be applied using the Park Sham device, secured to the skin with a self-adhesive pad. The procedure of manipulation is the same as for acupuncture, but without Deqi.
214488635|NCT06737744|OTHER|Active Games for Change (AG4C)|This intervention was carried out in Turkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The programme included a series of innovative, face-to-face active games with a non-formal approach that prioritised physical activity, specifically designed to support the development of social and emotional competencies identified for the first time in the field in a probation directorate serving young adult offenders.
214488636|NCT06737744|BEHAVIORAL|Active Games for Change Group Working|The Active Games for Change intervention program was implemented in Izmir, Türkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The AG4C intervention program included a series of innovative, face-to-face active games with a non-formal approach that prioritised support for developing social and emotional competencies of young adults with substance use problems, for the first time in the field.
214488637|NCT05197400|DIAGNOSTIC_TEST|preoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
214488638|NCT05197400|DIAGNOSTIC_TEST|postoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
214488639|NCT05321784|OTHER|Dermoscopy|Take digital dermoscopy images (DDI)
214488640|NCT05321784|OTHER|Digital Photography|Take smartphone clinical images (SCI)
214488641|NCT05321784|PROCEDURE|Self-Skin Examination|Perform self-skin exam (SSE)
214488642|NCT05321784|DEVICE|Skin Examination with Sklip|Apply Sklip System
214488643|NCT05321784|PROCEDURE|Skin Examination|Undergo in-person full body skin examination (FBSE)
214488644|NCT05321784|OTHER|Survey Administration|Ancillary studies
214488645|NCT05480098|DRUG|Brimonidine Topical|Topical brimonidine intraoperatively for hemostasis
214488646|NCT06863285|OTHER|Educational|"intervention included the usual counselling by pharmacist e.g. Patients Education regarding Medications~* Pharmacist counseling patients regarding their disease and severity~* Pharmacist counseling (5- to 10-minute sessions) on the proper and safe use of medication.~* Pharmacist counseling patients regarding the importance of their therapy (treatment), non-pharmacological treatment like diet and exercises.~pharmacist counselling regarding the preventive measures that prevent patient from triggers that can initiate asthmatic attacks."
214488647|NCT06887140|DIAGNOSTIC_TEST|Echocardiography|"* First echocardiography: within 24 hours after study enrollment,~* Second echocardiography: 48-72 hours after the initial echocardiography.~* The recorded echocardiographic parameters include:~  * Morphological and Functional Parameters~ * Mitral Valve Flow Parameters~ * Tissue Doppler Echocardiography Parameters~ * STE Parameters for Left Ventricle Assessment~ * STE Parameters for Right Ventricle Assessment"
214488648|NCT06756412|PROCEDURE|Temporomandibular Joint Arthrocentesis|The symptomatic temporomandibular joint (TMJ), either right or left, will be anesthetized using an auriculotemporal nerve block and intracapsular anesthesia. The arthrocentesis procedure will be performed using the double-puncture technique. A 21-gauge needle will be inserted into the posterior region of the joint capsule, targeting the upper joint compartment at a point located 10 mm anterior to the tragus. A second 21-gauge needle will be introduced into the anterior region of the joint capsule, also targeting the upper compartment, at a point located 20 mm anterior to the tragus. The upper joint compartment will then be irrigated with a minimum of 200 mL of saline solution through one of the needles.
214488649|NCT06756412|PROCEDURE|Self Exercise Following Arthrocentesis|Following the arthrocentesis procedure described for the other study group, patients will undergo a standardized exercise regimen based on established literature. The regimen includes two sets of movements. The first set involves freely opening the jaw, shifting it right, left, and forward, and repeating these movements while applying finger resistance-closing the mouth against the pressure or forcing the jaw open with the fingers. Each movement will last 10 seconds and be performed 10 times daily. The second set aims to improve the mandibular condyle-articular disc relationship. Patients will open their mouth as wide as possible, advance their lower jaw fully, and close their teeth in an edge-to-edge position. These movements will be performed three times daily for 5 minutes after meals.
214488650|NCT06734182|DRUG|Envafolimab injections+intravenous Disitamab Vedotin+carboplatin|Biological: Envafolimab 300 mg by subcutaneous injections every 3 weeks (Q3W), given on cycle day 1; Biological: Disitamab Vedotin 2.5mg/kg by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;
214488651|NCT06735365|OTHER|CRRT|Hemodiafiltration
214488652|NCT06808061|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus plantarum KABP-51
214488653|NCT06808061|DIETARY_SUPPLEMENT|Placebo|maltodextrin
214488654|NCT06890429|BIOLOGICAL|RSV/Flu-01E|Participants will receive single intranasal injection of RSV/Flu-01E vaccine in 0.5 ml, containing 8.4 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the F antigen of respiratory syncytial virus
214488655|NCT06890429|OTHER|Placebo|Participants will receive single intranasal injection of physiological buffer solution in 0.5 ml
214488656|NCT06747312|DRUG|Belimumab+SOC|10mg/kg once a month for 18 months
214488657|NCT06747312|DRUG|SOC|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
214488658|NCT05821283|PROCEDURE|exercise program consisting of supervised exercise and physical activity|The Physical Activity Group (PAG) included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking). Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions.The physical activity program was applied as moderate intensity (maximum heart rate 50-70%) walking exercise. The patients were recommended to walk for 30 minutes, 3 days a week (total of 90 minutes) for the first 3 weeks, and 30 minutes 5 days a week (total of 150 minutes) for the 2nd 3 weeks
214488659|NCT05821283|PROCEDURE|exercise program consisting of only supervised exercises.|The Control Group (CG) included in the program consisting of only supervised exercises. Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions
214488660|NCT06797414|OTHER|Pilate Exercises|"PILATES EXERCISE METHODS:~1. The cranium, triceps, back, and shoulder blades against the mat, then breath while maintaining muscle contraction .~2. Arm circles (both directions) on the mat, then use strong ribcage breathing to connect into scapula.~3. Diamond press: lie prone on a mat, using the lower part of the trapezius and serratusanterior muscles to slide shoulder blades out and down. Move into slight back extension maintaining this position.~4. Diamond press: repeat above but add lateral arm movement to back extension .~5. Arm slides 90°: lies supine on mat with arms bent at 90° and thumbs on floor. Slide elbows on floor toward waistline while contracting serratus anterior muscle.Repeat on the floor with other fingers. Always maintain proper neck alignment .~6. Arm circles on a tiny barrel while lying on back with the head and neck supported by the barrel. Opened chest, then link the scapula to the barrel. Hold this position while performing arm circles."
214972880|NCT04851106|DIAGNOSTIC_TEST|Endoscopic ultrasound|Diagnosis of pancreatic adenocarcinoma with endoscopic ultrasound.
214972881|NCT05848960|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral supplement|2 supplements per day
214972882|NCT05848960|OTHER|Mediterranean diet|Mediterranean diet
214972883|NCT00388791|DRUG|Systane Free|
214972884|NCT00370500|DRUG|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
215083870|NCT04528615|BEHAVIORAL|CCK Printed Materials|This group did not attend any in-person sessions and was only provided with select CCK written materials.
215083871|NCT01867957|BIOLOGICAL|Low-dose GC1109|50ug/dose
215083872|NCT01867957|BIOLOGICAL|High-dose GC1109|100ug/dose
215083873|NCT01867957|BIOLOGICAL|Low-dose Placebo|0.9% Saline 0.5 mL
215083874|NCT01867957|BIOLOGICAL|High-dose Placebo|0.9% Saline 1.0 mL
215083875|NCT04942665|DRUG|Indocyanine green|Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).
215083876|NCT04942665|DEVICE|PINPOINT Endoscopic Fluorescence|The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.
215083877|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Oral Solution
215083878|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 125 mg|Oral Solution
215083879|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 250 mg|Oral Solution
215083880|NCT03554772|DRUG|Placebo|Oral Solution
215083881|NCT03729193|BEHAVIORAL|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
215083882|NCT03148145|BEHAVIORAL|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
215083883|NCT03148145|BEHAVIORAL|Message Delivery by Smartphone|Message Delivery by Smartphone
215083884|NCT05136898|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
215083885|NCT05110469|DRUG|Magnesium sulfate|"IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
215083886|NCT05110469|DRUG|Meperidine|"IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
215083887|NCT05709522|BEHAVIORAL|Neurocognitive tools|Neurocognitve and psychological tools
214972885|NCT04644406|OTHER|Efficacy of the Pertuzumab-Trastuzumab combination|The efficacy of the pertuzumab in combination with one of the biosimilars of Trastuzumab will be estimated by measuring the PFS at 6 months after the beginning of the treatment.
214972886|NCT02353026|DRUG|Intravenous Artesunate|Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
214972887|NCT01975558|BIOLOGICAL|Sampling at baseline, one week after baseline, two weeks after baseline|
214972888|NCT01975558|BIOLOGICAL|Sampling at baseline, during radiotherapy and after|
214972889|NCT00299065|DRUG|Zileuton injection|
214972890|NCT02869789|DRUG|Nivolumab in combination with Ipilimumab|Specified dose on specified days
214972891|NCT02389959|DRUG|Bevacizumab|Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
214972892|NCT02389959|DRUG|Placebo (Saline)|4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
214972893|NCT03199352|OTHER|RYGB hand-sewn|Patients will have the RYGB anastomosis hand-sewn
215083888|NCT03784846|BEHAVIORAL|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
215083889|NCT03784846|BEHAVIORAL|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
215083890|NCT00390481|PROCEDURE|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
214972894|NCT03199352|OTHER|RYGB linear-staple|Patients will have the RYGB anastomosis performed using a linear staple.
214972895|NCT01566604|DRUG|NVA237|Delivered via a single dose dry powder inhaler
214972896|NCT01566604|DRUG|Placebo|Delivered via a single dose dry powder inhaler
214972897|NCT00339417|DRUG|Albendazole|
214972898|NCT00339417|DRUG|Ivermectin|
214972899|NCT05067855|OTHER|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
214972900|NCT03225170|BEHAVIORAL|Self Affirmation (SA)|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.
214360855|NCT04010630|DRUG|Sodium bicarbonate infusion|"Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion.~Bicarbonate infusion recommendations will be as follow: a central line is recommended, infusion will be slow (125-250ml in 30 min, no intravenous push), careful surveillance of metabolic alkalosis, cardiogenic pulmonary edema, kalemia, natremia and calcemia. Repeated arterial blood gases will be suggested to monitor these critically ill patients and physicians will be reinformed of the potential side effects of sodium bicarbonate infusion."
214360856|NCT05830994|PROCEDURE|G-POEM|An Endoscopic submucosal tunnel is formed and extended to the first part of the duodenum, followed by a pyloromyotomy, beginning approximately two centimetres proximal to the pylorus and ending in the first part of duodenum.
214360857|NCT05830994|PROCEDURE|Sham|Endoscopy is performed and tissue samples are collected from fundus and antrum as part of the Sham procedure
214360858|NCT03610295|PROCEDURE|PPI group|The patients underwent cataract extraction, posterior capsulotomy, anterior vitrectomy combined with prophylactic peripheral iridectomy.
214360859|NCT03610295|PROCEDURE|cataract extraction|The patients underwent cataract extraction, posterior capsulotomy combined with anterior vitrectomy and leave the iris intact.
214360860|NCT00163579|DRUG|Bryophyllum|
214488661|NCT06797414|OTHER|Whole-body vibration|Subjects were placed in a modified push-up position , put their hands in the middle of the platform, shoulder width apart, elbows slightly flexed, and their lower extremities were supported by kneeling on the floor . Vibration protocol included 5 sets of 60 s duration, at 5 mm amplitude and 30 Hz frequency, with a rest period of 60 s between sets . The subjects were reminded kneeling but upright and detached from the platform between sets.
214488662|NCT06797414|DEVICE|Hot Pack|for 10 to 15 minutes
214488663|NCT06745076|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214488664|NCT06745076|PROCEDURE|Computed Tomography|Undergo CT scan
214488665|NCT06745076|DRUG|Dacarbazine|Given IV
214488666|NCT06745076|DRUG|Doxorubicin|Given IV
215083891|NCT05544175|PROCEDURE|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation: Spinal cord stimulation affects nerve tissues with a defined electrical current. We will use low-voltage electrical stimulation of the posterior roots of the spinal cord in the MRI region of the localized conus medullaris. Electrodes are inserted epidurally from a laminotomy in the lumbosacral region.~Physiotherapy will be based on recommendations for spinal patients."
215083892|NCT04805203|OTHER|blood sample analyses|maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
215083893|NCT00867087|DRUG|inotuzumab ozogamicin (CMC-544)|1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
215083894|NCT00867087|DRUG|rituximab|375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
215083895|NCT03597178|DEVICE|senofilcon A|ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
215083896|NCT03564964|DRUG|SUVN-502|Tablet
214488667|NCT06745076|PROCEDURE|Echocardiography Test|Undergo echocardiography
214488668|NCT06745076|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214488669|NCT06745076|BIOLOGICAL|Nivolumab|Given IV
214488670|NCT06745076|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214488671|NCT06745076|DRUG|Vinblastine|Given IV
214488672|NCT06745076|OTHER|Questionnaire|Complete questionnaire
214488673|NCT05301335|DEVICE|SCONE|The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes
214488674|NCT06754566|BEHAVIORAL|Caregiver-Assisted Rehabilitation with Strategy Training|CAR-ST is a home-based rehabilitation that guides both stroke survivors and their caregivers to implement strategy training for addressing daily activity limitations after stroke. The caregiver, as an active partner, not only supervises the participant but also co-participates in the practice. Caregivers are instructed on when and how to provide assistance during task practice, using physical, verbal, or visual guidance. As the participant's performance improves, the caregiver is empowered to motivate them to exert greater efforts, encouraging higher repetitions, longer durations of the same task, and an increased level of difficulty.
215083897|NCT02088073|DRUG|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
215083898|NCT02088073|DRUG|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
215083899|NCT03972319|DIETARY_SUPPLEMENT|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
215083900|NCT04693104|DEVICE|PVA Hydrogel|PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.
214360861|NCT00163579|OTHER|Placebo|
214360862|NCT02162784|DRUG|Budesonide/Procaterol, 180/10mcg X1|one puff
214360863|NCT02162784|DRUG|Budesonide/procaterol 180/10 mcg X 2|2 puffs
214360864|NCT02162784|DRUG|Albuterol HFA MDI 100mcg X2|HFA MDI, 100mcg, 2 puffs
214360865|NCT00768820|DRUG|methylphenidate, fluoxetin, risperidone|first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
214360866|NCT06525948|DRUG|rhTPO|rhTPO
214360867|NCT06525948|DRUG|Cyclosporin A|cyclosporine A
214360868|NCT02608398|OTHER|no intervention|NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
214360869|NCT01523054|DRUG|Metoprolol- Toprol XL|Extended release tablet, 200mg once daily for 4 days
214360870|NCT01523054|DRUG|Metoprolol- Lopressor|Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
214360871|NCT06490562|DRUG|PDCy|Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD
214360872|NCT06490562|DRUG|Non Cy|Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
214488675|NCT06754566|BEHAVIORAL|Strategy Training|Compared to CAR-ST, ST is a home-based rehabilitation that guides stroke survivors only to implement strategy training for addressing daily activity limitations after stroke.
214488676|NCT06754566|BEHAVIORAL|Education|Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequala, and adaptive skills for impaired functions are provided.
214488677|NCT06281054|PROCEDURE|Revascularization|Performing PCI or CABG
214488678|NCT06847425|PROCEDURE|Sphenopalatine Ganglion Block trans oral approach saline injection|The sphenopalatine block will be done by the end of the operation using a trans-oral approach at the greater palatine foramen with the help of a Macintosh blade number 3 for good visualization of the hard and soft palate using a 25 Gauge 1.5 inch needle curved at 45 degrees 25 mm from the tip and filled with 1.5 ml of normal saline. The greater palatine foramen is located posteromedial to the third maxillary molar and anteromedial to the pterygoid hamulus and maxillary tuberosity. The foramen will be identified by digital palpation, and the needle will be inserted until reaching the bone then redirected slightly until the foramen is localized and the needle easily gets in the greater palatine canal. aspiration will be done to ensure that no blood vessels are punctured, and the solution will be injected.
214488679|NCT06847425|PROCEDURE|Sphenopalatine ganglion block trans oral approach bupivacaine injection|The sphenopalatine block will be done by the end of the operation using a trans-oral approach at the greater palatine foramen with the help of a Macintosh blade number 3 for good visualization of the hard and soft palate using a 25 Gauge 1.5 inch needle curved at 45 degrees 25 mm from the tip and filled with 1.5 ml of bupivacaine. The greater palatine foramen is located posteromedial to the third maxillary molar and anteromedial to the pterygoid hamulus and maxillary tuberosity. The foramen will be identified by digital palpation, and the needle will be inserted until reaching the bone then redirected slightly until the foramen is localized and the needle easily gets in the greater palatine canal. aspiration will be done to ensure that no blood vessels are punctured, and the solution will be injected.
214488680|NCT05510921|OTHER|Minimalist music group|Participants in this group will listen individually a live session of minimalist music piano piece, in a break room in the oncology sector, lasting between 10 and 15 minutes.
214488681|NCT05510921|OTHER|Minimalist music + birdsongs group|Participants in this group will listen individually a live session of minimalist music piano piece with the superposition of bird song sounds, in a break room in the oncology sector, lasting between 10 and 15 minutes.
214488682|NCT06836037|DRUG|Efinopegdutide|Subcutaneous injection
214488683|NCT06836037|DRUG|Placebo|placebo matching efinopegdutide
214488684|NCT06830941|DRUG|Iron isomaltoside|Intravenous infusion of 1000mg iron isomaltoside as a single dose for over 15min. Iron isomaltoside 1000mg was diluted in 100ml of 0.9% saline.
214488685|NCT06830941|DRUG|Ferrous succinate|Patients received ferrous succinate treatment orally given as 200mg twice a day for 8 weeks.
214488686|NCT06786377|GENETIC|saliva sampling|saliva sampling
214488687|NCT03487185|DEVICE|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
214488688|NCT03487185|OTHER|Sleep Advice Control|Initial sleep advice counseling alone
214488689|NCT04338152|BEHAVIORAL|Family Focused Therapy for Clinical High Risk Youth (FFT-CHR)|Family-Focused Therapy (FFT) has been tested in randomized trials involving persons with bipolar disorder, depression, and clinical high-risk syndromes. FFT-CHR provides families with psychoeducation (sessions 1-6) about prodromal symptoms and the role of the family in helping maintain stability. Clients are supported in building coping skills and monitoring thoughts, perceptions, and mood. The family formulates a prevention action plan to prevent prodromal symptoms from escalating into full episodes. Communication training (sessions 7-13) teaches families to express positive and negative feelings, listen actively, make positive requests for change, and communicate clearly through role-playing and between-session practice. In problem solving (sessions 14-18) participants learn to break down problems into smaller ones, evaluate pros/cons, and choose solutions to implement.
214488690|NCT04338152|BEHAVIORAL|Enhanced Care (EC)|Enhanced care (EC) has been tested as a family educational treatment in CHR and bipolar youth. The first 3 sessions of EC involve the CHR person and family (parents, siblings) and cover the same content as the psychoeducational module of FFT in abridged form. The objective of these sessions is to develop a prevention action plan. Then, the CHR person is offered monthly individual sessions with the same clinician over the next 5 months, for a total of 8 sessions over 6 months. The individual sessions focus on applying the prevention action plan when symptoms emerge, and supportive, nondirective problem-solving regarding areas of conflict with family, with peers or in the educational or occupational arena. The clinician also serves as case manager.
214488691|NCT06747988|DEVICE|Traction Device|After circumferential incision and trimming the submucosa at the incision's edge, dissection is initiated until approximately 20 to 30% of the anal side (for colonic lesions) or oral side (for gastric lesions) of lesion has been dissected leaving a flap of at least 1 cm in length. Once the mucosal flap is created the X-tack device is introduced through the endoscope channel. The first tack is placed on the opposite wall of the lesion, the 2nd and 3rd tack will then be placed next to each other on the mucosal flap portion of the lesion. The 4th tack does not have to be placed but can be used to generate further traction at any time. Clips can be placed along the suture and clipped to the wall at any point to change angulation of traction. The sutures can then be cut and released from the tissue
214488692|NCT06747780|BEHAVIORAL|Text messaging|A digital booklet, text messages for two weeks, and two family-based activity boosters
214488693|NCT06747780|BEHAVIORAL|Control (Usual care)|Control only
214488694|NCT02728336|PROCEDURE|Cardiac MRI|
214360873|NCT02230956|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
214360874|NCT02230956|DRUG|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
214360875|NCT00338884|DRUG|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
214488695|NCT05406349|BEHAVIORAL|Self-navigation task|Participants will perform a self-navigation task with two experimental conditions: Either they will be asked to walk towards a visible wall-mounted sign, or they will be asked to find and learn a hidden target location within the experimental room.
215083901|NCT04693104|DEVICE|Synvisk-One®|Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
215083902|NCT04510883|BEHAVIORAL|PACO|The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
215083903|NCT04510883|BEHAVIORAL|Waiting list + PACO|Waiting list + PACO
215083904|NCT04972227|DRUG|CY6463|oral tablets
215083905|NCT04972227|DRUG|Placebo|oral tablets
215083906|NCT01430923|DRUG|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
215083907|NCT01430923|DRUG|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
215083908|NCT03417596|OTHER|Control|Routine treatment
215083909|NCT03417596|BEHAVIORAL|Vestibular Rehabilitation|Exercise and rehabilitation programme was individualized
215083910|NCT02059551|PROCEDURE|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
215083911|NCT04389112|OTHER|biopsy|Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
215083912|NCT04634708|OTHER|No intervention|No intervention due to observational design
215083913|NCT05135195|OTHER|In-House Developed VR Platform - AMD, DR, Glaucoma|Participants will conduct experiments using commercial VR headsets and controllers. Visual impairments will be systematically simulated in VR. There are three visual impairment simulations (AMD, DR, and glaucoma) at three levels of severity (mild, moderate, or severe). Symptoms' simulation tools include a gaussian blur shader, distortion shader, and a culling mask with a gray spot in the middle.
215083914|NCT05135195|OTHER|In-House Developed VR Platform - Glaucoma|In the second set of experiments, a multidimensional visual impairment simulation of a single pathology (glaucoma) will be used at three levels of severity (mild, moderate, or severe). The post-processing package to simulate includes glare, difficulty in light, change adaptation, ambient occlusion, visual clutter, and overall blurred effect. The shader graph package will be used to create a distortion localized on assets surfaces only.
215083915|NCT00241631|DRUG|Fluticasone Propionate|500 u
215083916|NCT00241631|DRUG|placebo|
215083917|NCT00241631|DRUG|Theophylline|Theophylline placebo capcule
215083918|NCT03604874|DRUG|Oxytocin|intravenous infusion
215083919|NCT03286946|PROCEDURE|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
214360876|NCT05196464|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Workshop|ACT workshops are single-day workshops that last 5-6 hours. The workshops will 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from unhelpful thoughts) and strategies to willingly face experiences that cannot be changed; and 2) Committed Action Training to help Veterans clarify what matters most to them (e.g., valued domains including family, friends, spirituality, career) and what they want to stand for in life, how they want to behave, and what strengths and qualities they want to develop. Within this context, the workshop will encourage engagement in, rather than avoidance of, actions consistent with valued directions, including engagement in healthcare. Workshop participants will be given homework related to implementing a key coping skill.
214488696|NCT05406349|BEHAVIORAL|Observation task|Participants will sit on a chair in a corner of the room (RNS participants) or watch a video that was recorded from the corner of the room (EMU participants). They will be asked to keep track of another person's location who is walking around the room, and to press a button whenever the other person crosses a previously-learned target location.
214488697|NCT06702657|DEVICE|balloon dilatation and/or stenting|balloon dilatation and/or stenting immediately after randomization
214488698|NCT06702657|DRUG|medication|medication after randomisation, mechanical thrombectomy again if necessary, avoiding balloon dilatation and/or stenting.
214488699|NCT00391443|DRUG|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg)
215083920|NCT03286946|PROCEDURE|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
215083921|NCT05180318|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
214488700|NCT00391443|DRUG|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
215083922|NCT05180318|DRUG|0.9% saline|0.9% saline
215083923|NCT05679167|BEHAVIORAL|Supervised digital training with focus on core stability|After randomization, Group 1 will be digitally supervised by experienced physiotherapist.
214488701|NCT04952129|DRUG|Selenomethionine|Seleno-amino acid
214488702|NCT04952129|DRUG|Methylselenocysteine|Seleno-amino acid
214488703|NCT04079517|DRUG|Tamoxifen|A registered SERM drug, Tamoxifen.
215083924|NCT05679167|BEHAVIORAL|Supervised digital training with focus on aerobic exercise|After randomization Group 2 will be digitally supervised by experienced physiotherapist.
214360877|NCT05196464|BEHAVIORAL|Treatment as usual (TAU)|TAU will consist of a consult to a mental health provider at their rural clinic. The patient will then be scheduled for an intake and offered traditional mental health treatment options. Treatment options are likely to include outpatient individual psychotherapy, psychotherapy groups, or medication management.
214360878|NCT06117280|OTHER|Paraxanthine 200 mg|For the three-day test cycle, participants will take one capsule per day amounting to 200mg of paraxanthine.
214360879|NCT06117280|OTHER|Paraxanthine 300 mg|For the three-day test cycle, participants will take one capsule per day amounting to 300mg of paraxanthine.
214360880|NCT06117280|OTHER|Placebo|The placebo will contain resistant dextrin. For the three-day test cycle, participants will take one capsule per day amounting to 300mg of resistant dextrin.
214360881|NCT02396745|DEVICE|Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))|"TECR will be performed to resect the entire length and area of BE lesion.~ECM PLACEMENT:~Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA)."
214360882|NCT06126354|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
214360883|NCT06126354|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
214360884|NCT06126354|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
214360885|NCT06126354|DRUG|Human Growth Hormone|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
214488704|NCT05650320|DRUG|0.3% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
214488705|NCT05650320|DRUG|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
214488706|NCT05650320|OTHER|0% OPA-15406 vehicle|Twice-daily administration for 4 weeks.
214488707|NCT01028963|DRUG|Placebo|Placebo capsules once daily
215083925|NCT05679167|BEHAVIORAL|Non-supervised daily physical activity|After randomization Group 3 will receive training instruction regarding daily physical activity.
215083926|NCT03883113|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
215083927|NCT03883113|BIOLOGICAL|Saline|Sodium Chloride Placebo
215083928|NCT03883113|BIOLOGICAL|H3N2 (A/Belgium/2417/2015)|Challenge Agent
215083929|NCT00237068|DRUG|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
215083930|NCT01767077|DIETARY_SUPPLEMENT|Butter oil|Daily intake of 40 g butter oil
215083931|NCT01767077|DIETARY_SUPPLEMENT|Cream|Daily intake of 100 g cream (40%)
214360886|NCT06126354|DRUG|Dexamethasone Oral|Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.
214360887|NCT06126354|OTHER|[6,6-2H2] D-glucose|"Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.~(Non-investigational)"
214488708|NCT01028963|DRUG|pioglitazone|pioglitazone 30 mg tablet once daily
214488709|NCT01028963|DRUG|CCX140-B|CCX140-B capsules once daily (Group C)
214488710|NCT01028963|DRUG|CCX140-B|CCX140-B capsules once daily (Group D)
214488711|NCT05993650|OTHER|Inspiratuar Muscle Training Group|Inspiratory muscle training will be done for 15 minutes/session, 2 times/day, or 30 minutes/day if tolerated, 5-7 days/week (one under supervision and others at home), for a total of 6 weeks. Applications made at home will be followed with a diary. Inspiratory muscle training will be performed using an inspiratory muscle training device (PowerBreathe®) working with the threshold loading principle.In the first week of the training, 30-50% of the maximal inspiratory pressure (MIP) measured in the initial evaluation of the individual will be adjusted according to the patient's tolerance, and inspiratory muscle training will be performed. Respiratory muscle strength measurement will be repeated every week in the individuals in the training group. 30-50% of the new MIP value obtained will be calculated and adjusted by calculating the new training workload for the application of inspiratory muscle training in the following weeks
214972901|NCT03225170|BEHAVIORAL|Control|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. The control group will rank the list and be asked to write about the 9th ranked item and why it might be important to someone else.
214972902|NCT01204034|DRUG|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
214972903|NCT03710330|DRUG|normal saline|110 ml normal saline IV just before skin incision
214972904|NCT03710330|DRUG|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
215083932|NCT04526353|DRUG|Oxybutynin 1 mg/ml Syrup|"The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.). It will be administered at the dose of 0.1 mg/kg/twice a day to patients randomized to the study treatment group. The dose will be adapted to the child's weight to the nearest kilogram.~The recommended dosage for older children with neurologic bladder is 0.3 to 0.4mg/kg/day, whilst the dosage we will be using is effectively 0.2mg/kg/day. This is because we are taking into account the absence or pharmacological studies of oxybutynin use in children \<1 year of age, as well as their specific liver metabolism. Furthermore, the dose of 0.1mg/kg twice daily is the dose used in children within the same age group in the study by Casey et al, 2012"
215083933|NCT04534101|BEHAVIORAL|Virtual Reality Mindfulness|This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.
214488712|NCT05993650|OTHER|Thoracic Expansion Exercise Group|"Individuals in this group will be given thoracic expansion exercises and patient education. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of inhale a deep breathing + holding the deep breath for 3 seconds + slowly exhale all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
214360888|NCT06126354|DRUG|20% D-glucose (aq)|"20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)"
214488713|NCT05025826|OTHER|Phycocare|Phycocare every day during 9 months (except days of chemotherapy: no Phycocare)
214488714|NCT05025826|OTHER|Placebo|Placebo every day during 9 months (except days of chemotherapy = no Placebo)
214488715|NCT06821594|DRUG|Furosemide|Furosemide 20mg/2ml and digoxin 0.5mg/2ml given 0.2 ml into the wart base once weekly for 5 weeks
214488716|NCT02446405|DRUG|Enzalutamide|
214488717|NCT02446405|DRUG|NSAA|
214488718|NCT02446405|DRUG|LHRHA or Surgical Castration|
214488719|NCT06852105|DRUG|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops were instilled into the inferior conjunctival vault of both eyes
215083934|NCT02838615|PROCEDURE|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
215083935|NCT03184363|DRUG|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
215083936|NCT05357963|PROCEDURE|Sternotomy application|The chronic pain findings of the patients who underwent sternotomy will be questioned at the postoperative 3rd month.
215083937|NCT04931290|PROCEDURE|Supracapsular Ahmed Glaucoma Valve plate delivery technique|incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.
215083938|NCT00902018|DRUG|Eltrombopag|The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
214360889|NCT06126354|DIETARY_SUPPLEMENT|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp.~(Non-investigational)"
214360890|NCT06126354|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|"Device: Harvard Apparatus PHD ULTRA CP syringe pump Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.~(Non-investigational)"
214360891|NCT06126354|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|"Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.~(Non-investigational)"
214360892|NCT06126354|OTHER|Normal saline|Normal saline (0.9% NaCl, aq), variable rate (as needed)
214360893|NCT06126354|OTHER|Human albumin|Human albumin (5%, aq), 0.4 g per 100 mL of infusion (0.4% (w/v) in insulin and OCT/GCG/GH bags)
214360894|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
214360895|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
214360896|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
214360897|NCT05103020|DRUG|intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Oxaliplatin : HAI 100mg/m2 IV over 2-hr, day 1 Leucovorin : 400mg/m2 IV over 2-hr, day 1 5-Fluorouracil : 2400mg/m2 infusion for 46-h Irinotecan : 180mg/m2 IV over 1.5-hr, day 1
214360898|NCT05103020|DRUG|IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Irinotecan : 180mg/m2 IV over 1.5-hr, day 1 Leucovorin : 400mg/m2, IV over 2-hr, day 1 5-Fluorouracil : 400mg/m2 IV bolus, day 1 5-Fluorouracil : 2400mg/m2, infusion for 46-h
214360899|NCT04766762|PROCEDURE|Acupuncture combined with placebo|This group will include 48 patients. Patients in this group will receive acupuncture combined with placebo. Participants are in the supine position. The bilateral Tianrong (SI 17) acupoints are needled for 1-1.5 inch with the direction tilted back 45±5 degrees. The bilateral Fengchi (GB 20) acupoints are needled for 0.5-1 inch with the direction tilted to nose. The bilateral Neiguan (PC 6) acupoints are also needled for 0.5-1 inch with the straight direction. In addition, 4-6 additional acupoints can be identified according to different syndrome types of patients. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Meanwhile, the dosage of placebo is 1 capsule twice a day and the treatment duration also lasts 8 weeks.
214360900|NCT04766762|PROCEDURE|Sham acupuncture combined with flunarizine hydrochloride|This group will include 48 patients. Participants in this group will receive sham acupuncture plus flunarizine hydrochloride. Participants are in the supine position and sham acupuncture is conducted. The bilateral Tianrong (SI 17) acupoints, Fengchi (GB 20) acupoints and Neiguan (PC 6) acupoints are selected, and 4-6 additional acupoints can be identified according to the syndrome type of the participants. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Moreover, the dosage of flunarizine hydrochloride is 5mg twice a day and the treatment duration also lasts 8 weeks.
214360901|NCT01982357|DEVICE|Laser Speckle Imaging and Diffuse Optical Spectroscopy|Laser Speckle Imaging and Diffuse Optical Spectroscopy
214488720|NCT06852105|DRUG|0.1% hyaluronic acid|0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
214488721|NCT06837038|DEVICE|rhythmic auditory stimulation|The intervention group was treated with a gait rhythm device under the supervision of the researchers. The complete gait training was conducted once a day for 15 minutes for 7 consecutive days. Each patient wore inertial sensors at both ankles during gait training to collect gait information during walking.
214488722|NCT06837038|DEVICE|No rhythm stimulation|The control group received gait training without rhythmic auditory stimulation under the supervision of the researchers. The complete gait training was conducted once a day for 15 to 20 minutes for 7 consecutive days. Each patient wore inertial sensors at both ankles during gait training to collect gait information during walking.
214488723|NCT06749418|DRUG|Eplerenone|Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.
214488724|NCT06748313|OTHER|Mango Pickle (Water-Based)|The ingredients used in Mango Pickle (Water-based) are Raw mangoes, Carrots, Lemon, Green chili, Gum Berry (Lasora), Grewia asiatica (Phalsa), Sea salt, Fenugreek seeds whole, Fenugreek mashed, Fennel seeds, Chili flakes, Coriander seeds, Turmeric powder, Cumin, Black seeds, Bay leaves, Mashed garlic, Mustard oil, Vinegar, and Water. The pickle's fermentation process will be completed in 6-7 days, and it will be ready to use.
214488725|NCT06748313|OTHER|Mango Pickle (Oil Based)|The ingredients used in Mango Pickle (Oil-based) are Raw mangoes, Carrots, Lemon, Green chili, Gum Berry (Lasora), Grewia asiatica (Phalsa), Sea salt, Fenugreek seeds whole, Fenugreek mashed, Fennel seeds, Chili flakes, Coriander seeds, Turmeric powder, Cumin, Black seeds, Bay leaves, Vinegar, Mashed garlic, and Mustard oil. The pickle's fermentation process will be completed in 6-7 days, and it will be ready to use.
214488726|NCT06748313|OTHER|Carrot Pickle (Water-Based)|The ingredients used in Carrot Pickle (Water-Based) are Carrots, Spring garlic, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
214488727|NCT06748313|OTHER|Radish Pickle (Water-Based)|The ingredients used in Radish Pickle (Water-Based) are Radish, Spring garlic, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
214488728|NCT06748313|OTHER|Onion Pickle (Water-Based)|The ingredients used in Onion Pickle (Water-Based) are Onion, Vinegar, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 3-4 days, and it will be ready to use.
214488729|NCT06748313|OTHER|Lemon & Chili Pickle (Water-Based)|The ingredients used in Lemon \& Chili Pickle (Water-Based) are Lemon, Green Chili, Turmeric, Vinegar, water, and salt. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
214488730|NCT06750718|DEVICE|Virtual Reality (VR)|Oculus Quest 2 (OQ2) advanced 256 GB all-in-one virtual reality headset, Wi-Fi will be used.
214488731|NCT06750718|OTHER|Comprehensive Sensorimotor Training|An exercise program consisting of Cervical JPSM, Cervical movement sense, and Oculomotor control exercises.
214488732|NCT06750835|PROCEDURE|SPSIP block|Serratus posterior superior intercostal plane block
214488733|NCT06750835|PROCEDURE|SAP block|Serratus anterior plane block
214972905|NCT03710330|DRUG|0.5 gm tranexamic acid|0.5 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
214360902|NCT01066325|BEHAVIORAL|Neuro Emotional Technique|"NET is considered an alternative stress-reduction technique. Its aim is to remove neurological abnormalities which have a specified physiopathological pattern. The goal of NET is to normalize the aberrant patterns through a physical correction.~During the NET procedure, various psychological components of the anxious state are considered: cognitions, emotions, and behaviours. These various components are explored for a physiological reaction in the participant. Once a physiological reaction is found, the practitioner helps the participant identify the specific emotion. The procedure is concluded when the patient no longer feels distress or discomfort. Following the intervention, patients frequently report feeling subjective relief."
214360903|NCT01066325|OTHER|Stretching Instruction|This arm is the Active Control Arm and will receive two 20-minute sessions of Stretching Instructions. During these instructions, participants will hold stretches for not longer than 5 seconds, which in not likely to have any therapeutic effect.
214360904|NCT01970982|OTHER|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
214488734|NCT06750835|PROCEDURE|Paravertebral block|"* The block will be administered under ultrasound guidance at the T2-T5 levels.~* A total of 15 mL of 0.25% bupivacaine will be injected into the paravertebral space on the side of the surgery."
214488735|NCT06750796|BEHAVIORAL|The Half Swaddling Application|Half swaddling application in term babies
214488736|NCT06647342|DRUG|Bleomycin|In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.
214360905|NCT01970982|OTHER|Smoking abstinence (SA)|SA for 5 days in confinement
214488737|NCT06805279|PROCEDURE|Axillary Vein Cannulation|"This study aims to evaluate the potential advantages of using the hockey stick ultrasonography probe for axillary vein cannulation and determine whether this probe enhances axillary vein imaging, accelerates the central vein cannulation procedure and reduces the rate of complications compared to the linear probe"
214972906|NCT01243060|DRUG|Almorexant|100mg
214972907|NCT01243060|DRUG|Almorexant|200mg
214972908|NCT01243060|DRUG|Zolpidem 10mg|10mg
214972909|NCT01243060|DRUG|Placebo|One-time dose of Placebo
214972910|NCT04060953|OTHER|Health-Related Quality of Life Report|Subject report and interpretation guide based on SPADE cluster scores
214972911|NCT02634073|DRUG|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
214972912|NCT02634073|DRUG|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
214972913|NCT00132535|DRUG|sulfadoxine-pyrimethamine intermittent preventive treatment|
214972914|NCT00132535|DRUG|chloroquine|
214360906|NCT01970982|OTHER|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
214360907|NCT05032001|DRUG|Biguanide, DPP4 inhibitors, SGLT2 inhibitors|Oral antidiabetic treatment during twelve weeks
214360908|NCT01146496|DEVICE|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
214360909|NCT03148223|DEVICE|auriculotherapy|The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
214360910|NCT04851483|DRUG|BAY2328065|Solid Form, Oral administration.
214488738|NCT06816173|DRUG|Propofol group|"Induction phase: Administer fentanyl at a dose of 2-3 mcg/kg, and after 3 minutes, administer propofol intravenously at a dose of 2.0 mg/kg.~Maintenance phase: Infuse propofol (4-12 mg/kg/h) and maintain a constant infusion of remifentanil at a rate of 0.05-0.4 μg/kg/min. Subsequently, perform regional block (0.25% ropivacaine 0.5 ml/kg) or caudal block (lower limbs or perineal area: 0.25% ropivacaine 0.5 ml/kg; lower abdomen/inguinal area: 0.25% ropivacaine 0.75 ml/kg). After the local anesthetic has taken full effect, stop the infusion of remifentanil."
214488739|NCT06816173|DRUG|Remimazolam group|"Induction phase: Administer fentanyl at a dose of 2-3 mcg/kg, and after 3 minutes, administer remimazolam intravenously at a dose of 0.45-0.55 mg/kg.~Maintenance phase: Infuse remimazolam (1-3 mg/kg/h) and maintain a constant infusion of remifentanil at a rate of 0.05-0.4 μg/kg/min. Subsequently, perform regional block (0.25% ropivacaine 0.5 ml/kg) or caudal block (lower limbs or perineal area: 0.25% ropivacaine 0.5 ml/kg; lower abdomen/inguinal area: 0.25% ropivacaine 0.75 ml/kg). After the local anesthetic has taken full effect, stop the infusion of remifentanil."
214488740|NCT06820320|DRUG|oral iohexol|Upon diagnosing chylous ascites, patients received oral iohexol treatment, a critical intervention in our therapeutic armamentarium. The initial oral dose was standardized to ensure a balance between efficacy and patient safety. In the event of a less than optimal response or significant drainage within the first 24 hours, a second identical dose of Iohexol was considered to maintain therapeutic concentration levels in the body.
214679331|NCT03481764|GENETIC|HRC-test|"Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used."
214360911|NCT04851483|DRUG|Placebo|Matching placebo of BAY2328065.
214679332|NCT01264965|DRUG|long acting oxycodone|10mg twice daily
214679333|NCT01264965|DRUG|extra strength acetaminophen|1,000 mg twice daily
214972915|NCT01668836|DRUG|Resveratrol|1 pill daily containing 500 mg/d of resveratrol for 30 days
214972916|NCT01668836|BEHAVIORAL|Caloric restriction|Diet of 1000kcal per day for 30 days
214972917|NCT05916222|BEHAVIORAL|Dynamic Temporal and Tactile Cueing (DTTC)|DTTC is a motor-based intervention where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment follows a temporal hierarchy where children receive multisensory cueing to establish accurate movements. First, the child imitates the clinician's production. If inaccurate, the child simultaneously produces the target with the clinician while cueing is provided. Upon achieving accuracy within simultaneous productions, the target is practiced within direct imitation while the clinician adds/fades cues based on the child's productions. When the child accurately produces the target in direct imitation, the target is practiced with varied prosody. Next, the target is practiced within delayed imitation where a child produces a word following a 2-3 second delay after the clinician's production. Upon accurately producing the target at all levels, the word is practiced within spontaneous productions.
214360912|NCT04665635|PROCEDURE|Rectosigmoid resection|Most of the colorectal involvements are observed in the seromuscular layer. In seromuscular infiltration, resection of the rectosigmoid colon or shaving of tumoral implants without resection can be performed.
214360913|NCT06579118|OTHER|Laughter yoga|The women in the experimental group were given laughter yoga sessions by the researcher.
214360914|NCT02503748|OTHER|Online tutorial|website informing about treatment options in localized prostate cancer
214360915|NCT03609112|OTHER|The WISC-V|The WISC-V (Weschler, 2016) which is measured with several indices: Verbal Comprehension Index (VCI), Visual Spatial Index (VSI), Working Memory Index (WMI), Fluid Reasoning Index (FRI), Processing Speed Index (PSI), and Full Scale IS (FSIQ).
214972918|NCT02779985|DIETARY_SUPPLEMENT|Lycium Barbarum mixed meal|This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
214360916|NCT03609112|OTHER|The NEPSY-II|The NEPSY-II (Korkman et al., 2012). The Narrative Memory subtest is designed to assess verbal memory using organised language material.
214360917|NCT03609112|OTHER|The Child Executive Function Evaluation Battery CEF|The Child Executive Function Evaluation Battery CEF (Roy et al., 2021), which aims to evaluate the four main components of executive function (inhibition, working memory, flexibility and planning).
214360918|NCT03609112|OTHER|"The CONNERS 3 long version"|"The  CONNERS 3 long version  (Conners, 2008), which assesses attentional skills by means of a questionnaire to be completed by parents."
214360919|NCT03609112|OTHER|"The BRIEF"|The 'BRIEF' (Gioia et al., 2013; parent version, teacher version), which is a behavioural evaluation inventory of executive functions completed by parents and teachers and which makes it possible to determine whether the child has, for example, difficulties with organisation, planning or behavioural regulation.
214360920|NCT03609112|OTHER|"The PEDS-QL quality of life"|"The PEDS-QL quality of life (Tessier et al., 2009) that will be completed by the parents and the patient concerns the day to- day functioning of the child (in school, relationships to others, physical abilities and emotional state)."
214360921|NCT03609112|OTHER|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort)|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort) which assesses fatigue in everyday life.
214488741|NCT06820320|PROCEDURE|Lymphangiography and Embolization|"When conservative methods fall short in resolving chylous ascites, our protocol advances to precise interventional treatments. The escalation begins with ultrasound-guided lymphangiography. Through unilateral or bilateral inguinal lymph node access, iodized oil contrast is infused via a 9 ml/hour micro-pump, meticulously monitored by fluoroscopic imaging at 3-5 minutes intervals.~Following precise localization of the leakage site, embolization is performed with a sequence of carefully calibrated steps. The process entails cone-beam CT scanning and 3D reconstruction for a clear depiction of the leak, followed by direct needle access to the lymphatic rupture under DSA guidance. A fine guidewire is inserted above the rupture, which facilitates the delivery of an embolizing mixture of iodized oil and NBCA glue. This is done with the utmost precision to prevent any spillage, ensuring the embolization's success and marking the conclusion of the procedure."
214488742|NCT05054257|DRUG|Autologous CAR19 T lymphocytes|First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
214488743|NCT06673342|BEHAVIORAL|Nutritional Counseling|Nutritional counseling based on Stephan's Curve. The Stephan's curve is a diagram that shows how the acidity of the oral cavity changes with consumption of food, specifically with added sugar. A laminated Stephan's curve will be used to show the drop of pH (acidity) based on the subject's reported daily consumption of food and snacks. Recommendations will be provided on a balanced diet according to the American Dental Association guidelines and recommendations on reducing the frequency of snacking.
214488744|NCT04285957|OTHER|Questionnaire administration pre test|"Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);"
214488745|NCT04285957|OTHER|Questionnaire administration - validation|Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
214488746|NCT06757179|DIETARY_SUPPLEMENT|Elysium Naso Gola|"Elysium Naso Gola Supplement is a dietary supplement designed to soothe the upper respiratory tract, providing a range of benefits thanks to the properties of its natural ingredients. Its anti-inflammatory, antibacterial, antifungal, antiviral, antioxidant, and prebiotic activities suggest a comprehensive product for supporting respiratory health.~Mullein promotes the functionality of the respiratory mucous membranes. Thyme supports nasal and throat well-being, aids in the fluidity of bronchial secretions, and has antioxidant properties."
214360922|NCT03609112|OTHER|The Family Functioning Inventory FAD)|The Family Functioning Inventory FAD (Speranza et al., 2006) is used to assess the family functioning of the child and his/her family. The short version is used as an indicator of general functioning.
214360923|NCT03609112|OTHER|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort)|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort) which assesses fatigue in everyday life.
214360924|NCT03298009|DRUG|Canagliflozin 100mg|2-week intervention
214360925|NCT03298009|DRUG|Placebo oral capsule|2-week intervention
214488747|NCT06757179|OTHER|Placebo|Placebo
214972919|NCT02779985|DIETARY_SUPPLEMENT|Control mixed meal|This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
214972920|NCT01987856|PROCEDURE|Blastocyst morphology|microscopic examination only
214972921|NCT05562063|DRUG|Sotagliflozin|Daily administration of sotagliflozin (2x200 mg, PO, OD) for 6 months.
214972922|NCT05562063|DRUG|Placebo|Matching placebo for 6 months.
214972923|NCT05263934|BIOLOGICAL|Depemokimab|Depemokimab will be administered
214972924|NCT05263934|BIOLOGICAL|Mepolizumab|Mepolizumab will be administered
214972925|NCT05263934|DRUG|Placebo matching mepolizumab|Placebo matching to mepolizumab will be administered.
214972926|NCT05263934|DRUG|Placebo matching depemokimab|Placebo matching to depemokimab will be administered.
214972927|NCT06638671|DRUG|Metformin Hydrochloride|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
214972928|NCT06638671|DRUG|Placebo|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
214972929|NCT05335811|DRUG|4-[18F]Fluoro-1-Naphthol|By vein (IV)
214972930|NCT02889224|OTHER|Obese|
214972931|NCT02889224|PROCEDURE|Hypercortisolism|
214972932|NCT02889224|OTHER|Hydrocortisone|
214972933|NCT02889224|OTHER|Control|
214360926|NCT03298009|RADIATION|PET imaging|1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
214360927|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
214360928|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
214360929|NCT01505023|DIETARY_SUPPLEMENT|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
214360930|NCT04496219|DEVICE|Acupuncture Therapy|Undergo acupuncture therapy
214360931|NCT04496219|BIOLOGICAL|BCG Solution|Given by intravesical injection
214972934|NCT00194935|DRUG|Topotecan|
214972935|NCT05854420|PROCEDURE|Modified anterior Lamellar Recession|ALR is one of the procedures used to treat cicatricial entropion and trichiasis. Few studies present the effect of modifications to this procedure in trachomatous entropion and trichiasis. Because trachoma is common in our country, there is a probability that the number of surgeries for TT will rise.
214972936|NCT05800756|DRUG|pyrotinib combined with trastuzumab, dalpiciclib and letrozole|Six 4-week cycles of dalpiciclib orally, 125mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28, and pyrotinib orally, 320mg, day 1-28, and trastuzumab, injection, 8 mg/kg loading dose in cycle 1, 6mg/kg in cycles 2-6, intravenous drops, 1 cycle on day 1-21.
214360932|NCT04496219|OTHER|Best Practice|Receive standard of care symptom management
214488748|NCT06860087|DIETARY_SUPPLEMENT|Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (200 µg/d)|50 Pregnant women with gestational diabetes mellitus will receive an oral supplementation of 200 µg of chromium picolinate (Nutraxin, B'IOTA Laboratories, Istanbul, Turquie) per day for 06 weeks, starting from their 28th week of pregnancy. 02 fasting blood samples will be taken: one just before the supplementation begins and the other upon its completion, to assess biomarkers of glucose and lipid metabolism, oxidative stress, and inflammation.
214488749|NCT06860087|DIETARY_SUPPLEMENT|Dietary Supplement: Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (400 µg/d)|50 Pregnant women with gestational diabetes mellitus will receive an oral supplementation of 400 µg of chromium picolinate (Nutraxin, B'IOTA Laboratories, Istanbul, Turquie) per day for 06 weeks, starting from their 28th week of pregnancy. 02 fasting blood samples will be taken: one just before the supplementation begins and the other upon its completion, to assess biomarkers of glucose and lipid metabolism, oxidative stress, and inflammation.
214488750|NCT04962139|DRUG|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
214972937|NCT02296658|RADIATION|intensity-modulated radiotherapy|A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
214360933|NCT04496219|OTHER|Quality-of-Life Assessment|Ancillary studies
214360934|NCT04496219|OTHER|Questionnaire Administration|Ancillary studies
214360935|NCT03508648|DRUG|GTx-024|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
214360936|NCT03508648|DRUG|Matching Placebo|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
214360937|NCT06265350|DRUG|Cadonilimab|Cadonilimab, 375mg，Q3W， IV
214360938|NCT06265350|DRUG|Bevacizumab|Bevacizumab, 7.5mg/kg，Q3W， IV
214360939|NCT06265350|PROCEDURE|Cryoablation|Patients accepted Cryoablation of pulmanary metastases
214360940|NCT04775680|BIOLOGICAL|ADG106 injection|ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
214360941|NCT04775680|BIOLOGICAL|PD-1 antibody injection|PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle
214360942|NCT05918068|DRUG|Metformin 500 mg/day|Metformin 500 mg/day in addition to non-pharmacological therapy
214972938|NCT02296658|DRUG|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
214972939|NCT00719160|DRUG|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
214972940|NCT00719160|DRUG|Placebo|Placebo 20 mg twice a day for 9 days
214972941|NCT01417975|BEHAVIORAL|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
214972942|NCT01417975|BEHAVIORAL|Passive Sitting Group|Participants will be required to sit passively on a chair for 10 minutes.
214972943|NCT03383991|PROCEDURE|Reverse Total Shoulder Arthroplasty|
214972944|NCT03383991|PROCEDURE|Hemiarthroplasty|
214488751|NCT04962139|OTHER|Vehicle Cream|ON101 Cream Placebo
214972945|NCT06028737|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
214972946|NCT06028737|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
214972947|NCT06028737|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
214972948|NCT06028737|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
214972949|NCT02638974|OTHER|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
214972950|NCT03081247|DRUG|BGF 320/14.4/9.6 µg MDI|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
214972951|NCT03081247|DRUG|BFF 320/9.6 µg|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
214972952|NCT05694858|COMBINATION_PRODUCT|Lignocaine-loaded maltose microneedle array patch|A biodegradable maltose microneedle array patch containing 12.5 mg lignocaine that will be applied on the participant's dorsal aspect of the hand for 30 minutes prior to venepuncture.
214972953|NCT05694858|DRUG|EMLA 5% patch|EMLA 5% cream applied on the dorsum of the participant's hand which will be subsequently covered with PVA-PET adhesive for 30 minutes prior to venepuncture
214972954|NCT06448949|OTHER|Flow Diverter Implantation|Patients must undergo flow diverter implantation and have DSA examinations of the parent artery and TCCD examinations of Flow Diverter Implantation performed preoperatively, three days postoperatively, and six months postoperatively.
214972955|NCT04014231|PROCEDURE|Diagnostic Imaging|Undergo placement of single wave application
214972956|NCT04014231|OTHER|Laboratory Biomarker Analysis|Correlative studies
214972957|NCT03576638|DRUG|Accordion Pill Carbidopa/Levodopa|AP 50/500 TID days 2-7
214972958|NCT03576638|DRUG|Sinemet CR 25Mg-100Mg Extended-Release Tablet|25/100 1.5 pills five times/day
214972959|NCT03462784|OTHER|Demographic, physical examination, data will becollected .|"Demographic data collected includ clinical diagnosis, sex, race, genotype, and phenotype.~Historical data included information regarding immunizations, infection exposures, surgical procedures, organ dysfunction(Organ dysfunction was defined as a history of requiring medical treatment for heart disease, diabetes (Type 1 or 2), hypoparathyroidism, hypothyroidism, growth hormone deficiency, or gonadal failure) age at transfusion initiation, chelation therapy, type of RBC product, transfusion reactions, and antigen matching. Data will be collected from chart review, patient interviews, blood banking records, and laboratory"
214972960|NCT04907214|DRUG|Empagliflozin 25 MG|Oral empagliflozin daily
214972961|NCT06421389|DRUG|Tranexamic Acid Powder|2g of sucralfate powder, 1g of tranexamic acid powder, and 1g of barium will be sprayed through the endoscopy precisely on the bleeding site
214972962|NCT03988153|COMBINATION_PRODUCT|Probiotic Milk Formula|Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
214360943|NCT05918068|COMBINATION_PRODUCT|Metformin 500 mg/day plus vitamin B6 300 mg/day|Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy
214972963|NCT02727049|OTHER|Osteopathic manipulative medicine (OMM)|Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
214972964|NCT03782714|DEVICE|Low-level laser therapy|It is a diode laser device that has laser set at low level, used for pain relief and inflammation reduction to induce healing
214972965|NCT04710719|DRUG|Triamcinolone Injection|Post surgical injection at site of keloid with TAC for 3 injections
214972966|NCT04710719|DRUG|Triamcinolone Injection and 5-fluorouracil injection|Post surgical injection at site of keloid with TAC and 5FU for 3 injections
214972967|NCT03030677|PROCEDURE|Pectoralis II block & catheter without Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
215083939|NCT00902018|DRUG|Romiplostim|three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
215083940|NCT00902018|OTHER|healthy controls|single blood draw for all measures included in the intervention arms
215083941|NCT03622671|PROCEDURE|Skeletonized LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
215083942|NCT03622671|PROCEDURE|Pedicled LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
215083943|NCT05700292|OTHER|High-intensity Interval Training|Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge \& knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.
214360944|NCT05918068|OTHER|non-pharmacological therapy|non-pharmacological therapy (healthy lifestyle modifications)
214360945|NCT03756103|DRUG|SPH3127 tablet Dose 1|Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
214360946|NCT03756103|DRUG|SPH3127 tablet Dose 2|Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
214360947|NCT03756103|DRUG|SPH3127 tablet Dose 3|Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
214360948|NCT03756103|DRUG|SPH3127 tablet Placebo|Oral SPH3127 tablet placebo, once daily for 8 weeks.
214360949|NCT00599612|DRUG|GW856553|A dose of 10mg GW856553 containing 50µCi of \[14C\]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
214360950|NCT01981733|DEVICE|geko|The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
214360951|NCT00765674|DRUG|Aliskiren|150 and 300 mg tablets
214360952|NCT00765674|DRUG|Amlodipine|5 and 10 mg capsules
214360953|NCT00765674|DRUG|Hydrochlorothiazide (HCTZ)|12.5 and 25 mg capsules
214360954|NCT00765674|DRUG|Placebo|tablet
214360955|NCT00765674|DRUG|Placebo|capsules
214360956|NCT04560257|DEVICE|High flow nasal cannula HFNC|High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
214360957|NCT00905918|DIETARY_SUPPLEMENT|vitamin E|Given orally
214360958|NCT00905918|OTHER|laboratory biomarker analysis|All patients undergo biomarker analyses
214360959|NCT02036489|DRUG|Vincristine|
214360960|NCT02036489|DRUG|Daunorubicin|
214360961|NCT02036489|DRUG|Prednisone|
214360962|NCT02036489|DRUG|L-asparaginase|
214360963|NCT02036489|DRUG|Ciclophosphamide|
214360964|NCT02036489|DRUG|Metotrexate|
214360965|NCT02036489|DRUG|ARA-C|
214360966|NCT02036489|DRUG|Hidrocortisone|
214360967|NCT02036489|DRUG|Mercaptopurine|
214360968|NCT02036489|DRUG|VP-16|
214360969|NCT02036489|DRUG|Dexametasone|
214360970|NCT02382198|DRUG|Glycopyrrolate|Drug to reduce drooling in patients with Parkinson's Decease.
214360971|NCT02382198|DRUG|Placebo|
214360972|NCT00305799|PROCEDURE|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
214360973|NCT02158676|DIETARY_SUPPLEMENT|Prebiotic|Fructooligosaccharides
214360974|NCT02158676|DIETARY_SUPPLEMENT|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
214360975|NCT02158676|OTHER|Placebo|Maltodextrin
214360976|NCT05584891|PROCEDURE|mastoidectomy and mastoid oblitration|Forty pediatric patients with cholesteatoma indicated for radical mastoidectomy or modified radical mastoidectomies will be enrolled in our study and we will be grouped into two groups: one will undergo radical mastoidectomy alone and their operation results will be compared to other group which includes twenty pediatric patients with mastoid obliteration operation.
214360977|NCT01769300|BEHAVIORAL|Clinical decision support for medication titration|Electronic health record-based clinical decision support for ADHD medication titration.
214360978|NCT03097705|DIAGNOSTIC_TEST|OCT (Optical coherence tomography)|RNFL AND IOP MEASUREMNTS
214972968|NCT03030677|PROCEDURE|Pectoralis II block & catheter with Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
214972969|NCT03030677|OTHER|catheter insertion|catheter insertion after Lidocaine dissection
214360979|NCT00990990|DRUG|PNU-100480|100 mg BID for 14 days
214488752|NCT05460520|BEHAVIORAL|VOR Readaptation|"The stimulus will be a combination of horizontal visual motion and a head maneuver. The subject will sit in a stationary chair, and a treatment provider will stand behind the subject. While the subject views the slow horizontal motion up to 10°/s of vertical stripes, the provider will gently hold the head of the subject above the ears and tilt the head in the roll (side-to-side) or pitch (up-down) plane by approximately ±20° at the frequency of 0.2 to 0.05 Hz for up to 10 min. The treatment will be repeated with breaks of approximately 5 min. A treatment session will last no longer 120 min including the breaks.~In Groups 1, 3, and 4, subjects will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius, and full-field visual motion will be generated with light projected on the wall of this chamber. In Group 2, visual motion will be presented on the screen of a VR headset. Unlike groups 3 and 4, groups 1 and 2 do not receive any complementary treatment."
214488753|NCT05460520|BEHAVIORAL|VOR Habituation|The subject will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius. Physical motion will be generated by rotating the chair sinusoidally to the left and right, and full-field visual motion will be generated with light projected on the wall of this chamber. Velocity storage will be weakened by inducing a conflict between physical and visual motions. Subjects will be first treated with a stimulus with a peak speed of 5°/s. The stimulus speed will be gradually increased from 5°/s on Day 1 to 40°/s on Day 5. In total, the subjects are expected to undergo 200-280 min of treatment over the five days, broken up into several 10-20 min sessions per day with a 10-min break in between. If signs or symptoms of motion sickness are reported by the subject (nausea, sweating), the session will be immediately paused. Treatment may be continued after a short rest if the discomfort is alleviated or on the following day.
214972970|NCT01023594|PROCEDURE|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
214972971|NCT01900041|DRUG|Pantovigar|1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
214972972|NCT01900041|DRUG|Minoxidil 2% only|1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
214972973|NCT04912843|DRUG|NR082 injection|Intravitreal injection（IVT）
214972974|NCT04912843|DEVICE|Sham Injection|Sham Intravitreal Injection
214972975|NCT01171157|OTHER|Routine sample collection|Collection of routine nasal/throat swab samples
214360980|NCT00990990|DRUG|Placebo|to match 100 mg BID for 14 days
214360981|NCT00990990|DRUG|PNU-100480|300 mg BID for 14 days
214972976|NCT03902769|PROCEDURE|Prescribing conventional chemotherapy while with holding allo-SCT|Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT
214972977|NCT05545176|OTHER|termination of resuscitation rules|Use retrospective data to analyze the accuracy termination of resuscitation rules and further develope a termination of resuscitation rule.
214360982|NCT00990990|DRUG|Placebo|to match 300 mg BID for 14 days
214360983|NCT00990990|DRUG|PNU-100480|600 mg BID for 14 days
214360984|NCT00990990|DRUG|Placebo|to match 600 mg BID for 14 days
214972978|NCT01997008|BEHAVIORAL|Intervention|Positive Affect Skills Training
214972979|NCT02100046|DRUG|Zarontin® (ethosuximide) and Stodal®|
214972980|NCT03857698|OTHER|Conservative Physical Therapy|"Patients who were discharged from the hospital and received the sutures will be supervised 2 days a week for 8 weeks. Exercise programs will be promoted individually.~* Ice application for pain, edema control~* Patellar mobilization~* Three-way straight leg lifting exercises~* Isometric exercises around the hips and knees~* Active assisted, active, resistant knee range of motion exercises~* Heel shift exercises in supine and sitting~* Hip abduction on the side lying~* Stretching exercises for patients with gastrosoleus, hamstring, hip flexor muscles~* Neuromuscular Electrical Stimulation (NMES) for quadriceps muscle of patients will be applied. The isometric quadriceps contraction observed during the procedure will be required to actively participate in the patients."
214972981|NCT03857698|OTHER|Body Stabilization Exercise|"In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~* Consecutive shoulder flexion and extension in supine~* Building a bridge~* Lower body and hip flip~* Single leg extension with bilateral arm elevation~* Resilient leg stretch with bilateral arm elevation~* Hip external rotation in lateral hospitalization~* Side-lying arm opening~* Shoulder girdle retraction on ball, horizantal abduction and extension"
214360985|NCT00990990|DRUG|PNU-100480|1200 mg QD for 14 days
214360986|NCT00990990|DRUG|Placebo|to match 1200 mg QD for 14 days
214360987|NCT00990990|DRUG|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
214360988|NCT00990990|DRUG|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
214360989|NCT00990990|DRUG|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
214360990|NCT00990990|DRUG|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
214488754|NCT05460520|BEHAVIORAL|Visual Motion Desensitization|The subject will be situated in darkness and view the movement of a visual pattern presented on a disk, sized 1 m in diameter and placed 1 m away from the subject with its center at the eye level. The disk will be rotated clockwise and counter-clockwise for up to 10 min at a fixed maximal speed within a treatment session but varying across sessions between 5 to 60°/s. Within a single session, the visual stimulus will be first presented with the subject sitting upright in a chair, and then the treatment will be repeated with the subject standing. The disk will be mounted on a vertical sled, so the center of rotation can be kept at the eye level when sitting and standing. A treatment session will be repeated or conducted with an increased visual motion speed up to 60°/s according to the subject's readiness. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions per day with a 10-min break in between
214488755|NCT05460520|BEHAVIORAL|Opposing visual motion stimulus|"The investigators characterize gravitational pull as a misaligned sense of upright in the velocity storage mechanism, and hypothesize that that this misalignment can be corrected with an opposing visual motion stimulus, e.g., backward pulling will be corrected with upward visual motion.~Patients in Group 5 will undergo view visual motion in a physical setting, and those in Group 6 under a VR setting. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions of 1-10 min per day with an approximately 5-min break in between."
214488756|NCT06746727|BEHAVIORAL|Acceptance and Commitment Therapy for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE)|This single-arm intervention will pilot a new, manualized intervention adapted from existing interventions using Acceptance and Commitment Therapy (ACT) to address alcohol use, PTSD, social functioning, and IPV use. ACT for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE) aims to assist Veterans in developing skills central to psychological flexibility (e.g., acceptance, mindfulness, commitment to values-based action) to improve their relationship functioning and decrease IPV use in the presence of PTSD symptoms (e.g., anger, irritability, detachment from others) and alcohol use issues (e.g., cravings, triggers, disconnection from valued roles).
214488757|NCT06747741|PROCEDURE|PNF stretching(Contract relax with agonist contraction)|1.Passively dorsiflex the patient's foot then ask to perform active planterflexion against resistance and hold for 7-10 sec then ask patient to perform dorsiflexion to the maximum available range.
214488758|NCT06747741|PROCEDURE|Conventional physical therapy|"Static Stretching:(Seated Calf Stretch With a Resistance Band)~1. Sit on the floor with your legs extended.~2. Loop a resistance band around one foot, holding both sides of it with your hands.~3. Gently pull your toes toward your shin until you feel the stretch in your calf.Repeat on the other side.~Isometric Calf Raise:~1. Stand with feet shoulder-width apart and arms at sides.~2. Engage your abs for stability and roll up onto the balls of your feet, lifting both heels off the floor.~3. Hold for 5 seconds, then return to the starting position. Frequency : 5 reps with 5-7Sec hold,3 days per week for 4 weeks (alternatively)"
214488759|NCT06717295|DIAGNOSTIC_TEST|DiNanoQ: A multi-cancer early detection (MCED) blood test|"Procedure: Participants will undergo a single blood draw at baseline.~Sample Analysis:~Platelet Isolation: Platelets will be extracted from the collected blood samples.~RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer."
214488760|NCT06717295|OTHER|DiNanoTrack: Therapeutic Response Monitoring Blood Test|"Procedures:~Blood Sample Collection: Participants will have blood samples drawn at three time points:~Baseline: Before therapy initiation. 6 Weeks Post-Therapy Initiation: To monitor early treatment response. 6 Months Post-Therapy Initiation: To assess longer-term therapeutic outcomes.~Sample Analysis:~Platelet and Immune Cell Isolation:~Platelets: Extracted from each blood sample to continue monitoring RNA profiles.~Immune Cells: Separated from the blood samples to analyse immune response to therapy.~RNA Analysis:~Platelet RNA: Analysed to observe changes in transcriptomic profiles over time using AI-based tools.~Immune Cell RNA: Examined to assess transcriptomic changes associated with therapeutic responses.~Data Correlation:~Therapeutic Response Assessment: RNA profiles from platelets and immune cells will be correlated with clinical outcomes to identify biomarkers predictive of treatment efficacy, progression-free survival, relapse, and drug resistance."
215083944|NCT05700292|OTHER|Moderate-intensity continuous training|Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.
215083945|NCT04053751|PROCEDURE|closed suctioning system|a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
214360991|NCT00990990|DRUG|Linezolid|300 mg QD for 4 days (open label)
214360992|NCT01825681|BEHAVIORAL|Positive Affect|Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
214360993|NCT05902832|BEHAVIORAL|EmotiPlay|EmotiPlay is a computer-based intervention program, designed to enhance emotion recognition (ER) by addressing multiple modalities of emotional cues (facial expressions, tone of voice, body language),
214360994|NCT02432105|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
214360995|NCT02432105|PROCEDURE|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
214360996|NCT05618795|OTHER|minimal gap arthoplasty v/s aggressive gap arthoplasty|Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
215083946|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 2-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
215083947|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 1-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 24-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of the participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
215083948|NCT06000631|BEHAVIORAL|Conventional Therapy with a 1-hour session|The other independent OT will be responsible for providing conventional therapy in the same location as the ROC-Stand training for a total of 24-week intervention based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general purpose of the training is to facilitate the developmental scales and improve mobility, socialization, and upper limb use in functional tasks.
215083949|NCT05867290|BEHAVIORAL|Mindful music-listening with sleep hygiene|5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
215083950|NCT04216940|DEVICE|mechanical preparation of root canal system|Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems
215083951|NCT00273754|DRUG|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
215083952|NCT00273754|DRUG|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
215083953|NCT02157441|PROCEDURE|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
215083954|NCT03523273|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
215083955|NCT03523273|DRUG|Placebo|Placebo administration will match the study drug.
215083956|NCT03081676|DRUG|Glimepiride 1Mg Tablet|Glimepiride
215083957|NCT03081676|DRUG|Glucagon-like Peptide-1|GLP-1 infusion
214488761|NCT06747494|PROCEDURE|General Anesthesia|Participants will receive a one-time general anesthesia dose during the total joint arthroplasty procedure as per standard of care.
214972982|NCT05282628|BEHAVIORAL|Building Better Brains and Behavior program (B4 Preterm)|The program couples online learning modules with video conferencing sessions with a trained therapist to review skills and practice implementing the skills with live coaching. Online modules include didactic content, video clips of parents modeling the skills, and exercises. Parents will complete intervention modules sequentially in conjunction with scheduled 1:1 videoconference sessions with a trained therapist. Videoconference sessions with the therapist will be scheduled weekly, once parents have completed their modules. During these sessions, the therapist will review the online materials and provide active coaching to the parent on how to use the skills with their child (e.g., labeled praise, reflective responses). Each session follows a manualized therapy protocol to optimize content fidelity. Parents will be instructed to practice the parenting skills for 5 minutes each day to promote mastery in the home environment.
214972983|NCT01655225|DRUG|LY3023414|Administered orally. Dose of 20 to 600 mg, as determined in Part A.
214972984|NCT01655225|DRUG|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
214972985|NCT01655225|DRUG|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
214488762|NCT06747494|PROCEDURE|Spinal Anesthesia|Participants will receive a one-time spinal anesthesia dose during the total joint arthroplasty procedure as per standard of care.
214488763|NCT06746389|DIETARY_SUPPLEMENT|3000 IU per Day Spray|Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding
215083958|NCT03081676|DRUG|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
215083959|NCT03081676|DRUG|Placebo Oral Tablet|Placebo
215083960|NCT03081676|DRUG|Placebo infusion|Placebo (saline)
215083961|NCT03668054|DRUG|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
215083962|NCT05618730|DEVICE|punctum plug insertion|"EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily."
214360997|NCT04304664|OTHER|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
214360998|NCT04621110|DRUG|intranasal dexmedetomidine|Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure. To assess the level of sedation the study will use Ramsay sedation scale.
214360999|NCT04621110|DRUG|intranasal fentanyl|Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
214361000|NCT04621110|DRUG|intravenous ketamine (ketalar®)|Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
214361001|NCT04621110|DRUG|intravenous midazolam|Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
214361002|NCT04807465|DEVICE|G-Premio Bond in etch&rinse mode|The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.
214361003|NCT04807465|DEVICE|G-Premio Bond in selective-etch mode|The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.
214361004|NCT04807465|DEVICE|G-Premio Bond in self-etch mode|The adhesive system was applied to the enamel and dentin surfaces.
214361005|NCT03283774|OTHER|current clinical practice|quality management (data registration, drug prescription, diagnostic and clinical tests ...), in primary care of patients with diabetes mellitus
214488764|NCT06746454|OTHER|Video Instructed Training Group|"Pre-test measurements were taken to determine the baseline values of the athletes before the training packages specific to their group. The pre-test measurements included a landing error scoring system, knee position error sense, and frontal plane projection angle. After the pre-test measurements, 2 training packages with special instructions were performed for the video instructed training (VIT) group. The special instruction for the VIT group included a previously prepared video of a successful vertical jump landing task. This video was shown to the VIT group. Immediately after the training packages, post-test measurements were taken. The post-test measurements included the same tests as the pre-test measurements. A follow-up test was taken 7 days after the measurements. The follow-up test included the same measurements as in the pre-test and post-test phases."
214488765|NCT06746454|OTHER|Verbal Combined Focus Instructed Training Group|"Pre-test measurements were taken to determine the baseline values of the athletes before the training packages specific to their group. The pre-test measurements included landing error scoring system, knee position error sense, and frontal plane projection angle. After the pretest measurements, 2 training packages with specific instructions were performed for the CSE group. The special instruction given to the CSE group consisted of the following sentence, which included the both internal and external focus of attention; focus on how hard you push yourself off the ground and how fast you straighten your knees during this push-off. Immediately after the training packages, post-test measurements were taken. The post-test measurements included the same tests as the pre-test measurements. A follow-up test was taken 7 days after the measurements. The follow-up test included the same measurements as in the pre-test and post-test phases."
214972986|NCT01655225|DRUG|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
214361006|NCT05944523|PROCEDURE|Erector Spina Plan Block|Preemptive erector spina plan block and postoperative erector spina plan block were applied to patients undergoing thoracotomy. The effect of the time of application on intraoperative opioid consumption was compared with the Nociception Level Index pain monitor.
214361007|NCT00036881|DIETARY_SUPPLEMENT|zinc sulfate|
214972987|NCT01655225|DRUG|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
214972988|NCT01655225|DRUG|Abemaciclib|Administered orally
214972989|NCT01655225|DRUG|Letrozole|Administered orally
214972990|NCT03615313|BIOLOGICAL|PD-1 antibody expressing mesoCAR-T cells|Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
214972991|NCT05871840|OTHER|Repeated Low-Level Red-Light (RLRL) Therapy|This treatment device was made by Eyerising SuzhouXuanjia Optoelectronics Technology, which has been on the market and used widely for amblyopia treatment for the past decade in China. This device is certified as a class IIa device by the China National Medical Products Administration. It consists of semiconductor laser diodes, which deliver low-level red light with a wavelength of 650 ±10 nm at an illuminance level of approximately 1600 lux through the pupil to the fundus. Based on calculations completed by an independent lab, the light power going through a 4-mm pupil is 0.29 mW and is classified as class 1 under the International Electrotechnical Commission 60825-1:2014 standard, which is at a level considered safe for direct ocular exposure that would not create retinal thermal hazard.
215083963|NCT05618730|DRUG|Eye Drops, Lubricant|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
214361008|NCT00036881|OTHER|placebo|
215083964|NCT02723370|BEHAVIORAL|Staff multi-component implementation strategy|Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
214972992|NCT06634147|BEHAVIORAL|Exercise|"Multicomponent individualized exercise intervention As mentioned earlier, patients in the control group (G0) will receive the usual care currently provided to other patients, which includes a referral to physical therapy if needed.~The intervention for the multicomponent physical exercise intervention group (G1) will consist of a multicomponent physical training program that includes progressive and supervised aerobic endurance, strength, and balance training lasting 4-7 days during their hospitalization. This will be supervised by the research team from the Geriatrics Unit. Additionally, after hospital discharge, they will receive individualized guidelines to engage in multicomponent physical exercise for 3 months, along with individualized recommendations from the Nutrition and Dietetics Service of HUN.~The multicomponent physical training program will consist of chair squat exercises. The main part of the training will utilize machines for strength training for the lower extremit"
214361009|NCT06122714|DRUG|AZD4144 Part A|Part A: Participants will be administered a single oral dose on Day 1.
214361010|NCT06122714|DRUG|AZD4144 Part B|Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
214361011|NCT06122714|DRUG|Placebo Part A|Part A: Participants will be administered a single oral dose of matching placebo on Day 1.
214361012|NCT06122714|DRUG|Placebo Part B|Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
214361013|NCT00962728|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
214361014|NCT00962728|DEVICE|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
214361015|NCT06218017|DEVICE|High flow nasal oxygen fist|Patients in the two study group first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min) or underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min).
214361016|NCT06218017|DEVICE|High flow nasal oxygen later|Patient in this group underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min)
214361017|NCT04365582|DRUG|Azithromycin|500 mg day 1 ; 250 mg/day for 4 days
214488766|NCT06745973|DRUG|EPI-003|Intravenous (IV) infusion.
214488767|NCT06741462|DEVICE|Digital health assistant ADELE A0004|The digital health assistant ADELE A0004 (ADELE for short) improves the daily lives of patients with care level and enables them to deal better and more independently with the everyday burdens resulting from the need for care. Participants in the intervention group were provided with ADELE to use during the study period for e.g., tracking of daily reminders, voice-based recording, interpretation and classification of their vital signs and body conditions.
214488768|NCT06741254|OTHER|Stress Ball|During the NST procedure (average 20-30 minutes), the pregnant woman will lie on her left side. A stress ball will be placed in the right hand of the pregnant woman. The pregnant woman will be instructed to squeeze the stress ball for 2-3 seconds and then relax the hand and arm. This process will be repeated throughout the NST.
214488769|NCT06748183|OTHER|Functional Power Training|Group A will participate in Functional Power Training (FPT) alongside routine physical therapy The exercise protocol aims to enhance strength, mobility, and endurance through resistance training across various functional activities. It includes exercises such as running, walking, chair pushing, stair climbing, propelling a stable scooter, and sideways walking, all performed at 50-70% of the participant's maximum speed. Resistance is added using methods like dragging a loaded box with a belt during running and walking, pushing a chair with a loaded box underneath, wearing a loaded vest while climbing stairs, and attaching a loaded box to a scooter for propulsion exercises. Each exercise involves 6 to 8 repetitions lasting 25 seconds, followed by 30 to 50 seconds of rest. This structured regimen focuses on controlled movement and endurance, providing a comprehensive approach to improving physical performance.
214488770|NCT06748183|OTHER|Routine physical therapy|Routine physical therapy for a child with Cerebral Palsy involves hot pack for muscle relaxation and isometric exercises to enhance motor skills, muscle strength, and coordination. Passive stretching will be given as a treatment plan. Therapists employ sit to stand exercise to improve gait, posture, and overall functional abilities. Regular progress evaluations are conducted to adjust interventions, ensuring ongoing improvements.
214488771|NCT06894147|PROCEDURE|Genicular nerve pulse radiofrequency|After performing a diagnostic block with 1 mL of 1% lidocaine on the superior medial, lateral, and inferior medial genicular nerve branches, patients who experience more than 50% benefit from the procedure will undergo pulsed radiofrequency aplication.
214488772|NCT06892301|DRUG|YOLT-203|The IP is administered intravenously at the predetermined dose.
214361018|NCT04365582|DRUG|Hydroxychloroquine|200 mg x 3/day for 10 days
214361019|NCT04365582|DRUG|Lopinavir 200Mg/Ritonavir 50Mg Tab|400/100 mg (2 tablets) x 2/day for 15 days
214361020|NCT02245958|OTHER|No Intervention|No treatment (intervention) was administered.
214361021|NCT05598216|DIAGNOSTIC_TEST|no intervention, Serum LDL cholesterol calculation|The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)
214488773|NCT06768060|BEHAVIORAL|Short mindfulness-based intervention|The intervention includes a short mindfulness-based intervention with a duration of 5 minutes. It involves a sitting mediation focused on breath adapted from the existing protocols of the Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT). The intervention is audio-guided and will be delivered via headphones.
214488774|NCT06760897|DIETARY_SUPPLEMENT|Gastrogenic Microbiota|Take 1 sachet of gastric-origin probiotic powder (containing 5 x 1011 CFU per sachet) twice daily for 8 weeks.
214488775|NCT06760897|OTHER|Placebo|similar powder administered twice daily
214488776|NCT06754761|DRUG|[14C] AZD6738|radiolabeled AZD6738 / ceralasertib
214488777|NCT06754761|DRUG|AZD6738 / ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR
214488778|NCT06754371|DRUG|tranexamic acid|intravenous infusion of tranexamic acid 1g (20ml) 10min before skin dissection
214488779|NCT06754371|DRUG|normal saline|intravenous infusion of normal saline 20ml 10min before skin dissection
214488780|NCT06754332|DRUG|human chorionic gonadotropin|The POI patients receive a single intramuscular injection of 10,000 units of human chorionic gonadotropin.
214361022|NCT05558657|OTHER|Home-based, acupressure combined with nursing education|"The intervention group will focus on 11 acupoints on the abdomen (RN12, RN4, ST25), back (BL20, BL21, BL22, BL23, BL24, BL25), and limbs (LI4, ST36). The participants or their caregivers can perform acupressure 30 minutes after meals and twice a day. Participants can choose between two sets of acupressure: (1) Acupressure of the abdominal and back acupoints in a seated position, or (2) Acupressure of the abdominal and limb acupoints in a supine position. Each session lasts approximately 15 minutes.~Besides, the intervention group will also receive nursing education on the basis of receiving acupressure intervention including (1) dietary guidance: help patients to formulate a reasonable diet plan, (2) cultivate regular defecation habits, (3) understand appropriate defecation environments and postures, and (4) Moderate exercise to increase gastrointestinal motility."
214488781|NCT04198194|DIAGNOSTIC_TEST|Predictors of events|Apple Heart \& Movement Study in Apple Research app
214361023|NCT05558657|OTHER|Home-based, manual light touch of the abdomen combined with nursing education|Control group or their caregivers will apply the manual light touch to the abdomen in any direction or body position at home. In keeping consistent with the intervention group, abdomen touching will also be administered twice daily for approximately 15 minutes each for 10 days. Participants will also receive nursing education.
214361024|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (full intervention)|The full ENRICH pilot intervention will consist of content related to diet, physical activity, stress/mental health, sleep, tobacco cessation, and child health. The investigators will use an adapted version of the Mothers and Babies stress management intervention to address mental health, an adapted version of the HEALTH curriculum to address diet/physical activity, and an adapted version of the INSIGHT curriculum to address child health.
214361025|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (partial intervention: only diet and physical activity)|The partial ENRICH intervention will focus only on diet and physical activity.
214361026|NCT00225433|DRUG|follitropin beta|Follitropin beta
214488782|NCT04908514|DRUG|ADX-629|ADX-629 administered orally twice daily (BID) for approximately 12 weeks.
214488783|NCT05977023|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of bipolar depression
214488784|NCT05977023|DRUG|Placebo Cap|Use of placebo as a comparator.
214488785|NCT06757673|DEVICE|Robot-Assisted Therapy using Kebbi Air|Participants in this group will engage with the Kebbi Air smart robot, which is programmed with interactive scripts designed to enhance social-emotional regulation skills. The intervention includes weekly 30-minute sessions over a 12-week period, where the robot simulates real-life social scenarios and provides verbal and visual responses to guide participants in developing emotional and social skills. Occupational therapists will supervise these sessions to ensure the appropriateness of interactions and provide additional support as needed.
214488786|NCT06757673|BEHAVIORAL|Sensory Integration Therapy|Participants in this group will receive traditional sensory integration therapy guided by occupational therapists. The therapy focuses on improving sensory processing and emotional regulation through structured activities targeting visual, auditory, and tactile stimuli. Each session is conducted weekly, lasting 30 minutes, for a total of 12 weeks. The therapy aims to help children adapt to sensory inputs and enhance their ability to engage in social interactions and manage emotions effectively.
214488787|NCT06757907|DRUG|Acyclovir 400 MG|Acyclovir is used to treat infections caused by certain types of viruses.
214488788|NCT06757907|DRUG|Ganciclovir (GCV)|Ganciclovir is an anti-viral drug
214488789|NCT06757452|DIETARY_SUPPLEMENT|Supplement with curcuminoids|Cal LX is a food-grade dietary supplement based on turmeric, it has been designed to improve physical resistance during exercise, accelerate post-exercise recovery, and reduce the feeling of muscle soreness. Cal LX was determined as not cytotoxic or genotoxic. The supplement or placebo dosage was one (1) 250 mg capsule 45 minutes before exercising.
214488790|NCT06757452|OTHER|Physical excercise|Participants performed 45 minutes of physical activity twice a week. The intervention program included a five-minute warm-up, composed of two series of joint mobility and three series of eight seconds of lower limbs stretching. Then, a routine of intermittent training composed of four six-minute rounds was directed. Each routine included running for 10 seconds and a pause between them. The first round had a 20 s pause, the second round 15 s, and the third and fourth rounds 10 s. Between the rounds was a two-minute passive pause. Finally, three series of twenty seconds of elongation of the lower extremities were required as colling down.
214972993|NCT04957524|DEVICE|iStim TENS unit and Transvaginal Probe|"iStim TENS unit and Transvaginal Probe are both commercially available products. TENS units work by delivering small electrical impulses through electrodes either attached to the skin or through a transvaginal probe.~iStim transvaginal probe will be inserted vaginally to provide transvaginal electrical stimulation."
214972994|NCT05898841|DRUG|Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day|DTG/RPV will be administered in combination as 50/25 mg/day tablets or separately as DTG 50 mg/d tablets together with RPV 25 mg/d tablets. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART (Highly Active Antiretroviral Therapy) components are respected.
214972995|NCT05898841|DRUG|Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day|TDF 245 mg/d or TAF 25mg/d together with FTC 200 mg/d and RPV 25 mg/d. They may be administered as single tablets or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART components are respected.
214361027|NCT00225433|DRUG|ganirelix acetate|Ganirelix acetate
214361028|NCT05066464|OTHER|Fluid Resuscitation|Fluid Resuscitation for Suspected Sepsis in Paediatric Emergency Departments
214361029|NCT03053050|DRUG|SEL|Tablets administered orally once daily
214361030|NCT03053050|DRUG|Placebo to match SEL 6 mg|Tablets administered orally once daily
214361031|NCT03053050|DRUG|Placebo to match SEL 18 mg|Tablets administered orally once daily
214488791|NCT06759246|PROCEDURE|implant placement|Placement of short implants for the rehabilitation of single-tooth edentulism in atrophic maxillae near the maxillary sinus.
214488792|NCT06760195|PROCEDURE|Intra-arterial hypothermic magnesium sulfate infusion|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 330 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 30 ml MgSO4 solution will be infused into the ischemic territory at 15 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min.
214361032|NCT00057668|BEHAVIORAL|Multi-Setting Early Intervention|
214361033|NCT00057668|BEHAVIORAL|Community Intervention|
214361034|NCT06669195|DEVICE|Intravascular lithotripsy group|20 subjects with stent under-expansion in calcified coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Intravascular lithotripsy group.
214361035|NCT06669195|DEVICE|high-pressure balloon group|20 subjects with stent under-expansion in calcified coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of high-pressure balloon group.
214361036|NCT06670950|DRUG|SYT-510|Oral formulation A fasted
214361037|NCT06670950|DRUG|SYT-510|Oral formulation B fasted
214361038|NCT06670950|DRUG|SYT-510|Oral formulation A fed
214488793|NCT06760195|PROCEDURE|Endovascular thrombectomy|All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.
214488794|NCT06760195|DRUG|Intravenous thrombolysis|All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
214488795|NCT06759883|COMBINATION_PRODUCT|local dishes using the my plate concept|The intervention in this study consists of replacing the ready-to-use therapeutic foods prescribed in phase 2 of the management of acute severe malnutrition with balanced local dishes.
214488796|NCT06760065|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin|Keverprazan Hydrochloride, a potassium-competitive acid blocker (P-CAB), is administered at a dose of 20 mg twice daily in combination with Amoxicillin 0.75 g four times daily for 14 days. This dual therapy is designed to provide rapid and sustained gastric acid suppression and evaluate its efficacy in eradicating Helicobacter pylori.
214488797|NCT06760065|DRUG|Susceptibility-Guided Quadruple Therapy|Participants in this arm will receive quadruple therapy tailored to individual H. pylori resistance profiles, including a proton pump inhibitor (Esomeprazole 20 mg), Bismuth Potassium Citrate 220 mg, and two antibiotics selected based on susceptibility testing (e.g., Amoxicillin, Clarithromycin, Metronidazole, Levofloxacin, or Furazolidone). The regimen is administered for 14 days to optimize eradication outcomes.
214488798|NCT06760091|OTHER|baseline data collection and follow-up|At the time of enrollment, baseline characteristics will be collected, and each subject will be followed up for 2 years through face-to-face, telephone, or online visits. During the follow-up period, the clinical prognosis will be recorded.
214488799|NCT06759779|DEVICE|inspiratory muscle training|Inspiratory muscle training will be performed
214488800|NCT06759779|DEVICE|expiratory muscle training|Expiratory muscle training will be performed
214488801|NCT06759051|DEVICE|tDCS|The stimulation pattern for the true intervention was that the current level ramped up from 0 to 2 mA for the first 10 seconds of stimulation, then maintained at 2 mA for 19 minutes and 40 seconds, and then ramped down from 2 mA to 0 mA for the last 10 seconds, all over a 20-minute period.
214488802|NCT06759051|DEVICE|Sham (No Treatment)|In contrast to the active intervention, the sham intervention consisted of a current ramp from 0mA to 2mA for the first 20 seconds of stimulus onset, followed by a ramp down to 0mA. the current was maintained at 0mA for 19 minutes and 20 seconds, and then the current was ramped from 0mA to 2mA for the last 20 seconds, followed by a ramp down to 0mA. The entire procedure lasted the same as the active intervention, which lasted for 20 minutes.
214488803|NCT06759688|BEHAVIORAL|Carbohydrates restriction|"Patients followed a low carbohydrate dietary approach (LCDs). It means lower than 130 grams carbohydrates per day with special restriction restrictions on:~* Artificial sugars (e.g., sweets, baked goods, pasta, bread).~* Also, rice, butter made from vegetable oils and all types of oils except olive oil.~They were allowed:~* All types of fresh fruits and vegetable.~* Boiled potatoes."
215083965|NCT06126952|DRUG|Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)|"2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day"
215083966|NCT06126952|DRUG|Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray|2 sprays per nostril of Placebo twice daily.
214361039|NCT06670950|DRUG|Placebo|Oral formulation
214361040|NCT06669741|DEVICE|Placebo|One group will receive placebo therapy (identical shoulder brace and arm sleeve absent of semiconductor fabric)
214361041|NCT06669741|DEVICE|Shoulder Sleeve|One group will receive active therapy (active semiconductor embedded shoulder brace and arm sleeve)
214361042|NCT03129828|DRUG|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals \< 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
214361043|NCT06516289|DRUG|HRS-1167|a highly selective PARP1 inhibitor
214361044|NCT06516289|DRUG|Famitinib|a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
214361045|NCT06516289|DRUG|Camrelizumab|a humanised anti-programmed death-1 (anti PD-1) antibody
214361046|NCT06586255|RADIATION|Concurrent Immunotherapy and Radiation Therapy|Radiation therapy will begin between 12 to 18 weeks from the start of adjuvant nivolumab. Patients will receive radiation therapy for about 6 weeks.
214361047|NCT06595108|RADIATION|Stereotactic body radiotherapy|Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and they should begin stereotactic radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.
214361048|NCT03171298|PROCEDURE|Laparoscopic Assisted Transanal Total Mesorectal Excision|"* Abdominal approach with laparoscopic mobilization of the left colon~* Laparoscopic isolation and transection of inferior mesenteric vessels .~* Transabdominal dissection of the upper rectum and mesorectam.~* Insertion of transanal platform and the creation of pneumorectum.~* Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~* Transanal dissection of lower and mid mesorectam~* The specimen will be extracted transanally"
214361049|NCT06669793|DEVICE|biolimus-coated balloon|238 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Biolimus-coated balloon.
214488804|NCT06761560|DIAGNOSTIC_TEST|Pharmacokinetic based dosage change|This study will compare 2 groups of sickle cell patients that are receiving hydroxyurea. Group A will have an increase in their dosage based on the pharmacokinetic result over a period of 12 months and Group B will have an increase in their dosage based on the standard of care follow-up over a period of 12 months. The aim is to evaluate if the group A can reach MTD faster than than the Group B
214488805|NCT06761560|DIAGNOSTIC_TEST|Pharmacokinetic dosing|Patient with sickle cell disease will undergo one pharmacokinetic test after taking 12 months of hydroxyurea to evaluate HU-AUC at that timepoint
214488806|NCT06830135|DEVICE|Continues glucose monitoring with remote glucose monitoring for 90 days|CGM + RPM
214488807|NCT03944941|DRUG|Avelumab|Given IV
214488808|NCT03944941|DRUG|Cetuximab|Given IV
214488809|NCT06515223|DEVICE|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation Mapping and Pelvic Floor Muscle Training
214488810|NCT06349707|OTHER|other: Observational|For 18 ICU patients, retrospective collection of routine bioclinical database (ICCA db)
214488811|NCT06837714|OTHER|PİLATES GROUP|A total of 16 sessions were applied for 8 weeks, 2 sessions per week.
214488812|NCT06837714|OTHER|Behavioral: lifestyle changes|presentation including lifestyle changes was prepared and training was provided.
214488813|NCT01871766|DRUG|Vincristine|"Dosage and route of administration:~* \< 1 year of age=0.025 mg/kg intravenously (IV)~* \> 1 year and \< 3 years= 0.05 mg/kg IV~* ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants."
214488814|NCT01871766|DRUG|Dactinomycin|"Dosage and route of administration:~* \< 1 year=0.025 mg/kg IV push~* ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes."
214488815|NCT01871766|DRUG|Cyclophosphamide|"Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)"
214488816|NCT01871766|PROCEDURE|Surgical Resection|Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
214488817|NCT01871766|PROCEDURE|Radiation|Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
214488818|NCT01871766|DRUG|Bevacizumab|Dosage and route of administration: 15 mg/kg/dose/day IV.
214488819|NCT01871766|DRUG|Sorafenib|Dosage and route of administration: 90 mg/m\^2/dose twice daily.
214488820|NCT01871766|DRUG|Myeloid Growth Factor|"If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used."
214488821|NCT01871766|PROCEDURE|Lymph Node Sampling|"Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients."
214488822|NCT01871766|DRUG|Irinotecan|Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m\^2 IV (maximum dose 100 mg/day) daily x 5.
214488823|NCT01871766|DRUG|Ifosfamide|Dosage and Route of Administration: During interval compressed therapy - Age \> 1 year: 1800 mg/m\^2/day IV x 5 Age \<1 year: treat with 50% doses calculated on a m\^2 basis.
214488824|NCT01871766|DRUG|Etoposide|"Dosage and Route of Administration:~Age \>1 year 100 mg/m\^2/day IV x 5 Age \< 1 year treat with 50% doses calculated on a m\^2 basis"
214488825|NCT01871766|DRUG|Etoposide Phosphate|Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m\^2/day IV.
214488826|NCT01871766|DRUG|Doxorubicin|"Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days."
214488827|NCT01871766|DRUG|Dexrazoxane|"Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.~Age ≥1 year, 375 mg/m\^2 IV over 15-30 minutes Age \<1 year, 187l.5 mg/m\^2 (i.e., a 50% dose reduction) IV over 15-30 minutes."
214488828|NCT01871766|DRUG|^1^1C-methionine|Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
214679334|NCT03550716|PROCEDURE|mTESE|mTESE is performed according to the initial description by Schlegel (4). General anesthesia is used. Midline incision of the scrotum is made and carried down to the level of the tunica vaginalis, which is opened to deliver the testis. Equatorial incision is made and the testis bivalved. The operating microscope is used to identify plump-appearing seminiferous tubules, and biopsies are taken from these areas. These samples are examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24G angiocatheter. The procedure is stopped if spermatozoa are found. If no plump tubules are found, random biopsies targeting every area of the testis are taken. If necessary the procedure is carried out on the contralateral testis. Hemostasis is obtained with careful bipolar cautery, and the tunica albuginea and the tunica vaginalis are closed with a running 4-0 Vicryl. Standard scrotal closure is performed and gentle pressure dressing is applied.
214361050|NCT06669793|DEVICE|paclitaxel-coated balloon|237 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of paclitaxel-coated balloon.
214361051|NCT01296451|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
214361052|NCT01296451|BIOLOGICAL|AdCh3NSmut|genetic vaccine against Hepatitis virus infection
214361053|NCT01296451|BIOLOGICAL|AdCh3NSmut1|genetic vaccine against Hepatitis virus infection
214361054|NCT06670248|PROCEDURE|Debridement Surgery|Surgical debridement of burn wounds involving ≥ 20% of the TBSA, including debrided and donor sites.
214361055|NCT06670248|DIAGNOSTIC_TEST|Sdc-1 Level Measurement|"Measurement of plasma sdc-1 levels in different situations to assess endothelial glycocalyx damage using an enzyme-linked immunosorbent assay (ELISA):~Preoperatively:~* Upon admission to the Burn Unit.~* 24 hours after admission to the Burn Unit.~* Prior to the start of surgery, after anesthetic induction.~* If surgery is performed after the fifth day following the burn, an additional sdc-1 measurement will be taken on the fifth day of hospital admission.~Postoperatively:~* 6 hours after surgery.~* 24 hours after surgery.~* 48 hours after surgery."
214361056|NCT06668311|OTHER|play dough|"1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, play dough will be given to the child.~5. The child will be allowed to play with the play dough during the nebulizer treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes."
214361057|NCT06668311|OTHER|picture book reading|"1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, the child will be given a picture book.~5. Picture book will be read to the child during the treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes."
214361058|NCT02434809|PROCEDURE|Bronchoscopic Implantation|Calypso transponders
214361059|NCT02434809|DEVICE|Cone-Beam CT-Guided|
214361060|NCT02434809|RADIATION|stereotactic body radiation treatments|
214361061|NCT02459574|PROCEDURE|AVATAR-AF ablation|Experimental ablation protocol
214361062|NCT02459574|DRUG|Anti-Arrhythmic therapy|"Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed."
214361063|NCT02459574|PROCEDURE|Conventional AF ablation|Conventional ablation procedure
214361064|NCT05924126|OTHER|empiric antibiotic therapy|septic ICU patient given broad spectrum antibiotic therapy
214361065|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
214361066|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
214361067|NCT00251745|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
214361068|NCT06626191|PROCEDURE|Interscalene brachial plexus block|"Interscalene brachial plexus block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
214361069|NCT06626191|PROCEDURE|Serratus posterior superior intercostal plane block|"Patients will undergo serratus posterior superior intercostal plane block using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
214361070|NCT06626191|PROCEDURE|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
214361071|NCT05399953|OTHER|Myofascial Release Technique|"Sternocleidomastoid, Upper trapezius, Suboccipital region, Scalenes, Pectoral release, Scapular and hyoid mobilization techniques.~Duration: 6 weeks, 1 supervised session per week, and the session lasted 30 minutes."
214361072|NCT05399953|OTHER|Exercise|"Therapeutic exercise: passive and active range of motion, strengthening and postural exercise in order to improve shoulder and cervical mobility, muscle flexibility, strength and endurance, postural control and movement patterns; 2) stretching of pectoral muscles and serratus anterior; 3) scar tissue massage to reduce scar tissue's stiffness.~Duration of the intervention: 6 weeks (1 supervised session and 2 individual per week). Each exercise will be done 1-3 sets and 5-10 repetitions.The session lasted 30 minutes.~Exercise diary will be utilized in order to follow the exercise program."
214361073|NCT05399953|OTHER|Scar Tissue Massage|Circular, Up and Down, Side to Side technique
214361074|NCT04675138|OTHER|No intervention will be provided to the subject|No intervention will be provided to the subject
214361075|NCT00636649|DRUG|Escitalopram|10-20 mg
214361076|NCT00636649|DRUG|Placebo|Placebo
214361077|NCT04508699|OTHER|semantic learning|Experimental semantic learning from linguistic context task
214361078|NCT04839679|BEHAVIORAL|Culturally Oriented Educational Brochure|Culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner
214361079|NCT04839679|BEHAVIORAL|Mayo Clinic Educational Booklet|"An Introduction to Radiation Simulation and Treatment- Barbara Woodward Lips, Patient Education Center"
214361080|NCT04780334|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
214361081|NCT04780334|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
214488829|NCT06793072|DIAGNOSTIC_TEST|Leptin concentration in blood serum|Fasting plasma leptin concentration measurement with results expressed in pg/ml and comparison across all study arms
214488830|NCT06793072|DIAGNOSTIC_TEST|Resistin concentration in blood serum|Fasting plasma resistin concentration measurement with results expressed in pg/ml and comparison across all study arms
214488831|NCT06793072|DIAGNOSTIC_TEST|Omentin-1 concentration in blood serum|Fasting plasma omentin-1 concentration measurement with results expressed in pg/ml and comparison across all study arms
214361082|NCT06414070|BEHAVIORAL|Jenga Dada|Jenga Dada aims to empower women participating in community-based economic groups by training them to recognize inequality, challenge it, and work toward positive changes in their lives related to finances, health, and relationships and increase social support on these issues within the groups. Jenga Dada is expected to include eight modules: 1) overview of the intervention, 2) gender roles, 3) economic control and abuse, 4) intimate partner violence (IPV), 5) reproductive coercion (RC), 6) family planning (FP), 7) financial literacy, and 8) life goals. The Jenga Dada intervention is group discussion-based and draws on two effective interventions: ARCHES (a facility-based contraceptive counseling intervention providing support for RC and IPV) and Girls Invest (a mobile health application with integrated modules on gender, IPV, and financial literacy). The intervention will be facilitated by a local NGO in partnership with group leaders.
214488832|NCT06752135|PROCEDURE|cervical biopsies/conization,|Diagnostic laparoscopy was used in selected cases to evaluate potential peritoneal spread.
214488833|NCT06752135|DIAGNOSTIC_TEST|imaging tests (TCTB, TC-PET, MRI)|The staging procedures included imaging such as chest CT, abdomino-pelvic MRI, and PET-CT to assess tumor spread and lymph node involvement.
214488834|NCT06752135|DRUG|neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel)|Patients received three cycles of platinum-based neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel), followed by imaging to assess treatment response.
214488835|NCT06752135|PROCEDURE|hysterectomy, salpingo-oophorectomy, and lymphadenectomy|Eligible patients underwent radical surgery, including hysterectomy, salpingo-oophorectomy, and lymphadenectomy, with adjuvant therapy administered as needed based on surgical findings. Follow-up included regular clinical exams, imaging, and tests to monitor for recurrence.
214488836|NCT06752135|RADIATION|brachytherapy|alternative to cCRT-B.
214488837|NCT06751732|OTHER|Craniocervical Flexion Training (CCFT)|CCFT is a targeted intervention aimed at improving neuromuscular control in the cervicoscapular and craniocervical regions through low-load endurance exercises. A pressure biofeedback unit placed behind the neck sets a baseline at 20 mmHg, ensuring relaxed neck muscles. Participants open the mouth 20 mm to activate deep cervical flexors and minimize superficial muscle use, maintaining head contact with the surface while gazing 45 degrees below the horizontal. Pressure is increased in 5 mmHg steps (20 to 40 mmHg), with each level held for 10 seconds, followed by a 10-second rest. CCFT can also be performed seated, reducing sternocleidomastoid activity and promoting longus colli thickness for functional training.
214488838|NCT06751732|OTHER|Diaphragm Respiratory Training|Patients will undergo a 15-minute diaphragmatic respiratory training session, focusing on smooth diaphragmatic breathing with gentle expirations.
214488839|NCT06751732|OTHER|Cervical Mobilization and Traction|A physiotherapist will perform a low-velocity, passive cervical joint mobilization technique (Oscillation technique) based on the regimen described by Maitland.(17) This will be followed by cervical spine traction while patients continue diaphragmatic breathing.
214488840|NCT06751732|OTHER|Digital Compression on Muscle Trigger Points|Digital compression will be applied for 90 seconds on identified trigger points in the craniocervical muscles, not exceeding eight trigger points in each session.
214488841|NCT06751732|OTHER|Passive Stretching of Neck Muscles|Passive stretching will be performed three times for neck flexion and rotation associated with ipsilateral flexion directions, using moderate force within the patient's pain limits, and maintained for 30 seconds.
214488842|NCT06751732|OTHER|Instruction on Postural Correction|Physiotherapists will provide instructions on postural correction, addressing craniocervical extension, cervicothoracic flexion, protraction of shoulders, increased thoracic kyphosis, and flattened lumbar lordosis. Patients will be guided on correcting these postural abnormalities through craniocervical flexion, cervicothoracic extension, shoulder retraction, thoracic spine extension, and normalization of lumbar lordosis.
214488843|NCT06758115|PROCEDURE|Tuina (Massage) Therapy|"Operation Method:~Correct abnormal joint alignment - Manipulatively realign the vertebral segments and pelvis affected by scoliosis.~Correct abnormal muscle function - After realigning the vertebral bodies to their normal position, stretch the corresponding tight and shortened muscles while strengthening the muscles that need to be lengthened.~Restore joint stability - After adjusting the vertebrae and muscles, instruct the patient to hold the corrected posture for at least 10 seconds, then relax for 10 seconds. Repeat this cycle 3-5 times.~Restore sensorimotor control - Provide appropriate movement disturbances to patients maintaining the corrected posture to enhance proprioception and motor memory in the corresponding muscles.~The total duration of the manipulation is 20-25 minutes. Treatment is performed twice a week for a total of 12 weeks."
215083967|NCT06126952|DRUG|Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray|"2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day"
215083968|NCT03213574|OTHER|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
215083969|NCT03213574|OTHER|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
215083970|NCT03538184|PROCEDURE|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
215083971|NCT03538184|PROCEDURE|Drill|Preparation of implant beds entirely with conventional implant drills
215083972|NCT01457950|DRUG|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
215083973|NCT01457950|DRUG|placebo|double-blind phase: placebo subcutaneous injection, single dose
215083974|NCT01457950|DRUG|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
215083975|NCT00435162|DRUG|Valsartan 0.25 mg/kg|once daily
215083976|NCT00435162|DRUG|Valsartan 1.0 mg/kg|once daily
215083977|NCT00435162|DRUG|Valsartan 4.0 mg/kg|once daily
215094408|NCT04713332|DIETARY_SUPPLEMENT|placebo|Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
215094409|NCT03945019|BIOLOGICAL|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
214488844|NCT06762652|OTHER|Wash-in period|The goal of the wash-in period between the control and intervention period is to intensively educate and train physicians to use the algorithm as intended during daily postoperative care. The coordinating investigator along with the local principal investigator will be responsible for this training. Training will be performed in a standardized approach in order to guarantee uniformity across centres.
214488845|NCT06762652|DIAGNOSTIC_TEST|Algorithm-based care|During the intervention period, (participating) patients will receive algorithm-based care. The RESCUE algorithm is a consensus-based clinical care algorithm developed to standardize postoperative care. The algorithm includes the same modalities as applied in usual care, and does not include novel/experimental modalities, but rather offers a novel, standardized approach to guide the use of common modalities during postoperative care. The daily objective evaluation of patients' condition, vital signs and biochemical parameters is thought to aid early diagnosis of complications after esophagectomy which enables treatment before systemic symptoms become apparent and prevent development of sepsis. Physicians are always allowed to deviate from the RESCUE, but reasons for deviating will be recorded.
214679335|NCT03550716|PROCEDURE|TESA|In general anesthesia an 18 gauge needle is introduced into each testis, and negative pressure applied with a 10 ml syringe. Multiple passes throughout the entire testis, numbering 50-100 passes, are made through a single percutaneous/tunical entry and continued until tissue is visible in the hub of the needle. This is removed by brisk extraction of the needle and pressure held to tamponade bleeding. The aspirated tissue is examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24 gauge angiocatheter.
214488847|NCT06770244|BEHAVIORAL|positive psychology-based intervention package|The postpartum depression intervention program will be developed in accordance with the principles of positive psychology, incorporating online psychological interventions as the primary mode of delivery. Specifically, psychological courses and training based on positive psychology will be conducted in addition to the usual community-based primary health care. Interventions use formats that include online videos and supplemental materials. The aim of the intervention is to help pregnant and postpartum women understand mental health, enhance positive emotions, improve negative emotions, maintain interpersonal relationships, and explore life meaning. Additionally, one-on-one online consultations based on positive psychology will be offered to high-risk women.
215083978|NCT06350942|PROCEDURE|one trocar-assisted retroperitoneoscopic ureteroureterostomy (OTAU)|A 12 mm transverse incision was made just above the iliac crest, followed by careful dissection of the fascia and muscle layer to expose the Gerota's fascia. Entry into the retroperitoneal space was achieved with a 10-mm balloon trocar, allowing for pneumoretroperitoneum establishment. Using a 10-mm laparoscope equipped with a Maryland dissector, the ureters were dissected and isolated, followed by careful exteriorization of both upper and lower pole moiety ureters with a Babcock grasper. The pathological upper pole moiety ureter was transected, preserving the normal lower pole moiety ureter and shared blood supply, and closed with a Vicryl 4/0 suture. Subsequently, an end-to-side ureteroureterostomy was performed with a 6/0 Polydioxanone running suture, with antegrade insertion of a double J stent if not previously conducted. A final retroperitoneoscopic evaluation ensured proper anastomosis alignment, and the incision was closed without drainage.
215083979|NCT04529369|PROCEDURE|Middle lobe only Photoselective vaporization of the prostate (PVP)|Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
215083980|NCT04529369|PROCEDURE|Complete PVP|Traditional Photoselective vaporization of the prostate PVP
215083981|NCT03204799|OTHER|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
215083982|NCT03204799|DRUG|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
214361083|NCT06877078|BEHAVIORAL|Constipation information via Podcast|"The podcast is 30 minutes long, and includes information on constipation explained by a gastroenterologist specialised in defecation disorders, as well as patients' experience with constipation after surgery.~The podcast is developed in collaboration with Silkeborg Regional Hospital and the Central Denmark Region's Centre for Competence Development.~Patients will get access to the podcast after randomisation, and will be able to listen to it throughout the study period."
214361084|NCT06883162|DRUG|Varenicline|Participants will be randomized 1:1 to varenicline or matched placebo. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1 mg b.i.d. starting on Day 8. Dosing of 2 mg per day will be maintained for the next 11 weeks.
214361085|NCT06883162|BEHAVIORAL|Counseling|Research staff will provide skills-based counseling at weekly visits. Weekly counseling sessions will include discussion of online intervention modules, while providing skills-based strategies focused on enlisting social support, recognizing triggers, managing craving/withdrawal/stress, etc. Staff will use motivational enhancement techniques to address tobacco cessation, cannabis reduction or abstinence, and medication adherence.
214361086|NCT06883162|BEHAVIORAL|Psychosocial modules|Participants will have access to online modules addressing tobacco and cannabis co-use to support cessation and/or reduction. Content includes 12 virtual modules combining cognitive behavioral therapy (CBT) and motivational enhancement (MET) to address tobacco, cannabis, and their co-use.
214361087|NCT06733233|DRUG|T-DXd combined with immune checkpoint inhibitor|Subjects who are eligible for the study and have signed informed consent will receive T-DXd in combination with an immune checkpoint inhibitor. The specific dosing regimen is as follows: T-DXd (5.4 mg/kg i.v. q3w) every 3 weeks for a total of 8 courses. Teraplizumab (240 mg/kg i.v. q3w), 1 course every 3 weeks for a total of 8 courses.
214361088|NCT06891040|DRUG|VC005 Placebo group|VC005 Placebo group with Local topical application
214361089|NCT06891040|DRUG|VC005 groups|VC005 group with Local topical application
214361090|NCT06732310|BEHAVIORAL|Pregnant Moms' Empowerment Program|Women who receive the PMEP complete a structured set of sessions delivered over the course of 5 weeks, each session lasts 2 hours in duration: (1) becoming a group \& safety planning, (2) identifying and understanding sources of stress, (3) strategies to build resilience and resolve conflict, (4) perinatal health and infant care, and (5) positive parenting.
214361091|NCT06732310|BEHAVIORAL|Reminiscing and Emotion Training|Each of the 5 RET sessions are 1 hour in duration. The program is manualized and each session includes teaching/review of skills, instructions/activity with rationale, reminiscing practice, and immediate video feedback by a family coach.
215083983|NCT03204799|DRUG|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
215094410|NCT03945019|OTHER|Placebo SC|Subcutaneous injection of Placebo SC
214488848|NCT06759467|DIAGNOSTIC_TEST|AI-Driven Virtual Biopsy for Diagnosis of Peritoneal Exfoliative Cytology-Positive Gastric Cance|"The intervention involves the use of an artificial intelligence (AI)-driven virtual biopsy technology for the non-invasive diagnosis of gastric cancer with positive peritoneal exfoliative cytology (PEC). Unlike traditional biopsy methods, which require invasive procedures to obtain tissue samples, this intervention utilizes AI algorithms to analyze non-invasive biomarkers derived from patient samples such as blood, urine, or peritoneal lavage fluid.~The AI model is designed to integrate various data types, including transcriptomic profiling, imaging data, and other biomarkers, to predict the presence of PEC-positive gastric cancer. This technology employs advanced machine learning techniques to identify molecular and cellular features indicative of peritoneal metastasis, providing a diagnostic tool that is potentially more sensitive and less invasive than conventional methods.~The intervention is unique in its ability to combine multi-omics data (such as gene expression and imaging."
214488849|NCT06749080|BEHAVIORAL|Assist Reablement (including education and mentoring)|Reablement on-line education will be standard and mandatory for both intervention groups. Mentoring will be formed according to the pre-requisites at the site.
214488850|NCT06760910|PROCEDURE|tDCS Stimulation|Anode tDCS or sham stimulation for amblyopia of Adolescents
214361092|NCT06732310|BEHAVIORAL|Pregnancy - Active Control|Women who are not randomized to the PMEP participate in a contact-equivalent, nondirective social support group.
214361093|NCT06732310|BEHAVIORAL|Enhanced Case Management|Families randomized to this attentional control condition will receive enhanced case management. They will be mailed a kit containing 5 packets to be opened weekly. Each packet includes a family activity and a newsletter with parenting materials (e.g., Adventures in Parenting curriculum developed by NICHD) that were selected to not overlap with RET content (e.g., reading together, fitness, etc.). Using mothers' responses regarding access to resources on the Family Resource Scale (Dunst \& Leet, 1987), which is completed during the baseline visit, mothers will also receive referrals to community resources for items rated as inadequate.
214488851|NCT06760910|DEVICE|Anodal tDCS|Anodal tDCS
214488852|NCT06760910|DEVICE|Sham tDCS|Sham tDCS
214488853|NCT06776276|BEHAVIORAL|Tai Chi exercises|Tai-chi (TC) is a kind of CAM Qigong exercises, is a type of classic Chinese martial arts. It entails deliberate, slow-motion physical movements that are done alongside inward concentration, awareness of breathing, and the inherent power or energy in the body. It promotes general purposes of health and spirituality. It is generally accessible and offered to older people in public places.
214488854|NCT06775548|OTHER|Aerobic Exercises + Vitamin E|"For aerobic exercise, patient will perform cycling. The patient will perform stationary bike with an intensity of 60-85% of MHR by using Karvonean formula for duration of 30 minutes for 4 days/ week. Participants will be advised by the physical therapist to sit on a cycle ergometer with back supported, hands holding the handle bar and feet firmly placed on the pedals.~The imprint of FITT protcol by ACSM for aerobic exercise will be as follows, Frequency: 4 days/week Intensity: 60-85% of MHR Time: 30 minutes Type: Stationary bike"
214488855|NCT06775548|OTHER|Resistance Exercises + Vitamin E|The strength training protocol will focus on 10 major muscles of the body. The sessions will be performed for 4 days per week, lasting approximately 30 minutes. The training will be divided in a systematical manner, on first- and third-day participant will perform strength training of upper limb and abdominal muscles that include: Biceps, Triceps, Pectoralis Major, Deltoid, and abdominal muscles. On second and fourth day, participant will perform strength training of lower back and lower limb muscles that include: Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight bearing exercises will be calculated using 1 Repetition Maximum (RM) method. The protocol will be divided as follows: 2 days the participant will perform exercises for upper limb and 2 days, patient will perform exercises for lower limb.
214488856|NCT06775548|OTHER|Aerobic Exercises + Vitamin D|For aerobic exercise, patient will perform cycling. The patient will perform stationary bike with an intensity of 60-85% of MHR by using Karvonean formula for duration of 30 minutes for 4 days/ week. Participants will be advised by the physical therapist to sit on a cycle ergometer with back supported, hands holding the handle bar and feet firmly placed on the pedals. The imprint of FITT protcol by ACSM for aerobic exercise will be as follows, Frequency: 4 days/week Intensity: 60-85% of MHR Time: 30 minutes Type: Stationary bike
214488857|NCT06775548|OTHER|Resistance Exercises + Vitamin D|The strength training protocol will focus on 10 major muscles of the body. The sessions will be performed for 4 days per week, lasting approximately 30 minutes. The training will be divided in a systematical manner, on first- and third-day participant will perform strength training of upper limb and abdominal muscles that include: Biceps, Triceps, Pectoralis Major, Deltoid, and abdominal muscles. On second and fourth day, participant will perform strength training of lower back and lower limb muscles that include: Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight bearing exercises will be calculated using 1 Repetition Maximum (RM) method. The protocol will be divided as follows: 2 days the participant will perform exercises for upper limb and 2 days, patient will perform exercises for lower limb.
214679336|NCT06109623|OTHER|observation|To observe the changes and differences of steroid hormones between stress urinary incontinence group and control group.
214679337|NCT06109623|OTHER|sex hormone|Six indicators of steroid hormones (estrogen, testosterone, follicle stimulating hormone, luteinizing hormone, pituitary prolactin, progesterone)
214679338|NCT00542685|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
215083984|NCT04018976|DEVICE|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
215083985|NCT04018976|DEVICE|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
215083986|NCT04018976|DEVICE|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
215083987|NCT05525754|PROCEDURE|computed tomography-guided nasotracheal intubation|Before intubation, the lower part of the nasal valve region, aka the narrowest area of the nasal passage, was measured by calculating the distance between the anterior border of the inferior concha and the septal cartilage
215083988|NCT00533065|DRUG|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
215083989|NCT02963987|OTHER|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
215083990|NCT00715364|DRUG|NTx™-265: rhCG, then rEPO|"* rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
214361094|NCT06750731|DEVICE|Tappt|"Tappt is a web-based system designed to record participants medication taking behavior and bowel symptoms. Participants will be assigned smart labels for their specific vedolizumab regimen, which will be used by participants to record their vedolizumab use. Participants will be shipped smart labels to be affixed to an IV card for the first three infusions and for subsequent infusions or injections. At the time of a vedolizumab dose, participants will scan the smart label by tapping it with their mobile device to verify that they are taking the medication. Each day that vedolizumab is due, patients will receive a reminder through SMS message. If participants fail to scan the label at a given time (as expected by their specific medication regimen), they will receive an end of day text message reminder. Participants will also complete a patient reported outcome assessment at baseline, weekly for 6 weeks, and then monthly for the entire 22 weeks of the study triggered by the system."
214361095|NCT04854291|OTHER|Administration of donor FMT|Intracaecal infusion of FMT
214361096|NCT04854291|OTHER|Administration of placebo|Intracaecal infusion of carrier solution
214972996|NCT05898841|DRUG|Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.|Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
214972997|NCT01342354|RADIATION|Stereotactic Radiation 10 Gy|10 Gy three times over 10 days
214972998|NCT01342354|RADIATION|Stereotactic Radiation 12.5 Gy|12.5 Gy three times over 10 days
214972999|NCT01342354|RADIATION|Stereotactic Radiation 15 Gy|15 Gy three times over 10 days
214973000|NCT06134362|DRUG|CAB LA|Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
214973001|NCT05455710|DEVICE|VigiApp|mobile application containing a patient identification module; post-discharge surveillance questionnaire with questions related to signs and symptoms of SSI previously validated; possibility of attaching and sending a photograph of the surgical wound; field for exchanging messages between professional and patient; issuing an alert / reminder to fill in the data in the application; in addition to establishing interoperability with the system used by the hospital's SCIH, containing a login for each health professional, which allows access to the answers, images and messages sent by surgical patients, categorizing risk and issuing alerts in suspected cases of SSI.
215083991|NCT00715364|DRUG|Saline Placebo|"* Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation"
215094411|NCT01462877|DRUG|fenofibrate|Fenofibrate Capsule 200mg qd orally
214361097|NCT05451251|DEVICE|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine lesion
214361098|NCT05911503|DRUG|2% Ganciclovir Eye Drops|Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
214361099|NCT00230828|DRUG|bifeprunox|
214361100|NCT01610427|PROCEDURE|Blood sample collection|Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
214361101|NCT00499031|BIOLOGICAL|Cetuximab|Given IV
214361102|NCT04779970|OTHER|Cessation of ongoing treatment|Cessation of ongoing treatment
214361103|NCT02579954|BEHAVIORAL|Rehabilitation|
214361104|NCT06121154|DIAGNOSTIC_TEST|SARC-F questionnaire|"The SARC-F scale has 5 questions which evaluate strength, assistance in ambulation, rising from a chair, stair climbing, and falls. The cut off point for predicting sarcopenia is score 4; 4 and more means risk of sarcopenia."
214361105|NCT06121154|DIAGNOSTIC_TEST|Gait speed|Low gait speed was defined as walking below than 0.8 meters per second.
214361106|NCT06121154|DIAGNOSTIC_TEST|The chair rise test|the chair rise test (measures the strength of leg muscles), it measures the time taken for 5 times of rising from the sitting position without using arms, and was defined as low when the time taken was more than 15 seconds
214361107|NCT06121154|DIAGNOSTIC_TEST|Grip strength|Grip strength was measured with a hand-held dynamometer (Baseline, White Plains, New York, USA), and the cut-off thresholds were 32 kg for males and 22 kg for females
214361108|NCT06121154|DIAGNOSTIC_TEST|Visual analog scale|The visual analogue scale (VAS) was used for measuring general body pain severity, which was assessed from 0 (no pain) to 10 (worst possible pain)
214361109|NCT04547010|DIETARY_SUPPLEMENT|Soy Isoflavone supplement|Participants received 60 mg of soy-isoflavone supplement per day.
214361110|NCT00477230|DEVICE|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
214361111|NCT00477230|DRUG|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
214361112|NCT01259050|DRUG|Zinc and Copper|Optizinc 90 mg/d Copper 1 mg
214361113|NCT00643058|BIOLOGICAL|LPS endotoxin|"Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated~High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated~Diluent Challenge: 3 X Sterile saline inhalation (2 ml)"
214361114|NCT03780348|DIAGNOSTIC_TEST|New Method|A 'new' WHZ tool will be used to assess children.
214361115|NCT03780348|DIAGNOSTIC_TEST|Existing Method|'Existing' WHZ tools will be used to assess children
214361116|NCT01143688|DRUG|albuterol|
214361117|NCT01143688|DRUG|placebo inhaler|
214361118|NCT01143688|PROCEDURE|placebo acupuncture|
214361119|NCT01785680|OTHER|Integrated Protocol|Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC\>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.
214361120|NCT01785680|OTHER|Current protocol|Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
214361121|NCT00970879|DRUG|cotrimoxazole|800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
214973002|NCT06554288|DRUG|Trihexyphenidyl|6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
214361122|NCT00970879|DRUG|mefloquine|mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
214973003|NCT05934851|PROCEDURE|Frozen-Section Directed Excision|Frozen-Section Directed Excision (FSDE) is a surgical technique with evaluation of margin status during the surgical procedure, similar to the established Mohs Surgical Technique. The use of FSDE may ensure negative margins, decrease unnecessary excision of healthy tissue and has the potential to greatly reduce positive margins.
214973004|NCT05934851|PROCEDURE|Wide Local Excision|Standard of care surgical technique utilized for VIN 2, VIN3, VIN 2/3 or High-grade Dysplasia NOS
214973005|NCT05388981|BIOLOGICAL|SBT115301|Immunomodulatory dimeric fusion protein
214973006|NCT05388981|BIOLOGICAL|Placebo|Matched placebo
214973007|NCT06432933|OTHER|No preventive oxygen therapy (2L)|Participants will not receive preventive oxygen 2L during the first postoperative night after bariatric surgery.
215083992|NCT05135858|DRUG|Glucarpidase|Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)
215083993|NCT05135858|DRUG|Methotrexate (MTX)|MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
215083994|NCT01765426|BIOLOGICAL|TDV|TDV suspension for intradermal administration
215083995|NCT01765426|DRUG|Placebo|Phosphate buffered saline (PBS)
215083996|NCT00481312|DRUG|Dexmedetomidine|Continuous Infusion
215083997|NCT00481312|DRUG|Midazolam|Continuous Infusion
215083998|NCT01983722|DRUG|Stiripentol|
215083999|NCT02307292|DEVICE|POLARIS Peripheral Vascular Self Expanding Stent System|
215084000|NCT01510184|DRUG|Zevalin|Zevalin administered intravenous infusion.
215084001|NCT01510184|DRUG|Y-90-Zevalin|Y-90-Zevalin administered by intravenous infusion.
215084002|NCT01510184|DRUG|Rituximab|Rituximab administered by intravenous infusion.
215084003|NCT01510184|DRUG|In-111 Zevalin|In-111-Zevalin administered by intravenously.
215094412|NCT02857101|OTHER|dosage of calprotectin|
215094413|NCT06179420|OTHER|total cumulative gonadotrophin usage|total dosage in IU
214361123|NCT03974620|BEHAVIORAL|Individual Placement and Support|Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.
214361124|NCT03974620|BEHAVIORAL|Cognitive Remediation Therapy|This is an evidence based intervention that aims to improve cognitive functioning.
214361125|NCT00135369|DRUG|stavudine extended-release, lamivudine, efavirenz|
214361126|NCT05236686|PROCEDURE|Hepato-celiac lymphadenectomy|Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
214361127|NCT03839264|DIAGNOSTIC_TEST|Graft stenosis and thrombosis|
214361128|NCT04021810|DEVICE|Continuous Positive Airway Pressure (CPAP) and patient education|Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
214361129|NCT04021810|DEVICE|Mandibular Advancement Device|Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
214361130|NCT05596370|DIAGNOSTIC_TEST|cell free DNA in blood and urine, metabolite/microbiome in urine and stool|cell free DNA in blood and urine, metabolite/microbiome in urine and stool
214361131|NCT03195868|DEVICE|Realief Therapy|Patients will be treated using class IV laser using a proprietary algorithm developed by REALief neuropathy centers
214361132|NCT03502655|OTHER|Experimental: Intervention message (first phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
214361133|NCT03502655|OTHER|Placebo Comparator: Control message (first phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
214361134|NCT03502655|OTHER|Experimental: Intervention message (second phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a care provider
214361135|NCT03502655|OTHER|Placebo Comparator: Control message (second phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a care provider
214361136|NCT04852874|PROCEDURE|Ultrasound-guided Quadratus Lumborum Block|"Low dose spinal anesthesia will be done at L3-4 lumbar vertebrae with bupivacaine 2.5 mg (0.5 ml Marcaine 0.5%) and fentanyl 25 µgm (0.5 ml) of fentanyl amp (100 µgm/ 2ml) to be added to 1.5 - 2 ml of free water to form total volume of 2.5- 3ml according to the patient height aiming level of T6 sensory level.~Quadratus lumorum block:~After 4 to 5 minutes, ultrasound guided quadratus lumborum block (QL 1,2,3) will be done unilaterally, using low-frequency convex probe, taking into consideration the total volume of injectate not exceeding 0.4 ml /kg of (bupivacaine 0.5%) to avoid local anesthesia systemic toxicity. This is equal to 0.8 ml/kg of (bupivacaine 0.25%).~After confirming the correct position of the needle, 0.2-3 ml/kg of 0.25% bupivacaine plus 1.5 mg dexamethasone and magnesium sulphate of 100 mg will be injected in each site of the QL 1,2,3 using the lean body weight. The lean body weight will be calculated by omni lean body mass online calculator."
214361137|NCT00510094|BEHAVIORAL|Friend to Friend program|Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.
214361138|NCT00510094|BEHAVIORAL|Psychoeducational attention control intervention|Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
214361139|NCT05374226|BIOLOGICAL|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
214361140|NCT04553341|DEVICE|Navigated repetitive transcranial magnetic stimulation|In these patients we will apply the following protocol: after the initial nTMS mapping of the according function, patients will be stimulated on 20 consecutive days by a series of rTMS pulses. The frequencies (1-20 Hz), number of pulses (100-1,000), and stimulation intensities (50-130% resting motor threshold = rMT = individual lowest stimulation intensity that evokes positive muscle responses) will be applied in dependency of the individual patients comfort and the evoked effect. Stimulations will be applied to the eloquent brain region, which is infiltrated by the tumor.
214361141|NCT01380951|DRUG|telbivudine|telbivudine 600mg/d 96 weeks
214361142|NCT01315093|DRUG|Heparin, Low-Molecular-Weight|Heparin from start till hcg test
214361143|NCT01315093|DRUG|no heparin|
214361144|NCT03409666|DEVICE|Taperloc Complete Microplasty stem|Total hip replacement with Taperloc Complete Microplasty stem and G7 acetabular shell with E1 liner
214361145|NCT03409666|DEVICE|Taperloc Complete Reduced Distal stem|Total hip replacement with Taperloc Complete Reduced Distal stem and G7 acetabular shell with E1 liner
214361146|NCT00733603|OTHER|Global Therapeutic Massages (GTM)|Non-specific somatic treatment with full-body Western massage.
214361147|NCT00733603|OTHER|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
214361148|NCT03462732|DEVICE|Endotracheal tube|Nasotracheal intubation will be done with endotracheal tube
214361149|NCT03462732|DEVICE|Nelaton catheter|plus nelaton catheter
214361150|NCT00361140|DRUG|Busulfan|"Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs."
214361151|NCT00361140|DRUG|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
214361152|NCT06174584|DRUG|Hypertonic saline|Hypertonic saline
214488858|NCT06775171|BEHAVIORAL|video training group|"Creation of the Education Booklet While creating the education booklet that includes the definition of BY, the areas where it frequently develops, risk factors, classification, prevention and situations where it requires professional support, it will be created by the researcher by scanning the current literature and taking the opinions of the Faculty Members from the Nursing Fundamentals field in terms of scope, comprehensibility and scientific content.~Creation of Videos The videos will be prepared in five separate videos that will include the definition of BY, the areas where it frequently develops, risk factors, classification, prevention and situations where it requires professional support in line with the education booklet. QR codes of the prepared videos will be created. Each video will be planned to be 5-10 minutes. The videos will be checked by the Advisor Faculty Member and corrections will be made in line with his/her suggestions."
214488859|NCT06779721|OTHER|Sestrin-2|Sestrin-2 levels were studied in three different groups
214488860|NCT04468178|DEVICE|Total joint arthroplasty of the glenohumeral joint|The arthroplasty of the glenohumeral joint will be performed as an anatomical reconstruction after primary or post-traumatic osteoarthritis.
214488861|NCT06776302|DIAGNOSTIC_TEST|Raise of blood flow through the brain|At each patient two test are preformed. The first test is based on increasing blood flow through the brain through a controlled gradual infusion of norepinephrine (noradrenalin). The patient will receive such an infusion immediately upon admission and stabilization in the Department of Intensive Internal Medicine and then in the period of 6, 12, 24, 48 and 72 hours after admission. The second test is based on passive elevation of the lower extremities. The second test will also be performed on the patient immediately upon admission and stabilization in the Department of Intensive Internal Medicine and then in the period of 6, 12, 24, 48 and 72 hours after admission.
214488862|NCT06640543|OTHER|Kinesiotape|Postnatal women with low back pain will be treated with kinesiotape, three times per week for 4 weeks
214488863|NCT06640543|OTHER|Myofascial release|Postnatal women with low back pain will be treated with myofascial release for 25 minutes three times per week for 4 weeks
214488864|NCT06765447|PROCEDURE|hemostasis with 3% NaOCl in direct pulp capping|after pulp exposure bleeding was control by placing a cotton pellet soaked with 3%NaOCl over the pulpal wound upto 1 minutes.If hemostasis was not achieve with in 1mins we again use soaked cotton pellet of 3% NaOCL for another 1 mint until the hemostasis acheived. Tooth with excessive uncontrollable bleeding even after 5 mins was excluded from the study; however, definite treatment was provided to the patient.The time used to control bleeding was recorded for each tooth by using stop watch.Once hemostasis is achieved, exposed pulp was capped with biodentine.
214679339|NCT00542685|DRUG|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
214361153|NCT06174584|OTHER|Cow Milk|Cow Milk
214361154|NCT05732441|DRUG|Huange capsule|Huange Capsule was orally administered (Zhejiang Kangenbe Pharmaceutical Co., Ltd., specification: 0.4g×60 tablets/bottle, GuoYaoZhunZi Z20110006). Administration method: 1.6g each time, three times a day, 40min after breakfast, lunch and dinner. The treatment course was four weeks.
214679340|NCT00542685|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
214361155|NCT06732739|OTHER|percussions with teach-back breathing exercise|"patient will receive Teach Back Breathing Exercises like pursed lip breathing, DE breathing and diaphragmatic breathing Teach-back breathing exercises refer to a method of instructing individuals in breathing techniques and then having them demonstrate or teach back the instructions to ensure comprehension and mastery. This educational approach is commonly used in healthcare settings, particularly when teaching patients how to perform various breathing exercises for therapeutic purposes. Patients were informed about the importance of regular chest percussion I will use the clapping technique which provided by cupped hand for 3 minutes in 5 positions of drainage (upper lobes-apical and posterior segment, apical and anterior segment, right upper lobe-posterior segment, left upper lobe-posterior segment, lower lobes- apical segment) with assisted suction three times/shift for four days, and then each patient will be observed."
214361156|NCT06732739|OTHER|PERCUSSION|similar to Group A, each patient underwent individual interviews. Patients were educated on the significance of regular chest percussion. The clapping technique, executed with cupped hands, was applied for 3 minutes in five drainage positions (upper lobes - apical and posterior segment, apical and anterior segment, right upper lobe - posterior segment, left upper lobe - posterior segment, lower lobes - apical segment). This procedure, including assisted suction three times per shift, was administered for four consecutive days.
214361157|NCT05452655|BEHAVIORAL|Multidisciplinary Intensive Rehabilitation|"The rehabilitation program will last for 6 consecutive weeks and involves the execution of 30 sessions, 5 days a week lasting 160 '/ day each (80' motor; 40 'cognitive and 40' speech therapy rehabilitation) for 3 days a week and 180'/ day (80 'motor; 60' cognitive and 40 'speech therapy rehabilitation) for 2 days a week. The EXP group will receive 18 sessions (3 times a week) of treadmill (20 min), balance exercises and functional reinforcement (20 min). The remaining motor sessions will be defined based on the patient's therapeutic needs.~The cognitive treatment will be proposed both in traditional mode (3 times a week) and through the support of semi-immersive Virtual Reality Rehabilitation System (VRRS) (2 times/week). The VRRS treatment is structured in 2 sessions per week (60 min) for 6 consecutive weeks.~The speech therapy program will include clinical and instrumental evaluations and innovative techniques will be used for the treatment (biofeedback with Vitalstim)."
214361158|NCT05452655|BEHAVIORAL|Muscle-stretching and active mobilization exercises|The control group subjects will undergo a home-based self-treatment program for 40 '/ day for 6 consecutive weeks consisting of muscle-stretching and active mobilization exercises.
214361159|NCT02969720|DIETARY_SUPPLEMENT|Phytosterols|Oral daily consumption of 2 grams of phytosterols (8 ml) per 180 days.
214361160|NCT02969720|DIETARY_SUPPLEMENT|Titanium Dioxide|Oral daily consumption of Titanium Dioxide (8 ml) per 180 days.
214361161|NCT03687567|PROCEDURE|Preimplantation genetic diagnosis|
214361162|NCT06206967|OTHER|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about thromboembolism pathophysiology and its management, healthy-lifestyle habits, benefits of early-mobilisation, and any questions patients may have would be answered.~Additionally, an early-mobilization program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
214361163|NCT06206967|OTHER|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
214361164|NCT04299880|DRUG|Napabucasin|Oral
214361165|NCT04299880|DRUG|Nab-paclitaxel|Intravenous
214361166|NCT04299880|DRUG|Gemcitabine|Intravenous
214361167|NCT04299880|DRUG|Nivolumab|Intravenous
214679341|NCT00542685|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
214973008|NCT06432933|OTHER|Preventive oxygen therapy (2L) standard care|Participants will receive preventive oxygen 2L during the first postoperative night after bariatric surgery, standard care.
214973009|NCT04536701|BEHAVIORAL|Mood Monitoring and Behavioral Recommendation System|The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions will be provided to family caregivers via text messages on project Smart phones at the right moments aimed to help improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers.
214973010|NCT02201342|DRUG|Udenafil|Drug
214361168|NCT04299880|DRUG|Paclitaxel|Intravenous
214361169|NCT04299880|DRUG|Irinotecan|Intravenous
214361170|NCT04299880|DRUG|Leucovorin|Intravenous
214361171|NCT04299880|DRUG|5Fluorouracil|Intravenous
214361172|NCT04299880|DRUG|Bevacizumab|Intravenous
214361173|NCT02221401|DRUG|Linagliptin/Metformin FDC|
214361174|NCT02221401|DRUG|Linagliptin|
214361175|NCT02221401|DRUG|Metformin|
214361176|NCT01708330|DRUG|Lidocaine|2% Lidocaine gel
214361177|NCT01708330|DRUG|Placebo gel|odorless, colorless gel will be used as a placebo
214361178|NCT02546830|DEVICE|FreeO2 v2.2 active|"* Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
214361179|NCT02546830|DEVICE|FreeO2 v2.2 with manual oxygenation|"* Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
214361180|NCT01730885|OTHER|Comparison of different Blood Glucose Meters|
214361181|NCT03925701|DRUG|Vildagliptin|vildagliptin twice daily
214679342|NCT01797107|DRUG|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
214679343|NCT04197297|DIAGNOSTIC_TEST|CT and MRI Scans|CT and MRI scans will occur before and after radiation therapy.
214679344|NCT03807999|DRUG|Nab-paclitaxel|
214679345|NCT03807999|DRUG|Gemcitabine|
214679346|NCT02508168|DRUG|Alogliptin|Alogliptin 12.5 mg tablets
214679347|NCT02508168|DRUG|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
214973011|NCT04167358|DRUG|Linerixibat|All participants will receive linerixibat.
214973012|NCT06572540|DEVICE|Transthoracic cryoablation|Transthoracic cryoablation will be performed under the guidance of CT.
214973013|NCT06572540|DEVICE|Transbronchial cryoablation|Transbronchial cryoablation will be performed under the guidance of navigation bronchoscopy and CBCT.
214973014|NCT03954093|DEVICE|Transcranial direct current stimulation|tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
214361182|NCT03925701|DRUG|vildagliptin\metformin|vildagliptin\\metformin twice daily
214361183|NCT04401514|DEVICE|Rocking chair therapy|20 min long rocking therapy with music cure. The therapy can be extended if needed
214361184|NCT03432364|GENETIC|ST-400 Investigational product|Single dose of ST-400 following chemotherapy conditioning with busulfan
214361185|NCT03544346|OTHER|Exploratory brain and general health assessment|Exploratory brain and general health assessment
214488865|NCT06765447|PROCEDURE|hemostasis with diode laser in direct pulp capping|Hemostasis was achieved by exposure to Primo dental diode laser by medency (980 nm), at 0.5 W(medency Primo laser) .During laser application patients, operator and assistant were asked to wear protective eye shields.The laser energy of wavelength 980 nm introduced to the exposure site through a 400 µm optical fiber in a non contact mode for 2-3 seconds at exposure site for three times at 10s time interval to achieve complete hemostasis.For disinfection same diode laser of wavelength 980nm with energy set at 1W used in non contact mode in circular motion in the cavity .Biodentine was used as pulp capping agent.
214488866|NCT06876025|OTHER|questionnaires|Application of the questionnaires Measure of Participation and Environment - Children and Youth, (PEM-CY), or Measure of Participation and the environment - young children (YC-PEM), and the Pediatric Disability Assessment Inventory (PEDI).
214488867|NCT06891716|OTHER|[18F]ACI-19626|\[18F\]ACI-19626 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of TDP-43 deposits.
214488868|NCT06891248|PROCEDURE|Osteopathic Manipulative Treatment|See treatment arm
214488869|NCT06891105|DIETARY_SUPPLEMENT|Lactogemikan (Probiotic Supplement)|This intervention involves daily supplementation of Lactogemikan from Pescado Company, which contains Lactobacillus plantarum, a well-known probiotic strain. The probiotic is intended to improve gut microbiota balance, which may lead to improved nutritional status and health outcomes in hemodialysis patients. The dosage is one tablet daily for a duration of six months.
214488870|NCT06891105|DIETARY_SUPPLEMENT|Lactogemikan + Prebiotic Fiber (Synbiotic Supplement)|This intervention involves daily supplementation of Lactogemikan (containing Lactobacillus plantarum) combined with prebiotic fibers from oat (3g per day). The synbiotic is designed to provide the benefits of both probiotics (to balance gut microbiota) and prebiotics (to support the growth of beneficial bacteria). This intervention is intended to improve the nutritional status of hemodialysis patients over a 6-month period. The dosage is one tablet daily, combined with 3g of oat fiber.
214679348|NCT02508168|DRUG|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
214973015|NCT01622933|BIOLOGICAL|DC Vaccine + IFN|"Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks."
214973016|NCT01622933|BIOLOGICAL|AdVTMM2/DC Vaccination|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
214973017|NCT03844048|DRUG|Venetoclax|oral; film-coated tablets or tablets for oral suspension
214973018|NCT06958003|OTHER|Air Therapy|3-5 minutes of air therapy in addition to routine diaper care
214973019|NCT05533060|OTHER|No intervention|patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected
214361186|NCT00538551|OTHER|Database|Database
214361187|NCT00617578|DEVICE|ATP One Shot ON|"The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery"
214361188|NCT00617578|DEVICE|ATP One Shot OFF|Standard defibrillation shock delivery
214679349|NCT03593304|DRUG|Injection Mecobalamin|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
214679350|NCT03593304|DRUG|Tablet Pyridoxine hydrochlorid|Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
214679351|NCT03593304|DRUG|Normal saline|Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
214361189|NCT02808936|PROCEDURE|Remote ischemic preconditioning|three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff
214361190|NCT02808936|PROCEDURE|Sham control|The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
214679352|NCT03593304|DRUG|Oral Placebo|Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
214361191|NCT05654896|DRUG|Ceftriaxone Sodium|Antibiotic will be administered prophylactically for TACE
214361192|NCT01199484|OTHER|Cow's milk|
214488871|NCT06762158|RADIATION|Neoadjuvant Chemoradiotherapy|"Neoadjuvant chemoradiotherapy:~1. Radiation dose: 1.8Gy/Fx, DT41.4Gy/23Fx.~2. Concurrent chemotherapy: Albumin-bound paclitaxel 60mg/m² + Cisplatin 25mg/m² on D1, D8, D15, D22, D29."
214679353|NCT02332356|DRUG|azathioprine or adalimumab and infliximab|
214679354|NCT02411227|BEHAVIORAL|VR Driving|Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
214679355|NCT04866420|BEHAVIORAL|The MenFAS Study|A cross over repeated exposure randomized design observational study
214679356|NCT02202031|BEHAVIORAL|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
214973020|NCT06516042|DRUG|Dihydroartemisinin-piperaquine|Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.
214973021|NCT06843148|DRUG|Niacin (250mg)|"Niacin will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:~* Week 1: 250mg~* Week 2: 500mg~* Week 3 to Week 12: 750mg (3 x 250mg caplets)"
214973022|NCT06843148|DRUG|Placebo Oral Tablet|"Placebo will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:~* Week 1: 250mg~* Week 2: 500mg~* Week 3 to Week 12: 750mg (3 x 250mg caplets)"
214361193|NCT03704155|DRUG|Botulinum toxin type A|Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.
214361194|NCT03704155|OTHER|Physical Therapy|"Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~* Passive stretching of lower limbs,~* Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~* Strengthening of the antagonist muscles with the application of BoNT-A;~* Static and dynamic balance training;~* Up and down stairs;~* Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion."
214361195|NCT03043079|DIAGNOSTIC_TEST|Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity|Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
214361196|NCT06490757|DRUG|Baricitinib|An ancillary study will be performed in a subgroup of 12 patients to assess the variation of the results of PET-CT with 18FDG from baseline to 3 months. The variation of tumor features assessed by PET-CT with 18FDG after three months of treatment, will be assessed. The median value of the SUV max and tumor to non-tumor ratio of the SUV max value for each HCA lesion between the PET CT with 18FDG performed at baseline and after 3 months of treatment will be assessed.
214488872|NCT06762158|DRUG|neoadjuvant immunotherapy|Begins on the second day after the completion of concurrent chemoradiotherapy, and no later than one week. Toripalimab 240mg Q3W, for a total of two cycles.
214488873|NCT06762158|PROCEDURE|Surgery|Preoperative assessment is conducted 3 weeks after the last neoadjuvant immunotherapy, and surgery is performed within 4-6 weeks. All patients undergo minimally invasive radical esophagectomy, either McKeown or Ivor-Lewis, with extended two-field or three-field lymph node dissection.
214488874|NCT06762158|DRUG|adjuvant immunotherapy|Whether to undergo postoperative adjuvant immunotherapy is determined based on the pathological response. Patients with pCR are only observed without receiving adjuvant treatment, while those not reaching pCR receive one year of adjuvant Toripalimab.
214973023|NCT00549549|DRUG|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
214973024|NCT00549549|DRUG|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
214488875|NCT06748300|BEHAVIORAL|web- based education|breastfeeding education
214488876|NCT04150965|DRUG|Elotuzumab, pomalidomide, dexamethasone|Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
214679357|NCT02202031|BEHAVIORAL|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
214973025|NCT00549549|DRUG|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
214679358|NCT02087319|OTHER|hair loss, baldness (patient's own platelet-rich plasma)|hair loss, baldness
214679359|NCT05645484|DRUG|18F-PFPN|18F-PFPN (dose: 3.0-5.4 MBq/kg) will be injected intravenously prior to imaging.
214973026|NCT00549549|DRUG|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
214973027|NCT03344835|OTHER|No intervention|
214973028|NCT05286853|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Participants receiving institutional standard of care will have a kidney biopsy followed by 2 REACT injections into biopsied and non-biopsied contralateral kidneys 3 months (+30 days) apart and will be followed for 5 years (60 months) since last REACT injection.
214973029|NCT05286853|PROCEDURE|Sham Comparator|Participants receiving institutional standard of care will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 3 months (+30 days) after the first sham procedure. Participants will be followed for 5 years (60 months) since last sham REACT injection.
214973030|NCT05385198|BEHAVIORAL|VOICE care|"I phase:build a relationship with parents and where the Values of the parents and NICU staff is shared.~II phase: discuss with the parents the Opportunities the parents can have to be more involved in the care of their baby.~III phase: Integration of the involvement of the parents in the care of their baby. The experiences of parents need to be shared with the NICU staff. Any raising issue about the involvement of care by the parents can be discussed and see if improvement is needed.~IV phase:Control of the knowledge about the care of their baby before going home and if the parents have any issues which need to be arranged before discharge.~V phase:Evaluation. During this conversation the overall experiences of the parents will be discussed and if there are any further questions related to the care of their baby at home will be explored and discussed."
214973031|NCT00303030|PROCEDURE|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
214973032|NCT00303030|PROCEDURE|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
214973033|NCT05246891|OTHER|rehabilitation nursing|Functional respiratory rehabilitation and motor exercise plan.
214973034|NCT03564470|DRUG|Chidamide|Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
215094414|NCT04123223|BEHAVIORAL|Cognitive Remediation|Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.
215094415|NCT04123223|BEHAVIORAL|Computer Games|Sham placebo treatment
215094416|NCT01875718|DRUG|UC1010|
214973035|NCT03564470|DRUG|Dasatinib|Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
214973036|NCT01394536|DEVICE|Battery-operated electroacustimulation device (Inactive)|In the sham arm, this device will not be turned on. The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
214973037|NCT01394536|DEVICE|Battery-operated electroacustimulation device (Active)|The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
214973038|NCT04536662|DRUG|Hydrocortisone|The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.
214973039|NCT04536662|DRUG|Prednisone|The initial dose of prednisone (5mg/tablet) was 3mg/m2/day to the maximum dose of 15mg. The dosage ratio was 1:2 and the administration time was 8:00 and 21:00.
214973040|NCT04536662|DRUG|Dexamethasone|The initial dose of dexamethasone (0.75mg/tablet) was 0.3mg/m2/day to the maximum dose of 0.75mg and the administration time was 21:00.
214973041|NCT05775419|COMBINATION_PRODUCT|Consolidation chemotherapy (4 courses)|Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen;
214973042|NCT05775419|COMBINATION_PRODUCT|Concurrent chemotherapy (2 courses)|Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week\*2cycles; DDP 75mg/m2 ivgtt, d2, 3week\*2cycles;
214973043|NCT06557135|PROCEDURE|Carotid Artery Stenting (CAS)|CAS involves inserting a catheter or tube into an artery in the brachial or the femoral, and then threading the catheter through the arteries of the body to the location of the stenosis within the carotid artery in the neck. A stent is then placed in the stenosis and holds the artery open.
214973044|NCT04974528|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
214973045|NCT04974528|BIOLOGICAL|Rapid-acting Insulin Analog|"Pharmaceutical form: clear and colorless solution for injection~Route of administration: subcutaneous"
214973046|NCT04974528|BIOLOGICAL|Basal Insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214973047|NCT06320951|DRUG|Vericiguat 10 MG|The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
214973048|NCT06320951|OTHER|Placebo|The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.
214973049|NCT06320951|OTHER|Insulin Sensitivity Test|An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.
214973050|NCT06320951|OTHER|Resting Energy and Exercise Energy Expenditure Assessment|Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.
214973051|NCT06320951|OTHER|White Adipose Tissue Biopsy|Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.
214973052|NCT06320951|OTHER|MRI-PET Scan for Brown Adipose Tissue Volume Assessment|Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.
214973053|NCT03461458|DRUG|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose-derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Immune Progenitor and Cell Therapeutics Laboratory using current good manufacturing practices (cGMPs).
214973054|NCT00292552|OTHER|Novel endpoint determination|Novel endpoint determination
214973055|NCT01787006|DRUG|Cetuximab|Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total
214973056|NCT01787006|DRUG|Cisplatin, 5-FU|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle"
214973057|NCT01787006|RADIATION|Radiotherapy|59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
214973058|NCT00000863|DRUG|Sitamaquine|
215084004|NCT03671707|BEHAVIORAL|Brief AWARD advice|"Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~1. Ask: smokers will be asked about their smoking behaviour~2. Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~3. Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~4. Refer smokers to smoking cessation services if they agree.~5. Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline"
215094417|NCT01875718|DRUG|Placebo|
214679360|NCT05645484|DRUG|18F-FDG|18F-FDG (dose: 3.7-5.4 MBq/kg) will be injected intravenously prior to imaging.
214679361|NCT00000309|DRUG|Risperidone|
214361197|NCT03320018|DRUG|Hydrogen|Hydrogen will be infused into bags of normal saline solution and administered intravenously, or hydrogen generating tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.
214361198|NCT03320018|DRUG|Minocycline|"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."
214361199|NCT03320018|OTHER|Placebo Hydrogen|"Normal saline solution will be administered intravenously, in place of hydrogen solution.~Placebo tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days."
214361200|NCT03320018|OTHER|Placebo Minocycline|Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
214361201|NCT06514144|DRUG|BGF|budesonide/glycopyrrolate/formoterol fumarate
214361202|NCT04657744|DRUG|Sphingomod|1 capsule contains 0.5 mg Fingolimod
214361203|NCT04657744|DRUG|Gilenya|1 capsule contains 0.5 mg Fingolimod
214361204|NCT04147039|BEHAVIORAL|MINISTOP 2.0|The MINISTOP 2.0 is a behavioural change program aiming to promote healthier diet and physical activity among 2.5-year-old children. The program consists of features such as information, monitoring and feedback (dietary key variables, physical activity, screen time) and it is built around 13 themes during the 6-month period.
214361205|NCT00993655|DRUG|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
214361206|NCT00993655|DRUG|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
214361207|NCT00993655|DRUG|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
214361208|NCT00969384|BEHAVIORAL|Active awareness/Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
214361209|NCT01082094|BIOLOGICAL|ACRX-100|Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
214361210|NCT00743769|DRUG|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
214361211|NCT00743769|OTHER|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
214361212|NCT04012996|DEVICE|prodisc C SK and/or Vivo|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
214361213|NCT04012996|DEVICE|Mobi-C Cervical Disc|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
214361214|NCT02408575|DEVICE|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
214361215|NCT02408575|DEVICE|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering"
214361216|NCT02292017|DEVICE|Embolization of intracranial aneurysm|Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
214361217|NCT04984707|DRUG|KX0826|AR antagonist
214361218|NCT04984707|OTHER|Placebo|Placebo of KX-826
214361219|NCT03284788|BEHAVIORAL|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
214361220|NCT01953393|OTHER|Low-dose TNF-alpha|
214361221|NCT04828564|DRUG|Ribavirin Capsules|Ribavirin 200 mg capsules
214361222|NCT04828564|DRUG|Favipiravir|Favipiravir 200 mg tablets
214361223|NCT05399225|DIAGNOSTIC_TEST|Platelets to lymphocytes ratio and procalcitonin|Platelets to lymphocytes ratio and procalcitonin in sepsis
214361224|NCT05861362|RADIATION|Curative radiotherapy|Curative radiotherapy as indicated by the patient's disease and prescribed by the treating radiation oncologist
214361225|NCT05861362|BEHAVIORAL|5:2 intermittent fasting|Two nonconsecutive days of fasting per week that could be chosen freely according to the patient's weekly schedule.
214361226|NCT06525844|PROCEDURE|regenerative endodontic therapy using I-PRF|Blood will be taken from medial cubital vein
214679362|NCT05876650|OTHER|Pilates exercises|Pilates exercises starts with warm up, followed by 6 main exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow. The session will end with the cool down exercises. Each exercise will be repeated 10 times for 5 sets. Patients will be treated 3 times per week for 4 consecutive weeks.
215084005|NCT03671707|DRUG|Nicotine replacement therapy sampling|Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
215084006|NCT03671707|BEHAVIORAL|Active referral|Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
215084007|NCT03671707|BEHAVIORAL|Very brief advice|Subjects will receive general advice to quit
215094418|NCT01167868|DRUG|FosD|oral tablet
214488877|NCT04150965|DRUG|Anti-LAG-3|"Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long."
215084008|NCT03671707|BEHAVIORAL|Leaflet|Subjects will receive a standard leaflet on perinatal smoking by Department of Health
214361227|NCT06525844|PROCEDURE|blood clot|Other: BC According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
214361228|NCT03958084|DIAGNOSTIC_TEST|Straight Leg Raise|The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.
214361229|NCT03026790|OTHER|Medication management|Individualized management of medications for pain
214361230|NCT03026790|OTHER|Non-pharmacological pain management|Individualized management of non-medication pain treatment approaches
214361231|NCT03026790|DRUG|Buprenorphine-Naloxone|Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
214361232|NCT04209478|DRUG|Tramadol hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration
214361233|NCT03313518|DEVICE|tDCS|15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.
214361234|NCT03313518|DEVICE|Sham tDCS|15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
214361235|NCT03182699|DIAGNOSTIC_TEST|cardiac MRI|non contrast heart MRI at baseline and after 1 year of therapy
214361236|NCT03182699|DIAGNOSTIC_TEST|echocardiography with strain|echocardiography at baseline and after 1 year of therapy
214361237|NCT03182699|DIAGNOSTIC_TEST|Laboratory tests|drawing blood from dialysis machine
214361238|NCT03182699|DIAGNOSTIC_TEST|Body composition monitoring|Measurement with BCM (Fresenius) machine
214361239|NCT03182699|DIAGNOSTIC_TEST|lung ultrasound|ultrasound
214361240|NCT04596202|BEHAVIORAL|Supine position|After the infants are treated and fed, they will be given the supine position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
214361241|NCT04596202|BEHAVIORAL|Prone position|After the infants are treated and fed, they will be given the prone position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
214361242|NCT04596202|BEHAVIORAL|Lateral position|After the infants are treated and fed, they will be given the left or right position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period. These processes will continue until the 4 positions are completed. Infants will stay in each position for 2 hours.
214361243|NCT01169714|DRUG|0.1 mg PF-04995274|0.1 mg PF-04995274, qd, for 14 days or placebo
214361244|NCT01169714|DRUG|1 mg PF-04995274|1 mg PF-04995274, qd, for 14 days or placebo
214361245|NCT01169714|DRUG|10 mg PF-04995274|10 mg PF-04995274, qd, for 14 days or placebo
214361246|NCT01169714|DRUG|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
214361247|NCT01169714|DRUG|1.0 mg PF-04995274|1.0 mg PF-04995274, qd, for 14 days or placebo
214361248|NCT01169714|DRUG|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
214361249|NCT01855854|DRUG|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
214361250|NCT01176721|DEVICE|t-VNS verum|Active stimulation of the left auricle by t-VNS
214361251|NCT01176721|DEVICE|t-VNS placebo|Sham stimulation of the left auricle with the t-VNS device
214361252|NCT06057623|OTHER|Evaluation of central and peripheral neuromuscular fatigue|To define peripheral and central component of fatigue, the investigators will test, before, during and after the fatigue task, the force produced during a Maximal Voluntary Contraction (MVC) and the force produced by the electrically evoked Resting Twitch (RT) produced, at rest, 5 seconds after the MVC.
214488878|NCT04150965|DRUG|Anti-LAG-3 + Pomalidimide + Dexamethasone|Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
214488879|NCT04150965|DRUG|Anti-TIGIT|"Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days."
214488880|NCT04150965|DRUG|Anti-TIGIT + Pomalidimide + Dexamethasone|Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
215084009|NCT04075968|OTHER|Cognitive exercise|Cognitive exercise will be applied
215084010|NCT04075968|OTHER|Home exercise|Home exercise will be applied
214361253|NCT06791473|DIAGNOSTIC_TEST|AI-Based Diagnostic and Prognostic Model|This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, imaging data, and genetic information, to predict the risk of cancer. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of cancer risks. By analyzing historical health data, the model aims to predict potential cancer developments, improving early detection and treatment outcomes.
214361254|NCT02096328|DRUG|POL7080|Intravenous infusion
214361255|NCT02775292|BIOLOGICAL|Aldesleukin|Given SC
214361256|NCT02775292|DRUG|Cyclophosphamide|Given IV
214361257|NCT02775292|DRUG|Fludarabine Phosphate|Given IV
214488881|NCT06825598|BEHAVIORAL|Constraint-induced movement therapy|Constraint-induced movement therapy is a therapy for post-stroke patients to improve their motor functions
214488882|NCT06825598|DIAGNOSTIC_TEST|Magnetic resonance imaging|Magnetic resonance imaging is performed to monitor the changes in the brain of post-stroke patients along the course of intervention
214488883|NCT05501548|DRUG|Olaparib|Olaparib 300mg by mouth twice daily
214488884|NCT05501548|DIETARY_SUPPLEMENT|Vitamin C|Ascorbic acid 1g/kg administered intravenously twice weekly
214488885|NCT06774157|OTHER|A session combining motor imagery and listening to low frequency sounds|Prospective study of the efficacy of the Allyane procedure after knee sprain
214488886|NCT06774157|OTHER|Standard management - Control group|Active extension (e.g. by lateral raising of the quadriceps, strengthening of the quadriceps) quadriceps)
214488887|NCT06774157|OTHER|Standard management - Control group|Flexor inhibition (e.g. massage, hamstring stretching)
214488888|NCT06774157|OTHER|Standard management - Control group|Active flexion (e.g. strengthening the flexors)
214488889|NCT06847568|DRUG|Adrenaline|Intracoronary 10 mcg adrenaline will be given via the guiding catheter in study group after restoration of epicardial coronary flow of the culprit vessel and achievement of TIMI I flow either after wiring and/or passage of a deflated balloon and/or PTCA with a small balloon, and/or use of thrombus aspiration and before stenting.
214488890|NCT06869343|OTHER|Physical Therapy|Subjects will begin physical therapy at either 2 or 6 weeks s/p a rTSA.
214488891|NCT06878768|DEVICE|Additional free breathing MR acquisitions|
214679363|NCT05876650|OTHER|Yoga|Yoga will start with warm up followed by 6 yoga poses which are Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow poseThe session will end with a cool down pose. Each yoga pose will be held for 8-10 breathes Patients will be treated 3 times per week for 4 consecutive weeks.
214361258|NCT02775292|OTHER|Laboratory Biomarker Analysis|Correlative studies
214361259|NCT02775292|BIOLOGICAL|Nivolumab|Given IV
214361260|NCT02775292|BIOLOGICAL|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
214361261|NCT02775292|BIOLOGICAL|NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Given ID
214361262|NCT02775292|PROCEDURE|Positron Emission Tomography|Correlative studies
214361263|NCT01718028|OTHER|Propylene glycol 0.6% ocular emulsion|
214361264|NCT01718028|OTHER|Sodium chloride 0.9% saline solution|
214361265|NCT03104699|DRUG|AGEN2034|Anti-programmed cell death protein-1 (PD-1) Monoclonal Antibody
214361266|NCT04329065|BIOLOGICAL|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
214361267|NCT04329065|DRUG|Paclitaxel|Given via infusion
214361268|NCT04329065|BIOLOGICAL|Trastuzumab|Given IV
214361269|NCT04329065|BIOLOGICAL|Pertuzumab|Given IV
214361270|NCT04329065|DRUG|Docetaxel|Given IV
214488892|NCT06799988|BEHAVIORAL|Digitally Delivered Lifestyle Performance Medicine intervention|Participating is realized by downloading the application to their phone with the privacy statement for participation in the study must be read and accepted before use can begin. Application can be removed at any stage. Intervention protocol and implementation responsibility is in the University of Helsinki and digital coaching tools is provided by the Metabite Ltd. Digital tool in the intervention is Metabite (https://www.metabite.com/) with specified version designed with the Finnish Defense Force. All content within the application is based on scientific evidence and has been reviewed for relevance and applicability to the Finnish context by local healthcare professionals
214488893|NCT06885736|BEHAVIORAL|Resistance exercise|Participants assigned to the resistance exercise group will be asked to perform exercises 3 times a week for the intervention period. The first 3 sessions of the exercise will be performed under the supervision of a qualified exercise specialist to ensure that the participants are happy with the exercises and are performing them appropriately. These will also be group sessions to encourage participants to build social connections to support them during the intervention. A similar group social session will take place at week 4 and then every 4 weeks of the study to overcome any issues with the exercises and to ensure progression to an appropriate intensity.
214679364|NCT05832164|OTHER|Multifactorial intervention|"* Adherence to a Mediterranean diet.~* Progressive aerobic and anaerobic exercise program.~* Review of polypharmacy~* Group socialization activities"
215084011|NCT01863134|DRUG|Eptifibatide|
214361271|NCT04329065|DRUG|Carboplatin|Given IV
214361272|NCT04329065|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
214361273|NCT04329065|PROCEDURE|Biopsy Procedure|Undergo biopsy
214361274|NCT04329065|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215084012|NCT01863134|DRUG|Placebo|
215084013|NCT00808535|PROCEDURE|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
215084014|NCT00025168|DRUG|gemcitabine hydrochloride|
214361275|NCT05365321|DRUG|WP1122|Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
214361276|NCT05687968|BEHAVIORAL|Real-Time Personalized Dietary Feedback (via AI and Nutritionist)|"* Behavioral: 3D/AR MetaFood Portion Size and Nutrition Education~* Behavioral: Nutrition and Physical Activity Educational Videos"
214361277|NCT05687968|BEHAVIORAL|conventional nutrition education by dietitian|The participants receive conventional health and nutrition education from state registered dietitian.
214361278|NCT00378001|DRUG|FSH-IBSA|
214488894|NCT06885736|DIETARY_SUPPLEMENT|Protein Intake|The aim of this arm of the intervention is to ensure a protein intake of 1.6g/kg/day, as this was the intake level identified as the level after which no further effect was found on muscle mass in the meta-regression from (Morton et al., 2018). For the initial 2 weeks of the study, we will ask participants to consume 2 protein drinks, containing 25g protein (3g leucine), per day - one in the morning and one in the evening. At this stage, we won't know the magnitude of reduction of protein intake following initiation of semaglutide/tirzepatide treatment. After 2 weeks, when the first assessment of dietary intake after beginning semaglutide/tirzepatide treatment occurs, the additional protein will be based on the amount required to ensure 1.6g/kg/day with an aim to spread protein evenly across the day and aim for at least 25g protein (3g leucine) per meal or snack.
214488895|NCT06885736|COMBINATION_PRODUCT|Resistance exercise + protein intake|Participants in this arm will follow the above resistance exercise and protein intake interventions
214488896|NCT06830967|OTHER|Prehabilitation|Prehabilitation will consist of exercise therapy, smoking cessation, nutritional counselling, psychological intervention and patient education.
214361279|NCT00378001|DRUG|GONAL-F|
214361280|NCT01690130|DEVICE|Transcranial Magnetic Stimulation (Neuronetics)|Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
214361281|NCT01690130|DEVICE|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
214361282|NCT00152464|DRUG|Placebo|Pharmaceutical form: Oral drops Route of administration: Oral use
214973059|NCT04904679|DEVICE|Pars plana Vitrectomy with internal limiting membrane peeling|"The pars plana 23-gauge (23G) vitrectomy technique will be performed with removal of the internal limiting membrane (ILM) (when adhered to the macula) and placement of either an amniotic membrane plug or an ILM flap in the macular hole. This will be followed by a fluid-air exchange and buffering gas infusion (12.5% C3F8).~The amniotic membrane plug will be prepared using a dermatological punch with a diameter of 1 to 2 mm, depending on the size of the macular hole as measured by OCT. It will be positioned inside the macular hole using 23G forceps, with its chorionic side facing the retinal pigmented epithelium (RPE).~The ILM flap will be created at the time of peeling-with an inverted flap in primary cases and a free flap in refractory cases. It will be positioned over the hole (inverted flap) or inside the macular hole (free flap) using 23G ILM forceps.~These techniques will be assisted by the use of an extra lighting sclerotomy."
214973060|NCT00248651|DRUG|Amitriptyline|25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
214973061|NCT00248651|DRUG|Escitalopram|10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
214973062|NCT00248651|DRUG|Placebo|Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
214973063|NCT02688933|DRUG|HOE901-U300 (Insulin Glargine 300 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
214973064|NCT02688933|DRUG|Lantus (Insulin Glargine 100 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
214973065|NCT02688933|DRUG|Mandated back ground therapy|Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
214973066|NCT04664101|BEHAVIORAL|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
214973067|NCT04664101|OTHER|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
214973068|NCT01275144|DRUG|LY2216684|Administered orally
214973069|NCT01275144|DRUG|Placebo|Administered orally
214973070|NCT01275144|DRUG|Lorazepam|Administered orally
214973071|NCT05053269|OTHER|good body weight growth|body weight growth after birth is consistent with the growth curve
214973072|NCT05053269|OTHER|poor body weight growth|body weight growth after birth is inconsistent with the growth curve
214973073|NCT00828113|DRUG|varenicline|Extension of 1 mg twice daily treatment to 52 weeks
214361283|NCT00152464|DRUG|Levocetirizine|Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use
214361284|NCT01644734|DRUG|Spiriva HandiHaler|
214361285|NCT06845046|DIETARY_SUPPLEMENT|w-3 fatty acid|omega-3 fatty acid supplement
214361286|NCT06845046|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine supplement
214361287|NCT06845046|OTHER|Control Diet|Control Diet high in unsaturated fat
214361288|NCT02398929|DRUG|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily
214973074|NCT00828113|DRUG|varenicline|Double-blind switch to placebo after 12 weeks of open-label therapy
214361289|NCT02398929|DRUG|Placebo|Placebo tablets will be given once daily for 2 weeks during the run-in period.
214973075|NCT00828113|BEHAVIORAL|Individual smoking cessation counseling|Brief (\<10 minutes) smoking cessation counseling delivered at clinic visits
214973076|NCT03767842|DEVICE|Visor System|Subjects are monitored one time with the Visor System.
214973077|NCT00152113|PROCEDURE|Hematopoietic Stem Cell Transplantation|Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment
214973078|NCT00152113|DEVICE|CliniMACS|
215084015|NCT00025168|DRUG|irinotecan hydrochloride|
214973079|NCT00152113|DRUG|See intervention description|Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
214973080|NCT02952690|DEVICE|Glidescope® with tip manipulated stylet|The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
215084016|NCT00025168|RADIATION|radiation therapy|
215084017|NCT00002368|DRUG|Nevirapine|
215084018|NCT00002368|DRUG|Lamivudine|
215084019|NCT04842474|OTHER|Gaze stability exercises and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
215084020|NCT02024022|DRUG|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
215084021|NCT02024022|DRUG|Individualized approach|
215084022|NCT00058526|BIOLOGICAL|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
215084023|NCT00497237|DRUG|Beclomethasone plus formoterol fixed combination|100+6 pMDI
215084024|NCT00497237|DRUG|Fluticasone plus salmeterol fixed combination|diskus 250/50
215084025|NCT03143673|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
215084026|NCT02266277|OTHER|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
215084027|NCT02266277|OTHER|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
215084028|NCT02266277|OTHER|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
215084029|NCT02266277|OTHER|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
215084030|NCT05618782|DRUG|LEVI-04|Intravenous infusion
214361290|NCT01088139|DIETARY_SUPPLEMENT|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
214361291|NCT03188848|DRUG|BPI-3016|Single-dose subcutaneous injection of BPI-3016
214361292|NCT03188848|DRUG|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
214361293|NCT04466748|DRUG|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.
214361294|NCT04466748|DRUG|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
215084031|NCT05618782|OTHER|Placebo:|Placebo dose intravenous infusion
215084032|NCT00694096|DRUG|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
215084033|NCT02011620|OTHER|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
215084034|NCT03900923|DRUG|98% pure CBD|A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
215084035|NCT02430896|DRUG|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
215094419|NCT01167868|DRUG|Placebo|oral tablet
214361295|NCT06201338|PROCEDURE|Screening of preoperative frailty|"The day before the surgery, a multimodal evaluation is performed regarding :~Cognitive assessment: Mini mental State evaluation (MMSE) test Physical functional assessment: Chair raising Addiction assessment: Fagerstrom Assessment of the social environment: environmental assessment Nutritional assessment: Grip test Quality of life: completion of SF 36 scale and QOR15 scale"
214361296|NCT01642680|OTHER|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
214361297|NCT01642680|OTHER|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
214361298|NCT04719780|BEHAVIORAL|Emotionally Focused Therapy for Individuals|Emotionally Focused Therapy for Individuals (EFIT) is formulated as a transdiagnostic treatment to treat depression and anxiety, adapted from the well-studied Emotionally Focused Therapy. EFIT has been formulated as an attachment-based alternative to current cognitive approaches (e.g., Cognitive Behavioural Therapy). The strong evidence for insecure attachment as an underlying factor in psychopathology, especially depression and anxiety, positions this theory well as a foundational principle to support psychotherapy for these conditions.
214361299|NCT04719780|BEHAVIORAL|Self-Help CBT Training|Individuals in the Waitlist Control Group will receive access to MoodGym, a self-help online program that helps teach CBT interventions. This access will last 15 weeks and is self-driven, meaning participants proceed through the program at their own pace.
214488897|NCT06830967|BEHAVIORAL|Exercise therapy|Exercise therapy will consist of tailored 6-week prescribed exercise program consisting of 150-minutes of moderate-vigorous exercise weekly based on patient-to-patient resource availability (eg. neighborhood walk, body-weight exercises). It will target moderate intensity (11-13 on the Borg Rating of perceived exertion scale) and will be adjusted throughout the program as required. It will target aerobic, strength and inspiratory muscle training (IMT). Participants will receive a logbook where the exercise specialist will prescribe the intensity, type, time, and frequency of aerobic, strength and IMT exercises. Each time the participant performs the prescribed home-based exercises they will register their activity in the logbook provided. Exercise specialist will review the logbook every week and will adjust the home-based exercise plan accordingly to ensure both safety and exercise progression.
214361300|NCT03436329|PROCEDURE|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
214488898|NCT06830967|BEHAVIORAL|Smoking cessation counselling|Smoking cessation will be provided through motivational interviewing with a counselor who will assess participant's smoking status, willingness and readiness to quit and provide prescriptions for nicotine replacement therapy in combination with non-nicotinic pharmacotherapy (Varenicline, Buprorprion) as appropriate
214973081|NCT02952690|DEVICE|Glidescope® with standard-curved tip|The style is curved in accordance with the curve of GVL blade
214973082|NCT01365130|DRUG|jevtana|Cabazitaxel 25mg/m2, IV every 21 days until progression
214973083|NCT03683836|DIAGNOSTIC_TEST|No intervention|No intervention
214973084|NCT06165211|OTHER|Nature sound listening|The intervention group listened to nature sounds for 30 minutes during hemodialysis. Nature sounds consisting of bird, wind and tree sounds will be played.
214973085|NCT06165211|OTHER|Routine care|Patients will watch the program they want on the bedside TV during hemodialysis.
214973086|NCT03391102|OTHER|Observational study|
214973087|NCT00535652|DRUG|Ertapenem|powder for infusion, 1 gram I.V., single dose over 30 min.
214973088|NCT04621799|DRUG|Fibrin sealant|The intra-annular delivery of non-autologous fibrin into the annulus
214973089|NCT04819165|OTHER|COVID-19|Impact of covid-19 on infections associated with health care devices.
214973090|NCT02523430|PROCEDURE|interventional therapy|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
214973091|NCT02825914|DIETARY_SUPPLEMENT|Casein glycomacropeptide (CGMP)|
214973092|NCT02825914|DIETARY_SUPPLEMENT|Placebo|
214973093|NCT01516723|DEVICE|Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)|Recanalization of totally occluded coronary arteries
214361301|NCT03436329|PROCEDURE|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
214361302|NCT00269490|BEHAVIORAL|Yoga Nidra|
214973094|NCT05931874|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the study self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the study. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the study app and provide Fitbit data to the study team in real-time.~The core study app will support BCS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
214973095|NCT05931874|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
215084036|NCT02430896|DRUG|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
215084037|NCT01790282|DRUG|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
214361303|NCT05159622|BEHAVIORAL|Water Up! at Home|1: Addressing physical barriers to replace SSB with water at home: Participants will receive a personal, reusable bottle of water, a National Sanitation Foundation-certified water filter pitcher and one additional filter cartridge 2: Addressing sociocultural barriers to change individual perceptions: The curriculum has 6 topics delivered in 12 sessions: a) water for your health (diabetes/obesity among Latinos); b) health benefits of water vs. SSB, c) sugar content of SSB, d) safety \& affordability of filtered tap water vs. bottled beverages, e) access and promotion of SSB vs. water in your community, f) tips for improving water taste, perceived susceptibility, severity, costs and benefits. 3: Addressing sociocultural barriers to increase skills: During each session, participants will be asked to perform hands-on learning activities (e.g., measure sugar content in SSB, take pictures of themselves explaining to their family members the key messages of various lessons).
214361304|NCT02368808|BEHAVIORAL|Abangane Support Group|The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
214361305|NCT01000168|OTHER|Treadmill therapy and conventional walking therapy.|"The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period."
214361306|NCT05190250|DIAGNOSTIC_TEST|Pipelle biopsy|Ultrasonographically confirmed implantation window. Collection of material with use of Pipelle biopsy. Collection of 5 ml venous blood.
214361307|NCT00361374|DIETARY_SUPPLEMENT|eicosapentaenoic acid|1 gram/day
214361308|NCT00361374|DIETARY_SUPPLEMENT|docosahexaenoic acid|1 gram/day
214361309|NCT00361374|DRUG|Placebo|980 milligram/day
214361310|NCT01421433|DRUG|Tandrilax|Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
214973096|NCT05931874|BEHAVIORAL|Buddy|"Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the study app modules the participant has access to for their assigned condition.~The study app include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcast (one every 3 weeks) during the first 24 weeks of the intervention. Each webinar will provide social support training and peer discussion of challenges and successes in providing BCS with MVPA support."
214488899|NCT06830967|BEHAVIORAL|Nutritional counselling|Nutritional counseling will be provided through consultation with a registered dietician. Participants will be educated on correct portion sizes, building a balanced plate, learning sources and importance of protein, importance of timing and spacing of meals, along with practicing mindful eating. Promotion and encouragement of dietary changes to ensure balanced intake with adequate protein, weight management, and the regulation of blood glucose will be discussed. Possible barriers to attain the proposed dietary changes and ways to overcome them will also be discussed along with the importance of perioperative nutrition. Based on estimated habitual protein intake, participants will receive a tailored dietary advice aiming a total protein intake of 1,2-1,5g /kg daily, unless contraindicated. Also, participants will be recommended to evenly 'spread' their protein intake over 3 meals with a minimum of 25-30 gram of protein/ meal.
214488900|NCT06830967|BEHAVIORAL|Psychological intervention|"Participants will receive one hourly session of psychological intervention called surgical stress tolerance training with a trained counselor. In this session the psychosocial specialist will address the patient's anxieties, coping strategies, and post-operative expectations, with the goal of optimizing psychological well-being and ways of coping with surgery. The importance of the patient's active participation in the preparation for surgery and healing process will also be discussed. All participants will be given instructions on relaxation and deep breathing techniques."
214488901|NCT06830967|BEHAVIORAL|Patient Education|Patient education will be provided through virtual consultations with a vascular surgery nurse practitioner. These consultations will describe to the patient their journey pre and post-operatively, what to expect and what they are likely to experience, both physically and emotionally. These consultations will also ensure participants have a support person at home available for supervision during prehabilitation and available during their recovery. Additionally, they will ensure that their home is organized for their discharge from hospital and if required, an occupational therapy home consultation may be organized.
214488902|NCT06883929|DEVICE|virtual reality glasses|"Animation video application with virtual glasses by the researcher himself was applied. The application was performed in a quiet environment in the patient's room, in a sitting area where the child was comfortable.~position and wearing virtual goggles over his eyes."
214488903|NCT06883929|DEVICE|virtual reality goggles|vr 360 degree screen viewing
214488904|NCT06736301|DEVICE|a fully covered stent|a double pig-tail stent for cross fixation of a fully covered stent
214488905|NCT06738199|DIETARY_SUPPLEMENT|dietary iron supplementation|This study aimed to compare the absorption kinetics of iron bound to a glycoprotein matrix (GPM) with those of ferrous bisglycinate chelate (FBC) and ferrous fumarate (FF).
214488906|NCT06744634|OTHER|Romania group|The questionnaire which was prepared by researchers will be performed by older adults from Romania. The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
215084038|NCT01790282|DRUG|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
215084039|NCT01065948|DEVICE|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
214361311|NCT01421433|DRUG|Dolamin Flex|Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
214361312|NCT00501176|PROCEDURE|Plastic and metalic stent inserion|Patient randomizes to metal or plastic insertion prior to Whipple procedure
214361313|NCT00616187|DRUG|interferon beta treatment to add-on atorvastatin treatment|IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)
214361314|NCT00616187|DRUG|untreated to atorvastatin treatment|no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
214361315|NCT00591890|DRUG|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
214361316|NCT03440749|OTHER|luminous stimuli|The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.
214361317|NCT06579521|OTHER|Alcohol|A standard dose of alcohol will be administered (volume calculated with regard to age, sex assigned at birth, height, and weight) in the form of vodka and combined with mixer at a 1:4 ratio to reach a target breath alcohol concentration of .08%.
214488907|NCT06744634|OTHER|Turkey Group|The questionnaire which was prepared by researchers will be performed by older adults from Turkey The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
214679365|NCT02968043|OTHER|physiotherapeutic scoliosis specific exercises|Physiotherapeutic scoliosis specific exercises (PSSE) is recommended as a first step in the treatment of AIS to halt curve progression by SOSORT guidelines. The PSSE program will be personalized according to the subject's curves characteristics. The program includes patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living. A physiatrist will give a detailed explanation of the aims, importance, methods, and procedure of an intervention to patients and their parents. Each subject will receive guidance from multiple physiotherapists to ensure that the treatment effects are the result of the protocol and not any particular physiotherapists.
214973097|NCT05931874|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the study app.
214361318|NCT03603080|DRUG|Administration of weight loss drug (Metformin or Topiramate)|Patients in this arm will receive either Metformin (500 mg, twice per day) or Topiramate (50 mg, once per day) starting at 4 weeks after laparoscopic sleeve gastrectomy
214361319|NCT04701151|DRUG|Bacillus Calmette Guerin|The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
214361320|NCT03105414|DEVICE|Mechanical ventilation|Mechanical ventilation
214361321|NCT00505245|OTHER|Interview|Complete interview
214361322|NCT00505245|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
214361323|NCT00505245|OTHER|Questionnaire Administration|Complete questionnaires
214361324|NCT03384173|DEVICE|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 48 hours after birth to monitor regional tissue oxygenation for the first 7 days of age.
214361325|NCT04632602|OTHER|physiological effects of awake prone position in COVID 19 patients|"Study of physiological effects of awake prone position in COVID 19 patients on lung inhomogeneity assessed by Electrical Impedance Tomography (EIT), gas exchange and dyspnea score (Borg Scale).~Measurements will be performed at baseline (on supine position), then patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours. EIT records will be performed during the last 30 minutes of each period, blood gas and dyspnea score at the end of each period."
214361326|NCT05267392|DRUG|Durvalumab|Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion
214361327|NCT05267392|OTHER|standard of care RT/RCT|standard of care RT/RCT
214361328|NCT03509974|DEVICE|Osseointegrated Steady State Implant|Bone anchored, bone conduction hearing system
214361329|NCT03919136|DEVICE|Wrist-worn measurement device (LiveMetric)|Evaluation of the wrist-worn measurement devices accuracy referenced to interventional (A-line) measurements.
214361330|NCT00464646|DRUG|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
214361331|NCT00464646|DRUG|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
214361332|NCT00464646|DRUG|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
214488908|NCT06744634|OTHER|Croatia Group|The questionnaire which was prepared by researchers will be performed by older adults from Croatia. The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
214488909|NCT06890832|DRUG|50 mg cabazitaxel|50 mg cabazitaxel to be taken every week for 6 cycles (3 doses per cycle), 10 mg prednisone to be taken daily till end of cycle 6
214488910|NCT06890832|DRUG|100 mg cabazitaxel|100 mg cabazitaxel to be taken every week for 6 cycles (3 doses per cycle), 10 mg prednisone to be taken daily till end of cycle 6
215084040|NCT03236012|DRUG|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
215084041|NCT04381325|DRUG|MSB0254 Injection|"An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W)."
214488911|NCT06890832|DRUG|200 mg cabazitaxel|200 mg cabazitaxel to be taken every 3-week for 6 cycles (1 dose per cycle), 10 mg prednisone to be taken daily till end of cycle 6
214488912|NCT06740994|PROCEDURE|conventional landmark paramedian technique|"a blind landmark scanning will be done and skin marking of the best palpable spinous process will be made.~the site of injection will be determined by palpation. continuous spinal anesthesia will be performed via paramedian approach."
214361333|NCT00464646|DRUG|Trastuzumab|"Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses"
214361334|NCT00464646|DRUG|Bevacizumab|"Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses"
214361335|NCT01174420|DEVICE|Use of ologen Collagen Matrix in trabeculectomy|After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
214488913|NCT06740994|PROCEDURE|preprocedural ultrasound guided midline technique|"a preprocedural ultrasound scanning will be done, and skin marking of the best quality space will be made.~the site of injection and the insertion angle of the needle will be determined by ultrasound.~continuous spinal anesthesia will be performed via midline approach."
214488914|NCT06888089|OTHER|AI-assisted MatchMiner Platform|A medical record data analysis tool that uses conjunction machine learning and natural language processing models to predict changes in treatment and prognosis and ascertain progression of disease and metastatic sites using retrospective imaging reports. MatchMiner is an established clinical operations tool at Dana-Farber Cancer Institute that links OncoPanel next-generation sequencing data to basic clinical information and clinical trial eligibility criteria to suggest biomarker-selected therapeutic trials for participants.
214488915|NCT06809153|BEHAVIORAL|Putting Children First|An online parenting intervention for families experiencing high inter-parental conflict during divorce or separation. Children in these families are at greater risk of adverse health outcomes such as mental illness, substance use, and social adjustment problems. Putting Children First will include evidence-based parent training and employ motivational interviewing to increase engagement, will promote parallel parenting to help parents minimize conflict, thereby mitigating negative health outcomes in their children.
214488916|NCT06843278|OTHER|maternal breast milk|Very preterm infants receiving maternal breast milk
214488917|NCT06843278|OTHER|Donor breast milk|Very preterm infants receiving donor breast milk
214488918|NCT06855459|DEVICE|Biophoton Generators|Users will be receiving biophotons emitted from the 4 devices during sleep and other time.
214679366|NCT02968043|OTHER|generalised physiotherapy exercises|Generalised physiotherapy exercises includes stretching and strengthening activities. Little evidence is in favor of generalised physiotherapy exercises. Each subject will receive guidance from multiple physiotherapists.
214973098|NCT05931874|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the study app.
214973099|NCT05547386|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214973100|NCT05547386|DRUG|Gallium Ga 68 Gozetotide|Given IV
214973101|NCT05547386|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
215084042|NCT00190138|DEVICE|Bi-ventricular pacing|
215084043|NCT03719404|PROCEDURE|sodium hypochlorite|sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
214361336|NCT01174420|DRUG|Use of Mitomycin-C in trabeculectomy|After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
214361337|NCT05423925|PROCEDURE|Bipolar hysteroscopic myomectomy|Bipolar hysteroscopic myomectomy.
214361338|NCT05423925|PROCEDURE|Monopolar hysteroscopic myomectomy|Monopolar hysteroscopic myomectomy
214361339|NCT01615328|DEVICE|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
214361340|NCT01615328|DEVICE|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
214361341|NCT01261702|DRUG|Placebo|Normal saline IV
214361342|NCT01261702|DRUG|magnesium sulphate|The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
214361343|NCT00487409|PROCEDURE|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
214679367|NCT00000404|BEHAVIORAL|Patient education in self-care of knee OA|
214679368|NCT01667575|DRUG|Esomeprazole|antisecretary drug of the quadruple therapy
214361344|NCT00487409|PROCEDURE|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
214361345|NCT00177060|DRUG|hydromorphone|
214361346|NCT01090570|DRUG|PLX3397|Once-daily oral capsules
214361347|NCT03338894|BEHAVIORAL|Yoga|1 Hour yoga class
214361348|NCT06231238|BEHAVIORAL|Balance Acceptance and Commitment Therapy|Balance-ACT is an ACT-based psychological intervention specifically designed for people with PCS/LC. Balance-ACT will use ACT techniques and mindfulness and will focus on establishing a balance psychologically and physiologically and regulating homeostasis. More specifically, Balance ACT will aim to regulate behaviours such as sleep, stress and activity, which can subsequently have an impact on homeostasis and physiology. Balance-ACT will also encourage people to live a values-based life and set goals according to their values.
214361349|NCT04900129|COMBINATION_PRODUCT|Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%|inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.
215084044|NCT03719404|PROCEDURE|chlorhexidine|Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
215084045|NCT06086652|DIAGNOSTIC_TEST|PET/CT|detection of possible primary tumor
215084046|NCT00295230|PROCEDURE|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
214361350|NCT00626028|DRUG|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
214361351|NCT00626028|DRUG|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
214361352|NCT00626028|DRUG|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
214679369|NCT01667575|DRUG|Amoxicillin|antibiotic of the quadruple therapy
214679370|NCT01667575|DRUG|Clarithromycin|antibiotic of the quadruple therapy
214361353|NCT03965156|PROCEDURE|1) Ultrasound guided Erector spinae block|In the lateral position, after skin sterilization, erector spinae plane block will be performed at the level of T9. Counting down from the spine of seventh cervical vertebrae, the spine of the nine thoracic vertebrae (T9). A linear low frequency ultrasound transducer (US) (3-5 MHz) will placed sagittal 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between transverse processes. A 22-gauge short bevel needle will be inserted in cranial-caudal direction towards transverse process (TP) in plane to the US transducer until needle touched the TP crossing all the muscles. The location of the needle tip will be confirmed by visible normal saline fluid separating erector spinae muscle off the bony shadow of the transverse process on ultrasound imaging. Then 20 ml of bupivacaine 0.375% plus plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side of the back.
214361354|NCT03965156|PROCEDURE|Ultrasound guided transversus abdominis plane block|in supine position and after skin sterilization. The linear high frequency transducer (6-13 MHz) will be placed in the transverse plane to the the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. The three abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) are visualized. The needle inserted in plane and advanced anterior to posterior under continual visualization until the tip between the internal oblique and the transversus abdominis muscle. After negative aspiration, a 20 ml of bupivacaine 0.375% plus 5ug/ml adrenaline (1:200000) will be injected. The success of the injection will be confirmed by separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in between. The procedure will be repeated following the same steps on the other side.
214973102|NCT03909646|DRUG|Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram|A layer of methylaminolevulinc acid 160 mg/g cream (about 1 mm thick) is applied to the lesion, with a clinical margin of 5-10 mm surrounding of normal skin and then covered by an occlusive dressing. After 3 hours the occlusive dressing will be removed and the area is illuminated with Omnilux or Actilite (Galderma). After PDT the treatment site is covered again with the above mentioned occlusive dressings during 48 hours. Treatment is performed by an authorized nurse in the hospital. Two sessions should be administered with an interval of one week between sessions.
214973103|NCT03909646|DRUG|5Fluorouracil|5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.
214973104|NCT03909646|OTHER|Surgical excision|Local anesthesia with lidocain 1% (1-2ml) will be used before performing standard surgical excision with 5 mm safety margin followed by routine histological examination. The skin will be closed using cutaneous sutures, which will be removed after 1-2 weeks. The surgical excision will take place in the hospital by the treating physician
214361355|NCT00003132|DRUG|bryostatin 1|
214361356|NCT00003132|DRUG|cisplatin|
214361357|NCT03112018|BEHAVIORAL|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
214361358|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
214361359|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
214361360|NCT03112018|BEHAVIORAL|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
214361361|NCT03112018|BEHAVIORAL|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
214361362|NCT01371214|BEHAVIORAL|PLIÉ (Preventing Loss of Independence through Exercise)|Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
214361363|NCT04321239|BEHAVIORAL|Positive STEPS|Individuals in the intervention group will meet with a community health worker at an in-person or virtual study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and any associated materials, and choose a day and time for future weekly telephone sessions. Participants will also be given a wearable physical activity tracker at the orientation session to use throughout the course of the program. They can choose to report daily step counts either by automatically syncing to an app or by manual reporting via text message. The program will be delivered over 6 weeks. Each week participants will complete a web-based module and have one telephone session with the community health worker to discuss that module and to set a related goal. Participants will also set weekly goals related to walking, which will be informed and tracked by daily step-counts from the physical activity tracker.
214361364|NCT03270605|PROCEDURE|Myomectomy|Surgical removal of uterine fibroid
214361365|NCT01984684|DRUG|delafloxacin|
214361366|NCT01984684|DRUG|vancomycin|
214361367|NCT01984684|DRUG|aztreonam|
214361368|NCT02599415|DEVICE|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
214361369|NCT04584164|DEVICE|sialendoscopy|The patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
214361370|NCT05718375|DRUG|CU01-1001|CU01-1001
214361371|NCT05718375|DRUG|Placebo|Placebo
214361372|NCT04685902|DEVICE|One-way speaking valve|One-way speaking valve is a small device that attaches to the tracheostomy tube, to allows tracheostomy patient to breathe in through his or her trach tube. After the inhalation, the speaking valve closes. Air is breathed out (exhaled) up through the vocal cords, then through the mouth and nose.
214488919|NCT06745726|DRUG|Zestril|N/A, this is an observational study.
214973105|NCT04108195|DRUG|Daratumumab|Participants will receive daratumumab.
214973106|NCT04108195|DRUG|Talquetamab|Participants will receive talquetamab.
214973107|NCT04108195|DRUG|Teclistamab|Participants will receive teclistamab.
214361373|NCT01368367|OTHER|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
214361374|NCT04303949|OTHER|Behavioral:|Facilitating couples reduce anxiety, depression and grief through e-book education.
214361375|NCT01115257|PROCEDURE|vitrectomy|The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.
214361376|NCT01115257|PROCEDURE|panretinalphotocoagulation|Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
214361377|NCT03368820|OTHER|No intervention|Treatment left at the discretion of the participant
214361378|NCT04575051|OTHER|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
214361379|NCT04575051|OTHER|Engage Model|The Engage Model is a chronic care approach to supportive hearing loss self-management of ARHL. Engage includes (a) hearing screening for all residents, (b) an individualized communication plan for those with an identified hearing loss (e.g., one-to-one, group, telephone, television plans, hearing aid trouble shooting, communication strategies, etc.), (c) provision of simple, non-custom amplifiers, (d) referral to audiology if needed, and (e) ongoing support provided by trained personnel (Communication Facilitator) under the supervision of the audiologist.
214488920|NCT06810869|DRUG|human induced pluripotent stem cell derived exosomes （GD-iExo-003）|human induced pluripotent stem cell derived exosomes （GD-iExo-003）
214488921|NCT06810869|DRUG|a placebo of exosomes derived from human induced pluripotent stem cell for injection|a placebo of exosomes derived from human induced pluripotent stem cell for injection
214488922|NCT06818513|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
214488923|NCT06818513|DIETARY_SUPPLEMENT|Gastrostomy|Feeding begins through the gastrostomy tube. A registered dietitian will develop a tailored feeding plan, specifying the type and amount of nutrition. Healthcare providers regularly monitor the patient's tolerance to feeding, checking for any signs of complications. Adjustments to the feeding regimen may be made based on the patient's progress and nutritional needs.
214488924|NCT06818513|DIETARY_SUPPLEMENT|Oral tube feeding|During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214488925|NCT06601257|DRUG|Vancomycin (IV)|Vancomycin weight-based or kidney function-based dosing
214488926|NCT06891365|DRUG|NNC0581-0001|NNC0581-0001 will be administered subcutaneously.
214488927|NCT06891365|DRUG|Placebo (NNC0581-0001)|Placebo matched to NNC0581-0001 will be administered subcutaneously.
214488928|NCT06796192|OTHER|Visible Light Exposure - Treated zones|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 minutes after application.
214488929|NCT06796192|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
214488930|NCT06795932|DEVICE|Tendon Vibration|"Vibration can create kinesthetic illusions when applied at some modalities. The vibration will be put at 80 Hz and 1 mm of amplitude for 10 seconds to create 1 illusion/minute, during 20 minutes.~Two interventions per week, for three weeks. Total : 6 interventions"
214488931|NCT06795932|OTHER|Exercices|Standardized exercise protocol, performed daily for 3 weeks, with a diary.
214488932|NCT06795932|DEVICE|Tendon vibration|"Tendon vibration will not induce kinesthetic illusions, since it will be applied 40 Hz and 1 mm of amplitude for 10 seconds.~Two interventions per week, for three weeks. Total : 6 interventions"
214488933|NCT06846814|DIAGNOSTIC_TEST|CEM protocol|"The intervention consists of Second-Look Ultrasound (SLUS) performed following Contrast-Enhanced Mammography (CEM) to further evaluate additional lesions detected during routine breast imaging.~When CEM identifies additional or suspicious lesions not clearly characterized by mammography alone, targeted ultrasound is conducted to assess lesion morphology, vascularity, and acoustic characteristics. Radiologists with expertise in both CEM and ultrasound interpretation will perform SLUS to determine whether the lesions require biopsy, short-term follow-up, or no further action. Findings will be correlated with histopathological results (if biopsy is performed) or follow-up imaging to assess diagnostic accuracy."
214488934|NCT02469662|DEVICE|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
214679371|NCT01667575|DRUG|Bismuth Potassium Citrate|one of a component of a quadruple therapy
214679372|NCT01667575|OTHER|long duration (14 day)|
214679373|NCT01596842|DRUG|Omega-3 fatty acid ethylester 90|Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
214973108|NCT04108195|DRUG|Pomalidomide|Participants will receive pomalidomide.
214973109|NCT04622969|BEHAVIORAL|Healthy Child Development Program|The Healthy Child Development Program is a family-based intervention focused on strengthening positive behaviors in children, managing misbehavior, and addressing healthy lifestyle choices.
214973110|NCT05708898|DEVICE|Pharyngeal exerciser|
214973111|NCT05708898|DEVICE|sham pharyngeal exerciser|
214361380|NCT05616988|OTHER|psychological-clinical intervention with three days of expressive writing by Pennebaker|"The psychological-clinical intervention involves five interviews with three days of expressive writing by Pennebaker. During the psychological-clinical interviews the following aspects will be explored:~* Emotions and expectations related to the breast reconstruction process.~* Feelings related to the perception of one's own body image to promote an integration between the image of one's body and the aspects related to one's own identity and femininity.~* Thoughts and feelings related to one's relational and social life.~Expressive writing is a technique devised by Pennebaker (1986), who states that expressing deeper thoughts and feelings through writing can improve the physical and psychological health of the individual. The writing task consists of writing about a traumatic experience or a significant event for the person, for a controlled period (usually 15-30 minutes) and on consecutive days (from 2 to 3 days)."
214361381|NCT00095524|DRUG|Aripiprazole|
214361382|NCT02554968|OTHER|Questionnaires|
214361383|NCT04136951|OTHER|PREVENT clinical decision support|PREVENT clinical decision support tool consideres five patient risk factors as significant predictors of patient's priority for the first homecare nursing visit: (a) Presence of wounds (either surgical or pressure ulcers); (b) a documented comorbid condition of depression; (c) need for assistive equipment, assistive person, or both for toileting; (d) number of medications; and (e) number of comorbid conditions. Each risk factor was assigned a specific score based on the logistic regression weights. For instance, for a wound (e.g., pressure ulcer, vascular ulcer), the patient received a score of 15 points. For each additional co-morbid condition, one point was added to the final score. Summing the scores for the factors generated a cumulative score. The optimal cut-off point was established based on the regression model performance statistics, indicating that patients with a score greater than 26 points are a high priority for the first nursing visit.
214361384|NCT00672074|DRUG|Ipamorelin|IV
214361385|NCT00672074|DRUG|placebo|IV
214361386|NCT04171466|OTHER|Ciprofloxacin + Metronidazole|Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.
214361387|NCT04171466|OTHER|SH-DS01|SH-DS01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
214488935|NCT04219709|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
214488936|NCT04219709|OTHER|Standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
214488937|NCT04603898|DIETARY_SUPPLEMENT|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days
214488938|NCT04603898|DIETARY_SUPPLEMENT|Carbon-13 Ascorbic Acid Oral Load|Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.
214488939|NCT06780787|BIOLOGICAL|Balstilimab|Given IV
214973112|NCT05969730|DRUG|Baricitinib 4 MG|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, baricitinib 4-mg daily plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm A). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
214973113|NCT05969730|DRUG|Azathioprine 1.5-2.5 mg/kg|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, azathioprine 1.5-2.5 mg/kg plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm B). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
214679374|NCT01596842|OTHER|Olive oil|Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
214679375|NCT01596842|OTHER|cholecalciferol|if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
214679376|NCT06429683|OTHER|Sexually transmitted diseases training for young adolescents aged 17-21|Education
214679377|NCT02487628|DEVICE|HQ® Matrix Soft Tissue Mesh|
214679378|NCT02487628|DEVICE|ULTRAPRO® Partially Absorbable Lightweight Mesh|
214679379|NCT06215898|OTHER|LSVT-BIG Group via Telerehabilitation|An aerobic supervised exercise protocol was implemented four times a week for four weeks in LSVT-BIG Group via a Tele-rehabilitation model.
214679380|NCT03075462|DRUG|Fluzoparib|Fluzoparib either at 40,60,80mg twice daily,capsule oral.
214679381|NCT03075462|DRUG|Apatinib|Apatinib at 250mg once daily, tablet oral
215084047|NCT04626089|DRUG|metformin glycinate|Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
215084048|NCT04626089|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
215084049|NCT04540458|OTHER|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
215084050|NCT04540458|OTHER|Placebo|Mother or Mother/Father is given a picture of 3D ultrasound of fetus
215084051|NCT05991765|OTHER|Digit Tip Wound|Digit Tip Wound Exudate Sample Collected while Dressing Change
215084052|NCT05991765|OTHER|Split Skin Donor Site Wound|Split Skin Donor Site Wound Exudate Sample while Dressing Change
214361388|NCT04171466|OTHER|Placebo|Placebo capsules for SH-DS01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
214361389|NCT01039701|DRUG|AZD1446|capsules, oral, 3 times daily
214361390|NCT01039701|DRUG|Placebo|capsules, oral, 3 times daily, 4 weeks
214361391|NCT01859481|DRUG|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
214361392|NCT01859481|DRUG|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
214361393|NCT01859481|DRUG|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
214361394|NCT00210795|DRUG|epoetin alfa|
214361395|NCT05794542|DEVICE|Cue X|Cue X is used with augmented (mixed) reality glasses. These glasses are similar to virtual reality glasses except you can see the real world around you with digital images overlain. The Cue X software is used on two existing devices, the Microsoft HoloLens and the Magic Leap.
214361396|NCT02017340|DRUG|Nilvadipine|8mg of Nilvadipine taken once a day at lunch time for 78 weeks
214361397|NCT02017340|DRUG|Placebo|8mg Placebo tablet taken once a day at lunch time for 78 weeks
214361398|NCT06359938|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
214361399|NCT06359938|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
214361400|NCT01817179|OTHER|FES neuroprosthesis to dorsiflexors on affected leg|
214361401|NCT06097312|OTHER|Data collection|The schedule of office visits and all treatment regimens will be determined by the treating health care provider. No interventions are administered as part of this protocol (observational study).
214361402|NCT00562887|BIOLOGICAL|Placebo|every 4 weeks, IV
214361403|NCT00562887|BIOLOGICAL|ABT-874|400 mg IV every 4 weeks
214361404|NCT00562887|BIOLOGICAL|ABT-874|700 mg IV every 4 weeks
214361405|NCT03923348|DEVICE|Leva device|The leva® Pelvic Digital Health System by Renovia Inc is a novel tool for subjects with urinary incontinence to train and strengthen pelvic floor muscles via directional mechano-transductive feedback on performance in the privacy of their own homes.
214361406|NCT02423187|OTHER|No Intervention|
214361407|NCT06217328|DEVICE|Revi System Treatment|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable
214361408|NCT06217328|DEVICE|Revi System - Delayed Activation|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable. The system will be implanted but it will not be turned on until 4 months post implant procedure.
214361409|NCT05198466|DEVICE|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
214361410|NCT05198466|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
214361411|NCT03583554|DRUG|Placebo|Single dose of 4 placebo oral capsules
214361412|NCT03583554|DRUG|AV-101 720 mg|Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules
214361413|NCT03583554|DRUG|AV-101 1440 mg|Single dose of 4 360 mg AV-101 oral capsules
214361414|NCT03178266|DEVICE|Knee Arthroplasty|Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
214361415|NCT02472964|BIOLOGICAL|Trastuzumab|Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
214361416|NCT02472964|BIOLOGICAL|MYL- 1401O|MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
214361417|NCT02472964|DRUG|Paclitaxel|Paclitaxel 80mg/m2 IV over 60 minutes weekly.
214361418|NCT02472964|DRUG|Docetaxel|Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
214361419|NCT01215292|DRUG|Acyline|300 mcg/kg on Day 1
214361420|NCT01215292|DRUG|Testosterone gel|5 gm of 1% T Gel applied transdermally for 10 days
214361421|NCT01215292|DRUG|ketoconazole 400|400 mg PO daily, Days 3-10
214361422|NCT01215292|DRUG|Ketoconazole 800|800 mg PO daily, Day 3-10
214361423|NCT01215292|DRUG|Dutasteride|2.5 mg PO daily, Day 3-10
214361424|NCT01215292|DRUG|Anastrozole|1 mg PO daily, Day 3-10
214361425|NCT01215292|DRUG|Placebo ketoconazole|placebo to mimic ketoconazole
214361426|NCT02543034|DEVICE|Betafoam Wound Dressing|Foam dressing including Betadine iodine
214361427|NCT02543034|DEVICE|Petrolatum Gauze|Gauze dressing
214488940|NCT06780787|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214488941|NCT06780787|BIOLOGICAL|Botensilimab|Given IV
214488942|NCT06780787|DRUG|Capecitabine|Given PO
214488943|NCT06780787|PROCEDURE|Computed Tomography|Undergo CT
214488944|NCT06780787|PROCEDURE|Digital Rectal Examination|Undergo digital rectal exam
214488945|NCT06780787|PROCEDURE|Endoscopic Biopsy|Undergo biopsy with endoscopic exam
214488946|NCT06780787|DRUG|Fluorouracil|Given IV
214488947|NCT06780787|DRUG|Leucovorin Calcium|Given IV
214488948|NCT06780787|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214488949|NCT06780787|DRUG|Oxaliplatin|Given IV
214488950|NCT06780787|RADIATION|Radiation Therapy|Undergo radiation therapy
214973114|NCT05254886|OTHER|NEMO nurse-led program|"The NEMO nurse-led program will consist of a single nursing consultation conducted on the day of the inclusion visit during which the nurse will:~* Report the presence of pre-existing comorbidities/EIMs~* Detect the presence of risk factors~* Implement recommendations for the detection and/or management of comorbidities/EIMs."
214973115|NCT05607576|OTHER|Uncovered CGM during radiologic procedures|Dexcom G6 CGM will not be covered during radiologic procedures.
214361428|NCT02543034|DEVICE|Allevyn Wound Dressing|Foam dressing
214361429|NCT05001100|OTHER|rehabilitation|rehabilitation
214361430|NCT04672941|DRUG|Tiotropium bromide plus Olodaterol|Tiotropium bromide plus Olodaterol
214361431|NCT00765388|DEVICE|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
214361432|NCT00765388|DEVICE|Hollister|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
214361433|NCT01846182|DRUG|Duloxetine|serotonin norepinephrine reuptake inhibitor
214361434|NCT01846182|DRUG|Pregabalin|alpha-2-alpha subunit calcium channel ligand
214361435|NCT01846182|DRUG|Placebo|Placebo
214488951|NCT06780787|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
214488952|NCT06773832|DIAGNOSTIC_TEST|Real-time Artificial Intelligence Model for Diagnosing Colorectal Polyp Pathology and Endoscopic Classification|"During the AI model development phase, the aim is to include as many samples as possible. Given the focus on the diagnostic accuracy of serrated lesions, we retrospectively collected approximately 400 cases serrated lesions with pathological diagnosis by the department of pathology at Peking Union Medical College Hospital to date. Additionally, we matched with 400 cases each of hyperplastic polyps, conventional adenomas, and early-stage colorectal cancer, totaling approximately 1600 cases.~The model employs mainstream AI classification algorithms to construct the model and compare the predictive performance of different models. Utilizing the dataset established in the first phase, which contains static images of polyp lesions along with their corresponding pathological diagnosis and endoscopic classifications, we developed and optimized the AI model. Then the model will be be compared with endoscopists in a prospective cohort to investigate the efficacy."
214488953|NCT06762574|OTHER|Low Level Laser Therapy|Low Level Laser Therapy sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low intensity light therapy. The effect is photochemical not thermal. The light triggers biochemical changes within cells and can be compared to the process of photosynthesis in plants, where the photons are absorbed by cellular photoreceptors and triggers chemical changes.
214488954|NCT06762574|OTHER|Placebo Low Level Laser Therapy|Placebo Low Level Laser Therapy:turning on the device with covering probe by aluminum foil and ask patient to wear sun glasses to obtain the placebo effect.
214488955|NCT06863376|DRUG|Carbocysteine 375 MG|Carbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. It is actually approved for clinical use as adjunctive therapy of respiratory tract disorders
214488956|NCT06863376|OTHER|Physical activity, walking, and calorie restriction|• The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients
214488957|NCT01225081|DRUG|ipragliflozin|oral
214488958|NCT01225081|DRUG|Placebo|oral
214488959|NCT01225081|DRUG|Pioglitazone|oral
214488960|NCT04990479|BIOLOGICAL|GAd-PEV|Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).
214488961|NCT04990479|BIOLOGICAL|MVA-PEV|Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).
214679382|NCT03808623|DEVICE|MAC with NOVOCART Basic|"NOVOCART® Basic is a biphasic, collagen-based matrix to support the biological reconstruction of localized and full-thickness cartilage damages after treatment with bone marrow stimulation techniques (microfracture). The procedure is called matrix associated chondrogenesis (MAC). It is a single-step procedure.~NOVOCART® Basic is tailored to fit the prepared defect size and is inserted in the defect area after microfracture. The NOVOCART® Basic device component is fully resorbed over a period of a few months as new reparative cartilage tissue is generated and integrated with the surrounding host tissue."
214679383|NCT05508360|DEVICE|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
214361436|NCT01398150|DIETARY_SUPPLEMENT|Beverage made to look like the cranberry beverage|one 15 ounce bottle of beverage consumed daily
214488962|NCT06888947|PROCEDURE|use immediate implant in socket with collagen cone|use immediate implant in socket with collagen cone
214488963|NCT06762171|PROCEDURE|open wedge high tibial osteotomy|All procedures will be performed based on the technique recommended by the AO international knee expert group. Biplanar osteotomy, which comprises osteotomies in the axial and frontal planes, will be performed in all cases. Ascending frontal osteotomy, leaving the tibial tuberosity on the distal fragment, will be also performed. All osteotomies will be performed without the use of additional bone grafts, and the opening of the osteotomy was maintained with a Tomofix plate (Orthomed-E Co., Egypt). Wound closure will be performed in layers.
214679384|NCT05536453|DEVICE|Lumbar Interbody Fusion Devices|Posterior Lumbar Interbody Fusion device placed to treat symptoms associated with degenerative disc disease
214973116|NCT02094794|DRUG|etoposide|Given IV
214973117|NCT02094794|DRUG|cyclophosphamide|Given IV
214361437|NCT01398150|DIETARY_SUPPLEMENT|Beverage made from cranberry compounds|one 15 ounce bottle consumed daily for 70 days
214361438|NCT00796770|BIOLOGICAL|Dendritic Cell Vaccine|"Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~1. two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~2. an opportunistic infection~3. a CDC class C-defining event (defined in appendix 2)~4. a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48."
214361439|NCT04582474|OTHER|Dengue module and rapid diagnostic tests|Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines
214361440|NCT00001926|DRUG|O15|
214361441|NCT00001926|DEVICE|Cadwell rTMS|
214361442|NCT02794376|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|
214361443|NCT02794376|BEHAVIORAL|Waiting Period|
214361444|NCT02087631|DRUG|Extended-release quetiapine fumarate|Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
214361445|NCT04080050|DRUG|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy|No investigational product will be administered in this study. All participants have previously received a one-time intravenous infusion of RGX-501 in a separate clinical trial
214361446|NCT01435538|BEHAVIORAL|Care pathway.|The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
214361447|NCT06136975|DEVICE|Low-level laser therapy|The treatment was once a week for eight weeks. The patient was in a supine position. The gain medium of the laser was Gallium-Aluminum-Arsenide. The laser was introduced into vagina via a silicon vaginal probe inserted by a doctor for 30 minutes (wavelength 660nm, power density 18.17mW/cm2, energy density 0.018J/cm2s, total energy density 32.4J/cm2).
214361448|NCT04840810|PROCEDURE|In-plane Axis|"In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis."
214361449|NCT04840810|PROCEDURE|Out of plane Axis|"In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis."
214361450|NCT02471196|DRUG|ORM-12741|ORM-12741 low dose twice a day
214361451|NCT02471196|DRUG|ORM-12741|ORM-12741 high dose twice a day
214361452|NCT02471196|DRUG|Placebo|Placebo twice a day
214361453|NCT06580873|DRUG|DOVATO|HIV-1 medication
214361454|NCT05417880|DRUG|Oral Hypoglycemic Agents,Oral|Control group with routine current oral hypoglycemic agents for 3-6 months
214361455|NCT05417880|DRUG|Voreta|Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
214361456|NCT05417880|DRUG|Voreta plus SunnyD PRO|Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
214361457|NCT02853890|OTHER|Questionnaires during hospitalization for delivery|Questionnaires during hospitalization for delivery (one questionnaire completed by doctors about different technic of analgesia and anesthesia and one questionnaire completed by women about pain, and feeling about the different techniques of analgesia and anesthesia used during delivery, eventually caesarean section or uterine revision)
214361458|NCT03457519|DEVICE|Children's Automated Respiration Monitor (ChARM)|The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
214361459|NCT05970627|DRUG|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
214361460|NCT05970627|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
214361461|NCT05970627|DRUG|S1|S-1 orally intake as perioperative chemotherapy
214361462|NCT06347302|BIOLOGICAL|Blood sampling|Two tubes will be taken, the first tube (Tube 1) for specialised lipid analysis. The second tube (Tube 2) for routine biochemical analysis
214361463|NCT06347302|OTHER|vitreous sampling|Intra-operative vitreous sampling: systematic collection of the vitreous humour during vitrectomy for vitreoretinal surgery such as retinal detachment, epiretinal membranes and macular holes.
214361464|NCT06347302|OTHER|Sub-retinal fluid sampling|Sub-retinal fluid sampling consists of collecting the sub-retinal fluid that is systematically aspirated during retinal detachment surgery in order to dry the detached retina and allow retinopexy to be performed.
214361465|NCT06347302|OTHER|Retinal tissue sampling|cutting and aspiration of the retina using the vitreotome opposite the tear to allow access to the sub-retinal fluid.
214361466|NCT02342886|DRUG|Moxifloxacin|Oral
214361467|NCT02342886|DRUG|PA-824|Oral
214361468|NCT02342886|DRUG|Pyrazinamide|Oral
214361469|NCT02342886|DRUG|HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|Oral
214361470|NCT02342886|DRUG|HR (rifampicin plus isoniazid combination tablets)|Oral
214361471|NCT04160325|DIETARY_SUPPLEMENT|postoperative 3-month exclusive enteral nutrition|postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months
214361472|NCT04160325|DRUG|azathioprine|azathioprine
214361473|NCT04160325|OTHER|normal diet|normal diet
214361474|NCT01025440|DEVICE|Continuous Positive Airway Pressure|"Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:"
214361475|NCT01328080|RADIATION|Targeted UV-B|Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)
214361476|NCT01319266|DRUG|Hydrocodone Bitartrate extended-release tablet|Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
214361477|NCT00285142|DRUG|rosiglitazone|
214361478|NCT06134830|DRUG|RAI|Radioactive iodine
214488964|NCT06762171|PROCEDURE|Arthroscopic partial lateral patellar facetectomy|Diagnostic arthroscopy will be performed in all cases to assess Patellofemoral articular cartilage degeneration , assess the lateral compartment and exclude any other pathology. The knee is taken throughout a range of motion to directly visualize the impingement of the lateral patellar facet against the trochlea. Next, a radiofrequency probe is used to outline the area to be resected along the lateral patellar facet While maintaining the knee at 20 degrees of flexion, a 5.5-mm burr is introduced, and under arthroscopic visualization, the overhanging portion of the lateral patellar facet is carefully resected. Once the bony resection is complete, the knee is dynamically re-evaluated (through flexion and extension) for residual impingement and to assess for improvements in patellar mobility. Patellar tracking is assessed to verify that there is no catching in flexion and that patellar mobility is improved.
214488965|NCT06724016|DRUG|HM16390|HM16390 will be administered subcutaneously using syringes (35mg/mL) on Day 1 of every 3-week treatment cycle
214488966|NCT06754514|DEVICE|liver retraction|A different way to lift the liver during bariatric surgery
214488967|NCT06890156|BEHAVIORAL|ENREACH child-parent-teacher triad|"Prior to enrolling study participants, we will conduct sensitization meetings with each selected government primary school. These meetings will be oriented toward community leaders, caregivers of children with or without disabilities, and school management committees to introduce them to the program, ensure the inclusion of all children, and address concerns related to gender, poverty, and disability.~A disability-inclusive module will be delivered to preschoolers in their regular pre-primary classrooms by trained pre-primary teachers. This module will cover foundational skills, the importance of play, communication, socio-emotional learning, and strategies for adapting the curriculum to accommodate children with disabilities.~ENREACH parent group school readiness intervention package will be provided to parents during monthly parent-teacher meetings, facilitated by trained preschool teachers."
214488968|NCT06886399|DRUG|"AS-Probionorm"|"Phase II of the clinical trial of the medicine included 210 study subjects with identified clinical and/or microbiological signs of dysbiosis. 3 groups of 70 research subjects will be formed.~Group 1 - study subjects with an identified decrease in intestinal microflora activity; Group 2 - study subjects with an identified fungal (candidiasis) infection; Group 3 - study subjects with active pathogenic microflora.~Dosage regimen for first group - 1 sachet (1 g) 2 times a day (morning and evening) 15 min prior food , with an interval of 12 hours. The total duration of study subjects' participation in the study is 28 days. Dosage regimen for the second and third groups - 2 sachet (2 g) 2 times a day (morning and evening) 15 min prior food , with an interval of 12 hours. The total duration of study subjects' participation in the study is 28 days."
214488969|NCT06769672|OTHER|active tDCS with dual-task training|participants receive three 20-minute active tDCS treatment and three 60-minute COGMOTION dual-task exercise sessions per week for four consecutive weeks.
214488970|NCT06769672|OTHER|sham tDCS with dual-task training|participants receive three 20-minute sham tDCS treatment and three 60-minute COGMOTION dual-task exercise sessions per week for four consecutive weeks.
214488971|NCT06746974|DEVICE|Shockwave|In the Shockwave group, will be applied focused shockwaves therapy of 1500 impulses at 0.01 mJ/mm2 over the painful area or the pathologic flexor tendon to each participant under the supervision of a physiatrist. The ESWT will be conducted once weekly for 4 weeks with a sham splint (DIP joint blocking splints) for at least 8 hours per day for 6 weeks.
214488972|NCT06746974|DEVICE|Splint|In the splinting group, will be provided a PIP blocking splint at least 8 hours per day for 6 weeks with the sham shockwave (the patients close their eyes, extend their hand through a partition, apply shockwave device head with gel on the patient's finger, and play a mobile phone sound that mimics the sound of a real shockwave machine) once a week for 4 weeks.
214488973|NCT05362474|DRUG|Montelukast|10mg orally once a day
214488974|NCT05921266|DIETARY_SUPPLEMENT|Urolithin A|Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels daily).
214679385|NCT05741710|DRUG|Methylone|Methylone capsules, given orally, once a week for 4 weeks
214973118|NCT02094794|RADIATION|total marrow irradiation|Undergo TMLI
214361479|NCT05314036|OTHER|Standardized test meal|During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal.
214361480|NCT05480475|DRUG|Dabigatran etexilate|On Day 1 (Treatment A1) and on Day 9 (Treatment C1) a single oral dose of 75 mg dabigatran etexilate will be administered under fasted conditions.
214361481|NCT05480475|DRUG|Rosuvastatin|On Day 3 (Treatment A2) and on Day 11 (Treatment C2) a single oral dose of 10 mg rosuvastatin will be administered under fasted conditions.
214361482|NCT05480475|DRUG|Daridorexant|On Day 7 and Day 8 (Treatment B), on Day 9 and Day 10 (Treatment C1), and on Day 11 through 14 (Treatment C2) subjects will receive 50 mg daridorexant o.d. under fasted conditions.
214361483|NCT00343928|OTHER|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
214361484|NCT02930733|DRUG|Bupivacaine|30 ml %0,25 bupivacaine bilaterally
214361485|NCT02930733|DRUG|Saline|2 ml saline subcutaneously bilaterally
214361486|NCT01395381|DRUG|Placebo|placebo given once
214361487|NCT01395381|DRUG|Albendazole|single dose albendazole given at the time of enrollment
214361488|NCT00400335|DRUG|Nanomilled testosterone|
214361489|NCT00400335|DRUG|commercially available dutasteride|
214361490|NCT00400335|DRUG|Nanomilled dutasteride|
214361491|NCT06246604|DIAGNOSTIC_TEST|Ultrasound screening for lower limbs DVT|Using a linear ultrasound probe (7.5-12 MHz) a compression ultrasound of the lower limbs is performed, from the hip to the ankle. The exam is completed by the use of Doppler.
214361492|NCT06246604|DIAGNOSTIC_TEST|Standard-of-care|Ultrasound examination of lower limbs is performed according to clinical risk of DVT
214361493|NCT01372306|DRUG|Reminyl|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
214361494|NCT00274638|DRUG|Telmisartan & Hydrochlorothiazide|
214361495|NCT00274638|DRUG|Losartan & Hydrochlorothiazide|
214361496|NCT00274638|PROCEDURE|ABPM|
214361497|NCT00862134|DRUG|PR104|770 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
214361498|NCT00862134|DRUG|docetaxel|75 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
214361499|NCT00862134|DRUG|docetaxel|60 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
214361500|NCT00862134|DRUG|Granulocyte colony-stimulating factor|Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
214361501|NCT06236750|DEVICE|EPIFIX|EPIFIX® is an allograft derived from dehydrated human amnion/chorion membrane. EPIFIX is a medical device in Japan (Generic name: Material using human amniotic membrane for promotion of tissue healing) for use on intractable ulcers that are non-responsive to existing therapies for the purpose of promoting wound healing.
214361502|NCT00002258|DRUG|Interleukin-3|
214361503|NCT02291731|DRUG|Continuous use of topical autologous serum|Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
214361504|NCT06470165|PROCEDURE|Priority-matching correction technique in DLS|"For Type 1 global coronal malalignment (GCM), TL/L curve makes the primary contri- bution on C7PL shifting. First, inserting pedicle screws bilaterally. Second, aggressively decreasing the magnitude of TL/L curve. Third, moderately leveling L4 endplate to pull the fusion segments to the middle line with hand pressure on the convexity of TL/L curve. If the correctability of the key curve was limited, the correction of the minor curve would be con- vergent.~For Type 2 GCM, LS curve makes the primary contribution on C7PL shifting. First, releasing LS curve from the concave side using facetectomy after screws inserted. Second, performing L4-5 or L5-S1 trans- foraminal lumbar interbody fusion (TLIF) from the con- vexity of the fractional curve, with cages inserted at the concave side to assist deformity correction. Third, compressing the convexity of LS to horizontalize L4 endplate, followed by moderate manipulative reduction of TL/L curve to adjust intraoperative coronal balance."
214361505|NCT06470165|PROCEDURE|Traditional correction technique in DLS|"In concave coronal malalignment (CM), the correction of the main curve improves the CM, thus we can talk about convergent corrective objectives. The ability to correct the CM depends on the correctability of the main curve. The need of three-column osteotomies in order to obtain correction of CM depends on the location and flexibility of the main curve.~The correction of convex CM depends on the correction of the lumbosacral curve. The correction strategy will depend on many factors including the driver of the deformity, which should always be fused, but also the degeneration and stiffness of the compensatory curve which can lead to more extended fusion. The need of three-column osteotomies depends mainly on the stiffness of the lumbosacral curve."
214361506|NCT05776173|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
214361507|NCT01871831|DEVICE|6 blood glucose monitoring systems for self-testing|
214361508|NCT06262568|OTHER|assess the nurse knowledge and practices.|assess the nurse knowledge and practices.
214361509|NCT04967235|OTHER|Conventional Exercise-based Cardiac Rehabilitation Session|"This session will be composed of:~I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of treadmill aerobic exercise at an intensity of 60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus; IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position."
214361510|NCT04967235|OTHER|Dance-based Cardiac Rehabilitation Session|I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of dance therapy. The intensity of the choreography will be set at the same range as the conventional exercise-based session. (60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus); IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position.
214361511|NCT02191267|RADIATION|[F18]-T807|\[F18\]-T807 PET Scan to measure tau deposition in the brain.
214361512|NCT02191267|RADIATION|[F18]-Florbetapir|\[F18\]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
214361513|NCT02191267|DEVICE|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
214361514|NCT02191267|GENETIC|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
214361515|NCT00360438|DRUG|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
214361516|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
214361517|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
214361518|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
214361519|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
214361520|NCT00316082|DRUG|Placebo|Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
214361521|NCT00316082|DRUG|metformin|Tablets, Oral, 500-2000 mg, as needed (12 months LT)
214361522|NCT00528775|DRUG|HPPH|4 mg/m2 IV
214361523|NCT00528775|PROCEDURE|endoscopic procedure|Treatment with 150 joules from laser
214488975|NCT05921266|OTHER|Placebo|Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of inactive capsules (4 capsules daily).
214488976|NCT06742450|OTHER|Constant current (CC) subthalamic nucleus deep brain stimulation|For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant current (CC) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant current (CC) mode will be maintained.
214488977|NCT06742450|OTHER|Constant voltage (CV) subthalamic nucleus deep brain stimulation|For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant voltage (CV) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant voltage (CV) mode will be maintained.
214488978|NCT06741423|OTHER|Radiomics Algortihm|A radiomics algorithm designed to distinguish retroperitoneal fibrosis from other retroperitoneal tumors and provide recommendations for clinical treatment decisions.
214488979|NCT06081426|OTHER|Non-ketogenic Diet|Consuming a non-ketogenic diet
214488980|NCT06081426|OTHER|Ketogenic Diet|Consuming a ketogenic diet
214488981|NCT06081426|OTHER|No diet|Participants without Bipolar Disorder will not participate in the diet phases of the study
214488982|NCT06757855|DRUG|Olverembatinib|"induction therapy：40mg,QOD；~consolidation maintenance therapy: If patients with CMR are reduced to 30mg."
214488983|NCT06757855|DRUG|Venetoclax|"induction therapy：leverl 0: 100mg d-2; 200mg d-1; 400mg d1-14~leverl -1: 100mg d-2; 200mg d-1; 400mg d1-7~leverl 1: 100mg d-2; 200mg d-1; 400mg d1-21~consolidation maintenance therapy: 400mg d1-7"
214488984|NCT06757855|DRUG|Azacitidine|"induction therapy：75mg/m2/d, d1-7~consolidation maintenance therapy: 75mg/m2/d, d1-7"
214488985|NCT05121051|PROCEDURE|Biospecimen Collection|Undergo collection of blood, buccal cell, and nasal epithelial cell samples
214488986|NCT05121051|DIETARY_SUPPLEMENT|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
214488987|NCT05121051|DRUG|Placebo Administration|Given PO
214973119|NCT02094794|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
214973120|NCT02094794|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
214361524|NCT01011829|DRUG|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
214361525|NCT01011829|DRUG|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
214361526|NCT00587964|RADIATION|Stereotactic Radiosurgery|"All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY."
214488988|NCT05121051|OTHER|Questionnaire Administration|Ancillary studies
214488989|NCT06751966|COMBINATION_PRODUCT|Combination Product: Conventional third-line therapy|Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.
214488990|NCT06751966|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
214488991|NCT06191848|DRUG|Tirzepatide|Participants will receive tirzepatide subcutaneously
214488992|NCT06191848|DRUG|Placebo|Participants will receive placebo subcutaneously
214488993|NCT01675440|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
214973121|NCT04467515|DRUG|CAM-H2|All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
214488994|NCT05731856|DEVICE|Apollo Wearable|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phones. Participants will use the Apollo for at least 30 minutes after waking up and at least 30 minutes before bed on the corresponding settings for those times of the day. They will be given the Apollo Device TVS (10-200 Hz) to borrow, which they will be instructed to wear daily. They will be asked to wear the device until all study data is collected.
214488995|NCT00207480|BEHAVIORAL|Brief, motivational interviewing intervention|
214488996|NCT06791564|DEVICE|AVELI|Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.
214488997|NCT05180539|BEHAVIORAL|SPLASH Intervention Condition|Two-session in person group discussions focusing on behaviors in drinking contexts
214488998|NCT05180539|BEHAVIORAL|Control Condition|Two-session in person group discussions focusing on college health behaviors
215084053|NCT02495064|DRUG|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
215084054|NCT03352583|DIETARY_SUPPLEMENT|Protein|40g calcium caseinate
214361527|NCT06079905|OTHER|Nonoperative treatment|Nonoperative treatment
214361528|NCT06079905|OTHER|Operative treatment|Operative treatment
214361529|NCT05965687|PROCEDURE|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
214361530|NCT05965687|PROCEDURE|Nasal oxygen|For nasal oxygen group, patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
214361531|NCT05965687|DRUG|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
214361532|NCT01163097|DRUG|Palifermin|40 µg/kg IV bolus injections for three consecutive days
214361533|NCT01163097|DRUG|Heparin|Heparin continuous IV infusion
214361534|NCT00208143|DRUG|Quetiapine|
214361535|NCT00208143|DRUG|Risperidone|
214361536|NCT01429480|PROCEDURE|Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block|
214361537|NCT01429480|PROCEDURE|Preoperative Ultrasound Guided Posterior TAP Block|
214488999|NCT05220501|DIAGNOSTIC_TEST|Micro-US Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MicroUS targets will be identified and sampled.
214489000|NCT05220501|DIAGNOSTIC_TEST|MRI Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MRI targets will be identified and sampled.
214489001|NCT03779984|DEVICE|Red Rubber Catheter|Experimental group will be intubated with red rubber catheter guidance
214489002|NCT03779984|DEVICE|Standard nasal tracheal Intubation|Control group will be intubated with standard nasal tracheal tube without guidance
214489003|NCT05990790|DRUG|Desflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
214361538|NCT01429480|DRUG|Patient controlled analgesia|
214489004|NCT05990790|DRUG|Sevoflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
214361539|NCT02959632|BEHAVIORAL|Animal Assisted Therapy|Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
214361540|NCT01569438|DRUG|Gefapixant|50 or 300 mg tablets for a total daily dose of 50, 100, 150, 200, 250 or 300 mg BID, orally with food for 4 weeks
214361541|NCT01569438|DRUG|Placebo|Dose matched placebo tablets, BID, orally, with food for 4 weeks
214361542|NCT03031964|DEVICE|revision multihole acetabular cup|post market study of multi hole revision acetabular cup
214361543|NCT01337895|OTHER|Low dairy|No more than 1 serving per day
214361544|NCT01337895|OTHER|High dairy|4 or more servings per day
214489005|NCT05990790|DRUG|Propofol|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
214679386|NCT05741710|DRUG|Placebo|Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
214361545|NCT03651167|OTHER|Survey|Participants will complete a survey online
214361546|NCT02083016|DEVICE|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
214361547|NCT02083016|DEVICE|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
214361548|NCT00452387|DRUG|Mitoxantrone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Mitoxantrone 9mg/m2~Dose Level -1 Mitoxantrone 12mg/m2~Dose Level 1 Mitoxantrone 12mg/m2"
214361549|NCT00452387|DRUG|Prednisone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Prednisone 5mg bid~Dose Level -1 Prednisone 5mg bid~Dose Level 1 Prednisone 5mg bid"
214361550|NCT00452387|DRUG|Sorafenib|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Sorafenib 400 mg QD~Dose Level -1 Sorafenib 400 mg QD~Dose Level 1 Sorafenib 400 mg bid"
214361551|NCT03649230|DRUG|300mg netupitant/0.5mg palonosetron hydrochloride|Antiemetic (NK1 receptor antagonist/5-HT3 receptor antagonist)
214489006|NCT02566889|DRUG|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
214489007|NCT06952166|BEHAVIORAL|Qigong (Baduanjin)|Participants will receive 24 sessions of Baduanjin training over 12 weeks (2 sessions per week). Each session will last for 60 minutes. Baduanjin consists of eight forms of gentle movements, and it takes about 10 to 15 minutes to complete a full cycle. Participants will learn to practice each form gradually over the first 12 sessions. In the remaining 12 sessions, the participants will go through all the movements 2-3 times, with guided practice on rhythmic breathing and mind regulation (attention to body and breathing) to be performed in coordination with the movements. The training will be delivered by an instructor after training by the project team.
214679387|NCT00871858|DRUG|anastrozole|Given orally
214679388|NCT00871858|DRUG|fulvestrant|Given intramuscularly
214679389|NCT01737164|BEHAVIORAL|Aerobic Exercise|
214679390|NCT02305251|OTHER|Survey|Standard Gamble Survey
214679391|NCT00898261|GENETIC|microarray analysis|
214361552|NCT05047198|PROCEDURE|Control - Catheter Ablation for VT|"Currently standard of care involves surgical resection of myocardial scarring in structural heart disease. Imaging is performed to identify culprit areas for ablation, pre procedural imaging involves echocardiography, CT scanning and PET imaging to assess cardiac function, ischemia, inflammation and scarring. Radiofrequency energy is delivered via catheter to the targets and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. A conventional approach will be used advancing multiple catheters via femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, scar, identified during endocardial mapping. CA procedures for VT are often long, averaging approximately 5 hours ."
214361553|NCT05047198|PROCEDURE|Treatment - Non-Invasive Radio Ablation for VT|Patients undergoing a non-invasive RA procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. A non-invasive electrophysiology study is performed under light sedation using ECGi mapping. This procedure requires only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the ECGi mapping system. The multimodal imaging data is digitally fused and combined with the ECGi data to identify the VT circuit(s) and to attain the targets for radio-ablation. This analogue process is performed off-line by a physician team. The treatment plan is sent for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators remotely. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.
214361554|NCT01693068|DRUG|Pimasertib|Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
214361555|NCT01693068|DRUG|Dacarbazine|Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
214361556|NCT00579280|DRUG|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
214361557|NCT00579280|DRUG|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
214489008|NCT06952166|BEHAVIORAL|Mindfulness-based intervention|Participants will receive mindfulness-based intervention with the same duration and frequency as qigong group. The intervention incorporates psychoeducation on mindfulness and stress management and group-based mindfulness practice about breathing, awareness of body sensations, thoughts, stretching, and walking. All the mindfulness practices are based on publicly accessible audio recordings. The training will be delivered by an instructor after training by the project team.
214489009|NCT06952166|BEHAVIORAL|Physical exercise|Participants of the physical exercise group will receive training of a series of low-to-moderate intensity physical activities for the same duration and frequency as qigong group. The physical activities include stretching, flexibility exercise, balance exercise, and aerobic exercise. The training will be delivered by an instructor after training by the project team.
214489010|NCT06500572|OTHER|Landmark Guided Intercostobrachial Nerve Block|In addition to the supraclavicular plexus block, the intercostobrachial nerve block block will be performed without ultrasound guidance and based on the traditional method using superficial anatomy and nerve pathway by subcutaneous injection of 20 mL of bupivacaine 0.25% at the site of the pulse.
214489011|NCT06500572|OTHER|Ultrasound Guided Intercostobrachial Nerve Block|The patient's head will be turned to the opposite side while the patient is in the supine position and the shoulder to be treated will be elevated 5- 10 cm. The high-frequency linear ultrasound probe (12-4 MHz) and the region to be treated will be prepared in sterile conditions and placed transversely across the external jugular vein at 3-4 cm above the clavicle. Between the anterior and middle scalene muscles, the imaging of the brachial plexus showed three to five hypoechoic circles. The entry will be in-plane technique using an 80-mm block needle from lateral to medial. After confirming the needle insertion site with 2 mL saline solution, a 20 mL bupivacaine 0.25% will be administered.
214679392|NCT00898261|GENETIC|reverse transcriptase-polymerase chain reaction|
214973122|NCT06441604|DRUG|Extended-release Buprenorphine|"First 10 participants will receive XR-BUP 16mg in single-blind fashion. If at least 90% of the participants who received 16mg successfully complete induction (success defined as experiencing no BPOW),10 additional participants will receive a 24mg dose in a single blind fashion.~If at least 90% who received 24mg successfully complete induction (success defined as experiencing no BPOW), 10 additional participants will receive a 32mg dose in a single blind fashion."
214973123|NCT05646030|DIAGNOSTIC_TEST|TAP-II|The TAP-II device will be compared to lancet capillary sampling and the venipuncture
214973124|NCT05646030|DIAGNOSTIC_TEST|Lancet capillary sampling|The lancet capillary sampling will be compared to TAP device and the venipuncture
214973125|NCT05646030|DIAGNOSTIC_TEST|Venipuncture|The venipuncture will be compared to TAP device and the lancet capillary sampling
214361558|NCT00579280|DRUG|placebo|placebo
214679393|NCT00898261|OTHER|flow cytometry|
214679394|NCT00000711|DRUG|Zidovudine|
214973126|NCT05972343|DEVICE|Cryoablation|Takes place at single time point.
214973127|NCT06969014|DEVICE|Microwave ablation|Microwave ablation of lung tumors
214973128|NCT04252625|DRUG|Q-Urol|Q-Urol is an over-the-counter herbal supplement manufactured by Farr Laboratories. It is a combination product composed of quercetin, pollen extract, bromelain, and papain.
214679395|NCT00000711|DRUG|Sargramostim|
214361559|NCT05478655|OTHER|visual analog scale|VAS was studied: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital and further 1, 3, 6, 12 months after the injury; 5) at the rehabilitation stage. Intervals between analgesia were also studied.
214361560|NCT01624675|DRUG|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (\>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing \>= 45 kg was 3.0 mg. For subjects weighing \>=45 kg, the maximum daily dose was 3.0 mg.
214361561|NCT01624675|DRUG|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
214361562|NCT04407390|DIETARY_SUPPLEMENT|Nicotinamide riboside|The patients will receive 1 g of nicotinamide riboside or placebo orally every morning for 14 days.
214489012|NCT06500572|OTHER|Serratus Plane Block|The patient will be placed in the lateral decubitus position with the area to be treated on the upper side. The high-frequency linear ultrasound probe and the region to be treated will be sterilized. The ultrasound probe will be placed on the anterior line at the level of fourth and fifth ribs. Images of the muscle's latissimus dorsi and serratus anterior, the ribs, and the pleura will be obtained. Subsequently, with the in-plane technique, an 80-mm block needle will be advanced between the latissimus dorsi and the serratus muscles planes in a caudal to the cranial direction. There is no blood or air in aspiration. After confirming the location of the needle with 2 mL of saline solution, (20 mL of bupivacaine 0.25%) will be administered between the two muscles.
214489013|NCT05858879|OTHER|Notification of patients and clinicians|"Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan and a recommendation that they discuss this finding and initiation of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification.~Usual Care The usual care arm will not receive any additional notification beyond this standard of care."
214489014|NCT04518943|BEHAVIORAL|Walking|Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
214489015|NCT06797180|DEVICE|Virtual Reality Education for Dementia Caregivers|This group will receive 100 minutes of BPSD foundational education followed by 100 minutes of VR-based training focused on managing BPSD.
214489016|NCT03928041|DEVICE|Device: EVOS Lumbar Interbody System (EVOS-HA)|All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
214489017|NCT02932618|BIOLOGICAL|Vonicog alfa|Lyophilized powder and solvent to prepare solution for injection.
214489018|NCT02932618|BIOLOGICAL|Antihemophilic Factor (Recombinant)|Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
214489019|NCT03699163|DIAGNOSTIC_TEST|Breath sample|Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
214489020|NCT04090541|OTHER|Rigid Tape|Non-Elastic Tape
214489021|NCT04090541|OTHER|Kinesiology Tape|Tape can be elongate only one direction
214973129|NCT04252625|DRUG|Placebo|placebo capsule
214361563|NCT04407390|DIETARY_SUPPLEMENT|Placebo|Placebo
214361564|NCT02510144|DRUG|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
214489022|NCT04090541|OTHER|Biomechanical Tape|Tape can be elongate only two direction
214489023|NCT01443260|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
214489024|NCT06513507|DIETARY_SUPPLEMENT|Cannabigerol (CBG)|The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
214489025|NCT03844152|DIETARY_SUPPLEMENT|Fermented whey concentrate|The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability. The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose. The research team will provide non-descriptive bottles of drink to all volunteers. The flavour of the FWC will be masked by the flavoured water. In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers. At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study. The daily energy content of the FWC is 4kcal.
214973130|NCT06355440|BEHAVIORAL|Financial Navigation|"One-on-one information support with material booklets during hospitalization. Weekly financial navigation information will be sent via WeChat after discharge for 1 month.~The financial navigation encompasses comprehensive information support:~* Strategies on patient-physician costs discussion~* Skills for inquiring and tracking treatment-related costs~* Basic knowledge about health insurance~* Guidance on accessing and applying for financial assistance~* Suggestions for returning to normal life and work~* Strategies for holding a financial-related family meeting"
214973131|NCT06355440|OTHER|Usual Care|Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
214361565|NCT02510144|DRUG|Skin Prep Benzoyl Peroxide|3 day preoperative skin prep prior to surgery
214361566|NCT00956566|BEHAVIORAL|dietary intervention|dietary counseling, group teaching
214361567|NCT05604625|DEVICE|Van-Beek activator and a headgear|12 patients will receive Van-Beek activator and a headgear
214361568|NCT05604625|DEVICE|Andresen activator|12 patients will receive Andresen activator.
214361569|NCT02029079|DIETARY_SUPPLEMENT|E+|300 ml E+ per day (525 kcal, 22.5 gram protein) for 35 days.
214361570|NCT02322008|BIOLOGICAL|infliximab and adalimumab|In this retrospective, observational study, no interventions were undertaken by the researchers.
214973132|NCT06420089|DRUG|Senza5 CART5|The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
214973133|NCT05321368|BEHAVIORAL|LINKED-HEARTS Program|The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
214361571|NCT05046054|DEVICE|transcutaneous electrical nerve stimulation|transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
214361572|NCT05046054|DEVICE|Placebo transcutaneous electrical nerve stimulation|Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
214973134|NCT04832607|OTHER|Multivirus (CMV, EBV, AdV)-specific T cells|Cell therapy product which is individually produced for each patient and administered via IV bolus injection.
214973135|NCT02983578|DRUG|Danvatirsen|Given IV
214973136|NCT02983578|BIOLOGICAL|Durvalumab|Given IV
214361573|NCT00694005|PROCEDURE|kissing balloon|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
214361574|NCT00694005|PROCEDURE|"without kissing balloon angioplasty leave alone"|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
214361575|NCT00328432|DRUG|celecoxib 400 mg bid|
214361576|NCT00977665|DRUG|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
214361577|NCT00977665|DRUG|placebo|placebo tablet for 48 weeks
214489026|NCT00124735|DRUG|Rocuronium bolus maintenance|Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
214489027|NCT00124735|DRUG|rocuronium continuous infusion maintenance|Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
214973137|NCT00000411|PROCEDURE|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.
214973138|NCT00000411|OTHER|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
214973139|NCT04391842|COMBINATION_PRODUCT|Sustained Acoustic Device with 1% Diclofenac patch|"Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 with 1% diclofenac patch~Other Names:~* ZetrOZ ultrasound device~* wearable ultrasound device~* long duration ultrasound~* LITUS device~* long duration low intensity device"
214973140|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with limited number of TEE clips|The intervention group would be limited to fewer than 20 TEE clips per case (versus the average of \~ 80-100 TEE clips per case).
214973141|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist|The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
214973142|NCT04881214|OTHER|Pulmonary rehabilitation|pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months
214973143|NCT00810199|DRUG|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg IV every 4 weeks.
214973144|NCT00810199|DRUG|methotrexate|Approximately 15-17 mg methotrexate capsule orally once a week.
214973145|NCT00810199|DRUG|placebo|Placebo matching methotrexate capsule taken orally once a week.
214973146|NCT04296708|OTHER|Exergame Training|An exergame combines exercise and gaming in a holistic approach.
214973147|NCT00006146|BIOLOGICAL|Approved influenza virus vaccine.|
214361578|NCT00404365|OTHER|counseling intervention|
214361579|NCT00404365|OTHER|screening questionnaire administration|
214361580|NCT00404365|OTHER|study of socioeconomic and demographic variables|
214361581|NCT00404365|PROCEDURE|psychosocial assessment and care|
214361582|NCT00668902|DRUG|[13C]Pantoprazole|\[13C\]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
214361583|NCT00349479|BEHAVIORAL|Barrier assessment / interactive educational intervention|"Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education."
214361584|NCT06216054|DRUG|LPM3770164 sustained release tablet|administrated orally
214361585|NCT06216054|DRUG|LPM3770164 sustained release tablet simulant|administrated orally
214361586|NCT02115633|DEVICE|Walkasins ON|Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.
214361587|NCT02115633|DEVICE|Walkasins OFF|Subjects will be wearing a device that is turned off.
214361588|NCT01221987|PROCEDURE|Cervical sampling|Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types
214361589|NCT01221987|OTHER|Data collection|Questionnaire completion
214361590|NCT04262518|DEVICE|Outcomes4Me Mobile App|A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
214361591|NCT01159054|DRUG|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
214361592|NCT00808275|DIETARY_SUPPLEMENT|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
214361593|NCT00381069|BEHAVIORAL|Family & Community Recreation Center Intervention|The two year intervention involves changing the environment and policies in community recreation centers to promote physical activity and healthy eating choices. The Recreation Specialist will meet with recreation center staff monthly to create action plans that work towards this goal. Family Health Coaches will be in contact with intervention families twice a month either through a phone consultation, workshop at the recreation center,or home visit. Intervention families will receive a monthly mailing highlighting tips for healthy eating and physical activity. MOVE families will be encouraged to utilize the recreation center as a resource in supporting their child's physical activity and healthy eating behaviors.
214361594|NCT05258786|BEHAVIORAL|Pre-labor ultrasound as a visual biofeedback device for maternal pushing education and pelvic floor training|"1. Ultrasound examination with the screen turned to the provider will assess the bladder movements at rest and during contraction of the pelvic floor and fetal head descent at rest and during pushing.~2. The provider will turn the screen to the patient and explain the anatomical landmarks: bladder, fetal head, birth canal direction.~3. A repeat of the first stage (1) with the screen turned to the patient: the biofeedback process. Bladder displacement will serve as a marker of pelvic floor contraction, and the delta in the progression angle will serve as a marker for effective pushing.~4. Finally, the provider will turn the screen again from the patient and repeat the first stage."
214361595|NCT01356355|DRUG|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
214361596|NCT01356355|DRUG|Placebo|One capsule twice a day daily till ureteral stent in situ
214973148|NCT00637026|DRUG|Gefitinib|Iressa
214489028|NCT00630487|DRUG|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
214489029|NCT00630487|DRUG|Somatropin|Fixed doses for patients: MALE: \< 45y 0,4 mg, \> 45y 0,2mg FEMALE: \< 45y 0,5mg, \>45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
214489030|NCT04910438|OTHER|STIs screening and care|"* Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).~* Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM."
214489031|NCT03958019|OTHER|RESTORE II Program|Detailed in arm description
214489032|NCT02261506|OTHER|7 days of adequate antibiotic treatment durations|We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.
214489033|NCT02261506|OTHER|14 days of adequate antibiotic treatment durations|
214489034|NCT02446444|DRUG|Enzalutamide|
214489035|NCT02446444|DRUG|Conventional NSAA|
214489036|NCT02446444|DRUG|LHRHA|
214489037|NCT02446444|RADIATION|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
214489038|NCT06324981|BEHAVIORAL|Generic text messages|The same unidirectional text message will be sent each week for 9 weeks.
214489039|NCT06324981|BEHAVIORAL|Interactive AI chatbot text messaging|Each week for 9 weeks, patients will be sent four messages that are specific to the LE8 topic for that week and with each message, they will be invited to engage with the chatbot to ask more questions about that topic. The first message of the week will be informational about the topic consistent with how the AHA provides information: 1) to understand readings and levels, 2) to encourage people to track levels, and 3) to offer specific skills building strategies. The fourth message will ask them to report out on short term (i.e., things they can do that week) plans for self-management for that topic and again invite their engagement with the chatbot to reinforce support for their plans.
214489040|NCT06324981|BEHAVIORAL|Proactive pharmacist support|Pharmacists that will proactively facilitate effective engagement with patients.
214973149|NCT01448252|BIOLOGICAL|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
214361597|NCT01356355|DRUG|Tolterodine|One capsule twice a day daily till ureteral stent in situ
214361598|NCT01774513|DEVICE|Procore-Needle|
214973150|NCT01448252|BIOLOGICAL|T cell vaccination|Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
214361599|NCT01947465|BIOLOGICAL|Hepatitis A vaccine and tetanus vaccine|Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
214489041|NCT06213493|DIAGNOSTIC_TEST|measurement of RNAs|RNAs will be measured in heart tissues and in peripheral blood mononuclear cells
214489042|NCT06730893|OTHER|SDM protocol|Card news and Videos related to general knowledge and treatment of low-risk thyroid cancer
214489043|NCT06455475|OTHER|Derm-Maxx|Derm-Maxx™ Dermal Matrix is an acellular human dermis graft sterilized using the Tutoplast® Tissue Sterilization Process.
214489044|NCT05902572|OTHER|No intervention|Observational data collection only.
214489045|NCT02879656|PROCEDURE|non-operative treatment|conservative treatment with 5 weeks cast immobilization
215084055|NCT06066905|DRUG|chidamide and azacitidine|"chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally."
215084056|NCT01180816|DRUG|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
214361600|NCT04718428|DIAGNOSTIC_TEST|Nail Ultrasonography|The MyLab 60 (Esaote Biomedica Genoa, Italy) device and linear probe were used. Nails were examined in B-mode grayscale and power Doppler.
214361601|NCT06560047|PROCEDURE|Catheter ablation|Catheter ablation with pulmonary vein isolation will be the study intervention. Patients randomized to the intervention arm will undergo catheter ablation within six weeks of randomization. In the waiting-time for ablation, patients will receive standard treatment for AF and HF, as per current guideline recommendations. Catheter ablation will be performed at one of six high-volume ablation centers in Denmark. Mode of catheter ablation will be at the discretion of the operator. Radiofrequency ablation, cryo-balloon ablation and pulsed-field ablation will be utilized. The treating physician should ensure successful pulmonary vein isolation after ablation with either post-procedural mapping or pacing, as per current standards. Only pulmonary vein isolation will be performed during the ablation procedure.
214361602|NCT01005940|DEVICE|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
214361603|NCT02674893|DRUG|Liraglutide|
214361604|NCT02674893|OTHER|Observation alone|
214361605|NCT03860857|RADIATION|Amyloid PET scan|Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
214361606|NCT03860857|DRUG|Tau PET scan using MK-6240|Tau Positron Emission Tomography scan using radio tracer MK-6240
214361607|NCT03860857|BEHAVIORAL|Neurocognitive testing|A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
214361608|NCT03860857|OTHER|MRI|High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
214361609|NCT05356806|OTHER|Supportive periodontal and periimplant care|"Periodontal and peri-implant maintenance therapy will be carried out at baseline, 3 and 6-month visit. This session will include the removal of biofilm and calculus on teeth and implants (except those that have just been restored) with an ultrasonic device using a plastic tip ( for implants. and a conventional metal tip ( for teeth. At the end, polishing will be done with a rubber cup~Subsequently, patients will be explained that they must continue with their usual oral hygiene technique on their teeth, using the same type of brush (which can be electric or manual), interproximal devices, toothpaste or mouthwash used to date. Finally, they will receive specific instructions for the supragingival biofilm control in the area of the new restoration and will be given interdental brushes that suit to the space"
214361610|NCT03965897|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|Overall, the goal of the ACT intervention is to cultivate psychological flexibility: to help Veterans respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. It increases patients' awareness of behaviors that exacerbate the pain (such as struggling with it) and recognition of avoidance strategies that interfere with life engagement.
214361611|NCT03965897|OTHER|Attention Control (AC)|Information on any other coping practices will be omitted. The group facilitators will present one topic at a time, using the Pain Manual, and the participants will discuss and reflect about issues and experiences related to each topic. If necessary, the group facilitators will raise specific discussion questions to facilitate group dialogue and participant involvement.
214361612|NCT02228265|OTHER|Cytology Specimen Collection Procedure|Undergo blood and tissue collection
214361613|NCT02228265|DRUG|Enzalutamide|Given PO
214361614|NCT02228265|OTHER|Laboratory Biomarker Analysis|Correlative studies
214361615|NCT06470321|BEHAVIORAL|Flexiquit Computerized Smoking Cessation Program|Flexiquit is an avatar-led, self-directed computerized program delivering evidence-based techniques to assist with smoking cessation. It includes motivational interviewing, psychoeducation on nicotine addiction, cognitive-behavioral strategies for coping with cravings, relapse prevention, and stress/emotion regulation skills training. Participants receive the program over 6 months and their adherence is monitored. The program provides tailored feedback to support abstinence.
214361616|NCT00233922|DEVICE|Osteosheet(r)|
214361617|NCT00000154|PROCEDURE|Vitrectomy|
214489046|NCT02879656|PROCEDURE|operative treatment|surgery with volar locking plate with modified Henry's volar approach
214489047|NCT04370704|DRUG|INCAGN02385|INCAGN02385 administered intravenously
214489048|NCT04370704|DRUG|INCAGN02390|INCAGN02390 administered intravenously
214489049|NCT04370704|DRUG|INCMGA00012.|INCMGA00012 administered intravenously
214489050|NCT04599296|DEVICE|Hip brace|Hip brace
214489051|NCT06177769|DEVICE|LMA classic|Airway is secured with LMA clasic
214489052|NCT06177769|DEVICE|LMA Proseal|Airway is secured with LMA proseal
214489053|NCT06177769|DEVICE|I-gel|Airway is secured with I-gel
214489054|NCT06131437|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
214489055|NCT06131437|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
215084057|NCT01448785|DEVICE|abiliti system implant|Subjects will receive implanted abiliti System.
215084058|NCT01448785|DEVICE|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
215084059|NCT00792025|DRUG|sunitinib malate|
215084060|NCT01434329|GENETIC|DNA methylation analysis|
215084061|NCT01434329|GENETIC|gene expression analysis|
215084062|NCT01434329|GENETIC|microarray analysis|
214361618|NCT01400503|DRUG|Siltuximab|Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
214361619|NCT00058123|DRUG|poly ICLC|
214361620|NCT01767740|DEVICE|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
214361621|NCT01767740|DEVICE|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
214361622|NCT05242328|PROCEDURE|Ultrasound-guided erector spinae plane block|Ultrasound-guided erector spinae plane block
214489056|NCT06131437|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
214489057|NCT05513586|DRUG|TAK-771|Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
214489058|NCT03111537|OTHER|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
214489059|NCT03111537|OTHER|E-Cigarette|Use of E-cigarette: multiple flavors offered.
214489060|NCT03111537|OTHER|Nicotine Gum or Lozenge|Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
214489061|NCT06662357|BEHAVIORAL|Behavioral Treatment|"Family Connections Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
214489062|NCT04265872|DRUG|Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis|injection into a vein
214489063|NCT06771791|OTHER|oral provocation test|Progressively increasing doses of peeled fresh Golden apple or placebo will be consumed by the patient (4g, 12g, 40g, 120g) with a time interval of 20 minutes between each dose.
214489064|NCT06772662|PROCEDURE|Tubing Direction|We are studying the procedure of placing the Cryotherapy Tubing in two different directions: up vs down
214489065|NCT06996691|PROCEDURE|Erector Spinae Plane Block (ESPB) group|30ml of 0.25% levobupivacaine for erector spinae block at level of T5
214489066|NCT06996691|PROCEDURE|Serratus Anterior Plane Block (SAPB) group|30 mL of 0.25% levobupivacaine injected anteriorly to the rib and deep to the serratus anterior at level of 5 th rib
214489067|NCT06995755|BEHAVIORAL|atlas|A theoretically-grounded, highly individualized text messaging intervention that 1) provided information on current climate-related and environmental risks (e.g., high temperatures, air quality alerts, asthma triggers etc.) that might adversely affect a user's current health conditions; 2) linked users to local zip-code matched resources to mitigate their specific risk (e.g., cooling centers, hurricane shelters); 3) implemented a full range of best practices in tailored health behavior change communications to personalize ongoing communications regarding the link between human actions and extreme weather based on the user's level of concern about and belief in climate change; and 4) provided customized actionable tips for addressing climate change to promote climate efficacy at the individual, community, and policy/advocacy level based on the user's level of motivation.
214489068|NCT01459107|PROCEDURE|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
214489069|NCT01459107|DRUG|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
214489070|NCT06995807|OTHER|EL-SHIN THERAPY|"Participants will be randomly assigned to Group A and Group B. Group A : Attend a talk on Malaysia Tourism + current coping strategies.~Group B : EL-SHIN® Therapy + current coping strategies. Duration of therapies: 2 weeks Assessments using (i) DASS-21 (ii) MHQoL (iii) SLEEP QUALITY SCALE (SQS) at baseline, after 1st week \& 2nd weeks for both groups. Assessment will be done on end of 3rd week to see effect when EL-SHIN Therapy Stopped.~Group B participants: Attend a workshop on administration of EL-SHIN® Therapy. Will reinitiate EL-SHIN Therapy on the 4th week and assess on the 8th day to see the effect."
214489071|NCT05393531|DEVICE|Mandibular advancement device (MAD)|Active therapy
214361623|NCT05242328|PROCEDURE|surgical thoracoscopic intercostal nerve block|surgical thoracoscopic intercostal nerve block
214361624|NCT06285877|PROCEDURE|Conventional therapy sessions|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise.
215084063|NCT01434329|OTHER|laboratory biomarker analysis|
214361625|NCT06285877|PROCEDURE|Conventional therapy sessions plus Nintendo Switch|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise plus one hour a week of Nintendo Switch.
214361626|NCT04728321|BIOLOGICAL|AK104 lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
214361627|NCT04728321|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
214361628|NCT01970826|PROCEDURE|Single Dental Implants|place single unit dental implants, 2 mm below crestal bone and follow manufacturer guidelines.
214361629|NCT01970826|PROCEDURE|Sterilized Aseptic|Operatory room will be prepared totally aseptic
214361630|NCT01970826|PROCEDURE|Sterilized Clean|Operatory room will be prepared clean but not aseptic
214361631|NCT01970826|PROCEDURE|Full-Mouth Dental Implants|dental implants for full-mouth implant rehabilitation.
214361632|NCT01970826|PROCEDURE|Partial Rehabilitation|two or more implants to support partial rehabilitation
214361633|NCT01970826|PROCEDURE|Duration of Surgery|it will be measure the amount of time to perform the dental implant surgery. It will be measured from the time that the surgeon does the first incision until the last suture is made.
214361634|NCT02235948|DRUG|folic acid supplementation|0.8mg folic acid/day
214361635|NCT01142206|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
214361636|NCT01142206|BEHAVIORAL|Physical Activity|All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
214361637|NCT01142206|BEHAVIORAL|TV Watching + Physical Activity|The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
214361638|NCT03876405|DEVICE|smartskin non-invasive sensory feedback|"The sensory feedback system used was a simple non-invasive, non-electronic system based on air-mediated pressure. A silicone glove with bulbs (35 mm in length) volar in every fingertip was made and applied on a VariPlus Speed hand (OttoBock), size 7¾.~The sensory feedback system was embedded in the prosthetic socket."
214489072|NCT05393531|DEVICE|Continuous positive airway pressure (CPAP)|Active therapy
214489073|NCT06995846|DIAGNOSTIC_TEST|Bacterial DNA Levels in Ascites|The bactDNA was detected by droplet digital polymerase chain reaction (ddPCR).
214489074|NCT06858995|OTHER|to measure the residual activity on the Totally Implantable Venous Access Port|VOI (volume of interest)TIVAP at 4 ml were drawn manually on the chamber of the TIVAP on each tomography. Blood background was determined by an VOI (volume of intesrest of Right Auricle on the right atrium. The VOIRA was automatically delineated on the CT by XXX. Standardized Uptake Value (SUV)max, SUVpeak, SUVmean were extracted from the VOIs and unilateral comparisons of superiority were performed using Wilcoxon tests. A qualitative analysis along the (TIVAP) catheter was performed: positive if an uptake was superior to the blood background and negative if any.
214361639|NCT05222282|OTHER|Sexual Health|Prevention of sexual dysfunction
214361640|NCT05627102|OTHER|Experimental Group|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
214361641|NCT05627102|OTHER|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
214489075|NCT06670274|DRUG|HC002 SAD|"Part 1 will enroll 32 participants across 4 cohorts.~Route of administration: Oral Dose interval and frequency: Single oral dose range across 4 cohorts."
214489076|NCT06670274|DRUG|HC002 MAD|"Part 2 will enroll 24 participants across 3 cohorts.~Route of administration: Oral Dose interval and frequency: Once daily for 7 days"
214489077|NCT06670274|DRUG|Placebo|Matching placebo will be administered across SAD and MAD
214489078|NCT03598998|BIOLOGICAL|Pembrolizumab|Given IV
214361642|NCT05327881|DIAGNOSTIC_TEST|Plasma renin concentrations will be measured at enrollment and at 24, 48, and 72 hours. Whole blood lactate measurements will be performed according to normal standard of care.|"Measurement of Whole Blood Lactate Concentrations:~Whole blood lactate concentrations were measured using ABL 800 series analyzers. The IRB (Institutional Review Board) protocol specified that lactate concentrations could be obtained as part of routine care, but lactate concentrations were not measured independently for research purposes.~Measurement of Plasma Renin Concentrations:~Discarded whole blood samples (waste blood samples) in EDTA (ethylenediaminetetraacetic acid) (BD Vacutainer, 4 mL) tubes were prospectively collected from each patient at the time of study enrollment and at 24, 48, and 72 hours.~Plasma active renin levels were measured using the active renin enzyme-linked immunosorbent assay kit (DRG International, Township, NJ)"
214489079|NCT03598998|DRUG|Pralatrexate|Given IV
214489080|NCT05585346|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
214489081|NCT05585346|DRUG|Oral vitamin B1|Oral vitamin B1 10mg, times/day
214489082|NCT06997705|BEHAVIORAL|Optimized VMS|Building on the Systematic Medical Visits (VMS) the Optimized VMS, optimizes these services for in-school and out-of-school adolescents by expanding availability of VMS services through community and facility platforms and building capacity of health workers to provide integrated services. Also the intervention will involve demand generation activities such as community sensitization.
214489083|NCT05794932|DIAGNOSTIC_TEST|Stress test|"Diagnostic Test:~* Maximum effort test (CPET) on a cycloergometer~* Leg muscle strength assessment~* Leg muscle mass, composition and water compartments (segmental bioelectrical impedance)~* Spirometry, arterial blood gaz, NO/CO transfer"
214489084|NCT06810453|OTHER|A 5 cc venous blood sample was obtained|A 5 cc venous blood sample was obtained just before anesthesia induction and at the end of surgery.
215084064|NCT01434329|OTHER|medical chart review|
214361643|NCT04072510|BEHAVIORAL|Self-esteem group|"The intervention will comprise of 6 sessions of group self-esteem therapy which uses a cognitive behavioural approach. The therapy has been manualised into a 76 page treatment protocol and will be administered by Assistant Psychologists employed at Newbridge House receiving weekly supervision from a Clinical Psychologist. The self-esteem group is based on Melanie Fennel's cognitive behavioural model of low self-esteem addressing thoughts, feeling and behaviours. The group aims to improve self-esteem and build positivity.~The sessions are structured and laid out in the following overview:~Week 1, Session 1: What is self-esteem and an introduction to CBT Week 2, Session 2: How might low self-esteem develop? Week 3, Session 3: Negative automatic thoughts Week 4, Session 4: Challenging negative automatic thoughts Week 5, Session 5: Creating new coping strategies Week 6, Session 6: Building positivity"
214361644|NCT04072510|BEHAVIORAL|Treatment as Usual|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
215084065|NCT03610503|OTHER|Music|Participants in this arm will listen to music during the EMG testing
215084066|NCT05936502|OTHER|Extranodal extension|Extranodal extension presence or absence on radiology and pathology assessment
215084067|NCT04083261|OTHER|DNA Genotek Oragene 600|Saliva-based DNA sample collection kit
215084068|NCT03564821|DRUG|Ivosidenib|Ivosidenib is an inhibitor of the protein IDH1
215084069|NCT03351114|DRUG|Crisaborole|Apply Crisaborole 2% ointment to affected skin twice per day.
215084070|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental|40 Gy / 15 Fractions EBRT + HDR-Brachytherapy
215084071|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care|45 Gy / 25 Fractions EBRT + HDR-Brachytherapy
215084072|NCT04583254|DRUG|Concurrent Chemotherapy|Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
214361645|NCT02616874|DRUG|MVA.HIVconsv vaccine|Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
214361646|NCT02616874|DRUG|Romidepsin|Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
214361647|NCT05944965|DRUG|Atomoxetine 80 mg plus Oxybutynin 5 mg|80mg Atomoxetine and 5mg Oxybutynin administered 30mins prior to bed
214361648|NCT05944965|DRUG|Atomoxetine 80 MG|80mg Atomoxetine administered 30 mins prior to bed
214361649|NCT05944965|DRUG|Placebo|Placebo and placebo (sugar pill) administered 30 mins prior to bed
214361650|NCT02417818|DEVICE|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
214361651|NCT02417818|DEVICE|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
214361652|NCT01249248|DEVICE|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
214489085|NCT06810453|PROCEDURE|low-flow anesthesia|Low-flow anesthesia, also known as inhalational anesthesia method, is a type of anesthesia that is performed using a semi-closed, rebreathing system containing at least 50% fresh gas. Generally, low-flow anesthesia is used in anesthesia practices because it reduces costs, prevents environmental pollution, increases the humidity of gases, and reduces heat loss. Another important benefit of low-flow is that it requires closer monitoring of patients, which allows for early detection of complications during general anesthesia, thus improving patient safety. Concerns about low-flow anesthesia being used infrequently in the past have been addressed by the introduction of modern anesthesia workstations with sophisticated monitoring and safety features, which have made low-flow anesthesia widely used in most centers.
214489086|NCT02701283|DEVICE|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
214489087|NCT02701283|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
214489088|NCT06479174|BEHAVIORAL|CHAMPS-TR|Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).
214679396|NCT03244891|OTHER|Increase of central volume|"Mild hypovolemia will be induced in healthy volunteers by 12 hours fasting. Three conditions will be considered for the analysis, each of them both during spontaneous breathing and positive pressure ventilation:~1. baseline~2. after fluid shift induced by passive head down position at 15 degrees~3. after fluid challenge with Ringer acetate 15ml\*kg in head down position~A total of six steps will be considered for the analysis"
214361653|NCT02925676|DEVICE|hyposafe H02|hypoglycaemia notification device
214361654|NCT04629482|OTHER|Brain networks activity|The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.
214361655|NCT01394900|BEHAVIORAL|CNU Intervention|Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.
214361656|NCT01394900|BEHAVIORAL|WP Intervention|Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
214679397|NCT03244891|OTHER|Ventilation mode|"Each previous step will be done in two respiratory conditions:~1. spontaneous breathing~2. noninvasive ventilation via facial mask in pressure support mode at 8 cmH2O above positive end expiratory pressure of 5 cmH2O, inspiratory fraction of oxygen of 0.25 In both conditions respiratory rate will be set at 18 breaths per min following a metronome"
214679398|NCT00298610|DRUG|Artesunate|Intravenous Artesunate (2.4 mg/kg) once a day for three days
214679399|NCT00298610|DRUG|Malarone|(proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
214679400|NCT06192446|DRUG|Survey using a questionnaire.|An observational study conducted in a cross-sectional manner using a questionnaire.
215084073|NCT00450671|PROCEDURE|Collagen Plug Placement|
214361657|NCT01975896|BEHAVIORAL|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
214361658|NCT05929469|BEHAVIORAL|App|Participants will receive an mHealth program.
214361659|NCT05929469|BEHAVIORAL|Fully Automated Kick-Off|As an orientation to the study, participants will receive a fully automated kick-off session.
214361660|NCT05929469|BEHAVIORAL|Human-Enhanced Kick-Off|As an orientation to the study, participants will receive a kick-off session that includes time with a study interventionist.
214361661|NCT05929469|BEHAVIORAL|Check-In|Participants will receive a check-in with a study interventionist.
214361662|NCT05929469|BEHAVIORAL|Counseling|Participants will receive counseling from a study interventionist.
214361663|NCT00826306|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
214679401|NCT03465852|BEHAVIORAL|ChiCAS|Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
214679402|NCT03236350|DEVICE|Active autoRIC® (CRIC Treatment)|The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
215084074|NCT00450671|PROCEDURE|Seton placement|
214361664|NCT06217367|DRUG|50 mg Diphenhydramine|Participants ingest 50mg of diphenhydramine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
214361665|NCT06217367|DRUG|10 mg Loratadine|Participants ingest 10 mg of loratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
214361666|NCT06217367|DRUG|5 mg Desloratadine|Participants ingest 5 mg of desloratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
214361667|NCT06217367|OTHER|Placebo (Sugar Pill)|Participants ingest placebo pill orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
214361668|NCT04845048|BIOLOGICAL|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute
214489089|NCT06757062|DEVICE|Kinesiology Tape|The kinesiology tape (KT) is applied with the dorsal application for the treatment of carpal tunnel syndrome (CTS). This method is utilized and explained in Krause et al. (2020). This study will assess the efficacy of the application method as well as the varying effects of the color of the KT. Red KT will be compared to skin tone KT. The skin tone KT will be color-matched as closely as possible to each participant's skin tone to reduce the effect of the KT color. In this way, the study's second purpose is to understand the potential effect of color on psychological function and performance in the context of aggressive first-person shooter esports games.
214489090|NCT06746168|PROCEDURE|Locoregional anesthesia|The FTB + iPACK group will receive 12 ml 0,5% ropivacaine for the FTB and 20 ml of ropivacaine 0.5% for the iPACK block under US guidance after spinal anesthesia
214489091|NCT06746168|PROCEDURE|Local Anesthetic Ropivacaine|The control group (LIA) will receive 120 ml 0.25% ropivacaine for surgical LIA placement.
214489092|NCT06918431|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
214489093|NCT06918431|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214489094|NCT06918431|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and/or biopsy
214489095|NCT06918431|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and/or biopsy
214489096|NCT06918431|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214489097|NCT06918431|DRUG|Cyclophosphamide|Given IV
214489098|NCT06918431|DRUG|Cytarabine|Given IT
215084075|NCT05094479|BEHAVIORAL|Health information delivered via health app|Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
215084076|NCT00872378|DRUG|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
215084077|NCT00872378|DRUG|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
215084078|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d
215084079|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
214489099|NCT06918431|DRUG|Cytarabine|Given IV or SC
214489100|NCT06918431|DRUG|Daunorubicin Hydrochloride|Given IV
214489101|NCT06918431|DRUG|Dexamethasone|Given PO
214489102|NCT06918431|PROCEDURE|Echocardiography|Undergo echocardiography
214489103|NCT06918431|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214489104|NCT06918431|DRUG|Mercaptopurine|Given PO
214489105|NCT06918431|DRUG|Methotrexate|Given IT
214489106|NCT06918431|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214489107|NCT06918431|BIOLOGICAL|Rituximab|Given IV
214489108|NCT06918431|DRUG|Vincristine Sulfate|Given IV
214489109|NCT03236428|DRUG|Daratumumab|Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
214489110|NCT06680297|DIETARY_SUPPLEMENT|Carbohydrates loading|Patient who is randomised in the intervention group will receive Nestle drink 2hours before the operation and a night before operation. They will receive 10mls/kg a night before operation and 5mls/kg 2 hour before operation of the carbohydrate drink.
214489111|NCT06680297|DIETARY_SUPPLEMENT|Control group|Patient assigned to this group will receive standard surgical fasting treatment which include 6hrs of fasting and 2 hrs of clear fluid prior operation
214489112|NCT06870058|DRUG|NH280105- SAD|Dose formulation: Capsule Route of administration: oral
214489113|NCT06870058|DRUG|NH280105- MAD|Dose formulation: Capsule Route of administration: oral
214489114|NCT06870058|DRUG|Placebo|Matching placebo comparator
214489115|NCT06869512|BEHAVIORAL|SUCCESS|6 group-based sessions with 25 minutes of didactic content, 25 minutes of facilitated support group, and 10 minutes of group physical activity
214489116|NCT06832332|BEHAVIORAL|alternative birthing positions|In this stage, students will be given a simulated breech birth with alternative birth positions as opposed to the traditional position in the second stage of labor.
214489117|NCT05418101|DRUG|VIS171|Participants will receive VIS171 via SC route of administration.
214489118|NCT05418101|DRUG|Placebo|Participants will receive Placebo via SC route of administration
214489119|NCT07015749|DRUG|Placebo|Participants with asthma will receive Placebo at the corresponding dose and dosing interval.
215084080|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
215094420|NCT01407523|DRUG|Levetiracetam|"* Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily"
215084081|NCT04359290|DRUG|Ruxolitinib administration|Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.
215084082|NCT00492479|DRUG|Kinerase Pro+Therapy Line day repair, serum, night repair|
215084083|NCT00492479|DRUG|Kinerase Pro+Therapy Line Ultra rich day repair|
215084084|NCT00492479|DRUG|LubriDerm|
215084085|NCT01476189|DRUG|Experimental paracetamol formulation|experimental
215084086|NCT01476189|DRUG|Marketed paracetamol|Marketed paracetamol
215084087|NCT01476189|DRUG|Higher dose marketed paracetamol|Higher dose marketed paracetamol
215084088|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours."
215084089|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects."
215084090|NCT00055354|PROCEDURE|Acupuncture|
215084091|NCT00055354|BEHAVIORAL|Cognitive Behavioral Therapy|
215084092|NCT05636384|OTHER|Home-based care|"Home-based medical care is based on a specialized home-based medical team approach, including following:~1. Specialized Home-Based Medical Team Approach~2. Initial Assessment and Education~3. Initial Home Visits and Education~4. Multidisciplinary Team Meeting~5. Regular Assessment After the Initial Visit"
215084093|NCT02125357|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
215084094|NCT02125357|DRUG|Enzalutamide|160mg PO OD as per standard of care.
215084095|NCT04024332|DRUG|ACT-541468|ACT-541468 25 mg; administered orally
215084096|NCT01665430|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
215084097|NCT02310230|DEVICE|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
215084098|NCT01663701|OTHER|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
215084099|NCT01663701|OTHER|Usual care|Patients are managed according to admitting doctors' orders
214361669|NCT04510805|DEVICE|NextDose (nextdose.org)|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
214489120|NCT07015749|DRUG|IBI3002|Participants with asthma will receive IBI3002 at the corresponding dose and dosing interval.
214489121|NCT05836675|OTHER|Intradialytic exercise|The exercise program will be carried out during dialysis time. Participants will be asked to carry out cycling for 15-20 minutes, resistance exercises, and Kegel exercises during the first 2 hours of their regular routine hemodialysis session. Exercise can be done with rest periods as necessary.
214973151|NCT05867134|BEHAVIORAL|Removal of postoperative lifting restrictions|"Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to return to activity as tolerated/comfortable and stop activity if pain present."
214973152|NCT04312243|DRUG|Inhaled nitric oxide gas|Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
214973153|NCT03337620|DEVICE|Tx360|Tx360 used to deliver active and placebo drug interventions to SPG.
214973154|NCT00000887|DRUG|Nelfinavir mesylate|
214973155|NCT00000887|DRUG|Lamivudine|
214973156|NCT00000887|DRUG|Zidovudine|
215084100|NCT01939132|DRUG|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
215084101|NCT03625830|DEVICE|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
215084102|NCT03625830|DEVICE|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
215084103|NCT01371643|DRUG|Octreotide LAR|
215084104|NCT01371643|PROCEDURE|transsphenoidal surgery|
215094421|NCT02973776|DRUG|LEO 90100 aerosol foam|
215084105|NCT06200922|OTHER|Pelvic physiotherapy|All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.
215084106|NCT05245630|PROCEDURE|Robotic arm assisted PET/CT guided biopsy|"After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done."
215084107|NCT05245630|PROCEDURE|PET fused CT-Fluoroscopy guided biopsy|CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
215084108|NCT03350893|COMBINATION_PRODUCT|Emulsion base with probiotics|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10\^9 cells/ g-cream)
215084109|NCT03350893|OTHER|Emulsion base|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
215084110|NCT01567202|PROCEDURE|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
215084111|NCT01567202|DRUG|Chemotherapy|Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
215084112|NCT01567202|RADIATION|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
215084113|NCT01567202|BIOLOGICAL|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
215084114|NCT01567202|DRUG|blank placebo|Saline that has the same appearance with DC vaccine.
215084115|NCT03249935|DRUG|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
215084116|NCT02727556|BEHAVIORAL|visual images|
215084117|NCT04785625|COMBINATION_PRODUCT|Bupivacaine Hydrochloride|INL-001 (bupivacaine hydrochloride) implant
215084118|NCT04785625|COMBINATION_PRODUCT|Placebo collagen-matrix implant|Placebo collagen-matrix implant
214489122|NCT06874244|DRUG|Local Anesthesia (lidocaine hydrochloride)|Injection of lidocaine as local anesthesia
214489123|NCT06874244|DRUG|Iontophoresis of Tetracaine and oxymetazoline|Injecting Tetracaine Hydrochloride 4% with 0.5% Oxymetazoline to the oral tissue using iontophoresis technique
214489124|NCT06693648|DRUG|AMZ001 Diclofenac gel|Diclofenac gel applied once daily
214489125|NCT06693648|DRUG|Placebo gel|Matching placebo gel applied once daily
214679403|NCT03236350|DEVICE|Sham Control autoRIC® (Sham Control)|The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
214679404|NCT05387395|OTHER|NO intervention|no intervention
215084119|NCT05140837|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score & Stroop test|MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.
215084120|NCT05140837|DRUG|Drug therapy|Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
215084121|NCT02170363|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
215084122|NCT04553653|OTHER|checklist|The checklist will be implemented and healthcare providers use the checklist to manage the patients.
215084123|NCT02261129|DRUG|Telmisartan film-coated tablet|
215084124|NCT02261129|DRUG|Telmisartan uncoated tablet|
215084125|NCT00320749|DRUG|Capecitabine|Will be give on days 8-21
215084126|NCT00320749|DRUG|Docetaxel|Will be given on days 1 and 8,
215084127|NCT00320749|DRUG|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
215084128|NCT01669421|DRUG|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
215084129|NCT03589391|DEVICE|LOR measurement via device|The epidural technique is totally performed in a sterile field without any harm to the patient. The LOR measurement is monitored via the bespoke device used during the epidural procedure.
215084130|NCT02477735|DEVICE|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
215084131|NCT03630198|DRUG|Corticosteroid with lidocaine|Intralesional corticosteroid injection
215084132|NCT03630198|DRUG|Corticosteroid with normal saline|Intralesional corticosteroid injection
215084133|NCT00004729|BEHAVIORAL|Ketogenic diet|
215094422|NCT02973776|DRUG|Dermoval®/Dermovate®|
215094423|NCT02973776|DRUG|Diprosone|
215084134|NCT00167102|DRUG|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
215084135|NCT03551977|BEHAVIORAL|iCanCope with Pain|The participants are free to use the Norwegian iCanCope with Pain app as much as they want during the 8 week intervention period. The only support available is technical support.
215084136|NCT03551977|BEHAVIORAL|iCanCope with Pain control|The participants are free to use the Norwegian iCanCope with Pain control app as much as they want during the 8 week intervention period. The only support available is technical support.
215084137|NCT01561755|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
215084138|NCT01561755|DRUG|Placebo|Placebo - 2gr/kg over 2 days of saline
215084139|NCT04412122|OTHER|Kinesio Taping|In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
215084140|NCT04412122|OTHER|Breathing Exercise|Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
215084141|NCT04412122|OTHER|Kinesio Taping+Breathing Exercise|In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
215084142|NCT04412122|OTHER|Control Group|No intervention was performed to reduce pain in the control group.
215084143|NCT06136286|DEVICE|Blood Flow Restriction (BFR) Cuff|The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
215084144|NCT04129905|BIOLOGICAL|BNP blood sample test|Performed during normal recommended follow-up of the HCM patients.
215084145|NCT04129905|DIAGNOSTIC_TEST|Electrocardiogram|Performed during normal recommended follow-up of the HCM patients.
214679405|NCT04981340|BEHAVIORAL|Diaphragmatic breathing|Same as previously described
214973157|NCT03821987|DRUG|Fludarabine|Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX (cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
215084146|NCT04129905|DIAGNOSTIC_TEST|Holter ECG|Performed during normal recommended follow-up of the HCM patients.
215084147|NCT04129905|DIAGNOSTIC_TEST|Echocardiography|Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
215084148|NCT04129905|DIAGNOSTIC_TEST|Air venous plethysmography|Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
215084149|NCT04129905|DIAGNOSTIC_TEST|Upper member arterial Doppler echography with analysis of FMD|Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
215094424|NCT02973776|DRUG|Elocon|
214973158|NCT04916717|OTHER|Counseling|Face-to-face and telephone counseling were applied to individuals in the intervention group.
214973159|NCT00174200|DRUG|Risperidone 2 mg|
214361670|NCT04719689|OTHER|Dry needling|Experimental group 1 got this intervention containing Dry needling for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus lumborum
214973160|NCT06005363|DRUG|Dexmedetomidine|dexmedetomidine infusion
214973161|NCT06005363|DEVICE|anesthesia depth monitoring|intraoperative anesthesia depth monitoring to keep BIS 40-60
214679406|NCT04981340|BEHAVIORAL|Standard urotherapy|Same as previously described
214679407|NCT03077945|BEHAVIORAL|heart rate variability biofeedback and cognitive reappraisal|
214679408|NCT03077945|BEHAVIORAL|control tasks|
214679409|NCT04830995|DIETARY_SUPPLEMENT|moderate restricted diet (1800-2000 kcal/day) for four weeks|high intensity interval training 3 sessions for four weeks
214679410|NCT00717418|DRUG|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
214679411|NCT05868993|DRUG|Dose of 0.5% Ropivacaine|Dose varied by 5mL of 0.5% Ropivacaine
214679412|NCT03483688|BIOLOGICAL|CD19-directed CAR-T cells|CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
214973162|NCT01754064|DEVICE|Cardiac Rhythm Management device|
214973163|NCT02089048|DRUG|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
214679413|NCT02519751|DIETARY_SUPPLEMENT|D3 Creatine|One dose of D3 Creatine (60mg capsule) given orally on Day 1
214973164|NCT00105742|PROCEDURE|Diagnosis|
214973165|NCT00715403|DRUG|BIBF 1120|
214973166|NCT02175225|DRUG|Deferoxamine Mesylate|
214973167|NCT02175225|DRUG|Placebo (for Deferoxamine Mesylate)|
214973168|NCT01707641|DIETARY_SUPPLEMENT|CD#2|patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
215084150|NCT04129905|BIOLOGICAL|Endothelial function biomarkers|Performed specifically for the research. Blood sample test, 5 minutes.
215084151|NCT04197063|BEHAVIORAL|Sweetened beverage portion size limit|
215084152|NCT03627312|COMBINATION_PRODUCT|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
215084153|NCT03627312|COMBINATION_PRODUCT|Placebo|Fruit juice drink only
215084154|NCT03627312|OTHER|Treatment as Usual|Young Offenders Intervention Programme
215084155|NCT06361602|OTHER|inapplicable|inapplicable
215084156|NCT03454867|DEVICE|Hemofiltration|
214973169|NCT01707641|OTHER|bicarbonate sodium mouthwash|Patients will be asked to wash their mouth with bicarbonate sodium several times per day
215084157|NCT03454867|PROCEDURE|Standard acute ischemic stroke treatment|
215084158|NCT02804698|BEHAVIORAL|Education intervention|13-week educational and physical activity intervention
214361671|NCT04719689|OTHER|Dry cupping|Experimental group 2 got this intervention containing Dry cupping for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum
214973170|NCT03832647|COMBINATION_PRODUCT|Epiduo|100 per arm Adapalene/ Benzoyl Peroxide
214973171|NCT03832647|DRUG|Salicylic Acid|Salicylic Acid
214973172|NCT03832647|OTHER|Hydréane légère|moisturizer
214361672|NCT03138148|OTHER|Routine mechanical ventilation|Routine mechanical ventilation in PICU amid children with acute respiratory failure
214361673|NCT03993548|BEHAVIORAL|Wellness Element 1 - Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
214361674|NCT03993548|BEHAVIORAL|Wellness Element 2 - Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
214973173|NCT05155748|OTHER|Continuous education and knowledge exchange|The intervention is educational and directed at the complete nursing home care team.
214973174|NCT05829499|DEVICE|HPMC-HA eyedrops|Ocular drops based upon HPMC and HA
214973175|NCT05656196|OTHER|Chinese herbal tea VGH-DESJS-1|Chinese herbal tea VGH-DESJS-1.
214973176|NCT02582333|OTHER|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
214679414|NCT02519751|DIETARY_SUPPLEMENT|Creatine|Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
214679415|NCT02796690|OTHER|nasal swabs will be collected|After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
214973177|NCT01883895|DEVICE|Forgionei-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
214973178|NCT01883895|OTHER|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
214973179|NCT01883895|OTHER|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
214973180|NCT03532737|DRUG|Pembrolizumab|Adding PD-1 inhibitor to the standard of care
215084159|NCT00278369|BIOLOGICAL|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
215084160|NCT00278369|BIOLOGICAL|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
215084161|NCT02740543|DRUG|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
215084162|NCT01620502|DIETARY_SUPPLEMENT|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
215084163|NCT04380103|DRUG|XELOXIRI/Bevacizumab|bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
215084164|NCT00164398|BEHAVIORAL|HIP: HIV Intervention for Providers|
215094425|NCT02973776|DRUG|Locoid|
215094426|NCT02973776|OTHER|LEO 90100 foam vehicle|
215094427|NCT02917915|OTHER|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
214973181|NCT03969615|DEVICE|SuperNO2VA nasal positive airway pressure devic|SuperNO2VA nasal positive airway pressure device utilizes supplemental oxygen and an adjustable pressure limiting valve to maintain upper airway latency
214973182|NCT03969615|DEVICE|Supplemental oxygen|5lpm of supplemental oxygen
214973183|NCT02010112|OTHER|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
214973184|NCT02164955|DRUG|IMNOVID|IMNOVID (pomalidomide) as prescribed in routine clinical practice
214973185|NCT05440981|DEVICE|iTind device|Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.
214973186|NCT05593484|OTHER|Standard Referral|Schools in the control condition will use standard referral, as determined by the school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
214973187|NCT05593484|OTHER|Specialty Telemedicine Access for Referrals (STAR)|The STAR intervention will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the STAR intervention and send the information asynchronously to an audiologist for review.
214973188|NCT05456893|PROCEDURE|Procedure: endoscopic biopsy|Per-endoscopic biopsies
214973189|NCT05456893|PROCEDURE|Blood sampling|Blood sampling
214973190|NCT05456893|PROCEDURE|stool sampling|stool sampling
214973191|NCT05816915|BEHAVIORAL|Cognitive behavioral therapy|Subjects will receive professional lifestyle intervention conducted by STOB organization. Using CBT and the so-called third wave of CBT, especially mindfulness, the patients will be guided by certified experts to increase motivation and to change eating and exercise habits, which will be mapped before and after the intervention.
214973192|NCT06221371|DRUG|rhTNK-tPA|rhTNK-tPA (0.25 mg/kg, maximum dose 25mg) is given as a single, intravenous bolus (injection over 5 to 10 seconds) immediately upon randomization. EVT should be performed as soon as possible after rhTNK-tPA administration.
214973193|NCT06221371|DEVICE|direct EVT|During the study period, NMPA-approved stents are permitted. EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team.
214973194|NCT02938117|OTHER|cycling exercises|
214973195|NCT01325545|OTHER|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
214973196|NCT06987682|OTHER|Balance training|Participants will don a safety harness that is secured to an overhead track. Each balance training session will involve 45 minutes of visual feedback balance training (VFBT) (Figure 1) followed by 45 minutes of reactive balance training (RBT), totaling 90 minutes. This combination will ensure all systems of postural control are targeted by the training, and that both standing and stepping are practiced. For both groups, FES and tSCS will be set up, including placing electrodes and setting stimulation amplitudes.
214973197|NCT06295458|DEVICE|David Delight Plus Device|Flicker exposure via a light and sound device-based stimulation-provided sensory stimulation device. The DAVID Delight Plus device consists of light-emitting goggles and sound-emitting headphones that are turned on and off with a repetition rate of 40 Hz connected to a controller operated by the participant or study partner (if the participant elects to have an optional study partner). At the baseline visit, light and sound intensity levels (auditory: 0-80 dBA, visual: 0-1400 lux) will be programmed into each participant's controller based on their unique response to tolerance and EEG entrainment testing which occurred at screening. The participant may not detect gamma-flicker frequency.
214973198|NCT06295458|OTHER|Sham Therapy|Sham therapy will be provided in the same manner as the flicker light. The difference is that it will be a constant light and sound from the same device instead of the 40hz light treatment and sound.
214973199|NCT00807365|DRUG|GHRH|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
214973200|NCT00185042|DRUG|Pactimibe, CS-505|
214973201|NCT06726473|DIAGNOSTIC_TEST|Wet Blood Gas Analyzer (ABL90)|This group involves the use of the ABL90 wet blood gas analyzer for measuring arterial whole blood samples. The results obtained from the ABL90 analyzer will be compared with those obtained from the EG-i30 dry blood gas analyzer
214973202|NCT06726473|DIAGNOSTIC_TEST|Dry Blood Gas Analyzer (EG-i30)|This group involves the use of the EG-i30 dry blood gas analyzer for measuring arterial whole blood samples. The results obtained from the EG-i30 analyzer will be compared with those obtained from the ABL90 wet blood gas analyzer.
214973203|NCT05072210|OTHER|Mobile Intervention|Active mobile data will be used to provide automated, personalized notifications to frontline healthcare workers. Key information on mental health and links to access additional health resources will be available on the mobile platform.
214973204|NCT01939730|DRUG|Rituximab|375 mg/m\^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
215084165|NCT03368716|BEHAVIORAL|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
215084166|NCT01673815|OTHER|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
215084167|NCT00387413|DRUG|Duloxetine|Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
215084168|NCT00387413|DRUG|GSK189254|Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
214361675|NCT03993548|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
214489126|NCT07022769|BEHAVIORAL|LLM-facilitated cognitive debiasing aid|"As part of the intervention, patients first respond to a series of questions about their beliefs regarding their symptoms (e.g., What's usually behind these symptoms?), with responses transcribed verbatim via tablet. These responses are input into a Large Language Model (LLM), which generates a brief, supportive summary of the patient's beliefs, shared back with the patient to encourage self-awareness and reflection. Patients are then invited to consider prompts such as, What emotions or circumstances might be influencing your thinking? with their reflections again transcribed. The LLM analyzes these reflections to identify potential signs of emotional distress or maladaptive beliefs, and this output is again provided to the patient. The LLM summary of identified maladaptive beliefs is then also shown to the clinician ahead of the consultation to support more tailored, empathetic communication."
214489127|NCT06336681|DEVICE|PrO2Fit Device|The flow-resistive protocol using the device requires participants to maximally inhale as hard as they can and as long as they can against a small leak (2mm diameter hole) until task failure. This records maximum inspiratory pressure (MIP) and sustained maximal inspiratory pressure (SMIP) values which will be recorded and the best is chosen for the software template by the participant to continue their training session (previously described in arm/group description). The use of the device occurs three times a week, and used for 6-8 weeks.
214489128|NCT04591080|DEVICE|GUMMETAL Orthodontic Wire|Orthodontic archwire made of TiNbTaZr alloy.
214489129|NCT04591080|DEVICE|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
214489130|NCT06870513|PROCEDURE|Antegrade Cerebral Perfusion via Axillary Artery|In antegrade cerebral perfusion (ACP), patients underwent cannulation of the right axillary artery using an interposition Dacron graft (7 mm) connected to a cardiopulmonary bypass (CPB) circuit. During surgery, ACP delivered oxygenated blood flow directly into the brain arteries to maintain cerebral protection during the period of deep hypothermic circulatory arrest (DHCA), enabling the surgical team to perform the distal aortic anastomosis safely.
214489131|NCT06870513|PROCEDURE|Retrograde Cerebral Perfusion via Superior Vena Cava|In retrograde cerebral perfusion (RCP), cannulation of the superior vena cava (SVC) was performed to deliver blood flow in reverse direction during deep hypothermic circulatory arrest (DHCA). This method aimed to provide cerebral protection by supporting cerebral metabolism during the surgical repair of acute Type A aortic dissection.
214489132|NCT07022704|DRUG|Doxapram|Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT
214679416|NCT00174161|BEHAVIORAL|self-care, health behavior|
214679417|NCT05607290|BEHAVIORAL|Cognitive-Behavioral Treatment|12 sessions of Cognitive-Behavioral Treatment for Alcohol Use Disorder
214679418|NCT06248320|PROCEDURE|Sigh ventilation|Sigh breaths were delivered from intubation to extubation. Intervention primarily conducted in the following three stages: 1. From intubation to surgical opening of the chest cavity; 2. From the surgical closure of the chest cavity close and continue unit the operating room exiting; 3. From Intensive Care Unit (ICU) arrival to Spontaneous breathing trial (SBT) start.
214973205|NCT01939730|DRUG|GM-CSF|250 mcg subcutaneously 3 times a week for 8 weeks.
214973206|NCT06749210|BEHAVIORAL|Tango|The intervention being studied is a 16 session intervention (2x4-week modules), delivered over an 8-week period by community-based individuals with expertise in dance and patient care and certified in Adapted Tango or AdapTango dance instruction. Steps available to teach, including order and cues to teach them, are detailed in Hackney's AdapTango manual. All steps are based on the Argentine Tango steps that emerged within working class community centers in Buenos Aires, Argentina (milongas) in the late 1800s and have been adapted by the investigators for use as medical exercise among people with mobility deficits. Of note, Argentine Tango is distinct from, and the precursor for, the American Tango style of competitive ballroom dance: where American Tango highlights showmanship and complicated footwork, Argentine Tango prioritizes connection between partners and musicality within a basic walk motion.
214973207|NCT04491461|DIETARY_SUPPLEMENT|Herbal tea blend|1 cup of freshly brewed tea from an herbal tea blend.
214973208|NCT04491461|DIETARY_SUPPLEMENT|Warm water|1 cup of warm water
214973209|NCT00847418|DRUG|esketamine hydrochloride|
214973210|NCT03810456|BEHAVIORAL|Intensive Cognitive Behavior Therapy (iCBT)|Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
214973211|NCT03810456|BEHAVIORAL|Standard Cognitive Behavior Therapy (sCBT)|Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
214973212|NCT00738426|DEVICE|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
214973213|NCT00738426|DEVICE|Sham device|non-therapeutic light energy output
214361676|NCT03993548|BEHAVIORAL|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on Social Connectedness; adherence documented online daily
214361677|NCT03993548|BEHAVIORAL|Wellness Element 5 - Nutrition|Daily wellness element focusing on Nutrition; adherence documented online daily
214361678|NCT03993548|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
214361679|NCT03993548|BEHAVIORAL|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
214361680|NCT02151266|BEHAVIORAL|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
214361681|NCT02151266|BEHAVIORAL|Exercise Only|
214361682|NCT02151266|BEHAVIORAL|Stretching and Flexibility|
214361683|NCT03511755|DEVICE|Transdermal Electrical Neuromodulator (TEN)|Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7).
214973214|NCT06404619|BEHAVIORAL|Education program|The message emphasizes the importance of quality of life and positive psychology. The concept of quality of life is described as multidimensional, also the message highlights the steps to change one's lifestyle, including self-reflection, habit modification, and commitment to a comprehensive lifestyle change include importance of physical activity, management of stress, quality and quantity of sleep and specific recommendations are provided regarding drinking water, organizing meals, and adopting a healthy balanced diet with attention to portion sizes. The message also discussed fitness foods that aid digestion and promote a healthy body. The message introduced the Healthy Eating Plate.
214973215|NCT00082212|BIOLOGICAL|Cetuximab|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
214973216|NCT04825951|OTHER|CS 2000|treating growing Skeletal growing Class III patients
214973217|NCT03127319|DRUG|apatinib docetaxel zoledronic|apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
214973218|NCT03127319|DRUG|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
214973219|NCT02717728|PROCEDURE|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.~Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.~Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
214973220|NCT02717728|PROCEDURE|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.~Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.~Device: Dressing~Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
214973221|NCT06765356|DEVICE|Farapulse Catheter System|"The FARAWAVE PFA Catheter is a sterile, single use, over-the-wire, non-deflectable device that is used with the FARASTAR Catheter Connection Cable and FARASTAR Generator to enable delivery of Pulsed Field Ablation energy for irreversible electroporation. The FARAWAVE PFA Catheter has five (5) variably deployable splines. The five splines are undeployed during insertion and removal and during use can deploy continuously from an undeployed state through a partially deployed (basket-shaped) configuration to a fully deployed (flower-shaped) configuration with five petals."
214973222|NCT06765356|DRUG|Low-dose Colchicine|For participants in the colchicine sub-study, 0.3 mg BID Colchicine. Colchicine will be prescribed to the patient starting 5 days prior to ablation. Patient will continue the colchicine for 3 weeks post-ablation.
214973223|NCT07062835|BEHAVIORAL|Perioperative Paediatric Application|"Children in the experimental group will start receiving interactive perioperative preparation training with the PeroPap application 1 day before surgery and play the PeroPap game. Children will learn about the operation process by watching and playing the PeroPap character's cartoon story about the operation process. They will also listen to the song PeroPap is having surgery and play the PeroPap Game in the application, which they can play before and after surgery. At the same time, in the parent module, information will be provided for parents with the cartoon story PeroPap is Having Surgery."
214973224|NCT07062835|OTHER|Control|"In order to meet the perioperative health care needs of the children and their parents in the control group, when they applied to the outpatient clinic for anaesthesia consultation on the working day before the operation, standard individualised care interventions will be provided according to their needs preoperatively and until their discharge, and children and parents will be given surgery preparation training with the education booklet PeroPap is Having Surgery."
214973225|NCT07073625|OTHER|Stress Ball|Children arriving at the hospital's emergency department and meeting the study criteria will be randomly assigned to the stress ball group. Before inhalation therapy, the child will begin squeezing the chosen stress ball. This will distract their attention, transforming the frightening hospital environment into a fun one. The questionnaires will be completed by the nurse and family five minutes before, during, and after the inhalation therapy.
214973226|NCT07073625|OTHER|Reading Storybook|The storybook for the children will be selected by child psychologists. The book will be read to the children by their parents. The storybook reading will begin 15 minutes before the inhalation therapy and will be completed before the treatment begins. The storybook will be read to the children only once.
214973227|NCT07073131|OTHER|Vicryl Rapide suturing|Post episiotomy vicryl rapide suturing material is used for stitching episiotomy laceration.
214973228|NCT07073131|OTHER|Chromic catgut suturing|Post episiotomy chromic catgut suturing material is used for stitching episiotomy laceration
214973229|NCT07072780|DEVICE|Low-Level Laser Therapy (904 nm)|Low-level laser therapy using the LTU-904 device (RianCorp, Australia) at a wavelength of 904 nm, applied to the fibrotic area of the upper limb after CDPT.
214973230|NCT07072780|DEVICE|Low-Level Laser Therapy (650 nm)|Low-level laser therapy using the Salus Talent device (Remed, USA) at a wavelength of 650 nm, applied to the fibrotic area of the upper limb after CDPT.
214973231|NCT07072780|DEVICE|Sham Laser Therapy|Placebo laser therapy with no active laser emission, administered after CDPT.
214973232|NCT07071961|DRUG|Regorafenib (CT)|Given by po
214973233|NCT07071961|DRUG|Lorigerlimab|Given by IV
214973234|NCT07072442|DRUG|Western Medicine|Western medicine treatment only
214973235|NCT07072442|PROCEDURE|herbal medicine and acupuncture|Western medicine combined acupuncture and herbal medicine treatemnt
214973236|NCT07072442|DRUG|herbal medicine|Western medicine combined herbal medicine
214973237|NCT07072442|PROCEDURE|acupuncture|western medicine combined acupuncture
214973238|NCT06821477|OTHER|Superficial EMG|Superfiscial EMG during ASLR without knee brace follow by EMG during ASLR with knee brace under certain commands
215084169|NCT00387413|DRUG|GSK189254 Placebo|Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
215084170|NCT00387413|DRUG|Duloxetine Placebo|Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
215084171|NCT01286987|DRUG|Talazoparib|Oral capsule with multiple dosage forms given once daily
215084172|NCT05563116|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium (CAC) score (part of routine workup)|Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
215084173|NCT01997814|DRUG|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
215084174|NCT01997814|DRUG|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
215084175|NCT00681694|RADIATION|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
215084176|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
215084177|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
215084178|NCT06160856|DIAGNOSTIC_TEST|Abdominal ultrasound|Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score
215084179|NCT04662073|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
215084180|NCT04662073|DRUG|Placebo|Placebo to match camostat administered orally four times daily
215084181|NCT00000224|DRUG|Buprenorphine|
215084182|NCT03407495|DRUG|IOP Injection (MPB-1523)|one dose, once IV injection at Day 1
215084183|NCT04182321|DRUG|Metformin & Entecavir|Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
215084184|NCT04182321|DRUG|Placebo & Entecavir|Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
215084185|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 1|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
215084186|NCT06465264|DRUG|Amlodipine group 1|"One Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
215084187|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 2|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil (240 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
215084188|NCT06465264|DRUG|Allisartan Isoproxil group 2|"One Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
215084189|NCT04461574|DEVICE|Orcellex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
215084190|NCT04461574|DEVICE|Cervex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
215084191|NCT02009293|OTHER|Cough monitor|questionnaires about cough and quality of life
215084192|NCT02088502|DRUG|N-acetylcysteine|
215084193|NCT02088502|DRUG|Theophylline|
215084194|NCT02088502|DRUG|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
215084195|NCT04733170|DIAGNOSTIC_TEST|KnowNow SARS-CoV-2 Rapid Antigen Test|KnowNow SARS-CoV-2 Rapid Antigen Test for the detection of Covid-19 in saliva, as compared to high sensitivity reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal swabs as the reference test method
215084196|NCT00183378|BEHAVIORAL|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
215084197|NCT00183378|BEHAVIORAL|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
215084198|NCT00183378|BEHAVIORAL|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
215084199|NCT00183378|BEHAVIORAL|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
215084200|NCT02387125|BIOLOGICAL|CMB305|
214361684|NCT03816774|DRUG|PEG split-dose and simethicone|Patients in active comparator arm are instructed to take 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
214361685|NCT01381796|DRUG|NP101|comparison of NP101 with minor patch modifications
214361686|NCT01381796|DRUG|sumatriptan succinate|tablet, 100 mg
214361687|NCT01169675|DRUG|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
214361688|NCT01169675|DRUG|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
214361689|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
214361690|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
214361691|NCT01169675|DRUG|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
214361692|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
214361693|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
214361694|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
214361695|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
214361696|NCT01169675|DRUG|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
214361697|NCT01169675|DRUG|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
214361698|NCT01169675|DRUG|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
214361699|NCT05197894|DEVICE|Virtual Reality|The intervention is a Virtual Reality experience within a selected application using an Oculus Quest 2 ©, as previously in the relevant intervention arm.
214361700|NCT03987841|BEHAVIORAL|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. The intervention will comprise components of MBSR and DSME and will be delivered in a group setting with 8 weekly sessions. A trained masters-level interventionist will deliver the integrated intervention.
214361701|NCT02354664|OTHER|Thoracic MRI|Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
214361702|NCT02354664|OTHER|Spirometry|Upright forced vital capacity (FVC)
214361703|NCT02354664|OTHER|Inspiratory Load Compensation|A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
214361704|NCT02354664|OTHER|Maximal Inspiratory Pressure|Measure the maximal airflow on inhalation
214361705|NCT02354664|OTHER|Resting Breathing Pattern|The breathing pattern will be assessed when the subject is seated and in a relaxed state.
214361706|NCT02354664|OTHER|Respiratory Muscle Endurance Test|Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
214361707|NCT01763879|OTHER|The PCV-VCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
214361708|NCT01763879|OTHER|The VCV-PCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
214361709|NCT03875027|PROCEDURE|proximal femur replacement|patient with proximal femur fracture or those in whom previous surgery on hip is failed and treated with replacement of proximal femur implant
214361710|NCT05268679|OTHER|Biospecimen Collection|A blood of a sample of 2 x 7 mL will be collected for the analysis of the anti-SARS-CoV-2 T-cell response during a scheduled check-up as part of their routine follow-up
214361711|NCT05268679|OTHER|Questionnaire|Patients who have received SARS-CoV-2 vaccination will be asked to complete the Vaccine tolerance questionnaire
214361712|NCT05268679|OTHER|Electronic Health Record Review|For heart transplant recipients who were offered vaccination against SARS-CoV-2 medical records will be reviewed retrospectively.
214361713|NCT00180726|PROCEDURE|Blood sampling, Endoscopic Bronchoscopy, Spirometry|
214361714|NCT02365519|BIOLOGICAL|LME636 ophthalmic solution|
214361715|NCT02365519|BIOLOGICAL|LME636 Vehicle|Inactive ingredients used as a placebo comparator
214361716|NCT02291679|DRUG|Linaclotide|
214361717|NCT02291679|DRUG|Matching Placebo|
214361718|NCT00737555|DRUG|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
214361719|NCT03004794|OTHER|medical records review|
214361720|NCT02048072|DRUG|Gilenya|Autonomic testing during first dose administration of Gilenya.
214361721|NCT03909126|BIOLOGICAL|Boostrix administered during gestational diabetes screening|Boostrix administered during gestational diabetes screening
214361722|NCT03909126|BIOLOGICAL|Boostrix administered in high volume obstetric clinic|Boostrix administered in high volume obstetric clinic
214361723|NCT05081869|OTHER|Exercise Program|An online yoga-based exercise program will be applied for 16 sessions in individuals' own environments. The exercise program will consist of stretching, mobilization, stabilization, strengthening and relaxation exercises.
214361724|NCT05081869|OTHER|Education Program|There will be video training on the subject for both groups.
214679419|NCT05848245|DEVICE|low suction|This group receives low-volume intraoral suction during procedures. Low suction typically refers to standard saliva ejectors, which provide minimal suction power and are commonly used in routine dental treatments.
214973239|NCT07072052|OTHER|No intervention planned|No interventions planned
215084201|NCT02387125|BIOLOGICAL|G100|
215084202|NCT02387125|DRUG|Metronomic CPA|
214361725|NCT05711979|BEHAVIORAL|AARC|There will be 10 90min weekly sessions. The first half of each session will consist of health education discussing diet, physical activity and screen time. Participants will set goals for themselves and their families. The investigators will check-in on goals and barriers to achieving goals in each session following the initial session. The second half of the sessions will focus on mindfulness based stress reduction including brief meditation, discussion of mindful eating and mindful parenting. This intervention will adapt an already-existing evidence-based obesity prevention program which has been administered to over 100 families (COACH), and it will add mindfulness-based stress reduction, tailored to African American women.
214489133|NCT07023510|DIAGNOSTIC_TEST|AI-ECG driven echocardiography|The intervention utilizes a previously validated deep learning model based on 12-lead electrocardiogram (ECG) data to screen for moderate-to-severe valvular heart diseases (VHD). The model processes raw ECG signals and integrates age and sex to enhance prediction. (doi: 10.18632/aging.205835.) Participants identified as high-risk for any moderate-to-severe VHD by the algorithm of artificial intelligence-powered electrocardiogram (AI-ECG) in this intervention arm will receive transthoracic echocardiography to confirm diagnosis and guide further management.
214489134|NCT06696092|DEVICE|Hemostatic Agent|WoundClot Surgical may be used in a single target bleeding site of each subject.
214361726|NCT04932876|BIOLOGICAL|SARS - COV 2 VACCINE|Vaccination for SARS - COV 2
214361727|NCT00002292|DRUG|Pentamidine isethionate|
214361728|NCT05539092|OTHER|changing angle of bed|Before the cardiac catheterization procedure: patients' demographic characteristics and health relevant data will be collected on the first day of admission. the researcher will change angle of bed from 15° to 45°.
214361729|NCT00377325|DRUG|Cyclosporine|4 mg/Kg/day; daily; liquid form; 6 months
214361730|NCT00604032|DRUG|Atralin (tretinoin) Gel, 0.05%|Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
214361731|NCT05676632|OTHER|Routine Clinical Care|All participants attending the Achilles Tendon Rupture clinic will receive usual clinical care
214361732|NCT04457557|OTHER|Reduced concentration of local anesthetic (ropivacaine)|Reduced concentration of ropivacaine We usually use 0.5% ropivacaine in our facility. The intervention group used 0.15% ropivacaine 15 ml
214361733|NCT04457557|OTHER|Usual concentration of local anesthetic (ropivacaine)|0.5% ropivacaine 15ml
214361734|NCT03249155|BEHAVIORAL|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip is composed by images and sounds of the gestures. The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif\_example)
214361735|NCT03249155|BEHAVIORAL|CUE - visual and auditory|patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
214361736|NCT03900702|BEHAVIORAL|Gaze-driven training games|Training games are played on a PC with attached eye-tracker. Games include embedded training principles to improve attentional control including resistance to distraction and inhibitory control.
214361737|NCT04548063|OTHER|6,000 word consent form|Mock consent form with consistent content in approximately 6,000 word length.
214361738|NCT04548063|OTHER|4,000 word consent form|Mock consent form with consistent content in approximately 4,000 word length.
214361739|NCT04548063|OTHER|2,000 word consent form|Mock consent form with consistent content in approximately 2,000 word length.
214361740|NCT04450108|DIAGNOSTIC_TEST|Vivatmo pro FeNO Test|Breath gas analysis
214361741|NCT00653640|PROCEDURE|body weight supported treadmill training|BWSTT for 12 weeks, 3 times per week
214489135|NCT06697678|OTHER|No Intervention: Observational Cohort|No intervention
214489136|NCT06828510|DEVICE|With device|"Medical Device Installation Visit (V2, Day 0 + 21 ± 10 days): This visit, lasting approximately 1.5 hours, takes place in a consultation room at the center. A representative from ORTHOPUS adapts and installs the Partner on the patient's wheelchair, and an initial training session on the use of the medical device is provided.~Use of the Medical Device in Ecological Conditions (between V2 and V3): Between Day 21 and Day 42, the patient is invited to use the MD without restrictions in real-life conditions.~Final Evaluation Visit (V3, three weeks after V2, up to four weeks if necessary): The assessment session for the primary outcome-functional goal achievement using the GAS method-is conducted following the SCED (Single-Case Experimental Design) procedure, with multiple introduction-withdrawal phases and randomized phase sequencing and repeated measures :"
214489137|NCT07031063|DRUG|DTG/3TC|Dual therapy of 2 drugs co-formulated in 1 tablet: Dolutegravir 50 mg/ lamivudine 300 mg, it is the experimental group
214489138|NCT07031063|DRUG|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)|It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.
214489139|NCT07034053|DRUG|Clofarabine|Patients receive i.v. clofarabine in a dose-escalation regimen
214489140|NCT06711042|DIAGNOSTIC_TEST|functional tests and radiographic analysis|In this observational study, no active interventions or treatments will be administered to the participants. Both groups (Control Group and Experimental Group) will undergo clinical evaluations, including functional tests (WOMAC, Harris Hip Score, Oxford Hip Score, SF-12, TUG) and radiographic analysis (angular measurements). The participants' outcomes will be compared based on their implant placement (within or outside the Functional Safe Zone).
214489141|NCT06713720|DEVICE|Remote Ischemic Conditioning Device|Participants in this group will use a remote ischemic conditioning device that applies five cycles of 5-minute inflation at 200 mmHg followed by 5-minute deflation on both arms, twice daily, for at least five days per week over one year. The device is designed to enhance retinal oxygenation and reduce hypoxia-related damage.
214489142|NCT06713720|DEVICE|Sham Remote Ischemic Conditioning Device|Participants in this group will use the same remote ischemic conditioning device set to an inflation pressure of 60 mmHg to simulate the treatment. This placebo intervention follows the same timing and cycle frequency as the active intervention group.
214489143|NCT06715163|DIETARY_SUPPLEMENT|Dose 1 (42mg) of DAO|DAO extract is obtained from pea sprout dehydrated powder. Lowest dose of DAO administered in this study
214973240|NCT07072299|PROCEDURE|DEB-BACE|Drug-Eluting Bead microspheres used for embolization: Drug-Eluting Bead microspheres 1tube was loaded and adsorbed chemotherapy. End point of embolization: stagnation of blood flow in tumor feeding artery
214361742|NCT00653640|PROCEDURE|traditional physical therapy|traditional PT for 12 weeks, 3 times per week
214361743|NCT05572138|DIAGNOSTIC_TEST|Body Impedance Analysis|Body Impedance Analysis
214361744|NCT00725296|BIOLOGICAL|Remicade (Infliximab)|Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
214973241|NCT05280093|DEVICE|AtriCure ISOLATOR Synergy Surgical Ablation System|Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
214973242|NCT01408212|PROCEDURE|Acupuncture treatment|"Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.~* Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22~* Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)"
214973243|NCT02216279|DRUG|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
214973244|NCT06938828|OTHER|Observational cohort group|As this is an observational cohort study, there will be no intervention. In this study, only retrospective data will be collected for subsequent analysis. Similarly, the aim is to assess the relationship between the time on sick leave and the type of physiotherapy treatment received by patients. As this is an observational and retrospective cohort study, there is no risk derived from the development of the study for the subjects whose data form part of the study.
214973245|NCT05556252|OTHER|Hydrogenated water consumption|Participants will start consuming hydrogenated water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml hydrogenated water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) hydrogenated water in total. In this way, participants will be provided with hydrogenated water for three cycles.
214973246|NCT05556252|OTHER|Drinking water consumption|Participants will start consuming drinking water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml drinking water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) drinking water in total. In this way, participants will be provided with drinking water for three cycles.
214973247|NCT00464685|DRUG|Dexamethasone|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
214973248|NCT00464685|DRUG|Sham injection|Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
214973249|NCT00464685|PROCEDURE|Laser Photocoagulation|Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
215084203|NCT05553977|DRUG|Bowel preparation for colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
215084204|NCT05553977|PROCEDURE|Colonoscopy|Colonoscopy will be performed to every patient included in the study
214361745|NCT03657277|DEVICE|Micropatch|Each micropatch contains 50 tiny projections (800 um in length)
214361746|NCT04431466|DRUG|Ivermectin|SOC plus different dosing regimens of Ivermectin
214361747|NCT04431466|OTHER|Standard of Care|Standard treatment for COVID-19
214361748|NCT02136940|DRUG|AMA0076|
214361749|NCT02136940|DRUG|Placebo|
214361750|NCT00772226|DEVICE|music pillow|according to randomisation patients will receive with/without music.
214361751|NCT00772226|DEVICE|pillow without music|According to randomisation patients will receive a pillow with/without music
214361752|NCT02200731|BEHAVIORAL|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
214361753|NCT01031810|DRUG|tranylcypromine|MAO-Inhibitor 60mg-120mg
214361754|NCT04339192|PROCEDURE|Minimally Invasive Tricuspid Surgery|minimally invasive tricuspid surgery including endoscopy-assist right minithoracotomy, vacuum-assist single femoral venous drainage without dissecting or snaring vena cava, direct right atriotomy through pericardium and the beating-heart technique.
214361755|NCT01456026|DIETARY_SUPPLEMENT|Glycated beta-lactoglobulins.|oral, 20 g, single administration
214361756|NCT01456026|DIETARY_SUPPLEMENT|Non-glycated beta-lactoglobulins|20 g, oral, single administration,
214361757|NCT00253669|OTHER|laboratory biomarker analysis|
214361758|NCT00253669|OTHER|physiologic testing|
214361759|NCT00253669|PROCEDURE|management of therapy complications|
214361760|NCT03089437|BEHAVIORAL|Prolonged Standing|Subject will stand for 12 hours and undergo a high fat tolerance test the subsequent day
214361761|NCT03089437|BEHAVIORAL|Prolonged Sitting|Subject will sit for 12 hours and undergo a high fat tolerance test the subsequent day
214361762|NCT03961789|OTHER|patients undergoing opioid replacement therapy|patients undergoing opioid replacement therapy
214361763|NCT03360942|DEVICE|SCC DBS|Deep Brain Stimulator
214361764|NCT03083899|OTHER|Out-patient clinic on demand (patient-initiated)|Free use of any resources in the out-patient clinic
214361765|NCT03083899|OTHER|Scheduled out-patient clinic|Scheduled use of the out-patient clinic
214679420|NCT05848245|DEVICE|intraoral suction|This group receives conventional intraoral suction, likely using high-volume evacuators (HVE), which are more effective than low suction. This arm serves as the comparison or standard-of-care group against which other interventions are evaluated.
214679421|NCT05848245|DEVICE|high & low suction|Participants in this group receive both high-volume and low-volume intraoral suction simultaneously. The combined use aims to optimize fluid and aerosol control, with high suction capturing larger volumes and low suction assisting in continuous evacuation.
214679422|NCT05848245|DEVICE|extra-oral suction & low suction|This group receives a combination of extra-oral suction (a device placed outside the mouth to capture aerosols at the source) and low-volume intraoral suction. This setup is designed to reduce airborne particles during procedures by controlling both intraoral and environmental aerosols.
214679423|NCT05848245|DEVICE|Extra-Oral Suction and Intraoral Suction|This group is treated using both extra-oral suction and intraoral suction, likely high-volume. The dual approach targets aerosol containment both at the oral cavity level and in the surrounding air, representing a comprehensive strategy for infection control during aerosol-generating procedures.
214679424|NCT03309670|OTHER|Psychiatric future|Former young psychiatric patients are contacted to determine their psychiatric outcome.
214973250|NCT06432348|OTHER|Reformer pilates|Before starting the exercises, a 5-minute warm-up session was performed. The reformer Pilates exercise program included movements such as the Footwork Series (Toes, Heels, Tendon Stretch, V Position), Supine Arm Series (Pull, Circle, Pull Head Up, Triceps Press), Short Box Series (Round, Flat Back, Twist), Short Box and Arm Series (Chest Fly, The Gift, Rhomboid, Biceps Curl, Rowing, Triceps), Long Box Series (Swan, Pulling Fly), Stomach Massage (Round, Twist), Knee Stretch (Round, Flat Back), Hip Work Series (Double Leg Press, Hamstring Pulls, Leg Circle, Frog), Elephant, and Side Stretch. Participants had two-minute rest intervals after the Supine Arm Series, Short Box, Arm Series, and Knee Stretch movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Reformer Pilates sessions and three team training days.
214973251|NCT06432348|OTHER|Mat Pilates|Before the exercises, a 5-minute warm-up session was performed. The mat Pilates exercise program included movements such as Rol Up, One Leg Circle, Double Leg Straight Lower, One Leg Stretch, Criss Cross, Toe Top, Shoulder Bridge, Seated Tracking, Spine Twist, Up-Down Side Kick, Front-Back Side Kick, Circle Side Kick, Flight, Swan, Rest Position, Swimming, Push Up, Long Stretch, Cat Cow, Mermaid Stretch. The participants had two-minute rest breaks after the toe-top, spine twist, and circle side-kick movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Mat Pilates sessions and three team training days.
214973252|NCT01208272|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
214973253|NCT01208272|BEHAVIORAL|Interpersonal Therapy (IPT)|
214973254|NCT05714553|DRUG|Fosifloxuridine Nafalbenamide|Intravenous infusion
214973255|NCT05714553|DRUG|Leucovorin|Intravenous infusion
214973256|NCT05714553|DRUG|Pembrolizumab|Intravenous infusion
214973257|NCT05714553|DRUG|Docetaxel|Intravenous infusion
214973258|NCT06141967|DEVICE|WITHINGS Sleep Analyzer|"Potentially eligible patients will be offered to participate in the study, the information leaflet will be given to them and the informed consent form will be signed if the patient agrees to participate in the study.~In hospitalization in Endocrinology:~* Realization of the current care report~* Including systematic achievement of EPWORTH and BERLIN scores~* Activation of the WSA throughout the duration of the hospitalization~* Completion of a feasibility questionnaire for the team~* Quantification of the non-usable screening technique~* Completion of a patient experience questionnaire at the end of the stay~* In the event of published positive criteria either for the BERLIN questionnaires, EPWORTH questionnaires or WSA, the patient will be referred to the VISAS center for definitive diagnostic evaluation by polygraphy or polysomnography."
214973259|NCT03621956|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
214973260|NCT03621956|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
214973261|NCT02242617|DEVICE|Positive Airway Pressure (PAP)|Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open
214973262|NCT02242617|DEVICE|Mandibular Advancement Splints (MAS)|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep
214973263|NCT04015362|PROCEDURE|Sub-threshold intermittent pulsed magnetic stimulation|Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord
214973264|NCT04015362|PROCEDURE|Sham|Application of sham magnetic stimulation to spinal cord
214973265|NCT02414282|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
214973266|NCT00598728|BEHAVIORAL|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
214973267|NCT04576013|DEVICE|Peripheral nerve stimulation (PNS)|Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
214973268|NCT04576013|BEHAVIORAL|Intensive upper extremity motor training|
214973269|NCT00587067|DRUG|FLOXURIDINE|"\[0.16\* mg/kg/day X 30 ml\] / pump flow rate~\* If the patient is \>25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles."
214489144|NCT06715163|DIETARY_SUPPLEMENT|Placebo|Contains the same excipients as the DAO tablets but without the diamino oxidase content
214489145|NCT06715163|DIETARY_SUPPLEMENT|Dose 2 (84mg) of DAO|DAO extract is obtained from pea sprout dehydrated powder. Medium dose of DAO administered in this study
214489146|NCT06715163|DIETARY_SUPPLEMENT|Dose 3 (210mg) of DAO|DAO extract is obtained from pea sprout dehydrated powder. Highest dose of DAO administered in this study
214489147|NCT06713538|OTHER|Equine assisted therapy|The intervention will last for 12 sessions, with two 1.5-hour sessions per week. The program is offered to patients in addition to their usual daily schedule. These 12 sessions will be organized as follows:
214489148|NCT06713538|OTHER|Physical activity|The subjects will independently carry out 12 sessions (2 sessions of 90 minutes per week for 6 weeks) of moderate-intensity physical activity. The endurance activity should be performed according to the patient's capabilities and fatigue levels.
214489149|NCT06713928|OTHER|Oral hygiene with dog therapy|The DAT session is divided into two phases: a pre-sitting phase in which the patient could interact with the dog, touching, caressing and playing with him, under the supervision of the dog-trainer. This phase lasted about 15 minutes. The second phase was a during-sitting phase in which the dog was in the chair, next to the patient, during the entire oral hygiene procedure, under the supervision of the dog-trainer.
214489150|NCT07032285|DRUG|Cirtuvivint|Cirtuvivint (SM08502) will be administered orally at 80 mg/day, 5 days on/2 days off. Cirtuvivint is supplied as tablets containing 10 mg or 50 mg of the active pharmaceutical ingredient (API). Cirtuvivint is taken with water once a day (on dosing days) at the same time every day. Doses will be taken without food (foo restriciton 1 hour before treatment and 2 hours afterdosing). Doses delayed by 12 hours will be considered missed and should not be taken. If vomiting occurs,the dose must not be retaken. Cirtuvivint is dosed in 28-day continuous cycles (28 days of treatment will beconsidered as one cycle) Treatment will continue until disease progression, unacceptable toxicity or investigator/patient decision
214679425|NCT02853331|BIOLOGICAL|Pembrolizumab|Intravenous infusion
214679426|NCT02853331|DRUG|Axitinib|Oral tablet
214679427|NCT02853331|DRUG|Sunitinib|Oral capsule
214973270|NCT03604003|DRUG|potassium losartan|treated with bedtime or awakening doses of potassium losartan
214973271|NCT01094288|DRUG|Alisertib|Alisertib ECT
214973272|NCT01094288|DRUG|Docetaxel|Docetaxel IV infusion
214973273|NCT02611882|DRUG|Ga-68 labeled HBED-CC PSMA|The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 μg Ga-68 HBED-CC PSMA.
214973274|NCT02611882|DEVICE|Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective
214973275|NCT02611882|DEVICE|Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.
214973276|NCT01317940|DIETARY_SUPPLEMENT|Vitamin D and Calcium Citrate|"Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)~Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months"
214973277|NCT04152200|DRUG|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
214973278|NCT06039189|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
214973279|NCT06039189|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
214973280|NCT02687672|BIOLOGICAL|Stem Cell Transplantation|Transplantation of autologous stem cells
214973281|NCT02637596|PROCEDURE|Radiofrequency ablation|After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
214973282|NCT05703542|DRUG|BXCL701|Tablet, taken Orally
214973283|NCT04980014|DRUG|NesinaAct® Tablet|NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.
214973284|NCT00593814|DEVICE|GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability|Implant
215084205|NCT01228604|DRUG|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
214973285|NCT04912076|DRUG|BM41|Subcutaneous injection of increasing doses of BM41
214973286|NCT04912076|OTHER|Placebo|Subcutaneous injections of placebo containing aluminium hydroxide.
214973287|NCT04912076|DRUG|ALK Alutard SQ Betula verrucosa|Subcutaneous injections with increasing doses of Alutard according to cluster up-dosing scheme.
215084206|NCT03423108|BEHAVIORAL|G150|This group will receive 150 min/week of combined exercise training, structured and supervised.
215084207|NCT03423108|BEHAVIORAL|G300|This group will receive 300 min/week of combined exercise training, structured and supervised.
214489151|NCT07033416|BEHAVIORAL|Approach Bias Modification|ABM is a computerised training aiming to train the participants to avoid drug-related images (by pushing a joystick which causes the image to disappear) and approach positive images (by pulling a joystick which causes the image to expand). Each training session lasts 15 minutes and it takes place once per week for 4 weeks.
214489152|NCT07033416|BEHAVIORAL|Treatment as usual|Participants receiving TAU are not trained to avoid drug-related images and approach positive images.
214489153|NCT06880822|BEHAVIORAL|Closed-Loop and Neuroplasticity-Based Mindfulness Program|The intervention includes three weekly 90-minute face-to-face mindfulness training sessions and daily guided self-practice using a closed-loop, neuroplasticity-based mobile app over 8 weeks. Training integrates mindfulness practices (e.g., mindful eating, body scanning) to help caregivers apply mindfulness in daily life. During self-practice, participants listen to a lesson, monitor distractions, and refocus on their breathing. Initial trials start at 20 seconds, adjusting by 10% if focused or decreasing by 20% if distracted, helping participants regulate attention. Progress is stored to continue in later sessions, with instant feedback during trials and delayed feedback on overall progress. Facilitators provide weekly follow-ups via the app to monitor caregivers' progress.
214489154|NCT06880822|BEHAVIORAL|Traditional Mindfulness Program (Without the Closed-Loop Approach)|Family caregivers in the traditional mindfulness group will participate in general mindfulness practices (e.g., mindful eating, body scanning, and mindful walking) without the closed-loop approach. These practices aim to help caregivers learn mindfulness skills and integrate them into their everyday life. Sessions will be delivered through a mobile approach with the same group size, duration, and frequency as the intervention groups.
214489155|NCT06880822|BEHAVIORAL|Psychoeducation|Family caregivers in the control group will receive self-directed e-learning on dementia care with support from a registered nurse experienced in dementia care or elderly care. This group will serve as a control for socialization and interaction aspects with peers and the interventionist (nurse). The self-directed learning will be delivered through a mobile approach, maintaining the same group size, duration, and frequency as the intervention groups. Educational content will include brief sessions on dementia care, caregiving skills, and group sharing of caregiving tasks.
214489156|NCT07038304|RADIATION|Metastasis directed radiotherapy|According to guidelines, in the case of oligoprogression next line systemic treatment is recommended. This study investigates the potential delay of NEST and rPFS by MDRT.
214489157|NCT07038577|OTHER|Fenugreek Seed Powder|Participants in the intervention group received 10 grams of ground Fenugreek seed powder, administered twice daily (before breakfast and dinner), for a total of 3 months. The Fenugreek powder was consumed mixed with water, in addition to the participants' regular antidiabetic medications and a standardized meal plan. The supplement was provided in a non-encapsulated, natural powdered form, and was not combined with any other herbal or pharmaceutical products.
214489158|NCT07038187|BEHAVIORAL|Music Listening (Binaural Beats via Gnaural)|Modern 'relaxation' music regularly includes binaural beats. Binaural beats can be defined as a sensation produced by the arrival of sine tones of different frequencies in each ear. This sensation is created by the difference in frequency between the two tones reaching the ear. Music with binaural beats has been associated with reduced anxiety and increased relaxation by activating theta and delta wavelengths in the electroencephalography (EEG). The authors used Gnaural (GPL-2.0), a freely programmable sound generator, for the binaural beats. Two pieces of instrumental 7 Hz binaural beats were used, a piano and an instrumental. The music volume was between 50-60 decibels and was at a level where the participant could hear the healthcare professional performing the procedure.
214489159|NCT07039487|OTHER|Blood sampling collection|"CBC performed on the background of an EDTA tube, collected routinely allowing neutrophil fluorescence measurements.~This tube will then be passed over on the automaton for a CBC measurement with leukocyte differentiation."
214679428|NCT05808088|OTHER|Hypnotherapeutic sound-files|The participants have access to hypnotherapeutic sound files which they can use as the please.
214679429|NCT05176210|DRUG|PS1|PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
214973288|NCT05187221|BEHAVIORAL|CVS Group|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.
214973289|NCT00829556|DEVICE|Integuseal|
214973290|NCT02593500|DRUG|Budesonida Pulmictan® 200 µg|
214973291|NCT02593500|DRUG|Budesonide 200 µg|
214973292|NCT02022553|PROCEDURE|usual rectal cancer surgery|
215084208|NCT05761678|OTHER|Questionnaire quality of life|"Quantitative - Validated online self-questionnaires scientifically to assess quality of life and support perceived social. Items created for the study concerning socio-demographic characteristics and satisfaction of health services concerning the accompaniment of the transidentity.~Qualitative - Semi-structured interviews based on a guide maintenance."
214361766|NCT04648150|DEVICE|Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms|Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial
214361767|NCT06158698|DRUG|Colchicine|Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
214361768|NCT06158698|OTHER|Placebo|Placebo 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
214973293|NCT02022553|PROCEDURE|RACHEL|
214973294|NCT00093522|BIOLOGICAL|autologous tumor cell vaccine|
214973295|NCT00093522|BIOLOGICAL|keyhole limpet hemocyanin|
214973296|NCT00093522|BIOLOGICAL|therapeutic autologous dendritic cells|
214973297|NCT00093522|DRUG|fludarabine phosphate|
214973298|NCT00093522|PROCEDURE|conventional surgery|
215084209|NCT03488888|DRUG|Normal Saline 0,9%|Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
215084210|NCT03488888|DRUG|Bupivacaine|Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
215084211|NCT06384274|OTHER|Emotional Freedom Technique|All people have an energy body. If the energy flow is interrupted, emotions such as stress and fear arise. By clicking on energy points to improve energy flow, the individual gets rid of energy blockages.
214489160|NCT07038525|OTHER|Suturing training|This intervention involves basic suturing skills training delivered either in-person or online. In the in-person group, participants receive live instruction and hands-on supervision. In the online group, participants watch a standardized video tutorial and receive remote feedback via Zoom. All participants use identical suturing kits and are evaluated using the same OSATS checklist by a blinded assessor. The content and learning objectives are standardized across both formats.
214489161|NCT07038096|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
214489162|NCT07038096|DRUG|ZG005|ZG005 will be administered as an intravenous (IV) infusion.
214489163|NCT07038603|OTHER|BAPP-VR|A carefully considered adaptation of a BA protocol enhanced with the use of VR
214489164|NCT07038434|DIAGNOSTIC_TEST|Multimodal AI-Based Pain Assessment|A non-invasive, multimodal diagnostic procedure combining self-reported pain scales (NRS, DN-4, BPI), wearable biosignal acquisition (EDA, EMG, HRV, EEG), facial thermography (HIRA system), video-based facial expression analysis, linguistic interview, and the Stroop Test. Data are used to train and validate machine learning models for automatic pain assessment in chronic pain patients.
214489165|NCT07038226|BIOLOGICAL|Placebo|a visually identical capsule containing skim milk powder
214489166|NCT07038226|BIOLOGICAL|Oral capsule-delivered FMT|Oral capsules of lysophilized fecal microbiota
214489167|NCT07037849|DEVICE|Robot-assisted overground gait training|Post-stroke patients were required to complete a session of robot-assisted training, which involved nine repetitions of 5-meter overground walking (three trials for each of the three controllers).
214489168|NCT07039370|DEVICE|TMS|"Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique approved for the treatment of major depressive disorder (MDD), particularly in individuals with treatment-resistant depression (TRD). TMS targets the left dorsolateral prefrontal cortex (DLPFC), a brain region often underactive in depression, and modulates neural activity through magnetic pulses.~This study aims to evaluate the effects of TMS on plasma proteomic and metabolomic profiles in patients with TRD. Participants will undergo 20 sessions of intermittent theta burst stimulation (iTBS) over four weeks. Blood samples will be collected before and after treatment to identify molecular changes associated with clinical response. Healthy controls will provide single-time-point blood samples for baseline comparison. Findings may support the development of biomarker-based strategies for personalized treatment in psychiatry."
214489169|NCT06716957|OTHER|Schroth exercise|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
214489170|NCT06716957|OTHER|Dynamic Stabilization exercises|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 12 weeks
214489171|NCT06708455|BIOLOGICAL|RAPA-201 Rapamycin Resistant T Cells|Autologous Rapamycin-Resistant Th1/Tc1 Cells
214489172|NCT06708455|DRUG|Chemotherapy Prior to RAPA-201 Therapy|Carboplatin + Paclitaxel Regimen (CP Regimen)
214489173|NCT06874829|OTHER|Electrical Muscle Stimulation|EMS will be applied bilaterally to the wrist flexor and elbow extensor muscles using a portable EMS stimulator (Compex Rehab 400, Medicompex SA, Ecublens, Switzerland). Four 2 mm thick, self-adhesive electrodes (5x5 cm) will be placed on the superficial aspect of each muscle group. The athletes will simultaneously receive EMS intervention with a pulse frequency of 75 Hz and a duration of 400 μs (19 seconds rest between pulses) during bench press and triceps pushdown exercises. Bench press and triceps push down exercises will be performed with 30% 1TM, 30-15-15-15 repetitions and thirty seconds rest between sets.
214489174|NCT06874829|OTHER|Blood Flow Restriction|The arterial occlusion pressures (AOP) of the athletes randomized to the experimental group will be obtained automatically with the digital LED display CAC device BFR Unit (Fit Cuffs BFR Unit, Denmark). The AOP pressure device BFR Unit (Fit Cuffs BFR Unit, Denmark) will be used to apply 50% occlusion pressure during exercise. Bench press and triceps push down exercises will be performed with 30% 1TM, 30-15-15-15 repetitions and thirty seconds rest between sets.
214489175|NCT06874829|OTHER|Low-Load Resistance Exercise|Bench press and triceps pushdown exercises will be performed with 30% 1RM, 30-15-15-15 repetitions and 30 seconds rest between sets.
214489176|NCT06719791|DRUG|Sirolimus|Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 0.5 mg per dose for BSA \<1.2 m², 1 mg per dose for BSA 1.3-2.1 m², and 1.5 mg per dose for BSA \>2.2 m².
214679430|NCT05176210|DRUG|Placebo|Placebo will be provided as a 120 mg tablet.
214679431|NCT01828827|DRUG|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
214973299|NCT04802434|BEHAVIORAL|Strengthening Skills Program|The Strengthening Skills Program is a new, multi-component intervention. It includes three components: (1) Forming habits to compensate for the difficulties many adults with ASD have with thinking flexibly, planning, and time management. It will emphasize habit-forming behaviors to compensate for weaknesses in functional skills by training on practical techniques; (2) Content from the PEERS Social Skills program to target social challenges, and (3) strategies derived from Mindfulness Based Stress Reduction to target emotion regulation.
214973300|NCT04802434|BEHAVIORAL|PEERS Social Skills Program|PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
215084212|NCT06384274|OTHER|Virtual Reality Glasses|It is aimed to reduce the patient's anxiety by making her feel like she7 he is there by watching and listening to relaxing content of the beach and nature.
215084213|NCT01658137|OTHER|Prudent Diet|This intervention lasts 2 weeks (14 days).
215084214|NCT01658137|OTHER|Typical Western Diet|This intervention lasts 2 weeks (14 days).
215084215|NCT00933920|DRUG|Aliskiren|
215084216|NCT00933920|DRUG|Aliskiren|
214361769|NCT01009268|PROCEDURE|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
214489177|NCT07040007|BEHAVIORAL|Strengthening Exercises|"In the strengthening exercises, the amount of weight was determined based on 40 to 60 percent of the one-repetition maximum. Each exercise was performed in two sets of six to eight repetitions. The exercise sessions lasted approximately 40 minutes and included a 10-minute warm-up, 20 minutes of strengthening exercises, and a 10-minute cool-down period. To perform the strengthening exercises, resistance bands (Theraband), dumbbells, weighted balls, sandbags, and a resistance bicycle were used. The exercises were performed for both the upper and lower extremities.~For the upper extremities, shoulder abduction, elbow extension, and shoulder extension exercises were performed using a theraband; elbow flexion, shoulder flexion, and elbow extension exercises were performed using dumbbells; and shoulder abduction exercises were performed using a weighted ball. For the lower extremities, knee extension, hip extension, and hip abduction exercises were performed using a resistance bicycle."
214489178|NCT07040007|BEHAVIORAL|Balance Exercises|"Each session was carried out over approximately 40 minutes, consisting of a 10-minute warm-up, 20 minutes of balance exercises, and a 10-minute cool-down period. The exercises were individually planned based on the participant's performance. To perform the balance exercises, supportive equipment such as balance discs and Pilates balls, as well as environments such as soft surfaces and stairs, were used.~The balance exercises applied during the intervention included standing on a balance disc with weight shifting, walking on a soft surface, tandem walking, walking while stepping over obstacles, and cross-step walking. Additionally, seated balance activities, standing trunk rotations using a Pilates ball, sit-to-stand exercises from a chair, and stair climbing exercises were also performed as part of the program."
214489179|NCT07038707|OTHER|Extract the serum and feces of the patients for standard screening of early biomarkers|In this study, blood and fecal samples from patients with herpes and herpes neuralgia were collected for genomic sequencing of the gut microbiota and metabolome analysis, etc. Based on the principle of diffusion tensor imaging, by measuring the anisotropic diffusion of white matter around the corpus callosum at the horizontal level of the lateral ventricle body, the lymphatic system clearance function is quantified
214489180|NCT07038707|OTHER|Meningeal lymphatic vessel imaging|The functional changes of the cerebral lymphatic system in patients with PHN were detected by meningeal lymphatic vessel imaging
214489181|NCT07039448|BEHAVIORAL|Acupressure|The acupressure intervention including the five acupoints. The acupressure will be performed once a day for 10 days in a group setting with same sex, supervised by a trained psychiatric nurse and preferably at least 2 hours after a meal.
214489182|NCT07039448|BEHAVIORAL|Sham Comparator|The sham group will be trained to perform acupressure in a similar way to the intervention group, except that they will use five sham acupoints. After completion of the project, patients in the sham group will receive the same interventions as the intervention group.
214489183|NCT07038291|OTHER|Not applicable- observational study|Observational study without intervention
214973301|NCT00715559|DRUG|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
214973302|NCT06422169|DEVICE|ArToFILL|ArToFILL is an injectable medical device (class III) intended for use as a temporary filler in joints. It is a sterile, non-pyrogenic, colorless and transparent hyaluronic acid gel of non-animal origin. ArToFILL is a hydrogel consisting of a mixture of two different molecular weights of hyaluronic acid, for a total HA concentration of 2.7 %.
214973303|NCT00903643|OTHER|Physical examination|Physical examination and multiple questionnaires will be administered
214973304|NCT02699996|OTHER|Questionnaire Administration|Complete interview
214973305|NCT02699996|BEHAVIORAL|Telephone-Based Intervention|Complete the self management + peer mentoring intervention with videoconferencing
214973306|NCT00151333|DRUG|SRA-333|
214973307|NCT01288599|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery where adnexectomy or cystectomy is performed.
214973308|NCT00500448|DEVICE|Electrical Stimulation|Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
215084217|NCT04546295|OTHER|Brushlink application|Brushlink application + Interproximal brush
214361770|NCT01774149|DEVICE|Few Touch Application|Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.
214973309|NCT03373214|BIOLOGICAL|Na-GST-1|Na-GST-1/Alhydrogel®
214973310|NCT03373214|BIOLOGICAL|CPG 10104|CPG 10104
214973311|NCT00965107|DRUG|Thiopental|Thiopental given as a bolus dose of 2,5 mg/kg.
214973312|NCT00965107|DRUG|Propofol|Propofol given as a bolus dose of 1 mg/kg.
214973313|NCT01095835|DRUG|Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg|PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
214973314|NCT01095835|DRUG|Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg|PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
214973315|NCT01095835|DRUG|Lamivudine (LAM)|Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
214973316|NCT05719896|DRUG|DT01 tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
214973317|NCT05719896|DRUG|Placebo tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
214973318|NCT05719896|DRUG|DT01-Placebo tablets|Each subject was given orally 2 DT01 tablets and 1 Placebo tablet, three times per day for 8 weeks
215084218|NCT04546295|OTHER|Water-flosser|Water-flosser
214361771|NCT01774149|DEVICE|Diastat|Users get the Few Touch Application with Diastat module activated.
214973319|NCT04331288|DRUG|PT150|Intervention 1 includes PT150 with alcohol consumption
215084219|NCT04546295|OTHER|Interproximal brush|Interproximal brush alone
215084220|NCT02982317|PROCEDURE|Manual palpation identification lumbar spine|
215084221|NCT02982317|PROCEDURE|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
215084222|NCT02982317|PROCEDURE|Lumbar level identification gold standard ultrasound|
215084223|NCT01294943|DEVICE|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
215084224|NCT05910034|DRUG|Trilaciclib+Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
215084225|NCT05910034|DRUG|Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
214361772|NCT06191913|DEVICE|Near-infrared spectroscop|Before the induction of anesthesia, INVOS pediatric SomaSensor probe (Coviden, Dublin, Ireland) was placed on the patient's forearm and then connected to a monitor, which was used to continuously measure and assess the dynamic changes in the StO2
214361773|NCT00657618|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
214361774|NCT04110405|BEHAVIORAL|Stepped Care|This stepped care model involves three steps. Step 1 is a peer and nurse co-led 8-session group based upon BRIDGES. Step 2 is peer or nurse led 6-session individual meetings based upon Interpersonal Psychotherapy. Step 3 is primary care physician led medication treatment with Amitriptyline.
215084226|NCT05910034|DRUG|Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
215084227|NCT04031274|DEVICE|TAVI|Trascatheter aortic valve implantation
215084228|NCT04031274|DEVICE|TMVR/r|Transcatheter mitral valve replacement/repair
215084229|NCT05084560|DRUG|AWZ1066S|Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
215084230|NCT05084560|DRUG|Placebo|Placebo
215084231|NCT00387179|DRUG|Melatonin|5mg, pill, once
215084232|NCT00387179|DRUG|Methylxanthine|2.9 mg/kg, pill, once
215084233|NCT00387179|PROCEDURE|Light Therapy|Bright light exposure
215084234|NCT03074266|DIAGNOSTIC_TEST|GEM Hemochron 100 ACT|Activated Clotting Time
215084235|NCT04972708|GENETIC|Cross-sectional genetics study|Cross-sectional genetics study
214361775|NCT04110405|BEHAVIORAL|Standard of Care plus Healthy Lifestyle|Standard outpatient care supplemented with literature on healthy lifestyles will serve as an enhanced control condition. In each clinic, non-specialty mental health care is available in the form of counseling from doctors or nurses along with psychiatric medication management. Given the difficulties faced by women in Tajikistan, ethical responsibility compels us to enhance the control condition by having nurses distribute written materials on healthy eating, physical fitness, and personal hygiene, at a reading level which will be widely accessible.
214361776|NCT03389542|PROCEDURE|Surgery|Early mitral valve repair
214361777|NCT03389542|OTHER|Clinical interview and echocardiography|Clinical interview and echocardiography every 6 months.
214489184|NCT07039682|DEVICE|Digital HIV Education and Self-Screening (EKSTRIM Model)|Participants in this arm will receive access to the EKSTRIM platform, a web-based digital tool designed for adolescents. The platform includes interactive educational content on HIV prevention, a self-assessment screening tool to evaluate individual HIV risk, and online peer educator support. The intervention will be implemented over a 6-week period. Participants will be encouraged to use the platform independently, with monitoring of access logs and engagement levels.
214489185|NCT07039318|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells
214489186|NCT07039318|DRUG|Normal Saline (Placebo)|Normal Saline (Placebo)
214489187|NCT07038512|DEVICE|Floora Pelvic Rehabilitation Vaginal Dilator|The Floora Pelvic Rehabilitation Vaginal Dilator, created by Hyivy Health Inc, is a multi-therapy hand held ergonomic intravaginal wand device that is designed to be used in the comfort of the user's home. The Floora has two main therapeutic functions, controllable dilation and thermal therapy. It is the first vaginal dilator that performs auto-dilation using one or two air chambers inflated from the device surface by an internal pump, eliminating the need for reinsertion. The device is equipped with biosensors that measure the pressure from the vaginal canal which allows this device to provide a gradual and gentle stretch to the pelvic floor muscles. The thermal therapy is achieved through an electrical circuit, changing the temperature of the device in small increments. Users are able to force-stop and change the temperature and dilation settings during a session.
215084236|NCT01438801|DRUG|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
215084237|NCT02001415|OTHER|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
215084238|NCT02001415|OTHER|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
215084239|NCT02001415|OTHER|Orthokeratology|Orthokeratology lenses.
215084240|NCT00215566|DRUG|DDP733|
215084241|NCT01591421|DRUG|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
215084242|NCT01591421|DRUG|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
215094428|NCT02917915|OTHER|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
214361778|NCT02610738|BEHAVIORAL|Junior KICk-OFF education programme|The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
214361779|NCT06656299|DEVICE|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block
214361780|NCT06656299|DRUG|Bupivacaine injection|5 ml local anesthetic for each trocar sides
214489188|NCT07038824|DRUG|ENTR-601-45|intravenous infusion
214489189|NCT07038824|DRUG|ENTR-601-45 - matching placebo|intravenous infusion
214361781|NCT06656299|DRUG|paracetamol, tramadol, and ondansetron|"As standard multimodal analgesia, 20 min before the end of the surgery patients will receive 1 g of paracetamol, 1-2 mg/kg of tramadol, and 4 mg of ondansetron via intravenous infusion.~All patients will be recovered in the PACU, and after confirming an Aldrete score of \>9, a PCA (patient-controlled analgesia) device will be installed with morphine prepared at a dose appropriate for the patient's age. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. When patients have a Numerical Rating Scale (NRS) score is ≥ 4, 1 mg/kg iv tramadol will be administered as a rescue analgesic"
214361782|NCT00642187|DRUG|budesonide|
214361783|NCT00642187|DRUG|Placebo|
214361784|NCT01083251|DRUG|Peginterferon + Vitamin D|180 mcg/week + 400 IUX2/day
214361785|NCT01083251|DRUG|Peginterferon|180 mcg/week
214361786|NCT01083251|DRUG|Sebivo|Telbivudine 600 mg daily
214361787|NCT01083251|DRUG|entecavir+ vitamin d|entecavir 1 mg daily+ vitamin d
214489190|NCT06702618|DRUG|TQB3616 capsule+Fulvestrant Injection|TQB3616 capsule is a CDK2/4/6 inhibitor and Fulvestrant injection is an anti-estrogen medication, and its pharmacological mechanism mainly exerts its therapeutic effect by inhibiting the action of aromatase.
214489191|NCT06884800|PROCEDURE|Laparoscopic toupet fundoplication|Patients will undergo laparoscopic toupet fundoplication.
214361788|NCT01880723|DRUG|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
214489192|NCT07039643|OTHER|Pilates exercise|This study investigates a novel Pilates-based rehabilitation program for Achilles tendinopathy (AT). While eccentric loading is the standard treatment, many patients experience persistent symptoms or poor adherence. Pilates emphasizes core stability, neuromuscular control, and functional movement, offering a holistic approach that addresses kinetic chain dysfunction and movement impairments often overlooked in standard protocols. This trial will assess the feasibility and effectiveness of Pilates in improving pain, function, and movement quality in adults with AT. To our knowledge, this is the first clinical trial to evaluate Pilates as a targeted intervention for AT.
214489193|NCT07039643|OTHER|Alfredson protocol|At our knowledge this is the first study that will compare the most popular protocol in Achilles Tendinopathy to an alternative exercise method
214973320|NCT04331288|OTHER|Beverage|The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
214489194|NCT07032532|DRUG|Golidocitinib|Golidocitinib 150mg orally once daily in a 21-day cycle
214489195|NCT07032532|DRUG|Golidocitinib plus CHOP|Golidocitinib 150mg orally every other day with CHOP (Cyclophosphamide: 750mg/m2, IV, d1 ; Doxorubicin: 50mg/m2, IV, d1; Vincristine: 1.4mg/m2, IV, d1 ; Prednison: 100mg, po, d1-5) in a 21-day cycle for 6 cycles.
214489196|NCT07039994|OTHER|Standard intervention|"Routine intervention in the service:~* Good control: In-person visit every 4 weeks.~* Poor control: Nurse calls at 1 week to assess and decide on treatment changes, visits, or referral. In-person visit by need or after 1 month."
214489197|NCT07039994|OTHER|E-health intervention|"Combined system using ICT and in-person care. It includes spontaneous use (symptom tracking, messages, reminders via app) and scheduled use:~* Good symptom control: Basic Telematic Evaluation (BTE) at 1 month. If stable, videoconference at 2 months, BTE at 3 months, and in-person visit at 4 months.~* Poor symptom control: BTE at 1 week. If warning signs appear, a nurse evaluates by phone and may adjust treatment, schedule a visit (in-person or video), or refer to emergency care. In-person visit by need or after 1 month."
214489198|NCT07038395|DEVICE|workflow|Placement of the surgical device and its effect on workflow
214973321|NCT05362708|DEVICE|Clinical - Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort during a port-a-cath procedure.
214973322|NCT02408042|DRUG|Pembrolizumab|
214973323|NCT02408042|DRUG|Etoposide|
214973324|NCT02408042|DRUG|Ifosfamide|
214973325|NCT02408042|DRUG|Mesna|
214973326|NCT02408042|DRUG|Carboplatin|
214973327|NCT02408042|DRUG|Brentuximab vedotin|
214973328|NCT02408042|DRUG|Rituximab|
214973329|NCT04545801|DRUG|0.25 mg/kg of Ketamine|patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
214973330|NCT04545801|DRUG|20ml of normal saline solution|20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
214973331|NCT03884881|DIAGNOSTIC_TEST|metagenomic next generation sequencing|Pathogens in the NGS group will be tested by NGS，then according the NGS results, adjust antibiotics
214973332|NCT03884881|DIAGNOSTIC_TEST|Conventional pathogen detection|Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics
214973333|NCT03884881|DRUG|Meropenem，Imipenem，Caspofene，Osstat|Meropenem，Imipenem，Caspofene，Osstat
214973334|NCT05743530|DEVICE|TENS - transcutaneous electrical nerve stimulation|Pre-operative day 1 till postoperative day 14.
214973335|NCT05743530|OTHER|Placebo|Pre-operative day 1 till postoperative day 14.
214973336|NCT01198002|DRUG|LY2127399|Administered Subcutaneously (SC)
214973337|NCT01198002|DRUG|Placebo Q2W|Administered SC
214973338|NCT01198002|DRUG|Placebo Q4W|Administered SC
214973339|NCT01198002|DRUG|Methotrexate|Methotrexate is a background therapy.
215094429|NCT00535821|DEVICE|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
214361789|NCT01880723|DRUG|Placebo saline|nebulized 3mL normal saline) using a Power Neb2 nebulizer
214489199|NCT06882525|PROCEDURE|Lidocaine (drug)|Lidocain subcuteous infiltratyion will be done to rush area.
214489200|NCT06888999|OTHER|In vitro exposure to workplace by VR plus CAU|During the VR-session, guided by the psychotherapist, participants are virtually exposed to their workplace using VR glasses. Based on the experience of the participants during the vitual visit to their workplace, the psychotherapist can adjust the therapy. In addition Care As Usual is provided (see description active comparator).
214489201|NCT06888999|OTHER|CAU: Psychotherapy focused on return to work|Psychotherapy focused on return to work, provided by a psychotherapist specialized in counseling cabin crew.
214489202|NCT06725784|DEVICE|ReHandyBot|"The ReHandyBot is a platform for hand rehabilitation with two degrees of freedom, namely forearm pronation/supination and finger flexion/extension. This device allows performing exercises targeting somatosensation and motor functions. Different exercises are implemented using virtual reality and haptic feedback; the interaction forces between subjects and ReHandyBot are measured by force sensors in the handles, allowing the control of a virtual hand and the physical interaction with the virtual environment. Mechanical properties (e.g., size, stiffness) of the objects displayed in the virtual environment are rendered by the motion/force of the instrumented handles. The type and difficulty level of the exercises are patient-specific and are automatically adapted throughout the therapy.~The duration and frequency of the therapy sessions with ReHandyBot depend on the specific patient's needs and are set according to the therapist's instructions."
214489203|NCT03803787|DRUG|Inhaled budesonide|Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
214489204|NCT06728462|DIETARY_SUPPLEMENT|Amorphous calcium carbonate|The usual dose for oral use is 5 ACC tablets (equal to 1000 mg calcium element) daily given after meals.
214489205|NCT06656975|BEHAVIORAL|Brief Cognitive Therapy|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
214489206|NCT06656975|BEHAVIORAL|Social Prescribing|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
214489207|NCT06656975|OTHER|Enhanced Usual Care|Participants will receive an informational booklet on improving loneliness. Participants may initiate or continue Collaborative Care for other conditions on a not research basis.
214489208|NCT06722547|OTHER|Standard PR|PLB, ACBT, Aerobic exercise, Education
214489209|NCT06722547|OTHER|Standard PR plus Respiratory Muscle Stretching|Standard PR plus Respiratory Muscle Stretching (RMS)
214489210|NCT06723145|DRUG|Aspirin|perioperative aspirin continuation
214489211|NCT06723145|DRUG|Aspirin interruption|Aspirin interruption 5-7 days before surgery
214679432|NCT04807946|PROCEDURE|lower third molar extraction|"All surgeries were performed by the same expert surgeon (RP), with the buccal approach using local anesthesia, and included the following maneuvers:~* luxation of the coronal portion of the tooth/root in an ipsilateral or parallel direction with respect to the IAN position and running, in order to minimize nerve compression;~* post-extraction residual bone cavity inspection using a Zeiss 4x300 magnification optical system to better identify intra-operative nerve exposure.~No material was inserted into the residual cavity, neither by regeneration nor by haemostasis.~After one week, sensitivity was tested on both sides with the tactile test using a 27-gauge needle tip and, if a difference was found, the patient was followed up once a week for the first month and every two weeks thereafter, until he/she reported to perceive the pin-prick test in the affected side the same way as the healthy side."
214973340|NCT05702008|OTHER|Rabies Information Education and Communication Material|The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1\&ipp=All\&lang=1\&level=2\&sublinkid=502\&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
214973341|NCT02501408|DEVICE|propriofoot prosthesis|Adaptation of the device and evaluation after 1 month at home using the studied device
214489212|NCT06724692|OTHER|Ultra-processed breakfast|With this intervention, participants will consume ultra-processed foods
214489213|NCT06724692|OTHER|Low-processed breakfast|With this intervention, participants will consume low-processed foods
214489214|NCT06607276|DRUG|Adebrelimab and capecitabine|Adebrelimab: 1200mg, IV, q3w for one year; capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
214489215|NCT06607276|DRUG|capecitabine|capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
214489216|NCT05856266|PROCEDURE|Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)|Ultrasound examination
214489217|NCT05856266|OTHER|Haemophilia Joint Health Score (HJHS)|Functional joint examination
214679433|NCT01079793|DRUG|ixabepilone|
214679434|NCT01079793|PROCEDURE|adjuvant therapy|
214361790|NCT04915573|DIAGNOSTIC_TEST|Specimen|Sputum will be collected in clean disposable containers
214361791|NCT04247672|DEVICE|Total Knee Arthroplasty (uncemented rotating platform ATTUNE)|All patients receive an uncemented ATTUNE rotating platform knee system.
214361792|NCT03846648|DRUG|Cypep-1|"Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest."
214361793|NCT02434133|PROCEDURE|Blood Draw/Data Collection|Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
214361794|NCT00817362|DRUG|IPI-504|IPI-504 IV infusion 300 mg/m2
214361795|NCT00817362|DRUG|Trastuzumab|Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
214361796|NCT00863174|DRUG|SPARC147709|SPARC147709 injection
214361797|NCT00863174|DRUG|Reference147709|Reference147709 injection
214489218|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (400mg of nitrate per serving)|Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
214489219|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (trace amounts of nitrate per serving)|Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
214489220|NCT06733220|PROCEDURE|Surgery for strabismus|Patients will undergo surgery to correct strabismus, congenital or acquired
214679435|NCT01079793|RADIATION|intensity-modulated radiation therapy|
214679436|NCT05398874|COMBINATION_PRODUCT|Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)|120 mg leaf extract , twice daily in addition to Diclofenac 100 mg Once daily + paracetamol 1g Twice daily
214973342|NCT04268407|DRUG|Amoxicillin Clavulanate|compare the duration of antbiotic use: 2 day versus 7 day
214973343|NCT03040167|PROCEDURE|PEC 1 block|Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.
214489221|NCT01830595|DRUG|Recombinant Lactoferrin|
214489222|NCT01830595|DRUG|Placebo|
214489223|NCT04809584|DRUG|F18-DCFPyL|Participant will be injected iv with 9 mCi ± 20% of 18F-DCFPyL
214489224|NCT04809584|DRUG|Gadolinium|Contrast agent
214489225|NCT04809584|PROCEDURE|Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan|Imaging test that combines PET (positron emission tomography) and MRI (magnetic resonance imaging)
214489226|NCT06573385|OTHER|Questionnaire|Questionnaire application
214489227|NCT06812871|DRUG|furmonertinib|furmonertinib (160mg, once a day, continuous administration); bevacizumab (7.5 mg/kg body weight, once every 3 weeks); Pemetrexed (50 mg intrathecal injection chemotherapy, once every 3 weeks, up to 9 cycles).
214679437|NCT05398874|COMBINATION_PRODUCT|placebo in addition to the standard treatment|placebo in addition to the standard treatment
214679438|NCT00319618|DRUG|Gefitinib|
214679439|NCT00319618|DRUG|Docetaxel|
214679440|NCT00778323|PROCEDURE|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
214679441|NCT03511638|DEVICE|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
214679442|NCT03511638|DEVICE|Alcon VISCOAT®|Ophthalmic viscosurgical device
214679443|NCT02967523|DEVICE|DEB-TACE with Surefire Precision Infusion System|Subjects have undergone/will undergo DEB-TACE using the Surefire Precision Infusion System.
214679444|NCT02609477|DRUG|Istradefylline|Istradefylline 40, 80, 160 mg
214679445|NCT02609477|DRUG|Phentermine 45 mg|Phentermine 45 or 90 mg
214679446|NCT02609477|OTHER|Placebo|Placebo
214679447|NCT05700240|DEVICE|orthokeratology|rigid contact lenses
214679448|NCT05700240|DEVICE|single-vision spectacle correction|simple wear of spectacle
214679449|NCT03989063|BEHAVIORAL|Instructions to perform a motor task (external vs. internal focus instructions)|During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).
214679450|NCT03383367|BEHAVIORAL|Tempo Colo|Reminder letter for people at high risk of colorectal cancer.
214679451|NCT06172543|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants were assigned to ingest a single serving daily of either A) a 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb); or B) a 25-gram dose of Whey Protein Isolate + 25-gram dose of carbohydrate powder + 5-gram dose of creatine monohydrate (Creatine) for a 17-21-day period.
214679452|NCT06172543|DIETARY_SUPPLEMENT|Control|A 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb)
214679453|NCT03322683|PROCEDURE|Physiotherapy treatment with physium device.|This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 45 minutes.
214679454|NCT03322683|PROCEDURE|Conventional physiotherapy treatmen|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
214973344|NCT03040167|DRUG|Bupivacaine with epinephrine|Treatment group
214973345|NCT03040167|DRUG|Normal saline|Placebo group
214973346|NCT02668965|PROCEDURE|Intrauterine hCG (pregnyl)|
214973347|NCT00001322|DRUG|Leuprolide Acetate 3.75|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
214973348|NCT00001322|DRUG|Estradiol|Transdermal Estradiol, 100mcg/day by skin patch
215094430|NCT00535821|DEVICE|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
214361798|NCT00326131|DRUG|Oral Taxane|
214361799|NCT03703466|DRUG|Abemaciclib|Administered orally.
214973349|NCT00001322|DRUG|Progesterone|Progesterone suppository, 200mg vaginally twice/day
214973350|NCT00001322|DRUG|Placebo suppository|Placebo suppository twice daily
214973351|NCT00001322|DRUG|Placebo patch|Placebo by skin patch
214973352|NCT00116688|BIOLOGICAL|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
214973353|NCT02074202|DRUG|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
214973354|NCT02074202|DRUG|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
214973355|NCT00057291|BEHAVIORAL|Responsive caregiving|Responsive caregiving consisted of operational circumstances and training of caregivers.
214973356|NCT01719549|DRUG|Dovitinib|"* Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~* Study drug: TKI258 capsule~* Dose: 500mg p.o. qd~* Every 3 weeks"
214973357|NCT05141006|DRUG|BOTOX|Injection into the bladder
214973358|NCT05141006|DRUG|Placebo for BOTOX|Injection into the bladder
214973359|NCT03593200|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214973360|NCT06109012|PROCEDURE|duct diversion|the patient benefited from a diversion of the bile ducts complicated by ruptured cysts with anaphylactic shock
214973361|NCT00449839|DRUG|Insulin Aspart|"A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted."
214973362|NCT04006145|DRUG|Elobixibat|Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
214973363|NCT04006145|DRUG|Placebo oral tablet|Placebo identical in appearance to active drug
214973364|NCT00010257|DRUG|carboplatin|Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles
214973365|NCT00010257|DRUG|paclitaxel|225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles
214973366|NCT03799614|DEVICE|RMBand lower dose|Light-weight portable device that delivers low dose vibration to the arm
214973367|NCT03799614|DEVICE|RMBand higher dose|Light-weight portable device that delivers higher dose vibration to the arm
214973368|NCT01996371|DEVICE|Pedicle Screw|
214973369|NCT00785083|DRUG|FTY720|
214973370|NCT00785083|DRUG|Placebo|
214973371|NCT02754232|OTHER|Telemedical training|Intervention will involve resistance training and anaerobic training
214973372|NCT02750631|OTHER|Triple Therapy|The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
215094431|NCT05946512|BEHAVIORAL|yoga|yoga breathing techniques for dysfunctional breathing
215094432|NCT05946512|BEHAVIORAL|social contact|social contact as active comparator
214361800|NCT06665607|PROCEDURE|Intrinsic Mucle Training|Conventional physiotherapy treatment and the intrinisc foot muscles strengthening program for 8 weeks.
214973373|NCT03913234|DRUG|Ribociclib, Trastuzumab, Letrozole|Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
214973374|NCT00453375|DRUG|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
214973375|NCT00453375|DRUG|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
214973376|NCT02092454|DRUG|Benzocaine|topical otic solution
214361801|NCT06667115|OTHER|PNF exercise|Foundational PNF D2 shoulder flexion exercise incorporating shoulder flexion, abduction, and external rotation. This exercise was performed at a metronome-guided pace of 14 beats per minute to establish a consistent baseline.
214973377|NCT02092454|DRUG|Placebo|topical otic solution
214973378|NCT06309823|DRUG|MAS825|MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2.
214973379|NCT03976908|DEVICE|Deep Brain Stimulation|High frequency deep brain stimulation in the medial geniculate body of the thalamus.
214361802|NCT06667115|OTHER|PNF exercise with virtual reality gaming|Combined the PNF D2 shoulder flexion exercise with a virtual reality motion capture game (the U-Ball game).
214361803|NCT06667115|OTHER|PNF with concurrent feedback|"PNF exercise with the addition of auditory concurrent feedback (Sword) which referenced the action of unsheathing a sword in a diagonal upward direction."
214973380|NCT01249417|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
214973381|NCT01249417|DRUG|Placebo|I.M. injection on day 1 of a single treatment cycle.
214973382|NCT05634655|OTHER|no interventions between two groups|no interventions between two groups
214973383|NCT03388424|DIAGNOSTIC_TEST|quantification of microbiota|For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis
214973384|NCT00723827|DRUG|Temozolomide|Administration of temozolomide based on the product labeling.
214973385|NCT00723827|RADIATION|Radiotherapy|Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
214973386|NCT02938468|DRUG|Dexamethasone|
214973387|NCT02938468|PROCEDURE|Any surgical intervention aim at treating chronic subdural hematoma|
214973388|NCT00126594|DRUG|Sorafenib Tosylate|Given orally 400 mg orally (PO) every 12 hours
214973389|NCT00126594|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given subcutaneously (SC) 0.5 million with +/- 5 % variance (0.475 MU - 0.525 MU); Dose level 0: 0.5 X 10\^6 international units twice daily
214973390|NCT00126594|OTHER|Laboratory Biomarker Analysis|Correlative studies
214973391|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.015mg/mL
214361804|NCT06610617|DEVICE|transcranial direct current stimulation (tDCS)|tDCS designed to facilitate the excitability of the left dlPFC or sham stimulation on separate visits separated by at least one week in random order, using a double-blinded, within-subject crossover design. Electrode placement and current parameters will be optimized to each participant with the goal of generating an average electric field of 0.25 V/m within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA using the Stimweaver algorithm. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort
214361805|NCT06610617|DEVICE|Sham tDCS|Active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention delivers currents and mimics the sensations induced by tDCS, but does not significantly influence cortical tissue.
214489228|NCT06069570|BIOLOGICAL|KB-GDT-01|KB-GDT-01 is an allogeneic, gamma delta T-cell suspension product manufactured from the isolation of healthy donor peripheral blood mononuclear cells (PBMC). The KB-GDT-01 cells are cryopreserved in vapor phase liquid nitrogen (LN2) in 50 mL CryoMACS® cryobags for a total of 200 × 106 viable cells/bag. The KB-GDT-01 cryopreserved product is thawed and administered intravenously (IV) until the entire bag is infused by gravity. Low dose radiotherapy (LDRT) will be administered to selected tumor sites (maximum of 5 isocenters) at 1.0 Gy/fraction on Days 1 and 2, followed by the KB-GDT-01 IV infusion on Day 3. LDRT will be repeated on Days 8 and 9, and the 2nd KB-GDT-01 IV infusion on Day 10.
214489229|NCT06841926|DRUG|ZX-7101A dry suspension|Test formulation (T) : ZX-7101A dry suspension Specification: 10 mg/ bag Dosage：40 mg (4 bags)、 once
214489230|NCT06841926|OTHER|ZX-7101A tablet|Reference formulation (R): ZX-7101A tablet Specification: 40 mg/ tablet Dosage：40 mg (1 tablet)、 once
214489231|NCT06843057|OTHER|Kinesio taping|Kinesio taping is a therapeutic technique that involves applying a special elastic tape to the skin to support and stabilize muscles and joints without restricting their range of motion.
214489232|NCT06843057|OTHER|Mulligan's mobilization with movement techniques|Mulligan's mobilization with movement (MWM) techniques involve the application of a sustained manual force or glide to a joint while the patient actively performs a movement that is typically painful or restricted.
214489233|NCT06843057|OTHER|Conventional physiotherapy|Mulligan Mobilization with Movement, Ultrasound Therapy, Active assisted ROM exercises for shoulder, Capsular Stretching exercises
214973392|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.05mg/mL
214973393|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.15mg/mL or 0.025mg/mL
214973394|NCT04207905|OTHER|Healthy Michigan Plan (HMP) coverage with work requirements|For those who are not in the Exempt for Research Purposes group, to be eligible for HMP coverage beginning January 1, 2020, enrollees ages 19-62 must report 80 hours per calendar month of community engagement activities, such as employment, education, job training, job search activities, participation in substance use disorder (SUD) treatment, or community service.
214973395|NCT01041222|DRUG|ISIS 333611|5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
214973396|NCT03769649|DEVICE|CelluTite|CelluTite: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
214973397|NCT02815306|DEVICE|Polyaxial brace|The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
214973398|NCT01421498|DRUG|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
214361806|NCT06172972|BEHAVIORAL|Atraumatic nursing care|Children in the intervention group were allowed to choose a distracting method (foam balloons, stress balls, musical books) to be occupied with during the procedure
214361807|NCT06669026|DIETARY_SUPPLEMENT|vitamin D loaded Poly lactic-co-glycolic acid nanoparticles gel|Scaling and root debridement then inject gel in the pocket
214361808|NCT06669026|DIETARY_SUPPLEMENT|vitamin D3 gel (regular non-nanoparticle form)|Scaling and root debridement then inject gel in the pocket
214973399|NCT01421498|DRUG|Placebo|Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
214973400|NCT05793021|DIAGNOSTIC_TEST|Blood sample|Blood sample pre and post surgery to determine the level of FKBP51s protein
214973401|NCT01290718|DRUG|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
214973402|NCT01290718|DRUG|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
214973403|NCT06521177|OTHER|Hand Serum and Glove|Participants will apply the Hand Serum to both hands daily for 8 weeks. During Weeks 7-8, participants will also wear a glove on one hand. The intervention aims to improve skin health and appearance on the hands, assessed through questionnaires and expert skin grading.
214973404|NCT01895985|DRUG|Latanoprostene bunod|
214973405|NCT03118050|BEHAVIORAL|Resistance exercise training|Supervised resistance exercise training, 3 times a week for 3 months
214973406|NCT03118050|BEHAVIORAL|Bed rest|Bed rest for 5 days, followed by standard rehabilitation for 2 days
214973407|NCT03118050|BEHAVIORAL|Intensive physical therapy|Intensive weight bearing PT, daily, during bed rest
214973408|NCT04035616|DIETARY_SUPPLEMENT|microbial cell preparation [MCP]|active microbial cell preparation
214973409|NCT04035616|OTHER|placebo|inactive ingredient
214973410|NCT04733924|OTHER|Aqueous extract of roots plus leaves of Withania somnifera 125 mg|One capsule before breakfast for 84 days
214973411|NCT04733924|OTHER|Aqueous extract of roots plus leaves of Withania somnifera 250 mg|One capsule before breakfast for 84 days
214973412|NCT04733924|OTHER|Microcrystalline Cellulose|One capsule before breakfast for 84 days
214973413|NCT05619328|DRUG|Vitamin B combination tablet|Once daily, with some liquid with or after a meal
214973414|NCT05619328|DRUG|Placebo Tablet|Once daily, with some liquid with or after a meal
214973415|NCT04546633|DRUG|KAF156|Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
214973416|NCT04546633|DRUG|LUM-SDF|Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
214973417|NCT04546633|DRUG|Coartem|Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
214361809|NCT06669026|OTHER|Poly lactic-co-glycolic acid nanoparticles placebo gel|Scaling and root debridement then inject gel in the pocket
214489234|NCT06820073|BEHAVIORAL|Global Postural Reeducation (RPG) using the K-Stretch hammock|The intervention involves Global Postural Reeducation (RPG) using the K-Stretch hammock. This therapeutic approach focuses on sustained stretching of muscle chains to improve posture, reduce cervical and lumbar musculoskeletal discomfort, and enhance flexibility. Participants complete 12 sessions over six weeks, with two 30-minute sessions per week. Each session includes guided exercises that target muscle imbalances, improve alignment, and alleviate tension caused by prolonged sedentary behavior. The K-Stretch hammock provides support for optimized stretching and alignment during the exercises.
214489235|NCT06817473|BEHAVIORAL|CAST|CAST is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated AS, particularly the amplification of cognitive stress symptoms including perceived confusion and memory problems. CAST is a fully computerized, 1-hour intervention. CAST contains video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension). Procedures draw heavily on standard CBT techniques; AS, a core vulnerability for anxiety and depression is targeted using these procedures. In this study, participants complete CAST as a group alongside other participants.
214489236|NCT06817473|BEHAVIORAL|HET|The HET protocol covers standard healthy lifestyle behaviors as well as broad coping strategies to address stress. HET is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors. Content includes healthy eating, hydration, sleep and rest, stress management as well as other healthy lifestyle tips. HET was administered in a group format for this study.
214489237|NCT06820580|OTHER|Salutogenic Approach Based Interview|Salutogenic Approach Based Interviewing Program consists of 8 sessions. The interview will be conducted for four weeks and on two specific days of the week. Interviews will be conducted in groups of 6-8 people. The interview will last 30-40 minutes on average.
214489238|NCT04940624|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
214489239|NCT04940624|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
214489240|NCT06752083|DIETARY_SUPPLEMENT|AHCC® (Active Hexose Correlated Compound)|3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.
214489241|NCT06752083|BIOLOGICAL|Gardasil 9®|Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.
214489242|NCT06862700|OTHER|Vasopressor Exposure Levels|This is an observational study with no active intervention. The study evaluates the association between natural variations in vasopressor exposure levels (measured by Vasoactive-Inotropic Score, VIS) and clinical outcomes in patients receiving VA-ECMO for cardiogenic shock.
214489243|NCT04751331|BIOLOGICAL|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113)
214489244|NCT04751331|BIOLOGICAL|Saline|0.9% saline administered as an intravenous bolus
214489245|NCT06862232|PROCEDURE|"Modified Winograd Bird Flap Technique"|"In the first group (n=36), the modified Winograd Bird Flap technique will be performed for medially ingrown toenails. Local anesthesia with 1% lidocaine will be administered at the base of the first toe, and a temporary tourniquet will be applied using a sterile glove to minimize bleeding.~This technique modifies the Winograd method, optimizing functional and cosmetic outcomes while reducing recurrence rates. A sparrow-shaped incision will be made, encompassing the lateral nail bed, proximal germinal matrix, and underlying bone tissue, improving surgical access while preserving the healthy nail structure.~Granulated and infected tissue will be excised completely down to the periosteum to prevent recurrence. The wound will be sutured using 3/0 prolene sutures, ensuring optimal healing and minimal scarring. This method aims to reduce pain, shorten recovery time, and improve patient satisfaction compared to traditional approaches."
214973418|NCT04536363|DRUG|Analogs, Prostaglandin E1|"Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days"
214973419|NCT04536363|DRUG|Standard therapeutic protocol|"Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours"
214361810|NCT06669026|PROCEDURE|only mechanical debridement|Scaling and root debridement
214361811|NCT06669650|OTHER|PGx guided personalized post-operative pain management|Patients in the intervention group will receive post operative opioid therapy based on their pharmacogenomic results. Patients who are poor CYP2D6 metabolizers or rapid CYP2D6 metabolizers with moderate or severe pain, will be prescribed either oral hydromorphone 2mg every 4 hours as needed or oral hydromorphone 4mg every 4 hours as needed, respectively. Patients who are intermediate or normal CYP2D6 metabolizers with moderate or severe pain will receive oxycodone 5mg or oxycodone 10mg every 4 hours as needed respectively similar to the treatment offered to the control subjects. Normal or intermediate CYP2D6 metabolizers who are concomitantly taking a drug which is a strong CYP2D6 inducer will be treated as if they are in the rapid metabolizer group, and normal or intermediate patients that are concomitantly taking a drug which is a strong CYP2D6 inhibitor will be treated as if they were a poor metabolizer.
214361812|NCT06669650|DRUG|Oxycodone|oxycodone
214361813|NCT06669650|DRUG|Hydromorphone|hydromorphone
214361814|NCT06670157|OTHER|Detachable Clip|After the varicose vessels basically disappeared under the endoscope, the removable titanium clamp was removed
214361815|NCT06670235|BEHAVIORAL|Upright Birthing Position|This intervention involves encouraging participants to use an upright position during labor and delivery, which may include : squatting, based on their preference and comfort level. Healthcare staff will support the participants in maintaining an upright position throughout labor as much as possible to evaluate its effects on maternal and newborn outcomes.
214361816|NCT06670235|BEHAVIORAL|Lithotomy Birthing Position|Participants in this arm will be positioned in the lithotomy position during labor and delivery, which is a common practice in clinical settings. In this position, the mother lies on her back with her legs supported in stirrups. This intervention serves as the control condition to provide a baseline comparison for evaluating outcomes against the upright birthing position.
214361817|NCT06669169|DRUG|Jia Shen Tablet Placebo|Jia Shen Tablet Placebo contains 4 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
214361818|NCT06669169|DRUG|Low dose Jia Shen Tablet|Low dose Jia Shen Tablet contains 2 tablets (0.47 g per tablet) and 2 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
214361819|NCT06669169|DRUG|High dose Jia Shen Tablet|High dose Jia Shen Tablet contains 4 tablets (0.47 g per tablet),take orally, 2 times a day for 12 weeks
214361820|NCT06669299|PROCEDURE|Re-Do ventricular tachycardia ablation|1\. Programmed ventricular stimulation (PVS); 2. Mapping during Sinus Rhythm (SR) or right ventricular pacing in pacing dependent patients; 3. Late Potentials identification; 4. VT(s) induction with diastolic pathway mapping when possible; 5. Catheter Ablation in SR or, at the operator's discretion, in VT if tolerated by the patient; 6. If VT is not inducible or the diastolic pathway is not mappable, a substrate ablation approach will be performed. 7. PVS is repeatedly attempting to reinduce VT after completing; 8. Endpoint: non-inducibility of any VT.
214361821|NCT06669299|DRUG|Antiarrhythmic Drug Therapy (amiodarone, sotalol, or mexiletine)|The patients with a positive NIPS already on antiarrhythmic drugs (AAD) before the index procedure will re-start the original antiarrhythmic therapy. Patients who were not on AAD will start a new drug at the operator's discretion (amiodarone, sotalol, or mexiletine) according to clinical practice.
214361822|NCT06670989|BEHAVIORAL|Fixation training|Training (adapting) microsaccades during fixation
214361823|NCT03915782|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning (RIC): Four cycles of \[5 minutes of brachial cuff inflation at 200 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
214361824|NCT03915782|DEVICE|Patients with a sham procedure of remote ischemic conditioning|Sham procedure: Four cycles of \[5 minutes of brachial cuff inflation at 30 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
214361825|NCT06140199|PROCEDURE|Pit-picking surgery|Patients are placed in left-side position. After shaving, cleaning and scrubbing of the skin with alcoholic chlorhexidine, double strong tape is placed on the right buttock in order to increase exposure. Local anaesthesia is administered before incision with 20 ml xylocaine or lidocaine 1-2%. In principle, all sinusoidal pits are cut out with a margin of at least 1 mm with a biopsy core punch (4 mm, 6 mm or 8 mm depending on pit size) or an oval excision of the pits is performed. Hair and debris is removed from the sinus tracts with a small surgical spoon or mosquito clamp. Rigorous de-epithelialisation of the underlying sinus is performed with the spoon through every pit, whilst removing even more debris and hairs. At the end of the procedure a debris washout is performed with saline solution, the wounds are left open for secondary healing and sterile dressings are applied.
214361826|NCT06140199|PROCEDURE|Pit-picking surgery with Sinus Laser assisted Closure|The pit picking procedure is described above. Subsequently, a radial diode laser probe at 1470 nm wavelength is used for delivering homogeneous (360 degrees) energy to the surrounding epithelium. The laser energy is 13 Joule, given continuously. First, a 'preparatory laser treatment' is performed to extract any missed hairs or debris, after which the sinus tracts are cleansed with a surgical spoon again. During the following definitive procedure, the probe is withdrawn at an approximate speed of 1 cm per three seconds, causing the small sinus tracts to shrink and close. Large sinus tracts remain open because very large sinus tracts or cavities cannot be closed with the 3mm laser fibre. The injury to the endothelium will cause granulation and create oedema for collapsing of the tract. The remaining open wounds are left open for secondary healing and sterile dressings are applied.
214361827|NCT05338333|DEVICE|Lehfilcon A multifocal contact lenses|Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia
214489246|NCT06862232|PROCEDURE|Classic Winograd Technique|"The classic Winograd technique, a widely used traditional surgical approach, will be performed. Local anesthesia with 1% lidocaine will be administered, and a temporary tourniquet will be applied. A linear incision will be made to separate the nail bed from the soft tissue, followed by the excision of the lateral nail bed and germinal matrix in a linear fashion to ensure complete removal of the affected nail portion. The wound will then be sutured using 3/0 prolene sutures.~This method is a standard approach for ingrown toenail surgery, offering high recurrence prevention rates but carrying a risk of cosmetic and structural nail alterations."
214973420|NCT05937880|DRUG|Leflunomide|When patients appeared with rashes and treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rashes do not subside or fresh rash still appears, and it frequently repeats more than 3 times during hospitalization. Leflunomide would be administered
214973421|NCT00243919|BEHAVIORAL|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
214973422|NCT00243919|BEHAVIORAL|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
214973423|NCT00243919|BEHAVIORAL|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
214973424|NCT06437925|DIETARY_SUPPLEMENT|probiotic ayran drink|The test group has received probiotic ayran drink for 6 weeks
214973425|NCT06437925|DIETARY_SUPPLEMENT|Placebo ayran drink|The control group has received placebo ayran drink for 6 weeks
214973426|NCT00612820|DRUG|GSK256066|200mcg bd,
215084243|NCT06027411|DEVICE|qER (qER EU 2.0)|Qure.ai's emergency room software solution qER (qER EU 2.0) is an AI medical device, developed by training a deep-learning algorithm using over 300,000 scans labelled by expert radiologists. qER has been shown to be accurate in identifying a range of abnormalities in NCCT head scans as well as prioritising them for urgent review and radiologist reporting. It is designated as a clinical support tool and, when used with original scans, can assist the clinician to improve efficiency, accuracy, and turnaround time in reading head CTs.
215084244|NCT00113646|DRUG|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
214973427|NCT00612820|DRUG|fluticasone propionate|200mcg od,100mcg bd
214361828|NCT05338333|DEVICE|Lotrafilcon B multifocal contact lenses|Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia
214361829|NCT05338333|DEVICE|CLEAR CARE®|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
214361830|NCT06670209|DRUG|GZR18 and metformin|GZR18: 3 mg-18 mg Metformin: 500 mg
214361831|NCT06670703|DIAGNOSTIC_TEST|Obesity|diagnosis as obese patients
214973428|NCT04817306|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
214973429|NCT02182401|DRUG|BI 207127 NA|Days 3-8 and days 25-30
215084245|NCT00113646|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
214361832|NCT06670183|OTHER|Dietary patterns|Dietary patterns such as regular meat-eater, occasional meat-eater, pescatarian, and vegetarian; Mediterranean diet.
214361833|NCT06670183|OTHER|Food groups and Nutrients|Dietary components, such as oily fish, dairy product, supplements, fibre, vitamin D supplements.
214361834|NCT06670183|OTHER|Alcohol intake|Frequency and intake of alcoholic beverages was measured by self-reporting the weekly frequency of different types of alcoholic beverages, e.g., the number of pints of beer/cider consumed per week and measures of spirits or liquors consumed per week were collected to assess consumption of beer/cider and spirits.
214361835|NCT06670183|OTHER|Vitamin D status|Serum 25(OH)D was measured once at baseline through a non-fasted blood draw during any season of the year.
214361836|NCT06672471|OTHER|No Post Operative Antibiotics for intervention group|No Post Operative Antibiotics in patients going clean contaminated head and neck surgery
214361837|NCT06672471|OTHER|Post Operative Antibiotics for one day|Control group will receive perioperative as well as post operative antibiotics for one day
214361838|NCT03800823|BEHAVIORAL|Parent group|In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
214973430|NCT02182401|DRUG|BI 201335 NA|Days 15-30
214973431|NCT02182401|DRUG|Midazolam|Days 1, 7, 23 and 29
214973432|NCT02182401|DRUG|Tolbutamide|Days 1, 7, 23 and 29
214973433|NCT05273762|DEVICE|FlowTriever|Mechanical thrombectomy for pulmonary embolism
214973434|NCT01805895|DRUG|Minocycline|This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
214973435|NCT02059239|DRUG|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
214973436|NCT02059239|DRUG|Carmustine|300 mg/m2 on Day -6
214973437|NCT02059239|DRUG|Etoposide|100 mg/m2 on days -5 to -2
214973438|NCT02059239|DRUG|Melphalan|140mg/m2 on Day -1
214973439|NCT02059239|DRUG|Cytarabine|200 mg/m2 on days -5 to -2
214973440|NCT02059239|DRUG|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
214973441|NCT02059239|BIOLOGICAL|Autologous Stem Cell Transplantation|
214973442|NCT02059239|BIOLOGICAL|Allogeneic Stem Cell Transplantation|
214973443|NCT02059239|DRUG|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
214973444|NCT00254436|DRUG|Procrit (epoetin alfa)|Weekly dose
214973445|NCT02762032|DIETARY_SUPPLEMENT|PrimaVie Herbal Supplement 125|125 mg to take BID for 14 weeks in Arm 1
214973446|NCT02762032|DIETARY_SUPPLEMENT|PrimaVie Herbal Supplement 250|250 mg to take BID for 14 weeks in Arm 2
214973447|NCT02762032|DRUG|Placebo|Placebo supplement to take BID for 14 weeks in Arm 3
214973448|NCT01319565|DRUG|Aldesleukin|Arm 1 and Arm 2 - Days 1 to 4: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) for up to 5 days (maximum 15 doses).
214973449|NCT01319565|DRUG|Cyclophosphamide|Arm 1 and Arm 2 - Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mL D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
214973450|NCT01319565|DRUG|Fludarabine|Arm 1 and Arm 2 - Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
214973451|NCT01319565|BIOLOGICAL|Young TIL|Arm 1 and Arm 2 - Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
214973452|NCT01319565|RADIATION|Total Body Irradiation (TBI)|Arm 2 - Days -3 to -1: Ondansetron 0.15 mg/kg IV x 1 dose pre-TBI. Patients will then receive 2 Gy TBI twice a day for 3 days (total dose 12 Gy) using a linear accelerator in Radiation Oncology.
214973453|NCT02048800|DRUG|Treosulfan|Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged \< 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged \> 12 months)
215084246|NCT03069170|BIOLOGICAL|Stem Cell Transplantation|Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
215094433|NCT06025799|BEHAVIORAL|Mindfulness-based stress reduction intervention|The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
215094434|NCT00718341|DRUG|AF056|
215094435|NCT00718341|DRUG|Placebo|
214361839|NCT03800823|BEHAVIORAL|mHealth component|After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
214361840|NCT03800823|BEHAVIORAL|Standard care|Standard care for overweight and obesity.
214489247|NCT06862232|PROCEDURE|Modified Noel Technique|"Local anesthesia with 1% lidocaine will be administered, and a temporary tourniquet will be applied. A 4-6 mm semi-elliptical incision will be made adjacent to the lateral borders of the nail bed to access the granulated tissue.~Unlike the Bird Flap technique, this method preserves both the nail bed and proximal germinal matrix, ensuring that only the inflamed soft tissue and granulated tissue are excised. The remaining tissue will be sutured subungually using 3/0 prolene sutures, promoting proper healing and maintaining the nail's structural integrity. This technique is designed to be less invasive while effectively treating infected and inflamed tissue."
214489248|NCT06671600|PROCEDURE|Osteopathic Manipulative Treatment|"Osteopathic manipulative treatment(OMT) protocol will be applied to the cranial, cervical, thoracic, and ribcage regions. OMT procedures performed on the treatment group will consist of~1. suboccipital decompression/release~2. base spread~3. occipitoatlantal (OA) decompression~4. venous sinus drainage~5. compression of the fourth ventricle~6. cervical myofascial (unilateral perpendicular stretch)~7. thoracic inlet release (direct or indirect)~8. Bilateral rib raising~9. thoracoabdominal diaphragm doming (direct technique)~10. pedal pump (Dalrymple lymphatic pump)"
214489249|NCT06671600|PROCEDURE|Sham (No Treatment)|The sham group will serve as the control group and will receive a light touch-control procedure based on prior study utilizing light touch.
214489250|NCT06739551|DRUG|Methotrexate (drug)|oral methotrexate 10 mg per week for 12 weeks
215084247|NCT05401695|DEVICE|HA330 hemoadsorption technique|Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group. We will select a blood circuit for each machine according to the patient's body weight. Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein. HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session. The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor. After the end of the HA session, CRRT will be continued if required.
215084248|NCT03040414|DEVICE|MedtronicMinimed 670G 3.0 hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
215084249|NCT03040414|DEVICE|Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
215084250|NCT05679544|BIOLOGICAL|Characterization of early biological effects following exposure to PAHs|Biological samples collected in period of exposure and after holidays
215084251|NCT05826691|PROCEDURE|Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).|Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction
215084252|NCT01709942|DRUG|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
215084253|NCT01709942|DRUG|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml
215084254|NCT05922410|RADIATION|cone beam computed tomography|cone beam computed tomography
214489251|NCT06739551|DRUG|Acitretin|oral acitretin 50 mg once daily for 12 weeks
214489252|NCT06596356|DRUG|[14C] TS-172|Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution
214489253|NCT06858033|DEVICE|Clear aligner|The effects of treatment on periodontal parameters (plaque index, gingival index, bleeding index on probing), salivary parameters (stimulated/unstimulated flow rate, stimulated/unstimulated pH, buffering capacity) and oral microorganism counts (S. mitis, S. salivarius, S. mutans, C. albicans) of children treated with labiolingual spring hawley and clear aligners were investigated.
214679455|NCT03995407|DIETARY_SUPPLEMENT|Peptamen®|Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.
215084255|NCT03351686|DRUG|Tranexamic Acid|Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
215084256|NCT04688541|DEVICE|Optitip Catheter (LinC Medical)|The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
215084257|NCT04688541|DEVICE|Foley catheter|Foley catheter
214361841|NCT04278287|RADIATION|Radiotherapy|59.92Gy and 2.14Gy in 28 fractions to PGTV and 50.4Gy and 1.8Gy in 28 fractions 5 days every week in 5.5 weeks.
214361842|NCT04278287|DRUG|Albumin-Bound Paclitaxel|100mg/d weekly,repeatedly on the first day,by intravenous infusion in 5-6 weeks.
214361843|NCT04278287|DRUG|Cisplatin|25mg/m2 weekly,by intravenous infusion in 5-6 weeks.
214489254|NCT06858033|DEVICE|Labiolingual spring hawley|The effects of treatment on periodontal parameters (plaque index, gingival index, bleeding index on probing), salivary parameters (stimulated/unstimulated flow rate, stimulated/unstimulated pH, buffering capacity) and oral microorganism counts (S. mitis, S. salivarius, S. mutans, C. albicans) of children treated with labiolingual spring hawley and clear aligners were investigated.
214361844|NCT05261178|OTHER|Evaluation of satisfaction and the level of daily living activities using the prosthesis|Evaluation of satisfaction with using the prosthesis with TAPES (Trinity Amputation and Prosthesis Experience Scale) and the level of daily living activities using the prosthesis with SF-36 (Short Form-36)
214361845|NCT06669286|PROCEDURE|implant placement using navigated surgery near alveolar nerve|Dental implant placement in proximity of alveolar nerve (within 2 mm) using navigated surgery.
214361846|NCT06670846|DEVICE|Lollipop|Distraction using a Lollipop 15 minutes before anesthesia
214361847|NCT06670846|DRUG|distraction using intranasal Midazolam|Distraction using intranasal Midazolam 15 minutes before anesthesia
214361848|NCT06670300|DRUG|cardonilimab|Subjects will receive cardonilimab 10mg/kg once every three weeks; The maximum duration of administration is 2 years until disease progression or death, toxicity becomes intolerable, subject voluntarily requests withdrawal, or investigator determines that subject needs to withdraw from the study.
214361849|NCT06669559|OTHER|DROM-Test|DROM test: a tool for assessing the ability to decide on returning home
214361850|NCT00254202|DRUG|Iloperidone|
214361851|NCT00254202|DRUG|Ziprasidone|
214361852|NCT00254202|DRUG|Placebo|
214361853|NCT05505656|DIAGNOSTIC_TEST|hysteroscopic guided endomyometrial biopsy|we will obtain hysteroscopic guided endomyometrial biopsy in cases of adenomyosis
214361854|NCT06678178|BEHAVIORAL|Control (QR) Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Control (QR) labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
214679456|NCT03995407|OTHER|Usual Care|"Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations."
214361855|NCT06678178|BEHAVIORAL|Warning High Climate Impact Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Warning High Climate Impact labels will be displayed beneath select items. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
214361856|NCT06678178|BEHAVIORAL|Traffic Light Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Traffic Light labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
214361857|NCT06678178|BEHAVIORAL|Climate Grade Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Climate Grade labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
214679457|NCT02383329|DIETARY_SUPPLEMENT|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
214361858|NCT06678178|BEHAVIORAL|Numeric Carbon Footprint Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Numeric Carbon Footprint labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
214361859|NCT05073133|GENETIC|OAV101|A single Gene Therapy IV infusion at 1.1e14 vector genome (vg)/kg over approximately 60 minutes
214679458|NCT00004346|DRUG|chenodeoxycholic acid|
214361860|NCT01356875|DRUG|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
214361861|NCT01356875|DRUG|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
214361862|NCT06669143|DRUG|Zanubrutinib|160 mg bid, po, day 1-21, a maximum of 2 years.
214361863|NCT06669143|DRUG|Lenalidomide|25 mg qd, po, day 1-10, a maximum of 2 years.
214679459|NCT00004346|DRUG|lovastatin|
214679460|NCT01812720|DRUG|carfilzomib|Given IV
214489257|NCT06778889|BEHAVIORAL|Undergraduate Medical Students|This is an observational study without any intervention. Data will be collected using standardized questionnaires to assess physical activity, mental health, and stress levels in the participants.
214489258|NCT06876376|PROCEDURE|intraoperative ultrasound for the assessment of bowel deep infiltrating endometriosis|Women with posterior compartment deep infiltrating endometriosis with or without bowel involvement scheduled for surgical treatment at the Department of Obstetrics, Gynecology, and Reproductive Medicine of Dexeus University Hospital.
214489259|NCT06879860|PROCEDURE|3D Mesh Single-Suture Fixation|3D mesh fixation in 1 points
214489260|NCT06879860|PROCEDURE|3D mesh Non-FIxation|3D mesh fixation with non-flxation
214679461|NCT01812720|DRUG|dexamethasone|Given PO
214679462|NCT01812720|OTHER|laboratory biomarker analysis|Correlative studies
214679463|NCT06013787|BEHAVIORAL|"Nuestras Historias"|"Nuestras Historias is a digital story curriculum that is displayed on a small solar-powered tablet. The curriculum is a collection of 7 digital stories used to discuss health issues during pregnancy that the community identified as important. The digital stories are short videos that combine local photos and local voices sharing real-life narratives about experiences during pregnancy. The videos were made in collaboration with community health workers and local mothers."
214679464|NCT04110834|DRUG|itraconazole gel once daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
214361864|NCT05878197|BEHAVIORAL|Straw phonation|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, straw phonation on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, straw phonation on word and sentence level, pitch variations Day 4: straw phonation in spontaneous speech, combination exercises"
214361865|NCT05878197|BEHAVIORAL|Resonant voice therapy|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, resonant voice therapy on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, resonant voice therapy on word and sentence level, pitch variations Day 4: resonant voice therapy in spontaneous speech, combination exercises"
214361866|NCT05878197|BEHAVIORAL|Vocal Hygiene|"Participants of the control group will receive a sham treatment, including the exact same games, drawing assignments, etc. as in the experimental groups. However, no SOVT or other active vocal techniques will be practiced. Vocal hygiene guidelines (e.g. avoid screaming, imitating voices, sufficient hydration etc.) will be kept equally in the four groups. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations Day 3: breathing exercises, vocal hygiene recommendations Day 4: combination exercises"
214361867|NCT02611466|DRUG|ASP7962|Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
214361868|NCT02611466|DRUG|Naproxen|Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
214973454|NCT01268267|DEVICE|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
214973455|NCT00125918|DRUG|tadalafil|tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
214361869|NCT02611466|DRUG|Placebo|Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
214361870|NCT04427202|BEHAVIORAL|Referral to harm reduction services|Participants are referred to harm reduction services
214361871|NCT06624137|DRUG|Serotonergic Psychedelic|"Any serotonergic or classic psychedelic that exhibits mainly Serotonin 2A receptor (5-HT2AR) agonism and is judged to produce subjectively similar effects."
214361872|NCT06624137|DRUG|Placebo|Matched Placebo
214361873|NCT06120907|OTHER|Data collection|The data include phenotypic data, treatments administered, response to treatment, Three-dimensional total body images, biopsies and blood plasma.
214361874|NCT01538550|PROCEDURE|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
214361875|NCT01538550|PROCEDURE|iFOBT|Biennial screening with iFOBT
214361876|NCT06701539|DRUG|Liposome bupivacaine group|After standardized anesthesia induction, bilateral scalp nerve block (supprorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was performed with liposome bupivacaine stock solution, and 1-2ml was injected into each block site.
214361877|NCT06701539|DRUG|Ropivacaine group|After standardized anesthesia induction, bilateral scalp nerve block (supraorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was administered with 0.5% ropivacaine, and 1-2ml was injected into each block site.
214361878|NCT06720662|DIETARY_SUPPLEMENT|Icosapent-ethyl ester capsules|Icosapent-ethyl ester (4.0 g of EPA) taken twice a day (2.0 g/day x 2) for six months.
214361879|NCT06720662|DIETARY_SUPPLEMENT|Corn oil Control|Corn oil twice a day (2.0 g/day x 2) for six months.
214361880|NCT06720051|PROCEDURE|Intraosseous dexamethasone injection after 3rd molar surgery|In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing
214489261|NCT06877442|DIAGNOSTIC_TEST|serum level of neurofilament light chain|labarotory investigation to evaluate serum level of neurofilament light chain
214489262|NCT06882161|BIOLOGICAL|Acetal resin|Effect of acetal resin versus Polyether ether ketone (PEEK) partial dentures on abutment teeth supporting structures in Kennedy class I mandibular partial denture cases
214489263|NCT06746467|DEVICE|pentacam|evaluate corneal changes by pentacam
214973456|NCT00125918|DRUG|tadalafil|tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
214973457|NCT00125918|DRUG|tadalafil|tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
214973458|NCT00125918|DRUG|tadalafil|tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
214973459|NCT00125918|DRUG|placebo|placebo tablet taken by mouth once a day for 16 weeks
214973460|NCT03514550|DRUG|Propofol|Propofol will be used for anesthesia during surgery
214973461|NCT03514550|DRUG|Sevoflurane|Sevoflurane will be used for anesthesia during surgery
214973462|NCT03514550|PROCEDURE|Epidural block|Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
214973463|NCT00703300|DRUG|bortezomib|Given IV
214973464|NCT00703300|DRUG|decitabine|Given IV
214973465|NCT00703300|OTHER|pharmacological study|Correlative studies
214973466|NCT00703300|OTHER|laboratory biomarker analysis|Optional correlative studies
214361881|NCT06720051|PROCEDURE|Submucosal dexamethasone injection after 3rd molar surgery|In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery.
214361882|NCT04948099|DRUG|VIB1116|VIB1116
214361883|NCT04948099|DRUG|Placebo|Placebo
214973467|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr \>80 mL/min)
214973468|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
214973469|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - \<50 mL/min)
214973470|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr \<30 mL/min and not on hemodialysis)
214973471|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
214973472|NCT03847740|DEVICE|Isometric Trumb Force handle|Compare the pattern of neuromuscular blocking drug between two devices applied on the same patient during general anesthesia.
214361884|NCT06723366|DRUG|Angong Niuhuang Pill (ANP)|Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)
214361885|NCT06723366|OTHER|Control (Standard treatment)|Blank control
214361886|NCT06722482|DEVICE|FDBA|Twenty five participants will receive FDBA in anterior extraction sockets as part of the alveolar ridge preservation procedure.
214361887|NCT06722482|DEVICE|CEBX|Twenty five participants will receive CEBX in anterior extraction sockets as part of the alveolar ridge preservation procedure.
214361888|NCT06723678|PROCEDURE|Two distally inclined 45-degree angle posterior implants|During the surgery, two axially placed anterior implants and two distally inclined 45-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients.
214361889|NCT06723678|PROCEDURE|Two distally inclined 30-degree angle posterior implants|During the surgery, two axially placed anterior implants and two distally inclined 30-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients
214361890|NCT05227833|DRUG|Vonoprazan fumarate (Vonaspire)|Patients assigned to Vonoprazan (vonaspire) tablets will receive a daily dose of 20 mg before breakfast starting from the first day of band ligation.
214361891|NCT05227833|DRUG|Pantoprazole 40mg|Patients assigned to Pantoprazole tablets (Controloc OR Antopral OR Perloc) will receive a daily dose of 40 mg before breakfast starting from the first day of band ligation.
214361892|NCT05227833|OTHER|Placebo|No Intervention
214361893|NCT04219033|OTHER|EEG(Electroencephalogram) change|patients are found to have characteristic EEG change
214361894|NCT06722976|OTHER|Multicomponent exercise programs|"The program is organized into three phases: (1) Initial assessment; (2) Multicomponent training sessions; (3) Final assessment.~1. The initial assessment will consist of physical fitness tests (lasting around 1 hour) and Neuropsychological Assessment tests (lasting around 1.5 hours).~2. The multicomponent training sessions will last 3 months, twice a week, 50 minutes each session.~3. The final assessment will be the same as the initial assessment (physical fitness tests (about 1 hour) and Neuropsychological Assessment tests (about 1.5 hours)."
214361895|NCT06723873|OTHER|Kinesiology Taping|The treatment group received Kinesiology Taping around the trunk extensors, lower and middle trapezius, supraspinatus, deltoid muscle group, and serratus anterior muscle.
214489264|NCT06885554|DEVICE|SANA|SANA is an audio-visual stimulation device found to reduce symptoms commonly found in AjDs. SANA is an eye mask that delivers coordinated pulses of light and sound that facilitate relaxation in the wearer. The device's mechanism of action is neuromodulation through audiovisual stimulation (AVS). When the brain receives a stimulus through the eyes or ears, it emits a responsive electrical charge, called a Cortical Evoked Response (CER). The brain responds by synchronizing to it, a process known as Frequency Following Response (FFR). FFR can be used to trigger each electrical pattern to facilitate a state of relaxation. The Sana device utilizes AVS to induce FFR.
214489265|NCT06716086|OTHER|shape memory alloy-based orthosis|The home program with the shape memory alloy-based orthosis contains warm-up part and correction part. The SMA-based orthosis is an improvement over traditional dynamic splint. This corrective device uses shape memory alloy as an elastic component specifically designed to address finger joint stiffness. It provides continuous force for stiff joint in order to address stiffness.
214973473|NCT04361084|OTHER|traditional simulated training|traditional simulation using actors as standardised patients playing out scenarios plus pre and post questionnaires and semi structured interviews
214973474|NCT04361084|OTHER|mixed reality simulation|using immersive technologies to create a virtual reality simulated training scenario's plus pre an post questionnaires and semi structured interview's
215084258|NCT01778374|OTHER|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
215084259|NCT01778374|OTHER|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
214361896|NCT06723873|OTHER|Placebo Kinesio Taping|In the control group, kinesiology tape was applied without tension and in a manner that did not target specific muscle groups or respect the anatomical origin and insertion points.
214489266|NCT06716086|OTHER|conventional stretching program|The home program for the stretching group includes active joint range of motion exercises and passive stretching exercises. Participants will follow instructions to perform various joint movements, with a focus on their restricted fingers.
214489267|NCT06747065|PROCEDURE|Radiotherapy|Radiotherapy post-mastectomy prepectoral implant-based breast reconstruction (IBBR)
214361897|NCT06733064|DIETARY_SUPPLEMENT|Supplementation of vitamin D3|Supplementation of vitamin d3 at a dose of 4000 iu / day
214361898|NCT06733064|DIETARY_SUPPLEMENT|Placebo|Vegetable oil as a placebo
214361899|NCT06732570|DEVICE|high intensity laser|the patient will be in supine position with shoulder uncovered from clothes and wearing laser protective eye glass to protect eye from laser radiation, the dose will be selected from device pathologies list programs number thirty-four with 30% power, frequency continuous, density 16 j/cm2, time automatically adjusted by the device according to the width of scanning area ( superiorly from the acromioclavicular joint down to end of biceps tendon and medially from the coracoid process to the middle fiber of deltoid laterally) and the infrared will be ON.
214361900|NCT06732570|OTHER|manual therapy|manual therapy (mulligan shoulder abduction, deep transverse friction technique on the supraspinatus tendon, scapular mobilization, caudal and posterior humeral mobilization) three session weekly over 5 weeks.
214361901|NCT06732570|OTHER|exercise therapy|therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch supine ex, pectoralis minor flexibility (focused and gross stretch) and posterior capsule modified sleeper stretching ex's from side)
214361902|NCT06733948|DEVICE|Dental stent|Dental stent is personalised device for tongue depressing and immobilisation during RT. The aims are to reduce unnecessary RT doses to adjacent non-target healthy tissue, including the tongue, adjacent oral mucosa, parotid glands/ submandibular glands, and temporomandibular joints. Dentists will take impression of the teeth on moulds, and measure the height to raise the bite, the stent is then fabricated as methyl methacrylate resin in the dental laboratory. The resin base extends to the tongue and a flat plate depresses the tongue. This device will be placed before each RT fraction.
214361903|NCT06733948|OTHER|No dental stent|No dental stent used during chemoradiation treatment
214489268|NCT06742749|PROCEDURE|Proximal level|For the proximal level of psoas tenotomy at the pelvic brim, the hip was slightly flexed to relax the iliopsoas muscle; the iliacus muscle fibers were retracted anteriorly until the deeply seated posteromedially psoas tendon was isolated and transected
214489269|NCT06742749|PROCEDURE|Distal level|For the distal level of iliopsoas tenotomy just above the lesser trochanter, the thigh was put in the position of FABER (flexion, abduction, and external rotation). A curved right-angle hemostatic clamp was used to retract and bring the iliopsoas tendon into the field. Then, the tendinous fibers were transected.
214489270|NCT06742216|DRUG|Monosialoganglioside|Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
214679465|NCT04110834|DRUG|itraconazole gel twice daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
214679466|NCT04110834|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
214973475|NCT06514079|PROCEDURE|Esophageal dilatation with steroids injection|Under general anesthesia with the patient in the left lateral position. A single-channel endoscope was used. Endoscopic bougie dilatation was performed using Wire-guided Polyvinyl dilator Savary Gilliard/SG. Long-acting steroids triamcinolone acetonide was injected via 25-gauge sclerotherapy catheter. One mL solution of triamcinolone acetonide 40mg/ml was diluted with one mL of saline, in a 2 mL disposable syringe, and 0.5 mL each was injected at the proximal margin of the stricture in four quadrants, 2 mL solution in four quadrants
214973476|NCT03871153|DEVICE|Durvalumab|"Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1"
214679467|NCT06143579|DRUG|FOLFOX-HAIC+Lenvatinib+Envolizumab|"FOLFOX-HAIC: Oxaliplatin 130 or 85 mg/m2; leucovorin 200 mg/m2; fluorouracil 400 mg/m2 intravenous bolus followed by fluorouracil 2400 mg/m2 continuous infusion over 23 hours, Q3W, 2 to 4 cycles;~Lenvatinib: 8 mg/day (BW \< 60 kg) or 12 mg/day (BW ≥ 60 kg), PO, 3-4 cycles;~Envolizumab: 300 mg, SC, Q3W, 3-4 cycles."
214973477|NCT03871153|DRUG|Paclitaxel|Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36
214973478|NCT03871153|DRUG|Carboplatin|Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36
214973479|NCT03871153|RADIATION|Radiation|1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).
214973480|NCT03871153|PROCEDURE|Surgical Resection|Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.
214973481|NCT00802711|RADIATION|3-dimensional conformal radiation therapy|Given twice a day for 10 fractions
214973482|NCT00802711|RADIATION|brachytherapy|Given twice a day for 10 fractions
214973483|NCT02318849|BEHAVIORAL|Web intervention|interactive website using social media and gamification
214973484|NCT03175081|DRUG|Ropivacaine|Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
215084260|NCT01550341|DRUG|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
215084261|NCT01550341|DRUG|Placebo Oral Tablet|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
215084262|NCT01479595|DRUG|QBX258|QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
215084263|NCT01479595|DRUG|Placebo|The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
215084264|NCT03159689|OTHER|Mixed Tree Nuts|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz mixed tree nuts
215084265|NCT03159689|OTHER|Pretzels|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz pretzels
214361904|NCT06732934|OTHER|exercise (Basic Body Awareness Therapy|"Body Awareness Therapy is a patient-centered physiotherapy approach that also includes mental health, focusing on movement awareness training. This therapy primarily consists of exercises aimed at improving postural disorders, balance, and muscle tension. It aims to help individuals experience and accept bodily responses while increasing coping strategies.~The therapy includes body scanning, integration of sound and movement, stretching exercises, and exercises focusing on body alignment and midline orientation.~Floor exercises: body scanning, stretching, strength accumulation, sound resonance.~Seated exercises: body alignment, trunk rotation, head and neck movements. Standing exercises: support surface perception, midline elevation and lowering, bilateral arm movements, rotation, one-legged balance, voice exercises, and group movements."
214361905|NCT06732934|OTHER|exercise (aerobic exercise)|"The continuous exercise protocol specified by the American College of Sports Medicine (ACSM) will be applied under supervision on a treadmill. The exercise duration will follow ACSM recommendations, starting at 30 minutes in the first week and increasing to 45 minutes by the 12th week.~Exercise intensity will be assessed using the target heart rate method (220 - age). The intensity of aerobic exercise will be set at a moderate level (64-77% HRmax), according to ACSM guidelines.~During exercise, heart rate will be monitored through a heart rate monitoring device. A 5-minute warm-up and a 5-minute cool-down exercise will be performed before and after each session, with an intensity of 50-60% of the maximum heart rate."
214489271|NCT06742216|DRUG|Placebo|Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
214489272|NCT06732167|PROCEDURE|GBR Lyoplant|GBR surgical procedure with simultaneous implant placement including membrane placement
214679468|NCT03854162|DEVICE|SMART Guide|The device manufactured according to a digital plan based on patient anatomy. Guiding sleeves are used, through which bone drills are applied. These sleeves sit in a plastic template that is a negative of the patient's dentition, so that the guide is properly stabilized during the operation. The position of the sleeves is calculated from the surgical plan in a way that they guide the drills in the planned position.The material of the template is medical plastic, the sleeves are made of medical steel.The device is applied by the dentist during the implant surgery. The template is placed on the remaining dentition of the patient and stabilized this way. By this, the sleeves are also stabilized in their planned position. Access through the soft tissue can be prepared through the given sleeve with a circular trephine, but the system also supports flap surgery. As access has been established, the dentist performs the surgical protocol as planned.
215084266|NCT03818347|DEVICE|oxyhydrogen generator (AMS-H-03)|Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term
215084267|NCT03818347|DEVICE|analogue machine|This machine has the same apperance and gas condition
215084268|NCT05268744|DRUG|Micronutrient|Subject will take micronutrient supplement daily for 8 weeks
215084269|NCT01862341|DIETARY_SUPPLEMENT|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
215084270|NCT02255565|DRUG|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
214489273|NCT06732167|PROCEDURE|GBR Bio-Gide|GBR surgical procedure with simultaneous implant placement including membrane placement
215084271|NCT02255565|DRUG|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
214489274|NCT06739837|DIAGNOSTIC_TEST|traditional physiotherapy|Participants in this arm will undergo traditional physiotherapy exercises for managing tennis elbow.
214679469|NCT03425799|DRUG|Sodium Chloride 0.9% Inj|Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
214679470|NCT03425799|DRUG|Tranexamic Acid|Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
214679471|NCT05553379|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement at each visit
214973485|NCT03175081|DRUG|Normal saline|Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
214973486|NCT03184311|OTHER|High-intensity interval training (HIT)|Supervised 12-week HIT 3 times per week on a bicycle ergometer.
214973487|NCT03184311|OTHER|Moderate-intensity contiuous training (MCT)|Supervised 12-week MCT 3 times per week on a bicycle ergometer.
214973488|NCT01136018|PROCEDURE|insertion needle via intentionally lateral direction.|evaluation of iodinated contrast flow patterns in caudal epidurography with intentional lateral caudal approach
214973489|NCT03444844|DRUG|Ga-68 P16-093 PET/CT scan|IV injection followed by PET/CT scanning
214973490|NCT04919317|DRUG|Dexamethasone 4mg|The experimental group received 4mg dexamethasone added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
214973491|NCT04919317|DRUG|Saline|The control group received 1mL of 0.9% saline added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
214973492|NCT04856111|DRUG|Pirfenidone|Same as arm description
214973493|NCT04856111|DRUG|Nintedanib|Same as arm description
214973494|NCT00230048|BEHAVIORAL|Brief computer-delivered intervention|Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
214973495|NCT06053385|OTHER|Melatonin sleep lotion|7 g of lotion applied to hands and arms one hour before bedtime
214973496|NCT06053385|OTHER|Placebo control lotion|7 g of lotion applied to hands and arms one hour before bedtime
214973497|NCT06059469|DIAGNOSTIC_TEST|Ga-PSMA PET/CT|Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment
214973498|NCT05259488|DIETARY_SUPPLEMENT|immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
214973499|NCT02421692|OTHER|Progressive Rehabilitation|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
214973500|NCT02903342|OTHER|Leaflet|A leaflet designed from data obtained from previous qualitative and quantitative studies.
214973501|NCT06087770|DRUG|SM3321|Intravenous infusion, once a week, 28 days for a dosing cycle
214361906|NCT06732622|DEVICE|Laser acupuncture|"Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Sri, Vicenza, Italy).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment.~Acupoints:~we chose 5 acupoints on the affected side. This includes ST2 (Si Bai), ST4 (Di Cang), ST6 (Jia Che), GB14 (Yang Bai), GB20 (Feng chi). We choose 6 acupoints bilaterally, including LI4 (He Gu), LI11 (Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), and LR3 (Tai Chong)."
214361907|NCT06732622|DRUG|Steroids|Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 12 days.
214679472|NCT03241056|BEHAVIORAL|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
214973502|NCT06232096|DRUG|MBS314 Injection|"Phase Ia: The patients confirming to the eligibility criteria will be assigned to 1 of the 7 dose groups (0.03/0.09/0.3/0.9 mg \~ 0.3/1.5/9.0/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS314 as per the schedule specified in the respective arms.~Phase Ib/Ⅱ: Based on the results of Phase Ⅰa, 1 or 2 recommended doses will be selected for Phase Ⅰb. Recommended Phase II Dose (RP2D) will be selected for Phase Ⅱ."
214361908|NCT06732622|DEVICE|Sham laser acupuncture|"Patients in the laser acupuncture group (Sham group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Sri, Vicenza, Italy).~The Sham LA group received the same laser device and the same acupoints. The device showed the same red light but did not emit a laser, administered for 3 times per week in the 4 weeks.~Acupoints:~we chose 5 acupoints on the affected side. This includes ST2 (Si Bai), ST4 (Di Cang), ST6 (Jia Che), GB14 (Yang Bai), GB20 (Feng chi). We choose 6 acupoints bilaterally, including LI4 (He Gu), LI11 (Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), and LR3 (Tai Chong)."
214361909|NCT06733714|DEVICE|Transcranial Alternating Current Stimulation|An alternate eletric current of 1.6mA in theta frequency is applied in the scalp, using two eletrodes (5x5cm). The eletrodes are located aiming for the left dorsolateral prefrontal Cortex area.
214361910|NCT06733714|DEVICE|Digital Cognitive Training|Using a tablet, the participant will do exercises that were designed to stimulate cognitive domains, especially attention and memory. In this case, we use the BrainHQ platform.
214679473|NCT03241056|OTHER|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
214679474|NCT00480454|BIOLOGICAL|MVA 85A|intradermal vaccine
214679475|NCT01478750|DIETARY_SUPPLEMENT|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
214973503|NCT05797025|OTHER|To assess pressure pain threshold and pinch grip strengths.|To assess pressure pain threshold and pinch grip strengths.
214973504|NCT00405301|DRUG|Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)|Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.
214973505|NCT04216147|OTHER|PNE|Percutaneous Needle Electrolysis: the application of galvanic current through an acupuncture needle.
214679476|NCT01478750|PROCEDURE|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
214679477|NCT02067312|OTHER|Thai massage|
214679478|NCT02883582|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
214679479|NCT02883582|DEVICE|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
214679480|NCT02718794|PROCEDURE|Simulation training|spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
214679481|NCT02718794|PROCEDURE|Problem-based learning|spend 3 hours for PBL steps with each of 10 nurse anesthetist students
214679482|NCT04183257|DRUG|oral vitamin D|oral Vitamin D 400IU will be given and will be escalated every 2 weeks.
214973506|NCT04216147|PROCEDURE|Surgery for CTS|Median nerve release
214973507|NCT06561633|DRUG|Sugammadex administration|After surgery was completed while the train-of-four ratio was zero, a steady-state intravenous anesthesia was maintained to keep a BIS value within the range of 40-60 for at least 5 minutes. Patients received sugammadex 2 mg.kg-1 after completed surgery.
214973508|NCT02577640|DIETARY_SUPPLEMENT|Soy bread|Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (\~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
215084272|NCT02255565|DRUG|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
215084273|NCT04333953|OTHER|No intervention|No intervention, observational study
214679483|NCT00844428|DRUG|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
214679484|NCT02563184|BIOLOGICAL|Fluzone|
214679485|NCT03290300|DEVICE|Vivaer Stylus|Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
214679486|NCT06858800|PROCEDURE|LTRI technique|"Hematoma distraction Artroplasty (HDA): A dorso-radial incision in the CMC joint was used in order to perform a trapezectomy. The thumb was displaced at its anatomical position (subtle opposition with 30º abduction) and fixed percutaneously with a 1.5mm K-Wire for three weeks along with a cast. This allowed to act the postoperative hematoma as an interposition between first-metacarpal and the scaphoid.~Ligament reconstruction with tendon interposition (LRTI): A complete removal of the trapezium bone with a radial-volar incision was made with posterior resection of the articular surface of the first metacarpal bone, and ligament transfer with a loop from hemi-tendonectomy of the flexor carpi radialis (FCR) was used to cushion the joint while occupying the space of the resected bone following modified Weilby Garcia-Elias technique"
214679487|NCT06858800|PROCEDURE|HDA technique|A dorso-radial incision in the CMC joint was used in order to perform a trapezectomy. The thumb was displaced at its anatomical position (subtle opposition with 30º abduction) and fixed percutaneously with a 1.5mm K-Wire for three weeks along with a cast. This allowed to act the postoperative hematoma as an interposition between first-metacarpal and the scaphoid
215084274|NCT03398265|BEHAVIORAL|Treatment Navigation (Intervention)|Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.
215084275|NCT03398265|OTHER|Control|Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
215084276|NCT05959629|DEVICE|Waterlase Express™, BIOLASE®|Er,Cr:YSGG laser 2780nm (Waterlase Express™, BIOLASE®) with 300μm tip (EdgePro #3) will be placed into the mid-root of the canal. The tip will be activated and slowly withdrawn to the orifice (1-2mm/sec) following the manufacturer settings (energy 15 Millijoule (mJ), repetition rate 50 Hertz (Hz), 0% air, 0% water).
215084277|NCT05959629|OTHER|Sodium Hypochlorite|Root canals will be instrumented up to size 30/0.04 taper using 1.5cc of 3% NaOCl in between files.
215094436|NCT04022018|RADIATION|Adaptive radiotherapy|CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
214679488|NCT01373645|DEVICE|Yinyi stent|subjects with Yinyi stent implantation
214679489|NCT05189015|DRUG|Olmesartan|\- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
214679490|NCT04804852|OTHER|sarcopenia assessment|evaluation of sarcopenia by CT san at the C3 vertebrae
214679491|NCT04416516|BIOLOGICAL|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
214679492|NCT00260000|DRUG|5,6,7,8-tetrahydrobiopterin|
214679493|NCT03618225|DRUG|Oral Duloxetine 60mg|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
214679494|NCT03618225|DRUG|placebo pill|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
214679495|NCT05328843|DRUG|PB119|"Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration."
214679496|NCT06133010|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
214679497|NCT06133010|BIOLOGICAL|Placebo|Sterile liquid for injection
214679498|NCT00004184|BIOLOGICAL|monoclonal antibody 4B5 anti-idiotype vaccine|
214679499|NCT00004184|BIOLOGICAL|sargramostim|
214679500|NCT00004184|DRUG|alum adjuvant|
214679501|NCT00444210|DEVICE|DL6049 (injectable poly-L-lactic acid)|
214679502|NCT05888714|DEVICE|Experimental FES cycling|Using the experimental, new FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
214679503|NCT05888714|DEVICE|Comparator FES cycling|Using the comparator, marketed FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
214679504|NCT05888714|OTHER|Conventional physical therapy|Conventional physical therapy for muscle strengthening, for 16 treatment sessions (twice a week, for 8 weeks).
214361911|NCT06888986|BEHAVIORAL|VR Dementia Prevention Health Education Module|A virtual reality (VR) cognitive health education program designed to enhance knowledge related to dementia, improve health literacy, boost self-efficacy, and shape attitudes towards dementia. Participants engage with 360-degree immersive VR modules using VR headsets that simulate real-world scenarios related to dementia. The intervention comprises five interactive VR sessions, each addressing important topics in dementia prevention and management. Trained research staff will guide participants to ensure safe and effective interaction with the VR system.
214679505|NCT02606786|OTHER|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
214679506|NCT05662358|DRUG|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
214679507|NCT05662358|DRUG|Alendronate|oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
214679508|NCT05662358|DRUG|Placebo|oral placebo weekly
214679509|NCT04379518|OTHER|Best Practice|Receive standard of care
214679510|NCT04379518|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
214679511|NCT04379518|DRUG|Rintatolimod|Given IV
214679512|NCT01301911|DRUG|Cipatinib|Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
214679513|NCT02234115|DRUG|Leuprolide Mesylate|Subcutaneous injection of 50mg Leuprolide Mesylate
214679514|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
214679515|NCT01815437|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
214973509|NCT05316558|BEHAVIORAL|Body Confident Coaching|The Body Confident Coaching program is a five-module online program aimed at upskilling coaches in identifying and tackling body image concerns among girls in sport. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
214973510|NCT04310722|OTHER|None intervention. This is an observational study.|None intervention. This is an observational study.
215084278|NCT00712569|BEHAVIORAL|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
214361912|NCT04915183|OTHER|Placebo|Placebo will be formulated to also contain a white powder such that the atorvastatin and placebo are indistinguishable even if a capsule is opened.
214361913|NCT04915183|DRUG|Atorvastatin|Subjects will be provided with atorvastatin (40 mg) or placebo to be taken daily by mouth or by feeding tube. The tablets may be taken whole or crushed according to patient swallowing capabilities and preference.
214361914|NCT06777758|DRUG|Remimazolam|Remimazolam
214361915|NCT06777758|DRUG|Propofol|Propofol dose reduction ratio
214361916|NCT07090668|DEVICE|taVNS device|"Sparrow Link taVNS device from Spark Biomedical, a non-invasive, adhesive earpiece placed on the tragus of the ear to deliver vagal nerve stimulation. The stimulation level is titrated by the investigator to a perceptible but comfortable intensity. Patients cannot adjust the settings themselves, though adjustments can be made upon request.~The device consists of a disposable earpiece connected by a cable to a battery-powered controller (3 AAA batteries). It emits a biphasic, rectangular waveform with a 100 µs interphase and a maximum output of 95V."
214679516|NCT01815437|DIETARY_SUPPLEMENT|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
214973511|NCT06354491|DEVICE|Magnetic Resonance Imaging (MRI)|MRI procedures will include a 20-25 exam with periodic breath holds. The imaging series will be conducted twice to assess repeatability.
214361917|NCT07094347|DEVICE|inspiratory muscle training|Powerbreathe® threshold resistance loading device (POWERbreathe, HaB International) will be used for this training program that strengthens the inspiratory muscles. The PowerBreathe® device is a threshold device that creates resistance to inspiration. This resistance is created by the spring tension in the device mechanism. The device has a mechanism that is adjusted according to 9 different levels in its mechanism specific to the individuals using it.
214679517|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Extract|Same quantity of mushroom extract in a capsule
214679518|NCT03148171|OTHER|WERK Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
214679519|NCT01276847|DRUG|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing \> 100 kg on Day 1, and Weeks 4 and 16
214679520|NCT01276847|DRUG|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
214679521|NCT00164424|DRUG|Acyclovir|
214679522|NCT01732263|DRUG|SSP-004184|All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
214679523|NCT01899144|DRUG|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
214679524|NCT01899144|DRUG|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
214679525|NCT01899144|DRUG|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
214679526|NCT03312673|OTHER|Interview and tests of drawing.|The intervention will take place with patients followed for asthma at the Croix Rousse hospital. Patients agreeing to participate in the study will come to the hospital for one hour and a half. They will answer questionnaires and tests of drawing. Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
214679527|NCT04756089|DEVICE|Electronic breast pump|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
214361918|NCT01516047|DRUG|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
214489275|NCT06739837|COMBINATION_PRODUCT|Non-immersive VR therapy|Participants undergo a VR-based rehabilitation program targeting tennis elbow symptoms. Sessions last 30 minutes, conducted 3 times per week for 6 weeks. Exercises focus on improving grip strength, wrist flexibility, and functional movement through interactive VR environments that visually engage the affected arm, promoting adherence and motivation without full immersion. The VR setup includes headsets or screens that enable visual interaction, enhancing the rehabilitation experience. The goal is to alleviate pain, increase range of motion, and restore muscle strength.
214361919|NCT01516047|DRUG|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
214361920|NCT02651766|PROCEDURE|Cupping massage|Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
214361921|NCT06388694|OTHER|Pharmacist Care|Pharmacists will provide ADHD medication refill orders in response to secure message requests by parents, under the authorization of appropriate physicians.
214361922|NCT06388694|OTHER|Primary Care Physician Care|Primary care pediatricians will provide ADHD medication refill orders in response to secure message requests by parents. This is usual care.
214489276|NCT06886022|PROCEDURE|Colorectal cancer procedures|Procedures
215084279|NCT00712569|BEHAVIORAL|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
214361923|NCT01602536|BEHAVIORAL|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
214361924|NCT01602536|BEHAVIORAL|Twitter|Twitter quit-smoking group
214361925|NCT01046539|DRUG|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
214361926|NCT01046539|DRUG|Placebo|0 mg
214973512|NCT06354491|DEVICE|Ultrasound (US)|In each ultrasound exam, each participant will be scanned by two sonographers to evaluate inter-operator variability. Each exam will take approximately 60 minutes to complete. The imaging series will be conducted twice to assess repeatability.
214361927|NCT06950619|GENETIC|Whole Genome Sequencing|Genetic testing will be performed to find variants in genes involving congenital cataract and/or ocular diseases (keratitis, keratoconus, corneal dystrophies, ectopia lentis, glaucoma, retinitis pigmentosa, coloboma and aniridia) and dental anomalies (tooth agenesis, supernumerary teeth, Hutchinson teeth, mulberry molars). Cutaneous appendage anomalies will be also evaluated in clinical history for ascertaining ectodermal diplasia.
214361928|NCT06950619|OTHER|Cephalometric tracing|Cephalometric tracing will be performed on lateral cephalometric radiographs if present and not taken on purpose for the study
214973513|NCT00731822|DRUG|GW685698/GW642444|GW685698/GW642444
214361929|NCT04514341|OTHER|Short Message Service (SMS)|Patients with FIT orders receive seven messages over 60 days to remind them to return their kits for testing. Patients with colonoscopy orders receive eight messages to remind them to schedule an appointment for a colonoscopy over 90 days. After confirming their colonoscopy appointment, the patient gets educational messages on bowel preparation.
214489277|NCT06886308|DEVICE|Repetitive trans-spinal magnetic stimulation|For repetitive trans-spinal magnetic stimulation - rTsMS (high-frequency or sham), volunteers will be positioned comfortably in a lateral decubitus position. High-frequency rTsMS will be applied with an eight-shaped coil over the tenth thoracic vertebra (10 Hz; 100 pulses per train, 20-second interval between trains; 100% resting motor threshold). For sham rTsMS, two coils will be used: (i) a coil connected to the stimulator will be placed behind the patient (away from the spine) to generate the characteristic sound, and (ii) another coil, disconnected from the stimulator, will be placed on the tenth thoracic vertebra. Both real and sham stimulation will last 20 minutes. Gait training with body weight support will be performed on a Biodex Rehabilitation treadmill for 20 minutes. Researchers will assist the patient in foot placement, knee extension, and pelvis/trunk alignment. Body weight support and treadmill speed will be adjusted based on the patient's performance.
214489278|NCT06885814|DRUG|Adebrelimab: 20mg/kg day1, Q3W, 3 times|Concurrent Chemoradiotherapy combined with Immunotherapy，including： Radiotherapy: intensity modulated radiotherapy, PGTV 50-50.4Gy/25-28F, 1.8-2Gy/F, 5 times a week; Chemotherapy: paclitaxel 50mg/ m2 + cisplatin 25mg/ m2, intravenous infusion of day1, once a week, a total of 5 times; Adebrelimab: 20mg/kg day1, Q3W, 3 times.
214973514|NCT04585919|BEHAVIORAL|Paired Screening Intervention|The intervention is the implementation of a paired outreach strategy to patients in need of colorectal cancer screening to offer FIT testing and to complete screening for social determinants of health. These screening activities are part of routine practice but the intervention that is being implemented is the paired outreach for both CRC screening and SDOH screening.
214973515|NCT02551458|OTHER|Systematic surgery|
214973516|NCT02551458|OTHER|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
214973517|NCT02432599|RADIATION|F18-choline PET examination|F18-choline PET examination will be performed before surgery
214973518|NCT06211400|OTHER|Whole body vibration exercise|6-week supervised whole body vibration exercise programme (training sessions three times per week lasting 10 min) alongside a lifestyle education programme
214973519|NCT00137553|DRUG|Sulfadoxine-pyrimethamine (Fansidar)|
214679528|NCT04756089|OTHER|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
214679529|NCT01203462|OTHER|Probiotic strain of Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
214679530|NCT01203462|OTHER|No Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
214679531|NCT00493389|DRUG|Adrenocorticotrophic hormone|
214973520|NCT05294952|GENETIC|real time PCR|diagnostic test
214973521|NCT03602105|BEHAVIORAL|Exercise|Exercises in group and/or individually
214361930|NCT04514341|OTHER|Remote Patient Navigation|Patient navigators at our partner FQHCs called patients who received a screening order for more than 60 days but failed to complete it or who had a positive stool-based test and needed a follow-up diagnostic colonoscopy.
214361931|NCT04295005|DRUG|Empagliflozin|film coated tablet
214361932|NCT04295005|DRUG|DPP-4i|film coated tablets, specifically Sitagliptin
214361933|NCT04295005|DRUG|GLP-1-RA|subcutaneous injection or tablet
214489279|NCT06749730|DRUG|Adebrelimab|adepelizumab ,1200mg, q3w
214489280|NCT06749730|DRUG|Apatinib|apatinib，250mg，QD
214489281|NCT06749730|DRUG|gemcitabine and cisplatin|cisplatin 25mg/m2，gemcitabine 1000mg/m2 d1,d8，q3w
214489282|NCT06751459|DEVICE|MEMO Patch 2 - 14-day Monitoring|A wearable ECG monitoring device used for continuous 14-day monitoring to detect atrial arrhythmias during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to assess early recurrence of atrial arrhythmias.
214679532|NCT00695994|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
214973522|NCT05218187|DEVICE|G-EO End-Effector Gait Trainer|The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.
214361934|NCT01128803|PROCEDURE|injection of the cell therapy product|Between D-15 and D-30: Cytapheresis D0: 1st injection of the cell therapy product D21: 2nd injection of the cell therapy product D42: 3rd injection of the cell therapy product and 1 injection of dendritic cells not loaded D45: cutaneous biopsies if induration \> 2mm
214361935|NCT06176261|DRUG|Datopotamab Deruxtecan|Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.
214361936|NCT06234293|DEVICE|near-infrared light device|Nurses will have to find the vein for the PIVC using the near-infrared light device.
214361937|NCT00596843|BEHAVIORAL|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
214361938|NCT00596843|BEHAVIORAL|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
214361939|NCT01834755|OTHER|Evaluation of psychological phenotype|
214361940|NCT02647606|PROCEDURE|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
214361941|NCT02647606|DEVICE|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
214361942|NCT02647606|DEVICE|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
214489283|NCT06751459|DEVICE|MEMO Patch 2 - 1-day Monitoring|A wearable ECG monitoring device used for 1-day monitoring during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to detect early recurrence of atrial arrhythmias.
214489284|NCT06751459|DEVICE|MEMO Link|A supplementary ECG monitoring device used alongside MEMO Patch 2 during the 1st monitoring session.
214489285|NCT05098847|DRUG|Sintilimab|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
214489286|NCT05098847|DRUG|Lenvatinib|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214489287|NCT05098847|DRUG|Cryoablation|Cryoablation treatment starts at day 0. Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
214973523|NCT05218187|OTHER|Conventional Physical Therapy Treatment|Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking
214973524|NCT04276441|DEVICE|Heart healthy Engagement Program with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.
214973525|NCT04276441|DEVICE|Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.
214361943|NCT02647606|DEVICE|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
214361944|NCT00400907|OTHER|clinical observation|
214361945|NCT00400907|PROCEDURE|management of therapy complications|
214361946|NCT03912493|DEVICE|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
214361947|NCT03912493|OTHER|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
214361948|NCT02614495|DRUG|Surufatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
214361951|NCT02295839|BEHAVIORAL|Sleep Hygiene and Relaxation Education|Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
214361952|NCT03350568|OTHER|Total dietary NEAC assessed at baseline|
214361953|NCT02559336|OTHER|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
214361954|NCT03751631|DRUG|Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)|Fixed combination tropicamide 1%-phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
214361955|NCT03751631|DRUG|Tropicamide 1% ophthalmic solution (TR)|Tropicamide 1% ophthalmic solution administered with the Optejet microdose dispenser
214361956|NCT03751631|DRUG|Phenylephrine 2.5% ophthalmic solution (PE)|Phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
214361957|NCT02937961|BIOLOGICAL|Early SLED|withing 6 to 12 hours
214361958|NCT02937961|BIOLOGICAL|Late SLED|when absolute indications will meet
214361959|NCT00140504|OTHER|Medcheck message|Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
214361960|NCT00428090|DRUG|Rosiglitazone|XR (extended release) oral tablets
214361961|NCT04818294|DEVICE|Pain treatment by electrostatic charge to the whole body|"Study Type is Observational as participants in the study receive therapeutic interventions in the therapy cabin as part of routine medical care and a researcher studies the effect of the intervention.~The study includes all persons who are already receiving therapy in the mentioned facilities, no external, specifically selected persons, but existing patients suffering from chronic pain who meet the specified conditions.~The therapy aims to alleviate chronic pain by applying an electrostatic charge of 50'000 Volt to the whole body in the special, electrically insulated cabin. The treatment is done upon the instructions of a physician. It is done with the patient standing up in the treatment cabin. The person is charged and discharged several times over the course of 2x 4 minutes. The charge can be felt on the skin and it can be seen through bristling of the hairs on the body. This treatment is repeated once a week."
214489288|NCT06894550|BEHAVIORAL|Participants will be escorted to high altitude and undergo a series of test|"Participants will be escorted to high altitude and undergo the following examination both at 540 and 3545m above sea level:~* 12-lead electrocardiogram~* Transthoracic echocardiography with measurement of left and right ventricular dimension and function, global longitudinal strain and transvalvular gradient~* Symptom-limited cardiopulmonary stress exercise test with a ramp protocol with a focused echocardiography for the assessment of cardiac output and transvalvular gradient and blood gas analysis~* 24 hours wearable rhythm monitoring~* Blood Work: cardiac biomarkers (Troponin T, CK, CK-MB, NT-pro-BNP), blood gas analysis, Hemoglobin, Hematocrit, Leucocytes, Thrombocytes, Creatinin, eGFR, Sodium, Potassium, ASAT, ALAT, Bilirubin)"
214489289|NCT06742229|DEVICE|Research Ultrasound scan|Both the study groups will be asked to undergo a research scan performed by an FDA approved ultrasound device
214973526|NCT06290089|OTHER|Enterotoxigenic E. coli (ETEC) strain|Challenge strain
214973527|NCT06475365|OTHER|Sodium chloride gargle|15mL salt water gargle
214361962|NCT02159131|DRUG|Ethinyl Estadiol|EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
214361963|NCT02159131|DRUG|Levonorgestrel|LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
214361964|NCT02159131|DRUG|GSK1265744|GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
214361965|NCT01034267|DRUG|F2695 SR|Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
214361966|NCT04051268|BIOLOGICAL|Vi-DT Typhoid Conjugate Vaccine|1 dose of Investigational Product
214361967|NCT04051268|BIOLOGICAL|PQed Typhoid Conjugate Vaccine|1 dose of Active Comparator
214361968|NCT04051268|BIOLOGICAL|Vi Polysaccharide Vaccine|1 dose of Active Comparator
214361969|NCT00003780|BIOLOGICAL|tumor infiltrating lymphocyte therapy|
214361970|NCT00003780|DRUG|gemcitabine hydrochloride|
214361971|NCT03255824|DRUG|Dexmedetomidine and Midazolam|Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery.
214361972|NCT03255824|DRUG|Propofol, Midazolam, and Fentanyl|Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
214361973|NCT01168193|OTHER|No intervention|
214361974|NCT03967431|OTHER|Narrative Enhancement and Cognitive Therapy (NECT)|Narrative Enhancement and Cognitive Therapy includes two introduction meetings, three psychoeducation meetings, seven cognitive restructuring meetings, seven narrative enhancement meetings and one summing up meeting.
214489290|NCT06742775|OTHER|physiological signal acquisitions|"Subjects will be fitted with non-intrusive devices. In a semi-recumbent position, they will be asked to perform~* 10 minutes of resting breathing~* 10 cycles consisting of a 20-second apnea, to be performed at the end of inspiration, and 1 minute 40 of breathing (100 seconds).~This single participation session will last a total of one hour for the volunteer (equipment, recording, de-equipping), including 30 minutes of acquisition."
214489291|NCT06742567|DRUG|Apixaban 2.5 MG PO BID|Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT.
214489292|NCT06742567|DRUG|Control (Standard treatment)|DAPT plus guideline directed medical therapy
214489293|NCT06744894|DRUG|Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy|Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.
214489294|NCT06741826|PROCEDURE|Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.|Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.
214489295|NCT06821711|OTHER|Intensive LDL-C control|"By Statin, Ezetimibe, or PCSK9i, prescribed according to LDL-C level at baseline and follow-up;~For patients with baseline LDL-C level \< 3.0 mmol/L, it is recommended to start lipid control by statin + PCSK9i; for LDL-C level ≥ 3.0 mmol/L, statin + ezetimibe + PCSK9i"
214489296|NCT06821711|OTHER|Conventional LDL-C control|"By Statin, Ezetimibe, or PCSK9i, prescribed according to LDL-C level at baseline and follow-up;~For patients with baseline LDL-C level \< 3.0 mmol/L, it is recommended to start lipid control by statin alone or statin + ezetimibe; for LDL-C level ≥ 3.0 mmol/L, statin + PCSK9i"
214489297|NCT06752928|DEVICE|Dexcom G7 rtCGM|The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 CGM System or G7) is a glucose monitoring system that continuously measures glucose in the interstitial fluid. It aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments
214489298|NCT06752928|DIAGNOSTIC_TEST|Capillary Blood glucose Testing (POC)|POC glucose meters measure whole blood and convert the results to plasma glucose concentrations, which is the standardized form used in clinical practice.
214489299|NCT06753656|PROCEDURE|Open Surgery|Open surgery technique: A longitudinal incision is made over the lateral malleolus, followed by sharp dissection down to the bone. The fracture is reduced under direct visualization and fixed with a plate and screws.
214679533|NCT00695994|DRUG|gemcitabine and carboplatin|"Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion."
214679534|NCT03634046|PROCEDURE|Percutaneous transforaminal endoscopic discectomy|The same as the descriptions in experimental group.
214679535|NCT03634046|PROCEDURE|Radiofrequency ablation|The same as the descriptions in active comparator group.
214679536|NCT02213757|DRUG|Premarin vaginal estrogen cream|
214679537|NCT02213757|DRUG|Placebo vaginal cream|Inactive vaginal cream manufactured to mimic Premarin vaginal cream
214679538|NCT05197244|BEHAVIORAL|Culinary Medicine Intervention|A 2-hour practical culinary medicine program facilitated by a culinary dietitian at a hospital-based teaching kitchen, followed by 3 virtual group follow-up sessions occurring monthly, each lasting approximately 30 minutes. The follow-up sessions will be facilitated by a culinary dietitian and will be conducted using a secure telephone/video conference platform.
214361975|NCT01866943|DRUG|Tranexamic Acid|Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
214361976|NCT01866943|DRUG|Normal Saline Solution|
214361977|NCT03288610|DIAGNOSTIC_TEST|Preoperative copeptin level|Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
214361978|NCT00687999|DRUG|pegylated interferon alpha and ribavirin|standard pegylated interferon alpha and ribavirin
214361979|NCT05360082|OTHER|[11C]UCB-J PET|11C-labeled SV2A binding PET radioligand
214361980|NCT05360082|OTHER|[18F]SynVest-1 PET|18F-labeled SV2A binding PET radioligand
214361981|NCT00863655|DRUG|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
214361982|NCT00863655|DRUG|Exemestane|Exemestane 25 mg orally daily.
214361983|NCT00863655|DRUG|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
214361984|NCT02976441|RADIATION|Radiation therapy|
214361985|NCT02976441|DRUG|Temozolomide|
214361986|NCT02976441|PROCEDURE|Stem cell collection|
214361987|NCT02976441|PROCEDURE|Stem cell infusion|
214361988|NCT03211364|OTHER|Glenohumeral mobilization|Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.
214361989|NCT03211364|OTHER|Scapular mobilization|
214361990|NCT02157779|BEHAVIORAL|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
214973528|NCT06641102|OTHER|Self-Guided Program (Tier 1)|"The study intervention is a smartphone application.~Tier 1: self-guided program, includes videos, guided meditations, and worksheets that are delivered to users in 10 different topical modules. Two modules are delivered per week, with email reminders. It will emphasize that PRT is a practice that requires users to come back to the material regularly to help retrain the brain often (just like how you need to practice and complete exercises between PT sessions)."
214361991|NCT02157779|BEHAVIORAL|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
214361992|NCT02445313|DEVICE|Nidek MP-3|Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
214361993|NCT04351503|OTHER|Study A|Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed. For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.
214361994|NCT04351503|OTHER|Study B|Study B: collection of epidemiological surveillance data to describe the epidemiology of the SARS-CoV-2 outbreak. The epidemic transmission of Influenza viruses in the City of Basel serves as an important reference to identify similarities and differences to the pandemic SARS-CoV-2 situation. In addition data collected during the Influenza projects - in particular data on statistical blocks of the city, e.g. population density, income and living space will be re-used. Already collected and stored samples such as serum and respiratory material (leftover material) will be (re-) used.
214361995|NCT04351503|OTHER|Study C|Study C: data collection for viral evolution. Respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution. No additional material will be collected.
214361996|NCT04351503|OTHER|Study D|"Study D: collection of safety and efficacy data of different treatment modalities. Currently the following treatments are considered as part of the treatment:~1. Lopinavir/Ritonavir~2. Hydroxychloroquine~3. Tocilizumab~4. Eculizumab~5. Ruxolitinib~6. Remdesivir~7. Treatment with convalescent plasma blood count, blood chemistry and pulmonary function test (collected on a routine basis during hospitalization and in the outpatient setting)."
214361997|NCT02855307|OTHER|60-minute exercise|Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
214361998|NCT02855307|DEVICE|Insulin pump|Patient's insulin pump will be used to infuse insulin.
214361999|NCT02855307|DEVICE|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
214362000|NCT02855307|DRUG|Insulin|Patient's usual fast-acting insulin analog will be used.
214362001|NCT02855307|OTHER|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
214362002|NCT01930357|BIOLOGICAL|Purified Vero Rabies Vaccine Serum Free (VRVg)|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
214362003|NCT01930357|BIOLOGICAL|Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
214362004|NCT05801211|PROCEDURE|primary tumor resection|"primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)"
214362005|NCT04000841|BEHAVIORAL|Mindful You mobile app|"The CRSR intervention consists of a native mobile application for Android and iOS devices. The mobile app includes:~* Guided meditations of varying length designed to connect the user to the present moment and a place of calm through culturally aligned exercises grounded in spirituality, orality, self-empowerment, and resilience.~* User-customized notifications prompting users to reflect and engage with the app, such as providing African American proverbs and quotes and asking simple questions like What are you grateful for today?~* Scheduled messages on the importance mindfulness as a way increase control over physical and psychological health~* User-customized reminders to do specific meditations and display personally selected images or messages."
214362006|NCT01826227|PROCEDURE|Positron Emission Tomography|
214362007|NCT01826227|RADIATION|18F-Fluoro-2-deoxy-D-lucose|
214362008|NCT01826227|PROCEDURE|Cytoreductive surgery|
214362009|NCT05287555|OTHER|Telemonitoring Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, SpO2 sensor and modems.
214362010|NCT05287555|OTHER|Standard Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, and modems
214362011|NCT03294330|DRUG|IC-Green KIT|fluorescence lymphangiography with the use of IC-Green
214362012|NCT00430248|DRUG|Febuxostat|Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
214362013|NCT00430248|DRUG|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
214362014|NCT00430248|DRUG|Allopurinol|"Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.~Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily."
214362015|NCT00002402|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
214973529|NCT06641102|OTHER|Coach Assisted Program (Tier 3)|"The study intervention is a smartphone application.~Tier 3: one-on-one coaching program that sets users up with trained PRT coaches who will walk them through the program individually. Users will meet with the assigned coaches once per week for an hour-long Zoom-hosted session that covers the same information as Tier 1, however in a completely personal and individualized way, focusing on the content that is most relevant for the user/patient at the time of the session. Tier 3 users will also receive materials from their coaches (e.g. videos, meditations, etc.) to support their own practice between session."
214362016|NCT00002402|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
214362017|NCT00002402|BIOLOGICAL|Aluminum hydroxide|
214973530|NCT06641102|OTHER|Standard of Care (SOC)|SOC is defined as a comprehensive clinical care plan, including a consultation with physiatrist and prescribed interventions, which will capture a comparison representative of all potential interventions that are recommended for an individual.
214973531|NCT04089046|BEHAVIORAL|TEAM-UP for Teens|TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
214973532|NCT04089046|BEHAVIORAL|Enhanced Care (EC)|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
214973533|NCT05879458|DRUG|Ritlecitinib|200 mg QD for 8 weeks followed by 100 mg for 16 weeks
214973534|NCT05549622|OTHER|Low-soluble fiber diet|12 older adults (\>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
214362018|NCT01911039|BIOLOGICAL|Regulatory T Cells|
214362019|NCT06532318|BIOLOGICAL|Platelet rich plasma|Freshly prepared autologus platelet rich plasma
214362020|NCT06532318|DRUG|Pfizer Depo-medrol|Methylprednisolone acetate 20mg/ml injection
214362021|NCT05892315|PROCEDURE|Repeated subgingival instrumentation|Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
214362022|NCT05892315|PROCEDURE|Supragingival scaling|Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
214362023|NCT05775588|PROCEDURE|Lung volume reduction surgery with endobronchial valve implantation|the patient would undergo Lung volume reduction surgery with endobronchial valve implantation
214362024|NCT02813187|BIOLOGICAL|cellular and tissue based therapy|
214362025|NCT02813187|PROCEDURE|debridement|
214362026|NCT02813187|PROCEDURE|advanced wound therapy|
214362027|NCT02813187|DIETARY_SUPPLEMENT|Nutritional screening|
214362028|NCT06491771|DEVICE|TargetCool|The patients were treated with TargetCool via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week
214362029|NCT02249819|DEVICE|transcranial direct current stimulation|Soterix 1x1 anodal tDCS
214362030|NCT05849779|DRUG|Inhaled sedation with sevoflurane|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
214362031|NCT05849779|DRUG|Intravenous sedation (current practice)|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
214362032|NCT04769726|DIETARY_SUPPLEMENT|almonds|almond intervention (20 g) before three major meals (60g per day) for 3 days in subacute phase, before OGTT in the acute phase ad for 3 months in chronic phase
214362033|NCT06468774|PROCEDURE|Laparoscopic surgery|"The patients in the MALS group will be treated through transperitoneal ventral approach for the laparoscopic release of the celiac artery. Median arcuate ligament and any muscle or nerve tissue crossing the cranial surface of the celiac artery will be divided to release the celiac artery from compression.~In the patients with CMI open antegrade or retrograde bypass to celiac artery or superior mesenteric artery or both will be performed.~For operative treatment will be performed in general anaethesia whereas the endovacular treatment with PTA with stent for CMI will be performed in local anaethesia."
214362034|NCT00002558|BIOLOGICAL|filgrastim|
214362035|NCT00002558|DRUG|carboplatin|
214362036|NCT00002558|DRUG|etoposide|
214362037|NCT00002558|DRUG|ifosfamide|
214362038|NCT00002558|DRUG|paclitaxel|
214362039|NCT00002558|PROCEDURE|peripheral blood stem cell transplantation|
214362040|NCT02295514|BIOLOGICAL|PTP1B dosage|PTP1B sampled and dosed during sepsis
214679539|NCT01175239|GENETIC|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
214973535|NCT05549622|OTHER|High-soluble fiber diet|12 older adults (\>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
214973536|NCT02511327|DRUG|Infant pertussis vaccination|Infants receive pertussis vaccines according to the national recommended schedule
214362041|NCT06038760|PROCEDURE|Resection|Patients undergo a resection from a lesion, and give 40mL of blood
214489300|NCT06753656|PROCEDURE|Minimally Invasive Surgery|Closed surgery technique: A 2-3 cm longitudinal incision is made distal to the lateral malleolus to allow for plate placement. A periosteal elevator is used to create a pathway for the plate. The fracture is reduced in a closed manner using reduction clamps, and the plate position is confirmed fluoroscopically. A second longitudinal incision is made proximal to the fracture, and the plate is temporarily fixed with Kirschner wires. The plate is then used as an external guide, with screws placed through mini-incisions. The fracture is fixed with the plate-screw system in a minimally invasive manner.
214489301|NCT06769620|DRUG|ORT247|ORT247 will be provided to study sites in single-use, sterile vials for infusion. Each dose will be prepared with normal saline for infusion.
214489302|NCT06769620|DRUG|Placebo|Placebo consists of normal saline
214489303|NCT06763822|BEHAVIORAL|close eyes|ask participants to close their eyes for rest
214489304|NCT06763822|BEHAVIORAL|cold compress|cold compress on participants' eyes for rest
214489305|NCT06768931|OTHER|Biolosion (oral probiotic compound preparation)|Biolosion (oral probiotic compound preparation) will be administered in the experimental arm. Biolosion will be taken every night from day 1 to day 21 after each cycle of immunotherapy-chemotherapy.
214489306|NCT06758726|DRUG|Mitoxantrone Hydrochloride Liposome combined with BU/Cy|Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day -9, iv Busulfan (3.2mg/kg/d) on day -7\~-5, iv Cyclophosphamide (60 mg/kg/d) on day -3\~-2, iv
214489307|NCT06764251|DRUG|Tislelizumab + SOX|tislelizumab combined with SOX
214489308|NCT06772545|PROCEDURE|Epidural Analgesia|Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.
214489309|NCT06772545|DEVICE|Paravertebral Block|Using an in-plane technique, the puncture needle was advanced from lateral to medial under real-time ultrasound guidance to the target paravertebral space, passing through the intercostal fascia, avoiding the parietal pleura, and positioning the needle tip superior to the costotransverse ligament. After confirming needle tip placement, 10 mL of 0.5% ropivacaine was slowly injected in divided doses, observing for the spread of the local anesthetic to ensure adequate distribution within the PVS for effective block.
214489310|NCT06772545|DEVICE|Transversus Abdominis Plane Block|The plane of blockade and whether to perform a single or double injection technique were determined based on the incision location. Under real-time ultrasound guidance, the puncture needle was advanced to the target transversus abdominis plane. After confirming needle tip placement, 10 mL of 0.5% ropivacaine was injected slowly in a fractionated manner while observing the local anesthetic spread to ensure effective blockade.
214489311|NCT06772545|DEVICE|patient-controlled intravenous analgesia (PCA)|The patient-controlled analgesia (PCA) device was programmed to deliver bolus doses of 15 μg fentanyl, with a 10-minute lockout period and no background infusion. The PCA solution consisted of 1 mg fentanyl and 8 mg of tropisetron mixed in 100 mL of normal saline.
214489312|NCT06772883|BEHAVIORAL|sexual education and counseling|The women included in the Working Group were contacted by phone and invited to the hospital. Sexual education and counseling were provided in accordance with the PLISSIT model. A total of 5 interviews were conducted with the women, the first face-to-face interview and the subsequent ones by telephone. FSFI assessments in the study FSFI assessments were performed 5 times (initial, 1st, 3rd, 6th months and 1 year later). According to the PLISSIT model, their sexuality and any problems since the previous assessment were discussed and a short counseling was given if necessary.
214489313|NCT06772883|OTHER|control group|routine clinical care
214489314|NCT06773728|DEVICE|Record occlusal contacts|Register using a digital device (t-scan) the occlusal contacts
214679540|NCT04665544|PROCEDURE|SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.|"The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).~The null hypothesis is that the detectionrate does not differ between the two techniques."
214679541|NCT03865069|OTHER|Mode of ventilation (Volume Guarantee)®|This is a volume-targeted mode of ventilation aimed at delivering the set tidal volume of gas by automatically adjusting the peak inspiratory pressure (PIP) on a breath-by-breath basis. Theoretically this should minimise variation in tidal volume delivery as lung compliance and the infant's condition changes. This function is achieved by an automated servo-controlled mechanism. The upper PIP limit can be set by the clinician as a safety mechanism.
214973537|NCT05186129|DRUG|Clopid® 75 mg Tablet|Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
214973538|NCT05186129|DRUG|Plavix® 75mg Tablet|Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
214973539|NCT05669118|PROCEDURE|Tooth Autotransplantation|Place another tooth in the place of the newly extracted tooth in the same patient.
214973540|NCT05669118|PROCEDURE|Immediate implant|Place a dental implant immediately after tooth extraction.
214362042|NCT04085848|OTHER|music therapy|4 music therapy sessions during a period of time of 48 hours. Each session lasts 30 minutes.
214362043|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 5 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
214362044|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 10 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
214362045|NCT05538624|DRUG|AVB-001 (Dose Escalation Phase)|One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).
214362046|NCT05538624|DRUG|AVB-001 (Dose Expansion Phase)|The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.
214362047|NCT04989959|DRUG|[18F]PT2385|\[18F\]PT2385 infusion
214973541|NCT02127658|OTHER|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
214679542|NCT03865069|OTHER|Mode of ventilation (Volume control Ventilation)|Volume-Controlled ventilation (VCV) is a type of 'volume targeted' mode. It aims to target be supported the desired tidal volume by delivering a set volume (chosen by the clinician) irrespective of the underlying lung mechanics. The ventilator will generate whatever peak inspiratory pressure is necessary to deliver this volume. There is constant inspiratory flow pattern (a square flow waveform) and peak volume and inspiratory pressure delivery are achieved at the end of inspiration. During the 'control period' of 12 hours without VG, infants will using VCV A/C (assist control) as is our current clinical standard.
214679543|NCT00751881|DRUG|Placebo|"Film-coated tablet~Oral administration"
214679544|NCT00751881|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
215094437|NCT04022018|RADIATION|no adaptive radiotherapy|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
214362048|NCT04989959|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after \[18F\]PT2385 infusion
214362049|NCT04989959|PROCEDURE|Biopsy|CT-guided tumor biopsy
214679545|NCT02812030|OTHER|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
214679546|NCT01950884|DRUG|Ezetimibe|Ezetimibe tablets
214973542|NCT02127658|OTHER|Sodium Hypochlorite|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
214973543|NCT02127658|DRUG|Mupirocin ointment|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
214362050|NCT02362529|DRUG|Minocycline|50 mg and 100 mg capsule, oral administration
214362051|NCT02362529|DRUG|Placebo|Lactose monohydrate in identical gel capsules to minocycline, oral administration.
214362052|NCT02362529|DRUG|Celecoxib|100 mg and 200 mg capsules, oral administration.
214362053|NCT00447148|PROCEDURE|3-dimensional coronary angiography|3-dimensional coronary angiography
214362054|NCT02166424|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
214362055|NCT02166424|DIETARY_SUPPLEMENT|Olive oil|
214362056|NCT02660710|DRUG|R-CHOP|maximum of 6-8 cycles of R-CHOP over 18-24 weeks
214362057|NCT05214274|OTHER|No intervention would be taken|No intervention would be taken
214362058|NCT02045394|OTHER|Chest X-ray|
214362059|NCT02045394|OTHER|computed tomography of the chest|
214362060|NCT02045394|PROCEDURE|Bronchoscopy|In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
214679547|NCT01950884|BEHAVIORAL|Lifestyle|lifestyle
214679548|NCT00370656|DRUG|Pregabalin|capsule, 150mg bd, 300mg bd
214679549|NCT00370656|DRUG|Duloxetine|Capsule, 60mg on, 60mg bd
214679550|NCT00370656|DRUG|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
214679551|NCT03798561|DRUG|ASN008 TG|ASN008 TG
214679552|NCT03798561|DRUG|Placebo TG|Placebo TG
214679553|NCT06022679|OTHER|CBCT|CBCT examination in supine position A computerized 3D-analysis using Dolphin Imaging 11.95 software was performed in each CBCT.
214679554|NCT00890968|DRUG|Triamcinolone Acetonide (TAC) DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
214679555|NCT00890968|DRUG|Placebo DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
214679556|NCT00707018|DEVICE|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
214973544|NCT04741438|DRUG|Nivolumab and IPILIMUMAB|"The combination of Nivolumab+Ipilimumab will be given to patients as follows:~* Nivolumab: 3 mg/kg IV over 30 minutes every 2 weeks for 4 cycles.~* Ipilimumab 1 mg/kg IV over 60 minutes every 6 weeks for 4 cycles. After completion of 4 courses with ipilimumab, patients continue receiving nivolumab IV at the dose of 480 mg Q4W in the absence of disease progression or unacceptable toxicity for a maximum of 18 months.~Nota Bene: A cycle is defined as a 6-weeks period.~The planned treatment period is 24 months~Nivolumab and Ipilimumab must be injected the same day every 6 weeks (Q6W). In case of toxicity, dose will be delayed, but will not be reduced."
214973545|NCT04741438|DRUG|Pazopanib Oral Tablet [Votrient]|"Treatment by pazopanib 800 mg/day per os, continuously during a maximum 24 months.~In case of toxicity, dose will be delayed and reduced."
214973546|NCT02539069|DEVICE|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
214973547|NCT06200935|DIETARY_SUPPLEMENT|Probiotic blend|Administration of one stick of combined probiotics per day for 5 months
214973548|NCT02558049|OTHER|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
215094438|NCT00710385|DRUG|Heroin|Heroin (25 mg)
215094439|NCT00710385|DRUG|Naloxone|.4 mg
215094440|NCT00710385|DRUG|Low Bup Dose|4 and 8 mg
215094441|NCT00710385|DRUG|High Bup Dose|8mg and 16 mg
215094442|NCT00710385|DRUG|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
214362061|NCT02979938|OTHER|Semen analysis and semen PCR for Zika virus|Every two weeks subjects provide a semen sample which is analysed and then frozen for RT-PCR and viral load. Semen sample testing for the presence of ZIKV (Institute of Tropical Medicine, Belgium) will be performed using both a ZIKV-specific, in-house duplex real-time RT-PCR, targeting a 102bp and 121bp sequence of the NS5 gene and the RealStar® Zika Virus RT-PCR Kit (Altona). Quantitative viral load RNA measurements will be expressed utilizing threshold cycle values because a standardized viral load reference method is not available. To test for infectivity of ZIKV in semen, ZIKV isolation will be attempted in semen samples with a high viral ZIKV load (i.e. positive ZIKV PCR result and Ct-values below 30) by inoculation in Vero cells.
214362062|NCT01754467|BEHAVIORAL|NEAT!|Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
214362063|NCT02065336|DRUG|ARC-520|
214362064|NCT02065336|DRUG|Placebo|
214362065|NCT02065336|DRUG|entecavir|
214362066|NCT02065336|DRUG|chlorpheniramine|In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
214362067|NCT05418036|DRUG|Sotalol Oral Tablet|Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
214489315|NCT06773728|DEVICE|Tracking of jaw movement|An optical jaw tracking system (Modjaw, Modjaw) is going to be implemented
214362068|NCT03118583|DIETARY_SUPPLEMENT|300 mg/day of dietary supplement containing carrageenan|300 mg/day of dietary supplement containing carrageenan.
214489316|NCT06773728|DEVICE|Tracking of jaw movement|Jaw tracking will be performed using an optical jaw tracking system (Zebris, Zebris medical)
214489317|NCT06764173|OTHER|Oat drink|6 dl of oat drink daily
214489318|NCT06764173|OTHER|Cow's milk|6 dl of cow's milk daily
214489319|NCT06775145|DEVICE|HD-R_cDC+cTBS & sham-L_aDC+iTBS|HD-tES inhibitory waveform (cDC+cTBS) applied to the right dorsolateral prefrontal cortex (DLPFC) for 10 minutes, followed by sham excitatory waveform (aDC+iTBS) stimulation applied to the left DLPFC for 10 minutes.
214489320|NCT06775145|DEVICE|sham-R_cDC+cTBS & HD-L_aDC+iTBS|Sham inhibitory waveform (cDC+cTBS) stimulation applied to the right DLPFC for 10 minutes, followed by HD-tES excitatory waveform (aDC+iTBS) applied to the left DLPFC for 10 minutes.
214489321|NCT06775145|DEVICE|HD-R_cDC+cTBS & HD-L_aDC+iTBS|HD-tES inhibitory waveform (cDC+cTBS) applied to the right DLPFC for 10 minutes, followed by HD-tES excitatory waveform (aDC+iTBS) applied to the left DLPFC for 10 minutes.
214489322|NCT06775145|DEVICE|sham-R_cDC+cTBS & sham-L_aDC+iTBS|Sham inhibitory waveform (cDC+cTBS) stimulation applied to the right DLPFC for 10 minutes, followed by sham excitatory waveform (aDC+iTBS) stimulation applied to the left DLPFC for 10 minutes.
214489323|NCT06771518|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy using 4D technique by irradiating the initial sites of disease (primary tumor and involved hilo-mediastinal lymph nodes). The treatments must be provided with the modulated intensity technique (IMRT or VMAT), treatments with conformal technique (3DCRT) are not permitted, where necessary, the Simultaneous Integrated Boost (SIB) technique can be used.
214362069|NCT03078348|OTHER|Fecal Immunochemical Test (FIT) Kit|Free FIT Kits distributed at study entry.
214362070|NCT03078348|BEHAVIORAL|Culturally targeted Photo Novella Booklet|Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
214362071|NCT03078348|BEHAVIORAL|Screen for Life Brochure|Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
214489324|NCT06771518|DRUG|Atezolizumab 1200 mg e.v. q21|Radiotherapy treatment associated with Atezolizumab 1200 mg i.v. q21 administered according to clinical practice
214489325|NCT06771362|PROCEDURE|ART with Bulk-Fill composite|Restoration using Bulk-fill flowable self-cured composite
214362072|NCT03657433|DIETARY_SUPPLEMENT|Ferrous sulfate 325mg|Oral tablets supplied for home use
214362073|NCT03657433|DRUG|Ferumoxytol|Ferumoxytol will be administered in two infusions, one week apart
214489326|NCT06771362|PROCEDURE|ART with Glass Ionomer|Restoration Using High-Viscosity Glass Ionomer Cement
214362074|NCT01970462|DRUG|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
214489327|NCT06831331|OTHER|REK-diet|Personalized diet- the participants will get individual advice how to adapt their habitual diet to the Nordic Nutrition Recommendations 2023
214489328|NCT06831331|OTHER|RICH-diet|Diet rich in nutrients and with high quality protein
214679557|NCT00707018|DEVICE|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
214679558|NCT01065129|DRUG|G-CSF|
214362075|NCT01970462|DRUG|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
214679559|NCT01065129|DRUG|Plerixafor|
214679560|NCT01065129|DRUG|Azacitidine|
214679561|NCT05679726|BEHAVIORAL|massage|reflexology foot massage
214679562|NCT02119104|DRUG|Prevenar (13v)|Prevenar (13v)
214679563|NCT03870581|BEHAVIORAL|AI-based social software management model|a AI-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
214973549|NCT02824107|BIOLOGICAL|blood sample|
214973550|NCT02824107|BEHAVIORAL|questionnaires for psychosocial factors|
214973551|NCT02262780|DRUG|Low dose of telmisartan|
214973552|NCT02262780|DRUG|High dose of telmisartan|
214973553|NCT02262780|DRUG|HCTZ|
214973554|NCT02142816|DEVICE|Doppler|Fluid therapy guided by doppler
214973555|NCT02142816|OTHER|PVI'|Fluid therapy guided by PVI
215094443|NCT00710385|DRUG|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
214362076|NCT03311412|DRUG|Sym021|Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
214362077|NCT03311412|DRUG|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
214362078|NCT03311412|DRUG|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
214362079|NCT05439902|DRUG|Tamsulosin|One 0.4mg Tamsulosin capsule taken per day for 30 days
214362080|NCT05439902|DRUG|Placebo|one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose
214362081|NCT04538326|BEHAVIORAL|Exercise|Participants performed stepping movements that were either cued by the investigator or interacted with a video game. There were three video game exercises that all involved stepping in either a repeated or a random pattern that was either self-paced or game paced.
214362082|NCT04467554|DEVICE|T-chair|Participants will receive 15 sessions of intervention, four weeks in total with a duration of one hour for each session. The focus of the intervention will be trunk rehabilitation.
214362083|NCT01320007|DRUG|Preset increase in frusemide dose|"All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week."
214362084|NCT01320007|OTHER|No intervention|The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
214362085|NCT01841346|PROCEDURE|Procedure: PCI|
214362086|NCT00932776|DEVICE|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
214362087|NCT00932776|DEVICE|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
214362088|NCT03339323|OTHER|Exercise|TKA patients do the exercise intervention
215084280|NCT00712569|BEHAVIORAL|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
215084281|NCT03109262|PROCEDURE|Computed Tomography (CT)|As part of PET/CT and SPECT/CT scans.
215084282|NCT03109262|PROCEDURE|Positron Emission Tomography (PET)|As part of PET/CT scan
215084283|NCT03109262|DEVICE|90-Yttrium (Y-90) Glass Microspheres|Radiolabel for PET/CT scan
215084284|NCT03109262|DIAGNOSTIC_TEST|Technetium 99mTc albumin aggregated (99mTc-MAA)|Radiolabel for 99mTc-MAA SPECT/CT Scan
215084285|NCT03109262|PROCEDURE|Single-photon emission computerized tomography (SPECT) scan|As part of SPECT/CT scan
214362089|NCT02351804|DRUG|Ropivacaine + dexamethasone|Adductor canal block, single bolus
214362090|NCT02351804|DRUG|Ropivacaine + placebo|Adductor canal block, single bolus
214362091|NCT02753049|BEHAVIORAL|Peer led mHelath behavioral intervention|A trained peer adherence coach will schedule five, weekly-60 minute, 'ACCESS' sessions, delivered to participants via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
215084286|NCT00028431|BIOLOGICAL|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
214362092|NCT01631084|OTHER|JADE|"Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.~Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate."
214362093|NCT01631084|OTHER|DIAMOND|Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
214362094|NCT00003796|DRUG|irofulven|
214362095|NCT06015867|DIETARY_SUPPLEMENT|Dietary Intervention with Wholemeal Bread with Yeast|Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).
214362096|NCT06015867|DIETARY_SUPPLEMENT|Dietary Intervention with Wholemeal Sourdough Bread|Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.
215084287|NCT04405544|DIAGNOSTIC_TEST|CT-scan|chest CT-scan
215084288|NCT04405544|DIAGNOSTIC_TEST|EEG|Electroencephalography
214489329|NCT06056141|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
215084289|NCT04405544|DIAGNOSTIC_TEST|EP|Evoked potential
215084290|NCT04405544|DIAGNOSTIC_TEST|Pulse oximetry|Pulse oximetry
215084291|NCT04405544|DIAGNOSTIC_TEST|Blood tests|Blood tests
215084292|NCT01920763|OTHER|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
215084293|NCT02878668|PROCEDURE|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
214362097|NCT03689335|PROCEDURE|Operative|Open reduction and internal fixation, using a plate and screws (the exact surgical approach and fixation technique utilised will be at the discretion of the treating surgeon)
214362098|NCT03689335|DEVICE|Humeral brace|Immobilisation in a U-slab or hanging cast, followed by application of a lightweight prefabricated humeral brace
214362099|NCT00134550|DRUG|Atorvastatin (10 mg or 80 mg)|
214362100|NCT04042155|DRUG|dabigatran, rivaroxaban, apixaban or edoxaban|Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.
214362101|NCT06579924|PROCEDURE|Disposable mini-PCNL|Mini-PCNL carried out using disposable scope
214362102|NCT06579924|PROCEDURE|Re-usable mini-PCNL|Mini-PCNL carried out using re-usable scope
214362103|NCT00617981|DRUG|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
214362104|NCT00617981|DRUG|5% Dextrose Solution|Single 30 minute intravenous infusion
214362105|NCT02311530|DRUG|Felodipine|Extended Release Tablets, 10mg
214362106|NCT02311530|DRUG|Felodipine (Plendil®)|
214362107|NCT02281669|DRUG|Pentostam|Intralesional injection of Pentostam
214362108|NCT05039372|BEHAVIORAL|TRAINING AND CONSULTANCY|TRAINING AND CONSULTANCY
214679564|NCT03870581|BEHAVIORAL|Human-based social software management model|a Human-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
214679565|NCT00391638|DRUG|TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
214362111|NCT04905615|OTHER|Data-driven and teacher led school based strategies.|The intervention is individualised to each school, depending on the teacher led strategies which are data-informed
214362112|NCT02316769|PROCEDURE|King Vision video laryngoscope|Patient intubated with the King Vision Video Laryngoscope
214362113|NCT02316769|PROCEDURE|McGrath MAC video laryngoscope|Intubation with the McGrath MAC video laryngoscope
214362114|NCT00578955|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
214362115|NCT00578955|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
214362116|NCT00578955|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
214489330|NCT06056141|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 20F with 30ml balloon)
214489331|NCT05346718|OTHER|Ragweed pollen, birch pollen, clean air (placebo)|Participants are exposed for 4 hours in the Fraunhofer Allergen Challenge Chamber with varying pollen concentrations of ragweed or birch pollen and once with clean air, serving as a placebo exposure.
214489332|NCT06822166|DRUG|rifampicin|rifampicin capsule，600 mg
214489333|NCT06822166|DRUG|Fluconazole|Fluconazole capsules: 400 mg for the first dose and 200 mg for the remaining doses
214489334|NCT06822166|DRUG|Omeprazole|Omeprazole enteric-coated capsules: 20 mg
214489335|NCT06822166|DRUG|midazolam|midazolam injection 0.05 mg/kg was administered intravenously
214489336|NCT06822166|DRUG|ET-26|the dose is 0.8 mg/kg, single dose, Infusion time was 60seconds ± 5seconds
214362117|NCT00122226|DRUG|Lopinavir/ritonavir + zidovudine + lamivudine|
214362118|NCT00122226|DRUG|Lopinavir/ritonavir + nevirapine|
214362119|NCT03758963|DEVICE|R:GEN Selective Retina Therapy|Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
214489337|NCT06734936|OTHER|Playing videos with sgg|Playing videos with sgg
214489338|NCT06746532|BIOLOGICAL|Intranasal breast milk|"Own-mother's fresh breast milk (within 4 hours of having been expressed), is administered intranasally to neonates with hypoxic-ischemic encephalopathy receiving therapeutic hypothermia, starting from the first day of life and continuing for 28 days.~Dose: 2 times daily, 0.4 ml in each nostril."
214489339|NCT06746103|PROCEDURE|Surgery|Surgery may be instrumented stabilization surgery alone, instrumented stabilization and decompression, or decompression surgery alone.
214489340|NCT05453851|PROCEDURE|Pancreatectomy|Undergo pancreatectomy
214973556|NCT03471052|PROCEDURE|Radiofrequency ablation (RFA)|"Ablation using the Barrx RFA System is a new technique for field ablation in the oesophagus. It has been used for eradication of diseased epithelium of all three subclasses of Barrett's oesophagus (non-dysplastic Intestinal metaplasia (IM), Low grade dysplasia (LGD) and High grade dysplasia (HGD). The BarrxTM RFA System uses ultra short pulse RF energy delivering 40Watts/cm2 power density and 12Joule/cm2 energy density, and affects the mucosa whilst preserving the submucosa.~Clinical trials have suggested that it is safe and effective for treating non-dysplastic IM, LGD and HGD in Barrett's oesophagus . Long term data show the effect to be durable over 5 years."
214973557|NCT02585869|DRUG|Gemcabene 150 mg|Blinded capsules and tablets, 150 mg, once daily, 84 days
214973558|NCT02585869|DRUG|Gemcabene 300 mg|Blinded capsules and tablets, 300 mg, once daily, 84 days
214973559|NCT02585869|DRUG|Gemcabene 600 mg|Blinded capsules and tablets, 600 mg, once daily, 84 days
214973560|NCT02585869|DRUG|Gemcabene 900 mg|Blinded capsules and tablets, 900 mg, once daily, 84 days
214973561|NCT02585869|DRUG|Placebo|Blinded capsule and tablets, once daily, 84 days
214973562|NCT03738930|BEHAVIORAL|AI based mHealth system|AI based mHealth system is used to deliver self-management contral message and health education message to make patients take notice of bleeding events after PCI.
214973563|NCT06582875|DRUG|Tirzepatide|Titrated to dose of 5 mg once weekly subcutaneous
214679566|NCT00391638|BIOLOGICAL|PEGASYS 180μg (Interféron pégylé alpha -2a)|Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
214362120|NCT04483310|BEHAVIORAL|MR therapy.|MR therapy is based on 4 steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
214362121|NCT04483310|BEHAVIORAL|breathing-distraction exercise|The control intervention is based on a breathing exercise, the patients should entail slow deep breaths, while repeatedly counting from 1-10
214362122|NCT00526643|DRUG|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
214362123|NCT00526643|DRUG|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
214362124|NCT02804087|DEVICE|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
214362125|NCT02804087|OTHER|Sham Implantation|Sham Implantation
214489341|NCT05453851|OTHER|Quality-of-Life Assessment|Ancillary studies
214489342|NCT05453851|OTHER|Treatment Planning|Undergo IV autologous islet cell transplant
214973564|NCT06582875|OTHER|Placebo|Titrated to dose of 5 mg once weekly subcutaneous
214973565|NCT04261439|DRUG|NIZ985|NIZ985 injection
214362126|NCT03888664|DRUG|gamma interferon|1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
214362127|NCT00677235|DEVICE|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
214362128|NCT00677235|PROCEDURE|PTA|Treatment of stenoses with PTA only
214362129|NCT04437238|OTHER|KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
214362130|NCT04437238|OTHER|Control - Usual care|Participants allocated to the control condition will receive care as usual.
214973566|NCT04261439|DRUG|Spartalizumab|Spartalizumab infusion
214973567|NCT04261439|DRUG|Tislelizumab|Tislelizumab infusion
214973568|NCT01443858|DRUG|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
214973569|NCT01443858|DRUG|Nicotine Patch|"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."
214973570|NCT01443858|DRUG|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
214973571|NCT06810882|DRUG|Perineural ondansetron|Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml (4 mg) ondansetron. At the same time, 15 ml saline will be injected slowly IV over 15 minutes.
214973572|NCT06810882|DRUG|Intravenous ondansetron|Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml saline. At the same time, 4 mg (2 ml) ondansetron mixed with 13 ml saline (total 15 ml) will be slowly injected IV over 15 minutes.
214973573|NCT03540264|DEVICE|Clearfil Majesty TM|Tooth wear - composite resin
214973574|NCT03540264|DEVICE|Vita-Enamic®|Tooth wear - polymer-infiltrated-ceramic-network
214973575|NCT02987296|DIETARY_SUPPLEMENT|Immunonutrition with arginine|Nutritional beverage containing supplemental arginine taken 3 times per day
214973576|NCT02987296|DIETARY_SUPPLEMENT|Immunonutrition without Arginine|Nutritional beverage without supplemental arginine taken 3 times per day
214973577|NCT01711112|DRUG|Docetaxel|Treatment will be continued until progression, unacceptable toxicity, or refusal
214973578|NCT01222000|DRUG|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
214973579|NCT01222000|DRUG|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
214973580|NCT03589807|BIOLOGICAL|A/H7N9|Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
214973581|NCT03589807|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
214973582|NCT03589807|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
214973583|NCT03589807|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
215094444|NCT00710385|DRUG|Placebo (PCB)|Placebo control administration
215084294|NCT03906656|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
214362131|NCT04550988|OTHER|feasibility study|The aim of this study is to evaluate the possibility of establishing a patient-based ultrasound monitoring of the knee (representing a target joint accessible with any hand) with a handheld device.
214362132|NCT03016767|PROCEDURE|Manual oral stimulation protocol|
214362133|NCT03521726|DRUG|Amoxicillin|Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.
214362134|NCT03521726|DRUG|Rabeprazole, Amoxicillin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
214362135|NCT01040260|OTHER|Counseling|Smoking cessation counseling
214362136|NCT01040260|BEHAVIORAL|Contingency management|Use of tangible rewards for abstinence from smoking
214362137|NCT01040260|DRUG|Nicotine patches|Nicotine patches
214362138|NCT06215014|OTHER|Isometric handgrip training|Participants will train three days per week at home for 1 month using a reliable and validated digital handgrip dynamometer (DynX, MD System, Inc., Westerville, USA) in a seated position. The isometric handgrip training protocol will consist of four sets (2 for each hand) of two-min sustained contractions starting at 30% of maximum voluntary contraction (MVC) interspersed by 1-min resting periods (a total of 12-min). All training sessions will be remotely supervised via Zoom or phone call by a research team member to ensure compliance with the exercise prescription. Before each training session, MVCs will be re-assessed over three repetitions, each separated by 30-s, to ensure an accurate exercise prescription. The highest value will be used to determine the target intensity of the session
214362139|NCT01732848|DRUG|BMS-986094/INX-08189|
214362140|NCT01732848|DRUG|Placebo matching BMS-986094/INX-08189|
214362141|NCT02753855|DRUG|Telavancin|A single dose of telavancin as a 1-hour intravenous infusion
214973584|NCT02517957|DRUG|Furoic acid loperamide hydrochloride cream|Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
214362142|NCT04759690|BEHAVIORAL|Action observation|Action observation group: The participants will first watch the conventional balance exercises with the action observation method on video for 15 minutes.After watching of conventional balance exercise for 45 minutes in 5-10 repetitions.
214362143|NCT04759690|BEHAVIORAL|Exercise group|Exercise group is the control group.TheParticipants will only do the conventional balance exercise without action observation for 45 minutes in 5-10 repetitions.
214489343|NCT06758258|DEVICE|Negative Pressure Wound Therapy|"Preparations for NPWT:~1. Impressions \& Model:~   Lower jaw impressions were taken with alginate and modified trays for optimal tissue recording.~   Dental plaster models were created.~2. Splint Fabrication \& Connection:~2mm hard splints were thermoformed and modified for vacuum. Intraoral splint fit was assessed, and soft acrylic ensured an airtight seal. The irrigation hose was connected to the splint via cyanoacrylate adhesive. 3. NPWT Application: The physiodispenser pump was operated in reverse at reduced power (10-20%). Three 1-hour NPWT sessions were performed."
214973585|NCT02517957|DRUG|Mullite ointment|Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
214973586|NCT02517957|DRUG|3% boric acid solution|3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
214973587|NCT02517957|DRUG|Zine oxide|In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
214973588|NCT01534273|DRUG|LY2886721|Administered orally.
214973589|NCT01534273|DRUG|Placebo|Administered orally.
214973590|NCT03746925|PROCEDURE|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
214973591|NCT03746925|PROCEDURE|SuperPATH|SuperPATH approach surgery to replace the hip.
214973592|NCT02357225|DRUG|Pyridostigmine Bromide|Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
214973593|NCT00891280|DRUG|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
214973594|NCT00398944|DEVICE|Evaluation of the impact of a guideline based computerized decision support system.|
214973595|NCT03586050|DEVICE|Microwave ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
215084295|NCT03906656|DEVICE|KAFO/SCO|Current knee ankle foot orthosis that the subject was wearing at baseline
215084296|NCT04094649|DEVICE|Ultrasound Vagus Nerve Stimulation (DECIMA)|This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
215084297|NCT02810938|DEVICE|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
214362144|NCT01451879|DRUG|Rituximab|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
214362145|NCT01451879|DRUG|Miglustat|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
214362146|NCT02370433|DRUG|Intravenous Neostigmine and Glycopyrrolate|
215084298|NCT05690620|BEHAVIORAL|laughter yoga|Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
214362147|NCT02370433|DRUG|Transdermal Neostigmine and Glycopyrrolate|
214362148|NCT01509781|PROCEDURE|Insertion of suction drain(s) following mastectomy|One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
214362149|NCT01509781|PROCEDURE|Adaptive skin sutures.|Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
214362150|NCT00228072|PROCEDURE|Suction-curettage|
214489344|NCT06758258|DEVICE|Sham Therapy|The same preparations will be conducted for the sham application arm, except that the peristaltic pump of the physiodispenser will remain inactive during application.
214489345|NCT06757998|PROCEDURE|Mesh|Compare between On-lay versus pre-peritoneal hernioplasty in incisional lumbar herni
214489346|NCT06757465|OTHER|Counseling education based on Watson's Theory of Human Caring|In this study, a total of 75 interviews were conducted with 25 participants in the intervention group in three sessions. During the interviews, counseling training based on Watson IBK developed by the researchers was applied. Each session lasted between 30-45 minutes per participant. The first session was conducted face-to-face, and the second and third sessions were conducted using online platforms (Zoom, Microsoft Teams, WhatsApp video call) within the scope of telehealth applications. Sessions were structured according to the individual needs of the participants and the durations were arranged flexibly when necessary. Telehealth applications provided easy access to the participants during the counseling process and supported the continuity of individual counseling services.
214489347|NCT06756867|OTHER|hand massage with violet oil|In this study, individuals receiving hemodialysis treatment will be massaged with 2% violet oil for 5-7 minutes on the hand on the non-fistula arm during the dialysis session, 3 times a week for six weeks.
214489348|NCT06756867|OTHER|hand massage with jojoba oil|Hand massage with jojoba oil for hemodialysis patients 3 times a week for 6 weeks
214489349|NCT06757829|BEHAVIORAL|inspiratory muscle training and acupucnture like transcutanoeus electrical nerve stimulation|sickle cell disease patients whose number will be 20 patients will be trained with IMT (threshold inspiratory muscle training) and treated with AC-tens. The number of sessions per week will be three sessions for IMT or AC-tens for 12 weeks. the IMT will be performed for six sets of respiratory training cycles and the set will contain 10 respiratory cycles. Also the session of AC-tens will be 45 minute on bilateral Ex-B1 acupoint. the parameters of AC-tens will be four hertz and 200 microsecond pulse duration.
214489350|NCT06757829|BEHAVIORAL|inspiratory muscle training|sickle cell disease patients whose number will be 20 patients who will trained with IMT (threshold inspiratory muscle training). The number of sessions per week will be three sessions for IMT for 12 weeks. the IMT will be performed for six sets of respiratory training cycles and the set will contain 10 respiratory cycles.
214489351|NCT06757127|OTHER|ERAS Protocol Adaptation for Emergency Laparotomy|The intervention incorporated a comprehensive quality improvement approach, including a presentation, live demonstrations, and an instructional video to support the implementation of ERAS protocols. These methods emphasized the key components outlined by the ERAS ® Society guidelines for emergency laparotomy, ensuring that participants understood the importance of each protocol step and its application in clinical practice. As part of the quality improvement initiative, efforts were made to engage key stakeholders, including local governance and healthcare authorities, to align the intervention with policy frameworks. Training materials, including videos and manuals, were reviewed by a consultant surgeon to ensure accuracy and relevance. Additionally, a consultant surgeon conducted individual demonstrations in the operating room and ward, supplemented by weekly morning meetings with nurses, anesthesiologists, residents, and doctors for one month.
214489352|NCT06757894|DRUG|Zuberitamab|375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)
214489353|NCT06757894|DRUG|Bendamustine|90 mg/m², administered on D1-2 of C1-C6
214362151|NCT04570436|DRUG|gabapentin 600 mg|participants will receive an oral dose of gabapentin 600 mg
214362152|NCT04570436|DRUG|gabapentin 1200 mg|participants will receive an oral dose of gabapentin 1200 mg
214362153|NCT04570436|DRUG|gabapentin 1800 mg|participants will receive an oral dose of gabapentin 1800 mg
214362154|NCT04570436|DRUG|diazepam 20 mg|participants will receive an oral dose of 20 mg dose of diazepam
214362155|NCT04570436|OTHER|placebo|participants will receive an oral dose of placebo
214362156|NCT01635257|OTHER|Ultrasound scan|A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
214362157|NCT04444167|BIOLOGICAL|AK104|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
215084299|NCT05690620|OTHER|Control|"The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied."
215084300|NCT04583202|OTHER|Exposure to placebo|Patients are exposed to a placebo for 4h in the Alyatec EEC
215084301|NCT04583202|OTHER|Exposure to allergen|Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
214362158|NCT04444167|DRUG|Lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months
214362159|NCT04111757|DEVICE|Technolas® TENEO 317 Model 2|LASIK eye surgery
214362160|NCT03386201|DRUG|Intravenous Methylene blue|Methylene blue fluorescence cholangiography during laparoscopic cholecystectomy
214362161|NCT00929162|DRUG|ZD4054 Zibotentan|10 mg oral tablets once daily
214362162|NCT00929162|DRUG|Paclitaxel|175mg/m2 IV on day 1 every 3 weeks
214362163|NCT00929162|DRUG|Carboplatin|Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
214362164|NCT00929162|DRUG|Placebo|matching placebo for ZD4054 10 mg
214362165|NCT00107250|DRUG|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
214362166|NCT00107250|DRUG|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
214362167|NCT00107250|DRUG|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
214362168|NCT00107250|DRUG|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
214362169|NCT04506957|DEVICE|Pulse CO-Oximetry Hemoglobin measurement transcutaneous|this is an observational Investigation, in which transcutaneous continuous hemoglobin detection using Pulse-CO-Oximetry is compared with co-oximetrically measured Hemoglobin using a blood gas analyzer device
214362170|NCT02891720|DEVICE|Proteus Sensor System|The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
214362171|NCT00762944|DEVICE|Biomet TMJ Replacement System|Total replacement of the temporomandibular joint with a Biomet TMJ Replacement System
215084302|NCT00663286|DRUG|IDP-110|Topical application for 12 weeks
215084303|NCT00663286|DRUG|Clindamycin|Topical application for 12 weeks
215084304|NCT00663286|DRUG|Benzoyl peroxide|Topical application for 12 weeks
215084305|NCT00663286|DRUG|Vehicle|Topical application for 12 weeks
215084306|NCT04819230|BEHAVIORAL|Cognitive Bias Modification|A four-week computerized attentional and interpretive bias modification protocol in which participants complete both ATT and ITT tasks twice per week, totaling to eight experimental sessions (see experimental arm for more detail.)
214362172|NCT04202939|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
214362173|NCT00489385|DRUG|Albinterferon|
214362174|NCT00489385|DRUG|Ribavirin|
214362175|NCT00489385|DRUG|Albuferon|
214362176|NCT02133534|DRUG|Atorvastatin|
214362177|NCT02495480|DEVICE|A novel disposable sheath|a new sheath will be placed on the endoscope in sheathed group
214362178|NCT01274182|BIOLOGICAL|GP2013|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
214362179|NCT01274182|BIOLOGICAL|MabThera|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
214362180|NCT01274182|BIOLOGICAL|Rituxan|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
214362181|NCT05353998|OTHER|CDS with Sleep Navigation|The Sleep Navigation program will involve 1-3 meetings between the Sleep Navigator (SN) and the participating family. Participants will also complete baseline and post-intervention assessments, and about 10 to 15 caregivers will be randomly invited to participate in an interview on the acceptability and feasibility of the program. The SN will provide: SDB and sleep health psychoeducation using Patient-Family Education handouts and videos that are currently part of usual care practices; Care coordination for scheduling of specialty care referral(s) for clinical SDB evaluation; Problem-solving for family-identified barriers to accessing specialty care; and Motivational interviewing to enhance family engagement, communication, and collaboration with the family's medical team.
214362182|NCT05353998|OTHER|CDS-only|Participants will complete baseline and post-intervention assessments. Participants will be able to follow-up with their primary care clinician as needed.
214362183|NCT02355002|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
214362184|NCT03371810|BEHAVIORAL|Bright light therapy|Mobile therapeutic light (10.000 LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419). Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.
214362185|NCT03371810|BEHAVIORAL|Physical exercise|"During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually.~Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity."
214362186|NCT04594031|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ \>1x10E6/kg)
214362187|NCT03533426|PROCEDURE|Serratus anterior plane catheter block|Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.
214362188|NCT03533426|PROCEDURE|Patient controlled analgesia|The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
214362189|NCT05569746|DRUG|INM004|Two 4 mg/kg doses of INM004, 24 h (±2 h) apart, will be assessed. Each dose will be administered as an intravenous infusion during 50 min.
214362190|NCT05569746|OTHER|SoC|Standard of care
214362191|NCT03132428|DRUG|INOmax|Nitric oxide gas for inhalation provided via mechanical ventilation or non invasive ventilation
214362192|NCT01510275|DEVICE|Combined use of RESPIVOL® and RESPILIFT®|Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
214362193|NCT01510275|DEVICE|Combined use of RESPIVOL® and RESPILIFT®|Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
215084307|NCT04819230|BEHAVIORAL|Cognitive Bias Control|A four-week computerized attentional and interpretive stimuli protocol in which participants complete both ATT-C and ITT-C tasks twice per week, totaling to eight control sessions (see placebo control arm for more detail.)
215084308|NCT01595191|OTHER|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
215084309|NCT01595191|OTHER|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
215084310|NCT04753554|DEVICE|ORI group|The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
215084311|NCT04753554|OTHER|Conventional group|In this patient group oxygenation will be managed as usual, using blood gas analysis.
215084312|NCT00343915|BIOLOGICAL|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, \& 6)
214362194|NCT03879746|DRUG|Tamsulosin|drug will be used in treatment of premature ejaculation
214362195|NCT03879746|DRUG|Paroxetine Hydrochloride|drug will be used in treatment of premature ejaculation
214362196|NCT03879746|OTHER|placebo|tablets without active substance will be given to patients suffering from premature ejaculation
214362197|NCT04020848|OTHER|Review of past medical history, clinical exam, and electroencephalogram, polysomnography and urine samples of melatonin and pupillometry.|Review of past medical history; review of paroxysmal events; identification of presence of seizures \& epilepsy \& epilepsy classification; characterization of the non-paroxysmal features; degree of paroxysmal, non-paroxysmal disability indices; Vineland II adaptive behavior scales scoring; behavioral evaluation; presence of a genetic mutation; pharmacological treatments already used; AHC paroxysmal events assessement during the time of study; patient calendar for the follow up of events, for the follow up of epileptic seizures; whether, or not, there was occurrence of a serious or potentially life-threatening event (status epilepticus, apnea requiring intervention, or death) during time of study; growth and somatic complaints; further information concerning family history \& comorbidities; past instrumental \& biochemical investigations (ECG, cardiac ultrasound results if done as part of patient's follow-up); electroencephalogram; polysomnography; urine samples of melatonin ; pupillometry
214362198|NCT04020848|OTHER|The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire|Sleep Disturbance Scale for Children ; Horne \& Ostberg Circadian Typology Questionnaire
214362199|NCT02444390|PROCEDURE|Biopsy|biopsy of a metastasis
214362200|NCT02200796|OTHER|Control Meal|High carbohydrate meal
214362201|NCT02200796|OTHER|Low Protein Meal|Omelet with 15 g of protein
214489354|NCT06757816|PROCEDURE|accessory rod and iliac fixation for distal augmentation for S1 fixation.|patients who were admitted to the spine unit and needed extension of fixation for L5 S1 fusion due to failed previous surgery, instability, or degenerative changes ,infection, tumors and pseudoarthrosis.
214489355|NCT06750471|BIOLOGICAL|Dupilumab|Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.
214973596|NCT05920499|OTHER|AUDIT and Feedback|"AUDIT and Feedback is a well-known quality intervention that according to the last Cochrane review leads to small but potentially important improvements in professional practice (Ivers N et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, 6:Cd000259).~Standardized automated AUDITs are available in most EHR systems in Belgium. Feedback, on the other hand, is only available in specific registration networks. At study baseline the performance in INTEGO practices will be measured. Afterwards a standardized clinical AUDIT to identify patients that may benefit from pneumococcal vaccination will be implemented in the EHR of all INTEGO practices. The Feedback will only be implemented in the intervention group."
214973597|NCT04912492|BEHAVIORAL|RealConsent1.0|A web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors.
214973598|NCT04912492|BEHAVIORAL|RealConsent2.0|A revised and updated web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors, but also integrates new program segments into RealConsent 1.0 specific to how alcohol use can inhibit SV intervention at multiple steps of the decision-making process.
214973599|NCT04912492|BEHAVIORAL|Stress Management|A web-based multimedia program designed to help individuals recognize the symptoms and sources of stress and provide them with a wide variety of powerful tools for managing stress.
214973600|NCT04912492|BEHAVIORAL|Alcohol intoxication|Men assigned to moderate alcohol dose condition (target BrAC .08%) with NIAAA approved alcohol administration procedures
214973601|NCT04912492|BEHAVIORAL|No-Alcohol Placebo|Men assigned to an no-alcohol placebo control condition.
214973602|NCT04598217|OTHER|anesthesiologist|non-interventional observational
214973603|NCT04663685|OTHER|Exercise program|Participants received two 1-on-1 exercise sessions per week to start. Each session lasted 30 minutes. As progress was made, participants were encouraged to exercise independently outside the structured sessions while continuing to receive a 1-on-1 session each week. The individualized exercises were aligned with functional movements to promote personal relevance: balance, pull, squat, push, hinge, lift \& carry and calf raise.
214973604|NCT04663685|OTHER|Nutrition education|Participants received a nutrition education booklet and had access to five online videos that correspond to key topics in the booklet (reading nutrition labels, types of protein, foods containing protein, incorporating protein into meals, spreading protein in meals throughout the day). Participants attended three 60-minute nutrition Q\&A sessions led by a dietitian, where the group reviewed content from the booklet and videos, and discussed personalized strategies to increase protein intake.
214973605|NCT03713671|DIAGNOSTIC_TEST|gait analysis|Computerized gait analysis system will use to evaluate spatio-temporal gait parameters
214973606|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
214973607|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
214973608|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
214973609|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
214973610|NCT01435759|DRUG|Antidepressant + Placebo|oral, once daily for 8 weeks
215084313|NCT00343915|BIOLOGICAL|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 \& 6)
215084314|NCT00343915|BIOLOGICAL|placebo|In the primary study: 1 deep intramuscular injection (month 1)
214362202|NCT02200796|OTHER|Moderate Protein Meal|Omelet with 30 g of protein
214362203|NCT02200796|OTHER|High Protein Meal|Omelet with 45 g of protein
214489356|NCT06748105|DRUG|Dapagliflozin (DAPA)|"Participants will receive 10mg/day of dapagliflozin orally. The administration will occur within a synchronous range, meaning that the time difference between dapagliflozin administration and glucocorticoid administration should not exceed 12 hours."
214362204|NCT02483897|DRUG|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
214362205|NCT02483897|DRUG|Normal Saline placebo drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
214362206|NCT01358695|BIOLOGICAL|ANT-1207|The interventions differ by dose of investigational product applied.
214362207|NCT01358695|BIOLOGICAL|Botulinum Toxin, Type A|The interventions differ by dose of investigational product applied.
214362208|NCT01358695|BIOLOGICAL|Botulinum Toxin Type A|The interventions differ by dose of investigational product applied.
214362209|NCT04934579|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
214362210|NCT04934579|DRUG|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
214362211|NCT04934579|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
214362212|NCT01758835|OTHER|Splint 3 weeks|A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.
214362213|NCT01758835|OTHER|Cast 3 weeks|A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.
214489357|NCT06749535|RADIATION|group 1|The aim of my study, we should diagnose diabetes on time. If diabetes mellitus untreated or uncontrolled for a long they directly affect all over the body, mostly they caused chronic disease due to hyperglycemia that damages the blood vessels. Rapture or damages the blood vessels of the lung causes COPD.
214489358|NCT06749613|DIETARY_SUPPLEMENT|digestive enzymes|A jar or single-dose sachets containing the digestive enzymes in the form of powder will be provided to each patient at the study entry. Patients will be instructed to use the powder formulation according to manufacturer instructions and according to the meals that they consume per day, for 1 month. Participants will be asked to return the jar or the single dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned. To reduce the placebo effect, patients will be misinformed that half will take a placebo formulation, randomly. Participants will be asked to return the jar or the single-dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned.
214489359|NCT06749561|DIAGNOSTIC_TEST|Group 1|To Compare the safety and effectiveness of boyh types
214489360|NCT06752772|DEVICE|Smart watch|Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.
214489361|NCT06752772|BEHAVIORAL|Dashboard with nudging system|Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.
214973611|NCT05661019|OTHER|Obtain Myotrace measurements|Myotrace measurement equipment, consisting of an application (i.e. non-medical software) running on a Philips laptop, Porti7 data acquisition system and software (Twente Medical Systems International (TMSi), Netherlands) (CE-approved), ECG cables, and three standard ECG (for EMG) electrodes. Also an on the shelf accelerometry sensor and respiration belt (TMSi) are used for the NRD measurement (CE-approved).
214973612|NCT01211145|DRUG|Placebo|Placebo nasal spray
214973613|NCT01211145|DRUG|Zolmitriptan|0.5 mg nasal spray
214973614|NCT01211145|DRUG|Zolmitriptan|2.5 mg nasal spray
214362214|NCT01758835|OTHER|Cast 6 weeks|standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
214973615|NCT01211145|DRUG|Zolmitriptan|5.0 mg nasal spray
214362215|NCT01269996|DRUG|Janumet, Lantus|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
214362216|NCT01269996|DRUG|metformin, gliclazide, protaphane|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
214362217|NCT02470130|BEHAVIORAL|relaxation|5 min of conversational relaxation red by one of the instructor between simulation and debriefing
214362218|NCT02403882|BEHAVIORAL|Order|In the order intervention, the investigators place the targeted product at the front of the line for the treatment. For the control, the investigators place the targeted product at the end of the line.
214362219|NCT02403882|BEHAVIORAL|Packaging|In the packaging intervention, the investigator present the targeted product in the original package. In the control, the investigator repackage the targeted product in clear, plastic bags.
214362220|NCT02403882|BEHAVIORAL|Pricing|In the pricing intervention, the investigators price all or targeted products in the treatment. In the control, the investigators do not price the products.
214362221|NCT02403882|BEHAVIORAL|Relative Proportions|The investigators adjust the amount of the targeted good available relative to the other products. In the treatment, the targeted good is a larger proportion of the total goods offered in the section, while in the control the shares of the targeted and other goods are equal.
214362222|NCT02403882|BEHAVIORAL|Default Option|In an early site, the investigators offer a targeted product without an alternative. The subjects can accept or reject the offer. The subjects are told that an alternative product is available later. At the site where the alternative product is available, investigators offer subjects the opportunity to exchanged the targeted product for the alternative product.
214973616|NCT02558764|DEVICE|portable (pocket) negative pressure wound treatment device|PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.
214489362|NCT06752772|DEVICE|Digital Health Coach (DHC)|Participants will be assigned to a DHC and the DHC will be providing them with remote health coaching assistance for a duration of 6 months, upon successful enrolment.
214489363|NCT06756269|BIOLOGICAL|Medium dose for 15-HPV vaccine|Participants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
214362223|NCT02915848|DEVICE|PC+S group|PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
214362224|NCT04322604|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
214489364|NCT06756269|BIOLOGICAL|High dose for 15-HPV vaccine|Participants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
214362225|NCT04322604|OTHER|Placebo|Placebo
214362226|NCT04969484|OTHER|Telehealth visit|ImPACTT Telehealth visit with the PC provider
214362227|NCT05241704|PROCEDURE|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the ulcer under complete aseptic operative setting
214362228|NCT05241704|PROCEDURE|Endovenous ablation of superficial venous reflux|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
214362229|NCT01238055|DRUG|Docetaxel + Sunitinib|"Docetaxel 60 mg/m2 iv, every 3 weeks~Sunitinib 37.5 mg qd daily, every 3 weeks"
214362230|NCT01238055|DRUG|Docetaxel only|Docetaxel 60 mg/m2 iv
214362231|NCT05543850|DEVICE|Bi-hormonal closed-loop control|During bi-hormonal closed-loop control insulin and glucagon are administered to the developed closed-loop algorithm. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the closed loop period.
214362232|NCT05543850|DEVICE|Open-loop control|During open-loop control the patients will use their usual diabetes therapy. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the open loop period.
214362233|NCT01786486|DEVICE|Amplatzer Cardiac Plug|
214362234|NCT05038280|BEHAVIORAL|Let's Talk about Children intervention|The LTC -intervention includes two steps: Let´s Talk about Children discussion and Let´s Talk about Children network meeting. Students, students´ parents, and a teacher take part in the LTC -discussion. The LTC logbook is used as the framework for the discussions. The LTC discussion depicts the child's ordinary day in all developmental contexts and an action plan is made with parents to enhance the identified strengths and to give support in vulnerabilities. When the action plan is difficult to carry out without further participants, the LTC-Network meeting is planned with parents (and sometimes also the child). LTC-Network meeting provides a forum for case-based cross-sectoral collaboration, including also the families and their social network.
214362235|NCT00740961|BEHAVIORAL|compliance monitoring|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
214362236|NCT00740961|DRUG|systemic chemotherapy|Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
214362237|NCT00740961|OTHER|medical chart review|A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
214489365|NCT06756269|BIOLOGICAL|Placebo|Participants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
214489366|NCT06756269|BIOLOGICAL|9-HPV vaccine|Participants aged 9-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
214489367|NCT06754800|DIAGNOSTIC_TEST|Polysomnography in routine care|Children performed a polysomnography in routine clinical care
214489368|NCT06755515|DRUG|Rulonilimab|"Drug: Rulonilimab Description: iv, 200mg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles."
214973617|NCT04346576|DIETARY_SUPPLEMENT|Probiotics prevent health problems in children|A controlled field trial was conducted with 1,036 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n=518) consumed fermented milk 65 mL/day containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group (n=493) were not given any. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline, after 4, 8, and 12-week intervention and after the 4-week follow-up period.
214973618|NCT01793753|DRUG|Propofol|
214973619|NCT04368507|DRUG|YYB101|"1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity~2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity"
214973620|NCT06237933|BEHAVIORAL|Enhanced intervention via social networking site (SNS)|We plan to organize a private Facebook group serve as platform to provide the intervention content. To ensure confidentiality, this Facebook group is completely private and the group member is invited only by study staff. The participants of intervention group received information about the private Facebook group and privacy settings and were instructed to join the Facebook group. The intervention comprises three parts. Doctor patient interaction: The interventionist (physicians and dietitians) act as health coach will provide evidence-based topics related to weight loss on Facebook discussion board every two weeks
215084315|NCT01237262|DRUG|Adalimumab, etanercept, infliximab|"Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.~Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks."
214362238|NCT00740961|OTHER|study of socioeconomic and demographic variables|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
214362239|NCT00740961|OTHER|survey administration|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
214362240|NCT00740961|PROCEDURE|cognitive assessment|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
214362241|NCT00740961|PROCEDURE|psychosocial assessment and care|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
214362242|NCT05767684|BIOLOGICAL|Dendritic Cell Vaccine|Approximately 1.5 x 10\^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
214362243|NCT05767684|DRUG|Lenvatinib|Lenvatinib 10mg/day on day 43-77
214362244|NCT05767684|DRUG|Nivolumab|Nivolumab 3mg/kg on day 43, 57 and 71.
214489369|NCT06755515|DRUG|Placebo|"Drug: placebo Description: iv, every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles."
214489370|NCT06755515|DRUG|cisplatin/carboplatin + paclitaxel ± bevacizumab|cisplatin/carboplatin + paclitaxel ± bevacizumab
214489371|NCT06751524|DRUG|Botensilimab|Administered via an intravenous (IV) infusion of Botensilimab + Balstilimab combination (BOT+BAL).
214489372|NCT06751524|DRUG|Balstililmab|Administered via an IV infusion of Botensilimab + Balstilimab combination (BOT+BAL).
214973621|NCT06237933|BEHAVIORAL|Standard intervention|In the session, the participants are instructed by an interventionist to have a reduced calorie diet and regular physical activity. Calorie intake was prescribed based on baseline weight at 1200 kcal/d for individuals who weighed less than 90 kg, 1500 kcal/d for those who weighed 90 to less than 115 kg, and 1800 kcal/d for those who weighed 115kg or more. The interventionist will give each participants dietary recommendation and sample meal plans are provided to facilitate adoption. The interventionist will prescribe non-supervised moderate-to-vigorous physical activity to participants. Participants should start moderate-to-vigorous physical activity at 100 minutes per week and increased at 4-week intervals until a prescription of 300 minutes per week was achieved
214973622|NCT01579513|DRUG|Methylprednisolone|Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
214973623|NCT01579513|DRUG|Placebo|Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
214973624|NCT02390271|OTHER|emotion focused therapy training|The Cardiac Coherence Training (CCT) incorporates a series of emotion-refocusing and restructuring techniques involving the use of biofeedback to control heart rate variability
214973625|NCT00570401|DRUG|dasatinib|
214973626|NCT04650074|DRUG|LIDOCAINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
214973627|NCT04650074|DRUG|LIDOCAINE 20 mg + KETAMINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
215084316|NCT03244319|DRUG|Edoxaban|Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight \<60kg or concomitant use of certain P-glycoprotein inhibitors).
215084317|NCT03244319|DRUG|Warfarin|All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
215084318|NCT03244319|DRUG|parenteral anti-coagulant (UFH)|parenteral anti-coagulant (UFH)
214362245|NCT01969019|DRUG|methylprednisolone, prednisone|
214362246|NCT03205371|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
214362247|NCT03205371|BIOLOGICAL|MMR|Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
214362248|NCT03205371|BIOLOGICAL|Varicella|Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
214362249|NCT03205371|BIOLOGICAL|DTaP-IPV-HB-Hib|Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
214362250|NCT03205371|BIOLOGICAL|PCV13|Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
214362251|NCT04038528|BEHAVIORAL|telemonitoring of T2DM|"Baseline record of:~* Weight~* Height~* BMI~* Abdominal circumference~* Winsor Index~* ECG~* Retinography~* Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups.~Telemedicine group (intervention):~* Blood sugar (two measurements per week).~* Body weight (weekly)~* Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed~Control group (control):~Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications.~Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter"
214362252|NCT01851174|DRUG|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion
214362253|NCT01851174|DRUG|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion
214489373|NCT06755788|DEVICE|RT-CGM|In the RT-CGM group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. RT-CGM monitoring will also be employed during surgery. A tablet in the operating room will be configured with low and high glucose alerts set at 3.9 mmol/L and 10.0 mmol/L, respectively. When an alarm is triggered, arterial blood gases will be rechecked, and glucose levels will be adjusted based on the arterial blood glucose results. If interstitial glucose values do not reach the intervention threshold, arterial blood gas measurements are recommended every 30 minutes.
214489374|NCT06755788|DEVICE|Control|In the control group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. CGM monitoring will also be employed during surgery, but the CGM interstitial glucose readings and alerts will be masked during the operation. The final intraoperative glucose management approach will be determined by the anesthesiologist, considering the patient's condition and surgical circumstances. The anesthesiologist can choose the intravenous insulin adjustment protocol we recommend.
214489375|NCT06752161|OTHER|Urine analysis|Urine analysis and culture for Screening and diagnostic tools for UTI in pregnant women
214489376|NCT06751953|COMBINATION_PRODUCT|Conventional third-line therapy|Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.
214489377|NCT06751953|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
214489378|NCT05178472|OTHER|Immunotherapy|Receive SOC immunotherapy
214489379|NCT05178472|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214489380|NCT05178472|PROCEDURE|Vertebroplasty|Undergo vertebroplasty
214973628|NCT04650074|DRUG|LIDOCAINE 20 mg + KETAMINE 40 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute"
214973629|NCT02849587|DRUG|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
214973630|NCT05619731|OTHER|Geriatric oncology tele-consultation and pharmaceutical tele-expertise|tele consultation
215084319|NCT05006144|OTHER|sequenced trunk co-activation exercises|"* Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~* Righting and protective reactions~* Functional stretching exercises."
214362254|NCT04426643|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space
214362255|NCT04426643|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
214362256|NCT03142048|OTHER|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
214489381|NCT06758284|OTHER|Laughter Yoga|The first component of the intervention is laughter therapy, which is a combination of warm-up exercises, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy via WhatsApp video call. Laughter yoga will be a single session and will last approximately 30 minutes.
214362257|NCT01175603|BEHAVIORAL|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
214362258|NCT05414591|DRUG|DWP16001 drug A|1 tablet, Oral, once daily single dose
214362259|NCT05414591|DRUG|DWP16001 drug B|3 tablet, Oral, once daily single dose
214362260|NCT03227679|OTHER|Nicotine Metabolite Ratio|This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
214362261|NCT03227679|DRUG|Varenicline|FDA-approved smoking cessation pharmacotherapy
214362262|NCT03227679|DRUG|Bupropion|FDA-approved smoking cessation pharmacotherapy
214362263|NCT03227679|DRUG|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
214362264|NCT03143725|DRUG|GLPG1972|Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
214489382|NCT06756789|PROCEDURE|Laparoscopic Roux-en Y Gastric bypass (RYGB)- Conventional approach|The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, standard limb lengths of 75cms BP limb and 125cms Alimentary limb were measured and performed, irrespective of the total bowel length
214973631|NCT05460546|DRUG|Jincaopian Tablets high dose|Jincaopian Tablets 0.2g tid p.o.
214973632|NCT05460546|DRUG|Jincaopian Tablets low dose|Jincaopian Tablets 0.1g tid p.o.
214973633|NCT05460546|OTHER|Placebo|Placebo tid p.o.
214973634|NCT00023868|DRUG|FOLFIRI regimen|
214973635|NCT00023868|DRUG|cisplatin|
214973636|NCT00023868|DRUG|doxorubicin hydrochloride|
214973637|NCT00023868|DRUG|fluorouracil|
214973638|NCT00023868|DRUG|irinotecan hydrochloride|
214973639|NCT00023868|DRUG|leucovorin calcium|
214973640|NCT00023868|DRUG|mitomycin C|
214973641|NCT03312816|OTHER|cookies enriched with POP|Cookies
214973642|NCT03976752|DRUG|Genvoya|"Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic."
214973643|NCT04741009|DEVICE|CI632 Slim Modiolar Electrode|Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode
214973644|NCT05944185|DRUG|αPD1-MSLN-CAR T Cells|αPD1-MSLN-CAR T Cells
214973645|NCT01234597|DRUG|INSULIN GLARGINE (HOE901)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214973646|NCT01234597|DRUG|INSULIN GLULISINE (HMR1964)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
214973647|NCT00260546|PROCEDURE|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
214973648|NCT03503110|OTHER|electrocorticography with electrostimulation|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
214973649|NCT03503110|OTHER|dRMI|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
214973650|NCT05628246|OTHER|Telemedicine|Telemedicine
214973651|NCT05628246|OTHER|In-person|In-person
214973652|NCT04202497|DRUG|TAK-418|TAK-418 orally.
214973653|NCT04202497|DRUG|[18F]MNI-1054 (radiotracer)|\[18F\]MNI-1054 injection.
214973654|NCT05290948|DRUG|intravitreal injection of bevacizumab with acetazolamide tablets|intravitreal injection of bevacizumab with acetazolamide tablets
214973655|NCT05290948|DRUG|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
214973656|NCT04609657|OTHER|Flavored carbonated soft drink (CSD)|Beverage
214973657|NCT03940196|DEVICE|NovoTTF-100L(O)|Patients receive continuous TTFields treatment using the NovoTTF-100L(O) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen/pelvis. The treatment enables the patient to maintain regular daily routine.
214973658|NCT03940196|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.
214973659|NCT06119230|BEHAVIORAL|Activity Counselling|Participants will receive a one hour goal setting session with a physiotherapist where they will use the feedback forms to create activity goals for the upcoming week of collection.
214973660|NCT03026946|DRUG|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
214973661|NCT03026946|DRUG|cyclosporin A|Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
214973662|NCT06280898|PROCEDURE|Remote ischemic conditioning|Remote ischemic condition
214362265|NCT01463956|DRUG|Boceprevir|Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
214973663|NCT05007119|PROCEDURE|Mckenzie Extension Protocol|"Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
214973664|NCT05007119|PROCEDURE|Cupping|Cupping with blood letting
214973665|NCT06467214|BEHAVIORAL|CONNECTED|CONNECTED is a manualized, peer-led, group-based social isolation intervention for diverse veteran populations in VA primary care settings. It is delivered via videoconference through individual and group sessions over 8 weeks.
214973666|NCT06467214|BEHAVIORAL|VET BEFRIENDING|VET BEFRIENDING (attention control arm) consists of weekly social interactions with a research assistant (RA) over videoconference or phone.
214362266|NCT01463956|BIOLOGICAL|Peg-Interferon α-2b or Peg-Interferon α-2a|Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
214489383|NCT06756789|PROCEDURE|Laparoscopic Roux-en Y Gastric bypass (RYGB)- Tailored approach|The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, limb lengths are tailored according to the total small bowel length, 1/3rd of the total bowel length is measured and in that 3/8th and 5/8th were kept as BP limb and alimentary limb respectively.
214489384|NCT06757387|DRUG|chidamide and golidocitinib|Enrolled patients will receive combination therapy with golidocitinib (150 mg QD or 150 mg QOD) and chidamide (20 mg BIW or 25 mg BIW)； If the MTD is determined at Dose Level 1 (chidamide 20 mg BIW / golidocitinib 150 mg QD), Dose Level 0 (chidamide 20 mg BIW / golidocitinib 150 mg QOD) will be further investigated. If the MTD is not established after escalating to Dose Level 2 (chidamide 25 mg BIW / golidocitinib 150 mg QD), the recommended Phase 2 dose (RP2D) will be determined through investigator consensus.
214489385|NCT06756698|OTHER|conventional treatment plus music intervention|Each music therapy session will include 5 stages. In stage 1, an emotional assessment is conducted to observe the patient's current emotional experience and feelings (provide a VAD score), which lasts about 1 minute. In stage 2, relaxation exercises (breathing relaxation, progressive muscle relaxation, and imaginary relaxation) are conducted under the guidance of the therapist to the music corresponding to the relaxation target VAD, which lasts about 8 minutes. In stage 3, the patient independently selects the music and discusses it with the therapist, which lasts about 10 minutes. In stage 4, the patient listens to resource and positive-oriented music and discusses specific topics with the therapist, which lasts about 10 minutes. Finally, in stage 5, the therapist again conducts an emotional assessment of the patient and observes the patient's current emotional experience and feelings, which lasts about 1 minute.
214489386|NCT06756698|OTHER|conventional treatment|The conventional treatment group received DBT group therapy 5 times a week, each session lasting 1 hour, and also received individual personalized therapy twice a week.
214489387|NCT06757257|DRUG|fostamatinib|oral administration
214489388|NCT06756633|OTHER|Respiratory Function Test|A spirometer (microQuark, COSMED) will be used to assess respiratory functions. During a forced expiratory maneuver after a deep, full inspiration, airway and lung volumes are measured. During the measurement, a deep inspiration followed by a strong, fast, and continuous expiration until unable to exhale anymore should be performed. The expiration time should be at least 6 seconds, and if necessary, extended up to 15 seconds. More than eight repetitions at one time are not recommended.
214489389|NCT06756633|OTHER|Structured light plethysmography|Participants' thoracoabdominal movements will be assessed using the PneumoCare device that measures with the SLP technique. The evaluation begins with positioning participants wearing a white tank top, t-shirt, or with a bare chest. In our study, measurements will be taken with participants seated, supported by their backs, and their chest area exposed. The participant's age, height, and weight information are entered into the system. After the participant is positioned, the lights of the SLP measuring device are set up 90-100 cm away to encompass the chest area. The light field, which is in a checkerboard pattern, rectangular or square, should align its upper edge with the participant's clavicles and its lower edge with the anterior-superior iliac spine. During this measurement, the participant is asked to look straight ahead and breathe normally for five minutes. At the end of the measurement, the three-dimensional movements of the chest and respiratory parameters are recorded.
214973667|NCT05010278|PROCEDURE|Latarjet|Patients followed up 6 months after a Latarjet procedure
214973668|NCT01777841|OTHER|Electronic Care plan delivery|
214973669|NCT01777841|OTHER|Standard care|
214973670|NCT05716009|DRUG|Dose Escalation -tagraxofusp-erzs|Sequential dose levels of tagraxofusp-erzs dependent on patient response. Fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
214973671|NCT05716009|DRUG|Dose Expansion at RP2D -tagraxofusp-erzs|Following the dose escalation portion, the expansion dose and schedule (RP2D) will be determined. Patients will continue to receive fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
214973672|NCT06018337|DRUG|DB-1303/BNT323|IV
214973673|NCT06018337|DRUG|Capecitabine|Oral
214973674|NCT06018337|DRUG|Paclitaxel|IV
214973675|NCT06018337|DRUG|Nab-paclitaxel|IV
214973676|NCT02115607|DRUG|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
214973677|NCT06318026|BEHAVIORAL|Centralized Intervention|A centralized intervention by a social worker or counselor, added to usual care that systematically offers outreach and shared decision-making for symptoms due to alcohol use
214973678|NCT06318026|OTHER|Primary Care Intervention|A primary care intervention added to usual care that uses state-of-the-art implementation interventions to systematically encourage primary care providers to offer routine shared decision-making for symptoms due to alcohol use.
214973679|NCT04616560|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214973680|NCT04616560|PROCEDURE|Echocardiography Test|Undergo echocardiography
214973681|NCT04616560|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214973682|NCT04616560|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
214973683|NCT04921345|DRUG|Nemolizumab|Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.
214362267|NCT01463956|DRUG|Ribavirin|Ribavirin: capsules 200 mg (weight-based daily dose: \<65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; \>105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
214362268|NCT02246335|DEVICE|Cemented total hip arthroplasty|
214362269|NCT02246335|DEVICE|Cemented hemiarthroplasty|
214489390|NCT06756633|OTHER|6 Minute Walking Test|"For Ambulatory Participants:~Exercise capacity will be assessed using the Six-Minute Walk Test (6MWT). The test will be performed according to ATS/ERS guidelines . The test involves walking for six minutes at a submaximal level in a 20-meter corridor. Blood pressure, heart rate, respiratory rate, oxygen saturation, and dyspnea, general fatigue, and leg fatigue according to the Modified BORG Scale (MBS) will be assessed before and after the test. Participants can stop and rest during the test. In such cases, the test duration is paused, and the rest time is recorded, then the test resumes from where it was left off. The distance walked in meters at the end of the test is recorded."
214489391|NCT06756633|OTHER|6-Minute Peg Board Ring Test|"For Non-Ambulatory Participants:~The 6-Minute Pegboard Ring Test will be used to assess upper extremity exercise capacity . Pre- and post-test evaluations of heart rate, blood pressure, respiratory rate, and MBS for dyspnea and fatigue will be made. The board used for the test has a total of 6 holes spaced 10 cm apart horizontally and another set of 6 holes 20 cm below aligned with the top row. There are four 20 cm long iron rods suitable for the holes. A total of 20 rings suitable for the iron rods will be used. The iron rods will be placed in the designated holes according to the patients' shoulder width. An adjustable chair will be used to suit the patients' heights, and the distance between the chair and the board will be adjusted according to arm length. Patients will be asked to place the rings from top to bottom and bottom to top with both hands simultaneously. The total number of rings placed in six minutes will be recorded in units."
214489392|NCT06756633|OTHER|Hand Grip Strength|Hand grip strength will be measured using a digital hand dynamometer (CAMRY Digital Hand Dynamometer) . The device handle will be adjusted according to the participants' hand size. The test is conducted while seated, with the dominant upper extremity in 90 degrees of elbow flexion. Participants are asked to squeeze the dynamometer as strongly as possible. The value displayed on the dynamometer is recorded. The measurement is repeated three times, and the average of the three measurements is taken to determine the participant's hand grip strength. The measurement takes five minutes and does not need to be repeated.
214489393|NCT06759545|OTHER|Dietary MOH recommendations and daily addition of 42 ml (three tablespoon) at each morning of EVOOEH|Dietary intervention study: high-risk pregnant women receiving a link to MOH general dietary recommendations for pregnancy (MOH recommendations) with addition of three tablespoon (42 ml) EVOOEH (up to 0.8% free acidity) per day at each morning for four weeks during the first half of pregnancy (gestational ages between 8 to 16 weeks)
214489394|NCT06759545|OTHER|Dietary MOH recommendations|Dietary intervention study: high-risk pregnant women receiving a link to MOH general dietary recommendations for pregnancy (MOH recommendations) for four weeks during the first half of pregnancy (gestational ages between 8 to 16 weeks)
214973684|NCT04921345|DRUG|Nemolizumab|Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
214973685|NCT01157611|BEHAVIORAL|Mentoring program|mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
214973686|NCT05911477|DRUG|RhBMP-2|1mg RhBMP-2 for one fusion-level
214973687|NCT00102596|DRUG|1-Octanol|1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
214973688|NCT01031303|BIOLOGICAL|DTacP-IPV combined vaccine (TETRAXIM™)|0.5 mL, Intramuscular
214973689|NCT03366857|DRUG|Oxygen 30 %|The oxygen concentration will be set at 30%.
214362270|NCT04777812|DIAGNOSTIC_TEST|Rectal and buccal swabs|The oral and intestinal flora is collected from buccal and rectal swabs.
214362271|NCT02835339|DRUG|Magnesium sulfate 4g loading dose, 1g/hr infusion|
214362272|NCT02835339|DRUG|Magnesium sulfate 6g loading dose, 2g/hr infusion|
214973690|NCT03366857|DRUG|Oxygen 80 %|The oxygen concentration will be set at 80%.
214973691|NCT01660867|DRUG|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo =\> nebulized epinephrine + 3% saline
214973692|NCT01660867|DRUG|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone =\> nebulized epinephrine + 0.9% saline
214973693|NCT05580484|PROCEDURE|Second surgery|The primary outcomes were adhesion severity and adhesion area in the lower ab-dominal cavity, as determined through direct visual observation of a laparotomy wound or laparoscopic observation from stoma closure wound.
214973694|NCT00424281|DRUG|Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability|
214973695|NCT02890316|OTHER|Homeopathy remedy|Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.
214362273|NCT02401581|OTHER|Catheter|The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
214362274|NCT00508443|RADIATION|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
214362275|NCT05968651|DRUG|Oxytocin nasal spray|Single acute administration of 24 international units (IU) oxytocin
214362276|NCT01077544|DRUG|Nilotinib|"Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water."
214362277|NCT02947347|DRUG|ibrutinib|ibrutinib 560mg administered orally
214362278|NCT02947347|DRUG|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
214362279|NCT02947347|DRUG|rituximab|rituximab 375mg/m\^2 IV
214489395|NCT06759272|GENETIC|CYP2C19 genotype-guided antiplatelet therapy|A panel of genes including CYP2C19\*2 (rs4244285) and CYP2C19\*3 (rs4986893) will be genotyped using the real-time PCR and the expected turnover time will be 48 hours. Patients who are identified to have reduced function CYP2C19 allele will receive 90 mg ticagrelor and patients with wild-type CYP2C19 allele will receive clopidogrel 75 mg in the next scheduled dose. The switching done from clopidogrel to ticagrelor is supported by Antiplatelet Therapy Switching Clinician Guideline, whereby in the maintenance or low risk phase, there is generally no need to administer a loading dose of ticagrelor; one can switch directly to ticagrelor maintenance dose 24 hours after the last dose of clopidogrel
214489396|NCT06748625|BEHAVIORAL|Luci Coach-Assisted Intervention|The Luci intervention is a personalized behaviour change program delivered via an interactive web platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement. Participants will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining SMART goals to progressively adopt and maintain a healthier lifestyle. Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24.
214489397|NCT06761092|DRUG|Nebulized Dexmedetomidine for Post-Anesthesia Delirium in Preschool Children|"Nebulization with the anesthetic drug dexmedetomidine at a dose of 2 mcg/kg body weight, diluted to 3 ml with 0.9% normal saline, administered before the induction of anesthesia in the reception area.~After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room"
214489398|NCT06761092|PROCEDURE|Nebulized 0.9% Normal Saline|Nebulization with normal saline 0.9% 3 ml, administered before the induction of anesthesia in the reception area. After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room
214489399|NCT02382003|BEHAVIORAL|Positive Cognitive Bias Modification - Interpretation|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will then assign a benign (rather than threatening) meaning to the scenario.
214489400|NCT02382003|BEHAVIORAL|50/50 Cognitive Bias Modification - Interpretation|This condition follows the same design and content as the Positive Training conditions, except the word fragments differ; rather than consistently resolving the scenario in a positive direction, half of the scenarios will end with a negative (anxiety-congruent) word fragment, and half will end with a positive word fragment.
214489401|NCT02382003|BEHAVIORAL|Anxious Imagery Prime|We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime at the start of each session will enhance effects.
214489402|NCT02382003|BEHAVIORAL|Neutral Imagery Prime|At the start of each session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.
214489403|NCT05699226|DEVICE|Soterix Medical Incorporated 4x1 adapter|Device permits individualized amplitudes
214489404|NCT05699226|DEVICE|Traditional ECT device|FDA approved ECT device with fixed amplitude.
214489405|NCT02606526|BIOLOGICAL|BCG at birth|See previous description
214489406|NCT02606526|BIOLOGICAL|Control arm: Delayed BCG|See previous description
214489407|NCT03612258|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging scans will be completed to assess neural responses to painful, non-painful sensory, and emotion-eliciting stimuli.
214489408|NCT06800482|BEHAVIORAL|online outpatient follow-up|The investigators use Huayitong APP for the post-operating follow-up of participants with papillary thyroid cancer
214489409|NCT06754293|BEHAVIORAL|rehabilitation exercise|"The intervention group will participate in a home-based exercise program alongside standard rehabilitation guidance. Patients will receive exercise materials developed by the intervention team, along with a detailed explanation of the program, including its components, specific exercises, and expected benefits.~The exercise program focuses on aerobic warm-ups and functional training, targeting key areas such as the hands, arms, shoulders, hips, legs, and back. It is designed to meet the rehabilitation needs of breast cancer patients undergoing endocrine therapy after surgery, addressing their unique challenges and enhancing recovery.~The intervention team, composed of specialists in breast cancer treatment, rehabilitation therapists, nursing experts, and methodologists, has created a professional exercise guidance manual. This manual provides detailed descriptions of exercise types, specific methods, and safety precautions. To ensure effective implementation, instructional videos have"
214362280|NCT06087510|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative analgesia.
214362281|NCT04341623|OTHER|Cetaphil Pro Eczema moisturizer|All 30 patients to receive
214362282|NCT04341623|BEHAVIORAL|Electronic interaction|10 patients to electronic surveys about moisturizer use
214362283|NCT04341623|BEHAVIORAL|GPSkin|Measuring moisture in the skin
214362284|NCT00881491|DRUG|Double Antibiotic Paste|ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
214362285|NCT00881491|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
214362286|NCT00881491|DRUG|Mineral Trioxide Aggregate|standard material providing an apical barrier
214362287|NCT03923959|DRUG|Tranexamic Acid Injectable Solution|100 cc normal saline mixed with 1g of tranexamic acid in solution
214362288|NCT03923959|OTHER|Placebo|100 cc normal saline
214489410|NCT06751745|BEHAVIORAL|Online Emotional Intelligence Training|The intervention is a 4-week online Emotional Intelligence (EI) training program for Bangladeshi youth. It includes weekly one-hour sessions focusing on self-awareness, self-regulation, social awareness, and relationship management. Led by experts, the program uses interactive activities and practical exercises to enhance emotional skills. Pre- and post-training assessments with the Bengali Emotional Intelligence Scale measure outcomes.
214489411|NCT06841614|BIOLOGICAL|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
214489412|NCT06841614|BIOLOGICAL|Inmazeb|Inmazeb (REGN-EB3), developed by Regeneron, is a cocktail of 3 neutralising humanised mAbs directed against 3 epitopes of the EBOV GP (atoltivimab, maftivimab and odesivimab). It is indicated for the treatment of EVD in adult patients (including pregnant women) and in children, including neonates born to mothers with confirmed EVD.
214489413|NCT06841523|DEVICE|Intelligent Pressure and Temperature-Controlled Ureteroscope System|RIRS procedure for upper ureteral or renal stone lithotripsy with Intelligent Pressure and Temperature-Controlled Ureteroscope System
214489414|NCT06841523|DEVICE|Conventional Ureteroscope|RIRS procedure for upper ureteral or renal stone lithotripsy with conventional ureteroscope
214489415|NCT06841250|PROCEDURE|intravitreal injection of anti-VEGF|Ranibizumab is injected into the vitreous under aseptic conditions as part of routine DME treatment
214489416|NCT06841666|DRUG|Atomoxetine|Atomoxetine, 0.5-1.2 mg/kg/day, administered in the evening for six months.
214489417|NCT06841666|DRUG|Placebo|Placebo identical in form and dosing schedule for six months.
214489418|NCT06842758|OTHER|Rehabilitation Treatment|Group A patients came to our department to perform rehabilitation treatment. They underwent rehabilitation treatment for a total of 20 rehabilitation sessions, performed on a daily basis lasting 60 minutes, on a 1:1 basis with a physical therapist, . They performed postural re-education and posterior kinetic chain strengthening exercises.
214489419|NCT06842758|OTHER|None Treatment|Group B patients did not undergo rehabilitation treatment. They underwent subcutaneous Teriparatide drug treatment on a daily basis for the treatment of osteoporosis
214973696|NCT02890316|RADIATION|Radiation as adjuvant therapy for breast cancer|Daily radiation therapy.
214973697|NCT02667652|PROCEDURE|short biliarypancreatic limb|biliarypancreatic limb:50cm;roux limb:150cm.
214973698|NCT02667652|PROCEDURE|long biliarypancreatic limb|biliarypancreatic limb:100cm;roux limb:100cm.
214973699|NCT04483466|DRUG|Methotrexate|Methotrexate is vibrant yellow-orange colored powder with physical properties of near insolubility in water formulated into methotrexate tablets containing an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, and yellow. The chemical name is N-\[4-\[\[(2,4-diamino-6pteridinyl)methyl\]methyl amino\]benzoyl\]-L-glutamic acid. Methotrexate is an anti-metabolite that is a folate antagonist that inhibits lymphocyte proliferation and functions as an immunosuppressant in arthritis.
214973700|NCT04483466|DRUG|Placebo|Placebo
214362289|NCT04918147|DRUG|elotuzumab|Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
214362290|NCT04918147|DRUG|placebo for elotuzumab|The placebo for elotuzumab is 0.9% sterile normal saline for injection.
214362291|NCT04918147|DRUG|methylprednisolone|Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
214362292|NCT04918147|DRUG|diphenhydramine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
214362293|NCT04918147|DRUG|acetaminophen|Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
214362294|NCT04918147|DRUG|famotidine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
214362295|NCT04918147|DRUG|prednisone|Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
214973701|NCT05473299|DEVICE|Xeltis Hemodialysis Access (aXess) graft|The aXess graft is a sterile, regenerative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
214973702|NCT01832337|PROCEDURE|Limb remote ischemic preconditioning (LRIP)|Limb remote ischemic preconditioning (LRIP) consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
214973703|NCT05032014|OTHER|M9|one times a day during the whole treatment
214973704|NCT05032014|OTHER|placebo|placebo
214973705|NCT00069264|DRUG|E7389|E7389 Dose-escalation starting at 0.25 mg/m\^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
214973706|NCT06514430|DRUG|Phenazopyridine|200mg PO Phenazopyridine taken prior to the Botox® injection procedure as an analgesic.
214973707|NCT06514430|DRUG|1% lidocaine with sodium bicarbonate|50cc of 1% lidocaine with 50cc sodium bicarbonate injected into the bladder lumen prior to the Botox® injection procedure.
214973708|NCT06409663|BIOLOGICAL|NVX-CoV2705 Vaccine|All injections will be administered in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant at each injection.
214973709|NCT05658393|BEHAVIORAL|ReLiver-N App|Web-based mobile health application for patients with liver cirrhosis
214973710|NCT05040087|OTHER|Intensification of diabetes medication based largely on HbA1c levels|Use of diabetes Rx in controls will be guided largely by HbA1c levels.
215084320|NCT05006144|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
214362296|NCT04273139|DRUG|IBRUTINIB|Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days
214362297|NCT04273139|DRUG|Venetoclax|Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.
214362298|NCT04496726|OTHER|Pacran and Sapnov P quillaja|Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.
214362299|NCT03227354|DEVICE|Vittamed 205|non-invasive Intracranial Pressure measurement
214362300|NCT01375114|DRUG|Panax Ginseng|400 mg by mouth twice daily from Day 1-29.
214362301|NCT01375114|DIETARY_SUPPLEMENT|Placebo|Placebo by mouth twice daily for 4 weeks.
214362302|NCT01375114|BEHAVIORAL|Questionnaires|Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
214489420|NCT06812039|DRUG|HAIC combined with sintilimab and donafenib|"HAIC: Two cycles, Q3W. The chemotherapy regimen consists of oxaliplatin 85 mg/m² over 2 hours and raltitrexed 2 mg/m² over 1 hour.~Donafenib: Treatment should begin the day after the completion of the first HAIC, with an initial dose of 0.1g bid p.o.. The investigator may increase the dose to 0.2g bid depending on the patient's condition.~Sintilimab: Administration may begin after the first HAIC, 200 mg iv Q3W. After surgery, continued sintilimab and donafenib for 6 cycles."
214489421|NCT06812039|DRUG|Sintilimab and Donafenib|Donafenib: an initial dose of 0.1g bid p.o. The investigator may increase the dose to 0.2g bid depending on the patient's condition. Sintilimab: 200 mg iv Q3W. After surgery, continued sintilimab and donafenib for 6 cycles.
214489422|NCT06812039|PROCEDURE|Surgery|After surgery, received sintilimab and donafenib for 6 cycles.
214973711|NCT05040087|OTHER|Intensification of diabetes medication based on glucose levels|Use of diabetes Rx in the intensive Rx groups will be guided by participants' self-monitored blood glucose levels (SMBG), with management aimed to keep glucose levels within the normal range.
214973712|NCT06801379|DRUG|Inhaled Melatonin (100 μg)|An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.
215094445|NCT01325714|BEHAVIORAL|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
214362303|NCT05208281|DRUG|GNR-055 1.0-2.0-3.0 mg/kg|Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
214362304|NCT05208281|DRUG|GNR-055 2.0 mg/kg|Weekly IV infusion (lyophilized powder) 2.0 mg/kg
214362305|NCT05208281|DRUG|GNR-055 3.0 mg/kg|Weekly IV infusion (lyophilized powder) 3.0 mg/kg
214362306|NCT05590247|BEHAVIORAL|Intermittent Fasting Diet|Patients will follow the 16: 8 traditional intermittent fasting model, where they may only consume calories during 1 continuous 8-hour period of the day. Water may be consumed during fasting.
214362307|NCT02760849|OTHER|Laboratory Biomarker Analysis|Correlative studies
214362308|NCT02760849|PROCEDURE|Oophorectomy|Undergo ISDO
214362309|NCT02760849|OTHER|Quality-of-Life Assessment|Ancillary studies
214362310|NCT02760849|PROCEDURE|Salpingectomy|Undergo ISDO
214362311|NCT02760849|PROCEDURE|Salpingo-Oophorectomy|Undergo RRSO
214362312|NCT03453398|OTHER|Shifts working hours with different schedules|"Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study."
214362313|NCT03556111|PROCEDURE|Sticky bone augmentation|"1. Autogenous sticky bone augmentation for the first group~2. Autogenous sticky bone preparation with xenograft usage~3. After 5-month of bone grafting; esthetic implant placement"
214362314|NCT05508503|DIAGNOSTIC_TEST|Test of methylated NTMT1 and MAP3K14-AS1|A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.
214362315|NCT05508503|DIAGNOSTIC_TEST|FIT|Fecal immunochemical test（optional）
214362316|NCT05321719|BEHAVIORAL|Comparison Condition|In this Phase II project, BR2S will be evaluated for efficacy relative to a usual care control. Investigators expect BR2S to improve outcomes on behavioral change, self-efficacy, establishment of a dental home, knowledge, and attitudes in real settings relative to the usual care condition. The outcome measures include a direct clinical dental measure as well as observational measures of parental behavior. The study will also provide important information regarding the various types and combinations of BeReady2Smile product components for dissemination. The long-term goal of the program is to help parents provide the foundation for a lifetime free from preventable oral disease.
214489423|NCT01801709|GENETIC|intracerebral administration of AAVrh.10cuARSA|
214973713|NCT06801379|DRUG|Oral Melatonin (4 mg)|Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
214362317|NCT05321719|BEHAVIORAL|BeReady2Smile video only|"The video will be viewed at the Head Start site after informed consent and T1 questionnaires and plaque assessment. The video will include concrete demonstrations and feature diversity in settings and actors in video content derived from actual peer-based parenting education sessions. Parents' ability to see themselves in the content makes them more likely to engage in discussions about dental health. Supporting these conversations has been identified as an important need. For example, in a recent environmental scan prepared by the Association of State and Territorial Dental Directors the lack of communication strategies was identified as a gap in oral health educational resources. Specifically mentioned was the lack of oral health curricula that support interactive communication between families and home visitors. Families struggle with such dialogues."
214362318|NCT05321719|BEHAVIORAL|BeReady2Smile video and BeReady2Smile app completely self-guided|In addition to the BeReady2Smile video as described above, the BeReady2Smile app includes: (a) presentation of concepts, behaviors, and examples via video and text, (b) electronically presented check-in questions recorded to a database for review, (c) capture of a 5-minute video of parent-child interactions uploaded for later review by the parent, using a mobile application, (d) daily dental activities (homework), and (e) program feedback recorded to the database. BeReady2Smile will be designed such that before the parent can go on to a new area of learning, the parent must complete the previous lesson. Participants can go back and review previous material in a non-linear format. The database and log-files record all computer activities to track use of each intervention component.
214362319|NCT05321719|BEHAVIORAL|"Complete BeReady2Smile video and BeReady2Smile app guided by a Coach"|"In addition to the BeReady2Smile video and BeReady2Smile app described above, the complete intervention includes support via phone and text from a trained facilitator/coach who builds supportive one-on-one relationships with the parent and gives feedback on parent-recorded videos of parent-child interactions of tooth-brushing, designed to facilitate learning and promote engagement with their oral health professional; and tools to create a long-term follow-up plan. Dental behaviors will be tailored for children's developmental level (e.g. twice daily tooth brushing for preschoolers and limiting sugar sweetened beverages or milk in bottles at bed for infants)."
214362320|NCT03338829|BEHAVIORAL|Positive incentive|Compensation is paid for each glucose test completed
214362321|NCT03338829|BEHAVIORAL|Loss aversion|Fixed compensation is offered to patients and they can earn a range of compensation at the completion of pregnancy depending on overall glucose testing adherence
214362322|NCT05115825|BEHAVIORAL|Behavioral Intervention|Attend Mobile Pain Coping Skills Training
214362323|NCT05115825|OTHER|Quality-of-Life Assessment|Ancillary studies
214362324|NCT05115825|OTHER|Questionnaire Administration|Ancillary studies
214362325|NCT06032559|BEHAVIORAL|MORE|MORE plus TAU
214362326|NCT06032559|BEHAVIORAL|SMP|SMP plus TAU
214362327|NCT06032559|OTHER|TAU|TAU only
214362328|NCT05535478|BEHAVIORAL|STRIDE|a. Targeted providers for STRIDE program: i. Clinical staff at the LTCF who participate in deprescribing at the facilities (physicians (MDs), physician's assistants (PAs), nurse practitioners (NPs), clinical pharmacists): clinical staff members caring for LTCF residents with ADRD and diabetes at 6 LTCFs in the Ohio and Michigan areas will be invited via email from the LTCF leadership to participate in the STRIDE education program. The STRIDE program consist of practical algorithms and educational material, which they are free to view at any time, and participation in 2 webinars and monthly telementoring calls
214362329|NCT05934370|OTHER|Home-Based Environmental Interventions (HEI)|"Housing Specialist will conduct an environmental home assessment to identify asthma triggers.~• The participant will receive the following Breath Easy at Home Kit Products:~* HEPA filtered upright vacuum cleaner~* HEPA-filtered air purifier~* Hypoallergenic latex free mattress and pillow covers~* Healthier household cleaners~* Non-toxic pest control devices for rodent control~* Safe products to locate and kill roaches."
214362330|NCT05163418|DEVICE|Foot orthosis for flat feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
214362331|NCT05163418|DEVICE|Foot orthoses for high arches feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
214973714|NCT03859050|OTHER|bronchoscopy with intrabronchial administration of lipopolysaccharide|The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
214973715|NCT06298357|BEHAVIORAL|Immediate Start - Virtual Reality|Participants will use a Meta Quest virtual reality headset and play video games for exercise and mindfulness. They will start using the headsets in the hospital and then will continue to do so for 8 weeks after hospital discharge.
214973716|NCT06298357|BEHAVIORAL|Delayed Start - Virtual Reality|Participants will receive usual care in the hospital and outside of the hospital for 8 weeks. After the 8 week post-discharge period, participants will use a Meta Quest virtual reality headset and play video games for exercise and mindfulness for an 8 week period.
214973717|NCT06384027|OTHER|Non-invasive ventilation|Ventilation support that does not require an artificial airway that aims to reverse respiratory muscle fatigue and decrease the work of the respiratory muscles, maintaining a positive pressure, allows alveolar recruitment, preventing atelectasis and airway collapse. NIV can be administered using continuous positive airway pressure (CPAP) or two levels of airway pressure (Bi-level).
214973718|NCT05067972|DRUG|PF-07260437|B7-H4 x CD3 bi-specific mAb
214973719|NCT05067972|DIAGNOSTIC_TEST|B7-H4 IHC|B7-H4 expression
214973720|NCT05608304|BEHAVIORAL|Formal mindfulness induction|The formal mindfulness induction will consist of a 10-minute audio recording of a sitting meditation, guiding the participant to consciously and repeatedly bring their attention to their breath and inner experience with nonjudgmental acceptance.
215094446|NCT01325714|BEHAVIORAL|Enhanced Usual Care|"In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.~Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain."
215094447|NCT06938308|DEVICE|LMA Igel|adults allocated to the LMA Igel group, an LMA Igel device will be inserted intraoperatively
215094448|NCT06938308|DEVICE|LMA Protector|adults allocated to the LMA Protector group, an LMA Protector device will be inserted intraoperatively
214362332|NCT05280301|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
214362333|NCT04310995|DRUG|Nicorandil 5mg tid|oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
214362334|NCT04310995|DRUG|Diltiazem 180mg qd|oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
214362335|NCT04310995|DRUG|Isosorbide Mononitrate 50mg qd|oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
214362336|NCT04632927|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
214362337|NCT04632927|BIOLOGICAL|Ustekinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
214362338|NCT03575325|DRUG|CPX-351|The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed through a central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period.
214362339|NCT06433908|DRUG|Salbutamol HFA-152a|100 µg (ex-valve), given at 20-second intervals.
214362340|NCT06433908|DRUG|Salbutamol HFA-134a|100 µg (ex-valve), given at 20-second intervals.
214362341|NCT06126783|DRUG|IBI311|The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
214362342|NCT03452007|DEVICE|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of \[5-6-5\]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
214362343|NCT04576091|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214362344|NCT04576091|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT scan
214362345|NCT04576091|DRUG|Elimusertib|Given PO
214362346|NCT04576091|BIOLOGICAL|Pembrolizumab|Given IV
214362347|NCT04576091|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
214362348|NCT04576091|OTHER|Quality-of-Life Assessment|Ancillary studies
214362349|NCT04576091|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214362350|NCT01882322|DRUG|Prograf|oral
214362351|NCT01882322|DRUG|Advagraf|oral
214362352|NCT03589079|GENETIC|Sanger and/or Next Generation Sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS)
214362353|NCT00135005|DRUG|AMN107, STI571|
214362354|NCT05323539|OTHER|Evaluating Thyroid Volumes by ultrasonography|The inclusion criteria are ; having a prediagnosis of surgically planned endometrioma and to undergo gynecological surgery for a reason other than endometriosis (control group). Among the patients with pre-diagnosis of endometriosis, who applied to our clinic during the study period and accepted to participate in the study, thyroid volumes will be measured by ultrasonography during the preoperative hospitalization. The pathological diagnosis of the patients will be confirmed and patients with different results will be excluded from the study (such as malignancy, endometriosis prediagnosis but different pathology detected etc.) In the same period, gynecological surgery was planned for another reason and patients without endometriosis will form the control group.
214362355|NCT00146835|BIOLOGICAL|Pediarix|1 or more injections
214973721|NCT05608304|BEHAVIORAL|Informal mindfulness induction|The informal mindfulness induction will consist of on-screen instructions guiding participants through the completion of four routine tasks (washing hands, drinking water, laying down, listening to music) with mindful awareness and acceptance over the course of 10 minutes.
214362356|NCT00146835|BIOLOGICAL|Licensed DTPa containing vaccine|1 or more injections
214362357|NCT00146835|BIOLOGICAL|Prevnar®: (Wyeth)|Concomitant vaccination
214362358|NCT03465280|PROCEDURE|Microdebrider|Removal of lesions via microdebrider
214362359|NCT03465280|PROCEDURE|Cold-steel surgery (forceps)|Removal of lesions via forceps
214362360|NCT03465280|PROCEDURE|Carbon dioxide laser|Removal of lesions via carbon dioxide laser
214362361|NCT03465280|PROCEDURE|Potassium titanyl phosphate (KTP) laser|Removal of lesions via KTP laser
214362362|NCT03465280|PROCEDURE|Pulsed dye laser|Removal of lesions via pulsed dye laser
214362363|NCT03465280|PROCEDURE|Radiofrequency ablation|Removal of lesions via radiofrequency ablation
214362364|NCT03465280|PROCEDURE|Monopolar suction diathermy|Removal of lesions via monopolar suction diathermy
214362365|NCT03465280|PROCEDURE|Plasma coagulation|Removal of lesions via plasma coagulation
214362366|NCT03465280|PROCEDURE|Other|Removal of lesions via other methods
214362367|NCT03465280|OTHER|Adjuvant therapies|All adjuvant therapies
214362368|NCT00533377|DRUG|CP-533, 536|Active study drug
214362369|NCT00533377|DRUG|Placebo|Placebo vehicle
214362370|NCT00533377|PROCEDURE|Standard of Care|Standard surgical procedure
214362371|NCT00533377|DRUG|CP-533,536|Active study drug
214362372|NCT00533377|DRUG|CP-533,536|Active study drug
214362373|NCT00533377|DRUG|CP-533,536|Active study drug
214362374|NCT03328299|DRUG|Dexmedetomidine|20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
214362375|NCT03328299|DRUG|bupivacaine|20 ml of 0.5 % bupivacaine
214362376|NCT06304818|DRUG|SCTB14|SCTB14,IV
214362377|NCT05560048|DIETARY_SUPPLEMENT|rice protein RP-80N|rice protein RP-80NY were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
214362378|NCT05560048|DIETARY_SUPPLEMENT|placebo|placebo were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
214362379|NCT05522725|OTHER|Single-use wipes installed at the bedside|
214362380|NCT05770999|OTHER|Lavender application|Lavender application
214362381|NCT04658147|DRUG|Nivolumab|Nivolumab 480mg will be administered as a 30 minute IV infusion (-/+15min) at cycle 1 day 1 and at cycle 2 day 1 (28 days) then every month for up to 12 months. Intravenous administration of Nivolumab (480 mg) will occur on Cycle 1 and 2 of the study then every 28 days up to a year. Nivolumab will be administered on Day 1 of each cycle for 10 doses/ months (whichever occurs first) for adjuvant.
214362382|NCT04658147|DRUG|Relatlimab|Patients will receive 480 mg Relatlimab intravenously (-/+15min) on cycle 1 day 1 and at cycle 2 day 1 (every 28 days) for up to 1 year co-administered with Nivolumab.
214362383|NCT04796818|PROCEDURE|Diffusion Weighted Imaging|Undergo IVIM DWI
214362384|NCT03054792|DIAGNOSTIC_TEST|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
214362385|NCT03054792|DIAGNOSTIC_TEST|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
214362386|NCT03054792|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
214362387|NCT05339529|DRUG|Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.
214362388|NCT05339529|DRUG|Blank control|Blank control
214489424|NCT06842368|PROCEDURE|Hyaluronic Acid (HA)|"Hyaluronic acid is one of the essential components of extracellular matrix, which plays a predominant role in tissue morphogenesis, cell migration, differentiation, and adhesion. It has been recently reported that hyaluronic acid increases osteoblastic bone formation in vitro through increased mesenchymal cell differentiation and migration.~It has demonstrated that Hyaluronic acid not only acted as a carrier of growth factors and cell but also stimulated bone formation through chemotaxis, proliferation and differentiation of mesenchymal cells into osteoblasts.~Although Hyaluronic acid shares bone induction properties with growth factors as bone morphogenic protein 2 and osteopontin"
214489425|NCT06842368|PROCEDURE|Vitamin D|"It was shown that locally applied vitamin D3 in combination with bovine bone mineral matrix improved the bone formation and strengthened the site of the fracture in ovariectomized rats.~Local application of vitamin D3 also proved to be promising in promoting osteo- genesis and mineralization for restoration of bone defects. Grounding on this incites, it has been suggested that vitamin D3 might exert a positive local effect on alveolar bone regeneration"
214973722|NCT05608304|BEHAVIORAL|Active control task|Participants assigned to the active control condition will be prompted to download a single-page document containing 100 letters, numbers, and symbols, and a grid of 100 boxes. Following along with a guided audio, participants will be instructed to place all of the characters in the grid in a specific order over the course of 10 minutes. A version of this task has been used in previous studies by our team (Carsley \& Heath, 2019; Petrovic et al., 2022) and has been shown not to impact mindfulness levels, and was thus deemed an appropriate neutral attention task for this study.
214973723|NCT03666247|BEHAVIORAL|HealthMindr Application|From baseline to 3-month post-test, participants in the intervention arm are granted access and instructed to interact regularly with the HealthMindr messaging platform. The HealthMindr messaging platform delivers messages relevant to both general audiences of sexually-active MSM, as well as messages relevant only to specific subgroups of HIV-positive men, and currently higher and lower risk HIV-negative men. Answers provided during the assessments determine which subset of messages are delivered to app users, with information such as HIV status, changes in self-reported risk behaviors, or other factors that influence the relevance of any given message. The HealthMindr application also offers free condoms, lube, and a HIV and STI testing kits.
215084321|NCT05006144|OTHER|selective dorsal rhizotomy|All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact. After opening the dura, the posterior nerve roots of L2 to S1 were identified and divided into 3 to 6 rootlets. At L2, from 30% to 50% of the posterior nerve rootlets were sectioned without selective stimulation. Selective electric stimulation of each nerve rootlet was performed from L3 to S1. The percentage of rootlets sectioned at each level (table 3) was determined by the surgical team based on the electromyographic results obtained intrasurgically and knowledge of the presurgical assessment results. The laminae were replaced on the completion of the rootlet stimulation and secured with sutures in the yellow ligament and the supraspinous ligament.
215084322|NCT00948948|DEVICE|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~* Gel-filled device which is available in smooth surface and textured surface (Siltex®)~* Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
215084323|NCT01093781|DRUG|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
215084324|NCT02047201|RADIATION|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
215084325|NCT02047201|RADIATION|PET/CT|Assessing tumor response using FDG-PET/CT.
215084326|NCT02047201|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
215084327|NCT02047201|DRUG|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
215084328|NCT02047201|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
214362389|NCT05773768|DEVICE|EHRA-PATHS software tool|Newly developed care pathways integrated into a care-management software tool
214362390|NCT02612311|BIOLOGICAL|Obinutuzumab|Obinutuzumab: IV infusion
214362391|NCT02612311|BIOLOGICAL|Ublituximab|Ublituximab: IV infusion
214362392|NCT02612311|DRUG|TGR-1202|TGR-1202: Oral daily dose
214362393|NCT02612311|DRUG|Chlorambucil|Chlorambucil: Oral dose
214362394|NCT04672551|BEHAVIORAL|EMDR Treatment|Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
214489426|NCT06862453|OTHER|Normal Saline (Placebo)|The blinded control group (n = 6) of the main cohort will receive normal saline as placebo, also by DVI.
214489427|NCT06862453|BIOLOGICAL|PfSPZ-LARC2 Vaccine|Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) contains a deletion of two genes, the Mei2 and LINUP genes, and undergoes developmental arrest in the late liver stages without releasing merozoites into the blood stream (blood stage parasites).
214489428|NCT06862453|BIOLOGICAL|PfSPZ Challenge (NF54)|Main cohort participants will undergo homologous CHMI using DVI of 3.2x10\^3 PfSPZ of PfSPZ Challenge (NF54), which are infectious cryopreserved Pf sporozoites.
214489429|NCT06617780|RADIATION|X-ray (wrist)after 3 months and CT (wrist) the day after closed reduction|One addition x-ray and on addition CT scan of the wrist
214489430|NCT06870500|DRUG|Methotrexate|"1. Assess the response of psoriasis and psoriatic arthritis to Methotrexate.~2. Assess the relation between Card14 gene(rs 34367357 ) Polymorphism in psoriatic and psoriatic arthritis patients and their clinical response to methotrexate"
214489431|NCT06870500|DRUG|Placebo|Placebo
214489432|NCT06767007|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will begin SBRT treatment within 2 weeks after the first round of chemotherapy. Intensity-modulated radiation therapy (IMRT) technology will be used, with a target gross tumor volume (GTV) of 5-8Gy/5 sessions, a total dose of 25-40Gy equivalent to a biological effective dose (BED) of 37.5-72Gy, administered from Monday to Friday. For patients who have previously received pelvic radiotherapy, the re-irradiation dose will be 3-5Gy/5 sessions, a total dose of 15-25Gy equivalent to a BED of 19.5-37.5Gy, administered from Monday to Friday.
214489433|NCT06767007|DRUG|PD1|The PD-1 monoclonal antibody used is Sintilimab 200mg every 3 weeks
214973724|NCT03666247|BEHAVIORAL|Waitlist|Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States (AIDSVu) and resources to locate HIV testing services and prevention information in their area. No information recommending frequency of testing will be given in the welcome greeting.
214489434|NCT06767007|DRUG|Chemotherapy|First-line chemotherapy regimen of rectal cancer, using a second-line regimen primarily based on fluorouracil, such as a tri-weekly CAPOX or a bi-weekly mFOLFOX6/FOLFIRI/FOLFOXIRI + targeted therapy
215084329|NCT01212614|PROCEDURE|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
214489435|NCT06745453|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block
214489436|NCT06745453|PROCEDURE|Sham Procedure|Sham Procedure
214489437|NCT06763692|DEVICE|LIFU Neuromodulation|Subjects will undergo a single LIFU of the target brain region
215084330|NCT05562180|BEHAVIORAL|Customized meal plan and grocery delivery|Participants will use an app to customize their meal plans
214489438|NCT06764147|DRUG|ET-26HCl|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
214489439|NCT06744140|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|To Evaluate the breast Magnetic Resonance Imaging (MRI) in detecting Ductal Carcinoma In Situ (DCIS) lesions among high-risk breast cancer patients while keeping the histopathology as a GOLD standard
214489440|NCT04479787|DEVICE|Spinal Cord Stimulation|Utilization of BURSTDR stimulation
215084331|NCT00022724|DRUG|temsirolimus|
215084332|NCT03597477|DRUG|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
215084333|NCT01792375|PROCEDURE|Concurrent membrane sweeping with Dinoprostone|"Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix."
215084334|NCT01792375|DRUG|10mg Dinoprostone vaginal insert|"For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening"
215084335|NCT06496438|DIETARY_SUPPLEMENT|Psychobiotics|Dietary Supplement: A four probiotic regime, containing Lactobacillus rhamnosus, Bifidobacterium animalis subsp. lactis, Bifidobacterium breve, and Bifidobacterium longum at a concentration of 1, 000,000,000 CFU.
215084336|NCT06496438|OTHER|Placebo|The placebo regime, containing powdered glucose polymer, will be identical in packaging, appearance, consistency, and solubility in drinking water, thus making it impossible to recognize which are placebo and which the therapeutic formulation. Both will be identically standardized by the same pharmaceutical company \[Uni-Pharma, Greece\].
215084337|NCT00667654|DRUG|CNTX-4975|Testing a range of dosing configurations to optimize patient tolerability
214362395|NCT00715429|DRUG|vitamin d|After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
214489441|NCT04479787|OTHER|Conventional Medical Management|Assessing type of CMM, location and frequency.
214489442|NCT06832267|DRUG|Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)|Rituximab: 375 mg/m2 intravenously on day 3,7; Methotrexate: 1.5-3.5 g/m2 intravenously on day 1,14(≤65 ,3.5g/m2；\>65,1.5g/m2); Temozolomide 150 mg/m2 on days 3-7； Thiotepa:40 mg/m2 intravenously on day 17。 Treatment will be given for 4 cycles（28 days for each cycle）, and patients who achieve a CR or better can choose to undergo ASCT or WBRT(23.4Gy).
214362396|NCT00715429|DRUG|placebo|After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
214489443|NCT06767397|DIAGNOSTIC_TEST|general anesthesia|To evaluate the factors that affect the hemodynamic stability in patients undergoing spinal anesthesia and general anesthesia during pelvic surgery.
214489444|NCT06765083|DIAGNOSTIC_TEST|POCUS of the hip|POCUS of the hip (proximal femur) by the (resident) emergency physician, prior to radiograph imaging.
214362397|NCT01409538|OTHER|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
214362398|NCT01409538|OTHER|Control condition|"This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control."
214362399|NCT06647836|OTHER|Efficacy observation|Observation about the efficacy of sq-NSCLC patients receiving immunotherapy combined with or without chemotherapy as first-line treatment.
214489445|NCT06792422|DRUG|Oral semaglutide|"Participants will receive oral semaglutide once daily.~1. Starting dose 3 mg/day for one month (day 1-28)~2. Intermediate dose 7 mg/day for one month (day 29-56)~3. Maintenance dose 14 mg/day (day 57-182)"
214489446|NCT06792422|DRUG|Placebo|"Participants will receive an oral placebo once daily.~1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28)~2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56)~3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)"
214489447|NCT06787339|DRUG|Capecitabine|Capecitabine 650mg/m2, bid, p.o for 1 year
214489448|NCT06766188|OTHER|Online Video training for Teachers based on Reading for all|"Reading intervention over a year for students with intellectual disabilities who use AAC. This study included teachers from 14 different schools and 8 municipalities and their students. It is two arms in the intervention, with approximately 7 schools and their teachers in video training for teachers and in person mentoring for teachers. The schools are randomized into these two groups, but in both groups, they will carry out the same intervention.~The students in both groups will work explicitly and systematically with the reading material Reading for all, which is based on the research of, among others, Janice Light and David McNaughton, and their reading program Accessible Literacy Learning (ALL)."
214489449|NCT06762756|BEHAVIORAL|Messages on tobacco packaging labels|The intervention was messages of the benefits of smoking cessation formatted as tobacco packaging labels with three conditions. Participants viewed the messages online. There were four messages in each condition. The intervention was informed by relevant patient and public groups.
214489450|NCT06811740|PROCEDURE|Individualized cluster management|Individualized cluster management for treatable traits
214489451|NCT06811740|PROCEDURE|Routine asthma treatment|Routine asthma treatment according to current guidelines
214489452|NCT06765252|DRUG|Capecitabine-based chemotherapy|Participants receiving capecitabine in an oral dose of 1,000-1,250 mg/m2 twice daily for the first 14 days of each 21-day cycle.
214362400|NCT00957476|DIETARY_SUPPLEMENT|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
214362401|NCT00185185|DRUG|Olmesartan medoxomil|
214489453|NCT06766084|PROCEDURE|CABG|All patients underwent isolated CABG and retrospectively followed to asses clinical outcomes of the two different revascularization techniques
215084338|NCT05463068|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
215084339|NCT00228046|DRUG|Divalproex Sodium|
215084340|NCT00228046|DRUG|Methylphenidate|
215084341|NCT00228046|DRUG|Dextroamphetamine|
214362402|NCT00185185|DRUG|Atenolol|
214489454|NCT06765915|DRUG|Avapritinib|After allo-HSCT, CBF-AML patients who have kit mutation would receive avapritinib for maintenance therapy.
214489455|NCT06786728|DRUG|frusemide|in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group
214489456|NCT06788626|DRUG|Semaglutide 0.5 mg|0.5mg semaglutide injection before and 1 week after endovascular treatment.
214489457|NCT06788626|OTHER|Standard medical treatment|Standard medical management
215084342|NCT00228046|DRUG|Mixed Amphetamine Salts|
215084343|NCT00228046|BEHAVIORAL|Family Counseling|
215084344|NCT00228046|BEHAVIORAL|Behavior Management Training with Parents|
215084345|NCT01410292|OTHER|GI and fiber meals|meals with different fiber content and glycemic index
215084346|NCT01410292|OTHER|meals|four different meal regarding GI and fiber content
214362403|NCT00185185|DRUG|Hydrochlorothiazide|tablets
214362404|NCT00185185|DRUG|olmesartan medoxomil|tablets
214362405|NCT00185185|DRUG|atenolol|tablets
214362406|NCT06537154|PROCEDURE|Active Surveillance|Participant found to have a cCR will be randomized to either standard of care or investigational active surveillance.
214362407|NCT06537154|PROCEDURE|Control arm - Definitive bladder treatment|Standard of care, consisting of radical cystectomy or chemo-radiation of the bladder
214489458|NCT06637774|DEVICE|Aspirometer|a triaxial accelerometer and a contact microphone affixed with tape to patient neck, a data accrual infrastructure, algorithms that decode swallow physiology noninvasively
214489459|NCT06637774|DEVICE|Videofluoroscopic X-ray|MBS is a fluoroscopic diagnostic test to evaluate swallowing physiology. Its images are judged by humans trained to do so.
214489460|NCT04095572|DRUG|intravesical instillation with HA-CS|intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)
214489461|NCT04095572|DRUG|intravesical instillation of sterile purified water|intravesical instillation of sterile purified water (packed and labelled according to Good Manufacturing Practice at IBSA Farmaceutici Italia Srl in Lodi, Italy to provide adequate blinding)
215084347|NCT00882908|DRUG|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
215084348|NCT00882908|DRUG|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
215084349|NCT00882908|DRUG|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
215084350|NCT00882908|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
215084351|NCT01532544|DRUG|Ilomedin and Integrilin|Continuous infusion
215084352|NCT01532544|DRUG|low molecular weight heparin.|
215084353|NCT05506839|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
214973725|NCT05448742|DEVICE|Biplanar PSI slope-reducing MOWHTO.|High tibial osteotomy (HTO) is a widely performed procedure in case of varus knee with medial compartment osteoarthritis (OA), with medial-opening wedge version performed more often than lateral-closing wedge one. While in most cases the goal of medial-opening wedge HTO (MOWHTO) is isolated correction of coronal limb alignment, intentional or unintentional increase of posterior tibial slope (PTS) after MOWHTO can occur, however its extent is usually limited and depends on accurate hinge axis placement. One of the ideas developed to improve accuracy of hinge axis placement and accuracy of biplanar correction are Patient-Specific Instruments (PSI). Our intervention is novel, biplanar, medial-opening wedge, posterior tibial slope-reducing high tibial osteotomy aided by PSI, with tibial tuberosity serving as hinge axis.
214362408|NCT04085328|DEVICE|LID015385 soft contact lenses|Investigational silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
214362409|NCT04085328|DEVICE|Comfilcon A soft contact lenses|Silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
214362410|NCT05360056|DEVICE|DexCom G6|Wearable continuous glucose monitor
214362411|NCT04041362|BIOLOGICAL|UB-421|Monoclonal antibody by IV infusion plus standard ART
214362412|NCT04041362|OTHER|Antiretroviral Therapy (ART)|Standard ART
214362413|NCT05304338|DRUG|Chlorhexidine|Gargling with 10 mL 0.2% Chlorhexidine
214362414|NCT05304338|OTHER|Oil Pulling|In oil pulling therapy, a tablespoon of edible oil is placed in the mouth and swirled between the teeth for 15 to 20 minutes
214362415|NCT05304338|OTHER|Distilled Water|Gargling with 10 mL distilled water
214362416|NCT02742168|RADIATION|99mTc-3PRGD2|"Diagnostic group：For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group：patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment)，whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."
214362417|NCT01371331|DRUG|Tacrolimus granules|oral
214362418|NCT03422874|DRUG|MLN9708|MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
214362419|NCT03422874|DRUG|Nelfinavir|Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
214362420|NCT00330083|BIOLOGICAL|ALK Ragweed Tablet|
214362421|NCT00514735|PROCEDURE|Medtronic Cardiac Ablation System|Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.
214362422|NCT00514735|DRUG|Class I or III Antiarrhythmic Medications|Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
214362423|NCT03878810|BEHAVIORAL|Exergaming|A video game-based physical activity training applied using a commercial game console.
214362424|NCT04393441|DRUG|011516X (New Artificial Tear Formulation)|Topical eye drops
214362425|NCT04393441|DRUG|Systane Ultra Multidose|Topical eye drops
214362426|NCT04393441|DRUG|REFRESH PLUS®|Topical eye drops
214362427|NCT01432548|PROCEDURE|ischemic preconditioning|Surgery with ischemic preconditioning in liver resection
214362428|NCT03558048|DIAGNOSTIC_TEST|Blood draw|Subjects will have their blood drawn during clinic visits over the course of the study period to measure their serum prostate specific antigen levels.
214362429|NCT02316795|PROCEDURE|Sentinel lymph node biopsy|
214362430|NCT02316795|DEVICE|Goggle-based device with light-emitting diodes (LED)|
214362431|NCT02316795|DRUG|Indocynanine Green|This is a infrared fluorescence imaging contrast agent
214973726|NCT05230797|DRUG|Zinc oxide Propolis|antibacterial and anti-inflammatory
215084354|NCT04654871|DIETARY_SUPPLEMENT|Chondroitin Sulfate|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
215084355|NCT04654871|PROCEDURE|Resistance exercise training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
214362432|NCT01452750|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
214362433|NCT01452750|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
214362434|NCT01452750|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
214362435|NCT01452750|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
214362436|NCT01452750|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
214362437|NCT01452750|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
214362438|NCT03399032|DRUG|Caspofungin|"Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day~Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days."
214362439|NCT04787601|OTHER|Exercise|Cognıtıve-based neuromuscular exercıses will be applied.
214362440|NCT04787601|OTHER|Classic Training|Classic match preparation training
214362441|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
214973727|NCT05230797|DRUG|Zinc Oxide-Eugenol Cement|Antimicrobial and antiseptic
214489462|NCT06747676|DEVICE|Active: High-Definition transcranial Direct Current Stimulation (HD-tDCS)|Active high-definition transcranial direct current stimulation (HD-tDCS) will be delivered by a low-intensity direct current stimulator (Soterix Medical) using a 3x1 ring configuration with a central cathode over the contralesional temporo-parietal junction. During the stimulation, participants will perform tasks to stimulate correct visual verticality perception. Six active HD-tDCS sessions of 2mA for 20 minutes HD-tDCS, 3 times daily for 2 days with session intervals greater than 3 hours.
214973728|NCT00223002|DRUG|Chlorhexidine|sample collected at time of procedure and then analysed for bacterial contamination
214973729|NCT04531332|DRUG|Continuous infusion Linezolid|Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )
214973730|NCT04531332|DRUG|intermittent dosing linezolid|Linezolid 600 mg intravenous twice daily
214973731|NCT06486285|BEHAVIORAL|Auditory-cognitive dual-task training (ACDT)|The components of auditory training are designed based on an auditory training and aural rehabilitation program LACETM (Listening \& Communication Enhancement) developed by our study team member. The cognitive training was developed and tested feasible and valid in our study team's previous dual-task Zumba cognitive training.
214973732|NCT01091246|BIOLOGICAL|Q/LAIV (MEDI3250)|10 \^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
214973733|NCT01091246|BIOLOGICAL|FluMist/B/Yamagata|10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
214973734|NCT01091246|BIOLOGICAL|FluMist/B/Victoria|10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
214973735|NCT02287038|DRUG|Atomoxetine 80 MG|Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
214973736|NCT00417664|DRUG|Dexmedetomidine|Dexmedetomidine administered as part of anesthesia in cardiac surgery patients
214973737|NCT00417664|DRUG|Propofol|Propofol administered as part of anesthesia in cardiac surgery patients
214973738|NCT00417664|DRUG|Midazolam|Midazolam administered as part of anesthesia in cardiac surgery patients
214973739|NCT06517433|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
214973740|NCT02874313|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
214973741|NCT02874313|DRUG|Pharmacological treatment|Conventional pharmacological treatment with oral antidiabetic drugs or insulin
214973742|NCT02874313|OTHER|Conventional anti-diabetic diet recommendations|
214973743|NCT03481452|BEHAVIORAL|psychotherapy|NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.
214973744|NCT02731300|DEVICE|tDCS|brain stimulation by cathodal electrode at motor cortex
214973745|NCT00010504|PROCEDURE|Acupuncture|
214973746|NCT04652557|DRUG|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
214973747|NCT04652557|DRUG|Placebo|no active component
214973748|NCT01067534|DRUG|Salbutamol|Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
214973749|NCT02713178|DRUG|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
214973750|NCT02713178|DRUG|Placebo|Normal saline.
214973751|NCT04485728|BEHAVIORAL|Sleep Improvement Protocol Intervention for Hospitalized Antepartum Patients|Patients are getting sleep hygiene education and a sleep hygiene kit.
214973752|NCT00924846|PROCEDURE|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
214973753|NCT01298167|DEVICE|Cyanoacrylate tissue glue versus Fast absorbing gut|All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
214973754|NCT05483868|DRUG|AU-011|Administration of AU-011 intratumorally and intramurally
214973755|NCT05483868|COMBINATION_PRODUCT|AU-011 in Combination with Medical Laser Adminstration|AU-011 Intratumorally and Intramurally
214973756|NCT05483868|COMBINATION_PRODUCT|AU-011 in Combination with Medical Laser Administration|AU-011 Intratumorally
214973757|NCT01217827|BEHAVIORAL|Clinical Reminder|
214973758|NCT06354218|DRUG|Serplulimab|Serplulimab （4.5mg/Kg every 3 weeks）
214973759|NCT00280592|DRUG|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
214973760|NCT00280592|DRUG|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
214973761|NCT00183651|BEHAVIORAL|Standard dialectical behavior therapy (SDBT)|Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
214973762|NCT00183651|BEHAVIORAL|Individual DBT with no DBT group sessions (DBT-I)|Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
215084356|NCT04654871|PROCEDURE|Manual therapy / Joint Mobilization|Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
215084357|NCT04654871|PROCEDURE|THE therapy|Interferential and Heating for 20 min
214362442|NCT04217681|BEHAVIORAL|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
214362443|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
214489463|NCT06747676|DEVICE|Sham: High-Definition transcranial Direct Current Stimulation (HD-tDCS)|Six sessions (3 times daily for 2 days) of 2mA sham HD-tDCS cathode center over the contralesional TPJ for 20min. Direct current (DC) will be generated by a low-intensity direct current stimulator (Soterix Medical) and then split into the 3 high-density Ag/AgCl sintered ring electrodes. The sham stimulation condition will consist of the same positioning of the electrodes as the active condition, with a ramp-up to 2mA over 30 seconds and a subsequent ramp-down of 30 seconds.
214489464|NCT06768749|OTHER|Melatonin lotion|3 g lotion applied one hour before bedtime
214489465|NCT06768749|OTHER|Placebo lotion|3 g of placebo lotion (scent-matched control) applied one hour before bedtime
214489466|NCT06418061|DRUG|IBI3005|Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
214489467|NCT04939272|DRUG|Copanlisib Hydrochloride|"Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 for each cycle.~Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level."
214489468|NCT04939272|DRUG|Venetoclax|Patients receive venetoclax PO QD on days 1-28 for each cycle. Venetoclax will have a weekly dose ramp up in cycle one from 20mg, 50mg, 100mg, 200mg, and then 400mg daily thereafter starting from cycle 2.
214489469|NCT06825585|DEVICE|Orthokeratology with 5.0mm back optical zone diameter|The orthokeratology lenses used in this study were Double Reservoir Lenses (DRL) manufactured by Precilens (Creteil, France). The lenses feature a dual reverse-curve design with a back optic zone diameter (BOZD) of 5.0 mm.
214489470|NCT06825585|DEVICE|Orthokeratology with a 6.2 mm back optical zone diameter|The orthokeratology lenses used were Euclid lenses manufactured by Euclid Systems (Herndon, VA, USA). These lenses feature a four-zone, five-curve design with a back optic zone diameter (BOZD) of 6.2 mm.
214489471|NCT06892717|OTHER||
214679567|NCT05690594|OTHER|Self or straight administered questionnaire|"Self or straight administered questionnaire with 5 parts:~* General questionnaire (to collect socio-demographic data)~* ICIQ score to evaluate urinary continence~* FLQI score to evaluate fecal continence~* FSFI score to evaluate sexuality in women or IIEF-5 score to evaluate sexuality in men~* SF-12 score to evaluate quality of life The questionnaire will be sent to patients by email and/or mail. Patients will be able to either complete the questionnaire alone and return it to the primary investigator, or to request a telephone interview to help them to complete the questionnaire. The questionnaire is administered only once and the estimated response time to the questionnaire is between 30 minutes and one hour."
214973763|NCT00183651|BEHAVIORAL|Group Skills DBT with no DBT individual sessions (DBT-S)|DBT group skills training is 2.5 hours per week and includes individual case management.
214973764|NCT03338764|DRUG|SM-1|SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
214973765|NCT03338764|DRUG|Placebo|Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
214973766|NCT03345381|OTHER|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) involves breathing exercise followed by meditation.
214973767|NCT03345381|OTHER|Usual care|Treatment as usual
214973768|NCT00596271|BIOLOGICAL|IC51|
214973769|NCT00596271|BIOLOGICAL|HAVRIX|
214973770|NCT00596271|OTHER|Placebo|
214973771|NCT01105312|DRUG|letrozole|
214973772|NCT01105312|DRUG|panobinostat|
214973773|NCT01105312|GENETIC|RNA analysis|
214973774|NCT01105312|GENETIC|microarray analysis|
214973775|NCT01105312|GENETIC|reverse transcriptase-polymerase chain reaction|
214973776|NCT01105312|OTHER|enzyme-linked immunosorbent assay|
214973777|NCT01105312|OTHER|immunohistochemistry staining method|
214973778|NCT01105312|OTHER|laboratory biomarker analysis|
214973779|NCT04866966|BEHAVIORAL|Shared medical appointments for weight loss|Shared medical appointments providing education and lifestyle change recommendations to promote weight loss in obese patients
215084358|NCT05489627|PROCEDURE|Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement|"Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well."
215084359|NCT01449773|DIETARY_SUPPLEMENT|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
215084360|NCT01449773|DIETARY_SUPPLEMENT|Placebo|5 capsules/day containing corn and soybean oil
215084361|NCT01206686|BEHAVIORAL|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
215084362|NCT01206686|BEHAVIORAL|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
214489472|NCT06748742|DRUG|In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by the device|In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by using the fluorescence imaging equipment that comes with the device. Guided by real-time fluorescence imaging, the urethra is precisely dissected and severed in front of the bladder neck. Through this improved operation, the bladder neck is protected, the neck injury that is common in conventional surgical operations is reduced, and the reconstructive surgical operations necessary after loss are reduced, and the surgical efficiency is improved. By protecting the bladder neck, the sphincter is better preserved, postoperative urinary incontinence is reduced, and the surgical outcome is improved.
214489473|NCT06750549|DEVICE|ENGAGE-HF Mobile Application|"The mobile app aids ambulatory heart failure monitoring and patient engagement through several features:~Physiologic Monitoring: Daily tracking of blood pressure, weight, and heart rate using Bluetooth devices. Data is shown in graphical and tabular formats.~Health Status Assessment: Biweekly KCCQ-12 surveys and dizziness questions provide scores (0-100), helping visualize therapy benefits and medication adherence, and reducing clinician inertia.~Medication Checklist: Lists current medications and target doses for common heart failure therapies, encouraging adherence and optimization, with alerts for potential improvements.~Education: Animated videos from heart failure experts and societies explain medications, monitoring rationale, app features, and interpretation of data.~The app enhances heart failure management via consistent monitoring, assessment, medication adherence, and educational content."
214489474|NCT06744049|DEVICE|Transfer Direct System (TDS)|Class IIA medical device (according to rule 5 of Annex VIII of Regulation (EU) 2017/745 for medical devices). A semi-automated medical equipment designed to inject an embryo into the maternal uterine endometrium through the lumen of the female reproductive system.
214489475|NCT06739980|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
214489476|NCT06891183|RADIATION|Percutaneous thermal ablation of lung tumors|Percutaneous radiofrequency ablation
214489477|NCT06757569|DEVICE|PET|Feasibility assessment of using the Radialis PET Imager for the detection of amyloid plaque burden using PET amyloid tracer.
214489478|NCT06757374|DIAGNOSTIC_TEST|Resistin|Considering the HG effect on endocrinologic and metabolic complications, resistin levels in maternal serum may change in the presence of HG severity
214489479|NCT06759298|DRUG|methylphenidate|patient group will recieve methylphenidate
214489480|NCT06759298|DRUG|matched placebo tablet|placebo gtoup will recieve matched placebo tablet
214489481|NCT06748638|DRUG|Lactulose|At 20:00 the night before the examination, pour 2 boxes of lactilose into a cup, add 1000ml of water and drink it; 4 to 6 hours before the examination, dissolve the third box of lactulose into 1000ml water, and drink it; Until pale yellow or clear dung water is drawn.
214973780|NCT03890458|DRUG|DEVIT-3|The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
214973781|NCT01533116|DRUG|BIA 9-1067|
214489482|NCT06748638|DRUG|Lactulose+ linaclotide|1 capsule of linalotide (290ug) taken orally half an hour before meal at 12:00 noon on the previous day， and two doses were taken after 20:00 according to the above Lactulose-taking method.
214489483|NCT06748638|DRUG|polyethylene glycol (PEG)|a bag of PEG was dissolved into 1L at 20:00 1d before the examination, and was drunk at a constant rate within 2h; 4 to 6 hours before the inspection, dissolve the second bag of PEG into 2L water and drink it.
214973782|NCT01533116|DRUG|Placebo|
214973783|NCT01533116|DRUG|levodopa/carbidopa|
214973784|NCT01533116|DRUG|levodopa/benserazide|
214973785|NCT03024983|OTHER|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
214973786|NCT03024983|OTHER|Semolina soup|Semolina soup (322 g) eaten with 500 mL of water
214973787|NCT03024983|OTHER|Bread|Bread (122 g) eaten with 500 mL of water
214973788|NCT03024983|OTHER|Penne (fresh)|Cooked penne (132 g) eaten with 500 mL of water
214973789|NCT03024983|OTHER|Penne (dry)|Cooked penne (142 g) eaten with 500 mL of water
214973790|NCT03024983|OTHER|Spaghetti (dry)|Cooked spaghetti (142 g) eaten with 500 mL of water
214973791|NCT01351818|DRUG|Growth Hormone|
214973792|NCT03361241|OTHER|No Physiotherapeutic Intervention|"Experimental group will perform a balance training program in a virtual environment (using a gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) without verbal/manual physiotherapeutic intervention.~Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided.~Then the patient will be invited to start the game, and in the two attempts of the training no manual or verbal assistance will be provided. Physiotherapist participation during training will be restricted to ensuring patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game at the end of each attempt."
214973793|NCT03361241|OTHER|Physiotherapeutic Intervention|Control group will perform a balance training program in a virtual environment (gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) with verbal and manual physiotherapeutic intervention. Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided. Then the patient will be invited to start the game, and in the first attempt of the training physiotherapist will provide manual and verbal assistance, providing corrections on movement (avoiding compensatory movements). In the second attempt, no manual or verbal assistance will be provided (only ensuring patient safety, providing motivational verbal stimuli), allowing the patient to organize his or her performance.
214973794|NCT06145126|OTHER|Prednisolone|Predisolone is used as a tool to elicit a physiological response (toolbox trial) and not as a pharmaceutical agent/treatment.
214973795|NCT06145126|OTHER|Placebo|Placebo to predinisolon
214973796|NCT03568578|DRUG|Entecavir 0.5 mg|Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
214489484|NCT06748118|OTHER|Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action for therapeutic adherence.|This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake. The research does not anticipate any change in the patient's medical prescriptions.
214362444|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
214489485|NCT06754254|DIAGNOSTIC_TEST|blood biomarkers from the internal jugular vein|blood biomarkers (Aβ42/40, p-tau217, p-tau181, NFL, GFAP, etc.) from the internal jugular vein
214489486|NCT06761846|BIOLOGICAL|Sintilimab plus Chemotherapy|chemotherapy includes SOX and XELOX
214489487|NCT06764732|BIOLOGICAL|bioactive glass|supplied as resorbable form, (400-800um) particle siz
214973797|NCT03568578|DRUG|Anluohuaxian Pill 12g|Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
214973798|NCT04826627|OTHER|glycemia|capillary glycemia
214973799|NCT06331663|DRUG|Remifentanil|first start with remifentanil 5.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. Inadequate antinociception (Surgical Pleth Index(SPI) \> 80 and hyperdynamics (the increased heart rate (HR) and mean blood pressure (MBP) above 20% of baseline or HR\>100bpm and arterial blood pressure(ABP)\>180/100mmHg)) is defined as failure, therefore we increase remifentanil by 0.5 ng/ml; otherwise, the setting is considered successful without abovementioned situations.
214973800|NCT06310811|DRUG|RD06-04 Cells injection|Patient will be treated with RD06-04 cells when enrolled in the study
214973801|NCT03158168|DRUG|Candida Antigen|Candida Albicans Antigen injection
214362445|NCT00403416|DRUG|AEB071|
214362446|NCT00403416|DRUG|Mycophenolic Acid|
214362447|NCT04941040|DRUG|Opioid free anesthetics|"Patients will receive over the 10 minutes prior to induction:~* Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~* Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~* Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~* Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~* Lidocaine loading dose 1.5 mg/kg i.v. infusion.~* Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~* Dexmedetomidine 0.25-0.5 μg/kg/h~* Lidocaine 0.375-0.75 mg/kg/h~* Ketamine 0.0625- 0.125 mg/kg/h"
214362448|NCT04941040|DRUG|Opioid Anesthetics|Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
214362449|NCT04099108|COMBINATION_PRODUCT|Combined cycle ergometry and bolus amino acid supplementation|A 4-hour bolus amino acid supplement administered within 30 minutes after a 30-minute in-bed cycling session.
214362450|NCT00223834|BEHAVIORAL|single session of Motivational Interviewing|
214489488|NCT06764732|RADIATION|bioactive glass graft and PBM irradiation|The used laser parameters were set as: wavelength, 980 nm; power, 0.55 W; energy, 36 J; power density, 0.76 W cm2
214973802|NCT03158168|DRUG|Zinc Sulfate|Zinc Sulfate injection
215084363|NCT01206686|BEHAVIORAL|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
215084364|NCT05291936|DEVICE|PRECISION1® for Astigmatism Contact Lenses|TEST
214362451|NCT00244296|DRUG|Duloxetine hydrochloride|
214362452|NCT00244296|DRUG|placebo|
214362453|NCT03963908|BEHAVIORAL|AtEase|AtEase is a tailored pain self-management mobile app that tailors participant's feedback based on readiness to engage in pain self-management and preference for self-management strategies.
214362454|NCT03963908|BEHAVIORAL|Chronic Pain Education|CBT-based Education on Pain Self-Management for Veterans
214489489|NCT06764732|BIOLOGICAL|Platelet rich fibrin|10 ml of blood was withdrawn from the patient and immediately centrifuged for 10 minutes at 3000 revolutions/min and the layer of fibrin clot was obtained
214489490|NCT06760767|BEHAVIORAL|sexual therapy|In sexual therapy sessions, sexual education, cognitive restructuring, body awareness exercises, systematic desensitization, relaxation training, individual and partner home exercise training and dilator treatment were applied with the supervision of a physiotherapist. All techniques and stages were not applied in the same session and were used with a certain progression
214679568|NCT04522427|DEVICE|Use Multifocal and Extended Depth-of-Focus Intraocular Lenses(IOLs)|IOLs include AT LISA tri 839MP, AcrySof IQ PanOptix IOL, TECNIS Symfony EDOF
214679569|NCT04522427|DEVICE|Use Monofocal intraocular lenses(IOLs)|Monofocal IOLs include 409(Zeiss), AcrySof, TECNIS IOLS
214679570|NCT02662686|OTHER|Transfer according to morphological criteria|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
214973803|NCT06406335|OTHER|Health education program|Impact of A Multidimensional Health Education Program on Attention deficit hyperactivity disorder (ADHD)
214973804|NCT03898193|DRUG|Montelukast|Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus
214973805|NCT03898193|DRUG|Singulair|Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp \& Dohme B.V., the Netherlands
215084365|NCT05291936|DEVICE|MyDay® Toric Soft Contact Lenses|CONTROL
215084366|NCT02907853|BEHAVIORAL|Contingency Management|as described above
214973806|NCT00314158|DRUG|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop twice daily in each study eye for six months
214973807|NCT00314158|DRUG|Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension|One drop twice daily in each study eye for six months
214973808|NCT00314158|DRUG|Timolol 5 mg/ml eye drops, solution|One drop twice daily in each study eye for six months
215084367|NCT01789528|DRUG|CAZ-AVI|IV infusion
215084368|NCT01789528|DRUG|CXL|IV infusion
214489491|NCT06760767|BEHAVIORAL|Pelvic floor physiotherapy combined with sexual therapy|Pelvic floor physiotherapy combined with sexual therapy was applied in the experimental group. Sexual therapy techniques were added appropriately before, during and after the pelvic floor physiotherapy session. In the pelvic floor physiotherapy sessions, pelvic floor muscle training, biofeedback, electrotherapy, manual therapy applications, breathing exercises, stretching and relaxation exercises were applied with the physiotherapist. Pelvic floor physiotherapy techniques and stages were applied in the same session and followed a certain progression.
214362455|NCT00689221|DRUG|Cilengitide|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
214362456|NCT00689221|DRUG|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
214362457|NCT00689221|RADIATION|Radiotherapy|Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.
214362458|NCT04355351|OTHER|blood sampling|blood sampling done on hospital staff without sars-coV-2 symptoms
214362459|NCT04355351|OTHER|additional blood tubes|Additionnal blood tube taken during the classical blood sampling in hospital
214362460|NCT06171542|DEVICE|CTM Injection|All glenohumeral joint injections will be performed by a physician under the guidance of either ultrasound or fluoroscopy to ensure and document intra-articular needle placement. 2cc of CTM Flow will be injected. The glenohumeral joint will be injected with the medication under the discretion of the treating surgeon.
214362461|NCT02610348|BIOLOGICAL|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
214362462|NCT02610348|BIOLOGICAL|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
214362463|NCT04994834|DIETARY_SUPPLEMENT|Probiotics|Once a day daily intake of probiotics for at least 28 consecutive starting within 24 hours after birth
214362464|NCT01749982|OTHER|Placebo|
214362465|NCT01749982|DRUG|Choline bitartrate|
214362466|NCT01749982|DRUG|Betaine|
214362467|NCT01749982|DRUG|Choline bitartrate + Betaine|
214362468|NCT02302443|BIOLOGICAL|HM12470|Single dose subcutaneous administration ranging from a very low dose to high dose
214362469|NCT02302443|BIOLOGICAL|Active comparator|Single dose subcutaneous administration of active comparator
214362470|NCT02444455|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous infusion(5×10\^5/kg) once a day,a total of three times.
214362471|NCT04822038|DIETARY_SUPPLEMENT|Vitamin D3|5000 UI Vitamin D3 daily by 4 weeks
214362472|NCT04822038|OTHER|Dietary recommendations|Dietary recommendations based on food rich in 25 (OH) vitamin D
214362473|NCT04647149|BEHAVIORAL|Dietary Approach|Dietary approaches with energy restriction performed at different times of the day.
214362474|NCT04950374|OTHER|Moisturizer Body Lotion|The body lotion product is a moisturizing formulation intended for topical use on the whole body and face. It will be applied at least twice daily.
214362475|NCT04950374|OTHER|Lip Moisturizer|The lip product is a moisturizing formulation intended for topical use on the lips. It will be applied at least twice daily.
214362476|NCT00036569|PROCEDURE|adjuvant therapy|
214362477|NCT00036569|BIOLOGICAL|pegylated interferon alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
214362478|NCT01596582|BEHAVIORAL|Risk Assessment|Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid. The ACNI uses a point based system to stratify patients into low (mean rate of ACN \~3%) versus intermediate/high (\~ 8%) risk groups based on responses to 6 items: age (50-59, 60-69, 70+), sex (male/female), race/ethnicity (non-Hispanic black, other), smoking history (never, \<20 years, 20+ years), daily alcohol intake (\< 2 vs. \>/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never). The index represents a prototype version of the Advanced Colorectal Neoplasia Index (Am J Gastroenterol 2015;110:1062-71).
214362479|NCT01187693|OTHER|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
214362480|NCT00754026|PROCEDURE|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
214362481|NCT00754026|PROCEDURE|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
214362482|NCT05242991|DEVICE|Photobiomodulation therapy|Light therapy for the management of oral side effects related to radiotherapy, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief.
214362483|NCT04814329|OTHER|genetic characteristic|the underlying genetic characteristics that prodicting response
214362484|NCT01274195|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
214362485|NCT05798195|OTHER|conventional western medicine treatment|conventional western medicine treatment only
214489492|NCT06762210|OTHER|AI Molar Mind|a baseline oral health assessment using AI Molar Mind, which analyzes intraoral images and self-reported oral health data.
214973809|NCT05775627|BEHAVIORAL|Sleep Restriction|Participants are randomized into either a group (n=10) that is sleep restricted first or control first (n=10) group; the groups will crossover halfway through the protocol. Both arms are fed 3 meals and have access to ad libitum food between meals. Both groups will also undergo up to 3 mixed-meal tolerance tests to measure glucose tolerance.
214973810|NCT00190424|DRUG|CpG-ODN|
214973811|NCT02740959|DRUG|Astragalus Polysaccharides 500 mg|PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
215084369|NCT00201591|BEHAVIORAL|Exercise training for 10 weeks|
215084370|NCT04533542|OTHER|Measurement|Undergo sensory measurements
214362486|NCT05798195|DRUG|Dexamethasone oral tablet|treat with Dexamethasone for 2 weeks
214973812|NCT02740959|DRUG|Astragalus Polysaccharides 250 mg|PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
214973813|NCT02667301|DEVICE|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
215084371|NCT04533542|OTHER|Questionnaire Administration|Ancillary studies
214362487|NCT05798195|OTHER|Traditional Chinese medicine decoction|treat with strengthening spleen and tonifying lung decoction for 2 weeks
214362488|NCT03390439|DEVICE|Nd-Yap 1340nm laser|Each part of the abdomen will be treated with a therapeutic modality. The ND-yap 1340-nm laser will be used in the following parameters: 90 mtz / cm2 nozzle, 90 mJ / mtz power, 2.5 Hz frequency, 3 ms pulse duration, 1 pass.
214362489|NCT03390439|DEVICE|Microneedling|In the other segment of the abdomen, the dermaroller 2.5 mm will be applied, with ten to fifteen passes in the same direction and at least four crosses in the rolling areas.
214362490|NCT00204048|BEHAVIORAL|Observation (behavior)|Inpatients admitted in GenMed at the University of Chicago will be consented to participate in an inpatient interview that consists of questions related to quality of care and satisfaction. The patient will also be interviewed over the phone 30 days after discharge and will be asked questions related to current health and their satisfaction during their stay at University of Chicago.
214362491|NCT01986465|DRUG|Depomedrol|
214362492|NCT01986465|DRUG|Placebo|
214362493|NCT03240848|PROCEDURE|artificial intelligent clinic|Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
214362494|NCT03240848|PROCEDURE|normal clinic|Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
214362495|NCT03240848|PROCEDURE|experts diagnose|After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
214362496|NCT06191718|DEVICE|Mitral Valve Replacement|Foldax Mitral Valve Replacement
214362497|NCT02615574|BIOLOGICAL|αDC1 vaccine|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
214362498|NCT02615574|DRUG|CKM|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
214362499|NCT04635553|DRUG|Praziquantel 600 milligram|A single treatment with a dose of 40 milligram/kilogram (mg/kg)
214362500|NCT04808804|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|a noninvasive imaging technology used to obtain high resolution cross-sectional images of the retina
214362501|NCT04050826|DRUG|Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)|Topical application
214362502|NCT04050826|DRUG|Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., USA)|Topical application
214362503|NCT04050826|DRUG|Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)|Topical application
214362504|NCT04050826|DEVICE|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).~From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose)."
214362505|NCT04050826|PROCEDURE|Blood sampling|1 sample will be taken pre-dose and 12 samples post-dose.
214362506|NCT05356858|DRUG|zanubrutinib|zanubrutinib orally, 80mg bid for 1 year
215084372|NCT00047333|DRUG|erlotinib hydrochloride|Given PO
215084373|NCT00047333|OTHER|laboratory biomarker analysis|Correlative studies
215084374|NCT00047333|OTHER|pharmacological study|Correlative studies
215084375|NCT03168243|DIETARY_SUPPLEMENT|High Energy High Protein Tube Feed|Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
215084376|NCT02798770|OTHER|No Intervention Foreseen|
214362507|NCT04598724|OTHER|Surveys|Survey will be administered involving questions regarding knowledge and perception of palliative care.
214362508|NCT04435665|DRUG|NFX-179 Gel|gel for topical administration
214362509|NCT04435665|DRUG|Vehicle Gel|vehicle gel for topical administration
214362510|NCT01263834|DRUG|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
214362511|NCT01263834|DRUG|Mitomycin C|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
214362512|NCT00006352|BIOLOGICAL|BCG vaccine|
214362513|NCT00006352|BIOLOGICAL|monoclonal antibody BEC2|
214362514|NCT01064232|DRUG|Risperidone|Risperidone Tablets 1 mg
214362515|NCT03923933|DRUG|Chlorthalidone|Chlorthalidone
214362516|NCT03923933|DRUG|Bumetanide|Bumetanide
214362517|NCT06268158|BEHAVIORAL|Eye patch|The experimental group will fill out the patient introduction form, Richmond Agitation-Sedation Scale, Nursing Delirium Screening Scale and Richard-Campbell Sleep Scale on the first day. On the 4th day of the study, the Nursing Delirium Screening Scale and the Richard-Campbell Sleep Scale will be completed.
214362518|NCT02454101|PROCEDURE|cord milking|milking of the cord 5 times toward the neonate
214362519|NCT02454101|PROCEDURE|delayed cord clamping|delay clamping of the cord for 120 seconds
214362520|NCT05307848|OTHER|No intervention|No intervention
214362521|NCT00241579|DRUG|Smoked Cannabis|
214362522|NCT04073238|DEVICE|Low-level Red-light Therapy|In addition to wearing single vision spectacle lens with power for correcting distance refraction, low-level red-light therapy is performed twice per school day at home with an interval of at least 4 hours, each treatment lasting 3 minutes.
214362523|NCT00419263|DRUG|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
214362524|NCT00419263|DRUG|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
214362525|NCT00419263|DRUG|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
214362526|NCT05304169|DRUG|Leuprorelin Acetate (Eligard® 45 mg).|Semiannually Leuprorelin Acetate (Eligard® 45 mg).
214679571|NCT02662686|OTHER|Transfer according to the MitoScore results|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
214489493|NCT06761768|DRUG|Corticosteroids Triamcinolone Acetonide|ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine)
214489494|NCT06761768|DEVICE|extracorporeal shockwave|a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: low to moderate, adjusted based on patient tolerance; frequency: 5 Hz; 2000 shocks per session)
214489495|NCT06761768|DEVICE|extracorporeal shockwave(minimum intensity)|a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: minimum setting on the device; frequency: 5 Hz; 2000 shocks per session)
214489496|NCT06447532|PROCEDURE|Surgery (Mastectomy or quadrantectomy)|Surgery (mastectomy or quadrantectomy); Neoadjuvant chemotherapy
214489497|NCT06763237|DEVICE|abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS)|"The TEAS intervention is delivered using an electroacupuncture device (SDZ-V, Hwato, Soochow Medical Instruments Co., Ltd., China). Self-adhesive electrodes are placed at acupoints Zhongwan (RN12), bilateral Tianshu (ST25), Qihai (RN6), and Guanyuan (RN4). Stimulation is applied using dense-sparse wave alternating frequencies (3 Hz for 2 s cycles) at an intensity of 3-10 mA, adjusted to the participant's tolerance. Each session lasts 30 minutes, conducts once daily, five days per week, for a total of 40 sessions.~The ABA therapy focuses on enhancing skills in areas such as social interaction, communication, academics, motor function, and self-care. ABA is delivered in a variety of settings, including school, home, clinic, and other community settings. The goal of treatment is to help children function as independently and successfully as possible. Each session lasts 30 minutes, conducts once daily, five days per week, for a total of 40 sessions."
214489498|NCT06323837|DRUG|Mirtazapine|This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of mirtazapine (MZP) to increase methamphetamine (MA) abstinence among treatment-seeking medication for opioid use disorder (MOUD) adults.
214489499|NCT06323837|DRUG|Placebo|Placebo to match.
214489500|NCT06773403|DRUG|Upadacitinib|All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.
214489501|NCT06779045|DRUG|AK-1286|Cohort 1: 1 mg/d QD AK-1286 PO,DLT observation period: 21 days. Cohort 2: 2 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 3: 4 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 4: 5 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 5: 16 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 6: 24 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 7: 36 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 8: 50 mg/d BID AK-1286 PO,DLT observation period: 21 days.
214489502|NCT06752434|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
214489503|NCT06768554|OTHER|Level of blood sugar control (e.g., hemoglobin A1C), severity of infection, blood supply status, and other complications (e.g., peripheral neuropathy)|Level of blood sugar control (e.g., hemoglobin A1C), severity of infection, blood supply status, and other complications (e.g., peripheral neuropathy)
214489504|NCT06756945|DRUG|aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily|STEMI patients receive aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily
214679572|NCT00196495|DEVICE|Polypropylene Mesh|
214679573|NCT00627640|DRUG|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
214679574|NCT00627640|DRUG|Matching Placebo|Matching Placebo
214679575|NCT05811572|DEVICE|measurement of pelvic floor muscle with perinometer|Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
214679576|NCT04660903|PROCEDURE|Autologous fat cell transplantation|Up to 75 ml of fatty tissue mixture fluid
214679577|NCT01553539|DRUG|therapeutic angiotensin-(1-7)|Given SC
214973814|NCT02667301|DEVICE|Tympanic Cavity Air Exchange Test|Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
214973815|NCT02667301|DEVICE|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
214973816|NCT04753957|DRUG|micronized Progesterone|200mg micronized progesterone placed vaginally
214973817|NCT00053209|DRUG|gemcitabine hydrochloride|
214362527|NCT02044185|DRUG|salvage chemotherapy, total body irradiation|there are no direct interventions to our patients.
214362528|NCT06010082|BEHAVIORAL|Music Therapy|Music Therapy intervention will be delivered through instructed participants to empty their bladder and then listen to music for 30 min in a semi-fowler's position with their head and shoulders raised 30° in a quiet and dim environment, listening to the music of symphonic music.
214362529|NCT00975312|DRUG|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
214973818|NCT00053209|DRUG|pemetrexed disodium|
214973819|NCT04328428|OTHER|acupuncture|Use one acupuncture needle insert in a acupoint.
214973820|NCT03199950|DRUG|Haloperidol|Haloperidol 2dd1mg (08.00am - 10.00pm)
214973821|NCT03199950|DRUG|Placebo Oral Tablet|Placebo oral 2dd (08.00am - 10.00pm)
214362530|NCT00975312|DRUG|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
214362531|NCT03118024|DRUG|Crystalloid Solutions|crystalloid restrictive anesthesia protocol
214362532|NCT03118024|DRUG|Catecholamines|catecholamine restrictive anesthesia protocol
214362533|NCT01696201|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
214362534|NCT05035472|DRUG|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
214362535|NCT05035472|DRUG|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
214362536|NCT03115892|DRUG|Green Tea With Aloe Vera mouthwash|measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score
214362537|NCT03115892|DRUG|Chlorhexidine mouthwash|chlorohexidine mouthwash take two times per day for one week
214362538|NCT06405503|OTHER|NO INTERVENTION|NO INTERVENTION - OBSERVATIONAL ONLY
214362539|NCT02451527|DRUG|Digoxin|Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
214362540|NCT02451527|DRUG|PEX168|PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
214362541|NCT03311373|DRUG|Regimen A|2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure
214362542|NCT03311373|DRUG|Regimen B|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
214362543|NCT03311373|DRUG|Regimen C|2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure
214362544|NCT03311373|DRUG|Regimen D|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
214362545|NCT03208023|PROCEDURE|RESIPI Management Strategy|a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).
214362546|NCT03208023|OTHER|No intervention|No intervention
214362547|NCT03768258|DRUG|Testosterone Implant|Testosterone implants or combination testosterone + anstrozole implants used to treat symptoms of hormone/androgen deficiency
214362548|NCT06122740|OTHER|Turkish Validity and Reliability of The MAM-36 Scale|The aim of this study is to adapt the Manual Ability Measure-36 (MAM-36) scale to Turkish society and to make its validity and reliability in Turkish.
214362549|NCT03917368|OTHER|Ultrasound scan of the internal jugular veins|Participants, lying at their hospital bed, will maintain their head in a fixed position on the longitudinal axis, while an operator gently places a linear probe L12-RS (7.5-11 MHz), smeared with gel, on one side of the neck, at the middle level. A 15-sec video clip of the ultrasound images will be recorded. This procedure will be repeated on the other side of the neck. In addition, three electrodes will be placed on participants' chests and connected to the ultrasound system for simultaneously measuring the ECG signal.
214362550|NCT01758354|OTHER|Pompe disease newborn screening|DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
214362551|NCT01786967|DRUG|Fesoterodine Fumarate|FDA approved anticholinergic medication used for treatment of urge urinary incontinence
214362552|NCT05536362|DRUG|TCI Propofol Injection|To decrease postoperative pain after cancer colon surgery
214362553|NCT04557930|BEHAVIORAL|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
214362554|NCT01563536|DRUG|ABT-267|Tablet
214362555|NCT01563536|DRUG|ABT-450|Tablet
214362556|NCT01563536|DRUG|ABT-333|Tablet
214362557|NCT01563536|DRUG|Ritonavir|Capsule
214362558|NCT01563536|DRUG|Ribavirin|Tablet
214362559|NCT03156660|BEHAVIORAL|Weight gain prevention (Group 1)|"Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~1. Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~2. Daily self-monitoring of steps and number of Small Changes~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Fit Bit Alta activity trackers to self-monitor steps"
214362560|NCT03156660|BEHAVIORAL|Weight loss intervention (Group 2)|"Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~1. Tailored calorie and fat goals based on their baseline weight.~2. Daily dietary intake and physical activity self-monitoring using a website or app.~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~5. Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~6. Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~7. Fit Bit Alta activity trackers to self-monitor steps"
214679578|NCT01553539|OTHER|laboratory biomarker analysis|Correlative study
214973822|NCT02611947|RADIATION|Low-dose chest CT scans|"Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm"
214362561|NCT03156660|BEHAVIORAL|Self-guided intervention (Group 3)|"Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~1. EatingWell Diet book.~2. Daily weight self-monitoring on the BodyTraceTM e-scale"
214362562|NCT01270126|DEVICE|Repetitive transorbital alternating current stimulation|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
214362563|NCT05232695|DIAGNOSTIC_TEST|metabolically healthy obese|Obese individuals will be divided into 2 groups as metabolic healthy and unhealthy obese, and their batokine concentrations will be compared.
214362564|NCT00844025|BEHAVIORAL|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
214362565|NCT00112879|DRUG|arsenic trioxide|
214362566|NCT00112879|DRUG|ascorbic acid|
214362567|NCT00112879|DRUG|dexamethasone|
214362568|NCT00112879|DRUG|thalidomide|
214362569|NCT00112879|PROCEDURE|anti-cytokine therapy|
214973823|NCT05282368|BEHAVIORAL|PHM™ Pathway|"The technological platform referred to as Preparing Heart and Mind™ (PHM™) is designed as a patient engagement pathway. This platform includes GetWellNetwork's proprietary workflow engine, Patient Pathways™ and functionality of the Health Loop platform. Specifically, PHM™ will be created on a customized GetWellNetwork patient engagement pathway, getwell \| Loop, which is a secure platform with a parent-facing app and an interactive dashboard for healthcare providers. The PHM™ getwell \| Loop is a care program with chapters that incorporate interactive resources for patient information and education, trackers as touch points for psycho-social/educational support, and tailors care with condition-specific content, as well as action items."
214973824|NCT02283658|DRUG|Everolimus|Given PO
214973825|NCT02283658|OTHER|Laboratory Biomarker Analysis|Correlative studies
214973826|NCT02283658|DRUG|Letrozole|Given PO
214973827|NCT00849563|OTHER|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
214973828|NCT01283100|DRUG|GSK1349572|50mg once every 24 hours for 7 days
214973829|NCT01283100|DRUG|GSK2248761|200 mg once every 24 hours for 7 days
214973830|NCT01858870|DRUG|lacosamide|routine clinical practice
214973831|NCT02076620|DRUG|L19TNFα|L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.
214973832|NCT02076620|DRUG|Doxorubicin|Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
214973833|NCT05996939|OTHER|To compare the efficacy of unstable shoes with that of conventional sports shoes in people with lower-limb primary and secondary lymphedema.|Unstable shoes were compared with conventional sports shoes, the objective being to evaluate possible differences in the evolution of lymphedema. During a clinical trial lasting eight weeks, we assessed quality of life, limb volume, and symptoms derived from lymphedema.
214973834|NCT02937480|OTHER|Task-specific training|The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
214973835|NCT02937480|OTHER|Global stretching, memory exercises, health care orientation|The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
214973836|NCT00847600|DIETARY_SUPPLEMENT|Pregnenolone|50 mg, caps.
214973837|NCT00847600|DIETARY_SUPPLEMENT|Placebo|caps
214973838|NCT00239070|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214973839|NCT04229043|DIETARY_SUPPLEMENT|Sports drink|Drink that will be ingested
214973840|NCT04229043|DIETARY_SUPPLEMENT|Water|Drink that will be ingested
214973841|NCT05003544|PROCEDURE|Group A|PENG BLOCK
214973842|NCT05003544|PROCEDURE|Group B|Intra-articular
214973843|NCT05003544|PROCEDURE|Group C|Quadratus lumborum block
214973844|NCT00005067|DRUG|motexafin lutetium|Given IV
214362570|NCT00112879|PROCEDURE|antiangiogenesis therapy|
214362571|NCT00112879|PROCEDURE|biological therapy|
214362572|NCT00112879|PROCEDURE|chemotherapy|
214362573|NCT00112879|PROCEDURE|drug resistance inhibition|
214362574|NCT00112879|PROCEDURE|growth factor antagonist therapy|
214362575|NCT00112879|PROCEDURE|non-specific immune-modulator therapy|
214362576|NCT00538590|DEVICE|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
214362577|NCT00538590|DRUG|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
214362578|NCT06059222|DRUG|Romosozumab|Romosozumab 210 mg/2.34 ml from baseline to month 11
214362579|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 12
214362580|NCT06059222|DRUG|Romosozumab|210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23
214973845|NCT00005067|DRUG|photodynamic therapy|Undergo photodynamic therapy
214973846|NCT02421354|OTHER|Laboratory Biomarker Analysis|Correlative studies
214973847|NCT02421354|BIOLOGICAL|Nivolumab|Given IV
214973848|NCT02421354|OTHER|Quality-of-Life Assessment|Ancillary studies
214489505|NCT06756945|DRUG|aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily|STEMI patients receive aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily
214489506|NCT06752863|DRUG|Hypotensive anesthesia in ear, nose and throat surgeries using labetalol and dexmedetomidine infusions|The study compares the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in patients having ear, nose and throat surgeries
214489507|NCT06753877|BEHAVIORAL|holistic rehabilitation|Holistic rehabilitation service All participants in the study were cared for in the inpatient unit. The same physician and nurses followed the participants for 1 month. The participants were regularly taking their medication and had no co-morbidities. All participants stayed in double rooms and all stayed with their caregivers. The assessments were carried out within the first 3 days of admission to the inpatient unit. The second assessments were repeated by the same professional. Rehabilitation interventions were provided by different therapists. Participants were given standard physiotherapy services (electrotherapy, exercise, gait training, hydrotherapy, respiratory therapy) and standard occupational therapy services. Occupational therapy interventions were provided by the researchers. Physiotherapy services were provided by physiotherapists working full-time in the hospital. Physiotherapy was provided 5 days a week and occupational therapy was provided 3 days a week.
214973849|NCT04181671|OTHER|Low Resistance training with venous blood flow restriction|"Total 20 males will participate in this group after warmup , Blood flow restriction will be provided through sphygmomanometer optimum pressure will be measured through following formula occlusion pressure (mmHg) = 0.514 (SBP) + 0.339 (DBP) + 1.461 (Arm circumference) + 17.236 then 30% of 1RM will be used for training . The standard protocol will be used which is four sets (1st set-30 repetitions, 2nd set-15 repetitions, 3rd set-15 repetitions, and 4th set-15 repetitions) with 30-60 s of interval between sets. ( the cuff must be deflated between sets of exercise) for 8 weeks (24) sessions on non-consecutive days. participants will be re-assessed for all baseline variables after 8 weeks of training biceps curls will be used for training.~Heart Rate and oxygen saturation will be measured during the session through Pulse oximeter"
214362581|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 6
214362582|NCT06059222|DRUG|Romosozumab|210 mg/2.34 ml from baseline to month 5
214362583|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 5 and month 18
214362584|NCT04240366|PROCEDURE|Control intervention|patients treated with balloon-based ablation of AF by PVI
214362585|NCT04240366|PROCEDURE|Experimental intervention|patients treated with balloon-based ablation of AF by PVI
214362586|NCT01256567|BIOLOGICAL|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
214362587|NCT01256567|DRUG|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m\^2) every 3 weeks.
214362588|NCT00004339|DRUG|tetrathiomolybdate|
214362589|NCT00004339|DRUG|trientine|
214973850|NCT04181671|OTHER|High Resistance training|Total 20 males will participate in this group after warm up. 80% of 1RM will be used for training, 3 sets of 8 repetitions will be used with 30-60 s of interval between sets. for 8 weeks (24) sessions on non-consecutive days.No blood flow restriction will be applied to this group Participants will be re-assessed for all baseline variables after 8 weeks of training. Bicep curls will be used for training.
214973851|NCT03964389|OTHER|"Pain Neuroscience Education (PNE)"|A lecture on neuroscience education (EN). The aim of this intervention is to provide participants with information in a clear and simple way so that patients can change their attitude to pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without tissue damage or with damage that justifies the perceived disproportion of pain.
214973852|NCT04852731|PROCEDURE|Cardiac MRI|Injected cardiac MRI
214973853|NCT04852731|OTHER|Blood collection|Blood collection (including genetics at the inclusion visit)
214973854|NCT04852731|PROCEDURE|Prolongation of the MRI examination|Prolongation of the MRI examination (4D flow sequence ; about 10 min)
214973855|NCT05962112|OTHER|Metabolic investigations after night-shifts|Metabolic investigations after night-shifts
214362590|NCT06333587|PROCEDURE|image-guided thermal ablation|image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
214362591|NCT06136221|BEHAVIORAL|LiverWatch Intervention|The LiverWatch Intervention will include standard cirrhosis care and include additional components utilizing the W2H system. Details on this intervention are included in the study arm description.
214362592|NCT06559501|BEHAVIORAL|Integrated case manager care|comprises 8 sessions delivered by case managers. Case managers will provide up to 6 low-intensity sessions in the hospital or the community (if the patient is discharged before completing the required sessions), with content and duration tailored to patient preferences. Post-discharge, patients will receive 2 follow-up sessions with case managers to ensure a smooth transition into the community.
214362593|NCT03136445|DRUG|Tranexamic acid (TXA).|IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.
214362594|NCT03136445|DRUG|Placebo|IV (saline) or oral placebo tablets
214362595|NCT05850091|DRUG|Rosuvastatin|Pharmacotherapy for reduction in LDL cholesterol level
214362596|NCT05850091|DRUG|Colchicine|Pharmacotherapy for inflammation inhibition
214362597|NCT05850091|DRUG|Placebo|Capsule with sugar pill that mimics active study drugs
214362598|NCT06030414|BIOLOGICAL|LMN-301|Intranasally administered powder.
214362599|NCT06264479|PROCEDURE|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
214489508|NCT06752616|DRUG|Sublingual Dexmedetomidine|Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs
214489509|NCT06752616|DRUG|Buccal midazolam|Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs
214489510|NCT06752616|DRUG|Oral lorazepam|Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs
214489511|NCT06756022|DRUG|Dolasetron mesylate injection|"1.8 mg/kg Dolasetron mesylate injection should be injected intravenously 30±10 min before chemotherapy infusion, with the maximum dose not exceeding 100 mg. It can also be mixed with apple juice or apple-grape juice for oral use, the oral dose is 1.8 mg/kg, the maximum amount is not more than 100 mg, taken orally within 1 h before chemotherapy.~Other antiemetic drugs, except dolasetron, are at the discretion of the subject's supervising physician in accordance with clinical practice."
214489512|NCT06749678|BEHAVIORAL|Prehabilitation|In addition to routine nursing measures, the prehabilitation group underwent prehabilitation measures during the conversion therapy period. It includes the following strategies: (1) Exercise: Exercise should be carried out when the patient's condition allows, and the exercise programme should be dynamically adjusted according to the patient's tolerance, and it is advisable to maintain the Borg score between 11\~13 points (i.e., subjectively feel relaxed or a little strained). (2) Nutritional support: ensure that the patient's daily energy intake is 20\~25kcal/kg (the target energy reaches 30\~35kcal/kg), and the protein intake is 1.2\~1.5g/(kg·d). (3) Psychological intervention: for patients with mild to moderate anxiety or depression, health education, music therapy and other psychological interventions are carried out. For patients with severe anxiety or depression, psychologists will conduct psychological consultation for patients and provide professional psychological therapy.
214489513|NCT06749678|BEHAVIORAL|Routine nursing measures|Routine nursing measures including: (1) general education: for different patients, cards and manuals were used to focus on the diagnosis and treatment matters such as examination, treatment, surgery and perioperative treatment, so as to alleviate the anxiety and fear of patients and better cooperate with hospital management. (2) Medical optimization: including smoking cessation, alcohol restriction, chronic disease control, etc. (3) Nutritional support: Routine dietary guidance and nutritional support are given, and intravenous or oral nutrition therapy is given to patients who are emaciated and have lost more than 3kg in the past one month. (4) Rehabilitation training: Carry out rehabilitation training education and guidance, including fist exercises, chest expansion exercises, deep breathing, sputum discharge, abdominal muscle strengthening training, etc.
215084377|NCT02370095|DRUG|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
214362600|NCT00233558|DRUG|adalimumab (up to 9 months exposure)|
214362601|NCT00233558|DRUG|methotrexate|
214362602|NCT03772067|DEVICE|Continuous glucose monitoring CGM|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the overall glucose levels measured with CGM installed in the arm during 14 days at baseline before diet intervention and after 14 days of the beginning of diet intervention
214362603|NCT03772067|DIAGNOSTIC_TEST|Clock Genes m RNA expression|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the blood levels of Clock Genes measured at baseline and after 14 days of diet intervention
214362604|NCT03772067|DIAGNOSTIC_TEST|Postprandial Glucose|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Glucose measured at meal test after 14 days of diet intervention
214362605|NCT03772067|DIAGNOSTIC_TEST|Postprandial Insulin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Insulin measured at meal test after 14 days of diet intervention
214679579|NCT01752517|DRUG|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
214679580|NCT03005535|OTHER|Vitaminized corn oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
214973856|NCT03283735|BEHAVIORAL|Elderly Enablement|The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group
214973857|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.
214973858|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.
214973859|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
214973860|NCT00846586|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
214973861|NCT00846586|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
214973862|NCT00846586|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
214973863|NCT06311058|DIETARY_SUPPLEMENT|Whey protein isolate|25g of whey protein isolate
214973864|NCT06311058|DIETARY_SUPPLEMENT|Protein + BAA|"* Protein drink - 25g of whey protein isolate~* Amino Acid Blend - 7g of protein (4g Leucine, 1g iso leucine, 1g valine, 1g arginine)"
214362606|NCT03772067|DIAGNOSTIC_TEST|Plasma GLP-1|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma GLP-1 measured at meal test after 14 days of diet intervention
214362607|NCT03772067|DIAGNOSTIC_TEST|DPP4 plasma activity|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial DPP4 plasma activity measured at meal test after 14 days of diet intervention
214679581|NCT03005535|OTHER|Olive oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
214679582|NCT01863563|DEVICE|QuickClot|1 application of treatment to each tonsil/adenoid removal area
214973865|NCT06311058|DIETARY_SUPPLEMENT|Placebo|• isocaloric-matched (25g) maltodextrin supplement
214973866|NCT00689338|DRUG|Anidulafungin|Anidulafungin Intravenous Administration
214973867|NCT00689338|DRUG|Fluconazole|Oral Administration of Fluconazole
214973868|NCT00689338|DRUG|Voriconazole|Oral Administration of Voriconazole
215084378|NCT02370095|DRUG|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
215084379|NCT01694277|DRUG|Masitinib|12 mg/kg/day
215084380|NCT01694277|DRUG|Sunitinib|50 mg/day
214362608|NCT03772067|DIAGNOSTIC_TEST|Ghrelin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Ghrelin measured at meal test after 14 days of diet intervention
214679583|NCT05547555|DIAGNOSTIC_TEST|embryo selection|The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A
215084381|NCT05622435|DEVICE|T10070, Plastic tube with a roll-on applicator filled with an ointment|6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.
214489514|NCT06828003|BEHAVIORAL|Resistance Training|The resistance training intervention will consist of two remotely-delivered exercise sessions per week for eight weeks (16 sessions total). One session will be a live, remotely delivered 1:1 class led by a qualified exercise professional (\~one hour). The second session will be unsupervised, completed by watching a pre-recorded workout video that will vary bi-weekly to elicit progressive overload. Pre-recorded workout videos will be emailed and feature the qualified exercise professional who will provide instruction to mimic live sessions. Both sessions will involve a dynamic warm-up (\~10 minutes), 8 resistance-band exercises (\~30-45 minutes), followed by a cool-down (\~10 minutes).
214489515|NCT06761911|DRUG|Brentuximab Vedotin (Bv)|1.2mg/kg/2w or 1.8mg/kg/3w
214489516|NCT06761911|DRUG|Sintilimab|200mg/3w
214489517|NCT06761911|DRUG|Tislelizumab|200mg/3w
214489518|NCT06761911|DRUG|Bendamustine|90mg/m2/3w
214489519|NCT06752629|DRUG|Bupivacaine and Dexmedetomidine|Adult patients will take 10 ml Bupivacaine 0.5% plus 2ml solution of Dexmedetomidine 1mic/kg in the bilateral T5\&6 preoperatively
214973869|NCT04118647|DRUG|Wu-Chu-Yu tang|Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
214489520|NCT06752629|DRUG|Bupivacaine and Fentanyl|Adult patients will take 10 ml Bupivacaine 0.5% plus 2ml solution of Fentanyl 20 microgram with the bilateral T5\&6 preoperatively
214489521|NCT06768125|RADIATION|Hypofractionated Radiation Therapy|95% PGTVp: 33 Gy in 3.3 Gy per session for 10 sessions, and 95% PTV1: 25 Gy in 1.5 Gy per session for 10 sessions, with an interval of 1-2 weeks, for a total of 2 cycles.
214489522|NCT06769893|DIAGNOSTIC_TEST|68Ga-NOTA-RCCB6 PET/CT Scan|"The imaging agent 68Ga-NOTA-RCCB6 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations.~Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection. The maximum mass dose of CD70 should not exceed 240ug, and the maximum volume of administration should not exceed 5 mL."
214489523|NCT06767657|PROCEDURE|CEA (carotid endarterectomy)|Intervention (CEA) is associated to both arms (group A and B)
214489524|NCT06776861|DRUG|PD-1 / PD-L1 monoclonal antibody|Patients with advanced breast cancer who have already received and continue to use immunotherapy, or are planned to receive immunotherapy, and have been recommended for radiotherapy after evaluation by a multidisciplinary team (MDT) in the early stage and have completed radiotherapy, are registered and followed up in this study.
214489525|NCT03732703|DRUG|Abemaciclib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
214489526|NCT03732703|DRUG|Enasidenib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
214489527|NCT03732703|DRUG|Cobimetinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
214489528|NCT03732703|DRUG|Erdafitinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
214973870|NCT02464137|RADIATION|radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
215094449|NCT00681993|OTHER|Standard Dose Dense Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
214489529|NCT03732703|DRUG|Venetoclax, dexamethasone, ixazomib, pomalidomide|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
214489530|NCT03732703|DRUG|Daratumumab, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
214489531|NCT03732703|DRUG|Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
214973871|NCT03113110|DRUG|Empagliflozin 10 mg|PTDM patients on previous antidiabetic treatment (\<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
214973872|NCT02915224|DRUG|Chlorambucil|Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
214973873|NCT02915224|DRUG|Obinutuzumab|Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
214973874|NCT00144430|DRUG|Pentostatin|The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.
214973875|NCT00655252|DRUG|Everolimus|
214973876|NCT00766324|DRUG|PHA-739358|6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
214973877|NCT00766324|DRUG|PHA-739358|24-hr IV infusion every 2 weeks in a 4-week cycle
214973878|NCT01414998|BEHAVIORAL|Stress Ball vs Nicotine-free E-Cigarette|"In a cross over design, participants will be randomly allocated to:~1. use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~2. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
214489532|NCT03732703|DRUG|Selinexor, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
214362609|NCT03772067|DIAGNOSTIC_TEST|Plasma CCK|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma CCK measured at meal test after 14 days of diet intervention
214362610|NCT03772067|DIAGNOSTIC_TEST|Plasma PYY|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma PYY measured at meal test after 14 days of diet intervention
214362611|NCT03772067|OTHER|Body Weight|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the body weight at baseline and every weeks of diet intervention
214362612|NCT03772067|DIAGNOSTIC_TEST|Blood levels of HbA1c|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing blood HbA1c measured at baseline and after 90 days of diet intervention diet intervention
214362613|NCT05411965|DRUG|BR3003(T)|"Test drug (T):BR3003 Boryung Pharmaceutical Co., Ltd."
214362614|NCT05411965|DRUG|BR3003B(R1)|"Reference drug 1 (R1): BR3003B of Celltrion Pharm, Inc."
214362615|NCT05411965|DRUG|BR3003C(R2)|"Reference drug 2 (R2): BR3003C of AstraZeneca Korea"
214362616|NCT03491761|BIOLOGICAL|PRP Treatment|PRP will be prepared using an Arthrex ACP® kit (a low-leukocyte Autologous Conditioned Plasma system). This is a single-spin system that concentrates platelets and separates red blood cells (RBCs) as well as white blood cells (WBCs) from the treatment product.
214362617|NCT03491761|BIOLOGICAL|HA Treatment|Euflexxa will be used for treatment. It will be prepared according to the package insert.
214362618|NCT06200766|DRUG|Mometasone furoate as a nasal spray|Subjects received 2 presses in each side nostrils at the same time point (± 1h).
214489533|NCT06773182|OTHER|Intermittent Fasting Intervention|A 14:10 intermittent fasting regimen, where participants fast for 14 hours and consume all meals within a 10-hour eating window daily.
214489534|NCT06773182|OTHER|Mediterranean Diet Intervention|A diet emphasizing whole grains, fruits, vegetables, olive oil, lean proteins, and minimizing processed foods.
214489535|NCT06773182|OTHER|Low FODMAP Diet Intervention|A diet limiting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols to manage gastrointestinal symptoms.
214489536|NCT06774443|OTHER|Neuropsychological assessment|Neuropsychological assessment consisting of tests measuring social cognition and memory
214489537|NCT06772389|OTHER|Peer Tutoring|"Peer tutoring is defined as individuals who are in a similar social group and are not professional teachers helping each other to learn and teach. For peer tutoring, the subject of EFM was grouped under 6 headings. The students in the Peer tutoring group were divided into groups of 6. The researcher explained a heading of the EFM subject to each of these 6 groups. Then, new groups were formed by taking one student from each group. In these new groups, each student explained his/her own subject to his/her peers."
214489538|NCT06773429|DRUG|E2 Valerate|To experimentally elevate E2 levels females received 6mg of E2 valerate (Progynova21©) on two consecutive days (in total 12mg).
214489539|NCT06773429|DRUG|Placebo|Placebo pills (blue-colored hard gelatine capsules filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) have been administered for the placebo-controlled condition.
214973879|NCT01414998|BEHAVIORAL|Nicotine-free E-Cigarette vs De-nicotinised Cigarette|"In a cross over design, participants will be randomly allocated to:~1. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~2. smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
214973880|NCT05098080|BIOLOGICAL|Hutrukin|Hutrukin that binds the human cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity. Hutrukin is a True Human™ therapeutic antibody. That is, the antibody was generated by a natural human immune response and was cloned directly from a human peripheral B lymphocyte. No in vitro affinity maturation or modifications have been made to improve its natural binding affinity. A true human antibody should be effectively non-immunogenic in humans and thus exhibit optimal activity and pharmacokinetics indistinguishable from native IgG1 immunoglobulin.
214973881|NCT05098080|BIOLOGICAL|Placebo|Placebo control for Hutrukin IV push.
214973882|NCT00170209|DRUG|Isoniazid|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
214973883|NCT00170209|DRUG|Rifampin|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
214973884|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER CT GUIDANCE|injection of triamcinolone in the facet joint under CT guidance
214973885|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER CT GUIDANCE|injection of triamcinolone around the dorsal ramus under CT guidance
214362619|NCT04656834|PROCEDURE|hand incision closure using monocryl sutures and skin glue|At the end of surgery, the investigator will close the incision using monocryl sutures and skin glue
214362620|NCT04656834|PROCEDURE|hand incision closure using simple nylon sutures|At the end of surgery, the investigator will close the incision using simple nylon sutures
214362621|NCT01894295|DIETARY_SUPPLEMENT|Placebo|Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks
214362622|NCT01894295|DIETARY_SUPPLEMENT|Vitamin D analogue|1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks
214362623|NCT03292250|DRUG|BYL719|Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
214362624|NCT03292250|DRUG|Poziotinib|Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
214362625|NCT03292250|DRUG|Nintedanib|Initial dose 200 mg twice per day orally according to study protocol.
214362626|NCT03292250|DRUG|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
214489540|NCT06774222|DRUG|Fruquintinib|Fruquinitinib: Take 4 mg QD for 2 weeks and stop for 1 week, every 3 weeks for a cycle; Standard chemotherapy: The selection of drugs is recommended by the 2024CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer, including SOX, XLOX or S-1, and the treatment cycle is one every 3 weeks
215084382|NCT03557346|DEVICE|the WAM-5500 binocular autorefractor/keratometer (Grand Seiko Co. Ltd., Hiroshima, Japan)|: Subjects underwent a basic ophthalmic examination and the accommodative response to refractive stimuli was measured. Refractive stimuli were given at 0.25 diopters (D) (4 m distance), 2D (50 cm), 3D (33 cm), and 4D (25 cm) and stimulation was applied with the eyes in binocular, monocular (dominant eye, non-dominant eye, ipsilateral, and contralateral), and pinhole conditions. In addition, changes in the astigmatic value and direction of the astigmatism axis under binocular stimulus were evaluated.
214362627|NCT03292250|DRUG|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
214362628|NCT05040451|DEVICE|Carillon Mitral Contour System|"The Carillon Mitral Contour System (XE2) consists of the following components:~* An implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~* A delivery system which consists of a custom 9F delivery catheter and a handle assembly."
214362629|NCT04801550|DEVICE|Millimeter waves local exposure|several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure
214362630|NCT05308329|DEVICE|Intra-coronary imaging device|Culprit/nonculprit lesions are accessed by intra-coronary imaging device including intravascular ultrasound and optical coherence tomography.
214362631|NCT05308329|BEHAVIORAL|PCI procedural characteristics|Procedural characteristics include the information about angiographical characteristics, type of stent, pre/post POBA, and thrombectomy.
214489541|NCT06773559|DIAGNOSTIC_TEST|plantar pressure, gait and static balance analysis|Plantar pressure, gait and static balance analysis performed using Ultium Insole SmartLead insoles.
214489542|NCT06773559|DIAGNOSTIC_TEST|trunk posture analysis|Trunk posture analysis was performed using Diers Formetric 4D.
214489543|NCT06759571|PROCEDURE|low level laser treatment|to evaluate the effect of low-level laser therapy (LLLT) bone healing when used prior and following enucleation of intra-body maxillary cystic lesions
214489544|NCT06758687|OTHER|Kinesiotape Application|"Before the appropriate taping is applied to the waist area, a small piece of kinesio tape will be attached to the participant's thigh area and an allergy test will be performed. If the participant does not have any complaints within 5-10 minutes, the participant will be taped. The tape to be used in this study will be waterproof, porous, breathable, 5 cm wide and 0.5 mm thick.~After the initial evaluation is completed, kinesio taping will be applied to the paravertebral muscles. First, the participant will be asked to perform trunk flexion while standing with their forearms supported by a table. While the participant is in this position, two I shaped tapes will be attached to the right and left sides of the spine (in the cranial direction) along the paravertebral muscle line without applying tension. Then, the field correction technique will be applied. While the participant is standing with their forearms supported on the table, four I tapes overlapping in"
214679584|NCT00530712|DEVICE|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
214679585|NCT00800033|BEHAVIORAL|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
214679586|NCT00800033|DIETARY_SUPPLEMENT|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
214679587|NCT02948192|OTHER|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
214679588|NCT03174860|DRUG|Diclofenac Potassium 50mg Tab|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
214362632|NCT05330065|DRUG|bevacizumab and camrelizumab|"Stage 1 was classical 3+3 dose escalation with pts assigned to one of the following 3 cohorts, Cohort A:Avastin 5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort B:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort C:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 200mg once every 2 weeks.DLT was observed for 28 days."
214362633|NCT01352598|RADIATION|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
214362634|NCT00091481|DRUG|Zemplar|
214362635|NCT02450318|OTHER|Slow-paced walking|Subjects will walk on a treadmill at a slow pace for 47 minutes
214489545|NCT06759324|DIETARY_SUPPLEMENT|Live kombucha (non filtered/ non pasteurized)|Participants receive a daily amount of 33 cl of live kombucha (non-pasteurized/ non-filtered) for 4 weeks (28 days).
214489546|NCT06759324|DIETARY_SUPPLEMENT|Pasteurized kombucha (non filtered)|Participants receive a daily amount of 33 cl of kombucha (pasteurized drink) for 4 weeks (28 days).
214489547|NCT06759324|OTHER|Control (sparkling water)|Participants receive a daily amount of 33 cl of sparkling water for 4 weeks.
214489548|NCT06774300|BEHAVIORAL|BASICS|The intervention is the BASICS protocol outlined in the BASICS manual. It includes an online self-administered assessment and then delivery of a feedback session either in-person or over Zoom.
214489549|NCT06774300|BEHAVIORAL|Online alcohol programming|This is a control intervention that is used as the first-line sanction for students at the two universities. It is an online program, informed by BASICS content, but contains no facilitator and is self-directed.
214679589|NCT03174860|DRUG|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
214679590|NCT03832868|BEHAVIORAL|Pre-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
214362636|NCT00093834|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
214362637|NCT00093834|DRUG|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
214362638|NCT00093834|DRUG|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
214489550|NCT06748248|OTHER|suspension Therapy|suspension therapy for individuals with Down syndrome is an approach that focuses on improving mobility and balance through different activities that will be conducted through universal exercise unit. This method involves organizing individuals with Down syndrome into two groups. Group A will perform Suspension Therapy in addition to routine physical therapy. These routine exercises will consist of stretching exercises (arm raises, chest stretch, leg swings, hamstring stretch, cat-cow poses, starfish stretch), strength and endurance training (like stepping, carrying light weights) and balance training (playing hopscotch and kicking a ball). The exercise program will gradually increase in intensity in accordance with each participant's functional improvement. Suspension Therapy will consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. Repeated corrective movements will be performed.
214489551|NCT06748248|OTHER|Routine Treatment|"Group B will perform routine physical therapy (RPT) alone. These routine exercises will consist of stretching exercises (particularly upper and lower body stretches and full body stretches). Stretches will be gentle and avoid bouncing. Hold for each stretch will be 15-30 seconds. Balance and coordination exercises (Walking on balance beams, obstacle courses) will be performed as RPT. The exercise program will gradually increase in intensity in accordance with each participant's functional improvement. These exercises will be carried out 5 days in a week for one hour daily.~Data will be assessed by assessor at baseline and at the end of 5th session of treatment (Pre and post)."
214489552|NCT06775184|DEVICE|a native video image system|The visualization of the glottic structures through the SaCoVLM™ imaging system is graded as follows: Grade1: Visibility of the lateral portion of the right epiglottic fold and part of the laryngeal inlet. Grade 2: Visibility of both epiglottic folds and part of the laryngeal inlet. Grade 3: Visibility of the laryngeal inlet and part of the vocal cords. Grade 4: Visibility of the entire vocal cords.
214489553|NCT06775184|DEVICE|Fiberoptic bronchoscope|The position of the i-Gel is checked using a fiberoptic endoscope
214489554|NCT06776107|OTHER|Risk factor present|Demographic, and severity.
214489555|NCT06776809|OTHER|Music listening|Selection of Sufi music will be played to the patients during the course of the operation.
214489556|NCT06776432|DRUG|Sivopixant|Administered as specified in the treatment arm
214489557|NCT06776432|DRUG|Placebo|Administered as specified in the treatment arm.
214489558|NCT06776432|DRUG|Acetazolamide|Administered as specified in the treatment arm
214489559|NCT06776432|DRUG|SASS-001|Administered as specified in the treatment arm
214489560|NCT06775288|OTHER|Hypoglycemia prevention and awareness program (HypoPAP)|Online hypoglycemia prevention and awareness training Supporting the prevention of hypoglycemia with the use of evidence-based diabetes-friendly plates Encouraging physical activity and supporting glycemic control with a pedometer Filling in a weekly problem-solving notebook Conducting weekly online problem-solving meetings Online counseling service when needed
214489561|NCT06777472|OTHER|lung-benefiting moxibustion|A kind of external treatment，the treatment theory is to treat winter diseases in summer.
214489562|NCT06777472|DRUG|"The specific drug comes from GINA (2024)"|"Refer to GINA (2024)."
214489563|NCT06775509|DEVICE|Ortho-K|Utilization of Ortho-K Contact Lenses for The Treatment of Myopia
214489564|NCT06777407|BEHAVIORAL|Brief Mindfulness-Based Intervention to Reduce Psychological Distress|The brief mindfulness-based intervention is an eight-week training program designed for groups of 15 to 20 participants. The weekly sessions will last 90 minutes for the first session and 60 minutes for the following seven sessions. The program will be led by a certified mindfulness trainer, who is not part of the research team and will be solely responsible for training-related activities.
214489565|NCT06777407|OTHER|Psychoeducational brochure|Information on self-care and managing psychological distress will be provided. Once the study is completed and the data has been collected, participants in the control group will receive the intervention.
214489566|NCT06775652|DRUG|Neoadjuvant Chemoradiotherapy|Patients assigned to the NCRT group received intravenous paclitaxel (135 mg/m²) and carboplatin (AUC=2-5) on day 1, administered every three weeks for two cycles. Concurrently, they received intensity-modulated radiotherapy (IMRT) with a total of 20 sessions (CTV 40 Gy, GTV 44 Gy) five days per week. All radiotherapy plans were reviewed by designated radiation oncologists before treatment to ensure quality control. Patients were assessed 4 to 6 weeks after completing NCRT following RECIST 1.1 criteria.
214679591|NCT03832868|BEHAVIORAL|Post-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
214973886|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone in the facet joint under fluoroscopy guidance
214973887|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone around the dorsal ramus under fluoroscopy guidance
214973888|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER ULTRASOUND GUIDANCE|injection of triamcinolone in the facet joint under ultrasound guidance
214973889|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|injection of triamcinolone around the dorsal ramus under ultrasound guidance
214973890|NCT00120471|DRUG|Tenofovir disoproxil fumarate|600-mg tablet taken orally once daily
214489567|NCT06775652|PROCEDURE|Adjuvant therapy|Patients in the AT group received surgery as soon as possible after randomization, followed by adjuvant therapy, postoperative adjuvant therapy based on pathological staging, as recommended by the NCCN Clinical Practice Guidelines for Esophageal and Esophagogastric Junction Cancers (2017 V4), starting one month post-surgery with either adjuvant chemotherapy or chemoradiotherapy. The adjuvant chemotherapy regimen was the same as the neoadjuvant chemotherapy regimen, and the adjuvant radiotherapy regimen and dose were administered according to guideline recommendations.
214489568|NCT06775652|PROCEDURE|Surgery|Surgery
214489569|NCT06775561|GENETIC|PARADIGM study aims to streamline the process from genomic characterization of RGD patients with ED/NMD to identification of the suitable personalized therapy.|Samples are collected by UO1/UO2/UO3. DNA/RNA samples are sent to UO3 for genome and transcriptome sequencing. In vitro systems or patient-derived cell models are used for in vitro experimental validation (UO2) or development of therapeutical approaches (UO2/UO4). Samples of cases still undiagnosed after the combined sequencing and validation approaches undergo long-read sequencing by an outsourcing facility. Sequencing data are transferred to UO1 for bioinformatic analysis and may be deposited into RDconnect for still inconclusive cases. Variants of interest from bioinformatic analyses and in vitro validations are collectively discussed by UO1/UO2/UO3 to evaluate their clinico-molecular significance and to be selected for testing therapeutic approaches by UO2/UO4. Blue arrows and shapes denote samples and personal data, while green data that make no identifiable person.
214489570|NCT06776757|DRUG|Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)|Sintilimab (100mg,150mg, 200mg; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）
214489571|NCT06776757|DRUG|Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)|Sintilimab (Based on Phase 1b recommended dose; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）
214489572|NCT06776081|OTHER|Weight loss without pharmacotherapy|Adults with obesity participating in the 12-week hypocaloric diet-induced weight loss intervention will be individually counseled by the Clinical and Translational Research Center (CTRC) bionutritionist to consume a hypocaloric diet consistent with current dietary recommendations for weight loss until a 6-10% weight loss is achieved.
214489573|NCT06768190|BEHAVIORAL|WhatsApp as usual|Pregnant women and their partners are instructed to use WhatsApp as normal for six weeks.
214973891|NCT00120471|DRUG|Tenofovir disoproxil fumarate|4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
214973892|NCT00120471|DRUG|Tenofovir disoproxil fumarate|6-mg/kg oral suspension taken at birth and daily for 7 days after birth
214973893|NCT01061606|DRUG|temsirolimus|Given IV
214973894|NCT00735007|DRUG|Rebif® New Formulation (RNF) using RebiSmartTM|RNF 44 mg, 3 times a week by subcutaneous injection.
214973895|NCT05447065|DIETARY_SUPPLEMENT|Vitamin D supplement|Only the experimental group (D) received the vitamin D supplement.
214973896|NCT03664115|DRUG|Itraconazole 200 mg|itraconazole 200 mg oral tablet daily, on a 21-day cycle.
214973897|NCT03664115|DRUG|Chemotherapy|"intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
214973898|NCT01789047|DRUG|Topiramate|Topiramate as adjunct to amantadine
214973899|NCT01789047|DRUG|Placebo|Placebo control
214973900|NCT01789047|DRUG|Amantadine|Existing treatment for all participants
214973901|NCT00012025|DRUG|fulvestrant|
214973902|NCT02078271|OTHER|FBDG group|The group received food based dietary guidelines for complementary feeding
214973903|NCT02078271|OTHER|Stimulation|The group received psychosocial stimulation
214973904|NCT02078271|OTHER|Combinded FBDG and stimulation|The group received both FBDG and psychosocial stimulation
214973905|NCT02078271|OTHER|Control group|
214973906|NCT06385171|DRUG|Botulinum toxin type A|The intervention involves the administration of Botulinum Toxin Type A, with dosages regulated according to FDA guidelines. Each injection site will receive a maximum of 4 units, adhering to the FDA's recommended dosage limits. Dosages administered will be tailored to each patient's needs and will be recorded in their individual patient information chart.
214973907|NCT03644017|DEVICE|WRAPSODY Stent Graft Placement|The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
214973908|NCT02700048|DRUG|intra-nasal naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
214973909|NCT02700048|DRUG|Intra-nasal saline|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
214973910|NCT00325741|DRUG|Hematopoietic Cell Transplantation|1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
214973911|NCT00002535|BIOLOGICAL|aldesleukin|
214973912|NCT00002535|BIOLOGICAL|lymphokine-activated killer cells|
214973913|NCT00002535|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214973914|NCT00002535|DRUG|cyclophosphamide|
214973915|NCT00002535|DRUG|indomethacin|
214973916|NCT01143285|OTHER|Early and active nutritional support.|The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
214973917|NCT05944575|DEVICE|active taVNS|The clip electrode will be attached to the cymba conchae of the left ear, the location of the auricular branch of the vagus nerve.
214362639|NCT05979909|DRUG|Mitomycin C|Mitomycin (40 mg in 40 mL of sterile water) will be administered through a Foley catheter, which will be clamped for two hours.
214362640|NCT05279170|OTHER|MAVEPPIC: MAsk VEntilation with Paratracheal Pressure In Children|"Pressure will be applied with two fingers in the area located between the trachea and the sternal head of the sternocleidomastoid muscle on the left side to compress the cervical esophagus.~The force applied (after measuring the equivalent force applied on a precision scale) will be about 10 - 15 N. This force will be adapted according to the child's body weight : 10 N below 20 kgs and 15 N between 20 kgs and 40 kgs"
214362641|NCT06152653|DRUG|n-acetylcystine (NAC)+ albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
214362642|NCT06152653|DEVICE|AeroEclipse-VersaPAP System|The AeroEclipse-VersaPAP System combine continuous positive inspiratory pressure and nebulizer in one system.
214362643|NCT02434380|DIETARY_SUPPLEMENT|Euro D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
214362644|NCT02434380|DIETARY_SUPPLEMENT|Euro D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
214973918|NCT05944575|DEVICE|sham-taVNS|The clip electrode will be attached to the lobule of the left ear that is not innervated by the auricular branch of the vagus nerve.
214973919|NCT02740816|OTHER|Comparative blood analysis|Collection of menstrual blood and systemic blood
214973920|NCT06489912|DIAGNOSTIC_TEST|WAIS IV|Psychological assessement
214973921|NCT06091566|DEVICE|UCon-Bar|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for either 4 weeks or 12 weeks using UCon with the Bar electrode
214973922|NCT00078286|DRUG|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
214973923|NCT00078286|DRUG|Placebo|Dosage ranging from 50 mg to 200 mg once a day
214973924|NCT04028362|DRUG|Neuromuscular Blocking Agents|Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
214362645|NCT02732366|BEHAVIORAL|Group-based exercise and peer coaching|Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
214362646|NCT02732366|OTHER|Usual PT and attention control grp class|The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
214362647|NCT04524468|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional 2-D transthoracic echocardiography was performed to all patients
214973925|NCT05108701|BEHAVIORAL|Individual Psychotherapy|Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
214973926|NCT02946359|DRUG|Crizotinib, bevacizumab|Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
214973927|NCT02340000|DRUG|standard dose amoxicillin/clavulanate|amoxicillin/clavulanate 875/125 + placebo bid x 7 days
214973928|NCT02340000|DRUG|high dose amoxicillin/clavulanate|Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days
214973929|NCT04191889|COMBINATION_PRODUCT|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets~Procedure:~1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on day 8 in the first HAIC cycle, once a day, for continuous medication.~3. The first dose of Camrelizumab was administered on day 4 of the second HAIC cycle, at a dose of 200 mg intravenously, every three weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
214973930|NCT01753609|DEVICE|Tulip capsule|swallowing Tulip capsule for up to 29 days
214973931|NCT01284894|DEVICE|Conventional manometry|Conventional esophageal manometry
214973932|NCT01284894|DEVICE|High resolution manometry|High resolution esophageal manometry
214973933|NCT04549493|BEHAVIORAL|Exposure Therapy|Exposure Therapy is used to reduce the symptoms of PTSD
214973934|NCT05414851|OTHER|Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet|Participants will consume two weeks of each diet, with a 4-6 week washout period in between. Meals and snacks are provided for convenience to enhance adherence to each dietary pattern, but subjects can add or include their own home-prepared foods as long as they meet dietary guidelines. Each dietary intervention will include an education session via Zoom teleconference, and at least 2 individual contacts by phone to address questions and assess for adverse events.
214973935|NCT00284921|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
214973936|NCT03074877|BEHAVIORAL|Family Check-Up|The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy
214973937|NCT03511768|DRUG|18F-AlF-NOTA-octreotide|One injection of 18F-AlF-NOTA-octreotide
214973938|NCT03511768|DEVICE|PET/CT|Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
214973939|NCT02668640|BIOLOGICAL|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
214973940|NCT03669588|BIOLOGICAL|ARGX-113|Intravenous administration of ARGX-113
214362648|NCT05228600|DRUG|YL-13027|"YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature."
214362649|NCT05568433|DIAGNOSTIC_TEST|Endoscopic ultrasound fine needle aspiration (EUS-FNA)|Patients with pancreatic cysts who underwent endoscopic ultrasound and endoscopic fine needle aspiration for diagnostic and therapeutic purpose. A sample of the cyst fluid and frozen serum was collected from the patients and stored at minus 80 degrees.
214489574|NCT06768190|BEHAVIORAL|WhatsApp-based psycho-socio-educational intervention (WeLove)|The intervention comprises six sessions, including psychoeducation, communication training, sleep hygiene, stimulus control, cognitive restructuring, and behavioural activation. Each session has two short videos, quizzes, forums, and homework. The content is presented through a virtual midwife using storytelling of real-life scenarios, animation, and case vignettes about psychological and sleep problems during pregnancy. A virtual midwife acts as an educator to explain the prevalence, causes, and factors of psychological and sleep problems. Every session will concentrate on certain courses and offer specialised advice to expectant mothers and their partners. Using the security links on the WhatsApp platform, each session takes 15 to 20 minutes to finish.
214362650|NCT02112981|DEVICE|Sirolimus Eluting Coronary Stent|BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.
214362651|NCT02112981|DEVICE|Everolimus-eluting Coronary stent|Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
214362652|NCT05081453|DEVICE|pavlik harness|The application of a pavlik harness will be carried out in the intervention group. It will follow a protocol similar to that of the treatment of hip dysplasia in terms of follow-up and safety
214362653|NCT02889653|DRUG|Any oral antithrombotics (antiplatelets or anticoagulants)|
214362654|NCT00291967|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
214362655|NCT01494168|PROCEDURE|Bariatric surgery (Roux-en-y bypass or sleeve gastrectomy)|Bariatric surgery
214362656|NCT04337814|DRUG|EMLA Cream|Topical anaesthetic cream
214362657|NCT04337814|DRUG|Ibuprofen|Oral analgesic syrup (non-steroidal anti inflammatory drug)
214362658|NCT04337814|DRUG|Placebo syrup|Placebo syrup similar to Ibuprofen
214362659|NCT04337814|DRUG|Placebo cream|Placebo cream similar to EMLA
214489575|NCT06768242|RADIATION|Cone beam CT|Each patient will undergo three cone beam CTs per session, and a total of three sessions.
214489576|NCT06768632|DRUG|Group 1: single-dose of test formulation+single-dose of reference formulation|Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
214973941|NCT03669588|BIOLOGICAL|Placebo|Intravenous administration of placebo
214362660|NCT00005600|PROCEDURE|management of therapy complications|
214362661|NCT00572741|DIETARY_SUPPLEMENT|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
214362662|NCT00572741|DIETARY_SUPPLEMENT|Placebo|cellulose
214362663|NCT00572741|DIETARY_SUPPLEMENT|folate|Folinic acid: Dose: 400 µg twice a day (BID)
214362664|NCT00572741|DIETARY_SUPPLEMENT|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
214362665|NCT00572741|DIETARY_SUPPLEMENT|vitamin C|Vitamin C 500 mg
214362666|NCT00572741|DIETARY_SUPPLEMENT|cod liver oil|Cod liver oil 1/2 teaspoon
214362667|NCT00572741|DIETARY_SUPPLEMENT|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
214362668|NCT00572741|DIETARY_SUPPLEMENT|carnitine|Acetyl L-Carnitine Dose: 250 mg
214362669|NCT00003334|DRUG|paclitaxel|
214362670|NCT00003334|DRUG|pegylated liposomal doxorubicin hydrochloride|
214489577|NCT06768632|DRUG|Group 2: single-dose of reference formulation+single-dose of test formulation|Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
214489578|NCT05130983|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
214973942|NCT01705041|DEVICE|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
214973943|NCT06167941|BIOLOGICAL|Lung cancer types|Cancer tissue matched to normal tissue, all from the same patient
214973944|NCT05988372|DRUG|Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine|Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
214973945|NCT05988372|DRUG|Albumin-paclitaxel + Gemcitabine|Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
214973946|NCT00369343|DRUG|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
214973947|NCT00369343|DRUG|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
214973948|NCT04208672|DEVICE|UMindSleep|CPAP titration will be provided for Obstructive Sleep Apneas Syndrome.
214973949|NCT04405323|DRUG|Lu AG06466|hard capsules, orally, single doses
214973950|NCT04405323|DRUG|Itraconazole|200 and 300 mg, capsules, orally
214973951|NCT01124747|DRUG|ASP1585|Oral
214973952|NCT01124747|DRUG|14C-Labeled ASP1585|Oral
214973953|NCT03035513|OTHER|Continuous spikes and waves during slow sleep (CSWS)|
214973954|NCT03189212|BEHAVIORAL|Usual Care Visit|Routine 6-month follow up appointment at the NYULMC transplant center
214973955|NCT03189212|BEHAVIORAL|Telemedicine Visit|TM visit conducted at the patient's dialysis unit as a replacement to usual 6 month routine f/u visit
214973956|NCT03132545|DIAGNOSTIC_TEST|SenseWear Armband (SWA) monitoring|Participants wore the SWA on their right arm
214973957|NCT03132545|DIAGNOSTIC_TEST|total body dual-energy X-ray absorptiometry|DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue
214973958|NCT00924924|BEHAVIORAL|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
215084383|NCT06177470|DEVICE|Accelerated deep iTBS|Accelerated intermittant teta burst deep Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
214362671|NCT02190539|OTHER|Homeopathic treatment|Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
214362672|NCT04115111|DRUG|Durvalumab|Durvalumab in monotherapy as second line treatment
214362673|NCT01972958|OTHER|comprehensive care|comprehensice assessment,physical activity training, community resources referral, health education.
214362674|NCT05238233|DRUG|Tropicamide|One drop will be given to participants
214362675|NCT05238233|DRUG|1% Pilocarpine|One drop will be given to participants
214362676|NCT05238233|DRUG|Proparacaine Hydrochloride|One drop will be given to participants
214362677|NCT05238233|DEVICE|Tono pen AVIA|Participant intraocular pressures measured
214362678|NCT05238233|DEVICE|VG4 Gonio|Participant iridocorneal angle measured
214362679|NCT05238233|DEVICE|Reichert phoropter|Participant screened for hyperopia \>+1 diopter
214362680|NCT01345721|BIOLOGICAL|MenACWY-CRM|
214362681|NCT03610126|PROCEDURE|volume controlled ventilation|the patients will be ventilated by volume controlled ventilation after insertion of the BASKA laryngeal mask airway
214362682|NCT03610126|PROCEDURE|pressure controlled ventilation|the patients will be ventilated by pressure controlled ventilation after insertion of the BASKA laryngeal mask airway
214362683|NCT00506064|DRUG|Melatonin|0.15 mg/kg by mouth (PO) Daily
214362684|NCT00506064|DRUG|Placebo|Two, three, or four starch tablet or capsules before bed
214362685|NCT00506064|BEHAVIORAL|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
214362686|NCT00501254|DRUG|Slow release acetyl salicylic acid|
214362687|NCT00501254|BEHAVIORAL|Antithrombotic effect|
214362688|NCT01764737|DRUG|VX15/2503|single dose intravenous administration
214362689|NCT01764737|DRUG|Placebo|single dose intravenous administration
214362690|NCT03682718|DEVICE|Transcervical Foley catheter|combined methods of induction of labor Floey Catheter with misoprstol
214362691|NCT03682718|DRUG|Misoprostol|Misoprstol inserted vaginally for induction of labor
214362692|NCT05087381|DRUG|FluvoxaMINE Maleate 50 MG|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
214489579|NCT06771804|DIETARY_SUPPLEMENT|Cricket Protein|Participants are provided with muffins containing either whey or cricket protein.
214489580|NCT06772454|DRUG|Antitumor therapy|"All patients received suglizumab + paclitaxel + carboplatin:~Suglizumab 1200 mg IV Q3W Paclitaxel (albumin-bound) 100 mg/m2 IV, D1, 8, 15, Q3W Carboplatin AUC=5 mg/mL/min IV Q3W A total of 4 administration cycles were given, and Suglizumab 1200 mg IV Q3W was maintained after 4 administration cycles"
214489581|NCT06772454|DRUG|Inhaled preparation for COPD|"60 patients were randomly assigned to the following two groups in a 1:1 ratio, with about 30 patients in each group.~Group A: Receiving a long-acting beta-2 agonist (LABA) + a long-acting anticholinergic (LAMA) combination: Glonium bromide formoterol inhalation aerosol (7.2ug/5ug, trade name: Biwapin, Astrazeneca), 2 inhalations twice a day.~Group B: Received inhaled glucocorticoid (ICS) +LABA+LAMA as a three-drug combination: budesonide/glononium bromide/formoterol :160ug/7.2ug/4.8ug, Astrazeneca), 2 inhalations twice daily."
214489582|NCT06774651|PROCEDURE|Procedure: Corneal lenticule extraction for advanced refractive correction (CLEAR)|Routinely conducted procedure using FEMTO LDV Z8 laser system for correction of Myopia.
214973959|NCT00924924|BEHAVIORAL|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
214973960|NCT02171000|DRUG|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
214973961|NCT05995938|BEHAVIORAL|Mindfullnes-Based Cognitive Therapy|Mindfullnes-Based Cognitive Therapy Effect on Adherence to Immunosuppressive Therapy in Liver Transplant Recipients
214973962|NCT06069804|DRUG|The TR group|Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
215084384|NCT06177470|DEVICE|Accelerated Sham iTBS|Sham accelerated intermittant teta burst Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
214489583|NCT06774651|PROCEDURE|Procedure: Small Incision Lenticule Extraction (SMILE)|Routinely conducted procedure using VisuMax laser system for correction of Myopia.
214489584|NCT06777719|DRUG|Eight Treg|"The experimental drug Eight Treg is given to patients with a peripheral IV infusion the day before the graft (cf section 5.1.5. Infusion of the experimental drug of this protocol) in addition to the maintenance protocol combining corticosteroids, tacrolimus and MPA which are classically pre-scribed in kidney graft patients from a living donor at the Nantes CHU."
214489585|NCT06777602|DRUG|[14C] MK-5475|\[14C\] MK-5475 is administered as a single IV bolus dose in healthy male participants on Day 1.
214489586|NCT06778681|OTHER|Cheer|"During voluntary muscle contraction subjects will be cheered with verbal encouragement (push, push, push) and clapping."
214489587|NCT06778733|DRUG|Clomiphane citrate|Clomiphene citrate 100mg/day from day 3 to day 7 of the cycle (5 days) will be added to the low-dose (150 IU) short GnRh antagonist protocol (recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE))
214489588|NCT06778733|DRUG|recombinant human Follicle-Stimulating Hormone (r-FSH-alfa)|"All patients will undergo ovarian stimulation with the standard-dose GNRH-antagonist protocol.~Ovarian stimulation will be initiated with 150 IU of of recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE)"
214489589|NCT06762678|DIAGNOSTIC_TEST|RNA sequencing and whole genome sequencing in a trio way|Patient is not required to be blinded
214489590|NCT02158507|DRUG|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
214973963|NCT06069804|DRUG|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
214489591|NCT06775743|DRUG|ORIENT-31 regimen|Sintilimab plus bevacizumab plus platinum-doublet chemotherapy
214489592|NCT06775743|RADIATION|SBRT|"Based on the results of the response evaluation, personalized SBRT will be arranged after cycle 4:~A. Complete response, CR: continue with maintenance therapy of PD-1 antibody + pemetrexed + VEGF antibody until disease progression, intolerable toxic side effects, or up to two years.~B. Stable disease, SD/partial response, PR: if the residual lesions do not exceed three organs and five lesions, and if the investigator deems SBRT feasible, curative-dose stereotactic radiotherapy covering all residual lesions will be administered, with dosing based on the NRG-BR001 study.~C. If the residual lesions exceed three organs or five lesions, SBRT (24 Gy/3 Fx) targeting 1-3 selected tumor lesions will be performed, and then continue with maintenance therapy of PD-1 antibody + pemetrexed + VEGF antibody until disease progression.~D. Progressive disease, PD: subsequent treatment is conducted according to the standard guidelines."
214489593|NCT06843460|BIOLOGICAL|Sotatercept|Single subcutaneous injection
214489594|NCT06843460|OTHER|Placebo|Single subcutaneous injection
214489595|NCT06765525|OTHER|Junior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system. Junior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
214489596|NCT06765525|OTHER|Senior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system.
214489597|NCT06765525|OTHER|Automated annotation of the DDH measurement through deep learning|Through randomization, a subset of the preliminary interpretations will be conducted by AI technology, and the study team will evaluate the degree of divergence between these AI-generated preliminary interpretations and the final interpretations.
214973964|NCT01406535|DRUG|Vardenafil|5 mg vardenafil per os twice daily
214973965|NCT01406535|OTHER|Placebo|5 mg placebo per os twice daily
214973966|NCT05763927|DRUG|Fruquintinib|Fruquintinib 5mg 2w on/1w off, 21d/cycle, totally 4 cycle.
214973967|NCT05763927|DRUG|Toripalimab|Toripalimab 200mg d1, 21d/cycle, totally 4 cycle.
214973968|NCT05763927|RADIATION|Short-course radiotherapy|25 Gy in 5 fraction, d22-26.
214973969|NCT05763927|PROCEDURE|TME|Surgical resection of the primary tumour in the rectum, 2-4weeks after the last dose of fruquintinib
214973970|NCT02546011|OTHER|Fetal Heart Rate Monitor|Standard of care, not part of research
214973971|NCT05571410|BEHAVIORAL|HTN Chat bot|Remote monitoring via automated messaging program
214973972|NCT01531400|OTHER|self-selected music|Investigators played self-selected background music in the music group
214973973|NCT01100502|DRUG|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
214973974|NCT01100502|DRUG|placebo|Every 21 days by IV infusion
214973975|NCT02841358|BIOLOGICAL|Blood sampling|
214973976|NCT02841358|BIOLOGICAL|Biopsy|
214973977|NCT04014218|DRUG|Inhalation Sedation|Inhalation Sedation by Administration of Sevoflurane
214973978|NCT04014218|DRUG|Intravenous Sedation|Intravenous Sedation by Administration of Propofol
214973979|NCT05005624|OTHER|ADL performance|"All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1\. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
214973980|NCT04298580|PROCEDURE|PVB block|PVB block before surgery versus after surgery
214973981|NCT03482271|OTHER|No intervention - data collection only|No intervention - data collection only
215084385|NCT00205842|DRUG|alvimopan|
215084386|NCT03880448|DRUG|Metronidazole|Metronidazole 500mg/8h/7days
215084387|NCT03880448|DRUG|Placebo|Cornstarch 500mg/8h/7days
214362693|NCT05087381|COMBINATION_PRODUCT|Fluvoxamine, Bromhexine|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
214489598|NCT06765525|OTHER|AI-assisted junior sonographer meaturement of DDH|Participants will receive visual cues from the DeepDDH system.
214489599|NCT06780722|OTHER|blood sampling|"* The first sample is taken at the start of the therapeutic stop.~* The second sample is taken when the mean arterial pressure drops to 45mmHg.~* The third sample is taken when circulatory arrest occurs.~* The fourth sample is taken at the start of extracorporeal circulation. These four samples will be destroyed at the end of the study."
214489600|NCT06781021|PROCEDURE|Tourniquet|In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.
214489601|NCT06781021|PROCEDURE|TXA|In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.
214489602|NCT06781463|OTHER|Registry (N/A)|This study is a registry, thus no research intervention is being directly tested.
214679592|NCT04830748|OTHER|Mechanical knee traction|Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).
214973982|NCT06291857|BIOLOGICAL|CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant|CIC will contain SARs-CoV-2 antigen (35 μg), tNIV antigens (2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains; 60 μg/strain
214973983|NCT06291857|BIOLOGICAL|Novavax COVID-19 Vaccine|Each 0.5 mL dose comprises 5 µg SARS-CoV-2 S protein and 50 µg Matrix-M adjuvant
214973984|NCT06291857|BIOLOGICAL|tNIV Vaccine|2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains (60 μg/strain), and Matrix-M adjuvant (75 μg)
214973985|NCT06291857|BIOLOGICAL|Fluzone High Dose|Fluzone High-Dose is supplied as a suspension for IM injection 0.5 mL with 60 µg per strain
214973986|NCT05895357|OTHER|Musictherapy|The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
214973987|NCT03007355|OTHER|peripheral perfusion index measurement|
214973988|NCT01374022|OTHER|ART Strategy|Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.
214973989|NCT01374022|OTHER|ARDSNet Strategy|Conventional mechanical ventilation strategy.
214973990|NCT01409239|DRUG|Intravenous insulin|24 hr IV insulin administered according to hospital guideline
214973991|NCT01409239|DRUG|Subcutaneous Insulin|basal bolus insulin using carb counting technique and insulin analogues
214973992|NCT01190813|DRUG|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
214973993|NCT01190813|DRUG|Placebo|Oral placebo tid
214973994|NCT01190813|OTHER|Patching|Two hours of daily patching
214973995|NCT06075472|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) is a therapeutic technique which involves specific training of respiratory muscles to yield improvements in inspiratory muscle strength and respiratory function.
214973996|NCT06075472|OTHER|Balance Exercises|Balance exercises involve functional movements at the individual's maximum level of independence.
214973997|NCT05837455|DEVICE|VENTANA MIB-1 Ki67 assay|Ki67 scoring determination (standard of care) utilizing the Ki67 MIB-1 assay (clone 30-9) (VENTANA) will be performed at baseline, Week 4 (+/- 14 days - high-risk group only), and at time of surgery in accordance with the International Ki67 in Breast Cancer Working Group guidelines.
214973998|NCT05837455|DEVICE|Oncotype DX® Recurrence Score|Oncotype DX® Recurrence Score (RS) testing - assessing expression of 21 genes including 16 cancer-related genes and 5 reference genes - will be performed as standard of care in a central laboratory (Exact Sciences) on RNA extracted from formalin-fixed paraffin-embedded core-biopsy samples.
214973999|NCT05837455|DEVICE|PAM50-based Prosigna breast cancer gene signature assay|This PAM50-based Prosigna breast cancer gene signature assay for intrinsic molecular subtype determination will be performed on formalin-fixed, paraffin-embedded (FFPE) core-biopsy samples.
214974000|NCT05837455|DRUG|Anastrozole|Standard of care
214974001|NCT05837455|DRUG|Combination anthracycline and/or taxane based treatment|Standard of care
214974002|NCT06063200|DRUG|Methylphenidate Pill|Single encapsulated pill
214974003|NCT04000438|DRUG|DF01|DF01: The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until spontaneous onset of labor or ripe cervix (Amniotomy/oxytocin without restriction).If not enough ripening cervical ripening according to clinical practice with intracervical ballon/prostaglandins
214974004|NCT04000438|DRUG|PL1|DF01: The subject receives sc injections of placebo solution once daily for up to 7 days until spontaneous onset of labor or ripe cervix (Amniotomy/oxytocin without restriction).If not enough ripening cervical ripening according to clinical practice with intracervical ballon/prostaglandins
214974005|NCT04826393|DRUG|ASP8374|every 3 weeks by intravenous infusion
214974006|NCT04826393|DRUG|cemiplimab|intravenous infusion
215084388|NCT03880448|PROCEDURE|periodontal surgery|periodontal surgery
214489603|NCT06782022|DRUG|5-Fluoro-Uracil|"Patients without common DPYD variant will be used for this study as a control group. Patients will receive the first 5-FU-dose based on their body surface area. 5-FU plasma concentrations will be measured during cycle 1. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.~Patients with a DPYD variant will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected and the 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached."
214489604|NCT06771531|DEVICE|transcranial direct current stimulation|tDCS can safely and selectively modulate cortical excitability (specifically neuronal firing likelihood) by transferring weak electrical currents between scalp electrodes. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA in this study.
214489605|NCT06771531|DEVICE|active sham stimulation|sham stimulation will implement the same protocol of the tDCS intervention; however, only very low-level currents (no more than 0.5 mA) are transferred between the same electrodes used for the tDCS throughout the 20-minute session. This strategy effectively mimics the cutaneous sensations and skin redness induced by creating only micro cortical electric fields.
214489606|NCT06769932|DIAGNOSTIC_TEST|preoperative computed tomography|subject's muscle mass from preoperative computed tomography (CT) images.
214489607|NCT03956680|DRUG|BMS-986301|Specified dose on specified days
214489608|NCT03956680|BIOLOGICAL|Nivolumab|Specified dose on specified days
214489609|NCT03956680|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214489610|NCT06860893|DRUG|Spinal Anesthesia with Bupivacaine|After obtaining return of cerebrospinal fluid, hyperbaric bupivacaine 5 mg/mL 1,5 mL (7,5 mg) and morphine 200 µg/mL, 0.5 mL (100 µg) was injected intrathecally.
214489611|NCT06860893|DRUG|Placebo|Local skin infiltration with lidocaine
214489612|NCT06875232|PROCEDURE|Living liver donors|Adults who are screened for living liver donation.
214489613|NCT06791083|DRUG|Envafolimab|150mg/m2 , IH， d1；Q3W
214489614|NCT06791083|DRUG|Fruquintinib|5 mg ，po，QD，d1-d14；Q3W
214489615|NCT06786650|DRUG|Tenoxicam Injectable Product|Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
214489616|NCT06786650|DRUG|ibuprofen|Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
214489617|NCT06840158|DRUG|Miotox (Botulinum toxin type A is a hemagglutinin complex)|"During the study, patients were injected with the investigational drug Miotox® .~For the treatment of spasticity and equine varus deformity of the foot in children with cerebral palsy, drugs were injected into two points of each head of the calf muscle (medial and lateral). In case of damage to one limb, the total dose was 4 units / kg of body weight per affected limb. In diplegia, the total dose was 6 units / kg of body weight for both affected limbs. The total total dose should not exceed 200 units.~This course of treatment is based on the current instructions for the medical use of Botox®."
214489618|NCT06840158|DRUG|BOTOX®|"During the study, patients were injected with the investigational comparison drug Botox®.~For the treatment of spasticity and equine varus deformity of the foot in children with cerebral palsy, drugs were injected into two points of each head of the calf muscle (medial and lateral). In case of damage to one limb, the total dose was 4 units / kg of body weight per affected limb. In diplegia, the total dose was 6 units / kg of body weight for both affected limbs. The total total dose should not exceed 200 units.~This course of treatment is based on the current instructions for the medical use of Botox®."
214679593|NCT04830748|OTHER|Therapeutic exercises|"Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force."
214679594|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, clarithromycin|non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
214679595|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, metronidazole|clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
214679596|NCT00002195|DRUG|Amprenavir|
214679597|NCT00002195|DRUG|Lamivudine|
215084389|NCT00048815|DRUG|Citalopram|Established Selective Serotonin Reuptake Inhibitor antidepressant
215084390|NCT00048815|DRUG|St. John's Wort|Natural extract from the St. John's Wort plant.
215084391|NCT00048815|DRUG|Placebos|Placebo pill
215084392|NCT01667562|DRUG|Erlotinib|Daily oral doses administered until disease progression or unacceptable toxicity or death.
214679598|NCT00002195|DRUG|Zidovudine|
214974007|NCT06653231|DRUG|local delivery of Curcumin gel|The test site will be completely undiluted curcumin gel through a 2 mL disposable syringe was placed in the test site
214974008|NCT02539017|DRUG|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
214974009|NCT02539017|BIOLOGICAL|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
214974010|NCT02214342|OTHER|Balance Training|"Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
214974011|NCT03159832|DRUG|SHR3824|All subjects were given SHR3824 20mg only one time.
214362694|NCT05087381|COMBINATION_PRODUCT|Fluvoxamine, Cyproheptadine|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
214362695|NCT05087381|DRUG|Niclosamide Pill|"The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
214489619|NCT06832748|OTHER|VR neck training|VR intervention 8 weeks. A VR headset is used for assessment and training of sensorimotor functions of the neck. The VR headset has a built-in sensor which can measure movements and give objective test and training results. The results serve as a guide for tailored home-based training programs, also performed with the VR headset in the experimental group. The participant performs the training at home, 15-20 minutes/day 5 days/week, initiallay divided into 3 sessions of 5 minutes each, while progression may lead to longer but fewer sessions. The program is individually tailored to target specific sensorimotor disturbances, and progressed during the intervention to increase the challenge. Participants will have video consultations with their physiotherapist once a week for the first 4 weeks, and every second week for the final 4 weeks. This can be adjusted to fit the participants needs. The VR is a novel technology, and this particular VR based training is not yet evaluated in research.
214489620|NCT06832748|OTHER|Endurance neck training|An 8-week traditional endurance neck training intervention. The training program consists of neck and shoulder exercises performed with body weight, rubber bands, and free weights. The training is carried out at home, 15-20 minutes per day, 5 days a week. The training is individualized and progressed during the intervention. Participants will have video consultations with their physiotherapist once a week for the first 4 weeks, and then every second week for the final 4 weeks. This can be adjusted to fit the participants needs. This intervention is often used in the clinic and has been evaluated in several research studies with good results to reduce neck pain. However, its effects on sensorimotor functions have been less evaluated. Also, its effects compared to novel VR-training still needs to be evaluated.
214489621|NCT05035563|BEHAVIORAL|Intervention. Early and integral communication strategy (EICS)|"This intervention will be implemented in patients since they are hospitalized in the ICU where is expected:~* Facilitate contact and communication between patients, families and the health team.~* Respond to the communication needs of family members.~* Reduce equipment overload and facilitate communication with families and patients, providing tools and timely support.~* Build a positive and trusting relationship of relatives and patients with health teams.~The intervention considers the following actions:~1. \- Training in communication to the health team~2. \- Written material~3. \- Family website~4. \- Standardized and daily telephone information~5. \- Health Team Support Strategy~6. \- Weekly multidisciplinary virtual meeting with the family~7. \- ICU diaries for family members"
214489622|NCT04233853|BEHAVIORAL|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
214974012|NCT01537770|PROCEDURE|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
214974013|NCT01537770|PROCEDURE|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
214974014|NCT05973955|BEHAVIORAL|Insomnia Treatment|The Insomnia Treatment is a version of Cognitive Behavioral Therapy for Insomnia adapted to individuals with hazardous alcohol use. It consists of the standard features of this well-established insomnia treatment in addition to adaptations that focus on alcohol use behaviors and alcohol-related thoughts that may be sleep-interfering as well as the provision of alcohol education material.
214974015|NCT05973955|BEHAVIORAL|Education Control|The Education Control intervention is an educational control that provides psychoeducation related to both sleep and to alcohol use.
214974016|NCT06111222|DEVICE|AT ELANA|The device is CE-approved. The device is a posterior chamber multifocal intraocular lens (IOL) indicated for aphakia after surgical extraction of the cataractous natural lens. The device is also indicated for non-cataractous, presbyopic patients (PRELEX) who seek greater independence from glasses for intermediate and/or near distances. It is an aspheric (aberration-neutral) IOL made of hydrophobic acrylic material, coated with heparin with modified C-loop haptics.
214974017|NCT05870540|DRUG|BPL-003|A single dose administered intranasally
214974018|NCT05870540|DRUG|BPL-003|A single dose administered intranasally (administered as 2 nasal sprays minutes apart)
214362696|NCT05087381|COMBINATION_PRODUCT|Niclosamide, Bromhexine|"The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days. Co-administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
214362697|NCT06100133|DIETARY_SUPPLEMENT|Ketone ester|Up to 100g ketone ester daily for 56 days
214362698|NCT01507805|DEVICE|EA preconditioning|EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
214362699|NCT01507805|DEVICE|sham EA preconditioning|Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
214362700|NCT03337646|DRUG|Lisdexamfetamine Dimesylate|Medication to treat ADHD
214362701|NCT00686881|BIOLOGICAL|Peginterferon alfa-2b (PegIFN-2b)|PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
214362702|NCT00686881|DRUG|Comparator: Stronger neo minophagen C (SNMC)|SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
214362703|NCT03303157|OTHER|no intervention|not relevant
214489623|NCT04233853|OTHER|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
214489624|NCT02544529|DRUG|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
214974019|NCT06659796|DEVICE|LifeVac|Removal of airway obstruction during choking emergency
215084393|NCT03125811|OTHER|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
215084394|NCT03125811|DRUG|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
215084395|NCT02130986|OTHER|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
215084396|NCT02130986|OTHER|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (\<1 hour goal) provide clinicians the procalcitonin result.
214362704|NCT00671931|DRUG|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
214362705|NCT00671931|DRUG|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
214489625|NCT02544529|DRUG|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
214489626|NCT06848452|OTHER|no-intervention|no-intervention
214489627|NCT05849727|DRUG|TQH3821 tablets 200 mg|TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
214489628|NCT05849727|DRUG|TQH3821 tablets matching placebo|TQH3821 tablets matching placebo without active substance.
214489629|NCT06655753|OTHER|Reliability and Validity|Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Temporomandibular Joint Disorders
214489630|NCT06854588|DIAGNOSTIC_TEST|Point-of-care ultrasound|POCUS screening will be conducted to measure the maximum diameters at end diastole of the aortic root, ascending aorta, aortic arch, and descending thoracic aorta.
214489631|NCT06853756|DEVICE|Ambu Auragain|Ambu Auragain was inserted after induction.
214489632|NCT06853756|DEVICE|I-gel|The I-gel device was inserted after induction.
214489633|NCT06820489|PROCEDURE|Conventional connective tissue graft after immediate implant placement|A pouch is made in the buccal mucosa extending 3 mm below the buccal bone crest. Thereupon, a free gingival graft is harvested from the palatal mucosa and de-epithelialized. The CTG is brought into the pouch and fixed with two single sutures onto the buccal mucosa. A healing abutment is installed, which is replaced by a provisional implant crown 2 days later. Sutures are removed 1 week after the surgery.
214974020|NCT06660914|PROCEDURE|Flexible Ureteroscopy|Ureteroscopic lithotripsy
214974021|NCT04721197|OTHER|Egg vouchers|30-day egg vouchers will be provided monthly, in addition to standard of care.
215084397|NCT02130986|OTHER|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~\< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~\> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~\> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~1. Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~2. For outpatients, antibiotic duration based on level (\> 0.25-0.5 ug/L:3 days; \> 0.5-1.0 ug/L:5 days; \>1.0 ug/L:7 days). Physician follow-up is recommended."
214974022|NCT04721197|OTHER|Standard of Care|Participants will continue to receive the standard of care. No egg vouchers.
214362706|NCT00671931|DRUG|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
214362707|NCT00671931|DRUG|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
214362708|NCT00671931|DRUG|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
214362709|NCT02908373|OTHER|Implementation of the coaching model|20 hours methodological help for each nursing home and an implementation kit
214362710|NCT04369014|DRUG|etomidate anesthesia|etomidate is used for induction and maintenance of general anesthesia
214362711|NCT04369014|DRUG|propofol anesthesia|propofol is used for induction and maintenance of general anesthesia
214362712|NCT02285439|DRUG|MEK162|• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
214362713|NCT02251327|DEVICE|Investigational Xpert DST test|One investigational test performed directly on the same sputum specimen.
214362714|NCT04419948|OTHER|White bread|White bread (120g) containing 54 g CHO
214362715|NCT04419948|OTHER|Butter|Butter 39 g
214362716|NCT04419948|OTHER|Refined olive oil|Refined olive oil (40 ml).
214489634|NCT06820489|PROCEDURE|Scarf connective tissue graft after immediate implant placement|No pouch is made in the recipient site. A free gingival graft is harvested from the palatal mucosa and de-epithelialized. The small CTG is fixed at the transmucosal aspect onto the buccal mucosa. A healing abutment is installed, which is replaced by a provisional implant crown 2 days later. Sutures are removed 1 week after the surgery.
214489635|NCT06820489|PROCEDURE|Dual zone concept after immediate implant placement|DBBM is applied and condensed up to the level of the buccal soft tissue margin. A healing abutment is installed, which is replaced by a provisional implant crown 2 days later. Usually, sutures are not needed in this group, unless minimal papilla opening was required to extract the tooth. In that case, sutures will be removed after 1 week.
214489636|NCT02923011|DEVICE|MRgFUS|Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma
214489637|NCT02923011|DEVICE|CTgRFA|Computed tomography-guided radiofrequency ablation of osteoid osteoma
214974023|NCT06610175|DEVICE|Quantitative MRI and anatomical MRI|The total scanning time will be approximately 40 minutes. Additionally, 10 healthy participants and 10 patients with symptomatic CDDD will undergo a second MRI with additional sequences for assessment of reproducibility on another day/time. Also: included participants will undergo neurologic examination and fill out questionnaires for NDI, VAS-arm, VAS-neck, WA-SI, EQ-5D-5L, CSI, mJOA and Nurick.
214362717|NCT04419948|OTHER|EVOO with 250 mg/kg oleocanthal|Extra virgin olive oil containing 250 mg/kg oleocanthal.
214974024|NCT06673303|BEHAVIORAL|Dynamic perceptual discrimination task|The study featured two task conditions, each of which required the integration of information from both stimulus dimensions. In each condition, participants viewed a stimulus containing motion and color information and were required to specify one of two possible responses. Within each condition, rules and the response mapping changed occasionally, but always by changing on a fixed feature dimension (ie. rightward/purple, leftward/orange). These uncued intra-dimensional shifts involved translational shifts in the learning boundary, requiring them to adapt their decision making within a familiar dimension. These shifts compelled participants to continuously adjust their learning strategies by focusing on the most relevant feature dimension.
214362718|NCT04419948|OTHER|EVOO with 500 mg/kg oleocanthal|Extra virgin olive oil containing 500 mg/kg oleocanthal.
214489638|NCT06766149|BEHAVIORAL|CogniFit Computerized Cognitive Training|In the CogniFit Computerized Cognitive Training, children will complete a range of tasks covering a range of game-like exercises targeting various cognitive skills, including working memory, attention, and inhibitory control, with automatic level advancement after each exercise.
214489639|NCT06766149|BEHAVIORAL|Cogmed Computerized Cognitive Training|In the Cogmed Computerized Cognitive Training, children will complete a range of tasks covering a range of game-like exercises targeting various cognitive skills, including working memory and attentional control, with automatic level advancement after each exercise.
214489640|NCT06768905|DRUG|Iomab-B|single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion.
214489641|NCT06768905|DRUG|CAR-T cell|CAR-T cell therapy
214489642|NCT06877455|PROCEDURE|Fractional CO2 laser assisted PDT|"One side of the body will receive fractional CO2 laser combined with methotrexate 1% gel , while the other side will receive topical methotrexate alone (or vice versa, randomized to avoid bias) for 3 months.~Laser therapy will be performed as 4 sessions of 3 weeks interval using fractional ablative CO2 10,600 nm laser device (Daeshin Enterprise Co., Ltd. Model: Multixel, Seoul, Korea). A single pass will be performed at the following parameters: pulse energy 42-45 mJ, density of 100 spots/cm2 depth level of 1-2 covering an area of 1 cm2 MTX gel will be prepared in the Department of Pharmaceutics at Assiut University Patients will be followed up for total 6 months (e.g., baseline, weeks 3, 6,9,12,15 and post-treatment at months 4 and 6)."
214974025|NCT06673303|DIAGNOSTIC_TEST|fMRI|Participant brain imaging data will be collected concurrently while performing the perceptual discrimination task.
214974026|NCT06884579|OTHER|Strength training, nutrition, and behavioral training|"This arm of the study consists of a supervised strength training program, conducted over 12 weeks with three weekly sessions. The sessions follow a wave-like periodization, with intensities ranging from 70% to 85% of 1-RM. Exercises focus on enhancing neuromuscular strength in the lower limbs, such as leg presses and hip extensions, under the supervision of a multidisciplinary team.~Participants will also receive nutritional guidance based on the Mediterranean diet, as well as cognitive-behavioral therapy strategies aimed at optimizing fatigue management and boosting energy levels."
215084398|NCT02130986|OTHER|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
215084399|NCT01129882|DRUG|Aripiprazole|Aripiprazole IM depot - 300 mg or 400 mg
214362719|NCT04419948|OTHER|Ibuprofen|Ibuprofen 400 mg
214362720|NCT02460692|DRUG|Placebos|Administration of vaporized cannabis plus either dronabinol or placebo pill
214362721|NCT02460692|DRUG|dronabinol|Administration of vaporized cannabis plus either dronabinol or placebo pill
214362722|NCT02460692|DRUG|Vaporized Cannabis 3.7% THC/5.6% CBD|Administration of vaporized cannabis plus either dronabinol or placebo pill
214362723|NCT00816881|DEVICE|flutter mucus clearance device|five minutes every session, four sessions per day
214362724|NCT03260868|DRUG|Insulin glargine, 300 units per milliliter (U/mL)|Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).
214362725|NCT03260868|DRUG|Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)|Subcutaneous injection.
214974027|NCT06884579|OTHER|Self-Guided and Unsupervised Program with General Recommendations|This arm of the study consists of a self-guided and unsupervised program based on physical exercise (3 times per week), nutrition, and cognitive-behavioral habits. Participants will access online modules that provide guidelines for performing resistance exercises with bands, dietary recommendations following the principles of the Mediterranean diet, and cognitive-behavioral techniques for fatigue management.
214974028|NCT01514942|DIETARY_SUPPLEMENT|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
214974029|NCT01514942|DIETARY_SUPPLEMENT|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
214974030|NCT01514942|DIETARY_SUPPLEMENT|D-chiro-inositol, manganese, folic acid, vit B12|D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
215084400|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
215084401|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
215084402|NCT04907968|DRUG|XMT-1536 (Upifitamab Rilsodotin)|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
215084403|NCT04907968|DRUG|Carboplatin|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
215084404|NCT01047800|BEHAVIORAL|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
215084405|NCT03745352|DRUG|Azacitidine|Given IV or SC
215084406|NCT03745352|DRUG|Pevonedistat|Given IV
215084407|NCT03763344|BEHAVIORAL|Perceptual Cognitive Training (PCT)|Perceptual Cognitive Training (PCT) will be performed by having individuals work with a visual perceptual training software program called NeuroTracker. This device uses Multiple Object Tracking at increasing difficulties to develop high-level brain functions critical to recovery \& cognitive health. By increasing in difficulty with each correct response and decreasing in difficulty when mistakes are made, brain function is constantly challenged. Each session (6 mins) delivers a series of mini-tests where the patient needs to remember key targets, then track them moving among distractors for several seconds and then identify them. Simple to do, but always challenging, NeuroTracker adaptively optimizes difficulty to each patient's level, maximizing cognitive stimulation every step of the way.
215084408|NCT03377738|DIAGNOSTIC_TEST|spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
215084409|NCT01904643|DRUG|lenalidomide|Given PO
215084410|NCT01904643|DRUG|mitoxantrone hydrochloride|Given IV
214362726|NCT03619460|PROCEDURE|piezoelectric extraction|Only Piezoelectric device will be used for surgical wisdom teeth extraction
214362727|NCT03619460|PROCEDURE|conventional extraction|Only manual instruments and burs on straight handpick will be used for wisdom teeth extraction
214362728|NCT03084926|DRUG|MP0274|Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
214362729|NCT04616261|BEHAVIORAL|Training|6 weeks of training
214362730|NCT04616261|DRUG|Formoterol|inhalation of 54 microg formoterol
214974031|NCT01514942|DIETARY_SUPPLEMENT|D-chiro-inositol, manganese, folic acid, vit B12|D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
214974032|NCT01514942|DRUG|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
215084411|NCT01904643|DRUG|etoposide|Given IV
215084412|NCT01904643|DRUG|cytarabine|Given IV
215084413|NCT05466695|DRUG|Tadalafil 5mg/sildenafil 25 mg|patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
214362731|NCT04616261|DRUG|Placebo|inhalation of placebo
214362732|NCT00003500|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214362733|NCT04437940|DIAGNOSTIC_TEST|Vaginal fluid Covid-19 PCR test|Vaginal fluid samples are tested for Covid-19
214362734|NCT01298999|DRUG|YF476|25 mg: one capsule to be taken by mouth once daily for 12 weeks.
214362735|NCT01298999|DRUG|Placebo|Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
214974033|NCT01514942|DRUG|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
214974034|NCT06634316|OTHER|Mediterranean diet|Mediterranean diet recommendations and daily physical exercise
214974035|NCT06634316|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral nutritional supplement|Hypercaloric, hyperproteic oral supplement combined with Mediterranean diet recommendations (2 per day) and daily physical exercise
214362736|NCT01869842|PROCEDURE|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
214362737|NCT01869842|PROCEDURE|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
214974036|NCT06634316|DIETARY_SUPPLEMENT|Protein module|Protein module (10g/day) combined with Mediterranean diet recommendations and daily physical exercise
214974037|NCT06634316|COMBINATION_PRODUCT|Vitamin D supplementation|Calcifediol supplement administered orally in order to reach sufficiency levels (30 ng/ml)
214974038|NCT06634316|COMBINATION_PRODUCT|Physical exercise|Physical exercise adapted to patients with heart failure (Cardiac rehabilitation)
214974039|NCT07047677|OTHER|Early assessment of tissue uptake of experimental ligands|Ex vivo evaluation of the binding of experimental radiolabeled ligands on human tissue using autohistoradiography
214974040|NCT05163392|DEVICE|Silverlon|SIlver-plated biopatch
215084414|NCT03916016|BEHAVIORAL|Enhanced Integrated Behavioral Health Care|The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.
215084415|NCT03916016|BEHAVIORAL|Usual Care|A collaborative model where medical and behavioral providers worked with each other episodically
215084416|NCT00641342|DEVICE|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
215084417|NCT00442091|DRUG|dandelion juice|10 ml bid for 20-30 days
215084418|NCT00247832|BEHAVIORAL|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
215084419|NCT00247832|BEHAVIORAL|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
215084420|NCT03876600|PROCEDURE|Replacement of permanent pacemakers for elective wear.|"START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day."
215084421|NCT01312389|BIOLOGICAL|OC-L/Montanide ISA 51 VG|All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.
214362738|NCT01869842|PROCEDURE|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
214362739|NCT01869842|PROCEDURE|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
214362740|NCT00541450|DRUG|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
214362741|NCT00541450|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
214362742|NCT00541450|DRUG|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
214362743|NCT00541450|DRUG|Matching placebo to pioglitazone|"matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks."
214362744|NCT00541450|DRUG|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
214362745|NCT00541450|DRUG|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
214362746|NCT03757000|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
214362747|NCT05934968|OTHER|Mad Dog cooking class series|This 6-week series consists of a once-weekly cooking class and educational session where a group of individuals with neuromuscular disability can come together to learn about the health benefits of an anti-inflammatory diet, receive instruction on how to cook selected anti-inflammatory recipes, and experiment with various pieces of accessible kitchen equipment that may increase their meal preparation skills. This series will also allow participants to share a meal together once per week.
214362748|NCT00455065|BEHAVIORAL|Whole Grain Foods|
214362749|NCT02262533|DRUG|Apixaban|
214362750|NCT02262533|DRUG|Atenolol|
214362751|NCT03439774|DEVICE|Topcon CT-800|tonometer
214362752|NCT03439774|DEVICE|Topcon TRK-2P|tonometer, pachymeter
214362753|NCT01550458|DRUG|mibefradil|25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
214362754|NCT01550458|OTHER|Placebo|1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
214362755|NCT00803452|DRUG|doxycycline|Oral doxycycline 100mg bid
214362756|NCT00803452|DRUG|azithromycin|topical 1% azithromycin daily to eye
214974041|NCT05163392|DEVICE|Control|Tegaderm without biopatch
214362757|NCT03011632|DRUG|Mometasone Nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
214974042|NCT04183725|DRUG|Reduning injection|"Reduning injection:~2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5.~Oseltamivir phosphate granules simulants:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5."
214974043|NCT04183725|DRUG|Oseltamivir phosphate granules|"Oseltamivir phosphate granules:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5.~+Reduning injection simulants: 2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5."
214974044|NCT02789969|DRUG|Hydromorphone|Hydromorphone 15mcg/kg IV
214362758|NCT03011632|DRUG|placebo mometasone|a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
214362759|NCT06304766|PROCEDURE|Laparoscopic ablation|Heat-based ablation modality performed by laparoscopy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.
214362760|NCT06304766|PROCEDURE|Open ablation|Heat-based ablation modality performed by laparotomy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.
214362761|NCT01818479|BIOLOGICAL|stem cell transplant|Open label, dose finding trial with two treatment regimens, Busulfan and Total Body Irradiation (TBI) with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.
214362762|NCT01818479|PROCEDURE|Stem cell transplant|
214362763|NCT03123965|DRUG|glecaprevir|Glecaprevir will be administered orally.
214362764|NCT03123965|DRUG|pibrentasvir|Pibrentasvir will be administered orally.
214362765|NCT05812001|BEHAVIORAL|Exergames-acceptance and commitment therapy (e-ACT)|In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.
214362766|NCT05812001|BEHAVIORAL|Acceptance and commitment therapy (ACT)|As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
214362767|NCT01340469|BIOLOGICAL|probiotics|Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
214362768|NCT00098969|DRUG|resveratrol|
214362769|NCT03757221|COMBINATION_PRODUCT|Ixazomib and Daratumumab|"Daratumumab will be administrated every week for the first 2 cycles. For cycle 3 to 6, it will be administrated every two weeks at day 1 and day 15. From cycle 7 until progression Daratumumab will be administrated every 4 weeks.~Ixazomib will be administrated every week three weeks on one week off at D1, D8 and D15 on a 28-d cycle basis.~Dexamethasone will not be given except one series of 4 days of dexamethasone, 20 mg/day or a maximum of 80 mg, for emergencies and complications at initiation of treatment."
214362770|NCT04839965|BIOLOGICAL|Ampion|Ampion administered via intravenous infusion
214362771|NCT04839965|OTHER|Saline|Placebo administered via intravenous infusion
214362772|NCT02816138|DRUG|Nicotine|Open-label transdermal nicotine patch
214362773|NCT00936442|DRUG|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
214362774|NCT00936442|OTHER|Educational materials|Reception of educational material on regular basis.
214362775|NCT05207514|DRUG|Nanoxel M|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
214362776|NCT05207514|DRUG|Taxotere|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
214362777|NCT05207514|DRUG|Doxorubicin|60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
214362778|NCT05207514|DRUG|Cyclophosphamide|600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
214362779|NCT03829124|DRUG|Propofol|Propofol 10mg/ml IV push slowly 0.5-2mg/kg
214362780|NCT03829124|DRUG|Ketamine|Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
214362781|NCT00137566|DRUG|acetaminophen (paracetamol)|Paracetamol tablets, 50 mg/kg/day for 3 days.
214362782|NCT00137566|OTHER|Placebo|
214362783|NCT01105611|DRUG|Raltegravir|400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
214362784|NCT01105611|DRUG|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
214362785|NCT04896268|DEVICE|Radiofrequency|Rafaelo's technique consists of delivering a low-temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end.
214362786|NCT04896268|DEVICE|Arterial ligation then recto-anal repair with Doppler|"The aim of arterial ligation is to de-arterialise the haemorrhoids by reducing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return."
214362787|NCT05189366|BEHAVIORAL|Sophrology|"Sophrology is a relaxation method that's sometimes referred to as hypnosis, psychotherapy, or a complementary therapy.~Sophrology uses techniques such as: hypnosis, visualization, meditation, mindfulness, breathing exercises, gentle movements, body awareness...~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Patients will receive 6 sessions of sophrology"
214362788|NCT05189366|BEHAVIORAL|Speech therapy|Speech therapy is a treatment that can help improve communication skills. patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
214974045|NCT02789969|DRUG|Fentanyl|Fentanyl 1.5mcg/kg IV
214974046|NCT03429621|DRUG|Simethicone 80 MG|Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
214974047|NCT07072884|DRUG|GC012F injection|Subjects who meet the CAR-T cell infusion criteria will receive GC012F Injection infusion within 48-72 hours after completion of lymphodepleting preconditioning.
214974048|NCT07073690|DRUG|Luspatercept|According to the product label
214974049|NCT07073677|DRUG|IN-115314 Ointment 1%|Twice daily(BID), for 56 day
214974050|NCT07073677|DRUG|IN-115314 Ointment 3%|Twice daily(BID), for 56 day
214974051|NCT07073677|DRUG|IN-115314 Ointment placebo|Twice daily(BID), IN-115314 Ointment Placebo for 28 days+ IN-115314 Ointment 3% for 28 days
214362789|NCT01190696|PROCEDURE|titanium elastic nailing|we inserted titanium nail in femoral fractures retrogradely
214362790|NCT01190696|DEVICE|Hip spica casting|we applied cast for three weeks in patients with femoral shaft fracture
214362791|NCT01814969|RADIATION|Hyperfractionated Radiochemotherapy|28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
214362792|NCT01814969|RADIATION|Hyperfractionated Radiotherapy|28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
214362793|NCT01265355|DIETARY_SUPPLEMENT|Anti-rotavirus protein|11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
214362794|NCT01265355|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 1 gm daily
214362795|NCT01695564|DEVICE|LARIAT LAA|The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.
214362796|NCT01695564|DEVICE|WATCHMAN|The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
214362797|NCT04398212|DIAGNOSTIC_TEST|mfERG (multifocal-retinogram)|mfERG will be performed for the students to document the effect of CVS on retina
214362798|NCT05387941|DRUG|Dexamethasone Ophthalmic|one drop daily in each eye with retinopathy of prematurity of a predefined stage.
214362799|NCT05166941|BEHAVIORAL|creative drama|In the training program, a total of six games were played about the experiences of psychiatric patients. The program was designed to be two game per week for four weeks.
214362800|NCT00981084|DRUG|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
214362801|NCT03375983|BIOLOGICAL|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
214362802|NCT03994068|DIAGNOSTIC_TEST|VIVO non invasive mapping|non invasive pre-procedural localization of PVC / VT origin
214362803|NCT04064879|OTHER|AD-SVF|Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.
214362804|NCT03583749|DRUG|Subcutaneous (SC) route for antibiotic treatment|Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
214362805|NCT03583749|DRUG|Intravenous (IV) route for antibiotic treatment|Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
214362806|NCT04011774|OTHER|PLANI-REV|Cognitive remediation program.
214362807|NCT04011774|OTHER|RELAXATION|Stimulation with no cognitive remediation.
214362808|NCT00331981|DRUG|Amisulpride|
214362809|NCT00363519|DRUG|Placebo|Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
214362810|NCT00363519|DRUG|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
214362811|NCT03830593|PROCEDURE|Laparoscopic Adrenalectomy|minimally invasive lateral transperitoneal adrenalectomy
214362812|NCT00551252|DRUG|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
214362813|NCT02883738|OTHER|tremor|evaluation of the intensity of the tremor
214362814|NCT00842140|DRUG|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
214362815|NCT00842140|DRUG|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
214362816|NCT00842140|DRUG|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
214362817|NCT01543061|DEVICE|OPTIVEtm Plus|1 drop in each eye four times a day for a period of 30 (± 3) days
214362818|NCT01543061|PROCEDURE|No treatment|One month of contact lens wear with no eye drop use
214362819|NCT01543061|DEVICE|Blink Contacts® Eye Drops|1 drop in each eye four times a day for a period of 30 (± 3) days
214362820|NCT05432076|DEVICE|Sleep Band and White Noise|"Not taking any sedative or anesthetic drug in the last 12 hours (Such duration of action) An average of 12 hours of sleepiness at the patient's departure and travel hindrance will.)~* Being extubated~* A Glasgow coma scale of 15 (to be investigated by the Glasgow coma scale).~* Baby dreams of boredom~* Besides pain (to the Wong Baker Face Scale used in the Pediatric Intensive Care Unit) evaluation)."
214362821|NCT05092191|DRUG|Cannabis oil vs placebo|"Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being."
214362822|NCT06724068|OTHER|Diabetes，Insulin resistance，Control|This retrospective study uses medical records and diagnostic data from patients with type 2 diabetes and healthy controls obtained from Qianfoshan Hospital from2019 to 2022
214362823|NCT06732765|OTHER|Pilates exercise program|Pilates exercise program Will be treated with WBV with Pilate Exercises. Before applying exercise, hot pack will be applied for 15-20minutes
214362824|NCT06732765|OTHER|Traditional physical therapy program|Traditional physical therapy program in form of stretching, strengthening and postural correction exercises
214362825|NCT06732128|OTHER|nature-based virtual reality applications and videos|Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.
214974052|NCT07072897|OTHER|Fluid bolus administration|fluid boluses 250 ml were given when required
214974053|NCT07072897|OTHER|Frusemide was given when required|fluid is given in a fixed regimen
214974054|NCT01778413|DRUG|ATRIPLA|
214974055|NCT07073742|PROCEDURE|CLaCS|CLaCS is hybrid outpatient procedure combining Nd:YAG 1064 nm laser treatment with injection of a sclerosant (either 70% glucose or 0.2% polidocanol foam).
214974056|NCT07073326|OTHER|HYPOTRAIN|8 weeks of 2/3 times per week, 1-h aerobic training (walking on a treadmill at 60-65% HRmax) while wearing a mask and air is delivered between 15 and 16 FiO2%
214974057|NCT07073326|OTHER|NORMOTRAIN|8 weeks of 2/3 times per week, 1-h aerobic training (walking on a treadmill at 60-65% HRmax) while wearing a mask and air is delivered between at normal (around 21) FiO2%
214974058|NCT05619289|DRUG|Ergocalciferol|One-time, oral dose of 300,000 IU of Ergocalciferol administered via 6 capsules.
214362826|NCT06732128|OTHER|nature-based videos|Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).
214362827|NCT04386434|BEHAVIORAL|Active for Life: Assisted Living|"Each intervention session will take place within the assisted living facility twice a week for 12 weeks.~Sessions will begin with 5-10 minutes of walking in the hallway. Participants will be encouraged to walk at their own pace and allowed to take breaks if needed.~Next, behavioral strategies based on the construct of self-efficacy from social cognitive theory and education about physical activity will be delivered. This component is scheduled between the walking and circuit training, lasts 15-20 minutes, and serves as a rest period.~Circuit training will focus on strength and balance. Approximately 8 exercise stations will be set up, and the exercises performed at each station will be changed approximately every 4 weeks. The circuit training will last \~30-40 minutes, with participants moving from one station to the next at their own pace and taking breaks in between."
214974059|NCT05619289|DRUG|Placebo|One-time, oral dose of 6 inert capsules matched to the active comparator
215084422|NCT01312389|BIOLOGICAL|Ampligen|All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.
215084423|NCT01312389|BIOLOGICAL|Prevnar|A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
214362828|NCT00953134|DIETARY_SUPPLEMENT|Ferrous fumarate (iron)|60 mg of ferrous fumarate
214362829|NCT00953134|DIETARY_SUPPLEMENT|folic acid|400 mcg folic acid
214362830|NCT05961852|DEVICE|Angioplasty|Angioplasty with cutting and drug-coated balloon
214362831|NCT00876915|DRUG|dalteparin injection|Potency is described in international anti-Xa units (IU). One unit (anti-Xa) of dalteparin sodium, average molecular weight 5,000, corresponds to the activity of one unit of the 1st International Standard for Low Molecular Weight Heparin (LMWH)with respect to inhibition of coagulation Factor Xa in plasma utilizing the chromogenic peptide substrate S-2765 (N-alpha-Benzyloxycarbonyl-D-arginyl-glycyl-arginine-pNA.2HCl).
214362832|NCT02138045|DRUG|Placebo treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
214362833|NCT02138045|DRUG|Liraglutide treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
214362834|NCT02880592|OTHER|Affinity Allograft|fresh hypothermically stored human amniotic membrane
214362835|NCT02880592|OTHER|Standard of care|offloading, debridement, infection management using appropriate dressings
214362836|NCT05584852|OTHER||no intervention
214362837|NCT01518855|DRUG|Nifedipine (Adalat, BAYA1040)|
214362838|NCT01518855|DRUG|Amlodipine (Norvasc)|
214362839|NCT01518855|DRUG|Diovan|
214362840|NCT04318184|PROCEDURE|Aerobic exercise|The aerobic exercise protocol was performed 3 times a week for 3 months on the treadmill. Loading periods were performed according to the heart rate maximum using the Karvonen formula (%60-80 Heart rate maximum)
214362841|NCT03362463|OTHER|Non-Interventional Study|Non-Interventional Study
214362842|NCT00176163|BEHAVIORAL|Operant behavioral treatment; Drug: THC|
214362843|NCT06366204|OTHER|Dietary Lysine Intakes|Participants consume 8 hourly meals that contain the assigned test lysine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 x Resting Energy Expenditure (REE) and adequate protein at 1.5 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and nitrogenous free cookies.
214362844|NCT00289887|DRUG|Comparator: losartan +/- HCTZ|Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
214362845|NCT00289887|DRUG|Comparator: Placebo|Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
214362846|NCT02879266|BIOLOGICAL|TetraVax-DV TV005|Contains 10\^3 plaque-forming units (PFUs) of rDEN1Δ30, 10\^4 PFUs of rDEN2/4Δ30(ME), 10\^3 PFUs of rDEN3Δ30/31-7164, and 10\^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm
214489643|NCT06735417|BEHAVIORAL|Indashyikirwa program|"Indashyikirwa training curriculum is delivered to heterosexual married couples in Syrian communities in Al-Hasakah governorate. The curriculum includes between 21 and 22 sessions, delivered to groups of up to 30 couples. Each week, participants will attend one session, lasting at least 3 hours.~Topics covered include: gender, power imbalance, triggers for GBV, conflict management, building healthy relationships, and coping mechanisms for managing GBV-related triggers.~The curriculum is designed to address both the wife and her husband and includes interactive exercises, take-home assignments, and reflections.~The sessions are delivered by trained facilitators."
214489644|NCT06756009|DIAGNOSTIC_TEST|Ophthalmic examination|Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
214489645|NCT06756009|DIAGNOSTIC_TEST|General Condition Examination|Various general condition examination, including blood pressure measurement, blood glucose testing, blood routine examination, coagulation function test, liver function test, etc.
214489646|NCT06762496|OTHER|Healthcare professionals|healthcare professionals (HCPs) targeted, including team members: we will involve 30 physicians (who are involved in the process of care towards patients with early breast cancer (10 oncologists, 10 breast surgeon, and 10 breast radiologists specifically) for the semi-structured interviews
214489647|NCT06762496|OTHER|Patients PDA group|Participants will receive via mail the final version of the PDA and a Qualtrics link with a battery of questionnaires
214489648|NCT06762496|OTHER|Patients control group|Participants will receive only the online link with the battery of questionnaires
214489649|NCT07039188|DEVICE|Use device in home environment|Patients will use the device in their home environment for four weeks.
214489650|NCT06777823|BEHAVIORAL|Social Rejection Task|All participants will receive this
214489651|NCT06832566|DRUG|Fludrocortisone 0.1 Milligrams (mg)|Treatment of hypotension with fludrocortisone 0.05mg/day in patients with secondary adrenal insufficiency before Ramadan fasting. Outcomes (number of fasted days and complications during fasting) will be compared between Ramadan fasting 2025 (with fludrocortisone) and Ramadan 2023 (without fludrocortisone).
214489652|NCT06069765|OTHER|TUPEX|"This program contains exercises with their own body weight or with Thera-bands for gaining strength in their shoulder and trunk muscles. It contains some progression exercise if needed.~Each session can last between 20 and 30 minutes. Children have to do each session three times a week during 8 weeks."
214489653|NCT06796842|OTHER|Ballistic Exercises|Ballistic training program was set for 6 weeks. Each week consisting of 5 exercises with sets of 3 and repetitions of 10,15 and 20 times, recovery time and training intensity differed each week.
214489654|NCT06796842|OTHER|Plyometric exercises|Plyometric training program was set for 6 weeks. With four exercises in 1st week. Five in 2nd and 3rd weeks, six exercises in 4th and seven exercises in last two weeks. Each exercise consisted of 3 sets with 10, 15 and 20 repetitions in each. Recovery time and training intensity differed each week.
214489655|NCT06888700|DEVICE|Transcranial direct current stimulation|The participant cohort recruited for this study consists of individuals with substance use disorder (SUD), specifically those addicted to drugs. During the intervention phase, this group will adhere to a strict non-pharmacological intervention protocol, meaning they will not receive any form of pharmacotherapy, neurosurgical intervention, or other neuromodulation-based cognitive interventions, including but not limited to techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). This design aims to ensure the internal validity of the study results and to exclude potential confounding effects of other interventions on neuroplasticity and cognitive function.
214489656|NCT06777173|DRUG|Peg interferon alfa-2b|NA combined with Peg interferon alfa-2b
214489657|NCT06844565|PROCEDURE|Immunohistochemistry procedure|"Briefly, all slides will be rehydrated, and antigen retrieval will be performed using sodium citrate (pH = 6.0) in a pressure cooker (EDTA buffer, pH = 8.4).~All slides will be blocked with endogenous peroxidase with 3% hydrogen peroxide and blocked non-specific protein with 2.5% bovine serum albumin in phosphate-buffered saline.~If the result shows non-specific ileitis, immunohistochemical staining for IL-12 and IL-23 will be performed using sandwich enzyme-linked immunosorbent assays (ELISA)."
214489658|NCT06744348|PROCEDURE|ENTİRE PAPİLLA PRESERVATİON|"The EPP technique is a tunnel-like approach of the defect-associated inter-dental papilla. Surgical loupes (3.3× magnification) with LED light illumination were used to increase visibility of the surgical site. Following a buccal intra-crevicular incision, a bevelled vertical releasing incision was performed in the buccal gingiva of the neighbouring inter-dental space and extended just beyond the mucogingival line to provide appropriate mechanical access to the intrabony defect."
214974060|NCT07072494|DRUG|CD19 CAR-T cells injection|Lymphodepleting pre-treatment will begin one week before the CAR-T cell infusion to reduce the burden of abnormal immune cells in the body, creating a favorable environment for the infused CAR-T cells. The suggested pre-treatment regimen is based on the FC regimen (Fludarabine + Cyclophosphamide).After the pre-treatment, patients will undergo CAR-T cell infusion, where the genetically modified T-cells are infused back into the patient's body.
214362847|NCT02879266|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
214362848|NCT01946022|DRUG|randomization between the two GnRH analogues (agonist and antagonist)|
214489659|NCT06892145|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
214974061|NCT07072715|BEHAVIORAL|PAPE Training|A neuromuscular activation protocol involving heavy banded squats (\~85% 1RM) to induce post-activation performance enhancement. Applied three times weekly over 8 weeks following the warm-up. Participants then continued with regular football training.
214362849|NCT01266850|BIOLOGICAL|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10\^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
214362850|NCT01266850|BIOLOGICAL|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
214362851|NCT04547088|DRUG|Camrelizumab|Anti-PD-1 targeted immunotherapy
214362852|NCT04547088|DRUG|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
214362853|NCT05981118|DRUG|Betamethasone dipropionate 0.05%|0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
214362854|NCT05981118|DRUG|Tapinarof|1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
214362855|NCT01139190|DRUG|PL3100|Oral administration
214362856|NCT01139190|DRUG|Naproxen|Oral administration
214362857|NCT04128293|DRUG|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
214974062|NCT07072715|BEHAVIORAL|Plyometric Training|A program of depth jumps designed to enhance explosive power, speed, and agility. Applied 3 times weekly over 8 weeks following the warm-up. Participants then continued with their regular football training.
214974063|NCT07072923|DRUG|Antibiotic loaded calcium sulfate beads|Calcium sulfate beads will be loaded with best available antibiotics based on surgeon/infectious disease specialist determination from the following options (vancomycin, daptomycin, cefazolin, cefepime, tobramycin, amphotericin B, micafungin, and voriconazole).
214974064|NCT07072923|DEVICE|Calcium sulfate beads (sham beads)|Calcium sulfate beads will be prepared without added antibiotics and placed during the second surgery.
214974065|NCT07072767|BEHAVIORAL|Digital education outreach intervention for kidney transplant access and human guide|Receives (1) donor search materials, (2) electronic resource access messages, (3) practical assistance to use the intervention and empower taking the outreach action and (4) telephonic human guide
214974066|NCT07072767|BEHAVIORAL|Digital education outreach intervention for kidney transplant access only (unguided)|Receives (1) donor search materials, (2) electronic resource access messages, and (3) practical assistance to use the intervention and empower taking the outreach action.
214974067|NCT04884139|DRUG|Dolutegravir/Lamivudine as a single pill|\- Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.
214974068|NCT04884139|DRUG|Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.|"* Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg~* Route of adminstration: oral~* Schedule of administration: once a day for 96 weeks."
214974069|NCT04819217|DIETARY_SUPPLEMENT|Active bamboo charcoal|During this 6 months' trial, eligible 120 patients with eGFR 15 \< eGFR \< 45 ml/min/1.73m2 and UACR \> 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.
214974070|NCT04819217|DIETARY_SUPPLEMENT|Probiotics|Probiotics
214362858|NCT04128293|DRUG|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
214362859|NCT00718822|OTHER|oxygen concentration in the culture atmosphere|
214362860|NCT01584180|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
214362861|NCT01584180|DEVICE|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad
214362862|NCT05419648|BIOLOGICAL|1 additional tube of blood|For all the patients included, a specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
214489660|NCT06884813|DRUG|Conventional nanohybrid multishade composite and hydrogen peroxide 40% in-Office Tooth Whitening System|Teeth restored with conventional multi shade nanohybrid Resin Based Composite (RBC) Filtek Z350Xt (3M ESPE, San Paul, MN, USA) subjected to bleaching using Opalescence Boost 40% In-Office Tooth Whitening System (Ultradent, Utah, USA)
214489661|NCT06884813|DRUG|Single shade nanohybrid composite and hydrogen peroxide 40% in-Office Tooth Whitening System|Teeth restored with One-shade Resin Based Composite (Omnichroma, Tokuyama Dental, Tokio, Japan) subjected to bleaching using Opalescence Boost 40% In-Office Tooth Whitening System (Ultradent, Utah, USA)
214489662|NCT06881836|DRUG|ONO-2020|ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily.
214489663|NCT06881836|DRUG|Placebo|Placebo group: Two ONO-2020 placebo tablets will be orally administered once daily.
214489664|NCT06842849|OTHER|Exercise program|Multimodal and multicompetent exercise program 2 days a week for 60 minutes and 1 day of walking exercise for 60 minutes.
214489665|NCT06842160|DEVICE|intervention group|A smart electrocardiogram watch based on the PPG algorithm for monitoring atrial fibrillation load after catheter ablation.
214489666|NCT06820151|OTHER|Sample collection|Sample collection: EVT sponges, tissue brushings and pinch biopsies
214489667|NCT06175936|OTHER|Laugther Yoga|Laughter yoga will be applied to the intervention group in 6 sessions (45 minutes each session).
214489668|NCT06764563|BEHAVIORAL|Mediterranean Medical Nutrition Therapy (counselling)|The participants in the intervention group will receive dietary guidance on the Mediterranean diet during 9 sessions over six months. The sessions which will be held in groups of ten individuals. In-person group sessions will be held three times: at the first meeting, after three months, and after six months. During the remaining six sessions, 6 online video sessions (by the institutional telemedicine program) will be delivered and include 60 minutes of nutritional educational sessions with a registered dietitian once a month
214489669|NCT06781112|DRUG|albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).|"Induction chemotherapy with PD-1 inhibitor combined with TPF regimen, administered every 3 weeks: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and PD-1 inhibitor ( 200mg).~All patients received 3 cycles of induction therapy followed by radical concurrent chemoradiotherapy combined with tislelizumab (200mg) treatment, Q3W. The cisplatin in the synchronous chemoradiotherapy regimen is administered once a week, with a dose of 40mg/m2 per dose, and the total dose of cisplatin does not exceed 100mg/m2. For patients who cannot tolerate cisplatin during synchronous radiotherapy and chemotherapy, cisplatin may not be combined."
214489670|NCT06790407|DIETARY_SUPPLEMENT|Mimio Study Product|Active ingredients in the Mimio study product include Nicotinamide 250mg, Ultra-Micronized Palmitoylethanolamide 600mg, Oleoylethanolamide 400mg, Spermidine 8mg; Other Ingredients: Hydroxypropyl-Methylcellulose (capsule), Silicon Dioxide, Magnesium Stearate.
214489671|NCT06790407|DIETARY_SUPPLEMENT|Placebo|Non-active study ingredients in the placebo include Micro Crystalline Cellulose 250mg, Hypromellose, Titanium Dioxide.
214489672|NCT06634680|PROCEDURE|Procedure: Selection of parent(mother or father) according to children preference|Children will choose the parent who will accompany them.
214489673|NCT06634680|PROCEDURE|Procedure: Both parents will accompany the children.|Both parents will accompany the children.
214489674|NCT03971669|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
214489675|NCT05725876|DRUG|Ustekinumab|Patients not on therapy and patients on therapy will undergo fluorescence molecular imaging.
214489676|NCT06776653|OTHER|Tovertafel Pixie|The Tovertafel Pixie® projector has a distracting effect, which can help divert the patient's attention while waiting for or undergoing treatment.
214489677|NCT06774885|DRUG|Folic Acid 1 Mg Oral Tablet|1 mg oral folic acid tablet
214489678|NCT06774885|DRUG|Folic Acid 5 Mg Oral Tablet|5 mg oral folic acid tablet
214489679|NCT06829758|BEHAVIORAL|Compartiendo Salud|The intervention proposed (Compartiendo Salud) is a multicomponent intervention based on prevention and on promoting the health of older adults that live alone. The community-based intervention consists in five workshops that are carried out during a week (one day for each workshop). The sessions (which last 2.5 hours each) are designed in an expository and participatory way, using gaming dynamics that foster learning and social interaction. The content of the workshops is the same for all BHDs. Each workshop addresses risk factors that predispose the population to experiencing more unwanted loneliness and social isolation. The concepts corresponding to each of the five sessions that comprise the intervention are: Sleep hygiene, Healthy and sustainable eating habits, Physical activity and exercise, Memory and music therapy, Digital literacy
214489680|NCT06386692|BEHAVIORAL|FCHVs-led community based educational physical activity intervention|This intervention will be designed to promote physical activity among adults
214489681|NCT06844097|BEHAVIORAL|Cervical Cancer Trans Inclusive Education (CC-TRAINED) Module|An online course designed to increase cervical cancer prevention clinical skills among medical students when working with Latinx transmasculine populations.
214489682|NCT06844097|BEHAVIORAL|Disaster Preparedness Course|An online course designed to improve professionals' skills and competencies for engaging in disaster preparedness.
214489683|NCT02542683|OTHER|structured physical activity program|a structured modest physical activity program
214489684|NCT06795802|BEHAVIORAL|Evaluative conditioning|The evaluative conditioning procedure is a learning technique performed on a monitor. It consists of being exposed to the repeated association of an object (conditioned stimulus, in our case, Physical Activity or fruit and vegetables) to stimuli with a positive or negative valence (unconditioned stimulus, US). The total duration of the CE is approximately 15 minutes.
214489685|NCT06837051|DEVICE|Conventional olfactory training device|"Four odorants are used: phenyl ethyl alcohol (PEA): rose, menthol: mint, citronellal: lemon, and eugenol: cloves. Training patients will receive four glass vials. Each contains one odorant (5 mL, soaked in cotton pads to prevent spilling) and is labeled with the name of the odorant.~Budesonide irrigation can effectively target the olfactory cleft area to provide anti-inflammatory effects."
214489686|NCT06837051|DEVICE|Modified olfactory training device|"The modified olfactory training device is based on the nasal bidirectional drug delivery system. The device uses breathing pressure to create positive pressure, significantly increasing the deposition rate of odors in the olfactory cleft area.~Budesonide irrigation can effectively target the olfactory cleft area to provide anti-inflammatory effects."
215084424|NCT04599868|DRUG|Magnesium sulfate|"Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h\& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed."
215084425|NCT01945736|DRUG|Methadone|To determine the PK of enteral methadone in children \> or = 90 days and \<18 years treated for opiate withdrawal per routine medical care.
215084426|NCT03135925|OTHER|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
214362863|NCT01695824|DEVICE|LAA occluder|The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
214362864|NCT01695824|PROCEDURE|RFA ablation|The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
214362865|NCT01695824|DRUG|Warfarin|"Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III."
214362866|NCT01862952|OTHER|starting of anti-epileptic drug treatment|
214362867|NCT03115294|DRUG|Theophylline|iv injection
214362868|NCT03115294|PROCEDURE|Ventilator positive end expiratory pressure adjustment|Positive end-expiratory pressure variation
214362869|NCT03115294|DEVICE|Videorecording|Myocardial movement videorecording
214362870|NCT04883307|BEHAVIORAL|Coaching|Professional development coaching based on a curriculum of positive psychology principles and coaching principles.
214362871|NCT04883307|BEHAVIORAL|Wellness resources|Residents in the control group received three emails across the 9 month study period that contained materials related to physician well-being such as personal development and resilience, mindfulness, and work life-integration. Materials included recommended readings, videos, and exercises and were curated by members of the Association of Women Surgeons who were not involved in the coaching program.
214362872|NCT00437645|DRUG|Valsartan 160 mg capsules|
214362873|NCT00437645|DRUG|Amlodipine 5 mg capsules|
214362874|NCT00437645|DRUG|placebo|capsules
214362875|NCT00707265|DEVICE|rhBMP-2/CRM/CD HORIZON® Spinal System|"The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.~The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used."
214362876|NCT00707265|DEVICE|Autograft/CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
214362877|NCT00412048|PROCEDURE|fMRI to detect MCI patients who will convert to Alzheimer's disease|There is a fMRI to be realized in the 3 arms. No drug is administered
214362878|NCT05618548|BIOLOGICAL|COVID-19 vaccine|COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).
214362879|NCT03019510|BEHAVIORAL|No exercise|No exercise will be done on the day of the study night to be tested
214362880|NCT03019510|BEHAVIORAL|Morning exercise|Early morning exercise will be done on the day of the study night to be tested
214362881|NCT03019510|BEHAVIORAL|Evening exercise|Evening exercise will be done on the day of the study night to be tested
214362882|NCT05049408|DIAGNOSTIC_TEST|MMP-1 Enzyme Linked Immunosorbent assay (ELISA)|The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
214489687|NCT06837051|DRUG|Budesonide irrigation|Budesonide irrigation can effectively target the olfactory cleft area to provide anti-inflammatory effects.
214489688|NCT05568030|BEHAVIORAL|Mindfulness|One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.
214489689|NCT05568030|BEHAVIORAL|Psycho-education|One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
214489690|NCT04710316|DIAGNOSTIC_TEST|SARS-CoV-2 screening by molecular biology|SARS-CoV-2 RT-PCR in nasopharyngeal swab targeting 2 regions of the viral genome
214489691|NCT04710316|DIAGNOSTIC_TEST|Serological screening|Serological screening of caregivers at D0, M1, M2, M3 (anti-nucleocapsid antibodies).
214974071|NCT05333497|DEVICE|the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument|Conventional electrical stimulation does not produce coordinated movement of multiple joints by stimulating several locally generated single ones simultaneously. The stimulation after the improved program, through different time output electrical stimulation on different parts of the muscles or muscle groups, forming the programmed motion. The purpose of this study is to achieve the rehabilitation goal of single joint - multiple joint - extensive movement, promote the coordination recovery of affected limb movement and relieve muscle fatigue.
214974072|NCT05333497|DEVICE|the fourth generation of low-frequency acupoint electric stimulation therapy instrument|In this study, the instrument of alternate acupoint electrical stimulation of flexor and extensor muscles combines traditional acupoint therapy with modern low-frequency electric stimulation technology, has the advantages of non-invasive and convenient application, and has a good effect on improving the range of motion of joints, relieving spasm, enhancing muscle strength, promoting the recovery of the central nervous system and other aspects.
214974073|NCT01278758|DRUG|ASA404, DMXAA or DXAA|
214974074|NCT06337500|DEVICE|Neurophysiological measure (EEG)|Cerebral electric activity recorded with EEG
214974075|NCT06337500|OTHER|Survey|Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed
214974076|NCT02605200|BEHAVIORAL|Psychologist Support|Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
214974077|NCT02605200|BEHAVIORAL|Pediatric Certified Diabetes Educators (CDEs) Support|Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
214489692|NCT06781515|OTHER|Peripheral and BM blood sample|Peripheral and BM blood samples will be analyzed with the ddPCR method
214489693|NCT06894303|DEVICE|Target CI v1.5 remote programming|Use of the remote programming function of Target CI v1.5 and the AB remote support application
214489694|NCT04959812|DRUG|Sufentanil|Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
214489695|NCT04959812|OTHER|Placebo|Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.
214974078|NCT02481050|DRUG|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
214974079|NCT03220841|DRUG|Adalimumab Injection|Standard dose adalimumab induction and maintenance
214974080|NCT03220841|DRUG|Thiopurine|Dose optimized thiopurine
214974081|NCT03220841|PROCEDURE|Endoscopic balloon dilatation|Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
214974082|NCT01386606|DRUG|Androxal (enclomiphene citrate)|"capsule oral~1X a day 6 weeks"
214974083|NCT01386606|DRUG|Testosterone|"topical gel~1X a day 6 weeks"
214974084|NCT03353376|BEHAVIORAL|group care with Empowerment model|Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
214974085|NCT04159714|DEVICE|Air Optix contact lens|Contact lens will be placed on the surface of the patient's eye and is to be used as a bandage
214974086|NCT06073288|OTHER|Surgical specimens of CD and no-IBD patients|Specimens of CD patients and patients without IBD-related disease (ex. diverticulitis) will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
214489696|NCT06766643|PROCEDURE|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic radiosurgery for liver lesions: with a total dose of 40\~50Gy/3\~5fraction;
214489697|NCT06766643|PROCEDURE|Radiofrequency ablation therapy|Radiofrequency ablation therapy:1 complete radiofrequency ablation of liver lesions for liver lesions
214489698|NCT06891157|DRUG|Chidamide plus R-CHOP|Chidamide Plus R-CHOP (Rituximab、Cyclophosphamide、Doxorubicin、Vincristine and Prednisone)
214974087|NCT03933488|DRUG|TAK-994|TAK-994 tablets.
214974088|NCT03933488|DRUG|TAK-994 Placebo|TAK-994 placebo-matching tablets.
214974089|NCT06449352|DRUG|Netarsudil|netarsudil 0.02%
214974090|NCT06449352|DRUG|Brimonidine|brimonidine 0.1%
214974091|NCT03246347|DRUG|ADT+Docetaxel+Enzalutamide|combination therapy as listed above
214974092|NCT06400212|OTHER|Cardiopulmonary exercise test|Participants undergo a cardiopulmonary exercise test following a standardised protocol used in national guidelines
214974093|NCT04923529|DRUG|TAS 102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery"
214974094|NCT04893161|DRUG|Belimumab|All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
215084427|NCT04408417|DEVICE|Prototype child safety seat with tension indicator lights|The prototype child safety seat is a convertible rear-facing seat with a harness system that includes tension indicator lights.
214489699|NCT06794762|OTHER|Conventional exercises|"Aerobic exercise and stretching exercises will be applied in the conventional exercise program.~A 20-30 minute walking will be done as aerobic exercise. Stretching exercises will be done for major muscle groups in 3 sets and 10 repetitions."
214489700|NCT06794762|OTHER|Core stabilization exercises in addition to conventional exercises|In addition to the conventional exercise program, core stabilization exercises will be applied. During the exercises, participants will be trained on neutralizing the spine and working the transverse abdominis and multifidus muscles, correct postural control, and performing the exercises with diaphragmatic breathing.
215084428|NCT04408417|DEVICE|Control child safety seat|The control child safety seat is a convertible rear-facing seat without tension indicator lights.
215084429|NCT01718249|OTHER|Implantable neurostimulation system|
215084430|NCT06252818|DEVICE|ReHub|ReHub provides support to rehabilitation professionals by offering information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation.
214489701|NCT06893445|PROCEDURE|Deep Tissue Massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
214489702|NCT06893445|PROCEDURE|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
214489703|NCT06747936|DRUG|AD-2281|PO, Once daily, 8weeks
214489704|NCT06747936|DRUG|AD-2282|PO, Once daily, 8weeks
214489705|NCT06747936|DRUG|Placebo of AD-2282|PO, Once daily, 8weeks
214489706|NCT02379351|DEVICE|In-Home Non-Stress Test Device|Airstrip® Sense4Baby™
214489707|NCT06909175|DEVICE|Transesophageal echocardiography|Portal vein velocities were measured using TEE and intraoperative doppler in patients undergoing living donor liver transplantation
214489708|NCT06423391|OTHER|NeuOst|As above
214489709|NCT06423391|OTHER|Control Intervention|As above
214489710|NCT06423391|OTHER|Usual Care|As above
214974095|NCT04361656|DRUG|PEG-ELS current standard of care|Standard of care for inpatient colonoscopy
214974096|NCT04361656|DRUG|PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)|The dose of Lubiprostone will be 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy if it is BEFORE 11 a.m., and Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS if colonoscopy is scheduled AT or AFTER 11 a.m..
214974097|NCT04016974|DRUG|Oral semaglutide|Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)
215084431|NCT01303302|DEVICE|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
215084432|NCT01303302|DEVICE|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
215084433|NCT03897218|DIETARY_SUPPLEMENT|oatmeal flakes with prebiotic food supplements|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
215084434|NCT03897218|DIETARY_SUPPLEMENT|millet flakes|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
215084435|NCT02775110|OTHER|Natalizumab discontinuation|Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
215084436|NCT05767502|DIAGNOSTIC_TEST|GCS-Pupil score|"GCS+attributed verbal score- Step 1 to obtain pupillary score:~* Patients with a motor (M) and eye-opening response (E) total score between 2 and 6 are assigned a verbal score of +1~* Patients with an M+E score of 7 are assigned a verbal score of +2~* Patients with an M+E score of 8-9 are assigned a verbal score of +4~* Patients with an M+E score of 10 are assigned a verbal score of +5~GCS+attributed verbal score- Step 2 to obtain the pupillary score:~The total score is obtained by subtracting the pupil score from the score obtained in the 1st step. Pupil score is scored as follows;~* 0 points if both pupils react to light,~* 1 point if a pupil does not react to light and has anisocoria,~* 2 points if both pupils do not react to light"
215094450|NCT00681993|OTHER|Standard Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
214489711|NCT06881940|OTHER|Rehabilitation Program|"Three of the five weekly sessions will take place at the gym in the Functional Unit of Breast Tumors at INCAN, under the supervision of Physical and Sports Medicine specialists and three physical therapists. These sessions allow for personalized feedback, enabling participants to confidently perform prescribed aerobic exercises at home on the remaining two days.~Each session starts with a 10- to 15-minute warm-up focused on joint mobility. Aerobic training is conducted at moderate intensity (40-59% VO2max or heart rate reserve), monitored with a Polar® FT1 device. Intensity is periodically adjusted based on the Borg Rating of Perceived Exertion and the talk test. Over 4-6 weeks, session duration will gradually increase to 90 minutes per week, remaining consistent thereafter.~Following aerobic training, resistance exercises targeting major muscle groups are performed using gym machines and dumbbells. The program includes seven exercises, progressively increasing load over 3-4 weeks."
214489712|NCT06881940|OTHER|No Rehabilitation Program|The control group will continue standard oncological treatment in addition to general recommendations regarding diet and physical activity, but without a structured exercise protocol.
214974098|NCT04016974|DRUG|Placebo|Placebo tablets once daily throughout the treatment period (day 1 to 84)
214974099|NCT06447714|BEHAVIORAL|smoke|cotinine detection
214974100|NCT03663270|DEVICE|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
214974101|NCT06446622|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
214489713|NCT06942858|DEVICE|Deep transcranial magnetic stimulation|M-100 Ultimate pulsed magnetic field stimulator is used for dTMS treatment. The coil is positioned 4 cm anterior to the scalp point and the foot motor cortex, corresponding to the ACC. A naturally cold HF001A coil is used to obtain a greater depth of stimulation, up to about 6 cm subcortical. The coil is an integrated coil for true and false stimulation loops. The intervention protocol is as follows: 30 treatments are given 5 times per week (Monday to Friday) for 6 consecutive weeks. Intervention mode: stimulation frequency 20Hz, stimulation intensity 100% RMT, number of serial pulses 50, sequence interval 20s, a total of 40 trials, 2000 pulses, stimulating the left and right ACC respectively.
214974102|NCT01022203|BEHAVIORAL|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
214974103|NCT01022203|OTHER|PTSD Family Education|The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
215084437|NCT05993780|OTHER|No drugs or biologial agents were used in our trial|Before the measurement, a recruitment maneuver was performed for 30-40 s at a PEEP level of 20 cmH2O. At four different PEEP levels of 15, 10, 5, and 0 cmH2O, a decreasing PEEP trial was performed, and the measurement results were recorded.The measurement time at each PEEP level was chosen as 10 minutes. At the end of the measurement, static compliance was measured by applying an end-inspiratory pause. Respiratory system elastance,static strain volume gain was calculated.The estimated lung volume recovered was calculated using the formula ∆EELV - (∆PEEP x Compliance PEEPlow) and compared with the volume gain.
215084438|NCT04689152|BIOLOGICAL|Cellgram-LC|Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
215084439|NCT03950687|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
215084440|NCT03950687|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
215084441|NCT04739397|DEVICE|Glare Testing|Vision in Cataract patients were tested with and without the EpiGlare Tester
215084442|NCT00993499|DRUG|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
215084443|NCT00993499|DRUG|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
215084444|NCT01948232|DRUG|Perindopril|Angiotensin converting enzyme inhibitor
214362883|NCT04123925|DRUG|Nivolumab|Locally advanced colon cancer must be documented at screening (within 21 days prior to initiation of study treatment) and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan Postoperatively, standard adjuvant chemotherapy will be administered in pathological III-stage and at investigator discretion in pathological II-stage at high risk
214362884|NCT03597568|DIETARY_SUPPLEMENT|Resveratrol|Oral supplementation for 6 weeks
214974104|NCT04472221|PROCEDURE|Arterioarterial synthetic graft|Synthetic poly tetraflouroethylene graft
214974105|NCT06211023|DRUG|SHR-1921|SHR-1921
215084445|NCT03423290|DEVICE|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
215084446|NCT03419390|DEVICE|combined Coaxial Optical Coherence Tomography (OCT) System|The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
215084447|NCT04682990|DEVICE|Tor Vergata Electronic Nose (TV eNose)|Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
214974106|NCT06211023|DRUG|carboplatin|carboplatin AUC 4
214974107|NCT06211023|DRUG|carboplatin|carboplatin AUC 5
214974108|NCT06211023|DRUG|platinum-based doublet chemotherapy|platinum-based doublet chemotherapy
214974109|NCT00903201|DRUG|SB656933|20 mg
214974110|NCT00903201|DRUG|SB656933|50mg
214974111|NCT00903201|DRUG|Placebo|placebo
214974112|NCT00560729|DIETARY_SUPPLEMENT|Renutryl 500|
215084448|NCT04682990|OTHER|Survey & Physical Exam|Perform a oriented survey for risk factors, symptoms and a complete physical exam.
215084449|NCT04682990|DIAGNOSTIC_TEST|TB LAMP test|Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
214362885|NCT03597568|OTHER|Placebo|Oral supplementation for 6 weeks
214362886|NCT05282797|DRUG|ANEB-001|Experimental Treatment
214362887|NCT05282797|DRUG|Placebo|Placebo comparator
214974113|NCT00560729|DIETARY_SUPPLEMENT|Generique|
214974114|NCT00560729|DIETARY_SUPPLEMENT|Generique + Renutryl 500|
214974115|NCT00002551|DRUG|fluorouracil|See arm assignments.
214974116|NCT00002551|DRUG|leucovorin calcium|See arm assignments.
214974117|NCT00002551|DRUG|levamisole hydrochloride|See arm assignments.
215084450|NCT04682990|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
215084451|NCT04682990|OTHER|Chest X-Ray|Perform anteroposterior chest X-ray (if required by the medical staff)
214362888|NCT06146491|DRUG|Oral tablet and transdermal patch|oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.
214362889|NCT05011968|DIETARY_SUPPLEMENT|Lettuce with not biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
214362890|NCT05011968|DIETARY_SUPPLEMENT|Lettuce biofortificated with Iodine|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
214362891|NCT03089684|OTHER|No intervention|No intervention
214974118|NCT00002551|RADIATION|radiation therapy|See arm assignments.
214489714|NCT06942858|BEHAVIORAL|cognitive behavior therapy|Each patient receives 12 individual sessions of 50 minutes twice a week for 6 weeks.The CBT therapists are nationally registered psychotherapists with systematic professional training and uniform training in CBT for anorexia nervosa to ensure consistency. They are also supervised by a CBT supervisor at the end of each session.
214489715|NCT06942858|DEVICE|Sham deep transcranial magnetic stimulation|M-100 Ultimate pulsed magnetic field stimulator is used for dTMS treatment. The coil is positioned 4 cm anterior to the scalp point and the foot motor cortex, corresponding to the ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field). A naturally cold HF001A coil is used to obtain a greater depth of stimulation, up to about 6 cm subcortical. The intervention protocol is as follows: 30 treatments are given 5 times per week (Monday to Friday) for 6 consecutive weeks. Intervention mode: stimulation frequency 20Hz, stimulation intensity 100% RMT, number of serial pulses 50, sequence interval 20s, a total of 40 trials, 2000 pulses, stimulating the left and right ACC respectively.
214489716|NCT06942858|OTHER|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
214489717|NCT06953778|DEVICE|Zio XT® Patch|For participants randomized to be systematically screened, ambulatory ECG monitoring of up to 14 days will be performed using the Zio XT® Patch (iRhythm Inc, San Francisco, CA). The Zio XT® patch is a small, cutaneous ambulatory ECG recording device that provides cardiac rhythm monitoring for up to 14 consecutive days (significantly longer than the 48 hours of monitoring provided by a typical Holter Monitor). The device is approved by the Food and Drug Administration and is in routine clinical use, including in the VA system.
214362892|NCT04835818|DIAGNOSTIC_TEST|Provide the panel report to the primary care physician|Point-of-care Multiplex PCR Respiratory Panel (BIOFIRE FilmArray) and Pneumonia Panel results (BIOFIRE FilmArray)
214362893|NCT00003617|DRUG|chlorambucil|
214362894|NCT00003617|DRUG|clarithromycin|
214489718|NCT06796257|OTHER|radiotherapy planning|In this study, CT localization images from 32 patients were retrospectively used for radiotherapy treatment planning. Three radiotherapy plans were designed based on different K-value intervals of the Monaco-Serial biological function constraint for the heart. The dose-volume parameters of the organs at risk were compared.
214679599|NCT05845164|DEVICE|tDCS|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~tDCS: The anode and cathode are two large 5 cm by 5 cm gel-based pads which are placed on the scalp. This reduces the risk of burn or irritation and increases conduction. The 2 electrodes are connected to the tKIWI device which delivers a low intensity electrical current (\</=2A), thereby polarizing membrane potential of neurons in the stimulated area. Current that flows from the cathode to the anode has an inhibitory effect on the stimulated area, while current that flows from the anode to the cathode is typically excitatory. We will be initiating bilateral stimulation of the Dorsolateral pre-frontal cortex (DLPFC), which has been shown in the literature to elicit a significant decrease in ambiguous risk-taking behavior in healthy human subjects and a decrease in impulsivity on a non-ambiguous risk task."
214679600|NCT05845164|DEVICE|tDCS Sham|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~The sham group will receive ramped up current from 0.0mA to no more than 0.5mA for the first minute at the initiation of each of the three ramp ups, after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle. The current delivered by tDCS is not strong enough to trigger an action potential in a neuron; instead its sub-threshold changes the pattern of already active neurons."
214362895|NCT00003617|DRUG|omeprazole|
214362896|NCT00003617|DRUG|tinidazole|
214489719|NCT05720299|DRUG|Akkermansia muciniphila|one tablet of AKK
214489720|NCT05720299|DRUG|Berberine|one tablet of Berberine
214489721|NCT05720299|DRUG|AKK Placebo|one tablet of AKK placebo
214489722|NCT05720299|DRUG|Berberine Placebo|one tablet of Berberine placebo
214679601|NCT03415464|OTHER|Exercise|neuromuscular training
214679602|NCT04918940|BIOLOGICAL|Determination of COVID-19 vacciantion efficacy|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
214679603|NCT02241850|OTHER|High intensity training|9 weeks of supervised high intensity training
215084452|NCT04682990|OTHER|Follow Up 5 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
214362897|NCT05858697|OTHER|Declining participation in the Aarhus intervention|Each year a fraction of the children invited into the Aarhus intervention decline to participated.
214362898|NCT05858697|BEHAVIORAL|Participation in the Aarhus intervention|A community-based multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. The intervention has a maximum duration of one year.
214362899|NCT04238026|PROCEDURE|Distal radial artery approach|Use of distal radial artery approach in coronary angiography and angioplasty
214362900|NCT03949166|OTHER|food during labor and delivery|The food that will be allowed during labor and delivery was approved by the anesthesia team. It includes - fruits, energy bars, yogurt,
214489723|NCT05039021|DEVICE|HARMONIC 1100 Shears|HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
214489724|NCT03580655|DRUG|Avapritinib|Avapritinib tablet
214489725|NCT05605613|DRUG|PD-1 Antibody|PD-1 Antibody, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1
214362901|NCT03159520|BEHAVIORAL|Advice sheet|Advice on management of post orthodontic pain
214362902|NCT00370630|DRUG|Avastin (Bevacizumab) and triamcinolone|
214362903|NCT00879138|DRUG|VA106483|
214362904|NCT00879138|DRUG|Sugar pill|
214489726|NCT05605613|DEVICE|BACE|Bronchial Arterial Chemoembolization
214974119|NCT05695703|OTHER|Core Strength Training Group|"The participants of experimental group will perform core strength training regime for 6 weeks (3 days per week). Each exercise session will last for a period of 45 mins, the exercises would be performed in 3 sets of 5 repetitions with 5 seconds hold time and 10 seconds rest between each repetition and a minutes rest in between each set.~Following exercises would be performed :~Bridge, Crunch, Plank, Side Plank, Mountain Climb."
214974120|NCT05695703|OTHER|Conventional Training Group|"The participants of conventional group will perform following exercises :~Running (10 repetitions X 3 sets), Jogging (10 repetitions X 3 sets), Stretching (10 repetitions X 3 sets)~Rest between Exercises : 10-15 Seconds Rest between Set of Exercises : 30-60 Seconds Cricketers will receive exercises for 8 weeks. There will be 3 sessions per week."
214489727|NCT03373916|BEHAVIORAL|Peer mentorship|The PREVAIL intervention will be delivered by a Certified Peer Support Specialist (CPSS) or Peer Recovery Coach. Participants will select a Peer to work with based on brief personal descriptions. Sessions may occur in-person (public place, the participant's home, or a research clinic space) or remotely (phone or video call). The first meeting will occur while the participant is hospitalized, and subsequent sessions will be scheduled per the participant's preferences, with a suggested frequency of twice weekly for weeks 1-2, weekly for weeks 3-8, and every other week for the last month. Sessions will last 1 hour on average and will consist of semi-structured conversations focused on protective factors such as hope, safety planning, and coping skills. Session structure and content are intentionally flexible to allow for general supportive listening, validation, sharing, and genuineness in the relationship, thereby increasing acceptability and implicit belongingness.
214489728|NCT03373916|BEHAVIORAL|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
214974121|NCT02981511|DEVICE|optiflow|Optiflow device used for preoxygenation
214974122|NCT04939467|DRUG|Pirfenidone 267 mg Oral Tablet|Fixed sequence use of active product, TID
214974123|NCT04939467|DRUG|Nintedanib 150 mg Oral Capsule|Fixed sequence use of active product, BID
214974124|NCT04939467|DRUG|BLD-0409 750 mg Oral Tablet|Fixed sequence use of active product, QD
214974125|NCT03906864|OTHER|Care Pathway|"The intervention group had the following as part of the integrated care pathway:~1. Medical assessment on admission for risk factors for falls.~2. A weekly assessment of complications including pain, deep venous thrombosis, anaemia, wounds and pressure ulcers, etc. The Confusion Assessment Method and the Geriatric Depression Scale were utilized.~3. Physiotherapy and occupational therapy guidelines with recommended milestones (set for the full, partial and non-weight bearing groups)~4. Physiotherapy Clinical Outcome Variables Scale (PTCOVS)16 was used by the physiotherapists in the intervention group to assess the baseline mobility, to define outcome goals and to direct treatment plans.~5. A postoperative hip precaution handout (containing information on avoiding hip prosthesis dislocation in patients with total hip replacement or hemiarthroplasty) was given to patients and their caregivers."
214974126|NCT01865357|OTHER|Brain MRI - Clinical and cognitive evaluation|"* Clinical evaluation (EDSS, MSFC)~* Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~* Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI"
214974127|NCT01865357|OTHER|Eye movement|Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
214974128|NCT04802200|OTHER|Data collect|Data collect following a vascular closure by MANTA
214974129|NCT01334086|DRUG|Aprepitant|Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
214974130|NCT05623410|BIOLOGICAL|ATGC-110|ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
214974131|NCT05623410|BIOLOGICAL|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
214974132|NCT05609994|DRUG|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
214974133|NCT06516640|BEHAVIORAL|Continuous Glucose Monitoring Academy|Educational materials as well as online sessions with diabetes educators.
214974134|NCT06516640|BEHAVIORAL|Standard Education|Standard of care receives general education about diabetes.
214974135|NCT06258434|DIAGNOSTIC_TEST|multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo)|Patients who are at high risk of developing CRC or confirmed CRC and willing to conduct colonoscopy examination will be asked to collect blood prior to bowl preparation for multiomics CRC screening test which using Reduced Representation Bisulfite Sequencing (RRBS) technology to obtain multidimensional variation information on cell-free DNA (cfDNA) methylation, end sequence, fragment size distribution, and copy number variation in the blood, and integrate analysis through machine learning algorithms to accurately assess the risk of colorectal cancer and advanced adenoma. and will be asked to collect stool sample for commercially available FIT assay. Colonoscopy and histopathologic examination are used as reference. The diagnosis information of each sample was blind to the participants who conduct the multiomics profiling, as well as the informatics who perform the integrate analysis.
214362905|NCT00444691|DEVICE|ultra-sonography|"o The ultrasonographic evaluation was performed on 38 joints: the 28 joints included in DAS28 (e.g. shoulderx2, elbowx2, wristx2, metacarpo-phalangeal (MCP)x10, proximal inter phalangeal (PIP)x10, kneex2) and also the metatarso-phalangeal (MTPx10). Systematic multiplanar gray-scale (mode B) and Power Doppler examination was carried out with commercially available real-time scanners using multi-frequency linear transducers (7-12 MHz).~The ultrasonographic evaluation was performed at baseline and 1, 2, 3, and 4 months after baseline."
214974136|NCT04009603|DRUG|Probiotic Agent|"Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit effects on the host.~Many clinical trials have been done on probiotic which show its use as a single or as an adjuvant drug therapy for various diseases with no or rare side effects. It is now frequently used agent for various diseases.~Apart from this many studies have been published related to effects of probiotics on PCOS, which shows effectiveness of probiotics when used for 8 to 12 weeks with no adverse effects observed by these micro-organisms but none of the study have compare it with standarad drug"
214974137|NCT04009603|DRUG|Metformin|"Metformin, an insulin sensitizer, is an oral biguanide that is most commonly prescribed for the management of type II diabetes mellitus and various symptoms of PCOS. It is derived from the extract of Galega officinalis.~It remediates hyperglycemia through activation of AMPK which stimulates glucose uptake and its consumption; promote fatty acid oxidation along with suppression of hepatic glucose production. It is also involved in increase GLUT4 translocation in the muscle and fat leading to decrease hepatic lipid synthesis. Moreover, It is also reported that it decreases gut absorption of glucose by increasing the glucagon-like peptide-1 (GLP-1) in this way, it reduces the insulin requirement too.All of these actions of metformin decrease insulin resistance and thus improve the state of hyperinsulinemia associated with diabetes and PCOS"
215084453|NCT04682990|OTHER|Follow Up & 15 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
214362906|NCT02250105|DRUG|ARI-3037MO|Lipid lowering
214362907|NCT02250105|DRUG|Placebo|Inactive
214362908|NCT03382782|BEHAVIORAL|BWLI|"BWLI includes group weight management classes, physical activity classes, individual sessions with a facilitator to address goals and barriers to weight loss, and weigh-ins.~A punch card system will be implemented to incentivize participation for BHL classes. Each participant from the BWLI condition will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in."
214362909|NCT03382782|BEHAVIORAL|BWLI & Peer Navigator|Participants receive the BWLI condition and partner with a peer navigator. Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on BWLI homework, attending health care appointments, and facilitating diet and exercise activities). A punch card system will be implemented to incentivize participation for BHL classes. Each participant from BWLI \& Peer Navigator will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in.
214362910|NCT03382782|BEHAVIORAL|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
214362911|NCT04186013|DRUG|Atezolizumab Injection [Tecentriq]|intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses
214362912|NCT04186013|RADIATION|External Beam Radiation Therapy (EBRT)|60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day
214362913|NCT01316510|DIETARY_SUPPLEMENT|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge
214362914|NCT01316510|OTHER|Placebo|Dilute Nutramigen formula
214362915|NCT01520740|DEVICE|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
214362916|NCT01520740|DEVICE|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
214362917|NCT02611739|DEVICE|Medi-Port|Treatment
214362918|NCT02611739|DEVICE|Medi-Port|Control
214362919|NCT01418274|DRUG|danoprevir|oral doses of danoprevir
214489729|NCT03194516|OTHER|Surveillance|The investigators propose an 8-week ketogenic diet intervention with pre-/post-intervention assessment of serum and tissue metabolic and inflammatory biomarkers, including metabolomics analysis, among a sample of 12 overweight or obese prostate cancer patients on active surveillance. There will be no randomization; all patients will receive the diet intervention.
214489730|NCT04541797|DRUG|Empagliflozin 10 MG|Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
214974138|NCT02296489|DEVICE|Capnostream20p|The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
214362920|NCT01418274|DRUG|escitalopram|oral doses of escitalopram
214362921|NCT01418274|DRUG|ritonavir|oral doses of ritonavir
214362922|NCT02377154|DEVICE|Slit lamp|Examination of cornea
214362923|NCT02377154|DEVICE|Autorefractor|Measurement of refraction
214362924|NCT02377154|DEVICE|IOLMaster 500|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
214362925|NCT02377154|DEVICE|Pentacam HR|Measurement of white-to-white distance; Keratometry
214362926|NCT02377154|DEVICE|LenStar LS900|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
214362927|NCT02377154|DEVICE|VERION Image Guided System|Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
214489731|NCT04541797|DRUG|Placebo|Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
214362928|NCT03233243|DRUG|Rosuvastatin Oral Tablet|Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
214489732|NCT04541797|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|Imaging: All patients will have stress CMR examinations at recruitment.
214489733|NCT03653364|DRUG|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age. Participants aged ≥ 3 months to \<12 months old received baloxavir marboxil, 2 milligrams per kilograms (mg/kg). Participants from birth to \< 4 weeks old and ≥ 4 weeks to \< 3 months old received baloxavir marboxil, 1 mg/kg.
214489734|NCT00299572|DRUG|alendronate (Fosamax)|
214489735|NCT00777894|RADIATION|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
214489736|NCT00777894|RADIATION|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
214489737|NCT00777894|RADIATION|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
214679604|NCT04936139|BEHAVIORAL|Art Therapy|"During the 12 planned sessions, different artistic disciplines will be used: visual arts, music, play, narrative, dramatization, movement and body expression.~Each session is structured in 3 phases:~i. A first part of encounter and contextualization, to make contact with oneself, with the art therapist and with the group through a relaxation or meditation activity (35 minutes).~ii. A second part, where the session continues with the work of artistic elaboration and production with the different materials and the different artistic languages (50 minutes).~iii. A third part where the participants will be invited to make a closing, a moment to welcome and share whoever wishes, the experiences that have been experienced. A dialogue is created between Work-Patient-Art Therapist (35 minutes)."
214974139|NCT04069715|DIETARY_SUPPLEMENT|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)|A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.
214974140|NCT04069715|OTHER|Placebo|Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
214362929|NCT03912454|OTHER|Autologous Bone Marrow Aspirate Concentrate (BMAC) Injection|Subjects will undergo bone marrow aspiration from the iliac crest. Bone marrow will be concentrated and injected into the symptomatic lumbar disc.
214362930|NCT03205397|OTHER|Experimental Group|Preparation for anesthesia (explanations, film, booklet), the presence of a parent in the operating room and the awakening of the child
214362931|NCT03205397|OTHER|usual care|Usual care
214974141|NCT02594319|BEHAVIORAL|Monetary incentives|
214974142|NCT02594319|BEHAVIORAL|Self monitoring|
214362934|NCT03191487|OTHER|ChimioPal|"Systematic collection of clinical and laboratory toxicities (TXs) during the 2-4 days preceding a chemotherapy (CT) session (48H before a session (D-2 towards the end of the afternoon) and a maximum of 96h before sessions occurring on Mondays (D-4 towards the end of the afternoon). Clinical TX data will be collected via ChimioPal (a self-questionnaire administered by smartphone) and laboratory TX data will be collected via Apicrpyt (secure messaging service) or a fax-to-email service. Data flow management by a nurse dedicated to this activity in each centre will be implemented. If the results of the assessment do not authorize CT, additional assessments may be prescribed. If the experimental data transmission does not occur, the usual pathways will be implemented.~Patient training on how to use a smart phone and the questionnaire will be performed by a nurse before the start of the first chemotherapy session, with reminders at the following sessions if required."
214974143|NCT05471388|DIAGNOSTIC_TEST|serum asprosin|assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
214362935|NCT03191487|OTHER|Usual pathways|In the standard arm, the usual management and logistic pathways will be respected. Only extra data collection is required by this study.
214362936|NCT00279292|PROCEDURE|Celiac Plexus Neurolysis|
214362937|NCT03515928|OTHER|Ultrasonic noise exposure|Group will be exposed to 40kHz ultrasonic noise at 110-120 dB SPL for 15 minutes.
214362938|NCT03515928|DIAGNOSTIC_TEST|Pure Tone Audiometry|Participants will undergo 2 (pre and post exposure) hearing tests
214362939|NCT02859610|OTHER|research on interactions between portal hypertension and microparticles|
214362940|NCT06020690|DEVICE|bioabsorbable steroid-releasing stent|The patient after functional endoscopic sinus surgery to treat their chronic sinusitis, the experimental device or active comparator device will be implanted to the sinus to prevent re-intervention (surgery or medicine).
214362941|NCT03500055|PROCEDURE|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
214362942|NCT00726206|OTHER|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
214362943|NCT03977090|DRUG|Geptanolimab Injection|GB226 3mg/kg, q2w, iv.
214362944|NCT03977090|DRUG|Fruquintinib|Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off
214362945|NCT04646239|DIAGNOSTIC_TEST|Heterologous stimuli|In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli
214362946|NCT04646239|DIAGNOSTIC_TEST|Neutralization assay|In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2
214362947|NCT03404492|OTHER|Stress echocardiography|A stress echocardiography will be performed in addition to the traditional patient care
214362948|NCT05179967|DEVICE|WeFlow-JAAA Stent Graft System|WeFlow-JAAA Stent Graft System consists of abdominal main body of inner embedded stent graft , abdominal main bifurcation stent graft, extension stent graft and branch stent graft. The abdominal main body of inner embedded stent graft is composed of abdominal main embedded covered stent and conveyor, the abdominal main bifurcated stent graft is composed of abdominal main bifurcated stent and conveyor, the extended stent is composed of extended stent graft and conveyor, and the branch vascular stent graft is composed of branch vascular stent and conveyor. The abdominal main body of inner embedded stent graft, abdominal main bifurcation stent graft, extension stent graft and branch vascular stent graft are pre-installed in the corresponding conveyor respectively.
214362949|NCT03488368|OTHER|observation|Observation of renal outcome parameters and adverse events in the follow-up beyond the 3-year trial phase of the original STOP-IgAN trial.
214362950|NCT00770107|DRUG|Thiamine|Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
214362951|NCT00770107|DRUG|Placebo|Placebo, once daily, for a duration of 4 weeks
214362952|NCT00900874|DRUG|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
214489738|NCT00686595|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV infusion.
214489739|NCT00488566|DRUG|GSK drug|GSK drug
214489740|NCT00488566|OTHER|Placebo|Placebo
214489741|NCT00488566|OTHER|Lamictal|Positive control
214489742|NCT00405990|BEHAVIORAL|Voluntary counselling and HIV testing in ANC for PMTCT|VCT for 30 minutes in ANC
214974144|NCT03205150|DRUG|LIK066|Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
214974145|NCT03205150|DRUG|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
214974146|NCT03040271|OTHER|Health-E-PALS-|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
214974147|NCT05721664|OTHER|Trianing program for nurse in how to provide evidence based practices for mechanically Ventilated Patients|"Short Name: (EBNPTP) for Caring of Mechanically Ventilated Patients in terms of standardized care.~Duration: Two weeks A number of Contact Hours: 30 hrs. associated arm (interventional arm): for study group of ICU Nurses working at National Hepatology and Tropical Medicine Research Institute (NHTMRI)"
214974148|NCT05876325|OTHER|FINassist Patient|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
214362953|NCT00900874|DRUG|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
214974149|NCT05876325|OTHER|FINassist Caregiver|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
214974150|NCT01026025|DEVICE|Duet TRS|This is a single arm study.
214974151|NCT05116917|DRUG|Nivolumab|3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle
215084454|NCT04682990|OTHER|Follow Up & 30 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
214362954|NCT05194904|DRUG|Dexmedetomidine|This is a prospective randomised clinical study designed to assess the effect of intravenous ketorolac versus intravenous dexmedetomidin on postoperative pain after hypospadias repair in children
214362955|NCT01490502|DRUG|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
214362956|NCT00337272|DRUG|Placebo|Placebo taken 30 minutes before bedtime days 1-28 of treatment period
214362957|NCT00337272|DRUG|Ramelteon|8 mgs daily for days 1-28 of treatment period
214362958|NCT03983187|DEVICE|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min/ Bid for 1 month
214489743|NCT00405990|BEHAVIORAL|VCT|HIV VCT for PMTCT
214489744|NCT05761626|OTHER|MP/Crs assessment < = 0.48 J/min/ml/cmH2O|Assessment of the ventilatory variables according to the MP/Crs value (\<= or \> 0.48 J/min/ml/cmH2O)
214489745|NCT06951308|DIETARY_SUPPLEMENT|Carbohydrate loading before surgery|Carbohydrate loading 2 hours before the surgery (400 ml of 12.5 maltodextrin and 400 ml of over-the-counter fruit-based lemonade)
214489746|NCT05288348|DRUG|Sufentanil 30 MCG Sublingual Tablet|30 microgram sublingual tablet administered using sublingual applicator
214489747|NCT05288348|DRUG|standard care pain treatment|standard care pain treatment given in Emergency Department
214489748|NCT06643169|BEHAVIORAL|home-based fall prevention program with multifactorial|"* Health Education~* Otago Exercises~* Assessing and Organizing the Safe Home Environment"
214974152|NCT05116917|DRUG|Ipilimumab|1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks
215084455|NCT01386541|DRUG|BYK324677|capsules, administered orally
215084456|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
214362959|NCT04439643|DEVICE|vascuCAP|time to event and phenotype classification model
214489749|NCT05789329|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|behavioral intervention aimed to reduce trauma-related guilt and shame
214489750|NCT05789329|BEHAVIORAL|Cognitive Processing Therapy|behavioral intervention aimed at reducing PTSD symptoms
214974153|NCT05116917|BIOLOGICAL|Influenza vaccine|Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days)
215084457|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
215084458|NCT01958853|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
215084459|NCT03891628|BEHAVIORAL|Modified Attachment and Biobehavioral Catch-up|Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
215084460|NCT03891628|BEHAVIORAL|Modified Developmental Education for Families|Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
215084461|NCT03576105|COMBINATION_PRODUCT|irrigation /sterile saline|mechanical removal of bacteria with sterile saline
215084462|NCT03576105|COMBINATION_PRODUCT|Conventional methylene blue as photosensitizer|Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
215084463|NCT03576105|COMBINATION_PRODUCT|Methylene blue for oral use as photosensitizer|Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
215084464|NCT03576105|COMBINATION_PRODUCT|Photodynamic therapy|Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
214362960|NCT02858141|OTHER|Data collection|
214489751|NCT06996288|DEVICE|Transpulmonary pressure-guided individualized PEEP|Transpulmonary pressure-guided individualized PEEP group was an intraoperative ventilation strategy based on esophageal pressure (Pes) monitoring of transpulmonary pressure-guided ventilation, using a small tidal volume (6-8 ml/kg of ideal body weight), maintaining the transpulmonary pressure in the safe range of 5-15 cmH2O PEEP for Pes+1 cm H2O level.
214489752|NCT06866249|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children. The test is designed to identify de"
214489753|NCT06866249|BEHAVIORAL|Test Of Sensory Functions In Infants (Tsfı)|Test Of Sensory Functions In Infants (TSFI) provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old.
214489754|NCT06866249|BEHAVIORAL|Brief Infant Sleep Questionnaire|"Infant sleep problems are among the most common problems presented to pediatricians. The extended version of the Brief Infant Sleep Questionnaire is a questionnaire developed by Sadeh to assess sleep problems and their causes in early childhood."
215084465|NCT01352741|DRUG|Tapentadol Prolonged Release|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
215084466|NCT01352741|DRUG|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
214489755|NCT06867406|DRUG|KPC000154 10mg Tablet Intervention|KPC000154 10mg Tablet administered orally in the morning once daily for 1 day
214489756|NCT06867406|DRUG|KPC000154 30mg Tablet Intervention|KPC000154 30mg Tablet administered orally in the morning once daily for 1 day
214489757|NCT06867406|DRUG|KPC000154 60mg Tablet Intervention|KPC000154 60mg Tablet administered orally in the morning once daily for 1 day
214489758|NCT06867406|DRUG|KPC000154 120mg Tablet Intervention|KPC000154 120mg Tablet administered orally in the morning once daily for 1 day
214489759|NCT06867406|DRUG|KPC000154 200mg Tablet Intervention|KPC000154 200mg Tablet administered orally in the morning once daily for 1 day
214489760|NCT06867406|DRUG|KPC000154 300mg Tablet Intervention|KPC000154 300mg Tablet administered orally in the morning once daily for 1 day
214489761|NCT06867406|DRUG|KPC000154 400mg Tablet Intervention|KPC000154 400mg Tablet administered orally in the morning once daily for 1 day
214974154|NCT05116917|RADIATION|SBRT|"* A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% \> 95%)."
214974155|NCT05538013|OTHER|Survey evaluation|Obesity awareness, physical activity, and sedentary time questionnaires will be applied to these cases.
215084467|NCT01352741|DRUG|Tapentadol Prolonged Release open label maintenance|100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
214362963|NCT04186780|OTHER|Shiitake cereal bar|patients with borderline cholesterol exposed to bars with Shiitake
214362964|NCT01699022|DRUG|Injection Cyclofem|"Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
215084468|NCT04902521|DEVICE|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (TMS) is a safe non-invasive technique that stimulates the brain using repetitive magnetic pulses to enhance neuroplasticity. TMS has been shown to produce lasting modulation of cortical activity and improve clinical symptoms of children with neurodevelopmental disorders including CP
215084469|NCT04902521|DEVICE|Sham Transcranial Magnetic stimulation|Sham Transcranial Magnetic stimulation will be given to the control group. During the Sham procedure patients will sit near the TMS but will not receive any magnetic pulses.
214489762|NCT06867406|DRUG|KPC000154 80mg multiple-dose Tablet Intervention（To Be Determined）|KPC000154 80mg tablet administered orally in the morning for 14 days
214362965|NCT02313857|BIOLOGICAL|Viralym-C|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-C infusion. If a patient has multiple Viralym-C infusions the schedule resets again at the beginning so follow up relates to the last Viralym-C infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
214362966|NCT05795530|PROCEDURE|cochlear implantation|surgery for bilateral hearing loss
214362967|NCT04629677|OTHER|Electronic Health Record Review|Review of medical records
214362968|NCT04629677|OTHER|Quality-of-Life Assessment|Ancillary studies
214362969|NCT04629677|OTHER|Questionnaire Administration|Complete questionnaires
214362970|NCT01572064|PROCEDURE|Blood sample|1 fasted blood sample taken for metabolomics
214362971|NCT01572064|OTHER|MRI Scan|1 single visit for MRI and MRS
214489763|NCT06867406|DRUG|KPC000154 120mg multiple-dose Tablet Intervention（To Be Determined）|KPC000154 80mg tablet administered orally in the morning for 14 days
214489764|NCT06867406|DRUG|KPC000154 40mg multiple-dose Tablet Intervention（To Be Determined）|KPC000154 120mg tablet administered orally in the morning for 14 days
214489765|NCT06867406|DRUG|Placebo-controlled（SAD）|A placebo used in a single-dose study where participants receive either the experimental drug or the placebo.
214489766|NCT06867406|DRUG|Placebo-controlled（MAD）|A placebo used in a multiple-dose study where participants receive either the experimental drug or the placebo.
214489767|NCT06865547|BEHAVIORAL|The 4A ProActive Management Model|This model focuses on four key areas - Active Education, Active Prevention Strategies, Active Management, and Active Follow-up. Active Education involves providing patients with detailed information on treatment regimens, potential AEs, and self-care through verbal education, reminder cards, and direct counseling. Active Prevention Strategies aims to directly reduce risks through nursing care bundles that incorporate supportive medications, fall risk assessments, and dietary guidance. Active Management establishes robust protocols for early AE reporting, rapid treatment, and standardized order sets. Active Follow-up comprises additional outpatient visits, patient surveys, medication refill coordination, and pharmacist/nurse follow-up calls to closely monitor patient adherence and symptoms.
214489768|NCT02016924|DRUG|ATV|Capsules administered once daily according to dosing recommendations per product monograph
214489769|NCT02016924|DRUG|DRV|Tablets administered once daily according to dosing recommendations per product monograph
214489770|NCT02016924|DRUG|Cobicistat|Tablets administered orally once daily with food
214489771|NCT02016924|DRUG|BR|Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
214489772|NCT02016924|DRUG|F/TAF|Tablets administered orally once daily
214974156|NCT03687983|DEVICE|GoldenFlow Peripheral Stent System|Performing anaesthetic and pathological angiography according to the standard method, and select appropriate stent specifications according to the contrast results. After 1:1 pre-expansion, the stent system will be imparted into the lesion location, the stent will be distally positioned and released. The Tip head will be reset and the conveyor will be removed. If necessary, local re-expansion can be carried out. Remove the catheter and suture the wound. Postoperative treatment and anticoagulation.
214362972|NCT04827485|OTHER|Gluteal squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
214362973|NCT04827485|OTHER|No squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will not perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
214362974|NCT05148325|DRUG|BAT4706|The administration cycle was proposed to be 3 weeks (Q3W), i.e., 21 days in a cycle, and the first 4 cycles were administered on the first day of each cycle.
214362975|NCT06174311|BEHAVIORAL|Active Cognitive Bias Modification|The intervention comprises three sessions and is provided online. Each session consists of two different tasks. To prevent order effects, these tasks will be presented to each participant in a random sequence. One of the tasks involves uncertain scenarios based on a scenario paradigm. At the end of these scenarios, participants will be asked to complete a missing letter in a word that in the scenario, followed by a comprehension question related to the scenario interpretation. Following each question, feedback will be provided regarding the correctness of the response. The other task is a word-sentence pair paradigm, where participants will be asked to assess whether these pairs are related, and feedback will also be provided.
214362976|NCT02899325|DRUG|Diagnostic PET/CT scans|These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.
214362977|NCT00002611|BIOLOGICAL|dactinomycin|
214362978|NCT00002611|BIOLOGICAL|filgrastim|
214362979|NCT00002611|DRUG|cyclophosphamide|
214489773|NCT02016924|DRUG|LPV/r|Solution administered orally
214489774|NCT02016924|DRUG|Third Unboosted Drug|ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
214489775|NCT02016924|DRUG|Cobicistat TOS|Tablets for oral suspension
214974157|NCT02723188|DEVICE|Sham stimulation (1.5 milliampere,30 seconds)|
214974158|NCT02723188|DEVICE|DC stimulation (1.5 milliampere, 20 minutes)|
214974159|NCT02723188|DEVICE|AC stimulation (1.5 milliampere,1.5 Hertz frequency)|
214974160|NCT00955500|DIETARY_SUPPLEMENT|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
214974161|NCT00955500|DIETARY_SUPPLEMENT|Maltodextrin|30 grams of oral maltodextrin daily
215084470|NCT02046850|DRUG|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
215084471|NCT02046850|DRUG|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
215084472|NCT02046850|DRUG|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
215084473|NCT02046850|DRUG|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
214362980|NCT00002611|DRUG|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
214974162|NCT04578704|OTHER|Vacuum formed retainer, fixed bonded retainer, vacuum formed and fixed bonded retainer|"Patients will be instructed to wear the removable vacuum form retainer for 8 to 10 hours per day and only removed the retainers during tooth brushing. (Thickett 2010), (Gill 2007).~The vacuum formed retainer will be constructed using thermoplastic material that will be purchased from manufacturer at 1.0mm thickness.~Meanwhile, bonded retainer will be done using Ormco ® response deadsoft retainer wire size 0.190 round, made in USA by ORMCO Corporation, the fixed bonded wire will be extended distal to the extraction spaces that were previously closed by fixed appliances on both the upper and lower arches. The bonded retainer will be wearing by patients for 24 hours.~Double regime retainer that will be comprised of vacuum formed and bonded retainer will be constructed using the same properties as vacuum formed retainer and bonded retainer. A standard oral and written instruction will be given to patients regarding retainer's uses. (Shawesh M et.al, 2009)."
214974163|NCT02182310|DRUG|BI 201335 low dose|
214974164|NCT02182310|DRUG|BI 201335 placebo|
214974165|NCT02182310|DRUG|Moxifloxacin|
214974166|NCT02182310|DRUG|BI 201335 high dose|
214974167|NCT01145365|PROCEDURE|Exam under anesthesia (EUA)|EUA established drainage of perianal fistulas \&/or abscesses will be done before patient begins medical therapy with certolizumab (Cimzia)
214974168|NCT00817622|DIETARY_SUPPLEMENT|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
214974169|NCT04243629|DRUG|Rapid-Acting Insulin|Novorapid or Humalog insulin delivered in a basal-bolus manner.
214974170|NCT04243629|DRUG|Placebo|Placebo (saline) delivered in a basal-bolus manner at a fixed ratio with insulin.
214974171|NCT04243629|DRUG|Pramlintide Acetate|Pramlintide acetate delivered in a basal-bolus manner at a fixed ratio with insulin.
214974172|NCT04243629|DEVICE|Artificial Pancreas|Tandem insulin pump, Dexcom G6 sensor, study smartphone running the iMAP algorithm.
214974173|NCT05563545|BIOLOGICAL|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m2 (D-5\~D-3), determined by tumor burden at baseline.
214974174|NCT06571162|OTHER|Clinical Pharmacy Team|Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.
214974175|NCT06571162|OTHER|Usual Care|Patient will receive usual care for their LDL-C management.
214974176|NCT00871624|DRUG|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
214974177|NCT00871624|DRUG|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
214974178|NCT04779424|OTHER|POCT|Capillary blood sample antibody point of care test
214974179|NCT00738712|PROCEDURE|MRI Magnetic Resonance Imaging|MRI
215084474|NCT04070326|DRUG|Lanadelumab|Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
215084475|NCT00468936|DRUG|Myfortic|enteric coated Cellcept pills in applicable dose for patient
215084476|NCT00537732|DRUG|omeprazole|20 mg daily
214362981|NCT00002611|DRUG|etoposide|
214362982|NCT00002611|DRUG|vincristine sulfate|
214362983|NCT00002611|PROCEDURE|conventional surgery|
214362984|NCT00002611|RADIATION|radiation therapy|
214362985|NCT02002026|PROCEDURE|Uterine artery ligation|Uterine artery ligation during cesarean section before delivery of the baby
214362986|NCT05052086|DIAGNOSTIC_TEST|Magnetomotoric ultrasound|Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.
214362987|NCT06182306|PROCEDURE|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
214362988|NCT00198484|DRUG|Vitrase|
214362989|NCT00772590|DRUG|Raltegravir|Tablets, 400mg, twice daily
214362990|NCT00772590|DRUG|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
214362991|NCT00772590|OTHER|raltegravir placebo|One tablet, twice daily
214362992|NCT00772590|OTHER|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
214362993|NCT00772590|DRUG|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
214362994|NCT05100186|DRUG|Dexamethasone 0.4 MG [Dextenza]|Dextenza
214362995|NCT01367028|DRUG|Trastuzumab, Docetaxel|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion"
214362996|NCT01367028|DRUG|Trastuzumab, Docetaxel, Bevacizumab|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg"
214362997|NCT01367028|DRUG|Trastuzumab+Docetaxel+NPLD|"6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion"
214362998|NCT01367028|DRUG|Trastuzumab+Docetaxel+NPLD+Bevacizumab|"6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg"
214362999|NCT01843998|DRUG|Sirolimus 0.1% Ointment|Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
214489776|NCT02016924|DRUG|F/TAF TOS|Tablets for oral suspension
214363000|NCT02079662|OTHER|Behavioral, Psychological or Informational Intervention|Undergo IO intervention
214363001|NCT02079662|OTHER|Best Practice|Undergo standard of care
214489777|NCT07007117|BIOLOGICAL|PHOX2B PC-CAR T Cells|The PHOX2B PC-CAR T cell investigational product is comprised of autologous human T cells that have been genetically modified to express a a PHOX2B-targeting chimeric antigen receptor (CAR) transgene.
214489778|NCT07005752|DRUG|CnU cap. 250mg & Ursa placebo tab. 200mg|CnU capsule(Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid) and Ursa placebo tablet will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.
214489779|NCT07005752|DRUG|Ursa tab. 200mg & CnU placebo cap. 250mg|Ursa tablet(Ursodeoxycholic Acid) and CnU placebo capsule will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.
214489780|NCT00673842|DEVICE|Implantable Cardioverter Defibrillator + Usual Care|Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD)
214489781|NCT00673842|OTHER|Usual care|Usual post-MI care
214489782|NCT05613894|DRUG|Cabozantinib|(177Lu)-PSMA-617 will be administered every 6 weeks for up to 6 cycles per SOC. Oral Cabozantinib taken daily at home.
214489783|NCT06826781|DEVICE|Q30 Q-Collar|Participants will complete a series of tests (sit-to-stand, resistive breathing, and graded bike test) while wearing a Q-Collar.
214489784|NCT06826781|OTHER|Not wearing Q-Collar|Participants will undergo the same study procedures without wearing the Q-Collar.
214489785|NCT05233267|OTHER|Blood sample|Dosage of neopterin
214489786|NCT06880757|OTHER|Radionuclide treatment with Lu-177 FAPI|Systemic radionuclide treatment with Lu-177 FAPI
214489787|NCT06880692|OTHER|Educational Materials delivered via the Tick App|Education about tick bite prevention
214489788|NCT06878300|DEVICE|Over the counter hearing aid (Lexie)|The study will compare user perceptions of two over-the-counter (OTC) hearing aids, with the Lexie B3 Pro serving as the reference device. Participants will be fitted with each device for a predetermined period in a randomized order to ensure balanced exposure.
214489789|NCT06878300|DEVICE|Comparator over the counter hearing aid|The comparator OTC hearing aid will undergo the same evaluation process as the Lexie B3 Pro, ensuring an equivalent and unbiased comparison. Participants will be provided with the comparator device along with its standard user instructions, including any mobile applications or self-fitting guidance designed for independent setup.
214489790|NCT07039474|DRUG|18F-G1|18F-G1 is injected intravenously with a dose of 0.06-0.08mCi/kg
214489791|NCT07038772|OTHER|Orthodontic treatment|Undergoing orthodontic treatment
214489792|NCT07039604|DEVICE|Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China|PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.
214489793|NCT07039097|PROCEDURE|Transcervical resection of septum|Transcervical resection of septum (TCRS) is divided into two categories: one is plasma hysteroscopic electrosurgical resection (actually TCIS), which uniformly uses a 7mm external diameter hysteroscopic electrosurgical resectoscope to reduce the difficulty of cervical dilation; the other is micro (5 or 7Fr) hysteroscopic cold knife incision, equipped with a 5Fr bipolar electrocoagulation stick for electrocoagulation and hemostasis.
215084477|NCT00537732|DRUG|omeprazole|20 vs. 60 mg daily, genotype dependent
214363002|NCT02079662|OTHER|Cognitive Intervention|Undergo IO intervention
214363003|NCT02079662|OTHER|Computer-Assisted Intervention|Undergo IO intervention
214363004|NCT02079662|OTHER|Counseling|Undergo counseling
214363005|NCT02079662|BEHAVIORAL|Exercise Intervention|Undergo IO intervention
214363006|NCT02079662|OTHER|Laboratory Biomarker Analysis|Correlative studies
214363007|NCT02079662|OTHER|Quality-of-Life Assessment|Ancillary studies
214363008|NCT02079662|OTHER|Questionnaire Administration|Ancillary studies
214363009|NCT01484639|OTHER|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
214363010|NCT01484639|OTHER|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
214363011|NCT00003163|BIOLOGICAL|filgrastim|
214363012|NCT00003163|BIOLOGICAL|sargramostim|
214363013|NCT00003163|DRUG|cyclophosphamide|
214363014|NCT00003163|DRUG|melphalan|
214489794|NCT07038265|BEHAVIORAL|Personalised treatment|Patients going through a personalized intervention program
214489795|NCT07038265|OTHER|Usual Care|Usual cardiac rehabilitation program
214489796|NCT06754020|DEVICE|Heart Rate Variability,HRV - ANSWatch|Please have the participant lie down and rest for 10 minutes, and remove any metallic items from their body. Next, put on the wrist-worn monitor, and avoid moving during the monitoring process. The device will emit a sound when the monitoring session is complete.
214489797|NCT06754020|DEVICE|Traditional Chinese Medicine Tongue Imaging|Use a camera to capture images of the tongue, and then have a Traditional Chinese Medicine (TCM) practitioner perform the diagnosis based on these images.
214489798|NCT06690788|BEHAVIORAL|Individual intervention condition (PreventT2)|PreventT2 will be delivered by a team of trained CDC National Diabetes Prevention Program (NDPP) Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the lifestyle intervention curriculum to be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National DPP, which has Full recognition from the CDC based on outcome data over the course of a number of years.
214489799|NCT06690788|BEHAVIORAL|Couple-based intervention condition (PreventT2 Together; couple-based adaptation of 2021 PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the NDPP)|PreventT2 Together will be delivered by a team of trained CDC National DPP Lifestyle Coaches to adults at high risk for diabetes and their partners. The lifestyle intervention curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (Diabetes Prevention Program) (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevent type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
214489800|NCT05812027|DIAGNOSTIC_TEST|Tumor and HLA Profiling|HLA genotyping and tumor tissue profiling for certain tumor-associated antigens and HLA LOH.
215084478|NCT02720601|DRUG|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
215084479|NCT00645528|OTHER|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
215084480|NCT01376063|DRUG|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
215084481|NCT03354832|OTHER|Foetal death|A midwife is in charge to interview the mother during the month following the lost of her infant.
215084482|NCT03354832|OTHER|New-born death|A midwife is in charge to interview the mother during the month following the lost of her infant.
215084483|NCT03354832|OTHER|Birth control for foetal death|A midwife is in charge to interview the mother during her hospital stay
215084484|NCT03354832|OTHER|Birth control for new-born death|A midwife is in charge to interview the mother during her hospital stay
215084485|NCT00020462|BIOLOGICAL|aldesleukin|
215084486|NCT00020462|BIOLOGICAL|autologous tumor cell vaccine|
214363015|NCT00003163|PROCEDURE|autologous bone marrow transplantation|
214363016|NCT00003163|PROCEDURE|peripheral blood stem cell transplantation|
214363017|NCT00003163|RADIATION|radiation therapy|
214363018|NCT03001297|BIOLOGICAL|Placebo|Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1
214363019|NCT03001297|BIOLOGICAL|MEDI5884 Dose 1|Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.
214363020|NCT03001297|BIOLOGICAL|MEDI5884 Dose 2|Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1
214363021|NCT03001297|BIOLOGICAL|MEDI5884 Dose 3|Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1
214363022|NCT03001297|BIOLOGICAL|MEDI5884 Dose 4|Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1
214363023|NCT02565914|DRUG|TEZ/IVA|Fixed dose tablet for oral administration.
214363024|NCT02565914|DRUG|IVA|Tablet for oral administration.
214363025|NCT06578910|DIAGNOSTIC_TEST|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
214363026|NCT06578910|OTHER|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
214363027|NCT01487317|DRUG|Rivastigmine transdermal patch|One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity \< 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity \< 10, the active treatment will be stopped
214363028|NCT01487317|DRUG|placebo patch|One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity \< 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity \< 10, the placebo treatment will be stopped
214363029|NCT05838807|DEVICE|Thermal Ultrasound|Participants in this group will receive thermal ultrasound treatment using a gel-coupled ultrasound probe that delivers continuous ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 5 minutes per session, three times per week, for four weeks. The intensity of the ultrasound wave will be set at 1.0 W/cm2 applied for 5 minutes. The treatment will be administered three times per week, for four weeks.
214489801|NCT07038161|PROCEDURE|Modified Cattell-Warren duct-to-mucosa pancreaticojejunostomy|Technical modification of the original Cattell-Warren technique in all the stitches of both posterior and anterior duct-to-mucosa layer, taking the pancreatic duct with more than 5mm of pancreatic parenchyma adjacent to the duct and towards the jejunal side, taking more than 5 mm of full-thickness jejunum including mucosa.
214489802|NCT07038161|BEHAVIORAL|Institutional Prehabilitation Protocol|Routine perioperative incentive spirometry, four extremities exercise, and nutritional optimization with albumin and Total Parenteral Nutrition
215084487|NCT00349687|BEHAVIORAL|self-control practice|
215084488|NCT06218381|OTHER|Very Brief Exposure to Combat Images|In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.
215084489|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure devices used: Proglide® (Abbott)
215084490|NCT03192033|DEVICE|Proglide® (Abbott)|Arterial closure device used: Proglide® (Abbott)
215084491|NCT03192033|DEVICE|Femoseal® (Terumo)|Arterial closure device used: Femoseal® (Terumo)
215084492|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure device used: Femoseal® (Terumo)
215084493|NCT01913704|DEVICE|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
214974180|NCT01797393|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
214363030|NCT05838807|DEVICE|Pulsed Ultrasound|Participants in this group will receive pulsed ultrasound treatment using a gel-coupled ultrasound probe that delivers pulsed ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 15 minutes with 25% duty cycle and intensity of 1.0 W/cm2.The treatment will be administered three times per week, for four weeks.
214363031|NCT05838807|DEVICE|Combined Ultrasound|Participants in this group will receive a combination of thermal and pulsed ultrasound treatments. The thermal ultrasound treatment will be administered first for 5 minutes, followed by the pulsed ultrasound treatment for another 15 minutes. The same parameters as described above will be used for each treatment modality. The combination treatment will be administered three times per week, for four weeks.
214363032|NCT05838807|DEVICE|Placebo Ultrasound|Participants in this group will receive a placebo ultrasound treatment that looks and feels identical to the active ultrasound treatments, but does not deliver any therapeutic effects. The placebo treatment will be administered using the same gel-coupled ultrasound probe for 15 minutes per session, three times per week, for four weeks, with the intensity set at 0 W/cm² and the temperature maintained at room temperature.
214363033|NCT00919074|PROCEDURE|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
214363034|NCT00919074|PROCEDURE|Pancreatic wire placement|Placement of a pancreatic wire to facilitate bile duct cannulation
214489803|NCT06729190|DEVICE|biofeedback|biofeedback therapy and FES at anti spastic muscles(shoulders flexors, elbow and wrist extensors) while doing specific exercises (including basic reaching, grasping, carrying, release
214489804|NCT06729190|PROCEDURE|Physical therapy program|Flexibility exercises for shorted muscles and spastic muscles, Strengthening training focusing on the trunk lower limb and upper limb muscles for weak muscles, Postural control exercise in different positions and different surfaces, General endurance training, Exercises to facilitate hand function, Exercises included, grasping a cube, transferring cube, removing and placing pegs, releasing cube and placing cubes. Strengthening exercises of the intrinsic muscles of the hand
214489805|NCT06882603|OTHER|hydrodissection|5 ml of 0.9% isotonic sodium chloride solution will be applied to the intracarpal area median nerve area once with the USG probe.
214489806|NCT06882603|OTHER|Steroid injection|1 ml of 3mg/ml betamethasone sodium phosphate or 3mg/ml betamethasone acetate solution will be applied with the USG probe.
214489807|NCT06882603|OTHER|Exercise|Performed with 6 different consecutive positions of the hand and wrist. 1- Wrist in neutral position, fingers and thumb in flexion 2- Wrist in neutral position, fingers and thumb in extension 3- Wrist and fingers in extension, thumb in neutral position 4- Wrist, fingers and thumb in extension 5- Forearm in supination, wrist and fingers in extension 6- Forearm in supination, wrist and fingers in extension, gentle stretching is applied to the thumb with the hand. Tendon gliding exercises: Performed to ensure isolated mobility of the flexor digitorum superficialis and profundus muscles in the canal. Tendon gliding exercises are performed in 5 different consecutive positions, respectively. 1- Fingers straight 2- Fingers in hook position 3- Fingers in fist position 4- Fingers in table shape position 5- Fingers in straight fist. The exercises will be asked to be done 10 times, once a day, every day for 3 weeks.
214502756|NCT06841289|COMBINATION_PRODUCT|Pediatric Invasive Pictorial Shield (PIPS)|It is a device used to distract children during clinical procedures (blood sampling, invasive procedures, etc.) by making them feel less pain, stress and fear. It is an 18x15 cm 3D printed device designed to be worn around the upper arm, above the elbow, and used to hide the procedure from view and attract the child's attention with stickers printed on one side. The device is fixed on the child's arm by means of a tourniquet that can be interchangeably attached. The child asked questions about the pictures related to the stickers to distract his/her attention from the procedure. While answering these questions, the child will not see the procedures and will pay attention to the pictures, while the procedural procedure (such as blood sampling, intravenous intervention) will be performed. For the children in this group, the pain, fear will be scored 1 minute before, during and 1 minute after the blood collection procedure.
214974181|NCT01797393|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
214974182|NCT01797393|OTHER|" Air assisted water injection."|Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
214974183|NCT01912976|DRUG|Er:YAG AFL-PDT|Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
214974184|NCT01912976|DRUG|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
214974185|NCT04539418|DRUG|Vitamin K 2|Patients will be monitored during the whole protocol.
214974186|NCT03246464|DEVICE|Orthokeratology lenses|Rigid gas permeable contact lenses
214974187|NCT03246464|DEVICE|Single-vision spectacles|Regular single vision spectacles
214974188|NCT00238407|DRUG|Docetaxel and Cisplatin|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
214974189|NCT00238407|RADIATION|Radiotherapy|Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
214974190|NCT06135181|DRUG|Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg|0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)
214363035|NCT04653402|DEVICE|Hydrocelectomy surgery|The standardized hydrocelectomy operation i.e. Eversion of the TVT sac
214363036|NCT01973660|DRUG|Lapatinib|
214363037|NCT01973660|DRUG|Trastuzumab|
214363038|NCT01973660|DRUG|Endocrine Therapy|Letrozole or tamoxifen will be prescribed according to patient's menopausal status
214363039|NCT01973660|DRUG|Paclitaxel|Only administrated if tumor progression is observed by US on week 6
214363040|NCT00378352|DRUG|Epoetin alfa|Randomized
214363041|NCT00005791|DRUG|cisplatin|
214363042|NCT00005791|DRUG|fluorouracil|
214363043|NCT00005791|DRUG|irinotecan hydrochloride|
214363044|NCT04419090|OTHER|web-based centralized service and message|Perform three cycles of cascade screening through several generation of family members of an index case. The contact of relatives will be initiated by the index case and supported by a web-based centralized service. The index case will be provided with a prepared email or Whatsapp message that the index case can further forward to his first-degree relatives. The email/message will contain a link to a secured web application with a code for the connection. By clicking on the link, the relative will connect to a specifically designed app. The app will provide information about the transmission mode of FH, the cardiovascular risk associated with FH and the way how to reduce this risk. The relative can then fill out information and provide agreement to be contacted for the study. The nearest specialized clinic will then contact the relative to organize further screening with similar processes.
214363045|NCT03610464|DRUG|Amphetamine Extended Release Suspension [Dyanavel]|1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
214363046|NCT05095272|BIOLOGICAL|HMPBS02-Pv|The blood-stage P. vivax master cell bank HMPBS02-Pv was also produced using blood collected from a consenting patient with naturally acquired malaria infection. The malaria infection was confirmed to be P. vivax by species-specific PCR at Pathology Queensland (accredited by the Australian National Association of Testing Authorities) and further confirmed by deep sequencing at the Sanger Institute. The clinical response to antimalarial chemotherapy was also demonstrated with this donor, who was successfully cured with artemether/lumefantrine.
214363047|NCT01197508|DRUG|TC-5214|Twice daily for 8 weeks.
214363048|NCT01197508|DRUG|Placebo|Twice daily for 8 weeks.
214974191|NCT06135181|DRUG|Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg|0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)
214974192|NCT06135181|DRUG|Matching placebo|0.9% sodium chloride by intravenous injection (at 2 mL/s)
214974193|NCT02887703|BEHAVIORAL|Sensory Augmentation|Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
214363049|NCT02264184|DRUG|Tamsulosin|
214363050|NCT02264184|DRUG|Paroxetine|
214363051|NCT01328301|OTHER|Experimental|For SDT training, subjects received short intervals of locomotion training with a treadmill. After walking for 30s, the subjects were given two minutes of rest. If they completed the first walking trial safely and without stumbling, the belt speed was increased by 10% on the next trial. However, if a subject failed to complete the first trial, the belt speed was decreased by 10% on the next trial. The speed of the treadmill was adjusted in each subsequent trial according to the same principle. Subjects usually completed 7-8 walking trials in one session. The belt speed was increased by a maximum of five increments within one training session.
214974194|NCT05871307|RADIATION|Preoperative Radiotherapy|Resection of brain mestases following
214363052|NCT01328301|OTHER|Speed-stable treadmill training|Subjects in the control group walked on the treadmill with the belt speed adjusted according to their fastest over-ground gait speed. There was no adjustment of the belt speed throughout the 30-minute steady-speed treadmill training session.
214363053|NCT06449131|DRUG|Platelet-Rich Plasma and Fibrin Glue|"Allogenic platelet-rich plasma with fibrin glue (PRP-FG) was derived from blood obtained from a blood bank. Peripheral blood (400 ml) was collected from a donor with a matching ABO blood type, and rigorous viral safety tests were conducted. Concentrated PRP (10 ml) was obtained by subjecting the sample to centrifugation at 4000 g for 15 min to separate the plasma from the sedimented platelets.~Fibrinogen was extracted from the separated plasma using cryoprecipitation. After freezing at -70°C followed by thawing at 4°C, fibrinogen concentrate (20 ml) was prepared by centrifugation at 6500 × g for 5 min. The concentrated PRP was combined with fibrinogen (30 ml).~Thrombin was generated from the plasma isolated during the second centrifugation step. The ionic strength and pH were adjusted to precipitate prothrombin. The resulting precipitate was separated by centrifugation and dissolved in a calcium ion solution, resulting in a final volume of 5 ml of thrombin solution."
214363054|NCT05477758|BEHAVIORAL|Collaborative care|Participants in the intervention group were allocated a receive a low-intensity programme of behavioural activation specifically designed for adults ≥65 with subthreshold depression. An allocated case manager (primary care mental health worker/ Improving Access to Psychological Therapy) delivered collaborative care for an intended 8-10 weeks. This ran alongside general practitioner (GP) usual care. Collaborative care in both CASPER and CASPER+ trial included weakly telephone/ face-to-face support, active surveillance and symptom monitoring
214363055|NCT05477758|OTHER|Usual General Practitioner (GP) care|Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.
214974195|NCT05871307|RADIATION|Intraoperative Radiation|While Resection
214974196|NCT05871307|RADIATION|Postoperative Radiotherapy|After resection
214363056|NCT05477758|BEHAVIORAL|Behavioral Activation Self-Help guide|Participants in the intervention arm were provided with a self-help booklet based on clear principles of BA for depression. The purpose of the booklet was to introduce simple behavioural strategies for improving mood. Participants were encouraged to (1) re-establish their daily routine, (2) increase meaningful activities and (3) reduce avoidance behaviours. Participants also received 3 phone calls at week 1, 3 and 6 designed to check the booklet had arrived and to encourage the use of the materials. All participants received their usual GP care
214489808|NCT06889896|DIAGNOSTIC_TEST|After Blood samples collection, these samples are analyzed at a central laboratory under blinded conditions using multiple detection methods to measure plasma levels of Aβ40, Aβ42, t-tau, and p-tau|The CLEAR-AD study is an ongoing population-based cross-sectional study, currently recruiting 400 participants in ten centers in China. The study includes cognitively normal controls, individuals with mild cognitive impairment (MCI) - categorized as amyloid-positive and amyloid-negative - as well as patients with dementia, also divided into amyloid-positive and amyloid-negative groups. All participants undergo amyloid PET scans using tracers such as AV1, AV45, and PIB. Blood samples are collected within three months prior to the PET scan or from existing samples collected after January 1, 2024, that meet quality standards. After collection, these samples are analyzed at a central laboratory under blinded conditions using multiple detection methods to measure plasma levels of Aβ40, Aβ42, t-tau, and p-tau181/217. The detection technologies included single-molecule immunoassay, digital immunoassay chips, magnetic particle chemiluminescence, and flow cytometry fluorescence. The objective i
214363057|NCT01588626|DRUG|AZD6140|tablet
214363058|NCT04749589|DIAGNOSTIC_TEST|iron deficiency|Its not an intervention. Its an observational study. The groups are defined based on their iron status
214363059|NCT02445040|DEVICE|Babylog VN500 in HFOV Mode|Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
214363060|NCT01873170|DRUG|levonorgestrel exposure|
214363061|NCT01873170|DRUG|DMPA exposure|
214363062|NCT01873170|DRUG|etonogestrel exposure|
214363063|NCT01873170|DEVICE|IUD insertion|
214363064|NCT01873170|DEVICE|subdermal contraceptive implant insertion|
214363065|NCT03170011|BEHAVIORAL|Exercise using the Biodex Sit2Stand Trainer|Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
214363066|NCT03536910|OTHER|Copeptin|Level of copeptin in maternal blood and umbilical cord blood
214363067|NCT04688424|DEVICE|FES|FES will be applied via surface electrodes placed over bilateral quadriceps muscles. FES-stimulation will be ramped from sensory level (the level at which the individual feels a cutaneous sensation from the stimulation) to the maximum-tolerated level using a closed loop system controlled by computer software Subjects will exercise at home, three times per week, with FES on for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
214363068|NCT04688424|OTHER|Cycling|Subjects will exercise at home, three times per week, without FES for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
214363069|NCT05122390|OTHER|Contraction Coper|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind.
214363070|NCT05122390|OTHER|Contraction Coper Plus|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind. Clinical guidance from a midwife during two different occasions is added to the group.
214489809|NCT06722534|DRUG|Celecoxib 400mg|Participants in the interventional group receive 200 mg celecoxib twice daily for 6 months
214974197|NCT02601755|BEHAVIORAL|iCanCope app and website|"In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources."
214974198|NCT02601755|BEHAVIORAL|Attention control group|"The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies."
214974199|NCT01328015|DRUG|Oxybutynin 5 mg pills|"½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks."
214974200|NCT01668420|OTHER|thermal stimulation|hot and cold/warm and cool pads applying.
214974201|NCT01009593|DRUG|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
214974202|NCT01009593|DRUG|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
214974203|NCT01537224|OTHER|Measure of the electrophysiological activity of the subthalamic nucleus|Local field recording of the subthalamic nucleus by mean of externalized electrodes in the immediate postoperative periode.
214974204|NCT05550636|DRUG|BI 1015550|BI 1015550
214974205|NCT05550636|DRUG|midazolam|midazolam
215084494|NCT05027334|OTHER|DiaMon - Mobile Application for Type 2 Diabetes mellitus and pre-diabetes|Each participant will be provided with a mobile application aimed at monitoring their clinical markers such as FBG and HbA1c. The mobile application consists of medical details and demographics as well as a section dedicated to daily glucose levels and record of physical activity.
215084495|NCT04194723|PROCEDURE|Antireflux Mucosectomy|ARMS aimed at resection of mucosa at gastric cardia to induce fibrosis and tighten the gastroesophageal junction and reduce acid reflux
215084496|NCT00057434|DRUG|multivitamin|
214489810|NCT06722534|DRUG|Placebo|Participants in the control group receive identically appearing placebo twice daily for 6 months
214363071|NCT01514526|DRUG|Dovitinib|"Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.~The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal."
214489811|NCT03744468|DRUG|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
214489812|NCT03744468|DRUG|Tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
214489813|NCT03744468|DRUG|LBL-007|Human anti LAG-3 IgG4-kappa antibody
214489814|NCT06395415|BEHAVIORAL|EQUIP|The intervention is delivered directly to participants' mobile phones using the Insight® platform, which allows for the implementation of assessments and interventions. Insight has been used in prior mHealth studies and allows for the delivery of tailored content based on parameters, such as intervention stage. The intervention has two stages: 1) Motivational enhancement (weeks 1-2) and 2) Skills and information (weeks 3-6). The first stage of messages will utilize personalized feedback and motivational interviewing prompts, while the second stage will provide health information on ENDS and skills, such as deep breathing. Content is tailored to motivation level (low/medium or high) and dual use status.
214489815|NCT06395415|BEHAVIORAL|Standard Care|Those in the standard advice group will be given offered a sample of NRT, instruction on its use, and will be encouraged to use in conjunction with standard web-based resources on ENDS and cessation over the course of a ten minute walk-through with study staff.
214489816|NCT06716450|DEVICE|Multiplo TP/HIV Antibody Test|"The Multiplo TP/HIV Antibody Test (MedMira Laboratories Inc., Halifax, NS), \[Multiplo TP/HIV Test\] is a single use, rapid, vertical-flow in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus (HIV) Type 1/Type 2 and Treponema pallidum (Syphilis) in human fingerstick blood. The Multiplo® TP/HIV Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than five minutes. The Multiplo TP/HIV Test has not yet sought approval for self-testing. All required pre and post-test counselling guidelines must be followed in each setting in which the Multiplo TP/HIV Test is used. Results are read visually."
214489817|NCT06737328|PROCEDURE|Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning|The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK) tip followed by copious irrigation with sterile saline
214489818|NCT06734429|OTHER|Urinary Artificial Sphincter|Urinary Artificial Sphincter is a device used for patients with urethral sphincter incompetence
214489819|NCT06744088|COMBINATION_PRODUCT|Del Nido cardioplegia|To assess the clinical outcomes of modified Del Nido cardioplegia in cardiac surgeries across different age groups,
214489820|NCT06746948|OTHER|dyadic psychological distress|There is no intervention among the cross-sectional study.
214363072|NCT04434807|PROCEDURE|Minimally invasive hematoma evacuation|Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences)
214489821|NCT05720468|OTHER|Exercise|Combined endurance and resistance exercise training
214489822|NCT05720468|OTHER|No Exercise|Continue usual level of physical activity; option to participate in exercise training program after 26-week intervention period
214489823|NCT06741956|BEHAVIORAL|Weapom Lifestyle Intervention to measure bone impacts using a Fitbit Versa wearable device and the Weapom App.|A. Program to increase physical activity and impacts For the intervention, a biosensor -wearable device- (Fitbit Versa) will be used. The device is linked to an App (Weapom) that will allow users to quantify the number of steps (including the rate of steps per minute), the impacts and their intensity. Users will be given feedback from the application on the level of achievement of the objectives proposed in the impact program (EV). It will be proposed to achieve 50 vertical and multidirectional jumps per day (milestone 1. The number of jumps\> 3.9 G per day will be recorded 28, divided between 3-5 sets of 10-20 repetitions with a minimum 1-2 minute rest between sets. A frequency between 4-7 days per week will be used. In the same way, it will be recommended to reach 10,000 steps per day (milestone 2. The number of daily steps will be recorded) and, as far as possible, at a rapid pace (milestone 3. The number of daily minutes walking at a pace over 110 steps/minute will be r
214489824|NCT06741605|OTHER||
214489825|NCT06743230|OTHER|Neuro athletic training|The neuroathletic training includes exercises that stimulate the visual, vestibular, and proprioceptive systems. The neuroathletic training includes 3 days per week for 8 weeks.
214363073|NCT05736562|DIETARY_SUPPLEMENT|Ritual Epre Multimineral-Vitamin Supplement|The Ritual Epre supplement is a commercially available multivitamin-mineral supplement designed for pregnant and lactating women.
214363074|NCT05736562|DIETARY_SUPPLEMENT|Placebo Control|This is a customarily designed blank placebo provided by Ritual.
214363075|NCT05009108|DIAGNOSTIC_TEST|Purdue Pegboard Test|"At first, each person will be asked to fill in the informed agreement and answer short questionnaire. Than he/she will be tested by the Purdue Pegboard Test according to the Czech version of extended manuals for those tests in only one session. Audio recording of verbal instructions will be used and whole testing process will be video recorded which is necessary for establishing the internal variability and variability of results of the Purdue Pegboard Test.~The results will be used only for establishing of the variability and inter-rater reliability of the Purdue Pegboard Test, not for patients' other interventions."
214489826|NCT06743230|OTHER|Conventional training|Conventional training includes flexibility exercises, strengthening exercises, running, balance and sport-specific technique work 5 days per week.
214974206|NCT06443294|BEHAVIORAL|Smoking cessation video series.|The intervention in this study is a series of six videos totally approximately 40 minutes. These videos are led by a doctoral psychology student with experience in working with tobacco smokers. Videos utilize empirically-supported strategies for smoking cessation.
214974207|NCT04510272|OTHER|Aloud Real-time Reading of ICU Diaries|Standard ICU diaries will be read aloud in real time daily to patients by ICU nurses/therapists/family members
214974208|NCT05426746|DRUG|ALT-100|intravenous infusion of drug substance diluted in 0.9% normal sterile saline
214363076|NCT04184726|BEHAVIORAL|Mindfulness Based Cognitive Therapy|mindfulness and cognitive behavioural therapy techniques taught in group sessions meeting once weekly for 8 weeks, and home practice between sessions.
214489827|NCT06748521|DRUG|R-CHOP + X|Eligible participants will receive 1 cycle of R-CHOP therapy with genotyping and ctDNA testing at C1D14. Chemotherapy sensitive patients with C1D14 ctDNA negative or ctDNA LFC ≥ 2 will continue to receive R-CHOP therapy for up to 6 courses. Potentially resistant patients with C1D14 ctDNA positive and LFC \< 2 were stratified by DLBCL genotyping and treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.
214489828|NCT06896110|DRUG|Nivolumab|Intrathecal nivolumab will be given at a flat dose of 40 mg
214489829|NCT06896110|DRUG|Azacitidine (AZA)|Intrathecal azacitidine will be dose-escalated with 4 dose levels (5, 10, 20, 40 mg) using a 3+3 design.
214489830|NCT06896110|PROCEDURE|lumbar puncture|Lumbar puncture for intrathecal delivery and collection of CSF
214489831|NCT06896110|DIAGNOSTIC_TEST|MRI Contrast|MRI Brain and full Spine (with and without contrast) will be performed prior to enrollment. During trial therapy, MRI Brain (with and without contrast) will be performed after cycle 1 and after that every 8 weeks (e.g. after cycle 3, cycle 5, etc…)
215084497|NCT01046240|DRUG|Palonosetron|Palonosetron 3 mg administered SC or IV
215084498|NCT00766246|DRUG|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
214363077|NCT01301391|DRUG|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
214489832|NCT06783075|OTHER|MILK|Drink containing amino acids in the composition of milk protein
214974209|NCT05426746|OTHER|Normal Saline|intravenous infusion of placebo (0.9% normal sterile saline)
214679605|NCT03114241|BEHAVIORAL|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
214363078|NCT02920697|DRUG|S 55746|S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
214363079|NCT00153998|DRUG|Cetuximab|
214489833|NCT06783075|OTHER|WHEAT|Drink containing amino acids in the composition of wheat protein
214489834|NCT03213457|DRUG|Estradiol/Norethindrone Acetate|Tablets
214679606|NCT01835990|DEVICE|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
214679607|NCT01835990|DEVICE|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
214679608|NCT05074095|OTHER|retrospective analysis|
214679609|NCT06440590|PROCEDURE|suprapectineal quadrilateral buttress plating|15 cases will undergo anatomical supra-pectineal quadrilateral plate
214489835|NCT03213457|DRUG|Placebo for Elagolix|Tablet
214489836|NCT03213457|DRUG|Elagolix|Tablet
214489837|NCT03213457|DRUG|Placebo for E2/NETA|Tablets
214489838|NCT06737146|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
214489839|NCT06740539|PROCEDURE|Catheter ablation of atrial fibrillation|Catheter ablation of atrial fibrillation
214489840|NCT06794632|OTHER|HANDY occupational therapy intervention|The HANDY occupational therapy intervention is occupation-centred and follows the Occupational Therapy Intervention Process Model (OTIPM), specifying the steps of a problem-solving process focused on enabling performance of tasks in everyday life. The HANDY occupational therapy intervention consists of six mandatory sessions of 120 minutes representing a combination of individual and group sessions. Each group includes a maximum of eight participants with hand osteoarthritis, facilitated by two OTs.
214679610|NCT06440590|PROCEDURE|Infra-pectineal plating|15 cases will undergo conventional manually contoured infra-pectineal plate
214489841|NCT06794060|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
214679611|NCT04133779|PROCEDURE|neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
214974210|NCT04273815|DRUG|TQ-A3334|TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
214974211|NCT04273815|DRUG|Anlotinib|Anlotinib is a multi-target receptor tyrosine kinase inhibitor.
214974212|NCT05570448|PROCEDURE|ARAT|For patients randomized to ARAT intervention, the area of cardia, along greater curvature will be cleaned followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC (30W, Effect 2) using the H-APC catheter. Next, the area of cardia, on either side will be injected in sequence using a methylene blue (0.5%) and normal saline (0.9%) using the H-APC catheter jet system (Effect 30-70). Next, the mucosa, starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W till golden-brown discoloration of the ablated tissue in 270-320 degree. For patients randomized to control or sham intervention, upper endoscopy with procedural sedation was performed followed by markings of landmarks followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time. No H-APC or submucosal injection or other intervention will be performed.
214489842|NCT06794060|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants swallow naturral vitamin C tablets 500mg with water, twice a day.
214489843|NCT06794060|OTHER|Placebo|Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
214489844|NCT04966702|DRUG|Albendazole Pill|Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants
214489845|NCT04966702|DRUG|Ivermectin Pill|Using a MDA approach, fieldworkers will administer ivermectin using directly observed treatment methodology to participants
214489846|NCT04966702|DRUG|Ivermectin Injectable Product|Veterinary ivermectin injectable will be given to livestock in the relevant cluster
214489847|NCT05966636|PROCEDURE|Fractional CO2 Laser Ablative Resurfacing|Fractional lasers stimulate scar improvement through production of microscopic patterns of dermal injury, vaporizing scar tissue and inducing neocollagenesis, subsequently improving scar tissue texture and range of motion, and decreasing symptoms such as pain and pruritis. Current clinical consensus is supportive that fractionated lasers are the most effective option for the treatment of scars. Other laser wavelengths and modalities used for vascular deformities and hair removal for instance, have an adjunctive role in improving scars and may be used in the same laser session. Case reports provide evidence of substantial improvement in sensory symptoms and physical mobility within days to weeks after each treatment.
214489848|NCT04233099|PROCEDURE|Raman analysis of saliva with data collection and analysis|Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.
214363080|NCT00153998|PROCEDURE|Liver resection|
214363081|NCT00153998|DRUG|Cetuximab and FOLFIRI|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
214363082|NCT00153998|DRUG|Cetuximab and FOLFOX|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
214363083|NCT02448940|DIETARY_SUPPLEMENT|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
214363084|NCT02448940|DIETARY_SUPPLEMENT|lactose|2 capsule a day containing lactose
214363085|NCT04128644|BEHAVIORAL|Thoughts & health|12 sessions of Thoughts \& Health. Baseline questionaires and follow up assessments
214363086|NCT04128644|OTHER|Treatment as Usual|Baseline questionnaires and follow up assessments, intervention as usual, Student Health
214363087|NCT02430467|BEHAVIORAL|Caregiver-guided pain management training (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.
214363088|NCT02430467|BEHAVIORAL|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
214489849|NCT00897702|OTHER|Blood draw|A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.
214489850|NCT00897702|OTHER|immunoenzyme technique|
214489851|NCT00897702|PROCEDURE|biopsy|
214489852|NCT00897702|PROCEDURE|histopathologic examination|
214489853|NCT06716840|DRUG|Remimazolam|participants in the remimazolam group received remimazolam besylate intravenously at an initial infusion rate of 0.2mg/kg/h and adjusted (maximum of 2 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale(RASS) score between - 2 and 0.If the maximum dose of remimazolam was insufficient to sedate, add rescue dexmedetomidine.
215084499|NCT00766246|DRUG|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
214363089|NCT04497792|DRUG|Empagliflozin 10Mg Tab|Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication
214363090|NCT04497792|DRUG|hypoglycemic therapy|hypoglycemic therapy.
214489854|NCT06716840|DRUG|Propofol|participants in the propofol group received propofol intravenously at an initial infusion rate of 1 mg/kg/h and adjusted (maximum of 4 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale (RASS) score between - 2 and 0.If the maximum dose of propofol was insufficient to sedate, add rescue dexmedetomidine.
214489855|NCT06748937|DRUG|Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD|Cohort 1 Arm 1
214489856|NCT06748937|DRUG|Alpibectir 45 mg OD plus Ethionamide 250 mg OD|Cohort 1 Arm 2
214489857|NCT06748937|DRUG|Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based|Active Comparator
214489858|NCT06748937|DRUG|Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD|Cohort 2 Arm 4
214489859|NCT06571422|DRUG|WJ47156|Monotherapy study: participate will recepit WJ47156 monotherpy with 3 dose groups; Combination therapy study: participate will recepit WJ47156 and other study drug if in the combination therapy period
214489860|NCT06571422|DRUG|JS001+Bevacizumab|Participants in Cohort1 of combination therapy phase will receive WJ47156 plus toripalimab and bevacizumab.Toripalimab and bevacizumab are administered intravenously.
214489861|NCT06571422|DRUG|JS207|Participants in Cohort2 of combination therapy phase will receive WJ47156 plus JS207. JS207 is administered intravenously.
214489862|NCT06805006|DEVICE|SSLF|Bilateral sacrospinous ligament fixation with i-Stitch device
215084500|NCT00766246|DRUG|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
215084501|NCT02953665|DRUG|Liraglutide|Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
214363091|NCT00717639|PROCEDURE|Diagnostic MR-Angiography|Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
214363092|NCT03600584|PROCEDURE|Modified one-layer duct-to-mucosa Pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
214363093|NCT03600584|PROCEDURE|Invagination pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
214363094|NCT02629991|DRUG|Intranasal Oxytocin (IN-OXT)|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
214363095|NCT02629991|OTHER|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
215084502|NCT02953665|DRUG|Placebo|Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
215084503|NCT01498185|DRUG|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
215084504|NCT01498185|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
215084505|NCT01993316|DEVICE|Mitsar 201 neurofeedback|
214363096|NCT03088592|DEVICE|Deep Brain Stimulation|Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
214363097|NCT03887338|OTHER|Transnasal Fiberoptic Laryngoscopy|Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.
214363098|NCT03718689|DEVICE|Laser etching|Acid etching
214363099|NCT03351855|BIOLOGICAL|HPV-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg by IV each time
214363100|NCT02133599|DRUG|IOHEXOL|Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
214363101|NCT03754179|DRUG|Dabrafenib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
214363102|NCT03754179|DRUG|Trametinib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
214363103|NCT03754179|DRUG|Hydroxychloroquine|Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2
214363104|NCT02799784|DRUG|UMEC/VI|ELLIPTA dry powder inhaler (DPI) will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5 mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
214363105|NCT02799784|DRUG|TIO/OLO|TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
214363106|NCT02799784|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed
214363107|NCT03695302|BEHAVIORAL|questionnaire|KAP questionnaire for fifth year undergraduate dental students.
214363108|NCT04636372|DEVICE|Intense pulsed light therapy|Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
214363109|NCT04636372|OTHER|Hot compress massage|Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
214363110|NCT00822081|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
214363111|NCT00822081|DRUG|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
214363112|NCT00822081|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
214363113|NCT00822081|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
214363114|NCT01624948|DRUG|Everolimus|Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
214363115|NCT01624948|DRUG|Mycophenolic acid dose reduction|Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
214363116|NCT03748290|DRUG|Pregabalin|Pregabalin 75 mg for 12 weeks
214363117|NCT03748290|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
214363118|NCT04237805|DRUG|SAF-189s|20mg，40mg，80mg，120mg，160mg，210mg，once daily
214363119|NCT01629914|BEHAVIORAL|Mindfulness Meditation|8-week, group-based mindfulness meditation intervention
214363120|NCT00466635|DRUG|GT267-004 (tolevamer potassium sodium)|
214489863|NCT06804863|BEHAVIORAL|Postoperative Regret Reduction through Immediate Quality of Life Intervention|Immediate intervention of the major impaired quality of life factors postoperatively to reduce patients' postoperative regret.
214489864|NCT06577415|DRUG|RAY1225|Administered SC
215094451|NCT00681993|OTHER|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
214363121|NCT03918863|OTHER|Neuromuscular electrical stimulation|Exercise protocol associated with neuromuscular electrical stimulation on vastus medialis and gluteus medius. Parameters: rectangular pulse shape, biphasic, symmetrical, pulse duration of 200μs, interbust interval of 10ms and frequency of 2.500Hz modulated in 50 bursts.
214363122|NCT03918863|OTHER|Exercise|Same protocol of exercises of the other group, without association of electrical stimulation.
214363123|NCT02745821|DEVICE|Pressure Wire Certus, St. Jude Medical, USA|FFR. CFR and IMR will be measured using the Pressure Wire Certus, St. Jude Medical, USA in target and non-target vessels. Changes in FFR, CFR and IMR post PCI of target vessels will also be recorded.
214489865|NCT06576752|OTHER|Digital follow-up and uptitration of medications at home after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
214489866|NCT06576752|OTHER|Follow-up and uptitration of medications at the hospital outpatient-clinic after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
214489867|NCT06805435|DEVICE|Continuous non-invasive blood pressure monitoring|A continuous non-invasive blood pressure monitoring cuff will be placed on the volunteers index finger (as intended) and 2nd toe (primary outcome).
214489868|NCT05413733|BEHAVIORAL|Digital care pathway|"Sessions of the digital neuropsychological program:~1. Subjective functional ability and goals~2. Fatigue after ABI~3. Attention and concentration~4. Memory~5. Memory strategies~6. Working memory and executive functions~7. Emotional reactions~8. Summary and future goals"
214489869|NCT05413733|BEHAVIORAL|Care as usual|The standard care of patients with ABI including all necessary outpatient rehabilitation visits. Neuropsychological visits may include a short period of psychoeducation with a clinical neuropsychologist.
214489870|NCT06808971|DRUG|Adebrelimab, Nab-paclitaxel, Oxaliplatin, Tegafur Gimeracil Oteracil Potassium Capsule|Adebrelimab combined with Nab-paclitaxel, Oxaliplatin andTegafur Gimeracil Oteracil Potassium Capsule
214489871|NCT06811571|BEHAVIORAL|the mobile-based early intervention|The theoretical framework of the intervention was based on Cognitive Behavior Therapy (CBT). We designed three modules, which were the Gaming behavior management, the Gaming cognition establishment and the Early intervention on risk and protective factors. The interventions included self-monitoring questionnaires, scientific popular articles, and online lectures.
214489872|NCT05999721|PROCEDURE|superficial parasternal intercostal plane block|Injection of 60 mL of bupivacaine 0.25% and epinephrine 2.5 µg mL-1
214489873|NCT05999721|OTHER|Standard care|"Operating Room:~Anaesthesia will be induced using midazolam (0.1-0.15 mg kg-1), fentanyl (5-10 μg kg-1), and rocuronium (0.6-1.2 mg kg-1); then, after tracheal intubation, anaesthesia will be maintained using isoflurane at one MAC, along with continuous fentanyl (3-5 μg kg-1 h-1) and midazolam (20-50 μg kg-1 h-1). Additional boluses of fentanyl will be administered according to the anesthesiologist's discretion.~Cardiothoracic Intensive Care Unit:~Continuous fentanyl will be maintained until tracheal extubation. All patients will receive intravenous multimodal analgesic drugs around the clock, including paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain persists, rescue doses of either intravenous tramadol or morphine will be administered.~Cardiothoracic ward:~The analgesic protocol includes around-the-clock intravenous paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain continues, rescue doses of oral oxycodone will be administered."
215084506|NCT05976464|DRUG|Magnesium sulfate in erector spinae plane block|"Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery."
214363124|NCT03426202|DRUG|Modafinil Oral Tablet|modafinil 200mg
214363125|NCT03426202|DRUG|Placebo Oral Tablet|placebo 200mg
214363126|NCT01546961|DRUG|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
214363127|NCT03909984|DEVICE|Nightwatch|Nocturnal monitoring for 2 months with three different seizure detection devices.
214363128|NCT03458884|OTHER|Cardiorespiratory interval training|A structured cardiorespiratory interval training program on an ergometer cycle 3 days a week for 8 weeks.
214974213|NCT05570448|PROCEDURE|Sham intervention (control)|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
214974214|NCT03011203|OTHER|physical exercise|In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
214974215|NCT00454961|DRUG|artemether-lumefantrine|
214974216|NCT00005793|DRUG|Cytarabine|
214974217|NCT00005793|DRUG|Daunorubicin|
214974218|NCT00005793|DRUG|Etoposide|
215084507|NCT04148612|DIAGNOSTIC_TEST|Opti-Me|Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
214974219|NCT00005793|DRUG|Topotecan|
214974220|NCT02048423|DRUG|Ketamine|IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
214974221|NCT02660255|DRUG|Cannabidiol|Formulation: 100mg/ml CBD (Epidiolex) Solution
215084508|NCT00946322|BEHAVIORAL|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
215084509|NCT01271257|DRUG|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
215084510|NCT03387943|DRUG|PLD|intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
214974222|NCT00729521|OTHER|facilitative system|The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
214363129|NCT04921631|BEHAVIORAL|Early Integration of Specialty Palliative Care with Critical Care|The PC team will visit the patient within 24 hours of randomization and the consultation will address the following domains of PC: illness understanding and goals of care conversations with patients/surrogates; symptom assessment and management; spiritual needs; patient and family coping and support; and care coordination and transitions. The initial family meeting will be scheduled to occur within two days of randomization. Follow-up visits will be conducted by the PC MD/APP every weekday. During this time, the ICU and PC team will be in daily communication. The PC team will continue to follow the patient in the hospital once discharged from ICU. Prior to discharge, the PC team will document patient goals and preferences for future treatment, coordinate appropriate PC services in the home and/or outpatient clinic settings and contact the patient's primary physician to provide an update on the patient's hospital stay.
214974223|NCT00729521|OTHER|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
214974224|NCT02334163|DRUG|Nitazoxanide|500 mg nitazoxanide tablets twice daily
214363130|NCT01949870|DRUG|Cisplatin|day1 and day8 at each cycle
214363131|NCT01949870|DRUG|Gemcitabine|day1 and day8 at each cycle
214363132|NCT01949870|DRUG|Selumetinib|25mg/day, 50mg/day and 75mg/day
214363133|NCT06086379|BEHAVIORAL|Compensatory Cognitive Training for COVID-19|CCT-C is a manualized group-based behavioral intervention (10 weeks, 2 hours per week, 20 hours total) designed to improve cognition and everyday functioning in patients with prolonged COVID-19 symptoms
214363134|NCT06086379|BEHAVIORAL|Holistic Cognitive Education|HCE provides the same frequency and amount of therapist and other group member contact as CCT-C, but does not provide training in cognitive or lifestyle strategies addressed in CCT-C. The HCE intervention provides information and discussion regarding common causes of and treatments for cognitive impairment.
214363135|NCT01682980|OTHER|Strength training|The strength training will be delivered 2-3 times per week for 12 weeks, 5-8 repetitions maximum in 3 series. The patients must warm up 5 minutes on an ergometer cycle. The following muscle groups will be trained: Quadriceps and hamstrings, hip muscles (abductors and extensors), calf muscles. A home exercise program will be delivered including one leg exercises and balance exercises. Progression will follow a 2+ principle. For instance, when the study participant is able to perform 2 more repetitions, more loads are required.
214363136|NCT01682980|OTHER|Aerobic exercise|The aerobic exercise program include ergometer cycling for at least 45 minutes 2-3 times a week on 75-80% of max heart rate will be required.
214363137|NCT04852653|PROCEDURE|Supplementary blood samples collection during the normal follow up of the patients|Supplementary blood samples collection during the normal follow up of the patients
214363138|NCT01821742|OTHER|Ultrasound cardiac output measurement|
214363139|NCT00075062|PROCEDURE|Flexible Sigmoidoscopy|
214974225|NCT02334163|DRUG|Oral lactulose|Oral lactulose (65%)
214363140|NCT00075062|PROCEDURE|Rectal Biopsy|
214363141|NCT05100888|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Theta-burst stimulation
214363142|NCT02363556|PROCEDURE|Misoprostol administered vaginally|
214363143|NCT02363556|PROCEDURE|Misoprostol administered buccally|
214363144|NCT02363556|PROCEDURE|Misoprostol administered vaginally with Dilapan|
214489874|NCT03443492|DRUG|S-1|Intervention is administered to patients in this Arm.
214489875|NCT03443492|DRUG|Leucovorin(oral )|Intervention is administered to patients in this Arm.
214974226|NCT02334163|DRUG|Metronidazole|250 mg metronidazole tablets every 8 hours
215084511|NCT03387943|DRUG|Cisplatin|cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.
215084512|NCT04400578|DEVICE|Trichloroacetic acid 85% (TCA)|Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
215084513|NCT02110888|DEVICE|Subcutaneous peripheral nerve stimulation|
215084514|NCT02110888|OTHER|SCS Only|
214363145|NCT02363556|PROCEDURE|Misoprostol administered buccally with Dilapan|
214363146|NCT03475550|OTHER|Standard of Care|The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
215084515|NCT04272008|DRUG|Segesterone Acetate and Ethinyl Estradiol|Annovera taken alone
215084516|NCT04272008|OTHER|Tampon|Annovera with tampon use
215084517|NCT04366557|OTHER|Manual therapy, exercises and education program|a six week body posture therapy consisted of manual therapy (once per week) and home exercises; education about pelvic floor
215084518|NCT04366557|OTHER|Education program|education about pelvic floor
215084519|NCT00000357|DRUG|Buprenorphine|
214489876|NCT03443492|DRUG|Gemcitabine|Intervention is administered to patients in this Arm.
214489877|NCT03443492|DRUG|Oxaliplatin|Intervention is administered to patients in this Arm.
214489878|NCT03443492|DRUG|Irinotecan|Intervention is administered to patients in this Arm.
214974227|NCT02334163|DRUG|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
214974228|NCT04260620|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
214974229|NCT06419491|OTHER|Partner notification by a trained counsellor|"One (or more if needed) interview with a partner notification trained counsellor is offered to index patients. During the interview, the counsellor gives information on partner notification, helps the index patients to remember their partners, to assess their HIV/sexually transmitted infection exposure and explains options to notify them.~During the interview, the index patient can choose to entrust the notification of some of their partners to the counsellor. However, according to French law, provider referral is permitted only when it is anonymous. Therefore, this option is reserved to partners with a lot of partners in order to limit the risk of identifying the index patient"
215084520|NCT01312649|BEHAVIORAL|Experimental psychology methods (computer tests)|
215084521|NCT01482897|DRUG|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
215084522|NCT01482897|DRUG|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
214363147|NCT02570126|BIOLOGICAL|Varilrix HSA-free|2 doses will be administered, one at Day 0 and the other at Day 42
214363148|NCT02570126|BIOLOGICAL|Varilrix™|2 doses will be administered, one at Day 0 and the other at Day 42
214363149|NCT02104622|DEVICE|ReWalk Rehabilitation 2.0|
214363150|NCT03912844|PROCEDURE|SIRT followed by liver resection or liver transplantation|The ESSURE registry is a prospective observational study. Patients are only asked to be enrolled when they are treated with SIR-Spheres microspheres followed by liver resection/liver transplantation or when SIRT has been performed with the intention to downsize/ downstage the tumor, to induce hypertrophy of the contralateral lobe, making the patient eligible for a future liver resection/transplantation. In no way will participation in the registry influence the way in which the patient is treated according to the treating clinician, or will it influence the quality of the treatment. If a patient is included in the registry, a documented decision of a multidisciplinary tumour board for the treatment algorithm including SIRT must be available. The follow-up periods depend on the treating clinician and local practice and guidelines. Typically, the follow ups are done every three months. So data of a single patient will be included over two years after the treatment.
214363151|NCT05649111|DRUG|Difluprednate Eye Drops|post-operative cataract surgery medication regimen. but different dosages between the 2 groups.
214363152|NCT00048464|PROCEDURE|Infusion of Activated & Expanded Autologous T Cells|
214363153|NCT06202326|DEVICE|renal artery doppler|doppler ultrasound follow up
214363154|NCT00917579|DRUG|Atorvastatin|A single 10 mg dose of marketed 10 mg atorvastatin tablets
214363155|NCT00917579|DRUG|Atorvastatin|A single 10 mg dose of new formulation of 10 mg atorvastatin
214363156|NCT00754338|DRUG|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
214363157|NCT00754338|DRUG|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
214363158|NCT00754338|DRUG|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
214363159|NCT02361320|PROCEDURE|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
214363160|NCT02361320|BEHAVIORAL|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
214363161|NCT02351219|DRUG|FOLFOXIRI|
214489879|NCT03443492|DRUG|5-FU|Intervention is administered to patients in this Arm.
214489880|NCT03443492|DRUG|Leucovorin(IV)|Intervention is administered to patients in this Arm.
214489881|NCT06625957|DRUG|NTCB02-1|3 Days infusion
215084523|NCT01482897|DRUG|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
215084524|NCT00488124|DRUG|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
215084525|NCT02119039|DEVICE|RGTA OTR 4120 (CACICOL20)|
215084526|NCT02119039|DEVICE|Genteal HA eye drops|
214363162|NCT04830826|PROCEDURE|Surgeries|Surgeries
214363163|NCT00511017|DRUG|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
214363164|NCT02098980|DIETARY_SUPPLEMENT|Vitamin D|
214363165|NCT03963674|OTHER|Diacutaneous fibrolysis|Diacutaneous fibrolysis over the gastrocnemious muscles
214363166|NCT03854968|OTHER|Quality control|The performance of the home mechanical ventilator of all patients in the study will be evaluated with a portable device
214363167|NCT04683926|DRUG|Desmetramadol|Analgesic
214489882|NCT06625957|DRUG|NTCB-C|3 Days infusion
214489883|NCT06876467|OTHER|Evaluation of cellular response|detection of HBsAg-specific T lymphocytes by spectral cytometry
214489884|NCT06876129|DEVICE|TMS|Subjects will either receive iTBS using a Magventure TMS device or 18-Hz H1 TMS using a dTMS Brainsway device plus placebo.
215084527|NCT03378089|BEHAVIORAL|Music Therapy|No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.
215084528|NCT03378089|BEHAVIORAL|No Music Therapy|Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
214974230|NCT05785962|OTHER|Vojta Therapy|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
214974231|NCT05145985|DIAGNOSTIC_TEST|Senior Fitness Test|"Senior Fitness Test is comprised of 6 individual test items and for a description of the trials. All fitness tests (1-6) were selected for analysis:~1. Arm Curl (AC) - measurement of upper body muscle endurance - numbers of arm curls as possible in 30 seconds (n)~2. 30-second Chair Stand (30SCS) - measurement of lower body strength; numbers of chair stand as possible in 30 seconds (n)~3. Back Scratch Test (BST) - measurement of upper-body flexibility; the best score to the nearest centimeter (cm)~4. Chair Sit and Reach Test (CSRT)- measurement of lower-body flexibility (specifically hamstring flexibility); the best score to the nearest centimeter (cm)~5. 8-Foot Up and Go (TUG) - measurement of agility (dynamic balance) and aerobic endurance; the best time of the two trails to the nearest 1/10th second (s)~6. 2-Minute Walk Test (2MWT) - measurement of (aerobic) endurance; the total number of times the right knee reaches the tape level in two minutes (n)"
214974232|NCT00933595|OTHER|Smoking Cessation|"A Motivational Interview session (\~40-50 minutes) will be delivered by a trained nurse coordinator.~Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day."
214974233|NCT01474395|DRUG|D-serine|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
215084529|NCT02073032|OTHER|No intervention, only observation|
215084530|NCT01747200|PROCEDURE|Sham rTMS|
215084531|NCT01747200|PROCEDURE|Bilateral rTMS at same frequency and in phase|
214363168|NCT00941993|DEVICE|Iontophoresis System (Acclarent)|Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
214363169|NCT00346021|BEHAVIORAL|Increasing hat use|Sun protection intervention that address sun protection knowledge, attitudes, social norms, and perceived behavioral controls. Intervention also provides free wide brimmed hats
214363170|NCT04385368|DRUG|Durvalumab + SoC chemotherapy|Experimental Treatment
214363171|NCT04385368|OTHER|Placebo + SoC chemotherapy|Placebo Comparator
214363172|NCT02200913|OTHER|core stabilization exercise|core stabilization exercise, 2 times/week, 10 weeks
214363173|NCT02200913|OTHER|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
215084532|NCT01747200|PROCEDURE|Bilateral rTMS at different frequencies|
215084533|NCT01747200|PROCEDURE|Bilateral rTMSat same frequency and out of phase|
215084534|NCT01747200|PROCEDURE|rTMS over TP8|
215084535|NCT01747200|PROCEDURE|rTMS over TP7|
214363174|NCT01197196|BEHAVIORAL|Behavioral Weight Loss Intervention|Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
214363175|NCT01197196|OTHER|Migraine Education|Participants assigned to this condition (Healthy Living for Migraine Relief \[HLMR\]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
214363176|NCT02740049|DRUG|VR588|Evaluation of the efficacy of a novel JAK/STAT inhibitor, VR588, in isolated epithelial cells from asthma patients
214363177|NCT01256411|DRUG|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
214363178|NCT01256411|DRUG|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
214363179|NCT01256411|DRUG|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
214363180|NCT04102202|DRUG|BOL-DP-o-05|BOL-DP-o-05
214363181|NCT04102202|DRUG|Placebo|Placebo
214363182|NCT01989026|BIOLOGICAL|BCG|
214363183|NCT03443882|DIETARY_SUPPLEMENT|Astaxanthin|an oral dose form
214363184|NCT04431193|DRUG|Oxytocin|Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
214363185|NCT06580977|BEHAVIORAL|cardiovascular training|Cardiovascular training will be performed in supervised sessions and in small groups of 2-5 persons at the study site. The training is performed on a cycle ergometer at 60% of peak power output (Wmax) for 30 min (i.e., 5 min warm-up, 20 min at 60% Wmax, 5 min cool-down) three times a week for twelve weeks. The exercise program will be increased by 5 min (max. 55 min) and 5% of intensity (in Watt) every two weeks. If participants report a too low (i.e., Borg scale ≤ 11) or too high (i.e., Borg scale ≥ 16) subjective rate of perceived exertion (RPE; Borg scale 6-20) intensity will be increased or decreased until the target levels are met (i.e., Borg scale 12-15). During training, heart rate, intensity (in Watt) and RPE will be monitored. Participants missing training sessions will be offered an additional week to perform up to three training sessions.
215084536|NCT02153346|OTHER|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
214974234|NCT01474395|DRUG|placebo|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
214974235|NCT01474395|BEHAVIORAL|Sensory Based remediation paradigm|Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (\~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
214974236|NCT00092196|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
214974237|NCT01837836|BEHAVIORAL|Health education|Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.
214363186|NCT06580977|BEHAVIORAL|stretching|The stretching training will be performed in supervised sessions and in small groups of 2-5 persons at the study site. Stretching training consists of lying, seated, and standing flexibility exercises (according to the recommendations of the American Parkinson´s Disease Foundation and the Parkinson Society Canada) for 30 min (i.e., 5 min warm-up, 20 min main part, 5 min cool-down) three times a week for twelve weeks. The exercise program will be increased by 5 min (i.e., adding additional repetitions and exercises; max. 55 min) every two weeks. Intensity of stretching exercises will be assessed by subjective rate of perceived muscle tension on a visual analog scale (VAS) from 0 to 10 and will be moderate defined as 5 to 7 on the VAS. During training VAS, heart rate, and RPE will be monitored. Participants missing training sessions will be offered an additional week to perform up to three training sessions.
214363187|NCT05338099|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"
214363188|NCT05338099|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"
214502757|NCT06841289|BEHAVIORAL|Distraction cards|Distraction cards consist of picture cards with various hidden pictures and patterns. These hidden pictures and patterns can only seen by the child if he/she looks carefully. During the procedure, the child is expected to focus on the cards and answerabout the pictures and shapes on the cards. In this study, 5X8 cm cards with various pictures and shapes will be used.
214974238|NCT03628443|DIAGNOSTIC_TEST|Fibroblast Growth Factor 23|A sample of blood is tested for levels of fibroblast growth factor 23
214974239|NCT00257790|DRUG|Tobramycin once a day|
215084537|NCT02153346|OTHER|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
215084538|NCT01912157|BEHAVIORAL|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
215084539|NCT00846040|OTHER|Reduced fat diet|RF (selective reduction of 85% of baseline fat calories per day)
215084540|NCT00846040|OTHER|Reduced carbohydrate diet|RC (selective reduction of 60% of baseline carbohydrate calories per day)
214363189|NCT02310529|BEHAVIORAL|Interpersonal Psychotherapy|"Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.~Intervention will be delivered by trained clinical psychologists."
215084541|NCT00846040|DRUG|Drug: f-18 fallypride|Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
214363190|NCT02241122|PROCEDURE|prostate biopsy|
214363191|NCT02123108|DRUG|Basiliximab|Peri-operative 40 mg IV dose within 4 hours of OLT Postoperative 20mg IV dose Day 4
214363192|NCT02123108|DRUG|Tacrolimus|Day #7 post-transplant or when serum creatinine (SCr) \< 1.8 mg/dl 6 months to 1 year: 0.03-0.1 mg.kg q12h po to maintain whole blood trough concentration of 3-5ng/mL
214502758|NCT06842121|DRUG|Sodium Glycerophosphate Injection|Organic phosphate (SGP) will be diluted with 500mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 60 mmol over 4 hours (h)
215084542|NCT00846040|DEVICE|fMRI|Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
215084543|NCT00846040|DEVICE|PET|Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
215084544|NCT06080646|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
215084545|NCT00957333|OTHER|ketamine|
215084546|NCT02485652|DRUG|HM61713|"800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
215084547|NCT04519047|BIOLOGICAL|PRP|Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
214489885|NCT06876129|COMBINATION_PRODUCT|D-serine + TMS|"D-serine, 80 mg/kg, oral administration, will be advised to be taken 1-hour prior rTMS treatment day (Mon-Fri) for 6 weeks. Dosing is based on maximal plasticity at 80 mg/kg, and clinical dose-finding studies demonstrating that doses between 60 - 120 mg/kg were superior in clinical effectiveness to 30 mg/kg and were safe.~Subjects will not be randomized into their TMS group and will either receive iTBS using a Magventure TMS device or 18-Hz H1 TMS using a dTMS Brainsway device. Subjects will have their TMS protocol/treatment determined at the time of consultation according to clinical appropriateness as is the standard of care at the TMS clinic at McLean Hospital."
214489886|NCT06876480|OTHER|Keyboard|Day 0 : Collection of the general data required for the study, installation of the computer device including the LifeCompanion software with the different scanning keyboards configurations and organizations. Day 0 to Day 8 : write, in copy, a text using each of the virtual keyboard configurations. Day 8 : copying a text proposed by the investigator of identical difficulty for each condition, for a duration of 15 minutes, per experimental condition. This copying exercise, with the recording of measurements, will be done for each experimental condition. Day 8 to Day 16 : write a copy of a text of his/her choice for 10 minutes, using each of the virtual keyboard configurations. Day 16 : in a text-entry evaluation situation, copying a text proposed by the investigator, of identical difficulty for each condition.
214489887|NCT06879470|DRUG|JY231 Injection|"This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with relapsed refractory B-cell leukemia.~Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 15 years to determine if the disease is under control."
214489888|NCT06885372|PROCEDURE|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
214489889|NCT06885372|PROCEDURE|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
214489890|NCT06747416|DRUG|KN057|KN057 will be administered subcutaneously once a week.
214489891|NCT06418269|OTHER|Therapeutic Play|"Children will be asked to fill in the Child Patient Identification Form, State Anxiety Scale in Children and Child Fear Scale 30 minutes before insulin treatment. Before the insulin treatment, the children in the experimental group will have their blood glucose measured and insulin administered on a doll using the therapeutic play method. The child will be told that the doll is hospitalized with a diagnosis of Type 1 diabetes and will be expected to assume the role of a nurse to administer insulin to the doll. Then, the steps of blood glucose measurement and insulin treatment (subcutaneous) will be explained to the child and the child will be asked to administer insulin to the baby. Within 10 minutes after subcutaneous insulin treatment, the child will be asked to fill out the State Anxiety Scale in Children and Child Fear Scale."
214489892|NCT06746077|OTHER|No intervention|No intervention
214489893|NCT06740032|OTHER|Transcutaneous vagus nerve stimulation|Investigation of the effects of vagus nerve stimulation on the autonomic and somatic systems together
214489894|NCT06740032|OTHER|Deep breath exercise|Investigation of the effects of vagus nerve stimulation on the autonomic and somatic systems together
214489895|NCT06746012|PROCEDURE|Discussion|Participate in think-aloud sessions
214489896|NCT06746012|OTHER|Educational Activity|Receive health coaching
214974240|NCT04735705|DEVICE|Cerviron|Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
214974241|NCT02546648|DRUG|Tranexamic Acid|
214974242|NCT02546648|DRUG|Tranexamic Acid Placebo|
214974243|NCT02546648|DRUG|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
214974244|NCT02221752|DIETARY_SUPPLEMENT|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate \[60 mg elemental iron\]) and the other with 0.40 mg folic acid from enrollment to delivery.
214974245|NCT02221752|DIETARY_SUPPLEMENT|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
214974246|NCT00226252|PROCEDURE|Instruction Only|Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.
214974247|NCT00226252|PROCEDURE|Instruction and Feedback|Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
214974248|NCT01645436|OTHER|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
214489897|NCT06746012|OTHER|Internet-Based Intervention|Use Healthy Buckeyes app
214489898|NCT06746012|OTHER|Internet-Based Intervention|Watch videos
214489899|NCT06746012|OTHER|Interview|Complete semi-structured interview
215084548|NCT00514345|GENETIC|gene expression analysis|
215084549|NCT00514345|GENETIC|polymorphism analysis|
215084550|NCT00514345|PROCEDURE|management of therapy complications|
214489900|NCT06746012|OTHER|Medical Device Usage and Evaluation|Wear Fitbiit and use exercise bands
215084551|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
215084552|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
214363193|NCT02123108|DRUG|Tacrolimus|Day #1 post-transplant to 6 months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL + 6 months to 1 year: maintain whole blood trough concentration of 5-8ng/mL
214489901|NCT06746012|OTHER|Questionnaire Administration|Ancillary studies
214489902|NCT06746012|OTHER|Supportive Care|Receive caregiver support
214489903|NCT06746012|OTHER|Survey Administration|Complete surveys
214489904|NCT06757985|PROCEDURE|a clinically guided resuscitation protocol,|a clinically guided resuscitation protocol, derived from EGDT and modified to match with the latest survival sepsis campaign guidelines
214489905|NCT06757985|PROCEDURE|a transthoracic bedside focused echocardiographic assessment|a transthoracic bedside focused echocardiographic assessment of the patient will be done, as a baseline ECHO in a three-step approach to monitor hemodynamics using Logiq P7, S5-1 ECHO probe;
214974249|NCT01935999|DEVICE|One piece closed pouch|A one piece closed pouch for the collection of stool from a colostomy stoma
214974250|NCT04718597|PROCEDURE|Robotic assisted inguinal hernia repair|Robotic assisted inguinal hernia repair with DaVinci Xi system instead of open repair
214974251|NCT04718597|PROCEDURE|Open inguinal hernia repair|Classical approach (open repair)
214974252|NCT01603680|PROCEDURE|Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow|Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
215084553|NCT03488589|DIAGNOSTIC_TEST|serum samples for HEV RNA PCR|serum samples HEV RNA PCR
215084554|NCT03419377|OTHER|Standard care and sexological counseling|6-8 sexological consultants in a period of six months
215084555|NCT06052111|DRUG|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
215084556|NCT06052111|DRUG|Group D (dexmedetomidine group)|The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
215084557|NCT02044601|DRUG|Onartuzumab|"Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I."
214974253|NCT01603680|PROCEDURE|Non circumferential spread in ultrasound-guided median and ulnar nerves block|Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
214974254|NCT00846144|DIETARY_SUPPLEMENT|copper sulfate|copper sulfate 3mg/d for a period of 6 months
215084558|NCT02044601|DRUG|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
215084559|NCT02044601|DRUG|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
215084560|NCT02044601|DRUG|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
215084561|NCT02044601|RADIATION|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
215084562|NCT00346502|DRUG|20% betulinic acid ointment|
215084563|NCT00346502|DRUG|BA|20% Betulinic Acid Ointment
215084564|NCT03037099|BEHAVIORAL|Enhanced GI Concept Education|
215084565|NCT04963114|BEHAVIORAL|art therapy|guided art tour and workshop
215084566|NCT06136572|DIAGNOSTIC_TEST|Rathus Assertiveness scale|Questionnaire completion
215084567|NCT00072891|BEHAVIORAL|telephone counseling|
215084568|NCT04220112|PROCEDURE|Real-Time Functional Magnetic Resonance Imaging (RT-fMRI)|RT-fMRI neurofeedback targeting down-regulation of the amygdala
215084569|NCT04220112|PROCEDURE|Sham Procedure|RT-fMRI with feedback non-contingently tied to their activation patterns (activation patterns from a prior participant)
214489906|NCT00177268|OTHER|Blood draw, skin biopsy or urine collection|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
214502759|NCT06842121|DRUG|Sodium Phosphates Injection|Inorganic phosphate (NaP) will be diluted with 500mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 60 mmol over 4 h
215084570|NCT03504813|OTHER|Physical activities program|To implement this line, the protocol of the VIVIFRAIL Project will be used as a reference. That protocol has different physical exercises, divided into itineraries, in order to adapt it to a person's capability. Several sessions of this research line will employ the use of videogames so that the elderly can explore new forms of physical activity and thus establish contact and expertise with new technologies. It is estimated that two sessions per week over two months are needed for each person to continue doing physical activity independently and with autonomy.
214363194|NCT02123108|DRUG|Mycophenolic Acid|Enteric coated mycophenolic acid 360-720 mg po bid
214363195|NCT02545777|DRUG|diclofenac sodium enteric-coated|
214363196|NCT02545777|DRUG|Oral medicine of tonifying spleen and descending turbid|Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
214363197|NCT02545777|DRUG|Steeping and washing medicine of descending turbid and clearing heat|Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
214363198|NCT02545777|DRUG|Wet wrapping medicine of descending turbid and clearing heat|Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
214363199|NCT05088070|DRUG|SPH 3348|2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach
214363200|NCT05088070|DRUG|SPH 3348|1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach
214363201|NCT05088070|DRUG|SPH 3348|2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
214489907|NCT06753032|DIAGNOSTIC_TEST|Positive Lens-Induced Defocus Using Spectacle Lenses (+2.00 D) for Myopic Participants|"Intervention Description: This group will be exposed to positive defocus induced by +2.00 D spectacle lenses. The lenses are designed to create optical blur to evaluate the effects on contrast sensitivity and visual fatigue. Measurements will be conducted at baseline, 2 weeks, and 4 weeks after exposure to assess changes in visual function."
214489908|NCT06753032|DIAGNOSTIC_TEST|Negative Lens-Induced Defocus Using Spectacle Lenses (-2.00 D) for Myopic Participants|"Intervention Description: This group will be exposed to negative defocus induced by -2.00 D spectacle lenses. The induced defocus will allow for the evaluation of its impact on contrast sensitivity and visual fatigue. Assessments will be carried out at baseline, 2 weeks, and 4 weeks."
214489909|NCT06753032|COMBINATION_PRODUCT|Positive Lens-Induced Defocus Using Spectacle Lenses (+2.00 D) for Non-Myopic Participants|"ntervention Description: This group will undergo positive defocus using +2.00 D spectacle lenses. The intervention aims to examine the effect of induced defocus on contrast sensitivity and visual fatigue in non-myopic participants. Data will be collected at baseline, 2 weeks, and 4 weeks."
214489910|NCT06753032|COMBINATION_PRODUCT|Negative Lens-Induced Defocus Using Spectacle Lenses (-2.00 D) for Non-Myopic Participants|Intervention Description: This group will experience negative defocus induced by -2.00 D spectacle lenses. The purpose is to evaluate how negative lens-induced defocus affects contrast sensitivity and visual fatigue in non-myopic participants. Measurements will be taken at baseline, 2 weeks, and 4 weeks.
214489911|NCT06755307|DIETARY_SUPPLEMENT|OMNiBiOTiC® Panda|Multistrain Probiotic OMNiBiOTiC® Panda containing: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactococcus lactis W58 and sunflower oil
214489912|NCT06755307|OTHER|Placebo|Placebo containing sunflower oil and maltodextrin
214489913|NCT06737770|PROCEDURE|osseointegrated surgery for transfemoral amputation|osseointegrated surgery for transfemoral amputation
214489914|NCT06807333|BEHAVIORAL|Pharmacist led Education|Pharmacist-led education for diabetic patients focuses on enhancing their understanding of the disease, improving self-management skills, and promoting better health outcomes. The education covers key aspects of diabetes, such as the importance of blood sugar control, the role of diet and exercise, and how to monitor blood glucose levels. Patients are also taught effective self-management strategies, including how to make healthy food choices, incorporate physical activity into daily routines, and manage potential complications. By providing tailored education, pharmacists aim to empower patients to take an active role in their care, which can lead to improved disease management, better glycemic control, and reduced risk of complications.
214489915|NCT06813547|BEHAVIORAL|emotional freedom techniques|emotional freedom techniques
214489916|NCT06813547|BEHAVIORAL|emotional freedom techniques and virtual reality|emotional freedom techniques and virtual reality
214489917|NCT06813547|BEHAVIORAL|control group/ none intervention|None intervention
214489918|NCT06814353|PROCEDURE|Intraoperative assessment of the site of origin and growth pattern|The assessment of the epicenter and extension and therefore the assumed origin of tumor growth is conducted by an experienced pediatric neurosurgeon blinded to group allocation based on the intraoperative impression. The anatomical features and site of origin are systematically documented on the surgical form in all cases of this study.
214489919|NCT06841757|BEHAVIORAL|Remote ischemic preconditioning|Patients will undergo Remote Ischemic Preconditioning using a blood pressure cuff inflated on the upper limb to induce ischemia and reperfusion, 40 mmHg above systolic pressure. The procedure will involve 3 cycles of inflation (5 minutes each) and deflation (5 minutes each) post intubation
214489920|NCT06813157|OTHER|MSC|The overall test process is as follows: screening period (V1): sign ICF, check the screening period, judge the criteria, record the baseline demographic information and the status of the subjects. Baseline period (V2): pre-transfusion assessment was performed to record the safety and other examinations of the subjects. During the treatment period (V3): according to the method and dose specified in the scheme, MSCs was treated for 5 times. Follow up period (V5): Safety and efficacy follow-up will be conducted at D14, M1, M2, M3, M6, M9, and M12 during the follow-up period.The subjects were followed up to M12 or those who met the withdrawal criteria withdrew early, whichever occurred first.
214502760|NCT03620500|BEHAVIORAL|Gross motor and developmental balance testing|Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
214363202|NCT05088070|DRUG|SPH 3348|4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
214974255|NCT05190796|OTHER|platelet indices|One sample of 20 mL venous blood was drawn by standard phlebotomy from all of the participants. This sample was kept for the evaluation of hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), erythrocyte count, leukocyte count, platelet count, platelet distribution width (PDW), MPV and plateletcrit by means of an automated commercial counter (Coulter counter, Max Instruments Laboratory). After this venous blood sample was conveyed into a sodium citrate tube, it was transported in a temperature-controlled container and collected in plastic provettes (Falcon blue cap) containing 3 mL of 3.8% sodium citrate dihydrate and 136 mM glucosium. Then the samples were sent to the laboratory.
214974256|NCT04630977|DIETARY_SUPPLEMENT|Multi-ingredient Pre-workout supplement|Every important issue has been detailed before.
214363203|NCT05088070|DRUG|SPH 3348|6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
214363204|NCT05088070|DRUG|SPH 3348|8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
214363205|NCT02450266|DEVICE|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
214363206|NCT02450266|DEVICE|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
214363207|NCT00189215|DEVICE|cardiac stabilizer instead of cardiopulmonary bypass|
214363208|NCT00954148|PROCEDURE|PET/CT|5 visits with PET/CT as only testing
214363209|NCT00954148|PROCEDURE|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
214363210|NCT03532802|DRUG|Metoprolol Succinate|"1. week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~2. week: steady state treatment with the maximum tolerated dose of the 1.week."
214489921|NCT06842108|OTHER|Exercise tolerance test|"• The ETT will be performed using Bruce protocol. The Bruce protocol is a standardized treadmill exercise test used in Exercise Tolerance Testing (ETT) to evaluate cardiovascular fitness and diagnose heart conditions. This protocol is divided into seven stages, each stage duration is 3 minutes and date will be recorded at the end of the each stage. The recorded data will include heart Rate, Rate pressure product (∆RPP), HRR1 and Blood Pressure.~STEP 1:~Patient Preparation~STEP 2:~Consent and history:~STEP 3:~Start of ETT:~• Graded Exercise~STEP 4:~Parameters Recorded During ETT:~* Heart Rate: Monitoring heart rate response to exercise stress.~* Exercise induced changes in heart rate (∆HR) along with change in rate pressure product (∆RPP) due to excercise intensity.~STEP 5:~Cardiopulmonary Fitness Assessment VO2 Max"
214489922|NCT06860451|DEVICE|TMS|The single-pulse TMS
214489923|NCT06861777|OTHER|Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy|"Neoadjuvant treatment:~adebrelimab 1200 mg/m2 d1+ paclitaxel d1/nab-paclitaxel d1,8, + cisplatin d1, Q2W×2 followed by chemoradiotherapy (paclitaxel /nab-paclitaxel + cisplatin + 41.4Gy/23f), surgical resection 4-8 weeks later neoadjuvant treatment."
214489924|NCT06861777|OTHER|chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin|"Neoadjuvant treatment:~chemoradiotherapy (paclitaxel /nab-paclitaxel + cisplatin + 41.4Gy/23f), followed by adebrelimab 1200 mg/m2 d1+ paclitaxel d1/nab-paclitaxel d1,8, + cisplatin d1, Q2W×2 surgical resection 4-8 weeks later neoadjuvant treatment."
214489925|NCT06861777|OTHER|TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]|"Neoadjuvant treatment:~TNT treatment \[TNT group one (phase 2) or TNT group two (phase 2)\] followed by surgical resection 4-8 weeks later adjuvant treatment: adebrelimab 1200 mg/m2 d1, W3Q, adjuvant treatment for one year"
214489926|NCT06861777|OTHER|Chemoradiotherapy|"Neoadjuvant treatment:~chemoradiotherapy (paclitaxel 50 mg/m2/nab-paclitaxel 60 mg/m2 d1, 8, 15, 22,29 + cisplatin 25 mg/m2 d1, 8, 15, 22,29 + 41.4Gy/23f), followed by surgical resection 4-8 weeks later. adjuvant treatment: non-pCR: adebrelimab 1200 mg/m2 d1, W3Q, adjuvant treatment for one year pCR: observation"
214489927|NCT06865755|DEVICE|integrated medication monitoring (MM) system|We have created a new integrated medication monitoring (MM) system consisting of baseline, 3-month, and 6-month surveys, smartphone-based ecological momentary assessment via an application installed on a smartphone (Digital Trails based on the UVA Sensus app), a wireless medication event monitoring system device (MEMS; Wisepill), and a wearable sensor (Fitbit), and data collected passively from smartphone sensors using the Digital Trails app. These sources of information will be used to understand predictors of medication taking behaviors and, after two months of monitoring, to deploy appropriate interventions which will be delivered via the Digital Trails app platform.
214489930|NCT06764056|DRUG|semaglutide|Participants receiving this intervention will be starting with a dose of semaglutide 0.25 mg. Physicians will follow Wegovy® Dosing Schedule guidelines, ending with a final dose of 2.4 mg at the fifth month. Type 2 diabetes participants wishing to stop at 1.0 mg will be allowed.
214489931|NCT06764056|OTHER|Diet|Participants receiving this intervention will be seeing a registered dietician at each visit. The individualized approach will be based on recent literature (mostly hypocaloric) by using different methods.
214489932|NCT06763809|DIETARY_SUPPLEMENT|PMS Capsule|Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
214489933|NCT06763809|DIETARY_SUPPLEMENT|Capsule Placebo|Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
214489934|NCT06763809|DIETARY_SUPPLEMENT|PMS Gummy|Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
214974257|NCT04630977|OTHER|Progressive Resistance Training|The information about it has been detailed in advance.
214974258|NCT04630977|BEHAVIORAL|Nutritional Patterns Guideline|This intervention has also been described in advance.
214363211|NCT03532802|DRUG|Placebo oral capsule|"1. week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~2. week: steady state treatment with the maximum tolerated dose of the 1. week"
214974259|NCT03370952|PROCEDURE|laproscopy|laparoscopic ovarian cystectomy
214974260|NCT03370952|PROCEDURE|combined laproscopic and minilaparotomy ovarian cystectomy|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:Delivery of affected ovary outside the abdominal cavity:~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
215084571|NCT03504813|OTHER|Relaxation training|Will take place with those participants who are included in the research lines of insomnia and risk of falls. It is estimated that two sessions per week for one month are needed.
214363212|NCT02228070|DEVICE|strabismus video goggles|
214363213|NCT00500877|BEHAVIORAL|Mood Management Phone Counseling for Smoking Cessation|Phone counseling addressed mood management and smoking cessation
215084572|NCT03504813|OTHER|Training of the pelvic floor|the intervention will apply to participants enrolled in the research line dealing with urinary incontinence during the six months of intervention, with a frequency of two sessions per week
214363214|NCT01443819|OTHER|Lumbar Transforaminal Epidural Corticosteroid Injection|"Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.~The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines."
214974261|NCT04493606|OTHER|SCI ProACTIVE Coaching (objective 1)|Peer coaches will conduct an assessment to understand patient's readiness, goals, barriers, preferences, and access to physical activity resources and mutually select tailored physical activity-enhancing strategies based on the assessment. These strategies include education (SCI exercise guidelines, safety, benefits, basics of physical activity, behaviour change techniques) and referral to appropriate peers, programs, and organizations. Goals will be based on the SCI Fitness Guidelines (targeting a goal of 20min of moderate to vigorous intensity aerobic exercise + 3 sets of strength training exercises for each major functioning muscle group at a moderate to vigorous intensity each 2x/week) and if ready, the Canadian SCI Physical Activity Guidelines (30 min 3x/week of moderate to vigorous intensity aerobic exercise + strength training 2x/ week). Ten 15-minute, video-conference or telephone sessions will be scheduled in accordance with patient needs and readiness with the peer coaches.
214363215|NCT01443819|OTHER|Physical Therapy|"Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).~Please note: There will be another PT evaluation at the end of 6 weeks."
214363216|NCT01443819|OTHER|Observation|If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
214363217|NCT04721925|BEHAVIORAL|Social media messaging|A motivational interviewing-based intervention delivered via private health coaching on social media for 8 weeks.
214363218|NCT03324893|DIAGNOSTIC_TEST|[F-18]-FCH PET/MRI|Subjects will undergo the \[F-18\]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
214363219|NCT01132326|DRUG|Droxidopa|Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
214363220|NCT01463722|OTHER|Amniotic fluid Lamellar Body Counting|fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
214363221|NCT05933759|BEHAVIORAL|Telemedical coaching|Individual telemedical coaching delivered by a nutritional consultant
214363222|NCT05933759|BEHAVIORAL|Low-Insulin-Method|Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps
214363223|NCT05373355|DRUG|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
214363224|NCT00952367|OTHER|Nasopharyngeal swab|Nasopharyngeal swab
214363225|NCT01926730|OTHER|Restriction diet|Selected food items will be limited in the participants diet
214363226|NCT01016080|DRUG|glutathione|250 mg capsules, twice daily, orally
214363227|NCT01016080|DRUG|placebo|250 mg capsules, twice daily, orally
214363228|NCT03414801|OTHER|Allergen Exposure|Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.
214363229|NCT00264420|DRUG|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
214363230|NCT04504331|DRUG|Infigratinib|Oral dose
214363231|NCT04504331|DRUG|Tamoxifen|Oral Dose
214363232|NCT04504331|DRUG|Omnipaque 350|IV contrast agent
214363233|NCT04504331|DRUG|Iopamidol|IV contrast agent
214363234|NCT04504331|DIAGNOSTIC_TEST|Computed tomography (CT)|Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.
214363235|NCT05120115|OTHER|Weight belt|Wearing belt around waist with various weights attached.
214363236|NCT06525493|PROCEDURE|Regional Anesthesia|The interventions are three different regional anesthesia techniques: Proximal Adductor Canal Block (ACB), iPACK (Interspace between the Popliteal Artery and the Capsule of the Posterior Knee), and Large-Volume Distal Adductor Canal Block (Large ACB distal). all three interventions were administered using ropivacaine 0.2%. However, there were differences in the volumes injected for each regional anesthesia technique. Proximal ACB: 15 mL of ropivacaine 0.2%. iPACK: 20 mL of ropivacaine 0.2%. Large ACB distal: 35 mL of ropivacaine 0.2%
214363237|NCT01911728|DRUG|MDV3100|Oral
214363238|NCT01911728|DRUG|Pioglitazone|Oral
214363239|NCT01911728|DRUG|Warfarin|Oral
214363240|NCT01911728|DRUG|Omeprazole|Oral
214363241|NCT01911728|DRUG|Midazolam|Oral
214363242|NCT02213562|DIETARY_SUPPLEMENT|200 mg of chrysanthemum flower oil|
214363243|NCT02213562|DIETARY_SUPPLEMENT|300 mg of chrysanthemum flower oil|
214363244|NCT02213562|DIETARY_SUPPLEMENT|400 mg of chrysanthemum flower oil|
214363245|NCT05018884|PROCEDURE|Observation of surgical site infections|No intervention is done, only observation of routine clinical practice
214363246|NCT04679181|OTHER|Telemedecine|telemedical consultation
214363247|NCT06313801|DRUG|Docetaxel|Docetaxel 50 mg/m2 intravenously on day 1
214363248|NCT06313801|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 on Day 1
214363249|NCT06313801|DRUG|Calcium folinate|200 mg/m2 2-hour intravenous infusion on day 1
214363250|NCT06313801|DRUG|Fluorouracil|2600 mg/m2 x intravenous infusion 24-hours (infusion of the samee of the total dose of fluorouracil for 48 hours) on day 1.
214363251|NCT06313801|PROCEDURE|Diagnostic laparoscopy|Access to the abdominal cavity by Hassen (3 trocars). Carboxyperitoneum - 12 mm of water column - stable pressure maintenance throughout the operation. Revision. Photo recording of 4 quadrants of the abdominal cavity from the paraumbilical port. The evaluation of the PCI index. The evaluation of other distant dissemination. Standard peritoneal lavage of 300 ml Sol. NaCl 0.9 % (37 ºС), with the exposure of 3-5 minutes (with Trendelenburg and Fowler position alternately) and the lavage aspiration, the transfer of the lavage for the cytological examination. Biopsy of perioneal lessions if needed.The operation is completed as standard with the extraction of laparoports and suturing of laparoport wounds.
214363252|NCT06313801|COMBINATION_PRODUCT|dPIPAC ( The description of the standard diagnostic laparoscopy procedure and the session of PIPAC (dPIPAC)).|Diagnostic laparoscopy described earlier and PIPAC session. The drugs for PIPAC - Docetaxel 50 mg/ m2 diluted with saline sodium chloride to a total volume of 200 ml. The rate of administration is 30 ml per minute. The maximum pressure in the injector system is 250 PSI. After the spray stage, the exposure is 30 minutes while maintaining the declared intraperitoneal pressure. After the exposure stage, only gas is removed from the abdominal cavity. The operation is completed as standard with the extraction of laparoports and suturing of laparoport wounds.
214363253|NCT02613819|RADIATION|SABR|"Renal cell carcinoma (RCC) is conventionally considered radioresistant to fully fractionated EBRT. In an effort to overcome the perceived radioresistance of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy."
214363254|NCT03574064|OTHER|Glucagon-Like Peptide-2 (GLP-2)|Glucagon-Like Peptide-2 (GLP-2) injection.
214363255|NCT03574064|OTHER|Glucose-dependent insulinotropic polypeptide (GIP)|Glucose-dependent insulinotropic polypeptide (GIP) injection.
214363256|NCT03574064|OTHER|GLP-2+GIP|GLP-2+GIP injection.
214363257|NCT03574064|OTHER|Placebo|Placebo injection.
214489935|NCT06763809|DIETARY_SUPPLEMENT|Gummy Placebo|Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
214489936|NCT06886061|DIETARY_SUPPLEMENT|The capsules contain Ergothioneine.|Take one 30 mg Ergothioneine capsule orally every day for a period of eight weeks.
214489937|NCT06886061|DIETARY_SUPPLEMENT|The capsules do not contain Ergothioneine.|Take one capsule devoid of Ergothioneine orally every day for a period of eight weeks.
214489938|NCT06885983|PROCEDURE|implant placement|Late implant placement without regenerative therapy
214489939|NCT06885983|PROCEDURE|Guided bone regeneration|Application of collagen membrane after implant placement.
214489940|NCT06882837|BEHAVIORAL|BUMP app|Participants in the experimental group will have access to the BUMP app, which aims to support them to control the amount and rate of weight gain during pregnancy, from baseline (early or mid-pregnancy) until they give birth. The app will prompt participants to regularly self-monitor their weight gain during pregnancy, and will provide access to a weight gain chart for tracking. Participants will receive feedback notifications about their weight gain trajectory, and will have access to information and tips on weight management during pregnancy.
214489941|NCT06891807|DEVICE|Robotics Assisted TKA|Skywalker Robotics Assisted TKA using Evolution Medial Pivot Knee
214489942|NCT06891807|DEVICE|Augmented Reality assisted TKA|Pixee Knee+ assisted TKA using Evolution Medial Pivot Knee
214489943|NCT06892132|OTHER|Supervised feeding intervention|Participants will be fed a peanut product during a supervised feeding visit and observed for an allergic reaction.
214489944|NCT06892132|OTHER|Handout|Participants will receive a handout on how to introduce peanut products.
214489945|NCT06763302|DRUG|Blinatumomab|The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
214489946|NCT06763029|DRUG|Irinotecan liposomes combined with cetuximab + vermofenib|Vermofenil 960mg orally twice daily; Irinotecan liposomes, 70mg/m2, d1, 90 min intravenously, Q2W; Cetuximab 500mg/m2, d1, Q2W;
214363258|NCT00708916|DRUG|CC-10004|20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
214363259|NCT01232010|DRUG|Mirodenafil|50mg Single Oral Dose of
214363260|NCT04563468|PROCEDURE|Strength inspiratory muscle training|Two training sessions per day consisting of 30 breaths (against external load of \~50% Pi,max; 4-5 minutes per session), 7 days/week (once/month supervised at the research center), for 6 months will be performed using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) according to an established method. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain external load at \~50% of Pi,max values. Ratings of perceived inspiratory effort on a modified Borg scale (4-5 out of 10) will also be used to support decisions on increasing training load.
214363261|NCT04563468|PROCEDURE|Endurance inspiratory muscle training|Two daily sessions of 30 breaths using TFRL device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) and will train at an inspiratory load of no more than 10% of their initial Pi,max. This training load will not be changed during the entire study period. Participants in the control group will be offered the active treatment upon completion of the study.
214363262|NCT02934152|DRUG|H pylori eradication|H pylori eradication
214363263|NCT02934152|OTHER|H pylori eradication timing|Early or late eradication
214363264|NCT01265602|DRUG|LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
214363265|NCT01265602|DRUG|LASW1510|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
214363266|NCT01265602|DRUG|vehicle of LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
214363267|NCT00065585|PROCEDURE|Accupuncture|
214489947|NCT06763861|OTHER|Biopsy|Biopsies from EAS
214489948|NCT06762847|DEVICE|Use of Conventional Silicone Prosthetic Liner|At this stage participant who will be fitted with a standard silicone liner typically used for transtibial prosthetics. Over a set duration, we will assess the liner's performance, particularly in terms of durability, comfort, skin health, and fit stability. Acting as the control group, this cohort will provide essential baseline data for comparison with the innovative prosthetic liner.
214489949|NCT06762951|OTHER|Pilates mat exercices|Pilates mat exercise which consists of (single leg stretch + Pelvic press + Swimming + Opposite arm and leg reach + Side to side), 3 sets of 10 repetitions.
214363268|NCT00850889|DEVICE|Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
214363269|NCT00850889|DEVICE|A gel of hyaluronic acid (concentration of 20 mg/mL)|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
214489950|NCT06762951|OTHER|Segmental control exercises|Segmental control exercise which consists of (Segmental control over primary stabilizers, Exercises in closed chain, and Exercises in open chain)
214363270|NCT05294796|COMBINATION_PRODUCT|Short course of antibiotherapy|Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
214363271|NCT05294796|COMBINATION_PRODUCT|Long course of antibiotherapy|Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
214363272|NCT04344639|OTHER|the incidence, risk factors, treatment, prognosis of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country|With this project, which is planned as a national multicenter prospective study, the incidence of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country and the risk factors associated with the disease, especially the detailed feeding history of the patient (when the first feeding is nourished, antibiotics and other treatments that are being used). Most epidemiological data such as the most common stage of the disease, treatment, prognosis, comparison with the data of other countries will provide important information for the neonatal health of our country.
214974262|NCT04493606|BEHAVIORAL|Implementation Intervention (objective 2)|"A training on how to deliver the ProACTIVE intervention will be delivered. Day 1 training will include an overview of the intervention, demonstration of the delivery of the intervention, and behavioural practice. Interventionists will practice delivering the intervention and record issues or questions to bring to the day 2 training. Day 2 training will include a refresher on intervention content, barriers identified during in-clinic/community practice will be addressed, and further behavioural practice with volunteer clients with additional feedback provided.~The trainer (Dr. Jasmin Ma) will provide monitoring and feedback during the first two months of implementation. Community of practice meetings will be held as needed to discuss challenges and facilitators to implementation. Feedback provided during community of practice meetings will be collected and used for iterative quality improvement of the intervention approaches."
214974263|NCT01929889|DRUG|Iloperidone|Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
214974264|NCT03652818|DRUG|Pre-Op pregabalin|Pre-op pregabalin will be administered 60 min prior to surgery.
214974265|NCT03652818|DRUG|Pre-Op Placebo 1|Placebo 1 will be administered 60 min prior to surgery.
214974266|NCT03652818|DRUG|Post-Op pregabalin|Post-op pregabalin will be administered Post-operatively.
214974267|NCT03652818|DRUG|Post-Op Placebo 1|Placebo 1 will be administered post-operatively.
214974268|NCT03652818|DRUG|Post-Op Placebo 2|Placebo 2 will be administered post-operatively.
214974269|NCT03652818|DRUG|Post-Op acetaminophen|Acetaminophen will be administered Post-operatively.
214974270|NCT03271138|DIETARY_SUPPLEMENT|Bifidobacterium infantis NLS super strain (Natren LIFE START®2)|2 capsules, 3 times per day, for daily total of 12x10\^9 CFU Bifidobacterium infantis NLS super strain
214974271|NCT03271138|OTHER|Placebo|2 capsules, 3 times per day, containing rice flour, hydroxypropyl and methylcellulose
214974272|NCT03034369|OTHER|Access to Care|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.
214974273|NCT03034369|OTHER|Depression Screening|Analysis of health care claims data for depression screenings at baseline and 12 months.
214974274|NCT03034369|OTHER|Patient-Provider Relationship|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.
214974275|NCT03034369|OTHER|Patient-Clinic Interactions|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.
214974276|NCT03034369|OTHER|Stigma|Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.
214974277|NCT03034369|OTHER|Provider Continuity|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.
214974278|NCT03034369|OTHER|Symptom Severity|Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.
214974279|NCT03034369|OTHER|Diagnoses|Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.
214974280|NCT03034369|OTHER|Social support|Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.
214974281|NCT03034369|OTHER|Preventive Screening|Analysis of health care claims data for preventive screenings at baseline and 12 months.
214363273|NCT01146301|DRUG|Clopidogrel|All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting
214363274|NCT02486601|DRUG|nab-paclitaxel|nab-paclitaxel : 150 mg/m2 D1 every 2 weeks
214363275|NCT02486601|DRUG|FOLFOX|Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
214974282|NCT03034369|OTHER|Inpatient Hospitalization Utilization|Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.
214974283|NCT03034369|OTHER|Inpatient Readmissions|Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.
214974284|NCT03034369|OTHER|Post-Admission follow-up|Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
214974285|NCT05724303|OTHER|8-week neuromuscular training program|Training program consisting of two neuromuscular training sessions per week
214974286|NCT06032728|DRUG|Sunitinib|The investigators randomly assign multimodal recurrence scoring system defined high risk patients of stage III ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation
214974287|NCT03583957|DEVICE|Observational only|Device is only observational and used to record EEG.
214489951|NCT06762951|OTHER|Traditional physical therapy|Traditional physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl-up exercise in supine, Back extensors exercise in prone, and Hip extensors exercises in prone along with ultrasound and Transcutaneous electrical nerve stimulation (TENS)
214489952|NCT06790927|DRUG|Usual Care|The doctor prescribes medication for patients and follow-up every 3 months
214489953|NCT06790927|DRUG|Standard Medical Therapy|The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks treatment, amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets after one month, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.
214489954|NCT06764394|OTHER|Exercise|home based exercise 5 days/week
214489955|NCT06764394|OTHER|Exercise|home based exercise plus myofacial release exercise Myofascial release exercises will continue for 6 weeks, 2 sessions per week and each session will continue for 30 minutes.All evaluations will be performed at the beginning of radiotherapy treatment and at the end of the 6th week.
214489956|NCT04261790|DRUG|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
214489957|NCT06766994|OTHER|intrathecal morphine|Preoperatively, patients will be injected with 200 μg morphine intrathecally with a 27G pencil point spinal needle at the L4-L5 or L3-L4 intervertebral space in a sitting position.
214489958|NCT06766994|OTHER|Erector Spinae Plane Block|Preoperatively, patients will be placed in the prone position before the operation and an ESPB block will be applied bilaterally at the T9 vertebra level with the help of USG. 0.25% bupivacaine 20 ml will be used bilaterally as the blocking fluid.
214489959|NCT06361329|DRUG|Homoharringtonine|Intravenous infusion
214489960|NCT06361329|DRUG|venetoclax|Orally by mouth
214489961|NCT06361329|DRUG|Cytarabine|subcutaneous injection or Intravenous infusion
214974288|NCT03583957|BEHAVIORAL|Psychological and Behavioral interaction with a seizure forecasting mobile app|Participants will be interacting with a mobile app to input perceived behavioral (e.g., number of hours slept and sleepiness) and psychological (perceived stress).
214974289|NCT03583957|COMBINATION_PRODUCT|Seizure Alerting and Prediction System|The combination of Epilog (device) and the Aura app (psychological and behavioral interaction) will be used to create a real-time seizure alerting and an hourly seizure forecasting system.
214974290|NCT04449965|DRUG|Povidone-iodine|This will be performed twice daily for two weeks.
214974291|NCT04449965|DRUG|Placebo|This will be performed twice daily for two weeks.
214974292|NCT02908139|DEVICE|BR-102 plus PWA|Monitoring of Arterial Stiffness and Central Aortic Pressure
214974293|NCT02908139|DEVICE|Tanita MC780 MA S|The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
214974294|NCT05190614|DIAGNOSTIC_TEST|The biotype of gingiva|The biotype of gingival was determined by periodontal probe.
214974295|NCT03735290|BIOLOGICAL|ilixadencel|Intra-tumoral injection
214974296|NCT03735290|DRUG|Pembrolizumab|Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
214974297|NCT05606861|OTHER|Mindfulness Based Interventions in Pediatric Nurses|This intervention are structured mindfulness program including meditation and breathing techniques .
214974298|NCT04938791|OTHER|Isometric activity|Participants will do elevation of upper limbs and mantain a 90º degree flexion position in an unsupported way.
214974299|NCT04535427|DRUG|L-arginine|Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
214489962|NCT06361329|DRUG|G-CSF|subcutaneous injection
214489963|NCT06361329|DRUG|Vindesine|Intravenous infusion
214489964|NCT06361329|DRUG|Daunorubicin|Intravenous infusion
214489965|NCT06361329|DRUG|cyclophosphamide|Intravenous infusion
214489966|NCT06361329|DRUG|Dexamethasone|Intravenous infusion or orally
214489967|NCT06361329|DRUG|L-ASP|subcutaneous injection
214489968|NCT04366310|DEVICE|capillary refill index|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
214974300|NCT04535427|DRUG|Placebo|Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
214974301|NCT01737606|DEVICE|Fast Cerebral Pulsatility Imaging|Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
214974302|NCT03597802|OTHER|Exercise at workplace - Three times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
214974303|NCT03597802|OTHER|Exercise at workplace - Four times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
214974304|NCT01930539|DEVICE|Ultraviolet B lamp|Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky, USA) was designed to use Ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
214974305|NCT04405258|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
214974306|NCT04405258|PROCEDURE|Left posterior wall isolation|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
214974307|NCT00624091|PROCEDURE|Cardiac surgery|Cardiac surgery within 48 hours of randomization
214974308|NCT00624091|PROCEDURE|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
214974309|NCT02960412|DRUG|furosemide|10mg lasix given intraoperatively
214974310|NCT02960412|DRUG|Normal Saline|Normal saline given intraoperatively as placebo
214974311|NCT02217748|OTHER|Survey questionnaire|
214974312|NCT02292576|OTHER|Cocoa Pure|Cocoa Pure.
214363276|NCT03882879|BEHAVIORAL|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 6 months, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief
214363277|NCT03882879|BEHAVIORAL|Pre-Intervention Study Visit|At the pre-intervention study visit, the study logistics will be reviewed, informed consent process will occur, the subject will complete a battery of pre-intervention assessments focused on overall mobility, gait, balance, mood, cognition, and quality of life, and the subjects will be prompted to share their expectations of and goals for the karate classes.
214363278|NCT03882879|BEHAVIORAL|Bimonthly Online Survey|All participants in both arms will receive a personalized email every two months directing them to indicate how frequently they have attended karate classes, how frequently they have engaged in exercise, how frequently they have fallen, whether their PD medication regimen has changed, and they will complete brief surveys about mood, camaraderie, and overall quality of life.
214363279|NCT03882879|BEHAVIORAL|6-month Study Visit|All participants in both arms will complete questionnaires and assessments of their PD symptoms, cognition, mood, camaraderie, and quality of life. Subjects will meet with a member of the study team to complete a series of physical and cognitive assessments. At this visit, subjects will review the initial expectations they shared at the pre-intervention visit and indicate if they thought their goals were achieved for the class.
214363280|NCT03882879|BEHAVIORAL|12-month Study Visit|At the 12-month study visit, the assessments from the baseline and 6-month study visit will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
214363281|NCT01712100|DRUG|Irbesartan|
214363282|NCT01712100|DRUG|Avapro|
214363283|NCT01641393|DRUG|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
214363284|NCT01641393|DRUG|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
214363285|NCT06068621|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"1. Azacytidine (75 mg/m2/day, days 1 to 7).~2. Cytarabine (75-100 mg/m2 bid, days 1 to 5).~3. Aclacinomycin(20 mg/day, days 1,3,5).~4. Chidamide (30 mg/day , days 1,4,8,11).~5. Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~6. Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
214974313|NCT02292576|OTHER|Placebo|Placebo.
214363286|NCT06068621|DRUG|"3+7"|"IA regimen:~1. Idarubicin (8-10 mg/m2) for 3 days .~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~1. Daunorubicin(60 mg/m2) for 3 days.~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."
214363287|NCT00298922|DRUG|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
214363288|NCT00298922|DRUG|Placebo|tablet orally thrice weekly for 24 weeks
214363289|NCT00959543|OTHER|MRI|MRI and clinical investigation
214489969|NCT04366310|PROCEDURE|rewarming|warming fingertip skin temperature using an instant hot pack
214489970|NCT06263166|BEHAVIORAL|Stress ball intervention|Women should squeeze and loosen the stress ball given to them during the vaginal examination and continue this process until the examination is completed.
214489971|NCT05934292|DRUG|Enlicitide Decanoate|Oral dose
214489972|NCT06565780|DEVICE|Device under test evaluation against references|"Subjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.~Device under Test: Aktiia.product-G0 References: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate."
214489973|NCT06542666|OTHER|Cognitive Functional Therapy|"The intervention focuses on addressing the maladaptive cognitive, physical, and lifestyle behaviors related to the disorder.~Cognitive functional therapy will focus on factors considered to contribute to the pain disorder, addressing the following topics:~1. The multidimensional nature of persistent pain, beliefs, emotions, and behaviors (movement and lifestyle) that can reinforce a vicious cycle of pain sensitization and disability.~2. Specific functional training designed to normalize maladaptive and provocative postural and movement behaviors as directed by the individual's presentation.~3. Targeted functional integration into daily activities that are avoided and/or provocative for the patient.~4. Counseling on physical activity and lifestyle, which will include promoting a gradual increase in physical activity based on the individual's preference and availability, advice on sleep hygiene, stress management strategies, and social re-engagement"
214974314|NCT05843409|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction may be associated with short-term effects on pain intensity and physical functioning. Patients will be randomized into 2 groups. The experimental group will receive MBSR sessions, with the frequency and duration specified in the study protocol. The sessions will be free and carried out by expert staff
214974315|NCT02090296|DRUG|Hydroxyurea|
214974316|NCT02090296|OTHER|Placebo|
214974317|NCT05869799|DIETARY_SUPPLEMENT|Vigiis 101 Lactobacillus Capsules|Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.0 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
214974318|NCT05869799|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
214974319|NCT05609669|OTHER|CADENCE program|The CADENCE program will consist of an integrated care pathway between the OBOT clinic, obstetric clinic, pediatric clinic, and behavioral health with multiple entry points, including emergency rooms, existing mobile harm reduction clinics, obstetric clinics, and delivery facilities. We also seek to provide wrap-around care for these families with peer support, care navigation, and robust community support, using existing Hillsborough County resources such as doula programs, Healthy Start, and other home visiting programs.
214489974|NCT06542666|OTHER|Exercises|"Individuals allocated to this group will perform stretching and strengthening exercises. The self-stretching exercises will target the upper trapezius and posterior shoulder region. Each stretching exercise will be performed for 3 repetitions of 30 seconds, with an interval of 10 seconds between repetitions.~The strengthening exercises will be performed using resistance elastic bands. Three sets of 10 repetitions will be performed for each strengthening exercise, with 1 minute of rest between sets. The strengthening exercises will target the lower and middle trapezius, anterior serratus, and the external and internal rotators of the shoulder."
214489975|NCT06726941|OTHER|Physiotherapy and Rehabilitation Practices|It was planned to give the participants a routine stroke rehabilitation program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, balance exercises, walking training and 20 minutes of bicycle ergometry, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. It was planned to give passive bicycle ergometry to patients without voluntary muscle movement and muscle strength, and active bicycle ergometry to participants with voluntary muscle movement and muscle strength, with the bicycle rehabilitation. It was planned to apply the exercise program to the patients for 5 days a week and for a total of 30 sessions. It will be recommended that they continue the medical treatment they are using during the treatment program. Routine evaluations will be made by the physiatrist before the rehabilitation program starts and 2 tubes of venous blood will be taken from the patients by an experienced nurse
214489976|NCT06744257|OTHER|Online Education tool|An online education tool that contains 4 modules
214489977|NCT06790667|DEVICE|Low Level Laser Therapy|Participants in this arm will receive Low-Level Laser Therapy (LLLT) using a Gallium Aluminum Arsenide (GaAlAs) semiconductor diode laser. The treatment involves a wavelength range of 650-808 nm with a power output of 775 mW. The therapy is administered by exposing tender points around the temporomandibular joint (TMJ) to the laser for 2 minutes per session. Each participant will receive treatment on alternate days (three sessions per week) over the course of three weeks. The goal is to assess the effectiveness of LLLT in reducing pain and improving mouth opening in patients with myofascial pain associated with Temporomandibular Disorders (TMD).
214489978|NCT06790667|DEVICE|Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)|Participants in this arm will undergo Transcutaneous Electrical Nerve Stimulation (TENS), utilizing a four-electrode unit. The device will be set to deliver electrical impulses at a frequency of 150 Hz with a pulse width of 200 µs. Electrodes will be placed over the cutaneous region between the TMJ and coronoid process to stimulate the trigeminal and facial nerves. Each treatment session will last 15 minutes and occur on alternate days, three times a week for three weeks. This therapy aims to provide pain relief and improve jaw function for patients suffering from myofascial pain associated with TMD.
214489979|NCT06745544|OTHER|Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)|The Rhythm- and Multitask-Based Activity (RYMA) program is a unique cognitive-motor exercise intervention designed for older adults with diabetes. It incorporates rhythm-based multitasking exercises, performed to improvised piano music, combined with Activities of Daily Living (ADL)-focused exercises. The intervention targets physical (strength, balance, and coordination) and cognitive (executive function, reaction time) components to reduce fall risk, improve bone health, and optimize cardiovascular outcomes. Delivered over 26 weeks, the program emphasizes social interaction to enhance adherence and long-term engagement.
214489980|NCT06834529|GENETIC|CAR2219-T cells|"Genetic: CAR2219-T cells Each subject will be infused with single dose of CD2219-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 5×10\^5 /kg, the medium dose is 1×10\^6 /kg, and the high dose is 2×10\^6 /kg.~Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD2219-CAR-T cells.~Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD2219-CAR-T cells."
214489981|NCT06769074|BIOLOGICAL|Platelet Rich Plasma|PRP injection into the midurethra and its instillation into urinary bladder
214489982|NCT06782594|DRUG|Mosapride Citrate Injection(high)|Mosapride Citrate Injection, iv, 8mg, bid, for 3 to 5 days
214489983|NCT06782594|DRUG|Mosapride Citrate Injection(low)|Mosapride Citrate Injection, iv, 4mg, bid, for 3 to 5 days
214489984|NCT06782594|DRUG|Placebo|Placebo, iv, bid, for 3 to 5 days
214489985|NCT06791226|DIAGNOSTIC_TEST|18F-AlF-FAPI PET/CT, 18F-FDG PET/CT|Subjects with orbital neoplasms underwent contemporaneous 18F-AlF-FAPI and 18F-FDG PET/CT for diagnosis and staging.
214489986|NCT06785766|BEHAVIORAL|Yoga-Based Exercise Program|This intervention is an 8-week yoga-based exercise program conducted with 60-minute sessions twice a week. The program aims to improve flexibility, mobility, and overall well-being. Each session consists of 5 minutes of warm-up, 5 minutes of breathing exercises, 40 minutes of yoga postures, 5 minutes of deep relaxation, and 5 minutes of meditation. The intervention adapts yoga postures based on participants' individual needs, offering a flexible approach. The difficulty of the yoga flows gradually increases over the 8 weeks. When necessary, postures are adapted using props like blocks, straps, blankets, and chairs. A physiotherapist guides participants, demonstrating correct techniques and providing verbal instructions. This program combines yoga, breathing exercises, and meditation to enhance physical and mental well-being, promoting long-term health benefits.
214489987|NCT06769373|DEVICE|Whirlpool Bath|This group of participants will receive an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, whirlpool bath (32-38 °C) 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.
214489988|NCT06769373|DEVICE|Contrast Bath|This group of participants will recieve an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, contrast bath therapy which consist of 4 minutes hot water (38°C) followed by 1 minute cold water (10°C) periods for 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.
214502761|NCT06515301|BEHAVIORAL|Intervention 1: Structured nurse-led telephone call reminders. Intervention 2: Home-visit reminders by health extension workers. Intervention 3: Application-based automated SMS text reminders.|Information already available
214502762|NCT05460741|OTHER|integrated exercise approach|Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.
214363290|NCT05493592|BIOLOGICAL|Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)|"Supervised re-training by an Adapted Physical Activity (APA) professional combined 100 g of pigeon peas 3 times a week~Physical activity protocol is standardized. It's the same than in the control arm.~The preparation of pigeon peas and their consumption will be standardized in terms of species cultivated, geographical origin and culinary preparation.~A follow-up of the food intakes standardized plus follow-up logbook, recording the weekly pigeon pea intake, will also be filled out by the participant. The addition of 100 grams of pigeon peas to the diet corresponds to an intake of about 980 mg of polyphenols, 360 mg of carotenoids and 570 mg of vitamin C (24). Thus, the patient's diet will be fortified with approximately 420 mg of polyphenols per day. This level of polyphenol supplementation is known to have beneficial effects on human health."
214363291|NCT02448251|DRUG|AC0010MA|Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
214363292|NCT03404570|DRUG|Dexmecamylamine HCl|Investigational drug
214363293|NCT03404570|OTHER|Placebo|Oral tablet containing no active drug.
214489989|NCT06766045|DIAGNOSTIC_TEST|Diaphragmatic Ultrasound|"Diaphragmatic ultrasound was performed bedside in the ICU with supine position. Diaphragmatic thickness was measured by placing the ultrasound on 8th-10th intercostal space between anterior and mid-axillary line with marker at 12 o'clock. B-mode ultrasound was used to measure the distance between thoracic and abdominal diaphragm which resulted in the diaphragmatic thickness at inspiration (DTi) and diaphragmatic thickness at expiration (DTe).~The ultrasound was then placed on the subcostal area between anterior and mid-axillary line with marker at 12 o'clock to observe the diaphragmatic motion on each side. Measurement of diaphragmatic excursion as well as recording and evaluation of diaphragmatic sliding and motion were performed during both inspiration and expiration using M-mode."
214363294|NCT03340402|RADIATION|Accelerated Partial Breast Irradiation|Proton radiation
214363295|NCT03340402|DEVICE|AlignRT|AlignRTTM uses infrared imaging to capture the 3D data of the patient's position to ensure accuracy of treatment delivery
214363296|NCT01498432|DRUG|Heliox21|For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
214489990|NCT06766045|DIAGNOSTIC_TEST|Fluoroscopy|Fluoroscopy test was conducted in cathlab with supine position and anteroposterior (AP) projection for at least 5 breathing cycles. The fluoroscopy recording was then expertised and interpreted by the pediatric cardiologist in charge.
214502763|NCT05460741|OTHER|educational program|educational program related to menstrual cycle will be given to females.
214502764|NCT06609187|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
214974320|NCT01591148|DRUG|propofol|Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
214974321|NCT04933318|OTHER|TENS|Transcutaneus electrical nerve stimulation (TENS)- analgesic current therapy
214974322|NCT04933318|OTHER|shamTENS|shamTranscutaneus electrical nerve stimulation (shamTENS)- analgesic current therapy
214363297|NCT01498432|DRUG|Air O2|For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
214974323|NCT04933318|OTHER|IFC|Interferential current therapy (IFC)- analgesic current therapy
214974324|NCT04933318|OTHER|shamIFC|shamInterferential current therapy (shamIFC)- analgesic current therapy
214974325|NCT03468088|BEHAVIORAL|Hand grip strengthening|Handgrip strengthening exercises will be added to the experimental group. This exercise is chosen based on literature review of EMG and biomechanical studies. Adjustable heavy grip hand gripper will be used as handgrip resistance at 10 repetitions maximum (RM). The exercise will be performed in standing position the patient's back will be rested in a wall, arm at 30º abduction, 60º abduction 90º abduction \& with 90º ER. In this positions, the patient will be performed 3 sets of 10 squeezes each at a 1-minute interval.
214974326|NCT03468088|BEHAVIORAL|Conventional treatment|Ultrasound therapy will be used to treat both groups. Ultrasound will be applied; while the patient will be seated in an adjustable chair with back support, feet on the floor. The chair will be positioned beside a table. The patient's shoulder will be rested on the table beside the body and elbow will be flexed at 90°. A round-headed probe will be used that is put in direct contact with the patient's skin over the shoulder joint. Ultrasound gel will be used on all surfaces of the head in order to reduce friction and assist in the transmission of the ultrasonic waves.
214974327|NCT02982707|DRUG|BMS-986177|Single oral dose
215094452|NCT00681993|OTHER|Standard Docetaxel, Doxorubucin and Cyclophosphamide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
214363298|NCT00435279|DRUG|Eszopiclone|Eszopiclone 3 mg
214363299|NCT00435279|DRUG|Placebo|Placebo
214363300|NCT00435279|DRUG|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
214363301|NCT06629363|OTHER|biobank|"The following samples will be collected :~* Serum samples and plasma sample: inclusion visit and follow up visit~* Urines samples : inclusion visit and follow up visit~* blood DNA: inclusion visit~* Blood RNA: inclusion visit and follow up visit"
214363302|NCT04409119|DEVICE|HIS/LBB pacing|3830 lead to HIS or LBB
214363303|NCT04409119|DEVICE|LV pacing|LV lead in a CS branch
214363304|NCT00664937|DRUG|montelukast sodium|single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
214363305|NCT00664937|DRUG|Comparator: placebo (unspecified)|single oral dose, before exercise challenge, of Pbo; 7 week duration.
214363306|NCT06488521|BIOLOGICAL|Complarate|Complarate solution, a subcutaneous injection at a single dose of 162 mg.
214363307|NCT06488521|BIOLOGICAL|Actemra®|Actemra® solution, subcutaneous injection at a single dose of 162 mg.
214363308|NCT06488664|BIOLOGICAL|GNR-068|GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.
214363309|NCT06488664|BIOLOGICAL|Stelara®|Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.
214363310|NCT05806229|PROCEDURE|Mid transverse process to pleura block (MTP)|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura.After negative aspiration to avoid intravascular injection levobupivacaine 0.5% and dexamethazone 4mg total volume 21ml will be injected
214363311|NCT05806229|PROCEDURE|Mid transverse process to pleura Sham block|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura. with 2ml normal saline subcutaneously will be injected
214363312|NCT05391854|DIETARY_SUPPLEMENT|Pep2dia|700 mg Pep2Dia® 15 min prior to breakfast and 700 mg Pep2Dia® 15 min prior to dinner
214974328|NCT06958484|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab|The patients with high-risk recurrence will be treated with Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment .
215084573|NCT03504813|BEHAVIORAL|Counseling about occupational performance|After the physical activity and relaxation programs, the counselling will start. With each participant, routines and daily activities will be planned that will be adequate according to different recommendations about urinary incontinence, insomnia and risk of falls. Different performance guidelines will be established in order to establish a good balance between activities. The guidelines can include the recommendations about adjustments to the environment. It is estimated that three sessions per week for two months are needed to incorporate advice and routines into the daily lives of participants.
215084574|NCT02725593|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
215084575|NCT02725593|DRUG|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
214363313|NCT05391854|DIETARY_SUPPLEMENT|Placebo|700 mg placebo 15 min prior to breakfast and 700 mg placebo 15 min prior to dinner
214363314|NCT05934812|DRUG|Oxytocin nasal spray|24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily
214363315|NCT05934812|DRUG|Placebo|Placebo liquid nasal spray administered twice-daily
214363316|NCT01525316|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
214363317|NCT01525316|DIETARY_SUPPLEMENT|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
214974329|NCT03091153|OTHER|Medication Review|In depth medication review with a focus on deprescribing
214974330|NCT01241279|DEVICE|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
214974331|NCT01241279|DEVICE|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
214363318|NCT02954354|DRUG|Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
214363319|NCT02954354|DRUG|Placebo to Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
214363320|NCT02954354|DRUG|Oseltamivir|75 mg capsules taken orally
214363321|NCT02954354|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir 75 mg capsules
214363322|NCT05166967|DRUG|Individual Antithymocyte globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
214363323|NCT05166967|DRUG|Antithymocyte globulin|A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
214363324|NCT06959992|BEHAVIORAL|Metaverse group|The activities will be conducted in a Metaverse platform with immersive features. Each session is divided into two parts (\~2 hours duration). First, a specific social context will be represented (environmental features and static avatars) and a microaggression scenario (adapted for the chosen context) will be described. Participants are engaged in the conversation by the moderator in order to identify various psychological manifestations regarding the context (according to the SORC model) and to come up with solutions for the main, model avatar (part of the research team). Second, the debriefing part of the session will allow participants to talk about their own experiences alongside specific self-compassionate exercises. Repeated measurements will be required: pre-intervention, mid-intervention, post-intervention and at follow-up (after 3 months).
215084576|NCT05764031|OTHER|Clinical pilates exercise|Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.
215084577|NCT05764031|OTHER|Aerobic exercise|Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
214363325|NCT06959992|BEHAVIORAL|Online asynchronously|The activities will be conducted asynchronously in an online platform where participants will be guided by the moderator through the same type of activities. First, a social context with specific microaggressions will be presented in a text format followed by the same requirements for participants (identifying various psychological manifestations regarding the context and coming up with solutions for the problematic situation). Second, participants will have the transcripts of several self-compassionate exercises to be done independently. A discussion forum will also require their active engagement. Repeated measurements will be required pre-interventions, mid-intervention, post-intervention and at follow-up (3 months).
214363326|NCT06411288|DRUG|AOC 1001 (del-desiran)|Del-desiran will be administered by intravenous (IV) infusion.
214363327|NCT06411288|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
214363328|NCT05867654|DRUG|Amoxicillin-clavulanate 875mg/125mg q12hrs|Oral antibiotic used based on indication
214363329|NCT05867654|DRUG|oral clindamycin 300mg q6hrs|Oral antibiotic used based on indication
214489991|NCT06765421|BEHAVIORAL|Intervention Group|"Intervention group activity involves three components:~1. Intervention group GPs will be provided with a long COVID 'toolkit'. The toolkit will be prepared by the study team in collaboration with expert clinicians and public and patient representatives as a resource for GPs to use in patient care.~2. GPs will attend an expert clinician / patient led long COVID educational session grounded in the findings of the toolkit.~3. Applying learnings to date, each GP will conduct case reviews of eight patients with long COVID attending their practice and provide patient care as appropriate."
214489992|NCT06767124|DIETARY_SUPPLEMENT|Ketogenic Supplement|Commercially available ketone ester drink
214489993|NCT06767124|OTHER|Placebo Drink|Placebo drink containing sunflower oil.
214489994|NCT05841420|DRUG|Gemcitabine|Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
214489995|NCT05841420|DRUG|Nab paclitaxel|Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
214974332|NCT03256617|OTHER|Cognitive reassurance training|The 2-day training program includes 3 sessions that will consist of interactive didactic lectures, solving case studies and role-playing activities. The first session uses lecture and cases to present models of pain and disability, evidence based predictors of disability and delayed recovery and evidence based interventions for patients with low back pain. The second session uses role playing and case studies help the providers to 1) develop skills in identifying maladaptive beliefs about pain in patients with low back pain and 2) develop the skills to address diagnostic uncertainty and negative pain beliefs and 3) develop skills to educate patients with low back pain. The third session will use role playing and case studies to refine the provider' skills in providing cognitive reassurance to patients with low back pain.
214974333|NCT04864743|DRUG|ADVATE|a single dose.
214974334|NCT04864743|DRUG|FRSW117|a single dose.
214974335|NCT02354326|RADIATION|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
214974336|NCT02354326|RADIATION|computed tomography|Undergo CT without VNC
214974337|NCT03445026|DIAGNOSTIC_TEST|dental panorama|radiographic examination
214974338|NCT05252858|DEVICE|nCAP Signal Relief Patch|nCAP Signal Relief Patch post-operatively applied to the subject's surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU)
215084578|NCT03208114|OTHER|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
215084579|NCT02220023|DRUG|INOmax Inhalation|
215084580|NCT01855152|OTHER|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
215084581|NCT01855152|OTHER|Treatment as usual|Treatment delivered as usual in the care home
214363330|NCT05867654|DRUG|Levofloxacin 750mg QID|Oral antibiotic used based on indication
214489996|NCT05351593|DRUG|Tafasitamab|Given IV
214489997|NCT05351593|DRUG|Lenalidomide|Given Orally
214489998|NCT02586974|DEVICE|Humigard|warmed and humidified CO2 insufflation
214489999|NCT06832917|DRUG|AK104 plus|SCRT followed by 6 cycles of cadonilimab (AK104) plus mFOLFOX6 as neoadjuvant therapy for patients
214490000|NCT06832917|DRUG|Chemo only|Short-course radiation (SCRT) followed by 6 cycles of mFOLFOX6 as neoadjuvant therapy for patients
214490001|NCT06769308|DEVICE|Sedation titration according to qEEG|Sedation will be titrated according to the EEG derived indexes (qCON/qNOX)
214490002|NCT06769308|PROCEDURE|Sedation titration according to standard of care|Sedation will be provided according to the standard of care of the unit (clinical scales)
215084582|NCT04596865|PROCEDURE|Pancreaticoduodenectomy|Date of surgery 01/06/2010 - 31/05/2015
215084583|NCT05438849|BEHAVIORAL|Mobile Health Application focused on behavioral treatments to treat urinary incontinence|Mobile health application for cell phones and computers that delivers evidence-based behavioral treatment for urinary incontinence, specifically tailored to women Veterans
215084584|NCT05438849|COMBINATION_PRODUCT|Practice Facilitation|The toolkit has 4 components: (1) Practice Facilitation Visits, (2) Mobile-health or mHealth Application Training (MAT) training, (3) Access and education on the Data Dashboard, and (4) Health information technology (HIT) assistance.
215084585|NCT04789694|OTHER|Physiological intervention|"* Rehabilitation specialist consultation (3x)~* Individualized home-based exercise plan~* Functional capacity measuring"
215084586|NCT04789694|BEHAVIORAL|Psychological intervention|"* Clinical psychologist consultation (3x)~* Anxiety and depression scoring~* Psychological support"
215084587|NCT04789694|DIETARY_SUPPLEMENT|Nutritional intervention|"* Nutritional specialist consultation (3x)~* Malnutrition scoring~* Dietary supplementation"
215084588|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
214363331|NCT00742092|DRUG|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
214363332|NCT00742092|DRUG|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
214490003|NCT06768502|OTHER|Community Based Approach (CBA)|The community-based approach on IPV and sexual violence is conceived as a dynamic process where community members willing to recover from life wounds induced by IPV and sexual violence agree to share their lived experiences in order to work on them accordingly and to support each other in this healing journey.
214490004|NCT06768203|OTHER|umbilical vein catheterization|In our NICU, UVC placement is a sterile bedside procedure carried out by pediatric residents, neonatology fellows, and neonatology specialists, using polyurethane, single-lumen catheters sized according to the infant's weight: 3.5 Fr for those under 1500 g and 5 Fr for those over 1500 g. Catheter placement is performed using the Modified Shukla-Ferrara Formula
214490005|NCT06768203|OTHER|Control|No umbilical vein catheter was inserted in these infants.
214490006|NCT06768723|OTHER|Warm-up (specifically, Post-Activation Performance Enhancement)|Assess which intervention delivered the best acute performance enhancements.
214490007|NCT06786078|DEVICE|Lily Device|Participants will wear the Lily Device at each chemotherapy session for the prescribed duration, where the device must be used during infusion and for at least two (2) hours and up to four (4) hours post infusion.
214490008|NCT06791278|BEHAVIORAL|Exercise|After-school childcare educators will participate in a professional development course on delivering pedagogical and child-friendly exercise sessions. The children will receive 1-2 weekly sessions of 45-60 minutes of child-friendly exercise during after-school childcare programs. Duration: 1 year.
214490009|NCT06792071|BEHAVIORAL|Radically Open Dialectical Behavior Therapy (RO DBT)|The intervention is a psychological treatment using Radically Open Dialectical Behavior Therapy (RO-DBT), consisting of individual therapy and skills training in group for approximately 22 weeks. Additionally, a parent group consisting of four sessions will be included as an adaptation to the adolescent group.
214490010|NCT06768047|OTHER|Microporous tape|Microporous tape is a dressing tape that was discovered to have scar modulating effects. It is made up of a conformable, inextensible, nonwoven fabric manufactured from 100% viscose and coated with a layer of acrylic adhesive. It is cheap, cost-effective, readily available, and relatively affordable for post surgical patients.
214490011|NCT06768047|OTHER|Tradition physical therapy|"Tradition physical therapy as stretching exercises and deep friction massage, Stretching is a form of physical exercise in which a specific muscle or tendon (or muscle group) is deliberately expanded and flexed in order to improve the muscle's felt elasticity and achieve comfortable muscle tone. The result is a feeling of increased muscle control, flexibility, and range of motion.~Deep friction massage also known as cross friction massage, is a specific connective tissue massage which maintain the mobility within the soft tissue structures of ligament, tendon, and muscle, and prevent adherent scars from forming."
214490012|NCT06788288|OTHER|Massage Chair session|The intervention is composed of a full-body relaxation massage offered by an automatic electric massage chair. The intervention will last for 3 months while the participant will change between massage and washout periods.
214490013|NCT06788288|OTHER|Washout period|During this phase, participants will spend on month without any intervention (massage) accounting for a washout period.
214490014|NCT03621813|BEHAVIORAL|Exercise Rehabilitation|This training is designed to improve fitness, target the major muscle groups for strength, and to improve balance. Aerobic exercise of walking on a treadmill will be performed. Thera-Bands will be used for resistance exercise for the lower and upper body. Balance program includes core exercises (stepping, weight shifts, etc.) and other progressive exercises.
214679612|NCT04133779|PROCEDURE|neurological evaluation, ecocolor-Doppler|For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
214490015|NCT03621813|OTHER|Control|Participants are instructed to maintain current activity level and are monitored for changes.
214490016|NCT06785571|DRUG|Nalbuphine hydrochloride injection|a loading dose of Nalbuphine hydrochloride injection administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)
214490017|NCT06785571|DRUG|Hydromorphone hydrochloride injection|A maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)
214490018|NCT06768606|BEHAVIORAL|EMPOWER Social-emotional learning curriculum|EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context. The STEM Academy program will implement a shortened version of the social-emotional learning curriculum to meet their timelines.
214974339|NCT05252858|OTHER|Standard of Care|Subjects will undergo surgery using the approved ERAS anesthetic and post-operative pain management protocols. At Shadyside Hospital, the ERAS Protocol for these subjects involves preoperative meloxicam 15mg PO, gabapentin 300mg PO, acetaminophen 1g PO. Intra-operative, patients receive a spinal block (bupivacaine) and propofol IV sedation. Postoperative pain medication is titrated to the individual patient's level of pain (0-10). 0.2 mg IV hydromorphone can be given for breakthrough pain, oxycodone 5mg PO for moderate pain (4-6) and oxycodone 10 mg PO for severe pain (7-10). Ketorolac 15 mg IV is given Q6H during the hospital stay. Discharge medication may be Norco 5-325mg as prescribed by the surgeon.
214974340|NCT06458114|OTHER|Assessment of caregiver feeling|The study group includes any caregiver who supported an extremely preterm newborn in a palliative care approach in the delivery room with as intervention type a questionnaire and individual semi-structured interview.
214974341|NCT02786303|DEVICE|Whole-body diffusion- weighted MRI|
214974342|NCT00301834|BIOLOGICAL|alemtuzumab|
214974343|NCT00301834|DRUG|busulfan|
214974344|NCT00301834|DRUG|cyclosporine|
214974345|NCT00301834|DRUG|fludarabine phosphate|
214974346|NCT00301834|DRUG|methotrexate|
214974347|NCT00301834|DRUG|methylprednisolone|
214363337|NCT05092321|BEHAVIORAL|Aquatic Occupational Therapy|Group of 4-8 children, paired with a swim buddy. Intervention techniques including discrete teaching, motor shaping, behavioral management, therapeutic relationship and individualized goals.
214363338|NCT06393322|OTHER|Depression e-Learning A|"Participants in Depression e-Learning A will be provided e-learning about depression, consisting of following components:~1. One multimedia e-learning lesson on depression;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.~1\. One multimedia e-learning lesson on depression; 2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
214363339|NCT06393322|OTHER|Depression e-Learning B|"Participants in Depression e-Learning B will be provided e-learning about depression, consisting of following components:~1. One multimedia e-learning lesson on depression;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.~1\. One multimedia e-learning lesson on depression; 2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
214363340|NCT06393322|OTHER|Anxiety e-Learning A|"Participants in Anxiety e-Learning A will be provided e-learning about anxiety, consisting of following components:~1. One multimedia e-learning lesson on anxiety;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
214490019|NCT06769542|BEHAVIORAL|Experimental (micro teaching)|The experimental group was taught using the micro-teaching method for 8 weeks. Psychomotor skills for drug administration were performed on models. Video recordings were taken while the students were performing the skills. These videos were evaluated by the instructor and the students and the students were given the opportunity to see their own mistakes. During 8 weeks, each student was given the opportunity to perform the applications and evaluate themselves. In addition, activities for drug applications were carried out with students within the scope of small group work. Micro teaching with 4 groups of 8 students was applied for 8 weeks.
214363341|NCT06393322|OTHER|Anxiety e-Learning B|"Participants in Anxiety e-Learning B will be provided e-learning about anxiety, consisting of following components:~1. One multimedia e-learning lesson on anxiety;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
214363342|NCT02470650|DRUG|elvitegravir/cobicistat/emtricitabine/tenofovir|1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
214363343|NCT02470650|DRUG|Darunavir|Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
214363344|NCT02470650|DRUG|abacavir/lamivudine|Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
214363345|NCT02470650|DRUG|Ritonavir|Ritonavir 100 mg recovered tablet once a day
214490020|NCT06768736|COMBINATION_PRODUCT|Personalised early warning system|Early warning system personalised forecasting messages
214490021|NCT06793657|DIAGNOSTIC_TEST|computed tomography and poppy seed|comparison of both interventions
214490022|NCT06737120|PROCEDURE|Mod-fgg|"Following an intrasulcular incision, 2 mm long horizontal incisions will be made on each side at the level of the gum line. From these incisions, divergent vertical release incisions will be made extending towards the alveolar mucosa. To prepare the recipient area, a thin partial thickness flap will be lifted and then removed. A foil template will be obtained by measuring the dimensions of the resulting area.~A horizontal incision will be made apical to the exposed root area of the target teeth at a distance corresponding to the height of the exposed root surface. Starting from the endpoints of this incision, two more slightly divergent incisions will be made in the coronal direction. Thus, a connective tissue pedicle flap will be formed and carefully separated from the periosteum. The pedicle graft will be turned over the exposed root surface and fixed with bioabsorbable sutures. The palatal graft will be sutured to cover the connective tissue."
214490023|NCT06737120|PROCEDURE|Fgg|The surgical procedures to be performed in this group will be the same as in the modified free gingival graft group, but no connective tissue pedicle flap will be performed.
214490024|NCT06797193|OTHER|Electronic Health Record Review|Ancillary studies
214490025|NCT06797193|PROCEDURE|Liver Biopsy|Undergo liver biopsy
214490026|NCT06797193|OTHER|Medical Device Usage and Evaluation|Undergo ultrasound with SHAPE technique
214363346|NCT02470650|DRUG|Lamivudine|lamivudine 300mg (Epivir) 1 recovered tablet
214363347|NCT02470650|DRUG|rilpivirine|rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
214363348|NCT03721939|DEVICE|FLEX Scoring Catheter|Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
214490027|NCT06797193|DRUG|Perflutren Lipid Microspheres|Given IV
214974348|NCT00301834|PROCEDURE|allogeneic bone marrow transplantation|
214974349|NCT00301834|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214974350|NCT00301834|PROCEDURE|peripheral blood stem cell transplantation|
214363349|NCT06118372|DRUG|Recombinant von Willebrand Factor|Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
214363350|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
214490028|NCT06797193|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
214974351|NCT00301834|PROCEDURE|umbilical cord blood transplantation|
214974352|NCT06473350|OTHER|The application of right lateral, supine, and prone positions to preterm infants after feeding|Each infant included in the sample group is fed at their routine feeding time (9:00 a.m.), followed by placement in the right lateral position. Immediately after this position is applied, as well as one hour and three hours later, data on heart rate, oxygen saturation, respiratory rate, pain level, and comfort level are recorded. This procedure is repeated after the subsequent feeding time (12:00 p.m.) for the supine position and after the feeding time following that (6:00 p.m.) for the prone position. This procedure is repeated for three consecutive days at the same feeding times and in the same sequence.
214974353|NCT03294642|DIETARY_SUPPLEMENT|Potatoes|Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.
214490029|NCT06737939|OTHER|intravenous ibuprofen|A systemic analgesic (NSAID) administered intravenously for pain management during prostate biopsy, without the need for additional invasive interventions.
214974354|NCT03294642|DIETARY_SUPPLEMENT|Carbohydrate Gel|Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
214974355|NCT03294642|DIETARY_SUPPLEMENT|Water|Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
214363351|NCT06496048|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
214363352|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
214363353|NCT06496048|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3wk
214363354|NCT00959933|DRUG|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
214363355|NCT00959933|DRUG|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
214363356|NCT01952184|DEVICE|CBSvit HS device|closed vitrification with closed storage
214363357|NCT01952184|DEVICE|Cryotop SC device|open vitrification with closed storage
214363358|NCT04495179|DRUG|AZD4635|Subjects will receive AZD4635 orally daily
214363359|NCT04495179|DRUG|Durvalumab|Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
214363360|NCT04495179|DRUG|Cabazitaxel|Subjects will receive intravenous cabazitaxel every 3 weeks
214363361|NCT06052241|DRUG|shampoos and scalp serums|shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
214363362|NCT02968420|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
214363363|NCT00673309|PROCEDURE|Stable Isotope Infusion study|Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
214363364|NCT00673309|DRUG|Insulin High Dose|Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.
214363365|NCT00673309|DRUG|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
214363366|NCT00673309|DRUG|Propranolol|Propranolol to be given daily throughout hospitalization until 95% wound healing.
214363367|NCT00673309|DRUG|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
214363368|NCT00673309|DRUG|Insulin Low Dose|Insulin administered IV until 95% wound healing
214363369|NCT00673309|DRUG|IGF-1/IGFBP-3|Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing
214363370|NCT00673309|DRUG|Itraconazole|Itraconazole administered until 95% wound healing
214363371|NCT00673309|DRUG|Growth Hormone and Propranolol|Growth Hormone and Propranolol given until 95% wound healing
214363372|NCT00673309|DRUG|Oxandrolone and Propranolol|Oxandrolone and Propranolol
214363373|NCT00673309|DRUG|Placebo or Control|Administration of Placebo or Control until 95% wound healing
214363374|NCT01512901|DRUG|Betamethasone Microsphere (DE-102） Low Dose|
214974356|NCT03599570|BEHAVIORAL|STOP-HPV performance feedback intervention|This intervention will be the addition of performance feedback (in the presence of communication skills).
214974357|NCT05053906|DEVICE|Endoscope|effect of FESS on eustachian tube function
214974358|NCT01811732|DRUG|Delafloxacin|Delafloxacin
214974359|NCT01811732|DRUG|Vancomycin|Vancomycin
214974360|NCT01811732|DRUG|Aztreonam|Aztreonam
214974361|NCT01811732|DRUG|Placebo|Placebo
214363375|NCT01512901|DRUG|Betamethasone Microsphere (DE-102） High Dose|
214363376|NCT01512901|DRUG|Sham|
214363377|NCT02355743|DRUG|rtPA lock therapy|"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."
214363378|NCT04131608|DIAGNOSTIC_TEST|CBC ,Serum ferritin ,HBA1C|Diabetic patients will be applied to CBC, HBA1C and serum ferritin
214363379|NCT06041984|DRUG|Glycopyrrolate|Intravenous injection of glycopyrrolate 0.2mg
214363380|NCT06041984|OTHER|Placebo|Intravenous injection of saline 1ml
214363381|NCT04212091|BIOLOGICAL|PGT121.414.LS|Administered via IV infusion or SC infusion, depending on the arm
214363382|NCT04212091|BIOLOGICAL|VRC07-523LS|Administered via IV infusion or SC infusion, depending on the arm
214363383|NCT00502255|DEVICE|Health Buddy system|Patients are followed on distance by the Health Buddy system.
214363384|NCT00502255|DEVICE|Telemonitoring in patients with heart failure|Health Buddy in patients home situation.
214363385|NCT06506578|RADIATION|Radiation|Radiation
214363386|NCT03225664|BIOLOGICAL|Pembrolizumab|Given IV
214363387|NCT03225664|OTHER|Pharmacokinetic Study|Correlative studies
214363388|NCT03225664|DRUG|Trametinib|Given PO
214363389|NCT05315349|OTHER|Complete ophthalmological check-up|Preoperatively, 3 to 7 days after surgery and 1 to 2 months after surgery: fundus, optical coherence tomography angiography (OCT-A)
214363390|NCT05315349|BIOLOGICAL|Blood sampling|Preoperatively and on Day 1 of surgery: 6 tubes of approximately 5 ml each, i.e. 30 ml
214363391|NCT02802800|OTHER|Plyometric training|Plyometric exercises
214363392|NCT01688700|DRUG|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
214363393|NCT05642481|DIAGNOSTIC_TEST|Therapeutic drug monitoring in plasma of mother and child and in breastmilk|Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
214363394|NCT00538135|BEHAVIORAL|Cognitive Behavioural Therapy|
214363395|NCT00538135|OTHER|Treatment as usual|Standard National Health Service treatment as usual for borderline personality disorder
214974362|NCT04173091|DIAGNOSTIC_TEST|No Intervention|No Intervention planed
214974363|NCT01105520|PROCEDURE|Diagnostic|SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
215084589|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
214490030|NCT06737939|OTHER|periprostatic nerve block|A local anesthetic injection targeting the periprostatic nerves to provide direct pain relief during the biopsy procedure, considered the gold standard for pain management in prostate biopsies.
214363396|NCT04357262|OTHER|StreaMD|Patients who are randomized to the intervention arm will be signed up for the automated text messaging program. Patients will receive automated text messages related to their surgery during the study period and can also ask questions through the text messages program, where automated messages will be sent based on the questions asked.
214363397|NCT03141320|OTHER|Interview/observation of social media comments|Interview with pregnant or postnatal women and observation of relevant social media comments
214363398|NCT01725828|DEVICE|Ultrasound|Using the Ultrasound to determine the location of the CTM.
214363399|NCT01725828|OTHER|External Palpation|Using External Palpation to identify cricothyoid membrane
214363400|NCT00421551|DRUG|Darunavir|during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
214363401|NCT00421551|DRUG|ritonavir|during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
214490031|NCT06838884|OTHER|6 minutes step test and bicycle ergometer|Evaluation
214490032|NCT06797011|BIOLOGICAL|High volume Plasma Exchange|High volume Plasma Exchange with minimum 3 sessions on alternate days
214490033|NCT06797011|OTHER|Standard Medical Treatment|Standard Medical Treatment includes stopping the offending drug,nutrition,injection NAC,Tablet UDCA,steroid in DILI AIH
214363402|NCT02264704|OTHER|High intensity exericse|Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
214490034|NCT06796465|OTHER|McKenzie with Progressive Postural Control Exercises|"The McKenzie Exercises focus on progressive spinal extension to alleviate back pain. Key steps include Extension in Standing, where patients lean backward and return to a neutral stance; Extension in Lying (Partial Range), involving partial pushups in a prone position; and Extension in Lying (Full Range), where patients fully extend their arms to achieve maximum spinal extension. Each movement is held for 1-2 seconds.~The PPCE program enhances core strength and stability through three stages. In the First Stage (2 weeks), core muscles are trained against gravity using movements like pelvic retroversion, crunches, and glute bridges. The Second Stage (3 weeks) incorporates a Swiss ball to challenge trunk muscles with instability. In the Third Stage (3 weeks), a Swiss ball, stretch bands, and a 5 kg sandbag are used to increase complexity on unstable surfaces. Each stage includes six movements, lasting 5 minutes each, for a total session duration of 30 minutes."
214490035|NCT06796465|OTHER|McKenzie without Progressive Postural Control Exercises|"Subject were treated with McKenzie exercises without the addition of Progressive Postural Control Exercises (PPCE).The exercises included the following:~Standing Extension Exercises: Patients leaned backward from a balanced standing position, arching their back before returning to a neutral stance.~Extension in Lying (Partial Range): Performed in a prone position with hands placed under the shoulders, patients lifted their upper torso in a motion similar to a push-up.~Extension in Lying (Full Range): Similar to the partial range extension, but with fully extended arms, aiming for the maximum tolerated extension. Each movement was sustained for 1-2 seconds."
214490036|NCT06796465|DEVICE|Hot Pack|for 10 to 15 minutes
214490037|NCT06325046|PROCEDURE|Computed Tomography|Undergo CT
214490038|NCT06325046|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
214974364|NCT00217282|DRUG|oxaliplatin, gemcitabine, bevacizumab|"Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90\* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.~Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:~Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression"
214974365|NCT01607593|DRUG|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
214974366|NCT00003146|DRUG|busulfan|
214974367|NCT00003146|DRUG|melphalan|
214974368|NCT00003146|DRUG|thiotepa|
214974369|NCT00003146|PROCEDURE|bone marrow transplantation|
214974370|NCT00003146|PROCEDURE|peripheral blood stem cell transplantation|
214974371|NCT03495063|DIETARY_SUPPLEMENT|Natural Caffeine|Consumption of 400mg of natural caffeine
214974372|NCT03495063|DIETARY_SUPPLEMENT|Synthetic Caffeine|Consumption of 400mg of synthetic caffeine
214974373|NCT00145886|DRUG|rhPTH|Subjects will be treated with rhPTH for 12 months.
214363403|NCT02264704|OTHER|Moderate intensity exericse|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
214363404|NCT02766569|DEVICE|ASD closure with the Occlutech Flex II ASD closure device|Monitoring of possible device related side effects with a minumum of 1 year follow-up.
214363405|NCT04534374|BEHAVIORAL|Resistance exercise|Barbell back squat, press, and deadlift for three sets of five repetitions with the weight closest to 75% of their estimated 1 repetition max. The participants were instructed to execute the movement with moderate speed (2s eccentric, 2s concentric, no pause in between). The rest period between sets and exercise movements was two to three minutes.
214363406|NCT04534374|BEHAVIORAL|Stretching exercise (sham exercise)|Participants completed a passive stretching exercise session for a similar duration of time as the resistance exercise (≈ 30 min) as sham intervention, which included 15-20 stretching movements twice, holding each for 30 seconds as recommended by ACSM.
214363407|NCT01311960|DRUG|bevacizumab eye drop 0.05%|bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
214363408|NCT01311960|DRUG|normal saline 0.9%|normal saline eye drop 0.9% will apply 4 times a day for 3 months.
214363409|NCT03189017|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
214490039|NCT06325046|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo near margin-less ART
214974374|NCT04630678|OTHER|Virtual Reality Therapy|Virtual reality games were applied to participants for 30 minutes.
214974375|NCT04630678|OTHER|Conventional Physiotherapy|Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.
214363410|NCT03189017|DRUG|Placebos|The placebo is a white, round, uncoated tablet.
214363411|NCT05817851|DRUG|Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)|in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
214363412|NCT05817851|DRUG|standard treatment|no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
214363413|NCT01812655|DEVICE|Virtual Reality|
214363414|NCT01812655|OTHER|Passive Distraction|
214363415|NCT03608930|DEVICE|Disposable Polypectomy Snare,JHY-SD-23-230-30-A1|The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
214363416|NCT00442143|PROCEDURE|Stem cell implantation|
214363417|NCT05916326|BIOLOGICAL|Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)|Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm
214363418|NCT05916326|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
214490040|NCT06325046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214490041|NCT06325046|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo standard SABR
214490042|NCT06325046|OTHER|Survey Administration|Ancillary studies
214490043|NCT05903352|OTHER|Stop antibiotic|Stop the antibiotic treatment on day S (stability criteria reached for 24 h or within 48 hours after the start of antibiotic treatment).
214490044|NCT05903352|DRUG|Continue the antimicrobial treatment|Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).
214974376|NCT04630678|OTHER|Activity Training|Unilateral, bilateral, and bimanual activity training that supported manual skills for 30 minutes.
214974377|NCT02799927|PROCEDURE|Indirect Pulp Treatment with Bioactive Dentin Substitute|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Biodentine and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
214974378|NCT02799927|PROCEDURE|Indirect Pulp treatment with Calcium hydroxide|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Ultra-Blend plus, and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
214974379|NCT00249704|DRUG|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
214363419|NCT01834131|BEHAVIORAL|Comprehensive Intervention|The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
214363420|NCT04210206|OTHER|PHE-diet|phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
214363421|NCT00194558|BEHAVIORAL|Internet co-management module|
214363422|NCT00561210|DIETARY_SUPPLEMENT|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
214363423|NCT00561210|DIETARY_SUPPLEMENT|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
214363424|NCT04540874|DRUG|BI 894416|BI 894416
214363425|NCT04540874|DRUG|Placebo|Placebo
214363426|NCT00134290|DRUG|metformin|
214363427|NCT00134290|BEHAVIORAL|"standard diet advice"|
214363428|NCT00134290|BEHAVIORAL|"personal diet advice"|
214363429|NCT05303779|OTHER|Exercise Interventions of Eye Muscles|Application of eye exercise for improving eye control post strabismus surgery
214363430|NCT05303779|DRUG|Medication and eye glasses|medication and eye glasses used post strabismus surgery
214490045|NCT06794918|DIAGNOSTIC_TEST|progressive relaxation exercise|Researchers will teach individuals pge exercises to help them relax
214490046|NCT06796088|OTHER|Treated zones exposed to Visible Light source|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
214490047|NCT06796088|OTHER|Untreated zone exposed to Visible Light source|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
214490048|NCT06794788|DEVICE|VR-The iWear|The immersive virtual reality device was used for this study from(Vuzix®, Rochester, New York, USA). The iWear consists of a lightweight high-end pair of video headphones that contain pair of VR goggles
214490049|NCT05453136|DRUG|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
214490050|NCT05453136|DRUG|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
214490051|NCT05453136|DRUG|Placebo to TS-142|Participants received repeated doses of placebo to TS-142 (oral tablet)
214490052|NCT06793813|DRUG|cadonilimab，bevacizumab，docetaxel|Patients receive Cadonilimab IV over 90 minutes on day 1. Patients also receive bevacizumab 7.5mg/kg IV on day 1 and docetaxel 60-75 mg/m2 IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
214363431|NCT01795365|OTHER|Active surveillance|
214363432|NCT01278134|DRUG|Copegus placebo|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
214363433|NCT01278134|DRUG|RO5024048|1000 mg bid orally, up to 24 weeks
214974380|NCT00249704|PROCEDURE|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
214974381|NCT00249704|PROCEDURE|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
214363434|NCT01278134|DRUG|danoprevir|100 mg bid orally, up to 24 weeks
214363435|NCT01278134|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
214363436|NCT01278134|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
214363437|NCT01278134|DRUG|ritonavir|100 mg bid orally, up to 24 weeks
214363438|NCT04924231|BEHAVIORAL|astigmatism|astigamatism at least 1 month after the cataract surgery
214490053|NCT06840236|BEHAVIORAL|Adapted Flu nudge messages|Adapted Flu nudge messages - digital health intervention aimed at improving influenza vaccination rates among adults with diabetes at Dario digital platform approach.
214490054|NCT06840236|BEHAVIORAL|Previously studied based on RCT|Previously studied flu nudge messages in RCT
214490055|NCT06370052|PROCEDURE|excision|excision of the affected area
214490056|NCT04418778|BEHAVIORAL|BEAR|Building Empowerment and Resilience Therapy group
214490057|NCT06793007|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic resonance imaging cholangiopancreatography
214490058|NCT05714059|DEVICE|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
214490059|NCT06840054|DRUG|Sodium Pentaborate Pentahydrate|will receive 1000 mg of sodium pentaborate pentahydrate daily along with donepezil.
214490060|NCT06840054|DRUG|Placebo|will receive a placebo along with donepezil
214490061|NCT04878029|DRUG|Cabozantinib S-malate|Given PO
214490062|NCT04878029|DRUG|Enfortumab Vedotin|Given IV
214490063|NCT04878029|OTHER|Quality-of-Life Assessment|Ancillary studies
214490064|NCT04878029|OTHER|Questionnaire Administration|Ancillary studies
214974382|NCT00249704|DRUG|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
214974383|NCT03168373|PROCEDURE|language rehabilitation therapy|language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
214974384|NCT05064254|OTHER|Treatment as usual (TAU)|TAU may include self-help methods, physician visit, provision of resources etc.
214363439|NCT06524674|DIETARY_SUPPLEMENT|Hydration Multiplier + Energy|Participants will be administered one oral serving of an oral rehydration solution containing caffeine and l-theanine
214363440|NCT06524674|DIETARY_SUPPLEMENT|Hydration Multiplier + Sleep|Participants will be administered one oral serving of an oral rehydration solution containing melatonin and l-theanine
214490065|NCT06838559|DRUG|Short-Duration Oral Prednisolone with Extended Tapering|In treatment arm A, oral prednisolone will be administered in tablet form (5 mg strength) as follows: an initial phase of 10 mg four times daily (total 40 mg/day) for 7 days, followed by a 15-day tapering phase-10 mg three times daily for 5 days, 10 mg twice daily for 5 days, and 10 mg once daily for 5 days. After tapering, a prolonged low-dose maintenance phase will be implemented, where 10 mg is given once daily twice a week for an additional 10 weeks. This regimen is designed to test whether a shorter high-dose course, combined with extended low-dose maintenance, can provide equivalent control of infantile epileptic spasms syndrome while reducing the adverse effects associated with longer high-dose therapy, compared to the standard 14-day high-dose regimen (treatment arm B).
214490066|NCT06838559|DRUG|Standard Oral Prednisolone Regimen with Tapering|Prednisone oral tablets, 10 mg, administered four times daily (40 mg/day) for 14 days, followed by a tapering phase over 15 days: 10 mg three times daily for 5 days, 10 mg twice daily for 5 days, and 10 mg once daily for 5 days. No further tapering will be implemented after the initial 14-day treatment period. This regimen represents the standard therapy for Infantile Spasms in Sri Lanka.
214490067|NCT04899674|DRUG|Elontril|Tablet
214490068|NCT04899674|DRUG|BI 1358894|Film coated tablet
214490069|NCT03685461|OTHER|Electrocochleography|Electrocochleography is a noninvasive method of monitoring for acoustic evoked electrophysiologic responses from the cochlea. A speaker in the external auditory canal presents a tone burst stimulus and a nearby electrode, in this case from the apical electrode of the cochlear implant, records changes in the electrical activity within the cochlea. Different functional elements within the cochlea have signature electrophysiologic responses that can be isolated and studied individually. Through the use of intracochlear electrocochleography during cochlear implant electrode insertion valuable insight can be gained about structural or physiological changes that may be occurring.
214490070|NCT06474533|DRUG|Fluorethyltyrosine (18-F)|Given intravenously (IV)
214490071|NCT06474533|PROCEDURE|Positron Emission Tomography (PET)|Undergo Imaging Procedure
214490072|NCT06114212|DEVICE|dTMS stimulation via the H4 coil|Deep repetitive transcranial magnetic stimulation (dTMS) uses transient electromagnetic fields to stimulate the brain and is approved by Health Canada and the FDA for the treatment of depression, anxious depression, obsessive-compulsive disorder, and tobacco use disorder. Compared to the traditional TMS, dTMS is able to target brain depths ranging from 2 to 6 cm. With the use of various H-coils, dTMS has been used to target specific neural networks with the aim of producing desired clinical effects in psychiatric populations. The intervention in this study is the H4 dTMS coil which stimulates the lateral prefrontal cortex and the insula in the brain.
214490073|NCT03774472|DRUG|Hydroxychloroquine|Given PO
214490074|NCT03774472|DRUG|Letrozole|Given PO
214490075|NCT03774472|DRUG|Palbociclib|Given PO
214490076|NCT06846099|DRUG|RP903|Ia:RP903 50mg, 100mg, 200mg, 300mg,350mg,or other dose, po qd for each 28-day cycle； Ib: RP903,RP2D,po qd for each 28-day cycle
214490077|NCT06847308|BEHAVIORAL|visual biofeedback through trans-perineal ultrasound|Trans-perineal ultrasound will be used to provide visual biofeedback during the active 2nd stage of labour, this for ten consecutive uterine contractions / pushing efforts
214490078|NCT06483789|DRUG|HB-1|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
214490079|NCT06483789|DRUG|Telmisartan Only Product in Oral Dose Form|Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
214490080|NCT06483789|DRUG|Verapamil Only Product in Oral Dose Form|Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
214363441|NCT06524674|DIETARY_SUPPLEMENT|Energy Comp|Participants will be administered one oral serving of a comparator oral rehydration solution containing caffeine and l-theanine
214363442|NCT06524674|OTHER|Sleep Comp|Participants will be administered one oral serving of a comparator oral rehydration solution containing melatonin and l-theanine
214974385|NCT05064254|OTHER|Mindful Adaptive Practice in Pregnancy Therapy|MAP teaches: a) recognition of personal maladaptive/ distressing patterns driving anxiety; b) how to relate differently; and c) cultivation of more adaptive ways of dealing with anxiety and learning how to effectively control it rapidly which allows re-engagement with life in more flexible ways.
214974386|NCT01350635|BIOLOGICAL|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
214974387|NCT05105074|DRUG|Intrathecal Morphine|Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
214363443|NCT06524466|DRUG|Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab|"SBRT: SBRT will be performed within 2-4 weeks after enrollment. The total radiation dose will be 24 Gy, delivered in 3 fractions on alternate days, to be completed within one week.~Lenvatinib: 8mg/day, begin immediately after enrollment. Lenvatinib should be discontinued one week before surgery.~Pucotenlimab: 200mg，3-week interval between cycles, begin immediately after enrollment, a total of four cycles of Puco treatment must be completed before surgery.~Surgical resection will be performed within 10-16 weeks after the completion of SBRT."
214363444|NCT03223974|DEVICE|Paclitaxel DCB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for \>30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
214363445|NCT03223974|DEVICE|DES|MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
214974388|NCT05105074|DRUG|Placebo|Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
214974389|NCT03472131|PROCEDURE|Unilateral Posterolateral Approach and Debridement|
214974390|NCT03472131|OTHER|Titanium cage insertion supplemented by screw fixation|
214974391|NCT03588273|DRUG|Amoxil 500 MG Oral Capsule|
214974392|NCT01861067|PROCEDURE|LESS-TLH|
214974393|NCT01861067|PROCEDURE|LESS-LAVH|
214974394|NCT04835545|OTHER|extreme hypercapnia induced by ventilation insufficiency|extreme hypercapnia
214974395|NCT06422728|OTHER|Unified Protocol for Anxiety Disorders|"The UP is planned in group therapy format and includes interventions on common transdiagnostic features. The sessions in the protocol are planned as follows:~Session 1 - Assessment: introduction, talking on group rules and the process, setting goals~Session 2 - Psychoeducation: the CBT model is introduced.~Session 3 - Emotions: the role of emotions are discussed.~Session 4, 5 \& 6 - Thoughts: the role of thoughts is mentioned. The participants learn to challenge unfunctional thoughts and generate alternative explanations. Also, exercises on excessive worry are applied.~Session 7 - Behaviors: the role of behaviors and the things that can/cannot be controlled are discussed.~Session 8 - Evaluation \& Maintaining Accomplishments: includes a review of what has been learnt during the group therapy and an evaluation on maintaining the accomplishments.~Session 9 - Follow-up session: one month later."
214974396|NCT06422728|OTHER|Client-centered Supportive Therapy|Client-entered therapy provides a non-directive supportive environment for the participants, that includes reflective listening and nonjudgmental and empathic communication. In this group, no CBT intervention will be applied. Through the supportive and non-directive environment, only the effect of relationship will be investigated as a common factor in psychotherapy.
214974397|NCT01682824|OTHER|Nutritional Assessment|Complete dietary intake assessment
214974398|NCT01682824|OTHER|Questionnaire Administration|Complete TFEQ-R18v2 questionnaire
214974399|NCT01682824|OTHER|Questionnaire Administration|Complete EQ-EMA questionnaire
214974400|NCT02091232|BIOLOGICAL|T Regulatory Cell Infusion|After blood is collected from the donor and recipient, the facility will sort out one particular kind of immune cell called a regulatory T cell which is strongly influenced by tolerance induction to minimize (suppress) responses to the donor cells. In this study, these regulatory T cells are the cells which will be given back to the recipient on Day 7 (+3 days) post-transplant.
214974401|NCT04654013|DEVICE|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (May 2022). The duration of the treatment for the Intervention participants will depend on when they leave employment at the factor. If they stayed for the full duration of the trial, they will have undergone a maximum of 18 months (December 2023).
214974402|NCT06360861|BIOLOGICAL|Allogenic placenta derived mesenchymal stem cells|Allogenic placenta derived mesenchymal stem cells, 3 million cells/kg body weight via intravenous injection.
214974403|NCT00003012|DRUG|CMF regimen|
214974404|NCT00003012|DRUG|cyclophosphamide|
214974405|NCT00003012|DRUG|epirubicin hydrochloride|
214974406|NCT00003012|DRUG|fluorouracil|
214974407|NCT00003012|DRUG|methotrexate|
214974408|NCT00076388|DRUG|Gefitinib|
214974409|NCT00076388|DRUG|Docetaxel|
215084590|NCT03959982|DEVICE|HHHFA Device|Participants will be instructed to use the HHHFA for at least 4 hours during their sleep but will be allowed to use it as long as they want during sleep.
214974410|NCT02935569|DEVICE|Compression HeadBand|"* commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~* Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery."
214974411|NCT03928457|OTHER|Parental questionnaire|Parental questionnaire on pregnancy history and environmental exposure
214974412|NCT03928457|OTHER|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (6 weeks) by placing a dosimeter inside the incubator
214974413|NCT03928457|OTHER|Follow-up of daily infants environmental and clinical parameters|Follow-up of daily infants environmental and clinical parameters: morphological characteristics, drugs, ventilatory support, dietary management, clinical outcomes, incubator data (temperatures…)
215084591|NCT03959982|DIAGNOSTIC_TEST|Spirometry|Pre and post spirometry using albuterol.
214363446|NCT04501510|DIAGNOSTIC_TEST|Ultrasonographic examination validation and testing|X-ray imaging as well as the ultrasonographic examination of the fracture and healing process in children will be performed. The validation of an usg will be done.
214490081|NCT06483789|DRUG|Placebo|Matched Placebo will be supplied as a tablet.
214490082|NCT06793826|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T combined vaccine|prefilled syringe injection intramuscular
214490083|NCT05975593|OTHER|Tumor collection via biopsy|"Cervical cancer: Pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 12 weeks after completion of radiotherapy, and recurrence."
214490084|NCT05975593|OTHER|Blood collection|"Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence"
214490085|NCT05975593|DEVICE|Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)|"Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence.~The imaging will be performed when possible."
214490086|NCT06832904|DRUG|pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy|Receive four neoadjuvant cycles of oral pyrotinib (400 mg) once daily, plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) , nab-paclitaxel (260 mg/m2) and carboplatin（AUC=5）every 3 weeks.
214490087|NCT05026125|DRUG|Remifentanil Injection|Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
214490088|NCT05026125|DRUG|Remifentanil Injection plus 30%|Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
214490089|NCT04831125|OTHER|Data collection|Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.
214974414|NCT03928457|OTHER|Nocturnal polysomnography|Nocturnal polysomnography (at 3 and 6 weeks of life, between 8 pm and 8 am) with recording of sleep (electroencephalography, electrooculography),
214974415|NCT03928457|DIAGNOSTIC_TEST|cerebral hemodynamics|cerebral hemodynamics (near infrared spectroscopy)
214490090|NCT06735053|OTHER|Virtual Reality group|Virtual reality group will perform online reality-based device following a therapeutic protocol supervised by a physiotherapist in which the level of demand will be adjusted to the patient's evolution. This programme provides a gamified and challenging online environment to enhance motor learning and induce sensorimotor adaptations. Additionally, they will receive conventional physiotherapy approach, oriented to the specific objectives of each patient, aiming to normalize tone, activate weakened muscles, facilitate movement, recover sensitivity, and compensate for functional deficits. Additionally, global kinesitherapy, motor coordination exercises, pedalier, vibration therapy (vibrosphere®), and analgesic electrotherapy will be performed if necessary.
214490091|NCT06735053|OTHER|Placebo virtual reality group|The control group will undergo a conventional physiotherapy program based on the normalization of tone, activation of weakened muscles and facilitation of normal movement, recovery of alterations in sensitivity, and compensation of lost functional deficits. In addition, global kinesitherapy exercises will be performed on a stretcher, motor coordination exercises, pedalier, vibration therapy (vibrosphere ®) and analgesic electrotherapy if necessary. Finally, in order to minimize the differences between the control and intervention groups, the participants of the control group will watch a 15-minute generic 2D video freely accessible on the Youtube platform from the VR glasses, without specific software.
214490092|NCT05155306|DRUG|BI 1358894, intended Commercial Formulation (iCF) (T)|A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning
214490093|NCT05155306|DRUG|BI 1358894, Trial Formulation 2 (TFII) (R)|A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning.
214679613|NCT04133779|PROCEDURE|medical history, vital signs, ecocolor-Doppler|For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
214974416|NCT03928457|DIAGNOSTIC_TEST|activity of the autonomic nervous system|activity of the autonomic nervous system (electrocardiography, analysis of heart rate variability)
214974417|NCT03348605|DEVICE|Phantom Stimulator, Cort X Sensorics, Spaichingen, Germany|"This system consists of a pressure sensing insole connected to regular TENS-Electrode patches which are applied to the receptive fields of the patients (evoking the sensation of heel and forefoot). The individually adjusted stimulation intensity on the systems regulatory box through a socked screw is set at the beginning of the testing phase, and not changed anymore.~The current is applied to mimic the roll-off-sensation while walking. This is done by locating two sets of electrodes on the receptive fields representing the heel and the ball of the foot respectively. Now the current is applied in an alternating manner coordinated with the walking of the participant. The coordination is made able through the pressure sensing insole."
214974418|NCT05989555|OTHER|Blood drawing|Blood is drawn twice in all subjects. Once before treatment with radioacitve iodine and once after.
214974419|NCT03384589|BIOLOGICAL|PCV13|Vaccine against pneumococcal disease
214974420|NCT05138146|DRUG|609A|"609A 200mg,IV, Day 1of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first.~Every 3 weeks a treatment cycle."
214974421|NCT05138146|DRUG|doxorubicin hydrochloride|60mg/m2 or 75mg/m2, IV, Day1of the1-6th treatment cycles only. Every 3 weeks a treatment cycle.
214974422|NCT05998681|OTHER|Breastfeeding and Basic Maternal-Neonatal Care and mobile messages|"Participants in the experimental group were provided with education on Breastfeeding and Basic Maternal-Neonatal Care at the hospital and mobile messages were sent with the same content as education program for 6 weeks after discharge."
214974423|NCT01969526|OTHER|Multifactorial intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
214974424|NCT02447419|DRUG|Gefitinib|Gefitinib 250mg will be administered orally daily
214974425|NCT05793411|OTHER|Questionnaire risk behaviors in adolescents with chronic diseases|Questionnaire risk behaviors in adolescents with chronic diseases
214363447|NCT05217342|DRUG|Diuretic therapy|Standard diuretic therapy according to the current guidelines
214363448|NCT06217757|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
214363449|NCT06217757|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
214490094|NCT06747533|OTHER|Standard Patient Education|"If participants are found to be eligible to take part in this study, participants will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups: the Standard Patient Education group or the Breathe Radiation Protocol Coaching group. This is done because no one knows if one study group is better, the same, or worse than the other group.~If participants are in the Standard Participants Education group, participants will receive standard of care participants education."
214490095|NCT06747533|OTHER|Breathe Radiation Protocol Coaching group|If participants are in the Breathe Radiation Protocol Coaching group, participants will have access to a video that helps guide participants through a relaxed breath hold for the radiation treatment and also access to a coach for questions about the breathing process during radiation. This coaching will take place in the week before participants undergo radiation planning.
214490096|NCT06746870|DRUG|IMM2510|"Cohort1:~Phase I #: 10 mg/kg or 20 mg/kg, Q3W, intravenous infusion Phase II \&: 20 mg/kg, Q3W, intravenous infusion~Cohort2:~Phase I #: 10 mg/kg or 20 mg/kg, Q2W, intravenous infusion Phase II \&: 20 mg/kg, Q2W, intravenous infusion"
214490097|NCT06746870|DRUG|Chemotherapy (pemetrexed + cisplatin/carboplatin)|Non-squamous non-small cell lung cancer (NQ-NSCLC): Pemetrexed 500 mg/m2 in combination with carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles, followed by maintenance treatment with pemetrexed
214974426|NCT02359461|DEVICE|Combination pulsatile Stendo3|
214974427|NCT06306976|PROCEDURE|Elective Midline Laparotomy|"Patients with midline ventral incisional hernia with a range of hernia morphology who plan to undergo open retromuscular VHR.~Hernia repair:~All study patients will have an open retromuscular repair with/without additional lateral MFR (TAR or EOR at the discretion of the operating surgeon). All repairs beginning with retrorectus dissection to the level of the linea semilunaris.~All patients will have permanent mesh reinforcement of the abdominal wall (large-pore, midweight polypropylene). Fascia will be closed over the mesh with 0 or 2-0 polydioxanone slowly absorbable suture using a small-bite technique and a 4:1 suture length:wound length ratio."
214974428|NCT06306976|PROCEDURE|Imaging: Ultrasound|"Ultrasound procedure will involve the following steps:~1\. For control group 1 and group 2 patients, Images will be taken at two points along the bilateral RA; at the level of the umbilicus and midway between the umbilicus and xiphoid process. Bilateral external oblique (EO), internal oblique (IO), and transversus abdominis (TA) images will be performed at the level of the anterior axillary line midway between the costal margin and iliac crest."
214974429|NCT06306976|OTHER|Tensiometry|"For all study patients, an analog spring-tensiometer will be used to assess intraoperative tension required to bring the fascia to the midline for closure. The tensiometer is attached to a clamp attached to the fascia at the midpoint of the hernia defect. Tension required for medialization to the midline will be performed after adhesiolysis (baseline), retrorectus dissetion, incision of the PLIO (if performed), and after completion of TAR or EOR (if performed).~Control group 2 patients will be undergoing first time laparotomy and will have tensiometry performed."
214974430|NCT04343352|OTHER|implementation of mobile epilepsy training program|"Mobile epilepsy training program will be applied to the application group for 3 months.~The mobile epilepsy training program developed within the scope of the thesis will be introduced to the parents in the application group and the participants will be uploaded to their phones via computer, and the use of the program will be taught in practice. In addition, the participants in the application group will be informed that the mobile epilepsy training program is not open to everyone during the research process, only the application group can use it. After the work is completed, the mobile application control group will be installed on the phones of the parents via computer, their application will be taught and applied."
214974431|NCT06466343|PROCEDURE|hysteroscopic resection of lower edge of cesarean scar niche|"Operative hysteroscopy will be used for surgical treatment in the cases. Hysteroscopic management of niche will be done according to the following steps: Operative procedure will be done postmenstrual, cervical preparation will be done by giving the patients misoprostol (misotac®) 400mcg two hours preoperative. Surgically, operative resectoscope (KARL STORZ, Germany,27 Fr gauge) will be inserted into the uterine cavity after cervical dilatation by Hegar uterine dilator up to 8. Distilled water will be used as distension media. Using a resectoscope, the lower edge of the niche will be trimmed, the base will be coagulated by using monopolar cutting current at 30-50 MHz.~The resected parts will be submitted together as one sampled specimen in one container of formaldehyde 30% (dissolved 800 ml water and 200 ml formaldehyde)"
215084592|NCT03959982|DIAGNOSTIC_TEST|6-minute walk|6-minute walk
215084593|NCT03959982|DIAGNOSTIC_TEST|CT scan|CT scan
214363450|NCT06217757|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 25 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
214490098|NCT06746870|DRUG|Chemotherapy (paclitaxel + cisplatin/carboplatin)|Squamous non-small cell lung cancer (SQ-NSCLC): Paclitaxel 175 mg/m2 + carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles.
214490099|NCT06746870|DRUG|Chemotherapy(Nab-paclitaxel)|Nab-paclitaxel, 100 mg/m2, 4 weeks as a cycle, administered on D1, 8, and 15 of each cycle.
214490100|NCT06823388|DEVICE|acupuncture|acupuncture
214490101|NCT06823388|DEVICE|pseudo-acupuncture|The pseudo-acupuncture device can simulate the sensation of acupuncture stimulation.
215084594|NCT03959982|OTHER|Medical Research Council dyspnea scale (MRC)|MRC questionnaire
215084595|NCT03959982|OTHER|St. George's Respiratory Questionnaire (SGRQ)|SGRQ questionnaire
215084596|NCT03959982|OTHER|COPD Assessment Test (CAT)|CAT questionnaire
215084597|NCT03959982|OTHER|Pittsburgh Sleep Quality Index (PSQI)|PSQI questionnaire
214363451|NCT06217757|DRUG|Sugemalimab|Sugemalimab will be administered by intravenous infusion at a dose of 1200mg on Day 1 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
214679614|NCT00002221|DRUG|Peripheral blood stem cells|
215084598|NCT03959982|OTHER|CASA-Q|CASA-Q questionnaire
214363452|NCT06217757|DRUG|Olaparib|Olaparib will be administered orally at a dose of 150mg qod Day 1,3,5,7 or 150 mg qd/150 mg bid/300mg in the morning and 150mg in the evening/300 mg bid on Day 1-7 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
214363453|NCT05177458|BEHAVIORAL|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% maximum heart rate) for 30 minutes on a treadmill.
214363454|NCT05177458|BEHAVIORAL|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at 40-50% of maximum heart rate) for 30 minutes.
214363455|NCT03176836|DIAGNOSTIC_TEST|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
214363456|NCT03176836|DIAGNOSTIC_TEST|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
214363457|NCT03176836|DIAGNOSTIC_TEST|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
214363458|NCT00586911|DRUG|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
214363459|NCT00586911|DRUG|Identical Placebo|Placebo
214363460|NCT06439563|DRUG|JP-1366 10 mg|JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
214363461|NCT06439563|DRUG|Lanston Capsule 15 mg|Lanston Capsule 15 mg orally once a day for up to 24 weeks
214490102|NCT05812859|DEVICE|Vaginal Orthosis (COSM Medical)|A vaginal orthosis will be 3-D printed by COSM Medical and provided for patients to use from week 2 through week 12 post-operatively. Device will be placed in morning and removed before bed daily.
214490103|NCT04095260|OTHER|Pre-season strength and conditioning program|The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
214490104|NCT05116774|DRUG|Eculizumab|Administered by intravenous infusion per current dose regimen
214490105|NCT05116774|DRUG|Ravulizumab|Administered by intravenous infusion per current dose regimen
214974432|NCT04046900|BIOLOGICAL|Vaginal microbiome transplant|Vaginal fluid from healthy donors
214974433|NCT04046900|DRUG|Oral Metronidazole|500mg oral metronidazole twice daily for 7 days
214490106|NCT05116774|DRUG|BCX9930|Administered orally twice daily
214490107|NCT06758492|DEVICE|Video laryngoscopy used to insert thin endotracheal catheter|Video laryngoscopy used to insert thin endotracheal catheter
214974434|NCT04046900|OTHER|Sterile saline|700 uL of sterile saline placed in the vagina as a placebo intervention.
214974435|NCT02758782|BIOLOGICAL|Golimumab|
214974436|NCT02758782|DRUG|Celecoxib|
214974437|NCT02666976|DRUG|Ilaprazole|Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
214363462|NCT06439563|DRUG|JP-1366 10 mg placebo|JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
214363463|NCT06439563|DRUG|Lanston Capsule 15 mg placebo|Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
214490108|NCT06758492|DEVICE|Direct laryngoscopy used to insert thin endotracheal catheter|Direct laryngoscopy used to insert thin endotracheal catheter
214490109|NCT03150862|DRUG|Pamiparib|Administered as specified in the treatment arm
214490110|NCT03150862|DRUG|TMZ|Administered as specified in the treatment arm
214974438|NCT05804812|BEHAVIORAL|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
214974439|NCT06203938|DEVICE|Transcranial infrared light stimulation|Trancranial infrared light stimulation administered via light-emitting diodes
214974440|NCT06203938|DEVICE|Sham|Identical to TILS, but with lights off
214974441|NCT04151069|OTHER|Procedure A|Up-dosing nut drink at home
214974442|NCT04151069|OTHER|Procedure B|Up-dosing nut drink at the hospital
214974443|NCT04151069|OTHER|Control group|Strict avoidance of tree nut consumption
214974444|NCT05494528|DRUG|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
214974445|NCT05494528|DRUG|Entecavir|Entecavir 0.5 mg once per day
214974446|NCT05488457|DRUG|deuterated oxytocin (d5OT)|Subjects will receive a 1 IU bolus of deuterated oxytocin (d5OT) intraoperatively during their nonemergent cesarean delivery.
214490111|NCT03150862|RADIATION|Radiation|Up to 60 Gy (total) over 6 - 7 weeks
214974447|NCT00685815|DRUG|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4
214974448|NCT00685815|DRUG|Placebo|250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4
215084599|NCT03959982|OTHER|Spirehealth Tag Device|Subjects will wear the Spirehealth Tag Device to measure heart rate, respiratory rate, sleep time, physical activity (movement), and calories burned with activity.
214490112|NCT06759948|DRUG|GC012F injection|"Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment, the infusion dose (CAR-T cells) and groups are as follows:~1. Dose group 1: 1 × 10\^5/kg;~2. Dose group 2: 2 × 10\^5/kg;~3. Dose group 3: 3 × 10\^5/kg; Note: For subjects weighing ≤70 kg: number of infused CAR-T cells = (1, 2 or 3) (±20%) × 10\^5 × body weight(kg); for subjects weighing \>70 kg: number of infused CAR-T cells (fixed doses of GC012F Injection) = (1, 2 or 3) (±20%) × 10\^5 × 70 kg."
214490113|NCT06758908|DEVICE|Antibiotic|SALI
214679615|NCT04077203|BEHAVIORAL|Biofeedback / No biofeedback|Biofeedback / No biofeedback
215084600|NCT00113750|BIOLOGICAL|TreeMATA MPL|
215084601|NCT02967939|DRUG|DA-2802|DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
215084602|NCT02967939|DRUG|Viread®|Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
214363464|NCT06047626|OTHER|Fatigue Reduction Diet|Sessions will be \~15 minutes for 8 sessions. The FRD maintains participants on a diet with their typical caloric intake as assessed at baseline, and replaces some of their calories with the following foods on a daily basis: at least 50% of servings grains to be whole grains (these would replace non-whole grain foods); 5 servings of vegetables (1 leafy green, 1 tomato, and 1 yellow/orange); 2 servings of fruit (1 high in vitamin C), both fruit and vegetables would replace some of the carbohydrates from non-fruit and vegetable sources; 1 serving of fatty fish and or 1 serving of nuts and/or seeds (2 servings of nuts and/or seeds for vegetarians), both the fish, the nuts, and seeds will replace existing sources of fats and proteins in the diet.
214363465|NCT06047626|OTHER|General Health Curriculum|These sessions will be matched counseling method, time spent (\~15 minutes per session), for 8 sessions. Registered Dietitians will discuss general health topics with the participant, excluding topics of diet and food.
214363466|NCT03640650|COMBINATION_PRODUCT|Dropless Therapy|The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
214363467|NCT03640650|DRUG|Usual Care|In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
214490114|NCT06759480|PROCEDURE|Laparoscopic radical hysterectomy based on space anatomy|This is a modified laparoscopic radical hysterectomy based on space anatomy. By identifying the vesicouterine ligament and four associated special spaces, the ureter can be completely liberated from the external aspect of the uterus. This skill not only reduces rate of surgical complications but also facilitates optimal tumor resection.
214490115|NCT06759480|PROCEDURE|Abdominal radical hysterectomy|This producre is a classic and traditional radical hysterectomy.
214490116|NCT06041256|COMBINATION_PRODUCT|AURN001|Corneal Endothelial Cells and Y27632
214490117|NCT06769659|DRUG|NPT 2042|NPT 2042 is a new drug being developed as an anti-seizure treatment
214490118|NCT06769659|OTHER|Placebo|Placebo Comparator
214490119|NCT06768619|DRUG|Group 1: single-dose of test formulation+single-dose of reference formulation|Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
214490120|NCT06768619|DRUG|Group 2: single-dose of reference formulation+single-dose of test formulation|Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
214490121|NCT06760247|PROCEDURE|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|endotracheal intubation by using direct laryngoscopy
214490122|NCT06750224|OTHER|Alexander technique|24 sessions for 8 weeks, per week 3 sessions will be given
214490123|NCT06750224|OTHER|Feldenkrais method|The method is divided into eight lessons according to 'Awareness Through Movement'. Each lesson will be given three times for one week.
214490124|NCT06750380|OTHER|Tailored mat exercise program|The Group A will receive TENS plus moist hot pack and follow the Tailored mat exercise program for 10 weeks, two times per week, in 45-min sessions under supervision of trained physical therapist. The choice of exercises will be made based on the suggested exercises of Wood for the treatment of back pain, while the easiest versions of each exercise would be selected in order for the program to be adapted to older adults. Patient's outcomes will be measured at baseline and after 10 weeks.
214490125|NCT06750380|OTHER|McKenzie exercises|The Group B will receive McKenzie exercises plus moist hot pack and TENS in the region of lumbar spine for 10 minutes and Mckenzie exercises of seven to ten repetitions for 45 min/session two times per week for ten weeks. Patient's outcomes will be measured at baseline and after 10 weeks.
214490126|NCT06398860|PROCEDURE|SIOHPS|The intervention is comprised of several core components such as targeted education, daily team reflections and support for systematic management. First, a two hour education will be conducted for management, HCW involved in patient safety work, safety representatives and intervention facilitators. The second core component is a short daily team reflection conducted by HCW at the unit in connection to the end of work shifts. These are standardized to support identification of situations at work related to both Safety I and II perspective for both occupational health and patient safety as well as learning. The third component includes risk assessment, planning and implementation of appropriate measures, follow up and evaluation, based in information identified in the second component. The steps in this component targets the management and should be conducted in close collaboration with HCW involved in patient safety work and the safety representatives.
214490127|NCT06398860|PROCEDURE|Wait-list|No intervention
214490128|NCT06762106|RADIATION|shockwave therapy|solid unite made with metal frame and case
214490129|NCT06762106|RADIATION|hot back|thermal hot back
214974449|NCT04566107|BEHAVIORAL|mHealth intervention|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses mobile health (m-Health) technology for daily messages and reminders to promote self-monitoring activities. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine).
214974450|NCT04566107|BEHAVIORAL|mHealth Plus|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses tailored self-management strategies (action planning, goal setting, and individual identified support needs) and mobile health (m-Health) technology for virtual visits, daily messages, and self-monitoring activities. The investigators will test the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the m-health platform. The NP will evaluate physiological and psychosocial status while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine). Participants will receive reminders through the platform.
214974451|NCT04080726|DRUG|HIP1601|Oral esomeprazole
214363468|NCT02380547|OTHER|Sonographic diaphragmatic measurements|
214679616|NCT03851679|DIAGNOSTIC_TEST|B-Type natriuretic peptide (BNP) serum values|"evaluation BNP serum values:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
214679617|NCT03851679|DEVICE|Pulmonary echography|"Pulmonary echography:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
214363469|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
214363470|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
214363471|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
214363472|NCT02549469|DRUG|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
214363473|NCT04653766|DRUG|Ir-CPI - Dose 1|6 participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
214490130|NCT06762353|PROCEDURE|3-month supportive peri-implant care (SPIC)|SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD \>4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 3-month frequency after surgical treatment of peri-implantitis.
214490131|NCT06762353|PROCEDURE|6-month supportive peri-implant care (SPIC)|SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD \>4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 6-month frequency after surgical treatment of peri-implantitis.
214490132|NCT06824805|BEHAVIORAL|Exercise|aerobic exercise for 30 minutes at 40-60% HRres
214490133|NCT06816056|OTHER|Manual Therapy|The patients included in the experimental group will receive a 50-minute physiotherapy intervention involving global passive mobilisation, calcaneocuboid mobilisation, talus-navicular mobilisation, talar manipulation, tibial displacement manipulation, tibiotarsal decompression, plantar fascia induction, tibiotarsal unwinding and triceps surae induction techniques
214490134|NCT06816056|OTHER|Placebo|The patients included in the control group will receive a 50-minute physiotherapy intervention in which the physiotherapist's hands and the times per technique will be the same as in the experimental group, but without applying any sliding, mobilisation or manipulation
214490135|NCT06826261|DEVICE|transcranial alternating current stimulation|The intervention employs transcranial alternating current stimulation (tACS), a non-invasive brain stimulation technique designed to modulate neural oscillations in targeted brain regions. tACS operates by applying low-intensity, alternating electrical currents through electrodes placed on the scalp, synchronizing with the brain's natural frequency patterns. In this arm, a frequency of 40 Hz (gamma frequency) is used to enhance oscillatory activity related to cognitive functions often impaired in Alzheimer's disease (AD). The Neuroelectrics Starstim-home device will be used. This compact, portable device allows for easy use within the home setting, reducing the need for daily clinic visits. Designated caregivers will administer the one-hour tACS sessions under remote supervision via a digital monitoring portal, which tracks adherence, technical performance, and safety data in real time.
214502765|NCT04827810|DRUG|Gamitrinib|This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
214502766|NCT06670313|OTHER|postop Erector spinae plane block|Postoperative ESP block was performed as the control group
214974452|NCT04080726|DRUG|HGP1705|Oral Nexium Tab
214974453|NCT04080726|DRUG|HIP1601 Placebo|Oral Placebo
214974454|NCT04080726|DRUG|HGP1705 Placebo|Oral Placebo
214974455|NCT04907292|OTHER|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
214974456|NCT03071211|DEVICE|Plug-unplug catheter management|Transurethral catheter is plugged with a plastic cap and participants are taught to unplug during the day when they feel the urge to void or at least every 4 hours.
214363474|NCT04653766|DRUG|Ir-CPI - Dose 2|6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
214363475|NCT04653766|DRUG|Ir-CPI - Dose 3|6 participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
214363476|NCT04653766|DRUG|Ir-CPI - Dose 4|6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
214363477|NCT04653766|DRUG|Placebo|For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
214363478|NCT01584765|DRUG|Prescription drugs with known hepatotoxicity|14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
214363479|NCT05840432|DEVICE|Postoperative hypotension prediction index|Performance of the hypotension prediction index (HPI) in predicting hypotension episodes in the first 12 h of cardiac surgery postoperative
214363480|NCT02563496|DRUG|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
214363481|NCT02563496|DRUG|Chloroquine|Subjects may receive chloroquine according to local/national treatment guidelines.
214363482|NCT03275025|DRUG|YRA-1909 low dose|A low dose of YRA-1909; daily oral intake for 12 weeks
214363483|NCT03275025|DRUG|YRA-1909 mid dose|A mid dose of YRA-1909; daily oral intake for 12 weeks
214363484|NCT03275025|DRUG|YRA-1909 high dose|A high dose of YRA-1909; daily oral intake for 12 weeks
214363485|NCT03275025|DRUG|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
214363486|NCT02515760|PROCEDURE|Bone marrow aspiration from the iliac crest|
214974457|NCT03071211|DEVICE|Continuous drainage catheter management|Transurethral catheter is attached to a continuous drainage bag.
214490136|NCT06826261|DEVICE|sham transcranial alternating current stimulation|The intervention employs transcranial alternating current stimulation (tACS), a non-invasive brain stimulation technique designed to modulate neural oscillations in targeted brain regions. tACS operates by applying low-intensity, alternating electrical currents through electrodes placed on the scalp, synchronizing with the brain's natural frequency patterns. In this arm, the stimulation will be delivered in 'sham' mode which is characterized by 30 seconds of tACS stimulation at the beginning and end of the protocol to help with blinding. During the rest of the stimulation period (1h) no stimulation will be delivered. The Neuroelectrics Starstim-home device will be used. This compact, portable device allows for easy use within the home setting, reducing the need for daily clinic visits. Designated caregivers will administer the sham tACS sessions under remote supervision via a digital monitoring portal, which tracks adherence, technical performance, and safety data in real time.
214363487|NCT02515760|DEVICE|Illinois bone marrow aspiration neddle|
214363488|NCT03717896|DRUG|200mg IV thiamine in 50mL 0.9% saline|Thiamine 200mg IV every 12 hours for 2 days
214363489|NCT03717896|DRUG|Placebo|50mL 0.9% saline
214363490|NCT06075108|OTHER|P-KIDs CARE|The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
214363491|NCT06974591|OTHER|Dental splints|Each participant will receive six custom-made dental splints to incrementally increase their VDO. These splints will alter the VDO in increments from 5 to 30 mm, specifically: 5, 10, 15, 20, 25, and 30 mm.
214363492|NCT06974591|OTHER|Dentures|Participants in this group will participate in balance and gait testing both with and without their dentures to examine how the presence or absence of dentures affects postural stability and movement.
214363493|NCT05625191|DIAGNOSTIC_TEST|Acoustic voice analysis|Acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in different voice conditions. Control participants will produce voice in breathy, typical, and pressed conditions. Patient participants will produce voice in typical production and in a resonant voice production. High-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition. Data will be collected using a head-mounted microphone.
214363494|NCT05625191|DIAGNOSTIC_TEST|High-speed videoendoscopy|High-speed videoendoscopy will occur on one repetition of a sustained /i/ in each requested condition. Exams will be recorded using the Phantom V311 high-speed camera (Vision Research, Wayne, NJ) connected to a Storz 70° rigid laryngoscope using a 400 Watt Xenon light source (Titan 400E).
214490137|NCT03987282|OTHER|Enhanced usual care (EUC)|Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
214363495|NCT04526795|DRUG|Cytarabine|Given IV
214490138|NCT03987282|BEHAVIORAL|Peer-based counseling|Peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT
214679618|NCT03851679|OTHER|urine collection|6 hour and 24 hour urine collection after Cesarean Section
214974458|NCT03669549|DRUG|Nevanimibe hydrochloride|During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.
214490141|NCT06588231|BEHAVIORAL|Individual rehabilitation exercise training|Under the guidance of a specialist, medium-and high-intensity interval training was conducted for 16 weeks, 3 times a week, 30-40 minutes each time, including the beginning of 5 minutes of warm-up and the last 5 minutes of cooling-off period, during which the exercise included 4 intervals, with the 85-95% pre intensity of HR reserve for 15-18 minutes, and then with the 50-70% pre intensity of HR reserve for 12-14 minutes, exercise for 3 minutes, and so on for 4 times. Warm-up and cooling-off periods can be done through stretching exercises, flexibility exercises (that is, neck, shoulders, upper back, buttocks and ankles) and low and medium intensity (50-70% heart rate reserve)
214490142|NCT06588231|DRUG|optimal medical therapy ：aspirin, clopidogrel, statins.|those in the control group were treated with routine antiplatelet drugs and lipid-lowering drugs after operation. Professional salesmen, according to the specific physical conditions of the patients, formulate corresponding recipes to ensure that the patients have a light diet, low salt, low fat and high nutritional value, and prohibit tobacco and alcohol.
214490143|NCT04445025|DRUG|Elagolix 200 MG|Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation
214490144|NCT04445025|DRUG|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation
214490145|NCT04445025|DIAGNOSTIC_TEST|Lab work|Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw
214974459|NCT04845997|BIOLOGICAL|COVID-19 Vaccine|Patients with rheumatic diseases who have been vaccinated for COVID-19
214974460|NCT04624113|DRUG|Tazemetostat|Epizyme will supply the study agent, which will be provided free of charge to the patient.
214363496|NCT04526795|DRUG|Fludarabine|Given IV
214363497|NCT04526795|DRUG|Pegcrisantaspase|Given IV
214363498|NCT06019117|DIETARY_SUPPLEMENT|Probiotic K10|clinical trial using 90 days of probiotic K10
214974461|NCT04624113|DRUG|Pembrolizumab|Pembrolizumab is commercially available
214974462|NCT00055341|DRUG|Peginterferon alfa-2a|
214363499|NCT06019117|DRUG|Placebo|clinical trial using 90 days of placebo controlled
214363500|NCT04288505|DIAGNOSTIC_TEST|VIRTUAL REALITY application|application on virtual reality headset
214363501|NCT02693990|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
214363502|NCT05258162|OTHER|Mobilization|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Mobilisations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~  3 days per week for 3 weeks. Oscillations for 2 minutes at 2-3 oscillations per second."
214363503|NCT05258162|OTHER|Muscle Energy Technique|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.~  3 days per week for 3 weeks."
214363504|NCT00680511|BEHAVIORAL|Adolescent Methamphetamine Treament (AMT)|AMT Group Therapy plus Functional Family Therapy (FFT)
214363505|NCT00680511|BEHAVIORAL|Functional Family Therapy (FFT)|FFT
214363506|NCT01522417|DRUG|Short Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
214490146|NCT05375903|DRUG|UGN-301|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
214490147|NCT05375903|DRUG|UGN-201|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
214490148|NCT05375903|DRUG|Gemcitabine|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
214490149|NCT06755957|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Posture exercise, stretching exercise, breathing exercise, back strengthening exercise, self-mobilization exercise, cat camel exercise and postural correction exercise will be applied.
214490150|NCT06755957|OTHER|CONTROL|Posture exercise, stretching exercise, breathing exercise, back strengthening exercise, self-mobilization exercise, cat camel exercise will be applied.
214490151|NCT04222062|DRUG|Carmustine 7.7Mg Wafer|GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
214490152|NCT06883604|RADIATION|Proton therapy.|Pencil beam scanning proton therapy to a dose of 20 or 29.75 Gy (RBE) after standard chemotherapy (2-4 ABVD).
214490153|NCT06884553|DEVICE|Robotic therapy (Gloreha Sinfonia system)|"Group A will receive rehabilitative treatment using the Gloreha Sinfonia system . The treatment regimen spans five weeks and encompasses a progressive series of exercises. Gloreha features an adaptable mechanical design developed for hand rehabilitation. Its activities involve grasping and releasing, facilitated through a lightweight and flexible orthosis. The device, comprising a robotic glove and mechanical arm, enables both finger mobility and upper limb support, facilitating semi-autonomous execution of motor tasks. Gloreha's versatility allows for exercises involving the entire upper limb, including motor-cognitive serious games utilizing virtual reality and interaction with real objects. Real-time feedback enhances patient self-assessment. Moreover, the robot incorporates an automated component interfacing with flexion sensors, gauging the patient's autonomous engagement in Occupational Therapy tasks and serious games."
214502767|NCT03737409|OTHER|Ambulatory Oxygen Therapy|Supplemental oxygen delivered during exercise and activities of daily living via a portable oxygen concentrator
214974463|NCT00055341|DRUG|Ribavirin|
214974464|NCT05262920|BEHAVIORAL|The BSM Intervention|The BSM intervention entailed a daily electronic journal for monitoring BF and BNP with feedings, bi-weekly texting for 6 weeks from a research nurse for informational support and to promote personalized goal-setting and problem-solving, and hyperlinks to eight uniform BNP educational modules (knowledge and skills) and online resources. 1. Fundamentals of BF (FBF), 2. Deep breathing (DB), 3. BNP non-pharmacological strategies (BNPS), 4. Guided imagery (GI), 5. Pain neurophysiology specifically related to BF (PN-BF), 6. Catastrophizing, 7. Stress reactivity, and 8. Common pumping issues and interventions (CPI).
214974465|NCT05262920|BEHAVIORAL|Attention Control|The Attention Control and Intervention groups both receive fourth-trimester care videos. The educational modules are the following: Urgent maternal warning signs, caring for the maternal body after birth; infant care; COVID-19 and infant health prevention; maternal and infant immunization; infant safety in the home; maternal and infant dietary recommendations; and national and health resources to support BF in the workplace
214974466|NCT06282991|DRUG|Lorlatinib|ALK/ROS1 tyrosine kinase inhibitor
214974467|NCT04577599|OTHER|Mobile Low-dose Computed Tomography (LDCT) Screening|Low Dose CT Scan of the Chest
214974468|NCT05068843|PROCEDURE|arthroscopic partial meniscectomy|In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.
214974469|NCT05068843|OTHER|Physical therapy|The treatment protocol consisted of a physical therapist-led incremental exercise program over a period of eight weeks, containing 16 sessions of 30 minutes each.
214502768|NCT03737409|OTHER|Sham Ambulatory Oxygen Therapy|Air delivered during exercise and activities of daily living via a portable oxygen concentrator that has been modified to deliver air
214502769|NCT06587789|DRUG|Ribociclib|Participants will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy (according to standard clinical practice, TAM or AI, with or without OFS).
214502770|NCT06592859|DIETARY_SUPPLEMENT|NMN|NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.
214363507|NCT01522417|DRUG|Eptifibatide|180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
214363508|NCT01522417|DRUG|Long Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.
214363509|NCT04406493|DIAGNOSTIC_TEST|Lung impedance technique|"COVID 19 patients are admitted to the Infectious Diseases Unit; they will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization, each patient will undergo this examination twice a day until discharge.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation.~The time between lung impedance started to decrease (expression of the lung fluids accumulation), and the need for mechanical ventilation will be measured."
214363510|NCT04023240|DRUG|68Ga-FAPI|"68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)"
214363511|NCT04023240|PROCEDURE|Computed Tomography (CT) scan|Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
214363512|NCT04023240|PROCEDURE|Positron Emission Tomography (PET) scan|PET images will be acquired.
214363513|NCT04788550|COMBINATION_PRODUCT|Fluoridated toothpaste|Group 1 will act as control group. Participants will be advised to brush twice daily using fluoridated toothpaste during the follow up periods. No other fluorides supplements will be allowed to use.
214490154|NCT06884553|OTHER|Occupational therapy|"Occupational Therapy is also recommended in Stroke Rehabilitation Clinical Guidelines. However, its implementation in rehabilitation services in Italy is still limited, presumably due to regulatory factors. For stroke patients, the goal of occupational therapy is to enhance the ability to perform activities of daily living, often focusing on the use of the hand and upper limb in purposeful tasks. Strategies employed by occupational therapists include assessment, treatment, compensation strategies, assistive technologies, and environmental adaptations.~Occupational therapy appears to enhance performance in activities of daily living and reduce the likelihood of impairment in these abilities, although the evidence is of low quality. There is also limited and moderately quality evidence in the area of occupational therapy for addressing depressive and anxiety symptoms in hospital-based rehabilitation for physical disabilities."
214974470|NCT02974868|DRUG|PF-06651600|200 mg QD during induction and 50 mg QD during Maintenance
214974471|NCT02974868|DRUG|PF-06700841|60 mg QD during induction and 30 mg QD during maintenance
214490155|NCT06884553|BEHAVIORAL|Control|Participants will be provided guidance by a skilled physiotherapist to follow a customized exercise regimen independently within the comfort of their homes. This program will specifically target the upper limb and will be tailored according to the evaluation performed at the initial assessment.
214974472|NCT02974868|DRUG|Placebo|Placebo
214974473|NCT02121171|DEVICE|Ologen Collagen Matrix|Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
214974474|NCT02121171|PROCEDURE|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
214974475|NCT01362764|DRUG|Abiraterone acetate suspension Formulation 1|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
214974476|NCT01362764|DRUG|Abiraterone acetate suspension Formulation 2|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
214974477|NCT01362764|DRUG|Abiraterone acetate tablets|Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
214974478|NCT02193750|DIETARY_SUPPLEMENT|Placebo|1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
214974479|NCT02193750|DIETARY_SUPPLEMENT|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
214974480|NCT02193750|DIETARY_SUPPLEMENT|High Oligosaccharide Group|1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
214974481|NCT01885013|DRUG|Metformin + Myocet + Cyclophosphamide|"Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os\*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~\* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
214974482|NCT01885013|DRUG|Myocet + Cyclophosphamide|"Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles"
214974483|NCT04726735|BIOLOGICAL|Samples of bladder tissue|Samples of bladder tissue collected between 2007 and 2011.
214974484|NCT05385146|OTHER|qigong|Chan-Chuang qigong with breathing meditation for 15 weeks
214974485|NCT03817606|DEVICE|Tritanium Posterior Lumbar Cage|Placement of Tritanium Posterior Lumbar Cage via TLIF procedure
214974486|NCT03817606|DEVICE|AVS UniLIF PEEK Posterior Lumbar Cage|Placement of AVS UniLIF PEEK Posterior Lumbar Cage via TLIF procedure.
214974487|NCT02436824|DRUG|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
214974488|NCT02436824|OTHER|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
214974489|NCT04479839|DIAGNOSTIC_TEST|Ultrasound of the airway|Placing ultrasound on the neck after intubation
214974490|NCT06074185|DRUG|Ipratropium Bromide|The study intervention involves implementing a treatment bundle that includes inhaled ipratropium bromide and dexamethasone.
215084603|NCT03191370|OTHER|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
214502771|NCT06592859|DIETARY_SUPPLEMENT|placebo|Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
214363514|NCT04788550|COMBINATION_PRODUCT|fluoride varnish (5% sodium fluoride)|Approximately 0.5-1.0ml fluoride varnish will be applied on the tooth surface (labially) with the paint-on method fom canines to canines. No other fluorides supplements will be allowed to use.
214363515|NCT04788550|COMBINATION_PRODUCT|CPP-ACP plus crème group|Pea size CPP-ACP plus crème on the tooth surfaces using a clean fingers twice daily after brushing their teeth with fluoridated toothpaste. No other fluorides supplements will be allowed to use.
214363516|NCT03538470|OTHER|Spa Treatment|"* Bath with immersion shower~* Overall penetrating shower~* Multiple local application cataplasm~* Individual physiotherapy~* Mobilisation pool"
214490156|NCT06734559|DIAGNOSTIC_TEST|Patients who have not antibiotic treatment for acute apical periodontitis in the last month and have not taken any anti-inflammatory medication in the past 24 hours.|Patients with acute apical periodontitis will first have masseter muscle measurements in the relevant area and then the decayed tooth will be treated with calcium hydroxide for 14 days. Then the dressing will be applied with calcium hydroxide again. At the end of 28 days, the patient will be measured again by ultrasonography and the initial and final data will be compared.
214490157|NCT06734559|OTHER|patients who have not acute apical periodontitis|Masseter measurements will be made from day 1 to day 28 in healthy subjects without acute apical periodontitis.
214974491|NCT03940872|DIAGNOSTIC_TEST|Self-questionnaire 3PDQ|"Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire.~\- An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once."
214974492|NCT00994305|DRUG|N-acetylcysteine|600 mg bid po 0-7 PO
214974493|NCT00994305|DRUG|control|No treatment: standard care provided. No N-acetylcysteine administration.
214974494|NCT02130947|BEHAVIORAL|Exercise|
214974495|NCT00297648|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
214974496|NCT00480571|DRUG|BL-1020|BL-1020 Low Dose
214974497|NCT00480571|DRUG|BL 1020 High Dose|BL 1020 High Dose
214974498|NCT05238636|PROCEDURE|Anti-reflux surgery - Stretta procedure or LINX device or laparoscopic fundoplication|This is an observational study. Patients will choose which anti-reflux procedure (Stretta, LINX or fundoplication) they undergo with their clinician, as is standard practice, after which they will be offered recruitment to this study, which will perform investigations to assess for changes in physiology and symptoms.
214974499|NCT02499055|BEHAVIORAL|FearFighter|FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
214974500|NCT03641261|OTHER|Therapeutic patient education program|WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team
214974501|NCT03212040|DIAGNOSTIC_TEST|needle biopsy|breast biopsy using different needle gauges
214974502|NCT00025389|BIOLOGICAL|bevacizumab|
214974503|NCT00025389|DRUG|carboplatin|
214974504|NCT00025389|DRUG|paclitaxel|
214974505|NCT00025389|PROCEDURE|conventional surgery|
214974506|NCT00025389|PROCEDURE|neoadjuvant therapy|
214974507|NCT05705999|DEVICE|transcranial magnetic stimulation|The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% RMT. The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10-minute break in between each session
214363517|NCT05725317|DEVICE|LID220365 contact lens|Investigational delefilcon A spherical contact lens made with a modified manufacturing process
214363518|NCT05725317|DEVICE|LID006961 contact lens|Commercially available delefilcon A spherical contact lens
214490158|NCT06890975|BEHAVIORAL|Lifestyle Coaching|"The schedule for the individual and group coaching sessions is summarized below:~* Individual Coaching: Six one-on-one online sessions with a trained dietician, starting with an initial 30-minute session at baseline, followed by sessions at one month and then every other month.~* Group Coaching: 60-minute group online sessions with up to 15 participants per group. Group sessions schedule: there will be a total of 13 group sessions. They will meet once a week for the first 4 weeks, twice monthly for the next 8 weeks of follow-up, and then monthly for the remaining follow-up until the 13th session."
214490159|NCT06890715|DRUG|Test product (T): Ramelteon Modified-Release Tablets|Oral, take 1 tablet at a time, once a day.
214490160|NCT06890715|DRUG|Reference product (R): Ramelteon Tablets|Oral, take 1 tablet at a time, once a day.
214974508|NCT02515435|DRUG|apatinib single agent|For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
214974509|NCT01876524|DEVICE|Transcranial Random Noise Stimulation|Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
214974510|NCT00368628|PROCEDURE|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
214974511|NCT01106131|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
214974512|NCT01106131|DRUG|Pioglitazone 15mg|Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
214363519|NCT00327626|DRUG|ISIS 113715|
214363520|NCT05675657|OTHER|No Block|The patients will receive general anesthesia.
214363521|NCT05675657|PROCEDURE|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
214363522|NCT05675657|PROCEDURE|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
214363523|NCT05525273|DRUG|Oral dabrafenib and trametinib|Neoadjuvant or postoperative treatment of patients with verified BRAF mutated papillary craniopharyngioma
214363524|NCT03062969|PROCEDURE|Cleavage stage biopsy group|"* intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~* Time lapse embryo culture~* Cleavage stage biopsy~* aCGH analysis~* Fresh euploid embryo transfer"
214490161|NCT06892028|DEVICE|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
214490162|NCT06892028|DEVICE|Sham Comparator|Sham Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG). No stimulation is provided.
214490163|NCT06894641|BEHAVIORAL|Cognitive Behavior Therapy for Older Adults (CBT-OA)|CBT-OA integrates modifications to standard CBT to consider age-related physical, cognitive and psychological changes. CBT-OA also integrates positive psychiatry principles for older adults to promote behavioural change and health attitude change.
214490164|NCT06749886|DRUG|Denosumab|Denosumab, 120 mg subcutaneous injection, every 21-28 days a cycle, given on the first day, a loading dose is given on d8 of the first cycle, and continued use
214490165|NCT06749886|DRUG|tislelizumab|Tislelizumab, 200 mg intravenous infusion, every 21 days a cycle, given on the first day, and continued use
214679619|NCT01072279|OTHER|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
214974513|NCT03903172|DEVICE|Abdominal binder|Abdominal binder
214974514|NCT01545388|DRUG|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
214974515|NCT01545388|DRUG|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
214974516|NCT01545388|DRUG|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
214974517|NCT01545388|DRUG|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
214974518|NCT01701245|DEVICE|GammaCore|vagal stimulation
214974519|NCT01909700|DEVICE|Single Incision Mesh|Single Incision Mesh is implanted for pelvic floor reconstruction
214974520|NCT01711697|RADIATION|stereotactic body radiation therapy|Undergo SBRT
214974521|NCT01711697|DRUG|carboplatin|
214974522|NCT01711697|DRUG|paclitaxel|
214974523|NCT01711697|RADIATION|radiation therapy|Undergo radiation therapy
214974524|NCT05295381|DEVICE|cough machine (CM)|Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
214363525|NCT03062969|PROCEDURE|Trophectoderm biopsy group|"* ICSI-IVF~* Time lapse embryo culture~* Day 3 zona pellucida opening~* Trophectoderm biopsy~* aCGH analysis~* Frozen-thawed euploid embryo transfer"
214363526|NCT03520764|DIETARY_SUPPLEMENT|New infant formula with synbiotics|Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.
214363527|NCT03520764|DIETARY_SUPPLEMENT|Standard infant formula with prebiotics|Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.
214363528|NCT00000727|DRUG|Pentamidine isethionate|
214363529|NCT00000727|DRUG|Pyrimethamine|
214363530|NCT00000727|DRUG|Sulfamethoxazole/Trimethoprim|
214363531|NCT00000727|DRUG|Sulfadoxine/Pyrimethamine|
214363532|NCT00000727|DRUG|Zidovudine|
214363533|NCT05579418|DRUG|Evolocumab|Evolocumab is an injection for management of dyslipidemia
214363534|NCT00344461|DRUG|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
214363535|NCT01839929|DRUG|Prograf|oral
214974525|NCT05295381|DEVICE|abdominal weight training (AWT)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
214974526|NCT03780582|BEHAVIORAL|AI-human interaction|Exploring what kinds of AI-human interaction improve radiologists detection accuracy.
214363536|NCT01839929|DRUG|Advagraf|oral
214363537|NCT02096523|OTHER|Blood collection for platelet protein samples|
214363538|NCT04189562|OTHER|SMS Intervention|Delivery of text messages will use the text messaging program Simple Online Family Intervention for ADHD (SOFIA).
214363539|NCT01229930|DRUG|carboplatin|
214363540|NCT01229930|DRUG|cediranib maleate|
214363541|NCT01229930|DRUG|paclitaxel|
214363542|NCT01229930|OTHER|laboratory biomarker analysis|
214363543|NCT01229930|OTHER|pharmacological study|
214363544|NCT01229930|PROCEDURE|quality-of-life assessment|
214490166|NCT06749886|DRUG|Docetaxel|Docetaxel, 60 mg/m2 intravenous infusion, every 21 days a cycle, given on the first day, and continued use.
214679620|NCT01072279|OTHER|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
214679621|NCT05496803|OTHER|routine education plus digital video disk|Parents receiving routine education plus digital video disk before their children receiving congenital heart disease catheterization. The DVD content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
214974527|NCT02633722|BEHAVIORAL|Lifestyle intervention B|Time limiting feeding from 8-5pm (TRFb)
214974528|NCT02633722|BEHAVIORAL|Lifestyle Intervention D|Time limiting feeding (12-9pm)
214974529|NCT00358358|DRUG|Fluticasone Propionate/Salmeterol 500/50mcg combination|
214363545|NCT05945433|DEVICE|anovo™ Surgical System|The anovo Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS during single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.
214490167|NCT06750900|OTHER|NORMAL CONDITION|They perform 3 lumbar extensions until the onset of pain without virtual reality
214490168|NCT06750900|OTHER|UNDERSTATED CONDITION|They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10%less than they are really moving.
214363546|NCT00000126|PROCEDURE|Surgery|
214363547|NCT03063294|OTHER|Online Toolkit|The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
214490169|NCT06750900|OTHER|OVERSTATED CONDITION|They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10% more than they are really moving.
214490170|NCT06738823|PROCEDURE|INTERVENTION GROUP : TRAINING WITH WIIFIT|RCT (RANDOMIZED CONTROL TRIAL) GROUP 1 : Wii FIT TRAINING TIGHT ROPE TENSION, SKI SLALOM, PENGUIN SLIDE, TABLE TILT GROUP 2 : VESTIBULAR REHABILITATION TRAINING WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
214490171|NCT06738823|PROCEDURE|VESTIBULAR REHABILITATION TRAINING|WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
214490172|NCT06891209|OTHER|Non-Interventional Study|Non-interventional study
214490173|NCT06756568|DIAGNOSTIC_TEST|Reduced Morbidity|Early and accurate diagnosis using ultrasound minimizes delays in treatment initiation, thereby preventing complications such as chronic pain and abscess formation. By reducing the severity and duration of the disease, ultrasound contributes to improved patient well-being and a quicker recovery trajectory.
214490174|NCT06760377|DIETARY_SUPPLEMENT|Dietary supplement Group|Subjects belonging to the experimental group will be provided with the PermeaIntest supplement, which they will take for 60 days, 1 sachet in the morning and 1 sachet in the evening in half a glass of water. Subjects will have a stool sample collected before and after ingestion of the dietary supplement.
214490175|NCT06751381|DEVICE|IVIM Imaging MRF Imaging|"IVIM imaging will be performed to evaluate microstructural and perfusion changes in the salivary glands of nasopharyngeal carcinoma patients undergoing radiotherapy. This technique quantifies diffusion and perfusion parameters, providing insights into early tissue damage.~MRF imaging will be used to quantify salivary gland tissue characteristics, including relaxation parameters (T1 and T2 mapping), to monitor radiotherapy-induced damage. The technique enables precise tissue characterization through multi-parametric MRI."
214490176|NCT06748781|PROCEDURE|Pulpectomy using 2.5% Calcium Hypochlorite root canal irrigant.|2.5% Calcium Hypochlorite used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.
214490177|NCT06748781|PROCEDURE|Pulpectomy using Saline as root canal irrigant|Saline used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.
214490178|NCT06754631|DRUG|Continuous Nebulization of Salbutamol|Children received continuous nebulization of salbutamol at a concentration of 0.3 mg/kg/hour for 4 hours, with a minimum of 5 mg/hour and a maximum of 15 mg/hour administered via High Output Extended Aerosol Respiratory Therapy (HEART).
214490179|NCT06754631|DRUG|Intermittent Nebulization of Salbutamol|were treated with intermittent nebulization of salbutamol at a dose of 0.15 mg/kg/dose, administered through a face mask with an oxygen flow rate of 6-8 L per minute. They Children received at least 2-3 nebulizations and no more than 7.5 mg/dose every 30 minutes for 4 hours.
214490180|NCT06761859|OTHER|Aromatherapy Inhalation in Psychiatric Nurses|Aromatherapy inhalation using 2% diluted lavender essential oil will be applied to 33 psychiatric nurses in the experimental group, 30 minutes before starting work, every other day during a week. The lavender essential oil to be used in the study will be dropped 3 drops onto a cotton handkerchief cut into a disc shape and fixed to the clothes of the psychiatric nurses, 20 cm away from their noses, and they will be asked to inhale it for 30 minutes.
214679622|NCT05496803|OTHER|routine education|Parents receiving routine education before their children receiving congenital heart disease catheterization
214679623|NCT02804802|OTHER|questionnaire|dietary habits and physical activity questionnaire
214974530|NCT00358358|DRUG|Fluticasone Propionate 500mcg|
214974531|NCT00358358|DRUG|Salmeterol 50mcg|
214974532|NCT02541617|PROCEDURE|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
214974533|NCT02541617|PROCEDURE|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
214974534|NCT04078464|OTHER|Mindfulness Training Alone|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 36 minutes.
214974535|NCT04078464|OTHER|Acute Physical Activity Alone|Physical activity will include a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
214974536|NCT04078464|OTHER|Acute Physical Activity and Mindfulness Training Together|Participants will listen to a pre-recorded mindfulness meditation which will guide them through a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
214974537|NCT04477135|OTHER|upper extremity pain|upper extremity pain in perinatologists due to working actively and performing ultrasonography every day
214974538|NCT04477135|PROCEDURE|ultrasonography|ultrasonography
214974539|NCT02338817|DEVICE|Diabetes Sentry|The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
214363548|NCT03063294|OTHER|Distance-based coaching|The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
214363549|NCT04760418|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)|A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use
214363550|NCT04584229|OTHER|Intervention|Intervention: comprehensive individual or collective interview, recorded and transcribed
214363551|NCT00142441|DEVICE|Pulsed dye laser|
214490181|NCT06755918|BEHAVIORAL|Control|Children will be monitored when fowler is in position during the use of nebulizers. In the Fowler position, the drug will be drained into the nebulizer chamber. Mask and nebulizer connections will be completed. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. Routine nursing care is applied during the use of nebulizer. During the use of a control group nebulizer, routine nebulizer will be used without video game and mask painting. After the receipt of the receipt, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
214490182|NCT06755918|BEHAVIORAL|Video game|Children will be monitoring while the fowler position during the use of nebulizers. While the Fowler position is in the position of the drug, the drug will be drained into the nebulizer reservoir. The nebul mask will be attached to cover the mouth and nose. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. At the same time, the Water-Sorting Game will be introduced while the use of nebul will be introduced and you will be asked to play. After the receipt of the receipt, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
214490183|NCT06755918|BEHAVIORAL|Mask painting|While the Fowler position is in the position of the drug, the drug will be drained into the nebulizer reservoir. The nebul mask will be attached to cover the mouth and nose. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. At the same time, mask painting process will be introduced while the use of nebul continues. For mask painting, six color paint will be given and the shapes and colors will be completely left to the child by leaving it to him. After the mask painting and receipt is finished, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
214490184|NCT06753318|DIAGNOSTIC_TEST|The assistance of the Joint-AI model|Predictions given by the Joint-AI model will be provided to the endoscopists during their diagnosis
214490185|NCT06753318|DIAGNOSTIC_TEST|The assistance of the interpretable Joint-AI model|Predictions given by the Joint-AI model and the results of the interpretability analysis will be provided to the endoscopists during their diagnosis
214490186|NCT06760026|PROCEDURE|2-octyl cyanoacrylate tissue adhesive applied continuously over the Pfannenstiel-type cesarean incision|2-octyl cyanoacrylate tissue adhesive applied continuously over the Pfannenstiel-type cesarean incision
214490187|NCT06760026|PROCEDURE|subdermal suture|wound closure with subdermal sutures using 2-0 nylon thread, under the same evaluation scheme
214490188|NCT03857646|DRUG|Intralipid, 20% Intravenous Emulsion|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
214490189|NCT03857646|DRUG|Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
214490190|NCT06760325|BEHAVIORAL|Tidal Model Intervention|"The model emphasizes long-term developmental care, extending support from hospital to home after discharge. This approach equips individuals with skills to understand and address challenges, emphasizing therapeutic interventions and sustained support through professionals or community groups. By focusing on the chaos and tide concepts of the Tidal Model, psychosocial interventions aim to enhance independence, manage symptoms, and improve quality of life.~In this arm, Tidal Model-based approaches will be applied during home visits to COPD patients. Within the scope of the intervention, psychosocial needs of patients will be assessed, individualized care plans will be created and symptom management and independence will be promoted by focusing on the chaos and tide concepts of the Tidal Model."
214974540|NCT06355024|DRUG|Inosine|oral inosine 200mg tid
214974541|NCT06355024|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
214974542|NCT02265965|DRUG|intravenous nitroglycerin|Infusion at started at time of hysterotomy and stopped at neonate delivery
214974543|NCT06552117|OTHER|an elastoMRI sequence|Addition of an MRI elasto sequence performed during MRI performed as part of the treatment
214974544|NCT02276469|BEHAVIORAL|peer support|peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
214974545|NCT04683640|DIETARY_SUPPLEMENT|GABA|Daily oral GABA for 4 weeks
214974546|NCT04683640|DRUG|Placebo|Daily oral Placebo for 4 weeks
214974547|NCT00445471|BEHAVIORAL|Mifne Approach to PDD|
214974548|NCT00445471|BEHAVIORAL|Treatment as usual|
214974549|NCT05670743|DRUG|38% silver diamine fluoride|Topical application of 38% silver diamine fluoride to dental caries lesions
214974550|NCT01867008|DEVICE|Nucleus CI422 Cochlear Implant with N6 Sound Processor|
214974551|NCT00371956|DRUG|raloxifene|60mg/day
214974552|NCT00371956|DRUG|placebo|tab 1 daily
214974553|NCT04613518|DRUG|BMS-986165|Specified Dose on Specified Days
214974554|NCT04613518|OTHER|Placebo Comparator|Specified Dose on Specified Days
214974555|NCT05252715|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.
214974556|NCT05252715|BIOLOGICAL|Meningococcal A and C Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.
214363552|NCT02660632|OTHER|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
214363553|NCT02660632|OTHER|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
214490191|NCT06767150|DRUG|a second infusion of ZOL when crosslaps levels reach 300 pg/mL|a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg/mL, no later than month-12
214490192|NCT06767150|DRUG|a rescue second infusion at month-12 (standard traitment)|a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome
214490193|NCT06765837|DEVICE|biolase laser|after secondary cleft lip surgery to improve wound healing and prevent scar formation laser was used with group I and Gel was applied to Group II
214490194|NCT06765837|DRUG|blue m gel|active oxygen releasing gel was used after the secondary cleft lip repair surgery
214490195|NCT06754358|PROCEDURE|LenSx|Participants undergo FLACS using LenSx femtosecond laser system
214490196|NCT06754358|PROCEDURE|Z8|Participants undergo FLACS using Z8 femtosecond laser system
214490197|NCT06769516|DEVICE|Auricular Vagus Nerve Stimulation (aVNS)|"This intervention involves transcutaneous auricular vagus nerve stimulation (taVNS) using the VagusStim device. The device consists of earphones tailored to fit the individual's ear size (S, M, L) and is connected to a TENS unit. The stimulation is applied to the tragus and concha of the ear for 30 minutes, three times a week, over a 4-week period. The device operates with a pulse duration of less than 500 microseconds, a frequency of 10 Hz, and in a modulated TENS mode. The current intensity is individually adjusted to the participant's sensory threshold. This method targets the vagus nerve to potentially regulate autonomic activity and improve symptoms of Irritable Bowel Syndrome (IBS).~The study combines this intervention with a low FODMAP diet for all participants, distinguishing it from studies focused solely on vagus nerve stimulation or dietary changes."
214974557|NCT00745303|PROCEDURE|Tai Chi Cuan|Tai Chi Cuan training for 3 months
214974558|NCT03665662|OTHER|Music|Intra-procedure music through headphones
214974559|NCT05668897|DRUG|GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
214974560|NCT05668897|DRUG|placebo of GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
214974561|NCT03200210|DRUG|Febuxostat|Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.
214974562|NCT03200210|DRUG|Placebo|Pills manufactured to mimic Febuxostat tablets
214974563|NCT01643330|GENETIC|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10\^13 DNase Resistant Particles (DRP) MYDICAR
214974564|NCT01643330|GENETIC|Placebo|Single intracoronary infusion
214974565|NCT05596071|DRUG|Sufentanil Citrate|Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
214974566|NCT05596071|DRUG|Ropivacaine 0.75% Injectable Solution|Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
214974567|NCT05596071|PROCEDURE|Epidural catheter|Intraoperative and postoperative analgesia
214974568|NCT05868590|OTHER|Toothpaste|Using two different toothpastes for removal of the dental plaque in children.
215084604|NCT03191370|DRUG|Local Anesthetics,Topical|Anesthetic spray
215084605|NCT01422668|OTHER|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
214974569|NCT05885451|DRUG|AMG 592|Administered as SC injection
215084606|NCT04759469|BEHAVIORAL|High-intensity interval training|High-intensity interval training is a form of intermittent training using relatively high exercise intensity
215084607|NCT04759469|BEHAVIORAL|Moderate intensity interval training|Moderate intensity interval training is a form of intermittent training using moderate exercise intensity
215084608|NCT02454062|DRUG|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
215084609|NCT02454062|DRUG|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
214363554|NCT02063126|DIETARY_SUPPLEMENT|ReConnect (NADH plus CoQ10)|"ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)"
214363555|NCT02063126|DIETARY_SUPPLEMENT|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
214363556|NCT00636610|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
214363557|NCT00636610|DRUG|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
214363558|NCT00636610|DRUG|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
214363559|NCT00636610|DRUG|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
214363560|NCT00636610|DRUG|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then fluorouracil 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
214363561|NCT04414267|BIOLOGICAL|BCG vaccine|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
214363562|NCT04414267|BIOLOGICAL|Placebo|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
214363563|NCT00646477|DEVICE|titration night|"Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:~in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.~in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events."
214363564|NCT05230173|OTHER|Pragmatic|"Patients randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the patients' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~Patients (and their providers) in either treatment arm will be allowed to stop or start new TIMs and other IBD-directed therapies in case of symptomatic relapse or intolerance to therapies, at the discretion of the treating provider-patient team."
214363565|NCT06313580|OTHER|Yogurt with added Spices|Consumption of twice daily yogurt with added spices for four weeks.
214363566|NCT06313580|OTHER|Yogurt without added Spices|Consumption of twice daily yogurt without added spices for four weeks.
214363567|NCT03661411|DRUG|Aspirin|100mg qd
214363568|NCT03661411|DRUG|Clopidogrel 75mg|75mg（after first dose of 300mg）qd
214363569|NCT03661411|DRUG|Alteplase|Iv at 0.9 milligrams per kilogram (mg/kg)
214363570|NCT03691116|BEHAVIORAL|Digital Health Profile|Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)
214363571|NCT03691116|BEHAVIORAL|Treatment as usual|Ordinary psychological assessment and counseling.
214363572|NCT02910648|BEHAVIORAL|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
214974570|NCT05885451|OTHER|Placebo|Administered as SC injection
214974571|NCT05901337|COMBINATION_PRODUCT|Cupping therapy with convential medical treatment|"Device:Cupping therapy device~Group A participants received Dry cupping therapy one session per week for 8 weeks with 6 days intervals between sessions and with cups applied to the skin for around 8 minutes. (In addition to convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin c~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
214974572|NCT05901337|DRUG|Convential medical treatment|"Group B participants received convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin C~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
214974573|NCT03414190|BEHAVIORAL|Mobile phone text message|The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order. The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. They will also receive simple and short text messages related to the importance of trial participation.
214974574|NCT03358550|DIAGNOSTIC_TEST|Accommodation Measurement|Accommodation was measured for different distances and light conditions.
214974575|NCT00555074|DRUG|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
214974576|NCT00555074|DRUG|Placebo|Placebo, BID, oral route during 6 weeks
214974577|NCT02900742|DRUG|YiQiFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
214363573|NCT01235468|BIOLOGICAL|ex vivo expansion|ex-vivo expansion of cord blood for transplantation
214363574|NCT05382182|DRUG|androgen deprivation therapy|outcome of hormonal treatment as androgen deprivation therapy on prostate cancer patient on survival and relapse
214363575|NCT05382182|RADIATION|external beam radiotherapy|outcome of radiotherapy as external beam radiotherapy on prostate cancer patient on survival and relapse
214363576|NCT04846452|DRUG|Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin|Patients with non-squamous NSCLC will receive sintilimab, anlotinib hydrochloride, pemetrexed, and cisplatin or carboplatin.
214363577|NCT04846452|DRUG|Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin|Patients with squamous NSCLC will receive sintilimab, anlotinib hydrochloride, albumin paclitaxel, and carboplatin.
214363578|NCT06270654|PROCEDURE|Erector spinae plane block|"After consent was obtained, patients will be randomised into control group and an intervention group. For patients randomized into the interventional group, bilateral erector spinae plane block will be performed under general anaesthesia in prone position before the operation. An experienced anaesthetist performs this under ultrasound guidance (using curvilinear probe) in a sterile method.~After identifying L3 transverse process, 21G Stimuplex needle will be inserted via in-plane method. Once needle placement is confirmed and aspiration is negative, 20ml of ropivacaine 0.375% with adrenaline 1:200,000 dilution will be given on each side."
214363579|NCT06270654|PROCEDURE|Skin infiltration LA|Pre incision of 0.375% ropivacaine 10ml local infiltration will be given to control group
214363580|NCT02118129|BEHAVIORAL|an educational video|
214363581|NCT02118129|OTHER|wait listed|
214363582|NCT04823260|DRUG|Nicotinamide Mononucleotide|Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells involved in fundamental biological processes. Depletion in the levels of NAD+ is associated with traits of aging, many age-related diseases like cancer, metabolic disorders and neurological disorders. Evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity and delaying the progression of age-related diseases
214363583|NCT04823260|OTHER|Placebo|Rice flour in white capsule resembling NMN
214490198|NCT06769516|BEHAVIORAL|Aerobic Exercise Therapy|"This intervention involves a structured aerobic exercise program designed to improve physical activity levels and modulate symptoms of Irritable Bowel Syndrome (IBS). Participants engage in walking exercises at a moderate intensity, maintaining 50-70% of their maximum heart rate, ensuring the ability to converse comfortably during the activity. The exercise sessions last for at least 30 minutes, three days a week, on alternate days, over a 4-week period.~Participants are individually trained and monitored to ensure proper technique and adherence to the exercise protocol. The intervention is combined with a low FODMAP diet, providing a multimodal approach to IBS symptom management. This distinguishes it from other interventions by emphasizing physical activity's role in enhancing gastrointestinal and overall health."
214490199|NCT06769516|BEHAVIORAL|Low FODMAP Diet Intervention|"This intervention involves the implementation of a low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet to manage symptoms of Irritable Bowel Syndrome (IBS). Participants receive individualized training on the diet before the study begins. The diet eliminates high FODMAP foods known to exacerbate IBS symptoms, such as certain fruits, vegetables, dairy products, and sweeteners, for a duration of 4 weeks.~Participants follow the prescribed dietary protocol under guidance, ensuring adherence and addressing specific nutritional needs. This intervention aims to reduce gastrointestinal distress by limiting fermentable carbohydrates, distinguishing it from other IBS management strategies that do not focus on dietary modifications."
214679624|NCT05347589|OTHER|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range.
214974578|NCT02900742|DRUG|YangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
214974579|NCT02900742|DRUG|YiQiYangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
214363584|NCT02355028|DRUG|LHA510 ophthalmic suspension|
214363585|NCT02355028|DRUG|LHA510 vehicle|Inactive ingredients used as a placebo comparator
214363586|NCT02355028|DRUG|Ranibizumab ophthalmic solution|For intravitreal (IVT) injection
214363587|NCT03948191|DRUG|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
214363588|NCT03948191|DRUG|99Tc-MDP(99Technetium-Methylenediphosphonate Injection)|15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
214363589|NCT05982457|BEHAVIORAL|virtual reality group|"Before the training, the Descriptive Information Form and the State and Trait Anxiety Inventory as a pre-test will be applied by face interview method. They will study for two hours. After the introduction and information, the lens and pupil distances of the virtual reality Glasses will be adjusted according to each student and students are expected to wear their vision. The application is the same for every student. Students will be introduced through the images projected to the computer simultaneously while in the application. Cervical dilation and effacement application will be monitored using virtual reality glasses. Next, the students will be asked to touch the woman's perineum with their hands to make her image transparent and we ask them to watch the cervix structures again. After the application, Learning Satisfaction and Self-Confidence in Learning Scale and State and Trait Anxiety Inventory will be applied as a post-test."
214363590|NCT03655795|BIOLOGICAL|Bronchial basal cells|Autologous transplantation of bronchial basal cells
214974580|NCT02900742|DRUG|Gemcitabine®|"Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops."
214974581|NCT02900742|DRUG|Pemetrexed®|"Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops."
214974582|NCT02900742|DRUG|Docetaxel®|"Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
214974583|NCT02900742|DRUG|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
214363591|NCT01024426|PROCEDURE|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
214363592|NCT01024426|OTHER|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
214363593|NCT01168284|BEHAVIORAL|Coping Effectiveness Training|
214363594|NCT04530292|BEHAVIORAL|Intervention by a pediatric nurse at the child's home|"The intervention will consist of a coordinated intervention by a pediatric nurse at the child's home to support the parents in the implementation of the theoretical knowledge acquired at the hospital.~Three home visits will be set up by a nurse during the first six months of the discovery of diabetes in the child. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit may be set up according to the needs of families."
214363595|NCT04107922|DIETARY_SUPPLEMENT|Glicoset|Patients will take a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
214363596|NCT04107922|OTHER|Placebo|Patients will take placebo
214363597|NCT03285139|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
214363598|NCT04887025|BIOLOGICAL|RGV004|a genetically-engineered vaccinia virus (encoding CD19/CD3 bispecific antibody)
214363599|NCT06113601|OTHER|There is no intervention.|There is no intervention in the study.
214363600|NCT03076099|DRUG|Dexmedetomidine|1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
214363601|NCT03076099|OTHER|normal saline|equal volume of normal saline was administered intravenously constantly after tracheal extubation.
214363602|NCT04719091|DEVICE|Lubricity|Oral spray
214363603|NCT01826474|DRUG|PRO045, 0.15 mg/kg/week|Subcutaneous injection
214363604|NCT01826474|DRUG|PRO045, 1.0 mg/kg/week|Subcutaneous injection
214363605|NCT01826474|DRUG|PRO045, 3.0 mg/kg/week|Subcutaneous injection
214363606|NCT01826474|DRUG|PRO045, 6.0 mg/kg/week|Subcutaneous injection
214363607|NCT01826474|DRUG|PRO045, 9.0 mg/kg/week|Subcutaneous injection
214363608|NCT01826474|DRUG|PRO045, selected dose|Subcutaneous injection
214363609|NCT01180348|DRUG|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
214363610|NCT01180348|DRUG|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
214363611|NCT00002155|DRUG|Indinavir sulfate|
214363612|NCT00002155|DRUG|Lamivudine|
214363613|NCT00002155|DRUG|Zidovudine|
214363614|NCT01971723|OTHER|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (\>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
214363615|NCT01971723|OTHER|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
214363616|NCT02323984|OTHER|miRNA Testing, Microemboli Monitoring, Delirium Assessment|Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
214363617|NCT02613104|OTHER|emotion recognition modification - sad>happy|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
214974584|NCT03768713|DRUG|Suvorexant|Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.
214974585|NCT03768713|DRUG|Placebo|Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
214974586|NCT03871530|OTHER|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
214974587|NCT03871530|OTHER|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
214974588|NCT03871530|OTHER|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
214679625|NCT05347589|OTHER|post isometric relaxation of the Quadratus lumborum|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
214363618|NCT02613104|OTHER|emotion recognition modification - sad>happy control|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
214679626|NCT00092144|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
214679627|NCT00092144|DRUG|Comparator: placebo / Duration of Treatment: 4 weeks|
214679628|NCT05325138|OTHER|Interview|Parents of girls aged 9-14yearsold will undergo an interview to determine their knowledge, attitudes and beliefs concerning HPV vaccination
214679629|NCT06480474|DEVICE|Deprexis|The internet-based self-help program used in this study, Deprexis, contains 10 modules ( based on different psychotherapeutic approaches, consistent with a cognitive-behavioral perspective) and accessible at any time via regular internet browsers on laptops, computers, tablets, or smartphones through a secure website. Participants can repeat all modules as often as they wish after completing the full sequence once.
214974589|NCT03871530|OTHER|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
214974590|NCT03871530|OTHER|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
214974591|NCT03871530|OTHER|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
214974592|NCT03871530|OTHER|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
214974593|NCT03871530|OTHER|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
214974594|NCT03871530|OTHER|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
214974595|NCT03871530|OTHER|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
214974596|NCT03871530|OTHER|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
214363619|NCT02613104|OTHER|emotion recognition modification - angry>happy|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.
214363620|NCT02613104|OTHER|emotion recognition modification - angry>happy control|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
214363621|NCT00551798|PROCEDURE|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
214363622|NCT05899686|DEVICE|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different anatomical locations in each subject.
214363623|NCT04932629|BIOLOGICAL|Ex-vivo cultivated Allogeneic limbal stromal stem cells|n this prospective intervention study patients with unilateral superficial corneal scars will undergo a surgical procedure and in the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x10\*6 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery
214363624|NCT04852016|BEHAVIORAL|Consent process with the addition of Digital educational platform (DEP)|In-patients being consented for laparoscopic cholecystectomy will be provided with a Digital Educational Platform (DEP), in the form of modules on an iPad. These participants will still undergo the usual standard verbal consent (SVC). Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using DEP.
214363625|NCT04852016|BEHAVIORAL|Consent process using the standard verbal consent (SVC)|In-patients being consented for laparoscopic cholecystectomy will go through the SVC. Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using SVC.
214363626|NCT04717726|DIETARY_SUPPLEMENT|Milk Thistle (MT)|Participants in the MT and EX + MT groups will be provided 900 mg of standardized milk thistle extract daily (300 mg three times per day before meals) over the 12-week regimen. We will use the standardized Jarrow Formulas Milk Thistle Veggie Caps containing 30:1 extract that is standardized to contain 80% total Milk Thistle seed flavonoids (polyphenols), including the critical Silymarin fractions isosilybinins A and B, silybinins A and B, silychristin and silydianin that is active against suppressing the UGT1A1 enzyme increasing plasma bilirubin. The capsules are free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Rationale for using this brand: There have been inconsistencies with previous studies that did not use a standardized silymarin extract, which may have contained low levels of the active polyphenolic flavonoids in the milk thistle plant, which varies in the plant's stems, leaves, roots, and flowers.
214363627|NCT04717726|DIETARY_SUPPLEMENT|Lactobacillus Gasseri (LAC)|Participants in the LAC and LAC + EX groups will receive two doses of 3 billion CFU of lactobacillus gasseri per day for a total of 6 billion CFU, the recommended upper level for supplementation of probiotic cultures. We will use Swanson brand Lactobacillus gasseri, whose capsules are also free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Importantly, this brand uses acid-resistant designed release capsules to improve the viability of the lactobacillus in the human stomach.
214363628|NCT04717726|BEHAVIORAL|Exercise (EX)|Participants in the EX, EX + MT, and EX + LAC groups will complete five weekly exercise sessions on their own, expending roughly 600 kcal per session. Participants will be provided a Polar A-300 heart rate monitor programmed for their individual attributes (height, weight, age, training status, gender), which gives a real-time estimate of energy expenditure during exercise. Participants will report to the lab once per week to download the exercise sessions and verify compliance. If participants are not compliant (defined as completing 85% of their assigned exercise sessions per month), they will be disqualified. This intervention has been successfully used by Dr. Flack in multiple studies to produce significant weight loss without dietary intervention in this population with a retention rate of over 90%
214363629|NCT04717726|DIETARY_SUPPLEMENT|Control (CON)|Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.
214490200|NCT06755463|OTHER|Self-acupressure education|Participants will undergo acupressure therapy for 8 weeks, with twice-weekly sessions between 8:00 AM and 10:00 AM. A certified practitioner will train participants on target points, pressure techniques, frequency, and duration. Practical demonstrations will ensure correct application. Groups of up to 10 participants will be trained in a comfortable setting and practice techniques under supervision until proficient. The treatment protocol, based on literature, focuses on beta-endorphin and hypocretin levels, cognition, and patient-reported outcomes (pain, fatigue, depression, and quality of life). Participants will apply 3-5 kg pressure for 2 minutes per point at 12 symmetrical points (LI4, SP6, GV20, HT7, EX-HN3, LV3) using rhythmic movements, totaling 24 minutes. They will receive a diary to track home practices and a visual guide explaining each point's location and steps for application.
214490201|NCT06749821|OTHER|Kinesio Tape|Kinesio tape (KT) is an elastic therapeutic tape used to treat sports injuries and various other disorders. It was first used by Dr. Kenzo Kase in 1979 to relieve pain and promote healing in soft tissues and is a method that is constantly being updated. The KT method is a therapeutic taping technique that relieves pain and facilitates lymphatic drainage by microscopically lifting the skin.
214490202|NCT06749821|OTHER|Placebo Tape (Arm 1)|In this application, taping was applied in the same way but with a plaster tape.
214490203|NCT06749821|OTHER|Control (no last irrigation)|No application was made.
214490204|NCT06760975|OTHER|Vestibular Habituation Exercises|The vestibular habituation exercise group follows a structured progression over six weeks. in week 1 participants perform large amplitude, rapid cervical rotations seated, completing 3 sets of five cycles each. By week 2, the exercises increase in complexity , incorporates standing pivots or seated trunk flexion extension. in week 3 the cervical rotations are continued with seated or standing posture. week 4 introduces a busy visual background during the exercise to challenge visual-vestibular integration. In week 5 the exercises are performed standing with the addition complex visual target against a busy background. finally week 6 includes most advance movement including standing pivots 180 degrees and brand-daroff exercises with further visual challenges of near and far targets in busy background. Each exercise session last for 2 minutes and is aimed at progressively enhancing vestibular processing and adaptability.
214490205|NCT06760975|OTHER|Ocular Reflex Excercises|The Ocular reflex exercises focuses on enhancing visual tracking and reflexes through targeted viewing exercises. In week 1, participants perform horizontal and vertical X1 viewing exercises with a near target, holding each position for 1 minute while seated. In week 2 the duration of the X1 exercises is extended to 2 minutes with the near target still in seated position. Week 3 shift to a far target for the X1 exercises and the participants performs them while standing increasing the challenge. By week 4 the exercise incorporate both near and far target in front of a busy background. extending the duration to 2 minutes while standing. In week 5 horizontal and vertical X2 viewing exercises are added with a plain background, while still using near and far targets in front of a busy background . finally week 6 continues the X1 and X2 exercises with near and far targets in a busy background, performed for 2 minutes while standing. This aims to improve visual tracking.
214490206|NCT06759077|DRUG|Dapagliflozin (DAPA)|adult patients with advanced CKD who will take SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally for 6months
214490207|NCT06515275|OTHER|Education via video (QR code links)|Video education on self-administered medications for women undergoing IVF treatment
214490208|NCT06752681|DRUG|DAY301|DAY301 will be administered as IV infusion
214974597|NCT03871530|OTHER|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
214490209|NCT06753799|BEHAVIORAL|The intervention group received training based on Social Cognitive Learning Theory.|One of the theories that provides a conceptual framework for the learning and behavior change process is Social Cognitive Learning Theory. Verbal information is commonly provided in the education of individuals with diabetic foot ulcers. The difference of this study from other studies is that an educational booklet, an educational video and a demonstration method with a diabetic foot model are used during the education within the scope of theory-based education.
214490210|NCT06753058|DIETARY_SUPPLEMENT|25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery.|Although 45 g of different carbohydrate solutions either Gatorade 54 g carbohydrate or clear apple juice 56 g carbohydrate in non-diabetic women have been recommended by SOAP, we preferred 25 g of carbohydrate, fantomalt, nutricia, diluted in the 330 mL in both diabetic and non-diabetic pregnant women.
214974598|NCT03871530|OTHER|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
214974599|NCT03871530|OTHER|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
214974600|NCT05616013|BIOLOGICAL|Bimagrumab|Human monoclonal antibody to the activin receptor type II
214974601|NCT05616013|DRUG|Semaglutide|Glucagon-like peptide-1 (GLP-1) receptor agonist
214363630|NCT05038384|OTHER|Survey Administration|Complete survey
214363631|NCT00618254|DRUG|Granisetron|
214974602|NCT05616013|OTHER|Placebo|Placebo
214490211|NCT06753058|BEHAVIORAL|Mother baby bonding|In the ERAS implemented group, mother-baby contact to promote early bonding was established, and both mother and baby were encouraged for breastfeeding. In the control group, only mother-baby contact was facilitated without proactive breastfeeding encouragement.
214490212|NCT06765005|DRUG|MG-K10|Subcutaneous injection, once every 4 weeks
214490213|NCT06763068|OTHER|Skeletal muscle mass and frailty|Measurement correlation variable
214490214|NCT06762236|OTHER|Pillatate Training|.The session will repeated three times per week for 6 weeks with 40-minute sessions In Pilates we include 5 Pilate exercise, The Hundred (Rhythmic Breathing), Single Leg Stretch (Rhythmic Breathing), side kick, Toe Taps (Set Breathing Pattern) ,leg pull front for 6 weeks.
214363632|NCT03144713|DRUG|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
214363633|NCT03144713|DRUG|Midodrine|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
214363634|NCT03144713|DRUG|Albumin|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
214363635|NCT00568048|BIOLOGICAL|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
214490215|NCT06762509|DRUG|Botulinum toxin type A|Local injection of botulinum toxin type A was given at the time of enrollment
214490216|NCT06757660|PROCEDURE|Furcation Repair|to evaluate the clinical and radiographic effects of chitosan and Naocl as an irrigation protocols applied during repair of furcation perforation.
214490217|NCT06761547|DRUG|magnsium sulfate|patients will take magnsium sulfate 15 mg/kg IV
214490218|NCT06761547|DRUG|Lidocaine (drug)|patients will take lidocaine2% 1 mg/kg
214490219|NCT06761547|DRUG|Saline|50 ml saline IV
214490220|NCT06761300|OTHER|Psychological assessment|Psychological assessment evaluation at different time points and its correlation with pain outcomes and satisfaction with the SCS intervention.
214490221|NCT06761599|DIAGNOSTIC_TEST|group 1|To determine treatment-induced pulmonary toxicity prevalence and risk factors in Hodgkin lymphoma patients during chemotherapy or radiation therapy.
214490222|NCT06826443|DRUG|Mosapride Citrate Tablets|Prokinetic Drug
214490223|NCT06826443|DRUG|Metoclopramide 10mg|Prokinetic Drug
214679630|NCT06480474|DEVICE|Deprexis with online forum|Those in this group will have access to deprexis ( same as the first group) as well as an online forum built for the study. This forum will feature a general discussion page where participants can ask and answer questions, and they will be divided into groups of 10 to share experiences if they wish. Additionally, there will be subforums related to specific modules of the program. Participants can share their experiences and ask questions related to the modules. A moderator will regularly check to ensure no personal or sensitive information is disclosed and will ask questions weekly to encourage contributions to the forum.
214974603|NCT05454592|BEHAVIORAL|Stress and Coping Online Outreach Program|3 videos and a resource library disseminated over the course of 9 weeks.
214974604|NCT06970769|OTHER|Vagus nerve stimulation|In our study, the auricular branch in the pinna was superficially stimulated with a TENS-based vagustim device for non-invasive vagus nerve stimulation. The application was performed in regular sessions with a physiotherapist according to the recorded protocol. This deactivation aimed at modulation of the autonomic nervous system via the vagus nerve.
214974605|NCT06970769|OTHER|Deep Breathing Exercises|In the study, the participants who were given deep breathing exercises were taught the correct technique in a semi-sitting position. During the exercises, deep breathing and relaxation periods were applied for certain periods. The respiratory rhythm was arranged as controlled inspiration and expiration. The participants were given an application practice so that they could continue the exercise at home.
214974606|NCT06970223|DRUG|Cabotegravir long-acting|A single CAB LA injection administered intramuscularly.
214974607|NCT06970223|DRUG|Lenacapavir long-acting|Two LEN LA injections administered subcutaneously.
214974608|NCT05010577|DRUG|BX004-A|Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
214974609|NCT05010577|DRUG|Placebo|Nebulized placebo
214363636|NCT00568048|DRUG|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
214363637|NCT04028986|DRUG|Ulipristal Acetate 5 MG Oral Tablet|use of ulipristalacetate OR surgery before fertility treatment
214363638|NCT04639674|DRUG|AST-120|If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
214363639|NCT01012232|DRUG|20 mL ropivacaine 5 mg/mL|
214363640|NCT01012232|DRUG|10 mL ropivacaine 10 mg/mL|
214363641|NCT00466882|DEVICE|Inamed Lap-Band System|Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
214363642|NCT01389193|DRUG|Ibudilast|Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
214363643|NCT01389193|DRUG|Placebo|Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
214363644|NCT04706702|BEHAVIORAL|Tele-EnhanceFitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
214363645|NCT02199236|RADIATION|endorectal brachytherapy|Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
214363646|NCT02199236|DRUG|concurrent capecitabine or 5-FU|"Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days."
214974610|NCT06456788|BIOLOGICAL|MMR vaccination|MMR vaccination status
214974611|NCT05492006|BEHAVIORAL|Indirect contact with nature|The participants will watch a video with validated images of nature from e-Nature Positive Emotions Photography Database (e-NatPOEM). Four fifteen-minute sessions will be held on four consecutive days, totaling 1 hour.
214363647|NCT02199236|BEHAVIORAL|Questionnaires|Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
214363648|NCT06249932|DRUG|Empagliflozin 25 MG|The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
214363649|NCT06249932|DRUG|Placebo|The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
214363650|NCT02953301|DRUG|resminostat|
214363651|NCT02953301|DRUG|Placebo|
214363652|NCT04858919|DIAGNOSTIC_TEST|3D transabdominal ultrasound|Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).
214363653|NCT04858919|DIAGNOSTIC_TEST|transrectal ultrasound|The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.
214363654|NCT04858919|DIAGNOSTIC_TEST|vaginoscopy|It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.
214363655|NCT01430260|DRUG|Ciclesonide|200 ㎍ once daily
214363656|NCT01430260|DRUG|Levocetirizine|5mg once daily
214363657|NCT01430260|DRUG|Ciclesonide & Levocetirizine|"* Omnaris (ciclesonide) 200 ㎍ once daily~* Levocetirizine 5mg once daily"
214490224|NCT06828068|DEVICE|Ultrasound (Scolioscan system), and EOS radiography system|"Scolioscan ultrasound system was reported to be reliable and valid for spinal deformity assessment. The system composes of an ultrasound scanner with a linear probe of 10 cm width and frequency range of 4-10MHz, a frame structure and a spatial sensor attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using phantom to assure accuracy of spine image formation and subsequent angle measurement. Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process. The probe will be steered from L5 to C7 spinous process for scanning. SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral. Coronal Cobb angle measurement on EOS radiographs will be used as gold standard."
214974612|NCT05492006|BEHAVIORAL|Intentional contact with nature|The participants will take a light walk in a park with green spaces guided by research team in a single 1-hour session, with an emphasis on sense-directed appreciation.
214974613|NCT05116202|DRUG|Nivolumab|Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
214974614|NCT05116202|DRUG|Ipilimumab|Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
214974615|NCT05116202|DRUG|RO7247669 2100 mg|RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
214974616|NCT05116202|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
214974617|NCT05116202|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
214974618|NCT05116202|DRUG|RO7247669 600 mg|RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
214363658|NCT04625712|PROCEDURE|Cholecystectomy|Cholecystectomy within the first week after a mild acute biliary pancreatitis
214363659|NCT04549363|DRUG|Belantamab mafodotin|Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.
214363660|NCT04606966|OTHER|Therapeutic Horseback Riding|Horse therapy
214363661|NCT04606966|OTHER|Barn Activity|Horsemanship group
214363662|NCT04606966|OTHER|Hybrid|Ground and riding activities
214974619|NCT04154514|DEVICE|A functional electrical stimulation device for post-stroke rehabilitation|Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.
214974620|NCT05217108|DEVICE|FitBit|All participants in each study group will receive a Fitbit. Participants will be asked to wear a Fitbit every day for 8 weeks to record the number of steps you take
214974621|NCT06380062|OTHER|Plasma concentration of choline|The exposure in this observational study is plasma concentrations of choline
214974622|NCT05135936|BEHAVIORAL|Hyperthermia Group|The first hyperthermia treatment of the series is carried out for the second aptitude test, directly following the randomisation in the intervention group at the Hospital for Naturopathy and Integrative Medicine in Bamberg. The hyperthermia treatment is then carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
214974623|NCT05135936|BEHAVIORAL|Sham-Group|The number of treatments is equal to the number of treatments in the intervention group.
214974624|NCT05717712|BIOLOGICAL|Ad-TD-nsIL12|After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3 days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
214974625|NCT00002314|DRUG|Ro 24-7429|
214974626|NCT02606240|DEVICE|CO2 removal with PRISMALUNG in ARDS|Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
214974627|NCT05537311|BEHAVIORAL|Social Engagement|30-45 minutes of social engagement provided to patients in ICU. Social engagement strategies including meaningful conversation, cognitive stimulation, and emotional support
214974628|NCT03651817|DEVICE|Mechanical ventilation|Patients will be ventilated with anesthesia machine according to the group they belong to
214363663|NCT01806987|BEHAVIORAL|KITS Program|The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
214490225|NCT06826417|DRUG|Xanax|double-blind randomized controlled clinical trial: in a double-blind manner, to receive Xanax
214974629|NCT01834339|BIOLOGICAL|AlloDerm|
214974630|NCT01834339|BIOLOGICAL|EVPOME|
214974631|NCT00768690|DRUG|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
214974632|NCT00768690|DRUG|ketoconazole|Tablet, see arms for intervention description
214974633|NCT00768690|DRUG|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
214974634|NCT04007328|DRUG|Methylprednisolone Sodium Succinate|methylprednisolone vial
214974635|NCT04007328|DRUG|Placebo|Normal saline manufactured to mimic methylprednisolone vial
214974636|NCT01016145|DRUG|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
214974637|NCT01016145|DRUG|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
214974638|NCT02408198|BEHAVIORAL|Anxiety intervention|The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
214974639|NCT00953290|DEVICE|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
214974640|NCT05358548|DRUG|Paclitaxel|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
214974641|NCT05358548|DRUG|Pemetrexed|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
214974642|NCT05358548|DRUG|5Fluorouracil|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
214974643|NCT05358548|DRUG|Carboplatin|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
214974644|NCT05358548|DRUG|Pembrolizumab|It is a type of immunotherapy and works by helping your immune system to kill cancer cells
214974645|NCT00441285|DRUG|Praziquantel|\- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
214974646|NCT00441285|DRUG|Albendazole|"* Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~* Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days."
214974647|NCT00441285|DRUG|ABZ Placebo|\- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
214974648|NCT00441285|DRUG|PZQ Placebo|\- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
214974649|NCT00152607|PROCEDURE|donor right hepatic lobectomy|
214974650|NCT05252741|OTHER|serum samples and punch skin biopsies|we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
214490226|NCT06826417|OTHER|placebo tablets|double-blind randomized controlled clinical trial: in a double-blind manner, to receive a placebo (identical in appearance to Xanax but without any active effects)
214490227|NCT06772610|DRUG|Ensartinib group|Ensartinib 200 mg, once daily, orally, for a continuous period of 2 years.
214490228|NCT06760000|DEVICE|Five seasons Sleep Tracking Mat|Non-contact mat monitoring sleep data through pulse wave detection
214490229|NCT06760845|DIAGNOSTIC_TEST|Imaging Time|Raman spectroscopy images of blood and urine
214974651|NCT05225545|DRUG|Sucrosomial Iron|Experimental Arm
214974652|NCT05225545|DRUG|Oral Iron|Active Comparator
214974653|NCT03587064|DEVICE|Conventional 3-lead CRT defibrillator system implantation|Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation
214974654|NCT03587064|DEVICE|2-lead CRT defibrillator system implantation|2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation
214974655|NCT03856697|DRUG|Abivertinib Maleate Capsules|patients receive the test drug (Abivertinib maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
214974656|NCT03856697|DRUG|Placebo Gefitinib Tablets|patients receive the test drug (Placebo Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
214974657|NCT03856697|DRUG|Gefitinib Tablets|patients receive the control drug (Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
214974658|NCT03856697|DRUG|Placebo Abivertinib Maleate Capsules|patients receive the control drug (Placebo Abivertinib Maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
214974659|NCT02256813|DRUG|BIRT 2584 XX|
214974660|NCT02256813|DRUG|Warfarin sodium|
214974661|NCT02256813|DRUG|Omeprazole|
214974662|NCT02256813|DRUG|Dextromethorphan hydrobromide|
214974663|NCT02256813|DRUG|Caffeine|
215084610|NCT03281551|DRUG|PZ01 CAR-T cells|Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
215084611|NCT00771290|PROCEDURE|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
214363664|NCT02669784|DRUG|Low Dose Contrast (Omnipaque) 40mL|The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
214363665|NCT02669784|DRUG|Low Dose Contrast (Omnipaque) 50 mL|The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
214363666|NCT03856879|BEHAVIORAL|Proactive E-consult|E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
214363667|NCT06979492|BIOLOGICAL|Prophylactic Transfusion Intervention group: Transfusion|"For participants randomized to the prophylactic transfusion intervention group, the first RBC transfusion will occur within 3 weeks of randomization. All transfusions will be managed per SOC.~SOC prophylactic RBC transfusion management is as follows: transfusions are performed at 3-6 week intervals with the intent to maintain a pre-transfusion hemoglobin S level at \<30%. All participants will have a complete blood count, reticulocyte count, hemoglobin fractionation, complete metabolic profile with LDH, ferritin, and type/screen at baseline and within 3 days of all monthly transfusions. All RBC transfusions must be compatible between the recipient and the donor and antigen matched for Rh (D/Cc/Ee) and Kell antigens at a minimum. For participants with a previous history of RBC alloimmunization, extended matched RBCs will be provided (Rh, Kell, Duffy, Kidd, S/s) per NHLBI/ASH guidelines to minimize further alloimmunization."
214679631|NCT06231940|OTHER|Complex Decongestive Therapy (CDT) in venous insufficiency,|Complex Decongestive Therapy (CDT) is a comprehensive treatment approach primarily used for lymphedema and related conditions, but it's also beneficial for chronic venous insufficiency and other edematous conditions. CDT aims to reduce swelling and maintain the reduction, improve skin condition, and alleviate symptoms. It typically involves two phases: an intensive phase to reduce swelling as much as possible and a maintenance phase to sustain the achieved results. The main components of CDT include: Manual Lymph Drainage (MLD),Compression Therapy, Exercise, Skin Care, Education and Self-Care:
214974664|NCT02256813|DRUG|Midazolam hydrochloride|
214974665|NCT02256813|DRUG|Vitamin K1|
214974666|NCT01388153|DRUG|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
214974667|NCT01388153|DRUG|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
214974668|NCT01388153|DRUG|Acarbose (Glucobay, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
214974669|NCT04784078|PROCEDURE|Coronary Angiography and Intervention|Transradial access puncture site
214974670|NCT03442647|DIAGNOSTIC_TEST|sinistrin clearance dynamic measurement|sinistrin clearance measurements will be performed before and 90 min after oral protein load
214974671|NCT04928781|BEHAVIORAL|Smoking Cessation Counseling|Smoking cessation counseling will be provided following standards set by the institution patients are receiving care at (Dartmouth-Hitchcock Medical Center).
214974672|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 25mg|25 μg oral inhalation via eFlow Nebulizer, once daily
214974673|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 75mg|75 μg oral inhalation via eFlow Nebulizer, once daily
214974674|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 200mg|200 μg oral inhalation via eFlow Nebulizer, once daily
214974675|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 200mg Jet|200 μg oral inhalation via inhalation via jet nebulizer, once daily
214974676|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 500mg|500 μg oral inhalation via eFlow nebulizer, once daily
214974677|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution1000mg|1000 μg oral inhalation via eFlow nebulizer, once daily
214974678|NCT02951312|DRUG|Placebo|Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
214974679|NCT00463645|PROCEDURE|microdialysis|
214974680|NCT00463645|PROCEDURE|microperfusion|
215084612|NCT02192762|BEHAVIORAL|Withdrawal regulation training|Withdrawal coping skills
215084613|NCT02192762|BEHAVIORAL|Relaxation training|Relaxation skills instruction
214490230|NCT06771752|OTHER|Questionnaire|The questionnaire will be made comprised of the questions taken from the Whole Day Matters Toolkit (WDMT) 24-hour movement questionnaire (The Canadian Society for Exercise Physiology, 2021), which is based on the official 24-hour movement guidelines (Ross et al., 2020) (see appendix). For diet quality, Mini-EAT, a short dietary screening tool will be used (Lara-Breitinger et al., 2023) (see appendix). The questionnaire will be open for two months during the football mid-season time period (January 15th to March 15th). The principal investigator will distribute the questionnaire digitally via Google Forms. It will be sent directly to sports staff professionals, individually and to football clubs and to universities to distribute to their cohort. Only people with the link will be able to access the questionnaire. Participants will answer the questionnaire, which will take roughly 10 minutes, completing the intervention.
214974681|NCT03512522|BEHAVIORAL|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in an online format.
214974682|NCT03512522|BEHAVIORAL|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in a printed (workbook) format.
214974683|NCT01651364|DRUG|Placebo|Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
214974684|NCT01651364|DRUG|Cabergoline|Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
214974685|NCT05150665|PROCEDURE|En-masse retraction|"Power chain and Crimpable hook for En-Masse Retraction Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 200 g per side) extending between the crimpable hooks and the miniscrew"
214974686|NCT05150665|PROCEDURE|Two step Retraction|"Retraction of canine started on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 150 g per side)followed by anterior teeth retraction on 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 160 g per side) extending between the crimpable hooks and the mini-screw."
214974687|NCT01206023|OTHER|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
214363668|NCT06979492|OTHER|Control group|"Participants randomized to the control group will be followed per SOC. SOC management for pregnant women with SCD includes but is not limited to~* Clinic appointments with an SCD provider every 2 months~* Lab draws - complete blood count, reticulocyte count, hemoglobin fractionation, complete metabolic profile with LDH and ferritin."
214363669|NCT06815640|OTHER|recovery|Fatigue protocol
214363670|NCT06977802|BEHAVIORAL|Digital Nutrition Education Mobile App for Healthy and Sustainable Eating|"This intervention is uniquely characterized by:~Dual Health-Sustainability Focus - Unlike most nutrition apps targeting weight loss, this integrates planetary health metrics (e.g., carbon/water footprints) alongside dietary guidance.~Psychobehavioral Personalization - Content is tailored to four predefined user profiles (e.g., Convenience-Seeker, Health-Conscious) identified through baseline questionnaires, adapting messaging strategies (e.g., time-saving tips vs. environmental appeals).~Biomarker-Validated Outcomes - Unlike apps relying solely on self-reports, efficacy is assessed via objective measures (urinary LC-MS metabolomics, fecal microbiota analysis).~Academic Development - Designed by nutrition scientists + AI engineers (University of Parma), with recipes aligned to Mediterranean/Planetary Diet standards"
214363671|NCT04608487|DRUG|Fludarabine|Intravenous infusion
214490231|NCT06776185|PROCEDURE|Liver Surgery|Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement. Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed
214974688|NCT01721447|DRUG|Optison echocardiography contrast agent|Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
214974689|NCT05796700|PROCEDURE|Microwave Ablation|"Microwave Ablation: A minimally invasive technique for HCC, MWA has the potential to eradicate larger HCCs with larger coagulation areas and is less affected by the heat sink effect caused by vessels around the tumor.~Laparoscopic Hepatectomy: The technique has been widely promoted worldwide with technical progress. In patients with cirrhosis, LLR has the potential advantage of reducing the risk of postoperative liver decompensation"
214974690|NCT01623921|DRUG|standard care treatment|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
214974691|NCT01623921|DRUG|Celecoxib|Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
214974692|NCT01623921|DRUG|Rosuvastatin|Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
214974693|NCT01623921|DRUG|Combined therapy|Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
214974694|NCT06316635|PROCEDURE|ventilation tube insertion|a paracentesis will be done to tympanic membrane. Glu will be aspirated and trapped.
214974695|NCT02358122|OTHER|Wholegrain rye|A variety of cereal foods providing \>100g/day wholegrain from rye
214974696|NCT02358122|OTHER|Wholegrain wheat|A variety of cereal foods providing \>100g/day wholegrain from wheat
214974697|NCT02358122|OTHER|Refined wheat|A variety of cereal foods providing 0g/day wholegrain
214974698|NCT06327412|OTHER|Aerobic exercise on the treadmill|According to the cardiopulmonary exercise (CPET) test, 40 minutes (5 minutes warm-up, 30 minutes exercise, 5 minutes cool-down) at an exercise intensity of 50-60% of the VO2 max (the maximum amount of oxygen that an individual can utilize during intense or maximal exercise) level recorded individually in patients, 5 days a week for 4 weeks.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily
214490232|NCT06776822|OTHER|Dynamic neuromuscular stabilisation|"The nervous system establishes programs that control human posture, movement and gait. This 'motor control' is largely established during the first critical years of life. Therefore, the Prague School emphasizes neurodevelopmental aspects of motor control in order to assess and restore dysfunction of the locomotor system and associated syndromes."
214490233|NCT05504278|DRUG|IBI351|recommended dose, po
214363672|NCT04608487|DRUG|Cyclophosphamide|Intravenous infusion
214363673|NCT04608487|BIOLOGICAL|Axicabtagene Ciloleucel|Intravenous infusion
214363674|NCT02821403|DEVICE|clear lens with regular coating|
214363675|NCT02821403|DEVICE|regular coating lens with yellow tint|
214363676|NCT02821403|DEVICE|clear lens with blue-light blocking coating|
214363677|NCT03289234|DRUG|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes
214363678|NCT02444065|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|The CBT intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol developed by the investigators. It uses standard CBT for eating disorders interventions, including orientation to the CBT model, psychoeducation, commitment and goal setting, behavioral strategies for normalizing eating and reducing bulimic symptoms, planning, and homework. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
214363679|NCT02444065|BEHAVIORAL|Motivational Interviewing (MI)|The MI intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol (Carter \& Bewell-Weiss, 2012). It uses standard MI for eating disorders interventions, including decisional balance, exploring values, readiness and confidence rules, and MI communication strategies. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
214363680|NCT02992990|PROCEDURE|Bladder tumor biopsy|Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
214363681|NCT04680455|OTHER|Online home-based strength training|Body weight exercises (i.e., squats, tricep dips, lunges, and push-ups) delivered online through Teams
214363682|NCT03862157|DRUG|Azacitidine|Given IV or SC
214363683|NCT03862157|DRUG|Pevonedistat|Given IV
214490234|NCT05504278|DRUG|Cetuximab|500mg/m\^2, Q2W, day1, i.v.
214490235|NCT05504278|DRUG|pemetrexed|500mg/m\^2, Q3W, day1, i.v.
214363684|NCT03862157|DRUG|Venetoclax|Given PO
214490236|NCT05504278|DRUG|Carboplatin|AUC=5, Q3W, day1, i.v.
214363685|NCT06085430|DEVICE|Kubota Glass|Kubota Glass employs white light producing micro-LEDs covered by masks which create a patterned target. The patterned images are defocused by micro-lenslets and projected to the retinal periphery by a central mirror. Parameters of interest to evaluate in this investigation include but are not limited to dioptric amount of defocus, brightness (cd/m2), spectrum of illumination, and shape of the target mask. In each scenario, right eyes will be exposed to the stimulus, whereas left eyes serve as controls. The order of exposures to the various stimuli will be randomized to participant and investigator.
214363686|NCT01592370|BIOLOGICAL|Nivolumab|Administered by intravenous (IV) infusion
214363687|NCT01592370|BIOLOGICAL|Ipilimumab|Administered by IV infusion
214490237|NCT05504278|DRUG|Sintilimab|200mg, Q3W, day1, i.v.
214490238|NCT05504278|DRUG|cis-platinum|75mg/m\^2, Q3W, day1, i.v.
214490239|NCT06775899|DEVICE|PC-Based Ultrasound Training Tool|An interactive, PowerPoint-based PC tool designed to simulate pathology recognition and ultrasound image optimization for medical students. It provides real ultrasound videos and images, allowing students to practice diagnostic interpretation and image acquisition in a structured training format.
214490240|NCT06775899|DEVICE|Traditional Ultrasound Simulator (VausSim)|A medium-cost ultrasound simulator used for hands-on training in thoracic and abdominal ultrasound. It allows medical students to practice probe handling, image acquisition, and pathology recognition in a controlled simulation environment.
215084614|NCT01798641|DEVICE|MIETHKE proGAV® / MIETHKE proSA®|The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
215084615|NCT00738764|BIOLOGICAL|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
214679632|NCT03020524|BIOLOGICAL|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
215084616|NCT02479776|BIOLOGICAL|stem cell injection|Injection of autologous bone marrow derived stem cells
215084617|NCT01709201|BEHAVIORAL|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
214363688|NCT01592370|BIOLOGICAL|Lirilumab|Administered by IV infusion
214363689|NCT01592370|BIOLOGICAL|Daratumumab|Administered by IV infusion
214363690|NCT01592370|DRUG|Pomalidomide|Administered PO
214363691|NCT01592370|DRUG|Dexamethasone|Administered PO and by IV infusion
214363692|NCT06597019|DRUG|Inclisiran|Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg and inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
214363693|NCT06597019|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
214363694|NCT06820658|DIAGNOSTIC_TEST|Neuromuscular Test|"To measure neuromuscular connectivity, Transcranial Magnetic Stimulation (TMS) will be used to stimulate regions of the cerebral cortex known to control specific muscles.~Electromyography (EMG) activity will then be measured from the following muscle groups: deltoid, biceps, extensor digitorum communis, abductor pollicis brevis, abductor digiti minimi, and first dorsal interosseous muscle."
214363695|NCT06820658|DIAGNOSTIC_TEST|DEXA|The DEXA test uses X-rays to measure how many grams of calcium and other bone minerals are packed into a segment of bone. The test also measures the amount of fat-free mass, and fat mass.
214363696|NCT06820658|DIAGNOSTIC_TEST|Mixed Meal Tolerance Test|Fasting blood will be collected for glucose, insulin, and c-peptide. Participants will be provided with a milkshake with a fixed amount of protein, carbohydrates, and fat. Glucose, insulin, and c-peptide will be measured at multiple time points (every 10 minutes) until four hours after consumption (50% Fat, 30% Carbohydrate HO, 20% Protein). Approximately 70mls of blood will be drawn during this time
214363697|NCT06820658|DIAGNOSTIC_TEST|Strength Test|Knee extensor strength will be tested by gradually increasing the workload on a pneumatic Keiser knee extension machine. The test will begin with a warm-up of 4-5 reps with one leg at 30-50 psi. Then the participant will increase the workload at self-selected intervals ranging from 5-20psi until a maximum effort is achieved. If a rep is failed, then the workload will be reduced by 5psi until a successful rep is performed or a workload is reached in which a successful rep had been previously achieved. Handgrip strength will be tested using a handheld dynamometer (Baseline® standard hydraulic hand dynamometer). The test is performed with the participant seated with the elbow unsupported and flexed at 90 degrees, forearm neutral, wrist held between 0-15 degrees of ulnar deviation (Horowitz, 1997). Maximum grip is the average of three 3-5 second trials.
214363698|NCT01775228|BEHAVIORAL|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
214363699|NCT06668246|DEVICE|Vision-S™ 700, an immersive and compact phoropter with a tunable-focus lens, and Vision-R™ 800, a phoropter with a tunable-focus lens without immersion, with cycloplegic refraction serving as the gold|As of today, no published clinical studies have been conducted with the Vision-S™ 700 neither Vision R 800
214363700|NCT05460325|DRUG|Lanadelumab|Lanadelumab subcutaneous injection
214363701|NCT06717685|DRUG|Adenosine|Adenosine is a medication belonging to class V antidysrhythmics, used to treat a type of irregular heart rhythm disorder known as paroxysmal supraventricular tachycardia (PSVT)
214363702|NCT06717685|DRUG|Verapamil Injection|Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart and slows electrical activity in the heart to control the heart rate.
214363703|NCT06723275|OTHER|Standardized assessments, guided tumor biopsy and biobanking|"Standardized assessment of Scores~* Guided tumor biopsy in patients listed for hepatocellular carcinoma with active tumor at listing in centers not perfoming tumor biopsy on a routine basis~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers"
214363704|NCT06723275|OTHER|Standardized assessments and biobanking|"* Standardized assessment of Scores~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers"
214363705|NCT04711889|DRUG|Ulinastatin|Ulinastatin is taken three times a day.
214363706|NCT04711889|DRUG|Blank control|Blank control
214363707|NCT07093320|OTHER|No intervention|No intervention
214363708|NCT03902054|BIOLOGICAL|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
214363709|NCT03902054|BIOLOGICAL|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
214363710|NCT03902054|BIOLOGICAL|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
214363711|NCT03902054|BIOLOGICAL|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
214363712|NCT03902054|BIOLOGICAL|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
214363713|NCT06190301|DRUG|Rituximab|Intralesional Rituximab Injection
214363714|NCT06190301|RADIATION|Involved Site Radiation Therapy|Involved Site Radiation Therapy
214363715|NCT01323530|DRUG|Eribulin mesylate|Intravenous (IV) bolus or infusion.
214363716|NCT01323530|DRUG|Capecitabine|Oral film-coated tablets.
214363717|NCT04608175|OTHER|Acupuncture|Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation.
214363718|NCT02395861|OTHER|neuro-electrophysiologic analyses|mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
214363719|NCT01314989|DRUG|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
214363720|NCT01314989|DRUG|Sugar pill|liquid placebo
214363721|NCT00253344|DRUG|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
214974699|NCT06327412|OTHER|Walking between 12-13 RPE (The Borg Rating of Perceived Exertion) according to the Modified Borg Scale|He/she will be asked to walk 40 minutes a day, 5 days a week, for 4 weeks. Training will be given for the first session in the hospital to ensure that the patient's walking pace is between 12-13 RPE according to the Modified Borg scale.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily.Treatment compliance will be increased by making weekly phone calls to patients in order to increase treatment compliance and evaluate compliance.
214974700|NCT00461825|DRUG|Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups|
214974701|NCT00461825|DRUG|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
214974702|NCT00461825|DRUG|Group B: CsA + CellCept(500 mg x 2/day)|
214974703|NCT00461825|DRUG|Group C: CsAm|
214974704|NCT01604889|DRUG|Epacadostat|
214363722|NCT00253344|DRUG|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
214363723|NCT00889057|DRUG|sorafenib|400 mg bid until progression or inacceptable toxicity
214363724|NCT03952702|PROCEDURE|Myopic overcorrection|Myopic overcorrection
214363725|NCT00048230|DRUG|bortezomib|
214363726|NCT05308550|DIAGNOSTIC_TEST|rapid RT-LAMP test to detect SARS-COV-2 RNA|rapid RT-LAMP test to detect SARS-COV-2 RNA
214363727|NCT03190551|OTHER|retroclavicular approach|Retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
214363728|NCT03190551|OTHER|costoclavicular approach|costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
214363729|NCT06070402|DEVICE|DIAL, a voice-controlled virtual assistant|Participants in the experimental group will test in their homes a device called DIAL, a voice-controlled virtual assistant designed to communicate with the elderly and help them in different contexts. They will use it for four weeks. They will receive an individual training session on how to use the device, an instruction sheet for its use and, in addition, they will receive telephone technical support throughout the study. Finally, the device will be uninstalled and all participants will be called back to answer the same survey they answered before the intervention.
214363730|NCT02802163|DRUG|Panobinostat|"Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase."
214363731|NCT02802163|DRUG|Carfilzomib|Induction Phase: Carfilzomib will be administered at 20 mg/m\^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m\^2 or 36 mg/m\^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
214974705|NCT01604889|DRUG|Placebo|Placebo
214974706|NCT01604889|DRUG|ipilimumab|ipilimumab 3 mg/kg IV
214974707|NCT01604889|DRUG|ipilimumab|Doses to be determined following the completion of Phase I of the study
214974708|NCT02322749|DRUG|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
214974709|NCT02322749|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
214974710|NCT02322749|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
214974711|NCT03675568|PROCEDURE|Non-cultured keratinocyte suspension|A new method for treatment of burn wounds
214974712|NCT03675568|PROCEDURE|Split skin Graft|A traditional method for treatment of burn wounds
214974713|NCT05749016|DRUG|inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen|Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. There was no robust evidence evaluating the combination of inetetamab with pertuzumab and neoadjuvant chemotherapy (paclitaxel + carboplatin) in the neoadjuvant setting. This study aimed to evaluate the efficacy and safety of inetetamab + pertuzumab+paclitaxel + carboplatin (TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally advanced HER2-positive breast cancer.
214974714|NCT02121860|DRUG|IDN-6556|
214974715|NCT05265117|PROCEDURE|HIPEC|HIPEC is given after primary or interval debulking surgery.
214974716|NCT00073918|DRUG|cyclophosphamide|Given IV
214363732|NCT02802163|DRUG|Lenalidomide|"Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21."
214974717|NCT00073918|DRUG|etoposide|Given IV
214974718|NCT00073918|RADIATION|iodine I 131 tositumomab|Given IV
214974719|NCT00073918|PROCEDURE|quality-of-life assessment|Ancillary study
214974720|NCT00073918|PROCEDURE|peripheral blood stem cell transplantation|Undergo ASCT given via central catheter
214974721|NCT02592317|DRUG|JNJ 56021927|JNJ 56021927 will be administered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
214974722|NCT02592317|DRUG|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.
215084618|NCT05275582|BEHAVIORAL|CARE|"Behavioral intervention including~-30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app of substance use behavior, mood, other behavioral processes 2 optional 15-minute phone calls with behavioral health educator"
214363733|NCT02802163|DRUG|Dexamethasone|Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
214363734|NCT03502486|OTHER|Moderate exercise|20 minutes of cycle ergometry at 50-60% of heart rate max
214363735|NCT03502486|OTHER|Intense exercise|20 minutes of cycle ergometry at 70-80% of heart rate max
214363736|NCT03502486|OTHER|Reading|20 minutes of seated reading
214363737|NCT01111123|DRUG|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
214363738|NCT01111123|DRUG|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
214974723|NCT02592317|DRUG|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
214974724|NCT02592317|DRUG|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
215084619|NCT05723926|DEVICE|Vine Filter|The Vine filters are designed to be implanted in the common carotid arteries in order to capture emboli coming from the heart or great vessels, before they can enter the anterior intracranial circulation. The filter is deployed percutaneously using a 22G needle under ultrasound guidance.
215084620|NCT04763512|DIETARY_SUPPLEMENT|Intact Cow's Milk Protein Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 4 months.
214363739|NCT02259179|DRUG|Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
214363740|NCT02259179|DRUG|Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
214490241|NCT06777212|BEHAVIORAL|Mindfulness Training Program|The Mindfulness Training Program is a 30-day behavioral intervention designed to help children with body-focused repetitive behaviors (BFRBs) such as nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program includes daily audio-guided exercises focused on mindfulness techniques such as deep breathing, body scans, and emotional awareness. Children will be encouraged to practice mindfulness for 10-15 minutes each day, with the goal of improving emotional regulation, reducing impulsive behavior, and enhancing self-awareness. Family support is involved, with parents helping children track their progress and offering reinforcement.
214363741|NCT03046615|DEVICE|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
214363742|NCT03046615|DEVICE|Standard Needles|Needles are placed in the muscles surrounding the eye to measure eye movements.
214363743|NCT01615874|DRUG|MF/F Metered Dose Inhaler (MDI) 25/5 mcg|MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
214363744|NCT01615874|DRUG|MF/F MDI 50/5 mcg|MF/F MDI 50/5 mcg, 2 inhalations BID
214363745|NCT01615874|DRUG|MF/F MDI 100/5 mcg|MF/F MDI 100/5 mcg, 2 inhalations BID
214363746|NCT01615874|DRUG|BDP hydrofluoroalkane (HFA) 80 mcg|BDP HFA 80 mcg, 2 inhalations BID
214363747|NCT01615874|DRUG|Montelukast tablets 5 mg (4 mg for children 5 years of age)|"Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age~OR~Montelukast chewable tablets 4 mg QD for children 5 years of age"
214490242|NCT06777212|BEHAVIORAL|Psychosocial Education Program|The Psychosocial Education Program is a 30-day behavioral intervention designed for children with body-focused repetitive behaviors (BFRBs), including nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program provides daily educational content in the form of articles and coping strategies. The intervention focuses on improving emotional regulation, promoting family support, and developing positive behavioral strategies. Parents play an active role by reviewing the content with their children and helping them apply the strategies in daily life. Behavioral and psychological assessments are conducted at baseline, one month, and three months to evaluate the program's impact.
214490243|NCT06775522|DRUG|YHP2205|Test drug: YHP2205 Comparator: YHR2401
214490244|NCT06775522|DRUG|YHR2401|Test drug: YHP2205 Comparator: YHR2401
214490245|NCT06768307|DRUG|First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC|"Cohort 1:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Concurrent Radiotherapy Phase: the fourth cycle will incorporate concurrent radiotherapy along with atezolizumab and chemotherapy.~Maintenance Phase: Atezolizumab monotherapy will be administered until disease progression or intolerance by the patient, with atezolizumab being administered for a maximum duration of 2 years.~Cohort 2:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Sequential Radiotherapy Phase: the fourth cycle will receive sequential radiotherapy in combination with atezolizumab.Final，Atezolizumab monotherapy will be continued until disease progression."
214974725|NCT05748730|BEHAVIORAL|iCHART|"The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
214974726|NCT05748730|BEHAVIORAL|Treatment As Usual|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
215084621|NCT04763512|DIETARY_SUPPLEMENT|Partially Hydrolysed Whey Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 16 months.
215094453|NCT00681993|OTHER|Standard Docetaxel and Cyclophosphamide|4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
214974727|NCT04344028|BEHAVIORAL|True Cognitive Training Program|The training program is a personal device-based adaptive version of a visual N-back task.
214363748|NCT01615874|DRUG|Rescue medication: short-acting beta-2 agonist (SABA) MDI|albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
214363749|NCT01615874|DRUG|Rescue medication: Prednisone/Prednisolone|Prednisone/Prednisolone for rescue medication, taken as directed
214363750|NCT05519280|BEHAVIORAL|the Biopsychosocial-Spiritual Group Intervention|The Experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
214363751|NCT01885728|DIETARY_SUPPLEMENT|An arginine rich nutritional supplement|Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
214363752|NCT06308679|DRUG|Empagliflozin 10 mg tablets|Empagliflozin 10 mg tablets (test drug)
214363753|NCT06308679|DRUG|JARDIANCE®|Empagliflozin 10 mg tablets (reference drug)
214363754|NCT01865708|DRUG|Ethanol Lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
214363755|NCT01735201|DRUG|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
214490246|NCT05168124|BEHAVIORAL|Acceptance Commitment Therapy for chronic fatigue|ACT was originally developed for the treatment of depression and anxiety. Recently, a single study investigated ACT as a therapeutic approach in CFS/ME and showed no negative effects on disease progression. ACT is characterized by acceptance- and mindfulness-based techniques, serves to promote acceptance and the development of new value goals, and can thereby open up new perspectives on life, which would be promising in terms of a reduction of symptom focus that seems to be a crucial effective factor for an improvement in exhaustion states. The intervention involves psychoeducation and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for anxiety disorders is adapted to the needs of patients with CFS, the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms.
214490247|NCT05168124|BEHAVIORAL|Micro breaks in everyday life for chronic fatigue|"In terms of break design in the work context, research in recent years has increasingly focused on so-called micro breaks (MB) - mini breaks of one to five minutes in length. Transferred to mini breaks in everyday life (MBEL), there have been found fundamentally positive effects in terms of performance, vitality and well-being, which could also have a positive impact on the clinical picture of CFS/ME. However, practically no research results are yet available with regard to the implementation of MB in everyday life of patients with CFS/ME. The effects of MB, on the other hand, have been tested several times in everyday work settings and showed desirable effects on mood, attention, fatigue, vitality, performance, and well-being."
214490248|NCT06771726|DEVICE|RedScar App|use of the RedScar© app on patients' smartphones. Patients will complete a brief health questionnaire and upload a wound photograph to the app, which will provide recommendations based on the risk of infection detected. Simultaneously, an in-person wound assessment will be conducted by the investigator to compare results.
214490249|NCT06772116|PROCEDURE|Focal Therapy|"Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where a PCa ISUP 2 or 3 has been identified (PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume).~Focal treatment will be performed using one of the following energy-based techniques: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted photodynamic therapy (VTP), or radiofrequency ablation (RFA). The specific technique will depend on the rules, approvals, and regulations of the country where the treatment is performed."
214363756|NCT01735201|DRUG|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
214490250|NCT06759844|BEHAVIORAL|Educational Booklet|A printed booklet containing general information on chronic disease management provided to participants for reference without interactive or digital features
214490251|NCT06759844|BEHAVIORAL|Mobile Health Application|A mobile health application that facilitates self-management of chronic conditions through daily education, personalized goal setting, and lifestyle monitoring. The intervention aims to improve participants' health behaviors and clinical outcomes by promoting active engagement with their health.
214363757|NCT01735201|DRUG|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
214490252|NCT06778590|PROCEDURE|Piezoelectric technique in third molar germectomy|Application of piezoelectric technique in third molar germectomy procedures
214490253|NCT06778590|PROCEDURE|Traditional technique in third molar germectomy|Application of traditional technique in third molar germectomy procedures
214490254|NCT06777940|OTHER|Kegel exercises|It consists of 25 patients who will receive Kegel exercises with Myokinetic active release of trigger points in quadratus lumborum, rectus abdominis and gluteus medius. Patient will be in lying position with empty bladder. Ask patient to tight pelvic floor muscle group and hold tight from 3-5 seconds Then relax muscle group from 3-5 seconds with Myokinetic therapy targeted at releasing muscle of quadratus lumborum, rectus abdominis and gluteus medius release was applied passively by sustained pressure for 8-10 seconds. This protocol consisted of three sets with 2 minutes of rest..Participants will be asked to perform exercise 30 times each session following hold and relax of muscle group for 3-5 seconds
214490255|NCT06778304|DRUG|Gonal F|The reference formulation is the recombinant human follicle-stimulating hormone injection (Gonal-f®) originally developed and produced by Merck Serono
214490256|NCT06778304|DRUG|jzb30|The test formulation is the recombinant human follicle-stimulating hormone injection (code: JZB30) produced by Shanghai Jingze Biotechnology Co., Ltd./Chengdu Jingze Biopharmaceutical Co., Ltd.
214490257|NCT06778044|OTHER|ReDirection 1.0|A free, anonymous, online, self-guided cognitive behavioral therapy (CBT) intervention. Consists of 6 modules.
214490258|NCT06778044|OTHER|ReDirection 2.0|A free, anonymous, online, self-guided, cognitive behavioural therapy (CBT) intervention. Consists of 5 modules and the option for asynchronous messaging with a ReDirection specialist.
214490259|NCT06778044|OTHER|Waitlist|Participants in the waitlist control will wait six weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing sexual urges and behaviour.
214490260|NCT06779110|PROCEDURE|Percutaneous Coronary Intervention|Using OCT to guide PCI in ISR
214490261|NCT06778668|PROCEDURE|TAP block with bupivacaine only|Patients undergoing laparoscopic cholecystectomy will receive TAP block with bupivacaine only after induction and before the surgical procedure begins.
214490262|NCT06778668|PROCEDURE|TAP block with bupivacaine and fentanyl|Patients undergoing laparoscopic cholecystectomy will receive a TAP block with bupivacaine and fentanyl after induction and before the surgical procedure begins
214490263|NCT06778902|DRUG|azacytidine|Azacytidine: 75mg/m2, d1-d5
214490264|NCT06778902|DRUG|R-GemOx|Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7
214974728|NCT04344028|BEHAVIORAL|Control Cognitive Training Program|The training program is a personal device-based adaptive version of a knowledge task (control).
214363758|NCT01735201|DRUG|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
214363759|NCT02643576|BEHAVIORAL|F&V Bonus|To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
214363760|NCT02643576|BEHAVIORAL|Restriction|To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality
215084622|NCT05400993|COMBINATION_PRODUCT|Chidamide|Chidamide: take orally twice a week,4 tablets/time (20mg/ time), the interval between two doses should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), the day before chemotherapy, 30 minutes after breakfast； Chidamide: 20mg, orally, twice a week, oral for two weeks and one week, a total of 8 cycles； Epirubicin 90mg/m2 , ivgtt, d1 Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle； sequential Docetaxel 100 mg/m 2, IVGtt, D1 Q3w, 4 cycle。
215084623|NCT04411420|BEHAVIORAL|Pain modulation with physical pain treatment|Examples of pain modulation with physical pain treatment include spinal manipulation, massage, or transcutaneous electrical nerve stimulation
215084624|NCT04411420|BEHAVIORAL|Telephone delivered self-management counseling for increasing physical activity|Centrally located physical therapy assistants will provide six weeks of telehealth consults to increase physical activity for the patient
215084625|NCT04411420|BEHAVIORAL|Telephone delivered behavioral treatment for participants with high risk for continued disability|Patients with a higher risk of developing chronic or persistent back pain will be identified using the nine question risk stratification start back screening tool (SBST) and will receive six additional weeks of physical activity instructions and additional pain modulation treatments as needed.
215084626|NCT04411420|BEHAVIORAL|Patient preference treatment protocol|the pain navigator will work through a shared decision making process with the patient to determine the preferred treatment protocol
215084627|NCT04411420|BEHAVIORAL|Nonpharmacological guideline adherent treatment protocol|the pain navigator will select only nonpharmacological guideline adherent treatment options for the patient
215084628|NCT04411420|BEHAVIORAL|Facilitated referrals to existing VA or non-VA pain management resources|the pain navigator will work with the referring physician to select only existing VA or non-VA pain management resources for the patient.
214363761|NCT02643576|BEHAVIORAL|Bonus & Restriction|To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
214363762|NCT01553318|DRUG|Ketotifen|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
214363763|NCT01553318|DRUG|Placebo (Sugar Pill)|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
214363764|NCT00892502|DRUG|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
214363765|NCT00892502|DRUG|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
214363766|NCT02238925|DRUG|CPX-351|
214363767|NCT04219852|OTHER|data collection|data collection
214363768|NCT03499522|OTHER|Observational group|"The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:~* Numerical scale of pain~* Short Form 36 Health Survey \[SF-36\].~* State-Trait Anxiety Inventory \[STAI\].~* Tampa Scale of Kinesiophofia \[TSK-11SV\].~* Pain catastrophizing scale \[PCS\].~* Coping Strategies Questionnaire \[CSQ\]."
214363769|NCT00209573|DRUG|fospropofol disodium|
214363770|NCT05095805|BEHAVIORAL|additional weight-bearing exercise|Nintendo Wii Balance Board, real-time visual feedback, weight-bearing assessment by center of pressure
214363771|NCT05095805|BEHAVIORAL|standard weight-bearing exercise|conventional training for fitting of initial prosthesis
214363772|NCT01976065|DRUG|Triple Antibiotic Paste|USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
214363773|NCT01976065|OTHER|Standard Treatment|Standard Treatment no use of study drug
214363774|NCT05794438|BEHAVIORAL|Static Approach Bias Modification|In the static approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc).
214363775|NCT05794438|BEHAVIORAL|Adaptive Approach Bias Modification|In the adaptive approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc). An algorithm continuously monitors the performance of the user and adjusts the ratio of congruent and incongruent trials accordingly to attain a desired difficulty curve.
214363776|NCT02218827|DRUG|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
214363777|NCT04156490|OTHER|No intervention is planned, this will be a purely retrospective trial.|Osmotic Therapy
214490265|NCT06779279|DEVICE|Water flosser and super flosser|Participant will use in one area superfloss and the other area waterfloss
214490266|NCT06779279|DEVICE|Orthodontic brush|Participant will use orthodontic brush to brush in the upper/lower quadrant
215084629|NCT05057507|DIAGNOSTIC_TEST|Atrial cardiac magnetic resonance imaging|To include assessment of atrial size, shape, function, fibrosis and fat
215084630|NCT05057507|DIAGNOSTIC_TEST|Atrial electro-anatomic mapping|To include assessment of atrial voltage and local activation time
215084631|NCT05057507|OTHER|Atrial fibrillation symptom questionnaire|To include assessment of atrial fibrillation symptoms and quality of life
215084632|NCT05057507|DIAGNOSTIC_TEST|Patch-based 2 week ambulatory monitor|To assess atrial fibrillation burden post-ablation
214363778|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
214363779|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
214363780|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
214363781|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
214363782|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
214363783|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
214490267|NCT06777264|BIOLOGICAL|Biological: single dose of Inaticabtagene autoleucel|Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.
214490268|NCT06767046|DRUG|KRAS-specific Autologous TCR-T cell injection|Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection
214490269|NCT06769971|DRUG|Ivonescimab|20mg/kg，IV infusion，Day1，Q3W
214490270|NCT06769971|DRUG|Cadonilimab|10mg/kg，IV infusion，Day8，Q6W
214490271|NCT06769971|DRUG|Etoposide|100mg/kg，IV infusion，Day1-3，Q3W
214974729|NCT04344028|BEHAVIORAL|Positive Expectation Induction|The message given to the participants emphasizes that the given training results in a positive change in cognitive abilities.
214363784|NCT04876794|DEVICE|ABLE Exoskeleton|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
214974730|NCT04344028|BEHAVIORAL|Negative Expectation Induction|The message given to the participants emphasizes that the given training results in a negative change in cognitive abilities.
214974731|NCT04037371|OTHER|Cold exposure|Participants were tested for white fat thermogenic activity against their environmental temperature exposure
214974732|NCT01542008|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
214974733|NCT01542008|BEHAVIORAL|broadly-directed, non-individualized education (EDU)|"EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed."
214974734|NCT05158140|BIOLOGICAL|V110|Single intramuscular (IM) dose of 0.5 mL V110, a pneumococcal polysaccharide vaccine (PCV), containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
214490272|NCT06769971|DRUG|Carboplatin|AUC 5，IV infusion，Day1，Q3W
214974735|NCT05158140|BIOLOGICAL|V114|Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F
214490273|NCT06767501|OTHER|E-GRAFT ™|E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.
214974736|NCT05158140|BIOLOGICAL|mRNA-1273|Single IM dose of 50 μg/0.25 mL mRNA-1273
214363785|NCT02042079|PROCEDURE|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
214363786|NCT05100264|OTHER|Vaginal washing with 5% acetic acid|Induction of labor (vaginal tablet dinoprostone and vaginal washing with 5% acetic acid)
214363787|NCT05100264|OTHER|Vaginal washing with 0.9% NS|Induction of labor (vaginal tablet dinoprostone and vaginal washing 0.9% NS)
214363788|NCT04563221|DEVICE|Prostatic artery embolization|Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention.
214363789|NCT06165406|PROCEDURE|Distal radial access|Distal radial access for coronary procedures
214363790|NCT00154206|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214363791|NCT02965222|DEVICE|the time-lapse videography|The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .
214490274|NCT06767501|DEVICE|FIBRACOL™|510K FDA cleared Collagen alginate dressing
214490275|NCT06750627|PROCEDURE|Continuous Erector Spinae Plane Block|Catheter are placed between the erector spinae muscle and the transversus processus with ultrasound guidance, blocking the dorsal and ventral ramus from the thorax and abdominal spinal nerves, at the level of T5. Local anesthesia is injected. Drugs used are Bupivacaine 0.25% with volume of 25 ml.
214490276|NCT06750627|DRUG|Multimodal Intravenous Analgesia|"Multimodal intravenous analgesia refers to the use of multiple intravenous (IV) agents with different mechanisms of action to provide effective pain relief. The goal is to achieve synergistic effects that improve analgesia while minimizing the doses of individual drugs, thereby reducing side effects. This approach is often used in perioperative and acute pain management.~Patient will receive combinations of opioid through Patient Controlled Analgesia (PCA) device, NSAIDs, and Paracetamol (Acetaminophen)"
214490277|NCT06763783|DRUG|Shingrix|all participants vaccinates with two doses of Shingrix vaccine
214490278|NCT06763783|DRUG|vaccination with 2 doses of Shingrix vaccine|all participants will receive vaccination with 2 doses of Shingrix vaccine. The response to caccine will be compared bitween patients treated with immunosupressive drugs and these not receiving immunosuppresive treatment
214974737|NCT05158140|BIOLOGICAL|Placebo for V110|Single IM dose of 0.5 mL placebo for V110
214974738|NCT05158140|BIOLOGICAL|Placebo for V114|Single IM dose of 0.5 mL placebo for V114
215084633|NCT04424927|BIOLOGICAL|PRV-015|Fully human monoclonal antibody against interleukin 15 (IL-15)
215084634|NCT04424927|OTHER|Placebo|Placebo
215084635|NCT06103487|GENETIC|No Intervention|Observational study
214363792|NCT03603223|BIOLOGICAL|Pembrolizumab|Given IV
214490279|NCT06768801|BEHAVIORAL|WPAPP-Latina|The WPAPP Latina intervention provides 1) educational information via modules and online resources and 2) coaching via an online forum with a chat function. The educational modules include 11 modules on physical activity promotion and 7 modules on depressive symptoms. The women are also invited to share their experiences with culturally matched interventionists (e.g., Spanish speaking graduate research assistant with expertise in depressive symptoms and physical activity) and with peer participants using a de-identified name in the online chat forum. Participants will be directed to information about physical activity with age-appropriate guidelines from the Centers for Disease Control and Prevention.
214490280|NCT06768359|PROCEDURE|Manual acupuncture and standard therapy|"Manual acupuncture is acupuncture needle insertion was done perpendicularly to the acupuncture points GV20, EXHN3, HT7, and PC6 using Huanqiu needle measuring 0.25 x 25mm with mild stimulation rotation technique at a speed of 60x/minute and needle retention for 30 minutes. Therapy was performed every day for 6 days.~Standard therapy is anxiolytic drugs and supportive psychotherapy given to patients according to the decision of the psychiatrist treating the patient."
214974739|NCT04279067|DEVICE|BCI-FES dorsiflexion therapy|"BCI technology enables direct brain control of external devices such as assistive devices and prostheses by translating brain waves into control signals. When BCI systems are integrated with functional electrical stimulation (FES) systems, they can be used to deliver a novel physical therapy to improve movement after stroke. The automated software will analyze the data to generate and calibrate a BCI decoder. In the online phase, the subjects will perform 20-25 BCI-FES runs. In each run, subjects will follow 10 alternating epochs of 10-s long idling/dorsiflexion textual cues, and respond by either idling or attempting dorsiflexion to elicit BCI-FES mediated contractions of the TA muscle."
214974740|NCT04279067|BEHAVIORAL|Physiotherapy one hour|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
214974741|NCT04279067|BEHAVIORAL|Physiotherapy two hours|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
214974742|NCT06810713|BEHAVIORAL|Gatekeeper training (e-learning)|"This training supplements existing modules for healthcare providers working with individuals experiencing suicidal thoughts (https://sp-reflex.zelfmoord1813.be/e-learning).~Specific information on working with men will be added:~* Information on suicidality among men and the importance of gender-sensitive care.~* Guidance on recognizing signs of suicidality in men and understanding gender differences in suicide-related communication.~* Insights into the impact of gender norms and socialization on suicidality and help-seeking behavior in men experiencing suicidal thoughts.~* Awareness of providers' own gender biases and the influence of societal gender norms in treating men with suicidal ideation.~* Recommendations for engaging men in treatment, with specific guidance on language and approaches for interacting with men who have suicidal thoughts.~Additionally, the e-learning will a model psychoeducation about the role of norms for men experiencing suicidal ideation."
214974743|NCT04414787|BEHAVIORAL|PCplanner|PCplanner-augmented care. The PCplanner mobile app will allow patients / family members to report their needs in a platform viewable by ICU physicians. Should the needs not improve over time, the palliative care team will be activated to contribute to care.
214974744|NCT06612164|OTHER|kefir|Commercial lactose-free kefir (Altinkilic, Turkey) beverage, which is produced from cow milk with 3.1% fat and 7.5% protein content and stored in appropriate conditions, was used in this study. The kefir (intervention) group was provided with 250 mL of plain lactose-free kefir containing at least 107-1010 probiotic bacterial strains (Lactobacillus, Lactic acid, Streptococcus, Acetic acid bacteria sp) and yeasts (Kluyveromyces marxianus, Torulaspora delbrueckii, Saccharomyces cerevisiae, Candida). The participants were asked to consume 250 mL of plain lactose-free kefir daily for 6 weeks. Any particular time was not specified for kefir consumption. Kefir consumption routine of participants was followed up by regular phone calls every week and evaluated by examining their consumption records. Those who consumed less than 85.0% (skipping kefir consumption maximum once a week) of the planned kefir consumption during the study period were excluded from the study.
214974745|NCT06871865|OTHER|Oculomotor Exercises|Oculomotor exercises are designed to improve eye movement control, coordination, and visual tracking.
214974746|NCT06871865|OTHER|Posture Exercises|Postural exercises help strengthen core muscles, improve alignment, and enhance stability. They are essential for maintaining proper posture, preventing pain, and reducing the risk of musculoskeletal imbalances.
214974747|NCT06871865|OTHER|Neck Stretching and Strengthing Exercises|Neck stretching and strengthening exercises help improve flexibility, reduce stiffness, and enhance muscle support for the cervical spine. They are beneficial for relieving neck pain, improving posture, and preventing injuries.
215084636|NCT02080325|OTHER|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
214363793|NCT04446611|DIAGNOSTIC_TEST|First antenatal care + test-of-cure|Single point-in-time molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and infection-specific test-of-cure 3 weeks post-treatment. Women with a positive test-of-cure will be re-treated. As CT/NG is a combined Xpert test, women who present with an incident infection (newly diagnosed infection) will be treated and managed accordingly.
214363794|NCT04446611|DIAGNOSTIC_TEST|First antenatal care + week 30-34 gestation (no test-of-cure)|Repeated molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and at week 30-34 gestation. No test-of-cure will be conducted for women with positive test results; however, additional treatment will be provided to women with persistent/recurrent vaginal discharge.
214363795|NCT05166538|DRUG|Ticagrelor|direct-acting oral P2Y12-receptor antagonist
215084637|NCT02080325|OTHER|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
215084638|NCT02976025|OTHER|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
215084639|NCT02976025|OTHER|Collaborative Care|Standard collaborative care implementation training and support.
215084640|NCT01057485|PROCEDURE|AF ablation and AV node ablation|AF ablation and AV node ablation
215084641|NCT01057485|PROCEDURE|AV node ablation|AV node ablation
214363796|NCT05166538|DRUG|Clopidogrel|platelet aggregation inhibitor
214363797|NCT04465279|DEVICE|Trifocal diffractive intraocular lens|Trifocal IOL having foldable single-piece fully diffractive pupil dependent aspheric IOL. Which have been made of hydrophilic acrylic with an ultraviolet (UV) and blue light inhibitor. It has an optic diameter of 6.15 mm and an overall diameter of 10.75 mm; it has +3.5D additional power for near vision and +1.75 D additional power for intermediate vision, consisting of 26 diffractive steps.
214363798|NCT03896009|DRUG|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 taken once upon onset of a qualifying migraine.
214363799|NCT03896009|DRUG|Meloxicam|Meloxicam taken once upon onset of a qualifying migraine.
214363800|NCT03896009|DRUG|Rizatriptan|Rizatriptan taken once upon onset of a qualifying migraine.
214363801|NCT03896009|DRUG|Placebo|Placebo taken once upon onset of a qualifying migraine.
214363802|NCT03178786|BEHAVIORAL|PAT sessions|PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
214363803|NCT05542940|OTHER|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading
214363804|NCT03496779|DRUG|Brentuximab Vedotin - induction|Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
214363805|NCT03496779|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
214363806|NCT03496779|DRUG|Brentuximab Vedotin - maintenance|"Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy"
214363807|NCT03496779|PROCEDURE|autologous or allogeneic stem cell transplantation|Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
214363808|NCT02127372|DRUG|Docetaxel, Cisplatin and STI571|"Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.~Phase 1 dose levels are:~* Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg~* Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg~* Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg~* Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg~* Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg~* Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg~Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II."
214490281|NCT06768359|PROCEDURE|Sham acupuncture and standard therapy|"Sham acupuncture is when acupuncture needles are inserted into acupuncture points, but do not actually penetrate the skin, only attached to the plaster. Therapy was performed every day for 6 days.~Standard therapy is anxiolytic drugs and supportive psychotherapy given to patients according to the decision of the psychiatrist treating the patient."
214490282|NCT06769152|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214490283|NCT06769152|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
215084642|NCT00340379|DRUG|Ziprasidone|Target dosage 120-160mg/day based on tolerance
215084643|NCT00340379|DRUG|Sertraline|Target dosage 150-200mg/day based on tolerance.
214363809|NCT02127372|DRUG|Docetaxel|
214363810|NCT02127372|DRUG|Cisplatin|
214363811|NCT05924542|BEHAVIORAL|Kelaa Mental Resilience App|"Users can track their stress, wellbeing, and resilience via short in-app questionnaires. The app uses inbuilt sensors in smartphones to measure sleep quality and quantity. Personalized feedback on questionnaire scores and on sleep data are given. Users access structured science-based content on factors contributing to reduced stress and improved well-being. Kelaa provides the user with evidence-based interventions grounded in current research, e.g., from sleep science and psychology. Users can choose from a variety of topics, based on their results from the tracking module and personal interest, and then journey through the self-selected goals. Each goal includes six to seven daily sessions, aiming to increase personal resources by providing information, exercises, and reflection. During each daily session, relevant research and expected benefits are outlined, before users are instructed, e.g., in specific stress management and resilience techniques, to encourage behavior change."
214363812|NCT05596643|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score-31|Standardized questionnaire to determine the level of autonomic dysfunction
214363813|NCT05596643|DIAGNOSTIC_TEST|r-r interval variability with normal breathing|electrophysiological test to detect parasympathetic dysfunction
214363814|NCT05596643|DIAGNOSTIC_TEST|r-r interval variability with deep breathing|electrophysiological test to detect parasympathetic dysfunction
214363815|NCT05596643|DIAGNOSTIC_TEST|Valsalva ratio|electrophysiological test to detect parasympathetic dysfunction
214363816|NCT05596643|DIAGNOSTIC_TEST|30:15 ratio|electrophysiological test to detect parasympathetic dysfunction
214363817|NCT05596643|DIAGNOSTIC_TEST|sympathetic skin response|electrophysiological test to detect sympathetic dysfunction
215084644|NCT00340379|DRUG|Haloperidol|Target dosage 6-8mg/day based on tolerance.
215084645|NCT02046694|DRUG|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight \>30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
214363818|NCT05596643|DIAGNOSTIC_TEST|blood pressure response to standing|clinical test to detect sympathetic dysfunction
214363819|NCT05596643|DIAGNOSTIC_TEST|blood pressure response to sustained handgrip test|clinical test to detect sympathetic dysfunction
214490284|NCT06769152|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
214490285|NCT06781125|DRUG|JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion|"JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability .~Anti-PD-1 antibody:Dosage and administration according to the instructions."
214490286|NCT06774911|OTHER|YUIT|Product with protein source from pea and rice.
214490287|NCT06774911|OTHER|P_PS|Product with protein source from soy protein.
214363820|NCT05596643|OTHER|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
214363821|NCT05596643|DIAGNOSTIC_TEST|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
214363822|NCT05596643|OTHER|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
214363823|NCT05596643|OTHER|Jenkins Sleep Evaluation Scale|Standardized questionnaire to investigate the sleep quality and disturbance
214363824|NCT05596643|OTHER|The Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue severity
214363825|NCT00000192|DRUG|Lamotrigine|
214363826|NCT01037842|DRUG|Mitiglinide|"mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks"
214363827|NCT01037842|DRUG|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
214363828|NCT00169000|DRUG|Capecitabine|"Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID"
214363829|NCT00169000|DRUG|Docetaxel|75 mg/m2 over one hour on day 8 of each cycle
214363830|NCT04444037|DEVICE|OCT-guided PCI|using optical coherence tomography imaging to help PCI procedure
214363831|NCT03008967|OTHER|Arthroplasty and postoperative rehabilitation.|Patients undergoing total knee or total hip arthroplasty and their response to postoperative rehabilitation.
214363832|NCT00498979|BIOLOGICAL|recombinant interferon alfa-2b|recombinant interferon alfa-2b
214363833|NCT00498979|DRUG|cisplatin|recombinant interferon alfa-2b
214363834|NCT00498979|DRUG|sodium stibogluconate|sodium stibogluconate
214363835|NCT00498979|DRUG|dacarbazine|dacarbazine
214363836|NCT00498979|DRUG|vinblastine|vinblastine
214363837|NCT03073148|DEVICE|Tangible Boost|Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
214363838|NCT03073148|OTHER|Placebo saline|"Participants will treat their lenses with a placebo Tangible Boost kit, which contains saline in place of the Tangible Boost solution."
214363839|NCT04618874|DIAGNOSTIC_TEST|Rapid on-site evaluation|Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).
214363840|NCT03728829|DRUG|Trastuzumab+TP|Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).
214363841|NCT01357616|DRUG|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
214363842|NCT01357616|DRUG|Brinzolamide 1% ophthalmic suspension|
214363843|NCT01357616|DRUG|Timolol 0.5% ophthalmic solution|
214363844|NCT01799564|PROCEDURE|Micropulse|Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
214363845|NCT06049264|OTHER|Thoracic spine manual traction with mobilization protocol.|The therapist will perform one 30-second bout of grade I or II central posterior-anterior mobilization at the T3 spinous process as described by Maitland et al. After the 30-second bout, the therapist proceeded to T4 and performed the same technique. This process was continued sequentially in a caudal direction to T8, for an overall intervention time of approximately 3 minutes. In addition to mobilization, thoracic spine traction will be also given in sitting position.
214363846|NCT06049264|OTHER|Thoracic manipulation protocol|To perform the manipulation, the stabilizing hand will be placed at the level immediately caudal to the restricted segment using a ''pistol grip''. Once the pre manipulative position will be achieved the patient will be instructed to take a deep inhalation and exhale. During the exhalation the treating clinician performed a high velocity, small amplitude thrust in a direction to facilitate relative closing or opening of the respective facet joint as indicated by the segmental examination.
214363847|NCT05399745|OTHER|Neurocognitive monitoring|Neurocognitive tests and MRI of the brain
214363848|NCT03247790|DRUG|Lasmiditan|Administered orally
214363849|NCT02281448|DRUG|BIA 2-093|
214363850|NCT02281448|DRUG|Contraceptives, Oral, Combined|
214363851|NCT02052310|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
214363852|NCT02052310|DRUG|Epoetin Alfa|Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.
214363853|NCT05465057|BEHAVIORAL|High intensity interval training (HIIT) + lifestyle intervention (TCOCT)|"The participants randomized for HIIT will perform supervised training sessions three times a week for 3 months. All HIIT programs consist of activities that involve 4 x 4 min. intervals at 90-95% of HRmax.~The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks."
214679633|NCT02255786|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
214363854|NCT05465057|BEHAVIORAL|Lifestyle intervention (TCOCT)|The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks.
214363855|NCT02650219|GENETIC|genetic analyses|
214363856|NCT00199615|PROCEDURE|PET|Intravenous injection of glucose labeled Fluor 18.Le patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during which the patient should not move.
214363857|NCT02380625|DRUG|Azithromycin|Adults (\>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to \<18 yrs): 30mg/kg (oral suspension) daily for 5 days
214363858|NCT02380625|DRUG|Sunitinib and Erlotinib|Sunitinib - Adults (\>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to \<18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (\>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to \<20kg): 3.5 mg/kg daily for 7 days; Children (\>20kg to \<30kg): 3.0 mg/kg daily for 7 days; Children (\>30kg to \< 18 yrs): 25 mg/kg daily for 7 days
214363859|NCT02380625|DRUG|Atorvastatin and Irbesartan|Atorvastatin - Adults (\>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to \<18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (\>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to \<18 yrs): 1 x 75mg tablet daily until discharge.
214363860|NCT02380625|OTHER|IV fluids and laboratory testing|All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
214363861|NCT05098470|DRUG|Metformin|1500-2000 mg per day for 8 weeks
214363862|NCT05098470|DRUG|Insulin Glargine|Long-acting insulin for 8 weeks
214363863|NCT05098470|DRUG|Dorzagliatin|Oral Glucokinase Activator 75 mg twice daily for 8 weeks
214363864|NCT05703100|OTHER|Incremental exercise test|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W)
214363865|NCT05703100|OTHER|Incremental exercise test under hyperthermia|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) performed at a room temperature of 35-38ºC (degrees Celsius).
214363866|NCT05703100|OTHER|Incremental exercise test under glycogen depletion|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) under glycogen depletion by performing an exercise protocol to deplete glycogen stores plus a low-carbohydrate diet 24 h before incremental testing
214363867|NCT01312870|DIETARY_SUPPLEMENT|Ensure, Abbott Nutrition|Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days
214363868|NCT01312870|OTHER|standard hospital diet|standard hospital diet
214363869|NCT03434327|OTHER|Strength Training|Eleven resistance training exercises performed on pneumatic resistance training machines using 2 second concentric and 3 second eccentric contractions at 75-80% of each subjects maximal strength. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
214363870|NCT03434327|OTHER|Power Training|Eleven resistance training exercises performed on pneumatic resistance training machines using maximum speed concentric and 3 second eccentric contractions at the load that produces the highest power for the individual. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
214363871|NCT02203240|OTHER|Cocoa|
214363872|NCT02203240|OTHER|Placebo|
214363873|NCT02656810|DRUG|Teriparatide|Single subcutaneous injection
214363874|NCT01505387|DIETARY_SUPPLEMENT|Litramine|Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
214363875|NCT01505387|DIETARY_SUPPLEMENT|Placebo|Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
214363876|NCT01941732|DRUG|Sildenafil|
214363877|NCT04669730|OTHER|usual care|Routine care
214363878|NCT04669730|BEHAVIORAL|Walk|Walk 30mins
214363879|NCT04669730|BEHAVIORAL|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
214363880|NCT04669730|BEHAVIORAL|Baduanjin plus walk|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
214363881|NCT04756557|OTHER|Experimental.|Tooth Brushing HAP 2x daily repeated cleaning of all teeth 3 min. using a standardized electric tooth brush Electric (powered) toothbrushes (Oral-B; P\&G, Schwalbach, Germany), brushing head: medium; will be changed every 2 months and a non-fluoridated tooth paste containing microcrystalline hydroxyapatite . HAP-toothpaste (Karex toothpaste with 10 % hydroxyapatite) If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexi-dine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
214679634|NCT04739124|OTHER|Follow-up questionnaires|"The patient normally follows the education program as usual but research specific data is collected:~* Biological sampling at the start and end of the education program (glycated hemoglobin).~* Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~* Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)"
214974748|NCT07016074|DRUG|Sodium Nitrate|The study drug is sodium nitrate capsule at a dose of 12mmol of nitrate. This medication will be given orally 1-8 hours before the planned contrast administration and then once per day for a total of four doses.
214974749|NCT07016074|DRUG|Placebo|The placebo control medication will be a capsule filled with lactose that will be taken in the same manner and schedule as the sodium nitrate capsule
214974750|NCT00919633|DRUG|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
214974751|NCT00919633|DRUG|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
214974752|NCT00919633|DRUG|ribavirin, USP|All patients will receive oral ribavirin
214363882|NCT04756557|OTHER|Active comparator|Tooth Brushing F 2x daily repeated cleaning of all teeth 3min.using a standardized electric tooth brush ((Oral-B; P\&G, Schwalbach, Germany) and a fluoridated toothpaste (Karex Base with sodium fluoride 1450 F-), brushing head: medium; will be changed every 2 months If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexidine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
214490288|NCT06781684|PROCEDURE|ulna shaft fracture fixation in children by intramedullary k wire|"* In the 1st group The Antegrade intramedullary k wire with appropriate diameter according to the child ulna diameter is introduced from the olecranon of the fractured ulna,cross the fracture site after good reduction under C arm in the anterioposterior and lateral views and the wire continues until reaching before the distal ulna .~* In the 2nd group The Retrograde intramedullary k wire with appropriate diameter is introduced from the diatal end of the ulna and cross the fracture site after good reduction under C arm and continues until reaching before the olecranon."
214363883|NCT02258139|DEVICE|B&L Investigational Contact Lens|The lens used in this study will be supplied by the Sponsor. All subjects will wear a -3.00D lens.
214490289|NCT06772688|PROCEDURE|orthognathic surgery|Maxillary repositioning and fixation with custom made plate
214490290|NCT06780072|OTHER|Activation Massage therapy|"Massage Sessions~Activation (Sports) massage The activation (sports) type of massage will be used as one of the massage interventions. This technique will be performed on a full body with more attention given to specific leg muscle groups such as the feet, the gastrocnemius, the femoral biceps and quadriceps and in upper body muscle groups such as the triceps, the rhomboid, the deltoid, the trapezius and head areas. Briefly, this type of massage involves a wide range of techniques that include effleurage, palmar sliding, pounding and hacking. The total duration of the activation message will be 30 minutes."
214490291|NCT06780072|OTHER|Relaxation Massage Therapy|Relaxation massage The Relaxation type of massage will be used as the second type of intervention in this study. This technique is designed to promote deep relaxation, reduce stress and enhance overall well-being. It is characterized by the use of four primary techniques performed on the full body, including the palms and feet. Specifically, these techniques consist of effleurage
214490292|NCT06782412|DIAGNOSTIC_TEST|[18F]AlF-FAPI-74 PET/CT|A \[18F\]AlF-FAPI-74 PET/CT will be performed at the same site of the screening visit (UZ Leuven, UZ Gent or UZ Antwerpen). Subjects are required to be sober four hours before the scan. The patient will get an IV line, through which the \[18F\]AlF-FAPI-74 will be injected in one bolus (3,5 MBq/kg). After 60 minutes, the acquisition on the PET/CT scan will take place. The CT will be a low dose CT with oral contrast. After the scan, participants will be observed at the department in case of adverse events. During this time, the participant can fill in the PRO. The estimated duration of this visit is three hours. If the patient receives neo-adjuvant therapy, a second \[18F\]AlF-FAPI-74 PET/CT will be performed maximum one month before surgery. If the planned surgery gets postponed after the second \[18F\]AlF-FAPI-74 PET/CT has been performed, we will have the possibility to perform one additional (i.e. third) \[18F\]AlF-FAPI-74 PET/CT, before the final surgery.
214679635|NCT04739124|OTHER|Interviews|Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.
214974753|NCT00919633|DEVICE|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
214974754|NCT00288119|DEVICE|Balloon Capsule Device|The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize \& protect the site-specific sample collection.
214974755|NCT00288119|PROCEDURE|Endoscopy|An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.
214974756|NCT06466434|OTHER|Prebiotic Food-Enriched Diet|Given by PO
215084646|NCT05055882|OTHER|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|Comparison of Adult-Onset Still's disease phenotypes
215084647|NCT02276118|DEVICE|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
215084648|NCT02276118|DEVICE|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
214363884|NCT06048731|DEVICE|Defibrillation using EV-ICD|Device: Defibrillation using the Extravascular ICD (EV-ICD)
214363885|NCT04749732|BEHAVIORAL|WalkingPad plus Psychological Intervention - PsyWPad Group|The 24-week walking program will be monitored by the WalkingPAD application that will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Transtheoretical Model of Change and the Theory of Planned Behavior.
214363886|NCT04749732|BEHAVIORAL|WalkingPad plus Virtual Assistant - CyberWPad Group|The 24-week walking program will be monitored by the WalkingPAD application, which will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support will be provided by a virtual assistant through daily and on-the-spot interactions and through support and motivational messages.
214363887|NCT04749732|BEHAVIORAL|WalkingPad group - Paper WPad Group|The 24-week walking program will be supported by a printed prescription of an individualized HbET previously defined on the WalkingPAD platform. However, this group of patients will not have the support of an application to monitor and record adherence to the program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Trans-Theoretical Model of Change and the Theory of Planned Behavior.
214363888|NCT02138630|DIETARY_SUPPLEMENT|Capsaicin|
214363889|NCT02138630|DIETARY_SUPPLEMENT|Placebo|Sugar capsule
214363890|NCT01391520|DRUG|deferiprone|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
214363891|NCT01391520|DRUG|Placebo|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
214490293|NCT06780540|OTHER|Operation Alert: Support prgram|"Substudy 1:~Testing of a newly developed psycho-education tool will occur across four partner hospitals and participating nonprofit organizations (NGOs). Victims of violence seeking care at these sites will receive immediate support, with the pilot study integrated into standard care practices. The psycho-education toolkit enhances the foundational care already provided. The tool supports healthcare providers in offering psycho-education about e.g. violence and (the effects) of trauma, ...~Substudy 2:~This pilot study evaluates the Operation Alert guidelines within the geriatrics departments of four hospitals. A geriatric assessment is standard care during admission to these departments. The pilot will be embedded into this existing practice to ensure alignment with routine care. Additional questions will be embedded in a geriatric assessment/intake focusing on older adults' well-being, relationships and social network, and potential life events (e.g. experiences of violence)."
214490294|NCT06780982|BEHAVIORAL|Balloon-Blowing exercise program|"he program begins with a one-on-one session on the first day of the research project and continues with home-based care through the LINE application on a smartphone for 5 weeks. The program consists of four steps:~1. Decision-Making in Self-Care~2. Setting Goals and Planning Self-Care~3. Self-Care Implementation: practicing the balloon-blowing exercise daily for 3 sets of 3 balloons per set (a total of 9 balloons/day), with a 1-minute rest between sets, over a period of 5 weeks.~4. Maintaining Self-Care Behaviors"
214490295|NCT06780982|BEHAVIORAL|Standard nursing care|The actions of nurses towards school-age children with obstructive sleep apnea at the hospital involve screening patient records and distributing educational materials in the form of brochures to individual pediatric patients and their parents. The knowledge provided in the brochures includes instructions on how to administer inhaled medication, avoiding allergens, performing facial and neck muscle exercises, and attending follow-up appointments as scheduled.
214490296|NCT06770010|BEHAVIORAL|Cogmed+|"Cogmed is a home-based, digital working memory training program compatible with tablet devices. The program, designed for children ages 7 and older, consists of engaging cognitive exercises that target skills involving visuospatial and verbal working memory. An essential component of Cogmed training involves assignment of an intervention coach who has access to detailed data on the user's training data. Families will have videoconference meetings once per week with an intervention coach to review progress, provide feedback and answer any questions that arise during treatment. In addition, participants' coaching calls will be supplemented with direct instruction on the use of memory strategies. Social support interventions will also be provided involving three primary approaches: (1) multi-family Cogmed Kickoff social events; (2) social incentives; and (3) peer navigator support."
214490297|NCT02355639|DRUG|Clobetasol propionate 0.05 % ointment|
214490298|NCT02355639|DRUG|Betamethasone dipropionate 0.064 % ointment|
214490299|NCT02355639|DRUG|Petrolatum ointment|
214490300|NCT06777134|OTHER|Assessment of pelvic floor dysfunction|Pelvic floor dysfunctions in patients with multiple sclerosis will be assessed using the Pelvic Floor Distress Inventory-20 (PFDI-20). The scale is designed to assess all symptoms related to pelvic floor disorders and the severity of the distress they cause. The PFDI-20 consists of 3 subscales and 20 items, with each item rated on a scale from 0 (none) to 4 (quite a bit). To determine the scale scores, the average of the responses for each item in the subscales is multiplied by 25, resulting in a subscale score ranging from 0 to 100, and a total score ranging from 0 to 300. The Turkish validity and reliability of the scale were conducted by Çelenay et al.
214490301|NCT06777134|OTHER|The Quality of Life Assessment|The quality of life of the patients will be assessed using the Multiple Sclerosis International Quality of Life Questionnaire. The questionnaire consists of 31 questions and 9 subscales. The lowest score that can be obtained from the scale is 0, the highest score is 124, and a high score indicates a low quality of life. The subscales of the questionnaire include daily living activities, psychological well-being, relationships with friends, symptoms, relationships with family, relationships with the healthcare system, emotional and sexual life, coping, and rejection. The Turkish validation of the questionnaire has been conducted.
214490302|NCT06777134|OTHER|Core endurance assessment|"Core endurance in patients will be assessed using McGill's core endurance tests Trunk Flexor Test: Patients sit at a 60° trunk angle with knees bent, arms crossed, and feet stabilized. Time holding the position is recorded.~Trunk Extensor Test: Patients lie prone with the pelvis stabilized, lift the upper body above table level, and hold. Time is recorded until the body drops.~Lateral Trunk Test: In a modified side plank (knees bent, elbow support), patients lift hips off the mat. Time is recorded until hips lower or extra support is needed."
214679636|NCT04766424|BEHAVIORAL|Sleep extension intervention|Participants will receive a fitbit and 8 weekly sleep-related educational materials via email and telephone coaching to review their sleep tracker data, set goals, trouble shoot any problems, and increase motivation.
214679637|NCT04766424|BEHAVIORAL|Health education|Participants will receive 8 weekly health education newsletters delivered via email.
214363892|NCT06296095|BIOLOGICAL|Cell therapy|Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
214363893|NCT00123032|BEHAVIORAL|Diet|Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
214363894|NCT00123032|PROCEDURE|Exercise|Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
214363895|NCT00892112|DRUG|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
214363896|NCT00892112|DRUG|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
214363897|NCT00236301|DRUG|CLIMASTON (drug)|CLIMASTON(drug)
214363898|NCT00236301|DRUG|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
214363899|NCT00236301|DRUG|placebo|placebo
214363900|NCT04750967|DRUG|Lidocaine 1% Injectable Solution|Repeated injections of lidocaine to greater occipital nerve and supraorbital nerve once a week for first four weeks then once a month for five months
214502772|NCT06665022|DEVICE|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode). For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
215084649|NCT02971241|BEHAVIORAL|Intergenerational Mobile Technology Opportunities Program|The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
215084650|NCT02947399|RADIATION|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
215084651|NCT03562234|DIAGNOSTIC_TEST|MR|Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging
215084652|NCT03562234|DIAGNOSTIC_TEST|LiMAx|Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
214363901|NCT04750967|DRUG|Amitriptyline|Amitriptyline 25 mg daily
214363902|NCT02015494|BIOLOGICAL|VAX2012Q|Recombinant influenza HA vaccine delivered IM
214363903|NCT04111003|PROCEDURE|local anesthesia|administering local anesthesia in the region of the planned restorative procedure
214363904|NCT04111003|PROCEDURE|Tooth restored using SFRC filling|Restoration of an endodontivally treated molar using a shor-fiber base filling and veneering composite
214363905|NCT04111003|PROCEDURE|Tooth restored using Ceramic indirect endocrown|Restoration of an endodontically treated molar using a ceramic indirect restoration
214363906|NCT06225856|DRUG|YY201|Oral administration under fasting state.
214363907|NCT02864225|DEVICE|Scalp electrode,|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
214363908|NCT02864225|DEVICE|Fetal doppler|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
214363909|NCT02864225|DEVICE|EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
214974757|NCT07034248|OTHER|Electrochemical biosensor|considering benefits of the nitrogen, sulfur-doped graphene quantum dot (NSGQDs) and 3-dimensional gold nanoparticle (AuNP), we used these materials for the construction of a novel electrochemical biosensor to apply the synergy contributions on the enhancement of the potential in clinical and cancer diagnostic applications. The synthesis of a novel nanocomposite through the integration of NSGQDs with AuNP yields a hybrid material (NSGQDs/AuNP) that combines the advantages of both its organic and inorganic properties, potentially revealing unique characteristics to enhance the electrochemical behaviors, which establishes a robust foundation for constructing a label-free electrochemical biosensor. This pioneering biosensor was then conjugated with PhaL (NSGQDs/AuNP/PhaL) through the amide bond between the COOH group of NSGQDs and the NH2 group of PhaL, which has the potential for the ultra-sensitive detection of cancer markers, featuring heightened electrochemical and sensing capabilitie
214974758|NCT06709781|OTHER|Control (no cooling modalities)|Subjects will exercise for 60 minutes in the heat while being exposed to no cooling modality.
214974759|NCT06709781|OTHER|Water Spray|Subjects will exercise for 60 minutes in the heat while being exposed to skin wetting. Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.
214974760|NCT06882733|DEVICE|Transcutaneous Electrical Nerve Stimulation，TENS|low frequency (4Hz) and sympathetic ganglion(T12.L1.L2) low frequency (4Hz) and gastrocnemius high frequency (80Hz) and sympathetic ganglion(T12.L1.L2) high frequency (80Hz) and gastrocnemius
214974761|NCT06686355|DRUG|Yiqilishui formula|Astragalus Root 30g, Angelica sinensis 30g, Honeysuckle Flower 30g, Capillary Artemisia Herb 15g, Giant Knotweed Rhizome 15g, Lepidium Seed 30g, Sichuan Lovage Rhizome 15g, Salvia Root 15g, Jujube Fruit 15g;
214974762|NCT06686355|OTHER|Placebo|5% Yiqilishui Granules + 95% Dextrin;
214363910|NCT03300791|OTHER|Admitted|Readmitted patients in the next months after an episode of aute heart failure will be recruited. Controls will be selected between those who were admitted in the baseline but not readmitted in this month.
214363911|NCT00420199|DRUG|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
214363912|NCT00420199|DRUG|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
214363913|NCT04433364|OTHER|biological samples, questionnaires and interviews|"Biological samples: to study impact of testing positive for SARS-CoV-2 during pregnancy samples taken in routine clinical care, samples from already existing research biobanks and the newly established COPE biobank will be used. Time-points: inclusion, at delivery mother and fetus. Covid-19 positive group only: 48-96 h, 2 months postpartum for mother and fetus.~Questionnaires: Women and partners in both groups will fill out electronical questionnaires at different time points during pregnancy and until 12 months postpartum based on validated instruments to test for differences in Self-Efficacy, Anxiety and Depression, Health-related quality of life, Sense of Coherence, PTSD Symptoms, Postpartum Bonding, Childbirth experiences and Self-Efficacy of Breastfeeding. The child's health will be assessed regarding infection until 6 weeks of age and development until 4 years.~Interviews: 24-40 women and partners in both groups. Interviews will be conducted 3 to 6 months after childbirth."
214363914|NCT05520463|PROCEDURE|Sacral lateral branch radiofrequency ablation under ultrasound guidance|Sacral lateral branch radiofrequency ablation will be performed under ultrasound guided approach.
214363915|NCT05520463|PROCEDURE|Sacral lateral branch radiofrequency ablation under fluoroscopy guidance|Sacral lateral branch radiofrequency ablation will be performed under fluoroscopy guided approach.
214363916|NCT05200130|OTHER|Home Exercise Group|The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.
214363917|NCT05200130|OTHER|Manual Therapy Group|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to shoulder and neck complex, active and resistant shoulder complex movements, shoulder complex mobilization, mobilization cervical joints.~The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex."
214363918|NCT05200130|OTHER|Telerehabilitation Group|The telerehabilitation program applied to the same home exercise group. In addition, to the home exercises, these patients will apply active mobilization called self-mobilization. Self-myofascial release, active glenohumeral joint mobilization, thoracic mobilization, and active cervical mobilization.
214363919|NCT00995982|BIOLOGICAL|VRC-FLUDNA056-00VP|
214363920|NCT06397599|OTHER|denture adhesive|use of adhesive for completely edentulous
214363921|NCT03608280|PROCEDURE|Bone autograft|The principle of this surgery is based on the removal of a portion of the outer bone layer from the vault of the skull in order to have a flat and solid bone element (cortical bone), which can be carved freehand to better replace the defective bone wall.
214679638|NCT02617121|DRUG|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
214679639|NCT02617121|DRUG|Ramosetron|ramosetron 0.3 mg iv at end of surgery
214679640|NCT02617121|DRUG|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
214679641|NCT01209208|DRUG|Budesonide|9 mg per day
214679642|NCT01209208|DRUG|Mesalamine|3 g per day
214974763|NCT06852053|DEVICE|Closed-loop Vibro-Tactile Stimulator|Vibro-Tactile stimulation when bradycardia is predicted or predicted.
214974764|NCT06852053|DEVICE|Control|Sham closed-loop vibrotactile stimulator
214974765|NCT06737601|DEVICE|shock waves|three sessions, weekly frequency
214974766|NCT06735885|DEVICE|Matter Neuroscience App|An iPhone smartphone application
214974767|NCT06735885|DEVICE|Stock Photos|Stock Photos
214974768|NCT06735885|OTHER|No Home Training|No Home Training
214974769|NCT01526785|DRUG|Alglucosidase alfa|4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
214974770|NCT07048366|BEHAVIORAL|Integrated Rehabilitation Program at the University Museum|This intervention consists of an 8-week integrated rehabilitation program, with weekly 60-minute sessions, conducted at the University Museum (Museo Universitario UD'A). The program includes mindfulness techniques, conscious breathing exercises, body scan meditation, mindfulness walking within the museum's exhibition spaces, specific stretching and mobilization techniques, and gratitude and recognition exercises, all framed by the artistic and cultural context of the museum. The museum environment is utilized as a therapeutic setting to amplify the benefits of the behavioral techniques.
214974771|NCT07048366|OTHER|Waitlist for Conventional Treatments|This arm of the study serves as the control group. Participants in this group will be placed on a waitlist for conventional treatments and will not receive the museum-based integrated rehabilitation program during the study period. They will not undergo any active intervention specifically tested within the scope of this study.
214974772|NCT03291821|DRUG|human menopausal gonadotropin|human menopausal gonadotropin subcutaneously
214974773|NCT03291821|DRUG|GnRH antagonist|GnRH antagonist subcutaneously
214974774|NCT03291821|DRUG|GnRH analog|GnRH analog subcutaneously
214974775|NCT03291821|PROCEDURE|Trophectoderm biopsy|Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
214974776|NCT03291821|DIAGNOSTIC_TEST|MitoScore|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
214974777|NCT03291821|PROCEDURE|Intracytoplasmic sperm injection|ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.
215084653|NCT02483260|DRUG|Ribavirin|"1. Loading dose, 33 mg/kg (maximum dose: 2.64 g)~2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses)."
214679643|NCT01209208|OTHER|Placebo|0 g per day
214679644|NCT02273323|OTHER|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
214679645|NCT02273323|OTHER|Placebo|Placebo: tea flavour, colouring and sugar
214363922|NCT03608280|PROCEDURE|Orbital reconstruction by 3D-printed porous titanium implant|"From data of a patient's CT-scan, it is possible to perform a mirroring. The unaffected orbit is mirrored onto the affected orbit, via a virtual treatment planning, in order to rely on facial symmetry to virtually restore healthy anatomy. From this simulation, the implant is 3D-printed by Selective Laser Melted (SLM) technique using titanium powder. This technique enabling the creation of custom-made implants is called computer-aided design and computer-aided manufacturing (CAD-CAM).~After sterilization, the implant is ready to be placed during a surgical procedure."
214490303|NCT06777134|OTHER|Hip strength assessment|The assessment of hip strength will specifically focus on the hip adductor and hip external rotator muscle strength. Both muscle groups are considered to be associated with the pelvic floor. Among the hip external rotators, the piriformis muscle functions as an internal stabilizer for the hip joint, while the obturator internus muscle shares fascial connections with the pelvic floor, playing a significant role in pelvic floor function. MR and EMG studies have demonstrated that the levator ani and gluteus maximus muscles are morphologically and functionally connected, and that the contraction of hip adductor and gluteal muscles facilitates the synergistic contraction of pelvic floor muscles. Based on this information, a handheld dynamometer will be used to measure the strength of the two muscle groups planned for evaluation. Measurements will be performed three times, and the average value will be recorded.
214490304|NCT06777134|OTHER|Tibialis posterior muscle activation|"The NeuroTrac Myoplus Pro (Quintet, Bergen, Norway) EMG device will be used for the superficial EMG analysis of the posterior tibialis muscle. During the assessment, single-use 30 x 30 mm round adhesive electrodes will be placed on the reference points. The active electrode will be positioned at the exact midpoint between the tibial tuberosity and the medial malleolus (32,33); the passive electrode will be placed 4 cm distal; and the reference electrode will be placed on the lateral malleolus.~The patient will be asked to perform isometric plantar flexion + inversion movement of the ankle against resistance for 10 seconds. The ankle isometric contractions will be performed in 3 repetitions, with a 20-second rest period between contractions. As a result of the assessment, parameters related to the muscle's strength, total work, and resting tone will be recorded in microvolts; the maximal voluntary contraction will be recorded as a percentage."
214490305|NCT06777134|OTHER|Tibialis anterior muscle activation|"The NeuroTrac Myoplus Pro (Quintet, Bergen, Norway) EMG device will be used for the superficial EMG analysis of the tibialis anterior muscle. During the assessment, single-use 30 x 30 mm round adhesive electrodes will be placed on the reference points. The active electrode will be positioned on the muscle body of the tibialis anterior, the passive electrode will be placed 4 cm distal, and the reference electrode will be placed on the lateral malleolus (34,35).~The patient will be asked to perform isometric ankle dorsiflexion against resistance for 10 seconds. The ankle isometric contractions will be performed in 3 repetitions, with a 20-second rest period between contractions. As a result of the assessment, parameters related to the muscle's strength, total work, and resting tone will be recorded in microvolts; the maximal voluntary contraction will be recorded as a percentage."
214490306|NCT06842771|OTHER|Normal Saline (0.9% NaCl)|"Women will undergo planned, laparoscopic gynecologic surgery with an intraperitoneal wash of 20 mL of saline (standard) at the end of the operation, prior to insufflation, release, and skin closure.~The wash will be instilled into the peritoneal cavity and the surgical area (over the vaginal cuff and along the bilateral pelvic sidewalls to the paracolic gutters).~All participants will rate their pain using a Visual Analogue Scale (VAS). The VAS is a numerical rating system where the scores range from zero (0) to ten (10), with zero indicating 'no pain at all' and ten indicating 'the worst possible pain'.~Participants will be asked to rate their current level of pain and also report their current dosage of pain medication at the following intervals: pre-operatively, 2 hours post-operatively, and 24 hours post-operatively."
214490307|NCT06842771|DRUG|Marcaine hydrochloride without epinephrine 0.5%|Women will undergo planned, laparoscopic gynecologic surgery with an intraperitoneal wash of 20 mL Marcaine hydrochloride (bupivacaine) without epinephrine 0.5% (the comparator) at the end of the operation, prior to insufflation, release, and skin closure. The wash will be instilled into the peritoneal cavity and the surgical area (over the vaginal cuff and along the bilateral pelvic sidewalls to the paracolic gutters). All participants will rate their pain using a Visual Analogue Scale (VAS). The VAS is a numerical rating system where the scores range from zero (0) to ten (10), with zero indicating 'no pain at all' and ten indicating 'the worst possible pain'. Participants will be asked to rate their current level of pain and also report their current dosage of pain medication at the following intervals: pre-operatively, 2 hours post-operatively, and 24 hours post-operatively.
214363923|NCT00306033|DRUG|Intravenous ImmuneGlobulin|
214363924|NCT01557387|OTHER|Endoscopic techniques|All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
214363925|NCT01257776|DRUG|Autologous adipose derived mesenchymal stem cells|Intra-arterial administration through a selective cannulation of target common femoral artery
214363926|NCT00372008|DRUG|Testosterone|
214363927|NCT00003835|DRUG|leucovorin calcium|Given IV
214363928|NCT00003835|DRUG|fluorouracil|Given IV
214363929|NCT00003835|DRUG|irinotecan hydrochloride|Given IV
214363930|NCT00003835|OTHER|laboratory biomarker analysis|Correlative studies
214363931|NCT05592795|OTHER|Whether ERCP or EST is carried out|This project systematically studies the physiological characteristics of biliary microecology in normal people, and explores the impact of ERCP and EST duodenal papillary incision on biliary microecology.
214363932|NCT05635578|BEHAVIORAL|sleep|reiki
214363933|NCT01129388|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
214363934|NCT01129388|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
214363935|NCT01129388|DRUG|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
214363936|NCT03980444|DEVICE|Basket of wire|(using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
214363937|NCT03980444|PROCEDURE|control group, no basket|"In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
214363938|NCT05873374|BIOLOGICAL|50 μg Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of 50 μg Baiya SARS-CoV-2 Vax 2
214490308|NCT06782737|OTHER|Dietetic interventión with mediterranean diet|Personalized dietary Mediterranean diet
214490309|NCT06775431|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|Pethidine will be administered intravenously in group A 0.5 mg/kg as premedication
214490310|NCT06775431|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally|0.2 mg/kg pethidine in trathecally will be administered with bupivacaine 0.5% in group B
214490311|NCT05619783|DRUG|AMX0035|Combination of 3 g phenylbutyrate and 1 g taurursodiol
214490312|NCT04307615|COMBINATION_PRODUCT|Oxygen + continuous positive airway pressure (CPAP)|Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment
214490313|NCT04307615|DRUG|Oxygen|Oxygen: 20 min treatment followed by 10 min rest and assessment
214490314|NCT06791694|OTHER|Resins, Composite|Graduate students; healthy maxillary central teeth and color measurements will be performed with 4 different methods in at least 32 patients aged between 18-40 years. Firstly, students will be asked to make color measurements using the traditional method with two different color scales (Vita classical and Vita 3D master). As the third method; the enamel color of the teeth will be determined on digital photographs using the buton technique. Finally, tooth color will be measured on the buccal surface of the central teeth using a spectrophotometer.
214490315|NCT04924491|BIOLOGICAL|Autologous thyTreg|Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
214490316|NCT05139979|BEHAVIORAL|Breathing and Wellness Webinar|"Simha Kriya : a 3-minute energizing breathing practice to expand lung capacity and improve immunity, to be practiced twice daily.~Nadi Shuddhi - a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.~Isha Kriya - a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily."
214490317|NCT05139979|OTHER|Routine Daily Activity|Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.
214490318|NCT06823531|OTHER|Not applicable (Observational Study)|Not applicable (Observational Study)
214490319|NCT03991156|DEVICE|Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|Audio Visual System
214490320|NCT03991156|OTHER|Quality of Life Survey, PedsQL3.0|Quality of life survey using the PedsQL 3.0 Cancer Module
214490321|NCT03991156|OTHER|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF).\[24\] is a survey to measure anxiety
214679646|NCT04788719|OTHER|Gait analysis|Gait analysis
214974778|NCT03291821|PROCEDURE|Ovarian puncture|Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
214974779|NCT03291821|DIAGNOSTIC_TEST|Preimplantation genetic test|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
214974780|NCT03291821|PROCEDURE|Embryo transfer|Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
214974781|NCT03291821|DIAGNOSTIC_TEST|Pregnancy test|A pregnancy test is used to determine whether a woman is pregnant.
214679647|NCT04180436|DRUG|rivaroxaban 20 mg once daily 8 days|Blood samples for the measurement of rivaroxaban PK parameters
214974782|NCT03291821|PROCEDURE|Embryo freezing|Embryo freezing is a method for cryopreserving embryos.
214974783|NCT03291821|PROCEDURE|Embryo thawing|Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
214974784|NCT01775423|DRUG|BBI608|
214974785|NCT02007720|DRUG|Serelaxin|Intravenous infusion
214974786|NCT02007720|DRUG|Placebo|Intravenous infusion
214974787|NCT02007720|OTHER|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
214974788|NCT06333886|DEVICE|Sacral electromyography|Assessment of neuro-sacral function using point-of-care sacral surface electromyography
214974789|NCT02522416|DEVICE|Central corneal thickness measurement|
214974790|NCT01461733|DRUG|amiodarone|standard dose amiodarone
214679648|NCT00651118|DRUG|Placebo|placebo
214679649|NCT00651118|DRUG|azelastine Hcl|azelastine Hcl 548 mcg
214679650|NCT00651118|DRUG|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
214679651|NCT00651118|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
214974791|NCT01461733|DRUG|Placebo|placebo delivered blinded
214974792|NCT03416192|DEVICE|MCO-HD|Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.
214974793|NCT03416192|DEVICE|high-flux HDF|Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter
214974794|NCT01505413|DRUG|Erlotinib|Erlotinib 100 mg po qd daily
214363939|NCT05873374|OTHER|Placebo|Intramuscular injection in the deltoid region of 0.5 mL/dose of 0.9% Sodium Chloride
214363940|NCT03387579|DRUG|Smoflipid 20% Lipid Emulsion for Injection|Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
214490322|NCT06843083|DIAGNOSTIC_TEST|CEM protocol|CEM combines low-energy mammography with high-energy contrast-enhanced imaging to highlight areas of neo-angiogenesis, which are indicative of malignancy. This intervention will be used to evaluate the diagnostic performance of CEM in detecting and characterizing breast lesions, especially in patients with dense breast tissue or inconclusive findings from routine mammography.
214490323|NCT06843083|DIAGNOSTIC_TEST|breast MRI|"MRI (Magnetic Resonance Imaging):~MRI will be used as an alternative imaging modality for breast lesion detection and characterization. MRI provides detailed soft tissue imaging and is widely used in the evaluation of high-risk patients or those with dense breast tissue. The results from MRI will be compared to CEM findings to determine which modality offers superior diagnostic accuracy and clinical impact."
214490324|NCT05591859|DEVICE|Restoration Anatomic Acetabular Shell|Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
214490325|NCT03869892|DRUG|Trifluridine/tipiracil hydrochloride (S95005)|Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
214490326|NCT03869892|DRUG|Capecitabine|Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
214363941|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
214363942|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
214363943|NCT03042455|DEVICE|Armeo and rTMS|"The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks."
214363944|NCT03042455|DEVICE|Armeo|The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
214490327|NCT03869892|BIOLOGICAL|Bevacizumab experimental|Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
214490328|NCT03869892|BIOLOGICAL|Bevacizumab control|Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
214490329|NCT06772792|DRUG|Alendronate|Oral administration
214490330|NCT06772792|DRUG|Enlicitide Decanoate|Oral administration
214974795|NCT01505413|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
214974796|NCT01505413|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
214974797|NCT02391051|RADIATION|HDR-Brachytherapy|HDR-Brachytherapy 2x 13,5 Gy
214974798|NCT06467695|DEVICE|BIOPAC Stimsola|Transcranial Electrical Stimulator
214974799|NCT06467695|DEVICE|BIOPAC Stimsola Sham (zero amps)|Transcranial Electrical Stimulator set to 0 amps
214974800|NCT04743622|DRUG|Monoprost|preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes
214974801|NCT04743622|DRUG|Xalatan|preserved latanoprost 1 drop once a day for 12 weeks to target eyes
214974802|NCT07061860|DEVICE|digital complete denture|different method of denture construction
214974803|NCT07061860|DEVICE|metal reinforced complete denture|different method of denture construction
214974804|NCT01725685|DRUG|FF 400 mcg|FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
214974805|NCT01725685|DRUG|UMEC 500 mcg|UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
214974806|NCT01725685|DRUG|FF/UMEC 400/500 mcg|FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
214974807|NCT06420388|DRUG|2% Lidocaine Gel|"The intervention group received 5 mL of 2% lidocaine gel applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.~The control group received 5 mL of a non-anesthetic water-based lubricant gel applied topically 3 times per day after surgery.~The application of the gels began immediately after surgery and continued for the postoperative period evaluated in the study.~Both groups received standard postoperative analgesics (acetaminophen, celecoxib, Dynastat/parecoxib as needed) in addition to the topical gel applications."
214974808|NCT06420388|DRUG|Water-based Lubricant Gel (K-Y Gel)|The intervention group received 5 mL of mL of a non-anesthetic water-based lubricant gel (K-Y gel) applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.
214974809|NCT06420388|DRUG|Standard Postoperative Analgesics|"Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous"
215084654|NCT04251052|PROCEDURE|Bilateral Salpingectomy|Undergo bilateral salpingectomy
214363945|NCT03042455|OTHER|Control group|The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
214363946|NCT04068350|OTHER|Pain questionnaire|Pain questionnaire, 3 months after surgery
214363947|NCT03466086|DEVICE|Test Eye Drops|blink® intensive TRIPLE ACTION 3 in 1 eye drops
214363948|NCT03466086|DEVICE|Control Eye Drops|Systane® BALANCE eye drops
214363949|NCT03605433|DRUG|Rivaroxaban|Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
214363950|NCT02235246|DRUG|Magnesium Sulfate|magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
214363951|NCT02235246|DRUG|Normal saline|Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
214363952|NCT04550962|DRUG|Dupilumab SAR231893|"Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:"
214363953|NCT06019195|OTHER|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
214363954|NCT02994914|OTHER|Onco Geriatric Evaluation|"Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy."
214490331|NCT06094881|DRUG|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 60 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
214490332|NCT04158141|DRUG|Carboplatin|Intravenously
214490333|NCT04158141|DRUG|Cisplatin|Intravenously
214490334|NCT04158141|PROCEDURE|Decortication|Undergo decortication
214490335|NCT04158141|RADIATION|Intensity-Modulated Radiation Therapy|Daily fractions
214490336|NCT04158141|DRUG|Pemetrexed|Intravenously
214679652|NCT03836118|PROCEDURE|Homologous intrauterine insemination (IUI)|"Patients were treated with HMG/rFSH according to classic protocols of therapy and monitoring. An injection of uHCG 5000 IU/ rHCG 250 mg was given to trigger ovulation. On the day of insemination, the semen sample was obtained through masturbation after a 2-5 day abstinence period and collected in a sterile cup. TMSC was determined by multiplying grade A or grade A + B sperm motility percentages by sperm volume and concentration. To evaluate sperm viability Eosin and Nigrosin (E\&N) staining was carried out according to WHO standards. Sperm capacitation was performed using density gradient centrifugation or swim-up procedure in order to remove seminal fluids and enhance sperm quality for IUI.~IUI was performed a t36 hours post-HCG. A fraction of the washed motile spermatozoa was inserted up to the uterine fundus and expelled into the uterine cavity. Daily treatment with micronized progesterone was prescribed for 14 days after IUI. Serum ß-HCG was determined 14 days after IUI."
214363955|NCT05851859|OTHER|Cardiac coherence|Use of Cardiac coherence (complementary respiratory training) during 6 month
214363956|NCT03062722|PROCEDURE|keyhole approach|The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
214363957|NCT00345449|BEHAVIORAL|Decision Aid|
214490337|NCT04158141|DRUG|Pemetrexed Disodium|Intravenously
214363958|NCT05979753|OTHER|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH IN SPRINTER
214490338|NCT04158141|RADIATION|Pencil beam scanning proton therapy|Daily fractions
214490339|NCT04158141|PROCEDURE|Pleurectomy|Undergo pleurectomy
214490340|NCT06835140|DRUG|Donor-derived CD123-CD16 bispecific antibody-modified NK cells|Patients enrolled sequentially received varying doses of NK cell infusions. The first three patients received 1×10⁷ cells/kg, the next three received 2×10⁷ cells/kg, and the final three received 4×10⁷ cells/kg.
214502773|NCT06665022|DEVICE|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
214363959|NCT01292954|DIETARY_SUPPLEMENT|Blueberries|low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period
214974810|NCT07063147|DIAGNOSTIC_TEST|TTE|All patients underwent TTE according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
214974811|NCT07066358|PROCEDURE|Simultaneous Bilateral RF Thalamotomy|This intervention involves simultaneous bilateral radiofrequency (RF) lesioning of the ventral intermediate nucleus (Vim) of the thalamus using a stereotactic frame under local anesthesia. The procedure begins with RF ablation on the side contralateral to the dominant hand. Intraoperative MRI is then performed to confirm the absence of hemorrhagic complications. If no bleeding or other adverse events are detected, the procedure proceeds to the contralateral Vim. If hemorrhage is identified, the surgery is terminated after unilateral treatment. This technique allows for immediate bilateral tremor reduction in patients with medication-refractory essential tremor, while prioritizing patient safety through intraoperative imaging-based decision-making.
214974812|NCT07066761|DEVICE|Laparoscopic lateral suspension with surgical mesh (LatGYNious)|Laparoscopic lateral suspension with LatGYNious (with uterus preservation or after hysterectomy)
214974813|NCT07068672|BEHAVIORAL|Kaleidoscope|A handheld kaleidoscope was used as a passive distraction tool during venipuncture. The device was introduced to the child 2 minutes before the procedure and remained in view during blood collection. It provided dynamic, colorful visual stimuli to help reduce pain and anxiety.
214974814|NCT07068672|BEHAVIORAL|Helicone|A helicone toy was used as an active distraction tool. Children held and rotated the device beginning 2 minutes before and during venipuncture. The interactive movement and shape-shifting design engaged the child's attention to reduce procedural pain and anxiety.
214363960|NCT01067170|DEVICE|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
214363961|NCT03351972|DRUG|Klean Prep|Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
214363962|NCT03351972|OTHER|Clear liquids only|Participants randomised to clear liquids only will receive guidance to only drink clear liquids before their procedure
214363963|NCT00335218|DRUG|Climodien / Lafamme (BAY86-5027)|1 tablet daily (2 mg EV + 2 mg DNG)
214363964|NCT00335218|DRUG|Placebo|1 tablet daily
214363965|NCT05311800|OTHER|Physical activity|Comparison of HIIT mode (running vs cycling)
214363966|NCT03964597|DIAGNOSTIC_TEST|Measurement of lens opacification|Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.
214679653|NCT03117049|DRUG|ONO-4538|360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
214974815|NCT07066644|PROCEDURE|central node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
214974816|NCT07072702|BEHAVIORAL|Managing Post-Injury Challenges (MPIC)|A brief evidence-informed intervention was developed to reduce post-injury perceptions of injustice. The intervention is referred to as 'Mastering Post-Injury Challenges' (MPIC). MPIC consists of 4 weekly 30-minute virtual meetings with a psychologist trained in the delivery of the intervention. MPIC is delivered concurrently with the physiotherapy treatment to which the injured worker has been referred. MPIC combines elements of validation, motivational interviewing, acceptance and problem-solving .
214974817|NCT07072390|OTHER|Measurement Tool for Clinical Competencies in Physiotherapy (MTCCP)|A culturally adapted Turkish version of the Measurement Tool for Clinical Competencies in Physiotherapy (MTCCP), used to evaluate clinical skills in final-year physiotherapy students.
214974818|NCT07073703|PROCEDURE|APA|2 adapted physical activity (APA) sessions per week for 4 weeks before and after surgery
214974819|NCT07073703|BEHAVIORAL|Therapeutic education workshops|Therapeutic education workshops tailored to individual needs, covering topics as physical activity, nutrition, treatments, fatigue, and relaxation.
214974820|NCT07073703|PROCEDURE|DAPAP|"Referral to the department's DAPAP for a 12-week bridge program, consisting of one session per week."
215084655|NCT04251052|PROCEDURE|Bilateral Salpingectomy with Oophorectomy|Undergo bilateral salpingo-oophorectomy
215084656|NCT04251052|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215084657|NCT04251052|OTHER|Quality-of-Life Assessment|Ancillary studies
214363967|NCT03094780|BEHAVIORAL|Quality of life counseling|Will receive quality of life counseling from PI, social workers, and physical therapists
214363968|NCT03094780|OTHER|Video-conference quality of life counseling|Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
214363969|NCT00144274|DRUG|Ambroxol Lozenge|
214363970|NCT04208516|PROCEDURE|Continuous Erector Spinae Plane Nerve Block|To be administered to subjects in the active comparator group receiving primary unilateral thoracic surgery.
214363971|NCT04208516|PROCEDURE|Continuous Quadratus Lumborum Nerve Block|To be administered to subjects in the active comparator group receiving primary major abdominal surgery.
214363972|NCT04208516|PROCEDURE|Single Erector Spinae Plane Nerve Block|To be administered to subjects in the experimental group receiving primary unilateral thoracic surgery.
214363973|NCT04208516|PROCEDURE|Single Quadratus Lumborum Nerve Block|To be administered to subjects in the experimental group receiving primary major abdominal surgery.
214363974|NCT04208516|DRUG|Lidocaine IV|To be given postoperatively as a continuous infusion at a dose of 50 mg/hr in the experimental group.
214363975|NCT04208516|DRUG|Ropivacaine 0.5% Injectable Solution|To be used in both treatment arms as nerve block initial bolus injection.
214363976|NCT04208516|DRUG|Dexamethasone|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
214363977|NCT04208516|DRUG|Dexmedetomidine|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
215084658|NCT04251052|OTHER|Questionnaire Administration|Ancillary studies
214363978|NCT04208516|DRUG|Lidocaine|To be used perineurally as a 0.25% solution in the active comparator group at a rate of 10 ml/hr per perineural catheter.
214363979|NCT05724979|OTHER|ZP-binding|The ZP is selective with regard to binding and can bind to normally functioning sperm, especially those with a normal acrosomal region
214363980|NCT04020341|DRUG|Gepotidacin|Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
214363981|NCT04020341|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
214363982|NCT04020341|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
214363983|NCT04020341|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
214363984|NCT00677352|DRUG|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
214363985|NCT00677352|DRUG|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
214363986|NCT05763628|DEVICE|Control Lens (stenfilcon A)|Daily Disposable Multifocal Contact Lens for 2 weeks
214363987|NCT05763628|DEVICE|Test Lens (senofilcon A)|Daily Disposable Multifocal Contact Lens for 2 weeks
214363988|NCT03756792|BEHAVIORAL|Normal Education Material|Patients will receive standard educational material about Mohs micrographic surgery.
214974821|NCT07073872|OTHER|IDEAL Discharge Education Program|Participants in the intervention group received the nurse-led IDEAL Discharge Education Program (IDEP) and the control group received a standard 15-minute face-to-face discharge education the day of discharge day. The IDEP is a nurse-led, structured discharge education program in accordance with IDEAL Discharge Planning that uses the teach-back method. IDEP is an individualized discharge educational program for surgical patients that utilizes the teach-back method and a printed booklet.
214974822|NCT07073872|OTHER|control group|This group receives routine hospital discharge instructions for 15 minutes on the day of discharge.
214974823|NCT07073638|DRUG|RESP30TB|Nitric Oxide agent
214363989|NCT03756792|BEHAVIORAL|Vignette|Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
214363990|NCT04791280|PROCEDURE|Faeces collection|"* faeces collection at inclusion~* follow-up visit 6 months after inclusion"
214363991|NCT05574725|DEVICE|Smartphone|review of the smartphone video on patients phone by general neurologist and epileptogist each separately with comment on onquality of video using videoquality scale(10), semiology, seizure diagnosis
214502774|NCT06668142|DEVICE|Beacon Platform|The Beacon Platform is a robotically assisted surgical (RAS) device. It enables the urologist, through software, to control and move surgical instruments for a variety of transurethral, endoscopic procedures
214974824|NCT07073638|DRUG|HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
214974825|NCT07072312|BEHAVIORAL|Adjuvant Patient Navigation for Tobacco Treatment|Patients in the study meet with the Patient Navigator two weeks after their first tobacco treatment visit and again after their second visit with the Tobacco Treatment Provider. The Patient Navigator will discuss psychosocial and other cessation barriers. The Patient Navigator will connect the patients with appropriate resources to help overcome these barriers.
214974826|NCT07073144|BEHAVIORAL|Virtual walking|Participants in the intervention group will wear a head-mounted display and hold a controller to swing their arm and control the virtual avatar walking in the virtual world. The intervention will include 10 scenarios of virtual walking intervention (1 scenario daily, each lasting for 15-20 minutes).
214974827|NCT07073144|BEHAVIORAL|Passive observing walking|Participants in the control group will be given 10 different walking videos in total, one for each day, each approximately 15 minutes in length.
214974828|NCT07073846|DRUG|Intravenous Lidocaine infusion + Standard Anesthesia|Continuous IV infusion of lidocaine 1 % (10 mg mL-¹) at 0.3 mL kg-¹ h-¹ (≈ 1.5 mg kg-¹ h-¹) from induction of anaesthesia to skin closure. No loading bolus, no post-operative infusion.
214974829|NCT07073846|DRUG|Intravenous Dexmedetomidine infusion + Standard Anesthesia|Continuous IV infusion of dexmedetomidine 1 µg mL-¹ at 0.3 mL kg-¹ h-¹ (≈ 0.3 µg kg-¹ h-¹) without loading dose, started after induction and stopped at skin closure. No post-operative infusion.
214974830|NCT07073846|DRUG|Lidocaine + Dexmedetomidine Combination (LIDEX) + Standard Anesthesia|Single syringe containing lidocaine 1 % (10 mg mL-¹) + dexmedetomidine 1 µg mL-¹, infused IV at 0.3 mL kg-¹ h-¹ (delivering ≈ 1.5 mg kg-¹ h-¹ lidocaine + 0.3 µg kg-¹ h-¹ dexmedetomidine) from induction to skin closure.
214974831|NCT07073846|DRUG|0.9 % Saline Placebo + Standard Anesthesia|Volume-matched IV infusion of 0.9 % normal saline at 0.3 mL kg-¹ h-¹ for the same duration and through the same delivery line as active arms; identical syringe appearance.
214974832|NCT07072104|BEHAVIORAL|Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 2|"* Behavioral testing: standardized neuropsychological battery (language, reading, attention, memory, intelligence)~* RFST: Reading-Free Screening Tool assessing pre-reading cognitive markers"
214974833|NCT07072104|DIAGNOSTIC_TEST|MRI - Grade 2|■ Diagnostic Imaging: structural and resting-state functional MRI (T1-weighted and rs-fMRI)
215084659|NCT04251052|PROCEDURE|Transvaginal Ultrasound|Undergo transvaginal ultrasound
215084660|NCT04251052|PROCEDURE|Ultrasound Imaging|Undergo pelvic ultrasound
214363992|NCT04329754|DEVICE|Cataract surgery|Cataract surgery with implantation of an intraocular lens (IOL)
214363993|NCT02892812|BIOLOGICAL|Pneumococcal conjugate vaccine|
214363994|NCT03594565|DRUG|Fluticasone Propionate|Local Fluticasone Propionate use prior to continuous glucose monitoring system insertion
214502775|NCT04025164|RADIATION|Hypofractionated Radiotherapy|daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
214502776|NCT04025164|RADIATION|Conventional fractionated Radiotherapy|daily fractions, 2 Gy per fraction, five fractions per week
214502777|NCT06994377|BEHAVIORAL|ED and quality of life assessment|Patients will undergo ED and quality of life assessments through specific questionnaires completion
214363995|NCT05886400|OTHER|SCAT6|The SCAT6 is a standardized assessment tool to diagnose a concussion. This tool will be used for the experiment utilizing the 6th edition to recreate the methods used in an athletic situation. The SCAT6 is broken down into multiple subtests to focus on specific aspects of a person's wellbeing that could be affected by a possible concussion. The assessments are created to measure an athlete's subjectively experienced symptoms, cognitive functioning and balance and postural stability (mBESS).
214363996|NCT05886400|OTHER|Visual/ Auditory Distraction|The purpose of this study is to examine the effect of environmental distractions on one's ability to complete the SCAT6. The environmental distractions will be visual and auditory by playing a sports event or sports clips during the completion of the assessment. The goal of this is to simulate the distraction of a sideline like a SCAT6 is typically used within athletic training.
214363997|NCT06580522|OTHER|Prone Position Group|After the children in the prone position group were weaned from noninvasive mechanical ventilation according and started to breathe spontaneously, they were prone positioned and monitored for 120 minutes (2 hours) every 20 minutes (0.min, 20.min, 40.min, 60.min, 80.min, 100.min, 120.min) with a head-monitor for peak heart rate, oxygen saturation, respiratory rate and blood pressure.
214363998|NCT06580522|OTHER|Supine Position Group|After the children in the supine position group were weaned from noninvasive mechanical ventilation according and started to breathe spontaneously, they were supine positioned and monitored for 120 minutes (2 hours) every 20 minutes (0.min, 20.min, 40.min, 60.min, 80.min, 100.min, 120.min) with a head-monitor for peak heart rate, oxygen saturation, respiratory rate and blood pressure.
214490341|NCT06808035|OTHER|Activity-Based Recovery Training|ABRT uses task-specific training to improve neuromuscular capacity. ABRT will be tailored to participant presentation. Activity-Based Locomotor Training consists of stepping, standing, and sitting activities on a body weight support (BWS) treadmill using a harness and while overground. Therapists and trainers provide hands-on assistance for safety and kinematics. BWS is varied during sessions with a goal of optimal kinematics at the lowest BWS. Activities performed standing will focus on alignment incorporating static, active, and dynamic tasks. Activities performed during overground are based on neuromuscular capacity and appropriate developmental and functional levels. Principles of ABRT will be shared with parents/caregivers to foster activity in the home and community. Activity-Based Upper Extremity Training uses task-specific training of the trunk and upper extremities administered in sitting or standing via manual facilitation or support in a stander for best posture.
214490342|NCT06808035|DEVICE|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation (scTs) is a non-invasive stimulation administered over the skin using a modulated biphasic or monophasic waveform at 15-90Hz and a carrier frequency of 5-10kHz. Bouts of scTs at the cervical, thoracic, lumbar, and/or coccygeal level will be administered midline or just lateral to the spinous processes during activity-based recovery training.
214490343|NCT06808594|DEVICE|APSI prosthesis implant|The adaptative proximal scaphoid implant (APSI) is a pyrocarbon partial scaphoid prosthesis, ovoid and unfixed, which replaces the proximal pole of the scaphoid and allows adaptative mobility in the movements of the first chain and restores the geometry of the carpus, thus preventing the evolution in SNAC (Scaphoid Non-union Advanced Collapse). Pyrocarbon has good compatibility with joint cartilage and bone, a modulus of elasticity similar to bone minimizing stress shielding effects and resorption. The implant is designed with two radii of curvature: in the frontal plane, the smaller radius of curvature corresponds to the scaphoid fossa, and the larger radius of curvature is directed anteroposteriorly to the transverse plane. When it's correctly positioned, the smallest radius of the curvature is visible in the anteroposterior view, whereas it's greater in the lateral view. These two axes of the implant make it adaptable to the kinematics of the wrist.
214363999|NCT06579456|OTHER|Surgical Training Intervention|Validation of a Formaldehyde-Free embalmed cadavers for recreate with more precision the experience of learning surgical endoscopy
214502778|NCT02409680|DRUG|Low dose aspirin|Daily administration of low dose (81 mg) aspirin \[also known as acetylsalicylic acid (ASA\], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
214502779|NCT02409680|DRUG|Placebo|Placebo
214974834|NCT07072104|BEHAVIORAL|Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 3|"* Behavioral testing: standardized neuropsychological battery (language, reading, attention, memory, intelligence)~* RFST: Reading-Free Screening Tool assessing pre-reading cognitive markers"
214974835|NCT07072130|OTHER|Control group (wet cotton)|The diaper area of the newborns in the control group was cleaned using only cottons moistened with boiled and warmed water. In the preparation stage, the cottons were placed in disposable containers and boiled and warmed water was poured over them to moisten the entire surface of the cottons. Excess water was removed by gently squeezing the cottons. After cleaning, the application was completed by drying the gland area with dry cotton.
214364000|NCT06579456|OTHER|Positive Control|training in models that emulate the rigidity, structure, dimensions, and haptic feedback of the anatomical structures to be treated.
214364001|NCT06579456|OTHER|Negative Control|Training proceeded in the rigid described skills acquisition platform, adding suture training using a perforable MMA-type woven fabric
214364002|NCT00716092|DRUG|Placebo (linagliptin)|once daily for 28 days
214364003|NCT00716092|DRUG|Placebo (linagliptin)|once daily for 28 days
214364004|NCT00716092|DRUG|Sitagliptin|100 mg once daily for 28 days
214364005|NCT00716092|DRUG|Placebo (sitagliptin)|once daily for 28 days
214364006|NCT00716092|DRUG|Placebo (sitagliptin)|once daily for 28 days
214364007|NCT00716092|DRUG|Linagliptin|5mg once daily for 28 days
214364008|NCT02270151|DEVICE|MyDiagnostick|Diagnostick strategy with MyDiagnostick
214364009|NCT01208948|DRUG|1,2 dithiolane 3 valeric acid|600 mg alpha lipoic acid per day
214364010|NCT03956472|PROCEDURE|Osteopathic protocol for improving drainage of LCS|Osteopathic intervention improving drainage of LCS and cerebral blood flow through opitmizing veinous circulation
214364011|NCT03956472|DEVICE|PEEP 10cmH2O|Breathing through a 10 cmH2O expiratory resistance for 10 min every 2 hours during 10h at 3842m high
214364012|NCT03956472|OTHER|Fake Osteopathic protocol|Placebo intervention
214364013|NCT03956472|OTHER|PEEP-Sham|PEEP 0 cmH2O (hidden)
214364014|NCT02713802|DRUG|Cudafol(R) (propofol, 1% [10 mg/mL])|Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
214364015|NCT02713802|DRUG|Diprivan(R) (propofol, 1% [10 mg/mL])|Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
214364016|NCT05025969|OTHER|Glioma data collection|Glioma data collection
214364017|NCT05025969|OTHER|Brain metastasis data collection|Brain metastasis data collection
214364018|NCT05741684|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy|iCBT was administered in an unguided fashion without human therapeutic support. Participants were instructed to progress through the eight core modules over an 8-week period. The modules comprised psychoeducational content centered around CBT, aimed at promoting the development of skills such as self-monitoring of emotions, cognitive distancing, cognitive reframing/restructuring, problem-solving, and mindfulness. In the event of technical difficulties during the intervention, participants were able to seek assistance.
214364019|NCT05741684|BEHAVIORAL|Attention Bias Modification|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 96 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
214364020|NCT02456766|DEVICE|FibroTouch|
214364021|NCT02456766|PROCEDURE|Liver Biopsy|
214364022|NCT03659448|DRUG|SGM-101|A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
214364023|NCT00325364|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months
214364024|NCT00325364|DRUG|Injectable insulin|patient specific dose, injectable, before meals, 24 months
214364025|NCT04557072|DRUG|Selective alpha-1-antagonist|Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
214364026|NCT04557072|DRUG|Non-selective alpha-1-antagonist|Patients treated with non-selective alpha-blockade (phenoxybenzamine)
214490344|NCT06653530|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed using polyglycolic acido thread. Needles have a gauge size of 23G, a shaft length of 60mm, and a thread length of 50mm, folded in half, and are applied to fourteen acupoints, including Zhongwan (CV12), Qihai (CV6), bilateral Tianshu (ST 25), bilateral Wailing (ST 26), bilateral Daheng (SP 15), bilateral Zusanli (ST 36), bilateral Pishu (BL 20), and bilateral Weishu (BL 21). After the thread is inserted into the body, the needle will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
214974836|NCT07072130|OTHER|Experimental group (baby oil-impregnated cotton)|Diaper area cleaning of newborns in the experimental group was performed only with cottons impregnated with baby oil. In the preparation of these cottons, a sufficient amount of baby oil was added to the cottons placed in disposable containers and the entire surface of the cottons was allowed to absorb the oil. Excess oil was removed by gently squeezing the cottons. After the cleaning process was completed, the diaper area was dried with dry cotton wool and the process was terminated.
214364027|NCT01144026|BIOLOGICAL|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
214364028|NCT01144026|BIOLOGICAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
214364029|NCT03129854|DEVICE|prostate cryotherapy|prostate cryotherapy added to experimental group within 6 months of ADT
214364030|NCT06370026|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
214364031|NCT03913598|OTHER|patient questionnaire|self-administered patient questionnaire regarding the different aspects of internet and social media use in dermatology patients
214364032|NCT00023153|DRUG|Adefovir Dipivoxil|
214502780|NCT02761616|OTHER|eBC treated participants|No intervention administered in this retrospective observational study.
214364033|NCT01063101|OTHER|Fucoidan (extract of Laminaria japonica)|Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
214364034|NCT01063101|OTHER|Placebo|Cellulose filled capsule - oral administration - 5 different dose levels - BID
214364035|NCT05727410|DRUG|nivolumab, docetaxel, cisplatin Group|Patients will be treated with nivolumab 360mg and plus docetaxel 60mg/m2 and cisplatin 60mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive radiation 59.4 Gy in 27 fractions. Boost RT of 6.6 Gy in 3 fractions to tumor bed and/or gross tumor will be optional in patients who had R1-R2 resection. If tumors are regarded inoperable after neoadjuvant therapy (due to high risk of post-operative complication, or metastatic disease), they will be off from this study and receive the appropriate treatment, though they will be also included in the efficacy and safety analyses.
214364036|NCT01875380|DRUG|Regorafenib|
214364037|NCT03388749|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
214364038|NCT00288483|DRUG|Policosanol|
214364039|NCT00781391|DRUG|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
215084661|NCT06320509|BIOLOGICAL|Continuous measurement of uPO2 (both groups)|uPO2 is collected continuously for the first 5 days of admission or until discharge from intensive care or removal of the urinary catheter.
215084662|NCT00628589|DRUG|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
214679654|NCT03117049|DRUG|Carboplatin|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
214490345|NCT06653530|OTHER|Sham thread embedding acupuncture|The protocol includes the same duration and frequency of sessions as for thread embedding acupuncture, but the treatment will be delivered superficially at non-acupuncture points 10mm from the lateral of the corresponding acupuncture and not above a meridian line. Needles without threads have a gauge size of 23G, and a shaft length of 60mm will be used. After the needle is inserted into the body, it will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
214974837|NCT07070219|DRUG|CTD402 CAR T Cell Injection|CAR T cells
215084663|NCT00628589|DRUG|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
215084664|NCT00628589|DRUG|Inhaled placebo|Inhaled placebo
215084665|NCT01066351|DRUG|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
215084666|NCT01066351|DRUG|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
215084667|NCT00031980|DRUG|cyclosporine|
215084668|NCT01151761|PROCEDURE|Stereotactic Body Radiotherapy|Standard of care
215084669|NCT01151761|DRUG|Gemcitabine|100 mg/m2, IV
215084670|NCT01151761|DRUG|Cisplatin|25 mg/m2, IV
215084671|NCT01151761|DRUG|Carboplatin|AUC 2, based on Calvert formula, IV
215084672|NCT01151761|DRUG|Capecitabine|1000 mg/m2, PO
215084673|NCT01151761|DRUG|5FU|200 mg/m2
215084674|NCT01151761|PROCEDURE|Liver transplantation|
215084675|NCT00524589|DIETARY_SUPPLEMENT|calcitriol|IV
214974838|NCT07072286|PROCEDURE|Regional Anesthesia|"* Supra-inguinal fascia iliaca block (SIFI)~* Lumbar erector spinae plane block (ESP)~* Transmuscular quadratus lumborum block (QLB) All blocks will be performed by experienced anesthesiologists under ultrasound guidance, using long-acting anesthetics (ropivacaine) at fixed concentrations and doses within weight-based safety limits."
214490346|NCT06817915|BEHAVIORAL|AI assisted assessment of SD-OCT scans|AI 2nd opinion report on nAMD treatment planning
214490347|NCT06816732|BEHAVIORAL|Nurse-led Modular Training|The intervention group participants filled out all the data collection tools in the first interview and three months later. They received modular training by phone 2 weeks, 4 weeks, 8 weeks, and 12 weeks after the first interview.The modular training addressed (1) defining hypertension, (2) systemic effects of hypertension, (3) general effects of antihypertension drugs, (4) regular medication and blood pressure monitoring, and (5) eating a healthy diet and being active (what to do for a better heart health and a more stable blood pressure)
214679655|NCT03117049|DRUG|Paclitaxel|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
214679656|NCT03117049|DRUG|Bevacizumab|Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
214679657|NCT03117049|DRUG|Placebo|Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
215084676|NCT00524589|DRUG|dexamethasone|Oral
215084677|NCT00524589|GENETIC|protein expression analysis|Correlative Study
215084678|NCT00524589|OTHER|laboratory biomarker analysis|Correlative Study
215084679|NCT01983605|DEVICE|LARIAT Suture Delivery Device|LAA exclusion procedure
215084680|NCT00115999|DRUG|alfimeprase|
215084681|NCT00902148|DEVICE|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
215084682|NCT02371200|DEVICE|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
215084683|NCT05320159|DRUG|Secukinumab|Included all the patients treated with secukinumab
215084684|NCT03037541|DRUG|Carac Cream|Carac Cream will be used once daily for seven consecutive days
215084685|NCT03037541|DRUG|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
215084686|NCT05746936|PROCEDURE|Roux en-Y gastric bypass|gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
215084687|NCT05740332|DRUG|Alcohol hand sanitizer foam|"1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)"
215084688|NCT06367088|DRUG|Cadonilimab|Patients were assigned to receive 10 mg/kg cadonilimab intravenously Q3W in combination with chemotherapy. The chemotherapy regimen is chosen by the physician.
215084689|NCT05875883|PROCEDURE|Neck ultrasound|The investigators will scan patients' necks with an ultrasound and look for anatomical landmarks to identify the phrenic nerve
215084690|NCT00272324|DRUG|Aspirin|
215084691|NCT00272324|DRUG|Folate|
215084692|NCT06979726|DRUG|Lasix ONYU|Providing subcutaneous furosemide to eligible patients
215084693|NCT06980922|DRUG|Guilu Erxian Jiao|A traditional Chinese herbal formula composed of Testudinis Carapax, Cervi Cornu, Lycii Fructus, and Ginseng Radix, manufactured by Sun Ten Pharmaceutical Co., Ltd. (License No. 016966). Administered orally at 4 grams per day before meals for 4 weeks.
215084694|NCT06981481|DEVICE|Breast tissue expander|Silimed brand breast tissue expander
215094454|NCT03898128|DRUG|Anti-CD22 Immunotoxin|Clinical data (treatment, survival, adverse events) of patients treated with anti-CD22 immunoconjugates from 2014 will be collected
215094455|NCT00444977|BEHAVIORAL|Case-management linkage intervention|dental care
215094456|NCT01468636|DRUG|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
215094457|NCT01468636|DRUG|Placebo|200mg BID x 8 weeks
214364040|NCT00781391|DRUG|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
214364041|NCT00781391|DRUG|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
214364042|NCT00781391|DRUG|placebo warfarin|placebo warfarin
214364043|NCT00781391|DRUG|placebo edoxaban|placebo edoxaban
214364044|NCT05817448|DIAGNOSTIC_TEST|HIF 1α and LC3B expression and MMP-9 level|"5ml of venous blood samples will be taken from all participants at 28-40 weeks of gestation for detcetion of MMP-9 level by Enzyme-Linked Immune Sorbent Assay (ELISA) kit.~Placental tissue sample in the maternal surface will be taken during CS in placenta previa group and similar location in maternal surface will be sampled after placental delivery in control group for histopathology and immunohistochemistry for detection of HIF 1α and LC3B expression"
214364045|NCT03390699|DIAGNOSTIC_TEST|Microbial profile|microbiological testing
214364046|NCT04032665|DIAGNOSTIC_TEST|Rivaroxaban|In stable CAD/PAD patients with previous PCI and DES-implantation treated with DAPT (ASA+clopidogrel) platelet rich plasma (PRP) and washed platelets as well as serum/plasma/urinary samples will be collected between 2 and 4 weeks before switching from DAPT to ASA + rivaroxaban (2,5 mg b.i.d.), between 2 and 4 weeks under monotherapy with ASA 100mg o.d., and between 2 and 4 weeks under therapy with ASA 100mg o.d. + rivaroxaban (2,5 mg b.i.d.) and treated ex vivo with rivaroxaban to asses platelet activation and function, platelet-triggered thrombin generation and platelet-dependent vascular inflammation.
214364047|NCT04745481|DEVICE|Trunk stabilization training device|"Conventional rehabilitation 30min daily, 20times 4weeks~+Trunk stabilization training device 30min daily, 20time 4weeks"
214364048|NCT04745481|DEVICE|Conventional rehabilitation|"Conventional rehabilitation 30min daily, 20times 4weeks~+Conventional rehabilitation 30min daily, 20times 4weeks"
214364049|NCT04535947|DRUG|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
214364050|NCT04535947|DRUG|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
214364051|NCT04309045|BEHAVIORAL|DBT|Today, the most well-known and established treatment for borderline personality disorder is Dialectical Behavior Therapy (DBT) that developed by Marsha Linhan in the 1990s. DBT is currently used in other disorders such as: eating disorders, addictions, impulse control problems and bipolar disorder. Various studies have found a beneficial effect for this treatment in various areas: decreased suicidal thoughts and attempts and self-harm behaviors, improvements in suicide attempts, anger levels, impulsive behaviors, depressive symptoms, The use of drugs, the percentage of dropouts from treatment, number Hospitalization and general function.
214364052|NCT04309045|BEHAVIORAL|DDP|DDP treatment is part of a trend of dynamic therapies to treat borderline personality disorder. The DDP focuses on deficiencies in the emotional experience processing and is performed in the form of weekly, individual sessions with a trained therapist over a 12-18 month period. Treatment is based on the need to correct three neurocognitive functions responsible for adaptive processing of emotional experiences: association (the ability to recognize, understand their existence, and experience a sequence of emotional experiences), attribution (the ability to make complex attributions about the self and others), and the ability to make realistic attribution, about the self and the other. Interventions that activate these three functions are the basis for DDP treatment.
214364053|NCT04309045|OTHER|control group|Patients on the waiting list for treatment, or patients in the hospital under routine care.
214364054|NCT06063798|OTHER|General anesthesia for laryngotracheal surgery|Patients undergoing general anesthesia and mechanical ventilation.
214364055|NCT06063798|OTHER|Mechanical ventilation by FCV|Mechanical ventilation is assured by Flow-controlled ventilation mode.
214364056|NCT06063798|OTHER|Mechanical ventilation by HFJV|Mechanical ventilation is assured by High frequency jet ventilation mode.
214364057|NCT03458455|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.
214490348|NCT06856148|BEHAVIORAL|Intervention: RPC Group|"The RPC model entails seven interrelated steps including a capacity building and collaboration phase. Throughout the implementation, researchers are provided direct access to intermediary support from our trained RPC fellows who facilitate RPC activity at each step coordinated by an implementation supervisor. Importantly, this model does not involve any lobbying. Consistent with NIH guidelines for grantees, the RPC instead aims to highlight and translate public health evidence…; conduct coalition building…; provide leadership and training, and foster safe and healthful environments. Specifically, implementation of the RPC model explicitly does not attempt to influence legislative actions, but instead facilitates honest brokerage in which researchers discuss evidence without indicating opinion or stance on how legislators should change specific policies, programs, or regulations."
214364058|NCT03458455|RADIATION|Stereotactic Radiosurgery|A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.
214364059|NCT03458455|DRUG|Ipilimumab, nivolumab or pembrolizumab|A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.
214364060|NCT03616184|DRUG|Ruxolitinib|Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.
214364061|NCT05241964|BIOLOGICAL|PRP|4\~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.
214364062|NCT06439355|BIOLOGICAL|Fasting blood test|metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays
214364063|NCT06439355|OTHER|Subject interview|socio-demographic data, medical and family history, treatment taken
214364064|NCT06439355|OTHER|Motor assessment|MDS-UPDRS scale PART III
214364065|NCT06439355|OTHER|Neurocognitive assessment|MoCA and MMSE scales
214364066|NCT06439355|OTHER|Nutritional assessment|anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skin fold, brachial circumference), bioelectrical impedancemetry (fat mass, lean mass, water mass and bone mass)
214490349|NCT06856148|BEHAVIORAL|Active Comparator: Control Group|"Control group participants will receive light touch research support, similar to previous work (e.g., an RPC associate will send publicly available research materials in response to research requests). This light touch control condition will increase responsiveness of state officials to survey follow up requests."
214490350|NCT06771882|OTHER|BMOS technique|"The researcher obtained 5cc soaked in a 2cm×2 cm piece of sterilized gauze for every intervention administration.~* The preterm neonates were positioned in the supine position and the head turned to one side~* The gauze was placed near the head, 2cm away from the nose for 2 minutes before feeding to stimulate an olfactory sense of preterm neonates 3 times per day (11 am, 2 pm, and 5 pm)."
214490351|NCT06586021|DEVICE|Aortoseal Endostapling System|Aortoseal Endostapling System
214490352|NCT04310644|OTHER|No intervention planned, but all patients get our standart treatment|Patients are selected from clinical Routine and get our standart Treatment based on their disease
214490353|NCT06857266|OTHER|Live Video-delivered Feedback|Feedback is delivered to students through a live video call.
214490354|NCT06857266|OTHER|In-Person Feedback|In-Person Feedback
214490355|NCT06857266|OTHER|Recorded Video-delivered feedback|Feedback is delivered via a personalized recorded video made by the instructor specific to the student's performance.
214490356|NCT03081403|DEVICE|Quantitative Sensory Testing|Study of detection thresholds of vibration, cold and pain related to the heat in the dominant hand of the subjects through the QST.
214490357|NCT06774976|OTHER|8-week Evidence-Based Neck Resistance Training Program|See arm/group description.
214490358|NCT06862336|PROCEDURE|intra-dialytic exercise program associated with medical treatment|"* Stretch for pectorals and calf muscles: Two sets - 3 times/ set.~* Breathing exercises associated with upper limb movement.~* Resistive exercise for hip abductors, hip flexors, and calf muscles by using theraband.~* Sit to stand strengthening exercises: -"
214490359|NCT06862336|PROCEDURE|inter-dialytic combined exercise program with their medications|receive the inter-dialytic combined exercise program with their medications. Like the study group except for diaphragmatic breathing instead of breathing with upper limb exercise.
214490360|NCT06771999|OTHER|Educational intervention by a clinical pharmacist|All participants will respond to two questionnaires, both validated in Romanian and some demographic information. One is the rPATD questionnaire that investigate attitudes towards deprescribing of medication and the other one is the HLS-EU-Q16 that investigates medical literacy of participants. After completion, the clinical pharmacist will give a brochure and a video about the process of deprescribing, information about the efficacy and the adverse reactions of medicines and the role of pacient in treatment decision. When participants come to another cancer treatment (after 14 , 21 or 28 days), the rPATD will be completed again.
214490361|NCT06861387|DEVICE|Cryotherapy|AtriCure's cryoICE cryoSPHERE probe will be inserted through one of the incisions used for VATS/RATS. Cryo-analgesia will be performed unilaterally on the intercostal nerve at the level Th3-Th7. Thus, cryo-analgesia will be applied on 5 intercostal levels. The probe will be placed at the inferior aspect of the ribs, posterior to the mid-axillary line, directly on the neurovascular bundle. One freezing cycle takes approximately 2 minutes and a temperature of between minus 50 and 70 degrees Celsius will be applied.
214364067|NCT06439355|OTHER|Taste tests|Recording of PEGs in response to a sucrose solution and a free fatty acid solution (prepared beforehand)
214364068|NCT05416957|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg administration under fasting condition
214364069|NCT04413630|OTHER|family workshop|The family workshop with 5 courses, with 6 families in one course The intervention of one course; 2 hours per session, one time per week, for a total of 6 weeks
214490362|NCT06861387|DRUG|PAiN - multimodal analgesia|Our standard postoperative pain management plan consists of intercostal nerve block, patient controlled analgesia and acetaminophen
214490363|NCT06863025|BEHAVIORAL|Neurofeedback training|Neurofeedback (NF) or electroencephalographic feedback (EEG) training refers to a type of computerized cognitive training that changes EEG patterns through operant conditioning. NF is a computerized rehabilitation technique but also a non-invasive neuromodulation approach, as it alters brain activity by delivering a stimulus. It is well-established for the treatment of conditions such as anxiety and ADHD. During NF rehabilitative training, the subject is provided with real-time EEG feedback, usually with a visual or auditory stimulus, with the aim of normalizing brain oscillations. Rehabilitation through NF training generally targets EEG frequencies that are affected and underlie the observed behavioral deficit (e.g., attentional dysfunctions).
214490364|NCT06863025|BEHAVIORAL|Standard cognitive therapy|This is the control intervention and it involves standard practice cognitive therapy in neurorehabilitation. Neuropsychologists and other clinicians test and train the patients' cognitive specific aspect (in this case, attention) with some validated tools and/or games
214490365|NCT06886763|OTHER|Liver innervation markers|Liver innervation markers will be quantified immediately after resection by transparisation technique.
214490366|NCT06884098|DRUG|AD-228B|AD-228B, 1Tab., Per Oral
214490367|NCT06884098|DRUG|AD-2284|AD-2284, 1Tab., Per Oral
214490368|NCT06887166|PROCEDURE|Platelet Rich Plasma|injection of PRP IN PERIANAL WOUNDS AFTER FISTULOTOMY OPERATIONS
214502781|NCT06211530|DEVICE|SpO2 Sensor Testing|Participants participating in this study will be connected sensors.The participants are exposed to a desaturation protocol. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
214502782|NCT07006532|DRUG|Tocilizumab|The trial is an open-labeled randomized clinical trial that evaluates the safety and efficacy of Tocilizumab as an add-on therapy to standard of care treatment of Plasmapheresis, IVIG, and Rituximab in treatment of CAMR in kidney transplant recipients.
214974839|NCT07072286|DRUG|Multimodal analgesia|All enrolled subjects will be treated according to the standard analgesic protocol for pelvic fractures, in accordance with available literature and institutional guidelines. Specifically, the protocols include the use of multimodal analgesia techniques in line with current clinical practice, including paracetamol, non-steroidal anti-inflammatory drugs, opioids.
214364070|NCT01185626|OTHER|SCP care|
214679658|NCT00042185|BEHAVIORAL|Dissonance Eating Disorder Prevention Program|In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.
214974840|NCT07073430|DEVICE|AI models with NBI|AI models for detecting intestinal adenoma in magnifying endoscopy with NBI.
214364071|NCT01429636|BEHAVIORAL|Modified Relaxation (MR)|The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
214364072|NCT01429636|BEHAVIORAL|Applied Relaxation (AR)|Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
214364073|NCT01535820|DRUG|Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
214364074|NCT01535820|DRUG|Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
214364075|NCT05079022|DRUG|Furmonertinib|Furmonertinib at 80mg dose will be administered orally once daily.
214364076|NCT05508230|OTHER|Hyaluronic Nasal Spray|Health care product - nasal application
214364077|NCT03802123|DRUG|⁸⁹Zr-Df-IAB22M2C|⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)
214364078|NCT01822587|DRUG|Propranolol, 40 mg|
214364079|NCT01822587|DRUG|Propranolol, 80 mg|
214364080|NCT01822587|DRUG|Placebo|
214364081|NCT04636658|OTHER|Incentive spirometer training|Incentive spirometer training 5 sessions a week, each session of 15 minutes, for 4 weeks
214364082|NCT04636658|OTHER|diaphragmatic resistance exercises|"Incentive spirometer with diaphragmatic resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient.~Digital spirometer training for 15 minutes. diaphragm breathing exercises with resistance for 30 minutes. 5 sessions a week, for 4 weeks"
214364083|NCT04225533|DRUG|SP16|All patients will receive a single dose of SP16
214364084|NCT04195308|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
214364085|NCT04195308|DEVICE|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214364086|NCT04195308|DEVICE|Open label TBS-DLPFC|"Patients will have the option of receiving active, open label aTBS treatment following sham.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
214364087|NCT04052464|OTHER|endometrium biopsy|All patients will have endometrium biopsy.
214364088|NCT04052464|OTHER|endometrium lavage|In some selected cases biopsy is preceded by endometrium lavage.
214364089|NCT04052464|OTHER|repeated endometrium lavage|Endometrium lavage is repeated during the same cycle.
214364090|NCT01290406|DRUG|BEZ235|
214364091|NCT05263466|DIAGNOSTIC_TEST|PET-MRI|For the diagnostic imaging aspect included in this pilot study, \[68Ga\]PSMA-11 will be used. This is a peptidomimetic agent with a covalently bound chelator (HBED-CC) that is FDA-approved in prostate cancer imaging. We will use PET-MRI to visualise a) the concentration and b) the distribution of this tracer to establish a functional map of primary brain tumour activity
214502783|NCT07007247|OTHER|Mind-WIN self-help only|The program lets participants work through the module content at their own speed. Part of the program involves keeping an online diary every two weeks to track symptoms. The results are categorized as mild, moderate, or severe depression. If participants have severe symptoms, the recommendation is to get professional help. If participants are taking medication to improve their depression, they can also use the online diary to track their mood and medication
214679659|NCT00042185|BEHAVIORAL|Healthy Weight Intervention|In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.
214679660|NCT00042185|BEHAVIORAL|Expressive Writing Control Condition|In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
214679661|NCT03215888|PROCEDURE|bariatric surgery|Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
214974841|NCT07072260|OTHER|Sham Stroking|Participants in this group receive a sham intervention consisting of light soft tissue stroking around the talocrural joint without joint manipulation. The application mimics the duration and setup of the experimental group but does not include any mechanical stimulus.
214364092|NCT05263466|PROCEDURE|Brain tumour biopsy|All patients included in our study will undergo stereotactic surgery for biopsy/resection of the tumour as part of the standard of care at KCH. During this study we will not vary from the surgical standard of care for primary brain tumours and will only extend the surgery time due to additional stereotactic biopsies (an additional 3 biopsies increasing the time of the operation by \~30 minutes). Professor Ashkan (KCH) has defined the additional surgical risk of performing these biopsies to be \~0%, since targeted biopsies will only be taken within the tumour just before resection. The stereotactic biopsy may be targeted to areas of high \[68Ga\]PSMA SUV within the tumour as defined by the PET MRI scan.
214364093|NCT04899050|DRUG|Cannabidiol (Epidiolex)|Use of Epidiolex to control absence seizures.
214490369|NCT06883877|OTHER|Multi-Modal Program (MMP)|MMP includes three modules: addressing psychological problems such as FCR; addressing problems related to breast cancer symptoms; and addressing tangible problems such as social support. Each module is divided into the chemotherapy period (hospitalization) and the chemotherapy interval (post-discharge). Each phase involves face-to-face, digital, and remote tools, with the intervention lasting 8 weeks. Each module has a different goal, and depending on the goal setting, the topic of the intervention is different. The goal of the information education stage is to improve patients' overall understanding of the disease and pay attention to the psychological problems of FCR. The goal of coping skills is that through the practice of coping skills, patients can learn to change thoughts, problem emotions, and behaviors. The objective of social support group interaction is to strengthen their social support networks.
214490370|NCT06883877|OTHER|Routine care|The control group will receive routine care.
214490371|NCT06744608|OTHER|Structured Myofascial Release|haftada 2 seans 8 hafta boyunca toplam 16 seans uygulama yapıldı
214490372|NCT06744608|DEVICE|tens (transcutaneous electrical nerve stimulation)|A total of 16 sessions of application were applied to the groups, 2 sessions per week for 8 weeks.
214490373|NCT06744608|BEHAVIORAL|lifestyle changes|A presentation including lifestyle changes was prepared and training was provided.
214490374|NCT06744530|PROCEDURE|stereotactic radiotherapy ablation|Single dose of 25 Gy up to 32.5 Gy on the myocardium in patients with therapy-refractory ventricular tachycardia
214490375|NCT06740552|DRUG|Evolocumab|Evolocumab 140mg every two weeks
214490376|NCT06740552|DRUG|Lipid Lowering Medication|Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.
214490377|NCT06737497|PROCEDURE|retrograde Intrarenal Surgery ( RIRS ) under local anesthesia|retrograde Intrarenal Surgery ( RIRS ) under local anesthesia
214974842|NCT07072260|OTHER|Activator Manipulation|Participants in this group receive a single session of activator-assisted manipulation using the Activator Adjustment Instrument (AAI) to the talocrural (ankle) joint. Six impulses (three anterior and three posterior) are applied with the ankle in a neutral position.
214974843|NCT07072273|OTHER|Probiotic Ointment|Ointment containing Lactobacillus reuteri BGR46
214974844|NCT07072156|OTHER|Stress ball|"First Interview: Consent is obtained; group allocation is done.~Pre-test: Patient information form, DT, STAI, and vital signs are assessed.~Intervention: Stress ball use for 15-20 minutes during chemotherapy.~Post-test: Same measurements are repeated."
214364094|NCT00047775|DRUG|BiDil|
214364095|NCT05011474|BIOLOGICAL|administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3|Adipose-derived mesenchymal stem cells isolated from subject's adipose tissue are pretreated with matrillin 3 and produced in spheroid form.
214364096|NCT04890535|DRUG|TBAJ-587|oral suspension
214490378|NCT06891989|OTHER|Mindfulness meditation (MM) Intervention|"Participants will be asked to download the Mindfulness Coach app that provides simple instructions and brief meditation exercises.This is a a gradual training program of 14 levels which will be completed in the first 2-3 weeks. Each level provides short readings about mindfulness and one or two guided meditations (a silent seated practice for increasing lengths of time plus typically an additional 8-13-minute meditation). As participants progress through the levels, they earn badges displayed in the app, and an image of a tree on the home screen grows as each successive level is completed.For the remaining weeks of the intervention, participants will select at least one (and ideally two) guided meditation per day from the complete list of available meditations.Participants will track their progress through weekly logs."
214490379|NCT06891989|OTHER|Health Education Active Control Intervention|Participants will be asked to download and use the free TED Talk app, which will have 50 TED talk videos related to health that range from 3-20 minutes. Participants will be asked to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week and complete weekly logs of the TED Talk app use.
214974845|NCT07072520|BEHAVIORAL|Questionnaire|Questionnaire including sociodemographic characteristics and dietary assessment
214974846|NCT07072520|OTHER|Body composition assessment|Body Composition Assessment via bioelectrical impedance analysis (BIA)
214974847|NCT07073651|OTHER|Moderate Intensity Aerobic Exercise|moderate intensity aerobic exercises (using treadmill training) 5 times per week for 12 weeks. Each participating child started the session with 5 minutes of warming-up exercises. Then the main exercise phase is performed at 50-60% of age-predicted peak heart rate using a treadmill for 30 minutes. Finally, a 5 min cool-down period is allowed, the total session took 40 minutes.
214974848|NCT07073651|OTHER|Dietary Advices|The Obese adolescent children participated in the study received diet advices based on a balanced low calorie diet (1500 Kcal)
214974849|NCT07073651|OTHER|Virtual reality games exercise|Virtual reality games exercises 5 times per week for 12 weeks. Each participating child started the session with 5 minutes warming up exercises then followed by the main part which was consisted of 30 min of exercise where the child played the game using virtual reality X-Box and did different physical activities that included both the upper and lower extremities according to the game's requirements, and after that a 5 min cool-down part that involved some static flexibility exercises to allow the heart rate to lower, the total session that would be applied about 40 min (including 30 mins of Virtual reality exercises)
215084695|NCT06981026|OTHER|Telemedicine-based prehabilitation and postoperative rehabilitation protocol, including physical activity monitoring, respiratory and postural training, and guidance via telehealth tools.|A combination of wearable technology, activity guidelines, educational support, remote monitoring with notifications and consultations with physiotherapists.
215094458|NCT01492413|BEHAVIORAL|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
215084696|NCT06985381|OTHER|Carotenoid-rich juice|The intervention is based on the additional consumption of 200 ml natural carotneoid-rich juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
214490380|NCT06888141|BEHAVIORAL|Virtual Sequential Emotional Processing Task|A 20-minute interactive session delivered 3 times over a one week period.
214490381|NCT06888141|BEHAVIORAL|Virtual Control Task|A time-matched (ie., 20 minute) interactive session delivered 3 times over a one week period.
214490382|NCT06747429|OTHER|High fat diet|Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 70% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and the remaining calories from carbohydrates (10-20%).
214679662|NCT00839098|OTHER|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
215084697|NCT06985381|OTHER|Control|Participants assigned to the control group are asked to drink additional 200ml of water a day to control liquid intake.
215084698|NCT00371969|BEHAVIORAL|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
215084699|NCT00371969|BEHAVIORAL|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
215084700|NCT06979817|OTHER|TLS-Informed Machine Learning Prognostic Model|This intervention involves the development and application of a machine learning-based prognostic model that integrates features derived from tertiary lymphoid structures (TLSs) identified in tumor pathology slides, along with clinical and immunological data, to predict overall survival and immune landscape in patients with locally advanced gastric cancer. The model utilizes digital pathology, image analysis, and advanced computational algorithms to quantify TLS-related characteristics and correlate them with patient outcomes. It is designed to stratify patients into risk groups and provide insight into the tumor immune microenvironment, aiming to support personalized treatment planning.
215084701|NCT06984692|OTHER|iRise curriculum|"Intervention group: The intervention group would download the iRise mHealth app (iRise app) via Canvas on the participant's respective smart phones, and based on the participant's own schedules and preferences, would complete different modules of iRise. The iRise app would include emergency management elements as received by the control group, but presented via smart phone-based content delivery (i.e., rather than rather than via the in-person modality utilized for the control group)."
215084702|NCT06984692|OTHER|Control Curriculum|The control group will receive standard training in crisis response and management, which is offered as a course on Emergency Management and Response at AKU, for which study participants from JPMC will also readily access. The course involves introduction to disaster terminology, emergency management cycle and hospital-based patient treatment guidelines. The control curriculum will offer a comprehensive focus on disaster preparedness, addressing important subjects such as emergency management techniques, disasters, and triage. The eight-hour training will be split into two parts, aiming to improve academic and practical understanding. The first part will be a didactic session, where participants will learn fundamental information through lectures and discussions. The second part will consist of hands-on training, allowing attendees to practice and apply learned concepts in simulated emergency scenarios.
215084703|NCT06604845|BEHAVIORAL|Group cognitive behavioural therapy (CBT)|"CBT based on Safren's manual CBT for ADHD/Mastering Your Adult ADHD20 adapted for group format. The program includes psychoeducation and cognitive restructuring and aims to improve ADHD symptoms, especially planning, organisation, attention and adaptive thinking. The CBT groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two clinicians."
214364097|NCT04890535|DRUG|Placebo|matching placebo oral suspension for TBAJ-587
214364098|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, for six weeks
214364099|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|20 mg, tablet, once daily by mouth, for six weeks
214364100|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|Placebo, tablet, once daily by mouth, for six weeks
214364101|NCT02732379|PROCEDURE|Lavender Aromatherapy|the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
214364102|NCT02732379|PROCEDURE|Rose Aromatherapy|the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
214364103|NCT02732379|PROCEDURE|Ginger Aromatherapy|the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
214364104|NCT02732379|PROCEDURE|Placebo Aromatherapy|the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
214490383|NCT06747429|OTHER|Standard diet|Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 30% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and 50-60% from carbohydrates.
214490384|NCT04121676|DRUG|AGEN2373|An Anti-CD137 Monoclonal Antibody
214490385|NCT04121676|DRUG|Botensilimab|Anti-CTLA-4 Monoclonal Antibody
214490386|NCT06732531|DRUG|BH011|BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour. It was administered once a week for 6 weeks during the induction treatment period and once a month for 12 months during the maintenance treatment period.
214490387|NCT06892054|DRUG|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|A minimum of 6 and a maximum of 15 patients will be enrolled to receive first-line chemotherapy (gem/nab-P or mFOLFIRINOX) in combination with sotorasib 960 mg daily (QD). The treatment with gem/nab-P and mFOLFIRINOX should be managed as per clinical practice.
214364105|NCT04031482|OTHER|No intervention, only standard care|"The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to~* analyse disease progression~* systematize findings about treatment processes~* identify potential influencing factors~* review any new diagnostic procedures~* identify potential test subjects for further study~* evaluate the safety of various treatment concepts"
214490388|NCT06746220|OTHER|Microbiota sample|Microbiota sample: one sample at inclusion and one sample at the end of the study
214490389|NCT06746220|OTHER|Salivary sample|Salivary sample: one sample at inclusion and one sample at the end of the study. In the morning, on an empty stomach.
214490390|NCT06746220|OTHER|Quality of life questionnaires|Quality of life questionnaires: 5 auto-questionnaires to be filled at inclusion and at the end of the study
214490391|NCT06746220|OTHER|Nutritional evaluation|Nutritional evaluation: food diary completed by participants for 3 consecutive days at inclusion and at the end of the study
214490392|NCT06746220|OTHER|Assessment of physical health|Assessment of physical health : 3 tests to assess strength and endurance. These tests will be performed at inclusion and at the end of the study.
214490393|NCT06746220|OTHER|Physical activity|Physical activity: 2 sessions per week for 6 weeks. For each session, 45 minutes of physical activity consisting of muscle strengthening and endurance exercises.
214490394|NCT06746220|OTHER|Treatment with placebo or probiotic|Treatment with placebo or probiotic: 1 capsule per day during 42 consecutive days. In the morning, on an empty stomach with a large glass of water 20 minutes before the meal
214490395|NCT06749470|DRUG|Jieyu Chufan Capsules|4 capsules, tid; 8 weeks
214490396|NCT06749470|DRUG|Jieyu Chufan Capsules simulant|4 capsules, tid; 8 weeks
214490397|NCT06750406|OTHER|mind body exercises|intervention might consist of a structured program of mind-body exercises designed specifically for pregnant women. This could involve a combination of yoga sessions, mindfulness meditation practices, deep breathing exercises, and progressive muscle relaxation techniques. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for 8 weeks
214974850|NCT07072754|OTHER|Mind-body therapy|The yoga program, led by a physiotherapist who is also a certified yoga instructor , with two sessions per week lasting one hour each. Foam yoga blocks, belts, and armless chairs were also available in the classes, where the participants were to support compliance with the program. The yoga program was planned as 10 minutes of centering and breathing practice, 10 minutes of warm-up practice, 30 minutes of supine, standing, sitting, prone, and supine yoga postures, and 10 minutes of relaxation. New postures were introduced every two weeks as the program progressed. After the eight-week session, the participants were encouraged to continue the program at home twice a week
214974851|NCT07072754|OTHER|Exercise|Patients in the exercise group were given a program that included warm-up, low-impact aerobic, strengthening, and cooling phases, totaling 60 minutes, repeated twice a week for eight weeks. Aerobic exercise was performed by standing still for 25 minutes at moderate intensity based on perceived effort. Strengthening exercises included one set of 10 repetitions for each movement. Exercises were progressed according to the modified Borg's scale. Strengthening exercises included core muscles such as the deltoid, abdominals, quadriceps femoris, and hamstrings and were performed using body weight or elastic resistance bands
214490398|NCT06750406|OTHER|relaxation exercises|It involves relaxation exercises including deep breathing, relaxing postures etc. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for 8 weeks
214490399|NCT06756087|RADIATION|Radiofrequency Ablation (RFA)/Vertebroplasty+Stereotactic Radiotherapy|"All patients received OsteoCool™ radiofrequency ablation + vertebroplasty for spinal metastatic tumors at the Department of Bone Oncology, Shanghai First People's Hospital.~Standard Control Group: Patients received SBRT (Stereotactic Body Radiation Therapy) from the Department of Radiation Oncology 2-3 weeks post-surgery. This included pre-radiation positioning, mold preparation, and radiation therapy. After radiation therapy, patients rested for 2 weeks before resuming their original anti-tumor treatment and starting follow-up.SBRT therapy was administered according to the recommendations, using one of the following dose and fractionation schemes: 4 sessions of 24 Gy, 5 sessions of 30 Gy, 6 sessions of 36 Gy, or 7 sessions of 42 Gy."
214490400|NCT06756087|PROCEDURE|Experimental|patients received OsteoCool™ radiofrequency ablation+vertebroplasty for spinal metastatic tumors at the Department of Bone Oncology, Shanghai First People's Hospital. patients continued their original anti-tumor treatment within 1-2 weeks based on their recovery. No further local intervention was performed at the surgical site, and normal follow-up was started.
214974852|NCT07073729|PROCEDURE|Corneal Neurotization|Surgical technique involving the transfer of healthy donor sensory nerves to the anesthetic cornea to restore corneal innervation and sensation in patients with neurotrophic keratitis.
214974853|NCT07073729|DRUG|Cenergermin|Topical recombinant human nerve growth factor (rhNGF) approved for the treatment of neurotrophic keratitis. Administered as eye drops, it promotes epithelial healing and nerve regeneration.
214974854|NCT07072377|BEHAVIORAL|Intensity of Nutritional Intervention|Participants will either receive High or Low intensity nutritional support.
214974855|NCT07072377|BEHAVIORAL|Remote or In-Person|Patients will either receive their support in-person or remotely.
214974856|NCT07073898|OTHER|Repeated Text Messages (TM+)|The text message notifies patients that they may be eligible for LCS and provides the patient with a connection to an registered nurse (RN) for LCS eligibility assessment and Shared Decision-Making (SDM) discussion. Response options include YES (to request that the HUB RN call the patient) or STOP (to opt out of any further messages).
214974857|NCT07073898|OTHER|Conversational Agent (CA)|The CA is designed to address specific hesitancy factors and barriers to Lung Cancer Screening (LCS). The CA uses a rule-based approach. CAs use a predefined conversation script with a fixed set of possible questions and responses to educate patients regarding the importance of LCS and engage them to be connected with RN for eligibility assessment and SDM.
214364106|NCT01497522|DRUG|Vildagliptin|vildagliptin 50 mg twice daily
214364107|NCT01497522|DRUG|Placebo|Matching Placebo of vildagliptin 50 mg twice daily
214364108|NCT04920357|DRUG|Vaccination|Persons that are vaccinated within the national and regional vaccine program are invited to participate in the follow-up study.
214364109|NCT03638206|BIOLOGICAL|CAR-T cell immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
214364110|NCT03945838|OTHER|Complete Decongestion Therapy|"It is given in two phases. First phase includes intensive therapy which aims to reduce the volume of the extremity. Second phase aims to preserve these reductions of volume.~All patients were prescribed lymphedema specific exercises and were advised to walk (for 30 minutes everyday) daywhile taking complete decongestive therapy. They were specifically informed that exercise does not aggravate the severity of their lymphedema.~Short stretch bandages were applied to the patients with self manual lymphatic drainage. Intensive phase was given 5 days a week, and short stretch bandages applied for 23 hours a day with 1 hour interval. To increase the local pressure on the areas required, foams were added. Patients were screened with arm circumferential measurements once a week. After gaining a plateau in the volumes, patients were prescribed compression garments."
214364111|NCT02456402|DEVICE|Drug Coated Balloon|If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
214364112|NCT02456402|DEVICE|Bare Metal Stent|BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.
214490401|NCT06751199|DRUG|human umbilical cord mesenchymal stem cells|Portal vein infusion human umbilical cord mesenchymal stem cells
214490402|NCT06751199|DRUG|allogeneic islet|Portal vein infusion of allogeneic islet
214490403|NCT06755502|COMBINATION_PRODUCT|Garlic oil|garlic oil mixed with zinc oxid powder, as root canal filling material
214490404|NCT06755502|DRUG|Calcium Hydroxide, Iodoform, paste|Metapex as root canal filling materials
214490405|NCT06760676|RADIATION|Pulsed low dose rate radiotherapy (PLDR)|Radiation 5 times per week, 2Gy each time which divided into 10 pulse doses, each pulse interval was 3 minutes, the dose rate was 0.067 Gy/min, and each treatment time was 30 minutes.
214490406|NCT06760676|DRUG|Alpaloritovorelli antibodies|PLDR external irradiation therapy was administered simultaneously with 5mg/kg Alpaloritovorelli antibodies for a 3-week regimen, the following maintenance treatment was 2 years.
214490407|NCT06761703|DEVICE|TAP® Micro Select Device (Touch Activated Phlebotomy)|The TAP Micro Select device will be used in an investigational capacity by participants for self-collection of whole capillary blood.
214490408|NCT06761443|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).
214974858|NCT07073898|OTHER|Educational Video|The educational video provides patients with information and answers commonly asked questions about LCS.
214974859|NCT07073898|OTHER|Proactive Patient Navigation (PPN)|Proactive patient navigation enables trained navigators to actively identify and reach out to patients who may need assistance completing LCS, rather than waiting for patients to seek help on their own.
214490409|NCT06761443|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).
214490410|NCT06784050|PROCEDURE|Bilateral Balanced Occlusion|Dentures designed under this scheme feature a fully bilateral balanced articulation, ensuring bilateral, simultaneous contact of the anterior and posterior denture teeth in both centric and eccentric positions. This occlusal scheme is aimed at promoting stability and functionality of the dentures during various mandibular movements.
214490411|NCT06784050|PROCEDURE|Monoplane Occlusion|This scheme utilizes zero-degree teeth to create a flat occlusal plane, which is designed to simplify the occlusal contacts and minimize the transmission of lateral forces during mastication. The aim is to improve masticatory efficiency by reducing the complexity of tooth contact
214490412|NCT05147636|PROCEDURE|Extubation with PEEP|No aspiration within the 3 minutes before extubation and extubation with 10cmH2O PEEP
214490413|NCT05147636|PROCEDURE|Endotracheal Aspiration|Aspiration during cuff deflation
214490414|NCT04056910|DRUG|ivosidenib and nivolumab|Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events. Nivolumab will be administered at 480 mg IV every 28 days.
214490415|NCT05029414|PROCEDURE|Endovascular Therapy|Endovascular treatment of stroke is the non-surgical treatment for the sudden loss of brain function due to blood clots. The blood clot is removed from the blood via devices (i.e. stent-retriever, aspiration catheters and balloon guide) to achieve revascularization.
214490416|NCT04505722|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered at a single dose of 5\*10\^10 virus particles (vp) on Day 1 (or Month 6 for placebo recipients) and as a single booster dose at Year 1.
214490417|NCT04505722|OTHER|Placebo|Participants will receive Placebo.
214974860|NCT07073898|OTHER|Reactive Patient Navigation (RPN)|Reactive patient navigation makes trained navigators available to those who seek assistance in completing LCS.
214974861|NCT07072247|GENETIC|CD19 and BCMA-targeted allogeneic CAR-T cells|Lymphodepletion chemotherapy followed by CD19 and BCMA-targeted allogeneic CAR-T cells infusion
214974862|NCT07073053|DRUG|Semaglutide 1.0 mg|add-on current standard treatment which includes SGLT2 inhibitor
214974863|NCT07073053|DRUG|Semaglutide 0.5 mg|add-on current standard treatment which includes SGLT2 inhibitor
214974864|NCT07073105|DIAGNOSTIC_TEST|tracheal ultrasound ( expert radiologist)|tracheal ultrasound, performed by expert radiologist, for preterm neonates for confirmation of ETT site
215084704|NCT06604845|OTHER|Activity group|The Activity group is a structured manualised group intervention designed for this and planned future studies of psychosocial treatments for adults with ADHD and/or autism. The program includes group discussions, peer-sharing and social every-day life activities. The Activity groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two trainers.
215084705|NCT06606067|DRUG|Duloxetine|30 mg daily 2 weeks before surgery and 1 week after surgery
215084706|NCT06606067|DRUG|Placebo|Placebo tablet daily
215084707|NCT06606431|BEHAVIORAL|Multileveled-community approach|One-to-one delivered interaction at relational level (Interpersonal Relations, Volunteers) Socio-health interaction at personalized level (Social Work) Group delivered interaction for volunteers (Group Dynamics) Community-level interactions (Social Cohesion, Community Networks)
214974865|NCT07073105|DIAGNOSTIC_TEST|tracheal ultrasound by trainee neonatologist|tracheal ultrasound, performed by trainee neonatologist ( after receiving training for the procedure) , for preterm neonates for confirmation of ETT site
214974866|NCT07073105|DIAGNOSTIC_TEST|Chest x-ray|chest xray done for confirmation of ETT site
214974867|NCT06899776|DEVICE|Abbott i-STAT point of care (POC) device|During the study period all ED patients with chest pain will have an extra lithium heparin blood sample obtained for each troponin test ordered and collected in the ED (typically 2, but this may range from 1-3 troponin measures), which will be used for immediate hs-cTnI measurement by research personnel using an Abbott i-STAT POC device.
214974868|NCT06148792|DRUG|Tafenoquine|oral treatment
214974869|NCT06148792|DRUG|Primaquine|oral treatment
214974870|NCT07073859|OTHER|Fluid expansion|Data will be collected retrospectively, after fluid expansion administration, by the prescribing physician through. These data will be collected from standard monitoring and/or from the patient's medical record. Data will therefore only be collected at a single point in time.
214974871|NCT07073040|DEVICE|Cold atmospheric plasma (CAP)|"CAP therapy will be administered once daily for the first five days and then every other day thereafter, for a total of 13 sessions. Each session will last approximately 25 minutes, as recommended by the manufacturer. During treatment, the affected limb will be enclosed in a sterile treatment bag, sealed with medical adhesive tape. The CAP device will operate in two sequential modes: a disinfection mode delivering ozone-rich (O₃) plasma-activated gas for 20 minutes, followed by a healing mode delivering nitric oxide (NO)-rich plasma-activated gas for 5 minutes. All procedures will be performed in accordance with the manufacturer's instructions and the device's standard operating protocol."
214364113|NCT01325285|DEVICE|RespirAct|"Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each:~1. Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)~2. 10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)~3. 20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)~4. Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)~5. 250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)~6. 500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)~7. Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)"
214364114|NCT02681614|DEVICE|Uronav guided biopsy|"All biopsies will be completed in the outpatient setting in the ambulatory operating room prior to routine prostate brachytherapy under general anesthesia.~Patients will be prepped in a dorsal lithotomy position with insertion of a Foley catheter. The perineum will be shaved as needed, and cleansed with antiseptic solution, and the scrotum will be elevated with a towel roll to expose the perineum."
214364115|NCT02681614|DEVICE|Magnetic resonance imaging|An MRI (magnetic resonance imaging) is a scan that uses radio waves and a strong magnetic field to provide images of internal organs and tissues. This is not part of the study but will have been done per standard treatment. An MRI will occur at the screening visit and last visit of the study.
214364116|NCT00420992|DRUG|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|capsules, up to 80 mg bid
214364117|NCT00420992|DRUG|Placebo|capsules, bid
214364118|NCT04390984|DRUG|Apatinib Mesylate, Gefitinib|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
214364119|NCT02003352|PROCEDURE|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
214364120|NCT03234153|DRUG|Durvalumab (Imfinzi)|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
214364121|NCT03234153|DRUG|Tremelimumab|Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
214364122|NCT04886479|OTHER|Control|No lens
214364123|NCT04886479|DEVICE|Test Lens|Low Dk HEMA contact lens worn for 3 hours
214364124|NCT00825422|DRUG|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
214364125|NCT01855217|DRUG|Sugammadex|1 mg/kg total BW based sugammadex reversal of deep block
214364126|NCT01855217|DRUG|Sugammadex|1 mg/kg ideal BW based sugammadex reversal of deep block
214364127|NCT01855217|DRUG|Placebo|0,9% NaCl
214364128|NCT03994458|BEHAVIORAL|Smartphone Full version application|Android smartphone experimental application include: rehabilitative self-administered evidence-based exercises (Strengthening and stretching), ergonomics, and education related to low back pain. The application includes videos, photos, text, and reminders.
214364129|NCT03994458|BEHAVIORAL|Samartphone limited version application|Android smartphone placebo application include: ineffective content that does not help in treating low back pain. The application includes only five posts in the general instruction and advises section about proper nutrition and few irrelevant reminders.
214364130|NCT03249610|BEHAVIORAL|Lifestyle intervention|Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors
214364131|NCT03105284|PROCEDURE|Liposuction|Fat harvest by liposuction (Colemans method)
214364132|NCT04834791|DRUG|Letrozole 2.5mg|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles
214974872|NCT07073040|DEVICE|Sham Procedure|Participants in the placebo group will undergo a sham procedure, in which the electric field required for plasma generation will be disabled, so that no plasma will be produced. Only the operating sounds of the device will be simulated, ensuring blinding for both participants and clinical staff.
214974873|NCT07073040|OTHER|Successful infrapopliteal angioplasty|All patients will undergo successful infrapopliteal angioplasty, with less than 30% residual stenosis confirmed by digital subtraction angiography.
214364133|NCT04834791|DRUG|Gonadotropin|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
214364134|NCT02756754|DEVICE|Radiofrequency ablation|The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.
214490418|NCT06784128|OTHER|Therapeutic Exercise Program|All patients were administered a therapeutic exercise program that included passive, active-assisted, and active range of motion exercises, stretching, strengthening, and mobilization exercises based on their level of movement restriction and pain intensity for 5 sessions per week for 2 weeks under the supervision of an experienced physiotherapist.
214490419|NCT06784128|OTHER|Hot Pack|As part of the treatment protocol, a hot pack was applied to the affected shoulder area for 30 minutes prior to any other therapeutic interventions. This initial application of heat was intended to promote muscle relaxation, increase local blood circulation, and reduce joint stiffness, effectively preparing the shoulder for the subsequent treatments, including therapeutic exercise, TENS and TECAR therapy. The hot pack was maintained at a temperature between 40-45°C, which is considered optimal for achieving therapeutic heat without causing discomfort or skin irritation.
214490420|NCT06784128|DEVICE|TECAR Therapy|TECAR therapy was administered using the BTL-6000 TR-Therapy PRO device which emitted energy at a frequency of approximately 500 kHz and used three types of electrodes: active, neutral, and static application electrodes. Each patient was seated in a comfortable position with the affected shoulder exposed, ensuring adequate support and stability throughout the treatment session. The affected shoulder was prepared with a conductive gel to enhance energy transfer. During the session, the capacitive electrode was initially applied, targeting the superficial muscles and tendons around the shoulder joint using circular or linear movements for 5 min. Following this, the resistive electrode was employed to target deeper structures, focusing on the joint capsule and rotator cuff muscles for 10 min. The output power was adjusted based on the patient's tolerance, ensuring a comfortable warm sensation without causing discomfort or burning feeling or pain.
214490421|NCT06784128|DEVICE|TENS|TENS was employed as a non-invasive pain management technique in this study, utilizing the Intellect Advanced device manufactured by Chattanooga Group. Electrodes were strategically placed over the affected shoulder, ensuring coverage of the most painful areas as well as relevant nerve pathways to maximize the analgesic effect. A symmetric biphasic waveform was selected, with a frequency of 100 Hz and a pulse duration of 100 microseconds. The intensity of the stimulation was adjusted according to the patient's tolerance, typically aiming for a strong, yet comfortable tingling sensation.
214974874|NCT07073599|OTHER|Creative Drama Education|"This study is a pre-test/post-test controlled experimental design aimed at evaluating the effectiveness of creative drama education on awareness of breast and gynecological cancers.~Students in the intervention group will receive creative drama-based training structured and implemented by the researcher. This training is designed to increase awareness of breast and gynecological cancers.~The effectiveness of the training will be assessed by comparing participants' awareness levels before and after the intervention. For this purpose, the following data collection tools will be used:~Personal Information Form Breast Cancer Awareness Scale Gynecological Cancers Awareness Scale The impact of the creative drama education on the awareness levels of students in the intervention group regarding breast and gynecological cancers will be evaluated through statistical analysis."
214974875|NCT07073352|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Participants will consume 1,000 mg of nicotinamide riboside (NR) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring. NR is a naturally occurring vitamin B3 derivative readily taken up by cells as a direct NAD+ precursor. Similar NR supplementation protocols are well-tolerated, boost NAD+ concentrations by \~100-140% achieving a steady state within 1-2 weeks, and increase SIRT activity in humans.
214974876|NCT07073352|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1,000 mg of placebo (microcrystalline cellulose) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring.
214974877|NCT07072949|OTHER|Metformin Monotherapy|Participants in this group (n = 30) received metformin alone, administered in a daily dose of 1000 to 2000 mg divided into two doses, over a period of four weeks.
214364135|NCT05908214|OTHER|wide pulse high frequency neuromuscular electrical stimulation training|Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks
214364136|NCT06016010|DRUG|USL|500mg of Achyranthis Radix Extract
214364137|NCT06016010|DRUG|USL Placebo|USL Placebo
214364138|NCT00053989|BIOLOGICAL|anti-thymocyte globulin|iv
214364139|NCT00053989|BIOLOGICAL|graft-versus-tumor induction therapy|iv
214364140|NCT00053989|BIOLOGICAL|sargramostim|iv
214974878|NCT07072949|OTHER|Metformin combined with probiotic (Normia® Jadran Galenski Laboratory) supplementation|Participants (n = 30) received metformin (1000-2000 mg/day, divided in two doses) combined with a probiotic supplement (1 capsule three times daily) over a four-week period.
214974879|NCT07072949|OTHER|Triple therapy - metformin, probiotic and ursodeoxycholic acid (Bilexin®, Bosnalijek)|Participants in this group (n = 30) were treated with a combination of metformin (1000 - 2000 mg/day), a probiotic (1 capsule three times daily) and ursodeoxycholic acid (UDCA, 1 capsule (250mg) three times daily) for four weeks.
214974880|NCT07064629|BEHAVIORAL|Relaxation in virtual reality with biofeedback.|In this intervention, biofeedback is provided based on the respiratory rate measured by a Vernier Go respiration belt. This belt sends signals (respiratory effort) to the application that calculates the level of synchronisation and gives the visual biofeedback in two forms: 1) a deer simultanously breathing with the participant (realtime biofeedback, present in the initial phase only), 2) a growing tree - if breathing is regulated following a given rhytm, a growing tree is giving the targeted biofeedback.
214364141|NCT00053989|BIOLOGICAL|therapeutic allogeneic lymphocytes|iv
214364142|NCT00053989|DRUG|cyclophosphamide|injection
214364143|NCT00053989|DRUG|fludarabine phosphate|iv
214364144|NCT00053989|DRUG|methylprednisolone|oral
214364145|NCT00053989|DRUG|mycophenolate mofetil|oral
214364146|NCT00053989|DRUG|tacrolimus|oral
214364147|NCT00053989|PROCEDURE|allogeneic bone marrow transplantation|iv
214364148|NCT00053989|PROCEDURE|peripheral blood stem cell transplantation|iv
214364149|NCT00053989|PROCEDURE|umbilical cord blood transplantation|iv
214364150|NCT05094401|DEVICE|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
214364151|NCT01534325|DEVICE|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
214364152|NCT01534325|DEVICE|Control|"The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance."
214364153|NCT01534325|DEVICE|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
214364154|NCT01372657|OTHER|biometry calculation|
214490422|NCT06755073|RADIATION|Pulmonary artery Doppler ultrasound|Doppler ultrasound of fetal pulmonary artery
214490423|NCT06840249|PROCEDURE|surgery|surgery by graft or repair or thrombectomy and completion angiography
214974881|NCT07064629|BEHAVIORAL|Relaxation in virtual reality without biofeedback|In this control intervention, participants' respiratory rate is still being measured by the respiratory belt VernierGo; however, they are not receiving any visual biofeedback inside the virtual relaxation application (no deer is present, the tree is constantly growing regardless of the breathing pattern of the participant).
214974882|NCT07072858|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging (CMR)|Cine CMR imaging was performed with steady-state free precession covering short axis continuously from the mitral annulus to the apical level in the 2-, 3- and 4- chamber views using the following parameters: repetition time (TR) = 3.73 ms, echo time (TE) = 1.87 ms, flip angle = 60°, slice thickness 8.0 mm. Cine images of all included patients were acquired prior to contrast administrations. Late gadolinium enhancement images (LGE) images were obtained 10-15 minutes after intravenous injection of gadolinium (0.1 mmol/kg at 3ml/s) at end-diastolic phase on the short axis (TR=6.09 ms; TE= 3.0 ms; flip angle 60°; thickness 8.0 mm) with breath-hold phase-sensitive segmented inversion recovery (PSIR) fast field echo sequence. T2-weighted sequence was performed using turbo spin-echo (TSE)-sequence (TR=1714-2000 ms; TE=8.04 ms; slice thickness 8.0 mm) to estimate myocardial edema. Images were analyzed on freely available validated cardiovascular image analysis software CVI42 (Circle Cardiovas
214974883|NCT07073716|OTHER|aerobic exercise|"the exercise protocol was applied following these characteristics~* frequency: 3-5 times /week along the whole study period~* intensity: 70% of the maximal heart rate (220- age x 70/100)~* duration: 50 min (warming up exercise movements (stretching and flexibility) in standing position, active phase of walking on a computerized treadmill, cooling down exercise movements (stretching and flexibility) performed in the seated position. being supervised by two trainers and the researcher. The researcher controlled the heartbeat 2 times through carotid pulse and At the end in order to restore the body to its initial state. all the patients could drink water during their training."
214974884|NCT07073716|DIETARY_SUPPLEMENT|phoenix seed|consuming 2 grams of phoenix seed powder dissolved in about 100 ml water 3 times/day
214490424|NCT05505799|OTHER|Intubation Checklist|A preprocedure checklist will be made available to clinicians, and they will be educated on proper use of the checklist
214490425|NCT05505799|OTHER|Standard Care|Clinicians will intubate as per their usual practice
214490426|NCT06744842|OTHER|genicular nerve block|genicular nerve block
214490427|NCT06744842|OTHER|Exercise|isometric exercise
214490428|NCT06745375|DEVICE|contact lens wear|participants wear two different powered contact lenses (one with actual power, and one +/- 2.00Ds) contact lenses. No 2nd arm
214490429|NCT06766929|DRUG|VSA012|subcutaneous injection
214490430|NCT06766929|DRUG|Placebo|subcutaneous injection
214490431|NCT06798051|DRUG|Roxithromycin tablets 150mg|Oral roxithromycin tablets，150mg Once every seven days，One cycle T drug, two cycles R drug
214490432|NCT04755595|DRUG|Botox Cosmetic Injectable Product|Acetylcholine release inhibitor and a neuromuscular blocking agent
214490433|NCT04755595|DEVICE|Juvéderm Voluma XC|Gel implants consisting of cross-linked hyaluronic acid
214490434|NCT04755595|DEVICE|Juvéderm Volbella XC|Gel implants consisting of cross-linked hyaluronic acid
214490435|NCT05417867|PROCEDURE|Biospecimen Collection|Undergo collection of stool and blood samples
214490436|NCT05417867|OTHER|Questionnaire Administration|Complete questionnaires
214364155|NCT01342224|BIOLOGICAL|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
214364156|NCT03261128|OTHER|Self-questionnaire|Filling of a self-questionnaire before each chemotherapy cure
214364157|NCT02679040|PROCEDURE|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
214364158|NCT02679040|DRUG|Chemotherapy|Chemotherapy treatment
214364159|NCT02679040|RADIATION|Radiation therapy|Radiation therapy
214364160|NCT03114280|DRUG|TPF2|Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
214364161|NCT03114280|OTHER|Radiotherapy with carboplatin|Radiotherapy (RT) combined with carboplatin
214364162|NCT03017430|DRUG|Pregabalin|Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
214364163|NCT03017430|DRUG|Clonidine|Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
214364164|NCT03017430|DRUG|Doxylamin|
214364165|NCT03017430|DRUG|Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)|
214364166|NCT05769738|DRUG|Furosemide|40mg (4ml) of furosemide to be nebulized 3 times daily for 3 days
214364167|NCT05769738|DRUG|Normal saline|4ml of normal saline to be nebulized 3 times daily for 3 days
214364168|NCT03471663|DRUG|D-0502|oral tablets
214364169|NCT03471663|DRUG|palbociclib|standard dose of palbociclib
214364170|NCT03226964|DEVICE|high flow nasal oxygen|humidified high flow nasal oxygen
214364171|NCT04085302|DEVICE|Digital Behaviour Change Intervention|14 days
214364172|NCT00382824|DIETARY_SUPPLEMENT|Coenzyme Q10|active drug
214974885|NCT07073716|COMBINATION_PRODUCT|aerobic exercise+ phoenix seed|"a specialized programme of aerobic exercise.the exercise protocol follow these characteristics~* frequency: 3-5 times /week along the whole study period~* intensity: 70% of the maximal heart rate (220- age x 70/100)~* duration: 50 min (warming up exercise movements (stretching and flexibility) in standing position, active phase of walking on a computerized treadmill, cooling down exercise movements (stretching and flexibility) performed in the seated position. being supervised by two trainers and the researcher. The researcher controlled the heartbeat 2 times through carotid pulse and At the end in order to restore the body to its initial state. all the patients could drink water during their training.~the specialized program of phoenix seed consumption (consuming 2 grams of phoenix seed powder dissolved in about 100 ml water 3 times/day)"
214974886|NCT07072182|DEVICE|Palatal wound will be covered with Ora-aid patch|Palatal wound will be covered with Ora-aid patch
214974887|NCT07072182|DEVICE|Palatal wound will be covered with Composite stent|Palatal wound will be covered with Composite stent
214974888|NCT07072182|COMBINATION_PRODUCT|Palatal wound will be covered with PRF|Palatal wound will be covered with PRF
214364173|NCT00382824|OTHER|Placebo|Placebo
214364174|NCT01058304|OTHER|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
214364175|NCT01058304|OTHER|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
214974889|NCT07073391|DEVICE|Recording with laminar arrays|Part of the intervention is reliant on FDA approved laminar recording electrodes already available in the US. The other part will be an investigational device that is currently being considered by the FDA for an Investigational Device Exclusion.
214974890|NCT07072650|DRUG|Dexmedetomidine|Studying combining a local anesthetic with dexmedetomidine (DEX) in a quadratus lumborum block (QLB) following a cesarean section (CS) in elective surgery in Bint Al-Huda Hospital.
214974891|NCT07072936|BEHAVIORAL|mediterranean diet|All questions of the intervention group, in which behavioural change was expected, were answered by the dietitian throughout the study and compliance with the diet was monitored with food consumption records.
214364176|NCT02850432|PROCEDURE|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
214364177|NCT02850432|OTHER|Conservative treatment|rehabilitation with medical therapy
214364178|NCT02317939|OTHER|instruction|online instruction tutorials at followup visits
214364179|NCT02317939|OTHER|standard baseline instruction|self-guidance at followup visits
214364180|NCT01820559|DRUG|Placebo|Tablets
214364181|NCT01820559|DRUG|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
214364182|NCT01820559|DRUG|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
214364183|NCT03732118|DEVICE|Eye-tracker Mobile EBT|Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
214974892|NCT07073196|PROCEDURE|Dental implant treatment (narrow implants)|Replacement of a missing molar tooth with a narrow dental implant
214974893|NCT07073196|PROCEDURE|Dental implant treatment (standard implants)|Replacement of a missing molar tooth with a standard dental implant
214974894|NCT07072169|DRUG|ABO2203 Injection|SC or IV
214364184|NCT04969237|DIAGNOSTIC_TEST|Vitamine D in blood samples|vitamine D values
214974895|NCT07072533|OTHER|blood flow restriction training|individual will do aerobic training .
214974896|NCT07073222|OTHER|Escape room game|Escape room games are live action team-based games where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal within a limited time.
214974897|NCT07072039|PROCEDURE|Paramedic Evaluation for acute COPD Exacerbation|The Paramedic Evaluation for Acute COPD Exacerbation (PEACE) program is a mobile integrated health initiative that aims to evaluate and treat COPD exacerbation in the home. The goal of the intervention is to expedite the recognition and treatment of COPD exacerbation as well as For this intervention, ambulatory teams can refer patients for PEACE visits when a patient has been identified as suffering from symptoms consistent with COPD exacerbation. Once a visit is requested via electronic health record order, a community paramedic presents to the patient's home within 2 hours, evaluates the patient using mobile diagnostic testing, and initiates pharmacological therapies protocolized by the pulmonary team. A standardized clinical approach and documentation strategy is used including a focused history and physical exam, venous blood gas, trending pulse-oximetry, and mobile x-ray. The community paramedic is supervised in real-time by an emergency physician to establish a care plan and di
214974898|NCT05231200|BEHAVIORAL|QI Team Building|Each NICU will create a core QI team composed of 6-8 multidisciplinary members including a parent advisor, when feasible. This team will lead the QI activities and education, and champion the culture and practice change in the unit.
214364185|NCT03489590|DRUG|PFP|"* Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
214364186|NCT01137188|DIETARY_SUPPLEMENT|Low calorie diet|Low calorie diet containing 800-1000 kcal/day
214364187|NCT04496102|DEVICE|Triathlon|Modern TKA design (Triathlon) with patellar resurfacing
214364188|NCT02967614|DRUG|[A]|One eye drop(about 40ul) / Day1 \~ Day8 / BID
214364189|NCT02967614|DRUG|[B]|One eye drop(about 40ul) / Day1 \~ Day92 / BID
214974899|NCT05231200|BEHAVIORAL|QI education|Each NICU QI team will receive standardized QI education using the 6-hour EPIQ Workshop which involves hands-on approach to enable teams to successfully implement QI projects together. EPIQ 10 Steps and QI Tools will be used to build the team's understanding of QI using realistic improvement opportunities based on the standardized care bundles identified in the trial.
214974900|NCT05231200|OTHER|Standardized care bundle- respiratory care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for stabilization and respiratory care in moderate and late preterm infants (MLPIs) including~1. establishing effective ventilation in the delivery room~2. prevention of hypothermia~3. early diagnosis and management of respiratory distress with continuous positive airway pressure (CPAP)~4. standardized approach for surfactant indications and administration~5. standardized approach for early extubation."
214974901|NCT05231200|OTHER|Standardized care bundle- nutritional care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for nutritional support in MLPIs including~1. early initiation of enteral or parenteral nutrition;~2. standardized tables for feeding initiation and progression~3. optimizing breastfeeding and use of mother's own milk~4. standardized approach for a transition from enteral nutrition via tube feeds to oral feeds."
214974902|NCT05231200|BEHAVIORAL|QI mentoring|Each NICU in the intervention arm will have one or more assigned members of the study team who are experienced in collaborative QI and EPIQ methods. The mentors will help local QI teams to engage frontline staff in QI and navigate the unit-specific challenges.
214974903|NCT05231200|BEHAVIORAL|Collaborative networking|The study team will conduct virtual meetings every 2 months for the NICUs in intervention arm allowing local QI teams to discuss progress, and share data. The investigators will arrange annual in-person or virtual meetings for the NICUs in the intervention arm to present projects, successes, and lessons learned. These NICUs will have continuing access to the data and will receive quarterly reports using statistical process control charts outlining the unit's performance compared to other units and to the group average.
214364190|NCT02967614|DRUG|[A]+[B](1)|One eye drop(about 40ul) / Day9 \~ Day100 / BID
214364191|NCT02967614|DRUG|[A]+[B](2)|One eye drop(about 40ul) / Day93 \~ Day100 / BID
214364192|NCT03716609|DIETARY_SUPPLEMENT|Magnesium Citrate|Pure Magnesium citrate powder 2.07 gram from NOW FOODS (Bloomingdale, IL, USA)
214364193|NCT03716609|OTHER|Food grade citrate acid|Food grade citrate acid 0.1 gram from San Fu Chemical Co., Ltd (Taipei, Taiwan)
214364194|NCT03716609|OTHER|Splenda(Sucralose)|Splenda 1.0 gram from Splenda(Carmel, Indiana, USA)
214364195|NCT05073757|DEVICE|Custom-made guides and plates|Patients will be included in the study and then followed clinically according to the routine care of orthognathic surgery with custom-made guides and plates. The only specific act this study is the completion of an OQLQ quality of life questionnaire by patients preoperatively and between 8 to 12 months postoperatively.
214364196|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Survivors|"CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
214364197|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Dyads|"CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
214364198|NCT05676255|BEHAVIORAL|Health Education|"HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support."
214364199|NCT06803355|DIAGNOSTIC_TEST|complete blood count, CRP, blood smear test, blood culture, chest X- ray|Inflammation markers obtained from all cases will be evaluated and used to differentiate between transient tachypnea of the newborn and congenital pneumonia.
214974904|NCT05231200|OTHER|Current practice- standard of care|All participating NICUs will be in the control arm during the first year prior to randomization to create a baseline of the current practices and between-units variation. NICUs in the control arm can continue conducting QI activities relevant to current practice, but without receiving the interventions outlined above until they transition to the intervention arm. The investigators will capture these activities and account for them in the analysis.
214974905|NCT07072013|OTHER|ribociclib|This is an observational study. There is no treatment allocation. The decision to initiate ribociclib was based solely on clinical judgement.
214364200|NCT04354012|COMBINATION_PRODUCT|methylene blue, gentian violet, and ovine forestomach wound dressings|"Hydrofera Blue is an antibacterial foam dressing that contains methylene blue and gentian violet to manage wounds. This is a safe, non-cytotoxic product that can be worn for 7 days while not inhibiting growth factors. This products wicks bacteria into the foam and away from the wound surface using natural negative pressure through capillary flow.~Endoform (ovine forestomach) is a natural dermal template used in all phases of wound healing. This product helps to stabilize, build, and organize tissue in acute and chronic wounds.~Hypafix tape aids in stabilization of wound dressings. This productIt is easy to apply, skin friendly, and comfortable to use."
214364201|NCT06236165|DRUG|N-acetylcysteine|Patients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
214364202|NCT02618967|BIOLOGICAL|AMG 570|7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
214364203|NCT02618967|BIOLOGICAL|AMG 570 Matching Placebo|Placebo administered as single dose subcutaneous in healthy volunteers.
214364204|NCT01368965|DEVICE|Ulthera® System treatment|Ulthera® System treatment delivering focused ultrasound energy
214974911|NCT06500741|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
214974912|NCT06776705|DEVICE|Low-intensity transcranial ultrasound stimulation|Low-intensity TUS, as an advanced modality of transcranial brain stimulation, enables to stimulate the deep brain structures with optimized focality and specific frequency.
214974913|NCT06290622|DRUG|Retifanlimab, INCAGN02385, INCAGN02390|"Treatment:~Retifanlimab -infused over 60 minutes for C1D1 followed by a 60-minute observation period. If no infusion related reactions are observed infusion may be reduced to 30 minutes and no further observation period is needed for future cycles. If there is a reaction continue with 60 minute infusion and observation period for following cycle. Retifanlimab should always be administered first.~INCAGN02385 and INCAGN02390 -individually administered over 30 minutes one after another. For first infusions of retifanlimab, INCAGN02385 and INCAGN02390, a 4 hour observation period is necessary after completion of all infusion. If no infusion related reactions are observed, for subsequent infusions no further observation period is needed for future cycles."
214974914|NCT06919224|OTHER|mHealth app + booklets|A mHealth app that has patient facing guidelines and engaging content and a booklet with the guidelines that are made to be patient-facing.
214974915|NCT06916091|DRUG|Eloralintide|Administered subcutaneously (SC)
214974916|NCT06916091|DRUG|Placebo|Administered SC
214974917|NCT06919653|BEHAVIORAL|The Workplace program to Improve the Safe Handling of hazardous drugs (WISH)|The WISH intervention is targeted to promote the adherence to chemotherapy handling guidelines among oncology nurses. The WISH intervention will include two components 1) an individualized online educational component on chemotherapy exposure and the safe handling guidelines with incorporating novel instructional technology tools and 2) debriefing sessions on the incidents of chemotherapy exposure.
214974918|NCT06934018|PROCEDURE|Surgery and procedure|"According to the Chinese Guidelines for the Diagnosis and Comprehensive Treatment of Liver metastases of Colorectal Cancer (2023 edition), R0 resection of metastatic tumors is satisfied, and the objective is to preserve sufficient functional liver tissue, and the surgical margin width is less than 7mm"
214974919|NCT06934018|PROCEDURE|Surgery and procedure|Combined with intraoperative B-ultrasound guidance, 3D reconstruction and intraoperative navigation, the surgical margin width of metastatic tumor was greater than or equal to 7mm
214974920|NCT06580457|BEHAVIORAL|Personal Causal Model + Personalized Feedback|Receive a personal causal model of one's personalized causes of substance use/urges, along with a 1-hour, live clinical feedback session to suggest how to apply these insights to one's own recovery.
214974921|NCT06933940|BEHAVIORAL|Nutrition Matters|The intervention will consist of two components: educational sessions and a structured PA component. The primary purpose of the educational sessions is to increase experimental group participants' scientific knowledge and skills in healthy cooking and eating. NUTRITION-MATTERS includes weekly 1.5-hour education sessions for a total of 12 weeks. The sessions will be sequenced carefully to blend brief lectures by experts, experience sharing by participants, and an interactive cooking demonstration. All participants will be provided with $20 of food that corresponds to the cooking demonstration and recipes in the participant handbook.The curriculum will include evidence based information on managing chronic diseases with nutrition and will be culturally tailored to include foods, music, and/or same race/ethnicity role models.
214974922|NCT06942104|DRUG|18F-TRX|Given Intravenously (IV)
214974923|NCT06942104|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging procedure
214974924|NCT06942104|PROCEDURE|Tumor Biopsy|May undergo tumor biopsy
214974925|NCT06942104|PROCEDURE|Blood Specimen Collection|Undergo blood sample collection
214974926|NCT06954038|DIETARY_SUPPLEMENT|Leonurus cardiaca extract 250 mg|Participants will receive a dietary supplement containing 250 mg of Leonurus cardiaca extract formulated in phospholipids. The supplement is administered as a single oral capsule, once daily in the morning, for 30 consecutive days.
214364205|NCT02625896|BEHAVIORAL|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
214364206|NCT01146509|DRUG|Aricept (donepezil hydrochloride)|Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
214364207|NCT00853814|BEHAVIORAL|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
214364208|NCT06198465|DRUG|adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil|adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；
214364209|NCT04189718|PROCEDURE|osseodensification protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with osseodensification protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in counter clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
214364210|NCT04189718|PROCEDURE|conventional implant site preparation protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with conventional implant site preparation protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
214364211|NCT04674241|DRUG|Dexmedetomidine|Ten minutes after anesthesia induction and endotracheal intubation, patients assigned to dexmedetomidine group were given a loading dose of dexmedetomidine 0.6 μg/kg over 10 minutes, followed by continuous infusion at a rate of 0.4 μg/kg/h until the start of dural closure.
214974927|NCT06954038|DIETARY_SUPPLEMENT|Placebo|Participants will receive a placebo capsule identical in appearance to the active supplement, administered twice daily for 30 consecutive days.
214974928|NCT06954038|DIETARY_SUPPLEMENT|Leonurus cardiaca extract 500 mg|Participants will receive a dietary supplement containing 500 mg of Leonurus cardiaca extract formulated in phospholipids. The supplement is administered as a single oral capsule, once daily in the morning, for 30 consecutive days.
214974929|NCT05379205|BEHAVIORAL|Prehabilitation program (4 week before the surgery)|This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.
214974930|NCT05379205|BEHAVIORAL|Postoperative program (12 week after the surgery)|"This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.~NOTE: Both preoperative and postoperative programs will be administer to the participants assigned to the intervention group."
214974931|NCT05379205|OTHER|Usual Care|Usual care group will follow the usual institutional pre-surgery care: (i) medication management, (ii) assessment of the surgery-derived risks, (iii) smoking cessation and peri-operative blood management. A trained nutritionist will evaluate the nutritional status of all patients at the baseline providing oral protein/vitamin supplementation, when necessary. Patients allocated to the control group will receive basic expert' advice on lifestyle changes.
214974932|NCT02503163|DRUG|KCT-0809 ophthalmic solution|
214490437|NCT06798103|PROCEDURE|Erector Spinae Plane Block|Erector spinae plane block will be performed using an ultrasound machine with a high frequency linear probe. The patients will be in sitting position to perform the block, the skin is sterilized and the transducer will be placed across the T7 spinous process then move laterally to identify transverse process of T7. Thereafter, the probe will be moved to a parasagittal plane to visualize skin and subcutaneous tissue layers, trapezius muscle, and lastly the erector spinae muscle just superficial to the transverse processes. The in-plane technique will be used, and the tip of the needle will be inserted in the fascial plane deep to the erector spinae muscle. After 2-3 mL of normal saline injection for hydro dissection to verify the correct needle tip placement, 30 mL of 0.25% bupivacaine will be injected deep to the erector spinae muscle. The same technique will be repeated on the contralateral side.
214490438|NCT06798103|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block will be performed using an ultrasound machine with a high frequency linear probe. The patients will be in sitting position to perform the block, the skin is sterilized and the transducer will be placed across the T7 spinous process then move laterally to identify transverse process of T7. Thereafter, the probe will be moved 3-5 cm laterally to identify the paravertebral space as the target injection site. After probe being rotated into transverse orientation, the needle will be inserted using the out-plane technique. Once the needle threads the internal intercostal membrane and arrives in the paravertebral space, 3 ml of normal saline will be injected firstly. If displacement sign of the pleura occurs, 25 ml of 0.25% bupivacaine will be then injected into the confirmed paravertebral space. The same technique will be repeated on the contralateral side.
214490439|NCT05407038|OTHER|Exercise Counseling|Receive call from health coach
214490440|NCT05407038|OTHER|Exercise Intervention|Undergo routine exercise
214490441|NCT05407038|OTHER|Internet-Based Intervention|Receive Android tablet
214490442|NCT05407038|OTHER|Interview|Complete a qualitative interview
214490443|NCT05407038|OTHER|Medical Device Usage and Evaluation|Wear Garmin Vivofit and Nonin 3150 WristOx2 pulse oximeter
214490444|NCT05407038|OTHER|Questionnaire Administration|Ancillary studies
214974934|NCT04194814|DRUG|crisaborole (2%) ointment|twice daily application on one forearm for 4 weeks (randomised site allocation)
214974935|NCT04194814|DRUG|betamethasone valerate 0.1% cream|twice daily application on one forearm for 4 weeks (randomised site allocation)
214974936|NCT02676804|OTHER|High-intensity, aerobic exercise.|"Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of \~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of \~10 - 12 and participants will be asked to complete this on their own."
214974937|NCT05139342|DEVICE|expiratory muscle strentgh training (EMST)|"All patients undergo EMST training, and results will be compared between groups.~After individual adjustment of the EMST device for each patient, the patient receives speeach adn instruction from a speech and language pathologist on the correct use of the EMST device. The intervention regime then consists of 5x5 breaths per day for 14 consecutive days."
214974938|NCT05675163|DIETARY_SUPPLEMENT|Vitamin K2|(K2VITAL® 1% MCT Oil)
214974939|NCT05675163|DIETARY_SUPPLEMENT|Placebo|Sunflower oil
214974940|NCT01092468|PROCEDURE|Diathermy|flap dissection with conventional diathermy
214974941|NCT01092468|PROCEDURE|Harmonic Scalpel|flap dissection using harmonic scalpel (FOCUS)
214974942|NCT02064244|OTHER|Ultrasound for measurement of Inferior Vena Cava size.|Focused bedside ultrasound will be performed for each patient as part of their routine care and initial assessment. The IVC size will be measured at the subcostal window, during inspiration and expiration, using the Sonosite cardiac probe P-21 (5-1 MHZ). The measurement is obtained by applying the M-mode, perpendicular to the IVC axis and 2 cm caudal from its junction with the right atrium.
214974943|NCT00329108|DRUG|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
214974944|NCT00329108|DRUG|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
214974945|NCT03615963|DIAGNOSTIC_TEST|echocardiography and coronary angiography|transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease
214974946|NCT01389232|DEVICE|SeriScaffold® Surgical Scaffold|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
214974947|NCT04269616|BEHAVIORAL|Order of pictographs provided to participants|The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).
214364212|NCT04674241|DRUG|0.9% saline|0.9% saline is administered with the same volume at the same speed as the other group.
214364213|NCT00464802|DRUG|MOA-728|
214364214|NCT00487617|PROCEDURE|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
214490447|NCT05081102|DRUG|FDC of oxycodone 5 mg/ibuprofen 400 mg|receive one (1) experimental drug tablet (FCD of oxycodone 5mg/ibuprofen 400mg) + one (1) Tylex® placebo.
214364215|NCT00762450|DRUG|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
214490448|NCT05081102|DRUG|Tylex|receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
214490449|NCT06656104|DEVICE|Reference strategy|Routine strategy based on the usual catheters and infusion systems used during the reference period
214490450|NCT06656104|DEVICE|Experimental strategy|EDELVAISS multi-infusion strategy as routine strategy during the experimental period
214490451|NCT00319696|DRUG|Bosentan 62.5 mg|Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
214490452|NCT00319696|DRUG|Bosentan 125 mg|Bosentan 125-mg oral tablets administered b.i.d. (target dose)
214490453|NCT06769100|DIETARY_SUPPLEMENT|Ketone Monoester (KET)|\- Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight). The ketone brand name: delta G Oxford Ketone Ester
214490454|NCT06769100|DIETARY_SUPPLEMENT|Ketone Monoester + Whey Protein (KET+PRO)|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 25g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
214490455|NCT06769100|DIETARY_SUPPLEMENT|Whey Protein (PRO)|"* 25g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
214490456|NCT06769100|DIETARY_SUPPLEMENT|Flavour matched placebo (CON)|\- Flavoured water (non-caloric bitter + citrus flavours)
214679663|NCT00839098|OTHER|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction \& Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
214974948|NCT04269616|BEHAVIORAL|Level of description in survival pictograph|The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).
214364216|NCT00762450|DRUG|fluoride|Rinse 3 times daily with assigned toothpaste slurry
214364217|NCT00762450|DRUG|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
214364218|NCT03905330|DRUG|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
214364219|NCT03905330|OTHER|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
214364220|NCT02007642|PROCEDURE|Blood sampling / Body fluid sampling|"During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method.~Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite..."
214490457|NCT06769100|OTHER|Resistance exercise|\- 8 sets of 10 reps at 90% of 10- repetition maximum (10-RM) of unilateral leg extension with 90 seconds rest in between sets.
214490458|NCT06734884|DRUG|Benralizumab 30 MG/ML [Fasenra]|Subcutaneous injection 30 mg at day 2, week 4 and week 8.
214679664|NCT03078673|OTHER|training intervention, motor skill training|cross country specific motor skill strength training
214974949|NCT03994380|DRUG|RhDNAse Inhalation Solution|rhDNAse 2.5 mg nebulizer daily for 4 weeks
214974950|NCT03082508|DEVICE|Algisyl|Algisyl device (implants) administered during a surgical procedure
214974951|NCT03082508|DRUG|Standard Medical Therapy|as per protocol
214364221|NCT04329962|OTHER|Blueberry Powder Food Product|Consume blueberry powder confection
214364222|NCT04329962|OTHER|Dietary Intervention|Consume blueberry extract confection
214364223|NCT04329962|OTHER|Questionnaire Administration|Ancillary studies
214364224|NCT04433884|DEVICE|Endotracheal intubation using a laryngoscope|Patients will undergo intubation using 2 different types of laryngoscopes and their hemodynamic response would be recorded
214364225|NCT02502201|OTHER|six-minute walk study indoors|Performance of a six-minute walk test according to American Thoracic Society standard.
214364226|NCT02502201|OTHER|six-minute walk study outdoors|Performance of a six-minute walk test.
214364227|NCT03077490|DEVICE|Transvaginal mesh Uphold TM Vaginal Support System|
214364228|NCT03077490|DEVICE|Transvaginal mesh Uphold TM Vaginal Support System.|
214364229|NCT06491472|DRUG|Ivonescimab|20mg/kg,IV,d1,Q3W
214364230|NCT06491472|DRUG|Gemcitabine|1000mg/m2, IV, d1/8, Q3W
214364231|NCT06491472|DRUG|Nab paclitaxel|125mg/m2, IV, d1/8, Q3W
214364232|NCT06491472|RADIATION|SBRT|5Gy \*5 F
214364233|NCT02001766|BEHAVIORAL|Exercise training|
214364234|NCT02563457|OTHER|periodontal manual treatment|periodontal manual treatment
214364235|NCT02563457|OTHER|no periodontal manual treatment|blood sampling
214364236|NCT06024226|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
214490459|NCT06734884|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Subcutaneous injection at day 2, week 4 and week 8
214490460|NCT06892405|DEVICE|SonoSite™ S Series ultrasound|"US measurements will be performed in the pre-operating room a~, patients are placed in supine position with the head in a sniffing position on a surgical pillow and using the 15 MHz linear array transducer of the SonoSite™ S Series ultrasound in transverse position. A scan is made from the skin surface of the floor of the mouth to the trachea exerting the minimum possible pressure to identify the structures correctly."
214974952|NCT00857506|DRUG|florbetapir F 18|370 Mega Becquerel (10 mCi)
214974953|NCT00313729|DRUG|temozolomide|Chemotherapy
214364237|NCT05989178|OTHER|Data Registry|Follow-up questionnaires sent every year for the 5 years following the patient's initial visit.
214679665|NCT03078673|OTHER|training intervention, maximal strength training|general maximal strength training
214974954|NCT03566225|DRUG|Pioglitazone|Insulin sensitizing agents
214974955|NCT03566225|DRUG|Metformin|Insulin sensitizing agent
214974956|NCT03566225|DRUG|Clomiphene Citrate|Induction drug
214974957|NCT06379373|OTHER|Spine manipulation; westren medicine|"First Cervical traction,than spine release method,Massage the neck for about 10 minutes to realease muscles.Doctor use his two hands work together to pull the neck forward and upward,meanwhile, the patient's head is passively rotated to the right to the maximum, being rotated slightly with appropriate force, Doctor's left thumb pushes the crooked spinous process to the right, and the reduction sound can be heard at this time.~If patient has upper thoracic spine misalignment, the dislocated segment needs to be adjusted.~If patient has scoliosis, the affected spine segment should also be adjusted. If patient's lumbar facet joints are misaligned, or one of the lumbar muscles is spasmal, also the disorder joints need to be adjusted."
214974958|NCT02402517|OTHER|Control|Non pulse extruded snack
214974959|NCT02402517|OTHER|Small particle size pea flour|Pulse extruded snack
214364238|NCT03300947|DRUG|Psilocybin 100 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
214364239|NCT03300947|DRUG|Psilocybin 300 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
214364240|NCT03300947|DRUG|Lorazepam 1 mg|A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
214364241|NCT05341349|BIOLOGICAL|Ipilimumab|Given IV
214364242|NCT05341349|BIOLOGICAL|Nivolumab|Given IV
214364243|NCT05341349|BIOLOGICAL|Pembrolizumab|Given IV
214364244|NCT05341349|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214364245|NCT05341349|PROCEDURE|Tumor Treating Fields Therapy|Undergo TTFields
214364246|NCT04865627|DEVICE|activity monitor|Both groups will wear three different activity monitors for one week. There is one observation moment which consists of four minutes lying, sitting, standing, walking and taking stairs. Participants will be filmed during this moment.
214364247|NCT05630547|DRUG|SAR443820|Tablet by oral administration
214364248|NCT05630547|OTHER|Placebo|Tablet by oral administration
214364249|NCT02998073|BEHAVIORAL|Stop, Now and Plan|SNAP program was developed to target justice-involved youth (6 years and older) who have problems with aggression, CD, and/or gang affiliation. SNAP focuses on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP treatment is delivered over a 13-week period.
214364250|NCT04518878|DRUG|Eltrombopag|Fixed dose of eltrombopag oral 25mg daily
214364251|NCT04518878|DRUG|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
214364252|NCT01920451|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBTI)|See arm description.
214364253|NCT03969862|DEVICE|NOVEOS® system|"The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark."
214364254|NCT03346629|DRUG|Mifepristone + Misoprostol|A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.
214364255|NCT03560427|DRUG|Duloxetine 60mg|"Patients will receive duloxetine, 60 mg tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
214364256|NCT03560427|DRUG|placebo|"Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
214364257|NCT02942108|PROCEDURE|piezo surgery|
214364258|NCT02942108|PROCEDURE|conventional surgery|
214679666|NCT03078673|OTHER|control group|regular training
214679667|NCT00121810|DRUG|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
214679668|NCT00121810|DRUG|Corticosteroids|As prescribed
214679669|NCT00121810|DRUG|Calcineurin inhibitors|As prescribed
214679670|NCT00121810|DRUG|Sirolimus|As prescribed
214974960|NCT02402517|OTHER|Large particle size pea flour|Pulse extruded snack
214974961|NCT02402517|OTHER|Lentil flour|Pulse extruded snack
214974962|NCT02402517|OTHER|Navy bean flour|Pulse extruded snack
214974963|NCT02402517|OTHER|Pinto bean flour|Pulse extruded snack
214974964|NCT05260814|DEVICE|Electric toothbrush with smart phone app|Scaling and root planing, oral hygiene instructions with use of Sonicare Diamond Clean Smart®.
214364259|NCT05916651|BEHAVIORAL|Learning to Offset Stress (LOS) (in Dutch: Leren Omgaan met Stress) training|The investigational treatment is the LOS training, which is an adaptation of two previously validated mindfulness-based programs: Mindfulness-Based Cognitive Therapy (MBCT) developed by Segal, Williams, and Teasdale (2002) and the Mindful2Work (M2W) program developed by de Bruin, Formsma, and Bögels (2018). The M2W program combines mindful physical activity, yoga, and mindfulness meditation to target stress symptoms and burn-out in adults. The LOS training was adapted from these programs to meet the needs of youth with internalizing problems. The training consists of 8 weekly 2-hour sessions that each comprise three elements: mindful physical activity (15-20 minutes), yoga (15-20 minutes), and mindfulness meditation exercises (80-90 minutes). In addition to attending group sessions, participants are invited to practice at home on a daily basis. Home practice consists of daily mindfulness practices comprising mindfulness exercises, yoga and mindful physical activity.
214974965|NCT04744298|OTHER|TheraPPP|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
214974966|NCT00789321|DRUG|Comparator: amlodipine besylate|Two 5 mg tablets amlodipine daily for 6 weeks.
214364260|NCT05916651|BEHAVIORAL|Care as usual|"Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen."
214364261|NCT01727739|DEVICE|Linvatec PLLA+TCP|Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
214364262|NCT01727739|DEVICE|Linvatec PLLA|Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
214364263|NCT01273454|DRUG|OROS Hydromorphone|8,16, 32 mg once a day for 4 weeks
214364264|NCT04358003|DEVICE|Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)|"Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected.~Study Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician."
214364265|NCT03869398|DIETARY_SUPPLEMENT|Tums|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
214364266|NCT03869398|DIETARY_SUPPLEMENT|Calcitriol|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
214364267|NCT03043508|OTHER|Chart Review|Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.
214364268|NCT03043508|BEHAVIORAL|Questionnaire|Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
214364269|NCT04779138|BEHAVIORAL|Increasing Willingness and Uptake of COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 vaccine hesitancy and increase willingness and uptake in COVID-19 vaccination.
214490461|NCT06893003|OTHER|Baby Bridge|The Baby Bridge program is an evidence-based implementation strategy aimed at enhancing early and continuous therapy services following NICU discharge for infants with alterations in neurodevelopment. The Baby Bridge program utilizes an occupational or physical therapist to see the infant and family in the NICU prior to discharge, complete a comprehensive neurodevelopmental and feeding assessment to inform targeted interventions, and provide early therapy services in the home environment within one week of discharge and weekly thereafter, until other community-based services commence. While most of the program occurs after NICU discharge, a hallmark of the Baby Bridge program is that families establish rapport with the therapist while the infant is still in the NICU. The therapist also educates the family on ways to support their infant's development between sessions and offers support and assistance during the transition from hospital to home.
214490462|NCT05972876|BEHAVIORAL|Blood flow restriction training|BFR will be achieved using an automatic personalized tourniquet system (MAD-UP, Angers, France) designed to automatically calculate limb occlusion pressure
214490463|NCT05972876|BEHAVIORAL|Resistance training|Resistance training will be performed without any blood flow restriction
214490464|NCT06752369|BEHAVIORAL|T1D-specific depression SSI|The T1D-specific depression SSI will include 1) psychoeducation about depression, including how behavior shapes feelings and thoughts, 2) a values assessment, where youth will identify key areas (i.e., family relationships, friendships, school, or hobbies) from which they draw (or once drew) enjoyment and meaning, and 3) the creation of an activity action plan, wherein youth identify (from pre-generated lists) and personalize (in guided exercises) three activities to target for change.
214490465|NCT06752369|BEHAVIORAL|T1D Educational|T1D Educational Material
214974967|NCT00789321|DRUG|Comparator: Placebo|Two 5 mg tablets placebo to amlodipine daily for 6 weeks
214974968|NCT05063253|DRUG|TG103|TG103 injection, SC, once weekly
214974969|NCT05063253|DRUG|Placebo|Placebo, SC, once weekly
214974970|NCT05788263|OTHER|neuroscience based aproach|exercise for pain
214490466|NCT06816394|DRUG|Tarlatamab|All subjects will receive a step dose (1 mg tarlatamab) on cycle 1 day 1 administered as a 60-minute intravenous (IV) infusion then 10 mg tarlatamab IV administered on cycle 1 day 8, cycle 1 day 15, and every 2 weeks (Q2W) thereafter.
214364270|NCT06104033|DEVICE|drug-coated balloon|For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.
214364271|NCT06104033|DEVICE|drug-eluting stent|When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.
214490467|NCT06118034|DRUG|Colchicine 0.5 MG|Take 0.5mg of colchicine tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
214364272|NCT01029054|DRUG|carfilzomib, lenalidomide plus dexamethasone|"Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push."
214364273|NCT01029054|DRUG|carfilzomib, lenalidomide plus dexamethasone|"Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg."
214364274|NCT04732455|DRUG|Lidocaine in Saline|Lidocaine IV infusion (2 mg/kg) in 200 ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle.
214364275|NCT04732455|DRUG|Duloxetine 30 MG|Oral Duloxetine tablet 30 mg once per day starting from the night pre chemotherapy during the whole period of chemotherapy cycle which expected to be three month
214490468|NCT06118034|DRUG|Placebo|Take 0.5mg of starch tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
214490469|NCT06850844|DEVICE|electrical impedance tomography|The individualized high PEEP with RMs group commences with a PEEP of 5 cm H2O and undergo an RM followed by a decremental PEEP trial. Pressure-controlled ventilation mode is set with a respiratory rate of 16 breaths per minute and ΔP=15 (ΔP is calculated by subtracting PEEP from the plateau pressure (Pplat). In intervals of 5 breaths, PEEP is incrementally increased by 5 cm H2O, starting at 5 cm H2O and reaching up to 20 cm H2O. The decremental PEEP trial is immediately performed following the first RM, beginning at a PEEP of 20 cm H2O with a respiratory rate of 15 breaths per minute. Every 30 seconds, PEEP is decreased by increments of 2 cm H2O until it reaches a minimum of 6 cm H2O. This decremental PEEP trial is succeeded by a second RM, after which the individualized PEEP level will be established as determined by the decremental PEEP trial and sustained until the completion of ventilation.
214490470|NCT06850844|DEVICE|Conventional Ventilation|Ventilation is set in volume-controlled mode with a tidal volume of 7 ml/kg predicted body weight (PBW), the respiratory rate is adjusted to target normocapnia (end-tidal carbon dioxide partial pressure between 35 and 45 mmH), an inspiratory to expiratory ratio of 1:2, and a PEEP of 5 cmH2O.
214679671|NCT01340287|DIETARY_SUPPLEMENT|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
214679672|NCT01340287|DIETARY_SUPPLEMENT|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
214679673|NCT02286011|BIOLOGICAL|MNC (Mononuclear cells)|"The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.~For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device."
214679674|NCT02286011|OTHER|Saline|The placebo, 2ml of saline, will be infused like in the experimental arm.
214974971|NCT02626416|DEVICE|LenZOC (mobile application)|The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
214974972|NCT06249516|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
214974973|NCT06249516|BIOLOGICAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
214974974|NCT05441800|OTHER|Observational Study|observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases
214974975|NCT04273321|DRUG|Methylprednisolone|Methylprednisolone 1mg/kg/day ivgtt for 7 days.
214974976|NCT02130869|BIOLOGICAL|CD133+ selected autologous stem cell infusion|Hematopoietic stem cells will be collected from children with high-risk solid tumors. After collection, they will be immuno-magnetically selected using CD133 as a marker in efforts to reduce tumor cell contamination in the stem cell graft. After high dose chemotherapy, those selected stem cells will be infused, followed shortly thereafter by an infusion of haploidentical natural killer cells.
214974977|NCT02130869|BIOLOGICAL|IL-2|Following infusion of haploidentical natural killer cells, interleukin-2 (IL-2) subcutaneously (SQ) will be given to support the in vivo survival of donor NK cells.
214679675|NCT05329688|PROCEDURE|novel nutrition program|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
214974978|NCT02130869|BIOLOGICAL|hu14.18K322A|Participants with neuroblastoma (Group A) will receive hu14.18K322A intravenously (IV).
214974979|NCT02130869|DRUG|Busulfan|Given IV - Group A only.
214974980|NCT02130869|DRUG|Melphalan|Given IV - All groups.
214974981|NCT02130869|BIOLOGICAL|GM-CSF|Given SQ - All groups.
214974982|NCT02130869|DRUG|Bendamustine|Given IV - Group B only.
214974983|NCT02130869|DRUG|Etoposide|Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
214974984|NCT02130869|DRUG|Cytarabine|Given IV - Group B only.
214364276|NCT04732455|DRUG|Normal saline|200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
214974985|NCT02130869|DRUG|Carboplatin|Given IV - Group C only.
214974986|NCT02130869|DEVICE|Haploidentical natural killer cell infusion|NK cell product will be collected from donors using leukapheresis procedures. The autologous hematopoietic stem cell graft product will be positively selected using the investigational CliniMACS device and CD133 Microbead reagent. Following standard laboratory procedures, the NK cell product will be enumerated and assessed for viable cell content. NK cells will be infused by slow IV push over 3 to 15 minutes immediately after processing, evaluation and release testing.
214974987|NCT02130869|BIOLOGICAL|G-CSF|Given SQ - All Groups.
214974988|NCT02130869|DRUG|Etoposide phosphate|In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
214974989|NCT02130869|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
214974990|NCT03964207|DRUG|Tiotropium Respimat® (T1)|inhalation solution
214974991|NCT03964207|DRUG|Tiotropium Handihaler® (T2)|Inhalation Powder
214974992|NCT04531865|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 7
214974993|NCT04531865|DRUG|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
214974994|NCT04531865|DRUG|Placebo tablets matching Mycophenolate Mofetil|Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
214974995|NCT03814564|DEVICE|NIRS monitoring|Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
214974996|NCT00966576|DRUG|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
214364278|NCT04823429|BEHAVIORAL|High intensity-interval training (HIIT)|"Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.~Without any exercise training"
214364279|NCT04823429|BEHAVIORAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
214364280|NCT01087892|DIETARY_SUPPLEMENT|Probiotic drink containing the live strain|Probiotic drink contains no strain
214364281|NCT01087892|DIETARY_SUPPLEMENT|placebo probiotic|Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
214364282|NCT02336334|DEVICE|Positioning measurement|Logging of posturing informations
214364283|NCT02336334|DEVICE|Patient feedback|Evaluation of patients questionary
214364284|NCT02336334|PROCEDURE|Usefulness of a sketch|Helping the patients to understand posturing positions by randomized allocation of sketches
214974997|NCT00717145|DRUG|risedronate|one risedronate 20 mg DR tablet
214974998|NCT00717145|DRUG|risedronate|One risedronate 20 mg DR tablet
214974999|NCT00717145|DRUG|risedronate|One risedronate 35 mg DR tablet
214975000|NCT00717145|DRUG|risedronate|One risedronate 35 mg IR tablet
214975001|NCT01962675|DEVICE|Transcranial direct current stimulation + step training|Direct current stimulation of motor cortex with low stimulation intensity
214975002|NCT01962675|BEHAVIORAL|Sham transcranial direct current stimulation + step training|Stepping over specified soft foam obstacles
214975003|NCT06307353|OTHER|trends of contraception methods|family planning practice will include number of women current use of family planning methods and its type planning fot ffuture pregnancy suggested duration before next pregnancy.women'ssatisfaction with family planning services atElBalyana urban Medical Center accessibility of the site suitability of waiting time
214975004|NCT02519725|OTHER|ICU diary|The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, the staff and the relatives. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
214490471|NCT06858670|PROCEDURE|Auxiliary Segmental Lingual Appliances|This intervention involves the use of auxiliary segmental lingual appliances specifically designed to level the Curve of Wilson at the second molars in patients undergoing labial fixed orthodontic treatment. The primary goal is to adjust the lingual inclination of the mandibular second molar, thereby achieving a more balanced and functional occlusal plane.
214490472|NCT06779019|DIAGNOSTIC_TEST|LSCI|LSCI evaluates at 2 timings:immediately after the mastectomy (prior to immediate reconstruction) and again following reconstruction (after the skin was sutured). The perfusion score was calculated by normalizing these values against the perfusion value of a control.
214490473|NCT06779019|DIAGNOSTIC_TEST|ICG (Indocyanine Green)|Performed immediately after the mastectomy (prior to immediate reconstruction) .Perfusion scores were determined by comparing the fluorescence intensity of the target area to that of the non-surgical region on the contralateral chest wall.
214490474|NCT06894316|DEVICE|Inspiratory muscle warm-up training|The Powerbreathe brand device was used to perform inspiratory muscle pre-activation. Two sets of 30 breaths were carried out at 40% of each participant's maximal inspiratory mouth pressure (MIP), with a one-minute rest in between. MIP was measured once at the first session, and that value determined 40% and 5% for IMpa and IMPpa, respectively, in later visits. Participants were seated, wearing a nose clip, instructed to exhale forcefully, then inhale forcefully against a closed airway for one to three seconds. Measurements were repeated until values within 5 cmH₂O of each other were obtained, recording the best result in cmH₂O.
214490475|NCT06894316|OTHER|General Warm-up Protocol|The participants engaged in a 10-minute jogging activity, which was followed by a 10-minute stretching exercise. Subsequently, the general warm-up protocol was completed with shooting drills tailored to the specific requirements of basketball, without inducing fatigue.
214490476|NCT06894316|DEVICE|Placebo inspiratory muscle warm-up training|The Powerbreathe brand inspiratory muscle warm-up device was employed to facilitate an exercise regimen comprising two sets of 30 breaths, performed at an intensity of 5% of the participants' maximal inspiratory mouth pressure (MIP), with a one-minute interval between sets. This minimal load was intended as a placebo-like condition for inspiratory muscle usage.
214679676|NCT04490668|BIOLOGICAL|Human albumin|Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
214679677|NCT00003369|DRUG|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
214975005|NCT04514900|BEHAVIORAL|Video Chat +Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide detailed weekly feedback on diet and exercise.
214364285|NCT02336334|DEVICE|Closure rate of macular holes|closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
214364286|NCT00611000|DIETARY_SUPPLEMENT|folic acid|
214364287|NCT00611000|GENETIC|DNA methylation analysis|
214364288|NCT00611000|GENETIC|gene expression analysis|
214364289|NCT00611000|GENETIC|microarray analysis|
214364290|NCT00611000|GENETIC|polymorphism analysis|
214364291|NCT00611000|OTHER|laboratory biomarker analysis|
214364292|NCT04688242|OTHER|Anal dilatation per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
214364293|NCT04688242|DRUG|administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
214975006|NCT04514900|BEHAVIORAL|Video Chat + Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
214364294|NCT05735574|OTHER|IPG infections|Infected IPGs
214364295|NCT04137692|OTHER|Red Blood Cell Transfusion|The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
214364296|NCT03167307|DRUG|Omega 3 fatty acid|Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
214364297|NCT03167307|DRUG|Placebo oil|medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
214364298|NCT01903850|DEVICE|spray cryotherapy|spray cryotherapy
214364299|NCT01492023|BEHAVIORAL|neuropsychological rehabilitation|attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
214364300|NCT06309108|OTHER|Education Booklet|The education group was given training with a education booklet
214679678|NCT00003369|DRUG|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
214679679|NCT00365976|DRUG|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
214679680|NCT00365976|DRUG|Placebo|Placebo nightly over duration of double blind study phase
214679681|NCT05840289|OTHER|fractionated first dose rituximab|Patients at high-risk to develop tumor lysis syndrome received a initial fractionated dose of rituximab over 2 or 3 days
214679682|NCT04993027|DRUG|Vancomycin Powder|Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.
214364301|NCT06309108|OTHER|Augmented Reality Group|The second of the intervention group was trained with augmented reality. Patients were able to see the augmented reality element with the 3DQR application.
214364302|NCT04763902|BEHAVIORAL|Time Restricted Eating (TRE) Schedule|\[See arm/group descriptions\]
214364303|NCT02164877|DRUG|pectin|Patients allocated to experiment group will receive 15g pectin each day
214364304|NCT01936857|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.
214490477|NCT06752148|COMBINATION_PRODUCT|neurofeedback intervention training game|"1. Issuance of training equipment and training in its use: For subjects randomly assigned to the intervention group, a volunteer who has received adequate training in the use of the equipment will issue the EEG monitoring electrodes (model: HXD-1) and paired PADs, and will provide an activated account for the use of the subject only and training in its use. Subjects will be provided with a short tutorial on how to use the APP, which is very user-friendly and suitable for elderly novices. An initial training session will consist of 3 training components and will be completed with a volunteer.~2. Training programme and supervision: The closed-loop neurofeedback training will consist of 3 parts, namely Digital Meditation, Brain Training and Sleep Induction. The brain training will consist of three games: Idea Chase, Idea Magic Ball and Focused Archery. The control subjects lived a normal life before the surgery, and all subjects underwent the surgery as planned."
214490478|NCT06852196|PROCEDURE|orthognathic surgery ,lefort 1,bsso ,DO|Le Fort I osteotomy is often used in the correction of dental occlusion and maxillary hypoplasia in cleft patients. In addition, the osteotomy may also improve patients' facial appearance and self-esteem
214490479|NCT06852196|PROCEDURE|distraction osteogenesis|Distraction osteogenesis is a surgical technique that uses body's own repairing mechanisms for optimal reconstruction of the tissues.
214490480|NCT06762886|DEVICE|Cycle ergometer|The case was lying back in a comfortable position on the stationary bike ergometer when the exercise test was conducted. The exercise test began with a 3-minute warm-up session of unloaded cycling on a cycle ergometer, and then progressed at a rate of 10 W per minute up to the subject's threshold. After cycling for 30 W to warm up, the intensity was raised by 15 W every 60 seconds until fatigue, after which the individuals cycled for 30 W to cool down. This treatment protocol was administered to each patient 3 times/week for a total of 15 minutes of treatment, broken into intervals of two to three minutes each.
214490481|NCT06762886|DEVICE|Low-level laser therapy|The laser probe was administered using the contact approach on the dorsal midline, in the depression below the spinous process of C7 at Governor Vessel, with the patient seated in a chair with back support (GV - 14 Dazhui). The primary power switch was activated. The following settings were used for applying laser puncture: 5 mW, the maximum average power. Type of laser: gallium arsenide (Ga-As), 904 nm wavelength, 5 kHz maximum repetition rate - Program: Maintaining programs for people who had their neck lymph nodes removed and have a low leukocyte count, up to 30 J/cm2 of energy, a 2 J/cm2 energy density, and protective glasses were required to prevent irreversible eye injury from either direct or indirect laser exposure. The treatment took place for 15 minutes.
214490482|NCT06750367|OTHER|Klapp method exercises|The researcher will administer Klapp method exercises to the participant for a period of 1 month (twice in a week for 50 min .The researcher will perform stretching of upper limb, neck and thoracic region to the participants as a baseline treatment. Klapps exercises program include four point walk followed by two point walk and back walk, breathing exercise from kneeling position, breathing exercise from quadrapedal position, simple bounce glide with simulanteos breathing, bunny hop greeting. Each exercise will be performed with 10 repetitions
214490483|NCT06750367|OTHER|At-Home exercise program|theywill begiven printed information on an at-home exercise program, such corrective exercises (Chin tuck, stretchingof neck extensormuscles andpectoral musclegroups instandingandsupinepositions) (16) ,posturecorrection exercises(Thisexerciseprogramconsistedof2strengthening(of thedeep cervical flexorsandshoulderretractors)(26) ,andbreathingexercises(Deep breathing is an exercise that can regulate breathing patterns and improve posture. The deep breathing that is done repeatedly can overcome stiffness in the thoracic cage and straighten the curve of thoracic kyphosis)(27).Theywillbeaskedtoperformtheperiodof1month twiceinaweekfor50minwith10repetitionsofeachexercise.
214490484|NCT06760663|BEHAVIORAL|The load-velocity relationship: Neuromuscular adaptations to resistance training|Comparing the impact of adjusting training load based on movement velocity on hypertrophy and neural adaptations.
214490485|NCT06749704|DIETARY_SUPPLEMENT|High protein diet|High protein diet
214490486|NCT06749704|DIETARY_SUPPLEMENT|Normal Protein diet|Normal protein diet
214364305|NCT01936857|DRUG|Methadone Maintenance Therapy|Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
214364306|NCT02475122|OTHER|azygos blood flow measurements by MRI|
214364307|NCT05011994|BEHAVIORAL|Maintenance intervention|"The intervention consists of action planning, text messages, and coordinator support.~At onset, each participant creates an action plan for physical activity with the help of a health professional:~* What types of physical activities?~* When and how often?~* Where and with who?~  2 auto-generated text messages are sent weekly for a duration of 12 weeks. The first prompts physical activity. The second asks if plans were reached. If yes, an automatic reply with positive reinforcement is generated. If no, an automatic reply asks if the participant wants to be contacted.~Participants are contacted by a coordinator either by answering text messages or if not answering the texts for a period of 2 weeks or more. Coordinator functions:~* Call participants replying to texts that they wish to be contacted~* Help participants establish contact to local activities involving physical activity~* Follow-up on and adjustment of action plan~* Offer guidance in physical activity"
214364308|NCT01939548|DRUG|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
214364309|NCT01939548|DRUG|Placebo|Placebo BID until the Week 12 visit
214364310|NCT01939548|DRUG|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
214490487|NCT04270045|DEVICE|Non-invasive forced airway oscillometry|This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.
214679683|NCT04848363|PROCEDURE|Quadratus lumborum block|QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
214364311|NCT00490282|RADIATION|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
214364312|NCT00490282|RADIATION|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
214364313|NCT01414621|OTHER|atrial tissue sample|atrial tissue sample from CABG patient
214364314|NCT00353587|DRUG|MBX-102|MBX-102 200 mg once daily for 16 weeks
214364315|NCT00353587|DRUG|MBX-102|MBX-102 400 mg once daily for 16 weeks
214364316|NCT00353587|DRUG|MBX-102|MBX-102 600 mg once daily for 16 weeks
214364317|NCT00353587|DRUG|Placebo|MBX-102 Placebo once daily for 16 weeks
214364318|NCT00353587|DRUG|Actos|Actos 30 mg once daily for 16 weeks
214364319|NCT00877825|PROCEDURE|dairy food control diet and high- and low- isoflavone soyfood diets|
214364320|NCT02361515|RADIATION|Moderate hypofractionated radiotherapy|Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
214364321|NCT02361515|RADIATION|Stereotactic radiotherapy|Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
214364322|NCT05204810|OTHER|Anticoagulation strategy|For each session of this cross-over study, a different anticoagulation therapy is used: either 1 dose of anticoagulant or 2 doses of anticoagulant
214679684|NCT06313281|PROCEDURE|Preoperative Antiseptic preparation prior to transnasal skull base surgery|The patient received one of three antiseptic preparation before transnasal skull base surgery
214679685|NCT02222987|DRUG|Terbogrel|
214975007|NCT04514900|BEHAVIORAL|Discussion Board for Social Support +Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
214975008|NCT04514900|BEHAVIORAL|Discussion Board for Social Support+Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide personalized, detailed weekly feedback on diet and exercise.
214975009|NCT03570216|OTHER|Cardiopulmonary exercise test|Participants will perform a graded cardiopulmonary exercise test to asses their cardiorespiratory fitness. It will also provide a peak exercise stimulus to examine acute changes in arterial stiffness, and to prescribe both moderate intensity continuous exercise and high intensity interval exercise.
214975010|NCT03570216|OTHER|Moderate-intensity continuous exercise|Participants will perform a 30-minute session of moderate-intensity continuous exercise.
214975011|NCT03570216|OTHER|High-intensity interval exercise|1 week later, participants will perform a 19-minute session of high-intensity interval exercise.
214975012|NCT01102023|OTHER|ordinary salt based- diet|
214975013|NCT01270035|DRUG|Adalimumab|To increase the ADA dose from 40 mg eow to 80 mg eow
214975014|NCT03496389|DRUG|Gabapentin|Gabapentin 300mg daily
214975015|NCT03496389|DRUG|Tramadol|Tramadol 50mg QID
214975016|NCT03496389|DRUG|Panadol|Panadol 500mg QID
214975017|NCT05573230|DRUG|Midazolam|Administered orally.
214975018|NCT05573230|DRUG|LY3502970|Administered orally.
214975019|NCT05573230|DRUG|Cyclosporine|Administered orally.
214975020|NCT06959693|DRUG|Cetuxima-β|500 mg/m², initial intravenous infusion (IV)\>120 min, subsequent IV \>60 min , D1，every 2 weeks
214975021|NCT06959693|DRUG|Envafolimab|a single fixed dose of 200 mg, subcutaneous injection(SC), every 2 weeks (Day 1 of each cycle \[D1\])
214975022|NCT06959693|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m² , IV, over 120 min, Day 1; Leucovorin 400 mg/m² (or Calcium Folinate 200 mg/m²), IV, over 120 min, D1; 5-FU 400 mg/m² , bolus injection, followed by 1200 mg/(m²·d) continuous IV for 2 days (total dose 2400 mg/m² over 46 - 48 hours)
214975023|NCT05859217|DRUG|Cabozantinib|Oral once per day, Days 1 - 21 every 21 days
214975024|NCT05859217|DRUG|Atezolizumab|Intravenous (IV) once every 21 days
214975025|NCT01078038|DEVICE|Cypher|Sirolimus-eluting stent implantation
214975026|NCT01078038|DEVICE|Xience V|Everolimus-eluting Stent implantation
214975027|NCT01405560|DRUG|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
214975028|NCT01405560|BIOLOGICAL|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
214975029|NCT01405560|DRUG|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
214975030|NCT03562078|BEHAVIORAL|Tai Chi Quan|the first section of Yang style 108 form, including 10-minute warm-up, 40-minute training, and 10-minute cool-down exercise, twice a week
215084708|NCT06607094|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
215084709|NCT00304018|BIOLOGICAL|anti-thymocyte globulin|
215084710|NCT00304018|BIOLOGICAL|sargramostim|
215084711|NCT00304018|DRUG|busulfan|
215084712|NCT00304018|DRUG|etoposide|
215084713|NCT00304018|DRUG|fludarabine phosphate|
215084714|NCT00304018|DRUG|prednisone|
215084715|NCT00304018|DRUG|tacrolimus|
214364323|NCT05204810|OTHER|Blood sampling|During the study sessions, blood sampling is performed from the arterial blood line at different time points (5min, 60min, 240min and at the dialysis end)
214364324|NCT05204810|OTHER|Scanning of hemodialyzer with micro-computed tomography|After the study sessions, the used hemodialyzers are scanned using a gold standard micro computed tomography technique.
215084716|NCT00304018|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
215084717|NCT00304018|PROCEDURE|umbilical cord blood transplantation|
215084718|NCT02775331|OTHER|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
215084719|NCT02775331|OTHER|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
215084720|NCT05193708|DEVICE|Windowed Bonding|A 3D printed tray/guide with open window for the orthodontic brackets
215084721|NCT05193708|DEVICE|Digital Indirect bonding tray|Vacuum formed on a 3d printer cast with brackets
214364325|NCT04198805|DIETARY_SUPPLEMENT|Vitamin E [(all-rac)-α-tocopheryl acetate]|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months
214364326|NCT04198805|DIETARY_SUPPLEMENT|Omega-3 fatty acid (DHA EE)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months)
214364327|NCT04198805|COMBINATION_PRODUCT|Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months
214490488|NCT05019027|DRUG|Beta blocker|"The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with 2 total periods, each period lasting between up to 6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down-titrated by 50% each week and until subsequently discontinued (or the lowest dose the subject can safely tolerate).~Other Names:~* acebutolol~* atenolol~* betaxolol~* bisoprolol~* carvedilol~* labetalol~* metoprolol succinate~* metoprolol tartrate~* nadolol~* nebivolol~* penbutolol~* pindolol~* propranolol"
214679686|NCT02222987|DRUG|Clopidogrel|
214679687|NCT01485679|OTHER|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
215084722|NCT05197582|OTHER|tele-monitoring|The symptoms of the patients were evaluated by calling the patients on the 1st, 5th, and 9th days of the quarantine by the researchers.
215084723|NCT01030874|OTHER|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
215084724|NCT01030874|OTHER|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
215084725|NCT01030874|OTHER|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
215084726|NCT01030874|OTHER|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
214364328|NCT04198805|OTHER|Placebo|Matching soybean placebo (3 capsules) of all arms daily for 6 months.
214364329|NCT00500942|BEHAVIORAL|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
214364330|NCT02624544|DRUG|esomeprazole|esomex 40 mg twice daily
214364331|NCT02624544|DRUG|desonide|topical corticosteroid desonid 0,1% b.i.d
214364332|NCT03179644|OTHER|Measurement of oesophageal pressure and pleural pressure|Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
215084727|NCT01030874|OTHER|Drug Recommendations|The protocol permits the study physician to recommend medications for orthostatic hypotension. The patient's clinical team can implement, ignore, or modify these recommendations and only the clinical team can write orders for them. Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily \[Mukai 2002; Grubb 2003\]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily \[Low, 1997\]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
215084728|NCT06994013|OTHER|High-frequency vibration foam rolling|Athletes will be performed three sets of HFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during HFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During HFVFR, the vibrator booster will be set to a frequency of 67 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.
215084729|NCT06994013|OTHER|Low-frequency vibration foam rolling|Athletes will be performed three sets of LFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during LFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During LFVFR, the vibrator booster will be set to a frequency of 35 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.
214364333|NCT04861987|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
215084730|NCT03761069|DRUG|PTC299|PTC299 will be administered per the treatment arm description
215084731|NCT01248754|PROCEDURE|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
215084732|NCT02356094|PROCEDURE|Pentacam|Corneal topography using Scheimpflug Pentacam examination
214364334|NCT03599349|DEVICE|Microfocused ultrasound w/ visualization|
214364335|NCT04209075|DIETARY_SUPPLEMENT|Biomebliss|BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.
214364336|NCT04209075|DRUG|Metformin|Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.
214364337|NCT04209075|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
214364338|NCT02149251|GENETIC|Pre-genetic diagnosis|
214364339|NCT02271256|DEVICE|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
214364340|NCT00141154|DRUG|Celecoxib|
214364341|NCT00141154|DRUG|Placebo|
214364342|NCT00141154|DRUG|Loxoprofen|
214364343|NCT00365443|BIOLOGICAL|V502|
214364344|NCT02666547|DRUG|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
214364345|NCT02666547|RADIATION|18F-FDG PET/CT|3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body
214364346|NCT02666547|RADIATION|18F-FET PET/CT|200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull
214364347|NCT05420103|OTHER|Accelerated Stroke Ambulation Program|Stroke Rehabilitation Program
214364348|NCT02329054|DRUG|Favipiravir|"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight."
214364349|NCT00512395|DRUG|epidural analgesia (Duracain/Fentanyl/Naropin)|naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
214364350|NCT02535910|DIETARY_SUPPLEMENT|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
214490489|NCT06851494|DEVICE|PMMA|Safety and efficacy evaluation of PMMA LinneaSafe 30% use for gluteal augmentation. Linnea Safe is a water-based gel containing Polymethylmethacrylate (PMMA) in concentrations of 2%, 10% or 30%. LInnea Safe is indicated for facial and body volumetric correction in cases of lipodystrophy due to the use of antiretrovirals in HIV-positive patients. It is also indicated for facial volumetric correction, and can be used in nasolabial folds, glabellar lines, corners of the mouth, upper lip lines, chin lines/chin lines, in the malar region, in acne scars, on the nose, to increase lips and facial contour.
214490490|NCT06816199|OTHER|Hyperbaric oxygen exposure|Between 1 week and 3 months after the traumatic brain injury, participants will receive hyperbaric oxygen therapy on a 2.0 ATA protocol for 60 minutes once a day, five times a week.
214490491|NCT06865430|DRUG|Tamsulosin Hydrochloride|Alpha blockers will be started and symptoms will be questioned.
214490492|NCT06865430|OTHER|Sham|Patients who were not started on alpha blockers will constitute this group.
214490493|NCT04446442|DEVICE|tDCS|A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
214490494|NCT06818435|DEVICE|Myval THV series|Transcatheter Aortic Valve Implantation
214490495|NCT06841874|DRUG|Taletrectinib|Oral capsule
214364351|NCT02535910|DIETARY_SUPPLEMENT|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
214364352|NCT02535910|DIETARY_SUPPLEMENT|Control|Subjects are asked to consume a breakfast without vitamin D
214490496|NCT06751212|PROCEDURE|Radiofrequency ablation alone|Endoscopic radiofrequency ablation (RFA) consists of delivering a 465 KHz energy waveform to the diseased tissue through an array of bipolar electrodes. The electrodes are mounted externally to the balloon, on an articulating platform attached to the distal end of the endoscope, or on a flexible catheter that penetrates the scope. The principle of radiofrequency ablation is that the action of high-frequency alternating current (HFAC) induces the movement of charged particles within the tissue to generate heat, which results in evaporation of water inside and outside the cell, drying, and solidifying and shedding to the point of aseptic necrosis.RFA has been demonstrated to safely, effectively, and durably eradicate early stage tumors of Barrett's esophagus as well as gastric low-grade endoepithelial neoplasia, and is said by a consensus of experts to be capable of treating moderately severe atrophic enterocolitis that has not yet progressed to gastric low-grade intraepithelial neoplasi
214490497|NCT06780761|OTHER|simulation training|The author further demonstrated taking body temperature, heart rate and its characteristics, respiratory rate and saturation, blood pressure and pain assessment in line with previously created cases on the NOELLE® Maternal Birthing Simulator with Advanced Resuscitation Neonatal M-W45111 to the students deployed in the intervention group. Furthermore the students were allowed to work individually on the infant simulator, their questions were answered and feedback was given to them. Students were also offered free time to work on the infant simulator. One week after the training, before proceeding with the clinical practice, the students were individually assessed on measuring the vital signs by 2 different observers and were administered the post-tests.
214490498|NCT06780761|OTHER|Classical training|Before proceeding with the clinical practice, the students deployed in the control group were trained on how to measure the five vital signs, which tools to use and why, and normal and abnormal vital sign values by demonstration and explaining on a pediatric nursing manikin. Then, volunteering students were given the opportunity to develop their vital sign measurement skills on a pediatric nursing manikin and feedback was provided to them. One week after the training, all students were individually assessed on measuring the vital signs by 2 different independent observers on the simulator neonatal used in the intervention group and they were administered the post-tests.
214490499|NCT06769230|OTHER|Core strengthening exercise|The participants will perform warm-up exercises including Cat and Camel, spinal movement (spinal flexion and extension cycles), and stretching exercises for the calf, hamstrings, quadriceps and lower back for about 5 minutes. After that, the women will be asked to perform core stability exercises including abdominal hollowing, bilateral knee raise, supine extension Bridge, straight leg rise from prone and alternate arm and leg raise from quadruped. Each exercise will be repeated for 10 times with 7-8 seconds hold and will be increased by four repetitions each week throughout the interventions. During each repetition for every exercise, the patient will be asked to contract her abdominal muscles and maintain this contraction while maintaining her normal breathing pattern.
214490500|NCT06769230|OTHER|sensory motor training|The participants will perform warm-up exercises including neck rotations, arm circles, ankle rotations, trunk rotations, trunk bending and extending for 5-10 mins. After warm up the women performs Bosu ball exercises including Bosu ball one Leg Bridge, Bosu Crunch, Bosu Sit ups, Bosu compressions, Bosu side crunch and Bosu bodyweight squat . Each exercise will be repeated for 6 repetitions in each set. At least 3 sets of each exercise are performed per session. Each exercise will be increased by five repetitions each week throughout the interventions.The total duration of each session is 45 minutes.
214490501|NCT06413576|DIAGNOSTIC_TEST|homocysteine measurement|measuring the serum level of homocysteine
214490502|NCT05789615|DRUG|Letermovir|Letermovir has achieved excellent therapeutic benefits globally but is still in its infancy in China. Letermovir obtained an implied license for a clinical trial in June 2020, and in November 2020, Letermovir submitted and accepted four new drug marketing applications in China, including injection and tablet formulations. On December 31, 2021, the China National Medical Products Administration (NMPA) approved letermovir for cytomegalovirus (CMV) seropositive adult recipients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) \[R+\] prevention of cytomegalovirus infection and cytomegalovirus disease. The commercial launch of letermovir is estimated to be in August 2022.
214490503|NCT06755242|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
214490504|NCT06768255|DRUG|Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT|Abiraterone Acetate（II）
214490505|NCT06768255|DRUG|Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT|Abiraterone acetate 1000 mg
214679688|NCT03749993|OTHER|Screening|Use of bpMRI for opportunistic prostate cancer screening.
214975031|NCT05418829|DRUG|AT-007|AT-007 20 mg/kg once daily
214975032|NCT04773223|PROCEDURE|Open surgery and complex EVAR due to AAA|"There will be two cohorts:~1. Patient undergoing open surgery~2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)"
214975033|NCT02830568|PROCEDURE|open donor nephrectomy|open donor nephrectomy
214975034|NCT02830568|PROCEDURE|standard and hand-assisted laparoscopic donor nephrectomy|standard and hand-assisted laparoscopic donor nephrectomy
214975035|NCT02830568|PROCEDURE|laparoscopic robotic-assisted nephrectomy|laparoscopic robotic-assisted nephrectomy
214364353|NCT03505112|OTHER|Goal-directed therapy|"The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).~After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI \<10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of \<10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion."
214490506|NCT04478279|DRUG|ST101|ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm
214490507|NCT04478279|DRUG|Temozolomide|Temozolomide
214490508|NCT04478279|RADIATION|Radiation|Radiation
214490509|NCT06892782|OTHER|Hot Water Pack Application|A hot water pack heated to 40-42°C will be applied to the lumbar region of the patient for 20 minutes at three intervals per day during the first 48 hours post-surgery.
214490510|NCT06796751|GENETIC|DNA/RNA sequencing and bioinformatic data analysis|"DNA will be extracted from peripheral blood or from somatic tissues. In some cases a skin biopsy will be performed to obtain fibroblasts for further analysis (DNA/RNA extraction and preparation of cell culture for high-throughput genomic and epigenomic technique (Hi-C).~LRS will be performed on extracted DNA using Oxford Nanopore Technology by two different approaches:~* Target, in samples with monoallelic alterations in genes related to autosomal recessive disease;~* Genomic in other cases.~Sequencing data will be analyzed through a dedicated bioinformatics pipeline, to reconstruct the tridimensional structure of chromatin and the regions"
214490511|NCT06845098|PROCEDURE|Total thyroidectomy|Total thyroidectomy
214490512|NCT06845098|PROCEDURE|Total thyroidectomy + RAIT|Total thyroidectomy + RAIT
214490513|NCT06845098|PROCEDURE|Thyroid one-sided lobe + isthmus resection|Thyroid one-sided lobe + isthmus resection
214490514|NCT06627855|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
214364354|NCT03818672|DRUG|Rifaximin|Rifaximin 550 MG BID
214364355|NCT03096405|DIAGNOSTIC_TEST|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus
214364356|NCT02215122|DRUG|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
214490515|NCT06627855|PROCEDURE|Sham treatment|The techniques in the therapy will be applied by imitating the techniques in the therapy for the fascial distortions determined according to the Manual Therapy Based on the Fascial Distortion Model.
214490516|NCT06418633|OTHER|60-minute walking test|Treadmill walking test in the morning, 2 hours after breakfast, following a clinical examination, resting 12-lead electrocardiogram and blood pressure measurement. After a 3-minute warm-up and walking of speed 2.5 km per hour, no incline, the speed and incline are gradually increased to reach a target heart rate close to the theoretical ventilatory threshold, around 70% of the theoretical maximum value (evaluated by Astrand's formula: 220-age), i.e. aerobic conditions of moderate intensity so that prolonged effort can be maintained. Test performed in presence of a physician trained in stress testing. Emergency cart and defibrillator available in the department. Intra-hospital vital emergency protocol in place, with resuscitation teams on standby. The cardiology department, in the same building, can be contacted in the event of a cardiological abnormality during the test or recovery. The test takes 60 minutes, including a 3-minute initial warm-up.
214490517|NCT06418633|DIAGNOSTIC_TEST|Static blood test|33.3 ml of blood will be taken from each participant whilst at rest, before undergoing the 60-minute walking test
214490518|NCT06418633|DIAGNOSTIC_TEST|Post-effort blood test|33.3 ml of blood will be taken from each participant immediately after undergoing the 60-minute walking test.
214490519|NCT06418633|OTHER|Electrocardiogram|An electrocardiogram will be carried out throughout the exercise period and during the first 30 minutes of recovery.
214490520|NCT06418633|OTHER|Blood pressure monitoring|Blood pressure will be monitored out throughout the exercise period and during the first 30 minutes of recovery.
214490521|NCT06909279|BEHAVIORAL|The Hanen Centre's More Than Words® program|The Hanen Centre's More Than Words® program is a globally used, parent coaching intervention delivered by speech-language pathologists (SLPs) to parents of children who have social communication challenges, which includes children with a confirmed or suspected diagnosis of autism. The training program is designed to provide parents with the tools, strategies, and support they need to help their children reach their full communication and social interaction potential.
214490522|NCT06901635|OTHER|Dual Task|In our study, manual dexterity and cognitive task performance during a dual task will be evaluated. Box and Block Test was used to assess dexterity and 4 different cognitive functions were used as cognitive tasks. Previous studies used one or two cognitive tasks when examining the relationship between cognitive task and dexterity performance during a dual task. This study will examine the effect of different cognitive tasks such as attention, memory, executive functions and working memory on the motor task requiring dexterity during a dual task.
215084733|NCT06330103|OTHER|Easy EF|AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.
214364357|NCT02215122|DRUG|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
214364358|NCT02215122|DRUG|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
214364359|NCT00006231|PROCEDURE|quality-of-life assessment|
214364360|NCT00006231|PROCEDURE|standard follow-up care|
214364361|NCT00006231|RADIATION|radiation therapy|
214490523|NCT06865287|OTHER|STR Group|"Both TPCT and STR groups will follow identical underwater rugby training sessions. Structure: Warm-up (15%): Land-based mobility (5 min) + in-water rondos (10 min). Small-Sided Games (30%): Tactical principles via modified scenarios. Full-Team Games (45%): 6v6, 5-min games with 3-min recovery. Cool-down (10%).~Training includes 20 sessions: 8 defensive (Containment, Recovery) and 12 offensive (Penetration, Offensive Coverage, Space).~SSGs focus on tactical principles:~Containment (4v4, restricted defensive movement) → Defensive positioning, communication.~Recovery (5v6, interception-based) → Quick transitions, passing accuracy. Penetration (4v2, lane-based) → Offensive coordination, defensive pressure. Offensive Coverage (6v6, restricted movement) → Off-the-ball play, passing options.~Space (3v4, defenders in pairs) → Forward movement, spatial awareness."
214679689|NCT02260193|DRUG|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
214679690|NCT02260193|DRUG|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
215084734|NCT06608381|PROCEDURE|Arm I (Total omentectomy),|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
215084735|NCT06608381|PROCEDURE|Arm II (Partial omentectomy)|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
215084736|NCT05257148|DRUG|Zofenopril 30 mg|Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
215084737|NCT05257148|DRUG|Nebivolol 5 mg|Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
215084738|NCT05257148|DRUG|Zofenopril 30 mg + Nebivolol 5 mg|Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
214364362|NCT03371875|BEHAVIORAL|Automated transition care reminders|The CHICA system will gather the elements of the TRAQ questionnaire and report the specific areas of deficiency to the physician. If a patient reaches the point of care transition (18 years), then an automated email is sent to a clinic nurse.
214490524|NCT06865287|OTHER|TPCT Group|"Both TPCT and STR groups followed identical underwater rugby training: Warm-up (15%), SSGs (30%), Full-Team Games (45%), Cool-down (10%). Training included 20 sessions: 8 defensive (Containment, Recovery) and 12 offensive (Penetration, Offensive Coverage, Space).~SSGs focused on tactical principles:~Containment (4v4) → Defensive positioning, communication. Recovery (5v6) → Quick transitions, passing accuracy. Penetration (4v2) → Offensive coordination, defensive pressure. Offensive Coverage (6v6) → Off-the-ball play, passing options. Space (3v4) → Forward movement, spatial awareness. The TPCT group engaged in 10-min reflective discussions post-warm-up, SSGs, and games. Prompts included: What key moments defined the activity? How effective were our decisions? How well did we contain attackers? What hindered or helped recovery? How could we improve movement and space usage? Players progressively led discussions, enhancing tactical awareness."
214490525|NCT06761664|OTHER|Platysma Exercise Group|The participants in this group will perform a platysma exercise for 7 days following third molar extraction surgery.
214490526|NCT06761664|OTHER|Control (Standard treatment)|Participants in this group will receive routine treatment following third molar extraction.
214490527|NCT06783114|BIOLOGICAL|Recombinant Botulinum Toxin Type A for injection (YY001)|Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort)/ 300 U (medium dose cohort)/ 400 U (high dose cohort).
214490528|NCT06783114|BIOLOGICAL|BOTOX®|Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort).
215084739|NCT07006649|DIAGNOSTIC_TEST|Opthtalmologic diagnosis tests|Volunteer will be tested with : measurement of visual acuity, slit-lamp examination, fundus examination, optical coherence tomography
215084740|NCT00662376|DIETARY_SUPPLEMENT|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
214975036|NCT04887363|BEHAVIORAL|Core exercise|Participants will receive12-week, 60 minutes, 36-session exercise-based core stability training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
214975037|NCT04887363|BEHAVIORAL|Tai Chi exercise|Participants will receive 12-week, 60 minutes, 36-session Tai Chi exercise training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
215084741|NCT05206071|BIOLOGICAL|CD19+22 CAR-T cells|Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
214364363|NCT02400138|OTHER|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
214975038|NCT02190188|DEVICE|Wedge Insole 5mm|
214364364|NCT02400138|OTHER|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
214975039|NCT02190188|DEVICE|Knee Brace|
214975040|NCT03556033|DRUG|Dapagliflozin|8 weeks treatment with dapagliflozin on top of insulin treatment
214975041|NCT03556033|DRUG|Placebo oral capsule|8 weeks treatment with placebo capsules on top of insulin treatment
214975042|NCT03658291|DRUG|Sanjin tablets|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.
214975043|NCT03658291|DRUG|Sanjin tablets simulants|levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
214975044|NCT03658291|DRUG|Levofloxacin|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
214975045|NCT04578366|DEVICE|Extracorporeal Shockwave Therapy|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
214364365|NCT04952506|DRUG|CKD-349 F1 Tab.|1T Single does
214975046|NCT04578366|OTHER|Conventional Treatment|hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
214975047|NCT01944657|DEVICE|Supplemental TMS|Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.
214975048|NCT01944657|DRUG|Standard Medication Monotherapy|These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
214975049|NCT02067858|RADIATION|Stereotactic Radiosurgery|
214364366|NCT04952506|DRUG|CKD-349 F2 Tab.|1T Single does
214679691|NCT02260193|DRUG|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
214679692|NCT05328778|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
214975050|NCT06001671|DRUG|BEBT-109|"BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd"
214975051|NCT01699750|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
214975052|NCT01699750|DEVICE|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
214975053|NCT01699750|DEVICE|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
214364367|NCT04952506|DRUG|D113 Tab.|1T Single does
214364368|NCT03288116|DIAGNOSTIC_TEST|Scheimplug imaging and contrast and sensitivity test|examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
214364369|NCT03221387|DEVICE|Humidified nasal high flow with oxygen|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
214364370|NCT03352791|BEHAVIORAL|DSM-H Hospice Edition performance improvement program|Patients in the performance improvement group will receive care from a care team who has received the DSM-H Hospice Edition performance improvement program
214364371|NCT03352791|BEHAVIORAL|Usual Care|control will receive usual care from a care team who has not received the performance improvement program.
214364372|NCT04944641|BEHAVIORAL|education on epilepsy|education on epilepsy, including epilepsy diary, pamphlet，discussion between patients and phone visits and so on
214364373|NCT04944641|DRUG|routine and proper antiepileptic drugs|routine and proper antiepileptic drugs
214364374|NCT03959462|DEVICE|real anodal transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
214364375|NCT03959462|DEVICE|sham transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
214364376|NCT02622854|PROCEDURE|plasma exchange|see arm description
214364377|NCT02622854|DRUG|conservative treatment|see arm description
214364378|NCT01474733|OTHER|educational intervention|series of lectures and workshops on health literacy
214364379|NCT04127838|BEHAVIORAL|Low Vision Occupational Therapy|Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
214364380|NCT00553696|DRUG|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
214364381|NCT00553696|DRUG|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
214364382|NCT00553696|DRUG|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
214364383|NCT00243880|DRUG|lovastatin|investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
214364384|NCT06221579|OTHER|No intervention, interviews with MCI patients as part of the development phase|No intervention, interviews with MCI patients as part of the development phase
214364385|NCT05845320|OTHER|ICIQ-UI SF questionnaire|validated arabic short form of ICIQ on urinary incontinence
214364386|NCT02507648|DRUG|Oseltamivir|1 tablet contains 75 mg oseltamivir
214364387|NCT02507648|DRUG|Tamiflu®|1 tablet contains 75 mg oseltamivir
214364388|NCT01723722|DRUG|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
214679693|NCT06047431|DRUG|QL1706H|QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
214679694|NCT00624130|DRUG|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
214679695|NCT00624130|DRUG|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
214975054|NCT01699750|DEVICE|BIOTRUE®|Contact lens care system, Phase 2
214975055|NCT01699750|DEVICE|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
214975056|NCT01699750|DEVICE|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
214975057|NCT00512525|DRUG|Ghrelin and saline (as placebo)|Intravenous infusion
214975058|NCT00664586|DRUG|Terameprocol (EM-1421)|Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
214975059|NCT02518334|OTHER|Alcohol consumption|28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
214679696|NCT03141801|DEVICE|DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training|cuff is inflated to 80% of an individuals limb occlusion pressure
214679697|NCT03141801|OTHER|Eccentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum
214679698|NCT03141801|OTHER|Concentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum
215084742|NCT05090514|BEHAVIORAL|Reading and Growth Mindset|Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
215084743|NCT05090514|BEHAVIORAL|Wait-list Control|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
215084744|NCT06631378|PROCEDURE|Transverse groin incision|The transverse incision is made parallel to the inguinal ligament either superiorly or inferiorly to the skin crease directly over the femoral artery. The subcutaneous tissue is dissected in the transverse direction till Scarpaes fascia after which the dissection is performed in the longitudinal direction along the line of the vessels. The lymphatic vessels are spared as much as possible. Any damaged lymph vessels are closed with surgical clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage. In case of difficulty with proper access to the femoral arteries, the incision can be extended either medially, laterally, or vertically.
215084745|NCT06631378|PROCEDURE|Longitudinal incision|The longitudinal incision is made directly over the femoral artery from the inguinal ligament. The subcutaneous tissue is dissected along the line of the vessel sparing the lymphatic vessels as much as possible. Any damaged lymph vessels are closed with clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage.
215084746|NCT05934708|BEHAVIORAL|Eccentric leg extension|Participants will complete a 10 x 10 eccentric leg extension on a Cybex Norm dynamometer. Upon arrival, participants will be asked their perceived readiness to perform on a 11 point numeric rating scale. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump. Half way through each set (i.e., after the 5th repetition) participants will be asked to rank their level of difficulty on a 11 point OMNI Res scale. This will occur during each set. Participants will have follow up blood draws, measures of muscle function (i.e, jump height) and soreness measured immediately after and 24 and 48 hours post-exercise.
214364389|NCT01723722|DRUG|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
214364390|NCT02771743|DRUG|Cisplatin|
214364391|NCT02771743|DRUG|Doxorubicin|
214364392|NCT02771743|DRUG|Etoposide|
214364393|NCT02771743|DRUG|Cyclophosphamide|
214364394|NCT02771743|DRUG|Ifosfamide|
214364395|NCT02771743|DRUG|Carboplatin|
214364396|NCT02771743|PROCEDURE|Tandem HDCT/auto-SCT|
214364397|NCT02771743|RADIATION|Radiotherapy|
214364398|NCT02771743|DRUG|Interleukin-2|
214364399|NCT02771743|DRUG|Isotretinoin|
214364400|NCT02771743|RADIATION|MIBG|
214364401|NCT03511833|DRUG|Morphine|IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----\> 0.1 ml/kg
214364402|NCT03511833|DRUG|Ketamine|IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---\> 0.02ml/kg
214364403|NCT02635802|DRUG|Remifentanil|"a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.~Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min."
214364404|NCT02635802|DRUG|Lidocaine|lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
214364405|NCT02635802|DRUG|Remifentanil+Lidocaine|a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
214364406|NCT02635802|DRUG|Midazolam|midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
214364407|NCT04292249|OTHER|Blood sampling|Analysis will be performed using commercially available analyses (suPARnostic® kit (validated to measure suPAR concentrations between 0.6 and 22 ng/mL) (ViroGates)). HsCRP will be measured by high sensitivity CRP assays (Tina-quant hs-CRP latex assay (validated to measure CRP concentrations between 0.3 - 20 mg/L) (Roche/Hitachi)). In patients with CRP\>20 mg/L a regular CRP-measurement will be performed.
214679699|NCT02942550|DRUG|Methylnaltrexone bromide (Relistor®).|
214364408|NCT02276222|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
214364409|NCT02276222|DRUG|Spiriva® 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
214364410|NCT06324266|DRUG|Cyclophosphamide|Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.
214679700|NCT02942550|DRUG|Sodium Chloride 9mg/mL|
214490529|NCT06783114|BIOLOGICAL|Placebo|Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection.
214679701|NCT02290639|BEHAVIORAL|Brief Cognitive Behavioral Treatment|Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
214364411|NCT06324266|DRUG|Lenalidomide|Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Lenalidomide monotherapy for 2 years.
214364412|NCT03668587|OTHER|Troponin Protocol|Feasibility and security of a rapid rule-out and rule-in troponin protocol in the management of NSTEMI in an Emergency Departement.
214364413|NCT05290831|DEVICE|VitalPatch|The VitalPatch continuously monitors skin temperature, activity, and electrocardiography.
214364414|NCT02115880|BEHAVIORAL|Prevention programme|Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
214364415|NCT05085925|BEHAVIORAL|Cognitive behavioral mindfulness intervention|The group that receives mindfulness-based stress reduction at their entry into the study will have 7 sequential sessions during 3 months, and later have a booster session in month 5
214364416|NCT05085925|BEHAVIORAL|Cognitive behavioral mindfulness intervention after 3-month wait list|Wait-list control patients will get no intervention at the start of the study and instead will be contacted by study personal 7 times to care for the patient in order to control for the 7 sessions performed in the intervention group. After three months they will be offered mindfulness-based stress reduction as 8 sequential sessions.
214364417|NCT06495931|DRUG|HRS-1780 tablets|HRS-1780 tablets, three times
214364418|NCT06495931|DRUG|HR20033 tablets|HR20033 tablets, nine times
214364419|NCT06495931|DRUG|HRS-7535 tablets|HRS-7535 tablets ，three times or nine times
214364420|NCT02680548|DRUG|0.9% saline|
214364421|NCT02680548|DRUG|0.25% bupivacaine hydrochloride injectable suspension USP|
214364422|NCT02680548|DRUG|4mg/cc methylprednisolone acetate injectable suspension USP|
214679702|NCT02290639|BEHAVIORAL|Minimal Contact|Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
214679703|NCT00876174|PROCEDURE|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
214975060|NCT00963534|DRUG|lenalidomide, bendamustine, rituximab|"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."
214364423|NCT05166044|BIOLOGICAL|EV71 Inactivated Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co,And inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
214364424|NCT00838955|DRUG|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
214364425|NCT02650050|RADIATION|Micropulsed laser photocoagulation|Micropulsed laser photocoagulation after 3 anti-VEGF injections
214490530|NCT06871059|BEHAVIORAL|Adapted Diabetes Prevention Program|Participants assigned to this group will participate in a group-based behavioural change program to improve diet and increase physical activity levels during 12 months.
214490531|NCT06871059|BEHAVIORAL|Usual Care|Participants assigned to this groups will receive usual care according to national guidelines
214975061|NCT00963534|DRUG|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
214975062|NCT02737358|DRUG|N-acetylcysteine (NAC)|NAC or matched placebo will be given to study participants for 8 weeks.
215084747|NCT06699589|BEHAVIORAL|Old SCHOOL Hip-Hop (Dementia Education)|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
214490532|NCT06520371|DEVICE|Percutaneous radiofrequency|For the percutaneous radiofrequency treatment, a medium electrode size will be placed on either side of the knee: one skin electrode on the inside and one on the outside of the knee for 15 minutes.
214364426|NCT05056779|DRUG|Nemolizumab|Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.
214364427|NCT05056779|DRUG|CD14152 placebo|Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
214364428|NCT02840357|OTHER|Purple Wheat Convenience Bars|Whole grain convenience bars manufactured with purple wheat
214490533|NCT06520371|DEVICE|Conventional radiofrequency|For the conventional radiofrequency treatment, a 50 Hz sensory stimulation will be performed with a 10 cm, 22 gauge, 10 mm active tip radiofrequency cannula. After receiving the appropriate sensory and motor stimuli, a radiofrequency of 90°C will be applied for 90 s.
214490534|NCT05061719|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
214490535|NCT04720625|BEHAVIORAL|Adapt2Quit|Motivational text messages and quitline facilitation text messages will be sent to participants; these participants will receive Adapt2Quit (experimental) messages as well as quitline facilitation messages.
214364429|NCT02840357|OTHER|Control Wheat Convenience Bars|Whole grain convenience bars manufactured with ordinary wheat
214364430|NCT03968432|BEHAVIORAL|MIAS&Q|There were two interventions compared in this study: 1) Be Sweet to Babies Videos and Pamphlet; and 2) Be Sweet to Babies Videos, pamphlet, and MIAS\&Q. The Be Sweet to Babies vaccination pain management videos and pamphlet were provided to all participants as this information is publicly available, and demonstrates the effectiveness of the evidence-based recommended vaccination pain management strategies for infants. In addition, a pamphlet was used which was developed in partnership with CHEO and Ottawa Public Health as a knowledge translation tool. Those in the intervention arm were also given MIAS\&Q included five questions and statements based on the MI approach consisted of four scaled questions and two open-ended questions, aimed to present brief informative and affirmative questions and statements to help the parents reflect on their own thoughts and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
214490536|NCT04720625|BEHAVIORAL|Control|Quitline facilitation text messages will be sent to participants; these participants will receive quitline facilitation-only messages.
214490537|NCT03188835|DIETARY_SUPPLEMENT|Diet|A 2 weeks of hypercaloric diet supplemented with fructose or glucose
214490538|NCT03188835|OTHER|cold exposure|Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
214490539|NCT03188835|RADIATION|18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
214490540|NCT03188835|RADIATION|11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
214490541|NCT03188835|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
214490542|NCT03188835|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
214490543|NCT03188835|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
214490544|NCT03188835|DEVICE|MRI/MRS|Visceral and cervico-thoracic MRI and MRS acquisition.
214679704|NCT00876174|PROCEDURE|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
214490545|NCT03188835|DEVICE|Electromyogram (EMG)|Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
214490546|NCT03188835|DEVICE|DXA|Lean mass will be determined by dual-energy X-ray absorptiometry
214490547|NCT03188835|DEVICE|Indirect calorimetry|VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
214490548|NCT06762990|RADIATION|Plain radiographs|Plain radiographs, including the lumbar spine, pelvis, and the upper half of both femora, will be obtained using the lowest radiation dose possible. The radiographs will be obtained in five positions representing the Muslim Prayers positions, namely 1-standing, 2-Sitting in 90 degrees (both 1 and 2 are the standard positions obtained in all previous studies), 3-bowing (Ruku), 4-prostration (sujud), and 5-sitting with knees bent (Tashahud).
214490549|NCT06762912|OTHER|Passive application of BFR cuff|The first experimental session will start by conducting the one repetition maximum (1-RM) test of unilateral knee extension of the dominant leg, in which the dominant side was identified by asking the participants which side they will use to kick a ball. Before conducting the 1-RM test, 5 minutes warm-up on the cycle ergometer at 75W will be done. Calibration of the dynamometer will be done before operating the machine with each participant, then the participant will be positioned on the dynamometer seat comfortably with ensuring the back is supported and the knee is aligned with the axis of rotation. The participant will be asked to complete one successful repetition of knee extension through full range of motion (ROM), with increasing load until the participant can no longer complete full knee extension ROM, 3 minutes of rest will be allowed between attempts until the 1-RM is identified.
214490550|NCT06762912|OTHER|Resistance exercise with BFR|"For both experimental sessions 2 and 3, the order of exercise condition will be randomly selected, either to be (1) the application of BFR cuff with resistance exercise, or (2) resistance exercise without the application of BFR cuff to decrease the incidence of learning effect. Cuff pressure during the application of BFR will be standardized to 50% of AOP.~The resistance exercise for both experimental sessions 2 and 3 will be exactly similar and will involve four sets of isometric knee extensions at an intensity of 20% of 1-RM with repetitions of 30, 15, 15, and 15 by using the isokinetic dynamometer machine, which has a good to excellent test-retest reliability for knee extension movement with ICC value of 0.95-0.99. To minimize cognitive and neuromuscular fatigue, the experimental sessions will be separated by a minimum of three days (72 hours)."
214490551|NCT06762912|OTHER|Resistance exercise without BFR|"For both experimental sessions 2 and 3, the order of exercise condition will be randomly selected, either to be (1) the application of BFR cuff with resistance exercise, or (2) resistance exercise without the application of BFR cuff to decrease the incidence of learning effect. Cuff pressure during the application of BFR will be standardized to 50% of AOP.~The resistance exercise for both experimental sessions 2 and 3 will be exactly similar and will involve four sets of isometric knee extensions at an intensity of 20% of 1-RM with repetitions of 30, 15, 15, and 15 by using the isokinetic dynamometer machine, which has a good to excellent test-retest reliability for knee extension movement with ICC value of 0.95-0.99. To minimize cognitive and neuromuscular fatigue, the experimental sessions will be separated by a minimum of three days (72 hours)."
214679705|NCT02389946|DEVICE|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
214679706|NCT02389946|DEVICE|Xience DES|
214679707|NCT01377467|DRUG|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
214679708|NCT00800761|DRUG|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
214679709|NCT00800761|DRUG|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
214975063|NCT02737358|OTHER|Placebo|Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
214975064|NCT05251584|DRUG|Mupirocin|Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
214364431|NCT03968432|BEHAVIORAL|Be Sweet to Babies Videos and Pamphlet|The Be Sweet to Babies vaccination pain management videos and pamphlet will be provided to all participants. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of sweet solution during vaccination, will be used. This pamphlet is a knowledge translation tool previously developed in partnership with the Children Hospital of Eastern Ontario (CHEO) and Ottawa Public Health and has been publicly available on the Ottawa Public Health Website since June 2013. The content presented about pain management for infants during vaccination is the same information as the video.
214490552|NCT06774456|DEVICE|instrumented 3D serious game (BE API 3.0)|It is composed of bimanual tasks integrated into a game scenario. The child is first equipped with markers on the upper limb (UL) and trunk (3D motion analysis and electromyography), and he/she can then play the game. There are several tasks ('piloting missions') to evaluate specific UL movements. The UL movements are recorded when the child is playing. The instruments of the set-up (wheel, turbo, etc.) are connected to the game to play and can also be used as measurements (grip strength, etc.). The markers are then removed. The total duration of the game is about 30-45 minutes, including placing/removing markers and the game.
214490553|NCT04566250|COMBINATION_PRODUCT|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
214490554|NCT04977583|BEHAVIORAL|Unmet Need Screening|"Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization."
214490555|NCT04977583|BEHAVIORAL|Unmet Need Referral - Resource Sheet|Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.
214490556|NCT04977583|BEHAVIORAL|Unmet Need Referral Assistance|Participants receive assistance from a Social Worker (SW) to facilitate connection to resources that can help to address unmet need(s) identified in the index screen. Assistance includes 1) conducting a standardized bio-psychosocial assessment; 2) motivational interviewing methods to uncover details of the Veteran's unmet needs and identify barriers to resolving the unmet needs, and; 3) developing an action plan for the Veteran to connect with resources and address needs. The SW will conduct initial follow-up by phone one week after the interview/action plan development, with planned subsequent phone outreach every two weeks for up to seven weeks.
214490557|NCT06952413|DRUG|Rituximab(Genetical Recombination)|Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.
214975065|NCT05251584|DRUG|Gentamicin|Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
214364432|NCT05176275|DIAGNOSTIC_TEST|68Ga-NOTA-RP25|The proliferation and distribution of CD19 CAR-T cells in lymphoma patients were investigated by PET / CT after injection of 68Ga-NOTA-RP25
214364433|NCT06128668|BEHAVIORAL|Yoga|Yoga will be applied
214364434|NCT02716948|OTHER|Laboratory Biomarker Analysis|Correlative studies
214364435|NCT02716948|BIOLOGICAL|Nivolumab|Given IV
214364436|NCT02716948|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
214364437|NCT03155789|PROCEDURE|Lumbar Fusion|"Standard Transforaminal Lumbar Interbody Fusion (S TLIF)~Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)~AxiaLIF Fusion"
214364438|NCT00255957|DRUG|HES administration|
214364439|NCT00255957|DRUG|Hydroxy Ethyl Starch administration to stroke patients|
214364440|NCT03645759|BEHAVIORAL|I'm Whole|I'm whole will provide 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration.
214364441|NCT03645759|OTHER|Education + usual care|Will receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
214364442|NCT03285425|OTHER|Natural history|Parent interview
214975066|NCT03622762|DRUG|green tea extract|Capsules of green tea extract, 400 mg twice a day, fasting
214975067|NCT03622762|DRUG|Placebo|Placebo capsules, 400 mg twice daily fasting
214975068|NCT02043977|DRUG|propofol injectable emulsion|
214975069|NCT01284868|DRUG|mirabegron|oral
214975070|NCT01284868|DRUG|Bisoprolol|oral
214975071|NCT01284868|DRUG|propranolol|oral
214975072|NCT01284868|DRUG|placebo|oral
214975073|NCT02119299|DEVICE|SMART device|Sensor Monitored Alimentary Restriction Therapy (SMART) device
214364443|NCT02264522|OTHER|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
214364444|NCT02264522|OTHER|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
214364445|NCT02264522|OTHER|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
214364446|NCT02264522|OTHER|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
214364447|NCT03126825|DEVICE|CP910/CP920 with noise reduction on|This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.
214975074|NCT06019871|PROCEDURE|Dialysis|Patients who have decided for dialysis either center haemo-dialysis or peritoneal dialysis
214364448|NCT03126825|DEVICE|CP910/CP920|The approved CP910 or CP920 Sound Processor.
214364449|NCT04109014|OTHER|FASTLANE II|"The intervention will consist of nine weekly hour-long individual counseling sessions. The FL II sessions utilize a combination of Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) to reduce sexual risk behaviors and mental health symptoms. Thus, individuals develop a toolbox for mood self-management to improve emotional self-regulation and reduce maladaptive coping mechanisms to minimize drug and sex risk behavior. Participants will be considered as completing the FASTLANE Intervention upon completion of the nine weeks of sessions."
214364450|NCT05751122|OTHER|Dynamic flex cast with neurodevelopmental treatment|"Neurodevelopmental therapy in combination with dynamic flex cast to treat experimental group.~Three times a week, 1 hour session per day.~Dynamic flex casting is casting which manipulate bone alignment and maintains range of motion or sustained stretch. Casting will be changed weekly for 3 months.~Neuro developmental approach is individualized treatment which is attuned to each child's specific problems, aims and goals.~Key elements in NDT are: facilitation (using sensory inputs to improve motor performance), management of compensatory motor behavior, and an overall management strategy (a 24-hour interdisciplinary management approach) NDT involves task specific postures and movements."
214364451|NCT05751122|OTHER|Rigid Ankle foot Orthosis with neurodevelopmental treatment|"Rigid ankle foot orthosis will be applied to ankle joint at the start of intervention.~Neurodevelopmental treatment will be applied to both groups with protocol; Three times a week, 1 hour session per day.~Assessment on 1st day,6th week and 12th week"
214364452|NCT01873430|DRUG|Melatonin|
214490558|NCT06952413|DRUG|Placebo|Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.
214490559|NCT06291233|BEHAVIORAL|Virtual Interview Training (VIT)|Teachers will administer the intervention (Virtual Interview Training) with the student participants. University of Michigan research staff will train all teachers (including sites in California) and will provide support as necessary throughout the intervention delivery process. Surveys will be captures several times throughout delivery as delivery is expected to be anywhere between 4 to 6 weeks long.
214490560|NCT06291233|BEHAVIORAL|Services-as-usual|Participants will receive services-as-usual at participants school or program for approximately 6 weeks. Those that are in the active control group will receive access to the e-learning content of the Rita/Travis intervention (not the practice interviews) and will be able to review the e-learning content with teacher's supervision. In addition, this group will review a series of video conversations with autistic adults about navigating the pathway to a career. Surveys will be collected at different time points after randomization.
214490561|NCT02118870|DRUG|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
214490562|NCT02118870|DRUG|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
214364453|NCT03652974|DRUG|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
214364454|NCT03652974|DEVICE|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
214490563|NCT01577524|DRUG|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
214490564|NCT01577524|DRUG|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
214490565|NCT02134171|OTHER|Biological and imaging investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide \[BNP\]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
214490566|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 3 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
214490567|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 8 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
214490568|NCT06231472|PROCEDURE|preoperative inferior vena cava measurement|preoperative inferior vena cava measurement
214490569|NCT04047784|DEVICE|Endobronchial ultrasound (EBUS)|"An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.~Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion. At the completion of the imaging the EBUS bronchoscope will be withdrawn."
214364455|NCT03652974|DRUG|amisulpride with Clozapine|amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
214364456|NCT03652974|DRUG|placebo with Clozapine|placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
214364457|NCT03918746|BEHAVIORAL|internet Attachment-Based Compassion Therapy (iABCT)|"The internet version of Attachment-Based Compassion Therapy (iABCT) will be developed to be totally self-applied over the Internet through the website www.psicologiaytecnologia.com designed by Labpsitec (Laboratory of Psychology and Technology, Universitat Jaume I, and University of Valencia). The iABCT will consist of eight sequential modules: Module 0) Welcome module: approaching to the compassion; Module 1) Preparing ourselves for compassion. Kind attention; Module 2) Discovering our compassionate world; Module 3) Developing our compassionate world; Module 4) Understanding our relationship with compassion; Module 5) Working on ourselves; Module 6) Understanding the importance of forgiveness; Module 7) Consolidating the practice of compassion~The content will present through texts, audios, videos, pictures, vignettes, and interactive exercises. Downloadable PDF files will be available so that users can review them offline."
214364458|NCT01648270|DRUG|buprenorphine|Session 1 Intravenous buprenorphine: 0.2 mg over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3 Intravenous buprenorphine 0.2 mg over 1 hr beginning 1 hr after starting cyclosporine Session 4 Sublingual buprenorphine: 2 mg after cyclosporine.
214364459|NCT05341258|DIAGNOSTIC_TEST|EtCO2|EtCO2
214490570|NCT04975217|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
214364460|NCT05341258|DIAGNOSTIC_TEST|PaCO2|PaCO2
214490571|NCT04975217|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
214490572|NCT04975217|OTHER|Questionnaire Administration|Ancillary studies
214490573|NCT04975217|PROCEDURE|Resection|Undergo standard of care resection
214490574|NCT04975217|PROCEDURE|Therapeutic Colonoscopy|Undergo colonoscopy
214490575|NCT02260973|DIETARY_SUPPLEMENT|Omega-3 (Triglyceride form)|
214490576|NCT06078813|RADIATION|Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)|Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume\_1 (PTV\_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV\_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV\_2 will remain the same through all dose levels. All doses are prescribed to the target volume.
214490577|NCT02422615|DRUG|Ribociclib|Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.
214490578|NCT02422615|DRUG|Fulvestrant|Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
214490579|NCT02422615|DRUG|Placebo|Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
214490580|NCT02034292|DRUG|Clopidogrel|
214975075|NCT00744939|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
214975076|NCT04533178|DEVICE|soft spinal brace|Use of a soft spinal brace 16 hours per day during the 6 week treatment period.
214975077|NCT04533178|OTHER|Resting from all sports activities|Resting from all sports activities
214975078|NCT03151369|DRUG|Morphine|patients with the visual analog scale over 3 will receive morphine
214975079|NCT04341935|DRUG|Linagliptin|5 mg Linagliptin administered by mouth once daily
214975080|NCT04341935|DRUG|Insulin regimen|Standard of care insulin regimen as per hospital protocol
215084748|NCT06699589|BEHAVIORAL|My Plate (Nutrition Education)|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
214364461|NCT02170025|DRUG|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
214364462|NCT02170025|DRUG|Placebo|Participants received matching placebo tid.
214364463|NCT02064543|OTHER|GAITRite|mobility test assessing gait parameters
214364464|NCT02064543|OTHER|ADPM|mobility test assessing gait parameters
214364465|NCT00572195|DEVICE|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
214490581|NCT02034292|DRUG|Aspirin|
214490582|NCT02034292|DRUG|APD791|
214490583|NCT02034292|DRUG|Placebo|
214490584|NCT00998413|BEHAVIORAL|Multifaceted intervention|multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
214490585|NCT00800579|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
214490586|NCT00800579|DRUG|Placebo|Inhaled volume-matched placebo in sterile saline
214490587|NCT01345422|OTHER|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
214490588|NCT03002259|DRUG|Dexamethasone|Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
214975081|NCT01607164|BEHAVIORAL|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
214975082|NCT00180908|DRUG|Etoposide, Ifosfamide, Methotrexate|
214490589|NCT03575624|BEHAVIORAL|Nutritional and goal-setting education, yoga|"This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice"
214490590|NCT01267370|DIETARY_SUPPLEMENT|Soy polysaccharide fiber|"Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and \> 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)"
214490591|NCT00995592|BEHAVIORAL|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
214490592|NCT01639131|DRUG|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
214490593|NCT01639131|DRUG|Docetaxel|intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
214490594|NCT01639131|DRUG|Filgrastim or Pegfilgrastim|filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
214490595|NCT00991549|BEHAVIORAL|interdisciplinary intervention or meeting-seminars|one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
214975083|NCT00180908|DRUG|Doxorubicin, Methotrexate|
214975084|NCT01249911|DIETARY_SUPPLEMENT|Lreuteri|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
214364466|NCT03994302|DRUG|Drug inducing antiphospholipid syndrome|Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
214364467|NCT05477732|DIETARY_SUPPLEMENT|Bifidobacterium longum OLP-01|Bifidobacterium longum OLP-01 is one of probiotics. Subjects in OLP-01 group will supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day for 12 weeks.
214364468|NCT05477732|OTHER|Placebo|Subjects in placebo group will supplement with placebo powder per day for 12 weeks.
214364469|NCT05570955|BEHAVIORAL|Text reminder|weekly text to remind use of drug
214364470|NCT03677011|DIAGNOSTIC_TEST|Andrositol® Test|The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure
214490596|NCT00166322|PROCEDURE|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
214490597|NCT01645566|BEHAVIORAL|instruction|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
214490598|NCT05049421|DIAGNOSTIC_TEST|Echocardiography|Full 2D and 3D echocardiography with special focus on right ventricular function
214490599|NCT04157894|OTHER|Standard long-lasting insecticidal net|Interceptor® (BASF) contains a pyrethroid insecticide
214490600|NCT04157894|OTHER|Chlorfenapyr insecticide treated net|Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
214490601|NCT04157894|OTHER|Piperonyl butoxide long-lasting insecticidal net|PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
214975085|NCT01249911|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
214975086|NCT02856958|PROCEDURE|Nerve decompression|
214975087|NCT02856958|OTHER|Non-operative|Physical therapy
214364471|NCT03677713|PROCEDURE|No nasal packing.|No nasal packing at the end of the surgery
214364472|NCT03677713|PROCEDURE|Nasal Packing|Patients will have nasal packing at the end of the surgery
214364473|NCT01643590|BIOLOGICAL|JVS-100 15 mg dose Injection|Intramyocardial Injection
214975088|NCT02452047|DRUG|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
214975089|NCT02452047|DRUG|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (\~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (\~180 to 360 mg CMS), depending on renal function, once every 12 hours
214975090|NCT02452047|DRUG|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
214975091|NCT02452047|DRUG|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
214975092|NCT01988207|BEHAVIORAL|Vocal Hygiene Training|Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
214364474|NCT01643590|BIOLOGICAL|Placebo Injection|Intramyocardial Injection
214364475|NCT01643590|BIOLOGICAL|JVS-100 30 mg dose injection|Intramyocardial Injection
214364476|NCT01285583|DRUG|TRO19622|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
214364477|NCT06276595|BEHAVIORAL|Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (TODOS)|The TODOS program consists of 11 weekly sessions conducted with girls ages 8-11 and their female caregivers. Five of the 11 sessions will be taught to small groups, and 6 of the Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room.
214975093|NCT01988207|BEHAVIORAL|Flow Phonation Exercises|Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
214975094|NCT04820907|DRUG|HCP1904-1|Take it once daily for 8 weeks orally.
214364478|NCT06276595|BEHAVIORAL|Control condition - 3 Monthly Group Activities in the Community|The control condition consists of 3 group sessions delivered monthly for three months. The first group session will occur at a community center and will consist of a meal and ice breaker activities. The second group session will consist of going to a movie at the local movie theatre The third group session will consist of going bowling at the local bowling alley.
214490602|NCT01681654|BEHAVIORAL|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
214490603|NCT01681654|BEHAVIORAL|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
214490604|NCT03172871|DRUG|Aripiprazole IM Depot|Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
214490605|NCT03172871|DRUG|Aripiprazole tablet|Oral aripiprazole tablets 10 to 20 mg daily
214490606|NCT05004207|DIAGNOSTIC_TEST|99mTc Scintigraphy|"After fasting for at least 8 to 12 hours, standardized meal mixed with 99mTc-sulfur colloid radiolabeled test will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens SYMBIA E dual head (SPECT) scanner in a format of at least 128 x 128 pixels. Anterior and posterior planar images (or a single left anterior oblique image) with the distal esophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and at 24 hours as was used for the initial images.~Next day LHBT will be performed after at least 12 hours of fasting. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analyzed for hydrogen every 15 minutes for 1 hour followed by every half hour for next 2 hour with LACTOFEN 2 device."
214490607|NCT02925988|DEVICE|EEG monitoring|Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
214490608|NCT03789071|DIAGNOSTIC_TEST|External ultrasound evaluation of the airway|Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
214490609|NCT00084435|DRUG|cisplatin|75 mg/m2 IV, Day 1, q 21 days for 3 cycles
214490610|NCT00084435|DRUG|docetaxel|15 mg/m2 IV, Day 1, 1 7 days for 6 doses
214490611|NCT00084435|RADIATION|radiation therapy|200 cGy/day, Days 1-5, q week for 6 weeks
214490612|NCT02956109|DRUG|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
214490613|NCT02956109|DRUG|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
214975095|NCT04820907|DRUG|RLD2001-1|Take it once daily for 8 weeks orally.
214975096|NCT02004223|RADIATION|Dose escalation using stereotactic boost|"This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.~The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.~Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes."
214490614|NCT02956109|DRUG|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
214490615|NCT02524769|DRUG|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
214975097|NCT03830021|BEHAVIORAL|Salt reduction program|Dietary and behavioural change program, led by nutritionists, including low sodium dietary advice; use of aromatic herbs and spices in food instead of salt; motivational activities; food diaries; restrict salty processed foods; eat more fresh foods and seasoning advice; problem solving exercises; digital bulletins; individual counselling reinforced at each clinic visit and shopping counselling at local supermarket.
214975098|NCT03830021|BEHAVIORAL|Healthy lifestyle program|Participants receive an educational healthy lifestyle program that includes 1) methods to cook healthier and the Mediterranean diet based on a high intake of fresh fruit and, vegetables, beans, grain legumes, lentils, nuts, cereals, and olive oil as source of fat; moderate intake of fish, poultry, yoghurt and cheese, low intake of salt, red meat, processed meats and sugar; 2) physical activity; 3) drink more water and reducing alcohol consumption; and 4) sleep education.
214975099|NCT00308867|PROCEDURE|Photodynamic Therapy|
214975100|NCT00308867|PROCEDURE|Cryosurgery|
214364479|NCT00902694|BEHAVIORAL|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
214975101|NCT02908334|DRUG|Sertraline|400 mg/day sertraline
214975102|NCT00288912|BEHAVIORAL|Health Education|12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
214364480|NCT00902694|OTHER|Control|group health classes quarterly with topics not related to weight
214364481|NCT01731236|DIETARY_SUPPLEMENT|Carnitine|Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
214364482|NCT01731236|DIETARY_SUPPLEMENT|Choline|Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
214364483|NCT01731236|DRUG|Antibiotics|Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
214364484|NCT01731236|DRUG|Choline and Aspirin|Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
214364485|NCT01731236|DRUG|Carnitine and Aspirin|Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
214364486|NCT03752216|DRUG|Niraparib|"Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria."
214364487|NCT06566131|BEHAVIORAL|Gamified mobile health app|Participants will receive visualized instructions about the PW use (e.g., search and download the app on App Store, navigate and understand key features, play puzzle games, and track step counts). During the 6-week intervention period, participants will receive reminders on wearing the accelerometer, using the app for potential incentives, and engaging in regular physical activities for health promotion.
214364488|NCT06679751|BEHAVIORAL|ID-TOUCH|ID TOUCH is a multi-pronged intervention to increase HIV testing and PrEP linkage that includes jail-based HIV care process improvements with post-incarceration outreach and linkage to community services.
214364489|NCT04658667|BIOLOGICAL|IHV01|IHV01 consists of the Full-Length Single Chain (FLSC) gp120-CD4 chimera subunit HIV-1 vaccine formulated in aluminum phosphate adjuvant. It is encoded by a synthetic gene, which contains a human codon-optimized HIV (BaL) gp120 sequence followed by human CD4D1D2, with a flexible 20-amino acid linker.
214364490|NCT04658667|BIOLOGICAL|A244|A244 consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE. The A244 gp120 envelope has an 11 amino N-terminal deletion, similar to the A244 protein used in AIDSVAX B/E. The aluminum hydroxide fluid gel (AHFG) adjuvant that is mixed with A244 consists of Rehydragel HPA that is diluted with sterile water for injection to a concentration of 5 + /- 1mg/mL.
214364491|NCT04658667|BIOLOGICAL|ALFQ|ALFQ (Army Liposomal Formulation) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA) with the addition of QS-21.
214364492|NCT04658667|OTHER|Placebo|Normal saline (Sodium Chloride for injection USP, 0.9%) will be used as placebo.
214364493|NCT03743649|DRUG|Haloperidol|Given IV
214364494|NCT03743649|DRUG|Lorazepam|Given IV
214364495|NCT03743649|OTHER|Placebo|Given IV
214364496|NCT03743649|OTHER|Quality-of-Life Assessment|Ancillary studies
214364497|NCT03743649|OTHER|Questionnaire Administration|Ancillary studies
214364498|NCT04969263|BIOLOGICAL|BNT162b2 vaccine (Pfizer/BioNTech)|30 microgram dose
214364499|NCT04969263|BIOLOGICAL|mRNA-1273 vaccine (Moderna)|100 microgram dose
214364500|NCT04314557|DEVICE|Renal denervation|Spyral device. Bilateral renal denervation.
214364501|NCT04058652|DEVICE|transcutaneous electrical nerve stimulation (TENS) unit|The transcutaneous electrical nerve stimulation (TENS) unit is a noninvasive, inexpensive, battery-operated device that was originally designed to provide modulation of the afferent nervous system to relieve pain. By providing alternating current through cutaneous electrodes, TENS activates large-diameter afferent fibers of the nervous system (A-delta, A-beta, C fibers), whose ascending signals are subsequently relayed to the central nervous system.
214364502|NCT01257906|DRUG|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel applied in the evening for 84 days
214364503|NCT01257906|DRUG|ZIANA®|Topical Gel applied in the evening for 84 days
214364504|NCT01257906|DRUG|Vehicle Control|Topical Gel applied in the evening for 84 days.
214364505|NCT01461876|DRUG|antiretroviral therapy|Standard of care antiretroviral therapy
214364506|NCT01959724|OTHER|Vitrectomy|
214364507|NCT02693743|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
214364508|NCT05316441|BEHAVIORAL|psychoeducation|Positive Psychotherapy is a recently emerged therapy method that works on talents. In the study, success skill development psychoeducation based on positive psychotherapy will be applied.
214364509|NCT01394393|BEHAVIORAL|Experiential-Cognitive Therapy for Obesity|Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, \& Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
214364510|NCT01394393|BEHAVIORAL|Behavioral cognitive Treatment|Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive-behavioral treatment approach described by Cooper and colleagues (Cooper \& Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
214364511|NCT01394393|DIETARY_SUPPLEMENT|Nutritional groups (NT)|5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
214975103|NCT00288912|BEHAVIORAL|Osteoarthritis Self-Management|12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
214364512|NCT04960865|OTHER|Kinesio Taping under tension.|Kinesio tape will be applied to participants under tension.
214490616|NCT05437952|DIETARY_SUPPLEMENT|Taurine and Exercise (Tau+Ex)|"Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks"
214490617|NCT05437952|OTHER|Placebo and Exercise (PL+Ex)|"Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks."
214490618|NCT05437952|DIETARY_SUPPLEMENT|Taurine (Tau)|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
214490619|NCT05437952|OTHER|Placebo (PL)|Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
214490620|NCT01606813|OTHER|Usual Care|Standard care
214490621|NCT01606813|BEHAVIORAL|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
214490622|NCT01606813|BEHAVIORAL|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
214490623|NCT01606813|BEHAVIORAL|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
214490624|NCT05973240|OTHER|Participation in an web-based survey|Patients who agree to participate will access a web-based survey (SurveyMonkey) via social media, mobile messages, or emails. The invitation will provide study details, eligibility criteria, and tasks. Patients will confirm inclusion/exclusion criteria upon access, and those ineligible will opt out. Data collection will take approximately 10 minutes per patient. Collected data will be sent to an electronic data collector and saved as an eCRF file in REDCap. The study will conduct two cross-sectional data collection rounds using web surveys to ensure anonymity. Convenience sampling will target anticoagulated patient associations' webpages and social media (e.g., Feder-AIPA, AICCA). In the second round, participants will be informed not to resubmit if they have already completed the survey to avoid overlapping responses.
214490625|NCT03656211|OTHER|Telephone interview|"Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview."
214490626|NCT05967858|OTHER|observation|no intervention
214490627|NCT04098575|DRUG|Empagliflozin|drug
214490628|NCT02029469|DEVICE|Ascension HRA device|Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
214490629|NCT05274321|DEVICE|Nanodropper|Device used for administering eye drops
214490630|NCT05274321|DEVICE|Standard Eye Dropper|Standard Eye Dropper used for administering eye drops
214490631|NCT03367338|OTHER|Low-phosphate diet|Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
214490632|NCT04630509|PROCEDURE|traumatic cataract extraction|Irrigation/aspiration of traumatic cataract in children with posterior chamber intraocular lens implantation
214490633|NCT03568175|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
214490634|NCT04540003|OTHER|Access to School Based Health Centre|The SBHC will be staffed by a family physician, two pediatricians and a developmental pediatrician, each with at least one half-day of clinic time per week from September through June. The SBHC is also staffed by a clinic coordinator who is responsible for booking appointments on a first-referral, first-serve basis.
214490635|NCT00418795|DRUG|recombinant human porphobilinogen deaminase (Porphozym)|
214490636|NCT03791996|PROCEDURE|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
214490637|NCT01356524|DRUG|Additional vaginal progesterone|The progesterone dose will be raised from 200 mg daily to 300 mg daily
214364513|NCT04960865|OTHER|Kinesio Tape without tension|Kinesio tape will be applied to participants without any tension.
214364514|NCT04960865|OTHER|Rigid Taping|Rigid Taping will be applied.
214364515|NCT04521855|OTHER|Questionnaire|Questionnaires in French on the quality of life, the burden of caregiving and a screening for depressive symptoms, completed during specific interviews.
214364516|NCT05684406|GENETIC|Genotyping|Genotyping by Real Time PCR
214364517|NCT01024608|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
214364518|NCT01024608|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered each morning for two weeks.
214490638|NCT01105975|DRUG|LY2484595|Administered daily by mouth for 12 weeks
214490639|NCT01105975|DRUG|Atorvastatin|Administered daily by mouth for 12 weeks
214490640|NCT01105975|DRUG|Simvastatin|Administered daily by mouth for 12 weeks
214490641|NCT01105975|DRUG|Rosuvastatin|Administered daily by mouth for 12 weeks
214490642|NCT01105975|DRUG|Placebo for LY2484595|Administered daily by mouth for 12 weeks
214490643|NCT01105975|DRUG|Placebo for Statins|Administered daily by mouth for 12 weeks
214490644|NCT00902213|BEHAVIORAL|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
214490645|NCT00902213|BEHAVIORAL|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
214975104|NCT05271565|DIETARY_SUPPLEMENT|Oligomeric enteral feeding|Oligomeric enteral formula
214364519|NCT05225064|BEHAVIORAL|Incentives to be vaccinated|Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
214364520|NCT05225064|DEVICE|Mask|Individuals are given cloth masks
214364521|NCT05225064|BEHAVIORAL|Encouragement to wear a mask|Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
214364522|NCT05225064|BEHAVIORAL|Vaccination made more convenient|Vaccines are conducted at the household-level rather than the village-level
214975105|NCT05271565|DIETARY_SUPPLEMENT|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
214975106|NCT02410759|DRUG|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm IM
214975107|NCT02410759|DRUG|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
214975108|NCT04751617|PROCEDURE|Pulmonary rehabilitation|Pulmonary rehabilitation will include: early mobilization with frequent posture changes and simple exercises in bed taking into account the patient's respiratory tract. Respiratory physiotherapy will also include improving diaphragm function along with training additional respiratory muscles. Active exercises of the upper limbs will be accompanied by gradual muscle strengthening. Aerobic regeneration will be carried out by walking along the hospital corridor, stationary bike and climbing stairs. Body balance therapy in closed systems in front of the mirror will also be included. After kinesiotherapy, the session will end with a vibration massage and relaxation of the whole body. Motivational breathing training will be used every 2 hours, 7 days a week, performed independently by the patient in the ward room. The physiotherapy process will be carried out 6 times a week and lasts 30-45 minutes a day. The duration of rehabilitation depends on the patient's condition: from 7 to 14 days.
214975109|NCT06120725|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
214975110|NCT06120725|DRUG|Clopidogrel|Efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
214975111|NCT01740232|PROCEDURE|trephination|Artroscopic meniskal repair with trephination.
214975112|NCT01740232|PROCEDURE|Normal meniscal repair|Artroscopic meniskal repair without trephination.
214975113|NCT03657069|DEVICE|Blossom|Undergo Implant Breast Reconstruction (IBR) with the Blossom Smart Expander Technology
214975114|NCT03657069|OTHER|Breast-Q -Reconstruction module (preoperative) version 2.0 satisfaction with breasts questionnaire|Ancillary studies
214975115|NCT05672563|DRUG|Saline infusion sonography for evaluation of cesarean scar|The intervention included the usage of balloon-less GIS catheter with a soft tapered tip inserted into the endocervical canal, with no use of a tenaculum or a cervical dilatator. Normal saline is slowly introduced into the uterine cavity via the catheter until achieving satisfactory distension and visualization of the uterine cavity using trans-vaginal ultra-sonographic imaging.
214975116|NCT00000732|DRUG|Sulfamethoxazole-Trimethoprim|
214975117|NCT00000732|DRUG|Zidovudine|
214975118|NCT05300386|DRUG|Escitalopram|We use Escitalopram 5\~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder
214975119|NCT04900454|BIOLOGICAL|DVX201|Single infusion of DVX201, an allogeneic NK cell therapy derived from CD34+ hematopoietic stem cells
215084749|NCT07029425|PROCEDURE|Procedure: craniosacral therapy techniques.|Participants in the experimental group will receive Manual Therapy (MT) designed for this study, which will include craniosacral therapy techniques. The sessions will last 40 minutes and will be conducted twice a week for the first 4 weeks, followed by once a week for the final 4 weeks.
215084750|NCT07029425|PROCEDURE|Placebo Group|The placebo group will receive a dummy treatment with a duration of 40min, twice a week for the firt 4 week, follwed by once a week for the final 4 week.
215084751|NCT04639219|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
214364523|NCT05225064|BEHAVIORAL|Social mobilization campaign to be vaccinated|Village-level social mobilization campaign to be vaccinated
214364524|NCT04491448|BEHAVIORAL|Social needs screening|Interview and referral for non-medical health-related social needs
214364525|NCT06626412|DIAGNOSTIC_TEST|Diagnostic Test: 18F-SynVesT-1 PET|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.
214364526|NCT06626412|DIAGNOSTIC_TEST|Volumetric MRI|Magnetic resonance imaging of brain volume.
214364527|NCT06320860|DEVICE|Kidney Stone Retrieval|Using FlexStone Basket aimability to retrieve kidney stones
214364528|NCT05937724|OTHER|Family Caregiving|Family caregiving and sibling inclusive
214364529|NCT06485076|OTHER|Early Palliative Care|see previous description
214364530|NCT05487664|DEVICE|Transcutaneous Auricular Neruostimulation (tAN)|The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
214364531|NCT02412137|OTHER|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
214364532|NCT06700915|DIETARY_SUPPLEMENT|Diaberine|Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.
214364533|NCT06700915|DIETARY_SUPPLEMENT|Placebo Capsule|Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.
214364534|NCT06698887|DRUG|Idecabtagene vicleucel|As per CA089-1043 study protocol
214364535|NCT04913363|OTHER|Green space|Green space in which activities take place
214364536|NCT03577587|DIETARY_SUPPLEMENT|Silitidil for 21 days|daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
214364537|NCT03577587|DIETARY_SUPPLEMENT|Placebo for 21 days|daily ingestion of Placebo preparation over time period of 3 weeks
214364538|NCT04981678|DRUG|Buprenorphine|Patients randomized to this group will reduce their buprenorphine dose prior to surgery.
214364539|NCT04981678|DRUG|Buprenorphine|Patients randomized to this group will continue their buprenorphine at the full prescribed dose.
215084752|NCT07033286|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
215084753|NCT07033286|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
214364540|NCT06719505|OTHER|ME|Exercises selected with a focus on the major muscle groups. There will be one protocol for the first 3 months and a second protocol for months 4-6, with the number of repetitions for each exercise varying from 3 sets of 8 to 10 repetitions, totaling 18 exercises.
214364541|NCT06719505|OTHER|PE|The stretching and strengthening exercises will target the major muscle groups, and at the end of each session (lasting approximately 60 minutes), the instructor will guide the participant through a relaxation exercise using an EVA foam roller. The exercises were selected to improve overall muscle strength, as traditionally applied in Pilates. There will be one protocol for the first 3 months and a second protocol for months 4-6, with 17 exercises in each protocol, varying from 3 sets of 8 to 10 repetitions.
214364542|NCT06721026|OTHER|Continuous intravenous stable isotope amino acid tracer infusion|During the single 12 h trial day, a primed continuous stable isotope infusion will run in order to assess muscle protein synthesis in the basal (4 h) and post-prandial (8 h) state.
214364543|NCT06721026|OTHER|Amino acid infusion|In order to assess muscle protein synthesis rates during continuous elevated plasma amino acid availability, the amino acid infusion solution Vamin®14 EF will be used. Vamin® 14EF contains 85g amino acids per liter and will be administered in the post-prandial period for 8 hours to ensure a constant rate of amino acid infusion over the full assessment period of the primary outcome measure.
214364544|NCT06722222|PROCEDURE|Gao's triple eversion carotid endarterectomy|The carotid sheath is dissected in front of the sternocleidomastoid muscle to expose sufficient lengths of the CCA, ECA, and ICA. After raising the systolic blood pressure to 180 mmHg and intravenously injecting 1 mg/kg heparin, the superior thyroid artery is lapped and severed, and the CCA is occluded proximally to the CCA plaque, based on the plaque location shown by preoperative CTA and by intraoperative arterial exploration. Subsequently, the ECA and ICA are blocked individually. The ICA is cut diagonally at the CCA fork and the ECA is transected approximately 5 mm above its beginning. The plaque is removed with tweezers after eversion of the ICA. This process is repeated for the ECA. Finally, the long segment of plaque in the CCA is stripped proximally, followed by thorough removal of the debris on the peeling surface using heparin irrigation.
214975120|NCT05319548|OTHER|Purple-Red Carrot Juice|Purple-Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), the non-provitamin A carotenoid, lycopene, as well as anthocyanins
214364545|NCT06722261|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods, grounded in cognitive, sociocultural, and linguistic theories, are applied to interventions that support sign language development in deaf children.
214364546|NCT06732661|PROCEDURE|Preserve pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 10 mm lateral to the esophagus is respected without dissection of pre-cardial fat pad.
214364547|NCT06732661|PROCEDURE|Dissect pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. Dissect the pre-cardial fat pad, and a security distance of 10 mm lateral to the esophagus is respected.
214364548|NCT06732492|DRUG|RD13-02 cell infusion|CAR-T cells
214364549|NCT06732973|DRUG|JS005|JS005：The drug was administered by a single subcutaneous injection
214364550|NCT06732700|OTHER|Integrated Neuromuscular Inhibition Technique and Posture Corrective Exercises.|INIT will be performed for experimental group and then posture corrective exercises will be performed and for control group only posture corrective exercises will be performed
214364551|NCT07064824|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
214364552|NCT07064824|BEHAVIORAL|Computer-Delivered Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
214364553|NCT07064824|BEHAVIORAL|Automated Text Reminders|Scheduled text reminder to take medication
214364554|NCT07081984|BIOLOGICAL|therapeutic tumor vaccine|TI-0093 injection will be administered intramuscularly on Day1, Day8, Day15, Day29 and Day43.
214490646|NCT06062641|DRUG|SR-GDP|Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
214490647|NCT06234683|OTHER|Web-based educational video on pneumococcal vaccination|Participants will receive a link to view a short video on pneumococcal vaccination.
214975121|NCT05319548|OTHER|Red Carrot Juice|Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), and the non-provitamin A carotenoid, lycopene, but does NOT contain anthocyanins..
214975122|NCT05319548|OTHER|Purple Carrot Juice|Purple carrot juice does NOT contain provitamin A carotenoids (beta-carotene, alpha-carotene), nor the non-provitamin A carotenoid, lycopene, but contains anthocyanins.
215084754|NCT07042048|DEVICE|EVD placement - image-guidance assisted|During EVD placement, an image-guided noninvasive systems will be used to assist the operator for EVD catheter tip navigation through a burr hole opening. The use of image-guidance system occurs once during initial EVD placement in this trial.
215084755|NCT07042048|DEVICE|EVD placement - AR assisted|During EVD placement, an AR system will be used to assist the operator for EVD catheter tip navigation through a burr hole opening. The use of AR occurs once during initial EVD placement in this trial.
214975123|NCT03792334|DEVICE|depth of anesthesia|monitoring of depth of anesthesia
214975124|NCT01878799|DRUG|GS-7977/GS- 5885 FDC|The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
214975125|NCT01112319|DEVICE|Elf care|elfcare device
214364555|NCT07087665|DEVICE|Wavelight Plus|"The WaveLight EX500 laser system, in conjunction with INNOVEYES Sightmap, is indicated for use in INNOVEYES Laser Assisted In-Situ Keratomileusis (wavelight plus1 LASIK) treatments:~* or the reduction or elimination of myopia or myopia with astigmatism, in eyes with spherical equivalent (SE) more than -1.00 and up to -9.00 diopters (D), with up to -8.00 D of spherical component (in minus cylinder format) and up to -3.00 D of astigmatic component at the spectacle plane, based on the INNOVEYES Sightmap Measured Refraction,~* in patients with magnitude of the spherical equivalent (SE) difference between the Manifest Refraction (MRSE) and the Sightmap measured refraction SE being less than 0.75D,~* in patients who are 18 years of age or older, and~* for patients with documentation of a stable manifest refraction defined as 0.5 D preoperative spherical equivalent shift over one year prior to surgery."
214364556|NCT07092787|BEHAVIORAL|Smartphone-based behavioral intervention|The proposed study will use a behavioral smartphone-based intervention in a 12-week RCT among clinically diagnosed ADHD adolescents in Hong Kong. Guided by a conceptual framework on SO in ADHD, we will implement specific strategies that counter the potentially addictive qualities of smartphones using built-in smartphone functions that have been previously shown to be effective.
214364557|NCT07092787|OTHER|Self-monitoring of smartphone use|Participants will receive information about the known benefits and risks of SO and activate their smartphones' screentime monitoring setting. They will receive weekly reminders to submit their smartphone usage data.
214364558|NCT06058832|DEVICE|Low-intensity Shockwave Therapy|patients will receive 6 sessions, once per week of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
214364559|NCT06058832|OTHER|Kegel Exercises|"* The patient was asked to perform short (1 second) and long-lasting (6-10 seconds) contractions of the target muscles. Later, the exercises will do with the patient sitting or standing.~* Patient asked to repeat the contractions daily. Each patient performed 15 short and 15 long-lasting contractions in a prone, sitting, or standing position. Patients asked to do 30 contractions in the morning 30 contractions in the evening"
214364560|NCT06940232|DIAGNOSTIC_TEST|Blood Test for Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Acute Biomarkers|All groups will have blood drawn per standard of care. Blood samples will be analyzed using Traumatic Brain Injury (TBI) cartridges for iSTAT Alinity device.
214364561|NCT04922554|DRUG|Omadacycline Oral Tablet|omadacycline 300 mg orally, once daily (150 mg tablets x 2)
214364562|NCT04922554|DRUG|Placebo|placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
214364563|NCT03716310|DIAGNOSTIC_TEST|platelet responsiveness evaluation|Blood samples were anticoagulated with 0.129 mmol/L of sodium citrate and then centrifugated for 10 min at 200 rpm; platelets aggregation was assessed with an AggRAM Advanced Modular System light transmittance aggregometer (Helena Laboratories, Beaumont, Texas, USA). Low-molecular-weight heparin (LMWH) was given at least 8 hours before any blood aggregation sample. Agonist used to initiate aggregation test were: -Adenosine diphosphate (ADP) to assess P2Y12-dependent platelet aggregation; (20 ng) - Arachidonic acid (AA) to assess cyclooxygenase-dependent platelet Adenosine diphosphate aggregation (1 mcg) - thrombin receptor-activating peptide-6 (TRAP-6) to assess protease-activated receptor 1-dependent platelet aggregation. Max aggregation reached (Aggmax), the slope of the curve (slope) and the latency time (lat) were analyzed for each agonist.
214364564|NCT05604924|OTHER|virtual reality training for cesarean section|Participants who received virtual reality training for cesarean section can learn the surgical procedures as if they were in a real field.
214364565|NCT04846088|OTHER|Product A|A 4mg nicotine pouch product
214364566|NCT04846088|OTHER|Product B|A 7mg nicotine pouch product
214364567|NCT04846088|OTHER|Product C|A 7mg nicotine pouch product
214364568|NCT04846088|OTHER|Product D|A 7mg nicotine pouch product
214364569|NCT04846088|OTHER|Product E|A 7mg nicotine pouch product
214364570|NCT04846088|OTHER|Product F|A 7mg nicotine pouch product
214364571|NCT04846088|OTHER|Product G|A 7mg nicotine pouch product
214364572|NCT04846088|OTHER|Product H|A 7mg nicotine pouch product
214364573|NCT04846088|OTHER|Product I|A 7mg nicotine pouch product
214364574|NCT05797922|DRUG|DWP16001|DWP16001 0.3mg
214364575|NCT04676425|DRUG|MK-8189|Administered at a dose of 4 mg via oral tablet
214364576|NCT01184599|DRUG|aliskiren|150 mg/day p.o.
214364577|NCT06398483|PROCEDURE|surgical fixation of acute bony mallet finger|"surgical fixation of acute bony mallet finger by micro plate will be performed under either Infraclavicular nerve blockage or digital block will be performed in all patients .fracture fragment will be reduced, The legs of the plate will be embedded in the terminal tendon to grasp the fragment. The plate will be fixed to the distal phalanx with a 1.3-mm screw.~surgical fixation of acute bony mallet finger by blocking K.wire will be performed under either infraclavicular nerve block or digital block. The injury will be surgically intervened with an extensor blocking k.wire. the distal phalanx was extended to maximum flexion and (K.wire) will be placed in the cephalic direction through the terminal band at an angle of 45 degrees to the mid-phalanx. Reduction of the fracture fragment will be achieved by bringing the distal phalanx to extension . the DIP will be transfixed with a second K-wire"
214364578|NCT06366191|OTHER|prevention algorithm|a health watch adapted to stress and dissociative symptoms
214364579|NCT06366191|OTHER|Standard care|Standard care for post traumatic stress disorder
214364580|NCT04036071|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ MIA cement free hip stem
214364581|NCT05217186|DIAGNOSTIC_TEST|Measurements|All infants wirth high risk of cp will be assessed by neuroimaging and Hammersmith Neonatal Neurological Examination (HNNE) at term age, Prechtl's General movements (GMs) assessments form birth up to 3-5 months, and will be assesed by Hammersmith Infant Neurological Examination (HINE) at 2,3,6,9 and 12th months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at the 3rd, 6th, and 12th months.
214975126|NCT01112319|OTHER|control group|regular physiotherapy treatment
214975127|NCT02026141|DRUG|Dexmedetomidine|
214975128|NCT02026141|DRUG|Normal Saline Placebo|
214975129|NCT02557724|PROCEDURE|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
214975130|NCT02557724|PROCEDURE|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
214975131|NCT04945785|OTHER|No intervention|no intervention
214975132|NCT01288690|BEHAVIORAL|Narrative Exposure Therapy|3, 1-1/2 hour sessions, individual, meeting weekly.
214364582|NCT04829721|OTHER|Educational Intervention with video|Women randomized to an educational video workshop group.
214364583|NCT02153801|PROCEDURE|During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .|"For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
214975133|NCT06524661|DEVICE|AS-OCT after vitrectomy|AS-OCT is a light based imaging technique of the anterior segment of the eye in this study it is used to measure the anterior chamber angle changes after pars plana vitrectomy.
214975134|NCT00751127|DRUG|PhXA41|One drop in the affected eye once daily for six months.
214975135|NCT00751127|DRUG|timolol|One drop in the affected eye twice daily for six months.
214975136|NCT05037162|DIAGNOSTIC_TEST|Biochemistry blood test|preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,
214975137|NCT05037162|DIAGNOSTIC_TEST|Hematology blood test|preformed on days 1-14 and day 28. complete CBC.
214364584|NCT00791843|DRUG|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
214975138|NCT05037162|DIAGNOSTIC_TEST|D-Dimer test (coagulation)|performed on days 1,2,7,14 and 28.
214975139|NCT05037162|DIAGNOSTIC_TEST|Inflammatory markers|performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ
214975140|NCT05037162|DIAGNOSTIC_TEST|Vital signs|performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.
214975141|NCT05037162|DIAGNOSTIC_TEST|VAS scale|performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.
214975142|NCT05037162|DIAGNOSTIC_TEST|WHO Ordinal Score|performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.
214975143|NCT05037162|DIAGNOSTIC_TEST|COVID-19-Related Symptoms assessment|performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.
214975144|NCT05037162|DIAGNOSTIC_TEST|COVID-19-Impact on Quality-of-Life Questionnaire|performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.
214364585|NCT06170775|OTHER|Pulp therapy|Pulp capping material
214364586|NCT06170775|DRUG|Sodiumhexametaphosphate|Sodiumhexametaphosphate
214364587|NCT06170775|OTHER|MTA|MTA
214975145|NCT05037162|DIAGNOSTIC_TEST|POST- COVID-19 Functional Status Scale:|performed on day 28. score: 0-3 ; a higher score indicates better recovery.
214975146|NCT05037162|DIAGNOSTIC_TEST|Pregnancy test|performed on days 1 and 28. women of childbearing potential must undergo a urine pregnancy test.
214975147|NCT05037162|DIAGNOSTIC_TEST|Physical examination|performed on days 1-14 and day 28. a full examination by a doctor.
214975148|NCT05037162|DIAGNOSTIC_TEST|PK parameters|"performed on day 1. will be performed only on 14 patients that will agree to participate in the PK analysis (only for Brazil,Spain).~The PK will be performed only for the first dose of drug, after patient received the first dose (5 puffs) the study staff need to follow the table below.~For each test, approximately 5 ml of blood will be drawn (equivalent to one teaspoon)"
214975149|NCT05037162|DIAGNOSTIC_TEST|SARS-CoV-2 test (PCR)|performed on days 1,14 and 28.
214975150|NCT05037162|DIAGNOSTIC_TEST|ECG|performed on days 1 and 28.
214975151|NCT05037162|DRUG|Treatment administration (twice a day)|performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)
214975152|NCT01702467|DRUG|GSK2647544|Capsules containing 0.5mg to 50mg of GSK2647544.
214975153|NCT01702467|DRUG|Placebo|Matching placebo capsules.
214975154|NCT01107145|DRUG|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
214975155|NCT01107145|DRUG|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
214975156|NCT01107145|DRUG|Chloroquine|Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
214975157|NCT03907696|OTHER|Anti-stigma interventions curriculum|educational curriculum aimed at reducing stigma
214364588|NCT01953614|OTHER|Chiropractic adjustment|
214364589|NCT01953614|OTHER|Sham adjustment|
214364590|NCT02497898|BIOLOGICAL|Cytokine-induced killer cells (CIK)|Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
214490648|NCT06234683|OTHER|Reminder email to be vaccinated|Participants will receive a reminder email to be vaccinated.
214490649|NCT02282709|DRUG|Daclatasvir|60 mg once daily
214975158|NCT04065243|OTHER|Overfeeding diet|Two weeks of overfeeding
214975159|NCT04065243|OTHER|Isocaloric diet|Two weeks of isocaloric weight maintenance
214975160|NCT01327794|GENETIC|polymorphism analysis|
214975161|NCT01327794|OTHER|immunologic technique|
214975162|NCT01327794|OTHER|laboratory biomarker analysis|
214975163|NCT01327794|OTHER|medical chart review|
214975164|NCT00327223|DRUG|imexon|
214364591|NCT03857503|DIAGNOSTIC_TEST|iFR|"Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization.~Angiograms will be made in at least two projections, and the treating physician will record his/her estimation of stenosis severity.~Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures."
214364592|NCT05988021|DRUG|CCX168|Administered orally.
214364593|NCT04495439|DEVICE|Augmentation with the ISS Study System|Augmentation with the ISS Study System
214364594|NCT04495439|OTHER|Augmentation with PMMA|Augmentation with PMMA (standard)
214490650|NCT02282709|DRUG|asunaprevir|100 mg BID
214490651|NCT03580551|BEHAVIORAL|Intervention Group|"Intervention group participants will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. Participants will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. During the first 6 weeks, the intervention group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end of week 6, the intervention group will be contacted to schedule a post-assessment for the end of week 8, which will include repeating all health measures, except for health status."
214502784|NCT07007247|OTHER|Mind-WIN blended care|The program lets participants work through the module content at their own speed. Part of the program involves keeping an online diary every two weeks to track symptoms. The results are categorized as mild, moderate, or severe depression. If participants have severe symptoms, the recommendation is to get professional help. If participants are taking medication to improve their depression, they can also use the online diary to track their mood and medication. In addition to the content provided by the Mind-WIN aftercare module participants get six digital contacts with a psychotherapist.
214502785|NCT07012512|DRUG|Use of phentolamine eye drops to reverse cycloplegia|Use of phentolamine 0.75% eye drops to reverse cycloplegia
214364595|NCT01718002|BEHAVIORAL|Educational video|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
214364596|NCT03717402|BEHAVIORAL|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
214975165|NCT04301050|OTHER|Yoga Intervention|Weekly 75-minute yoga classes.
214975166|NCT00565461|BIOLOGICAL|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
214975167|NCT04752371|DRUG|Camoteskimab (CERC-007, AVTX-007, AEVI-007)|Intravenous (IV) Infusion
214975168|NCT00596219|DRUG|celecoxib|celecoxib
214975169|NCT03139734|DEVICE|Sacral Neuromodulation|S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
214975170|NCT04794907|OTHER|Observation|Patient data will be collected from eye exams, surveys and medical record review.
214975171|NCT00119574|PROCEDURE|Collaborative Chronic Illness Model|
214975172|NCT05218876|OTHER|Low- to moderate intensity strength and endurance training|Combination of strength and endurance training with low- to moderate intensity during chemotherapy
214975173|NCT05218876|OTHER|High intensity strength and endurance training|Combination of strength and endurance training with high intensity during chemotherapy
214975174|NCT02672241|DRUG|Nimotuzumab|Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.
214975175|NCT02672241|DRUG|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
214975176|NCT01783743|OTHER|TT Training Program and TT Screening Card|The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
214975177|NCT02995993|DRUG|Moss-aGal (recombinant human alpha-galactosidase A produced in moss)|Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
214975178|NCT00358696|DRUG|tenofovir|See Detailed Description.
214975179|NCT04281082|DRUG|ursofalk|To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
214975180|NCT02966704|DIETARY_SUPPLEMENT|intrinsically labeled milk protein|
214975181|NCT04016376|DRUG|PVB Protocol|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
214975182|NCT04016376|DRUG|PECS-1|For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
214364597|NCT04395573|DEVICE|Accuro|ultrasound device (Accuro, Rivanna Medical, Charlottesville, VA) with automated pattern recognition software programmed (SpineNav3DTM technology) to calculate the depth to epidural space and identify bony landmarks
214364598|NCT04395573|DEVICE|standard ultrasound device|standard ultrasound device (o calculate the depth to epidural space and identify bony landmarks
214364599|NCT01371773|PROCEDURE|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
214490652|NCT03580551|BEHAVIORAL|Waitlist Control Group|"At week 8, waitlist control group will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. The waitlist control group will complete a post-assessment at the end of week 8, which will include all health status measures, except health status. Waitlist control group will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. Waitlist control group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end 14 weeks, waitlist control group will be contacted to schedule a final meeting, and to collect the adherence logs and satisfaction survey. At 16 weeks, the waitlist control group will not receive an additional post-assessment."
214490653|NCT03998098|DIAGNOSTIC_TEST|Oxygen Saturation (Oximetry)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
214490654|NCT03998098|DIAGNOSTIC_TEST|Heart Rate (Pulse)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
214502786|NCT07012512|DRUG|Pilocarpine 0.1%|Use of pilocarpine 0.1% to reverse cycloplegia
214502787|NCT07012512|DRUG|Combination of pilocarpine 0.1% and phentolamine 0.75%|Combination of pilocarpine 0.1% and phentolamine 0.75%
214975183|NCT04016376|DRUG|Serratus|For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
214975184|NCT04530045|OTHER|dosage of concentration of piperacillin and cefepim|Dosage of total plasma concentration of piperacillin and cefepim at different timepoints
214975185|NCT00619788|DEVICE|4.0-5.0mm AngioSculpt Scoring Balloon Catheter|The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
214975186|NCT06320210|BEHAVIORAL|Multicomponent program|The intervention is a multi-component program that includes in-depth training for current school teachers/staff who are critical in asthma care, restructured processes to identify students with asthma, technological adaptations to support integrated systems for asthma care and absenteeism, strategies to enhance communication about asthma within school and between school and home, protocols for routine care (e.g., participation in gym/recess) and emergencies, and education for all students about asthma.
214975187|NCT02771275|DEVICE|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
214975188|NCT02870647|OTHER|Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire|each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
214364600|NCT02244801|DRUG|darTreg infusion|"The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.~Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects."
214364601|NCT03501433|DIETARY_SUPPLEMENT|Nicotinamide riboside chloride (Niagen)|250 mg capsules 2x/day for 7 days
214364602|NCT03501433|DIETARY_SUPPLEMENT|Placebo|2x/day for 7 days
214364603|NCT01704625|PROCEDURE|Osteopathic Manipulative Treatment|The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
214364604|NCT01704625|PROCEDURE|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments.
214364605|NCT06216522|OTHER|Topical Sesame Oil|5 drops/0.25mls of sesame oil applied to the IV cannula site at 12 hourly intervals for 72 hours
214364606|NCT06216522|OTHER|Liquid paraffin oil|5 drops/0.25mls of liquid paraffin oil applied to the IV cannula site at 12 hourly intervals for 72 hours
214364607|NCT02565901|DRUG|Carboplatin|Given IV
214364608|NCT02565901|DRUG|Docetaxel|Given IV
214364609|NCT02565901|OTHER|Laboratory Biomarker Analysis|Correlative studies
214490655|NCT03998098|DIAGNOSTIC_TEST|Respiratory Rate|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
214490656|NCT03998098|DIAGNOSTIC_TEST|Blood Pressure|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings."
214490657|NCT00389194|DRUG|continuing AZT+3TC or switching AZT+3TC to TDF+ FTC|
214490658|NCT04433637|DIETARY_SUPPLEMENT|Cake + fruit juice|Cake+fruit juice experiment group, pregnant were allowed to consume fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST.
214490659|NCT04433637|OTHER|Video group|Music with motivational video experimental group, pregnant women were provided with fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST. During this waiting period, the researchers were informed about the development and changes in the body and the fetus specific to the gestational week and NST. Later, NST was applied, and during the procedure, the pregnant women were watched with music that provides relaxation with the video regarding the fetal development appropriate for the gestational week and changes in the mother.
214490660|NCT01752699|DRUG|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
214490661|NCT01752699|DRUG|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
214490662|NCT00195403|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
214490663|NCT01825850|DRUG|Gemigliptin|
214490664|NCT01825850|DRUG|Irbesartan|
214490665|NCT06003075|COMBINATION_PRODUCT|Nivolumab and Chemotherapy|3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks
214490666|NCT06003075|DRUG|Nivolumab|Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation
214490667|NCT06003075|PROCEDURE|Post Induction Surgery|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by surgery in patients whose tumors were unresectable stage IIIA-C at baseline on the basis of lymphadenopathy and are determined to be resectable after responding to induction chemotherapy-nivolumab. The participants have an option for post op XRT, then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles
214490668|NCT06003075|RADIATION|Post Induction XRT|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by concurrent Chemo and Nivo XRT (60Gy). Participants will receive concurrent thoracic radiation therapy using a standardized 3DCRT or IMRT technique on a linear accelerator operating at 2:6 MV beam energy. The target total dose of thoracic radiation therapy will be 60 Gy in 30 daily fractions of 2 Gy prescribed to the PTV. The participants then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles.
214490669|NCT02956642|DEVICE|Livongo Health System|Participants will be asked to use the Livongo Health System to manage their blood glucose.
214490670|NCT02956642|DEVICE|iHealth Glucose Meter|Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
214490671|NCT06156046|DIAGNOSTIC_TEST|skin prick test|Skin prick test for bee venom
214490672|NCT06156046|DIAGNOSTIC_TEST|Blood tests|IgE/G and T cell tolerance studies
214364610|NCT02565901|DRUG|Sirolimus|Given PO
214364611|NCT03310073|BIOLOGICAL|bOPV|Batch Number: 2042015
214364612|NCT03310073|BIOLOGICAL|Pentabio|Batch number: 5050115 The vaccine shall be given intramuscularly.
214364613|NCT03310073|BIOLOGICAL|IPV|The vaccine shall be given intramuscularly.
214364614|NCT01900262|OTHER|Strengthening|Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.
214364615|NCT01900262|OTHER|Balance Training|Participants will be asked to compete 8 weeks of functional balance training at home.
214364616|NCT01900262|OTHER|Stretching|Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
214364617|NCT03147235|BEHAVIORAL|vitrectomy with music listening|Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
214364618|NCT03177668|DRUG|YS110|Intravenous administration
214364619|NCT04000867|DEVICE|Transcutaneous Magnetic Stimulation (TCMS)|The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
214364620|NCT02909348|DRUG|Pembrolizumab|3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.
214364621|NCT01914094|BEHAVIORAL|Prehab|
214364622|NCT04550325|BIOLOGICAL|Kamada Anti-SARS-CoV-2|Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods
214364623|NCT04392466|OTHER|walking on the treadmill|Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.
215084756|NCT07042230|OTHER|Proprioceptive Neuromuscular Facilitation (PNF)|Proprioceptive Neuromuscular Facilitation (PNF) techniques were applied to the cervical region using rhythmic initiation, dynamic reversals, and contract-relax methods. Movements followed diagonal cranio-cervical patterns including flexion/extension with rotational components. Each session lasted 15-30 minutes, delivered three times per week for four weeks. Repetitions and sets were progressively increased based on patient tolerance. The goal was to enhance neuromuscular coordination, improve cervical range of motion, and reduce pain through active facilitation techniques.
215084757|NCT07042230|OTHER|Passive Vertebral Mobilization (PVM)|Passive Vertebral Mobilization (PVM) was administered using Maitland mobilization techniques applied to the cervical spine. Posteroanterior central and unilateral glides were performed with the participant in a prone position. Mobilizations started with Grades I-II during Weeks 1-2 and progressed to Grades III-IV in Weeks 3-4, depending on patient response. Each session lasted 15-20 minutes and was conducted three times weekly over four weeks. This passive manual therapy aimed to improve joint mobility, reduce muscle stiffness, and alleviate mechanical neck pain.
214364624|NCT02318043|DRUG|inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)|Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400\~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
214490673|NCT03380013|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Each neonate will have a structural exam completed assessing each body region (head, cervical, thoracic, lumbar, sacral, pelvic, rib cage, and abdominal regions) for underlying somatic dysfunctions prior to each treatment. The specific OMT techniques used will be left to the discretion of the treating physician and will not be based on a predetermined protocol. Treatment techniques will consist of myofascial release, balanced ligamentous tension, balanced membranous tension, and osteopathy in the cranial field. Total treatment time will be 15 minutes. The features of the osteopathic structural exam which will be recorded on paper by the treating physician at the time of the evaluation. The paper will be marked only with the research identifier.
214490674|NCT00940069|DRUG|pemetrexed|"'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks."
214490675|NCT01616537|OTHER|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
214975189|NCT02512887|DRUG|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
215084758|NCT07040748|BEHAVIORAL|Immersive VR-Based Multimodal Intervention (Virtual-METS)|This intervention consists of a 12-week, group-based program using immersive virtual reality technology (MK360) without head-mounted displays. Each 60-minute session combines mindfulness practices adapted from the Mindfulness-Based Stress Reduction (MBSR) program, cognitive training targeting attention, processing speed, memory, and executive function through realistic virtual environments (such as parks, markets, or home interiors), and chair-based physical exercises focused on balance, stretching, and muscle strengthening. The intervention is delivered in small groups of five participants, twice per week, for a total of 24 sessions, and is led by a trained neuropsychologist.
215084759|NCT07041437|DRUG|SHR-A2102|ADC
214364625|NCT05239988|OTHER|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
214490676|NCT05980247|DEVICE|Thimble Application|Use of of thimble application to practice mindfulness before needle procedure.
214490677|NCT06431737|DRUG|Amoxicillin|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid or 500 mg qid, clarithromycin 500 mg bid for 14 days
214490678|NCT00410423|DRUG|Bortezomib with mitoxantrone, etoposide and cytarabine|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
214975190|NCT02512887|DRUG|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
214975191|NCT00941850|PROCEDURE|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
214364626|NCT04494438|DRUG|Rituximab|
214364627|NCT03109821|OTHER|Home-based exercise|"The intervention reflects the standard rehabilitation practice at Elective Surgery Centre. 3 weeks after surgery the patients will receive a thorough instruction and supervision in the strength training exercises that they are to perform without supervision at their own homes the following 7 weeks. The instruction is conducted one-to-one by physiotherapists and supported by an instruction booklet with written and illustrated exercise descriptions. The exercises included are: hip abduction, flexion and extension with elastic band resistance and sit-to-stand and one-legged stance. The prescribed training load will be two sets with repetitions to failure and a relative load of 10 to 20 RM (Repetition Maximum), performed every second day (3-4 times a week).~Exposure: Performed exercise dose will be quantified as the total physiological exercise stimulus (Time under tension summary dose) recorded by a sensor (BandCizer) attached to the elastic exercise band."
214490679|NCT00410423|DRUG|Bortezomib 1.0mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
214975192|NCT06499194|OTHER|DASH diet|The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons
214975193|NCT05225948|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.
214490680|NCT00410423|DRUG|Bortezomib 1.3mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
214490681|NCT05581498|BEHAVIORAL|Exercise, Bike exercise and muscle strength exercise.|"Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks."
214502788|NCT07014319|DRUG|Maribavir|Participants will receive maribavir 400 mg twice daily starting from Week 1 and continuing until clearance of CMV. CMV clearance is defined as either an unquantifiable plasma CMV DNA titer (i.e., below the lower limit of quantification \[LLOQ\]) as assessed by the local laboratory, or a CMV DNA level below 500 IU/mL in plasma without evidence of CMV disease.
214502789|NCT07013838|DRUG|Deucravacitinib|Deucravacitinib is a new, oral, selective, allosteric inhibitor of TYK2. It was first approved in the United States on 09-Sep-2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
214975194|NCT05225948|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.
214975195|NCT01911832|PROCEDURE|esophagojejunostomy after total gastrectomy|
214975196|NCT01911832|PROCEDURE|Roux-en-Y gastrojejunostomy after subtotal gastrectomy|
214975197|NCT01911832|PROCEDURE|wide tube reconstruction after subtotal gastrectomy|
214975198|NCT01911832|PROCEDURE|narrow tube reconstruction after subtotal gastrectomy|
214975199|NCT02647138|OTHER|white noise|exposure to white noise
214975200|NCT06090838|PROCEDURE|Balloon Pulmonary Angioplasty (BPA)|A balloon pulmonary angioplasty is a minimally invasive intervention procedure to remove blood clots from the pulmonary arteries.
214975201|NCT03191799|DRUG|Emicizumab|Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
214975202|NCT02945436|BEHAVIORAL|Substance Use Brief Intervention|SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.
214975203|NCT02945436|BEHAVIORAL|Standard of Care (SOC)|Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
214975204|NCT02354287|PROCEDURE|Cold forceps polypectomy with pre lift|"Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue."
214975205|NCT04204005|DIETARY_SUPPLEMENT|Probiotics|"Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.~Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively."
214975206|NCT04478058|BEHAVIORAL|Live CBT|Weekly in-person Cognitive Behavioural Therapy
214975207|NCT04478058|BEHAVIORAL|e-CBT|Weekly online Cognitive Behavioural Therapy
214975208|NCT03017807|BIOLOGICAL|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
214975209|NCT00061789|DRUG|SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain|
214975210|NCT01262144|RADIATION|Radiotherapy|Radiotherapy for cervical cancer
214975211|NCT06435013|DRUG|Lenvatinib|Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
214975212|NCT04821063|DRUG|ITF2357 10 mg/mL|Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral
214975213|NCT04821063|DRUG|ITF2357 10 mg/mL|Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
214975214|NCT04821063|DRUG|Placebo|Dose: 20 mL; Dosage form: suspension; Route of administration: oral
214975215|NCT04821063|DRUG|Moxifloxacin Hydrochloride|Dose: 400 mg; Dosage form: tablet; Route of administration: oral
214975216|NCT04821063|DRUG|Placebo|Dose: 30 mL; Dosage form: suspension; Route of administration: oral
214975217|NCT05201092|DRUG|[14C]-Lu AG06466|\[14C\]-Lu AG06466 will be administered per schedule specified in the arm description.
214975218|NCT01380236|DRUG|ASM8|
214975219|NCT03228641|DEVICE|micro-excisional skin removal with coring needle|
214975220|NCT04149444|DRUG|Trifluridine/Tipiracil|Oral medication
214975221|NCT03054142|OTHER|no intervention|
214975222|NCT03345641|OTHER|describe precocious maternal impressions when confronting the premature birth of her infant|
214490682|NCT06755476|OTHER|Psychological Counseling Program|"The Psychological Counseling Program consists of 8 sessions for caregivers of individuals diagnosed with Alzheimer's.~Aims of the sessions:~Session 1: Introduction, Collection of pretest data Session 2: It is aimed to inform Alzheimer's caregivers about the disease and its symptoms.~Session 3: It is aimed to strengthen caregivers' coping skills. Session 4: It is aimed to inform Alzheimer's patients about daily care practices.~Session 5: It is aimed to provide information to Alzheimer's caregivers about coping with stress.~Session 6: It is aimed to provide information about medical and financial support that individuals diagnosed with Alzheimer's and their relatives can receive in the region they live.~Session 7: It is aimed to conduct Q\&A sessions on the problems that caregivers bring.~Session 8: Collection of posttest data Sessions will be completed in 8 weeks, one day a week. Each session is planned to last approximately 60 minutes."
214364628|NCT01436968|BIOLOGICAL|Aglatimagene besadenovec + valacyclovir|"Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
214490683|NCT06764342|RADIATION|Full-mouth scaling combined with antimicrobial photodynamic therapy|After full-mouth scaling procedures antimicrobial photodynamic therapy was carried out using a laser-activated disinfection device with a red laser emission (wavelength: 630 nm, irradiance: 2000-4000 mW/cm², spot size at the probe tip: 8 mm diameter) and high-viscosity methylene blue gel (0.1 mg/mL) which was applied at six spots on the tongue dorsum. Antimicrobial photodynamic therapy was also applied iIn sites with altered periodontal pocket depth (≥ 4mm). The dye remained in the pockets for 10 minutes to ensure full absorption and its excess was rinsed with sterile saline after laser exposure.
214490684|NCT06764342|PROCEDURE|full-mouth scaling|Full-mouth scaling within 24 hours, divided into two sessions of ultrasonic instrumentation followed by manual supra- and subgingival scaling and root planing. Tongue cleaning was performed with a tongue scraper.
214490685|NCT06862037|PROCEDURE|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication (LNF) is the most commonly performed anti-reflux surgery. LNF is performed in patients with GERD refractory to medication or those expected to require long-term medical treatment. During LNF, the fundus of the stomach is mobilized and wrapped 360 degrees around the lower esophagus to reinforce the lower esophageal sphincter (LES), preventing the reflux of gastric contents into the esophagus.
214490686|NCT03971500|DRUG|AntiPlatelet therapy|AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
214490687|NCT03971500|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
214490688|NCT05322629|BEHAVIORAL|PrEP adherence biofeedback|Services for women in the intervention arm includes bio-feedback adherence counseling based on urine lateral flow assays of tenofovir to measure adherence with rapid PrEP delivery .
214490689|NCT05322629|BEHAVIORAL|Standard of care counseling|Adherence counseling based on self report and following national guidelines
214490690|NCT06811168|OTHER|web based gamification|Kahoot gamificiation
214490691|NCT06811272|DRUG|Epcoritamab|Bispecific IgG1 antibody
214490692|NCT05699408|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
214490693|NCT05699408|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
214490694|NCT06811610|DIAGNOSTIC_TEST|Participants were tested for hearing using a new type of hearing detection device|Participants' hearing was tested using a portable audiometry device (E200) based on active noise-cancelling headphones, manufactured by Wuhan Doulisten Technology Co., LTD
214490695|NCT06811610|DIAGNOSTIC_TEST|Participants' hearing was tested using a new portable pure tone audiometry device|Participants' hearing was tested using a portable audiometry device (E200) based on active noise-cancelling headphones, manufactured by Wuhan Doulisten Technology Co., LTD
214490696|NCT06809387|OTHER|Brain stimulation|Participants will be included in the real and sham rTMS. Participants will perform speech and reading tasks before and after stimulation.
214490697|NCT05270525|DRUG|Ensifentrine|Ensifentrine twice daily administered with jet nebulizer for 8 weeks
214490698|NCT05270525|DRUG|Placebo|Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
214490699|NCT06122103|DEVICE|Clareon Monofocal|Clareon Monofocal Intraocular Lens (toric and non-toric)
214490700|NCT06122103|DEVICE|Light-Adjustable Lens|Light-Adjustable Lens (Intraocular Lens)
214490701|NCT06642545|DRUG|Disitamab Vedotin|Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks
214364629|NCT01436968|BIOLOGICAL|Placebo + valacyclovir|"Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
214490702|NCT06642545|DRUG|RC148|20mg/kg, intravenous infusion, once every 2 weeks
214490703|NCT06642545|DRUG|Albumin-bound Paclitaxone|125 mg/m2,intravenous infusion, D1-8, every 3 weeks
215084760|NCT07041437|DRUG|Adebrelimab|PD-L1 inhibitor
214490704|NCT06642545|DRUG|Toripalimab|240mg,intravenous infusion, once every 3 weeks
214490705|NCT03803969|DEVICE|ConfirmRx (Insertable Cardiac Monitor)|This study is designed to characterise the safety and performance of the ConfirmRx device by assessing quality of signal attained from the device with changes in posture and physical activity at implant and 30days post procedure. The study is also intended to assess gross migrations of the device at 30days post implant.
214975223|NCT04608071|PROCEDURE|A modified method for blind bedside placement of post-pyloric feeding tube.|Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.
214364630|NCT04418934|DEVICE|Hemanext One|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 56 days at 1-6°C.
214364631|NCT01827826|BEHAVIORAL|Telephonic intervention to prevent Diabetes Mellitus, Type 2|Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
214364632|NCT03966222|DEVICE|Endoscopic vein harvest|An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision.
214364633|NCT03966222|OTHER|Open vein harvest|Open vein harvest
214490706|NCT06651736|BEHAVIORAL|Low Vision Rehabilitation (LVR)|"The initial session will be with an LVR specialist that will recommend vision-enhancing devices and techniques to improve participant's vision and mobility functionality depending on needs. The devices will be given at no cost and include, but are not limited to: magnifiers that participants can hold or wear, glasses attachments that help filter out light to see better, or items that help with glare or seeing color. This session will be followed by at least one session with an occupational therapist, that will train participants to use the devices (take home and use) and recommend/teach ways to achieve functional goals.~Most participants will be asked to attend 2-4 visits, but additional visits may be needed depending on needs and progress toward functional goals. Additional visits if orientation and mobility training is also recommended. Participants will be asked to share experiences approximately 1-week after all visits."
214490707|NCT06651736|BEHAVIORAL|Emotion Regulation Therapy (ERT)|There will be ten 1-hour weekly sessions of specialized psychotherapy with an ERT-trained therapist. These are typically done virtually but may be able to provide in-person sessions to those where this is needed. At the beginning of each session, the therapist will give participant's several questionnaires to learn about participant's experience with ERT. Questionnaires will also be completed after all sessions are completed.
214490708|NCT04908020|OTHER|Follow-up patients|The intervention consists in the assessment of some psychological aspects (post traumatic stress symptoms and coping) of cancer patients in follow-up care, through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
214975224|NCT00000638|DRUG|Isoniazid|
214975225|NCT00000638|DRUG|Pyrazinamide|
214975226|NCT00000638|DRUG|Pyridoxine hydrochloride|
214975227|NCT00000638|DRUG|Rifampin|
214975228|NCT03289338|DRUG|Zoledronic Acid|Zoledronic acid 5mg intravenous once a month for 3 months
214975229|NCT03289338|DRUG|Methylprednisolone|Methylprednisolone 1gm intravenous once a month for 3 months
214975230|NCT03289338|DRUG|Placebos|Normal saline intravenous once a month for 3 months
214975231|NCT04140773|DIETARY_SUPPLEMENT|D-serine|Capsule D-serine
214975232|NCT04140773|OTHER|Placebo|Capsule D-serine
214975233|NCT06059040|PROCEDURE|eliminating gastric residual volume monitoring|eliminating gastric residual volume monitoring from routine care
214975234|NCT00728494|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Peginterferon alfa-2b will be administered according to the product's labeling.
214975235|NCT00728494|DRUG|Rebetol (ribavirin; SCH 18908)|Ribavirin will be administered according to the product's labeling.
214364634|NCT04407013|OTHER|Enhanced supportive care based on standardized care pathway|Enhanced supportive care based on standard care pathway is consisted of 1) symptom management (symptom assessment and according management) and 2) coping enhancement (nurse-led counseling). The enhanced supportive care will be provided 5 times, according to the standardized care pathway.
214364635|NCT04407013|OTHER|Control group with usual care|Control group will receive usual care (symptom monitoring only)
214364636|NCT03397680|DIAGNOSTIC_TEST|13C Urea Breath Test|After the H.pylori eradication treatment course completed, participants then was tested with 13C Urea Breath Test to confirm treatment effectiveness at least after ceasing PPI and antibiotics for 4 weeks.
214364637|NCT00990964|DEVICE|Attain Success Lead|Attain Success Lead
214364638|NCT03895164|BEHAVIORAL|Enhanced NE|Standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
214364639|NCT03895164|BEHAVIORAL|Standard NE|Standard nutrition education package from primary health care
214364640|NCT04932499|OTHER|Standard of Care|Participants randomly assigned to this intervention will receive standard of care given to all patients undergoing total knee arthroplasty at our institution as outlined in the Common Care Pathway for Total Joint Replacement. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.
214364641|NCT04932499|OTHER|Mindfulness Meditation|"In addition to standard of care, participants randomly assigned to the treatment group will be given a 45-60 minute teaching session on mindfulness meditation. Upon completion of this session, participants will be given homework recordings of a body scan exercise and asked to listen to the recording daily for the two-week period prior to surgery. Participants will be asked to listen to their recording immediately prior to their surgery and daily while in hospital. In addition, participants assigned to mindfulness intervention will receive standard of care as outlined in the control group. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative."
215084761|NCT07041515|OTHER|Mobile app|"This study will be conducted in two stages, recruiting patients scheduled for low anterior resection and those scheduled for ostomy restoration after low anterior resection. The pilot stage study will recruit 20 subjects without randomization to evaluate the feasibility of the management program app, and the second stage study will be a parallel experimental-control study, recruiting approximately 300 research participants, 150 from each group.~Patients scheduled for ostomy repair after low anterior resection and low anterior resection are required to fill out a consent form the day before, and participants are randomly assigned to one of two groups in a 1:1 ratio: the experimental group and the control group. Both groups are randomly assigned to four surveys. The types are three quality of life assessment questionnaires (QOL (EORTC QLQ-C30, CR-29, EQ-5D-L)) and a questionnaire related to bowel symptoms (LARS). However, patients undergoing ostomy repair are excluded from the preoperati"
215084762|NCT07041515|OTHER|standard|Subjects classified as control group will receive educational materials. One month and three months after surgery, a questionnaire related to bowel symptoms (LARS) will be administered by phone. The researcher will call the subjects and administer it according to the period. The results of the questionnaire related to bowel symptoms (LARS) administered by phone will be confirmed by the medical staff during outpatient treatment.
215084763|NCT07041632|OTHER|electro-acupuncture|electro-acupuncture for pain relief in egg collection in IVF
215084764|NCT07041632|OTHER|Conscious sedation|IVf egg collection using conscious sedation as the usual analgesia
215084765|NCT07040124|PROCEDURE|ti mesh|prebent titamesh on a 3-d virtually augmented model
214364642|NCT01175915|OTHER|Western therapy|"1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;~3. No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.~Intervention time: 3-7 days; Follow-up time: 3 days."
214364643|NCT01175915|OTHER|Reduning Injection|"1. Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;~2. Reduning Injection, 0.5\~15ml, depending on patient's condition, IV per day, or according to the instruction;~3. Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.~Intervention time: 3-7 days; Follow-up time: 3 days."
214364644|NCT01175915|OTHER|Reduning Injection plus western therapy|"1. General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;~2. Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;~3. Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.~Intervention time: 3-7 days; Follow-up time: 3 days."
214364645|NCT04199780|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS), stimulates specific areas of the brain via electric current passed through electrodes placed on the scalp. During tDCS, low amplitude direct currents penetrates the skull to enter the brain and modulates neuronal activity.
214502790|NCT07013838|DRUG|Adalimumab|TNFα inhibitors have already been used in TAK treatment. Several retrospective studies have demonstrated the treatment effects of these agents in patients with TAK, including disease remission, GC tapering and vascular inflammation control. According to the ACR and EULAR guidelines, TNFis are recommended to be considered in cases of relapsing or refractory TAK. These agents (including adalimumab) are the most frequently analyzed therapeutic modalities in recent studies of TAK.
214975236|NCT00728494|BEHAVIORAL|Patient Assistance Program|"The patient assistance program includes the following:~* Training by physicians or specialized nurses.~* Informational materials based on the To beat HCV program.~* Management of specific side effects."
214975237|NCT00914147|PROCEDURE|pulmonary function testing|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
214975238|NCT05192265|DRUG|Antimalarials, pyronaridine-artesunate|The main interventions investigated are pyronaridine-artesunate granules or tablets (Pyramax™) manufactured by Shin Poong Pharmaceuticals, Seoul, Korea. Pyramax granules come in sachets with each containing 60mg of pyronaridine/20mg of artesunate while Pyramax tablets contain 180mg pyronaridine/60mg artesunate.
214975239|NCT05192265|DRUG|Antimalarials, Artemether + Lumefantrine|Artemether-lumefantrine dispersible tablets (Coartem™, Novartis pharma) twice daily according to body weights. Each dispersible tablet of AL contains 20mg of artemether/120mg of lumefantrine).
214975240|NCT04772066|OTHER|Measure of medication adherence|Measure of medication adherence
214975241|NCT05638282|DRUG|Cendakimab|Specified dose on specified days
214975242|NCT05638282|DRUG|Placebo|Specified dose on specified days
214975243|NCT05925439|DEVICE|Tuohy needle group|Ultrasound-guided S1 transforaminal epidural block with Touhy needle
214975244|NCT05925439|DEVICE|Quincke needle group|Ultrasound-guided S1 transforaminal epidural block with Quincke needle
214975245|NCT00324922|DRUG|trimethoprim-sulfamethoxazole|trimethoprim/sulfamethoxazole 320/1600 mg po bid
214975246|NCT00324922|DRUG|vancomycin|1g iv bid
215084766|NCT07040124|PROCEDURE|3d peek mesh|milled 3d peek mesh
215084767|NCT07041567|OTHER|Inhalational anesthesia|"In Group D, patients undergoing bariatric surgery will receive low-flow inhalational anesthesia (0.5-1 L/min) with sevoflurane. The aim is to evaluate whether the reduced fresh gas flow rate decreases the incidence of postoperative atelectasis, assessed via pulmonary ultrasonography.~In Group N, patients undergoing bariatric surgery will receive standard-flow inhalational anesthesia (2-4 L/min) with sevoflurane. This group serves as the comparator to evaluate the impact of flow rate on postoperative atelectasis incidence."
214364646|NCT04199780|BEHAVIORAL|Cognitive-Behavioral (CB) intervention|CBI generally consist of cognitive coping strategies (e.g., distraction, relabeling, reducing pain-catastrophizing) and self-management (e.g., relaxation strategies, guided imagery) designed to enhance perceived control and reduce sympathetic nervous system tone.
214364647|NCT06110884|BEHAVIORAL|music therapy, speech therapy|receive group music therapy in addition to traditional language therapy
214364648|NCT06110884|BEHAVIORAL|speech therapy|receive only traditional language therapy
214364649|NCT05888506|DIETARY_SUPPLEMENT|Ketone Ester|Participants will consume the ketone ester beverage produced by KetoneAid prior to bedtime. Participants will consume 60 mL (30 grams ketones) of the ketone beverage.
214364650|NCT05888506|DIETARY_SUPPLEMENT|Placebo|Participants will consume the placebo supplement prior to bedtime. The placebo supplement will be a ketone ester-free, taste and viscosity-matched, beverage produced by KetoneAid.
214364651|NCT03974659|COMBINATION_PRODUCT|Transcranial magnetic stimulation|1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
214364652|NCT03329898|PROCEDURE|dried biological amnion graft|dried biological amnion graft. The amnion grafts were spread on the balloon end of disposable balloon uterine stent .
214364653|NCT03329898|DEVICE|disposable balloon uterine stent|the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.
214364654|NCT03329898|DRUG|estradiol valerate tablets|oral estradiol valerate tablets, which can promote endometrial growth after operation.
214364655|NCT03329898|DRUG|dydrogesterone Tablets|oral dydrogesterone Tablets
214364656|NCT02191072|DRUG|omalizumab|a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
214364657|NCT06574009|BEHAVIORAL|Multimodal pain care|Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage
214364658|NCT06574009|DRUG|Medication optimization|Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.
214364659|NCT06574009|DEVICE|Buprenorphine rotation|Subjects randomized to this arm at 6 months will be offered the chance to rotate from their full mu agonist opioid to buprenorphine using a standardized protocol
214364660|NCT06574009|OTHER|Opioid tapering|Subjects randomized to tapering will receive recommendations based upon the VA PBM's opioid tapering reference guide
214364661|NCT05100225|BIOLOGICAL|PTP-001|Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.
214364662|NCT05100225|OTHER|Placebo control|The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.
214364663|NCT04271943|BEHAVIORAL|Computer Based Exercises|For 8 weeks 3 days a week for 45 minutes See-ME Virtual Rehabilitation system with the physical therapist will perform cognitive and physical activity exercises
214364664|NCT04271943|DIETARY_SUPPLEMENT|Aerobic Exercises|For 8 weeks 3 days a week exercise bike with 5 min warm-up 35 min constant speed exercise 5 min cooling, a total of 45 min prescribed by the physiotherapist to the maximum heart rate will do aerobic exercise work. Cardiac values will also be monitored throughout the session
214364665|NCT03962244|DEVICE|EsoSponge|Endoscopically placed an EsoSponge for Negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
214490709|NCT06748235|OTHER|Intensive Strength Training|Comprehensive Hand Repetitive Intensive Strength Training and Routine Physical Therapy 60 minutes per session, three sessions a week, at a total of 30 sessions per ten weeks. Comprehensive hand repetitive intensive strength training included treadmill training for the upper limb with body weight supporting the using upper limb. The posture of an arm swing was to maintain the joints of the elbows and wrist as much as possible, and the shoulder joint was allowed to be flexed by 160 degrees .The posture of the arm stance supported the weight using metacarpal heads, hands, and elbows, and the shoulder joints were allowed to be flexed by 90 degrees.
214502791|NCT07012811|DRUG|Topical tretinoin 0.05%|Topical tretinoin cream 0.05% applied once daily at night
214502792|NCT07012811|DRUG|Topical tretinoin 0.05% + oral isotretinoin (0.5 mg/kg/day)|Topical tretinoin cream 0.05% once daily at night + oral isotretinoin capsule in the dose of 0.5 mg/kg/day
214975247|NCT02294279|DRUG|Qvar (100 mcg)|2 puffs twice daily; 400 mcg daily over 4 weeks treatment period
214975248|NCT02308800|DEVICE|Quantum™ Therapy - NPWT with Prontosan|Negative pressure wound therapy with Prontosan irrigation.
214975249|NCT02308800|DEVICE|Quantum™ Therapy|Negative pressure wound therapy without irrigation.
214975250|NCT00000798|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
215084768|NCT07041762|PROCEDURE|Rhomboid Intercostal Block with Sub-Serratus Plane Block|"Ultrasound-guided regional anesthesia combining two injections:~Rhomboid Intercostal Block (20 mL of 0.25% bupivacaine injected between rhomboid major and intercostal space)~Sub-Serratus Plane Block (20 mL of 0.25% bupivacaine injected between serratus anterior and ribs).~Both performed 30-45 minutes before Modified Radical Mastectomy under general anesthesia."
215084769|NCT07041762|PROCEDURE|Erector Spinae Plane Block|"Ultrasound-guided regional block with 30 mL of 0.25% bupivacaine injected into the paraspinal plane at the T4-T5 level, between the erector spinae muscle and the transverse processes.~Performed 30-45 minutes prior to general anesthesia for Modified Radical Mastectomy."
214364666|NCT03962244|DEVICE|Self-Expanding Metal Stent|Endoscopically placed self-expanding-metal-stent (SEMS) for negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
214364667|NCT01332227|DRUG|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
214364668|NCT01332227|DRUG|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
214364669|NCT01332227|DRUG|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
214364670|NCT01332227|DRUG|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
214364671|NCT00514943|DRUG|BIBW 2992|experimental drug taken once daily orally
214364672|NCT00514943|DRUG|Cetuximab|active comparator administered weekly intravenously
214364673|NCT04839029|PROCEDURE|Bipolar En bloc TURBT|patients subjected to Bipolar resection of bladder tumor by Collins loop
214364674|NCT04839029|PROCEDURE|Monopolar En bloc TURBT|patients subjected to Monopolar resection of bladder tumor by Collins loop (hot Knife)
214364675|NCT03764449|DRUG|Oral Balovaptan|"In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14."
214364676|NCT03764449|DRUG|IV Balovaptan|"In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan."
214364677|NCT03406819|DRUG|Nitroprusside Sodium|Intracoronary infusion 50\~100μg each time (repeated)
214490710|NCT06748235|OTHER|Routine Physical Therapy|Received 60 minutes per a session, three sessions a week, at a total of 30 sessions per 10 weeks by creating a home program, which consisted of a total of 8 exercises that enhanced the muscular strength of the upper limb including the triceps brachii and extensor carpi radialis, and conveyed an effect of reaching the muscles out. flexion and extension muscle strengthening with towel, hand grip and wrist extension muscle strengthening This exercise consisted of shoulder extension muscle, elbow flexion muscle, shoulder abduction muscle, and elbow extension muscle strengthening with a thera band, as well as hand grip, forearm with a velcro board, wrist extension muscle strengthening with sandbag and shoulder abduction-extension muscle strengthening with a thera band.
214490711|NCT06773195|DRUG|Ulixertinib|There are 3 planned dose levels of ulixertinib(450 mg BID, 300 mg BID, or 150 mg BID)
214490712|NCT06773195|DRUG|Ruxolitinib|Ruxolitinib for 28 day cycles.
214490713|NCT06763653|DEVICE|ULF therapy|ultra low frequency spinal cord stimulation
214490714|NCT06763653|OTHER|CMM|conventional medical management
214490715|NCT04739696|BEHAVIORAL|PEPRR|Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)
214490716|NCT04739696|BEHAVIORAL|Pep-Pal|Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
214490717|NCT06692309|PROCEDURE|cardiovascular surgery|Heart bypass surgery; Heart valve replacement surgery
214490718|NCT06696404|PROCEDURE|Combined Lumbar Plexus and Sacral Plexus Block|This intervention of Combined Lumbar Plexus and Sacral Plexus Block is assigned to Nerve block anesthesia group (NA group): A combined Lumbar Plexus Block (0.33% Ropivacaine 30ml) and Sacral Plexus Block (0.33% Ropivacaine 20ml) administered as a single injection.
214490719|NCT06696404|PROCEDURE|iliac fascial block|iliac fascial block administered as a single injection below the iliac fascial with 0.33% ropivacaine 30ml.
214975251|NCT02706288|OTHER|Weight loss with very low fat plant-based diet and regular exercise|Participants will lose \~7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
214975252|NCT06047405|DEVICE|Average Volume-Assured Pressure Support (AVAPS)|A setting on noninvasive ventilator that allows setting of maximum and minimum inspiratory pressure and sets a target tidal volume. The inspiratory pressure varies breath to breath to ensure pre-set tidal volume is delivered.
214364678|NCT03406819|DRUG|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
214364679|NCT03406819|DRUG|Heparinized saline|Intracoronary infusion 2ml for single time
214975253|NCT06047405|DEVICE|Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)|A setting on noninvasive ventilator that allows setting of inspiratory pressure, inspiratory time, expiratory pressure, and backup rate to deliver variable tidal volumes.
214975254|NCT02460510|DRUG|Mannitol|
214975255|NCT02460510|DRUG|3% hypertonic saline|
214975256|NCT00364065|DEVICE|Ferris PainWrap|
214975257|NCT00572091|DEVICE|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
214364680|NCT06956417|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy (CBT) is delivered by a psychologist over 10 individual (1:1) manualized videoconference sessions. The goal of this therapy is for participants to use their memory more normally (i.e., reduce avoidance and safety behaviors) and view memory lapses as less threatening.
214364681|NCT06956417|BEHAVIORAL|Cognitive rehabilitation|Cognitive compensatory strategy training (CCST), a traditional cognitive rehabilitation intervention, is delivered by a Occupational Therapist over 10 individual (1:1) manualized videoconference sessions. Participants optimize their use of current compensatory strategies and/or learn new ones suited to their needs and lifestyle. The goal is to minimize memory lapses in daily life.
214364682|NCT01100255|DRUG|Ketamine infusion|0.5mg/kg IV over 40 minutes
214364683|NCT01100255|OTHER|Saline|saline infusion
214364684|NCT05538195|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214364685|NCT05538195|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214490720|NCT06696404|PROCEDURE|spinal anesthesia|Spinal anesthesia was performed as a standard care of spinal anesthetic. The spinal puncture site is at L2-3 or L3-4. After the puncture needle reaches the subarachnoid space, 1% ropivacaine 0.8-2 ml, totaling 8-20mg, is injected. Depending on the center's practice, it may be replaced with an equivalent dose of bupivacaine .
214490721|NCT03687710|BEHAVIORAL|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
214490722|NCT06699498|DRUG|Benmelstobart|1200mg, D1, IV,q3w
214490723|NCT06699498|DRUG|Anlotinib|10mg，D1-14，po，q3w
214490724|NCT06699498|DRUG|Cisplatin|60mg/m2， D1， IV，q3w
214490725|NCT06699498|DRUG|Paclitaxel for Injection （Albumin Bound）|260mg/m2，IVgtt ，D1，q3w
214490726|NCT04629599|BEHAVIORAL|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
214490727|NCT04629599|BEHAVIORAL|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
214490728|NCT06073431|PROCEDURE|Biospecimen Collection|Undergo collection of blood and archived tumor samples
214490729|NCT06073431|PROCEDURE|Computed Tomography|Undergo PET/CT scan
214490730|NCT06073431|OTHER|Electronic Medical Record|Review of medical record
214490731|NCT06073431|OTHER|Medical Device Usage and Evaluation|Wear actigraph
214490732|NCT06073431|OTHER|Physical Performance Testing|Undergo physical function tests
214490733|NCT06073431|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214490734|NCT06073431|OTHER|Survey Administration|Complete surveys
214975258|NCT04067869|PROCEDURE|Blood samples|Blood sample containing 3 ethylene-diamine-tetra-acetic acid tubes (7ml), 3 dry tubes (7ml) and 5 citrated tubes, ie 9 tubes
214975259|NCT00520143|BIOLOGICAL|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
214975260|NCT03674268|DIAGNOSTIC_TEST|Management of the Contraversive Pushing Scale|Scale of evaluation of trunk control and pushing behavior in patients with stroke.
214975261|NCT00782197|DEVICE|PRGF Intraarticular injection|Three consecutive PRGF injections each one week apart.
214975262|NCT00782197|DEVICE|Hyaluronic Acid Intraarticular injection|Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
214975263|NCT02099513|DEVICE|The Mobile Health Platform|
214975264|NCT03439137|DRUG|MT-6548|Oral tablet
214975265|NCT03439137|DRUG|Darbepoetin alfa|Intravenous administration
214975266|NCT03439137|DRUG|MT-6548-matching placebo|Oral tablet
214975267|NCT03439137|DRUG|Darbepoetin alfa-matching placebo|Intravenous administration
214975268|NCT02517281|PROCEDURE|Biopsy|
214975269|NCT06375551|BEHAVIORAL|Optimizing Responses with Collaborative Assessments-Automated (ORCA-A)|"Participants will receive automated facilitation in the ORCA platform. This will entail prompts for group discussion based on group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Participants will have the option of using these prompts to discuss ORCA results in group decision discussions.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation."
214975270|NCT06375551|BEHAVIORAL|Optimizing Responses with Collaborative Assessments-Live (ORCA-L)|"A facilitator will guide group decision discussions using group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Facilitation will be either in-person or virtual, but occur live as in during real-time.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation."
214975271|NCT04866576|DIETARY_SUPPLEMENT|Q CAN PLUS|Active powder with fermented soy, 2 pouches per day, each pouch contains 12-15 gms of fermented soy
214975272|NCT04866576|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder with Whey protein and flavor (provided by BESO Biological Research, Inc.)
214975273|NCT01297686|OTHER|Karaoke Exercise|lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
214975274|NCT01297686|OTHER|Balance walking exercise|Walking along a straight line on the ground, for 5 sets of 30 strides
215084770|NCT07040241|PROCEDURE|Confocoal laser endomicroscopy-assisted ultrasound-guided pleural biopsy|Using the probe-based confocal laser endomicroscopy to detect the pleural, and ensure the biopsy location. Then, use the pleural biopsy tool to complete the pleural biopsy. The whole procession will under the ultrasound guidance.
214364686|NCT02878174|PROCEDURE|internal jugular vein catheterization|internal jugular vein catheterization using ultrasound (US) or US-based prelocation techniques
214490735|NCT00087685|DRUG|RAD001|10 mg by mouth Daily
214490736|NCT06825143|PROCEDURE|Ischemic preconditioning|The objective of this Intervention is to show that ischemic preconditioning (IPC) protects against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm, followed by 3 × 5-minute cycles of IPC in the opposite arm. IPC will be induced using a blood pressure cuff placed on the opposite upper arm and inflated to 220 mmHg for 5 min, followed by 5 min of deflation. This procedure will be repeated two additional times taking about 30 minutest to complete. Following a 10-minute rest phase, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
214490737|NCT06825143|DRUG|Intravenous lactate infusion|The objective of this Intervention is to show that an intravenous infusion of lactate protects against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm. Thereafter, a continuous intravenous infusion of lactate will be delivered in the contralateral arm. After systemic lactate reaches \~3 mmol/L, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
214490738|NCT06825143|PROCEDURE|No ischemic preconditioning (control)|The objective of this Intervention is to show that a control experiment without ischemic preconditioning does not provide protection against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm, followed by 3 × 5-minute cycles of no upper arm occlusion in the opposite arm. To avoid upper arm occlusion, a blood pressure cuff will be placed on the upper arm and inflated to a low pressure of 20 mmHg pressure to not influence blood flow through the arm. This control procedure will be repeated two additional times taking about 30 minutes to complete. Following a 10-minute rest phase, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
214490739|NCT06825143|DRUG|Normal Saline Infusion (Placebo)|The objective of this Intervention is to show that a placebo intravenous infusion does not protect against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm. Thereafter, a continuous infusion of normal saline that does not contain lactate will be delivered in the contralateral arm. After 20 minutes of the placebo infusion, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
214490740|NCT06825143|COMBINATION_PRODUCT|Ischemic preconditioning and intravenous lactate|The objective of this Intervention is to show that combining ischemic preconditioning (IPC) with an intravenous infusion of lactate provides the best protection against endothelial injury. First, baseline endothelial function to reactive hyperemia will be performed on the nondominant arm. Thereafter, a continuous intravenous infusion of lactate will be delivered in the contralateral arm. After that investigators will administer IPC using a blood pressure cuff placed on the same upper arm and inflated to 220 mmHg for 5 min, followed by 5 min of deflation. This procedure will be repeated two more times taking about 30 minutes to complete. The intravenous lactate infusion will be maintained. After a 10-minute rest phase and while lactate is still being infused, endothelial injury will be induced using a blood pressure cuff inflated to stop blood flow through the opposite arm (nondominant arm) for 20 minutes, followed by 15 minutes of cuff deflation. Endothelial function will be repeated.
214490741|NCT06890507|DRUG|N-Acetylcysteine (NAC)|The investigational product for this study is NAC 600 mg capsules. The NAC drug substance is sourced from a Good Manufacturing Practice (GMP)-certified supplier by Syntro Health Pty Ltd and tested on receipt
214502793|NCT03936478|RADIATION|MRIdian Radiation Treatment Unit|partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
215084771|NCT07040241|PROCEDURE|Ultrasound-guided pleural biopsy|Using ultrasound to detect the biopsy site and perform pleural biopsy.
215084772|NCT07041697|DEVICE|Light-emitting diode photobiomodulation therapy|For the intervention, the isolated arteries were assigned to three experimental groups. The first group (red) was exposed to light at a wavelength of 650 nm for 83 seconds. The second group (infrared) received irradiation at 940 nm for 94 seconds. The third group (mixed) was irradiated with a combination of red (650 nm) and infrared (940 nm) light for 73 seconds.
215084773|NCT07042191|BEHAVIORAL|Disco (Discussion of Cost) Provider Companion Intervention|A communication intervention for providers to assess financial toxicity in Cancer patients
214364687|NCT02173548|DRUG|Anakinra|
214364688|NCT02173548|DRUG|Placebo|
214364689|NCT02278068|DEVICE|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
214364690|NCT04535674|BIOLOGICAL|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
214364691|NCT06393348|DRUG|HRS-7535|HRS-7535
214364692|NCT06393348|DRUG|Placebo|Placebo
214364693|NCT05599009|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
214364694|NCT05599009|PROCEDURE|sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
214364695|NCT06048510|DIAGNOSTIC_TEST|Pregnant women|"Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).~The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.~Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin."
214364696|NCT01295645|DRUG|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
214490742|NCT06890507|DRUG|Placebo|To ensure appropriate blinding and to match the physical characteristics of the NAC capsules, the placebo capsules will be filled with dicalcium phosphate (DCP). DCP has been selected over microcrystalline cellulose due to the weight requirements of the NAC formulation.
214490743|NCT07032571|BEHAVIORAL|Core Behavioral Weight Loss Intervention|All participants receive a 12-week core behavioral weight loss intervention consisting of the following: daily self-monitoring of weight; weekly behavioral lessons and action plans to promote healthy eating and physical activity; and tailored feedback. The intervention will be delivered remotely via email and/or text message.
214490744|NCT07032571|BEHAVIORAL|Limit Red Zone Foods|Participants randomized to receive this component are given a goal to limit their Red Zone Foods (i.e., foods high in calories and low in nutrition) and are instructed to self-monitor them daily.
214490745|NCT07032571|BEHAVIORAL|Limit Eating Window|Participants randomized to receive this component are given a goal to limit their eating windows (i.e., follow time-restricted eating) and are instructed to self-monitor them daily.
214490746|NCT07032571|BEHAVIORAL|Increase Protein|Participants randomized to receive this component are given a goal to increase their protein intake and are instructed to self-monitor it daily.
214490747|NCT07032571|BEHAVIORAL|Increase Fiber Intake|Participants randomized to receive this component are given a goal to increase their fiber intake and are instructed to self-monitor it daily.
214490748|NCT06882265|BEHAVIORAL|Group Monitoring|In the intervention group (IG), participants receive a HR and SPO2 monitor watch and a pulse oximeter and will be monitored every 15 days by a nurse to check for non-adherence and/or technical failure, and/or exacerbations, and monthly to apply questionnaires.
214490749|NCT06882265|BEHAVIORAL|Control Group|In the control group (CG), participants receive only a pulse oximeter and will be monitored monthly by a nurse to administer the questionnaires.
214490750|NCT06881563|DRUG|Intrathecal Morphine|In this group, 300 μg of preservative-free morphine (Morphine Kalceks ®, Kalceks, AS, Riga, Latvija, 10mg/ml) diluted with sterile saline to a volume of 3 mL will be injected intrathecally.
214679710|NCT02838550|BEHAVIORAL|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
214975275|NCT01297686|OTHER|Forefoot extension exercise|The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended. The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
214364697|NCT01295645|OTHER|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
214364698|NCT00792896|BEHAVIORAL|family conference|family conference
214490751|NCT06881563|PROCEDURE|Epidural Analgesia|"Epidural analgesia with levobupivacaine and fentanyl mixture. For intraoperative intermittent analgesia, Epidural group will be given a loading dose of 5-10 milliliters of a mixture of 10 micrograms per milliliter (μg/mL) of fentanyl (Fentanyl Piramal Critical Care, 50 mcg/ml) and 0.25% levobupivacaine (Levobupivakain Kabi 5 mg/ml), followed by intermittent 4-5 mL boluses as needed throughout the surgery.~Postoperative continuous epidural analgesia in the epidural group will consist of 2 μg/mL fentanyl added to 0.1 % levobupivacaine at the rate 5-8 mL/h during the first 24 hours after surgery."
214490752|NCT07029529|DRUG|Apremilast 60mg|Apremilast 60mg/day
214490753|NCT07029529|DRUG|Apremilast 90mg|Apremilast 90mg/day
214490754|NCT07029529|OTHER|Placebo|Placebo
214975276|NCT01297686|OTHER|Standing one-legged balance exercise:|This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
214975277|NCT01297686|OTHER|Ankle inversion/eversion exercise|The foot is placed sideways at the edge of a step. After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
214975278|NCT01297686|OTHER|Gastrocnemius and soleus stretching|This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
214364699|NCT02239393|BIOLOGICAL|Mesenchymal Stem Cells|"Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.~Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product)."
214490755|NCT07038421|OTHER|Cognitive level|The cognitive function was assessed with the Montreal Cognitive Assessment (MOCA). The total score ranges from 0 to 30, and scores of 21 and above indicate normal cognitive status
214490756|NCT07038421|OTHER|Gait|The Dynamic Gait Index (DGI) was assessed for gait. The maximum total score is 24, with a lower DGI score indicating greater impairment in functional mobility and gait
214490757|NCT07038421|OTHER|Spasticity|Spasticity was assessed using the Modified Ashworth Scale (MAS). In the MAS, muscles were recorded as 0, 1, 1, 1+, 2, 3, and 4 according to the resistance they gave to passive movement.
214490758|NCT07038421|OTHER|Position sense|The position sense was measured using a dual digital inclinometer. The mean absolute error from three trials was recorded. As the mean absolute error increased, position sense deteriorated.
214490759|NCT07038421|OTHER|Plantar sense|Plantar sensation was evaluated with the Semmes-Weinstein monofilament test (SWMT). The smallest monofilament value felt and correctly identified was recorded as the patient's threshold for light touch and pressure sensation. As the value increases, the underfloor sensation worsens.
214490760|NCT07039279|BEHAVIORAL|Multicomponent Integrated Care Program|The multicomponent integrated care program is supported by a team of endocrinologist, dietitian, psychologist and research assistant with elements including medical therapy, cognitive behavioural therapy, e-care (TourHeart + platform), artificial intelligence chatbot, biofeedback, peer support
214490761|NCT07039279|OTHER|TourHeart + platform|TourHeart+ is a web-based program that provides mental health services that integrate both online and offline elements, opening up new possibilities for mental well-being. Participants will be introduced to the platform but the control group will not receive follow-up action. The platform is part of the multi-intervention care program and the participants in the intervention will receive follow-up action to engage their usage of the platform.
214490762|NCT07037992|DRUG|injection of local anesthesia solution|Injection of 30 mL local anesthetic solution bupivacaine 0.25%
214679711|NCT02838550|BEHAVIORAL|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
214679712|NCT01233219|DRUG|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.~Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS\<4 maximum x 3 daily.~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h)."
215084774|NCT07041983|DRUG|anti obesity medication|"Patients with obesity or overweight, with at least one weight-related comorbidity who are expected to start treatment with Semaglutide (Wegovy) or Terzepatide (Mounjaro) at enrolment will be eligible to enrol into the study.~Patients will be treated and observed according to normal clinical practice. Participation in this study does not limit the physicians' clinical decision making as to the most appropriate treatment for the patient during the course of the study"
215084775|NCT05786365|DRUG|Ketalar 50 MG/ML Injectable Solution|Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
215084776|NCT00405379|DEVICE|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
214364700|NCT03658564|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate Drink|Patients in Oral carbohydrate group consumed 400 ml Preoperative Oral Carbohydrate Drink Nutricia preOp® (12.5% carbohydrates, 0.5kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
214679713|NCT01354691|DRUG|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
214679714|NCT02958137|PROCEDURE|Arthroscopic Resection Arthroplasty|Surgical removal of the arthritic joint(s) using a minimally invasive technique.
215084777|NCT03094858|DEVICE|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
215084778|NCT03094858|DEVICE|Wristband|Wristband will monitor activity of all participants
215084779|NCT03094858|DEVICE|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
214364701|NCT04152902|OTHER|Objective outcome|The final outcome of surgical therapy was assessed according to a semi-quantitative scale graded as excellent, good, fair and poor, according to quantitative grades for dysphagia, reflux symptoms and oesophagitis
214364702|NCT04152902|OTHER|Quality of life|SF-36 Questionnaire
214490763|NCT07037992|DRUG|Injection of normal saline|Injection of 30 mL normal saline Natrium Chloride (NaCl) 0.9%
214490764|NCT07038499|OTHER||Participants are not assigned an intervention as part of the study.
214490765|NCT07039006|BEHAVIORAL|Training with EA feedback|Subjects will undergo reaching training that includes a 30-degree elbow flexion error 3 times in 1 week.
214490766|NCT07039006|BEHAVIORAL|Training without EA feedback|Subjects will undergo reaching training that does not include EA feedback 3 times in 1 week.
215084780|NCT00970814|BEHAVIORAL|BBCET|11 BBCET sessions
215084781|NCT00970814|BEHAVIORAL|BBCET|11 BBCET Sessions
215084782|NCT00970814|DRUG|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
215084783|NCT00970814|DRUG|Sugar Pill|500mg - 2000mg Once per day 16 weeks
215084784|NCT02010736|OTHER|Single treadmill gait training with additional loading|
214490767|NCT07038408|PROCEDURE|Angioplasty with DCB (bail-out BRS)|"Angioplasty starts with lesion preparation in both arms with a PTCA balloon catheter.~The lesion is treated with the Mozec SEB through femoral or brachial artery. The DCB should be delivered to the target lesion within 120 seconds of insertion into the guide catheter. Under fluoroscopic visualization, the DCB is inflated at least 30 seconds (single inflation). If the results are insufficient, multiple inflation is permitted. If despite appropriate delivery and inflation of the DCB, the results remain insufficient bail-out BRS should be performed.~Bail-out BRS is performed through femoral or brachial artery. After correct positioning, the BRS is deployed slowly, i.e. 10 seconds/atm up to 4 atm, then 5 seconds/atm up to nominal pressure or higher until desired expansion is obtained. After desired expansion obtained, pressure is maintained for 30 seconds before balloon deflation. After BRS implantation, Optical Coherence Tomography (OCT) is performed, if available."
214490768|NCT07038408|PROCEDURE|Angioplasty with BRS|Bail-out BRS is performed through femoral or brachial artery. BRS implantation is guided by OCT, if available. After correct positioning, the BRS is deployed slowly, i.e. 10 seconds/atm up to 4 atm, then 5 seconds/atm up to nominal pressure or higher until desired expansion is obtained. After desired expansion obtained, pressure is maintained for 30 seconds before balloon deflation. After BRS implantation, OCT is performed, if available.
214490769|NCT07037914|BEHAVIORAL|Education and Counseling|"The researcher will inform the mothers (n=25) that the My Baby is Safe Educational Program will be delivered individually through distance education via Microsoft Teams at times convenient for them, and that the program will be completed over 5 days. The scheduling will ensure that all modules included in the My Baby is Safe Educational Program are completed within one week at the latest. Mothers will be informed that they can receive telephone counseling from the researcher until their infants reach two months of age, and the researcher's phone number will be provided to them. During this period, the researchers will send weekly reminder messages to the mothers' phones, encouraging them to read the provided educational booklet and to watch the educational videos.~The researcher will maintain communication with the mothers and conduct a home visit on the 15th day postpartum. During this home visit, the researcher will assess the infant's sleep environment for safe sleep practices."
214490770|NCT07037914|OTHER|Leaflet|"No structured or planned education will be provided to the control group by the researchers during the study period. After the first assessment, the mothers in the control group will receive a brochure prepared by the researchers based on the literature, containing brief informational notes on SIDS and SBS.~The researcher will maintain communication with the mothers and conduct a home visit on the 15th day postpartum. During this visit, the researcher will observe the home environment where the infant resides and evaluate the infant's sleep environment in terms of safe sleep practices.~After data collection from the intervention group has been completed, the same intervention (My Baby is Safe Educational Program) will also be delivered to the mothers in the control group."
214490771|NCT07038655|DIETARY_SUPPLEMENT|Randomised 20g Protein Supplement|Participants receive a 20g protein feed of their randomised blend over the course of five hours split into aliquots every twenty minutes. The drink also contains a top up of 13C2 leucine stable isotope tracer, as well as uniformly labelled 13C spirulina and 2H labelled free amino acids for quantification of digestibility.
214490772|NCT07039357|DEVICE|Near-infrared (spectroscopy) for non-invasive assessment of glycated keratin of nail|both interventions will be applied in both participant groups
214490773|NCT07039773|DIETARY_SUPPLEMENT|Vital wheat gluten|Gluten-containing shake vs gluten-containing cookie
214490774|NCT07039773|DIETARY_SUPPLEMENT|Vital wheat gluten|Half of participants will receive gluten-containing shake first, then gluten-containing cookie next, and vice versa
214490775|NCT07038863|DIAGNOSTIC_TEST|Community screening for hepatitis B, C and delta in the Mongolian population living in France|"Screening will be organised in 11 centres in France, with 1 to 3 screening sessions per centre: patients will be informed of these screening sessions by the Mongolian Embassy in France, social networks and communities.~During this screening visit, Rapid Diagnostic Orientation Test (RDOT) will be carried out to screen for HBV and HCV. If the RDOT is negative for both viruses, an information on transmission and prevention of viral infection will be given.~If the RDOT is positive, confirmation of these tests by blood sampling will be organized and complementary biology (ASAT, ALAT, GGT, PAL, bilirubin total, bilirubin conjugated). If HBV RDOT positive, additional tubes will be collected for centralized analysis at the end of the study (VHD DNA, VHD genotyping, fibrotest and LCR1/2 test).~Once these confirmatory tests have been carried out, the patient will be referred to a hepatology consultation."
214490776|NCT07039903|BEHAVIORAL|Cognitive behavioral therapy (CBT) + Functional Remediation (FR)|VECTOR will provide a newly designed intervention, based on the adaptation of two existing evidence-based and effective interventions (CBT for ADHD and FR for BD)(Corrales et al., 2024; Torrent et al., 2013).
214490777|NCT07038044|DIETARY_SUPPLEMENT|Arginine-restricted diet|"Targeted Arginine Metabolism: The intervention zeroes in on arginine metabolism. As solid tumors often have arginine synthesis flaws and rely on external arginine, dietary restriction of arginine is a novel approach.~Dietary Intervention: The -Arg liquid diet in this study is precisely defined. Dosage is determined by patient weight, following 30 kcal/kg/day for energy and 1.5 g/kg/day for protein. A low - arginine food list is provided.~Study Design and Endpoints: It's a Phase I single - arm study. Its main goal is to evaluate the safety and tolerance of the combined treatment. Secondary and exploratory endpoints cover efficacy, nutritional state, and immune status."
214490778|NCT07038993|OTHER|Venous Pressure Monitoring|Measurement of venous pressure will be taken at dialysis machine pump speed set at 200ml/min, fistula needle gauge 16.
214679715|NCT04346394|DRUG|Yohimbine HCl|Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning
214679716|NCT05707845|DRUG|Medical treatment.|Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
214679717|NCT05707845|BEHAVIORAL|weight reduction|weight reduction in the form low caloric diet program for 12 weeks.
214364703|NCT04635579|DEVICE|Blood flow restriction|Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure
214364704|NCT03075384|PROCEDURE|computer-assisted navigation system|The computer-assisted navigation system was applied in treatment of unilateral complicated zygomatic fractures
214364705|NCT01053195|BEHAVIORAL|Lifestyle counseling|Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
214364706|NCT02531178|BIOLOGICAL|ABBV-257|subcutaneous injection
214364707|NCT02531178|BIOLOGICAL|Placebo|Placebo for ABBV-257
214364708|NCT04122248|OTHER|standard radiographic imaging|standard radiographic imaging
214364709|NCT04122248|DEVICE|cervical total disc replacement|Artificial disc replacement (ADR) in the cervical spine is a minimally invasive procedure that involves removing diseased disc tissue and replacing it with an artificial disc. The artificial disc is designed to preserve the spine\&#39;s natural motion while remaining securely attached to the surrounding vertebral bones. The goal of ADR is to help preserve the motion of the cervical spine or spinal segment after surgery, which can improve the quality of life for patients.
214364710|NCT06839092|PROCEDURE|oxaliplatin-based PIPAC|"Patients operated for pT4 pN0-2 cM0 pMMR colorectal cancer (of the colon, colorectal junction or high rectum) or patients operated for pT3-4 pN0-2 cM0 pMMR colorectal cancer with positive cytology or in patients with pT3-4 pN0-2 M1c pMMR colorectal cancer with limited peritoneal carcinomatosis which is limited to one abdominal quadrant and was resected during index surgery and no other distant lesion, will undergo 6 months of adjuvant systemic chemotherapy associated with 3 cycles of oxaliplatin-based PIPAC (4-6 weeks apart).~Each PIPAC session will include exploration laparoscopy (with PCI score), peritoneal lavage for cytology and biopsies of healthy peritoneum of the four quadrants + Douglas + omentum), and oxaliplatin-based PIPAC."
214364711|NCT06839092|PROCEDURE|Control (Standard treatment)|Patients operated for pT4 pN0-2 cM0 pMMR colorectal cancer (of the colon, colorectal junction or high rectum) or patients operated for pT3-4 pN0-2 cM0 pMMR colorectal cancer with positive cytology or in patients with pT3-4 pN0-2 M1c pMMR colorectal cancer with limited peritoneal carcinomatosis which is limited to one abdominal quadrant and was resected during index surgery and no other distant lesion, will undergo 6 months of adjuvant systemic chemotherapy, followed by exploration laparoscopy (including 300ml peritoneal lavage for cytology and seven punch peritoneal biopsies in the four quadrants of the abdomen, Douglas and omentum, as well as peritonectomy of 1 cm2) at 6 months after index surgery before entering a standard surveillance program.
214364712|NCT00676286|PROCEDURE|3T MR Imaging|3TR Imaging
214364713|NCT00676286|PROCEDURE|C-Choline PET Scanning|C-Choline PET Scanning
214364714|NCT00676286|PROCEDURE|Gene Rearrangement|Gene Rearrangement
214364715|NCT01800773|BEHAVIORAL|Written Exposure Therapy|Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
214364716|NCT01800773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
214364717|NCT05362981|OTHER|CAT|2 group programs, led by trained speakers, addressing specific ED topics through written, verbal and/or behavioral exercises,
214364718|NCT04874402|PROCEDURE|Prepectoral approach|Two sheets of contour, fenestrated ADM sutured together are trimmed in accordance with the measurement of the expander/implant and fixed to the pectoralis major muscle (superiorly, medially, and inferiorly) and serratus fascia (laterally), covering the entire anterior surface of the device
214490779|NCT07038993|OTHER|Color Doppler Ultrasound|Arteriovenous fistula (AVF) Access flow (QA) will be obtained using color Doppler ultrasound using the Mindray-M5 ultrasound system. AVF feeding arterial flow will be measured immediately proximal to the fistula. The QA volume will be obtained using the algorithm available on the system, which is based on the mean flow of two measurements.
214490780|NCT07038018|DIAGNOSTIC_TEST|AI-ECG Algorithm|AI-ECG Algorithm to detect LVEF\<=40%
214490781|NCT07038317|OTHER|Intervention|Intervention involves e-cigarette education messages tailored to participants' vaping status that will be sent out in SMS via text messaging three times per week over the course of 6 months.
214490782|NCT07038317|OTHER|Control|Participants will receive non-tobacco messages (messages about sun safety) three times per week over the course of 6 months.
214490783|NCT07039513|OTHER|Blood sampling collection|Collection of an additional of 2.7mL citrate tube of blood for a D-dimer dosage.
214490784|NCT07038070|DRUG|Vaginal estrogen tablet|The dosage of the vaginal estrogen will be one 10mcg tablet administered vaginally nightly for 2 weeks, then administered vaginally twice weekly for 14 weeks.
214490785|NCT07038070|DEVICE|Via Solv Wellness (Hyaluronic Acid Therapy)|The dosage of Via will be a pea-sized amount applied vaginally along the vaginal and vulvar walls nightly for 16 weeks.
214490786|NCT07037888|DRUG|Ketorolac|IV ketorolac intraoperative loading dose Ketorolac 10mg 1 tablet q6hrs to start on POD0
214490787|NCT07037888|DRUG|Control (Standard treatment)|hydrocodone-acetaminophen 5mg/325mg 1 tablet q6hrs PRN to start on POD0 30 tablets
214490788|NCT07037888|DRUG|Control (Standard treatment)|indomethacin 75mg 1 tablet QD to start on POD0 10 tablets
214490789|NCT07037888|DRUG|Control (Standard treatment)|diazepam 5mg 1-2 tablets q8hrs PRN to start on POD0 15 tablets
214490790|NCT07037888|DRUG|Omeprazole|20 mg qd
214490791|NCT07038629|DRUG|S1|PO, 40\~60mg，BID（d1-14，d22-35，two cycles)
214975279|NCT01297686|OTHER|Tissue-specific plantar fascia self massage|This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot. The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch. Same procedure is then repeated for the left foot.
214975280|NCT01297686|DRUG|Dexamethasone|"A 22-gauge, 1.5 needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area."
214975281|NCT01207843|BEHAVIORAL|Imaging|CT image validation and lesion measurement, as well as comparison of different CT phases
214975282|NCT06580015|PROCEDURE|Computed Tomography|Undergo PET-CT
214975283|NCT06580015|OTHER|Flotufolastat F-18 Gallium|Given IV
214364719|NCT04874402|PROCEDURE|Partial Subpectoral approach|The leading edge of the pectoral muscle is elevated and a subpectoral pocket is fashioned. The lower medial origin muscle fibers are released for anatomical expander seating. An ADM sling is sutured from the leading edge of the pectoralis muscle to the inframammary fold (over the expander) and laterally to close the expander pocket. In both groups, the size of the expander and the intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities.
214490792|NCT07038629|DRUG|Iparomlimab|IV infusion, 5mg/kg, q3w (Started within 8 weeks of completion of radiation)
214490793|NCT07038629|RADIATION|Radiation|Concurrent Radiation, 1.8Gy/f, 28f;
214490794|NCT07038889|DEVICE|C-Mill VR+ by Motek|Participants perform treadmill-assisted walking while interacting with non-immersive, game-like environments displayed on screens attached to the treadmill.
214490795|NCT07038889|DEVICE|Walk-over-Ground|This intervention utilizes the HTC VIVE Pro 2 system for a realistic, fully immersive VR-assisted overground gait therapy. The immersive VR environment is designed to mimic real-world scenarios and challenges, enhancing the rehabilitation process by engaging patients in naturalistic gait activities.
214490796|NCT07038148|PROCEDURE|Stapled reversal of gastric bypass to sleeve gastrectomy utilising stapling technique.|This research entails a single-stage laparoscopic conversion of gastric bypass to sleeve gastrectomy. The procedure entails the closure of the gastrojejunostomy with an endo-stapler and the reconstruction of the stomach by resecting along the greater curvature to create a sleeve gastrectomy. An intraoperative leak test will be conducted using methylene blue. Patients are monitored postoperatively for at least 24 hours, with subsequent assessments of nutritional status, weight, gastroesophageal reflux disease (GERD) symptoms, and quality of life at 3 and 6 months.
214490797|NCT06751472|DIAGNOSTIC_TEST|VPS (Verbal Pain Score)|İt is a pain intensity determination system based on the system where there person tells a point between 0=(no pain) 10=( unbearable pain) and to describe their pain
214490798|NCT06751472|DIAGNOSTIC_TEST|WOMAC (Western Ontario and McMaster Universities Arthritis Index) scale|It includes 24 questions under three sub-headings as pain, stiffness and physical function
214490799|NCT06881147|BEHAVIORAL|Multimodal physiotherapy program|"Multimodal physiotherapy program of 6 weeks (3 times a week for 45 minutes), each session will include:~* Soft tissue mobilization of inoculated muscles;~* Stretching exercises of the inoculated muscles;~* Strengthening of antagonist muscles;~* Motor learning exercises (attentive strategies, feedback-based cervical active exercises).~Exercises will be progressively difficult (increase of active ROM) according to clinical improvements."
214490800|NCT06717425|DRUG|PF-07976016|Taken once daily
214490801|NCT06717425|DRUG|Placebo|Taken once daily
214490802|NCT07038122|PROCEDURE|Laparoscopic resection|Laparoscopic resection of bowel and corresponding mesentery.
214490803|NCT07038122|OTHER|Neoadjuvant Therapy|Neoadjuvant Therapy aims to downstage the tumor including different chemotherapy, targeted therapy and immunotherapy.
214364720|NCT04469647|DIAGNOSTIC_TEST|Serology Test|"Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).~at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test."
214490804|NCT07037797|DIAGNOSTIC_TEST|Order of the FAST echography|Randomisation of the order in which probes are used
214490805|NCT07038486|DEVICE|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
214490806|NCT06715397|OTHER|No intervention|No intervention
214679718|NCT05707845|OTHER|exercise|aerobic exercise in the form of walking on treadmill for 30 minutes 3 times a week for 12 weeks.
214679719|NCT00633139|BIOLOGICAL|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
214679720|NCT04108767|BEHAVIORAL|Answer to standardized questionnaires in quality of life, health, lifestyle and behaviors|"The cross-sectional study will be conducted in all students in health sciences in 3rd year enrolled at the University Claude Bernard Lyon 1 (UCBL) and participating at the required medical consultation at the college Health Department of UCBL, over a period of 9 months.~The self-questionnaires will be completed by the students during the mandatory medical preventive visit at the university health center.~All dimensions investigated by the questionnaire are usually questioned by the caregivers during the consultation as part of the usual follow-up of students."
214364721|NCT02066402|DRUG|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
214364722|NCT02066402|DRUG|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
214364723|NCT02066402|DRUG|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
214364724|NCT02066402|DRUG|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
214975284|NCT06580015|OTHER|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
214975285|NCT06580015|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
214364725|NCT05035914|DRUG|Anlotinib Hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
214364726|NCT05154383|BIOLOGICAL|Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)|Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.
214975286|NCT01959100|DRUG|Azithromycin|250 mg x 3/week per os during a meal for a period of 2 years
214975287|NCT01959100|DRUG|Placebo|250 mg x 3/week during a meal for a period of 2 years
214975288|NCT04327778|PROCEDURE|Music Therapy|Automate music therapy every two weeks
214364727|NCT05154383|BIOLOGICAL|Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine|Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.
214364728|NCT00663325|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
214364729|NCT01977300|DRUG|Valproate|serum level of 50 to 125 ug/L
214364730|NCT01977300|DRUG|Lithium|serum levels of 0.6 to 1.2 mmol/L
214364731|NCT01977300|DRUG|Risperidone|1 to 6 mg/day
214364732|NCT01977300|DRUG|Olanzapine|5 to 25 mg/day
214364733|NCT01977300|OTHER|Placebo|manufactured to mimic risperidone and olanzapine
214364734|NCT04290351|PROCEDURE|band ligation|"Rubber band ligation will be applied to patients, and then phlebotonic will be prescribed.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
214975289|NCT05512663|DEVICE|Irreversible Electroporation (IRE)|The area of the prostate that was positive for cancer based on the transperineal prostate biopsy will be targeted for ablation via the NanoKnife System. An MRI/TRUS fusion device probe will be placed in the rectum and the prostate will be visualized in both sagittal and axial views. The ultrasound grid which was used during the mapping biopsy will be oriented using anatomical landmarks and used to identify the location of the positive biopsy cores. The NanoKnife Single Electrode Probes will be surgically inserted into the prostate through the perineum using MRI/TRUS fusion guidance and the ultrasound grid for guidance.
214975290|NCT04804137|OTHER|Blood|Blood samples are taken at each visit to the day hospital for a programmed injection of immunotherapy.
214975291|NCT04804137|OTHER|sputum|induced by saline aerosol sputum during each visit to the day hospital for a programmed injection of immunotherapy.
214975292|NCT04804137|OTHER|saliva|spontaneous saliva during each visit to the day hospital for a programmed injection of immunotherapy.
214975293|NCT04804137|OTHER|stool|Stool analyses will be carried out on a sample taken by the patient at home and brought back at the time of a day hospital.
214975294|NCT03046849|OTHER|next-generation sequencing|Use next-generation sequencing to test germline mutation.
214975295|NCT05131763|BIOLOGICAL|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
214975296|NCT02426801|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
214975297|NCT02426801|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
214364735|NCT04290351|DRUG|oral 450 mg diosmin+50 mg hesperidin|"450 mg diosmin + 50 mg hesperidin will be prescribed to patients undergoing band ligation.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
214364736|NCT04493931|DRUG|Gepotidacin|Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.
214364737|NCT04493931|DRUG|Cimetidine|Cimetidine tablets will be available as unit dose strength 400 mg and will be administered orally.
214364738|NCT04493931|DRUG|Rifampicin|Rifampicin Capsules will be available as unit dose strength 300 mg and will be administered orally.
214364739|NCT04493931|DRUG|Midazolam|Midazolam oral syrup 2 milligrams per milliliter (mg/mL) will be available to be administered orally.
214364740|NCT04493931|DRUG|Digoxin|Digoxin tablets will be available as unit dose strength 0.25 mg and will be administered orally.
214364741|NCT04493931|OTHER|Placebo matching to gepotidacin|Placebo matching to gepotidacin tablets will be administered orally.
214975298|NCT01727921|DEVICE|22 gauge ProCore needle biopsy|22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
214364742|NCT04372836|PROCEDURE|Vasopressin injection|The intervention consists of five steps: rupture the ovarian endometrial cyst and remove the ''chocolate fluid;'' inject diluted vasopressin solution into the interface between endometrioma and ovarian parenchyma; stop injecting until the solution overflow; separate the endometrioma away from the ovarian parenchyma; and coagulate bleeding spots and suture the ovary.
214364743|NCT00814424|DEVICE|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
214364744|NCT00814424|DEVICE|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
214364745|NCT04721379|BEHAVIORAL|Meditation|"1. Group 1 participants with unguided session simply close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be asked to relax with eyes closed for 30 minutes. After finishing the session, they fill out meditation depth questionnaire.~2. Group 2 participants with guided sessions close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be guided through relaxation and meditation session for 30 minutes with a Heartfulness trainer with continued recording. After finishing the session, they also fill out meditation depth questionnaire."
214364746|NCT02857530|DRUG|rhTPO|rhTPO
214364747|NCT02857530|DRUG|placebo|without rhTPO
214490807|NCT06886646|OTHER|Allogeneic Mesenchymal Stromal Cell Therapy|Patients in this arm will receive 4 injections of allogeneic mesenchymal stromal cells (CSM) derived from human umbilical cord. The doses will be 1.106 cells/kg administered intravenously at days 0, 7, 14, and 21. The injections are given after thawing, washing, resuspension, and adjusting the dose. The CSM treatment aims to control chronic active antibody-mediated rejection (cABMR), improve renal function, reduce proteinuria, and increase graft survival without changing the immunosuppressive regimen.
214975299|NCT01727921|DEVICE|25 gauge ProCore needle biopsy|25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
214975300|NCT05087589|DRUG|Tofacitinib|Tofacitinib 5mg was taken orally twice a day for 6 months
214975301|NCT05803460|BEHAVIORAL|Stage 1 Experimental A group: actual natural environment|Participants will go to the park and sit still for 20 minutes.
214975302|NCT05803460|BEHAVIORAL|Stage 1 Experimental B group: virtual reality natural environment|Participants will experience the virtual reality natural environment by the researcher for 20 minutes
214364748|NCT01738620|BEHAVIORAL|psychological counseling|
215084785|NCT00629746|DEVICE|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~1. The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~2. A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~3. The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~4. The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
215084786|NCT03794869|OTHER|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
214364749|NCT01738620|BEHAVIORAL|prevention of sleep disorders in ICU|
214364750|NCT04317508|DRUG|Topicale GelPatch (Benzocaine 18%)|Intervention group
214364751|NCT04317508|DRUG|Benzocaine oral gel 20%|control group
214364752|NCT05032365|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
214490808|NCT06886646|OTHER|Placebo (NaCl 0.9%) Treatment|Patients in this arm will receive placebo treatments, which will consist of 150 mL of saline (NaCl 0.9%) administered intravenously at the same intervals as the CSM group (days 0, 7, 14, and 21). The placebo will be administered under the same conditions as the treatment, and the participants and investigators will remain blinded to the group allocation. Like the CSM group, no changes will be made to the patients' immunosuppressive regimen.
214490809|NCT07038460|DRUG|Limertinib+sintilimab+chemotherapy|Experimental group patients receive Limertinib for 6 weeks. Within 7 days thereafter, imaging assessment will be performed. If no progression is observed, experimental group patients discontinue therapy for 1 week, then receive Sintilimab + Carboplatin/Cisplatin + Pemetrexed every 3 weeks for 3 cycles.
214490810|NCT07038460|DRUG|Limertinib+chemotherapy|Control group group patients receive Limertinib for 6 weeks. Within 7 days thereafter, imaging assessment will be performed. If no progression is observed, control group patients receive Lilotinib for next 9 weeks + Carboplatin/Cisplatin + Pemetrexed every 3 weeks for 3 cycles.
214490811|NCT07038460|PROCEDURE|surgery|The surgical procedure may involve minimally invasive surgery (video-assisted thoracoscopic surgery, robot-assisted surgery) or open thoracotomy. The surgical methods include lobectomy, combined lobectomy, pneumonectomy, sleeve resection, and ipsilateral systematic mediastinal lymph node dissection (for left-sided tumors, stations 4L, 5, 6, 7, and 9 should be included; for right-sided tumors, at least stations 2R, 3A, 4R, 7, and 9 should be included).
214490812|NCT07038460|DRUG|Osimertinib|Adjuvant treatment with Osimertinib for 2 years
214975303|NCT05803460|BEHAVIORAL|Stage 1 Control group: city environment|Participants will sit still for 20 minutes in a city environment.
214975304|NCT05803460|BEHAVIORAL|Stage 2 group|tree element virtual natural environment and tree and water element virtual natural environment experiences
214975305|NCT05803460|BEHAVIORAL|Stage 3 Experimental group: virtual reality natural environment|virtual reality natural environment programs for 2 time a week (40 mins/ every week) and 8weeks.
214975306|NCT05803460|BEHAVIORAL|Stage 3 Control group: routine care|Control group received routine care last for 8 weeks.
214364753|NCT05032365|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values
214364754|NCT00001507|DRUG|Monoclonal Antibody 3A1|
214364755|NCT00001507|DRUG|Monoclonal Antibody 95-5-49|
214364756|NCT00001507|DRUG|Monoclonal Antibody 95-6-22|
214490813|NCT06578585|DRUG|Ubrogepant|Tablet
214490814|NCT06578585|DRUG|Lu AG09222|Solution for injection/infusion
214975307|NCT01958905|DRUG|Artemether-lumefantrine fixed combination|
214975308|NCT03634423|BEHAVIORAL|Sweet Spot: Flexible high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975309|NCT03634423|BEHAVIORAL|Sweet Spot: Flexible low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975310|NCT03634423|BEHAVIORAL|Sweet Spot: Rigid high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975311|NCT03634423|BEHAVIORAL|Sweet Spot: Rigid low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975312|NCT03634423|BEHAVIORAL|FOTW: High incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975313|NCT03634423|BEHAVIORAL|FOTW: Low incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975314|NCT03634423|BEHAVIORAL|FOTW: High incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975315|NCT03634423|BEHAVIORAL|FOTW: Low incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975316|NCT03634423|BEHAVIORAL|Think Twice: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975317|NCT03634423|BEHAVIORAL|Think Twice: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975318|NCT03634423|BEHAVIORAL|WDR: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
214975319|NCT03634423|BEHAVIORAL|WDR: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
215084787|NCT03794869|OTHER|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of CORE.
214490815|NCT06578585|DRUG|Placebo|Solution for injection/infusion
214364757|NCT00001507|DEVICE|Baxter Isolex 3001 Stem Cell Selection System|
214364758|NCT00001507|DEVICE|Ceprate SC|
214364759|NCT05589870|OTHER|Multi-drug analysis of polypharmacy treatment|Multi-drug analysis to assess and provide insights for lowering the risk of ADRs and increasing the benefit of polypharmacy treatment
214364760|NCT05672979|DRUG|Brolucizumab Injection [Beovu]|brolucizumab 6mg intravitreal injection
214364761|NCT03676179|PROCEDURE|patella denervation|patella denervation
214364762|NCT03676179|PROCEDURE|patella non-denervation|patella non-denervation
214364763|NCT00266825|DRUG|DHA|600 mg DHA
214364764|NCT00266825|OTHER|Placebo capsule|Placebo capsule
214364765|NCT04285450|DIETARY_SUPPLEMENT|Vitamin K|1mg
214364766|NCT04285450|OTHER|Placebo|Lactose
214490816|NCT06884969|BEHAVIORAL|Test of Sensory Function in Infants|It was planned to use the Test of Sensory Function in Infants to evaluate the sensory development of infants. Test of sensory function in infants is frequently used to evaluate the sensory processing functions of infants aged 4-18 months.
214490817|NCT06884969|BEHAVIORAL|Peabody Motor Development Scale-2|Peabody Motor Development Scale-2 was planned to be used to assess motor development. Peabody Motor Development Scale-2 was designed to determine developmental delays in children between 0-72 months.
214490818|NCT06882174|DRUG|Scheduling of the time of pembrolizumab infusions|The intervention in this study is scheduling of the time of pembrolizumab infusions.
214490819|NCT06724432|DRUG|oral melatonin|Melatonin treated children receive a single dose of oral melatonin 0.5 mg/kg (for a max 10 mg) in a fixed volume of 5 mL of water , 1 hour before induction of anesthesia for surgery
214490820|NCT06724432|DRUG|Placebo|Children in the Control group receive 5 ml of 5% dextrose solution once 1 hour before induction of anesthesia
214975320|NCT01531634|BEHAVIORAL|Dynamic Cognitive Intervention Group|Twelve meetings of a Dynamic Cognitive Intervention group.
214975321|NCT04615936|OTHER|Methylene-Blue Photodisinfection|Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
214975322|NCT04671199|OTHER|MP 3000 monitor|Additional monitoring
214975323|NCT00748241|DEVICE|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
214975324|NCT05746806|RADIATION|Ultrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy|Ultrahypofractioned radiotherapy for patients with isolated local recurrence after radical prostatectomy in 5 fractions
214975325|NCT05746806|DRUG|Androgen deprivation therapy|"In combination to the radiotherapy a short term androgen deprivation drug for 6 months will be applied.~The preferred drug concept used is:~\- LHRH(Luteinizing hormone releasing hormone)-agonist with 3-month subcutaneous depot injection (e.g. Pamorelin® LA (Triptorelin) 11.25mg s.c.) in combination with nonsteroidal antiandrogen (e.g. Bicalutamide 50mg/day) as flare protection at least 5 days before and max. 15 days after first LHRH-injection~Alternatively the following oral drug concept can be used, if the patient rejects injections:~\- GnRH (gonadotropin-releasing hormone)-antagonist with tablet intake for 6 months (e.g. Orgovyx® Tablets 120mg; first day 360mg, after second day 120mg per day)"
214975326|NCT01240382|DRUG|3% DE-089 ophthalmic solution|
214975327|NCT01240382|DRUG|0.1% sodium hyaluronate ophthalmic solution|
214975328|NCT02076100|DRUG|Ruzasvir|Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
214975329|NCT06029972|DRUG|Tilpisertib Fosmecarbil|Tablets administered orally
214975330|NCT06029972|DRUG|Placebo|Tablets administered orally
214490821|NCT06889311|PROCEDURE|Subperiosteal hyaluronic acid injection overlay technique|using subperiosteal hyaluronic acid injection overlay technique showed promising results in treating lost interdental papilla which needs further assessment to its clinical effectiveness
214975331|NCT04654741|DRUG|Medroxyprogesterone Acetate|1 pill per day
214975332|NCT04654741|DRUG|Ganirelix Acetate|1 injection per day
214975333|NCT02456727|PROCEDURE|Group/Community Acupuncture|Acupuncture treatment in a group setting.
214975334|NCT02456727|PROCEDURE|Individual Acupuncture|Acupuncture treatment in an individual setting.
214975335|NCT04644172|BEHAVIORAL|Speed of Processing Training|"Testing involves trainer-guided practice of computerbased video games. The games require the player to identify targets that are presented very briefly. In the first level, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. SOPT is aimed at improving the fluidity of mental processing speed (not psychomotor reaction time) so that trainees can process more complex information over briefer periods of time. The training involves practice with feedback. The trainer teaches some task-specific strategies, offer suggestions, encouragement, and personalized modification of difficulty for enhancing performance. Speed and task difficulty level are tailored to trainee ability, trainees practice blocks of 16 trials with a goal of achieving performance of 10 to 12 correct trials for each training block."
214975336|NCT04644172|BEHAVIORAL|Instrumental Activities of Daily Living Shaping|In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
215084788|NCT01998893|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
215084789|NCT03856008|OTHER|Exercises focused on flexor muscles|Exercises emphasis flexor muscles.
215084790|NCT03856008|OTHER|Exercises focused on extensor muscles|Exercises emphasis extensor muscles.
214490822|NCT06889311|PROCEDURE|Tunneling with connective tissue graft.|Connective tissue graft base techniques have been for years the most predictable approach for treatment of interdental papillary defects. CTG can as a biological filler which enhances flap stability and wound strength. CTG also can promote coagulation cascade and protects the maturating fibrin clot (Tavelli et al. 2019). Moreover, CTG results in significant increase in gingival tissue thickness which positively improve tissue fill and soft tissue volume creeping which influence esthetic outcomes following periodontal regeneration
214490823|NCT06722807|PROCEDURE|sutureless, clampless partial nephrectomy|All subjects will undergo a clampless, sutureless robotic partial nephrectomy.
214490824|NCT06730672|DRUG|Volonib combined with Everolimus Formation|Volonib 200mg once daily and Everolimus 5mg once daily
214490825|NCT06730958|DIAGNOSTIC_TEST|serum Follistatin-like protein 1|Serum FSL1 level Test principle The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay(ELISA) to assay the level ofHuman Follistatin Like Protein 1(FSTL1) in samples. Add Follistatin Like Protein 1(FSTL1)to monoclonal antibody.Enzyme well which is pre-coated with Human Follistatin Like Protein1(FSTL1)monoclonal antibody, incubation; then, add Follistatin Like Protein 1(FSTL1)antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme. Then add Chromogen Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally becomes yellow. The chroma of color and the concentration of the Human Substance Follistatin Like Protein 1(FSTL1) of sample were positively correlated.
214490826|NCT06888674|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Neoantigen Therapeutics Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
214490827|NCT06888674|DRUG|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m², administered intravenously over 30 minutes on Day 1 and Day 8; Capecitabine: 1650-2000 mg/(m²·day), divided into two daily oral doses from Day 1 to Day 14.~Treatment cycles repeat every 3 weeks for 8 cycles, with the actual number of cycles determined by the investigator based on comprehensive evaluation of the patient's physical status, disease progression, and adverse reactions."
214490828|NCT06888674|DRUG|Sintilimab injection|Sintilimab Injection, 200mg, intravenous infusion, every 3 weeks
214490829|NCT06733428|DEVICE|Pachymeter|Measure the thickness of the cornea
214490830|NCT06423300|DEVICE|LIFT Implant|The LIFT implant provides a less invasive option for treatment of patellofemoral cartilage degeneration in the knee. the LIFT implant unloads the patellofemoral joint by elevating the patellar tendon to unload the joint compartment and realign the kneecap toward healthier cartilage
214490831|NCT06423300|OTHER|Tibial Tubercle Osteotomy|Tibial Tubercle Osteotomy
214490832|NCT07039799|BEHAVIORAL|Virtual Reality + Conventional Physiotherapy|This intervention involves the use of fully immersive virtual reality (VR) applications delivered through the Meta Quest 3 headset, integrated with hand-tracking technology. Participants engage in three custom-designed VR games aimed at improving shoulder, elbow, wrist, and hand functions. The games are tailored to individual functional levels and include progressive difficulty. Sessions are conducted twice per week for 8 weeks, each lasting approximately 40 minutes, under the supervision of a physiotherapist. This intervention is combined with conventional physiotherapy (excluding functional upper extremity exercises).
214490833|NCT07039799|BEHAVIORAL|Conventional Physiotherapy|This intervention consists of a standard physiotherapy program for individuals with Duchenne Muscular Dystrophy. It includes aerobic exercises, strengthening exercises, stretching routines, postural training, respiratory exercises, and functional upper extremity exercises. The sessions are delivered by a physiotherapist twice weekly for 8 weeks, with each session lasting approximately 40 minutes.
214490834|NCT07039578|BIOLOGICAL|CM336 Injection(Low dose group)|subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.
214490835|NCT07039578|BIOLOGICAL|CM336 Injection(High dose group)|subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.
214490836|NCT07038759|DEVICE|the Motion Estimation and Motion Compensation|Motion Estimation and Motion Compensation (MEMC) is a video processing technology designed to enhance display quality by interpolating additional frames, thereby reducing motion blur and stuttering in fast-moving scenes. This is achieved by estimating motion between video frames and generating intermediate frames, effectively increasing the frame rate (e.g., from 30 FPS to 120 FPS) and display refresh rate (e.g., from 30 Hz to 120 Hz).
214502795|NCT05861258|DRUG|Minocycline|Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
214975337|NCT04644172|BEHAVIORAL|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
214975338|NCT04644172|OTHER|Usual Care|Healthcare that is available for adults with cognitive impairment subsequent to COVID-19 in the community on a clinical basis. This includes commercially available, gamified, computerized cognitive training programs.
214975339|NCT04236037|PROCEDURE|ultrasound-guided pleural biopsy|Using ultrasound the optimal point of entry for thoracentesis is located. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site . Again, the area is wiped with disinfectant and a millimeter small skin incision is made with a pointed scalpel. Six US-guided biopsies of 1.2 millimetres using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core needle 18G, Temple, Arizona, USA). ) are taken from the parietal pleura. Thoracentesis is performed as described above using the same incision as the pleural biopsy.
214364767|NCT04452292|OTHER|Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma|Treatment assigned to targetable mutation. Or, for tumors that are by and large without any targetable mutation follow Large-Cell Neuroendocrine Carcinoma (NCCN) guideline-directed best front-line treatment for specific non-small cell carcinoma/adenocarcinoma.
214364768|NCT04452292|OTHER|Treatment for Small Cell Lung Cancer|Treatment assigned to a targetable mutation or the current standard-of-care regimen for the treatment of small cell lung cancer.
214490837|NCT06723899|OTHER|CanWork|CanWork is an online, occupational therapy intervention to develop knowledge and skills to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based modules and an individual meeting between the occupational therapist facilitator and each participant. Each of the five-week group-based modules consists of two components: (i) education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work and (ii) goal setting to facilitate application of knowledge and skills to work-related activities. Weekly topics include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues. The individual meeting between each participant and the occupational therapist is focused on designing a tailored return to work plan for each participant.
214490838|NCT06729892|DRUG|Esketamine at low dose|Esketamine at low dose was administered(0.2mg· kg-1, 5 ug· kg-1 continuous infusion) and drug dosage was adjusted(propofol and remifentanil) based on the new BIS baseline ( calculated from the pilot study).
215084791|NCT01158144|DRUG|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
214364769|NCT01939704|OTHER|Pediatric Primary Care Intervention|30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.
214364770|NCT01939704|OTHER|Pediatric Urgent Care Intervention|3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
214490839|NCT06729892|DEVICE|new BIS baseline|Close-loop TCI control was under new BIS baseline(calculated from pilot study) in the presence of esketamine at low dose.
214490840|NCT06729892|DRUG|an equivalent dose of saline|An equivalent dose of saline was given and closed-loop control stared.
214490841|NCT06729892|DEVICE|original BIS baseline|Drug dosage was adjused under close-loop control based on original BIS baseline.
214490842|NCT05733611|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus
214490843|NCT05733611|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
214490844|NCT05733611|BIOLOGICAL|atezolizumab|anti-PD-L1 monoclonal antibody
214490845|NCT05733611|BIOLOGICAL|bevacizumab|anti-VEGF therapy
214975340|NCT04236037|PROCEDURE|Thoracentesis|The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.
214975341|NCT01616043|PROCEDURE|Glyaderm|acellular dermis
214975342|NCT01616043|PROCEDURE|STSG|autologous split skin only
214975343|NCT00346866|DRUG|anecortave acetate|
214975344|NCT00685516|DIETARY_SUPPLEMENT|green tea|6 cups of green tea daily for 2-8 weeks
214975345|NCT00685516|DIETARY_SUPPLEMENT|placebo|6 cups of water daily for 2-8 weeks
214975346|NCT00685516|DIETARY_SUPPLEMENT|decaffeinated black tea|6 cups of decaffeinated black tea daily for 2-8 weeks
214975347|NCT04122261|DEVICE|the MicroHand S endoscopic instrument control system|Using the MicroHand S endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
214975348|NCT04122261|DEVICE|the da Vinci endoscopic instrument control system|Using the da Vinci endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
214975349|NCT02643693|OTHER|P3L|"Ad libitum use for a maximum of three hours.~P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime."
215084792|NCT01158144|DRUG|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
214364771|NCT02834702|DEVICE|Sinew acupuncture|The subject is asked to be on sitting posture. The skin around the needling points is disinfected with a 75% alcohol swap. A tube-guided, sterilized, disposal needle is then inserted (at a small angle to the skin) into the acupoint at 0.5-1 cun (depending on point location and body size of the subject). No needle sensation (deqi sensation) is required. A piece of surgical adhesive tape will be applied to the needle immediately after insertion.
214975350|NCT02643693|OTHER|VUSE|"Ad libitum use for a maximum of three hours.~VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime."
214975351|NCT02643693|OTHER|CC|Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
214364772|NCT02834702|DEVICE|Sham acupuncture|The procedure in the sham acupuncture group will be as similar to that of the acupuncture group as possible. In the sham acupuncture group, however, a mock plastic needle guiding tube is tapped on the surface of each acupoint (Ashi point and traditional acupoints) to produce some discernible sensation. A piece of adhesive tape is immediately applied to fix the needle on the dermal surface tapped, without needle insertion. In addition, a plastic tube-guided needle is superficially inserted at the sham point at less than 5mm in depth.
214364773|NCT01782443|DRUG|Ziv-aflibercept|
214364774|NCT03671174|DRUG|Prednisone|10mg once daily orally
214364775|NCT03671174|DRUG|Hydroxychloroquine|100mg to 200mg twice daily orally
214364776|NCT03671174|DRUG|Aspirin|50mg once daily orally
214364777|NCT03671174|DRUG|low molecular weight heparin|Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
214490846|NCT06733597|PROCEDURE|Cement|The cemented approach includes inserting cement into the femur and tibia prior to setting the prosthetic.
214490847|NCT06733597|OTHER|Cementless|The non-cement approach uses a different type of prosthetic that is placed tight against the bone and requires no other fixation material.
214490848|NCT06733597|PROCEDURE|Manual Surgery|The manual approach is the surgeon determining prosthetic placement using techniques developed during training.
214490849|NCT06733597|PROCEDURE|Robotic Surgery|The haptic robotic assisted approach uses a computer and robot to determine specific placement of the prosthetic.
214490850|NCT06732284|OTHER|Psychomotor vigilance task|Five PVT tests (before sleep at 7pm, 7am, 7:30am, 8am and 11am). The PVT is a 10-minute test designed to assess the vigilance and sustained attention by measuring reaction times (RT) to visual stimuli. During the test, participants are required to monitor the computer screen and press the response button as soon as a millisecond counter appears which will stop the counter and display the RT in milliseconds. The stimuli are randomly presented.
214490851|NCT06732284|OTHER|Video-polysomnography|Performed overnight as part of routine care (11 p.m. to 7 a.m.).
214975352|NCT00016536|DRUG|Naphthalene 2-sulfonate polymer|
214490852|NCT06732284|OTHER|Sleep and activity monitoring|Actimeter and sleep diary to assess the sleep-wake patterns of the participants in their natural environments over a two-week period.
214679721|NCT06671288|OTHER|Balloon-blowing exercises with abdominal & lumbar core muscle activation position.|"Patients in this group will recieve Balloon-blowing exercises with abdominal and lumbar core muscles activation position Total 4 weeks protocol will be followed in which 3 sessions per week will be supervised by physical therapist.~FREQUENCY: 3 times a week, INTENSITY : Moderate, TIME: 4 sets of balloon-blowing with 1 min rest (30 mins) TYPE: Balloon-blowing with abdominal \& lumbar core muscle activation position, DURATION : 4 weeks"
214679722|NCT06671288|OTHER|Diaphragmatic breathing exercise|Participants in this group will only be receiving diaphragmatic breathing exercise for 4 weeks. FREQUENCY: 3 times a week , INTENSITY: Moderate, TIME: 4 sets of diaphragmatic breathing with 1 min rest, TYPE: Diaphragmatic breathing, DURATION: 4 weeks
214490853|NCT06738901|BIOLOGICAL|SKP-0141|Human plasma-derived coagulation factor VIII concentrate
214490854|NCT06887179|PROCEDURE|HF focused POCUS|"* POCUS findings guide diuretic therapy adjustments by treating physicians~* POCUS is performed with handheld device Vscan air SL® or Vscan extend®, GE Healthcare.~* Sector probe and abdominal preset are used. Only B-mode is used.~* The image depth is 15 cm or more to evaluate the structures sufficiently.~* Patient position is supine or semirecumbent. For the pleural effusion exam, the preferred position is sitting.~  1. Lungs: Assessment of B-lines in midclavicular and midaxillary zones.~ 2. Pleural Effusion~ 3. Inferior Vena Cava~ 4. Ascites"
214490855|NCT06887179|PROCEDURE|Standard Care (in control arm)|Standard care assessment with NT-proBNP on every scheduled visit.
214679723|NCT06671028|DRUG|Ropivacaine and Lidocaine|Popliteal sciatic block using Ropivacaine 100 mg and Lidocaine 100 mg in 20 mL
214975353|NCT00016536|DRUG|Carbopol polymer|
214975354|NCT00005998|DRUG|carmustine|
214679724|NCT06671028|DRUG|Ropivacaine 0,5%|Popliteal sciatic block using ropivacaine 0.5% 20 mL
214679725|NCT06671145|DIAGNOSTIC_TEST|catheter ablation|Catheter ablation after differentiating Atrioventricular Nodal Reentry Tachycardia from Orthodromic Atrioventricular Reentry Tachycardia during electrophysiological study.
214975355|NCT00005998|DRUG|cyclophosphamide|
214975356|NCT00005998|DRUG|cytarabine|
214975357|NCT00005998|DRUG|dexamethasone|
214975358|NCT00005998|DRUG|etoposide|
214975359|NCT00005998|DRUG|filgrastim|
214975360|NCT00005998|DRUG|mitoxantrone hydrochloride|
214364778|NCT01122082|BEHAVIORAL|food preloads|Subjects will eat in the morning during breakfast 300g cottage cheese (627kJ - 147kcal; 13.2g carbohydrate, 0.3g fat, 23g protein) plus, according to the situations, either: 90g sucrose, HCB); 6g aspartame; 40g vegetable oil; 40g paraffin oil. Therefore two breakfast will have the same energy content (2072kJ - 495kcal), as did the other two(565 kJ - 135kcal).
214364779|NCT01291914|DRUG|FX005|Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)
214364780|NCT01291914|DRUG|Placebo 1 (Carrier)|Single intra-articular injection
214364781|NCT01291914|DRUG|Placebo 2 (Diluent)|Single intra-articular injection
214364782|NCT04069598|DIAGNOSTIC_TEST|Statin intolerance test|Statin intolerance test
214490856|NCT06889233|BEHAVIORAL|measuring cognitive functions, severity of autism , gross and fine motor skills|measuring cognitive functions by RAVEN measuring severity by CARS measuring fine and gross motor functions by BOT2
214490857|NCT02652052|OTHER|Standard of Care - Observation Only|Control Arm - Observation only
214490858|NCT02652052|DRUG|Group 2: Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
214490859|NCT02652052|DRUG|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
214975361|NCT00005998|DRUG|retrovirus vector LN|
214975362|NCT00005998|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214975363|NCT00005998|PROCEDURE|peripheral blood stem cell transplantation|
214975364|NCT00005998|PROCEDURE|radiation therapy|
214975365|NCT00492297|DRUG|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
214364783|NCT04295954|OTHER|Yoga Intervention|"It is an intervention based on Hatha yoga designed specifically to improve dysmenorrhea. This intervention consists of physical postures, also called asanas; meditation and breathing. It begins with a progression of various asanas until reaching the three central postures: cat, cobra and fish. The compensation asanas of these central postures are then performed, and it is closed with a relaxation. The program and Yoga Intervention have been triangulated by experts and piloted afterwards."
214364784|NCT03769402|DRUG|Citric acid|Citric acid ph1, 50% concentration solution
214490860|NCT06756464|DEVICE|ROHKEA: Virtual Reality Therapy|Using Interpretative Phenomenological Analysis (IPA): an exploration of the therapeutic benefits of a Virtual Reality enhanced Cognitive Behavioural Therapy (CBT) and movement (graded exposure) therapy 60-day chronic pain management programme (CPMP). Using the ROHKAE device and undertaking semi structures interviews, pain questionnaires and patient diaries to measure patient experience and pain management
214490861|NCT06829914|DEVICE|Shockwave Catheter|Shockwave™ IVL + DCB procedure
214490862|NCT06829914|PROCEDURE|CFA Endarterectomy|Standard CFA endarterectomy
214490863|NCT06758050|OTHER|Core strengthening exercises|By core strengthening exercise, could be improved pain, balance, and function in patients with patellofemoral pain syndrome. In that case, this will not only improve their postural stability and neuromuscular control, but we believe it will improve their overall functional, performance, and quality of life. Currently, limited evidence exists about the effectiveness of core strengthening exercises on pain, function and dynamic balance in patellofemoral pain syndrome. By addressing core strengthening exercise, physical therapists can advise new treatment methods for patellofemoral pain syndrome (Chevidikunnan et al., 2016)
214490864|NCT06758050|OTHER|Traditional treatment|hip and knee-focused exercises
214490865|NCT06734806|DIAGNOSTIC_TEST|Radiographic Imaging and Digital STL Analysis|This study utilizes radiographic imaging (bitewing radiographs) and digital analysis of archived STL files to evaluate the clinical performance of endocrown and overlay restorations. The STL files are processed using Materialise 3-matic software to calculate cemented surface areas. Radiographic imaging assesses the presence of secondary caries or other failures. These diagnostic methods provide quantitative and visual data to evaluate long-term outcomes of the restorations.
214490866|NCT06734806|DIAGNOSTIC_TEST|FDI Criteria Evaluation and Plaque Index Measurement|This intervention includes the evaluation of dental restorations using modified FDI criteria, assessed on a 5-point Likert scale that measures aesthetic, functional, and biological outcomes. Additionally, oral hygiene is assessed through the measurement of the plaque index, with a mean score calculated for each participant. The use of both FDI-based Likert scoring and plaque index measurements allows for a detailed evaluation of restoration performance and oral health status, combining subjective patient-reported outcomes with objective clinical metrics.
214490867|NCT06735768|DEVICE|rTMS treatment|Brightmind.AI´s rTMS protocol is applied
214490868|NCT06735768|DEVICE|Determination of motor hotspot and motor treshold|Determination of motor hotspot and motor treshold
214490869|NCT06735066|PROCEDURE|Ascending urethrocystography|"It will be performed after instructing the patient to evacuate the bladder. A contrast agent will be infused through the urethra under fluoroscopy, using a urethral catheter or Knutson's clamp at the external urethral meatus. When the bladder is full, an anteroposterior film and two oblique films will be taken. Voiding cystourethrography will be performed as a part of this imaging examination. From this procedure, the following findings may be diagnosed:~* Upper urinary tract: Vesicoureteral reflux (VUR); laterality and degrees of VUR will be defined.~* Bladder: Capacity (defunctionalized, Small-sized or contracted bladder), neurogenic bladder, bladder diverticulum, filling defects, etc.~* Urethra: Stricture and filling defects."
214490870|NCT06734949|OTHER|AI-guided patient classification|The intervention consist in firstly obtaining clinical, genetic, histopathological, MRI data from total 500 patients coming from the defined Cohorts. The adaptative AI-tool developed, based on data provided, will then identify multi-modal characteristics that will support patients' superclusters and their multi-omics signatures.
214490871|NCT06810297|PROCEDURE|Therapeutic Exercise|It will consist of an 8-week intervention divided into 2 weekly sessions, in which functional exercise will be combined with aerobic exercise. A progressive protocol will be carried out.The sessions will last approximately 60 minutes divided into a first aerobic part which will serve as a warm-up for the functional part, then a main part with approximately 6 exercises and, finally, a cool-down of 3 to 5 minutes with relaxation exercises and stretching.
214679726|NCT06673030|BEHAVIORAL|Using Kaleidoscope glasses during pulpotomy procedures|Kaleidoscope is an instrument that shows an infinite number of fascinating geometric shapes in the form of a flower, repeating and reflecting images of coloured goggle fragments in the front section in a prism mirroring the inner surface.
214975366|NCT04487990|DRUG|unfractionated Heparin|Addition of unfractioned heparin to CVVHD system already running under citrate regional anticoagulation.
214975367|NCT03541837|DRUG|Ropivacaine|ESP catheter
214364785|NCT03769402|DRUG|Control Test|Control group, xenograft was used to fill infrabony defects without treating bone surface
214364786|NCT00595504|DRUG|Ramelteon|Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
214364787|NCT00595504|DRUG|Placebo|Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
214364788|NCT00314925|DRUG|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10\^7 vp/kg), IV (in the vein) over 1 hour in a single administration
214364789|NCT03039595|OTHER|Ploidy and tumour:stromal ratio measurements|Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)
214364790|NCT02098213|OTHER|Immediate spa treatment|soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
214364791|NCT02098213|OTHER|Late Spa treatment|soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
214364792|NCT01291784|BIOLOGICAL|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
214364793|NCT05143827|OTHER|Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
214679727|NCT06673030|BEHAVIORAL|The Play-Doh Doctor Drill 'n Fill toy set|Consists of a plastic human head with slots into which Play-doh molded teeth can be inserted. A battery operated toy drill is used to drill into and clean the black, cavitated tooth model and filled with white Play-Doh compound to simulate cavity preparation and restoration using tooth colored cement.
214364794|NCT05143827|OTHER|Pasta manufactured with current wheat varieties (Claudio)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
214364795|NCT05410938|DRUG|Chemotherapy|Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
214364796|NCT00027001|BEHAVIORAL|Aerobic and Resistance Exercises|
214364797|NCT00027001|BEHAVIORAL|Qigong|
214364798|NCT02154633|BEHAVIORAL|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
214364799|NCT02154633|BEHAVIORAL|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
214364800|NCT00049374|BIOLOGICAL|oblimersen sodium|
214364801|NCT00049374|DRUG|dexamethasone|
214364802|NCT00049374|DRUG|thalidomide|
214364803|NCT01379872|OTHER|Non-Interventional Study|This is a non-interventional study
214364804|NCT04746573|DEVICE|Natrox Topical Oxygen Therapy|Device delivering humidified oxygen directly to the wound bed
214364805|NCT02872701|DRUG|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
214364806|NCT02872701|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
214364807|NCT02872701|PROCEDURE|Endoscopic or Thoracic Surgery|Endoscopic or Thoracic Surgery
214364808|NCT00187226|PROCEDURE|Radiation Therapy|External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
214364809|NCT00187226|PROCEDURE|Radiation Therapy|External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
214364810|NCT02182973|DIETARY_SUPPLEMENT|donor human milk|"Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.~GI-subscores from the Finnegan NAS Scoring system will be computed."
214364811|NCT01235546|DRUG|Azithromycin and standard of care|500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
214364812|NCT01235546|DRUG|Placebo and standard of care|250 cc normal saline, plus standard of care (cephazolin or clindamycin)
214364813|NCT01123382|DEVICE|Intramuscular Electrical Stimulator|A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
214364814|NCT01123382|OTHER|Outpatient Therapy|Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
214364815|NCT00885196|DRUG|Placebo|
214364816|NCT00885196|DRUG|AEB071|
214364817|NCT04704518|DRUG|Sodium Hyaluronate Ophthalmic 0.4%|Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.
214364818|NCT04704518|DRUG|Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%|Topical ophthalmic administration of one drop of Thealoz® Duo QID.
214364819|NCT00758238|OTHER|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
214364820|NCT03985891|DRUG|Anti-PD-1 Monoclonal Antibody JS001|Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
214364821|NCT03985891|DRUG|Chemotherapy|Folfox
214364822|NCT04334265|DRUG|Anluohuaxian|6g each time, twice a day
214364823|NCT01474096|OTHER|implementation strategy of Breastfeeding|implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
214364824|NCT02054806|BIOLOGICAL|Pembrolizumab|IV infusion
214364825|NCT00885092|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
214364826|NCT00885092|DEVICE|RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)|Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
214364827|NCT00885092|DEVICE|Senofilcon A contact lens (ACUVUE® Oasys™)|Commercially marketed silicone hydrogel contact lens for daily wear use
214364828|NCT00885092|DEVICE|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
214364829|NCT05288010|COMBINATION_PRODUCT|Cannabis|The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
214975368|NCT01408706|DEVICE|Miller Air tip|Miller Enema Air Tip is inserted into rectum prior to simulation and each radiation treatment.
214975369|NCT01408706|DEVICE|Radiadyne Immobilizer|Radiadyne Immobilizer is inserted into rectum prior to simulation and each radiation treatment
214975370|NCT06138210|DRUG|exosomes derived from human induced pluripotent stem cell for injection|Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, 1×10\^11particles/ml).
214975371|NCT06138210|DRUG|a placebo of exosomes derived from human induced pluripotent stem cell for injection|Exosomes placebo, 3.0ml
214975372|NCT00919880|DRUG|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL\*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
214364830|NCT04949659|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum
214490872|NCT06810297|COMBINATION_PRODUCT|Therapeutic exercise and sexual education|"The sexual education part will consist of a 4-week intervention divided into 1 session every two weeks in an online format, in which topics related to the pathology and self-knowledge will be addressed. The sessions will last approximately 60 minutes, divided into a first part of reception and welcome of the group (lasting approximately 5-10 minutes), then the main content will be divided differently in each session (the explicit content of each session will be detailed later) and will end with a farewell and closing of the online session (lasting approximately 5-10 minutes) together with the explanation of the homework.~In addition, they will also carry out the therapeutic exercise protocol."
214490873|NCT06743893|OTHER|Diagnosis and outcome of non traumatic chronic subdural haematoma in pediatric age groups|Diagnosis and outcome of non traumatic chronic subdural haematoma in pediatric age groups
214975373|NCT00919880|DRUG|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
214975374|NCT05414214|PROCEDURE|Thyromental Height Test|Thyromental Height Test (TMHT) : will be measured while a patient is lying supine with the head and neck are maintained in a neutral position using a pillow under the head. By using a digital depth gauge, the TMH is the vertical distance measured between the anterior border of the thyroid cartilage directly on the thyroid notch and the anterior border of the mentum.
214975375|NCT05414214|PROCEDURE|Sternomental displacement|Sternomental displacement (SMDD): While the patient is sitting with the head in a neutral position, SMD-neutral will be measured using a tape as the distance between upper borders of the manubrium sterni and the mentum. The SMD-extension will then be measured in the same way with the head extended on the neck. The difference between SMD-extension and SMD-neutral will then be calculated as SMDD.
214975376|NCT05414214|PROCEDURE|General anesthesia|patients will be pre-oxygenated with 100% oxygen for 3 minutes, anesthesia will be then induced intravenously using fentanyl 2 μg/kg, propofol 1 -1.5 mg/kg, and succinylcholine 1 mg/kg lean body weight. Mask ventilation will be maintained till complete muscle relaxation guided by a peripheral nerve stimulator. Using Macintosh laryngoscopy, an anesthetist who has at least three years experience and who will be blinded to the preoperative tests' results, determined the best laryngeal view by using Cormack-Lehane (CL) grading system from I-IV. External neck manipulation will be used when needed to obtain the best laryngoscopic view. Endotracheal intubation will then be accomplished. The number and duration of intubation attempts will be recorded.
214364831|NCT00946439|DEVICE|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
214364832|NCT06103214|OTHER|acute normovolemic hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a medical procedure that involves removing a certain volume of blood from a patient before surgery and replacing it with a volume expander or blood substitute. The goal of ANH is to reduce the need for blood transfusions during or after surgery. During the ANH procedure, a patient's blood is typically withdrawn and replaced with a crystalloid or colloid solution. This dilutes the patient's blood, reducing the concentration of red blood cells. The withdrawn blood is then stored and can be reinfused back into the patient after the surgical procedure is completed.
214364833|NCT06103214|OTHER|acute hypervolemic hemodilution (AHH)|The purpose of diluting the blood with fluids and removing some of the red blood cells is to decrease the viscosity of the blood. This can improve blood flow and oxygen delivery to tissues, especially in cases of decreased blood flow or oxygenation.
214364834|NCT00480701|DRUG|[123I]-IBVM|Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
214364835|NCT04782557|DIAGNOSTIC_TEST|EUS-guided portal vein and hepatic vein aspiration|EUS-guided portal vein and hepatic vein aspiration
214975377|NCT03693196|OTHER|PICF, Perio-paper®|PICF was collected from the mesio-buccal area of the implant by using paper tapes. Paper tapes were placed 1-2 mm inside the peri-implant sulcus by using a dental tweezer. After they were kept for 30 s, the paper tapes were placed in sterile microcentrifuge tubes which contained 200 µL phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. TNF-α, PGE2, RANKL, RANK, and OPG, which are immunological markers of peri-implant disease were compared between groups.
214975378|NCT03693196|OTHER|Subgingival Plaque, Hu-Friedy®|Subgingival plaque samples were collected about 15 min after PICF was collected. Supragingival plaque was carefully removed by using a sterile scale. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal area of the implant by using sterile plastic Gracey curettes during 30 s (Hu-Friedy). The samples collected were transferred to sterile microcentrifuge tubes containing 200 µL PBS. The tubes were kept at -80°C until the analysis day. Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus oralis, which are microbiological agents of peri-implantitis were compared between groups.
214364836|NCT03466424|RADIATION|preoperative short-course radiotherapy|Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
214975379|NCT03693196|OTHER|Williams probe, PCPNU-15 Hu-Friedy®|Clinical periodontal measurements were recorded using Williams probe. The plaque index, gingival index, pocket depth, bleeding on probing, clinical attachment level, and keratinised tissue width around the implant were recorded. The implants included were categorised into three groups, namely, healthy, peri-implant mucositis, and peri-implantitis. Panoramic radiographs were acquired to assess the interproximal bone levels around the implant.
214364837|NCT04843787|DRUG|SLV213|SLV213 oral capsule (200mg) BID
214364838|NCT04843787|DRUG|SLV213|SLV213 oral capsule (400mg) BID
214364839|NCT04843787|DRUG|SLV213|SLV213 oral capsule (800mg) QD
214364840|NCT04843787|DRUG|Placebo|Placebo oral capsule (200mg) BID
214364841|NCT04843787|DRUG|Placebo|Placebo oral capsule (400mg) BID
214364842|NCT04843787|DRUG|Placebo|Placebo oral capsule (800mg) QD
214364843|NCT04010240|OTHER|Retrospective cohort|Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.
214364844|NCT05374902|OTHER|Providing procedural informational animation video|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit, and the procedure was performed as in standard care.
214364845|NCT05374902|DEVICE|Buzzy|Buzzy® was placed on the injection site and it was turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
214364846|NCT05374902|COMBINATION_PRODUCT|Multiple interventions|Watching procedural informational animation video prior to venipuncture, and Buzzy application during venipuncture
214364847|NCT00212381|DRUG|di indolylmethane (DIM)|This is the agent being studies. Similar agents have been reported to have potential activity.
214364848|NCT00212381|DIETARY_SUPPLEMENT|Red rice bran|"this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules"
214364849|NCT04996615|OTHER|no intervention|no intervention
214364850|NCT03013023|BEHAVIORAL|BS|NNS, FT, positional support, and oral sucrose feeding
214364851|NCT03013023|BEHAVIORAL|Routine care|Routine NICU care
214364852|NCT03013023|BEHAVIORAL|PITP|Parents will learn to regulate infant responses while implementing caregiving activities.
214364853|NCT03013023|BEHAVIORAL|BS+PITP|Parents will learn to regulate infant responses while implementing caregiving activities. Supportive interventions, i.e., NNS, FT, positional support, and oral sucrose feeding, will be provided while infants are undergoing painful procedures.
214364854|NCT01017354|DRUG|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
214364855|NCT01017354|DIETARY_SUPPLEMENT|ViDe3 (CH)|60000 vitamin D3 orally and once per month
214490874|NCT06737393|PROCEDURE|Backfill|Participants undergoing laparoscopic hysterectomy have the bladder filled with 200 mL saline prior to Foley removal at the end of surgery.
214490875|NCT06893588|DEVICE|NEVA VS|cerebral artery dilation device
214975380|NCT03693196|OTHER|Demographic|Age, gender and state of smoking were compared between groups.
214975381|NCT06063889|DIAGNOSTIC_TEST|Maximal Rate of Force Development Test for Ankle Muscles|This test is designed to measure the maximal rate of force development in the ankle muscles, specifically the plantar flexors. It aims to assess the relationship between the strength of these muscles and the functional ability in patients with knee osteoarthritis. The results from this test will help to understand how lower limb muscle strength influences the symptoms and progression of knee osteoarthritis.
215084793|NCT05709925|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|The Graston Technique which is the Instrument Assisted Soft Tissue Mobilization is the use of a firm instrument to break tissue adhesions and mobilize scar tissue thus improving pain, range of motion and disability.
214364856|NCT01017354|DIETARY_SUPPLEMENT|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
214364857|NCT06229002|PROCEDURE|Transcranial alternative current stimulation (tACS) at alpha frequency|Single session of tACS
214364858|NCT06229002|PROCEDURE|Sham stimulation|Single session of tACS sham stimulation
214364859|NCT01730898|OTHER|Study product containing lutein|delivered in capsule form
214490876|NCT06894485|OTHER|Conventional therapy|"* Conventional range of motion (ROM) exercises~* Muscle strengthening exercises~* Fine motor skill exercises~* Functional rehabilitation exercises"
214490877|NCT06894485|OTHER|Sensory Training|"* Desensitization training (exposure to various textures and stimuli to improve sensory tolerance)~* Proprioceptive exercises (closed-eye position sense training, weight transfer exercises)~* Tactile stimulation"
214490878|NCT06747819|DIAGNOSTIC_TEST|Cervical Epidural Steroid Injection (CESI)|Participants in this group received CESI to reduce inflammation and alleviate pain in the cervical nerve roots.
214490879|NCT06747819|COMBINATION_PRODUCT|Neural Mobilization (NM)|Participants in this group underwent NM exercises aimed at improving nerve mobility and reducing symptoms related to nerve compression.
214490880|NCT06742918|OTHER|Placebo|Placebo was given to the Group IV which was 2 grams of glucose.
214490881|NCT06741917|DRUG|Levofloxacin|single dose of oral Levofloxacin (500mg/tab) before retrograde intrarenal surgery
214364860|NCT01730898|OTHER|Study product containing lutein|delivered in capsule form
214364861|NCT04878835|BIOLOGICAL|intralesional ranibizumab|Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL
214364862|NCT03059901|OTHER|Caminamos App|Mobile phone that encourages Latina women to walk together through social support.
214364863|NCT06509256|DRUG|Tranexamic acid injection|work aims to evaluate the role of tranexamic acid in bleeding control in gynecomastia surgery
214364864|NCT06193265|PROCEDURE|Discectomy|Discectomy is total or more often partial intervertebral disc surgical removal
214364865|NCT00645164|OTHER|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
214364866|NCT00645164|DRUG|Xenaderm|20 mg under Finn chambers
214364867|NCT02454192|BEHAVIORAL|CHAMPS|
214364868|NCT02346396|DEVICE|tDCS (use at home)|During 4 weeks (every week : 20 minutes / day during 5 days)
214490882|NCT06741917|DRUG|Cefmetazole (drug)|single dose of intravenous Cefmetazole (1000 mg)before retrograde intrarenal surgery
214490883|NCT06785246|OTHER|Grasshopper dashboard|Computer dashboard application for radiologists that displays relevant clinical information directly from the medical record
214490884|NCT06740279|OTHER|Assessment of upper limb function|Observational study of the changes in upper limb after SCI paralysis
214490885|NCT05270109|PROCEDURE|BiZact|"In the hot group the peritonsillar space is dissected and sealed in one step by a bipolar instrument (BiZactTM). The instrument uses Valley Lab adjustable bipolar energy. Energy is automatically adjusted and delivered to the tissue in order minimize thermal tissue damage and seal blood vessels less than 3mm in diameter while dividing the soft tissue."
215084794|NCT05709925|PROCEDURE|myofascial release|myofascial release through stripping technique to the lumbar region.
215084795|NCT05184101|DRUG|Unfractionated Heparin|Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
214364869|NCT02253355|DEVICE|Deep Brain Stimulation|
214364870|NCT05521425|DEVICE|"Helping Hands for CAPD bag exchange procedures"|"Training served as Treatment As Usual (TAU) for all participants; The difference between two groups was whether Helping hands were provided to participants for CAPD bag exchange procedures at home."
214364871|NCT03865602|BEHAVIORAL|Sepsis Transition And Recovery (STAR)|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 30 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 30 days following their discharge and then will be transitioned back to the next appropriate care location.
214364872|NCT03865602|BEHAVIORAL|Usual care|Patients and their providers will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
214364873|NCT02240433|DRUG|LY2157299|LY2157299 administered orally
214364874|NCT02240433|DRUG|Sorafenib|Sorafenib administered orally
214364875|NCT06579560|DIAGNOSTIC_TEST|Audiovestibular assessment in Patients with Fibromyalgia|Audiovestibular assessment in Patients with Fibromyalgia
214364876|NCT03911648|DRUG|0.5 ml.kg-1 bupivacaine 0.25%|Caudally
214364877|NCT03911648|DRUG|0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1%|Caudally
214364878|NCT00149305|OTHER|Genetic analyses|
214364879|NCT00149305|OTHER|Genetic analyses|
214364880|NCT05514912|DRUG|Cisplatin|Given IV
214364881|NCT05514912|DRUG|Gemcitabine Hydrochloride|Given IV
214364882|NCT05514912|DRUG|Infigratinib Phosphate|Given PO
214364883|NCT05514912|DRUG|Nab-paclitaxel|Given IV
214364884|NCT01531166|DRUG|pegylated Interferon-alpha 2a|Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
214364885|NCT06029101|PROCEDURE|posterior fossa craniectomy with or without duraplasty|craniectomy of occipital bone and duroplasty with graft to expand the shallow posterior fossa and reposition the cerebellar tonsils.
214364886|NCT04547374|OTHER|GaH Intervention|"Patients in this cohort will be referred for management/intervention with GaH.~However, the purpose of this program is not to define, control, or evaluate the specific details of the GaH process or procedure, but to evaluate its effectiveness as an alternative clinical care path in this setting. As such, the specific details and actions of the GaH care team in each patient interaction are left to their medical discretion."
214364887|NCT01362439|DRUG|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
214364888|NCT00114179|DRUG|capecitabine|Given orally
214364889|NCT00114179|RADIATION|radiation therapy|Undergo radiotherapy
214364890|NCT00114179|BIOLOGICAL|bevacizumab|Given IV
214364891|NCT00114179|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214364892|NCT00114179|DRUG|gemcitabine hydrochloride|Given IV
214364893|NCT03233802|BEHAVIORAL|Individualized Assess & Treatment (IATP)|See previous description
214364894|NCT03233802|BEHAVIORAL|Packaged Cognitive-Behavioral (PCBT)|See previous description
214364895|NCT03233802|BEHAVIORAL|Case Management (CaseM)|See previous description
214364896|NCT04108455|OTHER|Specimens Collected|Serum will be collected from patients at multiple times during pregnancy for later analysis.
214364897|NCT05273632|DRUG|Oxytocin|trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
214364898|NCT02216266|DRUG|Physostigmine|
214364899|NCT02216266|OTHER|Sodium Chloride solution|
214364900|NCT00063284|DEVICE|Magstim Rapid Magnetic Stimulator|
214364901|NCT04609267|DIAGNOSTIC_TEST|PHQ-9 - Mirror format|The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.
214364902|NCT00777374|DRUG|Patch|epicutaneous application of allergen patch
214364903|NCT00777374|DRUG|Placebo patch|epicutanoeus application of a placebo patch
214364904|NCT03116984|PROCEDURE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
214490886|NCT05270109|PROCEDURE|Cold Steel|"In the cold steel group the peritonsillar space is dissected with metal instruments, and bleeding is typically controlled by ligation or electrocautery."
214490887|NCT05018143|BEHAVIORAL|STARS|This intervention will use an online mobile application for teach life skills, coupled with peer mentoring to support the use of safety planning.
214490888|NCT05018143|BEHAVIORAL|Control condition|In this intervention, participants will receive the safety planning intervention.
214490889|NCT06846567|DRUG|BM2216 Extended-Release tablets（5.5mg）|5.5mg BM2216 Extended-Release ,test drug
214490890|NCT06846567|DRUG|Mirogabalin Besilate Tablets|15mg of Mirogabalin Besilate Tablets,reference drug
214490891|NCT06846567|DRUG|BM2216 Extended-Release Tablets(11mg)|11mg of BM2216 Extended-Release,test drug
215084796|NCT05883332|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-50%)
215084797|NCT05883332|OTHER|Oxygen|100% oxygen at 10 Liters/minute
214490892|NCT06846567|DRUG|BM2216 Extended-Release Tablets(16.5mg)|16.5mg of BM2216 Extended-Release Tablets,test drug
214490893|NCT06844682|OTHER|intervention group|Following the removal of the mattresses, the patient was placed in the semi-fawler position.
214490894|NCT06835309|OTHER|Pelvic floor muscles exercises|The exercises for strengthening the PFM were 10 contractions of 5 seconds, 15 contractions of 3 seconds, 20 contractions of 2 seconds, 20 contractions of 1 second (equal rest time between contractions), and 5 repetitions of maximum contractions while coughing (1-minute interval).25 The level of difficulty of the exercises throughout the 20 sessions was determined by the patient's position, starting in a supine position, then progressing to a sitting position and, finally, to a standing position
214490895|NCT06835309|OTHER|Pelvic floor muscles exercises and isokinetic strengthening of hip muscles|The hip muscle strengthening exercise was executed on Biodex multi-joint system isokinetic dynamometer. Muscle tension of the lower limbs was relieved by executing 5-minute warm-up exercises using a cycle ergometer before execution of the isokinetic exercise For each hip muscle group, eight repetitions per set for 4 sets were carried out for a single exercise with a 30 second break between each set. The patient's position were the same positions used in the testing procedure. The exercises were carried out 3 times a week and the hip muscles strength evaluation was conducted after the end of the program intervention
214490896|NCT06749769|BEHAVIORAL|simulation-based education|Patients will learn how to care for their stomata on a stoma simulator
214490897|NCT06751316|PROCEDURE|Conventional Pulpectomy|Removal of radicular pulp tissue, placing Zinc Oxide/Eugenol and covered by stainless steel crown
214490898|NCT06751316|PROCEDURE|MTA Pulpotomy|Removal of coronal pulp tissue, placing MTA and covered by stainless steel crown
214490899|NCT06671574|OTHER|Emotional intelligence and Relaxation techniques|In each session, participants will engage in exercises aimed at recognizing, understanding, and regulating their emotions. These interactive activities will foster personal reflection and group discussion, helping individuals identify emotions in various situations and their impact on behavior. This approach will enhance emotional awareness and equip participants with practical tools for managing stress and anxiety. Various relaxation techniques will also be introduced. Deep breathing exercises will teach participants to calm their minds and bodies, reducing tension. Guided meditation will help them focus inward, promoting mental peace and deep relaxation. Additionally, visualization exercises will encourage imagining calming scenarios, alleviating anxiety and improving overall well-being.
214502796|NCT07014241|OTHER|Family psychoeducation|The study intervention, tagged SPARKED (Supportive Program for Advancing Recovery, Knowledge, and Empowerment in Depression), is a co-designed family-based psychoeducational intervention for individuals with MDD and their family members or caregivers. The intervention will cover structured modules to enhance participants' understanding of MDD and its treatment, coping strategies, and self-efficacy skills. It will also focus on recognising early signs of relapse and empowering participants to engage actively in treatment decision-making.
214502797|NCT07012824|BEHAVIORAL|Crisis Response Planning|Crisis Response Planning (CRP) is a brief, one-time intervention that teaches individuals to notice warning signs of an impending crisis (e.g., suicidal crisis) and provide them with skills to help reduce suicide risk.
214502798|NCT07012824|BEHAVIORAL|Couples-based Crisis Response Planning|This intervention expands on traditional CRP by integrating the intimate partner into the intervention. Among service members, intimate partners are the group most likely to be told about suicidal thoughts prior to a suicide attempt.
214502799|NCT07012161|DRUG|Colecalciferol (Vitamin D3) 50000 UI|Participants will received vit d upto 6 months
214502800|NCT04506567|DRUG|225Ac-J591|Single cycle of fractionated dose of 225Ac-J591
214502801|NCT04506567|DIAGNOSTIC_TEST|68Ga-PSMA-HBED-CC injection|68Ga-PSMA-HBED-CC PET/CT before and after treatment
214502802|NCT04506567|DRUG|225Ac-J591|Single dose of 225Ac-J591 every 6 weeks x 4
214502803|NCT06697106|DRUG|Nonsteroidal anti-inflammatory drugs|Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.
214502804|NCT06697106|DRUG|Placebo|Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.
214502805|NCT06628167|BEHAVIORAL|Transportation|Participants with ordered low dose CT and participants with scheduled low dose CT are offered free transportation to and from appointment. Participants with ordered low dose CT are also offered assistance in connecting with scheduling staff.
214502806|NCT06628167|BEHAVIORAL|Scheduling|Participants with ordered low dose CT are offered assistance in connecting with scheduling staff.
214502807|NCT04884035|DRUG|CC-220|CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
214502808|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
214502809|NCT04884035|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
214502810|NCT04884035|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
214502811|NCT04884035|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
214502812|NCT04884035|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
214364905|NCT03116984|RADIATION|External- beam radiotherapy|We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
214364906|NCT00679328|DEVICE|Surgical implantation of OP-1 device or autograft bone graft material|Surgical implantation of OP-1 device or autograft bone graft material
214364907|NCT05777798|DEVICE|Hyalistil Bio PF|Moisturizing and lubricating ophthalmic solution
214490900|NCT06661395|DEVICE|Wingate Anaerobic Test with Virtual Reality|"Wingate Anaerobic Power Test Protocol, commonly used for assessing anaerobic capacity, involves a warm-up followed by testing. The warm-up includes 5 minutes of dynamic cycling, incorporating sprints. During the test, the athlete pedals at maximum effort for 30 seconds with added weight. Heart rate is monitored, and power output is measured every 5 seconds. Peak and average power values are calculated.~This protocol will be gamified for VR goggles. The warm-up simulates cycling in a forest. Athletes sprint for 5 seconds every minute to escape a train, with prompts on the screen. The testing phase includes a simulated race, with athletes pedaling at maximum effort for 30 seconds to compete against rivals, signaled by flares and a countdown."
214490901|NCT06861946|DIAGNOSTIC_TEST|Corvis ST|"Corvis ST is used to assess corneal biomechanical changes following vitrectomy with silicone oil tamponade, specifically:~Corneal stiffness and elasticity using the Stress-Strain Index (SSI) Corneal deformation response via Deformation Amplitude (DA)"
214490902|NCT06861946|DIAGNOSTIC_TEST|Conrneal endothelial cell density|"The study evaluates the impact of silicone oil tamponade on corneal endothelial cell density (ECD) in patients undergoing vitrectomy for retinal detachment. The intervention involves:~Preoperative and Postoperative Assessments at 1, 3, and 6 months to monitor changes in ECD.~Specular Microscopy to measure ECD (cells/mm²), coefficient of variation (CV) in cell size, and hexagonality (% of hexagonal cells)."
214490903|NCT06864091|OTHER|Rapid Manufacturing|The first intervention (I1) involves direct printing of the final prosthesis (rapid manufacturing, RM). The final prosthesis will be printed using a biocompatible rubber-like printable soft resin (Biomed Flex 80A resin, Formlabs, USA), and then will be colored and characterized to match the surrounding anatomy.
214490904|NCT06864091|OTHER|Direct Mould Making|In the second intervention (I2), the negative mold will be achieved directly, will be virtually designed based on an inverted STL file of prosthesis prototype/ pattern (direct mold making, DMM).
214490905|NCT06864091|OTHER|Indirect Mould Making|"the negative mold will be fabricated indirectly by printing the prosthesis prototype from resin for subsequent mold fabrication (indirect mold making, IMM). The printed prototype will be tried on the patient and adjusted in terms of shape, size and marginal fit.~After the try-in stage the prototype will be duplicated into wax by using silicone rubber molding and a conventional stone mold will be fabricated."
214490906|NCT05101096|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously (IV)
214490907|NCT06866067|DEVICE|PEEK clip|The overdentures were attached with PEEK clip . The retention of overdenture was assessed
214490908|NCT06866067|DEVICE|Nylon clip|The overdentures were attached with Nylon clip . The retention of overdenture was assessed
214490909|NCT06865716|DEVICE|Active noninvasive vagus nerve stimulation|The stimulation parameters include a 200µs stimulation width, at an intensity level of 10-50ma (adjusted for patient-comfort), at a frequency of 20Hz during 60min .
214490910|NCT06865716|OTHER|Chum electrode attached to patient's lower ear lobe|The clip stimulator is attached to the patient's lower ear lobe without stimulation.
214490911|NCT06867458|DEVICE|Antimicrobial photodynamic therapy (aPDT) nasal decolonization device|aPDT is a technique that employs a specific wavelength of light to activate a photosensitizer substance. Once activated, this photosensitizer reacts with surrounding molecules to produce radicals and reactive oxygen species. When activated in the presence of microorganisms, these molecules serve to disrupt membrane structure and protein cross-linking, leading to their death.
214490912|NCT05717686|DRUG|AHB-137 injection|AHB-137 will be administered
214490913|NCT05717686|DRUG|Placebo|Placebo will be administered
214490914|NCT06734546|OTHER|Exercise intervention|The exercise intervention entails 6 months of supervised exercise on a hometrainer at high or moderate intensity, 3 times per week
214490915|NCT06749665|DRUG|polidacanol 3%|Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany
214490916|NCT06749665|BIOLOGICAL|candida antigen|delayed type of hypersensitivity reaction is induced toward the injected antigen and the wart virus as well. This can increase the ability of the immune system to recognize and eradicate the human papillomavirus on various parts of the body and eliminate the necessity of local treatment for each wart
214490917|NCT06751875|DRUG|Lithium|Patients are randomized to either receive lithium or not.
214490918|NCT06841458|OTHER|Oral Supplement|Participants in the Active Comparator group will receive a dietary supplement designed to manage androgenetic alopecia (AGA). The intervention consists of one oral capsule per day for six months, containing active ingredients such as Saw Palmetto, Pumpkin Seed Oil, Pygeum africanum, L-Cystine, Oleanolic Acid, and Horsetail Extract.
214364908|NCT01133158|DRUG|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
214364909|NCT04851548|PROCEDURE|hyaluronic acid|after flap refection, the furcation area will be debrided then add hyaluronic acid 8% and cover it with a collagen membrane
214364910|NCT05127525|DRUG|IRX-101|IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
214490919|NCT06764069|DEVICE|Sensor Lead|The Glucotrack Sensor Lead will be inserted into the subclavian vein, using a Seldinger technique, where it will continuously measure blood glucose levels.
214502813|NCT04884035|DRUG|CC-99282|CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
214364911|NCT05127525|DRUG|Control|Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
215084798|NCT02546440|DRUG|Dimethyl fumarate|dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur
214490920|NCT06764368|DRUG|Adebrelimab + Apatinib|"Induction Phase:~Subjects will receive Adebrelimab (1200 mg, Day 1) + Etoposide (100 mg/m2, Days 1-3) + Carboplatin (AUC = 4-5, Day 1) / Cisplatin (75 mg/m2, Day 1) (as determined by the investigator) + Apatinib (250 mg, orally, once daily) in 3-week cycles (Q3W) for 4 to 6 cycles.~Maintenance Phase:~Adebrelimab (1200 mg, Day 1) + Apatinib (250 mg, orally, once daily) will be administered for 1 year or until one of the following occurs: disease progression, intolerable toxicity, withdrawal of informed consent by the subject, voluntary withdrawal from the study, or other protocol-specified reasons."
214490921|NCT06766591|DRUG|Ivonescimab combined with chemotherapy|Ivonescimab combined with chemotherapy. The specific chemotherapy regimen is based on the real world.
214490922|NCT05067478|DRUG|Vibegron|Vibegron to be administered.
214490923|NCT06837909|PROCEDURE|Transversus abdominis plane (TAP) block|A regional anesthesia technique in which a local anesthetic is injected into the transversus abdominis plane under ultrasound guidance to provide postoperative analgesia.
214490924|NCT06837909|PROCEDURE|Wound infiltration|A local anesthetic technique where bupivacaine with epinephrine is injected directly into the surgical wound sites to provide postoperative analgesia.
214490925|NCT05976945|BEHAVIORAL|Imagery Rescripting|In Imagery Rescripting patients imagine a different sequence of events matching their needs better than what actually happened in traumatic and other adverse (childhood) experiences.
214490926|NCT06847490|OTHER|No intervention (observational study)|This is an observational study aimed at developing and validating a predictive model for perioperative blood transfusion. The study utilizes retrospective clinical data from surgical patients to identify key risk factors associated with transfusion requirements. No experimental intervention will be applied to participants, as the study solely focuses on data analysis and model development.
215084799|NCT04355858|DRUG|SHR7390|MEK1/2 inhibitor
215084800|NCT04355858|DRUG|Famitinib|Multi-target tyrosine kinase inhibitor
214364912|NCT00115141|DRUG|Resiquimod|
214364913|NCT00831064|PROCEDURE|colonoscopy bowel prep|PEG, bisacodyl, NaP, PSMC and Mg-citrate
214490927|NCT01202708|DEVICE|On line hemofiafiltration|hemodiafiltration with the Gambro AK 200 ULTRA
214490928|NCT01202708|DEVICE|On line hemodiafiltration|On line hemodiafiltration with the Gambro AK 200 ULTRA System
214490929|NCT06796348|PROCEDURE|Radiofrequency ablation alone|RFA of a cancer in the thyroid gland.
214490930|NCT06796348|PROCEDURE|Surgery|Hemithyroidectomy of the thyroid lobe with cancer
215084801|NCT04355858|DRUG|SHR3162|PARP inhibitor
215084802|NCT04355858|DRUG|Pyrotinib|HER1 / HER2 receptor tyrosine kinase inhibitor
214490933|NCT05109689|BEHAVIORAL|ACT-P|ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).
214490934|NCT05109689|BEHAVIORAL|T4C|T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
214490935|NCT06571240|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
215084803|NCT04355858|DRUG|Capecitabine|In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.
215084804|NCT04355858|DRUG|SHR1210|PD-1 antibody
215084805|NCT04355858|DRUG|Everolimus|mTOR inhibitor
215084806|NCT04355858|DRUG|Nab paclitaxel|Albumin bound paclitaxel
215084807|NCT04355858|DRUG|SHR2554|EZH2 inhibitor
215084808|NCT04355858|DRUG|SHR3680|AR inhibitor
215084809|NCT04355858|DRUG|SHR6390|CDK4/6 inhibitor
215084810|NCT04355858|DRUG|SHR1701|anti-PD-L1/TGF-βRII bifunctional fusion protein
215084811|NCT04355858|DRUG|SERD|Fulvestrant
215084812|NCT04355858|DRUG|AI|aromatase inhibitor
215084813|NCT04355858|DRUG|VEGFi|Bevacizumab
215084814|NCT03275688|DIAGNOSTIC_TEST|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
215084815|NCT04253899|PROCEDURE|Appendectomy|Interval Appendectomy
215084816|NCT04253899|OTHER|Observation|observation and follow up
214364914|NCT05333354|OTHER|education strategy|The educational course of the experimental group will last for 6 weeks, including classroom teaching and simulated situational teaching. The classroom teaching will be divided into 3 times, a course of about 2 hours at a time; after the class, simulated situational teaching is also arranged for 4 hours at a time/ Caring for many patients with delirium, and performing related research. The simulated scenario lesson plan plans to design 3 major themes (delirium assessment, delirium risk factors, delirium prevention, each major theme will have 2 scenarios, each The simulation teaching exercise starts with pre-briefing, and after the end, debriefing reflection and discussion with the students.
214364915|NCT01127282|DRUG|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
214364916|NCT01127282|DRUG|Placebo (digestive tablet)|Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
214490936|NCT06315816|BEHAVIORAL|virtual reality glasses used during tooth extraction and extirpation treatment|The effect of virtual reality glasses used during tooth extraction and extirpation treatment under local anesthesia on anxiety and fear in 7-10 years old children
214490937|NCT06734377|DEVICE|Delta TMS|TMS will be administered at the frequency of delta oscillation (2.2Hz)
214490938|NCT06734377|DEVICE|Theta TMS|TMS will be administered at the frequency of theta oscillation (6.5Hz)
214490939|NCT06734377|DEVICE|Arrhythmic TMS|TMS will be administered arrhythmically. In this intervention, the inter-pulse intervals are randomized between delta and theta durations for each trial, ensuring the same total number of pulses but without rhythmic consistency
214490940|NCT04059406|DRUG|sapablursen|sapablursen administered subcutaneously
214490941|NCT06746090|BEHAVIORAL|Reminders|"Group A(Intervention): Patients who will be reminded daily via whatsapp text message.~Group B(Intervention): Patients who will be asked through a weekly phone call about elastic wear and then motivated."
214490942|NCT06779357|OTHER|Artwork|d. A 3-arm randomized control trial will be used: one arm with Zentangle workshops, the other arm with Pastel Nagomi Art, while the control group will receive usual care. Data collection from each participant will be conducted at 3-time points, at baseline (T0) before the 4-week weekly Pastel Nagomi Art or Zentangle Art program, right after the program (T1), and one month after the program (T2).
214364917|NCT01281644|DEVICE|Diode Laser|810 nm diode laser
214364918|NCT03404310|DIETARY_SUPPLEMENT|Zinc Sulfate|Participant will take one 220mg tablet twice daily for three months.
214364919|NCT03404310|OTHER|Placebo (Gelatin Tablet)|Participant will take one tablet twice daily for three months.
214490943|NCT06756815|OTHER|Cross bracing and conservative treatment|Week Exercise Training Frequency (sets x reps) Week 1-2 1. Cross Bracing (Isometric Holds) 2. Quad Sets 3. Straight Leg Raise 4. Ankle Pumps 5. Heel and Toe Raises 6. Glute Bridge 2 sets x 10 reps Week 3-4 1. Cross Bracing (Isometric Holds) 2. Hamstring Curls 3. Step-ups 4. Mini Squats (with support) 5. Leg Press 6. Lateral Leg Raises 3 sets x 12 reps Week 5-6 1. Cross Bracing (Isometric Holds) 2. Single-leg Balance (with support) 3. Lunges (with proper technique) 4. Squats (bodyweight) 5. Box Jumps 6. Lateral Step-ups 3 sets x 15 reps
214490944|NCT06756815|OTHER|Cross bracing and DNS with conservative treatment|"Week Exercise Training Frequency (sets x reps) Week 1-2~1. Cross Bracing (Isometric Holds)~2. DNS Core Activation (supine, prone positions)~3. Quad Sets~4. Straight Leg Raise~5. Ankle Pumps~6. Heel and Toe Raises~7. Glute Bridge 2 sets x 10 reps Week 3-4~1\. Cross Bracing (Isometric Holds) 2. DNS Core Stabilization (advanced activation) 3. Hamstring Curls 4. Step-ups 5. Mini Squats 6. Leg Press 7. Lateral Leg Raises 8. Pelvic Tilts 3 sets x 12 reps Week 5-6~1. Cross Bracing (Isometric Holds)~2. DNS Dynamic Stabilization (with resistance)~3. Single-leg Balance (with and without support)~4. Lunges (with added resistance)~5. Squats (bodyweight or weighted)~6. Box Jumps~7. Lateral Step-ups~8. Running Drills (if tolerated) 3 sets x 15 reps"
214975382|NCT06027840|DRUG|Varenicline|Varenicline prescription will follow the standard induction period: varenicline 0.5 mg once per day for Days 1-3, varenicline 0.5 mg twice per day for Days 4-7, then varenicline 1 mg twice per day (when varenicline reaches peak efficacy for tobacco cessation). Participants will remain on varenicline for 12 weeks total. Dose adjustments (e.g., reduction to 0.5 mg twice per day if 1 mg is not well tolerated) will be allowed at the discretion of the clinical pharmacist/APRN/physician.
214975383|NCT06027840|BEHAVIORAL|Counseling|Tobacco Treatment Service clinicians will deliver weekly counseling sessions, monitor participants for adverse events, and record participants' weekly cigarette and e-cigarette use. At the first counseling session clinicians will review medication proper use instructions, and potential side effects and strategies to address them at the first counseling session. Study medication refills will be distributed at 4-week intervals. Sessions will focus on quit plan preparation, supportive and practical cessation counseling, resetting quit dates, and relapse prevention.
214490945|NCT06756828|DRUG|Melatonin|3months melatonin
214975384|NCT06027840|BEHAVIORAL|Guided Self-Change Booklets|The booklet includes information on how to reduce and quit both cigarettes and e-cigarettes on their own, how to prevent relapse, how to set a quit date, and how to enroll in text-based support resources.
214975385|NCT01307956|DRUG|Fluorouracil|Given IV
214975386|NCT01307956|OTHER|Laboratory Biomarker Analysis|Correlative studies
214490946|NCT06756828|BEHAVIORAL|Cognitive behavioral therapy group for insomnia|15minutes of sleep hygiene education on the first day of visiting the hospital
214490947|NCT06757790|OTHER|A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section|A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section
214490948|NCT03392467|BIOLOGICAL|PNEUMOSTEM|human umbilical cord blood-derived mesenchymal stem cells
214490949|NCT03392467|OTHER|Placebo|normal saline
214975387|NCT01307956|DRUG|Leucovorin Calcium|Given IV
214975388|NCT01307956|DRUG|Oxaliplatin|Given IV
214975389|NCT01307956|BIOLOGICAL|Panitumumab|Given IV
214975390|NCT01307956|OTHER|Pharmacological Study|Correlative studies
214975391|NCT01307956|RADIATION|Radiation Therapy|Undergo radiation therapy
214975392|NCT01307956|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214975393|NCT00888654|DRUG|B-Dim|B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
214975394|NCT00888654|PROCEDURE|Radical Prosatectomy|
215084817|NCT02783378|DRUG|Gaviscon Syrup|
214364920|NCT04006561|RADIATION|A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy|Each freshly-diagnosed patient with primary CNS lymphoma will be treated with combined chemoradiation in a sandwiched way, in which 2 cycles of induction chemotherapy with intravenous methotrexate (MTX in a conventional dose of 1g/m2) and intrathecal MTX are followed by a complete course of hyperfractionated WBRT and then high-dose cytarabine for 2 cycles.
214364921|NCT06259422|DRUG|Iohexol|Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)
214364922|NCT06259422|DIAGNOSTIC_TEST|125I-iothalamate and 131I-hippuran|Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
214364923|NCT02132845|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
214364924|NCT02132845|DRUG|targeted therapy|Receive target-directed therapy
214364925|NCT02132845|PROCEDURE|therapeutic procedure|Receive standard of care therapy
214364926|NCT02132845|OTHER|laboratory biomarker analysis|Correlative studies
214364927|NCT00614081|DEVICE|Contrast-enhanced dynamic MRI|
214364928|NCT01755702|DRUG|Placebo|Placebo
214490950|NCT06757244|DRUG|Dostarlimab|Intra-venous (i.v) dostarlimab: day1 - d21: 500mg IV q3Weeks (cycle 1 to cycle 4) then 1000 mg IV q6Weeks (from cycle 5 onwards)
214490951|NCT06757244|DRUG|Vitamin D3 (Cholecalciferol)|Oral vitamin D3 8000 IU/d for 14 days, then 4000IU/d
214490952|NCT06757244|DRUG|mFOLFIRINOX Treatment Regimen|mFOLFIRINOX d1, d15, d29 cycle 1 to cycle 4 is administered as follow: oxaliplatin 85 mg/m2 on day1, IV infusion over 2 h, immediately followed by folinic acid 400 mg/m2 or calcium levofolinate 200 mg/m2 given as a 2-h IV infusion, with the addition of irinotecan 180 mg/m2 as per dose-level given as a 90-min intravenous infusion through a Y-connector immediately followed by 5- fluorouracil 2400 mg/m2 over 46 h continuous infusion.
214490953|NCT06757244|DRUG|LV5FU2|folinic acid 400 mg/m2 Or calcium levofolinate 200 mg/m2 2-h IV infusion 5- fluoro-uracil 2400 mg/m2 Over 46 h continuous infusion. From cycle 5 onwards, D1=D43
214490954|NCT06758921|DEVICE|Oscar Peripheral Multifunctional Catheter|"Oscar Peripheral Multifunctional Catheter encompasses three components: (i) Oscar Support Catheter with integrated Lock Grip, (ii) Oscar Dilator and (iii) Oscar PTA Balloon.~Single Oscar PTA Balloon is also available separately and can only be used together with the pre-supplied Oscar Support Catheter as indicated in the compatibility chart in the Instructions for Use (IFU)."
214490955|NCT06809803|DRUG|Extended-release sodium oxybate|Participants will take Extended-release sodium Oxybate (Lumryz) 4.5-9 g oral suspension in approximately ⅓ cup of water orally once a day before bedtime. Dosage of Lumryz will be the same as the equivalent total dose of the Non-Extended-release Oxybate (Xywav or Xyrem) that participants use before starting the study
215084818|NCT04589351|DRUG|Ezetimibe 10mg|Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
215084819|NCT04589351|DRUG|Placebo|Matching placebo
215084820|NCT03197974|BEHAVIORAL|Mindfulness for Bipolar|Brief online self-management program with email coaching support
215084821|NCT03197974|BEHAVIORAL|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
215084822|NCT03730831|BEHAVIORAL|Narrative Exposure Therapy|"8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling~-\> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder."
215084823|NCT03467490|BEHAVIORAL|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
214364929|NCT01755702|DRUG|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
215084824|NCT02046174|BIOLOGICAL|RENCA macrobeads|
215084825|NCT01620151|PROCEDURE|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
214364930|NCT01755702|DRUG|ibuprofen marketed formulation|ibuprofen marketed formulation
214364931|NCT01755702|DRUG|Paracetamol marketed formulation|Paracetamol marketed formulation
214364932|NCT03083314|PROCEDURE|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
215084826|NCT00016744|DRUG|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
215084827|NCT00016744|DRUG|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
214364933|NCT03083314|PROCEDURE|COMPLETE AXILLARY DISSECTION (ALND)|
215084828|NCT00016744|DRUG|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
214364934|NCT03006484|OTHER|No intervention|No intervention will be needed.
214364935|NCT00877279|DEVICE|CosmoDerm1|CosmoDerm1 is a single use syringe, injected into the mid dermal layer.
214364936|NCT00877279|DEVICE|Belotero Soft|Dermal Filler
214364937|NCT03514602|BEHAVIORAL|Multicomponent behavioral intervention|Pregnant patients in the intervention group will receive multicomponent interventions consisting of education, feedback, contingent financial incentives, and peer support. At initial intervention visit, they will choose a quit date within the next 14 days and sign a no-smoking pledge and a no-smoking contract. The contract lists the intervention components, the patient's and the counselor's responsibilities, importance of keeping scheduled visits, and rules on contingent incentives. After the quit date, pregnant women will meet with counselors daily for 5 consecutive days (Monday to Friday) for abstinence monitoring in weeks 1-2. The frequency of abstinence monitoring will decrease to twice a week (Monday and Thursday) in weeks 3-8, weekly in weeks 9-12, and biweekly in weeks 13 until delivery.
214490956|NCT06809803|DRUG|Non-extended-release oxybates|Participants will take Non-Extended-release Oxybates (Xyrem oral solution or Xywav oral solution) 4.5-9 g orally per night (divided into two doses, once before bedtime and another dose 2-4 hours later) at the same dose of Xyrem or Xywav that participants use before starting the study will be continued to compare with Extended-release sodium Oxybate (Lumryz)
214364938|NCT03514602|BEHAVIORAL|Education only control|"The control group will receive one 60-minute counseling mainly based on a pregnancy-tailored self-help booklet entitled Need Help Putting Out That Cigarette? distributed by the American College of Obstetricians and Gynecologists."
214364939|NCT02598986|DIETARY_SUPPLEMENT|Macronutrient supplementation|adding of phosphorus, potassium and magnesium
214975395|NCT04737525|DEVICE|Dental implant placement, bone and soft tissue augmentation on buccal site|"1. Atraumatic extraction~2. Palatinal positioning of tapered implant (BLX) 3.75mm diameter~3. 3-4 mm below vestibular gingival line or 1 mm below bone crest~4. Implant placement~5. Allogenic bone packing of the jumping distance and soft tissue grafting~6. Connective tissue graft (CTG) or porcine-derived membrane~7. Provisional restoration out of occlusion and mandibular movements~8. X-ray"
214364940|NCT00691938|DRUG|LBH589|
214975396|NCT05896436|BEHAVIORAL|Emotion Focused Therapy|12 sessions of Emotion Focused Therapy (EFT). The focus in EFT is to promote the individual's experiencing and facilitate participants' self-disclosure and openness to their own experience, rather than the therapist's agenda or techniques. Key processes within EFT include helping people overcome their avoidance of emotion, maintaining a collaborative focus on emotions, and exploring emotions in therapy.
214975397|NCT04614298|DRUG|KHK4827-Active|Single SC administration
214364941|NCT00691938|DRUG|Decitabine|
214364942|NCT04667299|DRUG|Rabeprazole|20mg bid
214364943|NCT04667299|DRUG|Bismuth potassium citrate|0.6g bid
214364944|NCT04667299|DRUG|Metronidazole|0.4g qid
214364945|NCT04667299|DRUG|Amoxicillin|1g bid
214364946|NCT04842578|OTHER|Cross- Section of CT Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the reading and comprehension of Cross- Section of CT.
214364947|NCT04842578|OTHER|3D simulation Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the overview of 3D simulation of pulmonary structure.
214975398|NCT04614298|DRUG|KHK4827-Placebo|Single SC administration
214975399|NCT03241095|PROCEDURE|OMT (Osteopathic Manipulative Treatment)|The co-hort will receive OMT. Each participant will perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. This co-hort will then be evaluated by the physician and be given OMT.
214364948|NCT04860518|DRUG|IFN beta-1a|Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised
214490957|NCT06743178|BEHAVIORAL|Photo of a person injecting drugs|Exposed to a photo of a person injecting drugs
214490958|NCT06743178|BEHAVIORAL|Photo of EMS responding to an overdose (White)|Exposed to a photo of EMS responding to an overdose (White)
214490959|NCT06743178|BEHAVIORAL|Photo of EMS responding to an overdose (Black)|Exposed to a photo of EMS responding to an overdose (Black)
214490960|NCT06743178|BEHAVIORAL|Photo of a person receiving treatment (Jail)|Exposed to a photo of a person receiving treatment (Jail)
214975400|NCT03241095|PROCEDURE|Sham intervention|The co-hort participants will each perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. Theythen be given a sham OMT procedure.
214975401|NCT04758728|PROCEDURE|Great saphenous vein stripping and varicectomies|Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.
214364949|NCT04860518|DRUG|Dexamethasone|Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised
214364950|NCT04807985|DEVICE|JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
214364951|NCT00452686|BIOLOGICAL|Boostrix|
214490961|NCT06743178|BEHAVIORAL|Photo of a person receiving treatment (Community)|Exposed to a photo of a person receiving treatment (Community)
214490962|NCT06743178|BEHAVIORAL|Photo of a person in recovery (White)|Exposed to a photo of a person in recovery (White)
214490963|NCT06743178|BEHAVIORAL|Photo of a person in recovery (Black)|Exposed to a photo of a person in recovery (Black)
214975402|NCT04758728|DRUG|Epinephrine Topical|Use of epinephrine/adrenaline solution 1:1000 topically
214975403|NCT04758728|DRUG|normal saline|Use of normal saline solution NaCl 0,9% topically
214975404|NCT00750763|DRUG|Colonlytely|Bowel preparation
214364952|NCT00452686|BIOLOGICAL|Chinese DT vaccine|
214364953|NCT01965782|DRUG|[^14C]-LY3023703|Administered orally
214364954|NCT01673763|DEVICE|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
214364955|NCT03776825|DEVICE|Permacol Paste|Permacol Paste Injection
214364956|NCT02753309|DRUG|Sirolimus|
214364957|NCT02755597|DRUG|Venetoclax|Participants self-administered venetoclax tablets by mouth QD in combination with bortezomib. Venetoclax was to be given before other agents administered on the same day, if applicable. Each venetoclax dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
214975405|NCT00750763|DRUG|Picolax/Picoprep|Bowel preparation
214364958|NCT02755597|DRUG|Bortezomib|Bortezomib (subcutaneous injection \[preferred\] or IV) was given following administration of venetoclax or placebo in Cycles 1 -8 on Days 1, 4, 8 and 11, and for Cycles 9 and beyond, on Days 1, 8, 15 and 22 and was to be administered per the prescribing information. The route of administration was to stay the same during the study.
214364959|NCT02755597|DRUG|Dexamethasone|Dexamethasone was to be given orally, administered per the prescribing information, the day of bortezomib dosing and the following day, given the protocol-defined dosing window (bortezomib dosing window is ± 1 day) is maintained. If bortezomib was interrupted or a dose is skipped, dexamethasone was to be administered as scheduled per protocol (unless dexamethasone was interrupted due to toxicity).
214364960|NCT02755597|DRUG|Placebo for venetoclax|Participants self-administered placebo tablets by mouth QD in combination with bortezomib. Placebo was to be given before other agents administered on the same day, if applicable. Each placebo dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
214364961|NCT01069354|DEVICE|Radiesse® Injectable Dermal Filler with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)
214364962|NCT01069354|DEVICE|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
214364963|NCT03692338|BEHAVIORAL|Exercise|Patients will be asked to complete 3 x 30 minute exercise sessions each week.
214364964|NCT05088369|DRUG|HM201|HM201 will be administered intravenously.
214364965|NCT05088369|DRUG|Placebo|Placebo will be administered intravenously.
214364966|NCT05088369|DRUG|HM201|HM201 will be administered intravenously.
214364967|NCT05088369|DRUG|Placebo|Placebo will be administered intravenously.
214364968|NCT02392325|BIOLOGICAL|rDEN1Δ30|Administered subcutaneously in 0.5 mL containing 10\^3.0 plaque-forming units (PFU)
214364969|NCT02392325|BIOLOGICAL|Placebo|Administered subcutaneously in 0.5 mL
214490964|NCT06743178|BEHAVIORAL|Photo of a family member of an overdose decedent|Exposed to a photo of a family member of an overdose decedent
214490965|NCT06759155|RADIATION|de-intensified radiation|Adjuvant radiation will be administered on a de-intensified schedule.
214490966|NCT06764537|PROCEDURE|Blood collection|Blood collection (40 mL) in glioblastoma patients
214490967|NCT06773702|OTHER|gastroenterology and otolaryngological evaluation|"* Gastroenterology evaluation: presence and intensity of esophageal symptoms of gastro esophageal reflux disease, high-resolution esophageal manometry, and 24-hour pH-impedancometry in the absence of PPI therapy.~* otolaryngological evaluation: presence and intensity of laryngopharyngeal reflux symptoms, laryngoscopy."
214490968|NCT06756347|PROCEDURE|Patients receiving landmark-based brachial plexus blocks|The operator will visualize anatomical structures in real time, identify the brachial plexus (supraclavicular approach), and guide the needle to the injection site under direct ultrasound visualization
214490969|NCT06756347|PROCEDURE|Landmark-Based Brachial Plexus Block|The operator will identify anatomical landmarks (e.g., interscalene groove, supraclavicular fossa) using palpation and surface anatomy. The needle will be inserted based on these landmarks, with no direct visualization of internal structures.
214490970|NCT06756347|DRUG|Bupivacaine|injected in both group as local anesthetic agent ( at a standardized concentration and volume) to ensure comparability.
214490971|NCT06755047|RADIATION|3D Ultrasound|3D placental volume and vascular indices
214975406|NCT00750763|DRUG|Fleet|Bowel preparation
214364970|NCT02392325|BIOLOGICAL|rDEN2Δ30-7169|Administered subcutaneously in 0.5 mL containing 10\^3.0 PFU
214975407|NCT03492229|OTHER|tDCS|1 mA of tDCS
214975408|NCT03492229|OTHER|AMT|Ankle motor training
214975409|NCT03492229|BEHAVIORAL|Treadmill training|High intensity treadmill training
214364971|NCT01260844|DRUG|briakinumab|single dose briakinumab and 2 doses of CYP substrates
214364972|NCT03536286|BEHAVIORAL|Encouragement|Households will be visited and encouraged to enroll in Asili
214364973|NCT00594854|DRUG|PN400 (VIMOVO)|PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
214364974|NCT00594854|DRUG|Diclofenac/Misoprostol|Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
214364975|NCT06201130|DIAGNOSTIC_TEST|Suctioning of artificial airway|Collection of tracheal aspirates in either the PICU or NICU will occur. We will instill 1 mL of normal saline, then perform bag ventilation, and then suction out aspirate. Suctioning is routinely performed for tracheostomy and endotracheal tube hygiene - for instance, it is performed on tracheostomies by caregivers at home. The aspirates that will be collected will be clinically indicated and otherwise would be discarded. If the patients weren't enrolled in this research, the aspirates would have been collected anyways.
214364976|NCT03309839|OTHER|Blood collection|A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.
215084829|NCT06045182|PROCEDURE|Maitland mobilization|Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.
214364977|NCT05807581|OTHER|physical activity|treadmill running 3 times weekly
214364978|NCT05807581|OTHER|iTBS|repetitive TMS stimulation 5 days weekly for two weeks
214490972|NCT06755047|RADIATION|2D ultrasound|2D placental criteria of invasion and color Doppler
214490973|NCT06756854|BIOLOGICAL|Biologic Agent: injectable platelet rich fibrin.|injection of I-PRF to thin gingival phenotype 3 times with 7 days interval between sessions.
215084830|NCT06045182|PROCEDURE|Piriformis stretch|Piriformis stretch will be given to this group. In first session piriformis stretch will be given for 10 sec with 10-second resting time in between with, 7 rep total of 1 set. For the 2nd and 3rd session repetitions will be increase to 8 and 10 respectively.
215084831|NCT06045182|PROCEDURE|Electrotherapy|Hot pack and TENS for 10 min
215084832|NCT00921414|DRUG|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
214364979|NCT05290857|OTHER|Restart DOAC within 7 days of clinical hemostasis after GI bleeding|"In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team).~High thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator"
214364980|NCT05290857|OTHER|Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding|"In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team).~Moderate thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months~The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team."
214490974|NCT06756854|OTHER|injecable platelet rich fibrin, and low level laser therapy radiation.|injection of I-PRF+ exposure to LLLT to thin gingival phenotype 3 times with 7 days interval between sessions.
214490975|NCT03849131|BIOLOGICAL|Biological collection|"Blood samples will be collected only once at enrollment, before initiation of a checkpoint inhibitor.~It will include:~* DNA samples collection~* RNA samples collection~* Blood sample collection"
214490976|NCT06761183|GENETIC|intracerebral stereotactic injection of NXL-001|intracerebral stereotactic injection of NXL-001: with 3 subjects in each group to receive a single stereo-tactically intracerebral injection of NXL-001 at escalating doses.
214490977|NCT06766461|DRUG|Double dosing of beta-lactam antibiotic|This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.
214490978|NCT06764004|GENETIC|Stem Cell Product|Human umbilical cord stem cells and exosomes will be used.
214490979|NCT06764004|BIOLOGICAL|Bleeding and clots|Exosomes obtained from human umbilical cord stem cells will be used
214490980|NCT06761521|DIAGNOSTIC_TEST|Peri-Implantitis and Peri-implant mucositis|peri-implant mucositis, peri-implantitis
214490981|NCT05601882|DRUG|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection.
214490982|NCT05601882|DRUG|Upadacitinib|Extended-release tablet
214490983|NCT06757608|OTHER|Assessment of postprandial metabolism after intake of different meat|30 healthy adults (15 male and 15 female) consumed sardines (Opisthonema oglinum, marine fish), tambaqui (Colossoma macropomum, freshwater culture), and beef (Bos taurus). The meal consisted only of meat, with 7g per BMI unit. The postprandial response was observed for 5 hours, after an overnight fast.
214490984|NCT05943041|DRUG|GB104(Level 1)|One capsule QD oral administration for 28 days
214490985|NCT05943041|DRUG|GB104(Level 2)|Three capsules QD oral administration for 28 days
214490986|NCT05943041|DRUG|GB104(Level 3)|Five capsules QD oral administration for 28 days
214490987|NCT06773338|BEHAVIORAL|Tetris|Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
214490988|NCT06773338|OTHER|No intervention|Participants do not receive any intervention.
214975410|NCT03957785|DEVICE|AlterG Treatment|All participants practiced one session a day of AlterG or TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, FAC-tailored physiotherapist assistance, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). BWS, physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the monthly LBPP gait training was carried out.
214975411|NCT02377856|DRUG|pegylated interferon alpha 2a, ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
214975412|NCT05537857|OTHER|High dietary salt|Controlled feeding study that varies in salt content.
214975413|NCT01947348|PROCEDURE|treatment with A3 SVF|Treatment interarticular and IV with A3 SVF
214975414|NCT00676117|DRUG|Esomeprazole (D961H)|20mg
214975415|NCT00676117|DRUG|Loxoprofen|60mg tablet
214490989|NCT06772493|DEVICE|ViewFlex X ICE System|Subjects to undergo cardiac ablation procedure utilizing the ViewFlex X ICE System
214490990|NCT06770608|PROCEDURE|micro-needling with topical human actrapid insulin|Micro-needling with topical application of 2ml of human actrapid insulin once monthly for 4 months
214490991|NCT06770608|PROCEDURE|Micro-needling with topical Platelet rich plasma|Micro-needling with topical application of 2ml Platelet rich plasma once monthly for 4 months
214490992|NCT06758778|DIETARY_SUPPLEMENT|CreNeuroS CNS Fish Oil Plus Softgel [380 mg of fish oil contains Eicosapentaenoic Acid (EPA) （as EE）342 mg; L-5- Methyltetrahydrofolate 1.875 mg; other Vitamins and Minerals]|Test product
214975416|NCT00004658|DRUG|ribose|
214975417|NCT00004658|DRUG|thymidine|
214975418|NCT00004658|DRUG|uridine|
214975419|NCT04071041|DRUG|Albumin Human|Administration of albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
214975420|NCT02605330|PROCEDURE|Fibrinogen plasma level|At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
214975421|NCT00698815|OTHER|Laboratory Biomarker Analysis|Correlative studies
214975422|NCT00698815|DRUG|Pemetrexed Disodium|Given IV
214975423|NCT00698815|DRUG|Sunitinib Malate|Given PO
214975424|NCT01755507|DRUG|norUDCA|Comparison of different dosages of norUDCA acid administered orally.
214975425|NCT01755507|DRUG|Placebo|
214975426|NCT04197271|PROCEDURE|Emergency Hernia Repair|Emergency repair of hernia using method selected by treating surgeon.
214975427|NCT04197271|OTHER|Conservative management|Treatment of hernia without resort to surgery
214975428|NCT00229671|OTHER|Survey 1|During the initial survey, we reviewed dispensed medications by having parents of patients with prescriptions under 21 read the medication label. We then asked questions about potential side effects, method of medication administration, communication regarding the medication with the pharmacist and the health care provider, and demographic information. Research assistants underwent several weeks of training to ensure a standardized approach to surveys.
214975429|NCT00229671|OTHER|Survey 2|If the parent completed the initial survey, we attempted a second survey 2 months after the index visit to capture persistent symptoms. Surveys were translated and back translated into Spanish and Cambodian and conducted by fluent bilingual interviewers. Surveys were pretested and revised based on 2 focus groups of parents representing a broad array of socioeconomic backgrounds.
214364981|NCT04635111|DRUG|TURALIO™|This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
214364982|NCT03683147|OTHER|Laboratory Biomarker Analysis|Correlative studies
214364983|NCT03683147|BEHAVIORAL|Meditation-Based Stress Reduction Program|Participate in 6-week online program
214975430|NCT05938218|DEVICE|Intervention|Virtual Reality assisted information Patients in the intervention group receive a VR instructional application lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures.
215084833|NCT00921414|OTHER|Watch and wait|No treatment patient follow-up every 2 months during 3 years
214364984|NCT03683147|OTHER|Quality-of-Life Assessment|Ancillary studies
214364985|NCT03683147|OTHER|Questionnaire Administration|Ancillary studies
214364986|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate|For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
214364987|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine|R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle
214364988|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second
214364989|NCT05518383|DRUG|Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin|Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
214364990|NCT05275192|DEVICE|Videoscope-assisted periodontal regeneration minimally invasive surgery|Use of a videoscope to improve visualization of periodontal defect during minimally invasive surgery
214364991|NCT05275192|PROCEDURE|Periodontal regeneration minimally invasive surgery|Conventional periodontal regeneration minimally invasive surgery without use of a videoscope
214364992|NCT05275192|PROCEDURE|Guided tissue regeneration surgery|Conventional guided tissue regeneration surgery for periodontal regeneration without use of a videoscope
214364993|NCT04219670|DIAGNOSTIC_TEST|Wearable sensors|Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.
214364994|NCT04426448|BEHAVIORAL|Brief Relaxation, Education And Trauma HEaling|A three-week psychological intervention for PTSD which comprise psychoeducation and breathing retraining to manage anxiety symptoms
214975431|NCT03901846|DEVICE|ColdZyme|ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin
214975432|NCT03089476|OTHER|Evaluating atopy in infants|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
214975433|NCT03089476|OTHER|Evaluating TEWL and STS in adults|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
214975434|NCT00575354|DRUG|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
214975435|NCT00575354|DRUG|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
215084834|NCT02252601|OTHER|HFDT test|
215084835|NCT02252601|OTHER|Pure tone Audiogram|
215084836|NCT02118597|DRUG|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
214364995|NCT05771337|DIAGNOSTIC_TEST|blood sample|blood sample
214364996|NCT04798664|BEHAVIORAL|Removal of Financial Barriers|Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
214364997|NCT04798664|BEHAVIORAL|Financial Incentives|Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
214364998|NCT04798664|BEHAVIORAL|Mobile Health Application|Episodic future thinking tool to overcome temporal discounting of future
214490993|NCT06758778|DIETARY_SUPPLEMENT|Vascepa® (Icosapent ethyl) 1000 mg Capsules, Deplin® (L-methylfolate Calcium) 7.5 mg Capsules|Reference product
214490994|NCT05755919|PROCEDURE|Epilepsy surgery|Epilepsy surgery will be performed as a part of the clinical management of patients with drug-resistant epilepsy.
214502814|NCT04884035|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
215084837|NCT02118597|DRUG|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
215084838|NCT02118597|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
215084839|NCT02118597|DRUG|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
215084840|NCT05853315|PROCEDURE|Surgery|Surgical Excision
215084841|NCT01891344|DRUG|Oral rucaparib|600 mg BID
214364999|NCT06577623|BEHAVIORAL|MINDful TIME|Group-based psychoeducational mindfulness-based intervention.
214365000|NCT06542458|BEHAVIORAL|Assessments|Participants will undergo a standard battery of neuropsychological measures, behavioral questionnaire, and functional assessment to monitor cognition and function over time. Clinical data obtained as part of standard of care will be collected from the medical record
214679728|NCT06673030|OTHER|Group 1 (Tell-Show-Do)|"In which Tell-Show-Do technique was done in three stages:~* Tell: The dental procedures were explained to the children using language and expressions appropriate for their age.~* Show: This began with showing the child the instruments and the topical anesthetic gel, high-speed handpiece and explaining the purpose of using the handpiece. and how the water removed using the suction device.~* Do: Performing the dental procedure immediately."
214365001|NCT06542458|OTHER|Neuroimaging volumetric measures|Neuroimaging volumetric measures will be obtained from already conducted standard of care neuroimaging.
214365002|NCT06542458|OTHER|Biofluid samples|Biofluid sampling data will be obtained through another protocol. All participants will be required to sign that consent to participate in this trial.
214365003|NCT04671784|OTHER|EUS-E|EUS-E
214365004|NCT05337514|BEHAVIORAL|Enhanced Engagement|EngAGE will allow care partners send older adults encouragement which will be read aloud to the older adult through the EngAGE app.
214365005|NCT05337514|BEHAVIORAL|Standard Engagement|Care partners can encourage their older adult partner using traditional / existing communication mechanisms.
214365006|NCT06335719|PROCEDURE|BES|Nerve biopsies during surgery + brief electrical stimulation therapy
214365007|NCT06335719|PROCEDURE|Standard of Care surgery|Nerve biopsies during surgery - no brief electrical stimulation therapy
214679729|NCT06671067|DEVICE|Remote dielectric sensing system|The remote dielectric sensing (ReDS) system is a non-invasive medical device that emits a low-power electromagnetic signal through the chest and lungs, which can accurately measure changes in lung fluid concentration.
214975436|NCT04423471|DIAGNOSTIC_TEST|Sociodemographic variables|"* Sociodemographic variables: Sex / Age / Marital status / Level of studies completed / Employment status.~* General clinical variables: Body mass index (BMI), Medical comorbidities and Charlson Comorbidity Index, Active drug treatments~* Clinical psoriasis variables: BSA, PASI, ScalpPASI, PPPASI, DLQI, time since the diagnosis of psoriasis, previous treatments for psoriasis.~* Clinical depression variables: Psychiatric diagnoses according to clinical interview and DSM-5 criteria, age of onset and time of evolution from the first episode of major depression, time of evolution of the current episode of major depression, previous treatments for depression.~* Psychopathological variables: HADS, PHQ-9, MADRS, GAD-7, SHAPS, The Irritability Questionnaire, PSS, FSS, MoCA.~* Immunological and biochemical variables: Acute phase biomarkers, Proinflammatory cytokines, Anti-inflammatory cytokines, HPA axis, Microglia activation, Neurogenesis.~* Result variables: Changes in PASI or MADRS scores"
214975437|NCT02882334|DEVICE|Finger Force Manipulandum|
214975438|NCT02882334|OTHER|Conventional physiotherapy|
214975439|NCT06125093|BEHAVIORAL|Incredible Years Autism Spectrum and Language Delays Parent Program (IY-ASLD®)|"The IY-ASLD® program is a weekly group-based intervention for parents of children presenting neurodevelopmental problems (ASD symptoms, communication or language difficulties). The group is formed by 6-10 parents, and it is led by a group leader and a co-therapist, trained in the model.~The intervention is manualized. It includes video modelling and emphasizes the importance of practice-based learning through role-playing. The IY-ASLD® program takes into consideration the different developmental levels of each child and pairs parents according to this variable in role-play and other one-to-one discussions. Weekly home tasks will be assigned to parents, and families will be phoned each week to encourage home-based practice.~The intervention will be conducted online. Even though the IY-ASLD® original intervention comprises 14 sessions, the online format requires 22 weekly sessions.~Fidelity to the intervention will be assessed in accordance with the regulations of the program."
214975440|NCT03313739|OTHER|An Educational Program|An educational program was designed for self-care during menopause using teach back method.
214975441|NCT06529341|OTHER|High-definition transcranial direct current stimulation|HD-tDCS stimulated AD left OFC (2 mA, 20 minutes, cathode electrode placed in the Fp 1 area, and the remaining four positive electrodes placed AF3, AF7, Afz, Fpz, forming a circular 41 focused electric field mode for stimulation, twice a day, 20 minutes interval for 5 days)
214975442|NCT06529341|OTHER|High-definition transcranial direct current stimulation pseudo-stimulation control group|The treatment parameters of the electrode were the same as the test group, the stimulation current rose to the same 2 mA current in the test group within 30 seconds, and the pre-stimulation for 1 minute, then gradually to 0 mA.
214975443|NCT04619017|BIOLOGICAL|Segmental allergen challenge|All subjects will undergo bronchoscopy with administration of standardized allergen extract to one segment of the lung.
214975444|NCT00485355|PROCEDURE|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
214975445|NCT00485355|PROCEDURE|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
214975446|NCT00750802|DRUG|AZD6280|10mg Capsule, oral, single-dose
214975447|NCT00750802|DRUG|AZD6280|40mg Capsule, oral, single-dose
214975448|NCT00750802|DRUG|Lorazepam|2mg tablet, oral single-dose
214975449|NCT00750802|DRUG|Placebo|
214975450|NCT00659087|PROCEDURE|Femoral Block|Those receiving femoral block postoperatively
214975451|NCT00659087|OTHER|Usual Care|Those receiving only usual pain management postoperatively
214975452|NCT02410447|DEVICE|Defocused shock wave therapy (DUOLITH® SD1)|
214365008|NCT03579316|DRUG|Adavosertib|Given PO
214365009|NCT03579316|DRUG|Olaparib|Given PO
214365010|NCT03579316|DRUG|Ceralasertib|Given PO
214365011|NCT06162741|BEHAVIORAL|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
214490995|NCT06775444|BEHAVIORAL|Breastfeeding Education Program Based on Planned Behavior Theory|"In addition to routine breastfeeding training at the hospital where the study is conducted, the intervention group will be given a 2-session Breastfeeding Training Program Based on Planned Behavior Theory.~Education Content:~The importance of breast milk, the benefits of breastfeeding, the dangers of artificial feeding, putting the baby to the breast, signs of hunger in the baby, the harms of bottle and pacifier, breastfeeding positions, breast-related problems, information sources about breastfeeding, birth and breastfeeding leave for working mothers, breastfeeding in the community, the importance of environmental and professional support during breastfeeding. Insufficient milk anxiety, increasing milk intake and production, situations where milk should be expressed, milk expression methods, storage conditions of breast milk, alternative feeding methods with expressed milk, methods to be applied to increase breast milk, differences between breast milk and formula milk."
214490996|NCT06775444|BEHAVIORAL|Routine Breastfeeding Training|The control group will receive routine breastfeeding education at the hospital where the study is conducted. Routine breastfeeding education includes the importance of breast milk and breastfeeding (benefits of breast milk and breastfeeding, correct breastfeeding technique and breastfeeding positions, time for the first feeding of the newborn, feeding method, expressing and storing breast milk, techniques for giving expressed breast milk as close as possible to breastfeeding, harms of bottle use, breast problems and coping methods). Pregnant women who give birth at the hospital where the study is conducted receive routine breastfeeding education from the breastfeeding nurse in the ward before being discharged.
214490997|NCT06776523|BEHAVIORAL|Problem Management Plus|"Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy involves handouts and homework reminders."
214490998|NCT06772428|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication; after completing the treatment cycle, patients who are assessed by the researchers as suitable for continued treatment may continue to receive therapy.
214490999|NCT06772428|RADIATION|standard treatment|radiotherapy ± chemotherapy
214491000|NCT06772805|DRUG|Nemtabrutinib|Oral Tablet
214491001|NCT06771245|DRUG|SYH9056|PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan
214491002|NCT06771245|DRUG|Levamlodipine|2.5mg PO once daily
214491003|NCT06771245|DRUG|Valsartan|80mg PO once daily
214491004|NCT06771245|DRUG|SYH9056 placebo|PO once daily
214491005|NCT06771245|DRUG|Levamlodipine placebo|PO once daily
214491006|NCT06771245|DRUG|valsartan placebo|PO once daily
214975453|NCT01639352|BIOLOGICAL|SOM230|Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
214975454|NCT04942886|DRUG|Baracle Tab.®|The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation.
214975455|NCT00317915|DRUG|Irbesartan treatment|
214975456|NCT05294861|OTHER|YesMdiet|In the YesMdiet, participants will consume Milk and Dairy products
214975457|NCT05294861|OTHER|NoMdiet|In the YesMdiet, participants will not consume Milk and Dairy products, only other sources of protein
214975458|NCT06028789|DIAGNOSTIC_TEST|Blood sample test|"The following groups of biomarkers will be examined:~* standard panel of inflammation markers: CRP, PCT, IL-6, Leukocyte count, differential blood count~* microbiology cultures according to the clinical status~* serum biomarkers: sCD64, sTREM-1, calprotectin, pentraxin 3~* flow cytometry: HLA-DR, CD14, CD16, CD40, CD45, CD64, CD163 expression on granulocytes and monocytes~* cell function assay: IL-18 and IFN-γ~* hematology: ICIS, Neutrophil-to-lymphocyte ratio - examined together with conventional hematological parameters.~The schedule of blood sample taking will be as follows:~A. the study group: preoperatively (T-1), 1st postoperative day (T1), 3rd postoperative day (T2), 7th postoperative day (T3), 10th postoperative day (T4)~B. the control group: at admission or the next day (T1), 3rd day of hospital stay (T2), 7th day of hospital stay (T3), 10th day of hospital stay (T4)"
214491007|NCT06771427|OTHER|acupuncture GB20 or GB20 plus BL2|acupuncture at acupoint GB20 or GB20 plus BL2 twice a week 8 weeks for efficacy evaluation.
214491008|NCT06771427|DRUG|Chinese herbal tea TBDESJS|Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.
214491009|NCT06777810|OTHER|The infected wound of the patient's foot ulcer was collected|The infected wound of the patient's foot ulcer was collected
214491010|NCT06779084|OTHER|contemporary fasting principle|(clear fluids for up to 2 hours before anesthesia)
214491011|NCT06779084|OTHER|conventional fasting time|(≥ 8 hours)
214975459|NCT06028789|PROCEDURE|Thoracic Aortic Surgery|Scheduled surgical intervention, i.e. replacement of pre-specified part of thoracic aorta by a vascular prosthesis.
214975460|NCT00379145|DRUG|trabectedin|
214975461|NCT03522116|OTHER|No intervention|No intervention
214975462|NCT02765152|OTHER|Conventional Physical Therapy|Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
214975463|NCT02765152|OTHER|Discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
215084842|NCT05361499|BIOLOGICAL|Sp_6B|Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
215084843|NCT05361499|DRUG|Amoxicillin 500 mg|Amoxicillin, 7 days, 2x 500 mg
215084844|NCT01903395|BEHAVIORAL|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
214491012|NCT06760689|DEVICE|virtual reality glasses|One of the videos chosen by the patient will be opened in the virtual reality glasses and will be played for 20 minutes.
214491013|NCT06760689|OTHER|scale|The patient received standard nursing care. Scales were filled in after the course.
214491014|NCT06763419|DEVICE|External low level laser therapy|Patients received 8 sessions of external diode laser (635 nm).
214491015|NCT06763419|DEVICE|Internal low level laser therapy|Patients received 8 diode laser (635 nm) sessions applied internally
214491016|NCT06738537|OTHER|Focus Groups/Quantitative Survey for Patients|5 quantitative focus groups will be conducted with 5-10 patients each to elicit the range of outcomes patients consider important when selecting treatment options. 100 quantitative surveys to characterize how patients with severe MR prioritize outcomes when making treatment decisions.
214491017|NCT06738537|OTHER|Focus Group/Quantitative Survey for HCPs|5 quantitative focus groups will be conducted with 5-10 providers to elicit the range of outcomes providers consider important when recommending treatment options to patients. 100 quantitative surveys to characterize how providers prioritize outcomes for patients with severe MR when making treatment recommendations.
214491018|NCT06738537|OTHER|Qualitative Focus Group|Qualitative focus groups will be conducted to determine barriers and facilitators to implementing shared decision making in multidisciplinary mitral valve heart team clinics.
214491019|NCT06640010|OTHER|Non-Interventional Study|Non-interventional study
214491020|NCT04484636|DIAGNOSTIC_TEST|FoundationOne®CDx and FoundationOne®Liquid|FoundationOne CDx is a FDA-approved broad companion diagnostic (CDx) that is clinically and analytically validated for solid tumors. The test is designed to provide physicians with clinically actionable information - both to consider appropriate therapies for patients and understand results with evidence of resistance - based on the individual genomic profile of each patient's cancer. Every test result includes microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions. FoundationOne®Liquid is a liquid biopsy test for solid tumors that analyzes circulating tumor DNA (ctDNA) in blood.
214365012|NCT06162741|BEHAVIORAL|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act. The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion."
214365013|NCT02684006|DRUG|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
214365014|NCT02684006|DRUG|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
214491021|NCT05411640|OTHER|Aerobic exercise with Blood flow restriction|Experimental group will be given aerobic exercises with blood flow restriction training. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. . Arterial occlusion of 60% will be achieved by Blood Flow Restriction apparatus. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
214491022|NCT05411640|OTHER|Aerobic exercise without Blood flow restriction|Active Comparator group will be given aerobic exercises. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
214491023|NCT05411640|OTHER|Patient Education and dietary modification|Participants will individually instruct to reduce total energy intake and increase physical activity, aiming at a 5% reduction in body weight. The participants will be given pamphlets providing general information on pre diabetes and dietary modifications. Total intervention protocol for the group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
214975464|NCT02765152|OTHER|Rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
214975465|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Esomeprazole|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
214975466|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Vonoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
214975467|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Tegoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
214975468|NCT01663402|DRUG|Alirocumab|Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
214975469|NCT01663402|DRUG|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
214975470|NCT01663402|DRUG|LMT|Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
214975471|NCT00514618|DRUG|Misoprostol|patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
214975472|NCT00514618|DIETARY_SUPPLEMENT|Placebo|patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
214975473|NCT03575702|DRUG|Uritos®|film-coated tablets 0.1 mg
214365015|NCT02684006|DRUG|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
214365016|NCT02650648|DRUG|cyclophosphamide|chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight\<70kg) or 1500mg/m\^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
214975474|NCT03575702|DRUG|Urotol®|film coated tablets, 2 mg
214975475|NCT06050213|DEVICE|Maxillary implant overdenture|maxillary overdenture retained by different number of implants
214975476|NCT01255163|DRUG|Exendin-4 SC|Exenatide 5 mcg or 10 mcg SC twice daily
214975477|NCT01255163|DRUG|Placebo SC|Placebo SC twice daily
214975478|NCT02423226|PROCEDURE|Computed tomography guided radioactive seeds implant|Computed tomography guided radioactive seeds implant were performed one week before chemotherapy.
214365017|NCT02650648|BIOLOGICAL|NK cells|Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10\^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.
214365018|NCT02650648|BIOLOGICAL|hu3F8|On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.68 mg/kg/day and infused over \~30-90 minutes
214365019|NCT02650648|DRUG|rIL-2|On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10\^5 U/m\^2/day.
214365020|NCT06024538|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
214365021|NCT05756387|DEVICE|Non-invasive ventilation|NIV as in standard care
214365022|NCT04112641|DRUG|Nicotinamide riboside|Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
214365023|NCT04112641|DRUG|Placebo capsules|Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
214365024|NCT05989100|BEHAVIORAL|Favourate taste stimulation|The taste stimulaiton for swallowing is completed with long swab. Taste solution will be prepared with sugar, salt, citric acid, or paprika mixed with water. And the swab will be immersed in the solution and freezed in -18℃ circumstances. Bilateral buccal mucosa，palate and tounge will be brushed. Four swabs will be used in a training session.
214365025|NCT05989100|BEHAVIORAL|Sour taste stimulation|Using sour swab to brush oral cavity and tounge.
214365026|NCT05989100|BEHAVIORAL|Thermal stimulation group|Only ice-water swab to brush oral cavity and tounge.
214365027|NCT00673972|RADIATION|gastric scintigraphy|"All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window."
214365028|NCT00579566|OTHER|Specimen protocol|The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
214365029|NCT01559298|DRUG|Aspirin (80 mg/d) + clopidogrel (75 mg/d)|Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
214365030|NCT01559298|DRUG|Aspirin|Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
214491024|NCT06852508|BEHAVIORAL|TwySHE|Interpersonal support from trained peers to access and use PrEP and contraception.
214975479|NCT02423226|DRUG|Systemic chemotherapy (FOLFIRI)|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
214975480|NCT04952259|DRUG|Shexiang Tongxin Dropping Pills + routine treatment|oral+percutaneous coronary intervention
214975481|NCT04952259|PROCEDURE|routine treatment|percutaneous coronary intervention
214975482|NCT02495389|DRUG|Mirabegron|Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.
214365031|NCT02106988|RADIATION|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
214365032|NCT02106988|DRUG|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
214365033|NCT02106988|DRUG|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
214365034|NCT02106988|DRUG|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
214365035|NCT02106988|DRUG|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
214365036|NCT02106988|DRUG|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
214365037|NCT02413580|BIOLOGICAL|IGIV-C|An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.
214365038|NCT00067015|DRUG|bicalutamide|
214365039|NCT00067015|DRUG|goserelin acetate|
214365040|NCT00067015|PROCEDURE|assessment of therapy complications|
214365041|NCT00067015|PROCEDURE|quality-of-life assessment|
214365042|NCT00067015|RADIATION|radiation therapy|
214975483|NCT05233735|OTHER|Enhanced Transcutaneous Delivery of Topical Betamethasone after the treatment with Tixel|Tixel Parameters: exposure time 6-8 milliseconds, 400-600 μm protrusion
214975484|NCT05233735|OTHER|Topical treatment|betamethasone ointment treatment once per day
214975485|NCT04351620|DRUG|Hydroxychloroquine|Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
214975486|NCT04474925|PROCEDURE|Brain Surgery|Surgery to remove brain metastases
215084845|NCT01742572|BEHAVIORAL|Diet|Change in dietary intake
214365043|NCT02328885|DRUG|DLI of the 20 fraction of the UCBT|Administration of 20 fraction of the UCBT
214365044|NCT04591522|OTHER|Healthy fecal bacteria liquid|Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
214491025|NCT06276686|OTHER|Supervised Vigorous intensity aerobic interval exercise|11-weeks course of aerobic and resistance exercise, delivered 2 weeks before long course NACRT, 5-weeks during NACRT and 4 weeks post NACRT. Alongside twice weekly unsupervised resistance exercise training.
214491026|NCT06816615|PROCEDURE|Percutaneous cholangioscopic-assisted treatment|The intervention administered is a percutaneous colangioscopic assisted technique that uses endoscopic Spyglass system. The endoscopic Spyglass system is designed to provide direct viewing and to guide both optical devices and accessories for lithotripsy in case of litiasic pathology and is equipped with a suitable bioptic clamp in case of biopsy collection. The use of the digital Spyglass catheter involves the preliminary percutaneous puncture of the bile ducts with a right, left or combined approach, and the subsequent execution of a cholangiographic study. Additional treatment sessions may be performed every 15-20 days in case of residual lithiasis. At the end of each session, an internal-external transeptic percutaneous drainage (ptbd) of adequate caliber (8-14 fr) is left in place to monitor any complications and maintain a route of access for sequential treatments.
214491027|NCT03655561|OTHER|Non interventional research|Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.
214491028|NCT06626685|OTHER|Clinical and instrumental examination|Each patient, consecutively afferent to the SC Cardiologia I of the ASST-PG23 in Bergamo with the diagnosis of acute or chronic HF, at enrollment will undergo to routine clinical and instrumental examination.
214491029|NCT06889441|BEHAVIORAL|Test of sensory function in infants|It was planned to use the Test of sensory function in infants to evaluate the sensory development of infants. The test of sensory function in infants is frequently used to evaluate the sensory processing functions of infants aged 4-18 months. It is used to determine whether an infant has a sensory processing problem and to what extent. It consists of 24 items. The test of sensory function in infants requires the infant to be stimulated and interacted with various materials. The total score varies between 0-49 and the test has normative values for different age groups. Although it is used from the fourth month onwards, the most reliable and valid results are obtained between 7-18 months.
214491030|NCT06889441|BEHAVIORAL|The Peabody Developmental Motor Scales-Second Edition|The Peabody Developmental Motor Scales-Second Edition is a standardized, norm-referenced assessment instrument designed to evaluate both gross and fine motor skills in children aged 0 to 71 months. It is frequently employed in clinical, educational, and research contexts to detect motor developmental delays, monitor developmental trajectories, and inform intervention strategies. Notably, higher scores on the scale reflect superior motor performance, indicating better developmental outcomes
214491031|NCT06889441|BEHAVIORAL|Infant/toddler sensory profile|"The infant/toddler sensory profile is a questionnaire filled out by the child's primary caregiver to collect information about sensory processing abilities. The test evaluates sensory processing in 6 different areas. These items consist of general, visual, auditory, vestibular, tactile and oral sensory processing. The caregiver evaluates the child's behavior on a 5-point scale. One point means almost always and five points means almost never. The caregiver's responses are summarized using standard scoring procedures and then interpreted in terms of the impact of a child's sensory processing abilities on the child and their family's lives. The scores are normative for age and are important in assessing sensory development."
214491032|NCT06746558|COMBINATION_PRODUCT|Potassium Nitrate Gel and Diode Laser Therapy|Participants in the experimental group receive treatment combining a desensitizing gel containing 5% potassium nitrate (Emoform Actisens) applied to affected teeth and diode laser therapy (980 nm). The laser is used with specific power settings (0.3W, 0.5W, 0.7W) for 20 seconds at each setting, followed by a second application of the gel and irradiation. The treatment aims to reduce dentinal hypersensitivity by occluding dentinal tubules and altering neural responses.
214491033|NCT06746558|DRUG|Potassium Nitrate Gel Alone|Participants in the control group receive treatment with a desensitizing gel containing 5% potassium nitrate (Emoform Actisens) applied to the teeth. The gel is applied twice using a microbrush in a rubbing motion for 2 minutes each time. No diode laser therapy is administered. This intervention aims to evaluate the standalone efficacy of the gel in reducing dentinal hypersensitivity.
214491034|NCT06754202|OTHER|Social activities with cognitive stimulation|"The nine-month program will include social activities following the Montessori action in the context of the agricultural multifunctionality such as horticulture, pet therapy, occupational therapy, sensory labs, physical activity held three days a week for five hours each day."
215084846|NCT02588703|BEHAVIORAL|Cognitive Behavioral Therapy|Coping Skills Treatment
215084847|NCT02588703|BEHAVIORAL|Usual Care|Existing DUI program group counseling
215084848|NCT03067493|BIOLOGICAL|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
214365045|NCT06639061|DEVICE|Hippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS)|"We will use fMRI resting state data to personalize a TMS inhibitory stimulation to a cortical location that is the most strongly connected to a deeper left hippocampal target.~5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation."
215084849|NCT00001065|DRUG|Amphotericin B|
215084850|NCT00121394|PROCEDURE|Chlorhexidine vaginal and infant wash|
215084851|NCT05203978|PROCEDURE|colonoscopy|Colonoscopy
214365046|NCT06639061|DEVICE|Sham stimulation using repetitive transcranial magnetic stimulation (rTMS)|We will use fMRI resting state data to personalize a TMS sham stimulation to a cortical location with near zero connectivity to a deeper left hippocampal target. 5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.
214365047|NCT03804710|DRUG|Developmental moisturizing cream 1|Participants will topically apply developmental moisturizing cream 1
214365048|NCT03804710|DRUG|Developmental moisturizing cream 2|Participants will topically apply developmental moisturizing cream 2
214365049|NCT03804710|OTHER|Standard cleanser soap|Participants will cleanse the entire face and both lower legs (between the knees and the ankles)with simple pure soap
214365050|NCT01268748|PROCEDURE|Conventional laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports
214491035|NCT06752733|PROCEDURE|electrical cardioversion|synchronized electrical shocks to restore normal sinus rhythm in patients with atrial fibrillation, performed under sedation
214491036|NCT06784661|DRUG|Lipid-Based Artificial Tear|This intervention consists of a lipid-based artificial tear formulation containing mineral oil and hydroxypropyl guar. It is designed to enhance the tear film's lipid layer and improve ocular surface stability. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
214491037|NCT06784661|DRUG|Non-Lipid Artificial Tear|This intervention consists of a non-lipid artificial tear formulation containing hydroxypropyl guar. It is intended to stabilize the aqueous layer of the tear film and maintain optical quality. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
214491038|NCT06669676|OTHER|acupuncture|patients will be given acupuncture in addition to standard medical treatment to prevent ponv
214491039|NCT06669676|OTHER|No acupuncture|patients will be given standard medical treatment to prevent ponv
214491040|NCT06761690|OTHER|hybrid simulated wound training|hybrid simulated wound training
214491041|NCT06812689|DIETARY_SUPPLEMENT|Flavanol|Natural cocoa powder containing 710 mg of flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
214491042|NCT06812689|DIETARY_SUPPLEMENT|Placebo|Alkalized cocoa powder containing no flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
214491043|NCT06812689|OTHER|Sugar water|250 mL of hot water with 6 g of sugar
214491044|NCT06748261|DIAGNOSTIC_TEST|CCTAI model|Using a derivative sub-cohort, the investigators aim to first develop an CCTA-based AI-assisted (CCTAI) screening model to distinguish patients with cardiac abnormalities from those normal controls. Second, the investigators target at developing a CCTAI diagnostic model with multi-classification output of cardiomyopathy diagnosis. Both models will be tested in internal validation cohort and external validation cohort.
214491045|NCT06762431|DRUG|Lenalidomide|Dose Level 1
214491046|NCT06762431|DRUG|Lenalidomide|Dose Level 2
214491047|NCT06835166|PROCEDURE|12-lead electrocardiography measurement|"Intraoperative 12-lead electrocardiography (EKG) measurement during laparoscopic sleeve gastrectomy in morbidly obese patients:~In all patients, pneumoperitoneum CO₂ intraabdominal pressure will be studied as 15 cmH₂O.~Intraoperatively, 12-lead ECG will be obtained at five position measurement points:~Procedure1. Supine-monitored; Procedure 2. After induction; Procedure 3. Under general anesthesia-Supine-abdominal inflated; Procedure 4. Abdominal inflated-(30% vertical) Reverse Trendelenburg; Procedure 5. Abdominal deflated-(30% vertical) Reverse Trendelenburg.~Hemodynamic monitoring \[systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate \] was recorded at 5 simultaneous measurement points.~All hemodynamic measurements and ECG recordings will be performed 3 minutes after the position change to ensure standardization, to allow the response to settle after the position change, and to prevent the possibility of exaggerated-incorrect data."
214491048|NCT05962489|OTHER|Clinically optimized deep brain stimulation|Participants will have DBS implanted as standard-of-care. We will be examining the effects of their regular clinical stimulation settings versus no stimulation.
214491049|NCT06786299|BIOLOGICAL|RD-IIT-001|Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
214491050|NCT06786299|DRUG|CD84-CART|Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
214491051|NCT06786923|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulator|Intervention Timing of Transcutaneous Auricular Vagus Nerve Stimulator: The intervention will begin 30 minutes before anesthesia induction and continue until the end of the surgery, terminating after the removal of the endotracheal tube in the PACU. The stimulation parameters are set as follows: frequency 25 Hz, pulse width 200 μs, 30 seconds on / 30 seconds off, with the current intensity set to the maximum amplitude the patient can tolerate (just below the pain threshold).
214491052|NCT06782750|OTHER|Physiotherapy|Traditional physiotherapy treatment was applied 5 days in a week, 1 hour in a day for 6 weeks.
214491053|NCT06321536|DRUG|Allogeneic Microbiota in Glycerol (9%) (AMG)|Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or 30mL instillation via an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.
214491054|NCT06795607|DIETARY_SUPPLEMENT|Probiotic|The experimental product is a dietary supplement manufactured by Cerbios-Pharma S.A, Each stick contains probiotic live cultures of Enterococcus lactis SF68® at a concentration of 10\^9 CFU, phytosterols, 6S-5MeTHF, maltose and silicon dioxide. Study participants will be given N°3 packs each containing 30 stick packs of 1.7 g each, in granulated form in sufficient quantity for the entire duration of the study (12 weeks). Subjects will be required to consume N°1 stick pack of the supplement daily after dinner for 12 continuous weeks. The product should be placed directly on the tongue and should be taken without water. After taking the product, the subject should drink half a glass of water to promote solubilization and transit. The supplement should be stored in a cool, dry place, away from light, moisture and direct heat sources to ensure the viability of the probiotic strain until the expiration date.
214491055|NCT06795607|DIETARY_SUPPLEMENT|Placebo|N°1 stick/day of placebo food supplement (i.e., stick without added probiotics), with the same intake modalities as probiotic.
214365051|NCT01268748|PROCEDURE|Experimental laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
214365052|NCT01900782|BIOLOGICAL|Intervention A|Prefilled syringe.
214365053|NCT01900782|BIOLOGICAL|Intervention B|Prefilled syringe.
214365054|NCT01900782|BIOLOGICAL|Placebo|Prefilled syringe to match experimental drug and active comparator.
214365055|NCT05524974|DRUG|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
214365056|NCT05524974|DRUG|Oxaliplatin|Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.
214491056|NCT06795295|PROCEDURE|Implant retained mandibular overdenture|Participants received dental implants to retain mandibular overdentures.
215084852|NCT02969590|DRUG|Leuprolide acetate|Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
214365057|NCT05524974|DRUG|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
214491057|NCT06797843|OTHER|"SPRG-based Resin Composite : (BEAUTIFIL II, Shofu Inc. Kyoto, Japan)."|A fluoride releasing, highly aesthetic dental material that is S-PRG (Surface Pre-reacted Glass Ionomer) based , has the ability to recharge fluoride and appropriate for patients with a high caries index.
214491058|NCT06797843|OTHER|Alkasite based restoration : Cention N|Cention N offers tooth-coloured esthetics together with high flexural strength. The new filling material belongs to the materials group of Alkasites. The patented alkaline filler increases the release of hydroxide ions to regulate the pH value during acid attacks. As a result, demineralization can be prevented. Moreover, the release of large numbers of fluoride and calcium ions forms a sound basis for the remineralization of dental enamel. The initiator system enables good chemical self-curing.
214491059|NCT06797843|OTHER|provisional Resin modified glass ionomer followed by Nanohybrid composite|"GC Fuji IX GP® EXTRA is the fastest setting glass ionomer on the market.The faster final set saves valuable chair time which provides improved stability against water, an important feature in challenging oral environments. This product contains a next generation glass filler which elicits higher translucency, fluoride release, reactivity and a faster setting time.~Then followed by Conventional Nano hybrid composite restoration(Neo Spectra® ST LV, Dentsply Sirona) which is nano-ceramic, light-cured, radiopaque, universal composite with novel SphereTEC filler technology."
214491060|NCT06793878|BEHAVIORAL|Living in Families With Emotions|This is an 8-week group-based psychosocial intervention teaching adolescents how to recognize their feelings, manage them, and talk about emotions through group discussions, live exercises, and games. The adolescents' caregivers are also provided with the same information, through two live sessions.
214491061|NCT05530421|DRUG|Selinexor|Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
214491062|NCT05530421|DRUG|Venetoclax|Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
214491063|NCT05530421|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
214491064|NCT03125954|OTHER|standardized exercise treatment for knee OA in Denmark (GLAiD)|objective measurement of physical activity before, during af after the GLAiD intervention
214502815|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
214502816|NCT07029035|BIOLOGICAL|İnjectable platelet-rich fibrin|Repeated application of I-PRF to the periodontal pockets in the test sites was performed twice: once immediately following scaling and root planing (SRP), and once at the third week.
214502817|NCT07029035|OTHER|Sterile saline (0.9%)|Control sites received a sham intervention consisting of sterile saline solution irrigation into the periodontal pockets, to mimic the procedural aspects of PRF placement without delivering any biologically active material.
214975487|NCT04474925|RADIATION|Stereotactic Radiosurgery|SRS uses many focused radiation beams to treat tumors within the brain
214975488|NCT01297283|OTHER|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
214975489|NCT01297283|OTHER|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
214365058|NCT05524974|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.
214365059|NCT05524974|DRUG|Nab paclitaxel|nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.
214365060|NCT04640532|DRUG|KRT-232|KRT-232, administered by mouth
214365061|NCT04640532|DRUG|TL-895|TL-895, administered by mouth
214975490|NCT05396287|DEVICE|MRI|Participants will undergo an MRI scan while participating in two breathing tests (hypercapnia and hypoxia) to measure brain blood flow.
214975491|NCT03642028|DRUG|Suvorexant|Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.
214975492|NCT03642028|OTHER|Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
214365062|NCT01489995|DRUG|A (migalastat)|150 mg migalastat HCl in the fasting state (reference arm)
214365063|NCT01489995|DRUG|B (migalastat)|150 mg migalastat HCl with simultaneous consumption of a glucose drink
214365064|NCT01489995|DRUG|C (migalastat)|150 mg migalastat HCl 1 hour before consumption of a high fat meal
214365065|NCT01489995|DRUG|D (migalastat)|150 mg migalastat HCl 1 hour before consumption of a light meal
214365066|NCT01489995|DRUG|E (migalastat)|150 mg migalastat HCl 1 hour after consumption of a light meal
214365067|NCT04802941|DEVICE|Neoadjuvant Chemotherapy by CDSS (MedicBK)|CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.
214365068|NCT04802941|DRUG|General practice|General practice
214365069|NCT06372821|DRUG|NIO752|Antisense oligonucleotide
214365070|NCT06372821|OTHER|Placebo|Saline
214365071|NCT00100451|PROCEDURE|exercise|
214975493|NCT01802385|DRUG|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
214975494|NCT03834493|BIOLOGICAL|Pembrolizumab|IV infusion
214975495|NCT03834493|DRUG|Enzalutamide|Capsules/Tablets
214975496|NCT03834493|DRUG|Placebo|IV infusion
215084853|NCT02969590|DRUG|Estrogen and Progesterone Replacement|Replace hormones exogenously to create an artificial cycle
215084854|NCT02969590|DRUG|Progestin|Synthetic progestin to assess effects on cervical mucus.
214365072|NCT02660827|DEVICE|Insulin Pump|Closed Loop Algorithm
214365073|NCT05748912|PROCEDURE|Therapeutic bronchoscopy for removal of mucus plugs|Research participants that meet the study inclusion criteria will undergo a research bronchoscopy to remove airway mucus plugs from 1 lung for the first 5 participants, and, if single lung mucus removal is well tolerated, on both lungs for the next 5 participants.
214365074|NCT01428076|DRUG|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
214365075|NCT01896570|PROCEDURE|Catheter ablation of subsequent atrial tachycardia|
214365076|NCT01832428|OTHER|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
214365077|NCT00520858|OTHER|Resistance Exercise (RE)|
214365078|NCT00520858|OTHER|Aerobic Exercise (AE)|
214365079|NCT00520858|OTHER|Resistance and Aerobic Exercise (RAE)|
214491065|NCT04121741|OTHER|Singing with Music Therapist|Music therapy sessions will begin with vocal and breathing warm-up exercises for about 10 minutes. The Music Therapist will play the songs (chosen from a list by the subject) to sing along to and will alter the characteristics of the music (volume, tempo, level of support) to ensure a successful experience for subjects and motivate them to put forth more effort into singing the song. The music therapist will continue to coach throughout the 30-minute session, reminding subjects of strategies practiced and how to implement those strategies while singing. Music therapy sessions will be led by Erica Flores, MT-BC, WMTR, Owner of Healing Harmonies Music Therapy, or a member of her team. Erica and her team of MTs were trained in Neurological Music Therapy.
214491066|NCT04121741|OTHER|Singing with Guided Video|The videos will include a vocal warm-up (10 minutes long). The subject will then have the option to select and sing two songs (10 minutes each), with offerings in four music genres including Folk, Pop, Country, and a Hymn. Each piece will vary in tempo, melodic contour, and rhythm. The total duration of singing via this format will be 30 minutes.
214491067|NCT04121741|OTHER|Control Arm|30 minute rest period, no singing will take place during this arm. During this rest period a member of the study team will assist the subject in a hearing test using headphones, a tablet, and a trumpet app. This is done to asses the current hearing level of the subject.
214365080|NCT04351867|DRUG|docetaxel plus oxaliplatin and capecitabine|docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
214365081|NCT04351867|DRUG|oxaliplatin plus capecitabine|oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
214365082|NCT04274673|DEVICE|measuring cotinine level|Measuring of the cotinine levels
214365083|NCT04602312|OTHER|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
214502818|NCT07028632|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
214975497|NCT06780267|DRUG|HRS-2129|HRS-2129; low dose
214975498|NCT06780267|DRUG|HRS-2129|HRS-2129; high dose
214975499|NCT06780267|DRUG|HRS-2129 placebo|HRS-2129 placebo
214975500|NCT05078775|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
214975501|NCT05929027|BEHAVIORAL|NoNo|"Participants in the G2 group will use the Twirlstone (knob-like) device to play a videogame called Nono's World. The Twirlstone is an electromechanical device that resembles a knob and a standard joystick (identical to the discontinued Atari CX-20 Controller). The knob can rotate or move in a push-pull fashion. To control the game's character (an axolotl called Nono), a signal about the knob motion is relayed to the computer wirelessly. This device has been certified by Johns Hopkins University's Clinical Engineering Services, where it was deemed less than minimum risk. The game has been custom built to allow participants to take control of the character using subtle manipulative finger movements to accomplish game-like tasks.~The investigators will use portable communication devices to carry out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
214975502|NCT05929027|BEHAVIORAL|occupational therapy - self directed|"Participants 5 daily sessions over 3 weeks consisting of self-administered, unsupervised occupational therpay. Additionally, participants will have 2, \<15 minutes telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. The intervention will focus on stretches, warm-up and strengthening exercises aimed at improving hand function.~The investigators will use portable communication devices for the purposes of carrying out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
214975503|NCT05559905|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
214975504|NCT05559905|DRUG|Placebo|Placebo capsule matched to molnupiravir taken twice daily by mouth.
214975505|NCT05559905|BIOLOGICAL|RSV A Memphis 37b|RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of \~4 Log10 plaque forming units (PFUs).
214975506|NCT06283212|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A)
214975507|NCT00388245|PROCEDURE|Percutaneous Coronary Intervention|
214975508|NCT00388245|PROCEDURE|Coronary Artery Bypass Grafting|
214975509|NCT04003103|DRUG|Islatravir|Islatravir 30 mg capsules taken by mouth.
214975510|NCT04003103|DRUG|Placebo|Placebo capsules taken by mouth.
214975511|NCT06958978|DEVICE|Quantum RF|Patented handpiece device designed for skin rejuvenation and tightening through intraoperative subdermal Radiofrequency treatment.
214975512|NCT02756910|DEVICE|iThermonitor (WT701)|Continuously monitor the axillary temperature during surgery
214975513|NCT06834126|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214975514|NCT06834126|PROCEDURE|Computed Tomography|Undergo CT
214975515|NCT06834126|DRUG|Consolidation Therapy|Receive CC with mFOLFOX6 or CAPOX
214975516|NCT06834126|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
214975517|NCT06834126|PROCEDURE|Gastrointestinal Endoscopy|Undergo endoscopy
214975518|NCT06834126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214491068|NCT06801080|OTHER|HealthySteps (https://www.zerotothree.org/our-work/healthysteps/)|Within the DoD, most elements of the civilian HS model copyrighted by ZeroToThree.org were implemented. However, there were some modifications to accommodate the unique environment of the military community. The pilot utilized the pre-existing Military Family Life Counseling Program (MFLC) staff to serve as HS Specialists at participating clinics. MFLCs were hired and trained in the HS model through the HS Institute provided by ZeroToThree.org. Although the DoD pilot offered all 3 tiers of targeted care standard for the HS model, note that the DoD pilot did not offer a 24-hour parent support line at tier 1. Also, the DoD pilot required participating pilot clinics to utilize a modified version of the Tufts Survey of Well-Being of Young Children (SWYC; https://www.tuftsmedicine.org/medical-professionals-trainees/academic-departments/department-pediatrics/survey-well-being-young-children) to provide augmented screenings for infants at all tiers of pilot service provision.
214365084|NCT05828966|DRUG|human chorionic gonadotropin (hCG)|H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute.
214365085|NCT05828966|DRUG|Magnesium sulfate|4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
214365086|NCT05031546|DRUG|Difelikefalin|IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)
214365087|NCT03381755|DRUG|half-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.
214491069|NCT06801080|OTHER|Treatment as Usual (TAU)|The comparison clinics included in this intervention were selected to represent pediatric care within military treatment facilities throughout the DHA medical system located at Army, Navy, Marine Corps, and Air Force facilities. There is variability in pediatric practice across military service branches. However, all clinics follow the American Academy of Pediatrics Bright Futures guidelines.
214491070|NCT03473223|BIOLOGICAL|Apolipoprotein A-I [human] (apoA-I)|Apolipoprotein A-I \[human\] (apoA-I) purified from human plasma for intravenous administration
214491071|NCT03473223|OTHER|Placebo|25% albumin solution diluted to 4.4%
214491072|NCT06838949|DRUG|herombopag olamine tablets|The patient received herombopag 5mg/d at the beginning of the day, was orally taken on an empty stomach in the morning, and could eat 2 hours after taking the drug, once a day for 24 weeks. Investigators will adjust the dosage of herombopag once a week according to the platelet count, with a maximum dosage of 7.5 mg per day. Efficacy and safety were evaluated once a week.
214491073|NCT06212453|PROCEDURE|Targeted Microwave Ablation|3D ultrasound-guided focal thermal ablation of the prostate transition zone
214491074|NCT02845596|DRUG|cyclosporine|cyclosporine
214491075|NCT02845596|PROCEDURE|Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
214491076|NCT02845596|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
214679730|NCT06672640|BEHAVIORAL|Remote Exercise Program|Participants in this group will engage in an eight-week exercise program conducted via video conferencing software. The sessions, which focus on balance, lower limb strength, and gait function, will be held twice weekly for 50 minutes each. Licensed physical therapists will supervise the sessions, and participants will exercise at home, with assistance from caregivers if necessary. The program aims to evaluate the effectiveness of remote exercise interventions in improving physical function and reducing the risk of falls in pre-frail older adults.
214975519|NCT06834126|DRUG|Papaverine|Given IV
214365088|NCT03381755|DRUG|standard-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.
214365089|NCT00665574|OTHER|ActaVisc and ActaVisc Mx Intra-articular Injection|ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
214365090|NCT00549588|OTHER|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
214365091|NCT00549588|OTHER|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
214365092|NCT00549588|OTHER|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
214365093|NCT00549588|OTHER|Intervention: none (only UV)|
214975520|NCT06834126|RADIATION|Radiation Therapy|Undergo RT
214365094|NCT04637334|PROCEDURE|Superior vena cava reconstruction|Endovascular therapy with percutaneous transluminal angioplasty (PTA) and, in recent years, with stenting of the SVC, has been performed with increasing frequency. An endovascular approach is the current standard of care to relieve SVC obstruction due to malignancy to obtain prompt relief of the rapidly emerging symptoms and improve quality of life,3 keeping in mind the short life expectancy of these patients. The role of endovascular therapy in SVC syndrome of nonmalignant etiology is undecided because long-term durability of this treatment method remains to be assessed.
214975521|NCT06834126|PROCEDURE|Total Mesorectal Excision|Undergo ToME
214975522|NCT03555851|DRUG|Cyclophosphamide|Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
214975523|NCT03555851|OTHER|Specimen collection|Buccal swabs will be obtained from donors for pharmacogenomics.
214975524|NCT05843253|DRUG|Ribociclib|Ribociclib PO qd on days 1-21
214975525|NCT05843253|DRUG|Everolimus|Everolimus PO qd on days 1-28
214975526|NCT05796791|DRUG|Ketamine Hydrochloride|IM ketamine given in weekly session for a total of 3 weeks
214975527|NCT05796791|BEHAVIORAL|Motivational enhancement therapy|Brief motivational based therapy
214975528|NCT06408207|BEHAVIORAL|CGM Academy|Educational materials as well as online sessions with diabetes educators.
214975529|NCT03899779|OTHER|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
214975530|NCT03899779|OTHER|Online hypnotherapy|12 weeks treatment with online hypnotherapy
214975531|NCT03899779|OTHER|Online psychoeducation|12 weeks treatment with online psychoeducation
214365095|NCT03467867|DRUG|Venetoclax|Venetoclax will be administered as described in the reporting arm.
214365096|NCT03467867|DRUG|Rituximab|Rituximab (IV) will be administered as described in the reporting arm.
214365097|NCT03467867|DRUG|Rituximab/Hyaluronidase Human|Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
214365098|NCT00491803|DRUG|Sildenafil|sildenafil 20 mg orally
214365099|NCT00491803|DRUG|Sildenafil|sildenafil 40 mg orally
214365100|NCT00387673|BEHAVIORAL|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
214365101|NCT03065270|OTHER|Use unstable shoes Masai Barefoot Technology (MBT)|Use of unstable shoes during 9 weeks, at least four hours per day.
214365102|NCT03065270|OTHER|Use conventional sport shoes|Use of conventional sport shoes during 9 weeks, at least four hours per day.
214365103|NCT03326531|OTHER|Not applicable for this study|Not applicable for this study
214365104|NCT00045305|DRUG|Cyclosporine|Immunosuppressant
214365105|NCT00045305|DRUG|Methotrexate|Antimetabolite
214365106|NCT00045305|DRUG|Photopheresis|Psoralens
214365107|NCT00045305|DRUG|Mycofenolate mofetil|an antibiotic with immunosuppressamt properties isolated from Penicillium spp
214365108|NCT00045305|DRUG|Pentostatin|Purine analogue
214365109|NCT00045305|PROCEDURE|allogeneic bone marrow|Unmanipulated allogeneic bone marrow
214365110|NCT00045305|PROCEDURE|peripheral blood stem cell|G-CSF mobilized peripheral blood stem cell
214365111|NCT00045305|RADIATION|Total body irradiation|a total of 600 cGy given in 3 200 cGy fractionated doses
214365112|NCT01440491|OTHER|Physiotherapy exercise|once a day, during 15 minutes, for 12 weeks
214365113|NCT01033357|DEVICE|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
214365114|NCT01033357|DEVICE|Lifespan® ePTFE Vascular Graft Only|Vascular Graft only
214365115|NCT00910442|DIETARY_SUPPLEMENT|Glutathione precursors|HIV+ patients were assigned to 7 day diets containing either NAC or Gln
214365116|NCT00955669|BIOLOGICAL|Symptoms and Objective Examination|5.0\*108\~5.0\*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
214365117|NCT03138096|BIOLOGICAL|Pb(PfCS@UIS4)-infected mosquitoes|Pb(PfCS@UIS4)-infected mosquitoes
214365118|NCT03138096|OTHER|Challenge infection P. falciparum|Challenge infection with bites of five infected Pf mosquitoes
214365119|NCT04830072|BEHAVIORAL|Brief AWARD advice and active referral to somking cessation services|The AWARD advice includes: (1) Ask about smoking history; (2) Warn about the high risk of smoking; (3) Advise to quit or reduce smoking as soon as possible; (4) Refer smokers to smoking cessation services (with a referral card); (5) Do it again: to repeat the intervention.
214365120|NCT04830072|BEHAVIORAL|Chat-based support through Instant Messaging apps|Participants in the intervention group will receive 3 months of chat-based support through Instant Messaging apps (e.g., WhatsApp, WeChat). The support mainly includes (1) regular messages on health warnings, benefits and methods of quitting, coping craving approach, and promotion to use the SC services; (2) real-time, personalized, and interactive behavioral and psychosocial support through Instant Messaging apps.
214365121|NCT04830072|OTHER|Leaflet|Leaflet on harms of smoking
214365122|NCT04830072|BEHAVIORAL|AR images|AR images of the harms of smoking and the benefit of abstinence.
214365123|NCT03037450|PROCEDURE|Miniinvasive corneal neurotization|Neurotization of a neurotrophic cornea
214491077|NCT02845596|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
214975532|NCT03829462|DRUG|Regorafenib|regorafenib tab 40 mg i.e 160 mg/day
215084855|NCT01280539|DEVICE|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
214365124|NCT05969171|DRUG|Surufatinib, gemcitabine, nab-paclitaxel|Nab-paclitaxel: 125mg/m2 intravenously, d1, 8; every 3 weeks for a treatment cycle, did not exceed a maximum of 6 treatment cycles. Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks for a treatment cycle. Surufatinib: 250mg, qd, po, every 3 weeks for a treatment cycle. Surufatinib and gemcitabine was continued until disease progression (PD, RECIST 1.1) or death (while the patient was on treatment) or toxicity became intolerant or other criteria for discontinuation of study therapy were met in the protocol. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
214365125|NCT05969171|DRUG|Nab-paclitaxel, gemcitabine|Nab-paclitaxel: 125mg/m2 intravenously, d1, 8; every 3 weeks as a treatment cycle, should not exceed a maximum of 6 treatment cycles. Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks as a treatment cycle, treatment until toxicity intolerance or disease progression, death, or other criteria for termination of study therapy as specified in the protocol. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
214365126|NCT02216773|PROCEDURE|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
214365127|NCT02216773|PROCEDURE|Portal vein embolization (PVE)|
214491078|NCT02845596|DRUG|methotrexate|methotrexate
214491079|NCT02845596|DRUG|fludarabine|fludarabine
214491080|NCT02845596|DRUG|cyclophosphamide|cyclophosphamide
214491081|NCT02845596|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
214491082|NCT02845596|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
214491083|NCT06810908|PROCEDURE|Internal fixation or bracing|Adult patients with humeral shaft fractures have been treated either with internal fixation or functional bracing according to the discretion of the treating surgeon.
214491084|NCT06873815|DRUG|Fluorescein Sodium|Patients will receive IV fluorescein sodium in the operating room before the vulvectomy procedure.
214975533|NCT03829462|DRUG|Irinotecan|irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
214365128|NCT03977038|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is prescribed as first-line treatment for TRD patients (4). rTMS is safe, tolerable and non-invasive neurostimulation procedure where powerful magnetic pulses are transmitted through the skull into the underlying cortical cortex with the aim of electrical current induction within the neural tissue. This study administers a standard dose of rTMS treatment to the TRD patient sample consisting of high frequency deep TMS (HF-dTMS) stimulation over left dorsolateral prefrontal cortex (L-DLPFC), at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks. The technology of dTMS, which will be used in this study, is an adaptation of the therapeutic intervention of rTMS with the advancement of possessing higher efficacy in targeting deeper brain regions of interest.
214365129|NCT04274894|DRUG|AndroGel 1.62%|AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
214365130|NCT05491148|OTHER|work conditions|an increased degree of responsibility for the life of newborns, high psycho-emotional stress, intellectual stress, an irrational work and rest regime, in connection with the COVID-19 pandemic, also using personal protective equipment against biological factors
214365131|NCT02279043|BEHAVIORAL|Interaction with users of IUC and non-IUC users|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users."
214491085|NCT06745570|BEHAVIORAL|Lifestyle Modification and Sleep Intervention|This study is being performed to develop, refine, and test the effects of a group lifestyle modification intervention augmented with a sleep intervention on weight loss, eating behaviors, and sleep outcomes. Results from this study will inform future studies to test the efficacy of this intervention. This intervention is being offered as part of a research study within Drexel University's WELL Center. Participants will receive remote, group-based, weekly weight loss and sleep coaching (90 minutes per coaching session) for 16 weeks.
214491086|NCT02848625|OTHER|Yoga|Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
214491087|NCT03907826|DRUG|PD-1 blocking antibody|Toripalimab 240mg, D1, every 3 weeks per cycle
214491088|NCT03907826|DRUG|GP|Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
214491089|NCT03907826|RADIATION|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
214975534|NCT06889129|OTHER|Experimental- Heat application|"Heat application + standard protocol=Hot Application Protocol~Hot application will start daily and continue until the completion of 4 weeks. The area will be checked for infection, scar tissue, inflammation, and incision before the application, and the procedure will be explained to the patient and their family.~The first application will be performed on the day the patient comes for chemotherapy, ensuring privacy by exposing only the application area and positioning the patient appropriately.~Patients will be asked to sit on a chair or couch with both feet immersed in a foot bath containing 5 liters of water, approximately 5 cm above their ankles, every night before bed for one month. The water temperature will be 40°C. The application will last for 30 minutes.~Patients will be advised to avoid contact with cold water, as well as the consumption of cold food and beverages."
214975535|NCT06889129|OTHER|Experimental-Cold application|"Cold application + standard protocol=Cold application will start daily and continue until the completion of 4 weeks.~The area will be checked for infection, scar tissue, inflammation, and incision before the application, and the procedure will be explained to the patient and their family.~The first application will be performed on the day the patient comes for chemotherapy, ensuring privacy by exposing only the application area and positioning the patient appropriately.~Patients will be asked to sit on a chair or couch with both feet immersed in a foot bath containing 5 liters of water, approximately 5 cm above their ankles, every night before bed for one month. The water temperature will be between 23-26°C. The application will be performed by the researcher on the day the patient comes for weekly chemotherapy treatment.~Patients will be advised to avoid contact with hot water, as well as the consumption of hot food and beverages."
214975536|NCT05621863|OTHER|Aim 1 Meal Challenge 1|A meal challenge will be provided that contains 1 serving of peaches and 2 servings of strawberries as a smoothie and 2 servings of tomatoes and 1 serving of carrot as a vegetable dish.
214975537|NCT05621863|OTHER|Aim 1 Meal Challenge 2|A meal challenge will be provided that contains 1 serving of banana and 2 servings of peaches as a smoothie and 1 serving of tomatoes and 2 servings of green beans as a vegetable dish.
214975538|NCT05621863|OTHER|Aim 1 Meal Challenge 3|A meal challenge will be provided that contains 2 serving of bananas and 1 serving of strawberries as a smoothie and 1 serving of green beans and 2 servings of carrots as a vegetable dish.
214975539|NCT05621863|OTHER|Aim 2 Typical American Diet|The diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. No bananas, strawberries, peaches, green beans, carrots, or tomatoes will be provided.
214975540|NCT05621863|OTHER|Aim 2 Typical American Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts less than or equal to 1 serving per day each.
214975541|NCT05621863|OTHER|Aim 2 Dietary Guidelines for Americans Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain whole grains and high amounts of fruits and vegetables, representative of the Dietary Guidelines for Americans. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts greater than or equal to 1 serving per day each.
214365132|NCT02279043|BEHAVIORAL|Interaction with non-IUC users only|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions."
214365133|NCT03848403|BIOLOGICAL|Ixekizumab|Administered SC
214365134|NCT02124265|DRUG|CeraLyte 90|"1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5\. Patients will be monitored according to standard of care.~a. If gastric residuals are \>300cc, ORT will be stopped and only IV fluid resuscitation will be used."
214491090|NCT06045351|DRUG|Vitamin D|"Intervention Group Initial 12 weeks;~* VD supplementation (600,000 IU I/M) once during the study period~* Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~* Calcium 1000 mg/day"
214491091|NCT06045351|OTHER|Active Comparator|"Active Comparator (Group B; n=71):~Initial-- 12 weeks;~* Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks~* VD supplementation (600,000 IUI/M) once during the study period~* Calcium 1000 mg/day~* Standard PCOS Continued"
214491092|NCT05991908|DRUG|Fludarabine, busulfan and melphalan|FLudarabine 150mg/m2 + Busulfan 6.4mg.kg + Mel 140mg/m2
214491093|NCT05991908|DRUG|Fludarabine and Busulfan|FLudarabine 150mg/m2 + Busulfan 12.8mg.kg
214491094|NCT06785753|DRUG|Irrigation Solution|normal saline will be used as irrigation solution
214491095|NCT03817229|BEHAVIORAL|Education microlearning sessions|mHealth education microlearning sessions
214491096|NCT03817229|BEHAVIORAL|Automated digital reminders|reminders from electronic monitors based on texts or lights/chimes
214491097|NCT03817229|BEHAVIORAL|Problem-solving mHealth module|mhealht problem solving module with 2 telehealth sessions with a therapist
214491098|NCT03817229|BEHAVIORAL|Individualized Adherence Feedback Report|Individual Adherence Feedback reports sent to parents weekly
214491099|NCT06770920|OTHER|use of an observer tool when not role-playing|Observers will use an observer tool (based on technical skills and specifically related to airway management during BLS) when they will be not role role-playing.
214491100|NCT06780228|BEHAVIORAL|chatbot-assisted clinical learning|The participants will recevie a self-developed web-based chatbot platform which is accessible via smartphones. It provides real-time dialogue with the chatbot through texts, visual aids, and audio files. The intervention will be available throughout the 12-week study. the chatbot is characterized by a gender-neutral persona, assumes the role of a friendly and empathetic clinical mentor. Its communication style can be described as calm, tolerant, supportive, and appreciative. Participants will receive weekly SMS notifications to remind them to consult with the chatbot.
214491101|NCT03524092|DRUG|Mirikizumab SC|Administered SC
214491102|NCT03524092|DRUG|Mirikizumab IV|Administered IV
214491103|NCT03524092|DRUG|Placebo SC|Administered SC
214975542|NCT05701111|BEHAVIORAL|Start with the Heart Students|The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.
214975543|NCT05701111|BEHAVIORAL|Start with the Heart Teachers|Pure Edge Inc will train teachers to deliver the Start with the Heart curriculum. The training emphasizes the neuroscience of stress and educator self-care. The teachers will implement the training in their respective classrooms for 6-8 weeks.
215084856|NCT02704923|DRUG|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
215084857|NCT02704923|DRUG|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
214365135|NCT02067260|DEVICE|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
214491104|NCT06781671|BEHAVIORAL|ComfortTheory|"Structured nursing interventions based on the Comfort Theory were applied to patients in the intervention group.~Patients were mobilized at least once during the day. Auxiliary materials believed to increase patient comfort, such as tablet computers, wired headphones, sleep headphones, and sleep masks, were provided.~Patients had face-to-face meetings with their families during the day and video calls in the evening.~Care interventions were minimized as much as possible for patients between 24:00-07:00 at night, and treatments were carefully planned around these hours.~Blood sampling was performed at 23:00 at night, and X-rays were taken at 07:00 in the morning.~The Patient Identification Form, General Comfort Scale, and Intensive Care Unit Environmental Stressor Scale were administered face-to-face by the researcher 48 hours after the patient\&amp;amp;amp;#39;s admission to the intensive care unit."
214491105|NCT06750679|OTHER|Compression bandage|A multicomponent inelastic compression bandage will be applied to the patient. Skin care and simple exercises will be added to intervention
214491106|NCT06750679|OTHER|Manual lymphatic drainage added to compression|Manual lymphatic drainage will be added to multicomponent inelastik compression bandage, skin care and simple exercises
214491107|NCT05754983|DRUG|Solid tumor patients receiving immunotherapy for the first time were included in the study|Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy
214365136|NCT02067260|DEVICE|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
214491108|NCT06678217|OTHER|Stroop task|The Stroop task will be used as a mild, acute stressor since it has effects on anxiety and autonomic response. In each Stroop task condition, four coloured visual stimuli will be presented on a computer screen for 3 s with 7 s inter-stimulus interval. The stimuli will be coloured words naming the colour of the ink in the nonconflict task condition (e.g. GREEN written in green ink) and a different colour in the conflict task condition (e.g. GREEN written in red ink). The participants were asked to name the colour of the stimuli. The test will be administered using the online version of PsyToolKit (Stoet, 2021).
214975544|NCT05701111|BEHAVIORAL|Cue Centered Therapy Counselors|The Early Life Stress and Resilience Program team members will train school counselors on Cue-Centered Therapy through self-paced online modules, virtual and in-person live training, and office hours as needed. Counselors will implement the intervention with eligible students for 15-18 weeks.
214975545|NCT05701111|BEHAVIORAL|Cue Centered Therapy Students|Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.
214975546|NCT05701111|GENETIC|iSWAB-DNA|Eligible students will give DNA buccal swabs at 2-3 time points for later analysis of genetic markers.
214365137|NCT00534131|PROCEDURE|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
214365138|NCT00534131|PROCEDURE|APPEAR Procedure|Perineal incision to reach the distal rectum
214365139|NCT00534131|PROCEDURE|Proctectomy|standard rectal excision which does not preserve the anal canal
214365140|NCT05608850|OTHER|Exercise Then Stretch|This arm (sequence) will perform an anti-gravity kinetic chain intervention and then a passive, partner-assisted stretching intervention, separated by a one-week washout period.
214365141|NCT05608850|OTHER|Stretch Then Exercise|This arm (sequence) will perform a passive, partner-assisted stretching intervention and then an anti-gravity kinetic chain intervention , separated by a one-week washout period.
214365142|NCT02386995|DEVICE|BIS monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia monitoring are then compared.
214365143|NCT02386995|DEVICE|Entropy monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia
214365144|NCT04474743|OTHER|No intervention - cross-sectional observational only|No intervention - cross-sectional observational only
214365145|NCT01270269|BEHAVIORAL|Behavioral: Physical and functional rehabilitation|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
214365146|NCT01270269|BEHAVIORAL|Behavioral: Cognitive, physical, & functional rehabilitation|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
214365147|NCT00303199|DRUG|ZIO-101 (Darinaparsin)|IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
214365148|NCT03234205|DEVICE|MRI scan|"MRI standard protocol with addition of:~* a second clinical respiratory belt besides belt usually installed for clinical examination~* a second clinical electrocardiogram sensor besides sensor usually installed for clinical examination~* 12 sequences during free respiration are added lasting supplementary 15 minutes~* Use of cardiac antennae usually used for cardiac MRI scans"
214491109|NCT06678217|OTHER|Cold pressor test|The participant lowers their hand in icy water to induce temporary tonic pain
214491110|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 \* 10\^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit \[SRAK-02 kit\] and third arm accessory).
214975547|NCT03041636|DRUG|Ruxolitinib|Given PO
214975548|NCT03041636|DRUG|Ruxolitinib Phosphate|Given PO
214365149|NCT05613738|DRUG|1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
214365150|NCT05613738|DRUG|1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
214365151|NCT05613738|DRUG|2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
214975549|NCT06551688|DIAGNOSTIC_TEST|Serum 25(OH)D level|The characteristics of 25 (OH) D3 are relatively longer half-life than 1.25 (OH)2 D3, stability, strong detection repeatability, and no biological activity. Generally, systemic levels of the more stable 25 (OH) D3 are considered to be the best index to reflect status of vitamin D in the individual patient
214365152|NCT04805255|RADIATION|Hypofractionated Stereotactic Radiotherapy|A course of hypofractionated stereotactic radiotherapy (HF-SRT) is delivered within 2 weeks with a cumulative dose of 3000 - 3500 cGy in 5 fractions.
214365153|NCT04510675|DEVICE|Test Article|Omeza Collagen Matrix
214365154|NCT04510675|OTHER|Negative Control|Occlusive Patch of 0.9% sodium chloride, NaCl
214365155|NCT02601989|DRUG|Tadalafil|
214365156|NCT02601989|DRUG|Placebo|Per oral intake of placebo for six weeks
214365157|NCT01479387|DRUG|[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received In-111 Zevalin.
214365158|NCT05310474|DEVICE|Knee Glider|The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA.
214975550|NCT06441318|DRUG|Povorcitinib|Povorcitinib will be administered at protocol defined dose.
214679731|NCT06672640|BEHAVIORAL|In-Person Exercise Program|Participants in this group will take part in an eight-week in-person exercise program at a senior welfare center. The sessions will be held twice weekly for 50 minutes and will be led by a licensed physical therapist. The exercise program, which includes balance, lower limb strength, and gait training, is identical to that of the remote exercise group, with the primary difference being the mode of delivery (in-person at the welfare center). This group aims to assess the effectiveness of direct supervision in a controlled environment.
214491111|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 \* 10\^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
214491112|NCT06821490|PROCEDURE|Targeted axillary dissection and subsequently a lymphadenectomy|Selective sentinel lymph node biopsy is performed, along with biopsy of the node marked at diagnosis. Subsequently, a lymphadenectomy is performed, with the three samples separated for pathological study during the same surgical procedure
214491113|NCT06030635|DEVICE|Measurement of compartment compressibility using the CPMX1 device|Patients will be monitored about every hour (+/- 30 min) for a total of 8 hours. Measurement time might be extended in case the patient undergoes trauma-related surgery during the measurement period and/or in case measurements are spaced further apart. Remaining measurements will be completed after the surgery. At each time point, three measurements of compartment compressibility will be conducted using the CMPX1 on both the affected (potential ACS) and healthy limb.
214491114|NCT06809439|PROCEDURE|Non-Surgical Intervention|Oral hygiene instructions including tooth brushing, flossing, and interdental brushing were given to all patient groups before non-surgical periodontal treatment. In both periodontitis groups, scaling, and root surface smoothing were performed using ultrasonic instruments (Woodpecker Medicals Ins. Co., USA) and Gracey Curettes (Hu-Friedy, Chicago, IL, USA) under local anesthesia once a week for 4 weeks.
214491115|NCT06809439|DIAGNOSTIC_TEST|Saliva Collection (Baseline)|Unstimulated saliva samples were collected from all participants between 9:00 and 11:00 am. Clinical periodontal measurements were performed after saliva collection to prevent contamination (bleeding, etc.). Participants refrained from brushing their teeth the morning before sampling and from eating, drinking, or smoking for at least 2 hours before sampling. Patients were asked to rinse their mouths with distilled water 5 minutes before saliva collection. A saliva sample was then collected by spitting directly into a sterile tube. Sample collection was continued for 5 minutes.
214491116|NCT06809439|OTHER|Probing|Clinical and radiographic evaluations were performed by trained and calibrated examiners at Ankara University (SY) and Ataturk University (OT). Clinical parameters of probing depth (PPD), clinical attachment level CAL, plaque index PI, and bleeding on probing (BOP) were recorded from six tooth regions (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, middle lingual, and disto-lingual) using periodontal probe. Bone loss was assessed using panoramic radiographs, confirming the diagnosis of periodontitis.
214491117|NCT06809439|DIAGNOSTIC_TEST|Saliva Collection (After treatment)|Unstimulated saliva samples were collected from all participants between 9:00 and 11:00 am. Clinical periodontal measurements were performed after saliva collection to prevent contamination (bleeding, etc.). Participants refrained from brushing their teeth the morning before sampling and from eating, drinking, or smoking for at least 2 hours before sampling. Patients were asked to rinse their mouths with distilled water 5 minutes before saliva collection. A saliva sample was then collected by spitting directly into a sterile tube. Sample collection was continued for 5 minutes.
214491118|NCT06339788|DRUG|HD-P023|Single dose administration of HD-P023
214491119|NCT06339788|DRUG|Teneligliptin|Single does administration of Teneligliptin and Empagliflozin High
214491120|NCT06339788|DRUG|Empagliflozin|Single does administration of Teneligliptin and Empagliflozin High
214491121|NCT06654167|OTHER|Low temperature (15℃) group|The exposure group will be exposed to low temperature (15℃) in a chamber for about 2 hours, resting during the whole period.
214491122|NCT06654167|OTHER|Moderate temperature (22℃) group|The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole period.
214491123|NCT06811766|OTHER|Strain-counterstrain|This is a technique that uses gentle body positioning passively to treat muscles and joints pain. So, this can be effective for neck pain in patients with CGH
214491124|NCT06811766|OTHER|Muscle energy techniques|This technique uses patient's own muscles to treat muscles and joint restrictions. So, this technique can be prove affective for neck pain and limited range in patients with CGH
214679732|NCT06672640|OTHER|Physical Activity Education|Participants in this group will receive educational materials about physical activity, including a booklet and one educational session. They will not participate in any structured exercise program but will be encouraged to maintain their usual activities. The control group serves as a baseline to compare the outcomes of exercise interventions against no structured exercise, focusing on evaluating usual care versus targeted exercise programs.
214975551|NCT06441318|DRUG|Placebo|Placebo will be administered at protocol defined dose.
214975552|NCT06441318|DRUG|Moxifloxacin|Moxifloxacin will be administered at protocol defined dose.
214975553|NCT03288038|DRUG|Rosuvastatin|
214975554|NCT03288038|DRUG|Ezetimibe|
214975555|NCT00209001|PROCEDURE|Acupuncture|Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
214975556|NCT00209001|PROCEDURE|Sham acupuncture therapy|Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
214975557|NCT04295577|OTHER|Niraparib|Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15\[13\].
214365161|NCT03034616|DEVICE|OLIVA device|"OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.~This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs"
214365162|NCT02317393|OTHER|K5-RGD PET|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
214365163|NCT02317393|OTHER|FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
214365164|NCT05316285|OTHER|Yoga exercise|Yoga lesson practices will be designed and implemented by instructors physiotherapists who have completed 200 hours of yoga instructor training (RYT-200). The yoga program, which will consist of one-hour sessions once a week, is planned to last 14 weeks. 4 weeks of classes will be theoretical lessons related to yoga philosophy, 10 weeks of yoga sessions will be applied every week on different concepts such as upper extremity and / or lower extremity focused strengthening and / or flexibility and breathing exercises. In addition to this training, students will be advised to repeat the practices once a week. Sessions will begin with breathing practices called pranayama, followed by yoga postures called asanas, and the sequence will be finished with savasana pose. In this pose, guided meditations will be performed on subjects such as body awareness and self-compassion.
214365165|NCT06562361|DRUG|[68Ga]Ga-DOTA-Cys-ATH001|Target dose of 200MBq \[68Ga\]Ga-DOTA-Cys-ATH001 corresponding to a maximum mass dose of 100 µg, administered as an intravenous bolus dose.
214365166|NCT00976352|DRUG|rAAV1-CMV-GAA (study agent) Administration|rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.
214365167|NCT00976352|OTHER|RMST|After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
214365168|NCT01330433|DEVICE|CoSeal Surgical Spray Group|"A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~* Patients weighing \< 3kg will receive 1ml of CoSeal~* Patients weighing 3-10kg will receive 1-2ml of CoSeal~* Patients weighing \>10kg will receive 2-4ml of CoSeal"
214365169|NCT02114151|DRUG|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
214365170|NCT02114151|DRUG|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
214365171|NCT04738526|OTHER|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate ceramic crown
214365172|NCT04738526|OTHER|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|conjunction with the two zirconium oxide raw materials 3Y-TZP and 5Y-TZP is responsible for producing a continuous, seamless progression of the shade and translucency within the material
214365173|NCT04738526|OTHER|natural tooth|natural tooth is composed of enamel. Enamel is on the surface of every tooth and it has a natural hue of white. However, the underlying dentin layer has a slightly yellowish color. This yellowish hue shows through the enamel in almost everyone
214365174|NCT01494584|DRUG|ezogabine/retigabine|ezogabine dose escalation
214365175|NCT06378892|DRUG|Lorlatinib|Platinum-pemetrexed based chemotherapy plus Lorlatinib will be administered for an induction phase of four cycles. The choice between Carboplatin or Cisplatin is entrusted to the clinician. Subsequently, patients with response or stability of disease at radiological assessment will start the maintenance phase with pemetrexed-Lorlatinib in 21-day cycles until progression, unacceptable toxicity, death, or withdrawal of consent.
214365176|NCT01666808|DRUG|FACBC|FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings
214365177|NCT01666808|RADIATION|Radiation therapy|External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
214491125|NCT06812065|DRUG|Hydrogen Peroxide 3 % Topical Solution|"Dressing: Like the Local Hyperthermia Group, use a cotton ball soaked in 3% hydrogen peroxide.~Irradiation: For seven sessions in three weeks, use simulated infrared light (without heat) with the same frequency as the Local Hyperthermia Group.~Local Hyperthermia treats the target warts(largest and most severe warts), while medication addresses all warts."
214502819|NCT07022106|OTHER|Myofascial Release Therapy (MRT) Group|"Myofascial Release Therapy (MRT) involves hands-on palpation to detect fascial restrictions, followed by 60-90 seconds of sustained pressure to release tension. In the supine position, the target areas include the superficial fascia, transversalis fascia, and extraperitoneal fascia, while in the prone position, the focus shifts to the thoracolumbar fascia and the erector spinae complex. This technique aims to restore mobility and reduce restrictions within the fascial system.~Frequency: Each patient will recieve a single session at their most painful day from this intervention."
214975558|NCT05259826|OTHER|biopsy sampling|"1. Biopsies are homogenised in buffer and used for the determination of mucosal IgE and inflammatory parameters.~2. Biopsies are used to isolate organoids, stimulate them with blood cells and food antigens and to study gene and protein expression."
214975559|NCT02398110|PROCEDURE|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
214975560|NCT02398110|PROCEDURE|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
214975561|NCT06101498|DIAGNOSTIC_TEST|Akut kidnet injury(AKI)|postoperative 24 hours
214975562|NCT06270108|DRUG|Riluzole|50mg twice daily (100mg total daily) for 56 days.
214975563|NCT01268163|DRUG|European Taxotere®|60-100 mg/m\^2 IV
214975564|NCT01268163|DRUG|American Taxotere®|60-100 mg/m\^2 IV
214975565|NCT01268163|DRUG|Hospira Docetaxel Injection|60-100 mg/m\^2 IV
214975566|NCT02240667|DRUG|Dabigatran etexilate|150 mg or 110 mg capsules twice daily
214975567|NCT02240667|DRUG|Vitamin K antagonists|International Normalized Ratio (INR) 2-3
214975568|NCT05518539|DEVICE|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
214975569|NCT03077893|DEVICE|Active Provant Therapy System|Treatment with active Provant Therapy System
214975570|NCT03077893|DEVICE|Inactive (sham) Provant Therapy System|Treatment with Inactive (sham) Provant Therapy System
214975571|NCT02690272|BEHAVIORAL|Psychic processes|Quantitative and qualitative aprroche of the psychic process
214491126|NCT06812065|DEVICE|Local Hyperthermia at 44℃|"(Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China) An infrared hyperthermia device was used to apply local hyperthermia at 44°C to the largest wart. The device includes a heating source, an infrared temperature monitor, an adjusting arm, a control circuit for temperature stabilization, and a display. It uses a tungsten-halogen lamp (wavelength: 760-2300 nm, peak at 1200 nm) to maintain the temperature of a 0.5\*0.5 cm skin area within ±0.1°C using a non-contact infrared feedback system.Hyperthermia: Conduct 44-degree Celsius, 30-minute sessions. Do it daily for the first 3 days, then 2 sessions every 7 days for 3 weeks, for a total of 7 sessions.~Dressing: Apply a cotton ball soaked in 0.9% saline to the warts, wrap it with plastic film for 1 hour, and do this once a day for 6 weeks. Local Hyperthermia treats the target warts(largest and most severe warts), while medication addresses all warts."
214679733|NCT06671886|BEHAVIORAL|E-trigger|The NCCP Intervention is multicomponent. First, the investigators will apply the e-trigger and calculate FIB-4, and second, will educate and train PACT personnel on how to deal with trigger positive patients as well as make treatment recommendations within an inter-professional team. The e-trigger will be generated every 3 months. The effectiveness of the trigger will be assessed using the outcomes previously mentioned.
214491127|NCT06813066|BEHAVIORAL|High Levels of Common Therapeutic Factors|The therapist large language model (LLM) is designed to show high levels of empathy, warmth, and genuineness. This setup aims to create a supportive and trusting therapeutic environment to improve patient engagement. High levels of these positive factors are linked to better psychotherapy outcomes and a stronger therapist-patient relationship.
214491128|NCT06813066|BEHAVIORAL|Low Levels of Common Therapeutic Factors|The therapist LLM for this group is designed to show low levels of empathy, warmth, and genuineness. This setup aims to examine how a less supportive and empathetic therapist affects psychotherapy sessions. Lower levels of these positive behaviors can lead to reduced patient engagement and a weaker therapist-patient relationship, potentially hindering therapy outcomes.
214491129|NCT06813066|BEHAVIORAL|Standard motivational interviewing|Motivational interviewing techniques as applied during the sessions on which the transcripts are based.
214491130|NCT06657612|OTHER|No intervention|No intervention
214491131|NCT06819644|DRUG|high flow oxygen therapy rate adjusted of lung volumes measured|Use of a technique based on non-contact measurement of lung volumes by depth camera in order to optimise the use of hihg flow oxygen therapy, with adaptation of the flow rate.
214491132|NCT06818058|DRUG|Brimonidine tartrate Gel|Once daily applications for 7 days
214491133|NCT06818058|DRUG|Placebo gel (no Brimonidine tartrate)|Once daily applications for 7 days
214491134|NCT06745336|DRUG|CS-001|CS-001 Topical Treatment
214491135|NCT06745336|DRUG|Placebo Topical Solution|Placebo Topical Solution
214491136|NCT06760858|DRUG|Tislelizumab|Tislelizumab: 200mg IV, day 1, Q3W, for a total of 3 cycles.
214679734|NCT06672913|BEHAVIORAL|skin to skin contact care|Early and regular skin to skin contact in NICU GA: \< 28 weeks: After the 72nd hour GA: 28 - 32 weeks: As soon as stabilization is ensured
214679735|NCT06672432|OTHER|CareMom (a mobile app-based 8-wekk cognitive behavioral therapy program)|The intervention is divided into daily tasks spread across eight weeks, with each day involving a variety of interactive elements such as videos, text-based content, guided reflections, and mental health check-ins. If the user misses a daily challenge, she can complete that challenge in the later days. Each week has a distinct focus that progressively builds the user's skills and understanding in managing emotional health. Tasks are designed to be short yet impactful, aiming to enhance engagement and adherence.
214679736|NCT06672432|OTHER|Matched Attention Control (a mobile app-based 8-week online relaxation training program)|This program is designed to mirror the structure and engagement level of the intervention group, providing participants with a similar amount of interaction and daily activities. Each day, participants in the control group will complete 1-2 daily tasks focused on relaxation techniques, such as breathing exercises, mindfulness meditation, and guided imagery. Each task is brief, approximately 3 minutes in duration, making it easy for participants to incorporate into their daily routine.
214679737|NCT05115461|DEVICE|Biodex Balance System™ SD|Postural stability index values (anteroposterior, mediolateral and overall) will be measured for static and dynamic conditions.
214975572|NCT04860479|DEVICE|ultrasound|ultrasonography to inguinal region
214975573|NCT02053493|DRUG|Isosorbide Mononitrate|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
214975574|NCT02053493|DRUG|Placebo|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
214975575|NCT01429844|DRUG|Tacrolimus|Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
214975576|NCT01429844|DRUG|Cyclosporine|Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
214491137|NCT06760858|DRUG|SOX|SOX: S-1 dosage based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 3 cycles.
214491138|NCT06760858|DEVICE|HIPEC|HIPEC: Docetaxel: 120mg, day 1, day 3.
214491139|NCT06760559|PROCEDURE|Intra-articular corticosteroid injection|Intra-articular hip injections with and without local anastesia and questionnaire about pain and anxiety related to the procedure was administered before and after the injection to the study and control groups.
214491140|NCT06762093|PROCEDURE|surgical repaire|"* Primary closure of lacerations~* Eyelid margin repair~* Eyelid crease reconstruction~* Eyelid transposition flaps or grafts~* Tarsorrhaphy"
214365178|NCT03220243|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
214365179|NCT00859079|DRUG|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
214365180|NCT00859079|DRUG|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
214679738|NCT05115461|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
214975577|NCT02084901|DEVICE|Drug-eluting biodegradable stent Orsiro implantation|Drug-eluting biodegradable stent Orsiro implantation
214975578|NCT02084901|DEVICE|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
214975579|NCT02965404|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
214365181|NCT01499082|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
214365182|NCT01499082|DRUG|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
214365183|NCT05678205|DRUG|AB-201|NK Cell Therapy
214365184|NCT05678205|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214365185|NCT05678205|DRUG|Fludarabine|Lymphodepleting chemotherapy
214365186|NCT05686005|DRUG|Oral tranexamic acid|4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
214365187|NCT05686005|DRUG|Intravenous tranexamic acid|15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.
214365188|NCT01457911|DRUG|Glimepiride and Metformin hydrochloride combination (HOE490)|Pharmaceutical form:tablet Route of administration: oral
214365189|NCT01457911|DRUG|Glimepiride (HOE490)|Pharmaceutical form:tablet Route of administration: oral
214365190|NCT00009802|DIETARY_SUPPLEMENT|calcitriol|
214365191|NCT00009802|DRUG|paclitaxel|
214365192|NCT03442712|OTHER|Auricular acupressure plus smartphone App|Semen Vaccaria laccaria will be kept in place by a piece of adhesive patch. Seeds will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear, that is, we will meet the subjects twice per week. Subjects will be requested to apply pressure on the acupoints thrice per day, preferably within 30 min before eating, pressing for 20 times using a constant rhythm to each point. Coaching on how to self-administer AA on the acupoints will be given to the subjects, and a return demonstration from the subjects will be required to ensure the skills are performed properly. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. In addition, the subjects will be asked to input the number of bowel open and compliance with AA performance per day into the App. The total treatment period will be 8 weeks.
214365193|NCT03442712|OTHER|Auricular acupressure|The participants will receive AA treatment and are required to perform daily self-administered seeds pressing, but no smartphone App will be provided, but a booklet containing relevant information will be provided to the subjects.
214365194|NCT04528836|DRUG|BBP-398 (Formerly known as IACS-15509)|oral capsules
214975580|NCT02965404|BIOLOGICAL|control live attenuated varicella vaccine|The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)
214975581|NCT02965404|BIOLOGICAL|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology
214975582|NCT03569397|OTHER|Music Therapy|Patients will be administered music therapy during the operation.
214975583|NCT04881344|PROCEDURE|laser hemorrhoidoplasty|"* Under local anesthetic (or general anesthetic if contraindications to local anesthetic),~* A laser optic fiber connected to a diode platform (Leonardo, Biolitec AG, Jena, Germany) will be applied threw a anoscope. After making a 1-mm opening at the external border of hemorrhoid pocket, the fiber will be introduced in the hemorrhoidal tissue. Several pulses, each lasting for 1.2 s, with a 0.6-s pause between pulses, will be delivered to the tissue.~* As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention),~* Postoperative care will consist of: normal diet, bulking laxatives, self-irrigation to the anal wound at six times per day and painkiller. Absence for work certificate will be made for 7 days for each patient and they will be told to return to work and normal daily activities as soon as they felt able."
214365195|NCT05378581|DEVICE|Virtual reality mask|virtual reality mask Deepsen® with age-appropriate software Birdy®
214365196|NCT05378581|OTHER|control arm|usual process
214365197|NCT06437990|PROCEDURE|Arteriovenous loop graft|Using saphenous vein graft to create an arteriovenous loop from the common carotid artery to the external jugular vein, providing vascular supply for a free functional gracilis muscle flap in patients with late-onset brachial plexus injury with concomitant subclavian or axillary artery injury.
214365198|NCT05000957|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1.5 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
214491141|NCT06761586|DRUG|AUR104|Once or twice a day
214679739|NCT05687760|BIOLOGICAL|bromelain|is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication
214365199|NCT05000957|DIAGNOSTIC_TEST|Blood analysis|Taking blood from a vein for clinical blood analysis, glucose test, hepatitis B, C viruses, human immunodeficiency viruses and syphilis test, blood clotting tests, blood type and rhesus factor determination (to include the participant in the study).
214365200|NCT05000957|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
214491142|NCT06774105|OTHER|Static Stretching|The protocol consisted in 2 sessions per week, each comprising 8 exercises of static stretching targeting all major muscle groups: 1) Hamstrings, 2) Knee Extensors, 3) Dorsal muscles, 4) Pectoralis muscles, 5) Elbow Flexors (biceps), 6) Elbow Extensors (triceps), 7) Adductors, and one day 8a) Spine Extensors while the second 8b) Spine Flexors. Each exercise involved 4 sets of 30 seconds of SS and 30 seconds of rest.
214491143|NCT06773104|PROCEDURE|immediate implant and grafting with autogenous tooth bone graft|"In autogenous tooth bone graft group:~Any restorations, caries, cementum, periodontal ligament and pulp tissue will be removed .The tooth will be grinded using dental bone mill and bone crusher Tooth particles will be sieved to particles size 300 to 1200 microns. The sorted particles will be immersed in 70 % ethanol and 5% Peracetic acid\* in a sterile container for 10 minutes to remove any soft tissue remnants, bacteria and smear layer (defatting and sterilization).~Tooth particles will be demineralized using 2% HNO3‡ for 20 minutes to expose the dentine organic matrix.~The bacteria-free particulate dentin will be washed with phosphate buffered saline‡ twice for 5 minutes to restore the PH balance to 7.4. In the same setting, after atraumatic extraction immediate implant will be inserted with graft"
214491144|NCT06773104|PROCEDURE|immediate implant with allogenic bone graft|after atraumatic extraction immediate implant will be inserted with allogenic bone graft
214491145|NCT06773585|DIAGNOSTIC_TEST|Psychiatric scale assessments, VR-Based Behavioral Assessment, Brain MRI|"This study is a minimal-risk study involving non-invasive, non-pharmacological interventions. Participants will continue receiving their usual medication or counseling treatments as part of their routine care during the study.~When participants come to the hospital for assessments, they will engage in clinical assessments and complete questionnaires over a period of 1-2 hours, undergo MRI scans, and participate in virtual environment-based behavioral assessments. They will have the option to take breaks during the assessments and can withdraw from the study at any time without providing a reason."
214491146|NCT06807710|OTHER|DNS Group|Dynamic neuromuscular stabilization exercises, on the other hand, are designed to achieve sagittal stabilization by utilizing the stabilizing function of the thoracic diaphragm muscle.
214491147|NCT06807710|OTHER|Pilates Group|Reformer pilates exercises, focusing on core stability, flexibility, postural alignment, and breath control using a Reformer Pilates machine under the supervision of a physiotherapist.
214679740|NCT05687760|DRUG|Calcium hydroxide|calcium hydroxide
214365201|NCT05000957|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography investigation to determine cardiac abnormalities (to include the participant in the study).
214365202|NCT05000957|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation, oncocytology (to include the participant in the study).
214365203|NCT05000957|DIAGNOSTIC_TEST|Colposcopy|Colposcopy investigation to determine pre-malignant and malignant lesions of cervix, vagina or vulva (to include the participant in the study).
214365204|NCT05000957|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
214365205|NCT05000957|DIAGNOSTIC_TEST|Doppler ultrasonography|Ultrasound investigation for assessing blood flow in the tissues of vulva region (to evaluate procedure efficiency).
214365206|NCT05000957|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
214365207|NCT05000957|DIAGNOSTIC_TEST|Biopsy of the vaginal wall|Sampling of the vaginal wall material in the posterior fornix area including the mucous membrane and muscle layer will be performed during colporrhaphy or any pelvic surgical procedure for histological, immunohistochemical studies, and optical coherence tomography (elastography) (to evaluate procedure efficiency)
214365208|NCT05000957|DIAGNOSTIC_TEST|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
214365209|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Distress Inventory Questionnaire|Pelvic Floor Distress Inventory Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
214679741|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy"
214679742|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy"
214975584|NCT04881344|PROCEDURE|mucopexy|"* Threw an anoscope, the hemorrhoidal cushion will be sutured using a half-circle (size 26) needle with a 2-0 poliglecaprone (Monocryl®, Ethicon, USA). Then, a continuous suture will be performed on the mucosa of the anal canal, and will terminate above the dentate line. The hemorrhoidal artery will be ligated by this suture. Then, the ligation will be tied to realize the hemorrhoidopexy.~* Same anesthetic technique and postoperative care as the intervention group. As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention)."
214975585|NCT04002791|DEVICE|VasoBand|Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression
214975586|NCT02764502|DEVICE|Pressure Gauge Manometer|Identification of epidural space
214975587|NCT02216383|DRUG|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
214975588|NCT02216383|DRUG|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
214975589|NCT02216383|DRUG|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
214975590|NCT00026091|DRUG|fenretinide|Given orally
214975591|NCT00026091|OTHER|laboratory biomarker analysis|Correlative studies
214975592|NCT00026091|OTHER|pharmacological study|Correlative studies
214365210|NCT05000957|DIAGNOSTIC_TEST|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
214491148|NCT06712940|BEHAVIORAL|Motivational Interviewing and Firearm Safety Training, with Case Management|"The basic principles of MI as applied to violence risk reduction in victims of gun violence are as follows: Express Empathy, Develop Discrepancy, Roll with Resistance, and Support Self-Determination/Self- Efficacy. MI practitioners offer themselves as a consultant while respecting the participant as the real expert in their own life. MI also affirms the patient's ability to make changes and communicates trust in the patient's judgments about readiness and plans for change. Motivational interviewing sessions will occur once a month, for six months with a licensed clinical social worker (LCSW).~The LCSW will additionally provide case management over the course of the six month study, and a one time firearm safety training that covers safe storage methods. At the end of the firearm safety training, the participant will be offered a biometric lock box for free."
214491149|NCT06818786|OTHER|Branded pack with new PHWs covering 50% of the pack without quitline information|Participants received and were required to view six images depicting a branded cigarette pack with a new set of six pictorial health warnings covering 50% of the pack, without quitline information.
214491150|NCT06818786|OTHER|Branded pack with new PHWs covering 85% of the pack without quitline information|Participants received and were required to view six images depicting a branded cigarette pack with a new set of six pictorial health warnings covering 85% of the pack, without quitline information.
214491151|NCT06818786|OTHER|Branded pack with new PHWs covering 85% of the pack with quitline information|Participants received and were required to view six images depicting a branded cigarette pack with a new set of six pictorial health warnings covering 85% of the pack, with quitline information
214491152|NCT06818786|OTHER|Plain pack with new PHWs covering 85% of the pack with quitline information|Participants received and were required to view six images depicting a plain cigarette pack with a new set of six pictorial health warnings covering 85% of the pack, with quitline information
214491153|NCT06818786|OTHER|Branded pack with the current set of PHWs covering 50% of the pack without quitline information|Participants received and were required to view 6 images depicting a branded cigarette pack with a current set of 6 pictorial health warnings covering 50% of cigarette packs without quitline information (It is the current pictorial health warnings implemented in Vietnam)
214491154|NCT06765928|DRUG|selinexor in combination with venetoclax|After allo-HSCT, intermediate-high risk MDS/AML patients are maintenanced with selinexor given in combination with venetoclax for 2 years
214679743|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly"
214679744|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly"
214679745|NCT01483573|OTHER|neural mobilization|stretch the nerve
215084858|NCT05346991|OTHER|Tobacco Free Teachers, Tobacco Free Society program|"The Tobacco Free Teachers, Tobacco Free Society (TFT-TFS) program provides teachers with the knowledge and skills to quit tobacco use, or to help someone else quit; it also helps schools comply with national tobacco control policies. School principals implement four TFT-TFS program components with teachers in their schools during school hours across an academic year (August-April):~* Adopting a school tobacco control policy~* Providing cessation support (e.g. distribution of self-help quit booklets and referrals to government cessation resources)~* Conducting monthly group discussions with teachers about tobacco~* Hanging six thematic posters in the school~With the goal of establishing a tobacco-free school environment, the program incorporates six program themes: 1. Teachers as Role Models; 2. Health Effects of Tobacco; 3. Motivation to Quit-or Help Others to Quit; 4. Skills to Quit; 5. Dealing with Withdrawal; and 6. Maintenance and Celebration."
215084859|NCT04774900|PROCEDURE|Administration of oxygen|Administration of high-flow oxygen via face mask to a high fidelity mannequin.
214365211|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Impact Questionnaire|Pelvic Floor Impact Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
214679746|NCT01483573|OTHER|straight leg raise|stretch the hamstring
214679747|NCT03461692|DRUG|patients under 14 years of age using Reduning injeciton|To assess in patients using Reduning injection's clinical features and drug adverse reaction during patients' hospital stay. The registry procedure will only for patients under 14 years of age using Reduning injection,observed from February 2018 to December 2018.
214365212|NCT05000957|PROCEDURE|Anterior and/or posterior colporrhaphy|Surgical procedure to repair pelvic organ prolapse followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
214365213|NCT05000957|PROCEDURE|Pelvic surgical procedure|Any pelvic surgical procedure which do not affect condition of vagina, vulva and paraurethral region followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
214365214|NCT05000957|OTHER|Physical examination|Pelvic examination (to include the participant in the study and observe throughout the study)
214365215|NCT05000957|OTHER|Сonsultation|Сonsultation of a therapist about the absence of contraindications for surgical treatment (to include the participant in the study)
214365216|NCT05000957|GENETIC|Buccal smear|"Buccal smear to performing genetic testing.~The following markers will be analyzed:~ESR1 rs2234693, ESR1 rs2228480, COL3A1 rs1800255, COL14A1 rs4870723, MMP9 rs3918253, MMP10 rs17435959, LOXL1 rs2304719, WNT4 rs3820282, MMP2 rs243865, TIMP2 rs2277698, CD31 / PECAM1 rs1131012, Ki67 rs11016076."
214365217|NCT01832948|DRUG|Endostar|
214365218|NCT01832948|DRUG|Oxaliplatin|
214365219|NCT01832948|DRUG|Folinic acid|
215084860|NCT04774900|PROCEDURE|Administration of drug in a nebulizer|Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.
215084861|NCT04774900|PROCEDURE|Securing intravenous line|Securing an intravenous line at the forearm of high fidelity mannequin.
215084862|NCT04774900|PROCEDURE|Administration of IV drug|Administration of bronchodilator via IV line to a high fidelity mannequin.
215084863|NCT04774900|PROCEDURE|Needle decompression of tension pneumothorax|Needle decompression of tension pneumothorax on a high fidelity mannequin.
215084864|NCT05420220|BIOLOGICAL|KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)|5 mg/kg Q3W IV
214365220|NCT01832948|DRUG|5-FU|
214365221|NCT02638948|DRUG|BMS-986142|BMS986142 specific dose on specific days
214365222|NCT02638948|DRUG|Placebo|Placebo of BMS-986142 specific dose on specific days
214365223|NCT02638948|DRUG|Methotrexate|Methotrexate specific dose on specific days
214365224|NCT06472466|BEHAVIORAL|Sleep/eating virtual reality self-help exposure-based intervention|"Participants will receive one of two possible interventions:~1. A virtual reality kitchen with foods with different caloric contents. Participants will be invited to explore the environment and interact with the stimuli they feel most comfortable with. Depending on their preference, they will be able to access the virtual kitchen in one of three different conditions: alone, accompanied by a pink elephant (designed to induce positive mood), or accompanied by a reassuring voice that will encourage them to interact with the food and face their fears.~2. A virtual reality bedroom with several objects, some of which will have a neutral valence for people with sleep difficulties, and others that will be related to insomnia, such as a mobile phone, electronic devices and a clock marking 3:00. Participants will be first told to move in the environment and they could not fall asleep. Then, they will receive specific instructions to cope with sleeping difficulties."
214365225|NCT06472466|BEHAVIORAL|Sleep/eating self-help written materials.|Participants allocated to the control condition will be invited to download self-help written materials about eating and sleep difficulties and helpful ways to cope with these.
214365226|NCT00764920|DEVICE|non-invasive imaging modalities for assessment of skin|skin imaging
214491155|NCT06748573|DEVICE|SafeGuard FocusTM compression bandage|"If randomized to the study group, The study device was applied immediately after pocket closure using following steps:~* Preparation: cleaning wound and surrounding area.~* Placement: application of isobetadine gauze and transparent bandage. Study device placement at the level of the pocket.~* Applying compression: inflation of 60ml of air. If oozing persisted 5ml increments were added (maximum of 120ml) until oozing stopped.~The study device was gradually deflated by removal of 20ml of air every 2 hours. When oozing occurred 5ml increments were added until oozing stopped. When all air was deflated the study device was left in deflated mode and changed by conventional bandage at discharge."
214491156|NCT06748573|DEVICE|Conventional bandage|If randomized to the control group, compressive bandage was applied immediately after pocket closure. The bandage was removed after 6 hours and changed by conventional bandage.
214491157|NCT06748859|OTHER|Counterstrain technique|In this group, participants will receive counterstrain technique on the Psoas major muscle and exercise training within two weeks.
214491158|NCT06748859|OTHER|Exercise therapy|participants who will assign to this group will receive exercise therapy within two weeks.
214491159|NCT06749873|OTHER|Background of different SP information|Sp was asked with the following baseline information: 1. 50 years of age and gender; 2. positive urea breath test; 3. asymptomatic; 4. family history of gastric cancer; 5. gastroscopy: atrophic gastritis; 6. untreated; and 7. no history of drug allergies.
214365227|NCT06116916|DRUG|KHK4951|KHK4951 eye drop for 36 weeks until end of the trial
214365228|NCT06116916|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
214491160|NCT06749522|RADIATION|high resolution ultrasonography|to compare high resolution ultrasonography finings with other imaging modalities(CT and MRI)
214491161|NCT06750770|DIAGNOSTIC_TEST|KDIGO CRITERIA|2012 KDIGO DIAGNOSTIC CRITERIA
214491162|NCT06764238|DRUG|Blinatumomab (Group A)|For Group A I/HR-ALL patients after induction remission phase, continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX) will be applied, subsequently followed by interim continuation, late intensification, and maintenance therapy
214975593|NCT04528316|BEHAVIORAL|Pilates Core Stability Exercises program|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~* Stage I: Warm-up: consists of four Pilates motions:~  1. Breathing:~ 2. Rolling back:~ 3. Coccyx-curl:~ 4. Hundred breathing:~* Stage II: Work-out: consists of twelve Pilates motions:~  1. Single leg stretch:~ 2. Straight leg raise:~ 3. Basic bridge:~ 4. Bridging variation:~ 5. Quadruped:~ 6. Clap with seal motion~ 7. Mermaid twist:~ 8. Swimming:~ 9. Double leg stretch:~ 10. Shoulder bridge:~ 11. Swan dive:~ 12. Leg full front:~* Stage III: Cool-down: consists of three Pilates motions:~  1. Rest position:~ 2. Cat with arm/leg extension:~ 3. Breathing:"
215084865|NCT05420220|COMBINATION_PRODUCT|Axitinib|5mg bid po
214365229|NCT05617755|BIOLOGICAL|AB-1015|autologous T cell therapy
214365230|NCT04920864|DEVICE|rTMS|Repetitive transcranial magnetic stimulation
214365231|NCT01527929|DRUG|Cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
214365232|NCT06052384|OTHER|Standard pain management combined with sleep disorder management|Standard pain management combined with sleep disorder management at M6, and M12
214365233|NCT02411565|DRUG|Fermented Wheat Germ Extract (FWGE)|5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
214365234|NCT02411565|DRUG|Placebo|Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
214365235|NCT02411565|OTHER|Standard of Care: Planned Surgery|Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
214365236|NCT02411565|OTHER|Quality of Life (QoL) Surveys: FACT-O|Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
214365237|NCT02963974|DEVICE|Cochlear implant|Implantation
214365238|NCT00810264|DEVICE|CRT Therapy - LV Lead Registry|Collecting long-term safety and efficacy data on a market-released left ventricular lead.
214491163|NCT06764238|DRUG|Venetoclax (nonRand Group)|For I/HR patients non eligible for blinatumomab randomization, venetoclax+ mini-hyperCVD will be applied after PVDL induction, subsequently followed by CAT as intensification, interim continuation, late intensification, and maintenance therapy
214365239|NCT04814836|PROCEDURE|Total-etch mode with 35% phosphoric acid (K-ETCHANT) (TE-A group)|35% phosphoric acid was applied to enamel and dentin for 10 s, washed and dried for 5 s. The universal adhesive, Clearfil Universal Bond Quick (CBQ) was applied to enamel and dentin surfaces with a single-use applicator, then gently air-dried for 5 s without waiting, and light-cured for 10 s.
214365240|NCT04814836|PROCEDURE|Selective-etch mode with 35% phosphoric acid (K-ETCHANT) (SE-A group)|35% phosphoric acid was used only on enamel for 10 s, then washed and dried for 5 seconds. Subsequently, the adhesive was applied in a similar manner to the TE-A group.
214365241|NCT04814836|PROCEDURE|Total-etch mode with Er, Cr: YSGG laser (Waterlase MD) (TE-L group)|the enamel margin and dentin surfaces of lesions were irradiated with an Er,Cr:YSGG laser (2780 nm, Waterlase MD, BioLase Technology, Inc., San Clemente, CA). Then the adhesive was applied in a similar manner to the TE-A group.
214365242|NCT04814836|PROCEDURE|Selective-etch mode with Er, Cr: YSGG laser (Waterlase MD) (SE-L group).|The laser system was applied in the same way as described in the TE-L group only on enamel surface. Subsequently, the adhesive was applied in the same way as described in the TE-A group.
214365243|NCT04814836|PROCEDURE|Self-etch mode Clearfil Universal Bond Quick (Kuraray, Japan) (SE group)|Universal adhesive system (CBQ) was applied to enamel and dentin surfaces without any previous etching. Then gently air-dried for 5 s without waiting, and light-cured for 10 s.
214365244|NCT00222833|DRUG|Aripiprazole|
214365245|NCT04197843|DEVICE|NaviCam (ANKON)|The NaviCam (ANKON) is a miniaturised wireless endoscope in a single use capsule. It can be remotely controlled with the patient in a magnetic console. The operator to the magnetic-driven NaviCam sits in a computer workstation and manipulates the capsule suspended in a waterfilled stomach. After careful examination of the stomach, the capsule is then allowed to passed through the pylorus into duodenum and small bowel. The patient wears harness with small bowel imaging capabilities.
214365246|NCT01830127|DRUG|Ribavirin|24 Weeks
214365247|NCT01830127|DRUG|BI 207127 high dose|24 Weeks
214975594|NCT04528316|BEHAVIORAL|Balance Program|Total Period: 12 Weeks. The designed HUMAC program will work on the modified clinical test of sensory integration of balance (mCTSIB) with eyes open and with eyes closed, the center of pressure (COP) and the limit of stability test (LOS).
214975595|NCT04528316|BEHAVIORAL|Coordination|"Total Period: 12 Weeks. Coordination will be assessed using BOT2, Bilateral coordination (Sub test No.4) composed of 7 items and Upper-Limb coordination (Sub test No.7) composed of 7 items too.~The raw scores are recorded first then it is converted into point scores, then subtest total point score is obtained by adding point scores."
214975596|NCT02828488|OTHER|No intervention|It is a descriptive study. No intervention
214975597|NCT04852250|OTHER|Virtual centralized multidisciplinary tumour board|Evaluation of radiologic imaging and general condition by a multidisciplinary expert gremium to recommend either secondary intervention or resection of metastases or continuation of systemic treatment
214975598|NCT04770506|OTHER|Data extraction from medical files|Data extraction from medical files
214975599|NCT05098873|OTHER|psychodynamic|intervention with adolescents through the presentation of questions to be completed
214975600|NCT00160108|BEHAVIORAL|dietary intervention|
214975601|NCT04805138|OTHER|Spectrophotometer|To objectively measure the discoloration of the peri-implant mucosa, spectrophotometric measurements of the buccal mucosa will be performed at study implant and at control tooth.
214975602|NCT02756702|DEVICE|All-Poly|Implantation of the VEGA PS using all-polyethylene tibia components
214975603|NCT01619865|DRUG|68Ga-DOTATOC PET/CT|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
214975604|NCT01494818|DEVICE|Hydrogen peroxide-based contact lens care system|
214975605|NCT01494818|DEVICE|PHMB-containing contact lens solution|
214975606|NCT01494818|DEVICE|Soft contact lenses|Contact lenses identical to habitual prescription worn per usual replacement regimen
214975607|NCT04737850|DRUG|Hetrombopag|Thrombopoietin receptor agonist
214975608|NCT04737850|DRUG|Placebo|Placebo with no active pharmaceutical ingredient
214975609|NCT04843982|DRUG|Esketamine hydrochloride|After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
214975610|NCT06335771|OTHER|Dietary consultation weight loss intervention|Participants will meet with a member of the study team biweekly for about 6 months.
214975611|NCT04790578|DEVICE|ZoeInsights Application|ZI is designed to promote PA behavior change and maintenance via self-monitoring of PA, symptoms, and other health data. Additional information for using ZI will be provided via a PDF-based user guide on installing and using the application, a live instructional webinar hosted by ZI developer Hanalytics Solutions, and access to continued support via email/telephone communication with study staff as well as Hanalytics Solutions. Reminders to complete self-monitoring tasks will be provided using daily push notifications scheduled according to participant preferences. Automatic graphs will be generated and displayed within the app to allow participants to visualize trends in physical activity, symptoms, and other health data. ZI can be accessed via a web browser on any device that is connected to the internet (e.g. computer, laptop, tablet, smartphone), or via a native android or iOS mobile application on a smartphone or tablet.
214975612|NCT04790578|BEHAVIORAL|EXCEL Exercise Class|The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
214975613|NCT00294814|DEVICE|Proximal anastomosis using Heartstring anastomotic device|
214975614|NCT00205114|BEHAVIORAL|Individualized multifactorial intervention for community-living high-risk older adults|
214975615|NCT00205114|BEHAVIORAL|Health professional education program about fall prevention|
214975616|NCT02898233|OTHER|Deprexis|Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
214975617|NCT02898233|DEVICE|Active low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Active LLLT includes 4 days, once per week for 4 weeks, during which LLLT is applied to two alternating positions on the participant's right forehead for 8 minutes total.
214975618|NCT02898233|DEVICE|Sham low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Sham LLLT includes 4 days, once per week for 4 weeks, during which sham LLLT (5 seconds active, 55 seconds sham) is applied to two alternating positions on the participant's right forehead for 8 minutes total.
214975619|NCT00791999|DRUG|CDP870 400mg|400mg CDP870 given every 2 weeks until Week22 (SC)
214975620|NCT00791999|DRUG|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
214975621|NCT00791999|DRUG|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
214365248|NCT01830127|DRUG|Faldaprevir|24 Weeks
214365249|NCT01830127|DRUG|Ribavirin|24 Weeks
214365250|NCT01830127|DRUG|BI 207127 low dose|24 Weeks
214365251|NCT01830127|DRUG|Faldaprevir|24 Weeks
214365252|NCT02569580|DEVICE|Topically|"use the No More medical device as anti lice treatment"
214365253|NCT06030674|OTHER|Secondhand cannabis emissions/smoke exposure|This is an environmental exposure performed in public places where people are consuming cannabis.
214365254|NCT00778479|DEVICE|Sepraspray|Max. 10g of Sepraspray
214365255|NCT02899494|OTHER|Antenatal classes|
214365256|NCT02899494|OTHER|Physical and psychic preparation|
214365257|NCT02131779|BEHAVIORAL|Men's Workshops|Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
214365258|NCT02131779|BEHAVIORAL|Co-Educational Workshops|One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
214365259|NCT04216030|OTHER|High Fe IP meal labelled with Fe-58|500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
214365260|NCT04216030|OTHER|Control OFSP meal labelled with Fe-57|500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
214365261|NCT06213701|DEVICE|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
214365262|NCT06213701|OTHER|Psychoeducation app|Psychoeducation app
214365263|NCT00567190|DRUG|Pertuzumab|Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
214365264|NCT00567190|DRUG|Placebo|Placebo (matching pertuzumab) was administered intravenously.
214365265|NCT00567190|DRUG|Trastuzumab|Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
214365266|NCT00567190|DRUG|Docetaxel|Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
214365267|NCT06388499|OTHER|TECC (Telerehabilitation and Exercise for Chronic Conditions)|"Exercise: Synchronous group exercise sessions will be delivered weekly via videoconferencing by a physiotherapist. Recordings of exercise sessions will be made available. Participants will be advised to perform additional exercise sessions at their own convenience to supplement the synchronous exercise sessions and facilitate adherence to physical activity guidelines.~Education: A synchronous educational webinar will be delivered each week. These will be delivered by relevant healthcare professionals and explore various aspects of self-management of health and well-being. Recordings of the webinars will be made available to participants.~Social component: At the end of each weekly synchronous group exercise session, participants will have the opportunity to engage in a 10-15-minute synchronous online social interaction with other participants in their exercise group via videoconferencing."
214365268|NCT06576726|OTHER|This study involves no intervention.|This study involves no intervention.
214365269|NCT03266783|DRUG|Apixaban|Refer to Apixaban group
214365270|NCT03266783|DRUG|Rivaroxaban|Refer to Rivaroxaban group
214365271|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend powder in hydrophobic matrix|5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
214365272|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend in pre hydrated form|0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
214365273|NCT01657058|DIETARY_SUPPLEMENT|No soluble viscous fibre blend|0g soluble viscous fibre blend margarine + white bread + jello
214365274|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend premixed with ½ carbohydrate gel|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
214975622|NCT00791999|DRUG|Placebo of CDP870|given every 2 weeks until Week22 (SC)
214975623|NCT00430846|DRUG|SGN-35|Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
214975624|NCT04694001|DEVICE|Use of the Atalante exoskeleton|A session includes stand-up, walks, exercises with or without the assistance of the exoskeleton, rotation, side and back step, squat and sitting.
214975625|NCT01876108|DRUG|H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
214975626|NCT02993848|OTHER|No intervention|
214975627|NCT05450913|DRUG|Priformis intramuscular injection with %2 lidocain|Priformis intramuscular injection will be administered with 5 cc 2% lidocaine, accompanied by a nerve stimulator under ultrasound guidance
214975628|NCT01077323|DRUG|exenatide|subcutaneous injection, dosing according to normal clinical practice
214975629|NCT01077323|DRUG|Other antidiabetic therapies|Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
214975630|NCT01077323|OTHER|No diabetes therapy|Subjects not diagnosed with diabetes
214975631|NCT05628701|PROCEDURE|Ileorectal anastomosis (IRA)|After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))
214975632|NCT05628701|PROCEDURE|Ileal pouch anal anastomosis (IPAA)|The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).
214975633|NCT05628701|PROCEDURE|ileostomy|no reconstruction is performed and the patient is left with his/her ileostomy
214975634|NCT01654770|DEVICE|video capsule endoscopy|
214975635|NCT01654770|DEVICE|double balloon enteroscopy|
214975636|NCT00120237|DRUG|Misoprostol|600 mcg oral misoprostol administered during third stage of labor
214975637|NCT06404892|PROCEDURE|Single-lung ventilation|Patients undergoing thoracic surgery and intraoperative single-lung ventilation.
214365275|NCT01657058|DIETARY_SUPPLEMENT|No soluble viscous fibre blend, ½ carbohydrate jello|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
214365276|NCT02226913|DRUG|2% lidocaine with 1:80,000 epinephrine|2% lidocaine with 1:80,000 epinephrine
214365277|NCT02226913|DRUG|sodium bicarbonate|8.4% sodium bicarbonate
214365278|NCT02226913|DRUG|placebo|sterile distilled water (Samen Pharmaceutical Co, Iran)
214365279|NCT01037348|DRUG|ranibizumab 0.5mg|
214365280|NCT02495025|BEHAVIORAL|Telephone-based developmental screening and care coordination|
214365281|NCT02170740|DRUG|BIBR 1048 MS - low dose|
214365282|NCT02170740|DRUG|BIBR 1048 MS - high dose|
214365283|NCT02170740|DRUG|BIBR 1048 MS + Pantoprazole|
214365284|NCT04753372|DRUG|Rivaroxaban 2.5 MG [Xarelto]|rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD
214365285|NCT05917795|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope (GIF-H190/GIF-HQ190; Olympus Medical Systems Corp., Tokyo, Japan) will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch. The final effect of ESG is the creation of a gastric tubule thus reducing the volume of the stomach. After the procedure, the final shape will be evaluated, to examine any gaps that would require additional closure, and to exclude bleedings and/or other complications.
214365286|NCT03341793|DIAGNOSTIC_TEST|Muscle biopsy and blood test|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
214491164|NCT06764238|DRUG|Blinatumomab (Group B)|For Group B I/HR-ALL patients after induction remission phase: a two 14-day cycles of blinatumomab, alternating with three cycles of HDMTX will be applied, subsequently followed interim continuation, late intensification, and maintenance therapy
214491165|NCT07039175|BEHAVIORAL|MINDSET|A behavior-change model informed mailed informational packet with tailored health information regarding the impacts of smoking/drinking on chronic disease and the benefits of stopping, followed by a brief motivational telephone booster call from a behavioral health provider.
214491166|NCT07039175|OTHER|Usual Care|All Veterans involved in this study will have a standard primary care (PC) appointment, which may include conversations/interventions related to drinking and smoking. This appointment is not controlled by the study team and we cannot comment on the extent to which smoking/drinking will or will not be discussed in the primary care appointment but we imagine this can range from no discussion/intervention at all to extensive conversations with the provision of medications, brief advice, etc.
214491167|NCT06772974|DRUG|Doxylamine Succinate USP|Tab. Doxylamine Succinate
214975638|NCT00509717|OTHER|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
214975639|NCT00509717|OTHER|control|educational manual
214975640|NCT04873089|OTHER|Cosmetic product|"It is a comparative study with two parallel groups of subjects:~* Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face~* Comparative group: no application of study product or reference product"
214975641|NCT03906812|OTHER|Telemetry|Bed type assignment
214975642|NCT03906812|OTHER|Unmonitored|Bed type assignment
214975643|NCT03898622|DRUG|Levothyroxine|levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels \> 1 and normal T4L
214975644|NCT06515548|DRUG|Vitamin D3 mouth wash|topical vitamin D oral mouth wash as every 10ml of the solution contains 3000 IU
214975645|NCT01768663|DRUG|Lumacaftor|tablet, 200mg taken every 12 hours
214975646|NCT01768663|DRUG|Ivacaftor|tablet, 250mg taken every 12 hours
214975647|NCT01768663|DRUG|Ciprofloxacin|750 mg taken every 12 hours
214975648|NCT01768663|DRUG|Itraconazole|200mg taken once daily
214975649|NCT01768663|DRUG|Rifampin|600mg taken once daily
214975650|NCT01811537|DEVICE|Artificial Chordae|
214975651|NCT01710020|DRUG|CP-690,550|CP-690,550 10 mg oral powder for constitution
214975652|NCT00427908|BIOLOGICAL|GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)|One intramuscular dose.
214975653|NCT00427908|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose.
214975654|NCT00427908|BIOLOGICAL|Meningitec™|One intramuscular dose.
214365287|NCT00313820|DRUG|Pregabalin|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
214365288|NCT00313820|DRUG|Placebo|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
214365289|NCT03248258|OTHER|Qualitative Interview or Focus group discussions|"The purpose of this study is to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care.~Secondly, to further understand patient perspective on the concept of de-escalation, in which patients reduce the amount of chemotherapy to avoid side effects and (2) consider how prognosis would impact their decision-making about reducing chemotherapy (as standard or care or within a clinical trial)."
214365290|NCT04072094|PROCEDURE|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
214365291|NCT04072094|PROCEDURE|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
214365292|NCT01625351|DRUG|alemtuzumab|Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
214491168|NCT06772974|DIETARY_SUPPLEMENT|Ginger|Ginger (zingiber officinale)
214365293|NCT01625351|DRUG|fludarabine|Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
214975655|NCT06328972|BEHAVIORAL|systemic therapy|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time. Direct feeding training: with powdered milk, once a day, 5 days a week.
214975656|NCT06328972|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
214365294|NCT01625351|DRUG|sirolimus|"Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy."
214365295|NCT01625351|DRUG|Busulfan|Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
214365296|NCT01625351|DRUG|melphalan|Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
214365297|NCT01625351|BIOLOGICAL|stem cells|Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
214491169|NCT06777849|BEHAVIORAL|Right to Play-Plus (RTP-Plus)|"The comprehensive curriculum comprises of themes: Social and Emotional Development and Sexual and Reproductive Health will be delivered by school teachers who will receive training from Right to Play and Aahung. There will be 60 sessions for two years."
214491170|NCT06777849|OTHER|Control|There will be no intervention given to control arm during two years of cluster randomised control trial (cRCT). However, a delayed intervention having teachers' training, will be provided to the control arm after the completion of endline for the duration of 3-4 months.
214491171|NCT06779006|BEHAVIORAL|Self-help acceptance and commitment therapy with behavioral activation|Internet-based self-help acceptance and commitment therapy with behavioral activation
214491172|NCT06775392|DRUG|bromelain-quercetin gel|bromelain-quercetin gel is prepared from capsules in laboratory
214491173|NCT06775392|DRUG|chlorhexidine gel|chlorhexidine gel is prepared in laboratory
214491174|NCT06775392|PROCEDURE|SRP|Scaling and root planing was done with ultra sonic and hand scaling
214491175|NCT06769815|OTHER|Blood sample|For febrile children at the time of inclusion : 6.25 ml to 8.25 ml of blood ; For non febrile children at the time of inclusion : 4 ml of blood ; For pregnant women at the time of inclusion : 5 ml of peripheral blood, 5 ml of placental blood, 20 to 40 ml of umbilical cord blood ; For new borns : drop of blood on child's heel each month and 5 ml of blood the 12th and last month.
215084866|NCT05694910|OTHER|Reiki|Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
215084867|NCT01975337|DRUG|Alisporivir|Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
215084868|NCT04080479|DIAGNOSTIC_TEST|Quadriceps Muscle Layer Fitness|The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
215084869|NCT04080479|DIAGNOSTIC_TEST|Muscle Strength|All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
215084870|NCT04080479|DIAGNOSTIC_TEST|Acute Physiology and Chronic Health Evaluation|All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
214365298|NCT01625351|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
214365299|NCT00211705|BEHAVIORAL|Diet|
214365300|NCT00211705|DRUG|Diet+pravastatin|
214365301|NCT01831622|DRUG|Ritalin|On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
214365302|NCT01831622|DRUG|Placebo|On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
214365303|NCT00860379|DRUG|Selenium1|2 ug/kg
214365304|NCT00860379|DRUG|Selenium2|4 ug/kg
214365305|NCT00860379|DRUG|Placebo|IV saline as placebo
214365306|NCT01515748|DRUG|Docetaxel (XRP6976)|Pharmaceutical form:solution for infusion Route of administration: intravenous
214365307|NCT01515748|DRUG|Oxaliplatin (SR96669)|Pharmaceutical form:solution for infusion Route of administration: intravenous
214365308|NCT01515748|DRUG|S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)|Pharmaceutical form:Tablet Route of administration: Oral
214365309|NCT03345498|DRUG|Entecavir|Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
214975657|NCT06328972|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
214975658|NCT02984982|DRUG|Alirocumab SAR236553|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214975659|NCT02984982|DRUG|Atorvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
214975660|NCT02984982|DRUG|Rosuvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
214975661|NCT02984982|DRUG|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
214975662|NCT02984982|DRUG|Bezafibrate|"Pharmaceutical form: tablet~Route of administration: oral"
214975663|NCT02984982|DRUG|Ezetimibe|"Pharmaceutical form: tablet~Route of administration: oral"
214975664|NCT02984982|DRUG|Antiplatelets|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
214975665|NCT02984982|DRUG|Anticoagulants|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
214975666|NCT02153918|BIOLOGICAL|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
214975667|NCT02153918|BIOLOGICAL|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
214975668|NCT05344846|OTHER|Guided imagery|The individuals in this group will be provided with guided imagery application. Guided imagery will be applied to the participants in the hospital environment 6-10 hours after the cesarean section. Afterwards, guided imagery application will be requested every day for two weeks.
214975669|NCT03970525|DEVICE|Venturi pump|The venturi pump makes use of the venturi effect to create a vacuum. The venturi effect creates a vacuum by the flow of a fluid, typically air, over an opening. In many phacoemulsification machines, this requires nitrogen tanks or a self-contained air compressor. The vacuum level is created within a rigid drainage cassette, to which the phaco aspiration tubing is connected. Since there is no milking of the aspiration line, the phaco tubing can be made rigid with low compliance.
214975670|NCT03970525|DEVICE|Peristaltic vacuum pump|"The peristaltic pump uses rollers to compress the phacoemulsification outflow tubing in a peristaltic manner, thereby creating flow and vacuum. The compression of the rollers on the tubing with the rotation of the pump physically moves fluid and creates a continuous milking action on the fluid column, The phaco machine can directly control this flow level, hence the term flow based, however, the preset vacuum level is only achieved once there is occlusion of the outflow line, typically at the phaco needle tip with cataract material."
214975671|NCT02162160|DEVICE|probiotic creme|Probiotic creme applied
214975672|NCT02162160|DRUG|Placebo|Creme without probiotics applied in same manner
214975673|NCT00447668|BEHAVIORAL|Yoga|Yoga for back pain
214975674|NCT00447668|BEHAVIORAL|Exercise|exercises for back pain
214975675|NCT00447668|BEHAVIORAL|Self-care book recommendations|Self-care book for back pain
214975676|NCT03832283|DIAGNOSTIC_TEST|CAD-MDD/CAT-DI screening via MyChart|Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).
215084871|NCT04080479|DIAGNOSTIC_TEST|Sequential Organ Failure Assessment|All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
215084872|NCT04080479|DIAGNOSTIC_TEST|Nutritional Risk Screening|All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
214491176|NCT06769815|OTHER|Urine sample|For febrile children : 10 ml of urine
214491177|NCT06769815|OTHER|oropharyngeal sample|For febrile children : oropharyngeal swab sampling
214491178|NCT06769815|OTHER|Optionnal : stool sample|For febrile children (only as part of the care of the child) : 5g stool
214491179|NCT06769815|OTHER|Optionnal : cerebrospinal fluid|For febrile children (only as part of the care of the child in case of suspected meningitis) : 4 additional drops of cerebrospinal fluid
214491180|NCT06769815|OTHER|placental biopsy|For pregnant women : placental biopsy the size of 2 rice grains
214491181|NCT06757725|DIAGNOSTIC_TEST|colour doppler of the renal artery and measurement of resistive index|using colour doppler to asses vascular resistance and resistive index
214975677|NCT03832283|DIAGNOSTIC_TEST|CAD-MDD/CAT-DI screening during clinic visit|During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).
214975678|NCT03832283|OTHER|CAT-DI monitoring via MyChart|Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (\<50) will indicate that a patient's MDD is in remission.
214365310|NCT03917667|DIAGNOSTIC_TEST|EWGSOP2|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia, considered as a dichotomous variable -yes/no- in presence of low grip strength + low muscle mass + low gait speed.
214975679|NCT03832283|OTHER|PHQ-9 monitoring during clinic visits|During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score \< 5 will indicate that a patient's MDD is in remission.
214975680|NCT02616783|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
214975681|NCT02616783|DRUG|TDF|300 mg tablet administered orally once daily
214365311|NCT04873570|DRUG|Moxifloxacin 400mg|Moxifloxacin 400mg IR tablet
214365312|NCT03535935|DRUG|Astragalus Powder|"3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.~Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week."
214365313|NCT03535935|OTHER|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
214365314|NCT05185531|COMBINATION_PRODUCT|PD-1 plus stereotactic body radiotherapy|neoadjuvant PD-1(Tislelizumab) plus stereotactic body radiotherapy (8 Gy × 3 fractions) in resectable HCC
214365315|NCT00460187|DEVICE|Percutaneous intervention of the carotid artery|
214365316|NCT06289075|OTHER|Intensive Care Unit (ICU) treatment|ICU treatment
214365317|NCT00014638|DRUG|letrozole|
214365318|NCT03001284|OTHER|NO intervention|
214365319|NCT05917639|DEVICE|Vitruvian plot|Visual (magnitude, uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
214365320|NCT05917639|DEVICE|Kilim plot|Visual (uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
214365321|NCT05917639|DEVICE|Summary of findings table|Written (magnitude, uncertainty) communication tool / interventional decision-making aid tool
214365322|NCT02571517|DRUG|Glucocorticoids|Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
214365323|NCT02571517|OTHER|Placebo|Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
214365324|NCT01811082|DRUG|Coenzyme A|Coenzyme A 400mg per day.
214365325|NCT01811082|DRUG|Pantethine|Pantethine 600mg per day.
214365326|NCT03610087|BEHAVIORAL|Low Intensity Intervention|Participants will have access via the online platform to the NAVIGATE self-help modules for physical activity, nutrition and quitting smoking with a list of community resources. Subjects will be sent a standard reminder emails once per week to complete their modules and connect with their main provider for any assistance.
214365327|NCT03610087|BEHAVIORAL|High Intensity Intervention|Participants will receive individualized treatment planning, in collaboration with a Care Coordinator, and the Virtual Care Team (VCT). Interactive modules on physical activity, nutrition and quitting smoking will be provided via the online platform. the virtual team will be engaged to provide treatment and/or recommendations regarding the following: increasing physical activity, improving nutrition and diet, smoking cessation (psychosocial support plus medications), and medication adherence. Participants in this arm will have weekly check-ins with their assigned Care Coordinator where they will be able to discuss VCT recommendations, and progress on their goals.
214365328|NCT04979975|OTHER|Placebo|PBO- placebo matching to UB-621
214365329|NCT04979975|BIOLOGICAL|UB-621 low-dose|fully human anti-HSV mAb
214365330|NCT04979975|BIOLOGICAL|UB-621 high-dose|fully human anti-HSV mAb
214365331|NCT00059358|DRUG|Ribavirin plus interferon alfa-2b|Oral tablets taken daily
214365332|NCT00059358|DRUG|Ribavirin|Oral tablet taken daily
214365333|NCT00059358|DRUG|Peginterferon alfa-2b|Subcutaneous injection
214365334|NCT01485042|DRUG|Pazopanib and TH-302|Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
214365335|NCT00990080|BIOLOGICAL|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
214365336|NCT03407794|OTHER|Fermented vegetable|The intervention is to consume 1/2 cup fermented vegetables every day for 6 weeks
214365337|NCT03407794|OTHER|Non-fermented vegetable|The intervention is to consume 1/2 cup of non-fermented vegetables every day for 6 weeks
214365338|NCT03406728|OTHER|PDSAFEX|PDSAFEX is a week by week, progressive, exercise protocol that is followed. It lasts 12 weeks.
214365339|NCT03406728|OTHER|CONTROL|Participants will be asked to maintain their day to day life as consistently as possible for the 12 week duration of the study.
214365340|NCT03406728|DEVICE|VIRTUAL REALITY|WorldViz Oculus Rift Move package (headset and software).
215084873|NCT04080479|DIAGNOSTIC_TEST|Energy and Protein Intake|The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
215084874|NCT03294135|BIOLOGICAL|Encepur Adults|One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
215084875|NCT00186537|DRUG|Rosiglitazone|
215084876|NCT00186537|DRUG|Fenofibrate|
215084877|NCT00186537|BEHAVIORAL|Weight Loss|
215084878|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair with TAP block|Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
215084879|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair without TAP block|No block administered during Laparoscopic ventral hernia surgery
214365341|NCT00790283|DEVICE|PTCA with stent implantation|"Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure."
214365342|NCT03213275|OTHER|Microbiome Sequencing, Neurophysiologic Assessment, Immunological test|Stool sampling, aEEG, VEP, NIRS, ydTCR, Treg, biomarker
215084880|NCT01420874|DRUG|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
214365343|NCT05437081|BEHAVIORAL|Latino Emerging Adults (LEA)|The LEA program involves two components, one for emerging adults (aged 18-23 years old) focused on identity development linked to cultural and familial strengths, and a parent component focused on support for emerging adult children. Each session is 4 sessions.
214365344|NCT04848428|BEHAVIORAL|Online mindfulness-based cognitive therapy|The first session will first focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies for the moderate-high risk profile patients. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
214365345|NCT04848428|BEHAVIORAL|Online standardized education|One 15-minute educational session on postoperative pain, the relationship between pain, thoughts and emotions and brief overview of strategies.
214365346|NCT04560491|DIAGNOSTIC_TEST|Intraoperative examination of sentinel node|Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.
214365347|NCT00553930|DRUG|Pegylated interferon alfa-2a and Ribavirin|All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
214365348|NCT00553930|DRUG|Pegylated interferon alfa 2a and Ribavirin|Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA\_HCV. Treatment will be discontinued for patients who did not achieve a decrease of \>= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
214365349|NCT04697277|DRUG|Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section|
214491182|NCT03834740|DRUG|Ribociclib|Ribociclib administered orally in 5 daily doses prior to resection
214491183|NCT03834740|DRUG|Everolimus|Everolimus administered orally in 5 daily doses prior to resection
214491184|NCT06781060|DEVICE|Faradic Nerve Stimulation Therapy+Standard Physiotherapy|This is electrical nerve stimulation with faradic type current to the injured nerve for conservative treatment of post injection sciatic nerve injury.
214491185|NCT06781060|DEVICE|Physiotherapy Standard Treatment with TENS machine therapy|The control group in which Standard Physiotherapy + TENS therapy will be provided to the participants.
214491186|NCT03556592|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
214491187|NCT03556592|DRUG|Caffeine|1x 100 mg tablet
214491188|NCT03556592|DRUG|Warfarin|2x 5 mg tablets
214491189|NCT03556592|DRUG|Omeprazole|1x 20 mg capsule
214491190|NCT03556592|DRUG|Metoprolol|1x 100 mg tablet
214491191|NCT03556592|DRUG|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
214491192|NCT06744023|OTHER|To examine the effect of the improved environment according to Watsons Human Care Theory on sleep quality, anxiety, and depression in patients undergoing open heart surgery.|"The patients who underwent open heart surgery and who were in the experimental group were admitted to the ward from the postoperative intensive care unit and the environment was improved for three days based on the improved environment of Watson's HCT, and on the morning of the fourth day in the clinic, the patients were interviewed face to face and the Personal Information Form, RSCQ and HAD Scale were completed. The following improvements were implemented within the scope of environmental improvement:~* Considering the seasonal conditions, the patient room was ensured to have appropriate temperature (18-26 °C) and humidity values (30-60%), and the temperature and humidity were gradually reduced and maintained in the appropriate range by monitoring at 21:00, 22:00, and 23:00 (Days 1, 2, and 3)~* In line with the environmental arrangements, the brightness of the light in the patient room was gradually reduced at 21:00, 22:00, and 23:00 using the Light Meter LM-3000 (Days 1, 2, and 3)"
214491193|NCT06846931|OTHER|Extracorporeal Shock Wave Therapy|By the same physiotherapist with more than 5 years of clinical experience, radial ESWT treatment with 2500 pulses, 10 Hz frequency, 2.5-3 bar pressure, is applied to the most painful point of the heel and surrounding soft tissues, plantar aponeurosis and Achilles tendon insertion area on the dorsum of the heel, once a week for a total of 3 sessions.
214365350|NCT05941130|DRUG|Combination of corticosteroid (methylprednisolone - Medrol, 16mg Pfizer Laboratories) therapy and non-steroidal anti-inflammatory (Ibuprofen 600mg Mylan) therapy|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative steroid anti-inflammatory"
214365351|NCT05941130|DRUG|Non-steroidal anti-inflammatory therapy (Ibuprofen 600mg Mylan)|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative non-steroid anti-inflammatory"
214365352|NCT04503525|OTHER|Nutritional assessment|Nutritional assessment in COVID patients
214365353|NCT01534026|DRUG|Aspirin|Current dose
214491194|NCT06846931|OTHER|Low Intensity Laser|A total of 28j (5.6jx5 points) are applied to the plantar fascia at 5 points on the heel by the same physiotherapist for 3 weeks, a total of 9 sessions (every other day) with the patient lying face down.
214491195|NCT06846931|OTHER|EXERCİSE|Exercise therapy is carried out by the patient for 3 weeks. Plantar fascia stretching exercises (exercises to stretch the membrane on the sole of the foot), gastrocsoleus stretching exercises (exercises to stretch the calf muscles), foot intrinsic muscle strengthening exercises (exercises to strengthen the muscles on the sole of the foot) are taught to the patients by the doctor and they are asked to perform them 2 times a day 10 times for a total of 3 weeks.
214975682|NCT02616783|DRUG|FTC|200 mg capsule administered orally once daily
214975683|NCT02616783|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
214975684|NCT02616783|DRUG|3TC|Tablet administered orally
214975685|NCT02616783|DRUG|Third agent|"Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG"
214975686|NCT00203801|DRUG|Sulfadoxine-pyrimethamine|
214975687|NCT00203801|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
214975688|NCT00203801|DRUG|Artemether-lumefantrine|
214975689|NCT01367015|OTHER|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
214975690|NCT01367015|OTHER|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
214975691|NCT04344301|OTHER|Audio recording|The investigators will audio record the visits of patients in the intervention group. An RA will enter the exam room and begin the recording with the patient's permission. The patient and clinician can choose to stop or start the recording at any time. Once the visit is complete, the RA will enter the room, turn off the recording, and bring the patient to a private room where the RA will follow standardized instructions demonstrating how to access recordings. Patient access to recordings will be possible via a secure web-based platform. Patients will also receive reminders to listen to their recordings.
214975692|NCT00955799|DRUG|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
214975693|NCT00955799|DRUG|Placebo|Double-blind treatment period of 29 weeks placebo
214975694|NCT03973580|BEHAVIORAL|Attentional Bias Modification (ABM) task|Participants will be presented with a fixation cross (500ms) followed by a pair of identity-matched, angry-neutral faces (1000ms). The pair presentation is replaced by a single arrow-probe (1000ms) in the position of the neural face. Inter-trial intervals (ITI) are 500ms. Participants indicate arrow direction (left or right) by pressing one of two buttons as quickly as possible. By responding to the probe that always replaces the neutral face, participants learn to attend to the non-threat cues and away from threat cues. There are 120 trials of angry-neutral faces in total, and 40 other catch trials with neutral-neutral faces.
214975695|NCT03973580|BEHAVIORAL|Control task|The control task is identical with the ABM task, except that in the 120 angry-neutral trials, the arrow-probe replaces the angry face and the neutral face with equal probabilities (60 trials each).
214975696|NCT01747499|DRUG|Azacitidine|
214365354|NCT01534026|OTHER|withdrawal of aspirin|Stopping current dose of aspirin
214365355|NCT01529125|DRUG|zidovudine, lamivudine, nevirapine|
214975697|NCT00571623|OTHER|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
214975698|NCT04036487|DRUG|Desflurane|Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.
214975699|NCT04036487|DRUG|Propofol|Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
214975700|NCT03111524|OTHER|Classroom Communication Resource|The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion
214975701|NCT03111524|OTHER|No intervention|No intervention is administered in this group as these are control groups
214365356|NCT02075879|BEHAVIORAL|Nurse-led interviewing|Participants in experimental arm received regular face-to-face interviews during dialysis sessions conducted by the designated case managers every week for 6 weeks and biweekly for another 6 weeks.
214491196|NCT05651594|PROCEDURE|Biopsy|Undergo tissue collection
214491197|NCT05651594|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214491198|NCT05651594|PROCEDURE|Computed Tomography|Undergo CT scans
214491199|NCT05651594|DRUG|Fluorouracil|Given IV
214491200|NCT05651594|DRUG|Leucovorin|Given IV
214975702|NCT00165126|PROCEDURE|Radiation therapy|Given as standard therapy
214365357|NCT02075879|OTHER|Brief group exercise|Participants in this arm only participated in the brief in-center exercise training. They received usual care from the nurse without the interviews and mutual goals developed.
214365358|NCT04558255|DIAGNOSTIC_TEST|A machine-learning method which can robustly discriminate early-stage lung cancer patients from controls|In our study, we intend to integrate molecular features obtained through liquid biopsy and clinical data of lung cancer patients, and develop and prospectively validate a machine-learning method which can robustly discriminate early-stage lung cancer patients from controls.
214365359|NCT02317926|DRUG|Levothyroxine|
214365360|NCT02317926|DRUG|Levothyroxine Plus Liothyronine|
214365361|NCT02317926|DRUG|Desiccated Thyroid Extract|
214365362|NCT04102579|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
214365363|NCT04102579|DRUG|Placebo|non-active dosage form
214365364|NCT05189951|OTHER|circular motion|The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.
214365365|NCT05189951|OTHER|vertical motion|The phlebotomy site was wiped vertically from top to bottom with a single maneuver.
214365366|NCT05189951|OTHER|circular+vertical motion|The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside.
214365367|NCT01269879|DEVICE|Flexi-Bar vibration device only|daily vibration training 10min twice
214365368|NCT01269879|DEVICE|Flexi-Bar + XCO-Trainer|"XCO-Trainer is a way to overload the cardiovascular system and the core muscles during running. An oscillating mass inside the XCO-Trainer is activated when the XCO is propelled forward and backward with force. The movement of the mass triggers a series of responses from the runners' body.~In addition Flexi-Bar vibration training as in the referred active comparator group"
214365369|NCT05288426|OTHER|No intervention|This is an observational study, with no intervention.
214365370|NCT05350943|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
214365371|NCT05350943|DRUG|Gemcitabine|1000 mg/m\^2 in 100ml saline solution IV, d1, Q3W
214365372|NCT05350943|DRUG|Oxaliplatin|85 mg/m\^2 in 500ml 5% glucose solution over 2 hours IV, d1, Q3W
214365373|NCT05350943|DRUG|Toripalimab|3mg/kg (body weight \< 60kg) or 240 mg（body weight\>= 60kg）in 250 saline soluation, IV, Q3W
214365374|NCT05350943|DRUG|Donafenib|0.2mg. P.O, BID, continuously
214365375|NCT02185625|DEVICE|Safe Delivery smartphone application|The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
214365376|NCT04885556|DEVICE|Tampon-like device for absorption of sexual fluids|Subjects will insert a tampon-like device to absorb sexual fluids after intercourse
214365377|NCT04021303|DIETARY_SUPPLEMENT|Experimental cereal|Cereal containing probiotics, prebiotic fiber and low carbohydrates
214365378|NCT04021303|DIETARY_SUPPLEMENT|Conventional cereal|Gluten free conventional cereal (from 4 to 6 months old) and conventional cereal with gluten (from 7 to 12 months old)
214365379|NCT03419364|DRUG|nicotinamide|2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
214365380|NCT01901107|DRUG|Kiklin capsules|oral
214365381|NCT01407081|BEHAVIORAL|Telerehabilitation Cognitive Strategy Training|The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
214365382|NCT04668196|DEVICE|High-flow nasal cannula treatment|Standard operating procedures represented by hihg-flow nasal cannula oxygen therapy
214365383|NCT04668196|DEVICE|Continuous positive airway pressure (CPAP) treatment|Standard operating procedures represented by continuous positive airway pressure (CPAP) therapy
214365384|NCT04668196|DEVICE|Noninvasive ventilation treatment|Standard operating procedures represented by noninvasive ventilation treatment
214365385|NCT01638325|DRUG|Insulin Lispro|Administered SC
214365386|NCT01638325|DRUG|BC106 insulin lispro|Administered SC
214365387|NCT03120754|PROCEDURE|Place the peritoneal drainage|In the experimental group, the abdominal drainage was not placed
214975703|NCT02903446|DRUG|Denosumab|Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
214365388|NCT03120754|PROCEDURE|No peritoneal drainage|Intraoperative placement of peritoneal drainage as control group.
214365389|NCT06124040|BEHAVIORAL|psychological assessment evaluation|"A prospective data collection will be performed with self-administered psychological measures, with the aim to compare two different groups of patients with cervical cancer neo diagnosis, candidates for non conservative surgery or radio-chemotherapy treatment, based on FIGO Gynecologic Oncology Committee Guidelines.~Test will be repeated at Time 0 (firs access in radiotherapy Day Hospital, or first access in hospital ward for surgery), and Time 1 (after 6 months)."
214365390|NCT06731959|DRUG|Flexlamose|Fexlamose solution via nebulizer for 28 days
214365391|NCT06731959|DRUG|Placebo|Placebo solution via nebulizer for 28 days
214365392|NCT06733883|OTHER|psychotherapy|Music therapy
214491201|NCT05651594|DRUG|Oxaliplatin|Given IV
214491202|NCT05651594|BIOLOGICAL|Pembrolizumab|Given IV
214491203|NCT05651594|DRUG|Propranolol Hydrochloride|Given PO
214491204|NCT05651594|OTHER|Questionnaire Administration|Perceived Stress Scale
214491205|NCT06760416|OTHER|Nursing Education|5 modules of online foot care training, motivational messages and informative videos for the patient who was given a foot care kit
214491206|NCT06496724|BIOLOGICAL|Albumin paclitaxel/neutrophil drug|Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. The final product for Albumin paclitaxel/neutrophil drug.
214491207|NCT06640868|BEHAVIORAL|MyChart nurse message|Receipt of a MyChart nurse message around 34 weeks encouraging RSV vaccination
214491208|NCT06640868|BEHAVIORAL|SMFM video|Receipt of SMFM video around 34 weeks encouraging RSV vaccination
214491209|NCT06640868|BEHAVIORAL|Visual aid|Receipt of a visual aide encouraging RSV vaccination at 28-30 wks
214491210|NCT06772558|DRUG|Desflurane Inhalation|Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.
214491211|NCT06772558|DEVICE|mechanical ventilation (MV)|Following induction, patients underwent mechanical ventilation in volume-controlled (VC) mode. Ventilation parameters were set using a GE Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA): tidal volume 6-8 ml/kg, positive end-expiratory pressure 0 cmH2O, inspiration/expiration ratio 1:2, respiratory rate 16 breaths/min, and inspired oxygen concentration of 41%.
214491212|NCT06810661|BEHAVIORAL|Mobility promotion|At the Georges-L. Dumont hospital, a patient mobilization program has been introduced on floor 4C that embeds Kinesiologists within care to visit patients daily. A team of Kinesiologists visit the patients daily to promote movement and help them mobilize to the best of their capabilities (e.g., walking, standing, or sitting on the edge of the bed). The investigators propose to continue this individualized model but incorporate activity and frailty measures in males and females with cardiovascular disease.
214491213|NCT06755723|OTHER|Rib fractures manangement|This is an observational study, so participants are not assigned interventions. However, the study investigates the outcomes of patients undergoing rib stabilization surgery as part of their routine clinical care. The exposure of interest includes surgical rib stabilization and its timing, combined with any related clinical and care procedures. The outcomes and clinical data collected reflect routine care practices.
214491214|NCT06761326|PROCEDURE|Ultrasound guided right infraclavicular approach of subclavian vein cannulation|All patients will be in supine position, with the arm abducted to 45 degrees , the angle of the arm will be increased to 90 degrees to best acquire the image.The probe will be placed in he parasgittal plane in the deltopectoral groove medial to the coracoid process . The image will be optimized regarding the depth , focus and the gain accorgingly for the best image of the axillary artery and vein similar to that acquired when performing an infraclavicular approach for brachial plexus block . The probe will be rotated to obtain a longitudinal image of the axillary vein . The needle will be introduced in real time imaging , in an inplane technique and blood will be aspirated , the guidewire will be introduced in real time imaging.The internal jugular vein will be scanned bilaterally via ultrasonography to exclude malposition of the guidewire and will be reported in case of such. The catheter will be introduced through the sheath and will be tunneled the skin.
214975704|NCT05506423|DEVICE|CycloPen Cyclodialysis System|The CycloPen Micro-Interventional Cyclodialysis System is used to create and cyclodialysis cleft and deliver allograft scleral tissue and/or viscous material to reinforce and maintain the cleft postoperatively.
214975705|NCT06120205|DEVICE|Teal Wand Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of vaginal cells and material using the Teal Wand Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A healthcare provider collected sample will be performed by a clinician after self-collection. The patient will serve as their own comparator/control.
214975706|NCT05794295|OTHER|Acoustic Stimulation (AS)|Acoustic Stimulation will be administered while participants have their sleep monitored.
214975707|NCT05794295|OTHER|SHAM Stimulation|No stimulation will be administered while participants have their sleep monitored.
214975708|NCT06469463|DEVICE|MRI|The healthy subjects in the control group will perform an MRI head scan, which will be used to construct 3D head models and headcasts.
214975709|NCT06469463|DEVICE|MEG|The healthy subjects will undergo hpMEG data while wearing 3D-printed headcasts created from high resolution MRI
214975710|NCT06469463|DEVICE|EEG|"The healthy participants will undergo a similar session using EEG recording, using a Polhemus Fastrak system for localization of EEG electrodes and precise co-registration with anatomy and hpMEG data.~The patients group will take part in the same EEG recording session."
214975711|NCT05511922|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
214975712|NCT05511922|DRUG|Drug: KVD900 300 mg|KVD900 Tablet 300 mg
214975713|NCT05214118|BEHAVIORAL|technology-based program|Participants will be asked to complete three 25-minute modules covering the transition from pregnancy to postpartum, possible neonatal abstinence syndrome (NAS) or neonatal withdrawal syndrome (NOWS), and interactions with child welfare.
214975714|NCT06020703|BEHAVIORAL|Fermented Food Diet|Subjects will incorporate 1 serving of fermented food a day and increase to 6 more each day as tolerated for 4 weeks. After the initial 4 weeks, subjects will eat 6 or more servings of fermented foods each day for 8 weeks.
214975715|NCT00727935|DRUG|Lidocaïne|
214975716|NCT00727935|DRUG|Ropivacaïne|
214975717|NCT00727935|DRUG|Placebo|
214975718|NCT02619097|DRUG|Pegol-sihematide injection|single dose
214975719|NCT04010461|DEVICE|TMS|Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex
214679748|NCT03250520|DRUG|Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania|Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
214975720|NCT04010461|BEHAVIORAL|n-back working memory task|Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)
215084881|NCT01420874|BIOLOGICAL|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
214975721|NCT03797898|OTHER|Parent Coach|The Parent Coach intervention uses a health educator who provides anticipatory guidance, psychosocial screening/ referral, and developmental/behavioral surveillance, screening, and guidance at each well-visit. The Parent Coach uses a parent-focused, pre-visit questionnaire to customize the visit to the parents' needs. Every well-visit includes a brief, problem-focused encounter with a clinician for a physical exam and any concerns that require a clinician's attention. Finally, an automated text message service provides for periodic, age-specific messages to reinforce key health messages from Parent Coach-led well-visits.
214975722|NCT04733586|PROCEDURE|Sonar guided fascia iliaca|Sonar guided fascia iliaca
214975723|NCT04733586|PROCEDURE|Sonar guided quadratus lumborum block|Sonar guided quadratus lumborum block
214975724|NCT04543175|OTHER|Taste disorder´s test|Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.
214975725|NCT00254865|DRUG|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
214975726|NCT05304845|DRUG|DWP14012|Potassium-competitive acid blocker
214975727|NCT05304845|DRUG|Aspirin|acetylsalicylic acid
214975728|NCT06558331|OTHER|Preoperative Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, preoperative
214975729|NCT06558331|OTHER|Postoperative 24th hour Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, postoperative 24th hour
214975730|NCT05074953|OTHER|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
214975731|NCT05572645|DRUG|Pyrotinib Plus Trastuzumab|treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
214975732|NCT05572645|DRUG|Pertuzumab Plus Trastuzumab|treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
214975733|NCT01717222|DRUG|Intraperitoneal Lignocaine|Patients will receive 100 ml of 0.2% lignocaine
214975734|NCT01717222|DRUG|Intravenous Lignocaine|Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
214975735|NCT06054386|OTHER|Attentional Bias Modification Training (ABMT)|The ABMT is aimed to modify attentional bias for negative stimuli in social anxiety by deliberately inducing the participant's attention to positive or neutral stimuli. In the training, after a pair of facial stimuli (e.g., threatening-neutral, neutral-neutral) are presented, a left or right arrow appears in one of the location. Participants are instructed to press the button in the correct direction as quickly and accurately as possible.
214975736|NCT06054386|OTHER|General Attention Control Training|The general attention control training aimed to improve participants' general attention control ability by asking them to press a left or right arrow in the correct direction. The basic design of attention control training is the same as the ABMT, but the attention control training does not aim to alter the direction of attention toward or away from certain stimuli.
214975737|NCT01081613|OTHER|89Zr-bevacizumab PET imaging|injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
214975738|NCT00086190|DRUG|paroxetine|Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
214975739|NCT00086190|DRUG|venlafaxine|Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
214975740|NCT00086190|OTHER|placebo|an inactive substance
214975741|NCT03115034|DRUG|Melatonin|Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
214975742|NCT03115034|DRUG|placebo|Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
214975743|NCT03115034|OTHER|blank|Patients under CEA without taking melatonin or placebo
214365393|NCT06646835|BEHAVIORAL|Stress Ball Intervention|The stress ball is a simple and effective tool for reducing anxiety and relaxation as a non-pharmacological method (Yanes et al., 2018). Due to the limited pharmacological options available for pregnant women to reduce anxiety during cesarean section, alternative, complementary or supportive non-pharmacological methods and low-risk approaches are needed (Baltacı \& Başer, 2020). It is thought that squeezing the stress ball may be advantageous in reducing anxiety.
214365394|NCT07088276|PROCEDURE|microneedling with topical crisaborole|From each patient 3 patches will be selected The first will have microneedling and topical crisaborole and NB UVB sessions The second will have microneedling and NB UVB sessions The third will be exposed only to NB UVB sessions The microneedling sessions will be every 2 weeks for 6 sessions
214365395|NCT02047591|OTHER|Relaxing-touch method|
214365396|NCT07089186|DRUG|Meropenem and Pralurbactam|3g，q8h，180min infusion，Dose adjustments are available for participants with eGFR(mL/min)
214365397|NCT07089186|DRUG|Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)|The main therapeutic agents anticipated for use, either in combination or as monotherapy, commonly include colistin, meropenem, tigecycline, amikacin, and ceftazidime-avibactam.
214365398|NCT00824096|PROCEDURE|Bronchoscopy|The patients in our ICU intubated for \> 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1\~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3\~4 days even with CLV \<24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
214365399|NCT02929355|OTHER|carotid assesment by duplex ultrasonography|
214365400|NCT02335008|DIETARY_SUPPLEMENT|Sucralose|2 packets per 12 fl oz
214491215|NCT06761326|PROCEDURE|Ultrasound guided left infraclavicular approach of subclavian vein cannulation|All patients will be in supine position, with the arm abducted to 45 degrees , the angle of the arm will be increased to 90 degrees to best acquire the image.The probe will be placed in he parasgittal plane in the deltopectoral groove medial to the coracoid process . The image will be optimized regarding the depth , focus and the gain accorgingly for the best image of the axillary artery and vein similar to that acquired when performing an infraclavicular approach for brachial plexus block . The probe will be rotated to obtain a longitudinal image of the axillary vein . The needle will be introduced in real time imaging , in an inplane technique and blood will be aspirated , the guidewire will be introduced in real time imaging.The internal jugular vein will be scanned bilaterally via ultrasonography to exclude malposition of the guidewire and will be reported in case of such. The catheter will be introduced through the sheath and will be tunneled the skin.
214491216|NCT04643574|BIOLOGICAL|NeoTIL|Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)
214491217|NCT04643574|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
214491218|NCT04643574|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
214975744|NCT06457139|DIAGNOSTIC_TEST|Glucose tolerance test (2 hour)|Early testing with the 2 hour glucose tolerance test will occur during their inpatient postpartum hospitalization.
214975745|NCT06457139|OTHER|Active Comparator|Subjects randomized to the comparison condition will receive the usual standard of care. The standard of care will consist of administration of educational materials adapted from the American Diabetes Association that discusses healthy lifestyle behaviors and the increased risks of developing T2DM after a pregnancy complicated by GDM.
215084882|NCT02767479|DRUG|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
215084883|NCT02767479|DRUG|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
214365401|NCT02335008|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
214365402|NCT01452997|DRUG|NSAI treatment|Ibuprofen 5% gel
214365403|NCT01452997|DRUG|Steroid treatment|Steroid intervention with 0.05% w/w clobetasone butyrate.
214365404|NCT04715516|BEHAVIORAL|alcohol brief intervention|Nested within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive an alcohol brief intervention. The strong evidence-base for alcohol brief intervention, amplified by Co-Investigators' Smith and Bragge's (BehaviourWorks) approaches to applied behaviour change, has provided the framework for the development of the alcohol brief intervention used in this study. This intervention comprises personalised feedback on alcohol consumption levels, comparison to gender/age drinking norms, and information and behaviour-change content regarding alcohol consumption (i.e. negative-framed messaging around alcohol risks and harms, positive-framed messaging on the health benefits of reducing alcohol intake, alcohol harm reduction strategies).
214365405|NCT04715516|BEHAVIORAL|lifestyle health promotion|Lifestyle health promotion specific to physical activity and maintaining a healthy weight, developed to be relevant to women attending breast screening services, will be provided.
214365406|NCT00965926|DRUG|YM178|oral
214365407|NCT03060655|BIOLOGICAL|PLGA-Mg material|The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.
214365408|NCT03060655|BIOLOGICAL|titanium alloy|Traditional fixation was titanium alloy. the clinical outcome was assessed.
214365409|NCT03662932|OTHER|Early intensive mobilization|"Early mobilization: mobilization with the hospital staff begins already on the day of surgery, and includes mobilization in and out of bed, rise up from a chair, standing and walking.~Intensive mobilization: mobilization more than 4 times a day in the first postoperative week."
214365410|NCT05639179|BIOLOGICAL|UCAR-T Cells|"UCAR-T Cellswill be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one:1×10\^6 cells/kg;Dose level two:2×10\^6 cells/kg;Dose level three:5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of UCAR-T Cells at the best dose verified in the first portion."
214365411|NCT04556994|OTHER|Phase 1 Cardiac Rehabilitation|"Step 1:Breathing exercises, 3 sets of 10 repetitions. Active upper and lower extremity exercises, 3 sets of 10 repetitions; bed inclined at 45°.~Step 2:Active exercises as in step 1. Stay in the upright position and perform walking on the spot for three series of 1 min.~Step 3:Active exercises as in step 2. Ambulation within the inpatient wards (7 min). Transfer to an allocated chair beside the bed (at least 30 min).~Step 4:Same exercises as in step 3. Ambulation within the inpatient wards (10 min). Transfer to an allocated chair beside the bed (at least 1 h).~Step 5:Same exercises as in step 4. Ambulation within the inpatient wards (15 min). Transfer to an allocated chair beside the bed (at least 2 h).~Step 6:Active exercises from the previous day. Ambulation within the inpatient wards (20 min). Step training (3 times continuously, 20 cm standardized step).~Step 7:Exercises from the previous day. Step training (6 times continuously, 20 cm standardized step)."
214365412|NCT04556994|OTHER|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Step 1 to step 6 of Phase 1 Cardiac Rehabilitation given to the patients along with Lower limb exercise on Paddler lasting 20 min (5-min warm-up, 10 min of low-intensity exercise, and 5-min recovery), 30 rpm ( rotation per minute)
214491219|NCT04643574|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.
214491220|NCT04643574|RADIATION|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to tumor lesions once before NeoTIL infusion.
214491221|NCT06812390|DRUG|Albumin infusion (25% albumin)|Albumin 25 gram infusion
214491222|NCT06812390|DRUG|Normal Saline (0.9% NaCl)|100 cc of normal saline
214679749|NCT05392322|OTHER|Self-help skills|Self-help skills were given to down's syndrome children 3 times per week upto 15 minutes.
214679750|NCT05392322|DEVICE|Virtual video reality gaming|Virtual video reality gaming was given to children with down's Syndrome 3 time per week upto 15 minutes.
214679751|NCT00410280|BIOLOGICAL|IMA-638 is a biologic|
215084884|NCT01956136|BEHAVIORAL|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
214365413|NCT02543658|DRUG|Neostigmine Methylsulfate 1 MG/ML|The initial dose was 1mg, intramuscular injection(IM) once every 12 hours. If there is no defecation after 12 hours, the dose is increased to 1mg IM once every 8 hours; if there is no defecation after 24 hours, the dose is increased to 1mg IM once every 6 hours. If the abdominal pressure drops below 12mmhg, neostigmine will be stopped, otherwise it will be used continuously for 7 days.
214365414|NCT02543658|COMBINATION_PRODUCT|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
214365415|NCT01343602|BEHAVIORAL|mod. Constraint-Induced Movement Therapy|"Therapists of the intervention group are trained in CIMT at home. During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training."
214365416|NCT01343602|OTHER|Therapy as usual|Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
214491223|NCT06812208|BEHAVIORAL|Teleultrasound with Philips Lumify ultrasound probes and Reacts software|"Clinicians at hospitals randomized to Arm 1 will be provided with Reacts licenses and trained to use Reacts with Philips Lumify devices immediately following the baseline training. Each hospital will be assigned to 2-3 radiologist supervisors (typically 1 Rwandan, 1 U.S.-based), with at least one available on each designated U/S clinic day to provide real-time teleultrasound mentorship. Clinician trainees scan the breast, document their independent findings and management plan in the study REDCap database, and then call the supervisor using Reacts. Reacts permits supervisor and trainee to see each other virtually; the supervisor can also view live U/S images and the trainee's probe and hand position to provide real-time feedback."
214491224|NCT06812208|BEHAVIORAL|Asynchronous virtual feedback|Clinicians at Arm 2 hospitals will save static images, with or without video at clinicians' discretion, onto the Philips Lumify tablets. These will be uploaded to a secure internet-based folder with case descriptions, and assigned U.S.- and Rwanda-based experts will be notified that images are available. Experts will review images within 24 hours and email feedback to trainees on imaging quality/ technique and management; trainees can also email questions.
214491225|NCT06842043|OTHER|AI-assisted model|physicians will be authorized to access the AI model's predictions during patient care as an additional decision-making reference. These predictions will be generated in seconds and can help identify issues such as tube misplacement (e.g., nasogastric tube, endotracheal tube) and pneumothorax through AI analysis of CXRs, which will alert the physician to review the images.
214491226|NCT06842641|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy
214491227|NCT06753812|OTHER|constraint induced movement therapy|Children in this group will receive constraint induced movement therapy for 10 sessions over 2 weeks, each session lasting 90 minutes, in addition to the treatment they receive 2 days a week at the special education and rehabilitation centers they attend.
214975746|NCT02574169|OTHER|alveolar recruitment maneuvers group 1|"Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
214975747|NCT02574169|OTHER|alveolar recruitment maneuvers group 2|"Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
214975748|NCT03012932|BEHAVIORAL|HPV self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
214975749|NCT05588986|OTHER|ultrasonography|Umbilical artery Doppler evaluation by ultrasonography just before the first dose of antenatal corticosteroid, 24 hours and 48 hours after the last dose.
214975750|NCT04232345|DRUG|AZD4831|Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.
214975751|NCT04232345|DRUG|Placebo|Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.
214975752|NCT00004547|PROCEDURE|Surgery|Patients will undergo cytoreductive surgery to remove as much tumor as possible. Part of the intestines, pancreas, stomach or the entire spleen may also be removed if they are affected.
214975753|NCT00004547|PROCEDURE|Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|
214365417|NCT01007864|DRUG|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
215084885|NCT01956136|OTHER|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
215084886|NCT02590562|OTHER|Routine clinical practice|
215084887|NCT00974688|BEHAVIORAL|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
215084888|NCT00974688|BEHAVIORAL|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
215084889|NCT02763254|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T cells
215084890|NCT05223062|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
215084891|NCT05223062|OTHER|Compliance-Questionnaire-Rheumatology (CQR)|"The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as low adherers (taking \<80% of their medication correctly). The four point Likert answering scale ranges from; Definitely don't agree (scored 1) to Definitely agree (scored 4) with lower scores indicating lower levels of adherence. Total score is between 0 and 100."
215084892|NCT05223062|OTHER|The Brief Illness Perception Questionnaire (BIPQ)|The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior. Each item is scored between 0 and 10. Maximum total score is 80. Higher scores represents that the patient has a concerned perception of illness.
215084893|NCT05223062|OTHER|The Beliefs About Medicines Questionnaire (BMQ)|The Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. It has a total of 18 questions scored with a 5-point Likert scale. Higher scores represent more powerful beliefs.
215084894|NCT05223062|OTHER|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing. The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
215084895|NCT05223062|OTHER|The Psoriatic Arthritis Quality of Life (PsAQoL)|The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life. It is a self-administered, 20-item questionnaire that takes about three minutes to complete. The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life. Total score is between 0 and 20.
214365418|NCT01007864|DRUG|pramipexole or ropinirole|continuation of pre-study treatment regimen
214365419|NCT01236079|BEHAVIORAL|Assisted referral & IVR|includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
214365420|NCT02368106|RADIATION|Radiation Therapy|targeted radiation treatment
214365421|NCT00962351|PROCEDURE|Total Hip Replacement|
214365422|NCT05600049|DEVICE|Prototypes (815-v1 001) to (815-v1 050)|"Application on brown spots located on the face and/or the hand (6 treatments during the study).~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
214365423|NCT05600049|DEVICE|Prototype (815-v1 051) to (815-v1 100)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
214365424|NCT05600049|DEVICE|Prototypes (815-v1 101) to (815-v1 150)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
214491228|NCT06753812|OTHER|Control (Standard treatment)|Children in this group will continue to receive their treatment at the special education and rehabilitation center they attend, two days a week for 40 minutes.
214491229|NCT06843200|BEHAVIORAL|Parent Group Discussion|A 2-hour interactive parent group delivered to 5-10 parents via zoom; discuss weight bias and discrimination; brainstorm ways to respond in parent-child interactions involving health and appearance; and identify action steps.
214491230|NCT06812351|DRUG|Osteon III collagen|Hydroxyapatite and tricalcium phosphate particles embeded in bovine collagen
214491231|NCT06812351|BIOLOGICAL|Blood clot|Induction of bleeding from apical papilla
215084896|NCT01158027|OTHER|gait evaluation|The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
214365425|NCT05600049|DEVICE|Prototypes (815-v1 151) to (815-v1 200)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
214491232|NCT06811051|BIOLOGICAL|Menthol lozenge|Patients in the menthol group will fill out the Patient introduction form, patient follow-up form, and numerical pain scale just before the first application. After 60 minutes after extubation, they will be asked to take the lozenge into their mouth without chewing or swallowing it and suck it, and the patient will be monitored until the lozenge is completely dissolved. After the first lozenge is finished, the patient follow-up form and numerical pain scale will be filled out. The second lozenge will be sucked 90 minutes after extubation. The third lozenge will be sucked 120 minutes after extubation and the patient follow-up form and numerical pain scale will be filled out.
214491233|NCT06811051|BIOLOGICAL|Clove lozenge|Patients in the clove group will fill out the Patient introduction form, patient follow-up form, and numerical pain scale just before the first application. After 60 minutes after extubation, they will be asked to take the lozenge into their mouth without chewing or swallowing it and suck it, and the patient will be monitored until the lozenge is completely dissolved. After the first lozenge is finished, the patient follow-up form and numerical pain scale will be filled out. The second lozenge will be sucked 90 minutes after extubation. The third lozenge will be sucked 120 minutes after extubation and the patient follow-up form and numerical pain scale will be filled out.
214491234|NCT06811051|OTHER|None-placebo|Before routine clinical procedures after surgery, the patients in the control group will fill out the Patient introduction form, Patient follow-up form, and Numerical pain scale. After 60 minutes after extubation; clinical procedures do not include any procedures or interventions and the patient follow-up form and Numerical pain scale will be evaluated. After 120 minutes after extubation; the patient follow-up form and numerical pain scale will be evaluated.
214679752|NCT03344159|DRUG|Spironolactone|Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
214679753|NCT03344159|DRUG|Placebo|Placebo daily for a total of duration of 12 weeks
214679754|NCT03344159|RADIATION|PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82|At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
214679755|NCT03344159|DIAGNOSTIC_TEST|Cardiac MRI (Gadolinium enhanced)|At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
214679756|NCT03527901|DIAGNOSTIC_TEST|GCF collection with aMMP-8 chair side test|
214975754|NCT00004547|DRUG|Postoperative dwell with paclitaxel and 5-FU|Intraperitoneal dwell chemotherapy with a combination of 5-FU and Paclitaxel will be delivered in the early postoperative period (day 7 today 12 after surgery). Patients will be premedicated with hydrocortisone (100 mg/intravenous push (i.v.p.)), diphenhydramine (50 mg i.v.p.) and ranitidine (50 mg i.v.p.) 30 minutes prior to delivering intraperitoneal chemotherapy. One liter of normal saline will be infused containing 5-FU (800 mg/M\^2) and 1 L of normal saline containing paclitaxel (125 mg/M\^2) will be infused over 60 minutes. The chemotherapy solution will be left in the abdominal cavity permanently for slow absorption.
214975755|NCT03902613|DRUG|Lurasidone|Participant will have an open label trial of lurasidone for eight weeks.
214975756|NCT00852813|DIETARY_SUPPLEMENT|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
214975757|NCT02262910|BIOLOGICAL|ES414|ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
214975758|NCT02027025|DRUG|SPARC1103 low dose|once daily
214975759|NCT02027025|DRUG|SPARC1103 high dose|once daily
214975760|NCT02027025|DRUG|SPARC Placebo|
214975761|NCT04044105|OTHER|Pamphlet education|Patients receive an educational intervention explaining proper opioid disposal
214975762|NCT04044105|OTHER|Pamphlet education + texts|Patients receive an educational intervention and text message explaining proper opioid disposal
214975763|NCT04087239|OTHER|HIV|
214975764|NCT05750030|COMBINATION_PRODUCT|FMT combined with Atezolizumab plus Bevacizumab|Single FMT from patients with HCC who responded to PD-(L)1-based immunotherapy to patients with HCC who failed to achieve complete or partial response (according to mRECIST) to atezolizumab/bevacizumab. After single FMT, patients will continue to receive atezolizumab/bevacizumab every 21-days according to protocol.
214975765|NCT05141513|RADIATION|High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)|After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.
215084897|NCT03684304|DEVICE|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
215084898|NCT00058149|DRUG|gemcitabine hydrochloride|
215084899|NCT00058149|DRUG|oxaliplatin|
215084900|NCT02605811|DRUG|temozolomide|
215084901|NCT02605811|RADIATION|prophylaxis cranial radiotherapy|2
215084902|NCT01293643|DRUG|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
215084903|NCT01293643|DRUG|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
215084904|NCT04736160|OTHER|collect data|The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators
214975766|NCT04795999|BEHAVIORAL|Project With|There are 12 lessons in Project With, typically delivered in six weekly sessions, with each session having two one-hour long lessons and a meal with facilitators in between the two lessons. Each lesson includes a discussion of selected literary works, including poetry, short stories, and excerpts from films and other videos. The curriculum is intended to be delivered to groups of 8-12 youth. In ideal program delivery, participants also share a meal with each other and with the Youth Advocate. Shared mealtimes create group cohesion and allow Youth Advocates to connect with participants on a personal level, building trust. At the end of the Project With curriculum, youth will partake in an offsite day excursion to Camp Eaton, a wooded camp outside of Los Angeles. At Camp Eaton, Youth Advocates will lead a Project With session, lunch, bonding activities and games, and an opportunity to engage in an outdoor activity.
214365426|NCT03391609|DRUG|placebo infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
214975767|NCT03828227|DRUG|OPTIMOX-bevacizumab|"Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~* Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks \[q2w\]),~* Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~* Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~* 5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~* No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~* Bevacizumab: 5 mg/kg IV (day 1, q2w),~* FA: 400 mg/m² IV/2h (day 1, q2w),~* 5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~* No 5-FU bolus"
214975768|NCT03828227|DRUG|Capecitabine plus bevacizumab|"* Bevacizumab: 7.5 mg/kg intravenous infusion \[IV\] (day 1; q3w),~* Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w)."
214975769|NCT01124669|GENETIC|DNA analysis|
214975770|NCT01124669|GENETIC|mutation analysis|
214975771|NCT01124669|OTHER|laboratory biomarker analysis|
214975772|NCT00633607|OTHER|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
214975773|NCT01939314|DRUG|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
214975774|NCT01939314|DRUG|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
214975775|NCT02930694|DRUG|JNJ-54175446 (capsule)|Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
214975776|NCT02930694|DRUG|JNJ-54175446 (suspension)|Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
214975777|NCT00410358|DRUG|Gimatecan|
214975778|NCT02530437|DRUG|Carboplatin|Given IV
214975779|NCT02530437|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
214975780|NCT02530437|OTHER|Laboratory Biomarker Analysis|Correlative studies
214975781|NCT02530437|DRUG|Paclitaxel|Given IV
214975782|NCT02530437|DRUG|Taladegib|Given PO
214975783|NCT01163552|PROCEDURE|Surgical debulking and Intrathoracic Hyperthermic Chemotherapy|Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
214975784|NCT04153279|BIOLOGICAL|CMV-TCR-T cells|Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
214975785|NCT02195635|DRUG|Telotristat etiprate|500 mg telotristat etiprate
214975786|NCT02195635|DRUG|Octreotide acetate|200 µg octreotide acetate three times daily
214975787|NCT06154837|DRUG|GSK3862995B|GSK3862995B will be administered.
214365427|NCT03391609|DRUG|Dexmedetomidine infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
214679757|NCT03527901|OTHER|Saliva collection|
214975788|NCT06154837|DRUG|Placebo|Placebo will be administered.
214975789|NCT03304080|DRUG|Anastrozole|1 mg orally daily, day 1 to day 28
214975790|NCT03304080|DRUG|Palbociclib|Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
214975791|NCT03304080|DRUG|Trastuzumab|8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
214975792|NCT03304080|DRUG|Pertuzumab|840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
214975793|NCT06611995|OTHER|observational study|Observational study without intervention
214975794|NCT06177171|DRUG|Olaparib|Given orally
214975795|NCT06177171|DRUG|ASTX727|Given Orally
214975796|NCT06687538|OTHER|Mobile application|The content of the mobile application training to be developed for patients who will undergo transurethral prostate resection will consist of 3 modules including preoperative, postoperative and discharge training process.
214975797|NCT07024550|DEVICE|Treatment with BTL-699-2 device|The treatment schedule with BTL-699-2 device will consist of six 24.5-minute treatments spaced 3-7 days apart. The therapy parameters will be adjusted according to patient feedback, but should never exceed 70% of the individual's MT in the active group.
214975798|NCT07024550|DEVICE|Treatment with BTL-699-2 device with intensity below therapeutic threshold|The treatment schedule with BTL-699-2 device will consist of six 24.5-minute treatments spaced 3-7 days apart. The intensity of the energy will be set below the therapeutic threshold.
214365428|NCT05559502|DEVICE|HFNO group|HFNO therapy make possible to perform tubeless anesthesia, providing perfect exposure of structure of the vocal cords.
214365429|NCT05559502|DEVICE|ET group|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
214975799|NCT04406467|DEVICE|Xen Gel Stent|Ab-interno or Ab-Externa Xen with closed or open conjunctiva.
214975800|NCT07073092|DRUG|propolis|propolis medicated jelly candy.
214975801|NCT07073092|DRUG|chlorohexidine mouthwash and topical antifungal|chlorohexidine mouthwash and topical antifungal
214975802|NCT06780930|DRUG|Vorasidenib|For oral administration once daily
214975803|NCT06780930|DRUG|Placebo|For oral administration once daily
214975804|NCT06055244|DRUG|Amantadine|Subjects will be give amantadine 100 mg twice daily.
214975805|NCT07072741|OTHER|Shamiri Queen of Katwe Intervention|The intervention involves screening the film Queen of Katwe to high school students in a school setting.
214975806|NCT07072806|DRUG|Letibotulinum toxin A|Letibotulinum toxin A (Botulax) is a botulinum toxin type A formulation developed for aesthetic indications. In this trial, it was administered as the test intervention. Each participant received 2 units injected at four forehead sites (total 8 units), diluted to 20 U/mL, on one side of the forehead. The diffusion characteristics and efficacy were compared with those of onabotulinum and prabotulinum toxin A in a double-blind, randomized, split-face design.
215084905|NCT00054691|DRUG|Iressa|250 mg by mouth daily
215084906|NCT02362126|DEVICE|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
215084907|NCT04120857|BEHAVIORAL|Gentle Stretching|60 minutes fo gentle stretching twice weekly for 8 weeks
214365430|NCT06448325|OTHER|Hip arthroplasty|Surgical treatment of the hip after osteoporosis fracture. The focus of the study is the prediction of further fractures (and therefore further surgical procedures) after the first one.
214365431|NCT02357004|DRUG|Carvedilol|CR 40 mg daily in addition to normal BP medications
214365432|NCT02357004|DRUG|Chlorthalidone|12.5 mg daily in addition to normal BP medications
214365433|NCT03362450|OTHER|Fetal ultrasound during the second or third trimester/ Postnatal surgery / Post mortem examination|Fetal ultrasound during the second or third trimester Postnatal surgery Post mortem examination
214365434|NCT04202926|DEVICE|real coil|active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
214365435|NCT04202926|DEVICE|sham coil|sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
214365436|NCT03248765|OTHER|post-surgical opioid use measured at 1 day and 1 week.|"Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).~2\) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit )."
214365437|NCT03456037|OTHER|hepatitis viruses|There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital.
214365438|NCT00662857|DRUG|Technosphere® Insulin Inhalation Powder|TI Inhalation Powder, two 15 U cartridges
214365439|NCT00662857|DRUG|Technosphere Insulin® Inhalation Powder|TI Inhalation Powder, one 30 U cartridge
214365440|NCT00662857|DRUG|RAA Population|RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
214365441|NCT02544464|DRUG|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
214365442|NCT02544464|DRUG|placebo|placebo (normal saline) is administered after anesthesia induction
214365443|NCT00989092|BIOLOGICAL|darbepoetin alfa|Administered subcutaneously.
214365444|NCT05750186|OTHER|Abdominal Massage|Abdominal massage is a noninvasive application that stimulates bowel movements by applying patting, kneading and vibration movements over the abdominal wall to the area where the intestines are located. It increases peristalsis, creates a mechanical and reflex effect on the intestines, reducing the individual's feeling of pain and discomfort.
214365445|NCT01487278|DRUG|misprostol|600 mcg misoprostol oral
214491235|NCT06819800|OTHER|Transparent Waterproof Flaster|"Patients determined by randomization method were divided into three groups. Patient Information Form, 'Patient Follow-up Form', 'Glasgow Coma Scale' and 'Braden Pressure Ulcer Risk Assessment Scale' were applied to the patients in the transparent waterproof flaster group, one of the experimental groups. Nasogastric tube care was applied at 24-hour intervals. The dorsum of the nose was first cleaned with saline and then disinfected with a skin antiseptic containing alcohol and chlorhexidine gluconate. Afterwards, a transparent waterproof flaster was applied. The transparent waterproof flaster was prepared using the nasal preparation by pants tape method technique. Afterwards, the Patient Follow-up Form, Glasgow Coma Scale and Braden Pressure Injury Risk Diagnostic Scale were re-administered by the investigator at 72 hours and at discharge. If pressure injury developed, the Nasogastric Tube-Related Pressure Injury Staging Form was completed."
215084908|NCT05256342|DRUG|Duloxetine 60mg|"Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily."
215084909|NCT05256342|DRUG|Etoricoxib 60 mg|One pill daily for 8 weeks
215084910|NCT05256342|DRUG|omeprazol|20 mg daily; will be taken with Etoricoxib from the second week of treatment
215084911|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Physics Forceps|Extraction of mandibular molars using physics forceps
214365446|NCT01487278|DEVICE|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
214365447|NCT00002864|DRUG|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
214365448|NCT00002864|DRUG|tamoxifen citrate|20 mg PO for 5 years
214365449|NCT00003578|DRUG|CHOP regimen|
214365450|NCT00003578|DRUG|carmustine|
214365451|NCT00003578|DRUG|cyclophosphamide|
214365452|NCT00003578|DRUG|cytarabine|
214365453|NCT00003578|DRUG|doxorubicin hydrochloride|
214365454|NCT00003578|DRUG|etoposide|
214365455|NCT00003578|DRUG|melphalan|
214365456|NCT00003578|DRUG|prednisone|
214365457|NCT00003578|DRUG|vincristine sulfate|
214365458|NCT00003578|PROCEDURE|autologous bone marrow transplantation|
214365459|NCT00003578|PROCEDURE|peripheral blood stem cell transplantation|
214365460|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 1, s.c., single-dose
214365461|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 2, s.c., single-dose
214365462|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 3, s.c., single-dose
214491236|NCT06819800|OTHER|Medical Silk Flaster|"Patients determined by randomization method were divided into three groups. Patient Information Form, 'Patient Follow-up Form', 'Glasgow Coma Scale' and 'Braden Pressure Wound Risk Assessment Scale' were applied to the patients in the medical silk flaster group, one of the experimental groups. Nasogastric tube care was applied at 24-hour intervals. The dorsum of the nose was first cleaned with saline and then disinfected with a skin antiseptic containing alcohol and chlorhexidine gluconate. Afterwards, a medical silk flaster was applied. The medical silk flaster was prepared using the nasal preparation by pants tape method technique. Afterwards, the Patient Follow-up Form, Glasgow Coma Scale and Braden Pressure Injury Risk Diagnostic Scale were re-administered by the investigator at 72 hours and at discharge. If pressure injury developed, the Nasogastric Tube-Related Pressure Injury Staging Form was completed."
214491237|NCT06819800|OTHER|Elastic Flaster|"Patients determined by randomization method were divided into three groups. Patient Information Form, 'Patient Follow-up Form', 'Glasgow Coma Scale' and 'Braden Pressure Wound Risk Assessment Scale' were administered to the patients in the control group, which was in the elastic flaster group. Nasogastric tube care was applied at 24-hour intervals. The dorsum of the nose was first cleaned with saline and then disinfected with a skin antiseptic containing alcohol and chlorhexidine gluconate. Afterwards, an elastic flaster was applied. The elastic flaster was prepared using the preparation of the nose by the pants tape method technique. Afterwards, the Patient Follow-up Form, Glasgow Coma Scale and Braden Pressure Injury Risk Diagnostic Scale were re-administered by the investigator at 72 hours and at discharge. If pressure injury developed, the Nasogastric Tube-Related Pressure Injury Staging Form was completed."
214491238|NCT06809738|PROCEDURE|reconstructive technique|"1. Analysis and limitation of the tissue injury. Bilateral testicular and spermatic cord dissection.~2. Formation of cutaneous flaps and bilateral inguinal neocavity.~3. Perineal-scrotal reconstruction with fascial facing and cutaneous flaps"
214502820|NCT07022106|OTHER|Kinesiotape (KT) Group|"Kinesio Taping (KT) Intervention~Description:~Participants will receive a standardized 3-tape sensory modulation technique using Kinesiotape, applied to the abdomen and sacrum to target fascial tension and visceral pain in primary dysmenorrhea.~Procedure:~Abdominal Application (Two Tapes, 0% Stretch):~Horizontal Tape: Placed between the iliac crests (lower abdomen) to reduce fascial tension.~Vertical Tape: Applied from the navel to the pubic symphysis to modulate visceral pain signaling.~Sacral Application (One Tape, 15-25% Stretch):~Horizontal Tape: Anchored across the S2-S4 vertebrae (at PSIS level) to activate the pain-gating mechanism via cutaneous-visceral reflexes.~Frequency/Duration:~Each participant will receive a single session at their most painful day from this intervention"
214975807|NCT07072806|DRUG|Prabotulinum toxin A|Prabotulinum toxin A (Nabota) is a botulinum toxin type A product approved for aesthetic use in South Korea and other countries. It was used as a comparator agent in this trial. Participants received subcutaneous injections at four forehead sites (2 units per site, 8 units total), diluted to 20 U/mL, on one side of the forehead in a randomized, split-face design.
214975808|NCT07072806|DRUG|Onabotulinum toxin A|Onabotulinum toxin A (Botox) is an FDA-approved botulinum neurotoxin type A formulation used for cosmetic treatment of glabellar lines and other facial wrinkles. In this study, it was injected subcutaneously into the forehead at four standardized sites at a dose of 2 units per site (8 units total), diluted to 20 U/mL, and used as a comparator in the split-face design.
215084912|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Conventional Forceps|Extraction of mandibular molars using conventional forceps
215084913|NCT05848700|DRUG|SEP-363856|SEP-363856 Tablet
215084914|NCT05848700|DRUG|Placebo|Placebo Tablet
215084915|NCT04830904|DEVICE|personalized Lycra garments|the subjects wear lycra garments during the assessment time and for some days after the assessment
215084916|NCT01763320|PROCEDURE|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
215084917|NCT01763320|DRUG|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
215084918|NCT02185157|OTHER|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
215084919|NCT02185157|OTHER|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
215084920|NCT03887260|DRUG|Morphine PCA pump|Morphine given postoperatively.
215084921|NCT03887260|PROCEDURE|ESP block|Regional anaesthesia technique performed under ultrasound guidance before surgery
215084922|NCT03887260|DRUG|Fentanyl|Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
215084923|NCT02055261|DEVICE|Low frequency DBS of the pedunculopontine nucleus|
215084924|NCT01430507|DRUG|Revamilast|Tablet, Low dose, Once daily for 12 weeks
215084925|NCT01430507|DRUG|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
215084926|NCT01430507|DRUG|Revamilast|Tablet, High dose, Once daily for 12 weeks
215084927|NCT01430507|DRUG|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
215084928|NCT01229943|BIOLOGICAL|Bevacizumab|Given IV
215084929|NCT01229943|DRUG|Everolimus|Given PO
215084930|NCT01229943|DRUG|Octreotide Acetate|Given IM
215084931|NCT06462534|BEHAVIORAL|Band-Frail Program|"Participants will complete 16 weeks of elastic band resistance training and diabetes management education.~Exercise Component:~The elastic band resistance training involves 12 exercises: chair sit-to-stands, seated chest press, seater upper back reverse fly, seated single arm row, seated single arm lateral raise, seated single arm bicep curl, seated single arm triceps extension, seated single leg quadriceps extension, standing hamstring curl, standing leg extension, and seated abdominal crunches.~There will be a one-minute rest between each set and a self-determined rest period between exercises.~Education Component:~A certified Diabetes Educator and registered dietitian will present information to participants covering topics relating to T2D management and nutritional information."
215084932|NCT05026892|OTHER|no intervention|no intervention, only collection of data
215084933|NCT03593681|DEVICE|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
214491239|NCT04855370|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds every 15 minutes for 12 to 24 hours. If two finger probes are available, measurements will alternate between fingers.
214491240|NCT06595329|PROCEDURE|Epidural analgesia|After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned puncture. The epidural space will be identified at the level of the tenth thoracic intervertebral space using the loss of resistance technique and an 18G Tuohy epidural needle. After placing the epidural catheter, 4 ml of local anesthetic Levobupivacaine 0.25% will be administered into the epidural space. After inducing general anesthesia, an additional 4 ml of Levobupivacaine 0.25% will be administered before the surgical incision. Subjects in the control group will receive an infusion of 0.125% Levobupivacaine for 24 hours after the procedure.
214491241|NCT06595329|PROCEDURE|Intrathecal opioid analgesia|After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned intrathecal puncture. Subsequently, at the selected site, the dura will be punctured using a spinal needle (25G Quincke spinal needle), and 0.3 mg of morphine will be administered to the patient. Following the intervention, the patient will be induced into general anesthesia.
215084934|NCT04075422|DRUG|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
214502821|NCT06700083|DRUG|SHR-6934 injection|SHR-6934 injection
215084935|NCT02781025|OTHER|Blood draw|A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
214502822|NCT06700083|DRUG|SHR-6934 placebo|SHR-6934 placebo
214502823|NCT06698861|DRUG|PEG-MetHuG-CSF|Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2
214502824|NCT06698861|DRUG|Neulasta (Amgen)|Single dose of Neulasta will be given SC injection at 6 mg in Cohort 2b.
214502825|NCT07033962|COMBINATION_PRODUCT|"Fractional CO2 laser and topical fluconazole microemulsion"|four sessions of fractional CO2 at 3weeks interval with a laser device (multixel, Daeshin enterprise co., LTD. (D.S.E) 105, 271, digital -ro, Guro-gu, Seoul, Koreaa) at a pulse energy of 140 mJ, a density of 150 spots/ cm2 and a depth of 1 cm combined with twice daily topical fluconazole microemulsion.
214502826|NCT07033962|COMBINATION_PRODUCT|"Urea 40% and topical fluconazole microemulsion"|urea 40% paste under occlusion once daily over 4 weeks followed by topical fluconazole microemulsion twice daily for 8 weeks.
215084936|NCT03987932|BEHAVIORAL|NEAT!2|Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.
215084937|NCT03987932|BEHAVIORAL|NEAT!2+Calls|Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
215084938|NCT03987932|BEHAVIORAL|Delayed NEAT!2|Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
215084939|NCT04864132|DIAGNOSTIC_TEST|6-minute walk test|This test assesses submaximal exercise capacity.
215084940|NCT04864132|DIAGNOSTIC_TEST|Incremental shuttle walk test|This test assesses maximal exercise capacity.
215084941|NCT03032614|DRUG|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
214365463|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 4, s.c., single-dose
214365464|NCT01010425|DRUG|Placebo|Placebo, s.c., single-dose
214365465|NCT01010425|DRUG|Human Growth Hormone|Human Growth Hormone, s.c., daily for 7 days
214365466|NCT05103683|DRUG|TORL-1-23|antibody drug conjugate (ADC)
214365467|NCT01075932|DIETARY_SUPPLEMENT|DHA-rich fish oil|Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
214365468|NCT01075932|DIETARY_SUPPLEMENT|Placebo|2 g placebo (olive oil) taken daily for 12 weeks
214502827|NCT07033455|DRUG|HRS-1893|Single dose of HRS-1893 orally administered
215084942|NCT03032614|DRUG|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
215084943|NCT03032614|DRUG|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
215084944|NCT02731222|OTHER|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
215084945|NCT02416986|BEHAVIORAL|6 hour smoking abstinence|
214365469|NCT05810181|OTHER|Interview|"The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication)."
214365470|NCT03511911|DIAGNOSTIC_TEST|evaluation of pelvic floor muscle function through the PHENIX instrument|the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.
214365471|NCT03511911|DIAGNOSTIC_TEST|vaginal palpation|vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength
214365472|NCT00945464|OTHER|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
214365473|NCT01494337|PROCEDURE|HOLEP|USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
214365474|NCT01494337|PROCEDURE|PVEP-XPS|Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
214491242|NCT06818110|OTHER|Exercise|The supervised exercise-training sessions will last \<1 hour, and exercise-training intensities will be individually tailored to each participant using the results from their CPET. Participants will be screened prior to each session to ensure that it is safe to perform exercise. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high-intensity (50%∆) for a predetermined amount of time. Five minutes of freewheel cycling will be performed at the start and end of the protocol for a warm-up and cool-down. Exercise sessions can be terminated by the participant at any time. Participants will have continuous ECG and SpO2 monitoring throughout the training session. Vital signs will be taken before (some during) and after each training session.
214491243|NCT06819046|DRUG|Rocklatan|netarsudil and latanoprost ophthalmic solution 0.02%/0.005%
214491244|NCT06819046|DRUG|Systane Ultra|artificial tears
214491245|NCT06824714|DRUG|glucocorticoid, immunosuppressants, targeted therapy|Drug intervention protocol will be determined by clinicians
214491246|NCT06878625|COMBINATION_PRODUCT|Sacituzumab Govitecan combined with Toripalimab|Sacituzumab Govitecan combined with Toripalimab
214491247|NCT06878625|COMBINATION_PRODUCT|Sacituzumab govitecan combined with anti-angiogenesis|Sacituzumab govitecan combined with anti-angiogenesis( Bevacizumab or Anlotinib Hydrochloride)
214491248|NCT06767904|DEVICE|Continous Oxygen by Bottles|Oxygen delivery by bottles giving a continous flow.
214491249|NCT06767904|DEVICE|Demand oxygen by Portable Concentrator|Oxygen delivery by consentrators, giving oxygen only when inhaling.
214491250|NCT06259929|DRUG|Abemaciclib 150 MG + Giredestrant 30 MG|Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery
214491251|NCT06828939|DEVICE|pulsed field ablation|single shot pulsed field ablation using a balloon-based system
214975809|NCT07073118|DEVICE|Endovascular treatment with placement of a flow-diverting stent|Flow diverter stents (FDS) are braided stents with specific porosity that promotes the flow redirection within the parent vessel and outside the aneurysm sac, and the endothelialization. The FDS placed in the parent artery and covering the aneurysm sac will promote the intra-aneurysmal blood stagnation and parent vessel wall healing. All of these promoting, the aneurysm's thrombosis and ist regression
214975810|NCT01009853|DRUG|Codeine Sulfate|15 mg tablet
214975811|NCT02507076|DRUG|isolated limb perfusion|Undergo ILP with melphalan
214975812|NCT02507076|DRUG|melphalan|Undergo ILP with melphalan
214975813|NCT02507076|PROCEDURE|quality-of-life assessment|Ancillary studies
214975814|NCT03071601|DRUG|Lidocaine-Prilocaine Cream 2.5-2.5%|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture
214975815|NCT03071601|DRUG|Lidocaine 1% Epinephrine 0.005mg/mL solution|Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
214975816|NCT01528371|DRUG|Midazolam|"1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started."
214975817|NCT01528371|DRUG|Normal Saline Solution (NSS)|"1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started."
214975818|NCT04420988|BIOLOGICAL|COVID-19 Convalescent Plasma|COVID-19 Convalescent Plasma from recovered COVID-19 patients transfusion into severely or life-threateningly ill COVID-19 infected patients
214491252|NCT06796933|OTHER|Silicon based products (silicon gel)|The participants will be treated with cosmetic creams such as Silicone-based products (silicone gels twice a day) for one month.
215084946|NCT02416986|BEHAVIORAL|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
214975819|NCT05005598|OTHER|catheter dysfunction|prevalence of catheter dysfunction
214365475|NCT05199779|BEHAVIORAL|Single Session Intervention Leveraging an Ultra-Brief Self-Compassion Exercise|This 20-second contemplative exercise includes draws from the science of habit formation and includes elements of self-soothing touch, somatic experiencing, and mindful self-compassion.
214365476|NCT05199779|BEHAVIORAL|Finger-Tapping Active Control|This 20-second finger tapping exercise involves touching each finger to the thumb on one hand and repeating for twenty seconds. This intervention was designed to control for the potential effect of assessment on outcomes, the effect of having an activity to do for the duration of the intervention (4 weeks), regression to the mean, time, or other nonspecific factors.
214491253|NCT06796933|DEVICE|Bioptron (polarized light therapy)|The participants will be treated by polarized light therapy (Bioptron) for 15 minutes, 3 sessions per week, for one month.
214975820|NCT03105011|BEHAVIORAL|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
214975821|NCT02859298|DEVICE|Uterine Cervix Polarimetric Imaging|Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
214975822|NCT04113694|DEVICE|Extended Infusion Set|Each subject is asked to wear each Extended Wear Infusion Set for at least 174 hours.
214365477|NCT06490107|DRUG|Durvalumab combined with S-1|"The treatment regimen for this study is as follows:~First 8 cycles of adjuvant therapy: Durvalumab 1500mg, (Day 1, IV, Q3W) and S-1 40mg/m2 (Day1-14, BID, Q3W), up to 8 cycles.~Maintenance therapy stage(6 cycles)：If the patients do not experience disease recurrence or intolerance after first 8 cycles of adjuvant therapy, then, Durvalumab 1500mg, (IV, Q4W), up to 6 cycles"
214365478|NCT02961023|OTHER|Exercise therapy|"3-week residential phase and 12-week outpatient phase.~Residential phase~* Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~* A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~* 1.5 to 2 hours of exercise will be performed daily, with rest intervals.~* At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~* Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~* A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~* Participants will be provided with a cycle ergometer, weights and a HR monitor~* Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary"
214365479|NCT01389830|BEHAVIORAL|Telephone Survey|Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
214365480|NCT04285008|DEVICE|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device (K191220), intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
214365481|NCT06075797|BEHAVIORAL|PediQUEST ResPOND|"PPC teams will have access to feedback reports and the PQ-ResPOND checklist (standardized framework to diagnosis and treatment of recurrent pain behaviors in children with severe neurologic impairment).~Integration of the PPC team into care will be achieved through (i) initial consultation (goals: identify treatment goals, and address recurrent pain), and (ii) follow-up: the team will contact or visit the family in response to feedback reports or for treatment monitoring purposes."
214365482|NCT03040713|DRUG|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie \[mCi\]) injection, single dose
214365483|NCT03040713|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
214491254|NCT06719544|DRUG|lithium carbonate|Oral capsule
214491255|NCT06719544|DRUG|enlicitide|Oral tablet
214491256|NCT04707937|OTHER|Online education|Access to online modules about brachytherapy education in addition to receiving regular standard of care education
214491257|NCT04707937|OTHER|Regular standard of care education|Access only to regular standard of care education
214491258|NCT06747897|DEVICE|MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)|Product experience is assessed based on the answers provided by participants on the questions provided to them using an online questionnaire.
214491259|NCT00115934|PROCEDURE|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
214491260|NCT00115934|PROCEDURE|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
214365484|NCT06797973|DRUG|Intrathecal Morphine|80 μg preservative-free morphine (0.2 ml) added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl
214365485|NCT06797973|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|0.2 ml of isotonic sodium chloride added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl.
214365486|NCT02723942|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.
214365487|NCT01224301|BEHAVIORAL|School based flu vaccine: Low intensity|Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.
214365488|NCT01224301|BEHAVIORAL|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
214365489|NCT03263884|DEVICE|Repetitive trancranial magnetic stimulation (rTMS) group|Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.
214365490|NCT03263884|DEVICE|Sham group|A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
214491261|NCT03646292|DRUG|Pioglitazone|The investigators will compare the degree of liver fat before and after pioglitazone monotherapy.
214365491|NCT01519531|DRUG|Placebo|Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
214365492|NCT01519531|DRUG|VIA-3196|Oral, daily dosing for 14 days
214365493|NCT01788865|DEVICE|cSEMS(Covered self-expandable dual-layered metal stent) implant|
214365494|NCT05134766|OTHER|Observation only|Based on type of SOC applied and the type of CAM products by subject's own decison
214365495|NCT05021510|OTHER|Simultaneous Cervical Traction & Neural Mobilization|Simultaneously Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
214365496|NCT05021510|OTHER|consecutive Cervical Traction & Neural Mobilization|consecutive Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
214491262|NCT03646292|DRUG|Empagliflozin|The investigators will compare the degree of liver fat before and after empagliflozin monotherapy.
214491263|NCT03646292|DRUG|Combination of pioglitazone and empagliflozin|The investigators will compare the degree of liver fat before and after pioglitazone and empagliflozin combination therapy.
214491264|NCT06152237|GENETIC|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
214491265|NCT06293651|DRUG|DA-4505|Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D
214491266|NCT06293651|DRUG|DA-4505 + Pembrolizumab|Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab
214502828|NCT07032363|OTHER|Core Implementation Strategies|"* Task Sharing/Revise Professional Roles~* Distribute educational materials/Dynamic Training/Address Stigma~* Clinician Implementation Team Meetings~* Partner with CoCT DoH~* Champion~* Audit and Feedback~* Stage Scale Up/Tailoring"
214365497|NCT03613311|DIAGNOSTIC_TEST|Urodynamic study|Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile
214975823|NCT04100213|BEHAVIORAL|Trier Social Stress Test|The TSST-G is a psychological paradigm which combines high levels of social-evaluative threat and uncontrollability in a group setting. The TSST-G will proceed in groups of three to five participants (from the same diagnostic group). The TSST-G consists of three phases: a briefing; the psychological test itself, followed by a debriefing phase. Each phase will last 40, 20 and 60 minutes, respectively. The briefing and debriefing of the TSST-G will be conducted by experienced psychotherapists. The TSST-G itself will be conducted by personal unknown to the participants.
214975824|NCT00001038|DRUG|Valacyclovir hydrochloride|
214365498|NCT04042857|DEVICE|Next Science Treatment Gel|Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.
214365499|NCT04737564|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC10)|"The ABC parenting targets include: nurturing children when they are distressed (Sessions 1 and 2), following the child's lead in play (Sessions 3 and 4), and avoiding harsh or frightening behavior (Sessions 5 and 6). Sessions 7 and 8 help parents consider how their own experiences of being parented affect their sensitivity, and Sessions 9 and 10 consolidate gains with additional practice. Session content focusing on parenting targets is guided by a manual. Additionally, parent coaches make frequent in-the-moment comments (at least once per minute) about parent-child interactions as they occur in session, and use video feedback."
214975825|NCT00001038|DRUG|Acyclovir|
214975826|NCT01802047|PROCEDURE|milk expression with electric pump|
214365500|NCT04737564|BEHAVIORAL|Attachment and Biobehavioral Catch-up, Brief (ABC3)|The 3-session Attachment and Biobehavioral Catch-up intervention (ABC 3) is a brief version of the standard protocol. Parents who receive ABC 3 will receive the first 3 sessions of the ABC intervention, which focus on enhancing parental sensitivity (i.e., nurturance to distress, following the child's lead) by providing in-the-moment feedback on parent-child interactions, video feedback, and discussion of manualized content. ABC 3 was adapted from the standard protocol based on modeling of session-by-session data that demonstrated that, on average, most of the change in parental sensitivity happens in the first several sessions of the intervention.
214365501|NCT04737564|BEHAVIORAL|Safe Environment for Every Kid (SEEK)|Safe Environment for Every Kid (SEEK) is an evidence-based screening and referral system to facilitate parents' access to services for risk factors for maltreatment, including: mental health, substance abuse, intimate partner violence, harsh parenting, major parental stress, and food insecurity. Parents first complete the SEEK Parent Questionnaire with the help of an outreach worker. Following the SEEK protocol, handouts will be provided that address the identified problems and parents will be referred to partnering organizations in the community. Any additional work is completed by phone. The developer of the intervention, Howard Dubowitz, is a consultant on this application and will provide support around effective implementation.
214365502|NCT03448445|OTHER|Usual care setting|usual care settings without any intervention
214975827|NCT01220570|DRUG|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
214975828|NCT01220570|DRUG|Ridaforolimus|Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
214365503|NCT04178057|BIOLOGICAL|GB222 3mg/kg|Injection, strength 100mg/bottle, intravenous infusion, 3mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; low dose group.
214365504|NCT04178057|BIOLOGICAL|GB222 5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 1.
214491267|NCT06804369|BEHAVIORAL|Intensive psychodynamic therapy (PDT)|The KLIPP treatment unit (UPC KU Leuven, campus Kortenberg) provides intensive psychodynamic treatment (PDT) for patients with different types of PDs. There are three different programs that differ in treatment intensity: (1) inpatient treatment program (5 days a week), (2) day treatment program (4 days a week), and (3) a part-time outpatient treatment program of two half days per week. Patients attend one of these programs and stay in the program for at least 6 months (with an average duration of 8 months). The programs include individual and group psychodynamic psychotherapy as well as art, music and psychomotor therapy.
214491268|NCT06819683|DEVICE|Nanosensor|"The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA. The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue."
214491269|NCT06895044|OTHER|ophtalmologic follow-up|alls exams included in ophtalmologic follow-up every 6 months for 5 years
214491270|NCT06895044|OTHER|ophtalmological follow-up|all exams included in ophtalmological follow-up including axial length mesurment every 6 moths
214491271|NCT06749782|RADIATION|TC|Radiation: Computed Tomography (CT)
214491272|NCT06754553|BEHAVIORAL|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
214491273|NCT06754553|BEHAVIORAL|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
214491274|NCT06754553|BEHAVIORAL|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
214491275|NCT06754553|BEHAVIORAL|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) administered at day 0 and day 56 (week 8)
214491276|NCT06754553|BEHAVIORAL|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) assessed at day 0
214491277|NCT06754553|BEHAVIORAL|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) administered at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
214491278|NCT06754553|PROCEDURE|Cardiac monitoring|Electrocardiogram realized at day 0, 28 and 56.
214975829|NCT01220570|DRUG|Dalotuzumab|Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
214975830|NCT03088059|DRUG|Afatinib|Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
214365505|NCT04178057|BIOLOGICAL|GB222 7.5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,7.5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 2.
214975831|NCT03088059|DRUG|Palbociclib|Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
214975832|NCT03088059|DRUG|standard of care|Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
214975833|NCT03088059|DRUG|IPH2201|protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
214975834|NCT03088059|DRUG|Durvalumab|Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
214975835|NCT03088059|DRUG|Niraparib|Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
214491279|NCT06744517|OTHER|Sprint Interval Training|6 sessions of sprint interval training over 2 weeks. Each session involves 4-6 x 30 second Wingate sprints with 4 minutes of recovery in between on a stationary bike
214491280|NCT06758635|BEHAVIORAL|VRET-O Group|Arm Description: the participants of this group will get 3 hours lasting online single session VR therapy
214491281|NCT06758635|BEHAVIORAL|Flash-O Group|Arm Description: the participants of this group will get 3 hours lasting online single session EMDR Flash therapy
214491282|NCT06758635|BEHAVIORAL|PYSCHOEDU-O Group|Arm Description: the participants of this group will get 1 hour lasting online psychotherapy
214491283|NCT06765876|BIOLOGICAL|Autologous CAR123 T lymphocytes|Anti-CD123 Chimeric Antigen Receptor (CAR) T-Cells (CART123)
214491284|NCT06762041|DRUG|Metformin treatment|Interested subjects with autism are treated with metformin with a standard dosage
214491285|NCT06758882|DRUG|Apalutamide|administration of non steroid androgenic receptor inhibitors plus androgen deprivation therapy
214491286|NCT06758882|DRUG|Androgen receptor (AR) inhibitor|administration of androgen deprivation therapy
214975836|NCT03088059|DRUG|INCAGN01876|INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
214975837|NCT00729742|DRUG|Comparator: erlotinib + dalotuzumab|"Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.~Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.~Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib."
214365506|NCT04178057|BIOLOGICAL|GB222 10mg/kg|Injection, strength 100mg/bottle, intravenous infusion,10mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; high dose group.
214491287|NCT06767787|PROCEDURE|laparoscopic sleeve gastrectomy|Participants undergoing laparoscopic sleeve gastrectomy (LSG) will be clinically assessed and provided consent to this procedure by one of the bariatric surgeons affiliated with the bariatric surgery program. LSG will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once they can tolerate a liquid diet. Patients will then attend regular follow-ups with their surgeons and the bariatric surgery program, in accordance with a standardized clinical pathway protocol.
214491288|NCT06767787|PROCEDURE|total knee arthroplasty|Patients undergoing unilateral total knee arthroplasty (TKA) will be clinically assessed and provided consent to their procedure by an orthopaedic surgeon trained in joint arthroplasty. TKA will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once physiotherapy clears them. Patients will attend regular follow-ups with their surgeon in accordance with a standardized clinical pathway protocol.
214491289|NCT06769867|RADIATION|PS-3D-DSA|undergo a PS-3D-DSA scan
214491290|NCT06769867|RADIATION|classic 3D-DSA|undergo a classic 3D-DSA scan
214491291|NCT05527691|BEHAVIORAL|SupportGroove|"An app-delivered program consisting of positive psychology-based activities, such as expressing gratitude, finding meaning, savoring, and fostering connections. Participants complete daily quests suggested through the app, some of which are completed on their own, and some with their partner."
214491292|NCT06755021|DIETARY_SUPPLEMENT|Whey Protein Milk-Derived Exosomes|WPMDE2 (Whey Protein Milk-Derived Exosomes 2) is an advanced nutritional supplement developed from natural milk components.
214491293|NCT06764017|DRUG|CHiR-DEL|Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large B-cell lymphoma (DLBCL) who are intolerant to chemotherapy.
214491294|NCT05349006|DRUG|Azathioprine|Dose related to weigh (100 mg for weight ≤ 50 kg and 150 mg for weight \> 50 kg) = 2 to 4 50mg oral caps, daily, during all the study period
214491295|NCT05349006|OTHER|Placebo|Dose related to weigh (100 mg for weight ≤ 50 kg and 150 mg for weight \> 50 kg) = 2 to 4 50mg oral caps, daily, during all the study period
214491296|NCT06734325|BEHAVIORAL|Mobile Oral Health Intervention|46 messages delivered over a 3-month period (12 weeks) via WhatsApp
214502829|NCT07032363|OTHER|Enhanced Implementation Strategies|"* Train the trainer~* Ongoing supervision and consultation"
214975838|NCT00729742|DRUG|Comparator: erlotinib monotherapy|Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
214365507|NCT00006048|DRUG|cisplatin|
214365508|NCT00006048|DRUG|gefitinib|
214365509|NCT00006048|DRUG|gemcitabine hydrochloride|
214365510|NCT04539821|OTHER|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials.
214365511|NCT04980664|OTHER|Integrated intervention strategies|Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
214365512|NCT05078151|DIAGNOSTIC_TEST|Whole-Body Diffusion Weighted MRI|MRI at baseline, after four and eight weeks of treatment and at disease progression or treatment discontinuation.
214365513|NCT01439607|OTHER|Bone marrow and blood sampling|Bone marrow and blood sampling
214365514|NCT01840553|DRUG|oral sodium phosphate tablets|
214365515|NCT01840553|DRUG|polyethylene glycol|
214365516|NCT03859414|DRUG|Therapeutic Dose 1|CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
214365517|NCT03859414|DRUG|Therapeutic Dose 2|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
214365518|NCT03859414|DRUG|Supra-therapeutic Dose|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
214365519|NCT03859414|DRUG|Placebo|CHF 5993 placebo pMDI
214365520|NCT00168545|BIOLOGICAL|Measles vaccine|
214365521|NCT00402480|DRUG|Hydroxyurea|
214365522|NCT02691182|DRUG|SPN-810|
214365523|NCT04167241|DIAGNOSTIC_TEST|Echocardiography|Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
214365524|NCT02333214|OTHER|Exergames and conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group exercises that are best accomplished using virtual scenarios, such as dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed using video games.
214365525|NCT02333214|OTHER|Conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed without the virtual environment.
214365526|NCT02525757|DRUG|MPDL3280A|"1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation."
214975839|NCT02628977|BEHAVIORAL|Peer Based Sleep Health Education and Social Support|Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
214365527|NCT02525757|DRUG|Carboplatin|AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
214365528|NCT02525757|DRUG|Paclitaxel|50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
214365529|NCT02525757|RADIATION|Radiation Therapy|60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
214365530|NCT01550198|DEVICE|Advanced hemodynamic monitoring|Comprehensive advanced hemodynamic monitoring
214365531|NCT02434094|BEHAVIORAL|eDAPT on-line training program|A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
214365532|NCT00845884|DRUG|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|"* Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~* Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days."
214365533|NCT04839263|PROCEDURE|"FAST TRACK protocol"|"Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~* Hospitalization on surgery day~* No prolonged fasting~Perioperative strategy:~* Pain control based on limited systemic opioid therapy use~* Anti-nausea prophylaxis~* Anaesthesia via IV propofol / remifentanyl~* Bladder catheter removal postoperative~Postoperative strategy:~* Pain control using balanced analgesia~* Gum chewing~* Early oral refeeding and rapid mobilization~* Venflon removal 6 hours post-op"
214365534|NCT02563002|DRUG|mFOLFOX6|Regimen consists of oxaliplatin 85 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
214365535|NCT02563002|DRUG|FOLFIRI|Regimen consists of irinotecan 180 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-FU 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
214491297|NCT06408428|DEVICE|PANAXIUM MicroECoG|The PANAXIUM microelectrode ( 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.
214491298|NCT06704698|DRUG|Liposomal bupivacaine|Thoracic paravertebral block with liposomal bupivacaine.
214975840|NCT02628977|BEHAVIORAL|Attention Control Group|Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
214975841|NCT02225418|DRUG|Ropivacaine|
214975842|NCT02225418|DRUG|saline|
214975843|NCT05280990|DIAGNOSTIC_TEST|mHBS|Preoperative FLRF assessment using 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS).
214975844|NCT05280990|DIAGNOSTIC_TEST|CT/MRI volumetry|Preoperative FLRF assessment using CT/MRI volumetry
214975845|NCT05510817|OTHER|Multiparametric assessment|neuropsychological assessment, PRO measures, non-conventional MRI metrics
214975846|NCT02674503|BEHAVIORAL|Walking|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.
214975847|NCT02674503|BEHAVIORAL|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
214975848|NCT00860639|DRUG|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
214365536|NCT02563002|BIOLOGICAL|Pembrolizumab|IV infusion
214365537|NCT02563002|BIOLOGICAL|Bevacizumab|IV infusion
214365538|NCT02563002|BIOLOGICAL|Cetuximab|IV infusion
214365539|NCT02123602|OTHER|core stabilization|
214365540|NCT02123602|OTHER|lower extremity training only|
214365541|NCT05682911|DRUG|Zingiber officinale L. tablets|Zingiber officinale L. tablets 500mg twice daily
214365542|NCT05682911|DRUG|Simvastatin 20mg|Simvastatin 20mg once a day for 2 months
214491299|NCT06704698|DRUG|Bupivacaine Hydrochloride|Epidural block with plane bupivacaine.
214975849|NCT06011863|PROCEDURE|Thoracic Epidural Analgesia|Thoracic Epidural Application: The epidural area will be accessed from the 7th (T7)-8th (T8) level of the thoracic vertebral midline with an 18 gauge (G) epidural needle using the hanging drip technique. After 2 ml of 2% lidocaine is administered and no spinal effect is observed, a mixture of morphine and local anaesthetic 3-4 mg morphine hydrochloride + 5 ml 0.5% bupivacaine + 2 ml 0.9% saline will be administered through the epidural needle at once and the epidural needle will be withdrawn and sterile dressing will be applied.
215084947|NCT02416986|BEHAVIORAL|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
214365543|NCT02745665|OTHER|flow mediated dilation (endothelial function)|
214365544|NCT02745665|OTHER|ABPI|
214365545|NCT02745665|OTHER|Pulse wave velocity and augmentation index|
214365546|NCT02745665|OTHER|blood pressure|
214975850|NCT06011863|PROCEDURE|Erector spinae plane block|Before induction of anaesthesia, the patient is placed on the operating table and placed in a forward tilted position. Asepsis and antisepsis conditions are provided. The linear USG probe is moved approximately 2-3 cm lateral to the spinous process T5 - T6 level on the side to be operated. The trapezius, rhomboid major and erector spinae muscles will be identified to find the correct probe position. A 22 gauge 50 mm or 22 gauge 80 mm single shot nerve blocks needle will be inserted through the skin in a cranio-caudal direction. With the needle resting on the transverse process, the plane between the erector spinae muscle and the transverse process will be verified by hydrodissection with 5 ml saline solution. Then 20 ml of 0.25% bupivacaine will be injected. The ESP block will be considered successful if the local anaesthetic spreads linearly up to the T8 - T9 level. The patient will then be placed in the supine position and general anaesthesia will be administered.
214975851|NCT03874793|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
214975852|NCT03874793|BEHAVIORAL|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
214975853|NCT04350593|DRUG|Dapagliflozin 10 milligram (mg)|Active Comparator: Dapagliflozin 10 mg
214975854|NCT04350593|DRUG|Placebo|Placebo Comparator
214975855|NCT03106116|DEVICE|Experimental: Enhanced External Counterpulsation|Enhanced External Counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy has been approved by the United States Food and Drug Administration (FDA) for the treatment of refractory angina and heart failure. Administration of 35-36 hours EECP therapy over a 7 week period, one hour session every working day.
214975856|NCT03106116|DRUG|Standard medical therapy|Guideline- driven standard medical treatment for 7 weeks
214975857|NCT02053103|DRUG|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
214975858|NCT02053103|DRUG|Placebo|Tablet, 0 mg, twice daily, 6 weeks
214975859|NCT03222726|OTHER|exercise group|less than 6000 steps/day or 40,000 steps/week
214975860|NCT03638128|DRUG|Denosumab|Solution for injection
214975861|NCT03638128|DRUG|Alternative osteoporosis medications|Alternative osteoporosis medication/s at the discretion of the investigator.
214975862|NCT02737761|BEHAVIORAL|Qualitative Interview and Adherence Measurements|Subjects will undergo an open-ended, semi-structured interview within two weeks of enrollment. The interview will be approximately 1 hour in length, performed by study staff who have been trained in qualitative research methods. This interview will be completed again 12 weeks later. Subjects will complete the MOS SAS, Automated Self-Administered 24-hour recall (ASA24), Life Orientation Test-Revised (LOT-R), Positive and Negative Affect Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Medical Outcomes Study Short Form-12 (SF-12) at baseline and again at 12 weeks.
214975863|NCT03484169|OTHER|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
214975864|NCT00489463|DEVICE|intra-uterine device (TCu 380A)|
214975865|NCT04678284|BEHAVIORAL|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide brief diabetes education as needed.
214975866|NCT05601349|BEHAVIORAL|Telehealth-based strategy|Teleducation course, based on the CPG recommendations
214975867|NCT00945243|DEVICE|Zero-P|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
214975868|NCT04832737|BEHAVIORAL|ADDapt Ability Framework|12 week individual therapeutic coaching intervention
214975869|NCT06349876|PROCEDURE|laparoscopic cholecystectomy|slandered laparoscopic cholecystectomy
214975870|NCT04187313|OTHER|INSTEP2 intervention package|"The Intervention will comprise: An electronic notification system, a standardized education about the signs and symptoms of TB and TB management and an individualised plan for each PP with respect to their approach to the diagnosis and management of TB suspects.~The electronic system is a refinement of the electronic referral and report-back system using a mobile phone 'app'. The system will enable essential data to be uploaded, consistent with National TB Control Programme forms.~The education package will be focused on TB suspect identification, provisional diagnosis and referral, including how to use the mobile phone 'app'. We will also develop a simple individualised approach for the management of TB suspects, which takes into account the context around each PP's practice, identifying the most efficient and feasible approach to obtaining a diagnosis and notifying TB patients."
215084948|NCT01384500|OTHER|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
214975871|NCT03571035|DIAGNOSTIC_TEST|Mandibular movements recordings by a mono vision system|To examine the mandible's movements, vision analysis was employed and performed with the digital camera which featured 1920 x 1080 resolution and was fixed on an aluminium extension arm attached to a headset worn by the subject.The camera was aligned parallel to the subject's face at a distance of 0.3 meters. The study used two 10 mm x 5 mm reference markers, which were accurately reproduced on the camera recorded images. In line, one marker was put on the medial cleft above the upper lip, and the other one was positioned below the first one in a straight line, in the middle of the chin. Then, the patient was asked to open maximally and close the mouth twice.To establish the mandible's trajectory, the line was drawn between the positions of the two markers to connect the two points. The line's parameters were calculated only during initial measurements and were constant throughout the study.
214975872|NCT02990000|BEHAVIORAL|Scientific Match|We have developed an innovative, personalized Match System based on provider track records determined with a multidimensional outcomes tool - the Treatment Outcome Package (TOP). Specifically, patients are assigned to therapists with previously established strengths (i.e., being historically effective) in treating their primary problems (e.g., depression, anxiety).
214975873|NCT05974761|OTHER|massage|The patient was placed in a lateral decubitus position with the physician standing on the ventral side of the patient, with the crotch resting on the anterior edge of the superior iliac crest, and the elbow rising from the medial side of the highest point of the superior iliac crest, follow the palpation (avoiding the L3 transverse process) along the steep edge of the skeleton slowly toward the spine, and focus on the painful points or cords by repeatedly applying the elbow press method and the elbow flick method for 1-2 minutes, and then the elbow tip contact to find the sinew knot and along the vertical direction of 3-5 times, the force should be deep penetration.
214975874|NCT05974761|OTHER|Traditional Chinese massage|Through the point, massage, bone-setting treatment
214975875|NCT04969289|BEHAVIORAL|Dr. Eric Digital Health Intervention|Dr. Eric is a user-informed, theory-based, digital health intervention that aims to improve adolescent male SRH. This ED-based intervention consists of two parts-an interactive, tailored app and 3 months of personalized, two-way text messaging. It is based on an evidence-based sexual health curriculum we developed using established behavioral theories, prior literature, input from key stakeholders, qualitative patient interviews, and our prior ED-based work.
214975876|NCT00108446|DRUG|dextromethorphan|
214975877|NCT00108446|DRUG|naloxone|
214975878|NCT00108446|DRUG|fentanyl|
214975879|NCT00108446|DRUG|lidocaine|
214365547|NCT02745665|OTHER|ramp test|
214365548|NCT01889173|DRUG|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
214365549|NCT01889173|DRUG|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
214365550|NCT01889173|DRUG|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
214365551|NCT01889173|DRUG|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
214365552|NCT03191695|OTHER|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
214365553|NCT04077619|BEHAVIORAL|Modern pain neuroscience approach|Modern pain neuroscience approach. The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
214365554|NCT04077619|BEHAVIORAL|Usual care physiotherapy|Usual care evidence-based physiotherapy The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
214365555|NCT05097846|DRUG|Group1 Vonoprazan Fumarate + amoxicillin + doxycycline|Vonoprazan Fumarate + amoxicillin + doxycycline
214365556|NCT05097846|DRUG|Group2 Vonoprazan Fumarate + furazolidone + doxycycline|Vonoprazan Fumarate + furazolidone + doxycycline
214365557|NCT05097846|DRUG|Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
214365558|NCT05097846|DRUG|Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
214365559|NCT01862822|OTHER|upright position|
214365560|NCT03447080|OTHER|Control|White Bread containing 50g carbohydrate
214365561|NCT03447080|OTHER|Control|White Bread containing 50g carbohydrate
214365562|NCT03447080|OTHER|Ricebran soybean milk|White Bread with rice bran soybean milk
214491300|NCT06022107|BEHAVIORAL|LDART|LDART is a newly developed web-based social support intervention that can be accessed by smartphone or computer. Each night, the participant sets a recovery goal for the next day (e.g., drink less than usual, go to a support group meeting). The next night, they log on to LDART to indicate whether they reached their goal for the day. Depending on their response, they will be shown either a celebratory or encouraging message from someone in the addiction recovery community, along with specific information on that person's recovery organization.
214491301|NCT06806098|BEHAVIORAL|Truth Initiative Digital Cessation Program|Truth Initiative's digital cessation program is a multimodal evidence-based, digital tobacco cessation program. Accessible on any web-enabled device, it was developed with the Mayo Clinic around tobacco dependence treatment guidelines, Social Cognitive Theory, and the Mayo Clinic model for engaging tobacco users in cessation treatment. It includes a personalized quit plan with AI-driven content recommendations, interactive exercises, educational videos, and emails; a dynamically tailored, bidirectional text message program; the longest-running online community dedicated to tobacco cessation; synchronous live chat coaching (sponsored version only); and pharmacotherapy decision support and delivery (sponsored version only).
214491302|NCT06806098|BEHAVIORAL|Usual Care|Smokefree.gov is a web-based tobacco cessation platform run by the National Cancer Institute of the National Institutes of Health since 2003 and represents the current standard of care for digital tobacco cessation in the U.S. As of 2020, the SmokeFree.gov Initiative (SFGI) consisted of a multimodal suite of interventions - 6 mobile-optimized websites, 9 text messaging programs, 2 mobile apps, and social media platforms.
214491303|NCT06302140|DRUG|[14C]-Nanatinostat|A single oral dose administered on Day 1 in a fasted state.
214491304|NCT06302140|DRUG|Nanatinostat (free base) tablets in combination with Valganciclovir|Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
214491305|NCT06302140|DRUG|Nanatinostat mesylate tablets in combination with Valganciclovir|Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
214491306|NCT06302140|DRUG|Single-agent Nanatinostat (free base) tablets|40 mg once daily under fed conditions until disease progression or unacceptable toxicity, whichever occurs first.
214491307|NCT06000787|RADIATION|External beam radiotherapy|Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B receive standard-of-care external beam radiotherapy to the brain tumor.
214491308|NCT06000787|RADIATION|131I-Metaiodobenzylguanidine (MIBG)|Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B receive the radiopharmaceutical 131I-Metaiodobenzylguanidine (MIBG) 15 mCi/kg via either a central or a peripheral IV catheter over 1.5 to 2 hours at a maximum rate of 500 mCi/hour.
214491309|NCT06778317|DIAGNOSTIC_TEST|Circulating mSEPT9 Biomarker Testing|"This intervention involves the analysis of the circulating epigenetic biomarker mSEPT9 through plasma samples collected from patients with cirrhosis. The mSEPT9 test evaluates the methylation status of the SEPT9 gene promoter using a triplicate assay. A switch in the test status, defined as a transition from triple-negative (no methylation detected in any triplicate) to at least one positive triplicate, is being investigated as a prognostic marker for the development of hepatocellular carcinoma (HCC).~The mSEPT9 test is conducted on plasma samples collected during routine blood draws at each of the 11 scheduled study visits. Samples are processed and analyzed in batches using specialized high-throughput equipment provided by Epigenomics/New Day Diagnostics. Results of the mSEPT9 test are not shared with clinicians during the study period to avoid influencing patient management, ensuring the test is purely investigational in this context."
214491310|NCT06302530|PROCEDURE|Stayer|"In group A, the intervention involves using the Strayer technique, an echo-guided recession of the gastrocnemius tendon, with local anesthesia and sedation as needed. The patient can be in a prone or supine position. Ultrasound will identify the sural nerve and blood vessels to prevent damage. The entry point is 2-3 cm distal to the medial head of the gastrocnemius. Local anesthetic is infiltrated, and blunt dissection creates a working space. V-shaped curettes widen the entry point without harming noble structures.~Under direct ultrasound control, a curved scalpel is inserted until reaching the medial border of the gastrocnemius tendon. Transection occurs progressively from medial to lateral while flexing the foot. Verification of complete tendon transection is done with a blunt dissector. Finally, a dressing with adhesive strips and an elastic bandage is applied, eliminating the need for sutures."
214491311|NCT06302530|PROCEDURE|Plantar transection|In group B, an echo-guided transection of the plantar tendon will be performed. Local anesthesia and sedation will be used as needed. The patient will be in prone or supine position. The plantar tendon will be identified ultrasonographically on the medial aspect of the gastrocnemius distal to the myotendinous junction. Local anesthetic will be infiltrated at that point to isolate the plantar tendon. An ultrasound-guided retrograde hook is introduced until the plantar tendon is engaged. Then proceed to retrograde transection of the tendon from lateral to medial, verifying complete section. At the end, a dressing with adhesive strips and elastic bandage, without sutures, will be performed.
214975880|NCT03988361|DIAGNOSTIC_TEST|Magnetic Activated Cell Sorting|At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group. Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.
214975881|NCT00557466|DRUG|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
214975882|NCT00557466|DRUG|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
214975883|NCT00557466|DRUG|placebo to indacaterol|Placebo TWISTHALER® device
214975884|NCT00557466|DRUG|placebo to formoterol|Placebo AEROLIZER® device
214975885|NCT00557466|DRUG|short acting β2- agonist|100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
214975886|NCT00435344|BEHAVIORAL|Pediatric Practice-Based Smoking Intervention|
214975887|NCT04492423|DIAGNOSTIC_TEST|VerifyNow PRUTest|VerifyNow PRUTest for platelet aggregation
214975888|NCT03268343|DRUG|Cytisine|Cytisine 1.5 mg Film-Coated Tablets
214975889|NCT00764101|BEHAVIORAL|Attentional Bias Modification|computerized training to reduce attentional bias in posttraumatic stress disorder
214975890|NCT05796713|OTHER|Hydrocephalus|Interview
214975891|NCT01321671|DRUG|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
214975892|NCT01321671|DRUG|Pregabalin controlled release, 330 mg, fasted|A single oral dose of 330 mg controlled release tablet administered fasted in the evening
214975893|NCT01321671|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
214975894|NCT02365350|PROCEDURE|STEINER-TAN Needle®|A purpose built new double lumen needle with little dead space.
214975895|NCT02365350|PROCEDURE|17 G single lumen needle|A conventional single lumen IVF aspiration needle.
214975896|NCT00683228|BEHAVIORAL|Counseling|Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
214975897|NCT00405171|DRUG|Nevirapine|
214975898|NCT03925142|OTHER|Controlled healthy vegetarian diet|The controlled healthy vegetarian diet will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern.
214975899|NCT03925142|OTHER|Controlled beef diet|The controlled beef diet will incorporate various cuts of lean unprocessed red meat into the healthy vegetarian eating pattern, as approved by the American Heart Association's Food Certification Program. The beef diet will isocalorically replace starchy vegetables and/or refined grains with 6 oz. of beef/day for five weeks.
214975900|NCT03756415|DEVICE|"DiMax Zero Total face mask R,"|a non-CO2 rebreathing device included directly in the full face mask
214365563|NCT03447080|OTHER|Soybean milk|White Bread with soybean milk
214365564|NCT03953235|BIOLOGICAL|GRT-C903|a shared neoantigen cancer vaccine prime
214365565|NCT03953235|BIOLOGICAL|GRT-R904|a shared neoantigen cancer vaccine boost
214365566|NCT03953235|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
214491312|NCT06302530|PROCEDURE|Baumann|It consists of an ultrasound-guided recession of the anterior gastrocnemius aponeurosis. Under local anesthesia, the myotendinous junction is accessed 3 cm proximal to the myotendinous junction, using saline for hydrodissection. Under ultrasound guidance, the entry portal is enlarged and a scalpel is introduced for transection of the aponeurosis and plantar tendon. The procedure is verified with a buttoned probe and does not require sutures. The patient wears a Walker boot for 4 weeks and follows a stretching protocol.
214975901|NCT03756415|DEVICE|traditional face mask|a traditional mask without a non-CO2 rebreathing device included directly in the full face mask
214975902|NCT01799447|BEHAVIORAL|Early intervention|Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
214975903|NCT00680329|DRUG|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
214975904|NCT00680329|DEVICE|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
214975905|NCT01571960|BIOLOGICAL|GEO-D03 DNA vaccine|Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
214975906|NCT01571960|BIOLOGICAL|MVA/HIV62B (MVA62B) vaccine|1 x 10\^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
214975907|NCT01571960|BIOLOGICAL|Placebo for GEO-D03 DNA|Administered as a 1-mL IM injection into the deltoid
214975908|NCT01571960|BIOLOGICAL|Placebo for MVA62B:|Administered as a 1-mL IM injection into the deltoid
214975909|NCT02007317|DRUG|Oshadi D & Oshadi R|Anti tumor agents
214975910|NCT00496769|DRUG|Apixaban|Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
214491313|NCT06302530|PROCEDURE|Gastro-Soleus|This technique adapts the Strayer technique to include the soleus. Under local anesthesia, access is gained 4-5 cm distal to the medial head of the gastrocnemius. Transection of the gastrocnemius aponeurosis and a superficial section of the soleus tendon are performed, all under ultrasound guidance. Without the need for sutures, the patient wears a Walker boot for 4 weeks and follows a progressive rehabilitation protocol.
214491314|NCT03416530|DRUG|Dordaviprone (ONC201)|Dordaviprone is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
214975911|NCT00496769|DRUG|Acetylsalicylic acid|Tablets, oral, 81-324 mg, once daily, up to 156 weeks
214365567|NCT03953235|BIOLOGICAL|ipilimumab|anti-CTLA-4 monoclonal antibody
214365568|NCT04465019|DEVICE|Exoskeleton Rehabilitation|The EKSO GT® was operated by a Licensed Physical Therapist who was certified to control the device. We followed a strictly established protocol for operating the device during the rehabilitation process as established by the company.
214365569|NCT06087341|OTHER|NKG2D-CAR memory T cell|Patients will be allocated in two groups: Arm A and Arm B. Both groups will receive an intravenous infusion of NKG2D-CAR memory T cells. Additionally, patients on Arm B will receive an intratumoral dose of NKG2D-CAR memory T cells (in accessible primary tumor and metastases). The distribution of patients on one arm or other will depend on their clinical characteristics described in the inclusion/ exclusion criteria. All patients will receive lymphodepleting chemotherapy prior to the infusion of NKG2D-CAR memory T cells according to the usual clinical practice in our center. Some patients will also receive low dose radiotherapy prior to infusion.
214365570|NCT04620291|BIOLOGICAL|UB-421 SC|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
214365571|NCT03520595|DRUG|Arnica 200 drug 3 pills,3 times daily for 3 days|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
214365572|NCT03520595|DRUG|Diclofenac Sodium 50mg twice daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
214491315|NCT03424525|DRUG|11C-Trimethoprim|\[11C\]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
214975912|NCT02486692|OTHER|AboutFace Website|AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and different treatments for PTSD.
214365573|NCT03520595|DRUG|Placebo pills and distilled water 3 pills,3 times daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
214975913|NCT00699777|DRUG|Risedronate|1 risedronate 150 mg tablet administered orally
214975914|NCT00699777|DRUG|Risedronate|2 risedronate 75 mg tablets administered as a single oral dose
214975915|NCT02344329|DEVICE|Topical wound dressing|Topical Wound Dressing
214365574|NCT04710745|DIAGNOSTIC_TEST|Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers.|Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).
214365575|NCT04710745|DIAGNOSTIC_TEST|Echocardiography|"ECHO parameters:~* E/e´~* Mean e' septal and lateral wall~* LA volume (Biplane Area-Length Method)~* Left atrial volume index~* Diameter of left atrium in PLAX~* Severe aortic stenosis~* Severe mitral regurgitation~* Severe tricuspid regurgitation~* Left ventricular end-diastolic diameter~* Interventricular septum~* Posterior wall~* LV Mass~* Left ventricular mass index"
214975916|NCT02344329|BIOLOGICAL|Human Amnion Allograft|Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
214975917|NCT02344329|OTHER|usual wound care|assessment, wound cleansing, debridement, moist wound environment, and off-loading
214975918|NCT04967053|PROCEDURE|sleeve gastrectomy|Laparoscopic sleeve gastrectomy gives long-standing improvement or resolution of obesity-related conditions and also survival benefit. It is highly cost-effective. Surgical procedures for the treatment of obesity.
214975919|NCT02477176|OTHER|Discectomy|Lumbar discectomy
214975920|NCT03278574|PROCEDURE|Mitral valve repair|Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
214975921|NCT03278574|DEVICE|Ring annuloplasty with posterior band|Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
214975922|NCT03278574|DEVICE|Ring annuloplasty with complete ring|Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
214975923|NCT06102317|OTHER|nursing consultancy with smartphone support|In the study, mobile application will be installed on the phones of the mothers in the initiative group and individual information will be provided about how the patients will use the smartphone application. . Information will be provided to patients for subsequent follow-ups. After the application is started to be used, notifications of the applications developed in Smart Mobile for the disease management process will be made to the mothers of the Initiative Group every two weeks for six months. In addition, the Initiative Group will continue to receive standard care practices such as examinations, examinations, tests, treatment, medical care and rehabilitation offered by the Home Health Services unit.
214975924|NCT01056692|DRUG|OC000459|Capsules twice daily for 15 days
214975925|NCT01056692|DRUG|Placebo|Capsules twice daily for 15 days
214975926|NCT00648180|DRUG|Doxycycline Monohydrate Tablets 100 mg|100mg, single dose fed
214975927|NCT00648180|DRUG|Adoxa Tablets 100 mg|100mg, single dose fed
214491316|NCT06770595|BEHAVIORAL|breastfeeding positions and attachment practice.|Breastfeeding clinical demonstration is a method of presentation of skills that shows how a particular procedure is performed in position and attachment breastfeeding. Respondents in this group will receive education provided face-to-face once with a duration of 40 minutes, with the following details: first, 25 minutes of education about breastfeeding position and attachment. In this case, the lactation counselor first explains the correct position and attachment for breastfeeding. Respondents were asked to carry out a practical simulation regarding the correct breastfeeding position and attachment using a doll, in this case, the lactation counselor will assess how the mother is positioned and attached. second, 10 minutes of education about swollen breasts and how to deal with them. third, a 10-minute question and answer session related to the educational material provided.
214491317|NCT05953948|OTHER|Intelligent Case Manage Platform (ICMP) and self-management program|This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
214975928|NCT00004862|BIOLOGICAL|filgrastim|
214975929|NCT00004862|BIOLOGICAL|oblimersen sodium|
214975930|NCT00004862|DRUG|cytarabine|
214975931|NCT00004862|DRUG|fludarabine phosphate|
214975932|NCT02644044|DRUG|Intrathecal methotrexate|12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
214975933|NCT00125450|PROCEDURE|Chest Physiotherapy with Forced Expiratory Technique|Chest Physiotherapy with Forced Expiratory Technique
214975934|NCT00125450|PROCEDURE|Nasopharyngeal Aspiration|Nasopharyngeal Aspiration
214975935|NCT00607243|BIOLOGICAL|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
214365576|NCT04710745|DIAGNOSTIC_TEST|ECG Holter monitor|Patient receives an ECG Holter for a 7-day monitoring.
214365577|NCT04710745|DIAGNOSTIC_TEST|Standardized Mini-Mental Status Exam (SMMSE)|A screening test for evaluating cognitive performance of patients done in the clinician's office.
214365578|NCT04879290|OTHER|FiO2 0.5|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 0.5 (50%)
214365579|NCT04879290|OTHER|FiO2 1|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 1 (100%)
214365580|NCT02028026|DRUG|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
214365581|NCT02028026|DRUG|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks
214365582|NCT02521662|DRUG|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
214365583|NCT02521662|DEVICE|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
214365584|NCT02521662|DRUG|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
214365585|NCT02521662|BEHAVIORAL|Behavioural support|Withdrawal-oriented behavioural support
214365586|NCT01844284|DEVICE|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
214491318|NCT06830434|PROCEDURE|Crown lengthening surgery|Following clinical and radiographic examinations and thorough case planning, surgical procedures were performed under local anesthesia by a single operator. After anesthesia, the distance from the gingival margin to the cementoenamel junction will be measured, and these values will be transferred to the gingival tissue to guide the procedure. Excess gingival tissue will be excised, and, when necessary, an osteotomy will be performed to re-establish the supracrestal attachment tissues.
214491319|NCT05663346|OTHER|Cannabis & Cancer digital educational intervention|The Cannabis \& Cancer intervention is available on Moodle learning management system in French language. It aims to influence nurses' self-efficacy, attitudes, intentions, and knowledge regarding the safe and efficient use of cannabis by young adults diagnosed with cancer.
214679758|NCT06318923|OTHER|Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment|"The demographic questionnaire collects demographic information: gender, age, level of education, laterality, history of psychiatric or neurological disorders.~The moral judgment task consists in completing 20 vignettes of moral dilemmas. Cognitive disorders will be assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. If the patient has taken the BICAMS battery recently (less than 6 months), and with no change in pathology since then, the results of these tests will be used in this study.~Affective disorders will be assessed using the following tests:~* The Beck Depression Inventory-Fast Screen (BDI-FS) to assess the level of depression,~* State trait anxiety inventory-Y (STAI-Y) to assess anxiety,~* Toronto Alexithymia Scale-20 (TAS-20)to assess alexithymia,~* The Empathy Quotient-8 (EQ-8) to assess participants' level of empathy,~* The Dot Probe Task to assess participants' emotional information processing style."
214975936|NCT01127100|DRUG|transdermal fentanyl matrix, gabapentin|"transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained."
214975937|NCT02118103|PROCEDURE|Spinal Manipulation|Lumbar spinal manipulation
214975938|NCT04271124|OTHER|exercise training|The patients are allocated to PR+ET group or PR Each group receive an exercise training
214975939|NCT01799759|BEHAVIORAL|Online intervention|Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
214975940|NCT01799759|OTHER|Completion of instruments only|Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
214975941|NCT04970212|DEVICE|BioTraceIO Lite|The BioTraceIO software will analyze the ultrasound images, and provide the physician with an estimated tissue damage map.
214975942|NCT02812186|PROCEDURE|Deep to Moderate NMB|"Rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a moderate NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade."
214975943|NCT02812186|PROCEDURE|Moderate to Deep NMB|"Rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 (deep NMB) the infusion will be adjusted to maintain the patient at this level of NMB."
214975944|NCT02812186|DRUG|Rocuronium|
214975945|NCT02184819|DRUG|levosimendan|24 hour continuous infusion at the rate of 0,1 µg/kg/min
214975946|NCT02184819|DRUG|Placebo|24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
214975947|NCT04897386|DRUG|Duvalizumab|Pemetrexed 850 mg, IV, Day1; Platinum 50mg / m2, IV, day1, once every 3 weeks, duvalizumab treatment, 1500mg, day1, a total of 4 cycles, once every 3 weeks. 4 cycles in total
214975948|NCT00956436|DRUG|BIIB022|IV Q3W
214975949|NCT00956436|DRUG|Sorafenib|Standard dosing of Sorafenib
214975950|NCT03273478|DEVICE|Endovascular treatment of bifurcation aneurysm with pCONUS2|"Patients suffering from a bifurcation aneurysm will be treated endovascularly with the pCONUS2 device.~* The patients do not face any additional risks by participating in the study as the treatment does not differ from the standard of care in any way.~* The patients will only be enrolled in the study if they give their written consent.~* If they do not wish to participate in the observational study or if they wish to withdraw from it at a later date, they will not have any disadvantages."
214975951|NCT01347463|PROCEDURE|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
214975952|NCT00455286|DRUG|Methotrexate|
214975953|NCT00455286|DRUG|Methylprednisolone|
214975954|NCT00455286|DRUG|Temozolomide|
214975955|NCT01614301|DRUG|dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus|"Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity"
214975956|NCT02425137|DRUG|S-1/Gemcitabine|Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
214975957|NCT00945841|BIOLOGICAL|inactivated split influenza vaccine|1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
214365587|NCT01844284|DEVICE|Absorb™ BVS|Subjects receiving Absorb™ BVS
214365588|NCT00611858|DRUG|Cetuximab|
214365589|NCT00611858|DRUG|5-Fluorouracil|
214365590|NCT00611858|RADIATION|Radiation|
214365591|NCT04519086|RADIATION|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis in patients with BMI \>30
214365592|NCT04519086|PROCEDURE|Laparoscopic appendectomy|All patients with BMI \>30, who are diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
214975958|NCT01307787|OTHER|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
214975959|NCT01307787|OTHER|no intervention|waiting list control group with no intervention
214975960|NCT02586376|DEVICE|0J LLLT|Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
215084949|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 70% 1RM combined with complex training|This group of subjects first performed 3 sets of 70% 1RM squats after a routine warm-up, 3 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
215084950|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 80% 1RM combined with complex training|This group of subjects first performed 3 sets of 80% 1RM squats after a routine warm-up, 2 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
215084951|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 90% 1RM combined with complex training|This group of subjects first performed 3 sets of 90% 1RM squats after a routine warm-up, 1 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
214365593|NCT04701463|DIETARY_SUPPLEMENT|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate|2 daily sachets (mid morning and mid afternoon) of an oral dietary supplement with L-glutamine and L-arginine and calcium beta-hydroxy-beta-methylbutyrate
214365594|NCT04701463|COMBINATION_PRODUCT|Placebo|Isocaloric formula
214365595|NCT05782725|OTHER|Comparison of laboratory test results in women in the 4 study arms|Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms
214365596|NCT00541918|DRUG|Diprivan (propofol, Astra Zeneca)|Total intravenous anesthesia with propofol
214365597|NCT00541918|DRUG|Sevorane (sevoflurane, Abbott)|inhaled anesthesia with sevoflurane
214365598|NCT02361125|DRUG|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
214365599|NCT02361125|BEHAVIORAL|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
214365600|NCT02960399|BIOLOGICAL|Zostavax®|Zostavax® immunization
214365601|NCT04735744|OTHER|Patients recovering from COVID19 receive usual care by allied health professionals|We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
214365602|NCT01187979|BEHAVIORAL|Cash incentives|Cash incentives paid to learners for reaching pre-determined milestones
214491320|NCT05663346|OTHER|Standard information regarding cannabis use in oncology|Participants will be offered basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
214491321|NCT06401031|DEVICE|Press Needle|Press needle is patch-type acupuncture needle which has a very small needle. This is placed onto acupuncture point and give a simultaneous stimulation, which is held in place with a small, sterile surgical adhesive patch.
214491322|NCT06401031|DEVICE|Sham Press Needle|Sham press needle is a surgical adhesive patch without needle, that is placed onto acupuncture point
214491323|NCT05065281|OTHER|Education|Training for health care professionals on how to identify and manage cases of elder abuse among their patients
214491324|NCT06889558|PROCEDURE|tenting titanium technique|technique used to increase bone augmentation and increase bone volume
214365603|NCT01187979|BEHAVIORAL|Life skills curriculum|Standard department of education lifeskills curriculum
214365604|NCT03172702|DRUG|Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
215084952|NCT06083532|BEHAVIORAL|Routine warm-up combined with complex training|This group of subjects first completed a 30-minute routine warm-up, then rested for 6 minutes, and then performed complex training consisted of maximum strength training (back squats) and plyometric training (drop jump). Back squat intensity \& repetition is 80% 1RM × 4, 4 sets, with an interval of 2 minutes; after resting for 3 minutes, perform a drop jump, Intensity \& Repetition is 50cm (height) × 10, 4 sets, with an interval of 2 minutes. Intervention training was conducted twice weekly for 12 weeks, and the intensity was gradually increasing over the 12 weeks.
215084953|NCT05190601|DEVICE|uroflowmetry|Qmax(ml/s),Qav(ml/s),Volume (ml)
214365605|NCT05458375|DRUG|Estradiol vaginal cream|Insert pea-sized amount of vaginal estradiol cream into vagina nightly for first two weeks and then twice weekly thereafter.
214365606|NCT01682993|OTHER|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
214365607|NCT01682993|OTHER|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
214365608|NCT02084459|BEHAVIORAL|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
214491325|NCT06889558|PROCEDURE|tenting titanium screw|technique used for increase bone voliume
214491326|NCT06763718|OTHER|Modified Qigong Breathing Exercise|"The exercise is recommended to be performed standing, or modified standing with trunk leaning forward and bilateral upper extremities support on countertop. Initial position: Stand up with feet shoulder-width apart, hands down along the body, or put palms on the abdomen. Take a deep breath, squaring shoulders, and pull in belly at the same time. Hold breath for 3 to 4 seconds, while keeping abdomen retracted with maximally contracting abdominal muscles. Exhale, so the shoulders go back to the starting position, while chest and abdominal muscles relax. Repeat this exercise 10 times. Note. If the stomach is difficult to draw in a standing position, it is possible to perform the exercise with both hands resting on support.~Duration: 30 minutes, 3 days/ week for 8 weeks"
214975961|NCT02586376|DEVICE|4J LLLT|4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.
214975962|NCT02586376|DEVICE|6J LLLT|6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.
214975963|NCT02586376|DEVICE|8J LLLT|8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
214975964|NCT01547715|BIOLOGICAL|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine
214975965|NCT06481787|DRUG|Vonorasan Fumarate|Vonorasan fumarate is taken 30min before breakfast and dinner.
214975966|NCT06481787|DRUG|Zuojin Pills|Zuojin Pills should be taken 30min after breakfast and dinner.
214975967|NCT02309086|BIOLOGICAL|Autologous dendritic cells transduced with Ad encoding NS3|Patients will receive 3 different dosis of the vaccine via subcutaneous injection
214975968|NCT05402709|OTHER|Posterior mobilisation technique|Posterior mobilisation technique were applied
214975969|NCT05402709|OTHER|Posterior capsule stretching|Posterior capsule stretching were applied
215084954|NCT01994772|PROCEDURE|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
215084955|NCT01994772|PROCEDURE|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
214365609|NCT05534022|DEVICE|Test myopia control lenses (BSL)|Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
214365610|NCT06433531|DRUG|TQH2929 Injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
214365611|NCT01186029|DRUG|aprepitant|Emend 40mg by mouth 30 minutes before procedure x 1
214365612|NCT03341078|DRUG|Ibudilast|Ibudilast capsules will be orally ingested twice daily for 6 weeks.
214491327|NCT06763718|OTHER|Control|No exercise will be given to the participants in the control group
214679759|NCT06318923|OTHER|MS questionnaire|This questionnaire collects key information on the participant's pathology: clinical form, date of first symptoms, diagnosis, last attack, as well as latest EDSS and functional scores.
214679760|NCT06318923|OTHER|MONTREAL COGNITIVE ASSESSMENT (MoCA) test|The MoCA is a screening tool for neurocognitive impairment, designed primarily to detect milder impairment. The MoCA is a short-answer questionnaire that includes a number of tasks to be completed by the individual. The items assessed are grouped into six subsections: short-term memory, visuospatial skills, executive functions, attention, concentration, working memory, language and orientation in time and space. The tests proposed are often more complex than those found in the mini-mental state examination (MMSE).
214975970|NCT03614403|DRUG|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
214975971|NCT01739881|DEVICE|Olympus Ultrathin Bronchofibervideoscope (XP260F)|The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.
214975972|NCT00511381|GENETIC|No intervention|No intervention
214975973|NCT06151379|OTHER|Neoadjuvant therapy|To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
214365613|NCT03341078|DRUG|Placebo Oral Tablet|Placebo capsules will be orally ingested twice daily for 6 weeks.
214365614|NCT06134180|BEHAVIORAL|CONFIDENCE-AI|Multicomponent psychoeducational intervention focused on financial wellbeing
214365615|NCT06254469|DRUG|[F-18]Flornaptitril|All participants will receive a single dose of F-18 FNT during an imaging visit.
214975974|NCT01530269|DRUG|C11-Sodium Acetate|PET Imaging with C11-Sodium Acetate
214975975|NCT02198534|DEVICE|Methodology of visual acuity assessment|
214975976|NCT05088772|DEVICE|Hyperbaric Oxygen Therapy|"Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 air breaks, typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference."
215084956|NCT06323798|DIAGNOSTIC_TEST|MRI|Standard paranasal sinus MRI
215084957|NCT01817101|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
215084958|NCT04690803|DRUG|air cooling|intervention is adding air-cooling to treatment
214491328|NCT06791967|BEHAVIORAL|home-based walking program|The home-based walking intervention involves five walking sessions per week over 12 weeks, with a target of 3,000 additional steps per session beyond daily activities. In the first week, participants in the experimental group will wear a smart wristband upon waking to record their average daily steps, which will guide their walking goals. By the 7th week, participants are expected to achieve at least 3,000 extra steps per session, completed in 30 continuous minutes. The wristband, synced via Bluetooth to its companion app, can store up to one month of walking data. Weekly phone follow-ups will record participants' daily step counts. No additional cloud uploads of personal data are required.
214491329|NCT06893289|OTHER|Exercise|Balance and proprioceptive exercises
214491330|NCT06893289|OTHER|Muscle strengthening|Strengthening of the lower limb muscles
214491331|NCT06858384|OTHER|Control (Standard treatment)|Participants in this arm will continue with their usual care without any pharmacist-led intervention during the 6-month study period. Physicians and patients will follow the standard clinical practice for PPI prescriptions. At the end of the 6-month period, the educational materials provided to the intervention group will be offered to the control group.
214491332|NCT06858384|OTHER|Pharmacist-Led Educational Intervention|Physicians and patients in this arm will receive a multi-faceted pharmacist-led educational intervention. This includes evidence-based deprescribing guidelines, brochures, videos, and decision aids to promote appropriate use of PPIs and reduce unnecessary prescriptions. The intervention is delivered in four parts: educational brochures, deprescribing algorithm, patient action plans, and video-based education sessions.
214975977|NCT01125098|OTHER|PRO-CT values|"* continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection~* continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability~* stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability~* stop antibiotics if all the PRO-CT values are \< 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value \< 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection."
215084959|NCT04790513|BIOLOGICAL|lerodalcibep|anti-PCSK9 small binding protein
215084960|NCT04790513|BIOLOGICAL|evolocumab|monoclonal antibody to PCSK9
215084961|NCT04790513|BIOLOGICAL|alirocumab|monoclonal antibody to PCSK9
215084962|NCT02403895|DRUG|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
214975978|NCT01965327|DRUG|Interferon Gamma-1b|"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection."
214975979|NCT00482937|DRUG|CD-NP|
214975980|NCT03342001|DRUG|Calcitonin|calcitonin nasal spray
214975981|NCT03980548|PROCEDURE|CABG|Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
214975982|NCT05036213|DRUG|BEET IT - Concentrate Beet root juice|Each bottle contains 75ml of concentrated beetroot juice with approximately 6.2mmol of inorganic nitrate. The product is provided by BEET IT, James White Drinks, Ipswich, UK.
214975983|NCT05036213|DRUG|BEET IT - Concentrate Beet root juice (nitrate depleted)|Each bottle contains 75ml of concentrated beetroot juice with depleted nitrate, thus, no inorganic nitrate is found in thisbeverage. The product is also provided by BEET IT, James White Drinks, Ipswich, UK.
215084963|NCT02403895|DRUG|paclitaxel|Taxane
214365616|NCT06543056|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 24 months.
214365617|NCT02152982|OTHER|Laboratory Biomarker Analysis|Correlative studies
214365618|NCT02152982|OTHER|Placebo Administration|Given PO
214365619|NCT02152982|OTHER|Quality-of-Life Assessment|Ancillary studies
214365620|NCT02152982|DRUG|Temozolomide|Given PO
214975984|NCT03477162|DRUG|Metformin|Metformin will be given to patients prior to surgery.
214975985|NCT01507181|DRUG|Ketamine|single dose IV ketamine, .5mg/kg infused over 40 minutes
214975986|NCT01507181|DRUG|Midazolam|single dose IV midazolam, .45mg/kg infused over 40 minutes
214365621|NCT02152982|DRUG|Veliparib|Given PO
214365622|NCT04377555|DRUG|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
214975987|NCT04161391|DRUG|TPX-0046|Oral TPX-0046 capsules
215084964|NCT02962596|OTHER|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
215084965|NCT03095586|OTHER|News items with spin|Interpretation of news items with spin
215084966|NCT03095586|OTHER|News items without spin|Interpretation of news items without spin
215084967|NCT02129478|DRUG|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
215084968|NCT02813668|BEHAVIORAL|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
214365623|NCT04697576|BIOLOGICAL|Ipilimumab|immune checkpoint inhibitor
214365624|NCT04697576|BIOLOGICAL|Nivolumab|immune checkpoint inhibitor
214365625|NCT04697576|BIOLOGICAL|Pembrolizumab|immune checkpoint inhibitor
214365626|NCT04697576|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Given IM and intratumorally. For this protocol the U.S. F.D.A recently approved the use of recently expired influenza vaccine (only until new seasonal vaccine is available anticipated Sept 1). Use of expired vaccine will not exceed 4 months past June 30th expiry date (October 30th).
214975988|NCT03136393|BEHAVIORAL|Community based dietary counselling|The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
214365627|NCT04697576|PROCEDURE|Resection|Undergo surgical resection
214365628|NCT04697576|BIOLOGICAL|Nivolumab + Relatlimab|immune checkpoint inhibitor
214365629|NCT02141763|DRUG|UCB4940 40 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
214365630|NCT02141763|DRUG|UCB4940 80 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
214365631|NCT02141763|DRUG|UCB4940 160 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
214365632|NCT02141763|DRUG|UCB4940 240 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
214365633|NCT02141763|DRUG|UCB4940 320 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
214365634|NCT02141763|DRUG|UCB4940 560 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
214365635|NCT02141763|OTHER|Placebo|"* Pharmaceutical Form: solution~* Concentration: 0.9 % sodium chloride~* Route of Administration: intravenous"
214365636|NCT05374954|BIOLOGICAL|Omicron COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
214365637|NCT05374954|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
214365638|NCT01870193|DIETARY_SUPPLEMENT|Glycine, cysteine (as n-acetylcysteine), alanine|"Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months"
214491333|NCT06801600|DRUG|Weight-based dosing|Hyperbaric bupivacaine 0.5% dosage will be calculated and administered intrathecally as 0.4 mg/kg or 0.08 ml/kg if body weight ≤ 15 kg and 0.3 mg/kg or 0.06 ml/kg if body weight \> 15 kg
214491334|NCT06801600|DRUG|Age-based dosing|Hyperbaric bupivacaine 0.5% will be administered at the dose of age divided by 5 (in ml). The age in months after the completion of a year was noted and considered as the next age if it is more than 6 months and the same age if it is ≤ 6 months.
214491335|NCT06834958|PROCEDURE|Appendectomy|Open surgery for appendix which is inflamed
214491336|NCT06886490|OTHER|Mediterranean diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Mediterranean diet: Animal : vegetable protein ratio - 70:30.
214491337|NCT06886490|OTHER|Planetary diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Planetary diet: Reduce consumption of red meat, moderate consumption of poultry, fish and seafood and their products, and eggs and dairy. Animal : vegetable protein ratio - 50:50
214365639|NCT06191419|OTHER|Odorants|Each smoker is assigned a CPAP nose mask. Odor sample bags are attached to the mask. Smokers open the valve, inhale once through the nose, close the valve, remove the bag from the mask and report on the odor.
214365640|NCT03892993|OTHER|Decision Aid|Use decision aid
214365641|NCT03892993|OTHER|Questionnaire Administration|Ancillary studies
214365642|NCT00432250|PROCEDURE|Cervical length ultrasound|
214365643|NCT03065387|DRUG|Everolimus|Given PO
214365644|NCT03065387|DRUG|Neratinib|Given PO
214365645|NCT03065387|DRUG|Palbociclib|Given PO
214365646|NCT03065387|DRUG|Trametinib|Given PO
214365647|NCT06412653|DRUG|Zinc Acetate Dihydrate|In this single arm trial, all participants will be receive the trial drug zinc acetate dihydrate orally. The Investigational medicinal product (IMP) will be given one hour after meal in a dosage which is recommended in Wilson Disease and has been given in this condition without observing severe adverse effects. If oral administration is not possible due to the disability level of the patient, the IMP can be mortared and suspended and can then be given as suspension orally or via the Percutaneous endoscopic gastrostomy. The total treatment duration in each patient is 6 months with stable dosage over the duration of the trial. If the therapy shows effects, the parents and participants may continue medication after the end of the trial. If not, they will stop the medication after the last visit at the trial site.
214365648|NCT03586661|DRUG|Copanlisib|Given IV
214365649|NCT03586661|DRUG|Niraparib|Given PO
214975989|NCT03136393|BEHAVIORAL|Community based antenatal counselling|The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
214365650|NCT05917652|BEHAVIORAL|Tool kit|The study team will develop and design key elements of the implementation intervention (toolkit) among a small group of burn and non-burn clinician stakeholders (4-6 total). The study team will use in-person interviews with stakeholders and a semi-structured interview guide to elicit feedback and assess face and content validity of the toolkit elements prior to deployment across the study hospitals. For those who consent to participation, the study team will conduct virtual teleconference interviews in-person using a secure videoconferencing platform while the person is not working, at a time convenient for them. Interviews will last between 45 and 60 minutes. The study team anticipates conducting 4-6 interviews to finalize toolkit elements prior to implementation.
214365651|NCT04026295|BEHAVIORAL|Short Burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Total duration of walking per session will be up to 30 minutes of the 30 second alternating intervals (30sec high / 30sec low/moderate) with rests as needed. Both groups will receive 40 sessions delivered 5x/week for 8 weeks. Initial speeds for high speed walking will be 75-80% of each participant's over ground baseline fast walking speed, and low/moderate speed will be 75-80% of self-selected speed calculated from the 10-Meter Walk Test.
214365652|NCT04026295|BEHAVIORAL|Traditional Locomotor Treadmill Training (TLTT)|TLTT group will receive the same number of sessions (40) delivered 5x/week for 8 weeks with a total duration of walking per session up to 30 minutes with rests as needed. TLTT will consist of walking at steady-state speeds. Initial treadmill speed will be 75-80% of over ground self-selected walking speed. The overall goal will be to achieve 30 minutes of walking at a steady-state walking speed within each session. Speed will be increased on the next session by .1 to .4mph when the subject can walk for 30 minutes on the treadmill at the current speed with an OMNI score of \< 6/10.
214365653|NCT05141019|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.
214365654|NCT04345393|BEHAVIORAL|Digital Transformation Network (DTN) Program|Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.
214365655|NCT04889573|GENETIC|Blood sample|The blood samples will be collected from healthy volunteers : 7 tubes of 7 ml with anti-coagulant Héparine Lithium and 1 tube of 7ml with anti-coagulant EDTA
214365656|NCT06250270|DIETARY_SUPPLEMENT|protein or placebo|casein protein (30g) or placebo (maltodextrin, 30g)
214365657|NCT06231355|DRUG|Performing paravertebral nerve block with lipo-bupivacaine|Paravertebral block is performed using liposomal bupivacaine.
214365658|NCT06231355|DRUG|Performing paravertebral nerve block with bupivacaine|Paravertebral block is performed using bupivacaine.
214365659|NCT01409161|DRUG|Arsenic Trioxide|Given IV
214365660|NCT01409161|DRUG|Gemtuzumab Ozogamicin|Given IV
214365661|NCT01409161|OTHER|Laboratory Biomarker Analysis|Correlative studies
214365662|NCT01409161|DRUG|Tretinoin|Given PO
214365663|NCT05617313|DRUG|Pembrolizumab|200 mg intravenously on Day 1 of cycle.
214365664|NCT05617313|DRUG|GT103|10mg/kg taken intravenously on Day 1 of cycle.
214365665|NCT06464653|DEVICE|Forel's Field H-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy. The targets used in this study is Forel's Field H. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
214365666|NCT05046301|PROCEDURE|Biospecimen Collection|Correlative studies
214365667|NCT05046301|OTHER|Contrast Agent|Given IV
214365668|NCT05046301|PROCEDURE|Contrast-Enhanced Mammography|Undergo contrast-enhanced mammography
214365669|NCT05046301|OTHER|Questionnaire Administration|Ancillary studies
214365670|NCT03854071|OTHER|intravenous fluid challenge|Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability
214365671|NCT04628442|PROCEDURE|Sinonasal Debridement Procedure|This is a medical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
214365672|NCT04628442|PROCEDURE|Nasal Polyp Removal|This is a surgical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
214365673|NCT04628442|PROCEDURE|Biopsy|A biopsy is optional and will remove a sample of inferior turbinate tissue from the nasal passage. It will be performed during a nasal polyp removal surgery already scheduled for patient care.
214365674|NCT04153227|DIAGNOSTIC_TEST|Bone mineral density (BMD)|Bone mineral density (BMD) is measured by Dual-energy X-ray absorptiometry (DXA). BMD provides a measure of bone mass.
214365675|NCT04153227|DIAGNOSTIC_TEST|Trabecular bone score (TBS)|The Trabecular Bone Score (TBS) is a novel gray-level texture measurement that can be extracted from DXA images. TBS provides a measure of bone quality (bone microarchitecture).
214365676|NCT04153227|DIAGNOSTIC_TEST|Fracture risk Assessment Tool (FRAX)|The Fracture risk Assessment Tool (FRAX) is a fracture risk calculator that estimates an individual's 10-year probability of incurring a hip or other major osteoporotic fracture.
214491338|NCT06886490|OTHER|Lactovegetarian diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Lactovegetarian diet: Reduce consumption of meat, fish and seafood and their preparations, and eggs and dairy products. Animal : vegetable protein ratio - 30:70.
214491339|NCT06886490|OTHER|Vegan diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Vegan diet: Excludes all animal and animal-derived products (meat, fish, seafood, dairy, eggs, honey).
214491340|NCT06886490|OTHER|Control diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Control diet: Reduce consumption of red meat, consumption of poultry, fish and seafood and their products, regular consumption of eggs and dairy products.
214491341|NCT06790108|DEVICE|Artificial intelligence device|This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
214975990|NCT03991390|OTHER|Visual Feedback and Core Stability exercises protocol|"This arm consists of 5 sessions per week, 60 minutes each. One session consists of 30 minutes of conventional physiotherapy and 30 minutes of Core Stability exercises and laser visual feedback exercises, on alternate days.~All sessions will be performed by the same physiotherapist."
214975991|NCT03991390|OTHER|Control stroke|"This arm consists of 5 sessions per week, 60 minutes each comprising usual physiotherapy treatment.~All sessions will be performed by the same physiotherapist."
214975992|NCT02355678|DRUG|dexamethasone|IV 0.5 mg/kg
214975993|NCT02355678|DRUG|Local anesthetic infiltration|Using 25 G-3.5 cm curved needle
214975994|NCT02355678|DRUG|General anesthesia|"Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).~Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%."
214975995|NCT02355678|PROCEDURE|Tonsillectomy|Mono-polar electrocautery or cold dissection
215084969|NCT06051747|PROCEDURE|Three-dimensional patient-specific bioprinting trachea implantation|The intervention entails the creation of a 3D cell-printed tracheal organ, achieved through the fusion of biopolymer materials and the bioprinting (3D cell printing) technique. This process involves distribution of nasal cavity stem cells (hNTSCs) and nasal septum cartilage cells (hNCs) within hydrogel matrices, culminating in the formation of a personalized tracheal structure.
214365677|NCT06013878|OTHER|Transfer Training with clinician|Participants will undergo transfer training with a clinician who is an expert on assisted transfer techniques if they are found to have skill deficits during the study. After training, a transfer assessment will be conducted to examine if the transfer skills of the caregiver have improved
214365678|NCT05809635|OTHER|Natural History Study|Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
214365679|NCT03844620|OTHER|Best Practice|Receive SOC
214365680|NCT03844620|OTHER|Laboratory Procedure|Undergo ctDNA testing
214975996|NCT02355678|PROCEDURE|gastric content suction|By orogastric tube
214975997|NCT02355678|DRUG|Tramadol hydrochloride|If Visual Analogue Scale was greater than 5
214975998|NCT02355678|DRUG|Propacetamol hydrochloride|If Visual Analogue Scale was between 4 and 5
214975999|NCT02355678|DRUG|Paracetamol Suppository|If Visual Analogue Scale was less than 4
214976000|NCT01980953|DRUG|GDC-0032 Phase III Tablet|Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
214976001|NCT01980953|DRUG|GDC-0032 Tablet|Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
214976002|NCT01980953|DRUG|GDC-0032 Capsule|Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
214976003|NCT02785393|DRUG|Sugar Pill|The administration of a sugar pill
214365681|NCT03844620|OTHER|Quality-of-Life Assessment|Ancillary studies
214365682|NCT03844620|OTHER|Questionnaire Administration|Ancillary studies
214365683|NCT03844620|DRUG|Regorafenib|Given by mouth
214491342|NCT06793683|DRUG|Bladder chemodenervation (Botox)|BoNT-A (Botox) 200 U will be injected into the detrusor (bladder wall muscle).
214491343|NCT06793683|PROCEDURE|Bladder Sham (Saline) Injection Procedure|20mL placebo (saline only), will be injected into the detrusor (bladder wall muscle).
214491344|NCT04884542|DEVICE|Revision Total Knee Arthroplasty|Total Knee Arthroplasty in case of failure of a previous operation.
214976004|NCT02785393|DRUG|Doxazosin|The administration of the Doxazosin medication
214976005|NCT05684848|DEVICE|Resveratrol + CMG|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
214976006|NCT05684848|DEVICE|Isotonic solution|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
214976007|NCT05037630|BEHAVIORAL|Self-guided Digital Tool for Problematic Alcohol Use|See arm/group-description
214976008|NCT00419185|PROCEDURE|Delamination of the Internal limiting membrane|
214976009|NCT03316846|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|
214976010|NCT03713463|OTHER|Oral Nutritional Supplement (ONS)|Per standard of care (SOC)
214365684|NCT03844620|DRUG|Trifluridine and Tipiracil Hydrochloride|Given by mouth
214365685|NCT05338658|DRUG|Peptide Alarm Therapy (PAT)|PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.
215084970|NCT00004142|DRUG|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
215084971|NCT00004142|DRUG|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
215084972|NCT00004142|PROCEDURE|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
215084973|NCT00004142|PROCEDURE|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
215084974|NCT02829892|DEVICE|Light therapy|14-days exposure with an innovative ambient light
214976011|NCT02657330|DRUG|SBP-101|Subcutaneous drug, escalating dose cohorts
215084975|NCT00145353|DRUG|Insulin NovoRapid versus Actrapid|
214976012|NCT01003106|DRUG|Ranibizumab 0.5mg (monthly)|Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
214976013|NCT01003106|DRUG|Ranibizumab 2.0mg (monthly)|
214976014|NCT01003106|DRUG|Pro re nata (prn) ranibizumab|
214976015|NCT01003106|PROCEDURE|Pro re nata (prn) Laser photocoagulation|
214976016|NCT01669434|DRUG|ACEI continuation|These chronic medications will be taken without interruption preoperatively.
214976017|NCT01669434|DRUG|ACEI omission|Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
214976018|NCT06200012|BEHAVIORAL|Multi-level stigma reduction intervention: educational training plus controlled substance agreement policy change|Pairing a professional training targeting known attitudinal and knowledge drivers of substance use stigma with a policy altering potentially stigmatizing features of controlled substance agreements.
214976019|NCT06200012|BEHAVIORAL|Single-level stigma reduction intervention: educational training|A professional training targeting known attitudinal and knowledge drivers of substance use stigma
214976020|NCT03794492|DRUG|Mycophenolate mofetil 500mg Tab. or 250mg Cap.|\- Orally, up to 1g BID(total 2g daily)
214976021|NCT03794492|DRUG|Tacrolimus|\- Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml
214976022|NCT03794492|DRUG|Methylprednisolone/prednisolone|\- Methyprednisolone 500mg / Prednisolone 5mg
214976023|NCT03794492|DRUG|Basiliximab|\- IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)
214976024|NCT00947206|BEHAVIORAL|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
214976025|NCT00947206|BEHAVIORAL|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
214976026|NCT06332222|DIETARY_SUPPLEMENT|Tart Cherry|7 day supplementation
214976027|NCT06332222|OTHER|Placebo|7 day supplementation
214976028|NCT01857752|DRUG|Temozolomide|
214976029|NCT05199246|DEVICE|Lower-limb powered dermoskeleton|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
214976030|NCT02860988|BEHAVIORAL|MCCC treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
214976031|NCT05423418|BIOLOGICAL|A244|Dose of A244 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
214976032|NCT05423418|BIOLOGICAL|B.63521|Dose of B.63521 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
214976033|NCT05423418|BIOLOGICAL|50μg ALFQ|Dose of ALFQ is 50μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
214976034|NCT05423418|BIOLOGICAL|100μg ALFQ|Dose of ALFQ is 100μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
214976035|NCT05423418|BIOLOGICAL|200μg ALFQ|Dose of ALFQ is 200μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
214976036|NCT00809796|DRUG|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
214976037|NCT02420639|DEVICE|Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.|Use of the Esophageal Cooling Device for control of patient temperature.
215084976|NCT03198455|DIETARY_SUPPLEMENT|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
215084977|NCT03198455|OTHER|Placebo|Drinking water with food coloring and salt
215084978|NCT03426358|DEVICE|LSM assessed by Elastographic Techniques|Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
215084979|NCT05170750|OTHER|Foams|Every subject will perform 24 randomized trials on force platform.
215084980|NCT05170750|OTHER|Foam / Orthopedic insole|3/5 of the initial population will perform static and locomotion task, with randomized conditions.
215084981|NCT02425605|RADIATION|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
215084982|NCT02425605|DRUG|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
215084983|NCT04657640|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) for 3 months intermittently
214491345|NCT06818630|OTHER|SkinCeuticals combination skin care products|"1. CE Ferulic Serum,~2. Discoloration Defense (3% Tranexamic Acid),~3. Triple Lipid Restore 2:4:2"
214976038|NCT01968421|DRUG|OM-85 BV|two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
214976039|NCT05158621|PROCEDURE|blood collection for research (next generation sequencing [NGS])|participants will have whole blood collected for NGS
214365686|NCT03131908|DRUG|GSK2636771|"Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I."
214976040|NCT05158621|PROCEDURE|blood collection for research (HLA typing)|participants will have whole blood collected for HLA typing
214976041|NCT05158621|PROCEDURE|blood collection for research (circulating tumor DNA [ctDNA])|participants will have whole blood collected for ctDNA detection
214976042|NCT02579629|DRUG|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
214976043|NCT02579629|DRUG|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
214976044|NCT02579629|DRUG|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
214365687|NCT03131908|DRUG|Pembrolizumab|Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
214365688|NCT05642468|DRUG|Ritivixibat|10mg tablet A3907 administered orally
214365689|NCT03482479|DRUG|Naltrexone Hydrochloride|Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks
214365690|NCT03482479|OTHER|Placebo Comparator|A placebo tablet which matches the drug will be taken daily for 6 weeks.
214365691|NCT05910385|PROCEDURE|laparoscopy|tubal ligation by laparoscopy or vnotes technique
214365692|NCT05910385|PROCEDURE|vnotes|tubal ligation by laparoscopy or vnotes technique
214365693|NCT04895475|BEHAVIORAL|SARS-CoV-2 vaccine|Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit. Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
214365694|NCT03703856|DRUG|Memantine|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
214365695|NCT03703856|DRUG|Placebo|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
214365696|NCT05493774|OTHER|Multi-person virtual reality simulation scenario training|Using multi-person virtual reality simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
214365697|NCT05493774|OTHER|Multi-person high-fidelity simulation scenario training|Using multi-person high-fidelity simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
214365698|NCT00812786|DRUG|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
214365699|NCT06430424|BIOLOGICAL|Relapsed glioblastoma|Paired tumor samples diagnosis/relapse
214365700|NCT02727296|DRUG|sevoflurane|General anesthesia with sevoflurane
214365701|NCT02727296|DRUG|propofol|General anesthesia with propofol
214365702|NCT06199258|DIAGNOSTIC_TEST|pulmonary function test|pulmonary function testing
214365703|NCT03641313|DRUG|Berzosertib|Given IV
214365704|NCT03641313|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT assisted biopsy
214365705|NCT03641313|PROCEDURE|Endoscopic Biopsy|Undergo endoscopic biopsy
214365706|NCT03641313|DRUG|Irinotecan|Given IV
214365707|NCT03641313|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214365708|NCT04642898|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
214365709|NCT04642898|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
214491346|NCT06818630|OTHER|Regular skin care procedure|"1. Regular moisturizing product (Phyto Corrective Gel),~2. sunscreen (Advanced Brightening UV Defense SPF50 PA++++)"
214491347|NCT06909227|PROCEDURE|surgery under general anesthesia|Only in children, \< 1 year old non-cardiac surgery
214491348|NCT02666898|DRUG|GA101|"Part 1 :6 cycles~Obinutuzumab/GA101:~First cycle:~D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v~Cycle 2 to 6 (every 28 days) :~D1 of every cycle: 1000 mg i.v PART 2 4 cycles~-patients have BM MRD \>10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1"
214491349|NCT02666898|DRUG|Ibrutinib|"Part 1 :6 cycles~Cycle 2 to 6 (every 28 days) :Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles~* patients in CR with BM MRD \< 10-4 : Ibrutinib alone 420mg daily~* patients with BM MRD \>10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine"
214491350|NCT02666898|DRUG|Cyclophosphamide|"PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine"
214491351|NCT02666898|DRUG|Fludarabine|"PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide"
214491352|NCT05252390|DRUG|NUV-868|NUV-868 is an investigational drug for oral dosing.
214491353|NCT05252390|DRUG|Olaparib|Olaparib
214491354|NCT05252390|DRUG|Enzalutamide|Enzalutamide
214491355|NCT05353257|DRUG|HLX10|"Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
214491356|NCT05353257|DRUG|carboplatin/cisplatin-etoposide|"Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice."
214491357|NCT05353257|RADIATION|Thoracic radiotherapy|Standard Thoracic Radiotherapy
214491358|NCT05353257|DRUG|Placebo|Placebo Q3W
214976045|NCT02579629|DEVICE|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
214365710|NCT04642898|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
214365711|NCT03574597|DRUG|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.
214365712|NCT03574597|DRUG|Placebo (semaglutide)|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
214365713|NCT01952223|DRUG|Cabazitaxel|Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
214365714|NCT01952223|RADIATION|Pelvic radiotherapy|"Prostate+pelvic RT (2 Gy fractions, 5 times per week):~* Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
214365715|NCT01952223|RADIATION|prostate radiotherapy|"Prostate-only RT (2 Gy fractions, 5 times per week):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
214365716|NCT03434678|DRUG|Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml|Patient will have their epidural started at the beginning of the surgery and receive fewer opioid drugs. The epidural is continued into the recovery room.
214365717|NCT03434678|DRUG|Propofol+ Rocuronium+ Fentanyl + Inhalational|Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
214365718|NCT03434678|PROCEDURE|Open Pancreaticoduodenectomy|Whipple' Procedure
214365719|NCT04654377|OTHER|Personalised education|Patients will be explained about their disease and possible outcomes based on clinical, biochemical and imaging data.
214365720|NCT05735587|OTHER|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (\~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
214491359|NCT05353257|RADIATION|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
214491360|NCT03997474|BIOLOGICAL|ATL001|ATL001 infusion
214491361|NCT03997474|DRUG|Checkpoint Inhibitor|Nivolumab
214491362|NCT03691220|BEHAVIORAL|Telemetric Intervention|Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
214491363|NCT06215469|DEVICE|Amma Portable Scalp Cooling System (PSCS)|The unit is a compact, mobile refrigeration unit which circulates liquid coolant at low pressure through a special cooling cap on the participant's head, administered during non-investigational, cancer treatment.
214491364|NCT06215469|OTHER|Questionnaires|Quality of Life (QoL) and device usage questionnaires
214491365|NCT04734821|PROCEDURE|Near Infra-Red Fluorescence Guided Surgery|ICG injection around tumor each four direction by endoscopy followed by NIR fluorescence guidance laparoscopic or robotic esophagectomy or gastrectomy
214976046|NCT06037317|DRUG|SY-3505|LTK tyrosine kinase inhibitor
214976047|NCT04795635|DEVICE|CMM + Axon Therapy|transcutaneous magnetic stimulation (tMS)
214976048|NCT05831800|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid balance. It is designed as an adhesive patch with four integrated electrodes. The outer electrodes are used to supply a low current, while the inner electrodes are used for voltage measurements.
214976049|NCT02899520|OTHER|Reference method|Electrostimulation associated to perineal training
214365721|NCT05735587|OTHER|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
214491366|NCT05617300|BEHAVIORAL|Mindfulness-Based Dementia Caregiving|Mindfulness Based Stress Reduction (MBSR) is a standardized program that is both psychoeducation and skills-based, which uses mindfulness meditation practices to help people better cope with their emotions. This study uses a version of MBSR designed specifically for care partners of people living with dementia (PLWD) called Mindfulness Based Dementia Caregiving. Mindfulness Based Dementia Caregiving (MBDC) is a program with 8 weekly 2 hour sessions (plus one extended practice 4 hour retreat) including both formal and informal mindfulness practices, role play, and lectures combined with some dementia-specific education. Participants learn how to incorporate mindfulness practices into day-to-day life to help cope with the challenges and stresses of dementia care.
214365722|NCT04064489|OTHER|TRIPscore|TRIPcast score calculation
214365723|NCT03744793|DRUG|Avelumab|Given IV
214491367|NCT06864507|DRUG|HS-10561|Single and multiple doses of HS-10561 orally
214491368|NCT06864507|DRUG|Placebo|Placebo
214976050|NCT02899520|OTHER|CMP ® method|Method based on Knowledge and Control of Perineum
214976051|NCT05697913|OTHER|Continued treatment adapted to the response|Instead of receiving a pre-specified number of treatment cycles, regardless of the result obtained, in the MRDI-driven treatment group patients continue receiving treatment until reaching a complete remission with negative MRD and Image, changing the therapeutic line if it is not obtained with the line current therapy. In this group of the patients the treatment was stopped only when this degree of deep response was achieved.
214976052|NCT02959801|PROCEDURE|Percutaneous mechanical thrombectomy|Aspirex catheters(Straub Medical AG, Wangs, Switzerland)
214976053|NCT05469646|DRUG|BI 1819479|BI 1819479
214976054|NCT05469646|DRUG|Matching placebo|Matching placebo
214976055|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 10 mg) or placebo
214976056|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 30 mg) or placebo
214976057|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 100 mg) or placebo
214976058|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 300 mg) or placebo
214976059|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 500 mg) or placebo
214976060|NCT04720443|DRUG|NIP292 tablets|NIP292 (oral tablet at dosage 1) or placebo
214976061|NCT04720443|DRUG|NIP292 tablets|NIP292 (oral tablet at dosage 2) or placebo
214976062|NCT01078493|DEVICE|MyCells® (injection of platelet rich plasma)|PRP contains at least 1,000,000 platelets per mm3 or 2-6 times the native concentration of whole blood at a pH of 6.5 to 6.7
214365724|NCT03744793|DRUG|Pemetrexed|Given IV
214365725|NCT00994981|DRUG|magnesium|Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
214365726|NCT00994981|DRUG|normal saline|Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
214365727|NCT03798938|OTHER|plant-based diet|subjects will be placed in plant-based diet and the effect of plant-based diet to the endothelial function will be monitored
214365728|NCT01446081|BEHAVIORAL|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
214365729|NCT06060457|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214365730|NCT06060457|BIOLOGICAL|mRNA-1345|Suspension for injection
214365731|NCT06060457|BIOLOGICAL|Fluzone HD|Suspension for injection
214976063|NCT01082029|DRUG|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
214976064|NCT01082029|DRUG|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
214976065|NCT04686916|DRUG|IP2018|Test drug
214976066|NCT04686916|DRUG|Placebo|Placebo
214976067|NCT04891172|BIOLOGICAL|Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)|"Intervention arm will receive single dose of 0.15g/kg C-IVIG. This will be infused within period of 16 hours intravenously. Additionally, all participants will receive same standard care.~Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics, anti coagulant"
214976068|NCT02516072|OTHER|RIPC|IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
214976069|NCT00830219|DRUG|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg, single dose fed
214976070|NCT00830219|DRUG|Requip® 0.25 mg Tablets|1 x 0.25 mg, single dose fed
214976071|NCT00569985|BIOLOGICAL|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
214976072|NCT00569985|DRUG|carmustine|Given IV
214976073|NCT00569985|DRUG|cyclophosphamide|Given IV
214365732|NCT03468010|RADIATION|chemoradiation|radiation with concurrent ciplatin
214365733|NCT03468010|DRUG|Paclitaxel, Cisplatin|The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel, Cisplatin once 3 weeks.
214365734|NCT01743079|DRUG|Telbivudine|LdT 600mg QD
214365735|NCT01743079|DRUG|Lamivudine|LAM 100mg QD
214365736|NCT03755830|OTHER|Skin biopsy|Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
214491369|NCT06798194|DIAGNOSTIC_TEST|Post-ablation MRI is used to evaluate whether the ablation area of the tumor is consistent with the highly conformal ablation thermal field provided by the AI model.|"This study developed an AI model that can provide optimal highly conformal ablation thermal field for HCC patients using ultrasound and MRI. Post-ablation MRI is used to evaluate whether the ablation area of the tumor is consistent with the highly conformal ablation thermal field provided by the AI model.~The patients were divided into:~1. Actual ablation zone of the tumor was consistent with the highly conformal ablation thermal field (consistent group);~2. Actual ablation zone of the tumor was inconsistent with the highly conformal ablation thermal field (inconsistent group)."
214491370|NCT06777238|DRUG|GZR18|Administered SC
214365737|NCT02061202|DRUG|Mometasone Furoate|inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
214491371|NCT06777238|DRUG|Placebo|Administered SC
214491372|NCT04495426|OTHER|Non-interventional study|There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
214976074|NCT00569985|DRUG|etoposide|Given IV
214976075|NCT00569985|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
214976076|NCT02901223|PROCEDURE|Standard quadrantectomy|standard conservative surgery with no use of any plastic techniques
214976077|NCT02901223|PROCEDURE|oncoplastic breast surgery|Integration of plastic techniques with oncological procedures
214976078|NCT02695069|PROCEDURE|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
214976079|NCT06371391|OTHER|No intervention|No intervention
214976080|NCT06388772|DRUG|QHRD106 Injection|250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1
214976081|NCT06388772|DRUG|placebo|placebo
214976082|NCT01735604|BIOLOGICAL|anti-CD20-CAR vector-transduced autologous T cells|anti-CD20-CAR vector-transduced autologous T cells
214976083|NCT01735604|OTHER|genetically engineered lymphocyte therapy|genetically engineered lymphocyte therapy
214976084|NCT01064011|PROCEDURE|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
214976085|NCT01064011|PROCEDURE|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
214976086|NCT02352857|OTHER|Sugar|100g of sponge cakes made with 24g of dextrose.
214976087|NCT02352857|OTHER|FOS|100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
214365738|NCT02061202|DRUG|Placebo|placebo training inhaler with the same instructions as the experimental group.
214365739|NCT03224013|PROCEDURE|LASIK|LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye
214365740|NCT05586152|DRUG|INV-102|INV-102 Ophthalmic Solution
214365741|NCT05586152|DRUG|Vehicle|Vehicle Ophthalmic Solution
214365742|NCT02676375|DRUG|Combination Bupropion + NRTs|
214365743|NCT02676375|OTHER|Extended Treatment|
214365744|NCT02676375|OTHER|Home Visits & Calls|
214365745|NCT02676375|DRUG|Monotherapy|
214365746|NCT00569582|DRUG|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
214491373|NCT00186784|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|treatment for 10 days
214491374|NCT03592797|OTHER|Laser acupuncture therapy|Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
214491375|NCT03592797|OTHER|Sham laser acupuncture therapy|Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
214976088|NCT01294423|DRUG|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
214976089|NCT01294423|DRUG|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
214976090|NCT01294423|DRUG|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
214976091|NCT01953029|PROCEDURE|cardiac imajing|Cardiac MRI
214976092|NCT05345184|BEHAVIORAL|Cognitive Behavioral Suicide Prevention for psychosis (CBSPp)|Cognitive and behavioral approach to suicide prevention tailored for individuals with psychosis
214365747|NCT04832828|DIAGNOSTIC_TEST|Roth´s Test|Subjets must count from 1 to 30 in their languages, and health professional will count seconds that last in take breath during the count.
214365748|NCT04803981|OTHER|SpoonfulONE|SpoonfulONE is a line of nutritional food products designed to help improve diet diversity starting in early infancy. SpoonfulONE covers a wide range of food proteins. Each product contains 30 mg of peanuts, milk, shellfish (shrimp), tree nuts (almond, cashew, hazelnut, pecan, pistachio, and walnut), egg, fish (cod and salmon), grains (wheat and oat), soy, and sesame.
214365749|NCT01533493|DRUG|Placebo|Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
214365750|NCT01533493|DRUG|Memantine Hydrochloride|Memantine will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
214365751|NCT01533493|DRUG|OROS-Methylphenidate|OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.
214365752|NCT05688748|OTHER|Dengue self-monitoring system|The system has a symptom monitoring algorithm whereby patient would be asked to report their symptoms thrice daily (9am, 2pm and 8pm). The algorithm is developed by the researchers which consist of primary care doctors, emergency physician and infectious disease specialists. If the patient reports warning symptoms (persistent vomiting, persistent diarrhoea, abdominal pain, bleeding, difficulty breathing, feel like fainting, difficulty carrying out usual activities, drowsiness, reduced urine output and reduced urine output), the system will advise patients to seek earlier medical care instead of waiting for the scheduled appointment the next day/other days.
214365753|NCT01011621|DRUG|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
214491376|NCT05792956|BEHAVIORAL|Using mobile app|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
214491377|NCT03202992|DRUG|ABI-1968|Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
214491378|NCT04484675|DRUG|Milrinone inhalation|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
214491379|NCT04484675|DRUG|Milrinone infusion|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
214491380|NCT04946682|DIAGNOSTIC_TEST|Types of etiological diagnostic methods|In Group of mNGS, all patients will be tested by meta next generation sequncing on admission, while patients in Group of PCR will be tested by polymerase chain reaction in accordance with the method in the guidelines.
214491381|NCT00926354|DRUG|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
214491382|NCT01223924|OTHER|placebo|placebo
214491383|NCT01223924|DRUG|M2ES|M2ES IV 7.5mg-90mg
214491384|NCT06112600|PROCEDURE|VR|Virtual reality glasses were used as a distraction method for children during vaccination.
214491385|NCT06112600|PROCEDURE|Kaleidoscope|Kaleidoscope toys were used as a distraction method for children during vaccination.
214491386|NCT01032668|DRUG|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
214491387|NCT04738201|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
214491388|NCT05909449|OTHER|exercises|participants will be given a structured home exercise program
214491389|NCT05561231|PROCEDURE|Intubation with C blade|Intubation with C blade of CMAC videolaryngoscope
214491390|NCT05561231|PROCEDURE|Intubation with D blade|Intubation with D blade of CMAC videolaryngoscope
214976093|NCT05345184|BEHAVIORAL|Services as Usual (SAU)|Standard psychiatric and behavioral services provided at community mental health (e.g., case management, medication management)
214365754|NCT01011621|DRUG|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
214491391|NCT03183050|BEHAVIORAL|Question Prompt List|Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.
214491392|NCT01692769|DRUG|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
214491393|NCT01692769|DRUG|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
214491394|NCT06951646|DRUG|Ivonescimab plus docetaxel|"For ctDNA-positive patients, escalation treatment will be administrated~1. Ivonescimab: Intravenous infusion (IV), 20 mg/kg, Day 1, every 3 weeks (Q3W);~2. Docetaxel: IV, 75 mg/m², Day 1, Q3W (The investigator may adjust the chemotherapy dose and schedule based on the patient's tolerance during treatment.)~All enrolled participants will continue treatment until one of the following occurs, whichever comes first:~* The investigator determines that there is no longer clinical benefit (based on imaging assessments and clinical status)~* Unacceptable toxicity~* Completion of 24 months of treatment~* Other discontinuation criteria specified in the protocol are met."
214976094|NCT04605900|DEVICE|Orthopedic Footwear|The orthopedic footwear used by the OF Group was manufactured by the company J. Andrade Ferreira Neves Lda. with materials suitable for the diabetic foot, as registered with INFARMED under registration ID 279515.
214976095|NCT04605900|DEVICE|Standard Footwear|In the SF Group, it was recommended to use standard shoes more suitable for diabetic foot, with some specific characteristics, such as sports or walking shoes. The acquisition or not of a more suitable shoes by the participants was at the discretion of each individual.
214365755|NCT03230773|DEVICE|Defibrillator model|Comparison of the performance of different public access defibrillators
214365756|NCT01528384|DRUG|ADI-PEG 20|4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
214365757|NCT02433743|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
214976096|NCT04605900|DEVICE|Plantar Orthoses|The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.
214976097|NCT04605900|BEHAVIORAL|Education on foot self-care|"An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal."
214365758|NCT01136122|DEVICE|CPAP Treatment|Effective CPAP treatment for one month
214976098|NCT00573664|DRUG|Gabapentin|single oral dose of 600mg gabapentin
214976099|NCT00573664|OTHER|lactose|Single dose
214976100|NCT03521310|PROCEDURE|Skin-to-skin|Neonates will get Skin-to-skin Contact with parent/caregiver continuously the first 6 hours after birth and as much as possible the first 72 hours after birth.
214976101|NCT03521310|PROCEDURE|Conventional care|Neonates will get Conventional care the first 72 hours after birth
214976102|NCT01825824|RADIATION|Stereotactic ablative radiotherapy|The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by \>48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
214976103|NCT03952819|DIAGNOSTIC_TEST|serum sclerostin|blood samples obtained
214976104|NCT00461058|DRUG|Actos|Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
214976105|NCT00461058|DRUG|aleglitazar|Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
214976106|NCT05573152|PROCEDURE|Control|All previously selected patients will be under passive warming by means of blankets
214976107|NCT05573152|PROCEDURE|Nursing|All previously selected patients will be under active air flow warming device at 43 Celsius
214976108|NCT02687854|DRUG|Apixaban|As prescribed by treating physicians
214976109|NCT02687854|DRUG|Vitamin K antagonist|As prescribed by treating physicians
214976110|NCT01145482|DRUG|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
214976111|NCT01145482|OTHER|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
214976112|NCT06472752|RADIATION|Neoadjuvant radiotherapy|Patients with a clear pathological diagnosis of high-risk UTUC were treated with a short course of 5 days of naSBRT: radiotherapy irradiation was directed to the primary lesion on the affected side and to the lymphatic drainage area, with a dose of 25 Gy (5 Gy\*5 days).The safety of the neoadjuvant radiotherapy dose and regimen can be evaluated by metrological ramping in the initial 5 patients, with subsequent patients following the optimal dose from ramping.
214976113|NCT06472752|COMBINATION_PRODUCT|Neoadjuvant drug therapy|Patients will concurrently complete at least 2-4 cycles of preoperative neoadjuvant chemotherapy/immunotherapy/ADCs as well.
214976114|NCT04635839|DRUG|Standard Dose of Unfractionated Heparin|5,000 units subcutaneous unfractionated heparin every 12 hours
214365759|NCT01992679|BEHAVIORAL|Exercise group|The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.
214365760|NCT05571293|DRUG|Botensilimab|Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.
214365761|NCT05571293|DRUG|Balstilimab|Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.
214365762|NCT06205342|DRUG|Mesenchymal Stem Cells|Autologous bone marrow derived MSCs
214365763|NCT06205342|OTHER|Other: Placebo|Control
214365764|NCT03628287|OTHER|Revised Care Coordination Program|Greater focusing, tailoring and cues for delivery of key components of Care Coordination
214365765|NCT03628287|OTHER|Original Care Coordination Program|Original Care Coordination
214365766|NCT04237753|BEHAVIORAL|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
214365767|NCT04237753|BEHAVIORAL|MyHealtheBladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
214365768|NCT00934284|OTHER|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
214365769|NCT00934284|OTHER|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
214365770|NCT05163522|DRUG|VH4004280|VH4004280 will be administered.
215084984|NCT04657640|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements (MMS) and loading dose of Iron and Folic Acid (IFA)|"Daily regimen of MMS for 3 months intermittently. MMS is the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) tablet containing fifteen micronutrients including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg).~For the first 5 weeks of the study, participants will also receive weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) as a loading dose, in addition to daily MMS."
215084985|NCT04844203|DIAGNOSTIC_TEST|Polygraphy with surface electrodes|Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG
214365771|NCT05163522|DRUG|Placebo|Placebo will be administered.
214365772|NCT05163522|DRUG|Midazolam|Midazolam will be administered
214365773|NCT03587662|DRUG|Doxorubicin|Given IV
214365774|NCT03587662|DRUG|Doxorubicin Hydrochloride|Given IV
214365775|NCT03587662|DRUG|Gemcitabine|Given IV
214365776|NCT03587662|DRUG|Gemcitabine Hydrochloride|Given IV
214365777|NCT03587662|DRUG|Ixazomib|Given PO
214365778|NCT03587662|DRUG|Ixazomib Citrate|Given PO
214365779|NCT05019261|OTHER|Multi-component Family Support Intervention|The multi-component intervention is designed to enhance the quality of clinician-family communication and help families manage the emotional and cognitive complexities of surrogate decision-making. It involves: 1) proactive clinician-family meetings; 2) use by surrogates of an interactive web-based tool throughout the ICU stay which is narrated by family members of ICU patients and includes stories and experiences from other families, self-care strategies, brief videos explaining what to expect during family meetings, a question prompt list, an interactive values clarification exercise, and an explanation of different treatment pathways for critically ill patients. 3. Prior to the proactive family meetings, the ICU team is provided with a summary of the family's main questions/concerns, their prognostic expectations, a summary of the patient's values and preferences, and surrogates' current ratings of the extent to which their psychosocial needs are being addressed in the ICU.
214365780|NCT05365490|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
214365781|NCT01853891|OTHER|dim light at night|
214365782|NCT05994703|DRUG|d-cycloserine|d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks.
214365783|NCT05994703|OTHER|Juul e-cigarette|Juul use as often as the participant likes for 12 weeks.
214365784|NCT03599752|DRUG|Chemotherapy|Receive chemotherapy
214365785|NCT03599752|PROCEDURE|Metastasectomy|Undergo pulmonary metastasectomy
214365786|NCT05094466|BEHAVIORAL|Behavioral Intervention|Receive peer support sessions
214365787|NCT05094466|OTHER|Counseling|Receive health coaching sessions
214365788|NCT05094466|PROCEDURE|Discussion|Attend focus groups
214365789|NCT05094466|OTHER|Educational Intervention|Receive handbook
214365790|NCT05094466|OTHER|Informational Intervention|Receive navigation sessions
214365791|NCT05094466|OTHER|Interview|Participate in interview
214365792|NCT05047120|BEHAVIORAL|Hypnosis enhanced cognitive behavioral therapy|This therapy entails subjects being induced into a state of relaxation and the receiving cognitive behavioral therapy for pain associated with a new spinal cord injury.
214365793|NCT05047120|BEHAVIORAL|Pain Education|This therapy entails subjects learning about the causes, mechanisms, and ways to reduce pain associated with a new spinal cord injury.
214365794|NCT04532606|DRUG|Remimazolam|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
214365795|NCT04532606|DRUG|Propofol|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.
214365796|NCT05091268|BEHAVIORAL|Exercise|"All participants will attend a four-hour pain education session including gynecologist, psychologist, sexologist, and physiotherapist at Akershus University Hospital.~The education will be held twice, with half of the participants at the time. The training group will then attend a 60 minutes weekly group training session led by a physiotherapist with specialist training in women's health over a period of four months. In addition, participants will perform a progressive home exercise program performed daily over the same period. The focus will be general strength training using own body weight and cardiovascular fitness (walking, low-impact aerobic exercise), stretching, and relaxation"
214365797|NCT03818087|BEHAVIORAL|Observational cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessments over a period of five years from registration.
214365798|NCT03412396|DRUG|Apalutamide|Given PO
214365799|NCT03412396|OTHER|Quality-of-Life Assessment|Ancillary studies
214365800|NCT03412396|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
214365801|NCT06058624|BEHAVIORAL|Veteran ACT for Chronic Pain (VACT-CP)|"Participants receive 7 online modules, provided as weekly sessions that feature Coach Anne as a virtual, animated treatment guide. All content is presented interactively, through text-based conversations with Coach Anne. Veterans will hear what Coach Anne says and respond to her using text-based dialogue options that will trigger different responses from Coach Anne as the conversation progresses, to allow the system to responsively interact in a personalized manner with the Veteran. Veterans will also be presented with videos (e.g., Veteran narratives, metaphors), in-module assessments (e.g., values assessments), and interactive opportunities for goal setting."
214491395|NCT06951646|OTHER|Standard Treatment|"For ctDNA-positive patients, continuing the original immunotherapy maintenance or immunotherapy combined with chemotherapy~• In the event of clinical progression, consider switching to treatment with Ivonescimab plus docetaxel, administered every 3 weeks."
214365802|NCT06058624|BEHAVIORAL|Online Pain School|"Participants will receive 7 modules (15 to 20 minutes each) of content based on a common non-ACT based VA treatment option, Pain School. The adaptation used for this study, Online Pain School, will support Veterans' self-management of their chronic pain by providing informational videos on chronic pain and its health impacts, short behavioral exercises to help with pain management, and psychoeducation on different wellness techniques for their pain management toolbox."
214365803|NCT05950646|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.01 ml/ kg/h (0.02 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
214365804|NCT05950646|DRUG|Esketamine|Esketamine will be infused at a rate of 0.01 ml/ kg/h (5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
214365805|NCT05950646|DRUG|Normal saline|Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
214365806|NCT05921227|BEHAVIORAL|VAULT Phase 6|VAULT is an input-based word learning intervention based on principles of statistical learning.
214365807|NCT05166304|DRUG|Rebamipide|patients will receive the standard therapy plus 100 mg Rebamipide three times daily
214365808|NCT05166304|DRUG|Placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
214491396|NCT00754065|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
214976115|NCT04635839|DRUG|Gestational Age-Based Dose of Unfractionated Heparin|"* First trimester (\< 14 weeks of gestation): 5,000 units subcutaneous unfractionated heparin every 12 hours~* Second trimester (14-28 weeks of gestation): 7,500 units subcutaneous unfractionated heparin every 12 hours~* Third trimester (\> 28 weeks of gestation): 10,000 units subcutaneous unfractionated heparin every 12 hours"
214365809|NCT02992951|DEVICE|DACC-Coated Post Operative Dressing|Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
214365810|NCT06385015|BEHAVIORAL|Tailored DPP Intervention|The intervention includes 19 sessions (18 in-person and 1 on-demand) covering 24 DPP modules; each session is approximately an hour in length and will be moderated by a trained lifestyle coach. Lifestyle coaches are accessible, collaborative, and culturally competent diabetes care and education specialists trained and certified in the CDC's National DPP curriculum to provide effective guidance and support for program participants. Each group will meet regularly during the academic year, with six in-person sessions delivered per 10-week quarter (for each of three quarters) to allow for breaks during final exams and scheduled school recess (e.g., spring break). It will take place on UCLA campus.
214976116|NCT03469544|OTHER|complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction|"complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
214976117|NCT01041170|DRUG|THC|
214976118|NCT01041170|DRUG|Rimonobant|
214976119|NCT01041170|DRUG|Rimonabant|
214976120|NCT00896493|DRUG|anti-thymocyte globulin|ATG will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg
214976121|NCT00896493|DRUG|cyclosporine|5 mg/kg PO or IV
214976122|NCT00896493|RADIATION|Lymphoid radiation|TLI is administered ten times in 80c- 120c Gy fractions on day -11 through day -7 and day -4 through day -1
214976123|NCT03185000|DRUG|TR004 (Treg immunotherapy)|Administered Intravenously (IV)
214976124|NCT02870868|BEHAVIORAL|Slow breathing|Slow breathing techniques from yoga
214976125|NCT04306523|OTHER|Observation|4 months: observation of infant feeding behavior, behavior/temperament; bio-specimen collection; body composition, sucking intensity/frequency, activity intensity/frequency; maternal reports of feeding and behavior/temperament; maternal biospecimen. 6 month: behavior/temperament assessment, physical activity, and body composition. 12 month: Feeding behavior, behavior/temperament assessment, physical activity, and body composition. 24 month: maternal reports of children's eating behavior, behavior/temperament.
214976126|NCT01217593|PROCEDURE|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
214976127|NCT01217593|PROCEDURE|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
214976128|NCT04211584|DEVICE|transradial interventions|percutaneous coronary interventions in stable patients - diagnostic and treatment
214976129|NCT03019848|DIETARY_SUPPLEMENT|Curcumin|
214976130|NCT03019848|OTHER|Placebo|
214976131|NCT05827848|DEVICE|Percutaneous peripheral nerve stimulation system|All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
214976132|NCT02744716|DRUG|Aspirin|low dose of Aspirin after operation
214976133|NCT02744716|DEVICE|intrauterine balloon|insert intrauterine balloon after operation
214976134|NCT04315441|DIAGNOSTIC_TEST|STEPS and AUDIT questionnaires|assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.
214365811|NCT06142656|DRUG|Metformin Hydrochloride tablet|Metformin Hydrochloride 850 mg oral tablet
214365812|NCT06142656|DRUG|Vildagliptin 50 MG|Vildagliptin 50 MG oral tablets
214365813|NCT05488626|DEVICE|Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily online adaptation.
214365814|NCT05488626|DEVICE|Non-Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily image guidance.
214365815|NCT05488626|DRUG|Chemotherapy|Concomitant chemotherapy per NCCN or other national guidelines.
214365816|NCT05488626|DRUG|Immunotherapy|Adjuvant immunotherapy per national or institutional guidelines.
214365817|NCT00542438|BEHAVIORAL|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
214365818|NCT00542438|BEHAVIORAL|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
214976135|NCT02532400|DRUG|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w
214976136|NCT02532400|DRUG|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6
214976137|NCT03013400|DRUG|Ebselen|Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
214976138|NCT03013400|DRUG|Placebo oral capsule|Placebo is identical in appearance to the ebselen capsules
214976139|NCT04882371|DRUG|Chemotherapy|Neoadjuvant Chemotherapy for Breast Cancer
214976140|NCT04882371|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Performed contrasted MRI for evaluate response of neoadjuvant chemotherapy
214976141|NCT04882371|DIAGNOSTIC_TEST|Positron emission tomography - Copmputer Tomography (PET-CT)|Performed contrasted PET-CT for evaluate response of neoadjuvant chemotherapy
214976142|NCT03881683|DIAGNOSTIC_TEST|HRD and BRCA mutations|Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
214976143|NCT00927407|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
214976144|NCT00927407|DRUG|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
214976145|NCT01739335|DRUG|Mifepristone Oral Tablet [Korlym]|2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
214976146|NCT01739335|DRUG|Placebo Oral Tablet|2 Placebo Oral Tablets once daily for 7 days
214976147|NCT04718922|DRUG|Chlorhexidine Gluconate 0.12 % Mouthwash|Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA
214976148|NCT04768140|PROCEDURE|Bobath treatment approach|scapulothoracic mobilization exercise, reaching in different directions in the supine position and upper extremity weight transfer exercise.
214976149|NCT04768140|PROCEDURE|Conventional physiotherapy|range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
214976150|NCT00619840|DRUG|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
214976151|NCT00619840|DRUG|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
214976152|NCT03991871|DEVICE|External Counter Pulsation (ECP) therapy|35 hours ECP treatment in 35 sessions
214976153|NCT05461066|BEHAVIORAL|CESAR training|Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.
214976154|NCT04333693|PROCEDURE|Vascular surgery|Open vascular, endovascular or hybrid procedures
214976155|NCT06228976|BEHAVIORAL|Mindfulness-based, smoking cessation focused text messages.|Participants will receive mindfulness-based, smoking cessation focused text messages everyday for 12 weeks.
214976156|NCT06228976|BEHAVIORAL|Educational messages|Text messages focus on the health risks of smoking and secondhand smoking, once everyday for 12 weeks.
214976157|NCT06228976|BEHAVIORAL|Control messages|Text messages focus on the general healthy lifestyle, once everyday for 12 weeks.
214976158|NCT04710212|OTHER|No intervention.|Observational study with no intervention.
214976159|NCT03532763|DIETARY_SUPPLEMENT|Tocotrienol-rich fraction|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: 200 mg Tocotrienol-rich fraction
214976160|NCT03532763|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: Palm olein
214976161|NCT02105324|DEVICE|Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
214976162|NCT02105324|OTHER|Usual Care|As a comparator control, usual diabetes camp care with the participant's own insulin pump.
214976163|NCT03057574|DRUG|Follitropin Alfa|Patients must be prescribed Follitropin Alfa (Gonapure®)
214976164|NCT05332223|DIAGNOSTIC_TEST|Full Polysomnography|Overnight PSG will be conducted using Alice version 6 system (Respironics, Pittsburgh, PA, USA). During PSG, the following variables will be monitored and captured. Sleep staging using electroencephalogram (four channels: C3-A2, C4-A1, O1-A2, O2-A1), electrooculogram (two channels: LOC-A2, ROC-A1), electromyogram (two channels: submental and anterior tibialis muscles). Respiratory effort using inductive plethysmograph sensors to detect thoracoabdominal movements. Oro-nasal airflow using pressure flow transducer and thermistor. Oxygen saturation using pulse oximetry and cardiac rhythm using electrocardiography. Other parameters that will also be monitored includes body position, presence of snoring and end tidal CO2 (EtCO2) measurement to detect hypercapnia. The attended PSG will be conducted in the sleep laboratory in Respiratory Unit, Hospital Taiping
215084986|NCT01632228|DRUG|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
214365819|NCT03681158|DRUG|sodium valproate|Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral
215084987|NCT01632228|DRUG|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
214491397|NCT00754065|DRUG|Ortho Tri Cyclen Lo|Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
214491398|NCT03776812|DRUG|Relacorilant|Relacorilant is supplied as capsules for oral dosing.
214491399|NCT03776812|DRUG|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30-40 minutes.
214491400|NCT05647889|DRUG|Jet lidocaine|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
214491401|NCT05647889|COMBINATION_PRODUCT|Ice|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
214976165|NCT04609137|PROCEDURE|Early drain removal|"Patients randomized to the experimental group, will have an early drain removal if DFA on POD1 is lower than 2000 U/L and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team. If DFA is greater than 2000 U/L, the drain will be maintained in place. If the sample on POD1 DFA is not available (e.g. drainage fluid is viscous and amylase value cannot be evaluated) or the sample could not be analyzed DFA will be evaluated on POD2, and drain removal will be considered if DFA is lower than 2000 U/L. If DFA on POD 3 is lower than 300 U/L, that is 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister according to the clinical team, the drain will be removed. Otherwise, the drain will be kept in place and the patient will then follow standard postoperative drain management."
214976166|NCT04609137|PROCEDURE|Standard drain removal|"Patients randomized to this group will receive the current standard of care, thus the drain will be maintained at least until postoperative day 5. If DFA on POD 5 is lower than 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team, the drain will be removed. If the drain is maintained in place beyond POD 5, it will be removed inhospital or after discharge when the daily amount is lower than 10 ml and there are no signs of ongoing infection"
214976167|NCT02691715|PROCEDURE|Endometrial saline plus curettage|
214976168|NCT02691715|PROCEDURE|Endometrial curettage|
214976169|NCT01679743|DRUG|Trastuzumab|Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
214976170|NCT01679743|DRUG|GRN 1005|GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
214976171|NCT04325880|DRUG|Mirabegron 50 MG|Patients in this arm will receive Mirabegrone 50 MG once daily
214976172|NCT04325880|DRUG|Tamsulosin|Patients in this arm will receive Tamsulosin o.4 MG once daily
214976173|NCT04325880|DRUG|Solifenacin Succinate 10 MG|Patients in this arm will receive Solifenacin Succinate 10 MG once daily
214976174|NCT04325880|DRUG|Placebo oral tablet|Patients in this arm will receive placebo oral tablet once daily
214976175|NCT05285111|BEHAVIORAL|Reconnecting to Internal Sensations and Experiences|The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
214976176|NCT05285111|BEHAVIORAL|Healthy Habits|"The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating."
214976177|NCT06429904|DRUG|Nimotuzumab+ NALIRIFOX|"Drug: Nimotuzumab Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg, 600mg, 400mg on Day 1, 8, 15, respectively, 28 days as a cycle, up to 6 cycles.~Other Names: h-R3~Drug: NALIRIFOX Patients will receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle, up to 6 cycles.~Other Names: NALIRIFOX"
214976178|NCT01868646|DRUG|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
214976179|NCT01868646|DRUG|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
215084988|NCT01632228|DRUG|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
215084989|NCT03263312|BEHAVIORAL|Exercise|Exercise training all patients enrolled.
215084990|NCT03508193|OTHER|Nutritional therapy|Whole-foods based smoothie designed to emulate formulas used in EEN
215084991|NCT00236496|DRUG|topiramate|
214491402|NCT05647889|OTHER|Standard PVC procedure|Standard PVC procedure will be applied
214491403|NCT05182229|OTHER|Home-based (a hybrid model) CDT|Participants will be provided therapist-administered, in person complete decongestive therapy (CDT) two times per week for two weeks (4 sessions), followed by real-time, virtual CDT consultations two times per week for three weeks (7 sessions) and one in person follow-up visit.
214491404|NCT05182229|OTHER|Clinic-based CDT|Participants will be provided therapist administered, in-person CDT two times per week for six weeks (12 sessions).
214491405|NCT06637111|PROCEDURE|Ultrasound guided office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem. The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia.~Transabdominal ultrasound will be used to guide the access of the hysteroscope to the uterine cavity"
214365820|NCT04772625|DEVICE|Patellofemoral arthroplasty|Insertion of an artificial joint between the front of the femur and the back of the patella. The femoral component consists of a metal implant, and the patellar component is a polyethylene implant. The two components replace the original articular cartilage of the patellofemoral joint.
214365821|NCT03543930|DEVICE|Postoperative preventive CPAP|Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2
214365822|NCT01371630|BIOLOGICAL|Blinatumomab|Given CIVI
214365823|NCT01371630|DRUG|Cyclophosphamide|Given IV
214491406|NCT06637111|PROCEDURE|Conventional office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem . The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia."
214491407|NCT03053960|DEVICE|Computed Tomography|Undergo helical CT scan
214491408|NCT03053960|DEVICE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
214976180|NCT02555592|PROCEDURE|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2\~4 weeks after adjuvant chemotherapy.
214976181|NCT00691275|DRUG|Ondansetron|
214976182|NCT00691275|DRUG|Saline|
214976183|NCT03613831|DEVICE|patient who used Rhythmia system and Orion catheter|suitable for Rhythmia system and Orion catheter according to relevant clinical guidelines and products instruction for use, per investigator's discretion
214976184|NCT03280407|DRUG|Capecitabine|Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
214976185|NCT03280407|DRUG|FOLFOX regimen (oxaliplatin/leucovorin/5FU)|Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
214976186|NCT03280407|DRUG|CAPOX (oxaliplatin/capecitabine)|Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
214976187|NCT00291369|DRUG|Interleukin-2|
214976188|NCT00291369|DRUG|Interferon alfa|
214976189|NCT00291369|DRUG|medroxyprogesterone acetate|
214976190|NCT02982759|BEHAVIORAL|Multi-Level Intervention|The multi-level interventions will include activities at the individual level, family level, school level, and community level.
214976191|NCT02982759|BEHAVIORAL|Genetic Newsletters|The comparison will receive generic newsletters
214976192|NCT03485534|DRUG|Tenofovir Disoproxil Fumarate|Viread 300mg
214976193|NCT03485534|DRUG|Tenofovir Disoproxil|Virehepa 245mg
214976194|NCT05495178|PROCEDURE|laparoscopic restorative proctocolectomy|laparoscopic restorative proctocolectomy
214976195|NCT04212767|PROCEDURE|Alveolar socket preservation with Platelet-rich fibrin|The sockets of the test group will be filled with two platelet-rich fibrin membranes followed by suture
214976196|NCT00896064|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
214976197|NCT00896064|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
214976198|NCT06313645|OTHER|Several biomarkers|Telomere length Mitochondrial DNA copy number (mtDNAcn) MitomiR long non-coding (lnc) RNA TERRA pro-oxidant cytokines \& chemokines
214976199|NCT01198405|DEVICE|Enhanced external counterpulsation|Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.
214976200|NCT01198405|DRUG|Guideline-driven standard medical therapy|Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
214365824|NCT01371630|DRUG|Cytarabine|Given IT and IV
214365825|NCT01371630|DRUG|Dexamethasone|Given IV or PO
214365826|NCT01371630|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214365827|NCT01371630|OTHER|Laboratory Biomarker Analysis|Correlative studies
214365828|NCT01371630|DRUG|Mercaptopurine|Given PO
214365829|NCT01371630|DRUG|Methotrexate|Given IT, IV, and PO
214365830|NCT01371630|DRUG|Prednisone|Given PO
214365831|NCT01371630|BIOLOGICAL|Rituximab|Given IV
214365832|NCT01371630|DRUG|Vincristine|Given IV
214365833|NCT00796380|DRUG|Xingnaojing|injection
214365834|NCT05694741|DRUG|AZD0186|Subjects will receive AZD0186 orally.
214365835|NCT05694741|DRUG|Placebo|Subjects will receive placebo orally.
214365836|NCT00406133|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor
214491409|NCT03053960|DEVICE|Cone-Beam Computed Tomography|Undergo CBCT scan
214491410|NCT03053960|DEVICE|Magnetic Resonance Imaging|Undergo MRI scan
214491411|NCT03053960|PROCEDURE|Therapeutic Conventional Surgery|Undergo resection of tumor
214491412|NCT03053960|PROCEDURE|Histopathologic Examination|Correlative studies
214976201|NCT01414478|OTHER|Protein Shake|Protein shake contains 30 grams of protein in 11 fluid ounces.
214976202|NCT00932256|DRUG|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
214976203|NCT04596969|OTHER|Soluble Fiber Dextrin|Ingredient based on resistant starch
214976204|NCT01748370|DRUG|Vitamin D supplementation in hypogonadal men|
214976205|NCT01748370|DRUG|Vitamin D supplementation in eugonadal men|
214976206|NCT01748370|DRUG|Placebo hypogonadal|
214976207|NCT01748370|DRUG|Placebo eugonadal|
214976208|NCT00407225|DRUG|Difluprednate Ophthalmic Emulsion|
215084992|NCT02961790|DRUG|Oxybutynin Chloride|Given PO
214365837|NCT04880395|DRUG|Intervention Arm: dolutegravir/lamivudine|1 pill QD
214365838|NCT04880395|DRUG|Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)|1 pill of each QD
214365839|NCT01087554|DRUG|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
214365840|NCT01087554|DRUG|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
214365841|NCT01087554|DRUG|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
214365842|NCT01087554|DRUG|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
214365843|NCT05082090|PROCEDURE|Spinal Surgery|Implanted with Orthofix Spinal products
214365844|NCT00618553|OTHER|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
214365845|NCT00618553|BEHAVIORAL|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
214365846|NCT04989075|OTHER|Oral prophylactic intervention|The oral prophylactic intervention will consist of the provision of specific package including a soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
214365847|NCT05759078|DRUG|Ferinject|The first dose of either FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7). If safety criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
214365848|NCT05759078|DRUG|Sodium Chloride 0.9% Inj|The first dose of placebo will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7).
214365849|NCT05261152|DRUG|drug product: capsules are containing S. boulardii, administered twice daily (250 mg)|Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
214365850|NCT01508429|OTHER|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
214365851|NCT01508429|DRUG|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
214365852|NCT03845153|DRUG|Metformin Retard 850 mg|tablet
214365853|NCT03845153|OTHER|Placebo|placebo tablet
214365854|NCT03744273|PROCEDURE|breast capsule biopsy|
214491413|NCT06274086|PROCEDURE|Two-session catheter-directed sclerotherapy|"After receiving the first session of catheter-directed sclerotherapy, each patient carries the catheter overnight and is closely monitored in the patient ward. Then, the patient receives the second session the next day. The catheter is removed after the second session.~The procedure was performed under intravenous sedoanalgesia using a combination of 25 mg pethidine hydrochloride and 50 mg fentanyl. Devices used during the procedure included:~* An 18-gauge, 20-cm Chiba biopsy needle (Cook, Bloomington, IN, USA);~* A 0.035-inch hydrophilic guidewire (Terumo, Tokyo, Japan);~* A 7- or 8.5-F pigtail catheter (Dawson-Mueller Drainage Catheter; Cook)."
214976209|NCT03843372|DEVICE|High flow nasal cannula|All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
214976210|NCT03006237|DRUG|IS-001|10mg, 20mg or 40 mg IV IS-001 drug administered during surgery
214976211|NCT03006237|DEVICE|da Vinci® Si/Xi Surgical System|robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging
214976212|NCT05482802|BEHAVIORAL|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
214976213|NCT05482802|BEHAVIORAL|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
214976214|NCT02337062|DRUG|APD421|
214365855|NCT01895972|DRUG|Latanoprostene bunod|
214365856|NCT06523530|DRUG|Goserelin Acetate 3.6 mg inj, implant|3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)
214365857|NCT04278118|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
214365858|NCT04278118|RADIATION|Photon Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
214365859|NCT04278118|RADIATION|Proton Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
214365860|NCT04278118|OTHER|Quality-of-Life Assessment|Ancillary studies
214365861|NCT04278118|OTHER|Questionnaire Administration|Ancillary studies
214365862|NCT06450834|DEVICE|Ostene|Soluble Bone Hemostasis Implant Material
214976215|NCT02337062|DRUG|Placebo|
214976216|NCT06258850|DRUG|Calcifediol Oral Capsule|One Hydroferol® soft capsule (0.266 mg) will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
214976217|NCT06258850|DRUG|Placebo|One soft capsule will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
215084993|NCT02961790|OTHER|Placebo|Given PO
215084994|NCT02961790|OTHER|Quality-of-Life Assessment|Ancillary studies
215084995|NCT02961790|OTHER|Questionnaire Administration|Ancillary studies
214365863|NCT05893927|OTHER|Diabetes education web site application|The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.
214365864|NCT06061497|OTHER|Abdomino-diaphragmatic breathing|Breathing should be done twice a day for 10 minutes.
214976218|NCT06078215|COMBINATION_PRODUCT|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysine in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset
214976219|NCT06082479|PROCEDURE|intraoral cryotherapy,ice gel|A cold pack (ice gel enveloped by a sealed plastic cover) measuring 2.5 x 5 centimetres was placed intraorally on the vestibular surface of the treated tooth. Each cold pack was kept for ten minutes.3 packs were used for each patient, for a total time of 30 minutes.Patients were instructed to remove the cold pack for 1-2 minutes if they felt extreme cold or a burning sensation .The temperature of the gel was checked by a digital thermometer (Brannan, UK) after it was removed from the freezer and kept in an ice box (Cosmoplast, UAE) containing a cooling gel (Exam Packaging, Belgium).
214976220|NCT02871674|BEHAVIORAL|Good Night Project|The behavioural interventions have been designed on the basis of three sources. Firstly, a systematic review conducted by the research team that examined the best evidence in the field in different countries. Secondly, a Delphi study, which aimed to identify behavioural interventions that can be used to manage sleep difficulties in Saudi Arabia in accordance with professionals' views and primary caregivers' needs, and which was also conducted by the research team. Thirdly, evidence-based practice resources that help in understanding and managing sleep difficulties will be translated into Arabic.
214976221|NCT01210638|DRUG|Oxymorphone|10 mg tablet
214976222|NCT04343183|DEVICE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.
214976223|NCT02560168|DEVICE|MyoVista device|MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device
214365865|NCT06061497|BEHAVIORAL|Usual Care|Health education Review of inhaler technique Check adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity
214365866|NCT05750628|DRUG|INE963|oral INE963
214976224|NCT02560168|DEVICE|Computed tomographic coronary angiography|Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
214976225|NCT02560168|DEVICE|Transthoracic Echocardiography|
214365867|NCT05750628|DRUG|KAE609 (Cipargamin)|oral KAE609 (Cipargamin)
214365868|NCT05750628|DRUG|SoC (Coartem)|SoC (Coartem)
214976226|NCT00785356|DRUG|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
214976227|NCT00785356|DRUG|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
214365869|NCT05750628|DRUG|KLU156|oral sachet KLU156 (KAF156 + lumefantrine)
214365870|NCT05718544|DRUG|Esketamine|Esketamine 50 mg is included in the mixture for patient-controlled analgesia.
214365871|NCT05718544|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
214365872|NCT05718544|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
214365873|NCT03664869|DRUG|BCG instillation therapy|Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
214365874|NCT03664869|DRUG|Sequential BCG and EMDA mitomycin C|"Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.~BCG instillation is performed as a standard instillation.~Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)"
214365875|NCT03057353|DEVICE|lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
214976228|NCT00785356|DRUG|Placebo|Placebo, 2 capsules daily for 3 months
214976229|NCT02888834|OTHER|Adverse drug reaction|
214976230|NCT03758729|DRUG|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
214976231|NCT03758729|RADIATION|Radiation Therapy|Radiation Therapy
214976232|NCT01559662|DIETARY_SUPPLEMENT|Sugared Chewing Gum (Juicy Fruit)|One stick of gum, 3 times daily from Postoperative day 1 to 7
214976233|NCT05452265|PROCEDURE|Endoscopic resection|Complete resection of gastric SETs was recommended if the tumor size was \>2 cm, presence of malignant features, or if the patient was symptomatic, declined periodical surveillance, and preferred to undergo diagnostic and therapeutic resection.
214365876|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle
214365877|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle
214365878|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 as IV infusion on Day 1 and 8 of 21-day cycle
214365879|NCT02753595|OTHER|Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg as IV infusion on Day -1 and 7 of 21-day cycle
214365880|NCT02753595|OTHER|Biologic: PEGylated recombinant human hyaluronidase|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
214976234|NCT02280252|DRUG|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
214976235|NCT02280252|RADIATION|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
214976236|NCT04267978|DRUG|recombinant human endostatin,temozolomide,irinotecan|"Temozolomide was given orally 200mg/m2 for 5 days in each cycle. Day 1 TMZ was administered 3-6 hours prior to irinotecan.~Irinotecan was administrated 125mg/m2 on day 1 and day 15. Recombinant human endostatin was administrated 15mg/d, daily for 14 days. One treatment cycle was defined as 28 days (4 weeks), even if treatment is held mid-cycle for toxicity.~Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.~The maximum number of treatment cycles was 12. After 12 cycles of treatment, if the investigator judges that the subject may continue to benefit from the regimen, the duration of treatment may be extended with the subject's consent."
214976237|NCT00002441|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
214976238|NCT03102502|DEVICE|EECP|Enhanced external counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. EECP enhances the aortic diastolic blood flow and coronary perfusion, leading to increased arterial wall shear stress in a pulsatile manner.
214976239|NCT03102502|DRUG|Medical therapy|Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
214976240|NCT02815085|OTHER|RecoverLINK technology|HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period
214976241|NCT01232790|DIETARY_SUPPLEMENT|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
214976242|NCT01232790|DRUG|Placebo|Placebo
214976243|NCT03238417|OTHER|Evidence-Based Quality Improvement|Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
214976244|NCT00821535|DRUG|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
214976245|NCT04163848|OTHER|Pollution|CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
214976246|NCT02788487|DEVICE|Tongue retaining device|Tongue retaining device is used for 3 weeks
214976247|NCT02788487|DEVICE|CPAP|CPAP is used for 3 weeks
214976248|NCT05306990|DRUG|Atorvastatin 40 Mg Oral Tablet|patients followed up for 3 months
214976249|NCT05306990|DRUG|Rosuvastatin 20 Mg Oral Tablet|patients followed up for 3 months
214976250|NCT05455827|OTHER|fMRI neurofeedback (A)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to enhance differences between the self-blame and other-blame conditions
214976251|NCT05455827|OTHER|fMRI neurofeedback (B)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to minimise differences between the self-blame and other-blame conditions
214976252|NCT00716612|DRUG|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
214976253|NCT00716612|DRUG|Placebo control|po Placebo QD
214976254|NCT02310074|DRUG|Pulsatile Gonadotropin Releasing Hormone|
214976255|NCT02310074|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (hCG)
214976256|NCT02310074|DRUG|Urinary Follicle-Stimulating Hormone|Urinary Follicle-Stimulating Hormone (uFSH)
214976257|NCT03918265|DRUG|Tacrolimus|On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
214976258|NCT01978457|DRUG|cocaine hydrochloride|
214976259|NCT01978457|DRUG|propranolol|
214976260|NCT01978457|DRUG|placebo|
214976261|NCT05540145|DRUG|SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody|"Drug: Paclitaxel(albumin-bound) 130mg/m2, ivgtt, D1, Q2w Drug: Oxaliplatin 70 mg/m2, ivgtt, D1, q2w Drug: S-1 40mg (body surface area \< 1.25m2), bid, D1-8, Q2w 50mg (body surface area \>1.25m2, \<1.5 m2), bid, D1-8, Q2w 60mg (body surface area \>1.5m2), bid, D1-8, Q2w Drug: Bevacizumab, 5mg/kg, ivgtt, D1, Q14d Drug: PD-1 antibody, 200mg, ivgtt, D1, Q21d Patients with Her-2 negative, MMR-proficient locally advanced esophagogastric junction or gastric adenocarcinoma will receive 6 cycles of neoadjuvant chemotherapy with or without antiangiogenesis. After comprehensive evaluations, patients who respond to chemotherapy will further receive 2 cycles of PD-1 antibody comibed with antiangiogenesis and chemotherapy as neoadjuvant therapy.~Drug: Pembrolizumab or sintilimab, 100\~200mg, ivgtt, D1, Q3w. Patients will make the final decision of PD -1 antibody according to their economic condition."
214976262|NCT00083915|DRUG|Cisplatin|20mg/m2 continuous infusion days -3 and -2.
214976263|NCT00083915|DRUG|Cyclophosphamide|800 mg/m2 continuous infusion days -3 and -2.
214976264|NCT00083915|DRUG|Adriamycin|20mg/m2 continuous infusion -3 and -2.
214976265|NCT00083915|DRUG|Etoposide|80mg/m2 continuous infusion -3 and -2.
214976266|NCT00083915|DRUG|Melphalan|200 mg/m2 IV over \<20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.
214365881|NCT04414449|OTHER|ICT-enabled Social-emotional Learning|ICT-enabled Social-emotional Learning
214365882|NCT00030693|BIOLOGICAL|recombinant fowlpox-B7.1 vaccine|Given intratumorally
214491414|NCT04761042|OTHER|WAYA-Wilderness|"The wilderness intervention includes challenging tasks in order to help participants' overcome and master new physical and psychological challenges in an unknown environment, with the idea to support self-efficacy, self-esteem, and ability to recover from adversity. The program is designed to encourage participants to connect with nature as to experience gratitude for the richness of the natural world, a sense of calmness and trust upon spending time in nature, and to be more physically active in nature.~Elements previously described Participants will continue in a three-month program at home (on-line supported) after the initial 8-days in order to empower participants to incorporate elements of the onsite wilderness program into their daily life. An individualized a plan for activities will be developed together with the participant.~After three months, there will be a re-visit with follow up on outcome measures and reconnection."
214491415|NCT04761042|OTHER|WAYA-Holiday|"An attention control group (information in Detailed description)"
214491416|NCT05889299|DRUG|OMS906 study drug|OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
214491417|NCT03042039|OTHER|New Care|New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
215084996|NCT04025502|DEVICE|Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System|The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
214491418|NCT02132455|PROCEDURE|colonoscopy|colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
214491419|NCT02348632|DRUG|JZP-110|
214491420|NCT05609734|OTHER|no intervention, only observational retrospective study|no intervention, only observational retrospective study
214491421|NCT01158417|DRUG|Placebo|oral
214491422|NCT01158417|DRUG|Resveratrol 40 mg oral three times a day|Drug
214491423|NCT01158417|DRUG|Resveratrol 500 mg oral once daily.|Resveratrol 500 mg oral once daily.
214491424|NCT02094560|DRUG|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
214976267|NCT00083915|DRUG|Thalidomide|200mg PO Continuing to Day +5, then hold until platelets \>50 thousand (K).
214976268|NCT00083915|DRUG|Dexamethasone|40 mg po days 1 - 4 (4 days)
214976269|NCT04555603|DRUG|Inlyta|axitinib
214976270|NCT04555603|DRUG|Bavencio|avelumab
214976271|NCT04555603|DRUG|Keytruda|Pembrolizumab
214976272|NCT01276977|DRUG|Zolmitriptan 5 mg Nasal Spray|Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
214976273|NCT01276977|DRUG|Eletriptan 40 mg tablet|Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
214976274|NCT01239797|DRUG|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
214976275|NCT01239797|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
214976276|NCT01239797|DRUG|Dexamethasone (Oral)|"On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug.~On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
214976277|NCT01239797|DRUG|Dexamethasone (IV)|"On weeks without Elotuzumab dosing: Not Applicable (N/A)~On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
214976278|NCT01239797|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
214976279|NCT06043466|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
214976280|NCT00122057|DRUG|antibiotic treatment|
214976281|NCT05567536|DRUG|Antiplatelet Agents|Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent
214976282|NCT05709665|OTHER|Time to Decision for eCPR|We evaluate during high quality CPR the time for decision for eCPR
214976283|NCT04158765|OTHER|DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).|DNA will be extracted from sperm using the DNeasy Tissue Kit and Telomerase activity in samples will be measured using a PCR- based assay.
214976284|NCT01192165|DRUG|Trametinib (GSK1120212)|Investigational small molecule targeted therapy (MEK1/2 inhibitor)
214976285|NCT01192165|DRUG|Docetaxel|Chemotherapy
214976286|NCT01192165|DRUG|Erlotinib|Small molecule targeted therapy (EGFR inhibitor)
214976287|NCT01192165|DRUG|Pemetrexed|Chemotherapy
214976288|NCT01192165|DRUG|Carboplatin|Chemotherapy
214976289|NCT01192165|DRUG|nab-Paclitaxel|Chemotherapy
214976290|NCT01192165|DRUG|Cisplatin|Chemotherapy
214491425|NCT01189149|PROCEDURE|IV fluids|Infants will be allocated to IV fluids
214491426|NCT01189149|PROCEDURE|Naso/oro gastric tube feedings|Infants will be allocated to naso/oro gastric tube feedings
214491427|NCT00612209|DRUG|ARQ 197|Treatment with ARQ 197
214491428|NCT05899699|DRUG|DAP-FLU ME|Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)
214976291|NCT05117853|DRUG|Autofluorescent detection + Injection of indocyanine green|"All four parathyroid glands will be actively sought for in every case selected for the use of AF/ICG, with AF verification of parathyroid tissue.~The timepoints of AF will be:~* 1 = after lateral dissection side 1 (side 1)~* 2= after lateral dissection side 2 (side 2)~The timepoints of ICG injection will be:~* 1 = after the first thyroid lobectomy (side 1)~* 2 = after the second thyroid lobectomy (side 2)~Scoring of the viability of parathyroid glands (adapted from Vidal Fortuny et al., 2016):~* 1 = black = not viable/vascularized~* 2 = grey = moderately viably/ moderately vascularized~* 3 = white = viable/well-vascularized"
214976292|NCT05117853|PROCEDURE|Gold standard of visual identification and evaluation of viability of the parathyroid glands.|Gold standard of visual identification and evaluation of viability of the parathyroid glands.
214976293|NCT05670444|DRUG|kelavit|The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
214976294|NCT01854814|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
214365883|NCT00030693|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|Given intratumorally
214365884|NCT00030693|OTHER|laboratory biomarker analysis|Correlative studies
214976295|NCT01854814|DRUG|Losartan|Maximum tolerated labeled dose of Losartan
214976296|NCT02064036|RADIATION|Stereotactic Radiosurgical Boost|Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
214976297|NCT02064036|DRUG|Casodex|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
214976298|NCT02064036|DRUG|Leuprolide|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
214976299|NCT01565863|BEHAVIORAL|Progressive Goal Attainment Program|The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
215084997|NCT01007071|DRUG|Human Growth Hormone (1-134)|Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
215084998|NCT01007071|DRUG|Placebo|Subjects randomized to placebo
215084999|NCT01741714|OTHER|Sham chiropractic manipulative therapy|Sham manipulation
214365885|NCT00030693|PROCEDURE|quality-of-life assessment|Ancillary studies
214365886|NCT01124760|DRUG|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
214365887|NCT01124760|DRUG|Diltiazem|Orally, daily beginning on Day 4 for 14 consecutive days
214365888|NCT01124760|DRUG|ketoconazole|200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
214365891|NCT04181203|DRUG|Apalutamide|"240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months."
214365892|NCT04181203|RADIATION|Salvage radiotherapy (SRT)|"The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images."
214365893|NCT04181203|DRUG|Luteinising Hormone Releasing Hormone agonist (LHRHa)|Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
214365894|NCT01570868|DRUG|Ponatinib|Starting dose: 45 mg by mouth once daily.
214365895|NCT02453581|DRUG|OZ439|OZ439 Powder for Oral Suspension
214365896|NCT04856722|PROCEDURE|mini-PNL|PCNL using miniature nephroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance.
214365897|NCT04856722|PROCEDURE|RIRS|RIRS using flexible ureteroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance. Holmium Laser lithotripter will be used for stone fragmentation.
214365898|NCT04856722|PROCEDURE|SWL|SWL using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
214365899|NCT04885062|DEVICE|Belun Ring|The Belun Ring sensor will be applied to the proximal phalanx of the index finger in the non-dominant hand of the participating individuals prior to their sleep onset in the sleep lab and will be removed upon awakening at the end of the sleep period on the following morning. The attended in-lab sleep study will be performed simultaneously in a standard fashion.
214365900|NCT04885062|DIAGNOSTIC_TEST|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
214365901|NCT06231862|DIAGNOSTIC_TEST|SeptiCyte (various)|mRNA expression scores
214365902|NCT06078462|OTHER|job related activities|Different types of effort offered by female physiotherapist and female dentist during clinical practicing with patients in internship year
214365903|NCT00744484|BEHAVIORAL|Training in water|45 minutes interval training in water, submaximal intensity, twice a week
214976300|NCT02135952|PROCEDURE|SRP|SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.
214976301|NCT02135952|OTHER|Placebo|Administration of placebo for 14 days started immediately after the first session of SRP.
214976302|NCT02135952|DRUG|MTZ+AMX|Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
214976303|NCT00434824|DRUG|Oral testosterone undecanoate (Andriol)|treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
214976304|NCT00434824|DRUG|Placebo|treatment for 12 months with placebo in divided doses
214976305|NCT00253136|DRUG|risperidone|
214976306|NCT05811481|PROCEDURE|TACE|Transcatheter Arterial Chemoembolization
214976307|NCT05811481|DRUG|Regorafenib|Regorafenib alone
214976308|NCT00458237|DRUG|Everolimus|Everolimus is being administered orally 7 days per week.
214976309|NCT00458237|DRUG|Trastuzumab|Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.
214976310|NCT03614000|OTHER|Screening Questionnaires|"Measurement tools:~* Social Responsiveness Scale (SRS-2) is a validated 65-item scale for the screening of ASD that requires parents to rate the child's behaviors in the previous 6 months. The questionnaire assesses interpersonal behavior, communication and repetitive/stereotypic behavior characteristics of ASD.~* The Aseba Questionnaires are validated diagnostic tools that can be filled in by the parents, teachers or children to evaluate various behavioral and emotional problems. The CBCL assesses internalizing (i.e., anxious, depressive and over-controlled) and externalizing (i.e., aggressive, hyperactive, noncompliant and under-controlled) behaviors.~* The VG\&O The VG\&O is a questionnaire developed in Dutch that gives a subscale of parental stress (OBVL), family functioning (VGFO), education habits (VSOG) and life events (VMG). The OBVL will be used"
214976311|NCT03893578|DEVICE|Mitral valve-in-valve|The Synecor Conveyor System shall be used to position the Edwards SAPIEN 3 valve at the mitral location.
214976312|NCT01126216|DRUG|Paclitaxel/Cisplatin|Experimental: Paclitaxel (20mg/m\^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m\^2/d) on days 1-4 and 29-32,
214976313|NCT01126216|RADIATION|Reduced RT|Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
214976314|NCT01126216|DRUG|5-FU/Cisplatin|Active Comparator: 5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33
214976315|NCT01126216|RADIATION|Standard RT|Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
214976316|NCT02787980|BIOLOGICAL|Additional taking blood|Additional blood collection of 1 ml during the biological workup usually done.
214976317|NCT02899611|DRUG|Valproate|ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.
214976318|NCT05925192|OTHER|Observational study|N/A - observational study
214976319|NCT06235671|PROCEDURE|Chiropractic care|6 weeks of chiropractic care
214976320|NCT02271321|OTHER|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
214976321|NCT00853762|DRUG|Atacicept 25 mg|Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
214976322|NCT00853762|DRUG|Atacicept 75 mg|Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
215085000|NCT01741714|OTHER|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
215085001|NCT00102297|DRUG|FG-3019|
215085002|NCT03094078|OTHER|News item with spin|Interpretation of news item with spin
214365904|NCT00744484|BEHAVIORAL|Training on land|45 minutes interval training on land, submaximal intensity, twice a week
214365905|NCT03087071|OTHER|Laboratory Biomarker Analysis|Correlative studies
214365906|NCT03087071|BIOLOGICAL|Panitumumab|Given IV
214365907|NCT03087071|DRUG|Trametinib|Given PO
214365908|NCT03768492|DRUG|Caffeine anhydrous 5% added to Lipoderm Cream Base.|Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
214491429|NCT05899699|DRUG|Adapalene .1% gel|Adapalene .1% gel
214976323|NCT00853762|DRUG|Atacicept 150 mg|Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
214976324|NCT00853762|DRUG|Atacicept 150 mg|Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
214976325|NCT03528148|BEHAVIORAL|cycling|Active cycling
214976326|NCT03528148|BEHAVIORAL|Physical therapy|Conventional physical therapy
214976327|NCT03059914|DEVICE|InterOss|Anorganic bovine bone mineral - Xenograft
214976328|NCT03059914|DEVICE|Bio-oss|Anorganic bovine bone mineral ( Xenograft)
214976329|NCT02873234|DRUG|Traditional Chinese Medicine|Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
214976330|NCT02873234|DRUG|Antidepressants|Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
215085003|NCT03094078|OTHER|News item without spin|Interpretation of news item without spin
215085004|NCT04757688|RADIATION|Cardiac radioablation (CRA)|CRA to 25 Gy in 1 fraction
214365909|NCT03768492|OTHER|Lipoderm Cream Base|Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
214976331|NCT02321852|DRUG|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
215085005|NCT02418208|DIAGNOSTIC_TEST|Performint EEG tests and BNA analysis|
214365910|NCT05591339|BIOLOGICAL|BCG vaccine (two doses, 4 weeks apart)|BCG vaccine provided intradermally at the upper arm.
214365911|NCT05591339|BIOLOGICAL|Saline placebo (Two doses, 4 weeks apart)|Participants randomized to the control group (placebo) will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
214365912|NCT03602118|DRUG|Phenobarbital Sodium Injection|Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
214365913|NCT05417620|BEHAVIORAL|Social Media Campaign|PrEP social influence campaign, which will use online approaches to promote PrEP within communities in addition to the standard of care activities. Messaging crafted with community input will be geographically targeted to women, parents/mentors, and male partners on Facebook, Instagram, and Whatsapp, all with the intention to promote PrEP for women at high risk of HIV infection and change community norms and influence around PrEP. A combination of static imagery and brief videos will be used to engage these groups via social media platforms. A Facebook page will be created and maintained that can be accessed by anyone anywhere, but will only be advertised/promoted in the intervention districts.
214365914|NCT05417620|BEHAVIORAL|PrEP Champions|Within venues served by the FSW and AGYW programs, the team will identify and train 1 venue-based PrEP champion per venue who will receive supplies (e.g. a hat, pin and posters, flyers, IEC material) to wear to promote PrEP, facilitate linkage between women interested in PrEP and the TB HIV Care PrEP programme. PrEP champions will be either peers with experience taking PrEP, venue managers or local influencers (e.g. women running shops next to the mobile serving AGYW) that have repeated contact with the women the programme is intended to serve. The final selection of PrEP champions will be made in consultation with the Community Advisory Groups, venues and by the programme who works closely with each of the sites.
214365915|NCT05417620|BEHAVIORAL|Community Mobilization|A PrEP community mobilization team (2 peers, including one woman and one man) will be recruited within each ward to promote PrEP. The team will present information about PrEP and the PrEP programme at the ward councilors meeting, at Learning Support Agent meetings with parents/guardians, at local events/fairs, community meetings and through engaging men, women and parents across the community through informal conversations. Teams will be wearing branded material and will focus on presenting factual information and decreasing PrEP stigma. Each team will focus on promoting PrEP within their own ward over the 6-month period.
214365916|NCT05417620|OTHER|Standard of Care|"Full-time peer educators employed by the TB HIV Care programme to engage women, layer PrEP promotion across prevention programs, and implement refer a friend strategies, information, education and communication (IEC) materials, service user testimonials, risk reduction posters to increase young women's perception of risk, working after hours/weekends to reach young women, working with school governing bodies, and door-to-door outreach."
214365917|NCT03821168|DRUG|injection of bevacizumab and erythropoietin|injection of bevacizumab and erythropoietin
214365918|NCT03821168|DRUG|injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
214365919|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with sublingual sprayable microemulsion.|Participants received sublingual sprayable microemulsion of vitamin D3 4000 IU daily for 30 days.
214365920|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with oil droplets|Participants received oil droplets of vitamin D3 4000 IU daily for 30 days.
214365921|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with capsules|Participants received capsules of vitamin D3 4000 IU daily for 30 days.
214365922|NCT02652741|DRUG|Enalapril Orodispersible Minitablet|8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
214365923|NCT02782169|DRUG|Pregabalin|Pregabalin 300 mg capsule (over encapsulated to maintain blinding)
214365924|NCT02782169|DRUG|Placebo|Matching placebo capsule with excipient to match Pregabalin
214365925|NCT01786928|OTHER|Resistance training|Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
214491430|NCT00144287|DRUG|Tipranavir/Ritonavir|
214491431|NCT00570466|BEHAVIORAL|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
214491432|NCT00570466|BEHAVIORAL|Web and DVD knowledge|Web and DVD based knowledge games
214976332|NCT02321852|DRUG|Placebo|Once daily oral administration of placebo mannitol for 7 days
214976333|NCT05866913|PROCEDURE|Sciatic nerve slippage.|Sciatic nerve slippage.
214976334|NCT05866913|PROCEDURE|Passive stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
215085006|NCT02501720|PROCEDURE|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
214976335|NCT05866913|PROCEDURE|passive shoulder mobilization.|passive shoulder mobilization.
214976336|NCT00560365|OTHER|laboratory biomarker analysis|
214976337|NCT00560365|PROCEDURE|computed tomography|
214976338|NCT00560365|PROCEDURE|magnetic resonance imaging|
214976339|NCT00560365|PROCEDURE|quality-of-life assessment|
215085007|NCT02501720|PROCEDURE|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
215085008|NCT02501720|PROCEDURE|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
215085009|NCT01905722|OTHER|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
215085010|NCT01905722|OTHER|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
214491433|NCT04255212|OTHER|Soft tissue treatment|Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
214491434|NCT04255212|OTHER|Mechaninsms explanation|Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
214491435|NCT04255212|OTHER|Control Group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
214491436|NCT04255212|OTHER|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
214491437|NCT06225336|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
214491438|NCT01302600|DRUG|Olesoxime|Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
214491439|NCT01302600|DRUG|Placebo|0.1ml/kg once a day with food at dinner.
214491440|NCT01171976|DRUG|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
214491441|NCT06157645|DEVICE|Prolene mesh|Application of mesh onlay post stoma closure
214491442|NCT05410106|DEVICE|PneuX Endotracheal Tube|The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.
214491443|NCT05410106|DEVICE|Standard care (Taperguard, Covidien)|Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.
214491444|NCT02779478|PROCEDURE|Bronchoscopy|
214365926|NCT02975973|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
214365927|NCT02347020|BEHAVIORAL|Normal Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0000-0800 h, with meals at 1, 5, 11, and 12.5 (snack) h after awakening every day for 5 days. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
214365928|NCT02347020|BEHAVIORAL|Normal Sleep/ Late Meal|The subject will be inpatient for 5 days and sleep between the hours of 0000-0800 h,with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
214491445|NCT04503395|DEVICE|ESAR treatment: Endograft + Heli-FX Endoanchor|ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
214491446|NCT04503395|DEVICE|FEVAR treatment : Fenestrated endograft|Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
214491447|NCT06288854|OTHER|weight gain each group|weight gain after 12 Weeks
214491448|NCT04436250|DRUG|Active comparator|The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
214491449|NCT04436250|DRUG|S-Ketamine Low dose|The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
214491450|NCT04436250|DRUG|S-Ketamine High dose|The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
214491452|NCT05770895|BIOLOGICAL|GS-2829|Administered intramuscularly
214491453|NCT05770895|BIOLOGICAL|GS-6779|Administered intramuscularly
214491454|NCT05770895|BIOLOGICAL|Placebo for GS-2829|Administered intramuscularly
214491455|NCT05770895|BIOLOGICAL|Placebo for GS-6779|Administered intramuscularly
214491456|NCT03244813|OTHER|Personalized activity program|Targeted physical activity
214491457|NCT04767009|DRUG|PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)|Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.
214491458|NCT04767009|RADIATION|SBRT|Patients with oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors will be treated with curative-intent SBRT of residual lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1/PD-L1 inhibitors will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
215085011|NCT01011803|OTHER|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were \[diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)\]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
214365929|NCT02347020|BEHAVIORAL|Late Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0330-1130 h, with controlled meals at 1, 5, 11, and 12.5 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
214365930|NCT02347020|BEHAVIORAL|Late Sleep/ Late Meal|The subject will be inpatient for 5 days, and sleep between the hours o 0330-1130 h, with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
214365931|NCT00771810|DRUG|TXA127|Once daily subcutaneous injection of 100 ug/kg
214491459|NCT04441567|OTHER|Right-size clinic visits|The curve created in Phase 1 will be used to guide the number of clinic visits based on PROMs reported by the participants in Phase 2.
214491460|NCT03432338|OTHER|inquiries|Inquires reported to clinician.
214491461|NCT01289314|PROCEDURE|TLH|Total laparoscopic hysterectomy (TLH)
214491462|NCT01289314|PROCEDURE|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
214491463|NCT06894927|DIAGNOSTIC_TEST|Screening HHIA questionnaire|"Completion of the abbreviated (screening) version of the standardized HHIA questionnaire (Czech version)."
214491464|NCT06894927|DIAGNOSTIC_TEST|Whispered voice test|Whispered voice test conducted following the standardized protocol.
214491465|NCT06894927|DIAGNOSTIC_TEST|Screening pure tone audiometry|Screening pure-tone audiometry at a level of 35 dB at the frequencies: 500, 1000, 2000, and 4000 Hz.
214491466|NCT06894927|DIAGNOSTIC_TEST|Pure Tone Audiometry|Clinical Pure Tone Audiometry
214491467|NCT06894927|DIAGNOSTIC_TEST|Tympanometry|Clinical Tympanometry
214491468|NCT06894797|RADIATION|Concurrent Chemoradiotherapy（Radiation + Capecitabine）|Capecitabine 825 mg/m\^2 Po BlD, Monday-Friday, on days of radiation treatment only, throughout the duration of RT Radiation：45-50Gy/25fractions/5 weeks，5fractions/week
214491469|NCT06894797|DRUG|irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection (50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
214491470|NCT06894797|DRUG|Oxaliplatin|Oxaliplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
214365932|NCT00771810|DRUG|TXA127|Once daily subcutaneous injection of 300 ug/kg
214365933|NCT00771810|DRUG|Placebo|Once daily subcutaneous injection of placebo
214491471|NCT06894797|DRUG|5-FU|5-FU (2400mg/m\^2) will be administered by intravenous infusion on 46h in a 2-week treatment cycle.
214491472|NCT06892067|COMBINATION_PRODUCT|Cosmetic Products|To evaluate and analyze the safety of commonly used ingredients in over-the-counter personal care and cosmetic products.
214491473|NCT06688357|DEVICE|Active NIR-PBM (MedX 1116, MCT502)|Near infrared light was delivered using two MedX Rehab Console systems (MedX Health, 1116). Each MedX console included a control unit and 3 superluminous light emitting diode (LED) clusters. Each LED cluster (3MedX MCT502) consisted of 52 near infrared diodes and 9 visible red diodes. The 9 red diodes were deactivated. The energy delivered by each cluster was 1 joule \[J\]/cm2 in 45 sec at treatment wavelength of 870 nm per each 20 min. The LED cluster has an irradiance of 22.2 mW/cm2, treats an area of 22.48 cm2, with an energy density of 26.64/cm2 per cluster (total energy of 599J/cluster). During each session, the 6 clusters were arrayed on the scalp in 2 configurations, 20 minutes per array. Each configuration targeted 6 transcranial sites, guided by the 10-20 system, for a total of 12 sites during the 40-min session. Total energy delivered was 599J/cluster X 12 sites = 7188J. Dosing was based on a pilot study. This intervention was given 3 times/week for 2 weeks.
214976340|NCT00956085|DRUG|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
214976341|NCT05584995|PROCEDURE|Control group|Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)
214976342|NCT05584995|PROCEDURE|BUAL group|"Bilateral Uterine Artery Ligation Technique:~All uterine surgeries will be conducted by externalizing the uterus as much as possible and holding it by the fundus. The BUAL will be done using absorbable suture no. 1 Vicryl (Vicryl 1, Ethicon, France, Neuvilly-sur-Seine, France) will be placed through an avascular space in the broad ligament and tied from the anterior to posterior aspects of the myometrium 2-3 cm medial to the descending portion of the uterine vessels. In all patients, the suture will be carried from the anterior to the posterior at 1 cm to the myometrium medial to the Uterine artery and will be knotted after passing it through the avascular region at 1 cm to the wide ligament section adjacent to the uterus in both sides. All patients will be examined for uterotonics during and after the surgery. The ovarian arteries will be assessed at the level of the ovarian hilum."
214976343|NCT01800045|DRUG|Pitolisant|1 capsule in the morning before breakfast
214976344|NCT01800045|DRUG|Placebo|1 capsule in the morning before breakfast
214976345|NCT02479750|DEVICE|ColdZyme® mouth spray|
214976346|NCT02479750|DEVICE|Placebo|
214365934|NCT04220177|DEVICE|SETA LATECBA Stent Grafts|ABK model is a bifurcated polyester graft partially corrugated which is sutured at the proximal end (renal) to a balloon expandable 316 L stainless steel stent. The proximal half part of the stent is uncovered by polyester graft providing the anchoring to the healthy aorta wall when the device is implanted, as well as the perfusion of the renal arteries. The remaining half part is covered by polyester graft providing sealing of the aneurysm when it is expanded upon on the graft fabric and aneurysm neck. The distal end of each branch has the anchorage site for sealing after the connection with the iliac extensions RIK. The diameter of the anchorage site varies with the different ABK codes. The end of one branch is cone-shaped after the anchoring diameter with the purpose of promoting insertion of iliac extension RIK. The connection to iliac arteries is achieved by completing the aortic trunk ABK with 2 iliac extensions RIK.
214365935|NCT00765232|DRUG|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
214365936|NCT00765232|DRUG|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
214365937|NCT00989248|OTHER|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
214365938|NCT04542018|OTHER|a low FODMAP diet for 4 weeks|low FODMAP diet for 4 weeks
214365939|NCT01953848|DRUG|EC905|Oral
214365940|NCT01832116|DRUG|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
214365941|NCT05275257|DEVICE|Use of Uricap Female, a New Urine Collecting Device|The uridome is changed daily by trained staff
214365942|NCT05721534|OTHER|Medication review|"Annual consultation focusing on pharmacological treatment. This specific consultation constituted the intervention. It included a structured review of the patient's health state, in addition to a structured medication review with a focus on appropriate medication and deprescribing."
214365943|NCT01127867|DIETARY_SUPPLEMENT|dietary intervention|dietary intervention
214365944|NCT00255931|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy and Relaxation/biofeedback
214365945|NCT00255931|BEHAVIORAL|Attention Placebo|Untrained relaxation
214365946|NCT01579734|DRUG|Tamoxifen|1 tablet, 5 mg / day for 5 years
214365947|NCT01579734|DRUG|Placebo|1 tablet day for 5 years
214365948|NCT05554952|COMBINATION_PRODUCT|MTA|Mineral trioxide aggregate (MTA) is composed of Portland cement, with 4:1 addition of bismuth oxide added so that the material can be detected on a radiograph. The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.
214365949|NCT01833338|DEVICE|Imaging|All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
214365950|NCT01792180|BEHAVIORAL|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
214365951|NCT03071055|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection
214365952|NCT06307015|RADIATION|De-escalation|Surgical resection of primary oropharyngeal tumour followed by de-escalated radiation therapy (30Gy) with concurrent platinum-based chemotherapy to oropharynx + neck, followed by surgical neck dissection
214365953|NCT06307015|RADIATION|Standard of care|Radiation therapy (70Gy) with concurrent platinum-based chemotherapy to oropharynx + neck
214365954|NCT02679261|DRUG|Atorvastatin|Oral administration atorvastatin 20 mg per day
214365955|NCT02679261|DRUG|Placebo|Oral administration placebo
214365956|NCT02652988|OTHER|Active-tDCS|Active home-based tDCS applied at home.
214365957|NCT02652988|OTHER|Sham-tDCS|Sham home-based tDCS applied at home.
214365958|NCT05938985|DIAGNOSTIC_TEST|Questionnaires and dry eye tests|Ocular Surface Disease Index (OSDI), National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), best visual acuity (BCVA) measuring, intraocular pressure, corneal fluorescein staining, lissamine green staining, Schirmer test type I and II, tear breakup time (TBUT) and noninvasive tear breakup time (NIBUT).
214365959|NCT05099042|OTHER|Recommendations and re-orientation towards appropriate physical, mental, and social health ressources|Resources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP.
214365960|NCT02373800|DEVICE|Cervical ultrasound with elastography|Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
214365961|NCT00566683|DRUG|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
214365962|NCT00566683|DRUG|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
214365963|NCT01647490|PROCEDURE|Permanent Cardiac Pacemaker Implantation|
214365964|NCT05566600|BIOLOGICAL|Human (allogeneic) iPS-cell-derived cardiomyocyte|10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium
214365965|NCT03907995|BEHAVIORAL|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
214491474|NCT06688357|DEVICE|Sham NIR-PBM (MedX 1116, MCT502)|The MedX sham intervention device is identical in all respects to the active device, except that the MedX console and diode clusters were modified to NOT deliver NIR light when turned on. The sham MedX devices were modified to deliver 'warmth', similar to that of the active devices. As with the active condition, a total of six sham interventions were given over a 2-week period, following the identical procedures described in the active condition.
214491475|NCT06754475|OTHER|Low-volume, high-intensity interval training|Low-volume, high-intensity interval training with an arm ergometer will be given two days a week for a total of eight weeks.
214491476|NCT06754475|DRUG|Standart medical treatment|Standart medical teatment
214491477|NCT02879318|DRUG|Gemcitabine|
214491478|NCT02879318|DRUG|Nab-paclitaxel|
214491479|NCT02879318|DRUG|Durvalumab|
214491480|NCT02879318|DRUG|Tremelimumab|
214491481|NCT06790771|DIETARY_SUPPLEMENT|High Dose Supplement|Participants in this intervention receive approximately 10 grams of the supplement, containing 9,000 mg of L-arginine, 200 mg of resveratrol, 500 mg of tart cherry, and 100 mg of vitamin C. The supplement is consumed in powdered form after an 8-hour fasting period. Following a 60-minute rest, participants eat an ad libitum meal to assess the supplement's effect on hunger and food intake. Blood samples are collected at eight specific time points to measure metabolic markers, including GLP-1 levels, while hunger is tracked using a 7-point satiety scale. This intervention aims to determine the effects of a high dose of the supplement on appetite suppression and metabolic responses.
214491482|NCT06790771|DIETARY_SUPPLEMENT|Low Dose Supplement|In this intervention, participants consume approximately 5 grams of the supplement, which contains 4,500 mg of L-arginine, 100 mg of resveratrol, 250 mg of tart cherry, and 50 mg of vitamin C. The protocol mirrors that of the high-dose intervention: participants arrive after fasting for 8 hours, consume the supplement, rest for 60 minutes, and eat the standardized ad libitum meal. Blood samples are taken at the same eight time points to assess metabolic responses, and hunger levels are measured using the same satiety scale. This intervention investigates whether a lower dose of the supplement can still significantly affect hunger and GLP-1 secretion.
214976347|NCT04761003|DEVICE|Thoracoscopy forceps|take pleural biopsy
214976348|NCT02461693|DRUG|Caffeine|200mg delivered as pill; one-time dose
214976349|NCT02461693|DRUG|Placebo|Lactose-based pill; one-time dose
214976350|NCT04664218|DEVICE|HIPEC device|To report the affordability on using the HIPEC machine of our design compared to the standard ones in poor places.
214976351|NCT00945646|DRUG|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops times two times a day.
214976352|NCT00945646|DRUG|Vehicle|Instill four times two times a day
214976353|NCT02000921|OTHER|VLNC cigarettes|Modified risk tobacco product
214976354|NCT02000921|OTHER|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
214976355|NCT02000921|OTHER|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
214976356|NCT02000921|OTHER|CN cigarettes|Experimental cigarettes with conventional nicotine content.
214976357|NCT03108482|DRUG|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
214976358|NCT03108482|DRUG|Tramadol (Ultram®)|Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
214976359|NCT03108482|DRUG|Celecoxib (Celebrex®)|Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
214976360|NCT03108482|DRUG|Placebo|Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
214976361|NCT04009616|DRUG|Aloe Vera mouthwash|rinsing with aloe vera mouthwash for 5 days.
214976362|NCT04009616|DRUG|Chlorhexidine mouthwash|rinsing with chlorhexidine mouthwash for 5 days.
214976363|NCT04009616|DRUG|Placebo mouthwash|rinsing with placebo mouthwash for 5 days.
214976364|NCT03794895|DEVICE|Doppler|Doing doppler for women having IUCD associated menorrhagia
214976365|NCT02675166|OTHER|Pediatric cancer young adult survivors|Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
214976366|NCT02051296|DRUG|Minocycline|RCT blinded placebo trial
214976367|NCT02051296|DRUG|placebo|RCT blinded placebo trial
214976368|NCT01893606|DRUG|N-acetyl-D-glucosamine|
214976369|NCT01893606|DRUG|placebo|
214976370|NCT04212117|OTHER|The Patient Activated Learning System (PALS)|Randomization into PALS arm.
214976371|NCT04212117|OTHER|WebMD|Randomization into WebMD arm.
214976372|NCT01189097|DRUG|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
214976373|NCT01189097|DRUG|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
214976374|NCT00359879|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
214976375|NCT00359879|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
214976376|NCT03986099|DIAGNOSTIC_TEST|Monitoring virus load|Near point of care
214976377|NCT00021788|PROCEDURE|islet cell transplantation|
214976378|NCT02735031|DRUG|Exenatide|6 weeks treatment with exenatide on top of insulin treatment
214976379|NCT02735031|DRUG|Placebo|6 weeks treatment with placebo on top of insulin treatment
215085012|NCT01657136|DRUG|Ivabradine|comparison of different drugs
215085013|NCT01657136|DRUG|Beta blocker|comparison of different drugs
215085014|NCT02042534|DRUG|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
214365966|NCT04088019|DRUG|Fixed drug combination (FDC) of ATT and Oral steroid|"In the first two week, patients receive FDC of ATT only. Oral steroid start to be given in week three.~The ATT regiment is continued for up to 6 months or more, in accordance with WHO guidelines. In the first two months the antibiotic combination given consisted of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. The next four months or continuation phases, the ATT given is rifampicin and isoniazid.~The following dosage and administration of oral steroids will be given to patients, according to guidelines from the American Journal of Ophthalmologists (Douglas A. Jabs et al, 2000):~Initial dose: 1mg/kg/day, with maximum adult oral dose 60-80 mg/kg and maintenance dose less than or equal to 10 mg/day. The tapering schedule: Over 40 mg/day, decrease by 10 mg/day every 1-2 weeks, 40-20 mg/day, decrease by 5 mg/day every 1-2 weeks, 20-10 mg/day, decrease by 2.5 mg/day every 1-2 weeks, 10-0 mg/day, decrease by 1 to 2.5 mg/day every 1-4 weeks."
214491483|NCT06790771|DIETARY_SUPPLEMENT|Placebo|The placebo intervention involves participants consuming a \~5 g inert powder with no active ingredients. Participants follow the same protocol as the other two interventions, including fasting, baseline blood collection, supplement (placebo) consumption, a 60-minute rest, and an ad libitum meal. Blood samples are collected at eight time points, and hunger levels are assessed with the 7-point scale. This intervention serves as a control, helping to determine whether observed effects in the other two interventions are attributable to the active supplement ingredients.
214365967|NCT02953938|BIOLOGICAL|Ranibizumab|"Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment"
214365968|NCT02953938|RADIATION|Grid&Direct short pulse laser photocoagulation|Grid\&Direct short pulse laser photocoagulation is a kind of laser treatment to retina within vascular arcades and used to suppress macular edema
214365969|NCT02142933|OTHER|vagino-perineal swab|
214365970|NCT05810168|OTHER|Dietary modifications|TDA and low FODMAP diet
214365971|NCT01220700|OTHER|Triclosane|Triclosane coated suture material
214365972|NCT01220700|OTHER|Control|Ordinary suture material
214491484|NCT06768541|PROCEDURE|THA using a short stem|Total Hip Arthroplasty using a collarless, triple-tapered cementless short stem (Optimys, produced by Mathys).
214491485|NCT06767670|OTHER|stainless steel crown|familiar method of managing multi-surface carious lesions in primary teeth
214491486|NCT06767670|OTHER|bioflex crown|aesthetic preformed pediatric crowns that offer the properties of both stainless steel and zirconia crowns
214491487|NCT06845124|DRUG|Cannabidiol capsules|800mg (trial arm 1) or 1200mg (trial arm 2) Cannabidiol capsules will be administered daily over the course of 14 days.
214491488|NCT06845124|DRUG|Naltrexone (drug)|All participants will receive 50mg Naltrexone daily as oral tablet throughout the study.
214491489|NCT06845124|DRUG|Placebo|Placebo capsules matching the cannabidiol capsules will be administered daily.
214491490|NCT02739477|DRUG|Favipiravir|"Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results."
214976380|NCT05387616|DRUG|Copanlisib|"Induction therapy will comprise 6 cycles of copanlisib, administered by intravenous Infusion at a dose of 60 mg on day 1,8,15 of cycles 1-6 to be given every 28 days.~Consolidation therapy will comprise another 24 weeks of copanlisib in patients with clinical Remission 28 days after the last induction cycle. It will be administered by intravenous Infusion at a dose of 60 mg on days 1 and 15 of cycles 7 - 12 to be given every 28 days.~Maintenance therapy will comprise another 72 weeks of copanlisib in patients with clinical remissions 28 days after the last consolidation cycle."
214976381|NCT05387616|DRUG|Obinutuzumab|"Induction therapy will comprise 6 cycles of obinutuzumab, administered by intravenous infusion at a dose of 1000 mg on days 1,8, 15 of cycle 1 and on day 1 of cycles 2 - 6 to be given every 28 days.~Consolidation therapy will comprise of another 24 weeks of obinutuzumab in patients with clinical remission 28 days after the last induction cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks.~Maintenance therapy will comprise another 72 weeks in patients with clinical remission 28 days after the last consolidation cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks."
214976382|NCT00915590|DRUG|Placebo|Custom eye drop eye three times a day in both eyes for a period of 6 weeks
214976383|NCT00915590|DRUG|IL-1Ra|5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
215085015|NCT02042534|DRUG|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
214365973|NCT00262587|DRUG|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
214365974|NCT00262587|DRUG|Placebo|Inhaled sugar powder in a placebo inhaler
214491491|NCT06287671|PROCEDURE|Colorectal resection or stoma closure|Elective open or minimally invasive resection for colorectal cancer, IBD or other benign colorectal disorder, or stoma closure
214491492|NCT06837506|DRUG|Rectus sheath block|Patients will receive rectus sheath block (20 ml bilaterally, bupivacaine 0.25%) after induction of general anesthesia.
214976384|NCT00873158|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
215085016|NCT02078102|DRUG|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
215085017|NCT02078102|DRUG|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
215085018|NCT01960543|DRUG|fentanyl 15 microg|
214491493|NCT06837506|DRUG|Intrathecal morphine|Patients will receive 150 µg intrathecal morphine after induction of general anesthesia.
214491494|NCT03311451|DEVICE|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
214365975|NCT02038894|DRUG|Intubated with Sevoflurane (IS)|Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
214365976|NCT02038894|DRUG|Intubated with Propofol (IP)|Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
215085019|NCT01960543|DRUG|Bupivacaine 7 mg|
214365977|NCT02038894|DRUG|Zofran - no intubation|A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
214365978|NCT02038894|DRUG|Propofol|
214365979|NCT03613675|DEVICE|Video games|"The 4 videos games consists of:~* Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~* Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~* Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~* Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes)."
214491495|NCT06758167|DRUG|XingpiJieyu formula|XingpiJieyu formula is a traditional Chinese medicine. It pays attention to the regulation of qi and blood. Previous studies have shown that its clinical effect of treating mild and moderate depression is significant, for example, it can effectively improve depressive mood and somatic symptoms, and increase peripheral blood ATP levels in patients with depression.
214491496|NCT06758167|DRUG|Placebo|Placebo, no therapeutic effect.
214491497|NCT06758167|DRUG|Escitalopram|A commonly used drug in MDD treatment.
214491498|NCT06768034|PROCEDURE|Intervention Group|Patients being referred to an internist or cardiologist after myocardial injury after noncardiac surgery
214491499|NCT06810219|DEVICE|Cognixion ONE|A wearable augmented reality brain computer interface with self contained computer and software to enable communication using the device input and output capabilities.
214491500|NCT06751264|PROCEDURE|Peritoneal combined with intrauterine water isolation|On the basis of the conventional peritoneal water isolation group, the improved technology group added additional intrauterine water isolation, and continued to inject ice saline to separate the endometrium on both sides.
214491501|NCT06751264|PROCEDURE|Peritoneal water isolation|Transabdominal injection of saline into the abdominal cavity to achieve complete separation of the uterus from the surrounding organs and structures
214491502|NCT06761651|DRUG|TAVO412|Biologic
214491503|NCT06163092|OTHER||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
214491504|NCT06761209|OTHER|blood sampling|For the study, a blood sample will be collected from the patient in order to do build up a serological library which will allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease.
214491505|NCT03872284|OTHER|oculomotor movement recordings, neurovisual assessment|Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
214491506|NCT06600789|DRUG|CT7439 Capsules (0.5 mg, 1mg, 3mg)|CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg in Cohort 1 on Cycle 0 Day 1, followed by a minimum 48 hours treatment -free period before continuous daily dosing in cycles of 28 days (Cycle1 onwards) until DLT or disease progression is observed.
214491507|NCT06751979|DIETARY_SUPPLEMENT|Probiotic treatment|Daily intake of a lozenge containing the probiotic strain S. salivarius M18.
214491508|NCT06751979|DIETARY_SUPPLEMENT|Placebo|Placebo
214491509|NCT06511843|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
214491510|NCT06511843|BEHAVIORAL|Lyrical Music|"A 4-minute audio recording of Leonard Cohen's song Hallelujah sung by Rufus Wainwright with choral accompaniment."
214491511|NCT06511843|BEHAVIORAL|Instrumental Music|A 4-minute audio recording of instrumental, theta wave music.
214491512|NCT06883851|OTHER|Structured pelvic floor rehabilitation|"The classic DDVAP therapy will be administered by the pediatric urologist. The classic urotherapy training recommended for enuresis will be provided by the physiotherapist. In addition, structured pelvic floor muscle rehabilitation (SPFMR) will be provided by the physiotherapist for 10 weeks. Each session is planned to last approximately 60 minutes.~SPFMR will include multiple interventions combined. Below is information about the brief interventions.~* Diaphragmatic Breathing Training~* Pelvic Floor Training with Biofeedback~* Core Stabilization Exercises~* Squat Exercises~* External Rotator Strengthing~* Adductor Strengthing~* Balance Training~* Home Exercises"
214491513|NCT06736366|DIETARY_SUPPLEMENT|Dietary supplement - Active comparator|Single dose intervention with Standard product Coenzyme Q10 (ubiquinone); 2 capsules - 100 mg total coenzyme Q10
214491514|NCT06736366|DIETARY_SUPPLEMENT|Dietary supplement - Experimental product|Single dose intervention with Experimental product; BMT® coenzyme Q10; 2 capsules - 100 mg total coenzyme Q10
214491515|NCT06734052|BEHAVIORAL|CAPPA|See CAPPA arm description.
214491516|NCT06734052|BEHAVIORAL|Health education|See health education arm description
214976385|NCT06445933|COMBINATION_PRODUCT|Vitamin B6|The intervention is taking Vitamin B6 orally from recruitment around 24-28 gestational weeks to 6 weeks post-partum. 75mg/ day before delivery and 50mg/ day after delivery.
214976386|NCT06445933|COMBINATION_PRODUCT|Placebo|Placebo
214976387|NCT02631941|DRUG|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
215085020|NCT01960543|DRUG|Bupivacaine 9 mg|
215085021|NCT01960543|DRUG|Levobupivacaine 7 mg|
215085022|NCT01960543|DRUG|Levobupivacaine 9 mg|
214976388|NCT02631941|DRUG|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2 denote Symbicort without oral activated charcoal administered in two different periods).
214365980|NCT02980055|PROCEDURE|collagen matrix|Surgical procedure for root coverage using collagen matrix
214365981|NCT02980055|PROCEDURE|connective tissue graft|Surgical procedure for root coverage using connective tissue graft
214365982|NCT03577639|OTHER||
214365983|NCT03158883|DRUG|Avelumab|Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 \[±2\] days).
214365984|NCT03158883|RADIATION|Stereotactic ablative radiotherapy (SAR)|SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.
214365985|NCT05125575|DRUG|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the Test (T) product was administered orally with 240 mL of water.
214365986|NCT05125575|DRUG|Glucophage® XR 1000 mg Prolonged Release Tablets|One tablet of the Reference (R) product was administered orally with 240 mL of water.
214365987|NCT02763514|DIETARY_SUPPLEMENT|3 g PronovaPure 150:500 EE EU|
214365988|NCT02763514|DIETARY_SUPPLEMENT|3 g PronovaPure 500:200 EE EU|
214365989|NCT02763514|DIETARY_SUPPLEMENT|3 g Placebo|
214365990|NCT04492579|OTHER|Gentle-UHT donor human milk supplementation|Providers referred mothers with newborns that fit the following criteria: exhibited insufficient milk supply, an infant with early weight loss born \>36 weeks gestation. Mother was given Gentle-UHT donor milk for supplementation, in addition to mother's own milk for the first week of the infant's life after hospital discharge.
214976389|NCT02631941|DRUG|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
214976390|NCT02631941|DRUG|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
214976391|NCT06227650|DEVICE|hybrid closed loop insulin delivery system|Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
214976392|NCT01790399|PROCEDURE|Excision of sentinel node(s)|Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)
214976393|NCT04603755|DEVICE|Electrical Impedance tomography|Electrical Impedance tomography recording during 5 minutes every day during 7 days
214976394|NCT00848016|DRUG|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
214976395|NCT05577416|PROCEDURE|Biopsy|Patients will undergo stereotactic biopsy by craniotomy or burr hole.
214976396|NCT05577416|DRUG|Part A: Safusidenib Erbumine|Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.
214976397|NCT05577416|PROCEDURE|Surgery (maximal resection)|Surgery: Maximal safe resection, within 24 hours of last dose of Safusidenib Erbumine.
214976398|NCT05577416|DRUG|Part B: Safusidenib Erbumine|Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.
214976399|NCT04816916|DRUG|AXA1665|AXA1665 administered TID with food
214976400|NCT04816916|DRUG|Placebo|Matching placebo administered TID with food
214976401|NCT01054963|BEHAVIORAL|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
214976402|NCT02280330|DIETARY_SUPPLEMENT|MNP group|MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.
214976403|NCT02280330|OTHER|Placebo group|The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
214976404|NCT00902863|BEHAVIORAL|YOGA|Patients with chronic pain will undergo a six week course of YOGA
214976405|NCT02858401|DRUG|Vesatolimod|Tablet(s) administered orally once every 2 weeks
214976406|NCT02858401|DRUG|Placebo|Tablet(s) administered orally once every 2 weeks
214976407|NCT02858401|DRUG|ARV regimen|Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
214976408|NCT03722576|DRUG|Vidofludimus calcium|During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
214976409|NCT00299520|DRUG|intravenous iclaprim or intravenous linezolid|
214976410|NCT03118180|BIOLOGICAL|CD19 targeted chimeric antigen receptor T cells|CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
214976411|NCT00299858|DRUG|Theophylline|"Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time."
214976412|NCT00889239|OTHER|lithia-disilicate-based crown|all-ceramic crown
215085023|NCT00642148|DRUG|GW856553|Active tablet
215085024|NCT00642148|DRUG|Placebo|Placebo tablet and inhaler
215085025|NCT00642148|DRUG|Seretide|Active comparator inhaler
214365991|NCT00005810|BIOLOGICAL|filgrastim|
215085026|NCT03586323|DRUG|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
215085027|NCT00035360|DRUG|PEG-Intron|
215085028|NCT01073540|DRUG|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
215085029|NCT01073540|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
215085030|NCT02510365|BIOLOGICAL|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
215085031|NCT00645879|DRUG|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
214365992|NCT00005810|DRUG|carboplatin|
214365993|NCT00005810|DRUG|docetaxel|
214365994|NCT00005810|DRUG|estramustine phosphate sodium|
214365995|NCT02635048|PROCEDURE|Mini Percutaneous Nephrolithotomy|patients undergo PNCL with 18Fr nephrostomy tract
214976413|NCT04474483|DRUG|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
215085032|NCT00645879|DRUG|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
215085033|NCT00645879|DRUG|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
215085034|NCT01025570|DRUG|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
215085035|NCT00885638|DRUG|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
215085036|NCT00885638|DRUG|placebo|A placebo tablet is given before ingestion of macronutrients
214365996|NCT02635048|PROCEDURE|Percutaneous Nephrolithotomy|patients undergo PNCL with 24Fr nephrostomy tract
215085037|NCT01533090|DRUG|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
215085038|NCT01533090|DRUG|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
215085039|NCT00598078|DRUG|Sodium Oxybate|Dose 1
214365997|NCT03323333|BEHAVIORAL|psychosocial counseling|A problem-solving and psychosocial skill-building intervention.
214491517|NCT06892223|DRUG|Monalizumab (anti-NKG2A monoclonal antibody)|Monalizumab (humZ270 mAb, IPH2201) is a humanized IgG4 monoclonal antibody targeting the NKG2A receptor on NK cells. Administered intravenously at a dose of 1 mg/kg on days +30 and +44 after haploidentical stem cell transplantation with post-transplant cyclophosphamide (PT-Cy) as GVHD prophylaxis, Monalizumab aims to enhance NK cell activity by blocking NKG2A. This intervention is unique in its timing, as it is given during a period when CD94/NKG2A+ NK cells are abundant, and its two-dose regimen is designed to optimize NK cell reconstitution. It targets patients with hematologic malignancies, such as AML and MDS, to improve GVHD-free and progression-free survival by enhancing NK cell-mediated immunity. This approach differs from other therapies by focusing on NK cell alloreactivity in the post-transplant setting. Cyclophosphamide is used as part of the pre-transplant conditioning regimen and is part of the inclusion criteria, but it is not part of the protocol-specific intervention.
214491518|NCT06758024|DRUG|Infliximab|IFX therapeutic drug monitoring before the second and third infusion and subsequent dashboard-guided dosing regimes suggested to attending gastroenterologists based on clinical and pharmacokinetics data
214491519|NCT06758024|DRUG|Infliximab|No IFX therapeutic drug monitoring before the second and third infusion and subsequent dosing regimes based on clinical data
214491520|NCT06757621|RADIATION|Regional Nodal Irradiation|Patients will receive chest wall / breast radiation with or without regional nodal irradiation
214491521|NCT06891508|OTHER|Venous blood sampling|Venous blood sampling (3 mL) via venipuncture from the antecubital fossa at the time of delivery
214491522|NCT06891508|OTHER|Tissues sampling|Sampling of the placenta and amniochorionic membranes (hAM) at delivery
215085040|NCT00598078|DRUG|Sodium Oxybate|Dose 2
215085041|NCT00598078|OTHER|Placebo|Dose 3
215085042|NCT04014140|PROCEDURE|Coronary artery bypass grafting surgery (CABG)|Patients with MVCAD will undergo CABG as per standard of care.
215085043|NCT00747669|DRUG|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
215085044|NCT05995223|OTHER|Submaximal exercise protocol|Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.
215085045|NCT03336372|DRUG|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
215085046|NCT01897753|DRUG|growth hormone|36 months
215085047|NCT02185014|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
215085048|NCT00353431|DRUG|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
215085049|NCT03873181|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.
214365998|NCT02536365|BEHAVIORAL|Sensory Integration Therapy|Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
214491523|NCT06891508|OTHER|Umbilical cord blood sampling|Umbilical cord blood sampling from the residual cord attached to the placenta immediately after clamping.
214365999|NCT02536365|BEHAVIORAL|Applied Behavioral Analysis|Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
214366000|NCT03061565|DRUG|erythropoietin|Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
214366001|NCT03061565|DRUG|Placebos|Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
214366002|NCT02159599|DRUG|Darunavir/Ritonavir|Darunavir/ritonavir (800/100 mg): QD (quaque die )
214366003|NCT02159599|DRUG|Lamivudine|Lamivudine (300mg) : QD
214491524|NCT06891534|OTHER|Continuous Feeding|Participants will receive 24-hour continuous feeds through an NG tube
214491525|NCT06891534|OTHER|Intermittent feeding|Participants will receive 3 boluses of feeding per day at regular meal times through an NG tube to mimic normal meals.
214491526|NCT06758947|DRUG|Upadacitinib 15 MG|oral tablet upadacitinib
214491527|NCT06758947|DEVICE|Cellcept Oral Product|active control group 2000mg MMF daily
214491528|NCT06760169|DEVICE|Surgery with ELIOS laser|This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these microchannels enhances the natural outflow of aqueous humor by bypassing the site of major resistance in the system. The usual duration of the ELIOS procedure is typically few minutes). The rest of the surgery does not deviate from standard phacoemulsification.
214491529|NCT06895564|RADIATION|Spinal Proton SBRT|Patients will be treated with spinal proton SBRT over 5 fractions, with a prescription dose of 6 Gray equivalent (GyE) per fraction to the planning target volume.
214491530|NCT05383495|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg \[100 mcg/mL (max 200 mcg or 2 mL)
214491531|NCT05383495|DRUG|Midazolam Nasal Spray|Intranasal midazolam 0.4 mg/kg \[5 mg/mL (max 10 mg or 2 mL)
214491532|NCT05383495|DRUG|Nitrous oxide|50% nitrous oxide in 50% oxygen by face mask
214976414|NCT04474483|OTHER|Placebo (Methylcellulose) capsule|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
214976415|NCT04499079|OTHER|Learning Health System|This is a system-level intervention designed to improve collaboration among personnel from the juvenile and behavioral healthcare systems.
214976416|NCT02513550|DRUG|Ixekizumab|Administered SQ
214976417|NCT02513550|DRUG|Placebo|Administered SQ
214976418|NCT01792739|DRUG|Lactobacillus casei variety rhamnosus granules|"Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
214976419|NCT01792739|DRUG|Placebo|"Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
215085050|NCT03225768|BEHAVIORAL|Guided Training|Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
214366004|NCT02159599|DRUG|Emtricitabine/tenofovir or abacavir/lamivudine|Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
214366005|NCT00760149|DRUG|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
214366006|NCT00101933|DEVICE|Medtronic DBS Therapy for epilepsy|Stimulation On
214366007|NCT00101933|DEVICE|Medtronic DBS Therapy for epilepsy|Stimulation Off
214366008|NCT04266379|DEVICE|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
214491533|NCT06767631|DIAGNOSTIC_TEST|threedimensional freehand ultrasound and instrumented spasticity assessment|To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.
214976420|NCT00193453|DRUG|Gemcitabine|1000mg/m2 30min IV, Day 1 \& 8
214976421|NCT00193453|DRUG|Docetaxel|30mg/m2, 30min IV, day 1 \& 8
214976422|NCT00193453|DRUG|Cetuximab|100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15
214976423|NCT02774317|BIOLOGICAL|Plasma|FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
214366009|NCT04266379|DEVICE|Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitoring|Insulin delivered subcutaneously by a pump and manage by the patient with the help of a CGM sensor
214366010|NCT04132843|DRUG|Gadobenate Dimeglumine|Given IV
214366011|NCT04132843|DRUG|Gadobutrol|Given IV
214366012|NCT04132843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214976424|NCT00290563|DRUG|MK0594|
214976425|NCT02204917|DRUG|OPTISON|Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
214976426|NCT02238730|DEVICE|Ultrabrief Right Unilateral|The first six electroconvulsive therapy sessions using ultrabrief (0.25 ms) right unilateral electroconvulsive therapy
214491534|NCT06753968|PROCEDURE|Laparoscopic Right Hemicolectomy With Transrectal/transvaginal Specimen Extraction (NOSES)|Transvaginal extraction, begins with the irrigation and disinfection of the vagina, followed by a transverse incision in the posterior fornix. The assistant then utilizes oval forceps to carefully extract the specimen bag through the incision, which is subsequently closed with continuous full-thickness sutures, using barbed sutures to ensure secure closure. Similarly, transrectal extraction begins with irrigation of the rectum using a dilute iodine solution, followed by a longitudinal incision along the anterior wall of the upper rectum. The specimen, along with the protective sleeve, is then removed using oval forceps, and the incision is closed with a continuous full-layer running suture once the specimen has been completely extracted.
214976427|NCT02238730|DEVICE|Brief Pulse Bitemporal|The first six electroconvulsive therapy sessions using brief pulse (0.5 ms) bitemporal electroconvulsive therapy
214976428|NCT04256343|OTHER|Deuterium Oxide (D2O) Dose|1 of 3 differing deuterium oxide (D2O) doses will provided to each of the participants to be consumed daily to assess muscle protein synthesis.
214366013|NCT03440684|OTHER|Exercise|"At the beginning of the training, participants were informed about the anatomy and biomechanics of core muscles and the effectiveness core stabilization exercises.~In all sessions, 5 minutes warm-up exercises and 5 minutes cool-down exercises were done before training. The exercises were first shown by the physiotherapist 2 to 3 repetitions and then the participants performed the exercise 10 to 12 repetitions.~Participants were included clinical pilates exercises for 6 weeks, which would be 3 days per week. Exercise programme were managed by one and the same physiotherapist. Each week the level of difficulty of the exercises was increased according to the tolerance of the participants and new exercises were added to the program."
214366014|NCT05938257|PROCEDURE|TMJ discopexy|Arthroscopic versus open TMJ discopexy
214366015|NCT02657031|DRUG|Prochlorperazine|prochlorperazine 10 mg IV
214366016|NCT02657031|DRUG|Ketamine|Ketamine 0.3 mg/kg IV
214366017|NCT02657031|DRUG|Diphenhydramine|Diphenhydromine 25 mg IV
214366018|NCT02657031|DRUG|Ondansetron|Ondansetron 4 mg IV
214366019|NCT02657031|DRUG|Normal Saline|Normal Saline 500 cc IV Bolus
214366020|NCT01561001|DEVICE|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
214366021|NCT02609165|DRUG|rhNGF 180 µg/ml eye drops solution|eye drops
214366022|NCT02609165|DRUG|vehicle eye drops|placebo
214366023|NCT04954599|DRUG|CP-506|CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3
214366024|NCT04954599|DRUG|Carboplatin|Antineoplastic agent, ATC Code: LO1X A02
214366025|NCT04954599|DRUG|Immune checkpoint inhibitor|Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4
214366026|NCT01245946|PROCEDURE|Photodynamic therapy|Photodynamic therapy: 2 sessions separated by 2 weeks of TDF with topical ALA20% for 1.5 hrs, then irradiated with red light (Waldmann lamp) at a fluence of 37 J/cm2 for 7-9 minutes. From the sixth week will begin adapalene 0.1% gel until 12 weeks
214366027|NCT01245946|DRUG|Conventional therapy|Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
214366028|NCT05554601|BEHAVIORAL|gamification with collaboration|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on collaboration
214366029|NCT05554601|BEHAVIORAL|gamification with competition|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on competition with each other
214366030|NCT04716348|PROCEDURE|muscle energy technique|muscle energy technique for suboccipital muscles
214366031|NCT00512512|PROCEDURE|Transoral Endoscopic Liver Biopsy|Liver will be biopsied with transoral endoscope instead of the laparoscopic instruments during laparoscopic gastric bypass
214366032|NCT05609084|PROCEDURE|Speech therapy|Patients will connect on an interface to pratice speech therapy
214366033|NCT05609084|PROCEDURE|Speech therapy assessment|Patients will be followed by an speech therapist
214366034|NCT03912558|PROCEDURE|Butterfly device implantation|The Butterfly device will be positioned and deployed with cystoscopy guidance
214366035|NCT04997954|DRUG|MediCabilis CBD oil|"The investigational product (MediCabilis 5% (50mg/ml) CBD Oil) will be supplied by BOD Australia, an Australian licensed manufacturer of medical grade cannabis.~The main components of MediCabilis 5% (50 mg/mL) CBD extract in MCT Oil are:~* Cannabis sativa L. dry extract~* Medium chain triglycerides (Ph Eur 0868) which are added in order to adjust the active constituent (cannabidiol) to the target content.~Each mL of MediCabilis provides:~* 50 mg of Cannabidiol (CBD+CBDA)~* Less than 2 mg tetrahydrocannabinol (THC)~* Non-active ingredient: Medium Chain Triglycerides (MCT) oil sourced from coconut"
214366036|NCT02748187|OTHER|CBASP|Interpersonal psychotherapy for chronic depression
214366037|NCT05114655|OTHER|Herbaceous Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from resins, bark, and flowers to apply three times daily for the purposes of inhalation.
214366038|NCT05114655|OTHER|Citrus Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from citrus peel, and flowers to apply three times daily for the purposes of inhalation.
214366039|NCT05114655|OTHER|Inert Oil|Participants are given an inert vegetable based oil blend to apply three times daily for the purposes of inhalation.
214366040|NCT03797521|DRUG|SXC-2023|SXC-2023 oral capsules
214366041|NCT03797521|DRUG|Placebo|Matching Placebo oral capsules
214976429|NCT05701813|DIETARY_SUPPLEMENT|INOSITOLS|4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.
214976430|NCT05701813|DIETARY_SUPPLEMENT|CELLULOSE|4.3 grams of cellulose once a day for 90 days.
214976431|NCT00749398|BIOLOGICAL|Infliximab|According to local country regulations.
214976432|NCT04566068|BEHAVIORAL|Intervention- Adapted Virtual Insomnia Program|4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors.
214976433|NCT04566068|BEHAVIORAL|Control- Enhanced usual care|Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
214679761|NCT05314595|PROCEDURE|bilateral uterine artery ligation|"* Spinal anaethesia with intrathecal morphia~* Transverse skin incision~* Adequate dissection of the bladder.~* Incision of the uterus above placental edge.~* Delivery of the fetus.~* Delayed cord clamping (60 seconds) if the baby appears well.~* Exteriorization of the uterus.~* Start Oxytocin infusion and uterine massage to ensure good uterine contractions immediately after delivery of the fetus. No trials of placental delivery will be made at this point.~* At this point, a gentile trial to deliver the placenta is performed~* A catheter is placed in the cervix from above to secure the cervical opening~* Compression is applied to the site of bleeding from placenta site~* Placental pouch is marked by multiple allies and is closed down to the multiple-8 suture.~* Blood loss is measured using the suction device and coated socked towels. In modified PPC, Bilateral uterine artery ligation will be done after exteriorization of the uterus in order to minimize the blood loss."
215085051|NCT02085525|OTHER|Nurse Practitioner Clinic|"The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs."
214491535|NCT06753968|PROCEDURE|Totally laparoscopic right hemicolectomy (TLRH)|Totally laparoscopic right hemicolectomy (TLRH), which involves performing intracorporeal anastomosis and specimen extraction through a small abdominal incision, further enhances the benefits of minimally invasive surgery. In the TLRH group, following the stapled side-to-side anastomosis, a small horizontal incision is made about 2 to 3 cm above the symphysis pubis, at the junction of the pubic hairline, to allow for specimen removal.
214491536|NCT06757400|OTHER|Mobilization|Mobilization will be conducted on an examination table with the subject in prone position. Therapist will place his hypothenar to the most hypomobile lumbar spine segment after assessment.It will be a posteroanterior (PA) direction tecnique, Maitland's GRADE 4, 3 sets of 60 seconds duration for each set.
214491537|NCT06757400|OTHER|manipulation|Manipulation will be conducted on an examination table with the subject in right lateral decubitus. It will be a rotary manipulation to the most hypomobile lumbar spine segment after assessment.
214491538|NCT04099823|OTHER|MRI screening form|Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
214491539|NCT04099823|DIAGNOSTIC_TEST|Urine pregnancy test|Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
214491540|NCT04099823|DIAGNOSTIC_TEST|MR brain|"You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging."
214491541|NCT06768086|PROCEDURE|Hysteroscopic myomectomy|"The hysteroscopic myomectomies were conducted during the follicular phase of the menstrual cycle. Throughout the surgical procedure, the intrauterine pressure was meticulously maintained at less than 80 mm Hg. Data on the duration of the surgical intervention, the volume of fluid administered, and the volume of fluid absorbed were collected. Complete resection was characterized as the total excision of the myoma. The determination of the completeness of myomectomy was made by the experienced surgeon during the surgical process. In instances where the resection was deemed incomplete, the decision to pursue a secondary surgical intervention was predicated on ultrasonographic evaluations, the symptomatic presentation of the patients, and, in certain circumstances, the findings from diagnostic hysteroscopy. Cases in which access to the uterine cavity was unfeasible were classified as failed procedures and were subsequently excluded from the study."
214491542|NCT06767839|OTHER|Transcutaneous Electrical Nerve Stimulation|The current parameters for the TENS to be applied in the study were determined as 100 Hz, 100 microsecond pulse duration, and asymmetric biphasic waveform. The current intensity will be increased until the person feels a tingling sensation and will be applied for a total of 20 minutes. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.
215085052|NCT04290793|DRUG|Pyrotinib|400mg administered as continuous oral once daily from the first day of the study
215085053|NCT04290793|DRUG|Epirubicin|90mg/m\^2 d1 iv Q2W for 4 cycles
214366042|NCT03078816|DEVICE|Activa PC Primary Cell Neurostimulator - (Model 37601)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
214366043|NCT03078816|DEVICE|Activa RC Rechargeable Neurostimulator - (Model 37612)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
215085054|NCT04290793|DRUG|Cyclophosphamide|600 mg/m\^2 d1 iv Q2W for 4 cycles
215085055|NCT04290793|DRUG|Taxanes|Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
214366044|NCT03078816|DEVICE|Activa SC Single Cell Neurostimulator (Models 37602/37603)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
214366045|NCT03078816|DEVICE|DBS Lead - (Model 3387|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
214366046|NCT03078816|DEVICE|DBS Extension - (Models 37085/6)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
214366047|NCT03078816|DEVICE|Patient Programmer - (Model 37642)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
215085056|NCT04290793|BIOLOGICAL|Trastuzumab|the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
214366048|NCT03078816|DEVICE|Test Stimulator - (Model 3625)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
214366049|NCT03078816|DEVICE|N'Vision Clinician Programmer - (Model 8840)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
214366050|NCT03078816|DEVICE|N'Vision Software Application Card - (Model 8870)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
214976434|NCT04283786|OTHER|Qualitative Interview|A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.
214976435|NCT03851263|BIOLOGICAL|Evolocumab|Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).
214976436|NCT00349141|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|
214366051|NCT05766917|BEHAVIORAL|peer education group|Patients in this group will receive the routine hospital care, in addition to the proposed peer education by trained peer
214366052|NCT04766268|OTHER|Prostate artery embolization|Prostate artery embolization (PAE) is a safe and effective minimally invasive interventional radiology procedure in which intraprostatic vessels are embolized to shrink the size of the prostate gland. LUTS is mainly categorized into irritative, obstructive, and mixed types. This has a variable impact on patients' quality of life by interfering with sleep, activities of daily living, anxiety, mobility, leisure, and effect on sexual activities. This trial aims to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
214366053|NCT00180635|DRUG|Aminoguanidine|500mg
214366054|NCT00180635|DRUG|Placebos|2ml
214366055|NCT00145015|BEHAVIORAL|Increased dietary intake of salmon or cod|
214366056|NCT05899842|DRUG|Protein pump inhibitor therapy systematically|Lansoprazole 30mg once per day
214366057|NCT05977426|OTHER|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
214366058|NCT02375295|DRUG|ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin|Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
214366059|NCT00669786|DRUG|Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)|
214366060|NCT05373095|BEHAVIORAL|PKC (adapted adherence counseling) and Conditional Cash Transfers|The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (\~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically \<$1.
214366061|NCT04410068|DEVICE|WARMTAC|Randomization to one of the arms previous to surgery.
214366062|NCT04410068|DEVICE|3M Bair Hugger|Randomization to one of the arms previous to surgery.
214366063|NCT00603577|DRUG|Placebo|Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
214366064|NCT00603577|DRUG|Xaliproden|1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
214366065|NCT05505474|DEVICE|IVF with the Neria™ Guard Subcutaneous Catheter|Use of the Neria™ Guard subcutaneous catheter for administration of subcutaneous medication in an IVF cycle.
214679762|NCT03246035|BEHAVIORAL|Intervention Group|For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline. Patients will then be referred to a Geriatrics Assessment Team, who will provide individualized recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.
214679763|NCT03246035|OTHER|Control Group (Standard Care)|For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
214679764|NCT04536415|DRUG|Oseltamivir Phosphate 75 mg capsules|Capsules, 75 mg, single, oral dose
214679765|NCT04536415|DRUG|Tamiflu capsules 75 mg|Capsules, 75 mg, single, oral dose
214679766|NCT01522651|DRUG|Ranolazine|Tablets administered orally twice daily.
214679767|NCT01522651|DRUG|Dronedarone|Capsule administered orally twice daily
214679768|NCT01522651|DRUG|Ranolazine placebo|Tablets administered orally twice daily.
214679769|NCT01522651|DRUG|Dronedarone placebo|Capsules administered orally twice daily
214679770|NCT06513221|DRUG|Chemotherapy, Bevacizumab, Adebrelimab|Adebrelimab: 1200mg，q3w Bevacizumab: 7.5mg/kg，q3w Fruquintinib: 4mg po d1\~d14, q3w Chemotherapy: XELOX/mXELIRI: conventional dose
214679771|NCT02650778|PROCEDURE|Breast ultrasound|automated whole breast ultrasound
214679772|NCT01746602|DRUG|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
214679773|NCT01746602|DRUG|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
214679774|NCT01746602|DEVICE|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
214976437|NCT01564004|OTHER|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
214976438|NCT03924323|DRUG|Escitalopram|8-weeks of treatment followed by 1-week taper down period
214976439|NCT03924323|OTHER|Placebo|Matching oral administration of inactive substance once daily
214976440|NCT04710004|DEVICE|Asynchronous distributed multi-electrode stimulation (ADMES) using an implantable neurostimulation device|Participants will receive asynchronous pulses distributed across a multi-electrode array of 16 micro-electrodes and stimulating at low (theta) frequencies.
214976441|NCT01088971|DIETARY_SUPPLEMENT|Duolac7S|1 capsule two times everyday for 6 weeks
214366066|NCT03777267|DEVICE|Active CR|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
214491543|NCT06767839|OTHER|High Voltage Pulsed Galvanic Stimulation|YVKGS is a monophasic waveform current with double peaks, short pulse duration and a voltage higher than 100 Volts, the frequency of which can be adjusted optionally. In the study, the current parameters of YVKGS were determined as a frequency of 100 Hz, continuous pulse, double peak monophasic waveform. The current intensity will be applied for 20 minutes at the voltage at which the person feels a tingling sensation. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.
214491544|NCT06767839|OTHER|Sham TENS|The current will be applied to the sham TENS group with the same parameters as the TENS group, and will be reduced and turned off after a while. In TENS application, people normally report that they no longer feel tingling after a few minutes of starting the application. Therefore, it will be explained to the sham TENS group that this situation is normal, and that they no longer feel tingling because they have become accustomed to the applied current.
215085057|NCT02526862|DEVICE|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
214491545|NCT06761729|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
214491546|NCT06458322|OTHER|Home dialysis or In-Center dialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or in-center dialysis (hemodialysis)
214491547|NCT00878319|PROCEDURE|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using dynamic compression plate
214491548|NCT00878319|OTHER|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
214491549|NCT04704219|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.
214491550|NCT04704219|DRUG|Lenvatinib|Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
214491551|NCT03741790|PROCEDURE|Ventilation|The difficult mask ventilation is defined as A) It is not possible for unassisted anesthesiologist to maintain the SpO2 \> 90% using 100% oxygen and positive pressure mask ventilation in a patient whose SpO2 \> 90% before anesthetic intervention; and/or B) It is not possible for unassisted anesthesiologist to prevent or reverse signs of inadequate ventilation during positive mask ventilation.
214491552|NCT03741790|PROCEDURE|Intubation|"The difficult endotracheal intubation is defined as  It is not possible to visualize any portion of the vocal cords with conventional laryngoscopy or when proper insertion of the endotracheal tube with conventional laryngoscopy requires more than three attempts or more than ten minutes."
214491553|NCT06203041|DIETARY_SUPPLEMENT|Vitamin D|Orally administered, daily dose of 5000 IU (125 mcg) Vitamin D3 for 28 days.
214491554|NCT06827041|BIOLOGICAL|Phage (Cytophage Technologies)|"Our phage is a new type of investigational treatment for bacterial infections. Our lytic, monophage preparation was provided by Cytophage Technologies and underwent rigorous testing to ensure final product potency (7 x 10\^9 PFU/dose), purity, fidelity, and safety; laboratory tests demonstrate phage in vitro efficacy against the S. epidermidis strain.~Phage prepared in injection-grade saline will be given via two routes: a) intravenously twice daily, and concomitantly, b) intraarticularly twice daily, for a total duration of 14 days."
214491555|NCT06832852|OTHER|Stepped care|During the first education session, participants will be provided with information pertaining to painful area, basic pain science, injury specific advice on load management, pain and activity management, lifestyle factors and physical activity. A general physical activity will be recommended (150-300 minutes of moderate-intensity activity per week). Then, participants will be directed to a website developed by the research team and patient partners. The website includes explanations of the various topics discussed during the session , explanatory videos, and summarized information. During the second educational session, the participant's condition will be reviewed, and their understanding of the topics covered in the first session and on the website will be assessed. A follow-up on the website will also be conducted. The physiotherapist will then answer the participant's questions and provide personalized advice based on their condition, along with long-term recommendations.
214679775|NCT01746602|DEVICE|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
214679776|NCT01746602|DEVICE|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
214679777|NCT03699345|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards CENTERA THV System and accessories
214679778|NCT00340327|DRUG|IMA-638|
214679779|NCT04644107|DRUG|Marizomib|Marizomib will be administered via IV
214679780|NCT06940635|DEVICE|closed-loop BCI-FES device|Closed-loop neurorehabilitation system that combines EEG-based brain-computer interface technology with functional electrical stimulation (FES) to facilitate neural and motor recovery.
214679781|NCT00302601|PROCEDURE|Scintigraphic interpretation|Not relevant
214679782|NCT02658656|DEVICE|ReWalk 6.0|Exoskeletal Assisted Walking Device
214366067|NCT06472596|DIAGNOSTIC_TEST|CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha|compare results of investigations in asthmatics and non asthmatics
214366068|NCT04679090|OTHER|Exercise Program|Participants will exercise twice a week for twelve weeks total.
214679783|NCT00284388|PROCEDURE|Simultaneous controlled power measurement|
214679784|NCT00284388|PROCEDURE|Surface EMG measurement|
214679785|NCT00247390|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
214366069|NCT05129943|DEVICE|active distraction|The subject receives the injection of local anesthesia while playing a game on a mobile phone mounted on the VR device using a PS4 controller.
214366070|NCT05129943|DEVICE|passive distraction|The subject receives the injection of local anesthesia while watching a cartoon on a mobile phone mounted on the VR device.
214366071|NCT04305314|OTHER|PRI (Enhanced Recovery after surgery protocol)|Standard use of Spanish perioperative guidelines (PRI)
214491556|NCT06832852|OTHER|Rehabilitation Care|The pragmatic rehabilitation program will include exercises aimed at improving strength, endurance, flexibility, capacity to sustain mechanical load and dynamic control. Manual therapy may be provided during the sessions, based on pragmatic clinical decision-making. Participants will also receive information pertaining to the painful area and advice on pain and load management, and on activity modification, integrated across the sessions.
214491557|NCT06832852|OTHER|Medical Care|The pragmatic medical intervention may include pharmacological management, education, physiotherapy referral or referral to a specialist as deemed necessary.
214366072|NCT00145093|DRUG|Baker's yeast (Bio Chromium)|
214366073|NCT02707835|OTHER|self massage|self massage, skin care education, manual lymph drainage exercise, compression garment
214976442|NCT01088971|DIETARY_SUPPLEMENT|starch|1capsule two times everyday for 6 weeks
214976443|NCT02400801|DRUG|triptorelin|gonadotropin-releasing hormone (GnRH) agonist
214976444|NCT02400801|DRUG|ethinylestradiol + dienogest|oral oestroprogestogen
214976445|NCT00529711|DRUG|Hypertonic lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
214976446|NCT00529711|DRUG|Ringer's lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
214976447|NCT04976127|DRUG|Talineuren|Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
214976448|NCT03617003|DRUG|WST11 mediated vascular targeted phototherapy (VTP)|All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
215085058|NCT02526862|DEVICE|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
215085059|NCT02526862|DEVICE|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
215085060|NCT04999215|DRUG|F-choline intravenous injection|Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
214366074|NCT02707835|OTHER|manual lymph drainage|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
214366075|NCT02707835|OTHER|epidermis fascia taping|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
214366076|NCT01889433|DRUG|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
214366077|NCT01889433|DRUG|Pegasys|180 µg subcutaneously, once a week
214491558|NCT03936933|DRUG|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
214491559|NCT03936933|DRUG|ZOLADEX® 3.6mg Injection|3.6 mg, Subcutaneously at every 28 days
214491560|NCT06770478|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT Scan|The imaging agent 68Ga-MY6349 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations. Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection.
214491561|NCT06774183|OTHER|Near vision glasses for presbyopia correction|Provision of near vision glasses for presbyopia correction to individuals who did not previously have glasses and have correctable presbyopia
214679786|NCT00247390|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
214679787|NCT05565677|DEVICE|micro-computed tomography scanning of lung tissue specimens|Micro-computed tomography will be utilized to scan surgically resected lung tissue specimens.
214679788|NCT05730439|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214679789|NCT05730439|DRUG|Nicotine Oral Pouch|Receive ZYN brand NP
214976449|NCT03617003|PROCEDURE|Endoscopy|Endoscopy of the bladder
214976450|NCT02805738|DRUG|CKD-390|CKD-390 1 Tablet (48 weeks)
214976451|NCT02805738|DRUG|viread|viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)
214976452|NCT00381212|BIOLOGICAL|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
214976453|NCT00662077|DRUG|Ibandronate|Ibandronate endovenous 3 mg every 3 months
214976454|NCT00662077|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
214976455|NCT06523621|DRUG|Nivolumab|2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle
214976456|NCT02277028|BEHAVIORAL|priming and task specific training|This task specific training protocol has been used in several clinical trials.
214366078|NCT00103766|DRUG|Alteplase|
214366079|NCT04300894|DEVICE|Mamma Mia|"Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs."
214366080|NCT04300894|OTHER|Mamma Mia Plus|Participants will use the Mamma Mia program, plus receive contact (phone calls or emails or texts) from study staff every few months.
214366081|NCT04016090|DIETARY_SUPPLEMENT|Folic Acid|Folic acid (5 mg)
214366082|NCT04016090|OTHER|Placebo|Placebo capsule
214366083|NCT02768363|BIOLOGICAL|aglatimagene besadenovec|Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
214491562|NCT06774261|DRUG|Phenserine|"Phenserine is a next generation AChE inhibitor being developed for the treatment of AD. Unlike currently marketed AChE inhibitors, it has additional mechanisms of action that also include a mediating effect on cell death pathways and anti-amyloid activity, which may confer disease-modifying effects in people with AD.~Phenserine was originally identified and developed by the United States (U.S.) National Institute of Aging (NIA), part of the U.S National Institute of Health (NIH).~The study intervention will be open label. No blinding will be performed. Participants and site staff will, however, will be blinded to the results of the exosome and blood/CSF biomarker evaluations until the study is completed."
214491563|NCT06774261|DRUG|Donepezil (Aricept®)|"The substance donepezil (under the brand name Aricept®) is a resale product. No additional manufacturing or labeling measures is necessary for this study.~The NIMP, donepezil will be available in 5 mg and 10 mg strengths (table 3) and will be dispensed by the local pharmacy at the hospital where the participant in the donepezil arm is included. We have based the use of donepezil as a treatment in the study on the original product from Pfizer, but it is also possible to use generic products of donepezil if this is what the local pharmacy has for dispensing. Participants randomized to treatment with donepezil will follow the treatment plan according to the patient information leaflet. . These tablets are approved for clinical use and comply with all relevant safety and efficacy standards."
214491564|NCT06775093|DRUG|GLP-1 receptor agonist|3 months
214491565|NCT06775093|DRUG|Metformin|3 months
214491566|NCT06775093|BEHAVIORAL|healthy lifestyle education|3 months
214491567|NCT06774898|DEVICE|Custom-molded lumbar-sacral orthosis|A custom-molded lumbar-sacral orthosis made according to the Vésinet method associated with measures designed to enhance adherence based on goal-setting techniques (i.e. personalized advice, self-determination of the wearing time, hotline) techniques and monitoring of adherence using a temperature sensor chip to provide feedbacks to participants on the wearing time at follow-up visits, and usual care (i.e. a standardized prescription of 20 outpatient physiotherapy sessions including active self-correction, spinal muscle strengthening, spine and lower limb stretching and learning of home-based exercises).
214679790|NCT05730439|DRUG|Nicotine Oral Pouch|Receive Rogue brand NP
214976457|NCT05193513|DEVICE|hybrid expanders|tow maxillary hybrid expanders supported anteriorly with tow miniscrews
214976458|NCT05510258|OTHER|Physiotherapy|TWO GROUPS CONTROL ND EXPERIMENTAL
214976459|NCT00993551|PROCEDURE|primary surgery for cleft palate|Surgery completed using the Sommerlad technique
214976460|NCT04198831|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
214976461|NCT04198831|OTHER|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
214976462|NCT04739228|BEHAVIORAL|Guided Written Disclosure Protocol Group|The writing task consists of three sessions of 20 minutes each, with an interval of one week between each other. In the first session, patients were asked to describe the onset of illness, describing chronologically and detailed places, images, sounds and actions, as they are followed and detached from the emotions. In the second session, the patients were asked to write about thoughts and emotions felt during the illness experience, talking about the impact that illness had on their daily lives and how it had changed their personal attitude to life itself. In the third and final session, the patients were asked to analyze subjective new skills acquired.
214976463|NCT04739228|BEHAVIORAL|Active Control Group|The writing task also consists of three sessions of 20 minutes each, with an interval of one week between each other. In all three writing sessions, patients were asked to report the daily activities during the last week, without focusing on the emotional aspects.
214976464|NCT05002972|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
214976465|NCT05564572|OTHER|Routine Health Status Assessment|Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
214976466|NCT04195594|OTHER|Nic's Keto Diet|Participants will be instructed to follow Nic's keto diet plan for 140 days. They will be asked to not exceed 20 g of carbohydrates (up to 5% caloric intake) and to consume the remaining 70% of calories from fat sources and 25% from protein sources.
215085061|NCT03085511|BEHAVIORAL|Egg breakfast (EB)|Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
214976467|NCT06272981|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.
214976468|NCT06852170|OTHER|Co-Design Sessions (CDS)|CDS uses principles and activities from Liberating Structures (LS) and Group Model Building (GMB). Each method uses semi-structured processes for engaging partners to collaborate with one another and address complex problems. Example activities and discussions include: identifying a shared vision for how data can inform decisions related to substance use service delivery and overdose prevention; identifying relevant data that should be disseminated; identifying decisions to be supported with data. Methods from human-centered design - an approach for developing products that are useful and easy to use - will be used to refine data products developed by the study team so that the data products are acceptable and useful to end users. Together, these three methods (Liberating Structures, group model building, human-centered design) will be used to engage partners to iteratively co-design products for disseminating data back to partners to inform their daily substance use service delivery.
214976469|NCT06852170|OTHER|Data products|Data products disseminate localized data from local, state, or regional-level data sources to local (i.e., county) decision makers to inform their daily decision-making. Data products in counties assigned to CDS will receive fully tailored data products, while no-CDS counties will receive standardized data products. A suite of data products will be made available to inform diverse decisions by a variety of end users. Data products will be identified and prioritized during CDS, but may include reports, policy briefs, journey maps, and technical assistance for data interpretation.
214976470|NCT06031259|DRUG|Idursulfase-IT|Idursulfase-IT intrathecally via IDDD.
214976471|NCT06031259|DRUG|Elaprase|Elaprase IV infusion.
214976472|NCT03494127|DEVICE|Use of GEL BALL FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
214976473|NCT03494127|DEVICE|Use of SQUISHINS FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
214976474|NCT05977608|BEHAVIORAL|Telephone Reminiscence Intervention|Participants will receive automatic calls three times a week asking their life experiences and personal memories. They can share as much or as little as they would like. They have up to 10 minutes to record their answer and can end the call at any time by hanging up.They will be able to share the stories online with their families if they want.
214976475|NCT05714033|PROCEDURE|Ventilatory Strategy To Prevent Atelectasis|Given
214976476|NCT05714033|PROCEDURE|Lateral Decubitus Strategy (LADS)|Given
214976477|NCT00918593|DRUG|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
214976478|NCT00918593|RADIATION|Radiotherapy|Radiotherapy according to hospital procedures.
214976479|NCT00918593|DRUG|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
214366084|NCT02768363|BIOLOGICAL|placebo|Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
214366085|NCT02768363|DRUG|valacyclovir|Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
214366086|NCT06095297|BEHAVIORAL|Processing Speed Training|"Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to rapidly distinguish targets from decoys, which trains how rapidly the player processes information received through their senses."
214366087|NCT06095297|BEHAVIORAL|In-lab Instrumental Activities of Daily Living Training|Participant will receive shaping on IADLS. Participants will receive training on everyday tasks with important cognitive components, in which the difficulty is increased in small steps over the course of treatment.
214366088|NCT06095297|BEHAVIORAL|In-lab Brain Health Training|Participants will receive training on healthy eating, sleeping, and relaxation techniques that have been shown to improve brain health.
214366089|NCT06095297|BEHAVIORAL|Transfer Package|"The Transfer Package was designed to try and bridge the gap between what is trained in the lab and what the participant does outside of the treatment setting. This components includes negotiation of a behavioral contract with participants at the outset of treatment regarding the responsibilities of the participant, family caregivers, if available, and the treatment team, self-monitoring, assignment of homework, review of homework by the trainer, and support of problem-solving by the participant."
214366090|NCT06095297|BEHAVIORAL|Follow Up Phone Calls|After completing training, participants will receive four follow up phone calls in the first month of training. Each call will separated by about a week. The focus of the calls will incorporating the lessons learnt during treatment into daily life.
214679791|NCT05730439|OTHER|Questionnaire Administration|Ancillary studies
214679792|NCT05730439|DRUG|Smokeless Tobacco|Receive usual SLT
214976480|NCT05617807|PROCEDURE|Nanoscopic partial meniscectomy|Patients will have a partial meniscectomy performed using the arthrex nanoscope and it will be compared to partial meniscectomy performed using standard arthroscopic equipment
214976481|NCT05617807|PROCEDURE|Standard Partial Meniscectomy|Patients will have partial meniscectomy performed using standard arthroscopic equipment
214976482|NCT03775083|DRUG|Currently approved medications|subjects will be treated according to current Department of Health and Human Services (DHHS) Center for Disease control and prevention (CDC), Society for Healthcare Epidemiology of American (SHEA guidelines for nPEP
214976483|NCT01897051|DRUG|Rifaximin + propranolol|"1. Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
214976484|NCT01897051|DRUG|Propranolol + Placebo|"1. Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
214976485|NCT06553690|OTHER|Brain Gym Therapy|Brain Gym Therapy is a structured program of physical movements designed to enhance cognitive function, reduce stress, and promote relaxation. The therapy is based on the principle that specific physical activities can stimulate brain function and improve overall mental and physical well-being.
214976486|NCT06232967|PROCEDURE|Primary tumor resection or not|For patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination, surgical decisions to perform exploratory thoracotomy only or primary tumor resection with wedge resection, segmentectomy, or lobectomy were based on surgeon experience and patient preference.
214976487|NCT04796766|DIAGNOSTIC_TEST|High frequency stimulation (HFS)|Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.
214976488|NCT04796766|DIAGNOSTIC_TEST|Low-frequency sinusoidal transcutaneous stimulation (sLFS)|Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.
214976489|NCT02360488|DEVICE|Telerehabilitation Therapy|18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
214976490|NCT02360488|BEHAVIORAL|In-Clinic Therapy|18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
214976491|NCT00426881|BEHAVIORAL|Exercise Training|Twice weekly resistance training for 52 weeks.
214976492|NCT00426881|BEHAVIORAL|Exercise training|Once weekly resistance training for 52 weeks.
214976493|NCT00426881|BEHAVIORAL|Exercise training|Twice weekly resistance training for 52 weeks.
214976494|NCT01107548|OTHER|Systematic detection of vascular risk factors and subsequent evidence-based treatment|
214976495|NCT05867056|DRUG|IMC-I109V Single Ascending Dose|Single dose administration of IMC-I109V
214976496|NCT05867056|DRUG|IMC-I109V Multiple Ascending Doses|Multidose administration of IMC-I109V
214976497|NCT05867056|DRUG|HBV HCC Module MAD|Multidose administration of IMC-I109V
214976498|NCT05211440|DIETARY_SUPPLEMENT|Placebo + Meal|Subjects will be directed to consume 1 placebo capsule containing maltodextrin, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a placebo capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
214976499|NCT05211440|DIETARY_SUPPLEMENT|BC-006 + Meal|Subjects will be directed to consume 1 capsule containing BC-006, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a BC-006 capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
214976500|NCT03503279|DEVICE|McGrath MAC® Video Laryngoscope|McGrath MAC® Video Laryngoscope have been developed to secure the airway and improve the management of difficult intubation. McGrath MAC® is a self-contained VL with a single-use blade; its structure is similar to the ML, but without the channel that guides the tube and a mounted LCD screen on the handle that is connected to a miniature camera with a light source at the tip of the blade, allowing the clinicians to directly observe surrounding anatomical airway structures during a tracheal intubation
214976501|NCT02851602|BIOLOGICAL|Blood sample|
214976502|NCT03666442|DRUG|XELOX|Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
214976503|NCT01064271|DRUG|Risperidone|Risperidone Tablets 1 mg
214976504|NCT04953507|PROCEDURE|Thermal Radiofrequency|Radiofrequency lesioning at level of T2 and T3 using 80°c for 120 seconds
214976505|NCT04953507|PROCEDURE|Chemical Neurolysis|injection of 1.5 ml of the chemical neurolytic agent (phenol in saline 8%) at each level
214976506|NCT05138978|DRUG|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
214976507|NCT05138978|DRUG|Colgate Cavity Protection|Toothpaste
214976508|NCT02370511|DEVICE|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
214976509|NCT06979531|DRUG|IMVT-1402|Administered once weekly by subcutaneous injection
214366091|NCT06095297|BEHAVIORAL|Vocational Rehabilitation|In partnership with the Alabama Department of Rehabilitation Services (ADRS), participants who are eligible may receive vocational rehabilitation. Participants will receive typical services offered by the ADRS. These could include career counseling, guidance regarding job retention or return-to-work, and guidance regarding workplace accommodations.
214366092|NCT06095297|BEHAVIORAL|Peer Mentoring|Participants who are eligible for vocational rehabilitation, and agree will also have a peer mentor, a co-worker that will be trained by our team, to reinforce strategies the participant learned during training, and to help the participant problem solve issues that may arise on the job during the first month after treatment. Peer mentors will meet with trainers during the month after treatment to make sure procedures are being followed and address any issues that may arise.
214366093|NCT06095297|BEHAVIORAL|Reaction Time Training|"Reaction time training involves trainer-guided practice of computer-based video games. Several different games will be featured that train how rapidly players react to threats and train eye-hand coordination."
214679793|NCT04755543|DRUG|LP002|600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
214976510|NCT06979531|DRUG|Placebo|Administered once weekly by subcutaneous injection
214976511|NCT06374459|DRUG|Zumsemetinib|Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.
214976512|NCT06374459|DRUG|Capecitabine|Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
214976513|NCT06374459|DRUG|Zoledronic acid|Standard of care. Will receive zoledronic acid or denosumab.
214976514|NCT06374459|DRUG|Denosumab|Standard of care. Will receive zoledronic acid or denosumab.
214976515|NCT00081887|DRUG|Clofarabine|Starting dose is 10 mg/m\^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
214976516|NCT03883243|DEVICE|Telecoaching|A telecoaching application linked to a step counter will be installed on a patients smartphone for 8 weeks. The application shows a daily goal (expressed as amount of steps per day) to the patient. This goal is weekly revised and patients themselves are able to increase the goal every week with 500 or 1000 steps/day. Every evening, they are able to check the daily feedback platform, which gives them insights in their physical activity pattern of the day and previous weeks. At a regular basis, 'tip of the day' messages appear as a pop-up, to keep patients motivated.
214976517|NCT06657560|DRUG|HRS-9231|HRS-9231
214976518|NCT01190085|DRUG|Ghrelin|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
214976519|NCT01190085|DRUG|Ghrelin|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
214976520|NCT01190085|DRUG|Saline solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
214976521|NCT06983366|DIAGNOSTIC_TEST|Lung Ultrasound|All enrolled patient will be subjected to Lung Ultrasound examination LUS
214976522|NCT02706262|OTHER|Metabolically abnormal obese - Mediterranean diet|The effect of consuming a Mediterranean diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a Mediterranean diet but will prepare all their food at home. No food will be provided during this portion of the study.
214976523|NCT02706262|OTHER|Metabolically abnormal obese - Low carbohydrate ketogenic diet|The effect of consuming a low-carbohydrate, ketogenic diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a low carbohydrate ketogenic diet but will prepare all their food at home. No food will be provided during this portion of the study.
214976524|NCT02706262|OTHER|Metabolically abnormal obese - Plant-based, very-low-fat diet|The effect of consuming a plant-based, very-low-fat diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a plant-based, very-low-fat diet but will prepare all their food at home. No food will be provided during this portion of the study.
214976525|NCT02706262|BEHAVIORAL|Annual Follow-up Visits|Metabolic health will be assessed 1 and 2-years after competing the diet intervention study. No intervention will be performed during the time.
214976526|NCT06817161|DEVICE|transcutaneous auricular vagus nerve stimulation|"The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles).~The dispositive is used every day at home, twice daily (during 30 minutes)"
214976527|NCT06817161|DEVICE|Placebo device|"The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles).~The dispositive is used every day at home, twice daily (during 30 minutes)"
214976528|NCT06655987|OTHER|Unrestrained Femoral Internal Rotation (UFIR) manipulation|This is the primary intervention applied to the experimental group. It involves a high-velocity, low-amplitude thrust at the greater trochanter of the affected hip, intended to improve joint mobility and potentially address neuromuscular dysfunction contributing to hip pain and weakness.
214976529|NCT06655987|OTHER|Sham manipulation|This serves as the control intervention. It involves gentle hand placement over the affected hip\&#39;s external rotators for a brief duration. This is intended to mimic the physical contact of the UFIR manipulation without actually delivering the therapeutic thrust.
214976530|NCT06981533|OTHER|Auricular acupressure therapy|Auricular acupressure will be performed using Cowherb seeds (Wangbuliuxing seeds) applied to specific acupoints, including Shenmen (TF4), Sympathetic (AH6a), Endocrine (CO18), Liver (CO12), Kidney (CO10), Subcortex (AT4), and Zero Point on one ear, with treatment administered once a week, alternating between the left and right ears. In total, auricular acupressure was applied 8 times over a period of 8 weeks. The first treatment session occurred 5-7 days prior to the onset of menstruation. Participants were instructed to perform acupressure at the acupoint sites three times daily-morning, noon, and evening-pressing each point for 1 minute per session.
214976531|NCT06981533|OTHER|Sham auricular acupressure therapy|Sham auricular acupressure therapy will be performed using similarly sized adhesive patches without seeds, applied to the same acupoint locations as in the intervention group. The procedure steps and the duration of the trial were the same as in the auricular acupressure group.
215085062|NCT03085511|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
215085063|NCT03085511|BEHAVIORAL|Weight Loss Diet|Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
215085064|NCT03085511|BEHAVIORAL|Cereal Breakfast (CB)|Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
214679794|NCT04755543|DRUG|Cisplatin|50mg/m2 IV on Day 1, Q2W
214976532|NCT06981533|OTHER|Lifestyle modifications|"Lifestyle modifications will be followed according to the Guidelines for the Management of Premenstrual Syndrome by the Royal College of Obstetricians and Gynaecologists (RCOG), which will include: Regular moderate exercise (such as walking, yoga, or swimming), stress reduction, and ensuring quality sleep (7-8 hours per night); Reducing intake of salt, sugar, and foods containing saturated fats; Increasing intake of high-fiber foods such as fruits and vegetables; Avoiding smoking, and limiting alcohol, and other stimulants."
214976533|NCT06855576|DRUG|Paracetamol ODT|Experimental Paracetamol 500 mg ODT
214976534|NCT06855576|DRUG|Alvedon film-coated tablet|Marketed Paracetamol 500 mg film-coated tablet
214976535|NCT06855576|DRUG|Panadol film-coated Tablet|Marketed Paracetamol 500 mg film-coated tablet
214976536|NCT05320835|BEHAVIORAL|HIV, HCV and overdose prevention|HIV, HCV and overdose prevention
214976537|NCT03933306|DRUG|Dexmedetomidine|Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.
214976538|NCT03933306|DRUG|Placebo|Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
214976539|NCT03933306|OTHER|Goal-directed blood pressure management|Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
214366094|NCT06095297|PROCEDURE|Trans-auricular Vagus Nerve Stimulation: High Intensity|The vagus nerve run from the brain to the external ear, throat, chest, and abdomen and controls, among other functions, the rest and relax response, which supports learning and turns down inflammatory processes. The rest and relax response can be turned on by electrically stimulating the vagus nerve. We will place electrodes on the external part of each ear and safely apply a microcurrent of at least 4 milliamps. Stimulation will administered for 10 minutes near the start and midway point of each treatment session.
214366095|NCT06095297|PROCEDURE|Trans-auricular Vagus Nerve Stimulation: Low Intensity|The vagus nerve run from the brain to the external ear, throat, chest, and abdomen and controls, among other functions, the rest and relax response, which supports learning and turns down inflammatory processes. The rest and relax response can be turned on by electrically stimulating the vagus nerve. We will place electrodes on the external part of each ear and safely apply a microcurrent of less than 4 milliamps. Stimulation will administered for 10 minutes near the start and midway point of each treatment session.
214366096|NCT06559163|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.
214366097|NCT06559163|DRUG|Placebo|Placebo
214366098|NCT04062890|DRUG|Vigabatrin Pill|Oral Vigabatrin Pill
214366099|NCT04062890|DRUG|Placebo oral tablet|Oral Placebo Pill
214366100|NCT06024616|BEHAVIORAL|TARANG|"TARANG is aimed to empower young women to navigate newly formed relationships, improve women's awareness of sexual reproductive health, and challenge inequitable gender norms, with an aim to reduce unintended pregnancies and increase use of family planning. The TARANG intervention for newly married women will include 14 group sessions delivered by trained moderators from Vikalp. It will cover three overarching themes, including norms, empowerment, and sexual and reproductive health and wellbeing.~Four light-touch sessions for mothers-in-law and one in-person session for husbands of newly married women will be conducted. For husbands, TARANG will include one 2-hour group session within the first month of the intervention, followed by regular and moderated content delivery via videos and take-home exercises over WhatsApp groups. Vikalp will conduct door-to-door listing, and a research team from NEERMAN will recruit households into the study depending on the eligibility criteria."
214366101|NCT05708755|DEVICE|Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)|Whole blood assay that evaluates T cell (CD4 and CD8) responses to cytomegalovirus (CMV) antigens via intracellular cytokine staining (ICS).
214366102|NCT05708755|DIAGNOSTIC_TEST|Donor-Derived Cell-Free DNA (dd-cfDNA) Assay|Determines the percentage of circulating cell-free DNA (cfDNA) in transplant recipients derived from donor grafts.
214366103|NCT05708755|DRUG|Valganciclovir|Delivered as standard of care for post-lung transplant immunosuppression and infection prophylaxis. Started on the first day post-transplant at a standard dose of 900 mg daily and continued for 12 months. Dose adjustments may be necessary based on renal function and/or adverse effects (e.g. neutropenia). Dose adjustments are standard based on package insert recommendations.
214366104|NCT02698254|BIOLOGICAL|Bevacizumab|
214366105|NCT02698254|OTHER|Quality-of-Life Assessment|Ancillary studies
214976540|NCT03933306|OTHER|Routine blood pressure management|Blood pressure is maintained according to routine practice, i.e., systolic blood pressure \> 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
214976541|NCT06611943|BEHAVIORAL|DietCoach|Participants are invited to give at least one dietary recommendation to a patient\&#39;s food purchase data using the DietCoach platform.
214976542|NCT06612216|OTHER|No intervention was carried out|This study observed differences in microbiota among different groups and therefore did not involve intervention.
214976543|NCT06993220|DIAGNOSTIC_TEST|Evaluation of residual congestion at discharge|"Evaluation of residual congestion at discharge will be made using:~* Clinical variables: composite congestion score calculated by summing the individual scores for orthopnoea, jugular venous distension and pedal oedema;~* Imaging variables: non-invasive left ventricular filling pressure, number of LUS B lines and the presence of pleural effusion, Venous Excess UltraSound (VExUS) score;~* Laboratory variables: hemoglobin and hematocrit, NT-proBNP, CA-125, ST2, troponin T, creatinine, AST, ALT, Na, K, urea, bilirubin, C-reactive protein."
214976544|NCT03882918|DRUG|OV101|Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
214976545|NCT06612905|OTHER|Detection of the time spent on social media|The time spent on social media will be assessed by using the social networking usage questionnaire (SONTUS) for all women in both groups (A and B).
214976546|NCT06612905|OTHER|Evaluation of body composition and basal metabolic rate|They will be evaluated using Inbody (Bodecoder)(CHL-818, made in China) and its software (2.2.1 apk)
214366106|NCT02698254|RADIATION|Radiation Therapy|Undergo radiation therapy with conventional fractionation
214976547|NCT06612905|OTHER|Evaluation of eating behavior among social media users|Scale of effects of social media on eating behavior (SESMEB) will be used for all women in both groups (A and B) to assess the effect of social media on their eating behavior. The SESMEB consists of one subscale and eighteen items. It is a reliable and valid scale, items scale is evaluated with five-point Likert scale. Each item is evaluated as 'always' five points, 'often' four points, 'sometimes' three points, 'seldom' two points and 'never' one point. There is no reverse coded substance. As it is mentioned in item analysis part, total score can be calculated. According to this minimum eighteen and maximum ninety points from SESMEB scale can be taken as total point. As a result, the increase in the person's scale score means that the level of being affected by the eating media increases.
214976548|NCT07001956|BIOLOGICAL|UTAA91 injection|After signing the informed consent form, eligible subjects will receive an infusion of UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, and safety.
214366107|NCT05390970|PROCEDURE|Platelet-rich plasma injection|Injection of autologous platelet-rich plasma into the anterior vaginal wall
214366108|NCT02935361|DRUG|Atezolizumab|Given IV
214366109|NCT02935361|DRUG|Guadecitabine|Given SC
214366110|NCT04226027|BEHAVIORAL|T2.coach|"T2.coach is a smartphone app for low-burden capture of diet and blood glucose (BG) levels and for reviewing past records, integrated with FitBit for captured of physical activity and sleep. All captured data are sent to the computational inference engine that uses machine learning methods and expert system to formulate personalized behavioral goals. Examples of behavioral goals include the following: For high carbohydrate breakfasts, reduce your carbs to be about 1 carb choice. Examples of 1 carb choice are 1 slice of whole wheat toast, 1 cup of oatmeal, or 1 apple. The T2.coach chatbot companion uses text messages to help individuals set goals that are consistent with evidence based guidelines for diabetes self-management, inferences on data captured with T2.coach, and their own preferences, as well as send individuals goal reminders and prompts for reflection on goal achievement."
214366111|NCT02525965|PROCEDURE|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin \>1cm
214366112|NCT02525965|PROCEDURE|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of wide resection margin \<1cm
214366113|NCT01218126|DRUG|losmapimod|comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg
214366114|NCT01218126|DRUG|placebo|placebo comparison with active
214366115|NCT03927469|OTHER|age, sex, hemiplegic side, stroke duration, First hospitalisation duration (day)|This is a retrospiective descriptive study
214366116|NCT00818116|DEVICE|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
214366117|NCT00913484|DRUG|Disulfiram|Disulfiram 250 mg per day
214366118|NCT00913484|DRUG|Placebo|Placebo daily
214366119|NCT04835155|PROCEDURE|Premature Infant Oral Motor Intervention (PIOMI)|The Premature Infant Oral Motor Intervention (PIOMI), developed by Dr. Brenda Lessen Knoll, was chosen for this study because it is the only oral motor program designed specifically for preterm babies as young as 29 weeks post menstrual age (PMA) and is the only program with a standardized training method and published intervention fidelity. The 5 minute therapy offers assisted movement to activate muscle contraction and movement against resistance to build strength in the perioral structures. The PIOMI has 8 steps where a provider uses a pinky finger to provide gentle stroking and pressure on the cheeks, lips, tongue, gums and palate to strengthen the oral sensory-motor functions and improve feeding efficiency. PIOMI ends with 2 minutes of NNS. NNS and oral stimulation have been found to mature the oral motor sensory system, and improve not only bottle feeding, but also breastfeeding.
214491568|NCT06774898|OTHER|Usual Care|Usual care consisting in a standardized prescription of 20 outpatient physiotherapy sessions including active self-correction, spinal muscle strengthening, spine and lower limb stretching and learning of home-based exercises
214366120|NCT00980070|DEVICE|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
214366121|NCT00980070|DEVICE|Lumbar Puncture Device|Lumbar Puncture positioner
214679795|NCT04755543|DRUG|Fluorouracil|2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
214976549|NCT06615102|DRUG|Angiotensin II|Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.
214976550|NCT06615102|DRUG|Noradrenalin|Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.
214366122|NCT00980070|OTHER|Standard of Care|Lumbar Puncture positioner
214366123|NCT03732183|BEHAVIORAL|Podcast SMART-3RP|28 daily podcasts, each 15 minutes.
214366124|NCT02241941|DRUG|Daptomycin|
214366125|NCT02254447|DRUG|Candesartan Cilexetil in formulation 1|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
214366126|NCT02254447|DRUG|Candesartan Cilexetil in formulation 2|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
214491569|NCT06774950|BEHAVIORAL|Physician-patient quality circle|"Intervention: (To be compared with standard care)~1. Interprofessionnal meeting per neighbourhood: (beforehand) Therapeutic patient education (TPE) training for healthcare professionals~2. Physician-patient quality circle t0 Group sessions (n= 3 to 6 patients) with doctor and therapeutic patient education specialist Clinical measurements - CM (incl. HbA1c, body composition, blood pressure). PROM evaluation questionnaires (EQ5D\&DIABQ)~3. Development of individualised T2D programme: with case manager~4. Quarterly follow-up: t3, t6, t9 months PROM follow-up (DIABQ\&PHQ9) +CM.~5. Evaluation of experience: t12 \& t18 months PREM\&PROM evaluation questionnaire +CM"
214679796|NCT04755543|BIOLOGICAL|OH2 oncolytic virus|106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
214679797|NCT03408574|DRUG|Nicotine patch, oral mecamylamine, placebo|Each participant randomly receives one active drug or placebo on each of three study days.
214679798|NCT01850563|DEVICE|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
214366127|NCT02254447|DRUG|ATACAND|Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
214491570|NCT06771050|PROCEDURE|Debridement and Implant Retention (DAIR)|"Intervention 1: DAIR- cleaning of infected joint including irrigation, debridement and exchange of modular components (those not fixed to bone) with implant retention.~Intervention 2: Single stage revision - cleaning of infected joint including irrigation, removal and placement of definitive new components which could be primary or revision components."
214976551|NCT03893929|DIAGNOSTIC_TEST|New Biological markers for prostate cancer diagnosis and management|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
214366128|NCT00942214|DRUG|Natalizumab|300mg, IV, every 4 weeks
214976552|NCT07016646|COMBINATION_PRODUCT|Self-Help Plus (SH+) and cash transfer|"SH+: Self-Help Plus (SH+) is a five-session stress management program developed by the World Health Organization (WHO) for groups of up to 30 participants. It is facilitated by non-specialists who undergo brief training and use pre-recorded audio along with an illustrated guide, Doing What Matters in Times of Stress, to teach stress management techniques. Designed for adults experiencing stress, SH+ is adaptable to diverse living situations and circumstances. Research has demonstrated its effectiveness in alleviating psychological distress and preventing the onset of mental health disorders. Its flexible format makes it an excellent complement to other mental health interventions, whether as an initial step in a stepped care approach or as a community-based program integrated with broader community initiatives.~Cash Assistance: A cash transfer of $300 or equal amount in Turkish Lira per participant ($60 or equal amount in Turkish Lira after each session)"
214366129|NCT06584864|DIAGNOSTIC_TEST|bedside ultrasound examination of the lumbar spinal canal|The ultrasound examination will be performed using a Lumify linear probe (frequency range 4-12 MHz). In the longitudinal projection, the doctor will assess the spinal cord endings by marking them with a sterile marker - a horizontal line on the patient's back. In the same projection, the doctor will designate a safe and optimal place (the greatest width of the dural sac) for performing a lumbar puncture by marking it with a sterile marker. Additionally, in the longitudinal projection, the researcher will measure the depth from the skin surface to the dura mater. Then, in the transverse projection, the doctor will confirm the absence of the spinal cord at the planned puncture site and the optimal amount of cerebrospinal fluid in the selected space. This information will be passed on to the operator, who will ultimately decide on the lumbar puncture site.
214366130|NCT04716179|DIAGNOSTIC_TEST|Sperm test|The semen sample will be collected and analyzed within an hour after collection.
214366131|NCT04716179|DIAGNOSTIC_TEST|hormone levels (testosterone, FSH, LH, prolactin)|Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.
214366132|NCT04716179|DIAGNOSTIC_TEST|SARS-CoV-2 Ig G levels|SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge
214366133|NCT04716179|OTHER|Testis pathology samples|Postmortem examination of the testes of patients deceased as a result of COVID-19 infection will be carried out using immunohistochemistry analysis.
214366134|NCT01860703|DRUG|Deferiprone|Ferriprox 500 mg tablets
214366135|NCT01860703|DRUG|deferiprone matching placebo tablets|deferiprone matching placebo tablets
214366136|NCT01860703|DRUG|moxifloxacin|Active control
214366137|NCT01860703|DRUG|placebo|moxifloxacin-matching placebo
214366138|NCT04064151|BEHAVIORAL|My Guide|12-week long health promotion Smartphone application
214366139|NCT06580639|OTHER|No intervention.|Blood sampling for analysis of mycobacterial growth inhibition assay (MGIA) analysis.
214366140|NCT01019044|PROCEDURE|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
214366141|NCT03825783|BIOLOGICAL|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
214366142|NCT03726255|PROCEDURE|Mesenchymal Stem Cell injection|curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)
214366143|NCT01423630|DIETARY_SUPPLEMENT|Probiotics and fruit fibre|probiotics and fruit fibre
214366144|NCT01188109|DRUG|Gemcitabine|"Standard of care chemotherapy and dosage~Dose - 1000 mg/m²~Schedule - Days 1 and 15; Q 28 days"
214366145|NCT01188109|DRUG|Cisplatin|"Dose - 50 mg/m²~Schedule - Days 1 and 15; Q 28 days"
214366146|NCT00530595|DRUG|candesartan or valsartan or losartan|
214366147|NCT05168826|DEVICE|SAPIEN 3 Transcatheter Heart Valve|Implantation of the SAPIEN 3 valve
214366148|NCT06050226|DRUG|MY008211A tablets|The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.
214366149|NCT06467331|OTHER|Hippotherapy|Hippotherapy, also known as horse-assisted therapy, is a form of animal-assisted therapy. It consists of regularly scheduled sessions designed to enhance functionality in individuals' lives and contribute to their overall health improvement.
214976553|NCT07016646|OTHER|Cash transfer|A cash transfer of $300 or equal amount in Turkish Lira per participant ($60 or equal amount in Turkish Lira each week for 5 weeks)
214366151|NCT06227247|BEHAVIORAL|Meals4Moms Intervention|A community-based, healthy living program including continued gestational diabetes (GDM) education, physical activity level monitoring, and delivery of medically-tailored GDM meals for the management of gestational diabetes in pregnant people.
214491571|NCT06771050|DRUG|Antibiotic Choice|"No intervention: Backbone antibiotic therapy only depends on the organism and is detailed in the protocol.~Intervention: Backbone antibiotic therapy plus rifampicin. Dosage 600-900mg per day orally for as long as oral antibiotic treatment continues, but not more than 12 weeks. Prescribed according to local recommended practices and dosed as per local therapeutic guidelines."
214976554|NCT07021222|PROCEDURE|Full Analysis|Population 1 receives all three groups of analyses:Clinical-metabolical analyses, Biological-biochemical analyses, and Biomechanical-functional analyses.
214366152|NCT06031883|DRUG|Ketamine|Total intravenous anesthesia in craniotomy
214366153|NCT05914064|DEVICE|Gravitas FT and Gravitas FT Monitor guidance|FT placed with guidance from the Gravitas FT system
214366154|NCT05914064|DEVICE|Gravitas FT System without placement guidance|SOC placement
214366155|NCT04180657|GENETIC|Protein C deficiency|The effect of protein C deficiency on ghrelin levels are investigated.
214366156|NCT04188977|OTHER|Usual Practice|OTP Directors are able to ask their state health officials permission to use interim methadone treatment. The state officials are in turn able to ask officials from the Center of Substance Abuse Treatment for permission to provide interim methadone treatment.
214366157|NCT04188977|OTHER|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
214366158|NCT00995072|DRUG|nebivolol and metoprolol succinate|Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
214366159|NCT00995072|DRUG|metoprolol succinate and nebivolol|Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
214366160|NCT02658864|DRUG|lafutidine|comparison of different doses, sex and medication conditions
214366161|NCT04696666|DEVICE|INSTYLAN (Sodium Hyaluronate 80mg/50ml)|The bladder instillation with INSTYLAN is a treatment involving a sterile solution of Sodium Hyaluronate (80mg/50ml) inserted into the bladder through a catheter and released after a short period of time.
214366162|NCT04776980|DIAGNOSTIC_TEST|Post Feraheme Infusion MRI|All participants will receive a ferumoxtyol (Feraheme) infusion 20-28 hours prior to a head MRI. In addition, a blood draw for liquid biopsy targeted tissue sampling during surgery and special iron and macrophage staining on the tumor tissue.
214366163|NCT04609033|DRUG|Bupivacaine|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
214366164|NCT04609033|DRUG|isotonic saline|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
214366165|NCT04609033|DRUG|Bupivacaine + morphine|instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure
214491572|NCT06771050|DRUG|Antibiotic duration Part A - Single stage revision|"Intervention Arm: Short course 6-week (42 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors.~Intervention Arm: Long course 12- week (84 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors."
214976555|NCT07021222|PROCEDURE|Partial Analysis|Population 2 receives two groups of analyses:Clinical-metabolical analyses and Biological-biochemical analyses.
214366166|NCT04609033|DRUG|Bupivacaine + morphine + ketamine|instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure
214491573|NCT06771050|DRUG|Antibiotic Duration Part B - Two stage revision|"Intervention Arm: Extended prophylaxis for 12 weeks after the 2nd stage revision surgery.~Intervention Arm: No extended antibiotic prophylaxis after the 2nd stage revision surgery.~Antibiotic choice by treating team with reference to the original causative organism(s), susceptibility and patient tolerability."
214491574|NCT06772948|OTHER|Asynchronised group|Health workers with musculoskeletal system disorders will be given pilates exercises asynchronously using the YouTube application.
214491575|NCT06772948|OTHER|Synchronized group|Using the Zoom application, healthcare workers with musculoskeletal disorders will perform pilates exercises synchronously.
214491576|NCT06772909|OTHER|No intervention (observational study)|no intervention
214976561|NCT06185686|OTHER|Cognitive testing|NIH Toolbox Cognitive Battery and the Novel Cognitive Measure (NCM)
214976562|NCT06185686|DEVICE|Resting State MRI/Precision functional mapping|At baseline (before the end of radiation therapy) and approximately 12 months after the completion of radiation therapy.
214976563|NCT07028723|OTHER|proprioceptive profile measurement|"Proprioceptive profile is measured by assessing static bipodal balance on a force platform. The patient is asked to stand motionless in bipodal support on a stable and then unstable floor, with vision masked by an eye mask. The investigators randomly apply a tendon vibration (80Hz) to the subjects' Achilles tendons or paravertebral muscles.~This vibration alters proprioceptive information in the vibrated zone, leading to a disturbance in postural balance and an increased displacement of the center of pressure, whose position is continuously calculated from the force platform's sensors.~Thus, depending on the amount of displacement of the center of pressure, the investigator calculates a proprioceptive weighting ratio (PWR) to deduce the weight assigned by the Central Nervous System to the various proprioceptive inputs during the postural task.~An PWR of 1 indicates 100% use of information from the ankle, while an PWR of 0 means 100% use of information from the hip."
214491577|NCT06771063|DRUG|WXSH0102/placebo|Administer WXSH0102 tablets/placebo orally.
214491578|NCT06771063|DRUG|fluconazole capsules/placebo|Administer fluconazole capsules/placebo orally
214679799|NCT04359823|DRUG|Lovastatin 2%, 2% Cholesterol Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
214976564|NCT06462391|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|Psychotherapy group (delivered virtually)
214976565|NCT04178304|DRUG|Prolotherapy with 25% Dextrose|Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
214366167|NCT05911204|OTHER|Questionnaire about intense noises exposure during pregnancy|Response to questionnaire given within 3 days after delivery about noise exposure
214491579|NCT06770725|BEHAVIORAL|Temporal Adaptation Intervention|The research on temporal adaptation intervention will be conducted through activities and individual sessions within the framework of temporal adaptation intervention. The activities included in the temporal adaptation intervention used in our research have been adapted for ADHD by referencing temporal adaptation training models in the literature.
214491580|NCT06770725|BEHAVIORAL|Conventional Occupational Therapy|The control group will be given a 10-week-long conventional occupational therapy intervention by the investigator (Fatma Temizkan). The intervention will consist of occupational therapy approaches such as; obstacle courses, sensory integration, motor skills training, cognitive skills training, sequenced activities and so on.
214491581|NCT06775756|RADIATION|IMRT with reduced-dose and reduced-volume cervical prophylactic irradiation|For N0 disease, only cover bilateral RPN and level II. For N1 disease, cover ipsilateral involved level plus subsequent level downword, and cover contralateral level RPN and level II. For N2 disease, cover ipsilateral involved level plus subsequent level downword. For N3 disease, cover ipsilateral involved level plus subsequent level downword, and ensuring a 2cm margin below GTVn if GTVn reach or near the sternoclavicular joint. Notably, for unilateral N3, the contralateral neck would only include RPN and level II. Prescribing dose for CTVn2 was 50Gy/33Fx.
214491582|NCT05120232|BEHAVIORAL|Unified Protocol|A transdiagnostic, cognitive behavioral therapy.
214491583|NCT05120232|BEHAVIORAL|Modified Unified Protocol (UP+)|A transdiagnostic, cognitive behavioral therapy.
214491584|NCT06770894|DRUG|Sitagliptin 100 mg|The study population will be randomly allocated in either intervention or placebo arm (1:1). Treatment (sitagliptin 100 mg) and placebo will be provide in identical packages by an experienced independent pharmacist. The recommended intake is one tablet a day, equivalent to sitagliptin 100 mg in the active-treated group, for the duration of the study (52 weeks)
214491585|NCT06770894|DRUG|Placebo Tablets|Placebo tablets 1 a day, provided in identical blisters.
214491586|NCT03222609|DRUG|Ruxolitinib|Tablet; Oral
214491587|NCT03222609|DRUG|Navitoclax|Film-coated tablet; Oral
214491588|NCT06764199|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT), a relatively new psychotherapy, incorporates psychopathological hypotheses and interventions based on contextual behavioral sciences and Relational Frame Theory.
214976566|NCT01265186|DEVICE|Bispectral Index|The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.
214976567|NCT01265186|DEVICE|Amplitude-integrated EEG|A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.
214976568|NCT00545623|PROCEDURE|Acupuncture|acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
214976569|NCT00545623|BEHAVIORAL|Relaxation Response|listening to CDs with verbal instructions of techniques to elicit relaxation response
214976570|NCT00545623|OTHER|sham acupuncture|sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
214976571|NCT04350827|DEVICE|Platelet Rich Plasma|Platelet rich plasma injection into patellar tendon
214491589|NCT06782464|PROCEDURE|Treatment|Treatment
214679800|NCT04359823|DRUG|Lovastatin 2% Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
214976572|NCT04350827|DEVICE|Platelet Rich Plasma plus IGF|Platelet rich plasma plus IGF injection into patellar tendon
214976573|NCT07056686|DIAGNOSTIC_TEST|Mammogram|Each patient will undergo a mammogram and echo of the breast used to detect early signs of cancer, such as tumors or calcifications, before symptoms appear.
214976574|NCT07072000|RADIATION|standard CTV delineation|The anterior border of CTV2 is delineated at the posterior 1/3 of the nasal cavity.
214976575|NCT07072000|RADIATION|reduced CTV delineation|The anterior border of CTV2 is defined as 5 mm anterior to the posterior nasal cavity anteriorly from the choanae.
214366168|NCT03131557|DEVICE|Line extension of the Phonak Audéo B product family|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
214366169|NCT03131557|DEVICE|Phonak Audéo B|Phonak Audéo B will be fitted to the participants individual hearing loss.
214366170|NCT03781752|DRUG|Methylphenidate|study to determine dose
214679801|NCT01437670|DRUG|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
214679802|NCT05402501|BEHAVIORAL|"Lifestyle intervention program Leef! met MS"|The lifestyle program consists of a three-months intensive program, followed by a 21-months 'inspiration' program with occasional meetings.
214366171|NCT01751828|DRUG|Sertraline|
214366172|NCT06171607|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
214366173|NCT06171607|DRUG|Perflutren Lipid Microspheres|Given IV
214976576|NCT07072793|DRUG|nirmatrelvir-ritonavir|Participants with confirmed diagnosis of Covid-19 and with mild to moderate symptoms at high-risk for progressing to severe disease
214366174|NCT06171607|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
214366175|NCT02306759|DRUG|Ketamine|Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes
214976577|NCT04417062|DRUG|Olaparib|Olaparib is taken by mouth, twice daily through out the 28 day study cycle.
214976578|NCT04417062|DRUG|Ceralasertib|Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.
214976579|NCT07073443|BEHAVIORAL|Experimental: Memory Therapy Group|Evaluation of the Effect of Memory-Based Recall Therapy on the Cognitive Status, Psychological Flexibility, and Cognitive Flexibility of Elderly Individuals Diagnosed with Dementia
214976580|NCT07072663|OTHER|Baseline and 3-month follow-up|"At baseline and day 90 (±14) post-enrollment:~1. Collect clinical data;~2. Administer multiple scales to assess clinical symptom severity and neuropsychological status;~3. Perform cranial diffusion tensor imaging (DTI) to evaluate glymphatic function and white matter integrity;~4. Collect peripheral blood and cerebrospinal fluid (CSF) samples for biomarker level analysis."
214976581|NCT07072663|OTHER|Baseline|"At baseline:~1. Collect clinical data;~2. Assess intracranial and extracranial arterial and venous systems;~3. Administer multiple scales to assess neuropsychological status;~4. Perform cranial diffusion tensor imaging (DTI) to evaluate glymphatic function and white matter integrity;~5. Collect peripheral blood samples for biomarker level analysis."
214976582|NCT07073482|OTHER|Using stress ball|The participant will be told that the stress balls will be used for 15 minutes during the surgery, and the researcher will inform the participant when the 15 minutes are up and the patient will be asked to release the balls.
214976583|NCT07071987|PROCEDURE|Thread Embedding Acupuncture+Electroacupuncture|Thread embedding acupuncture will be administered at bilateral ST36, ST37, and PC6 acupoints at 2h after surgery and electroacupuncture at same acupoints at 2h 24h, 48h, and 72h after surgery. Absorbable polydioxanone sutures will be embedded into subcutaneous tissue using sterile embedding needles. All procedures will be conducted by licensed acupuncturists following standardized operating protocols.
214976584|NCT07071987|PROCEDURE|Electroacupuncture|Electroacupuncture will be performed at the same bilateral acupoints (ST36, ST37, and PC6)
214976585|NCT06754046|DEVICE|RP-MUS|a standard urethral sling placement for treatment of stress urinary incontinence
214976586|NCT06754046|PROCEDURE|PAHG|A standard 2 mL dose injection of bulkamid (order and number will be at the discretion of the surgeon) will be given. Patients undergoing PAHG will be given sham incisions consisting of superficial suprapubic epidermal scratches with a needle and fibrin glue at expected sling exit sites.
214976587|NCT06835556|BEHAVIORAL|Cognitive Behavioral Therapy|Individuals will be assessed for which psychological factors are maintaining paranoia in their daily lives. They will collaboratively identify one maintenance factor to focus on (e.g. worry, anomalous experience, self-confidence, PTSD) for 8 weeks of individual therapy. Then, all participants will transition to 8 weeks of individual therapy focused on dropping safety behaviors and re-engaging in everyday life.
214976588|NCT06835556|BEHAVIORAL|TAU|Individuals will continue treatment as usual (TAU). In addition they will have contact with a study therapist weekly via phone to provide information on what treatment they received. Phone check-ins will last approximately 5-10 minutes.
214366176|NCT02306759|DRUG|Placebo|Normal saline 50ml, administered over 15 minutes
214366177|NCT00624299|DRUG|Botox|Botox injection (100 ius) per muscle
214366178|NCT00624299|OTHER|Saline|Saline injection
214976589|NCT06767072|BEHAVIORAL|Tailored Multichannel interventions|"To ensure the feasibility of the intervention, the intervention will be designed by an interdisciplinary team including academic researchers from different specialties (experts in the fields of community health, psychiatry health, and nutrition), as well as 3 research assistants.~The designing process for each individual in the intervention group involved the following 4 subsequent steps: (1) intervention nurses assess HBM constructs, which are used to collect data on each unique perception regarding overweight(Saghafi-Asl et al., 2020). (2) data are reviewed, identified, and summarized by the interdisciplinary team; (3) the interdisciplinary team then creates an intervention plan based on the summarized needs and (4) the intervention plan will be shared with the participant to ensure collaboration.~The intervention will adopt the strategies of the Diabetes Prevention Program (DDP) (The Diabetes Prevention Program (DPP), 1996)."
214976590|NCT06903208|DEVICE|STARMed VIVA Combo RF System|RFA is a kind of treatment that uses a long thin needle, called a probe, to melt the lipoma. After numbing the skin with a local anesthetic, using an ultrasound machine as a guide, the study surgeon will insert the probe into the center of the lipoma. The probe will then deliver heat to the lipoma, melting it. The ultrasound is a machine which bounces sound waves to create an image that the study doctor sees on a screen. These ultrasound images will help the study surgeon to accurately guide the probe to the correct location of the lipoma. Once the lipoma is melted, the study surgeon will aspirate any residual liquid out.
214366179|NCT05646667|OTHER|interscalene with Erector spinae plane block group|patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and US guided Erector spinae plane block at T2 using 10 ml of bupivacaine 0.5%.
214366180|NCT05646667|OTHER|Interscalene group|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
214976591|NCT06259695|DEVICE|Adjustable Aquatic Therapy Prosthesis|We will recruit up to three participants, who will attend up to two fitting appointments lasting up to one hour to assist in the design development. After the design of the prosthesis is completed, participants will attend three, 30-minute, aquatic therapy sessions with a physical therapist trained in aquatic therapy and utilize the prosthesis.
214976592|NCT06809725|DIAGNOSTIC_TEST|SPARK Cognitive Status Indicator (software support data collected via EEG)|"The SPARK Cognitive Status Indicator software (collected via EEG) is being validated to aid in the diagnosis of Alzheimer's disease in persons aged 65-90 with suspected cognitive impairment. The device, once validated, shall provide a clinician with a positive or negative output to indicate whether the subject's electroencephalogram (EEG) is consistent with EEGs of subjects diagnosed with Alzheimer's disease."
214976594|NCT06751576|DEVICE|Median LCS|End-to-end processing of chest LDCT DICOM images by an AI/ML tech-based SaMD to detect, localize, and characterize (assign a malignancy score) each detected pulmonary nodule. The output of the device is a DICOM File (Median LCS result report) summarizing results per patient.
214976595|NCT04236908|DRUG|NSAIDS|Naproxen 500mg by mouth twice a day as needed.
214366181|NCT04830475|DEVICE|Non invasive ventilation (NIV)|Patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
214366182|NCT04830475|DEVICE|Conventional Venturi Mask|Patients were offered VenturiMask with Fio2 60% at 15 l / m.
214366183|NCT02395939|PROCEDURE|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
214366184|NCT02395939|PROCEDURE|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
214679803|NCT01073345|PROCEDURE|Portal venous pressure|Portal venous pressure is measured by invasive means using an arterial canula
214366185|NCT02183987|OTHER|Active Knowledge Translation Intervention|"1. Access to CSN guidelines, \& provider- \& patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space \& disseminated to patients.~2. Educational whiteboard video will be made available as a resource for clinic staff \& patients.~3. Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (\>3 months) starting dialysis early (eGFR \>10.5 ml/min), for all incident dialysis patients from the clinic, with provincial \& national average comparisons. These reports, \& the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.~4. Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines \& evidence supporting an intent-to-defer strategy, \& will receive follow-up."
214366186|NCT02275676|OTHER|bioelectrical impedance analysis|
214366187|NCT02275676|OTHER|indirect calorimetry|
214491590|NCT06781047|OTHER|Trunk Focused Rehabilitation (TFR)|"Abdominal stabilization progression for TFR is applied with simultaneous breathing exercise for 3 days a week, 45 minutes a day, 8 weeks (24 sessions in total)(8).~1. Basic Abdominal Stabilization Training, Task-Focused Exercises (without spinal diagonal and rotational components)(8,12).~   Warm-up: 5 minutes, Global Stretching and Relaxation(9,10,11). Extremity load, elastic band, and unstable surface are added as stabilization is achieved in neurodevelopmental positions. Task-oriented exercises(12).~   Cooling Down: Warm-up exercises are repeated.~2. General Posture and Asymmetry Training Brochure (includes adolescent, family, and team members)(13-17).~The exercise starts with 3 seconds and gradually progresses to 10 seconds, 10 repetitions, and 3 sets.~The TFR group also receives Conventional Treatment 2 days a week, 40 minutes per day, for 8 weeks. The same treatment protocol is applied as the control group). Routine physiotherapists apply conventional treatment."
214491591|NCT06781047|OTHER|Conventional Rehabilitation (CR)|"Conventional treatment is applied to the group, 2 days a week, 40 minutes each session, for 8 weeks. It is an intervention performed by a physiotherapist who regularly follows up in a special education and rehabilitation center.~1. Normal Joint Movement (NEH)~2. Stretching for the lower, and upper extremities and around the hips~3. Lying activities~4. Curl up (assisted, unaided)~5. Bridging exercise, cat camel exercise, posterior pelvic tilt exercise~6. Walking training~7. Climbing and descending stairs~8. Weight transfer exercises at standing, sitting"
214491592|NCT06820372|OTHER|Electronic Drug Dosing and Decision Support Kidney (eDoseCKD) Tool|Thirty evidence, expert informed and validated computerized drug decision support algorithms of high risk medications will be utilized by community pharmacists for individuals with an eGFR \< 60 ml/min who are on one of the 30 target algorithms. The will be followed up to 3 months to assess effectivess, safety and whether the dose change was maintained.
214491593|NCT06776744|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|Eye Movement Desensitization and Reprocessing (EMDR) treatment. EMDR is one of the first-choice evidence based treatments for PTSD. During an EMDR session, the traumatic memory is brought to the surface including associated images, thoughts, feelings and body sensations, while simultaneously focusing on an external distracting stimulus (e.g., lateral eye movements).
214976596|NCT04236908|DEVICE|Battlefield Acupuncture|"Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men).~Battlefield acupuncture utilizes up to 10 ASP acupuncture needles (5 in each ear). The Battlefield Acupuncture points include: cingulate gyrus, thalamus, omega-2, point zero, and shen men. The semi-permanent needles are left in place and typically stay in place for 2-7 days. Needles will usually fall out on their own, can be removed by the patient or the patient can call study staff and come in for removal if desired."
214366188|NCT02815462|OTHER|FAMFACESG|\- PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.
214366189|NCT02815462|OTHER|Control|\- Usual hospital Care
214366190|NCT02815462|OTHER|FAMFACESG|\- PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.
214366191|NCT02815462|OTHER|FAMFACESG|"* For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up.~* For high and moderate risk patients \& have complex nursing and / or high functional needs, PNs will refer these patients for THC.~* For mild risk patients, PNs will refer them to care coordinator."
214366192|NCT02815462|OTHER|FAMFACESG|\- For low risk patients, PNs will continue usual hospital care.
214366193|NCT06442150|COMBINATION_PRODUCT|Low-Calorie Medicine Diet|Low-Calorie Medicine Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
214366194|NCT06442150|COMBINATION_PRODUCT|Low-Calorie Diet|Low-Calorie Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
214366195|NCT05646186|DIETARY_SUPPLEMENT|Personalized dietary intervention based on microbiome analysis|Personalized dietary intervention based on individual microbiome analysis
214366196|NCT05646186|DIETARY_SUPPLEMENT|Low-FODMAP diet|Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet
214366197|NCT03827122|DRUG|onabotulinumtoxinA|Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
214366198|NCT05382312|DRUG|GSK3036656|GSK3036656 will be administered.
214366199|NCT05382312|DRUG|Bedaquiline|Bedaquiline will be administered.
214366200|NCT05382312|DRUG|Delamanid|Delamanid will be administered.
214366201|NCT05382312|DRUG|RIFAFOUR e-275|RIFAFOUR e-275 will be administered.
214366202|NCT05382312|DRUG|BTZ-043|BTZ-043 will be administered.
214366203|NCT01417572|DRUG|lidocaine|to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
214366204|NCT00336674|BIOLOGICAL|Intranasal insulin|440IU Insulin
214366205|NCT00336674|OTHER|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
214366206|NCT01751438|OTHER|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
214976597|NCT04236908|DEVICE|GV26 with manual tonification|"Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle).~The protocol for using GV26 is as follows: With the patient in a seated position the acupuncturist places a 40mm needle in the acupuncture point GV26 (located on the philtrum, on the anterior midline, at the junction of the upper 1/3 and lower 2/3 of the distance from the nose to the margin of the upper lip). The acupuncturist then rapidly rotates the needle at the handle clockwise and counterclockwise (known as manual tonification) for 20-40 seconds at a time. The patient then stands up and assesses their pain. This will be performed up to 6 cycles. If a patient is unable to sit or stand, this may also be performed in a supine position with the patient attempting to sit or stand every 20-40 seconds."
214976598|NCT06497504|DRUG|Bepirovirsen|Bepirovirsen will be administered.
214976599|NCT06497504|DRUG|Placebo|Placebo will be administered.
214976600|NCT07073287|DEVICE|Cerebello-spinal direct current stimulation|csDCS influences both ascending and descending spinal pathways and reflex excitability, promoting prolonged functional neuroplastic changes.
214976601|NCT07073287|DEVICE|Sham Comparator|Masking for cerebello-spinal direct current stimulation involves the electric current stopping after 30 seconds, providing a sensation without producing neuromodulation.
214976602|NCT06935188|DRUG|Dalpicilib combined with cetuximab|The participants receive cetuximab in combination with Dalpiciclib until termination criteria are met. Participants receive cetuximab intravenously at a dose of 500 mg/m2 biweekly, or an initial dose of 400 mg/m² followed by weekly maintenance dose of 250 mg/m2. Dalpiciclib is administered orally at a dose of 150 mg once daily for 21 consecutive days, followed by a 7-day break. Each 28 days were deemed as a treatment cycle. If the patient vomits or misses a dose, it should not be made up on the same day. The next dose should be taken as usual.
214976603|NCT06935188|DRUG|cetuximab|The participants receive cetuximab alone until termination criteria are met. Participants receive cetuximab intravenously at a dose of 500 mg/m2 biweekly, or an initial dose of 400 mg/m² followed by weekly maintenance dose of 250 mg/m2.
214976604|NCT03991533|OTHER|multiparametric MRI|preoperative multiparametric MRI
214976605|NCT02357459|DRUG|FX006|Single 5 mL IA injection
214976606|NCT02357459|DRUG|Placebo|Single 5 mL IA injection
214976607|NCT02357459|DRUG|TCA IR 40|Single 1 mL IA injection
215085065|NCT04237038|PROCEDURE|laparoscopic Nissen fundoplication short gastric vessel division|Randomized clinical trial conducted in forty patients submitted to SGVD and forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life. A randomized clinical trial was conducted with 87 patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of Gastroesophageal reflux disease (GERD
214366207|NCT01751438|OTHER|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
214366208|NCT01751438|BEHAVIORAL|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
214366209|NCT01751438|OTHER|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
214366210|NCT02721082|BEHAVIORAL|Opt Out Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for all participants.
214366211|NCT02721082|DRUG|Nicotine Replacement Therapy|Unless they Opt Out all participants will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
214366212|NCT02721082|BEHAVIORAL|Opt In Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for participant's who are ready to quit smoking. For patient's not ready to quit, motivational counseling will be provided to participants based on principles of Motivational Interviewing.
214366213|NCT02721082|DRUG|Nicotine Replacement Therapy|Participants ready to quit will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
214366214|NCT00251862|BEHAVIORAL|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
214366215|NCT00251862|BEHAVIORAL|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
214366216|NCT00251862|BEHAVIORAL|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
214366217|NCT02134587|OTHER|Multifaceted educational intervention|"1. Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~2. Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~3. Distribution of educational material~4. Practical class to explain the correct fill of adverse drug events form~5. Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance."
214366218|NCT00265889|BIOLOGICAL|filgrastim|480 mcg beginning day +5
214366219|NCT00265889|DRUG|busulfan|11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
214366220|NCT00265889|DRUG|cyclophosphamide|60 mg/kg IV over 2 hours x 2 days
214366221|NCT00265889|DRUG|etoposide|60 mg/kg, IV
214366222|NCT00265889|DRUG|melphalan|150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
214366223|NCT00265889|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|autologous-autologous tandem hematopoietic stem cell transplantation
214366224|NCT00265889|RADIATION|radiation therapy|radiation therapy
214366225|NCT04373876|DEVICE|Subcutaneous Implantable Cardioverter Defibrillator|Patients implanted with a totally subcutaneous defibrillator system
214366226|NCT03503266|DRUG|[14C] MT-7117|14-C MT-7117
214366227|NCT03133026|DEVICE|Single operator cholangioscopy, Endoscopic biliary RFA|Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
214366228|NCT01952626|DRUG|Ondansetron|intravenous injection
214366229|NCT01952626|DRUG|Palonosetron|intravenous injection
214491594|NCT06380166|DIAGNOSTIC_TEST|Hepatitis C core antigen|Semi-quantitative, automated immunoassay detecting core antigen of hepatitis C virus.
214491595|NCT06819215|DRUG|VB15010|Oral PARP1 inhibitor
214491596|NCT06770829|BEHAVIORAL|DiaFOOTCare Program|The DiaFOOTCare Program includes initiatives to support diabetic foot self-management. An e-booklet on type 2 diabetes management and preventive foot care will be shared via WhatsApp or email, along with audio modules for convenient access. An interactive video featuring a simulated patient will visually demonstrate preventive foot care practices and will also be shared digitally. A 25-30-minute face-to-face training session will provide personalized education using a tablet. Goal-tracking cards will be introduced to collaboratively set three-month behavioral goals, with patients documenting their progress during the follow-up. SMS reminders will be sent three times weekly to reinforce adherence. Patients will have digital access to all DiaFOOTCare resources, including the e-booklet, audio modules, and video, for 12 weeks, ensuring accessibility via WhatsApp or email. These measures aim to enhance knowledge, behavior, and self-management practices in preventive diabetic foot care.
214502830|NCT07034404|BEHAVIORAL|Digital Adapted Physical Activity|"The digital Adapted Physical Activity (APA) program will be delivered via a digital platform and participants will be guided by an APA teacher to meet the WHO recommendations (i.e. 150 minutes of moderate intensity aerobic PA per week and muscle-strengthening activities that involve all major muscle groups twice weekly).~Participants will benefit from 10 visits with the APA teacher: an initial assessment to define personalized goals and familiarize participants with the digital platform, eight sessions to monitor progress and adapt the exercise program, and a final evaluation aimed at assessing outcomes and encouraging long-term adherence to physical activity. Daily physical activity will be objectively monitored using a Withings connected watch to provide feedback and track metrics such as step count."
214976608|NCT04394325|BEHAVIORAL|Digital information tool|The patients randomized to group A will receive verbal and written information regarding the digital information tool and how to use it, as well as verbal and written information about the study. They will also receive information about the different instruments and surveys they will be asked to answer at different occasions during the RT treatment period. The applied instruments for data collection will be administrated in person or by post at the baseline collection and by post (including pre-paid return envelope) on consecutive collections. Approximately 30 patients (in group A) will be asked to make regular notes in a notebook during the waiting period prior start of RT as well as during RT treatment period. Following completion of the RT treatment period individual in-depth and telephone interviews will take place with 10-12 patients that accept participation.
214976609|NCT00884442|DRUG|Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)|60 mg nifedipine
214976610|NCT00884442|DRUG|Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)|60 mg nifedipine
214976611|NCT01152671|DRUG|Placebo|single oral dose
214976612|NCT01152671|DRUG|RO5024048|single oral dose
214976613|NCT01493622|DRUG|minocycline|variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
214976614|NCT01493622|DRUG|placebo|variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
214976615|NCT06134063|DRUG|Xuanfei Baidu granule|Xuanfei Baidu granule will be administered twice daily for 7 days on the basis of basic treatment
214976616|NCT06134063|DRUG|Xuanfei Baidu granule Placebo|Xuanfei Baidu granule Placebo will be administered twice daily for 7 days on the basis of basic treatment
214976617|NCT02188160|DRUG|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
214976618|NCT02188160|DRUG|Placebo|Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
214976619|NCT01571843|OTHER|Forearm exercise program|Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
214976620|NCT01571843|OTHER|Walking program|Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
214976621|NCT03272204|BEHAVIORAL|No pubic hair|Natural pubic hair to fully removed pubic hair
214976622|NCT03272204|BEHAVIORAL|Pubic Hair|Removed pubic hair to natural pubic hair
214976623|NCT03847571|DRUG|Acetazolamide|Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
214976624|NCT00025779|DRUG|methylphenidate|
214976625|NCT00025779|DRUG|guanfacine|
214976626|NCT02117518|OTHER|blood drawing|
214976627|NCT00641563|DRUG|Dexmedetomidine|Infusion of dexmedetomidine
214976628|NCT00641563|DRUG|Midazolam|Midazolam infusion
214976629|NCT00641563|DRUG|Remifentanil|Infusion of remifentanil
215085066|NCT01571908|DRUG|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
214366230|NCT01711203|OTHER|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
214976630|NCT01655901|BEHAVIORAL|Active video gaming|
214976631|NCT01655901|BEHAVIORAL|Passive video gaming|
214976632|NCT01655901|BEHAVIORAL|Resting|
214976633|NCT00934375|DRUG|Aricept (donepezil hydrochloride)|5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
214976634|NCT00934375|DRUG|placebo|
214366231|NCT01711203|OTHER|General Strengthening|General abdominal and lower quarter musculature strengthening
214366232|NCT00416182|DRUG|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
214366233|NCT00416182|DRUG|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
214366234|NCT00071617|BEHAVIORAL|Youth-Nominated Support Team|
214976635|NCT04243278|DRUG|Low-dose aspirin|81 mg of low dose aspirin PO for 6 months
214491597|NCT06770829|BEHAVIORAL|Ministry of Health and Education|The active control group will receive routine outpatient follow-ups and a diabetic foot care brochure from the Ministry of Health, explained by the researcher and shared via WhatsApp or email for reference. Goal-tracking cards from the DiaFOOTCare program will be used to set individual diabetic foot self-management behavioral goals collaboratively during the initial interview. Patients will be instructed on how to complete the cards and maintain them over a three-month period. At the end of the follow-up, post-tests will assess outcomes using the Glycemic Control Form, Goal-Tracking Card, Diabetic Foot Knowledge Scale, Foot Care Behavior Scale, Nottingham Functional Foot Care Diagnostic Form, Diabetic Foot Development Follow-up Form, and Diabetic Foot Self-Management Scale. Educational resources, including the e-booklet, audio modules, and video developed in DiaFOOTCare, will also be shared via WhatsApp or email to provide additional support and enhance diabetic foot self-management.
214366235|NCT01525602|DRUG|PLX3397|PLX3397 tablets, 200mg
214491598|NCT06859125|DEVICE|Endo-Wing™ (Shangxian Minimal Invasive Inc, China)|Endo-Wing™ (Shangxian Minimal Invasive Inc, China) is a medical-grade soft silicone rubber device that is attached at the end of a colonoscope. It has 6 soft wing-like projections that are bendable and pliable, giving the endoscopist a superior visualization directly from its action of flattening the colonic folds and maintaining the central view of the colonoscope during withdrawal. This can improve the endoscopist's ADR.
215085067|NCT01571908|DRUG|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
214491599|NCT06859125|DEVICE|Standard Colonoscopy|Colonoscopies performed using Olympus Evis Exera III 90 series or Olympus Evis Lucera 260 series colonoscopes without Endo-Wing attached at the tip of the colonoscope
215085068|NCT01571908|DRUG|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
214366236|NCT01525602|DRUG|Paclitaxel|Paclitaxel IV
214366237|NCT02073461|DRUG|CD1579 2.5%|
214502831|NCT07034404|BEHAVIORAL|Control (Standard treatment)|Participants will receive standard care and advice on physical activity (based on the recommendations of the World Health Organization, WHO, and the European Alliance of Associations for Rheumatology, EULAR) through a document provided to them.
214679804|NCT01073345|PROCEDURE|Portal venous flow|Portal venous flow is measures using a noninvasive method (Doppler flow meter)
214679805|NCT01073345|PROCEDURE|Hepatic artery flow|Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
214976636|NCT04243278|DRUG|Placebo oral tablet|placebo PO for 6 months
214976637|NCT01757015|DRUG|NVA237|NVA237 (50µg, o.d. via SDDPI) in the morning,
214976638|NCT01757015|DRUG|Placebo to NVA237|Placebo to NVA237
214976639|NCT00276302|DRUG|IPI-504|"IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart."
214976640|NCT05458778|DEVICE|Daily test with urine by the product|Women perform the hCG test and share the test results
214976641|NCT01782339|DRUG|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8\* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~\*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
214976642|NCT00002557|DRUG|CHOP regimen|
214976643|NCT00002557|DRUG|doxorubicin hydrochloride|
214976644|NCT00002557|DRUG|etoposide|
214976645|NCT00002557|DRUG|leucovorin calcium|
214976646|NCT00002557|DRUG|methotrexate|
214976647|NCT02019355|DRUG|5-fluorouracil 5% cream|
214976648|NCT02019355|DRUG|Calcipotriol 0.005% ointment|
214976649|NCT02019355|DRUG|Vaseline|
214976650|NCT04670601|DRUG|Flurbiprofen Test 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
214976651|NCT04670601|DRUG|Flurbiprofen Reference 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
214976652|NCT00613795|DIETARY_SUPPLEMENT|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
214976653|NCT00613795|DIETARY_SUPPLEMENT|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
215085069|NCT01571908|DRUG|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
214366238|NCT02073461|DRUG|CD1579 5%|
214366239|NCT02073461|DRUG|Vehicle|
214366240|NCT05474274|OTHER|Machine learning algorithms|Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
214366241|NCT04349280|DRUG|Bintrafusp alfa|Participants will receive bintrafusp alfa.
214366242|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
214366243|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 10|Subjects will consume 10 grams of fructan
214976654|NCT04292236|DIETARY_SUPPLEMENT|Lauric Acid, Perilla Oil and Diindolylmethane|Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
214976655|NCT03256578|DEVICE|New Life Box Respiratory Function Monitor|The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
214366244|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
214366245|NCT00988403|DIETARY_SUPPLEMENT|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
214366246|NCT05576584|DRUG|GST-HG121 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
214976656|NCT02976883|OTHER|[18F]HX4 diagnostic PET/CT scan|Single intravenous injection of \[18F\]HX4 and PET/CT scan
214366247|NCT05576584|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
214366248|NCT03794622|OTHER|intramedullary nail fixation with bone marrow concentration|intramedullary nail fixation with bone marrow concentration
214366249|NCT03794622|OTHER|intramedullary nail fixation|intramedullary nail fixation only
214366250|NCT00478712|OTHER|Identification of genetic causes of Hirschsprung Disease|Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
214366251|NCT04168554|DEVICE|Telemedicine|Patient is examined using telemedicine
214366252|NCT06942494|DRUG|conventional medical treatment (TAU)|In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs, i.e., sertraline, fluoxetine and fluvoxamine)and tricyclic drugs(i.e., clomipramine) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD in children and adolescents. The drugs used in this study are commonly used in clinical practice and have a good safety profile. The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual, or the maximum dosage tolerated by the patients.
214366253|NCT06942494|BEHAVIORAL|Family-Based Self-help Book for Adolescents with Obsessive-Compulsive Disorder|The self-help book used in this study was independently developed by members of our research team. Its content is based on Exposure and Response Prevention (ERP). Adolescent patients with OCD will be instructed to read one chapter of the self-help book each week and complete the corresponding exercises. This 12-week intervention will involve self-guided practice conducted by the adolescent and their family members.Throughout the intervention period, adolescents and their caregivers may contact the therapist via WeChat to ask questions and upload records of their completed exercises. The therapist will respond to any questions within 48 hours by sending written messages via WeChat, with each family receiving no more than 30 minutes of such written guidance per week. All therapists will be required to keep a weekly log of the time spent providing guidance to each participating family.If a participating family does not initiate contact, the therapist will not provide proactive guidance.
214366254|NCT06944704|DRUG|Pentoxifylline|Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.
214366255|NCT05970822|DRUG|BC3402|Escalating of BC3402 will be administered IV(intravenous)
214366256|NCT05970822|DRUG|Azacitidine|Azacitidine will be administered daily
214366257|NCT04413591|BEHAVIORAL|Community based combination HIV prevention package|The intervention compares the efficacy of a community-based comprehensive HIV/STI prevention package compared to standard of care (HIV testing, counseling, and referrals) among Female Sex Workers.
214366258|NCT02532179|BIOLOGICAL|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
214366259|NCT03648112|DIETARY_SUPPLEMENT|Intervention 1|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes per day.
214366260|NCT03648112|DIETARY_SUPPLEMENT|Intervention 2|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes per day.
214366261|NCT03648112|DIETARY_SUPPLEMENT|Intervention 3|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes per day.
214366262|NCT03648112|DIETARY_SUPPLEMENT|Intervention 4|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes per day.
214366263|NCT03648112|DIETARY_SUPPLEMENT|Control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
214366264|NCT05887505|OTHER|Vitamin D|Oral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days
214366265|NCT05887505|OTHER|Placebo|Oral supplementation of placebo in 3 consecutive days.
214976657|NCT02371616|DEVICE|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
214976658|NCT02371616|OTHER|Sodium fluoride|1426 ppm fluoride as sodium fluoride
214976659|NCT02371616|OTHER|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
214976660|NCT02316925|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning
214976661|NCT02316925|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning
214976662|NCT04694092|DRUG|Intensive heart rate control with landiolol|Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin
214976663|NCT04694092|DRUG|Standard approach to heart rate control|Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
214976664|NCT00754741|BEHAVIORAL|Adherence information|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
214366266|NCT01105026|DEVICE|Alveolar Bone Defect Regeneration Following Tooth Extraction|"Patients underwent surgery under local anesthesia and minimally invasive periotomy was carried out with a surgical blade. Atraumatic extraction with forceps was performed. The extraction socket was carefully curetted to remove the granulation tissue and was rinsed with a physiologic solution. To evaluate the eligibility of the surgical site, the alveolar walls integrity was checked clinically and by means of extemporaneous peri-apical radiography.~Then, the socket was filled to the bone margin with Inion BioRestore™ (granules size 1 to 2 millimetres). Finally, single interrupted (5-0) sutures were tightened to promote the stability of grafted particles. Ten days after the surgery, sutures were removed."
214366267|NCT02681848|DRUG|Varenicline|Smoking cessation medication
214976665|NCT00754741|BEHAVIORAL|Adherence information plus motivational interviewing|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
214976666|NCT01861392|PROCEDURE|sensorio-motor training|
214976667|NCT00922636|DRUG|LY2216684|Taken in tablet form QD po.
214366268|NCT02681848|DRUG|Nicotine replacement therapy|
214679806|NCT05493865|BEHAVIORAL|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|This study will be a three-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents by comparing to a C-SMILE intervention group and a no-intervention waitlist control group.
214679807|NCT00021697|DRUG|AVP-923|
214679808|NCT00075244|DRUG|Replagal|
214976668|NCT00922636|DRUG|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
214976669|NCT00922636|DRUG|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
214976670|NCT00922636|DRUG|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
214976671|NCT00152347|DRUG|Botox|See Detailed Description
214976672|NCT05066529|PROCEDURE|dry-needling|Dry needling is a technique in which a fine needle is used to penetrate the skin, subcutaneous tissues and muscles to mechanically disrupt tissue without the use of anesthesia. Treatment is often used to treat myofascial trigger points.
214976673|NCT06391411|DIETARY_SUPPLEMENT|a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg)|In this three-arm randomized, controlled trial, with one arm represented by healthy subjects, eligible participants were randomly divided into two groups. Fifteen patients were randomly allocated to the intervention group and received, for 6 months, intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen and daily supplementation with a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg). The other fifteen patients was assigned to the control group and only received the intravitreal anti-VEGF treatment at a fixed regimen for 6 months
214976674|NCT06391411|DRUG|anti-VEGF treatment|Intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen for six months
214976675|NCT04706377|DIETARY_SUPPLEMENT|B12 fix 1000mcg|oral dispersible tablet with vitamin B12 1000mcg
214976676|NCT04706377|OTHER|Placebo|Placebo tablet
214976677|NCT00511719|DRUG|Technosphere Insulin|48U
214976678|NCT00511719|DRUG|Actrapid|24IU
214976679|NCT04331626|DRUG|Gemcitabine Injectable Product|Low dose chemotherapy drug combined with pd-1 antibody, Gemcitabine should be administered at 50% of the recommended dose, i.e. 500mg/m2, for 30 minutes by intravenous drip. Day 1 and day 8 administration.
214976680|NCT01966783|DRUG|Budesonide 2 mg suppository|per day
214976681|NCT01966783|DRUG|Budesonide 4 mg suppository|per day
214976682|NCT01966783|DRUG|Mesalazine 1 g suppository|per day
214976683|NCT01966783|DRUG|Budesonide 2 mg suppository/Mesalazine 1 g suppository|per day
214976684|NCT02212067|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
214976685|NCT02212067|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
214976686|NCT00824668|DRUG|biphasic insulin aspart 30|
214976687|NCT00824668|DRUG|insulin glargine|
214976688|NCT00824668|DRUG|insulin glulisine|
214976689|NCT02266017|BEHAVIORAL|Pain Coping Skills Training|
214976690|NCT00054288|DRUG|gemcitabine hydrochloride|
214976691|NCT00054288|DRUG|irinotecan hydrochloride|
214679809|NCT04582734|BEHAVIORAL|Cognitive-behavioural therapy|Cognitive-behavioural therapy intervention
214976692|NCT04377867|DRUG|Abatacept Injection [Orencia]|Patients on abatacept to control disease symptoms
214976693|NCT05771870|OTHER|Peer mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After understanding about the study, two master's degree students from Karabük University Institute of Graduate Studies of Child Health and Diseases Nursing consented to participate on a volunteer basis and became peer mentors in the study. All postgraduate students are pediatric nurses with at least two years of clinical experience who have completed their undergraduate nursing program."
214976694|NCT05771870|OTHER|Nurse mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After providing information about the research to bachelor's degree nurses who have worked in the Children's Units of Karabuk Training and Research Hospital for at least two years, two mentors for the nurse mentoring group were chosen on a volunteer basis. Mentors were taught on the concept of mentoring, the roles of the mentor, interpersonal relationships, and communication skills prior to the study."
214366269|NCT00656279|BEHAVIORAL|Intensive dietary phosphorus education|Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
215085070|NCT00378911|DRUG|sunitinib malate|Given orally
214491600|NCT05695339|DRUG|Resiniferatoxin|An injection of 1-2 ml bupivacaine 0.5% will be placed around the affected branch of the neuroma (aiming at its proximal end) and dorsal adjacent tissue including the skin dorsally to the neuroma. This is to prevent pain caused by any microscopic spills of RTX during the. A second local anesthetic depot will be placed 1-2 cm proximally to the injection site around the affected branch of the plantar nerve to prevent pain caused by passive current transmission by axonal RTX excitation. Following the course of the affected nerve branch and ultra-sound visualization of the injection site, 0.5-2 ml bupivacaine 0.5% will be injected perineurally. Once the site has sufficient nerve block, the required RTX dose in a solution of 0.25 ml will be injected directly proximal to the Morton s neuroma under ultra-sound visualization.
214491601|NCT03307382|DEVICE|SpyGlass DS Cholangioscopy|SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
214491602|NCT04100135|DEVICE|Actual device PFO closure|Actual PFO closure with the GORE® CARDIOFORM Septal Occluder
215085071|NCT03173911|DEVICE|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
214491603|NCT04100135|DRUG|Thienopyridine (clopidogrel or prasugrel)|Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
214491604|NCT04100135|DEVICE|Sham device PFO closure|Sham (simulated) device PFO closure with result of no device implantation and no PFO closure
214976695|NCT02626598|DEVICE|Blended Belotero|Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
215085072|NCT02387164|DRUG|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
215085073|NCT02387164|DRUG|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
215085074|NCT05804630|DRUG|Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)|As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
215085075|NCT05747482|OTHER|Surgery procedure|Omentectomy vs omental preservations during gastric surgery
214976696|NCT00236054|DRUG|Gabitril|
215085076|NCT01780714|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
215085077|NCT01780714|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
215085078|NCT00000558|DRUG|angiotensin-converting enzyme inhibitors|
215085079|NCT01297361|OTHER|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
215085080|NCT04851821|DRUG|Quercetin|Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
215085081|NCT03090074|BEHAVIORAL|Diet regime|Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
214366270|NCT04469686|COMBINATION_PRODUCT|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
214366271|NCT04469686|COMBINATION_PRODUCT|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator
214366272|NCT04469686|COMBINATION_PRODUCT|Twice daily placebo suppository administered with Sephure applicator|Twice daily placebo suppository administered with Sephure applicator
214976697|NCT01251952|DRUG|Denileukin Diftitox (Ontak)|"After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360."
214976698|NCT02797834|PROCEDURE|Endometrial fluid collection|
214976699|NCT05251350|PROCEDURE|surgery|our study is observational and we use secondary data
214976700|NCT00350883|BEHAVIORAL|Cognitive Therapy|Goal-oriented talk therapy
214976701|NCT00350883|OTHER|Treatment as Usual|Keep getting usual care
215085082|NCT03090074|BEHAVIORAL|Type of psychological support|Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
215085083|NCT02120092|DRUG|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
215085084|NCT02120092|DRUG|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
215085085|NCT02120092|DRUG|ASA|"7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)"
215085086|NCT02120092|DRUG|Placebo|7x 300mg acetylsalicylic acid placebo
215085087|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
215085088|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
215085089|NCT04481802|DEVICE|RadiaAce gel|Patients will apply the RadiaAce to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
214366273|NCT05351996|DEVICE|Kinesiotape|The participants received kinesiotape application three times with one-week intervals. Y strip tape was used. The interventionist applied the band to the rectus femoris muscle with facilitation technique.
214366274|NCT05351996|DEVICE|Sham-kinesiotape|"The participants received sham-kinesiotape application three times with one-week intervals.~In the sham group, the interventionist adhered KT to the rectus femoris transversely, without stretching."
214976702|NCT03160391|BEHAVIORAL|Music Training|Training curriculums were developed using guidelines set by the Ontario Ministry of Education (The Ontario Curriculum, 2009) for teaching music to grades 1 to 3. Music was delineated into duration, pitch, dynamics and other expressive controls, timbre, texture/harmony, and form. training included direct instruction and group activities. All training programs had the same structure: a warm-up period, following by instruction from a teacher, and then group activities to practically demonstrate the concepts learned. Both programs involved working towards a variety of ensembles.
214976703|NCT03160391|BEHAVIORAL|Dance Training|As with music training, dance was operationally defined by fundamental concepts for the art form, namely elements for body, space, time, energy, and relationship. The intervention involved both individual and group activities, with a combination of instruction and practical activities, and preparation for a final performance.
214366275|NCT05351996|OTHER|Home-based exercise program|Participants were taught exercise program training. The exercise intervention was based on quadriceps and knee flexor muscle group strengthening, and knee joint range of motion exercises, in their home.
214366276|NCT00806234|DRUG|Aripiprazole or Perphenazine|Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
214366277|NCT00806234|DRUG|Metformin|Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
214366278|NCT00806234|DRUG|Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine|Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
214366279|NCT04922151|DRUG|601|intravitreal recombinant humanized anti-VEGF monoclonal antibody
214366280|NCT04922151|DRUG|Ranibizumab|intravitreal recombinant humanized anti-VEGF monoclonal antibody
214366281|NCT03646032|BEHAVIORAL|SAAFE|After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.
214366282|NCT03646032|BEHAVIORAL|Control|This group will receive dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
214366283|NCT03348072|PROCEDURE|Cardiac surgery|Cardiac surgery
214366284|NCT00003979|DRUG|CHS 828|
214366285|NCT05347264|OTHER|gun massager|15 to 20 minutes along with hot pack.
214366286|NCT05347264|OTHER|transverse friction massage|15 to 20 minutes along with hot pack.
214366287|NCT03076970|DRUG|lasmiditan 200 mg|drug including single placebo tablet
214366288|NCT03076970|DRUG|Sumatriptan|drug including single placebo tablet
214366289|NCT03076970|DRUG|matching placebo|single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
214366290|NCT03893721|DIAGNOSTIC_TEST|arsenic exposure|analysis of hair samples for Arsenic using Agilent graphite tube atomizer 120
214366291|NCT03866941|BEHAVIORAL|causes of abuse synthetic cannibinoids|Epidemiological data (age, sex, residence, occupation, route of abuse, the cause of abuse and smoking) (2) Symptoms and signs (seizures, psychosis, hallucinations) (3) Injuries and their relation to violence (type of wound, type of instrument, number of injuries, external or internal injuries and assailant or victim).
214976704|NCT03586310|DEVICE|ear-EEG|soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
214976705|NCT04437758|DIETARY_SUPPLEMENT|Collagen and Vitamin C powder mix nutritional intervention|20 g collagen + 50 mg vitamin C daily, 60 min prior to exercise
214366292|NCT00034957|DRUG|Investigational drug|
214366293|NCT03688984|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Cognitive Behavioural Therapy for Insomnia (CBT-I) consists of six individual therapy sessions that last approximately one hour each. The sessions include psychoeducation about insomnia, goal setting, relaxation training, stimulus control, sleep consolidation and medication review. Additional components include cognitive therapy, sleep hygiene and mindfulness and relapse prevention.
214366294|NCT05807113|OTHER|Atopi intensive care BNO 3731|Crem twice daily
214366295|NCT05807113|OTHER|Benchmark product|Crem twice daily
214366296|NCT05980208|DRUG|Inetetamab|Inetetamab-based treatment for first-line treatment of HER2-positive MBC
214491605|NCT01084863|DRUG|CT-P6|CT-P6: administered every 3 weeks
214976706|NCT04437758|OTHER|Maltodextrin placebo powder|20 g maltodextrin placebo daily, 60 min prior to exercise
214976707|NCT04437758|OTHER|Maximum power training exercise|Explosive/power-based exercise training program 3 times/week at home consisting of drop jumps, box jumps, weighted jump squats loaded in a progressive manner weekly for 3 weeks. At baseline and at the end of each of the 3 weeks, measures of explosive performance are assessed in the lab (maximal isometric squat, counter-movement jump and squat jump)
214976708|NCT05598060|RADIATION|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
214976709|NCT06524388|DEVICE|adaptive cognitive training|The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.
214976710|NCT06524388|DEVICE|placebo cognitive training|Participants received cognitive training tasks of fixed difficulty.
214976711|NCT01726296|OTHER|educational intervention|Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
214976712|NCT01726296|OTHER|medical chart review|Complete patient medical chart audit
214976713|NCT05173077|PROCEDURE|Identification of specific VOCs in CRC tissue surgery material|Paired tissue samples will be taken during surgery for CRC. Tissue material from the same patient will be obtained from the cancerous tissue as well as from normal resected material without malignant infiltration. Minimum of 100 mg of each tissue per sample will be obtained. To compare the emission of VOCs in the CRC tissue surgery material to the emissions from normal tissue by GC-MS in a reasonable number of cancer cases.
214976714|NCT05173077|OTHER|Secondary validation study in general CRC screening settings|"Altogether at least 1000 individuals relatively healthy 40-64 years old population-based collected individuals will get recruited. Breath samples will be collected by asking the study subjects to breath into hybrid breath analyser.~To exclude significant colorectal lesions, laboratory-based FIT testing will be offered to the population cohort group for faecal occult blood in faeces. Serum and plasma samples will also be obtained to have them available if additional testing will be required. Individuals with a FIT test value over the cut-off value (\>10 microg/g faeces) will be invited to colonoscopy. The data analysis procedures and classification models will be tested in this general population and cross-checked against FIT and colonoscopy results."
214976715|NCT05173077|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a hybrid sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Strict requirements for subjects will be imposed prior to the breath sampling to standardise the breath sampling and to limit the influence of confounding factors.
214976716|NCT05173077|OTHER|Blood sample collection|Serum, plasma sampling for group description and stratification.
214366297|NCT03552133|DEVICE|Smart CO2|A lightweight, cylindrical reservoir attached to a face mask which monitors breathing breath-by-breath and automatically adjusts the level of dead space rebreathe volume so that CO2 will be increased and sleep apnea treated.
214366298|NCT00789815|DEVICE|Bispectral index guide propofol infusion|"Induction:~Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.~Maintenance:~Propofol infusion (3\~12 mg/kg/hour) to maintain BIS around 65\~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough."
214366299|NCT00789815|DRUG|Clinical-judged midazolam administration|"Induction:~Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S\* 2\~3.~Maintenance:~Midazolam: 2 mg/ 2min prn to keep OAA/S\* 2\~3 or if intolerance of procedure. Alfentanil as study arm.~\*Observer's assessment of alertness/sedation (OAA/S):~Class 5: Responds readily to name spoken in normal tone.~Class 4: Lethargic response to name called in normal tone.~Class 3: Responds only to name called loudly.~Class 2: Responds only to shaking.~Class 1: No response to shaking."
214366300|NCT05189626|OTHER|Muscle energy technique|Post Isometric relaxation(muscle energy technique) 3 days/ week for 4 weeks
214366301|NCT05189626|OTHER|Kaltonborn mobilizations|Kaltonborn mobilizations grade II and III will be performed on Glenohumeral joints 3 days/ week for 4 weeks.
214976717|NCT05173077|DIAGNOSTIC_TEST|Microbiota testing|Faecal samples for microbiota testing.
214976718|NCT05173077|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy will be used only according to the clinical indications.
214976719|NCT02063113|OTHER|Vulnerability and therapeutic changes in older patients with multiple myeloma.|
214976720|NCT05511857|BEHAVIORAL|Self-distancing, third-person self-talk.|The participants will engage in self-distancing, third-person self-talk.
214976721|NCT05511857|BEHAVIORAL|Self-immersed, first-person self-talk.|The participants will engage in self-immersed, first-person self-talk.
214976722|NCT05511857|BEHAVIORAL|Distraction|The participants will engage in a distraction task.
214976723|NCT00653874|DEVICE|BiliChek (jaundice assessment)|assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
214976724|NCT00653874|PROCEDURE|Transcutaneous bilirubinometry (TcB)|transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
214976725|NCT00653874|OTHER|Clinical asessment of bilirubin (CaB)|Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
214976726|NCT05229328|DIAGNOSTIC_TEST|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
214976727|NCT03332186|DRUG|BMS-986231|Intravenous infusion administration
214976728|NCT03028142|DRUG|1.5 mg RPL554 plus tiotropium|
214976729|NCT03028142|DRUG|6 mg RPL554 plus tiotropium|
214976730|NCT03028142|DRUG|Placebo plus tiotropium|
214976731|NCT01183364|DRUG|STA-9090 (ganetespib) with Docetaxel|One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
214366302|NCT02758353|DRUG|Community distribution of SP|SP delivered at both the community and facility level by trained CBHVs in three LGAs.
214976732|NCT01477801|DRUG|CHOLECALCIFEROL|"Standard guideline based therapy plus cholecalciferol:~Loading dose 300.000 U then 50.000 U every month for six months"
214976733|NCT01477801|DRUG|PLACEBO|Standard guideline based therapy plus placebo
214366303|NCT03139422|DRUG|Tranexamic Acid 500 MG|oral tablets
214366304|NCT03139422|DRUG|Calcium Dobesilate|oral tablets
214976734|NCT03482050|BIOLOGICAL|AstroRx|Astrocytes derived from human embryonic stem cells
214976735|NCT02810418|DRUG|LMB-100|Arms A1 and A2 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles Arm B1 (continuous infusion): Administered IV for 24, 48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles. Arm B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 14 day cycle for a maximum of 3 cycles.
214976736|NCT02810418|DRUG|Nab-Paclitaxel|Administered intravenously (IV) on days 1 and for Arms A1, A2 and B1 on day 8 of each 14-21 day cycle for a maximum of 2 (Arms A1, A2 and B1) or 3 (Arm B2) cycles
214976737|NCT02810418|DEVICE|Mesothelin Expression|Research blood test for Arm B1 eligibility
214976738|NCT02810418|DRUG|LMB-100|A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.
215085090|NCT04481802|DEVICE|Biafine|Patients will apply the Biafine to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
214366305|NCT02673398|OTHER|Comprehensive Geriatric Assessment|Ancillary studies
214366306|NCT02673398|OTHER|Laboratory Biomarker Analysis|Correlative studies
214366307|NCT02673398|DRUG|Neratinib|Given PO
214366308|NCT02673398|OTHER|Pharmacological Study|Correlative studies
214366309|NCT05181852|DRUG|IP2015, dose 1|Active
214366310|NCT05181852|DRUG|IP2015, dose 2|Active
214366311|NCT05181852|DRUG|Placebo|Placebo
214366312|NCT05181852|DRUG|Pregabalin|Comparator
214366313|NCT04679402|OTHER|Carbon monoxide 200 ppm in air|Low dose carbon monoxide
214366314|NCT03917940|DIETARY_SUPPLEMENT|Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral|Omega 3 fatty acids 1000 mg per day oral
214366315|NCT03917940|DRUG|Glimepiride|glimepiride 2 mg or 3 mg per day oral
214366316|NCT01906684|DRUG|Acthar Gel|Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
214366317|NCT01321554|DRUG|Lenvatinib|Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
214366318|NCT01321554|DRUG|Placebo|Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
214366319|NCT01321554|DRUG|Lenvatinib|"Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg."
214366320|NCT06119984|BEHAVIORAL|Community mobilization|The intervention focused on creating awareness, challenging social norms, and promoting actions against violence. To achieve these, the following activities were undertaken: introductory meetings, selection and training of model couples, structured workshops and small group meetings.
214366321|NCT03033654|OTHER|Sunscreen, Actinica|Two Consecutive Sunscreen Applications
214366322|NCT06013943|DRUG|Envafolimab+Gemox|"All of drugs were used for 6-8 cycles at the combined treatment stage, then Envafolimab and Gemcitabine continued at maintenance treatment stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 1 years.~Combined treatment stage: Envafolimab(150mg, iH, Q1W, Day1)+Gemcitabine(1000mg/m2, iv, Q3W, Day1 and Day8)+Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8);~Caintenance treatment stage: Envafolimab(400mg, iH, Day1, Q3W)+Gemcitabine(1000mg/m2, po, Day1-14, Q3W)."
214366323|NCT02063230|DRUG|Selumetinib 50mg|HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
214366324|NCT02063230|DRUG|Selumetinib 25mg|Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
214366325|NCT01410058|DIETARY_SUPPLEMENT|Moringa oleifera|leaf powder, 1.85g once daily, hard gelatin capsules
214976739|NCT01336725|BEHAVIORAL|Teaching life style changes|Single group: Teaching, group sessions, physical activity
214976740|NCT01336725|OTHER|Active participation|Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
214976741|NCT01336725|OTHER|Teaching|Morbid obesity group attend 40 hours of group sessions
215085091|NCT05873179|OTHER|role-playing for learning the clinical interview|role-playing for learning the clinical interview
214366326|NCT01410058|DRUG|Efavirenz 600mg|Efavirenz 600mg based regimen
214366327|NCT01410058|DRUG|Nevirapine 200Mg Oral Tablet|Nevirapine 200mg based regimen
214366328|NCT00389883|DRUG|Comparison of two anesthetics protocol|Comparison of two anesthetics protocol
214366329|NCT06414486|DIETARY_SUPPLEMENT|Dietary supplement group|One tablet per day for 3 weeks consumed for subjects randomized in the Dietary supplementation group. This will lead to an intake of 200mg per day of Red Panax Ginseng (corresponding to 22.4mg of ginsenosides and 20.2mg of rare ginsenosides).
214366330|NCT06414486|OTHER|Placebo group|One tablet per day consumed for 3 weeks for subjects randomized in the Control group. The product is composed of rice flour (50mg) and brown sugar (150mg).
214366331|NCT00402701|BEHAVIORAL|Walking School Bus Program|Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
214366332|NCT00647101|DRUG|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
214366333|NCT02737800|PROCEDURE|endometrioma aspiration|Transvaginal ultrasound guided aspiration
214366334|NCT02737800|DRUG|GnRh agonist ( Decapeptyl )|3 monthly doses of Decapeptyl 7.5mg intramuscular
214366335|NCT02737800|PROCEDURE|standard long stimulation protocol|Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.
214366336|NCT01439061|DEVICE|Device: easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
214366337|NCT03019146|OTHER|HIIT|
214366338|NCT03019146|OTHER|HOLD|
215085092|NCT00601861|DRUG|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
215085093|NCT02370641|DIETARY_SUPPLEMENT|PomX|1000 mg POMx daily for 4 weeks
215085094|NCT01964599|DIETARY_SUPPLEMENT|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
214366339|NCT03019146|OTHER|HUG|
214366340|NCT05256030|OTHER|Speed-based relearning training|Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
214366341|NCT05256030|OTHER|Neurodevelopmental Therapy|Neurodevelopmental Therapy
214491606|NCT01084863|DRUG|Herceptin|Herceptin: administered every 3 weeks
214366342|NCT01203930|DRUG|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
214366343|NCT01203930|DRUG|Rituximab|Rituximab 375 mg/m\^2 administered intravenously once weekly x 8 weeks
214366344|NCT05307770|DIETARY_SUPPLEMENT|Immediate Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
214366345|NCT05307770|DIETARY_SUPPLEMENT|Extended Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
214366346|NCT05995314|DIETARY_SUPPLEMENT|PLACEBO|3 mg/kg of cellulose (0 mg/kg of caffeine)
214366347|NCT05995314|DIETARY_SUPPLEMENT|3 mg/kg of caffeine|Ingestion of 3 mg/kg of body mass of caffeine
214366348|NCT05995314|DIETARY_SUPPLEMENT|6 mg/kg of caffeine|Ingestion of 6 mg/kg of body mass of caffeine
214366349|NCT01861886|DEVICE|ESS505 (BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
214366350|NCT03966053|DRUG|Trifluoperazine|Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
214366351|NCT04524143|OTHER|cervical mobilization|"Cervical mobilization techniques were applied in the study. Within the scope of application; rotation with traction, lateral gliding, anterior-posterior gliding with traction, bridging and stroking techniques to the paravertebral muscles were used. Mobilization were performed at grade A (mobilization in painless joint range) and grade B (continuous stretching at the end of the joint range). The mobilization were applied during 10 minutes.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
214366352|NCT04524143|OTHER|control|There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
214366353|NCT02124889|BEHAVIORAL|Weekly Internet surveys|Subjects will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
214366354|NCT00005954|DRUG|temozolomide|
214366355|NCT03166943|PROCEDURE|Systolic function by echocardiography|"Echocardiography for evaluation of systolic function:~* by biplane Simpson's method.~* by speckle tracking:"
214366356|NCT03166943|PROCEDURE|Diastolic function by echocardiography|"Echocardiography for evaluation of diastolic function:~* Left atrial Volume~* Mitral Inflow Patterns~  * Pulsed wave Doppler~ * Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.~* Tissue Doppler Annular Early and Late Diastolic Velocities~  * Pulsed wave tissue doppler imaging~ * Primary measurements include the systolic , early diastolic, and late diastolic velocities."
214366357|NCT01756664|OTHER|Sunscreen|
214976742|NCT06238180|DEVICE|VIOSync-SPI|The intervention in this study involves an AI-driven clinical decision-support system, VIOSync Sepsis Prediction Index (SPI), designed for the early prediction of sepsis in patients undergoing abdominal surgery. VIOSync integrates data from PPG-based wearable wireless devices that monitor vital signs, electronic health records, and laboratory tests. The AI model analyzes this multimodal data to proactively identify signs of sepsis providing an early warning score, the SPI, to clinicians. The distinguishing feature of this intervention is its use of real-time data and advanced AI analytics to enhance early sepsis detection, aiming to improve patient outcomes in postoperative care.
214366358|NCT01756664|OTHER|Vaseline|
214366359|NCT02565238|DEVICE|BioMonitor 2|Implantation of BioMonitor 2
214366360|NCT05850039|OTHER|Sampling|Sample collection: a small fragment of atrial wall will be collected
214366361|NCT01869790|OTHER|Different fat types|Saturated, monounsaturated fats
214366362|NCT00823784|PROCEDURE|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
214976743|NCT02224625|DRUG|2% CHG Cloth solution|Investigational CHG
214976744|NCT02224625|DEVICE|Vehicle Cloth|Excipients from CHG cloth only
214976745|NCT02224625|DRUG|Active Comparator|Active comparator
214976746|NCT02224625|OTHER|Saline|Negative control
214976747|NCT02224625|OTHER|SLS|Provides a slight irritation for a positive control
214976748|NCT00230035|PROCEDURE|Leukapheresis|
214366363|NCT00823784|PROCEDURE|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
214366364|NCT00003092|DRUG|paclitaxel|
214366365|NCT06184711|DEVICE|Transcranial Magnetic Stimulation+McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with Transcranial Magnetic Stimulation (TMS) will be applied to the first experimental group.
214366366|NCT06184711|DEVICE|Sham Transcranial Magnetic Stimulation +McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with sham Transcranial Magnetic Stimulation (TMS) will be applied to the sham comparator group.
214491607|NCT01084863|DRUG|Paclitaxel|Paclitaxel: administered every 3 weeks
214491608|NCT02377622|DEVICE|THERANOVA 400 dialyzer prototype AA|
214491609|NCT02377622|DEVICE|THERANOVA 400 dialyzer prototype BB|
214491610|NCT02377622|DEVICE|FX CorDiax 80 Dialyzer|
214491611|NCT02377622|DEVICE|FX CorDiax 800 Dialyzer|
214491612|NCT06811350|PROCEDURE|post-implementation cohort|Patients recieved a structured early mobilization pathway was introduced. The pathway included standardized assessments for patient stability and phased rehabilitation, progressing from passive to active mobilization.
214491613|NCT06812416|DIETARY_SUPPLEMENT|Qualia NAD+|Qualia NAD+
214491614|NCT06812416|DIETARY_SUPPLEMENT|Rice Flour Placebo|Rice Flour Placebo
214976749|NCT00230035|PROCEDURE|Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|
214491615|NCT06813391|OTHER|Patient Reported Outcome (PRO)|after enrollment, patient will answer to several PRO to assess their pain and overall well-being after their stroke
214976750|NCT00230035|PROCEDURE|Autologous CD34+HPC transplantation (HSCT)|
214976751|NCT00230035|PROCEDURE|Plasmapheresis|
214976752|NCT00230035|DRUG|Rabbit anti-thymocyte globulin|
214976753|NCT00230035|DRUG|Methylprednisolone|
214976754|NCT00230035|DRUG|Growth colony stimulating factor (G-CSF)|
215085095|NCT01964599|DIETARY_SUPPLEMENT|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
215085096|NCT01964599|DIETARY_SUPPLEMENT|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
215085097|NCT01964599|DIETARY_SUPPLEMENT|Control|
214366367|NCT06184711|DEVICE|Transcranial Magnetic Stimulation|Only Transcranial Magnetic Stimulation (TMS) will be applied to the second experimental group.
214366368|NCT00375362|DRUG|Nitroderm patch|
214366369|NCT04551599|DRUG|Danicopan|A single dose of danicopan (200 milligrams) will be administered orally.
215085098|NCT02133664|DRUG|lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
214366370|NCT04098406|DRUG|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.
214366371|NCT04098406|DRUG|Placebo|Placebo was liquid with identical color and taste
214366372|NCT01590290|OTHER|financial compensation|financial monetary reimbursement
214491616|NCT06806670|BEHAVIORAL|lifestyle intervention|exercise and dietary counselling
214491617|NCT04969146|BEHAVIORAL|Dyadic Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Dyadic Intervention. The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
214491618|NCT04969146|BEHAVIORAL|Patient Only Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Patient Only Intervention. The patient in the Patient Only Intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
214491619|NCT06891898|DEVICE|iLet Dosing Decision Software|Interoperable alternate glycemic controller
214976755|NCT00230035|DRUG|Corticosteroids|
214976756|NCT00230035|DRUG|Mycophenolate mofetil|
214976757|NCT00230035|DRUG|Azathioprine|
214976758|NCT00230035|DRUG|Intravenous immunoglobulin|
214976759|NCT00230035|DRUG|Methotrexate|
214976760|NCT00230035|DRUG|Rituximab|
214976761|NCT00230035|DRUG|Leflunomide|
214976762|NCT00048152|DRUG|Corticosteroids|As prescribed
215085099|NCT02133664|DRUG|Placebo|placebo lipoic acid and placebo oil
215085100|NCT02833792|DRUG|Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Intravenous administration
214366373|NCT06519994|DRUG|Artesunate vaginal inserts|Subjects will self-administer 200 mg of Artesunate vaginal insert daily for 5 days, on weeks 1, 3, 5.
214366374|NCT06519994|DRUG|Placebo vaginal inserts|Subjects will self-administer a placebo vaginal insert daily for 5 days, on weeks 1, 3, 5.
214366375|NCT04636554|OTHER|Phage Therapy|Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
214976763|NCT00048152|DRUG|Neoral|Low dose (target trough level 50-100ng/mL)
214976764|NCT00048152|DRUG|Neoral|Standard dose (target trough level 150-300ng/mL)
214976765|NCT00048152|DRUG|Zenapax|2mg/kg iv first dose, then 1mg/kg every 2 weeks
214976766|NCT00048152|DRUG|mycophenolate mofetil [CellCept]|1g po bid
214976767|NCT01276158|PROCEDURE|Ultrasound|Ultrasound used to place arterial line
214976768|NCT01276158|PROCEDURE|Doppler|Doppler used to place arterial line
214976769|NCT06286917|OTHER|NIV initiation in patients with ALS|NIV initiation according to standard care
214976770|NCT00697099|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
214976771|NCT00697099|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
215085101|NCT02833792|OTHER|Placebo|Intravenous administration
215085102|NCT03049267|DRUG|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
215085103|NCT03049267|DRUG|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
215085104|NCT02721121|PROCEDURE|circumferential pulmonary vein isolation|
215085105|NCT02721121|PROCEDURE|Linear ablation in addiction to circumferential pulmonary vein isolation|
215085106|NCT05753566|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
214366376|NCT03274635|BEHAVIORAL|Desk-based pedaling device and pedaling incentives provided|Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
214366377|NCT06815497|DRUG|Telmisartan|Telmisartan will be introduced as a 40 mg tablet to be taken orally once daily. In participants not experiencing telmisartan dose limiting toxicity, the dose will be escalated to a maximum of 80 mg
214491620|NCT06893263|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 4 different intraoral scanners (IOS) (Primescan, Dentsply; Element 5D) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file.
214491621|NCT06893263|PROCEDURE|Clamp placement on canine and 2nd molar teeth and rubberdam rubber band insertion|The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the canine and 2nd molar teeth. It was aimed to facilitate the second scanning process by expanding the isolation area to include 3 teeth. A flowable composite was applied by placing Teflon tape on the occlusal surface of the 1st molar to create a difference in its morphology.This stage was repeated in 2 different treatment sessions, blue rubber dam was preferred in one of the appointments and black rubber dam was preferred in the other.
214366378|NCT01132625|DRUG|AUY922|
214366379|NCT02886806|OTHER|BIS XP, Covidien, Ireland|Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
214366380|NCT02886806|OTHER|EV-1000 TM, Edwards Lifesciences, Irvine, California, USA|Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
214366381|NCT02088151|DEVICE|Selective retinal pigment epithelium laser therapy using the R:GEN Laser System|Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
214976772|NCT00697099|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection"
214976773|NCT01988467|OTHER|exposure to second hand smoking|The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
214976774|NCT02766647|BIOLOGICAL|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
214976775|NCT02766647|BIOLOGICAL|US-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
214976776|NCT04125069|PROCEDURE|Coronary Artery Bypass Graft (CABG)|Mitochondrial function will be studied on cardiac tissue collected intraoperatively at the time of placement of the ECC cannulas by the surgeon. Fragments from auricle dissection of the right atrium of the patient will be requalified as sample residues, and will be used immediately by the surgeon to measure mitochondrial respiration (measurement of oxygen consumption by oxygenation and permeability test of the external mitochondrial membrane by the addition of cytochrome C in the oxygen chamber).
214976777|NCT02169440|DRUG|BIA 9-1067|BIA 9-1067 25 mg
214976778|NCT02169440|DRUG|Warfarin|Warfarin 25 mg
214976779|NCT04702360|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
214976780|NCT04702360|DRUG|IVA|IVA monotablet for oral administration.
214976781|NCT04415801|DIAGNOSTIC_TEST|Repeated removal and re-placement of healing and prosthetic abutments|Repeated removal and re-placement of healing and prosthetic abutments
214976782|NCT00327483|BEHAVIORAL|Internet based education software|
214976783|NCT01299558|DRUG|fluticasone furoate//GW642444|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
214976784|NCT01299558|DRUG|fluticasone furoate|Single IV dose of FF (250mcg)
214976785|NCT01299558|DRUG|GW642444|Single IV dose of GW642444 (55mcg)
214976786|NCT03894995|OTHER|Installation of ventilation|The intervention is installation of a ventilating structure, in this case a window in the house roof.
214976787|NCT02303665|OTHER|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
214976788|NCT02303665|OTHER|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
214976789|NCT05252403|GENETIC|PTG-CARCIK-CD19|PTG-CARCIK-CD19 cells is a gene therapy medicinal product (GTMP) composed of genetically modified allogeneic T lymphocytes formulated as cell suspension in normal saline solution and freezing media
214976790|NCT01573000|BIOLOGICAL|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
214976791|NCT03353792|DEVICE|CL/AP system|CL/AP system enabled insulin pump/CGM combination
214976792|NCT03353792|DEVICE|usual diabetic care|usual diabetic care (insulin pump therapy) along with CGM recording
214976793|NCT02991391|OTHER|None, use of a questionnaire|Telephone health survey using 2015 Behavioral Risk Factor Surveillance Survey in Texas, Florida, South Carolina, and Kentucky that includes questions regarding tobacco exposure and respiratory symptoms
214976794|NCT02598453|DRUG|Ibandronate|Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
214976795|NCT06416631|PROCEDURE|artificial intelligence based screw planning|artificial intelligence technology helps to plan screws in robot assisted spinal surgery
214976796|NCT06416631|PROCEDURE|manually screw planning|the screw trajcetories are manually planned
214976797|NCT02814071|OTHER|Early enteral feeding|Early enteral feeding as per description
215085107|NCT05753566|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
214491622|NCT06893263|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 2 different intraoral scanners (IOS) (Primescan, Dentsply; Element 5D) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
214491623|NCT06893263|DEVICE|Taking images from the right lower jaw with an intraoral scanner|scanned with 2 different intraoral scanners (IOS) (Primescan, Dentsply; Element 5D) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
214491624|NCT06762288|DEVICE|Ultrasound|Sedation and local anesthesia to the surgical field will be applied as standard procedure and unilateral USG-guided TAP block will be performed to the patients who will undergo TAVİ.
214976798|NCT06221709|PROCEDURE|Conventional Radiofrequency (CRF group)|Radiofrequency will be performed with a 22-gauge CRF cannula, 10/15 cm long, 10mm curved active tip, at 90º for 90 seconds, introduced in the anteroposterior and lateromedial directions, to reach the teardrop landmark. Denervation of the articular branches of the Obturator Nerve will be performed in 2 cycles, starting lateral to the lateral edge of the obturator foramen, followed by a point approximately 1cm lateral to the first point. Next, the cannula will be repositioned in a more cranial location, parallel to the superolateral edge of the acetabular dome, to reach the sensory branches of the Femoral Nerve, performing 3 cycles at the 01, 12, and 11 o'clock positions. All lesions will be preceded by motor stimulation at 2,5V and cycles will be followed by the infusion of 2ml of 1% ropivacaine. After concluding the procedure, hip intraarticular infiltration will be performed as described for the control group.
214679810|NCT04463329|PROCEDURE|conventional two-operator versus single operator using Jedi grip axillary brachial plexus blockage|on goup C, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic. On Group J single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm.
214679811|NCT05179031|DIETARY_SUPPLEMENT|First Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
214679812|NCT05179031|DIETARY_SUPPLEMENT|Second Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
214976799|NCT06221709|PROCEDURE|Intraarticular Infiltration ( Control group)|For the control group (IA), an epidural anesthesia needle (22G spinal needle) will be used, positioned anteroposteriorly towards the central portion of the femoral neck, which will be introduced until transfixion of the anterior hip capsule through tactile sensitivity. After checking the correct positioning with the use of fluoroscopy and infusion of 3 ml of 50% diluted iodinated contrast, an infusion of 4 ml of 1% Ropivacaine and 80mg of methylprednisolone 40mg/ml will be done.
214976800|NCT04758455|DIAGNOSTIC_TEST|P53, Ki67 and Cyclin A IHC.|P53, Ki67 and Cyclin A immunohistochemical staining of formalin-fixed paraffin-embedded specimens of Wilms' tumour.
214976801|NCT00372138|PROCEDURE|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
214976802|NCT01364155|DRUG|LIM-0705|
214976803|NCT01364155|DRUG|Placebo capsules|
214976804|NCT02510937|DRUG|CC-90001|
214976805|NCT04072874|DRUG|Experimental topical (Curaleish Topical)|Curaleish is a formulation in lotion and cream. Curaleish lotion and Curaleish cream will be applied topically by each participant in all lesion until day 28 or 42, depending on the regimen to be evaluated. Study staff will be closely observing the safety assessment. The application until Day 28 or 42 will continue, even if the lesion has shown 100% re-epithelization before day 28 or day 42.
214976806|NCT04212429|DRUG|Levofloxacin Ophthalmic Product|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
214976807|NCT04212429|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
214976808|NCT00452374|DRUG|Cytarabine|1 g/m\^2 given IV for two days (Days 2 and 3).
214976809|NCT00452374|DRUG|Fludarabine|30 mg/m\^2 given IV for two days (Days 2 and 3).
214976810|NCT00452374|DRUG|Oxaliplatin|Starting dose of 17.5 mg/m\^2 IV for 4 days (Days 1 through 4).
214976811|NCT00452374|DRUG|Rituximab|375 mg/m\^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
214976812|NCT02144766|DRUG|ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
215085108|NCT05753566|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
215085109|NCT05246826|OTHER|Clinical Pilates Exercises|Pilates exercises; warm-up and cool-down exercises will be performed for 5 repetitions, while other exercises will be performed by the same physiotherapist as 10 repetitions depending on the patient's pain and fatigue. The exercises will be advanced at the end of the 3rd week.
214976813|NCT02144766|DRUG|saline|caudal block with 1 ml/kg of saline
214976814|NCT04744818|DIETARY_SUPPLEMENT|Iron syrup|Daily supplementation with iron
214976815|NCT04744818|DIETARY_SUPPLEMENT|Multivitamin syrup|Daily supplementation with multivitamins
214976816|NCT02047578|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
214976817|NCT02351934|DRUG|Furosemide|
214366382|NCT05194306|DRUG|Perla® Cold Preservation solution|Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
214366383|NCT05001880|BIOLOGICAL|Atezolizumab|Given IV
214491625|NCT06762288|PROCEDURE|Local anesthesia and sedation|Sedation and local anesthesia to the surgical field will be applied to the patients who will undergo TAVİ.
214491626|NCT06761924|PROCEDURE|Ultrasound-Guided Thoracic Paravertebral nerve block|The patients will receive ultrasound-guided TPVB with 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone (10 mL volume)
214366384|NCT05001880|BIOLOGICAL|Bevacizumab|Given IV
214366385|NCT05001880|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
214366386|NCT05001880|DRUG|Carboplatin|Given IV
214366387|NCT05001880|PROCEDURE|Computed Tomography|Undergo CT scan
214366388|NCT05001880|PROCEDURE|Cytoreductive Surgery|Undergo surgery
214976818|NCT02351934|DRUG|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
214976819|NCT02351934|DRUG|Gabapentin|Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
214976820|NCT03320356|OTHER|the French version of the Oxford Shoulder Score|
214976821|NCT06325163|DIAGNOSTIC_TEST|CBCT|Mandibular molar indicated for retreatment will be scanned using limited field of view CBCT to examine the number of canals
214976822|NCT06325163|DIAGNOSTIC_TEST|clinical examination under dental operating microscope|the number of canals will be examined by an a randomly assigned operator following gutta percha removal under dental operating microscope
214976823|NCT06325163|DIAGNOSTIC_TEST|canal detection AI software (diagnocat)|software used to analyze CBCT images and report the number of canals
214976824|NCT01115452|DRUG|5% Potassium nitrate|5% potassium nitrate solution
214976825|NCT01115452|DRUG|2.5% Potassium nitrate|2.5% potassium nitrate solution
214976826|NCT01115452|OTHER|Sterile water|Sterile water
214976827|NCT06290986|PROCEDURE|Pyrocardan® implant|Biconcave-shaped CMC-1 interposition implant
214976828|NCT06290986|PROCEDURE|Ligament reconstruction and tendon interposition (LRTI)|Weilby slightly modified as described by Burton and Pellegrini
214976829|NCT05310877|BEHAVIORAL|Values-Affirmation|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. Following the intervention session, participants will receive electronic pill box(es) that are labeled with the participants' most important core value(s) and will be asked to use these pill box(es) to take their HF medications for 4 weeks.
214976830|NCT05885217|OTHER|measure serum MicroRNA in acne vulgaris|Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)
214976831|NCT02659501|DRUG|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
214976832|NCT02659501|DRUG|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
214976833|NCT02659501|DRUG|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
214976834|NCT02659501|DRUG|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
214976835|NCT02659501|DRUG|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
214976836|NCT00937963|DIETARY_SUPPLEMENT|Palm DAG Oil|Use of Palm DAG Oil to replace palm oil traditionally used in foods
214366389|NCT05001880|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
214366390|NCT05001880|DRUG|Pemetrexed|Given IV
214366391|NCT05001880|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214366392|NCT05782543|PROCEDURE|Normothermic machine perfusion|To determine whether a 4-6 hour period of normothermic machine perfusion, following standard hypothermic machine perfusion, results in better graft function after transplantation, compared to hypothermic machine perfusion preservation alone of kidneys recovered from deceased donors aged 50 years or older
214366393|NCT00150579|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate|
214366394|NCT05284825|RADIATION|12 Gy in 6 daily fractions|12 Gy in 6 daily fractions
214491627|NCT06761924|PROCEDURE|Ultrasound-Guided Thoracic Paravertebral nerve block|ultrasound-guided TPVB with 10 mL of saline without knowing which treatment they are receiving, maintaining blinding throughout the study.
214491628|NCT06761066|DIETARY_SUPPLEMENT|NVP-NK4146|BID for 36 weeks orally
214491629|NCT06761066|DIETARY_SUPPLEMENT|NVP-NK4146 Placebo|BID for 36 weeks orally
214679813|NCT05179031|DIETARY_SUPPLEMENT|Third Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
214679814|NCT05179031|DIETARY_SUPPLEMENT|High protein tube feed|Nutritional product containing 25 g of available carbohydrates
214491630|NCT06770101|BEHAVIORAL|Behavioral: Enhanced Friendship Bench + Safety Planning|The protocol will include six sessions, starting with the development of the SP during the first session. Each of the following sessions will include SIBs and suicide risk assessments, SP check-ins and revisions, as well as FB problem-solving to address SIBs and suicide risk. SP+FB will be delivered by selection of young counselors (mixed genders, aged 20-35) who are motivated to work with young people. Counseling sessions will take place in a discrete location within the HIV clinic and be available on weekends. Each structured session lasts 30-45 minutes and conducted in the participant's local language (Chichewa). After 4 sessions of individual therapy, the counselor can refer participants not improving or with suicidal ideation to a supervisor trained in mental health to reassess and manage the case. Case management may include additional counseling or pharmacotherapy, at the discretion of the managing clinician. Participants may also receive text message support and peer-support.
214366395|NCT03705195|DRUG|Gliclazide|Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 \& 5.
214491631|NCT06770101|BEHAVIORAL|Augmented usual care|Care for suicidality in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic's psychiatric nurse, or, for acute cases or crises, referral to the psychiatric units at tertiary care hospitals (Bwaila Hospital in Lilongwe District). Nurses and clinicians at the study sites have been specifically trained to use the Tool for Assessment of Suicide Risk for Adolescents (TASR-A) to assess ALWH considered at elevated risk for suicide. For this study, usual care will be augmented by a trained study nurse who will provide mental health evaluation, brief supportive counseling, information, education and support on SIBs, and (if indicated) facilitation of referral to the clinic's psychiatric nurse or to Bwaila Hospital.
214491632|NCT06773884|OTHER|"Observational Analysis of Primary Hip Fracture Surgery Outcomes"|This study examines outcomes following standard primary hip fracture surgery by analyzing retrospective data from national health registries. The focus is on identifying perioperative and patient-related risk factors that influence outcomes such as reoperation rates, mortality, and secondary fractures within one year of surgery. No experimental or new intervention is introduced in this study.
214491633|NCT06774560|OTHER|CAD/Cam milled onlays|"The digital workflow in dentistry has proven in the past decades to be a time-efficient, multifunctional, effortless, and accessible approach. The inherited shortages milling machines represented by the incapability to produce accurate complex hollow structures may give preference to modern 3D ceramic printing.~Computer-aided-design/computer-aided-manufacturing (CAD/CAM) in dentistry is a digital subtractive approach for manufacturing indirect restorations. Nevertheless, waste materials and milling burs wearing are considered as key disadvantages of CAD/CAM technology, and are the main drive to improve 3D printing technology (additive manufacturing) as the latter has shown considerable efficiency in minimising wasted materials."
214491634|NCT06774560|OTHER|3D printed onlays|"3D printing technologies are developing more intensively in dentistry as this technology has the capacity to produce shapes or models with high accuracy and in a short time. This method of fabrication takes less time and money and saves on materials compared to CAD/CAM.~Although it seems that digital manufacturing technology has made great changes in the restorative dentistry field, this technology is still not fully in use. This is possibly because of the lack of studies and research on this technology, particularly in terms of clinical performance and patient-centred outcomes. 3D printing technologies are novel technologies with a lack of research; therefore, the processing of 3D printing materials is still controversial."
214491635|NCT06773156|DRUG|Adebrelimab + Apatinib|"Adebrelimab: Administered by intravenous infusion at a fixed dose of 1200 mg. The infusion should be completed within 30-60 minutes, with a maximum duration of 2 hours. The first dose is given on Day 1, with subsequent doses repeated every 3 weeks. Dose adjustments (either up or down) are not allowed during the study. A maximum delay of 9 weeks for treatment is allowed, or treatment may be terminated.~Apatinib: 250 mg, taken orally after meals, once daily, continuously. The investigator may temporarily pause the dose or adjust the administration schedule based on symptomatic treatment, such as changing to an every-other-day (qod) schedule or a 5-day-on, 2-day-off regimen. Once toxicity resolves, treatment may resume at the original dose.~The combined treatment of Adebrelimab + Apatinib for consolidation therapy should not exceed 24 months in total."
214679815|NCT05179031|DIETARY_SUPPLEMENT|High-protein tube feed with additional amino acid|Nutritional product containing 25 g of available carbohydrates
214976837|NCT05282147|DEVICE|Neocam|Screening within 72 hours of birth will be completed using the digital imaging device Neocam which painlessly images the eye's reflection firstly to infrared light and then to a brief green light flash.
214366396|NCT02073916|DRUG|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
214366397|NCT02073916|DRUG|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
214366398|NCT02073916|DRUG|Abraxane|albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor
214366399|NCT01580072|OTHER|self-monitoring for patients with severe COPD|Intervention Group entering vital parameters via Web Portal or automatic call center.
214366400|NCT01580072|OTHER|nurse-monitoring for patients with severe COPD|Nurses are entering vital parameters of the patient with mobile devices.
214366401|NCT00800969|PROCEDURE|FDG-PET-CT|Radiologic standard procedure
214366402|NCT05698134|DIAGNOSTIC_TEST|ROTEM|ROTEM is a commercially available whole blood Viscoelastic-Haemostatic Assay(VHA) point-of-care, global and dynamic haemostasis assessment tests that measures the viscoelastic changes occurring during the haemostatic process. They provide real-time, comprehensive reflection of the interaction between plasma, blood cells and platelets. It display hypo or hyper-coagulable features in patients with cirrhosis. It is widely used prior to cardiac, obstetric, trauma and liver transplant surgery to assess and correct for coagulation defects.
214366403|NCT05698134|OTHER|Standard of care|Standard of care
214366404|NCT06511336|DRUG|Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt|children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
214366405|NCT01783418|BEHAVIORAL|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
214491636|NCT06773416|COMBINATION_PRODUCT|CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health|Participants in Group 1 will receive CPAP therapy immediately upon enrollment alongside web-based sleep education through the Brain Health Pro (BHP) platform. The CPAP intervention includes a study-provided auto-titrating device, in-person mask fitting, and ongoing support from a study sleep technologist. Adherence will be monitored via remote data uploads. The BHP platform is a 45-week web-based formal educational program program designed to increase dementia literacy, foster engagement, and convey best available evidence for lifestyle changes that can mitigate dementia risk. This combined approach ensures simultaneous initiation of CPAP and educational reinforcement to optimize adherence and cognitive outcomes.
214491637|NCT06773416|COMBINATION_PRODUCT|Delayed CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health|Participants in Group 2 will begin with 4 months of BHP web-based sleep education before adding CPAP therapy for the remaining 4 months. CPAP setup and support are identical to the Early CPAP group. Participants in Group 2 will experience procedure similar to current clinical practices.
214491638|NCT06806839|PROCEDURE|dual plating|surgical fixation of the distal femur using two plates to enhance stability and fracture healing.
214491639|NCT06806839|PROCEDURE|single plating|surgical fixation of the distal femur using a single plate according to standard fixation protocols.
214491640|NCT05720507|BEHAVIORAL|Cafe Move|Participants will be offered the opportunity to choose from a number of physical function assessments and subsequently provided personalized reports of performance results.
214491641|NCT06733766|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radiofrequency ablation, laser ablation
214491642|NCT05091632|PROCEDURE|Electroencephalography|Undergo EEG
214491643|NCT05091632|OTHER|Questionnaire Administration|Complete questionnaires
214491644|NCT05500417|DRUG|ALFQ|ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
214491645|NCT05500417|BIOLOGICAL|CJCV2|Vaccine comprised of C. jejuni capsule conjugated to Cross-Reactive Material 197 (CRM197), a non-toxic mutant protein of diphtheria toxin. CJCV2 will be reconstituted in 1 mL of sterile water for injection (SWI). The resuspended CJCV2 product will be diluted with sterile 0.9% Sodium Chloride for Injection. 3 dosages for administration: 1 microgram, 3 micrograms, and 10 micrograms.
214491646|NCT06247124|BEHAVIORAL|multi-channel communication campaign to promote HPV vaccination|High school students will develop, implement, and evaluate a multi-channel communication campaign to promote HPV vaccination.
214491647|NCT06846047|DEVICE|electrical vestibular stimulation (EVS)|EVS involves electrically activating the vestibular nerves by passing small electrical currents through electrodes placed on the mastoid processes (behind the ears) via battery powered, constant current isolated stimulators.
214976838|NCT04715490|OTHER|The Multimedia Symptom Management Program Intervention|"The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support. The first part of the program will be conducted in the cardiology outpatient department. Participants will be instructed to read a HF handbook.~The second part of the program, structured telephone support, allowed the nurses to maintain contact with the participants in order to follow their progress. The participants will be scheduled to receive eight telephone coaching calls over a 3-month period."
214976839|NCT04715490|OTHER|Control group|The control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
214976840|NCT05022498|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
214976841|NCT02625701|PROCEDURE|Goal-directed therapy|Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
214976842|NCT02625701|PROCEDURE|Restrictive fluid therapy|Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
214976843|NCT04246463|DEVICE|Thoracic|Implant of a Relay stent graft system
214491648|NCT06846047|DEVICE|Sham Comparator|No current is applied during EVS treatment
214491649|NCT06796270|RADIATION|Hypofractionated radiotherapy|The patients with nasopharyngeal carcinoma were given the dose of large segmentation radiotherapy, 2.64Gy/ time, 5 times/week, a total of 25 times, a total of 66Gy/5 weeks.
214491650|NCT06741748|OTHER|Direct Warming Method|This intervention involves thawing vitrified blastocysts using a simplified, one-step direct warming method. The blastocyst is placed in a pre-warmed embryo culture medium for approximately one minute, then transferred directly into the embryo culture medium within a time-lapse system until ready for uterine transfer. The total thawing process takes approximately three minutes, reducing the duration and complexity of the procedure compared to conventional methods.
214976844|NCT04246463|DEVICE|Abdominal|Implant with an Anaconda or Treo Stent graft system
214976845|NCT04246463|DEVICE|Custom Device|Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device
214976846|NCT04246463|DEVICE|Illiac Artery|Implant with an Anaconda Iliac leg only
214976847|NCT03485586|DEVICE|Traditional ultrasound biometrics|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
214976848|NCT03485586|DEVICE|Lenstar|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
214976849|NCT01225549|DRUG|AZD5423|Suspension for nebulisation once daily 7 days
214976850|NCT01225549|DRUG|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
214976851|NCT01225549|DRUG|Placebo|Solution for nebulisation once daily 7 days
214366406|NCT06228521|OTHER|Liquid nitrogen sprayed|Liquid nitrogen sprayed on each wart using a standardised technique. Freeze-thaw cycle repeated up to 3 times per wart per session. 4 sessions at weekly intervals.
214491651|NCT06741748|OTHER|Conventional Multi-step Thawing Method|This intervention involves thawing vitrified blastocysts using a standard, multi-step process. The procedure includes sequential exposure of the blastocyst to different thawing solutions containing varying concentrations of cryoprotectants, followed by its transfer into an embryo culture medium in a time-lapse system. The overall process takes approximately 10-30 minutes.
214491652|NCT06817876|DEVICE|Care Buddy|Care Buddy mobile intervention will be a one-stop solution for caregivers of dementia patients and help them in their care-giving journey by providing them solutions to manage behavioural problems, physical conditions of their loved one. The app will be multi-component and will provide tools for the caregiver to manage their stress and burden. It will provide information on dementia, list of service providers, information on grief, financial support. This app will provide a platform for all enrolled caregivers to chat with each other and provide social support.
214491653|NCT06741722|DRUG|Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF|"The specific administration times and dosages for the DCMG chemotherapy regimen are as follows:~M: Mitoxantrone Hydrochloride Liposome Injection: 15 mg/m², IV, on Day 1, every 4 weeks (q4w); D: Decitabine: 20 mg/m², IV, Days 1-5, q4w; (or Azacitidine: 75 mg/m², IV, Days 1-7, q4w); C: Cytarabine: 100 mg, IV, every 12 hours on Days 1-5, q4w; For patients with hypoplastic bone marrow, the dose of cytarabine injection is 10 mg, every 12 hours, q4w; G: G-CSF: 5 μg/kg, subcutaneous injection, from Day 0 until the white blood cell count exceeds 10.0×10\^9/L, at which point chemotherapy is stopped; or Pegylated Recombinant Human Granulocyte Stimulating Factor Injection: 100 μg/kg, subcutaneous injection, on Day 0.~One cycle lasts for 4 weeks, with a planned administration of 1 or 2 cycles."
214491654|NCT06756152|DRUG|Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150|The most significant adverse events limiting the use of HSCT from an unrelated donor are graft-versus-host disease (GVHD) and prolonged immunodeficiency associated with the development of severe infectious complications. The use of post-transplant cyclophosphamide for the prevention of GVHD during allogeneic HSCT from unrelated and haploidentical donors has reduced the incidence of acute clinically significant GVHD in children to 25%, chronic GVHD to 12-30%, but the issue of GVHD control still remains extremely relevant. Emerging data on the use of abatacept, a selective blocker of the costimulatory signal from an antigen-presenting cell, in the prevention of intestinal GVHD and data on the effectiveness of Janus-kinase type 1/2 inhibitors (JAK-1/2) in the treatment and prevention of acute GVHD allow us to justify the use of these drugs in combination with post-transplant cyclophosphamide as a promising pharmacological platform for the prevention of GVHD.
214491655|NCT06737276|OTHER|Interactive fiction activities|The case studies were prepared using interactive fiction through Twine. Each case simulated a nursing consultation with a patient requiring dietary advice, and the patient's evolution depended on the students' choices. All cases created had similar structures, durations, and difficulties to avoid complexity-related bias. For each circumstance, three possible dietary advice options were offered to the patient: one option that would be ideal, one suitable option, and one unsuitable option.
214679816|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients|Nutritional product containing 25 g of available carbohydrates
214679817|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients (new formula)|Nutritional product containing 25 g of available carbohydrates
214679818|NCT05179031|DIETARY_SUPPLEMENT|ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
214679819|NCT05179031|DIETARY_SUPPLEMENT|Plantbased ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
214976852|NCT01225549|DRUG|Placebo|Solution for nebulisation once daily 7 days
214976853|NCT00578903|DRUG|Cytoxan|Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
214976854|NCT00578903|DRUG|Campath|Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
214976855|NCT00578903|RADIATION|Total Body Irradiation (TBI)|TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
214976856|NCT00578903|DRUG|FK-506|FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
214976857|NCT00578903|DRUG|Methotrexate|Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
214976858|NCT00578903|PROCEDURE|Stem cell infusion|Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10\^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10\^6 CD 34+ cells/kg should be collected, with a target of 10 X 10\^6/kg.
215085110|NCT05246826|OTHER|Clinical Pilates Exercises and Conventional Treatment|In addition to pilates exercises, a conventional treatment program will be applied. As part of the conventional treatment program, 20 minutes of Hotpack to the cervical area, 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation (TENS) to the painful area (80 Hertz (Hz), 100 microseconds (μs), until tingling is felt, asymmetrical biphasic rectangular waveform), 8 minutes to the cervical area Ultrasound (US) (4 minutes + 4 minutes, 1.5 watts/cm2, 1 MHz, continuous) will be applied.
214366407|NCT06228521|OTHER|980nm diode laser applied|980nm diode laser applied to each wart for 5 seconds at 2W power and 1mm spot size. 4 sessions at weekly intervals.
214366408|NCT00604838|DEVICE|AL-SENSE Diagnostic Absorbent Panty liner|worn for 12 hours
214366409|NCT00604838|DEVICE|AL-SENSE Diagnostic Absorbent Panty liner|Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
214976859|NCT00891813|DRUG|Zemplar (paricalcitol)|Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
214976860|NCT02581592|DRUG|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
214976861|NCT03377465|DIAGNOSTIC_TEST|ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin|ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
214366410|NCT06267456|DIAGNOSTIC_TEST|Upper Limb Rotation Test|The athlete is positioned with the shoulder, elbow lateral epicondyle, greater trochanter, and ankle lateral malleolus in contact with the wall. In the push-up position, the elbows are started at shoulder height with a 90° bend, and the feet are placed in a shoulder-width apart position. Athletes are instructed to perform a rotation of the shoulder and trunk by touching a vertically placed band on the wall for 15 seconds in the position of 90° abduction and 90° external rotation of the shoulder. The tested side is the upper extremity where the closed kinetic chain position is maintained.
214366411|NCT06267456|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Athletes were placed in a push-up position with a distance of 91.44 centimeters (cm) (3 feet) between their hands for the test position. Subsequently, they were instructed to touch one hand to the other as quickly as possible. The total number of touches within a 15-second period was recorded. Modified push-up position was used for women, and regular push-up position for men during this time. Prior to the test, a familiarization trial consisting of 5 repetitions was performed. The test was then repeated 3 times, and the average of these repetitions was recorded as the score. Individuals were given a 45-second rest period between repetitions. The normalized score, representing the touch count per individual's height, was calculated. The power score was obtained by multiplying the touch count by 68% of the individual's body weight in kilograms.
214366412|NCT06267456|DIAGNOSTIC_TEST|Upper Quarter Y Balance Test|The Upper Extremity Y Balance Test was created using three rulers placed on the ground in the medial, inferolateral, and superolateral directions. The rulers in the superolateral and inferolateral directions were positioned at a 90° angle to each other, while the ruler in the medial direction was placed at a 135° angle with respect to these two directions. In this test, both arms started in a push-up position with shoulder-width apart. The athlete was then instructed to touch, using their non-dominant hand, the maximum reachable point in the medial, inferolateral, and superolateral directions.
214366413|NCT00687570|DIETARY_SUPPLEMENT|Fresubin Energy Drink|Fresubin energy drink 30 kcal/kg\*dag-1, seven days before surgery
214366414|NCT00687570|DRUG|Laxabon®|Laxabon® 4 litres starting the day before surgery
214366415|NCT04791761|DRUG|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
214366416|NCT04791761|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
214366417|NCT04791761|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
214366418|NCT04791761|OTHER|Opioid disposal pouch|Half of the opioid group will be randomized assigned to an opioid disposal pouch arm. This pouch is a drug deactivation system that can be disposed in the trash in a household.
214366419|NCT04791761|OTHER|Opioid disposal education|An opioid disposal education document will be provided to all families in the opioid group. This education document has information on unused or expired prescription medication disposal and specific information about permanent collection sites within our health system, drug take-back locations, drug take back day, and disposing at home.
214366420|NCT01886911|OTHER|Attention Training Intervention Game|
214366421|NCT01886911|OTHER|Prosocial Training Intervention Game|
214366422|NCT01886911|OTHER|Control for Attention Intervention|
214366423|NCT01886911|OTHER|Control for Prosocial Intervention|
214366424|NCT03548207|BIOLOGICAL|JNJ-68284528|JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
214366425|NCT01756352|DRUG|18F-FET|Radiotracer, surrogate marker for protein synthesis
214366426|NCT01613638|OTHER|meconium samples + maternal self-questionnaire|meconium samples + maternal self-questionnaire
214366427|NCT06093906|BEHAVIORAL|Positive Processes and Transition to Health|See arm/group description for details regarding this intervention
214366428|NCT06093906|BEHAVIORAL|Progressive Muscle Relaxation|See arm/group description for details regarding this intervention
214366429|NCT01728519|DRUG|AllerT SC|AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
214366430|NCT01728519|DRUG|AllerT ID|AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
214366431|NCT01728519|DRUG|Placebo SC|Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
214366432|NCT01728519|DRUG|Placebo ID|Placebo intra-dermal injections on days 1, 7, 14, 21 and 56
214679820|NCT02370849|DRUG|nimotuzumab|nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
214976862|NCT02340455|DRUG|Pregabalin_male|Pregabalin 150mg bid 1day Men
214976863|NCT02340455|DRUG|Pregabalin_female|Pregabalin 150mg bid 1day Women
214976864|NCT02340455|DRUG|Placebo_Men|Placebo durg
214976865|NCT02340455|DRUG|Placebo_Women|Placebo\_Women
214976866|NCT00380900|DRUG|AGG-523|
214366433|NCT05270681|OTHER|Movement to Music|Participants will be educated on how to access prerecorded Move to Improve classes conducted by a professional dance instructor which will be accessible by computer or tablet 24/7 via a hyperlink. Classes last 45 minutes, and participants will be instructed to participate in the activity at least twice weekly, for 12 weeks. Each class uses movement to music combinations across different dance genres that build in intensity and sequence complexity, accompanied by music with faster beats, to encourage participants to achieve a moderate-vigorous level of physical and cognitive activity. Care partners will be present during each class to ensure safety and will also participate in the Move to Improve exercise program. The care partner and participant will be instructed to stand at a counter or behind a chair for safety during exercise.
214366434|NCT00415610|DRUG|nicardipine|"Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~* Started at 5mg/h~* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued."
214366435|NCT01184365|BEHAVIORAL|Energy Management Program|The program content over the four sessions is structured as follows: Session 1 is an introduction to the group, important concepts, and upcoming session topics; Session 2 further elaborates on the concepts introduced in session 1 and encourages self-reflection; Session 3 is the peer to peer contact by phone or in person to assist with problems and share tips that really worked; and Session 4 concludes the program and serves to consolidate information learned.
214366436|NCT01184365|BEHAVIORAL|Energy Management Program|The goal of the EnMP-2 is to control for group effects
214366437|NCT00310232|DRUG|Epoetin Alfa|
214366438|NCT01256853|DRUG|MVA Vaccine|The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.
214366439|NCT05473754|BEHAVIORAL|SUPER digital platform|SUPER digital platform was implemented to ensure synergy between ASD families, health services, and schools through different tools to share rehabilitative and educational objectives and strategies. It was designed following the ASD International Guidelines and the recommendations of the ICF-CY and was organized into two areas: General (to promote scientific knowledge on ASD) and Personalized (restricted virtual space for groups of users following an individual with ASD).
214366440|NCT02555540|BIOLOGICAL|Boostrix|Randomised assignment
214366441|NCT02555540|BIOLOGICAL|Placebo (Saline)|Randomised assignment
214366442|NCT00455975|DRUG|Bevacizumab|Bevacizumab
214366443|NCT00999466|DRUG|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
214366444|NCT00999466|DRUG|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
214366445|NCT05700500|PROCEDURE|shockwave therapy, barbotage and infiltration|ultrasound guided interventions
214366446|NCT04350710|OTHER|PEEP trial|Measurement of Recruitment-to-Inflation Ratio
214679821|NCT02370849|DRUG|cisplatin|cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
214679822|NCT02370849|DRUG|S-1|S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
214976867|NCT06375382|OTHER|acupuncture|We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
214976868|NCT06375382|OTHER|Sham acupuncture|Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
214976869|NCT05278897|DEVICE|Soft Tissue Adapted Biocompatible Hyaluronic Acid|1% sodium hyaluronate
214976870|NCT03371914|BEHAVIORAL|Management training and data feedback|The management training will consist of a variety of management topics, such as financial, workplace and staff management. The training will include a number of tools that the managers will be expected to bring back with them and use regularly at their site. There will be monthly refresher trainings for the managers via an online platform, where participants will interact about the topics covered in the training and others relevant to their work as managers. Participants will also receive monthly visualizations that compare the data that they enter via tablet monthly to both (1) their baseline data, and (2) to other sites' data. Outcomes that will be measured and reported back to sites include cost per client tested, number of condoms distributed, and number of FSW reached by educational interventions.
214976871|NCT02530775|PROCEDURE|instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
214976872|NCT02530775|PROCEDURE|non-instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
214976873|NCT00074893|DEVICE|piezoelectric wrist brace|
214976874|NCT03804658|DEVICE|Continue glucose monitor system|The cardiovascular risks and data from continue glucose monitor system
214976875|NCT00192114|DRUG|Enzastaurin HCl|1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.
214976876|NCT06270641|OTHER|ExerciseRx intervention|ExerciseRx is a cloud-based, HIPPA-compliant free software platform created for healthcare providers to prescribe and monitor physical activity as part of routine care. ExerciseRx translates clinically relevant activity data collected by the patient's existing personal smart devices (Android or iOS phone) into actionable metrics on a dashboard within the Epic electronic health record. Providers then use the platform to prescribe physical activity tailored to patients' ability levels and preferences. The platform incorporates behavior change strategies, including motivational feedback and nudges. It also facilitates a feedback loop with the provider, fostering caring patient-provider connections around activity promotion and behavior change. ExerciseRx leverages patients' personal smartphone capabilities to track, quantify, and tailor personalized physical activity solutions, which makes it more readily scalable as a solution across diverse patient populations.
214976877|NCT06523127|OTHER|Recording data from the ICU stay and the post-ICU follow-up.|Record analysis of the post-ICU follow-up with the Interpretative Phenomenological Analysis
214976878|NCT05475509|OTHER|Virtually reality|Before chemotherapy, saliva samples will be taken from the control group, Personal Information Form, State Anxiety Scale and Visual Analogue Scale (VAS) pre-test questionnaires will be applied to the patients who accepted to participate in the study, vital signs measurements will be made and post-test questionnaires will be applied at the 30th minute of chemotherapy, vital signs measurements will be made, and A saliva sample will be taken. In the experimental group, a saliva sample will be taken before chemotherapy.
214976879|NCT00984932|DRUG|Rosuvastatin|40 mg of rosuvastatin daily
214366447|NCT05531279|DRUG|PEG-rhG-CSF|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
214366448|NCT00412100|DRUG|Oxycodone naloxone prolonged release tablets (OXN)|
214491656|NCT06737276|OTHER|Role-play simulation|Role-play activity of the nursing consultation on dietary advice according to Nemec et al. (2021) recommendations. Ten case studies of a nursing consultation on dietary advice involving a nurse and a patient were designed with the consensus of a group of nursing professionals with expertise in food and nutrition, health literacy, and communication. Each student was assigned a role and provided with the necessary information to play their character or understand their patient's context. The information provided was different according to the role assigned. They had to perform a simulation of eight minutes, similar to the time available in the student's primary care consultations in the referral health system. Thus, the patient and the family member had to explain the situation or health problem, the professional would analyse it, and together, they would try to reach a therapeutic agreement. After the consultation, a debriefing was carried out.
214491657|NCT06860737|DEVICE|Novel plano spectacle lenses|Use of novel plano spectacle lenses for at least 8 hours a day with objective wearing time measured by smart frame and objective outdoor time measured by smart bracelet.
214491658|NCT06832865|DRUG|elranatamab|"Subcutaneously injected study drug, usually into the abdomen or lower stomach. Each vial of elranatamab contains a sufficient amount of product to ensure an extractable volume of 1.9 mL at a concentration of 40 mg/mL. The dosing is as follows:~* Cycle 1 Day 1: 12 mg/0.3 mL~* Cycle 1 Day 4: 32 mg/0.8 mL~* Cycle 1 Day 8, 15, 22: 76 mg/1.9 mL~* Cycles 2-6, Day 1 and 15: 76 mg/1.9 mL~* Cycles 7+, Day 1: 76 mg/1.9 mL"
214491659|NCT06832865|DRUG|Isatuximab SC|"Isatuximab (SAR650984) is an IgG1 derived monoclonal antibody binding selectively the human CD38 membrane protein. Subcutaneously (SC) injected study drug with each vial containing 140 mg/mL (1400 mg/10mL) isatuximab. Isatuximab SC will be injected using the investigational OBDS and in the following doses:~* Cycles 2-6, Day 1 and 15: 1400 mg/10 mL~* Cycles 7+ Day 1: 1400 mg/10 mL"
214679823|NCT02547077|PROCEDURE|Wound Closure with 2-octylcyanoacrylate|
214679824|NCT02547077|PROCEDURE|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
214976880|NCT04188054|BEHAVIORAL|Change in sleeping position|The new sleeping position requires you to re-position yourself in your bed when lying on your back so that your feet (and ankles) hang over the end of the mattress, i.e. off the end of the bed.
214976881|NCT04188054|BEHAVIORAL|No change in sleeping position|No change to your normal sleeping position
214976882|NCT00937339|DEVICE|Whole body vibration therapy|Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.
214976883|NCT00937339|DEVICE|Exercise on the vibration platform with the device turned off|Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
214976884|NCT06115018|PROCEDURE|Palatal surgery|Palate surgery has evolved from the ablative partial palate resections, which favored the removal of the soft tissue that obstructed the upper airway (UA), to more recent innovative reconstructive procedures that not only address the level of palatal obstruction, but the type of palatal or lateral pharyngeal wall collapse.
215085111|NCT03908645|DEVICE|Artificial intelligence assisted bowel preparation quality scoring system|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
214366449|NCT00319748|DRUG|852A|0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
214366450|NCT04354987|DRUG|CKD-391 10/10mg|Drug T: CKD-391 10/10mg(Other Name: Test Drug)
215085112|NCT03908645|DEVICE|Conventional human scoring|After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
215085113|NCT02617940|OTHER|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
215085114|NCT02617940|OTHER|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
214976885|NCT06115018|BEHAVIORAL|Oropharyngeal rehabilitation|Oropharyngeal rehabilitation (OPR) focus on the upper airway muscle including tongue muscle, palatal muscles and paryngeal muscles. The OPR for the treatment groups included three 30-minute sessions of OPR per day, and the exercise would be performed 3-5 days per week for 3 months. The performance of the home exercise will also be recorded by the force-sensing resistor. In addition to home exercise sessions, there will also be twice-weekly clinical visits to adjust the contents of OPR program and monitor training progress.
214976886|NCT06115018|COMBINATION_PRODUCT|Palatal surgery combined oropharyngeal rehabilitation|Participants will receive palatal surgery and post-surgery oropharyngeal rehabilitation (OPR). The palatal surgery and OPR describe as above.
214976887|NCT06202846|GENETIC|cfDNA analysis|"In order to compare the performance of the ctDNA test with techniques used in routine diagnostics, we will compare the results obtained by the ctDNA test with those obtained by FISH.~compare the results obtained by the ctDNA test and FISH. This will enable us to identify a potential diagnostic gain. We will compare the percentage of patients for whom a positive test result result was obtained by the lncDNA test (Y chromosome detection) to the percentage of patients for whom a positive result was obtained by FISH."
214976888|NCT04915235|BEHAVIORAL|Algorithm|Algorithm
214976889|NCT05983263|DRUG|Capsaicin|Capsaicin 8% patch (QUTENZA) apposed in coccygeal area
214976890|NCT00678418|DRUG|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
214976891|NCT00678418|DRUG|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
214976892|NCT00706680|DRUG|Thymoglobulin|methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
214976893|NCT03351712|BEHAVIORAL|ACT-Based Intervention and Activity Tracker WITH Feedback|Combining ACT and Behavioral Change
214976894|NCT03351712|BEHAVIORAL|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Medical Rehabilitation, Motivational Support and Psycho-Education
214976895|NCT03351712|BEHAVIORAL|Gold Standard Intervention and Activity Tracker WITH Feedback|Behavioral Change Condition - Activity Tracker
215085115|NCT00732355|DEVICE|Syph-Check POC|Rapid membrane test for syphilis antibodies
215085116|NCT04792333|DRUG|firibastat|Single oral dose of 500 mg administration on Day 1
214366451|NCT04354987|DRUG|D090, D337|D090 and D337 co-administration(Other Name: Reference drug)
214366452|NCT01179204|PROCEDURE|Preoperative heat stimulation|Preoperative short and long tonic heat stimulation
214366453|NCT00306982|BIOLOGICAL|Fluarix|
214366454|NCT03116048|OTHER|Chronic pain evaluation|Chronic pain assessment with study questionnaire
214366455|NCT05305287|DRUG|Pioglitazone|An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.
214366456|NCT05305287|OTHER|Placebo|Placebo for pioglitazone
214366457|NCT03087565|PROCEDURE|subtotal hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics . The abdomen is closed in layers; the wound is covered with a sterile dressing."
214366458|NCT03087565|PROCEDURE|Total hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Revision of all pedicles to ensure hemostasis.~The abdomen is closed in layers; the wound is covered with a sterile dressing."
214976896|NCT03351712|BEHAVIORAL|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|ACT-Based Intervention Standalone
214976897|NCT06422039|DRUG|HRS-7535（D）Tablets|One HRS-7535（D）Tablet is administered to healthy subjects.
214976898|NCT06422039|DRUG|HRS-7535（C）Tablets|Two HRS-7535（C）Tablets is administered to healthy subjects.
214976899|NCT00487903|DRUG|PB127 for Injectable Suspension|0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.
214976900|NCT03405727|DIETARY_SUPPLEMENT|Oral dietary supplements|Protein enriched diet
214976901|NCT01081197|OTHER|Psychiatric and somatic examinations and ,if clinical indicated, treatment|Patients referred to the clinic will be given optimal treatment for revealed psychiatric and/or somatic disease including conversational therapy, and if indicated therapeutic interventions with respect to any kind of disease.
214976902|NCT06550479|PROCEDURE|AVF|Distal forearm AVF for hemodialysis.
214976903|NCT03619473|BEHAVIORAL|Standard motorcycle child safety helmet|"Educational session followed by demonstration on~* proper helmet wearing~* how to differentiate non-standard and standard helmets~* how to keep motorcycle safe using ABCD concept~* importance of wearing bright clothes~* police summon for not wearing helmets~* live demo on poor performance of non-standard helmet~* giving away standard motorcycle child safety helmets~* oath taking by parents and children~* distribution and placement of VEM on parents' motorcycles"
214976904|NCT01584713|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
214366459|NCT06374446|OTHER|Classical Treatment|This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. All evaluations are made at the beginning and end of the groups.
214366460|NCT06374446|OTHER|Virtual Reality Combined with Classical Treatment|This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. In addition, individuals can take a 30-minute walk in the forest, do yoga, etc. with virtual reality glasses. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
214366461|NCT06374446|OTHER|Virtual Reality|Individuals in this group are given 30-minute walks in the forest, yoga, etc. with virtual reality glasses, 2 days a week, 2 times a day for 6 weeks. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
214976905|NCT01597986|DRUG|isavuconazole|oral
214366462|NCT06374446|OTHER|Control Group|This group will be given a handbook explaining the importance of exercise in individuals with long-term symptoms after Covid.
214976906|NCT01597986|DRUG|Oral Contraceptive (ethinyl estradiol / norethindrone)|contraceptive pill consisting of ethinyl estradiol and norethindrone
214976907|NCT04362124|BIOLOGICAL|vaccine BCG|Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.
214366463|NCT01659190|OTHER|Oiled-limestone liniment|
214366464|NCT00034255|DRUG|INGAP Peptide|
214366465|NCT02781402|PROCEDURE|4 weeks of Aerobic Training|The duration of aerobic training was 40 minutes for each session and 3 days per week with the intensity of 75-80% of their maximum heart rate. The participants were needed to walk or jog on treadmill during the first 10 minutes at the intensity of 50-60% of maximal heart rate (HR max). The aerobic training was followed by 4 x 4 minutes intervals at 75-80% HR max. The participants were given 3 minutes active breaks in between the intervals in which they can either walk or jog at 50-60% of maximal heart rate.
214366466|NCT03627884|DRUG|Sodium Bicarbonate Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
214366467|NCT03627884|DRUG|Normal Saline Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
214366468|NCT04620967|DRUG|Insulin aspart|Insulin aspart (Iasp) in insulin pump
214366469|NCT04620967|DRUG|Fast-acting insulin aspart|Fast-acting insulin aspart (Fiasp) in insulin pump
214366470|NCT01113502|DRUG|Eltrombopag|Oral formulation taken daily
214366471|NCT02238002|PROCEDURE|cataract surgery|The patients of both groups underwent cataract surgery
214366472|NCT01161979|DRUG|Zonisamide|Zonisamide capsules 100 mg
214366473|NCT01161979|DRUG|Zonegran|Zonegran Capsules 100 mg of EISAI INC
214366474|NCT00995501|DRUG|Dexamethasone Sodium Sulfate|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
214366475|NCT00995501|DRUG|Insulin|Insulin to maintain blood glucose 80-110 mg/dl.
214366476|NCT00995501|DRUG|anesthesia management|Light anesthesia to maintain BIS about 55
214366477|NCT00995501|OTHER|Dexamethasone - placebo|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
214976908|NCT04362124|OTHER|Placebo|A single dose intradermal application of normal saline solution.
214976909|NCT05739318|DEVICE|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is collapsed as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
214976910|NCT05739318|DEVICE|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is inflated as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
214976911|NCT00666302|DRUG|tacrolimus ointment|topical
214976912|NCT00666302|DRUG|pimecrolimus cream|topical
214976913|NCT03356652|PROCEDURE|Noninvasive electrical dyssynchrony study|"Ventricular activation maps will be acquired simultaneously with hemodynamic measurements using noninvasive mapping system (ECVUE, Medtronic Inc, USA). A thoracic computed tomographic scan will be acquired with the electrodes attached to the patient. Local ventricular activation times will be defined as the onset of the QRS complex or the pacing spike to the maximal negative slope of each unipolar electrogram.~Pacing leads will be placed in high right atrium, His-bundle region, right ventricular apex, high septal RV, coronary sinus posterior/lateral branch, coronary sinus anterior branch, lateral and septal region of endocardial LV in order to deliver CRT in 8 different configurations."
214366478|NCT00995501|OTHER|Insulin - Placebo|Insulin to maintain blood glucose 180-200 mg/dl.
214366479|NCT00995501|OTHER|Anesthesia management -Placebo|Deep anesthesia to maintain BIS about 35
214366480|NCT03002610|OTHER|Pls|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
214366481|NCT03002610|OTHER|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
214366482|NCT03002610|OTHER|Scientific abstract|Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
214366483|NCT05413980|OTHER|Moxifloxacin hydrochloride ophthalmic solution|Prospective observational study. There is no treatment allocation. Patients prescribed with 0.5% Moxifloxacin hydrochloride ophthalmic solution during the perioperative period of ophthalmic surgery are eligible to enroll into this study.
214366484|NCT05245578|DRUG|KX01 ointment 1%|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
214366485|NCT05245578|DRUG|Placebo ointment|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
214366486|NCT06291610|BEHAVIORAL|Clinical trial decision support intervention|"1. a patient decision aid tailored to clinical trial participation~2. decision coaching consultations carried out by trained healthcare professionals.~3. a training program in decision coaching will be an integrated part of the intervention."
214366487|NCT03343223|BEHAVIORAL|Intervention Group|"The goal of this research study is to evaluate the preliminary impact of a public-health-partnered tele-pharmacist model for pre-exposure prophylaxis (PrEP) delivery in a rural state (TelePrEP). In brief, PrEP involves daily use of a medication (i.e. Truvada) to prevent HIV infection among people at risk for infection due to sexual exposure or needle sharing."
214976914|NCT04182919|DRUG|Phlai|Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks
214976915|NCT04182919|DRUG|Placebo oral capsule|Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
214976916|NCT05176639|DRUG|VRDN-001 Phase 3 Cohort (THRIVE)|5 IV Infusions of veligrotug (VRDN-001) 10mg/kg
214976917|NCT05176639|DRUG|VRDN-001 Placebo|5 IV Infusions of veligrotug (VRDN-001) placebo
214976918|NCT05674240|DEVICE|Intrathecal Targeted Drug Delivery|Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.
214976919|NCT05674240|COMBINATION_PRODUCT|Conservative medical management|Including physical therapy, oral or transdermal medications and injections
214976920|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
214976921|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
214976922|NCT01704365|BIOLOGICAL|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
214976923|NCT01704365|BIOLOGICAL|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
214976924|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
214976925|NCT01704365|BIOLOGICAL|Placebo|0.5mL IM Injection
214976926|NCT00076037|BIOLOGICAL|HIV CTL MEP administered with RC529-SE adjuvant|
214976927|NCT00076037|DRUG|GM-CSF|
214976928|NCT03418259|DEVICE|KCS Medical Device|Patient treated 6 times with the Active KCS Medical Device during 2 weeks.
214976929|NCT03418259|DEVICE|KCS Medical Device|Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
214976930|NCT04192240|OTHER|WB Training with external feedback|WB during sit-to-stand and stepping with external feedback, follow by overground walking.
214976931|NCT04192240|OTHER|WB Training without external feedback|WB during sit-to-stand and stepping without external feedback, follow by overground walking.
214366488|NCT03617744|PROCEDURE|Sleeve gastrectomy|Open sleeve gastrectomy
214366489|NCT05280418|BIOLOGICAL|Tezepelumab|Monoclonal antibody designed for the treatment asthma.
214366490|NCT05280418|BIOLOGICAL|Placebo|Matched placebo.
214976932|NCT06332196|OTHER|Analysis of biological sample and clinical data|Analysis of biological sample and clinical data
214976933|NCT02718911|DRUG|LY3022855|Administered IV
214976934|NCT02718911|DRUG|Durvalumab|Administered IV
214976935|NCT02718911|DRUG|Tremelimumab|Administered IV
214976936|NCT01132183|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
214976937|NCT04477369|DRUG|DWJ1439|300mg single dose
214976938|NCT04477369|DRUG|DWJ1464|300mg single dose
214976939|NCT04477369|DRUG|DWC202003|300mg single dose
214976940|NCT04477369|DRUG|DWC202004|300mg single dose
214976941|NCT03539978|OTHER|SM-THINk|Patients will receive the SM-THINk enhanced discharge method.
214976942|NCT02728063|DIETARY_SUPPLEMENT|Lactibiane Tolerance|probiotics
214976943|NCT03812419|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
214976944|NCT03812419|DRUG|Pantoprazole 40mg|Pantoprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
214366491|NCT01701414|DRUG|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
214366492|NCT01701414|DRUG|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
214366493|NCT02227875|DRUG|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
214366494|NCT02227875|DRUG|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
214366495|NCT04209725|DRUG|CPX-351|Given during the induction and consildation phase and will consist of 44 mg/m\^2 daunorubicin with 100 mg/m\^2 cytarabine administered intravenously on Days 1, 3, and 5 during induction phase and Days 1 and 3 of consolidation phase.
214491660|NCT06832865|DEVICE|Isatuximab SC-OBDS|The On Body Delivery System (OBDS) also called Isatuximab SC Wearable Injection System, is a sterile, single-use, disposable, elastomeric, user-filled investigational medical device. The OBDD has a reservoir for the drug product (isatuximab). A self-contained, integrated needle (with manual insertion and automatic retraction mechanism) is provided within the OBDS. The OBDS will be used to inject isatuximab each time the participant receives isatuximab in this study. Study drug administration will be done by trained medical professionals in the clinic. The OBDS device will be prepared by the medical professional, placed on the abdomen using the adhesive (sticky) pads that are on the device, the study drug (isatuximab) will be injected, and then the device will be removed.
214491661|NCT02616666|DRUG|Dapagliflozin|The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
214491662|NCT02616666|DRUG|Standard of Care|The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
214491663|NCT06854744|PROCEDURE|lesion sterlization and tissue repair|evaluate and compare the clinical and radiographic effect of zinc oxide-ozonated olive oil (ZnO-OO) versus Modified Triple Antibiotic Paste (MTAP) as a Lesion Sterilization and Tissue Repair Technique in Primary Molars.
214491664|NCT06854744|OTHER|Zinc Oxide Ozonated Oil|Zinc Oxide Ozonated Oil
214491665|NCT06854744|OTHER|Modified Triple Antibiotic Paste|Modified Triple Antibiotic Paste
214491666|NCT06853873|BEHAVIORAL|The Counselling for Alcohol Problems in Pregnancy (CAP-Pre) intervention|"Five structured 60-minute counseling sessions (weekly, CHW-delivered).~Key components:~Motivational interviewing (MI) to enhance behavior change. Cognitive-behavioral strategies (CBT) for managing alcohol cravings. Goal-setting and self-monitoring for tracking progress. Problem-solving techniques and social support enhancement."
214491667|NCT06866873|BIOLOGICAL|CAR-T|CAR-T cell (CHXCART01) infusion intravenously once at a dose of 0.2-2 million cells/kg recipient body weight
214491668|NCT04305327|DRUG|Brodalumab|Solution for subcutaneous injection.
214491669|NCT04305327|DRUG|Ustekinumab|Solution for subcutaneous injection.
214491670|NCT04305327|DRUG|Placebo|The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.
214491671|NCT06769295|DRUG|AK112|non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
214491672|NCT06768814|BEHAVIORAL|Sub-acute stabilization|The sub-acute stabilization center (SASC) is for people who have had or are at risk for having an opioid overdose and have an encounter with Seattle Fire Department emergency medical services (EMS) in Seattle, WA. Those transported to the SASC are the intervention participants and two comparison groups will be utilized: eligible Seattle EMS patients who opt not to go to the SASC and King County residents, outside of Seattle, who meet the same eligibility criteria. A comparative interrupted time series analysis is planned to study the main effectiveness outcomes. Seattle Fire EMS will assess, refer, and arrange transport participants to the SASC. The SASC will offer an array of services including post-overdose monitoring, utilization of buprenorphine and methadone for the treatment opioid use disorder and opioid withdrawal, linkage to ongoing care for OUD, and provision of harm reduction services and supplies. The length of stay in the SASC will be limited to less than 24 hours.
214491673|NCT06780644|DRUG|Triple combination cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle."
214976945|NCT03184740|DEVICE|Active Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
214976946|NCT03184740|DEVICE|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.
214976947|NCT01447888|DRUG|150% Oral Morphine Equivalent (OME)|Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
214976948|NCT01447888|OTHER|Clinical Judgment|This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
214366496|NCT04209725|DRUG|Quizartinib|Given during induction, consolidation, and maintenance phases and will be taken orally at a dose of 30mg on Days 8-21 of induction phase, Days 6-21 of consolidation phase, and daily in maintenance phase.
214366497|NCT02657317|BEHAVIORAL|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
214366498|NCT02657317|OTHER|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
214366499|NCT01019538|OTHER|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
214366500|NCT00195026|DEVICE|Infrared Breast Scan|Patients already scheduled for breast biopsies will receive an additional infrared scan
214366501|NCT00975845|OTHER|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
214366502|NCT05322070|DRUG|Fluocinolone Acetonide Intravitreal Implant 0.18 mg|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
214366503|NCT00904514|GENETIC|gene expression analysis|
214366504|NCT00904514|GENETIC|microarray analysis|
214366505|NCT00904514|GENETIC|mutation analysis|
214366506|NCT00904514|GENETIC|polymerase chain reaction|
214366507|NCT00904514|OTHER|flow cytometry|
214366508|NCT00904514|OTHER|immunoenzyme technique|
214366509|NCT00904514|OTHER|laboratory biomarker analysis|
214366510|NCT02685644|PROCEDURE|Laparoscopic removal of cysts|Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.
214366511|NCT04732091|PROCEDURE|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.8 MHz S5-1 transducer
214366512|NCT03144414|PROCEDURE|Laparoscopic hysterectomy|Laparoscopic hysterectomy
214366513|NCT05343416|PROCEDURE|Open abdomen procedure|All patients underwent to open abdomen procedure
214366514|NCT03118921|DEVICE|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.
214366515|NCT03786952|BEHAVIORAL|Stress immediately before learning in males|Male participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
214366516|NCT03786952|BEHAVIORAL|Sham control immediately before learning in males|Male participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
214491674|NCT06780644|DRUG|Triple combination cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05% at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle"
214491675|NCT06782555|DRUG|Evofosfamide|Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.
214491676|NCT06782555|DRUG|Zalifrelimab|Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.
214491677|NCT06782555|DRUG|Balstilimab|Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.
214976949|NCT05870852|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be done once a week for 4-5 minutes in total 3 times with ESWT. 2000 impulses will be applied on calcinosis with 2.4 bar pressure and 5.0 Hz frequency.
214976950|NCT05870852|OTHER|PNF|PNF stretching techniques: It will be done with isometric contraction for 10 seconds against maximum resistance. 8-10 repetitions will be done. A 10-second listening interval will be left for active relaxation of the patient between the applications. PNF application will be done by the physiotherapist once a week. You will be asked to do the PNF stretching exercises taught once daily as a home program.
214976951|NCT01172873|DRUG|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
214976952|NCT01172873|BEHAVIORAL|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
214976953|NCT00983372|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
214976954|NCT00983372|DRUG|Diltiazem ER|One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
214976955|NCT00983372|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
214976956|NCT04175171|DRUG|Coprelotamab Injection|The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.
214976957|NCT04175171|DRUG|Trastuzumab Injection|The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.
214976958|NCT06281561|DRUG|Normal Saline|Female patients undergoing hysteroscopy receive nasal spray with normal saline before anesthesia
214976959|NCT06281561|DRUG|Dexmedetomidine|Female patients undergoing hysteroscopy receive nasal spray with dexmedetomidine before anesthesia
214491678|NCT04028973|OTHER|Single then dual task situation|Firstly, the participants have to perform the fatiguing task in simple task condition (control condition, i.e., muscle contraction alone). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same fatiguing task with a concomitant memory cognitive task (i.e. dual-task condition).
215085117|NCT06101602|OTHER|Dynamic Stretching with Floss Band|"Floss band involves wrapping a band made of natural rubber around the targeted joint or muscle for 1-3 minutes through active movement. The mechanism behind flossing is thought to have a three-fold effect, compression may stimulate the mechanoreceptors of the underlying fascia layer which causes the hyperemia of the targeted tissue, and leads to increased blood flow.~This intervention was applied in addition to dynamic stretching which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise."
215085118|NCT06101602|OTHER|Dynamic Stretching without Floss Band|In this group, only dynamic stretching was applied which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
215085119|NCT03855202|BIOLOGICAL|CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
214366517|NCT03786952|BEHAVIORAL|Stress 30 minutes before learning in males|Male participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
214366518|NCT03786952|BEHAVIORAL|Sham control 30 minutes before learning in males|Male participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
214366519|NCT03786952|BEHAVIORAL|Stress immediately before learning in females|Female participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
214491679|NCT04028973|OTHER|Dual then single task situation|Firstly, the participants have to perform the fatiguing task in dual-task condition (i.e. muscle fatiguing contraction with a concomitant memory cognitive task). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same muscle fatiguing task without a concomitant memory cognitive task (i.e. control condition).
214491680|NCT06793501|OTHER|Reablement intervention|Reablement's implementation in this study is characterized by a comprehensive assessment of the older person's everyday activities, both current and past. This is done through a person-centered interview using the Canadian Occupational Performance Measure (COPM). The COPM is based on the assumptions described in the theoretical framework of CMOP-E. Based on the assessment, the older adult selects a personal activity goal, which consists of an activity they consider meaningful and wish to improve. In collaboration with the older adult and staff, a goal-oriented support plan, also referred to as a training program, is developed to achieve the goal. Nursing assistant staff support the older persons in performing defined training activities and receive supervision from rehabilitation staff. The support plan and progress toward the activity goal are evaluated through regular reassessments during a fixed intervention period of eight weeks.
214491681|NCT06793501|OTHER|Control group|TAU includes a general approach where all activities that the older adult engages in during everyday life are considered rehabilitative. The staff are encouraged to motivate the older adult to do as much as possible independently, in order to prevent loss of function and maintain the ability to perform activities. The approach does not involve any direction toward specific activities where there is a rehabilitative need. It does not include any formulated goals or follow-up. Additionally, there is no specific education offered to the nursing assistants on how to encourage the older adult or how to follow-up up on the extent to which the approach is applied.
214976960|NCT05179954|OTHER|Metabolic testing|Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
214976961|NCT04690348|PROCEDURE|Craniotomy|Craniotomy
214976962|NCT04690348|RADIATION|Cesium-131 brachytherapy|Intracavitary Cesium-131 brachytherapy
214976963|NCT00359203|DEVICE|Dual chamber pacemeker|
214976964|NCT00190788|DRUG|Drotrecogin Alfa (Activated)|
214976965|NCT00190788|DRUG|placebo|
214976966|NCT00889941|PROCEDURE|LASIK|laser-assisted in situ keratomileusis
214976967|NCT05469529|DRUG|Dexmedetomidine|5mcg dexmedetomidine to be given intrathecally along with 0.5% bupivacaine.
214976968|NCT03147872|OTHER|2% Oxygen|2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
214976969|NCT01956890|DRUG|PET|18F-FLT PET and MRI of the breast
214976970|NCT04091464|BEHAVIORAL|Backward Walking Training|Training will consist of BW training on both a treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline BW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes BW, backward stepping, and functional exercises that incorporate BW movements.
214976971|NCT04091464|BEHAVIORAL|Forward Walking Training|Training will consist of FW training on both treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline FW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes FW, forward stepping, and functional exercises that incorporate FW movements.
214366520|NCT03786952|BEHAVIORAL|Sham control immediately before learning in females|Female participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
215085120|NCT03855202|BIOLOGICAL|PS+CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
215085121|NCT03855202|BIOLOGICAL|PS|PS,dose is 70mg/kg
215085122|NCT03855202|OTHER|Placeo|0.9% sodium chloride installation after 24 hours
215085123|NCT00825396|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
215085124|NCT06446908|BEHAVIORAL|Telehealth coaching for liver disease|"This study is an open-label, mono-centred, single-case experimental design with multiple base levels. The study will comprise 3 phases, alternating periods of observation (A) and 1 period of counselling (B) with an A1-B-A2 design.~PA will be assessed continuously using an accelerometer for 7 to 14 days per (A) phase. During phase (B), participants will receive the intervention, i.e. 6 x 45-minute, real-time, face-to-face, virtual sessions with a PA counsellor."
215085125|NCT00388284|DEVICE|Arterial Sealing|
215085126|NCT05782192|DRUG|SAL067|SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
215085127|NCT05782192|DRUG|Alogliptin|Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)
215085128|NCT05782192|DRUG|Placebo|placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
215085129|NCT03050762|OTHER|Data Collection|Participant information collected from either source document or direct participant response.
215085130|NCT03050762|BEHAVIORAL|Follow Up|Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
215085131|NCT01437176|DEVICE|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
215085132|NCT01437176|DEVICE|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
214679825|NCT02338076|DRUG|Petrolatum application under occlusion|"Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)~1 well will be empty and the other well will contain petrolatum~Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch~1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)"
215085133|NCT04612543|DEVICE|Genial Posterior Composite with Polyethylene Fiber|Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
214366521|NCT03786952|BEHAVIORAL|Stress 30 minutes before learning in females|Female participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
214366522|NCT03786952|BEHAVIORAL|Sham control 30 minutes before learning in females|Female participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
214366523|NCT03320616|DRUG|EYP001a|Oral EYP001a capsules - 100 mg strength
215085134|NCT04612543|DEVICE|Genial Posterior Composite|Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
215085135|NCT00018382|DRUG|rosiglitazone|
215085136|NCT00300482|DRUG|ABT-335|135 mg, daily, 12 weeks
215085137|NCT00300482|DRUG|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
215085138|NCT00300482|DRUG|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
215085139|NCT02593708|DRUG|Neratinib|
215085140|NCT02593708|DRUG|Paclitaxel|
215085141|NCT02593708|DRUG|Pertuzumab|
215085142|NCT02593708|DRUG|Trastuzumab|
215085143|NCT04352257|RADIATION|pelvic Ultrasound|pelvic and transrectal ultrasound
215085144|NCT01356732|DRUG|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
215085145|NCT00527020|DRUG|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
215085146|NCT00527020|DRUG|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
215085147|NCT00527020|DRUG|Placebo|Placebo tablets will be given to the subjects.
215085148|NCT01056120|DEVICE|Pro Kinetic Energy bare metal stent|PCI
214491682|NCT06835660|DEVICE|procedure of DCB implantation|Patients assigned to the DCB group (study group) will receive DCB inflation(s) at the level of the lesions according the DCB instructions for use (120 seconds inflation minimum). One or several DCBs will be inflated at the level of the lesions depending on lesions' lengths. The DCB diameter(s) will be the one(s) of the index diameter of the artery. Overlaps between zones that will receive DCB inflations will be of 10 mm to avoid any geographic miss.
214491683|NCT06835660|DEVICE|procedure of SEDES implantation|"SEDES implantation wille be performed according to the SEDES instructions for use. Stent(s) oversizing will be of 1 mm maximum. Overlaps between stents will be of 10 mm.~Completion angiogram will assess the technical success of the procedure (see endpoints definitions). The physician may then decide to add a bailout SEBMS because of flow limiting dissection and/or a new stenosis \>30%."
214491684|NCT04299191|DRUG|LAM561|"Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561."
214491685|NCT06359782|DRUG|C1 Esterase Inhibitor Injection [Cinryze]|C1 Esterase Inhibitor Injection \[Cinryze\]
215085149|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
214491686|NCT06359782|DRUG|Placebo|Sodium Chloride /physiological saline (0.9%) in equal volume dosed intravenous
215085150|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
215085151|NCT01459367|DRUG|Lansoprazole|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks."
215085152|NCT02120365|DRUG|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
214491687|NCT06845267|BEHAVIORAL|Chronotherapy|This study utilize and test different combinations of three types of interventions (zeitgebers) to entrain the circadian rhythm: 1) Light being the primary photic zeitgebers that directly entrain the SCN, 2) physical activity and 3) timing of eating) being non-photic zeitgebers that drive peripheral rhythms.
214491688|NCT06845267|BEHAVIORAL|Control|Control condition
215085153|NCT02120365|DRUG|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
215085154|NCT06284616|BEHAVIORAL|JASP-1|patients following the Juvenile Arthritis Support Program at the Pediatric Rheumatology Clinic
215085155|NCT00424411|DRUG|Inhaled human insulin (EXUBERA™)|
215085156|NCT01726673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
215085157|NCT01726673|DEVICE|Placebo sham|
215085158|NCT04832139|DRUG|Marstacimab PFP|300 milligrams (mg) subcutaneous injection marstacimab PFP
214491689|NCT06845085|PROCEDURE|Intervention|pulmonary vein re-isolation plus Vein of Marshall ethanol ablation in combination with block of mitral and tricuspid isthmuses and dome line
214491690|NCT06845085|PROCEDURE|Control|pulmonary vein re-isolation
215085159|NCT04832139|DRUG|Marstacimab PFS|300 mg subcutaneous injection of marstacimab PFS
214491691|NCT06844981|BEHAVIORAL|Latin Dance|Latin Dance intervention
215085160|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
215085161|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
215085162|NCT01719003|DRUG|Empagliflozin low dose qd|Empagliflozin low dose once daily
214491692|NCT06845709|OTHER|gaze stabilization exercise|Patients in group A will receive Gaze Stabilization Exercises with conventional baseline treatment
214491693|NCT06845709|OTHER|otago exercise|group B patients will receive Otago Exercises with conventional baseline treatment
214491694|NCT04003857|BIOLOGICAL|PNEUMOSTEM®|A single intratracheal administration of PNEUMOSTEM® (1.0 x 10\^7 cells/kg)
214491695|NCT04003857|BIOLOGICAL|normal saline|A single intratracheal administration of normal saline
214679826|NCT05047640|BIOLOGICAL|BNT162b2 vaccine|Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle
215085163|NCT01719003|DRUG|Empagliflozin high dose qd|Empagliflozin high dose once daily
215085164|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
215085165|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
215085166|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
215085167|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
215085168|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
215085169|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
215085170|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
215085171|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
215085172|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
215085173|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
215085174|NCT05451355|BEHAVIORAL|Family Safety Check-In|Prototype decision aid to support within-family communication and decision making about firearm storage.
215085175|NCT05451355|BEHAVIORAL|AAP Firearm Storage Web Page|Educational web page that discusses safe firearm storage practices.
214976972|NCT05499975|OTHER|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
214976973|NCT01898247|OTHER|Simulation-based mastery learning|Internal Medicine residents are randomly selected to undergo simulation-based mastery learning.
214976974|NCT05863819|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
215085176|NCT02189408|BIOLOGICAL|Platelet rich plasma|
215085177|NCT00581828|DRUG|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
215085178|NCT06484010|OTHER|SNAPPS Model of case presentation|"The intervention was the implementation of the SNAPPS model as a method of case presentation in out-patient settings.~All preceptors and residents in the SNAPPS group were sensitized and trained one week before the beginning of case presentations and data collection by a training session that was carried out by the authors at Brayati Primary Health Center training hall for a duration of more than two hours, the session included a preview of the traditional method, introduction to the SNAPPS method, role play and doubts clarification.~The training materials included a presentation explaining the SNAPPS method in details with examples, instructional videos, and handouts highlighting the six steps of the SNAPPS method.~Before the beginning of the presentation by 72 hours, there was a double check by the principal investigator with all participants regarding the method and all doubts were clarified."
215085179|NCT01256463|BEHAVIORAL|HIV prevention intervention|
215085180|NCT05767580|OTHER|evaluation|The Timed Get Up and Go test to assess dual-tasking, the 4m Walk Test to assess gait, and the Footprint Method to assess cadence
215085181|NCT04147975|DIAGNOSTIC_TEST|RaPID/BSI Test|RaPID/BSI Test
214366524|NCT03113123|DRUG|PrEP with Truvada®|"Associated with:~* STD screening/treatment for syphilis, gonorrhoea and chlamydiae~* HIV screening/therapy~* Questionnaire~* Addiction, social or psychological follow-up care if needed~* Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites."
214366525|NCT03128996|DRUG|RIC regimen|Days -60 to -21: hydroxyurea (30mg/kg/day po) \>6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if \< 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if \< 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
214366526|NCT03128996|DRUG|GVHD prophylaxis regimen|Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus \& Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
214366527|NCT02393287|OTHER|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
214366528|NCT03468933|DRUG|tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose
214366529|NCT03468933|PROCEDURE|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
214366530|NCT02790723|DRUG|sc-rAAV2.5IL-1Ra|Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.
214366531|NCT05088889|DRUG|Nivolumab|Nivolumab administered IV over 30 minutes at a dose of 360mg every 3 weeks
214366532|NCT05088889|DRUG|ipilimumab|Ipilimumab administered IV over 30 minutes at 1 mg/kg every 6 weeks
214366533|NCT05088889|RADIATION|Stereotactic body radiation therapy|Three fractions of 8 Gy, treated on alternate days
214366534|NCT05088889|RADIATION|Low dose irradiation|a single fraction of 2Gy will be given to the metastatic lesions at first progression
214366535|NCT05728255|DIAGNOSTIC_TEST|ABPM plys SCAFB|24-hour ambulatory blood pressure monitoring (ABPM) and of tilt-table Short Cardiovascular Autonomic Function Battery (SCAFB) which consists in carotid sinus massage (CSM) and head-up tilt test (HUT) performed one after the other in an uninterrupted sequence as a single procedure on a tilt table
214366536|NCT06561178|DIAGNOSTIC_TEST|molecular residual disease detection|ctDNA detection
214366537|NCT06211660|BEHAVIORAL|AI-based AR training system|Participants will use the AI-empowered AR training system to get individualized assessments of their hand wash performance. They will not be informed about the hand scanner results.
214366538|NCT06211660|BEHAVIORAL|Hand scanner and Video training|Participants will use an existing education program that has been demonstrated effective in our previous study (unpublished). In brief, the participants will be informed about their hand scanner results during the first HW attempt. They will also watch a training video about the 7 steps of hand washing.
214366539|NCT06258018|DRUG|Temodal|given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
214366540|NCT06258018|DRUG|Niraparib|given orally in continous
214366541|NCT04471155|PROCEDURE|Holep|laser enucleation of the gland versus open enucleation
214366542|NCT05685459|OTHER|Standard patient simulation model|Nursing students were trained with a standard patient simulation model for position and communication skills education.
214366543|NCT03033225|PROCEDURE|Endoscopic Ultrasound|Undergo EUS-guided PDT
214366544|NCT03033225|PROCEDURE|Fluorescence Imaging|Undergo fluorescence imaging
214366545|NCT03033225|DRUG|Photodynamic Therapy|Undergo EUS-guided PDT
214366546|NCT03033225|OTHER|Quality-of-Life Assessment|Ancillary studies
214366547|NCT03033225|OTHER|Questionnaire Administration|Ancillary studies
214366548|NCT03033225|DRUG|Verteporfin|Given IV
214976975|NCT05801003|DEVICE|Predilation with cutting balloon.|PCI will be performed under OCT guidance. Predilation of the lesion will be done with cutting balloon.
214366549|NCT01510431|DRUG|PROCHYMAL (remestemcel-L)|intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter
214491696|NCT06725862|PROCEDURE|Retrolaminar Block (RLB)|This intervention involves administering 0.25% bupivacaine (0.1 mL/kg) into the retrolaminar space at the L4 vertebral level using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.
214491697|NCT06725862|PROCEDURE|Caudal Block (CB)|This intervention involves administering 0.125% bupivacaine (1 mL/kg, maximum 20 mL) into the sacral canal using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.
214491698|NCT06833385|DIAGNOSTIC_TEST|Intraoral Scanning|Participants will first undergo intraoral scanning using a digital scanner to capture a 3D image of their dental arches. The procedure is non-invasive and requires no impression material. After one week, the same participants will undergo a polyvinyl siloxane (PVS) impression using conventional impression trays and materials
214366550|NCT06462508|DRUG|[18F]F-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
214491699|NCT06833385|DIAGNOSTIC_TEST|PVS Impression|Participants will first undergo a polyvinyl siloxane (PVS) impression, where an impression tray filled with PVS material is used to capture the shape of their dental arches. After one week, the same participants will undergo intraoral scanning using a digital scanner for a 3D image of their dentition.
214491700|NCT06815562|OTHER|Clinical team access to Placement Success Predictor (PSP) results|PSP is a machine-learning based clinical decision support tool that is designed to assist clinical team members in making placement decisions for youth.
214491701|NCT01001364|DRUG|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
214491702|NCT01001364|DRUG|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
214491703|NCT06815315|DIETARY_SUPPLEMENT|Multiple micronutrient supplementation|The multiple micronutrient supplementation composition follows the United Nations International Multiple Micronutrient Antenatal Preparation. Each MMS tablet contains 15 micronutrients, including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg) and is consumed daily.
214976976|NCT05801003|DEVICE|Predilation with conventional balloon|PCI will be performed under OCT guidance. Predilation of the lesion will be done with conventional balloon (semi-compliant or non-compliant)
214976977|NCT01463787|PROCEDURE|microsurgical varicocelectomy in inguinal approach|In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.
214976978|NCT01463787|PROCEDURE|microsurgical varicocelectomy in subinguinal approach|In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
214976979|NCT00904007|OTHER|Interactive Spaced Education (ISE) --- online education|"ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions."
214976980|NCT04458675|DEVICE|Vibrant capsule|The capsule vibration mechanically stimulates the inner wall of the GI and stimulates motility
214976981|NCT04458675|DRUG|Placebo|A biodegradable capsule, which visually similar to the Vibrant active capsule
214976982|NCT04521595|BEHAVIORAL|Weigh Smart Telehealth intervention|Trial of the group program (nutrition, exercise) delivered via telehealth through fruit street on the Eastern Shore and Western Maryland with use of noninvasive lifestyle tracking options (drink water aquarium app for water consumption and fitbit - steps, sleep monitoring) provides novel options for expansion of family- based lifestyle intervention to underserved areas. We plan as a pilot study to assess the sensitivity of noninvasive measures for the detection of sleep apnea (pediatric sleep questionnaire (PSQ) and fitbit sleep data) in comparison to clinically indicated polysomnography among children with clinical suspicion for sleep apnea.
214976983|NCT02793765|DRUG|Docetaxel|
214976984|NCT02793765|BIOLOGICAL|Sipuleucel-T|
214976985|NCT00902070|DRUG|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
214976986|NCT05626309|DRUG|Qizhu Yuling Prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
214366551|NCT06462508|DRUG|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
214366552|NCT06017024|DEVICE|microprocessor-controlled knee (MPK) assessment|The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
214366553|NCT05095610|DEVICE|Flash|Use of the device FreeStyle Libre, only commercialized system for intermitent continuous glucose monitoring.
214366554|NCT03509740|DRUG|tramadol|100 mg tramadol in 100 ml saline with slow infusion
214366555|NCT03509740|DRUG|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion
214366556|NCT01071564|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214366557|NCT01071564|OTHER|Laboratory Biomarker Analysis|Correlative studies
214366558|NCT01071564|OTHER|Pharmacogenomic Study|Correlative studies
214366559|NCT01071564|OTHER|Pharmacological Study|Correlative studies
214366560|NCT01071564|DRUG|Vismodegib|Given PO
214366561|NCT04999878|DRUG|Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum|"All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype."
214366562|NCT02863484|OTHER|surgery|pealing of the outer layer of the cavernous sinus
214491704|NCT06815315|DIETARY_SUPPLEMENT|Iron Folic Acid Supplementation|One IFAS tablet contains Iron (60 mg) and Folic Acid (2800 μg) and is taken weekly.
214491705|NCT06815315|BEHAVIORAL|Adolescent Nutrition Curriculum|The Adolescent Nutrition Curriculum includes five modules focused on promoting healthy behaviors to enhance nutrition, with an emphasis on consuming iron-rich foods.
214491706|NCT05899153|DEVICE|Biomotum Spark: Robotic ankle resistance|Robotic ankle exoskeleton that provides resistance to ankle plantarflexion.
214491707|NCT05899153|DEVICE|Audiovisual Biofeedback|Electromyography recordings from the plantarflexor muscles are used to provide audio feedback via a sound that plays when muscle activity is above target and a visual bar that displays real-time muscle activity.
214491708|NCT05899153|PROCEDURE|Multilevel Orthopedic Surgery|Musculoskeletal surgeries to address alignment, contracture, and other lower-extremity impairments. This study does not impact surgical decision making but evaluates changes in gait before and after surgery.
214491709|NCT00743951|BEHAVIORAL|1 Patient decision aid|"Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
214679827|NCT05047640|BIOLOGICAL|JNJ-78436735 Vaccine|Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
214976987|NCT05626309|DRUG|Placebo|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
214976988|NCT01032447|BEHAVIORAL|Navigator Support|Standard of Care
214976989|NCT03838939|OTHER|Therapeutic education|"Individual and group therapeutic education sessions will consist of :~* acquisition by patient of self-care skills such as performing subcutaneous injection,~* acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ..."
214976990|NCT03490955|OTHER|salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (canola oil) one time in the morning
214976991|NCT03490955|OTHER|salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
214976992|NCT03490955|OTHER|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
214976993|NCT03490955|OTHER|salad|Subjects will consume a vegetable salad without dressing (canola oil) and without black pepper one time in the morning
214976994|NCT03490955|OTHER|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (olive oil) one time in the morning
214976995|NCT03490955|OTHER|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (corn oil) one time in the morning
214976996|NCT03490955|OTHER|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (sunflower oil) one time in the morning
214976997|NCT03490955|OTHER|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (flaxseed oil) one time in the morning
214976998|NCT01826942|DEVICE|Lumenis UltraPulse single fractional CO2 laser treatment thin skin|
214976999|NCT01826942|DEVICE|Single fractional CO2 treatment at surgical area closure procedure on thick skin|
214977000|NCT03151850|OTHER|ulcerative colitis|We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
214977001|NCT03151850|OTHER|Control|We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
214977002|NCT05560620|BEHAVIORAL|Sleep Deprivation|Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.
214977003|NCT05560620|OTHER|Caffeine|On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.
214977004|NCT05560620|OTHER|No Caffeine|De-caffeinated coffee
214977005|NCT04666545|BEHAVIORAL|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
215094459|NCT04371341|PROCEDURE|erector spinae block by 0.25% bupivacaine|A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.
215094460|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy plus CME|
214679828|NCT02391844|DRUG|Oxycodone|Oxycodone with Acetaminophen Extended Release
215085182|NCT01540448|PROCEDURE|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
215085183|NCT01540448|PROCEDURE|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
215085184|NCT01540448|PROCEDURE|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
214977006|NCT01559805|BEHAVIORAL|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
214977007|NCT01559805|BEHAVIORAL|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
214977008|NCT02631395|OTHER|Exercise|Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.
214977009|NCT02631395|OTHER|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
215085185|NCT05586672|DEVICE|EEG-HR|Passation EEG-HR
215085186|NCT05586672|DIAGNOSTIC_TEST|ADI-R|Passation of ADI-R scale
215085187|NCT05586672|DIAGNOSTIC_TEST|ADOS-2|Passation of ADOS-2 scale
215085188|NCT05586672|DIAGNOSTIC_TEST|IDE|Passation of IDE scale
215085189|NCT05586672|DIAGNOSTIC_TEST|MSEL|Passation of MSEL scale
215085190|NCT05586672|DIAGNOSTIC_TEST|Dunn|Passation of Dunn scale
215085191|NCT01113489|DRUG|beclomethasone dipropionate|400 mcg/1 ml b.i.d.
214977010|NCT02415543|PROCEDURE|SIL-TEP Inguinal Hernia Repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single incision
214977011|NCT02415543|PROCEDURE|TEP Inguinal Hernia Repair|perform the multiport laparoscopic total extraperitoneal inguinal hernia repair
214977012|NCT00617357|DEVICE|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
214977013|NCT03806543|DRUG|Vancomycin|adult patients treated with intravenous vancomycin in intensive care unit
214977014|NCT00373503|DRUG|Lofexidine|alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
214977015|NCT00373503|DRUG|dronabinol|cannabinoid agonist hypothesized to decrease MJ withdrawal
214977016|NCT00373503|DRUG|Marijuana|marijuana intoxication, withdrawal and relapse assessed
214679829|NCT00457054|DRUG|Lithium|starting dose 600 mg increase as tolerated
214977017|NCT02524639|DRUG|Sirolimus|Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
214491710|NCT00743951|BEHAVIORAL|2 Usual care|"Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings."
214491711|NCT06849141|OTHER|Role Performance Strenghthening Program|This intervention was developed by the researcher within the scope of her doctoral dissertation. The intervention is an individual psychoeducation program; it was written and structured within the framework of cognitive behavioral therapy, based on the Roy Adaptation Model. The intervention was structured on the idea of empowering nurses working in pandemic units.
214491712|NCT03621670|BIOLOGICAL|Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)|Bexsero is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group.
214491713|NCT03621670|BIOLOGICAL|Prevnar13|Prevnar13 (PCV13) is to be administered intramuscularly on upper side of the left thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
214977018|NCT01917279|DRUG|Docetaxel plus Capecitabine|"Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase."
214977019|NCT01917279|DRUG|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
214366563|NCT03569384|COMBINATION_PRODUCT|Tele Rehab|The intervention group will obtain telerehabilitation
214366564|NCT06239870|DRUG|Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy|Each enrolled patient was given 2 cycles of induction chemotherapy combined with immunization, followed by immunization combined with chemoradiotherapy, and finally 2 cycles of consolidation chemotherapy combined immunization
214366565|NCT02020525|PROCEDURE|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
214366566|NCT02020525|PROCEDURE|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
214977020|NCT01917279|DRUG|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
214977021|NCT03792646|DIETARY_SUPPLEMENT|Whey protein|Exercise training + 20g whey protein
214977022|NCT03792646|OTHER|Exercise training|Strength exercise
214977023|NCT01764841|DRUG|Ciprofloxacin DPI (BAYQ3939)|Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
214977024|NCT01764841|DRUG|Placebo|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
214977025|NCT03311191|DEVICE|Measurement of skin oxygenation and oxygen consumption|Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.
214977026|NCT05639517|OTHER|Augmented Reality Based Telerehabilitation Application|Spinal stabilization training with augmented reality-based telerehabilitation will be applied twice a week for 8 weeks.
214977027|NCT05639517|OTHER|Training face-to-face|Spinal stabilization training will be applied face-to-face twice a week for 8 weeks.
214977028|NCT05289700|DEVICE|HBOT in Hyperbaric chamber|HBOT is the administration of oxygen (FIO2 = 100%) at a pressure higher than atmospheric pressure (2 ATA). The pressure increase is achieved by introducing compressed air into the hyperbaric chamber. This study will use a hyperbaric chamber that is already marketed, licensed and used in other diseases.
214977029|NCT05289700|DEVICE|Hyperbaric chamber for placebo|Hyperbaric chamber is the same chamber used for HBOT, but here with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers. All other aspects of the procedure are identical to those of the intervention. As in the intervention arm, there will be a compression period (although shorter), of 5 min, followed by 85 min at 1.3 ATA, then a decompression period of 5 min (total duration of 95 min).
214977030|NCT02865863|DIETARY_SUPPLEMENT|Eurycomalongifoliawater extract (Physta®)|
214977031|NCT02865863|DIETARY_SUPPLEMENT|Placebo|
214977032|NCT02865863|DIETARY_SUPPLEMENT|Multivitamin|
214977033|NCT00006015|BIOLOGICAL|trastuzumab|4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, \& 22)
214977034|NCT00006015|DRUG|fluorouracil|500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
214977035|NCT00006015|DRUG|leucovorin calcium|500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
214977036|NCT00006015|DRUG|oxaliplatin|85 mg/sq m IV infusion over 2 hours Days 1 \& 15 of each cycle
214977037|NCT00866905|DRUG|Ixabepilone|40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
214977038|NCT00866905|DRUG|Cyclophosphamide|600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
214977039|NCT00040599|DRUG|hMN14 (labetuzumab)|
215085192|NCT01113489|DRUG|placebo|1 ml b.i.d.
215085193|NCT05185895|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
215085194|NCT05185895|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
215085195|NCT00012090|DRUG|bicalutamide|
214491714|NCT03621670|BIOLOGICAL|Pediarix|Pediarix (DTPa-HBV-IPV) is to be administered intramuscularly on lower side of the left thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
215085196|NCT00012090|DRUG|goserelin acetate|
215094461|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy|
214491715|NCT03621670|BIOLOGICAL|Hiberix|Hiberix (Hib) is to be administered intramuscularly on lower side of the right thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
214366567|NCT02913664|DRUG|Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)|"Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)"
214366568|NCT02913664|BEHAVIORAL|Aerobic Exercise Training|Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.
214366569|NCT02913664|OTHER|Usual Care|Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
214366570|NCT02913664|BEHAVIORAL|Stretching Exercise|Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
214366571|NCT06350253|DIAGNOSTIC_TEST|Metabolic cart|RMR measurement via metabolic cart
214491716|NCT03621670|BIOLOGICAL|Rotarix|Rotarix (HRV) is to be administered orally as a 2-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) to all subjects in the MenB+PCV group and Placebo+PCV group.
214366572|NCT06350253|DIAGNOSTIC_TEST|MedGem|RMR measurement via MedGem
214366573|NCT06350253|DIAGNOSTIC_TEST|BIA|RMR estimation from BIA analysis
214977040|NCT05030844|BEHAVIORAL|IMB model based Diabetes Education and Motivational Interviewing|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
214366574|NCT06213532|BEHAVIORAL|Smoking Cessation Intervention|Multimedia program administered either remotely or in person
214366575|NCT06213532|OTHER|Saliva Collection|Saliva samples will be collected from each participant
214491717|NCT03621670|BIOLOGICAL|M-M-R II|M-M-R II (MMR) is to be administered subcutaneously on upper side of the right arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
214977041|NCT05824013|DIAGNOSTIC_TEST|thromboelastography (TEG®6s)|blood samples for conventional coagulation test were obtained in vacutainer tubes from an arterial line. Two blood citrate samples (3 ml, sodium citrate solution, Vacuette® Blood Tubes) were also collected for the laboratory conventional coagulation tests (aPTT, INR, D-dimer levels, Antithrombin III) and TEG®6s assessment. The TEG parameters include reaction time (R), clot formation time (K), angle or α (K angle), maximum amplitude (MA), and amplitude at 30 minutes (LY30)
214977042|NCT01492504|DRUG|Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)|Observational study - No Intervention \[(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)\]
214977043|NCT04630223|DIAGNOSTIC_TEST|endocan in umbilical cord blood|After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
214977044|NCT05970250|OTHER|Whole body vibration group|Whole body vibration apparatus (model Power plate -my5tm, made in United States) with frequency 30 - 40 Hz was used for the whole body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum.
214977045|NCT05970250|OTHER|Weight bearing exercises|Electronic treadmill Kettler- marathon model No 7899-800, made in Germany (as form of weight bearing exercises), which was adjusted to the subject's comfortable walking speed. Generally, during the treadmill training, its speed and inclination are electronically adjusted, and it is also provided with a control panel to display the exercise parameters. It allows for the comfortable running without joint or back pains through a perfect combination between aluminium-pertinax running deck, shock absorbers and overall shock-damping design.
214977046|NCT05970250|DRUG|vitamin D supplements and calcium|vitamin D supplements and calcium
215085197|NCT05788315|OTHER|Cultural Formulation Interview|The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.
215085198|NCT01735708|BEHAVIORAL|HIVPASS|
214366576|NCT06213532|OTHER|Survey Administration|Ancillary studies
214491718|NCT03621670|BIOLOGICAL|Varivax|Varivax (VV) is to be administered subcutaneously on upper side of the left arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
214491719|NCT03621670|BIOLOGICAL|Placebo (saline water)|Placebo is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the Placebo+PCV group.
214491720|NCT03621670|BIOLOGICAL|Prevnar 20|Prevnar 20 (PCV13) is to be administered intramuscularly as a booster dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.
214491721|NCT03275285|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214491722|NCT03275285|DRUG|carfilzomib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
215085199|NCT01735708|OTHER|Health Education|
215085200|NCT02190305|DEVICE|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
215085201|NCT01172730|DEVICE|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
215085202|NCT02784015|DRUG|Cisplatin|
215085203|NCT02784015|DRUG|Etoposide|
214977047|NCT05767489|COMBINATION_PRODUCT|electroencephalogram (EEG) and magnetic resonance (MR)|"High-resolution 3D T1 and T2 sequences, acquired in the sagittal plane and MR reconstructed in the remaining orthogonal planes, for morphological assessment of different cortical and subcortical.~EEG tracing involving recording channels such as eye tracking (eye-tracking: electrooculogram, pupillometry, saccades, fixation times on areas predefined areas), performance measures (response times), electrocardiogram and electromyogram proper to clinical acquisition"
214977048|NCT05355285|PROCEDURE|Glucose Clamp|Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.
214977049|NCT02488226|OTHER|Gaze-contingent eye-tracking technology|When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
214977050|NCT00992862|DRUG|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
215085204|NCT02784015|DRUG|Doxorubicin|
215085205|NCT02784015|DRUG|Cyclophosphamide|
215085206|NCT02784015|DRUG|Ifosfamide|
215085207|NCT02784015|DRUG|Carboplatin|
215085208|NCT02784015|RADIATION|Radiotherapy|
215085209|NCT02784015|DRUG|Thiotepa|
215085210|NCT02784015|DRUG|Melphalan|
215085211|NCT01971216|BEHAVIORAL|Relaxation|
214977051|NCT00992862|DRUG|Univasc® 15mg Tablets|
214977052|NCT03055884|DEVICE|tDCS|active tDCS versus sham tDCS
214977053|NCT03055884|BEHAVIORAL|Verbal paired-associate learning task|with or without repeated retrieval practice
214977054|NCT04632004|OTHER|Invitation to participate|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
214977055|NCT00484770|DEVICE|Brain Natriuretic Peptide Levels -- Diagnostic testing|
214366577|NCT01217931|DRUG|Pazopanib|800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.
214366578|NCT01217931|DRUG|Bevacizumab|10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.
214366579|NCT01217931|DRUG|Everolimus|10 mg by mouth once daily. A cycle consists of 4 weeks.
214366580|NCT02021838|OTHER|Lethality Assessment Program|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services.
214366581|NCT02021838|OTHER|Domestic Violence High Risk Team|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services and a team who monitors the clinical and criminal justice progress.
214366582|NCT04895865|BEHAVIORAL|RPE-based load and repetition number selection|Providing trainees with choices regarding the load and the number of repetitions to be performed per set and exercise
214366583|NCT04895865|BEHAVIORAL|Predetermined load and number of repetitions|Trainees predetermine the load and perform ten repetitions per set and exercise
214366584|NCT04862182|DIAGNOSTIC_TEST|Trans-perineal ultrasound|Intrapartum trans-perineal ultrasound in predicting the mode of delivery.
214366585|NCT05872568|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|The recommended dose range is 360 to 720mg,bid
214366586|NCT00063050|BEHAVIORAL|Physical activity and nutrition intervention|
214366587|NCT02515279|DRUG|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
214366588|NCT02515279|DRUG|Ribavirin|1000-1600 mg day orally for 48 weeks.
214366589|NCT02429765|DRUG|ACL/FOR|
214366590|NCT02429765|DRUG|Placebo|
214366591|NCT01417429|DRUG|Galantamine|8mg/a day or placebo
214366592|NCT01417429|DRUG|IV Nicotine|1.0 mg/70 kg of nicotine against saline
214977056|NCT00484770|OTHER|clinical assessment|
214977057|NCT01483638|DRUG|axitinib|5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
214977058|NCT01483638|DRUG|placebo|will be administered orally with the same schedule of axitinib
214977059|NCT01348724|DRUG|[14C] NKTR-118|Single 25 mg oral dose administered on Day 1
214977060|NCT01791985|DRUG|AZD4547 / anastrozole or letrozole|"Patients will continue or restart the NSAI which they have progressed\* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~\*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
214977061|NCT03440476|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
214977062|NCT03440476|BEHAVIORAL|Feedback-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The content is clearly automatically generated.
214977063|NCT03440476|BEHAVIORAL|Feedback-plus-personal-contact booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The email is sent from an individual on the research staff.
214977064|NCT03656627|DRUG|Nivolumab|"Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level."
214977065|NCT05733897|DRUG|hydroxychloroquine|Using hydroxychloroquine to treat nonalcoholic steatohepatitis
214977066|NCT00863382|DEVICE|Standard Event Monitor|Standard Event Monitor
214977067|NCT00863382|DEVICE|Sleuth Monitor|Implantable Sleuth Recorder
214491723|NCT03275285|DRUG|dexamethasone|"Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous"
214491724|NCT05338008|PROCEDURE|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
214977068|NCT02552108|BEHAVIORAL|Behavioural experiments for intolerance of uncertainty (BE-IU)|
214977069|NCT03598400|BEHAVIORAL|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
214977070|NCT03598400|BEHAVIORAL|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
214977071|NCT01309321|BEHAVIORAL|Perinatal Handwashing Promotion|Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
214977072|NCT01309321|BEHAVIORAL|Neonatal Health Promotion|Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
214977073|NCT04204161|BIOLOGICAL|CAR-T19/CAR-T22|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10\^5/kg-2.5x10\^8/kg .
214366593|NCT03528018|DEVICE|REACt system|The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements
214491725|NCT06191679|BEHAVIORAL|Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)|"DECIDES is a developmentally appropriate, engaging, and interactive web-based decision support intervention for AYA diagnosed with cancer (and their caregivers) that includes components written for low health literacy. Components include:~* Education on cancer and cancer treatments, including clinical trials~* An exercise to identify perceived barriers and benefits to treatment options~* An exercise to clarify personal goals for treatment that align with life goals~* Resources to support communication with the oncology health care team"
214491726|NCT04699747|DRUG|F-18 3F4AP|Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
214491727|NCT03656718|BIOLOGICAL|nivolumab|(Subcutaneous) Specified dose on specified days
214366594|NCT03528018|OTHER|Physical therapy|Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
214366595|NCT00226239|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV over 1 hour, day 1
214366596|NCT00226239|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
214366597|NCT00226239|DRUG|Cetuximab|Cetuximab dose will be 250 mg/m\^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
214366598|NCT00226239|PROCEDURE|Radiation Therapy|Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies\>6 MV may be utilized when appropriate to boost target localized centrally.
214366599|NCT02808624|DRUG|L-CARNOSINE|L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
214491728|NCT03656718|DRUG|rHuPH20|Specified dose on specified days Permeation enhancer
214491729|NCT03656718|BIOLOGICAL|nivolumab|(IV) Specified Dose on Specified Days
214491730|NCT04996134|DRUG|Domperidone Oral Product|10-30 mg of oral domperidone administered QID.
214491731|NCT06393725|BEHAVIORAL|Asynchronous Remote Lifestyle Intervention|A 1 year lifestyle intervention based on the Diabetes Prevention Program to be delivered asynchronously via a private Facebook group led by a professional weight loss counselor. In the subsequent year, a Peer-Led Maintenance Phase will occur in which a participant volunteer will lead the group after receiving a brief training.
214491732|NCT06393725|BEHAVIORAL|Synchronous Remote Lifestyle Intervention|A 1 year lifestyle intervention based on the Diabetes Prevention Program to be delivered synchronously via weekly videoconference group meetings led by a professional weight loss counselor. In the subsequent year, a Peer-Led Maintenance Phase will occur in which a participant volunteer will lead the group after receiving a brief training.
214977074|NCT05734261|PROCEDURE|Airway Oscillation System|After each methacholine dose administred, respiratory function will be measured by forced oscillation
214977075|NCT04014530|DRUG|Ataluren + Pembrolizumab|Ataluren and Pembrolizumab combination therapy
214977076|NCT02484014|OTHER|Tarang Adolescence Education programme|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
214977077|NCT02484014|OTHER|SEHER Intervention|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~* Awareness generation activities for all stakeholders in school~* Wall-magazine~* Speak-out box~* Competitions~* School Health Promotion Committee~* School health policies~* Peer groups of students of standard IX~* Workshops and talks for all the students from standard IX, and for teachers~* Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year."
214977078|NCT01155817|DRUG|Nilotinib|200, 400, 800, oral
214977079|NCT03754920|BEHAVIORAL|prolonged fasting|"Fasting for 5 days: Fasting with some fitness regimen, such as meditation and mild physical exercise;~Feeding for 3 days: Gradually distribute participants with rice flour, porridge and juice."
214977080|NCT05418465|DRUG|Huangqi Guizhi Wuwu decoction|Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
214977081|NCT05418465|DRUG|Dapagliflozin|Dapagliflozin, 10mg at a time, once a day. Oral administration.
214977082|NCT01937897|OTHER|Bi-lateral massage|Unilateral massage on the left side of the body.
214977083|NCT01103323|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
214977084|NCT01103323|DRUG|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
214977085|NCT01103323|OTHER|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
214977086|NCT00848523|DRUG|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
214977087|NCT03142945|OTHER|Traditional Physical Therapy|Physical therapy-based interventions
214977088|NCT03142945|OTHER|MDT based physical therapy|MDT based physical therapy
214366600|NCT03756428|PROCEDURE|Deep dry needling in tibialis posterior|The inspector, with gloves, disinfects the area to be treated with 70º alcohol. Once the alcohol is applied, the intervenor locates and takes the myofascial trigger point and places the needle with the guide tube resting on the skin of the patient. The inspector holds the guide tube between the index and middle fingers lightly touch the needle with the index finger of the other hand to insert the needle perpendicularly into the skin, directing it towards the inspector's thumb. Once the needle is inserted subcutaneously, the guide tube is removed. The controller deepens the needle to myofascial trigger point, and makes fast inputs and outputs into it. The rapid exit is made to the subcutaneous cellular tissue, outside the muscle, but not outside the skin. Next, hemostasis is performed in the area. Once this hemostasis is completed, the patient is incorporated and dressed.
214366601|NCT03756428|PROCEDURE|Sham technique in tibialis posterior|The patient lies on the stretcher without the trousers. The interventor, with the guide tube, simulates the technique of puncture in the right twin of the subject. The comptroller cleans the area with 70º alcohol. Once the alcohol is applied, he performs the simulated dry needling technique in a plane with his index and middle fingers with the guide tube. It is important that the subject has his head stuck in the hollow of the head of the stretcher throughout the technique to make a correct masking.
214366602|NCT01800968|DRUG|Liraglutide|Active Drug
214366603|NCT01800968|DRUG|Placebo|Placebo
214366604|NCT02865720|DRUG|CINRYZE 500 U|IV infusion administered twice weekly
214366605|NCT02865720|DRUG|CINRYZE 1000 U|IV infusion administered twice weekly
214366606|NCT04834466|BEHAVIORAL|Pain Level experience during orthodontic treatment|A questionnaire was given to patients who have started their orthodontic treatment to assess their pain level experience
214366607|NCT01426971|DRUG|IBUPROFEN + CAFFEINE|Pharmaceutical form: capsule Route of administration: oral
214366608|NCT01426971|DRUG|IBUPROFEN|Pharmaceutical form: capsule Route of administration: oral
214366609|NCT00050180|DRUG|Midazolam|
214366610|NCT00050180|DRUG|Indinavir|
214366611|NCT00050180|DRUG|Saquinavir|
214366612|NCT01753921|OTHER|this is not an intervention study|Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
214366613|NCT01753921|OTHER|this is not an intervention study|Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
214977089|NCT00372424|DRUG|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
214977090|NCT00372424|DRUG|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
214977091|NCT00372424|DRUG|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
214977092|NCT00072410|BIOLOGICAL|90Y-hu3S193|Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.
214977093|NCT00072410|BIOLOGICAL|111In-hu3S193|Patients received a single dose of 5 mCi 111In-hu3S193 together with the 90Y-hu3S193.
214977094|NCT01458067|DRUG|GSK2636771|Oral capsules
214977095|NCT02358057|DRUG|Dexmedetomidine|
214977096|NCT02358057|DRUG|Alfentanil|
214977097|NCT00480844|DRUG|Sertindole|Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
214977098|NCT00480844|DRUG|Risperidone|Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
214977099|NCT04157361|DIAGNOSTIC_TEST|Collection of breath condensate|Breath condensate will be collected from the patients involved in study.
214977100|NCT06428435|DIAGNOSTIC_TEST|Vision Test|Remote vision testing via digital screen
214977101|NCT05181371|PROCEDURE|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB) for VATS|Programmed Intermittent Bolus (PIB) of Levobupivacaine
214977102|NCT05181371|PROCEDURE|Ultrasound Guided ESP Block with Continuous Infusion (CI) for VATS|Continuous Infusion (CI) of Levobupivacaine
214366614|NCT01753921|DEVICE|MRI|MRI study of the brain will be performed at t=3months.
214977103|NCT06014060|PROCEDURE|24 Months DAPT|All subjects will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 12 months after randomization. The DAPT will last for 24 months after PCI.
214977104|NCT06014060|PROCEDURE|12 Months DAPT|All the subjects will receive aspirin (100 mg/day) + a placebo that is exactly the same in size, color, smell, taste and appearance as clopidogrel for 12 months after randomization. The DAPT will last for 12 months after PCI.
214977105|NCT02956382|DRUG|Ibrutinib|Ibrutinib is dispensed as a capsule.
214977106|NCT02956382|DRUG|Venetoclax|Venetoclax is dispensed as a tablet.
215085212|NCT03833570|DIETARY_SUPPLEMENT|Rapid Release Capsules Melatonin, 10 mg|Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.
214977107|NCT04213014|BEHAVIORAL|Guys/Girls Opt for Activities for Life (GOAL)|The 4 month (16-wk) GOAL intervention has 3 components: (1) After-school GOAL Club: 26 events (2 days/week; 120 min/event/day; 13 weeks due to no club during 3 school break weeks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school for parents and adolescents \[Zoom option if needed\]; 2nd and 3rd meetings delivered virtually and asynchronously for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality each week.
214977108|NCT06460233|PROCEDURE|Bariatric surgery - sleeve gastrectomy|Laparoscopic sleeve gastrectomy performed according to the current surgical standards
214491733|NCT06803303|DEVICE|sonoelastography|"Sonoelastography examination\[10,11\] will be performed using (GE logiqs8,) device system with a high-frequency (a 5-12 MHz linearMHz) linear probe. The procedure will be carried out by a radiologist , who is blinded to the MRI results.~Magnetic resonance imaging (MRI) \[12\] will be performed on the patients in our radiology department using a Philips Achieva 1.5 Tesla superconducting magnet (The Netherlands), shoulder joint MRI protocol included several imaging sequences, included coronal oblique T1 and T2 weighted fast spin-echo, coronal oblique proton density fat suppressed, oblique sagittal T2-weighted spin-echo and axial T1-weighted spin-echo Image evaluation will be conducted by experienced musculoskeletal radiologist, Then we correlate results of sonoelastography to that of MRI ."
214491734|NCT05838846|DRUG|Inhaled Milrinone|Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization, inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.
214491735|NCT05838846|DRUG|IV Milrinone|Patients will receive intravenous milrinone infusion at dosage of 0.3 - 0.75 mcg/kg/min with loading dose of 50 mcg/kg over 10 min. After cross clamp off and temperature of 32 degree, Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
214491736|NCT00214708|PROCEDURE|Screening for Tuberculosis|
214491737|NCT06792903|DRUG|CG101 high dose + artificial tear|Patient in this group received high dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive placebo CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
214491738|NCT06792903|DRUG|CG101 low dose + artificial tear|Patient in this group received low dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive high dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
214977109|NCT06404970|OTHER|Screening intervention|Intervention to improve identification and management of functional impairment among older Veterans in VA primary care settings. Intervention includes 5 components: (1) routine, standardized functional status measurement; (2) nursing screening followed by follow-up primary care provider assessment; (3) electronic tools and templates to facilitate screening, assessment, and documentation; (4) interprofessional educational session; (5) tailored reports on functional status
214977110|NCT06404970|OTHER|Standard bundle of implementation strategies|Standard strategies include champions plus system-level audit and feedback
214977111|NCT06404970|OTHER|Enhanced bundle of implementation strategies|Enhanced strategies include technical assistance plus clinician-level audit and feedback
214977112|NCT06312800|DRUG|Acamprosate|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
215085213|NCT03833570|DRUG|Miconaz oral gel|Antifungal agent
215085214|NCT03833570|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
215085215|NCT03833570|DRUG|Oracure gel|Topical analgesic gel
215085216|NCT03833570|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
215085217|NCT04883528|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
215085218|NCT04883528|DRUG|Placebo|sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
214977113|NCT06312800|DRUG|Placebo|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
214977114|NCT06312800|DRUG|Methazolamide|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
215085219|NCT00607854|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
215085220|NCT01573637|DRUG|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
215085221|NCT01573637|DRUG|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
215085222|NCT00382915|DEVICE|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
215085223|NCT04711941|BEHAVIORAL|Rehabilitation training|Rehabilitation with behavioural stimuli
215085224|NCT05531721|OTHER|Observation|Observation and retrospective data collection
214366615|NCT03266770|DEVICE|RELIEF Stent|The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).
214366616|NCT00281710|DRUG|Methylprednisolone|
214366617|NCT00796692|DRUG|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
214366618|NCT00796692|DRUG|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
214366619|NCT02021175|BEHAVIORAL|Tailored CBME Therapy via Technology|6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
214366620|NCT02021175|OTHER|Standard of Care|Referral to currently available resources for 6 sessions of a standard smoking cessation approach
214977115|NCT05315440|OTHER|graston tecnique|Graston technique involves the use of steel tools that are used non-invasively on the skin to identify and treat areas that have stiffness or inflammation. These areas can be located with greater precision than the manual technique precisely because the instruments do not compress in contact with the patient's skin, as is the case with the physiotherapist's fingertips. Thanks to the instruments it is therefore possible to detect the areas of altered consistency and to treat them by pressing a minimum pressure.
214977116|NCT05315440|OTHER|Conventional rehabilitation|30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
214977117|NCT04156126|OTHER|Blood Collection|Blood Collection
214977118|NCT05556980|PROCEDURE|totally laparoscopic distal gastrectomy|all the surgical procedure would be finished under laparoscopy
214977119|NCT02314728|DRUG|Misoprostol|Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
214977120|NCT02314728|DRUG|Oxytocin|Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
214977121|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 5 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 5 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
215085225|NCT00374894|DRUG|2,3-dimercaptosuccinic acid|
215085226|NCT00725244|DEVICE|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
214366621|NCT04130568|DIAGNOSTIC_TEST|INO survey|Garvin's Learning organisation tool
214491739|NCT06792903|DRUG|placebo + artificial tear|Patient in this group received placebo dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive low dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
214491740|NCT03211247|BIOLOGICAL|Part A Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
215085227|NCT00725244|DEVICE|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
215085228|NCT00461994|BEHAVIORAL|diet|
215085229|NCT00461994|BEHAVIORAL|exercise|
215085230|NCT00461994|BEHAVIORAL|diet and exercise|
214491741|NCT03211247|BIOLOGICAL|Part A Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
214491742|NCT03211247|BIOLOGICAL|Part A Placebo|Placebo patch, once daily
215085231|NCT03052140|DEVICE|Lamelleye Dry Eye Drops|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
215085232|NCT03052140|DEVICE|Optive Plus|Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
215085233|NCT02402686|DRUG|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
215085234|NCT04399954|DIETARY_SUPPLEMENT|Ketoflo|Ketoflo is a ready to use liquid feed for the dietary management of epilepsy and other conditions that may require a ketogenic diet. It has a 4:1 ratio of fat to carbohydrate and protein and can be administered enterally via a tube feeding or oral consumption.
214977122|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 10 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
214977123|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 20 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
214977124|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 30 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
214977125|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 15 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
214977126|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
214977127|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment (first 3 trial participants in the Expansion Cohort only; subsequent patients started treatment at Cycle 1, Day 1).~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
214977128|NCT03118934|DEVICE|Lotrafilcon B multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily wear basis and cared for with participant's habitual lens care solution
214977129|NCT03118934|DEVICE|Nelfilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
214977130|NCT03118934|DEVICE|Delefilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
214977131|NCT00842634|BIOLOGICAL|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
214977132|NCT00842634|OTHER|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
214977133|NCT06108999|DEVICE|Connettivina BIO cream and gauze|Connettivina Bio cream and gauze-pad efficacy and tolerability will be evaluated in the management of acute or chronic wounds of different etiology, according to instruction for use. Only one wound per patient will be considered for the treatment according to the study protocol. The schedule treatment will consist on a daily medication changes, according to the instruction for use and the clinical practice, for a maximum of 7 Visits.
214977134|NCT00758446|DRUG|BLX-028914|50 mg capsules, p.o, daily, 14 days
214977135|NCT00758446|DRUG|BLX-028914|15 mg capsules, p.o, daily, 14 days
214977136|NCT00758446|DRUG|placebo|capsules, p.o, daily, 14 days
214977137|NCT00248209|DRUG|Wellbutrin XL|Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
214977138|NCT03962621|RADIATION|Fotona 4D 1064 nm laser|The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
214366622|NCT03663686|DRUG|Litapiprant Tablet|Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
214977139|NCT03962621|RADIATION|Fotona 4D 2940 nm laser|Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass
214977140|NCT00914134|DRUG|Levodopa infusion|Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
214977141|NCT03718715|DRUG|Metformin|Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
214977142|NCT05916898|DEVICE|PCI with support of Shockwave Intravascular Lithotripsy|Coronary artery angioplasty of the primary lesion or optimization of the previously implanted stent with the support of Shockwave Intravascular Lithotripsy device
214977143|NCT04609683|DEVICE|AleriTM sensors|"AleriTM sensors are worn on the bicep or forearm and communicates through BLETM to a mobile App. The data is sent through the mobile App to web-based system processing where PHI is calculated and sent back to the mobile App.~The AleriTM sensor has a form factor similar to a conventional arm band, with a hockey puck shape of approximately 48mm in diameter and 15mm in thickness the AleriTM sensor is a non-significant risk (NSR) device as it does not meet the definition of significant risk device (21 CFR 812.3(m)) because it is: not an implant; is not purported or represented to support or sustain human life; its use is not of substantial importance in the diagnosis, cure, treatment, mitigation, or prevention of impairment of health; and it does not present a serious risk to the health, safety, or welfare of a subject."
214977144|NCT02895347|BEHAVIORAL|Surgical Simulation Practice Modules|The surgical simulation practice modules simulate surgical settings for suturing.
214977145|NCT03421938|OTHER|Walking Exercise|Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..
214977146|NCT02610517|BEHAVIORAL|Provider Training|All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
214977147|NCT02610517|BEHAVIORAL|Patient Intervention|Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
214977148|NCT01542450|DRUG|insulin detemir|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
214977149|NCT01542450|DRUG|insulin NPH|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
215085235|NCT04388046|DEVICE|Herbst fixed functional appliance|Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
215085236|NCT05343234|DRUG|Placebo|tree different placebo drugs with tree different names and scheduled will be given
215085237|NCT05352269|BIOLOGICAL|XBI-302|Fecal Microbiota Transplantation Capsules
214366623|NCT04118244|DIAGNOSTIC_TEST|lung recruitment maneuver|The ventilator was switched to pressure control ventilation, inspiratory time was increased to 50%, the peak inspiratory pressure gradient (above PEEP) was set at 15cm H2O, and PEEP was progressively increased to obtain a stepwise increase of peak inspiratory to 20, 25, and 30 cm H2O every three breaths. The final recruiting pressure of 30 cm H2O was applied for six breaths.
214366624|NCT05741216|OTHER|OTF Ocular Lubricant|Ocular lubricant in 1 of 3 test formulations
215085238|NCT05352269|BIOLOGICAL|XBI-302 Placebo|XBI-302 Placebo
215085239|NCT02590601|DRUG|Bromocriptine|
215085240|NCT02590601|OTHER|Guideline-driven medical therapy (GDMT)|
215085241|NCT03558074|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
215085242|NCT01544413|PROCEDURE|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
214366625|NCT05741216|OTHER|Ocular Lubricant|Commercially available ocular lubricant
214366626|NCT04360525|OTHER|Reasons|Causes of sigmoid volvulus
214366627|NCT03953339|PROCEDURE|Release or no release of the suprascapular nerve|
214366628|NCT00543595|DRUG|MK0916|
214366629|NCT04450602|DIETARY_SUPPLEMENT|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
214977150|NCT04028726|OTHER|Back-squat exercise|Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.
214977151|NCT03621033|PROCEDURE|colonic transendoscopic enteral tubing|The procedure colonic transendoscopic enteral tubing is as follows:The TET tube was inserted into the ileocecal junction through the endoscopy channel at the first time of the cecal intubation after examination and evaluation of the whole colon. Then, the colonoscope was removed from the colon while the TET tube was maintained at the ileocecal junction. Then the endoscopy was inserted into the ileocecum again for affixing the TET tube to cecum with titanium clips.
214977152|NCT02589145|DRUG|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I."
214977153|NCT02589145|DRUG|Vorinostat|1000 mg by mouth on Days -9 to -2.
214977154|NCT02589145|DRUG|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
214977155|NCT02589145|DRUG|Busulfan|"Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
214977156|NCT02589145|DRUG|Melphalan|60 mg/m2 by vein on days -3 and -2.
214977157|NCT02589145|DRUG|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
214977158|NCT02589145|DRUG|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
214977159|NCT02589145|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
214977160|NCT02589145|DRUG|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
214977161|NCT02589145|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
214977162|NCT02589145|DRUG|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
215085243|NCT05787132|OTHER|Balance Board therapy|Balance board therapy will be performed. balance board therapy has been shown to improve the sitting balance in children with cerebral palsy
214491743|NCT03211247|BIOLOGICAL|Part B Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
214977163|NCT02589145|PROCEDURE|Stem Cell Transplant|Stem cell transplant performed on Day 0.
214977164|NCT02589145|DRUG|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
214491744|NCT03211247|BIOLOGICAL|Part B Placebo|Placebo patch, once daily
214977165|NCT05739487|PROCEDURE|selective intra-arterial thrombolysis|IAT introduces rt-PA (50mg) directly into the ophthalmic circulation by super-selective microcatheterization
214977166|NCT00142649|BEHAVIORAL|diet|
214977167|NCT00142649|BEHAVIORAL|physical activity|
214977168|NCT04385433|DRUG|EXPERIMENTAL ARM|"Patients in the experimental arm will receive:~* Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
214977169|NCT04385433|OTHER|CONTROL GROUP|"Patients in the standard arm will receive:~* Daily placebo during 12 months (placebo initiation: first day of radiotherapy)~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
214977170|NCT04385433|RADIATION|Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)|Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
214977171|NCT01707888|PROCEDURE|Thoracoscopy/VATS|Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
215085244|NCT05787132|OTHER|Perceptual Motor therapy|Perceptual motor therapy will be performed, it has been shown to improve dynamic sitting in children with cerebral palsy.
215085245|NCT02610933|DRUG|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
215085246|NCT02610933|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2 supplementation
215085247|NCT03246490|OTHER|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
215085248|NCT02099305|OTHER|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
215085249|NCT01281228|DRUG|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
214977172|NCT03177148|BEHAVIORAL|Intervention by Clinicians|"•Parents will complete surveys after enrollment and at the end of intervention and participate in intervention visits by pediatric clinicians and telephonic counseling with Registered Dietitians (RDs).~Intervention by pediatric clinicians: up to 4 sessions of MI, in-person Intervention by RDs: up to 6 sessions of MI via telephone."
215085250|NCT01281228|DRUG|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
214977173|NCT03177148|BEHAVIORAL|Usual Care|Pediatric clinicians provide care as normal
214977174|NCT04990193|OTHER|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.
214977175|NCT04990193|OTHER|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was applied for eight hours every day for twelve consecutive weeks.
214977176|NCT04474886|DIETARY_SUPPLEMENT|Fresubin® powder fibre|2 servings per day
215085251|NCT01281228|DRUG|placebo|saline infusion
215085252|NCT04602767|DRUG|Vasopressin|Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP \< 65 mmHg
214366630|NCT04450602|OTHER|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
214366631|NCT04450602|OTHER|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
214366632|NCT04450602|OTHER|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
214977177|NCT02361775|DEVICE|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
214977178|NCT02361775|DEVICE|opioid iv pca|opioid pca consisting of hydromorphone
214977179|NCT02361775|DRUG|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
214977180|NCT02361775|DEVICE|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
214977181|NCT06410651|COMBINATION_PRODUCT|Nimotuzumab with chemoradiotherapy|Radiotherapy, 40-50.4Gy/20-28f. Nimotuzumab 400mg, ivgtt, W2d. Chemotherapy, S-1, 40-60mg/m2, on BSA，orally twice daily on radiotherapy days.
214977182|NCT02843126|DRUG|Trastuzumab|Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)
214977183|NCT02843126|BIOLOGICAL|NK immunotherapy|For each procedure, 10 billion cells will be infused for 4 times
214977184|NCT04522219|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|Acquisition of contrast enhanced ultrasound. Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients
214977185|NCT05923047|DRUG|Mepolizumab|Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment
215085253|NCT04602767|DRUG|Phenylephrine|Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP \< 65 mmHg
214977186|NCT05923047|PROCEDURE|Polypeptomy|This group will undergone in-office nasal polypectomy.
215085254|NCT00275756|DRUG|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp \& Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
215085255|NCT00275756|DRUG|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp \& Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
215085256|NCT00275756|DRUG|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
215085257|NCT00275756|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
215085258|NCT00275756|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
215085259|NCT00275756|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
215085260|NCT01406015|DRUG|Spironolactone|50 mg once daily for 6 weeks.
214977187|NCT03724357|DRUG|Vaxchora|One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
215085261|NCT01406015|DRUG|Placebo|Placebo-matching spironolactone once daily for 6 weeks.
215085262|NCT01840358|OTHER|Observation of hypoglycemias frequency 3 days before and after pump initiation|
215085263|NCT01755650|RADIATION|18F FPM|
214977188|NCT03237897|BEHAVIORAL|Preoperative education class|The preoperative enhanced recovery after surgery education class will be offered twice a week in coordination with anesthesia preoperative appointments to minimize inconvenience for patients. Patients will need to attend only one class. All participants will be offered the class. This class will be one hour in duration and will be taught by a surgical advanced care practitioner familiar with the details of colorectal surgery. The class will include detailed information about preoperative care, intraoperative care, and postoperative care.
215085264|NCT04179513|BIOLOGICAL|GB224 10mg|"10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
214977189|NCT03237897|BEHAVIORAL|Pedometer|A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge
214977190|NCT05582278|DRUG|D-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
214977191|NCT05582278|DRUG|HAIC|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
214977192|NCT05582278|DRUG|Lenvatinib|12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg
214977193|NCT05582278|DRUG|tislelizumab|tislelizumab 200 mg, every 3 weeks.
214977194|NCT00254553|DRUG|Testim 1% (testosterone gel)|Testim\_ 100 mg: two tubes of 50 mg of Testim\_per day
215085265|NCT04179513|BIOLOGICAL|GB224 20mg|"20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
214366633|NCT04450602|DIETARY_SUPPLEMENT|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
214366634|NCT04450602|OTHER|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
214366635|NCT04450602|OTHER|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
214977195|NCT00254553|DRUG|Placebo|two tubes of placebo per day
215085266|NCT06366542|OTHER|Vestibular Rehabilitation Therapy (VRT)|The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.
214977196|NCT00331838|DRUG|Semuloparin sodium|"0.8 mL solution in Type I amber glass vials~Subcutaneous injection"
214977197|NCT00331838|DRUG|Placebo (for Enoxaparin sodium)|"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
214977198|NCT00331838|DRUG|Enoxaparin sodium|"0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection"
215085267|NCT06366542|OTHER|Virtual reality exercises|The VR exercises included watching theraputic videos using the virtual reality goggles with static and dynamic balance exercises.
215085268|NCT06366542|OTHER|Optokinetic Stimulation exercises|Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.
215085269|NCT00050973|DRUG|bexarotene|
215085270|NCT00394901|DRUG|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
214977199|NCT00331838|DRUG|Placebo (for Semuloparin sodium)|"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
214977200|NCT02123719|OTHER|Surgery|
214977201|NCT02456194|DEVICE|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
214977202|NCT00742911|DRUG|Disulfiram|"Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram."
214977203|NCT00742911|DRUG|Copper Gluconate|"Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily"
215085271|NCT00394901|DRUG|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
215085272|NCT00394901|DRUG|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
215085273|NCT00394901|DRUG|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
215085274|NCT00144924|PROCEDURE|laparoscopy pyloromyotomy|laparoscopic pyloromyotomy
215085275|NCT00144924|PROCEDURE|open pyloromytomy|open pyloromyotomy
215085276|NCT01467115|RADIATION|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
215085277|NCT01467115|DRUG|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
214977204|NCT01419314|DEVICE|Splinting application to the lower extremities|Walkabout™ splints (Don Joy Orthopedics, Vista, CA, USA) will used in the splinting treatment. The Walkabout splint is a one-piece injection molded walking boot fitted with a rocker bottom allowing for ambulation. The participants will be fitted and instructed to wear the bilateral LE splints to sleep for the duration of the study (6 weeks).
214977205|NCT01419314|DEVICE|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study (6 weeks).
214977206|NCT01439035|DEVICE|MGH OFDI Imaging|Imaging of Duodenum with OFDI system
215085278|NCT01467115|BIOLOGICAL|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
215085279|NCT01467115|DRUG|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
215085280|NCT01467115|DRUG|Erythropoetin|Subcutaneous or intravenous
215085281|NCT01467115|DRUG|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
215085282|NCT01467115|DRUG|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
214366636|NCT04450602|OTHER|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
214366637|NCT05724355|DRUG|Dalpiciclib Isetionate Tablets, Camrelizumab|Dalpiciclib, D1-21, po, 150mg, qd, Q4W. Camrelizumab, iv, 200mg, D1, Q3W.
214366638|NCT04726020|OTHER|Intensive monitoring|periodic and planned monitoring nurse intervention with phone call
214366639|NCT04726020|OTHER|Standard monitoring|standard monitoring of adverse event reaction
214977207|NCT01945983|DRUG|Early norepinephrine|Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
214977208|NCT01945983|DRUG|Placebo|5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
214977209|NCT00965237|DEVICE|lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
214977210|NCT00965237|DEVICE|lotrafilcon B single vision contact lens|Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use
214977211|NCT00965237|OTHER|Over-reader spectacles|Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
214366640|NCT03325543|OTHER|Visual observation|Verbal instructions about the anatomy, function and how to perform the pelvic floor muscle contraction
214366641|NCT03325543|OTHER|Vaginal palpation (bidigital touch)|The physiotherapist touched the patients' perineal region (vulva, tendinous centre of the perineum and external region of the anal canal) with a spatula and asked them to identify the pointed region; and with the digital palpation, the physiotherapist touched the tendinous centre of the perineum, pressing it in the cranial direction, and instructed the patients to contract the pelvic floor muscle
214977212|NCT05185466|BEHAVIORAL|Nurse-Supported Self Management Programme|Training and incentives to improve nutrition habits and sleep health.
215085283|NCT01467115|DRUG|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
214366642|NCT04767867|OTHER|Pre-oxygenation|"Induction of anaesthesia after 2mins 45 seconds of pre-oxygenation with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions commenced until study conclusion.~Positive pressure ventilation commenced at Sp02 92%. Failure to intubate the patient during the first minute of apnoea results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after one minute of apnoea, and every two minutes during the apnoeic period."
214366643|NCT02706860|DRUG|Atorvastatin|
214366644|NCT02220894|BIOLOGICAL|pembrolizumab|
214366645|NCT02220894|DRUG|carboplatin|
214977213|NCT06080009|GENETIC|exome sequencing (retrospective) and exome and methylome sequencing (prospective)|"Three to nine sections will be used as the source of DNA for each tumor. The pathologist will identify and separate tumor tissue from normal tissue, and the two DNAs will be sequenced separately. Variants obtained from tumor and normal tissue will be compared, with different outcomes. Expected in this way are 1) somatic/tumor-specific variants (which are absent in normal tissue), 2) variants lost during tumor evolution due to segmental chromosomal deletion or other mechanisms that cause loss of heterozygosity. Using these two classes of variants, a clustering analysis will be performed at the end of the sequencing project to better define the phenotype and molecular signature of the tumors. In the prospective part of the project, the new tumors will be frozen fresh. This resource will allow methyloma analysis to be performed."
214977214|NCT05798715|DRUG|Gleptomet 50/1000(Metformin HCl & Sitagliptin)|Test drug
214977215|NCT05798715|DRUG|Janumet 50/1000(Metformin HCl & Sitagliptin)|Reference drug
214977216|NCT02926963|OTHER|samples collection : hair and skin biopsy|
214977217|NCT05947669|DRUG|Infliximab|Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.
214977218|NCT05947669|DRUG|Methylprednisolone|Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
214977219|NCT05947669|DRUG|Prednisolone|Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
214977220|NCT00732069|DRUG|Placebo|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
214977221|NCT00732069|DRUG|Ramipril|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
215085284|NCT04937335|OTHER|intratumoral hemorrhage|Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
215085285|NCT04288258|BEHAVIORAL|Telehealth-Based Health and Wellness Program (POWERS-TBI)|The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
215085286|NCT05302258|DIAGNOSTIC_TEST|Attenuation imaging in ultrasonography|Attenuation imaging in ultrasonography
215085287|NCT01503996|BEHAVIORAL|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
215085288|NCT05561465|PROCEDURE|Pterygomaxillary disjunction with interposition Y-shape plate|All patients will be treated under general anesthesia. The pterygoid plate will be fractured, pried up, and pushed backward. A Y-shape plate will be fixed to the lateral maxillary surface with its vertical limb and the other two limbs are turned to fit into the retro maxillary space preventing the reattachment of the fractured pterygoid plate
215085289|NCT00777400|DRUG|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
215085290|NCT01749592|DEVICE|cochlear implant|Surgical implantation of a cochlear implant device
215085291|NCT02448888|OTHER|Adapted exercise|2 months, 3 times/week
215085292|NCT02448888|OTHER|General exercise recommendations|2 months, 3 times/week
215085293|NCT05109221|DEVICE|ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients
214366646|NCT02220894|DRUG|paclitaxel|
214366647|NCT02220894|DRUG|pemetrexed|
214366648|NCT00293683|DEVICE|Insorb absorbable skin staple|
214366649|NCT05007392|DRUG|Dotinurad|Dotinurad oral tablets.
214366650|NCT05007392|DRUG|Febuxostat|Febuxostat oral tablets.
214366651|NCT05007392|OTHER|Dotinurad Matched Placebo|Dotinurad matched placebo oral tablets.
214366652|NCT05007392|OTHER|Febuxostat Matched Placebo|Febuxostat matched placebo oral tablets.
214366653|NCT01494844|DEVICE|Respiratory monitor patient interface.|Wear each interface for 20 minutes
214366654|NCT01844752|DRUG|NVN1000 1% Gel|Twice daily NVN1000 1% Gel for 12 weeks
214366655|NCT01844752|DRUG|NVN1000 4% Gel|Twice daily NVN1000 4% Gel for 12 weeks
214366656|NCT01844752|DRUG|Vehicle Gel|Twice daily Vehicle Gel for 12 weeks
214366657|NCT05405959|DEVICE|Kinesio tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
214366658|NCT05405959|DEVICE|Sham Kinesio Tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
214366659|NCT03344224|DIAGNOSTIC_TEST|laboratory test|laboratory test
214366660|NCT06296576|PROCEDURE|arterial ultrasound scan|An arterial ultrasound scan of the lower limbs with pulsed Doppler analysis of arterial flow spectra over the abdominal aorta, dorsal artery of the foot and lateral plantar artery, bilaterally
214977222|NCT00732069|DRUG|Valsartan|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
214977223|NCT00577317|PROCEDURE|Management of Therapy Complications|Receive standard home maintenance therapy and perform self-manual lymphatic drainage
214977224|NCT00577317|PROCEDURE|Management of Therapy Complications|Receive Flexitouch home maintenance therapy
214977225|NCT00577317|OTHER|Quality-of-Life Assessment|Ancillary studies
214977226|NCT03640169|OTHER|Health management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
214977227|NCT04460326|DRUG|Insulin glargine|Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10%
214977228|NCT04460326|DRUG|NovoLog|Novolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
214977229|NCT04460326|DRUG|Insulin Fiasp|Fiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
214977230|NCT04460326|OTHER|Standard carbohydrate diet|Standard carbohydrate diet as per usual hospital care (75g with each meal)
214977231|NCT06209073|OTHER|Virtual Reality exercise|after explaining the treatment method for patients, the patients will perform full body aerobic exercise by applying kick boxing to destroy walls of rock; the patient moves most of body muscles in this game. He or she flex and extend the shoulder and the elbow with flexion and extension in the knee. squatting exercise, endurance exercise, coordination for arm and shoulder exercise will also performed in virtual reality
214977232|NCT06209073|OTHER|conventional treatment|the patients will receive conventional treatment in the form of aerobic exercise, resistance exercise and endurance exercise.
214977233|NCT00631254|PROCEDURE|Allergen challenge|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
214977234|NCT00631254|PROCEDURE|Allergen challenge|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
214977235|NCT01331369|BEHAVIORAL|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
214977236|NCT01331369|OTHER|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
214977237|NCT02209363|DEVICE|auto-adjusting positive airway pressure|nightly use for 6 months
214977238|NCT02209363|OTHER|Nasal dilator strips|nightly use for 6 months
215085294|NCT03801330|OTHER|Usual Care Pulmonary Rehabilitation Program|Participants in the Usual Care Pulmonary Rehabilitation Program group will complete an 8 week clinic based Pulmonary Rehabilitation Program (usual care).
215085295|NCT03801330|OTHER|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete an 8-week home-based Pulmonary Rehabilitation Program using a software app (software)
214366661|NCT02446158|DRUG|Chlorhexidine gluconate|The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
214366662|NCT05977231|PROCEDURE|BT|A program of BT (including exercise and muscle training)
214977239|NCT01345812|DRUG|HP-HMG|100 - 300 IU for stimulation of women in ART treatment
214366663|NCT05977231|PROCEDURE|bPFMT|A bPFMT program at home
214366664|NCT05977231|PROCEDURE|iVES|An iVES program at home
214366665|NCT05977231|PROCEDURE|BT + bPFMT|Combination of BT and bPFMT
214366666|NCT05977231|PROCEDURE|BT + iVES|Combination of BT and iVES
214366667|NCT05977231|PROCEDURE|bPFMT + iVES|Combination of bPFMT and iVES
214366668|NCT06379919|PROCEDURE|Irrisept Irrigation|Irrisept Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device. Irrisept contains 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United Staes Pharmacopeia (USP). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle.
214366669|NCT06379919|PROCEDURE|Saline Irrigation Solution Delivery|Normal saline is isotonic and the most commonly used wound irrigation solution due to safety (lowest toxicity) and physiologic factors.
215085296|NCT01157208|OTHER|Diet A|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
214977240|NCT01345812|DRUG|recombinant FSH|100 -300 IU for stimulation of women in ART treatment
214977241|NCT00004293|DRUG|glucocerebrosidase|
214977242|NCT03686072|PROCEDURE|Cataract surgery with endoscopic goniosynechialysis|Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
214977243|NCT02151617|DRUG|PF-06743649|40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
214977244|NCT02151617|DRUG|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
214977245|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
214977246|NCT02151617|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
214977247|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
214977248|NCT02151617|DRUG|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
215085297|NCT01157208|OTHER|Diet B|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
215085298|NCT03564405|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
214977249|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
214977250|NCT02151617|DRUG|Placebo|Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
214977251|NCT02151617|DRUG|PF-06743649|Tablet, to be decided dose, once daily, 14 days
215085299|NCT00074373|OTHER|No intervention; observational|
215085300|NCT02662114|OTHER|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
215085301|NCT01886690|DRUG|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
215085302|NCT01886690|DRUG|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
215085303|NCT02360293|BEHAVIORAL|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
215085304|NCT02360293|BEHAVIORAL|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
215085305|NCT02671149|DIETARY_SUPPLEMENT|Water|Participants will receive two cups of 150ml plain water
214366670|NCT02453685|DRUG|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
214366671|NCT02453685|DRUG|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
215085306|NCT06466993|BEHAVIORAL|Intervention of standardized relaxing breathing|Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start
214977252|NCT02151617|DRUG|Placebo|Tablet, once daily, 14 days
214977253|NCT00583310|BEHAVIORAL|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
214977254|NCT06255080|OTHER|Training intervention|"The intervention consists of making the intervention group practice till proficiency using the 2019-version.~The control group practices till they have reached proficiency using the standard 2016-version.~We wanted to compare time to completetion for the intervention. For the follow-up test we invited all participants to return after 4-6 weeks (where no training was allowed) and made them practice till proficiency again using the standard 2016-version. Time to reach proficiency for the follow-up test was compared."
214977255|NCT03160716|DEVICE|Restylane Lyft with Lidocaine|a sterile gel of hyaluronic acid (HA)
214977256|NCT01443169|DRUG|Sequence 1 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977257|NCT01443169|DRUG|Sequence 1 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977258|NCT01443169|DRUG|Sequence 1 - Treatment C:Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214366672|NCT02453685|DRUG|insulin aspart|Injected s.c./subcutaneously once daily.
214977259|NCT01443169|DRUG|Sequence 1 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
215085307|NCT05562362|DRUG|RE-021, sparsentan|RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
214977260|NCT01443169|DRUG|Sequence 1 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
214977261|NCT01443169|DRUG|Sequence 2 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977262|NCT01443169|DRUG|Sequence 2 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
214977263|NCT01443169|DRUG|Sequence 2 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977264|NCT01443169|DRUG|Sequence 2 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977265|NCT01443169|DRUG|Sequence 2 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
214977266|NCT01443169|DRUG|Sequence 3 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977267|NCT01443169|DRUG|Sequence 3 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977268|NCT01443169|DRUG|Sequence 3 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
214977269|NCT01443169|DRUG|Sequence 3 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977270|NCT01443169|DRUG|Sequence 3 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
214977271|NCT01443169|DRUG|Sequence 4 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
214977272|NCT01443169|DRUG|Sequence 4 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977273|NCT01443169|DRUG|Sequence 4 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977274|NCT01443169|DRUG|Sequence 4 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
214977275|NCT01443169|DRUG|Sequence 4 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
214977276|NCT01831895|DEVICE|MobiusHD™|Implant that is placed in the carotid sinus to control hypertension.
214977277|NCT04036721|DRUG|Prolonged glucocorticosteroid (prednisone) regimen|Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
214977278|NCT04036721|DRUG|Short glucocorticosteroid (prednisone) regimen|Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
214977279|NCT05662020|BIOLOGICAL|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|9-19 years group (3 doses) and 20-26 years group (3 doses) will be vaccinated at months 0, 2, 6. 9-14 years group (2 doses) will be vaccinated at months 0, 6.
214977280|NCT05662020|BIOLOGICAL|GARDASIL® 9|20-26 years possitive control group will be vaccinated at months 0, 2 and 6
214977281|NCT02928796|BEHAVIORAL|Cognitive Stimulus|Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.
214977282|NCT04794751|DEVICE|JJVC Investigational Multifocal Contact Lens|senofilcon A C3
214977283|NCT04794751|DEVICE|Dailies Total 1® Multifocal Contact Lens|delefilcon A
214977284|NCT00914407|DRUG|Oxygen|100% Oxygen inhalation for 30 minutes
215085308|NCT02576665|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
215085309|NCT02576665|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
214366673|NCT02622165|BEHAVIORAL|The REWARD serious game intervention|The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
214977285|NCT04426097|PROCEDURE|Cervical Vagal Blockade|Cervical Vagal Blockade with 0.5 % ropivacaine 2.5 ml and 2% xylocaine 2.5 ml
214679830|NCT05365620|DEVICE|Mechanical In-Line Inexsufflation|In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.
214679831|NCT05365620|PROCEDURE|catheter suction|catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
214977286|NCT04426097|PROCEDURE|Without Blockade|Without Blockade
214977287|NCT04892732|DRUG|Budesonide|Budesonide dispensing claim is used as the reference group.
214977288|NCT04892732|DRUG|Budesonide-Formoterol|Budesonide-Formoterol dispensing claim is used as the exposure group.
214977289|NCT02395068|DRUG|Nimotuzumab|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.
215085310|NCT04316741|BEHAVIORAL|Snapcoach|A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
215085311|NCT03216486|DRUG|BPS804|IV administration of BPS804 in 5% Dextrose solution
215085312|NCT05647668|PROCEDURE|Laparoscopic fundoplication|Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
215085313|NCT06305715|DEVICE|Radiation Therapy|Enrolled subjects will be given radiation doses, at the discretion of the treating physicians, that range from 24-60 Gy in 1-15 fractions with a minimum biologically effective dose (BED\^10) of 58 Gy.
215085314|NCT06305715|DRUG|Targeted TKI therapy|Immediately following radiation therapy, subjects with an actionable driver mutation will receive a standard-of-care TKI. The choice of TKI will be at the discretion of the treating oncologist.
215085315|NCT01058135|OTHER|Hi-maize starch (Low dose)|resistant starch
214366674|NCT02925611|DRUG|Isoflurane|
214366675|NCT02925611|DRUG|Desflurane|
214366676|NCT00453986|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose
214366677|NCT00453986|BIOLOGICAL|Mencevax™ACWY|One subcutaneous dose
214366678|NCT00453986|BIOLOGICAL|Fluarix™|One intramuscular dose
214366679|NCT00303862|DRUG|cediranib maleate|Given orally
214366680|NCT00303862|OTHER|laboratory biomarker analysis|Correlative studies
214977290|NCT02395068|DRUG|irinotecan|"Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.~Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h"
214977291|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation|One dose of the full-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The full-strength conjugate vaccine consists of 25 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
215085316|NCT01058135|OTHER|Hi-maize starch (High-dose)|resistant starch
215085317|NCT01058135|OTHER|Control (starch)|rapidly digestible starch
215085318|NCT02273713|DRUG|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
214366681|NCT02778100|DRUG|Nasal Glucagon|Administered intranasally.
214366682|NCT02778100|DRUG|Oxymetazoline|Administered intranasally.
214366683|NCT01001052|DRUG|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
214366684|NCT00825266|DRUG|bosentan|Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
214977292|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation|One dose of the half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The half-strength conjugate vaccine consists of 12.5 mcg of Salmonella Enteritidis, 12.5 mg of Salmonella Typhimurium, and 25 mcg of Salmonella Typhi Vi.
215085319|NCT04833153|BEHAVIORAL|Person-First - Please (PFP)|PFP takes 10 weeks and consist of four modules: Information, Person, Autonomy and Dignity. Information module takes 1 hour contact on first week. The other modules will follow every third weeks, starting from week 2. So that on week 2, 5 and 8 researcher meet nurses in 4 hours education session. Between the modules, nurses can take contact online to the researcher.
215085320|NCT03043677|BIOLOGICAL|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
214366685|NCT00825266|DRUG|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
214977293|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation|One dose of the dilutional half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The dilutional half-strength conjugate vaccine consists of 12.5 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
214977294|NCT05525546|OTHER|Placebo|One dose of placebo is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The placebo consists of sterile phosphate-buffered saline (PBS) solution containing polysorbate 80, and 2-phenoxyethanol preservative.
214977295|NCT04321902|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
214977296|NCT02383524|PROCEDURE|Lumbar Radiofrequency Medial Branch Neurolysis|Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
214977297|NCT04297202|DRUG|Apatinib Combined With SHR-1210 Injection|"3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle: D1、D15、D31 : SHR-1210 200mg, I.V, q2w； D1-D20 : Apatinib 250 mg, orally, qd; D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation; After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. Three weeks is a treatment cycle with a total of 8 cycles~In each cycle:~D1: SHR-1210 200mg, I.V, q3w; D1-D21: Apatinib 250mg, orally, qd;"
215085321|NCT04871802|DIETARY_SUPPLEMENT|Taxifolin Aqua|Dietary supplement
215085322|NCT01510145|DRUG|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
215085323|NCT01900977|OTHER|Universal Testing with immediate ART|"• Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
215085324|NCT01900977|OTHER|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
215085325|NCT01900977|OTHER|Standard of Care|
214977298|NCT02491138|BEHAVIORAL|Appearance-based intervention|
214977299|NCT02491138|OTHER|Pamphlets|
214977300|NCT05476393|OTHER|Postoperative management|1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.
215085326|NCT00002177|DRUG|Hydroxyurea|
215085327|NCT00002177|DRUG|Nelfinavir mesylate|
215085328|NCT00002177|DRUG|Stavudine|
214977301|NCT00974363|PROCEDURE|Blood Sampling|A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
214977302|NCT02038556|BEHAVIORAL|cognitive behaviorial therapy -Insomnia|
215085329|NCT00002177|DRUG|Didanosine|
215085330|NCT00574665|OTHER|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
215085331|NCT04552548|OTHER|regional nerve block|Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.
215085332|NCT04398173|DIAGNOSTIC_TEST|multiparametric MRI|T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging
215085333|NCT02115841|DEVICE|"Enraf-Nonius Muscle stimulator"|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
214366686|NCT03152383|BEHAVIORAL|Training trials|"A highly preferred edible item will be selected to teach the contingencies for the assessment. Materials to engage in the work response (i.e., button press) will be placed within arm's reach of the child, and the edible item will be in sight. The therapist will deliver a vocal prompt for the child to engage in the work response (e.g., press the button and you can have some candy). If the child engages in the response, the therapist immediately delivers the edible item. The therapist will guide the child to engage in the instrumental response, and will then gradually begin to fade the prompt level. If the child makes an error at any level of prompting, the therapist will guide the participant to emit a correct response. The edible item will be delivered to the child each time that the child responds correctly at any prompt level."
214977303|NCT01562977|DRUG|Rituximab, Gemcitabine, Oxaliplatin, Dexametasone|until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
214366687|NCT03152383|BEHAVIORAL|Progressive Ratio Session|The child will be guided to engage in the instrumental response then the stimulus will be immediately delivered for 30 seconds. The leisure item or the individual who will provide attention will be directly outside of the session room. If the child emits the work response, they will be allowed access to either a leisure item or to attention (depending on the condition) for 30 seconds. The child is initially required to respond one time, then they will be required to respond two times to gain access to the item or attention (then 4, then 8, and so on) such that the response requirement progressively increases according to a pre-determined schedule. A minimum of 3 sessions will be conducted for each condition. The amount of time required for participation depends on the child's responding, and caregiver availability. Participation may take as little as a couple hours, or as long as 3-4 hours per day for approximately one week.
214977304|NCT04221919|DRUG|β -Blockers|Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
214366688|NCT03152383|BEHAVIORAL|Re-test|10 children with ASD will return to repeat the progressive ratio (PR) assessment one week after completing it the first time to examine the reliability of the measure.
214366689|NCT03152383|BEHAVIORAL|Pairing Protocol|15 children with ASD will receive an intervention designed to increase social approach after completing the PR assessment. Participants will attend 2 hour appointments 3-5 days per week in which a therapist will deliver highly preferred items, play with the child, work on teaching communication skills, and teach the child to comply with demands. After completing the intervention (once the child is willingly staying near and interacting with the therapist and complying with instructions), the PR assessment will be repeated to measure change due to the intervention.
214366690|NCT01459861|PROCEDURE|Canal Block and Capsular Injection|Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.
214366691|NCT01459861|PROCEDURE|Femoral Nerve Block with Tibial Nerve Block|Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.
214977305|NCT05705830|DEVICE|Pulse magnetic therapy|Pulse magnetic therapy SM-II (2019102133903)
214977306|NCT05705830|DRUG|Selective serotonin reuptake inhibitors （SSRI）|Anti-anxiety Drugs
214977307|NCT05705830|DEVICE|Shame magnetic therapy|Shame magnetic therapy
214977308|NCT01754519|PROCEDURE|Therapeutic Conventional Surgery|Undergo wide local excision breast surgery
214977309|NCT01754519|RADIATION|Radiation Therapy|Undergo SFRT
214977310|NCT01754519|OTHER|Laboratory Biomarker Analysis|Correlative studies
214977311|NCT01754519|OTHER|Quality-of-Life Assessment|Ancillary studies
214977312|NCT04145856|DIETARY_SUPPLEMENT|I31 probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
214977313|NCT04145856|COMBINATION_PRODUCT|I31 probiotic combined to Alverine/Simethicone|"* I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~* Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)"
214977314|NCT04145856|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
214977315|NCT04247516|BEHAVIORAL|Online-intervention group I (IGI)|Narrative-based online intervention program to promote self-regulatory competences.
214977316|NCT04247516|BEHAVIORAL|Online-intervention group II (IGII)|Narrative-based online intervention program to promote self-regulatory competencies plus gamification strategies.
214977317|NCT06108908|BEHAVIORAL|Reminder|1\. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.
214977318|NCT03280459|PROCEDURE|robot-assisted cystectomy|Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy
214977319|NCT03459625|BEHAVIORAL|Mindfulness-Based Stress Reduction (MSBR)|MBSR includes eight weekly 2.5-hour group sessions, a day-long (6hr) meditation retreat on the weekend during week six, 45 minutes of daily home practice guided by instructional audio CDs, and an MBSR parent workbook. Formal mindfulness exercises aim to increase the capacity for mindfulness and include a body scan, mindful yoga, and sitting meditation. Participants are also taught to practice mindfulness informally in everyday activities. In session, didactic instruction on stress physiology and using mindfulness for coping with stress in daily life is provided. Participants practice formal mindfulness exercises, break into dyads to discuss their daily homework practice, and meet as a larger group to ask questions related to the practice of mindfulness in everyday life.
214977320|NCT03459625|BEHAVIORAL|Psychoeducational Support Group (PE)|The PE consists of 8-weekly 2.5-hour sessions, a day-long (6hr) Family Resource Fair during week six, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Weekly topics for discussion include Preparing for Individualized Education Plan (IEP) meetings, Communicating with Teachers, Advocacy, Sibling Issues, and Community Resources.
214977321|NCT01981668|DRUG|cabazitaxel|Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
214366692|NCT04791982|BEHAVIORAL|Educational sessions|Firstly, the literature was scanned and a education booklet prepared after the opinions of 5 academic nurses, who are experts in the field of oncology, was used. The booklet was included colorectal cancer treatment, symptoms that may develop due to chemotherapy and information on their control, psychosocial support of caregiving family members. Interviews and educational sessions with family members who agreed to participate in the study were held in one-on-one and face-to-face meeting room. These interviews lasted approximately 45 to 60 minutes for each family member. In the interviews, a educational booklet containing information on nutrition, exercise, symptom management, physical aspects of care and disease-specific care was used to present information to caregivers. All of educational sessions were performed by the single researcher.
214977322|NCT04103190|DEVICE|cerebral MRI|"Patients who agree to participate in the study will perform a 3T multi-parametric MRI with advanced spectroscopic imaging techniques and standard protocol.~A neurological consultation will take place during the inclusion visit as well as a questionnaire and a control MRI at 1 year and 2 years +/- 1 month."
214977323|NCT00780975|DRUG|Aplidin (plitidepsin)|Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
214366693|NCT03295487|PROCEDURE|TVT-O|transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
214366694|NCT00522626|DEVICE|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
214977324|NCT02145455|DEVICE|Unity Total Knee Replacement System|
214977325|NCT02145455|DEVICE|Unity Total Knee Replacement System|
214977326|NCT04525430|OTHER|childbirth education|"The 1st Session: General information about labor: Factors affecting labor, early signs of labor, signs of the start of labor, steps of labor, and procedures applied during labor.~The 2nd Session: Methods of coping with birth contractions: Breathing exercises, relaxation exercises, massage, changing position, music, cold/warm application, focus, and walking."
214977327|NCT04525430|OTHER|childbirth education and was subjected to a birth plan|In the birth plan created by the researchers, the pregnant women considered the process from the start of labor to the end of labor and marked the expectation from and preferences about this process on the birth plan.
214977328|NCT02993198|DRUG|Carvedilol|
214977329|NCT00288652|DRUG|[S,S]-Reboxetine|
214977330|NCT04471701|BEHAVIORAL|Environmental exposure and clinical features|Environmental exposures and clinical features are measured by means of a self-administered 38-item on-line questionnaire containing mainly mandatory and closed questions divided into six sections: i) socio-demographic data; ii) clinical evaluation; iii) personal characteristics and health status; iv) housing conditions; v) lifestyle; and vi) behaviours following the lockdown.
214977331|NCT04879017|DRUG|FHD-286|FHD-286 as a single agent
214977332|NCT03728062|BEHAVIORAL|Mindfulness meditation|Guided mindfulness meditation focused on breath sensations, thoughts and emotions.
214977333|NCT03728062|BEHAVIORAL|Physical exercise|Cardio exercise at gym like rowing, eliptical, cycling, or running outside.
214977334|NCT04054544|DIETARY_SUPPLEMENT|Gluten powder 4g|Gluten powder 4g oral BID
214977335|NCT00100399|BIOLOGICAL|Fluarix|
214977336|NCT03179735|DRUG|Essential oils|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
214977337|NCT03179735|DRUG|Cetylpyridinium Chloride 0.7 mg/ml|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
214977338|NCT03179735|DRUG|Placebos|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
215085334|NCT02357862|PROCEDURE|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
215085335|NCT01239888|DRUG|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
215085336|NCT01239888|DRUG|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
215085337|NCT01239888|DRUG|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
215085338|NCT02903758|OTHER|cross sectional|
215085339|NCT05529355|DRUG|Envafolimab plus Endostar and S-1|Immunotherapy combined with chemotherapy and anti VEGFR therapy
214366695|NCT00147680|DRUG|Paclitaxel, Carboplatin|
214366696|NCT05900726|DIAGNOSTIC_TEST|High Resolution Anorectal Manometry|A test used to measure the strength of the muscles in the anal canal
215085340|NCT05529355|DRUG|Envafolimab plus Endostar|Immunotherapy combined with anti VEGFR therapy
215085341|NCT05529355|DRUG|Envafolimab plus S-1|Immunotherapy combined with chemotherapy
215085342|NCT05823844|DRUG|Suvorexant|Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.
215085343|NCT05823844|DRUG|Placebo|The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
215085344|NCT02312219|DRUG|Folic Acid|1 mg folic acid once daily
215085345|NCT02312219|DRUG|Placebo|placebo once weekly
215085346|NCT02312219|DRUG|Low Dose Methotrexate|An anti-inflammatory drug
215085347|NCT00383734|DEVICE|Newfill|1 to 7 injections of drug
214977339|NCT03044314|DRUG|Iloprost and nitric oxide administration|Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
215085348|NCT00383734|DEVICE|Eutrophill|1 to 7 injections of drug
215085349|NCT03100812|BEHAVIORAL|More intensive CHW Intervention|Group A participants will attend 4 monthly 90 minute group health education sessions that provide the tools and strategies to promote heart health to Filipino American individuals, families, and communities on high blood pressure and CVD. The CHWs will lead these sessions utilizing NHLBI's Healthy Heart Healthy Family, A CHW's Manual for the Filipino Community. Each of the group health education sessions will discuss different content related to CVD, hypertension, and other CVD risk factors. The first session focuses on assessing heart disease risk and recognition of heart attack signs. The second session focuses on physical activity and weight management and blood pressure control. The third session addresses control of cholesterol, and diabetes. The final 4th session teaches participants about nutrition and living smoke free.
214977340|NCT04830566|OTHER|Myofascial release technique|Myofascial technique on the thoracolumbar fascia and lumbar paraspinal muscles
214977341|NCT04830566|OTHER|Simulated Myofascial Release technique|Superficial hands contact on the lumbar area
214977342|NCT02743364|OTHER|Laboratory Biomarker Analysis|Correlative studies
214679832|NCT05608317|DEVICE|ALLEVYN Non-Adhesive|"ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction.~ALLEVYN Non-Adhesive consists of the following layers:~* Breathable top film~* Highly absorbent foam core~* Non-adhesive wound contact layer"
214977343|NCT02743364|OTHER|Placebo Administration|Given PO
214977344|NCT02743364|OTHER|Quality-of-Life Assessment|Ancillary studies
214977345|NCT02743364|OTHER|Questionnaire Administration|Ancillary studies
214977346|NCT02743364|DRUG|Simvastatin|Given PO
214977347|NCT01338324|DRUG|Simvastatin|Simvastatin 20 mg single dose on day 1
214977348|NCT00969228|BIOLOGICAL|Rotarix ™|Two oral doses
214977349|NCT00969228|BIOLOGICAL|Placebo|Two oral doses
214977350|NCT02563899|DRUG|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
214977351|NCT02563899|DRUG|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
214977352|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 1|Volunteers will be fed with a high volume, high energy density test meal.
214366697|NCT05900726|DIAGNOSTIC_TEST|Endoanal Ultrasound|An examination of the anal canal (back passage) that allows us to see the muscles involved in passing stool and the tissues that surround these.
214366698|NCT05900726|OTHER|Bowel diary|A daily diary to assess episodes of faecal incontinence
214977353|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 2|Volunteers will be fed with a high volume, low energy density test meal
214977354|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 3|Volunteers will be fed with a low volume, high energy density test meal
214977355|NCT04751695|BIOLOGICAL|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
214977356|NCT03781726|DRUG|glecaprevir/pibrentasvir treatment|combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
214977357|NCT01035749|BIOLOGICAL|GSK Biologicals' Influenza investigational vaccine GSK2340274A|One or two doses administered intramuscularly
214977358|NCT01035749|BIOLOGICAL|GSK Biologicals' Influenza investigational vaccine GSK2340273A|Two doses intramuscularly
214977359|NCT01035749|BIOLOGICAL|Placebo (saline)|One dose intramuscularly
215085350|NCT03100812|BEHAVIORAL|Less Intensive CHW Intervention|Individuals randomized to the less intensive CHW intervention will have the baseline, 4 month, and 8 month interviews and blood pressure measurements will be collected in those succeeding time points. Participants will also receive a 30 minute one on one session from the CHW and a referral to a physician if needed.
215085351|NCT01842594|DRUG|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
215085352|NCT00769249|OTHER|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
214366699|NCT05900726|OTHER|MYMOP2|Questionnaire to assess individual symptoms, general wellbeing and activity in faecal incontinence
214366700|NCT05900726|OTHER|FIQOL|Questionnaire to assess the quality of life with faecal incontinence
214366701|NCT05900726|OTHER|FISI|Questionnaire to assess the severity of faecal incontinence
214491745|NCT06748898|OTHER|TENS-WAA|Before anesthesia induction, two paired of electrode pads will be placed on the upper area 1 and 2 with the skin of the treatment area exposed, and the upper and lower juxtaposition method will be adopted. The electrodes were placed close to the skin and connected with TENStem eco basic (Wuxi Jiajian Medical Device Co., Ltd.). Upper area 2 is at the middle of the palmar side of the forearm, between the palmaris longus and flexor carpi radialis.Upper area 1 is between the ulnar border on the little finger side and the flexor carpi ulnaris tendon.Stimulation parameters of TENS-WAA are alternating dense-disperse wave with a frequency of 2Hz and a pulse width of 200μs, and a frequency of 100Hz with a pulse width of 150μs, alternating every 3 seconds ，intensity required to reachthe maximum tolerable level without causing pain, continuous stimulation until the end of surgery.
214491746|NCT06748898|OTHER|non TENS-WAA|Before anesthesia induction, two paired of electrode pads will be placed on the same position without current stimulation.
214977360|NCT06157229|OTHER|MAT|"The protocol consists of four phases: 1) immobilization phase, 2) early protective phase, 3) intermediate phase and 4) late phase. The detailed guideline can be found in the following article:~Gaunt, B. W., Shaffer, M. A., Sauers, E. L., Michener, L. A., McCluskey, G. M., \& Thigpen, C. A. (2010). The American Society of Shoulder and Elbow Therapists' Consensus Rehabilitation Guideline for Arthroscopic Anterior Capsulolabral Repair of the Shoulder. Journal of Orthopaedic \& Sports Physical Therapy, 40(3), 155-168. https://doi.org/10.2519/jospt.2010.3186"
214977361|NCT06157229|OTHER|CABRR|"The protocol consists of four phases: 1) immobilization phase, 2) early phase, 3) intermediate phase and 4) advanced phase.~The protocol comprises education, modified cognitive behavioral therapy, neuromuscular control exercises, kinetic chain exercises, range of motion enhancing exercises, strength and conditioning exercises, and sport-specific exercises. The protocol is currently unpublished."
214977362|NCT01892332|DRUG|epidural block with lidocaine and fentanyl|"The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%."
214977363|NCT02245711|BIOLOGICAL|Stem Cell|
214977364|NCT00661635|DRUG|placebo|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
214977365|NCT00661635|DRUG|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
214977366|NCT00661635|DRUG|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
214977367|NCT00794664|DRUG|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
214977368|NCT00794664|DRUG|Placebo|1 mL weekly subcutaneous injections for 26 weeks
214977369|NCT03708445|DIAGNOSTIC_TEST|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using antibody of aminoacyl-tRNA synthetases"
214977370|NCT02232204|BEHAVIORAL|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
214977371|NCT01173315|DIETARY_SUPPLEMENT|vitamin and mineral supplementation|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
214977372|NCT02434874|DEVICE|StimGuard Sacral Nerve Stimulator System|The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
214977373|NCT04890808|DIETARY_SUPPLEMENT|Inosine|Patients will be dosed with two 500 mg capsules of Inosine twice daily for 36 months
214977374|NCT04890808|DIETARY_SUPPLEMENT|IP6|Patients will be dosed with two 500 mg capsules of IP6 twice daily for 36 months
214977375|NCT02923999|DRUG|P2G12 Dose Cohort 1|single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
214977376|NCT02923999|DRUG|P2G12 Dose Cohort 2|single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
214977377|NCT02923999|DRUG|P2G12 Dose Cohort 3|single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
214366702|NCT05900726|OTHER|Follow up call|At 28 days and 3 months post final pelvipower or sham session to assess faecal incontience after study period
214366703|NCT05900726|OTHER|St Mark's incontinence score|A score of incontinence
214491747|NCT03710928|OTHER|very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein."
215085353|NCT00769249|OTHER|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
215085354|NCT00769249|PROCEDURE|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
214366704|NCT06184672|OTHER|dry needling|"the area is disinfected by the use of 0.5% chlorhexidine digluconate alcohol solution. The physiotherapist in charge of the intervention uses sterile nitrile gloves, using dry needling needles with dimensions of 0.30 x 50 mm is used. This technique, designed by Hong, applies speed both at the entrance, in order to provoke the local spasm response and at the exit. The inputs and outputs are performed until the REL disappears or until the tolerance threshold of the patient is reached.~Immediately after performing the puncture, ischemic compression is performed on the treated muscle, in order to decrease the duration and intensity of post-puncture pain. For this, a digital pressure is made to the point where the patient's sensation ceases to be pressure and becomes pain. Once the patient is noted that pain is repeated again the art up to a total of 2 minutes"
214977378|NCT01062308|PROCEDURE|Taping and Sham Taping|"Taping shoulder with Hospiplast tape.~Taping the shoulder after acute stroke to prevent shoulder injury and pain.~Taping the shoulder after acute stroke and compare with sham taping group.~Treatments:~1. Positioning technique~2. Handling technique~3. Range of motion exercises~4. Taping technique"
214977379|NCT01062308|PROCEDURE|Sham Taping|Shoulder Taping for 14 days which will be changed after every 3 days.
214977380|NCT00457730|DRUG|Duloxetine|Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
214977381|NCT00457730|DRUG|Placebo|Subjects are randomized to either Duloxetine or Placebo
214977382|NCT01305564|DEVICE|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
214977383|NCT06521970|DIAGNOSTIC_TEST|The kyphosis angle|The subject was positioned in a neutral standing position. the short side of the phone was placed on the T1-3 spinous process and the protractor was set to 0°. Subsequently, the phone was placed on the T12, and the angular value displayed on the screen was recorded as the kyphotic angle.
214977384|NCT06521970|DIAGNOSTIC_TEST|dynamic postural performance|The test measures spinal alignment deviations during static loading in the 90° shoulder flexion position. The test measurements are made in a standing position with arms 90° flexed, without weight, and after 30 seconds with weight.
214977385|NCT06521970|DIAGNOSTIC_TEST|forward head position|The individual stands with his heels and pelvis in contact with the wall. The severity of kyphosis is interpreted by measuring the distance between the occiput and the wall in cm with the head facing forward. The intensity of kyphosis is classified as mild (≤5 cm), moderate (5.1-8 cm) and severe (\>8 cm)
214977386|NCT03049878|DRUG|Paracetamol Codeine|preoperative administration
214977387|NCT03049878|DRUG|Placebo Oral Tablet|preoperative administration
214977388|NCT04692987|OTHER|Decision-aid video|Decision-aid video will be developed to disseminate knowledge and to raise awareness on colorectal cancer screening
214977389|NCT01289886|DRUG|BR-A-657|20, 60, 120, 240, 360, 480mg or placebo tablet
215085355|NCT06455410|DRUG|GP|gemcitabine + cisplatin
215085356|NCT06455410|DRUG|Adebrelimab|a PD-L1 inhibitor
215085357|NCT06455410|DRUG|concurrent chemoradiotherapy (CCRT)|concurrent chemoradiotherapy (CCRT)
215085358|NCT02338934|DRUG|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
215085359|NCT04710914|DRUG|Prolonged sedation with isoflurane|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
215085360|NCT04710914|DRUG|Prolonged sedation with midazolam|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
214366705|NCT03479697|DEVICE|HIRREM|Technology
214366706|NCT03479697|OTHER|Continued Current Care|Continue their current clinical care.
214366707|NCT01942681|DRUG|Propiverine Hydrochloride|Administrate Propiverine Hydrochloride for 12 weeks
214366708|NCT03460028|BEHAVIORAL|Yoga Condition|Participants randomized to the Yoga Condition will participate in an integrated yoga program consisting of yoga postures, breathing exercises, and concentration/meditation practices.
214366709|NCT00066482|BIOLOGICAL|bleomycin sulfate|Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children \< 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)
214977390|NCT02150928|DRUG|Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|"* Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~* All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~* Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit"
214977391|NCT00020657|DRUG|dolasetron mesylate|
214977392|NCT00020657|DRUG|granisetron hydrochloride|
214977393|NCT00020657|DRUG|ondansetron|
214977394|NCT00020657|DRUG|prochlorperazine|
214977395|NCT00020657|PROCEDURE|quality-of-life assessment|
214977396|NCT01967459|DRUG|Cholecalciferol|Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)
214977397|NCT01967459|DRUG|Cholecalciferol|Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
214977398|NCT02646683|DRUG|vedolizumab|
215085361|NCT05908708|DEVICE|Medtronic 780G® hybrid closed loop|"Medtronic 780G® hybrid closed loop system uses the commercial auto-mode with an insulin pump and continuous glucose monitoring."
215085362|NCT05021692|BEHAVIORAL|Web-based support program for pregnant women with preeclampsia based on the Health Promotion Model|support program
214366710|NCT00066482|BIOLOGICAL|filgrastim|Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC \> 5,000/uL
214366711|NCT00066482|DRUG|cisplatin|Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children \< 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
214977399|NCT04782817|OTHER|Recommendation for high flow nasal cannula oxygen therapy order set|Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.
214977400|NCT04782817|OTHER|Provider choice standard care order set|Participants will receive order set with provider choice of standard care therapy.
214977401|NCT06297070|BEHAVIORAL|Whole Health Lifestyle Care for Reproductive Well-being pilot program|The program consists of an individual Integrative Health and Medicine (IHM) consultation with a CWH IHM provider, 4 Shared Medical Appointments (SMA), and 4 individual Health and Wellness Coaching (HWC) sessions. The SMA sessions occur at the UH CWH Beachwood office conference and movement rooms. The HWC sessions are virtual. The consultations are either virtual or in person at UH CWH Beachwood.
214977402|NCT05499091|PROCEDURE|Skin biopsy, blood sample, urine sample|blood samples, urine samples, skin samples.
214977403|NCT06388967|DIAGNOSTIC_TEST|PANcreatic cancer Exosome Early detectiON (PANXEON)|This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it
214977404|NCT07048236|DIAGNOSTIC_TEST|Specimen and clinical data collection|Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, pulmonary function test,Questionnaire
214977405|NCT01702909|DRUG|Interleukin-2|Interleukin-2
214977406|NCT00054496|DRUG|erlotinib hydrochloride|
215085363|NCT01840254|DRUG|dexmedetomidine|
215085364|NCT01840254|DRUG|normal saline|
215085365|NCT00533650|DRUG|MK0429|
214977407|NCT06699615|OTHER|Once time de-identified Qualtrics survey|Once time de-identified Qualtrics survey
215085366|NCT01827332|DRUG|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
215085367|NCT01827332|DRUG|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
215085368|NCT00186212|BEHAVIORAL|workbook/journal on coping with breast cancer|
215085369|NCT00186212|BEHAVIORAL|standard educational materials on breast cancer|
215085370|NCT05172453|OTHER|comprehensive management algorithm for preventing mother-to-child transmission of HBV|"To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the Management algorithm for prevention of mother-to-child transmission of hepatitis B virus based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents."
215085371|NCT00546260|DRUG|placebo|administration of iv bolus prior to angiography
215085372|NCT00546260|DRUG|PRT060128 Potassium|administration of iv bolus prior to angiography
215085373|NCT05285124|DRUG|Melatonin|Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
214366712|NCT00066482|DRUG|cyclophosphamide|Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children \< 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
214977408|NCT02440061|DRUG|Synthetic human AG|Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
214977409|NCT02440061|DRUG|Arginine|Arginine hydrochloride (5 g) intravenously over 45 seconds.
214977410|NCT02440061|DRUG|0.9% saline solution|A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
214977411|NCT04720989|PROCEDURE|Bathing With Baby Cleanser and water|Late preterm and term newborns, whose informed consents are obtained by their parents to participate in the project, will be given their first baths according to the intervention group they are assigned to. Before the first bath / after birth, preterm newborns in all groups will be wiped only once with a clean towel without removing the vernix caseosa. Newborns who were bathed before the application of the study will be excluded from the study. As the most appropriate time for bath time, 30 minutes after the end of the feeding and treatment of the newborns, the bath application will be made at any time between 9 pm and 3 pm.
214977412|NCT04720989|PROCEDURE|Bathing With only Water|Preterm infants will have their first baths only with water.
214366713|NCT00066482|DRUG|etoposide|Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children \< 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
214977413|NCT01419535|DRUG|Mifepristone|Mifepristone 50mg tablet by mouth every six hours for nine days.
214977414|NCT01419535|DRUG|Placebo|Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
215085374|NCT05285124|OTHER|Placebo|Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS
215085375|NCT05285124|OTHER|HD-tDCS|Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes
215085376|NCT01976897|OTHER|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
215085377|NCT01976897|OTHER|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
215085378|NCT01976897|OTHER|Heel - interface pressure measurements|"The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm\^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media."
215085379|NCT05221112|OTHER|diagonal pattern training|patients will receive proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.
215085380|NCT05221112|OTHER|single plane training|patients will receive single plane training of proprioceptive neuromuscular facilitation in control group
215085381|NCT05655143|BEHAVIORAL|Balance training|"Participants will undergo a 4-week balance training protocol modified from that described previously.~Participants will undergo supervised exercise three times per week for approximately 30 minutes per session. The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task."
214366714|NCT00066482|PROCEDURE|conventional surgery|Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy
214366715|NCT00066482|BIOLOGICAL|MESNA|Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
214366716|NCT03634124|BIOLOGICAL|Blood test|Additional blood test of 4,5 ml of venous blood
214679833|NCT04054778|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
214977415|NCT01124812|OTHER|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|"Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:~1. Cohorts 1, 2 \& 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 \& 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 \& 3. Treatment cycles will be repeated every 28 days.~2. Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.~3. Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).~   * Total treatment duration is 8-16 weeks"
214977416|NCT04020419|DRUG|PediaBerry|PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
214366717|NCT03634124|OTHER|Doppler ultrasound|Vascular ultrasonic vascular exploration of the lower limbs
214366718|NCT03375502|DRUG|Varicella Vaccine|The subject will receive investigational product or comparator.
214366719|NCT06244277|DRUG|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
214366720|NCT06244277|DRUG|Zolpidem|Zolpidem 10Mg Tab 10mg tablet once daily
214366721|NCT06328530|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
215085382|NCT04546373|DRUG|Niraparib|Patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria. The study comprises a single study visit, in which the patient will give her informed consent to participate (when the patient is alive) and the physician will extract the study data from the patient's medical charts. All eligible deceased and consenting living patients at the participating centers will be included. Data will be directly retrieved from hospital medical records and reported in the electronic Case Report Form (eCRF).
215085383|NCT00823277|OTHER|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after \~ 1 Year.
215085384|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
215085385|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
215085386|NCT03622034|OTHER|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
215085387|NCT05801055|DRUG|Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone|The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
215085388|NCT03582904|PROCEDURE|tDCS|real or sham tDCS delivered to primary motor cortex
215085389|NCT05154604|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
214366722|NCT06328530|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
215085390|NCT03855631|GENETIC|Intervention on primary cultured cells|The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
215085391|NCT04836676|DEVICE|C-REX Device|"The investigational devices are C-REX LapAid Cath or C-REX RectoAid Cath. C-REX LapAid Cath consists of an invasive surgical part, i.e. anastomotic ring comprised of two LapAn coupled by DMC/DM, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX RectoAid Cath consists of an invasive surgical part, i.e. an anastomotic ring comprised of RectoAn and LapAn, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX LapAid Cath and C-REX RectoAid Cath are easy to use, with unique possibility to control and validate the integrity of the anastomosis during and after surgery."
215085392|NCT06177093|RADIATION|MR Linac delivered Radiotherapy|All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
215085393|NCT05749653|DRUG|Bi-annual CDTI|Bi-annual CDTI
215085394|NCT04794660|DIAGNOSTIC_TEST|HPV DNA Test|Screening for HPV using a HPV DNA test
215085395|NCT04794660|DIAGNOSTIC_TEST|VIA triage test|"VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer"
215085396|NCT04794660|PROCEDURE|Treatment by ablative treatment|Cryotherapy or Thermal Ablation are performed on the cervix.
215085397|NCT04794660|PROCEDURE|Colposcopy|Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
215085398|NCT00316524|BIOLOGICAL|MVA-BN® (IMVAMUNE)|1x 10E8\_TCID50
214366723|NCT00413270|DRUG|nilotinib|
215085399|NCT00316524|BIOLOGICAL|Placebo|Tris-Buffer
215085400|NCT05286372|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
214366724|NCT04962425|DRUG|Trastuzumab|Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
214366725|NCT05667467|PROCEDURE|Care Bundle Implementation|"In this study, the control group received standard care. The nurse group was given training on the implementation of the care bundle. A cardiac surgery care bundle was applied to the study group by clinical nurses."
214366726|NCT02432872|DRUG|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
215085401|NCT02287753|OTHER|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
214679834|NCT04054778|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
214977417|NCT03828955|DIETARY_SUPPLEMENT|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.
215085402|NCT05840692|DRUG|Escitalopram 20 mg|Antidepressant
214977418|NCT03828955|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bags of starch placebo of similar appearance per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
214977419|NCT00929838|BEHAVIORAL|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
215085403|NCT05840692|DRUG|Placebo|
215085404|NCT04199819|DRUG|entecavir|Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis.
215085405|NCT03056963|BEHAVIORAL|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
215085406|NCT03056963|BEHAVIORAL|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
215085407|NCT00513955|DRUG|bortezomib|
215085408|NCT00513955|DRUG|cyclophosphamide|
215085409|NCT00513955|DRUG|doxorubicin hydrochloride|
215085410|NCT00513955|DRUG|prednisolone|
215085411|NCT00513955|DRUG|vincristine sulfate|
215085412|NCT00513955|OTHER|questionnaire administration|
215085413|NCT00513955|PROCEDURE|quality-of-life assessment|
215085414|NCT01305603|DRUG|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
215085415|NCT01305603|PROCEDURE|Injection|Injection under ultrasound-guidance
214977420|NCT00929838|BEHAVIORAL|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
214977421|NCT00929838|BEHAVIORAL|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
214977422|NCT00929838|BEHAVIORAL|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
215085416|NCT05737277|DRUG|Gabapral|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period."
214366727|NCT02432872|DRUG|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
214977423|NCT02344316|DRUG|Melatonin|Taken at 9 PM or 1 hour before bedtime, whichever is earlier
214977424|NCT02344316|OTHER|Placebo|Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
214366728|NCT02659761|DRUG|dolutegravir/abacavir/lamivudine|600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks
214977425|NCT02260960|DIETARY_SUPPLEMENT|Omega-3 (Triglyceride form)|
214977426|NCT01369459|BEHAVIORAL|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
214977427|NCT05231889|DEVICE|Silverway guidewire|The Silverway guidewire is a newly developed guidewire to overcome the problems the Radifocus guidewire has
214977428|NCT05231889|DEVICE|Radifocus guidewire|The Radifocus guidewire is a hydrophilic coated guidewire that is used when a standard J-tip guidewire does not cross a vascular anomaly
214977429|NCT02374320|DRUG|liposomal bupivacaine|injected as an axillary block
214977430|NCT01814007|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
215085417|NCT05737277|DRUG|Placebo|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period"
215085418|NCT05951712|DRUG|Simethicone 150mg|Impact of simethicone on the mucosal visibility of stomach and duodenum
215085419|NCT05951712|DRUG|N Acetyl cysteine 600mg|Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
214366729|NCT01118364|OTHER|Cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving"
214366730|NCT01118364|OTHER|tobacco|"a cigarette tobacco trade mark Drum 45 minutes before simulating or real driving"
214366731|NCT02464800|PROCEDURE|Vitrectomy for proliferative diabetic retinopathy|25-gauge vitrectomy
214366732|NCT03055143|DRUG|SPARC-08-038|2 mg/ml intravenous infusion
214366733|NCT03055143|DRUG|Ref-08-038|2 mg/ml intravenous infusion
214366734|NCT04322123|DRUG|Hydroxychloroquine Oral Product|Hydroxychloroquine 400 mg BID
214366735|NCT04322123|DRUG|Hydroxychloroquine + azithromycin|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
214366736|NCT03322280|PROCEDURE|TACE combined with iodine-125 seeds implantation|Conventional TACE with lipiodol was performed. Then Iodine-125 seed implantation into PVTT is conducted 7-10 days after TACE when liver function tests demonstrated values comparable to those obtained before TACE.
214366737|NCT03322280|PROCEDURE|TACE|Only conventional TACE with lipiodol and chemotherapy drugs was performed.
214366738|NCT01547897|DRUG|NOX-E36|0.5 mg/kg study drug or placebo as SC injections twice a week
214366739|NCT03740308|DEVICE|Locally Made Zirconia Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. Locally Made Zirconia Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
214491748|NCT03710928|OTHER|standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
214491749|NCT05198960|DRUG|Direct Oral Anticoagulants|Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.
214491750|NCT05198960|DRUG|Low-dose aspirin|Patients allocated to receive LDA: Aspirin 100 mg OD once daily.
214977431|NCT00975728|DIETARY_SUPPLEMENT|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
214366740|NCT03740308|DEVICE|ZR Zirconia Crwons NuSmile ® Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. ZR Zirconia Crwons NuSmile ® Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
215085420|NCT05951712|DRUG|Simethicone 150mg plus N Acetyl cysteine 600 mg|Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
215085421|NCT05951712|OTHER|Placebo|Impact of water on the mucosal visibility of stomach and duodenum
214366741|NCT01367509|DRUG|Methylnaltrexone (MNTX)|
214977432|NCT02670369|BEHAVIORAL|Sitting time prompt|Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
214977433|NCT03940833|BIOLOGICAL|BCMA CAR-NK 92 cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
214491751|NCT06748651|DRUG|Allocetra|Intra-articular injection of Allocetra performed once on Day 1 of the study
215085422|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
215085423|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
214977434|NCT07060638|DRUG|IL-22|F-652 (IL-22) is a fusion protein of human IL-22 with IgG2 fragment, and has anti-inflammatory effects
214977435|NCT07060638|DRUG|Prednisone|Prednisone is an adrenal glucocorticoid with anti-inflammatory effects
214977436|NCT07060638|DRUG|Acamprosate|Acamprosate is a propane-1 sulfonic acid with anti-ethanol dependency effects
214977437|NCT07060638|DRUG|Prednisone placebo|Matching placebo
215085424|NCT01238978|DRUG|Vildagliptin|
215085425|NCT01238978|DRUG|"Usual Care"|
214366742|NCT05925933|OTHER|Intervention|high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.
214366743|NCT02475785|DEVICE|FFRD and mini plates group|FFRD direct loading over mini plates inserted in the mandibular symphysis
214366744|NCT02475785|DEVICE|Conventional FFRD|FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
215085426|NCT05105893|OTHER|Dates group|Seven dates to be provided to patients
215085427|NCT02318290|DRUG|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
215085428|NCT02698722|OTHER|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
215085429|NCT04438460|BIOLOGICAL|Blood test|"For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery."
214366745|NCT00552084|DRUG|Fish oil|Fish oil supplements 4 gms will be taken daily for 24 weeks.
214366746|NCT00552084|DRUG|Placebo|Placebo supplements will be taken daily for 24 weeks.
214977438|NCT07060638|DRUG|IL-22 (F-652) Placebo|Matching Placebo
214977439|NCT07060638|BEHAVIORAL|Motivational Interviewing (MI)|MI is an evidence-based counseling style to overcome ambivalence to treatment in AUD patients
214977440|NCT07060638|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is an MI-based approach that includes 2-4 behavioral treatment sessions based on the Platform Treatment Manual
214977441|NCT07060638|BEHAVIORAL|Usual Care|defined as a brief intervention with advice not to drink alcohol-containing beverages and referral to a 12-step program
214977442|NCT00901043|DIETARY_SUPPLEMENT|Walnut supplementation|Eight weeks of walnut supplementation
214977443|NCT00901043|DIETARY_SUPPLEMENT|Ad lib diet|Eight weeks without walnut supplementation
214977444|NCT03863847|PROCEDURE|Neurofeedback|The patients will receive neurofeedback on pain related brain-activity, and through training, learn to control said brain-activity.
214977445|NCT03863847|PROCEDURE|Sham|The patients will receive sham neurofeedback on non-pain related brain-activity, and through training, learn to control said brain-activity.
214977446|NCT04235400|DIAGNOSTIC_TEST|No Dye BreakUp Time|Measurement without dye of the tear meniscus height (TMH) which give an rapid hint on the quantity of tears present on the ocular surface, the measure in real time of the tear osmolarity and, at last, the analysis of the thickness of the tear's layer by interferometry (measurement of the light fringes reflected by the tears when illuminated with polarized light, whereby the complete layer or the lipid layer alone can be evaluated separately depending on the machines used) and of the assessment of the quality of the Meibomian glands (non-contact imaging by infrared illumination).
214977447|NCT04022317|BIOLOGICAL|Biocon Insulin R|Biocon Insulin R is a short-acting human insulin, produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing Pichia pastoris (yeast).
215085430|NCT05280249|OTHER|both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air.
215085431|NCT04393688|COMBINATION_PRODUCT|Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter|"Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
214977448|NCT04022317|BIOLOGICAL|Humulin®R|Humulin® R is a polypeptide hormone structurally identical to human insulin synthesised through recombinant deoxyribonucleic acid (rDNA) technology in a non-pathogenic laboratory strain of Escherichia coli bacteria.
214977449|NCT02100124|BEHAVIORAL|Reproductive Life Planning (RLP)|
214977450|NCT02100124|BEHAVIORAL|Contraceptive Action Planning|
214977451|NCT02100124|BEHAVIORAL|Contraception information|
214977452|NCT04360265|OTHER|No Investigational Product|No investigational product will be administered in this follow-up trial.
214977453|NCT04360265|DRUG|Adjuvant Immunomodulatory (IM) Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive IM therapy.
214977454|NCT06761339|DIETARY_SUPPLEMENT|Azka Nasal and Throat for Children|Azka Nasal and Throat for Children is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in pediatric patients. The intervention involves administering 7.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days. The supplement is intended to alleviate symptoms of nasal and throat irritation, reduce phlegm, and improve overall respiratory comfort. Azka Nasal and Throat for Children has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in pediatric respiratory care.
214977455|NCT06761339|DRUG|Prospan cough Syrup|The active comparator, Prospan Cough Syrup is a plant-based herbal medicinal product containing the active ingredient Hedera helix (ivy leaf extract), standardized to ensure consistent pharmacological efficacy. The syrup is formulated as an oral liquid preparation with a pleasant taste suitable for pediatric and adult use. The intervention involves administering 2.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days.
214977456|NCT07061548|OTHER|No Intervention: Observational Cohort|No intervention
214977457|NCT06758583|DRUG|Dapiglutide 7.5 mg|Single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL.
215085432|NCT05262686|DRUG|Belimumab|Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
215085433|NCT05262686|DRUG|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
215085434|NCT03047291|DRUG|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
215085435|NCT03047291|DEVICE|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
214366747|NCT00316810|DRUG|Alemtuzumab|Day 0: Campath 30 mg i.v. infusion over 3-6 hours
214366748|NCT00316810|DRUG|Rabbit Anti-Human Thymocyte Globulin|Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
214977458|NCT07072221|DRUG|BCL regimen|"Induction therapy period (28 days\*6)~Bendamustine; Specification: 100mg per vial; 90mg/m2 d1-2, ivgtt.; for age≤70 years; 70mg/m2 d1-2, ivgtt.; for age\>70 years;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks, po.; for age≤70 years; 15mg biw for 2 weeks, po.; for age\>70 years;~Lenalidomide Specification:10mg per tablet; 10mg qd d1-d21, po.; for age≤70 years; 10mg qd d1-d14, po.; for age\>70 years;"
214366749|NCT03403322|OTHER|Kinesio taping|An experienced physiotherapist placed the base of the Kinesio taping strip, over rectus femoris muscle, 3cm bellow the anterior iliac spine, without tension. From this point, the Kinesio taping was placed up to the upper edge of the patella and stretched to 100% tension. It was, then, bi-sectioned, circled the patella and ended in the tuberosity of the femur, without tension. In order to avoid interference in the electromyography signals, a section was held at Kinesio taping at the point where the electrode was placed.
214366750|NCT03403322|OTHER|Without taping|Children performed functional activities without tape
214366751|NCT00489333|DRUG|ProAlgaZyme|
214491752|NCT06850532|OTHER|IGF-1|The effects of NMES coupled with HIIT and MICT on IGF-1 and substrate metabolism has not been studied earlier.
215085436|NCT00350428|PROCEDURE|Laser Preipheral Iridotomy and phacoemulsification|
215085437|NCT00721721|BEHAVIORAL|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
215085438|NCT00721721|BEHAVIORAL|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
215085439|NCT00721721|DIETARY_SUPPLEMENT|Potassium Supplementation|60 mmol potassium supplement
215085440|NCT04665531|PROCEDURE|Erector Spinae Catheter|Patients in the experimental group will receive the Erector Spinae Catheter with an initial bolus ob 20ml 0,5% levobupivacaine prior the surgery and will be administered local anesthetics for 48 hours post-operatively.
215085441|NCT04665531|PROCEDURE|Intercostal block|Patients in the comparative group will receive standard treatment, i.e. the multi-level intercostal block with 20ml 0,5% levobupivacaine administered at the end of the surgery by the surgeon.
215085442|NCT04665531|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
215085443|NCT05661266|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
215085444|NCT02476136|DRUG|paroxetine, duloxetine, fluoxetine or venlafaxine|
215085445|NCT02246608|DEVICE|NPWT Standard of Care plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
215085446|NCT02246608|DEVICE|Routine NPWT Standard of Care|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
215085447|NCT02366117|BEHAVIORAL|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
215085448|NCT06537557|OTHER|the early in-hospital temperature management protocol for heat stroke patients|The early in-hospital temperature management protocol for heat stroke includes early identification, selection of cooling methods for rapid cooling, precise target temperature management, and dynamic monitoring. Effective temperature management will be implemented for heat stroke patients to improve their outcomes.
215085449|NCT03654885|DEVICE|XEN-45 Gel Stent|XEN-45 gel stent device implant
215085450|NCT03654885|PROCEDURE|Trabeculectomy|Trabeculectomy surgery
215085451|NCT04408768|OTHER|standard protocol for stroke patients|Standard protocol for stroke patients
214977459|NCT07072221|PROCEDURE|Cohort 1 (ASCT-eligible)|"Autologous hematopoietic stem cell transplantation~SEAM conditioning~Simustine 250mg/m2 orally, d1;~Etoposide 200mg/m2 intravenous infusion, d2-d5;~Cytarabine 400mg/m2 intravenous infusion, d2-d5;~Metformin 140mg/m2 intravenous infusion, d6;"
214977460|NCT07072221|DRUG|Cohort 2 (ASCT--ineligible)|"Maintenance therapy period (2 years)~Chidamide; Specification: 5mg per tablet; 15mg biw for 2 weeks per 3 weeks, po.;"
215085452|NCT06960031|OTHER|PET/CT technique|"Hybrid positron emission tomography (PET) and computed tomography (CT) images will be performed using Philips hybrid system equipped with a 16 MDCT scanner.~The whole-body PET images from the skull vault down to the knee will be performed using several bed positions acquisition, each bed is approximately 15cm axial filed with 4mm special resolution. The time of acquisition of the emission scan is about 2 min for each bed, with a total time range between 12 and 17 min."
215085453|NCT06834984|DIETARY_SUPPLEMENT|Prebiotic, probiotic, postbiotic combination|The product consists of two probiotics, Lactobacillus rhamnosus LGG and Bifidibacterium animalis subsp. lactis BB-12, supplied at a total concentration of 11B CFU's, a prebiotic consisting of 1 × 106 Plaque Forming Units (PFU) LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae bacteriophages, marketed as PreforPro, and tributyrin- a stale form of butyrate
215085454|NCT06834984|DIETARY_SUPPLEMENT|Placebo|Placebo pill containing stomach acid-resistant outer vegan capsule (hypromellose, gellan gum), hi oleic safflower oil, inner vegan capsule (hypromellose, gellan gum) microcrystalline cellulose, ascorbyl palmitate, silica
215085455|NCT03460353|DRUG|Dexamphetamine|Patients are tested for their normal prescription dexamphetamine medication
215085456|NCT03858179|DEVICE|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for applications during the training and/or detraining periods will be 30 Joules (J) per site (180 J per thigh). PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
215085457|NCT03858179|DEVICE|Placebo|Placebo PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
215085458|NCT04642157|OTHER|ELIOS|"ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~* A systematic initial contact with an ELIOS web-clinician~* Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~* The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician"
215085459|NCT04642157|OTHER|other resources contacts|"Three types of resources will be suggested via the ELIOS website:~* The General Practitioner (GP)~* The closest medico-psychologic center (CMP)~* The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation."
214977461|NCT06826313|BIOLOGICAL|VRT106|Intravenous drip administration
214977462|NCT06769594|DEVICE|Investigational CT Scan|All pre-contrast testing and administration of supporting medications shall be done according to the hospital's SOC. Images will then be compared with the previously acquired imaging conducted as standard of care. The investigational scan takes between 10-30 minutes.
215085460|NCT05587244|DEVICE|Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners|Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners
215085461|NCT03622164|RADIATION|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)|CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.
214491753|NCT06844747|OTHER|erector spinae plane block(ESPB)|ESPB group received US-guided plane block, WI group received local anaesthetic wound infiltration
214491754|NCT06846502|PROCEDURE|Pulmonary vein isolation|Compared to conventional radiofrequency (RF) ablation, which is performed with a power set of 30-40 Watt for a duration of 20-30 seconds, ablation with higher power and shorter duration (vHPSD, 90W/4sec) may result in more continuous and more durable ablation lesions with a similar safety profile, while reducing procedure duration.
214491755|NCT06846190|OTHER|mCIMT|mCIMT+ Hot pack will be applied and unaffected hand will be immobilized by a volar resting splint extending from finger tips to the proximal forearm. Use splint every day for at least 5 waking hours daily for 4 weeks and perform daily activities. Program of mCIMT every other day, 3 times per week during a 4-week period.
214491756|NCT06846190|OTHER|VR|VR+ Hot pack will be applied. 25 minutes of VR program, every other day, 3 times per week for 4 weeks. Each VR session continued for 10 minutes then 5 minutes rest after that again 10 minutes VR session will do.
214491757|NCT06846021|OTHER|Disease status|According to the disease status, patients are divided into four groups including healthy donors, initial patients with high activity, patients with deformities and patients with clinical remission
215085462|NCT03622164|RADIATION|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)|CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
215085463|NCT05020795|PROCEDURE|Endovascular thrombectomy|Clot retrieval for large vessel occlusion in acute ischaemic stroke
215085464|NCT05570435|BIOLOGICAL|Blood collection|Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
214366752|NCT04900623|DEVICE|NavDx HPV ctDNA Testing|Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.
214366753|NCT04900623|RADIATION|Radiotherapy|Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
214366754|NCT04900623|DRUG|Chemotherapy drug|"Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy."
214366755|NCT05484388|DEVICE|SN2|Investigational device absorption level Normal
214977463|NCT06828679|OTHER|Acupuncture|Patients will receive 12 weeks of acupuncture with 3 half-hour sessions weekly. Acupoints will include (1) a basic formula of 8 Bo's abdomen acupoints (paretic side, 0.5cm depth vertically) \[66\]; (2) 12 conventional acupoints (bilateral, opposite to paretic side first, 1-4 cm depth vertically) \[67\]; and (3) 3 scalp acupoints (opposite to paretic side, 0.5-cm depth at 15-30 degrees) \[68\]At most 3 additional supplementary acupoints will be included, depending on the clinician's professional judgement. Sterile needles will be used after skin disinfection. Manual rotating manipulation \[69\] will be performed every 10 minutes on the conventional acupoints to achieve De-qi sensation \[70\]. Abdomen and scalp acupoints do not require De-qi. Subjects will be monitored throughout the course of therapy with face-to-face assessments by blinded and trained clinicians after 0, 4, 8, 12 weeks of intervention. Clinical scales will also be recorded at 0 (A0), 8 (A½), and 12 weeks (A1).
215085465|NCT06456268|DEVICE|VibraCool mechanical stimulation and neuromodulatory therapeutic device|"Multiple studies have shown that vibration sources applied to muscles prior to exercise reduced soreness and lactate dehydrogenase production, and increased range of motion at 48 and 72 hours. Acute pain results from fast A nerves transmitting nociceptive information to the dorsal column, where the substantia gelatinosa's interneurons prioritize competing A mechanoreceptor and C-fibers to slow pain transmission. One study observed that stimulation of A mechanoreceptors shut the gate on pain transmission, an inhibitory mechanism known as gate control. Multiple physical methodologies leverage gate control physiology for pain relief, such as vibratory massage therapy and electrical stimulation to varying degrees. However, the use of vibratory massage to improve pain control and reduce opioid use following ACLR has not been well studied, and to our knowledge there are no randomized control trials (RCTs) evaluating the use of this modality compared to standard ice or cryocompression."
215094462|NCT01589913|BEHAVIORAL|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~1. Introduction to participants and online system~2. Knowledge regarding ICDs~3. Strategies for behavior change~4. Psychological models for anxiety and depression~5. Strategies to cope with avoidance, anxiety and depression~6. Resume, evaluation, resolution of open questions, goal setting, good bye"
215094463|NCT00721175|DEVICE|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
215094464|NCT00721175|DEVICE|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
215094465|NCT02198690|OTHER|Mammography decision aid|
215094466|NCT02198690|OTHER|Home safety pamphlet|
215094467|NCT05705661|DEVICE|HIGH FREQUENCY CHEST WALL OSCILLATION|The HFCWO device used a triangular wave form which increases the airflow velocity more than other devices. Therefore, clearing sticky airway mucus and alveolar exudates and maintaining airway patency has become currently the most urgent issue in the ventilatory management of patients with severe COVID-19.
214366756|NCT05484388|DEVICE|SP3|Investigational device absorption level Plus
214366757|NCT05435352|PROCEDURE|Core needle biopsy|An additional core needle biopsy is taken to run the Pear Bio test. Test results are not used to inform treatment. Approved neoadjuvant therapy regimens are given to the patient as per standard of care to observe response.
214366758|NCT00820937|PROCEDURE|Single photon emission computed tomography and Magnetic Resonance Imaging|
214366759|NCT01338025|DRUG|HAART regimen|The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
214366760|NCT01338025|DRUG|3TC or FTC monotherapy|The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
214491758|NCT04040764|PROCEDURE|Tritanium uncemented Total Knee Replacement|This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
214491759|NCT06459388|OTHER|Stabilizing Reversals and Rhythmic Stabilization|3 sets with 15 repetitions in each session, 5 days per week for 8 weeks.
215094468|NCT04652674|BEHAVIORAL|Telemedicine visit|A postoperative visit with the patient's surgeon conducted remotely via audio/video smartphone app
215094469|NCT04652674|BEHAVIORAL|In-person postoperative visit|A standard-of-care in-person postoperatively visit with the patient's surgeon
215094470|NCT01640665|DRUG|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
215094471|NCT01640665|DRUG|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
215094472|NCT04108728|DIAGNOSTIC_TEST|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
215094473|NCT02790814|DEVICE|Moyo strap-on|Continous measurements
215094474|NCT02790814|DEVICE|Hand-held fetoscope|Intermittent measurements
215085466|NCT06456268|DEVICE|Cryocompression (Game Ready, Bregs) device|Cryotherapy has also been used as an adjunctive post-operative therapy to reduce pain and inflammation following anterior cruciate ligament reconstruction (ACLR). It has been shown to decrease local metabolism, resulting in reduced pain and inflammation. Multiple studies have shown the benefits of using cryotherapy after ACLR, and more recently dynamic intermittent compression has been shown to improve circulation while reducing the risk of skin necrosis associated with static permanent compression. A recent meta-analysis including ten RCTs found significant reductions in post-operative VAS pain scores and breakthrough opioid consumption when using cryotherapy, such as Game Ready or Breggs ice therapy, following ACLR.
215085467|NCT06456268|DEVICE|Standard ice packs|Cold also provides peripheral gate-control relief via small, slow C-Fibers that transmit low level pain. In addition to local pain relief, intense cold can raise the A pain threshold distant to the location. The mechanism has been called descending or diffuse noxious inhibitory relief, or more recently conditioned pain modulation (CPM). Injections, aches, and infiltration of local anesthesia and dermal fillers are relieved by applying cold. For acute injury, near freezing cold relieves pain by suppressing the local metabolic production of inflammation and concomitant tissue ischemia from hypoxia due to the increased metabolic rate.
215085468|NCT03918850|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
215085469|NCT03918850|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
215085470|NCT02418312|DRUG|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
215085471|NCT02418312|DRUG|Placebo|placebo plus thienopyridine
214366761|NCT05159089|BEHAVIORAL|Socioecological model apply to reduce physical activity drop out in type 2 diabetes patients|"To implement this model this intervention aims to address three key elements: 1) prepare the user; 2) structure the action; and 3) design the context.~These goals will be worked in each session of Nordic Walking during the warm-up and cool-down and, if necessary, during the session (as long as it's non-stop or slowing down)."
214491760|NCT06459388|OTHER|Pelvic Proprioceptive Neuromuscular Facilitation|The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.
214977464|NCT06828679|OTHER|control group|Subjects in this group will receive the typical post-stroke care offered to stroke survivors of Hong Kong. This care emphasizes restoring function and independence through a comprehensive approach. Physical therapy focuses on improving mobility with exercises and training; occupational therapy helps patients relearn essential daily living skills, facilitating a smooth transition back to everyday life. Speech therapy is integral for addressing communication challenges, and psychological support is provided to help patients manage the emotional impact of stroke. All subjects will receive the above care for 8 weeks (≥3 hourly sessions per week). Clinical scales will be recorded at 0 (A0), 4 (A½), and 8 weeks (A1).
214977465|NCT06828679|DEVICE|Robotic Training|For this treatment group, CMC (corticomuscular coherence)-EMG-triggered control will assist wrist extension with hand open and wrist flexion with hand close alternately by mechanical pneumatic support \[60\]. During wrist-hand extension, the pneumatic fingers will assist a hand-open motion with constant inflation till the inner pressure reaches 90kPa; during the wrist-hand flexion, the pneumatic fingers will deflate constantly to assist a hand-close motion. To trigger ENMS assistance, two criteria must be met: (1) the average EMGs of target muscles exceed a pre-defined threshold, and (2) a significant CMC peak value with peak frequency in the beta band is captured. Here, the target muscle groups will be the extensor digitorum and extensor carpi ulnaris (ED-ECU) and flexor digitorum and flexor carpi radialis (FD-FCR), and the EMG and CMC will be evaluated during sustained contraction of these muscles over a 3-sec window.
215085472|NCT05477576|DRUG|RYZ101|RP3D as determined in Phase 1b
215085473|NCT05477576|DRUG|Everolimus|Everolimus
215085474|NCT05477576|DRUG|Sunitinib|Sunitinib
215085475|NCT05477576|DRUG|Octreotide|High-dose octreotide
215085476|NCT05477576|DRUG|Lanreotide|Lanreotide
215085477|NCT00803413|BEHAVIORAL|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
215085478|NCT00803413|BEHAVIORAL|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
215085479|NCT00803413|BEHAVIORAL|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
215085480|NCT00803413|BEHAVIORAL|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
215085481|NCT00828399|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine 30g/day
215085482|NCT00828399|DIETARY_SUPPLEMENT|Whole protein|Oral whole protein 30 g/day
215085483|NCT04949542|BEHAVIORAL|Bolster|Bolster is a native mobile app that provides on-demand content to caregivers of young adults with early psychosis to support their caregiving skills and knowledge of psychosis.
214491761|NCT06818955|DRUG|Orlistat 120 mg|Orlistat 120 mg po tid
214491762|NCT06802484|OTHER|Experimental: Pre-Menopausic|The physical exercise program, lasting for 26 weeks, was conducted with an uninterrupted weekly frequency of 3 sessions, on non-consecutive days, in the late afternoon (at 7:30 PM), each lasting 60 minutes.
215085484|NCT04949542|BEHAVIORAL|Control|Exemplar resources provided in the control arm will include a selection from the National Alliance on Mental Illness and Mental Health America designed to support caregivers helping loved ones access care.
215085485|NCT02303782|DRUG|OTX015|
215085486|NCT02303782|DRUG|Vidaza (azacitidine)|
215085487|NCT01307202|DRUG|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
214366762|NCT05159089|BEHAVIORAL|Nordic Walking|Sessions will be progressive: the first month will long 30 minutes, the second month 35 minutes, and the third month 40 minutes (without 10 minutes warm-up and 10 minutes cool-down each session). The track will not have more than 100 accumulate high and will allow doing 5 kilometers without stopping. The meeting point will be between the Biomedical Research Park (Barcelona) and Hospital del Mar (nearby CAP Sant Joan). All sessions will be conducted by an instructor of nordic walking physiotherapists.
214491763|NCT06802484|OTHER|Experimental: Post- Menopausic|The physical exercise program, lasting for 26 weeks, was conducted with an uninterrupted weekly frequency of 3 sessions, on non-consecutive days, in the late afternoon (at 7:30 PM), each lasting 60 minutes.
214491764|NCT06802614|DEVICE|BLEACHING GEL A|Carbomer 940 hydrogel + 6% Hydrogen Peroxide
214491765|NCT06802614|DEVICE|5% NF_TiO2|Bioactive nanoparticles
214491766|NCT06802614|DEVICE|BLEACHING GEL B|Hyaluronic Acid hydrogel + 6% Hydrogen Peroxide
214491767|NCT06802614|RADIATION|VISIBLE LIGHT IRRADIATION|Low intensity visible light irradiation (405 nm)
214491768|NCT06802614|DEVICE|Whiteness HP 35%|Commercially available bleaching gel
214977466|NCT06828679|DEVICE|Neuromuscular Electrical Stimulation Group|For this treatment group, constant NMES (70V, 40Hz, 0-300µs square wave bursts \[63\]) will be delivered to the ED-ECU and FD-FCR muscles to assist in wrist-hand extension and flexion, respectively. The pulse width of NMES will be individually adjusted to achieve the maximum muscle contraction with the minimum stimulation intensity. The control strategy of CMC-EMG-triggered NMES will be the same as that used in the robot.
214977467|NCT06833333|PROCEDURE|Central venous catheter|Central venous catheter will be introduced to measure central venous pressure
214977468|NCT06833333|DIAGNOSTIC_TEST|IVC collapsibility index|In supine position, IVC will be assessed in the anteroposterior plane in the subxiphoid view using two-dimensional mode till an optimal view of IVC entering the right atrium will be obtained. Then, measurement of its collapsibility will be done.
214977469|NCT00453908|DRUG|Alfuzosin|
214977470|NCT00916578|RADIATION|Radiation Therapy|50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
214977471|NCT00916578|DRUG|Capecitabine|During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
214977472|NCT00265434|DRUG|Pulmozyme|
214977473|NCT02262897|DRUG|Nab-paclitaxel|Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
214977474|NCT02576899|BEHAVIORAL|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
214977475|NCT02576899|BEHAVIORAL|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
214977476|NCT05953727|OTHER|Low level laser therapy with proprioceptive stimulation|10 minutes of low level laser therapy and 10-15 minutes of proprioceptive stimulation and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
214977477|NCT05953727|OTHER|Low level laser therapy without proprioceptive stimulation|10 minutes of low level laser therapy and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
214977478|NCT02746835|OTHER|Exercise program for fall prevention|"Set of exercises to improve the following parameters:~balance, endurance, muscle strength, flexibility."
214977479|NCT02324686|DRUG|vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
214977480|NCT01477281|DRUG|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
214977481|NCT01477281|DRUG|Venaflon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
215085488|NCT01307202|DRUG|Placebo|Placebo will match the the gabapentin pill and will be given orally.
214366763|NCT06022328|BIOLOGICAL|Assessment of the epigenetic age|Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis
214366764|NCT02381522|OTHER|Remote Ischemic Pre-conditioning|
214366765|NCT02381522|OTHER|Sham RIPC|
214491769|NCT06802614|DEVICE|Whiteness HP Automixx 6%|Commercially available bleaching gel
214491770|NCT06804174|OTHER|use of gonadotropins|Comparison of endometrial proteome during the window of implantation between stimulated and spontaneous cycles.
214491771|NCT05599048|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
214491772|NCT05599048|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
214491773|NCT05599048|DRUG|13C,15N-Urea|Given IV
214491774|NCT06267924|DEVICE|Otoband Experimental|Participants will be randomly assigned to use the Otoband Experimental device to determine effectiveness in providing temporary relief to symptoms of vertigo.
214491775|NCT06267924|DEVICE|Otoband Sham|Participants will be randomly assigned to use the Otoband Sham device to determine effectiveness in providing temporary relief to symptoms of vertigo.
214491776|NCT06815887|DRUG|Bupivacaine|Patients received the combined pectoralis nerve block II (PECS II) (20 mL) and stellate ganglion block (5 mL) using 0.5% bupivacaine (local anesthetic) without magnesium sulfate.
214491777|NCT06815887|DRUG|Bupivacaine + Magnesium sulfate|Patients received the combined (20 mL) pectoralis nerve block II (PECS II) and stellate ganglion block (5 mL) using 0.5% bupivacaine (local anesthetic) mixed with 2.5 mL magnesium sulfate (10%), i.e., 250 mg.
214491778|NCT06854991|OTHER|Active VR-PAT|Virtual Reality Pain Alleviation Tool (VR-PAT) hosted on a Pico Neo 3 Pro Eye headset. Both engagement and immersion.
214491779|NCT06854991|OTHER|Passive VR-PAT|VR-PAT hosted on a Pico Neo 3 Pro Eye headset, with the active game participation removed. Immersion with engagement removed.
214977482|NCT00194129|DRUG|Lithium|Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
214977483|NCT00194129|DRUG|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
214977484|NCT00194129|DRUG|Placebo|Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
214977485|NCT01266616|BIOLOGICAL|Profectus HIV MAG pDNA vaccine|3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
214977486|NCT01266616|BIOLOGICAL|IL-12|Administered at Weeks 0, 4, and 12
214977487|NCT01266616|OTHER|Placebo|Saline injections at Weeks 0, 4, and 12
214977488|NCT00801944|DRUG|Solifenacin succinate|oral
214977489|NCT00801944|DRUG|Placebo|oral
214977490|NCT02332603|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
214977491|NCT02332603|DRUG|Isotonic Sodium Chloride|Placebo
214977492|NCT02158689|DRUG|Letrozole|
215085489|NCT04312607|DIAGNOSTIC_TEST|BCR-ABL gene PCR|peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
215085490|NCT03483870|DRUG|Morphine Sulfate|200 ug morphine sulphate will be injected intrathecally
214491780|NCT06854991|OTHER|iPad|VR-PAT hosted on an Apple iPad. Engagement with immersion removed.
214491781|NCT06827574|OTHER|Sciatic nerve flossing technique|Group A 16 subjects were treated with Sciatic Nerve Flossing Technique. Subjects were in sitting position. Nerve Flossing Technique was performed actively with the participant sitting on a chair. The participant was flex the knee of the target lower extremity backwards beside the chair, as far back as possible and flex the neck at the same time, holding both the flexed knee and neck in this position for 10 seconds. The participant in turn will extend the neck and the knee of the target lower extremity, abduct and then flex the hip until pain is felt and do not push beyond that point. This extended position was maintained for 10 seconds. The above procedure of Nerve Flossing Technique was repeated for 15 times, 3 sets with an interval of 5 minutes between each set. As the nerve becomes less sensitive, the participant can increase the stretching effect by dorsiflexion the ankle and extending the toes of the foot upward towards the shin.
215085491|NCT03483870|DRUG|Placebo|2 mL of normal saline 0.9% IV injection
215085492|NCT03483870|DRUG|Granisetron|2 mL of 2 mg granisetron IV injection
215085493|NCT02209948|DRUG|Temozolomide|
215085494|NCT01335841|DEVICE|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
215085495|NCT04562597|DRUG|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
215085496|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
215085497|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
215085498|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
214679835|NCT03919916|PROCEDURE|Serratus plane block|Placement of initial local anaesthetic bolus and catheter for continuous infusion in the plane between latissimus dorsi and serratus anterior in the midaxillary line at the level of the 5th rib
214679836|NCT03919916|OTHER|Patient controlled analgesia|Computerised pump device facilitating the patient self administration and titration as needed of morphine
214977493|NCT02158689|DRUG|human menopausal gonadotropin (hMG)|
214977494|NCT04907123|OTHER|Intensive sodiuria-guided diuretic treatment|Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment
214977495|NCT04907123|OTHER|Standard diuretic treatment|Stepwise diuretic therapy based on diuresis assessment
214977496|NCT05209659|OTHER|Pragmatic Mobilization|"The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.~Other Name: Non-thrust manipulation (pragmatically applied)"
214977497|NCT01433159|DRUG|HP011-101 (Xenaderm Ointment)|The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
214977498|NCT01433159|DRUG|Standard Care|No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
214977499|NCT00084240|DRUG|Azithromycin/Chloroquine|
214977500|NCT00084240|DRUG|Sulfadoxine-Pyrimethamine/Chloroquine|
214977501|NCT01100853|DRUG|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
214977502|NCT03277937|PROCEDURE|angiography in EUS-injection of coils + CYA|Doppler imaging will be used to allow direct visualization of the varices flow. The gastric vessels will be followed from the cardia to the proximal part of the esophagus, to detect the feeding vessel (FV). Once the FV has been found, a 19-gauge EUS-FNA will be used to access the vessel. An angiography will be performed using 5-10 ml of water-soluble contrast under fluoroscopy, to ensure intravascular location and study varix flow direction. Finally, patients will be treated by EUS-deployment of coils followed by CYA injection. The coils will be delivered into the vessel through the FNA needle, using the stylet as a pusher. The 2-Octyl-CYA will be used. It will be injected always after the coils deployment and then 1 mL of saline solution will be used to flush the glue completely.
214366766|NCT05884216|DEVICE|Entarik Feeding Tube System|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System is designed to aid qualified operators in the placement of the Entarik Feeding Tube (Entarik FT) into the stomach of patients requiring enteral feeding. The Entarik FT is equipped with sensors designed to provide information about the location of the tube tip relative to the stomach, thus assisting in reducing the incidence of misplacement during first positioning. The Entarik Monitor also monitors the feeding tube position continuously during the course of feeding and automatically and in real-time alerts of tube migration."
214366767|NCT05884216|DEVICE|Entarik Feeding Tube System without monitoring|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System will collect data from the Entarik Feeding Tube. There will be no monitoring or dislodgement alerts, and no placement guidance."
214977503|NCT02624999|BIOLOGICAL|AlloVax™|AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
214366768|NCT06456632|OTHER|Intervention Su Jok Therapy|Su Jok Therapy
214366769|NCT03017079|DIETARY_SUPPLEMENT|semi-solid agent with standard enteral feeding|after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 minutes
214366770|NCT03017079|OTHER|standard enteral feeding|Intermittent enteral feeding is applied less than 60 minutes
214366771|NCT03512652|DEVICE|Patello|The Patello is a new intervention device which mobilizes the Patella passively and continuously in cranial-caudal direction to increase Patella mobility.
214491782|NCT06827574|OTHER|Active Release Technique|Group B 16 subjects were treated with Active Release Technique. Subjects were in prone position. ART was performed actively by the participant lying on a bed. The participant was dorsiflex the foot of the target lower extremity, holding the dorsiflexion foot in this position for 10 seconds. The participant in turn was plantar-flexed the foot of the target lower extremity. This dorsiflexion position was maintained for 10 seconds. The above procedure of Active Release Technique was repeated for 15 times, 3 sets with an interval of 5 minutes between each set. As the muscles becomes more flexible, the participant can increase the flexibility effect by plantar flexing the foot.
214491783|NCT06826534|BEHAVIORAL|Cardio-oncology rehabilitation|Least 60 minutes of physical activity each day including vigorous-intensity and strengthening activities at least 3 days per week
214491784|NCT06826352|BEHAVIORAL|Active Distraction|The video games will be played by children during the procedure.
214491785|NCT06826352|BEHAVIORAL|Passive Distraction|The cartoons will be selected by the children related to their interests. The cartoons are included Pepee, Niloya, Tom and Jerry, Masha and The Bear and others.
214491786|NCT06854120|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
214977504|NCT02624999|DRUG|Cisplatin|Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
214977505|NCT00532051|DEVICE|OCT measurements|This study is about a new imaging method to study the front part of the eye. This imaging method is called Optical Coherence Tomography (OCT) which provides detailed cross-sectional (layered) views of structures in the eye. The OCT system scans a beam of light across the eye to take a picture. OCT provides a more detailed image than other imaging methods of the eye such as ultrasound, CT scan (computed tomography), and MRI (magnetic resonance imaging). In addition, OCT imaging does not touch the eye. OCT is routinely used in imaging structures in the back of the eye (retina) and cornea. This study uses high-speed FDA approved OCT systemsThe measurements from the OCT systems are used in selecting IOL power.
214977506|NCT02858466|RADIATION|MRI scan|
214977507|NCT01423825|BIOLOGICAL|Sub C gp140 Vaccine|100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
215085499|NCT04562597|DRUG|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
215085500|NCT04562597|DRUG|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
215085501|NCT04480034|PROCEDURE|Bariatric procedures|All standard, laparoscopic bariatric procedures endorsed by SICOB (Società Italiana della Chirurgia dell'Obesità, Italian Society of Obesity Surgery) and by IFSO (International Federation of the Societies of Obesity Surgery), will be considered: sleeve gastrectomy, R-en-Y gastric bypass, one anastomosis gastric bypass, single anastomosis duodeno-ileal bypass with sleeve. The selection criteria for the surgery candidates will comply to the latest guidelines for bariatric surgery endorsed by SICOB, IFSO and EAES (European Association of Endoscopic Surgery). All the participating centers will follow the usual recruitment protocol. Restart of the bariatric elective surgery is based on the guidelines of SICOB for the bariatric surgery restart in Italy during the COVID-19 phase 2-3 of endemics.
214977508|NCT01423825|BIOLOGICAL|MF59C.1 Adjuvant|MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
214366772|NCT06220357|DIAGNOSTIC_TEST|Indocyanine Green|The patients were split into three different groups, the patient were given ICG with three different concentrations in a double-blind randomized manner postoperatively. The fluorescence emitted was quantitatively analyzed using the ImageJ software to ascertain the mean gray values, providing a robust measure of the ICGA concentration. The imaging was captured using a FLUORO 4000XL type NIR camera, positioned at a distance of 15-20 cm perpendicular to the flap.
214366773|NCT04504656|OTHER|observation of postoperative leak, stenosis, mortality|detect complications in both groups
214977509|NCT01423825|OTHER|Sodium chloride|Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
215085502|NCT05883046|OTHER|Performance-Enhancing Substances|All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
215085503|NCT05883046|OTHER|Placebo|20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
215085504|NCT05883046|OTHER|Baseline (Control)|No supplement conditions
214366774|NCT02964676|PROCEDURE|ab interno trabeculectomy with Trabectome|123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly
214366775|NCT02964676|PROCEDURE|trabeculectomy|123 PACG will be recruited to receive trabeculectomy to reduce IOP
214366776|NCT05547295|OTHER|Numeric prevention|Numeric information for prevention of pressure sores thgrough digital tool MEDIASCREEN
214366777|NCT05547295|OTHER|Paper prevention|Information for prevention of pressure sores in classic way with paper
214977510|NCT02442609|OTHER|questionaire|questionaire before surgery
214977511|NCT01682096|RADIATION|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
214977512|NCT01682096|PROCEDURE|Exercise stress echocardiography|Limited by symptoms
214977513|NCT03788694|DRUG|Ketamine|8 doses of intranasal ketamine; 40 mg per dose.
214977514|NCT03109483|OTHER|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
214977515|NCT05299866|DRUG|S-ketamine|After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
214977516|NCT05299866|DRUG|Placebo|After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
214977517|NCT00670059|GENETIC|single embryo transfer without aneuploidy screening|without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
214977518|NCT00670059|GENETIC|single embryo transfer with aneuploidy screening|with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
214977519|NCT00825123|DRUG|Ivabradine|Ivabradine 10 mg once
214977520|NCT00825123|DRUG|Metoprolol|Metoprolol 50 mg once
214977521|NCT00825123|DRUG|Placebo|Lactose powder
214977522|NCT01190891|PROCEDURE|Manual Physical Therapy|Same as arm description
214977523|NCT01190891|PROCEDURE|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
214977524|NCT00044291|DRUG|atamestane|
214977525|NCT00044291|DRUG|toremifene|
214977526|NCT00044291|DRUG|letrozole|
214977527|NCT00044291|DRUG|aromatase inhibition|
214977528|NCT00044291|PROCEDURE|hormone therapy|
214977529|NCT00044291|PROCEDURE|endocrine therapy|
214977530|NCT00044291|PROCEDURE|antiestrogen therapy|
214977531|NCT00266708|DRUG|Risedronate|risedronate 35 mg weekly
214977532|NCT00266708|DRUG|Placebo|Risedronate Placebo 35 mg weekly
215085505|NCT04944732|DIAGNOSTIC_TEST|laboratory examination, auxiliary examination, pathological results|Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)
215085506|NCT05295147|OTHER|Palmar Grasp Reflex Stimulation|The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
215085507|NCT06613360|DRUG|CLN-978|Specified dose on specified days
215085508|NCT02961192|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
215085509|NCT02961192|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
215085510|NCT02961192|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
215085511|NCT02630017|DRUG|ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
215085512|NCT02630017|DRUG|ADHD placebo first, methylphenidate second|double-blind, counter-balanced administration
215085513|NCT02630017|DRUG|Non-ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
215085514|NCT02630017|DRUG|Non-ADHD placebo first, methylphenidate second|
215085515|NCT05348746|OTHER|Advanced Analysis of Polymorphism|Assessment of Plasmodium falciparum drug resistance. Target P. falciparum drug resistance genes: Pfk13 propeller, Pfdhfr and Pfdhps. The polymorphisms analysis of the propeller domain of the Pfk13 gene will be performed by PCR amplifications and subsequent sequencing. Analysis of Pfdhfr gene at codons 51, 59, 108 and Pfdhps gene at codon positions 436, 437, 540, 581, 613 will be done by means of amplifications and subsequent Sanger sequencing. Molecular studies will be performed only for research purposes and will have no impact on the clinical management of study patients.
215085516|NCT00289198|DRUG|FF|fluticasone furoate 110 μg nasal spray
214977533|NCT00348400|DRUG|Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost|
214366778|NCT06088277|BEHAVIORAL|TM HIV|Participants will receive 5 intervention text messages (TM) about HIV risk and testing per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
214977534|NCT01926028|BIOLOGICAL|NDV-3A|0.5mL injection IM
214977535|NCT01926028|BIOLOGICAL|NDV-3|0.5mL injection IM
214977536|NCT01926028|BIOLOGICAL|Placebo|aluminum hydroxide and buffered saline
214977537|NCT03012269|BEHAVIORAL|Working memory training|
214977538|NCT02932436|DRUG|Empagliflozin|10 mg per os daily for 12 weeks
214977539|NCT02932436|DRUG|Placebo|amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
215085517|NCT00289198|DRUG|Placebo|placebo nasal spray
215085518|NCT06053957|PROCEDURE|early mobilization|early mobilization program
215085519|NCT01176565|DRUG|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
215085520|NCT00724412|OTHER|Systane|Dry Eye relief eye drops
215085521|NCT00724412|OTHER|Optive|Dry Eye relief eye drops
215085522|NCT05141656|OTHER|No intervention will be considered in this study.|No intervention will be considered in this study.
215085523|NCT02406443|DRUG|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
214977540|NCT04892069|DRUG|Insulin Degludec/Insulin Aspart|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
214977541|NCT04577872|OTHER|Pelvic floor muscle training|The treatment for the sitting group comprised 8 sessions, with a 1-hour combined pelvic floor muscle training (cPFM-T) session each week in a group and 15 minutes of individual home training, six times a week for a total of 8 weeks of treatment. All training sessions comprised warming-up, gradual muscle strengthening and relaxation exercises. In the study, before and after the training programme, we used a self-administered questionnaire.We measured changes in pelvic floor muscle activity with a vaginal surface electromyographic instrument. We performed the transversus abdominis measurements at the same time as the vaginal measurements and pelvic floor muscle tasks.
215085524|NCT02406443|OTHER|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
214977542|NCT01130272|DRUG|Eluxadoline|Tablets, orally, twice daily.
215085525|NCT03087526|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
215085526|NCT06070090|PROCEDURE|Acupuncture|The traditional East Asian methods of treating disease by inserting needles along specific pathways or meridians.
215085527|NCT01062061|BIOLOGICAL|VARIVAX™|Attenuated live varicella vaccine
215085528|NCT05436977|DIAGNOSTIC_TEST|coronary OCT|Intermediate coronary lesions will be evaluated by OCT
215085529|NCT05436977|DIAGNOSTIC_TEST|68GaDOTATATE PET/CTCA|Intermediate coronary lesions will be evaluated by68GaDOTATATE PET/CTCA
215085530|NCT06773299|BEHAVIORAL|PAT+HEALTH curriculum - Nigeria|This intervention is an adaption of the PAT Curriculum and the HEALTH intervention specifically tailored for the Nigerian context.
215085531|NCT05713695|BEHAVIORAL|Full MISSION|MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery.
214977543|NCT01130272|DRUG|Placebo|Matching placebo oral tablets twice daily.
214977544|NCT01548404|DRUG|Placebo|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
214977545|NCT01548404|DRUG|Dupilumab|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
214366779|NCT06088277|BEHAVIORAL|TM HL|Participants will receive 5 intervention text messages (TM) about promoting healthy living (HL) per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
214977546|NCT03559634|DIAGNOSTIC_TEST|Intervention Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. Contraceptive choices being offered include the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. The participant can then decide if they would like to start a medication they qualify for in the ED.
214977547|NCT03559634|OTHER|Control Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. This includes the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. Participants will then be given follow up information on outpatient locations where they can receive these contraceptive methods.
214977548|NCT00641056|DRUG|Exenatide Once Weekly|subcutaneous injection, 2.0mcg, once weekly
214977549|NCT00641056|DRUG|Insulin Glargine|subcutaneous injection, variable dose, QD
214977550|NCT00737048|DRUG|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
214977551|NCT00737048|DRUG|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
215085532|NCT05713695|BEHAVIORAL|Linkage Only Delivered by a Peer Specialist|Linkage only is provided via Peer Specialists whom have lived experiences similar to that of our participants. Linkage only includes informal treatment planning and linkages and supports to needed community services.
215085533|NCT05929586|OTHER|"The combined C-it DU-it intervention: community data use for ANC"|"Combining data linkage (C-it) with work improvement teams for community data use (DU-it) to improve antenatal clinic uptake. Our short name C-it DU-it (pronounced see-it; do-it) is an acronym intended to convey 'seeing' linked data (C-it) and 'doing' or acting on the data (DU-it)"
215085534|NCT04839341|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
215085535|NCT04907526|BIOLOGICAL|Autologous mononuclear cells|Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.
215085536|NCT04603417|DIAGNOSTIC_TEST|Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI|This cross-sectional study will present the participants with an instrumental pain avoidance learning task, while we record continuous Magnetoencephalography (MEG) brain signals, and other autonomic measurements. All patients will complete behavioral, neuropsychological and pain assessments to rate their current pain, disability, fear, anxiety, and depression using standardized scales.
215085537|NCT06512896|OTHER|FOLactis|Evaluate the safety,tolerability, efficacy of intraluminal injection of FOLactis combined with chemotherapy, target therapy, and immunotherapy
214366780|NCT06545981|OTHER|Lumbar puncture and administration of medication|Patients with idiopathic intracranial hypertension will receive lumbar puncture and will be given medication to reduce intracranial pressure by neurologists. The lumbar puncture and the administration of medication are not part of this study, patients would also receive these without participating in the study.
214977552|NCT00737048|DRUG|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
214977553|NCT00737048|DRUG|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
215085538|NCT00504790|DRUG|GSK923295|anti-mitotic compound
214977554|NCT04175717|OTHER|physiotherapy-led follow-up programme|In this study arm, the participants will receive a nine weeks exercise programme and four education sessions. During the exercise programme, the patients will exercise twice per week under supervision and once by themselves. The supervised exercise sessions will consisted out of a combination of a cardiopulmonary and strength training and the unsupervised session will be an activity, which the participants like doing. Additionally, when the patient shows a reduced maximal inspiratory pressure (indication for a reduced diaphragm strength), the patient will also be ask to do an inspiratory muscle training at home. Furthermore, they will participate in education sessions, where they learn things about the intensive care unit, the post-intensive care syndrome, relaxation techniques and how to carry on with exercising.
214977555|NCT05352646|DRUG|Autologous memory lymphocyte Injection (NewishT), low-dose group|Recruited participants in low-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 4 weeks, a total of 2 times.
214977556|NCT05352646|DRUG|Autologous memory lymphocyte Injection (NewishT), high-dose group|Recruited participants in high-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 2 weeks, a total of 4 times.
214977557|NCT05591521|OTHER|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
214977558|NCT01530542|DRUG|oxycodone hydrochloride|oxycodone hydrochloride 5 mg tablet under fasted conditions
214977559|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
214977560|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
214977561|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
214977562|NCT01530542|DRUG|marketed oxycodone hydrochloride|1 x oxycodone hydrochloride 15 mg tablet under fed conditions
214977563|NCT03821961|PROCEDURE|Metabolic Surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
214977564|NCT03210740|DRUG|AM001 Cream, 7.5%|Active Cream
214977565|NCT03210740|DRUG|Vehicle Cream|Placeo
214977566|NCT05645198|DRUG|Oozfix|Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
214977567|NCT05645198|DRUG|Greenplast|Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
214977568|NCT05941806|DRUG|pr Sandoz Tamsulosin|Sandoz Tamsulosin, the study drug, is an alpha1-adrenergic blocking agent approved by Health Canada for men with bladder outlet obstruction symptoms associated with benign prostatic hyperplasia.
214977569|NCT05941806|DRUG|Glucose|Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec
214977570|NCT00004817|DRUG|phenytoin|
214977571|NCT00004817|DRUG|valproate sodium|
214977572|NCT01086488|DRUG|FOSCAN|Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
214977573|NCT03498677|BEHAVIORAL|presentation order|section presentation one
214977574|NCT03498677|BEHAVIORAL|alternative presentation order|section presentation two
215085539|NCT03435562|OTHER|JUUL electronic cigarette|Effects of JUUL electronic cigarette use.
214366781|NCT06653855|OTHER|Dry Static Cupping|A myofascial decompression cupping set with a precision pressure pump will be used to perform dry static cupping to the adductor and hamstring muscle groups of the affected limb, using a negative pressure of 300mmHg for eight minutes each.
214366782|NCT06653855|OTHER|Placebo cupping|The same protocol will be used as stated for the Dry static cupping intervention, with the only difference being that the cup will be pumped to 50mmHg instead of 300mmHg.
214366783|NCT06653855|OTHER|Standard physical therapy treatment|"Treatment will consist of typical physical therapy interventions performed for patients with spasticity of the lower extremity after stroke. These may include, but not be limited to:~* Balance exercise~* Therapeutic exercise~* Neuromuscular/muscular coordination exercise~* Manual (hands on) therapy~* Gait training~The treating physical therapist is left with the autonomy of the standard physical therapy treatment (within the above stated groups of interventions) because patients with the diagnosis of stroke do not all present with the same type or level of impairment. Furthermore co-morbidities (e.g., hypertension) and/or functional level (wheelchair bound vs. independent ambulator) may necessitate different treatment strategies. Therefore, while the general categories of treatment will remain the same across all study patients, it is expected that the treating physical therapist provides patient-specific interventions."
214366784|NCT02781129|OTHER|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
214366785|NCT01439659|BEHAVIORAL|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
214366786|NCT01439659|DIETARY_SUPPLEMENT|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
214366787|NCT05391828|DEVICE|Zimmer-Biomet Persona Medial Congruent (MC) Bearing Design|TKA will be performed using the MC Bearing Design. The MC bearing provides medial stability and lateral mobility to facilitate more natural motion.
214366788|NCT05391828|DEVICE|Zimmer-Biomet Persona Posterior-Stabilized (PS) Bearing Design|TKA will be performed using the PS Bearing Design. The PS bearings are designed to provide ±1.5 degrees varus/valgus constraint and ± 5.5 degrees internal/external rotation constraint.
215085540|NCT03435562|OTHER|IQOS electronic cigarette|Effects of IQOS electronic cigarette use.
215085541|NCT03435562|OTHER|Own Brand cigarette|Effects of own brand cigarette use.
215085542|NCT04214639|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
215085543|NCT04214639|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
214366789|NCT04549155|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
215085544|NCT01131741|DRUG|Epinephrine|This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
215085545|NCT01131741|DRUG|Control|This group receives 3 mL of saline IV during operation.
215085546|NCT03579212|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
215085547|NCT02519868|DEVICE|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
215085548|NCT02519868|DEVICE|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
215085549|NCT00265265|DRUG|Atomoxetine|
215085550|NCT04759365|DRUG|ASN51|ASN51 formulation for oral capsule
214977575|NCT01657617|RADIATION|Boost Stereotactic Body Radiation Therapy|"The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:~Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.~Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy."
214977576|NCT04020367|PROCEDURE|biopsy of mucosa's olfactory|intervention under general or local anesthesia
214977577|NCT06257732|OTHER|Exercise|The exercise interventions in this study include High-Intensity Interval Training (HIIT), involving brief bursts of intense exercise; Resistance Exercise, focusing on strength and muscle endurance; and Fatmax Exercise, tailored to optimize fat oxidation during aerobic activity.
214977578|NCT06257732|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will be employed as a counseling technique to elicit behavior change by fostering collaborative and empathetic conversations, enhancing motivation for positive lifestyle modifications in individuals with liver fat accumulation.
214977579|NCT04602286|OTHER|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
214977580|NCT03774108|DRUG|Metformin Hydrochloride 850 MG|8 weeks tratment with oral metformin
214977581|NCT03774108|OTHER|Placebo|8 weeks tratment with oral placebo
215085551|NCT04759365|DRUG|Placebo|Placebo formulation for oral capsule
215085552|NCT03573700|DRUG|Cyclophosphamide|Given IV
214366790|NCT03678935|OTHER|Low FODMAP diet|The intervention group follows the low FODMAP diet for 4 weeks.
215085553|NCT03573700|DRUG|Fludarabine|Given IV
215085554|NCT03573700|DRUG|Mesna|Given IV
215085555|NCT03573700|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
215085556|NCT03573700|BIOLOGICAL|CD19- specific CAR engineered autologous T-cells (SJCAR19 product)|Given IV
215085557|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
214366791|NCT04964219|DRUG|S-ketamine|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
214977582|NCT03228082|DEVICE|Home Blood Pressure Monitoring (HBPM)|Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
215085558|NCT02757859|OTHER|Lavage|Receive EIPL-S
215085559|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
215085560|NCT02757859|OTHER|Lavage|Receive EIPL-D
215085561|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
215085562|NCT04667897|DRUG|601 1.25mg|Solution for injection (intravitreal use)
215085563|NCT04667897|DRUG|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
215085564|NCT05834010|BIOLOGICAL|Fecal Microbiome Transplant|Fecal matter from healthy age/sex matched established and screened donors, recruited from the Danish Blood-donor system
215085565|NCT06614504|OTHER|Varying the nicotine content of cigarettes|Altering the nicotine content of the tobacco research cigarettes
215085566|NCT06614504|OTHER|Varying the nicotine content of e-cigarettes|Altering the nicotine content of the research e-cigarettes
215085567|NCT01101698|DRUG|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
215085568|NCT01101698|DRUG|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
215085569|NCT01414764|OTHER|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
214977583|NCT04040439|DRUG|Dexmedetomidine Hydrochloride|"\[Sedation during and after mechanical ventilation in the intensive care setting\] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate."
214977584|NCT01309386|DRUG|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
214977585|NCT01309386|DRUG|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
214977586|NCT04785729|DRUG|Almonertinib combine with Pyrrolitinib|110mg,qd Almonertinib+（240mg/320mg/400mg）,qd Pyrrolitinib
214977587|NCT00778050|DRUG|Amoxicillin 600mg|
215085570|NCT01414764|DRUG|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
215085571|NCT00387374|BIOLOGICAL|bevacizumab|Given IV
215085572|NCT00387374|DRUG|paclitaxel|Given IV
215085573|NCT00387374|DRUG|carboplatin|Given IV
215085574|NCT00387374|RADIATION|radiation therapy|Undergo radiotherapy
215085575|NCT00221624|DRUG|Peginterferon alfa-2a|
215085576|NCT00221624|DRUG|ribavirin|
215085577|NCT00221624|DRUG|amantadine|
214977588|NCT00224263|DRUG|Lingzhi (Ganoderma)|
215085578|NCT02208453|DEVICE|InSpace Implantation|InSpace device Implantation
215085579|NCT03481920|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.
215085580|NCT03481920|DRUG|Avelumab|Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
215085581|NCT03180398|DEVICE|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
215085582|NCT01143051|DRUG|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
215085583|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
214366792|NCT04964219|DRUG|Placebo|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
214366793|NCT04350892|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|"This surgery is often called gastric bypass. It is a weight-loss surgery that involves creating a small stomach pouch and bypassing part of the small intestine.~If you decide with your doctor to have gastric bypass, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the Roux-en-Y gastric bypass."
214977589|NCT05676229|DIETARY_SUPPLEMENT|Probiotic blend|Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858
214977590|NCT05676229|DIETARY_SUPPLEMENT|Placebo|Maltodextrin only (vehicle)
214977591|NCT04811157|DIETARY_SUPPLEMENT|Test product|200 g/day of unsweetened yogurt supplemented with a dietary fiber blend
214977592|NCT04811157|DIETARY_SUPPLEMENT|Control product|200 g/day of unsweetened yogurt
214977593|NCT04249479|OTHER|CM Temperature (20° C)|CM will be administered at 20° C (room temperature).
214977594|NCT04249479|OTHER|CM Temperature (37° C)|CM will be administered at 37° C (pre-heated).
214977595|NCT04249479|OTHER|Weight|The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.
214977596|NCT05626569|DRUG|PD-1 combined with SBRT|Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
215085584|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
215085585|NCT03159507|DIETARY_SUPPLEMENT|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
215085586|NCT03036345|DEVICE|Dual-monitoring|Monitored using both INVOS and FORE-SIGHT monitors.
215085587|NCT03362099|DRUG|Varenicline Tartrate or bupropion|the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
215085588|NCT01013155|DRUG|perindopril erbumine|8 mg tablet
215085589|NCT02536066|BEHAVIORAL|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
215085590|NCT00987896|DEVICE|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
215085591|NCT02094742|PROCEDURE|biopsy|
215085592|NCT03112525|DIAGNOSTIC_TEST|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
214977597|NCT03529500|DIAGNOSTIC_TEST|Caries detection - dmtf index|"Dental caries experience was recorded using the dmft index, which was employed following the recommendations of the WHO to establish the prevalence and severity of caries. Active visible white spots were also recorded. The examinations were performed in duplicate for each child with the aim of establishing inter-examiner agreement using the Kappa statistic which demonstrated good agreement (K = 0.81).~The criteria adopted for the determination of prevalence followed by guidelines of the Oral Health Surveys - Basic Methods, 4th edition (WHO, 1997) described in the examiner's manual and annotator's manual produced by the coordination team of the Brazil Oral Health Project. The severity and prevalence of dental caries were determined based on the dmft index."
214366794|NCT04350892|PROCEDURE|Sleeve Gastrectomy (SG)|"Sleeve gastrectomy, is a weight-loss surgery that involves removing about 80% of the stomach.~If you decide with your doctor to have sleeve gastrectomy, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the sleeve gastrectomy."
214977598|NCT03529500|DIAGNOSTIC_TEST|Saliva flow rate|Samples of non-stimulated saliva were collected from the participants for five minutes using two aspirator tubes connected to a 15-ml Falcon tube. One aspirator tube was positioned under the child's tongue and the other was attached to the aspirator device. After five minutes, the amount of saliva was measured for the determination of salivary flow. Collections were performed between 9 and 11 am and the time of the last meal was recorded. At least a one-hour interval was required between the last meal and the collection of the saliva sample. The volume of saliva was measured. The salivary flow volume was calculated and expressed as ml/min. The following categories were considered in the analysis of salivary flow: \< 0.1 ml/min = xerostomia; 0.1 to 0.6 ml/min = very low flow; 0.7 to 0.9 mL/min low flow; 1.0 to 2.0 ml/min = normal flow; and \> 2.0 ml/min = high flow.
214977599|NCT03529500|DIAGNOSTIC_TEST|Saliva Buffering Capacity|an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC). The saliva/acid solution was shaken in a q 220 vortex tube agitator (Quimis, Diadema, SP, Brazil) for 15 seconds. Next, pH was determined in a portable pH meter (KASVI K39-0014P, Curitiba, PR, Brazil) for the determination of the SBC. The following categories were considered: ≥ 5.5 = very good buffering capacity; 5.4 to 5.0 = good buffering capacity; 4.9 to 4.5 = medium good buffering capacity; 4.4 to 4.0 = low buffering capacity; and ≤ 3.9 very low buffering capacity.
214977600|NCT00243763|DRUG|TKI258|
214977601|NCT05449899|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
214977602|NCT05449899|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
214977603|NCT05449899|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
214977604|NCT05449899|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
214366795|NCT04350892|BEHAVIORAL|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Participants will be placed on a 800 kcal/day diet for meal replacement (Optifast) provided by the investigator for 12 weeks. Participants will be monitored weekly by the study dietician and medical staff.
214366796|NCT06423326|PROCEDURE|Biopsy|Undergo biopsy
214366797|NCT06423326|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214366798|NCT06423326|DRUG|Cisplatin|Given IV
214366799|NCT06423326|PROCEDURE|Computed Tomography|Undergo CT
214366800|NCT06423326|DRUG|Gemcitabine|Given IV
214366801|NCT06423326|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214366802|NCT06423326|DRUG|Nab-paclitaxel|Given IV
214366803|NCT06423326|PROCEDURE|Pancreatic Surgical Procedure|Undergo surgical resection
214366804|NCT06981299|DRUG|PROT-001|Orally bioavailable small molecule kinetic stabilizer of lambda light chains (λLCs).
214366805|NCT06602193|DRUG|BIIB122 225 mg|Administered as specified in the treatment arm
215085593|NCT03112525|GENETIC|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
215085594|NCT05353712|OTHER|SUCROSE|50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
215085595|NCT05353712|OTHER|CONTROL|35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
214366806|NCT06602193|OTHER|BIIB122-Matching Placebo|Administered as specified in the treatment arm
214366807|NCT03175770|PROCEDURE|transoral radiofrequency Resection in Oropharyngeal Tumor Surgery|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
214366808|NCT04114734|BEHAVIORAL|Park Rx|Participants will be advised to visit a specific park at a specific frequency and duration
214366809|NCT06233279|DEVICE|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
214366810|NCT06233279|DEVICE|Sham Stimulation|Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
214491787|NCT06753422|DIETARY_SUPPLEMENT|Kefir|"200 ml/day kefir~The primary intervention in our study is the daily consumption of kefir (200 ml/day). No additional drug or medical device was used during the intervention or data collection process. The study focused solely on kefir consumption and its effects on athletic performance and gut microbiota."
214491788|NCT06713447|DRUG|NTI164|This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164) specifically formulated to target inflammation in various neurological conditions. The dose of 20mg/kg has been selected based off existing clinical trial evidence for NTI164, and is similar to the dose of other cannabis-based drugs used in neurology. The safety of NTI164 has been rigorously tested in several ongoing paediatric clinical trials through blood tests and clinician-rated surveys.
214491789|NCT06863519|PROCEDURE|Endoscopic treatment|After the patient is enrolled, HVPG testing is performed, and appropriate endoscopic treatment is selected as a secondary prevention method. HVPG testing is performed again after regular endoscopic treatment.
214491790|NCT06877013|OTHER|Placebo challenge|2 sachets per day over 7-day challenge
214491791|NCT06877013|OTHER|Fiber's mix (among 4 doses) - intervention phase 1|2 sachets per day over 7-day challenge
214977605|NCT05449899|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
214977606|NCT00146562|DRUG|Darbepoetin Alfa|Given day before chemotherapy of red blood cell count is below normal
214977607|NCT00146562|DRUG|Pegfilgrastim|Given as an injection the day before chemotherapy for a total of 8 injections
214977608|NCT00146562|DRUG|Paclitaxel|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
214977609|NCT00146562|DRUG|Doxorubicin|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
214977610|NCT00146562|DRUG|Cyclophosphamide|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
214977611|NCT01674725|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
214977612|NCT01674725|DRUG|Ribavirin|Tablet
214977613|NCT03567408|PROCEDURE|Selective PCI|Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
214977614|NCT03567408|DRUG|Bivalirudin|Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
214977615|NCT06195423|BEHAVIORAL|Stop OsteoARthritis (SOAR) program|"The SOAR program is a 6-month, online-delivered (videoconferencing), PT-guided knee health program which consists of;~1. Knee Camp: Includes interactive education, and 1:1 physiotherapy knee exam and counseling session to co-identify home-based exercise-therapy and physical activity goals to address participants' unique functional limitations. Participants are given a wrist-worn activity monitor to wear 24hours/day.~2. Individualized Weekly Home-based Exercise-Therapy and Physical Activity Program: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises and physical activity are tracked with an online form and the activity monitor. Participants can also attend an optional weekly group class.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counselling: Each week, participants attend a 1:1 physiotherapist counseling session to modify exercise-therapy and physical activity goals."
214977616|NCT06195423|BEHAVIORAL|Living Well after ACLR program|Participants in the minimal intervention CONTROL group will receive access to a 30-minute educational video (knee anatomy, ACLR information, general exercise, physical activity, and goal-setting principles), a best practice workbook, one video-recorded virtual session with a physiotherapist (naïve to SOAR) who will explain the booklet and answer questions but not volunteer information beyond the video or booklet and the same wrist-worn activity tracker as the experimental group.
214977617|NCT00756626|BEHAVIORAL|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
214977618|NCT01403662|DRUG|Minocycline|Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
214977619|NCT05775380|DRUG|Pioglitazone 45 mg|We investigated the role of pioglitazone hydrochloride 45mg/day for five days in patients admitted for coronary artery bypass grafting (CABG) in order to investigate vascular SPhk1 expression, vascular transcriptome and proteome remodeling, as well as S1P content in HDL
214977620|NCT03568201|DIAGNOSTIC_TEST|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
214977621|NCT01304797|DRUG|MM-302 Monotherapy|Escalating doses of MM-302 as a single agent
214977622|NCT01304797|DRUG|MM-302 in combination with trastuzumab|Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
215085596|NCT05353712|OTHER|ARA20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
215085597|NCT05353712|OTHER|ARA40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
214366813|NCT06665386|PROCEDURE|hypothermia|"Patients who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to either the control group or the IA-SCI group. Control group patients will receive BMM and EVT. IA-SCI group patients will receive BMM and EVT, and additionally a selective intraarterial cooling infusion. The specific method is as follows:~* Pre-recanalization: During the procedure, a micro-catheter used to deploy the stent retriever is threaded coaxially into the common femoral artery through the guide catheter. The microcatheter is advanced over a microguide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4℃) is infused into the ischemic territory at a rate of 10 mL/min via the microcatheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~* Post-recanalization: Following vessel recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL"
214366814|NCT05963607|OTHER|Weighted blanket|A blanket sewn with extra weight in it.
214366815|NCT06599567|OTHER|Traditional therapy|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises
214366816|NCT06599567|OTHER|Graded motor imagery|Cold-Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, graded motor imagery training (body right-left discrimination exercise, imagining the movement and exercising the opposite limb in front of the mirror).
214366817|NCT06599567|OTHER|Nintendo Wİİ|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, games involving your relevant shoulder such as boxing and bowling on the Nintendo Wii game console.
214977623|NCT01304797|DRUG|MM-302 in combination with trastuzumab q3w|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
214977624|NCT01304797|DRUG|MM-302 in combination with trastuzumab and cyclophosphamide|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
214977625|NCT04184401|DRUG|Ascites replacement with albumin and hartmann's solution|"Combined strategy for ascites replacement~* 30% of ascites: replacement with 5% albumin~* 40% of ascites: replacement with Hartmann's solution"
214977626|NCT04184401|DRUG|Ascites replacement with hartmann's solution|"Hartmann's solution only strategy for ascites replacement~\- 70% of ascites: replacement with Hartmann's solution"
214977627|NCT03758469|DRUG|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
214366818|NCT04838041|DRUG|Asciminib 40 MG|40 mg by mouth (PO) when used with imatinib.
214491792|NCT06877013|OTHER|Best fiber's mix - intervention phase 2|2 sachets per day over 7-day challenge
214491793|NCT06866704|PROCEDURE|catheter ablation|In the experimental group, patients receive pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI), circumferential BOX ablation around bilateral pulmonary veins, and mitral isthmus ablation. In the control group, anhydrous alcohol is first injected into the Marshall vein, followed by radiofrequency catheter ablation to complete PVI, BOX lesion sets, and mitral isthmus ablation.
214491794|NCT06744114|DIAGNOSTIC_TEST|Consciousness in the Emergency Department|To determine the common and definitive etiologies of altered level of consciousness in emergency department.
214491795|NCT06740981|OTHER|Food diary|A food and beverage diary will be collected for five days starting from the initiation of noninvasive ventilation, with caloric and protein intake quantified by a Nutrition Physician Specialist.
214977628|NCT03758469|DRUG|rifampin , HSK3486|Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
214491796|NCT06892951|DRUG|Caspofungin Acetate 50 MG|The experimental treatment will be administered once daily for up to seven days, through the nebulization route by the means of a disposable vibrating mesh Aeroneb solo® nebulizer with the valved mask (Galway, Ireland). Before generating aerosol, resuspension of the caspofungin powder will be carried out in the same manner than for the IV route, into 10.5 mL saline serum. Preparation of the experimental drug (re-suspension) will be unblindly carried out in a distinct medical office by a nurse neither involved in the healthcare of the included patients, nor in the other parts of the study, data recording or outcome assessment. Once reconstituted, the suspension is expected to be limpid, with neither odour nor foam. Thereafter, its administration will be blindly completed by the clinical staff in charge of the enrolled patient.
214491797|NCT06892951|DRUG|Physiologic saline|Procedures will be exactly the same than those described above for the experimental group, but caspofungin will be replaced during the seven days of intervention by 10mL of 0.9% saline nebulized in the control group for a 15 minute-long process of nebulization (from d-1 to d-7).
214491798|NCT06892886|DEVICE|Virtual Reality|Four tasks, uni and bi-manuals, will be proposed for the treatment of the patient's paretic upper limb in virtual-apartment for improving the relevance and the transferability of the movements requested.
214491799|NCT05338632|DRUG|Narcan 40 MG/ML Nasal Spray|naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
214491800|NCT05338632|DRUG|Naloxone Hydrochloride|Naloxone 0.4mg/mL
214977629|NCT00103454|DRUG|GW685698X|
214977630|NCT00644761|DRUG|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
214977631|NCT02672072|OTHER|Simulation during the study (5-day specific training with dedicated scenario done by an ICU expert simulation team)|
214977632|NCT02672072|OTHER|questionnaire to define the presence of job strain at 6 months|
214977633|NCT02672072|OTHER|questionnaire to define the presence of job strain at 12 months|
214977634|NCT02900352|DRUG|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
214977635|NCT02900352|DRUG|Placebo|Placebo
214977636|NCT05343325|DRUG|Tislelizumab|Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
214977637|NCT05343325|RADIATION|Low-dose radiotherapy|Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.
214977638|NCT03074695|PROCEDURE|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm cerebral spinal fluid (CSF) position. No intrathecal dosing
214366819|NCT04838041|DRUG|Asciminib 40 MG Twice Daily|40 mg twice daily when used with nilotinib.
214366820|NCT04838041|DRUG|Asciminib 80 MG daily|80 mg daily when used with dasatinib or taken alone.
214491801|NCT05338632|DRUG|Nalmefene HCl injection|Nalmefene 1 ng/mL
214491802|NCT06748612|BIOLOGICAL|Pentavalent vaccine|Whole-cell pertussis pentavalent vaccine (wP-Penta): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate
214491803|NCT06748612|BIOLOGICAL|Hexavalent vaccine|Whole-cell pertussis hexavalent vaccine (wP-Hexa): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate, and inactivated polioviruses to all three poliovirus types: type 1 , 2 and 3
214491804|NCT06748612|BIOLOGICAL|Inactivated poliovirus vaccine (IPV)|one dose of IPV (0.5 mL) contains inactivated polioviruses to all three poliovirus types: type 1, 2 and 3
214491805|NCT06748612|BIOLOGICAL|Bivalent oral polio vaccine (bOPV)|Contain two poliovirus types: type 1 and 3
214491806|NCT06748612|BIOLOGICAL|Fractional IPV( fIPV)|The dose of fIPV is 0.1 mL or 1/5th of a full dose
214977639|NCT03074695|PROCEDURE|Standard Epidural (EPL)|Standard epidural placement
214977640|NCT03074695|DRUG|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm CSF position. No intrathecal dosing. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
214977641|NCT03074695|DRUG|Standard Epidural (EPL)|Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
214366821|NCT04838041|DRUG|Imatinib|Maximum dose of 400 mg PO once daily.
214366822|NCT04838041|DRUG|Nilotinib|Maximum dose of 300 mg twice daily.
214366823|NCT04838041|DRUG|Dasatinib|Maximum dose of 100 mg PO once daily.
214977642|NCT02419872|DRUG|Marketed antagonists|Medication for each patient is determined by the physician based on the patient's individual clinical profile and in accordance with the approved indication and label of the prescribed drug
214977643|NCT00053885|DRUG|PTK787/ZK 222584|oral
214977644|NCT02552485|OTHER|No intervention was applied, because it is an observational study|
214977645|NCT04345003|DEVICE|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
214977646|NCT01774981|DRUG|Placebo|Administered IV
214977647|NCT01774981|DRUG|LY3016859|Administered IV
214977648|NCT01227369|OTHER|OPSAT-Q|A linguistically validated Korean version of OPSAT-Q
214977649|NCT00960193|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
214977650|NCT00960193|OTHER|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
214977651|NCT02360046|DRUG|Hydrocortisone|Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
214977652|NCT02360046|DRUG|Placebo|Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
214977653|NCT03362944|BEHAVIORAL|Active Music Therapy|The intervention consists of a standardized series of Music Therapy tasks, all based at a constant rhythmic pulse.
214977654|NCT03362944|BEHAVIORAL|Passive Music Therapy|The intervention consists of a series of recorded listening tracks, matched in style to the active intervention, all based at a constant rhythmic pulse.
214977655|NCT01324102|BEHAVIORAL|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
214977656|NCT05719181|BIOLOGICAL|rhBMP-2|Recombinant Human Bone Morphogenetic Protein-2 with an Absorbable Collagen Sponge .
214977657|NCT01235065|DEVICE|type of laryngoscope|Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
214977658|NCT00468117|PROCEDURE|Islet transplantation|
214977659|NCT00468117|BIOLOGICAL|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
214977660|NCT00468117|BIOLOGICAL|Daclizumab or Basiliximab|Daclizumab or Basiliximab will be used for subsequent transplants.
214977661|NCT00468117|BIOLOGICAL|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
214977662|NCT00468117|BIOLOGICAL|Allogenic human purified pancreatic islets|200 ml suspension of allogenic human purified islets
214977663|NCT00386334|DRUG|Eszopiclone|2 mg tablet once per day in the evening
214977664|NCT00386334|DRUG|Placebo|Tablet one per day in the evening.
214977665|NCT01091922|DIETARY_SUPPLEMENT|Low flavanol cocoa beverage|23 mg of total flavanols from cocoa
214977666|NCT01091922|DIETARY_SUPPLEMENT|High flavanol cocoa beverage|495 mg of total flavanols from cocoa
214977667|NCT05781867|OTHER|Manual therapy and conventional physical therapy treatment|manual therapy (chest mobilization, diaphragmatic myofascial release, myofascial release for pectoralis minor, pectoralis major, scaleni ),pursed lip breathing, diaphragmatic breathing and active range of motion exercises of upper limbs
214977668|NCT00902577|DRUG|FMISO|FMISO PET scans
214977669|NCT00902577|OTHER|MRI|Undergo MRI
214977670|NCT00902577|OTHER|PET|Undergo FMISO PET scan
214977671|NCT00902577|OTHER|MRS|
214977672|NCT03537066|DEVICE|CPAP|All patients included will be treated by CPAP
214977673|NCT03702660|OTHER|GIP(3-30)NH2|Peptide derived from the naturally occuring gut hormone GIP
214977674|NCT03702660|OTHER|Peripheral venous cannulation|Intravenous access for infusions
214977675|NCT03702660|OTHER|GLP-1|Peptide infusion
214977676|NCT01236924|OTHER|Global postural reeducation|
214977677|NCT05342896|BEHAVIORAL|MIND diet|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines.
214977678|NCT05342896|BEHAVIORAL|Mind diet plus Forest Bathing|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines. Forest Bathing will be another session per week, 2 hours forest bathing sessions on 4-consecutive weekends in a country park at daytime with sunny, cloudy or drizzling conditions. The walking distance for each forest bathing is one to two kilometres. The coach-to-participant ratio is approximately 1:16. Participants will then be required to self-practice 2h FB in the country park at daytime at the weekends of 8th week and 12th week of the intervention.
214977679|NCT06213558|DEVICE|Rectangular and square striaght archwire technique|The Effect of Rectangular Versus Square Archwire on Maxillary Canine Retraction
214977680|NCT02191826|DRUG|SOM0226|Oral
214977681|NCT05263362|OTHER|no intervention|At one timepoint patients will get physical examination of the breasts, medical photographs will be taken, and they will fill in five questionnaires about satisfaction of the breasts, quality of life and general health.
214977682|NCT03211065|DRUG|20% subcutaneous immunoglobulin|Subcutaneous Immunoglobulin
214366824|NCT06606574|OTHER|Titration protocol|A standardized titration protocol for ITB will be used and the ITB dose will be increased to the next step if 1) there is persistent hypertonia identified on the dystonia screener or ASAS total spasticity, or 2) there is room for improvement on the D-FIS, and 3) there are no detrimental side effects (e.g., worsening head control). This will be continued until 1) dystonia and spasticity have been eliminated or no longer deemed as functionally impairing by the medical team, 2) side effects prevent further titration, or 3) a maximum dose of 2000 mcg/day has been reached. Once steady state is reached, this new dose becomes the maintenance dose for the rest of the trial. If there are detrimental side effects, the child will be seen weekly to confirm resolution of side effects. If side effects persist, the child will be reduced at each visit to the previous step. Once side effects are controlled, this new dose becomes the child's maintenance dose for the rest of the trial.
214366825|NCT06984003|OTHER|stretching exercises|a brief explanation, by a trained physical therapist, of stretching exercise program and of how to practice these active stretching exercises as a home program 3 times per week for 4 weeks.
214977683|NCT00001567|DRUG|Roferon-A|
214977684|NCT02745288|PROCEDURE|inferior alveolar nerve block|"A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.~The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood."
214977685|NCT02903979|OTHER|HVGIC|In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
214977686|NCT02903979|OTHER|Indirect pulp capping|In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
214977687|NCT02653846|PROCEDURE|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
214977688|NCT02653846|PROCEDURE|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
214977689|NCT04998708|OTHER|Relaxation technique|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM)32. We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
214977690|NCT01517217|PROCEDURE|No girdle|No girdle is used for the first five postoperative days
214977691|NCT01517217|PROCEDURE|Girdle|Girdle the first five postoperative days
214977692|NCT00117390|PROCEDURE|Measurement of inulin clearance|
214977693|NCT04443335|BEHAVIORAL|continous feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. Patients in the CF group received continuous feeding with constant velocity by enteral feeding pump over one day.
214977694|NCT04443335|BEHAVIORAL|sequential feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. In the SF group, continuous feeding was changed into time-restricted feeding. The total daily dosage of enteral nutrition was equally distributed during three time periods at 7-9:00, 11-13:00 and 17-19:00. Other times of the day were fasting times. Enteral nutritional suspension in each time period was administered at a uniform rate within two hours by an enteral feeding pump.
214977695|NCT05115799|OTHER|Manual Therapy, Physiotherapy, Kinesiology, Scar Massage|"The physiotherapist performs passive kinesitherapy on the mastectomized patient with lymphatic thrombus, and scar massage when the arm maintains its greater range of mobility.~The patient will never present pain during the rehabilitation session above 5 in Pain Scale Analog Scale."
214977696|NCT05115799|OTHER|Kinesiotherapy, Physiotherapy, Health Education|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
214977697|NCT00254371|PROCEDURE|Androgen Replacement|
214977698|NCT00597259|DRUG|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
214977699|NCT00597259|DRUG|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
214366826|NCT05560854|BEHAVIORAL|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
214491807|NCT06742658|OTHER|Rapid Move|A short-stay PACU where patients recover from anaesthesia, are continuously monitored, and prepared for discharge within an hour after surgery.
214491808|NCT06748482|BEHAVIORAL|Counseling|a 15-minute-consultation session with the clinical pharmacist will include detailed and personalized advice on how each patient should take his prescribed medications, the best time to take them, the possible drug-drug interactions, the possible adverse effects such as post operative nausea and vomiting (PONV), bleeding, fever and infection and the required action. A written paper outlining the main points including the detailed protocol with times and doses will be handed to the patient at the end of the consultation. Moreover, a recorded voice note with the detailed protocol will be sent to the patients via the WhatsApp application
214491809|NCT06766331|OTHER|Integrated care|Receipt of infectious diseases laboratory testing and/or PrEP for HIV within a single substance use disorder clinic appointment.
214977700|NCT00583648|OTHER|Urinanlysis|sending a Urine sample to the laboratory for processing
214977701|NCT00345085|DEVICE|Wavefront and Contrast Sensitivity|
214977702|NCT03962400|PROCEDURE|Reinforcement Learning|New computer based procedure for determining dose using a decision support tool
214977703|NCT03962400|PROCEDURE|Heath Care Provider|Warfarin dose will be determined by a qualified health care provider
215085598|NCT05353712|OTHER|TAG20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
214977704|NCT04237948|DEVICE|transcranial direct current stimulation (tDCS)|cerebellar tDCS consists in the application of a low intensity (1-2 mA) steady current through a surface scalp electrode over the cerebellum
214977705|NCT04237948|BEHAVIORAL|Physical therapy|Hospitalized patients will undergo a 60 minutes physical treatment improving gait and postural instability for four weeks of time
214977706|NCT03017092|BEHAVIORAL|Tablet-guided tobacco intervention|This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
214977707|NCT00746369|BEHAVIORAL|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
214977708|NCT06227169|BEHAVIORAL|JJ-COPES Training|• The JJ-COPES training is derived from an empirically supported CBT manual designed for outpatient treatment of suicidal adolescents. JJ-COPES training focuses on teaching 4 primary treatment strategies plus a caregiver session to community-based clinicians.
214977709|NCT00374010|BEHAVIORAL|Patient-Centered Advance Care Planning|"The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:~1. Representational assessment (10 - 15 minutes);~2. Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);~3. Creating conditions for conceptual change (5 minutes);~4. Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and~5. Summary (3 - 5 minutes)"
215085599|NCT05353712|OTHER|TAG40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
215085600|NCT01605227|DRUG|cabozantinib|Tablets taken orally once-daily
214366827|NCT04823884|PROCEDURE|open distal chevron osteotomy|Through a 4-cm-long dorsomedial skin incision the V-shaped osteotomy with the apex 1-2 mm superior to the center of the metatarsal head is performed. The angle of the chevron is 60° to 90°. The direction of the osteotomy is angled toward the center of the third metatarsal head. After shifting the metatarsal head laterally, fixation is achieved by usage of one cannulated screw (3.0 mm or 2.5mm). Prominent bone ridges are resected with a saw. A distal soft tissue procedure is performed in every case through the same skin incision. The adductor hallucis tendon is detached from its insertion at the phalangeal bone and from the lateral border of the fibular sesamoid. The transverse intermetatarsal ligament is released and a T-shaped capsulotomy is performed to allow reposition of the sesamoids. Sesamoid position is controlled by sight. After closing of the medial capsula skin is closed with nylon sutures.
214366828|NCT04823884|PROCEDURE|minimally invasive distal chevron osteotomy|The osteotomy is performed percutaneously through a dorsomedial incision of 3-5 mm. An electric motor-driven machine used for the osteotomy. To prevent overheating the reamer is frequently rinsed with sterile saline. The medial eminence is excised and the V-shaped osteotomy is performed. The apex of the osteotomy is identified by fluoroscopy and centered 1-2 mm superior to the center of the metatarsal head. The angle of the osteotomy amounts to 60-90 degrees as well. Bone debris is washed out with sterile saline. A lateral soft-tissue release is undertaken through a separate lateral incision of 3-5 mm. The distal fragment is shifted laterally and fixed with a canulated screw of 3.5mm. Residual bone ridges are reamed. Position of the metatarsal head and the K-wire is controlled by fluoroscopy. The skin is closed with a nylon sutures.
214366829|NCT01855776|DEVICE|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
214366830|NCT01855776|BEHAVIORAL|Cash Incentives|Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
214491810|NCT06766409|BEHAVIORAL|A community group-based demonstration counseling method|At the community level, a perinatal woman in the intervention arm will get individual family planning counseling along with group-based counseling that includes a planned demonstration of all possible techniques.
214491811|NCT06766409|BEHAVIORAL|An individual family planning counseling|The control group's pregnant and postpartum women will simply get standard individual FP counseling in accordance with Ethiopian national recommendations.
214491812|NCT06760117|DRUG|Irinotecan (CPT-11)|Irinotecan will start at a dose of 50mg/m² and escalate to explore the maximum tolerated dose.
214491813|NCT06760117|DRUG|Temozolomide (TMZ)|TMZ：100mg/m2/d，d1-5
214491814|NCT06760117|DRUG|Vincristine|VCR: 1.5mg/m2/d(≯2mg), d1
214491815|NCT04943172|DEVICE|Hancock-Jaffe bioprosthetic venous valve (VenoValve®)|Surgical implantation of the VenoValve device
214491816|NCT06766448|OTHER|robotic training|continuous passive mobilization and robotic therapy on armeo sping
214491817|NCT06766448|OTHER|conventionnal rehabilitation|rehabilitation sessions with a physiotherapist
215085601|NCT01605227|DRUG|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
215085602|NCT05210868|DRUG|CM355|"1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug"
215085603|NCT01391598|DRUG|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
215085604|NCT01391598|DRUG|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
214491818|NCT05691972|DEVICE|Restylane Contour|a sterile, biodegradable, transparent gel of nonanimal cross-linked HA (20 mg/mL) with the addition of lidocaine hydrochloride (3 mg/mL)
214977710|NCT04905043|DRUG|Acalabrutinib|Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).
214977711|NCT04905043|DRUG|SmartPill®|Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
214977712|NCT00106002|DRUG|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
214977713|NCT04041817|OTHER|Trigger setting of pressure support ventilation|Trigger variations will be performed following increasing steps of 3 L/min every 15 minutes, from 0.2 to 15 L/min (0.2 - 3 - 6 - 9 - 12 - 15).
214977714|NCT02704767|DRUG|Apatinib|a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
214977715|NCT02704767|DRUG|Tarceva|
214977716|NCT02704767|DRUG|Placebo|
214977717|NCT04753034|DRUG|TER-101|Active Comparator
214977718|NCT04753034|DRUG|Vehicle|Placebo Comparator
214977719|NCT04896216|BEHAVIORAL|Stigma Reduction Intervention|Care providers will complete the Stigma Reduction Intervention curriculum. This study uses a modified Zelen design. Control arm participants will be aware that they are part of an observational study but not that they are in the control arm of an intervention study. This avoids artificially inducing changes to the standards of medical care in facilities randomization to the control arm, a common consequence in RCTs to evaluate population based services.
214977720|NCT05374096|OTHER|Patient-Chosen Music|Music played into headphones.
214977721|NCT05374096|OTHER|Placebo|Silence into headphones.
214977722|NCT04215835|DRUG|letrozole then misoprostol|"Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
214977723|NCT04215835|DRUG|placebo then misoprostol|"Drug: Placebo placebo for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
214977724|NCT05899361|DEVICE|Electromagnetic Guided Laparoscopy|Standard Care
214977725|NCT05899361|DEVICE|Ultrasound|Standard Care
215085605|NCT05878756|OTHER|Functional Strength Training|In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
215085606|NCT02823184|BIOLOGICAL|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
215085607|NCT03271073|DRUG|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
214977726|NCT04895501|OTHER|running flexible shoes|21kms of running flexible shoes followed by a time-to-exhaustion run.
214977727|NCT02143817|DIETARY_SUPPLEMENT|L-citrulline supplementation|
215085608|NCT04287569|DEVICE|Record during endoscopy of video-endoscopy sequences and reflectance|Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
214977728|NCT02143817|OTHER|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
214977729|NCT04382534|COMBINATION_PRODUCT|Respiratory rehabilitation|Health education and energy saving techniques, chest activity training, local lung dilation techniques, breathing training, airway clearance training, aerobic exercise, resistance training
214977730|NCT06313463|DRUG|Carrellizumab + Capecitabine|Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Carrellizumab 200mg IV D1（Q3W），8 cycles in total
214977731|NCT06313463|DRUG|Placebo + Capecitabine|Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Placebo 200mg IV D1（Q3W），8 cycles in total
214977732|NCT04372368|BIOLOGICAL|COVID-19 Convalescent Plasma|1-2 units of COVID-19 convalescent plasma will be administered over 1 to 2 hours (rate of 100 to 200 mL/hr)
214977733|NCT02765737|OTHER|Dehydrated Human Amnion/Chorion Membrane|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
215085609|NCT01163773|OTHER|MILK|"Consumption of the 2 experimental diets~1. Milk diet~2. Control diet"
215085610|NCT00402714|PROCEDURE|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
214977734|NCT02765737|DEVICE|Mepilex Ag|
214977735|NCT02097498|OTHER|Directed feedback|Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
214977736|NCT02097498|OTHER|Basic Videolaryngoscopy Videos|Group will watch a series of educational videos related to common airway management errors.
215085611|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
215085612|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
215085613|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
215085614|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
214977737|NCT00672802|DRUG|Ramelteon and Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
214977738|NCT02173782|DRUG|Berodual® Respimat ® high dose|
214977739|NCT02173782|DRUG|Berodual® Respimat ® low dose|
214977740|NCT02173782|DRUG|Berodual® MDI|
214977741|NCT02173782|DRUG|Placebo|
215085615|NCT03093974|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d dosing).~The 1 MIU/mL CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (\~10 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d (morning and evening) over a period of 12 months.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g., salbutamol /albuterol), supplied by the Sponsor, could be taken to improve tolerability."
215085616|NCT03093974|OTHER|Placebo|1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
215085617|NCT05418153|DEVICE|Tecnis Synergy IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
215085618|NCT01144260|DRUG|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
215085619|NCT01866423|DRUG|orteronel|Given PO
214977742|NCT00501631|DRUG|VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
214977743|NCT00501631|DRUG|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
214977744|NCT01249131|DRUG|Cobimetinib|Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
214977745|NCT03656341|BEHAVIORAL|2 Feet 4 Life|2 Feet 4 Life consists of four weekly group intervention sessions of one hour each. 2 Feet 4 Life includes self-management teaching, interactive lecture, and group activities, including instruction and demonstration of routine foot care. The program includes education regarding appropriate footwear and how to find it, evidenced based practices on hygiene, skin care and self-care of the lower extremities, nail trimming and filing, and care of common foot problems.
214977746|NCT03336125|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D (40µg/day) will be compared with placebo
214977747|NCT03336125|DIETARY_SUPPLEMENT|Placebo|120 mg olive oil
214977748|NCT00137709|DRUG|Sodium valproate|Week 1 \& 2 - 200mg twice daily Week 3 onwards - 400mg twice daily
215085620|NCT01866423|OTHER|laboratory biomarker analysis|Correlative studies
215085621|NCT05411861|DRUG|Analgesic Non Narcotic|Injection of protocol-specified volume of local analgesic
215085622|NCT06159205|OTHER|standard exercises|Standard exercises for TKA patients.
215085623|NCT06159205|OTHER|core stability exercises|Core stability exercises for TKA patients.
214366831|NCT01855776|BEHAVIORAL|Charitable Incentives|Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
214366832|NCT01855776|OTHER|Usual Care|"The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating."
214366833|NCT03538951|DRUG|10% VDA-1102|200 mg twice-daily for 12 weeks
214366834|NCT03538951|DRUG|20% VDA-1102|200 mg once-daily for 12 weeks
214491819|NCT06768216|OTHER|Indianized version of Mediterranean Diet|Indo Mediterranean diet will have Carbohydrates 40-45%, fats 30-35% and proteins 15-20%. Mediterranean diet, it will be specified to use Mustard oil, use of specific fruits like orange, apple, mosambi (avoid high glycemic fruits), use more of green leafy vegetables, Use of multigrain atta (Home made- 10 kg of multigrain atta will have - 8 kg of wheat + 500g each of Ragi+Bajra+ Jowar + Chana dal flour).
214977749|NCT00137709|DRUG|Lamotrigine|Week 1 - 25mg mane Week 2 - 25mg twice daily Week 3 - 25mg mane, 50mg nocte Week 4 onwards - 50mg twice daily
214977750|NCT00179140|DRUG|nutritional supplementation|oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
214977751|NCT00179140|BEHAVIORAL|exercise|either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
214977752|NCT02837588|DEVICE|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
214977753|NCT04236843|DIETARY_SUPPLEMENT|Feces|Feces from healthy donor
214977754|NCT04717635|BIOLOGICAL|Canakinumab|Provide as 150 mg/1 mL solution for subcutaneous injection and administer 4mg/kg every 4 weeks.
214977755|NCT01005238|DRUG|Lamivudine|
214366835|NCT03736603|BEHAVIORAL|PIPA Intervention Bundle 1|"The PIPA intervention bundle 1 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation"
214366836|NCT03736603|BEHAVIORAL|PIPA Intervention Bundle 2|"The PIPA intervention bundle 2 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation~6. Mobile App"
214366837|NCT04704063|DRUG|Tocotrienols / Vitamin E|Palm Tocotrienols complex
214366838|NCT04704063|DRUG|Placebo control|Placebo matching Tocovid Suprabio
214366839|NCT04058795|BEHAVIORAL|Cancer Distress Coach (CaDC) App|an app that provides participants with tools to manage their stress in the moment they experience it.
214977756|NCT01005238|DRUG|Telbivudine|
214977757|NCT05025930|DEVICE|endoscopic surgical instrument control system (SP1000: single-port laparoscopy)|The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
214977758|NCT05025930|DEVICE|endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)|The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
214977759|NCT01245101|DRUG|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
214977760|NCT01245101|DRUG|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
214977761|NCT03073772|BEHAVIORAL|Computer-based cognitive training|A total of 36 training sessions, approximately 20 minutes long each. Five different tasks were used in training all tapping different aspects of cognitive control such as updating, shifting, visuo-spatial working memory and episodic memory binding.
214977762|NCT03073772|BEHAVIORAL|Physical fitness training|A total of 36 training sessions, approximately 40 minutes long each, with physical fitness training performed as group indoor cycling. The participants were instructed to attain a load of approximately 65-80% of their maximum heart rate.
215085624|NCT01549535|DEVICE|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
214977763|NCT01014234|DRUG|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
214977764|NCT01014234|DRUG|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
214977765|NCT05009355|DRUG|Vitamin C|antioxidant
214977766|NCT04215367|DIETARY_SUPPLEMENT|High phenolic EVOO intake|During the pilot dietary intervention patients with CLL consumed before their meals, 40 ml/day high phenolic EVOO for 6 months
214977767|NCT04215367|DIETARY_SUPPLEMENT|No High phenolic EVOO intake|Medical record of each patient's was followed during 6 month before dietary the intervention
214977768|NCT04456686|DRUG|LY3016859|LY3016859 given IV.
214977769|NCT04456686|DRUG|Placebo|Placebo given IV.
214977770|NCT03836586|BEHAVIORAL|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
214977771|NCT03836586|BEHAVIORAL|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
214977772|NCT03670992|PROCEDURE|duodenal-pancreatectomy|surgical removal of metastatic repetitions in pancreas and/or other distal sites
214977773|NCT05058963|BEHAVIORAL|Mantram repetition program|"Week 1: Define and describe the characteristics of a mantram as taught by Eknath Easwaran and how it relates to posttraumatic stress (PTSD) Week 2: Identify ways to choose and use mantram repetition for training attention and targeting craving.~Introduction to substance craving and identify triggers for use. Week 3: Describe the relationship between the PTSD/stress response, mantram repetition and the relaxation response Week 4: Describe at least two benefits of slowing down versus automatic pilot for stress reduction Week 5: Describe at least two benefits of one-pointed attention versus multitasking for stress reduction Week 6: Demonstrate how one-pointed attention and slowing down complement each other for making healthy choices Week 7: List at least five strategies for making mantram repetition a part of your life Week 8: Discuss applications of mantram repetition, one-pointed attention and slowing down for overall health and substance use"
214977774|NCT00494663|DRUG|DIO-902|150mg tablet once per day for 16 weeks
214977775|NCT00494663|DRUG|DIO-902|300mg tablet once per day for 16 weeks
214977776|NCT00494663|DRUG|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
214977777|NCT00494663|DRUG|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
215085625|NCT00497328|DRUG|N-acetylcysteine|
214977778|NCT00494663|DRUG|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
214977779|NCT00494663|DRUG|DIO-902|300mg DIO-902 tablet daily for 16 weeks
214977780|NCT00494663|DRUG|DIO-902|450mg DIO-902 tablet for 16 weeks
215085626|NCT00497328|DRUG|Sodium Bicarbonate|
215085627|NCT03172091|DEVICE|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
215085628|NCT03172091|DEVICE|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
215094475|NCT05857904|DEVICE|CT-FFR|CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.
214977781|NCT00494663|DRUG|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
214977782|NCT01252368|BIOLOGICAL|hypertension|patients taking daily ACE inhibitors or sartanes
214977783|NCT02007902|OTHER|Evaluation of the relationship plasma protein levels - neonatal hemodynamics|"* Patient inclusion at birth~* Total plasma protein values measurement on cord blood sample at birth~* Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler~* Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth~* Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 \[regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy\] will be monitored over 24 hours after birth."
214977784|NCT00639119|DRUG|Ropinirole|8 + 8 weeks cross-over placebo controlled
214977785|NCT02532036|BIOLOGICAL|Aerosol inhaled MVA85A|
214977786|NCT02532036|BIOLOGICAL|Intramuscular MVA85A|
214977787|NCT02532036|BIOLOGICAL|Intramuscular Saline placebo|
214977788|NCT02532036|BIOLOGICAL|Aerosol inhaled Saline placebo|
214977789|NCT06195085|RADIATION|CT-guided radioactive iodine-125 seed implantation|The CT-guided radioactive iodine-125 seed implantation procedure mainly consisted of preoperative treatment planning, intraoperative seed implantation and postoperative dosimetric evaluation. All procedures were performed as per relevant guidelines and regulations.
215085629|NCT06416176|OTHER|Mindfulness-Based Stress Reduction (MBSR) Program|Participants in the experimental group received an 8-week MBSR program by an MBSR instructor. Each meeting were planned as a 3-hour session that completes the mindfulness training procedures by doing an opening meditation of 30- 45 minutes about that week, after the information about the meeting topic of the week is discussed. Experiences after meditation were shared with the group. Each week, the meeting topic and meditation continued with different contents, and practice meditations on the subject were held every week and home exercises were given. Home practice meditations were performed by listening to the guide audio recording with headphones. All home exercises in the training content were followed up on a daily basis and recorded.
215085630|NCT04509245|BEHAVIORAL|Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone|During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
215085631|NCT02000011|OTHER|comprehensive geriatric assessment (CGA)|
215085632|NCT02000011|OTHER|Geriatric intervention plan (GIP)|
215085633|NCT06076096|OTHER|Suprainguinal fascia iliaca block|The design of this study involved the retrospective analysis of data. Data was gathered from adult patients falling into the American Society of Anesthesiology (ASA) categories I to III, who were scheduled for elective lower limb surgical procedures. More specifically, patients who had undergone SIFIB either as the primary anesthesia approach or as part of their anesthesia regimen were included. Those who had received general anesthesia, neuraxial anesthesia, or infiltration anesthesia were excluded from the study. Importantly, all patients who participated in the study provided written informed consent for both their involvement in the study and the publication of their data.
215085634|NCT00307567|BIOLOGICAL|Pneumococcal (vaccine)|
215085635|NCT00810901|BEHAVIORAL|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
215085636|NCT00810901|BEHAVIORAL|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
215085637|NCT03789695|DRUG|Dabigatran Etexilate|Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
215085638|NCT02177643|DRUG|Diacerein|Diacerein oral capsules
214977790|NCT06458348|BEHAVIORAL|Local opera appreciating and Medical gymnastics training|To construct a local opera viewing combined medical gymnastics training program for elderly patients with post-stroke cognitive impairment, and to explore its feasibility, acceptability and safety.
214977791|NCT00743210|DRUG|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
215085639|NCT02177643|DRUG|Placebo|Placebo oral capsules
215085640|NCT04151251|BEHAVIORAL|Patient Empowerment|Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep
214366840|NCT04058795|BEHAVIORAL|CaDC + mCoaching|The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.
214366841|NCT04058795|BEHAVIORAL|mCBT|8 mobile sessions with a therapist to receive cognitive behavioral therapy.
214366842|NCT06668376|DEVICE|Leg Sleeve|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
215085641|NCT04151251|OTHER|Sleep Kit|Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
215085642|NCT02931604|DEVICE|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
215085643|NCT06296160|OTHER|Intervention Group|"A- (Intervention Phase= (Day-1) + (Day-15)~1. Obtain a lung ultrasound after the midweek dialysis session.~2. The 8-zone lung ultrasound method calculates the number of B-line scores.~3. Reduce the dry weight by 500 g if the B-line score is \>0.54/zone (BLS\>5). considered a day one.~4. The dry weight will be reduced only if the arterial blood pressure at the end of the session is BP \>110/60 mmHg and the patient had no hypotension episode during the session.~5. The adjustment of dry weight based on lung ultrasound should not be made on the same day as the standard approach adjustment (Regular monthly clinical standards modification.~6. Check the Blood Pressure 3 times/ day on the non-dialysis following the ultrasound.~7. Check the ambulatory blood pressure for 48 hours (Baseline on day 1 and Follow-up on Day 60).~B - Observational Phase= (Day-30) + (Day-45) + (Day-60)\]."
214977792|NCT00743210|DRUG|Placebo|Placebo, 3 grams once per day for 3 weeks.
214977793|NCT01329198|DEVICE|NeuroPace RNS® System Deep Brain Stimulator|Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
214977794|NCT04823234|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound signs in Covid 19 positive pregnant patients
214977795|NCT04974073|DRUG|PHY606|Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
214977796|NCT02349555|DIETARY_SUPPLEMENT|Nutritional Supplement Blend|It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
215085644|NCT00873379|DIETARY_SUPPLEMENT|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
214679837|NCT01477151|DRUG|Volatile anesthetic|"The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration."
214977797|NCT01189448|DRUG|Pyrimethamine/Sulfadiazine|"Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.~Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy."
215085645|NCT00873379|DIETARY_SUPPLEMENT|placebo|half a white placebo tablet
215085646|NCT03730766|DRUG|Esomeprazole|Proton pump inhibitor
215085647|NCT03730766|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
215085648|NCT03730766|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
215085649|NCT01193166|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
215085650|NCT01193166|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 12 months
215085651|NCT01193166|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
214366843|NCT06668376|DEVICE|Placebo|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
214366844|NCT05601869|DEVICE|RECOVER Prosthetic Ankle-Feet System|The RECOVER prosthetic ankle-feet system includes a single prosthetic ankle joint that can be easily attached to 3D printed feet. The feet are designed to fit specifically within different footwear.
214366845|NCT06987786|OTHER|Massage|"Soft tissue mobilization (STM), also known as massage, is a form of manual therapy. STM consists of many different categories of treatment, but all involve a hand's on application. During the session, the Dr. Cook will use techniques such as kneading, stretching, and deep tissue manipulation to target the affected areas. The total time of application will be 30 minutes. This hands-on approach is theorized to reduce muscle tension, improve blood circulation, and promote relaxation. STM stimulates the release of endorphins and serotonin, which are natural painkillers and mood enhancers."
214491820|NCT06768216|OTHER|Low Fat Diet|Low fat diet will have 50-60% carbohydrate, 20-30% fat (with \<10% saturated fat), and 20% protein. In the Low Fat Diet group, there will be only be restriction of total fat content to less than \<30%. They can use whichever household oil, consume any fruit or vegetables, any atta and no restriction on diary or non-vegetarian diet. Along with this, both groups will be given a list of do's and dont's. In the list of Do's , it will be mentioned to Eat plenty of vegetables, Fruits, Nuts, Whole grains, Screen time of less \<2 hrs /day (According to American academy of pediatrics) and Average hours of sleep in a day for age 8-18 = 8-9 hrs (According to American academy of sleep medicine). In the dont's list, it will be mentioned to avoid Sugar, Soda, Beverages, cold drinks, processed juices, processed food, junk foods, Maida, Ice cream, Creamy Desserts, Biscuit, chips and cake.
214491821|NCT06768216|OTHER|Physical Activity|At least 45- 60 mins of exercise (peer group activity - cycling, football, brisk walking),
214491822|NCT06770062|DIAGNOSTIC_TEST|Cardiac MRI|Each subject will receive two cardiac MRI scans (with and without contrast), one preoperative and another 6-12 months after. The duration of each MRI is approximately 45-60 minutes
215085652|NCT01193166|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
215085653|NCT01193166|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
215085654|NCT01193166|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
215085655|NCT01193166|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
215085656|NCT01193166|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
215085657|NCT06288971|OTHER|Self-adaption web-based software for the rehabilitation of EF and visuo-spatial abilities|\- Self-adaption web-based software integrated with neuropsychomotor activities in small groups to strengthen EF. The training will take place bi-weekly, for 3 months, for approximately 60 minutes per meeting. For the intervention will be used the Bee-bot, a robot to be programmed to achieve objectives set in space, allows to stimulate navigation, visuospatial working memory and planning skills (the activities will be taken from those already used in our previous studies in children with typical development and BES (Di Lieto et al., 2020)).
214977798|NCT01189448|DRUG|Spiramycine|"Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures"
215085658|NCT06288971|OTHER|Tele-rehabilitation of EF and specific cognitive processes underlying academic skills|\- Tele-rehabilitation intervention on FE (RuntheRAN and MemoRAN). The training will be conducted at home, with periodic meetings with the clinician, for 3 months, for approximately 4/5 days a week for approximately 30/40 minutes per day. An adult (e.g. a family member) will support the child in the treatment and ensure that the exercises are carried out adequately at home. One of the following tele-rehabilitation software will be used: RuntheRAN (RidiNet, Coopertiva Sociale Anastasis), a software that aims to strengthen the prerequisites of reading by requiring the timed and progressively faster naming of colour matrices or black and white figures. MemoRAN (RidiNet, Cooperativa Sociale Anastasis), which involves rapid naming exercises of stimuli (figures and colors) presented in matrices, within tasks that require inhibition, cognitive flexibility and updating in working memory.
215085659|NCT06288971|OTHER|Game-based tools for the rehabilitation of EF and motor planning|\- MondoELLI intervention (Cooperativa Sociale Anastasis) integrated with neuropsychomotor activities. The game-based app involves activities in small groups to strengthen various components of EF (interference control, inhibition, working memory, flexibility). The activities are organized with increasing difficulty, according to the self-adaptive algorithm, and within a narrative context.
215085660|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
215085661|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
215085662|NCT01289106|BIOLOGICAL|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
215085663|NCT04467476|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
215085664|NCT01800656|PROCEDURE|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
215085665|NCT01800656|PROCEDURE|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
215085666|NCT00327574|BEHAVIORAL|Home heath education +/_ GP training|
215085667|NCT00002427|DRUG|Hydroxyurea|
215085668|NCT00002427|DRUG|Stavudine|
215085669|NCT00002427|DRUG|Didanosine|
215085670|NCT01627444|PROCEDURE|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
214366846|NCT06987786|OTHER|Talk-based therapy|Talk based therapy includes an innovative, evidence-based psychosocial therapy designed to provide rapid and effective pain management for individuals suffering from chronic pain. This single-session, intervention equips patients with essential pain relief skills through a combination of cognitive behavioral therapy (CBT) techniques, mindfulness principles, and pain neuroscience education. The program focuses on teaching patients how to identify and reframe distressing thoughts, practice relaxation techniques, and develop personalized pain management plans.
214366847|NCT01582191|DRUG|Everolimus|Given PO
214366848|NCT01582191|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214366849|NCT01582191|OTHER|Pharmacological Study|Optional correlative studies
214366850|NCT01582191|DRUG|Vandetanib|Given PO
214366851|NCT06991101|DRUG|Ruxolitinib|"During Radiation Therapy phase: 20 mg ruxolitinib will be self-administered orally (PO) twice every day (BID), starting on Day 1 for 6 weeks. Then there will be a 4-week break after radiotherapy is complete.~Maintenance phase: Occurs thirty days (4 weeks) after receiving the last dose of radiotherapy. Ruxolitinib 20 mg will be self-administered PO BID, starting on Day 1 in consecutive 28-day cycles.~Either phase:~Aside from the 30-day break, ruxolitinib will be continued daily until disease progression or treatment intolerance. Ruxolitinib should be administered at approximately the same time each day. The tablets should be swallowed whole with water and should not be opened, broken, or chewed. The dose may be reduced in the case of certain adverse events."
214366852|NCT06991101|DRUG|Temozolomide|"During Radiation Therapy phase: 75 mg/m\^2 will be self-administered PO once every day, starting on Day 1, for 6 weeks. Then there will be a 4-week break after radiotherapy is complete.~Maintenance phase: Occurs thirty days (4 weeks) after receiving the last dose of radiotherapy. Temozolomide 150-200 mg/m\^2 will be self-administered PO BID, starting on Day 1 to Day 5 of each cycle for six cycles.~Either phase:~The dose may be reduced in the case of certain adverse events."
214366853|NCT06991101|RADIATION|Radiation Therapy|Radiation will be administered every weekday (Monday to Friday) in 2 Gy fractions for 30 fractions during a 6-week period (60 Gy total).
214366854|NCT06989164|OTHER|Post prandial testing|A variety of foods, supplements, and short prescriptive exercise will be tested to see which one helps mitigate the rise is postprandial glucose after eating carbohydrate containing foods.
215085671|NCT01133275|DRUG|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
215085672|NCT01133275|DRUG|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
215085673|NCT00900146|DRUG|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
215085674|NCT00900146|DRUG|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
214366855|NCT05614947|DIETARY_SUPPLEMENT|Powdered tart cherry|500 mg freeze-dried tart cherry per capsule
214366856|NCT05614947|DIETARY_SUPPLEMENT|Placebo|500 mg colored cornstarch per capsule
215085675|NCT00900146|DRUG|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
215085676|NCT00700102|DRUG|Chemotherapy|As prescribed
215085677|NCT00700102|DRUG|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
215085678|NCT00415064|DRUG|Perifosine|Perifosine given in either 50 mg or 100 mg / day
215085679|NCT00415064|DRUG|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
215085680|NCT00415064|DRUG|Dexamethasone|Dexamethasone given in 20 mg / day
214977799|NCT03242785|OTHER|Self-monitoring/Self-titration|"The intervention of the ADAMPA trial is not pharmacological but an intervention that modifies usual clinical practice. The intervention of self-monitoring and self-titration of the medication is composed of 3 elements:~1. Education of the patient: information and training on hypertension, its risks, management, the benefits of an adequate control and the generic measures for an optimal control.~2. Training for self-monitoring: Patients will be trained to perform the self-measurement of blood pressure correctly (and recording their values in the sheet enabled for this purpose)~3. Training for self-titration: patients will be instructed on the target BP numbers, individualized for each patient, on the mode of action against specific figures, including self-adjustment of drug treatment."
214977800|NCT01219608|DIETARY_SUPPLEMENT|Glutamine 0.5 g/kg/day|Glutamine 0.5 g/kg/day
215085681|NCT01811303|OTHER|D-fagomine|Measure the changes produced on the postprandial Glycaemic response
215085682|NCT02525939|DRUG|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
215085683|NCT02525939|DRUG|Placebo|matching placebo tablets
215085684|NCT01028716|DRUG|Cyclophosphamide|Given IV
215085685|NCT01028716|BIOLOGICAL|Filgrastim|Given SQ
214366857|NCT06439914|DRUG|[89Zr]Zr-DFO-emapalumab|Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started
214366858|NCT05365776|BEHAVIORAL|Graded Exposure Therapy|Graded exposure therapy is delivered by a psychologist over 12 individual (1:1) secure videoconference sessions. The core active ingredient is graded situational exposure to foster habituation and challenge beliefs that the avoided activities are dangerous. Homework exercises involve planned exposure exercises in the home and community to support generalization.
214366859|NCT05365776|BEHAVIORAL|Prescribed aerobic exercise|Participants will be asked to complete 30 minutes of aerobic exercise on 5 days/week for a 12-week period. Participants select the mode (e.g., swimming, jogging, bicycling) and location of exercise (e.g., outdoors, a gym or community centre, at home). The initial exercise intensity target will be based on the Buffalo Concussion Bike Test. The target progression will be 3-5 beats per minute every two weeks.
214679838|NCT03323229|DIAGNOSTIC_TEST|Enhanced communications & ultrasound|Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (\<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
214679839|NCT00664092|OTHER|Residential|living in a democratic, resident-run setting
214679840|NCT00664092|OTHER|Residential|Professionally-run substance abuse recovery setting
214679841|NCT04339569|DIAGNOSTIC_TEST|Biomechanical analysis|3D analysis of landing manoeuvres.
214977801|NCT01219608|DIETARY_SUPPLEMENT|Glutamine 1 g/kg/day|Glutamine 1 g/kg/day
214977802|NCT01219608|DIETARY_SUPPLEMENT|Enteral Nutrition|Ordinary Enteral Nutrition
214977803|NCT04833374|DRUG|Methylprednisolone|Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
215085686|NCT01028716|DRUG|Fludarabine Phosphate|Given IV
215085687|NCT01028716|DRUG|Mycophenolate Mofetil|Given PO
215085688|NCT01028716|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
215085689|NCT01028716|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
215085690|NCT01028716|DRUG|Tacrolimus|Given IV or PO
215085691|NCT01028716|RADIATION|Total-Body Irradiation|Undergo total-body irradiation (TBI)
215085692|NCT03292419|PROCEDURE|Topography-guided LASIK|LASIK surgery
215085693|NCT03413098|DEVICE|Nasal CPAP mask|Investigative Nasal Mask to be used for OSA therapy
215085694|NCT04254159|OTHER|Superimposed Neuromuscular Electrical Stimulation|NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
215085695|NCT04254159|OTHER|Quadriceps Strengthening|Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
215085696|NCT04254159|BEHAVIORAL|Patient Education Program|The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
215085697|NCT04254159|OTHER|Aerobic Exercise Training|Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
215085698|NCT05590000|DEVICE|Gemini SCS neuromodulation system|This neurostimulation system is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, angina pectoris and peripheral vascular disease.
215085699|NCT03040869|OTHER||
215085700|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant group(A)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).
215085701|NCT02980094|DIETARY_SUPPLEMENT|Milk Oil group(O)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
215085702|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant and oil(AO)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).
215085703|NCT02980094|DIETARY_SUPPLEMENT|Milk Control group(C)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)
215085704|NCT00196859|DRUG|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
215085705|NCT00196859|DRUG|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
215085706|NCT02897752|DEVICE|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
215085707|NCT02897752|OTHER|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
215085708|NCT02688582|OTHER|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
215085709|NCT00011414|DRUG|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
214977804|NCT00473083|DRUG|Minocycline|Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
214977805|NCT00473083|DRUG|Clindamycin 2% in hydrocortisone 1% lotion|"Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles."
214977806|NCT00473083|DRUG|Erlotinib|Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
214977807|NCT00473083|DRUG|Topical clindamycin 2%, triamcinolone acetonide 0.1% soln|Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
215085710|NCT04287803|DRUG|Methoxyflurane|Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores \>=4
215085711|NCT00536874|DRUG|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
215085712|NCT00536874|DRUG|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
215085713|NCT00536874|GENETIC|protein expression analysis|
215085714|NCT00536874|GENETIC|proteomic profiling|
215085715|NCT00536874|OTHER|diagnostic laboratory biomarker analysis|
215085716|NCT00536874|PROCEDURE|adjuvant therapy|
214977808|NCT01976000|PROCEDURE|multi-slice Computed Tomography angiography and three-dimensional reconstruction software|
214977809|NCT00003360|RADIATION|iodine I 131 monoclonal antibody A33|
214977810|NCT00402935|OTHER|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
214977811|NCT00402935|PROCEDURE|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
214977812|NCT00402935|PROCEDURE|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
214977813|NCT00402935|PROCEDURE|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
214977814|NCT02415530|BEHAVIORAL|Combined home visiting and group intervention|home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3\~6 months
214977815|NCT02415530|OTHER|No intervention|No intervention
215085717|NCT00536874|PROCEDURE|neoadjuvant therapy|
215085718|NCT00536874|PROCEDURE|therapeutic conventional surgery|
215085719|NCT03186014|DEVICE|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
215085720|NCT00070252|DRUG|Capecitabine|Given PO
215085721|NCT00070252|DRUG|Docetaxel|Given IV
214977816|NCT00880841|DRUG|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
215085722|NCT00070252|OTHER|Laboratory Biomarker Analysis|Correlative studies
215085723|NCT00070252|OTHER|Pharmacological Study|Correlative studies
215085724|NCT00070252|DRUG|Tipifarnib|Given orally (PO)
215085725|NCT00762996|DEVICE|etafilcon A|contact lens
215085726|NCT00762996|DEVICE|omafilcon A|contact lens
215085727|NCT05460598|OTHER|beddings with cooling effects|beddings with cooling effects (mattress topper and bed linen)
215085728|NCT05460598|OTHER|commonly used bedding|commonly used bedding
215085729|NCT02988999|DIETARY_SUPPLEMENT|D-allulose|D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.
215085730|NCT02988999|DIETARY_SUPPLEMENT|erythritol|non-calorie sweetener
215085731|NCT04610489|DIAGNOSTIC_TEST|Quidel Sofia SARS Antigen FIA|Obtained via bilateral mid-turbinate swab.
215085732|NCT05458089|DIAGNOSTIC_TEST|18F-FDG|18F-FDG intravenous injection
215085733|NCT06356779|PROCEDURE|Local ablative therapy (LAT)|Surgical metastasectomy, stereotactic ablative radiotherapy, thermal ablation, or electroporation to all oligometastatic lesions
215085734|NCT05529342|BIOLOGICAL|Gene modified therapy|No investigational cell product will be administered
215085735|NCT04278937|DRUG|Azithromycin Tablets|one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
215085736|NCT02689076|OTHER|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
215085737|NCT02689076|OTHER|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
215085738|NCT04798742|PROCEDURE|Gluteus maximus transfer|Gait analysis study of 15 patients with gluteus medius disruption
215085739|NCT06373770|DIAGNOSTIC_TEST|Ayres sensory integration therapy|"A. Jean Ayres, is a theory and practice that targets a person's ability to process and internally integrate sensory information from their body and environment. Sensory information may be visual, auditory, tactile, proprioceptive, and/or vestibular in nature. ASI uses individually tailored activities that utilize just right challenges to an individual's existing patterns of sensory processing and motor planning and encourage movement and organization of self in time and space. ASI incorporates specialized equipment and materials in purposeful and playful activities in order to improve adaptive behavior."
214366860|NCT05365776|OTHER|Enhanced usual care|Usual care (education about concussion from the website: concussion.vch.ca/) will be enhanced through email message support.
214679842|NCT04339569|OTHER|Fatigue protocol|A circuit of different tasks (e.g. jumping, sprinting forward and backward, side-stepping exercise) was performed to induce fatigue.
214977817|NCT02915835|DRUG|Riociguat|riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
214977818|NCT02915835|DRUG|Placebo|Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
214977819|NCT00967122|PROCEDURE|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
214977820|NCT00072553|DRUG|celecoxib|
214977821|NCT00072553|DRUG|fluorouracil|
214977822|NCT00072553|DRUG|leucovorin calcium|
214977823|NCT00072553|DRUG|oxaliplatin|
215085740|NCT06373770|DIAGNOSTIC_TEST|Behaviour Therapy|The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis.
215085741|NCT05892367|OTHER|Transbrachial Access for Interventions|Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
215085742|NCT02723890|DEVICE|Tyto Device|
214679843|NCT01228266|BIOLOGICAL|autologous mesenchymal stem cells|A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
214977824|NCT00072553|PROCEDURE|adjuvant therapy|
214977825|NCT00072553|PROCEDURE|conventional surgery|
214977826|NCT00072553|PROCEDURE|neoadjuvant therapy|
214366861|NCT06859541|BEHAVIORAL|Culturally Adapted Play-Based Behavioural Intervention|The Culturally Adapted Play-Based Behavioural Intervention (PPBI) integrates traditional Tamil games and folk storytelling to enhance social, emotional, and communication skills in children with Autism Spectrum Disorder (ASD). This 12-week structured program focuses on engagement, motor development, language, emotional regulation, social interaction, and real-world skill application, making it a culturally relevant and accessible intervention for improving adaptive behaviours.
215085743|NCT02452853|PROCEDURE|HR|"HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
215085744|NCT02452853|DRUG|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
215085745|NCT02182674|DRUG|Placebo Combivent HFA|
215085746|NCT02182674|DRUG|Combivent HFA|
214366862|NCT06859541|BEHAVIORAL|Applied Behaviour Analysis|The ABA-based program utilized structured techniques focused on positive reinforcement, imitation training, guided communication, and step-by-step skill-building. The primary goal was to reduce problem behaviors while reinforcing desirable social and communication skills. Parents and teachers were provided with structured training on how to apply ABA strategies consistently at home and school.
214491823|NCT06763757|BEHAVIORAL|Art Therapy Program|The Art Therapy Program consists of 12 weekly group sessions, each lasting 90 minutes, designed to improve emotional well-being and quality of life in solitary older adults. Participants engage in structured activities that include creating art (e.g., drawing and painting), observing and interpreting art pieces, and reflective discussions to explore personal emotions and experiences. The sessions are led by trained facilitators under the supervision of licensed occupational therapists. This intervention follows a thematic progression: initial sessions focus on building trust and self-expression, mid-sessions deepen emotional awareness, and final sessions culminate in a creative project reflecting the participant's personal growth. Unlike other interventions, this program is tailored specifically for older adults living alone, addressing their unique challenges of isolation and reduced social interaction.
214491824|NCT06755268|OTHER|listening to nature sounds (the sound of birds, water flowing in a river, wind or walking in the forest) based music|Listening to nature sounds (the sound of birds, water flowing in a river, wind or walking in the forest) based music during the angiography procedure.
214977827|NCT05551416|OTHER|Identification of risk factors|Demographics, life habits and risk factors studies
214977828|NCT05551416|OTHER|Characterization of premalignant gastric lesions|Identification and characterization of premalignant gastric lesions through high definition endoscopic study. Concordance between endoscopic and histological classifications
214977829|NCT05551416|OTHER|Identification of biomarkers|Multiomic studies
214977830|NCT05551416|OTHER|Identification of gastric cancer hereditary predisposition|Genomic studies for the identification of individuals with hereditary GC predisposition
214977831|NCT03059667|DRUG|Atezolizumab|Atezolizumab at 1200 mg IV every 3 weeks
214977832|NCT03059667|DRUG|Topotecan|oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
214977833|NCT03059667|DRUG|Carboplatin|In accordance with the summary of product characteristics.
214977834|NCT03059667|DRUG|Etoposide|In accordance with the summary of product characteristics.
214977835|NCT00113607|DRUG|Trabectedin|Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
214977836|NCT00113607|DRUG|DOXIL|Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
215085747|NCT02182674|DRUG|Combivent (CFC)|
215085748|NCT02182674|DRUG|Placebo Combivent (CFC)|
215085749|NCT05832736|PROCEDURE|Robotic hemi-prostatectomy with urethral preservation|Robotic hemi-prostatectomy with urethral preservation
214977837|NCT00113607|DRUG|Dexamethasone|Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
214977838|NCT01418339|DRUG|Aripiprazole|Aripiprazole tablet administered orally once a week.
215085750|NCT06254664|DRUG|Tiotropium 18 µg inhalation powder, hard capsule|Tiotropium 18 µg administered using Zephir inhaler
215085751|NCT06254664|DEVICE|Zephir inhaler|Tiotropium 18 µg administered using Zephir inhaler
214977839|NCT01418339|DRUG|Placebo|Aripiprazole-matching placebo tablet administered orally once a week.
214977840|NCT03885908|OTHER|in-person geriatric co-management|"The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
214977841|NCT03885908|OTHER|automated geriatric co-management|Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention.
214977842|NCT00909844|DRUG|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
214977843|NCT01766362|PROCEDURE|PRPC using Pascal laser|
215085752|NCT02944565|BIOLOGICAL|Daratumumab|Given IV
215085753|NCT06260137|PROCEDURE|Rhomboid intercostal block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle before surgery.
215085754|NCT06260137|PROCEDURE|Rhomboid intercostal and subserratus plane block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle and the serrates anterior muscle before surgery.
215085755|NCT01143896|OTHER|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
214977844|NCT03003234|PROCEDURE|Duodenogastroscopy|Catheter goes through the mouth in the duodenum to take duodenal biopsies.
214977845|NCT03003234|DEVICE|Duodenal aspiration catheter|Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
214977846|NCT03003234|DIETARY_SUPPLEMENT|Nutri drink|Liquid meal of 200 ml.
214366863|NCT06669624|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|10-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.
214977847|NCT06343116|DRUG|Nimotuzumab injection|Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
214977848|NCT06343116|DRUG|Placebo|Placebo will be administered weekly (dose of placebo depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
214977849|NCT06343116|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest.
214977850|NCT01338896|DRUG|Rotigotine transdermal patch|8 mg/24 h, transdermal patch 8 mg/24 h, 2 days
214366864|NCT06669624|OTHER|Waitlist with 4-month delay, then ABC|A 4-month waitlist period, after which they will also receive the home-based ABC program (same as Intervention group).
214366865|NCT06993064|DIETARY_SUPPLEMENT|4000 IU of Vitamin D3|Vitamin D supplementation in Mexican subjects with Type 2 Diabetes Mellitus
214366866|NCT06994832|BEHAVIORAL|Visual Array|Single side-by-side visual array
214366867|NCT06994832|BEHAVIORAL|Narrative Visual Array|Evolving narrative with sequential visual arrays
214366868|NCT00684437|BEHAVIORAL|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
214366869|NCT00684437|BEHAVIORAL|Questionnaire|Questionnaires taking 15-30 minutes to complete.
214366870|NCT05571280|DIETARY_SUPPLEMENT|Nutritional Supplementation|"The Small-quantity lipid-based nutrient supplementation (SQ-LNS) consists of micronutrients delivered in a lipid-based vehicle. All pregnant women (as of 12 weeks self-referred) within households who were randomly included in the study in the nutritional supplementation arm and their children as of 6 months of age will receive the SQ-LNS.~● Pregnant women: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake.~Total = 12/13 months approximately.~● Children from 6 months of age: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake. Total = 18 months.~The distribution will be made by ADECOS on a fortnightly basis.~A family ration will be distributed: family supplementation is presented in a basket of locally produced basic foods that complement the usual diet. The caloric distribution of the basket will be 45% of cereals, 30% of pulses, and 25% in oil, and 1 kg of iodized salt."
214366871|NCT05571280|BEHAVIORAL|Money transfers|The distribution of the amounts will be made through the corresponding financial providers, together with the Municipal or Communal Administration authorities, the Assistants of Community Activities, the Investigator's personnel, and the ADECOS. The distribution frequency will be every 3 months until the end of the study.
214366872|NCT05571280|BEHAVIORAL|Standard intervention|"The activities included are the following:~1. Community interventions against malnutrition and promotion of adequate nutrition: raise awareness of malnutrition and training mothers to recognize signs of malnutrition.~2. Community interventions in promoting hygiene and proper sanitation: a) Promotion of Community-Led Total Sanitation approach (CLTS)strategy: community awareness of the entire population included in the cluster about the dangers of open defecation, and the direct link to malnutrition; b) Promotion of Baby-Wash strategy: to make the community aware of the problems and consequences of unsafe water consumption.~3. Biannual supplementation with vitamin A for children from 6 to 24 months of age.~4. Biannual deworming (albendazole/mebendazole) for children from 12 months to 24 months of age and pregnant women as of 2nd quarter.~5. Malaria prophylaxis with sulfadoxine-pyrimethamine (SP) in pregnant women as of 13 weeks of pregnancy."
214366873|NCT06671548|DRUG|Relugolix|"* Relugolix (40 mg) tablet administered orally once daily；~* megestrol acetate (1 mg) administered orally once daily；~* medroxyprogesterone acetate (2 mg) administered orally once daily"
214977851|NCT00706004|DRUG|lubiprostone|lubiprostone 24 microgram capsule taken twice daily for 4 weeks
214977852|NCT01064479|DRUG|Carboplatin|Given IV
214977853|NCT01064479|DRUG|Cisplatin|Given IV
214977854|NCT01064479|DRUG|Docetaxel|Given IV
214977855|NCT01064479|DRUG|Erlotinib Hydrochloride|Given PO
214977856|NCT01064479|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214977857|NCT01064479|OTHER|Pharmacological Study|Optional correlative studies
214977858|NCT01064479|OTHER|Placebo|Given PO
214977859|NCT01064479|OTHER|Quality-of-Life Assessment|Ancillary studies
214977860|NCT00216255|DRUG|Pagoclone|
214977861|NCT00216255|DRUG|Placebo|
214977862|NCT06342232|BEHAVIORAL|Neurofeedback mindfulness|The participants used a portable EEG headband to complete 10 minutes of neurofeedback mindfulness practice for 8 weeks. While being seated comfortably, they could modify their brains rates based on the audio neurofeedback they received.
214977863|NCT06342232|BEHAVIORAL|Simple attention controlled task|The controlled group of this project also received an intervention which included an audiobook. While wearing the headband, the controlled participants muted their neurofeedback sounds and only focused on an audiobook while remaining relaxed. A summary of their brain states was given to them when completing their practice every day.
214977864|NCT03226444|DRUG|0.005% Lacripep|One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
214977865|NCT03226444|DRUG|0.01% Lacripep|One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
214977866|NCT03226444|DRUG|Placebo|One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
214977867|NCT04069117|DRUG|letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)|letrozole /antagonist protocol
214977868|NCT00466817|OTHER|Placebo|9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
214977869|NCT00466817|DRUG|Valganciclovir|Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
214977870|NCT05918536|DIAGNOSTIC_TEST|evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT|Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT
214977871|NCT04517292|DRUG|Eribulin,cisplatin|Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
214977872|NCT04517292|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
214977873|NCT03093181|OTHER|Washout / Standard Cleanser|Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
214366874|NCT06671548|DRUG|Relugolix placebo|"Relugolix (0 mg) tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~megestrol acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~medroxyprogesterone acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor."
214366875|NCT06999213|OTHER|Assist|The device will provide assistive torques to support either ankle, knee, and/or hip movements.
214366876|NCT06999213|OTHER|Resist|The device will apply resistive torques to exaggerate gait asymmetries, facilitating error augmentation.
214366877|NCT06999213|OTHER|Slack|The device will be worn but will not generate any torque.
214366878|NCT01387139|DRUG|Ketamine|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
214366879|NCT01387139|DRUG|Ketamine Co-administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
214491825|NCT06751849|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
214977874|NCT03093181|OTHER|Test product|Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
214366880|NCT06670872|DRUG|Eravacycline combination therapy group|"Physicians determine the combination regimen of eravacycline, which may include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., based on the pathogen identification and susceptibility results, and the China Guidelines for Diagnosis, Treatment, and Prevention of Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria. The combined drugs are used according to their instructions for use or clinical practice guidelines."
214977875|NCT03093181|OTHER|Positive control cleanser|Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
214977876|NCT03093181|OTHER|Positive control moisturiser|Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
214977877|NCT00038766|DRUG|semapimod|semapipmod 60 mg IV x 5 days
214977878|NCT00038766|DRUG|semapimod|IV 30 mg x 5 days
214977879|NCT00038766|DRUG|placebo|placebo IV
214366881|NCT02697851|DRUG|Microgynon 30®|
214366882|NCT02697851|DRUG|Evotaz®|
214491826|NCT06751849|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
214679844|NCT02685384|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
214366883|NCT07002762|DIETARY_SUPPLEMENT|Burdock ( Arctium lappa L.) root extract in a form of a nutritional additive|Gastric soluble capsules each containing: 750 mg of burdock ( Arctium lappa L.) root extract in the form of a nutritional additive
214366884|NCT07002762|OTHER|Placebo|Gastric soluble capsules each containing: Maltodextrin, silicon dioxide, calcium stearate, food colourants
214366885|NCT05610852|PROCEDURE|Transvesical Single Port Robotic Partial Prostatectomy|A foley catheter is inserted on the sterile field. A suprapubic midline incision is made and the da Vinci SP surgical system is docked percutaneously directly to the bladder. Prior to the operation, a radiologist identifies and segments tumors and the urethra. A transrectal ultrasound probe is inserted and secured into a fixed position. The Koelis software is utilized to fuse MRI and ultrasound images to identify the target lesion in real-time, allowing for intraoperative guidance. The ultrasound probe rotates automatically, allowing for localization of the tumor intraoperatively. Then depending on the area of the tumor, a Hemi or quadrant resection is completed while preserving the nerves, vas deferens, and seminal vesicles. The urethrovesical anastomosis is then performed.
215085756|NCT05114122|PROCEDURE|Vonlay Ceramic restorations|vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
214366886|NCT05610852|PROCEDURE|High-intensity focused ultrasound (HIFU)|Three contoured measurements are required for the MR fusion system to reproduce the volume of the prostate. Following this, the area to be targeted will be selected in graded fashion from the anterior to posterior of the prostate. Once planning of ROI (region of interest) is complete, the HIFU treatment may begin. Quadrant or hemi ablation will be performed based on the size and complexity of the tumor. The distal margin of the ablation will be kept at least 4 mm away from the external sphincter. The rectal temperature and its distance from the probe will be carefully monitored throughout the procedure.
214366887|NCT05251454|PROCEDURE|Brain Stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase).
214366888|NCT06621238|BEHAVIORAL|Music|Listen to Music
214366889|NCT07009171|DRUG|KDS2010|KDS2010 will be administered orally once daily, three tablets per day, for 12 weeks. Dosage will be either 120 mg or 180 mg depending on the assigned group.
214366890|NCT07009171|DRUG|Placebo|Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, three tablets per day, for 12 weeks.
214366891|NCT04839354|DRUG|L-Arginine Hydrochloride|A one-time L-arginine hydrochloride loading dose of 200 mg/kg will be administered intravenously (IV) followed by a standard dose of 100 mg/kg given by IV three times per day (TID).
214366892|NCT04839354|OTHER|Normal saline|A placebo of normal saline will be administered by IV with a loading dose of 2ml/kg followed by 1ml/kg given by IV three times per day (TID).
214491827|NCT06751849|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
214977880|NCT01219582|DRUG|Glucobay M (Acarbose/Metformin, BAY81-9783)|Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
214977881|NCT06506123|DEVICE|Artificial Intelligence Detection and Classification of Patient-Ventilator Dyssynchronies|Machine learning algorithm to detect and classify patient-ventilator dyssynchronies, which is integrated in the mechanical ventilator (Fleximag Max, Magnamed, Brazil).
215085757|NCT05114122|PROCEDURE|Onlay Ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
214491828|NCT06753292|PROCEDURE|active gas aspiration|surgeon will be instructed to actively aspirate the intraperitoneal CO2 gas
214491829|NCT06753292|PROCEDURE|pulmonary recruitment maneuver|patients will receive the PRM which consisted of five manual pulmonary inflations, where each positive pressure inflation will be done for 5 s at a maximum pressure of 30 cm H2O, manually by using the APL valve in the anesthesia machine. The patient will be in a Trendelenburg position (30°). The fifth positive pressure inflation lasted for approximately 5 s. During that time, the patient will be closely monitored, while the anesthesiologist performed PRM
214679845|NCT02254668|OTHER|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
214977882|NCT04620577|OTHER|antibiotic|normal saline
214977883|NCT04210986|DIETARY_SUPPLEMENT|Fisetin|Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.
214977884|NCT04210986|DRUG|Placebo oral capsule|Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
215085758|NCT02084238|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
215085759|NCT03146780|PROCEDURE|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
215085760|NCT03146780|PROCEDURE|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
214977885|NCT02740842|BEHAVIORAL|Interpersonal behavioral change communication|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
215085761|NCT03146780|PROCEDURE|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
215085762|NCT03146780|PROCEDURE|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
215085763|NCT02398695|OTHER|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
215085764|NCT05107973|OTHER|Baduajin|The intervention will consist in a 1 hour supervised Baduajin sessions conducted once a week a certified instructor with more than 10 years of experience. Each session will start with 5 min of warm up, 50 minutes of Baduajin and 5 min of cool down. In the main part the participants exercise the wholes set of Baduajin that consist of eigth forms.
214977886|NCT02740842|BEHAVIORAL|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
214366893|NCT01999166|RADIATION|radiography (X-ray)|
214366894|NCT01999166|GENETIC|DNA sampling|
214977887|NCT04971603|OTHER|Acupuncture|"All acupuncture operations were done by registered Chinese medicine practitioner. Sterile, disposable acupuncture needles (0.25mmin diameter and 40mmin length) were used, which were purchased from HuaTuo acupuncture instrument.~Principal points: Neiguan (PC 6) \*, Sanyinjia (SP 6) \*, Weizhong (BL 40) \*, Baihui (GV 20), Shuigou (GV 26) \*, Zusanli (ST 36) \*, Quchi (LI 11) \*, Waiguan (TE 5) \*, Hegu (LI 4) \*, Huantiao (GB 30) \*, Yanglingquan (GB 34)\* (Grading of recommendation: C, level of evidence: IV).~Supplementary points: If upper limbs hemiplegia occurs, add Jianliao (TE 14) and Shousanli (LI 10); if lower limbs hemiplegia occurs, add Xuanzhong (GB 39) and Taichong (LR 3); if a deviation of the mouth or tongue occurs, add Dicang (ST 4) and Jiache (ST 6)."
214977888|NCT04322032|DRUG|Reference drug|D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.
214977889|NCT04322032|DRUG|Test drug|CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
214977890|NCT00542893|DRUG|Genasense® (G3139, oblimersen sodium)|
214977891|NCT00542893|DRUG|Genasense followed by DTIC; then DTIC alone|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
214977892|NCT00542893|DRUG|DTIC alone; then Genasense followed by DTIC|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
214977893|NCT02378662|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO
214977894|NCT01159574|DRUG|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
215085765|NCT00693004|DRUG|PRX-03140|
215085766|NCT00693004|DRUG|Donepezil|
215085767|NCT00693004|DRUG|Placebo|
214977895|NCT01159574|DRUG|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
214977896|NCT01159574|DRUG|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
214977897|NCT05276791|OTHER|EMR|Endoscopic mucosal resection, according to standard care
214977898|NCT05276791|OTHER|ESD|Endoscopic submucosal dissection, according to standard care
214977899|NCT00572689|DRUG|Exenatide|10 microgram injected sub-cutaneously once
215085768|NCT00000120|DRUG|Erythromycin Ointment|
215085769|NCT00000120|DRUG|Silver Nitrate Drops|
214366895|NCT05879627|DRUG|BAT8007 for injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
214977900|NCT00572689|GENETIC|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
214977901|NCT05982327|PROCEDURE|ORIF|fixation of scapular fractures by plate and screws
214977902|NCT03369574|DRUG|Reslizumab|reslizumab administration
214366896|NCT06676280|DRUG|Aspirin|Patients will take aspirin 100 mg/day.
214366897|NCT06676280|DRUG|High-intensity statin|Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.
214366898|NCT06676280|DRUG|Guideline-directed statin therapy|as 2018 Cholesterol Clinical Practice Guidelines.
214366899|NCT05420636|DRUG|Iadademstat|Patients will be treated with iadademstat given at a dose of 150 microgram PO administered on a 5 day on-2 day off schedule every week (days 1 through 21)
214366900|NCT05420636|DRUG|Paclitaxel|Patients will be treated with Paclitaxel given at a dose of 80 mg/m2 intravenous administration weekly day 1, 8 and 15 (days 1 through 21).
214679846|NCT02254668|OTHER|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
214977903|NCT01940822|OTHER|Energy Drink|
214977904|NCT01940822|OTHER|Placebo Drink|
214977905|NCT02897557|DEVICE|Insulet Artificial Pancreas (AP) System|
215085770|NCT02074072|DEVICE|15 degree left-lateral tilt wedges|The wedges are made of aluminium
215085771|NCT02074072|DEVICE|30 degree left-lateral tilt wedges|The wedges are made of aluminium
214491830|NCT06777095|OTHER|Routine Treatment + I Taping|Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. In addition to routine treatment, I taping (a total of 5 times every 3 days) was performed. Two I-shaped kinesio tapings were applied on the paraspinal muscles from the posterior superior iliac spine to the T12 level. 50% tension was applied to the area of the tapes outside the anchor points.
214977906|NCT04189016|DEVICE|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
214977907|NCT02965924|DRUG|Phenylephrine 2.5%|Instilling phenylephrine 2.5% eye drop
214977908|NCT01627548|BEHAVIORAL|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
214977909|NCT03343548|DRUG|magnesium sulfate|2cc of magnesium sulfate ( 50%) will be administered epidurally
214977910|NCT03343548|DRUG|normal saline|2cc of normal saline will be administered epidurally
215085772|NCT04668924|PROCEDURE|Epi-on PiXL in high oxygen|After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for \< 45 Diopters (D) 7.2J/cm\^2 will be used; for 45-50D 10J/cm\^2 will be used; for \> 50D 15 J/cm\^2 will be used.
215085773|NCT05854953|DEVICE|Hawley retainers in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
215085774|NCT05854953|DEVICE|Hawley retainers in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
215085775|NCT05854953|DEVICE|VFRs in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
215085776|NCT05854953|DEVICE|VFRs in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
215085777|NCT05854953|DEVICE|Baseline characteristics|Hawley retainers and VFRs that are newly constructed will be used as baseline samples. The samples will be taken for microbial, physical and mechanical tests.
215085778|NCT02275728|OTHER|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
215085779|NCT02275728|OTHER|Eletromyography Biofeedback|
215085780|NCT00533858|DRUG|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
215085781|NCT00784732|DRUG|QAV680|
215085782|NCT00784732|DRUG|QAV680|
215085783|NCT00784732|DRUG|Mometasone Furoate|
215085784|NCT00675896|DRUG|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
215085785|NCT00675896|DRUG|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
215085786|NCT01077180|DEVICE|Implantation of the Rheos System|Open label
215085787|NCT01077180|OTHER|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
215085788|NCT06519461|BEHAVIORAL|Family-centered teaching model|The program comprised two parts: (1) Didactic lessons: and (2) Hands-on practice. The didactic lessons were designed to prepare interns' knowledge and skills. The hands-on practice were designed to provide opportunities of family-centered experience to work with caregivers and children.
215085789|NCT00849875|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
215085790|NCT00849875|DRUG|Dacarbazine|Intravenous administration Chemotherapy
215085791|NCT03358641|OTHER|level of physical activity|According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
215085792|NCT03510871|DRUG|nivolumab, ipilimumab|All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
215085793|NCT00086502|DRUG|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
214366901|NCT06623396|BIOLOGICAL|M28z1XXPD1DNR CAR|Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.
215085794|NCT00086502|DRUG|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
215085795|NCT00086502|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
215085796|NCT00086502|DRUG|Metformin|"Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"
215085797|NCT02662179|OTHER|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
214977911|NCT02282462|OTHER|Reg Pressure|Regulated Suction using the Thopaz+ digital chest drainage device
215085798|NCT02662179|OTHER|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
214977912|NCT02282462|OTHER|Unreg Pressure|Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
214977913|NCT02282462|OTHER|Active Suction (Dig)|Thopaz+ digital chest drainage device set at -20cmH2O at the patient
214977914|NCT02282462|OTHER|Active Suction (Trad)|Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
215085799|NCT02662179|OTHER|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
215085800|NCT02662179|OTHER|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
215085801|NCT06373783|PROCEDURE|subepithelial connective tissue graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of the canine and the mesial of the first molar in the palate. Connective tissue dimensions were approximately 10x5x2 mm. The graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and an electronic caliper during surgery.
215085802|NCT06373783|PROCEDURE|de- epithelize gingival graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. A shallow horizontal incision was made at ≈3 mm apical from the gingival margin of the maxillary molar teeth using a number 15 scalpel blade. Subsequently, a parallel horizontal incision, at ≈ 4 mm apical from the first horizontal incision, was traced in conjunction with two vertical releasing incisions to delineate a rectangular area. Then, the uppermost epithelial layer was scraped off using a size 11 scalpel tip. The connective tissue graft to be taken from the palate area was 10x5x2 mm in size, and the graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and electronic caliper during surgery.
215085803|NCT06373783|DIAGNOSTIC_TEST|ultrasonography|"Clinical parameter measurements (probing depth (PD), clinical attachment level (CAL), gingival recession depth and width, keratinized tissue width and height) were taken on the day of surgery, the 3rd days, the 14th days, the 1st month, the 3rd months and the 6th months.~Ultrasonography measurements A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the receiver site in the buccal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit pulsatility index (PI) = (Vmax-Vmin) (Vmean) (Vmax is peak systolic flow velocity. Vmin is diastolic flow velocity and Vmean is mean flow velocity.) The mean PI values of each patient were measured."
215085804|NCT04927104|DEVICE|PEEK Knee Prosthesis|After subjects drop out of the study for any reason, the researchers can perform revision surgery using the prosthetic joint that is now routinely used.
215085805|NCT01304329|DRUG|BI 10773|Medium dose oral administration
215085806|NCT01304329|DRUG|simvastatin|Medium dose oral administration
214491831|NCT06777095|OTHER|Routine Treatment + Star Taping|Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. In addition to routine treatment, star taping (a total of 5 times every 3 days) was performed. Four I tapes, one vertical, one horizontal and two at a 45° angle to the vertical tape, were applied to the point of maximum pain in the lumbar region. 25% tension was applied to the midpoint of the tapes except for the ends.
214491832|NCT06777095|OTHER|Routine Treatment|Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. No taping was applied.
214491833|NCT06773923|DEVICE|PCL Scaffold|patients with their jaw/maxilla in which the 3D scaffold with PCL will be inserted.
214491834|NCT06773923|DEVICE|PTFE + Bio-Oss®|patients with jaw/maxilla which will be regenerated using the conventional technique using a titanium reinforced polytetrafluoroethylene (PTFE) membrane (Cytoplast® brand) and filling the space with Bio-Oss xenograft (Geistlich
214679847|NCT02322892|DRUG|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
214977915|NCT02282462|OTHER|Passive Drainage (Dig)|"Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)"
214977916|NCT02282462|OTHER|Passive Drainage (Trad)|"Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')"
214977917|NCT02666222|DEVICE|The Esteem Hearing Implant|The Esteem® Hearing Implant is designed to improve hearing in subjects suffering from moderate to severe hearing loss that is sensorineural in origin. The Esteem® has been approved by FDA for the US market under Pre-Market Approval P090018 and this study fulfills the requirement for one of the Post Approval Studies.
214977918|NCT03149536|DIAGNOSTIC_TEST|Pharmacogenetic test|To develop a pharmacogenetic prediction test
214977919|NCT04781712|BEHAVIORAL|Modular mHealth for Tailored Rehabilitation|an individually tailored self-management through the mHealth app with a smart band worn on the wrist
214977920|NCT00562406|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
214977921|NCT00562406|PROCEDURE|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
214977922|NCT02443623|BIOLOGICAL|Vaccination with ACAM2000|In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
214977923|NCT05919628|OTHER|ResPsyPark group|Evaluation of the parkinson's disease patient's score over different psychological questionnaires and a therapeutical observance questionnaire
214977924|NCT00942136|DRUG|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
215085807|NCT01304329|DRUG|simvastatin|Medium dose oral administration
215085808|NCT01304329|DRUG|BI 10773|Medium dose oral administration
215085809|NCT02973568|OTHER|Observational Study|
215085810|NCT01174017|RADIATION|Iodine 125 standard loose brachytherapy seeds|radioactivity 0.4 U per seed, prescribed dose 144 Gy
215085811|NCT01174017|RADIATION|AnchorSeed Iodine 125 brachytherapy prostate implant|activity 0.4 U per seed, prescribed dose 144 Gy
215085812|NCT02964832|DEVICE|Grasp method|
215085813|NCT02964832|DEVICE|Armband-in-hand method|
215085814|NCT02964832|DEVICE|Armband-on-arm method|
215085815|NCT01897649|DIETARY_SUPPLEMENT|NUTRIOSE FB06|15g/day NUTRIOSE FB06
214366902|NCT06122727|PROCEDURE|total knee arthroplasty|In detail, in the STANDARD group, patients will undergo a primary TKR by implanting a prosthetic model of the same standard design for all using the usual surgical technique and instrumentation (based on the use of guide intramedullary of femur and extramedullary of tibia); in the PERSONALIZED group, patients will undergo a primary TKA by implanting a prosthetic model (YourKnee, Rejoint) with design based specifically on each patient's actual knee morphology and using PSI surgical technique and instrumentation. In both groups, the approach of the basic prosthetic design base will be of the Cruciate-Retaining (CR) type with congruent polyethylene (PE), with standard and customized for the STANDARD and CUSTOM group, respectively.
214366903|NCT07010289|OTHER|Prepared Meals|Participants will receive the intervention of weekly home meal delivery, consecutively for 4 weeks, delivered to their home. The meals will be provided by Providence Community Kitchen, which is a program of Second Harvest Food Bank of Northwest NC. During the 4 weeks of meal provisions, participants will receive 7 family style frozen dinners delivered to the participant's home weekly. Meals are frozen, have minimal preparation time, and can be heated by oven.
214366904|NCT07010289|OTHER|Grocery Gift Cards|Participants will receive weekly grocery store gift cards, consecutively for 4 weeks. During the 4 weeks of gift card provisions, participants will receive (1) $40.00 grocery store gift card weekly, mailed to participants' home address by study staff.
214366905|NCT07010289|OTHER|Standard of Care|Participants will receive the current standard for care for families endorsing inpatient food insecurity during a hospitalization, which include provision of printed and electronic food access resources. Currently, all families with positive food insecurity screening are met by a community health worker in the hospital who reviews current food access status with families (including enrollment in federal nutrition programs) and provides them with printed and electronic resources of nearby food pantries and other food access resources available to them at time of discharge from the hospital.
214366906|NCT06209320|DRUG|Lower dose atropine sulfate eye drops|administer to eyes
214366907|NCT06209320|DRUG|Low dose atropine sulfate eye drops|administer to eyes
214366908|NCT06209320|DRUG|placebo|administer to eyes
214366909|NCT07014020|GENETIC|RB001|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
214366910|NCT07014202|COMBINATION_PRODUCT|Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy|Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy in patients with advanced NSCLC who have not progressed after 4-6 cycles of first-line platinum-containing chemotherapy combined with immunotherapy and who have an oligo-residual status confirmed by PETCT.
214366911|NCT07014202|DRUG|Immunotherapy (with or without chemotherapy) maintenance therapy|Immunotherapy (with or without chemotherapy) maintenance therapy in patients with advanced NSCLC who have not progressed after 4-6 cycles of first-line platinum-containing chemotherapy combined with immunotherapy and who have an oligo-residual status confirmed by PETCT.
214366912|NCT04120233|DRUG|Placebo|Matched placebo administered orally
214366913|NCT04120233|DRUG|MW151, 10mg|10 mg MW151, 1 x 10mg capsule administered orally
214366914|NCT04120233|DRUG|MW151, 20mg|20 mg MW151, 1 x 20mg capsule administered orally
215085816|NCT01897649|DIETARY_SUPPLEMENT|GLUCIDEX 21|15g/day GLUCIDEX 21
215085817|NCT06367907|OTHER|schema therapy|In this study, we aim to investigate the mode of action of the core therapeutic techniques implemented in schema therapy (ST), a psychotherapy that particularly addresses deficits of emotion regulation and of social interaction in personality disorders.
215085818|NCT04416607|DRUG|Corifollitropin Alfa|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
215085819|NCT04416607|DRUG|Menotropins|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
215085820|NCT00062608|BEHAVIORAL|Written self-disclosure|
215085821|NCT03209232|DRUG|Infliximab|Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
215085822|NCT06385717|RADIATION|chemo-radiation|different Chemo-radiotherapy regimen
215085823|NCT05331703|OTHER|designed physical therapy program in addition to program of virtual reality.|physical therapy program in addition to program of virtual reality.
215085824|NCT05331703|OTHER|designed physical therapy program in addition to program of mirror therapy.|physical therapy program in addition to program of mirror therapy.
214491835|NCT06242873|OTHER|Gait training with/without TSCS|To assess the safety and impact of paired stimulation and training on gait in children with iSCI, participants will participate in 24 total sessions. Two sessions will involve assessment only and 22 sessions will include two hours of therapy. Sessions will occur at least three times per week, but may be scheduled as many as five times per week. In each session, participants will receive 60 minutes of treadmill training followed by strengthening, segmental task practice, and gait-based interventions. Participants will receive stimulation based on their group assignment (TSCS or sham).
214977925|NCT00942136|DRUG|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
214491836|NCT03860792|BEHAVIORAL|Ketogenic Diet|Three-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
214491837|NCT03860792|BEHAVIORAL|Therapeutic Lifestyles Changes Diet|Three-month diet intervention that is low in fat and cholesterol, high in fruits, vegetables, and whole grains, and moderate in protein.
214491838|NCT06725173|GENETIC|Targeted Long-read sequencing|All patient's will undergo targeted long-read sequencing to resolve genomic and epigenomic signatures of the RB1 gene
214491839|NCT04352166|DRUG|extended-release buprenorphine (BXR)|Three monthly injections will be provided during the course of the 12 week trial.
214491840|NCT04352166|DRUG|sublingual buprenorphine (BSL)|On a weekly basis patients will be provided with sublingual buprenorphine to take up to 24 mg daily.
214491841|NCT00898365|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214977926|NCT00942136|DRUG|Placebo|Placebo Suspension as a single dose.
214977927|NCT00942136|DRUG|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
214977928|NCT02841124|OTHER|interviews|face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
214977929|NCT00169299|DRUG|Black cohosh|
214977930|NCT00169299|DRUG|Multibotanical preparation|
215085825|NCT05481424|OTHER|Biodynamic|This will be a nine-hour lighting scheme that includes three modes: morning, noon, and afternoon. It mimics natural lighting by providing blue-enriched bright lighting in the morning and yellowish dimmed lighting in the afternoon. The lighting scheme is designed to satisfy the visual lighting needs of office workers while maintaining a robust circadian clock.
215085826|NCT05481424|OTHER|Active Placebo|"We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness during working hours. This condition is designed to serve to requirements: (1) to simulate a conventional, well-lit office lighting in compliance with the WELL standard V1 recommendations for circadian lighting design, and (2) to provide an Equivalent Melanopic Lux (EML) equal to the geometric average of EML delivered by the Biodynamic condition. Participants will receive a similar dose of lighting under both the Placebo and Biodynamic conditions; however, the time factor is ignored in the Placebo, and hence the method of delivery is different (constant versus dynamic)."
215085827|NCT05870917|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20％ x 10\^6 anti-BCMA CAR+T cells/kg respectively
215085828|NCT04101617|BEHAVIORAL|Oral Health education including printed educational material|Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
215085829|NCT00525629|DIETARY_SUPPLEMENT|Walnuts|48 Grams of Walnuts Daily
215085830|NCT00525629|DIETARY_SUPPLEMENT|Control|Control Diet with No Walnuts
214491842|NCT00898365|OTHER|Laboratory Biomarker Analysis|Correlative studies
214491843|NCT06891482|BEHAVIORAL|Telerehabilitation|Intervention: Each enrolled participant within the telerehabilitation + usual care rehabilitation part will be provided a Fitbit® Charge 5 tracker, connected with the smartphone application Fitbit on the participant\&#39;s smartphone by creating a Fitbit user account, and the tracker will be configured for each participant. A smartphone will be provided if the participant does not have a smartphone. Participants will be asked to continue wearing their tracker on their non-access arm at all times, other than bathing, for the 3-months study duration. Each week during this telerehabilitation phase, the physiotherapist (PT) will follow-up the participants' step counts during hemodialysis. Participants will receive feedback on their activity level and will be motivated by the PT, along with specific step goals for the upcoming week. The PT gives advise on how to incorporate more walking into participants' daily routine with specific attention for shared decision making during this feedback
214491844|NCT02039401|BIOLOGICAL|VM202|
214491845|NCT05720065|DRUG|Botulinum toxin type A|Randomized double-blind administration
214491846|NCT05720065|DRUG|Isotonic saline 0,9%|Randomized double-blind administration
214977931|NCT00169299|DRUG|Multibotanical preparation + dietary soy counseling|
214977932|NCT00169299|DRUG|Conjugated equine estrogen +/- medroxyprogesterone acetate|
214977933|NCT04032132|DRUG|curcumin paste|curcumin is a herb used for medical purpose
214977934|NCT04032132|PROCEDURE|curettage|open flab debridement surgery
214977935|NCT01533532|DRUG|KLH-2109|
214977936|NCT01533532|DRUG|KLH-2109|
214977937|NCT01533532|DRUG|KLH-2109|
214977938|NCT01533532|DRUG|placebo|
215085831|NCT02745717|DRUG|Thymoglobulin|administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
215085832|NCT02745717|PROCEDURE|Cord blood|transfusion of one unit of at least 4/6 HLA loci matched cord blood.
215085833|NCT02745717|DRUG|Cyclosporine Oral Product|administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
215085834|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
215085835|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
214679848|NCT02322892|DRUG|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
214977939|NCT00853294|DRUG|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
214977940|NCT00853294|DRUG|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
214977941|NCT01474486|DRUG|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
214977942|NCT04753866|DEVICE|Facial scanner|The Bellus3D facial scanner will be used to scan the patient before and after implant rehabilitation in order to produce .obj files that allow 3D comparisons and to obtain discrepancy values regarding lip support.
214977943|NCT03839134|DEVICE|DentalVibe® Comfort Injection System|Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.
214977944|NCT03839134|DRUG|Lidocaine Epinephrine|Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
214977945|NCT05817123|OTHER|Questionnaires|"Administration of the following questionnaires:~* Mutuality scale~* Pittsburgh Sleep Quality Index (PSQI)~* Epworth Sleep Scale (ESS)~* Sleep Condition Indicator (SCI)~* International Physical Activity Questionaire (IPAQ)~* Mediterranean diet score (MDS)~* Quality of Life SF 12~* Hospital Anxiety and Depression Scale (HADS)"
214977946|NCT03797859|PROCEDURE|Apneic ventilation|Ventilation by THRIVE
214977947|NCT04534309|BEHAVIORAL|Written Weight Loss Material|Participants will receive written weight loss material by email.
214977948|NCT04534309|BEHAVIORAL|Weight Loss App|Participants will receive written weight loss material as well as instructions for using a free weight loss app on their phone or computer.
214977949|NCT04534309|BEHAVIORAL|Behavioral Lifestyle Weight Loss Intervention (Coaching)|Participants will receive weekly coaching phone calls to encourage regular dietary, exercise, and self-monitoring practices which encourage gradual, healthy weight loss.
214977950|NCT03504917|DRUG|Balovaptan|Participants will receive 10 mg of oral administration balovaptan once a day (QD).
214977951|NCT03504917|DRUG|Placebo|Participants will receive matching placebo.
215085836|NCT00283816|DRUG|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
215085837|NCT00283816|DRUG|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
215085838|NCT00283816|BEHAVIORAL|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise \& behavior modification skills on a regular weekly basis over the 24 week study
215085839|NCT00283816|BEHAVIORAL|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
215085840|NCT00283816|PROCEDURE|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
214366915|NCT04120233|DRUG|MW151, 40mg|40 mg MW151, 2 x 20mg capsule administered orally
214366916|NCT04120233|DRUG|MW151, 80mg|80 mg MW151, 1 x 80mg capsule administered orally
214366917|NCT04120233|DRUG|MW151, 160mg|160 mg MW151, 2 x 80mg capsule administered orally
214977952|NCT04219189|OTHER|Vaping condition|Participants will be asked to use a JUUL device to vape 20 puffs over 20 minutes. Participants will use JUUL pods with \~5% nicotine by weight. The anticipated amount of nicotine that will be absorbed with 20 puffs is approximately 1.6 mg, which is equal to approximately 1.5 cigarettes.
214977953|NCT04219189|OTHER|Control condition|Participants will have access to an uncharged JUUL device with an empty pod for 20 minutes.
214977954|NCT01381497|DRUG|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
215085841|NCT00283816|PROCEDURE|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
215085842|NCT00283816|PROCEDURE|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
215085843|NCT00283816|PROCEDURE|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
214366918|NCT06689553|DEVICE|Automated Continual Fluid Removal System|The intraperitoneal device is percutaneously implanted via mini laparotomy, under local anaesthesia and sedation, and connected to the wearable rechargeable pump through extracorporeal tubing. The device aims to remove excess fluids in heart failure patients with diuretic resistance
214679849|NCT01104259|DRUG|veliparib|Given PO
215085844|NCT00283816|DRUG|placebo|placebo capsules, two capsules BID
215085845|NCT05528900|DIAGNOSTIC_TEST|allergy test|allergy test are oral food challenge , prick test and IgE blood rate
214977955|NCT01381497|DRUG|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
214977956|NCT04870996|DEVICE|tDCS|tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.
214977957|NCT04870996|BEHAVIORAL|Cognitive Training|All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.
214977958|NCT02381236|DRUG|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
214977959|NCT05654038|BIOLOGICAL|Anti-CD19 UCAR-NK cells|"The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set three different dose levels of UCAR-NK cells:Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg."
214977960|NCT05322096|DRUG|RGH-706|"Capsules~Oral administration"
214977961|NCT05322096|DRUG|Placebo|"Capsules~Oral administration"
214977962|NCT03473405|DEVICE|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
214977963|NCT03473405|OTHER|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
214977964|NCT03101020|OTHER|Active Visceral Manipulation|Visceral manipulation techniques consists of deep manual pressure in certain points of the abdomen and the amount of pressure will be respected according to the participant discomfort or pain. It will be performed cardia mobilization, pylori mobilization, Oddi's sphincter mobilization, duodenum-jejunum valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.
215085846|NCT02575118|DEVICE|Restoration of dental caries with dental composite|
215085847|NCT04423601|DRUG|SHR6390 tablet|single oral dose of SHR6390 or co-administered with itraconazole.
214977965|NCT03101020|OTHER|Standard care physiotherapy|The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.
214977966|NCT03101020|OTHER|Placebo Visceral Manipulation|The placebo intervention involves light touch at the same regions of the techniques the active visceral manipulation, and no intention on the part of the therapist to impart any therapeutic technique
214977967|NCT02228252|OTHER|Whey protein|
214977968|NCT02228252|OTHER|Casein|
214977969|NCT02228252|OTHER|Gluten protein|
214977970|NCT04233879|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
214977971|NCT04233879|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.
214977972|NCT04233879|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
214977973|NCT04233879|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL taken by mouth.
214679850|NCT01104259|DRUG|cisplatin|Given IV
214977974|NCT02040714|PROCEDURE|Osteotomy + Long Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
214977975|NCT02040714|PROCEDURE|Osteotomy + Short Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
214977976|NCT02040714|PROCEDURE|Nonoperative Observation|Group will not undergo any surgical or invasive procedures during course of treatment.
215085848|NCT04423601|DRUG|Itraconazole capsule|200 mg itraconazole was administered in the morning.
215085849|NCT04900610|DIETARY_SUPPLEMENT|MenaQ7 ®, Nattopharma, ASA, Hovik, Norway|daily per os supplementation of 1mg MK-7
215085850|NCT02191839|DRUG|Alpha 1-Antitrypsin|
215085851|NCT03508323|DRUG|Teneligliptin|20mg/qd
215085852|NCT03508323|DRUG|Placebo|1T/qd
215085853|NCT04313322|BIOLOGICAL|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
215085854|NCT01643876|BEHAVIORAL|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
215085855|NCT04603222|DEVICE|SUMMIT BRUSH|SUMMIT BRUSH used for the treatment of blepharitis
215085856|NCT04603222|OTHER|Ocusoft Lid Scrub Original Foaming Eyelid Cleanser|treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
214679851|NCT01104259|DRUG|vinorelbine tartrate|Given IV
214679852|NCT01104259|OTHER|laboratory biomarker analysis|Correlative studies
214679853|NCT01104259|OTHER|pharmacological study|Correlative studies
215085857|NCT03368014|BEHAVIORAL|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
214977977|NCT02040714|PROCEDURE|Multiple Epiphyseal Drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
214977978|NCT00003837|DRUG|nelarabine|
214977979|NCT00826839|DRUG|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
214977980|NCT00826839|DRUG|E2 patch/antagonist|"Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses."
214977981|NCT01868659|BEHAVIORAL|Diagnostic checklist|Diagnostic checklist used before patient discharged
214977982|NCT01868659|BEHAVIORAL|Usual care with no diagnostic checklist|Patient receives usual care with no research intervention
214977983|NCT00869869|DRUG|melatonin|2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
215085858|NCT05932121|PROCEDURE|Thyroid lobectomy via trans-axillary approach|Patient with PTC underwent thyroid lobectomy via trans-axillary approach
215085859|NCT05932121|PROCEDURE|Thyroid lobectomy via open approach|Patient with PTC underwent thyroid lobectomy via open approach
215085860|NCT06213337|OTHER|Foot care training with virtual classroom|Providing foot care training once every two weeks in virtual classes created via the Google meet application.
215085861|NCT06213337|OTHER|Foot care training with SMS support|Total of 60 SMS messages containing foot care information will be sent, one every day.
215085862|NCT06213337|OTHER|Foot care training with virtual classroom and SMS support|Providing foot care training once every two weeks in virtual classes created via the Google meet application. Furthermore, total of 60 SMS messages containing foot care information will be sent, one every day.
215085863|NCT01051206|DRUG|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
215085864|NCT04410744|DIAGNOSTIC_TEST|Ultrasonographic examination|All clinical examinations (physical exam) and ultrasounds are performed by a single surgeon and a single radiology resident supervised by the same abdominal radiology consultant, respectively.
215085865|NCT02525913|DEVICE|RFA Applicator|
215085866|NCT05911438|DRUG|Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)|Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
215085867|NCT05911438|OTHER|Basic Treatment|Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
215085868|NCT01656369|PROCEDURE|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
214491847|NCT06700980|OTHER|Focus Group|Dutch-speaking patients, Dutch- and/or French-speaking general practitioners and Dutch- and/or French-speaking representatives from pertinent organizational and policy sectors will be questioned in heterogeneous focus groups, identifying barriers and facilitators to the use of technological translation tools in Brussels out-of-hours primary care services for Dutch-speaking patients and French-speaking general practitioners.
215085869|NCT01656369|PROCEDURE|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
214977984|NCT00869869|DRUG|placebo|placebo
214977985|NCT03303495|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
214977986|NCT03303495|DRUG|CPT-11|180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
214977987|NCT03303495|DRUG|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
214977988|NCT03303495|DRUG|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
214977989|NCT03303495|DRUG|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
214977990|NCT02948647|OTHER|Standard of care plus sugar-reduction education|This is a 12-week intervention where subjects will be educated on how to monitor their added sugar consumption. They will be asked to eliminate consumption of sweetened beverages for the 12-week period and will be receiving a weekly delivery of water bottles to their homes to displace the sweetened beverages in their home environment.
214977991|NCT04851132|RADIATION|Radiotherapy|IMRT (Intensity Modulated RT) or 3D-CRT (three-dimensional conformal radiotherapy); 95% PGTV 59.92Gy/2.14Gy/28f; 95% GTVnd 59.92Gy/2.14Gy/28f; 95% PTV 50.40Gy/1.80Gy/28f; 5 days a week; 6 weeks.
214977992|NCT04851132|DRUG|Durvalumab|Durvalumab 1000 mg, intravenously (IV), on Day 1 of radiotherapy, every 3 weeks for up to 18 administrations.
214366919|NCT05725928|BEHAVIORAL|Mobility technician|Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.
214366920|NCT06688578|DEVICE|Subperceptual Stimulus|For each test participants will be stimulated using a subperceptual electric signal that is optimized to improve their gait.
214491848|NCT06878976|DRUG|Solriamfetol 75mg, 150 mg, or 300 mg|Taken once daily.
214491849|NCT06095960|BEHAVIORAL|Telehealth MOM|Patients will receive enhanced standard of care plus remote blood pressure monitoring, remote thermometer, and a 10- to 14-day post-partum telehealth visit.
214977993|NCT03918811|PROCEDURE|Positive Pressure Extubation Technique|Positive-pressure extubation is performed by only one operator. Ventilator parameters are set to pressure support ventilation mode, with an inspiratory pressure of 15 cm H2O and PEEP of 10 cm H2O. Then, the cuff is deflated, and the ETT is removed without endotracheal suction. Once the ETT is removed, a suction catheter is introduced through the mouth to suction secretions drawn to the oropharynx by the air flow from the ventilator passing between the ETT and the larynx.
214977994|NCT03918811|PROCEDURE|Traditional Extubation Technique|Traditional extubation is performed by 2 operators. Without reconnection to the ventilator, the closed suction system catheter is introduced by one of the operators into the ETT and suctioning is initiated. The cuff is immediately deflated by the other operator, and the ETT is removed with continuous endotracheal suction during the whole procedure by the first operator.
214977995|NCT05733663|DIAGNOSTIC_TEST|Endoscopic procedure with duodenal biopsy|"* In all patients the investigators will analyse coeliac serology, DQ-genotype, and results of two duodenal biopsy sampling (one at diagnosis before starting the GFD and another sampling during follow-up with GFD) for assessment of both histopathology and intraepithelial lymphocyte subpopulations by T-cell flow cytometry. In addition, clinical, serological, and histological response to GFD will be evaluated.~* T-cell flow cytometry assay is performed as previously described by our group in previous studies. In all patients, an additional duodenal biopsy sample is taken from the second-third portion of the duodenum at the same endoscopic procedure that for histopathology. The normal cut-off values for the IEL cytometric pattern in our laboratory are CD3+TCRγδ+ IEL ≤8.5% (≤mean + 2SD) and CD3- IEL ≥10% (10th percentile). The cut-offs define four intraepithelial lymphogram patterns: normal, isolated decrease in CD3- cells, isolated increase in TCRγδ+ cells, and the coeliac lymphogram."
214977996|NCT03585270|DRUG|Clazosentan|Clazosentan will be administered as a continuous intravenous infusion at the dose of 15 mg/hour for up to 14 days.
214977997|NCT03585270|DRUG|Placebo|Placebo will be administered at the same infusion rate as clazosentan for up to 14 days.
214977998|NCT05654571|DIAGNOSTIC_TEST|mammography|All patients are checked for mammography every year after surgery.
214977999|NCT02117258|DRUG|Z-360|Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
214978000|NCT02117258|DRUG|Placebo|Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
214978001|NCT00603031|OTHER|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
214978002|NCT00603031|OTHER|NaCl|infusion with NaCl for 120 minutes as placebo-arm
214978003|NCT00603031|OTHER|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
214978004|NCT03292016|DRUG|APL-130277|APL-130277 sublingual thin film
214978005|NCT03292016|DRUG|APO-go|Subcutaneous APO-go
214978006|NCT03292016|DRUG|Apokyn|Subcutaneous APOKYN
214978007|NCT01042626|OTHER|Oral peptones load|Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
214978008|NCT04735042|DRUG|Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill|association between SGLT2-inhibitor and DPP4-inhibitor
214978009|NCT04735042|DRUG|Empagliflozin or Dapagliflozin Pill|SGLT2-inhibitor: diabetic oral drug with diuretic properties.
214366921|NCT06688578|DEVICE|Sham Comparator|During intervention trial, sham comparator will consist of same stimulation device but no actual electrical stimulation will be provided by device during intervention trial.
214366922|NCT07016815|DEVICE|Wearable wrist heart rate and activity monitor|A commercially available smart watch capable of continuous monitoring of heart rate and activities including daily steps count and daily activity level, detection of arrythmia using a proprietary FDA approved algorithm14, and measuring peripheral capillary oxygen saturation will be provided to the patient. Patients will be encouraged to wear the watch as often as possible during daytime and during sleep. Data gathered will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patient.
214366923|NCT07016815|DEVICE|Bluetooth enabled body weight scale with bioimpedance analysis|An electronic scale which measures bioimpedance using bioelectrical analysis from foot-to-foot impedance and body fluid percentage (BF%) using a proprietary equation15,16 will be provided to the patients. Patient will be encouraged to measure their bodyweight (BW) and bioimpedance twice per day, one in the morning, and one before bath, with minimal clothing. Both data will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patients.
214366924|NCT07016815|DEVICE|Bluetooth enabled electronic blood pressure device|An electronic cuffed arm blood pressure monitor will be provided to the patient with instruction on how to perform proper blood pressure measurement at home16. Patients are encouraged to take at least 2 blood pressure reading daily, one in the morning and one in the evening. Blood pressure reading will be transmitted wirelessly to an online platform provided by the manufacturer accessible only by the research team and the patients.
214366925|NCT07016815|DEVICE|mobile application|a mobile Application through which data from remote monitoring and wearables will be incorporated, and instruction for medication titration and education on heart failure management will be provided to the patients.
214491850|NCT06095960|OTHER|Enhanced Standard of Care|Patients will receive enhanced standard of care which includes: education on symptoms and when to call their healthcare provider, comprehensive 6-week post-partum visit, and any healthcare deemed necessary by providers.
214978010|NCT05630872|DRUG|Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC|Dolutegravir (DTG) 50 mg orally BID (\~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.
214978011|NCT05630872|DRUG|DTG 50 mg orally QD plus TDF/3TC|DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).
215085870|NCT00159575|DRUG|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
215085871|NCT00885768|PROCEDURE|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
215085872|NCT02068118|DEVICE|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
215085873|NCT03233295|DRUG|Vitamin D3 B.O.N. Injection|cholecalciferol 200,000IU
215085874|NCT03990805|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection
215085875|NCT03990805|DRUG|saline|saline, 1 time injection
214978012|NCT05630872|DRUG|2HPZM|Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen
214978013|NCT05630872|DRUG|2HPM|Daily rifapentine-moxifloxacin plus isoniazid regimen
214978014|NCT04623710|DRUG|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
215085876|NCT00102713|DRUG|Divalproex Sodium (Depakote Sprinkle Capsules)|
215085877|NCT03844113|DRUG|Carnosine|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
215085878|NCT03844113|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
215085879|NCT02801890|BIOLOGICAL|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
215085880|NCT00650520|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
215085881|NCT00650520|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
215085882|NCT02267954|OTHER|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
215085883|NCT04798040|OTHER|cold application|To reduce pain, cold application is applied around the drain before the drain is removed.
215085884|NCT04798040|OTHER|lavender oil inhalation|To reduce pain, lavender oil is inhaled prior to drain removal.
215085885|NCT04798040|OTHER|oxygen administration|To reduce pain, oxygen is inhaled prior to drain removal.
215085886|NCT01169584|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
215085887|NCT00542737|BEHAVIORAL|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
215085888|NCT04831528|DRUG|Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others|After PD, patients received ctDNA testing, and different research protocols were selected according to different gene states of ctDNA, as follows: 1.No secondary changes related to drug resistance were found. Cetuximab cross-line + second-line chemotherapy (FOLFOX/FOLFIRI/ Irinotecan monotherapy, etc.) was used.2. If there is a RAS secondary mutation, change of beacizumab bead sheet resistance + second-line chemotherapy (FOLFOX/XELOX/stand for kang single-agent FOLFIRI mXEIRI/Iraq, etc.);3. If BRAF secondary mutation occurs, replace it with vimofenib + cetuximab + irinotecan;4. If HER2 amplification occurs, replace it with trastuzumab + lapatinib or trastuzumab + pertuzumab;5. In case of other secondary mutations, bevacizumab plus second-line chemotherapy should be replaced.
215085889|NCT04373447|PROCEDURE|lap fundus-calot cholecystectomy|use laparoscopic fundus-calot approach
214491851|NCT06750120|DIETARY_SUPPLEMENT|Family food ration|Monthly household food rations providing 5 daily food groups and a mean of 165 kcal/per capita/day
214491852|NCT06750120|BEHAVIORAL|Optimal weight counseling|Counseling on health gestational weight gain and post partum weight loss
214978015|NCT03195439|DEVICE|TTP|TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
214978016|NCT02506387|DEVICE|mitraclip|The decision to implant mitraclip is not part of this observational study but is made by the heart-team.
215085890|NCT04373447|PROCEDURE|open cholecystectomy|use open approach
215085891|NCT01515475|PROCEDURE|Glasses|Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
214366926|NCT00099892|DRUG|vildagliptin|
214366927|NCT05047185|DRUG|Deucrictibant low dose|Deucrictibant softgel capsules for oral use (PHVS416)
214491853|NCT06750120|OTHER|Enhanced Usual Care|"Enhanced usual care includes~1. Usual care: free standard pregnancy, postnatal, and infant care through Ministry of Health services.~2. Enhancements to usual care: Participants in both arms will be enrolled in Maya Health Alliance's free care navigation program. In this program, navigators accompany patients to clinical visits at national hospitals, provide interpretation, and cover emergency transportation cost."
214491854|NCT06740591|DEVICE|HD-tDCS|The HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
214978017|NCT05339958|DIETARY_SUPPLEMENT|Nutrafol® Men Hair Growth Nutraceutical|Nutrafol® Men contains patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin).
214978018|NCT05339958|OTHER|Placebo Supplement|The placebo capsules contain no active ingredients.
214978019|NCT04690465|BEHAVIORAL|Resistance training|"Participants will receive a 16-week resistance training program, with 3 times a week (a total of 48 training sessions) and 60 minutes per session intervention, which is adopted from the 12-week resistance training program introduced in the book Growing Stronger: Strength Training for Older Adults (Seguin et al., 2002), with minor modifications under the advice of Physical Fitness Association of Hong Kong, China (PFA)."
214978020|NCT04690465|BEHAVIORAL|Eight-form Yang-style Tai Chi program|The active concurrent control group will receive Eight-form Yang-style Tai Chi program which has been confirmed feasible and will be taught by the qualified coach.
214978021|NCT02115984|DRUG|Panagen|
214978022|NCT02115984|DRUG|Placebo|
214978023|NCT02115984|PROCEDURE|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
214978024|NCT04771910|OTHER|Topical cream with live probiotic bacteria|Application of the probiotic cream once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as placebo cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
214978025|NCT04771910|OTHER|Placebo cream|Application of the placebo cream (same formulation as probiotic cream except live probiotic bacteria) once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as probiotic cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
215085892|NCT01852279|DEVICE|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
214366928|NCT05047185|DRUG|Deucrictibant high dose|Deucrictibant softgel capsules for oral use (PHVS416)
214978026|NCT01464268|DRUG|Riboflavin|Administration of riboflavin every 2 minutes for the duration of UV exposure.
214978027|NCT01464268|DRUG|Riboflavin|Administration of riboflavin every 1 minute for the duration of UV exposure.
215085893|NCT01852279|DEVICE|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
215085894|NCT04407065|DRUG|Double trigger|Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
214366929|NCT05047185|DRUG|Placebo|Matching placebo capsules for oral use
214366930|NCT06627933|OTHER|No intervention|No intervention
214366931|NCT06627270|DRUG|Metronidazole|Participants will receive metronidazole (500 mg t.i.d. x 10 days)
214366932|NCT06627270|OTHER|Chlorhexidine|Mouth rinse chlorhexidine (10 ml t.i.d. x 10 days)
214491855|NCT06740591|DEVICE|Sham High-Definition Transcranial Direct Current Stimulation(sham HD-tDCS)|The Sham HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
214491856|NCT06618976|DRUG|Sotagliflozin|Sotagliflozin 400 mg, P.O. once daily for 1 month.
214978028|NCT02414698|PROCEDURE|Percutaneous Hydrodiscectomy|The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
214978029|NCT02414698|DRUG|TESI|Transforaminal epidural steroid injections given in the lumbar spine.
214978030|NCT00225745|PROCEDURE|Blood draw|One blood draw prior to first treatment
214978031|NCT06326736|PROCEDURE|Surgery|Tumors of patients with pancreatic cancer must be radiographically resectable, and subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation.
214978032|NCT06326736|DRUG|Camrelizumab|Camrelizumab will be administered 6 weeks post-tumor resection.
214978033|NCT06326736|BIOLOGICAL|SJ-Neo006|SJ-Neo006 will be prepared as personalized tumor Vaccines and administered 9 weeks post-tumor resection (+/- 2 weeks).
214978034|NCT06326736|DRUG|Gemcitabine+Abraxane|Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.
215085895|NCT04407065|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
215085896|NCT02496169|DEVICE|eucaLimus|Percutaneous Coronary Intervention (PCI)
215085897|NCT02501564|DRUG|Naproxen Sodium Codeine|One tablet twice a day
215085898|NCT02501564|DRUG|Placebo|One tablet twice a day
214366933|NCT01750138|DRUG|Glutamine|
214366934|NCT01750138|DRUG|Dextrose powder|
214366935|NCT07022886|PROCEDURE|achalasia treatments|esophageal achalasia treatments
214366936|NCT05631730|DRUG|Flecainide|Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
214491857|NCT06618976|DRUG|Empagliflozin|Empagliflozin 10 mg, P.O. once daily for 1 month.
214491858|NCT06755567|DIAGNOSTIC_TEST|MRI-based radiomics-clinical model|Response to NACI was predicted using MRI-based radiomics-clinical model.
215085899|NCT01420627|BIOLOGICAL|EZN-2279|Weekly administration of EZN-2279 via IM injection
215085900|NCT01420627|BIOLOGICAL|Adagen|
214491859|NCT06742476|DEVICE|nasal cannula|In the apneic oxygenation group, nasal cannula will be employed to administer continuous oxygenation, utilizing a flow rate of 0.2 L/kg, during the apneic phase while tracheal intubation is performed. Successful intubation will be confirmed by auscultation and the appearance of a square wave capnogragh.
214491860|NCT06894667|DRUG|Antioxidant gel|An intraoral gel containing Tea Tree oil (Tebodont®, Dr. Wild \& Co. AG, Basel) would be applied to the gingival pockets after scaling and root planing
214491861|NCT06894667|DRUG|Antimicrobial gel|An intraoral gel containing 0.5% Chlorhexidine (PERIOPLUS+ FORTE, Curaprox, Curaden) would be applied to the gingival pockets after scaling and root planing
214491862|NCT06284941|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound guided iliac fascia block, administered with 30ml of 0.25% ropivacaine+0.05% methylene blue
214491863|NCT06847581|DEVICE|JAME|JAME is a wearable device able to monitor movements of the upper limbs and, through an ad-hoc algorithm based on machine learning, can recognize tremor and suppress it through TENS
214491864|NCT06766513|OTHER|Actimetry|actimetry will be performed continuously during these 104 hours.
214978035|NCT02133157|DRUG|Sulfatinib|Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
214978036|NCT01804088|DEVICE|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
214978037|NCT03160040|DRUG|Minocycline IV|This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
214978038|NCT01038687|DRUG|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
214978039|NCT01038687|DRUG|placebo|placebo
214978040|NCT06065644|DEVICE|CTMA|Induced displacement of the Sacroiliac joint
214978041|NCT05030649|DEVICE|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
214978042|NCT05030649|DEVICE|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
214978043|NCT00000694|DRUG|Interferon alfa-2b|
214978044|NCT00000694|DRUG|Zidovudine|
214978045|NCT00000694|DRUG|Sargramostim|
214978046|NCT05057221|DRUG|Uproleselan|Uproleselan 20 mg/kg BID up to maximum dose of 2500 mg, infused IV over 20 minutes on days 1-7 or until hospital discharge. It should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.
215085901|NCT00837876|DRUG|Sorafenib|400 mg taken by mouth 1 time per day.
215085902|NCT00837876|DRUG|Erlotinb|150 mg taken by mouth 1 time per day.
214491865|NCT06766513|OTHER|Subjective assessments|The subjective assessments of the patient's awake/sleep state will be collected every 2 hours during the night and at least 3 times during the day, for a total of at least 8 assessments per 24-hour period, over a duration of 104 consecutive hours (slightly more than 4 days, starting at midnight and ending at 8 :00 AM, to cover 4 full days and 4 full nights).
214491866|NCT06766513|OTHER|questionnaire|MOCA : Montreal Cognitive Assessment
214491867|NCT06766513|OTHER|questionnaire|SF-36 The Short Form (36)
214491868|NCT06766513|OTHER|questionnaire|CRS-R (Coma Recovery Scale-Revised)
214978047|NCT04849793|OTHER|Acupressure|Before starting the application, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. . The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes
214978048|NCT02567383|RADIATION|Radiation|5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
214978049|NCT02567383|DEVICE|Hyperthermia; Thermotron RF-8|40 minutes within 2hr after irradiation
214978050|NCT02567383|DRUG|Cisplatin|20mg/m2 per week for 6 weekly cycles before radiotherapy
214978051|NCT02567383|DRUG|Taxotere|10-12mg/m2 per week for 6 weekly cycles before radiotherapy
214978052|NCT06373341|BEHAVIORAL|VR training for arm and hand rehabilitation|The intervention group will participate in training with a VR-exergame for 4 weeks after inclusion. For this training a Meta Quest VR-headset with a game specifically designed for and with ICU patients that was previously pilot tested for feasibility and safety will be used under supervision of a researcher or caregiver until the patient feels ready to practice alone.
214978053|NCT00001781|DRUG|CGP 77116|
214978054|NCT01076543|OTHER|Laboratory Biomarker Analysis|Correlative studies
215085903|NCT02716701|BEHAVIORAL|Exercise Group|
215085904|NCT02716701|OTHER|Control Group|
215085905|NCT02716701|OTHER|wristband activity tracker|
215085906|NCT00391001|DRUG|Taurine|double-blind, placebo-controlled, adjunctive medication
215085907|NCT05543018|DIAGNOSTIC_TEST|Electroretinogram|Retinal function assessment using electroretinogram
214491869|NCT06766513|OTHER|questionnaire|GOSE (Glasgow Outcome Scale-Extended)
214491870|NCT06766513|OTHER|questionnaire|GCS (Glasgow Coma Scale)
214491871|NCT05841927|DIETARY_SUPPLEMENT|Docosahexaenoic acid supplement|Docosahexaenoic acid supplement
214978055|NCT01076543|DRUG|Lenalidomide|Given PO
215085908|NCT05543018|PROCEDURE|Vitrectomy operation|Vitrectomy operation to treat retinal detachment
215085909|NCT03480789|DRUG|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
215085910|NCT03480789|DEVICE|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
215085911|NCT03422692|BIOLOGICAL|BioXclude amnion-chorion membrane|BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure
215085912|NCT03422692|BIOLOGICAL|Mem-Lok collagenous membrane|Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
215085913|NCT01690351|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
215085914|NCT01690351|DRUG|PF-05089771|Capsules TS formulation- fasted
214978056|NCT01076543|DRUG|Temsirolimus|Given IV
214978057|NCT04072029|PROCEDURE|Phacoemulsification with intraocular lens implantation|Phacoemulsification (2.2mm coaxial, viscoelastic shield, experienced surgeon) with intraocular lens implantation (acrylic hidrophobic)
214978058|NCT02016989|DEVICE|RGTA OTR4120 (CACICOL20)|
214978059|NCT02016989|DEVICE|physiological salt solution|
214978060|NCT05434455|DEVICE|RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion|RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
214978061|NCT03368313|DEVICE|Circaid|Circaid is a velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
214978062|NCT04144192|DRUG|Lidocaine patch 1.8%|
214978063|NCT04144192|DRUG|Lidocaine 5% patch|
214978064|NCT04144192|DRUG|Lidocaine 2% Injectable Solution|
215085915|NCT02552251|BIOLOGICAL|Hormonal balance measurements|
215085916|NCT02552251|BIOLOGICAL|metabolic balance measurements|
215085917|NCT02552251|BIOLOGICAL|bone balance measurements|
215085918|NCT02552251|BEHAVIORAL|quality of life assessment|
214366937|NCT05631730|DRUG|Metoprolol|Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
214366938|NCT05248100|BEHAVIORAL|Conditional Cash Transfer|The intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (\~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
214366939|NCT01165775|DEVICE|Dexcom Seven Plus Continuous Glucose Monitoring System|Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
214366940|NCT07030595|DRUG|AP301|Three times a day, administered orally with three meals at a daily dose level from 2.1g to 9.1g
214978065|NCT01905618|BEHAVIORAL|Web-based curriculum on tobacco dependence treatment|"The University of Massachusetts Medical School's web-based course, Basic Skills for Working with Smokers was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play."
214978066|NCT01905618|BEHAVIORAL|Tobacco Counseling Role Play|The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
214978067|NCT01905618|BEHAVIORAL|Preceptor Training and Teaching Medical Students|The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
215085919|NCT01393938|OTHER|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
215085920|NCT05585515|BEHAVIORAL|Sleep deprivation|Total sleep deficit of consecutive 8 hours
214366941|NCT07030595|DRUG|Sevelamer carbonate (Renvela®)|Three times a day, administered orally with three meals at a daily dose level from 2.4g to 9.6g
214491872|NCT05841927|DIETARY_SUPPLEMENT|ASD placebo|ASD placebo
215085921|NCT05585515|BEHAVIORAL|Sleep restriction|Total sleep deficit of cumulative 8 hours
215085922|NCT03819452|DIAGNOSTIC_TEST|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
215085923|NCT02020772|OTHER|coordinating primary health care|
215085924|NCT02020772|OTHER|usual primary health care|
215085925|NCT06000306|DIAGNOSTIC_TEST|Digital Droplet PCR|Measurable residual disease Monitoring by Digital Droplet PCR in the Early Posttransplant Period
215085926|NCT00788580|DRUG|pazopanib hydrochloride|
215085927|NCT00788580|DRUG|temsirolimus|
215085928|NCT00788580|PROCEDURE|immunoenzyme technique|
215085929|NCT00788580|PROCEDURE|laboratory biomarker analysis|
215085930|NCT00788580|PROCEDURE|pharmacological study|
215085931|NCT00170196|DRUG|prednisone|
215085932|NCT01747252|DIETARY_SUPPLEMENT|RGC|
215085933|NCT01747252|DIETARY_SUPPLEMENT|RGC|
215085934|NCT01747252|DIETARY_SUPPLEMENT|Resveratrol|The equivalent of 150 mg resveratrol
215085935|NCT00130923|DRUG|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
215085936|NCT00130923|DRUG|oral risperidone|0.50-6.00 mg oral risperidone daily
215085937|NCT02488291|DRUG|0.25 sufentanil|with different dosage
215085938|NCT02488291|DRUG|0.5µg/ml sufentanil|0.5µg/ml sufentanil
215085939|NCT02488291|DRUG|0.1% ropivacaine|0.1% ropivacaine
215085940|NCT00480259|BEHAVIORAL|hyperproteic nutrition|
214366942|NCT07030595|DRUG|AP301 Low Dose|Three times a day, administered orally with three meals at a daily dose level of 0.375g.
214978068|NCT01905618|BEHAVIORAL|Booster Session|The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
214491873|NCT06347601|OTHER|Without Intervention|Without Intervention
214491874|NCT06829927|BEHAVIORAL|e-book|Patients with pilot application will not be included in the study. Patients who agree to participate in the study will be informed by the researcher about the purpose and process of the study, and their written and verbal informed consent will be obtained. Patients will be informed that the decision on whether or not to participate in the study is entirely their own, that no money will be deducted from their health insurance or any money will be paid to them, that the data to be collected from this study will only be used within the scope of the research, and that confidentiality will be strictly ensured. Pretests (Personal Information Form, Urinary Catheter Self-Efficacy Scale and Comfort Scale) will be administered to the patients whose consent is obtained.
214366943|NCT07031518|DEVICE|Syde|Actimyo/Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
214366944|NCT07031518|DIAGNOSTIC_TEST|The Self-Paced 40-meter Walk Test (SPWT)|Assesses walking speed over a fixed distance by having participants walk as quickly and safely as possible, but without running, along a 40-meter course.
214366945|NCT07031518|DIAGNOSTIC_TEST|30-second chair stand test (30s-CST)|It is a simple assessment of lower body strength and endurance. Participants are instructed to stand up and sit down from a chair as many times as possible in 30 seconds.
214366946|NCT07031518|DIAGNOSTIC_TEST|The Timed up and go test (TUG)|During this standardized test, the subject is observed and timed while he/she rises from a chair, walks 3 meters, performs a 180° turn, walk back toward the chair and sits down.
214978069|NCT02199769|OTHER|Clinical Decision Support|Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
214978070|NCT03502538|DEVICE|Curaprox 5460 Ultra Soft|The toothbrush Curaprox 5460 Ultra Soft will be the tested toothbrush model, in order to asses its efficacy in plaque removal. Therefore, the study participants should brush their teeth using this toothbrush model, following the instructions of the investigator. From the data collect related in plaque removal the results will be arrived at.
214978071|NCT03502538|DEVICE|Oral-B Indicator Plus|Following the same method of the Curaprox group intervention, the participants should brush their teeth using the Oral-B Indicator Plus toothbrush and based on the data collect, the results will be compared with the first group of intervention.
214366947|NCT07031518|DIAGNOSTIC_TEST|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC 3.1)|The WOMAC is a widely used self-administered health status measure for evaluating pain, stiffness, and function in patients with osteoarthritis of the hip or knee. The WOMAC measures three separate dimensions: pain (5 questions), stiffness (2 questions) and function (17 questions).
214366948|NCT07031518|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S)|"The PGI-S is a patient-reported measure that evaluates the perceived severity of a condition based on a standardized scale, ranging from none to very severe."
214491875|NCT06827899|DRUG|veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)|Specified dose on specified days
214491876|NCT06649864|DRUG|Autologous adipose derived mesenchymal stromal cells (AMSC)|Adipose derived autologous mesenchymal stromal cells; \[\~500,000 cells/cm2\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution.
214491877|NCT05917522|BIOLOGICAL|Abatacept|Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector
214491878|NCT05917522|PROCEDURE|Standard of Care at US Transplant Centers|Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))
214978072|NCT01393145|DRUG|Combination Fluticasone /Formoterol 12/250 μg|Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
214978073|NCT01393145|DRUG|Seretide Diskus (salmeterol/fluticasone) 50/250 μg|Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
214978074|NCT04880434|DRUG|Fludarabine|Administered intravenously
214978075|NCT04880434|DRUG|Cyclophosphamide|Administered intravenously
214978076|NCT04880434|BIOLOGICAL|Brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
214978077|NCT00667641|DRUG|bortezomib|Starting dose level 0.70mg/m2
214978078|NCT00667641|DRUG|paclitaxel|Starting dose level 40mg/m2
214978079|NCT03601169|DIETARY_SUPPLEMENT|Low Dose MMFS-205-SR|Twice daily, oral 500mg tablets
214978080|NCT03601169|DIETARY_SUPPLEMENT|High Dose MMFS-205-SR|Twice daily, oral 500mg tablets
214978081|NCT03601169|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
214978082|NCT05944835|OTHER|Analyzed on the post-operative scanner|Analyzed on the post-operative scanner
214978083|NCT05222880|DEVICE|JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3|TEST Lens
214978084|NCT05245383|OTHER|ten products (S01~S10) and two blank (BK1, BK2)|"S01 Functional Peptides Recovering Essence EX S02 Advanced Revitalizing Eye Cream S03 Advanced Revitalizing Lotion S04 NB-1 Anti-Sensitive Repair Activator S05 NB-1 Anti-Sensitive Repair Toning Extract S06 Ginseng Vitality Serum S07 Ginseng Revitalizing Age-defense Essence Cream S08 Ginseng Age-defense Eye Cream S09 Revital Energy Balance Gel S10 Revital Energy Tightening Body Lotion BK1 Water BK2 Blank ten products and two blank, 24 hours single application patch test on the back."
214978085|NCT03727490|OTHER|Repair|The subscapularis will be repaired.
214978086|NCT03727490|OTHER|Standard Treatment|No repair will be performed
214978087|NCT05518123|DRUG|Rimegepant|Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase
215085941|NCT02922166|DRUG|SRX246|oral capsule
215085942|NCT02922166|DRUG|Placebo|oral capsule
215085943|NCT00005632|BIOLOGICAL|MUC1-KLH vaccine/QS21|
215085944|NCT04373499|BEHAVIORAL|Virtual Teach to Goal|Virtual Teach-to-Goal is an educational module that teaches children how to use their inhaler properly; this is done with an IPAD. In the module, the child will complete a series of questions as a pre-assessment, watch a video about how to use the inhaler properly, and then answer a series of questions as a post-assessment. If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions.
215085945|NCT04373499|BEHAVIORAL|Brief Intervention|There is a handout that describes proper inhaler technique. The RA reads the handout to the child.
215085946|NCT02075632|DRUG|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
215085947|NCT00599456|DIETARY_SUPPLEMENT|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
215085948|NCT00599456|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
215085949|NCT03924999|COMBINATION_PRODUCT|Combined decongestive treatment (CDT) & Combined exercise|Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 30 sessions.
215085950|NCT03924999|COMBINATION_PRODUCT|Intermittent pneumatic compression & Combined exercise|Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
215085951|NCT03924999|COMBINATION_PRODUCT|Combined exercise|30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
215085952|NCT05025722|OTHER|Non Interventional|This is an observational study.
214366949|NCT07031518|OTHER|Pain Level Diary|Patients will record their specific OAK average pain level during the day using the VAS scale of 0-10 points for one week at the beginning of each month of recording.
214366950|NCT07031518|OTHER|Qualitative Interview|This interview is designed to better understand the patient's perspective on the impact of osteoarthritis of the knee on their motor function and to inform the selection of digital tools in upcoming clinical studies.
215085953|NCT02251132|DRUG|TPV low 1|
215085954|NCT02251132|DRUG|TPV low 2|
215085955|NCT02251132|DRUG|TPV medium|
215085956|NCT02251132|DRUG|TPV high 1|
214978088|NCT05518123|DRUG|Placebo|Matching placebo with every other day dosing during DBT phase
214978089|NCT04256980|DRUG|Pemigatinib|Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule
214978090|NCT05802017|OTHER|Allergen-specific substitute diet|Substitution of IgG4 allergen-specific reactive foodstuffs for equivalent foodstuffs with similar nutritional value.
215085957|NCT02251132|DRUG|TPV high 2|
215085958|NCT02251132|DRUG|RTV low|
215085959|NCT02251132|DRUG|Ritonavir high|
215085960|NCT02251132|DRUG|Radiolabelled erythromycin|
214366951|NCT06877026|DEVICE|FibroScan|Day 1 = 5 FibroScan examinations Day 2 = 4 FibroScan examinations
214366952|NCT06877026|OTHER|Liver Enzymes|Day = 1 blood collection for liver enzymes. Day 2= 1 blood collection for liver enzymes.
214978091|NCT03994913|BIOLOGICAL|CAR-CD19 T Cells|"The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion."
214978092|NCT05650203|DRUG|JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006|"1. JS009 as Monotherapy in first cycle of dose escalation and as the triple combination therapy will be administered in subsequent cycles：JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).~2. Triple combination therapy in dose expansion：JS009, 1 or 2 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).~3. Triple combination therapy in indication expansion：JS009, 1 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w)."
215085961|NCT04907435|PROCEDURE|simultaneous operations|simultaneous operations
214366953|NCT03779906|DRUG|Isovue|Isovue will be given to all subjects per the standard of clinical care.
214366954|NCT04909970|OTHER|Self-hypnosis|Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
214366955|NCT04909970|OTHER|Control (Waiting list)|Usual practice during the first 16 weeks. At the end of study, the participant will practice Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
215085962|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
215085963|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
215085964|NCT00764907|DRUG|asparaginase|Given IV during reinduction
215085965|NCT00764907|DRUG|cyclophosphamide|Given IV during reinduction
215085966|NCT00764907|DRUG|cytarabine|Given IV during reinduction
215085967|NCT00764907|DRUG|daunorubicin hydrochloride|Given IV during reinduction
215085968|NCT00764907|DRUG|dexamethasone|Given IV or orally during reinduction
215085969|NCT00764907|DRUG|doxorubicin hydrochloride|Given IV during reinduction
215085970|NCT00764907|DRUG|etoposide|Given IV during reinduction
215085971|NCT00764907|DRUG|ifosfamide|Given IV during reinduction
215085972|NCT00764907|DRUG|leucovorin calcium|Given IV during reinduction
215085973|NCT00764907|DRUG|mercaptopurine|Given orally during reinduction
215085974|NCT00764907|DRUG|methotrexate|Given orally during reinduction
215085975|NCT00764907|DRUG|prednisone|Given intrathecally during reinduction
215085976|NCT00764907|DRUG|thioguanine|Given orally during reinduction
215085977|NCT00764907|DRUG|vincristine sulfate|Given IV during reinduction
215085978|NCT00764907|DRUG|vindesine|Given IV during reinduction
215085979|NCT03022500|DRUG|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
215085980|NCT02067325|OTHER|Thai massage|
214366956|NCT06717191|DRUG|biosimilar insulin glargine|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
214366957|NCT06269757|BEHAVIORAL|Individualized Exercise Program|"The individualized exercise program involves an initial 2D individual running evaluation designed for runners of all ages and abilities, to help improve performance and prevent injury. During the assessment patients receive a one-on-one evaluation with an exercise physiologist that includes:~* Running analysis;~* Training program review;~* Strength and flexibility assessment;~* Review of running video;~* Personalized final report."
214978093|NCT05867758|OTHER|Psychosocial group intervention|"The psychosocial group intervention is composed of 8 weekly sessions of 90 minutes each and the receiving of self-help digital materials. Both organized as following: 2 on isolation, loneliness and social connection, 2 on well-being, 2 on the use of digital tools, 2 on the fostering of socialization with peers.~To evaluate the effects of the blended intervention and of the two conditions we will ask participants to fulfill the following clinical questionnaires: ULS-6 (Russell et al. 1980), MSPSS (Zimet et al., 1988), GAD-7 (Spitzer et al., 2006), PHQ-9 (Kroenke, Spitzer \& Williams, 2001), SWLS (Diener et al., 1985), MLQ (Steger et al., 2006) before starting the intervention in presence and online (T0), at the end of that period (T1) and 2 months after (T2)."
214978094|NCT03113370|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil capsules
214978095|NCT03113370|DIETARY_SUPPLEMENT|Placebo|Olive Oil
214978096|NCT00003677|DRUG|Dolastatin 10|IV bolus once every 21 days.
214978097|NCT06508255|BEHAVIORAL|Early Time-Restricted Eating|Eat between 8:00 and 16:00 for 2 weeks
214978098|NCT06508255|BEHAVIORAL|Late Time-Restricted Eating|Eat between 13:00 and 21:00 for 2 weeks
214978099|NCT01563523|DRUG|activated recombinant human factor VII|Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
214978100|NCT01563523|DRUG|placebo|Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
214978101|NCT00068276|DIETARY_SUPPLEMENT|cholecalciferol|
214978102|NCT06284499|OTHER|measuring tooth stability after orthodontic treatment using a Periotest® device.|The tooth mobility was determined by taking three repeat measurements from each tooth and calculating the average of these measurements, using a Periotest® device.
214978103|NCT04754893|DEVICE|Healthdot application|Healthdot device is applied on subject's chest after surgery
214978104|NCT03667768|PROCEDURE|Glass ionomer sealant|
214978105|NCT03667768|BEHAVIORAL|Non-sealant (toothbrushing)|
214978106|NCT01996111|PROCEDURE|Injection of 1.0 cc of 0.9% Saline|Injection of 1.0 cc of 0.9% Saline into affected area
214978107|NCT01996111|PROCEDURE|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
214978108|NCT01996111|PROCEDURE|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area
214978109|NCT01996111|PROCEDURE|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
214978110|NCT04809441|OTHER|Diet change|A specific very low-calorie diet (\<800kcal/day), and 2 daily sessions of 15 minutes of anaerobic physical exercise depending on the capacity of the participants, were designed
214978111|NCT05430165|OTHER|Standard mHealth screening (triage) tool|"Standard mHealth triage tool administered to eligible trauma patients by phone at 2 weeks, 1 month, 3 months, and 6 months post-hospital discharge. The mHealth triage tool is a survey that includes a 7-item questionnaire to identify their need for follow-up care.~The need for follow-up care at any of the 4 follow-ups is defined as a flagged response to ≥1 question on the 7-item screening survey."
215085981|NCT02579681|DRUG|dimethyl fumarate|dimethyl fumarate administered as per the arm description
215085982|NCT04683458|DEVICE|Drug-coated device|The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
215085983|NCT03758690|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
215085984|NCT04738253|DIAGNOSTIC_TEST|Ultrasonography|The ultrasound measurement s of the axillary recess capsule thickness.
214679854|NCT03802838|DEVICE|acupuncture|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
214978112|NCT04511325|OTHER|Potato Regimen|100 grams cooked white russet potato with the skin
214978113|NCT04511325|OTHER|Refined Grain Regimen|75 grams of cooked long-grain white rice
214978114|NCT06352814|OTHER|Activities-based locomotor training (physical therapy)|AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
214978115|NCT03977012|DRUG|Buprenorphine|5\~20 mcg
214978116|NCT04586049|DEVICE|MRI|Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.
214978117|NCT04586049|DEVICE|Transcranial Doppler Ultrasound|Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.
214978118|NCT04586049|OTHER|Sympathetic Nerve Activity|Participants will undergo sympathetic nerve activity testing while participating in a breathing test.
214978119|NCT06367075|DRUG|Cadonilimab|injectable solution
214978120|NCT06367075|DRUG|Adriamycin|injectable solution
214978121|NCT06490055|DRUG|Paclitaxel|Gastric cancer second-line Chemotherapy (paclitaxel plus ramucirumab)
214978122|NCT04094311|BIOLOGICAL|CTL019|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
214978123|NCT04840472|DRUG|111I-n panitumumab|Imaging Agent
214978124|NCT04840472|PROCEDURE|Single photon emission computed tomography/computed tomography (SPECT/CT) scans|Day 1 to 5 (Day of Surgery inclusive)
214978125|NCT06683911|DRUG|non Opioids|It is planned to avoid opioid side effects by applying opioid-free anesthesia during the perioperative period.
214978126|NCT06683911|DRUG|Opioid|Routine general anesthesia in cardiac surgery
214978127|NCT03058354|DRUG|Propofol|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
214978128|NCT03058354|PROCEDURE|general anaesthesia|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
214978129|NCT04630028|DRUG|Ustekinumab Dose Based on BSA and Body Weight|As per BSA and body weight Ustekinumab will be administered SC and IV.
214978130|NCT04630028|DRUG|Matching Placebo|Placebo will be administered subcutaneously.
215085985|NCT03652519|BEHAVIORAL|Exercise Training|Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
215085986|NCT06347250|PROCEDURE|Nerve Block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214679855|NCT03802838|DRUG|Amisulpride|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
214978131|NCT05549180|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo|The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo
214978132|NCT05549180|DRUG|Dovato 50Mg-300Mg Tablet + Biktarvy placebo|The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo
214978133|NCT03988140|DEVICE|Dental Implant Placement and subsequent prosthetic reabilithation|Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
214978134|NCT02368132|BEHAVIORAL|Group Delivered TEP|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
215085987|NCT06347250|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
215085988|NCT06347250|BEHAVIORAL|routine therapy|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
215085989|NCT06347250|PROCEDURE|placebo block|the patients were provided with normal saline. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
215085990|NCT04159363|OTHER|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
215085991|NCT05918653|OTHER|Home Healthcare|No intervention in this study
215085992|NCT05102617|DEVICE|PicoSure Pro Device|This device will be used for up to 4 treatments over the designated areas.
215085993|NCT05102617|DEVICE|PicoSure Device|This device will be used for up to 4 treatments over the designated areas.
215085994|NCT05102617|DRUG|Topical Cosmeceuticals|Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.
215085995|NCT05028517|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
215085996|NCT05028517|OTHER|Coaching|A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
215085997|NCT02738476|PROCEDURE|Patellofemoral arthroplasty|
215085998|NCT05891028|DRUG|68Ga-EB-ss-CPT|68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
214978135|NCT02368132|BEHAVIORAL|Individual Delivered TEP|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
214978136|NCT02543047|DEVICE|Angioshield|Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery
214978137|NCT00608400|DIETARY_SUPPLEMENT|Clarinol CLA|0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
214978138|NCT02134093|DRUG|Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium|Anesthesia induction:midazolam (0.03\~0.05 mg/kg), sufentanil(0. 5\~0.8 μg/kg), etomidate ( 0.2\~0.6mg/kg) and rocuronium(0.6mg/kg)
214978139|NCT02134093|DRUG|Dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
214978140|NCT02134093|DRUG|Normal saline|Continuous pump infusion normal saline with identical volume of dexmedetomidine.
215085999|NCT05891028|DRUG|64Cu-EB-ss-CPT|64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
215086000|NCT05510882|OTHER|different treatment modalities for OSA|Group I: patients will be treated with CPAP. Group II: patients will be treated with digitally fabricated MAD. Group II: patients will be treated with physical therapy.
215086001|NCT00006799|DRUG|megestrol acetate|
215086002|NCT00006799|PROCEDURE|quality-of-life assessment|
215086003|NCT01445522|DRUG|ABT-888|
215086004|NCT01445522|DRUG|Cyclophosphamide|
215086005|NCT02087202|DRUG|Magnesium Sulfate|magnesium sulfate is added to the patients
215086006|NCT02087202|DRUG|ketamine|ketamine is added to the patients.
215086007|NCT00359567|DRUG|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
215086008|NCT00359567|DRUG|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
214366958|NCT06269757|BEHAVIORAL|Standard Physical Therapy|Standard of care physical therapy for ITB band syndrome involves exercises designed to target structural weaknesses such as hip abductor weakness. Typical exercises include but are not limited to hip flexor stretches, side lying hip abduction, figure 4 bridges, lateral walks with exercise bands, and side planks.
214366959|NCT07034183|DRUG|PRD001|PRD001 capsules will be provided for oral administration
214366960|NCT07034183|DRUG|Placebo|Placebo capsules will be provided for oral administration
214366961|NCT06711770|BIOLOGICAL|Blood sample|Four tubes of 7 mL collected at baseline, 3 weeks, 6 weeks, 12 weeks, 6 months, 12 months and 24 months (end of chemo-immunotherapy) or in case of relapse
214366962|NCT06732908|DIETARY_SUPPLEMENT|LipoMicel Berberine|Berberine powder in a LipoMicel matrix encapsulated in soft gel.
214366963|NCT06732908|OTHER|Placebo|microcrystalline cellulose
214366964|NCT06732544|OTHER|snoezelen room|During the travail, projectors, starry ceiling visuals and blue light LEDs will be used for visual stimuli, speakers will be used as auditory stimuli, diffusers will be used for olfactory stimuli, and therapy dough will be used for touch stimuli.
214366965|NCT06732544|OTHER|routine delivery room|General practice
214366966|NCT06722053|OTHER|virtual reality and digital education|Breastfeeding education through virtual reality and digital education
214366967|NCT06722053|OTHER|virtual reality and digital education and lemon scent|virtual reality and digital education and lemon scent inhalation
214366968|NCT06733402|DRUG|Trifarotene Cream 0.005%|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
214366969|NCT06733402|DRUG|AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
214366970|NCT06733402|DRUG|AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
214366971|NCT06733402|DRUG|Placebo|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
215086009|NCT04943458|OTHER|Monitoring of cerebral autoregulation|Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
215086010|NCT04492709|DRUG|Midazolam|The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
215086011|NCT04492709|DRUG|AZD5718|The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
215086012|NCT01744678|BEHAVIORAL|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
215086013|NCT01744678|BEHAVIORAL|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
214978141|NCT02134093|DRUG|Maintenance of anesthesia , propofol, remifentanil,vecuronium|Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.
214978142|NCT02133430|DEVICE|Bispectral index, as measured by a BIS processor|Comparisons of incidence of postoperative delirium.
214978143|NCT05002595|DRUG|H. pylori eradication|Antimicrobial agents for H. pylori eradication
214978144|NCT03597737|DEVICE|Pain APP|pain app Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
215086014|NCT05280106|PROCEDURE|Pre-dilution online hemodiafiltration with citrate dialysate|After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. Phase 1 used CD with 50% of the heparin dose of the baseline. Phases 2 and 3 used 25% heparin and no heparin, respectively. New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase. The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
215086015|NCT05280106|PROCEDURE|Post-dilution hemodiafiltration with citrate dialysate|same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
215086016|NCT01480713|DRUG|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
214366972|NCT06732076|BEHAVIORAL|web based education|web based education
214978145|NCT02599532|DRUG|apixaban|Study subjects will be given a single-dose of apixaban 10 mg.
214978146|NCT03174444|BEHAVIORAL|Small Media|Bilingual brochures and access to bilingual website
214978147|NCT05646368|DIETARY_SUPPLEMENT|Formulation #1|Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement
214978148|NCT05646368|DIETARY_SUPPLEMENT|Formulation #2|Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
214978149|NCT02354612|DRUG|TRC105|
214978150|NCT02354612|DRUG|Bevacizumab|companion therapy selection depends on companion therapy used in the parent study
214978151|NCT02354612|DRUG|Axitinib|companion therapy selection depends on companion therapy used in the parent study
214978152|NCT02354612|DRUG|Pazopanib|companion therapy selection depends on companion therapy used in the parent study
215086017|NCT01480713|DRUG|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
215094476|NCT05857904|DEVICE|QFR|Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
214978153|NCT02354612|DRUG|Capecitabine|companion therapy selection depends on companion therapy used in the parent study
215094477|NCT03447093|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
214978154|NCT04232839|DRUG|BI 894416 Reference Formulation|R1 - 60 milligram (6 x 10 milligram tablets) BI 894416 Reference Formulation, immediate release (IR) tablets taken orally with 240 mL of water after an overnight fast of at least 10 hours.
214679856|NCT03478878|DRUG|Vitamin A Palmitate|Provide vitamin A to participants with pre/post assessments of vision.
214679857|NCT00943293|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
214978155|NCT04232839|DRUG|BI 894416 Formulation A2|T1 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
215086018|NCT02980744|BEHAVIORAL|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
214978156|NCT04232839|DRUG|BI 894416 Formulation C2|"T2 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T5 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast."
214978157|NCT04232839|DRUG|BI 894416 Formulation D2|T3 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation D2, extended release (ER) capsule (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
214978158|NCT04232839|DRUG|BI 894416 Formulation F2|"T4 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T6 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast."
214978159|NCT00972270|DEVICE|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
214978160|NCT00972270|DEVICE|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
214978161|NCT03821038|BIOLOGICAL|CYT107|IV twice a week at 10µg/kg for 3 weeks
214978162|NCT03821038|DRUG|Placebos|IV twice a week at the same volume for 3 weeks
215086019|NCT04524650|DIAGNOSTIC_TEST|the level of vWF|the peripheral level of vWF
215086020|NCT04938999|BEHAVIORAL|Music-visual guided physical activity (MVgPA)|"The MVgPA adopts the information-motivation-strategy model to address the personal and environmental challenges in PA initiation and maintenance of adults with intellectual disability.~To support the staff of residential care facilities in implementing 24 sessions of MVgPA in 12 weeks, the first six sessions will be led by the RA1 and co-facilitated by the staff, while the subsequent sessions will be conducted by the staff only. At week 6, another set of MVgPA will be implemented to increase the participant's interest; two sessions will be co-facilitated by RA1. At weeks 6 and 9, the RN and RA1 will hold a meeting with the staff of the residential care facilities to acknowledge the achievement of the staff and adults with ID, as well as to address any of their concerns related to the implementation of MVgPA, and to identify the facilitators and tackle barriers to the implementation of the MVgPA."
214679858|NCT00943293|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
215086021|NCT04938999|BEHAVIORAL|Usual care|As control group, residential care facilities will conduct their usual activities during the study period. A trained RA will record the activities conducted by the residential care facilities during the study period.
215086022|NCT02696499|DRUG|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
214491879|NCT05071482|DRUG|Flumatinib|Flumatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Flumatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
215086023|NCT02696499|DRUG|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
215086024|NCT05920044|OTHER|balance and proprioception training program.|"The program will include exercises focused on improving ankle stability and joint position sense, such as single-leg stance, wobble board, and resistance band exercises.~Participants will attend two supervised sessions per week and perform home-based exercises 3-4 times per week.~Progression of exercises will be individualized based on participant performance and tolerance."
214491880|NCT05071482|DRUG|Imatinib|Imatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Imatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
214491881|NCT04671771|DEVICE|InnAVasc Arteriovenous Graft (IG) surgical implant|The InnAVasc Arteriovenous Graft (IG) is a hemodialysis vascular access graft, intended for implantation in the lower or upper arm using standard vascular techniques, in patients requiring hemodialysis
214978163|NCT05444816|DEVICE|Personalised Neurofeedback training at home|"The already available Brain Hero® EEG device will be mailed to the subject's home, along with clear video instructions regarding its use (within the app), as previously established in a beta usability study with optimal results.~All game training will take place at home, while the caregivers of patients will receive instructions either online or telephonically from the investigating team. The team is also ready with tips and tricks to keep the child motivated and facilitate the flight of the game hero in the direction of interest.~Patients will be instructed to play a minimum of 20 min for four times a week, under supervision by their caregiver(s). Patients will be provided with a training plan, including all planned months of training and advanced examinations. Instructions will also be provided, verbally and written, and the investigating team will engage in video sessions or direct meetings with the parents to make sure all instructions are properly followed."
214978164|NCT00159315|PROCEDURE|Inhalation Challenge with ATP|
214978165|NCT00159315|PROCEDURE|Inhalation Challenge with AMP|
214978166|NCT01705938|DRUG|SP-333|
214978167|NCT03830268|DIETARY_SUPPLEMENT|No MCT intake with breakfast, no lunch|Water given with a regular standardize breakfast and water given at noon without lunch.
214978168|NCT03830268|DIETARY_SUPPLEMENT|No MCT intake with lunch, no breakfast|Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
214978169|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik|BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
214978170|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik with low-carbs breakfast|BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
214978171|NCT03830268|DIETARY_SUPPLEMENT|20g of Betaquik|BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
214978172|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik with lunch, no breakfast|BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
214978173|NCT02806440|DRUG|Low dose naltrexone|Active comparator
214978174|NCT02806440|DRUG|Placebo|Placebo comparator
214978175|NCT05667766|DIAGNOSTIC_TEST|Release of Extended Pharmacogenomics Report at Week 1|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) by Week 1. Whole genome sequencing on a broader number of actionable variants as per international guidelines for cancer supportive care (identical to study arm) will be reported on at Week 13.
215086025|NCT05920044|OTHER|Usual care|"Participants will continue their usual care, including general strength and flexibility exercises.~No specific balance and proprioception training will be provided."
215086026|NCT05164588|OTHER|Statistics|Study and analyze the medicolegal aspects of different eye trauma cases ( patterns of injuries, mechanisms, causes, site of trauma and outcome)
214491882|NCT01251562|DRUG|Sterile Compound C31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
214491883|NCT02819882|OTHER|No intervention|
214491884|NCT03295773|DIAGNOSTIC_TEST|3DRA|
214491885|NCT05661682|DRUG|Tralement|Tralement with Manganese Sulfate
214978176|NCT05667766|DIAGNOSTIC_TEST|Release of Extended Pharmacogenomics Report at Week 13|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.
214978177|NCT05927532|DEVICE|Argyle Safety Fistula Cannula with Anti-Reflux Valve|The Argyle Safety Fistula Cannula with Anti-reflux Valve will be used 3x a week for 12 weeks in subjects with an arteriovenous fistulae (AVF) fistula
214978178|NCT03707834|BEHAVIORAL|Antenatal Obesity Treatment (AO)|Participants in the treatment (AO) arm will receive a 4-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; and 4)WIC provider counseling Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
214978179|NCT00714974|DEVICE|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
214978180|NCT01673178|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
214978181|NCT01673178|DRUG|25 mg PF-05231023|25 mg IV once a week for 4 weeks
214366973|NCT06733818|OTHER|Functional assessment of physical performance|Functional assessment of physical performance was performed with the Alusti test. This 10-question test was developed to assess physical performance in the geriatric population 13 and has been validated in Turkish 14. This test evaluates limb range of motion and muscle strength, ability to move from supine to sitting position, sitting balance, ability to stand up from sitting position, standing, walking, walking distance, ability to stand on tandem and single leg with eyes closed. The results of this test, which is scored out of 100, indicate the level of activity. 0-30, interpreted as totally dependent; 31-40, highly dependent; 41-50, moderately dependent; 51-60, slightly dependent; 61-75, good activity; 76-90, very good activity; and 91-100, excellent activity.
214366974|NCT06732063|DEVICE|endodontic retreatment|Re-treatment of previously failed root canal treatments
214366975|NCT06732583|BIOLOGICAL|Tuberculosis (TB) vaccine (Ad5-105K)|1 doses of Ad5-105K vaccine (1 x 10\^8 vp)) on Day 0, Nebulized Inhalation (IH) through mouth
214366976|NCT06732583|BIOLOGICAL|Placebo|1 doses of placebo on Day 0, IH
214366977|NCT06732583|BIOLOGICAL|Ad5-105K|1 doses of Ad5-105K vaccine (2 x 10\^8 vp)) on Day 0, IH
214366978|NCT06732583|BIOLOGICAL|Placebo|1 doses of placebo on Day 0, IH
214366979|NCT06733662|BEHAVIORAL|Experimental: Education-based motivational interviewing Group|The Effect of Motivational Interviewing-Based Education on Treatment Adherence and Self-Care Agency in COPD Patients
214366980|NCT06733688|DRUG|Tedizolid Phosphate Oral Formulation 1 (Reference)|Oral administration
214366981|NCT06733688|DRUG|Tedizolid Phosphate Oral Formulation 2 (Test)|Oral administration
214366982|NCT06732297|BEHAVIORAL|dyadic art therapy intervention for parent-child relationship in vulnerable families|The Stronger Family Through Art Therapy (SFAT) is a dyadic art therapy intervention developed to improve the parent-child relationship in vulnerable families. Service users of the SFAT programme will receive a progressive support from workshops, dyad art therapy, and an innovative art-based self-care tool developed with a multidisciplinary team to meet the needs of enhancing family communication and strengthening emotional bonding.
214366983|NCT07050238|BEHAVIORAL|Life Force|5-session, group-based, skills training program tailored specifically for active-duty Soldiers aimed at mitigating harmful and high-risk behaviors and promote Mental Toughness
214366984|NCT03520322|DEVICE|Mastoid Oscillator|The oscillator will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
214366985|NCT03520322|DEVICE|Control Device|The control device will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
214366986|NCT06732050|DEVICE|nociception guided treatment|For the nociception level-guided group the same standard narcosis will be applied whilst ensuring that the NOL® level value will be maintained between 10 and 25.
214491886|NCT05661682|DRUG|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese Sulfate
214491887|NCT06282055|OTHER|No intervention|Observational prospective longitudinal data collection
214491888|NCT06439823|DEVICE|ActiMyo®/Syde®|Subjects will be equipped with magneto-inertial sensors (ActiMyo®/Syde®) and passive reflective markers belonging to the MoCap® motion capture system.
214491889|NCT06491381|PROCEDURE|Cesarean delivery|The cesarean section will begin with a Pfannenstiel incision above the pubic bone, followed by blunt dissection to separate tissue layers and retracting the rectus muscles for peritoneal cavity access. A transverse or vertical peritoneal incision will expose the uterus, and a transverse incision on the lower uterine segment will be made for delivery. The baby will be delivered, the umbilical cord clamped and cut, and the baby handed to the pediatric team. The placenta will be detached and delivered, and the uterus will be closed with multiple layers of sutures. The abdominal layers will be closed with absorbable Polyglactin (Vicryl) sutures for the rectus sheath and subcutaneous tissue, and non-absorbable Polypropylene sutures for the skin. A sterile dressing will be applied to protect the wound and promote a clean healing environment, ensuring proper surgical technique, tissue handling, and minimizing post-operative complications.
214978182|NCT01673178|DRUG|50 mg PF-05231023|50 mg IV once a week for 4 weeks
214978183|NCT01673178|DRUG|100 mg PF-05231023|100 mg IV once a week for 4 weeks
214366987|NCT06733246|DEVICE|Aspiration 0|Ceretrieve is a neuro-thrombectomy aspiration catheter deigned for clot removal in AIS patients.
214366988|NCT06732635|PROCEDURE|Enhanced recovery after surgery (ERAS)|Enhanced recovery after surgery (ERAS) programs are designed to achieve early recovery after surgery and a shorter length of stay (LOS) at hospital.
214491890|NCT05479006|DEVICE|Transcranial direct current stimulation (high- definition)|20 minutes, 2 mA stimulation.
214366989|NCT06733805|BEHAVIORAL|Portrait + Therapeutics Letter|"In the context of audit and feedback interventions, Portrait is a document produced by the physician organization Therapeutics Initiative that provides personalized prescribing feedback for BC clinicians. Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual prescriber's prescribing practice, benchmarks or targets, a succinct review of the best-available evidence on the topic, and recommendations for future action.~The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and provide reference for the data presented in the Portraits."
214491891|NCT03976960|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
214491892|NCT06471127|BEHAVIORAL|Pseudoword learning paradigm task|Pseudoword learning is an experimental learning task by which participants view two novel objects (a target and a foil) and simultaneously hear an audio recording of the pseudoword name of one of the two objects. Participants must choose (via mouse click) which object corresponds to the word presented, immediately after which feedback is provided.
214491893|NCT06410547|OTHER|LLM|A LLM-based comparison between treatment and guideline.
214491894|NCT06618703|RADIATION|Blood sample, urine sample, osteodensitometry|Blood sample, urine sample, osteodensitometry
214978184|NCT01673178|DRUG|150 mg PF-05231023|150 mg IV once a week for 4 weeks
214978185|NCT05199792|DIAGNOSTIC_TEST|Dotarem|(Dotarem) (0.4 ml/kg (0.2 mmol/kg))
214978186|NCT06085521|DRUG|LNK01001 Dose A|Capsules taken orally
214978187|NCT06085521|DRUG|LNK01001 Dose B|Capsules taken orally
214978188|NCT06085521|DRUG|placebo|Capsules taken orally
214978189|NCT04550078|DIETARY_SUPPLEMENT|Calcium Carbonate|Subjects receive a single-dose of 800 mg calcium as calcium carbonate provided in 6 capsules with a standardized breakfast served in the morning.
214978190|NCT04550078|DIETARY_SUPPLEMENT|Calcium Permeate|Subjects receive a single-dose of 800 mg milk calcium as calcium permeate provided in 6 capsules with a standardized breakfast served in the morning.
214978191|NCT04550078|DIETARY_SUPPLEMENT|Placebo|Subjects receive a single-dose of 0 mg calcium as placebo with maltodextrin provided in 6 capsules with a standardized breakfast served in the morning.
214978192|NCT00767572|DRUG|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
214978193|NCT00767572|DRUG|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
214978194|NCT04554589|DRUG|Glycopyrrolate 0.2 MG|injections
214978195|NCT04554589|DRUG|normal saline|normal saline
214978196|NCT03620799|PROCEDURE|Manual therapy|A manual intervention technique is employed to the intervention group based on a roller treatment.
214978197|NCT00510614|DRUG|tinidazole|1 gram twice weekly for 12 weeks
214978198|NCT00510614|DRUG|Placebo|one pill twice weekly for 12 weeks
214978199|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
214978200|NCT05032144|DRUG|Placebo|Intravenous injection
214978201|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
214978202|NCT05032144|DRUG|Placebo|Intravenous injection
214978203|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
214978204|NCT05032144|DRUG|Placebo|Intravenous injection
214978205|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
214978206|NCT05032144|DRUG|Placebo|Intravenous injection
214978207|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
214978208|NCT05032144|DRUG|Placebo|Intravenous injection
214978209|NCT04020211|DEVICE|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
214978210|NCT03479112|BEHAVIORAL|Flashcards|Participants will be provided with Flashcards depicting how to correctly apply a tourniquet to an extremity wound.
214978211|NCT03479112|BEHAVIORAL|Audio-kit|Participants will be provided with an audio-kit with accompanying visual cues describing and depicting how to correctly apply a tourniquet to an extremity wound.
214978212|NCT03479112|BEHAVIORAL|B-Con training|Participants will undergo the Bleeding control for the injured (B-Con) basic course.
214978213|NCT03479112|BEHAVIORAL|B-Con training retention|Evaluation of retention of Bleeding Control for the injured basic course
214978214|NCT02141906|OTHER|Oncozene-DEB-TACE|ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
214978215|NCT04083560|DRUG|Vit B12|Vitamin B12 250mcg
214978216|NCT00002935|DRUG|porfimer sodium|
214978217|NCT03698292|DRUG|Itopride|Prokinetic Drug
214978218|NCT03698292|DRUG|Metoclopramide 10mg|Prokinetic Drug
214978219|NCT00295165|DRUG|Sargramostim (Leukine)|Sargramostim 6 mcg/kg subcutaneously once daily
214978220|NCT00295165|DRUG|Placebo|Placebo subcutaneously once daily
214978221|NCT01368419|DRUG|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
214978222|NCT01368419|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
214978223|NCT01859182|DRUG|selumetinib|Given PO
214978224|NCT01859182|DRUG|Akt inhibitor MK2206|Given PO
214978225|NCT01859182|OTHER|laboratory biomarker analysis|Correlative studies
214978226|NCT01859182|OTHER|pharmacogenomic studies|Correlative studies
214978227|NCT01859182|PROCEDURE|quality-of-life assessment|Ancillary studies
214978228|NCT01954849|DIETARY_SUPPLEMENT|Probiotic formulation|
215086027|NCT02256267|DRUG|LY2835219|Administered orally
215086028|NCT02256267|DRUG|Rifampin|Administered orally
215086029|NCT04598126|OTHER|Traditional physical therapy|Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
215086030|NCT04598126|OTHER|patient education manual +traditional physical therapy|"Patient educational Manual~\+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/"
215086031|NCT01898949|OTHER|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
214491895|NCT05018611|BEHAVIORAL|LifeSkills Mobile|A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
215086032|NCT02072187|DIETARY_SUPPLEMENT|Active|
215086033|NCT02072187|DIETARY_SUPPLEMENT|Placebo|
214491896|NCT05395663|BEHAVIORAL|Community health worker|A trained navigator (e.g. OSU Extension staff) will have 3 meetings with the participants in Arm 2. These meetings will be held in person, on the phone, or in zoom.
215086034|NCT05730647|OTHER|None intervention (observational study)|None intervention (observational study)
215086035|NCT04200768|OTHER|Prospective data and sample collection|Performance of measurements of adiposity, extra collection of blood samples
215086036|NCT00600041|DRUG|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
215086037|NCT00600041|DRUG|Placebo|Identical infusion manner like experimental arm
215086038|NCT05692310|OTHER|placing a standard central venous line|Patients will benefit from the technique of central venous line placement by conventional ultrasound.
215086039|NCT05692310|OTHER|placement of a central venous line using an ultraportable ultrasound device|Patients will have a central venous line placed using an ultraportable ultrasound device
215086040|NCT04557787|DEVICE|SpeediCath® Standard female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
215086041|NCT04557787|DEVICE|New intermittent Variant 1 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
215086042|NCT04557787|DEVICE|New intermittent Variant 2 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
215086043|NCT00376805|DRUG|Fludarabine|administered intravenously 25 mg/m\^2 times 5 doses
215086044|NCT00376805|DRUG|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
215086045|NCT00376805|RADIATION|Total body irradiation|200 cGy (gray) on day -1
215086046|NCT00376805|OTHER|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10\^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
215086047|NCT00376805|BIOLOGICAL|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
215086048|NCT00605553|DRUG|Placebo|"Placebo oral capsules~Placebo for 7 days"
215086049|NCT00605553|DRUG|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
215086050|NCT00259298|DRUG|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
215086051|NCT05182580|DIAGNOSTIC_TEST|Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema|If patients receive a negative result they do not see the retina specialist
215086052|NCT05445206|DEVICE|CardioPulmonary Management Device (CPM)|CPM device is used in tangent with reference capnography device.
215086053|NCT02916407|DRUG|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%."
215086054|NCT02916407|DRUG|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%."
215086055|NCT04460586|DRUG|Omadacycline Injection [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
215086056|NCT04460586|DRUG|Omadacycline Oral Tablet [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
215086057|NCT05122923|DEVICE|Serious Game S'TIM|Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient
215094478|NCT03447093|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
214366990|NCT06732869|BEHAVIORAL|eHealth physical activity coaching intervention|Patients will attend a PR program and in week 5 of PR will receive an eHealth PA coaching intervention until 6 months after end of PR. The PA goals will be prescribed through a phone call and the personalisation of goal prescription will be based on an algorithm considering patient's performance in the previous week, perceived easiness of achieving the previous goal and confidence to change it. If patient does not achieve the goal, reasons, barriers to PA and strategies to overcome them will be identified. Patients will receive a daily notification about their goal achievements, at 6PM every day, giving them the possibility to increase their PA to achieve the goal, if they have not reached it yet. Patients will also receive personalized notifications sent manually by the researcher whenever appropriate. PA goals will be prescribed on a weekly basis.
214491897|NCT05747599|BEHAVIORAL|Intervention with contingent incentives and text-based support|Contingent incentives on abstinence from alcohol, tobacco, and cannabis; Text-based support based on educational components
214491898|NCT06569992|OTHER|VIS, TIES|The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
214679859|NCT00943293|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
214679860|NCT01345877|PROCEDURE|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
214978229|NCT01328964|DRUG|Fluticasone propionate|fluticasone propionate 44 mcg
214978230|NCT01328964|DRUG|Budesonide|budesonide
214978231|NCT01328964|DRUG|Montelukast|montelukast
214978232|NCT01561417|DRUG|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
215086058|NCT06545266|PROCEDURE|micro-fragmented adipose tissue injection|Micro-fragmented adipose tissue was obtained through the Lipogems kit and intraarticularly injected after an arthroscopic debridement.
215086059|NCT02476110|DIETARY_SUPPLEMENT|Oral nutritive supplements|
215086060|NCT03286777|DIETARY_SUPPLEMENT|Placebo|Mannitol and silicon dioxide capsules
215086061|NCT03286777|DIETARY_SUPPLEMENT|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide capsules
215086062|NCT03286777|DIETARY_SUPPLEMENT|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
214491899|NCT06199349|DRUG|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
214491900|NCT06199349|OTHER|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial
214491901|NCT06890533|DRUG|Experimental: YZJ-4729|Loading dose + demand dose
214491902|NCT06890533|DRUG|Placebo Comparator: Saline|Loading dose + demand dose
214491903|NCT06890533|DRUG|Active Comparator: Morphine|Loading dose + demand dose
214491904|NCT06837649|BEHAVIORAL|The mindfulness-based Tai Chi Chuan|Studies have shown that compared with the Tai Chi Chuan, MTCC is more relaxing to practitioner. The Tai Chi Chuan section is based on the Yang's movements, which not only conform to the basic technical characteristics, such as the steps, stance, techniques, movement of the center of gravity, and the coordination of the whole body between the movements, but also are clear, smooth, simple, easy to learn, and beautiful. The mindfulness section is complemented by soothing, soft music to guide the practitioner to focus on himself and return to inner peace. The essence of the program is to help practitioners focus their attention and achieve inner peace during practice. Through the practice of MTCC, practitioners are encouraged to face the difficulties they encounter in reality and to develop a positive and open mind to deal with negative emotions and thoughts in daily life.
214978233|NCT01561417|DRUG|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
214978234|NCT01032564|OTHER|The elastography (elasticity imagery)|This diagnosis mean use the ultrasonography to measure the tissues answer under pressure
214978235|NCT04125979|OTHER|In minimally invasive surgery，Vagus nerve preservation|In minimally invasive surgery for lung cancer, the experimental group retained the pulmonary branches of vagus nerve
214978236|NCT04125979|OTHER|In minimally invasive surgery，Vagus nerve is not preserved|In minimally invasive surgery for lung cancer, the control group did not retain the vagus nerve.
215086063|NCT04448015|OTHER|Perinatal Opioid Use Disorder Education and Enhanced Perinatal Care|University of Utah clinicians will provide face-to-face, online, and written training materials for health, mental health, and substance use service providers in Carbon and Emery Counties, UT.
215086064|NCT00334997|PROCEDURE|endoscopic surgery|
215086065|NCT00334997|PROCEDURE|laser surgery|
215086066|NCT00334997|RADIATION|radiation therapy|
215086067|NCT06477471|OTHER|MetProrenes|Take one slow-release capsule twice a day, after meal.
215086068|NCT05569876|OTHER|Controlled hypoglycemic state|Voice sampling is performed in different glycemic states (euglycemia and hypoglycemia).
215086069|NCT04014543|OTHER|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
214978237|NCT03687632|BIOLOGICAL|ST266|1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
214978238|NCT05813756|OTHER|Post-diagnosctic psychoeducational intervention|Participants are randomized to the intervention group. In this group, the participant receives 10 one-hour individual sessions of psychoeducational intervention, bi-monthly, with an evaluation at mid-term (T1:T0+\~2.5 months), at the end of the intervention (T2 : T0+\~5 months) and 3 months after the intervention (T3 : T0+\~8 months). At the same time psychological questionnaires and scales will be completed
214978239|NCT04213664|OTHER|prognosis|cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival
214978240|NCT03880747|PROCEDURE|Vagus nerve-preserving distal gastrectomy|Laparoscopic distal gastrectomy with the preservation of the celiac and hepatic branch of the vagus nerve.
215086070|NCT01969500|BEHAVIORAL|Mobile Application|
215086071|NCT01969500|BEHAVIORAL|Treatment as Usual (TAU)|
215086072|NCT06486688|BEHAVIORAL|Centralized Virtual SBIRT|Brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician
215086073|NCT04704427|DEVICE|Non-invasive BCI training|In the experimental group, the participants receive non-invasive rehabilitative BCI training. The training using the lower limb orthosis targeted the patient's ability to walk.
215086074|NCT04704427|OTHER|Traditional Physiotherapy protocol|In the control group，the participants receive the traditional physiotherapy protocol, including muscle strength training, balance training and walking training, etc.
215086075|NCT01921413|DEVICE|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
215086076|NCT04969848|OTHER|Wearable sensor|IMU sensor (as part of eMSGait device) worn at the hip during T25FW
215086077|NCT00000765|DRUG|Zidovudine|
215086078|NCT00000504|DRUG|encainide|
215086079|NCT00000504|DRUG|moricizine|
215086080|NCT00000504|DRUG|flecainide|
214366991|NCT06732869|BEHAVIORAL|pulmonary rehabilitation|Patients will attend pulmonary rehabilitation program for 10 weeks. Pulmonary rehabilitation is evidence-based multidisciplinary intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to exercise training, education, self-management intervention aiming at behaviour change, known to improve health status and psychological well-being, reducing dyspnoea and healthcare utilization and hospitalization. In this study, pulmonary rehabilitation programs will have 20 sessions, twice a week, including exercise training (aerobic and strength training), educational sessions about topics as medication, smoking cessation, energy conservation techniques, physical activity, stress and anxiety management, breathing control, inhaled therapy and nutrition; nutritional and psychosocial counselling. Education session about PA importance and recommendations will be also provided in both arms.
214679861|NCT02125331|PROCEDURE|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
214978241|NCT03854331|BEHAVIORAL|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
215086081|NCT00000504|DRUG|imipramine|
215086082|NCT03454815|PROCEDURE|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
215086083|NCT03080545|DRUG|Enstilar 0.005%-0.064% Topical Foam|Topical foam
215086084|NCT04521998|DEVICE|electroacupuncture|Electroacupuncture used to reduce the inflammation was proved previously.
214978242|NCT03854942|DRUG|Placebo|Placebo oral tablet daily
215086085|NCT04521998|DEVICE|TENS|Patients who unlike needles would like to choose TENS as treatment for pain relief.
215086086|NCT01448005|DEVICE|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
215086087|NCT04591743|DEVICE|Active TCS|TCS active at 1 Hz on the right DLPFC for 6 weeks
215086088|NCT04591743|DEVICE|Placebo TCS|Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
215086089|NCT04591743|DRUG|nicotine treatment|at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
215086090|NCT04591743|OTHER|Questionnaires|"EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART"
215086091|NCT03362229|PROCEDURE|Fixation|A well reduced medial malleolus fracture will undergo internal fixation, guided by the surgeon's skill and expertise
215086092|NCT03362229|PROCEDURE|Non-fixation|A well reduced medial malleolus fracture will be left without fixation
215086093|NCT03947970|DRUG|[14C] CR845|Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
215086094|NCT00376701|DRUG|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
215086095|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
215086096|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
215086097|NCT00376701|DRUG|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
215086098|NCT00613080|DRUG|capecitabine|1650 mg/m\^2/day orally 5 days/week during radiotherapy.
215086099|NCT00613080|DRUG|oxaliplatin|
215086100|NCT00613080|PROCEDURE|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
215086101|NCT00613080|RADIATION|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
214978243|NCT03854942|DRUG|Naltrexone|Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days
214978244|NCT04801251|DIAGNOSTIC_TEST|Echocardiographic examination|Each patient included will undergo full cardiac physical examination and echocardiographic examination
214978245|NCT00449163|BIOLOGICAL|Bevacizumab|
214978246|NCT00449163|DRUG|Floxuridine|
214978247|NCT00449163|DRUG|Irinotecan|
215086102|NCT00613080|DRUG|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1."
215086103|NCT03757130|DRUG|AMG 598|AMG 598 administered by subcutaneous injection
214978248|NCT00449163|DRUG|Leucovorin|
214978249|NCT04547855|DRUG|anlotinib combined with dose-dense temozolomide|Temozolomide Capsule 150mg, p.o., qd, d1-7,15-21,4 weeks one cycle; Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
214978250|NCT04881812|DEVICE|Drug-Coated Balloons|Percutaneous coronary intervention of residual disease adjacent to a chronic total occlusion with a paclitaxel drug-coated balloon (minimal stenting strategy).
215086104|NCT03757130|DRUG|Placebo|Placebo matching to AMG 598 administered by subcutaneous injection
215086105|NCT03757130|DRUG|Liraglutide|Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
215086106|NCT02523768|DRUG|ATG-F|
215086107|NCT02523768|DRUG|Simulect|
215086108|NCT02226549|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
215086109|NCT02226549|DRUG|VDV|VDV 80 mg tablet administered orally once daily
215086110|NCT02226549|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
215086111|NCT01257490|BEHAVIORAL|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
215086112|NCT05506488|DRUG|Dasatinib 100 MG + Quercetin (1000 MG)|The intervention group will receive intermittent orally administered dasatinib (100 mg/day) plus quercetin (1000 mg/day) on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
215086113|NCT05506488|OTHER|Placebo|The placebo group will receive intermittent orally administered placebo tablets on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
215086114|NCT02726880|BEHAVIORAL|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
215086115|NCT02726880|BEHAVIORAL|Referral for care|Referral for mental health issues and family support services
215086116|NCT06053736|DEVICE|REVIVE Contact Lens|REVIVE Contact Lens
215086117|NCT05351723|OTHER|Exercise + cognitive training + education|"The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention."
215086118|NCT06157944|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
215086119|NCT00152568|BEHAVIORAL|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
215086120|NCT01268917|DRUG|aspirin|aspirin 100mg daily until the surgery day
215086121|NCT01268917|DRUG|aspirin|aspirin is stopped 5-7 days before operation
215086122|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|oral consumption in beverage
215086123|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|Oral consumption in beverage
215086124|NCT01375803|OTHER|Placebo|Oral consumption in beverage
215086125|NCT01269385|BIOLOGICAL|alemtuzumab|Given subcutaneously
215086126|NCT01269385|BIOLOGICAL|rituximab|Given IV
215086127|NCT01269385|DRUG|PGG beta-glucan|Given IV
214366992|NCT07051187|DRUG|WGc0201|Wgc0201 will be administered by intramuscular route, with a total of 9 doses.
214366993|NCT02553460|DRUG|ITMHA|Given intrathecally (IT).
214366994|NCT02553460|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
214366995|NCT02553460|DRUG|Mitoxantrone|Given IV.
214366996|NCT02553460|DRUG|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
214366997|NCT02553460|DRUG|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
214366998|NCT02553460|DRUG|Bortezomib|Given IV.
214366999|NCT02553460|DRUG|Vorinostat|Taken PO or NG.
214367000|NCT02553460|DRUG|Cyclophosphamide|Given IV.
214367001|NCT02553460|DRUG|Mercaptopurine|Given PO or NG.
214367002|NCT02553460|DRUG|Methotrexate|Given IV, IM or PO.
214367003|NCT02553460|DRUG|Leucovorin Calcium|Leucovorin rescue PO or IV.
214679862|NCT02159391|BEHAVIORAL|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
214679863|NCT05627934|DIAGNOSTIC_TEST|qICG|Evaluation of bowel fluorescence by pixel software, qICG
214679864|NCT06848153|OTHER|Plantar Vibration|The patients in the study group will receive plantar vibration intervention with a frequency of 100 Hz on the affected plantar region for 30 minutes each day over 3 consecutive days.
214679865|NCT06848153|OTHER|Placebo Plantar Vibration|The patients in the placebo group will receive placebo plantar vibration intervention with a frequency of 100 Hz on the affected plantar region, without touching the skin, for 30 minutes each day over 3 consecutive days.
214679866|NCT05336266|DRUG|Ketorolac Tromethamine|Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days
214679867|NCT03867669|OTHER|Open Bay Unit|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
214679868|NCT03867669|OTHER|Single patient room|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
214367004|NCT02553460|DRUG|Cytarabine|Given IV.
214367005|NCT02553460|DRUG|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
214367006|NCT02553460|DRUG|Vincristine|Given IV.
214367007|NCT06865651|DRUG|Remibrutinib|tablets
214367008|NCT06865651|DRUG|Placebo|tablets
214367009|NCT07059546|DRUG|Adrenomedullin|The participants will receive continuous intravenous infusion of 20 mL of 19.9 pmol/kg/min adrenomedullin over 20 minutes.
214367010|NCT07059546|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
214367011|NCT07057037|DRUG|NEMO-103 Injection|15mL(at least 12mL), solution for Intravenous injection, single dose
214491905|NCT06890871|RADIATION|Intensity-modulated radiotherapy|Radiotherapy With Immunotherapy and Anti-Angiogenic Therapy
214491906|NCT06890871|DRUG|Immunotherapy Therapy|Radiotherapy With Immunotherapy and Anti-Angiogenic Therapy
214491907|NCT06843993|BIOLOGICAL|MK-2060|Single doses of MK-2060 administered via IV infusion on Day 1 according to randomization.
214978251|NCT04881812|DEVICE|Drug-Eluting-Stent|Percutaneous coronary intervention of the chronic total occlusion and residual coronary artery disease with an everolimus-eluting platinum chromium coronary stent (complete stenting strategy).
214367012|NCT07058064|PROCEDURE|Electrocardiogram|"All participants receive a standard 12-lead ECG when they present for follow-up 1 year after completion of anthracycline-based therapy. All participants will also record a 6-lead Kardia (AliveCor, Mountain View, CA, USA) and 1-lead Apple Watch (Apple, Cupertino, CA, USA) ECG with Mayo-owned or participant-owned devices.~Longitudinal participants will receive an Apple Watch to use during this study if they do not have their own (and agree to download the app) and will be able to transmit ECGs anytime anywhere from their Apple Watch from before the initiation, all through the treatment, up to 1-year after anthracycline-based therapy. For validation, these participants will transmit ECGs from their smart watch at the time of routine follow-up visits (at 3-, 6- \& 9-months post therapy visits) along with 6-lead Kardia ECGs, and 12-lead standard ECGs."
214367013|NCT07058064|PROCEDURE|Echocardiogram|All participants will have an echocardiogram as part of standard of care when they present for their follow-up 1 year after completion of anthracycline-based therapy.
214367014|NCT07058064|PROCEDURE|LVEF echocardiogram|Participants will undergo a limited LVEF echocardiogram at the 6-month post therapy visit.
214367015|NCT07058064|OTHER|Apple Watch|"Longitudinal participants will receive an Apple Watch to use during this study if they do not have their own (and agree to download the app) and will be able to transmit ECGs anytime anywhere from their Apple Watch from before the initiation, all through the treatment, up to 1-year after anthracycline-based therapy. For validation, these participants will transmit ECGs from their smart watch at the time of routine follow-up visits (at 3-, 6- \& 9-months post therapy visits) along with 6-lead Kardia ECGs, and 12-lead standard ECGs.~Longitudinal participants will be asked to transmit weekly cardio fitness (estimates of peak VO2) from baseline to 1-year post therapy."
214491908|NCT06843993|BIOLOGICAL|Placebo|Single doses of placebo administered via IV infusion on Day 1 according to randomization.
214491909|NCT01207336|DEVICE|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
214491910|NCT06792305|PROCEDURE|Starting by anterior ring fixation in vertical shear pelvic ring injuries|The procedure will involve addressing the pelvic ring anteriorly with open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate. The goal isto achieve anatomical reduction and stable fixation to restore the integrity of the pelvic ring. Fixation of the posterior ring will be achieved using a single sacroiliac screw in S1. The goal of posterior fixation is to achieve stability and alignment of the posterior pelvic structures.
214491911|NCT06792305|PROCEDURE|Starting by posterior ring fixation in vertical shear pelvic ring injuries|the procedure will involve fixation of the posterior ring which will be achieved by using a single sacroiliac screw in S1. Then open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate.
214491912|NCT06885346|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
214491913|NCT06885346|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
214679869|NCT00482872|GENETIC|gene expression analysis|
214978252|NCT00606307|DRUG|ITF2357|50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.
214978253|NCT00597272|BIOLOGICAL|KLH conjugates with GD2L and GD3L|6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
214978254|NCT00380263|DRUG|PACAP38|10 pmol/kg/min given one time
214978255|NCT02349035|DEVICE|Compare control of multifunction transradial prosthesis|Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.
214978256|NCT02349035|PROCEDURE|Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.|Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
214978257|NCT04386902|DEVICE|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface.
215086128|NCT01269385|OTHER|flow cytometry|Correlative studies
215086129|NCT01269385|OTHER|laboratory biomarker analysis|Correlative studies
215086130|NCT01269385|GENETIC|DNA analysis|Correlative studies
215086131|NCT01269385|GENETIC|fluorescence in situ hybridization|Correlative studies
214367016|NCT07058064|PROCEDURE|Biospecimen collection|Undergo blood draw
215086132|NCT01269385|GENETIC|polymerase chain reaction|Correlative studies
215086133|NCT01269385|GENETIC|polymorphism analysis|Correlative studies
215086134|NCT01269385|GENETIC|mutation analysis|Correlative studies
214367017|NCT07058064|OTHER|Questionnaires|Participants fill out 2 questionnaires: 1) the Kansas City Cardiomyopathy-12 (KCCQ-12) Questionnaire, and 2) the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ore 30 (EORTC QLQ-C30) to evaluate health related quality of life and heart failure symptoms.
214367018|NCT07058064|OTHER|Cardio-pulmonary exercise test|Undergo CPET to assess the response of heart and lungs to exercise.
214367019|NCT07058064|OTHER|6 minute walk test|Complete a 6MWT, to see how far participants can walk on a hard, flat surface for 6 minutes
214367020|NCT07058064|OTHER|Grip strength test|A hand-held device called a dynamometer will be used to measure the muscle strength in hand/forearm
214367021|NCT06838832|BIOLOGICAL|Allogenic CD19-CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6× 10\^6 cells/kg); Phase 2 : dose of RP2D.
214367022|NCT06838832|DRUG|Fludarabine|"Intravenous fludarabine 30\~50 mg/m\^2/day on days~-5, -4, and -3."
214367023|NCT06838832|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/ day on days -5, -4, and -3.
214367024|NCT03830151|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
214491914|NCT06234631|DRUG|Epidiolex oral solution|"Participants assigned to CBD will take the medication one hour before or two hours after eating a meal.~If participants can't tolerate the full-strength dose, the participant can decrease the dosing to 0.75 milliliter twice a day. If this is still not well tolerated, dosing can further be decreased to 0.75 milliliter once per day in the evening."
214679870|NCT00482872|GENETIC|mutation analysis|
214679871|NCT00482872|GENETIC|polymerase chain reaction|
214679872|NCT00482872|GENETIC|polymorphism analysis|
214679873|NCT00482872|OTHER|flow cytometry|
214367025|NCT03830151|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
214367026|NCT06810310|DRUG|Psilocybin (high dose)|PEX010 is the psilocybin produced by Filament
214367027|NCT06810310|DRUG|psilocybin (low dose)|1mg psilocybin, produced by Filament
214367028|NCT06865521|DIETARY_SUPPLEMENT|Akkermansia Probiotics|After enrollment, patients will receive anti-PD-1 monoclonal antibody + Tyrosine kinase inhibitor (TKI, e.g., regorafenib, fruquintinib) treatment or anti-PD-1 monoclonal antibody ± chemotherapy (etc., CAPEOX \[oxaliplatin+capecitabine \], XELIRI \[irinotecan+capecitabine \]) ± Bevacizumab treatment (anti-PD-1 monoclonal antibody, chemotherapy, and bevacizumab every 3 weeks, TKI every 4 weeks), along with daily continuous administration of Akkermansia probiotics (Songke, dose: 1 capsule/day, taken with breakfast), until disease progression, intolerable toxicity, or patient withdrawal from the study.
214367029|NCT06758011|DEVICE|ivWatch|Patients wear ivWatch device at time of already scheduled chemotherapy on study.
214367030|NCT06105021|DRUG|AFNT-211|Engineered TCR T-Cell
214491915|NCT06234631|OTHER|Placebo|Participants will be instructed to take one hour before or two hours after eating a meal.
214679874|NCT00482872|OTHER|laboratory biomarker analysis|
214679875|NCT04710524|DRUG|Placebo|Placebo BID for 13 weeks
214679876|NCT04710524|DRUG|FM101 150 mg BID|FM101 (150 mg) BID for 13 weeks
214679877|NCT04710524|DRUG|FM101 300 mg BID|FM101 (300 mg) BID for 13 weeks
214679878|NCT05429723|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.
214679879|NCT05429723|DRUG|HS-10383 Placebo|Placebo for HS-10383
214679880|NCT02669927|OTHER|Observational|
214679881|NCT05874219|DRUG|Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU|The intervention Sprayed 1 to 3 times /day
214679882|NCT05874219|DRUG|Mupirocin 2% ointment|10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm
214679883|NCT00628511|DEVICE|ARES (Apnea Risk Evaluation System)|application of portable monitoring device with PSG
214679884|NCT00295399|DEVICE|The Jerusalem Telerehabilitation System|
214978258|NCT00828711|DRUG|MVI 100|Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
214978259|NCT00828711|DRUG|MVI 150|Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
214978260|NCT00828711|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
214978261|NCT05213299|PROCEDURE|AURICULAR ACUPUNCTURE|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, the investigators use press tack needles to perform auricular acupuncture.
214978262|NCT05213299|OTHER|PLACEBO|For this intervention, instead of needles, the investigators use four pieces of tape.
214978263|NCT03778008|DRUG|Recombinant bovine basic fibroblast growth factor|Recombinant bovine basic fibroblast growth factor is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of recombinant bovine basic fibroblast growth factor at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
214978264|NCT03778008|COMBINATION_PRODUCT|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
214978265|NCT04308863|DRUG|Chitosan scaffold/ MTA pulp dressing material|Chitosan 3-D porous scaffold will be prepared. The chitosan scaffolds will be examined with the Scanning electron microscopy (SEM) to analyze the surface of the chitosan scaffolds. The scaffolds will be sterilized by Ethylene oxide and stored until further use. A piece of 2-mm thick chitosan scaffold will be gently placed onto the pulp chamber floor and covering the canal orifices, and then a 2-3 mm thick layer of fast setting EndoCem Zr MTA will be applied onto the chitosan scaffold and will be gently condensed with moistened cotton pellet to attain adequate thickness which will be confirmed radiographically. MTA will be allowed to set for 4-5 mins.
214978266|NCT04308863|DRUG|MTA pulp dressing material|MTA will be gently placed over the fresh pulp wound using an MTA carrier to a thickness of 2-3 mm. It will be condensed lightly with moistened cotton pellet to attain adequate thickness and confirmed radiographically. MTA will be allowed to set for 4-5 mins.
214978267|NCT05311826|PROCEDURE|STANDARD PHYSIOTHERAPY TREATMENT|"The standard postoperative rehabilitation process starts from the first postoperative day. Two sessions are provided daily, with the exception of Sunday and Saturday afternoon. A single physiotherapy session, lasting 30 minutes, can include bed exercises for upper and lower limbs and recovery of autonomy (sitting position, standing and ambulation). In this phase, the sessions are characterized by educational and counseling activities.~The patient will be encouraged to carry out the activities independently."
214978268|NCT05311826|PROCEDURE|EXPERIMENTAL diaphragmatic breathing exercise|The subjects in the intervention group (EXP) will receive, in addition to standard physiotherapy treatment, diaphragmatic breathing exercise. Four exercises in different position (supine and side lying) will be provided for each physiotherapy session by a senior physiotherapist. Patients will be instructed to perform the same exercises independently to achieve relaxation and relief of pain symptoms.
215086135|NCT00682136|PROCEDURE|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
215086136|NCT00350467|DRUG|ER OROS paliperidone and Olanzapine|
215086137|NCT00755534|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
215086138|NCT00755534|DRUG|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
215086139|NCT00755534|DRUG|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
214491916|NCT06790797|OTHER|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
215086140|NCT00755534|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
215086141|NCT03553498|DRUG|IV acetaminophen|acetaminophen given intravenously
215086142|NCT03553498|DRUG|IV placebo|given intravenously
215086143|NCT03553498|DRUG|hydromorphone|hydromorphone given intravenously
215086144|NCT04941807|DEVICE|Platelet-rich plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
215086145|NCT04941807|DEVICE|Platelet-poor plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
215086146|NCT04239794|DRUG|Propofol|General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
215086147|NCT04239794|DRUG|Sevoflurane|General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
215086148|NCT05309213|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level:5 x 10\^4 CAR+ T cells/kg,1x 10\^5 CAR+ T cells/kg,3 x 10\^5 CAR+ T cells/kg,1 x 10\^6 CAR+ T cells/kg
215086149|NCT02741570|BIOLOGICAL|Nivolumab|
214491917|NCT06782711|PROCEDURE|cranioplasty|In this pivotal study of a medical device, patients with bone loss undergo a computed tomography scan, which is used to create a three-dimensional model of the lesion. After validation, the model is printed using PEEK material, and subsequently, the skull is repaired through cranial reconstruction (cranioplasty).
214491918|NCT06782711|DEVICE|customized skull implants made of polyetheretheretherketone (PEEK) using 3D printing|customized skull implants made of polyetheretheretherketone by three-dimensional printing in patients undergoing cranioplasty
215086150|NCT02741570|BIOLOGICAL|Ipilimumab|
215086151|NCT02741570|DRUG|Cetuximab/Erbitux|
215086152|NCT02741570|DRUG|Cisplatin/Platinol|
215086153|NCT02741570|DRUG|Carboplatin/Paraplatin|
215086154|NCT02741570|DRUG|Fluorouracil/Adrucil|
215086155|NCT01100567|DEVICE|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
215086156|NCT01738113|OTHER|Open Kinetic Chain exercise|"1. Hamstrings strengthening exercise~2. Quadriceps strengthening exercise~3. Hamstrings stretch~4. Hip extensors and abductors strengthening~5. Calf-muscles stretching~6. Strength exercise of ankle dorsiflexors \& plantar flexors"
215086157|NCT01738113|OTHER|Closed kinetic chain exercise|"1. Foot sliding from sitting~2. Seated Toe Raises~3. Hamstrings and quadriceps co-contraction from sitting~4. Bridging exercise~5. Sitting-to-standing~6. Side-to side, forward and backwards weight shifting~7. Lunge exercise~8. Squatting exercise~9. Standing Toe Raises~10. Standing Hamstrings Stretch"
215086158|NCT02316210|DEVICE|electrical stimulation|
215086159|NCT01005212|DRUG|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
215086160|NCT05649592|DIAGNOSTIC_TEST|Magnetic Resonance Hydrolipid Separation Imaging|"MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5."
215086161|NCT01058512|DRUG|NOV-205|"There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"
215086162|NCT05209308|DRUG|Zandelisib|Zandelisib taken orally for 7 days of each 28 day cycle
215086163|NCT05209308|DRUG|Rituximab|Rituximab IV for 6 cycles
215086164|NCT05209308|DRUG|Venetoclax|Orally - Ramp up weeks 1-5
215086165|NCT00821249|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
215086166|NCT00821249|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
215086167|NCT00821249|DRUG|Dexamethasone, steroid; oral|Part 3: standard of care.
215086168|NCT02004145|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
215086169|NCT02004145|BEHAVIORAL|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
215086170|NCT03234439|BEHAVIORAL|myStrength|myStrength is a digital self-care behavioral and wellness platform
215086171|NCT05145855|OTHER|Patient-tailored multimodal neglect rehabilitation|Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
215086172|NCT05876247|OTHER|Electromagnetic Articulography|Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
214367031|NCT07065448|OTHER|physical performance tests|All participants underwent the 4-meter Gait Speed Test, the Short Physical Performance Battery (SPPB), the Timed Up and Go (TUG) test, and the Elbow Performance Test twice, with a 7-10-day interval between sessions. In the Elbow Performance Test, a 1-kilogram sandbag was fixed to the distal forearm of the dominant arm, and participants were asked to perform 30 consecutive elbow flexion-extension movements.
214679885|NCT00575822|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
214679886|NCT00575822|DEVICE|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
214679887|NCT03913949|DRUG|APG-2575|Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
214679888|NCT03277573|DRUG|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.
214679889|NCT03277573|DRUG|Placebo|Inactive ingredient
214679890|NCT05057988|BEHAVIORAL|Empowered Relief class|The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
214679891|NCT02832804|DEVICE|transcranial Direct Current Stimulation|Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
214679892|NCT00013039|BEHAVIORAL|Computer reminders|
214679893|NCT02005653|DRUG|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
214679894|NCT02005653|DRUG|Albendazole|Experimental
214679895|NCT02005653|DRUG|Doxycycline|Experimental
214679896|NCT01423240|DRUG|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
214679897|NCT01423240|DRUG|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
214679898|NCT01423240|DRUG|Placebo|Placebo once daily orally in the evening
214679899|NCT02758886|BEHAVIORAL|Animal assisted activity|Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals
214679900|NCT02758886|BEHAVIORAL|Animal photos|A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats
215086173|NCT00170989|DRUG|valsartan plus hydrochlorothiazide|
215086174|NCT04515368|BIOLOGICAL|Immunization|Immunisation with one of four licensed vaccines
215086175|NCT03206632|DRUG|BI 690517|single dose
214679901|NCT02758886|BEHAVIORAL|Observing human-animal interaction|Participants watched others participate in petting dogs and cats, while they waited in line for 10 minutes. Participants did not physically touch any animals during this time.
215086176|NCT03206632|DRUG|Placebo|single dose
215086177|NCT06201351|DEVICE|adaptive radiotherapy|MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
215086178|NCT01819987|BEHAVIORAL|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
215086179|NCT01819987|BEHAVIORAL|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
215086180|NCT00600691|DRUG|Finasteride|one tablet (5mg) of finasteride
215086181|NCT00000262|DRUG|30% Nitrous oxide|
215086182|NCT00000262|DRUG|0.4% Sevoflurane|
214367032|NCT06829862|OTHER|Own Doctor Education|The self-applied online program will comprise a 3-month behavioural intervention seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the internet-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their specialist doctor.
214679902|NCT00002206|DRUG|Adefovir dipivoxil|
214679903|NCT02633072|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AMO® Tecnis® multifocal intraocular lenses with an addition of +2.75 D in the distance-dominant eye and +3.25 D in the fellow eye.
214679904|NCT03232424|DEVICE|NovoTTF-200A|"* Begins the day prior to radiotherapy start and continues until the end of temozolomide maintenance cycle #2 or until evidence of disease progression or unacceptable toxicity.~* Arrays are removed immediately prior to radiotherapy and replaced immediately thereafter."
214679905|NCT03232424|DRUG|Temozolomide|"Concomitant phase:~* 75 mg/m2 per day for 42 days concomitant with radiotherapy.~* Begins 1 day prior to XRT start.~Maintenance phase:~* Begins 4 weeks after concomitant phase completion (+/- 1 week).~* Each cycle is 28 days (5 days of drug treatment followed by 23 days without).~* Cycle 1: 150 mg/m2 once daily for the first 5 days of each treatment cycle.~* Subsequent cycles: daily dose increased to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
214679906|NCT03232424|RADIATION|3D conformal or intensity modulated radiation therapy (IMRT)|Radiotherapy will commence 4 weeks after the definitive surgical procedure (+/- 1 week), to a total dose of 54.0 - 60.0 Gy, delivered in 1.8 - 2.0 Gy fractions over 6 - 7 weeks. XRT target volumes will be determined utilizing all available imaging studies that best delineate extent of disease. Fusion image registration for treatment planning will be utilized as possible. Either 3D conformal or intensity modulated radiation therapy (IMRT) will be utilized.
214679907|NCT01009996|PROCEDURE|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
214679908|NCT06554938|DEVICE|water pik|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
214679909|NCT06554938|DEVICE|Super floss|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
214679910|NCT01038284|BEHAVIORAL|Patient education|Pharmaceutical care of patients with PAH
214679911|NCT01038284|OTHER|Data collection|Clinical and biological data, treatment, medication errors and ADEs
214679912|NCT04332341|DRUG|Nicotinamide riboside (NR)|Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
214679913|NCT02597842|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|Electric stimulation was given through electrode attached to specific acupoints
214679914|NCT02191917|PROCEDURE|Respiratory muscle strength measurements by different techniques.|
214679915|NCT02717871|DEVICE|PACK-CXL|"Local anesthesia~\- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~\- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~* 3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~* Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~* Homatropin or Scopolamin, if anterior chamber reaction~* Systemic NSAID/NSAR, if substantial pain~* Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching"
214679916|NCT02717871|DRUG|Cefazolin in combination with either tobramycin or gentamicin|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml)."
214679917|NCT02717871|DRUG|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
214679918|NCT02717871|DRUG|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
215086183|NCT00000262|DRUG|0.2% sevoflurane|
215086184|NCT00000262|OTHER|Placebo|
215086185|NCT02956304|OTHER|PMv stimulation (iTBS)|PMv stimulation (iTBS)
215086186|NCT02956304|OTHER|PMv inhibition (cTBS)|PMv inhibition (cTBS)
215086187|NCT02956304|OTHER|Control (SHAM)|Control (SHAM)
215086188|NCT02644902|OTHER|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
214978269|NCT01661738|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|360 subjects were divided into three groups (120 subjects in each group), children (2\~6 years of age), early youth (7\~15 years of age) and adult (16\~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
215086189|NCT02644902|OTHER|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
214367033|NCT06829862|OTHER|Unknown Doctor Education|The self-applied online program will comprise a 3-month behavioural intervention seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same intervention, but in this case supported by audiovisual instructions given by a doctor outside the patient.
214367034|NCT07068763|RADIATION|Lymph-node-sparing short-course radiotherapy|Three-dimensional conformal or intensity-modulated radiotherapy targeting only the primary tumor bed (no regional lymph nodes), delivering a total dose of 25 Gy in 5 Gy fractions over five consecutive days.
215086190|NCT00000429|DRUG|Calcium carbonate|
215086191|NCT01667146|OTHER|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH \> 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
214367035|NCT07068763|DRUG|Capecitabine|Oral capecitabine 1,000 mg/m² administered twice daily on Days 1-14 of each 21-day cycle, for a total of four cycles.
214367036|NCT07068763|DRUG|PD-1/CTLA-4 inhibitor (Aiparolitoworixureli injection)|Intravenous PD-1/CTLA-4 bispecific monoclonal antibody at 5 mg/kg every 3 weeks for four cycles, starting on Day 8 after completion of radiotherapy.
214367037|NCT06901193|BEHAVIORAL|Virtual Reality Mindfulness intervention|Mindfulness will be offered via a virtual reality headset; participants will use the virtual reality mindfulness program 3 times per week (15 minutes at a time) for 8 weeks.
214367038|NCT06812143|BEHAVIORAL|Strength training|This intervention involves strength training with lighter loads and higher repetitions.
214367039|NCT06812143|BEHAVIORAL|Strength training|This intervention involves conventional strength training with higher loads and moderate repetitions.
214367040|NCT06854419|DIETARY_SUPPLEMENT|Placebo Drink|Take one bottle of the product every morning on an empty stomach
214367041|NCT06854419|DIETARY_SUPPLEMENT|Blood Peach Extract Drink|Take one bottle of the product every morning on an empty stomach
214367042|NCT06854419|DIETARY_SUPPLEMENT|Rose Apple Extract Drink|Take one bottle of the product every morning on an empty stomach
214978270|NCT06055413|OTHER|Remote patient monitoring (RPM) bundle|"Patient-families will be given a remote patient monitoring (RPM) bundle with tools to measure objective and subjective information about the child at home that are shared with the home ventilator provider team through an electronic dashboard. The tools include a device to measure carbon dioxide, a digital tablet, a digital weight scale, and a digital application that connects to the child's electronic health record. Each child will be assigned an individualized remote monitoring schedule (timing and data type) based on their indication for ventilation and ventilator regimen at enrollment."
214978271|NCT06025292|OTHER|Lean Pork vs Plant-Based Protein|Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources.
214978272|NCT02033759|DEVICE|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
214978273|NCT02033759|OTHER|Anxiety Questionnaire|21 item questionnaire
214978274|NCT02033759|OTHER|Traditional Circumferential Measurements|
214978275|NCT05691101|OTHER|CISB with IV PCA group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine 4 ml/hour was injected through the continuous brachial plexus block catheter. IV-PCA with fentanyl (basal flow 0 ml with patient selected bolus 14 mcg, lockout 10 minutes) was started."
214978276|NCT05691101|OTHER|CISB group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine (4 ml/hour with patient selected bolus 5 ml, lockout 60 minutes) was injected through the continuous brachial plexus block catheter."
214978277|NCT04327921|BEHAVIORAL|Peer navigation social support for smoking cessation|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's. Also, motivational interviewing/guidance will also be used to determine whether enhanced treatment (using a Peer Navigator to navigate smoking cessation, obtain medication and treatment, improve adherence to treatment, and provide social support for quitting) will increase participant's quit attempts and smoking cessation rates.
214978278|NCT04327921|BEHAVIORAL|Standard Condition|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's.
214978279|NCT00308945|DRUG|travoprost 0.004% (drug)|local drop application
214978280|NCT00308945|DRUG|latanoprost 0.005% (drug)|local drop application
214978281|NCT03912740|DRUG|Dexmedetomidine|Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.
214978282|NCT03912740|DRUG|sodium chloride|Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)
214978283|NCT03912740|DRUG|Remifentanil|Both groups will have remifentanil analgesia guided by the Nol-Index
214978284|NCT06807918|DIETARY_SUPPLEMENT|Kenetik|Drink a single dose of ketone supplement 25g, three times, randomly given at 1 of 2 MRI scan visits, 1 of 2 FDG PET/CT scan visits, and 1 of 2 alcohol bar lab visits.
214978285|NCT06807918|OTHER|magnetic resonance imaging scan|Each subject will undergo 2 research MRI scan evaluations of the brain (up to 90 min.). The MRI is FDA-approved 7.0T Magentom Prisma scanner (Siemens Medical Solutions USA, Inc., Malvern, PA) with an approved radiofrequency head coil.
214978286|NCT06807918|OTHER|fludeoxyglucose-18 positron emission tomography scan|Each subject will undergo 2 FDG PET/CT scans. FDG is a positron emitting radiopharmaceutical. In addition to the radioactive FDG tracer, a low-dose CT of the chest is typically performed with the FDG PET/CT for the purpose of anatomical registration and attenuation correction of PET images. There are no separate diagnostic CT scans performed as part of this study.
215086192|NCT01667146|OTHER|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
215086193|NCT02813395|DEVICE|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
215086194|NCT02813395|DEVICE|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
215086195|NCT01564524|PROCEDURE|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
215086196|NCT02700165|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform the treatments.
215086197|NCT00378248|BEHAVIORAL|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
215086198|NCT00378248|BEHAVIORAL|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
214978287|NCT06807918|OTHER|Alcohol bar lab|Each subject will undergo 2 alcohol bar labs. Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%.
214978288|NCT06807918|OTHER|Placebo beverage|Drink a single dose of placebo beverage, that will look and taste the same as the ketone supplement. Subjects will recieve the beverage three times, randomly given at 1 of 2 MRI scan visits, 1 of 2 FDG PET/CT scan visits, and 1 of 2 alcohol bar lab visits, opisite of the Kenetik beverage.
215086199|NCT05847413|DRUG|Verapamil|Subjects will receive oral verapamil for 12 weeks
215086200|NCT04902651|DEVICE|HM242-Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
214367043|NCT06866925|DEVICE|Transcranial stimulation|A randomized, 2-arm, sham-controlled study, patients with Down syndrome presenting with major depressive episode (DSM5) with catatonic features will be randomly allocated to receive 15 sessions of either active (20 min, 2mA, ramp up/down 30 sec) or sham tDCS (20 min, ramp up/down 30 sec at the beginning and at the end of each stimulation session), thrice daily. Each stimulation session will be spaced at least two hours apart. The anode will be placed over the left DLPFC, the cathode over the right DLPFC using the Beam F3 algorithm in order to individualize target location based on head circumference, tragus to tragus and inion to nasion distances.
215086201|NCT04902651|DEVICE|Intrasite Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
215086202|NCT00595933|OTHER|sugar-free chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
215086203|NCT00595933|OTHER|chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
214367044|NCT06848244|BEHAVIORAL|Appetite Awareness Training (AAT)|Partcipants will receive the AAT delivered as 16 core sessions over six months as well as six maintenance sessions over the course of 12 months.
214367045|NCT06848244|BEHAVIORAL|Diabetes Prevention Program (DPP)|Partcipants will receive the DPP delivered as 16 core sessions over six months as well as six maintenance sessions over the course of 12 months.
214978289|NCT06815965|DRUG|neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase 14 (p38α). It is administered orally in 40 mg capsules.
214978290|NCT02479074|DRUG|Montelukast (High FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days
215086204|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
215086205|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
215086206|NCT00595933|DRUG|mouth spray|Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
215086207|NCT00595933|DRUG|mouth spray|Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
215086208|NCT03627169|DEVICE|MATRx plus|The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
215086209|NCT01680627|BEHAVIORAL|CASI|
215086210|NCT02273570|DRUG|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
215086211|NCT02273570|DRUG|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
214978291|NCT02479074|DRUG|Prednisolon, Montelukast (High FeNO)|Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.
214978292|NCT02479074|DRUG|Montelukast (Low FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
214367046|NCT07075068|DIAGNOSTIC_TEST|Behavioral and Functional Performance Assessment Battery|This study will include only observational functional assessments. No active intervention will be performed.This observational protocol will involve standardized assessments of lower extremity coordination (LEMOCOT), movement speed (30-meter sprint), and smoking-related behavioral patterns (Fagerström Test for Nicotine Dependence). These tools will be used to evaluate the potential impact of cigarette addiction on physical performance in young adults. No therapeutic or pharmacological intervention will be applied.
214367047|NCT07078045|OTHER|Arterial pressure monitoring|We will perform oscillometric arterial pressure measurements at different limb sites.
214367048|NCT07076446|BIOLOGICAL|IgPro|IgPro20 is a solution for infusion for subcutaneous administration.
214367049|NCT07081386|OTHER|Laparoscopic Training using the LAPARO Analytic simulator|Participants in the experimental group will undergo a 3-hour in-person laparoscopic training session using the LAPARO Analytic simulator. The session will be supervised by an experienced General Surgery tutor and will include real-time performance analytics to guide skill acquisition relevant to laparoscopic appendicectomy.
215086212|NCT01638104|DRUG|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
214491919|NCT06791720|BEHAVIORAL|music-based cognitive-motor dual-task training/exercise|Participants is engaged in 4 sessions for each training, including rhythmic marching, singing familiar songs, dance workout with elastic bands and stretching exercise with relaxing music. This combination of physical and cognitive activities aims to improve overall well-being by integrating music and movement, making the exercise both enjoyable and beneficial for mental and physical health. Rhythmic aerobic exercises to music focuses on rhythm and movement accuracy. Listening and singing familiar songs is cognitively stimulating. Dance workout allows strength and endurance training with music. Stretching exercise with relaxing music improves the range of movement in major muscle and tendon groups.
214978293|NCT02764801|DRUG|Ultrasound contrast agent (Contrast-enhanced ultrasound)|Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
214978294|NCT02764801|DEVICE|Logiq E9 Scanner (Contrast-enhanced ultrasound)|Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
214978295|NCT04964115|OTHER|Cohort study|This cohort study does not involve an intervention
215086213|NCT01638104|DRUG|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
215086214|NCT00385398|DRUG|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
215086215|NCT00385398|DRUG|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
215086216|NCT00385398|RADIATION|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
215086217|NCT00797680|OTHER|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
215086218|NCT00797680|OTHER|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
214367050|NCT07081386|OTHER|Laparoscopic Training using a classic Box Trainer|Participants will receive a single, 3-hour in-person laparoscopic training session using a Classic Box Trainer. Training will be supervised by an experienced General Surgery tutor and focused on key technical skills required for laparoscopic appendicectomy.
214367051|NCT07081672|PROCEDURE|Ultrasound-guided interscalene brachial plexus block (ISB)|The intervention consisted of an ultrasound-guided interscalene brachial plexus block (ISB) administered to patients in Group B prior to general anesthesia. The block was performed using a posterior in-plane approach with real-time ultrasound visualization. A total of 20 mL of 0.125% bupivacaine was injected around the C5-C6 nerve roots under sterile conditions by experienced anesthesiologists.
214367052|NCT07081672|PROCEDURE|General Anesthesia (control group)|General anesthesia without regional block
214367053|NCT07080255|PROCEDURE|Adams-Berger Reconstruction|The Adams-Berger procedure involves anatomical reconstruction of the distal radioulnar joint (DRUJ) ligaments using a palmaris longus tendon graft. Bone tunnels are drilled in the radius and ulna, and the graft is passed through these tunnels to reconstruct the dorsal and palmar radioulnar ligaments. This technique is designed to restore stability in patients with chronic post-traumatic DRUJ instability.
214491920|NCT06791720|BEHAVIORAL|Social Gatherings|Participants in the social control group will have a social gathering at the participating center once weekly over the 16 weeks. They will also continue to receive the usual care offered by the centers, such as social support, and health education.
214491921|NCT04557423|BEHAVIORAL|Community-Based Education|A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
214491922|NCT04557423|BEHAVIORAL|Navigation to Screening|Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
214978296|NCT01088633|OTHER|Exhaled particle analysis|"At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.~Visit 3:~After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2."
214978297|NCT06596291|DRUG|EG110A|Participants treated with EG110A
214978298|NCT00103948|DRUG|Aricept|
214978299|NCT06612814|DRUG|Fluzoparib|Parp inhibitor
215086219|NCT05570890|DEVICE|electrical noise stimulation|The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.
215086220|NCT05570890|DEVICE|Sham stimulation|Participants will not receive stimulation.
215086221|NCT05570890|DEVICE|Foam|The foam will be used to make an unstable surface.
215086222|NCT04222855|DRUG|Diltiazem|Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
215086223|NCT05996614|PROCEDURE|PRP in skin grafts|topical application of platelet rich plasma before resurfacing with STSG in Post burn raw areas
215086224|NCT05996614|PROCEDURE|conventional methods in skin grafts|fixation of the graft with stitches and staplers
215086225|NCT03845972|PROCEDURE|SSFTB|Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
214367054|NCT07080255|DEVICE|TightRope®-Augmented Adams-Berger Reconstruction|This intervention combines the standard Adams-Berger procedure with the addition of the TightRope® (Double Loop Lift System) device to provide dynamic stabilization of the DRUJ. The TightRope® system consists of a FiberWire suture passed through 2.7 mm bone tunnels in the radius and ulna and secured with cortical metal buttons. It allows for early mobilization and enhanced postoperative joint stability.
214367055|NCT07079761|BEHAVIORAL|Experiment 1: Three-day aversive conditioning, extinction, and extinction retention testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Extinction training will occur followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on extinction retention as well as reinstatement of conditioned psychophysiological reactions will be assessed.
214367056|NCT07079761|DRUG|Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.|On Day 2 of Experiment 1, a 1.7 mcg/kg dose of IV Allo will be administered over 5 minutes at the completion of extinction training to raise resting plasma Allo plus pregnanolone (PA) levels by 1500 pg/ml. This will be followed by a 4-5-hour continuous infusion of IV Allo at 2.6 mcg/kg/hr to maintain resting plasma Allo levels at the target level.
214491923|NCT04557423|BEHAVIORAL|HPV Self-Sampling|An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
214978300|NCT06612814|DRUG|Dalpiciclib|CDK4/6 inhibitor
214978301|NCT06612814|DRUG|Fulvestrant/AI|Endocrine therapy
215086226|NCT00139256|DRUG|Betamethasone|Betamethasone injection
215086227|NCT02011490|DRUG|sugammadex|sugammadex 4 mg/kg IV bolus
215086228|NCT03783104|DIETARY_SUPPLEMENT|B12 Supplement|Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
215086229|NCT00162279|DRUG|Abatacept|
215086230|NCT01244633|DRUG|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
215086231|NCT01363583|DRUG|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
215086232|NCT01363583|DRUG|normal saline|0.5-1.5 ml/hour during 4 days
215086233|NCT00221975|DRUG|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
215086234|NCT00221975|DRUG|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
214367057|NCT07079761|BEHAVIORAL|Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Extinction training will occur followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on extinction retention as well as reinstatement of conditioned psychophysiological reactions will be assessed.
214491924|NCT06755086|DRUG|18-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
214491925|NCT06832319|BEHAVIORAL|PERSONALIZED FEEDBACK|Students in the study group will be asked to intervene in a simulated situation in the management of bleeding during pregnancy. It will be filmed with a camera so that students can see their own mistakes after the simulated scenario. After the scenarios are completed by the students in the control group, the mistakes in the clinical situations will be analyzed by the researchers and students in the form of questions and answers and the necessary feedback will be given to them.
214491926|NCT05827068|BIOLOGICAL|mRNA-1011.1|Sterile liquid for injection
214491927|NCT05827068|BIOLOGICAL|mRNA-1011.2|Sterile liquid for injection
214491928|NCT05827068|BIOLOGICAL|mRNA-1012.1|Sterile liquid for injection
214491929|NCT05827068|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214491930|NCT05827068|BIOLOGICAL|mRNA-1010.2|Sterile liquid for injection
214491931|NCT05827068|BIOLOGICAL|mRNA-1010.3|Sterile liquid for injection
214978302|NCT07002554|DEVICE|Bright light therapy|the Verilux® HappyLight® Lumi Plus light therapy box, which delivers UV-free, full-spectrum LED light at an intensity of 10,000 lux
214978303|NCT07002554|DEVICE|dim red light|The control group will use the same light box device, configured to emit dim red light. This will be achieved by setting the box to its lowest brightness setting and overlaying a translucent red filter over the light display. This setup is intended to maintain the appearance and experience of light exposure while minimizing any therapeutic effect.
214978304|NCT06613022|OTHER|Instrument Assisted Soft Tissue Mobilization first Control second|Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.
215086235|NCT00221975|DRUG|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).
215086236|NCT06453603|DRUG|PRP injection|Receive pes anserinus PRP injection
215086237|NCT06453603|DRUG|corticosteroid injection|Receive pes anserinus corticosteroid injection
214367058|NCT07079761|OTHER|Matching IV Placebo|On Day 2 of Experiment 1, participants randomized to placebo will receive IV matching placebo over 5 minutes at the completion of extinction training followed by a continuous infusion of matching placebo over the next 4-5 hours. The matching IV placebo will be administered according to the same per kg dosing regimen as that for active drug.
214491932|NCT06842979|DEVICE|Inspiratory Muscle Training (IMT)|The IMT protocol will consist of home-based high-intensity daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure measured and adjusted weekly based on the modified Borg scale from 4 to 6 regarding respiratory effort performed during the session. Patients were also informed to perform knack maneuver in daily activities that may cause sudden intra-abdominal pressure overload.
214491933|NCT06842979|DEVICE|Sham IMT|The IMT protocol will consist of home-based daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to the lowest intensity of the IMT Threshold device. Patients were also informed to perform knack maneuver in daily activities that may cause sudden intra-abdominal pressure overload.
214491934|NCT06749574|DIAGNOSTIC_TEST|stability ball exercises|articipants in the first group performed stability ball exercises designed to enhance balance, core stability, they were introduced to the stability ball with instructions on maintaining proper posture, alignment, and safety to prevent injuries. The program included exercises such as the Stability ball bridging, stability ball bird dog and stability ball pelvic tilts were included to activate the lower abdominal muscles and glutes through gentle, controlled movements
214491935|NCT06749574|DIAGNOSTIC_TEST|dead bug exercise|The second group focused on dead bug exercises, Participants performed exercises such as extending one arm and the opposite leg while lying on their backs, ensuring their spine remained neutral and their lower back stayed pressed into the floor. Variations included alternating opposite arm and leg movements and holding the extended position to increase the challenge and enhance core stability. These exercises were performed slowly to maintain control and improve movement precision over the eight-week period
214491936|NCT06749574|COMBINATION_PRODUCT|Combined Groupo|The third group combined stability ball and dead bug exercises for a comprehensive training approach targeting both core stability and balance. Participants alternated between dead bug exercises, which required controlled arm and leg extensions while lying on their backs, and stability ball exercises such as the ball with bridging and bird dog. Throughout the eight weeks, participants were encouraged to maintain proper posture, alignment, and a neutral spine during all activities to ensure safety and effectiveness
214491937|NCT06827366|BEHAVIORAL|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'
214491938|NCT06770075|OTHER|Observational|Participants will not receive any study intervention. During the six month study period, participants will complete four active assessments at Months 0, 1, 3 and 6, and data from the study-provided wearable (Fitbit Charge 6) and sensors from the participant's smartphone (through the Brightline app) will be collected passively throughout.
214491939|NCT06155695|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be administered using the Starstim system. We will use the freely available Simulation of Non-Invasive Brain Stimulation (SimNIBS) software to optimally target the rVLPFC and left TPJ in each subject. Finite element models will be generated using T1 and T2 scans. We will generate multiple models to maximize on-target stimulation and minimize off-target stimulation, as determined by ratio of the summed current density within and beyond target regions of interest (ROIs). tDCS current in the active stimulation condition will be maintained at 2.0 milliamps (mA) for the first 45 minutes of each one-hour training session. Sham stimulation the same current, only the current will be ramped down to 0 mA after 30 seconds. Our previous research has shown this method to produce indistinguishable skin sensation. During tDCS, patients will be monitored for possible negative side effects.
214491940|NCT06155695|BEHAVIORAL|Auditory Cognitive Control Training (ACCT)|ACCT incorporates a subset of components from Cognitive Enhancement Therapy found to have early benefits on the cognitive deficits of interest to the proposed studies and can be conducted more time-efficiently to achieve our specific goals. ACCT involves approximately 3 hours of computerized neurocognitive training using cognitive control and processing speed training software developed by Ben-Yishay and colleagues. Deficits in cognitive control are addressed with computer training exercises containing simple stimuli with little inherent emotional or motivational salience. ACCT requires individuals to be vigilant, inhibit irrelevant stimuli, and shift attention between auditory and visual modalities. Computer training exercises facilitate reaction time in a temporal mode using auditory cues (The Attention Reaction Conditioner), spatial focusing with visual cues (the Zero Accuracy Conditioner), and temporal vigilance with auditory and visual cues (Time Estimates).
214491941|NCT06766383|BEHAVIORAL|GPT-simulated patients|GPT-simulated patients
214978305|NCT06613022|OTHER|Control first Instrument Assisted Soft Tissue Mobilization second|This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
214978306|NCT07011472|OTHER|Decision-Aid with 2-options|This decision aid offers 2 options for post-operative analgesic: a non-opioid combination (ibuprofen/acetaminophen) or an opioid (hydrocodone).
214978307|NCT07011472|OTHER|Decision aid with 3 options|"This decision aid offers 3 options for post-operative analgesic: a non-opioid combination (ibuprofen/acetaminophen), an opioid (hydrocodone), or a non-opioid combination with a just-in-case opioid prescription."
215086238|NCT02111291|BIOLOGICAL|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
215086239|NCT02111291|BIOLOGICAL|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
215086240|NCT03697993|DRUG|Fosfomycin tromethamine|Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.
214367059|NCT07079761|BEHAVIORAL|Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Brief exposure to the conditioned stimulus will be followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on reconsolidation blockade and reinstatement of conditioned psychophysiological reactions will be assessed.
214491942|NCT06766383|BEHAVIORAL|traditional role-playing|traditional role-playing
214679919|NCT02717871|DRUG|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
214978308|NCT06629506|DEVICE|MicroMatrix® Flex|MicroMatrix® Flex is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, partial thickness burns, skin tears), draining wounds. The device is intended for one-time use.
214978309|NCT06629506|DEVICE|MicroMatrix® UBM Particulate|MicroMatrix® UBM Particulate is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
214978310|NCT06629506|DEVICE|Cytal® Wound Matrix 2-Layer|Cytal® Wound Matrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
214978311|NCT06030154|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
215086241|NCT03697993|DRUG|Levofloxacin|750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
215086242|NCT03759041|DRUG|Vancomycin Pre-Treatment|Four times per day dosing of vancomycin pre-treatment
215086243|NCT03759041|DRUG|Placebo for Vancomycin Pre-Treatment|Four times per day dosing of placebo pre-treatment
215086244|NCT03759041|DRUG|SER-287|Once-daily dosing of SER-287
215086245|NCT03759041|DRUG|Placebo for SER-287|Once-daily dosing of Placebo for SER-287
215086246|NCT03971604|DRUG|Vitamin A|treated with Vitamin A
215086247|NCT03971604|DRUG|Vitamin E|treated with Vitamin E
214367060|NCT07079761|DRUG|Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.|On Day 2 of Experiment 2, a 28 mcg/kg dose of IV Allo will be infused over 30 minutes following brief reactivation of aversively conditioned psychophysiological reactions, after which IV fluid only (0.9% normal saline) will be administered over 4-5 hours.
214367061|NCT07079761|BEHAVIORAL|Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Brief exposure to the conditioned stimulus will be followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on reconsolidation blockade and reinstatement of conditioned psychophysiological reactions will be assessed.
215086248|NCT06119438|OTHER|Aromatherapy|Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized
215086249|NCT03823872|OTHER|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
215086250|NCT03823872|OTHER|Normal feeding|Normal feeding= consume food per normal schedule
215086251|NCT06464094|OTHER|User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Single group enrollment to examine user-acceptance and user experiences, while soliciting user feedback on wearability compliance (patient) and proposed clinical workflows using the most recent Vitaliti™ CVSM device.
214367062|NCT07079761|OTHER|Matching IV Placebo|On Day 2 of Experiment 2, matching IV placebo will be infused over 30 minutes following brief reactivation of aversively conditioned psychophysiological reactions, after which IV fluid only (0.9% normal saline) will be administered over the 4-5 hours. The matching IV placebo will be administered according to the same per kg dosing regimen as that for active drug.
214367063|NCT07080151|OTHER|Cardiac imaging|Patients who underwent CTA or CAG, with or without other cardiac imaging modelities (OCT, IVUS, or CMR) will be enrolled in this registry.
214367064|NCT04458610|BIOLOGICAL|Rituximab|Given IV
214367065|NCT04458610|DRUG|Zanubrutinib|Given PO
214367066|NCT06767800|DRUG|TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy|TQB2102 for injection is an antibody-coupled drug Benmelstobart is a Programmed cell death -Ligand 1 (PD-L1) Antibody
214367067|NCT06767800|DRUG|TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy|TQB2102 for injection is an antibody-coupled drug Benmelstobart is a PD-L1 Antibody
214367068|NCT06767800|DRUG|TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy|TQB2102 for injection is an antibody-coupled drug
214367069|NCT07082673|DIETARY_SUPPLEMENT|Sea Buckthorn (Hippophae rhamnoides L.) botanical extract 500 mg.|Dietary supplement based on sea buckthorn extract (Hippophae rhamnoides L.) at a dose of 500 mg - DOSE A (1 capsule of supplement + 2 capsules of placebo).
214679920|NCT05257239|OTHER|no intervention|National University Health System,
214679921|NCT04964921|OTHER|Device: ANSiScope Plus|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
215086252|NCT04294550|OTHER|Naloxegol|28 days of therapy with 25 mg/day of Naloxegol on cancer patients using opioids and suffering for opioids induced constipation not relieved by first-line laxatives.
215086253|NCT03342352|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
214978312|NCT06030154|BEHAVIORAL|Amplification of Positivity Therapy|Amplification of Positivity Therapy
214978313|NCT06030154|BEHAVIORAL|Surveys and Interviews|Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
214978314|NCT01450020|OTHER|educational intervention|Receive ACS material
215086254|NCT03342352|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
215086255|NCT03342352|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
215086256|NCT03342352|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
214978315|NCT01450020|OTHER|questionnaire administration|Ancillary studies
214978316|NCT01450020|OTHER|counseling intervention|Undergo PN session
214978317|NCT01450020|OTHER|survey administration|Ancillary studies
214978318|NCT01450020|PROCEDURE|quality-of-life assessment|Ancillary studies
214978319|NCT06338943|DIAGNOSTIC_TEST|Echocardiography|Echocardiography to diagnose HFpEF
214978320|NCT06338943|OTHER|Questionnaire|Questionnaire to determine the presence of adverse pregnancy outcomes history
214978321|NCT05455333|OTHER|Questionnaires|Sends and returns questionnaires to families.
214978322|NCT03122392|DEVICE|AMS 800|AMS 800 Artificial Urinary Sphincter
214978323|NCT04788095|BEHAVIORAL|Behavioral Intervention|Participate in an app-based mindfulness program
215086257|NCT03342352|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
215086258|NCT03342352|DRUG|Cetuximab|Cetuximab administered intravenously at the protocol-defined dose weekly.
215086259|NCT03342352|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
215086260|NCT04384107|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in PCV13 plus 2 additional serotypes (22F, 33F) in each subcutaneous 0.5 mL single dose.
215086261|NCT04384107|BIOLOGICAL|PCV13|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each subcutaneous 0.5 mL single dose.
214978324|NCT04788095|OTHER|Quality-of-Life Assessment|Ancillary studies
214978325|NCT04788095|OTHER|Questionnaire Administration|Ancillary studies
214978326|NCT05619471|DEVICE|VIO Imaging|Skin conditions that are candidates for skin biopsies
214978327|NCT06924502|OTHER|Protective Balm|The test product will be applied in addition to an additional washing product in the test area.
215086262|NCT00276614|DRUG|bortezomib|
215086263|NCT00044824|DRUG|Fexofenadine|
214978328|NCT06502847|OTHER|Exosome profile study|Neonatal serum and maternal exosome profiles will be studied in all groups.
214978329|NCT04025216|BIOLOGICAL|CART-TnMUC1|Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR)
214978330|NCT04025216|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
214978331|NCT04025216|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
214978332|NCT05162456|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
214978333|NCT05162456|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
214978334|NCT05112978|DIAGNOSTIC_TEST|MRI|MRI genu non contrast
214978335|NCT03136575|BEHAVIORAL|Qigong|a 30 minutes exercise program, 3 times a week and lasts for 6 weeks during radiotherapy course
214978336|NCT03136575|BEHAVIORAL|Wait-list control|patients enrolled in this group are informed orally to have exercise only and are arranged in a waiting list
214978337|NCT01548599|OTHER|Multi-sectoral agricultural intervention|Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
214978338|NCT06378177|BIOLOGICAL|LVGN6051 Monoclonal Antibody Injection|LVGN6051 Monoclonal Antibody Injection:1 mg/kg or 2 mg/kg, every 3 weeks(Q3W) , on the first day of the treatment cycle for up to 2 years.
214978339|NCT06378177|BIOLOGICAL|toripalimab Injection|toripalimab Injection: 240mg fixed dose,Q3W, on the first day of the treatment cycle for up to 2 years.
214978340|NCT06378177|DRUG|Paclitaxel injection|paclitaxel Injection:5ml:100 mg/m2(80 mg/m2 or 60 mg/m2 can be used if necessary),Q3W,on the first and eighth day of the treatment cycle for up to 2 years
215086264|NCT00229580|BEHAVIORAL|3 session brief intervention with health behavior feedback|
215086265|NCT00229580|OTHER|treatment as usual|
215086266|NCT00552448|DEVICE|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
215086267|NCT00801060|DRUG|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
215086268|NCT00801060|DRUG|FCR|Dosage, schedule, and duration in the protocol
215086269|NCT02990195|OTHER|Chyme reinfusion|
215086270|NCT00744666|DRUG|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
215086271|NCT03928626|BEHAVIORAL|Regulation of craving|Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.
215086272|NCT03928626|BEHAVIORAL|Control (NO REGULATION)|In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
215086273|NCT00523497|DEVICE|Non invasive mechanical ventilation|
215086274|NCT03002272|DEVICE|TAVR|subjects that underwent TAVR more than 3 years ago
215086275|NCT03002272|DEVICE|SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
215086276|NCT06508372|DRUG|Topical thymoquinone Ointment|One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
215086277|NCT06508372|DRUG|topical placebo ointment|In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
215086278|NCT04412694|DRUG|Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).|Preoperative oral dexamathasone supplementation in a single dose of 8mg.
214978341|NCT03310567|DRUG|Epacadostat + pembrolizumab|Each patient would be administered epacadostat orally twice a day and pembroluzimab by infusion once in a cycle of 21 days
214978342|NCT05571813|DRUG|CKD-341|A single dose of 1tablets under fasting condition
215086279|NCT04412694|DRUG|Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).|Preoperative oral supplementation of sweetener in a single dose.
215086280|NCT04412694|DIAGNOSTIC_TEST|Preoparative blood laboratory tests|Preoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum.
215086281|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 6 hour|At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
214978343|NCT01474343|GENETIC|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
214978344|NCT03218501|DRUG|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
214978345|NCT03218501|DRUG|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
214978346|NCT03218501|DRUG|Placebo|Placebo is to be administered orally once daily for 2 weeks
214978347|NCT01626170|OTHER|laboratory biomarker analysis|Correlative studies
214978348|NCT05630196|DRUG|LY3857210|Administered orally
215086282|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 24 hour|At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
214367070|NCT07082673|DIETARY_SUPPLEMENT|Sea buckthorn (Hippophae rhamnoides L.) 1500 mg.|Dietary supplement based on sea buckthorn (Hippophae rhamnoides L.), at a dose of 1500 mg - DOSE B (3 capsules of supplement).
214367071|NCT07082673|DIETARY_SUPPLEMENT|Placebo|Placebo (3 capsules of placebo).
214367072|NCT07076706|DRUG|minoxidil + finasteride|topical foam: 5%minoxidil+0.075%finasteride
214367073|NCT07076706|DRUG|minoxidil + finasteride|topical foam: 5%minoxidil+0.1%finasteride
214367074|NCT07076706|DRUG|Placebo foam|Topical placebo foam
214978349|NCT05630196|DRUG|Placebo|Administered orally
214978350|NCT05258552|PROCEDURE|enema|preoperative enema
214978351|NCT00976365|DIETARY_SUPPLEMENT|THL-P|20ml/bottle, TID, 24weeks
214978352|NCT04818775|DEVICE|HemaClear|HemaClear Model A
214978353|NCT04818775|DEVICE|Pneumatic Tourniquet|Pneumatic Tourniquet
214978354|NCT03438266|DEVICE|JUVÉDERM VOLUMA® XC injectable gel with cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
214978355|NCT03438266|DEVICE|JUVÉDERM VOLUMA® XC injectable gel with needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
215086283|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory drainage fluid tests at 24 hour|At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
215086284|NCT04412694|PROCEDURE|Total thyroidectomy|Patients will undergo total thyroidectomy under general anesthesia.
215086285|NCT04412694|OTHER|Symptomatic hypocalcaemia at 6 hour|At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
215086286|NCT04412694|OTHER|Symptomatic hypocalcaemia at 24 hour|At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
215086287|NCT04412694|OTHER|Postoperative pain at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
214367075|NCT04312867|BEHAVIORAL|Project STRONG|Project STRONG is a 6-module web-based, dyadic intervention for middle school boys and their parents to complete. Its goal is primary prevention of adolescent dating violence by targeting parent-child communication and emotion regulation ability.
214978356|NCT00878865|DRUG|Alprazolam|1 mg tablet one oral dose
214978357|NCT00878865|DRUG|Alprazolam|1 mg tablet
214978358|NCT00352118|BIOLOGICAL|filgrastim|subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
214978359|NCT00352118|BIOLOGICAL|pegfilgrastim|If applicable on day 5, repeating every 3 weeks for 2 courses.
214978360|NCT00352118|DRUG|cisplatin|Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
214978361|NCT00352118|DRUG|docetaxel|Intravenous over 1 hour on day 1.
215086288|NCT04412694|OTHER|Postoperative pain at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
214978362|NCT00352118|DRUG|fluorouracil|Intravenous continuously on days 1-4.
214978363|NCT00352118|PROCEDURE|conventional surgery|As appropriate, neck dissection.
214978364|NCT00352118|RADIATION|radiation therapy|60 Gy 5 days/week x 6 weeks with cisplatin
214978365|NCT05320471|OTHER|This is an observational study|This is an observational study
215086289|NCT04412694|OTHER|Postoperative nausea and vomiting at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
215086290|NCT04412694|OTHER|Postoperative nausea and vomiting at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
215086291|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
215086292|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
215086293|NCT01447160|DRUG|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
214978366|NCT03710954|DIAGNOSTIC_TEST|Experimental Group|All volunteers were evaluated by numerical pain scale and Fuzzy scale. This procedure was performed to compare the efficacy of the Fuzzy Scale demonstrating greater accuracy of quantification of skeletal muscle pain
214978367|NCT06173284|DRUG|611|subcutaneous injection
215086294|NCT05478291|OTHER|Vitamin D supplementation|Appropriate diet and physical activity counselling to both groups. Supplementation with Vitamin D and oral Calcium-Doses of cholecalciferol (commercial name, Calcirol) 60,000 IU (sachets, dissolved in half glass milk) once per week for eight weeks for the intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer. After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated.If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 IU per day will be given as a maintenance dose. Equal doses of calcium carbonate (1gm per day, commercial name Calcal) will be given to both the groups.
215086295|NCT04001595|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
214367076|NCT04312867|BEHAVIORAL|Health Promotion|Health promotion is a 6 module web-based, health information program designed to provide health content similar to that provided in a middle school health class. This program is designed to mirror Project STRONG for time and delivery method.
214978368|NCT06173284|DRUG|Matching placebo|subcutaneous injection
214978369|NCT02308046|DRUG|Terconazole|
214978370|NCT02308046|DRUG|Placebo|
215086296|NCT02337166|DEVICE|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
215086297|NCT02337166|PROCEDURE|Periodontal flap surgery|
214978371|NCT05497752|OTHER|cervical rehabilitation program|"(Positional release technique on trapezius muscle): The subject was supine The therapist applied Pressure by pinching the trapezius muscle between the thumb and fingers.~Suboccipital muscle release):~The patient will be in a Supine lying position therapist places both his palms at suboccipital region with upward pressure causing a stretch and distraction for 30 seconds. This technique was performed 3 times in one session with a rest interval of 1 minute after each time.~(Stretching of pectoralis muscle):. once daily Stretching with repetition of five, three times a day for 1week"
214978372|NCT05497752|OTHER|control group|Relax shoulders and neck sufficiently look down turn face to the right turn face to the left incline head to the right incline head to the left turn shoulders round and round slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening).
215086298|NCT01522404|DRUG|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
215086299|NCT01522404|DRUG|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
215094479|NCT01142024|DRUG|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
215094480|NCT01142024|DRUG|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
214367077|NCT07087171|OTHER|Artificial intelligence-Machine learning report with accurate personalized probabilities of having a live birth rate|Patients included in the prospective arm will receive the Univfy® PreIVF Report with their accurate personalized probabilities of having a live birth rate (Univfy®) together with a medical explanation by their physician
214367078|NCT07085637|OTHER|intravenous infusion of hydrogen nanobubbles (HNB) administered twice weekly over a 5-week period|"This study investigated a novel intervention using intravenous hydrogen nanobubbles (HNBs), which are microscopic hydrogen gas bubbles encapsulated in liquid, offering enhanced stability, deep tissue penetration, and sustained antioxidant and anti-inflammatory effects. Unlike other hydrogen therapies (such as inhalation or hydrogen-rich water), this method delivers HNBs directly into the bloodstream.~Participants were randomized into six groups: one control group receiving saline and five intervention groups receiving escalating doses of HNBs (5-25 mL) over 10 intravenous infusions in 5 weeks. This intervention is distinct for its dose-response design, intravenous delivery, and combined evaluation of cardiovascular function and quality of life (SF-36)-a patient-centered approach not commonly found in similar studies."
214367079|NCT07086885|BEHAVIORAL|Resistance band training|Four-week resistance band training intervention (15 mins 3x per week). Written and video instructions on the exercises were provided inlcuding guidance on increasing resistance over the weeks.
214367080|NCT06905652|DRUG|R-3,4-methylenedioxymethamphetamine|A dose of 300mg enantiomeric R-MDMA will be administered.
214367081|NCT06905652|DRUG|S-3,4-methylenedioxymethamphetamine|A dose of 100mg enantiomeric S-MDMA will be administered.
214367082|NCT06905652|OTHER|Placebo|Placebo (Mannitol)
214367083|NCT06777316|DRUG|CGT4859|CGT4859 is a selective FGFR2/3 inhibitor
214679922|NCT01530399|DRUG|MDCO 1|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
214978373|NCT05658939|OTHER|Phone/Internet survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone/internet for patients.
214978374|NCT04577066|OTHER|GA2|15 volunteers will receive 50 GA2-infected mosquito bites. The GA2 parasite is a new genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and should not be able to cause malaria in humans.
215086300|NCT01397604|DRUG|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
215086301|NCT01397604|DRUG|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
215086302|NCT01397604|OTHER|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
215086303|NCT03237130|PROCEDURE|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
215086304|NCT04866355|OTHER|Lumbar spine manipulation|Lumbar spine manipulation
214367084|NCT07089056|PROCEDURE|transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 5 cm).The stimulation intensity will be set at 2 mA. The stimulation will last for 20 minutes, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
214978375|NCT04577066|OTHER|GA1|10 volunteers will receive 50 GA1-infected mosquito bites. The GA1 parasite is a genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and is not able to cause malaria in humans.
214978376|NCT04577066|OTHER|Placebo|5 volunteers will receive 50 uninfected mosquito bites.
214978377|NCT04600869|OTHER|Naturalistic Decision-Making Model-based Oncofertility Care Education|We designed the education program according to Klein's NDM model, which explored the reasoning mechanism behind decision-making (Klein, 1993). It depends on the on-the-job training date in each unit. The education program consisted of the following: (1) Information accumulation: explanations of common cancer therapies related to subsequent infertility, psychological and mental change in cancer survivors with infertility, the necessity and method of early determination of fertility intention, and type of fertility preservation. (2) Sense-making: situational case sharing, emphasis on the guidance interaction between experienced and novice nurses to understand the patient's situation. (3) Decision-making: how to provide support, how to correspond, and attitudes toward people with strong fertility intention.
214978378|NCT02392780|DRUG|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
214978379|NCT02392780|DRUG|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
215086305|NCT04866355|DRUG|Hyoscine and Ibuprofen|hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
215086306|NCT03654287|OTHER|Treatment|The CELS way to intervene severe sepsis and refractory shock
215086307|NCT01349062|DRUG|"Kallunk oxide (Immunotherapy) "|"The study is assigned Arm 1 above 450 cu/mm\^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
215086308|NCT04858685|OTHER|early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.
215086309|NCT02698371|DEVICE|G1-Control: Futurabond®DC-SE (FBDC_SE)|Futurabond®DC (FBDC) adhesive by self-etch (SE) mode bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
215086310|NCT02698371|DEVICE|G2-Control: Futurabond®DC_SE_EE|Futurabond®DC adhesive by self-etch mode with selective enamel etching (FBDC-SE-EE) bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
215086311|NCT02698371|DEVICE|G3: Futurabond® U - ER (FBU_ER)|FuturabondU® (FBU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
215086312|NCT02698371|DEVICE|G4: Futurabond® U - SE (FBU_SE)|FuturabondU® (FBU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
215086313|NCT02698371|DEVICE|G5: Adhese® Universal - ER (ADU_ER)|Adhese®Universal (ADU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
215086314|NCT02698371|DEVICE|G6: Adhese® Universal - SE (ADU_SE)|Adhese®Universal (ADU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
215086315|NCT02498574|DEVICE|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
215094481|NCT03897036|DRUG|CX-4945|API powder-in-capsule in 200 mg strength
214679923|NCT01530399|DRUG|MDCO 2|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
214978380|NCT02392780|DRUG|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
214978381|NCT03318185|PROCEDURE|gasless single-port laparoscopic surgery|The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.
214978382|NCT03318185|PROCEDURE|conventional laparoscopic surgery|The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.
215086316|NCT02498574|BEHAVIORAL|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
214367085|NCT07089056|DEVICE|sham transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 5 cm).The stimulation intensity will be set at 2 mA. The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead for 20 minutes. However, there will be current only during the first 10 seconds and the last 10 seconds.
214679924|NCT01530399|DRUG|MDCO 3|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
215086317|NCT05697666|OTHER|Modulation of the depth of the neuromuscular blockade|"Analysis of the respiratory mechanics at two times:~* Facial train of four = 0, indicating a deep neuromuscular blockade~* Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade"
214679925|NCT01530399|DRUG|MDCO 4|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
214679926|NCT01530399|DRUG|Tranexamic Acid|Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.
214679927|NCT01530399|DRUG|Saline|A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.
214679928|NCT00653835|DRUG|Ezetimibe + Simvastatin|oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
214679929|NCT00653835|DRUG|Simvastatin|oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
214978383|NCT02313402|DEVICE|EOL (Eye On Line)|the intervention consists in training program allowing a gradual acquisition of the eye-writing
214978384|NCT01549574|DRUG|crizotinib|Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
214978385|NCT01549574|DRUG|esomeprazole|Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
214978386|NCT00553774|DIETARY_SUPPLEMENT|Cocoa Flavanols|Cocoa Flavanols (BD for 21 - 28 days)
214978387|NCT00553774|OTHER|Placebo|Placebo (BD 21 - 28 Days)
214978388|NCT04626323|PROCEDURE|Roux-en-Y gastric bypass|"1. Pneumoperitoneum closed with Veress needle~2. Identification of Treitz angle~3. Measurement of biliary loop (50 cm)~4. Bowel transection with linear stapler (white load)~5. Measurement of the alimentary limb (100 cm)~6. Laterolateral Entero-anastomoses (white load)~7. Construction of gastric pouch distant about 3 cm from the esophageal-gastric junction with stomach section in the small curvature.~8. Linear cutting anastomosis (gastrojejunostomy) from about 1 to 1.2 cm~9. Anastomosis integrity evaluation by methylene blue test and/or perioperative air.~Expected surgical time: 60 minutes"
214978389|NCT04626323|DRUG|Best medical treatment|Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
214978390|NCT05314309|DIAGNOSTIC_TEST|Comparison of two tests (FIT and mtFIT) in the same bowel movement|Invitees for the Dutch National CRC screening program will be randomly selected by the Screening Organization and invited to participate in this study, where next to the current FIT, participants will also perform the mtFIT in one bowel movement. Both tests will be analysed and if one of the two test results is positive, the individual will be referred for colonoscopy.
214978391|NCT05088265|DEVICE|Bigfoot Unity Diabetes Management System|The Bigfoot Unity System is a wirelessly connected set of hardware and software that is intended for use by people with diabetes mellitus who use disposable insulin pens for self-injection of insulin. Bigfoot Unity consists of the Abbott FreeStyle Libre 2 Sensor, two durable insulin pen caps (one each for specific rapid-acting and long-acting insulin pens) and an iOS-specific mobile App.
214978392|NCT01244867|BIOLOGICAL|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
214978393|NCT01244867|BIOLOGICAL|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
214978394|NCT01244867|BIOLOGICAL|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
214978395|NCT01244867|BIOLOGICAL|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
214978396|NCT01244867|BIOLOGICAL|Placebo|2 doses given 21 days apart of the placebo
214978397|NCT02124824|DRUG|BQ-123|Endothelin subtype A antagonist
214978398|NCT00356018|BEHAVIORAL|Compliance|
214978399|NCT06514287|BEHAVIORAL|Individualized intervention|It is a pragmatic intervention where three priorities were identified for physical activities in daily routines, considering the difficulty of the goal, the family's daily routines, opportunities for practice, and time available for practice. The therapist is a consultant, sharing information, educating, and instructing in ways that encouraged engagement of participants in the intervention process. The intervention plan was implemented via online consultation using WhatsApp text, audio, and video messaging for asynchronous and synchronous communication. The focus of intervention was incorporating practice of goals into daily activity routines.
214978400|NCT03485625|DRUG|Lidocaine|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
215086318|NCT03734029|DRUG|Trastuzumab deruxtecan (DS-8201a)|DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
215086319|NCT03734029|DRUG|Capecitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
215086320|NCT03734029|DRUG|Eribulin|Administered according to label, as one option for Physician's Choice (determined before randomization)
215086321|NCT03734029|DRUG|Gemcitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
215086322|NCT03734029|DRUG|Paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
214367086|NCT07089056|PROCEDURE|immobilization|The researchers will use an upper limb fixation splint to fix the right upper limb of the participants, with the elbow joint flexed at 90 degrees, to ensure that all movements of the wrist, metacarpophalangeal joints, proximal interphalangeal joints, and interphalangeal joints are completely restricted. To avoid discomfort caused by the splint, soft bandages will be wrapped around the hand, and the splint will be adjusted to fit the shape of the hand. Ensure that the fingertips are visible to ensure good blood circulation. The subjects need to wear the upper limb fixation splint for 16 hours. Instruct the subjects to minimize movement and use of the right upper limb as much as possible. During the immobilization process, pay attention to checking if the participants have numbness or other discomfort, as well as whether the blood flow is good. If any adverse symptoms occur, the immobilization will be immediately terminated.
215086323|NCT03734029|DRUG|Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
215086324|NCT01930760|BEHAVIORAL|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
215086325|NCT01930760|BEHAVIORAL|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
215086326|NCT03081858|DRUG|TSD-001|Administered via intravesical instillation.
215086327|NCT01182974|DRUG|paracetamol|1 gr of paracetamol PO/PZ/PR
215086328|NCT01182974|DRUG|dypirone|1 gr PO/PZ/PR/IM
214367087|NCT07088419|DRUG|Tinidazole|2 grams orally on day one followed by 500mg orally twice daily on days 2-10
214491943|NCT06755931|BEHAVIORAL|quilling set|After the intervention group is determined in randomization, half an hour before the cardiac catheterization and angiography procedure, without premedication treatment, the researcher will be asked to choose 2 animal and plant figures, samples of which have been previously made, through a quilling set, in cooperation with the researcher. It will be done with the child in a 15-20 minute period, accompanied by the researcher, with 2 figures chosen by the child. With the opportunity for the child to choose the color and figure he/she wants, the child will be at the center of the work. The figure will be given as a gift to the child and the survey forms will be filled out again 5 minutes after the application, before the premedication treatment. In order to prevent bias in the research, the descriptive information form and fear and anxiety scales will be taken by the evaluation of three people: the researcher, the parent and the child.
215086329|NCT02120703|DRUG|Pregabalin|Pregablin 75 mg per oral two times a day
214491944|NCT06755931|BEHAVIORAL|Control|Before the procedure, while the child is in the patient room, the details of the research will be explained, their consent will be obtained and the Introductory Information Form will be filled in by the parent, and the Fear Scale and State Anxiety Scale will be filled in by the child and the parent. After the control group is determined in randomization, the researcher will apply the posttest without premedication treatment half an hour before the cardiac catheterization and angiography procedure. No separate intervention will be applied. In accordance with ethical principles, after the procedure, 2 Quilling figures chosen by the control group and the child will be prepared with the help of the researcher, and the prepared figures will be gifted to the child.
215086330|NCT02120703|DRUG|Gabapentin|Gabapentin 200 mg twice daily per oral
215086331|NCT05704660|BEHAVIORAL|Adjusted Cognitive-biased modification task|The intervention of the proposed project is based on a go/no-go task in which older adults need to quickly decide whether or not they should react to the stimulus. A rectangle containing an image, or a word will be presented on a screen. In the intervention group, older adults will be instructed to restrain their actions when the rectangle is tilted to the right and to react by pressing a key on the keyboard when the rectangle is tilted to the left, irrespective of the content of the rectangle (because the training is meant to be implicit). In order to train inhibitory processes counteracting the automatic attraction to sedentary behavior, 90% of the rectangles tilted to the right (counterbalanced across participants) will contain a picture or a word related to sedentary behavior. To foster the automatic attraction toward physical activity, 90% of the rectangles tilted to the left will contain a picture or a word related to physical activity.
215086332|NCT05704660|BEHAVIORAL|Cognitive-biased modification task|In the comparison group, instructions will be identical, but the percentage of physical activity and sedentary stimuli will be equal in each tilt condition (i.e., 50% sedentary stimuli and 50% physical activity stimuli in both right- and left-tilted rectangles)
215086333|NCT03929926|OTHER|Best Practice|receive usual care
215086334|NCT03929926|BEHAVIORAL|Cancer Educational Materials|Receive educational materials via mail
214367088|NCT07088510|PROCEDURE|Hysteroscopic resection|Participants will undergo a hysteroscopy where a camera is placed on the inside of the uterus. Then a resector will be used to remove the pregnancy loss under direct visualization.
214978401|NCT03485625|DRUG|Ketorolac|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
214367089|NCT07088510|PROCEDURE|Manual Vacuum Aspiration|Participants will undergo a manual vacuum aspiration with ultrasound guidance for treatment of early pregnancy loss. This is when pregnancy loss is suctioned by a machine from the uterus.
214367090|NCT07088601|DRUG|Oral ondansetron strips|In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group O will receive oral ondansetron in the form of an oral soluble film 4 mg strip.
214978402|NCT03485625|DRUG|paracetamol|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
214978403|NCT04642989|OTHER|Sham Treatment|All movements of facial effleurage except applying pressure
215086335|NCT03929926|OTHER|Behavioral, Psychological or Informational Intervention|Receive shared decision making and lung cancer screening information
215086336|NCT03929926|OTHER|Counseling|Undergo decision counseling session
215086337|NCT00131456|DRUG|Venlafaxine|375mg/day
215086338|NCT00131456|DRUG|Placebo|Placebo
214367091|NCT07088601|OTHER|Placebo (oral peppermint strip)|In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group C will receive a placebo in the form of an oral peppermint strip.
214367092|NCT04814368|BIOLOGICAL|canakinumab|Canakinumab 600 mg single intra-articular injection (into the knee) on Day 1
214679930|NCT02307019|OTHER|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
214679931|NCT02307019|OTHER|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
214679932|NCT00193440|DRUG|Rituximab|
214679933|NCT00193440|DRUG|CHOP|
214679934|NCT00193440|DRUG|CVP|
214679935|NCT00193440|DRUG|Ibritumomab Tiuxetan|
214679936|NCT04230486|DEVICE|Cross-model Visual Auditory Rehabilitation|Subjects will put on a virtual reality rehabilitation system which will present sights and sounds.
214679937|NCT01515982|BEHAVIORAL|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
214679938|NCT01515982|BEHAVIORAL|Control Group|All participants were asked not to commence any new exercise regimen.
214679939|NCT03215264|DRUG|hydroxychloroquine|600-1200mg daily
214679940|NCT03215264|DRUG|entinostat|3-5mg weekly
214679941|NCT03215264|DRUG|regorafenib|160mg daily
214679942|NCT01598584|DRUG|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
214679943|NCT01598584|DRUG|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
214679944|NCT01977209|DRUG|Gossypol|
214679945|NCT01977209|DRUG|Placebo|
214679946|NCT00188500|BEHAVIORAL|atkins diet|
214679947|NCT00188500|BEHAVIORAL|ability to follow low carbohydrate diet|
214679948|NCT03803540|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via duodenal infusion
214679949|NCT02819648|DRUG|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
214679950|NCT02819648|OTHER|Control|Milk Tablet
214679951|NCT01840020|PROCEDURE|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
214679952|NCT01840020|PROCEDURE|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
214679953|NCT02027688|OTHER|q6 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
214679954|NCT02027688|OTHER|q3 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
214978404|NCT04642989|OTHER|Facial Effleurage|Facial massage to remove any lymphatic blockages
215086339|NCT00979849|DRUG|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
215086340|NCT00979849|DRUG|Placebo|Solution for nebulisation, inhaled
215086341|NCT04512508|DIAGNOSTIC_TEST|Self test sample|Self test sample, DNA analysis, Biopsy and Anoscopy
215086342|NCT00262847|BIOLOGICAL|Bevacizumab|Given IV
215086343|NCT00262847|DRUG|Carboplatin|Given IV
215086344|NCT00262847|OTHER|Laboratory Biomarker Analysis|Correlative studies
214367093|NCT04814368|BIOLOGICAL|LNA043|LNA043 40 mg intra-articular injection (into the knee) every 4 weeks, on Days 15, 43 and 71
214367094|NCT04814368|OTHER|Placebo to canakinumab|Placebo to canakinumab single intra-articular injection (into the knee) on Day 1
214679955|NCT04645459|OTHER|low phosphorus meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
215086345|NCT00262847|DRUG|Paclitaxel|Given IV
214679956|NCT04645459|OTHER|control meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
215086346|NCT00262847|OTHER|Placebo|Given IV
215086347|NCT00262847|OTHER|Quality-of-Life Assessment|Ancillary studies
215086348|NCT03562416|DRUG|Nintedanib|Nintedanib (BIBF 1120, Ofev)
215086349|NCT03562416|DRUG|Placebo Oral Tablet|Placebo
214367095|NCT07081971|OTHER|Bioheat Patch|Bioheat Patch for pain relif
215086350|NCT01124981|DRUG|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
215086351|NCT01124981|DRUG|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
215086352|NCT00290667|BIOLOGICAL|pegfilgrastim|
215086353|NCT00290667|BIOLOGICAL|rituximab|
215086354|NCT00290667|DRUG|cyclophosphamide|
214367096|NCT07081971|OTHER|Placebo Patch|placebo Patch
214367097|NCT07093216|BEHAVIORAL|Exercise|6 month exercise intervention
214367098|NCT07093424|OTHER|scoring|magnesium depletion score calculation
214367099|NCT07094880|DRUG|Tab. Methotrexate 25mg/week|Tab. Methotrexate will be given orally in one arm at a dose of 25 mg/week
214367100|NCT07094880|DRUG|Inj. Methotrexate 25mg/week|Inj. Methotrexate 25 mg/week will be given subcutaneously in another arm
215086355|NCT00290667|DRUG|doxorubicin hydrochloride|
215086356|NCT00290667|DRUG|prednisone|
215086357|NCT00290667|DRUG|vincristine sulfate|
215086358|NCT00290667|OTHER|pharmacological study|
215086359|NCT00290667|RADIATION|radiation therapy|
215086360|NCT03901404|PROCEDURE|Myomectomy Operation|Patients undergoing myomectomy for myoma uteri
215086361|NCT03966885|BEHAVIORAL|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
215086362|NCT03966885|BEHAVIORAL|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
215086363|NCT02212769|DRUG|Losartan 50mg|Losartan 50mg once daily for 7 days
215086364|NCT02212769|DRUG|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
215086365|NCT06562582|DRUG|Bisoprolol Oral Tablet|Timing of drug intervention after PCI
215086366|NCT06562582|DRUG|Ramipril Oral Product|Timing of drug intervention after PCI
215086367|NCT06562582|DRUG|Dapagliflozin Oral Product|Timing of drug intervention after PCI
215086368|NCT03880838|BEHAVIORAL|Personal testimonial|Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
214367101|NCT07093762|DRUG|Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel|Atezolizumab: 1200 mg IV every 3 weeks; Bevacizumab: 15 mg/kg IV every 3 weeks; Carboplatin: AUC 5 IV every 3 weeks; Paclitaxel: 175 mg/m² IV every 3 weeks. Treatment cycles: After 4-6 cycles, continue Atezolizumab + Bevacizumab as maintenance therapy until disease progression or unacceptable toxicity.
214367102|NCT07092644|DEVICE|UltraSonic Cardiac Output Monitor (USCOM®)|Using USCOM, the haemodynamic evaluation will be performed at the time of diagnosis of congenital heart desease and then every two weeks until delivery. A further evaluation will be performed immediately after delivery (within 72 hours).
214367103|NCT07093944|DRUG|N-Acetylcysteine (NAC) Treatment|Parkinson's disease patients receive NAC (1200 mg/day) for one year.
214491945|NCT06779370|DRUG|Calcium Silicate|Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium silicate-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
214679957|NCT02629601|BEHAVIORAL|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
214367104|NCT07093944|DRUG|Placebo|Parkinson's disease patients receive Placebo similar to the real drug, with no active ingredient
214367105|NCT07093450|OTHER|Educational Quality Improvement Intervention|The intervention will be delivered at the cluster level. It will include an initiation visit, when educational sessions and an operations manual will be delivered to the ICU. These will consist of cognitive aids for antimicrobial initiation and duration decision-making, based on recent recommendations from guidelines, societies and regulatory authorities. In this visit, an assessment of barriers and facilitators for implementation of the behavioral change will be done, so that local adaptations can be done by the clinicians championing the implementation. Additionally, monthly, one-day audits will be done, which will be used to provide feedback to the ICU during the intervention phase regarding the suggested recommendations for antimicrobial decision-making.
214367106|NCT07093112|DIETARY_SUPPLEMENT|Psychobiotic supplement|"The psychobiotic supplement consists of Bifidobacterium lactis CCT 7858 and Lactobacillus rhamnosus CCT 7863, at a final concentration of 1 x 10\^10 CFU/g (GABBIA® Biotechnology, Santa Catarina, Brazil).~The intervention will be administered once daily for 90 days, spanning the pre-season and start-season phases with an interval and restarting for 90 days until the end-season phase."
214367107|NCT07093112|DIETARY_SUPPLEMENT|Placebo|The placebo consists of maltodextrin. The intervention will be administered once daily for 90 days, spanning the pre-season and start-season phases with an interval and restarting for 90 days until the end-season phase.
214978405|NCT04642989|DRUG|Antibiotics|"Appropriate standard-of-care antibiotics as determined by the physician."
214978406|NCT04942704|OTHER|Non interventional Imaging - MRI|MRI Scanning using short protocols
214978407|NCT02171351|DEVICE|effect of neuromuscular electrostimulation (NMES)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuromuscular electrostimulation (NMES).
214978408|NCT02171351|DEVICE|effect of neuro electrostimulation (NES)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuro electrostimulation (NES)
214978409|NCT02171351|OTHER|effect of voluntary contractions (VC)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of voluntary contractions (VC)
214978410|NCT01587885|DRUG|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
214978411|NCT01587885|DRUG|Omeprazole 20 mg|Tablets, orally
214978412|NCT02517619|DRUG|Dexamethasone Phosphate Ophthalmic Solution|40 mg/mL
214978413|NCT02517619|DRUG|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate (1%)
214978414|NCT02880423|PROCEDURE|tubal ligation group II|"Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .~The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries"
214978415|NCT02880423|PROCEDURE|salpingectomy group I|women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
214978416|NCT02975596|OTHER|Awareness|Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.
214978417|NCT02975596|OTHER|Education|Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
214978418|NCT02975596|OTHER|Empowerment|"Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines."
214978419|NCT02975596|OTHER|Accessibility|Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
214367108|NCT07093229|OTHER|Ultrasound exam of quadriceps muscles (left/right) and gait analysis|"Ultrasound exam (initial and after 3 months) - with SonoScape S9Pro; the investigators exam the thickness of the quadriceps muscle group between the superficial fat-muscle interface and the cortex of the femur and calculate the quadriceps muscle index as sum of both muscle thickness RT and LT cm/height2 (m2). The exam is conducted by a qualified sonographer. The examination is carried out on a one-on-one basis in a private setting where only the participant and the sonographer are present.~Gait analysis with wireless system - BTS G-WALK; the investigators consider four gait parameters: Timed Up-and-Go (TUG) test, Symmetry index, Six Minutes Walking Test (6 MWT), and Walk cadence or average cadence (steps/min)."
214978420|NCT03243149|DEVICE|fMRI - GE Medical System|"Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.~The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy."
214978421|NCT00450957|DIETARY_SUPPLEMENT|lycopene|Given orally
214978422|NCT00450957|OTHER|pharmacological study|Correlative studies
214367109|NCT07093229|OTHER|Electrotherapy measures: transcutaneous nerve stimulation, ultrasound and low intensity laser; each one daily , applied on both lower limbs, for 10 days. Kinetic measures daily|The gait training is the distinguish aspect in rehabilitation program. Usually, KOA training include only kinetic measures, without gait control training
214367110|NCT07093229|OTHER|Gait training|This type of special kinetic training includes Frenkel exercises for lower limb muscles and virtual / mirror exercises for different types of gait
214367111|NCT07094529|BEHAVIORAL|Recumbent Exercise Bike to induce mild hypoglycemia|"The participant rides the recumbent exercise bike at their preferred speed and records the distance travelled until there is onset of mild hypoglycemia, determined by capillary blood glucose test result 3.0 to 3.8 mmmol/L.~Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams~The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes."
214491946|NCT06779370|DRUG|Calcium hydroxide|Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium hydroxide-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
214491947|NCT06830382|DIAGNOSTIC_TEST|Positron emission tomografy with [68Ga]Ga-ABY-025|Investigational Medicinal product (IMP):\[68Ga\]Ga-ABY-025 (all patients)
214491948|NCT06812104|DRUG|KK2845_1|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
214491949|NCT06812104|DRUG|KK2845_2|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
214978423|NCT05415306|BEHAVIORAL|Attention Bias Modification|Attention bias modification (ABM) is a procedure for treatment of depression, with the intention of supplementing cognitive behavioural therapy (CBT) or as a treatment on its own. ABM procedures modify attention biases in emotional disorders, resulting in subjects learning to deploy their attention toward the more positive stimuli (Jonassen et al., 2018). A computerized attention bias modification intervention for depression involves repeatedly redirecting the attention of the subject away from emotionally relevant threat cues, and towards neutral (non-threatening) stimuli (Amir et al., 2009). The location of the probe will replace the relatively positive stimulus in the pair with 100% probability.
214978424|NCT05415306|BEHAVIORAL|Deep-breathing training|In most deep breathing studies, participants are required to alter their breathing pattern to a specific frequency for a specific duration of time. In the present study, participants will be required to perform deep-breathing at a rate of 6 breaths per minute for 9 minutes.
214978425|NCT05415306|BEHAVIORAL|Sham Training|This condition is identical to the Attention Bias Modification condition with the except of the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
214978426|NCT01346865|DRUG|Cilostazol|Cilostazol 100mg bid
215086369|NCT03880838|BEHAVIORAL|Forks Over Knives Documentary|Participants will be mailed the documentary Forks Over Knives, which provides scientific arguments promoting a plant-based and whole foods diet. The behavioral effect of this documentary comes from watching the documentary and potentially choosing to order a free cookbook (participants are given this opportunity in the letter accompanying the documentary). The effect of the diet itself is not a central part of the intervention, as people can choose to adopt or not adopt any part of the diet.
215086370|NCT03880838|BEHAVIORAL|Commitment nudge|At the end of the letter promoting a plant-based diet, participants will be asked to write dates and personal signatures committing to watching the documentary. They will be asked to mail back this written commitment. Stating one's intentions to implement certain behavior is meant to increase the likelihood of follow-up behavior. This request might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
214491950|NCT06812104|DRUG|KK2845_3|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
214491951|NCT06812104|DRUG|KK2845_4|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
214491952|NCT02254746|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
214978427|NCT01346865|DRUG|Placebo|Placebo 1tablet bid
214978428|NCT03020485|OTHER|Isomaltulose|Isomaltulose is a disaccharide made up of one molecule glucose and fructose with a (α1-6) linkage.
214978429|NCT03020485|OTHER|Sucrose|Sucrose is normal table sugar
214367112|NCT07094529|BEHAVIORAL|Delaying food to induce mild hypoglycemia,|"At the study visit, in front of the study nurse, the participant takes their usual clinical care dose of sulfonylurea or basal insulin. If the participant's usual clinical care includes insulin with a rapid-acting component, then its dose is reduced based on the study protocol.~No food intake (water is allowed) until there is onset of mild hypoglycemia, determined by a capillary blood glucose test result 3.0 to 3.8 mmol/L.~Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams~The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes."
214367113|NCT07094581|DIAGNOSTIC_TEST|USG|Masseter Muscle Thickness and Internal Echogenic Bands Assessed by Ultrasonography
214367114|NCT07092943|DEVICE|Lung protective ventilation|The patient in this group will receive tidal volume at 6-8 ml/kg of ideal body weight with PEEP of 5 cm of H2O and plateau pressure will be kept less than 30cm of H2O.
214367115|NCT07092943|DEVICE|Driving pressure guided ventilation|They will receive tidal volume of 6-8 ml/kg of ideal body weight and initial PEEP of 5 cm of water. Principal investigator will then incrementally increase PEEP by 2 cm of water till a value 15 cm of water PEEP is reached or Plateau pressure becomes equal to 30 cm of water or driving pressure starts to increase or there is change in any hemodynamics. Each incremental PEEP will last for 3 respiratory cycles before moving on to next value. PEEP value with lowest driving pressure will then be selected for the duration of surgical procedure
214367116|NCT07094295|OTHER|perioperative blood transfusion|The PBT group received the red blood cell concentrate units during surgery and up to one month postoperatively.
214491953|NCT06435312|DRUG|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants
214978430|NCT05130424|DRUG|Herombopag|Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication
214978431|NCT06235112|DEVICE|Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment|The intervention involves electronic health record, email, or letter notification about the presence of coronary artery calcification on chest CT and recommendation of preventive therapy. This is based on results of the automatic detection of coronary artery calcification from AI device (software).
214978432|NCT02783612|OTHER|glucose buddy application|
214978433|NCT01058447|DRUG|AZD1981|Oral tablet, 250 mg, single dose
215086371|NCT03880838|BEHAVIORAL|Prevention nudge|As part of the letter promoting a plant-based diet, one paragraph will describe the risks of not taking action. This phrasing reframes the status quo as contributing to future loss (e.g., costs of medication and operations). In effect, the letter encourages participants to focus on preventing this loss by taking action. This additional text might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
215086372|NCT01875042|DEVICE|TENS|Transcutaneous electrical nerve stimulation
215086373|NCT01875042|DEVICE|Sham TENS|Sham Transcutaneous electrical nerve stimulation
215086374|NCT01565395|DRUG|Incobotulinum Toxin A|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
215086375|NCT01565395|DRUG|placebo|Sterile preservative free 0.9% saline
215086376|NCT04595877|DRUG|Dipyrone administration|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
215086377|NCT04595877|BEHAVIORAL|Pain assessment|"Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain)."
215086378|NCT04595877|BIOLOGICAL|beta-endorphin immunoreactivity|Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.
215086379|NCT04595877|OTHER|Placebo administration|Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
214978434|NCT00958074|DRUG|vorinostat|Given PO
214978435|NCT00958074|OTHER|flow cytometry|correlative study
214978436|NCT00958074|OTHER|laboratory biomarker analysis|correlative study
214978437|NCT03102762|DRUG|Botulinum Toxin Type A|Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
214978438|NCT03102762|DRUG|Normal saline|The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
215086380|NCT05332808|OTHER|questionnare|collecting data about treatment and quality of life
215086381|NCT05399004|OTHER|Survey Administration|Complete surveys
215086382|NCT01309776|DRUG|Tianeptine|week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
215086383|NCT01309776|DRUG|Escitalopram|week1 : 5mg/day q.d., week2: 10mg/day q.d.
215086384|NCT04902664|BEHAVIORAL|Patient education materials|Patients receive a text-message and email with educational materials about medical testing.
214679958|NCT02629601|BEHAVIORAL|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
214679959|NCT02629601|BEHAVIORAL|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
214679960|NCT02629601|BEHAVIORAL|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
214679961|NCT02629601|BEHAVIORAL|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
214978439|NCT00989885|OTHER|Questionnaire and polysomnography|Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
215086385|NCT04902664|BEHAVIORAL|Physician peer-comparison email|Physicians receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals.
215086386|NCT04902664|BEHAVIORAL|Physician education materials|Physicians receive reference materials on medical test interpretation and incidental findings.
215086387|NCT04902664|BEHAVIORAL|General visit preparation materials|Patients receive a text-message and email with general visit preparation tips.
215086388|NCT01441011|BEHAVIORAL|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
214367117|NCT07093645|DEVICE|SEL4@ll|SEL4@ll is a school-based digital intervention targeting students aged 10-16 (Primary and Secondary Education). It combines: (1) a serious game with five missions promoting SEL skills (1/week), playable online at home or school; (2) a digital teacher handbook with classroom activities used 1-2 times per week; and (3) online surveys to assess impact. The program lasts 8 weeks: 2 weeks for pre/post assessments and 6 weeks of gameplay and classroom sessions. Surveys are administered online (3 waves), and optional focus groups are conducted with a subsample of students. Teachers complete an online evaluation after implementation.
214367118|NCT07093671|OTHER|MBT + NBCI|The MBT for CHR-P intervention consists of 24 weekly individual psychotherapy sessions, supplemented by monthly mentalization-based family therapy sessions. Both patient and family sessions will last 50 minutes. These psychotherapeutic sessions will complement those received though NBCI by strengthening mentalizing abilities aiming to reduce or prevent detrimental outcomes, by prohibiting or restricting some usual techniques in NBCI treatment (e.g., interpretation, cognitive challenge and Socratic dialogue) and by emphasizing certain techniques (e.g., empathic validation, active management of emotional arousal) which are only sporadically and irregularly used during NBCI treatment. Overall, the program is designed to improve patients' capacity to understand their own and others' mental states and, within interpersonal settings, how these patterns contribute to conflict and psychological distress.
214367119|NCT07093788|DEVICE|super high-pressure balloon|preparation strategy for calcified lesions after unsatisfactory dilation
214367120|NCT07093788|DEVICE|intravascular lithotripsy (IVL)|preparation strategy for calcified lesions after unsatisfactory dilation
214367121|NCT07092774|DEVICE|Ablation|Ablation procedure using the Thermocool Smarttouch SF
214978440|NCT06029764|PROCEDURE|extended one-level interbody fusion|For patients who have vacuum signs in the intervertebral disc adjacent to the surgical segment but are asymptomatic and not unstable, the intervertebral fusion surgery is extended to one segment and followed up immediately after surgery, 3 months, 6 months, and annually within 1 to 5 years. Take lumbar spine MR to determine the degree of degeneration progression of adjacent segments and whether revision surgery is needed. Take X-rays of the lumbar spine in frontal and lateral + flexion and extension positions, and CT-three-dimensional reconstruction to judge the bony fusion of the intervertebral fusion.
214978441|NCT02433847|DRUG|Mosapride|
214978442|NCT01228006|DIETARY_SUPPLEMENT|NatusGerin|1 capsule, 2 times a day.
214367122|NCT05655026|DEVICE|NIV, HFNO|Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.
214367123|NCT03577067|PROCEDURE|Liver resection for primary and secondary disease|Liver resection in parenchyma-sparing setting for primary and secondary disease
214367124|NCT00129922|DRUG|paclitaxel|
214491954|NCT06828497|PROCEDURE|Technique of posterior quadratus lumborum block (QL 2 block):|The patient was in the lateral position, and the US probe was placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe was placed in the midaxillary line, and at this juncture, the layers of abdominal layers started to taper. When the probe was placed in the posterior axillary line as per the posterior approach, sonoanatomy showed first the transversus abdominis disappearing, then the internal oblique and external oblique forming aponeurosis, and the appearance of the QL muscle was noticed. The posterior aspect of the QL muscle was confirmed, and a 22-G block needle was guided, in plane, and the needle tip was inserted into this aspect of the QL muscle. Following aspiration, the local anesthetic was injected into the lift behind the QL muscle. The same procedure was performed bilaterally
214679962|NCT00205504|DRUG|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
214679963|NCT04175197|DEVICE|Drug Coated Balloon|Legflow Drug Coated Balloon
214679964|NCT03537768|DRUG|Ulipristal Acetate|UPA Tablet
215086389|NCT01441011|BEHAVIORAL|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
215086390|NCT03143998|DRUG|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
215086391|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
215086392|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, no irradiation|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
214367125|NCT00129922|DRUG|Fluorouracil|
214367126|NCT00129922|DRUG|Epirubicin|
214367127|NCT00129922|DRUG|Cyclophosphamide|
214367128|NCT05139667|DRUG|Corticosteroid Topical|topical tacrolimus and corticosteroids
214367129|NCT04904770|DEVICE|Scoop stretcher|Already included in arm/group description
214367130|NCT04904770|DEVICE|Vacuum mattress|Already included in arm/group description
214367131|NCT01194570|DRUG|Ocrelizumab|Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.
214367132|NCT01194570|OTHER|Placebo|Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.
214679965|NCT03537768|DRUG|Levonorgestrel|LNG Tablet
214679966|NCT03537768|DRUG|Levonorgestrel|LNG Tablet (x2)
214679967|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
215086393|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
215086394|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, no irradiation|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
215086395|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
214367133|NCT06009601|DIAGNOSTIC_TEST|Pectus Study Form|"Pectus study forms consisting of clinical and radiological measurements of patients aged 3-18 years who applied to the outpatient clinic with chest deformity will be filled in in detail.~In addition, this study form includes 'Quality of Life Evaluation Form in Pectus Deformity', 'Social Comparison Scale', 'Sleep Disorder Scale for Children', 'Anxiety Disorders Screening Scale in Children', 'Pediatric Quality of Life Questionnaire' designed for patients and their relatives. PedsQL)', 'SRS-22 Patient Questionnaire', 'Beck Anxiety Scale' and 'Informed Consent Form' designed for patients and their relatives."
214367134|NCT06009601|DIAGNOSTIC_TEST|Adams Test|Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 7 degrees in patients who meet the inclusion criteria will be included in the study by filling out an informed consent form
214367135|NCT06009601|DIAGNOSTIC_TEST|Scoliosis Graphy|"ATR (angle of trunk rotation) values above 7 degrees on bunnell scoliometer were determined. Afterwards, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis graphy will be requested.~Coronal, sagittal balance; coronal and sagittal cobb angles will be measured from posterior-anterior (PA) (posterior-anterior) and lateral (lateral) scoliosis radiographs."
214367136|NCT06009601|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~There are 2 types of disorders that cause problems with air moving in and out of the lungs:~Obstructive. This is when air has trouble flowing out of the lungs due to airway resistance. This causes a decreased flow of air.~Restrictive. This is when the lung tissue and/or chest muscles can't expand enough. This creates problems with air flow, mostly due to lower lung volumes."
214367137|NCT01337674|DRUG|MK-4618|Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
214367138|NCT01337674|DRUG|Placebo for MK-4618|Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
214367139|NCT01337674|DRUG|Metoprolol|Previously prescribed daily dose of open-label metoprolol for the duration of the study
214367140|NCT01337674|DRUG|Amlodipine|Previously prescribed daily dose of open-label amlodipine for the duration of the study
214491955|NCT06828497|PROCEDURE|Technique of erector spinae plane block:|The patient will be placed in a sitting position. Under aseptic conditions, a high-frequency linear transducer will be placed on the spinous process at the T8 level on the parasagittal plane and then slide 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle. Using the in-plane technique, the needle was advanced between the transverse process and erector spinae muscle. The correct location was confirmed, and local anesthetic was injected between the muscle and transverse process. The same procedure was performed bilaterally
214491956|NCT05277519|DEVICE|Vibrations|Sequenced muscle vibrations during 30 min., 3 times a week during 5 weeks
214491957|NCT06902051|DEVICE|Lateral Decubitus position|Lateral Decubitus position with a special device
214491958|NCT06902051|DEVICE|Lateral Decubitus device|Lateral Decubitus postion with a special device
214679968|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan|Pre-treatment scan
214978443|NCT01228006|OTHER|Placebo capsules|1 capsule, 2 times a day
214978444|NCT01596569|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.
214978445|NCT01596569|BEHAVIORAL|Cognitive Intervention|"Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.~All participants receive weekly cognitive treatment sessions for 10 weeks."
214978446|NCT02779491|BEHAVIORAL|5-a-day fruit and vegetable mobile phone application|5-a-day fruit and vegetable mobile phone application
214978447|NCT03309553|OTHER|Current Primary Care Referral Process|Children who screen positive for hearing loss will receive the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
214978448|NCT03309553|OTHER|Telemedicine Referral Process|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
214978449|NCT04117022|DIETARY_SUPPLEMENT|DVS supplementation|Oral supplement. Each subject will be given the carotenoid supplement of DVS formula. The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland). Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA. To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
214978450|NCT06144255|DRUG|Intranasal insulin|"Enrolled Participants for this trial will come for 3 study visits. The doses will be administered in varying order: participants will be randomized to one six possible permutations of the intranasal study doses (0, 500, 1000 U) of intranasal insulin at each visit.~Participants will undergo a fMRI scan before and after receiving intranasal doses. Additionally, participants will have blood samples taken."
214978451|NCT00752089|DRUG|NaF/ KNO3/isopentane Dentifrice|Experimental toothpaste
214367141|NCT00006364|DRUG|omacetaxine mepesuccinate|Given IV or SC
214367142|NCT00006364|OTHER|pharmacological study|Correlative studies
214367143|NCT00006364|OTHER|laboratory biomarker analysis|Correlative studies
214367144|NCT04123678|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|AI-based decision support tool
214367145|NCT04021017|DRUG|Estradiol Hemihydrate Transdermal System|Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
214367146|NCT04805060|DRUG|TQB2858 injection|TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
214367147|NCT06370364|OTHER|Nurses' Practice of Safe Blood Transfusion|Nurses' Practice of Safe Blood Transfusion
214679969|NCT03463694|OTHER|Na Cl solution|\~2.6% NaCl solution prepared from sea salt
214978452|NCT00752089|DRUG|NaF/KNO3 Dentifrice|Experimental toothpaste
214978453|NCT00752089|DRUG|NaF Dentifrice|Active comparator
214978454|NCT00752089|OTHER|Placebo Dentifrice|Placebo comparator
214978455|NCT03962608|DEVICE|Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
214978456|NCT03962608|DEVICE|Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
214978457|NCT02018133|DRUG|Vitamin D 2mg daily for 2 weeks oral paricalcitol|vitamin D 2 capsules daily
214978458|NCT02018133|DRUG|Placebo|placebo 2 capsule daily
214978459|NCT00028717|BIOLOGICAL|filgrastim|
214978460|NCT00028717|BIOLOGICAL|rituximab|
214978461|NCT00028717|DRUG|cyclophosphamide|
214978462|NCT00028717|DRUG|doxorubicin hydrochloride|
214978463|NCT00028717|DRUG|prednisone|
214978464|NCT00028717|DRUG|vincristine sulfate|
214978465|NCT04927910|OTHER|Ture self-acupressure|8-week intervention of self-acupressure on acupoints
214978466|NCT04927910|OTHER|Sham self-acupressure|8-week intervention of self-acupressure on non-acupoints
214978467|NCT04927910|OTHER|Usual care|routine care by hospitals
214978468|NCT05635903|PROCEDURE|Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Continuous nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
214978469|NCT05635903|PROCEDURE|Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser|Intermittent nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
214978470|NCT05635903|PROCEDURE|Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser|standard intermittent nebulisation of 0.9% saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser
214978471|NCT01248897|OTHER|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
214978472|NCT03572712|OTHER|No Interventional study|every patient will be monitored with a blood gase, a nocturnal oximetry and a transcutaneous capnography
214978473|NCT00190268|DRUG|3,4-diaminopyridine|3,4-diaminopyridine
214978474|NCT00158353|BEHAVIORAL|GirlPOWER! mentoring program|GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.
214367148|NCT02697279|PROCEDURE|Traditional Incision and Drainage.|Control Group- Standard treatment of a simple cutaneous abscess with traditional I\&D technique with or without packing utilizing a standard I\&D kit.
214367149|NCT02697279|PROCEDURE|Loop drainage|Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I\&D kit and the cuff of a sterile glove for a loop device.
214367150|NCT00503022|DRUG|ACZ885|
214367151|NCT04649502|COMBINATION_PRODUCT|Metformin|Metformin in combination with doxycycline
214679970|NCT02234583|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
214679971|NCT02801097|DRUG|RRx-001|
214679972|NCT02801097|DRUG|Irinotecan|
214679973|NCT01740440|DEVICE|BMR Face|BMR Face used in accordance with manufacturer IFU
214978475|NCT00158353|BEHAVIORAL|Traditional mentoring|Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
214978476|NCT03961867|DRUG|Docetaxel|"S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Docetaxel 40mg/m2/3w from the second to the seventh cycles."
214978477|NCT03961867|DRUG|Oxaliplatin|"S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Oxaliplatin 130mg/m2/3w from the first to the eight cycles."
214978478|NCT03318263|DIAGNOSTIC_TEST|next-generation sequencing (NGS)|ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
215086396|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, no irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
215086397|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, irradiation|Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
214367152|NCT05654792|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation in cases of severe aortic stenosis
214367153|NCT03571958|BEHAVIORAL|BMI|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
214978479|NCT04458896|BEHAVIORAL|Stand When You Can|"Intervention strategies can be customized to different environments based on consultation with management. Some strategies will be mandatory:~* Education session: group information session during the first week of the intervention (30min) to discuss sedentary time (ST), health risks, strategies to reduce ST, goal setting, \& the identification of barriers and motivators to reducing ST. Group discussion will be encouraged to increase self-motivation and self-efficacy. An information workbook will be given to each attendee for their personal use and goal setting.~* Point of decision prompts (ie: signs that encourage standing; see attachments) will be placed in common areas of the facility, and/or given as pamphlets to residents.~* An intervention package will be provided to the Activity Coordinator and Manager of the facility. This package will provide an introductory letter along with materials to promote reduced sedentary time in the facility"
214367154|NCT04436263|BEHAVIORAL|Supplement|A sufficient quantity of the winery by-products will be extracted on an industrial scale and capsules will be produced, each one containing 110mg of phenolic compounds (gallic acid equivalents).Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
214367155|NCT04436263|BEHAVIORAL|Placebo|A look-alike placebo containing maltodextrin will be prepared.Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
214367156|NCT05115344|DRUG|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
214367157|NCT05115344|DRUG|flonoltinib 50mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
214367158|NCT05115344|DRUG|flonoltinib 100mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
214367159|NCT05115344|DRUG|flonoltinib 150mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
214367160|NCT05115344|DRUG|flonoltinib 225mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
214367161|NCT05115344|DRUG|flonoltinib 325mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
214491959|NCT06931054|OTHER|Acupuncture|"The principle of traditional acupuncture and auricular acupressure is to alleviate withdrawal symptoms. Acupuncture therapy for smoking cessation is generally considered safe, but some people may experience mild side effects. These can include soreness, bruising, or bleeding at the needle insertion sites, dizziness, fatigue, or lightheadedness after treatment. Occasionally, individuals may feel nausea or discomfort during or after the session. In rare cases, infections can occur if proper hygiene protocols are not followed. Overall, most side effects are temporary and resolve shortly after treatment.~Primary Acupoints The selection of body acupuncture points follows specific guidelines\[11-12\], including three head points (Baihui, Shenting, Yintang ), three hand points (Neiguan, Kongzui, Lieque), and three foot points (Zusanli, Sanyinjiao, Taichong). For auricular acupoints, selection is based on corresponding areas (Mouth), syndrome differentiation of zang-fu organs and meridians (Hea"
214679974|NCT04723108|OTHER|Destek V4 Virtual Reality Headset|The DESTEK V4 is a smartphone VR headset made by DESTEK, a manufacturer based in the US. This mobile virtual reality headset is compatible with most iOS and Android smartphones, as long as their screen size is between 4.5 and 6.
214679975|NCT00086710|DRUG|Fuzeon|
214978480|NCT02227641|BIOLOGICAL|CMV/EBV specific T-cell|Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
214978481|NCT05671081|DRUG|Dexmedetomidine|patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 0.5 μg/kgof Dexmedetomidine for each injection
214978482|NCT05671081|DRUG|Magnesium sulfate|patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 2 mg/kg Magnesium sulfate for each injection
214978483|NCT05671081|DRUG|Narcotic Analgesics|patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
214978484|NCT00000755|BIOLOGICAL|rgp120/HIV-1MN|
214978485|NCT00000755|DRUG|Zidovudine|
214978486|NCT03114293|BEHAVIORAL|Smartphone App|The app includes an EBPI and physical activity feedback
214978487|NCT02930785|DRUG|BAY987517|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-104)"
214978488|NCT05945095|OTHER|Gum chewing group|The mothers in the experimental group, on the other hand, will chew sugar-free gum for at least 15 minutes, starting from the second hour after the surgery.
214978489|NCT00052104|BEHAVIORAL|Cognitive-Behavioral Family Systems Intervention|
214978490|NCT02731196|BEHAVIORAL|Exercise Intervention|Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
214978491|NCT00231790|DRUG|MK-0634 50 mg|one capsule orally, once daily in morning
214978492|NCT00231790|DRUG|MK-0634 125 mg|one or three capsules orally, once daily in morning
214978493|NCT00231790|DRUG|Placebo for MK-0634|one, two, three or four capsules orally once daily in morning
214978494|NCT05232227|DRUG|Primaquine double dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets
214978495|NCT05232227|DRUG|Primaquine single dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US
214978496|NCT00695227|DIAGNOSTIC_TEST|Screening for Barrett's Esophagus|
215086398|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, no irradiation|Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
214978497|NCT06238414|OTHER|Early psychotherapeutic intervention|The case group will receive an 8-session early psychological intervention The intervention consists of eight face-to-face sessions that include techniques from the dialectical behavioral (DBT), mentalization based therapy orientation (MBT), and narrative approach, concretely an adaptation from the ASSIP therapy. The sessions will be conducted by a clinical psychologist with expertise in psychotherapy. There will be two 60-minutes sessions per week.
214978498|NCT03027947|DEVICE|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
215086399|NCT03899064|DRUG|Challenge: Control, irradiation|No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
215086400|NCT00607113|DRUG|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
215086401|NCT00607113|DRUG|RAD001|10 mg By Mouth Daily For 21 Days
215086402|NCT01442792|DRUG|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
214679976|NCT05178953|DRUG|Zinc Sulfate 220 mg Capsules|Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
215086403|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
215086404|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
215086405|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
215086406|NCT00784485|DRUG|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
215086407|NCT01550393|GENETIC|proteomic profiling|
215086408|NCT01550393|OTHER|enzyme-linked immunosorbent assay|
215086409|NCT01550393|OTHER|laboratory biomarker analysis|
215086410|NCT01550393|OTHER|medical chart review|
215086411|NCT02127294|DEVICE|transcatheter patent foreman ovale closure|
215086412|NCT04459975|OTHER|Non interventional study|"Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient.~Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis"
214367162|NCT02617875|OTHER|conventional EMS physician|A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.
214367163|NCT02617875|OTHER|tele-EMS physician|The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
214367164|NCT02644590|DRUG|Melatonin|Detailed in arm description
214367165|NCT03790995|PROCEDURE|Robot assisted laparoscopic prostatectomy|
214978499|NCT05353088|OTHER|scapular stabilization|Scapular stabilization exercise aims to restore scapular position, orientations, motor control of muscles, and movement pattern, thereby attaining stability of scapula for better kinematics of shoulder.scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II)
215086413|NCT04095130|DIAGNOSTIC_TEST|23Na Magnetic resonance imaging|Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
214367166|NCT05593757|DRUG|Quinidine|Oral quinidine
214367167|NCT05593757|DRUG|Verapamil|Oral verapamil
214367168|NCT02119143|DIETARY_SUPPLEMENT|vitamines and minerals|given for 24 weeks, after 4 week wash out of all supplements and dietetic products
214367169|NCT02119143|DIETARY_SUPPLEMENT|placebo|given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
215086414|NCT00031460|DRUG|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m\^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
215086415|NCT00031460|DRUG|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
215086416|NCT02210832|BEHAVIORAL|Best practices|
215086417|NCT02210832|BEHAVIORAL|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
215086418|NCT01401699|DEVICE|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
215086419|NCT06337591|PROCEDURE|VI-RADS|Patients with suspected bladder cancer underwent multiparametric magnetic resonance imaging (mMRI) and vescical imaging reporting and data system (VI-RADS) score calculation. After trans-urethral resection of bladder (TURB), the results of biopsy were compared to the VI-RADS score to verify their concordance.
215086420|NCT01547091|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
215086421|NCT01547091|DRUG|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
215086422|NCT01547091|BIOLOGICAL|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
215086423|NCT03987906|BEHAVIORAL|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
215086424|NCT01722292|DRUG|LY2940680|Administered orally
215086425|NCT01722292|DRUG|Carboplatin|Administered IV
214679977|NCT05178953|DRUG|Pentoxifylline|Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
214679978|NCT05498961|OTHER|Gallstone characteristics|stone size, number, the thickness
214978500|NCT05353088|OTHER|Thoracic extension exercises|Thoracic extension involves concurrent posterior rotation (external torsion) and depression of the posterior ribs with elevation of the anterior ribs. Bending to the side is a combination of spinal segments side bending, ribs on the same come together while ribs on the opposite side separate.Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
214978501|NCT04232007|DEVICE|closed-loop system for vasopressor administration|closed-loop system for vasopressor administration
214978502|NCT01658280|DEVICE|EBUS-TBNA|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
215086426|NCT01722292|DRUG|Etoposide|Administered IV
215086427|NCT01722292|DRUG|Placebo|Administered orally
215086428|NCT04397458|DRUG|Saline|0.9% saline on each side
215086429|NCT04397458|DRUG|Bupivacaine|0.25% bupivacaine (50mg) on each side
215086430|NCT04397458|DRUG|Dexamethasone|3mg preservative-free dexamethasone on each side
214978503|NCT05493826|OTHER|No intervention|Non-interventional study based on secondary use of hospital medical record
214978504|NCT06323759|OTHER|educational intervention|In antenatal breastfeeding education: Theoretical contributions on BF (physiology of lactation, frequency complications), hands-on workshop, Provision of educational tools to promote the learning environment: breastfeeding booklet, educational video on breastfeeding, link to a BF specific platform, access to a telephone platform. In short-term postnatal breastfeeding education: Three systematic fallow-up at home or at midwives' office are planned. During these visits, a time of systematic discussion is planned with the nursing mothers. Their knowledge and ability to manage their breastfeeding are checked. The physiology of lactation, the gestures of breastfeeding and the occurrence of common complications are systematically recalled by the liberal midwife. In long-term postnatal breastfeeding education: Invitation of nursing mothers to breastfeeding information meetings at 2nd and 4th month after birth. These meetings will be facilitated either by the liberal midwives.
214978505|NCT00001566|BIOLOGICAL|therapeutic autologous dendritic cells|3 syringes containing 1 x 10\^6peptide pulsed dendritic cells
214978506|NCT00001566|DRUG|indinavir sulfate|Oral dose, 350 mg/m\^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
214978507|NCT00001566|PROCEDURE|peripheral blood stem cell transplantation|Harvested autologous T cells, minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
215086431|NCT02080260|DRUG|regorafenib|Single agent drug therapy with regorafenib
215086432|NCT06491810|OTHER|Arm crank exercise|The arm ergometer exercise will be the only intervention implemented during the study.
215086433|NCT02968381|BEHAVIORAL|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
215086434|NCT02968381|BEHAVIORAL|Control Condition|Telephone coaching using standard cognitive behavioral methods
215086435|NCT00596583|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
215086436|NCT00596583|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
215086437|NCT01614171|BIOLOGICAL|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
214978508|NCT01088087|DIETARY_SUPPLEMENT|colostrum|colostrum, 2g, 2 times a day, for 3 weeks
215086438|NCT05462639|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
215086439|NCT03075995|OTHER|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
215086440|NCT00697294|DIETARY_SUPPLEMENT|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
215086441|NCT06544031|BEHAVIORAL|Healthy Nutrition Education Program|The program consists of two sessions totaling 2 hours. The first session includes a traditional presentation on healthy nutrition, and the second session involves an interactive question and answer segment. The intervention aims to improve nutritional knowledge and attitudes towards healthy eating among elderly residents.
214367170|NCT00432874|PROCEDURE|wound hydration method|Anterior vs lateral wound hydration
215086442|NCT02008422|DRUG|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
215086443|NCT02008422|DRUG|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
215086444|NCT02008422|DRUG|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
215086445|NCT04345172|DEVICE|sub-Tenon's block with a lacrimal dilator group or a Wescott scissors|"Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space."
215086446|NCT01650740|DRUG|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
214367171|NCT00908492|BEHAVIORAL|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
214367172|NCT00908492|BEHAVIORAL|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
214367173|NCT05265663|RADIATION|stereotactic ablative radiotherapy|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days within a maximum overall treatment duration of 14 days.
214367174|NCT05810246|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory)|"68Ga-NY104 PET/CT is expected to be completed within 21 days following screening. Participants will be administered a single, intravenous bolus of 68Ga-NY104 (1.8-2.2 MBq per kilogram bodyweight). PET/CT scanning will occur at 45 -75 minutes following injection of 68Ga-NY104.~Conventional imaging should be performed within one month from 68Ga-NY104 PET/CT. It includes contrast-enhanced MRI of brain and contrast-enhanced CT of abdomen and pelvis.~68Ga-NODAGA-LM3 PET/CT is optional in patients with evidence of or in suspicion of pheochromocytoma, paraganglioma, or pancreatic neuroendocrine tumor. They are encouraged to undergo exploratory 68Ga-NODAGA-LM3 PET/CT for better evaluation of neuroendocrine tumors. The decision, however, is up to the participants. 68Ga-NODAGA-LM3 PET/CT should be performed within one month after 68Ga-NY104 PET/CT. The details of 68Ga-NODAGA-LM3 PET/CT are similar to 68Ga-NY104 PET/CT."
214978509|NCT05885932|PROCEDURE|Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor|All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
214978510|NCT05885932|DRUG|Aspirin and clopidogrel or ticagrelor|All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
214978511|NCT05885932|PROCEDURE|mono anti-platelet therapy|mono anti-platelet therapy
214978512|NCT00383799|DRUG|iv Amiodarone|
214978513|NCT00383799|DRUG|iv Procainamide|
214978514|NCT06317012|PROCEDURE|Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate|"Le Fort I osteotomy will be performed with the aid of a surgical guide through the mucosal incision at the maxillary vestibule region, providing adequate surgical exposure.~The planned position will be obtained using a customized titanium plate for precise maxillary position and fixation as planned virtually on the software."
214978515|NCT00787826|BIOLOGICAL|Live Francisella Tularensis Vaccine|"Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20."
214978516|NCT05398107|BEHAVIORAL|Experimental: Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design aimed at promoting maternal mental health and supportive parenting. The BEAM Program app is hosted on the University of Manitoba secure servers and is designed/managed by Tactica Interactive. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or Doctoral-Level Clinical Psychology Student) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in a prior iteration of the BEAM program. Parent coaches will engage with participants on the community peer support forum and will also attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve symptoms of anxiety and depression as well as parenting skills, and will emphasize self-compassion, effective communication practices, and social support networks.
214978517|NCT05398107|BEHAVIORAL|Control: MoodMission|"MoodMission will be used as our Standard of Care control group. MoodMission is an app based on CBT principles which creates tailored missions for mothers. These missions are based on self-reported mood and are aimed to improve mental health symptoms."
214978518|NCT04768088|OTHER|Falling Training|For the falling training, participants will be instructed to initially land softly with increased knee and hip flexion and then smoothly fall to the direction of the movement while transferring the weight from the feet to the hands and subsequently to the lateral trunk and hip. The training program includes three one-hour training sessions over a week with one or two days between two sessions. Each training session will begin with a warm-up protocol. Participants will progressively increase the task difficulty and decrease the thickness of the mat. For each training session, participants will perform a minimum of one successful practice trial for each task difficulty and each landing direction on the thicker mat and then complete a minimum of three successful practice trials for each task difficulty and landing direction on the thinner mat. The last training session involves falling on a 0.5-inch mat, which is the same as the surface for the post-training and retention assessments.
214978519|NCT02917746|DRUG|Imiquimod|Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
214978520|NCT02917746|PROCEDURE|Large Loop Excision of the Transformation Zone|Patients in this group are treated with LLETZ.
214978521|NCT01153919|BIOLOGICAL|romiplostim|Given subcutaneously
214978522|NCT01153919|DRUG|ribavirin|Given orally
214978523|NCT01153919|OTHER|placebo|Given subcutaneously
215086447|NCT01650740|DRUG|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
214367175|NCT04968691|OTHER|Telerehabilitation based exercise treatment|The telerehabilitation group will be shown how to do the exercises online by the researcher before each session, 3 sessions a week for 6 weeks, with mobile telecommunication applications, and it will be ensured that the patients do the exercises correctly and are followed up. In addition, at the beginning of each week, videos with the exercise content of that week will also be sent.
214367176|NCT04968691|OTHER|Home based exercise treatment|n the study, exercise cards were given to the control group and the exercise treatment they were asked to do at home 3 sessions a week for 6 weeks
214367177|NCT00752843|DRUG|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
214978524|NCT01153919|BIOLOGICAL|PEG-interferon alfa-2a|Given subcutaneously
214367178|NCT02943850|BIOLOGICAL|Stem cell (HPC) implantation|All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
214367179|NCT02943850|DEVICE|Stereotactic surgical device|A newly developed stereotactic frame is being evaluated as a part of this trial
214367180|NCT01308606|DRUG|TMC435 HPMC capsule|Single intake of one 150-mg capsule without food
214367181|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after high-fat breakfast
214367182|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule without food
214367183|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after standardized breakfast
214367184|NCT01308606|DRUG|TMC435 gelatin capsule|Single intake of one 150-mg capsule without food
214367185|NCT02355067|BEHAVIORAL|Social Media Intervention|These women will participate in the intervention through the online Facebook group.
214367186|NCT02355067|BEHAVIORAL|Traditional In-Person Intervention|These women will participate in the intervention through a traditional weekly meeting of a group in-person.
214978525|NCT01153919|OTHER|laboratory biomarker analysis|Correlative studies
214978526|NCT03361046|DEVICE|Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)|Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses
214978527|NCT02914834|OTHER|Acupuncture|Standardized acupuncture treatment administered for 30 minutes each session
214978528|NCT02914834|OTHER|Non-pain related video health education|Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
214978529|NCT05748899|BEHAVIORAL|Ujjayi pranayama|this group will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
214978530|NCT01213381|DRUG|Iniparib (SAR240550 - BSI-201)|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
214978531|NCT01213381|DRUG|Gemcitabine|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
214978532|NCT01213381|DRUG|Carboplatin|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
214978533|NCT03060473|DRUG|Azithromycin|Azithromycin 1 gm PO once
214978534|NCT03060473|DRUG|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
214978535|NCT03060473|DRUG|Ampicillin|Ampicillin 2 gm IV every 6 hours for 2 days
214978536|NCT03060473|DRUG|Amoxicillin|Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
214978537|NCT02172976|DRUG|Gemcitabine|
214978538|NCT02172976|DRUG|Oxaliplatin|
214978539|NCT02172976|DRUG|5-Fluorouracil|
214978540|NCT02172976|DRUG|Irinotecan|
214978541|NCT02172976|DRUG|Natriumfolinate|
214978542|NCT00975416|BEHAVIORAL|Cognitive Behavioral Therapy|Intranasal oxytocin given in the context of cognitive behavioral therapy
214978543|NCT00975416|DRUG|Intranasal Oxytocin|Intranasal oxytocin given in the context of cognitive behavioral therapy
214978544|NCT00975416|DRUG|Placebo|Placebo given in the context of cognitive behavioral therapy
214978545|NCT00109096|DRUG|Pemetrexed|
214978546|NCT01653275|OTHER|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
214978547|NCT03037840|DEVICE|Low intensity amplitude-modulated RF EMFs|Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
214978548|NCT04301973|OTHER|Stool collection|There is no intervention with a product in this study. The healthy subject has just to come 2 times in the clinical trial unit for clinical exam including urinary pregnancy test, fill life habits and diet questionnaires, and provide one stool sample for the 2nd visit, after 2 weeks of alimentary restrictions.
214978549|NCT05812248|DIAGNOSTIC_TEST|Perioperative cardiac biomarker measurement|High-sensitivity cardiac troponin T is measured within 7 days prior to surgery and at day 1 and day 2 after surgery. N-terminal pro-B-type natriuretic peptide is measured within 7 days before surgery.
214978550|NCT01690663|DRUG|Bupivacaine 0.25%|
214978551|NCT01690663|DRUG|Dexamethasone|
214978552|NCT01690663|DRUG|normal saline|placebo
214978553|NCT03555149|DRUG|Regorafenib|Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
214978554|NCT03555149|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
214978555|NCT03555149|DRUG|Imprime PGG|Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
215086448|NCT01650740|OTHER|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
215086449|NCT01570049|DRUG|Bendamustine|for injection
215086450|NCT04113460|OTHER|Yoga|Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
215086451|NCT05351268|RADIATION|Radioactive seed brachytherapy|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
215086452|NCT03344627|DRUG|Meropenem standard dose|"* Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection."
215086453|NCT03344627|DRUG|Meropenem high dose|"* Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection"
215086454|NCT00592332|DRUG|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
215086455|NCT00592332|OTHER|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
215086456|NCT00471887|BIOLOGICAL|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
215086457|NCT03150628|DRUG|Perioperative chemotherapy|Perioperative chemotherapy
215086458|NCT03150628|PROCEDURE|Cytoreduction|Cytoreductive surgery
215086459|NCT03150628|DRUG|HIPEC|Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
215086460|NCT02442258|DRUG|ABT-493|A single dose of ABT-493 will be given orally in combination with ABT-530.
215086461|NCT02442258|DRUG|ABT-530|A single dose of ABT-530 will be given orally in combination with ABT-493.
215086462|NCT03354624|DRUG|Sterile solutions of recombinant human nerve growth factor (NGF)|The intramuscular injections of NGF cause muscle soreness.
215086463|NCT04306939|OTHER|venipuncture|Research blood collection is also an option via venipuncture if the subject is not scheduled for clinical testing. This will also be limited to 21cc of blood, up to 4 time a year, and with the approval of the attending physician.
215086464|NCT04306939|BEHAVIORAL|Questionnaires|PROMIS-43 Profile, PROMIS-29 Profile, Global Health Scale and Hospital Anxiety and Depression Scale (HADS). Additional assessments can be approved and administered per specific disease sub-category.
215086465|NCT04306939|OTHER|Additional Sample Collections|We may also contact subjects to request additional blood, saliva, cheek swab, hair, urine, or stool with their permission. This will be limited to no more than 4 teaspoons of blood and will happen no more than 4 times per year.
214367187|NCT00800839|DRUG|Busulfan|Starting dose of 32 mg/m\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
214978556|NCT03555149|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
214978557|NCT03555149|DRUG|Isatuximab|Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
214978558|NCT03555149|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
214978559|NCT03555149|DRUG|Idasanutlin|Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
214978560|NCT03555149|DRUG|AB928|AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
214978561|NCT03555149|GENETIC|LOAd703|LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
214978562|NCT04244136|DEVICE|contrast CT|contrast CT abdomen fir measurement of the volume of expected residual normal renal tissue before surgery
214978563|NCT00706316|BIOLOGICAL|EBV-Specific CTLs and CD45 Mab|"One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2"
214978564|NCT05480059|OTHER|A questionnaire|A Questionnaire-based Assessment of the Psychiatric Co-morbidities and Health-related Quality of life in Patients with Irritable Bowel Syndrome
214978565|NCT03876925|DRUG|CT053PTSA|Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
215086466|NCT05693792|OTHER|Observational|No treatment regimen will be deployed in this follow-up study.
215086467|NCT02847559|BIOLOGICAL|Bevacizumab|Given IV
215086468|NCT02847559|PROCEDURE|Electric Field Therapy|Undergo electric field therapy using Optune device
215086469|NCT02847559|DEVICE|NovoTTF-200A Device|Undergo electric field therapy using Optune device
215086470|NCT02847559|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
215086471|NCT06581133|DEVICE|Alarm system|Generic alarm system programmed to sound during the night to try to induce arousals from sleep.
215086472|NCT05467371|BEHAVIORAL|Parenting Action Plan|The parenting action plan a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby.
215086473|NCT05467371|BEHAVIORAL|Safe Kids Home Safety Checklist|Safe Kids created a home safety checklist to help keep kids safe, room by room.
215086474|NCT05662852|BIOLOGICAL|Tdap|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Suspension manufactured by Sanofi Pasteur
215086475|NCT01912690|OTHER|aerobic training|
215086476|NCT01912690|OTHER|aerobic and strength training|
214367188|NCT00800839|DRUG|Fludarabine|Dose of 40 mg/m\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
214978566|NCT04451018|OTHER|evaluation of arterial anomalies in upper limbs|evaluation of arterial anomalies in upper limbs with doppler ultrasound
214978567|NCT03352284|DEVICE|Straumann Pure Ceramic Implant|The surgical technique begins with the lift of a vestibular mucoperiosteal flap respecting the papillae of the adjacent teeth. After the alveolar bone is exposed, the sequence of drilling and placement of the intra-bone fixation are carried out. In case of fenestrations or dehiscence, they are treated by xenograft and collagen-absorbable membrane. Once the implant is placed, a healing cap or provisional prosthesis is placed depending on the torque achieved. Finally, the flap is replaced and sutured.
214978568|NCT05284175|DRUG|Orelabrutinib|Orelabrutinib, orally, 50 mg QD
214978569|NCT06330714|OTHER|Symptoms of chronic illness.|"The patient is advised to monitor BP and body weight daily in a standardized fashion as described below:~* Body weight should be measured in the morning without clothes or shoes after emptying the urinary bladder but before breakfast.~* BP should be measured in the morning preferably using the right arm, sitting comfortably in a chair after 5 minutes of rest in the seated position."
214978570|NCT00898937|GENETIC|microarray analysis|tumor specimen will be assessed by microarray analysis
214978571|NCT00898937|PROCEDURE|breast biopsy|A breast biopsy will be done to obtain a tumor specimen
214978572|NCT06222801|DRUG|Tumor necrosis factor alpha|Antitumor agent. Immunomodulatory agent.
214978573|NCT06222801|DRUG|Interferon gamma|Immunostimulating agent.
214978574|NCT01367197|BEHAVIORAL|exercise training|group based exercise training
214978575|NCT03386526|DRUG|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
214978576|NCT05791617|DIAGNOSTIC_TEST|cardiac PET/MRI|Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
214978577|NCT05791617|DIAGNOSTIC_TEST|Inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
214978578|NCT05791617|DIAGNOSTIC_TEST|Diagnostic Test: NT-proBNP|NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
214978579|NCT05939687|PROCEDURE|mesh|We'll use mesh repair for prevention of stoma-site hernias in the study group.
214978580|NCT05939687|PROCEDURE|non-mesh|We'll use the layered ligature suturing of the abdominal wall without mesh implantation in the control group.
214978581|NCT00352183|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40mg
214978582|NCT00352183|DRUG|Simvastatin|Simvastatin 40mg
214978583|NCT03863353|BEHAVIORAL|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
214978584|NCT05715619|BIOLOGICAL|VRELysin™|A cocktail of lytic Enterococcus-specific bacteriophages orally administered with sodium bicarbonate solution
214978585|NCT05715619|OTHER|Placebo|Placebo orally administered with sodium bicarbonate solution
214978586|NCT06580223|DRUG|Aspirin 100mg|Aspirin, enteric coating of tablets, oral administration
215086477|NCT05934318|DIETARY_SUPPLEMENT|L-citrulline|Twice daily 6.0 g sachet, each containing 5.00 g of quality-assured L-citrulline powder, 0.66 g maltodextrin and 0.30 g lactose anhydrous, 0.03 g citric acid, 0.01 g lemon flavour + antenatal standard of care with enhanced monitoring
214367189|NCT00800839|DRUG|Cyclophosphamide|Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
214367190|NCT02350712|DRUG|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
214367191|NCT02350712|DRUG|Cetuximab|Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
214367192|NCT02350712|DRUG|Cisplatin|Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
215086478|NCT04414124|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
215086479|NCT04414124|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
214367193|NCT02350712|DRUG|Carboplatin|Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
214978587|NCT06580223|DRUG|Rivaroxaban 10mg|Rivaroxaban, tablets, oral administration.
214978588|NCT05647187|DIAGNOSTIC_TEST|Serum Interleukin 17 levels|Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)
214978589|NCT05647187|RADIATION|NB-UVB|patients will be exposed to narrow band UVB twice weekly for three months
214978590|NCT01389778|DRUG|Metformin ER|Metformin ER 1500 mg for 12 weeks
214978591|NCT01389778|DRUG|Metformin|
214978592|NCT02935920|BEHAVIORAL|Individualized, tailored follow-up program|Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
214978593|NCT01166919|DEVICE|Matrix Radiofrequency|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
214978594|NCT02121977|DEVICE|Elevate Anterior and Apical|
214978595|NCT02121977|PROCEDURE|Native Tissue Repair for pelvic organ prolapse|
214978596|NCT02005796|OTHER|Dietary intervention|
214978597|NCT00448656|PROCEDURE|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
214978598|NCT05810701|OTHER|Comprehensive geriatric assessment and individualised physical training|Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
214978599|NCT00328705|DEVICE|Implantable Cardioverter Defibrillator|
214978600|NCT05817669|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
214978601|NCT05817669|BIOLOGICAL|Placebo|Patients receiving placebo infusions
215086480|NCT05702086|OTHER|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.
215086481|NCT04809259|DEVICE|Isothermal pouch|The study will verify it the use of an isothermal pouch to maintain the content of an elastomeric pump at 10° to 15°C avoids unacceptable meropenem degradation over the 24 hour infusion period.
215086482|NCT05775146|RADIATION|stereotactic body radiation treatment (SBRT)|SBRT uses 3D imaging to target high doses of radiation to the affected area. There is very little damage to the surrounding healthy tissue. SBRT works by damaging the DNA of the targeted cells. Then, the affected cells can't reproduce, which causes tumors to shrink.
214367194|NCT03753451|PROCEDURE|treatment of periodontal disease|Patients with periodontal disease received treatment of periodontal disease through ultrasound or manual scaling of dental calculations. In addition to receiving instructions to improve oral health, such as the correct use of dental floss, adequate time and the correct way to brush.
214367195|NCT02489786|DRUG|patients take 0.25 mg of digoxin daily except friday|
214491960|NCT06931054|DRUG|Nicotine Replacement therapy|Each eligible participant will be prescribed a two-week supply of NRT by a registered smoking cessation nurse following the initial counseling session. The nurse will determine the appropriate type and dosage of NRT based on the participant's level of nicotine dependence and lifestyle habits, and provide instructions on how to use the medication. NRT can cause some potential side effects such as nausea, headaches, dizziness, and insomnia, with vivid dreams being common for those using patches. Method-specific side effects include skin irritation from patches, mouth or throat irritation from gums or lozenges, and nasal or throat discomfort from inhalers and sprays. These symptoms usually lessen as the body adjusts, but persistent or worsening side effects may require medical attention. According to current smoking cessation medication guidelines from the Department of Health\[10\], participants who smoke 20 or more cigarettes per day will be prescribed 4 mg nicotine gum (or lozenges) or 2
214491961|NCT06931054|BEHAVIORAL|Smoking cessation counseling|The first step for smoking cessation nurses is to assess each participant's smoking behavior using a baseline questionnaire. In the second step, informed consent will be obtained from the participants. The third step involves smoking cessation counseling using the 5A (Ask, Advise, Assess, Assist, Arrange) and 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) frameworks as outlined in the smoking cessation manual published by the Department of Health. During this step, the nurse will also assess the type and dosage of NRT suitable for the participant. In the fourth step, participants will be introduced to TCM therapies, and arrangements will be made for consultations with a TCM practitioner.
214978602|NCT04583982|OTHER|T-Detect™ SARS-CoV-2 Assay|T-Detect™ SARS-CoV-2 Assay is an investigational device that is indicated to assess T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19. These results will not be shared with the participant.
214978603|NCT03240419|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
214978604|NCT03240419|DIETARY_SUPPLEMENT|Placebo|capsule manufactured to mimic probiotic capsules.
214978605|NCT03884335|PROCEDURE|laparoscopic radical prostatectomy|The surgery was carried out by laparoscopy. Intraoperative anesthetic maintenance was performed with TCI of propofol infusion for bispectral index between 40 and 60, restrictive administration of fluids or goal-directed parenteral fluid administration, normothermia, normotension and optimal intraoperative analgesia were maintained following the criteria of ERP. Afterwards, patients were awoken from general anaesthesia and transferred to the post-anaesthesia care unit (PACU) for a 6-hour follow-up prior to transfer to conventional ward.
214978606|NCT01891214|OTHER|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)|
215086483|NCT00889889|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
214367196|NCT02489786|DRUG|patients take 0.25 mg of digoxin daily except thursday and friday|
214367197|NCT02489786|DRUG|patients take 0.125 mg of digoxin daily|
214367198|NCT02489786|DRUG|digoxin dose is calculated using Jusko-Koup method and given daily|
214367199|NCT03340480|DRUG|NVP-1402|Oral
214367200|NCT00939484|OTHER|Pharmacological Study|Correlative studies
214367201|NCT00939484|DRUG|Vismodegib|Given PO
214978607|NCT00773617|BEHAVIORAL|ICAT|ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.
214978608|NCT00773617|BEHAVIORAL|CBT|CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
214978609|NCT00411320|DRUG|oral steroid-dexamethasone|2 week steroid trial
214978610|NCT01434446|BEHAVIORAL|Sound stimulation|Listening to sound stimuli at the lowest audible level.
214978611|NCT01330082|OTHER|Adjunctive Photodynamic Therapy|using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
214367202|NCT05947214|OTHER|Myofascial Decompression Therapy|Group A will be given myofascial decompression therapy.15 minute's moist heat will be given first. Patient was lied prone on couch with their upper torso unclothed, covered with massage oil than placed cup on skin and suction will created by pump. Than drawn over skin along the spine from cervical to thoracic up to lateral border maintain the suction within skin throughout the procedure. The cup massage will conducted for approximately 10 minutes. Patients were informed that the treatment area may become patchy and there are chances of ecchymosis on the same area.
214978612|NCT01330082|OTHER|Light-emitting diod Irradiation|625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark
215086484|NCT00889889|BIOLOGICAL|Placebo|Placebo
215086485|NCT00447473|DRUG|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
214978613|NCT01330082|OTHER|applying Photosensitizer|toluidine blue O is applied at the bottom of each periodontal pocket
214978614|NCT05572203|DIETARY_SUPPLEMENT|Intrinsically labelled protein|It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
214978615|NCT06405893|BEHAVIORAL|Mindful breathing exercise|Participants do a 10 minute guided mindful breathing exercise or participants do listen to a 10 minute control recording
214978616|NCT04268355|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
214978617|NCT03470077|DRUG|IV nalbuphine 0.1 mg/kg with induction of anesthesia.|"Group A: 40 patients will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.~."
214978618|NCT03470077|DRUG|IV nalbuphine 0.1 mg/kg at the end of surgery.|Group B: 40 patients will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
214978619|NCT04061785|OTHER|Judo4Balance - 12 week judo inspired exercise program|12 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
214978620|NCT05658068|BEHAVIORAL|SAFE Spaces training and coaching|Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching.
214978621|NCT02819713|OTHER|ultrasound gel|
214978622|NCT02819713|OTHER|Instillagel|
214978623|NCT06501521|DIAGNOSTIC_TEST|Diagnostic test|No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
214978624|NCT03810183|DRUG|QAW039|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care
214978625|NCT03810183|DRUG|Placebo|Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
215086486|NCT00447473|DRUG|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
215086487|NCT00447473|DRUG|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
215086488|NCT00215215|DEVICE|Vagus Nerve Stimulation Therapy|
215086489|NCT03529097|DRUG|0.9% Sodium-chloride|2 liters of 0.9% NaCl IV fluids
214367203|NCT05947214|OTHER|positional Release Therapy|Group B will be given Positional Release technique (PRT) after application of moist heat pack for 15 minute. The subjects received PRT will be in supine lying with the therapist sitting on the affected side, tender points were located along with the upper fibers of trapezius muscle. The subject's head was laterally flexed towards the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90 degree and adds slight flexion or extension to fine-tune. The ideal position of comfort achieved was held for a period of 90 sec and followed by passive return of body part to an anatomically neutral position continued for 5 minutes. Treatment duration was 3 sessions per week for 4 weeks.
214367204|NCT02130934|PROCEDURE|Cardiac 3D MRI|
214367205|NCT01957917|OTHER|NAC (Nutritional Assessment and Counseling)|
214367206|NCT01957917|OTHER|Cash Transfer|
214367207|NCT01957917|OTHER|Food Assistance|
214367208|NCT06524076|PROCEDURE|Partial Pulpotomy|After removing caries high-speed handpiece with water coolant using a round diamond bur. Once there is an exposure, the bur is changed with another sterile one with which the superficially inflamed pulp tissue will be gently removed to a depth of 1-3 mm beneath the pinpoint pulp exposure that occurred at the end of caries removal. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.
214367209|NCT06524076|PROCEDURE|Complete pulpotomy|After removing caries with a large round bur, the access cavity will be opened. Excavation of inflamed coronal pulp tissues will be done using a sharp excavator. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.
214367210|NCT05217095|DEVICE|Convergence Dialyzer|The Convergence dialyzer with design changes made to FX Coral 600 dialyzer will be tested together with Sidecar. In the dialyzer is integrated centrifugal-flow blood pump.The centrifugal-flow blood pump replaces the peristaltic roller pump of the extracorporeal circuit which pumps blood from patient to the dialyzer and from dialyzer to the patient. The centrifugal-flow blood pump is designed to transport blood from the patient to the dialyzer, and after purification, return the blood to patient.
214978626|NCT00072449|BIOLOGICAL|rituximab|
215086490|NCT03529097|DRUG|Placebos|2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
215086491|NCT03529097|DRUG|Optalgin, Voltaren, Morphine|Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
215086492|NCT04757948|PROCEDURE|Acupuncture|Acupuncture of acupoints P-6 and St-36
215086493|NCT04757948|DEVICE|TENS|TENS of acupoints P-6 and St-36
215086494|NCT04757948|DEVICE|Sham-TENS|Sham-TENS of acupoints P-6 and St-36
215086495|NCT03602885|BEHAVIORAL|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
215086496|NCT03602885|BEHAVIORAL|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
215086497|NCT04298905|OTHER|CHW mHealth patient intervention for trigger escalation|"The CHW dashboard is a tablet-based, per-patient summary of the patient intervention. It is this dashboard that identifies a trigger to escalate the adherence intervention. This dashboard is created by receiving information from the patient's smartphone application as well as the National Health Laboratory Service (NHLS) data feed of laboratory results. The monitoring features included in this dashboard:~1. NHLS laboratory results: Dashboard receives and flags NHLS results for any positive smear or culture (new positive after prior negative results) or detectable viral load (with prior viral suppression)~   1. Triggered, escalating adherence coaching:~  2. Safety monitoring: reports all abnormal laboratory values to provider~2. Appointment keeping (RETAIN):~   a. Triggered, escalating adherence coaching~3. vDOT submissions:~   a. Triggered, escalating adherence coaching~4. Symptom reports:~   1. Triggered, escalating adherence coaching"
215086498|NCT04786418|OTHER|Standard of care|Participants allocated to the control group will be given standard clinical information regarding healthy eating, physical activity and management of weight, in line with current NHS practise.
215086499|NCT04786418|DIETARY_SUPPLEMENT|Low-calorie diet|The LCD intervention group, will received a well validated, commercially available, intensive weight management protocol Counterweight-Plus.
215086500|NCT06323967|BEHAVIORAL|Large unconditional cash transfers plus voluntary peer support.|These participants will receive monthly cash transfers of $1,500 ($750 twice per month) via debit card for 24 months and can elect to participate in peer support services plus usual care from shelter staff.
215086501|NCT06323967|BEHAVIORAL|Nominal cash transfers|These participants will receive monthly cash transfers of $50 via debit card for 24 months plus usual care from shelter staff.
214978627|NCT06550778|BEHAVIORAL|Mindfulness-based emotional regulation intervention|"The intervention was conducted once a week for 6 weeks, with each session lasting 90-120 minutes, including a 30-minute parenting course each week. The intervention program was divided into 6 themes, including Entering mindfulness, feeling the connection between emotions and the body, Dealing with negative emotions, Moderate emotional expression, Mindfulness to relieve anxiety, Learning to be grateful and Embrace future life. The intervention content integrates mindfulness training, parental mindful parenting exercises and emotion regulation skills. For details, refer to Greenland's Mindfulness Games, Bögels' Mindful Parenting Manual, mindful breathing and meditation in MBSR and MBCT, as well as emotion regulation skills. The intervention location was the activity room of the child and adolescent psychology unit of the hospital."
214978628|NCT02064556|DRUG|Amlodipine 10mg|Amlodipine 10mg 1T, PO, QD for 9days
214978629|NCT02064556|DRUG|Amlodipine 10mg/Candesartan 32mg|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
215086502|NCT06323967|BEHAVIORAL|Passive comparison group|These families will receive usual care from shelter staff. They will be followed anonymously in administrative records only.
215086503|NCT05443412|DIAGNOSTIC_TEST|Diagnostic test for prostate cancer|All recruited patients will undergo investigations including urine for spermine, blood for miRNA, TRUS, and MRI prostate. Patients with high suspicion of Clinically significant prostate cancer in any one step (urine, blood, ultrasound, OR MRI) will be offered an image-guided prostate biopsy.
215086504|NCT05567419|DIAGNOSTIC_TEST|Biological assays|PCR and NGS-WGS on stools and respiratory samples
215086505|NCT05792527|DRUG|L-carnitine|One 500 mg tablet twice daily after meals
215086506|NCT04694495|DIAGNOSTIC_TEST|16S rRNA gene sequencing of cervical secretions|"1. 16S rRNA gene sequencing of vaginal secretions: using NGS technology to assess the microbiota of the vaginal secretions~2. Microecology assessment of vaginal secretions: morphology test, functional assessment and Nugent score assessment of the vaginal secretions are included.~3. Genotyping of HPV and detection of sexually transmitted diseases pathogens based on the cervical exfoliated cells~4. Thinprep cytologic test of cervical exfoliated cells: to evaluate the grade of cervical intraepithelial neoplasia"
215086507|NCT05632328|DRUG|AGEN1423|via IV, dosage per protocol, once every 2 weeks for up to 8 weeks
215086508|NCT05632328|DRUG|Botensilimab|via IV, dosage per protocol, once evert 2 weeks, up to 2 years
214367211|NCT02607982|DRUG|Paclitaxel|PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
214367212|NCT02607982|DRUG|Oxaliplatin|oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.
214367213|NCT02607982|RADIATION|Radiotherapy|Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
214491962|NCT06931054|OTHER|Auricular acupressure|First, one ear will be routinely disinfected with 75% medical ethanol. In the experimental group, the auricular acupressure tape contains Semen Vaccariae. Using forceps or tweezers, an auricular acupressure tape will be applied to specific acupoints on one ear for participants in the experimental group, followed by pressing the tape for 1 minute. The auricular tape will remain in place for two days, and participants will be instructed to self-press the acupoints 3 to 5 times daily, for 1 minute per acupoint each time. During the use of the auricular acupressure, if withdrawal symptoms occur, participants can immediately press the acupoints. The pressure applied should be tolerable, and the pressing duration should last until the withdrawal symptoms subside. Participants will also record the number of presses each day.
214978630|NCT02750995|BIOLOGICAL|NPMW-peptide vaccine|Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
214978631|NCT02750995|DRUG|Azacitidine|Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
215086509|NCT05632328|DRUG|Gemcitabine|per standard care
215086510|NCT05632328|DRUG|Nab-paclitaxel|per standard care
215086511|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
215086512|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
215086513|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
215086514|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
215086515|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
215086516|NCT00002055|DRUG|Pentamidine isethionate|
215086517|NCT05891054|BEHAVIORAL|Active breaks|Two active breaks are taken daily in a predetermined time slot. The development of each break is done through access to a specific digital platform where students follow the instructions of an avatar, which is in charge of guiding the realization of the active break. Each active rest involves a total of 4 minutes of activity, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed, ending with a brief return to calm consisting of two deep breaths. The activities selected for each of the active breaks include aerobic and strengthening activities of moderate and vigorous intensity.
214367214|NCT01224925|PROCEDURE|Direct pulp capping with Dycal|Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling
214367215|NCT01224925|PROCEDURE|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
214367216|NCT03122561|DRUG|Paracetamol 500 mg tablet at morning|Single dose oral paracetamol will be administered at 8.00 am
214367217|NCT03122561|DRUG|Paracetamol 500 mg tablet at midday|Single dose oral paracetamol will be administered at 2.00 pm
214491963|NCT06931054|OTHER|Sham acupressure|"The sham tape resembles the genuine auricular acupressure tape with Semen Vaccariae but is a regular adhesive tape designed to minimize stimulation of the acupoints.~The sham auricular tape will be applied to non-smoking cessation acupoints, including:~* Elbow Acupoint located in the third section of the triangular fossa between the middle cartilage and the rim cartilage of the ear, primarily used for treating elbow pain.~* Ankle Acupoint located near the apex of the superior crus of the antihelix, used for treating arthritis.~* Urethra Acupoint located on the helix above the rectum acupoint, used for treating symptoms such as frequent urination or painful urination."
214978632|NCT03220022|DRUG|Cyclophosphamide|Given IV
214978633|NCT03220022|DRUG|Doxorubicin Hydrochloride|Given IV
214978634|NCT03220022|DRUG|Etoposide|Given IV
214978635|NCT03220022|BIOLOGICAL|Filgrastim|Given SC
214978636|NCT03220022|DRUG|Ibrutinib|Given PO
214978637|NCT03220022|OTHER|Laboratory Biomarker Analysis|Correlative studies
215086518|NCT05891054|BEHAVIORAL|Physically active learning|"The physically active learning is carried out once a week for 1 hour outside the classroom, where physical activity (through movement, jumping, strengthening exercises, throwing, etc.) is incorporated into academic mathematics classes.~The mathematics teachers (with the support of the research team) are in charge of teaching the physically active classes. Prior to the development of each class, the research team, together with the mathematics teachers involved, meet and design the class according to the contents to be addressed."
214367218|NCT03122561|DRUG|Paracetamol 500 mg tablet at night|Single dose oral paracetamol will be administered at 8.00 pm
214367219|NCT03381001|PROCEDURE|embryo transfer after thaw and culture|embryos will be kept in culture after thawing for one day before transfer for the uterus
214367220|NCT03381001|PROCEDURE|embryo transfer with no culture|embryos will be transfer with no culture after thaw
214367221|NCT01720732|BEHAVIORAL|Lifeline NET|Short Version of Narrative Exposure Therapy
214367222|NCT05808738|BEHAVIORAL|therapeutic play|therapeutic game will be played to prepare children for hydrotherapy treatment
214367223|NCT02309437|DRUG|Oxycodone|Use oxycodone to treat patients with mild pain caused by radiation mucositis.
214367224|NCT02309437|DRUG|Oxycodone|Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
214367225|NCT01645826|DRUG|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
214367226|NCT01645826|DRUG|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
214367227|NCT02178059|DRUG|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate (delivered dose) per inhalation
214367228|NCT02178059|DRUG|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate (metered dose) per inhalation
214367229|NCT03014765|OTHER|EDOP|no intervention
214367230|NCT00621608|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
214367231|NCT00621608|PROCEDURE|Placebo Hyperbaric Oxygen Chamber|Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
214367232|NCT05848921|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
214367233|NCT05848921|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
214978638|NCT03220022|BIOLOGICAL|Pegfilgrastim|Given SC
214978639|NCT03220022|OTHER|Pharmacological Study|Correlative studies
214978640|NCT03220022|DRUG|Prednisone|Given PO
214978641|NCT03220022|BIOLOGICAL|Rituximab|Given IV
214978642|NCT03220022|DRUG|Vincristine Sulfate|Given IV
214978643|NCT01656044|PROCEDURE|wound care management|Receive SSD
214978644|NCT01656044|PROCEDURE|wound care management|Receive NPT
214978645|NCT05220488|OTHER|Assessment|Parameters such as physical activity and fear of covid will be evaluated in asthmatic and healthy children and adolescents.
214978646|NCT05963399|DEVICE|CAREUP platform|The Experimental Group will test the CAREUP platform at home for 12 months.
214978647|NCT00323063|DRUG|gemcitabine hydrochloride|Given IV
214978648|NCT00323063|DRUG|imatinib mesylate|Given orally
214978649|NCT03228901|DRUG|Oxytocin|Administration of the hormone oxytocin
214978650|NCT03228901|DRUG|Placebos|
214978651|NCT03786380|DRUG|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily.
215086519|NCT05688826|DIETARY_SUPPLEMENT|Sugar|75 g sugar dissolved in 0.8 dl water and flavored with lemon. Ingested during 5 minutes
214367234|NCT04957017|BEHAVIORAL|Training|"After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training"
214367235|NCT05178121|BEHAVIORAL|eLearning Training in Suicide Safety Planning|The training includes a web-based didactic in suicide safety planning, interactive practice in counseling microskills with a chat bot, role-playing safety planning with a standardized patient, and reviewing automated feedback on safety planning counseling skills generated from a computer coding system.
214367236|NCT04569110|OTHER|Not applicable. Observational study. Retrospective analysis of samples.|Not applicable. Observational study. Retrospective analysis of samples.
215086520|NCT05880914|PROCEDURE|miRNAseq analysis|Identify miRNA in serum and prepare a miRNA sequencing library for novel analysis.
215086521|NCT05880914|DRUG|Standard treatment for bone disorder|Participants will be prescribed a clinically indicated bone-targeted treatment for osteoporosis or bone disorder related to CKD. (non-experimental)
214367237|NCT00245102|DRUG|sorafenib tosylate|Given orally
214367238|NCT02733809|DRUG|Sorafenib|Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.
214367239|NCT01953003|DRUG|vinflunine|intravenous administration day 1 once every 3 weeks, 280 mg/m²
214491964|NCT06931054|OTHER|Sham acupuncture|"The TCM practitioner will perform needle insertion 2-3 mm beside the selected acupoints (at non-specific sham points) using normal needling techniques but without manipulating the needles, in order to minimize any physiological effects."
214978652|NCT06433167|OTHER|Pedobarographic analysis|During the pedobarographic analysis, the patient takes steps on the platform at a regular walking speed, with arms relaxed at the sides, following a natural gait. In static analysis, measurements are taken while the patient remains stationary on the platform with arms in a relaxed position beside the body. Five measurements are separately recorded for both feet during the phases of stepping, heel strike, and toe lift. These measurements capture the highest pressures on the back of the foot, the middle part of the foot, and the inner, middle, and lateral sides of the front of the foot, including the toes. The pressure, force, and pressure-time integral corresponding to each area are then used to determine how and for how long these areas are exposed to pressure.
214978653|NCT02973828|PROCEDURE|Imaging|This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
214978654|NCT01664091|RADIATION|post-mastectomy radiation therapy (PMRT)|
214978655|NCT01664091|DEVICE|tissue expander (TE)|
214978656|NCT01664091|DEVICE|acellular dermal matrix (ADM)|
214978657|NCT02143232|DEVICE|remote patient monitoring (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
215086522|NCT06546709|BIOLOGICAL|LASSARAB+ aPHAD-SEat 700rU|Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
214491965|NCT06886347|DRUG|Penplimab Injection|"Penplimab Injection: Intravenous infusion of Penplimab 200 mg Q3W, with a 3-week treatment cycle.~Anlotinib Hydrochloride Capsules: 10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks.~Gemcitabine injection: Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles."
215086523|NCT06546709|BIOLOGICAL|HDCV Comparator|Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M
214367240|NCT01953003|DRUG|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
214367241|NCT01835262|DRUG|Morphine|Morphine: 0.1 mg /kg given as IVP
215086524|NCT06546709|OTHER|Normal Saline Placebo|Sterile 0.9% sodium chloride for injection, USP, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each mL contains sodium chloride 9 mg
214367242|NCT01835262|DRUG|Ketamine|Ketamine:0.3 mg/given as IVP
214367243|NCT06230458|DIAGNOSTIC_TEST|FeNO-test|Fractional Exhaled Nitric Oxide (FeNO)- test
214978658|NCT05861375|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.
214978659|NCT06261723|PROCEDURE|non-chirurgical periodontal treatment|The non-chirurgical periodontal treatment (scaling and root planing) is the gold standard procedure in therapy for periodontitis. It involves the mechanical removal of plaque and bacterial deposits, creating a local microbial environment in harmony with periodontal health and promoting the replacement of damaged periodontal tissues with collagen-rich connective tissues. This favors a shift in the composition of the oral microbiota from a community dominated by Gram-negatives to one dominated by Gram-positives.
214978660|NCT00761228|DRUG|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
214978661|NCT00761228|DRUG|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
214978662|NCT03057886|DEVICE|Comparative thermometers to compare with a new device|The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
214978663|NCT05448638|PROCEDURE|the combination of transversus thoracic muscle plane and pectoral nerves blocks|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle. For the transversus thoracic muscle plane block, ropivacaine 0.375%,15ml was injected between the transversus thoracic muscle and the internal intercostal muscle.
214978664|NCT05448638|PROCEDURE|the pectoral nerves block only|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle.
214978665|NCT06602544|DEVICE|Robotic Apparel|A robotic apparel system is a portable, lightweight textile-based wearable robot that is worn around the waist and thighs. The apparel provides assistive flexion moment about the hip joint during the swing phase of gait by spooling in a cable that connects the thigh wraps to the front of the waist belt. Inertial measurement units embedded in the thigh wraps are used to control the timing of the robotic apparel assistance. Robotic apparel assistance magnitude is delivered as a small percentage of the bodyweight of the wearer.
214978666|NCT02783898|DEVICE|AliveCor Heart Monitor|Smart phone based ECG event recorder
215086525|NCT06546709|BIOLOGICAL|LASSARAB+ aPHAD-SEat 1400rU|Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
215086526|NCT02351349|OTHER|multidisciplinary intervention|multidisciplinary intervention
215086527|NCT03873506|DRUG|transplantation of hUC-MSCs|Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
215086528|NCT06105294|BEHAVIORAL|time-restricted eating|Restrict eating to a 10-hour window.
215086529|NCT01971268|DEVICE|Dental Implant|place dental implants according to manufacturer guidelines
215086530|NCT01971268|DEVICE|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
215086531|NCT01971268|DEVICE|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
215086532|NCT01357876|OTHER|Metformin|withdrawral
215086533|NCT03895177|DIAGNOSTIC_TEST|contrast enhanced computed tomography|pancreatic protocol CT with 80kVp tube voltage and more than 500mA tube current acquire late arterial phase and portal venous phase using volus tracking method
215086534|NCT02606266|DRUG|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
215086535|NCT00440310|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
215086536|NCT00440310|PROCEDURE|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
215086537|NCT00440310|DEVICE|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
215086538|NCT00440310|DRUG|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
215086539|NCT00440310|DRUG|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
214367244|NCT02629835|OTHER|intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution|
214367245|NCT02629835|OTHER|intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone|
215086540|NCT03631277|DEVICE|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
215086541|NCT03631277|DRUG|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
215086542|NCT01650415|DRUG|Erythropoietin|twice a week for 1 month
215086543|NCT01650415|DRUG|Placebo erythropoietin|twice a week for 1 month
215086544|NCT00460590|BIOLOGICAL|MVA 85A|ID vaccine
215086545|NCT00534378|DRUG|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
215086546|NCT05022823|DEVICE|Compression sleeve, worn during exercise|Participants wear their daytime compression sleeve during the DPRE program.
214978667|NCT06301789|DRUG|Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries|Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle
214978668|NCT02480738|BEHAVIORAL|Computerized Cognitive Training Apparatus|"CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process."
214978669|NCT02039258|DRUG|CANA/MET XR FDC|Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
214978670|NCT04771845|DEVICE|Transcranial Magnetic Stimulation|Magnetic stimulation to alter neural activity
215086547|NCT05022823|DEVICE|Adjustable Compression (AC) garment, worn during exercise|Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.
215086548|NCT05022823|DEVICE|Compression sleeve, daytime wear|Compression sleeve worn for at least 12 hours per day, seven days a week.
214978671|NCT02345005|DEVICE|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
214978672|NCT02067520|DRUG|intrathecal hydromorphone (IT hydromorphone)|
214978673|NCT02143219|DRUG|Oxaliplatine|Oxaliplatine : 85mg/m², 2-hours IV infusion (D1),
214978674|NCT02143219|DRUG|Folinic acid|Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
214367246|NCT05614414|PROCEDURE|tracheal intubation by Videolaryngoscope|The investigators performed laryngoscopy using a McGrath video-laryngoscope with a number 4 blade.
214367247|NCT05614414|PROCEDURE|tracheal intubation by direct laryngoscope|The investigators performed laryngoscopy using either a Macintosh laryngoscope using a number 4 blade.
214367248|NCT02681575|BEHAVIORAL|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
214367249|NCT04099602|OTHER|Baby Massage|Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
214367250|NCT00979823|OTHER|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
214367251|NCT00979823|OTHER|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
214367252|NCT03324438|BEHAVIORAL|Home Telehealth T1D C2oYoT1-HR|1\) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
214367253|NCT03324438|BEHAVIORAL|Personalized Behavioral Health|1\) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
214491966|NCT06886347|DRUG|Antitinib Hydrochloride Capsules|10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks.
214491967|NCT06886347|DRUG|Gemcitabine|Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles.
214491968|NCT06516627|BEHAVIORAL|Positive Labels|"Products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best)."
214978675|NCT02143219|DRUG|Irinotecan|"Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts~* Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.~* Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance."
215086549|NCT05022823|BEHAVIORAL|Decongestive Progressive Resistance Exercise program|"Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually."
214367254|NCT03324438|BEHAVIORAL|Personalized Adherence Feedback|1\) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
214978676|NCT02143219|DRUG|5-FU|"5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:~* If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one~* If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course."
214978677|NCT03416439|OTHER|lifestyle intervention|lifestyle intervention program carried out by trained professionals
215086550|NCT05022823|BEHAVIORAL|Home exercise program|Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.
215086551|NCT04578639|DRUG|Rituximab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
215094482|NCT06507033|DEVICE|Mobile application and an arm volume measurement device|The intervention consists mainly of two steps; (a) development of a mobile application with an arm volume measurement device (b) evaluation of the effectiveness of the products. Five components will be involved in the development of the mobile application. These components are; (I) exercise, (II) education, (III) coping mechanisms, (IV) arm volume measurement/recording and (V) appointment, exercise and measurement reminder panel. Exercise videos will include stretching exercises for the shoulder and arm as recommended in the guidelines
214978678|NCT03119597|DIETARY_SUPPLEMENT|Wild Blueberry Powder-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
214978679|NCT03119597|DIETARY_SUPPLEMENT|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
214978680|NCT03040232|OTHER|biomechanical assessment|biomechanical and strength assessment of both groups
214978681|NCT06139848|OTHER|Traditional Physical Therapy|Conventional therapy include heating therapy for 10 mints, Bridging exercises (10 rep, 3 sets), Paraspinal muscle stretch.
214978682|NCT06139848|OTHER|Posterior-anterior spinal mobilization, prone press up Techniques|"Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions."
214978683|NCT01741415|BEHAVIORAL|SIDI|
214978684|NCT01741415|BEHAVIORAL|SC|
214367255|NCT01788696|RADIATION|Group A - Early Imaging|Total of 3 scans
214367256|NCT01788696|RADIATION|Group B - Delayed Imaging|Total of 2 scans
214367257|NCT02243644|DRUG|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
214367258|NCT02243644|DRUG|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
214978685|NCT04726826|DIAGNOSTIC_TEST|Diagnostic and prognostic biomarkers|Observational study of biomarkers predictive of morbidity and mortality in febrile children
214978686|NCT02831582|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Given PO.
214367259|NCT03092375|DRUG|Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|daily
214367260|NCT03092375|DRUG|Ribavirin 200Mg Tablet|Weight-based 1000-1200 mg
214367261|NCT01043016|PROCEDURE|Photodynamic therapy|patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
214367262|NCT04806295|OTHER|any/all treatments for blood cancer|Following people undergoing any/all treatments for blood cancer.
214367263|NCT00291759|DRUG|Tamoxifen|
214367264|NCT00291759|DRUG|Anastrozole|
214367265|NCT04945421|DRUG|Sintilimab|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
214367266|NCT04945421|DRUG|IBI310|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
214367267|NCT02448667|DIETARY_SUPPLEMENT|FAXE Kondi|Sucrose and glucose containing softdrink
214491969|NCT06516627|BEHAVIORAL|Spectrum Labels|"All products will display an expanded Guiding Stars label that show an overall rating indicating their healthfulness using star ratings: 1 star (Poor), 2 stars (Fair), 3 stars (Good), 4 stars (Better), or 5 stars (Best)."
214491970|NCT06516627|BEHAVIORAL|FDA High In Labels|Products that contain high levels (i.e., ≥20% DV per serving) of saturated fat, sodium, or added sugars will display a label indicating which of these nutrients the product is high in.
214978687|NCT02831582|OTHER|Placebo|Given PO.
214978688|NCT04470973|DRUG|Cefuroxime|Patients receive cefuroxime as part of standard care.
214978689|NCT04470973|DRUG|Amikacin|Patients receive amikacin as part of standard care.
214491971|NCT06516627|BEHAVIORAL|FDA Traffic Light Labels|"All products will display a Nutrition Info label showing whether the amount of saturated fat, sodium, and added sugars in 1 serving of the product is low (\<5% DV), medium (≥5 to \<20% DV), or high (≥20% DV). Low will be shown in green, Medium in yellow, and High in red."
214491972|NCT06740903|DRUG|inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h|Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h intraoperatively
214978690|NCT01201642|DRUG|Prednisolone|Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
214978691|NCT01201642|DEVICE|acupuncture|The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
214978692|NCT01201642|OTHER|other treatment|common medicine or other physical treatment which are different from those 5 Arms Previously.
214978693|NCT03464760|DIETARY_SUPPLEMENT|3.5g of spirulina per day in 1% silicone|5 tablets of 700mg per day
214978694|NCT03464760|DIETARY_SUPPLEMENT|placebo|5 tablets per day of potato-based placebo
214978695|NCT01560247|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy using a MindFrame device
215086552|NCT04578639|DRUG|Ocrelizumab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
215086553|NCT05925088|OTHER|Focus group|Participants will take part in a 1 hour focus group.
215086554|NCT06378463|OTHER|Cognitive remediation + active tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive active brain stimulation."
215086555|NCT06378463|OTHER|Cognitive remediation + sham tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive sham brain stimulation."
215094483|NCT00043927|DRUG|topotecan/cisplatin|
215094484|NCT00043927|DRUG|etoposide/cisplatin|
215094485|NCT06939660|DEVICE|BCI-SCS-EXS|"Participants will undergo a BCI-SCS-EXS intervention designed to enhance neurorehabilitation for spinal cord injury (SCI). The intervention includes:~1. BCI Implantation: High-density ECoG electrodes placed over the motor cortex to decode lower limb movement intent.~2. SCS Electrode Implantation: 5-6-5 paddle electrodes implanted at T11-L2 to deliver targeted spinal cord stimulation.~3. System Calibration: BCI-SCS synchronization to trigger stimulation parameters based on decoded motor intent. SCS-EXS integration to provide synchronized gait assistance.~4. Rehabilitation Training: Daily training sessions (60 minutes, 5 times/week for 1 year) combining BCI-SCS-EXS.~5. Follow-Up: Safety and efficacy assessments at 1, 2, 3, 6, and 12 months post-intervention.~This intervention aims to promote neuroplasticity and functional recovery through brain-controlled spinal activation and synchronized exoskeleton assistance."
214978696|NCT00726609|DRUG|Posaconazole|The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
214978697|NCT00549393|DRUG|2% Chlorhexidine gluconate cloth|Daily bathing
214978698|NCT02405819|OTHER|'My Care Plan'|'My Care Plan' is a patient-initiated survivorship care planning tool.
215086556|NCT02020876|OTHER|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
214491973|NCT06740903|DRUG|inj. lignocaine infusion @1-2 mg/kg/h|Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. lignocaine infusion @ 1-2 mg/kg/h intraoperatively
215086557|NCT03671408|OTHER|clinical measurements|only clinical parameters were recorded
215086558|NCT05403892|DIAGNOSTIC_TEST|level laser lunge test|In order to perform the Level Laser Test, the operator 1 places a laser lever on the ground one metre aside and 50 cm forward the ankle to be examined. This laser (a 2-class laser not harmful to the eyes) maintains a linear laser light beam perpendicular to the floor. The examined leg is placed further forward to the other one, as it happens in the DLT. The teenage performs a forward lunge perpendicularly to the laser line, the heel positioning 50 cm from the laser line. Operator 1 has the subject perform a lunge while operator 2 measures the distance from the kneecap to the laser line. The measurement, deducted by 50 cm, leads to the heel-to-wall distance (value used to DLT).
214367268|NCT02448667|DIETARY_SUPPLEMENT|Faxe Kondi Free|Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
214367269|NCT01231529|DRUG|GSK1349572|All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
214367270|NCT01857882|OTHER|Decision Support Workshop|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience"
214978699|NCT02405819|OTHER|'Survivorship Care Plan Builder'|'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
214978700|NCT05143463|DRUG|NS101 IV infusion|Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
214978701|NCT06180057|DRUG|Chenodeoxycholic acid|Two capsules were administered orally
214978702|NCT06180057|DRUG|Chenodeoxycholic acid leadiant|Two capsules were administered orally
214978703|NCT05939908|OTHER|Using Jamar Dynamometer for Grip Strength.|Hand grip strength as a marker by using JAMAR hand grip dynamometer in patients with T2DM.
214978704|NCT04600349|BEHAVIORAL|Identity Oriented Psychotrauma Therapy|The method will be presented to the group at the beginning of the first group session. Then every person from the experimental group will set an Intention connected to the emotional or physical difficulties they experience in their lives. Then the person will choose for every word in their Intention, a representative from the support group who will resonate with that word. The focus of every Intention should be the current illness and the traumatic or stressful events which happened before the disease onset.
214978705|NCT04600349|DRUG|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
215086559|NCT05403892|DIAGNOSTIC_TEST|dorsiflexion Lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the teenage stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The teenage is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The teenage steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
215086560|NCT01519999|BEHAVIORAL|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
214367271|NCT04190628|DRUG|ABM-1310|"Part A: Starting dose at 25 mg by mouth twice daily.~Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A.~Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
214978706|NCT01048424|DEVICE|RESPeRATE|"RESPeRATE is a commercially available, walkman-like device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate."
214978707|NCT01048424|OTHER|Urinary Incontinence Pamphlet|The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.
214978708|NCT02622243|DRUG|Tiotropium|long acting muscarinic antagonist
215086564|NCT01459991|OTHER|Walnut|Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
215086565|NCT01459991|OTHER|MyPyramid|Participants will follow a USDA MyPyramid style diet for lactating moms.
215086566|NCT01236872|DIETARY_SUPPLEMENT|Beetroot juice|250ml once of beetroot juice
215086567|NCT01236872|DIETARY_SUPPLEMENT|Water|250ml once of low-nitrate mineral water
215086568|NCT05491421|DRUG|ZT002|"Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
215086569|NCT05491421|OTHER|Placebo|"Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
215086570|NCT02421263|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
215086571|NCT01987219|DRUG|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
215086572|NCT01987219|DRUG|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
215086573|NCT01987219|OTHER|placebo|Saline solution 3 cc NA
215086574|NCT02154685|BEHAVIORAL|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
215086575|NCT02154685|BEHAVIORAL|Non-Retrieval Extinction|Neutral cue exposure.
215086576|NCT01610596|DRUG|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
215086577|NCT01610596|DRUG|Placebo|
215086578|NCT01510171|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
214367272|NCT04190628|DRUG|Cobimetinib|"Part B: orally administered once daily.~Part C-3 and C-4: Continuous once daily oral dose from Part B, administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Dose formulation is 60 mg capsules."
214978709|NCT02622243|DRUG|glycopyrronium|long acting muscarinic antagonist
214978710|NCT02622243|DEVICE|Respimat|inhaler device used to deliver active tiotropium or placebo
215086579|NCT01510171|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
215086580|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
215086581|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
214367273|NCT02558582|BEHAVIORAL|respiratory and exercise therapy|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
214491974|NCT05410860|DRUG|Etripamil NS 70 mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
214978711|NCT02622243|DEVICE|Breezehaler|inhaler device used to deliver active glycopyrronium or placebo
215086582|NCT01519674|DRUG|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
215086583|NCT01519674|DRUG|metformin|Subjects will continue on their pre-trial metformin treatment.
214367274|NCT02558582|BEHAVIORAL|respiratory and exercise therapy with supplemental oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
214367275|NCT02512679|DRUG|Cyclophosphamide Dose Level 1|given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
214367276|NCT02512679|DRUG|Cyclophosphamide Dose Level 2|Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
214367277|NCT02512679|DRUG|Cyclophosphamide Dose Level 3|Level 3 will be 35mg/kg as a one-time dose.
214367278|NCT02512679|DRUG|Cyclophosphamide Dose Level 4|Level 4 will be no cytoxan.
214367279|NCT05312567|DRUG|FP-101|daily oral tablet administration (b.i.d.)
214367280|NCT01104740|OTHER|Biological sample collection|Blood (serum) sample collection
214367281|NCT05009524|DEVICE|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
214367282|NCT05009524|DEVICE|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
214491975|NCT05410860|DRUG|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
214491976|NCT06766227|BEHAVIORAL|iEndSmokin App|Mobile Health App that includes educational material and psychological programs based on CBT.
214491977|NCT06766227|BEHAVIORAL|Educational Session|It will include lectures and distribution of educational material about smoking health risks and strategies to quit.
214491978|NCT06767176|DIETARY_SUPPLEMENT|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|7 doses, taken daily, 70 ml shots, consumed in the morning before the start of fasting
214978712|NCT01307813|DEVICE|Overstitch Endoscopic Suturing System|"Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.~Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model"
214978713|NCT00683423|DRUG|BMS-741672|Tablets, Oral, 100 mg, once daily, 3 weeks
214978714|NCT00683423|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
214978715|NCT01516138|DRUG|GIK|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
214978716|NCT01516138|DRUG|Control|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
214978717|NCT00913341|DRUG|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)|
214978718|NCT00913341|DRUG|Alprazolam Tablets, 1 mg (The Upjohn Company)|
214978719|NCT01145664|DRUG|Herbal concentrate-granules plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
214978720|NCT01145664|DRUG|Reduning Injection plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
214978721|NCT01145664|DRUG|Western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
214978722|NCT00485862|DRUG|Atomoxetine Hydrochloride|
214978723|NCT00485862|DRUG|Sertraline|
214978724|NCT00485862|DRUG|Placebo|
214978725|NCT02979704|DRUG|Rosuvastatin|45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
214978726|NCT02979704|DRUG|Atorvastatin|45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
214978727|NCT05604898|DRUG|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be administered subcutaneously.
214978728|NCT05604898|OTHER|Placebo|Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.
214978729|NCT05604898|DRUG|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be provided at pre-specified time intervals.
214978730|NCT05604898|OTHER|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
214978731|NCT01350219|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
215086584|NCT04523090|DRUG|Nitazoxanide|Nitazoxanide (NTZ) is licensed in the USA for treatment of diarrhoea caused by Cryptosporidium parvum and Giardia lamblia. NTZ is a pro-drug for tizoxanide, which also has broad spectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against Coronaviridae. NTZ was identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. In vitro studies evaluating tizoxanide, the active circulating metabolite of NTZ, inhibits the replication of broad range of influenza A and B, HIN1, H3N2, H3N2V, H3N8, H5N9, H7N1 and oseltamivir resistant strain and coronaviruses . It has been shown to have anti-viral activity against several viruses including Ebola, hepatitis B and C, rotavirus and norovirus.
215086585|NCT04523090|DRUG|Placebo|Placebo pills with no active ingredient.
214491979|NCT06840730|DRUG|Botulinum Toxin A (Botox )|TX-A will be injected into the masseter and temporalis muscles (30 and 15 units per side, respectively) following a standardized protocol.
214367283|NCT01599390|OTHER|Data collection|"The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.~Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted."
214367284|NCT00553501|BIOLOGICAL|epratuzumab|Days 1, 8, 15, 22 and weeks 12, 20, 28, \& 36: 360mg/sq m IV
214367285|NCT00553501|BIOLOGICAL|rituximab|Day 3, 8, 15, 22 and weeks 12, 20, 28, \& 36: 375mg/sq m IV
214367286|NCT03503539|PROCEDURE|Mini percutaneous nephrolithotomy|
214367287|NCT03503539|PROCEDURE|Retrograde intrarenal surgery|
214367288|NCT02898779|DRUG|Primaquine, R-Primaquine, S-Primaquine, SR Primaquine|"Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ."
214367289|NCT00004401|DRUG|botulism immune globulin|
214367290|NCT02293395|DRUG|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
214491980|NCT06747962|PROCEDURE|A1 pulley release and pull out tenolysis|A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley under direct vision. Flexor digitorum superficialis and flexor digitorum profundus tendons or flexor pollicis longus tendon (for the thumb) will be gently pulled out of the wound with two mosquito forceps to break any adhesions. The wound will be closed primarily with sutures. The patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.
214978732|NCT03327324|BEHAVIORAL|Sleep Using Mentored Behavioral and Environmental Restructuring|SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
214978733|NCT01394289|BIOLOGICAL|Lolium allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
214978734|NCT01007799|DIETARY_SUPPLEMENT|vitamin D placebo|12 weeks of placebo
214978735|NCT01007799|DIETARY_SUPPLEMENT|Vitamin D|12 weeks supplementation based on serum vitamin D levels
214978736|NCT00160511|DRUG|Levetiracetam|
214978737|NCT00133198|DRUG|Pramipexole|
214978738|NCT03257748|RADIATION|Laser Therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
214978739|NCT03257748|RADIATION|LED therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
214978740|NCT02855489|BEHAVIORAL|Attitudes Only|
214978741|NCT02855489|BEHAVIORAL|Norms Only|
214978742|NCT02855489|BEHAVIORAL|Perceived Behavioral Control Only|
214978743|NCT02855489|BEHAVIORAL|Intentions Only|
214978744|NCT02855489|BEHAVIORAL|Three Constructs|
214978745|NCT02855489|BEHAVIORAL|Four Constructs|
214978746|NCT00499811|DRUG|vorinostat|Given orally
214978747|NCT00499811|OTHER|pharmacological study|Correlative studies
214978748|NCT01927094|DIETARY_SUPPLEMENT|Probiotic|Comparison of probiotics vs. ORS
214978749|NCT01927094|DIETARY_SUPPLEMENT|ORS|ORS ad libitum
214978750|NCT04264208|DRUG|68-Ga RM2.|PET radiopharmaceutical
214978751|NCT04264208|DRUG|68-Ga PSMA11|PET radiopharmaceutical
214978752|NCT04264208|DEVICE|PET/MRI|PET/MR scanner by GE healthcare
214978753|NCT00771368|DRUG|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
214978754|NCT05966233|DRUG|R-DHAP|"* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1"
214978755|NCT05966233|DRUG|Pola-R-DHAP|"* Polatuzumab Vedotin 1.8 mg/kg IV on D1~* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1"
214978756|NCT06123702|BEHAVIORAL|Fear extinction|Extinction of conditioned fear response
214978757|NCT06123702|DRUG|Cannabidiol Cap/Tab|12 50-mg capsules
214978758|NCT06123702|DRUG|Placebo|12 placebo capsules
215086586|NCT05135481|PROCEDURE|phrenectomy|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
215086587|NCT05135481|OTHER|Increased lactation support|Management in group 2 will include increased lactation care both during hospital stay and post discharge.
214367291|NCT02293395|DRUG|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
214367292|NCT02293395|DRUG|Clopidogrel|Clopidogrel 75 mg once daily orally.
214367293|NCT02293395|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily orally.
215086588|NCT00799591|OTHER|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
214491981|NCT06747962|PROCEDURE|Simple A1 pulley release|A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley vision. After release, the patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.
215086589|NCT05982119|DEVICE|ActiMyo/Syde|"The two watches can be worn as wristwatch or placed near the ankle and on the wheelchair.~* Patients with DMD or FKRP mutation will wear the ActiMyo°/Syde° during 3 months at baseline and then for one month every 3 months.~* Patient with FSHD, DM1, CMT, CNM will wear the ActiMyo°/Syde° will wear the ActiMyo/Syde° during 3 months at baseline and then for one month every 6 months.~* Control subjects \>4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month 11 months after inclusion.~* Control subjects \<4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month every 6months after inclusion."
215086590|NCT03908736|DRUG|Zinc Picolinate 15 Mg|zinc picolinate, 15 mg/day for 6 months
214978759|NCT03874442|OTHER|CliniPup serious game|"The interactive game is played at home by the children on a computer or tablet before the surgery. The SERES Pain in Children-game is created with realistic scenarios based on scientific literature about perioperative pain and fear in children. The primary goal of the game is to provide the children insight in the impact of their personal choices on their well-being and on their environment by giving the children information about the day of the surgery. The ultimate aim of the game is to create a change in behaviour, enhance children's coping strategies and reduce the burden of pain and fear in the children and parents."
214978760|NCT05202834|DEVICE|UltraClear|Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on human skin
214978761|NCT04168034|BEHAVIORAL|iParent2Parent Program|In addition to standard care, parents in the experimental group will receive the iParent2Parent program. The iParent2Parent program is a tailored peer mentorship program that provides modeling and reinforcement by peers (trained parents of children with JIA) to parents of children diagnosed with JIA.
214978762|NCT04168034|BEHAVIORAL|Waitlist Control|The control group will receive standard care but without the iParent2Parent program
214978763|NCT05731310|DRUG|Angong Niuhuang Pill|Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
214978764|NCT02060357|DEVICE|Optical coherence tomography|
214978765|NCT00032773|DRUG|pentostatin for injection|
215086591|NCT06397560|RADIATION|PRDR|Proton pulsed reduced dose rate (PRDR) technique, to a dose of 54 Gy in 30 fractions (treatments) with proton radiotherapy. Treatments will occur once per day on consecutive weekdays.
214978766|NCT05589974|DRUG|Verteporfin|Chronic CSC are receiving one treatment before the observation period.
215086592|NCT03573349|DRUG|Ketamine|We will enroll 20 adults (aged 18-65 years) with treatment-resistant depression and will provide two i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), and following ketamine treatment (change biomarkers). This will be an open-label feasibility trial.
214367294|NCT02816034|BEHAVIORAL|Visuo-motor rotation|Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.
214367295|NCT02816034|BEHAVIORAL|Explicit strategy|Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target
214367296|NCT00242528|DRUG|Zoledronic acid|
214367297|NCT00253201|DRUG|galantamine hydrobromide|
214367298|NCT01716143|PROCEDURE|radiofrequency catheter ablation|
214367299|NCT03287739|BEHAVIORAL|Assessment of behavioral biometric impairments|Assessment of behavioral biometric impairments
214367300|NCT02000739|GENETIC|Genetically Informed Therapy|If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
214491982|NCT06790199|BEHAVIORAL|"Incredible Years® Helping Preschool Children with Autism program (IY-HPCA)"|The IY-HPCA® program is a face-to-face 6-session group-based intervention for preschool teachers of children aged 2-5 with ASD or language and communication difficulties. Sessions last 3 hours, are delivered weekly, and are led by two trained co-leaders who have experience working with children on the autism spectrum. The program covers three main topics: (1) language development, (2) social interactions, and (3) emotion literacy and self-regulation. Teachers learn about coaching language, imitation, sensory routines, social communication, use of pretend and puppet play, and self-regulation skills. Visual supports such as picture schedules, choice cards, command and feelings cards are used, and practices are tailored to children's communication and play level stages. The intervention is structured and includes role-playing techniques and video visualization.
214978767|NCT05928923|DEVICE|CPAP|CPAP usage 3 months
214978768|NCT01552486|OTHER|Chiropractic Spinal Manipulative Therapy|Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
215086593|NCT00379977|BIOLOGICAL|diphtheria, tetanus, pertussis & Hib vaccine|
215086594|NCT04100694|DRUG|MCLA-128|
215086595|NCT05744557|OTHER|num Vapocoolant|Spray will be administered for 4 to 6 seconds from a distance of 3 to 6 inches to desired sites of skin
214367301|NCT01023568|DEVICE|Macintosh blade|Intubation with Macintosh blade laryngoscope
214978769|NCT01552486|OTHER|Usual Care|Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
214978770|NCT01565577|BIOLOGICAL|MenbVac|Blood test
214978771|NCT02578017|BEHAVIORAL|Mobile DOT|Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
214978772|NCT01404910|DEVICE|Apheresis using Liposorber LA-15 System|The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
214978773|NCT00417196|DRUG|QAX576|
214978774|NCT03447548|BEHAVIORAL|Neurofeedback processing speed training|Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm
214978775|NCT03447548|BEHAVIORAL|Active control|Commercially available games on tablet
214978776|NCT01065012|DRUG|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
215086596|NCT06816043|DRUG|MK-8527|Oral Capsule
214367302|NCT01023568|DEVICE|Glidescope|Intubation with Glidescope laryngoscope.
214367303|NCT01023568|DEVICE|Truview PCD|Intubation with Truview PCD laryngoscope.
214367304|NCT06065878|PROCEDURE|IPACK + Genicular Nerve Block|IPACK and Genicular Nerve block were applied with the same total volume of local anesthetic as the control group.
214978777|NCT01065012|DRUG|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
215086597|NCT06816043|DRUG|FTC/TDF|Oral Tablet
215086598|NCT00851578|DEVICE|WATCHMAN|WATCHMAN LAA Closure Device
215086599|NCT00315107|DRUG|Alesse|
215086600|NCT05423938|DIETARY_SUPPLEMENT|Diabetic|It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA\&DHA
215086601|NCT05423938|DIETARY_SUPPLEMENT|Control|It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
215086602|NCT00005574|DRUG|Gentamicin|
215086603|NCT04424225|DRUG|Psilocybin|25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
214367305|NCT04331535|DIAGNOSTIC_TEST|Polygenic risk score (PRS)|Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.
214978778|NCT01065012|DRUG|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
215086604|NCT04424225|DRUG|Niacin|100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
214978779|NCT01065012|DRUG|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
214978780|NCT01065012|DRUG|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
215086605|NCT06645028|BEHAVIORAL|Intensive treatment programme|"Intervention Group: 8-day intensive treatment where each treatment day consists of the following schedule:~Physical activity: 30 minutes Prolonged Exposure (PE): 90 minutes Physical activity: 30 minutes Lunch Physical activity: 60 minutes Eye Movement Desensitization and Reprocessing (EMDR): 90 minutes Physical activity: 30 minutes (omitted on days 4 and 8) Dinner Psychoeducation (omitted on days 4 and 8) Participants stay at the SÄS patient hotel during the treatment (with a three-day weekend break between treatment days 1-4 and 5-8). The treatment concept includes therapist rotation, meaning that participants switch therapists between PE and EMDR sessions. The purpose of this is to increase focus on the processing process rather than the relationship between the therapist and the client."
215086606|NCT06645028|BEHAVIORAL|Treatment as Usual (TAU)|Control group: 16 treatment sessions (90 minutes in duration) either Eye movement desensitisation and reprocessing (EMDR) or Prolonged Exposure (PE) in a standard outpatient format-weekly sessions. Participants can choose to attend 6 sessions of Psychoeducation for PTSD in a group format before starting EMDR or PE.
215086607|NCT06980116|DRUG|EXS73565|EXS73565 oral administration
215086608|NCT06980389|COMBINATION_PRODUCT|Node-Sparing Radiotherapy plus first-line therapy|Patients will receive node-sparing modified short-course radiotherapy, followed by standard first-line chemotherapy combined with a PD-1 inhibitor starting 2-5 days after radiotherapy. Treatment will continue until disease progression or the occurrence of unacceptable toxicity.
215086609|NCT06980389|COMBINATION_PRODUCT|First-line treatment|Patients will receive standard first-line chemotherapy combined with a PD-1 inhibitor. Treatment will continue until disease progression or the occurrence of unacceptable toxicity.
215086610|NCT06980129|OTHER|Rehabilitation in the home|Participants will receive home-based therapy from a MDT team, including physiotherapists, occupational therapists, social workers, dietitians, medical practitioners, psychologists, and pharmacists. Participants will be transferred to RITH once they achieve a level of mobility (+/- assistance) that enables them to manage at home. As per usual care, the disciplines required, frequency of visits, duration of visits, and duration of rehabilitation will be based on the patient's specific needs. There will be weekly MDT conferences to discuss patient progress led by medical staff. Telehealth care may be incorporated into the RITH program, subject to patient preference and provider availability. If the participant deteriorates during the RITH program, the escalation plan mandated by the LHD HITH Department will be followed to ensure appropriate care is provided. As for UCIR, discharge occurs when patients achieve sufficient walking and functional ability with available assistance.
214367306|NCT06342089|OTHER|Type I diabetes milletus|the exposure is type I diabetes milletus
214367307|NCT05646394|DRUG|Dual antiplatelet therapy|Aspirin plus any of clopidogrel, ticagrelor or prasugrel
214367308|NCT05646394|DRUG|Combined antithrombotic therapy|Combination of a vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with low-dose aspirin.
214978781|NCT01065012|DRUG|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
214978782|NCT03708471|PROCEDURE|Hybrid ablation|This intervention including thoracoscopic surgical ablation, percutaneous catheter ablation and cardiovascular risk control.
215086611|NCT06980129|OTHER|Usual care inpatient rehabilitation|Participants will receive care in a rehabilitation ward or subacute hospital, including therapy from a MDT team. Discharge occurs when patients achieve sufficient walking and functional ability with available assistance, typically within 1-3 weeks, though this varies.
215086612|NCT06980441|BEHAVIORAL|Problem Management Plus with Emotional Processing module|PM+ EP comprises of Problem Management Plus, an evidence-based low intensity psychological intervention developed by the World Health Organization (WHO), with an additional Emotional Processing module specifically to address psychological distress related to trauma exposure. The core of the intervention is designed for adults impaired by distress in communities exposed to conflict and adversity; it consists of CBT techniques that have been adapted for communities that do not have good availability of specialist care. The additional module was developed by researchers treating refugee youth (Alozkan Sever et al, 2021). For this study, PM+ EP will be a six-session individual and guided support program. The original sections of PM+ are available in many languages including Farsi, and the additional EP module will be translated by PoMA's Afghan translator. The sessions cover the topics of managing stress, strengthening social support, staying well and persevering.
214367309|NCT05646394|DRUG|Vitamin K antagonist standard intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0
214978783|NCT03708471|PROCEDURE|Thoracoscopic surgical ablation|This intervention including thoracoscopic surgical ablation and cardiovascular risk control.
214367310|NCT05646394|DRUG|Vitamin K antagonist high intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0
214367311|NCT00224770|DRUG|MIS+Cathflo Activase (drug)|MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
214367312|NCT00224770|PROCEDURE|Intraoperative stereotactic CT-Guided Endoscopic Surgery|Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
214367313|NCT00233441|DRUG|CELIVARONE (SSR149744C)|
214367314|NCT03227016|DRUG|veliparib|Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.
214978784|NCT06415461|BIOLOGICAL|PremierMaxCB®-Platinum (CFL001);|Stem Cell: Human cell, tissue, and cellular or tissue-based product (HCT/P) manufactured from umbilical cord blood
214978785|NCT03458520|DIAGNOSTIC_TEST|PET/MR imaging|undergo PET/MR imaging
214978786|NCT03458520|DIAGNOSTIC_TEST|MR imaging|Undergo MR imaging
214978787|NCT03458520|DIAGNOSTIC_TEST|PET/CT imaging|Undergo PET/CT imaging
214978788|NCT06363266|BEHAVIORAL|TEMPO|"Stage 1 interventions (weeks 1-12): TEMPO.~After 12 weeks, the benefit of the initial assignment will be assessed. Benefit is defined as a score \< 3 on the ESAS-r anxiety item (range 0-10) or a decrease \>= 2 points from eligibility screening. If both dyad members had anxiety symptoms at recruitment, both must meet the benefit criterion. If one member no longer meets the criterion, the dyad is considered did not benefit.~Stage 2 interventions (weeks 13-25): TEMPO or lay guidance.~1. TEMPO responders will continue with TEMPO. Dyads who did not benefit will be re-randomized to:~   1. Stepping up to lay guidance (8 x 20-minute calls via phone or Teams). Guides will receive TEMPO training and conduct semi-structured exit interviews.~  2. More time with TEMPO for dyads who benefited from it.~2. Non-responders to usual care in Stage 1 will be stepped up to TEMPO."
215086613|NCT06979661|DIAGNOSTIC_TEST|Haystack™ ctDNA Assay|A personalized, tumor-informed circulating tumor DNA (ctDNA) test that analyzes blood samples to detect minimal residual disease (MRD) and guide postoperative treatment decisions for patients with Stage II-III non-small cell lung cancer (NSCLC) following surgical resection. The test results will help determine whether patients should receive postoperative radiation therapy (PORT) and/or systemic therapy adjustments.
215086614|NCT01563289|DRUG|Ibuprofen|3 times a day
215086615|NCT01563289|DRUG|Placebo|3 times a day
215086616|NCT02259140|PROCEDURE|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
215086617|NCT02259140|PROCEDURE|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
215086618|NCT04646226|DEVICE|AV graft|The purpose of the surgery is to connect a large vein in the arm to a nearby artery indirectly by inserting a graft material (graft surgery)
214978789|NCT06363266|OTHER|Active Monitoring dyads' anxiety|"Stage 1 interventions (week 1-12): Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices).~Stage 2 interventions (week 13-25): Dyads not responding to active monitoring will be stepped up to TEMPO; responders to active monitoring will only be invited to complete the follow-up measures."
214978790|NCT06357624|OTHER|Mulligan mobilization|The SNAGS technique was applied to 3 sets of 10 repetitions with 15-30 seconds rest between sets while the participants were in a sitting position. A physiotherapist applied passive motion to facet joints at each spinal level. The participant was questioned in which direction he/she felt pain during cervical ROM and the application was carried out in the painful/limited directions.
215086619|NCT04646226|PROCEDURE|surgical intervention for creation of a fistula|The purpose of the surgery is to connect a large vein in the arm to a nearby artery directly (fistula surgery)
215086620|NCT05821374|DRUG|Deucravacitinib|6 mg tablet
214978791|NCT06357624|OTHER|Self-Mobilization|For the self-mobilization technique, each participant was asked to extend a pain-free while pushing upwards from the transverse processes of the treated vertebra with the thumbs of both hands. In addition, the middle or index finger of the right hand was asked to pull the treated vertebra to the right side, while at the same time, left rotation was asked at the pain limit. Self-mobilization was applied every day, twice a day, five times.
215086621|NCT03494218|DIAGNOSTIC_TEST|Nociception Coma Scale (NCS)|Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.
215086622|NCT00722202|DRUG|ERB-257|
215086623|NCT00722202|OTHER|placebo|
215086624|NCT00123266|DRUG|Microplasmin|2 mg/kg, IA over 75 mins
215086625|NCT06660498|DRUG|Pomalidomide 2 mg|Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
215086626|NCT06660498|DRUG|Placebo|Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
215086627|NCT06660498|DRUG|Aspirin 75 mg|Auxiliary Medicinal Product
215086628|NCT03309293|BIOLOGICAL|blood samples|blood samples
214367315|NCT03227016|DRUG|Topotecan|Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
214367316|NCT00231673|DRUG|Topiramate|Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
215086629|NCT05859815|BEHAVIORAL|Physical Therapy|As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.
214367317|NCT05458596|BEHAVIORAL|Screen-based simulation|In the research, training will be given to the sample group on intimate partner violence against women through screen-based simulation.
214367318|NCT05074355|DRUG|Azacitidine|Azacitidine is a hypomethylating agent that works by activating certain genes in the body to help cells mature and to kill abnormal bone marrow cells.
214367319|NCT05074355|DRUG|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells.
214491983|NCT05807321|DEVICE|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry and balloon expulsion test may be used as reference. Anorectal manometry and balloon expulsive test are standard methods for anorectal functional measurement.
215086630|NCT05748704|OTHER|Short-term modified fasting|STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
215086631|NCT01313819|DRUG|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
215086632|NCT06607055|DIAGNOSTIC_TEST|Blood collection|HLA-DR dosage, at the time of inclusion and once a week then
215086633|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666) IV|intravenous infusion
215086634|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666)|exposed via pregnancy and lactation
214978792|NCT01190917|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT social skills curriculum is manualized and anchored in CBT strategies, such as problem identification, affective education, performance feedback, and weekly homework activities to facilitate generalization. The curriculum is a compilation of lessons targeting key social deficits in children with ASD, such as nonverbal communication, emotion recognition, and theory of mind. Structured teaching includes defining skills, breaking them down into simple, concrete steps, modeling the skill through role-play, and introducing a game or activity to practice the target skill. The approach to the parent group will be psychoeducational with a focus on reviewing target skills, rationale for teaching target skills, homework, progress or obstacles, and identifying strategies to promote generalization. Parent information handouts will be provided.
214978793|NCT01190917|BEHAVIORAL|Play Therapy|The social play group is manualized, led by a trained clinician and support staff, follows a specific routine, and contains a parent group component. Group leaders will follow participants' interests and suggestions for games. Group leaders utilize strategies such as reflective functioning statements on the child's behaviors to build emotion-focused play skills. The therapeutic setting incorporates play designed to encourage emotion-focused play including make-believe (dolls, houses), sensory (e.g. play-doh), and cooperative play (e.g. board games) toys. The approach to the parent group will be supportive rather than psychoeducational. Parents will set the agenda for discussion, facilitated by the group leader.
215086635|NCT07018089|BEHAVIORAL|iWork.Comp|The iWork.COMP is a short-term and low-time consuming internet delivery CFT-based intervention specifically designed to mitigate the impact of toxic leadership styles through the development of compassionate motivation in the workforce of EU hospitals. The iWork.COMP encompasses 8 individual sessions (20 minutes each; mixed format including text, audio and video presentations), which will be available weekly for participants at the KEEPCARING website (https://keepcaring.eu). Each session has three parts. Part 1 encompasses a brief check-in on the stress level of the participant at that moment and on the source of their stress (if applicable). In Part 2, the theme of the session is developed. Finally, Part 3 encompasses a brief check-in on the stress level of the participant at the end of the session and on the usefulness of the session; an optional open question to provide feedback will also be displayed.
215086636|NCT04060628|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|
215086637|NCT06703892|BIOLOGICAL|GF-CART01|CAR positive viable T cells-Mid
214978794|NCT00361452|DRUG|nebulized epinephrine and nebulized albuterol|
214978795|NCT05554497|BEHAVIORAL|Mindfulness-based stress reduction curriculum|Standard 8-week mindfulness-based stress reduction curriculum
214978796|NCT04458519|OTHER|Probiorinse|Nasal irrigations with probiotic twice-daily for a period of fourteen days
214978797|NCT04458519|OTHER|Saline solution|Nasal irrigations with saline-only twice-daily for a period of fourteen days
214978798|NCT03080935|DRUG|Evolocumab|Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
214978799|NCT02306876|DRUG|PF-06412562 3mg BID|PF-06412562
214978800|NCT02306876|DRUG|PF-06412562 15mg BID|PF-06412562
214978801|NCT02306876|OTHER|Placebo|Placebo
214978802|NCT01614470|DRUG|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
214978803|NCT01614470|DRUG|Placebo|oral use, administered twice a day (q12h)
215086638|NCT06703892|BIOLOGICAL|GF-CART01|CAR positive viable T cells-High
215086639|NCT06703892|BIOLOGICAL|GF-CART01|CAR positive viable T cells-Low
215086640|NCT07040657|PROCEDURE|Sentinel Lymph Node Detection/Cervical Methylene Blue Injection|Sentinel Lymph Node (SLN) detection using cervical methylene blue injection is a surgical technique designed to identify the primary lymph nodes responsible for draining the uterus in patients with endometrial cancer. The procedure involves injecting methylene blue dye into specific locations within the cervical stroma to enable lymphatic uptake. The dye subsequently travels through the lymphatic channels, allowing for intraoperative visual identification of the sentinel nodes. This targeted approach facilitates selective SLN excision for pathological evaluation, providing critical information about lymphatic involvement while minimizing the extent of surgical dissection. The effectiveness of SLN mapping is contingent upon the accuracy of the injection technique and the anatomical distribution of lymphatic drainage.
215086641|NCT07040826|DRUG|Xiidra|Administered on Day 1 to subjects in Group B, and on Day 8 to subjects in Group A as part of a crossover study design.
215086642|NCT07040826|DRUG|Lifitegrast|Administered on Day 1 to subjects in Group A, and on Day 8 to subjects in Group B as part of a crossover study design.
214978804|NCT03804281|PROCEDURE|Test group|The surgery will be done with the use of 4x magnification loop, the knives are micro blades and micro-sutures 7//0 used with the microsurgical instruments kit
215086643|NCT07030244|BEHAVIORAL|Moodpep|See arm description
215086644|NCT07041489|DIETARY_SUPPLEMENT|Active Comparator- Xtressé™ Supplement and Serum|"Participants will receive 3 month supplies 3 times during the study. Participants will apply serum and take supplements daily.~Participants in the Intervention group will receive Xtressé™ Supplements and Serum in Part A and Part B of the study.~Participants in the Placebo Group will receive Xtressé™ Supplement and Serum in Part B of the study only."
214978805|NCT03804281|PROCEDURE|Control group|esthetic crown lengthening with conventional approach with an internal bevel incision, following CEJ anatomy, this will be followed by an intra-sulcular incision, removal of the strip of outlined marginal gingiva and elevation of a mucoperiosteal ﬂap to the level of the alveolar bone crest.
214978806|NCT04157010|DRUG|Tocilizumab|
214978807|NCT04157010|DRUG|Methotrexate|
214978808|NCT01219543|DRUG|AZD1480 Daily|Oral Dose, Capsule, Daily Dosing
214978809|NCT01219543|DRUG|AZD1480 BID|Oral Dose, Capsule, BID Dosing
214978810|NCT03733808|DEVICE|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
214978811|NCT01255215|DRUG|Inhaled Nitric Oxide|Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
214978812|NCT02175121|DRUG|Placebo|Tablet, once daily for 28 days
214978813|NCT02175121|DRUG|PF-06291874|Tablet, 15 mg, once daily for 28 days
214978814|NCT02175121|DRUG|PF-06291874|Tablet, 35 mg, once daily for 28 days
214978815|NCT02175121|DRUG|PF-06291874|Tablet, 75 mg, once daily for 28 days
214978816|NCT02175121|DRUG|PF-06291874|Tablet, 150 mg, once daily for 28 days
214978817|NCT04010279|PROCEDURE|preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.
214978818|NCT00244049|BEHAVIORAL|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
214978819|NCT00244049|OTHER|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
214978820|NCT02313051|DRUG|Everolimus|mTOR inhibitor
214978821|NCT02313051|DRUG|Goserelin|
214978822|NCT02313051|DRUG|Letrozole|
214978823|NCT04332263|OTHER|Neuromuscular Electrical Stimulation - NMES|NMES will be applied through an alternating biphasic current, with a stimulation frequency of 80 Hz and 1 ms pulse duration. Tetanic evoke forces (EF) at a 50% level of a supra-maximal single-pulse peak EF (i.e., 10-12% of a maximal voluntary isometric contraction) will be used. NMES protocol will be performed five times a week, lasting 20 minutes. Muscle fatigue will be evaluated every 5 min of the intervention, and will be used to determine the NMES protocol termination. A 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol will be used to terminate the fatigue protocol.
214978824|NCT04813523|DRUG|Pembrolizumab Injection [Keytruda]|Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
214978825|NCT03167554|OTHER|Sham comparator|The electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
215086645|NCT07041489|DIETARY_SUPPLEMENT|Placebo Comparator- Placebo Supplement and Serum|"Participants will receive 3 month supplies 3 times during the study. Participants will apply serum and take supplements daily.~Participants in the Placebo Group will receive Placebo Supplement and Serum in Part A of the study only."
215086646|NCT07041424|PROCEDURE|treatment group 1: total etch bonding agent used with rebonding technique|class 1 composite restoration is done using total etch type bonding agent and rebonding technique applied
214978826|NCT03167554|OTHER|Experimental group 1|Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec.
214978827|NCT03167554|OTHER|Experimental group 2|Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle, 120 microamps, 1 min 20 sec.
214978828|NCT02144870|BEHAVIORAL|Habit Reversal Training|awareness training, competing response training
214978829|NCT02144870|BEHAVIORAL|Resources activation|
214978830|NCT05593588|DRUG|Fisetin|20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
214978831|NCT05593588|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
214978832|NCT02936375|DRUG|Iguratimod|25mg twice a day, orally administrated
214978833|NCT02936375|DRUG|Cyclophosphamide|1g/m², every 4 weeks, intravenous
214978834|NCT02936375|DRUG|Azathioprine|2mg/kg·d, once a day, orally administrated
214978835|NCT02936375|DRUG|Steroids|Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
214978836|NCT02072642|DEVICE|active light therapy : Light therapy: DayVia lamp 10000 lux|4 weeks of active light therapy with DayVia lamp 10000 lux
214978837|NCT02072642|DEVICE|Placebo light therapy|4 weeks with Placebo light therapy
214978838|NCT03779347|DRUG|Praziquantel|Praziquantel to treat schistosomiasis during pregnancy
214978839|NCT03779347|DIAGNOSTIC_TEST|UCP-LF CAA|UCP-LF CAA to diagnose Schistosomiasis during pregnancy
215086647|NCT07041424|PROCEDURE|treatment group 2: self etch bonding agent used with rebonding technique|class 1 composite restoration is done using self etch type bonding agent and rebonding technique applied
214978840|NCT03779347|DIAGNOSTIC_TEST|composite diagnostic|composite diagnostic reference test based on extensive egg microscopy, serology, qPCR on egg DNA, and POC-CCA to diagnose Schistosomiasis during pregnancy
214978841|NCT05908396|DRUG|IGM-2644|IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
214978842|NCT03025633|OTHER|PEARL|PEARL, is a commercially available PC-based tool that provides a realistic and functional 3D model of a linac and, having uploaded example treatments it can demonstrate the treatment procedure and also relevant anatomical information.
214978843|NCT03053882|OTHER|mouthwash|mouthwash containing herbal peppermint or green tea
214679979|NCT03914287|OTHER|Self-Myofascial release|The Self-Myofascial release protocol for the lower limbs using a Foam Roller will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; release of the myofascial components of the back of the leg using a Foam Roller; release of the myofascial components of the anterior part of the leg using a Foam Roller; release of myofascial components of the hamstring region using a Foam Roller; release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; and release of the myofascial components of the pelvitrochanteric muscles using a Foam Roller in a sitting position.
214978844|NCT02557399|DRUG|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
215086648|NCT07041034|BEHAVIORAL|Active Comparator Group|"The group will receive:~1.Foundational Education: A structured session introducing key concepts of BPSD, symptom recognition, and general management approaches. 2.Simulation-Based Training: An interactive training module using case-based simulation to illustrate common BPSD scenarios and guide caregivers in applying appropriate strategies.~This group will not receive the protocol-based intervention component."
215086649|NCT07041034|BEHAVIORAL|Experimental Group|"The intervention consists of three components:~1. Foundational Education: A structured session introducing key concepts of BPSD, symptom recognition, and general management approaches.~2. Simulation-Based Training: An interactive training module using case-based simulation to illustrate common BPSD scenarios and guide caregivers in applying appropriate strategies.~3. SUNAM Protocol Training: Instruction on a structured, theory-informed protocol aimed at identifying and addressing underlying factors that contribute to BPSD in institutionalized residents."
215086650|NCT07041047|DEVICE|APAISANT SERUM - INGROWN NAILS|Topical application of APAISANT SERUM - INGROWN NAILS twice daily for 7 days.
215086651|NCT07041411|PROCEDURE|maxillary sinus elevation through transcrestal approach using OSSIX® Bone|After a careful radiologic analysis, using a surgical guide, maxillary sinus elevation through transcrestal access to sinus mucosa was achieved. The elevation of the maxillary sinus mucosa was performed through micro-elevators and graft material was inserted.
214978845|NCT02557399|DRUG|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
214978846|NCT02557399|DRUG|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
214978847|NCT01170325|DRUG|Divalproex Sodium|
214978848|NCT01170325|DRUG|Placebo Comparator|
214978849|NCT00689689|DEVICE|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
214978850|NCT00689689|DEVICE|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
214978851|NCT02712957|DRUG|NEO6860|TRPV1 antagonist
214978852|NCT02712957|DRUG|NEO6860 placebo|Inactive substance
215086652|NCT07040254|BEHAVIORAL|Father-Inclusive Antenatal Education Program|A structured six-week antenatal education program designed for pregnant women and their spouses. The program included sessions on pregnancy care, labor, breastfeeding, newborn care, and postpartum health. Fathers in the intervention group attended the program alongside their partners and were actively engaged in discussions and learning activities related to breastfeeding support. The goal was to enhance paternal awareness and involvement to improve maternal breastfeeding adaptation and both maternal and paternal breastfeeding self-efficacy. No additional materials were provided beyond the scheduled sessions.
214978853|NCT02712957|DRUG|Naproxen|NSAID
214978854|NCT02712957|DRUG|Naproxen placebo|inactive substance
214679980|NCT00008294|DRUG|FOLFOX regimen|
214679981|NCT00008294|DRUG|dexamethasone|
214978855|NCT02848664|DEVICE|Dysphagia retraining with device|Patients used the device for 60 trials of retraining swallowing at home each day and also had the device turned on throughout the day in automatic mode to intermittently trigger every few minutes to trigger a swallow for saliva control
214978856|NCT05778474|OTHER|Healthy subjects|"Participants' ground spontaneous speed overground will be tested by means of the 10-meter walking test. Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised. Participants will walk on a treadmill mounted on force sensors. The test sequence will be the following:~1. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.2 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Walking. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds.~3. Walking with a rigid ankle-foot orthosis. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds with an ankle-foot orthosis on the dominant lower limb.~Participants will repeat the last point (n°3) with the ankle-foot orthosis on the non-dominant lower limb. A 3-min pause will follow each section."
214978857|NCT05778474|OTHER|Pathologic group|"Participants will walk on a treadmill mounted on force sensors. They will walk freely, under tight supervision, but without hanging to any support. The test sequence will be the following:~4\. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~5\. Walking. Participants will walk at 0.4 m s-1 for at least 30 seconds. Participants will be informed a few seconds before the changes in belts' velocities with a verbal warning."
214978858|NCT01121510|DEVICE|closure device|the invasive specialist must carefully manage the difficult balance of patient anticoagulation and coagulation for stopping the bleeding at the femoral artery puncture site. the QuickClose design 9 system is designed to benefit the patients and the medical staff by improving the process. the risks to patients associated with this study are considered reasonable in comparison to the anticipated benefits to the subjects, and the scientific knowledge that can be gained from the study.
214978859|NCT01784874|BIOLOGICAL|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
214978860|NCT01784874|BIOLOGICAL|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
214978861|NCT00402727|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
214978862|NCT00402727|DRUG|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
214978863|NCT05868538|DIAGNOSTIC_TEST|Serum calprotectin and IMA concentrations|Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.
214978864|NCT03546712|OTHER|Tactile Localization|tactile localization is help to assess touch sensation
214978865|NCT03580070|BIOLOGICAL|Immunotherapy|Patients with primitive head and neck squamous cells carcinoma diagnosed on surgical resection or biopsic sample, between 2008 and 2015. They were included when expressing p16 as assessed by immunochemistry and positive HPV DNA by in situ hybridation or positive HPV PCR
214978866|NCT04996420|DEVICE|Clearsight non invasive hemodynamic monitoring|Goal directed fluid therapy fuided by Clearsight monitoring
214978867|NCT00099112|GENETIC|microarray analysis|
214978868|NCT00099112|PROCEDURE|biopsy|
214978869|NCT00099112|PROCEDURE|evaluation of cancer risk factors|
214978870|NCT03529253|DRUG|Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily|Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
214978871|NCT03529253|DRUG|Rosuvastatin calcium10mg|Rosuvastatin10mg/daily by oral for 9 months.
214978872|NCT00004002|DRUG|bortezomib|
214978873|NCT01655316|DRUG|Verapamil|
214978874|NCT04951089|DEVICE|i-gel Supraglottic device insertion|i-gel insertion for oxygenation
214978875|NCT04951089|DEVICE|Air-Q SP 3G Supraglottic device insertion|Air-Q SP 3G insertion for oxygenation
214978876|NCT04022330|OTHER|Blood sampling|The blood sampling will be done just before surgery
214978877|NCT05562869|DRUG|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
214978878|NCT04645563|OTHER|Sending thorax ct video images via smartphone applications|Video images of the patients will be sent via smartphone application to infectious disease specialist for consulting.
214978879|NCT01405898|DIETARY_SUPPLEMENT|beetroot juice|Beetroot juice 4 weeks 250ml daily
214978880|NCT01405898|DIETARY_SUPPLEMENT|Nitrate-free beetroot juice|Nitrate-free beetroot juice 4 weeks 250ml daily
214978881|NCT01148394|OTHER|Multimodal rehabilitation|
214978882|NCT03800316|DEVICE|Video Consultation|Video consultation with emergency medicine physicians for patients that are critically ill prior to arrival in the ED
214978883|NCT00015002|DRUG|Betamethasone|"coded study medication is 12 mg of betamethasone (or placebo) given as 2 ml intramuscular injection in 2 doses, 24 hours apart (the Course). Patients administered weekly courses for 4 weeks, until 33 weeks 6 days gestation or delivery, whichever occurs first."
214978884|NCT02764437|BIOLOGICAL|Whole lung antigen challenge, segmental allergen challenge|Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
214978885|NCT04806269|DEVICE|Fitbit and Glandy|Data collection from wearable devices (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) Fitbit collects user's heart rate, activity, and sleep data. Glandy collects user's subjective symptom scores.
214978886|NCT01687218|DRUG|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
214978887|NCT01687218|DRUG|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
214978888|NCT01687218|DRUG|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
214978889|NCT01835912|OTHER|Sodium Citrate Dihydrate|Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
214978890|NCT02894333|BEHAVIORAL|behavioral observation|
214978891|NCT03301636|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
214978892|NCT03301636|DRUG|Nivolumab|Nivolumab will be administered intravenously every 2 weeks starting on day 1.
214978893|NCT03301636|DRUG|Indoximod|Indoximod will be administered orally every 12 hours starting at Day 1
214978894|NCT00302978|BEHAVIORAL|Behavior therapy|
214367320|NCT04557839|OTHER|Traditional physical therapy balance exercise|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward~• Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
214367321|NCT04557839|OTHER|proprioception based balance training|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward all exercise done under following condition.~* eyes open firm surfaces~* Eyes open soft surfaces~* Eyes closed firm surfaces~* Eyes closed soft surfaces (the soft surfaces will be a foam mate with 2.5 cm thick )~* These exercise will perform with turning the head side to side ad up and down~* Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
214978895|NCT05862051|PROCEDURE|Local Ablative Therapy|LAT modalities allowed include surgical resection, stereotactic radiotherapy (SRT), laparoscopic or percutaneous thermal ablation \[radiofrequency ablation (RFA) or microwave ablation (MWA)\]. The LAT modalities will be delivered by specialists in the field (surgeons, radiation oncologists and/or interventional radiologists). The precise mode of delivery and number of times the LAT modality is delivered is case-dependent and is determined at a multi-disciplinary meeting (MDM).
214978896|NCT05862051|PROCEDURE|Standard first-line systemic treatment|Standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
214978897|NCT03606564|OTHER|study of fasting time among pediatric patients undergoing day care surgery|parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
214978898|NCT02084511|DRUG|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
214978899|NCT02084511|DRUG|BI 1026706|BI 1026706
214978900|NCT02084511|DRUG|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
215086653|NCT07040228|DRUG|Regorafenib combined with Toripalimab and Albumin paclitaxel|Regorafenib combined with Toripalimab and Albumin paclitaxel as the third line treatment for patients with advanced pancreatic cancer
215086654|NCT03106415|DRUG|Binimetinib|Given PO
215086655|NCT03106415|OTHER|Laboratory Biomarker Analysis|Correlative studies
215086656|NCT03106415|BIOLOGICAL|Pembrolizumab|Given IV
214367322|NCT03760601|BEHAVIORAL|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
214679982|NCT00008294|DRUG|floxuridine|
214679983|NCT00008294|DRUG|fluorouracil|
214978901|NCT02084511|DRUG|Celecoxib|Celecoxib capsule
215086657|NCT07040722|OTHER|Baseline|During the baseline, children will carry out their standard paper-and-pencil exercises for writing difficulties (that their perform during usual rehabilitation).
215086658|NCT07040722|OTHER|Intervention|During the intervention, they will carry out usual exercises and they will use VR 15 minutes during each session
215086659|NCT06892444|DIETARY_SUPPLEMENT|Yellow Sweet Corn|Participants will consume 1.5 cups daily of yellow or white canned sweet corn.
215086660|NCT06892444|DIETARY_SUPPLEMENT|White Sweet Corn|1.5 cups daily of canned yellow sweet corn
214679984|NCT00008294|DRUG|leucovorin calcium|
214679985|NCT00008294|DRUG|oxaliplatin|
215086661|NCT01637389|OTHER|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
215094486|NCT05977166|DEVICE|hyperbaric oxygen therapy|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
215086662|NCT01637389|OTHER|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
215086663|NCT04146961|DEVICE|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
215086664|NCT02614040|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
215086665|NCT02614040|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
215086666|NCT00293709|DRUG|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
215086667|NCT06903780|OTHER|Survey using a questionnaire.|A short 23-item survey concerning patients' experiences of their biologic treatments for their severe asthma.
215086668|NCT04993729|DRUG|T89 capsule|"T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID."
215086669|NCT04993729|DRUG|Placebo capsule|Placebo capsules, p.o. TID.
215086670|NCT02785458|BEHAVIORAL|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
214367323|NCT03963661|BEHAVIORAL|c-SIGHT (computorized spatial innatention grasping home-based therapy)|C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
214367324|NCT00861614|DRUG|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
214367325|NCT00861614|DRUG|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
214367326|NCT03391765|DRUG|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
214367327|NCT03391765|DRUG|Placebo solution for IV infusion on Day 15|0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
214367328|NCT01056588|BEHAVIORAL|CO-Contingent|In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).
214367329|NCT01056588|BEHAVIORAL|Control condition|In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
214367330|NCT02687321|OTHER|Determination of CA 125 and HE4, Computed tomography|Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
214679986|NCT05635552|DIAGNOSTIC_TEST|Dynamic retinal vessel analysis (DVA)|DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.
214679987|NCT05635552|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.
214679988|NCT05635552|DIAGNOSTIC_TEST|Biochemistry and immune phenotyping|Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.
215086671|NCT03552211|DRUG|biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
215086672|NCT03552211|OTHER|propensity score|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
214367331|NCT03540511|DIAGNOSTIC_TEST|postoperative troponin|assess postoperative troponin levels after cardiac surgery in patients with renal dysfunction
214367332|NCT04426396|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire, CT-FFR computed by coronary CT angiography
214978902|NCT06323785|DEVICE|Active whole-body hyperthermia|Active water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
214978903|NCT06323785|DEVICE|Sham whole-body hyperthermia|Sham water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
214978904|NCT01555658|DRUG|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)
215086673|NCT01804582|OTHER|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
215086674|NCT00344734|DRUG|Ng-monomethyl-L-arginine (drug)|
215086675|NCT00408096|PROCEDURE|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
215086676|NCT02608580|OTHER|Survey|
215086677|NCT00520013|DRUG|bevacizumab|
215086678|NCT00520013|DRUG|erlotinib|
215086679|NCT00520013|DRUG|paclitaxel|
215086680|NCT00520013|DRUG|carboplatin|
215086681|NCT02227823|DRUG|Pyridostigmine Bromide|
215086682|NCT02426190|OTHER|Anti-gravity treadmill|The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
214367333|NCT02331797|DEVICE|Endoscopic Technique|Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
214367334|NCT02331797|DEVICE|Microscopic Technique|Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
214367335|NCT01255592|DRUG|AZD5069|Oral dose bid
214367336|NCT01255592|DRUG|Placebo|Oral dose bid
214367337|NCT06453122|OTHER|Oral care|The intervention group procedure will be carried out in the same way and frequency of the control group, however, replacing the chlorhexidine solution 0.12% for mineral water. Oral hygiene will be carried out by the nursing team, which will be blind to the indices to be evaluated. The team will be previously trained to carry out hygiene procedures by the team of ICU dental surgeons.
214978905|NCT01555658|DRUG|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)
214978906|NCT02749344|OTHER|FET after endometrial preparation|Patients included in the protocol will begin progesterone supplementation 48 hours before scheduled embryo transfer once it has been established that the endometrium is at least 7 mm and there is a leading follicle.
214978907|NCT01733277|OTHER|Magnetic Resonance Imaging (MRI)|All participants from both arms will be subjected to MRI
214978908|NCT00763789|OTHER|local anaesthesia and remifentanil sedation|
214978909|NCT00763789|OTHER|total intravenous anaesthesia|
214978910|NCT04454424|DRUG|BAY1817080|Study intervention BAY1817080 will be administered orally with tablet(s).
214978911|NCT04454424|DRUG|Midazolam|Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.
214978912|NCT04313517|OTHER|Yoga|Each yoga session included warm-up practices (for the large joints, spine, and extremities), Simple postures (Asana), breathing exercises (pranayama) and meditation/relaxation. All the yoga participants were given handouts to practice everyday at work as its feasible
215086683|NCT02426190|OTHER|PENS - neuro-muscular stimulation|The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
215086684|NCT02426190|OTHER|Anti-gravity treadmill & PENS - neuro-muscular stimulation|The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
214367338|NCT02035332|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
214367339|NCT02452684|DRUG|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
214367340|NCT05297474|OTHER|MRI|No intervention was performed in this study.
214367341|NCT03554993|DRUG|CC-99677|CC-99677
214367342|NCT03554993|OTHER|Placebo|Placebo
214978913|NCT03363971|DRUG|Zhi Kang Capsule|0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
214978914|NCT03363971|DRUG|Simulant agent for Zhi Kang Capsule|0.3g/capsule,oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
214978915|NCT01548807|DRUG|Everolimus (RAD001)|
214978916|NCT02630810|OTHER|Early oral hydration|starting oral hydration 1 hour following Cesarean Section using 100 ml clear water
214978917|NCT02630810|OTHER|Delayed oral hydration|starting oral hydration 6 hours following Cesarean Section using 100 ml clear water
214978918|NCT03427710|DRUG|CiVi007|cholesterol lowering drug
214978919|NCT03427710|OTHER|Placebo|matching placebo to CiVi007
214978920|NCT02964130|OTHER|No name|
214978921|NCT02701621|OTHER|MIRT-AT|Aquatic therapy
214978922|NCT02701621|OTHER|MIRT|Land-based Therapy
214978923|NCT06160336|OTHER|Transcutaneous Electrical Nerve Stimulation|"Phase 1: Participants undergo a comprehensive assessment in a single experimental session (mapping session) aimed at mapping the regions and sensations that can be electrically stimulated. This mapping protocol is conducted on both the intact and amputated limbs.~Phase 2: This phase comprises a 4-week experimental protocol, including:~1. four mapping sessions conducted at the onset of each week, where the protocol is randomly applied to the participant's intact and amputated limb.~2. three stimulation sessions held over three consecutive days in the initial week to assess the participant's ability to discern stimuli of varying intensities.~3. ten sessions utilizing an end-effector gait rehabilitation robot, aiming to train the participant in walking using the proposed sensory feedback restoration system based on TENS under controlled and repeatable experimental conditions."
214978924|NCT05943353|OTHER|Pentoxifylline|Prominently, Pentoxyfilline (PTX) is a methylxanthine derivative, is an inhibitor of phosphodiesterase activity and increases intracellular cAMP levels, which play an important role in sperm motility. The ability of PTX to improve sperm motility was first recognized in the study of Turner et al (1978). One of the advantages of PTX is that it significantly reduces the time to find and select motile sperm in cases of completely immotile sperm. In recent years, many studies have demonstrated the effectiveness of PTX for the group of spermatozoa, sperm carrying severe abnormalities. Therefore, the use of a sperm motility inducer such as PTX is a potential method to replace traditional ICSI sperm selection methods. Therefore, we performed this study with the aim to evaluate the effectiveness of PTX to select sperm in ICSI on the group of sperm that were completely immotile after ejaculation and obtained from the procedure.
214978925|NCT00944710|DRUG|Atropine|Weekend atropine 1%
214978926|NCT00944710|DEVICE|Plano lens|plano lens over the sound eye
214978927|NCT00944710|DRUG|Atropine|Weekend atropine 1%
214978928|NCT04845334|BEHAVIORAL|RR intervention|"The short psychological intervention consists of a narrative interview and a psychocorporeal intervention. Narrative interview: this is an interview aimed at exploring the experience and awareness of illness. The sharing of the dimension of pain and suffering, the verbalization of emotions, the narration of the history of illness, expectations and fears related to the intervention will be aimed at an emotional and cognitive restructuring of the experience of illness, improving the perception of internal resources and resilience.~Psycho-corporeal intervention:it is a training to the psychophysiological technique of the Relaxation Response (R.R.) of Hebert Benson (Mind-Body Medical Institute of Havard), aimed at stress management and consequently at reducing the perception of pain"
214978929|NCT00887484|DRUG|BENZOYL PEROXIDE/ CLINDAMYCIN|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
214978930|NCT00887484|DRUG|BENZOYL PEROXIDE/ ADAPALENE|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
214978931|NCT02943772|OTHER|Local hypothermia|Cooled brick
214978932|NCT02943772|OTHER|Control|Control brick
214978933|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
214978934|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
214978935|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
215086685|NCT02426190|OTHER|Recumbent or Nu-step bike|This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
215086686|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
215086687|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
215086688|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
214367343|NCT06510452|DRUG|2000 mg of Cefazolin|receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
214367344|NCT06510452|DRUG|500 mg of Metronidazole IV|receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
214367345|NCT06510452|DRUG|NACL 0.9% 100 ml|receive 100 ml NACL0.9% without any antibiotics in it.
214367346|NCT00551070|OTHER|Laboratory Biomarker Analysis|Correlative studies
214367347|NCT00551070|OTHER|Pharmacological Study|Correlative studies
214367348|NCT00551070|DRUG|Selumetinib|Given PO
214367349|NCT00551070|DRUG|Selumetinib Sulfate|Given PO
214367350|NCT05324969|BEHAVIORAL|MM-based MI|9 remote mindful-based MI sessions will be delivered to promote participating parents' mindful eating, mindful movements, and mindful family interactions. Parents will be encouraged to act as changing agents for their families.
214978936|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
214978937|NCT00898066|GENETIC|cytogenetic analysis|marrow and peripheral blood
214978938|NCT00898066|GENETIC|fluorescence in situ hybridization|marrow and peripheral blood
214978939|NCT01298947|DEVICE|Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems|comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
214978940|NCT04226417|DEVICE|Transcranial direct current stimulation|Dual/ Sham tDCS will be applied in 2 mA, 20 mins before the home-based exercise program in 3 times per week for 4 weeks (12 sessions)
214978941|NCT04523012|OTHER|Seroprevalence of SARS-CoV-2 infection in patients with HIV infection|On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
215086689|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
215086690|NCT00685646|DRUG|antiandrogen therapy|Up to 24 courses of therapy
215086691|NCT00685646|DRUG|zoledronic acid|Up to 24 courses of therapy
215086692|NCT02082223|BEHAVIORAL|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
215086693|NCT06909461|OTHER|Pain neuroscience education|The pain neuroscience education group will be receive a 70-min pain neuroscience education.
215086694|NCT06909461|OTHER|Red-flags education|The control group will be receive a 70-min red-flags education.
215086695|NCT05977452|DIAGNOSTIC_TEST|Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale|Patients with PICC placement will be assessed by the Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale（Chinese version） to predict the risk of PICC-related thrombosis. The time of evaluation are the day during PICC placement, 24-48h after PICC placement, and every time when patients receive PICC maintenance.
215086696|NCT06905054|DRUG|Fenofibrate (drug)|Once daily fenofibrate for 36 months
215086697|NCT06905054|DIAGNOSTIC_TEST|Blood draw for the laboratory assessment|Serum assessments will be performed every 3 months during the study period
215086698|NCT06905054|DIAGNOSTIC_TEST|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|Participants will undergo a quantitative gadoxetate-enhanced MRI and MRCP at baseline, and at 12 months and 36 months of trial participation.
215086699|NCT04839848|DEVICE|Lichtenstein mesh repair|A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures
215086700|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
214978942|NCT01204671|BIOLOGICAL|Influenza vaccine GSK2321138A|One intramuscular injection
214978943|NCT01204671|BIOLOGICAL|FluarixTM|One intramuscular injection
214978944|NCT01204671|BIOLOGICAL|Influenza vaccine GSK2604409A|One intramuscular injection
215086701|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
215086702|NCT05124587|OTHER|No intervention group|No intervention group
215086703|NCT02677844|DRUG|Abemaciclib|Administered orally
215086704|NCT02677844|DRUG|Placebo|Administered orally
215086705|NCT02677844|DRUG|Loperamide|Administered orally
215086706|NCT01555554|DRUG|Propranolol Hydrochloride|"Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol."
215086707|NCT01555554|OTHER|Placebo|"The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo."
215086708|NCT02083887|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu
215086709|NCT06306664|DEVICE|Bioptron|Bioptron safely treats arthritis, neck \& back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
215086710|NCT06306664|OTHER|Placebo Comparator|Patients will receive ice application+Exercises program designed for jumper knee
214367351|NCT05324969|OTHER|healthy education|9 health education emails will be sent to participating parents in the control group
214367352|NCT05994144|OTHER|VIDEO OBSERVED THERAPY|Video-observed therapy is the usage of teleconferencing to observe anti-TB medication ingestion.
214367353|NCT00082394|DRUG|Trizivir|
214367354|NCT00082394|DRUG|atazanavir|
214367355|NCT00082394|DRUG|Combivir|
214367356|NCT01539876|PROCEDURE|Fine needle aspiration assessing tumour TNFa levels|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
214367357|NCT00838682|DRUG|omeprazole sodium IV|Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
214367358|NCT00838682|DRUG|Rabeprazole|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
214367359|NCT02026856|DRUG|sodium selenite pentahydrate|
214367360|NCT02026856|OTHER|placebo - continuous saline NaCl 50 ml|
214491984|NCT06894121|OTHER|Greater Occipital Nerve Pulsed Radiofrequency (Unilateral)|Greater Occipital Nerve (GON) Pulsed Radiofrequency (PRF) treatment is performed under sterile conditions in the operating room. The patient is positioned in the prone position with neck flexion. Under ultrasound guidance at the proximal (C2) level, the needle is carefully placed near the GON, targeting the space between the Obliquus Capitis Inferior (OCI) muscle and C2's bifid spinous process. After proper sterilization, a linear ultrasound probe is used transversely over the occipital protuberance to locate the C1 and C2 vertebrae. Once identified, the RF needle and electrode are inserted laterally to medially using in-plane technique. A sensory stimulation test is done, and the PRF therapy is applied at a 45V setting, 5 Hz, and 5 ms pulse width for 360 seconds, with a maximum temperature of 42°C. No drug injections are administered during the procedure. Post-procedure, the patient is monitored for at least 1 hour before discharge after a general and neurological evaluation.
214491985|NCT06894121|OTHER|Bilateral GON PRF Treatment:|"Greater Occipital Nerve (GON) Pulsed Radiofrequency (PRF) treatment is performed under sterile conditions in the operating room. The patient is positioned in the prone position with neck flexion. Under ultrasound guidance at the proximal (C2) level, the needle is carefully placed near the GON, targeting the space between the Obliquus Capitis Inferior (OCI) muscle and C2's bifid spinous process. After proper sterilization, a linear ultrasound probe is used transversely over the occipital protuberance to locate the C1 and C2 vertebrae. Once identified, the RF needle and electrode are inserted laterally to medially using in-plane technique. A sensory stimulation test is done, and the PRF therapy is applied at a 45V setting, 5 Hz, and 5 ms pulse width for 360 seconds, with a maximum temperature of 42°C. No drug injections are administered during the procedure. Post-procedure, the patient is monitored for at least 1 hour before discharge after a general and neurological evaluation.~Bilater"
214978945|NCT05909540|PROCEDURE|Posterior facet distraction and fusion|With the patient in prone position, cervical traction was only intraoperatively after anesthesia with weights of approximately 5-8 kg during surgery. Monitoring of the spinal cord with motor evoked potential and somatosensory evoked potential were used throughout the surgery. Using a posterior midline incision, the occiput to the C2 spinous process was surgically exposed, separated to the lateral edge of the C1-2 joint, and cut off at the C2 nerve root to expose the C1-2 articular surface Quantitative reduction techniques included the following steps .1) Facet joint release and cage implantation technique 2)Adjusting POCA by cantilever and occipitocervical fixation technique.
214978946|NCT00691522|DRUG|Xerecept|
214978947|NCT05267210|OTHER|Questionnaire|"1. Back Pain and Body Posture Assessment Instrument for Adults (BackPDE-Y) This questionnaire assesses pain and risk factors associated with back pain. The questionnaire includes questions that include demographic, socio-economic, hereditary and behavioral risk factors. The questionarie consists of 20 questions in total.~2. Musculoskeletal Health Questionnaire (CIS-SS) The questionnaire included pain/stiffness (during the day and night), physical function (walking and dressing), physical activity level, involvement of symptom-related work/daily life and social activities/hobbies, difficulty sleeping, fatigue, emotional well-being, diagnosis and It consists of a total of 14 questions evaluating the understanding of the treatment and the overall effect of the disease."
214367361|NCT04684225|OTHER|Hand Therapy via Telerehabilitation|Hand Therapy via Telerehabilitation
214679989|NCT05635552|DIAGNOSTIC_TEST|Handgrip strength test|Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.
214679990|NCT05635552|DIAGNOSTIC_TEST|Questionnaires (Patient reported outcomes)|The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms
214367362|NCT04684225|OTHER|Hand Therapy via home-exercises|Hand Therapy via home-exercises
214367363|NCT00292175|PROCEDURE|Narrow Band Imaging|
214367364|NCT00292175|PROCEDURE|colonoscopy|
214367365|NCT04793919|DRUG|Mylotarg|See the protocol
214367366|NCT04793919|DRUG|Arsenic Trioxide|See the protocol
214367367|NCT04793919|DRUG|All-trans retinoic acid|See the protocol
214367368|NCT02424084|DEVICE|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy
214367369|NCT01667913|OTHER|6 minutes walking test|
214367370|NCT06200337|PROCEDURE|Fine needle acupuncture|All participants underwent three 24-hour apart sessions. In each session, the acupuncturist inserted two sterile needles into the left and right acupoints with a 90-degree angle and 0.5 to 1 cun in depth for TB3, 0.3 to 0.5 cun for BL65, and 0.3 to 0.5 cun for SP3. The acupuncturist rotated the needle at an angle of 180-270 degrees within 1 minute, with a frequency of 60 - 120 times/minute for stimulation.
214367371|NCT02104362|RADIATION|exclusive single-fraction irradiation|
214367372|NCT03133104|OTHER|Antenatal corticosteroids|Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
214367373|NCT04344041|DRUG|cholecalciferol 200,000 IU|Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.
214367374|NCT04344041|DRUG|cholecalciferol 50,000 IU|Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose
214367375|NCT03202472|DEVICE|Implanted Medical Device|Radiofrequency tag
215086711|NCT03924583|DIAGNOSTIC_TEST|Duplex ultrasonography|Ultrasound examination of whole vena cava venous system with central venous catheter inserted, using duplex US method to detect catheter related thrombosis
215086712|NCT04790825|PROCEDURE|Full mouth scaling and root planing (FMSRP)|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
215086713|NCT05826730|OTHER|Eccentric Exercises|Eccentric Exercises for neck muscles.
214367376|NCT03202472|PROCEDURE|Mammography|Undergo mammogram for image-guided placement of radiofrequency tag
214367377|NCT03202472|OTHER|Questionnaire Administration|Ancillary studies
214978948|NCT00264147|DRUG|etoricoxib|Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
214978949|NCT00264147|DRUG|etoricoxib|Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
214978950|NCT00264147|DRUG|etoricoxib|Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
214978951|NCT00264147|DRUG|etoricoxib|Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
214978952|NCT00264147|DRUG|Comparator: placebo|Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
214978953|NCT00264147|DRUG|etoricoxib|Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
214978954|NCT00264147|DRUG|Comparator: diclofenac|Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
214978955|NCT05256823|DRUG|Celecoxib|Patients will be treated with Celecoxib twice daily for 48 weeks.
214978956|NCT05256823|DRUG|nucleos(t)ide analogue|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
214978957|NCT04827277|PROCEDURE|Reverse Total Shoulder Replacement|Participants will be randomized to a reverse total shoulder replacement
215086714|NCT04291794|DRUG|Propofol|2mg/kg single bolus
214367378|NCT03202472|PROCEDURE|Radiofrequency (RFID) -Guided Localization|Undergo radiofrequency-guided localization
214367379|NCT03202472|PROCEDURE|Ultrasonography|Undergo ultrasound for image-guided placement of radiofrequency tag
214367380|NCT03675451|DRUG|89ZR-DF-IAB2M|injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan
214367381|NCT03675451|DRUG|68Ga-PSMA-HBED-CC|Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
214978958|NCT04827277|PROCEDURE|Anatomic Total Shoulder Replacement|Participants will be randomized to an anatomic total shoulder replacement
214978959|NCT03508778|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
214978960|NCT03508778|DEVICE|AcrySof IQ PanOptix Trifocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
214978961|NCT03508778|PROCEDURE|Cataract surgery|Cataract surgery per investigator's standard practice
214978962|NCT03464435|DRUG|Tacrolimus|All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. 0.1% tacrolimus will be continued for the last 5 months.
214367382|NCT03987126|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
214367383|NCT03987126|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
214367384|NCT04500860|DRUG|Low dose tadalafil 5 mg|Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence
214367385|NCT04500860|DRUG|Tolterodine 4 Mg Oral Capsule, Extended Release|To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder
214679991|NCT00541086|DRUG|anastrozole|1 mg per day, orally
214978963|NCT03234465|BIOLOGICAL|AG013|AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.
214978964|NCT03234465|OTHER|Placebo|Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.
214978965|NCT04040517|DIAGNOSTIC_TEST|Evoked potential audiometer|The ASSR \[ steady state response\] test stimuli are modulated pure tones with insert earphone..
215086715|NCT04291794|DRUG|Propofol Injection [Diprivan]|Tritiated Target-Controlled Infusion
214367386|NCT04500860|DRUG|Placebo|Placebo drugs
214978966|NCT00986414|DRUG|AFQ056|
214978967|NCT00986414|DRUG|AFQ056|
214978968|NCT00986414|DRUG|AFQ056|
214978969|NCT00986414|DRUG|AFQ056|
214978970|NCT00986414|DRUG|AFQ056|
214978971|NCT00986414|DRUG|Placebo|
214978972|NCT02493972|PROCEDURE|GelPort|Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
214978973|NCT02493972|PROCEDURE|laparotomy|laparotomy will be performed if indication confirmed by manual exploration
214978974|NCT03106077|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
214367387|NCT03817892|OTHER|Guidance of the External Chest Compression|The CPRmeter® device is positioned on the patient's chest with a disposable adhesive. In the situation of guidance of the External Chest Compression the rescuers have access in real time on the screen to visual feedback on the quality of the External Chest Compression performed and indications of possible corrections to improve the quality of the External Chest Compression . In the case of non-guidance of the External Chest Compression , a mask is position on the screen in order to hide the feedback information.
214367388|NCT03817892|OTHER|Rhythm of a relay 4 minutes|The duration or rhythm of a relay is the time during which a rescuer performs External Chest Compression before being relayed by another rescuer. This time is 2 minutes in non intervention group according to the current guidelines and 4 minutes in experimental group.
214367389|NCT02385734|OTHER|Concentrated Growth Factor Membrane|Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
214367390|NCT02385734|PROCEDURE|Coronally Advanced Flap|Periodontal plastic surgery technique
214367391|NCT04670133|DIETARY_SUPPLEMENT|Inulin|Supplementation with a prebiotic, specifically inulin.
214491986|NCT06276621|BEHAVIORAL|Family Bridge Program|The Family Bridge Program consists of 7 components, delivered by a trained lay navigator, the Guide. The program includes: (1) orientation to the hospital, unit, room, and hospital resources (e.g., toiletries, loaner phone chargers); (2)unmet social needs assessment, followed by connection to appropriate resources (e.g., food vouchers, community-based transportation); (3)communication and cultural preference assessment (eg, preferred language, comfort asking questions, and health-related cultural beliefs), which is communicated to the medical team and documented in the electronic health record;(4)communication coaching for parents/caregivers to help them clarify and practice asking questions of the medical team; (5)emotional support via daily check-ins during the hospital stay; (6)assistance with logistics ; and (7)one follow-up phone call, 2 days post-discharge, to address remaining questions and connect families to ongoing services if needed.
214491987|NCT06276621|BEHAVIORAL|Care as usual - resources only|Families randomized to the control arm will receive FBP written resources, which the Guide (and interpreter, as needed) will review with them over \~5-15 minutes one time. This includes information on hospital services (e.g., cafeteria coupons), community resources (e.g., food and housing support), the structure and roles of the medical team, and the daily hospital schedule. Parents will be informed that their child's nurse is available to help them.
214978975|NCT03627104|DIETARY_SUPPLEMENT|Normoprotein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
214978976|NCT03627104|DIETARY_SUPPLEMENT|Normoprotein diet with vegetable protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
214978977|NCT03627104|DIETARY_SUPPLEMENT|High-protein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
214978978|NCT03627104|DIETARY_SUPPLEMENT|High-protein diet with vegetable protein|ach patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
214978979|NCT00541242|DRUG|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
214978980|NCT00541242|DRUG|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
214367392|NCT04670133|DIETARY_SUPPLEMENT|Maltodextrin|Supplementation with maltodextrin (placebo)
214978981|NCT04309032|PROCEDURE|retrograde bladder filling with 0.9% normal saline 250cc prior to removal of foley catheter|0.9% NS 250cc was introduced before foley catheter removed for discharge
214978982|NCT03548077|BEHAVIORAL|POWERPLAY|"All men from participating worksites are invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
214978983|NCT00900939|BEHAVIORAL|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
215086716|NCT04697186|DRUG|Berberine|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
215086717|NCT04697186|DRUG|Amoxicillin|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
215086718|NCT04697186|DRUG|Rabeprazole|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
215086719|NCT04697186|DRUG|Amoxicillin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
215086720|NCT04697186|DRUG|Clarithromycin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
215086721|NCT04697186|DRUG|Rabeprazole|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
214367393|NCT04483154|DEVICE|Coala Heart Monitor|The Coala Heart Monitor (Coala Life AB, Sweden) is a CE and FDA-cleared device for real-time, remote monitoring of 2-lead ECG as well as heart and lung sounds. The Coala Heart Monitor automatically detects for 9 of the most common arrhythmias and has an integrated stethoscope for remote auscultation. It is paired wirelessly with the patient's smartphone and results are provided instantly both to patient and to connected provider in the cloud-based Coala Care portal.
214367394|NCT04378192|DEVICE|Laryngeal mask airway|Insertion of laryngeal mask airway before intubation of a morbidly obese patient
214367395|NCT04378192|DEVICE|face mask|use of face mask before intubation of a morbidly obese patient
214367396|NCT04422613|DIAGNOSTIC_TEST|pulmonary anomalies 4 months after documented COVID-19 pneumonia|Characterization of pulmonary damage with a complete pulmonary assessment 4 months after COVID-19 pneumonia,
214367397|NCT04158414|DIAGNOSTIC_TEST|PET/MR scan|500 cancer patients referred to PET-CT assessment will undergo PET/MR scan as well, and the net data will be compared. The overall data will be investigated in groups and subgroups of patients that share similar clinical characteristics and represent cancer patients in different time points during the natural history of their disease. Data analysis will be performed both visually and quantitatively using different MR and PET parameters according to the patient group. Specific populations will be detailed in the next sections per malignancy.
214367398|NCT05274932|OTHER|BFR resistance exercise|4 sets (30, 15, 15, 15 reps).
214367399|NCT04069325|DRUG|simiaowan|pills, 6g twice daily (BID), oral, 12 weeks
214367400|NCT04069325|DRUG|placebo|pills, 6g twice daily (BID), oral, 12 weeks
214367401|NCT04069325|DRUG|febuxostat|tablets, 40 mg once daily (QD), oral, 12 weeks
214367402|NCT04372628|DRUG|Lopinavir/Ritonavir 400 mg/100 mg|Lopinavir/Ritonavir tablets
214978984|NCT00900939|BEHAVIORAL|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
214978985|NCT05681117|OTHER|multi-component nutrition education|"Classroom-based nutrition education 40 minutes once a week for 4 weeks~SMS Reminders SMS reminders containing healthy nutrition tips 2 times a week, 1 weekday, 1 weekend, starting with nutrition education and throughout the education (4 weeks)~Brochure Distribution Brochures prepared in accordance with the content of classroom-based nutrition education were distributed immediately after the nutrition education.~Controversial Supermarket Tour Nutrition label reading activity aimed at gaining the ability to evaluate product contents, in line with the information explained in module 4, in the supermarket tour planned to be organized once with an appropriate number of student groups (maximum 7 people) after the nutrition education"
214367403|NCT04372628|OTHER|Placebo|Unmatched placebo
214367404|NCT00194688|DRUG|H. pylori treatment|
214491988|NCT06275217|BEHAVIORAL|Mindfulness-based yoga program|The intervention includes mindfulness-based components and yoga practice. Once a week for 10 weeks, with 1.5 hours in each session (30 minutes mindfulness-based practice and 1 hour yoga practice). A well-trained research personnel will facilitate the mindfulness-based section, and a qualified yoga instructor will facilitate the yoga section.
214491989|NCT06275217|OTHER|Psychoeducation|Knowledge of perinatal mental health, stress-related management, postnatal nutrition, exercise habit and sleep hygiene will be provided to the participants in the psychoeducation group. It is a group-based intervention delivered in hybrid mode including face-to-face and online group-based class. Once a week for 10 weeks, with 1.5 hour in each session.
214679992|NCT00541086|DRUG|exemestane|25 mg per day, orally
214978986|NCT04119934|BEHAVIORAL|Smoking Cessation Intervention Tool|A personalized smoking cessation infographic is provided to the physician/NP alongside the patient's regular spirometry report.
214978987|NCT06378424|OTHER|Cold Application|Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
215086722|NCT04697186|DRUG|Bismuth|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
215086723|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the reception area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the treatment room after meeting the child in the reception area while wearing the friendly attire.
215086724|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the treatment area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the treatment room after meeting the child in the reception area while wearing the conventional attire.
215086725|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in both reception and treatment areas in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the reception area and treatment room.
214367405|NCT00580658|DEVICE|Medtronic Activa Gpi|Activa Therapy, Gpi
214367406|NCT02662725|DRUG|IPILIMUMAB|
214367407|NCT02662725|RADIATION|Stereotactic radiosurgery|
214367408|NCT03010839|PROCEDURE|Modified Remote Ischemic Preconditioning|mRIPC will be induced at 24 h, 12 h and 1 h before surgery and once before induction of anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
214367409|NCT03010839|PROCEDURE|Control|Control group witnout remote ischemic preconditioning
214367410|NCT00751764|DRUG|Moxidectin|
214367411|NCT00192062|DRUG|gemcitabine|
214978988|NCT06378424|OTHER|Heat Application|Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
214978989|NCT06378424|OTHER|Vibration Application|With individuals in this group, the Buzzy® device was used to provide vibration. The Buzzy® device, at room temperature, was placed by the researcher on the peripheral intravenous catheterization application area before the application was performed. For one minute before the application, a slight, non-discomforting vibration was applied to the intervention area. As the Buzzy® device can be used more than once, it was disinfected after each use and before being used with another individual. In this study, the body of the device was used, and only vibration was applied to the individuals in this group.
214978990|NCT01274533|DRUG|Lenalidomide|25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
214978991|NCT02008526|BEHAVIORAL|Text Messages Transmitted by Peer Health Educators (TXT-PHE)|"Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
214978992|NCT02008526|BEHAVIORAL|Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
214978993|NCT05247762|DEVICE|Acupuncture|The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
215086726|NCT06122883|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the reception area and treatment room.
215086727|NCT06050668|COMBINATION_PRODUCT|Essential Amino Acid Supplementation|Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
215086728|NCT00550433|DEVICE|Bazedoxifene/Conjugated Estrogens|
215086729|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
215086730|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
215086731|NCT04052438|DIAGNOSTIC_TEST|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
215086732|NCT02084680|BEHAVIORAL|community health workers|community health workers offering individual prenatal education to pregnant women
215086733|NCT00292838|DRUG|fluticasone 25, 50, 100, 200 mcg|
215086734|NCT05068063|DRUG|Bupivacaine Injection|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
215086735|NCT05068063|DRUG|normal Saline|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
215086736|NCT04015583|BEHAVIORAL|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
215086737|NCT03630302|DEVICE|DBS|Deep Brain Stimulation
215086738|NCT04542668|OTHER|Cycling then running|Ergometer cycling Treadmill running
215086739|NCT04542668|OTHER|Running then cycling|Treadmill running Ergometer cycling
215086740|NCT04542668|OTHER|Inotropy|Adrenaline induced inotropy
215086741|NCT04542668|OTHER|Resting|Subjects must be minimally physically active
215086742|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
215086743|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
214367412|NCT00192062|DRUG|vinorelbine|
214367413|NCT00010855|BEHAVIORAL|Self-hypnotic relaxation|
214367414|NCT02529826|PROCEDURE|Testicular Biopsy|An open testicular biopsy will be performed by an attending urologist under general anesthesia.
214367415|NCT01086748|DRUG|Risperidone|Administered orally.
214367416|NCT01086748|DRUG|Placebo|Administered orally.
214367417|NCT01086748|DRUG|LY2140023|Administered orally.
214367418|NCT00877084|OTHER|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
214367419|NCT00877084|OTHER|Usual care|usual care according to clinical pathway for COPD, No training
214367420|NCT04424862|DRUG|Prednisone, ciclosporin and mycophenolate mofetil|Multitarget Therapy
214367421|NCT04424862|DRUG|Ponticelli Regimen|Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days Month 2: Oral cyclophosphamide (2.0 mg/kg/d, maximum dose 100mg/d) for 30 days Month 3: Repeat Month 1 Month 4: Repeat Month 2 Month 5: Repeat Month 1 Month 6: Repeat Month 2
214367422|NCT03315143|DRUG|Sotagliflozin|Sotagliflozin was administered as a tablet(s), orally once daily.
214367423|NCT03315143|DRUG|Placebo|Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
215086744|NCT05265884|DEVICE|Kinesiotaping|The tape is waterproof, porous, and adhesive. The width is 5 cm and thickness of 0.5 mm will be used in this study. This tape is with elastic core wrapped within cotton and capable of stretching up to 140-150%, applies heat-sensitive acrylic adhesive to avoid risk of latex allergy .The tape without medicinal properties is water resistant and can remain on the skin for 3 to 5 days. It will be applied two times per week for one month
214367424|NCT03982602|OTHER|Ketogenic diet|Subjects will be provided with the Ketogenic diet in the form of tube feeds once the decision is made to start the patient on diet.
215086745|NCT05265884|BEHAVIORAL|traditional therapy intervention|traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
215086746|NCT00003136|BIOLOGICAL|filgrastim|
215086747|NCT00003136|DRUG|amifostine trihydrate|
214978994|NCT02757157|BEHAVIORAL|Water-based walking|"Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
215086748|NCT00003136|DRUG|carboplatin|
215086749|NCT00003136|DRUG|cyclophosphamide|
215086750|NCT00003136|PROCEDURE|peripheral blood stem cell transplantation|
215086751|NCT05389475|PROCEDURE|anoplasty in treatment of post hemorroidectomy anal stenosis|Diamond flap versus V-Y flap
215086752|NCT01053013|BIOLOGICAL|RENCA macrobeads|
215086753|NCT01135914|DRUG|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
215086754|NCT01135914|PROCEDURE|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
215086755|NCT00442832|DRUG|TD-1792|TD-1792 2 mg/kg/day IV
215086756|NCT00442832|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
214367425|NCT00810836|DRUG|BG00012|oral
214367426|NCT00810836|DRUG|BG00012|Oral
214367427|NCT00810836|DRUG|placebo|oral placebo
214367428|NCT02609880|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.
214367429|NCT02609880|BEHAVIORAL|Psychoeducation|Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
214978995|NCT02757157|BEHAVIORAL|Land-based walking|"Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
214367430|NCT03205540|PROCEDURE|Continuous epidural block|Continuous epidural block at level L2-3 or L3-4 with 0.0625% bupivacaine + fentanyl 2 mcg/ml infusion epidurally 5 ml/hr for 48 hours postoperatively.
214367431|NCT03205540|PROCEDURE|Bilateral single-shot bilateral adductor canal blocks|Bilateral single-shot adductor canal blocks, ultrasound guidance, with 0.33% bupivacaine 15 ml on each side.
214978996|NCT04991714|DRUG|Lactisole|sweet taste inhibitor (decreases sweetness)
214978997|NCT04991714|DRUG|Rebaudioside M|Sweetener (increases sweetness)
214978998|NCT04991714|OTHER|Sucrose|10% Sucrose corresponding to a regular soft drink
214367432|NCT01280838|BEHAVIORAL|Hombre Seguro|A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.
214491990|NCT06519123|OTHER|Ambient Digital Scribes|AI technology used to populate clinical notes.
214491991|NCT06888479|BIOLOGICAL|hepatitis B vaccine|Three doses of hepatitis B vaccine
214491992|NCT05613413|DRUG|Cabozantinib 40 MG|Cabozantinib is taken my mouth
214679993|NCT00541086|DRUG|letrozole|2.5 mg per day, orally
214978999|NCT01118052|OTHER|Laboratory Biomarker Analysis|Correlative studies
214979000|NCT01118052|BIOLOGICAL|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given intraperitoneally
215086757|NCT04594460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
215086758|NCT04594460|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
215086759|NCT05518370|OTHER|Hippotherapy simulator training|Hippotherapy simulator training will be designed for the individual basis.
215086760|NCT05518370|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
215086761|NCT03808753|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
215086762|NCT03808753|OTHER|mini fluid challenge (mFC)|The mFC is performed by injecting a first aliquot of 100 ml of crystalloid over 1 minute before completing the 4 ml/kg-FC over the residual 9 minutes.
215086763|NCT04333940|PROCEDURE|periapical surgery|clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
215086764|NCT01838265|PROCEDURE|Transrectal Ultrasound-Guided Biopsy|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
214979001|NCT05261165|PROCEDURE|hysterectomy|Hysterectomy as primary surgical treatment of endometrial cancer. Abdominal laparotomy approach was performed without intrauterine manipulator (NonManip). Endoscopic - total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy or robotic hysterectomy was performed with use of intrauterine manipulator (Manip). It was Hegar dilatator (ManipHe) or Koh-Rumi device (ManipKoRu).
214979002|NCT05423834|DRUG|Tenofovir alafenamide|Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.
214979003|NCT05423834|DRUG|Entecavir|Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.
214979004|NCT04188600|DIETARY_SUPPLEMENT|Libicare|"The main ingredients of Libicare® are:~* Trigonella Foenum-graecum (Trigonella)~* Tribulus Terrestris (Tribulus)~* Turnera Diffusa (Damiana)"
215086765|NCT01838265|PROCEDURE|MRI Ultrasound Biopsy|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
215086766|NCT01838265|BEHAVIORAL|Expanded Prostate Cancer index Composite Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
215086767|NCT01838265|BEHAVIORAL|Short-Form 12 of Health Related Quality of Life Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
215086768|NCT01838265|BEHAVIORAL|Memorial Anxiety Scale for Prostate Cancer|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
215086769|NCT01838265|PROCEDURE|Plasma/Serum Sample for biomarkers|Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
215086770|NCT01838265|PROCEDURE|Urine Sample for Biomarkers|Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
215086771|NCT01838265|PROCEDURE|Blood Tests for Blood Urea Nitrogen and Creatinine|Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
215086772|NCT01838265|PROCEDURE|Blood Test for Serum PSA|Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
215086773|NCT03695380|DRUG|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
215086774|NCT03695380|DRUG|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
215086775|NCT03695380|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
215086776|NCT03225261|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
215086777|NCT03225261|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
215086778|NCT02262819|DRUG|S. aureus|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
215086779|NCT02337972|DRUG|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
215086780|NCT02699450|DRUG|Faricimab|Faricimab will be administered by IVT injection in the study eye.
215086781|NCT02699450|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
215086782|NCT02798991|DRUG|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
215086783|NCT02798991|DRUG|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
214979005|NCT04188600|DIETARY_SUPPLEMENT|active control|Selenium and vitamins B complex
215094487|NCT05977166|DEVICE|breathing exercise|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
215094488|NCT05977166|DRUG|medical treatment|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
215094489|NCT01818440|OTHER|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
215094490|NCT01818440|OTHER|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
215094491|NCT06473935|OTHER|Questionnaires and focus groups|"Participation in the research involves completing a test battery composed of self-administered questionnaires, all validated in the Italian language.~Additionally, qualitative data will be collected through semi-structured interviews (conducted in person or online, based on individual preferences) and focus groups, both lasting between 90 and 120 minutes."
215094492|NCT00024375|DRUG|DHA-paclitaxel|
214491993|NCT05613413|DRUG|Pembrolizumab 200mg|Pembrolizumab is given intravenously
215094493|NCT03082352|DRUG|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
215094494|NCT03082352|DRUG|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
215094495|NCT01781351|OTHER|Taping the ankle|
215094496|NCT00111540|DRUG|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
215094497|NCT02794389|DRUG|N-acetyl cysteine|
215094498|NCT02794389|DRUG|Placebo|
214979006|NCT01171378|DRUG|Ofatumumab|"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"
214979007|NCT05696951|OTHER|Transamine 200mg iv|In the intervention group, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes at the end of the surgery. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) SF. The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
214979008|NCT02949947|DRUG|Ferric Carboxymaltose|15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
215086784|NCT02466113|OTHER|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
214979009|NCT02949947|DIETARY_SUPPLEMENT|Iron Supplements|Participants take iron supplements by mouth every day for up to 3 months.
214979010|NCT02949947|BEHAVIORAL|Questionnaire|Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
214979011|NCT03993483|BEHAVIORAL|Unilateral resistance exercise|The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
214979012|NCT01187316|DEVICE|Transcutaneous electrical nerve stimulation|Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.
214979013|NCT01187316|OTHER|Physiotherapy|Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
214979014|NCT00193375|DRUG|Irinotecan|50mg/m2 days 1 \& 8 each 21-day cycle 1 \& 2, 28-day cycle 3 \& 4
214979015|NCT00193375|DRUG|Carboplatin|AUC 5
214979016|NCT00193375|DRUG|Bevacizumab|10mg/kg IV every 2 weeks for 10 doses starting week 16
214979017|NCT00193375|RADIATION|Radiation|
214979018|NCT00254514|DRUG|somatropin|
214979019|NCT00492726|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
214979020|NCT00492726|DRUG|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
214979021|NCT02343861|BEHAVIORAL|Tailored leaflet group|Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
214979022|NCT02343861|BEHAVIORAL|Control group|Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
214491994|NCT05613413|DRUG|Pembrolizumab 400mg|Pembrolizumab is given intravenously
214491995|NCT06851299|DRUG|trop2-ADC|Accept ADC monotherapy
214491996|NCT06851299|DRUG|ADC +anti-angiogenic drug|Accept ADC combined with anti-angiogenic drug
214979023|NCT01494636|DRUG|GSK2339345 (solution)|3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
214979024|NCT01494636|DRUG|GSK2339345 (nebulised)|25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
214979025|NCT01494636|DRUG|Placebo (0.9% sodium chloride solution)|Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
214979026|NCT01494636|DRUG|Lidocaine|40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
214979027|NCT01896063|PROCEDURE|Electroacupuncture|
214979028|NCT06254989|OTHER|Aerobic Exercise|"Participants will engage in aerobic exercise at HNH fitness at a minimum of 2 days a week for 12 weeks. Participants will have their daily step count collected via the Fitbit during this period. VO2 measurements will also be collected during active intervention using the UNCCRI protocol.~The structured aerobic exercise program (Weeks 3-14) will entail 30 minutes of aerobic activity, 3 days a week, on the treadmill, at a goal of between 50 to 70% of predicted VO2 maximum heart rate. All structured aerobic program sessions will take place at Holy Name Health (HNH) Fitness and will be overseen by our collaborator and Director of Human Performance (Reg Grant). Exercise data will be recorded in the Technogym MyWellness cloud. Participants who drop out or discontinue attendance (defined as 4 consecutive sessions missed without notification of absence) before completion of the 12-week study intervention period will be replaced."
214979029|NCT04012528|OTHER|ERAS program|ERAS program
214979030|NCT01608880|DRUG|nitroglycerin ointment|Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
214979031|NCT01608880|DRUG|Polysporin ointment|Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
214491997|NCT06851299|DRUG|ADC + PD1 monoclonal antibody +anti-angiogenic drug|ADC combined with PD1 monoclonal antibody and anti-angiogenic drug
214491998|NCT04586478|BIOLOGICAL|single dose of CNCT19|Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
214491999|NCT06892743|PROCEDURE|US-guided external oblique intercostal plane block (EOIPB)|US Guided external oblique intercostal plane block (EOIPB) or Posterior TAP Block:
215086785|NCT02466113|OTHER|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and \<12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
215086786|NCT02719119|PROCEDURE|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
215086787|NCT02719119|PROCEDURE|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
215086788|NCT06907797|BEHAVIORAL|TRIAL Web-Based Application|A web-based application that provides disease and trial education and access to resources provided by the Leukemia and Lymphoma Society (LLS). iPads will be provided to participants for 14 days.
214979032|NCT03521557|BEHAVIORAL|Gaze and Postural Stability|The duration and content of the GPS intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
214979033|NCT03521557|BEHAVIORAL|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
214979034|NCT00483535|DRUG|GW273225|GW273225 will be available as 25 milligram tablets.
214979035|NCT00483535|DRUG|COC|COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
214979036|NCT02230891|DRUG|Carvedilol|Carvedilol is a non selective beta blocker
214979037|NCT02230891|DRUG|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
214979038|NCT02230891|OTHER|Usual care|standard care as per primary care provider
214979039|NCT04767464|OTHER|Compass Course|The Compass Course is an 8-session group course designed to address purpose in life of those with Breast Cancer. Enrollment in this arm will involve participation in the Compass Course virtually.
214979040|NCT04078971|OTHER|Western diet|Subjects in this intervention will follow a normal western diet
214979041|NCT04078971|OTHER|ketogenic diet|Subjects in this group will follow a low carbohydrate ketogenic diet
215086789|NCT05593614|DRUG|ATX01 10%|A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
215086790|NCT05593614|DRUG|ATX01 15%|A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
215086791|NCT05593614|DRUG|Placebo|A 100 mL bottle of hydrogel formulation containing no active substance
215086792|NCT03986047|DEVICE|Thermal care|Wearing of a light elastic lower back heating wrap, which heats up to 40°C within 30 minutes and maintains this temperature continuously for 8 hours. Heat wrap will be worn during the day for 8 hours on 7 consecutive days.
215086793|NCT03986047|OTHER|Exercises|In addition of exercises performed with the physiotherapist at the first session, exercises will be performed at home five times over the next 7 days, for approximately 30 minutes each performing day. Three different categories of exercises will be given: 1) Functional activities exposure (sitting, sit-to-stand, lifting, bending, etc.); 2) cognitive contraction of trunk muscles and basic trunk motor control exercises; 3) mobility of the lumbar spine and preferential direction of movement. Exercises will be chosen and adapted for each participant by a physiotherapist, in function of pain presentation and intensity, and response to exercises.
215086794|NCT03986047|DEVICE|Sham|The same lower back wrap as the Thermal care group will be used, but cooled down to room temperature (opened in advance). The wrap will be worn following the same parameters (duration, frequency) than the Thermal care group.
214367433|NCT01280838|BEHAVIORAL|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
214979042|NCT02404545|DEVICE|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
214979043|NCT02473185|DRUG|Methylphenidate|Cross-over
214979044|NCT05637983|PROCEDURE|US-guided femoral puncture vs Fluoroscopy-guided puncture|US-guided femoral puncture and Perclose ProGlide®/Prostyle implantation compared to Fluoroscopy-guided puncture and Perclose ProGlide®/Prostyle in TAVR
214979045|NCT00952666|DEVICE|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
214979046|NCT04577105|DIAGNOSTIC_TEST|Simple chest tomography|The images were acquired with a Siemens 256-slice multidetector tomograph (SOMATOM DEFINITION FLASH 128x2) following the recommended parameters for low-dose simple chest tomography. The chest topogram was acquired using 35 mA, 100 Kv, and 6 mm slices, then the chest tomographic slices holding inspiration in a cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, a pitch of 1, and slices 1 mm with a total of 110 DLP, which is calculated with the conversion factor for thorax a total of 1.5 mSv. Multiplanar reconstructions with Kernel filters B26f, B50f, and B70 for mediastinum and lung, respectively, at 1 mm slices.
214979047|NCT02911454|OTHER|Infant formula|
214979048|NCT06294288|BIOLOGICAL|LP-003 Dose 1 (Single)|A single dose of LP-003 (Dose 1) was administered intravenously.
214979049|NCT06294288|BIOLOGICAL|LP-003 Dose 2 (Single)|A single dose of LP-003 (Dose 2) was administered intravenously.
214979050|NCT06294288|BIOLOGICAL|LP-003 Dose 3 (Single)|A single dose of LP-003 (Dose 3) was administered intravenously.
214979051|NCT06294288|BIOLOGICAL|LP-003 Dose 4 (Single)|A single dose of LP-003 (Dose 4) was administered intravenously.
215086795|NCT03986047|BEHAVIORAL|Education for the management of acute low back pain|Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.
215086796|NCT01344629|DRUG|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
215086797|NCT01344629|DRUG|Telmisartan|Telmisartan 80 mg tablet
214492000|NCT06758141|OTHER|3D printed educational model|3D Printed Advanced Cardiac Model
214979052|NCT06294288|BIOLOGICAL|LP-003 Dose 5 (Single)|A single dose of LP-003 (Dose 5) was administered intravenously.
214979053|NCT06294288|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered intravenously.
214979054|NCT06294288|BIOLOGICAL|LP-003 Dose 6 (Multiple)|LP-003 (Dose 6) was administered multiple times subcutaneously.
214979055|NCT06294288|BIOLOGICAL|LP-003 Dose 7 (Multiple)|LP-003 (Dose 7) was administered multiple times subcutaneously.
214979056|NCT06294288|BIOLOGICAL|LP-003 Dose 8 (Multiple)|LP-003 (Dose 8) was administered multiple times subcutaneously.
214979057|NCT06294288|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times subcutaneously.
214979058|NCT04347408|DIAGNOSTIC_TEST|Covid-19 Antibody testing (IgG and IgM)|Antibody testing for previous exposure to Covid-19
214979059|NCT04347408|OTHER|Blood Storage|Storage of blood for multi-omics analysis
214979060|NCT04687852|OTHER|Conservative and Non-conservative treatments|This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.
214979061|NCT05569798|DIAGNOSTIC_TEST|Whole body point of care ultrasound scan|"The INSIGHT Scan is a whole-body PoCUS scan which comprises imaging the following windows:~1. subcostal~2. inferior vena cava cardiac view~3. left hemidiaphragm~4. bladder~5. right hemidiaphragm~6. six major central veins (left/right internal jugular/ subclavian/ femoral veins)~The scan should take no more than 10 minutes to perform. Simple yes/no questions are asked for each window to identify any significant abnormalities. For example, is the left ventricle bigger than the right ventricle; is there a pleural effusion; is the bladder distended etc.~The scan is reported in the intensive care online medical notes and reviewed by the clinical team as soon as possible."
214979062|NCT01162733|DRUG|Vancomycin|15mg/kg
214979063|NCT01162733|DRUG|Vancomycin|30mg/kg
214979064|NCT03175887|DEVICE|TMS|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
214979065|NCT04966286|OTHER|multimedia education|The MLEP intervention was based on a literature review of prior research on the content and format of self care related multimedia education programmes
215086798|NCT01344629|DRUG|Amlodipin|Amlodipin 5mg tablet
215086799|NCT00767234|PROCEDURE|Observation|Standard of Care
214367434|NCT00111670|DRUG|DPP-IV Inhibitor|Escalating doses po bid or qd
214367435|NCT00111670|DRUG|Placebo|po bid or qd
214367436|NCT04789265|OTHER|instrumented- assisted soft tissue mobilization (IASTM)|IASTM is a new, non-invasive, conservative therapeutic approach. Instead of the therapist's hands and fingers in treatment, these devices are used to provide contact mobilization power. AYDM intervention, such as friction, rubbing massage treatments, requires the therapist to apply a significant amount of pressure. The main purpose of IASTM is to eliminate scar tissue and to restore the normal function of the tissue following soft tissue regeneration.
214367437|NCT03895411|DRUG|sotalol|Oral sotalol 2.5mg/kg/time, per 12h
214492001|NCT06758141|OTHER|Slide-based presentation|Slide-based presentation
214492002|NCT05862324|BIOLOGICAL|TAC01-CLDN18.2|TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
214979066|NCT01835106|PROCEDURE|Epidural catheter is used postoperatively|
214979067|NCT01835106|PROCEDURE|Fascia iliaca compartment catheter is used postoperatively|
214979068|NCT04301856|DRUG|CFTR Modulators|CFTR modulators as recommended in routine care by the french health authorities
214367438|NCT03895411|DRUG|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h
214979069|NCT06802913|DRUG|Inhaled Melatonin (100 μg)|An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.
214979070|NCT06802913|DRUG|Oral Melatonin (4 mg)|Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
214979071|NCT00232700|DRUG|Escitalopram|
214979072|NCT00733278|DEVICE|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
214979073|NCT05994963|DRUG|sisunatovir|Administered as either capsules in fasted state or tablet in fasted or fed state.
214979074|NCT00988702|BEHAVIORAL|Dan Tian Breathing|Dan Tian Breathing for one month
215086800|NCT02227836|DEVICE|Allergy Patch Testing|
215086801|NCT05915624|OTHER|telephone counseiling|One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
215086802|NCT05408507|BEHAVIORAL|ABC123 Framework|This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced cancer and to test the delivery of goal-concordant care. This patient-centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation, and a guided goals of care discussion.
215086803|NCT03634371|DRUG|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
214367439|NCT03895411|DRUG|betaloc|Oral betaloc 0.5mg/kg/time ,pre 12h
214367440|NCT00549757|DRUG|Aliskiren|Aliskiren 150 mg film-coated tablets
214492003|NCT00353496|DRUG|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
215086804|NCT03634371|DRUG|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
214367441|NCT00549757|DRUG|Placebo|Placebo to match aliskiren 150 mg film-coated tablets
214492004|NCT00353496|DRUG|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
214679994|NCT00541086|DRUG|tamoxifen citrate|20 mg per day, orally
215086805|NCT02148432|DRUG|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
214367442|NCT01055730|OTHER|Pulmonary rehabilitation|Structured education and supervised exercise program, lasting between 6 and 9 weeks.
214367443|NCT00778128|DRUG|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
214367444|NCT00778128|DRUG|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
214367445|NCT01720290|DRUG|repaglinide|Dose individually adjusted
214367446|NCT01720290|DRUG|metformin|Dose individually adjusted
214492005|NCT05892055|OTHER|MRI Procedure|All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
214492006|NCT05662904|BIOLOGICAL|Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion|CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor
214492007|NCT05662904|DRUG|Gemtuzumab Ozogamicin|Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
214679995|NCT00386893|PROCEDURE|simultaneous EEG/fMRI|fMRI/EEG recordings
214979075|NCT00988702|BEHAVIORAL|Progressive muscle training|Progressive muscle training for one month
214979076|NCT01288300|BEHAVIORAL|Picture good health/Imaginate una buena salud|Diabetes education, self-empowerment training, exercise, patient navigator
214979077|NCT01288300|BEHAVIORAL|Diabetes lecture|Diabetes self-management lecture
214979078|NCT06231641|DRUG|Lemborexant 5 MG [Dayvigo]|Lemborexant 5 mg will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
214979079|NCT06231641|OTHER|Matching Placebo|Matching placebo will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
214979080|NCT06607575|OTHER|Control group|"1. The procedure for heel blood collection will be performed.~2. Pain assessment will be performed with the N-PASS scale during and after the procedure."
214979081|NCT06607575|OTHER|Warming|"1. The cotton sock will be warmed under the heater for 3 minutes. The sock will be put on the newborn and taken off after 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
214979082|NCT06607575|OTHER|Vibration|"1. A rechargeable toothbrush will be prepared for the newborn to whom vibration will be applied. The vibration process will be applied to the midline of the gastrocnemius muscle for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
214979083|NCT06607575|OTHER|Warming and vibration|"1. After the socks are warmed, they will be put on the newborn\&#39;s feet and both warming and vibration will be applied for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
215086806|NCT02148432|DRUG|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
215086807|NCT00678548|BEHAVIORAL|Pleasant guided imagery|CD with pleasant guided imagery
214367447|NCT01720290|DRUG|metformin|Dose at 1000 mg/day
214367448|NCT02641392|DRUG|GED-0301|Mongersen
214367449|NCT02641392|OTHER|Placebo|Placebo
214367450|NCT00309530|DRUG|5-fluorouracil, levamisol, interferon|
214679996|NCT00386893|DEVICE|fMRI|
215086808|NCT00678548|BEHAVIORAL|Pain diary|Filling out a pain diary
214367451|NCT03197012|DRUG|90Y-DOTA-TOC|Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
214679997|NCT03378011|OTHER|phototherapy|phototherapy either UVA1 or topical PUVA on acral vitiligo
214679998|NCT03032185|DEVICE|Transcutaneous Elevtrical Nerve Stimulation|
214679999|NCT00791440|BEHAVIORAL|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
214680000|NCT00791440|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
214680001|NCT01680419|BEHAVIORAL|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
215086809|NCT03772418|DRUG|Cream Base|The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
215086810|NCT03772418|DRUG|Pomegrante and Ginkgo biloba group|The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
214979084|NCT06821035|BEHAVIORAL|Garnering Resilience in Traumatized youth and families (GRIT)|Dyads randomly assigned to Garnering Resilience in Traumatized youth and families (GRIT) will receive a community health worker delivered psychoeducational intervention that includes 6 weekly sessions focused on: 1) supportive health coaching to garner resilience via psychoeducation and the promotion of buffering protective factors in both youth and caregivers and 2) facilitating self-regulation using heart rate variability (HRV) biofeedback.
214979085|NCT06821035|BEHAVIORAL|Digital Citizenship Curriculum (DCC)|Dyads randomly assigned to DCC will receive a community health worker-delivered, school grade-specific intervention that includes 6 weekly sessions focused on helping youth navigate the complexities of living in a digital world.
214979086|NCT00058253|DRUG|tanespimycin|Given IV
214979087|NCT00058253|DRUG|docetaxel|Given IV
214979088|NCT06458985|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|The Disclosing Recovery intervention is designed to help people in treatment for opioid use disorder (1) make key decisions regarding disclosure, including whether, why, what, how, and when to disclose, and (2) build skills to disclose, including planning what to say, practicing disclosure, and preparing for negative responses.
214979089|NCT06612892|DEVICE|Virtual reality games in immersive VR modality|virtual reality involved three characters: a muscular boxer, a superhero, and a rock climber, with patients performing tasks in standing or sitting. Each experience takes 6 minutes, with 5-minute intervals between. Experimenters will instruct users on hand controls and virtual body observation.
215086811|NCT00780286|DEVICE|Polymer based lubricating liquid|5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
215086812|NCT00780286|DEVICE|Moi-Stir|2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
215086813|NCT01828138|DIETARY_SUPPLEMENT|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
214979090|NCT06612892|DEVICE|Virtual reality show in passive VR modality:|In this modality the patient was asked to have a comfortable seat wearing the head set without holding the controllers , the therapist will play a relaxing show as a nature view or colorful scene as a sort of relaxation and mind distraction for around 20 minutes while asking the patient to perform upper limb muscle ROM exercise in active or active assisted form.
214979091|NCT06612892|OTHER|traditional physiotherapy|Includes stretching exercise for upper limb muscles affected by burn, scar tissue release , and splinting technique.
214979092|NCT06612021|PROCEDURE|Beautibond universal adhesive|HEMA free universal adhesive
215086814|NCT01828138|DIETARY_SUPPLEMENT|Placebo|Placebo are given in 5 days
214367452|NCT03197012|DRUG|68Ga-DOTA-TOC|In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
214367453|NCT02256670|BEHAVIORAL|Text Message Application|Two-way text messaging application addressing adherence with adjuvant endocrine therapy
214367454|NCT04116749|OTHER|Water|Drink water freely until 2 hours before anesthesia.
214367455|NCT04897984|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
214367456|NCT01694784|BEHAVIORAL|Quantitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
214367457|NCT01694784|BEHAVIORAL|Qualitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
215086815|NCT00693472|DRUG|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
215086816|NCT00693472|DRUG|Placebo|Matching placebo capsule administered orally every 12 hours
214979093|NCT06612021|PROCEDURE|Tetric N universal bond|HEMA containing universal bond
215086817|NCT00693472|DRUG|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
215086818|NCT00693472|DRUG|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
215086819|NCT01556061|DEVICE|DMAC|The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
215086820|NCT01556061|DEVICE|CMAC|The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
215086821|NCT00202813|DEVICE|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
215086822|NCT04063787|DEVICE|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
215086823|NCT00003231|DRUG|cisplatin|
215086824|NCT00003231|DRUG|docetaxel|
215086825|NCT00003231|PROCEDURE|surgical procedure|
215086826|NCT00003231|RADIATION|radiation therapy|
215086827|NCT05240768|DIAGNOSTIC_TEST|Fractional flow reserve, instantaneous wave-free Ratio|Clinical outcomes observed for patients with moderate coronary lesions in whom coronary revascularization was deferred due to a negative physiologic study.
214979094|NCT01471977|OTHER|education,counseling, default tracers,quality of care|these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
214979095|NCT00003039|DRUG|alvocidib|
214979096|NCT06992882|DRUG|Capecitabine|capecitabine (1000-1250mg/m2, orally, bid, D1-14, q3w) and trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6 mg/kg, q3w, subcutaneous or intravenous for 1 year)
214979097|NCT06992882|DRUG|Paclitaxel|paclitaxel (80mg/m2, qw, D1, 8, 15, intravenous, q3w) trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6mg/kg, q3w, subcutaneous or intravenous for 1 year)
215086828|NCT04349241|DRUG|favipiravir|pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor
214367458|NCT01694784|BEHAVIORAL|Narrative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
214367459|NCT01694784|BEHAVIORAL|Framed Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
215086829|NCT04349241|DRUG|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
215086830|NCT05747417|OTHER|prismatic glasses|prism glasses ranging from 4-10 prism diopters
214492008|NCT06774924|DEVICE|Echoscopy examination using the echOpen probe|"In addition to standard care, each patient will have a systematic 4-point echoscopy examination using the echOpen probe: liver, spleen, lymph nodes, thyroid and, depending on symptoms, lung, kidney, bladder, abdomen.~The echOpen probe is CE marked. It will be used for all indications except certain areas of the body (thyroid, lymph nodes, bladder, liver, spleen, kidney, bladder and lymph nodes).~In addition to echoscopy with the echOpen probe, patient and physician satisfaction questionnaires will be used as part of this study."
214492009|NCT06773624|OTHER|PET/CT-enterography with 68Ga-DOTATOC|Patients underwent to PET/CT-enterography with 68Ga-DOTATOC
214492010|NCT06772324|DRUG|NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group|Very-low dose group will receive medication on arrival before completing the relevant assessment tests; the very-low dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch and replaced with a 0mg patch before returning home from the examination.
214979098|NCT01645150|BEHAVIORAL|Progressive strength training|12 weeks of supervised progressive strength training
214492011|NCT06772324|DRUG|NORSPAN Buprenorphine Transdermal Patchs for Lower dose group|The lower dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch.
214492012|NCT06772324|DRUG|NORSPAN Buprenorphine Transdermal Patchs for higher dose group|The higher dose group will be administered 1/3 of a 5mg buprenorphine transdermal patch.
214979099|NCT00481884|OTHER|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
215086831|NCT02089152|OTHER|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
215086832|NCT05270226|BEHAVIORAL|The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)|"The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists)."
215086833|NCT06176495|DIAGNOSTIC_TEST|Educational Text Messages|"The educational content will be targeted about Diabetes Education and will be guideline based with what complies to the standards of care instituted by the American Diabetes Association.~They text messages will comprise content related to general diabetes knowledge, diabetes management and control, coping with diabetes, and guidance on adopting a healthy lifestyle."
215086834|NCT05545644|BEHAVIORAL|Brief Family-Involved Treatment for Alcohol Use Disorder|Up to 3 sessions of counseling involving a patient with alcohol use disorder and a concerned family member
215086835|NCT02142881|OTHER|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of \<130 mmHg.
214680002|NCT01680419|BEHAVIORAL|PREP|"The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others."
214979100|NCT00481884|OTHER|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
214680003|NCT01742468|DIETARY_SUPPLEMENT|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
214979101|NCT06996184|DRUG|Vamifeport (PR formulation)|Vamifeport will be administered orally
214979102|NCT04398719|RADIATION|[11C]PBR28|The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan
214979103|NCT04398719|DRUG|Low-dose lipopolysaccharide|Subjects will receive intravenous lipopolysaccharide.
214979104|NCT04398719|DRUG|Intradermal Capsaicin|A small dose of capsaicin will be administered by intradermal injection.
214979105|NCT04833894|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of Efgartigimod
215086836|NCT02142881|OTHER|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
215086837|NCT04170270|DRUG|Omeprazole|"Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours."
215086838|NCT00099229|DRUG|Licarbazepine|
215086839|NCT02973191|DRUG|JCAR015|
215086840|NCT01797380|DRUG|Placebo|Placebo daily for duration of double-blind portion of trial
214979106|NCT06314152|PROCEDURE|Lightweight mesh fixation in 3 points or 1 point|Lightweight mesh fixation in 3 points
214979107|NCT05812950|BEHAVIORAL|GST|Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)
214979108|NCT05812950|BEHAVIORAL|CBT-E|Outpatient eating disorder treatment (20-40 weekly individual sessions)
214979109|NCT07025629|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One tablet of dapagliflozin 10 mg will be administered once daily from randomization and for 12 months period +/- 15 days..
214979110|NCT07025629|DRUG|One tablet of placebo of dapagliflozin 10 mg|One tablet of placebo of dapagliflozin 10 mg will be administered, per os, once daily from randomization and for 12 months period ± 15 days.
214979111|NCT07026890|OTHER|Evaluation visits|"3 assessment visits (initial (V1), intermediate (V2) and final (V3).~A series of motor assessments carried out by the physiotherapist:~* Timed Up and Go Test (TUG)~* 10 m walk test (TM10)~* Functional Reach Test (FRT)~* Minimum Motor Test (TMM)~* 10 m walk test combined with a verbal task such as naming different animals"
214979112|NCT07026890|OTHER|Rehabilitation sessions|Usual treatment: 4 to 5 rehabilitation sessions per week, each lasting 45 minutes.
214680004|NCT01742468|DIETARY_SUPPLEMENT|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
214680005|NCT00908297|DIETARY_SUPPLEMENT|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).~Dose escalation:~* 300 mg for two weeks~* 600 mg for two weeks~* 1200 mg for two weeks~* 1800 mg for final two weeks"
214680006|NCT02223221|PROCEDURE|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
214680007|NCT02223221|GENETIC|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
214680008|NCT02223221|OTHER|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
215086841|NCT01797380|DRUG|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
214979113|NCT07026890|OTHER|Virtual reality sessions|3 virtual reality sessions per week, each lasting 30 minutes.
214979114|NCT07026890|OTHER|Additional rehabilitation sessions|3 additional rehabilitation sessions per week. These sessions correspond to standard rehabilitation sessions.
214979115|NCT03141359|RADIATION|SBRT|Primary tumor SBRT
214979116|NCT03141359|DRUG|Carboplatin|concurrent chemotherapy
214979117|NCT03141359|DRUG|Paclitaxel|concurrent chemotherapy
214979118|NCT03141359|DRUG|cis Platinum|concurrent chemotherapy
214979119|NCT03141359|DRUG|Etoposide|concurrent chemotherapy
214979120|NCT03141359|RADIATION|IMRT|mediastinal radiation
214979121|NCT03141359|DRUG|Durvalumab|adjuvant immunotherapy
215086842|NCT06421402|OTHER|Air quality monitoring at patient's home|"Indoor Air Quality:~\- MICA-INBIOT system: temperature (ºC), humidity (%), CO2 (ppm), total Volatile Organic Ccompounds (VOCs) (ppb), Formaldehyde (µg/m3); and Particulate Matter (PM) 1/2.5/4/10 (µg/m3)~Outdoor Air Quality:~\- Aeris Weather platform: NO, NO2, NOx, SO2, SO3, CO, and PM10, all expressed in µg/m3"
215086843|NCT06421402|OTHER|Questionnaires: Baseline & every six months|"General surveys:~* PROMs: ICHOM Adult Set; encompassing Patient Reported Outcomes Measurement Information System (PROMIS 10), World Health Organization Wellbeing Index (WHO 5) and World Health Organization Disability Assessment Schedule (WHO-DAS 12) questionnaires.~* PREMs: Patient-Reported Indicator Survey (PaRIS)~Disease specific questionaires:~* COPD: COPD Assessment Test (CAT); modified Medical Research Council (mMRC) Dyspnea scale.~* Asthma: Asthma Control Test (ACT); Test of Adherence to Inhalers (TAI-12); Asthma Quality of Life Questionnaire (mini AQLQ); Sino-Nasal Outcome Test (SNOT-22)."
214492013|NCT06575595|BIOLOGICAL|Tulisokibart|single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)
214492014|NCT01906853|BIOLOGICAL|BCG|
214492015|NCT01746849|BIOLOGICAL|Palifermin|
214492016|NCT01746849|BIOLOGICAL|Lupron|
214979122|NCT06697236|OTHER|EPICES score|"EPICES score used to group participants as precarious and non precarious."
214492017|NCT01746849|PROCEDURE|peripheral blood stem cell transplantation|
214492018|NCT01746849|RADIATION|Total-Body Irradiation (TBI)|
214492019|NCT01746849|DRUG|Thiotepa|
214492020|NCT01746849|DRUG|Cyclophosphamide|
214492021|NCT01746849|DRUG|Degarelix|
214680009|NCT01595256|BEHAVIORAL|muscular strength|12-week moderate intensity walking program
214680010|NCT06201572|OTHER|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared. The data management platform provides intelligent management of patients' out-of-hospital follow-up, and the dynamic physiological indicators and psychological assessment data of patients are mastered through the hospital port, so as to provide telemedicine guidance for patients, so as to improve the prognosis of hypertensive emergency patients.
214680011|NCT00722592|DRUG|Vintafolide|2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
214979123|NCT06697236|OTHER|PICS evaluation|"* Assessment of physical symptoms using the Timed up and go test (TUG)~* Assessment of depressive symptoms using the PHQ-8 and anxiety symptoms using the GAD-7 and screening for post-traumatic stress disorder using the IES-R~* Assessment of cognitive disorders using the MoCA"
214979124|NCT06697236|OTHER|PICS-F evaluation|"* Assessment of depressive symptoms using the PHQ-8 and anxiety symptoms using the GAD-7~* Screening for post-traumatic stress disorder using the IES-R"
215086844|NCT06421402|DIAGNOSTIC_TEST|Lung function Testing: Baseline & every six months & during exacerbations|"* Forced Spirometry: Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1)~* Forced Oscillation Technique: Impedance, resistance and reactance.~Ancillary measurements: Systemic arterial pressure and pulse oximetry."
215086845|NCT06421402|OTHER|EMR & registry data|"Electronic Medical Records (EMRs): Updated every twelve months to track clinical events from Hospital and Primary Care databases.~Registry data: from the Catalan Health Surveillance System (CHSS)."
214367460|NCT05008029|PROCEDURE|In situ immobilization|Immobilization with an above-elbow cast. A 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow supervised by a pediatric orthopedic surgeon will perform the procedure without reduction, sedation, or anesthesia. Analgesia will be administered with paracetamol at doses of 10-15 mg/kg/dose or tramadol 0.5-1mg/kg/dose. Supposing immobilization is not satisfactory, or the patient or family member does not authorize the procedure to be carried out by staff in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
214979125|NCT06725147|BEHAVIORAL|AI enabled wellness chatbot|Elomia uses generative AI to respond to user input about psychological stress and distress. It was trained on the responses of real therapists with expertise in cognitive-behavioral therapy. It provides an array of wellness interventions including exercises for calming; • exercises for falling asleep; • grounding techniques; • exercises to reduce anxiety; • breathing exercises; • exercises to improve self-esteem.
214979126|NCT06725147|BEHAVIORAL|Penn Digital Wellness Resources|This active control intervention consists of a variety of digital wellness and stress management resources that are freely available to all Penn students.
214979127|NCT01081626|DRUG|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
214979128|NCT04703985|DIETARY_SUPPLEMENT|Enteral Nutrition|Protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
214979129|NCT01503983|DRUG|Trastuzumab|Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
214979130|NCT01503983|DRUG|Capecitabine|Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
214979131|NCT01503983|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
214979132|NCT06778486|OTHER|Artificial Intelligence Chatbot|The intervention is a generative artificial intelligence large language model chatbot that has a structured prompt with fill-in-the-blank style questions that the participant will complete.
214979133|NCT06942897|DIETARY_SUPPLEMENT|Melissa officinalis supplement|This intervention consists of a standardized oral dietary supplement containing 400 mg of Melissa officinalis extract formulated in phospholipids. The supplement is administered once daily for 3 weeks to evaluate its potential effects on mood, stress perception, and cortisol levels in healthy adults.
214979134|NCT06940648|DEVICE|The study is to evaluate the use of the Virtuoso Endoscopy System to perform safe and effective bladder lesion excisions.|This study is to evaluate the use of the Virtuoso Endoscopy System (VES), which is a robotic enhanced system, to perform safe and effective bladder lesion excisions.
214979135|NCT06955325|DRUG|Icotinib|Oral icotinib tablets (125 mg) administered three times daily (TID) for up to 1 year or until disease recurrence or unacceptable toxicity. Icotinib is an EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing mutations.
214979136|NCT06955325|DRUG|Rezivertinib|Oral rezivertinib capsules (100 mg) taken once daily (QD) for up to 1 year or until disease recurrence or unacceptable toxicity. Rezivertinib is an EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing mutations.
214979137|NCT06955325|DRUG|Ensartinib|Oral ensartinib capsules (225 mg) taken once daily (QD) for up to 1 year or until disease recurrence or unacceptable toxicity. Ensartinib is an ALK/ROS1 tyrosine kinase inhibitor designed to inhibit ALK/ROS1 fusion-driven NSCLC.
214979138|NCT06955325|DRUG|Benmelstobart|Intravenous infusion of bemosumab 1200 mg every 3 weeks (Q3W). Treatment continues for up to 4 cycles initially, and may be extended (maintenance) for up to 3 years or until disease recurrence or unacceptable toxicity. Bemosumab is a monoclonal antibody under investigation for immunotherapy in NSCLC.
214979139|NCT06955169|DRUG|[177Lu]Lu-DOTATATE|The treatment regimen consists of 4 (+2 optional) administrations of \[177Lu\]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).
214979140|NCT06955169|OTHER|Standard of Care treatments|Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Local SOC therapy with one of the following agents: bevacizumab, everolimus, hydroxyurea, or sunitinib.
214979141|NCT01697241|OTHER|Supervised exercise|Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions
214979142|NCT01697241|OTHER|Patient education|The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
214979143|NCT00788333|DRUG|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
214979144|NCT00788333|DRUG|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
214979145|NCT00154388|DRUG|Imatinib mesylate|
214979146|NCT02757196|DRUG|Rituximab plus methylprednisolone|rituximab （1000mg IV day1, week 3, week 17 , and week 19）
214979147|NCT02757196|DRUG|methylprednisolone|1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
214979148|NCT00564980|PROCEDURE|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
215086846|NCT06421402|DEVICE|Communication channel - Health Circuit Mobile App (Herranz C. JMIR 2023)|Health Circuit: chat, short questionnaires (Likert scale). As needed.
215086847|NCT06421402|DEVICE|Physiological data - Beat One Watch|Enhanced with real-time physiological data tracking (heart rate, steps walked and Heart Rate Variability (HRV))
214367461|NCT05008029|PROCEDURE|Reduction under general anesthesia|The participants will receive paracetamol at 10-15 mg/kg/dose or tramadol 0.5-1 mg/kg/dose for pain control until the time of surgery. Under general anesthesia, radius closed reduction, and above-elbow casting will be performed. After the reduction maneuvers, the radius reduction is satisfactory if the translation in the coronal and sagittal planes of less than 50% and angulation in the same planes is less than 10 °. If the radius does not remain reduced, it is unstable. Unstable fractures require percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block. The procedures will be carried out by a 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow under the supervision of a child orthopedist. Suppose reduction is not satisfactory or the patient or parent doesn´t authorize the procedure performed by personnel in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
214367462|NCT05852132|PROCEDURE|pars plana vitrectomy(PPV)|Vitrectomy was performed for severe non-proliferative diabetic retinopathy, but panretinal photocoagulation(PRP) was not performed
214367463|NCT05852132|PROCEDURE|Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP)|PPV was performed for severe non-proliferative diabetic retinopathy with PRP.
214979149|NCT00564980|PROCEDURE|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
215086848|NCT06421402|DEVICE|Patient Empowerment|Mobile App Health Circuit: follow-up of the personalized action plan agreed with the patient \& reference doctor
215086849|NCT06421402|OTHER|Characteristics of exacerbations|Health Circuit: home-based oscillometry, daily disease-specific questionnaire during the acute episode and continuous assessment of physiological variables.
215086850|NCT02884375|OTHER|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~* comorbidities (CIRS G)~* polypharmacy (number of medications)~* social environment (primary caregiver, support at home, friends , family, living alone)~* urinary and/or fecal incontinence"
214367464|NCT05852132|PROCEDURE|Panretinal photocoagulation(PRP)|Only PRP was used for severe non-proliferative diabetic retinopathy.
214367465|NCT04748081|PROCEDURE|hepatectomy|hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4)
214979150|NCT04364490|DEVICE|Copernicus noVF|Advanced gait training sessions by the computerized BWS system, named Copernicus®, without visual feedback.
214979151|NCT04364490|DEVICE|Copernicis VF-Plus|Advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance.
214367466|NCT05700084|DRUG|Utidelone Capsule (Part 1)|"At least 3 dose cohorts are planned, and 14-26 cases are expected. Cohort 1: 2 cases are planned, and the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days, in a 21-day cycle respectively."
214367467|NCT05700084|DRUG|Drug A Utidelone Capsule (Part 2: Group A-B)|"Utidelone Capsule at Part 2 in Group A-B will be administered at 60 mg/m2/d.~At Cycle 0, on day 1, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration).~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration). Subjects will receive the drug on day 1-5 with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
214367468|NCT05700084|DRUG|Drug A Utidelone Capsule (Part 2: Group B-A)|"Utidelone Capsule at Part 2 in Group B-A will be administered at 60 mg/m2/d.~At Cycle 1, on day 1-5, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration), with 21 days as a cycle.~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration), with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
214979152|NCT04364490|OTHER|Control group|Usual care
214979153|NCT04375124|BIOLOGICAL|Biological/Vaccine: Angiotensin peptide (1-7) derived plasma|angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants
214979154|NCT04832217|OTHER|Pyrenees´ Beef diet|24 participants were randomly assigned to a Pyrenees' beef diet, 3 serving per week during of 8 weeks.
214979155|NCT00964704|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
214979156|NCT00964704|DRUG|capecitabine [Xeloda]|added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
214979157|NCT00964704|DRUG|docetaxel|background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
214979158|NCT00964704|DRUG|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
215086851|NCT01199276|DRUG|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
215086852|NCT01199276|DRUG|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
214367469|NCT05700084|DRUG|Drug B Utidelone Injection (Part 2: Group A-B)|"Utidelone Injection at Part 2 in Group A-B will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 1, subjects will be administered Utidelone Injection on day 1-5 with 21 days as a cycle."
214979159|NCT01402856|OTHER|Education|An educational program targeting HS students on the risks of distracted driving that was 60-min long \& utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, \& interactive games simulating distracted driving.
215086853|NCT01881022|BEHAVIORAL|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
215086854|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
215086855|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
214979160|NCT01493817|OTHER|laboratory biomarker analysis|Correlative studies
214979161|NCT04085640|OTHER|Obturator nerve block with ropivacaine 0.2%.|20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
214979162|NCT04085640|OTHER|Obturator nerve block with isotonic saline|20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.
214979163|NCT00480116|BIOLOGICAL|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
214979164|NCT00480116|BIOLOGICAL|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
214979165|NCT00480116|BIOLOGICAL|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
214979166|NCT03473990|OTHER|High-intensity interval training|2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)
214979167|NCT00190034|DRUG|N-Acetylcysteine 600mg/tab|
214979168|NCT03344471|OTHER|Passation of questionnaires|Specific questionnaires (Perinatal PTSD Questionnaire evaluating the Post-Traumatic Stress Disorder) and (NEO-FFI evaluating personality)
214979169|NCT03813108|BIOLOGICAL|CPS-immunization|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.
214979170|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
214979171|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
214979172|NCT03813108|BIOLOGICAL|CPS-immunization (A/L)|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.
214979173|NCT03813108|DRUG|Atovaquone / Proguanil Oral Tablet [Malarone]|All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
214979174|NCT04685954|DEVICE|Filtek Bulk-Fill Posterior|Bulk-fill restorative composite
215086856|NCT05682989|PROCEDURE|Urodynamic investigations before and after a mesh surgery protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.
214367470|NCT05700084|DRUG|Drug B Utidelone Injection (Part 2: Group B-A)|"Utidelone Injection at Part 2 in Group B-A will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 0, all patients will be administered Utidelone Injection on day 1, with 21 days as a cycle."
214367471|NCT05700084|DRUG|Capecitabine|1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals. It is administered continuously for 14 days from day 1 to day 14, with a 21 day treatment cycle.
214367472|NCT05700084|DRUG|Utidelone Capsule (Part 3)|Utidelone capsule: 60 mg/m2/d, administered once a day on an empty stomach, continuously for 5 days from day 1 to day 5, with a treatment cycle of 21 days.
214979175|NCT04685954|DEVICE|Filtek Ultimate Universal|Incremental restorative composite
214979176|NCT01965873|DIETARY_SUPPLEMENT|Enteral nutrition|Same as arm description
214979177|NCT00870727|DRUG|Aripiprazole oral product|Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
214979178|NCT00870727|DRUG|Placebo oral capsule|Placebo will be identical in size and appearance to study drug.
214979179|NCT00879853|BEHAVIORAL|Interpersonal Therapy|
214979180|NCT04038827|DIAGNOSTIC_TEST|D-CEC counting|By means of preliminary bulk separation step with the CellSearch system, single CEC will be sorted
215086857|NCT05682989|PROCEDURE|Urodynamic investigations before and after a robotic-assisted sacrocolpopexy protocol.|All surgeries were performed using a DaVinci robotic system (Intuitive® Surgical Inc., Sunnyvale, California,US) with standardized technique and materials. Patients were positioned in dorsal lithotomy and steep Trendelenburg position. Trocars were placed bilaterally, and an assistant port was placed laterally. The peritoneum was opened medial to the ureter to develop an avascular space. The mesh was placed on the posterior and anterior vaginal wall and fixed at the level of anterior longitudinal ligaments S1/S2 by sutures. An intraoperative clinical examination was performed to ensure the mesh was in a tension-free position.
214979181|NCT06053229|DEVICE|percussive massage|30 minutes of percussive massage will be administered twice per day during the 10 day immobilization period using a percussive massage device
214979182|NCT06053229|COMBINATION_PRODUCT|Leg Immobilization|All subjects will have their left leg immobilized using an immobilization brace for 10 days
215086858|NCT05682989|PROCEDURE|Urodynamic investigations before and after a hysterectomy with trans-vaginal mesh repair|In summary, a vertical incision was made in the anterior vaginal wall to access the vesicovaginal space. The sacrospinous ligament was dissected, and an applicator was inserted and positioned over the SSL. The anchor was fixed to the SSL and the thread was attached to the mesh. The mesh was then adjusted in a tension-free manner, excess mesh was cut, and the incision was closed with suture.
215086859|NCT00276094|DRUG|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
215086860|NCT00276094|DRUG|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
215086861|NCT00276094|DRUG|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
215086862|NCT00276094|DRUG|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
215086863|NCT03542851|DRUG|Pentetrazol (PTZ)|BTD-001 is an oral capsule of PTZ.
214979183|NCT06167057|DRUG|Mitomycin/Gemcitabine|UTUC treatment
214979184|NCT06167057|DRUG|Saline|UTUC treatment
214979185|NCT03337412|OTHER|Adapted physical activity|"Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire"
214979186|NCT04270773|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|Vaccine administrated
214979187|NCT04089722|DRUG|Deoxycholic Acid|The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.
214979188|NCT00720278|DRUG|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
215086864|NCT03542851|DRUG|Placebo oral capsule|Placebo will be presented as oral capsule.
215086865|NCT00991783|DRUG|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
215086866|NCT01511809|DRUG|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
215086867|NCT00283972|DEVICE|LAP-BAND System|
215086868|NCT00918268|BIOLOGICAL|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
215086869|NCT00331227|DRUG|Isotonix OPC-3 (flavonoid supplement)|
215086870|NCT03589365|OTHER|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
215086871|NCT03250039|DRUG|PF-04965842|14C labeled PF-04965842
215086872|NCT03250039|DRUG|Absolute Bioavailability|Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
215086873|NCT03182595|DRUG|Paracetamol|Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
215086874|NCT00573560|DEVICE|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
214979189|NCT00720278|DRUG|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
214979190|NCT00720278|DRUG|Placebo|0 mcg Placebo daily
214979191|NCT04947891|PROCEDURE|Intensive recovery management|Intensive recovery management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
214979192|NCT01712516|DRUG|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
214979193|NCT01712516|DRUG|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
214979194|NCT01712516|DRUG|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
215086875|NCT02737995|DRUG|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
215086876|NCT00690287|DRUG|AZD6370|Oral single doses a+b+c, o.d., suspension
215086877|NCT00690287|DRUG|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
215086878|NCT00690287|DRUG|Placebo|Placebo
215086879|NCT02282371|DRUG|Cetuximab|
215086880|NCT02282371|DRUG|BYL719|
214979195|NCT01712516|DRUG|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
214979196|NCT00968487|BIOLOGICAL|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
214979197|NCT00968487|OTHER|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 °C (-0.4 °F) (or colder) within 6 hours of collection.
214979198|NCT02729857|DIETARY_SUPPLEMENT|SFA muffin|Muffin rich in saturated fat.
214979199|NCT02729857|DIETARY_SUPPLEMENT|PUFA muffin|Muffin rich in polyunsaturated fat.
214979200|NCT01020422|PROCEDURE|Reduction mammaplasty|Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
214979201|NCT04656613|BIOLOGICAL|Gam-COVID-Vac|the Gam-COVID-Vac is combined 2 -component vector vaccine against the SARS-СoV-2-induced coronavirus infection
214979202|NCT04656613|OTHER|placebo|Placebo Comparator
214979203|NCT00869414|DRUG|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
214979204|NCT00869414|DRUG|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
214979205|NCT00869414|DRUG|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
214979206|NCT01181167|DRUG|edoxaban|
215086881|NCT02282371|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
215086882|NCT02428920|BEHAVIORAL|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
215086883|NCT04336527|BEHAVIORAL|Home Treatment with Peer Support|After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.
215086884|NCT04336527|BEHAVIORAL|Home Treatment without Peer Support|After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).
215086885|NCT00078065|DRUG|Xcellerated T Cells|
215086886|NCT03947528|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fed condition
215086887|NCT00987493|BIOLOGICAL|rituximab|day 1 at a fixed dose of 375mg/m2
215086888|NCT00987493|DRUG|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
215086889|NCT00987493|DRUG|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
214680012|NCT00722592|DRUG|pegylated liposomal doxorubicin (PLD)|50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
214979207|NCT01181167|DRUG|enoxaparin sodium|
214979208|NCT00161213|DRUG|gemcitabine hydrochloride|
214979209|NCT00161213|DRUG|imatinib mesylate|
214979210|NCT05027854|OTHER|TMS or tES|Transcranial magnetic or electric stimulation
214979211|NCT05027854|OTHER|sham TMS or tES|Sham transcranial magnetic or electric stimulation
214979212|NCT00327158|PROCEDURE|Transesophageal transducer|One time use of reamer during surgery
214979213|NCT00327158|PROCEDURE|echocardiography|takes photos of right atrium during the reaming processes
214979214|NCT04755010|DEVICE|Linq II implantable cardiac monitor|Implantation of Linq II implantable cardiac monitor
214979215|NCT03042845|DEVICE|Tiger cardiac catheter|Tiger cardiac catheter
214979216|NCT03042845|DEVICE|Judkins 3.5L/4R cardiac catheters|Judkins 3.5L/4R cardiac catheters
214979217|NCT04149340|DRUG|Cataract surgery|Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
214979218|NCT03928366|DRUG|Propofol|sedation
214979219|NCT03928366|DRUG|Remifentanil|remifentanil
214979220|NCT02433769|DEVICE|TOFscan|"Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)"
214979221|NCT02433769|DEVICE|TOF-Watch-SX|Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
214979222|NCT06285500|OTHER|Patient-specific treatments|Treatment will be decided specifically for the patient based on biomarker test results.
214979223|NCT01384877|DRUG|Lidocaine|10mg/kg by subcutaneous infusion over 5.5 hours
214979224|NCT01384877|DRUG|Placebo (D5W)|Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
214979225|NCT03938571|PROCEDURE|Duodenal Switch|
215086890|NCT01341626|BEHAVIORAL|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
215086891|NCT01341626|BEHAVIORAL|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
215086892|NCT00215514|DRUG|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
215086893|NCT00215514|DRUG|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
215086894|NCT00215514|DRUG|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
215086895|NCT00215514|PROCEDURE|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
215086896|NCT00797238|OTHER||No intervention in this study
215086897|NCT01873729|DRUG|Naltrexone|Adults with ADHD
215086898|NCT02630420|DRUG|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
215086899|NCT02463032|DRUG|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
215086900|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
215086901|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
214979226|NCT05412277|OTHER|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.
214979227|NCT03630393|OTHER|Pneumoperitoneum Pressure 6 mmHg|A pneumoperitoneum insufflation pressure of 6 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
214979228|NCT03630393|OTHER|Pneumoperitoneum Pressure 15 mmHg|A pneumoperitoneum insufflation pressure of 15 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
214979229|NCT02388451|DEVICE|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
214979230|NCT00618293|DRUG|Haemate HS|intravenous infusion of Haemate (dosage dependent on body weight)
214979231|NCT00618293|OTHER|NaCl-solution|intravenous infusion of 0.9%NaCl-Solution
214979232|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
214979233|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
215086902|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
215086903|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
215086904|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
215086905|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
215086906|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
215086907|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
215086908|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
215086909|NCT00532792|BIOLOGICAL|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
215086910|NCT00854217|PROCEDURE|acute normovolemic hemodilution|
214367473|NCT06423755|OTHER|Swimming programme|A session plan will be followed, which included aims, objectives, learning outcomes and suggested core aquatic skills and swimming activities under each section. The session will consist of a session brief, a warmup, core aquatic skills, swimming strokes (front crawl, backstroke, breaststroke, and hybrid strokes), a cool down and a session debrief; following the guidance developed in study three.
214979234|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
214979235|NCT00408499|DRUG|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
215086911|NCT02945553|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
215086912|NCT02945553|DEVICE|Microstimulation|Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
215086913|NCT02513758|OTHER|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
215086914|NCT01618617|DIETARY_SUPPLEMENT|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
215086915|NCT01618617|DIETARY_SUPPLEMENT|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
215086916|NCT04557475|DRUG|Aspirin|Two tablets daily with dinner
214367474|NCT06423755|OTHER|Standard Physiotherapy care|Treatment delivered by the physiotherapist could include exercise, advice, education, and manual therapy; they will be offered up to 6 sessions.
214367475|NCT01649830|RADIATION|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
214979236|NCT00408499|DRUG|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
214979237|NCT01077492|OTHER|Virtual Bronchoscopy Navigation|Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
214979238|NCT00435071|PROCEDURE|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
214979239|NCT00435071|PROCEDURE|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
214979240|NCT01042795|DRUG|Sunitinib|Sunitinib 37.5 mg daily X 16 weeks
214979241|NCT00524433|DRUG|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
214367476|NCT01649830|DRUG|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
214367477|NCT02139098|DRUG|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
214367478|NCT02139098|DRUG|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
214979242|NCT00524433|DRUG|placebo|
214979243|NCT00039403|DRUG|7-hydroxystaurosporine|Given IV
214979244|NCT00039403|DRUG|gemcitabine hydrochloride|Given IV
214979245|NCT00039403|OTHER|pharmacological study|Correlative studies
214979246|NCT00039403|OTHER|laboratory biomarker analysis|Correlative studies
214367479|NCT02139098|DRUG|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
214367480|NCT02139098|DRUG|Placebo|Placebo
214367481|NCT03261284|DIAGNOSTIC_TEST|D-dimer-guided adjustment stratege|D-dimer-guided adjustment stratege
214367482|NCT03261284|DIAGNOSTIC_TEST|Thepeautic-heparin therapy|0.3-0.7U/ml of anti-Xa activity or APTT 1.5-2.5 times of control
214367483|NCT05273125|BEHAVIORAL|Gait disorders and falls risk assessment|Implementation of a standardized assessment of the fall risk and gait disorders in the memory clinic in addition to usual care.
214367484|NCT01573936|OTHER|Physical therapy, occupational therapy, psycotherapy, medical consultations|The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
214979247|NCT00702780|DRUG|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
214979248|NCT00702780|DRUG|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
214979249|NCT02273401|DRUG|BI 11054 CL|
214979250|NCT02273401|DRUG|Placebo|
214979251|NCT01586195|DRUG|Vemurafenib|Vemurafenib 960 mg BID
214979252|NCT00997334|DRUG|Erlotinib|
214979253|NCT02828865|DEVICE|Irreversible Electroporation (IRE) System|
214979254|NCT01694693|DRUG|Orencia|No Intervention
214979255|NCT05588258|OTHER|Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.|Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.
214979256|NCT04785417|OTHER|touch screen tablet|traditional occupational therapy in addition to games on tablet
214979257|NCT05883865|DRUG|Fenofibrate|Fenofibrate is orally administrated daily with food for at least 1 week during pregnancy
215086917|NCT03039894|OTHER|Gradebook Game|Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
215086918|NCT05252221|OTHER|ATC Intervention|The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
215086919|NCT00624416|DRUG|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
215086920|NCT00160199|DRUG|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
215086921|NCT00160199|DRUG|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
215086922|NCT00768404|DRUG|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
215086923|NCT03003078|DEVICE|OncoSil™|The implantation of OncoSil™
214367485|NCT01839006|PROCEDURE|dismembered pyeloplasty|Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
215086924|NCT00266838|DRUG|Maxidex; Lacrystat|6 times daily, for 20 weeks.
215086925|NCT04118907|DEVICE|multiple sensory stimulation|The patients were recruited to record their medical history, and the hearing level, tinnitus indicators, vestibular function and tinnitus disability indicators were tested. Then the patients were randomly divided into six groups. They received the corresponding stimulation 20 minutes a day, 5 days a week for 3 weeks. After the last stimulation, the above tests were repeated immediately, one week later and three months later.
215086926|NCT01922063|BEHAVIORAL|Physiotherapy Intervention|20x 30 min sessions of physiotherapy
215086927|NCT01922063|BEHAVIORAL|Sham neck massage|20x 30 minutes sessions of neck massage
214979258|NCT01376869|DIETARY_SUPPLEMENT|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
214979259|NCT01376869|OTHER|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
214979260|NCT02402400|DRUG|Sub Lingual Ticagrelor|180mg sub-lingual ticagrelor
214979261|NCT03107429|DRUG|Acetazolamide|Acetazolamide tablets were placed in capsules to make them look similar to placebo.
214979262|NCT03107429|DRUG|Placebo|Placebo was a sugar based placebo placed in a capsule.
214979263|NCT03107429|OTHER|Trendelenburg Position|Placed in Trendelenburg Position
214979264|NCT02078544|OTHER|Integrated Molecular Analysis|
214979265|NCT05889975|DEVICE|interdental brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
214979266|NCT05889975|DEVICE|single tufted brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
214979267|NCT05889975|DEVICE|water irrigator|using water irrigator after manual tooth brushing twice daily with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation for 30 days
214367486|NCT03154489|OTHER|acenocoumarol|medication review with follow-up in acenocoumarol treatment
214367487|NCT03154489|OTHER|control|group
214367488|NCT03220399|DRUG|NVP-1603-1 (P)|1capsule, single oral dosing
214367489|NCT03220399|DRUG|NVP-1603-2 (T)|1tablet, single oral dosing
214367490|NCT03220399|DRUG|NVP-1603-1 and NVP-1603-2 (P+T)|1capsule and 1tablet co-administration, oral single dosing
214367491|NCT03559101|OTHER|Distilled water|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
214367492|NCT03559101|OTHER|Medical Food 1|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
214367493|NCT03559101|OTHER|Medical Food 2|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
214979268|NCT00114556|DRUG|zoledronic acid|
214979269|NCT04830735|DRUG|Dasatinib Anhydrous|Given PO
214979270|NCT04830735|DRUG|Placebo Administration|Given PO
214979271|NCT00419705|DEVICE|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
214979272|NCT05553327|BEHAVIORAL|Multimodal prehabilitation|"* Physical state: individualised physical status will be evaluated by a physiotherapist. A specific training program and pelvic floor exercises sessions will be led by a physiotherapist.~* Nutritional state: individual nutritional status will be evaluated by a nutritionist and intervention will be done if applicable. A nutrition group session will be held.~* Mental health: mindfulness group sessions led by psychologists will be held."
214979273|NCT03768193|PROCEDURE|Deep serratus anterior plane block|Deposition of local anaesthetic in the space between the serratus anterior muscle and the external intercostal muscle, at the level of the 4th-5th rib, in the midaxillary line. Procedure performed under ultrasound guidance. Catheter - based infusion of local anaesthetic into this space for 48 hours.
215086928|NCT00023686|PROCEDURE|surgery|
215086929|NCT00023686|RADIATION|radiation|
215086930|NCT00849602|DRUG|Placebo|Placebo bid for three days
215086931|NCT00849602|DRUG|Chloroquine|Chloroquine bid for three days
215086932|NCT00493428|DRUG|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
215086933|NCT04674501|PROCEDURE|Cardiac evaluation and blood sampling|"Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets."
215086934|NCT04220437|OTHER|no interventin|Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
214367494|NCT03559101|OTHER|Pedialyte|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
214367495|NCT03559101|OTHER|Gatorade|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
214367496|NCT01346319|DRUG|ABT-SLV361|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
214367497|NCT01346319|DRUG|placebo|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
214979274|NCT03768193|PROCEDURE|Surgically-placed paravertebral block|Surgically-placed paravertebral block catheters for continuous local anaesthetic infusion of 0.125% levobupivacaine at 8-12mls/ hr for 48 hours.
214979275|NCT00495053|DRUG|hMaxi-K|Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
215086935|NCT03371173|DRUG|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
214367498|NCT06491849|OTHER|Peri-implant Condition Evaluation|This intervention involves a detailed clinical evaluation of peri-implant conditions in patients who have received orthodontic mini implants. The assessments include measuring periodontal parameters such as probing depth, bleeding on probing, mucosal redness, plaque index, gingival index, and implant stability. The evaluations are conducted at specified intervals during and after orthodontic anchorage treatment to monitor changes and ensure the health of peri-implant tissues.
214367499|NCT04591028|DRUG|Indocyanine green|A one time injection of IDC prior to the day of scheduled surgery.
214367500|NCT01843543|OTHER|Mindfulness Based Stress Reduction Course|The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
214367501|NCT02423681|DEVICE|ThermoSmart|Heated humidification as first intention (HH1st) with ThermoSmart
214367502|NCT02423681|DEVICE|Without ThermoSmart|ThermoSmart is switched off
214979276|NCT00495053|OTHER|Placebo|Matching placebo (PBS-20% sucrose)
215086936|NCT00494910|BEHAVIORAL|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
215086937|NCT00494910|BEHAVIORAL|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
215086938|NCT04589143|DRUG|Agomelatine|Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks
215086939|NCT04589143|DRUG|Placebos|Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
215086940|NCT00190047|DRUG|DP-b99|
214979277|NCT02654678|DRUG|Enalapril Orodispersible Minitablet|Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
214979278|NCT04309513|BEHAVIORAL|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device. Their devices and an accompanying app will provide them with an ongoing real time calculation of the PAI score.
214979279|NCT04309513|BEHAVIORAL|Step Counter to motivate physical activity|Step Counter to motivate physical activity
214979280|NCT06262984|OTHER|Therapeutic Play|The researcher will demonstrate the nasopharyngeal swabbing process on the doll with the children who have chosen a therapeutic play group, using a therapeutic play method, and play with the child. The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
214979281|NCT00730184|DIETARY_SUPPLEMENT|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
214979282|NCT00730184|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
214367503|NCT04432701|BEHAVIORAL|proactive extubation|when children is breathing spontaneously and adequately in PACU,endotracheal tube was removed directly
214367504|NCT05002205|OTHER|Questionnaires|Participants will be followed up by means of online surveys and 2 study visits.
214367505|NCT05002205|OTHER|spirometry|During two study visits, the lung function will be measured (FVC, FEV1)
214367506|NCT05002205|OTHER|ECG|During two study visits, the presence of arrhythmia will be explored.
214367507|NCT05002205|OTHER|1 minute sit to stand test|Physical endurance is tested during 2 study visits.
214367508|NCT05002205|OTHER|Vital parameters|blood pressure, pulse, weight
214367509|NCT00908401|OTHER|Breastmilk|Breastmilk: 0.2 ml
214367510|NCT00908401|OTHER|Oral Sucrose|oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
214367511|NCT06214286|DEVICE|Shockwave|Shockwave therapy
214367512|NCT06214286|OTHER|Kinesio taping|Kinesio taping application
214979283|NCT06069388|PROCEDURE|diaphragm technique|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
214979284|NCT06069388|PROCEDURE|conventional therapy|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
214979285|NCT02617537|DRUG|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
214979286|NCT02617537|DRUG|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
214979287|NCT05182944|DRUG|A：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
214979288|NCT05182944|DRUG|B：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
214367513|NCT06214286|OTHER|conventional physical therapy|conventional physical therapy
214492022|NCT06181500|OTHER|Home-based multicomponent exercise intervention program|A novel home-based multicomponent exercise intervention program was designed using a multimodal training circuit. This 24-week circuit program was created to improve functional (resistance) and aerobic health. Participants will be asked to train two to three times a week for 45 minutes. They will be supervised via videoconference by a trained kinesiologist from the EPIC Center at the Montreal Heart Institute. If desired, participants can complete their exercises with a partner, friend, or relative to facilitate communication. Participants will be asked to document the perceived intensity of their exercises in a booklet after each workout. The perceived intensity of their exercises will be measured by a validated effort perception scale graduated from 0 to 10 (Borg scale; Williams, 2017). Progressions will increase every five weeks and will be subject to modification if not properly tolerated or if found to be below a 3 on the Borg rate of perceived exertion scale (moderate intensity).
214492023|NCT06734637|DRUG|Peginterferon α-2b injection|Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).
214492024|NCT06842784|OTHER|Ambient heat stress|3-hour ambient heating in 44°C and 20% relative humidity
214979289|NCT05182944|DRUG|A：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
214367514|NCT04067401|BEHAVIORAL|Wingman Connect|Wingman-Connect combines group and individual skill training. Group exercises build cohesion, belonging and shared purpose, and promote value of healthy unit, giving and receiving support. Individual skills promote the ability to thrive during transitions, manage stressors and meet career goals, and decrease barriers to utilizing organizational resources (family, health). The training has a total of 22 modules comprised of specific learning objectives and activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
214492025|NCT06883370|COMBINATION_PRODUCT|ultrasound-guided transversals fascia plane block with ropivacaine|using 0.375% ropivacaine of 0.4mls/kg
214492026|NCT06885099|DEVICE|FemPulse System|Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.
215086941|NCT01130090|DEVICE|Adjustment of back-up respiratory rate on bi-level ventilator|"3 consecutive nights in randomized order, in either S (Spontaneous) mode, ST (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in ST (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort"
215086942|NCT05133713|DEVICE|Catheter directed therapy|Thrombectomy
215086943|NCT05133713|DRUG|Systemic anticoagulation|Conservative therapy
214492027|NCT06864260|OTHER|Built Environment|Built environment modifications include sidewalks, sidewalk cuts, traffic-calming devices, crosswalks, transit improvements, green space, street trees, beautification, signage, lighting, wellness van
214492028|NCT06864260|OTHER|Social Environment|Neighborhood coalition, Community Leadership Academy (LHSA), community-led events, community health workers
214492029|NCT06818604|DEVICE|CPAP|Participants randomized to this group will receive auto-CPAP therapy. The device will be initiated by a respiratory therapist at GF Strong Rehabilitation Centre. Settings will be adjusted to achieve a device efficacy index \< 5 events per hour.
214492030|NCT06818604|DEVICE|BiPAP|Participants will receive BiPAP S mode therapy for 4 weeks. The device will be initiated by a respiratory therapist at GF Strong Rehabilitation Centre with initial settings of IPAP 8 cmH2O and EPAP 3 cmH2O. Settings will be modified to a maximum tolerated level to achieve a tidal volume of 8 mL/kg ideal body weight and SpO2 \> 95%. Overnight oximetry will be performed to ensure at least 4 hours of device use, and settings will be adjusted to achieve a DEI \< 5 events per hour.
214492031|NCT04670536|DEVICE|PASS LP implants|Thoraco lumbar arthrodesis
214492032|NCT04670536|DEVICE|PASS DEGEN|Thoraco lumbar arthrodesis
214979290|NCT05182944|DRUG|B：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
214979291|NCT03456661|DRUG|Levobupivacaine|Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.
214979292|NCT03456661|DRUG|Levobupivacaine + Dexmedetomidine|Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
214979293|NCT05440032|DIAGNOSTIC_TEST|Semi-quantitative electrochemical leukocyte esterse test strip|Electrochemical assay to detect level of leukocyte esterase in sample
214979294|NCT05440032|DIAGNOSTIC_TEST|Roche Chemstrip|Urinalysis chemstrip
215086944|NCT04828291|BEHAVIORAL|Benign Behavioral Interventions|This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
215086945|NCT03352453|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
215086946|NCT03352453|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
215086947|NCT02904122|OTHER|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
215086948|NCT02146677|OTHER|Osteopathic manipulative treatment|
214367515|NCT04067401|BEHAVIORAL|Stress Management|Stress management training reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
215086949|NCT02146677|OTHER|Sham therapy|
215086950|NCT02146677|OTHER|Usual care|
215086951|NCT00088790|DRUG|AZD5438|
214367516|NCT02496338|OTHER|Training program about menopausal health isues|A three sessions raining program about health issues during menopause for spouses of 45-60 years old
214367517|NCT03717090|OTHER|No intervention|Sample collection study Sample collection and collection of laboratory values
214367518|NCT03891121|DEVICE|Occlusal Splint|Occlusal splints are appliances that were usually applied to the upper jaw and covering all teeth and they are made of autopolymerizing acrylic resin. It is produced by using 2 mm thick hard acrylic between the maxilla and mandible as defined by the Okeson.
214492033|NCT04670536|DEVICE|PASS TULIP PRIME|Thoraco lumbar arthrodesis
214979295|NCT02683109|DRUG|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
214979296|NCT02683109|DRUG|Placebo|
214979297|NCT02683109|DRUG|Tiotropium|
214979298|NCT02683109|DRUG|Olodaterol|
214979299|NCT01099644|BIOLOGICAL|131 I-8H9|Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
214979300|NCT03599596|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
214979301|NCT03599596|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
214979302|NCT02267941|OTHER|observation|Data were collected by a disigned form. Statistic software was used to analyze clinical data.
214979303|NCT03740464|DRUG|long-acting granulocyte colony stimulating factor|A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
215086952|NCT02606227|BEHAVIORAL|Financial incentive|Vouchers
215086953|NCT02606227|OTHER|No financial incentive|No financial intervention
215086954|NCT03343080|DRUG|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
215086955|NCT03343080|OTHER|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
215086956|NCT04940897|OTHER|Use of CareSens ketone meter|Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
215086957|NCT02893826|DRUG|EG-1962 (nimodipine microparticles)|
215086958|NCT02893826|DRUG|Enteral Nimodipine|
215086959|NCT02368912|DRUG|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
215086960|NCT02368912|DRUG|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
214979304|NCT03740464|DRUG|Short-term granulocyte colony stimulating factor|Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
214367519|NCT03891121|DRUG|Botulinum toxin type A|We diluted 100-U freeze-dried BTX-A with 1.0 milliliters of sodium chloride, resulting in a dose of 1.0 U per 0.1 mL. We administered all skin injections by using a 1-inch 30-gauge needle. Patients were placed with the Frankfurt horizontal plane parallel to the floor.
214979305|NCT04137198|DRUG|Sufentanil|intranasal administration of Sufentanil Forte 0,5mcg/kg as first dose and 0,3mcg/kg as titration doses
214979306|NCT00546403|DRUG|Modafinil|Adjunctive treatment with titrated dose of modafinil
214979307|NCT00546403|DRUG|Placebo|Adjunctive treatment with placebo
214979308|NCT00183430|DRUG|Prazosin|Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
214979309|NCT00183430|DRUG|Placebo|Placebo capsules are taken orally twice per day at 10 am and bedtime.
214979310|NCT00183430|BEHAVIORAL|Psychotherapy|All participants will undergo psychotherapy during medication treatment period.
214979311|NCT05076227|DRUG|IM injection of vaccination (mRNA vaccination)|mRNA vaccination
214979312|NCT05076227|DRUG|IM injection of vaccination (vector based vaccination)|vector based vaccination
214367520|NCT03629418|DRUG|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
214492034|NCT00627432|DRUG|gemcitabine hydrochloride|
214979313|NCT04625036|DIAGNOSTIC_TEST|Single passive leg movement|"The investigation consists of a non-invasive evaluation by ultrasounds performed on the common femoral artery investigating the speed of arterial blood flow \[Leg Blood Flow LBF\] and diameter of vessel with a dedicated ultrasound system (General Electric Medical Systems, Milwaukee, WI) using Doppler method, before and after a passive flexion-extension movement of the knee. A linear probe will be used with a frequency of 5 MHz. Using the diameter of the artery and the average volume (Vmean), the LBF will be calculated every second with the formula=Average volume\*PiGreco\*(vessel diameter / 2)2\*60.~The subject will be placed in a sitting position for 20 minutes before the test. The protocol consists of image acquisition for 60 seconds (basal measurement), followed by a passive flexion-extension of the knee (single passive leg movement). The knee flexion will be performed by health care personnel at a rate of 1 Hz. At the end of the movement, the recording will continue for 60 seconds."
214979314|NCT06134635|DRUG|Statins|Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
214979315|NCT06134635|DRUG|Evolocumab|Evolocumab 140mg twice a month, subcutaneous injection
214979316|NCT00930020|DRUG|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
214979317|NCT00930020|DRUG|Matched placebo|matched placebo (cornstarch) once a day for 5 days
214979318|NCT05981924|OTHER|Perioperative Music Therapy|Music therapist will play customized music in the perioperative period on the basis of oxycodone analgesia
214979319|NCT02961842|DRUG|500 mL Colloid Preload|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
214979320|NCT02961842|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
214979321|NCT02961842|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
214979322|NCT02961842|DRUG|Intrathecal Fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space
214979323|NCT02961842|DRUG|500 mL Crystalloid Coload|Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
214979324|NCT02961842|DRUG|1000 mL Crystalloid Coload|Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
214979325|NCT02961842|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
214979326|NCT02961842|RADIATION|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
214979327|NCT02961842|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
214979328|NCT02849028|BEHAVIORAL|sleep disorder|The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
214979329|NCT00526474|DRUG|Vorapaxar|2.5-mg tablet daily for at least 1 year
214979330|NCT00526474|DRUG|Placebo|matching tablet daily for at least 1 year
214979331|NCT05388799|OTHER|Educational intervention|In addition to standard care, brochure-supported education will be given to patients who are scheduled for nose surgery.
214979332|NCT03845894|DRUG|Liposomal bupivacaine|Interscalene brachial plexus blockade using liposomal bupivacaine (expanded with plain bupivacaine)
214979333|NCT03845894|DRUG|Bupivacaine with adjuvants|Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.
214979334|NCT05232552|DRUG|Anlotinib hydrochloride|anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
214979335|NCT05232552|DRUG|induction chemotherapy|docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
214979336|NCT05232552|RADIATION|concurrent chemoradiation|definitive IMRT (GTV\>66Gy) concurrent with 2 cycles of DDP (100mg/m2 d1) and anlotinib (12mg d1-14) every 21 days
214979337|NCT03759080|PROCEDURE|mental practice|training of mental practice to do the pattern of proprioceptive neuromuscular facilitation
214979338|NCT03759080|PROCEDURE|proprioceptive neuromuscular facilitation|upper limb Pattern: Flexion -Abduction- External rotation
214979339|NCT02328508|DEVICE|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
214979340|NCT02987881|BEHAVIORAL|Home-based aerobic exercise and nutritional counseling|Moderate walking and running with nutritional counseling at study visits.
214979341|NCT01490411|DRUG|Placebo|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
214979342|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
214979343|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
215086961|NCT02368912|DRUG|ASP1707 single dose fasted|Oral, healthy young male
215086962|NCT02368912|DRUG|ASP1707 single dose fed|Oral, healthy young male
214367521|NCT03629418|DRUG|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
214492035|NCT00627432|DRUG|oxaliplatin|
214979344|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
214367522|NCT02150018|OTHER|non invasive ventilation|
214367523|NCT03120962|DRUG|Oxycodone|Oxycodone 20mg/day, for 4 weeks
214979345|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
214367524|NCT03120962|DRUG|Gabapentin|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
214492036|NCT06851208|OTHER|Emotional intervention|Emotional intervention Description: The participant will watch a short video-clip with negative emotional content while simultaneously experience experimentally induced pain.
214492037|NCT06851208|OTHER|Emotional intervention|Description: The participant will watch a short video-clip with positive emotional content while simultaneously experience experimentally induced pain.
214979346|NCT00187408|DRUG|Low Molecular Weight Heparin (dalteparin)|
214979347|NCT02471443|PROCEDURE|Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
214979348|NCT00426270|DRUG|Octagam 10%|Octagam 10% was supplied as a ready-to-use solution in glass bottles.
214979349|NCT05424341|OTHER|Muscle Energy Technique|For Gastrocnemius muscle, subject will be in supine position keeping knee fully extended and therapist on affected side in walking position. The subject's ankle joint will be dorsiflexed until a resistance feel and will ask to hold this position and exert 20% of force towards plantar flexion for a period of 5 to 7 seconds. Resistance will be released and relaxation of 5 seconds will be given during which the ankle will was passively dorsiflexed to a new barrier. 5 repetitions will be given.
214979350|NCT05424341|OTHER|Counterstrain Technique|Therapist places thumb on tender point at plantar fascia insertion while patient in supine position with ipsilateral knee flexed. Plantar flex the toes and ankle while monitoring sore site with thumb, curling around tender point until monitoring thumb feels symptomatic relief. Supination/pronation of foot will be added if necessary. The position of ease will be maintained for 90 secs until tissues beneath monitoring thumb softens. Tender spot is re-evaluated once the foot is returned to neutral without moving the thumb. It will be repeated 3 times for 30 secs resting interval in-between
214979351|NCT00910598|DRUG|glatiramer acetate|20 mg daily s.c. for 1 year
214979352|NCT04135534|DRUG|group A|mutonpain 0.05 mg/kg
214979353|NCT04135534|DRUG|group B|mutonpain 0.1 mg/kg
214979354|NCT04135534|DRUG|group C|mutonpain 0.2 mg/kg
214979355|NCT02057770|DRUG|busulfan|
214979356|NCT02057770|DRUG|fludarabine phosphate|
214979357|NCT02057770|RADIATION|total-body irradiation (TBI)|
214979358|NCT02057770|PROCEDURE|Stem cell transplant|
214979359|NCT02057770|DRUG|cyclophosphamide|
214367525|NCT03120962|DRUG|Famciclovir|Famciclovir 500mg three-times daily for 7 days
214367526|NCT00994357|DEVICE|Real-time CGM|See previous description.
214367527|NCT00994357|OTHER|Standard care|See text.
214367528|NCT05195931|DIAGNOSTIC_TEST|preload challenge|reduction in preload by head-up tilt and increase in preload with saline infusion
214367529|NCT05195931|DIAGNOSTIC_TEST|afterload challenge|reduction in afterload with nitroprusside and increase in afterload with phenylephrine
214492038|NCT06851208|OTHER|Emotional intervention|Description: The participant will watch a short video-clip with neutral emotional content while simultaneously experience experimentally induced pain.
214492039|NCT06790706|DRUG|DOMVANALIMAB + ZIMBERELIMAB|Patients will be treated with intravenous Domvanalimab at flat dose of 1200 mg + intravenous Zimberelimab at flat dose of 360 mg, administered every 3 weeks (Q3W, one cycle = 3 weeks).
214979360|NCT02057770|DRUG|tocilizumab|
214979361|NCT01450813|DRUG|Saline 0.06 ml/kg|IV Infusion x1 prior to laryngoscopy
214979362|NCT01450813|DRUG|Rocuronium 0.2 mg/kg|IV Infusion x1 prior to laryngoscopy
214979363|NCT01450813|DRUG|Rocuronium 0.4 mg/kg|IV Infusion x1 prior to laryngoscopy
214979364|NCT01450813|DRUG|Rocuronium 0.6 mg/kg|IV Infusion x1 prior to laryngoscopy
215086963|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
215086964|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
215086965|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
215086966|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
215086967|NCT02368912|DRUG|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
215086968|NCT02368912|DRUG|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
215086969|NCT02989051|OTHER|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
214979365|NCT05301439|PROCEDURE|Restoration with Resin|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Selective removal of carious tissue with dentin spoons at the dentin-enamel junction.~Cleaning the cavity with water. Application of the Universal Adhesive System (Shofu). Excess removal. Application of a new layer of adhesive system. Light rubbing and excess removal. Photoactivation - 20s. Insert Bulk Fill Resin (Shofu) in 4mm increments. Photoactivation for 20. Preservation. Clinical and radiographic control at 1, 3, 6 and 12 months."
214979366|NCT05301439|PROCEDURE|Hall Technique|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Clinical evaluation through inspection of the texture of the remaining dentin with a rounded exploratory probe.~Cleaning the cavity with water. Take drying. Proof of the steel crown. Relative isolation. Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~Clinical and radiographic control at 1, 3, 6 and 12 months."
215086970|NCT02989051|OTHER|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of \>85% of normal fluid recommendations (for a healthy child).
215086971|NCT05162053|DRUG|vicagrel Capsules|Oral administration for 7 days under fasting
214979367|NCT05301439|PROCEDURE|Conventional Steel Crown|"* Prophylaxis;~* Relative isolation;~* The preparation of the tooth will be performed conventionally with reduction of the occlusal, mesial and distal surface of 1 to 1.5 mm and selective removal of the decayed tissue;~* Cleaning the cavity with water;~* Slight drying;~* Trial of steel crown;~* Relative isolation;~* Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~* Clinical and radiographic control at 1, 3, 6 and 12 months."
214979368|NCT00208364|DEVICE|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
215086972|NCT05162053|DRUG|Clopidogrel Tablets|Oral administration for 7 days under fasting
214979369|NCT02147171|DIETARY_SUPPLEMENT|VisionAce|
214979370|NCT02147171|DIETARY_SUPPLEMENT|Placebo|
214979371|NCT04483414|DRUG|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
214979372|NCT04483414|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
214979373|NCT01368510|BEHAVIORAL|Intensive Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered daily 5 days/week for 4 weeks
214979374|NCT01368510|BEHAVIORAL|Waitlist|Minimal contact waitlist weekly for 4 weeks
214979375|NCT06297512|DRUG|Radiotherapy, Temozolomide, Doxorubicin|"Radiation treatment Concomitant TMZ: 75mg/m2/day per OS for 7 days per week, from the first day of radiotherapy to the last (maximum cumulative dose 3150mg/m2), with possibility of earlier initiation on clinician's judgment.~After 1 month (4-5 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Adjuvant TMZ: 2 cycles at increasing doses (150-180 mg/m2) per OS for 5 consecutive days 28 days apart~After 3 months (12 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Dox 4 cycles with 37.5mg/m2/day by continuous infusion over 48 hours (2 days) every 28 days (maximum cumulative dose 300mg/m2)~And after 4 weeks ± 7 days from the end of Dox treatment they will receive:~TMZ adjuvant 12 cycles at increasing doses (150-180 mg/m2) by OS for 5 consecutive days 28 days apart (maximum cumulative dose 16200 mg/m2);"
214979376|NCT01429090|PROCEDURE|blood sampling|blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
214979377|NCT01429090|DRUG|Vagantin®|administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
214979378|NCT01429090|DRUG|methantheline solution|administration 100 ml methantheline solution (100 mg methantheline bromide)
214979379|NCT01429090|PROCEDURE|Measurement of salivation|"Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing"
214979380|NCT01429090|PROCEDURE|Measurement of accommodation|Accommodation was measured with the optometer according to Schober (Velhagen 1972)
214979381|NCT01429090|PROCEDURE|Pupillometry|Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
214979382|NCT05190627|DRUG|Loratadine|Loratadine 10mg/day added to rapamycin for 12 months
214979383|NCT05190627|DRUG|Placebo 10mg/day added to rapamycin for 12 months|Placebo in the same type of capsule than the experimental drug
214979384|NCT02709746|DRUG|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
214979385|NCT02709746|DRUG|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
214979386|NCT02709746|DRUG|Fluoxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
214979387|NCT02709746|OTHER|Placebo|Encapsulated tablet
215086973|NCT01241760|DRUG|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
215086974|NCT01241760|DRUG|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
215086975|NCT01241760|DRUG|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
215086976|NCT01241760|DRUG|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
215086977|NCT03728491|DEVICE|Simulator|US Mentor simulator, lung module, provided by 3D Healthcare Systems
215086978|NCT03728491|DEVICE|Healthy figurants|Medical students or volunteers without any pathology in thorax
215086979|NCT05834491|DEVICE|minimal shoes and foot strengthening and flexibility exercises|Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
215086980|NCT05834491|DEVICE|Supportive Footwear, foot orthotic device and foot flexibility exercises|sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
215086983|NCT04268433|OTHER|N/A - Non-interventional study|"Stages:~1. Patient information and written informed consent (3 Copies. To be carried out \>24 hours after receiving the patient information sheet)~2. Physiological recording set up (ECG, BP, sensor and respiratory band)~3. Control period - no music played~4. Series of pieces of music without tempo control~5. Repeat series of pieces of music with tempo control~6. Participant leaves the study"
214367530|NCT05195931|DIAGNOSTIC_TEST|contractility assessment|heart rate changes will be made by increasing heart rate with external pacemaker/defibrillator. Contractility will be adjusted by dobutamine infusion. Patients will exercise at a constant pump speed and also with pump speed increases.
214979388|NCT03933163|DRUG|Resveratrol|Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.
215086984|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for MIP-1 alpha
215086985|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for IL-6
215086986|NCT05754060|OTHER|Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
214979389|NCT03073486|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
215086987|NCT06139562|BEHAVIORAL|Time-Restricted Feeding|Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
215086988|NCT06139562|BEHAVIORAL|Extended-Time Feeding|Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
215086989|NCT04642924|DRUG|SGM-101|Fluorescence-guided surgery
214979390|NCT03073486|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
214979391|NCT01224379|DEVICE|Topping off system|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
214979392|NCT01224379|DEVICE|monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
214979393|NCT04716244|OTHER|interview/focus group/questionnaire|"Prior to the meetings, participants will be asked to fill in a questionnaire with demographic data including age, family status, number of pregnancies, number of children, education, and employment, history of preeclampsia or GDM, family history of CVD, and self-reported height and weight We will conduct up to 8 groups or until we reach saturation of themes. For the teleconference focus groups, the number of participants will be limited to 6 women per group, as recommended from previous research on teleconference focus groups51. The face to face focus groups will include up to -12 women. The expected duration of each group, will last 1-2 hours.~We will conduct up to 36 in-depth interviews. The expected duration of each interview will last 30 minutes to -1.5 hours.~Participants will be asked for their consent to record the meetings, audio only. The discussions will be then transcribed. An interview guide will be followed."
214979394|NCT03123081|PROCEDURE|Umbilical Cord Milking|At birth the cord of a depressed newborn is clamped immediately and cut 30 cm from the umbilicus. After completion of initial steps, if required, positive pressure ventilation (PPV) is given for 30 seconds, along with UCM. The cord is untwisted and held in a vertical position. It is milked 3 times towards the baby at a speed of 10 cm/s and then clamped 3 cm from the umbilicus. After completion of PPV along with UCM, if the baby requires further resuscitation, the NRP 2015 guidelines will be followed. Depressed newborns who respond to initial steps of resuscitation with normal breathing and heart rate of 100 bpm or higher, will receive UCM after this.
214979395|NCT00383526|BIOLOGICAL|Inactivated, split-virion influenza vaccine|Vaccine
214367531|NCT01477853|DRUG|Sitagliptin|Sitagliptin 100 mg tablet orally daily
214367532|NCT01477853|DRUG|Atorvastatin|Atorvastatin 80 mg tablet orally daily
214367533|NCT01477853|OTHER|Placebo to sitagliptin|Placebo to sitagliptin tablet orally daily
214367534|NCT01477853|OTHER|Placebo to atorvastatin|Placebo to atorvastatin tablet orally daily.
214979396|NCT00383526|BIOLOGICAL|Inactivated, split-virion influenza vaccine|Vaccine
214979397|NCT06450769|OTHER|Aronia juice|100% aronia juice, 100 mL/day, twelve-week follow-up
214979398|NCT06450769|OTHER|Mediterranean diet|An individually planned nutrition program suitable for the energy-restricted Mediterranean diet
214979399|NCT06450769|OTHER|Low-fat diet|An individually planned nutrition program suitable for the energy-restricted low-fat diet
214979400|NCT02755753|DRUG|Lansoprazole|Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
214979401|NCT02755753|DRUG|Rebamipide|Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
214979402|NCT02755753|DRUG|Rebamipide-placebo|Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
215086990|NCT03689244|DRUG|Selexipag|oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration
215086991|NCT03689244|DRUG|Placebo|Oral tablets without active compound
215086992|NCT01705158|DRUG|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
214680013|NCT00722592|OTHER|EC20|During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
215086993|NCT01846559|BIOLOGICAL|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
215086994|NCT01846559|DRUG|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
215086995|NCT01846559|DRUG|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
215086996|NCT00053547|DRUG|paricalcitol injection|
215086997|NCT04412213|OTHER|Stuttering severity instrument for school-age children (SSI-3 Arabic version)|Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
214979403|NCT01483118|DRUG|Cinnamon Extract|Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.
215086998|NCT01565564|BEHAVIORAL|Shared glycaemic control care within the local three-tier's antenatal care network|"* Individualized dietary and physical activity consultation plus group diabetes education~* Self blood glucose monitoring~* Insulin therapy if indicated~* Self blood glucose monitoring~* Insulin therapy institutions if indicated;"
215086999|NCT00227513|DRUG|bortezomib|Given IV
215087000|NCT00227513|DRUG|vorinostat|Given orally
215087001|NCT03738007|DEVICE|HA IDF II|Treatment with HA IDF II (YVOIRE volume)
215087002|NCT03738007|DEVICE|Perlane|Treatment with Perlane
214979404|NCT01483118|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing ground cereal.
214979405|NCT03518359|BEHAVIORAL|Enhanced Stress Resilience Training (ESRT)|ESRT involves six weekly 90-minute group classes and one 2 - 4 hour retreat. Classes focus on developing mindfulness skills (i.e. sustained attention, open monitoring, emotional regulation, meta-cognition) in the context of skills and concepts for managing stress, particularly in practicing medicine. Homework consists of 20 minutes per day of mindfulness exercises following guided meditation CDs or videos of movement-based practice, and practice will be reported periodically by text. A 3-hour outdoor retreat occurs at week six. The central exercises of ESRT are the body scan, sitting meditation, chi gong and yoga. For both arms, the weekly teaching sessions occur on a workday morning during protected time at Parnassus, Mission Bay or Zuckerberg San Francisco General Hospital campus.
215087003|NCT00199667|DRUG|Mycophenolate Mofetil|
215087004|NCT02359214|DIETARY_SUPPLEMENT|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
215087005|NCT02359214|OTHER|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
215087006|NCT04928729|OTHER|Pursed Lip Breathing|PLB with frequency of three times daily for First 3 days of week for a duration of 5-10 mins is perform.
215087007|NCT04928729|OTHER|Pursed Lip Breathing +DB|PLB+DB with frequency of three times daily for Last three days of week for a duration of 10-15 mins is perform.
215087008|NCT04928729|OTHER|Conservative care|Participants will be having different dose as per tolerance 5 times daily.
215087009|NCT00288314|PROCEDURE|Magnetic Resonance Imaging, Functional|Structural and functional MRI
215087010|NCT03394690|DIETARY_SUPPLEMENT|green coffee|2 capsuls
215087011|NCT03394690|OTHER|control|2 capsuls
215087012|NCT00858663|RADIATION|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
215087013|NCT00858663|DRUG|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
214367535|NCT01477853|DRUG|Metformin (open-label)|Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
214367536|NCT01477853|DRUG|Glimepiride (open-label)|Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.
214367537|NCT01477853|DRUG|Glimepiride (double-blind)|Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.
214367538|NCT01477853|DRUG|Placebo to glimepiride|Phase B: placebo to glimepiride tablet orally daily.
214367539|NCT02331862|DRUG|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
214367540|NCT03659604|BEHAVIORAL|'SmartLife' with tailored feedback|'SmartLife' game with tailored feedback: mobile exergame with tailored feedback. Feedback will be based on accelerometer data from a sensor that is integrated in a T-shirt. The sensor captures individually calibrated accelerometer data and is paired with the mobile exergame. Depending on the physical activity intensity of the player, the game challenge and feedback adapts individually in real-time.
215087014|NCT06508008|PROCEDURE|continuous negative pressure suction|(1) Open the mouth with a tongue depressor; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) Insert a suction tube into the mouth to aspirate phlegm.
215087015|NCT06508008|PROCEDURE|Intermittent negative pressure sputum suction through oral pharyngeal airway|(1) Insert the oropharyngeal airway parallel into the oral cavity; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) The suction tube is inserted into the deep oral cavity through the middle lumen of the oropharyngeal airway; (4) Intermittent negative pressure for suction and suction of sputum
215087016|NCT04539860|DEVICE|Transdermal Optical Imaging|Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
215087017|NCT00819455|BEHAVIORAL|Experimental|Active Life style modification-motivation by I.T technology
214979406|NCT03518359|BEHAVIORAL|Active Control|Control group participants will meet for 6 weeks, 90 minutes each week, for classes focuses on stress management through rest and exercise, with equivalent protected time and small group bonding but without the use of contemplative practices. Topics will include the history of surgery, patient perspective, the physician personality, technical mastery, fallibility and limits, balancing compassion and detachment and knowing when not to operate. For daily practice, control participants will be asked to devote 20 min per day to stress management through rest and exercise again reported daily by text.
214979407|NCT03757416|OTHER|Data collection|If it has been determined that the patient will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome, the patient will be asked to participate in this data collection study.
214979408|NCT02870491|BEHAVIORAL|Free Distribution|Caretakers of children under 5-years-old will have access to free ORS and zinc
214979409|NCT02870491|BEHAVIORAL|Preemptive Delivery|Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
214979410|NCT03474224|DEVICE|Ev1000 Clinical Platform from Edwards Lifesciences|The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
214979411|NCT01816321|DRUG|Corifollitropin alfa|Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
214979412|NCT01816321|DRUG|recombinant FSH|recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
214979413|NCT01816321|DRUG|Ganirelix|Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
214979414|NCT01816321|DRUG|hp HMG|hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
214367541|NCT03659604|BEHAVIORAL|'SmartLife' without tailored feedback|'SmartLife' without tailored feedback: mobile exergame without tailored feedback. The mobile exergame will not be paired to any sensor. The participant can play the mobile game, yet, will not receive any real-time feedback or adjustment in the game on physical activity intensity.
214367542|NCT03659604|BEHAVIORAL|No game|Passive control: School classes will be asked to continue their daily life as usual.
214367543|NCT01050816|PROCEDURE|Chondron(autologous chondrocyte) Implantation|"* Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~\*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation."
214367544|NCT00248781|DEVICE|Telecommunications system|
214367545|NCT00248781|DEVICE|attention control|health education
214367546|NCT01102244|DRUG|Tobradex ST|tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days
214367547|NCT01102244|DRUG|Azasite|azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
214680014|NCT04561817|DRUG|Ipatasertib|400mg PO daily: day 1-21 of 28 day cycle
214979415|NCT02035566|OTHER|Telehome Care Monitoring|Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
214979416|NCT01206465|DRUG|pralatrexate|Given IV
214979417|NCT01206465|DRUG|fluorouracil|Given IV
214979418|NCT01206465|OTHER|laboratory biomarker analysis|Correlative studies
215087018|NCT00819455|BEHAVIORAL|Control arm (usual care/standard care arm)|Life style modification only once
215087019|NCT04069923|OTHER|Magnesium-based Bone Void Filler|Given intraoperatively
215087020|NCT01166061|BIOLOGICAL|Placebo|Solution resembling active solution but without peptides
214367548|NCT05454150|DEVICE|balloon-expandable valve|Sapien 3/Ultra, Edwards Lifesciences©
215087021|NCT01166061|BIOLOGICAL|ToleroMune Grass|1 x4 administrations 4 weeks apart
215087022|NCT03296631|OTHER|collection of diapers with fresh stools|collection of diapers with fresh stools
215087023|NCT02138240|BEHAVIORAL|Social network intervention|The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
215087024|NCT04945967|PROCEDURE|New Method|Physiological flexion in therapeutic positioning, oral stimulation, stimulation of synergistic movements, and stimulation for non-nutritive sucking by using special designed pacifier for premature infant.
215087025|NCT04945967|PROCEDURE|Conventional Method|Oral stimulation and non-nutritive sucking stimulation using usual pacifier.
214979419|NCT01206465|GENETIC|DNA analysis|Correlative studies
214979420|NCT01206465|OTHER|high performance liquid chromatography|Correlative studies
214979421|NCT01206465|GENETIC|polymerase chain reaction|Correlative studies
214367549|NCT05454150|DEVICE|self-expanding valve|Evolut R/Pro, Medtronic©
214979422|NCT01206465|GENETIC|nucleic acid sequencing|Correlative studies
214979423|NCT01206465|OTHER|pharmacological study|Correlative studies
214979424|NCT01206465|OTHER|pharmacogenomic studies|Correlative studies
214979425|NCT01206465|GENETIC|polymorphism analysis|Correlative studies
214979426|NCT02158897|OTHER|Prolon diet|3 cycles of a 5-day Prolon diet very month
214979427|NCT04517682|DIAGNOSTIC_TEST|RT-PCR|The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples
214979428|NCT04630743|BEHAVIORAL|Cognitive and Behavioral intervention for the Management of Episodic Breathlessness|The cognitive and behavioral brief intervention comprises two parts: In a first module, the intervention and the study team is introduced, the definition of episodic breathlessness is given and the individual characteristics of breathlessness episodes are recorded. Goals of the intervention are discussed. In a subsequent module on patient education and the strategies, the patient and intervention executor discuss the patients' assumptions about episodic breathlessness including triggers and already used management strategies for breathlessness episodes. This follows the presentation of the non-pharmacological strategies: movement of air/ handheld fan, forward lean, diaphragmatic breathing, distraction, pursed lips breathing, long breaths out and relaxation training. The patient selects 2-3 strategies and trains them with the intervention executor.
214979429|NCT02089347|BIOLOGICAL|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
214979430|NCT02089347|BIOLOGICAL|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
214979431|NCT04825665|OTHER|Continuous force|"A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar, bypassing the second premolar and attaching to the upper first premolar. The buccal tipping force will be checked and reactivated to the original level on the 28th day of the 8 week study period."
214979432|NCT04825665|OTHER|Intermittent force|"A buccally directed tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar and attaching to the upper first premolar. The buccal tipping force will be removed every 21 days for a 7-day rest period, where a passive wire of the same gauge and material of the cantilever spring (0.017 x 0.025 beta-titanium-molybdenum alloy) will be placed instead to maintain the position of the upper first premolar during the rest period."
214367550|NCT01107860|DEVICE|Computed Tomography|In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
214367551|NCT01107860|DEVICE|Computed Tomography|In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
214367552|NCT05410600|OTHER|Arm ergometer smart trainer cycling program|Arm ergometer exercise training using the smart trainer.
214979433|NCT02184104|DIETARY_SUPPLEMENT|Caffeine|
214979434|NCT03908346|OTHER|Decision Aid for Surrogate Decision Makers of Comatose Survivors of Cardiac Arrest|a decision aid has been created that is a four page document meant to support surrogate decision makers for comatose survivors of cardiac arrest
215087026|NCT02261233|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
214367553|NCT02132364|OTHER|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
215087027|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
215087028|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
215087029|NCT00314301|DEVICE|loaded sit-to-stand training|
215087030|NCT00287794|DRUG|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
215087031|NCT01591863|DRUG|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
215087032|NCT01196494|PROCEDURE|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
214367554|NCT05120089|OTHER|muscle energy technique and myofacial release (physiotherapy techniques)|Each technique will be applied for three month (3 session/week)
214979435|NCT02783066|DEVICE|Offloading boot: PulseFlow|A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
214979436|NCT06464627|BEHAVIORAL|Physical activity|16 weeks
214979437|NCT02121197|DRUG|Ozurdex|
214979438|NCT00586560|DRUG|Kareniticin and cyclophosphamide|"An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity."
214979439|NCT02017002|PROCEDURE|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
214979440|NCT02017002|PROCEDURE|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
214979441|NCT00551369|RADIATION|SBRT|SBRT delivered in 3 fractions of 20 Gy/fraction over 1.5 to 2 weeks for a total of 60 Gy
215087033|NCT03294070|COMBINATION_PRODUCT|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
214979442|NCT03927443|DRUG|SDP-133|one drop
214492040|NCT06790706|DRUG|DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4|Patients will be treated with intravenous Domvanalimab at flat doses of 1600 mg + intravenous Zimberelimab at flat dose of 480 mg, administered every 4 weeks (Q4W), together with an induction treatment of intravenous FOLFOX-4 (Oxaliplatin 85 mg/m2 IV, L-folinic acid 200 mg/m2 IV, and fluorouracil 400 mg/m2 IV bolus on Day 1, fluorouracil 2400 mg/m2 IV continuous infusion over 46-48 hours starting on Day 1) given every 2 weeks, for 4 months (one cycle = 4 weeks).
214492041|NCT06775795|DIETARY_SUPPLEMENT|Oat milk|Participants will consume one portion of plant-based milk alternative (oat) which will provide approximately 200 µg of iodine
214492042|NCT06775795|DIETARY_SUPPLEMENT|Soya milk|Participants will consume one portion of plant-based milk alternative (soya) which will provide approximately 200 µg of iodine
214492043|NCT06775795|DIETARY_SUPPLEMENT|Cow's milk|Participants will consume one portion of semi-skimmed cow's milk which will provide approximately 200 µg of iodine
214979443|NCT03927443|DRUG|Lumigan|one drop
214979444|NCT04259333|DRUG|Celecoxib 200mg|Celecoxib tablet
214979445|NCT04259333|DRUG|Acetaminophen, Codeine Drug Combination|acetaminophen-codeine-caffeine tablet
214979446|NCT00560716|DRUG|CYC116|Dose escalation of CYC116
214979447|NCT00926523|OTHER|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
214979448|NCT00926523|OTHER|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
214979449|NCT00926523|OTHER|Spirometry|To assess subjects lung function
214979450|NCT00926523|OTHER|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
214979451|NCT00719901|DRUG|obatoclax mesylate|Given IV
214979452|NCT00719901|DRUG|bortezomib|Given IV
214979453|NCT00719901|OTHER|laboratory biomarker analysis|Correlative studies
214492044|NCT06746714|BEHAVIORAL|Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia)|The Hypoglycemia Champion (HC) pharmacist reviewed patient charts before conducting proactive outreach. They did not contact subjects with active psychiatric issues or those admitted to a skilled nursing facility. The patient's care team (PCP and APM) were also contacted for peer consent. The outreach process involved an initial phone call with a secure electronic message or mailed letter (for those without secure KPNC patient portal access) if the initial call was unsuccessful. A second and third phone call attempt was made for non-responders.
214492045|NCT06746714|BEHAVIORAL|Usual care, after system-side dissemination of HOAP|Patients had their diabetes treated as usual by their diabetes care provider or primary care physician, after system-wide dissemination of HOAP.
214680015|NCT04561817|DRUG|Paclitaxel|80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
214979454|NCT01548963|PROCEDURE|Intensive glycemia control|Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
214979455|NCT05465395|PROCEDURE|Upper Cervical Adjustemnt|Upper cervical adjustement
214979456|NCT05465395|PROCEDURE|Thoracic Adjustemnt|Thoracic adjustment
214979457|NCT04905992|OTHER|Hypertonic saline at 6%|Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.
214979458|NCT04905992|OTHER|Airway clearance techniques (oscillating positive expiratory pressure therapy)|Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home
214979459|NCT00516971|DRUG|Esomeprazole 20mg once daily|
214979460|NCT02902926|BEHAVIORAL|Low FODMAPs Diet|Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
214979461|NCT02902926|BEHAVIORAL|Diet instruction|Answer the doubt and help the patient get the diet knowlege about the IBS.
214979462|NCT04393727|BIOLOGICAL|CONVALESCENT PLASMA|Convalescent plasma will be collected by healthy donors, cured by COVID-19 and, after standard preparation and dosage of neutralizing antibodies, will be administered to patients with SARS-CoV2 pneumonia
214979463|NCT03101306|OTHER|MR scans|Additional imaging using MR scans.
214979464|NCT01256307|OTHER|training and educational program|8 weeks
214979465|NCT01256307|OTHER|educational program|8 weeks
214979466|NCT01122173|DEVICE|Ablation|Atrial fibrillation ablation procedure
214979467|NCT02598674|DRUG|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
215094499|NCT05749952|DEVICE|Symphonie Aqua Digital System|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
214979468|NCT02598674|PROCEDURE|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
214979469|NCT02598674|PROCEDURE|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
214979470|NCT02598674|PROCEDURE|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
214979471|NCT02598674|DRUG|Gadolinium|Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.
214979472|NCT05111717|DRUG|Desflurane|Peripheral venous blood samplesof patients will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). Anesthesia maintenance will be provided with 40% O₂ and minimum alveolar concentration (MAC) in 60% air with 6% desflurane. DNA will be obtained from blood samples with the help of DNA isolation kit, and global DNA methylation analysis will performed by ELISA method.
215087034|NCT03160469|DEVICE|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) \& class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
215087035|NCT01375465|DEVICE|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
215087036|NCT00848341|DEVICE|GUIDANT ICD SYSTEM|
214979473|NCT05815966|BEHAVIORAL|The effect of emotion recognition and empathy focused education program|"Emotion recognition and empathy-oriented education program is a group-based, interactive program that includes techniques such as vision development, brainstorming, painting and drawing, recital, role-playing, gamification and information notes, which requires the active participation of children. Within the program; There are trainings aimed at establishing bilateral relations, gaining in-group commitment, expressing emotions comfortably, feeling that they are not alone, and learning new resources that will make them feel good when they feel bad.~The aims of education; children,"
214979474|NCT02923869|DRUG|Levobupivacaine|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
214979475|NCT02923869|DRUG|Bupivacaine|Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
214979476|NCT01184872|DRUG|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
214979477|NCT01184872|DRUG|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
214979478|NCT03225430|BEHAVIORAL|Cognitive behavioural treatment for tics|Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.
214979479|NCT03225430|BEHAVIORAL|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
214979480|NCT02576470|BEHAVIORAL|Biofeedback|Motor learning is improvement in movement overtime, followed by retaining what was learned. To determine whether movements are improving, kinematics must be assessed over time, beginning with defining specific kinematic goals, then continually re-evaluating goals throughout rehabilitation while providing the participants with biofeedback. Biofeedback is fundamental in motor learning, because it increases guidance and motivation, supplements losses in intrinsic feedback (proprioception), and facilitates generalization and retention. Biofeedback enhances the training of novel movements and could be essential for training swallowing maneuvers. Biofeedback training will occur 3 times.
214979481|NCT02576470|DEVICE|Transcranial Direct Current Stimulation|Weak direct currents can be applied non-invasively, transcranially and painlessly. Such application leads to transient changes in corticomotor excitability that are fully reversible. There are no known risks of tDCS of the brain, other than mild local discomfort at the electrode sites.The tDCS sessions will be separated by at least 24hrs, the electrode pads will not be used more than 4 times and they will be clean with a sterile saline solution.
214979482|NCT02576470|BEHAVIORAL|Financial Reward|Motor learning training can be enhanced by adjuvant techniques such as non-invasive neural stimulation and explicit reward. Both influence the primary motor cortex (M1), a key neural substrate of motor skill learning. Non-invasive neural stimulation reduces dysphagia after stroke as measured with subjective swallowing severity scales, however it is unknown whether it could also enhance swallowing maneuver training. Explicit reward (i.e. financial) incentivizes successful gains during motor training. Explicit reward has never been investigated in swallowing rehabilitation. However, it has been shown that increasing stress and financial penalty can reduce swallowing frequency in healthy adults.
215087037|NCT00499902|DRUG|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
215087038|NCT00969436|BIOLOGICAL|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
215087039|NCT00969436|BIOLOGICAL|Priorix™|Subcutaneous injection
215087040|NCT00969436|BIOLOGICAL|Varilrix™|Subcutaneous injection
215087041|NCT01228292|DRUG|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
215087042|NCT01228292|DRUG|Citrasate|Citrasate is infused as a dialysate
215087043|NCT04731207|DEVICE|Optovue®|Optical coherence tomography and optical coherece tomography angiography
215087044|NCT05895903|DEVICE|Screw expander|threadform screw expanders with special condensing burs for lateralization and compaction of bone
215087045|NCT05895903|DEVICE|Osseodensification drills|special drills to expand narrow alveolar ridges.
215094500|NCT05749952|DEVICE|Symphonie Aqua System (Non-Digital)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
214680016|NCT00532883|DRUG|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
214367555|NCT05165342|DEVICE|Rexon-eye|a technique in which low-intensity, high-frequency (a spectrum of frequencies ranging from 4 MHz to 64 MHz) electric currents are administered to a biological tissue through contact electrodes
214367556|NCT02036203|DEVICE|SCu300A IUB|Spherical copper contraceptive
214367557|NCT02036203|DEVICE|TCu380A IUD|T-shaped copper IUD
214492046|NCT06747169|DRUG|Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin|All patients were treated with a combination therapy consisting of sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin. The study is designed to assess the efficacy and safety of this treatment regimen in the specified population.
214492047|NCT05652400|OTHER|Exposure to antiretroviral therapy|Outcomes will be compared with regard to current or previous exposure to antiretroviral therapy.
214492048|NCT06788925|DEVICE|Patients support with survival coverage|"Following calls to emergency medical services, handled by the ground SMUR/SAMU or the air SMUR (HéliSMUR), the operator collects essential information on the nature of the incident and the apparent condition of the injured. A medical team is thus mobilized on site. It takes over from the rescue team (e.g. the SDIS fi refi ghters) who are generally the fi rst to arrive on the scene.~Eligible patients will be randomly assigned consecutively to one of two groups: control (use of the survival blanket) and experimental (use of the Therm'Up breastplate).~Any traumatized person at risk of hypothermia or in hypothermia in a pre-hospital environment, having given verbal consent to participate in the study and meeting the inclusion criteria"
214492049|NCT06788925|DEVICE|Patients support with active thermic jacket|The intervention Description is exactly the same, except that the patient will be given a ThermUp jacket
214979483|NCT02576470|BEHAVIORAL|targeted dysphagia training maneuver|training swallowing maneuvers or compensatory techniques (referred to as targeted dysphagia training throughout this document) that might reduce their swallowing pathophysiology
214979484|NCT02576470|RADIATION|Videofluoroscopy (VF) and Barium|The videofluoroscopy (VF) and barium will be used to record swallowing in all participant groups. This will capture full resolution VF images of all subjects in real time in the lateral view. From the digital recording, image sequencing will be exported to an image processing computer system and archived. The image intensifier will be focused on the lips, posterior pharyngeal wall, hard palate, and just below the upper esophageal sphincter (UES), providing a full view of the oral cavity and neck. A simultaneously recorded time-code will facilitate frame-by-frame data analysis. VF is the only option for visualizing swallowing kinematics during the pharyngeal swallow.
214979485|NCT02576470|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be used to provide a single-pulse to the brain.
214979486|NCT02576470|DEVICE|Submental Electromyography|Submental Electromyography (sEMG) is used to train participants swallowing maneuvers.
214979487|NCT03920956|OTHER|ABPM service by Pharmacists|Patients will receive ABPM services provided by a pharmacist and complete a patient satisfaction survey
214979488|NCT03794596|DRUG|Avelumab|Colourless odourless aqueous solution for infusion at dose of 10mg/kg
214979489|NCT03794596|DRUG|Aspirin|300mg tablets
214979490|NCT03794596|DRUG|Lansoprazole (Proton Pump Inhibitor)|300mg capsule
214979491|NCT00651209|DRUG|Tenofovir|All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
214492050|NCT06829680|OTHER|Pilates|"The participants were given a total of 12 sessions of Pilates training, applied twice a week for 6 weeks, and each session lasted approximately 60 minutes. The 60-min session consisted of warm up and cool down (5 min each) and the main active phase (50 min).~In the main active phase; One leg stretch, Double leg stretch, One leg circle, Heels together toes apart, Shoulder bridge, The hundreds, Chest lift, Criss cross, Clam, Side bend, Arm opening, Cobra, Breast stroke, Swimming, Modified push-up, Plank, Leg pull prone and Squat exercises were performed. The exercises were applied with 10 repetitions in the first 3 weeks and with 20 repetitions in the last 3 weeks."
214680017|NCT00532883|DRUG|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
214680018|NCT00532883|OTHER|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
214680019|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
214680020|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
214979492|NCT02123641|OTHER|Heavy resistance training|Supervised heavy resistance training three times weekly for 52 weeks.
214979493|NCT02123641|OTHER|Moderate intensity training|Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.
214979494|NCT02123641|OTHER|Control|No training
214979495|NCT00965614|OTHER|MCG|Cardiac Arrhythmia,Heart Disease
214979496|NCT01988324|OTHER|FDHT-PET scan|
214979497|NCT01988324|OTHER|FES-PET scan|
214979498|NCT01988324|OTHER|CT-scan|
215087046|NCT04807803|DIAGNOSTIC_TEST|Assessment of Minimal hepatic encephalopathy (MHE)|Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
215094501|NCT01459913|DRUG|Telaprevir|Tablet
214367558|NCT01186445|DRUG|morphine chlorhydrate|1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
214367559|NCT01186445|DRUG|saline solution|3 ml of saline solution , intracoronary injection during reperfusion
214367560|NCT03036358|OTHER|teledermatology consult|Information from the dermatologic assessment will be entered into the patients chart.
214367561|NCT03036358|OTHER|Routine Care|The dermatologic assessment will occur but not added to the patients medical record. Dermatology may still be consulted but will be at the prerogative of the treating hospitalist.
214367562|NCT01532128|DRUG|rasagiline|1 mg rasagiline (single-dose)
214367563|NCT01532128|DRUG|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
214367564|NCT04992351|PROCEDURE|WALANT|WALANT as anesthesia method for upper and lower limb palstic surgery operations
214979499|NCT01988324|OTHER|Bone scintigraphy|
214979500|NCT01988324|OTHER|Tumor biopsy|
215087047|NCT03327168|DRUG|Adenosine|Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
215087048|NCT03327168|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET/CT scan.
215087049|NCT01669408|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
215087050|NCT01479946|DRUG|Electrochemotherapy|bleomycin together with electroporation
215087051|NCT00627536|DRUG|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
215087052|NCT00627536|DRUG|Placebo|Matched to avotermin dosage strength
215087053|NCT00868673|DIETARY_SUPPLEMENT|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
215087054|NCT00868673|DIETARY_SUPPLEMENT|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
215087055|NCT03926962|DRUG|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
215087056|NCT03926962|DRUG|Placebo Oral Tablet|Visually matching placebo
215087057|NCT02448953|PROCEDURE|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
215087058|NCT02448953|PROCEDURE|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
215087059|NCT00070681|PROCEDURE|Polysomnography|
215087060|NCT01495520|DRUG|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
214367565|NCT01718327|DRUG|Sunitinib|sunitinib dose :37.5mg/day
214367566|NCT04866615|DIAGNOSTIC_TEST|Optvue OCT|Optical coherence tomography
214367567|NCT05375474|DRUG|Oral anticoagulation therapy|Vitamin-K antagonists (warfarin)
214367568|NCT05375474|DRUG|Single antiplatelet therapy|Aspirin
214367569|NCT05016154|BEHAVIORAL|Online Group CBT intervention|Group of participants complete 10 weeks of Online Group CBT intervention
214367570|NCT05016154|BEHAVIORAL|SilverCloud guided|Group of participants make use of the SilverCloud guided app
214492051|NCT06829680|OTHER|Whole Body Vibration|"The participants were given a total of 12 sessions of WBV training, applied twice a week for 6 weeks.~The vibration parameters were set as frequency: 20 Hz, amplitude: 2-3 mm, duration: 30-60 s and rest period: 60 s. The application time of the WBV training was 30 s for the first two weeks, 45 s for the next two weeks and 60 s for the last two weeks.~The individuals were asked to maintain squat, shoulder bridge and quadruped positions statically for the first two weeks. Starting from the third week, they were asked to perform reciprocal upper extremity flexion and extension movements during the positions. The application was repeated 3 times in each position."
214492052|NCT06801405|DRUG|antibiotic prophylaxis|Antibiotic prophylaxis before percutaneous nephrostomy
214492053|NCT06746142|RADIATION|Deep inspiration breath hold radiotherapy|Participants will be trained for 2-3 days for obtaining the desired breathing cycle by trained technologists. No extra equipment will be needed. At first, they will be assured and asked to relax. Then instructed to breath in and out twice followed by a slow, deep breath in to a comfortable higher level than normal and to hold it for at least 20 seconds then again breath normally. Once they are ready with expected breath holding, simulation will be done. Treatment will also be given in this breath holding position.
214979501|NCT03426345|DRUG|Placebo|Placebo injected subcutaneously twice daily.
215087061|NCT01495520|DRUG|Placebo|os, pill, b.i.d., 30 days
214367571|NCT05016154|BEHAVIORAL|SilverCloud Unguided|Group of participants make use of the SilverCloud Unguided app
214367572|NCT05016154|BEHAVIORAL|Mood Flow|Group of participants make use of the Mood Flow app
214367573|NCT00948974|BEHAVIORAL|Cognitive Therapy|"Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., if I attempt to initiate a conversation I'll humiliate myself), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005)."
214492054|NCT06746142|RADIATION|Free breathing radiotherapy|Patient will be advised for free breathing during simulation and treatment.
214979502|NCT03426345|DRUG|Relamorelin|Relamorelin 10 μg injected twice daily for 12 weeks.
214979503|NCT00689065|DRUG|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
215087062|NCT05976451|COMBINATION_PRODUCT|melatonin with collagen matrix|(CMX) with melatonin in the esthetic zone using Modified Coronally Advanced Tunneling Technique (MCAT)
215087063|NCT05976451|COMBINATION_PRODUCT|connective tissue graft (CTG)|control group connective tissue graft using Modified Coronally Advanced Tunneling Technique (MCAT)
215094502|NCT01459913|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
215094503|NCT01459913|DRUG|Ribavirin|Tablet
214367574|NCT00948974|BEHAVIORAL|Acceptance and Commitment Therapy|ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, \& Emmelkamp, 2009).
214492055|NCT04980300|BEHAVIORAL|Intervention|Participants in the Intervention arm will receive five virtual consultation sessions, delivered by a physical therapist over 12 weeks (at Weeks 1, 2, 4, 7, and 10) and lasting approximately 45-60 minutes each. Each session will focus on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis. Participants will be provided with an exercise manual, tracking log, educational manual, and a step counter. Participants will be prescribed up to 6 exercises (quadriceps, hip abductor/gluteal, hamstrings/gluteal, calf, balance) and daily walking step goals. Progression will be a joint decision by the participant and physical therapist. Education will include information on knee osteoarthritis, managing pain, being active, weight loss, dealing with setbacks, and progressing activity. The physical therapist will also discuss barriers and facilitators to meeting and progressing goals as appropriate.
214492056|NCT04980300|BEHAVIORAL|Control|Participants in the Control arm will receive access to a study-specific website that navigates them to a variety of web-based resources on knee osteoarthritis. Topics for the various resources include an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis. Sessions range from 20 - 70+ minutes.
214492057|NCT06740188|DRUG|5-hydroxytryptamine balanced antidepressants trazodone|The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone
215087064|NCT02492256|DEVICE|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
214680021|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
214680022|NCT01205191|BEHAVIORAL|Cell-phone supported CBT|Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
214680023|NCT01205191|BEHAVIORAL|CBT with digital audio player support|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
214680024|NCT01205191|BEHAVIORAL|CBT|CBT for anxiety disorders
214680025|NCT00601588|DRUG|Sertraline|
214680026|NCT00086840|DRUG|temsirolimus|Given IV
214680027|NCT00086840|OTHER|laboratory biomarker analysis|Correlative studies
214979504|NCT03594006|BEHAVIORAL|CCI; cancer care coordination instrument|Designed to assess cancer patients' perceptions of care coordination
214979505|NCT05581563|PROCEDURE|total knee arthroplasty(TKA)|Knee replacement, also called knee arthroplasty or total knee replacement, is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap. This surgery may be considered for someone who has severe arthritis or a severe knee injury.
214979506|NCT00116142|DRUG|Docetaxel|60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
214979507|NCT00116142|DRUG|Androgen Hormonal Suppression and Radiation|Total Androgen Ablation and external beam radiation therapy
215087065|NCT02492256|DEVICE|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
215087066|NCT02492256|DEVICE|ILR implantation|Implantation the ECG loop recorder according to standard procedure
215094504|NCT05718193|DIAGNOSTIC_TEST|DeFrame|The DeFrame system is applicated during colonoscopy. The DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, notifying the endoscopists of the presence of the lesion.
215094505|NCT05718193|DIAGNOSTIC_TEST|Classified DeFrame|The Classified DeFrame system is applicated during colonoscopy. The Classified DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, the color of the rectangle box will turn blue when the polyp is considered as an adenoma, notifying the endoscopists of the presence of the lesion.
215094506|NCT05718193|DIAGNOSTIC_TEST|conventional colonoscopy|conventional colonoscopy
214680028|NCT01967420|BEHAVIORAL|Cognitive remediation|CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
214680029|NCT01967420|BEHAVIORAL|Social cognition training|The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
214680030|NCT05916677|OTHER|Virtual Reality-training in Theory of Mind|"Two social scenarios will be used in a virtual environement. Experimenter and subject participate in the scenario as friends of the main character, Nicolas. During the training session, experimenter asks structured questions about participant's awareness of a mental state. In the case of a wrong answer, a feedback-correction is provided via the avatar's thought bubbles. The participant has access to all avatars thought bubbles. In this way, he is able to compare the desires, beliefs or false beliefs of each story character.~Participants included in this condition will also have an eye-tracking assessment before and after the training procedure."
214979508|NCT00116142|DRUG|Androgen Suppression Therapy and Radiation Therapy|Total Androgen Ablation and External Beam Radiation Therapy
214979509|NCT03534024|DIETARY_SUPPLEMENT|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicelle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
214979510|NCT03534024|DIETARY_SUPPLEMENT|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomcielle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
214367575|NCT03940820|BIOLOGICAL|ROBO1 CAR-NK cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
214367576|NCT01742377|PROCEDURE|Patients with GerdQ positive|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
215087067|NCT05205369|BEHAVIORAL|10-week home-based Yi Jin Bang exercise program|Each participant in this group will do a home-based Yi Jin Bang exercise program four times a week for ten consecutive weeks, which consists of ten minutes of warm-up, 18 minutes of Yi Jin Bang exercise (ten exercises), and ten minutes of cool-down. To learn how to conduct the home-based exercise session, each participant will be invited to one introductory session before starting the prescribed exercise program. Two experienced Yi Jin Bang instructors will lead the introductory session. Besides, in order to monitor participants' adherence and help them to conduct self-training, we will use the Zoom Meeting application. Zoom can capture and record participants' movements through the webcam. During the introduction sessions, we will teach participants how to use Zoom. Furthermore, we will provide support for adherence to the home exercise sessions through telephone calls or e-mail every two weeks.
215087068|NCT05205369|BEHAVIORAL|10-week home-based usual exercise therapy program|Among exercise therapy in the treatment of SAPS, stretching and strengthening protocols are often used . Therefore, participants in this group will do a standardized home-based stretching and strengthening exercise program four times per week for ten weeks, which is set up according to a previous study. This program has been demonstrated that can be effective in reducing pain and improving function in patients with SAPS. For strengthening exercises, elastic bands will be used. To learn how to conduct the self-training program, each participant in this group will also be invited to one introductory session before starting the prescribed exercise training. Two certificated physiotherapists will lead the introductory session. In addition, a video demonstration clip will be given to each participant to provide a home reference, and the Zoom Meeting application will be used to help monitor the exercise.
215087069|NCT01295736|DRUG|Sildenafil|Sildenafil 20 mg TID per os during 90 days
215087070|NCT01295736|DRUG|placebo|Placebo pills TID per os during 90 days
214979511|NCT02463383|DRUG|Ibuprofen Tab 400 MG|400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
214979512|NCT02463383|DRUG|Placebo tab|A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
214979513|NCT00644059|BIOLOGICAL|Adjuvanted trivalent inactivated subunit influenza vaccine|Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
214979514|NCT00644059|BIOLOGICAL|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine|For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
215094507|NCT01915823|DRUG|azelastine hydrochloride and fluticasone propionate|
215094508|NCT01915823|DRUG|Dymista vehicle|
215094509|NCT00457223|PROCEDURE|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
214979515|NCT00644059|BIOLOGICAL|Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine|"1. Meningococcal vaccine: two IM injections~2. Tick-borne encephalitis vaccine: two IM injections"
215094510|NCT00987701|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
214367577|NCT01742377|PROCEDURE|Patients with GerdQ negative|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
214367578|NCT01742377|PROCEDURE|Normal volunteers|Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
214367579|NCT01394354|DRUG|Vorinostat|"Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.~The dose level of Vorinostat will be escalated in each new cohort:~if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o."
214367580|NCT01394354|DRUG|Bortezomib|1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles
214367581|NCT01394354|DRUG|Doxorubicin|18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
214367582|NCT01394354|DRUG|Dexamethasone|40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
214367583|NCT00238433|BIOLOGICAL|filgrastim|5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC\> 1500 for 2 consecutive days.
214367584|NCT00238433|DRUG|busulfan|3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
214367585|NCT00238433|DRUG|melphalan|50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
214979516|NCT02054780|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
215087071|NCT03765151|DEVICE|low-level laser therapy|LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.
215087072|NCT03765151|OTHER|orthodontic retention|All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
214367586|NCT00238433|DRUG|thiotepa|250 mg/m2/day/iv on days -3 and -2
214367587|NCT00238433|PROCEDURE|bone marrow ablation with stem cell support|The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
214367588|NCT00238433|PROCEDURE|peripheral blood stem cell transplantation|Performed 36-48 hours following last chemotherapy dose.
214367589|NCT01825668|OTHER|Plant Sterols|
214367590|NCT01825668|OTHER|High cholesterol|
214367591|NCT01825668|OTHER|Placebo|
214367592|NCT03440931|DIAGNOSTIC_TEST|Ultrasound scan|Transvaginal ultrasound scan to assess ovaries
214367593|NCT00580814|DRUG|Experimental: methylphenidate treatment|subjects received mehtylphenidate treatment for 12 months
214367594|NCT02548767|OTHER|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
214367595|NCT02548767|OTHER|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
214367596|NCT02548767|OTHER|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
214680031|NCT05916677|OTHER|Traditional training in Theory of Mind|The same two social scenarios are presented to the participant in a story-telling form. Participant has access to thought bubbles via an illustrated book. These trainings will take place in the same number of sessions and took place for a duration equivalent to those used in low immersion Virtual Reality mode. Each training session (EFB, BE, SOFB, ERA, FP, EFP) will be illustrated via visual aids taken from screenshots of the two virtual environments and the target protagonists.
214680032|NCT02039180|DRUG|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
214367597|NCT02548767|OTHER|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
214367598|NCT06579703|DRUG|Ketorolac|"Randomized to a single dose of:~Arm A: 15 mg/mL (per mL) Arm B: 30 mg/mL (per mL)"
214367599|NCT06579976|OTHER|No intervention|This is an observational study, no intervention will be implemented.
214680033|NCT02039180|DRUG|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
214367600|NCT06580366|DRUG|Sennosid A+B|Bowel Preparation
215087073|NCT00002762|BEHAVIORAL|patient interviewing to obtain menstrual history|
214367601|NCT06580366|DRUG|Sodium Picosulfate/Magnesium Oxide/Citric Acid|Bowel Preparation
214367602|NCT03520166|OTHER|Medium frequency electrotherapy (interferential currents)|Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.
214367603|NCT03520166|OTHER|No treatment|No treatment
214367604|NCT05854225|DRUG|Thiotepa|Thiotepa is an alkylating agent that is routinely used in solid tumors, but it is able to cross the blood-brain barrier into the center.
214367605|NCT01814748|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly
214367606|NCT01814748|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
214367607|NCT01814748|DRUG|Metformin|Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
214367608|NCT06578975|DIAGNOSTIC_TEST|HT-ENDO-MOS-A13|Mutli-Omics based biomarker to diagnose primary hypertension or endocrine forms of hypertension; primary aldosteronism, pheochromocytoma/functional paraganglioma or Cushing syndrome.
214367609|NCT06578975|OTHER|Normal diagnosis|Standard diagnosis for endocrine hypertension
214979517|NCT02054780|BEHAVIORAL|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH."
215087074|NCT00002762|PROCEDURE|blood sampling|
215087075|NCT05818514|DRUG|[11C]AZ14132516|Injection of radioligand for PET examinations
215087076|NCT00167661|DRUG|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
215087077|NCT04905355|DEVICE|Virtual reality|The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
215087078|NCT01571869|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
215087079|NCT01571869|OTHER|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
215087080|NCT03396055|OTHER|specific rehabilitation exercise|specific rehabilitation exercise for patients with cervical myelopathy
215087081|NCT03306641|DEVICE|Test Contact Lens|Daily disposable contact lens
215087082|NCT03306641|DEVICE|Nelfilcon A|Focus Dailies All Day Comfort contact lens (nelfilcon A)
215087083|NCT03766269|DRUG|Dronabinol|Dronabinol coadministered with patient's existing Baseline Opioid.
215087084|NCT02446873|OTHER|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
215087085|NCT06198855|DEVICE|QMon-20 device|Automatic Blood pressure measurement with QMon-20 device in the waiting room for 20 minutes every 5 minutes.
215087086|NCT05764668|DRUG|Zihua Wenfei Zhisou Granule|14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
215087087|NCT05764668|DRUG|Placebo|14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
215087088|NCT06162533|BIOLOGICAL|Vaccination against SARS-CoV-2|Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2
215087089|NCT03365141|DRUG|Triamcinolone acetonide 0.4mg/cc|"* Intralesional injection of dilute triamcinolone acetonide with 2% lidocaine (400mg/20 mL) would be performed to reduce pain when injecting the drug.~* Once weekly, for a total of 12 weeks"
215087090|NCT03365141|DEVICE|Phototherapy (NBUVB or excimer laser)|NBUVB or excimer laser treatment weekly
215087091|NCT03365141|DRUG|Topical tacrolimus|Application of topical tacrolimus ointment twice a day
215087092|NCT04772144|BEHAVIORAL|behavioural and cessation aids|information, motivational interview, refferal to healty life-centers, free cessation aids
215087093|NCT02789410|DRUG|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
215087094|NCT02789410|DRUG|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
215087095|NCT05108597|DRUG|Misoprostol|400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
215087096|NCT03927352|BIOLOGICAL|SCT630|Administered by subcutaneous injection
215087097|NCT03927352|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
215087098|NCT00536887|DRUG|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
215087099|NCT04825990|DRUG|Pembrolizumab|200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
215087100|NCT01605942|DRUG|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
215087101|NCT01605942|DRUG|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
215087102|NCT01243528|OTHER|Laboratory values|Laboratory values which represent nutritional status
215087103|NCT03641846|OTHER|DornierAries2 LiST device + 5 mg Tadalafil|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
215087104|NCT03641846|OTHER|DornierAries2 LiST device + Placebo Pill|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
215087105|NCT04869033|OTHER|Farinelli's Breathing Exercise|after 1 minute of normal breathing, follow this instruction; inhale 2 seconds, suspend 2 seconds, exhale 2 seconds. inhale 3 seconds, suspend 3 seconds, exhale 3 seconds. inhale 4 seconds, suspend 4 seconds, exhale 4 seconds. inhale 5 seconds, suspend 5 seconds, exhale 5 seconds. inhale 6 seconds, suspend 6 seconds, exhale 6 seconds. This cycle lasted 1 minute (60 seconds), called Farinelli's breathing (FB). When participants finished these cycle, repeated it again 4 times. 1 minute of NB + 4 minutes of FB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
215087106|NCT04869033|OTHER|Diaphragmatic Breathing Exercise|after 1 minute of normal breathing, inhale 2 seconds and exhale 2 seconds with nasal airway. Continued breathing this pattern until 4 minutes, then back to normal breathing 1 minute . 1 minute of NB + 4 minute of DB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
215087107|NCT01866033|DRUG|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
214367610|NCT06462911|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) - Spanish/Espanol|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The entire HOBSCOTCH program has been translated into Spanish for people with epilepsy who speak Spanish.
214367611|NCT06579274|DRUG|Parecoxib|Parecoxib (Dynastat) 40 mg solution for injection is for intravenous administration. Parecoxib may be given as an intravenous injection for 30 minutes directly into a vein or through an intravenous infusion set.
214367612|NCT06579274|DRUG|Placebo|Placebo intravenous injection can be administered quickly and directly into a vein or through an intravenous infusion set.
214367613|NCT03901196|DIAGNOSTIC_TEST|Elemental analysis|LIBS multi elemental analysis of the specimen
214367614|NCT04044456|BEHAVIORAL|Goal Management Training|"GMT: is a 10-session intervention to improve planning and problem solving. Interactive Power Point modules are administered by a cognitive therapist. Each session builds on the steps of a five-stage planning and problem-solving strategy. Veterans will be taught to generate and verbalize the following five-steps: stop-what am I doing?, define the goal, list the steps, learn the steps; then, check-am I doing what I planned? The five-stage strategy is then incorporated into a variety of activities in the laboratory and in-home assignments."
214979518|NCT01448733|DRUG|Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening|Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
214979519|NCT03139539|DEVICE|Ioban|
214979520|NCT01499485|DRUG|Acetazolamide|"Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of acetazolamide 500 mg .~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of acetazolamide 500 mg.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day."
214979521|NCT01499485|DRUG|Placebo|"Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of placebo.~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of placebo.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day."
214979522|NCT02431598|DRUG|gadoxetate disodium|
214979523|NCT02431598|DRUG|gadoterate dimeglumine|
214979524|NCT02431598|DRUG|Saline|
214979525|NCT05475639|OTHER|Axillary Diclofenac phonophoresis|axillary diclophenac phonophoresis (voltaren gel) will be received three times per week for four weeks
214979526|NCT05475639|OTHER|Post isometric facilitation|Post isometric facilitation exercise will be received three times per week for four weeks
214979527|NCT05475639|OTHER|Traditional physiotherapy|Traditional physiotherapy will be received three times per week for four weeks
214979528|NCT02497469|DRUG|Vedolizumab|Vedolizumab infusion
214979529|NCT02497469|DRUG|Adalimumab placebo|Adalimumab placebo-matching injection
214979530|NCT02497469|DRUG|Adalimumab|Adalimumab injection
214979531|NCT02497469|DRUG|Vedolizumab placebo|Vedolizumab placebo-matching infusion
214979532|NCT06228404|DRUG|Enhanced autologous PSMA-CAR T|"3 escalated dosing cohorts are designed to explore safety and efficacy of enhanced autologous PSMA-CAR T:~cohort A： CART-PSMA cells 0.25×106/kgBW, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort B： CART-PSMA cells 0.75×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort C： CART-PSMA cells 2×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;"
214979533|NCT02818504|OTHER|Wize Mirror|Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
214979534|NCT04906798|DRUG|CKD-385|Test Drug
214979535|NCT04906798|DRUG|D744|Reference Drug
214979536|NCT00051701|DRUG|alemtuzumab|
214979537|NCT03916588|BEHAVIORAL|Individualized Care Plan|Medical, neuropsychological, and social assessment of patient's cognitive, behavioral, medical, and environmental needs with a focus on improving quality of life, reducing health care utilization, and improving staff/family caregiving burden along with a specific plan to address and monitor identified patient and staff/facility needs
214979538|NCT02986776|BEHAVIORAL|Inpatient Care|21 days of inpatient substance misuse treatment
214979539|NCT02986776|BEHAVIORAL|Outpatient Care|21 days of outpatient substance misuse treatment
214979540|NCT03479554|OTHER|Early antihypertensive treatment|"The CATIS 2 trial is designed to test BP reduction strategies-early antihypertensive treatment vs. delayed antihypertensive treatment-rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial.~BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:~* Step 1 (within 24 hours after randomization): To lower systolic BP by 10-20% with an average of 15% (but systolic BP not lower than 130 mmHg and diastolic BP not lower than 80 mmHg) within the first 24 hours after randomization based on the participant's admission BP levels.~* Step 2 (within 7 days after randomization): To achieve systolic BP below 140 mmHg (but not lower than 120 mmHg) and diastolic BP below 90 mmHg (but not lower than 70 mmHg) and maintain this BP level afterward."
214979541|NCT03479554|OTHER|Delayed antihypertensive treatment|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP \<140 mmHg (but not lower than 120 mmHg) and diastolic BP \<90 mmHg (but not lower than 70 mmHg) in two weeks. A BP check-up visit will be conducted in two weeks. If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.
214979542|NCT01168895|DRUG|Cipro Inhale (Ciprofloxacin, BAYQ3939)|32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
214979543|NCT01168895|DRUG|Cipro Inhale (Ciprofloxacin, BAYQ3939)|48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
215087108|NCT01866033|DRUG|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
215087109|NCT01866033|DRUG|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
214367615|NCT04044456|BEHAVIORAL|Attention Training|"Attention Process Training (APT-III) will be administered for a second weekly session in addition to the GMT session. Each session will be 2 hours/ week for 10 weeks. Veterans will also engage in BrainHQTM attention training at home for one-hour, five days/ week comprised of selected components of BrainHQ from Posit Science Corporation. This web-based computerized CRT modality of cognitive training is a restorative or bottom-up approach that targets basic cognitive skills such as arousal and vigilance processes, attention and information processing, and directly engages fundamental attention-control skills through repetitive graded exercises."
214367616|NCT04044456|BEHAVIORAL|Brain Health Workshop|. BHW was developed specifically for consistency with GMT session length and contact with the facilitator49. BHW is an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered. To match time and contact of attention training, control participants will meet with the therapist for a separate two-hour session from BHW
215087110|NCT01866033|DRUG|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
215087111|NCT04591249|BEHAVIORAL|Physical activity intervention|Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is \<8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
214979544|NCT04023578|DEVICE|RHEO KNEE XC|Microprocessor controlled knee using Magneto-Rheologic techonology.
214979545|NCT01005667|DEVICE|BirthTrack|Measurement of cervical dilation and head station
214979546|NCT06216418|DEVICE|BRFS-18G-S100WH|A facial tissue fixation material made of polydioxanone (PDO).
215087112|NCT04591249|OTHER|Usual care|Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
215087113|NCT01335529|DRUG|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"* Screen period from Week-8~* Standard treatment from day 0 to week 4 (W4)~* Three-drug-regimen (Boceprevir introduction) from W4 to W8~* HCV RNA determination at W8 determines treatment group and participation duration:~  * If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~ * If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
215087114|NCT00737594|DRUG|Placebo|Matching placebo capsules for oral administration
215087115|NCT00737594|DRUG|Cobiprostone|Cobiprostone capsules for oral administration
215087116|NCT00265070|DRUG|Gefitinib|250 mg tablet oral daily dose
215087117|NCT00459537|DRUG|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
215087118|NCT00459537|DRUG|amorolfine nail lacquer|5 % amorolfine nail lacquer
215087119|NCT04593459|DIETARY_SUPPLEMENT|Probiotic|See Arm description
215087120|NCT04593459|DRUG|Metformin Hydrochloride|See Arm description
214367617|NCT04044456|BEHAVIORAL|National geographic movies|participants will select movies to watch and answer a few questions about to equate the time and therapist interaction to attention training in arm 1.
214367618|NCT01972529|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
214979547|NCT06216418|DEVICE|MINT Lift FINE+|A facial tissue fixation material made of polydioxanone (PDO).
214979548|NCT02889068|OTHER|Blood sample|
214979549|NCT06473441|BEHAVIORAL|Tele-Rehabilitation Therapy|Twice-weekly sessions with remote supervision and guidance from therapists.
214979550|NCT06473441|BEHAVIORAL|Health Education|Health education based on individual assessments.
214979551|NCT06473441|BEHAVIORAL|Exercise Prescription|Exercise prescription tailored to individual needs.
214979552|NCT06473441|BEHAVIORAL|Home Exercise Equipment Use|Use of a home exercise bike, resistance bands, respiratory muscle training device, and a portable heart rate monitor.
214979553|NCT06473441|BEHAVIORAL|Exercise Log|Logging daily exercise intensity and duration in a rehabilitation diary
214979554|NCT06473441|BEHAVIORAL|Follow-Up Calls|Regular follow-up calls to monitor progress and address any issues.
214979555|NCT01472055|DRUG|Fludarabine|"1. Fludarabine 40 mg/m\^2 once a day intravenous administration over 30 min~2. Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr~3. Population pharmacokinetics analysis~4. Comparative analysis of population pharmacokinetics in pediatric and adult patients~5. Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate"
214979556|NCT06429865|DIAGNOSTIC_TEST|cytosponge|Use of cytosponge as a tool to patients who need surveillance after endoscopic submucosal dissection for esophageal squamous cell carcinoma
214979557|NCT02227095|BEHAVIORAL|Exercise|Heart rate monitors worn by each child at each session
214979558|NCT02227095|BEHAVIORAL|After-school program|Supervised recreational program with token economy
214979559|NCT02824445|DEVICE|individualized Transcranial Magnetic Stimulation|
215087121|NCT04593459|DIETARY_SUPPLEMENT|Probiotic Placebo|See Arm description
215087122|NCT03159104|DRUG|Tenoten for children|Tablet for oral use.
215087123|NCT03159104|DRUG|Placebo|Tablet for oral use.
215094511|NCT00987701|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
215094512|NCT01064687|DRUG|LY2189265|
214367619|NCT01972529|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
214367620|NCT01972529|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
214367621|NCT01972529|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
214367622|NCT01872533|OTHER|Hypoxia Exposure|Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at \~ 15% O2 (ca. 2400 m elevation).
214367623|NCT00268827|DRUG|Kaletra soft-gel capsules switched to Kaletra tablets|
214680034|NCT02039180|DRUG|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
214680035|NCT01640587|DRUG|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
214680036|NCT01640587|DRUG|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
214680037|NCT06058494|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.
214680038|NCT00076219|PROCEDURE|renal replacement therapy|renal replacement therapy
214979560|NCT03846934|DEVICE|Ultrasonography thoracic|Thoracic ultrasonography will be performed as soon as possible after admission to the ED, without delaying the start of treatment and in addition to routine thoracic radiography.
214979561|NCT00984412|PROCEDURE|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
215087124|NCT06542991|OTHER|transcranial magnetic stimulation|During treatment, the patient underwent cTBS targeting the left SMA for 7 consecutive days. Each treatment day comprised six rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
215087125|NCT00242307|DRUG|Roflumilast|
215087126|NCT04243928|OTHER|kinesio taping|apply kinesio taping on dorsi flexors muscles
215087127|NCT01076621|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
215087128|NCT03705910|OTHER|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
214367624|NCT00268827|DEVICE|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
214367625|NCT01844271|DEVICE|Low Level Laser (LLL)|"Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.~We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.~In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups."
214367626|NCT03262610|DRUG|Setmelanotide|daily subcutaneous injection
214367627|NCT00783731|DRUG|Low dose midazolam|
214367628|NCT03393195|BEHAVIORAL|Time-restricted Eating plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study. The eating plan will consist of eating during a specified 8 hour window and fasting for the remaining 16 hours of the day.
215094513|NCT01064687|DRUG|Exenatide|
215094514|NCT01064687|DRUG|Placebo|
215094515|NCT01064687|DRUG|Metformin|
215094516|NCT01064687|DRUG|Pioglitazone|
214367629|NCT03393195|BEHAVIORAL|Consistent Meal timing plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study.The eating plan will consist of eating three structured meals each day during three specified meal windows.
214367630|NCT01606527|DRUG|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
214367631|NCT02274857|PROCEDURE|Standard PVI Ablation|Standard PVI procedure without FIRMap.
214680039|NCT00149851|DRUG|Tegaserod|
214680040|NCT06027242|DIETARY_SUPPLEMENT|oral glutamine|10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
214680041|NCT06027242|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
214680042|NCT03233776|DRUG|Anakinra|Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
214680043|NCT05527171|BEHAVIORAL|Virtual Reality Mindfulness Meditation|Participants will be immersed in a virtual environment of their choosing. While in the virtual environment, participants will follow a guided mindfulness meditation script. Participants will complete the intervention 3 times a week over the course of 8-weeks.
214680044|NCT05527171|BEHAVIORAL|Virtual Reality Sham|Participants will be immersed in a virtual environment of their choosing, such as at a beach, forest, or lake.
214680045|NCT04494503|DRUG|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
215094517|NCT04316156|DEVICE|Uincare Homeplus|Interactive digital healthcare system
214367632|NCT02274857|PROCEDURE|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
215087129|NCT03705910|OTHER|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
215087130|NCT00456599|DRUG|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
214367633|NCT04894201|RADIATION|Dental Panoramic Radiographs|Exposure to dental panoramic radiographs
214492058|NCT06740188|DRUG|Citalopram hydrobromide combined with zolpidem|the control group was given citalopram hydrobromide combined with zolpidem
215087131|NCT00456599|DRUG|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
215087132|NCT00456599|PROCEDURE|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
215087133|NCT05173935|PROCEDURE|Percutaneous endoscopic gastrostomy|Gastrostomy tube placement using an endoscopic camera inserted via the mouth into the stomach to place the tube.
215094518|NCT04316156|OTHER|Brochure|Brochure
214367634|NCT00948298|DRUG|Vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
214492059|NCT05128006|OTHER|New patient teledermatology visit|new patient teledermatology visits
214492060|NCT05186636|OTHER|KPI reports|Quarterly
214492061|NCT05186636|OTHER|Prescriber reports|Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices
214492062|NCT05556629|OTHER|No Intervention|This is a non-interventional study.
214492063|NCT04588506|PROCEDURE|Lower Trapezius Tendon Transfer Technique|Lower Trapezius tendon used in repairing cuff tear
214680046|NCT04494503|DRUG|Rituximab|Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
214680047|NCT04494503|DRUG|Ibrutinib|Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
214367635|NCT00948298|DRUG|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
214367636|NCT03871179|DIAGNOSTIC_TEST|ASD Diagnostic Device|"The ASD Diagnostic Device is a machine learning algorithm-based software as a medical device that is incorporated into a parent/caregiver-facing mobile application, the Cognoa App, used outside of a clinical setting"
214367637|NCT00939874|DRUG|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
214367638|NCT00330174|DRUG|Acamprosate|2 333mg tablets three times daily
214680048|NCT04735185|OTHER|Autologous stem cells|In this intervention participants will receive a 2 mL intradiscal injection into each affected disc of autologous bone marrow-derived mesenchymal stem cells from bone marrow aspirate of the posterior ilium.
214367639|NCT05295966|OTHER|Cognitive therapy|Cognitive therapy
214367640|NCT05295966|BEHAVIORAL|Physiocognitive Integration|Physiocognitive Integration
214367641|NCT05019833|DEVICE|Signals collection|A non-CE marked embedded software will be temporarily uploaded in the implanted device, in order to enable the collection of sensors signals.
214367642|NCT05199610|DRUG|aumolertinib|A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.
214492064|NCT04588506|PROCEDURE|Latissimus Dorsi Tendon Transfer Technique|Latissimus Dorsi tendon used in repairing cuff tear
214492065|NCT04588506|PROCEDURE|Pectoralis Tendon Transfer Technique|Pectoralis tendon used in repairing cuff tear
214680049|NCT04735185|DRUG|Corticosteroid|In this intervention participants will receive a 1 mL intradiscal injection of the steroid methylprednisolone (40 mg/mL) into each affected disc.
214680050|NCT04735185|DRUG|Local anesthetic|In this intervention participants will receive a 1 mL intradiscal injection of the local anesthetic bupivacaine 0.5% into each affected disc.
214680051|NCT04514367|DRUG|ANX005|Intravenous Infusion
214680052|NCT06443281|DIAGNOSTIC_TEST|Neurophysiology|Pain-related evoked potentials and nerve conduction studies
214680053|NCT06443281|DIAGNOSTIC_TEST|Cardiovascular test|Blood pressure control, orthostatic intolerance test, baro-reflex sensitivity, heart-rate variability
214492066|NCT06094218|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
214492067|NCT06094218|BEHAVIORAL|Treatment as usual (TAU)|Behavioral health treatment as it is typically provided at the treatment site.
214492068|NCT01347255|DRUG|LEO90100 cutaneous spray, ointment|once daily application, 4 weeks
214492069|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate|once daily application, 4 weeks
214680054|NCT06443281|DIAGNOSTIC_TEST|Experimental pain paradigms|Temporal summation of pain, conditioned pain modulation
214680055|NCT06443281|DIAGNOSTIC_TEST|Quantitative sensory testing|Thermal and mechanical sensory testing
214680056|NCT06443281|DIAGNOSTIC_TEST|Clinical pain phenotype|Pain drawings, plus and minus signs of pain
214680057|NCT03691012|DIAGNOSTIC_TEST|Circulating tumour DNA testing|Circulating tumour DNA testing
214680058|NCT02392546|DRUG|elobixibat|
214680059|NCT02392546|DRUG|placebo|
214680060|NCT04048967|BEHAVIORAL|Professional development|professional development of preschool staff
214680061|NCT01172288|DRUG|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
214680062|NCT01172288|DRUG|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
214367643|NCT01520818|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50
215087134|NCT05173935|PROCEDURE|Radiologically-inserted gastrostomy|Gastrostomy tube placement using a temporary nasogastric tube placed from nose to stomach and fluoroscopy (x-rays).
215087135|NCT05987436|OTHER|Supervised Aerobic Exercise|Group 1 exercised for six weeks, five sessions per week under the supervision of a medical doctor in the aerobic exercise laboratory.
215087136|NCT02431390|DEVICE|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
215087137|NCT02431390|BEHAVIORAL|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
215087138|NCT04924478|BIOLOGICAL|Mepolizumab|Patients will be receiving this treatment as part of their standard clinical care
215087139|NCT00478309|OTHER|counseling intervention|
215087140|NCT00478309|OTHER|educational intervention|
215087141|NCT04958746|DRUG|Ciprofol|intravenous bolus
215087142|NCT04958746|DRUG|Propofol|intravenous bolus
215087143|NCT04722757|PROCEDURE|ta-IPAA|A trans-anal port (gelpoint path, Applied Medical®) will be used for transanal acces and pneumopelvis will be created. The initial purse string is to be placed approximately 3cm above the dentate line, followed by a rectotomy. The perirectal dissection is then continued and should be pursued for at least 5cm. More proximal dissection can be done by transabdominal access. After completion of the proctectomy, a double purse string anastomosis is performed after creation of the J-pouch. A defunctioning loop ileostomy can be placed according to surgeon's preference.
215087144|NCT04722757|PROCEDURE|tabd-IPAA|Patients in the control group will undergo a rectal dissection by laparotomy, Pfannenstiel incision, (hand-assisted) laparoscopy, single port laparoscopy or robotic surgery, but performed from the abdominal side (tabd-IPAA). Dissection will be performed down to the pelvic floor and include the distal rectum. It is anticipated that most dissection will occur using the TME plane, however, close rectal dissection is also acceptable. Transection of the distal rectum approximately 2 cm above the dentate line will be performed using a linear stapler of the surgeon's choice. After placing the anvil in the J-pouch, a circular stapler will be introduced through the sphincter and a circular anastomosis will be performed. A defunctioning loop ileostomy can be placed according at the surgeon's discretion.
215087145|NCT01999218|DRUG|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
215087146|NCT01999218|DRUG|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
215087147|NCT01999218|DRUG|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
215087148|NCT01999218|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
215087149|NCT01999218|DRUG|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
214367644|NCT01520818|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70
214367645|NCT01520818|DRUG|biphasic human insulin 30|Administered subcutaneously (s.c., under the skin), twice a day
214367646|NCT03470779|OTHER|Physiotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
214492070|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle|once daily application, 4 weeks
214492071|NCT01347255|DRUG|Daivobet® ointment|once daily application, 4 weeks
214680063|NCT03819946|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.
214680064|NCT03819946|OTHER|Standard esophageal temperature probe|If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
214680065|NCT03100331|OTHER|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
214680066|NCT02407574|DEVICE|External Pacing Box|Atrial pacing using an external pacing box
214680067|NCT04788199|OTHER|Closure of mesenteric defects using glue|Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
214680068|NCT00012727|PROCEDURE|Matching Symptom Severity to Service Intensity|
214680069|NCT00428727|DRUG|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
214680070|NCT00428727|DRUG|placebo patch|daily application during 90 days
215087150|NCT01999218|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
215087151|NCT01999218|DRUG|Sitagliptin|Open label, oral, once daily, rescue medication as required.
215087152|NCT06301139|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Infant formula based on goat milk for 4 weeks at volume depending on the infant
214979562|NCT05341024|OTHER|Pelvic Floor Muscle Training in female CrossFit and functional fitness exercisers|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the participants in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (clinical exams of pelvic floor muscle function by observation and vaginal digital palpation) and instructions on how to perform the training program. The program consists of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The participants will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 16 weeks and the exercises will take approximately 10 minutes per day to perform.
214979563|NCT00305162|DRUG|Cangrelor (P2Y12 inhibitor)|IV bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
214680071|NCT02409420|BEHAVIORAL|Physiotherapy informed by Acceptance and Commitment Therapy|PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
214979564|NCT00305162|DRUG|clopidogrel (oral P2Y12 inhibitor)|600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
214979565|NCT00305162|DRUG|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
214979566|NCT00305162|DRUG|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
214979567|NCT00305162|DRUG|Placebo capsules - as soon as possible after randomization|Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
214979568|NCT01774591|DRUG|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
214979569|NCT01774591|DRUG|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
214680072|NCT03472482|DIAGNOSTIC_TEST|non-invasive retinal imaging|
214979570|NCT02679664|DRUG|Rosuvastatin|20 mg tablet of rosuvastatin
214979571|NCT02711462|DRUG|PF-06687234|PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
214979572|NCT02711462|DRUG|Placebo|In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
214979573|NCT06106750|DEVICE|Endoscopic nasobiliary duct cutting|Endoscopic retrograde cholangiopancreatography and endoscopic nasobiliary duct placement and drainage are conducted first. Upon achieving a postoperative state marked by satisfactory nasobiliary duct drainage and overall patient stability, the procedure entails the employment of endoscopic scissors. The tools are applied to make an incision on the external segment of the nasobiliary duct, positioned beyond the aperture of the primary duodenal papilla. Then extracting the severed nasobiliary duct and retaining the portion inside the duct.
214979574|NCT06106750|DEVICE|Bilateral plastic stent|Standard protocol for the placement of bilateral biliary plastic stents in the management of malignant hilar biliary tract stenosis
214979575|NCT02991274|PROCEDURE|genomic testing of T790M mutation|patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
215087153|NCT06301139|DIETARY_SUPPLEMENT|Cow's milk-based infant formula with probiotic drops|Infant formula based on cow's milk with probiotic Lactobacillus reuteri drops for 4 weeks at volume depending on the infant
215087154|NCT00040807|DRUG|docetaxel|
215087155|NCT00040807|DRUG|irinotecan hydrochloride|
215087156|NCT06002516|OTHER|RELIEF-pathway|"The personalized web-based education tool contains information on:~* Information of cause and symptoms of functional dyspepsia, irritable bowel syndrome and uncomplicated symptomatic cholecystolithiasis;~* Symptom checker based on the ROME III and ROME IV criteria;~* Red flags symptoms defined as direct or indirect signs of upper GI hemorrhage.~* Lifestyle adjustments to improve abdominal symptoms and quality of life.~* Information on effect of upper gastrointestinal endoscopy, colonoscopy and laparoscopic cholecystectomy.~After the web-based education tool is completed we will offer an additional visit at the Prevention and Lifestyle clinic, this is optional and not obligatory."
215087157|NCT00629473|DRUG|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
215087158|NCT00629473|DRUG|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
215087159|NCT00629473|DRUG|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
214680073|NCT02134314|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
214680074|NCT02134314|DRUG|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
214367647|NCT03470779|OTHER|Psychotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
214367648|NCT04606277|OTHER|Smartphone addiction scale, physical activity scale and depression questionnaire|Telephone addiction of the subjects was measured. Then, physical activity levels were questioned, and finally depression scale was applied.
214367649|NCT00546780|DRUG|Tanespimycin|Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
214367650|NCT00546780|DRUG|Bortezomib|Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
214367651|NCT01506895|DRUG|darapladib|Experimental compound 160 mg dose
214367652|NCT01506895|DRUG|placebo|Placebo to match
214367653|NCT01595893|DRUG|Oral Vitamin D 3|40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
214367654|NCT01595893|DRUG|Miglyol 812 N|Neutral oil of esters extracted from coconut and palm kernel
214367655|NCT05347979|DRUG|Dabigatran Etexilate|Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.
214367656|NCT05347979|DRUG|Relacorilant|Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.
214367657|NCT04469881|BEHAVIORAL|VR|"Participants will be asked to do the following things:~1. Wear VR goggles for the duration of the surgery~2. Answer questions about their experience with the VR goggles~3. Give permission for the researchers to collect information about the anesthesia medications used, pain medications used, and reported pain scores during the surgery and during recovery in the hospital"
214979576|NCT05912868|DEVICE|Endoscopic Mini/Less Open Sublay Repair|The traditional techniques are open sublay or transabdominal intraperitoneal onlay mesh (IPOM) repair. In order to avoid the risks -large trauma to the abdominal wall with pain and infection, lesion of intraabdominal organs - a new hybrid technique - small skin incision, wide endoscopic dissection of the retrorectus space with implantation of a large mesh - was developed (EMILOS -Endoscopic Mini/Less Open Sublay).
214979577|NCT01787552|DRUG|LDE225|
214979578|NCT01787552|DRUG|INC424|
214979579|NCT01556217|DRUG|JNJ-39393406|Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
214979580|NCT01556217|DRUG|Placebo|Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
215087160|NCT01800318|DEVICE|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
215087161|NCT01800318|BEHAVIORAL|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
215087162|NCT01800318|DEVICE|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
215087163|NCT01800318|BEHAVIORAL|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
215087164|NCT04050267|DRUG|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
214367658|NCT00835848|DRUG|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
214367659|NCT00835848|DRUG|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
214367660|NCT02403180|DEVICE|DACP MF|Nelfilcon A multifocal contact lenses
215087165|NCT04050267|OTHER|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
214367661|NCT02403180|DEVICE|PROCLEAR 1D MF|Omafilcon A multifocal contact lenses
214367662|NCT00041782|DRUG|Dalteparin (Fragmin)|200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
214367663|NCT05711537|DEVICE|Auricular Acupressure with Vaccaria 600t ear seeds|Auricular Acupressure utilizing vaccaria 600 t ear seeds applied to 5 designated sites to each ear. Both ears will have seeds applied. Participants will be asked if they consent to having their intervention session photographed and audio recorded in collaboration with the BAA press training and intervention fidelity study.
214367664|NCT01876290|DRUG|Dexamethasone and Ondansetron|Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
214492072|NCT06768151|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
214979581|NCT00000575|DRUG|Placebo|Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
214979582|NCT00000575|DRUG|Nedocromil|Four 2 mg puffs bid + two 90 Og puffs albuterol prn
214979583|NCT00000575|DRUG|Budesonide|Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
214367665|NCT01876290|DRUG|Placebo|Placebo
214492073|NCT06768151|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
214979584|NCT03423069|DIETARY_SUPPLEMENT|Diet low in FODMAPs|A strict restriction of all high FODMAP foods for the time of observation. All these foods will be identified by appropriate nutritional visits and alternatives will be suggested to ensure the diet is nutritionally adequate.
214979585|NCT03423069|DIETARY_SUPPLEMENT|Specific dietary advice for IBS|Dietary recommendations such as limitation of alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoidance of chewing gums and sweeteners containing polyols; small and frequent meals; avoidance of stressful conditions and eating slowly.
214979586|NCT06095908|DRUG|Bupivacain|Bupivacain administered with two different ways to the patients, postoperative pain recorded
214979587|NCT03002896|BEHAVIORAL|Pep-Pal|Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.
214979588|NCT03002896|OTHER|Treatment as Usual|
214979589|NCT00282217|DRUG|Sirolimus|
214979590|NCT00113477|DRUG|Q10|
214979591|NCT00113477|DRUG|Selen|
214979592|NCT02806167|OTHER|Clinical algorithm|Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
214979593|NCT02618746|OTHER|Telerehabilitation|
214979594|NCT02618746|OTHER|Hospital based Rehabilitation|
214979595|NCT03273062|DRUG|Tolcapone 200 MG|Tolcapone 200 MG TID
214979596|NCT03273062|OTHER|Placebo|Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
214979597|NCT00417066|DRUG|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
214979598|NCT00417066|DRUG|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
214979599|NCT05283746|DRUG|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
214979600|NCT05246254|DIAGNOSTIC_TEST|Frailty index scale|There are clinically common scales for assessing weakness and delirium.
214979601|NCT03955172|DRUG|Everolimus|Patients will received everolimus (CERTICAN), oral form, at the necessary dose to obtain trough levels between 6 and 8 ng/ml, during 6 months. Everolimus will replace the anti-proliferative drug they have before (azathioprine or mycophenolic acid). Everolimus will be associated with corticosteroids (prednisolone) and a calcineurin inhibitor (tacrolimus or cyclosporin).
214979602|NCT02679976|DEVICE|etafilcon A|Marketed Multifocal Contact Lens
214367666|NCT00232830|DEVICE|drug-eluting stent|Cypher Sirolimus-eluting Coronary Stent
214367667|NCT00232830|DEVICE|bare-metal stent|any bare-metal stent brand
214367668|NCT01876316|DRUG|Moxifloxacin|single oral administration of 400mg of moxifloxacin
214367669|NCT01876316|DRUG|Placebo|single oral administration of 400mg of placebo
214367670|NCT01304030|BEHAVIORAL|Empathy Training Modules|The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.
214367671|NCT01304030|BEHAVIORAL|Residency Training as usual|Residents will receive their typical didactic and clinical education
214367672|NCT03399643|DRUG|Atezolizumab|Atezolizumab is administered via IV 1200 mg every 3 weeks
214979603|NCT01951716|DRUG|Graded Glucose Infusion with Placebo|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
214979604|NCT01951716|DRUG|Graded Glucose Infusion with GIP Alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
214979605|NCT01951716|DRUG|Graded Glucose Infusion with xenin-25 alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
214367673|NCT05135416|PROCEDURE|chewing gum Group|control of consciousness chewing gum listening to bowel sounds assessment of pain
214367674|NCT05135416|PROCEDURE|Control group|control of consciousness listening to bowel sounds assessment of pain
214492074|NCT01952873|OTHER|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
214979606|NCT01951716|DRUG|Graded Glucose Infusion with GIP plus xenin-25|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
214979607|NCT01951716|DRUG|Meal Tolerance Test with Placebo|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
214979608|NCT01951716|DRUG|Meal Tolerance Test with xenin-25|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
214979609|NCT06369636|PROCEDURE|Thyroid Surgery|EGRI scores and airway ultrasonographic values will be recorded in patients who undergo thyroid surgery.
214979610|NCT02333253|DRUG|cetrotide|0.25 cetrotide S.c was added on when leading follicle reach \>12 mm
214979611|NCT06312982|DRUG|Tislelizumab|Enrolled patients will receive tislelizumab 3 times after initiation of radiotherapy.
214367675|NCT02526043|PROCEDURE|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy
214367676|NCT02526043|PROCEDURE|Open hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery
214367677|NCT02845401|OTHER|Stop NA therapy|Cases will stop antiviral therapy
214367678|NCT04194567|OTHER|Black Ragi|Pancakes made out of the dark ragi
214979612|NCT06960993|BEHAVIORAL|Intervention website|Website that includes experiential information, stress and coping resources, educational content, and links to trusted websites with additional educational content and links to psychosocial resources for transplant recipients and caregivers.
214979613|NCT06960993|BEHAVIORAL|Enhanced Usual Care (Control) Website|Website that includes stress and coping resources, educational content, and links to trusted websites with additional educational content and links to psychosocial resources for transplant recipients and caregivers.
214979614|NCT06960928|DRUG|Low-dose sirolimus|"Participants will take sirolimus, at home, for 12 weeks (3 months).~* 1 pill once a week for 2 weeks (1mg)~* 2 pills once a week for 2 weeks (2mg)~* 4 pills once a week for 8 weeks (4mg)"
214979615|NCT06960928|DRUG|Placebo|"Participants will take a matching placebo, at home, for 12 weeks (3 months).~* 1 pill once a week for 2 weeks (0mg)~* 2 pills once a week for 2 weeks (0mg)~* 4 pills once a week for 8 weeks (0mg)"
214979616|NCT02009943|DRUG|Ferric carboxymaltose|One time dosing
214979617|NCT02009943|DRUG|Iron sucrose|Goal-directed dosing
214979618|NCT02499562|DRUG|Hydronidone|The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
214979619|NCT02499562|DRUG|Placebo|
214979620|NCT02499562|DRUG|Entecavir|
214979621|NCT03691636|DEVICE|Eyelash prostheses|Eyelash prostheses are essentially specialized eyelash extensions
214979622|NCT03691636|DEVICE|5.0% Lifitegrast Ophthalmic Solution|5.0% Lifitegrast Ophthalmic Solution
214979623|NCT05484830|PROCEDURE|Individualized HDR-approach|"Heparin concentration necessary to achieve target ACT \> 480 sec. calculated based on individual HDR-curve.~If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required."
214979624|NCT05484830|PROCEDURE|Conventional ACT-approach|"Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA).~Additional heparin until ACT \> 480 sec. If ACT \< 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT \> 480 sec. during normothermic CPB, and target ACT \> 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT \> 40 seconds, additional protamine (25-50 mg i.v.)."
214367679|NCT04194567|OTHER|White Ragi|Pancakes made out of the white ragi
214367680|NCT00122642|PROCEDURE|Alcohol-lock|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
214367681|NCT00122642|DRUG|placebo-lock|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
214367682|NCT02158117|DRUG|nasal naloxone|one puff in one nostril with the subject is lying down
214367683|NCT02365675|DEVICE|Cotton gauze with petrolatum|
214367684|NCT02365675|DEVICE|Cellulose acetate with petrolatum|
215087166|NCT00664326|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
214492075|NCT01952873|OTHER|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
214492076|NCT04303260|BEHAVIORAL|Physical exercises|The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.
214492077|NCT06299020|BEHAVIORAL|intermittent fasting|fasting from predawn to sunset (no eating and no drinking), for approximately 16 hours.
215087167|NCT03612843|OTHER|Observational dry needle|No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
214367685|NCT02365675|DEVICE|Nanocrystalline silver (Acticoat)|
214367686|NCT02365675|DEVICE|Carboxymethylcellulose with ionic silver (Aquacel Ag)|
214367687|NCT03364855|OTHER|Star excursion balance test|Star excursion balance test,
214367688|NCT03364855|OTHER|Kinesthetic Ability Trainer 2000|Kinesthetic Ability Trainer 2000
214367689|NCT03364855|OTHER|SEBT and KAT 2000|Star excursion balance test and Kinesthetic Ability Trainer 2000
214367690|NCT01450748|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
214367691|NCT01450748|DRUG|Placebo|matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
214492078|NCT05935644|BEHAVIORAL|ORCHID|The intervention includes 8 modules, which are delivered online, approximately 30 minutes per session, and participants will engage a minimum of once per week. Participants may also meet online or in-person with a navigator, up to 4 times.
214492079|NCT05781360|DRUG|SIM0237|SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens
214492080|NCT05709860|BEHAVIORAL|EMC2 PrEP Educational Tool|Patients will receive an interactive PrEP Educational Tool. This interactive tool will be securely sent via the patient portal. After logging into their portal, patients will have the opportunity to review the information on their own time.
215087168|NCT00387647|DRUG|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
215087169|NCT04833959|DRUG|89Zr-panitumumab|Imaging Agent
215087170|NCT01057524|DEVICE|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
214979625|NCT06014177|BEHAVIORAL|STIckER|"STIckER is an interactive and personalized intervention based on the principles of SDM that has been designed with input from the AYA ED patients and providers. STIckER guides AYA patients through a series of steps, beginning with scanning your STIckER. Participants complete risk assessments, SDM modules, and conclude with an anonymous final digital infographic that informs an SDM conversation with the medical provider. This decision aid seamlessly integrates into the ED workflow, recommending appropriate STI testing for high-risk individuals and using SDM concepts for those at intermediate risk."
215087171|NCT01057524|OTHER|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
215087172|NCT03556020|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
215087173|NCT00885300|DRUG|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
215087174|NCT00885300|DRUG|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
215087175|NCT04429399|OTHER|decrease the positive end expiratory pressure (PEEP)|decrease the PEEP going from high (according to ExPress Trial) to low level
215087176|NCT04429399|OTHER|mechanical features assessment|evaluation of the mechanical features of respiratory system
215087177|NCT04429399|OTHER|shunt assessment|evaluation of the pulmonary shunt during two different ventilation setting
215087178|NCT02952560|OTHER|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
215087179|NCT02032407|DRUG|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
214367692|NCT05001360|DRUG|XBI-302 + Nivolumab|After gut preparation, a single dose of FMT will be performed via oral administration. Subsequently, nine combined treatment cycles that composed of anti-PD-1 infusions (Nivolumab at 240 mg, q2w) and additional FMT capsules, and 3 single treatment cycles of anti-PD-1 infusions will be administered.
214367693|NCT02958592|OTHER|two-dimensional shear-wave elastography (SWE)|performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection
214367694|NCT00330915|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
214979626|NCT06014177|OTHER|Control|"After enrollment but before the start of their clinical visit, AYA participants assigned to a provider in the control arm will scan a QR code. They will receive a prompt stating, If you would like to be tested for a sexually transmitted infection today, please tell your medical doctor."
214979627|NCT02305264|DRUG|18F-DPA-714 and 18F-FDG|"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."
214979628|NCT03881436|DIAGNOSTIC_TEST|MRI with DTI sequence|"At the end of the planned sequence, but before any contrast agent injection:~* Acquisition of a an additional anatomical T2 SPACE sequence~* Acquisition of a tractography DTI sequence"
214979629|NCT04500951|OTHER|Optimized resting environment|"Alarms from feeding pumps will be relayed to the nurse call system for all intervention periods. Alternatively meals will be timewise reorganized to not interfer with the intervention resting periods. Signs reminding staff not to disturb will be posted for all intervention periods.~For each patient the close team of rehabilitation professionals will agree upon a guideline suggesting the optimal resting environment for the specific patient. The guideline wil be based on knowledge gathered from relatives on pre-injury preferences. Furthermore, the guideline will be developed based on a toolbox of possible intervention representing best practice. The toolbox has been designed according to the categories of the International Classification of Functioning.~The intervention will designed individually for each patient."
215087180|NCT02191605|BEHAVIORAL|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
215087181|NCT02191605|BEHAVIORAL|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
215087182|NCT00584207|PROCEDURE|radiofrequency ablation|Intraoperative RFA of uterine fibroids
215087183|NCT05406609|OTHER|Cost|Costs of operating room, drugs and equipments which are used by anesthesia
215087184|NCT05406609|OTHER|Time|Time of using operating room
215087185|NCT03737877|OTHER|Diet modification|"The parents will have four group sessions with a nutritional therapist, where in depth advice and information about the diet will be provided. Ongoing support will also be provided throughout the study by use of a closed Facebook or WhatsApp group (whichever the parents choose as most appropriate). The diet is based on five main principles:~* Eat at least seven portions of different varieties of fruit and vegetables each day.~* Have a 12 hour overnight break from food (water only during this time).~* Drink a Kefir drink each day - provided free of charge.~* Eat a microbiome friendly, protein rich, breakfast from our menu.~* Reduce sugar and artificial sweeteners."
215087186|NCT03809910|DEVICE|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
215087187|NCT03809910|DEVICE|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
214367695|NCT02428322|DIETARY_SUPPLEMENT|Placebo|Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.
214367696|NCT02428322|DIETARY_SUPPLEMENT|VItamin D3|Soft gel capsules will contain 2,000IU vitamin D.
214979630|NCT04500951|OTHER|Standard resting environment|The control condition, standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward. Pressure ulcers and positioning believed to induce pain will be avoided.
214979631|NCT03055936|DRUG|Levodopa|Levodopa 50 mg or 100 mg or 150 mg
214979632|NCT03055936|DRUG|Carbidopa|Carbidopa 12.5 mg or 25 mg or 65 mg
214979633|NCT03055936|DRUG|ODM-104|ODM-104 50 mg or 100 mg
214979634|NCT03167242|DRUG|KAF156|KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
214979635|NCT03167242|DRUG|Coartem|Coartem comes as 20/120 mg dispersible tablets or 80/480 mg tablets for oral administration. Coartem was administered twice daily for 3 days as active comparator.
214979636|NCT03167242|DRUG|Lumefantrine Solid Dispersion Formulation|LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.
214979637|NCT03971760|OTHER|Suction drain removal|Removal of negative pressure suction drain left in place to drain the surgical space after a neck surgery
214979638|NCT04059718|BEHAVIORAL|SCI Thrive Peer-Led Online Self-Management Program|6 week online course in self-management for individuals with spinal cord injuries. This was developed by a team using principles of cognitive behavioral techniques.
214979639|NCT02125240|DRUG|Icotinib|125 mg three times daily (375 mg per day) by mouth
214979640|NCT02125240|DRUG|Placebo|1 tablet three times daily by mouth
214979641|NCT01464567|PROCEDURE|"T Tube Spontaneous Breathing Trial"|"T Tube ventilation for 30 minutes"
214979642|NCT01464567|PROCEDURE|Pressure Support Ventilation|Pressure-Support Ventilation for 30 minutes
214979643|NCT01203696|DRUG|Amlodipine|For patient with suboptimal angina control: oral 2.5-10mg daily
214979644|NCT01203696|DRUG|Amlodipine|For patient with suboptimal BP control: 2.5-10mg daily po
214979645|NCT00764218|DEVICE|Positive airway pressure treatment|Positive airway pressure treatment as long as necessary
214979646|NCT00764218|OTHER|No positive airway pressure treatment|No treatment
214979647|NCT02552927|DEVICE|Chest shield with aluminum foil (CALF)|
214979648|NCT02552927|DEVICE|SHIELD|
214979649|NCT04547400|OTHER|assessment|Assessments of balance, gait, lower extremity position sense, and foot sole sense
214979650|NCT03211507|OTHER|Computer-assisted telephone interview|Occupational history
214680075|NCT05237882|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
214979651|NCT03211507|GENETIC|Genetic analysis|To include analysis of known susceptibility markers
214492081|NCT05709860|BEHAVIORAL|Discrete Scheduling of a Dedicated PrEP Visit|Within the interactive PrEP Educational Tool, patients who choose to will have the opportunity to discretely schedule a dedicated PrEP visit with a primary care clinician trained on PrEP delivery. The clinician will have time reserved to allow for 'rapid' scheduling.
214492082|NCT06733740|PROCEDURE|ultrasound-guided thermal ablation|ultrasound-guided thermal ablation to treat tumor
214492083|NCT06827730|DIAGNOSTIC_TEST|Point of care ultrasound|The investigator uses PoCUS to investigate thoracic or abdominal pain after anamnesis and clinical examination. The investigator reports the anamnesis, clinical examination, and PoCUS results in the patient's medical file. PoCUS images are recorded according to the procedures of the study centers and the capacities of the ultrasound machines.
214492084|NCT06819748|DRUG|The cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone|The patient receive the cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone as incision local anesthesia at the end of surgery
214979652|NCT04490408|PROCEDURE|long surgical bypass|long surgical bypass and hybrid approaches in patients with multilevel critical lower limb ischemia.
214979653|NCT04490408|PROCEDURE|Hybrid approach|Hybrid approach including bypass and endovascular revascularization
214979654|NCT02542969|DRUG|Simvastatin|
214979655|NCT02542969|DRUG|Rosuvastatin|
214979656|NCT02542969|DRUG|MGL-3196|
214979657|NCT06550323|DEVICE|Group using virtual reality glasses|Group using virtual reality glasses: During the procedure, individuals will wear glasses.
214979658|NCT02253264|DRUG|Rituximab|
214979659|NCT00566488|BIOLOGICAL|Thymus/Parathyroid Transplantation|Thymus tissue, thymus donor, mother of thymus donor, \& parental parathyroid donor screened for transplant safety. Depending on T cell phenotype \& function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre \& post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis \& graft rejection.
214979660|NCT04102826|DEVICE|Functional electrical stimulation (FES)|Functional electrical stimulation combined with mobile arm support to restore upper limb function.
214979661|NCT05143424|DRUG|Morphine Sulfate|Morphine sulfate 30 mg tablets as a single dose twice
214979662|NCT01836237|DEVICE|Alexis - a wound protector|Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
214979663|NCT04119648|BEHAVIORAL|CAMS-4Kids|The Collaborative Assessment and Management of Suicidality (CAMS-Jobes, 2006; 2016) is an evidence-based, therapeutic framework for addressing suicide risk in the adult population. CAMS-4Kids, the research intervention used in this study, is a 10-session developmentally-sensitive adaptation of CAMS for children ages 5 - 11 years old.
214367697|NCT03022201|DRUG|DA-9701|Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
214367698|NCT03022201|DRUG|Domperidone|Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
214367699|NCT03022201|DRUG|Placebo domperidone|
214367700|NCT03022201|DRUG|Placebo DA-9701|
214367701|NCT00118716|DRUG|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol
214367702|NCT00118716|DRUG|Fluticasone Propionate|Fluticasone Propionate
214367703|NCT04436666|DEVICE|motivational video production through virtual reality glasses|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
214367704|NCT04436666|OTHER|Ice Application|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
214367705|NCT03665844|DEVICE|SmartSleep Boost On|"SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS)."
214367706|NCT03665844|DEVICE|SmartSleep Boost Off|SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
214367707|NCT00801801|DRUG|Docetaxel + Sorafenib|Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle. Tumor response to treatment will be evaluated after every 8 weeks. Treatment with metronomic chemotherapy and sorafenib will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with sorafenib will then continue until disease progression, intolerable toxicity or withdrawal of consent.
214492085|NCT06819748|DRUG|0.5% ropivacaine|The patient receive 0.5% ropivacaine as incision local anesthesia at the end of surgery
214492086|NCT06799039|DRUG|Xylitol|Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Patients will be consecutively enrolled into one of five dosing including 1g, 2g, 5g, 7g and 9g.
214492087|NCT06758765|PROCEDURE|Erector Spinae Plane Block|ESPB was applied to the patients in a sitting position. A high-frequency linear probe was used. Under sterile conditions, the USG probe was placed longitudinally approximately 2 cm lateral to the T4 spinous process. Skin, subcutaneous fat tissue, m. trapezius, rhomboid muscles, erector group muscles, transverse process, intercostal muscles, pleura and lung movements were visualized from superficial to deep structures. 1 ml of 2% lidocaine was injected into the estimated needle entry area. Then, with the block needle the m. trapezius, mm. rhomboidei and erector spinae muscles were passed in order with the in-plane method and the needle was brought into contact with the transverse process. Fascial separation was confirmed with 1-2 ml of saline solution and the block was performed by injecting 20 ml of 0.375% bupivacaine. The distribution of the drug was confirmed by observing it with USG.
214979664|NCT02536911|DRUG|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
214979665|NCT05931263|DRUG|C-BEAM Regimen|Chidemide，carmustine, etoposide, cytarabine, and melphalan
214979666|NCT05931263|DRUG|BEAM Regimen|carmustine, etoposide, cytarabine, and melphalan
214979667|NCT02629978|PROCEDURE|CT-guided percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
214979668|NCT00637013|PROCEDURE|Acromioplasty|Arthroscopic or open acromioplasty
214979669|NCT00637013|PROCEDURE|Physiotherapy|Physiotherapy according to a standardized protocol
214979670|NCT05577728|DRUG|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
214979671|NCT05577728|DRUG|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)"|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference."
214979672|NCT01909804|DRUG|SOF|400 mg tablet administered orally once daily
214367708|NCT01916005|DEVICE|18F-FDG PET/CT|
214367709|NCT01445652|DEVICE|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
214979673|NCT01909804|DRUG|VEL|Tablet administered orally once daily
214979674|NCT01909804|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214367710|NCT01445652|OTHER|Spectacles|Spectacles per current prescription
214979675|NCT04182958|DRUG|(14C)-OPC-61815|On the morning of Day 1, all subjects will receive a single IV infusion of (14C) OPC-61815
214979676|NCT01938196|DRUG|KWA-0711|
214979677|NCT01938196|DRUG|Placebo|
214979678|NCT03292510|OTHER|GO-OUT Group|Following a baseline assessment, eligible participants will be stratified by site, and randomly assigned to receive the 1-day educational workshop and 3-month outdoor mobility program (GO-OUT intervention). Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline.
214979679|NCT03292510|OTHER|Workshop Group|the 1-day workshop plus reminders. Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline
214979680|NCT04713072|BIOLOGICAL|ABY-035|ABY-035 solution for injection
214979681|NCT04713072|BIOLOGICAL|Placebo|Placebo to ABY-035 solution for injection
214979682|NCT00260988|DRUG|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
214979683|NCT00260988|DRUG|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
214979684|NCT02144701|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Given PO
214979685|NCT02144701|OTHER|laboratory biomarker analysis was not performed because of no differences in the clinical outcomes|Correlative studies
214979686|NCT01491425|DEVICE|rhBMP-2/ACS//LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
215087188|NCT03809910|DEVICE|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
214979687|NCT01491425|DEVICE|Autogenous Bone//LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
214979688|NCT00909168|DRUG|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|"FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6"
214979689|NCT06177288|COMBINATION_PRODUCT|DEBIRI Combined With Chemotherapy and Bevacizumab|After dissolving 100 mg of irinotecan in water for injection or 4ml of 5% glucose water.use 2mL of 70μm uniform particle size microspheres for loading and adsorption for 5minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
214979690|NCT02125890|DRUG|Tranexamic Acid|two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
215087189|NCT03809910|DEVICE|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
215087190|NCT02379468|DRUG|Pedyphar Ointment|
215087191|NCT02379468|DRUG|Panthenol|Ointment
215087192|NCT06104098|DEVICE|D005 vaginal mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
214979691|NCT04151511|PROCEDURE|Continuous Erector Spinae Plane Block|"1. Continuous Thoracic Epidural Thoracic Epidural Analgesia~2. Continuous Erector Spinae Plane Block"
214979692|NCT05403645|DIAGNOSTIC_TEST|Movement With Mobilization|with the help of Movement With Mobilization technique
214979693|NCT05403645|DIAGNOSTIC_TEST|Exercise Therapy|with the help of Exercise Therapy technique
214979694|NCT04500444|OTHER|exercise training|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.
214979695|NCT03795506|DEVICE|Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment|12 weeks of overnight treatment with active TLA device
214979696|NCT03795506|DEVICE|Placebo TLA Device|12 weeks of overnight use of placebo TLA device
214979697|NCT03217591|DRUG|IW-1973|Oral Tablet
214979698|NCT03217591|DRUG|IW-1973|Oral Tablet
214979699|NCT03217591|DRUG|Placebo|Oral Tablet
214979700|NCT02200146|DRUG|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
214979701|NCT02200146|DRUG|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
214979702|NCT00249834|DRUG|Gonal-f|GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
214979703|NCT00249834|DRUG|Recombinant human chorionic gonadotrophin (r-hCG)|When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
214979704|NCT04726553|DRUG|Anifrolumab|Anifrolumab is a monoclonal antibody which inhibits the Interferon alpha beta receptor (IFNAR) which is the main transducer of signals from Type I interferons.
215087193|NCT02248363|OTHER|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
215087194|NCT05067751|DEVICE|hearing aid with directionality|Hearing directionality allows users the ability to focus on voices and other signals of interest, reducing background noises that are unimportant.
215087195|NCT04787055|DEVICE|Receiver-in-canal hearing instrument|Receiver-in-canal hearing instrument
215087196|NCT05874622|DRUG|VC005 tablets|VC005 groups repeat administration for 4 weeks
215087197|NCT05874622|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 4 weeks
214979705|NCT04726553|DRUG|Standard of Care|Standard of Care treatments for Systemic Lupus Erythematosus
215087198|NCT04129411|DEVICE|RFA|Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.
215087199|NCT05408910|DRUG|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.
214680076|NCT06395142|OTHER|pedal walking|Pedal walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation. A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during pedal walking in stroke participants.
214979706|NCT05324306|DEVICE|combat application tourniquets (CAT)|"CAT tourniquets have been indicated for use in emergency situations revolving around a wounded limb, such as hemorrhage control.22-23 CAT tourniquets are the official tourniquet of the US Army since in 2005.~We will deploy well-studied and FDA approved combat application tourniquets (CAT) on both thighs of volunteer healthy adult subjects while measuring blood pressure in the upper extremities."
214979707|NCT05458986|OTHER|Media Intervention|Watch an educational video
214979708|NCT05458986|OTHER|Best Practice|Receive usual care
215087200|NCT05408910|DRUG|Placebo|Participants in this arm will receive placebo three times daily for 14 days.
214367711|NCT06097754|DIETARY_SUPPLEMENT|Ketone ester|"Ketone ester: A total of 300g ketone ester supplementation will be provided in one of the 72h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude"
215087201|NCT02726061|BEHAVIORAL|Internet-based psychological support|A behavioral therapy called Problem Solving Therapy, conflict management training, and stress management training will be administered via an interactive multimedia program (PATH) to participants referred from their Employee Assistance Program and the general public for the management of depression, stress, and conflict.
215087202|NCT03647267|DEVICE|Pneumatic Vitreolysis (C3F8 injection)|Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
215087203|NCT03647267|OTHER|Observation|No intervention; sham injection only
214492088|NCT06758765|PROCEDURE|Pectoral Nerve Block|"The PECSI and PECSII blocks were applied concurrently.~In patients who will undergo PECS II, sterile conditions were prepared with the arm on the side to be operated on in the supine position and 90 degrees of abduction. The lateral and pectoral branches of the thoracoacromial artery were visualized between the PM and Pm muscles at the level of the 4th rib under USG guidance. The blocking needle was directed between the PM and Pm muscles for PECS I, 1-2 ml of saline was injected to verify fascial spread, and 10 ml of 0.375% bupivacaine was applied. Afterwards, fascial spread was confirmed by injecting 1-2 ml of saline between the pectoralis minor muscle and the serratur anterior muscle, and PECS II was performed by injecting 10 ml of 0.375% concentration bupivacaine. The distribution of the drug was confirmed by observing it with USG."
214979709|NCT05458986|OTHER|Questionnaire Administration|Ancillary studies
215087204|NCT02432352|BEHAVIORAL|Our Family Our Future|The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
215087205|NCT03659058|DRUG|silymarin|silymarin 140 three times daily
215087206|NCT03659058|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
214680077|NCT06395142|OTHER|visual-deprivation walking|visual-deprivation walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation.A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during visual-deprivation walking in stroke participants.
215087207|NCT03659058|DRUG|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
214979710|NCT04627636|OTHER|Myofascial trigger points pressure (MTrP) release|Myofascial trigger points pressure (MTrP) release technique, the initial step was to recognize and find the trigger points (TP) , and The second step after TP palpation was the MTrP release technique, as follow, by one or both hands, the thumbs or four fingers of the therapist applied a maintained pressure, pushing internal toward the middle
215087208|NCT03659058|DRUG|Colchicine|Colchicine 0.6
215087209|NCT03659058|OTHER|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
214367712|NCT06097754|DIETARY_SUPPLEMENT|Placebo|"Placebo: Water, 5% sucralose (w/w), octaacetate (1 mM)~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude"
214367713|NCT02708979|OTHER|University exam-period|This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
214680078|NCT00343304|DEVICE|Robot|
214680079|NCT00343304|DEVICE|Ergometer|
214979711|NCT04627636|OTHER|Shockwave therapy application|The JEST-2000 (JOEUN Medical, Dae-Jeon, South Korea) was used for the ESWT. The application of pressure pulses of ESWT was centered around the flexor muscles with hypertonia
214979712|NCT04627636|OTHER|conventional therapy|Passive ROM exercises performed by the therapist and Bobath Neurodevelopmental Approach (prolonged stretch): The Intervention methods for Bobath involved the activation of key points of control for the reduction of tone
215087210|NCT01904656|BEHAVIORAL|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
215087211|NCT01904656|BEHAVIORAL|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
214979713|NCT04673773|BEHAVIORAL|A Massive Open Online Course|Same as intervention
215087212|NCT05107583|BEHAVIORAL|Low-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (\<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
215087213|NCT05107583|BEHAVIORAL|High-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (\~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
214492089|NCT06759766|COMBINATION_PRODUCT|Garlic-Lemon Extract irrigant|"garlic (Allium sativum) Shows a wide range of therapeutic effects due to the presence of allicin, ajoene \& other thiosulfinates. It has antibacterial effect against wide range of gram-positive and gram-negative bacteria, anti-inflammatory, antioxidant, antiviral, antifungal, antitumor, immunomodulatory effects and tissue-dissolving capacity (Siddique, et al., 2020). According to (Elheeny., 2019) Allium sativum extract can be used efficiently as an irrigant for pulpectomy of primary molar root canals.~Lemon (Citrus Limon) as well has curative properties such as, antibacterial, antiviral, antifungal, anti-inflammatory, anti-cancerous activities and removal of the smear layer as well. Due to presence of ascorbic acid, phenolic acids, polyphenols, and dietary fibers.~the combination of Garlic-Lemon has been tested in adult teeth as an irrigant and showed an effective result equal to NaOCl (Siddique, et al., 2020)."
214979714|NCT01566110|DIETARY_SUPPLEMENT|Gluten Free Diet|Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
214979715|NCT04775030|DRUG|CBD occlusal appliance|Occlusal appliance manufactured with CBD molecules released from material to patients oral cavity during sleep time
214979716|NCT04775030|DEVICE|Acrylic resin occlusal appliance|Acrylic resin occlusal appliance during sleep time
214979717|NCT06284421|DEVICE|Shore durometer|The durometer will be held on the exterior of the lower uterine segment and fundus to measure the hardness reading at each location.
214979718|NCT00537888|DRUG|fluconazole|Intravenous or oral 400 md/d
215087214|NCT05107583|BEHAVIORAL|Fasted Exercise|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
214492090|NCT06759766|OTHER|physiological saline|Normal saline solution exhibits no adverse effects on the developing successors; Serves primarily to facilitate root canal cleaning during the irrigation process, in comparison to other commercial synthetic irrigants such as Sodium hypochlorite (NaOCl), Chlorhexidine (CHX), Ethylenediamine tetra acetic acid (EDTA) which exhibit potential side effects and cytotoxic reactions (Sayadizadeh et al., 2019).
214979719|NCT01251042|DEVICE|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
214979720|NCT00269152|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles
214979721|NCT00269152|DRUG|cisplatin|75 mg/m\^2, intravenous (IV), every 21 days x 4 cycles
214979722|NCT00269152|DRUG|carboplatin|area under the curve (AUC) 5 milligrams per milliliter\*minute (mg/ml\*min), intravenous (IV), every 21 days x 4 cycles
215087215|NCT05996042|BEHAVIORAL|Time-restricted diet|"On Tuesdays, Thursdays and Saturdays, only eating is allowed between 7am and 3pm. The rest of the time, only drinking pure water is allowed, which is an eight-hour eating window and a 16-hour fasting period.~On Mondays, Wednesdays and Fridays, under the unified guidance of the physical education teachers of the Health Science Department from 6:00 PM to 7:00 PM, the venue is the gymnasium and sports field of Peking University Health Science Center. The exercise items include aerobics, yoga and comprehensive physical training."
215087216|NCT01350115|DRUG|LDE225|supplied as 100 mg capsules
215087217|NCT01350115|DRUG|Placebo|supplied in capsules
215087218|NCT05079477|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
215087219|NCT05079477|BEHAVIORAL|Exposure to calorie information|Calories for all beverages and foods
215087220|NCT06137729|DRUG|PF-07899895|Participants will receive oral ascending doses.
215087221|NCT06137729|DRUG|Placebo|Participants will receive matching placebo.
215087222|NCT05987488|BIOLOGICAL|ShigETEC live, attenuated, oral vaccine|"Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses."
215087223|NCT05987488|OTHER|Placebo|"Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart."
215087224|NCT04948307|DEVICE|OXD01 digital therapy|OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.
215087225|NCT04948307|OTHER|Standard of Care|Sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling
214979723|NCT04249427|DRUG|Erenumab Prefilled Syringe|140mg Erenumab, pre-filled syringe given by subcutaneous injection
214979724|NCT04249427|OTHER|Placebo|Placebo, pre-filled syringe given by subcutaneous injection
214979725|NCT03886272|DRUG|BI 730357 (Test)|tablet
214979726|NCT03886272|DRUG|BI 730357 (Reference)|tablet
214979727|NCT05179408|BEHAVIORAL|Targeted-telerehabilitation|Participant-chosen targets: 1) inspiratory muscle training + walking (to reduce dyspnea and improve physical activity/stept count; 2) resistance training (to reduce fatigue and improve role/social function; 3) mindfulness training (to reduce fear of cancer recurrence and anxiety)
215087226|NCT05918055|DRUG|KPT-8602|5-10 mg PO daily for 10-14 days based on dose level
215087227|NCT05918055|DRUG|Inqovi|Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.
214979728|NCT05179408|BEHAVIORAL|Waitlist|8-week waiting period prior to targeted telerehabilitation
215087228|NCT04758923|PROCEDURE|Cholecystectomy|Under General anaesthesia cholecystectomy and CBD exploration
215087229|NCT05837858|OTHER|whole grain-wheat flour food+standardized meals|whole grain food made by 50 g whole grain wheat flour
215087230|NCT05837858|OTHER|refined wheat flour food+standardized meals|refined grain food made by 50 g refined wheat flour
215087231|NCT01820052|DRUG|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
215087232|NCT01820052|DRUG|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
215087233|NCT01095120|DRUG|Tesetaxel|"For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.~For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.~For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2."
215087234|NCT05013424|DRUG|Formulation A: OnabotulinumtoxinA|Intramuscular Injection
215087235|NCT05013424|DRUG|Formulation B: OnabotulinumtoxinA|Intramuscular Injection
215087236|NCT05013424|DRUG|Formulation C: OnabotulinumtoxinA|Intramuscular Injection
215087237|NCT06957158|DIAGNOSTIC_TEST|Peripheral venous blood|Peripheral venous blood was collected before and after the surgery to measure the total serum calcium levels.
215087238|NCT06957158|DIAGNOSTIC_TEST|Arterial blood|Arterial blood was collected before anesthesia induction and after removal of the artificial airway to measure ionized calcium levels.
215087239|NCT02491424|DEVICE|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
215087240|NCT02461316|OTHER|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
215087241|NCT00373945|DRUG|Observational Study|
215087242|NCT03769987|OTHER|observation|observe patients every 6 months
215087243|NCT05648019|BIOLOGICAL|Anti-CD19 CAR T-cells|A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
215087244|NCT06065891|PROCEDURE|PALN resection|Resection of paraaortic lymph nodes in pancreatic cancer
215087245|NCT01545427|DRUG|Imatinib mesylate|200 mg bid for 6 months
215087246|NCT01545427|OTHER|Placebo|Placebo coated to match appearance of Gleevec identically.
215087247|NCT00960479|DRUG|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
215087248|NCT00960479|DRUG|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
215087249|NCT06587685|DRUG|PG-011Gel|Twice daily for 52 weeks or 44 weeks
215087250|NCT06587685|DRUG|Vehicle|Vehicle Gel twice daily for 8 weeks
215087251|NCT03519295|DRUG|MPDL3280A|MPDL3280A administered every 2 weeks at 800 mg for 12 months.
215087252|NCT03519295|DRUG|mDCF|8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks
215087253|NCT06416722|OTHER|Cognitive-Motor Dual Task Activities|Patients included in this group will be given additional cognitive tasks (e.g. counting months, subtracting 5 from 100) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).
215087254|NCT06416722|OTHER|Motor-Motor Dual Task Activities|Patients included in this group will be given additional motor tasks (e.g. passing the ball from the right hand to the left hand while standing on a soft surface, clapping) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).
215087255|NCT06416722|OTHER|Cognitive-Motor & Motor-Motor Dual Task Activities|Simultaneously with balance and large amplitude functional activities (such as stepping forwards-sideways-backwards, sitting and standing), patients included in this group will be given additional cognitive (e.g. counting while standing with feet closed) and motor (e.g. passing the ball from the right hand to the left hand while standing on a soft surface) tasks in accordance with the physiotherapist's commands.
215087256|NCT04715646|DRUG|Brivaracetam|"Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses.~Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral~Oral solution Concentration: 10 mg/ml Route of administration: oral"
214979729|NCT06415435|DEVICE|Radiofrequency Microneedling|Sylfirm X radiofrequency microneedling device
214979730|NCT04001556|DIAGNOSTIC_TEST|Minor Salivary gland Biopsy|Minor salivary gland biopsy with injection of lidocain
214979731|NCT04001556|DIAGNOSTIC_TEST|ARFI|Acoustic Radiation Force Impulse on Major Salivary Glands
214979732|NCT04001556|DIAGNOSTIC_TEST|MSG US|Ultrasonography of Major Salivary Glands
214979733|NCT02926105|BEHAVIORAL|T&E Home-based exercise programme|"T\&E exercises programme consists of home-based individually tailored balance and functional strength tests and exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months."
215087257|NCT06030180|DEVICE|EsoGuard|EsoGuard is a set of genetic assays and algorithms for the assessment of specific methylation patterns of DNA encoding the genes vimentin (VIM) and cyclin A1 (CCNA1)
214680080|NCT06553378|OTHER|Geriatric Oncology Supportive Clinic|Subjects in the intervention arm will be seen within four weeks of recruitment. Clinical assessment involves a Comprehensive Geriatric Assessment (CGA) and Supportive Care Assessment conducted by a geriatric-oncologist. Both clinical assessments and targeted interventions are supported by a multi-disciplinary team comprising the geriatrician, geriatric trained nurse, physiotherapist, occupational therapist, speech therapist, pharmacist, dietician, and medical social worker. We will conduct an initial GOSC assessment, with a follow up review during oncology treatment. Subsequently, further GOSC clinic sessions duration of follow up will be determined by the subject's underlying disease, symptom burden and clinical course during treatment.
214979734|NCT02926105|BEHAVIORAL|Otago|Otago exercises programme consists of home-based individually tailored balance, strength and walking exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
214979735|NCT02926105|BEHAVIORAL|Helsana booklet|Helsana programme consists of a booklet with recommendations and 10 exercises performed 3x a week over 12 months.
214979736|NCT05325996|DIAGNOSTIC_TEST|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) using the Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures the visual field in an ophthalmic setting.
214979737|NCT05325996|DIAGNOSTIC_TEST|visuALL H|visuALL H a new portable perimeter measuring the visual field and acuity in a non ophthalmic setting.
214979738|NCT05325996|DIAGNOSTIC_TEST|iCare Home Tonometer|iCare HOME tonometer is a device developed for patients/subjects to measure their eye pressure at home.
214979739|NCT05325996|DIAGNOSTIC_TEST|Spectralis Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a computerized picture measuring the thickness of the inner layer of the retina that makes the optic nerve.
214979740|NCT01886508|PROCEDURE|Nerve-spring radical hysterectomy|Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
214979741|NCT01886508|PROCEDURE|radical hysterectomy|Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
214979742|NCT00098241|DRUG|Certican|
214979743|NCT05148637|DRUG|Maintenance of general anesthesia by Sevoflurane|Anesthesia was maintained by inhalational anesthesia (sevoflurane) titrated by monitoring of patient sensitivity index of the Masimo
214979744|NCT05148637|DRUG|Maintenance of general anesthesia by Desflurane|Anesthesia was maintained by inhalational anesthesia (desflurane) titrated by monitoring of patient sensitivity index of the Masimo
214979745|NCT05148637|DRUG|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions)|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions) titrated by monitoring of patient sensitivity index of the Masimo
214979746|NCT00250822|DRUG|Gemcitabine and Oxaliplatin|"Dose:~Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 \& 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 \& 16"
214979747|NCT01119690|DIETARY_SUPPLEMENT|Cold-pressed turnip rapeseed oil (CTPRO)|"1. In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.~2. In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO."
214979748|NCT01119690|DIETARY_SUPPLEMENT|milk fat|"1. In dietary period of 6 to 8 weeks: 37.5 grams of butter.~2. In the 5-hour oral glucose and fat tolerance test: glucose and cream"
214979749|NCT02576392|BEHAVIORAL|Intervention|Intervention consisted of a mailing 2 weeks prior to surgery, another 2 weeks post surgery, and a pharmacist intervention if a refill of opioid medication was requested within 90 days of surgery.
214979750|NCT06308471|OTHER|Baby massage was applied to the intervention group (n=20) of the study|The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.
215087258|NCT06481566|RADIATION|stereotactic ablative body radiotherapy|The residual primary lung lesions after first-line Almonertinib will be delivered stereotactic ablative body radiotherapy.
215087259|NCT06059716|BEHAVIORAL|Gluten detection technology|Portable technology to sense gluten after ingestion
214979751|NCT06308471|OTHER|Oral stimulation|The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.
214979752|NCT01350817|DRUG|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
214979753|NCT01350817|DRUG|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
214979754|NCT03260608|BEHAVIORAL|Telesupport|In the intervention will be carried out eight weekly phone calls of psychoeducation and support on the disease of the relatives approaching different themes.
215087260|NCT06059716|BEHAVIORAL|Continuous telemedicine monitoring|Regular follow-up with an expert dietitian
215087261|NCT04095364|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
215087262|NCT04095364|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215087263|NCT04095364|DRUG|Carboplatin|Given IV
214979755|NCT00931632|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
214979756|NCT00931632|DRUG|Placebo|Nitrogen gas will be administered in the same manner as the experimental drug.
214979757|NCT01844037|DEVICE|OneShot Ablation System|Renal denervation
215087264|NCT04095364|PROCEDURE|Imaging Procedure|Undergo medical imaging
215087265|NCT04095364|DRUG|Letrozole|Given PO
215087266|NCT04095364|DRUG|Paclitaxel|Given IV
215087267|NCT00892359|DRUG|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
214979758|NCT05208996|DRUG|siCoV/KK46|"The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg."
215087268|NCT06195995|DEVICE|Transcranial alternating current stimulation-true stimulus|Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
214367714|NCT02708979|OTHER|University non-exam-period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
214680081|NCT05322863|DEVICE|High-definition Transcranial Direct Current Stimulation|The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
214979759|NCT02569892|DEVICE|Pascal Retinal Laser Photocoagulator|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
214979760|NCT05504096|DEVICE|Actxa BGM Tracker (GLO2)|Wrist-worn wearable
215087269|NCT01551524|BIOLOGICAL|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
215087270|NCT06166329|OTHER|chair lift test|repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute
215087271|NCT06219421|OTHER|Clinical data reuse|Clinical data reuse
215087272|NCT03617055|DIAGNOSTIC_TEST|serum cystatin c|Blood sample for serum cystatin c will be taken on the first and third days of life for all neonates with clinical or laboratory signs of perinatal asphyxia who are admitted to NICU for early detection of AKI in the study group.
214979761|NCT05504096|DEVICE|SVT In-Ear Prototype (IEP)|In-Ear wearable
214979762|NCT01904890|BEHAVIORAL|CRC Prevention and Screening Education|Refer to Arm Description
215087273|NCT00245648|DRUG|fibrinolytic therapy or combination reduced fibrinolytic therapy|
215087274|NCT05397639|DRUG|Masupirdine 50 mg|Tablet, Once Daily
215087275|NCT05397639|DRUG|Masupirdine 100 mg|Tablet, Once Daily
215087276|NCT05397639|DRUG|Placebo|Matching Placebo Tablet, Once Daily
215087277|NCT02525406|OTHER|All surgeries performed from Jan 01, 2010 to Aug 31, 2020|
215094519|NCT02574741|BEHAVIORAL|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
215094520|NCT02574741|DRUG|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
215094521|NCT02574741|DRUG|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
215094522|NCT06110455|OTHER|Neuromuscular Training exercises|The 8 week exercise intervention consists of 25 minute group sessions of Neuromuscular training supervised by a physical therapist.
214367715|NCT02708875|OTHER|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
214367716|NCT02708875|OTHER|Glucose Challenge|Glucose drink (50g glucose)
214680082|NCT06211504|DEVICE|ProStop, sinus tarsi implant (STI)|Insertion of a sinus tarsi implant (ProStop from Arthrex) in sinus tarsi
214979763|NCT01904890|BEHAVIORAL|Nutrition Education|Refer to Arm Description
214367717|NCT00454571|DRUG|pazopanib hydrochloride|Given PO
214979764|NCT02923700|BIOLOGICAL|Leukocyte-rich PRP intra-articular injections|
214979765|NCT02923700|BIOLOGICAL|Leukocyte-poor PRP intra-articular injections|
214979766|NCT03474796|BEHAVIORAL|Eye-tracking|Visualisation of 4 photographic scenarios (surgical situations), questionnaire, eye-tracking
214367718|NCT00454571|DRUG|leuprolide acetate|
214367719|NCT00454571|DRUG|goserelin acetate|
214367720|NCT01273025|DIETARY_SUPPLEMENT|Lime powder regime|1 sachet of lime powder regimen with 200 ml of water
214367721|NCT01398670|BIOLOGICAL|Insulin Lispro|"a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50~The drugs would be administered subcutaneously"
214367722|NCT01398670|BIOLOGICAL|Insulin Lispro|"Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50~The drugs would be administered subcutaneously"
214979767|NCT03045939|DEVICE|cervical ripening device|insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
214979768|NCT03372798|PROCEDURE|ICE/IVUS imaging during atrial fibrillation ablation|Intravascular ultrasound imaging of the left atrial wall thickness with ICE/IVUS during atrial fibrillation ablation
214979769|NCT00526422|PROCEDURE|Dental Preventive|
214979770|NCT04037124|PROCEDURE|Cervical procedure|simple hysterectomy, radical hysterectomy or fertility sparing surgery
215087278|NCT06570642|BEHAVIORAL|Physical Activity Goals mHealth Intervention|On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
215087279|NCT06570642|BEHAVIORAL|TYPE/CONTEXT enhancement|TYPE/CONTEXT augments intervention effects by providing tailored recommendations for activity types and contexts that satisfy personally-important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk will be used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm will then recommend the corresponding activity type or context while accounting for reported constraints (e.g., ability, access). These details will be incorporated into a tailored recommendation provided to participants each Sunday as they make activity plans for the upcoming week. Specifically, the program will randomly select either type or context (i.e., location, audio, social) recommendations and will rotate every two weeks. For TYPE, participants' top 3 activity types are recommended; for CONTEXT, participants' top 3 activity contexts are recommended.
215087280|NCT06570642|BEHAVIORAL|SAVOR enhancement|SAVOR implements a brief savoring exercise on the smartphone that takes place either after the planned physical activity session or during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer three open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty. Savoring prompts will rotate daily and have a day lag built in every week (i.e., Week 1 Monday Savoring Prompts are Week 2 Tuesday Savoring Prompts).
215087281|NCT04886986|DRUG|225Ac-J591|30 - 40 KBq/kg (dose-escalation) every 8 weeks, for up to 2 cycles. Administered together with 177Lu-PSMA-I\&T. Intravenous administration.
215087282|NCT04886986|DRUG|177Lu-PSMA-I&T|6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
215087283|NCT04886986|DRUG|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening, 12 weeks, 24 weeks. Imaging agent for PSMA PET/CT.
215087284|NCT05313529|DRUG|Liraglutide|Liraglutide will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study
215087285|NCT05313529|DRUG|Empagliflozin|Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
214367723|NCT01744886|PROCEDURE|maintain oxygenation during one lung ventilation|"All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.~If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung."
214979771|NCT03188055|OTHER|Best Case/Worst Case communication tool|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.~The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
214979772|NCT00623532|BEHAVIORAL|Mind-body exercises|
214979773|NCT00623532|BEHAVIORAL|Adapted Tai-chi|
215087286|NCT05313529|DRUG|Linagliptin|Iinagliptin will be initiated at 5mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
215087287|NCT05538988|DRUG|Cemiplimab|Cemiplimab is a recombinant human IgG monoclonal antibody known as a programmed cell death 1 (PD-1) immune checkpoint inhibitor. The PD-1 pathway is an immune system checkpoint that may be exploited by tumour cells to escape active T-cell surveillance. Cemiplimab binds to PD-1 on T cells and blocks the interaction with its ligands, PD-L1 and PD-L2. Inhibition of the receptor/ligand signaling restores the anti-tumour immune response
215087288|NCT05053841|DRUG|Metformin|
215087289|NCT06564896|DEVICE|CPAP Airsense 10 vs Air-Mini|Patients' satisfaction and CPAP efficacy
214680083|NCT06211504|PROCEDURE|Conventional surgery|MDCO - medial displacement calcaneal osteotomy FDL transfer - flexor digitorum longus tendon transfer to the navicular bone Spring ligament repair - reconstruction of the spring ligament Strayer's procedure - gastrocnemius recession (if necessary) Cotton osteotomy - medial cuneiform opening wedge osteotomy (if necessary)
214680084|NCT06176040|DRUG|TAVO101|TAVO101 IV Infusion.
214680085|NCT04925414|DRUG|oxygenotherapy|High concentration mask delivering 15L/min of oxygen
214680086|NCT04925414|DRUG|placebo air aerosol|High concentration mask delivering 15L/min of air
215087290|NCT05013268|DRUG|Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin|"* Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~* Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~* Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none"
215087291|NCT05063266|OTHER|Deep Breathing Exercise|control groups received deep breathing exercise 6 days a week for two weeks. Deep breathing exercises includes diaphragmatic breathing and pursed lip breathing.
215087292|NCT05063266|OTHER|Inspiratory muscle Training|Treatment group received inspiratory muscle training 20 minutes 6 days a week for two weeks.IMT was done by using pressure threshold device.
215087293|NCT00240110|DRUG|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
214979774|NCT03139552|OTHER|Apple Crisp|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of apple crisp in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
214979775|NCT03139552|OTHER|Tea|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of tea in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
214979776|NCT03139552|OTHER|Oatmeal|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe of oatmeal in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
214979777|NCT04512807|DIAGNOSTIC_TEST|AMH|AMH \& PREGNANCY
214979778|NCT04321577|PROCEDURE|Radical surgery|Radical surgery is proposed to participants with pT1b, pT2 or pT3 tumors in the cholecystectomy specimen without evidence of disseminated disease with staging imaging techniques. A resection of the gallbladder bed or an anatomic resection of the hepatic segments IVb/V is performed. A lymphadenectomy of the hepatic hilum is associated in all cases. Common bile duct resection is performed in patients with involvement of the cystic margin.
214979779|NCT01257347|BEHAVIORAL|Disclosure of adherence report to clinician|During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (\<10 minutes) in the interpretation and use of the report at the time of enrollment.
214979780|NCT01257347|DEVICE|MedSignals pillbox|(Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
214979781|NCT03204643|BEHAVIORAL|BH-VPN|A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
214979782|NCT01768325|DEVICE|EUS-TCB needle (QuickCore) standard of care|"* The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
215087294|NCT00240110|DRUG|Placebo|Control arm
215087295|NCT00240110|DRUG|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
215087296|NCT04872998|BEHAVIORAL|Step Count Reduction|Subjects reduce daily step counts by approximately 70% through monitoring and recording from step-count monitor
215087297|NCT00469326|DRUG|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
215087298|NCT06520007|DRUG|Doxycyclin|The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
215087299|NCT05611502|DEVICE|TMS|TMS will be administered in a pattern that is either excitatory or inhibitory.
215087300|NCT05467592|OTHER|Standard Physical Therapy care|All therapy will be given as it would have routinely been administered in the clinic. Standard care for all patients includes physical therapy and chiropractic treatment at each visit. There is a nurse practitioner on site. If necessary, patients can receive trigger point injections to the musculature around the back and neck, platelet rich plasma, or headache injections by the nurse practitioner. These interventions vary on a case by case basis. Involvement in the study will not impact the patients plan of care. We will collect this information as confounders and factor into statistical analysis.
215087301|NCT04638127|BEHAVIORAL|PREEMIE PROGRESS|PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).
215087302|NCT04638127|BEHAVIORAL|Attention Control|usual care and welcome videos
215087303|NCT02696993|PROCEDURE|Cognitive Assessment|Ancillary studies
214680087|NCT02835638|DEVICE|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
215087304|NCT02696993|BIOLOGICAL|Ipilimumab|Given IV
215087305|NCT02696993|OTHER|Laboratory Biomarker Analysis|Correlative studies
215087306|NCT02696993|BIOLOGICAL|Nivolumab|Given IV
215087307|NCT02696993|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214680088|NCT03736083|DEVICE|Freestyle Libre Blood Glucose Monitor|The intervention arm of this study will begin using the Freestyle Libre glucose monitor within 2 weeks of their diabetes diagnosis
214680089|NCT00057616|DRUG|CC-5013|
214367724|NCT03431402|DRUG|Hyperbaric oxygen|\- HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition
214367725|NCT02436811|BEHAVIORAL|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
214979783|NCT01768325|DEVICE|EUS-Guided biopsy needle (ProCore)|"* The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
214979784|NCT04260516|DRUG|N-acetyl cysteine|Mucolytic and antioxidant drug
214979785|NCT04381065|DEVICE|Personal KinetiGraph® (PKG®) System|"The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch~* Data-driven report known as the PKG®~The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® also provides an assessment of daytime somnolence and an indication of propensity for impulsive behaviors."
214492091|NCT06891378|OTHER|Intrevention group (mHealth group)|"1. Receive a customized rehabilitation exercise program after surgery and perform rehabilitation exercises while watching videos~2. Check recovery of shoulder joint range of motion~3. Write an exercise diary (check exercise schedule and post-exercise condition)~4. Check activity level through step count collection~5. Check exercise records and contact to confirm reason if exercise was not performed"
214979786|NCT04381065|DEVICE|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch"
214979787|NCT05023122|DIETARY_SUPPLEMENT|vitamin D3|vitamin D3 (cholecalciferol) 800 IU QD
214492092|NCT06891378|OTHER|control group (usual care)|"This group performs home rehabilitation exercises using in-hospital educational materials.~Control group data are retrospectively collected and matched using propensity score methods."
214492093|NCT06778603|DRUG|a targeted probe B7H3-IRDye800CW|B7H3-IRDye800CW was synthesized by conjugating IRDye800CW NHS Ester and Anti-B7H3 antibody.
214979788|NCT05023122|DIETARY_SUPPLEMENT|calcium|calcium citrate 600 mg QD
214979789|NCT00221013|PROCEDURE|"augmented CRRT regimen"|We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
214979790|NCT03604939|DIAGNOSTIC_TEST|Evaluation of social, cultural and behavioral factors|Evaluation of the social, cultural and behavioral factors that impact the uptake of the NCD prevention and control services among women, using the RARE methodology
214979791|NCT03604939|DIAGNOSTIC_TEST|Evaluation of the feasibility and acceptability of delivery of early detections services|Evaluation of the feasibility and acceptability of delivery of the NCD early detections services by the trained community health workers at home settings
214979792|NCT01820663|OTHER|Modified Atkins Diet|A high fat, high protein, low- carbohydrate diet
214979793|NCT01820663|OTHER|Control diet|The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
214979794|NCT03017222|DRUG|Ondansetron|Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.
214979795|NCT03017222|DRUG|Ramosetron|Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
214979796|NCT00261105|DRUG|telithromycin|
214979797|NCT05217030|OTHER|Animal assisted therapy|Patients in AAT group had handler place dog on bed and patient's hand was placed on dog. Bedside RN measured GCS, RLAS, LoCmds before and after intervention
214979798|NCT03035448|BEHAVIORAL|Questionnaires|"Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete."
214979799|NCT03035448|OTHER|Video Presentation|Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
214979800|NCT03307421|OTHER|debriefing without instructor|"The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.~The sequence of scenarios for each binomial will also be determined by randomization."
214979801|NCT03307421|OTHER|debriefing with instructor|The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.
214979802|NCT01984957|PROCEDURE|Muscle biopsy|open muscular biopsy of the deltoid under local anaesthesia
214979803|NCT03618875|OTHER|ice pack|ice pack was placed on eyelid 5 minutes prior to IVIT
214979804|NCT03618875|OTHER|room temperature pack|room temperature pack was placed on eyelid 5 minutes prior to IVIT
214367726|NCT02436811|BEHAVIORAL|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
214367727|NCT02436811|BEHAVIORAL|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
215087308|NCT02696993|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
214367728|NCT02471092|OTHER|Skim milk products|Milk treatments will be served with 58g of breakfast cereal.
214367729|NCT03595332|OTHER|Summer activity program|Children receive a summer scorecard to facilitate access to local facilities for exercise.
214367730|NCT02493400|OTHER|No intervention in the follow up study.|
214680090|NCT05456100|BEHAVIORAL|Expressive Helping|Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
214680091|NCT05456100|BEHAVIORAL|Expressive Writing|Expressive writing involves emotional disclosure writing over four weeks.
214680092|NCT05456100|BEHAVIORAL|Factual Writing|Factual writing involves writing facts about cancer treatment and experiences over four weeks.
214367731|NCT04770064|DRUG|High-dose/short-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take approximately 20 mg/kg of body mass for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration.
214680093|NCT00511082|DRUG|OPB-31121|100-mg tablet Dose: OPB-31121 50, 100, 200, 400, 600, 800, and 1000 mg Dosage regimen: ingestion with water after breakfast Treatment period: 4 weeks Mode of Administration: oral administration of OPB-31121 once daily
214680094|NCT03249350|BEHAVIORAL|Standard Contingency Management (CM)|"CM utilizes behavior modification \& cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
214680095|NCT03249350|BEHAVIORAL|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
214680096|NCT06004115|DRUG|Lorazepam|1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form
214680097|NCT06004115|OTHER|Placebo|placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form
214680098|NCT02631187|DEVICE|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
214680099|NCT01776268|OTHER|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
214680100|NCT04057963|OTHER|Conventional plus Functional Inspiratory Muscle Training Group|functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.
214680101|NCT04057963|OTHER|Conventional Physiotherapy Program|conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
214680102|NCT06404008|BEHAVIORAL|REST|After randomization, individuals will attend an in-person training session in the REST protocol. This is a 15 minute controlled breath protocol that includes 3 yoga breathing techniques: 3-part dirgha breath, alternate nostril breathing, and 2:1 breathing. Each technique will be completed for 5 minutes, for a total of 15 minutes. After the training session, participants will practice the REST protocol for 15 minutes twice a day with guidance from research staff over zoom (Days 1-7) with daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and exacerbation education. On Day 8, participants will attend the Trial Session where they will complete the REST protocol (15 minutes) while vitals, lung function, and ECG measurements are taken. Surveys will be administered before and after the REST protocol to document patient reported stress and dyspnea.
214680103|NCT06404008|OTHER|Education|After randomization, individuals will attend an in-person education session led by a research coordinator. For the following 7 days, the research staff will call patients daily and provide daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and COPD exacerbation education. On Day 8, participants will attend the Trial Session where they will do spontaneous breathing (15 minutes) while vitals, lung function, and EKG measurements are taken. Surveys will be administered before and after the spontaneous breathing period to document patient reported stress and dyspnea. After the study, participants will be asked to complete a close out survey and interview over zoom.
214979805|NCT03748134|BIOLOGICAL|Sintilimab|For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
214979806|NCT03748134|DRUG|Cisplatin|75mg/m\^2 IV Q3W day 1
214979807|NCT03748134|DRUG|Paclitaxel|87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle
214979808|NCT03748134|DRUG|Fluorouracil|800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
214979809|NCT03748134|DRUG|Placebo|For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
214979810|NCT05859607|PROCEDURE|laparoscopic cholecystectomy|conventional laparoscopic cholecystectomy with calculation of difficulty scorings
214979811|NCT03380286|DEVICE|Firehawk|Firehawk stent
214979812|NCT05994547|DRUG|Byfavo|For induction and maintenance of sedation
214367732|NCT04770064|DRUG|Low-dose/sustained-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take one, 100 mg capsule of fisetin daily for 90 days.
214367733|NCT04770064|OTHER|Oral placebo capsule|Participants will be asked to take one, 100 mg oral placebo capsule (corn starch) daily for 90 days.
214367734|NCT04110002|BEHAVIORAL|Injury Prevention Program|
214492094|NCT06839833|DIAGNOSTIC_TEST|APOL1 Genotyping|The APOL1 Genotyping CTA will identify individuals who are homozygous or compound heterozygous for apolipoprotein L1 (APOL1) high-risk genotypes (G1 and G2). The individuals who are identified as being homozygous or compound heterozygous for the APOL1 high-risk genotypes are candidates for enrolment onto an pharmaceutical company-sponsored, Phase 2b clinical trial which is investigating the safety and efficacy of a synthetic antisense oligonucleotide (ASO) for the treatment of APOL1-mediated kidney disease (AMKD).
214492095|NCT06764420|DIETARY_SUPPLEMENT|Glutamine Oral Suspension|Participants in this group will receive an oral suspension containing 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. This control intervention serves to compare the effects of glutamine alone with the combined arginine and glutamine treatment. In addition to the glutamine suspension, patients in this group will receive general measures and analgesic drugs according to the WHO scale to manage symptoms of mucositis.
214680104|NCT05533554|BEHAVIORAL|Brief Intervention Based on the Theory of Planned Behavior to Reduce Alcohol Consumption in University Students|Cognitive-behavioral intervention where the key concepts of the Theory of Planned Behavior were operationalized from which two intervention sessions were formed and the most appropriate techniques were chosen to influence the key concepts of the theory: behavioral beliefs, subjective norms, perceived behavioral control and self-efficacy. The program is made up of 3 evaluation sessions (pre and post a month later) and 2 intervention sessions with a duration of 120 minutes each.
214680105|NCT01388010|OTHER|1-Fermented Probiotic Dairy Product (test)|
214680106|NCT01388010|OTHER|2-Milk-based non-fermented dairy product(control)|
214680107|NCT05994651|BEHAVIORAL|Tidal Model improvement model|"1. st interview Pre-assessment Application of measurement tools~2. nd meeting Orientation Concept of recovery, change phase of the individual, Holistic Evaluation, Creation of Personal Safety Plan 3. Interview Process planning Setting goals, Starting One-on-One Sessions~4th meeting Healing is possible, accepting his illness, overcoming change, emphasizing his strengths, instilling hope 5.-6. interview Empowerment Coping with crisis, reducing anxiety, relaxation exercises, individual roles, assertiveness, strengthening self-esteem 7.-8. Interview Maintaining control of life, taking responsibility for behavior, appropriate expression of anger, feeling, thinking and Taking responsibility for recovery, discovering behaviors 9th interview Creating a supportive environment Increasing new interactions, relationships, social skills 10th meeting Evaluation Finalizing the personal security plan, using new knowledge and behaviors in the healing journey, evaluation of the process"
214680108|NCT00988962|BEHAVIORAL|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
214680109|NCT01188798|DRUG|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
214680110|NCT01188798|DRUG|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
214680111|NCT00611130|DRUG|vigabatrin|Tablets twice a day for 9 weeks
214680112|NCT00611130|DRUG|placebo|tablets twice daily for 9 weeks
214680113|NCT06208709|DEVICE|carpal arch space augmentation (CASA)|A BOA brace with a balloon that is affixed internally. The device applies a small cyclic force of to the wrist. The cycles include a brief period of force applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep.
214680114|NCT06208709|DEVICE|standard of care (SOC)|A BOA brace that can be adjusted to the arm of the participant.
214680115|NCT02795767|DRUG|Emicizumab|Emicizumab will be administered as per the schedule specified in the respective arm.
214680116|NCT00999752|DRUG|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
214680117|NCT00999752|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
214680118|NCT01571674|PROCEDURE|Manipulation + Exercise Group|"First 2 sessions~* High-velocity, low-amplitude manipulations to the thoracic spine.~* Low-velocity mid to end-range mobilizations to the cervical spine.~* Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
214680119|NCT01571674|PROCEDURE|Exercise Group|"First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
214367735|NCT06320886|DIAGNOSTIC_TEST|Diagnostic Test|Use both ultrasonography and Computed tomography scan to diagnose the causes of Acute Abdominal Pain in Adults.
214367736|NCT01804101|OTHER|Laboratory Biomarker Analysis|Correlative studies
214367737|NCT01804101|DRUG|Liposomal Cytarabine-Daunorubicin CPX-351|Given IV
214367738|NCT00656604|GENETIC|proteomic profiling|at the time of each procedure.
214367739|NCT00656604|PROCEDURE|lumpectomy or mastectomy|removal of breast tumor or removal of the entire breast in which the tumor is located
214367740|NCT00656604|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Prior to initiation of treatment
214680120|NCT04490954|DEVICE|brain biological electrical impedance tomography|Patients diagnosed with brain supratentorial tumors through MRI/CT are evaluated with brain biological electrical impedance tomography. And the brain biological electrical impedance tomography is used to monitor the cerebral edema situation of patients with brain edema
214680121|NCT04490954|DEVICE|MRI/CT|Patients diagnosed with brain supratentorial tumors through MRI/CT
214979813|NCT05994547|DRUG|Midazolam|For induction and maintenance of sedation
214979814|NCT05371561|DEVICE|reusable respirators|Dentist wearing reusable respirator will examin the patient
214979815|NCT04321772|OTHER|High Intensity Interval Resistance Training|Subjects trained one leg with HIIRT
214979816|NCT04321772|OTHER|Traditional Resistance Training|Subjects trained the other leg with HIIRT
215087309|NCT02654236|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
214367741|NCT00656604|PROCEDURE|histopathologic examination|After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer
215087310|NCT02654236|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
215087311|NCT02247180|BEHAVIORAL|cognitive rehabilitation|
215087312|NCT02247180|BEHAVIORAL|standardized cognitive training|
215087313|NCT05192213|DRUG|Vitamin C|Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
215087314|NCT05192213|OTHER|Placebo|Patients will receive 2 placebos (every 6 hours and every 12 hours) + Hydrocortisone (50 mg every 6 hours) for 7 days.
215087315|NCT06265623|OTHER|No active intervention, but observational follow-up|Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years
214367742|NCT00656604|PROCEDURE|magnetic resonance spectroscopy|Prior to initiation of treatment
214367743|NCT04833764|DRUG|Rosuvastatin|Oral administration of 20 mg rosuvastatin for at least 3 months
214367744|NCT04906525|BEHAVIORAL|Resistance training|Participants will undergo 6 weeks of supervised resistance training
214367745|NCT04906525|OTHER|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
214367746|NCT03786861|PROCEDURE|corneal WFG group|TransPRK using ESIRIS flying spot excimer laser system (SCHWIND AMARIS®500E, SCHWIND eye-tech-solutions, Kleinhostheim, Germany), with 500 Hz repetition rate for faster treatments and scanning spots and with smart pulse technology. Eye-tracking during laser ablation was achieved using a 1050 Hz infrared eye tracker centered on the pupil. Static cyclotorsion control (SCC) compensation was obtained for all patients in corneal WFG group.
214367747|NCT03786861|PROCEDURE|aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free patterns provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
214367748|NCT03257332|PROCEDURE|Low Anterior Resection for Rectum Cancer|Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
214367749|NCT01201811|DRUG|Azacitidine|Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
214367750|NCT02718703|DEVICE|Blood Glucose Monitoring System.|In vitro diagnostic medical device
214367751|NCT00117676|DRUG|TDF|300 mg tablet administered orally once daily
214367752|NCT00117676|DRUG|ADV|10 mg tablet administered orally once daily
214367753|NCT00117676|DRUG|TDF placebo|Tablet administered orally once daily
214367754|NCT00117676|DRUG|ADV placebo|Tablet administered orally once daily
214367755|NCT00117676|DRUG|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
214367756|NCT00952822|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
214367757|NCT01715974|DRUG|GM-CSF group|30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test
214367758|NCT01715974|DRUG|CONTROL|saline infusion every day from the day of embryo transfer through the day of beta HCG test
214367759|NCT02643862|DRUG|Xolair|Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria
215087316|NCT03814434|PROCEDURE|Non-Surgical treatment|Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation
215087317|NCT03814434|PROCEDURE|Surgical Treatment|Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
215087318|NCT00869830|OTHER|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
215087319|NCT01655147|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
215087320|NCT01655147|DRUG|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
215087321|NCT06507800|OTHER|Observational cohort|Cancer incidence after AHSCT for an autoimmune indication.
215087322|NCT04788862|BIOLOGICAL|P. falciparum infected erythrocytes|Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.
215087323|NCT06303245|OTHER|ABDOMINAL BINDERS|will be given abdominal binders along with basic physiotherapy care. Physiotherapy care will include sitting exercises such as deep breathing exercises, protected huffing technique will be performed to improve gases exchange and remove secretion. In supine exercises such as basic ROM, ankle pumps, pelvic rolling, leg sliding will be performed. Each exercise will be of 10 repetition. This exercise will be given for 2 days per week for 6 weeks. Along with these exercises education related postural management and breastfeeding positions will also be guided
215094523|NCT06110455|OTHER|Hip and Knee Muscular Strength exercises|The 8 week exercise intervention consists of 25 minute group sessions of progressive resistance training, supervised by a physical therapist.
215094524|NCT01632644|OTHER|Survey/Interview|Each group will be surveyed and interviewed.
215094525|NCT01207245|OTHER|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
214367760|NCT02643862|DRUG|Placebo|Placebo
215094526|NCT06316440|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
215087324|NCT06303245|OTHER|TENS|will receive TENS with high frequency (F=100Hz and T=100μs), intensity according to patient's pain threshold, duration of 30 continuous minutes, 2 cm above and below incision, with electrodes transversally positioned and crossing the incision. Two treatment sessions will be done per week for the period of 6 weeks. This group will be given tens along with abdominal binders with basic physiotherapy care. (23) In this treatment female's abdomen will be measured by a standard inch tape, then, according to the abdominal circumference, the binder will be fastened for 6 weeks. The binder will be placed tightly at the lower abdominal level with the incision positioned at the middle part of the binder. Participants will be asked to note the time to record the duration of binder wearing before taking the break. The binder will be opened between 10 pm and 8 am. This group will be given abdominal binders along with basic physiotherapy care
214367761|NCT04284449|OTHER|Whole-practice cognitive optimization|This intervention is a whole-practice intervention that may include nutritional assessment \& supplementation, determination of food sensitivities and dietary changes, natural products such as herbal anti-inflammatories, assessment of whole body-burden of toxicants (such as heavy metals and fungal toxins) and steps to reduce exposures, and behavioral changes such as exercise, meditation, and sleep hygiene optimization.
214680122|NCT01949493|DEVICE|mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
214680123|NCT01949493|OTHER|Care as usual|Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
214680124|NCT01450371|DEVICE|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
214680125|NCT01450371|DEVICE|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
214680126|NCT04263922|DRUG|Huaiqihuang granules|Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
214680127|NCT04263922|DRUG|Valsartan capsule|Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
214680128|NCT02553915|OTHER|Placebo|Soybean oil placebo
214680129|NCT02553915|DRUG|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
214680130|NCT02553915|DRUG|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
214680131|NCT02553915|DRUG|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
214680132|NCT00199186|DRUG|imatinib|
214680133|NCT00199186|DRUG|vincristine|
214680134|NCT00199186|DRUG|cyclophosphamide|
214680135|NCT00199186|DRUG|cytosine arabinoside|
214680136|NCT00199186|DRUG|dexamethasone|
214680137|NCT00199186|DRUG|idarubicin|
214680138|NCT00199186|DRUG|methotrexate (intrathecal)|
214680139|NCT00199186|DRUG|AraC (intrathecal)|
214680140|NCT00199186|DRUG|dexamethasone (intrathecal)|
214680141|NCT04722133|DRUG|HERZUMA+mFOLFOX|Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
214680142|NCT02947139|DRUG|Co-administration of DWC20155/DWC20156|
214680143|NCT02947139|DRUG|DWC20161|
214680144|NCT00233636|DRUG|Iressa (Gefitinib)|
214680145|NCT00233636|PROCEDURE|Radiotherapy|
214680146|NCT03061968|BEHAVIORAL|acupressure|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
214680147|NCT01564654|DEVICE|iTotal KRS|Total Knee Replacement System
214680148|NCT01016483|DRUG|Pimasertib|
214680149|NCT01016483|DRUG|Gemcitabine|
214680150|NCT01016483|DRUG|Placebo|
214680151|NCT02192710|PROCEDURE|electronic tab|classic use of an electronic tab with age specific games
214680152|NCT02192710|DRUG|Midazolam oral intake|
214680153|NCT01379443|OTHER|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
214680154|NCT06269211|DRUG|Toripalimab|240mg IV, Q3W
214680155|NCT02805088|OTHER|Electroencephalographic recordings|
214680156|NCT02805088|OTHER|neuropsychological evaluation|
214680157|NCT02805088|OTHER|clinical evaluation of symptoms|
214680158|NCT02295098|OTHER|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
214680159|NCT02295098|OTHER|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
214680160|NCT01294254|DRUG|Oleogel-S10|Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
214680161|NCT01294254|PROCEDURE|Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site|wound is covered conventionally by applying one half of the Mepilex cut
214680162|NCT03288584|DRUG|Tocilizumab (Actemra®)|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
214680163|NCT03288584|DRUG|Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
214680164|NCT03288584|DRUG|Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
214680165|NCT00614003|BEHAVIORAL|Decision support skills building Intervention|Decision support skills
214979817|NCT01492348|BEHAVIORAL|STEPS UP|"The STEPS UP intervention enhances RESPECT-Mil in several ways:~1. Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.~2. Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, \& primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.~3. Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.~4. Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components."
214979818|NCT01492348|BEHAVIORAL|OUC|"Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist."
214979819|NCT02247466|DRUG|Rocuronium and Sugammadex|
214979820|NCT02001571|DRUG|Abiraterone acetate|On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
214979821|NCT03242317|DRUG|Mitomycin C|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
214979822|NCT03242317|DEVICE|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
214979823|NCT06188117|OTHER|'Digital Game Addiction Awareness Training'|"Experimental Group The 'Digital Game Addiction Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.~The training program will be implemented in line with the headings 'Digital Game Addiction Definition, Diagnostic Criteria, Frequency, Symptoms, Physical, Psychological and Social Problems Caused by Excessive Digital Game Playing, Recommendations for Parents to Prevent Digital Game Addiction'."
214979824|NCT01618968|DRUG|MTX|"* Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~* Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~* Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)"
214979825|NCT05794815|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
214979826|NCT05794815|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
214979827|NCT00456872|DRUG|lidocaine|
214979828|NCT04000178|DEVICE|polyurethane stent|patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
214979829|NCT04000178|DEVICE|silicone stent|silicone stent
215087325|NCT03137628|OTHER|colectomy, GA and MV|"general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance \[sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h\].~mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5."
214680166|NCT05908383|DRUG|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
214979830|NCT00144599|DRUG|MRA(Tocilizumab)|
214979831|NCT00144599|DRUG|placebo|
214979832|NCT01039766|DRUG|Oxytocin|A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
214979833|NCT01039766|DRUG|placebo - saline nasal spray|A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
214979834|NCT01259947|DRUG|Lippia alba (Mill.) N. E. Brown ethanolic extract|1-2 drops per kilogram per day, PO, twice a day
214979835|NCT04347772|DIETARY_SUPPLEMENT|Oral Nutrition Support|Intensive Nutrition Intervention
214979836|NCT05637034|DIAGNOSTIC_TEST|68Ga-DOTA-F2 PET/CT and 18F-FDG|Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
214979837|NCT02821494|BIOLOGICAL|Hespecta|A dose escalation of Amplivant® conjugated peptide
215087326|NCT03204890|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
215087327|NCT03925051|DRUG|Prolia®|mAb targeting RANKL. human monoclonal antibody targeting RANKL.
215087328|NCT03925051|DRUG|CMAB807|human monoclonal antibody targeting RANKL.
215087329|NCT05713539|OTHER|Metal block|Small sheet of copper will be used when cooled to the designated temperature
214979838|NCT05652127|OTHER|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14
215087330|NCT03168360|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
215087331|NCT00536952|DRUG|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
215087332|NCT00536952|DRUG|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
215087333|NCT00536952|RADIATION|Radiation Therapy|5 days per week for 4 weeks
214680167|NCT05908383|OTHER|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
214367762|NCT06222216|OTHER|Chilled Needle|Before subcutaneous injection, 26G sterile disposable needles will be kept in the refrigerated compartment of the refrigerator for at least 24 hours. Immediately before SC injection, the needle will be removed from the refrigerator, placed in the ice box and placed next to the patient's bed. The needle temperature will be kept at 0-2 degrees Celsius in the ice box and controlled using an LCD digital thermometer. If Enoxaparin Sodium is in the ready injector, the drug in the injector will be drawn into the injector suitable for 1 cc SC injection application without loss of dose. The needle of the prepared syringe will be replaced with a cooled needle. Afterwards, the injection will be made in the designated area (outer side of the upper arm) in accordance with the SC injection procedure steps. After the injection, the patient's pain assessment will be made and marked on the ILC, and ecchymosis assessment will be made after 24, 48 and 72 hours.
214492096|NCT06764420|DIETARY_SUPPLEMENT|Arginine and Glutamine Oral Suspension|Participants in this group will receive an oral suspension containing 5 grams of arginine and 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. The swish and swallow technique involves patients swishing the solution around the oral mucosa to ensure even distribution before swallowing. This intervention aims to evaluate the combined effect of arginine and glutamine on reducing the severity of radiation-induced mucositis, improving mucosal healing, and providing symptomatic relief.
214680168|NCT00287833|OTHER|placebo|Given orally
214680169|NCT00287833|DRUG|Bowman-Birk inhibitor concentrate|Given orally
215087334|NCT02763436|PROCEDURE|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
215087335|NCT01549873|DRUG|propofol|Propofol adjusted to maintain the bispectral index at 40-60.
215087336|NCT01549873|DRUG|Desflurane|Desflurane adjusted to maintain the bispectral index at 40-60.
215087337|NCT02048410|DIETARY_SUPPLEMENT|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
215087338|NCT02048410|OTHER|low satured diet|
215087339|NCT04097977|OTHER|An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work) targeting young people with mental health difficulties.|"An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work).~Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group.~Network meetings The RENEW-S network meetings is fundamental for this approach. First meeting between the young person and the facilitator is about what the young person can expect, and information about the principles and ideas behind RENEW-S. The RENEW-S process consists of 4 general phases: 1) a mapping process 2) the development of a team to support goal attainment 3) implementing the plans 4) preparation for exiting RENEW.~Youth group The group is structured around the same agenda each time, starting with a presentation round, followed by an activity within the topic of the day, and finishing with sharing experiences of the activity in plenum. The young people can find inspiration regarding themes and exercises in the RENEW manual."
214680170|NCT02896426|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
214979839|NCT02952651|PROCEDURE|Pulse oximeter|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
214979840|NCT04778852|DEVICE|Experimental: EksoGT|EksoGT is an overground wearable gait trainer. The therapy will be carried out 3 days a week for 4 weeks.
215087340|NCT03330184|DRUG|Berberine Hydrochloride group|
215087341|NCT03330184|DRUG|Bifidobacterium group|
215087342|NCT03330184|DRUG|Berberine Hydrochloride and Bifidobacterium group|
215087343|NCT03330184|DRUG|placebo|
215087344|NCT02623504|DRUG|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
215087345|NCT02623504|DRUG|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
215087346|NCT03247127|RADIATION|Hippocampal avoidance whole brain radiotherapy|Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
215087347|NCT05205655|BEHAVIORAL|collection of odour samples|Odours will be collected by participants by putting sterile compresses under the armpits for at least 4 h.
215087348|NCT00480389|DRUG|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
215087349|NCT01107613|BEHAVIORAL|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
215087350|NCT00885794|DRUG|Ranibizumab|3 intravitreal injection every 5 weeks
215087351|NCT02239146|DRUG|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
214367763|NCT06222216|OTHER|Control Group|SC injection will be administered to the control group in accordance with the clinical routine. No different action will be applied. The injection will be made in accordance with the SC injection protocol with a needle at room temperature, without applying any tools or procedures. After the injection, the patient's pain will be evaluated and marked on the VAS, and ecchymosis will be evaluated after 24, 48 and 72 hours.
214367764|NCT03264651|DRUG|enobosarm|Oral combination therapy of enobosarm and anastrozole
214680171|NCT02896426|BEHAVIORAL|Positive Solutions For Families|Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
214680172|NCT04209868|DRUG|Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection|As per arm description
214979841|NCT04778852|OTHER|Functional kinematic training|Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
214979842|NCT05359471|DEVICE|Bone densitometry|It is the standard method for diagnosing osteoporosis. In the central DXA examination, which measures bone density of the hip and spine, the patient lies on a padded table.
214979843|NCT05359471|OTHER|Questionnaires|Smoking and drug related questionnaires will be used as variable to see dependence, how it impacts participants activities/health or determining whether they are light/moderate/heavy smoker
214979844|NCT05359471|DEVICE|Review of medical chart|History of previous liver diseases including hepatitis B, C, and HIV
214979845|NCT00721799|DRUG|18F-Fluorothymidine PET scan|18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
214979846|NCT03342729|BEHAVIORAL|Intervention|Participants receive the AMP 10-week program immediately
214979847|NCT03342729|BEHAVIORAL|Control|Participants will not received the AMP 10-week program immediately, rather will wait 3-months
214979848|NCT05383742|DRUG|Rifampicin (RIF)|Rifampicin 35 mg/kg
214979849|NCT05383742|DRUG|Isoniazid (INH)|Isoniazid 10 or15 mg/kg
214979850|NCT05383742|DRUG|Linezolid (LZD)|1200 mg
214979851|NCT05383742|DRUG|Pyrazinamide (PZA)|25 mg/kg
214979852|NCT05383742|DRUG|ethambutol (EMB)|20 mg/kg
214979853|NCT05383742|DRUG|Rifampicin|10 mg/kg
215087352|NCT02239146|DRUG|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
215087353|NCT03769311|DRUG|Cetuximab|Monoclonal antibody against epidermal growth factor receptor (EGFR)
214367765|NCT05809206|OTHER|Glutes maximus strength protocol|"The subjects attended physical therapy two times. Per week for a total of 10 visits. Each session lasted approximately 30 minutes. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) were added. Each exercise was performed for 10 repetitions. Elastic resistance was added to the fire hydrant, hip extension in prone and dead lift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
214680173|NCT04209868|DRUG|0.9% Sodium Chloride 20mL Injection|As per arm description
214680174|NCT04558645|OTHER|Online Survey|Online surveys will be applied to all participants
214680175|NCT02083445|OTHER|cognitive activities|Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
214979854|NCT05383742|DRUG|Isoniazid|5 mg/kg
214979855|NCT01845779|DRUG|DCF regimen|
214979856|NCT04865588|PROCEDURE|rotational atherectomy|angioplasty with rotational atherectomy - a rotating instrument used to break up the calcification
214979857|NCT04865588|DEVICE|cutting balloon|a balloon with microsurgical blades on its outer surface which make longitudinal incisions in the calcified area in order to open resistant clogs
214979858|NCT04865588|DEVICE|plain old balloon|current standard treatment of stent placement
214979859|NCT03573037|DRUG|Oral anticoagulant|1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
214979860|NCT01776970|DRUG|Cannabis Sativa extract Oromucosal spray|Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
214979861|NCT02031523|DRUG|Sanjie analgesic capsule|Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
215087354|NCT05811117|DIAGNOSTIC_TEST|There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.|We will study patients that undergo autopsy after CAR T cell infusion.
215087355|NCT05518708|DRUG|BI 3032950|BI 3032950
215087356|NCT05518708|DRUG|Placebo|Placebo
215087357|NCT01263145|DRUG|Akt Inhibitor MK2206|Given PO
215087358|NCT01263145|OTHER|Laboratory Biomarker Analysis|Correlative studies
215087359|NCT01263145|DRUG|Paclitaxel|Given IV
215087360|NCT01263145|OTHER|Pharmacological Study|Correlative studies
215087361|NCT00465140|DRUG|creatine supplementation|
215087362|NCT00465140|BEHAVIORAL|aerobic exercise training|
215087363|NCT04897763|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
214367766|NCT05809206|OTHER|Gluteus medius strength program|"Strengthening exercises for Gluteus Medius subdivisions:~The anterior GMED exercise: side lying abduction exercise The middle GMED exercise: wall press Exercise The posterior GMED exercise: was the pelvic drop exercise"
214367767|NCT05809206|OTHER|Corrective Exercises|"The following low back corrective exercises were given:~To stretch the tight lower back muscles: Seated Forward Bend and Full Squat held for 5 sec and Repeated for 3 times, once a day.~To strengthen the weak lower abdomen: Draw in and Reverse Crunch 3 seconds, repeated 5 times, once a day.~To stretch the tight hip flexors: held for 10-15 seconds repeated 5 times on both legs, once a day.~To stretch the tight quadriceps: held for 3 seconds, repeated 5 times on each side, once a day.~To strengthen weak hamstrings: Kick Butts 2 sec, repeated 8 times, once a day."
215087364|NCT01133119|DRUG|Standard of Care|Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
215087365|NCT01133119|DRUG|Standard of Care plus bupivacaine|"Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.~Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician."
214367768|NCT05809206|DEVICE|Ultrasound|US was administered in continuous mode at PSIS with patient in prone lying position, with a frequency of 1 MHz and intensity of 0.8 W/cm2 for 5 minutes every alternating day
214367769|NCT05742828|BEHAVIORAL|Virtual Seating Coach|Power wheelchair intervention
214979862|NCT02031523|DRUG|placebo|oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
214979863|NCT00143338|DRUG|Inhaled insulin|
214979864|NCT01890655|DRUG|MT-1303-Low|
214979865|NCT01890655|DRUG|MT-1303-Middle|
215087366|NCT00175409|PROCEDURE|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
215087367|NCT00175409|PROCEDURE|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
215087368|NCT06263322|BEHAVIORAL|Actionable remotely generated health data|Remotely captured, patient generated health data will be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
215087369|NCT06263322|BEHAVIORAL|Non-Actionable remotely generated health data|Remotely captured, patient generated health data is captured, but will not be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
214367770|NCT01040702|DRUG|methylphenidate|a single doses of 10-20 mg in each one of two visits
214367771|NCT01040702|DIETARY_SUPPLEMENT|sweetener pill|a capsule containing a sweetener pill
214367772|NCT02577055|PROCEDURE|myomectomy|Surgical ablation of all fibroids
214367773|NCT02577055|PROCEDURE|embolisation|Embolisation of the peri-myoma vascular network, with non-resorbable particles of \>500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.
214367774|NCT02621580|DEVICE|Pan-Retinal Photocoagulation|"Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.~During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment."
215087370|NCT05710133|OTHER|food|alectinib-d6 will be administered with breakfast on day 1 to determine the food-effect
215087371|NCT05710133|OTHER|fast|alectinib-d6 will be administered after an overnight fast of minimal 10 hours on day 9 to determine the food-effect
215087372|NCT05991232|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
215087373|NCT06962163|DIAGNOSTIC_TEST|[68Ga]Ga-PentixaFor PET/CT|\[68Ga\]Ga-PentixaFor PET-CT is performed after patient inclusion. The patient is treated as per standard of care until disease progression. Then another \[68Ga\]Ga-PentixaFor PET-CT is performed.
214492097|NCT06802952|DEVICE|rTMS|RTMS using pseudo stimulus intervention in weeks 1-2, for a total of 10 days. After resting for 2 weeks, enter the 3-4 weeks of real stimulation, with 5 days of intervention per week for a total of 10 days. Application of rTMS for 1Hz low-frequency intervention, with intervention parameters of 1400 sessions, 100% exercise threshold, and a total of 23 minutes per session. After each target intervention, rest for half an hour to one hour.
214492098|NCT06791837|BEHAVIORAL|EXERCISE|each group will undergo a max test and a submaximal exercise test
214492099|NCT06839014|OTHER|Exercise|Perform 30 minutes of TENS unit exercise muscle stimulation each day for 3 days a week for the duration of cancer treatment.
214492100|NCT06430684|DRUG|Empagliflozin 10 MG|Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older
214979866|NCT01890655|DRUG|MT-1303-High|
214979867|NCT02823353|DRUG|Fenofibrate|Fenofibrate 200mg/day
214979868|NCT02823353|DRUG|UDCA|UDCA 13-15mg/kg/day
214979869|NCT02664142|PROCEDURE|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
215087374|NCT05740124|BEHAVIORAL|slip recovery training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after slipping.
215087375|NCT05740124|BEHAVIORAL|alternative balance training|Participants practice standing and walking under varied sensory conditions.
215087376|NCT05055518|DRUG|APL-102 Capsules|"Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102."
215087377|NCT05996471|BIOLOGICAL|VH3810109|VH3810109 will be administered.
215087378|NCT05996471|DRUG|Cabotegravir|Cabotegravir will be administered.
215087379|NCT05996471|DRUG|Standard of care (SOC)|Pre-baseline SOC antiretroviral therapy (ART) will be administered.
215087380|NCT05996471|BIOLOGICAL|rHuPH20|rHuPH20 will be administered.
215087381|NCT03635164|DRUG|Durvalumab|Patients will receive one dose of neoadjuvant durvalumab 1500 mg approximately 3-6 weeks prior to standard of care surgery. It will be given concurrently with the first dose of radiation (RT). Patients will receive up to six doses of durvalumab and radiation post-operatively.
215087382|NCT03635164|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting RT dose level will be given as 6 Gy for 2 fractions (12 Gy total) every other day over approximately one week to sites of gross disease only to minimize exposure to normal tissue. If toxicity develops and surgery is delayed by more than 8 weeks (qualifying as a DLT), the radiation dose will be dropped per protocol for the next set of patients. If this dose is tolerated, the dose will be increased to 6 Gy for 3 fractions (18 Gy total) for the next 3 patients.
214367775|NCT03072940|OTHER|Clinical investigations|Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging
214367776|NCT01296022|DEVICE|Implantation of subcutaneous ICD|Implantation of subcutaneous ICD
214979870|NCT02664142|PROCEDURE|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
214979871|NCT02664142|DRUG|Anaesthetics|Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
214979872|NCT03720678|DRUG|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
214979873|NCT03720678|DRUG|mFOLFOX|Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
214979874|NCT02559037|DEVICE|Acupuncture and moxibustion|"Acupuncture acupoints: CV12, bilateral ST36, ST37, SP6, SP9, SP4, LR3 and LI3. Disposable acupuncture auxiliary device and 0.30\*40mm or 0.30\*25mm acupuncture needles (hwato, suzhou medical supplies factory co., LTD.) were used. The needles were directly inserted 20-30mm into the skin and elicited a de-qi sensation. The needle was kept for 30 min.~Moxibustion acupoints: bilateral ST25 and ST36. Using mild-warm moxibustion, The surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint. Moxibustion and acupuncture were performed at the same time, once every other day, three times a week, a total of 12 weeks of treatment. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
214979875|NCT02559037|DEVICE|Sham acupuncture and moxibustion|"The acupoints used are same to the experimental group. Same disposable acupuncture auxiliary device and 0.35 \* 40mm acupuncture needle (flat and blunt needle tip, Hwato, Suzhou Medical Supplies Factory Co., Ltd.) was selected. When the needle was pricked to the acupoint, it did not penetrating into the skin. The subject only felt slight pain and do not have the de-qi sensation.~Sham moxibustion : by using the same moxa stick, The surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint. Sham acupuncture and sham moxibustion were performed at the same time. They were treated once every other day, three times a week, a total of 12 weeks. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
214979876|NCT02091700|OTHER|Indocyanine Green ICG|
214979877|NCT04356937|DRUG|Tocilizumab|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"
214979878|NCT04356937|DRUG|Placebos|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"
214979879|NCT01331317|DRUG|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
214979880|NCT03533751|BIOLOGICAL|Etokimab|Humanized monoclonal antibody, administered by subcutaneous injection
214979881|NCT03533751|DRUG|Placebo|Administered by subcutaneous injection
214979882|NCT02028598|DRUG|Treatment 1|An oral single dose administration
214979883|NCT02028598|DRUG|Treatment 2|An oral single dose administration
214979884|NCT02028598|DRUG|Treatment 3|Co-administration of oral single doses
214979885|NCT05252637|PROCEDURE|Laparoscopic Fascial Posterior Vagina Duplication|Laparoscopic Fascial Posterior Vagina Duplication with absorbable sutures for posterior prolapse (plus standard Sacral Colpopexy)
214367777|NCT01296022|DEVICE|Implantation of transvenous ICD|Implantation of transvenous ICD
214367778|NCT04332510|OTHER|Intact formula|600 ml of infant formula with intact protein
214367779|NCT04332510|OTHER|Partially hydrolyzed formula|600 ml of infant formula with partially hydrolyzed protein
214367780|NCT04332510|OTHER|High protein formula|600 ml of infant formula with high protein level
214367781|NCT04332510|OTHER|Human breast milk|600 ml of breast milk, safe for human consumption
214367782|NCT05547425|DEVICE|Blur Obfuscation|Blurring is applied to objects and people in the background of images.
214367783|NCT05547425|DEVICE|Edge Obfuscation|Objects and people in the background of images are replaced with an outline of the object.
214492101|NCT06565442|DEVICE|NeuraSignal transcranial doppler robot|measure cerebral blood flow correlated with arterial blood pressure to generate individualized cerebral autoregulatory curves
215087383|NCT03635164|PROCEDURE|Standard of Care Therapy|Patients will proceed to surgical resection 3-6 weeks after radiation as recommended by the ENT surgeon.
215087384|NCT04730869|OTHER|Standard Treatment Plus Metabolic Therapy Program|"See description under Arms."
215087385|NCT01633203|DRUG|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea."
215087386|NCT01596335|DRUG|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
214492102|NCT06611111|DRUG|Ceftriaxone (Rocephin®)|Slightly yellow liquid.
214492103|NCT06611111|DRUG|Dextrose 5% (D5W)|Colorless liquid
214492104|NCT02278185|DRUG|Enzalutamide|Given PO
214979886|NCT06555445|OTHER|BREATHING EXERCISE|Participants will be guided to adopt a deep breathing practice by emphasizing the use of the diaphragm muscle, thereby minimizing the contribution of accessory muscles during inspiration. This approach fosters the efficiency of respiratory mechanics, aiding in the mitigation of dyspnea symptoms. Participants are directed to undertake these exercises 2-3 times per day, dedicating 15-20 minutes per session, consistently over a period of 2 months. Pursed-Lip Breathing .This technique involves exhaling through semi-closed lips, creating a resistance that helps control the rate of exhalation and, thus, optimizes lung volumes and capacities. This exercise is recommended to be performed similarly to diaphragmatic breathing, 2-3 times daily for 15- 20 minutes per session for a period of 2 months
214492105|NCT02278185|DRUG|leuprolide acetate|Given SC or IM
214979887|NCT06555445|OTHER|BREATHING EXERCISE REGIMEN COUPLED WITH BREATHER DEVICE|The resistance on the BREATHER device will be adjusted to match each participant's abilities and progression. The resistance level will be challenging yet manageable, ensuring participant comfort. Each daily session will consist of 15-30 minutes with the BREATHER device and can be split into two shorter sessions if necessary. The total duration of this treatment protocol will span 2 months. The BREATHER device will be employed for both inspiratory and expiratory muscle training. Alongside the device usage, specific breathing exercises, such as diaphragmatic and pursed lip breathing, will be performed
214979888|NCT03311308|DRUG|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
214979889|NCT03311308|DRUG|Metformin|500 mg, by mouth, twice a day for nine weeks.
214979890|NCT06607406|RADIATION|Accelerated radiotherapy|6 fractions per week, BID fractions one day per week
214979891|NCT06607406|RADIATION|Conventional radiotherapy|5 fractions per week, daily M-F
214979892|NCT06985199|BEHAVIORAL|Enhanced Usual Care Group|A culturally-adapted mobile health platform will be used in the intervention to enable participants to record blood pressure and heart rate readings at home and store data in the mobile platform. Providers will have access to the store data using a provider-facing app.
214979893|NCT00419536|DRUG|LBH589|
215087387|NCT01596335|DRUG|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
215087388|NCT02246192|PROCEDURE|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
215087389|NCT02246192|PROCEDURE|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
215087390|NCT06634849|DRUG|PTT-4256|Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohort 1-3 will receive 10mg, 20mg \& 40mg. Following review by SRC on 08May2025, Cohort A4 participants will receive 80mg PTT-4256 daily.
215087391|NCT00499382|PROCEDURE|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
215087392|NCT00499382|PROCEDURE|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
215087393|NCT03627065|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
215087394|NCT05077462|DRUG|C52R1M Tab. and C52R2 Tab.|Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
214492106|NCT02278185|DRUG|goserelin acetate|Given SC or IM
214492107|NCT02278185|DRUG|histrelin acetate|Given SC or IM
214492108|NCT02278185|DRUG|triptorelin|Given SC or IM
214492109|NCT02278185|DRUG|degarelix|Given SC or IM
214492110|NCT06918340|DRUG|Diclofenac|Group II: 5-6 puffs of topical 1% diclofenac spray will be applied before radial artery blood gas sampling.
214492111|NCT06918340|DRUG|Lidocaine spray|Group I: 5-6 puffs of topical 10% lidocaine spray will be applied before radial artery blood gas sampling.
214492112|NCT06918340|OTHER|Placebo|Group III: 5-6 puffs of topical 70% alcohol solution spray will be applied before radial artery blood gas sampling.
214492113|NCT04107233|BEHAVIORAL|Audit and Feedback|Charts for enrolled physicians will be audited and they will receive feedback, consisting of tailored reports and one-on-one meeting with colleague to review at baseline, 3 months and 6 months
214492114|NCT06259097|DRUG|Misoprostol|25 mcg vaginally every 6 hours
215087395|NCT05077462|DRUG|AJU-C52H|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
215087396|NCT04928209|OTHER|Speech-Language Teletherapy|Access to speech-language teletherapy will be provided as a supplement to Usual Care for subjects randomized to this group. Access is provided by way of 1) direct referral by the clinical team to a teletherapist; 2) availability of a teletherapy slot. All teletherapy providers will be licensed speech-language pathologists (SLPs) and/or credentialed teachers of the deaf (TODs) with specialized training to work with children who are D/HH using an LSL approach. Fluent English and Spanish speaking providers will be matched to the child's home, native language. Teletherapy itself is within routine clinical care and is not considered a research activity. Children who randomize to the Low TT study arm will receive access to an 18-month course of weekly teletherapy, in accordance with the centers' standard of care. The exact details of the therapy course and frequency will be determined based on individual family needs.
215087397|NCT01883011|DRUG|Piracetam|
214492115|NCT06259097|DRUG|Pitocin|3-6 mL intravenously every hour
214492116|NCT06931717|DRUG|Cemiplimab|Cemiplimab, 350 mg i.v., every 3 weeks (±3 days), for 4 cycles, followed by 700 mg i.v., every 6 weeks (±1 week) for 6 cycles or until relapse or unacceptable toxicities, whichever occurs first.
215087398|NCT01883011|OTHER|Placebo|
215087399|NCT05549375|DEVICE|MyHand System Hand Rehabilitation|15 1-hour patient specific sessions using the MyHand System to help improve Hand function in the affected hand of stroke survivors
215087400|NCT06075992|OTHER|experimental group|An experimental application will not be made to premature babies in this group.
215087401|NCT01838785|DRUG|18F-DTBZ AV-133|
215087402|NCT04524455|DRUG|Blinatumomab|Blinatumomab will be administered as a continuous intravenous infusion (cIV).
215087403|NCT04524455|DRUG|AMG 404|AMG 404 will be administered as an intravenous infusion (IV).
215087404|NCT04524455|DRUG|Dexamethasone Premedication|Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
215087405|NCT03234296|DRUG|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
214367784|NCT05547425|DEVICE|Cartoon Obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
214367785|NCT05547425|DEVICE|Raw images|No editing is performed on images.
214367786|NCT00428558|DRUG|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
214979894|NCT03980067|OTHER|Virtual Reality Game|The virtual reality headset, device, and software, created by Stanford's Childhood Anxiety Reduction through Innovation and Technology (CHARIOT)program/Weightless Studio, LLC will be utilized in this study. Children in the VR intervention group will be allowed to select a distraction-based game to play with active VR content featuring interactive avatars and interactive experiences tailored to the pediatric population that allow players to do things such as control penguins sliding down a mountain while collecting pebbles for points, control puppies running in space to collect treats to the rhythm of music, and control an asteroid miner exploring an asteroid belt and collecting points based on color of asteroids collected. The game will last a minimum of 5 minutes in duration, provided participant tolerance. The participant may play longer if desired prior to receiving procedural sedation and the total length of activity played will be documented.
214979895|NCT02112253|DEVICE|Deep brain stimulator ventral electrode up to 2 mA|
214979896|NCT02112253|DEVICE|Deep brain stimulator ventral electrode up to 3 mA|
214979897|NCT02112253|DEVICE|Deep brain stimulator dorsal electrode up to 2 mA|
214979898|NCT02112253|DEVICE|Deep brain stimulator dorsal electrode up to 3 mA|
214979899|NCT02112253|DEVICE|Deep brain stimulator empirical programming|
214979900|NCT03557593|OTHER|Educational|Multi component educational intervention in long-term care
214979901|NCT06661525|DEVICE|Free Flap NIRS|Monitoring of tissue oxygenation after Free Tissue Transfer (FTT) surgeries.
214367787|NCT00428558|DRUG|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
214367788|NCT01319799|OTHER|Open heart surgery|TCD count of microembolic signals during surgical aortic valve replacement
214367789|NCT00783380|BIOLOGICAL|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
214367790|NCT00783380|BIOLOGICAL|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
214367791|NCT01473693|OTHER|MRI Screening Form, MRI, Demographic / Medical Data form|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes."
214367792|NCT01473693|OTHER|MRI Screening Form, MRI. Demographic / Medical Data|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.~MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes"
214367793|NCT00186316|BIOLOGICAL|Idiotype-pulsed allogeneic dendritic cells|
214367794|NCT01250535|DRUG|Warfarin|10 mg, po, single dose on day 7
214367795|NCT01250535|DRUG|Placebo|po, once a day, days 1 through 14
214367796|NCT01250535|DRUG|Lovastatin|40 mg, po, once a day, days 1 through 14
214367797|NCT05227755|DIETARY_SUPPLEMENT|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
214492117|NCT05364762|DRUG|Cyclophosphamide|Given IV
214492118|NCT05364762|DRUG|Itacitinib|Given PO
214979902|NCT06612996|DRUG|Tramadol|Intravenous tramadol
214979903|NCT06612996|DRUG|Magnesium sulphate|Intravenous magnesium sulphate
214979904|NCT06612996|OTHER|Saline|Normal saline
214979905|NCT06380920|DEVICE|"AI Mindful Eating App"|"The investigators propose on design of an AI Mindful Eating App, to enhance individual's healthy lifestyle with subsequent weight-loss. Based on gut-brain axis, this is anticipated to be achieved by using CBT, in place of medication, to alleviate food addiction and proper nutrition intake during proper metabolic conditions and time, which are coordinated via AI."
214979906|NCT06380920|BEHAVIORAL|Outpatient regular follow-up|Outpatient regular follow-up
214979907|NCT07006987|DEVICE|A non-invasive blood-based (HerResolve)|A non-invasive blood-based test can detect endometriosis as compared to diagnostic laparoscopy
214979908|NCT02969785|OTHER|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
215087406|NCT03234296|OTHER|Placebo|Intravenous placebo followed by per oral placebo
215087407|NCT02262078|DRUG|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
215087408|NCT02262078|OTHER|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
215087409|NCT02194322|DRUG|BIBN 4096 BS - in single rising doses|
215087410|NCT02194322|DRUG|Placebo|
215087411|NCT02161276|DRUG|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
215087412|NCT02161276|DRUG|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
215087413|NCT03361904|PROCEDURE|Colonoscopy|Total colonoscopy : All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were: patients scheduled for partial colonoscopy, interventional colonoscopy (for stent insertion, stenosis dilation).
215087414|NCT02120963|BEHAVIORAL|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
215087415|NCT01688739|DRUG|Erenumab|Administered by subcutaneous injection or intravenous injection
215087416|NCT01688739|DRUG|Placebo|Administered by subcutaneous injection or intravenous injection
214979909|NCT02969785|OTHER|G2: back strengthening exercises|Specific back exercises. The Group 2 (G2) will perform therapy including back strengthing exercise on a Roman chair machine to perform flexion and extension of trunk with load progressive training.
214979910|NCT03025373|OTHER|Visuo-acoustic stimulation|Controlled visual and acoustic stimulation in a virtual reality setting
215087417|NCT00996801|DRUG|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
214979911|NCT03255356|OTHER|Survey|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
214979912|NCT05117060|DRUG|LEO 152020 tablet|LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.
214979913|NCT05117060|DRUG|LEO 152020 placebo tablet|LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except that it does not contain the medical ingredient LEO 152020. LEO 152020 placebo is a tablet for oral administration.
214979914|NCT02440893|DIAGNOSTIC_TEST|Corus CAD (ASGES)|
214979915|NCT01466738|BIOLOGICAL|HRV-16 (100 TCID50)|Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
214979916|NCT01466738|BIOLOGICAL|HRV-16 (1000 TCID50)|Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
214979917|NCT01911416|DRUG|LDE225|
214979918|NCT04158219|BEHAVIORAL|Behavioral activation for health and depression (BA-HD)|Consistent with successful BA manuals, we plan to conduct up to 10 sessions of treatment over 12 weeks (the recommendation will be at least 8 sessions; scheduling of sessions will be flexible and conform to patient preference). The initial two sessions will be about 50 minutes long and later sessions will be 20-30 minutes long. Sessions can be done on site or over the phone; home visits will be offered for sessions 1-2 if a participant cannot travel. Treatment sessions will use behavioral activation techniques to assess participant values and link these values to behavior change. Goal-setting will focus on sequential, idiographic behavior change (tobacco use, medication adherence, physical activity, and diet) and be accompanied by educational materials and commercially available tools (e.g. activity trackers, pillboxes).
214979919|NCT03213847|DEVICE|Superb microvascular imaging (SMI) (Toshiba)|to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
215087418|NCT00996801|DRUG|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
215087419|NCT00996801|DRUG|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
214367798|NCT05227755|DIETARY_SUPPLEMENT|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
214367799|NCT00408148|DRUG|Placebo|Undistinguishable placebo tablets
214367800|NCT00408148|DRUG|Rimonabant|White film-coated, for oral administration containing 20 mg of active rimonabant
214367801|NCT04623073|PROCEDURE|Total Hip arthroplasty via a Direct Anterior Approach|Total Hip arthroplasty via a Direct Anterior Approach
214367802|NCT05003102|DRUG|Dexmedetomidine Hydrochloride - Cycling|Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.
214367803|NCT05003102|DRUG|Fentanyl - PICU Standard|fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
214979920|NCT05965752|OTHER|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
214367804|NCT05003102|DRUG|Dexmedetomidine Hydrochloride - PICU Standard|Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr
214979921|NCT05965752|OTHER|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
214979922|NCT05965752|OTHER|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
214979923|NCT05965752|DEVICE|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
214979924|NCT05965752|DEVICE|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
214979925|NCT03934671|DEVICE|Antioxidant dressing (active product)|"Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary.~Device: Reoxcare®"
214979926|NCT03934671|DEVICE|Usual care dressing that create a moist environment (standard clinical practice)|Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings). Compression bandage if necessary
215087420|NCT00996801|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
215087421|NCT00996801|DRUG|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
215087422|NCT00996801|DRUG|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
215087423|NCT02335632|DRUG|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
215087424|NCT02335632|DRUG|Placebo|For probiotics
215087425|NCT03066362|OTHER|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
214979927|NCT03048045|PROCEDURE|Supportive Periodontal Treatment (SPT)|Assessment of Gingival Bleeding Index and Plaque Control Record, re-instruction and re-motivation to effective individual plaque control, professional tooth cleaning, application of a fluoride gel. Twice a year a periodontal charting with probing pocket depths (PPD) and vertical attachment Level (PAL-V) are obtained at 6 sites per tooth. Thirty seconds after probing bleeding on probing (BOP) is recorded. Sites exhibiting PPD = 4 mm and BOP as well as sites with PPD \>/= 5 mm are scaled subgingivally. Assignment of SPT intervals is performed according to the periodontal risk assessment (PRA).
214979928|NCT02074514|DRUG|Sofosbuvir|400 mg tablet administered orally once daily
214979929|NCT02074514|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214979930|NCT04039620|OTHER|Observational study, no interventions expected|No interventions are planned
214979931|NCT05098327|DRUG|Pioglitazone 30 mg|pioglitazone 30 mg dose 1 tab daily will be given for 12 weeks
214979932|NCT05098327|DRUG|Placebo|placebo pills containing cellulose 1 pill daily will be given for 12 weeks
214367805|NCT00004408|DRUG|poloxamer 188|
214979933|NCT03842904|DRUG|Trimbow pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
214979934|NCT03842904|DRUG|Fostair pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
214979935|NCT01274351|DRUG|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
214979936|NCT00535613|DRUG|Propofol|IV, single bolus at completion of anesthetic, 0.1 ml/kg
214979937|NCT03546673|BEHAVIORAL|Self-Regulation Condition|
214979938|NCT03546673|BEHAVIORAL|Emotional Disclosure Condition|
214979939|NCT02215850|DRUG|SLC-0111|
215087426|NCT02144831|DRUG|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
215087427|NCT00011011|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
214979940|NCT00032591|PROCEDURE|Weekly patient self-testing of prothrombin time|
214367806|NCT05306366|DRUG|[11C]-Lu AF90103|PET ligand administrated as a single intravenous bolus injection
214367807|NCT04555096|DRUG|GC4419|180 Minute IV Infusion
214367808|NCT04555096|DRUG|Placebo|180 Minute IV Infusion
214367809|NCT03951038|PROCEDURE|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
214367810|NCT03951038|PROCEDURE|Lateral TLIPB group|"both sides of the spine, a single injection of ropivacaine by nerve stimulating needle under ultrasound-guided between the longissimus and iliocostalis muscles .~The regimen of Lateral TLIPB group is0.2% 20ml ropivacaine and the regimen of PCIA is same with PCIA group."
214367811|NCT00295763|DRUG|Thyrogen (thyrotropin alfa for injection)|"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."
214492119|NCT05364762|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell infusion
214979941|NCT00032591|OTHER|High quality anticoagulation management (HQACM) with conventional monthly testing|HQACM with testing every 4 weeks and as indicated for out of range values, medication/clinical changes.
214979942|NCT03767712|DIAGNOSTIC_TEST|Comparison of the levels of antinuclear antibodies (ANA) by indirect immunofluorescence on a Hep-2 cell line.|To analyse whether patients with pertrochanteric femoral fracture with consecutive gamma-nailing develop any laboratory signs of transient autoimmunity (comparison of the levels of ANA; in order to overcome the problem of subjective semiquantitative evaluation, the novel method of automated digital fluorescence microscopy will be used)
214979943|NCT04281329|PROCEDURE|Magnetic resonance imaging|Cardiac magnetic resonnance imaging before catheter ablation.
214979944|NCT01860859|PROCEDURE|Closure of the hysterotomy at the time of primary cesarean|
214979945|NCT06757010|DRUG|NE3107|NE3107 20 mg BID
214979946|NCT06757010|DRUG|Placebo|Placebo BID
214979947|NCT05907265|BEHAVIORAL|Behavioral: ONCOBrain_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
214979948|NCT05907265|BEHAVIORAL|Behavioral: Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
214979949|NCT00413023|DRUG|GW679769|
214979950|NCT04127370|PROCEDURE|Bariatric Surgery|The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
214979951|NCT00196599|DRUG|emtricitabine, FTC (drug)|
214979952|NCT00196599|DRUG|didanosine, ddI (drug)|
214979953|NCT00196599|DRUG|efavirenz (drug)|
214979954|NCT03946059|DEVICE|iTBS then cTBS|repetitive transcranial magnetic stimulation applied with intermittent theta-burst stimulation protocol applied in week 1 and continuous theta-burst stimulation protocol applied in week 2.
214979955|NCT03946059|DEVICE|cTBS then iTBS|repetitive transcranial magnetic stimulation applied with continuous theta-burst stimulation protocol applied in week 1 and intermittent theta-burst stimulation protocol applied in week 2.
215087428|NCT03454516|OTHER|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
215087429|NCT01013415|DRUG|HAART|
215087430|NCT01013415|BIOLOGICAL|T cells|
215094527|NCT03256747|DEVICE|NMES|NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
214367812|NCT04175795|BEHAVIORAL|My Personal Brain Health Dashboard|"The intervention of this study is grounded in the knowledge-to-action framework (Graham et al., 2006) and consists of providing feedback by sending participants their personalized health outcome profiles. As mentioned above, the context of our study is the BHN cohort. For all participants enrolled in the parent study, data on wide spectrum of health outcomes have been gathered. As part of the knowledge translation plan, a personalized profile of specific modifiable health outcomes called as My Personalized Brain Health Profile has been created for each participant (Appendix B). The profile covers information on brain health outcomes, health and quality of life ratings, and lifestyle factors."
214367813|NCT03263832|DIAGNOSTIC_TEST|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
214492120|NCT05364762|OTHER|Quality-of-Life Assessment|Ancillary studies
214979956|NCT04630548|DEVICE|Intrauterine copper device|The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).
214979957|NCT05184855|DIETARY_SUPPLEMENT|Blueberry|Blueberry powder intake
214979958|NCT05184855|DIETARY_SUPPLEMENT|Placebo|Placebo powder intake
214979959|NCT04322136|PROCEDURE|Pleurodesis via Video-assisted thoracoscopic surgery|Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon. This is expected to take about 1 hour. Between one and three ports are used to insert a camera and instruments into the chest cavity. Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion. The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis. A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.
214979960|NCT04322136|DEVICE|Indwelling pleural catheter (with talc pleurodesis if suitable)|Once the indwelling pleural catheter is inserted, the pleural fluid will be evacuated as completely as possible. If the lung fully re-expands, 4-5g of sterile graded talc will be instilled via the IPC. The participant will then be discharged on a daily drainage regimen for 14 days. At review in clinic on day 14, the participant will be assessed for spontaneous pleurodesis (\<50ml drainage on 3 consecutive drainage attempts). If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal. Otherwise the participant will switch to a symptom-guided drainage regimen. If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc. The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate.
214979961|NCT03053739|DRUG|Sildenafil 20mg and Bosentan 62.5mg|Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
214979962|NCT03053739|DRUG|Sildenafil 20mg and Placebo|Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
214979963|NCT02678117|DRUG|Pregabalin & Placebo|
214979964|NCT02678117|DRUG|Magnesium sulphate & Placebo|
214979965|NCT02678117|DRUG|Pregabalin & Magnesium sulphate|
214979966|NCT02678117|DRUG|Placebo|
214979967|NCT00374634|DRUG|rFSH drug dose|"Individual rFSH dose (50, 75 or 100 IU rFSH/day)"
214979968|NCT00374634|DRUG|"Standard rFSH dose"|"Standard rFSH dose was 75 IU/day"
214979969|NCT04946812|OTHER|Split-belt treadmill training|18 sessions of SB-TM training, where the velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%.
214979970|NCT02417025|BEHAVIORAL|PE|Prolonged Exposure
214979971|NCT00798005|DRUG|XRP0038 (NV1FGF)|
214979972|NCT00539396|DRUG|Technosphere Insulin|
214367814|NCT05608096|DEVICE|Hemoperfusion|Commercial membrane for extracorporeal blood purification (hemoperfusion)
214367815|NCT04182763|OTHER|CoA-Z|People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.
214367816|NCT04182763|OTHER|Placebo|The placebo is a strawberry-flavored syrup that looks and tastes like CoA-Z but has no active CoA-Z in it.
214492121|NCT05364762|DRUG|Tacrolimus|Given IV or PO
214492122|NCT06256718|OTHER|Educational Intervention|Evidence-based strategy (PC TEACH)
214492123|NCT05683873|PROCEDURE|Electrocardiogram|Inclusion visit, V1, V2 and V3
214680176|NCT02083445|OTHER|Exercise program|Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
214492124|NCT05683873|PROCEDURE|transthoracic echocardiography|V1, V2 and V3
214492125|NCT05683873|BIOLOGICAL|standard biology|Inclusion visit
214492126|NCT05683873|BIOLOGICAL|determination of serum GDF-15, osteoprotegerin and ST-2|Inclusion visit, V1, V2 and V3
214680177|NCT02083445|DEVICE|Muscle electro-stimulation|A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
214680178|NCT02083445|OTHER|Intermittent hypobaric hypoxia|
214979973|NCT02281708|DRUG|vinorelbine plus cisplatin|"Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days~* vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks"
214979974|NCT03699592|BEHAVIORAL|Reach Home and Read Toolkit|The toolkit currently includes one age-appropriate book along with a set of educational pamphlets explaining the importance home literacy. These educational materials focus on appropriate literacy milestones and descriptions of how parents can engage with their children around books. In addition, we will create an information sheet outlining zipcode-specific community literacy resources, including location and information on how to access the library, where to obtain low-cost books, and a schedule of literacy promotion activities in their community (e.g. community reading sessions). All materials will also be translated into Spanish by a certified interpreter, and will be reviewed to ensure that they are written at a fifth grade reading level. Additionally, EDCI families receiving this intervention will also receive an additional new book at each home visit conducted during the study period.
214367817|NCT06579339|OTHER|xylitol chewing gum|Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
214367818|NCT01250990|DRUG|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
214979975|NCT05333211|DRUG|Ortho-R/PRP|Ortho-R® is a freeze-dried drug/biologic combination product containing a chitosan component and trehalose, a disaccharide that acts as a lyoprotectant during the lyophilization process and calcium chloride, which acts as a PRP coagulation agent.
215087431|NCT06414161|DIETARY_SUPPLEMENT|mix of (green tea and peppermint)|"Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract."
214979976|NCT01762488|PROCEDURE|Ablation of the renal arteries|Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
214979977|NCT01762488|PROCEDURE|Renal angiography|Renal angiography by femoral access
215087432|NCT00812903|BEHAVIORAL|Exercise|Training exercises chosen with background in knowledge of intelligent training
215087433|NCT01737294|DRUG|Qutenza exposure|Cutaneous patch
215087434|NCT03227068|OTHER|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
215087435|NCT03227068|OTHER|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
215087436|NCT02270723|DRUG|"5% Human Albumin  Behring"|Intravenous infusion of 5% Human Albumin during major surgery
215087437|NCT02270723|DRUG|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
215087438|NCT02804750|DRUG|CORT125134|
215087439|NCT02559414|DRUG|Aspirin|
215087440|NCT02559414|DRUG|Clopidogrel|
215087441|NCT01660100|PROCEDURE|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
215087442|NCT01660100|PROCEDURE|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
214979978|NCT00313690|DRUG|Bortezomib, Docetaxel and Cisplatin|
214979979|NCT03312738|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) was administered in a blinded manner by continuous oral daily dosing.
214979980|NCT03312738|DRUG|Exemestane|Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.
214979981|NCT03312738|DRUG|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) was administered in a blinded manner by continuous oral daily dosing.
214367819|NCT01250990|OTHER|Placebo|Placebo
214367820|NCT04995679|PROCEDURE|Implant of metaphyseal sleeves in Total knee arthroplasty|Implant of metaphyseal sleeves in Primary and revision TKA
214979982|NCT01130844|DRUG|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
214979983|NCT01130844|DRUG|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
214979984|NCT01130844|DRUG|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
214979985|NCT03350386|DRUG|FYU-981|Single administration
214979986|NCT03350386|DRUG|Oxaprozin|Repeated administration
215087443|NCT03369431|DIETARY_SUPPLEMENT|Vivomixx|Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
214979987|NCT00872547|DEVICE|DePuy ASR™ Hip System|Resurfacing system
214979988|NCT00872547|DEVICE|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
214979989|NCT05426590|DEVICE|Specular biomicroscopy|Specular microscopy will be done before and 3 weeks after cataract surgery
215087444|NCT03369431|DIETARY_SUPPLEMENT|Placebo|4.4 grams of maltose and silicon dioxide per sachet
215087445|NCT05917132|OTHER|Nutritionnal intervention|Participants will be provided with meals corresponding to each diet during the week. Participants will be required to eat only the meals provided.
214367821|NCT05321355|DEVICE|Implantation of vagus nerve stimulation according to clinical indication|no interventions, only observation
215087446|NCT01973608|DRUG|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
215087447|NCT01973608|DRUG|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
215087448|NCT01973608|DRUG|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
215087449|NCT01973608|DRUG|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
215087450|NCT01973608|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
215094528|NCT03256747|DEVICE|NMES-placebo|NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
214367822|NCT00004670|PROCEDURE|pallidotomy|
214367823|NCT04304352|DRUG|Vinorelbine|Metronomic Vinorelbine 40 mg orally thrice a week
214367824|NCT04304352|DRUG|Capecitabine|Metronomic Capecitabine 500 mg, thrice daily
214367825|NCT04304352|DRUG|Cyclophosphamide|Metronomic Cyclophosphamide 50 mg daily
214979990|NCT06183138|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
214979991|NCT00003062|DRUG|temozolomide|
214979992|NCT05888519|OTHER|FID123300 ocular lubricant|Investigational ocular lubricant
214367826|NCT00942617|DRUG|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
214367827|NCT01468298|OTHER|Isostretching|All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
214492127|NCT05683873|BIOLOGICAL|Ultrasensitive Troponin-Ic|Inclusion visit, V1, V2 and V3
214492128|NCT05683873|OTHER|Collection of clinical and radiological data|Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data
214979993|NCT05888519|OTHER|FID123301 ocular lubricant|Investigational ocular lubricant
214979994|NCT05888519|OTHER|FID122505 ocular lubricant|Comparator ocular lubricant
214979995|NCT03885973|DRUG|Lactobacillus plantarum|Fermented milk containing probiotic Lactobacillus plantarum for three weeks
214979996|NCT03885973|DRUG|Placebo|Fermented milk containing placebo for three weeks
214979997|NCT03895801|DRUG|IFX-1|intravenously administered
214492129|NCT05683873|OTHER|72-hour continuous Holter-ECG recording|V1
214492130|NCT06336655|DEVICE|IABP|LV unloading via intra-aortic balloon pump (IABP)
214979998|NCT03895801|DRUG|Placebo-IFX-1|intravenously administered
214979999|NCT03895801|DRUG|Glucocorticoid (GC)|orally administered
214980000|NCT03895801|DRUG|Placebo-Glucocorticoid (Placebo-GC)|orally administered
214980001|NCT03405311|DEVICE|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device
215087451|NCT05674799|BEHAVIORAL|NDPP-NextGen|"NDPP-NextGen will incorporate content on preconception/prenatal health into standard NDPP. Participants will be encouraged to make sustainable improvements in diet and activity, but without pre-set goals to better accommodate diverse, low-income populations. Upon pregnancy, recommendations will adjust to support appropriate GWG, breastfeeding, and postpartum weight loss. We will provide education on diet and activity during pregnancy/postpartum, including sufficient energy intake and exercise safety to support the growing fetus. NDPP-NextGen will include 3 strategies to better engage young women. (1) Pre-sessions to increase knowledge of diabetes risks, self-efficacy, and readiness to change using motivational interviewing techniques. (2) Delivering classes remotely (via phone- and video-conference) to facilitate participation regardless of inclement weather, dependent care, illness, transportation, etc. (3) Offering classes specially for young women to increase personal relevance."
215087452|NCT04458831|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214367828|NCT01468298|OTHER|Global Posture Reeducation|All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
214367829|NCT03721640|OTHER|electrocardiogram|Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.
214367830|NCT00156143|PROCEDURE|Blood sample|
214980002|NCT03405311|OTHER|Palpation|The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
215087453|NCT04458831|DRUG|Pomalidomide|Pharmaceutical form: oral
215087454|NCT04458831|DRUG|Dexamethasone|Pharmaceutical form: oral
214980003|NCT05029661|DIAGNOSTIC_TEST|Carotid ultrasound|"* Ultra-COMPASS measurements (longitudinal + cross-sectional) Shear wave elastography: plaque stiffness Strain elastrogaphy: plaque deformation B-mode visualization: geometry~* Intima-media thickness~* Pulse wave velocity"
214980004|NCT02466399|DRUG|POLAT-001|Subconjunctival injection
214980005|NCT02466399|DRUG|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
214980006|NCT01123330|BEHAVIORAL|Motivational Interviewing|
214980007|NCT05385406|DIAGNOSTIC_TEST|HPV genotyping|Genotyping will be obtained by the Xpert system which uses 5 color channels containing primers and probes for the detection of specific genotypes or pooled results as follows: i) HPV 16, ii) HPV 18/45 in pooled result, iii) HPV types 31, 33, 35 52, or 58, in pooled result, iv) HPV types 51 or 59, in pooled result, and v) HPV types 39, 56, 66 or 68 in pooled result.
214980008|NCT05385406|DIAGNOSTIC_TEST|Visual inspection after application of acetic acid|"After application of acetic acid and Lugol's iodine, the cervix will be assessed using simplified ABCD criteria (A= acetowhite lesion within the transformation zone, B = spontaneous bleeding or upon slight touch, C (optional) = Lugol-positive coloring of acetowhite lesions, D = diameter \> 5mm of acetowhite lesion)."
215087455|NCT04458831|DRUG|Carfilzomib|Pharmaceutical form: solution for infusion
215087456|NCT04066348|BIOLOGICAL|Etanercept|To treat blast or noise induced tinnitus
215087457|NCT04066348|OTHER|Saline|Placebo
215087458|NCT06394869|DIAGNOSTIC_TEST|Cxbladder Triage Plus|Cxbladder Triage Plus is a lab developed, test that is using RNA and DNA biomarkers in the urine to assess the likelihood of the presence of urothelial carcinoma in the bladder.
215087459|NCT01829568|DRUG|Ibrutinib|Given PO
215087460|NCT01829568|DRUG|Lenalidomide|Given PO
215087461|NCT01829568|BIOLOGICAL|Rituximab|Given IV
215087462|NCT05339984|PROCEDURE|Partial hepatectomy (open approach)|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
215087463|NCT05339984|PROCEDURE|liver transplantation|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
215087464|NCT05339984|PROCEDURE|Portal vein embolization|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
215094529|NCT00563043|PROCEDURE|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
214980009|NCT04689542|OTHER|Sit-To-Stand test|The 1-minute sit-to-stand test will be realized with or without a surgical facemask covering the face of the patient with COVID-19
214980010|NCT01592214|OTHER|Placebo|Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
214980011|NCT01592214|DRUG|XF-73 in 2% Klucel gel|XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
214367831|NCT00156143|PROCEDURE|Radiography|
214367832|NCT00046501|DRUG|Lantus (insulin glargine [rDNA origin] injection)|
214367833|NCT00046501|DRUG|Humulin N|
214367834|NCT00046501|DRUG|Humulin L|
214367835|NCT00046501|DRUG|Lispro|
214367836|NCT03814733|DRUG|Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
214367837|NCT03814733|DRUG|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
214367838|NCT03814733|DRUG|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
214367839|NCT03814733|DRUG|Rapastinel Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
214367840|NCT03814733|DRUG|Alprazolam Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
214367841|NCT03814733|DRUG|Ketamine Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
214367842|NCT00523159|DRUG|Endoxana, IMA901, Leukine|a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
215087465|NCT05048433|BEHAVIORAL|implementation strategy for active learning to promote physical activity|The experimental arm includes using a multifaceted implementation strategy to support the use of active learning approaches. The strategy will consist of a series of skills-based staff trainings, identifying program champions to help lead efforts within the school, establishing an audit and feedback system to monitor the use of active learning, and a reinforcement system to recognize staff who are successfully implementing.
214367843|NCT00523159|DRUG|IMA901 and Leukine|Intradermal injection of GM-CSF followed by intradermal injection of IMA901
215087466|NCT05048433|BEHAVIORAL|Usual Implementation support|Usual support consists of the potential to access general resources from the district wellness department. These resources include access to funds to send staff to external trainings and general guidance for how to use active learning approaches.
214980012|NCT01592214|DRUG|XF-73 in 4% Klucel gel|XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
214980013|NCT00283179|DRUG|Aripiprazole|
215087467|NCT06455878|BEHAVIORAL|Full usage of diet management app group and with the full usage of an intelligent weight scale|Subjects will use the fully functional diet management application and an intelligent weight scale with full function designed for obese heart failure patients to help them losed weight and invitigate some important composite cardiovascular endpoint.
214980014|NCT00283179|DRUG|Risperidone|
215087468|NCT06455878|BEHAVIORAL|Limited usage of diet management app group and with the limited usage of an intelligent weight scale|Subjects will use the limited function diet management application and an intelligent weight scale with limited function designed for obese heart failure patients as a comparator.
214367844|NCT02019628|DIETARY_SUPPLEMENT|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
214367845|NCT03741101|DRUG|Trametinib|treatment
214367846|NCT04176341|OTHER|a systematic proposal for non pharmacological interventions targeting the subject's empowerment among slackline, mindfulness, adapted physical activity, self-hypnosis, and Qi Gong|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
214367847|NCT01097252|RADIATION|radiation|radiation with cisplatin 40mg/m2, 6 cycles, every week
214367848|NCT01097252|DRUG|weekly cisplatin|weekly cisplatin 40mg/m2, 6 cycles
214367849|NCT01097252|DRUG|tri-weekly cisplatin|cisplatin 75mg/m2, 3cycles, every 3 weeks
214367850|NCT05003050|OTHER|Meditation|Holistic natural therapy
214367851|NCT05003050|OTHER|Pranic Healing|Energy therapy
214980015|NCT02208908|OTHER|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
214367852|NCT03402256|BEHAVIORAL|Text Message|In addition to the SC interventions, participants in the Text Message condition received text messages. Participants received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Participants will receive messages targeting known predictors of alcohol abstinence and relapse, including (1) craving, (2) identification of high-risk situations, (3) identification of triggers, (4) stress level, (5) coping skills, and (5) quality of life. The text messages will include motivational messages and behavior-change techniques (e.g. coping with cravings and urges to drink, trigger identification, high-risk situation identification). Messages will encourage participants to continue with sobriety and focus on the success they have achieved so far.
214367853|NCT06141330|DIETARY_SUPPLEMENT|D Max Drops|Vitamin D
214980016|NCT03964948|DIAGNOSTIC_TEST|Kidney MRI|An MRI examination will be completed per research MRI protocol.
214980017|NCT03953742|DRUG|CPI-200|CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
214980018|NCT03408899|DRUG|PC-1005 gel|PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
214980019|NCT05572580|OTHER|questionnaire|the patients are asked to fill in a questionnaire
214492131|NCT05587374|DRUG|Cadonilimab|Cadonilimab 10mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 14 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
214492132|NCT05587374|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
214492133|NCT05587374|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
214492134|NCT05587374|RADIATION|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
214492135|NCT06928389|DRUG|Ivonescimab, docetaxel|Patients will receive ivonescimab and docetaxel as an IV injection
214980020|NCT06399601|OTHER|Drug allergy training program|Two identical didactic courses on drug allergy were designed. Each course will last 12 hours and conducted over 2 consecutive days (6 hours each day). All candidates will attend physically and on-site. Various aspects of drug allergy with pre-set learning objectives will be taught in-person by instructors (physicians or nurses specializing in drug allergy nominated by the University of Hong Kong). Course materials and instructors will be identical for each course.
215087469|NCT04066569|OTHER|Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam|"After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions"
215087470|NCT04066569|OTHER|Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)|"After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo."
215087471|NCT05324020|BEHAVIORAL|Medication adherence eHealth intervention|"The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies)."
215087472|NCT06583811|DRUG|Remifentanil|to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.
215087473|NCT06583785|OTHER|Black rice (Intervention)|210 g of cooked black rice
215087474|NCT06583785|OTHER|Brown rice (Control)|210 g of cooked brown rice
215087475|NCT06583772|DIAGNOSTIC_TEST|VR-based 9-hole peg test|The volunteers will first undergo a physical 9-hole peg test. After the physical test is completed, the VR-based 9-hole peg test will be performed.
215087476|NCT05525598|BEHAVIORAL|"One step at a time"|\[see 'arms' section for full description\]
215087477|NCT05525598|BEHAVIORAL|"Get started"|\[see 'arms' section for full description\]
214367854|NCT06141330|DRUG|Azithromycin 250 milligram Oral Capsule|Anti Biotic
214367855|NCT06141330|DRUG|Adapalene|Retinoid
214367856|NCT06508047|DEVICE|Informed Vital Core App|Informed Vital Core App will be initiated by the study staff to take a measurement, which takes 60 seconds to calculate and report a breathing rate value.
214367857|NCT05292859|BIOLOGICAL|Neoantigen specific TCR-T cell drug product|No study drug is administered in this study. Patients who have received Neoantigen specific TCR-T cell drug product will be evaluated in this trial for long-term safety and efficacy
214367858|NCT03673306|OTHER|Clinical outcomes|Clinical outcomes
214492136|NCT06928389|DRUG|Placebo, docetaxel|Patients will receive placebo and docetaxel as an IV injection
214492137|NCT06786715|DEVICE|Retrograde intrarenal surgery using DISS|Retrograde intrarenal surgery using Direct in scope suction for renal stone up to 3 cm
214492138|NCT06786715|DEVICE|Retrograde intrarenal surgery using FANS|Retrograde intrarenal surgery using Flexible and navigable suction for renal stone up to 3 cm
214492139|NCT01470144|DRUG|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
214492140|NCT03871036|DRUG|Tremelimumab|See experimental arm description for more details.
214492141|NCT03871036|DRUG|Durvalumab|See experimental arm description for more details.
214492142|NCT03871036|DRUG|Paclitaxel|See experimental arm description for more details.
215087478|NCT05542914|BEHAVIORAL|electronic screening and brief intervention.|e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.
215087479|NCT05542914|BEHAVIORAL|Men's Health Project (MHP)|This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.
215087480|NCT05792644|DRUG|crizotinib for rearrangement-negative, high phosphorylated ALK patients|Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
214980021|NCT00606008|DRUG|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
214367859|NCT05384028|OTHER|Nurse -led case management|This study would apply case management to the whole course management of AMI patients from admission to 6 months after discharge. Pharmacists, nutritionists, rehabilitation specialists and psychiatrists led by nurse would take the initiative to conduct individualized assessment and health guidance, and case managers would participate in the whole process of inpatient diagnosis and treatment. Coordinating multidisciplinary medical resources to jointly implement diagnosis and treatment and rehabilitation for patients can improve the quality of care.
214367860|NCT05384028|OTHER|Routine inpatient care and post-discharge follow-up management|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
214367861|NCT02202746|DRUG|Lucitanib|Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
215087481|NCT01453517|BEHAVIORAL|Behavioral intervention for regain after bariatric surgery|6 week intervention targeting dietary behavioral adherence, stress management, and distress tolerance skills to prevent weight regain
214367862|NCT04426864|OTHER|Supervised Aerobic Plus Stretching Exercises|An exercise prescription was developed for each woman based on the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70 % ergospirometric VO2max (moderate-intensity) was determined by the submaximal treadmill test. The participants were instructed to perform their exercises at 50 % of VO2max for six weeks. At seventh their exercise intensity was increased to target HR corresponding to 70 % of VO2max. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY). Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. The exercise program was applied 3 days a week for 12 weeks.
214492143|NCT06935994|DRUG|Aspirin 81 mg Enteric Coated Tab - 1 tablet|Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
214492144|NCT06935994|DRUG|Placebo|Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
214492145|NCT01663363|DEVICE|LASIK correction of myopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
214492146|NCT06788795|DEVICE|Device with Phone App|This is the intervention where the patients will be given both the wearable dehydration device as well as the phone app
214492147|NCT06788795|DEVICE|Device without Phone App|This is the intervention where the patients will receive the device alone
215087482|NCT00504140|DRUG|Etoposide|100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
215087483|NCT00504140|DRUG|Interferon Alpha|5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days
215087484|NCT05155501|PROCEDURE|Robot-assisted radical prostatectomy (RP)|The conventional approach to prostate cancer surgery
215087485|NCT05155501|PROCEDURE|Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)|A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate.
215087486|NCT04545437|OTHER|Admission to ICU|Exposure is admission to an Intensive Care Unit
215087487|NCT05216055|COMBINATION_PRODUCT|Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline|Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg) Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug) Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg) Normal saline 0.9%, 18.5mL
215087488|NCT05216055|DRUG|Liposomal bupivacaine|Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
215087489|NCT00046930|BIOLOGICAL|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
214980022|NCT05828342|PROCEDURE|Endotracheal tube cuff inflation with the loss of resistance syringe method|The cuffs of the endotracheal tubes will be inflated with the epidural loss of resistance syringe, the syringe piston will be released, the syringe piston will be pushed back with oscillation, and then the cuff pressures will be measured and recorded with a cuff manometer (VBM Cuff Pressure Gauge) and an electronic injector that measures cuff pressure (AG Cufill). A three-way vein valve will be used when making this measurement. During the measurement, an epidural resistance loss injector will be attached to one valve, a cuff manometer attached to another valve, and an electronic injector (AG Cufill) measuring cuff pressure to the third track. With this technique, the possibility of leakage due to insertion and removal during measurements will be eliminated.
214980023|NCT01055990|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
214980024|NCT01055990|OTHER|blood fix|The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
215087490|NCT00046930|BIOLOGICAL|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
214980025|NCT06452342|DRUG|Tranexamic acid|Tranexamic acid 1.5 grams, orally, three times a day during menstrual cycle for the 3 month study period
214980026|NCT06452342|OTHER|No Tranexamic acid|Routine clinical care without Tranexamic acid
215087491|NCT00046930|DRUG|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
215087492|NCT00046930|DRUG|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
215087493|NCT00046930|DRUG|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
215087494|NCT00046930|DRUG|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
215087495|NCT02311569|DRUG|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
215087496|NCT03924921|OTHER|autogenic training|autogenic training
215087497|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
215087498|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
215087499|NCT00290875|BEHAVIORAL|Use of Xrays for diagnosis|
215087500|NCT02994368|OTHER|Observation|
214367863|NCT04426864|OTHER|Supervised Resistance Plus Stretching Exercises Group|According to the data obtained from 1-RM tests, an exercise prescription was developed for each woman. The participants were instructed to perform their exercises with 50% of 1-RM for six weeks. In the 7. week, weights were increased to 70-80% of 1-RM. The number of sets increased progressively (10 repetitions per set; 1 set in the first two weeks; 2 sets in the 3rd and 4th week; 3 sets in the 5th and 6th week). The muscle groups which were involved in resistance exercises were bilateral biceps, deltoid, trapezius, pectorals, serratus anterior, latissimus dorsi, levator scapulae, rhomboid, gluteal, quadriceps, hip adductor and abductor, hamstring, gastrocnemius and abdominal muscles. Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. Stretching exercises were given for the muscle groups they worked on. The exercise program was applied 3 days a week for 12 weeks.
214367864|NCT04426864|OTHER|Home-based Stretching Exercises Group|Each exercise was described to the patient by visually. For each muscle group exercise was performed for 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. Exercise program was applied 3 days in a week during 12 weeks. Each participant was called every 2 weeks to maintain compliance.
214367865|NCT01842113|DRUG|Rifaximin|Rifaximin 550mg by mouth twice a day
215087501|NCT01560455|DEVICE|single stent|single stent
215087502|NCT01560455|DEVICE|two stent|culotte
215087503|NCT01207349|BEHAVIORAL|Secondary prevention intervention trial|Close follow-up by nurses, exercise physiologist and dieteticians
215087504|NCT01207349|BEHAVIORAL|standard follow up|
214367866|NCT01842113|DRUG|Lactulose|Lactulose 30ml by mouth three times a day
215087505|NCT01113580|BIOLOGICAL|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
214367867|NCT01842113|DRUG|Lactulose Placebo|Lactulose Placebo 30ml three times a day
214367868|NCT01842113|DRUG|Rifaximin Placebo|Rifaximin Placebo twice a day
214367869|NCT03210662|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214367870|NCT03210662|BIOLOGICAL|Pembrolizumab|Given IV
215087506|NCT00695552|BEHAVIORAL|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
215087507|NCT00695552|BEHAVIORAL|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
215087508|NCT03113695|DRUG|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
215087509|NCT03113695|DRUG|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
215087510|NCT03113695|DRUG|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
215087511|NCT05149560|DRUG|Ticagrelor 90mg|All patients will be prescribed ticagrelor as monotherapy
215087512|NCT04587154|OTHER|low-fat vegan diet with 1/2 cup soybeans daily|Weekly instructions will be given to the participants in the intervention group about following vegan diet with 1/2 cup of soybeans daily.
215087513|NCT04873037|DEVICE|BTL Emsella Chair|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
215087514|NCT04873037|DEVICE|Sham BTL Emsella Chair|The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (less than 10%) power.
215087515|NCT02978703|DRUG|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
215087516|NCT01352637|DRUG|DCS (D-Cycloserine ) + Prolonged Imaginal Exposure|50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
215087517|NCT01352637|DRUG|DCS (D-Cycloserine ) + Virtual Reality Exposure|50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
215087518|NCT01352637|DRUG|Placebo + Prolonged Imaginal Exposure|Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
214367871|NCT03773393|BIOLOGICAL|CK0801|CK0801 (a Cord blood-derived T-regulatory cell product)
214367872|NCT05298150|OTHER|Dynamic cycling|The dynamic cycling involves smart bike that changes according to participants' performance.
215087519|NCT01352637|DRUG|Placebo (sugar pill) + Virtual Reality Exposure|Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
215087520|NCT03238118|OTHER|Attention bias modification training|"Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
214367873|NCT05298150|OTHER|Forced cycling|The same smart bike as used for dynamic cycling, but its adaptive capacity will be disabled. In this case, the bike will behave as standard exercise stationary bike. It will not change its performance according to participants' response.
214367874|NCT00501826|DRUG|Cyclophosphamide|Given IV
214367875|NCT00501826|DRUG|Cytarabine|Given IV
214367876|NCT00501826|DRUG|Dexamethasone|Given IV or PO
214367877|NCT00501826|DRUG|Doxorubicin Hydrochloride|Given IV
214367878|NCT00501826|DRUG|Mercaptopurine|Given PO
214367879|NCT00501826|DRUG|Methotrexate|Given IV and PO
214367880|NCT00501826|DRUG|Nelarabine|Given IV
214367881|NCT00501826|DRUG|Pegaspargase|Given IV
214367882|NCT00501826|DRUG|Prednisone|Given PO
214367883|NCT00501826|DRUG|Venetoclax|Given PO
214367884|NCT00501826|DRUG|Vincristine Sulfate|Given IV
214367885|NCT05139875|DRUG|Betamethasone Dipropionate / Betamethasone Sodium Phosphate|Single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate (Diprospan) injections to affected knee
214367886|NCT05139875|DRUG|Triamcinolone Acetonide 40mg/mL|Single intra-articular Triamcinolone Acetonide injections to affected knee
214367887|NCT04723823|OTHER|Motor or sensory imagery with fMRI|Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury
214367888|NCT06441565|DRUG|Fruquintinib|A treatment cycle of 4 weeks, with 5 mg orally once daily for 3 weeks, followed by a 1-week break
214367889|NCT06441565|DRUG|Fluorouracil|2.8 g/m² (400mg bolus + 2.4g/m² continuous infusion) given every 2 weeks through hepatic arterial infusion
215087521|NCT03238118|OTHER|Attention Control Training|"Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
214980027|NCT03963440|OTHER|Exercise Adherence Rating Scale (EARS)|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
214980028|NCT05325359|BEHAVIORAL|L test|"It is an expanded version of the TUG and is designed to assess advanced functional ambulation with more detail available elsewhere. It is recorded when the participant gets up from the chair, walks 3 m to a cone, turns 90° to the right, continues to walk 7 m to the next cone, turns 180° left around the cone, then returns to the chair the same way. The test time is recorded, starting with the word go and ending with the participant's back touching the back of the chair."
214980029|NCT00596492|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
214980030|NCT00596492|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
214980031|NCT04937790|BEHAVIORAL|Core stabilization group(CSG)|Exercises training of this group occurs from 3 stages. In the stage 1 covering the first two weeks, core stabilization exercises are going to be applied 3 sets of 10 repetitions except side plank. Side plank is going to be performed 3 sets of 10 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, exercises are going to be performed 3 sets of 12 repetitions except bride dog, plank and side plank. These exercises are going to be applied 3 sets of 15 seconds. Patients are going to perform exercises of stage 3 from 6 to 8 weeks. Exercises of stage 3 are going to be practiced 3 sets of 15 repetitions except bride dog, side plank and plank exercises which are going to be applied 3 set of 20 second. All stages include the same exercises except modified push-up exercise includes instead of plank exercise in stage 1. All of the exercises are going to practiced 3 days a week for 8 weeks. One of the sessions is estimated to take approximately 45-60 minutes.
215087522|NCT03238118|OTHER|Psychoeducation|Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
215087523|NCT02537405|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
214367890|NCT06441565|DRUG|Oxaliplatin|85 mg/m² given every 2 weeks through hepatic arterial infusion
214367891|NCT04994158|COMBINATION_PRODUCT|Drugs, procedures|standard of care only. non interventional registry.
214492148|NCT05747794|BIOLOGICAL|eftilagimod alpha|APC activator, MHC II agonist
214492149|NCT05747794|DRUG|Paclitaxel|paclitaxel will be given as standard of care (chemotherapy)
215087524|NCT02537405|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
215087525|NCT01934309|BEHAVIORAL|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
215087526|NCT02189278|BEHAVIORAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
215087527|NCT00002254|DRUG|Alovudine|
214367892|NCT02288754|DIAGNOSTIC_TEST|Blood test|No intervention except to collect blood for diagnostic test development
214367893|NCT02744833|DRUG|GMI-1271|
214367894|NCT02744833|DRUG|Enoxaparin Sodium (Lovenox®)|
214367895|NCT00423384|DRUG|Placebo|Placebo
214367896|NCT00423384|DRUG|Ibandronate|I.v.
214367897|NCT05864781|BEHAVIORAL|Jigsaw Technique|Jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
214367898|NCT04481737|BEHAVIORAL|Peer-delivered and Technology Support Integrated Illness Management and Recovery|PDTA-IIMR is delivered by a peer support specialist with the use of guided IIMR eModules and a smartphone application designed to complement in-person eModule sessions. The eModules are designed to be reviewed with a peer support specialist and consumer during one-hour, weekly, telephonic sessions in a community setting. Each eModule includes videos and experiential learning tasks on psychoeducation and coping skills training.
214492150|NCT05747794|OTHER|placebo|placebo matching eftilagimod alpha
214492151|NCT06737315|PROCEDURE|Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning|The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK)
214492152|NCT06789874|PROCEDURE|Intralesional Saline|Intralesional Saline injected in scars
214492153|NCT06789874|PROCEDURE|35% trichloracetic acid peel|35%Trichloracetic acid peel was applied to scars monthly for 3 months
214492154|NCT06890286|DRUG|BR3006|One tablet administered alone
214492155|NCT06890286|DRUG|BR3006A|One tablet administered alone
214492156|NCT06890286|DRUG|BR3006B|One tablet administered alone
214492157|NCT06890286|DRUG|BR3006C|One tablet administered alone
214680179|NCT02864745|DEVICE|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
214980032|NCT04937790|BEHAVIORAL|Wobble board group (WBG)|Patients in this group are going to perform exercise on computerized wobble board. This device is going to provide unstable surface to patient and offer visual feedback about their movement qualities. The 8 weeks program consists of 3 stages and each stage includes six exercises. In the first stage covering the first two weeks, repetitive exercises are going to be practiced 3 sets of 10 repetitions; time controlled exercises are going to be practiced 3 sets of 20 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, repetitive exercises are going to be performed 3 sets of 12 repetition and time controlled exercises are going to be performed 3 sets of 25 seconds. Stage 3 is going to last from 6 to 8 weeks. In this stage, repetitive exercises are going to be practiced 3 sets of 15 repetitions and time controlled exercises are going to be practiced 3 sets of 30 seconds. One of the sessions is estimated to take approximately 45-60 minutes.
214980033|NCT04805268|DIAGNOSTIC_TEST|18F FDG PET/CT|18F FDG PET/CT imaging (fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography).
215087528|NCT03974737|DEVICE|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
215087529|NCT06965192|BEHAVIORAL|Visual|Physician participants will view the visual decision support before entering the patient's room during the intervention period, with the option to share with the patient.
214367899|NCT04481737|BEHAVIORAL|Peer support|Peer support is a non-manualized form of social support, frequently coupled with instrumental support, that is mutually offered or provided by persons having a mental health condition to others sharing a similar mental health condition to bring about a desired social or personal change. Peer support specialists are provided with 1-hour of supervision each week
214367900|NCT05780489|DIAGNOSTIC_TEST|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
214367901|NCT03897257|DRUG|UHE-103A1 cream|Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
214367902|NCT03897257|DRUG|UHE-103A2 cream|Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
214367903|NCT03897257|DRUG|UHE-103B cream|Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.
214980034|NCT00571675|DRUG|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
214980035|NCT00571675|DRUG|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
214980036|NCT02014272|DRUG|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
214980037|NCT02014272|DRUG|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
214980038|NCT01863771|DRUG|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
214980039|NCT01863771|OTHER|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
214980040|NCT04621331|DRUG|Roxadustat|HIF-PH inhibitor for treatment of anemia in CKD
214980041|NCT03281044|DRUG|Fecal microbiota capsules|Patients will receive FMT capsules DE containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
214980042|NCT03281044|DRUG|Placebo oral capsule|The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
215087530|NCT06965192|OTHER|No intervention|No intervention
215087531|NCT05639751|DRUG|PRT3789|PRT3789 will be administered by intravenous infusion
215087532|NCT05639751|DRUG|Docetaxel|Docetaxel will be administered by intravenous infusion
215087533|NCT05082259|DRUG|ASTX660|ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).
215087534|NCT05082259|DRUG|Pembrolizumab|"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
215087535|NCT05153070|DRUG|Cyclosporin|• Ciclosporin: 5mg/kg, twice a day, oral, between Day 1 and Day 60
214367904|NCT03897257|DRUG|UHE-103A1B cream|Investigational combination-therapy cream (containing drug A \[low dose antifungal\] + drug B \[keratolytic\]).
214367905|NCT03897257|DRUG|UHE-103A2B cream|Investigational combination-therapy cream (containing drug A \[high dose antifungal\] + drug B \[keratolytic\]).
214367906|NCT04348305|DRUG|Hydrocortisone|Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
214367907|NCT04348305|DRUG|Sodium Chloride 9mg/mL|Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
214367908|NCT06220955|OTHER|centric relation registration|centric relation registration using conventional and digital methods
215087536|NCT05153070|DRUG|ILT101|• ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.
214367909|NCT06220955|OTHER|maximum intercuspation registration|maximum intercuspation registration
214367910|NCT03611348|DRUG|Latanoprost|"Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~* To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded."
214367911|NCT03611348|DEVICE|Microneedling|A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
214367912|NCT06732557|OTHER|Traditional treatments|Isometric exercise for deep neck flexors and sub occipital release
214367913|NCT06732557|OTHER|muscle energy technique|Muscle energy technique for upper trapezius, elevator scapulae and sternocleidomastoid
214367914|NCT06732557|OTHER|Mulligan Mobilization|Mulligan mobilization in the form of SNAGS for rotation, lateral flexion, extension and flexion
214492158|NCT06936124|PROCEDURE|Deep Brain Stimulation of the Pedunculopontine Nucleus|The DBS implantation procedure targeting the PPN involves a neurosurgical operation performed under general anesthesia. During the procedure, thin electrodes are implanted in the PPN with the aid of advanced pre-operative imaging (MRI and CT scan) to confirm precise targeting. This device generates and transmits electrical impulses to the PPN, which can be adjusted to optimize therapeutic outcomes.
214980043|NCT03627676|PROCEDURE|Cryoablation|Two percutaneous cryoprobes would be used for all patients. The 17-Gauge cryoprobes is introduced into the masses under US guidance. Mean distance to the skin has to be 5mm at least. Although US guidance is used, a non-enhanced CT scan may be used to assess the position of the cryoprobes before ablation, and to obtain a baseline examination in order to avoid thermal injuries to adjacent tissues such as the bowel during the ice growth. No ice extension to the skin has to be observed during cycles assessed by real-time US monitoring. Each cryoablation procedure involves 3 successive cycles: 10 minutes freeze with Argon gas, followed by 9 minutes passive and 1 minute active thawing with Helium gas, followed by a second 7 minutes freeze. The ice covered the entire targeted lesion on the short axes is visualize by US or CT-scan performed at the end of the three cycles or after repositioning. At the end of the cryoablation procedures, the probes are removed through active thawing.
214980044|NCT06098989|PROCEDURE|Radio frequency ablation|Radio frequency ablation
214492159|NCT06938984|DEVICE|Sham Comparator|Massaging the quadriceps with one of the Human TECAR probes with the device turned off for 10 minutes
214492160|NCT06938984|DEVICE|Capacitive mode before|Capacitive mode applied to the quadriceps for 10 minutes
214492161|NCT06938984|DEVICE|Resistive mode before|Resistive mode applied to the quadriceps for 10 minutes
214492162|NCT06938984|DEVICE|Capacitive mode after|Capacitive mode applied to the quadriceps for 10 minutes
214492163|NCT06938984|DEVICE|Resistive mode after|Resistive mode applied to the quadriceps for 10 minutes
214980045|NCT02106481|DRUG|Femoral Nerve Catheters|"Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.~Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)"
214980046|NCT02106481|DRUG|Single Shot Femoral Nerve Blocks|The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
215087537|NCT05153070|DRUG|Placebo|• Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.
215087538|NCT06107816|BEHAVIORAL|Usual Care|Visit with a primary care provider and referral for diabetes self-management education and support (DSME/S) sessions
215087539|NCT06107816|BEHAVIORAL|F&V Rx alone|Usual Care plus four F\&V prescriptions that are independent of DSME/S attendance
215087540|NCT06107816|BEHAVIORAL|F&V Rx plus DSME/S|Usual Care plus four F\&V prescriptions that are dependent on DSME/S attendance
215087541|NCT03826680|PROCEDURE|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia
215087542|NCT03826680|PROCEDURE|Direct laryngoscopy|Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
214367915|NCT06473584|DIAGNOSTIC_TEST|Diabetes detection|Fasting glycemia on blood sample
214492164|NCT06890585|DRUG|ZCR-CHOP|Zanubrutinib, Chidamide, and Rituximab Induction Therapy Sequentially Combined With or Without CHOP
214492165|NCT06890585|DRUG|R-CHOP|R-CHOP
214492166|NCT06940180|DRUG|Toripalimab|An anti-PD-1 monoclonal antibody, single-use vial, via intravenous (into the vein) infusion per protocol.
214492167|NCT06940180|DRUG|Carboplatin|An antineoplastic agent, multi-dose vials, via intravenous (into the vein) infusion per standard of care.
214492168|NCT06940180|DRUG|Docetaxel|A taxoid antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.
214367916|NCT06901388|PROCEDURE|Non-surgical peri-implant therapy|Standardized non-surgical therapy consisting of mechanical debridement of peri-implant sites using ultrasonic instruments, combined with personalized oral hygiene instruction. The intervention is delivered in a single session. No adjunctive antimicrobials are used. Follow-up is scheduled 3 months after therapy for clinical and psychometric re-evaluation.
214367917|NCT07076797|OTHER|EXERCISE TRAINING|PHYSIOTHERAPY PROGRAM
214367918|NCT07076797|OTHER|NMES|PHYSIOTHERAPY PROGRAM
214492169|NCT06940180|RADIATION|Radiation Therapy|per standard of care
214492170|NCT06940180|DRUG|Cisplatin|An antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.
214492171|NCT06880965|DIAGNOSTIC_TEST|testing implant stability|testing implant stability by using the periotest device
214492172|NCT06880965|DRUG|use concentrated growth factor.|short implants assisted over denture in combination with concentrated growth factor.
214367919|NCT07092488|PROCEDURE|Advanced Platelet-Rich Fibrin Plus (A-PRF+) Revascularization Procedure|The intervention consists of the advanced platelet-rich fibrin plus (A-PRF+) revascularization protocol. It includes minimal mechanical instrumentation of the root canal, disinfection using sodium hypochlorite irrigation, and intracanal medicaments-initially calcium hydroxide followed by triple antibiotic paste. Peripheral venous blood was drawn from each participant into anticoagulant-free sterile tubes. The blood was immediately centrifuged at 1300 rpm for 8 minutes to obtain the A-PRF+ clot, which was then used as the scaffold material, extending through the root canal into the coronal cavity. The cavity was permanently sealed with glass ionomer cement. This protocol aims to promote regenerative healing and continued root development in necrotic immature permanent teeth.
214367920|NCT07092722|DIETARY_SUPPLEMENT|LN18178|400 mg, One capsule to be consumed in the morning after breakfast with water for 12 Weeks
214367921|NCT07092722|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed in the morning after breakfast with water for 12 Weeks
214492173|NCT06880965|RADIATION|marginal bone loss calculation|marginal bone loss calculation by digitized periapical radiograph
214492174|NCT06952725|BEHAVIORAL|online quit-smoking support group with intelligent chatbot|In the intervention arm (N=60), each quit-smoking peer support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). This chatbot will monitor all posts in the group and seek to comprehend these posts using the training it has been provided. If a group member makes a post and no one responds with about 10 seconds, the chatbot will respond using one of its 25 response libraries created from knowledge bases, which contain over 1k responses in total. In effect, the intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so.
214492175|NCT06952725|BEHAVIORAL|online quit-smoking support group with unintelligent bot|In the control arm (N=60), the support groups will be connected to our original automated message-posting bot running on our secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot; it will not respond to posts if no human group member does but, instead, remain silent. However, it will post the same daily discussion topic, and at the same time of day, as the intelligent chatbot.
214980047|NCT00488397|OTHER|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
214980048|NCT06132971|BEHAVIORAL|New Beginnings Program|
214980049|NCT01218308|BIOLOGICAL|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
214980050|NCT01218308|BIOLOGICAL|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
214980051|NCT06432387|OTHER|Patients undergoing complex thoraco-abdominal aortic aneurysm repair|Patients undergoing complex thoraco-abdominal aortic aneurysm repair
214980052|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT)- 45 Gy|Dose of SBRT - 45 Gray (Gy) in five fractions
214980053|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 47.5 Gy|Dose of SBRT - 47.5 Gray (Gy) in five fractions
214980054|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)|
214980055|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)|
214980056|NCT04639882|BEHAVIORAL|Personalized normative feedback|Information presenting perceived and actual drinking norms.
214980057|NCT03843996|DEVICE|Treatment - Stratamed|To determine if Stratamed is more effective than standard of care therapy in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure.
214980058|NCT05139355|COMBINATION_PRODUCT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
214980059|NCT05396690|DRUG|Remimazolam Injection [Byfavo]|Induction dose: 6 mg/kg/h with sufentanil Maintenance dose: 1\~2 mg/kg/h with sufentanil If arousal occurs during surgery, rapidly increase the infusion rate of remimazolam to 12 mg/kg/h and infuse for 1 minute. If the patient's arousal persists after these measures, stop remimazolam infusion and replace with another drug.
214980060|NCT05396690|DRUG|Sevoflurane|Induction dose: 2\~3 mg midazolam with sufentanil Maintenance: Adjust the concentration to be BIS 35-65 based on 0.5 mac If arousal occurs during surgery, raise the concentration of sevoflurane to 1.5 MAC (increase the total gas flow rate to 8 l/min) and if arousal persists after 1 minute, administer midazolam 2-3 mg.
214980061|NCT01248455|DRUG|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
214980062|NCT04116333|DEVICE|Endotracheal tube introducer|Use of endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
214980063|NCT04116333|DEVICE|Macintosh laryngoscope|Use of the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
214980064|NCT03777501|BEHAVIORAL|non-random whole body vibration|Each participant will receive the treatment about one hour after the administration of medicine. For non-random whole body vibration group, participants will be required to maintain the erect standing position on the vibratory platform and the frequency and amplitude of vibratory stimuli will be 6Hz and 3mm respectively. Each treatment includes five sessions and each session is composed of one minute whole body vibration and one minute rest.
214980065|NCT03777501|BEHAVIORAL|occupational therapy|Participants will receive the occupational therapy including dynamic balance training and functional ambulatory training.
214980066|NCT00304629|DRUG|galantamine|
214980067|NCT01117870|OTHER|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
215087543|NCT02300519|OTHER|blood sampling|Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer
215087544|NCT03808337|RADIATION|Stereotactic Body Radiotherapy/SBRT|Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.
214980068|NCT01117870|OTHER|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
214980069|NCT05623800|OTHER|PREM-Kit|The PREM-Kit, which was created based on the Information-Motivation-Behavioral Skills model, is used in a series of HIV education sessions as part of the intervention. Over the course of three sessions, there will be a total of six weeks (one session for every two weeks). Three sub-modules, namely HIV facts and information, motivation for HIV preventive behavior, and behavioral skills for HIV prevention, will be emphasized in each session to the participants via flip chart and health educational videos. Additionally, participants will receive a QR code that gives them access to the PREM-Kit's e-flip chart, which they can see at a later time.
215087545|NCT03808337|DRUG|Systemic Therapy/Standard of Care|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
215087546|NCT05921188|BEHAVIORAL|VAULT Phase 4|Children will receive an input-based word learning treatment that is designed based on principles of statistical learning.
215087547|NCT03093493|DIAGNOSTIC_TEST|Genotyping|Genotyping by next generation sequencing
214367922|NCT07092891|PROCEDURE|Ultrasound-Guided Supraclavicular Block|Ultrasound-guided supraclavicular brachial plexus block using a high-frequency linear ultrasound probe-real-time visualization of the brachial plexus for precise anesthetic delivery.
214367923|NCT07092891|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution|30 mL used for supraclavicular brachial plexus block
214367924|NCT07092891|DEVICE|Ultrasound|Imaging for block placement
214367925|NCT07092891|DEVICE|Infrared Thermography Camera|Skin temperature monitoring
214367926|NCT07092891|DEVICE|Pulse Oximeter|Perfusion Index monitoring
214367927|NCT07094659|BEHAVIORAL|Task-Specific Balance Training|Participants in the intervention groups will receive 8 weeks of task-specific balance training that includes both functional tasks and predictable perturbations specific to slips and trips. Sessions will be completed 2x per week for 8 weeks (16 sessions total).
214367928|NCT07094659|BEHAVIORAL|Treadmill Perturbation Training|Participants in the treadmill perturbation training group will receive 8 weeks of training that includes exposure to slip-like and trip-like perturbations delivered via motorized treadmill. Sessions will be completed 2x per week for 8 weeks (16 sessions total).
214367929|NCT07094659|BEHAVIORAL|Conventional Balance Training|Participants in the conventional balance training group will receive 8 weeks of training that includes conventional exercises designed to improve balance control. Sessions will be completed 2x per week for 8 weeks (16 sessions total).
214492176|NCT03459196|DEVICE|THERMOCOOL SMARTTOUCH SF-5D Catheter|radiofrequence ablation with THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode
214980070|NCT03851289|COMBINATION_PRODUCT|platelet-rich fibrin and calcium sulfate|
214980071|NCT03851289|COMBINATION_PRODUCT|platelet-rich fibrin and xenograft|
214980072|NCT05944796|OTHER|Diathermy|The patients belonging to the experimental group will undergo 10 diathermy sessions. The control group will have the same sessions but in athermy (placebo)
214980073|NCT05944796|OTHER|Placebo|The patients belonging to the placebo group will undergo 10 placebo sessions (athermya)
214980074|NCT04942067|DRUG|APG-2575+ Pd|APG-2575 + Pomalidomide 4mg QD x 21 days + dexamethasone (40 mg for patients ≤ 75 years old or 20 mg for patients \> 75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle
214980075|NCT04942067|DRUG|APG-2575 + DRd|APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg for patients \> 75 years old) once weekly, and daratumumab will be administered intravenously at a dose of 16 mg/kg (or 1800 mg administered subcutaneously if commercially available) weekly in cycles 1 and 2 and then every 2 weeks in cycles 3 to 6 and every 4 weeks thereafter.
214980076|NCT01951300|OTHER|Gallium-68 citrate|Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
215087548|NCT04152499|DRUG|SKB264|SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
215087549|NCT06013137|OTHER|Therabot|The participants assigned to the experimental group will interact with an artificial intelligence therapy chatbot to alleviate symptoms associated with depression, anxiety, and eating disorders. The control group will not have access to this smartphone chatbot app.
215087550|NCT02317809|DRUG|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
215087551|NCT02317809|DRUG|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
215087552|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC|Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type
214367930|NCT07094178|PROCEDURE|Corticosteroid Injection|This intervention consists of a single injection of corticosteroids administered directly into the affected tendon of the shoulder. Corticosteroids are anti-inflammatory drugs used to rapidly reduce inflammation and pain associated with tendinopathy. The injection is performed under aseptic conditions by a trained physician. The aim is to provide quick pain relief and improve shoulder function, although effects may be temporary.
214680180|NCT02864745|OTHER|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
214680181|NCT05780853|DIAGNOSTIC_TEST|Tablet Game-based Assessment - YARN assessment service|Tablet game-based assessment to assess neurodevelopmental profile.
214680182|NCT05780853|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System, Third Edition (ABAS-3)|A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.
214492177|NCT05970042|BEHAVIORAL|GameDay Ready|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. The GameDay Ready program promotes increasing physical activity, reducing sedentary time, and improving dietary habits through education, behavioral self-monitoring, and goal setting. Each 60-minute intervention session includes a brief educational component followed by a group discussion of weekly progress. Following a short warmup walk, participants engage in group-based competitive physical activities and then a short cooldown walk. Participants then set individual and group-based goals for the upcoming week and discuss strategies for overcoming barriers to achieving goals. The program is sensitive to intersectional influences of gender, race, and rurality on health; and strategies to enhance motivation are threaded throughout the program.
214492178|NCT05970042|BEHAVIORAL|Walking and General Health Education|Participants receiving the comparison program will complete a 12-week walking and general health education program. Group sessions meet once per week at a publicly accessible walking track, and each 60-minute session consists of a brief educational component on a health topic followed by walking and socializing during the remainder of the session.
214492179|NCT05452941|DIAGNOSTIC_TEST|Diagnostic test on urine samples|Testing by BinaxNOW® S. pneumoniae and serotype-specific urine antigen detection (UAD) assays (UAD-1 and UAD-2).
214980077|NCT01065818|DRUG|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
214980078|NCT01592955|DEVICE|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
214980079|NCT02186041|DEVICE|Sacral Nerve Modulation|
214980080|NCT05170113|DIETARY_SUPPLEMENT|Alpinia galanga formulation|Alpinia galanga formulation capsule- 1 capsule daily
214980081|NCT05170113|DIETARY_SUPPLEMENT|Theacrine formulation|Theacrine formulation capsule- 1 capsule daily
214980082|NCT05170113|DIETARY_SUPPLEMENT|Caffeine formulation|Caffeine formulation capsule- I capsule daily
214980083|NCT05170113|DIETARY_SUPPLEMENT|Placebo|Placebo capsule- 1 capsule daily
214980084|NCT01400048|DIETARY_SUPPLEMENT|Aloe vera effervescent tablet (AVH200)|250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
214980085|NCT01400048|DIETARY_SUPPLEMENT|Placebo control|60mg Ascorbic acid
214980086|NCT04236284|DEVICE|Home-based tDCS|tDCS is a non-invasive neuromodulation technique that has been used to improved cognitive functions. It will be administered with a constant current intensity of 2 mA57 for 20 min per session/ 10 sessions total daily for 2 weeks (Monday to Friday). The device is a Soterix 1x1 tDCS mini-CT Stimulator (Soterix Medical Inc., NY) with headgear and 5 \_ 7 cm saline-soaked surface sponge electrodes.
214980087|NCT04236284|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged Exposure Therapy is a treatment for PTSD that includes the following components: a) psycho-education about the common reactions to traumatic events and presentation of the treatment rationale (sessions 1 and 2), b) repeated in vivo exposure to traumatic stimuli (in vivo exercises are assigned as homework during sessions 3 through 11), c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 through 11; patients listen to session audiotapes for homework between sessions), and d) relapse prevention strategies and further treatment planning (session 12).
214980088|NCT02271451|DEVICE|Q collar|collar worn around neck
214980089|NCT06021327|PROCEDURE|Erector spinae plane block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 3 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact the tip of the T4 transverse process , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. Adequacy of the block will be confirmed by ultrasonographic visualization of fluid spread (seen as a lifting of the erector spina muscles in both block) and after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
214980090|NCT06021327|PROCEDURE|Retrolaminar block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 1 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact T4 lamina of the vertebra , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. And after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
214980091|NCT03455517|DRUG|Venetoclax|Venetoclax and rituximab association
214980092|NCT03455517|DRUG|Rituximab|Venetoclax and rituximab association
214980093|NCT00703235|DRUG|Bevacizumab|
214980094|NCT04015739|DRUG|Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination|"Patients will receive a combination of these 3 drugs :~Bevacizumab 15mg/kg q3w IV, Olaparib 300mg BD Per Os; and Durvalumab (MEDI 4736) 1.12g IV q3w"
214980095|NCT00354315|BEHAVIORAL|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
214980096|NCT01088555|DRUG|Sodium thiosulfate|Oral administration of sodium thiosulfate pentahydrate 5% solution (American Regent) 10ml BID x 7 days
214980097|NCT04213443|OTHER|Analysis of a patient registry|Analysis of a patient registry.
214980098|NCT03106688|DIAGNOSTIC_TEST|fMRI imaging|Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
214980099|NCT03106688|DIAGNOSTIC_TEST|[11C]carfentanil PET scan|\[11C\]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
214980100|NCT03106688|DIAGNOSTIC_TEST|[18F]FMPEP-d2 PET scan|\[18F\]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
214980101|NCT03106688|DIAGNOSTIC_TEST|[18F]-FDG PET scan|Brain and body insuin stimulated glucose uptake is measured with radioligand \[18F\]-FDG.
214980102|NCT03106688|DIAGNOSTIC_TEST|Physical activity measures and fitness tests|Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
214680183|NCT05780853|OTHER|Demographic questionnaire|Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
214680184|NCT06361745|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
215087553|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex PosteriorStabilized (PS) knee implant type
215087554|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex Revision knee implant type
215087555|NCT06504524|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
215087556|NCT06504524|DRUG|Standard of Care|control arm
215087557|NCT06975358|PROCEDURE|Alveolar decortication plus CGF injection|Experimental sides will receive CGF injection (70 units) disto-buccal and disto-palatal to the maxillary canine after performing decortication. After administration of local anesthesia, two-line flap will be performed from the mesial surface of the maxillary second premolar to the distal surface of the maxillary canine Mucoperiosteal flap will be reflected in the buccal side. Two millimeters of marginal crestal bone will be held intact and using a high-speed drill and a round carbide bur (1mm diameter) under copious saline irrigation, the cortical wall will be penetrated to reach marrow spaces. Multiple perforations (10 holes for standardization) in the cortical bone will be created. The surgical site will then rinsed, and the flap will be repositioned and sutured.
215087558|NCT06975358|PROCEDURE|canine retraction without acceleration|in the control side, the maxillary canine will be retracted without any acceleration procedure
214367931|NCT07094178|PROCEDURE|platelet-rich plasma injection|This intervention involves a single injection of Platelet-Rich Plasma (PRP), which is prepared from the patient's own blood through a process of centrifugation to concentrate platelets. PRP contains growth factors that may promote tissue healing and regeneration. The injection is administered under aseptic conditions into the affected shoulder tendon by a trained physician. The goal is to enhance long-term recovery of tendon function and reduce pain.
214367932|NCT07094360|OTHER|Land-based exercise program|Land-based exercise program
215087559|NCT01969877|DRUG|cetuximab|
214367933|NCT07094360|OTHER|Hydrotherapy besides Land-based exercise program|Hydrotherapy besides Land-based exercise program
214367934|NCT07093970|DRUG|MRG006A|Administrated intravenously
215087560|NCT01969877|DRUG|cisplatin|
215087561|NCT06454149|OTHER|MALT lymphoma|New diagnosis with gastric MALT lymphoma
214367935|NCT07093775|OTHER|Tumor grade (I or II vs. III)|We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score
214680185|NCT02270398|BEHAVIORAL|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
214367937|NCT07094165|DRUG|Dexmedetomidine|Following 2 hours of bilateral muscle compression, rats in the dexmedetomidine group underwent a 1-hour period including both laparotomy and continuous intravenous dexmedetomidine infusion.
214367938|NCT07094165|DRUG|Remifentanil|Following 2 hours of bilateral muscle compression, rats in the remifentanil group underwent a 1-hour period including both laparotomy and continuous intravenous remifentanil infusion.
214492180|NCT06404320|BEHAVIORAL|PA program - MoveU.HappyU|"Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch.~Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week."
214492181|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 25mg|Given PO
214680186|NCT02270398|BEHAVIORAL|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
214680187|NCT02270398|BEHAVIORAL|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
214367939|NCT07094165|PROCEDURE|Laparotomy|A standardized laparotomy was carried out for 1 hour, during which the abdominal cavity was opened and subsequently closed. This procedure aimed to mimic the physiological impact of a one-hour surgical operation.
214367940|NCT07094165|PROCEDURE|Compression|Bilateral compression was applied to the gastrocnemius muscles for a duration of 2 hours.
214367941|NCT07094867|OTHER|customized Z shaped miniplate|Planning was done using Mimics Innovation Suite 15.0 software for surgical planning, surgical simulation, and modeling of a custom-made Z-pattern plate installed on a standard personal computer system. The milling of a plate design on a titanium block was be done.
214367942|NCT07094867|OTHER|conventional two miniplates|Mobilization of the fracture, removal of any soft tissue entrapped within the fracture line, and management of teeth in the fracture line, either by extraction or preservation. Followed by bone reduction into proper anatomical occlusion. Then conventional two miniplates was used according to Champy's osteosynthesis lines
214492182|NCT04047706|DRUG|Nivolumab|Given IV
214680188|NCT03464058|DRUG|BOS172767 tablets|Oral tablets
214680189|NCT03464058|DRUG|BOS172767 liquid capsules|Oral capsules
214680190|NCT03464058|DRUG|BOS172767 micronized capsules|Oral capsules
214680191|NCT03464058|DRUG|BOS172767 immediate release capsules|Oral capsules
214680192|NCT03464058|DRUG|BOS172767 matching placebo capsules|Oral capsules
214680193|NCT03464058|DRUG|BOS172767 matching placebo tablets|Oral tablets
214680194|NCT03464058|DRUG|Rabeprazole|Oral tablets
215087562|NCT03035253|DRUG|OMP-305B83|
215087563|NCT03035253|DRUG|FOLFIRI|Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
215087564|NCT03035253|DRUG|FOLFOX|Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
215087565|NCT06980324|OTHER|integrated neuromuscular inhibition technique|"integrated neuromuscular inhibition technique consists of:~* ischemic compression~* Positional release~* Muscle energy technique"
214980103|NCT03106688|DIAGNOSTIC_TEST|Laboratory measurements|Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
214980104|NCT03106688|DIAGNOSTIC_TEST|Questionnaires|All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
214980105|NCT03106688|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
214980106|NCT05846750|DRUG|Obinutuzumab|"Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions)；~Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression"
214980107|NCT05846750|DRUG|lenalidomide|"Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6；~Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression"
214980108|NCT03885947|BIOLOGICAL|Cord blood stem cells|CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .
214980109|NCT03885947|DRUG|Valproic Acid|Valproic Acid (VPA) expanded cord blood stem cells
214980110|NCT03885947|DRUG|Fludarabine|Fludarabine 150 mg/m2
214980111|NCT03885947|DRUG|cytoxan|Cytoxan 50 mg/m2
215087566|NCT06980324|OTHER|conventional physical therapy treatment|"Conventional physical therapy treatment:~* Ultrasound~* Hotpacks~* Iliotibial band stretching~* Static quadriceps and hamstring exercises"
214680195|NCT03658330|DRUG|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
214367943|NCT01901068|DEVICE|MonoMax|Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
214680196|NCT04937894|DRUG|Tigecycline|Efficacy and safety of Tigecycline
214980112|NCT03885947|DRUG|Thiotepa|Thiotepa 10 mg/m2
214980113|NCT03885947|BIOLOGICAL|TBI|TBI 400cGy
214980114|NCT01477307|OTHER|Hypocaloric diet|Eurodiet,standardized hypo-caloric diet, during 3 weeks
214367944|NCT07092605|DRUG|GLP-1|Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.
214367945|NCT07092605|DRUG|Placebo|Sublingual Placebo (weekly) for up to 6 months
214367946|NCT07093710|DRUG|Golidocitinib|"Cohort1: 150mg, po, qd;~Cohort2: 150mg, po, qod and 150mg, po, qd (phase Ib); RP2D (II study)"
214367947|NCT07093710|DRUG|Mitoxantrone Hydrochloride Liposome|Cohort 1: 15 mg/m2, IV, D1 and 18 mg/m2, IV, D1 (phase Ib); RP2D (II study)
214367948|NCT07093710|DRUG|GemOx|Cohort 2: Gemcitabine：1g/m2，IV，D1; Oxaliplatin：100mg/m2, IV，D1
214367949|NCT07092618|DRUG|Metformin|Increasing doses from 500mg/d to 2000mg/d metformin
214367950|NCT07092618|DRUG|Rapamycin|Increasing doses from 1mg/wk to 6mg/wk rapamycin
214367951|NCT07092618|DRUG|Naltrexone|Increasing doses from 1.5mg b.i.d. to 4.5mg b.i.d. low-dose naltrexone
214367952|NCT07092618|DIETARY_SUPPLEMENT|Vitamin C|Placebo control - increasing doses from 250mg/d to 1000mg/d vitamin C (ascorbic acid)
214367953|NCT07094633|PROCEDURE|Kegel Exercise Group|The patient was positioned in a supine lying position, with the therapist standing beside them for guidance. They were instructed to engage and contract their pelvic floor muscles for 3 to 5 seconds, followed by a relaxation phase of 3 to 5 seconds.
214367954|NCT07094633|PROCEDURE|Clamshell Exercise Group|The patient was positioned in a side-lying posture with both knees flexed at 90 degrees. One hand was placed on the hip for stability, while the other supported the head. The therapist, standing nearby, instructed the patient to lift the top knee as high as comfortably possible while keeping the feet together. The position was held for 3 to 5 seconds, after which the knee was slowly lowered back to the starting position.
214367955|NCT07093086|DRUG|Triple-targeted CAR-T Therapy|Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
214367956|NCT05514210|BEHAVIORAL|heart team meeting and discussion|When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.
214367957|NCT07093047|OTHER|Questionnaire administration|Participants are required to complete a survey collecting anonymous data
214980115|NCT01057355|PROCEDURE|EUS and/or ERCP with ethanol injections of pancreatic cyst|Lavage of cyst with 80% ethanol
214980116|NCT04474340|DRUG|COVID-19 Convalscent Plasma|The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
215087567|NCT06981013|OTHER|balance based torso weighting|The intervention in this study is the Balance-Based-Torso-Weighting (BBTW) which will be applied on individuals with MS and healthy controls. It involves the strategic placement of weights based on the assessment of the loss of balance in three dimensions: anterior-posterior, lateral, rotational to counteract the balance loss.4 The BBTW Evaluation Tool Kit will be used to determine the location of the weights. It consists of an adjustable testing vest; rigid orthotic; five pounds worth of weights divided into 1/16, 1/8, 1/4, 1/2 lb. increments; and exam evaluation forms (www.motiontherapeutics.com).
214367958|NCT07093177|BEHAVIORAL|Telerehabilitation Unit|Telerehabilitation is the use of information and communication technology (ICT) to deliver rehabilitation services remotely in participants' homes or other settings. A telerehab unit consists of a touchscreen tablet, a portable bike, elastic bands, and a pulse oximeter. A mobile Wi-Fi hotspot device will be provided for participants who have limited or no internet connection for the duration of the study. The telerehab unit is designed to work in areas with limited internet connectivity as all multimedia materials are stored locally on the tablet.
214367959|NCT06941831|OTHER|Digital Dashboard-Supported Sugira Muryango Implementation|Arm investigating technology-supported delivery of Sugira Muryango, specifically, the use of a Digital Dashboard tool developed in partnership with the University of Rwanda. Developed using co-design and user interface/user experience techniques, the Dashboard (a) streamlines collection of data on evidence-based intervention quality and reach; (b) improves visibility and searchability of implementation data by region; (c) facilitates caregiver mental health and social services referrals and follow up, and (d) serves as a training platform with resources to enhance lay worker fidelity (content-specific skills) and competence (cross-cutting skills) in evidence-based intervention delivery.
214367960|NCT06941831|OTHER|Usual Care - Sugira Muryango Implementation|Sugira Muryango intervention is delivered using traditional supervision, data entry, and quality monitoring tools.
214980117|NCT00692575|BEHAVIORAL|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
214980118|NCT00692575|OTHER|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
214980119|NCT04383197|BEHAVIORAL|Endurance exercise training|Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
214980120|NCT04383197|DRUG|Semaglutide|3 months of therapeutic treatment with semaglutide
214980121|NCT04951141|BIOLOGICAL|anti-GPC3 CAR-T cells|A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.
214980122|NCT00839124|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
214980123|NCT00839124|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
215087568|NCT06980597|BIOLOGICAL|OL-108|OL-108 will be given through IV bolus with ascending dose levels to determine the maximum tolerated dose (MTD)
215087569|NCT05681195|DRUG|Pemetrexed|Participants will receive 900 mg/m\^2 via IV infusion over 10 minutes every 3 weeks x 4-8 induction cycles (21 days per cycle) as part of the induction therapy.
215087570|NCT05681195|DRUG|Zanubrutinib|"Participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 3-19 of each induction cycle x 4-8 cycles (21 days per cycle) as part of the induction therapy.~For those on maintenance therapy, participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 1-28 of each maintenance cycle (28 days per cycle) until the transplant (if applicable) or disease progression."
214980124|NCT04082052|BEHAVIORAL|Single Session Interventions|A single session intervention either active (for self-dislike) or placebo (feelings disclosure)
214980125|NCT02896166|OTHER|microwave ablation|eligible patients will be treated with microwave ablation in the primary tumor sites
214980126|NCT04058496|OTHER|Blood sampling|Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission
215087571|NCT05681195|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT will occur in participants who are candidates for this procedure according to standard of care institutional protocols
215087572|NCT05681195|RADIATION|Whole Brain Radiation Therapy (WBRT)|WBRT will occur in participants who are candidates for this procedure but not candidates for ASCT according to standard of care institutional protocols
215087573|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
214367962|NCT06944509|DEVICE|treatment with the Azurion system with Xres5|treatment with the Azurion system with Xres5
214367963|NCT06944509|OTHER|Azurion with Clairy IQ|Azurion system with the standard of care (ClarityIQ/Xres4)
214492183|NCT04047706|RADIATION|Radiation Therapy|Undergo radiation therapy
214492184|NCT04047706|DRUG|Temozolomide|Given PO
214492185|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 50 mg|Given PO
214492186|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 100 mg|Given PO
214980127|NCT02025075|DRUG|Rocuronium|Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
214980128|NCT01064544|PROCEDURE|light therapy with the device: EnergyLight|2 hr of light therapy during each hemodialysis session
214980129|NCT03766035|DEVICE|SpyGlass DS I - II|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
214980130|NCT02391831|OTHER|Strength, function and activity measurements|
214980131|NCT02391831|OTHER|Muscle MRI|
214980132|NCT02391831|OTHER|Electrophysiology measurements|
214980133|NCT02391831|OTHER|Blood sampling for biomarker analysis|
214980134|NCT03236454|DEVICE|DC-Stimulator MC, NeuroConn|20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
214980135|NCT00095979|DRUG|ixabepilone|Given IV
214367964|NCT05797103|DEVICE|A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands|Electrolyzed water spray group will use the novel electrolyzed water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate. Untreated tap water group will use the untreated tap water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate.
214980136|NCT04384900|PROCEDURE|Prone position ventilation|Patients are placed in a prone position using specialized equipment.
214980137|NCT04960215|DRUG|Coenzyme Q10|Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.
214980138|NCT04960215|DRUG|Placebo|A soft gelatin capsule containing soy oil, 5 capsules a day.
214980139|NCT01120262|GENETIC|gene expression analysis|
214980140|NCT01120262|GENETIC|polymorphism analysis|
214980141|NCT01120262|OTHER|laboratory biomarker analysis|
214980142|NCT03469115|DIAGNOSTIC_TEST|Serum blood|Serum blood test for laboratory analysis to determine level of alpha defensin
214980143|NCT00239148|DRUG|E1 and G1|
214980144|NCT06525116|OTHER|MRD|Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)
214680197|NCT05764798|DRUG|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
214980145|NCT02763774|OTHER|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
214980146|NCT02763774|OTHER|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
214367966|NCT00791323|DRUG|Ketorolac 0.4%|One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
214367967|NCT00791323|DRUG|Lubricating Eye Drop|One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
214367968|NCT00207584|DRUG|Doxycycline treatment|
214680198|NCT05764798|DRUG|Control group: Placebo combined with zolpidem|Placebo and zolpidem orally for 8 consecutive weeks
214367969|NCT03698565|OTHER|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
214980147|NCT02763774|OTHER|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
214980148|NCT00270023|DRUG|epoetin alfa|
214980149|NCT01719250|DRUG|Buparlisib|Given PO
214367970|NCT02235545|DEVICE|St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
214367971|NCT05062486|DRUG|Resveratrol, Quercetin, Curcumin (RQC)|100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
214367972|NCT05062486|DRUG|Curcumin|1000 mg curcumin BID
214680199|NCT00840645|DRUG|YM178|Oral
214980150|NCT01719250|OTHER|Laboratory Biomarker Analysis|Correlative studies
214980151|NCT01719250|OTHER|Questionnaire Administration|Ancillary studies
214980152|NCT03671070|DRUG|Epinephrine|IV Low dose Boluses
214980153|NCT03671070|DRUG|Traditional management of shock|"1. Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~2. Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~3. Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency."
214980154|NCT03173417|BIOLOGICAL|IM19 CAR-T|T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
214980155|NCT03173417|DRUG|fludarabine and cyclophosphamide|Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
214980156|NCT02932657|OTHER|Non interventional study|First individual interviews will be set up with teenagers of Nantes University Hospital . Then, focus group will be conduct with patients and professionals in Nantes and Foch University Hospital.
214980157|NCT03785028|BEHAVIORAL|working memory and attention|working memory and attention tasks
214980158|NCT03098316|DIAGNOSTIC_TEST|Metabolomics analysis of patient samples|Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
214367973|NCT06431503|OTHER|Tok-Sen Massage|Press the wedge and tapping: the strength for pressing the wedge is 1000g±50g, the height for mallet free fall(instead of beating by arm)10cm±2cm. For Pressure massage, the strength for pressing the wedge is 1500g±50g.
214367974|NCT06431503|OTHER|Pressure Massage|Press the wedge: the strength for pressing the wedge is 1500g±50g,
214680200|NCT04163146|DIAGNOSTIC_TEST|Measurements of PEF and FEV1|Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
214980159|NCT02791256|DRUG|Ribavirin|
214980160|NCT02791256|DRUG|peginterferon alfa-2a|
214980161|NCT01746719|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
214980162|NCT01746719|DRUG|Etodolac|500 mg tablet once a day
214980163|NCT05704816|OTHER|Spinal anesthesia application|The success of the needles with different tip designs and thicknesses used in spinal anesthesia application
214980164|NCT03337516|BIOLOGICAL|Blood sampling|Blood sampling in order to assess cytarabine pharmacokinetics
215087574|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
214367975|NCT05673070|DIETARY_SUPPLEMENT|Ritual Epre Multivitamin-mineral supplement|The Ritual Epre supplement uses methyl folate instead of folic acid and has higher vitamin D and biotin contents compared to the control supplement.
214367976|NCT05673070|DIETARY_SUPPLEMENT|control MVI|The control MVI supplement is a commercially available product from another brand. Since this MVI doesn't contain DHA, a pill of DHA will also be provided to participants in this group.
214367977|NCT05838261|PROCEDURE|Pharyngeal flap|Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap will be evaluated with patient- and parent reported outcome measures before and after the surgery.
214367978|NCT01878929|DRUG|Allergen(Tree, Grass, Weeds)|Greer is manufacture of all allergen extract used in this study.
214492187|NCT04668729|OTHER|Chiropractic Manipulation|"Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position."
214492188|NCT00002866|BIOLOGICAL|filgrastim|
214492189|NCT00002866|DRUG|docetaxel|
214492190|NCT00002866|DRUG|epirubicin hydrochloride|
214492191|NCT02325466|DRUG|Aspirin|Aspirin 81mg
214492192|NCT02325466|DRUG|Ticagrelor|ticagrelor 90 mg
214492193|NCT02325466|DRUG|Aspirin Placebo|
214492194|NCT02325466|DRUG|Ticagrelor Placebo|
214492195|NCT04644042|PROCEDURE|Glenohumeral arthroscopy + Arthroscopic Subacromial Decompression|In addition to the glenohumeral athroscopy a lateral portal will be used to access the subacromial space. The subacromial space will be decompressed with removal of inflamed bursal tissue and acromioclavicular osteophytes, release of the coracoacromial ligament, and, if deemed necessary by the surgeon, acromioplasty performed ad modum Caspari.
214492196|NCT04644042|PROCEDURE|Glenohumeral arthroscopy + lateral skin incision|Glenohumeral arthroscopy is performed as a standard investigational procedure. The patient is put under general anesthesia and positioned in the 'beach chair position'. An anteriorsuperior portal and a posterior mid-glenoid portal are used as entry to the joint. The following structures are investigated as a minimum: the articular surface of the humeral head and the glenoid, labrum, the long biceps tendon and its attachment at the superior labrum, the undersurface of the supraspinatus and the infraspinatus tendon, the subscapularis tendon and the glenohumeral ligaments. To allow for the best possible blinding a skin incision (mimicking the one used for arthroscopic subacromial decompression) is performed on the lateral side of the shoulder of the participants in the control group. The obturator is introduced in the subcutaneous tissue and a slight circular release is performed. The deltoid fascia is not perforated and the subacromial space is not entered.
214492197|NCT00070486|DRUG|carboplatin|given IV
214492198|NCT00070486|DRUG|celecoxib|given PO
214492199|NCT00070486|DRUG|gemcitabine hydrochloride|given IV
214980165|NCT03337516|GENETIC|Genetic analysis|Genetic analysis in order to determine genetic polyporphism of Deoxycytidine Kinase and Cytidine Deaminase
214492200|NCT00070486|DRUG|zileuton|given PO
214492201|NCT03676088|PROCEDURE|root coverage|recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
214492202|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
214492203|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
214492204|NCT02894554|DRUG|Telbivudine|
214492205|NCT02894554|DRUG|Lamivudine|
214492206|NCT03986840|OTHER|Exercise training|A multicomponent exercise program
214980166|NCT04221334|DEVICE|Electric Toothbrush|Electric Toothbrush used to remove dental plaque and resolve gingivitis
214980167|NCT04221334|OTHER|oral health care application|phone application that shows the user brushing efficiency real time
214980168|NCT03175497|DRUG|Telatinib Mesylate|Telatinib mesylate tablets will be administrated twice a day orally
214980169|NCT04345276|DRUG|Danoprevir+Ritonavir|Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.
214367979|NCT02785640|BEHAVIORAL|Hourly prompts to stand delivered by Microsoft Outlook|Prompt group
214367980|NCT05271058|OTHER|Control group|23 eyes that didn't receive any intraoperative steroids
214367981|NCT05271058|DRUG|Dexamethasone group|23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.
214980170|NCT02104440|BIOLOGICAL|"Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro"|
214980171|NCT00591799|DEVICE|The Jarvik 2000 Ventricular Assist System|Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
215087575|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
215087576|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
215087577|NCT06979843|OTHER|A psychosocial model|"The first aim is to evaluate if participating in the psychosocial model (including Team Young and PRISM) maintains or improves psychological resilience, psychological wellbeing, quality of life and hope among AYAs at a six-month follow-up, compared to time of diagnosis. The second aim is to evaluate how participants in the model of psychosocial support (including Team Young and PRISM) experience it with regard to acceptability, relevance and benefit.~The design is a longitudinal cohort study."
214367982|NCT05271058|DRUG|Triamcinolone (TA) group|23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
214367983|NCT00089089|DRUG|decitabine|Given IV
214680201|NCT03195634|DRUG|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate \>55 beats per minute, or up to 12.5 mg/day
214680202|NCT06077630|OTHER|No intervention|There is no intervention, observational study
215087578|NCT06980701|BEHAVIORAL|AI OHI group|The participants will receive personalized OHI such as toothbrush and interdental cleaning to specific areas provided by AI. An mHealth system will be used to detect intraoral photograph of anterior teeth and analysis of the photograph and label the gum condition as Healthy (green)/questionable (yellow)/diseased (red) within 2 minutes by AI. Then specific OHI to each particular site would be provided by AI according to tested results on the photograph
215087579|NCT06980701|BEHAVIORAL|Dental professionals OHI group|ll participants will receive personalized OHI by dental professionals. This instruction includes brushing and interdental cleaning in each particular dental site. If they have any personal concern or unclear points regarding oral hygiene practice, they can ask.
214680203|NCT05037903|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive and behavioral interventions aimed at increasing behavioral activation, and reducing procrastination and inattentive symptoms.
214680204|NCT03883048|OTHER|Observation of bronchiectasis with pulmonary hypertension|
214680205|NCT02998008|BEHAVIORAL|high intensity interval training|
215087580|NCT02603445|DRUG|BCL201|
215087581|NCT02603445|DRUG|Idelalisib|
215087582|NCT05837767|RADIATION|Stereotactic body radiotherapy|The primary site requiring palliative radiotherapy will receive conventional SBRT dosing of SBRT (or an alternate standard-of-care schedule).
215087583|NCT05837767|RADIATION|Lattice Radiation Therapy|A second metastatic site (GTV volume at least 100 cc) will receive elective palliation with a lattice RT pattern (LRT).
215087584|NCT06980909|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
215087585|NCT06980909|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors
215087586|NCT06980909|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
214367984|NCT00089089|OTHER|pharmacological study|Correlative studies
214367985|NCT00089089|OTHER|laboratory biomarker analysis|Correlative studies
214367986|NCT00501189|BIOLOGICAL|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
214367987|NCT01592903|GENETIC|Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|"* Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.~* Sample digestion through controlled enzymes.~* Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .~* Culture of these cells.~* Morphological and genetic characterization.~* Assessment of pluripotent potential from isolated cells.~* Analysis of the degree of functionality."
214680206|NCT03384290|DRUG|PRS-060|Drug
214680207|NCT03384290|DRUG|Placebo|PRS-060 Matching Placebo
214680208|NCT05762185|DEVICE|nursing consultation|nursing consultation
214680209|NCT05297539|OTHER|Point light display|Visualization of point-light human actions
214680210|NCT04770142|DEVICE|TIRA catheter|treat hypertrophic obstructive cardiomyopathy
214680211|NCT03078608|BEHAVIORAL|Mindfulness meditation program (administered via mobile app)|Mobile app-based/online mindfulness meditation program
214680212|NCT03078608|BEHAVIORAL|Progressive muscle relaxation (via mobile app)|Mobile app-based/online progressive muscle relaxation program
214680213|NCT03811600|DIAGNOSTIC_TEST|PD1/PD-L1 exosomal expression|exosomal PD1/PD-L1 expression
214680214|NCT00723840|OTHER|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
214680215|NCT06095973|DRUG|GB-6002|Depending on the cohort, volume will be varied to administer.
214680216|NCT06095973|DRUG|Placebo|Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.
214680217|NCT06095973|DRUG|Naropin injection|Single dose of Naropin s.c. injection.
214680218|NCT03422991|OTHER|Blood sampling and Quality of life questionnaire.|Blood sampling and Quality of life questionnaire.
214680219|NCT06649903|BEHAVIORAL|Chiropractic|high speed low amplitude neck manipulation
214680220|NCT06649903|BEHAVIORAL|Osteopathy|the stomach and liver technique was applied
214680221|NCT03868553|OTHER|No intervention|observational study
214980172|NCT03844841|DRUG|Propofol|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced via the continuous infusion of propofol using a target-controlled infusion (TCI) pump. The effect-site propofol concentration will be initially set to 1.5 µg/ml, unless the patient is already sedated by fentanyl. Subsequently, an effect-site propofol concentration of 1 µg/ml will be chosen adjusted stepwise (using steps of 0.3 µg/ml) to reach a target score of 2-3 on the MOAA/S scale. In case of pain fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
215087587|NCT06981572|PROCEDURE|Modified Enhanced Recovery After Surgery Protocol|This study is to determine the comparison of the effectiveness of the ERAS modification protocol with the standard protocol in reducing length of stay and improving postoperative outcomes for pediatric patients at RSCM who underwent major gastrointestinal surgery using the ERAS modification method. This study is a single-blind clinical trial. Research subjects will be randomly divided into two groups, namely the group who underwent surgery with the ERAS modification protocol and the group who underwent surgery without the ERAS modification protocol. Modified ERAS protocol will be applied during perioperative
215087588|NCT04511117|OTHER|Control group|ProTaper Next rotary system and iRoot SP sealer with composite restorations.
214980173|NCT03844841|DRUG|Dexmedetomidine|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced with a loading dose of dexmedetomidine (0.8 µg/kg) over 10 minutes. The maintenance dexmedetomidine dose is adjusted to the appropriate sedation criteria for CA (0.4 µg/kg/h) and for a target score of 2-3 on the MOAA/S scale. In case of pain, additional fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
214980174|NCT01126892|DRUG|Nilotinib|
214980175|NCT01079780|BIOLOGICAL|cetuximab|Given IV
214980176|NCT01079780|BIOLOGICAL|ramucirumab|Given IV
214980177|NCT01079780|DRUG|irinotecan hydrochloride|Given IV
214980178|NCT02696889|PROCEDURE|ROSE-1 Protocol|A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur.
214980179|NCT05496023|DEVICE|Percutaneous coronary intervention|"1. Pre-PCI angio-FFR was calculated and virtual pullback was generated~2. Automated algorithm to calculate delta angio-FFR per unit length and co-registered onto coronary angiogram was developed~3. PCI was performed using 2nd generation DES"
214980180|NCT02081989|PROCEDURE|Renal denervation|Renal denervation
214980181|NCT03322293|DRUG|Aminolevulinic Acid Topical 20% Topical Solution|PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
214980182|NCT03322293|DEVICE|BLU-U blue light phototherapy illuminator|Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.
214980183|NCT01392599|PROCEDURE|SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)|After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
214980184|NCT01093768|DRUG|Oxytocin|
214367988|NCT01561859|BEHAVIORAL|Cognitive Enhancement Therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
214680222|NCT03477188|BEHAVIORAL|Somatosensorial and Vestibular Exercises|In the experimental group, the subjects who were taken to the somatosensorial and vestibular exercises program after pre- treatment evaluations. The subjects in this group were given classical physiotherapy and somatosensorial combined with vestibular exercise performed 5-7 days a week, 1 set of 10 times with physiotherapist control. In the content of the training, in addition to the general physiotherapy program applied for Brunnstrom and Bobath exercises and spasticity inhibition according to in-bed mobility, Flask and spasticity conditions in the experimental group, a mutual study program was prepared with Cawthorne-Cooksey and Frenkel exercises in the bed, then balance and walking will be performed with the exercises
214980185|NCT01093768|DRUG|Vasopressin|
214980186|NCT03435055|DRUG|Nitrous Oxide Gas for Inhalation|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanesthetic levels (35% inhaled concentration) over 40 minutes.
214980187|NCT01937988|OTHER|Doula Arm|
214980188|NCT05580016|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activation Receptor measurement|In addition to the standard of care, Soluble Urokinase Plasminogen Activation Receptor levels will be measured in patients.
214980189|NCT01178294|BIOLOGICAL|OBI-1|Intravenous infusion
214980190|NCT02953730|DRUG|PEG-rhG-CSF|
214980191|NCT02948816|BEHAVIORAL|Facebook|Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.
215087589|NCT04511117|OTHER|Endocrown group|ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
214980192|NCT02948816|BEHAVIORAL|Facebook + Food|Participants will spend 30 minutes on a Facebook page that is food related posts.
214980193|NCT02948816|BEHAVIORAL|Colouring|Participants will spend 30 minutes colouring quietly.
214980194|NCT02431689|PROCEDURE|IVF/ICSI|controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.
214980195|NCT00022477|DRUG|BMS-247550|
215087590|NCT06450613|DEVICE|radiofrequency ablation|HCC Radiofrequency ablation
215087591|NCT06450613|OTHER|percutaneous ethanol injection|HCC percutaneous ethanol injection
214367989|NCT01561859|BEHAVIORAL|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
214980196|NCT03913962|OTHER|indirect calorimetry|Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
214980197|NCT05052580|OTHER|COVID-19 Testing|Participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known COVID-19 exposure on day 0. If the COVID-19 tests are negative, the participant will remain in the school environment. A positive COVID-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines.
214980198|NCT03712280|DRUG|MNK6106|1 gram tablet of MNK6106 for oral administration
214492207|NCT06453174|OTHER|Adherence to the first prescribed antipsychotic medication|We shall compare adherence to the first prescribed antipsychotic medication and pragmatic clinical and functional outcomes between two cohorts of patients with first-episode psychosis. One cohort will be comprised of patients treated before the implementation of an early intervention in psychosis model of Personalised Precision Psychiatry including pharmacogenetics, and the other of patients treated under this new model. Also, we shall compare the pharmacogenetic profiles and possible phenocopies (variations of phenotypes produced environmentally, e.g., due to polypharmacy, rather than genetically) between these first episode psychosis patients and a national cohort of patients with longer-term psychotic disorders or with other mental health conditions, to evaluate potential implications for clinical management at different stages of a psychotic illness, and across mental disorders.
214492208|NCT01818180|DIETARY_SUPPLEMENT|URELL|
214492209|NCT01818180|OTHER|Placebo|
214492210|NCT05370378|OTHER|Hold Relax with Agonist Contraction|"1. Participant will be in prone lying and heating pad will be applied on gluteal region for 10 to 15 minutes.~2. Passive sustained stretch to piriformis will be applied for 10 seconds.~3. The participant will be asked to actively contract the muscle for about 10 seconds (isometric contraction) and then relax.~4. Immediately after that participant is ask to again actively contract the muscle against therapist resistance for 6-10 seconds.~5. Ask the participant to relax while therapist will apply stretch the muscle to its new tissue tension barrier position and this position will be maintained for 30 seconds.~6. This maneuver is repeated for 3 to 4 repetitions, each starting from where the previous finished."
214492211|NCT05370378|OTHER|Active Release Therapy|"1. Specific muscle will be warmed up by applying heating pad for 10 to 15 minutes.~2. Patient will be positioned prone lying and the therapist will be standing at the side of affected limb.~3. Therapist will apply deep pressure at the area of tenderness while patient will actively move the limb from internal to external rotation repeatedly.~4. This maneuver will take about 15 minutes to complete in one session and will be applied alternatively 3 days a week for two weeks.~5. After this, cold pack is applied and general ROMs and strengthening exercises are performed to prevent soreness"
214492212|NCT05456932|DRUG|Intravenous iron|Included participants will receive intravenous iron therapy, the dosage will be based on national pharmaceutical formulary.
214980199|NCT03712280|DRUG|Rifaximin|550 mg tablet of rifaximin for oral administration
214367990|NCT05385458|BEHAVIORAL|ACT Intervention|Acceptance and Commitment Therapy
214367991|NCT05385458|OTHER|Usual Care|Usual Care Services
214367992|NCT05897567|OTHER|resistance training|All participants perform a four-day resistance training aimed to stimulate a hypertrophic response.
214367993|NCT05897567|OTHER|ketogenic diet|Subjects allocated to the ketogenic diet arm (KD group) consume less than 50 g of carbohydrates per day.
214367994|NCT05897567|OTHER|western diet|Subjects allocated to the western diet arm (WD group) consume a standard diet based on 55% of their daily calories from carbohydrates.
214367995|NCT00780650|DRUG|Atomoxetine|80 mg oral dose, once per day for 6 weeks
214492213|NCT05456932|DRUG|Ferric maltol|Included participants will receive oral iron therapy with ferric maltol (twice a day 30mg for 12 weeks)
214492214|NCT05456932|DRUG|Ferrous fumarate|Included participants will receive oral iron therapy with ferrous fumarate (twice a day 100mg for 12 weeks)
214492215|NCT05586503|DIAGNOSTIC_TEST|ECG-gated CTAs|ECG-gated CTAs will be performed instead of static CTAs comparing to standard of care
214492216|NCT03658616|DRUG|WO3970|Application of cream to each axilla
214980200|NCT04818099|DRUG|Vortioxetine 10 mg|Vortioxetine will be used with a dosage of 10mg once a day, for 2 months.
214980201|NCT04818099|OTHER|Placebo|Placebo will be used with a dosage of one tablet once a day for 2 months.
214980202|NCT00236743|DRUG|topiramate|
214980203|NCT03797352|OTHER|Multicomponent exercise|To identify frailty and other potential health issues, and determine if Multicomponent exercise helps at-risk elderly to have better health outcomes.
214980204|NCT04268693|OTHER|urine collection|Collect three urine samples either in the clinic or at home. This will occur prior to starting neoadjuvant chemotherapy, and again at the end of the scheduled course of neoadjuvant chemotherapy.
214980205|NCT03736252|DEVICE|Orthosis provision|Hely and Weber CMC controller
214980206|NCT05251597|OTHER|green exercise with aerobic exercise|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. It is mostly applied in the form of brisk walking in the open air.
214980207|NCT03802552|DRUG|Cefadroxil|oral one-time dose of cefadroxil
214980208|NCT03802552|DRUG|Cephalexin|oral one-time dose of cephalexin
214980209|NCT01939912|DRUG|Adenosine|Antiarrhythmic agent.
214367996|NCT00780650|DRUG|Placebo|80 mg dose once per day for 6 weeks
214367997|NCT01257464|DRUG|Sitagliptin|100mg po one dose
214367998|NCT01257464|DRUG|Placebo|Sugar pill po one dose
214367999|NCT06325137|DIAGNOSTIC_TEST|Transcriptome analyses|A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0) and after 6 weeks at the definition of steroid sensitivity/unresponsiveness (time 1, t1).
214368000|NCT03727009|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
214368001|NCT04133103|PROCEDURE|first ambulation at 4 hour after operation|Two groups were conducted for first ambulation at 4 or 24 hours aftër operation
215087592|NCT07018583|BEHAVIORAL|Pharmacist's Counseling and Self-Management Application Program|This interventional study is structured around established counseling principles and self-management theory, consisting of six sequential stages: Initial Disclosure, Problem Assessment, Commitment to Action, Skill Enhancement, Monitoring, and Follow-up and Evaluation. These stages are delivered through both in-person pharmacist counseling and a dedicated mobile application. The intervention follows a repeated-measures design, with assessments conducted at 3 and 6 months after enrollment.
214980210|NCT05847608|DIETARY_SUPPLEMENT|Omega-3|Daily consumption of 500 mg DHA and 750 mg EPA in liquid form
214980211|NCT05847608|DIETARY_SUPPLEMENT|Placebo|Oleic Acid, Linoleic Acid
214980212|NCT01300403|OTHER|Flutter valve|Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
214980213|NCT01300403|OTHER|expiration with the glottis open in lateral posture (ELTGOL)|This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
214980214|NCT01300403|OTHER|Control|Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
214980215|NCT04894058|PROCEDURE|Ureteroscopic lithotripsy|"After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz."
214980216|NCT06147934|DIAGNOSTIC_TEST|Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Liver biopsy will be conducted by experienced interventionists and reported by pathologists. There should be a maximum interval of no more than 1 month between the liver biopsy and ultrasound examination, and the length of specimen should be more than 1.0cm."
214980217|NCT00733967|DRUG|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
214980218|NCT00733967|DRUG|Placebo|Matching oral placebo capsules as control.
215087593|NCT07018583|BEHAVIORAL|Usual Care|Usual care or Standard pharmacy practices such as medication reviews, patient education during the initial visit or when medication changes occur, and counseling upon patient request. No additional structured counseling or self-management tools are provided.
215087594|NCT07016152|BIOLOGICAL|Glyconjugate Klebsiella pneumoniae bivalent vaccine|CHO-V08 is a glycoconjugate bivalent vaccine in sterile suspension.
215087595|NCT07015229|PROCEDURE|septorhinoplasty|To provide scientific contribution to more effective and timely pain management strategies in the postoperative period by evaluating the time-dependent course of pain scores and the effect of analgesic intervention timing on clinical outcomes in patients who underwent septorhinoplasty and who are followed in the postanesthetic care unit.
215087596|NCT05982444|PROCEDURE|water vapor thermal therapy (Rezum) for prostate|all patients underwent rezum therapy for bph are evaluated for its effectiveness for long period
214368002|NCT03329287|BEHAVIORAL|SCBT|SCBT, one hour per session.
214368003|NCT03329287|DRUG|SSRIs and/or SNRIs|SSRIs and/or SNRIs at a recommended dosage.
214492217|NCT03658616|DRUG|Placebo (WO3988)|Application of cream to each axilla
214492218|NCT00179751|DRUG|CC-5013|
214680223|NCT03477188|BEHAVIORAL|Conventional Group|In the control group, The subjects who were taken into the study were taken to the classical physiotherapy based on Bobath and Brunnstrom will be applied to increase the mobilization and spasticity up to the discharge stage known as 5-7 days a week
214980219|NCT03248297|DRUG|Azithromycin|Azithromycin tablet
214492219|NCT00179751|DRUG|gemcitabine|
214680224|NCT06324487|OTHER|Progressive Exercises|Electrotherapy, stretching of the capsules, strengthening, ROM exercises, proprioceptive exercises
214492220|NCT03562338|OTHER|Manual Therapy and Exercise (Physiotherapy Intervention)|Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.
214492221|NCT03562338|OTHER|Usual Care (Physiotherapy Intervention)|Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
215087597|NCT06868836|DRUG|JS207|JS207 (10 mg/kg or 15 mg/kg, IV, d1)
214368004|NCT03329287|BEHAVIORAL|Psychological Placebo|Supportive and relaxation therapy, one our per session.
214368005|NCT00940238|DRUG|Citalopram Hydrobromide|
214368006|NCT03701295|DRUG|Azacitidine|Given IV or SC
214368007|NCT03701295|DRUG|Pinometostat|Given IV
214492222|NCT06433713|DRUG|Lidocaine IV|They received IV infusion of 2 mg/kg per hour of lidocaine starting with skin incision, which was maintained until skin closure. This was done using a syringe pump with the calculated amount of lidocaine added to 50 ml of normal saline infused at a rate of 50 ml/hr.
214492223|NCT06433713|DRUG|Placebo|0.9% normal saline infusion
214680225|NCT06324487|OTHER|Blood Flow Restriction Therapy|Strengthening exercises performed by using cuff surrounding proximal part of the arm.
214680226|NCT06079476|DRUG|Romosozumab|Single-use prefilled syringe for SC injection.
214368008|NCT05751174|OTHER|pediatric patients affected by severe burns|All patients admitted to the pediatric intensive care unit affected by severe burns involving more than 10% of the body surface will be enrolled.
214368009|NCT03305874|OTHER|Exposure to CBCIN risk score|The computer-based contrast induced nephropathy (CBCIN) risk score and associated standard hydration strategy will be displayed on a monitor in front of the treating interventional cardiologist during the entirety of the PCI case. Since this scoring system and hydration strategy are both available in the peer-reviewed literature, clinical use of these data and implementation of a CIN-avoidance strategy is not experimental; however, the display of these data to interventional cardiologists is experimental. Based on exposure to these data, the treating interventional cardiologist may use the information as clinically appropriate (i.e. it is not the basis for clinical decisions).
214680227|NCT04156646|DRUG|Balovaptan|Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
214680228|NCT04156646|DRUG|Esomeprazole|Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
214680229|NCT04485169|PROCEDURE|Therapeutic Plasma Exchange|a. 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
214680230|NCT04847830|DEVICE|Er:YAG laser (Waterlase)|The WaterLase iPlus tissue cutting system is a unique device with diverse, hard- and soft-tissue dental applications. It utilizes advanced laser and water atomization technologies to safely and effectively cut, shave, contour, roughen, etch, and resect oral hard-tissue, and direct laser energy to perform oral soft-tissue removal, incision, excision, ablation and coagulation.
215087598|NCT06868836|DRUG|Pemetrexed|Pemetrexed (500 mg/m², IV, d1)
214492224|NCT00000119|DEVICE|Heparin Surface-Modified Intraocular Lens|
215087599|NCT06868836|DRUG|Carboplatin or cisplatin|Platinum-based chemotherapy (carboplatin: AUC5, d1 or cisplatin 75 mg/m², d1) every 3 weeks (Q3W) for a total of 4 cycles
214368010|NCT01677221|DEVICE|Acleara Acne Treatment System|
214368011|NCT04947371|DRUG|Anlotinib Hydrochloride|Oral anlotinib hydrochloride 12 mg/d
214368012|NCT00403897|DRUG|Polyethylene glycol 3350 Na bicarbonate NaCl KCl|6.9g sachet, oral
214368013|NCT04639193|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
214492225|NCT01074294|DRUG|OPDC-34712|OPDC-34712 tablets, daily, Orally.
214492226|NCT01074294|DRUG|Placebo|Matching-placebo tablets, daily, Orally.
214492227|NCT01074294|DRUG|Stimulant Therapy|Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
214492228|NCT00412646|DRUG|TMC125|
214492229|NCT05427305|DRUG|TAB008|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
214492230|NCT05427305|DRUG|Bevacizumab|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
214492231|NCT01746706|DEVICE|PET amyloid tracer (Florbetapir F18 AV45 F18|
214492232|NCT05661708|DRUG|Chitosan|Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect
214492233|NCT02572700|OTHER|Clinical examination, blood sampling, ultrasonic assessment, and questionnaires|Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.
214492234|NCT01925144|DRUG|Baricitinib|Administered orally
214492235|NCT01925144|DRUG|Omeprazole|Administered orally
214492236|NCT03197649|PROCEDURE|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
214492237|NCT02043041|OTHER|Number of DBS Spots|The number of DBS spots on the card constitutes the experimental condition.
214492238|NCT01488656|DIETARY_SUPPLEMENT|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
214680231|NCT04847830|PROCEDURE|root surface dbridement|root surface debridement under local anaesthesia
214980220|NCT03248297|DRUG|Azithromycin and amoxicillin|azithromycin and amoxicillin
214980221|NCT03248297|DRUG|Placebo|Placebo tablet
214980222|NCT05789966|GENETIC|Genetic Risk Estimate+Health Coaching|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated through phone or Zoom calls to provide an explanation of each participant's own genetic risk of CHD as well as lifestyle modification measures.
214980223|NCT05789966|DEVICE|Genetic Risk Estimate + Fitbit Functions+Health Coaching|"Intervention: Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well"
214980224|NCT04206865|DRUG|Sacubitril-Valsartan|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion
214368014|NCT04639193|DRUG|Eszopiclone|Eszopiclone tablet (encapsulated)
214368015|NCT04639193|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone
214368016|NCT04639193|DRUG|Venlafaxine|Venlafaxine capsule
214980225|NCT04206865|DRUG|Standard Oral Vasodilators|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
215087600|NCT04786587|DIAGNOSTIC_TEST|blood test|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~the blood test for dosage of phosphatidylethanol will be offered to all eligible pregnant women in each maternity clinic of the study during the recruitment period. There will not be different arms in this study."
214980226|NCT04554472|DIAGNOSTIC_TEST|Intraoperative ultrasound|During the surgery, the standard AP and lateral x-rays will be performed. Additional projections (lateral 30 degrees tilt, and dorsal tangential view) will also be registered. Finally an intraoperative ultrasound of the wrist extensor tendons will be taken, checking the compartments individually in order to detect invasion of the dorsal cortex by the screws. In case of no protrusion, the patient will be registered as a correct fixation. Otherwise, it will be specified which position of the plate and which compartment the screw/s protrude. A screw with a correct measurement will then be replaced and implanted and recorded as a measurement error.
214980227|NCT03894358|DIETARY_SUPPLEMENT|FeFum and 7.5 g prebiotic mixture|"The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture~The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:~Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.~Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically."
214980228|NCT03894358|DIETARY_SUPPLEMENT|FeFum and 3 g prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion
214980229|NCT03894358|DIETARY_SUPPLEMENT|Fefum and no prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
214980230|NCT05379920|BEHAVIORAL|High Volume Aerobic Exercise|Aerobic exercise is completed for 30 minutes, 5 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
214980231|NCT05379920|BEHAVIORAL|Low Volume Aerobic Exercise|Aerobic exercise is completed for 20 minutes, 3 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
214980232|NCT02415972|OTHER|Ultrasound perfusion imaging|Dynamic perfusion imaging of brain parenchyma with modern ultrasound is possible with the use of ultrasound contrast media that serve as echo signal amplifier.
214980233|NCT00566085|PROCEDURE|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
214980234|NCT05269329|DRUG|XC8, film-coated tablets, 20 mg/day|20 mg/day (1 tablet twice a day)
214980235|NCT05269329|DRUG|XC8, film-coated tablets, 40 mg/day|40 mg/day (2 tablets twice a day)
214980236|NCT05269329|DRUG|XC8, film-coated tablets, 80 mg/day|80 mg/day (4 tablets twice a day)
215087601|NCT04786587|OTHER|self-administered questionnaire|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~A self-report, including the T-ACE, is the usual prenatal consultation procedure in the three maternities of the study. The specific procedure for the study is to perform a blood test for dosage of phosphatidylethanol in eligible pregnant women after informed consent."
215087602|NCT06471530|DRUG|TE-8105 SAD Cohort 1|Each participant will receive one dose of TE-8105 0.5 up to 1.5mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
214368017|NCT01106430|DRUG|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
214368018|NCT01106430|DRUG|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
214368019|NCT03175627|DEVICE|Filtek One|Restoring a posterior permanent tooth in need of a filling applying Filtek One using bulk fill technique.
214368020|NCT03175627|DEVICE|Filtek Z250|Restoring a posterior permanent tooth in need of a filling applying Filtek Z250 using incremental filling technique.
214368021|NCT01341977|DEVICE|Alcon MPDS|Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses
214368022|NCT01341977|DEVICE|ReNu Fresh MPS|ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
214980237|NCT05269329|DRUG|Placebo|1, 2, or 4 tablets twice a day
214980238|NCT01267279|DRUG|Zoledronic acid|Zoledronic acid per protocol
214980239|NCT01267279|OTHER|Placebo|Placebo
215087603|NCT06471530|DRUG|TE-8105 SAD Cohort 3|Each participant will receive one dose of TE-8105 1.5 mg or less than or equal to 2.5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
215087604|NCT06471530|DRUG|TE-8105 SAD Cohort 5 (Adaptive cohort)|Each participant will receive one dose of TE-8105 less than or equal to 6 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
215087605|NCT06471530|DRUG|TE-8105 MAD Cohort 1|Each participant will receive 0.5mg up to 1.5mg of TE-8105 injection via SC injection into the abdomen on Day 1 and then once every 2 weeks for 5 doses.
215087606|NCT06471530|DRUG|TE-8105 MAD Cohort 2|Each participant will receive 9 doses of TE-8105 injection via SC injection into the abdomen starting from Day 1 every 2 weeks. Dose will be titrated up by 0.5mg every 4 weeks, with dose levels of 1.5mg (2 doses), 2.0 mg (2 doses), 2.5 mg (2 doses) and 3.0 mg (3 doses)
215087607|NCT06471530|DRUG|TE-8105 SAD Cohort 2|Each participant will receive one dose of TE-8105 0.75mg injection via subcutaneous (SC) injection into the abdomen on Day 1.
214980240|NCT04752930|DIAGNOSTIC_TEST|ctDNA monitoring|Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled, and diagnostic laparoscopy will be performed immediately after enrollment. Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months in patients with negative peritoneal metastasis. Laparoscopy will be performed when imaging suggested peritoneal metastasis (oligometastases). Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
214980241|NCT04752930|DIAGNOSTIC_TEST|Imageology|Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled. and there will be no need to conduct endoscopic exploration immediately after enrollment. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months until imaging suggested peritoneal metastasis (oligometastases). Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
214980242|NCT00259935|DRUG|topotecan|topotecan
214980243|NCT01559441|DIETARY_SUPPLEMENT|Beetroot Juice with oral fat load|140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)
214980244|NCT01559441|DIETARY_SUPPLEMENT|Carbohydrate control drink with oral fat load|140 mL (low-nitrate) carbohydrate control drink
214980245|NCT01880606|PROCEDURE|colonoscopy with endomicroscopy|Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
214368023|NCT02579564|DRUG|Gemcitabine|
214368024|NCT02579564|DRUG|Vinorelbine|
214492239|NCT01488656|DIETARY_SUPPLEMENT|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
214492240|NCT02284113|DEVICE|iovera°|Use of iovera° device to administer treatment Focused Cold Therapy
214492241|NCT02284113|DEVICE|iovera° Sham|iovera° device used for sham treatment
214492242|NCT03006367|DRUG|NFC-1 100 mg|
214492243|NCT03006367|DRUG|NFC-1 200 mg|
214492244|NCT03006367|DRUG|NFC-1 400 mg|
214492245|NCT03006367|DRUG|NFC-1 800 mg|
214492246|NCT03756896|DRUG|Carfilzomib|Given IV
214980246|NCT03528421|BIOLOGICAL|IM19|CAR-T cells
214980247|NCT03528421|DRUG|Fludarabine|Two days before cell infusion, all patients will be treated with fludarabine for 3 days
214980248|NCT03528421|DRUG|Cyclophosphamide|Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
214980249|NCT04786769|DRUG|Ferric carboxymaltose|Intravenous ferric carboxymaltose according to baseline weight and hemoglobin
214980250|NCT03176771|DRUG|MT-5199|MT-5199 40 mg capsules
214980251|NCT03176771|DRUG|Placebo|MT-5199 placebo capsules
214980252|NCT03846869|DIAGNOSTIC_TEST|major cations|blood sample
214368025|NCT02579564|DRUG|Paclitaxel|
214368026|NCT02579564|DRUG|Pemetrexed|
214492247|NCT03756896|DRUG|Dexamethasone|Given PO
214492248|NCT03756896|DRUG|Pomalidomide|Given PO
214492249|NCT03809416|DEVICE|Lasers|Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
214368027|NCT02579564|DRUG|Oncorine|
214368028|NCT02579564|DRUG|Endostar|
214368029|NCT02579564|DRUG|Cisplatin|
214368030|NCT01500330|PROCEDURE|cupping massage|the upper back is covered in massage oil the cupping glass is drawn along the back muscles
214368031|NCT01500330|PROCEDURE|Progressive muscle relaxation|standardized programme on muscle relaxation according to Jacobson
214368032|NCT02094443|DRUG|Alisporivir|ALV 100 and 200 mg soft gel capsules administered orally
214368033|NCT02094443|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
214368034|NCT05280769|OTHER|oral nicotine pouch - 2 mg|"On brand oral nicotine pouch with 2 mg of protonated nicotine in original flavor"
214368035|NCT05280769|OTHER|oral nicotine pouch - 4 mg|"On brand oral nicotine pouch with 4 mg of protonated nicotine in original flavor"
214368036|NCT05280769|OTHER|oral nicotine pouch - 8 mg|"On brand oral nicotine pouch with 8 mg of protonated nicotine in original flavor"
214492250|NCT03809416|OTHER|Platelets Rich Plasma|Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
214492251|NCT03809416|COMBINATION_PRODUCT|Lasers plus Normal Saline Solution|Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
214492252|NCT02696161|OTHER|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
214492253|NCT02696161|OTHER|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
214492254|NCT01866215|OTHER|exercise|cycling at 100W during 60 min
214368037|NCT05280769|OTHER|Smokeless tobacco|Participant's typical brand of smokeless tobacco
214368038|NCT05605470|BIOLOGICAL|ChulaCov19 BNA159 vaccine (50 mcg)|Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
214980253|NCT02879292|OTHER|Spinal anesthesia|Spinal Anesthesia
214980254|NCT04614506|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
214980255|NCT04614506|DEVICE|Electroencephalogram (EEG)|These will be an ambulatory EEG recordings that span 24 hours and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
214492255|NCT01866215|DIETARY_SUPPLEMENT|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
214980256|NCT02445469|OTHER|MRI exam of the brain|MRI exam of the brain
214980257|NCT03030521|DIAGNOSTIC_TEST|the aortic delamination test|The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.
214980258|NCT06440928|BEHAVIORAL|mobilization|mobilization and exercise to be applied to patients with chronic lateral epicondylitis
214980259|NCT06440928|OTHER|standard treatment|standard treatment
214980260|NCT06440928|OTHER|deep friction|deep friction
214980261|NCT00000948|DRUG|Aldesleukin|Il-2
214980262|NCT00000948|DRUG|ART|antiretroviral therapy for the treatment of HIV
214980263|NCT04326257|DRUG|Nivolumab+Relatlimab|IV administration of both Nivolumab and Relatlimab
214980264|NCT04326257|DRUG|Nivolumab+Ipilimumab|IV administration of both Nivolumab and Ipilimumab
214368039|NCT05605470|BIOLOGICAL|Pfizer/BNT vaccine (30 mcg)|Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
214492256|NCT01866215|DIETARY_SUPPLEMENT|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
214492257|NCT03853161|OTHER|Vapotherm|A form of non invasive ventilation used in newborns
214492258|NCT03853161|OTHER|NIPPV|A form of non invasive ventilation used in newborns
214492259|NCT02901522|OTHER|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
214492260|NCT02901522|OTHER|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
214492261|NCT02901522|OTHER|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
214980265|NCT02980016|DRUG|rifapentine + isoniazid|Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
214980266|NCT02980016|DRUG|Isoniazid|Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
214980267|NCT02365883|DEVICE|Photoacoustic Imaging System|manufactured by Endra
214368040|NCT05605470|BIOLOGICAL|COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)|Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
214368041|NCT02514018|BIOLOGICAL|Live-attenuated varicella-zoster virus vaccine|Commercial vaccine used to prevent shingles
214368042|NCT01424930|DRUG|Abiraterone|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
214368043|NCT01424930|DRUG|Prednisone|Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
214368044|NCT02913066|OTHER|S-1 concurrent radiotherapy|Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~33 planning target volume times, 60\~66 Gray/28\~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1\~ 14 days, 21 days for a cycle.
214492262|NCT02901522|OTHER|Teleconsultation|The general practioner received phone call to asthma care.
214492263|NCT06570629|DEVICE|Oronasal CPAP|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
214492264|NCT06570629|DEVICE|Nasal CPAP plus Chinstrap|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
214492265|NCT05378347|DEVICE|Medtronic Endurant II or Endurant IIs Stent Graft System|EVAR treatment with Medtronic Endurant II/IIs Stent Graft System
214492266|NCT05378347|DEVICE|Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis|EVAR treatment with Excluder / Excluder Conformable Stent Graft System
214492267|NCT06461910|DRUG|Serplulimab|200 mg, i.v., D1, Q3W
214492268|NCT06461910|DRUG|thymalfasin|4.8mg,sc,biw
214492269|NCT06461910|DRUG|Oxaliplatin|130 mg/m2, i.v., D1, Q3W
214980268|NCT00687934|DRUG|STA-9090|This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
214980269|NCT00626288|DRUG|Mesalazine|Mesalazine 800mg t.i.d. 12 weeks
214980270|NCT00626288|DRUG|Placebo|Placebo cpr, t.i.d. 12 weeks
214980271|NCT04925102|OTHER|Standardized treatment protocol for cerebral palsy|Passive and active range of motion (ROM) exercises of all joints, prone positioning, slow prolonged manual stretching (30 minutes daily), standing frame for children with GMFCS IV-V, supported sitting, supported walking, lower limb serial casting (if needed), active strength training, progressive resistance training, functional exercises, sensory integration: therapeutic activities to organize sensation from the body and environment, bimanual training: repetitive task training in the use of two hands together, context-focused therapy: changing the task or the environment, the occupational therapy, cognitive behaviour therapy and home programmes.
214980272|NCT04741048|DEVICE|CI624 Slim 20 Electrode|Cochlear Ltd CI624 cochlear implant with Slim 20 Electrode
214980273|NCT03385733|OTHER|inspiratory muscle training|The treatment group received IMT. Patients were trained using an inspiratory threshold-loading device
214980274|NCT02024061|BEHAVIORAL|Peer support|
214980275|NCT02024061|BEHAVIORAL|Regular treatment|The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
214980276|NCT02059707|DEVICE|LARIAT RS Suture Delivery Device|LARIAT RS Suture Delivery Device
214980277|NCT03541993|DIETARY_SUPPLEMENT|Resveratrol|
214980278|NCT03541993|OTHER|Placebo|
214980279|NCT04550117|PROCEDURE|Insertion of Intraspinal pressure monitor|A fiberoptic pressure monitoring wire will be placed into the subarachnoid space at the site of traumatic spinal cord injury
214980280|NCT03276208|OTHER|Prenatal Massage|We will utilize moderate pressure Swedish massage (SM) that utilizes long slow strokes known as effleurage and kneading strokes known as petrissage. A specific routine will be performed on each participant with focus on low back, upper back, shoulders, and neck musculature. Consistent moderate pressure, which is lighter than deep tissue massage but deeper than brush strokes, will be used.
214980281|NCT03276208|OTHER|Mindfulness|The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
214980282|NCT01997125|DEVICE|Neural Bridge System|Implanted device
214980283|NCT01514916|DEVICE|mechanical anastomosis without suture|The Vascular Join device is intended to be used to create sutureless end-to-end anastomosis between an artery and a venous or synthetic graft conduit. Any type of e-PTFE and Dacron conduits can be used.
214980284|NCT05805449|PROCEDURE|Surgery|Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.
214980285|NCT05805449|OTHER|Platelet-rich plasma (PRP)|Participants will have 40-50cc of peripheral whole blood drawn into a syringe pre-loaded with acid citrate dextrose (ACD) anticoagulant and concentrated PRP harvested by double centrifugation technique using the manufacturer's kit and benchtop centrifuge. This typically yields 5-8cc of PRP that is 18-times more concentrated than baseline.
214980286|NCT05805449|DEVICE|Matrix|"Participants will receive 200g of paste matrix and 200g injected at the following sites: the internal opening closure site at level of the sphincter muscle, within the walls of the fistula tract along its length, and within the tissue of an advancement flap particularly at areas of tissue apposition."
214980287|NCT03805334|OTHER|Touchpoints|Touchpoints are worn on either the wrists or ankles. They deliver a low level vibration in an alternating fashion to the skin.
214980288|NCT01753349|BIOLOGICAL|Botulinum toxin type A|Investigators were free to prescribe any BoNT A preparation, including Dysport, Botox and Xeomin.
214980289|NCT00914121|DRUG|SKI-606|
214980290|NCT00914121|DRUG|Placebo|
214980291|NCT00914121|DRUG|Moxifloxacin|
214368045|NCT02913066|OTHER|S-1 plus Cisplatin concurrent radiotherapy|Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~30 planning target volume times, Gross tumor volume of primary tumor60\~66 Gray/28\~33), synchronous chemotherapy S-1 70 mg/m2 1\~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1\~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1\~ 14 days, plus cisplatin 25mg/m2 1\~ 4 days, 21 days for a cycle.
214368046|NCT02982525|DIETARY_SUPPLEMENT|No Mussels|Habitual diet only
214492270|NCT06461910|DRUG|Tegafur|oral administration: body surface area \< 1.25, 40 mg each time; body surface area ≥ 1.25 to \< 1.5, 50 mg each time; body surface area ≥ 1.5, 60 mg each time, twice daily for each treatment cycle at D1-D14
214680232|NCT03682588|OTHER|Physical activity|The Functional exercise group performed functional exercise training for 45 minutes twice a week for 14 weeks. The Stretching exercise group performed stretching exercises with the same duration and frequency.
214980292|NCT05728476|PROCEDURE|Vitrectomy combined with ILM peeling|Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.
214980293|NCT05728476|DRUG|Conbercept intravitreal injection|Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
214980294|NCT04676204|DRUG|Cladribine|Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults.
214980295|NCT04676204|DRUG|Dimethyl fumarate|Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
214368047|NCT02982525|DIETARY_SUPPLEMENT|One mussel portion|1 x 75g mussel portions provided per week
214368048|NCT02982525|DIETARY_SUPPLEMENT|Two mussel portions|2 x 75g mussel portions provided per week
214368049|NCT02982525|DIETARY_SUPPLEMENT|Three mussel portions|3 x 75g mussel portions provided per week
214368050|NCT00426608|DRUG|metyrapone|Metyrapone will be available as 250 mg dose capsule.
214368051|NCT00426608|DRUG|alprazolam|Alprazolam capsules will be available with dose strength of 0.25mg
214368052|NCT00426608|DRUG|placebo|GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
214368053|NCT00426608|DRUG|GSK561679|GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
214980296|NCT04676204|DRUG|Fingolimod|Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
214980297|NCT04676204|DRUG|Teriflunomide|Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
214980298|NCT04676204|DRUG|Ozanimod|Ozanimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.
214980299|NCT04676204|DRUG|Diroximel fumarate|Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
214980300|NCT03022409|DRUG|Ceralasertib|"Ceralasertib is an oral agent and will be dosed at 160 mg. Ceralasertib tablets should be taken at the same time each day, approximately 12 hours apart (maximum ± 2 hour window) with one glass of water.~Ceralasertib is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members."
214980301|NCT03022409|DRUG|Olaparib|"Olaparib is available as a green film-coated tablet containing 100 mg or 150 mg of Olaparib. Patients will be administered Olaparib orally twice daily at 300 mg bid. The Olaprib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose \[poly (ADP ribose)\] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents."
214980302|NCT02944292|PROCEDURE|Deepening of sedation|Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
214980303|NCT02944292|DRUG|Propofol|"Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered)."
214980304|NCT03588117|BEHAVIORAL|Physician-supervised nonsurgical weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
214980305|NCT06436716|RADIATION|MRI|Every patient needs an MRI to assess spinal cord injury. This is one of the clinically necessary examinations.
214980306|NCT02732639|DRUG|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
214980307|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination."
214980308|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once."
214980309|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing."
214980310|NCT05762575|OTHER|knotting methods|The volunteers in experimental group study new knotting technology.
214368054|NCT03286751|DRUG|LY900014|Administered SC
214368055|NCT03286751|DRUG|Insulin Lispro|Administered SC
214492271|NCT03885232|BEHAVIORAL|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
214980311|NCT02142842|BIOLOGICAL|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
214980312|NCT00677638|DEVICE|Ventor Embracer|Implantation of Ventor Embracer
214980313|NCT01149941|DRUG|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
214980314|NCT01780623|DEVICE|Bright white light|
214980315|NCT01780623|DEVICE|Dim red light|
214368056|NCT00648128|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
214368057|NCT00648128|DRUG|Clarithromycin|single-dose 500 mg immediate-release oral dose'
214368058|NCT00626730|PROCEDURE|adjuvant therapy|
214368059|NCT00626730|RADIATION|radiation therapy|
214368060|NCT01438125|OTHER|MF-4181|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
214368061|NCT01438125|OTHER|Standard surgical wound closure|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
214368062|NCT04406480|GENETIC|CGH-array and exome sequencing|A blood sample will be used for CGH-array and exome sequencing
214368063|NCT02389257|DEVICE|MINIMAG / MEG|
214368064|NCT02389257|DEVICE|MINIMAG / ECG|
214368065|NCT02116348|DRUG|Cerebrolysin (Nerve growth factor)|Cerebrolysin will be given to the intervention group
214368066|NCT04547725|OTHER|CRS followed by IP and systemic chemotherapies|Complete cytoreductive surgery (CRS) + normothermic intraperitoneal chemotherapy (N-IPEC) + systemic chemotherapy
214368067|NCT05651854|OTHER|pranayama breathing|Bhramari and sheetali pranayama breathing
214980316|NCT04549194|BIOLOGICAL|Blood collection|A blood sample will be collected before during and after the treatment.
214368068|NCT01621880|DRUG|bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
214368069|NCT01621880|DRUG|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
214368070|NCT01127646|DRUG|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
214680233|NCT01964365|DRUG|Cresto 20mg|tablet, rosuvastatin 20mg
214680234|NCT01964365|DRUG|Fenofibric acid 135mg|capsule, fenofibric acid 135mg
214368071|NCT01127646|DRUG|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
214368072|NCT01127646|DRUG|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
214368073|NCT02887430|OTHER|foot reflexology therapy|standard care and foot reflexology
214368074|NCT03921814|DEVICE|Treatment with IPL device|Exposure of body parts to the IPL device
214368075|NCT01568268|DRUG|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
214680235|NCT01964365|DRUG|Cresto 20mg, Fenofibric acid 135mg|rosuvastatin 20mg, Fenofibric acid 135mg
214680236|NCT02396407|BEHAVIORAL|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children \< 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
214680237|NCT03687034|DRUG|Temozolomide|Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
214680238|NCT03687034|DEVICE|Optune|Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
214680239|NCT02769260|OTHER|Toothbrushing|Normal toothbrushing without toothpaste or antiseptic mouthwash.
214680240|NCT03762252|OTHER|Dry needling|A solid filiform needle will be inserted over active trigger points in the scalene muscles for 30 seconds. The aim will be to elicit local twitch responses or the referred pain pattern of the scalene muscles.
214680241|NCT03762252|OTHER|Manual Therapy|The therapist will apply manual compression over active trigger points in the scalene muscles for 30 seconds
214680242|NCT00026468|DRUG|exisulind|
214680243|NCT05616065|OTHER|Blinding to academic performance of candidate|Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.
214680244|NCT05616065|OTHER|Usual Interview methodology|Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
214680245|NCT00751101|DRUG|Nicotine patch|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
214680246|NCT01019408|DRUG|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
214680247|NCT02850614|BEHAVIORAL|gaming application to encourage physical activity|
214680248|NCT02850614|DEVICE|FitBit|
214680249|NCT00758303|DRUG|Low Dose TRIA-662|One Capsule 3 times a day
214680250|NCT00758303|DRUG|High Dose TRIA-662|3 Capsules 3 times daily
214680251|NCT00758303|DRUG|Placebo for TRIA-662|Matching Placebo for TRIA-662 taken 3 times a day
214680252|NCT03332004|DRUG|Indocyanine Green|0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
214680253|NCT03882840|BIOLOGICAL|ITNK cell therapy|Infusion of ITNK/CAR-ITNK cells
214680254|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
214680255|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP and G100|"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
214680256|NCT00784784|BIOLOGICAL|Fluviral|One dose
214680257|NCT00784784|DRUG|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
214680258|NCT06258629|DIAGNOSTIC_TEST|Flowcytometry on bone marrow aspiration|Flowcytometry on bone marrow aspiration
214980317|NCT04549194|DRUG|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route daily over 1 month.
214492272|NCT03885232|OTHER|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
214980318|NCT04549194|BEHAVIORAL|Psychological questionnaires|"The participants will fill in several psychological questionnaires before, during and after treatment administration:~* Life Event Checklist~* Moral injury~* Posttraumatic Checklist~* Burnout Assessment Tool~* State-Trait Anger Expression Inventory-2~* Ruminative Response Scale - Reconsidered~* Deployment Risk and Resilience Inventory-2~* Questionnaire about tobacco use"
214368076|NCT01568268|DRUG|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
214980319|NCT04549194|DEVICE|Photoplethysmography|Photoplethysmography recording will be performed before during and after the treatment.
214980320|NCT04549194|DRUG|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route daily over 1 month.
214980321|NCT04081688|DRUG|Atezolizumab 1200 MG in 20 ML Injection|Given IV every 3 weeks (cycle is 21 days)
214980322|NCT04081688|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT between cycle 1 and cycle 2 (each cycle is 21 days)
214980323|NCT04081688|DRUG|Varlilumab 3 mg/kg|Given IV every 3 weeks (cycle is 21 days)
214980324|NCT03798236|DRUG|PBF-1650 oral capsules|Adenosine A3 receptor (AA3R) antagonist
214980325|NCT03798236|DRUG|Placebo oral capsule|solid microcrystalline cellulose
214368077|NCT03566459|OTHER|CBOC offering Tele-MOUD to Veterans|CBOC offering medications for opioid use disorder (MOUD) using telemedicine
214368078|NCT03566459|OTHER|CBOC not offering Tele-MOUD to Veterans|CBOC not offering medications for opioid use disorder (MOUD) using telemedicine
214368079|NCT00582257|BEHAVIORAL|questionnaires|Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
214368080|NCT04963205|DEVICE|Adjustable bed backrest|The adjustable bed backrest facilitates for the individual high lying with a fowler (90 degrees raised head and trunk) and/or semi fowler position (30-45 degrees raised head and trunk) which enables patient's lung expansion. The diaphragm is pulled downwards by the gravity allowing for lung expansion and improved ventilation. In addition, the upper airways are stretched in order to prevent upper airway narrowing during sleep (flow limitation, snoring, obstructive sleep apnea). The position relaxes the tension of the abdominal muscles, allowing for improved breathing. Patients can define their own most comfortable position during the night. Elevated body position over 30 degrees from supine position is a requirement for the intervention group. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
214492273|NCT06179992|DEVICE|GGED mobile app|The intervention will be done through an app named GGED, which is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
214492274|NCT04844879|DEVICE|NextAR TKA system|The NextAR TKA system is a surgical guidance system which measures intra-operatively the effect of prosthesis alignment and positioning on soft tissue balance.
214492275|NCT01315132|DEVICE|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
214980326|NCT03457857|OTHER|Cleanser|Cosmetic Baby Cleanser/Shampoo
214980327|NCT03457857|OTHER|Cleanser and Lotion|Cosmetic Baby Cleanser/Shampoo and Baby Lotion
214980328|NCT02838745|DRUG|Pemetrexed|
214980329|NCT02838745|DRUG|Cisplatin|
214980330|NCT02116868|DEVICE|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
214980331|NCT02116868|DRUG|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
214980332|NCT02116868|DRUG|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
214980333|NCT01023204|DRUG|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
214980334|NCT06115655|DIAGNOSTIC_TEST|cfDNA methylation detection|Extract cfDNA from bile and plasma, and perform methylation detection.
214980335|NCT05024279|DEVICE|Left bundle branch area pacing|"Left bundle branch area pacing will be applied as established in the literature using commercially available equipment.~In case of unsuccessful application of left bundle branch area pacing, cross-over to right ventricular pacing is allowed."
214980336|NCT05024279|DEVICE|Right ventricular pacing|Right ventricular pacing as the standard, established form of pacing will be applied in the control group. No cross-over to the intervention arm is anticipated.
214980337|NCT03348449|OTHER|Collection of data|Outcome of patients will be collected from charts to evaluate primary and secondary objectives
214980338|NCT00138528|DRUG|Fluvastatin|
214980339|NCT02455128|OTHER|Therapeutic listening|Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
214980340|NCT02662569|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214980341|NCT02662569|DRUG|Atorvastatin|Administered orally once a day
214980342|NCT02662569|OTHER|Placebo|Placebo to evolocumab administered by subcutaneous injection
214980343|NCT06163118|DIAGNOSTIC_TEST|Deglut'G test|"Two tests to assess swallowing disorders using the Deglut'G tool will be carried out by a nurse or a caregiver from the Geriatric Short-Stay Unit, at visit 1.~The tests can be taken successively, or spaced apart by a time defined by the medical team, and will be taken blind to each other.~The average test administration time will be measured during the study, but the test should not exceed 10 minutes depending on the patients.~The Deglut'G tool consists of an initial administration of gelled water (1 to 3 teaspoons), to identify if a cough occurs. In the event of a cough, the oral treatment is stopped; if the cough is absent, a new step this time consists of the administration of water (1 to 3 sips). In case of cough, the food will be mixed, the liquids thickened, and the medicinal treatments crushed. If there is no cough, foods and liquids can be taken as normal."
214980344|NCT06163118|DIAGNOSTIC_TEST|SLP swallowing test|"At visit 1, 1 to 2 hours after the last Deglut'G test, a second swallowing test will be carried out by a SLP according to his skills and according to his usual practice, independently of the Deglut'G tool.~This test should not exceed 20-30 minutes depending on the patient."
214980345|NCT06163118|DIAGNOSTIC_TEST|ENT doctor swallowing test|"At Visit 2 (day 7 +/- 3 days after the inclusion), still as part of the short-stay hospitalization, the patient will meet an ENT doctor who will carry out an examination aimed at detecting swallowing disorders, according to his usual practice, of independent of the Deglut'G tool.~The examination should not exceed 20-30 minutes depending on the patient."
214980346|NCT05719168|DEVICE|Body Surface Gastric Mapping|64-channel electrode array placed on the outer abdomen
214980347|NCT00289211|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
214980348|NCT00289211|DRUG|Placebo (saline)|
214980349|NCT01279746|DEVICE|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
214980350|NCT00630916|DEVICE|Mitroflow Aortic Heart Valve|Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
214980351|NCT05265702|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 12 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
214980352|NCT04053582|BEHAVIORAL|AMT|The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 3 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).
214980353|NCT04053582|BEHAVIORAL|Sham|The session will be done on an individual basis. Sham group will receive artificial neurofeedback while focusing on the physical sensations of the breath. The session will last one hour, including 3 sham neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with artificial neurofeedback (70s).
214980354|NCT00003686|DRUG|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
214980355|NCT00003686|DRUG|Placebo|Placebo 5 mg po qid x 4 weeks
214980356|NCT00243243|DRUG|Recombinant Factor VIIa|intravenous infusion of Factor VIIa
214980357|NCT00243243|DRUG|Placebo|intravenous infusion of placebo (sterile water)
214980358|NCT04703413|DEVICE|LoFric® OrigoTM and LoFric® SenseTM|The investigational device is either a CE-marked LoFric® OrigoTM , 40 cm, CH12/CH14 or LoFric® SenseTM, 15 cm, CH12. They are all intermittent urinary catheters with a Nelaton tip from a more sustainable manufacturing process. All subjects will use the investigational device for 30 days each.
214980359|NCT01685879|OTHER|Rice|Rice portion containing 50 g total carbohydrate
214980360|NCT01685879|OTHER|Rice|Rice portion that provides 50 g total carbohydrate.
214980361|NCT01685879|OTHER|Rice|Rice portion that provides 50 g total carbohydrate.
214980362|NCT01685879|OTHER|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
214980363|NCT04174066|OTHER|blood sample|blood sample during planned in the follow-up of patients.
214980364|NCT04174066|OTHER|tissue sample|tissue sample during planned in the follow-up of patients.
214368081|NCT04963205|OTHER|Standard bed|Sleeping in a standard bed, in a position below 30 degrees from supine position. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
214368082|NCT01725269|DRUG|AIR001|All doses specified are the amount loaded into the I-neb AAD System nebulizer.
214368083|NCT03454165|COMBINATION_PRODUCT|BNC105P|BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.
214368084|NCT03454165|COMBINATION_PRODUCT|Ibrutinib|A novel BTK inhibitor.
214980365|NCT04174066|OTHER|excreta|urine sample during planned in the follow-up of patients.
214980366|NCT05338463|DRUG|Fespixon Cream|"1. Name : Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 20 weeks"
214980367|NCT00400244|PROCEDURE|Wheelchair skills traing program|
214492276|NCT03260569|DRUG|Inhaled Nitric Oxide|Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
214492277|NCT03260569|DRUG|Placebo|Nitrogen plus oxygen
214492278|NCT05718791|DIAGNOSTIC_TEST|blood sample|blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant
214492279|NCT02711332|OTHER|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
214368085|NCT03793725|DRUG|SHR1210|Anti-PD-1 Antibody
214368086|NCT03793725|DRUG|Apatinib|Anti-angiogenic drugs
214492280|NCT02711332|OTHER|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
214492281|NCT06521151|DIETARY_SUPPLEMENT|egg based diet|egg based diet and audio based nutrition education group (arm-1), egg based diet alone group (arm-2), and audio based nutrition education alone group (arm- 3).
214980368|NCT02005107|DRUG|Venlafaxine IR and Venlafaxine XR|
214980369|NCT05198141|DRUG|Letrozole tablets|GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
214680259|NCT05713305|PROCEDURE|Online-based self-help psychological intervention|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists
214680260|NCT05713305|PROCEDURE|Provide online mental health knowledge|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news
214680261|NCT06074822|OTHER|Residual neuromuscular biopsy|recovery of residual neuromuscular biopsy (nerve ans muscle)
214680262|NCT05183581|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
214680263|NCT04171128|BEHAVIORAL|antibiotic stewardship efforts|The local antibiotic team plan to implement procalcitonin use among the hospital physicians. the interventions are not ready yet.
214980370|NCT05198141|PROCEDURE|laparoscopic salpingectomy|laparoscopic salpingectomy
214980371|NCT02425306|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
214980372|NCT02425306|DRUG|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
214368087|NCT01914835|BEHAVIORAL|Motivational Chess|"The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).~The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions)."
214368088|NCT04675450|DRUG|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
214368089|NCT04675450|DRUG|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
214368090|NCT05226182|OTHER|visualisation of a digital care path|The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
214368091|NCT06319417|DIETARY_SUPPLEMENT|HT treatment|Total consumption of 60 mg/day of HT
214368092|NCT06319417|DIETARY_SUPPLEMENT|Placebo treatment|Consumption of placebo treatment of 4 caramels/day
214368093|NCT03577860|DRUG|Bupivacaine 4 mL|The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000
214368094|NCT03577860|DRUG|Bupivacaine 15 mL|The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
214492282|NCT02731599|PROCEDURE|treadmill training with cues|20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
214492283|NCT03840902|DRUG|M7824|Participants received intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
214680264|NCT00292474|DEVICE|percutaneous coronary intervention|
214680265|NCT02956174|DEVICE|Co-Cr single crown|
214680266|NCT02956174|OTHER|Periodontal parameters|
214680267|NCT01729598|DRUG|Valproic Acid|generic valproic acid tablets packaged in placebo-matched capsules.
214680268|NCT01729598|DRUG|Placebo|Placebo capsule without active study medication in identical capsules as experimental medicine.
214680269|NCT01905397|DEVICE|Conventional wound therapy|Sterile bandages and wound coverings
214368095|NCT03917004|DRUG|Nitroglycerin|"The starting rate of nitroglycerin was 0.25 μg / kg / min and the mean arterial pressure (MAP) decreased to 80% of the baseline but not less than 70%.The drug infusion rate was adjusted so that the MAP was maintained in the range to the suture, and the administration was stopped and the blood pressure was gradually returned to the pre-depressurization level."
214680270|NCT01905397|DEVICE|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
214680271|NCT05427071|DEVICE|Magnetic seed localization|Magnetic seed guided localization
214980373|NCT02425306|DRUG|polyICLC|polyICLC, local adjuvant
214980374|NCT02425306|DRUG|Cyclophosphamide|Cyclophosphamide, systemic adjuvant
214980375|NCT01932385|DRUG|Sorafenib|
214980376|NCT01932385|OTHER|Best Supportive Care|
214980377|NCT06170710|DRUG|Anti-PD-1 monoclonal antibody|"Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W"
214980378|NCT06170710|OTHER|Postoperative CCRT|Postoperative chemoradiotherapy
214980379|NCT02978469|OTHER|Life style changing: reducing sedentary behavior|"The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities."
214980380|NCT04023201|OTHER|Nocturnal symptoms|Parkinson's disease patients with or without nocturnal symptoms
214980381|NCT00838071|DRUG|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
214368096|NCT00227526|BEHAVIORAL|Prehabilitation|
214368097|NCT01662063|DRUG|Tocilizumab|TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
214368098|NCT04782934|DEVICE|The YANG SENSOR is an active implantable device, for Real Time Continuous Glucose, Lactate and Ketone Measurement|The YANG SENSOR is an active implantable device, that is intended to be implanted in the subcutaneous abdominal tissue, approximately 10mm below the skin. The SENSOR is battery powered. The battery is wirelessly recharged through the skin by the YANGEXD, using a charging coil ('Donut') applied to the skin with an adhesive patch at the level of the SENSOR. The 'Donut' also receives data from the sensor.
214368099|NCT03369275|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
214368100|NCT03369275|OTHER|Placebo|Placebo, with excipients, will be administered intravenously.
214368101|NCT04791072|OTHER|Exercise|Breathing exercise training Use of incentive spirometry Aerobic exercise training Strengthening exercises
214368102|NCT01293058|DRUG|Intranasal naloxone|spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
214980382|NCT01108939|DRUG|Antimalarial treatment|
214980383|NCT01108939|OTHER|Observation|
214980384|NCT00121004|BEHAVIORAL|Advance Directive Selection|
214980385|NCT00003819|BIOLOGICAL|QS21|
214980386|NCT00003819|BIOLOGICAL|TF(c)-KLH conjugate vaccine|
214980387|NCT00003819|BIOLOGICAL|Thomsen-Friedenreich antigen|
214980388|NCT00003819|BIOLOGICAL|keyhole limpet hemocyanin|
214980389|NCT03945513|DRUG|LPRI424 (dienogest/ethinylestradiol)|One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
214980390|NCT02108301|DRUG|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
214980391|NCT01075776|DRUG|C-type natriuretic peptide (CNP)|360 pmol/min for 15 minutes intra-arterially
214980392|NCT01075776|DRUG|Saline|Sodium Chloride 0.9% intra-arterially 0.5ml/min
214980393|NCT01075776|DRUG|Acetylcholine|2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
214980394|NCT01299584|DRUG|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
214980395|NCT04079790|DRUG|Gepotidacin|Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.
214980396|NCT04079790|DRUG|Placebo|Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
214980397|NCT00390689|DRUG|Pramipexole 0.125 mg tablet|
214980398|NCT00390689|DRUG|Pramipexole 0.5 mg tablet|
214980399|NCT04397978|RADIATION|Stereotactic radiotherapy|Local ablative therapy with SRT
214980400|NCT01253161|DRUG|Pasireotide Long Acting Release (LAR)|Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
214980401|NCT03972033|BEHAVIORAL|EMDR|"Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm."
214368103|NCT01293058|DRUG|Intravenous|Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
214368104|NCT06425380|OTHER|Resistant Potato Starch|Participants will receive 4 weeks of resistant potato starch 20 grams (g) twice daily. Bob's Red Mill® potato starch will be used. Every patient will receive the same dose and there are no dose titrations.
214368105|NCT01537302|DEVICE|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
214368106|NCT02313909|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
214368107|NCT02313909|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|100 mg, once daily, orally, tablet
214368108|NCT02313909|OTHER|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
214368109|NCT02313909|OTHER|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
214368110|NCT02082925|OTHER|Patient has to get up his hand when he defined his dyspnea threshold during 6MWT|
215087608|NCT06471530|DRUG|TE-8105 SAD Cohort 4|Each participant will receive one dose of TE-8105 3 mg or less than or equal to 5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
214368111|NCT02799615|DRUG|Infliximab|No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician
214368112|NCT05180266|OTHER|Therapeutic Touch|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form, PSQI,MRS and MENQOL. After pre-test data collection, women will be given an appointment for therapeutic administration.The therapeutic touch group will be applied to the therapeutic touch group once a week for four weeks in a suitable room in the Faculty of Nursing and on the specified day and time by the researcher.At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
214368113|NCT05180266|OTHER|Music Listening Group|Each of the women was informed about the purpose and content of the study at the first meeting, and informed consent was obtained from the women who met the conditions for participation and accepted to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. Music stream, music will be uploaded to mobile phones. He will be asked to listen to music (relaxation music in the relaxation exercises CD prepared by the Turkish Psychological Association) for 30 minutes before going to sleep every day for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again
214980402|NCT03972033|BEHAVIORAL|CBT|"Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm."
214980403|NCT03871556|DIAGNOSTIC_TEST|LOGIQ P6 Diagnostic Ultrasound|Ultrasound measurements of subcutaneous fat thickness
214980404|NCT05012267|OTHER|16-hour PP|PP according to previous study
214980405|NCT05976789|DEVICE|Sound therapy using low-level background sound|"This study will use an FDA-regulated device, a tinnitus masker, as one of the sound therapy options in Aim 2.~The tinnitus masker will provide low-level background sound for hyperacusis relief."
214980406|NCT05976789|BEHAVIORAL|Remote counseling using HAT-Online|This study will implement Hyperacusis Activities Treatment-Online, a four-week remote counseling program in Aim 1.
214980407|NCT05976789|OTHER|Sound therapy using successive approximations|This study will use the approach of successive approximations with the participants' bothersome sounds in Aim 2.
214980408|NCT01924533|DRUG|Olaparib|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
214980409|NCT01924533|DRUG|Paclitaxel|IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
214980410|NCT01924533|DRUG|Placebo|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
214368114|NCT05180266|OTHER|Control Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. No action will be taken on the control group for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
214368115|NCT00169559|DRUG|GW590735|1µg to 20µg daily doses of GW590735
214368116|NCT00169559|DRUG|fenofibrate|Marketed Drug
214368117|NCT01583686|DRUG|Fludarabine|Days -5 to Day -1: Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
214368118|NCT01583686|BIOLOGICAL|Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
214368119|NCT01583686|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
214492284|NCT03840902|DRUG|Placebo|Participants received intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
214492285|NCT03840902|DRUG|Durvalumab|Participants received intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
214492286|NCT03840902|DRUG|Etoposide|Participants received etoposide 50 mg/m\^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
214680272|NCT02676349|DRUG|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
214980411|NCT01310283|OTHER|xylitol mints and fluoride varnish|Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
214980412|NCT02747927|DRUG|Placebo|TDV placebo-matching SC injection.
214980413|NCT02747927|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV SC injection.
214980414|NCT05363228|BEHAVIORAL|Therapy by Dance and Movement|Therapy by dance and movement is based on the principals of movement-analysis by Rudolf Laban and Irmgard Bartenieff. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
214980415|NCT05363228|BEHAVIORAL|Tai Chi|Tai Chi is based on somatic approach. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
214980416|NCT00017251|BIOLOGICAL|oblimersen sodium|Given IV
214980417|NCT00017251|DRUG|carboplatin|Given IV
214980418|NCT00017251|DRUG|etoposide|Given IV
214980419|NCT00017251|OTHER|pharmacological study|Correlative studies
214980420|NCT00017251|OTHER|laboratory biomarker analysis|Correlative studies
215087609|NCT04912895|DEVICE|PneumoniaCheck|Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
215087610|NCT06053398|DRUG|Phenylephrine|Intraoperative phenylephrine infusion Phenylephrine infusion to be titrated as needed to target a mean arterial pressure (MAP) \> 65 mm Hg.
215087611|NCT06053398|DRUG|Norepinephrine|Intraoperative norepinephrine infusion Norepinephrine infusion to be titrated as needed to target a MAP \> 65 mm Hg.
215087612|NCT07032090|BEHAVIORAL|Health education|Participants will receive face-to-face health education, followed by 12 sessions of laughter yoga.
215087613|NCT07032090|BEHAVIORAL|Laughter Yoga|The intervention groups will receive a total of 12 sessions of laughter yoga, delivered by the researcher over 6 weeks, twice a week, each lasting 40-45 minutes.
214680273|NCT02676349|RADIATION|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
214680274|NCT02676349|PROCEDURE|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
214680275|NCT02676349|DRUG|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
214980421|NCT05412134|DEVICE|Pro2 - 75% of participant's MIP|"Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP."
214980422|NCT05412134|DEVICE|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
214980423|NCT05720403|OTHER|pilates group|Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates training.
215087614|NCT07032454|OTHER|High Caffeine Consumption|Individuals consuming 300 mg or more of caffeine daily, meeting DSM-5/ICD-10 criteria for caffeine dependence.
215087615|NCT07032454|OTHER|Low Caffeine Consumption|Individuals consuming caffeine within recommended levels (20-200 mg/day).
215087616|NCT07041892|OTHER|Prebiotic Supplement + Synbiotic Supplement + Topical Lotion + Unscented Soap|"The intervention includes 4 products:~1. An oral prebiotic dietary supplement~2. An oral synbiotic dietary supplement~3. A topical lotion~4. An unscented bar of soap"
214492287|NCT03840902|DRUG|Pemetrexed|Participants received pemetrexed at a dose of 500 mg/m\^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
214492288|NCT03840902|DRUG|Carboplatin|Participants received carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
214492289|NCT03840902|DRUG|Paclitaxel|Participants received paclitaxel intravenously at a dose of 45 mg/m\^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
214492290|NCT03840902|DRUG|Cisplatin|In combination with etoposide, participants received cisplatin 50 mg/m\^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants received cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
214492291|NCT03840902|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Participants received IMRT 5 fractions per week for about 6 weeks (Total 60 gray \[Gy\]).
214492292|NCT00003593|DRUG|asparaginase|Given IV
214492293|NCT00003593|DRUG|cytarabine|Given IT
214492294|NCT00003593|DRUG|daunorubicin hydrochloride|Given IV
214492295|NCT00003593|DRUG|methotrexate|Given IV
214492296|NCT00003593|DRUG|therapeutic hydrocortisone|Given IT
214492297|NCT00003593|DRUG|thioguanine|Given IV
214492298|NCT01170624|DEVICE|ICD|Paradym CRT model 8750 - Paradym DR model 8550 - Paradym VR model 8250
214492299|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSight®)|
214492300|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflex®).|
214492301|NCT03660930|DRUG|Sirolimus Albumin-bound Nanoparticles|Given IV
214492302|NCT03660930|DRUG|Pazopanib hydrochloride|Given PO
214680276|NCT05379426|OTHER|Impact COVID-19 pandemic|Battery of screening tests and the semi-structured interview focusing on the difficulties experienced by the older adult during the pandemic period.
214680277|NCT05774457|BEHAVIORAL|Voice training|Traditional vs. virtual reality
214680278|NCT06333470|OTHER|Primary angle closure diseases|Primary angle-closure suspect (PACS), which is characterized by appositional angle closure, is the earliest stage of primary angle closure diseases and can finally progress to primary angle-closure glaucoma (PACG).
215087617|NCT05066646|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
215087618|NCT04507451|PROCEDURE|inspiratory and expiratory muscle training|inspiratory muscle training using threshold IMT device expiratory muscle training using a bottle filled of water
215087619|NCT04507451|PROCEDURE|inspiratory and expiratory exercises|inspiratory exercise using fractionated inspirations expiratory exercise using a bottle filled with water at a minimum level
215087620|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 10 mg/d|L-Ergothioneine 10 mg/d
215087621|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 25 mg/d|L-Ergothioneine 25 mg/d
215087622|NCT04556032|OTHER|Placebo|0 mg/d L-Ergothioneine
214680279|NCT04263662|OTHER|Analgesia-Sedation algorithm|The analgesia-sedation algorithm is a suggested protocol for approach to providing analgesia and sedation to patients admitted to the pediatric ICU who are newly intubated. The approach focuses on using dexmedetomidine as the primary sedative, non-opioids as the primary analgesia, then stepwise approach to adding in adjunctives (e.g. opioids, non-benzodiazepines) with the intention of minimizing benzodiazepine exposure and utilizing minimal-dose effective analgesia/sedative dosing.
214368120|NCT01583686|DRUG|Aldesleukin|Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
214492303|NCT05813795|DRUG|Ecnoglutide Low Dosage|Subcutaneous Injection
214980424|NCT03072186|DEVICE|near-infrared light nasal endoscope used with ICG|Using the near-infrared light nasal endoscope with ICG will identify anatomical landmarks and and tumor characteristics to provide a clear demonstration of the blood supply.
214980425|NCT03120611|OTHER|Virtual Reality Exercise|Game developed by the Kinect, adapted to the lying position of participants.
214980426|NCT03120611|OTHER|Conventional exercise intradialysis|Aerobic exercise (cycling) and strengthening exercise for lower limbs using elastic bands and gravity
214980427|NCT01482559|DRUG|Dopamine hydrochloride|Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
214980428|NCT01482559|DRUG|Dextrose 5%|IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
214980429|NCT00915174|DRUG|Neramexane|25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
214980430|NCT06523179|OTHER|quantify the impact of genetic risk factors|the impact of genetic risk factors for the development of NAFLD-HCC and their interaction with acquired risk factors, on the incidence of the disease in a prospective cohort of patients at risk, through a score capable of predicting NAFLD-HCC and selecting patients for whom screening is cost-effective.
214980431|NCT04643886|DRUG|GEM103|Biological
215087623|NCT03458702|BEHAVIORAL|YogaFit|For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)\], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.
215087624|NCT03458702|BEHAVIORAL|Quiet Rest|Participants completed 30 min of quiet rest
214980432|NCT01339065|DRUG|Ketamine|determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
214980433|NCT01441986|DRUG|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
214980434|NCT01441986|DRUG|Amantadine|Amantadine hydrochloride 100 mg; tablets; single, oral dose.
214980435|NCT01441986|DRUG|Pacebo 1 (placebo for Amantadine)|Talets for oral use; single dose.
214980436|NCT01441986|DRUG|Placebo 2 (fo Dextromethorphan)|Capsles for oral administration; single dose.
214980437|NCT01549158|DRUG|torasemide-PR|Single oral dose of torasemide PR 10 mg
214980438|NCT01549158|DRUG|Furosemide-IR|Single oral dose of furosemide IR 40 mg
214368121|NCT03859258|DEVICE|Transvaginal sonography|Niche is assessed using TVS, SIS (cases only) and office hysteroscopy
214368122|NCT04005534|DRUG|Standard group|Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
214368123|NCT04005534|DRUG|Preemptive group|Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
214492304|NCT05813795|DRUG|Ecnoglutide Medium Dosage|Subcutaneous Injection
214492305|NCT05813795|DRUG|Ecnoglutide High Dosage|Subcutaneous Injection
214680280|NCT03766750|DRUG|LIMA association|1 coated tablet, oral, once a day.
214368124|NCT01249469|OTHER|skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
214368125|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.0008%|
214368126|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.001%|
214368127|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.0012%|
214368128|NCT00637130|DRUG|TRAVATAN|
214492306|NCT05813795|DRUG|Placebo|Subcutaneous Injection with matched volume
214492307|NCT03509909|BEHAVIORAL|Hatha yoga|Manualized hatha yoga
214492308|NCT03509909|BEHAVIORAL|Supportive physical activity|Manualized stretching and strengthening
214492309|NCT03831334|DRUG|oral minoxidil|Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
214680281|NCT03766750|DRUG|Tradjenta|1 coated tablet, oral, once a day.
214680282|NCT03766750|DRUG|Forxiga|1 coated tablet, oral, once a day.
214980439|NCT01549158|DRUG|torasemide-IR|Single oral dose of torasemide IR 10 mg
214980440|NCT02332265|OTHER|Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)|The SAFE program was developed \& implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, \& Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission \& partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices \& sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings \& Loans Groups, 3) building capacity of local governance structures \& 4) integrating HIV education \& gender empowerment into programs through training \& education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
215087625|NCT01390779|DEVICE|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
214980441|NCT05512117|DEVICE|Midline insertion|Midline catheter insertion
214980442|NCT02390232|BIOLOGICAL|liver biopsy|A small needle is inserted into the liver to collect a tissue sample
214980443|NCT02390232|BIOLOGICAL|collection of stools|collection of stools
214980444|NCT02390232|BIOLOGICAL|blood sample|collection of blood sample
214980445|NCT00971113|DIETARY_SUPPLEMENT|sc-FOS and Sideritis euboea extract|"dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea"
214980446|NCT04275336|DRUG|EMLA application|A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse perform IV cannulation for them.
214980447|NCT04275336|BEHAVIORAL|Distraction techniques|Multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They will also be taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
214980448|NCT04275336|OTHER|EMLA cream and distraction techniques|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
214980449|NCT04664205|OTHER|High Intensity Interval Exercise|One session of high intensity interval exercise
214980450|NCT04664205|OTHER|Moderate Intensity Continuous Exercise|One session of calorically matched moderate intensity exercise
214980451|NCT04664205|OTHER|Control|No exercise, resting measures
214980452|NCT00128128|DRUG|Cranberry juice cocktail|Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
214980453|NCT03886909|BEHAVIORAL|Exercise|The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
214368129|NCT00637130|OTHER|Vehicle|
214680283|NCT06286852|BEHAVIORAL|Administration of K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)|Administration of 1) K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)
214980454|NCT03886909|BEHAVIORAL|Prehabilitation Education|Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
214368130|NCT04367558|PROCEDURE|Minimally invasive, in-office, RF reduction of the affected area|Usage of RF needle to treat one or more of the affected areas
214368131|NCT01218880|DRUG|M2ES 7.5mg|M2ES Dosage：7.5mg/m2
214368132|NCT01218880|DRUG|M2ES 15mg|M2ES Dosage：15mg/m2
214368133|NCT01218880|DRUG|M2ES 30mg|M2ES Dosage：30mg/m2
214368134|NCT01218880|DRUG|M2ES 45mg|M2ES Dosage：45mg/m2
214368135|NCT01981525|DRUG|Metformin|Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
214368136|NCT04860960|DRUG|Hydroxypropyl-beta-cyclodextrin|Dose is 2000 mg/kg body weight provided every 2 weeks intravenously
214680284|NCT06286852|BEHAVIORAL|Administration of ChEDE- Child Version of the EatingDisorder Examination|Administration of ChEDE- Child Version of the EatingDisorder Examination
214680285|NCT05664685|DRUG|Optimized bismuth quadruple therapy|Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
214680286|NCT05664685|DRUG|Control|Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
214980455|NCT01494207|BEHAVIORAL|Wellness counseling|Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
214980456|NCT05024383|OTHER|Chemical sensitivity|Chemical sensitivity will be evaluated with paper taste strips embedded with varying concentrations of capsaicin solutions (activates TRPV1) and allyl isothiocyanate solutions (activates TRPA1) applied to the tongues of healthy subjects and site of cancer in oral cancer patients.
214980457|NCT05024383|OTHER|Mechanical sensitivity|Mechanical sensitivity will be evaluated via von Frey filaments applied to the tongues of healthy subjects and and site of cancer in oral cancer patients.
214980458|NCT05233813|BEHAVIORAL|Active Body and Mind|The intervention group attended three 45-min group exercise lessons per week and wore a Fitbit activity tracker during the weekdays for 12 weeks combined with weekly feedback and personalized activity goals.
214980459|NCT03639168|DRUG|Chidamide combined with cisplatin|Chidamide combined with cisplatin
214980460|NCT03113045|OTHER|seated time|Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
214980461|NCT00748202|DRUG|C1-Esterase Inhibitor|1000 I.E.
214980462|NCT00049816|BEHAVIORAL|Walking exercise|30 minutes/day, 3 times/week for 52 weeks
214980463|NCT00049816|BEHAVIORAL|Cycling Exercise|30 minutes/day, 3 times/week for 52 weeks
214980464|NCT05516303|GENETIC|Genetic polymorphism|One blood tube will be taken for genetic testing
214980465|NCT05516303|DIAGNOSTIC_TEST|Measurement of fingolimod and fingolimod-phosphate concentrations|Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time
214368137|NCT04860960|DRUG|Placebo|0.5N saline provided every 2 weeks intravenously
214368138|NCT03472456|DRUG|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
214680287|NCT01541592|OTHER|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of \~1 tablespoon per hour so that the total infusion time will be 6 hours.
214680288|NCT01455571|DRUG|HM781-36B|Q1DX14/2W for 3W HM781-36B
214680289|NCT03621969|OTHER|Physical exam and medical history|This will be completed by a medical doctor on the research team
214368139|NCT03472456|DRUG|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
214368140|NCT02676401|DRUG|MT-3995 Low|
214980466|NCT02073786|DEVICE|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
214980467|NCT02073786|DEVICE|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
214368141|NCT02676401|DRUG|MT-3995 Middle|
214368142|NCT02676401|DRUG|MT-3995 High|
214368143|NCT01431001|DEVICE|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)|The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
214368144|NCT00250913|BEHAVIORAL|Telephone-based physical activity counseling program|
214368145|NCT03919786|PROCEDURE|topical local anesthesia of pulmonary vein combined with vagus nerve block|"Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex."
214368146|NCT03293576|BEHAVIORAL|Volitional Help Sheet|"This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan)."
214680290|NCT03621969|DIAGNOSTIC_TEST|Assessments|One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)
214980468|NCT00709189|DRUG|Norgestimate/Ehinyl Estradiol; Folic acid.|
214368147|NCT06495567|DIETARY_SUPPLEMENT|Creatine|For 7 days, participants will take a 20mg creatine supplement each day.
214368148|NCT06495567|DIETARY_SUPPLEMENT|Dietary methionine tracer and protein intake|On the study days participants will ingest 8 hourly meals of controlled amino acid intake, fortified with the necessary macronutrients. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g/kg/d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
214980469|NCT02709317|BEHAVIORAL|Prevention Intervention|
214980470|NCT02709317|BEHAVIORAL|Brief Intervention|
214368149|NCT05083325|DRUG|Oseltamivir 75mg Test Drug capsules|Investigational Medicinal Product
214980471|NCT01105052|BEHAVIORAL|Self-help CBT-I|Comparison between Bibliotherapy with and without support to a wait-list control group
214980472|NCT02716740|DIETARY_SUPPLEMENT|Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week|After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
214980473|NCT04550299|OTHER|Surgical technique combined with a specific choice of the material for the ligament reconstruction|The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice
215087626|NCT03208920|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
215087627|NCT03208920|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
215087628|NCT00195000|DRUG|Mylotarg|6 mg/m2 on day 1
214680291|NCT03621969|DEVICE|Patient Instruction and use of Device (RePlay)|"1. providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~2. improving assessment and evaluation of patients involved in future interventional studies,~3. producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home."
214368150|NCT05083325|DRUG|Oseltamivir 75mg capsules Reference Product capsules|Tamiflu (Roche Pharma (Switzerland) AG, Basel)
214680292|NCT03974646|BEHAVIORAL|Nurse-led self-management Program|Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
214680293|NCT00230386|DEVICE|MRI|
214680294|NCT00594152|DRUG|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
214680295|NCT02099799|BEHAVIORAL|Pedometer and Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
214680296|NCT04942418|OTHER|Multicolor hybrid ceramic laminate veneers.|Multi shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
214680297|NCT04942418|OTHER|Multicolor fieldspathic ceramic laminate veneers.|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
214980474|NCT06050681|BEHAVIORAL|Mindfulness Training|Participants will be asked to complete 21 mindfulness sessions within the Calm app on their own time and at a location of their choosing. They will be instructed to complete the '7 Days of Calm' program within the first two weeks of the intervention, the '7 Days of Managing Stress' program during weeks 3 \& 4 of the intervention, and the 'Letting Go of Anxiety' program during the final two weeks of the intervention. The sessions have a mean run time of 11.76 minutes. Each 7-day program will be completed within a 2-week period, which equates to about one session every other day, but can be completed at any interval within those 2 weeks. All 21 sessions will be completed within a 6-week period.
214980475|NCT02910232|DEVICE|bone void filler|Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
214980476|NCT03153670|OTHER|fMRI|DBS patients will undergo fMRI scanning. For each patient, scans will be performed using a selection of DBS settings. fMRI responses will be analysed to evaluate brain responses on different DBS settings. These results will be provided to the programming clinician to guide them choose the optimal setting for each patient at the clinician's discretion.
214980477|NCT05720819|DEVICE|Combined biofeedback-virtual reality device|The study's biofeedback-VR device was developed in collaboration with students and faculty at the University of Washington Global Innovation Exchange program. The system included an Oculus Go mobile VR headset (wireless, portable, head-mounted display, with screen providing a 101° field of view with 2560 x 1440 resolution at a 60-72 Hz frame rate; Oculus VR, LLC, Menlo Park, CA/USA) and with built-in speaker, in addition to a Polar H10 heart rate monitor (electrocardiogram, or ECG, to measure heart rate; Polar Electro Inc., Bethpage, NY/USA), with customized software programmed for the study using the Unity3D game engine (Unity Technologies, Bellevue, WA/USA). Individuals in the experimental arm are asked to use this device for 10 minutes daily, on at least 3 days per week.
214980478|NCT01498302|OTHER|diagnostic laboratory biomarker analysis|
214980479|NCT01498302|OTHER|flow cytometry|
214980480|NCT00599560|GENETIC|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
215087629|NCT00195000|DRUG|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
215087630|NCT02404922|DRUG|CTP-730|
214368151|NCT01501708|DRUG|Caspofugin based combination therapy|"Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~* All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~* In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given."
214368152|NCT04751201|BEHAVIORAL|Mindfulness open and circular program|"At the end of the first and the last cycle, as well as 3 weeks after the last cycle, the patient will be invited to answer different questionnaires evaluating his or her quality of life (HADS, QLQC30, FA12). This is why the observation period is 3 months (3 cycles of 3 weeks + 3 weeks).~Similarly, some of the patients included in the study will be asked to complete a semi-structured interview at the end of the MAEva programme.~Patients and nursing staff participating in the study will be asked to complete a satisfaction questionnaire"
214368153|NCT01686555|DRUG|ABT-199|Tablet
214368154|NCT01686555|OTHER|Placebo|Tablet
214368155|NCT00293267|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
214492310|NCT04410146|DEVICE|SQUID Embolization|Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent
214492311|NCT04410146|DEVICE|SQUID Embolization and Surgical Evacuation|Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent and the surgical evacuation of the sub-dural hematoma
214368156|NCT00293267|DRUG|Comparator: Placebo|Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
214492312|NCT04410146|PROCEDURE|Surgical Evacuation|Surgical evacuation of the sub-dural hematoma
214492313|NCT04410146|OTHER|Other: Medical Management|Standard
214492314|NCT06008301|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.
215087631|NCT02404922|DRUG|Placebo for CTP-730|
215087632|NCT04088084|DIETARY_SUPPLEMENT|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
215087633|NCT00545532|DRUG|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
215087634|NCT00545532|OTHER|placebo|Placebo matched to oseltamivir po twice daily for 10 days
215087635|NCT00002514|BIOLOGICAL|sargramostim|
215087636|NCT00002514|DRUG|asparaginase|
215087637|NCT00002514|DRUG|cyclophosphamide|
215087638|NCT00002514|DRUG|cytarabine|
214492315|NCT06572839|OTHER|Amnio-Maxx|Amnio-Maxx Dual Layer Amnion Patch is processed using aseptic techniques, treated with a saline solution and dehydrated.
214492316|NCT02238769|DEVICE|18F-FluoroethylCholine PET|18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
214492317|NCT04100538|BEHAVIORAL|health coach|"The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes."
214680298|NCT00863928|DRUG|belladonna 16.2 mg and opium 60 mg suppository|belladonna 16.2 mg and opium 60 mg suppository
214680299|NCT05534555|DIAGNOSTIC_TEST|FebriDx|Testing of finger-prick blood sample using FebriDx
215087639|NCT00002514|DRUG|daunorubicin hydrochloride|
214368157|NCT00602056|OTHER|Redesigned immunization card|A low cost nad simplified redesigned immunization card
214680300|NCT03750110|OTHER|Intervention|"In addition to usual care, personalised feedback from the participants screening appointment will be provided;~* For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~* For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided."
214368158|NCT00602056|OTHER|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
214368159|NCT00602056|OTHER|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
214368160|NCT04009369|OTHER|Direct access to a PT|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
214492318|NCT04522570|DEVICE|Laser ablation|Single session with Diode laser ablation system; one or two applicators will be used for treatments; one to three illuminations; fixed output power of 3 watts (W); pullback technique; delivered energy: 1200-1800 Joules (J) varying according to tumor volume; treatment under local anesthesia +- conscious or moderate sedation;
214492319|NCT04522570|DEVICE|Cryoablation|Single session with Argon-based cryoablation system; one 17 Gauge (G) V-probe applicator will be used for treatments; fixed gas delivery of 100%; treatment under local anesthesia +- conscious or moderate sedation;
214680301|NCT03750110|OTHER|Usual Care|Smoking cessation support in line with NICE PH48 guidelines
214680302|NCT05016128|DRUG|S-ketamine|S-ketamine is used for preventing postoperative hyperalgesia,thus reducing the patient's acute postoperative pain
214680303|NCT05016128|DRUG|saline|saline is used for control
215087640|NCT00002514|DRUG|dexamethasone|
214368161|NCT03086330|DRUG|Semaglutide|Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
214368162|NCT03086330|DRUG|Placebo|Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
214368163|NCT02360319|DRUG|Any FDA approved antipsychotic agent|Investigators are free to choose the most appropriate treatment for their clients
214368164|NCT02360319|DRUG|aripiprazole long acting injectable formulation|
214368165|NCT03074227|OTHER|Allogeneic faecal transplantation|"Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor."
214492320|NCT04522570|DEVICE|Radiofrequency ablation|Single session with radiofrequency generator; one 17 Gauge (G) V-tip applicator with a 1 to 4cm active tip; moving-shot technique or multiple overlapping shot technique with 60 Watts (W) output power; treatment under local anesthesia +- conscious or moderate sedation;
214492321|NCT03433794|BEHAVIORAL|Alcohol 101 Plus (TM)|It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
214492322|NCT03433794|BEHAVIORAL|Booster|Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
214492323|NCT03433794|BEHAVIORAL|Lilly for Better Health|This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
214492324|NCT00404742|DRUG|Placebo|PO BID
214492325|NCT00404742|DRUG|LX211|0.2 mg/kg, twice a day (BID)
214492326|NCT00404742|DRUG|LX211|0.4 mg/kg, twice a day (BID)
214492327|NCT00404742|DRUG|LX211|0.6 mg/kg, twice a day (BID)
214492328|NCT05425953|OTHER|No intervention other than obtaining biopsies|Biopsies will be obtained.
214492329|NCT06447389|OTHER|retraction cordu (SURE-CORD®PLUS)|The evaluation of the effectiveness of retraction cords in determining the restoration margin in the fabrication of short fixed partial dentures for patients with missing teeth.
214492330|NCT04042532|DEVICE|Theta-burst stimulation (TBS)|We will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.
214492331|NCT06486532|BEHAVIORAL|HeartBeet Clinic|16 weeks of group based lifestyle medicine coaching covering the six pillars of lifestyle medicine. The six pillars of lifestyle medicine include regular physical activity; a whole-food plant-based diet; restorative sleep; limiting substance use (e.g., tobacco and alcohol use); having meaningful social connections; and stress management. Groups will be led by clinician or health coach expert.
214492332|NCT06486532|BEHAVIORAL|Self-paced education|Self-paced course and workbook with no contact with study clinician or health coach expert
214492333|NCT03049072|RADIATION|Protons and Carbon Ions|
214680304|NCT04460287|DIETARY_SUPPLEMENT|DHA Wet Mixing method|Children will drink milk contain 100 mg DHA wet mixing daily for 30 days
215087641|NCT00002514|DRUG|etoposide|
215087642|NCT00002514|DRUG|imatinib mesylate|
215087643|NCT00002514|DRUG|leucovorin calcium|
215087644|NCT00002514|DRUG|mercaptopurine|
215087645|NCT00002514|DRUG|methotrexate|
214980481|NCT01963468|BEHAVIORAL|Early language intervention|Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
214980482|NCT01578772|DRUG|Telmisartan|80mg tablets po daily for 6 weeks
214980483|NCT00705419|DRUG|Vicriviroc maleate|Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
214492334|NCT05468034|BEHAVIORAL|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
214492335|NCT06673511|PROCEDURE|Lymph node visualization|Resect the developing lymph nodes and the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
214492336|NCT06673511|PROCEDURE|No visualization of lymph nodes|Resect the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
214492337|NCT06997640|DIAGNOSTIC_TEST|Dynamic Stretching Protocol|Participants assigned to Group A will undergo a structured dynamic stretching protocol, designed to enhance lumbar flexibility, core muscle activation, and postural alignment, specifically targeting the pelvic inclination associated with radicular low back pain (RLBP). The intervention will be administered three times per week under the direct supervision of a qualified physiotherapist. Each session will last for 30 minutes, beginning with a 5-minute warm-up involving light aerobic activity such as marching or gentle trunk rotations to prepare the body for movement. This will be followed by 20 minutes of dynamic stretching exercises, focusing on the major muscle groups that influence pelvic and lumbar mobility.
214492338|NCT06997640|COMBINATION_PRODUCT|Neural Mobilization Technique Protoco|Participants in Group B will receive a standardized neural mobilization intervention, targeting the sciatic nerve and lumbar plexus, known to contribute to pain and restricted mobility in radicular low back pain (RLBP). The treatment will be conducted three times per week, with each session lasting 30 minutes under the guidance of an experienced physiotherapist trained in neurodynamic techniques. The session will begin with a 5-minute preparatory phase to position the participant comfortably and explain the sequence of movements. This will be followed by 20 minutes of gentle neural mobilization techniques, including nerve sliders and tensioners, performed through movements such as the Straight Leg Raise (SLR) sliders and the Seated Slump mobilization technique.
214492339|NCT06454604|BEHAVIORAL|Meta Quest 3 VR Headset with noise cancelling headphones|Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
214492340|NCT04144907|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
214492341|NCT02533973|DRUG|Xamiol® gel|
214680305|NCT04460287|DIETARY_SUPPLEMENT|DHA Dry Blending Method|Children will drink milk contain 100 mg DHA dry blending daily for 30 days
214680306|NCT04460287|DIETARY_SUPPLEMENT|Fish Oil|Children will have this intervention every day for 30 days
214680307|NCT02354391|DRUG|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
214680308|NCT02354391|DRUG|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
214980484|NCT00705419|DRUG|Vicriviroc maleate|Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
215087646|NCT00002514|DRUG|prednisone|
214492342|NCT02533973|DRUG|Daivonex® scalp solution|
214680309|NCT02354391|PROCEDURE|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
214680310|NCT06821256|DEVICE|Anodal transcranial direct current stimulation (a-tDCS)|tDCS is delivered by a battery-driven constant current stimulator throught a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the over the cerebellum area (2 cm under the inion, using a 7 × 5 cm sponge electrode), with the cathode being applied either to the right deltoid muscle (arm 1: cerebellar stimulation) or over the spinal lumbar enlargement (2 cm under T11; arm 2: cerebellar-spinal stimulation) using a sponge electrode of the same size as the anode. Durng real stilumation a costant current of 2mA is applied for 20 minutes.
214680311|NCT06821256|DEVICE|Sham stimulation|For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation
214680312|NCT05985070|DIETARY_SUPPLEMENT|Oral Sucrosomial iron|30 mg capsule
214680313|NCT05985070|DIETARY_SUPPLEMENT|Oral Ferric maltol|30 mg capsule
214980485|NCT00705419|DRUG|Placebo|Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
215087647|NCT00002514|DRUG|thioguanine|
215087648|NCT00002514|DRUG|vincristine sulfate|
215087649|NCT00002514|PROCEDURE|allogeneic bone marrow transplantation|
215087650|NCT00002514|PROCEDURE|autologous bone marrow transplantation|
215087651|NCT00002514|PROCEDURE|peripheral blood stem cell transplantation|
215087652|NCT00002514|RADIATION|radiation therapy|
214980486|NCT00705419|DRUG|Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg|Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
214980487|NCT02457975|DEVICE|670nm PBM|Battery operated, hand-held, 10 cm2 Light Emitting Diode (LED) array designed to deliver 50 mW/cm2 of light for 90 seconds resulting in a light dose of 4.5 Joules/cm2
214980488|NCT02457975|DRUG|intravitreous VEGF-inhibitors|Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
214980489|NCT00423046|BIOLOGICAL|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
214980490|NCT00423046|BIOLOGICAL|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
214980491|NCT00423046|BIOLOGICAL|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
215087653|NCT03505489|PROCEDURE|Deep inhalation technique|Use of deep inhalations for administration of inhalant
215087654|NCT03505489|PROCEDURE|Tidal breathing technique|Use of tidal breathing for administration of inhalant
215087655|NCT03505489|DRUG|Methacholine|Methacholine direct bronchoconstrictor used for bronchoprovocation challenge
215087656|NCT03505489|DRUG|Mannitol|Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
214368166|NCT03074227|OTHER|Autologous faecal transplantation|Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
214368167|NCT04387630|DRUG|Metformin|Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.
214368168|NCT04387630|DRUG|Placebo oral tablet|Simethicone 60 mg three times daily.
214368169|NCT05195073|BIOLOGICAL|Laparoscopy|3 D laparoscopy
215087657|NCT01394614|BIOLOGICAL|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
215087658|NCT03835884|DRUG|AR-13503 Implant 10.6 Dose|AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
214368170|NCT02953743|DRUG|Lenvatinib|Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
214492343|NCT06827067|BEHAVIORAL|Simulation application with standard patient|Before the encounter with the standard patient (SH), a preliminary interview was held with the nurses in the briefing room, where the content and purpose of the application were explained to the nurses, and the story of the SH was told to the nurses in line with the prepared scenario. Three nurses were interviewed for each scenario. The nurses communicated with the SH for 10-15 minutes and each interview was conducted using video recordings. Those who finished the interview with the SH watched the scenario of the other group as observers, and at the end of each 3 scenarios, the debriefing phase was carried out for an average of 60-90 minutes.
214492344|NCT06827067|BEHAVIORAL|Theoretical training|The trainings, each of which lasted 40-45 minutes on average, were conducted in a total of 7 sessions.
215087659|NCT03835884|DRUG|AR-13503 Implant 21.2 Dose|AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
214368171|NCT06472401|OTHER|Integrated Learning Support System|"Students will receive simulation preparation with an Integrated Learning Support System consisting of:~* Educational technology in comic book format~* Virtual monitoring system with tutors~* Psychological follow-up~* Music listening and relaxation session"
214368172|NCT06472401|OTHER|Standard Learning Model|"Students will receive standard simulation preparation consisting of:~\- Expository and dialogued theoretical class."
214368173|NCT05471648|DRUG|420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection|Healthy volunteers receive pertuzumab (EG1206A, 420 mg, single dose)
214368174|NCT05471648|DRUG|Perjeta (EU origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (EU origin) 420 mg, single dose)
214368175|NCT05471648|DRUG|Perjeta (US origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (US origin), 420 mg, single dose)
214680314|NCT05753761|BEHAVIORAL|Behaviour- & Imaging-Guided Stepping Training Early Post-Stroke (BIG STEPS) intervention|Using baseline accelerometry data, personalized goals of replacing sedentary time with stepping time will be developed.
214680315|NCT03392519|OTHER|Chronic stroke|MRI data acquisition and behavioral test
214980492|NCT00423046|BIOLOGICAL|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
214980493|NCT03432481|PROCEDURE|Unicompartmental Knee Arthroplasty Surgery|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
214980494|NCT03432481|DEVICE|Bodycad Unicompartmental Knee System (BUKS)|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
214980495|NCT03487770|DRUG|Aripiprazole Oral Solution|Aripiprazole 2\~15 mg/day (2\~15 mL/day)
214980496|NCT03487770|DRUG|Placebo Oral Solution|Placebo 2\~15 mg/day (2\~15 mL/day)
215087660|NCT03835884|DRUG|AR-13503 42.4 Dose|AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
215087661|NCT03835884|DRUG|AR-13503 63.6 Dose|AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
215087662|NCT00459693|DRUG|[11C]PBR28|
215087663|NCT03205852|OTHER|questionnaire|fulfillment of questionnaire
215087664|NCT01149486|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
215087665|NCT01149486|DRUG|Hyzaar®|100/25 mg Tablets
215087666|NCT01004016|DRUG|KPS-0373|
215087667|NCT01004016|DRUG|Placebo|
215087668|NCT04202510|PROCEDURE|Glaucoma and Cataract Surgery|Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
214368176|NCT05085119|PROCEDURE|Stepwise modifications of FiO2|FiO2 will be increased stepwise from 30 to 100% (40, 60 and 80%), and then decreased with the same FiO2 reverse steps.
214368177|NCT04069000|BEHAVIORAL|Mindfulness-based social-emotional learning program|Grade 3 teachers implement MindUP in their classrooms over the academic year. MindUP is a manualized program informed by cognitive-developmental neuroscience, contemplative science, positive psychology, and social-emotional learning. The curriculum consists of 15 sequential lessons taught in 10-15 minute chunks and cross-curricular extension activities. There are four lesson units: Getting Focused (introduction to brain structure and function, the core practice, and how focused awareness affects brains and feelings), Sharpening Your Senses (focus on internal experiences such as mindful smelling and tasting), It's All About Attitude (focus on cognitive experiences such as positive mindset, perspective-taking, and practicing gratitude), and Taking Action Mindfully (performing acts of kindness to others and building positive relationships). An essential component is the core practice, a focused breathing exercise and mindfulness practice that is implemented three times daily.
214368178|NCT04069000|BEHAVIORAL|Regular grade 3 program|Grade 3 teachers are expected to implement activities to achieve a number of pre-specified social-emotional learning outcomes that are identified by the Ministry of Education. Educators have leeway over how they achieve these curriculum expectations and they will report on a weekly basis regarding their implementation of social-emotional learning activities.
214368179|NCT04983758|OTHER|Oral Rehabilitation with dental implants|Patients have been treated with oral dental implants supporting fixed dental prostheses
214368180|NCT03627039|DRUG|SGLT2|All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)
214368181|NCT03627039|DRUG|Metformin|Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
214368182|NCT01302470|PROCEDURE|Primary epicardial placement of left ventricular lead|Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
214368183|NCT01302470|PROCEDURE|Transvenous placement of left ventricular lead|Conventional placement of left ventricular leads performed in the electrophysiology department.
214368184|NCT03833297|DRUG|Drugs inducing hepatological toxicity|Drugs susceptible to induce hepatological toxicities
214368185|NCT03941275|DIAGNOSTIC_TEST|Bi-plane fluoroscopy|In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead
214680316|NCT06663358|DRUG|Pegunigalsidase-alfa|Administered via intravenous (IV) infusion under conditions of routine clinical care
214680317|NCT00539721|DRUG|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
214980497|NCT04056208|DRUG|Pistachio|Unsalted pistachios
214980498|NCT04056208|OTHER|Usual care|Advice and resources will be provided
214980499|NCT03776448|DIETARY_SUPPLEMENT|Sativa Nigra oil Softgels|Nigella sativa, a flowering plant native to southwest Asia, is considered one of the most important healing medicinal plants in Islamic culture. The use of its richly colored black seeds has been recommended in the prophetic medicine. It's also known by various other names amongst different cultures. Importantly, its seed is known in Arabic as 'habat al Baraka' which translates literally to 'the seed of blessing'.The active ingredient is believed to be thymoquinone richly present in the oil extract of its seeds. Apart from mild occasional gastrointestinal disturbance, black seed oil has no side effects and is considered very safe. .
214368186|NCT04886882|OTHER|placebo comparator|solution containing 0.9 % sodium chlorine
214368187|NCT04886882|OTHER|sham comparator|vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
214680318|NCT00539721|DRUG|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
214680319|NCT00539721|DRUG|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
214368188|NCT04886882|OTHER|Experimental drug 1|A cream containing 10 % MgSO4.vaseline, beeswaxpolyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
214680320|NCT00539721|DRUG|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
214680321|NCT00539721|DRUG|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
214680322|NCT00539721|DRUG|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
214680323|NCT03078101|DRUG|Empagliflozin 10 MG [Jardiance]|administered orally once daily
214980500|NCT03776448|DIETARY_SUPPLEMENT|Activated Charcoal Softgels|This supplement is manufactured by \[Arkopharma Pharmaceutical Laboratories\] and is available commercially. The use of activated charcoal softgels as a placebo is documented in several other clinical trials. The single most relevant characteristic of charcoal is its minimal if any gastrointestinal absorption. As a result, it does not undergo any metabolism and is excreted completely in feces. This makes charcoal an attractive placebo choice for small trials or when manufacturing a specific placebo is not feasible. Charcoal softgels are black in color and resemble black seed oil softgels to a great extent.
214980501|NCT00830128|DRUG|pregabalin (Lyrica)|Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
214980502|NCT05401565|DRUG|Balovaptan|Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period
214980503|NCT05401565|DRUG|Placebo|Matching placebo
215087669|NCT02111655|DEVICE|Second generation surveillance of AVF|"Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound."
215087670|NCT02111655|PROCEDURE|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
214680324|NCT03078101|DRUG|Placebo Oral Tablet|administered orally once daily
214680325|NCT05114863|OTHER|Product A1|Usual Brand (UB) filtered, non-menthol cigarette
214980504|NCT04463134|DRUG|NTM drug treatment|NTM drug treatment according to guideline and sensitivity test results
215087671|NCT02111655|PROCEDURE|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
214680326|NCT05114863|OTHER|Product B|40007388, A Non-Combusted Cigarette Variant and product use Mode A
214680327|NCT05114863|OTHER|Product C|40007388, A Non-Combusted Cigarette Variant and product use Mode B
214492345|NCT06827587|DRUG|Efgartigimod + Telitacicept (1-week interval) group|"Drug 1: Efgartigimod~Generic Name: Efgartigimod Formulation: Injection (Intravenous) Dose: 10 mg/kg Frequency: Once a week Route of Administration: Intravenous infusion Duration: 4 weeks (Week 0 to Week 4) Drug 2: Telitacicept~Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 25 weeks (Week 5 to Week 29)"
214492346|NCT06827587|DRUG|Efgartigimod + Telitacicept (2-week interval) group|"Drug 1: Efgartigimod~Generic Name: Efgartigimod Formulation: Injection (Intravenous) Dose: 10 mg/kg Frequency: Once a week Route of Administration: Intravenous infusion Duration: 4 weeks (Week 0 to Week 4) Drug 2: Telitacicept~Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 24 weeks (Week 6 to Week 29)"
214492347|NCT06827587|DRUG|Telitacicept-only group|Drug: Telitacicept Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 30 weeks (Week 0 to Week 29)
214492348|NCT06819137|OTHER|Gingival visibility exceeding 3 mm during smiling|Obtaining gummy smile photographs in accordance with the inclusion criteria specified in the study's materials and methods section.
214492349|NCT03623295|OTHER|Blood sample|Blood withdrawal.
214680328|NCT05114863|OTHER|Product D|40007386, A Non-Combusted Cigarette Variant and product use Mode B
214680329|NCT05114863|OTHER|Product A2|Usual Brand (UB) filtered, menthol cigarette
214680330|NCT05114863|OTHER|Product E|40007385, A Non-Combusted Cigarette Variant and product use Mode A
214680331|NCT05114863|OTHER|Product F|40007385, A Non-Combusted Cigarette Variant and product use Mode B
214680332|NCT05114863|OTHER|Product G|40007387, A Non-Combusted Cigarette Variant and product use Mode B
214680333|NCT05114863|OTHER|Product H|40007386, A Non-Combusted Cigarette Variant and product use Mode B
214980505|NCT01572402|OTHER|Bagueutte Cheese Gourmet (Crocodille)|180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
214680334|NCT05114863|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
215087672|NCT02111655|PROCEDURE|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
214368189|NCT04886882|OTHER|Experimental drug 2|A cream containing 10 % MgSO4.vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
214368190|NCT04886882|DRUG|Centella asiatica|A cream containing Centella asiatica
214368191|NCT00386503|DRUG|Artesunate + Amodiaquine|
214492350|NCT03623295|OTHER|Questionnaire|Online questionnaire about the bleeds that patients experienced in the past.
214492351|NCT03623295|OTHER|MRI-imaging|MRI imaging of joints.
214492352|NCT03623295|OTHER|Physical examination|Physical examination of joint status.
214492353|NCT07038031|BEHAVIORAL|Promotion a food habits|They develop the service learning project to promote a healthy food habits in diferent social organitzations of the territory. It consists to do an interview to identify nutritional educational needs, and do 3 nutritional workshops to participants from this organitzations. Each workshop has 1 hour, and is addreced to a small group of participants (8-15 maximum), always with the supervision of the professional of the social organitzation.
214492354|NCT06737796|BEHAVIORAL|Finger Feeding|feeding method
214492355|NCT06737796|BEHAVIORAL|syringe feeding|feeding method
214680335|NCT02648035|BIOLOGICAL|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
214680336|NCT04031378|RADIATION|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation|SBRT to a single dose of 24 Gy to up to 3 sites
214680337|NCT04031378|DRUG|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months|SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
214680338|NCT02046915|DRUG|Imnovid (pomalidomide)|
214680339|NCT02046915|DRUG|Dexamethasone|
214680340|NCT02046915|DRUG|Endoxan (Cyclophosphamide)|
214680341|NCT06611631|PROCEDURE|Hyaluronic acid pulpotomy|"1. After complete hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder to reach suitable consistency (1:1 ratio by volume) then gentle condensation in the pulp chamber will be done by a moistened cotton pellet and then the rest of the pulp chamber will be filled by glass ionomer restoration .~2. Tooth will be restored with stainless steel crown."
214680342|NCT06611631|PROCEDURE|mineral trioxide aggregate pulpotomy|"1. After complete hemostasis, MTA+ saline will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of glass ionomer restoration.~2. Tooth will then be restored with stainless steel crown."
214680343|NCT00772967|DRUG|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
214680344|NCT00772967|DRUG|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
214680345|NCT00772967|DRUG|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
214980506|NCT01572402|OTHER|Cous-cous sandwich|235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
214980507|NCT01572402|OTHER|McCountry sandwich (McDonald's)|150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
214980508|NCT05690880|DEVICE|Foresee Home|The ForeseeHome Monitoring System, a non-significant risk device, is prescribed by eye care providers to patients as part of their clinical care. Notal Vision Monitoring Center (NVMC) is an independent diagnostic testing facility responsible for clinical monitoring of FSH data. The NVMC communicates with the patients (for training on the use of the device, troubleshooting of device issues, adherence monitoring, etc.) and with the patients' eyecare providers (for reporting FSH alerts, monitoring of clinical outcomes to assess device functionality and ongoing need for the device, etc.).
214980509|NCT02886923|DEVICE|Hioxifilcon A Test|contact lens made with hioxifilcon A material
214980510|NCT02886923|DEVICE|Hioxifilcon A With Cosmetic Ring Control|contact lens made with hioxifilcon A material with a cosmetic ring on the lens
214980511|NCT04625335|OTHER|No Massage Protocol|Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.
215087673|NCT02111655|PROCEDURE|urea method|Quarterly recirculation with urea method.
215087674|NCT03790436|DIETARY_SUPPLEMENT|Betaquik|"Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik."
215087675|NCT00874406|DRUG|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
215087676|NCT00874406|DRUG|folfox4|folfox4 will be done within 28 days after liver resection
215087677|NCT04364061|OTHER|Moderate Intensity Continuous Exercise|Participant completed a moderate intensity continuous cycling exercise (MICE) during 35 min at 60-65% thPHRmax
215087678|NCT04364061|OTHER|High-Intensity Interval Exercise (1)|Participant completed a high-intensity interval cycling exercise (HIIE 1) during 20min with 60 cycles of speeding up for 8s and pedaling slowly for 12s at 80-90% thPHRmax
215087679|NCT04364061|OTHER|High-Intensity Interval Exercise (2)|Participant completed a high-intensity interval cycling exercise (HIIE 2) during 20min with 10 x 1-min bouts at 80-90% thPHRmax, separated by 1-min recovery bouts
215087680|NCT04431310|OTHER|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic|The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
214368192|NCT04218448|OTHER|Hypnorelaxation|"Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes.~The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of adapted suggestions and metaphors, adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. Using the elements previously supplied by the patient, the investigator tells a story which allows the patient to focus his attention on something other than the performance of the somatosensory evoked potentials examination. The investigator, thanks to hypnosis, allows the development"
214368193|NCT02481544|BEHAVIORAL|Gratitude Journaling Plus SOC|
214368194|NCT02481544|BEHAVIORAL|Memorable Events Journaling Plus SOC|
214368195|NCT02695030|DEVICE|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
214368196|NCT05019664|DEVICE|Affixus Natural Nail System|Intramedullary nailing designed for fixation and stabilization of fractures or osteotomies of the humerus. Nails are comprised of proximal and antegrade/retrograde.
214368197|NCT06579729|BEHAVIORAL|Dietary intervention for low free sugars|After baseline data collection, the intervention group received a 30-60 minute educational session with a dietitian and clinicians, including a health education prescription. Interventions occurred at weeks 1, 12 and 24, with routine evaluations of disease, diet, physical activity, and adherence. Follow-ups at 48 weeks assessed NAFLD extent, dietary profile, and health knowledge for both subjects and guardians.
214368198|NCT02274389|DRUG|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
214368199|NCT06580379|PROCEDURE|Spine surgery|Spine surgery, such as fusion requiring the need for precise intraoperative registration and navigation
214368200|NCT01344668|OTHER|Enhanced Diabetes Education|Provide enhanced diabetes education
214368201|NCT01344668|OTHER|Standard Diabetes Education|Provide Standard Diabetes Education
214492356|NCT05942911|DRUG|IHL-675A|Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.
215087681|NCT03078738|DRUG|OMT-28|OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
215087682|NCT03078738|OTHER|Matching Placebo|Microcrystalline cellulose
215087683|NCT05507632|COMBINATION_PRODUCT|Donafenib plus Sintilimab in combination with transarterial chemoembolisation|Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)
215087684|NCT01789138|BEHAVIORAL|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
214980512|NCT04625335|OTHER|Prophylactic Therapeutic Massage|Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.
214980513|NCT02461537|DRUG|HAM|High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)
214980514|NCT02461537|DRUG|LDAC and/or Mitoxantrone|Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)
214980515|NCT02862301|BIOLOGICAL|blood sample|
214980516|NCT04829071|BEHAVIORAL|Explicit motor learning|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
214980517|NCT04829071|BEHAVIORAL|Implicit motor learning|Participants will walk on a treadmill that drives their right and left legs to move at two different speeds.
214980518|NCT02244671|PROCEDURE|fat, PRP, botulinum toxin|fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
214980519|NCT02244671|DRUG|botulinum toxin|botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
214980520|NCT02244671|DEVICE|PRP|autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
214980521|NCT01331811|OTHER|Development of a diagnosis algorithm|"At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:~* interview on anamnesis~* clinical examination~* evaluation of HIV infection stage~* hematology and biochemistry tests~* CD4 count~* HIV viral load~* IGRA~* chest radiograph~* Abdominal ultrasonograph to detect abdominal lymphadenopathy~* Tuberculin skin test~* gastric aspirates, sputum and string tests according to the age of children~* nasopharyngeal aspirate~* stool sample~* lymph node fine needle aspirate or other specimen collection if applicable~Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it."
215087685|NCT02362230|DRUG|Icotinib|Icotinib 125 mg BID
215087686|NCT03029195|DEVICE|Nasoalveolar molding therapy|Presurgical infant orthopedics
215087687|NCT02435407|BEHAVIORAL|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
215087688|NCT02435407|OTHER|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
215087689|NCT01480973|RADIATION|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
215087690|NCT05207332|DIETARY_SUPPLEMENT|CHO+PRO|A vegan product containing carbohydrate and protein
215087691|NCT05207332|DIETARY_SUPPLEMENT|CHO|containing carbohydrate
215087692|NCT00359333|DRUG|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
215087693|NCT01298102|BIOLOGICAL|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
214368202|NCT02999828|BIOLOGICAL|inactivated EV71 vaccine (KMB-17)|3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
214368203|NCT06072534|DRUG|"Mivacurium Chloride"|emergence modified sequence intubation
214368204|NCT02749357|DEVICE|30 minutes Lokomat|"30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
214980522|NCT06044103|DRUG|PDB + PCS|Pudendal nerve block (PNB) with ropivacaine AND Patient-controlled sedation with propofol by the participant
214368205|NCT02749357|DEVICE|60 minutes Lokomat|30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
214368206|NCT03810625|DRUG|D-0502|D-0502 oral tablets
214368207|NCT06116565|BIOLOGICAL|CM310|CM310, subcutaneous injection
214368208|NCT00627484|PROCEDURE|Gastric bypass|NOTE: the surgery is not paid for by the study
214368209|NCT00627484|PROCEDURE|Gastric banding|NOTE: the surgery is not paid for by the study
214368210|NCT00627484|PROCEDURE|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
214368211|NCT00627484|BEHAVIORAL|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
214368212|NCT05421455|DRUG|Group A|treat participants with biologics
214368213|NCT05421455|PROCEDURE|Group B|treat participants with surgery
214368214|NCT05408806|OTHER|Exercise Interventions|Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.
214368215|NCT04334473|PROCEDURE|phacoemulsification and Intraocular lens implantation|Standartd surgical procedure with small incision to remove catarct using ultrasound waves. it can be done by topica, local or general anaesthesia acoording to patients general fitness and preference.
214492357|NCT05942911|DRUG|Cannabidiol|Formulated using UniGel™ technology by ProCaps®. The CBD soft gel capsules contain 75 mg CBD oil solution. These capsules look identical to the IHL-675A UniGel™ capsules, to aid double-blinding
214980523|NCT03444558|DIETARY_SUPPLEMENT|Natural supplement containing chlorogenic acid and luteolin|50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
214980524|NCT03444558|OTHER|Placebo (without any active ingredients)|50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
214980525|NCT05944939|PROCEDURE|Surgical extraction of impacted third molar|After surgical extraction of mandibular impacted teeth concentrated growth factor placed in socket closure done with help of silk 3.0 suture
214368216|NCT04334473|DIAGNOSTIC_TEST|Ultrasound Biomicrosopy (UBM)|A diagnostic test using ultrasound waves to evaluate the anterior chamber depth, angle and lens vault.
214492358|NCT05942911|DRUG|Hydroxychloroquine|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules each contain a 100 mg HCQ tablet. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
214492359|NCT05942911|DRUG|Placebo|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
214492360|NCT00326677|BEHAVIORAL|Problem Solving Therapy|6 to 8 Problem Solving Therapy sessions over the course of 6 to 16 weeks followed by 3 booster PST sessions over the course of 2 years
214980526|NCT04415346|BIOLOGICAL|HU-014 Inj|Clostridium botulinum type A
214980527|NCT00623675|DIETARY_SUPPLEMENT|Mineralox C|Mineralox C 2 capsules three times a day.
214980528|NCT02183363|DRUG|BI 1356 - Tablet TFII|
214980529|NCT02183363|DRUG|BI 1356 - Tablet iFF|
214980530|NCT02183363|DRUG|BI 1356 - Tablet TFIIb|
214980531|NCT06454786|OTHER|Simulation Method|Management of cardiogenic shock scenario on an advanced simulation mannequin
214980532|NCT00808340|DEVICE|balafilcon A|multifocal contact lens
214980533|NCT00808340|DEVICE|senofilcon A production|multifocal contact lens
214980534|NCT00808340|DEVICE|senofilcon A test|multifocal contact lens
214980535|NCT03568435|OTHER|Non-Interventional|Non-Interventional
214980536|NCT02402374|DEVICE|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
214980537|NCT02402374|DEVICE|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
214368217|NCT02726802|OTHER|physical therapy vs. primary care interventions|Subjects with acute (\< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
214492361|NCT00326677|BEHAVIORAL|Dietary Education|6 to 8 Diet Education sessions over the course of 6 to 16 weeks followed by 3 booster Diet Education sessions over the course of 2 years
214492362|NCT06673368|DRUG|NRCT-101SR, NRCT-202XR|NRCT-101SR in combination with NRCT-202XR or NRCT-202XR alone
214492363|NCT02044497|DRUG|oral oxycodone|
214980538|NCT02980315|OTHER|CAR-T cells|the patients treat with CAR-T cells
214980539|NCT01612195|PROCEDURE|Anal fistula plug|All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
214980540|NCT06516120|BEHAVIORAL|RGS-app|Participants use the RGS-app on a smartwatch once for 1.5 hours during the measurement. The RGS-app consists of augmented reality games to provoke upper limb movement.
214980541|NCT03617887|OTHER|Experimental group|"Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus.~The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region in the control group, and a specific work of gluteus medius, added to the previous one, in the experimental group."
214980542|NCT03617887|OTHER|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise. The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region.
214980543|NCT01218802|DRUG|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
214980544|NCT01218802|DRUG|Placebo|participants will take a sugar pill daily for 96 weeks
214980545|NCT02778217|PROCEDURE|Culture media renwal|
214980546|NCT03019484|BEHAVIORAL|Breastfeeding support|Self-efficacy
214980547|NCT01776086|BEHAVIORAL|Neurological testing|
214980548|NCT05802888|DRUG|Tetracycline 500mg tid|Amoxicillin 1000mg bid +Tetracycline 500mg tid +Bismuth+Esomeprazole 40mg bid
214980549|NCT05802888|DRUG|Tetracycline 500mg qid|Amoxicillin 1000mg bid +Tetracycline 500mg qid +Bismuth+Esomeprazole 40mg bid
214980550|NCT03665337|BEHAVIORAL|mTranS-C|MOBILE HEALTH
214980551|NCT03665337|BEHAVIORAL|Control|MOBILE HEALTH
214680346|NCT02247206|BEHAVIORAL|Behavior Therapy for Tics (CBIT)|CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
214680347|NCT00693355|OTHER|Sodium butyrate|sodium butyrate
214980552|NCT02758418|OTHER|TAO|"TAO is a self-applied online treatment program and consists on the computerized version of the traditional CBT protocol for Adjustment Disorders.~The treatment protocol comprises different therapeutic components (see section Intervention) which are presented to the patients through 7 modules (one of them introductory). The Internet platform allows audiovisual resources (videos, illustrations, music and exercises that provide quick feedback) to be included, that makes the program more interactive."
214980553|NCT03329885|DRUG|BMS-986251|Escalating oral dose
215087694|NCT03913845|DRUG|lidocaine with epinephrine|One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
215087695|NCT03913845|DRUG|Normal saline with epinephrine|Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
215087696|NCT05129514|OTHER|Manual Lymphatic Drainage (MLD)|The participant will be placed in a supine position and manual lymphatic drainage will be performed for 50 minutes. During the three intervening days, daily 50 minute sessions of manual lymphatic drainage will be provided.
214368218|NCT05950425|OTHER|Aspiration training|"Pre-test application; All mothers whose children are hospitalized in the PICU will be filled in the questionnaires after verbally expressing and signing the informed consent before being admitted to the intensive care unit and starting the education.~In practice; The mother of the child who is planned to be discharged from the intensive care unit is given training a week before. Aspiration training will be given to the Experimental I group with the video method, and to the Experimental II group with the picture training booklet method. The materials of these trainings will be given to the mothers and they will be asked to look after them when they come to the next care.~Final test application; scales will be filled in the mother on the day of the child's discharge."
214368219|NCT02955472|DRUG|GLA5PR GLARS-NF3 tablet 150mg|A new formulation(3rd.) of Pregabalin CR tablet
214368220|NCT02955472|DRUG|GLA5PR GLARS-NF1 tablet 150mg|A new formulation(1st.) of Pregabalin CR tablet
214368221|NCT04667975|DRUG|CKD-702|In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.
214368222|NCT01567332|DEVICE|SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
214680348|NCT00693355|OTHER|NaCl|NaCl
214680349|NCT00693719|DRUG|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
214680350|NCT00693719|DRUG|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
214680351|NCT02865044|OTHER|Wax Ester Marine Oil|Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules) consumed once, in clinic, at t=0.
214980554|NCT03329885|OTHER|Placebo|Escalating oral dose
214980555|NCT03622450|DRUG|Colistin|Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
214980556|NCT03622450|DRUG|Carbapenem + Aminoglycoside/ Quinolone|Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
214680352|NCT02865044|OTHER|Ethyl Ester Marine Oil|Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule), consumed once, in clinic, at t=0
214980557|NCT00521183|DRUG|Cytochlor|The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
214980558|NCT00521183|DRUG|Tetrahydrouridine|A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
214980559|NCT00521183|RADIATION|Radiation Therapy|One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
214980560|NCT02037893|DRUG|Antipyrine and Benzocaine otic solution|antipyrine 54 mg and benzocaine 14 mg
214368223|NCT01567332|DEVICE|SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
214368224|NCT06274814|PROCEDURE|U/S guided Type 2 Pectoral Nerve Block|20 mL separates the pectoralis major and minor muscles, while 10 mL separates the serratus and pectoralis major muscles
214980561|NCT02037893|DRUG|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL
214980562|NCT02037893|DRUG|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 mL
215087697|NCT01562405|DRUG|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
214368225|NCT06274814|PROCEDURE|U/S guided RIB combined with the sub-serratus plane block (RISS)|he ipsilateral arm was abducted. RISS was performed. Using a 6-13 MHz linear ultrasound probe was placed medial to the medial border of the scapula in the oblique sagittal plane.. A 100-mm 21-gauge needle was inserted at the level of T5-6 in the ultrasound view. A single dose of 20-mL 0.25% bupivacaine was injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography. Thereafter, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for the sub-serratus block at the T8-9 level. The needle was advanced from its previous position, and an additional 20 mL of 0.25% bupivacaine was injected.
214368226|NCT04731779|DRUG|cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
214368227|NCT04731779|DRUG|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
214368228|NCT04995185|RADIATION|(18)F-fluoromisonidazole (FMISO)|Patients do not need to be fasted prior to intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole. Scanning will be performed two hours after the injection. Patients will be scanned with their thermoplastic shell used in routine radiotherapy treatment for 10 minutes, followed by approximately 5 minutes scan of the upper chest.
214368229|NCT02413060|OTHER|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
214368230|NCT02413060|BEHAVIORAL|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
214368231|NCT01954355|DRUG|LDE225|400, 600 and 800 mg OD
214368232|NCT01954355|DRUG|Paclitaxel|80 mg/m2 (days 1, 8, 15)
214680353|NCT04671680|DEVICE|LiDCO CNAP Monitoring Equipment|A continuous non-invasive arterial blood pressure monitor for rapidly changing hemodynamics.
214680354|NCT01418768|OTHER|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
214680355|NCT02446366|OTHER|Laboratory Biomarker Analysis|Correlative studies
214680356|NCT02446366|OTHER|Quality-of-Life Assessment|Ancillary studies
214980563|NCT02037893|DRUG|Placebo Otic solution|Placebo otic solution will be glycerin that is dehydrated
214980564|NCT02039934|OTHER|High intensity interval training|"The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.~Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down."
214980565|NCT06404437|DIAGNOSTIC_TEST|Auscultation|Auscultation at five auscultation points using a digital stethoscope and a smartphone
215087698|NCT01562405|DRUG|Lenalidomide|15 to 25 mg days 1-21, given orally
215087699|NCT01562405|DRUG|Dexamethasone|40 mg days 1,8,15,22; given orally
215087700|NCT01562405|DRUG|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
215087701|NCT01873053|DRUG|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
215087702|NCT01873053|DRUG|Placebo|
215087703|NCT04367103|DRUG|Norepinephrine|prophylaxis for hypotension
215087704|NCT04367103|DRUG|Phenylephrine|standerd prophylaxis for hypotension
215087705|NCT00232388|PROCEDURE|Blood draw|
215087706|NCT00241514|DRUG|Esomeprazole|
215087707|NCT02073838|DRUG|Ribavirin|
215087708|NCT02073838|DRUG|Vismodegib|
215087709|NCT02073838|DRUG|Decitabine|
214980566|NCT03950453|BEHAVIORAL|Parenting Mindfully for Health Nutrition (PMH)|"PMH will include included the following components:~1. mindfulness strategies as outlined in the MBSR manual,~2. mindful parenting concepts,~3. mindful eating and awareness of family choices;~4. self and child monitoring of food intake, PA and emotional reactivity;~5. utilizing mindfulness for emotion regulation and distress tolerance,~6. behavioral strategies of goal setting and implementing increasing frequency of healthy food intake and physical activity (PA)"
214980567|NCT03950453|BEHAVIORAL|Contact Control Nutrition (C+N)|Contact Control Group where parents engage in a quiet, relaxing, but stimulating activity and also nutrition counseling.
214980568|NCT03950453|OTHER|Non-randomized historical control (WLC) assessment only|Non-randomized, historical control group with only assessments during intervention and follow-up period.
214980569|NCT06436989|OTHER|hot purified water|Hot purified water,drink once a workday,almost 360mL.Buy from regular channels.
214980570|NCT00380172|DEVICE|Rheopheresis blood filtration|
214980571|NCT05316064|BIOLOGICAL|probiotic|oral administration of probiotic at 9 log CFU/day for 12 weeks to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab.
214980572|NCT05316064|OTHER|placebo|oral administration of primarily carrier without the probiotic for 12 weeks
214980573|NCT03538080|DEVICE|ACCUVEIN plus ultrasound|"Intervention is marking of the saphenous veins with ACCUVEIN system. The AccuVein® AV400 vein illumination system is a laser imaging system that detects superficial veins up to 10 mm deep and digitally displays, through a projected red light, a map of the vascularization on the surface of the skin. in real time, allowing clinicians to check vein permeability and position.~This system is portable and lightweight. It can be easily cleaned, and requires no calibration or adjustment. It does not require any contact with the patient. Second time is completion of marking by ultrasound if necessary"
214368233|NCT03581084|DRUG|N-acetylcysteine|Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
214680357|NCT02446366|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated SBRT
214680358|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
214680359|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
214680360|NCT05770414|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by caregivers and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching caregivers to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
214680361|NCT00379938|BIOLOGICAL|VAI-VP705 (parvovirus B-19 vaccine)|Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
214680362|NCT00379938|DRUG|Placebo|Saline control
214680363|NCT00379938|BIOLOGICAL|MF-59|Adjuvant
214680364|NCT04172831|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
214680365|NCT04172831|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
214680366|NCT01041573|BIOLOGICAL|IC51 Japanese Encephalitis|6 mcg or 3 mcg im. at day 0 and day 28
214680367|NCT01041573|BIOLOGICAL|Havrix®720|0.5 ml im. at day 0 and month 7
214680368|NCT01041573|BIOLOGICAL|Prevnar|0.5 ml im. at day 0 and day 56 and month 7
214680369|NCT02365532|DRUG|GS-6615|GS-6615 tablets administered orally
214680370|NCT02365532|DRUG|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
214680371|NCT02365532|DRUG|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
214680372|NCT02365532|DRUG|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
214680373|NCT02832492|BEHAVIORAL|pupil near response|
214680374|NCT02064218|DRUG|Anti-hypertensive drugs|
214680375|NCT00950781|PROCEDURE|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
214680376|NCT02564822|PROCEDURE|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
214680377|NCT02813330|OTHER|Subcutaneous sterile water injection|sterile water injection in two points of low back pain
214680378|NCT02813330|OTHER|saline injection|Saline injection in two points of low back pain
214680379|NCT02711748|DEVICE|electrostimulation|Electrostimulation using manual defibrillator
214680380|NCT02711748|DEVICE|cardiopulmonary resuscitation|CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
214680381|NCT04471740|PROCEDURE|CSF shunt diversion|Clinical response to a CSF shunt insertion
214680382|NCT01738139|DRUG|Imatinib Mesylate|Given PO
214680383|NCT01738139|BIOLOGICAL|Ipilimumab|Given IV
214368234|NCT01361425|DRUG|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
214680384|NCT03152864|BEHAVIORAL|Full Package|Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
214680385|NCT04372355|DRUG|WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.
214980574|NCT03538080|DEVICE|Ultrasound only|Intervention is marking with ultrasound imaging as in usual practice.
214980575|NCT02351947|OTHER|upper limb rehabilitation for chronic stroke|subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
214980576|NCT06019572|PROCEDURE|Spine decompression and fixation surgery|Surgery is performed by either an anterior or posterior approach. Anterior approach is performed with either discectomy or corpectomy accompanied fusion, while the posterior approach consist in a bilateral laminectomy accompanied by fusion.
214368235|NCT01361425|DRUG|placebo|placebo 500mg 8/8h, orally
214368236|NCT00990717|BIOLOGICAL|NK-92 cells|"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~* Level I: 1x10\^9 cells/m\^2~* Level II: 3x10\^9 cells/m\^2~* Level III: 5x10\^9 cells/m\^2"
214368237|NCT01241695|DIETARY_SUPPLEMENT|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
214680386|NCT02688114|PROCEDURE|Baseline surveillance endoscopy|All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
214680387|NCT02688114|PROCEDURE|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
214680388|NCT02688114|PROCEDURE|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
214980577|NCT02371681|DRUG|Treatment|Different Drug combinations
214980578|NCT02371681|RADIATION|PET/CT Scan|PET/CT Scans
214368238|NCT01241695|DIETARY_SUPPLEMENT|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
214368239|NCT04867356|OTHER|Spinal Stabilization Exercises (SSE)|"Spinal stabilization exercises (SSE) including bridging, planks and tummy tuck-in will be performed. Each participant received a total 7 session thrice a week sessions in two weeks, . Each session had lasted for 30-40 minutes. Spinal stabilization exercises were repeated 5-15 times depending on the endurance of patients.~Home exercise plan will also be given e.g. postural care, precautions in lifting and carrying weights etc."
214368240|NCT04867356|OTHER|Spinal Stabilization Exercises (SSE) & Latissimus Dorsi Stretching (LDS)|In experimental group in addition SSE group interventions, participants will receive the latissimus dorsi stretching (LDS). Each participant received a total 7 session thrice a week sessions in two weeks. Each session had lasted for 30-40 minutes. each stretch of latissimus dorsi was of 20-30 seconds with 10-20 repetitions in each session.
214680389|NCT02688114|PROCEDURE|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
214680390|NCT02688114|PROCEDURE|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
214680391|NCT05522114|PROCEDURE|TMJ injection using patient specific guide|Prefabricated patient specific guide used to guide the needle into the superior joint space of TMJ while real time MSCT evaluate the accuracy of needle position. Sodium hyaloronate injected within the superior joint space.
214680392|NCT00502710|DRUG|Placebo|Placebo po daily.
214680393|NCT00502710|DRUG|RO4876904|Escalating doses, at a starting dose of 12.5mg po daily.
214680394|NCT01052012|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; SABER-Bupivacaine /Once
214680395|NCT01052012|DRUG|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
214680396|NCT01052012|DRUG|SABER-Placebo|Injectable Solution; SABER-Placebo/Once
214680397|NCT03952312|BEHAVIORAL|Oncotool Intervention (symptom reporting + TKI education)|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.
214680398|NCT03952312|BEHAVIORAL|Oncotool Control (health information)|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
214680399|NCT02228512|DRUG|Pomalidomide|Part A: 5 mg po daily for 21 days (full course) Part A: 5 mg po daily for 4 days (short course) Part B: 5 mg po daily for 5 days (Phase I/II dose) Part C: Phase I/II dose) po daily Day 1-21 of 28 day cycle for up to 12 cycles.
214680400|NCT02228512|DRUG|Rituximab|Part A: 375 mg/m2 day 22 (full course) Part A: 375 mg/m2 day 5 (short course) Part A: 375 mg/m2 day 1 (omit pomalidomode) Part B: 375 mg/m2 day 1
214680401|NCT02228512|DRUG|Prednisone|Part B: 60 mg/m2/day po x 5 days (day 1-5
214680402|NCT02228512|DRUG|Etoposide|Part B: 50 mg/m2/day CIVI over 24 hrs x 4 days
214680403|NCT02228512|DRUG|Doxorubicin|Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
214680404|NCT02228512|DRUG|Vincristine|Part B: 0.4 mg/m2/day CIVI over 24 hrs x 4 days
214680405|NCT02228512|DRUG|Cyclophosphamide|Part B: 750 mg/m2 Day 5
214680406|NCT00388752|PROCEDURE|Acupuncture|
214980579|NCT02371681|PROCEDURE|Sample Collection|Sample Collection
214980580|NCT03247777|OTHER|Traditional strengthening|dead lifts, bench press, wrist curls, and lat pulldowns as examples
215087710|NCT01433302|PROCEDURE|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
214368241|NCT06276270|DEVICE|Mucopad HA|The product is a Class III Medical Device incorporating a medicinal substance (antiseptics-octenidine) within the composition made of sodium hyaluronate polysacharide stabilised by calcium chloride. Device is administered directly onto the area affected by mucositis.
214680407|NCT04500288|DEVICE|LEFT Device|LEFT device is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland.
214680408|NCT05757999|DRUG|Magnesium Sulphate|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
214680409|NCT05757999|DRUG|Saline|The patients will be pretreated with an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min before induction of anesthesia.
214680410|NCT04100070|BEHAVIORAL|Monitoring of the patients|"Follow-up of the patients during the 12 months study periods including :~* visits with the diabetologist/pediatrician~* contacts with the service provider (nurses' visits) (more in intensive group)~* personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)"
214680411|NCT04850911|DRUG|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.
214680412|NCT04850911|OTHER|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
214680413|NCT00878228|DRUG|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
214680414|NCT00878228|DRUG|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
214680415|NCT02138578|RADIATION|SBRT|
214680416|NCT02138578|RADIATION|RFA|
214680417|NCT02973646|DRUG|Entecavir or Tenofovir|Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
214680418|NCT02973646|DRUG|Peginterferon Alfa-2B|
214680419|NCT00398528|DRUG|Glatiramer acetate, (Copaxone®)|
214680420|NCT00398528|DRUG|IFN-β-1a, (Avonex®)|
214680421|NCT02152423|DRUG|LOVENOX|LMWH
214680422|NCT02152423|DRUG|ENOXAMED|LMWH
214680423|NCT00883428|OTHER|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
214680424|NCT02159092|BEHAVIORAL|Contingency Management|Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
214680425|NCT02384369|DRUG|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
214680426|NCT00740506|BEHAVIORAL|Frequency of Intercourse|
214680427|NCT05164276|OTHER|Head position|Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
214680428|NCT05938439|DEVICE|MAGUS placement|"An upper endoscopy will be performed with the use of fluoroscopy under general anaesthesia with orotracheal intubation. The delivery system will be placed over a guidewire, under fluoroscopy. The main steps are the following:~* Placement through the endoscope of a soft guidewire through the upper GI tract;~* Insertion of the MAGUS system on the guidewire;~* Advancement of the MAGUS system until proximal magnet reach the top of the septum;~* Release and placement of the proximal magnet at the bottom of the septum, pouch side;~* Meeting of the distal and proximal magnet on both sides of the septum, by pulling on the delivery system;~* Release of the distal magnet and activate the retractable wire;~* Insure that wire is not blocked and unblocked it if applicable.~Endoscopy and contrast injection will be performed before and after placement to ensure the correct positioning of the magnets."
214680429|NCT02151539|OTHER|medical chart review|Ancillary studies
214680430|NCT02151539|OTHER|quality-of-life assessment|Ancillary studies
214680431|NCT04632329|DEVICE|Negative Pressure Treatment via the Mercury Multi-Pressure Dial|Negative Pressure Treatment via the Mercury Multi-Pressure Dial
214680432|NCT00233220|BEHAVIORAL|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
214680433|NCT00233220|BEHAVIORAL|Usual Care|Patients will receive usual care.
214368242|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus every 2 weeks pump|IGSC 20% syringe daily push dosing for 16 weeks followed by every 2 weeks pump dosing for 16 weeks or the reverse sequence
215087711|NCT05223881|DEVICE|13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)|After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
215087712|NCT06762964|DRUG|Dapagliflozin tablet|Patient will take a 10mg tablet of Dapagliflozin once daily for 24 weeks
214680434|NCT01105338|BEHAVIORAL|Green tea drink|Green tea drink
214980581|NCT03247777|OTHER|Functional Strengthening|diagonal chops, one leg deadlifts, lateral plyometrics as examples
215087713|NCT06762964|DRUG|Placebo Tablet|Patient will take 10mg placebo tablet once daily for 24 weeks
215087714|NCT03221790|OTHER|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
214368243|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus once a week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by once weekly ambulatory pump administration dosing for 16 weeks or the reverse sequence
214368244|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus 2 times per week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by 2 times/week ambulatory pump administration on preselected days (eg, Monday and Thursday) not less than 3 days apart for 16 weeks or the reverse sequence
214980582|NCT03717103|DRUG|IBI188|Part A: 0.1 mg/kg IV QW, 0.3 mg/kg IV QW, 1 mg/kg IV QW. Part B: 1mg/kg IV D1+3, 10, 20, 30 mg/kg IV D8 QW or 45mg/kg D8 IV Q3W.
214980583|NCT02485665|DEVICE|Extracorporeal biofeedback device (Any Kegel)|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy. Enrolled patients in intervention group should be performed PFME regularly, based on following protocols: total exercise time (10 minutes/day), intensity (1.2 kgf), tension duration (10 sec/ 1 contraction), total exercise number (4 times/day)
214980584|NCT01505283|DRUG|NaCl 0.9%|epidural administration of 6 ml of NaCl 0.9%
214980585|NCT01505283|DRUG|Sufentanil|epidural administration of sufentanil 10 µg
214980586|NCT01505283|DRUG|lidocaine|epidural administration of lidocaine 50 mg
214980587|NCT03368807|DEVICE|Continuous Glucose Monitoring|Commercially available
214368245|NCT03814798|BIOLOGICAL|IGSC 20% 150 mg/kg|loading dose of IGSC 20% consisting of 5 consecutive daily doses of 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of IGSC 20% 150 mg/kg starting Week 1 (Day 8) through Week 32 using an infusion SC pump
214368246|NCT03358056|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.
214492364|NCT04990921|COMBINATION_PRODUCT|Palliative Radiation and Pembrolizumab|Stereotactic radiation therapy will be administered as clinically indicated.
214980588|NCT03368807|DRUG|Insulin Lispro|As prescribed.
214980589|NCT01102309|DEVICE|Robot therapy (NeReBot)|Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy
214980590|NCT01102309|OTHER|Conventional therapy|Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
214980591|NCT05107661|BEHAVIORAL|Telephone Prompt|Scripted messaging to remind subjects to complete their colorectal screening (colonoscopy or fecal test)
214980592|NCT00861133|DEVICE|Sleuth AT Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
214492365|NCT05043077|DRUG|Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (6.5 μL) for 3 doses with 5-minute intervals
214492366|NCT05043077|DRUG|Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (28-34 μL) for 3 doses with 5-minute intervals
214492367|NCT06753097|DEVICE|Continuous finger-cuff arterial pressure monitoring|Arterial pressure will be monitored using continuous non-invasive finger-cuff arterial pressure monitoring.
214492368|NCT06893250|BIOLOGICAL|PRP injection|Platelet rich plasma, blood from the patient that is centrifuged.
214492369|NCT06893250|BIOLOGICAL|ADSTEM Inj. (Adult human mesenchymal stem cells)|Adipose tissue stem cells, from abdominal fat.
214492370|NCT06893250|BIOLOGICAL|Injection|PRP + adipose tissue stem cells
214492371|NCT06893250|BIOLOGICAL|Saline (NaCl 0,9 %) (placebo)|Sterile saline injection.
214492372|NCT06888531|COMBINATION_PRODUCT|Neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors for the treatment of locally advanced resectable esophageal squamous cell carcinoma|Toripalimab: intravenous infusion, 240mg, D1, Q3W, for 2 consecutive doses; or Envorimab: subcutaneous injection, 400mg, D1, Q3W, for 2 consecutive doses. Albumin-bound paclitaxel: intravenous infusion, 50mg/m2, D1, QW, for 5 consecutive doses. Carboplatin: intravenous infusion, AUC=2, D1, QW, for 5 consecutive doses. Radiotherapy: 41.4Gy/1.8Gy/23F, D1-5, 5 times per week.
214492373|NCT06893601|DRUG|Parasternal block|A block containing 0.9% NaCl solution was applied to the Saline group just before the sternum was closed by the surgeon, while a bilateral parasternal block using 0.25% bupivacaine was applied to the bupivacaine group. The solutions used for the parasternal block were colorless and indistinguishable to ensure blinding.
214492374|NCT06741566|DRUG|intranasal saline group|3 ml of saline 0.9 % twice daily for 2 days preoperatively at fixed time ( 9 am and 6 pm)
214980593|NCT03905733|DEVICE|Optiflow|supply of oxygen at 2 L / min/ kg through Optiflow
215087715|NCT00706329|DEVICE|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
214368247|NCT03831243|RADIATION|Stereotactic body radiotherapy|Treatment will be prescribed to the periphery of the target, i.e. 80% of the dose should cover 95% of the PTV. The organ at risk (OAR) dose constraints will be in accordance with the recommendations from the report of the American Association of Physicists in Medicine (AAPM) task group 101. Image-guidance will consist of cone-beam CT in combination with 6 degrees of freedom corrections using robotic couch.
214368248|NCT03831243|RADIATION|3D-conformal radiotherapy|In the standard setting, 95% of the PTV should receive 95% of the prescribed dose while near maximum dose (Dnear-max) in the PTV should not exceed 107%. Image-guidance will consist of portal images showing the relevant bony anatomy.
214368249|NCT06089356|DRUG|zolmitriptanee|zolmitriptane tablet daily
214368250|NCT06089356|DRUG|topiramate|topiramate once daily
214368251|NCT06089356|DRUG|Valproate|valproate once daily
214368252|NCT00834106|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
214492375|NCT06741566|DRUG|intranasal insulin|20 IU of regular insulin on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
214492376|NCT06741566|DRUG|Intranasal dexmedetomidine|1.5 mic/kg on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
214492377|NCT06896474|BEHAVIORAL|Shared Decision-Making Training and Decision Aid|The intervention includes training surgeons in shared decision making techniques and providing eligible participants with a tailored breast cancer treatment decision aid prior to the initial surgical consultation.
214492378|NCT06045507|DRUG|MK-8527|MK-8527 capsule
214492379|NCT06045507|DRUG|Placebo to MK-8527|Placebo capsule matched to MK-8527
214492380|NCT06738524|BEHAVIORAL|Fighting with Digital Addiction|The purpose of this training is to raise awareness among young people about the signs, causes and consequences of addictive use of technology and how to avoid excessive use of technology and technology addiction.
214492381|NCT06736938|DRUG|Propofol 1%|Propofol 1% is infused intravenously, initially at a bolus dose of 0.5 mg/kg followed by a maintenance dose in a continuous infusion of 0.5-1.0 mg/kg/hour.
214492382|NCT06736938|DRUG|Midazolam|Midazolam is administered intravenously at an initial dose of 2 mg, as a bolus, followed by aliquots of 0.5 mg or 1 mg.
214492383|NCT06736938|DRUG|Pethidine|Pethidine (100 mg/2 ml) is administered intravenously at a dosage of 0.5 mg/kg.
214492384|NCT06894693|BIOLOGICAL|RS001 injection|CD19-CAR-mbIL15-DNT Cells.
214980594|NCT00843492|DRUG|Fondaparinux sodium|After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg \[0.5mL\] (1.5 mg \[0.3mL\] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
215087716|NCT02362204|BEHAVIORAL|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
215087717|NCT05845944|OTHER|Video-supported education group|Providing training on nutrition with a nasogastric tube in pediatric patients with a video-supported education method
215087718|NCT02421926|DRUG|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
215087719|NCT02022241|DRUG|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
215087720|NCT03829345|DRUG|Olaparib|Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.
214492385|NCT06738511|DIAGNOSTIC_TEST|blood sampling|Molecular signature using plasma sample
214680435|NCT01105338|DIETARY_SUPPLEMENT|green tea capsules|green tea capsules
214680436|NCT01105338|OTHER|Green tea placebo capsules|Green tea placebo capsules
214680437|NCT01105338|DIETARY_SUPPLEMENT|Lycopene capsules|Lycopene capsules
214680438|NCT01105338|OTHER|Lycopene placebo capsules|Lycopene placebo capsules
214680439|NCT01105338|OTHER|Tomato rich diet|Tomato rich diet
214980595|NCT00843492|DRUG|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
215087721|NCT04564248|OTHER|Website access|website access will be provide to families
214368253|NCT00834106|BIOLOGICAL|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
214368254|NCT03258216|DIAGNOSTIC_TEST|panendoscopy|panendoscopy
214492386|NCT06738511|OTHER|stool sampling|Stool sampling (by the participant)
214492387|NCT06738511|OTHER|colonoscopy|Colonoscopy will be performed in the course of a screening programme
214492388|NCT06405295|OTHER|no intervention|Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention
214492389|NCT05578846|DRUG|Treatment A|Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.
214492390|NCT05578846|DRUG|Treatment B|Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.
214492391|NCT05578846|DRUG|Treatment C|Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.
214980596|NCT01198912|DRUG|placebo|during 56 days
214980597|NCT01198912|DRUG|doxycycline 100 mg|during 56 days
215087722|NCT00094718|BIOLOGICAL|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
215087723|NCT00094718|BIOLOGICAL|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
215087724|NCT02614482|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
215087725|NCT00231231|DEVICE|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
215087726|NCT00231231|DEVICE|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
215087727|NCT03910166|PROCEDURE|drug-coated balloon catheter（Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
215087728|NCT03910166|PROCEDURE|Intracranial artery stent system（APOLLO）|stent assisted angioplasty
214368255|NCT03258216|DIAGNOSTIC_TEST|tongue image|capture tongue images by Automatic Tongue Diagnosis System
214368256|NCT01980238|DEVICE|cannula ileostomy|
214368257|NCT01980238|DEVICE|loop ileostomy|
214368258|NCT01980238|DEVICE|LAR|
214368259|NCT03721575|PROCEDURE|Scarpa's preserving hernio-abdominoplasty|Scarpa's fascia is preserved during hernio-abdominoplasty
214368260|NCT03721575|PROCEDURE|Classical hernio-abdominoplasty|Scarpa's fascia is removed during hernio-abdominoplasty
214368261|NCT00000379|DRUG|Fluoxetine|
214680440|NCT00863629|DRUG|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
214680441|NCT00668525|DRUG|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
214368262|NCT00000379|BEHAVIORAL|EMDR|
214368263|NCT03477279|BEHAVIORAL|Enhanced Couple HIV Testing and Counseling|"Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced.~Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another."
214680442|NCT00668525|DRUG|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
214680443|NCT00668525|DRUG|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
214680444|NCT03468023|PROCEDURE|Short arm cast|Application of a below-elbow cast
214680445|NCT03468023|PROCEDURE|Long arm cast|Application of an above-elbow cast
214680446|NCT02088944|DRUG|Infliximab|
214680447|NCT00492401|DRUG|decitabine|Given IV
214680448|NCT00492401|OTHER|laboratory biomarker analysis|Correlative studies
214680449|NCT00492401|OTHER|pharmacological study|Correlative studies
214680450|NCT00492401|OTHER|high performance liquid chromatography|Correlative studies
214680451|NCT00492401|GENETIC|microarray analysis|Correlative studies
214680452|NCT00492401|GENETIC|RNA analysis|Correlative studies
214680453|NCT00492401|OTHER|mass spectrometry|Correlative studies
214680454|NCT00492401|GENETIC|DNA methylation analysis|Correlative studies
214680455|NCT00492401|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
214680456|NCT05730608|OTHER|18F-FDG PET/CT|Included breast cancer patients will undergo a 18F-FDG PET/CT scan in addition to conventional imaging with CT and bone scintigraphy.
214680457|NCT06133777|OTHER|Respiratory variability monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
214680458|NCT03509753|DIETARY_SUPPLEMENT|High Fiber|See intervention description.
214680459|NCT03509753|DIETARY_SUPPLEMENT|Low Fiber|See intervention description.
214680460|NCT02868125|RADIATION|X ray radiography|All studied patients will undergo an x-ray radiography of the operated hip. This protocol is a part of the investigators' common practice policy regardless of the study.
214680461|NCT05126225|BEHAVIORAL|Stigma reduction|The intervention is modularized to have eight weekly sessions of 2-hour group discussions, led by a trained facilitator. The facilitator applies the principle of CBT and provides psychoeducation to promote the awareness and understanding of HIV stigma as well as training to help participants acquire alternative coping skills, such as relaxation techniques.
214680462|NCT03693365|PROCEDURE|PEEP trial|Positive end-expiratory pressure (PEEP) is increased from 5 to 10 cmH2O during one minute.
214680463|NCT03279510|DEVICE|hearing aids|Subjects are fit with hearing aids.
214680464|NCT01765764|DRUG|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
214680465|NCT01765764|DRUG|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
214680466|NCT00929578|DRUG|Fluphenazine|Intralesional injection of Fluphenazine
214680467|NCT00929578|DRUG|Placebo|Intralesional injection of placebo
214680468|NCT01893593|OTHER|Intervention|Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems
215087729|NCT05909774|DEVICE|"Test with Atalante exoskeleton in continuous walk type"|"The continuous walk is smoother and more physiologic than the push and swing walk"
215087730|NCT00212186|DRUG|Selenium Supplements (essential nutrient)|
215087731|NCT03897530|BEHAVIORAL|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
215087732|NCT03897530|OTHER|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
215087733|NCT03897530|OTHER|Questionnaire Administration|Ancillary studies
215087734|NCT04846530|DEVICE|RHA® 1, RHA® 2, RHA® 3, and RHA® 4|For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
215087735|NCT00278330|DRUG|alvocidib|Given by infusion
215087736|NCT00278330|DRUG|vorinostat|Given orally
215087737|NCT00921310|DRUG|Pemetrexed|
215087738|NCT00921310|DRUG|Temsirolimus|
214680469|NCT01893593|OTHER|Control|Guideline summary and data feedback from a baseline medical record review
214980598|NCT06003361|DEVICE|Digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for depression.
214368264|NCT02341001|OTHER|Daily text message of support|
214368265|NCT01105923|OTHER|MAPLE|MAPLE is a CDS intervention within the EHR that will alert providers to problem lists gaps and present an opportunity to correct them.
214368266|NCT01456299|DRUG|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
214368267|NCT01456299|DRUG|Control|The control group, which received an infusion of normal saline
214492392|NCT06734091|DIAGNOSTIC_TEST|PrestoCHILL|PrestoCHILL (Milestone Medical Technologies, Inc.MI 49009, USA)which by reducing the tissue freezing time to less than 60 seconds should eliminate freezing artefacts and improve the quality of sections for morphological and IHC examination. In selected cases and according to the diagnostic algorithm required for the diagnosis of specific neoplasms, rapid IHC analysis will be performed with the Benchmark ULTRA® immunostainer (Ventana Medical Systems), which is already in place to confirm or exclude the suspected neoplasm, as well as to confirm the histotype. For the latter purpose, commercially available antibody panels for routine examinations will be used (Ventana/Roche,Ventana Medical Systems, USA).
214492393|NCT06747832|DRUG|iNK cells|Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.
214492394|NCT05642936|BEHAVIORAL|didactic health education control|didactic classroom-based comparison group that follows standard guidelines for diet, exercise and substance use with no stress reduction component
214492395|NCT05642936|BEHAVIORAL|Transcendental Meditation technique|a mental technique derived from the Vedic tradition of ancient India and practiced by anyone for 20 minutes twice a day sitting
214980599|NCT06003361|OTHER|Waitlist|Participants will wait for 5 weeks prior to receiving the intervention
214980600|NCT02110979|BEHAVIORAL|Use of a PDA to assist shared decision making|
214980601|NCT05724342|DRUG|rhTNK-tPA Thrombolysis|rhTNK-tPA Thrombolysis
214980602|NCT02553343|BIOLOGICAL|High-dose quadrivalent influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
214980603|NCT02553343|BIOLOGICAL|High-dose influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
214980604|NCT02553343|BIOLOGICAL|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
214368268|NCT01456299|DRUG|Remifentanil 2|"Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml."
214368269|NCT00525525|DRUG|Bevacizumab|Patients are given 10 mg/kg IV Q2 weeks.
214368270|NCT00525525|DRUG|Tarceva|Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
214368271|NCT00525525|DRUG|Temozolomide|Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
214368272|NCT03877458|OTHER|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
214368273|NCT03877458|OTHER|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
214368274|NCT03877458|OTHER|Placebo|Taking 1 placebo capsule at bed time everyday for three months.
214368275|NCT05130359|DIETARY_SUPPLEMENT|Placebo|take 2 tablets 2 hours before bedtime for 4 consecutive weeks
214368276|NCT05130359|DIETARY_SUPPLEMENT|Banana peel extract|take 2 tablets 2 hours before bedtime for 4 consecutive weeks
214368277|NCT05905302|OTHER|Forced and Voluntary Exercise|Participants will complete a forced exercise (FE) and voluntary exercise (VE) session. Forced exercise is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. Voluntary exercise is standard stationary cycling. FE and VE exercise sessions will be Off antiparkinsonian medication. The order in which exercise session is conducted first will be randomized. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre, during FE or VE and post-exercise).
214368278|NCT06246396|DRUG|Minocycline Hydrochloride|Minocycline Hydrochloride 100 mg twice daily
214368279|NCT06246396|DRUG|Placebo|Placebo
214368280|NCT05830162|DRUG|Placebo|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
214368281|NCT05830162|DRUG|Bioclavid (Amoxicillin and Clavulanic acid)|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
214368282|NCT05842408|DRUG|DA-5212|Test drug: DA-5212
214368283|NCT05842408|DRUG|DA-5212-R|Control drug: DA-5212-R
214368284|NCT06492278|BEHAVIORAL|SMART-3RP|The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
214980605|NCT02553343|BIOLOGICAL|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
214980606|NCT02833896|GENETIC|surgery|
214980607|NCT05660096|DEVICE|Cionic Neural Sleeve NS-100|Sleeve applies neuromuscular stimulation as patients walk to help contract appropriate muscles at appropriate times.
214980608|NCT00921323|BEHAVIORAL|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
214980609|NCT00921323|BEHAVIORAL|Control|The control group will be advised to continue to be physically active and record daily steps
214980610|NCT01677741|DRUG|Dabrafenib|Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
214980611|NCT04400461|OTHER|Data collection and clinical testing of subjects|"Clinical Testing: muscle strength. Muscle strength, as a component of physical function, will be assessed with the Medical Research Council sum score (MRC- SS) at discharge from the ICU and at discharge from the hospital.~Clinical testing: physical function. The Functional Status Score for the ICU (FSS-ICU) will be used to evaluate 5 functional tasks at discharge from hospital."
214980612|NCT00061581|DEVICE|Isolex 300i Stem Cell Selection|
214980613|NCT01973218|BIOLOGICAL|Meningococcal B Recombinant vaccine rMenB+OMV NZ|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
214980614|NCT01973218|BIOLOGICAL|Placebo|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
214980615|NCT01973218|BIOLOGICAL|Meningococcal ACWY-CRM conjugate vaccine|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
214980616|NCT03172598|DRUG|MT-8554 low dose|Capsule
214980617|NCT03172598|DRUG|MT-8554 middle dose|Capsule
214980618|NCT03172598|DRUG|MT-8554 high dose|Capsule
214980619|NCT03172598|DRUG|Placebo|Capsule
214980620|NCT00344695|DRUG|bupropion SR|
214980621|NCT00800358|DRUG|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
214980622|NCT00800358|DRUG|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
214980623|NCT01270477|OTHER|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
214980624|NCT04448119|DRUG|Favipiravir|Favipiravir is the experimental drug. The dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. The dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.
214980625|NCT04448119|DRUG|Favipiravir Placebo|Favipiravir Placebo is the placebo drug. For chemoprophylaxis, the dosage of favipiravir placebo is 8 tablets orally twice daily on day 1, followed by 4 tablets twice daily from days 2-25. The dosage of favipiravir placebo for treatment is 10 tablets orally twice daily on day 1, followed by tablets twice daily from days 2-14.
214980626|NCT00221819|DEVICE|heated humidifier (device)|
214980627|NCT00221819|DEVICE|Heat and moisture exchanger (device)|
214980628|NCT06183034|OTHER|Very Low Calorie Diet|Participants will receive a very low calorie diet as described in the arm/group
214980629|NCT03245281|DRUG|Diuretic Suspension (DS)|Stop diuretic consumption in the 48h before the follow-up visit
214980630|NCT03245281|DRUG|Diuretic Increase (DI)|Double diuretics dosage in the 48h before the follow-up visit
214980631|NCT03245281|DRUG|Diuretic and Medication Suspension (DMS)|Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
214980632|NCT00029822|DRUG|Alfuzosin (SL770499)|
214980633|NCT04344717|DRUG|Apixaban single dose|A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured
214980634|NCT04344717|DRUG|Apixaban steady-state|Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
214980635|NCT02941640|PROCEDURE|E group|The securing the base of appendix by endoloop.
214980636|NCT02941640|PROCEDURE|S group|The securing the base of appendix by Stapler.
215087739|NCT01895244|DRUG|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
214980637|NCT02941640|PROCEDURE|H group|The securing the base of appendix by Hem-o-lok clip.
214980638|NCT02941640|PROCEDURE|DS group|The securing the base of appendix by DS clip.
214980639|NCT02941640|DEVICE|Endoloop|
214980640|NCT02941640|DEVICE|Stapler|
214980641|NCT02941640|DEVICE|Hem-o-lok clip|
214980642|NCT02941640|DEVICE|DS clip|
214980643|NCT04533256|PROCEDURE|CytoSorb|three consecutive sessions of hemoadsorption in patients with sepsis
214980644|NCT03040401|DRUG|Cohort 1, Ceplene® and Proleukin®|"Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
214980645|NCT03040401|DRUG|Cohort 2, Ceplene® and Proleukin®|"Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
214980646|NCT03040401|DRUG|Cohort 3, Ceplene® and Proleukin®|"Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
214980647|NCT01441973|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|
214980648|NCT01149655|DRUG|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
214980649|NCT01149655|DRUG|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
214980650|NCT03686553|OTHER|laboratory-based data collection|laboratory-based surveillance of SSI
214680470|NCT04761380|DIAGNOSTIC_TEST|balloon-based tongue pressure measurement device|The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
214680471|NCT04115397|DRUG|Zoledronic Acid|Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
214368285|NCT06492278|BEHAVIORAL|Health Education Program|This is a multiple behavior change program that addresses sleep, exercise, nutrition, substance use, and working with one's healthcare team.
214980651|NCT02785198|DEVICE|Passive knee extensor machine|The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
214980652|NCT03874832|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
214980653|NCT01298830|DRUG|GLP-1 CellBeads|GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
214980654|NCT00550342|DRUG|rituximab|375 mg/m2 intravenously for 4 doses
214980655|NCT06612658|DIETARY_SUPPLEMENT|A novel, proprietary encapsulated form of Capsicum extract in beadlet form standardized to 2% capsaicinoids|This study will investigate the effect of the supplement on exercise performance.
214980656|NCT06612697|OTHER|Radiology|A retrospective analysis was conducted using systematic records from the Department of Radiation Oncology at our hospital. The study included patients diagnosed with nasopharyngeal carcinoma through endoscopic pathological reports from January 1, 1984, to December 31, 2022. Eligible patients had baseline imaging (CT or MRI) prior to treatment, received definitive radiotherapy at our institution, and were followed up long-term with complete medical records.
215087740|NCT05479123|DRUG|Propranolol three times a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit."
215087741|NCT05479123|DRUG|Propranolol twice a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit."
215087742|NCT05479123|DRUG|Timolol|Patients with a small (\<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
214368286|NCT06017219|DIETARY_SUPPLEMENT|spermidine|spermidine
214368287|NCT06437782|OTHER|Questionnaire completion|HLQ (Health Literacy questionnaire) will be completed by all included patients once.
214368288|NCT06164639|BEHAVIORAL|aspiration|Based on whether the patient meets the diagnosis of aspiration pneumonia.
214368289|NCT06164639|DIAGNOSTIC_TEST|bronchial alveolar fluid|Performing bronchoscopy.
214368290|NCT06164639|DEVICE|EIT V/Q test|Local pulmonary ventilation and perfusion are measured by electrical impedance tomography (EIT). For perfusion imaging, 10 ml of 5% saline is injected as a central venous bolus. The matching of ventilation and perfusion reveals intrapulmonary shunting.
214368291|NCT06164639|OTHER|Nitric oxide inhalation|According to the physician's judgment and the family members' consent, the patient is administered nitric oxide inhalation at a dosage of 20-30 parts per million (ppm).
214368292|NCT05288660|DRUG|ALXN1210|All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.
214368293|NCT05288660|DRUG|Placebo|All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.
214368294|NCT04899245|DIAGNOSTIC_TEST|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
214368295|NCT03088267|DRUG|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
214680472|NCT04115397|DRUG|Placebo|Placebo
214980657|NCT01118078|GENETIC|DNA methylation analysis|Undergo DNA methylation analysis
214980658|NCT01118078|GENETIC|gene expression analysis|Undergo gene expression analysis
214980659|NCT01118078|GENETIC|microarray analysis|Undergo microarray analysis
214980660|NCT01118078|GENETIC|reverse transcriptase-polymerase chain reaction|Undergo RT-PCR
214980661|NCT01118078|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214980662|NCT02471573|PROCEDURE|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
214980663|NCT02471573|PROCEDURE|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
214980664|NCT04030598|DRUG|Donidalorsen|Donidalorsen administered SC
214680473|NCT00935233|GENETIC|DNA analysis|
214680474|NCT00935233|GENETIC|polymorphism analysis|
214680475|NCT00935233|GENETIC|protein analysis|
214680476|NCT00935233|OTHER|laboratory biomarker analysis|
214980665|NCT04030598|DRUG|Placebo|Placebo matching solution administered SC
214980666|NCT05897671|OTHER|retrospective data analysis|Macular hole closure rate, visual acuity and OCT
214980667|NCT03150459|DRUG|Simvastatin 20 mg|Simvastatin 20 mg/day for 12 weeks (Group 1)
215087743|NCT01260025|DRUG|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
214368296|NCT03088267|DRUG|Placebo extended-release oral suspension|6, 7 or 8 mL PO
214368297|NCT04631263|DEVICE|Hyaluronic Acid|Injectable gel. Chin correction and augmentation for retrusion
214368298|NCT03899753|DEVICE|2-Octyl Cyanoacrylate and Mesh|2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
214368299|NCT03899753|DEVICE|2-Octyl Cyanoacrylate|Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
214980668|NCT03150459|DRUG|Simvastatin 40mg|Simvastatin 40 mg/day for 12 weeks (Group 2)
215087744|NCT05259644|DEVICE|laparoscopic sleeve gastrectomy|Surgical procedure - laparoscopic sleeve gastrectomy.
215087745|NCT05259644|OTHER|conservative treatment of obesity|Diet and exercise
214368300|NCT03585582|OTHER|Prospective follow-up|This is a prospective follow-up study to assess of outcomes at 1 year following the discharge from the hospitalization during which PARDS was diagnosed
214368301|NCT04321226|DEVICE|Femtosecond Laser guided Arcuate Keratotomy|Astigmatism will be reduced in cataract surgery using a low energy Femtosecond Laser device
214368302|NCT00003532|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214368303|NCT01156948|DRUG|misoprostol|400ug vaginally the day before surgery
214368304|NCT01156948|DRUG|oral misoprostol|400ug misoprostol orally the day before the surgery
214368305|NCT05822115|DEVICE|Reduction of breast hypertrophy by means of laparoscopic|"The research procedure is a breast reduction performed by means of laparoscopic surgery.~The project consists of removing a disc from the breast at the level of the base, thus causing peripheral skin slackening of 2 to 3 cm but circular. Both breasts are usually operated on at the same time. In case of asymmetry, only one side will be treated."
214368306|NCT01072461|BEHAVIORAL|HAS Training|Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
214368307|NCT01072461|BEHAVIORAL|HAT training|Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
214368308|NCT01072461|BEHAVIORAL|Bimanual Training|Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
214368309|NCT00623090|BEHAVIORAL|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
214368310|NCT00623090|BEHAVIORAL|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
214368311|NCT00623090|BEHAVIORAL|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
214368312|NCT05362565|BIOLOGICAL|Salivary Sampling|"The DNA study will be carried out from saliva sample~1 saliva sample per patient will be performed at the inclusion visit"
214368313|NCT03144895|PROCEDURE|Laying a radial or femoral arterial catheter|Laying a radial or femoral arterial catheter
214368314|NCT03403868|DIAGNOSTIC_TEST|conductance catheter|pressure volume loops are assessed via a special catheter (Conductance catheter)
214368315|NCT00257140|DRUG|levofloxacin|
214492396|NCT06754488|PROCEDURE|Posterior Reconstruction|"Reconstruct the bladder neck using the inverted tennis racket method to narrow the bladder neck opening and lengthen the posterior bladder wall. Measure the length of the extended part."
214680477|NCT00935233|OTHER|questionnaire administration|
214980669|NCT03150459|DRUG|Rifaximin 400 mg|Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)
214980670|NCT03150459|OTHER|Placebo of Simvastatin|Placebo of Simvastatin for 12 weeks (Group 3)
214680478|NCT00935233|OTHER|survey administration|
214980671|NCT03150459|OTHER|Placebo of Rifaximin|Placebo of Rifaximin for 12 weeks (Group 3)
214980672|NCT05550168|DEVICE|Low Level Laser therapy|The participants in the intervention group experienced a total of 7 session laser applications on their randomly determined molar region during the 12-week clinical trial period.
214980673|NCT06593418|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy, which delivers precise, high-dose radiation non-invasively to generate thermal scarring to myocardial targets causing VT
215087746|NCT05259644|DEVICE|endoscopic gastric plication|Endoscopic procedure - endoscopic gastric plication
215087747|NCT00002039|DRUG|Foscarnet sodium|
215087748|NCT03658070|DRUG|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
214980674|NCT06798207|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC).
214368316|NCT03749564|BEHAVIORAL|SMT|"The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
214980675|NCT07043556|OTHER|Artificial Intelligence-Based ROTEM Interpretation|A structured artificial intelligence-based evaluation system that analyzes ROTEM (Rotational Thromboelastometry) parameters and provides treatment recommendations. ROTEM case data are converted into standardized clinical scenarios and evaluated by AI models using a predefined template. The AI output is compared to the consensus of expert clinicians regarding the presence and type of coagulopathy and the need for therapeutic intervention (e.g., fibrinogen, protamine, platelets, PCC, plasma). This intervention does not involve any patient-facing activity and is performed on de-identified data only.
214980676|NCT04227717|DIAGNOSTIC_TEST|MRI with custom MRI spine coil|Participants will undergo MRI with custom MRI spine coil
214980677|NCT05079321|DEVICE|Hydra-PEG|Zen™ RC scleral lenses (Hydra-PEG coated)
214980678|NCT05079321|DEVICE|Uncoated|Zen™ RC scleral lenses (non-coated)
214980679|NCT06726460|DIAGNOSTIC_TEST|Nova Stat Profile pHOx Ultra Analyzer System(Nova)|This group involves the use of Nova for measuring serum and whole blood samples. The results from Nova will be compared with those obtained from P1.
214368317|NCT03749564|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
214492397|NCT06754488|PROCEDURE|anterior suspension|The anterior wall of the bladder was continuously sutured and fixed onto the muscular membrane of the lower margin of the symphysis pubis using a 3-0 barb suture.
214492398|NCT06753552|OTHER|Underwater US|7 min per session with an intensity of 0.9 W/cm2 for 20 sessions
214492399|NCT06753552|DEVICE|CFO|Custom made orthotics
214980680|NCT06726460|DIAGNOSTIC_TEST|Novel POCT dry electrolyte analysis system(P1)|This group involves the use of P1 for measuring serum and whole blood samples. The results from P1 will be compared with those obtained from Nova.
214980681|NCT07045584|DEVICE|Transcranial Alternating Current Stimulation|Intervention Group（tACS）: Receive tACS stimulation targeting the temporal pole, with stimulation frequency of 40Hz, using adapter power supply: voltage 9V, current set at 1.5mA, 6 times/day, 20min/session with 20min intervals between sessions, lasting for 5 days;
214980682|NCT07045584|DEVICE|transcranial Temporal Interference Stimulation|Intervention Group（tTIS）: Receive tTIS targeting the temporal pole, with stimulation frequency of 2040/2000HZ, using battery power supply: voltage 12V, current set at 1.5mA, 6 times/day, 20min/session with 20min intervals between sessions, lasting for 5 days;
214980683|NCT01941394|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells infusion
214980684|NCT02003144|BIOLOGICAL|eculizumab|
214980685|NCT02974933|DRUG|Apatinib combined with pemetrexed|For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
215087749|NCT02642146|DRUG|Calcium Channel Blockers|
215087750|NCT02642146|DRUG|Phosphodiesterase Inhibitors|
215087751|NCT02642146|DRUG|Endothelin receptor blocker|
214492400|NCT06646107|DEVICE|MInimed 780G|Minimed 780G HCL system (Metronic, Northridge, Ca, USA) is ConformitèEuropëenne(CE)-marked and includes additional functionality aiming to provide further protections from high glucose levels. When the system is used in Auto Mode automatically calculate the insulin dose based on information received from CGM. Signals are converted by the transmitter to sensor glucose values. Sensor values are then transmitted to the insulin pump. Sensor glucose and insulin delivery data are stored by the pump and may be uploaded. The HCL system can be programmed to automatically calculate insulin doses (both basal insulin and correction boluses) based on information received from CGM780G and the adherence to MD.
214492401|NCT06810739|DIAGNOSTIC_TEST|Cervical Cancer Screen-Triage-Treat Care Cascade|Cervical Cancer Screen-Triage-Treat Care Cascade: After providing informed consent, the study clinician will open a Case Report Form (CRF) for each patient which starts with a brief questionnaire, which will include the participant's demographic information and medical history, including HIV viral load and cluster of differentiation 4 (CD4) counts, previous cervical cancer screening results if previously screened, and result of rapid pregnancy test performed that day. Each participant will then be accompanied to a private location where the study nurse will provide counseling and instruction on how to appropriately perform the self-collection vaginal swab technique.
214980686|NCT00168948|DRUG|Sulfadoxin (12.5) Pyrimethamine (250 mg)|
214980687|NCT00006320|PROCEDURE|determine blood levels of anti-HIV drugs|
214980688|NCT00198991|DRUG|Cyclophosphamide|Cytostatic drug
214980689|NCT00198991|DRUG|Dexamethasone|Antileukemic drug
214980690|NCT00198991|DRUG|Vincristine|Cytostatic drug
214980691|NCT00198991|DRUG|Daunorubicin|Cytostatic drug
214980692|NCT00198991|DRUG|Asparaginase|Cytostatic drug
215087752|NCT02642146|DRUG|Prostanoids|
215087753|NCT02642146|DRUG|Other vasodilator|
215087754|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
215087755|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
214980693|NCT00198991|DRUG|Methotrexate|Cytostatic drug
214980694|NCT00198991|DRUG|Cytarabine|Cytostatic drug
214980695|NCT00198991|DRUG|Mercaptopurine|Cytostatic drug
214980696|NCT00198991|DRUG|G-CSF|Growth factor
214980697|NCT00198991|DRUG|Vindesine|Cytostatic drug
214980698|NCT00198991|DRUG|Etoposide|Cytostatic drug
214980699|NCT00198991|DRUG|Prednisolone|Antileukemic drug
214980700|NCT00198991|DRUG|Adriamycin|Cytostatic drug
214980701|NCT00198991|DRUG|Thioguanine|Cytostatic drug
214980702|NCT00198991|DRUG|Teniposide|Cytostatic drug
214492402|NCT06763367|OTHER|Face mask containing Centella sinensis|A half-face control test was used in this study. One side of the face was treated with a mask containing Asiaticum asiatica and the other side was treated with a mask without Asiaticum asiatica
214492403|NCT06763562|OTHER|Carbohydrate-first meal|Rice eaten first (150 grams), followed by edamame (150 grams) and butter (10 grams)
214492404|NCT06763562|OTHER|Carbohydrate-last meal|Edamame (150 grams) and butter (10 grams) eaten first, followed by rice (150 grams)
214492405|NCT06763978|DEVICE|Transcatheter PDA closure|Transcatheter PDA closure
214492406|NCT06819826|DRUG|SC0062 strength 10mg|Subjects will take 20 mg once daily for 108 weeks during the treatment period.
214492407|NCT06819826|DRUG|Placebo matched to SC0062|Subjects will take 20 mg once daily for 108 weeks during the treatment period.
214492408|NCT06767332|OTHER|eye movement desensitization and reprocessing (EMDR)|"EMDR is a psychological intervention that has historically been applied to the treatment of Post-Traumatic Stress Disorder (PTSD), but has since then been shown to be effective for a variety of anxiety disorders (e.g. fear of illness and specific phobia) (Logie \& de Jongh, 2014) and somatic complaints such as post-operative pain, medically unexplained symptoms and seizure-related post-traumatic stress (Dautovic, de Roos, van Rood, Dommerholt, \& Rodenburg, 2016; van Rood \& de Roos, 2009; Maroufi, Zamani, Izadikhah, Marofi, \& O'Connor, 2016).~With more than 25 randomized clinical trials, EMDR has been established as an evidence-based intervention for PTSD and PTSD symptomatology including physical symptoms and fear of future catastrophes (Balkom van et al., 2013)."
214492409|NCT06790459|DEVICE|UlfTens (Ultra-low-frequencies Transcutaneous electrical nervous stimulation)|ULFTENS device will be administered in the experimental group for 15 minutes
214492410|NCT06766032|DEVICE|CELL-Saver|The Cell-saver device allows for red blood cell reinfusion during cardiac surgery.
214492411|NCT06766032|DEVICE|SAME|The SAME device allows for red blood cell and platelet reinfusion during cardiac surgery.
214492412|NCT06769464|BEHAVIORAL|odor|present odor
214492413|NCT06740422|DRUG|Xuanhuang Runtong Tablet|A synthetic tablet is mainly composed of Radix Rehmanniae, Radix Scrophulariae, Radix Angelicae Sinensis, Semen Persicae, Herba Cistanches, Fructus Cannabis, Semen Cassiae, Fructus Aurantii Immaturus and Aloe.
214492414|NCT06740422|DRUG|Xuanhuang Runtong Tablet Simulator|Xuanhuang Runtong Tablet Simulator
214980703|NCT00198991|PROCEDURE|CNS irradiation|Cytostatic drug
214980704|NCT00198991|PROCEDURE|Mediastinal Irradiation|Irradiation
214980705|NCT00198991|PROCEDURE|Stem cell transplantation (SCT)|Stem cell transplantation
214980706|NCT00198991|DRUG|Idarubicin|Cytostatic drug
214980707|NCT00198991|DRUG|Fludarabine|Cytostatic drug
214980708|NCT00198991|DRUG|Cladribine|Cytostatic drug
214492415|NCT06794645|DRUG|Pembrolizumab|pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle
214492416|NCT06794645|DRUG|Pemetrexed Phase 2|pemetrexed 900 mg/m2 IV on Day 1 of each 21-day treatment cycle and supportive medications (folic acid, vitamin B12, and dexamethasone).
214492417|NCT06758609|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy
214492418|NCT06758609|DRUG|4°C saline infusion|Patients received a total of 350 ml of 4°C saline infusion in addition to mechanical thrombectomy (MT).
214492419|NCT06758609|DRUG|Normothermic saline infusion|Patients received a total of 350 ml of roomtemperature saline infusion in addition to mechanical thrombectomy (MT).
214492420|NCT06809868|GENETIC|RNA and DNA Sequencing|DNA and RNA sequencing will be conducted on both control participants and patients with sepsis who are admitted to the ICU.
214492421|NCT05791396|BIOLOGICAL|Donor - FMT|this intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
214492422|NCT05791396|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through colonoscopy
214492423|NCT06405984|DEVICE|Fetal Oxygenation Measurements|The Lumerah device, and Oxiplex ISS will be positioned on the maternal abdomen in various locations depending on the sonographic evaluation. The transvaginal sensor will be placed after rupture of the maternal membranes and appropriate descent of the fetus.This study is for data collection purposes only. Neonates of this study arm will also be monitored with the Oxiplex ISS system. This study is for data collection purposes only.
214980709|NCT02354768|DRUG|Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)|
214980710|NCT02354768|DRUG|Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone|
215087756|NCT00931801|DRUG|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
215087757|NCT00001307|DRUG|Oxygen-15 Water|
214680479|NCT01568580|DRUG|GreenGene|Dose : 10 \~ 50IU/kg Administration method : intravenous infusion or bolus
214980711|NCT01324947|DRUG|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
214980712|NCT04401332|OTHER|mobile health app|asthma symptom monitoring via a clinically integrated mobile health (mHealth) app installed on patients' smartphones
214980713|NCT06128018|PROCEDURE|Surgical gastrojejunostomy (S-GJ)|Surgical gastro-jejunostomy
214980714|NCT06128018|PROCEDURE|EUS-guided gastrojejunostomy (EUS-GJ)|Endoscopic Ultrasound guided gastro-jejunostomy
214980715|NCT00216593|DRUG|galantamine hydrobromide|
214980716|NCT00042913|BIOLOGICAL|epratuzumab|
215087758|NCT00001307|DRUG|Capsaicin|
215087759|NCT05661396|BEHAVIORAL|Serious game rehabilitation|Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
214980717|NCT06204497|PROCEDURE|Stent-based Diverting Technique|The stent-based diverting technique (SDT) contains two parts to achieve feces diversion One is a degradable solid intestinal stent to be implanted 20 cm from the terminal ileum and could be gradually degraded within 3-4 weeks. Another part is a drainage tube to be placed at the proximal 5-10 cm of the aforementioned stent. Given this SDT, intestinal contents could be diverted through the drainage tube, and the stent prevents the feces from entering the distal intestinal. After removing the drainage tube after 3-4 weeks, intestinal contents will freely access the distal intestinal space following the degradation of the stent. For patients, stoma reversal is avoided.
214980718|NCT02669706|DRUG|Pentamidine|Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
214980719|NCT04441346|RADIATION|Echocardiography|test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
214368318|NCT03749564|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
214368319|NCT03749564|BEHAVIORAL|Extended SMT|Additional 6 SMT sessions provided
214368320|NCT05502705|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery
214492424|NCT06751667|DEVICE|Urinary biomarkers|In a bid to reduce or replace surveillance cystoscopies multiple urinary biomarkers have been evaluated for the follow-up of the bladder cancer patients. These device will reduce the number of cystoscopies
214492425|NCT06766630|DEVICE|Silk fibroin surgical mesh|This product is a mesh patch made of mulberry silk by warp knitting and degumming. The main component is fibroin protein
214492426|NCT06821386|DIAGNOSTIC_TEST|Genetic study with nanopore sequencing|The study targets critically ill children under 18 months of age, employing third-generation genome sequencing technology to complete long-read sequencing within 8-11 days, analyzing single nucleotide variants, small insertions/deletions, and structural variations. Through this research, we aim to enhance diagnostic accuracy, enabling ICUs to provide personalized and precision care and treatment based on genetic information, thereby ensuring a greater level of health security for these children. We only draw 3-5cc whole blood once for exam.
214492427|NCT06610344|DIETARY_SUPPLEMENT|R-1,3-Butanediol|R-1,3-Butanediol 35 mL
214492428|NCT06768684|BEHAVIORAL|Brief behavioral counseling|Participants receive a two-session phone-based alcohol risk reduction intervention based on principles of harm reduction. Participants receive personalized feedback regarding how alcohol use may impact their health. Following a motivational enhancement exercise, participants are advised to reduce alcohol intake to within recommended limits. Evidence-based strategies are discussed (e.g., goal setting, self-monitoring, identifying and avoiding triggers, dealing with urges, pacing and spacing drinks, managing high risk situations, finding alternatives to alcohol, developing refusal skills, and enlisting social support). Educational materials addressing methods for cutting down are also provided, along with information about other available resources to support their efforts.
214492429|NCT06766097|DIETARY_SUPPLEMENT|mastic toothpaste|All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.
214492430|NCT06766097|DIETARY_SUPPLEMENT|Placebo toothpaste|All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.
214680480|NCT02008240|PROCEDURE|Needle aspiration of hydrosalpinx|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
214680481|NCT02008240|PROCEDURE|Salpingectomy|laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
214680482|NCT01597193|DRUG|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
214980720|NCT04267497|DRUG|Amphotericin B Liposomal 50 MG|Amphotericin B 50 mg powder for infusion diluted in 12 ml of sterile water. It will be administered by nebulized route 25 mg (6 ml), 3 times a week, for 6 weeks.
214980721|NCT04267497|OTHER|Placebo|Sterile water for injection. It will be administered by nebulized route: 6 ml, 3 times a week for 6 weeks.
214368321|NCT05502705|OTHER|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
214980722|NCT04494698|DEVICE|Duotherm VibraCool Back Device|Active New multimodal pain device
214980723|NCT04494698|DEVICE|TENS 8-channel unit|LG Smart TENS unit
214980724|NCT06748157|DEVICE|CardiaCare RR2|CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF.
214680483|NCT01597193|DRUG|anastrozole|1 mg/day
214680484|NCT01597193|DRUG|exemestane|The exemestane dose is 25mg daily.
214980725|NCT06748157|DEVICE|Sham Device|Sham device will be dispensed, which will create a sensation but not provide therapy
214980726|NCT06909240|OTHER|Progressive gait training|The focus of the intervention is on exercises that can improve venous return, and consists of progressive gait training at moderate and high intensity as well as guidance on progressive gait training. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to obtain 30 mins/day of gait training at moderate intensity. After 14 days, the patient receives physiotherapist guidance via telephone on progressive gait training and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achive 2 x 20 mins/week of muscle-strengtening activities at moderate or greater intensity. After one and two months of training, the patient will be guided via telephone on maintaining their current level of physical activity or possibly on further progression.
214368322|NCT06496217|DRUG|MBX 2109|Group 1: Subjects with mild renal impairment (eGFR ≥ 60 and \< 90 mL/min)
214368323|NCT06496217|DRUG|MBX 2109|Group 2: Subjects with moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min)
214980727|NCT06909240|OTHER|Standard Care (in control arm)|Standard care encompasses standard diagnostics with compression ultrasound examination, and a treatment procedure with anticoagulant medication, and compression stockings class III. Standard care also involves visits to the outpatient anticoagulation clinic, where patients with DVT are required to attend treatment sessions within the first 14 days and 90 days after diagnosis. Standard care will serve as a comparator to reflect the current treatment regimen.
214980728|NCT05498389|DRUG|EMB-01|EMB-01 is a bispecific antibody against epidermal growth factor receptor (EGFR) and the receptor tyrosine kinase Met (cMET).
214980729|NCT05498389|DRUG|Osimertinib|Osimertinib is an approved, third-generation EGFR tyrosine kinase inhibitor
214368324|NCT06496217|DRUG|MBX 2109|Group 3: Subjects with severe renal impairment (eGFR \< 30 mL/min), or kidney failure and not receiving dialysis
214368325|NCT06496217|DRUG|MBX 2109|Group 4: Matched healthy subjects with normal renal function (eGFR ≥ 90 mL/min)
214368326|NCT06057376|OTHER|Low-FODMAP diet group (LFD)|Each participant will be following a low-FODMAP diet group for 3 weeks, followed by 3 week break prior to second diet intervention.
214368327|NCT06057376|OTHER|Low Sugar diet group (LAS)|Each participant will be following a low added sugar diet group for 3 weeks, after 3 week break.
214492431|NCT06756971|DRUG|Propofol|Propofol will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation
214680485|NCT01597193|DRUG|fulvestrant|500 mg every 28 days
214680486|NCT01597193|DRUG|enzalutamide|160 mg (4 capsules) taken orally daily.
214680487|NCT01597193|DRUG|exemestane|The exemestane dose is 50 mg daily.
214680488|NCT02508701|BEHAVIORAL|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
214680489|NCT01144689|BEHAVIORAL|Mindfulness Training|8 sessions of behavioral treatment for smoking cessation
214680490|NCT01144689|BEHAVIORAL|Smoking Cessation Therapy|8 sessions of behavioral treatment for smoking cessation
214980730|NCT06275737|OTHER|Prehabilitation program|"Cohort 1 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 5 - cycle 6 or cycle 6 - cycle 8) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)~Cohort 2 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 2 - cycle 4) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)"
214980731|NCT06890611|DRUG|Bimagrumab|Administered SC
214980732|NCT06890611|DRUG|Tirzepatide|Administered SC
214980733|NCT06890611|DRUG|Bimagrumab + Tirzepatide Coformulation|Administered SC
214980734|NCT04729231|PROCEDURE|Nasalis Sling Flap|The nasalis sling flap involves alteration of the nasalis muscle to create a myocutaneous pedicle flap that will be used to fill in the wound.
214980735|NCT04729231|PROCEDURE|Lobed Transposition Flap|Lobed flap reconstruction involves the use of cutaneous tissue located adjacent to the nasal tip to fill in the wound. The flap will undergo a 90-degree arc to approximate the desired position.
214980736|NCT06951009|DEVICE|Colli-Pee|The Colli-Pee device is a first void urine self-sampling device. Participants will collect urine samples with this device three times during one week of study participation. Urine sample collection with this device will occur either in Week 1 or Week 2 of study participation, depending on the Participant's Arm assignment.
214368328|NCT02085148|DRUG|Regorafenib (BAY73-4506)|Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.
214368329|NCT02085148|DRUG|Vincristine (Cellcristin®)|Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.
214368330|NCT02085148|DRUG|Irinotecan (Irinotecan Cell pharm®)|Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.
214368331|NCT05808049|OTHER|MXP22 (Probiotic and antioxidant capsule)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
214492432|NCT06756971|DRUG|Dexmedetomidine|Dexmedetomidine will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation
214680491|NCT01455727|OTHER|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
214680492|NCT01455727|OTHER|Usual care|Control patients received usual care directed by their physician.
214680493|NCT03391440|DRUG|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
214492433|NCT06758037|DRUG|Drug therapy|"All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy. On the first day of enrollment, tissue NGS and peripheral blood ctDNA will be submitted for testing. For the remaining six cycles, the added drug (X) will be determined based on the NGS molecular typing results. Please refer to the grouping scheme for details.~HiR+X Dosing Scheme:~Hi: Zebtorizumab 375mg/m², d1; R: Lenalidomide 10-25mg d1-10 (maximum tolerated dose)~X:~For MCD/BN2/TP53: Ocalivumab 150mg qd For EZB: Chidamide 30mg biw~For N1-like and nonspecific types:~If EBV-positive: PD-1 monoclonal antibody 200mg Q3W"
214492434|NCT06757842|BEHAVIORAL|Mindfulness in Students|The mindfulness intervention includes eight 90-minute group sessions held weekly at Universidad de los Andes, co-facilitated by two instructors. One leads the activities, while the other assists with technical aspects, monitors adverse events, and provides participant support. Participants will receive mindfulness worksheets and are required to practice at home for 15 minutes daily. They will have access to an online platform with audiovisual materials to guide their practice and will complete home practice logs online. Skills taught include sitting meditation (focused on breathing, thoughts, emotions, or sensations), body scan meditation, standing meditation, and mindfulness of daily activities. Group discussions will cover topics such as defining mindfulness, managing stress and pain, the difference between mindfulness and being on 'autopilot,' and how perceptions affect stress, as well as the relationship between pain and suffering, and the acceptance of unwanted experiences.
214492435|NCT06750354|PROCEDURE|papworth technique|For Group A: The Papworth breathing technique consists of a series of diaphragmatic breathing and relaxation exercises, and teaches patients which muscles to use when breathing and how to avoid breathing too or too fast by emphasizing nose breathing. The technique is altered to suit activity; this allows the technique to be integrated by patients into their everyday lives with subsequent improvements in quality of life.
214492436|NCT06750354|PROCEDURE|aerobic training|"Aerobic training exercises are any activities that raise heart rate and make breathing somewhat harder. The activity you are doing must be constant and continuous. Examples of aerobic activities are~Walking or hiking Jogging or running Biking Swimming Rowing In-line skating Cross-country skiing Exercising on a stair-climber or elliptical machine"
214492437|NCT06757751|DIETARY_SUPPLEMENT|EVOO diet supplement|For 24 weeks, subjects in intervention arm will have their diet supplemented, daily, with an amount of 30 ml of EVOO (Extra Virgin Olive Oil).
214680494|NCT01819220|DRUG|amlodipine/valsartan|"This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
214980737|NCT06951009|DEVICE|standard of care 60 mL urine cup|Participants will collect clean catch urine samples with this device three times during one week of study participation. Urine sample collection with this device will occur either in Week 1 or Week 2 of study participation, depending on the Participant's Arm assignment.
214980738|NCT06951009|DIAGNOSTIC_TEST|Urinalysis|Participant samples will be analyzed by urinalysis to evaluate for leukocyte esterase (LE).
214980739|NCT06951009|DIAGNOSTIC_TEST|Sysmex UP-5000|Participant samples will be analyzed by the Sysmex UP-5000 to evaluate for white blood cells (WBCs) per microliter.
214980740|NCT03210532|DRUG|Telmisartan + Amlodipine + Rosuvastatin|Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
214980741|NCT03210532|DRUG|Telmisartan + Amlodipine|Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
214980742|NCT03210532|DRUG|Telmisartan + Rosuvastatin|Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
214980743|NCT02273947|DRUG|BMS-955176|Single dose by mouth for each treatment specified
214980744|NCT03912636|BEHAVIORAL|Diaphragmatic breathing|Subjects will perform Diaphragmatic breathing after the test meal.
214980745|NCT03912636|BEHAVIORAL|Deep Slow Breathing|Subjects will perform Deep Slow Breathing after the test meal.
214980746|NCT03912636|BEHAVIORAL|Normal breathing|Subjects will perform Normal Breathing (as a control) after the test meal as a control.
214980747|NCT04278352|BEHAVIORAL|Mindfulness Based Relapse Prevention|The intervention is a group skills training program that is delivered once weekly for eight weeks. Content focuses on mindfulness and cognitive-behavioral relapse prevention skills, including psychoeducation, experiential exercises, and between session homework assignments.
214980748|NCT05739916|DRUG|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
214368332|NCT05808049|OTHER|Placebo (Microcrystalline Cellulose)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
214368333|NCT04864574|OTHER|Garden installation|"Garden installation: 6 raised planting beds (4x6x16) configured in a single line with direct sun at least 6 hrs./day, close to hose bib, sufficient distances to allow working from most sides, vegetable vines spill over space, and storage unit for tools.~Planting beds constructed from a standard kit. Beds filled with high quality growing medium.~Plants selection criteria: a) documented harvest success in NC Piedmont; b) able to be eaten raw, c) harvest times at the same time (except strawberries).~Designated beds and plants: Bed 1: 4 pepper, 2 tomato; Bed 2: 20 bean on 2 mini-teepees, 2 cucumber (trellised); Bed 3: 1 yellow squash, 1 zucchini; Bed 4: 2 blueberry bushes, 12 strawberry; Bed 5: 2 cantaloupe. Bed 6: 2 watermelon. 2 Blackberries planted at ground level on trellis."
214368334|NCT02899780|DEVICE|Ultraviolet light emitting optical fiber|A ultraviolet light emitting optical fiber will be threaded through the existing catheter and withdrawn.
214368335|NCT03044964|DRUG|Ranolazine|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
214368336|NCT03044964|DRUG|Placebo|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
214368337|NCT04540705|BIOLOGICAL|Nivolumab|Specified dose on specified days
214368338|NCT04540705|DRUG|Axitinib|Specified dose on specified days
214368339|NCT04540705|DRUG|Cabozantinib|Specified dose on specified days
214980749|NCT05739916|DRUG|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
214980750|NCT00718601|DRUG|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
214980751|NCT02528032|OTHER|Echographic evaluation of heart function|Echocardiographic data collection and analysis, not fully exploited at present
214980752|NCT01351636|DRUG|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months
214980753|NCT01351636|DRUG|Non arotinolol group|Antihypertensive medications without arotinolol for 18 months
214980754|NCT01987115|PROCEDURE|Fascial manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
214980755|NCT01987115|PROCEDURE|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
215087760|NCT03333395|DRUG|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
214368340|NCT03598413|DIETARY_SUPPLEMENT|Omega-3|200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
214368341|NCT02561494|DRUG|Nefopam|
214368342|NCT02561494|DRUG|Saline|
214368343|NCT05684627|DIETARY_SUPPLEMENT|Fast mimicking diet group|Test group will be assigned to follow one cycle of a fasting mimicking diet the same day after receiving the full mouth non surgical periodontal treatment. The FMD program is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consist 5 days regimen that provides approximately 1.100 kilocalories for the first day ; approximately 750 kilocalories per day for the second to the fifth day. FMD group will need 5 visits.
215087761|NCT03333395|DRUG|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
215087762|NCT01275092|DEVICE|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
215087763|NCT02545816|DEVICE|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
215087764|NCT04386499|DIETARY_SUPPLEMENT|Resveratrol|mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6
215087765|NCT04386499|DIETARY_SUPPLEMENT|Folic acid|400 mcg of folic acid
215087766|NCT02506686|DRUG|Meropenem|Meropenem i.v.
215087767|NCT03462186|OTHER|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
215087768|NCT01635764|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
214368344|NCT05684627|PROCEDURE|Normal diet group|Normal diet (control) group after receiving the non surgical periodontal treatment (with periodontal Gracey curettes and ultrasonic scaler) will continue with their current diet.Normal diet group will need 5 visits.
214368345|NCT01950949|OTHER|300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation|
214368346|NCT01398280|DRUG|Topical aminocaproic acid (ACA) mixed with Vanicream|25% Aminocaproic acid cream twice daily for up to 12 weeks.
214368347|NCT01398280|DRUG|Vehicle cream|Vehicle cream moisturizer twice daily for up to 12 weeks
214368348|NCT05170165|OTHER|Using a clinical decision software to provide specific recommendation of a medication at a certain dosage|During routine follow-up, clinicians, cardiologists, and NPs who have a scheduled visit with an enrolled patient will be offered a medication recommendation. The medication recommendation will be generated by the clinical decision support tool. The software will advise the cardiologist whether an HF medication should be initiated, discontinued, or the dosage titrated and if the patient requires labs. In addition, the software, or decision engine (DE), will be run once weekly and every time the patient has new basic metabolic panel results. If the patient is admitted to the hospital, skilled nursing facility, or inpatient rehabilitation unit, the use of DE will be placed on hold until the patient is discharged and at home.
214368349|NCT00801008|BEHAVIORAL|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
214368350|NCT00057551|BEHAVIORAL|Brief Supportive Psychotherapy|brief supportive psychotherapy
214368351|NCT00057551|BEHAVIORAL|CBASP|psychotherapy developed for chronic depression
214368352|NCT00057551|DRUG|Medication Only|antidepressant medication
214368353|NCT00204295|DRUG|O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET|
214368354|NCT01222325|PROCEDURE|extracorporeal shockwave lithotripsy (SWL)|patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.
214980756|NCT05627115|DRUG|Tislelizumab, AVD, Radiotherapy|"GROUP A: Early stage disease without adverse features in CMR: 2 further cycles tislelizumab then radiotherapy then 200mg IV tislelizumab once every 3 weeks until a maximum of 2 years total treatment. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP B: Early stage disease with adverse features in CMR: 2 cycles of AVD plus tislelizumab then radiotherapy. PET-CT (PET2) 12 weeks after the completion of radiotherapy.~GROUP C: All early stage disease not in CMR: 4 cycles of AVD plus tislelizumab then PET-CT and radiotherapy. PET-CT 12 (PET2) weeks after radiotherapy.~GROUP D: Advanced stage disease in CMR: 4 cycles of AVD plus tislelizumab then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP E: Advanced stage disease not in CMR: 6 cycles of AVD plus tislelizumab then PET-CT then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy."
214980757|NCT02873689|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsule
214980758|NCT02873689|DRUG|Placebo|Dexlansoprazole placebo-matching capsules
214980759|NCT00350545|DRUG|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
214980760|NCT00350545|DRUG|Prednisone|1 mg/kg; po per day with taper
214980761|NCT00350545|DRUG|Cyclosporine A|trough 200-300 or lower; po
214980762|NCT00350545|DRUG|tacrolimus|trough 5-10 or lower; po
214980763|NCT03470467|OTHER|No intervention|No intervention planed
214980764|NCT03925155|DRUG|EZ scrub vaginal chlorhexidine 4% solution|Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
214980765|NCT03925155|DRUG|10% provodine-iodine vaginal preparation|Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
215087769|NCT03344263|DIAGNOSTIC_TEST|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
214492438|NCT06762015|BEHAVIORAL|Positive Nursing Practice Environments Promotion Program|A multi-component intervention program aimed at promoting positive nursing practice environments.
214492439|NCT06764745|DEVICE|PC Ventilation Modes|Following induction, Group I patients received mechanical ventilation using the PC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%. The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%.
214492440|NCT06764745|DEVICE|VC Ventilation Modes|Following induction, Group II patients received mechanical ventilation using the VC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%. The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%.
214492441|NCT06764745|DEVICE|PRVC Ventilation Modes|Following induction, Group III patients received mechanical ventilation using the PRVC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%. The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%.
214980766|NCT05992441|OTHER|SCALE DEVELOPMENT STUDY|"The study to be carried out is a scale development study. The steps to be followed for the scale development study are as follows;~1. Creating an item pool by making use of the literature review on the subject,~2. Questioning the relevance of the prepared question pool to the subject to be measured with the Expert Evaluation Form by experts in the field,~3. Pilot application,~4. Switching to the main study after the pilot application,~5. After the factor and item analyzes, the final arrangements regarding the item and form of the scale will be completed.~As a result of this study, an awareness scale related to physiotherapy will be created for individuals with breast cancer."
214980767|NCT03772223|DRUG|Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
214980768|NCT03772223|DRUG|Treatment B (Budesonide metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).
214980769|NCT03772223|DRUG|Treatment C (Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
214980770|NCT03143023|DRUG|arginine toothpaste|acid neutralizer toothpaste
214980771|NCT03143023|DRUG|fluoride toothpaste|bactericidal toothpaste
214980772|NCT01794702|DRUG|Decitabine|Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
215087770|NCT04118569|BEHAVIORAL|Narrative Intervention|Research staff conducts an open-ended, audio-recorded interview with the patient about their illness and how this illness has affected their psycho-social-spiritual well-being. The investigators will use the interview transcription to create a meta-narrative, which is then uploaded to the electronic medical record and the patient's primary nurse is notified that it is available to read.
215087771|NCT02002468|OTHER|Test result sent by letter|
215087772|NCT02002468|OTHER|Test result conveyed by general practitioners|
215087773|NCT04641949|PROCEDURE|Lower body negative pressure (LBNP)|LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
214492442|NCT06768424|DEVICE|Guided biofilm therapy|Use of Airflow Plus powder subgingivally on teeth with deep periodeontal pockets
214980773|NCT01794702|DRUG|Idarubicin|Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
214980774|NCT01794702|DRUG|Cytarabine|Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
214980775|NCT01794702|DRUG|Clofarabine|"Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion)."
214492443|NCT06768424|PROCEDURE|Platelet Rich Fibrin|Pack Platelet Rich Fibrin chops into the intrabony periodontla defect
214492444|NCT06768424|PROCEDURE|Minimally Invasive Surgical Technique|Periodontal intrabony defect is treated by minimally invasive surgical intervention
214980776|NCT00775879|DRUG|Induction with Sevoflurane|
214980777|NCT00948545|OTHER|Observational study - there is no intervention|Observational study - there is no intervention
214980778|NCT01729195|PROCEDURE|A ciprofloxacin containing bioabsorbable PLGA bone screw|The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
214980779|NCT04908618|OTHER|digital impression for normal abutment|Accuracy of scan body impression
214980780|NCT04908618|OTHER|open tray impression|Accuracy of open tray impression
214492445|NCT06777966|DRUG|nebulized tranexamic acid|patients will receive a preoperative nebulizer session of 500 mg of tranexamic acid. To ensure the blinding of the participating anesthetist and patient, patients in this group will receive an intravenous drip of 100 ml of 0.9% normal saline.
214492446|NCT06777966|DRUG|intravenous tranexamic acid|patients will receive a preoperative intravenous drip of TXA at a dose of 15 mg/kg in 100 ml of normal saline. To ensure blinding this group patients will receive 5 ml of 0.9% normal saline nebulizer session.
214492447|NCT03253835|DIAGNOSTIC_TEST|Single Group Assignment|
214492448|NCT06745700|BEHAVIORAL|Brief Behavioural Activation|"Behavioral: Brief Behavioral Activation.~A five-session telephone-based brief behavioral activation treatment.~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log.~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week.~Session 3-4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned. with life goals and values; creating a a maintenance plan.~Other group: care as usual."
214492449|NCT06745700|OTHER|Care as usual|Care as usual provided by Region Västamanland,
214492450|NCT06745349|BEHAVIORAL|Sleep Course|The Sleep Course previously developed and evaluated in Australia will be delivered to clients meeting participation criteria. The Sleep Course is four lessons long and is offered with once weekly therapist support for 8 weeks where clients are encouraged to email the assigned therapist for support each week. The therapist reviews client progress in the Course and emails clients once per week on a designated check in date. Sometimes the therapist will call the client. Phone calls are typically made if a client is not logging in or if the therapist feels that a phone call would be a helpful way to provide support.
214492451|NCT06744400|DRUG|Grafalon® administered during 5 consecutive days at 2 mg/kg/j|"This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 3 receives treatment in accordance with health recommendations as part of prophylactic treatment for acute rejection after allogeneic solid organ transplantation, at the minimum dose, i.e., 2 to 5 mg/kg/day for 5 to 21 days."
214492452|NCT06744400|DRUG|Grafalon® administered during 5 consecutive days at 1 mg/kg/j|"This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 2 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation."
214980781|NCT04908618|OTHER|closed tray impression|Accuracy of closed tray impression
214980782|NCT02265523|OTHER|Cycle ergometer|The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
214980783|NCT03191968|BEHAVIORAL|Supervised Physical Activity Plus Behavioral Counseling|In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
214980784|NCT03191968|BEHAVIORAL|Supervised Physical Activity Plus Exercise Counseling|In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
214980785|NCT02327455|PROCEDURE|Stress Dobutamine Echocardiographic using 4DE System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
215087774|NCT02822300|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-74\_R84-086)
215087775|NCT06196398|DRUG|Standard Medical Treatment on the basis of anti-platelet therapy|"1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued.~2. Intensive statin therapy: Statins with high doses~3. Blood pressure: below 140/90mmHg~4. LDL: less than 1.81mmol/L(70mg/dl)~5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7%~6. Cigarette and alcohol quitting~7. Oral anticoagulants for atrial fibrillation"
215087776|NCT03747900|DRUG|Botulinum Toxin Type A|200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
215087777|NCT03747900|COMBINATION_PRODUCT|Botulinum Toxin Type A and dry needling.|Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
215087778|NCT00040508|DRUG|Sirolimus|
214492453|NCT06744400|DRUG|Grafalon® administered during 5 consecutive days at 0,5 mg/kg/j|"This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 1 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation"
214492454|NCT06669572|DRUG|Pembrolizumab|"Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.~Pembrolizumab will be given for a maximum of 2 years (total 35 cycles) with dosing every 3 weeks."
214980786|NCT04765787|DRUG|Combination of Paracetamol 650mg + Orphenadrine 50mg|In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
215087779|NCT01186640|DRUG|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|"I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13."
215087780|NCT01186640|DRUG|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
215087781|NCT04104659|DRUG|MK 6240|"PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush."
215087782|NCT00494377|DRUG|duloxetine|
215087783|NCT04174651|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
214368355|NCT04037501|OTHER|Care Management|A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
214368356|NCT03209323|DEVICE|electroencephalography (EEG)|Four EEG channels were recorded using electrode positions as defined in the International 10-20 System with Ag/AgCl2 cup electrodes (Spes Medica) attached to the scalp with EC2 Electrode Cream (Grass Technologies). The impedance was set below 1 k, and the electrodes were attached to module S/5 E-EEG of the anaesthetic monitor S/5 (GE Healthcare).
214492455|NCT06669572|DRUG|Lenvatinib|Lenvatinib will be taken once daily, with or without food, at the same time each day.
214492456|NCT06767033|DEVICE|Ultrasound Guided Inferior Vena Cava Collapsibility Index Assessment|Before spinal anaesthesia, inferior vena cava collapsibility index was measured for all patients using Ultrasound device.
214492457|NCT06784700|OTHER|Massage|Participants will be positioned inside a massage chair for a 30-min, followed by an additional 30-minute period of lying down on a proper double bed.
214492458|NCT06784700|OTHER|No intervention|Subjects will not receive any massage program; instead, they will be rested for 30 minutes on an automatic switch-off electric massage chair and subsequently lay down for an additional 30 minutes on a proper double bed;
214492459|NCT06822946|DRUG|zhibitai capsule|2 capsule of Zhibitai capsule/time, 2 times/day, oral
214492460|NCT06822946|DRUG|zhibitai capsule|(1 capsule of Zhibitai capsules+1 capsule of Zhibitai capsule simulant)/time, 2 times/day, oral
214492461|NCT06655272|DRUG|Bacterial Lysate|Administration p.o. for 10 days per month for 3 months, two consecutive cycles.
214492462|NCT06655272|DRUG|Placebo|Matching placebo.
214492463|NCT06654401|DIAGNOSTIC_TEST|Transthoracic echocardiography|Standard assessment of the parameters of the left atrium: size, volume, volume indices
214980787|NCT02130219|DEVICE|Non-invasive intracranial pressure measurement|The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
214980788|NCT02130219|DEVICE|Brain MRI/CT|"1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume."
214368357|NCT03209323|DEVICE|bispectral index (BIS)|The BIS score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
214368358|NCT03209323|DEVICE|response and state entropy (RE and SE)|The respone and state entropy (RE and SE) score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
214980789|NCT02130219|PROCEDURE|Lumbar puncture and cerebrospinal fluid pressure measurement|Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
214980790|NCT03150043|DEVICE|Masimo Rainbow Pulse CO-oximeter|Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
214980791|NCT05104593|OTHER|Intervention tested (CAREPATH)|The intervention tested will be the CAREPATH system. CAREPATH consists of an integrated, patient-centred, flexible and modular system that will provide a viable solution for the improvement of the management of multimorbid elderly patients with Mild Cognitive Impairment or mild dementia, with the help of clinicians. CAREPATH will act on patients and their informal caregivers, and its main objective is to empower multimorbid patients with MCI or mild dementia to manage their health condition together with their informal caregiver by providing assistance and reinforcement to follow their individual care plans, so independence and quality of life will increase for both of them. The intervention will provide a personalized care plan and activities proposal (treatment, activities proposal, lifestyle changes, referrals etc.) to patients and caregivers, considering the various sources of patient data available through the CAREPATH platform, and with the help of clinicians.
214980792|NCT02855255|BEHAVIORAL|NHS 1-1 smoking cessation programme.|Smoking cessation using cognitive behavioural therapy/motivational interviewing
214980793|NCT02855255|BEHAVIORAL|Group smoking cessation programme|Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form.
214980794|NCT04938050|DIAGNOSTIC_TEST|Ultrasound|Ultrasound evaluation, with grayscale and color Doppler imaging.
214368359|NCT03209323|DEVICE|middle latency auditory evoked potentials (MLAEP)|value of A-line Auto Regressive Index (AAI) derived from middle latency auditory evoked potentials (MLAEP) (A-line Monitor, Danmeter A/S, Odense, Denmark) was observed which measures the central nervous system responsiveness to a specific auditory stimulus
214368360|NCT02680873|OTHER|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
214368361|NCT01201148|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|For participants receiving intermittent tDCS or oscillating TES, one electrode will be placed over the left pF3 electrode site (overlying the left dorsolateral prefrontal cortex and identified on the scalp using an EEG cap based on the 10/20 system) and the other over the right temporal area.
214980795|NCT00566826|BEHAVIORAL|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
214980796|NCT00566826|BEHAVIORAL|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
214980797|NCT05029492|OTHER|Low-calorie diet|Low-calorie diet of 1200 kcal for 3 months, modified every two weeks.
214980798|NCT05029492|OTHER|Visceral manipulation with diet|Visceral manipulation to the pelvic organs and their related structures (8 sessions, once per week in the first month then once every other week for two months) added to the same low-calorie diet as the group (A).
214368362|NCT03371940|BEHAVIORAL|Program ACTIVE Exercise|Please see the Exercise arm description above.
214368363|NCT03371940|BEHAVIORAL|Program ACTIVE CBT|Please see the Talk Therapy arm description above.
214492464|NCT06654401|DIAGNOSTIC_TEST|24-hour ECG Monitor|Assessment of cardiac arrhythmias according to 24-hour monitoring data
214492465|NCT06654401|PROCEDURE|Electroanatomic mapping|Intraoperative assessment of low voltage areas (potential fibrosis zones)
214492466|NCT06751888|OTHER|Controlled CO2 delivery|The use of a controlled CO2 delivery offers a straightforward way to increase arterial CO2. Controlled CO2 inhalation may offer a novel hemodynamic therapy for patients with Neurogenic Orthostatic Hypotension
214492467|NCT06751888|DEVICE|Controlled CO2 delivery (Sham)|For this intervention, we will be using this device set at 0% CO2 for our sham comparison.
214492468|NCT06773572|PROCEDURE|Autologous Exososomes procedure obtained from the patients' own platelets.|Intraovarian injection (into the ovarian cortex) was performed over four cycles, once a month in each ovary on days 7, 8, or 9 of the menstrual cycle. Blood was drawn using the selected PRP kit; in this case, all the PRP was placed into two 20 cc syringes, and the exosomes were filtered using the EXOSMAT kit for autologous platelet exosomes. A total of 5 to 6 cc of liquid composed exclusively of platelet-derived exosomes was obtained, with a concentration of 5 to 6 trillion exosomes per milliliter. Finally, 2 to 3 cc were administered to each ovary via the transvaginal route.
214492469|NCT06773572|PROCEDURE|Patient group for activated platelet growth factors|the plasma was placed in two 5 cc injectors to place 2 to 3 cc in each ovary (in the ovarian cortex) with the patient sedated. The PRP was placed transvaginally and using a follicular aspiration needle for the PRP group. All biostimulations were performed in early follicular phase (day 7, 8 or 9) in all groups according to their assigned technique.
214492470|NCT06773572|PROCEDURE|the control group|Finally, the control group received 2 to 3 cc of physiological solution in each ovarian cortex for 4 cycles as the two previous groups. All these procedures were performed transvaginally under controlled surgical sedation with follicular aspiration needle in the ovarian cortex and guided by transvaginal echosonogram
215087784|NCT04174651|BEHAVIORAL|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
215087785|NCT01390324|DRUG|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
215087786|NCT01390324|DRUG|Naratriptan|Tablets containing naratriptan 2,5 mg
215087787|NCT01390324|DRUG|Naproxen|Tablets containing naproxen 500 mg
215087788|NCT03990207|DEVICE|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
214368364|NCT03371940|BEHAVIORAL|Program ACTIVE|Please see the Talk Therapy + Exercise arm description above.
214680495|NCT01819220|DRUG|hydrochlorothiazide/telmisartan|"When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
214680496|NCT00607360|BEHAVIORAL|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
214680497|NCT04579068|BEHAVIORAL|Screening and Brief Intervention of Problematic Alcohol Use|Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
214980799|NCT04166214|OTHER|Imaging using intraoral cameras|The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.
214980800|NCT01100788|DIETARY_SUPPLEMENT|Short chain fructo-oligosaccharide (scFOS) 5 g|"Dietary Supplement: scFOS 5 g~Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew."
214980801|NCT01100788|OTHER|Placebo|Treatment without scFOS fiber
214980802|NCT01100788|DIETARY_SUPPLEMENT|Short chain fructooligosaccharide (scFOS) 8 g|Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
214368365|NCT03371940|BEHAVIORAL|Usual Care - No intervention|Please see the Usual Care arm description above.
214980803|NCT02431013|DRUG|Simvastatin|Simvastatin 40 mg on Day 1 \& Day 8.
214980804|NCT02431013|DRUG|Pravastatin|Pravastatin 20 mg on Day 1 \& Day 8.
214368366|NCT03330223|DEVICE|Clopidogrel group;Ticagrelor group|A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.
214368367|NCT03221621|PROCEDURE|Wide Excision|Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.
214368368|NCT03221621|DRUG|Adalimumab Injection|Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.
214368369|NCT02813837|BIOLOGICAL|CD19CART|Patients will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. The target dose range administered in this study is 1x10e5-1x10e7 CD19CART cells/kg. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.
214368370|NCT03531320|DRUG|D07001-softgel capsules|Active Ingredient:Gemcitabine hydrochloride
214368371|NCT01846793|DRUG|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
214368372|NCT05099926|BEHAVIORAL|Reducing Exercise Sensitivity with Exposure Training|"Participants complete 2, home-based intervention visits on a secure video visit platform. Video visits include psychoeducation, interoceptive exposure, and interoceptive counseling. For homework, participants are asked to document their weekly physical activity and exercise sensations in a journal.~Psychoeducation: Participants are educated about the benefits and safety of exercise and cardiac rehabilitation, the role of fear and anxiety in exercise avoidance, and the concept of interoceptive exposure.~Interoceptive Exposure: A gradual six-minute walk (G6MW) serves as a low-risk form of interoceptive exposure. Exercise sensations and ratings of perceived intensity and distress are collected before and after the G6MW.~Interoceptive Counseling: Participants review and reflect upon their pre-walking and post-walking physical sensations and ratings (intensity and distress) with a research team member. Homework is also reviewed."
214680498|NCT06403774|DRUG|Group that will undergo bowel preparation using laxatives (Two bowel X-M Solution 250 ml.)|A laxatives (Two bowel X-M Solution 250 ml.) will be applied for bowel preparation before hemorrhoidectomy. The drug was given to the patient at 3 o'clock (p.m.)before the surgery by mixing it with 1500ml of water.
214680499|NCT06403774|DRUG|Group that will undergo bowel preparation using enema (Two bowel E.S. Enema )|An enema (Two bowel E.S. Enema ) will be applied for bowel preparation before hemorrhoidectomy.The drug was administered to the patient at 00 o'clock (a.m.) and 06 o'clock (a.m.) before the surgery.
214680500|NCT03475394|OTHER|Chlorhexidine gel|0.1 ml of Chlorhexidine gel was administered into the periodontal pocket
214680501|NCT03475394|OTHER|Morus alba gel|0.1 ml of Morus alba gel was administered into the periodontal pocket
214680502|NCT03475394|OTHER|Placebo|0.1 ml of Placebo gel was administered into the periodontal pocket
214368373|NCT02362048|DRUG|ACP-196|
214368374|NCT02362048|DRUG|ACP-196 in combination with pembrolizumab|
214492471|NCT06764823|OTHER|Cryotherapy|In the cryotherapy group, after completing the biomechanical preparation, the root canals will be irrigated with 5 mL of 0.9% physiological saline solution at 2.5°C for 5 minutes; the solution will be stored in the refrigerator until use.
214980805|NCT02431013|DRUG|Cilostazol|Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.
214680503|NCT03184701|OTHER|Telehealth|Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
214980806|NCT02997163|DRUG|Talazoparib|Daily oral doses of talazoparib 0.5 mg
214980807|NCT01059331|DRUG|Pregabalin|150 mg x 2 daily for 2 days
214680504|NCT06359249|BEHAVIORAL|change of habits|change of habits
214980808|NCT01059331|DRUG|Sugar pill|1 tablet x 2 daily, for 2 days
214980809|NCT04518696|PROCEDURE|suprachoroidal buckling|"Location, marking and freezing of the retinal tear on the scleral side . Subretinal fluid is released from the outside of the sclera as needed. In the quadrant of the retinal tear, the spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. After the choroid was exposed, a pocket is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube . The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Once confirmed in accord with the needle position, sodium hyaluronate injection, usually need 0.2 mL to 0.5 mL, application of anterior chamber puncture or subretinal fluid stable intraocular pressure. Exit the duct and close the incision with scleral presutures."
214980810|NCT00434629|DRUG|Bexxar|"Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab.~1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein)."
214980811|NCT05029531|COMBINATION_PRODUCT|the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.|two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
214980812|NCT05786859|DRUG|Rifaximin 200 mg|Rifaximin Treatment Group:on the basis of comprehensive treatment of liver failure, Rifaximin will be added, three times a day, 400mg each time, for a total of 4 weeks, and we will observe until 12 weeks after withdrawal.
214980813|NCT05786859|OTHER|Standard Treatment without Rifaximin|The standard treatment group (control group), which will receive routine comprehensive treatment for liver failure without Rifaximin.
214980814|NCT03346239|BEHAVIORAL|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
214980815|NCT03346239|DRUG|Escitalopram|10-20 mg of Escitalopram
214980816|NCT03346239|BEHAVIORAL|Waitlist|Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
214980817|NCT02337764|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
214980818|NCT06238739|OTHER|Control - Standard Strategies for hypothermia prevention|Standard temperature management. Patients underwent one-hour pre- and post-operative warming with hot-air warming blankets at 38°C, without any other preoperative or intraoperative thermal protection measure.
214980819|NCT06238739|OTHER|Fluid warming before infusion and infiltration|Passive Measures: Patients underwent one-hour preoperative warming with hot air warming blankets at 38°C (100.4°F), operating room (OR) temperature was maintained at a minimum of 21°C (69.8°F), aseptic/antiseptic solutions along with infiltration fluid were all warmed to 38°C (100.4°F), and surgical fields were kept as dry as possible.
214980820|NCT06238739|DEVICE|Thermal convection blanket by water flow (Blanketrol)|Blanketrol: Patients underwent continuous intra-operative temperature protection, using a thermal convection blanket by water flow (Blanketrol®) at 40°C (104°F).
214368375|NCT03353064|OTHER|Vivify|A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.
214492472|NCT06764823|OTHER|Control|In the control group, the final irrigation will be performed using 5 mL of 0.9% physiological saline solution at room temperature for 5 minutes.
214492473|NCT06769828|DRUG|Ga-68-FAPI-46|Ga-68-FAPI-46 PET scan in colorectal cancer
214680505|NCT06359249|OTHER|change of habits + auto abdominal massage|change of habits + auto abdominal massage
214368376|NCT03353064|OTHER|EMS|Emergency medical service scheduled home visits for face to face troubleshooting of the NIPPV, environmental check and end-tidal CO2.
214368377|NCT03609567|OTHER|Aromatherapy|Aromatherapy using essential oils
214368378|NCT03609567|OTHER|Placebo|Aromatherapy using odorless placebo oil
214368379|NCT00644397|DEVICE|95-degree Angled Blade Plate|
214680506|NCT00734409|DEVICE|Bispectral Index (BIS) Monitor|BIS monitoring in addition to RASS assessments
214680507|NCT06139380|DRUG|Ketamine|This is medication which is commonly used for sedation in the emergency department. At the analgesic dose, this medication can be used to reduce the pain via other routes such as intranasal.
214680508|NCT06139380|DRUG|Sterile water|Intranasal sterile water was administered via syringe.
214980821|NCT06238739|DEVICE|Conductive fabric electric warming device (HotDog)|HotDog: Patients underwent permanent intra-operative thermal protection measures with conductive fabric electric warming device (HotDog®) at 40°C (104°F).
214980822|NCT04370496|PROCEDURE|Minimally invasive surgery using endoscopic stapler|Radical hysterectomy by minimally invasive surgery (laparoscopic or robotic) will be done with the help of an endoscopic stapler in cutting and suturing the uterine cervix.
214980823|NCT00745888|OTHER|Chemiluminescence Analyzer|measure reactive oxygen species
214980824|NCT06522321|BIOLOGICAL|i-PRF and FDBA|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with FDBA and I-PRF (experimental group) will be placed according to the standard protocol.~An immediate implant with FDBA( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with sutures"
214980825|NCT03422185|OTHER|No intervention|No intervention
214980826|NCT05863442|DRUG|Soliris 300 MG in 30 ML Injection|Active Comparator
214980827|NCT05863442|DRUG|TUR03 300 MG in 30 ML Injection|Investigational medicinal Product, eculizumab - Turgut
214368380|NCT00644397|DEVICE|4.5mm Condylar Locking Plate|
214368381|NCT00269035|DRUG|SB773812|SB-773812 tablets will be available with dose strength of 60 mg
214368382|NCT00269035|DRUG|Risperidone|Risperidone tablets will be available with dose strength of 3 and 6 mg
214980828|NCT05053490|OTHER|Static Stretching|Static stretches are those in which you stand, sit or lie still and hold a single position for a period of time.
214368383|NCT01636180|DRUG|Clopidogrel|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
214368384|NCT01636180|DRUG|Clopidogrel|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
214368385|NCT04983381|OTHER|Multimedia education video|The multimedia education video was a 30 minutes information-based patient education program and contained information about pelvic anatomy and how to practice vaginal examination. The same gynecologist (M.S.) (male) who 15 years of experience explained details of vaginal examination, who told about vaginal examination in this video to the study participants, also did the gynecologic examination. The gynecologic examination which contained pelvic ultrasound scan and vaginal examination lasted approximately 20 minutes practice.
214368386|NCT05488132|DRUG|anti-siglec-6 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
214368387|NCT01896882|OTHER|Sodium restriction|
214368388|NCT04365595|OTHER|Questionnaires, spirometry|Questionnaires targeting health-related quality-of-life, symptoms, anxiety and depression
214368389|NCT04523896|RADIATION|Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy|"\- Brachytherapy: Real time HDR prostate brachytherapy using a MRI-trans-rectal ultrasound image fusion protocol: single fraction of 15 Gy.~Planning software: Oncentra prostate (Nucletron)~\- External beam radiotherapy: Stereotactic ablative radiation therapy (SABR): 5 session in 5 consecutive days, 5 Gy per fraction to the prostate.~Intra-fraction gold seeds monitoring using Auto beam Hold solution (Varian) Planning software: Eclipse (Varian)."
214368390|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 1|Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
214680509|NCT01527604|OTHER|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
214980829|NCT05053490|OTHER|dynamic stretching|Dynamic stretching involves making active movements that stretch the muscles to their full range of motion.
214980830|NCT00000220|DRUG|Buprenorphine|
215087789|NCT01522144|BEHAVIORAL|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
215087790|NCT01174004|DRUG|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
215087791|NCT01174004|DRUG|placebo|placebo, tablet, once daily by mouth for 6 weeks
215087792|NCT05857449|DRUG|LPM3480392|Intravenous infusion
215087793|NCT00933244|DIETARY_SUPPLEMENT|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
215087794|NCT00933244|DIETARY_SUPPLEMENT|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
214980831|NCT02470741|DRUG|Letrozole|
214980832|NCT02470741|OTHER|Placebo|
215087795|NCT00933244|DIETARY_SUPPLEMENT|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
214980833|NCT00485836|DRUG|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
215087796|NCT03270267|OTHER|Questionnaires|
215087797|NCT03236168|DRUG|Ivermectin|A single weight based dose of ivermectin
215087798|NCT03236168|DRUG|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
215087799|NCT03236168|DRUG|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
215087800|NCT00514228|DRUG|sunitinib malate|"* Starting dose: 37.5 mg 3 x 12.5 mg capsule~* Reduced dose: 25 mg 2 x 12.5 mg capsule"
215087801|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
215087802|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
215087803|NCT01582048|DRUG|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
215087804|NCT00817648|DRUG|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
215087805|NCT00817648|DRUG|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
214980834|NCT00485836|DRUG|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
214980835|NCT00485836|DRUG|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
214980836|NCT05259631|DRUG|Sevoflurane|Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation
214980837|NCT05259631|DRUG|Propofol|Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation
214980838|NCT05478109|DRUG|[14C]XZP-3287|360 mg suspension containing 50µCi of \[14C\] XZP-3287
214980839|NCT01446705|OTHER|Active Health Information Exchange|Patients selected to share data between the VA \& external healthcare agencies.
215087806|NCT05532267|DRUG|Ciprofloxacin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
215087807|NCT05532267|DRUG|Ciproxin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
214368391|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 2|Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
214368392|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 3|Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
214368393|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 4|Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
214368394|NCT00724152|BEHAVIORAL|Cognitive Behavioral Therapy|A psychotherapeutic approach to tinnitus management which includes tinnitus education
214368395|NCT00724152|BEHAVIORAL|Tinnitus Education|An audiologic rehabilitative approach to tinnitus education.
214368396|NCT01417507|PROCEDURE|cognitive assessment|Undergo neurocognitive assessment
214368397|NCT01417507|PROCEDURE|magnetic resonance imaging|Undergo MRI
214368398|NCT01417507|OTHER|laboratory biomarker analysis|Correlative studies
214980840|NCT01446705|OTHER|Non-Active Health Information exchange|Patients not selecting to share data
214980841|NCT04238741|OTHER|Audio-recording of consent for anaesthesia for elective caesarean section|Antenatal women will be invited to attend 5-15 days before their caesarean section for an anaesthetic consent discussion with audio-recording. Participants will complete a questionnaire immediately following the recorded discussion and again within the 48 hours following their surgery, to establish their views on the process of audio-recording of consent and the potential usefulness/acceptability of the audio-recording.
214980842|NCT01680263|DEVICE|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval"
214980843|NCT01680263|PROCEDURE|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
214980844|NCT04814797|OTHER|Capnography data included in Lung Clearance Index measurement|Capnography data included in Lung Clearance Index measurement (a pulmonary function test included in routinely yearly follow-up of cystic fibrosis children) will be collected and analyzed
214980845|NCT03653741|DRUG|Perampanel 6 MG|Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
214980846|NCT04686032|OTHER|Advanced early Rehabilitation Program|Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS\* for incisional pain (30min)
215087808|NCT01826266|DRUG|PER977, Placebo|
215087809|NCT06020846|OTHER|Soleus Pushup Exercise|"Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time"
215087810|NCT06020846|OTHER|treadmill walk group 2|The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
215087811|NCT04072107|DRUG|sintilimab|Investigate whether capecitabine would be able to improve prognosis in patients at high risk groups
215087812|NCT04072107|DRUG|Capecitabine|Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
215087813|NCT04132635|DEVICE|artificial dermis|artificial dermis will be used after fully debridement of the wound
215087814|NCT04132635|OTHER|growth factor|growth factor
215087815|NCT05778773|PROCEDURE|TAVR (Transcatheter Aortic Valve Replacement)|Percutaneous aortic valve replacement, also known as percutaneous aortic valve implantation, transcatheter aortic valve implantation or transcatheter aortic valve replacement, is the replacement of the aortic valve of the heart through the blood vessels.
215087816|NCT05778773|PROCEDURE|AVR (Aortic Valve Replacement)|Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve through an open-heart surgery.
214680510|NCT01527604|OTHER|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
214980847|NCT04686032|OTHER|Early ambulation|Patient education \& Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
214980848|NCT05798312|OTHER|Customizable support material|Customizable support material will enable patients to identify their personal breast cancer information.
214680511|NCT04195074|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
214680512|NCT04195074|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
214680513|NCT04195074|DRUG|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
214680514|NCT03281226|DRUG|RIPE (2m) and RI (4m)|Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
214680515|NCT03281226|DRUG|RIPE+NAC (2m) and RI (4m)|Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
214980849|NCT05798312|OTHER|Non-customizable support material|Non-customizable support material will include general breast cancer information.
215087817|NCT05510661|DEVICE|Export Catheter|Manual thrombus aspiration with the use of export catheter during primary PCI
215087818|NCT05510661|DEVICE|Balloon catheter|Predilatation with balloon catheter
214680516|NCT03625219|DRUG|Prednisone|40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
214680517|NCT03625219|DRUG|Placebo|8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
214680518|NCT00962923|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
214680519|NCT04805021|OTHER|no intervention|no intervention
214680520|NCT00780000|DRUG|Alvespimycin|Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
214680521|NCT03298854|DEVICE|99mTc-MDP SPECT/CT|Delayed whole body images, using Symbia-T-Siemens dual headed gamma camera, will be obtained 2-3 hours after injection of 15-25 mCi of Tc-99m MDP (Methylene diphosphonate) followed by SPECT images of the lumbar spine and pelvis.
214680522|NCT05348005|DEVICE|Ovira Transcutaneous Electrical Nerve Stimulation Unit|TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
214680523|NCT02832726|DIETARY_SUPPLEMENT|Vitamin B12|
214680524|NCT00006346|PROCEDURE|psychosocial assessment and care|
214680525|NCT00006346|PROCEDURE|quality-of-life assessment|
214680526|NCT03785197|OTHER|Prolonged modified fasting|The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths
214680527|NCT01959308|OTHER||
215087819|NCT00539617|DRUG|Erlotinib|Tarceva single agent therapy: 150 mg/day PO
215087820|NCT00539617|DRUG|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
214368399|NCT01417507|OTHER|questionnaire administration|Ancillary studies
214680528|NCT00744146|BIOLOGICAL|Protexia|Single 50 mg IM dose
214680529|NCT00744146|BIOLOGICAL|Protexia|Single 100 mg dose
214680530|NCT00744146|BIOLOGICAL|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
214680531|NCT00744146|BIOLOGICAL|Protexia|Single 500 mg dose, IM
214680532|NCT00744146|BIOLOGICAL|Protexia|Single 750 mg dose, IM
214680533|NCT00984802|DRUG|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
214680534|NCT00984802|DRUG|Placebo control|Vehicle solution for IV administration single dose.
214680535|NCT03393013|DRUG|KZR-616|Subcutaneous Injection of KZR-616
214980850|NCT03631641|BIOLOGICAL|Nivolumab|Given IV
214980851|NCT04149418|OTHER|Yogurt|Low-fat flavored yogurt
214980852|NCT04149418|OTHER|Control food|Low-fat flavored soy pudding
214980853|NCT01677286|DRUG|Doxycycline 100 mg po bid x 12 months|100mg by mouth twice daily for 1 year.
214980854|NCT01258374|DRUG|Raltegravir|Raltegravir, 400 mg bid
214980855|NCT01258374|DRUG|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
214980856|NCT01855958|PROCEDURE|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
214980857|NCT01855958|PROCEDURE|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
214980858|NCT04208893|BEHAVIORAL|Exercise training|See description of Arms
214980859|NCT03356717|BEHAVIORAL|educational intervention with observer tool|To assess if the use of an observer tool by observers during high fidelity simulation improves learning outcomes
215087821|NCT00539617|DRUG|Leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
215087822|NCT00539617|DRUG|Oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
215087823|NCT00204867|OTHER|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
215087824|NCT00404170|DRUG|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
214980860|NCT03356717|BEHAVIORAL|educational intervention|without observer tool
214980861|NCT03052894|DEVICE|Hydraulic Monitoring Device|"The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.~This will be compared to measurements using a current monitoring device in the same patient."
215087825|NCT05308524|DIAGNOSTIC_TEST|ICU scoring system in covid 19|The intensive care unit (ICU) at Assiut University Hospital, which is supervised by the staff members of the Chest Diseases Department and designated to deal with critically ill Covid 19 patients.
214980862|NCT03052894|DEVICE|Standard EMG Monitoring Device|"Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.~This will be used as the clinical monitoring device and as a comparator."
214980863|NCT02815371|PROCEDURE|Needle Acupuncture|See above
214980864|NCT02815371|PROCEDURE|Laser Acupuncture|See above
215087826|NCT02699268|OTHER|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
215087827|NCT05918627|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
215087828|NCT05918627|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
215087829|NCT02312765|BEHAVIORAL|AirCare App|Tablet software to encourage adherence and support
215087830|NCT01805544|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
215087831|NCT06264284|PROCEDURE|epidural anesthesia|Emergency cesarean section (red code) with epidural anesthesia
215087832|NCT06264284|PROCEDURE|general anesthesia|Emergency cesarean section (red code) with general anesthesia
215087833|NCT04036994|DEVICE|Photobiomodulation therapy|All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
215087834|NCT04401839|DRUG|Oxytocin IV shot|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby
215087835|NCT04401839|DRUG|Oxytocin IV drip|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation
215087836|NCT04401839|PROCEDURE|Amr maneuver|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds
215087837|NCT04500236|OTHER|General anesthesia|Surgery under general anesthesia with the use of propofol
214368400|NCT01417507|PROCEDURE|quality-of-life assessment|Ancillary studies
214368401|NCT00227617|BIOLOGICAL|bevacizumab|5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
214368402|NCT00227617|DRUG|5-fluorouracil|2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
214368403|NCT00227617|DRUG|leucovorin|200mg/m2 IV q2 wk on day 1 over a 2-hour period.
214368404|NCT00227617|DRUG|oxaliplatin|200mg/m2 IV q 2 wk on day 1 over a 2-hour period
214368405|NCT04370925|PROCEDURE|Radical colectomy|Patients undergo radical resection of the primary colorectal cancer(open or laparoscopic/robotic)
214368406|NCT04370925|PROCEDURE|HIPEC|HIPEC(simultaneously or within 2days after resection) with mitomycin c (30 mg/m2) at 43°C for 90 minutes.
214368407|NCT04370925|DRUG|Systemic chemotherapy|"Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable."
214368408|NCT01751555|DRUG|Regimen:TDF+3TC+EFV|TDF+3TC+EFV for HIV/HBV co-infection
214368409|NCT04137848|PROCEDURE|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|OMT: 4-week manual therapeutic program with a weekly session of osteopathic examination and manipulation of somatic disfunctions in ambulatory setting. MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy.
214680536|NCT00013403|PROCEDURE|Blindness|
214980865|NCT02815371|PROCEDURE|Sham Laser Acupuncture|See above
214980866|NCT06017271|DIAGNOSTIC_TEST|CTPA (computed tomography pulmonary angiography)|The CTPA diagnosis suggest or did not suggest pulmonary embolism.
215087838|NCT04500236|OTHER|Hypno-analgesia|Surgery under Hypnosis session and analgesics
215087839|NCT04150692|BIOLOGICAL|Dara-SC|-Subcutaneous daratumumab and hyaluronidase-fihj
214680537|NCT02416687|DEVICE|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
215087840|NCT04150692|PROCEDURE|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
215087841|NCT04150692|PROCEDURE|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
214980867|NCT04447859|DRUG|Semaglutide|Slow semaglutide titration group vs. label recommended titration group (16-week flexible vs. 8-week semaglutide titration)
214980868|NCT04447859|OTHER|label recommended titration|label recommended titration
214980869|NCT04364516|DRUG|Anticoagulation|Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)
215087842|NCT00677755|DRUG|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
214368410|NCT04137848|PROCEDURE|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|"SOMT: 4-week of sham osteopathic therapeutic program with a weekly session of osteopathic examination and manipulation in ambulatory setting.~MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy."
214368411|NCT00404664|BEHAVIORAL|influenza vaccine, reminders letters, raffle prize|
215087843|NCT00677755|DRUG|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
215087844|NCT00570934|DIETARY_SUPPLEMENT|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
214368412|NCT02764034|DEVICE|Low level Laser diode machine|wavelength 635 Low level diode laser power control time control Continuous mode
214368413|NCT01160848|DRUG|Area cleaned with saline water and occluded with Tegaderm|
214368414|NCT01160848|DRUG|Area cleaned with saline water|
214368415|NCT01160848|DRUG|Area cleaned with Ethyl alcohol solution|
214368416|NCT01160848|DRUG|Visonac left on the skin for 24 hours in facial area one|
214368417|NCT01160848|DRUG|Visonac wiped off after one hour|
214368418|NCT01160848|DRUG|Visonac left on the skin 24 hours in facial area two|
214368419|NCT03859882|OTHER|Sleep deprivation|40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
214368420|NCT06442618|OTHER|Extracorporeal Shockwave Treatment (Group A)|Each session involved a 1:1 ratio of patient to physiatrist. The treatment modality was explained to the patient preliminarily, and before each session, the patients were clinically evaluated and the location of pain was identified.; so patients were asked to assume a comfortable position, and treatment with focal ESWTs was started as per the ISMST protocol
214368421|NCT06442618|OTHER|Nutraceutical Supplementation (Group B)|Participants in Group B performed home therapy with nutraceutical supplementation containing: hyaluronic acid (200 mg), collagen (5,000 mg), manganese (10 mg) and vitamin C (250 mg), daily for 30 days. Patients were advised to shake the compound, before taking, and to store it at room temperature not exceeding 25 °C, in a cool, dry place, away from light and heat sources. The compound is also free of gluten and lactose, so it can be safely administered.
214980870|NCT03367000|DIETARY_SUPPLEMENT|Ceprolac|The supplement was packed into two \~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.
214980871|NCT03367000|OTHER|Dietary counseling (DC)|Received standard dietary counseling at baseline and month 6.
215087845|NCT00570934|DIETARY_SUPPLEMENT|Calcium|1 gm calcium as calcium carbonate
215087846|NCT00570934|DIETARY_SUPPLEMENT|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
214368422|NCT06442618|OTHER|Combined Treatment (Group C)|Participants in group C were invited to come to our department\&#39;s outpatient clinics to perform treatment with focal ESWT; they had one session every six days for a total of 5 sessions lasting about 20 minutes each. Patients in this group took also additional nutraceutical therapy; they took a daily supplemental treatment of hyaluronic acid, collagen, vitamin C and manganese for 30 days.
214368423|NCT02240095|BEHAVIORAL|Intervention A - Online Clinical Questions Recorder|Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
214368424|NCT02240095|BEHAVIORAL|Intervention B - Online Evidence Retrieval Coach|Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
214980872|NCT03103958|DIETARY_SUPPLEMENT|Probiotic|"Probiatop is a live microbial preparation saches containing 1g of the formulation composed by Lactobacillus acidophilus NCFM, 10⁹, Lactobacillus rhamnosus HN001 10⁹, Lactobacillus paracasei LPC-37 10⁹, Bifidobacterium lactis HN019 10⁹ combined with Polydextrose.~Subjects will take two sachets per day after diluting them in 100 ml of water"
215087847|NCT00570934|DRUG|Placebo|Placebo
214980873|NCT03103958|DIETARY_SUPPLEMENT|Placebo|"The placebo sachets were prepared by substituting equivalent amounts of Maltodextrin for the probiotic powder.~Subjects will take two sachets per day after diluting them in 100 ml of water"
214980874|NCT01324297|OTHER|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
214980875|NCT00368251|OTHER|Placebo|"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg, 25 mg and 50 mg~* Route of Administration: Oral use"
214980876|NCT00368251|DRUG|BRV 2.5 mg|"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
214980877|NCT00368251|DRUG|BRV 25 mg|"* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
214980878|NCT00368251|DRUG|BRV 50 mg|"* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
214980879|NCT03294915|DIETARY_SUPPLEMENT|Resistant Starch|Addition of 42g per day of green banana flour (10g / day resistant starch) to the usual diet of study participants
214980880|NCT03294915|DIETARY_SUPPLEMENT|Placebo|Addition of 42g per day of mixture of guar gum, maltodextrin and cellulose to the usual diet of study participants
214980881|NCT03759925|OTHER|Nutritional Support|Weekly nutritional components: Month 1: equivalent of 3 meals/day in the form of 14 frozen meals, and breakfast bag with items to prepare 7 breakfast meals. Month 2: equivalent of 3 meals a day in the form of 7 frozen meals, grocery bags, and breakfast bags with items to prepare 7 breakfast meals. Month 3: the equivalent of 2 meals a day in the form of 7 frozen meals and grocery bags. Month 4: Participant choice to receive either 7 frozen meals or grocery bag with equivalent food for 1 meal a day. Month 5: Grocery bag with equivalent food for 1 meal a day Nutritional counseling component: Individual counseling with Registered Dietician monthly
214980882|NCT01627132|DRUG|Dasatinib|100mg QD
214980883|NCT04457856|BIOLOGICAL|TJ003234 injection|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)
214980884|NCT01156519|OTHER|Salivary Cortisol|"* Day 1: 1st salivary cortisol at 23 hours~* Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)~* Day 3: serum cortisol at 8 am~* Between Day 4 and Month 3: if serum cortisol at 8 am \> 18ng/mL:~* Cortisol for 24 hours~* dexamethasone suppression test (2mg/j during 2 days)~* Cortisol and ACTH cycle~* Noriodocholesterol scintigraphy"
214980885|NCT04031495|DEVICE|central vein cannulation|central vein cannulation
214980886|NCT03159143|DRUG|Docetaxel|Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m\^2.
214980887|NCT03159143|DRUG|Oxaliplatin|Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m\^2
214980888|NCT02613130|DRUG|Stannous fluoride toothpaste|
214368425|NCT02240095|BEHAVIORAL|Intervention C - Online Audit and Feedback|Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
214368426|NCT00637208|PROCEDURE|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
214368427|NCT00031486|DRUG|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
214368428|NCT00031486|DRUG|Placebo|Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
214368429|NCT03685591|DRUG|PF-06952229|Oral 7 days on / 7 days off - 28 day cycles (Part 1)
214980889|NCT02613130|DRUG|Potassium nitrate toothpaste|
214980890|NCT01450735|DEVICE|MANOS CTR™|The MANOS device is a carpal tunnel blade used to release the transverse carpal ligament in order to provide relief for Carpal Tunnel Syndrome.
214980891|NCT04597567|PROCEDURE|Metal removal|Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures
214368430|NCT03685591|DRUG|Enzalutamide|Prostate Cancer (Part 2). 160mg, capsules, orally, daily
214980892|NCT03707002|DIETARY_SUPPLEMENT|scFOS|daily intake for 6 weeks
214368431|NCT03403348|DRUG|JNJ-64417184|Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
214980893|NCT03707002|DIETARY_SUPPLEMENT|Maltodextrin|daily intake for 6 weeks
214980894|NCT03175211|DRUG|BI 456906|single dose
214980895|NCT03175211|DRUG|Placebo|single dose
214980896|NCT00064311|DRUG|ravuconazole|
214980897|NCT04670211|DEVICE|maxillary distractor|the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor
214368432|NCT03403348|DRUG|Placebo|Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
214980898|NCT00279084|DRUG|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
214980899|NCT00279084|DRUG|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
214980900|NCT06329167|DRUG|Daphnetin|150mg tid (3 capsules/time, 3 times daily) and gradient compression stockings.
214980901|NCT06329167|DRUG|Aescuven|150mg (2 capsules/time, 2 times daily) and gradient compression stockings.
214980902|NCT05276739|BEHAVIORAL|Bright Light|6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake).
214980903|NCT05276739|BEHAVIORAL|Time-restricted eating|6.5-hour restricted meal window (4 meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode.
214980904|NCT05276739|BEHAVIORAL|Dim light|dim light (\<3 lux) throughout the 16-hour wake episode
214980905|NCT05276739|BEHAVIORAL|12-h meal window|12-hour restricted meal window (4 meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
214980906|NCT02686996|DIETARY_SUPPLEMENT|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
214980907|NCT02686996|OTHER|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
214980908|NCT03984929|BEHAVIORAL|Conexion Localized|The localized version of Conexion is an online health information resource on diabetes and depression tailored for the target community.
214980909|NCT03984929|BEHAVIORAL|Conexion Generic|The generic version of Conexion is an online health information resource on diabetes and depression.
214980910|NCT03885557|OTHER|Group I Experimental DOS|After the application of hot pack treatment of 7-10 minutes, dynamic oscillatory stretch(DOS) technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
214980911|NCT03885557|OTHER|group II SS group|After the application of hot pack treatment of 7-10 minutes , Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
214980912|NCT03220503|PROCEDURE|endometrial injury|single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.
214980913|NCT04096690|DRUG|Pegaspargase|Pegaspargase 3750IU administered by intramuscular injection on Day 1 of each 21-day cycle for 6 cycles in induction treatment
214980914|NCT04096690|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 2 of each 21-day cycle for 6 cycles in induction treatment Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1 of each 21-day cycle for up to 28 cycles in maintenance treatment
214980915|NCT00607893|DEVICE|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
214980916|NCT00607893|DEVICE|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
214980917|NCT06102551|BEHAVIORAL|Recurrence after surgery|Recurrence after repair was the main outcome
214980918|NCT02889913|OTHER|No intervention only description|No intervention only description
214980919|NCT03097601|DIAGNOSTIC_TEST|ELR+CXCL cytokines levels are of sunitinib response|Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
214980920|NCT03170713|DRUG|arveles|800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
214980921|NCT03170713|DRUG|intrafen|800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
215087848|NCT04375397|DRUG|Ibrutinib|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
215087849|NCT04375397|DRUG|Placebo|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
215087850|NCT01276444|DEVICE|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
215087851|NCT01276444|DEVICE|transpulmonary thermodilution + central venous saturation|Described in details above
215087852|NCT03894384|DIAGNOSTIC_TEST|Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)|Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
214368433|NCT04499651|BEHAVIORAL|Navigation|Trained study navigators will provide one-on-one learning sessions and accompaniments to criminal-justice involved people to help link them to HIV/Hepatitis C care
214980922|NCT03170713|OTHER|placebos|150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
214980923|NCT02669849|DRUG|VX-210|
214980924|NCT02669849|DRUG|Placebo|
214980925|NCT02543840|OTHER|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
214368434|NCT01714804|DEVICE|Accell Evo3 Prospective Use|
214980926|NCT02543840|OTHER|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
214980927|NCT00581217|OTHER|Aquacel Ag|Aquacel Ag will be applied to one donor site.
214980928|NCT00581217|OTHER|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
214980929|NCT00980876|DRUG|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
214980930|NCT00980876|DRUG|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
215087853|NCT04754685|DRUG|Intra-articular injection of platelet-rich plasma|The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
215087854|NCT05440136|DRUG|LY3462817 (SC)|Administered SC.
214980931|NCT01955811|DRUG|Administration of platelet concentrate and taking blood samples|Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
214980932|NCT02915939|BEHAVIORAL|The Residential Care Transition Module|Residential Care Transition Module sessions focus on the experiences of the caregiver, the care recipient, and (potentially) other family members immediately following residential long-term care (RLTC) admission. The sessions are designed to establish a therapeutic rapport with the caregiver and the family; provide a safe environment to explore stressors; examine family relational dynamics as they relate to the RLTC placement decision itself as well as the roles different family members play in the life of the caregiver and relative in RLTC; identify new modes of communication to facilitate more effective interactions with other family members and care staff; and identify effective ways to advocate for improved quality of care for and quality of life of their relatives in RLTC.
214980933|NCT01525953|DRUG|Chemotherapy|Chemotherapy according to standard
214980934|NCT01525953|RADIATION|Radiotherapy|Radiotherapy according to local standard
214980935|NCT00348257|DEVICE|Hair removal by laser/IPL device|
215087855|NCT05440136|DRUG|Placebo (SC)|Administered SC.
215087856|NCT05440136|DRUG|LY3462817 (IV)|Administered IV.
214980936|NCT04745351|DRUG|Remdesivir|Administered as Intravenous (IV) infusion once daily
215087857|NCT05440136|DRUG|Placebo (IV)|Administered IV.
214368435|NCT01938248|DRUG|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age \> 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
214368436|NCT01938248|DRUG|aspirin|aspirin 81 mg once daily
214980937|NCT04745351|DRUG|RDV Placebo|Administered as IV saline once daily
214980938|NCT04745351|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
214980939|NCT01248416|DRUG|Aromatase Inhibitor|
214980940|NCT01248416|DRUG|Growth Hormone|
214980941|NCT01248416|DRUG|Aromatase Inhibitor and Growth Hormone|
215087858|NCT05400629|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
215087859|NCT02568449|DRUG|Nintedanib|Given PO
214368437|NCT01685138|DRUG|LDK378|LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
214368438|NCT02855931|PROCEDURE|Middle turbinate resection|
214368439|NCT02283281|DRUG|Tetrahydrocannabinol|1:1 THC to CBD standardized extract from cannabis plant
214368440|NCT02283281|DRUG|Dummy oromucosal|drops containing only Olive oil vehicle without the active compound (i.e.: without Cannabis oil)
214368441|NCT00975910|DRUG|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
214368442|NCT00975910|DRUG|saline|Saline arm: infused at the same rate as lidocaine
214368443|NCT06218225|DIETARY_SUPPLEMENT|Verum|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of study product Cycle 3 - first 15 days washout, remaining 15 days use of study product 4th cycle - 30-day washout
214368444|NCT06218225|DIETARY_SUPPLEMENT|Placebo|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of placebo Cycle 3 - first 15 days washout, remaining 15 days use of placebo 4th cycle - 30-day washout
214368445|NCT01542957|BEHAVIORAL|Combined Cognitive Behavioral and Dilemma-Focused Therapy|7 2-hour sessions of Group Cognitive Behavioral Therapy for Depression + 8 individual sessions of a Dilemma-Focused Intervention + 1 3-hour final group session. Manualized.
214368446|NCT01542957|BEHAVIORAL|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression. Format: 7 2-hour sessions in group + 8 individual sessions + 1 3-hour final group session. Manualized.
214368447|NCT06435104|OTHER|neoadjuvant chemotherapy|The neoadjuvant chemotherapy plan will be selected according to the recommendations of the NCCN guidelines and the Chinese CSCO guidelines for early breast cancer.The neoadjuvant chemotherapy plans include:AC-T(HP),TCb(HP),AC-TCb, in which A represents anthracycline, C represents cyclophosphamide, T represents taxane, Cb represents carboplatin, H represents trastuzumab, and P represents pertuzumab.
214368448|NCT06435104|OTHER|aromatherapy|Patients will inhale essential oils during the neoadjuvant chemotherapy courses.
214368449|NCT02432989|BEHAVIORAL|Exercise|Light-moderate exercise on a stationary bike and leisurely walks.
214368450|NCT02068495|DRUG|Candesartan cilexetil/Amlodipine besilate|Candesartan cilexetil/Amlodipine besilate tablets
214368451|NCT00736307|PROCEDURE|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
214368452|NCT03076268|BEHAVIORAL|Treinta Millones de Palabras - Visitas al Hogar|TMP-Visitas al Hogar is a cultural and linguistic adaptation of the TMW-Home Visiting curriculum into Spanish. The 12-module curriculum has been translated into Spanish and adapted to address concerns that are vital to mono- and bilingual Spanish-speaking families, including the broadening research base for when to introduce a second language to a child and the benefits of bilingualism.
214368453|NCT05547243|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine, Bivalent Low dose|50μg/dose
214368454|NCT05547243|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine, Bivalent High dose|100μg/dose
214368455|NCT05547243|DRUG|Placebo|Saline solution
214368456|NCT02693938|DEVICE|Follicular Euglycemic clamp|Follicular Euglycemic clamp during follicular phase
214368457|NCT02693938|DEVICE|Luteal Euglycemic clamp|Luteal Euglycemic clamp during luteal phase
214368458|NCT04663451|RADIATION|radioacive iodine therapy|Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
215087860|NCT04213170|DRUG|sintilimab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
215087861|NCT04527523|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT is an imaging method that uses light waves to create images of the retina.
214680538|NCT01009385|PROCEDURE|cervical epidural steroid injection|"* After aseptic preparation and skin infiltration with 1% lidocaine~* 20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~* identification of the epidural space confirmed by injection of contrast medium under fluoroscope~* injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~* Post-procedure, patients were observed for any adverse effects and followed with a neurological examination"
214680539|NCT01009385|PROCEDURE|epidural pressure measurement|"* The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~* Identification of the epidural space and measurement of EP was performed with a closed measurement system."
214980942|NCT05802433|DIETARY_SUPPLEMENT|Vitamin D3 supplement|10µg vitamin D3 supplement per day for 90 days
214980943|NCT06293742|DRUG|ECC5004|ECC5004 tablet will be administered orally.
214980944|NCT06293742|DRUG|Midazolam|Midazolam will be administered orally.
214980945|NCT06293742|DRUG|Rosuvastatin|Rosuvastatin will be administered orally.
214980946|NCT06293742|DRUG|Digoxin|Digoxin will be administered orally.
214980947|NCT06293742|DRUG|Atorvastatin|Atorvastatin will be administered orally.
214980948|NCT00300196|BIOLOGICAL|Ancrod (Viprinex)|0.167 IU/kg/hr IV for 2-3 hours
214680540|NCT02133378|DEVICE|Hemopatch|Baxter Hemopatch
215087862|NCT03019978|OTHER|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
215087863|NCT00610441|DRUG|MK-8777|
215087864|NCT00610441|DRUG|Placebo|
215087865|NCT02035956|BIOLOGICAL|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
214680541|NCT02133378|BEHAVIORAL|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
214680542|NCT00403702|DRUG|Oxane HD [oil-RMN3-mixture]|
214980949|NCT00300196|DRUG|Placebo|0.6 mL/kg/hr
214980950|NCT01244477|BEHAVIORAL|Group CPT-C|Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
214980951|NCT05090644|GENETIC|DNA analysis|GWAS
214980952|NCT06071416|PROCEDURE|Lateral sinus floor augmentation|maxillary sinus floor augmentation by lateral approach
214368459|NCT03819140|DRUG|Yasmin|Participants in each treatment arm will receive the medication Yasmin. However only the Cyclical OCP Therapy arm will take the sugar pills designated each month in the pill packs and the Continuous OCP Therapy arm will not.
214980953|NCT06071416|DRUG|Biphasic Calcium Phosphate|appliaction of BCP bone substitute
214980954|NCT06071416|PROCEDURE|Injectable platlets rich fibrin|centrifuge 10 ml of patient blood to get I-PRF that applied to the bone substitute
214980955|NCT04867759|PROCEDURE|Endometrial Biopsy|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
214980956|NCT00480714|BIOLOGICAL|BCG (SSI Strain)|
215087866|NCT04685629|DIAGNOSTIC_TEST|25 post ICU-patients|patients who were hospitalized in an intensive care unit
215087867|NCT04685629|OTHER|25 post non-ICU patients|patients who were not hospitalized in an intensive care unit
214980957|NCT01715246|OTHER|Infant Formula|
215087868|NCT01592617|DRUG|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
214980958|NCT03499795|BIOLOGICAL|VGX-3100|One milliliter (1 mL) VGX-3100 (deoxyribonucleic acid \[DNA\] plasmids encoding E6 and E7 proteins of HPV types 16 and 18) will be injected IM and delivered by EP using CELLECTRA™ 5PSP on Day 0, Week 4 and Week 12, and potentially Week 40.
214980959|NCT03499795|DEVICE|CELLECTRA™ 5PSP|IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 5PSP device.
215087869|NCT01173029|DRUG|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
214368460|NCT00929825|DEVICE|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
214680543|NCT00403702|DRUG|Densiron [(F6H8)|
214680544|NCT00797459|DEVICE|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
214680545|NCT03511261|DRUG|10% Curcumin mucoadhesive gel|Group 1 10%of mucoadhesive gel for topical application two times per day.
214680546|NCT03511261|DRUG|Curcumin capsules 500mg|Group 2 curcumin 500 mg capsules for oral intake two times per day
214980960|NCT02719977|DRUG|CX5461|
214980961|NCT02014623|OTHER|Grass pollen sublingual immunotherapy tablet|
214980962|NCT02014623|DRUG|Control|
214980963|NCT02741284|DRUG|Room air|
214980964|NCT02741284|DRUG|10L Oxygen by nonrebreather mask|
214980965|NCT03636256|DRUG|NanoDoce (direct injection)|Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
214980966|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Visit 2 Instillation|All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
214980967|NCT03636256|OTHER|Institutional Standard of Care|Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.
214980968|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Induction and Maintenance Instillations|Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
215087870|NCT05484817|DIAGNOSTIC_TEST|Assessment of cardiovascular risk factor, endocrine hormones and related biomarker|Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
214980969|NCT05181072|BEHAVIORAL|Enhanced in-person peer-motivation smoking cessation|Tobacco cessation classes will be offered in-person for a total of five sessions delivered weekly for five weeks and will utilize the CEASE Today Tobacco This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
214368461|NCT00929825|PROCEDURE|TENS|transcutaneous electrical stimulation
214980970|NCT05181072|BEHAVIORAL|Virtual peer-motivation smoking cessation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual
214980971|NCT05807282|OTHER|Interventions to Decrease Heat Stress among Latinx Farmworkers in Idaho|The interventions will be developed in collaboration with our study partners and will include increasing access to shade at the workplace, providing hydration packs to participants, and providing education regarding the signs and symptoms of occupational heat stress.
214368462|NCT06214845|PROCEDURE|Red blood cell EXchange (REX)|A single automated REX will be performed, as soon as possible after randomization.
214368463|NCT00689026|DRUG|Lubiprostone|Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
214368464|NCT00689026|OTHER|Polyethylene glycol with electrolytes|Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
214492474|NCT06762197|OTHER|Conventional treatment|Physical therapy can be beneficial for patients with piriformis syndrome, including stretching exercises, local massage, and superficial heat. Traditional stretching techniques include external rotation, hip flexion, and adduction. A hot pack on the trigger point area for 10 minutes followed by passive stretching for 30 seconds each.
214492475|NCT06762197|DEVICE|shockwave therapy|Shockwave therapy is a non-invasive alternative treatment for muscle disorders like sports and traumatic injuries, as it reduces pain and promotes soft tissue repair. In a study, patients in group A were treated with three sessions of Storz Medical Shock Wave MP100, each consisting of 2000 pulses with a total energy dose of 1080 mJ / mm. The study aimed to determine the location of the piriformis muscle in the prone position.
214492476|NCT06762197|DEVICE|low level laser therapy|Low Level Laser Therapy, also known as Photo-biomodulation, is a low-intensity light therapy that triggers biochemical changes within cells, similar to photosynthesis in plants. It can treat nociceptive and neuropathic pain, but central pain has not been proven responsive to low level laser therapy.
214492477|NCT06778850|DRUG|MDR-001|Oral administration of small molecule MDR-001 tablets
214492478|NCT06778850|DRUG|palcebo|Administered orally placebo
214492479|NCT05616260|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
214492480|NCT05616260|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
214492481|NCT05616260|DEVICE|Continuous Positive Airway Pressure|Standard CPAP device
214492482|NCT06779214|DIETARY_SUPPLEMENT|Prebiotic_L|subject will receive a low-dosage (1\*10\^5) of Bifidobacterium. animalis subsp.Lactis A6 Strain
214492483|NCT06779214|DIETARY_SUPPLEMENT|resveratrol_L|subject will receive a low-dosage (300mg/d) of resveratrol
214980972|NCT04615000|DIAGNOSTIC_TEST|SARS-CoV-2 serological assessment (IgG)|Periodic assessment of the serology status (SARS-CoV-2 specific IgG) with a 3 to 6 month interval
214980973|NCT00132886|DRUG|tolvaptan|
214368465|NCT01155752|DRUG|Pulmozyme single use ampule|• Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
214368466|NCT01155752|DRUG|placebo|identical placebo
214492484|NCT06779214|DIETARY_SUPPLEMENT|Prebiotic_M|subject will receive a medium-dosage (1\*10\^8) of Bifidobacterium. animalis subsp.Lactis A6 Strain
214492485|NCT06779214|DIETARY_SUPPLEMENT|Prebiotic_H|subjects will receive a high-dosage (1\*10\^10) of Bifidobacterium. animalis subsp.Lactis A6 Strain
214492486|NCT06779214|DIETARY_SUPPLEMENT|resveratrol_H|subject will receive a low-dosage (600mg/d) of resveratrol
214492487|NCT06779214|OTHER|placebo_Bif|subjects will receive placebo (one look-alike sunbstance that contains no prebiotics)
214492488|NCT06779214|OTHER|placebo_resveratrol|subjects will receive placebo (one look-alike sunbstance that contains no resveratrol)
214492489|NCT06772467|BEHAVIORAL|Intervention (Reiki)|Reiki was applied to this group twice a week for 4 weeks by a researcher who had a Reiki application certificate. Reiki sessions were applied to the patients before haemodialysis and the session duration was approximately 35-40 minutes. Reiki is applied to the seven major chakras and many minor chakras in the body. The chakras are located in the centre of the body, on a vertical line, in the front and back of the body. In this study, Reiki was applied to the patients twice a week for 4 weeks. Reiki sessions were performed before haemodialysis and each session lasted approximately 35-40 minutes. The vital signs of the patients were measured and recorded 3 times: before each Reiki session, after the Reiki session, just before the patient entered haemodialysis and after the haemodialysis session. After each session, patients with fistula were asked to mark the level of pain felt during catheter insertion on a visual analogue scale.
214680547|NCT03511261|DRUG|5% curcumin mucoadhesive gel + Curcumin capsules 250 mg|Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day
214680548|NCT03511261|DRUG|Placebo capsule|Group 4 placebo capsules for oral intake two times per day
214680549|NCT00886132|DRUG|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
214680550|NCT05606354|OTHER|Intervention group|Experimental
214980974|NCT05540431|DRUG|Activated Charcoal|RCT
214980975|NCT05540431|DIETARY_SUPPLEMENT|Probiotic|RCT
214980976|NCT05540431|OTHER|No intervention|RCT
214368467|NCT01383265|PROCEDURE|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
214980977|NCT04931615|DRUG|ARTISS 4mL Fibrin Sealant Topical Solution (Frozen)|Wound sealant
214980978|NCT04931615|OTHER|no ARTISS|Wound closed without sealant
214368468|NCT01383265|PROCEDURE|Water method|Control method will use plain water with water method for screening colonoscopy
214368469|NCT05311202|BEHAVIORAL|low-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 20 minutes of two sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
214492490|NCT06772467|BEHAVIORAL|EFT|"Emotional Freedom Technique (EFT) is a method that helps people manage their emotions and disturbing thoughts, helping to reduce their stress and anxiety. EFT is also called tapping.~EFT sessions were applied to the patients before haemodialysis and the session duration was approximately 35-40 minutes. Patients received 8 sessions of EFT. The vital signs of the patients were measured and recorded 3 times: before each EFT session, after the reiki session, just before the patient entered haemodialysis and after the haemodialysis session. After each session, patients with fistula were asked to mark the level of pain felt during catheter insertion on a visual analogue scale."
214980979|NCT02937376|DRUG|N-acetyl cystein|A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.
214980980|NCT02937376|OTHER|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
214980981|NCT02424825|BEHAVIORAL|Cooking Course|This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
214980982|NCT00183339|DRUG|Fluoxetine|Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
214980983|NCT00183339|DRUG|Placebo|Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
214980984|NCT05761847|OTHER|Pediatric Medication Therapy Management (pMTM)|The pMTM intervention is comprised of 3 activities: comprehensive review of the medication regimen; optimization of the medication regimen; and creation of the medication action plan.
214492491|NCT06775977|DIAGNOSTIC_TEST|Contrast Enhanced Ultrasound (CEUS)|Contrast Enhanced Ultrasound (CEUS) refers to the observation under ultrasound after the injection of ultrasound contrast agents, such as SonoVue or Lumason.
214492492|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $333|These subjects receive $333 each month for 76 months via debit card.
214492493|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $20|These subjects receive $20 each month for 76 months via debit card.
214980985|NCT01170585|DRUG|Rosuvastatin|All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.
214980986|NCT01170585|DRUG|Placebo|Placebo
214980987|NCT02548871|BEHAVIORAL|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
214980988|NCT03163628|BIOLOGICAL|Diagnostic performances of a combination of biomarkers|"3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.~The calculation of positive and negative likelihood ratios will be performed.~The targeted performances are:~* A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.~* A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3."
214980989|NCT01516216|DRUG|FOLFOX + bevacizumab|
214980990|NCT01516216|DIETARY_SUPPLEMENT|Vitamin D|
214368470|NCT05311202|BEHAVIORAL|moderate-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 30 minutes of three sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
214368471|NCT05311202|BEHAVIORAL|high-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 40 minutes of four sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
214492494|NCT06778213|BIOLOGICAL|NovoHelisen Depot|allergen immunotherapy treatment for 12 months with house dust mite allergen preparation
214680551|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation)|"Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours."
214980991|NCT04784130|BEHAVIORAL|Physical Activity|Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.
214980992|NCT04784130|BEHAVIORAL|Medication Adherence|Respondents will provide information on their medication adherence using a survey (questionnaire - MMAS-8).
214980993|NCT04784130|BEHAVIORAL|Dietary Modification|Respondents will complete food logs and surveys (three items from the Summary of Diabetes Self-care activities measure) for dietary intake.
214680552|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation) ECOMODYN|"TENS ECOMODYN® is applied to 4 treatment points, 5 minutes per point 2 times a day for 2 months.~A minimum rest period of 4 hours between 2 sessions on the same point must be respected Stimulation is performed directly with the bipolar probe of the TENS ECOMODYN® device on the painful area by fixed stimulation of 4 active pain points in 77Hz mode."
214980994|NCT03299985|OTHER|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
214980995|NCT03299985|OTHER|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
214980996|NCT03092427|DIETARY_SUPPLEMENT|VSL#3|Dietary Supplement
214980997|NCT03092427|OTHER|Placebo|Placebo
214980998|NCT01712282|BEHAVIORAL|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulse reserve increase of 50%
214980999|NCT03197636|DRUG|Pembrolizumab|Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
214981000|NCT05529537|OTHER|manual lymphatic drainage|In addition to conventional treatment for 4 weeks, manual lymph drainage will be applied to the patients.
214368472|NCT05311202|BEHAVIORAL|moderate-volume low-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 35 minutes of four sets of low intensity resistance exercise with 20 repetitions; (3) 5 minutes of cool down
214368473|NCT05311202|BEHAVIORAL|Control group|Reading a book related to cognitive function \& exercise for 40 minutes
214981001|NCT05529537|OTHER|excersize|upper extremity normal joint range of motion exercise, strengthening exercise, tendon gliding exercises
214981002|NCT03809390|PROCEDURE|Vaginal seeding|The same as that stated in arm descriptions.
214981003|NCT02674724|OTHER|Gym Group|"Patients from Gym Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period.~The initial load is established as 60% of one-repetition maximum strength test (1RM) applied for each exercise at the beginning of program. Patients will be encouraged to perform 3 sets of 8 to 12 repetitions. All subjects will be instructed to rest for 30-60 second intervals between sets."
214981004|NCT02674724|OTHER|Free Weights Group|Patients from Free Weights Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period. The program aim to recruit the same muscles requested in Gym Group. Investigators will apply six different exercises with patients lying supine,standing in stance, sitting and in four points kneeling. All exercises aim to strengthen abdominal muscles, trunk extensors, gluteus, quadriceps and scapula adductors. Patients will perform 3 sets of 8 to 12 repetitions, the load will be offered with dumbbells, elastics with different resistances and anklets.
214981005|NCT02674724|OTHER|Control Group|All three groups will be instructed to perform stretching exercises of trunk, leg and shoulder muscles, according to an illustrated booklet. Only the Control Group patients will be instructed to perform stretching exercises at home in the same 12-week period.
214981006|NCT05213091|OTHER|Otago Exercise Programme|The first four weeks will be Otago Exercise Programme training and practice. For the next weeks, there will be institution visits and telephone interviews. Individuals will be given an Otago Exercise Programme training booklet, exercise chart and exercise diary to better manage this process. The research will be conducted in small groups (average 6-8).
214981007|NCT00879190|DRUG|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
214981008|NCT00879190|DRUG|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
214981009|NCT03169569|PROCEDURE|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.
214981010|NCT03169569|PROCEDURE|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|All ESDs were performed according to the standard procedure sequence in the hemostatic group and control group except hemostatic powder application.
214981011|NCT06064240|OTHER|We do not have any intervention type|We do not have any intervention type
214981012|NCT00917696|PROCEDURE|Comparator: Iontophoresis and Laser Doppler with ATP|Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
214981013|NCT00917696|PROCEDURE|Comparator: Iontophoresis and Laser Doppler with Saline|Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
214981014|NCT01030146|DRUG|NeilMed® Sinus Rinse™ System with Isotonic Saline|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
214368474|NCT00308256|BEHAVIORAL|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
214368475|NCT00136786|DRUG|Memantine|
214368476|NCT01038388|DRUG|Bortezomib|1.3mg/m² given IV or subcutaneously
214368477|NCT01038388|DRUG|Lenalidomide|25 mg given PO
214368478|NCT01038388|DRUG|Dexamethasone|20 mg given PO
214368479|NCT01038388|DRUG|Vorinostat|100, 200, or 300 mg given PO
214368480|NCT05794048|BIOLOGICAL|Hepatocellular carcinoma|Tumor and liver biopsy
214368481|NCT05794048|BIOLOGICAL|Pancreatic adenocarcinoma|Tumor and pancreatic biopsy
214368482|NCT05794048|BIOLOGICAL|Pancreatic neuroendocrine tumor|Tumor and pancreatic biopsy
214368483|NCT00041730|BIOLOGICAL|Id-KLH|
214680553|NCT00935220|DRUG|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
214981015|NCT04606303|DRUG|Toripalimab combination with platinum-containing dual-drug chemotherapy.|"cisplatin + paclitaxel/ albumin-bound paclitaxel/ gemcitabine/ Pemetroxel+ Toripalimab (cisplatin 75mg/m2 (D1), paclitaxel 175mg/m2 (D1), or albumin-bound paclitaxel 260mg/m2 (D1), or gemcitabine 1250mg/m2 (D1, D8), or Pemetroxel 500mg/m2 (D1)), Toripalimab 240mg D1, Q3W.~If the patient is SD or PD, Toripalimab combined with platinum-containing dual-drug chemotherapy in the third cycle will continue, and a total of 4 cycles can be carried out at most, and the therapeutic effect will be evaluated after each cycle of treatment. If the patient is PR or CR at any time during the treatment (after treatment in the third or fourth cycle), the surgical treatment will be entered. If PR or CR is still not reached after treatment in the fourth cycle, the endpoint of the trial will be reached, theobservation of the patient will be finished, and the subsequent treatment will be decided by the clinician."
214981016|NCT01603602|BIOLOGICAL|botulinum toxin Type A|Intramuscular injections of botulinum toxin Type A into specified muscles of the upper limb on Day 1.
214981017|NCT01603602|DRUG|Normal Saline (Placebo)|Intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1.
214981018|NCT01176929|OTHER|Usual treatment and Prevention program|"Prevention program of recurrent suicidal acts includes three interventions:~* A series of three telephone calls ( the second week , one month and three months after discharge from hospital )~* A systematic telephone contact with the referring physician~* A telephone helpline for people who made a suicide attempt and referring physicians."
214981019|NCT01176929|OTHER|Usual Treatment|Usual Treatment
214981020|NCT04956809|DRUG|Dapagliflozin 10Mg Tab|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
214981021|NCT04956809|DRUG|Placebo|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
214981022|NCT02641054|DRUG|CVXL-0107|
214981023|NCT02641054|DRUG|Placebo|
214981024|NCT02641054|DRUG|Levodopa|
214981025|NCT02209064|DEVICE|Pericardial access|Access to the pericardium to enable further treatments.
214981026|NCT00666250|DIETARY_SUPPLEMENT|Xocai Activ drink|proprietary blend of cocoa powder and extracts of acai, grape and blueberry
214981027|NCT00272402|BEHAVIORAL|Cognitive Behavioral Intervention|Intervention consists of simulated case based learning for physicians.
214981028|NCT00272402|BEHAVIORAL|Office System Redesign Intervention|Intervention consists of clinical decision support within the electronic medical record.
214368484|NCT01819246|PROCEDURE|Aphersis Treatment Arm|
214368485|NCT01819246|OTHER|Control Arm|
214368486|NCT04069130|DRUG|400 mg of BIA 5-1058|1 x 400 mg capsule Oral, Fasted
214981029|NCT01669239|DRUG|Liposomal Doxorubicin|"Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
214981030|NCT01040819|DRUG|Pioglitazone|Patients will receive PIO 15 mg/d for one month, then 55 patients continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. Other non-diabetes drugs should not be changed. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin \>162 mg/d, steroids and prostaglandin analogs will be prohibited.
214981031|NCT06064448|DRUG|Sildenafil|Subjects were given sildenafil citrate, 25mg/capsule, once a night, one capsule each time, for 4 weeks.
214981032|NCT06064448|DRUG|Ningmitai capsule|The subjects took Ningmitai capsule, 0.38 g/capsule, 3 times a day, 4 capsules each time, after meals, and continued to treat for 4 weeks.
214981033|NCT06064448|DRUG|Ningbitai capsule + sildenafil|The subjects took Ningmitai capsule orally, 0.38 g/capsule, 3 times a day, 4 capsules each time, and took it after meals. Sildenafil citrate, 25mg/capsule, once a night, one capsule each time, was taken orally for 4 weeks.
214981034|NCT04748718|OTHER|Exercise-based injury prevention program|\~10-minute, 4+ times/week exercise-based injury prevention program. Includes flexibility, strengthening, balance, agility and plyometric exercises.
214368487|NCT05734963|GENETIC|DNA sequencing, RNA gene expression analysis, molecular profiling|Growth of organoids from tissue samples, collection of tissue, blood and saliva samples for DNA sequencing, RNA gene expression analysis, molecular profiling
214368488|NCT02415179|DRUG|Inhaled Mometasone/formoterol|Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
214368489|NCT02415179|DRUG|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
214368490|NCT00892489|DRUG|ER OROS Paliperidone|
214368491|NCT03258749|DRUG|Tiotropium|inhaled Tiotropium(18μg, qd)
214368492|NCT03258749|DRUG|Formoterol|inhaled formoterol(4.5μg, bid)
214368493|NCT03419481|DRUG|pembrolizumab|200mg every 3 weeks infusion
214368494|NCT03701984|DRUG|Lidocaine|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
214981035|NCT03073707|BEHAVIORAL|Sample collection|Stool samples will be collected from household members of children diagnosed with NTS infection. In addition stool samples of animals and rats will be collected as well as samples of the water supply of the household.
214981036|NCT04738383|PROCEDURE|Version 1: Paramedic|Instead of a physician, who is constantly present, a paramedic is present next to the instructor during the sessions, who can give first aid in case of an emergency and bridge the time until the ambulance arrives on site. The physician still acts as a supervisor visiting the group roughly every six weeks.
214981037|NCT04738383|PROCEDURE|Version 2: Physician-on-call|This version implicates that a physician is not physically present but is on call during the sessions and must be constantly accessible by phone and able to arrive within three minutes in case of an emergency. To ensure this, version two should be implemented in facilities, which are linked to cardiac or rehabilitation center.
214981038|NCT04738383|PROCEDURE|Version 3: Trained instructor|The sessions take place with the instructor only, who receives a comprehensive emergency training before and during the model phase and replaces the constantly present physician. Just like in the previous versions the physician still acts as a supervisor visiting the group roughly every six weeks.
214981039|NCT03056053|DRUG|Zolpidem|Commercially available tablets of zolpidem (5 or 10 mg) for oral use
214981040|NCT05409391|DEVICE|Insulin Titration System|A noval insulin titration system, which is based on deep learning
214981041|NCT02841696|DEVICE|Cardiac echography|The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
214368495|NCT03701984|DRUG|Tramadol|an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
214981042|NCT01260909|DEVICE|Real-time kV/MV Prostate Imaging|The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
214981043|NCT00618501|DRUG|cytarabine|
214368496|NCT03701984|DRUG|placebo|a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
214368497|NCT01273948|DRUG|Bavituximab|"1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or"
214368498|NCT01273948|DRUG|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
214368499|NCT04639128|DEVICE|Adductor Canal Catheter|The adductor canal catheter is a medical device that consists of a tunneled catheter connected to an analgesic solution-containing reservoir that slowly infuses the anesthetic over the first 2-3 postoperative days
214368500|NCT02870140|DEVICE|SUPRAFLEX|Percutaneous Coronary Intervention
214368501|NCT02870140|DEVICE|XIENCE|Percutaneous Coronary Intervention
214368502|NCT06448923|DRUG|Cannabidiol|25 mg of CBD tablets twice daily
214368503|NCT06448923|DRUG|Cannabidiol|50 mg of CBD tablets twice daily
214368504|NCT06448923|DRUG|Placebo|Matching placebo tablets twice daily
214368505|NCT06850987|PROCEDURE|non surgical periodontal therapy|All participants will have their non-surgical periodontal treatments completed after samples are taken and periodontal measurements are taken at the beginning.
214368506|NCT06850987|OTHER|measurement of periodontal clinical parameters|Periodontal measurements will be taken from all participants at baseline, 1 month, 3 months and 6 months
214368507|NCT06850987|OTHER|Gingival crevicular fluid samples will be collected|Gingival crevicular fluid samples will be collected from all participants at baseline, 1 month, 3 months and 6 months
214368508|NCT06228001|DEVICE|Actimyo|Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
214368509|NCT06577571|OTHER|CKM-EMPOWER|CKM-EMPOWER is a series of 11 just-in-time educational videos on topics related to caring for patients who opt for CKM: CKM overview, dysgeusia, fatigue, restless leg syndrome, uremic pruiritis, cramping, pain, volume overload, electrolyte abnormalities, anticipatory grief, and actively dying patient. Videos are approximately 5-10 minutes in length and intended to provide learners with a brief overiew on the definition of each issue, impact of the issue on a patient, assessment of the issue, and approaches to addressing the issue. Videos conclude with references to additional resources on each topic for more in-depth self-study. CKM-EMPOWER was created by a team comprised of a health educator, the principal investigator (nephrologist), a geriatrician and a physician dually trained in nephrology and palliative care and with feedback from a geriatric pharmacist and members of a national professional interest workgroup in kidney palliative care.
214368510|NCT00006257|DRUG|paclitaxel|
214368511|NCT00006257|DRUG|semaxanib|
214368512|NCT02703922|OTHER|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
214368513|NCT03157518|DIETARY_SUPPLEMENT|Seeking Health Probiota Bifido|• This is a proof of concept study to demonstrate that oral probiotic use can modulate the airway microbiome. After informed consent has been obtained, this study will consist of 2 visits over a four week time period. Each visit will include a blood draw (30ml) and a research bronchoscopy/ bronchoalveolar lavage (BAL) (200ml) visit . A urine pregnancy test will be done on all females of childbearing potential prior to the first BAL as well as a CBC, BMP, and blood clotting tests in all participants. Following the first BAL, subjects will be asked to take an over the counter probiotic supplement (Seeking Health Probiota Bifido) nightly which will be provided to the participant by the study coordinator until the 2nd BAL is performed 4 weeks after the first BAL.
214368514|NCT03934736|DRUG|HEPLISAV-B®|HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine for adults 18 years of age and older, consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).
214680554|NCT03637868|DRUG|Eribulin|Patients will receive eribulin 1.4 mg/m² administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
214981044|NCT00618501|DRUG|daunorubicin hydrochloride|
214981045|NCT00618501|DRUG|etoposide|
214981046|NCT00618501|DRUG|imatinib mesylate|
214981047|NCT00618501|DRUG|leucovorin calcium|
214981048|NCT00618501|DRUG|methotrexate|
214981049|NCT00618501|DRUG|prednisolone|
214981050|NCT00618501|DRUG|therapeutic hydrocortisone|
214981051|NCT00618501|DRUG|vincristine sulfate|
214981052|NCT00618501|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214981053|NCT01935089|DRUG|Pegylated Interferon alpha 2b|1µg/kg/week
214981054|NCT00489242|PROCEDURE|Procedure / Percutaneous angioplasty|
214981055|NCT01994213|DRUG|Famitinib|Famitinib 25 mg p.o. qd
214981056|NCT02052362|DRUG|ABT-450/r/ABT-267|ABT-450, ABT-267 and ritonavir
214981057|NCT00218907|PROCEDURE|Educational video|
214981058|NCT00723229|DRUG|acyclovir|Acyclovir 400 mg PO BID for 28 days
214981059|NCT02337491|DRUG|Pembrolizumab|
215087871|NCT04502121|BEHAVIORAL|EXPECT: Preoperative optimization of cardiac valve patient's expectations|The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
214368515|NCT00944502|DRUG|Dexamethasone|"Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days."
214981060|NCT02337491|DRUG|Bevacizumab|
214368516|NCT03856710|DEVICE|self-gripping mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
214368517|NCT03856710|DEVICE|Stapled mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
214368518|NCT00114010|DRUG|AMA1/Alhydrogel|
214368519|NCT04838990|OTHER|EDSS|Neurological Exam - EDSS (Expanded Disability Status Scale)
214368520|NCT04838990|OTHER|Discussion of symptoms, Patient reported outcome (MSIS)|Patients will be asked about their wellbeing
214368521|NCT03868865|BEHAVIORAL|Integrative mind-body-medicine group program|The mind-body-medicine group program focuses on support in coping with the disease, in lifestyle modification and in reduction of chemotherapy induced side effects. The self-contained modules of the mind-body-medicine group program can be followed in an individual order, to allow adoption to different chemotherapy concepts and continued access is possible. Patients can join in the group program eleven times for six hours each visit. They participate in every one of the eleven modules once.
214368522|NCT00394355|DRUG|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
214368523|NCT00394355|DRUG|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
214368524|NCT00394355|DRUG|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
214368525|NCT00394355|DRUG|montelukast|10 mg given once daily in the evening by mouth for 1 year.
214368526|NCT00575926|DRUG|LingZhi capsule|LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
214368527|NCT02053818|DRUG|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
214368528|NCT02053818|DRUG|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
214368529|NCT01527734|DRUG|Tetrodotoxin|15ug and 30ug once or twice a day for 1 or 2 days.
214368530|NCT01527734|DRUG|placebo|1ml once or twice a day for 1 or 2 days.
214492495|NCT06776536|DIAGNOSTIC_TEST|Transrectal ultrasound of the bowel endometriosis during operation|"This is a prospective, single-arm study aimed at evaluating the efficacy of intraoperative transrectal ultrasound (TRUS) in assessing rectal infiltration depth and length in patients with bowel involvement due to deep infiltrative endometriosis (DIE). The study will include 15-40 female patients aged 18-55, diagnosed with intestinal endometriosis preoperatively using transvaginal ultrasound and MRI, and scheduled for bowel resection.~Preoperative evaluations will include pelvic examination, imaging (TVUS and MRI), and pain assessment using a visual analog scale (VAS). During surgery, TRUS will be used to measure the depth and length of rectal involvement, and findings will be compared with preoperative MRI results."
214981061|NCT03261076|BEHAVIORAL|Strategies Enhancing Reading in Older Underperf. Students|Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
214981062|NCT04320498|BIOLOGICAL|prp injection|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
214981063|NCT04320498|DRUG|Anrecta|self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
214981064|NCT04320498|BEHAVIORAL|sitz bath|participants were told to take a hot water sitz bath once a day
215087872|NCT04952038|BEHAVIORAL|sleep disorder|ALS patients with or without sleep disorder
214981065|NCT04320498|DIETARY_SUPPLEMENT|nutrition regulation|The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
214981066|NCT03848559|DEVICE|Airway management with a submerged model|Airway management with a submerged manikin using different airway devices in randomized order
215087873|NCT05500300|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
214981067|NCT04325997|DEVICE|laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for laryngoscope intubation
214492496|NCT06775873|PROCEDURE|Modified diaphragmatic plication|Modified diaphragm plication (MDP) using a cutting stapler consists of four steps: clamping and lifting, depressing and resecting, cutting and verifying, and hemostasis and reinforcement.
214492497|NCT06780215|DRUG|Varenicline Tartrate Tablets|"Subjects in treatment group take varenicline tartrate tablets according to the following regimen:~Days 1-3: 0.5 mg/dose, once daily. Days 4-42: 0.5 mg/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 0.5 mg/dose, once daily."
214492498|NCT06780215|DRUG|Placebo|"Days 1-3: 1 tablet/dose, once daily. Days 4-42: 1 tablet/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 1 tablet/dose, once daily."
214981068|NCT04325997|DEVICE|video laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for video laryngoscope intubation
214981069|NCT05463965|BIOLOGICAL|QM1114-DP|Intramuscular injection
214981070|NCT05463965|BIOLOGICAL|OnabotulinumtoxinA|Intramuscular injection
214981071|NCT05463965|BIOLOGICAL|Placebo|Intramuscular injection
214981072|NCT01876095|PROCEDURE|Multidisciplinary medication review|"Consists of the following steps:~* 1\. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.~* 2\. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.~* 3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.~* 5\. Execution of pharmaceutical care plan according to agreed schedule."
214981073|NCT04999241|COMBINATION_PRODUCT|exclusive enteral nutrition|Administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks, then patients can administration of regular food.
214981074|NCT04999241|COMBINATION_PRODUCT|regular food|Administration of regular food in the induction phase and the later time.
214981075|NCT04722562|DRUG|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
214981076|NCT05620524|DRUG|Extra blood samples for determining exposure to 5-FU|Extra blood samples for determining exposure to 5-FU
214368531|NCT04141527|PROCEDURE|Spinal analgesia|Spinal analgesia (SA) was provided by a resident or specialist anaesthesiologist with the patient in a sitting or a recumbent position. A pencil-point needle, primarily 27 G (0.4 mm), otherwise 25 G (0.5 mm), was used for transdermal intrathecal administration of 2.0 ml of sufentanil 5 µg/ml (Sufenta®, Janssen-Cilag AB, Solna, Sweden) at low-lumbar level. Blood pressure was recorded before, immediately after, and at five-minute intervals for 20 minutes after the block. Any decrease in systolic pressure to \<100 mmHg or a decrease \>20% from the baseline level despite infusion of crystalloid was defined to indicate maternal hypotension.
214368532|NCT00286845|DRUG|Standard Chemotherapy|physician determined
214368533|NCT02119910|BEHAVIORAL|Technology Supported Manual|
214368534|NCT06578988|PROCEDURE|Mammography Images|Ultrasound and / or mammography are typically performed and reported by the imaging team at the same visit, with biopsy performed when indicated. This service is an important part of cancer care provision, with approximately half of the breast cancers diagnosed presenting via the symptomatic service rather than identified at screening.
214368535|NCT03365076|OTHER|Physical activity|Aerobic physical activity as stated in Arm A
214492499|NCT05139992|BIOLOGICAL|COVID-19 Vaccine|Vaccination against SARS-CoV-2 administered as part of standard of care
214492500|NCT01208974|PROCEDURE|Nipple-Sparing Mastectomy|Subcutaneous Mastectomy (SCM) to be performed, preserving the nipple and areola complex, after a frozen section of the tissue underneath the nipple-areola complex is sampled and found to be negative for tumor. Performed during Week 1.
214492501|NCT01208974|PROCEDURE|Breast Reconstruction|Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire. Performed during Week 1.
214492502|NCT01208974|PROCEDURE|Axillary Surgery|Axillary Dissection or Sentinel Node Biopsy (SNB) will be performed at surgeon's discretion.
214981077|NCT01235988|DRUG|Eltrombopag|Eltrombopag 50mg \& standard of care
214981078|NCT01235988|DRUG|Placebo|Placebo + standard of care
214981079|NCT05334667|OTHER|Routine management|Routine management
214981080|NCT05334667|DEVICE|CRRT|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
214981081|NCT05334667|DEVICE|PPH|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
214981082|NCT02627560|DRUG|Tranexamic Acid|moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
214981083|NCT02627560|DRUG|saline|moisten the surgical wound surface with 20 ml placebo (0.9% saline)
214368536|NCT00627380|BEHAVIORAL|Yoga lifestyle intervention|Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
214981084|NCT03176485|OTHER|Solar Simulator|A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
214981085|NCT01066234|RADIATION|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
214981086|NCT01066234|DRUG|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
214981087|NCT05751551|OTHER|Personalized, home-based motor-cognitive training|"The simultaneous motor-cognitive training in this study will be conducted in form of exergames (interactive video games) using Senso hardware (DIV-SENSO-H, Dividat GmbH, Schindellegi, Switzerland) - a stepping platform with 5 pressure sensitive plates which is connected to a screen. For the home-based training, a more mobile version of the Dividat Senso will be used: a foldable pressure-sensitive mat. In both devices, stimuli of exergames appear on the screen and the participants have to react by stepping in one of 4 directions (front, back, left, right).~The motor-cognitive training approach allows targeting different cognitive functions such as attention, executive functions, memory, and visuo-spatial functions as well as balance, and strength.~FITT-VP principles will serve as a guideline but based on the functional status of each participant (physical and cognitive), the training sessions will be personalized in terms of training content, intensity and duration."
214981088|NCT01873014|DRUG|chinese herbs-I|two agent per day, twice a day
214981089|NCT01873014|DRUG|chinese herbs-II|two agent per day, twice a day
215087874|NCT05500300|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
214368537|NCT00627380|OTHER|Standard of care|Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
214368538|NCT00070902|PROCEDURE|Lumbar side-posture spinal adjusting|
214368539|NCT03230708|OTHER|Erythrocytes derived MPs containing MTX|General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX
214368540|NCT03230708|DRUG|convention drugs|according to usage method of drugs
214368541|NCT04780373|OTHER|data collection|clinical data collection
214368542|NCT00529490|DRUG|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
214368543|NCT00529490|DRUG|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
214368544|NCT02813148|DRUG|Naloxegol|Non-interventional study of drug utilization
214368545|NCT00500903|DRUG|Alisertib|Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
214368546|NCT02731248|OTHER|Prospective screening study|Prospective screening study in newborns
214368547|NCT04211064|DIAGNOSTIC_TEST|Ultrasonographic measurement of optic nerve sheath diameter|Optic nerve sheath diameter will be measured at both neuromuscular blocks level.
214368548|NCT04211064|PROCEDURE|Deep neuromuscular block|Deep neuromuscular block will be obtained via appropriate dose of rocuronium.
214368549|NCT04211064|PROCEDURE|Moderate neuromuscular block|Moderate neuromuscular block will be obtained via appropriate dose of rocuronium.
214368550|NCT02447822|DRUG|Thymoglobulin|6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
214368551|NCT02452723|BIOLOGICAL|ISC-hpNSC|
214368552|NCT04284527|OTHER|Observational study|a reliability - validity study
214368553|NCT04373538|BEHAVIORAL|Trans-C for sleep and circadian function + Memory Support|The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
214368554|NCT02510430|BEHAVIORAL|Re-Patterning Sitting Time Group|This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
214368555|NCT02510430|BEHAVIORAL|Reducing Sitting Time Group|This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
214368556|NCT02510430|BEHAVIORAL|Usual Care|This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
214368557|NCT05096156|DEVICE|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
214368558|NCT01892059|PROCEDURE|Segmental artery clamping|Laparoscopic partial nephrectomy with segmental artery clamping will be performed for patients enrolled in this group.
214368559|NCT01892059|PROCEDURE|Main renal artery clamping|Laparoscopic partial nephrectomy with main renal artery clamping technique will be performed for patients enrolled in this group.
214981090|NCT01607658|DRUG|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
214981091|NCT01607658|DRUG|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
214680555|NCT04126369|OTHER|mindfulness intervention|The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.
214981092|NCT01607658|DRUG|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
214981093|NCT01607658|DRUG|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
215087875|NCT05500300|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
214981094|NCT02700399|DEVICE|Erigo® Hocoma|Robotics assisted tilt table, without functional electrical stimulation
214981095|NCT02700399|DEVICE|Traditional tilt table from Rehab-Care|Traditional tilt table
214981096|NCT02479841|OTHER|Self management program|
215087876|NCT05500300|DEVICE|RBS-IPI|"Subjects will receive RBS-IPI electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
214981097|NCT05608057|OTHER|Vitamin C mesotherapy|Vitamin C intra-mucosal injection; in which the site of interest will be anesthetized using a topical anesthetic agent (lidocaine gel or xylocaine gel) or infiltration anesthesia, followed by intra-mucosal field injections of 1-1.5 ml Cevarol (L-Ascorbic acid 1000 mg/5 ml
214981098|NCT05608057|RADIATION|Diode laser|Diode laser ablation: in which the site of interest will be anesthetized using infiltration anesthesia, followed by laser ablation. 980nm Diode laser will be applied using the following setting parameters: continuous mode with 980nm wavelength at 1.5 W output power.
214680556|NCT04126369|OTHER|psycho educative programme|The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.
214981099|NCT00906126|DRUG|Misoprostol|Oral misoprostol
214981100|NCT02069795|OTHER|Voice recording|
214981101|NCT03530293|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
214981102|NCT03530293|DRUG|Placebo oral capsule|non-active dosage form
214981103|NCT02607631|DRUG|Pembrolizumab|treated with Pembrolizumab 200 mg every 3 weeks
214981104|NCT00306254|DRUG|PD 0348292|
214981105|NCT00306254|DRUG|Enoxaparin|
214981106|NCT00231023|DRUG|Peribulbar Triamcinolone Acetonide|
214981107|NCT06157450|DRUG|ZSP1273|Participants receive ZSP1273 orally.
214981108|NCT00609817|DRUG|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
214680557|NCT06270940|PROCEDURE|Pulsed Radiofrequency (PRF) Treatment|PRF treatment maintains a temperature below 42°C and does not produce structural tissue damage around the needle. PRF exposure to the Dorsal Root Ganglion (DRG) induces c-Fos gene expression in the dorsal horn, which suggests a cellular response to the electric forces generated within the DRG. PRF has been found to relieve neuropathic pain by inducing long-term depression of synaptic transmission in the spinal cord, leading to a decrease in allodynia and hyperalgesia. It also modulates the inflammatory response in the injured area by decreasing the expression of pro-inflammatory cytokines, such as TNF-α, in the peripheral nerve and spinal cord, which is a major player in the development and maintenance of neuropathic pain. PRF is characterized by a 500 kHz current applied for 2 pulses per second, with each pulse lasting 20 milliseconds.
214981109|NCT00609817|DRUG|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
214981110|NCT02016846|DRUG|Liraglutide|
214981111|NCT02016846|DRUG|Placebo|
214981112|NCT02499588|DEVICE|Esteem Plus with ConvaTec Moldable Technology|
214981113|NCT02499588|DEVICE|Natura with ConvaTec Moldable Technology|
214981114|NCT02499588|DEVICE|Natura Accordion with ConvaTec Moldable Technology|
214981115|NCT02499588|DEVICE|Esteem synergy Plus with ConvaTec Moldable Technology|
214981116|NCT01668797|DRUG|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
214981117|NCT01668797|DRUG|Placebo|Placebo comparator for 52 weeks
214981118|NCT02987010|DRUG|IDH305|Isocitrate Dehydrogenase 1 inhibitor
214981119|NCT03387293|OTHER|LGI-LII Breakfast|This test meal with low GI and low FII amounts were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
214680558|NCT01938820|DRUG|entecavir|anti-viral therapy
214680559|NCT01938820|DRUG|Thymosin-α|antiviral and antifibrosis therapy
214680560|NCT00619931|DRUG|APD791|APD791 or matching placebo in escalating doses
214680561|NCT00985881|DEVICE|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
214680562|NCT00985881|DEVICE|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
214680563|NCT01636869|DRUG|Bupivacaine|"20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block."
214680564|NCT05186181|BEHAVIORAL|In situ fenestration|Interventional therapy of aortic dissection. In situ needle fenestration of left subclavian artery.
214981120|NCT03387293|OTHER|LGI-HII Breakfast|In crossover design, this test meal with low GI and high FII amounts were served as a breakfast to compare the LGI-LII Breakfast.
214680565|NCT01000064|DRUG|Vyvanse|30 mg - 70 mg capsules taken every morning for 6 weeks.
214680566|NCT01000064|PROCEDURE|fMRI|Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
214981121|NCT02530385|OTHER|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
214981122|NCT02530385|BIOLOGICAL|FMT Capsules|Capsules will be generated as per FDA-approved procedures
214981123|NCT03044418|OTHER|Application of ET laser tube in propofol anesthesia|The special ET laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
214680567|NCT01000064|DRUG|Placebo|Placebo capsules taken every morning for 6 weeks.
214680568|NCT00000849|DRUG|Aldesleukin|
214680569|NCT01518192|DRUG|doxycycline|100 mg bid; 15 days
214680570|NCT01518192|DRUG|cefuroxime axetil|500 mg bid; 15 days
214680571|NCT00759512|OTHER|Therapeutic Touch|
214981124|NCT01569022|DEVICE|CPAP|CPAP Treatment for 12 weeks
214981125|NCT01569022|DEVICE|MAD|MAD Treatment for 12 weeks
214981126|NCT03613493|DIAGNOSTIC_TEST|HPV self-sampling kit|The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.
214981127|NCT03613493|BEHAVIORAL|Culturally-targeted Fear Appeal Message|Participants will receive culturally-targeted and fear appeal messages in a graphically designed kit.
215087877|NCT05500300|DEVICE|HIFEM|"Subjects will receive HIFEM electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
215087878|NCT06414421|OTHER|Transcuten Electriacal Nerve Stimulation|In TENS group patients, 4 electrodes of the TENS device were placed 3-5 minutes before the biopsy procedure, and the application was started and TENS was applied throughout the procedure. continued. TENS was applied again for 30 minutes 2 hours after the procedure.
214680572|NCT00798967|DRUG|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
214680573|NCT00798967|DRUG|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
214981128|NCT03613493|BEHAVIORAL|Fear Appeal Message|Participants will receive fear appeal messages (only) in a graphically designed kit.
214981129|NCT03613493|BEHAVIORAL|Interview|Participants will be interviewed about experiences using the self-sampling tool (qualitative).
214981130|NCT05238662|PROCEDURE|pedicle screw fixation on one side and intervertebral cage on the other sided|pedicle screw fixation on one side and intervertebral cage on the other sided
214981131|NCT05238662|PROCEDURE|pedicle screw fixation and interbody cage on the same side|pedicle screw fixation and interbody cage on the same side
215087879|NCT03386734|PROCEDURE|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
215087880|NCT03386734|PROCEDURE|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
214680574|NCT00161304|DRUG|Testosterone Enanthate|Testosterone Enanthate
214680575|NCT00161304|OTHER|Placebo|placebo
214680576|NCT02474017|DRUG|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
214680577|NCT02474017|DEVICE|CRC749 inhaler|
214680578|NCT03515603|PROCEDURE|Endoscopic resection|Transsphenoidal endoscopic resection of pituitary adenoma
214680579|NCT03515603|PROCEDURE|Microsurgical resection|Transsphenoidal microsurgical resection of pituitary adenoma
214981132|NCT06266013|OTHER|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the lower limbs.
214981133|NCT01135342|BEHAVIORAL|Diet and exercise|Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
214981134|NCT01135342|BEHAVIORAL|Cognitive Behavioral Therapy|Standardized cognitive behavioral therapy for insomnia (8 classes)
214981135|NCT01135342|BEHAVIORAL|Passion and Balance|Attention-match sessions of general interest, but unrelated to diet, exercise, or sleep (8 sessions)
214981136|NCT00253942|PROCEDURE|Injecting bee venom as a treatment for OA|
214981137|NCT00433836|DRUG|Valsartan|Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
214981138|NCT00433836|DRUG|Enalapril|Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
214981139|NCT05601336|DRUG|Dapagliflozin 5 MG|SGLT2 inhibitor
214981140|NCT05601336|DRUG|Metformin Hydrochloride 1000 MG|metformin
214981141|NCT05601336|DRUG|Dapagliflozin/Metformin|SGLT2 inhibitor and metformin HCl extended-release
214981142|NCT05355155|DRUG|Bevacizumab Biosimilar IBI305|Patients received bevacizumab and FOLFOX4 every two weeks
214981143|NCT01877798|PROCEDURE|volume resuscitation, vasoactive drug|
214981144|NCT05722691|DRUG|Double-Stranded RNA sodium salt|Once intramuscular injection 5 mg (1 vial)
214981145|NCT05722691|DRUG|Placebo|Once intramuscular injection (1 vial)
214981146|NCT02446691|BIOLOGICAL|MenACWY|Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
214981147|NCT03650647|PROCEDURE|Carious dentin removal|Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
214981148|NCT00472420|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv every 3 weeks
214981149|NCT00472420|DRUG|First line chemotherapy|As prescribed
214981150|NCT00686972|DRUG|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
214981151|NCT01339312|BIOLOGICAL|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
214981152|NCT01339312|BIOLOGICAL|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
214981153|NCT01339312|BIOLOGICAL|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
214981154|NCT01339312|BIOLOGICAL|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
214981155|NCT03144232|DEVICE|Active rTMS|rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Study-treatment will be delivered at 120% rMT. Each active rTMS study-treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Study-treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.
214981156|NCT03144232|DEVICE|Sham rTMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of rTMS, combined with a TENS device which produces a small electric shock mimicking the feeling of active rTMS. This type of sham has been demonstrated to be indistinguishable from active rTMS.
214981157|NCT04489368|RADIATION|Neo-Adjuvant Radiotherapy|Neo-Adjuvant Radiotherapy via any technique, delivered concurrently with Neo-Adjuvant Chemotherapy.
214981158|NCT04489368|DRUG|Neo-Adjuvant Chemotherapy|Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.
214981159|NCT04489368|PROCEDURE|Esophagectomy|Esophagectomy, performed 4-6 weeks after completion of Neo-Adjuvant Concurrent ChemoRadiation
214981160|NCT00840125|DRUG|erlotinib|150mg tablet daily
214981161|NCT00840125|DRUG|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
214981162|NCT03022006|DRUG|elbasvir, grazoprevir|
214981163|NCT05397652|DRUG|Tranexamic Acid Injectable Product|Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
214981164|NCT05397652|DRUG|Placebo|Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
214981165|NCT02963480|PROCEDURE|Cardiac Surgery|
214981166|NCT06379126|DIAGNOSTIC_TEST|Test thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM）|Test TAT, PIC, tPAI·C and TM of blood of SIC patients.
214981167|NCT05946733|PROCEDURE|Group A|After induction of general anesthesia, oblique subcostal TAP blocks will be done(14) under the guidance of Sonosite ,superficial probe ,14-15 MHz ultrasound transducer
214981168|NCT05946733|PROCEDURE|Group B|After induction of general anesthesia, bilateral lateral TAP block will be performed (15) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz)
214981169|NCT05946733|OTHER|Group C|the analgesia will be maintained using a morphine patient-controlled analgesia (PCA) device set to give 1.5 mg bolus administration of morphine without a basic rate and 15 min lock-out time. The total amount of morphine administration will be recorded for the subsequent 24 h
214981170|NCT00000442|DRUG|naltrexone (Revia)|
214981171|NCT03877822|BEHAVIORAL|Habitual activity|Two days of habitual physical activity, under normal free-living conditions
214981172|NCT03877822|BEHAVIORAL|Bed rest|Two days of bed rest, to induce whole-body physical inactivity
214981173|NCT02104687|PROCEDURE|Flow group|After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.
214981174|NCT02104687|PROCEDURE|Press group|After induction, the parameters of MAP and CVP will be monitored in each of the patients.
214981175|NCT05150574|BEHAVIORAL|Core Health Program|8-week structured stress management and health behaviour change program
214981176|NCT05150574|BEHAVIORAL|Daily resting HRV|Take regular HRV readings in the morning
214981177|NCT05150574|BEHAVIORAL|Momentary HRV feedback|Take regular HRV readings throughout the day when stressed and perform mindfulness activity
214981178|NCT05150574|BEHAVIORAL|Behavioural initiation coaching|15-minute health coaching session in first week of program to help participant set goals and create an action plan
214981179|NCT05150574|BEHAVIORAL|Practice with feedback coaching|15-minute health coaching session in week 2 or 4 of program to help participant review goals and modify action plans if needed
214981180|NCT03467451|PROCEDURE|Endoscopic Mucosectomy|Endoscopic Mucosectomy with anchorage of the tip of the loop
214981181|NCT01755299|OTHER|"Regular 5-hour Energy"|Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)
214981182|NCT01755299|OTHER|"Decaf 5-hour Energy"|"Commercially available 5-Hour Energy Decaf product in the amount that is packaged (1.93 fl. oz.)"
214981183|NCT01755299|OTHER|Compounded concentrated caffeine liquid|"Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular 5-hour Energy"
214981184|NCT01755299|OTHER|Flavored bottled water|Bottled water will be flavored and colored to serve as a placebo product for this trial.
214981185|NCT00313235|BIOLOGICAL|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10\^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
214981186|NCT03217409|DRUG|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg
214981187|NCT03217409|DRUG|Rosuvastatin|Rosuvastatin 5Mg Tablet
214981188|NCT03430739|OTHER|No intervention|No intervention
214981189|NCT01026493|DRUG|temozolomide 60 mg x 21 days|Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
214981190|NCT01026493|DRUG|temozolomide 75 mg x 21 days|Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
214981191|NCT01026493|DRUG|ABT-888 20 mg x 21 days|20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
214981192|NCT01026493|DRUG|ABT-888 40 mg x 21 days|40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
214368560|NCT00072761|PROCEDURE|transfusion therapy|Those in the blood transfusion group will receive at least monthly blood transfusion therapy.
214368561|NCT04445636|DRUG|Dexmedetomidine|Caudal block with Dexametomedine as an adjuvant to bupivacaine.
214368562|NCT04445636|DRUG|Morphine|Addition of morphine as adjuvant to bupivacaine during caudal block.
214368563|NCT00753792|DRUG|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
214368564|NCT00753792|DRUG|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
214368565|NCT00753792|DRUG|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
214368566|NCT00529750|DRUG|IRBESARTAN|Tablets
214368567|NCT00529750|DRUG|Atenolol|Tablets
214981193|NCT01026493|DRUG|Temozolomide 150 mg x 5 days|150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)\*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
214981194|NCT01026493|DRUG|ABT-888 40 mg x 5 days|40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
214981195|NCT02674516|DEVICE|Transcranial direct current stimulation|
214981196|NCT02674516|DEVICE|Sham transcranial direct current stimulation|
214981197|NCT04653311|DEVICE|Endomina®|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
214981198|NCT06520956|BEHAVIORAL|Video based exercise group|In each session, 2 videos will be applied and each will be repeated 2-3 times, with a 3-minute rest break between each video. The total session will last an average of 20-30 minutes and 16 sessions of physical activity will be performed twice a week for a total of 8 weeks.
214368568|NCT01648348|BIOLOGICAL|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
214368569|NCT01648348|BIOLOGICAL|Bevacizumab|Given IV
214368570|NCT01648348|OTHER|Laboratory Biomarker Analysis|Correlative studies
214368571|NCT01648348|OTHER|Pharmacological Study|Correlative studies
214368572|NCT01648348|OTHER|Quality-of-Life Assessment|Ancillary studies
214368573|NCT02532556|DEVICE|Electrical stimulation (Digitimer)|Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
214368574|NCT00696410|DRUG|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels \~10-12.
214368575|NCT03249051|OTHER|Indirect Calorimetry|Energy need is being determined using indirect Calorimetry
214680580|NCT04348721|OTHER|online survey|"An online survey including 8 case-vignettes was sent to international liver transplant surgeons who had published on liver transplantation. The first part is related to surgeon's own experience. In the second part, the surgeons were asked to rate the difficulty of various situations in liver transplantation on a scale of 1 to 10 (level 1 was labeled as easier, and level 10 was labeled as difficult). In the third part, 8 case-vignettes corresponding to 8 clinical real-life situations are submitted to experts"
215087881|NCT02469714|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
215087882|NCT05751889|BEHAVIORAL|Serious Game|Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
215087883|NCT05751889|BEHAVIORAL|Traditional Health Education|Reading materials regarding HCV and safe sexual practice.
214680581|NCT06102161|PROCEDURE|Wedge resection|Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.
214680582|NCT05546788|PROCEDURE|scaling and root planing|subgingival Depridement
214680583|NCT05546788|DRUG|hydroxylated poly methoxy flavones|Received hydroxylated poly methoxy flavones extract solid dispersion incorporated into sodium carboxymethylcellulose gel
214680584|NCT05546788|DRUG|chlorhexidine|Received chlorhexidine gel
214680585|NCT05546788|DRUG|placebo|Received placebo gel
214680586|NCT02681887|DRUG|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
214981199|NCT02879214|RADIATION|Simultaneous boost along with chemo|Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
214981200|NCT00439972|DRUG|Ortho-Cyclen (R)|The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
215087884|NCT05551624|DRUG|Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet|Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
214368576|NCT06048770|BIOLOGICAL|RBI-4000|RBI-4000 intramuscular injection.
214368577|NCT06048770|BIOLOGICAL|RabAvert|RabAvert intramuscular injection.
214680587|NCT02681887|DRUG|Placebo|placebo tablet identical to circadian
214680588|NCT03138915|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
214680589|NCT03138915|PROCEDURE|CTA|Radiomic features were extracted from CTA images.
214680590|NCT05340400|OTHER|ROME IV Criteria|Collaborators will use Rome IV criteria for diagnosing IBS by the presence of the abdominal pain at least once a week in the last 3 months, in addition to at least two of the following: abdominal pain related to defecation, change in stool frequency, or shape.
214680591|NCT01415440|DRUG|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
214680592|NCT01415440|DRUG|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
214680593|NCT02131467|DRUG|Perampanel|oral drug
214680594|NCT00620204|DRUG|atorvastatin|atorvastatin 40mg qd for 1 year
214680595|NCT03670862|OTHER|CT|Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
214680596|NCT03090737|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
214680597|NCT03141307|BEHAVIORAL|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
214680598|NCT03141307|BEHAVIORAL|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
214981201|NCT00439972|DRUG|Ortho Evra (R)|Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
214981202|NCT00439972|DRUG|extended use of Ortho Evra (R)|The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
214981203|NCT00270673|PROCEDURE|Early lactate-directed therapy|
215087885|NCT00840580|DRUG|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
215087886|NCT00840580|DRUG|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
215087887|NCT03816280|PROCEDURE|Elective cardiopulmonary bypass (CPB)|All groups undergo elective cardiopulmonary bypass (CPB)
215087888|NCT03816280|PROCEDURE|Alpha-stat acid-base management|Acid-base status during CPB will be maintained using the alpha-stat regime
215087889|NCT03816280|PROCEDURE|pH-stat acid-base management|Acid-base status during CPB will be maintained using the pH-stat regime
215087890|NCT03223467|PROCEDURE|Bariatric surgery|Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
215087891|NCT05671796|GENETIC|Mesenchymal stem cell transplantation|Patients will undergo two autologous bone marrow stem cell transplantation into the lesion area
214680599|NCT03141307|BEHAVIORAL|Control|Standard of care, paper-based brochure
214680600|NCT05629416|BEHAVIORAL|Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples|"1. Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~2. Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~3. Support simplified and improved strategies for booking an interpreter to increase uptake.~4. Implement retention strategies to ensure interpreters receive workplace support.~5. Provide training in health terminology for interpreters.~6. Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~7. Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation."
214981204|NCT00601055|BEHAVIORAL|Problem Solving-Rx Adherence (PSA)|In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
214981205|NCT00601055|BEHAVIORAL|PID-C|In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
214981206|NCT04989673|OTHER|Biological sampling and collection (serum)|Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups
214981207|NCT04989673|OTHER|Biological sampling and collection (placenta)|Detection of dengue virus in the placenta of GE patients (additional tube of placenta)
214981208|NCT04989673|OTHER|Questionnaire|Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).
214981209|NCT04989673|OTHER|Data collection|Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).
215087892|NCT05671796|OTHER|Placebo|Patients will undergo two subcutaneous injections of 1 ml of glycophysiological solution into the lesion area by sham procedure
215087893|NCT03926312|DEVICE|Smart device-based cardiac rehabilitation|A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
215087894|NCT06090032|DEVICE|Ultrasound|We will use ultrasongraphy as a part of assessment in respiratory intensive care unit patients with ventilator associated pneumonia
215087895|NCT01229748|BEHAVIORAL|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
214680601|NCT06671080|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|All of these tests planned to be used in the study will be applied to adolescent amateur soccer players who meet the inclusion criteria.
214680602|NCT06672796|OTHER|Resisted Toe Spread Out Exercise|new resistance exercise phase in addition to the standard protocol
214680603|NCT06672796|OTHER|Toe Spread Out Exercise|Standart protocol of toe spread out exercise
214680604|NCT06672796|OTHER|Stretching exercise|Toe stretching
214680605|NCT02160977|PROCEDURE|total knee arthroplasty|
214680606|NCT03458000|DEVICE|PillCam UGI|An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
214680607|NCT03458000|OTHER|Standard of Care|Patient was admitted to hospital for care and received in-patient EGD.
214680608|NCT06672211|OTHER|video-supported training|Patients with stomas were provided with video-supported training in addition to standard stoma care training.
214680609|NCT06123416|BEHAVIORAL|Expressive Writing|Caregivers complete three 20-min writing sessions in which they write about an assigned topic - emotional or non-emotional.
214680610|NCT02858388|DEVICE|Sinuclean Nebules 45|Nebulization of solution
214981210|NCT00197678|DIETARY_SUPPLEMENT|Multivitamins-Multiples of RDA|20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
214981211|NCT00197678|DIETARY_SUPPLEMENT|Multivitamins-Single RDA|1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
215087896|NCT01229748|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
215087897|NCT01229748|BEHAVIORAL|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
215087898|NCT04741191|OTHER|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown), 3x/week on alternate days for 6 weeks at 40-60% of VO2max.
214981212|NCT04324749|OTHER|Roasted peanuts (group A)|After 2 weeks following a peanut-free diet, the participants of this group consume 25 g/ day of whole skin roasted peanuts (RP) within the habitual diet during 6 months.
214981213|NCT04324749|OTHER|Peanut butter (group B)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of peanut butter (PB) within the habitual diet during 6 months.
215087899|NCT04741191|OTHER|Conventional therapy|In bed activities (Active ankle and hand pumping exercise\* 15 Rep\* BD AROMS of extremities\* 15 Rep\* BD, Deep breathing exercises\* 15 Rep\* BD, Ambulation (walk 10-15 minutes below fatigue and onset of symptoms level\* BD) for 6 weeks.
214680611|NCT02858388|OTHER|Saline solution|Nebulization of solution
214981214|NCT04324749|OTHER|Control (group C)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of control supplement (containing the same proportion of macronutrients as peanuts and peanut butter) within the habitual diet during 6 months.
214981215|NCT03129932|DIETARY_SUPPLEMENT|gluten phase|2 cakes containing 9g of vital gluten/each will be consume during the 4 weeks of intervention
214981216|NCT03129932|DIETARY_SUPPLEMENT|placebo phase|2 cakes without gluten will be consume during the 4 weeks of intervention
214981217|NCT03319771|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
214981218|NCT03319771|BEHAVIORAL|Stretching-and-toning Exercise Training|12-weeks of supervised, stretching-and-toning exercise training
214981219|NCT00125008|BIOLOGICAL|Typhoid Vi vaccine|single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)
214981220|NCT00125008|BIOLOGICAL|Hepatitis A vaccine|720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults
214981221|NCT03636399|BEHAVIORAL|Standard GIST|13 group modules will be administered to outpatients in 12 x 2,5-3 hours sessions. Manualized intervention; In every group session a new topic is presented, discussed and practiced in group exercises. Homework assignments between sessions.
214981222|NCT03636399|BEHAVIORAL|Intensive GIST|13 group modules will be administered to inpatients during 4 weeks in hospital. Participants is admitted to a hospital unit for cognitive rehabilitation treating patients in acute and/or cronic phase. The participants are given extended leave every weekend to work on homework Assignments between each treatment week.
214981223|NCT02347046|DRUG|FYU-981, (Oral single dosing)|FYU-981, (Oral single dosing)
214981224|NCT02597413|PROCEDURE|Catheterization|Women in this group will be systematically catheterized before leaving the delivery room.
214680612|NCT02977091|OTHER|change in fitness level|fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
214680613|NCT00049413|BIOLOGICAL|rituximab|
214981225|NCT01795443|OTHER|Calibration|"Subjects will be seated on a table, feet dangling, blindfolded, arms crossed over the chest and held in place by bandages to minimize the visual and proprioceptive inputs that may contribute to the realization of the task.~The investigator uses an electronic goniometer to measure the maximal extension and flexion during a pelvic pivot. These measures will be used to determine a target position midway along the pelvic movement range."
214981226|NCT01795443|OTHER|Practice|"Propioception test: The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position.~Each subject will have three (non-measured) tries at the proprioception test without vibration, then three tries with low frequency vibration (20 Hertz), and then three tries with high frequency vibration (60 Hertz). Between each series of tries, a 2-minute rest period with walking is required."
214981227|NCT01795443|OTHER|Measures - no vibration|"The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
215087900|NCT05640206|PROCEDURE|i-PRF|Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
215087901|NCT05640206|PROCEDURE|Arthrocentesis|Arthrocentesis performed with two-needle technique
215087902|NCT03351556|BEHAVIORAL|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
215087903|NCT03351556|BEHAVIORAL|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
215087904|NCT00306644|DRUG|Rosiglitazone|study drug
215087905|NCT03002623|DRUG|CUDC-907|60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
215087906|NCT00843544|BEHAVIORAL|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~1. Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~2. Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~3. Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
215087907|NCT02109523|BEHAVIORAL|Motivational Interviewing (MI|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
214492503|NCT01208974|RADIATION|Prophylactic Nipple-Areolar Complex RT|Prophylactic Nipple-Areolar Complex Radiation Therapy per protocol. Administered between weeks 5 to 8.
214492504|NCT06511726|DRUG|Cadonilimab|Induction chemotherapy and immunotherapy: Cadonilimab + cisplatin + albumin-bound paclitaxel, for a total of 2 cycles (cisplatin 75 mg/m² + albumin-bound paclitaxel 260 mg/m² q3w, Cadonilimab 10 mg/kg q3w).
214680614|NCT00049413|DRUG|cyclophosphamide|
214492505|NCT05521516|DEVICE|Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge|Application of 5 days of percutaneous auricular neuromodulation with NSS-2 Bridge device
214492506|NCT05521516|DEVICE|Sham Treatment|Application of 5 days of a nonfunctional sham device
214492507|NCT06771986|OTHER|Observation|sRAGE levels were studied in three different groups
214680615|NCT00049413|DRUG|pentostatin|
214981228|NCT01795443|OTHER|Measures - low vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
214368578|NCT06969456|PROCEDURE|Exercise|Structured treatment sessions, each lasting 30 minutes, will be organized into distinct blocks. In the initial phases, participants will engage in exercises emphasizing core stabilization and general strength training, with a particular focus on forced expiration as a technique to ensure the proper activation of the transversus abdominis muscle. This methodology aims to mitigate adverse effects associated with increased intra-abdominal pressure. To optimize the activation of the transversus abdominis, patients will be instructed to perform a forced expiration while concurrently drawing the navel inward and upward toward the spine, maintaining the lumbar spine in a neutral position. During the initial exercises, ultrasound imaging of the transversus abdominis will be employed as visual feedback, enabling patients to observe muscle thickening during forced expiration. This visual feedback enhances the accuracy of muscle activation and exercise technique. Exercises will be progressively s
214492508|NCT06870721|PROCEDURE|arthroscopic dynamic anterior stabilization for recurrent anterior shoulder dislocation|arthroscopic dynamic anterior stabilization transferring long head of biceps to the anterior glenoid in patients with recurrent anterior shoulder dislocation
214492509|NCT06778395|DRUG|Dexlansoprazole 60 mg|once daily for 8 weeks
214492510|NCT06778395|DRUG|Vonoprazan 20 mg bid|twice daily for 8 weeks
214680616|NCT00827268|BEHAVIORAL|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
214981229|NCT01795443|OTHER|Measures - high vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
214981230|NCT05089214|DEVICE|Intra oral cameras|Diagnostic comparison of two intra oral cameras
214981231|NCT01380366|DRUG|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
214981232|NCT01380366|PROCEDURE|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
215087908|NCT02109523|BEHAVIORAL|volitional intervention|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
215087909|NCT02109523|BEHAVIORAL|Routine discharge counseling|
215087910|NCT02639338|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
215087911|NCT02639338|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
215087912|NCT04573426|DRUG|Acetaminophen|1,000mg liquid acetaminophen
215087913|NCT04573426|DRUG|Placebo|Liquid placebo solution
214492511|NCT06745830|OTHER|No intervention|No intervention
214492512|NCT06893848|OTHER|Culture Care program|"The Culture Care program modernizes the in-hospital environment by including art and culture proposed in the form of an individualized pathway. It will be offered primarily to hospitalized patients, but also available to families, caregivers and healthcare professionals. It will aim to create a new hospital experience, different from the one we've always known.~The Culture Care program will display posters illustrating works of art (paintings, drawings, photographs, etc.) along the hallways. These posters will be interactive, so that a QR code can be scanned to access musical content and audio podcasts (interviews and documentaries) accessible via bone-conduction headphones.~The Culture Care program is likely to reduce the sedentary behavior of hospitalized patients, by providing an attractive in-hospital environment that is likely to produce both physical and psychological benefits."
215087914|NCT04573426|BEHAVIORAL|Weight stigma vignette|Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
215087915|NCT04573426|BEHAVIORAL|Control vignette|Short vignette meant to have no effect on emotion describing a generic promotion process
215087916|NCT05922072|PROCEDURE|Nasogastric aspiration for measurement of Residual Gastric Volume|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
215087917|NCT05922072|PROCEDURE|Nasogastric Aspiration for Measurement of Gastric pH|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
215087918|NCT04609930|DRUG|Anti-PD-1 or anti-PD-L1|Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
214981233|NCT01380366|PROCEDURE|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
214981234|NCT01380366|OTHER|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
214368579|NCT06969456|PROCEDURE|TDCS|The transcranial direct current stimulation (tDCS) protocol will involve the application of a continuous current for 30 minutes, with an intensity ranging from 1 to 1.5 mA, targeting the left dorsolateral prefrontal cortex (DLPFC) during each session. Two saline-soaked sponge electrodes, each measuring 35 cm², will be employed to ensure adequate skin contact. In accordance with the international 10-20 EEG electrode placement system, the anodal electrode will be positioned at the F3 location, specifically targeting the left DLPFC. The reference electrode will be placed above the left eye to facilitate efficient current flow through the prefrontal region of the brain. To enhance both safety and efficacy, a 30-second ramp-up and ramp-down period will be incorporated at the commencement and conclusion of the stimulation session. This methodology is intended to minimize potential adverse effects and ensure an optimal stimulation experience for participants.
214492513|NCT06745557|BIOLOGICAL|denovoSkin(TM)|Transplantation of autologous dermo-epidermal skin substitute denovoSkin(TM) to the experimental area
214981235|NCT01380366|OTHER|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
214981236|NCT01380366|OTHER|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
214981237|NCT02295644|DEVICE|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
214981238|NCT03056924|BIOLOGICAL|Pneumococcal Pneumonia vaccine|Vaccination for pneumococcal pneumonia will be carried out with either the PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ) or the PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA). Either vaccine is administered in a single dose of 0.5 mL intramuscularly.
214981239|NCT03056924|BIOLOGICAL|Influenza vaccine|Influenza vaccination will be carried out with the 2017-2018 trivalent component vaccine (Afluria, Seqirus USA Inc., King of Prussia, PA) or for patients over 65 years of age (Fluzone, Sanofi Pasteur, Swiftwater, PA). Both of these vaccines are administered in a single dose of 0.5 mL intramuscularly.
214981240|NCT03056924|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccination with be carried out with a single antigen, recombinant hepatitis B vaccine (Energix B, GlaxoSmithKline, Research Triangle Park, NC). This vaccine is administered in a three dose series with 1.0 mL given intramuscularly at 0, 1, and 6 months. For patients receiving a booster, a single intramuscular dose of 1.0 mL will be given.
214981241|NCT02820662|OTHER|RETCAM|
214680617|NCT03604614|DRUG|Hyperthermic Intraperitoneal Chemotherapy|The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
214492514|NCT06745557|OTHER|STSG|Transplantation of autologous split-thickness skin to the control area
214492515|NCT06745739|BEHAVIORAL|Life Skills Training Workplace Prevention Program|A workplace health promotion intervention for youth age 16-24, adapted from the school-based Life Skills Training program. The program teaches participants the skills necessary to be productive in work and personal settings while also promoting healthy behaviors and preventing or reducing health risk behaviors. Program content focuses on goal-setting and problem-solving skills, stress and anger management skills, effective communication and conflict management skills, time and financial management, substance use risk reduction, and how to contribute to a healthy, safe, and drug-free workplace.
214492516|NCT06883539|DRUG|LXP1788 is administered intravenously via Port-A|LXP1788 Injection is formulated as a solution for injection and will be administered intravenously for 60 minutes on days 1, 8, 15, 22 of the cycle. Each cycle will be 28 days.
214492517|NCT06884696|OTHER|Blood samples for inflammatory markers|Blood sampling
214680618|NCT03604614|DRUG|Without Hyperthermic Intraperitoneal Chemotherapy|The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
214680619|NCT04654325|DIAGNOSTIC_TEST|conjunctival swab|Patients will have conjunctival swab for SARS-CV-2 genome detection
214981242|NCT02820662|BIOLOGICAL|Blood samples|
214981243|NCT06369480|PROCEDURE|Resection/Ablation of tumor|Curative treatment
214981244|NCT06369480|PROCEDURE|Palliative chemotherapy|Chemotherapeutic medications
214981245|NCT06369480|PROCEDURE|Neoadjuvant chemotherapy|Chemotherapeutic medications after surgery
214492518|NCT06884696|OTHER|Placental Extract|Placental sampling after caesarean section
214981246|NCT06369480|PROCEDURE|Stereotatic radiotherapy|Radiotherapy
214492519|NCT06752226|OTHER|action observation trainingAOT refers to an observational practice that has been used extensively for the goal of motor programming and enhances motor learning and performance|In AOT, motor-related information can be available through the visual function by encoding into the mental representation of the memory to organize the intended action
214680620|NCT00031577|DRUG|paclitaxel|
214680621|NCT00031577|RADIATION|radiation therapy|
214981247|NCT06369480|PROCEDURE|Best supportive care|Symptomatic treatment, non-curative treatment
214981248|NCT04365335|BEHAVIORAL|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
214981249|NCT04365335|BIOLOGICAL|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: DHEA, cortisol and chromogranine A levels
214981250|NCT04365335|OTHER|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
214981251|NCT04365335|BEHAVIORAL|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
214981252|NCT00650962|OTHER|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
214981253|NCT00650962|OTHER|Rhythm analysis|Rhythm analysis as soon as AED is ready
214981254|NCT01995916|BEHAVIORAL|Mindfulness Intervention|The Mindfulness Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
214981255|NCT01995916|BEHAVIORAL|Social Support Group|The Social Support Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
214981256|NCT03915743|OTHER|palliative care|complex and multi-faceted individualized palliative care
214981257|NCT00580320|DRUG|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
214981258|NCT03377439|OTHER|Platelet function tests|Platelet reactivity was measured by flow cytometry, filopodia detection and the platelet aggregation analyzer.
214981259|NCT05821049|OTHER|UPI65 (Low Dose)|Red colored Capsules
214981260|NCT05821049|OTHER|UP165 (High Dose)|Red colored Capsules
214981261|NCT05821049|OTHER|Placebo|Red colored Capsules
214981262|NCT00324155|DRUG|Ipilimumab|"Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent~In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression"
214981263|NCT00324155|DRUG|Placebo|Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
214981264|NCT00324155|DRUG|Dacarbazine|Intravenous solution; intravenous; 850 mg/m\^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
214981265|NCT02204189|DRUG|TongFuSan|TongFuSan 1g
214981266|NCT05964062|DEVICE|active rTMS treatment|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
214981267|NCT05964062|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
214981268|NCT02531685|OTHER|Placebo|Placebo: 0.9% Sodium Chloride injection.
214981269|NCT02531685|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.
214981270|NCT04817878|COMBINATION_PRODUCT|Developmental assessment|Physical development assessment (head circumference, length, weight), Neurodevelopment assessment at 36 to 40 weeks of correction (GMS assessment, NBNA assessment), neurodevelopment assessment at 18 months, 24 months, and 36 months (ASQ scale, Language assessment, Wei-style scale), audiovisual screening, etc.
214981271|NCT03021915|OTHER|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
214981272|NCT00075075|DRUG|Infliximab|
214981273|NCT02768987|BEHAVIORAL|Bright 1 Bodies|A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
214981274|NCT06144372|DEVICE|Electroconductive and Electrohydraulic types|The patients were randomly assigned to two types of lithotripter.
214981275|NCT04800497|PROCEDURE|Hepatic resection|Hepatic resection for HCC
214981276|NCT05677399|OTHER|aquatic exercise and peloidotherapy|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
214981277|NCT02928484|DIETARY_SUPPLEMENT|Probiotic mix CBP-004019/C|One capsule per day of the probiotic mix CBP-004019/C during one month.
214981278|NCT02928484|DIETARY_SUPPLEMENT|Placebo|One capsule per day of the placebo (maltodextrin) during one month.
214981279|NCT03546465|DRUG|ropeginterferon alfa-2b|6 subjects in each cohort will receive a single dose by subcutaneous injection
214981280|NCT03307174|DRUG|Bupivacaine|
214981281|NCT03307174|DRUG|Fentanyl|
214981282|NCT02173613|OTHER|procalcitonine|"The recommendations will be based on the level of PCT: 4 levels of advice will be given:~* It is highly recommended to stop antibiotics if PCT \<0.1ng/ml, and the recommended stop if 0.1ng/ml \<PCT \<0.25 ng / ml.~* It is recommended to continue treatment if 0.25 ng / ml \<PCT ng / ml.~* Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level."
214981283|NCT01923519|PROCEDURE|bronchofiberscopy|
214981284|NCT05017844|DRUG|KSR-001-04|One drop to both eyes four times a day for 12 weeks
214492520|NCT06747104|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension
214368580|NCT06969456|PROCEDURE|ShamTDCS|The device will be configured to produce an upward gradient for 30 seconds, identical to that used in the experimental group, followed by a downward gradient for another 30 seconds. Consequently, the control group will feel a similar tingling on their scalp as the experimental group. This stimulation will occur for a total of 60 seconds, which is insufficient to induce changes in cortical excitability. Studies have demonstrated that this approach effectively ensures patient blinding.
214680622|NCT06287125|DEVICE|Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147|"Laboratory investigations:~erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021).~Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field).~24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA).~Serum CD147~Radiological investigations:~* Chest X-ray~* Renal Doppler~* Multi-parametric MRI"
214981285|NCT05017844|DRUG|KSR-001-02|One drop to both eyes four times a day for 12 weeks
214981286|NCT05017844|DRUG|KSR-001-03|One drop to both eyes four times a day for 12 weeks
214981287|NCT03179358|DEVICE|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
214981288|NCT05948085|DRUG|Zavegepant 10 mg IN|All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
214981289|NCT04519424|BIOLOGICAL|CSL324|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
214981290|NCT04519424|DRUG|Placebo|Normal saline (0.9% sodium chloride)
214981291|NCT01012050|DEVICE|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
214981292|NCT01012050|OTHER|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
214981293|NCT01096940|DRUG|AZD1656|Oral tablet, BID dose
214981294|NCT01096940|DRUG|simvastatin|Oral tablet, single dose
214981295|NCT01760902|BEHAVIORAL|Diet and Physical Activity|The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
214981296|NCT00158808|BIOLOGICAL|Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib|
214368581|NCT06971588|OTHER|Music intervention|The intervention will involve patient-chosen music.
214981297|NCT00846053|DIAGNOSTIC_TEST|FDG-PET|All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, \[18F\]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue \[18F\] FDG uptake. Patlak graphical analysis was used to determine the rate of \[18F\]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.
214981298|NCT01334294|DEVICE|ForeseeHome|The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.
214981299|NCT00111761|DRUG|Irinotecan|Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.
214981300|NCT00111761|BIOLOGICAL|Panitumumab|Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
214492521|NCT06747104|OTHER|Placebo|Performing manipulations without a two-second preliminary tension of the joint capsule in the shoulder and elbow joints.
214492522|NCT06750575|DIAGNOSTIC_TEST|Invasive measurements|Blood and urine samples will be collected during the study.
214981301|NCT00111761|DRUG|5-Fluorouracil|Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.
214981302|NCT00111761|DRUG|Leucovorin|Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
214981303|NCT01824017|OTHER|Blood Draw|
214981304|NCT02386852|DRUG|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
214981305|NCT02386852|DRUG|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
214981306|NCT02386852|DRUG|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
215087919|NCT00576030|OTHER|hab cof with water|habitual coffee drinker provided with water
214680623|NCT04019496|DRUG|antibodies against calcitonin-gene related peptide or its receptor|the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
214680624|NCT00204633|DRUG|Darbepoetin alfa|
214680625|NCT06757140|DRUG|Alprazolam|Participants will receive varying non-therapeutic experimental doses of oral alprazolam, alone and in combination with oral oxycodone
214680626|NCT06757140|DRUG|Oxycodone|Participants will receive varying non-therapeutic experimental doses of oral oxycodone, alone and in combination with oral alprazolam
214680627|NCT06757140|DRUG|Placebo|Participants will receive inactive oral doses
214492523|NCT06842550|BEHAVIORAL|MAintAin Activity with Arthritis|Participants will receive up to five health coaching sessions led by a trained provider. The aim is to motivate people to meet their physical activity goals, look at their options, make choices and plans, identify challenges, and help them through these changes related to their physical activity and maintenance. Session 1: One to one session with a physical activity coach Session 2-5: Group sessions with approx. 8-10 other people living with arthritis. In the sessions participants will: • Set, reflect and adapt your activity goals • Learn to problem solve • Develop action plans to build new habits. • Learn about opportunities such as walking groups, aqua aerobics and yoga classes are available in your community • Have the support of peers in the group. Please note that these sessions are not exercise classes.
214492524|NCT06845540|DRUG|Metformin|Participants received oral metformin tablets for the treatment of melasma. The initial dose was 500 mg once daily for four weeks. At week 4, participants who tolerated the medication well increased their dose to 500 mg twice daily for the remaining eight weeks of the study. Participants were instructed to avoid other melasma treatments during the trial and to use sunscreen (SPF 30 or higher) daily.
214981307|NCT04918862|DRUG|Granisetron|210 patients were enrolled, divided into two groups \[Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron\]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery
215087920|NCT00576030|OTHER|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
214368582|NCT04196426|BEHAVIORAL|Nutrition education intervention about osteoporosis and calcium|The intervention is designed and developed based on the Intervention Mapping Process and the Health Belief Model. Topics of the intervention include: the importance of osteoporosis and risk factors, role of calcium in bone health and controlling the disease, calcium recommendations and sources, role of vitamin D and physical activity in calcium absorption and bone health, and how to identify calcium-rich foods in the locality and prepare meals with local calcium-rich foods. A recipe booklet containing recipes using local calcium-rich foods will be given to the participants after the end of the two nutrition lessons. Interactive activities are incorporated in each lesson to encourage the participation of participants.
214368583|NCT05340855|BEHAVIORAL|Wiidookaage'win Facebook Group|A 30-day Facebook group prototype that is moderated by two women who will post various forms of media addressing opioid recovery, mindfulness, stress management, and resiliency.
214368584|NCT00033358|DRUG|medroxyprogesterone|Given intramuscularly
214368585|NCT00033358|DRUG|ethinyl estradiol|Given orally
214368586|NCT00033358|DRUG|norgestrel|Given orally
214368587|NCT00033358|OTHER|laboratory biomarker analysis|Correlative studies
214368588|NCT01951638|DRUG|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
214368589|NCT01951638|DRUG|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
214368590|NCT01951638|DRUG|Placebo|
214368591|NCT01185067|DRUG|grape seed extract (MegaNatural BP, Polyphenolics, Inc.)|Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
214368592|NCT01811212|DRUG|Cabozantinib S-malate|Given PO
214368593|NCT01811212|OTHER|Laboratory Biomarker Analysis|Correlative studies
214368594|NCT04648540|DRUG|Dexmedetomidine 0.5 mic/kg/h|"In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~* Dexmedetomidine 0.5 mic/kg/h~* Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours"
214368595|NCT04648540|DRUG|Fentanyl 1 mic/kg/hr|In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
214368596|NCT03684486|BEHAVIORAL|rehabilitation by effort|
214492525|NCT05763966|OTHER|No intervention|Observational study where participants are followed over time
214492526|NCT06798818|DEVICE|Ultra-rapid therapeutic hypothermia induction by total liquid ventilation|Vent2Cool System is a targeted temperature management device used to induce ultra-rapid therapeutic hypothermia by total liquid ventilation.
214492527|NCT06849570|OTHER|Minimal distension|Patients receive tidal volume (VT) of 6 mL/kg and conservative positive end-expiratory pressure (PEEP) setting.
214492528|NCT06849570|OTHER|Maximal Recruitment|Patients receive tidal volume adjusted to limit plateau pressure (∆P) to 14 cmH2O and the highest possible PEEP while maintaining plateau pressure (PPLAT) ≤ 27 cmH2O.
215087921|NCT00576030|OTHER|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
215087922|NCT00576030|OTHER|non-hab cof with water|non-habitual coffee drinkers given water
214368597|NCT00421720|DRUG|Sufentanil|
214368598|NCT00421720|DRUG|Remifentanil|
214492529|NCT06849570|OTHER|Prone position + early NMBAs|NMBAs given as soon as possible after randomization
214492530|NCT06849570|OTHER|Prone position + rescue NMBAs|NMBAs given only as a rescue
214680628|NCT05091489|OTHER|Qualitative assessment about PrEP acceptability|Qualitative research among key-populations, community and healthcare workers, and decision and policy makers, including focus group and semi-directive interviews
214680629|NCT02444637|DRUG|Rivastigmine|
214981308|NCT00746551|DRUG|Ferli-6® (Continental Pharm co., ltd.)|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
214981309|NCT00746551|DRUG|Venofer® (Vifor AG, St. Gallen, Switzerland)|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
214981310|NCT05621161|DRUG|Postoperative analgesia management|Intravenous paracetamol 1 gr and a dose of 0,5 mg/kg-1 tramadol intravenously will be performed on all patients 30 min before the end of the surgery for postoperative analgesia. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol including 10 mg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine IV will be administered.
214981311|NCT04265677|OTHER|Telemedicine FCR|Parents/guardians will be able to join family centered rounds using telemedicine (audio and visual)
215087923|NCT00576030|OTHER|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
215087924|NCT00576030|OTHER|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
215087925|NCT00493636|DRUG|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
214368599|NCT03163355|OTHER|a gelling agent|Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
214981312|NCT04265677|OTHER|Standard of care|Parents/guardians will not be able to join family centered rounds using telemedicine (audio and visual)
214368600|NCT00032279|DRUG|Visilizumab|
214368601|NCT01080508|OTHER|tracheal ventilation with regular tube|Description of the pressure waveforms during tracheal ventilation
215087926|NCT00493636|DRUG|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
215087927|NCT00493636|DRUG|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
215087928|NCT00493636|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
215087929|NCT01893359|DRUG|riboflavin ophthalmic solution, 0% dextran|
215087930|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
214368602|NCT01080508|OTHER|ventilation after intubation with special tube|Description of the pressure waveforms during esophageal ventilation
214368603|NCT06139757|DEVICE|Oura ring|Patient will wear Oura ring before and after embryo transfer. They will be blinded to sleep data during this period. Thus the intervention of wearing the ring to track sleep will not affect outcomes, but rather track the outcome of sleep.
214368604|NCT04523155|DIETARY_SUPPLEMENT|Medically tailored meals|10 meals per week for 3 months
214368605|NCT02080780|DRUG|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
214368606|NCT02080780|DRUG|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)
214368607|NCT02382068|DRUG|Dexamethasone|Given via intratympanic injection
214368608|NCT02382068|OTHER|Placebo|Given via intratympanic injection
214368609|NCT02382068|DRUG|Cisplatin|"Standard of care treatment with the following treatment course criteria:~1. Dose: \> 50 mg/m2~2. Frequency: q3 -q4 weeks~3. Cycles: 7 maximum"
214368610|NCT05606757|DRUG|BOTOX Dose A|Injection; intramuscular
214368611|NCT05606757|DRUG|Placebo for BOTOX|Placebo
214368612|NCT05606757|DRUG|BOTOX Dose B|Injection; intramuscular
214368613|NCT05606757|DRUG|BOTOX Dose C|Injection; intramuscular
214368614|NCT00451165|PROCEDURE|laparoscopic colorectal surgery|laparoscopic colorectal surgery
214368615|NCT00724581|DRUG|Amiodarone|intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
214368616|NCT04923113|DIAGNOSTIC_TEST|Histology，13C urea breath test，Stool antigen test，Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori|The above 5 detection methods will be performed in patients who meet the inclusion criteria to detect H. pylori infection
214368617|NCT04923113|DRUG|Rabeprazole，Minocycline，Amoxicillin and Colloidal bismuth pectin|Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days
214368618|NCT04451122|OTHER|cleansing the eyelid margins|using eyelid cleaning wipes to cleansing the eyelid margins
214368619|NCT00282893|PROCEDURE|transluminal ballooning|
214368620|NCT00282893|OTHER|currently existing therapies for the treatment of vasospasm|
214368621|NCT06336616|BEHAVIORAL|Behavior Activation|Participants will be taught to identify meaningful activities, set goals, use environmental cues, self-reward, to identify barriers and facilitators, and learn new skills to support them to develop self-management skills and new habits.
214368622|NCT03642041|BEHAVIORAL|smoking|smoking behavior
214368623|NCT05563194|DEVICE|Heating prototype (Prototype 1)|A wearable that heats and vibrates to help distract from pain. It can be wrapped around any joint with temperature and vibration settings allowing CYP to set the device to their needs.
214368624|NCT05563194|DEVICE|Physio tool (Prototype 2)|A motivational physiotherapy tool that incrementally lights up as the CYP do their prescribed stretches, emphasising a sense of progression and making it a more engaging activity.
214368625|NCT05563194|DEVICE|Communication tool (Prototype 3)|A wearable to help communication in the classroom between the teacher and pupil. The child can alert the teacher if they need help, through vibration, without attracting the attention of their classmates, reducing embarrassment.
214368626|NCT04417686|PROCEDURE|arterial embolization|arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
214368627|NCT01298505|DRUG|PF-03654764 2.5mg plus fexofenadine 60mg|PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
214368628|NCT01298505|DRUG|PF-03654764 5mg plus fexofenadine 60mg|PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
214368629|NCT01298505|DRUG|placebo|placebo given twice daily for 7 days
214368630|NCT00459342|DRUG|dasatinib|Given orally
214368631|NCT02686034|DEVICE|gammaCore-S|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
214981313|NCT01220791|OTHER|In vitro fertilization treatment for infertility|IVF treatment
214981314|NCT03962361|OTHER|Concentration of circulating microparticles.|The microparticles contained in the blood sample will be isolated by ultracentrifugation and quantified by flow cytometry. The microparticles concentration will be determined by the number of microparticles per uL of plasma, based on the volume of the sample, the flow rate of the cytometer and the number of fluorescent events.
214981315|NCT02707497|DRUG|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
214981316|NCT02707497|DRUG|Placebo|The control group will not use any platelet-increased drugs.
214981317|NCT00496561|BIOLOGICAL|subcutaneous immunotherapy (House Dust Mites)|subcutaneous immunotherapy (House Dust Mites)
214981318|NCT00496561|OTHER|placebo of subcutaneous immunotherapy (House Dust Mites)|placebo of subcutaneous immunotherapy (House Dust Mites)
214981319|NCT05123573|BEHAVIORAL|Clinical Skills|evaluate the students' ability to demonstrate essential clinical skills, clinical reasoning and problem-solving skills, management of life-threatening medical conditions, management of common medical problems, and placing the patients' needs and safety at the center of the care process.
214981320|NCT01317563|DIETARY_SUPPLEMENT|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
214981321|NCT01317563|DIETARY_SUPPLEMENT|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
214981322|NCT05545475|DRUG|Low molecular weight heparin|Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
214981323|NCT02385786|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
214981324|NCT00171249|DRUG|STI571 400 mg|STI571 capsules and tablets
214981325|NCT00171249|DRUG|STI571 600 mg|STI571 capsules and tablets
214981326|NCT06202859|DEVICE|MIE|Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.
214981327|NCT03786835|OTHER|Protein supplementation and regular physical activity|To determine if high protein diet and/or regular physical activity improves muscle and bone health
214981328|NCT00244439|DRUG|MALG|30 minute application
214368632|NCT02686034|DEVICE|gammaCore-S Sham|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
214368633|NCT01440426|PROCEDURE|Autologous connective tissue graft with rotated papilla flap|Subepithelial connective tissue graft harvested from hard palate
214368634|NCT01440426|DEVICE|Collagen matrix construct (Mucograft)|Mucograft Collagen Matrix combined with rotated papilla flap
214368635|NCT00468221|DRUG|Ozone Exposure|Low dose ozone exposure in chamber
214368636|NCT03256825|DIAGNOSTIC_TEST|Rapid diagnostics alone|Urine samples present at the laboratory at opening on weekdays will be screened using urine flow cytometry and microscopy of centrifuged gram stained urine. Samples found positive for significant mono microbial bacteriuria will be investigated further by using direct automated phenotypic identification and antimicrobial susceptibility determination.
214981329|NCT00244439|DRUG|Ovide (malathion) lotion 0.05%|8-12 hour application
214981330|NCT00244439|DRUG|Permethrin 1%|10 minute application
214981331|NCT02462265|DRUG|Oshadi D & Oshadi R;|Oshadi D (180mg/TID) \& Oshadi R (180mg TID) will be administrated;
214981332|NCT02462265|DRUG|salvage therapy cytosar and mitoxantrone|Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
215087931|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
214368637|NCT03256825|OTHER|Real-time antimicrobial stewardship decision support|"A clinical microbiologist will be give RADS by phone to a designated clinician with the aim of:~1. Switch to active treatment if non-working empirical treatment~2. De-escalate broad spectrum empiric treatment when feasible~3. Promote early intravenous to per oral switch~4. Shorten treatment duration"
214368638|NCT02154984|BEHAVIORAL|behavioral dietary intervention|Follow tRD
214368639|NCT02154984|BEHAVIORAL|telephone-based intervention|Receive coaching calls
214368640|NCT02154984|OTHER|laboratory biomarker analysis|Correlative studies
214368641|NCT03846102|DRUG|Levobupivacaine|Levobupivacaïne for injection 7.5 mg/kg diluted with Sodium Chloride 0,9%
214981333|NCT04386785|DEVICE|Radiofrequency (RF) Thermal Ablation of Incompetent Perforator Veins|The physician operator will access the IPV and advance the device to the target treatment position using ultrasound guidance. After providing local anesthesia to the vein and surrounding tissues, thermal ablation energy is delivered to the vein wall. After treatment is complete, the device is removed and vessel closure confirmed with duplex ultrasound.
214981334|NCT02025608|DRUG|Pramipexole|
214981335|NCT02025608|DRUG|Placebo|
214981336|NCT06545305|PROCEDURE|Lensectomy and vitrectomy|Corrections
214981337|NCT01202500|PROCEDURE|reducing treatment to 3 months|The treatment will be stopped after 3 months
214981338|NCT01202500|PROCEDURE|registered length of treatment|The treatment procedure will follow the actual recommandation
214981339|NCT03826251|PROCEDURE|Nasogastric tube removal|Nasogastric tube was removed immediately after surgery
214981340|NCT02797028|DIETARY_SUPPLEMENT|Anthocyanidins capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
214981341|NCT02797028|DIETARY_SUPPLEMENT|Placebo capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
214981342|NCT02797028|DRUG|Allopurinol|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
215087932|NCT01893359|PROCEDURE|Laser-assisted in situ keratomileusis|
215087933|NCT01394887|DRUG|Metformin|850 mg of metformin twice daily over 12 weeks
215087934|NCT01394887|DRUG|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
215087935|NCT06077370|DEVICE|deep TMS|Deep Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
214680630|NCT05060991|DRUG|Reduction in antimetabolite immunosuppression|Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination
214981343|NCT04014010|OTHER|Blood pressure|"Systolic Blood Pressure (SBP)~1. Maximum change from preoperative SBP, in a) absolute change (mmHg), and b) relative change (%)(emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative SBP~3. Longest single episode (minutes) below a) 80, b) 90, and c)100 mmHg~4. Cumulative duration (minutes) below a) 80, b) 90, and c)100 mmHg~Mean Arterial Pressure (MAP)~1. Maximum change from preoperative MAP, in a) absolute change (mmHg), and b) relative change (%) (emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative MAP~3. Longest single episode (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg~4. Cumulative duration (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg"
214981344|NCT04014010|OTHER|Heart rate|"1. Maximum change (beats per minute, BPM) from preoperative heart rate (positive and negative)~2. Relative change (%) from preoperative heart rate (positive and negative)~3. Maximum pulse variation (maximum heart rate minus minimum heart rate)~4. Longest single episode (minutes) a) below 60, and b) above 100BPM~5. Cumulative duration (minutes) a) below 60, and b) above 100BPM"
214492531|NCT06845917|DEVICE|Remote Patient Monitoring system|"RMS consists of an initial assessment visit and system installation: A nurse trained by the EPOCA team will conduct a comprehensive assessment of the patient's needs during a home visit within 48 hours of enrollment. This includes collecting biometric measurements, socio-economic profile, and completing a questionnaire with the patient. The initial visit also includes a consultation with a physician. All the information is transmitted to a digital platform accordingly a personalized care plan (PCP) will be defined. The nurse installs a telemonitoring kit for the patient and gives them instructions on how to use it.~The PCP manager will be responsible for implementing and overseeing the patient care plan, including informing the relevant stakeholders. Patients will be monitored via regular data feedback from the connected devices, the physician and the PCP manager. The PCP manager will treat any identified anomalies or abnormalities and implement the necessary changes on the PCP."
214680631|NCT05547438|DRUG|NTS-104 TRIS|Subjects will receive a single IV infusion of either 0.8, 4, 8, or 16 mg/mL NTS-104 depending on the Cohort number
214492532|NCT03778944|PROCEDURE|Mannitol infusion|Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
214492533|NCT03778944|PROCEDURE|Dopamine infusion|Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
214680632|NCT05547438|DRUG|Placebo|Subjects will be administered an IV infusion of placebo and the same duration and volume as the subjects administered NTS-104 TRIS in the cohort
214981345|NCT04014010|OTHER|Use of hemodynamic medications (i.e. special medications for blood pressure)|"1. Vasopressor/inotrope use (yes vs. no): phenylephrine, norepinephrine, epinephrine, vasopressin, dobutamine, or milrinone~2. Infusion of any vasopressor/inotropes above (yes vs. no) (identified by unit of weight over time)~3. Phenylephrine/ephedrine bolus (yes vs. no) (identified by unit of weight only)~4. Vasodilator use (yes vs. no): labetalol, esmolol, nitroglycerin, nitroprusside~5. Infusion of any vasodilator above (yes vs. no) (identified by unit of weight over time)"
214981346|NCT04014010|OTHER|Oxygen saturation by pulse oximetry (SpO2)|"1. Longest single episode (minutes) below a) 88, and b) 90%~2. Cumulative duration (minutes) below a) 88, and b) 90%"
214981347|NCT04014010|OTHER|End-tidal Carbon dioxide (EtCO2)|"1. Longest single episode (minutes) a) below 30, and b) above 45mmHg~2. Cumulative duration (minutes) a) below 30, and b) above 45mmHg"
214492534|NCT03778944|PROCEDURE|Adequate hydration|Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
214492535|NCT06860139|BEHAVIORAL|Health literacy intervention|The intervention will be developed in co-creation with patients and nurses in the clinic, based on their needs.
214492536|NCT06754774|DIAGNOSTIC_TEST|Shoulder Endurance Test|Each patient receive the same intervention, the Shoulder Endurance Test (SET). The Shoulder Endurance Test assesses the endurance of the shoulder muscles in an open kinetic chain.
214680633|NCT02811458|BEHAVIORAL|Transdiagnostic Cognitive-Behavioral Therapy|Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
214680634|NCT02620332|DRUG|MultiPepT1De injection|A mix of peptides
214680635|NCT02620332|OTHER|Placebo|Water for injection
214680636|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwN) plus active varenicline tablets|"The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes.~EC device:~Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid.~Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph."
214981348|NCT03435588|PROCEDURE|EUS|Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.
214680637|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline|"The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL).~Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph."
214680638|NCT03630614|DRUG|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline|The ECwN group use EC liquids containing 12 mg/mL of nicotine. Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
214680639|NCT01513798|BEHAVIORAL|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
214981349|NCT03435588|PROCEDURE|FNA with ROSE|Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.
215087936|NCT06077370|DEVICE|Sham TMS|Sham Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
214368642|NCT03846102|DRUG|Placebo|Sodium Chloride 0,9% for injection/infusion.
214492537|NCT06755801|DRUG|Nevibolol|Beta-blockers are the first-line treatment for patients with stable angina secondary to classic epicardial atherosclerotic disease, where their clinical benefits are well-established (4). However, their efficacy has not yet been demonstrated in ANOCA patients with MVD, where beta-blockers are frequently used due to their physiological plausibility. Beta-blockers act by competitively inhibiting catecholamine receptors. The therapeutic benefits of beta-blockade in patients with stable angina are mediated by a reduction in myocardial oxygen demand. Myocardial oxygen demand depends on heart rate, contractility, and left ventricular wall tension, all of which are reduced with beta-adrenergic blockade. The reduction in wall tension is partly mediated by the antihypertensive action of these drugs. The decrease in heart rate occurs both at rest and during sympathetic activation such as exercise or stress. The negative inotropic effect of these drugs also contributes to reducing myocardial oxyg
214492538|NCT06755801|DRUG|Placebo|Placebo
214981350|NCT03435588|PROCEDURE|FNB alone|Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).
214981351|NCT02779140|BIOLOGICAL|NTM-1632|Monoclonal antibody mixture of XB10, XB18, and XB23
214981352|NCT02779140|OTHER|Placebo|Placebo
214492539|NCT06878742|DRUG|Intravenous dobutamine 5 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 5 mcg/kg/min.
214981353|NCT00333567|DRUG|Lumiracoxib|
214981354|NCT02037672|DRUG|metformin|
214981355|NCT02037672|DRUG|metformin and roflumilast|
214981356|NCT03209479|DRUG|Glatiramer acetate|Copaxone subcutaneous injection syringe
214981357|NCT00502567|DRUG|AZD2171|oral tablet once daily
214368643|NCT03846102|DRUG|Acetaminophen|Acetaminophen 500 milligram tablet
214368644|NCT03846102|DRUG|Morphine|Morphine 1 mg/ml solution for infusion.
214368645|NCT03846102|PROCEDURE|Fascia Iliaca Compartment Block with Levobupivacaine|Ultrasound guided Fascia Iliaca Compartment Block with levobupivacaine placed in the emergency department by an emergency physician.
214368646|NCT03846102|PROCEDURE|Fascia Iliaca Compartment Block with placebo|Ultrasound guided Fascia Iliaca Compartment Block with placebo placed in the emergency department by an emergency physician.
214368647|NCT05140330|BEHAVIORAL|ALAPAGE workshop|7 weekly group sessions over 2 months (1 introduction session, 2 physical activity sessions and 4 nutrition sessions) and 1 evaluation session at 3 months
214492540|NCT06878742|DRUG|Intravenous dobutamine 7.5 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 7.5 mcg/kg/min.
214492541|NCT06878742|DRUG|Intravenous dobutamine 10 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 10 mcg/kg/min.
214492542|NCT06878742|DRUG|Intravenous dobutamine 12.5 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 12.5 mcg/kg/min.
214492543|NCT06878742|DRUG|Intravenous dobutamine 15 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 15 mcg/kg/min.
214492544|NCT06617923|DRUG|Senaparib|Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.
214492545|NCT06617923|DRUG|Temozolomide|Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.
214492546|NCT06743724|DEVICE|repeated transcranial magnetic stimulation treatment|Patients with low score of Maternal Care Rating Scale received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 2 week.
214981358|NCT00502567|DRUG|FOLFOX|intravenous infusion
215087937|NCT00201123|DRUG|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
215087938|NCT00201123|DRUG|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
215087939|NCT00201123|OTHER|Placebo|
214492547|NCT06763276|OTHER|Virtual Reality Group|In the study, a 400-gram virtual reality (VR) headset with an anti-reflective lens system was used, compatible with all earphones with screens ranging from 4.5 to 7.0 inches. The virtual reality (VR) headset, which was lightweight enough for children to wear, was supported on three sides to fit securely on the children's heads and was disinfected after each use. For the experimental group, the compartment at the front of the virtual reality (VR) headset was removed. The earphone was placed into the removed compartment, which was then reinserted. Subsequently, the YouTube virtual reality (VR) feature was activated on the phone, making it ready for viewing.
214492548|NCT06765577|OTHER|Finger Blood Pressure Measurement|Finger Blood Pressure Measurement were taken from three digits: the thumb (F1), the middle finger (F2), and the little finger (F3) from both arms.
214492549|NCT06752525|DRUG|Bupivacaine|patients will receive SPGB block with 2 ml volume on each side (1.5 mL of bupivacaine 0.5% + 0.5 mL of magnesium sulphate 10%).
214492550|NCT06752525|DRUG|Magnesium Sulphate 500 mg|patients will receive SPGB block with 2 ml volume on each side (1.5 ml bupivacaine 0.5% plus 0.5 ml saline).
214368648|NCT05140330|BEHAVIORAL|control workshop|3 evaluation group sessions over 2 months and 1 session at 3 months. After those 4 sessions, the participants will benefit from an ALAPAGE workshop
214368649|NCT02775955|DRUG|RX0041|Active
214368650|NCT04578327|DEVICE|Prosthetic hand|Different types of conventional prosthetic limbs will be used by subjects.
214368651|NCT04578327|PROCEDURE|Peripheral Nerve Interface|Different types of peripheral nerve stimulation will take place
214368652|NCT03659422|OTHER|Modified Paleolithic diet|The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
214368653|NCT00566579|PROCEDURE|Cryotherapy|Double freezing technique
214368654|NCT02863679|DRUG|Tetracaine hydrochloride gel|Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
214368655|NCT04665154|DRUG|MAS825|single dose i.v. and s.c.
214368656|NCT04665154|DRUG|Placebo|single dose i.v. and s.c.
214680640|NCT01513798|BEHAVIORAL|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
214981359|NCT00502567|DRUG|Pemetrexed|intravenous infusion
214981360|NCT00502567|DRUG|Irinotecan (administered with & without Cetuximab)|intravenous injection
214981361|NCT00502567|DRUG|Docetaxel|intravenous infusion
214981362|NCT03936569|DRUG|Marketed Toothpaste|Marketed stannous fluoride (0.454%) toothpaste
214981363|NCT03936569|DRUG|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
214981364|NCT03608826|DEVICE|Investigational LINQ™ HF RAMware|The Reveal LINQ™ device and the 2090 programmer are market-released, but once the investigational LINQ™ HF RAMware is downloaded into the devices, they are considered investigational.
214981365|NCT00094991|DRUG|Muraglitazar|
214981366|NCT02694133|PROCEDURE|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
214981367|NCT02694133|PROCEDURE|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
214981368|NCT02171546|DRUG|Dabigatran etexilate capsules|
214981369|NCT02171546|DRUG|Quinidine sulfate tablets|
214981370|NCT02171546|DRUG|Fexofenadine tablets|
214680641|NCT05029115|DRUG|SGLT2 inhibitor|Dapagliflozin, Empagliflozin
214368659|NCT06733090|DRUG|0.12% chlorhexidine glucanate solution|The superiority of two different solutions over each other will be examined with a standard maintenance.
214368660|NCT06733090|DRUG|0.2% chlorhexidine glucanate solution|0.2% chlorhexidine glucanate solution
214368661|NCT06731972|OTHER|Exercises|Classical massage, stretching, functional exercises, electrical modalities, thermal agents, home exercises, etc., plus home exercises.
214368662|NCT06731972|DEVICE|Mobile game|mobile application games (such as Temple Run, Flappy Bird, Angry Birds, etc., or games the patient is already playing) as part of their home exercise program.
214492551|NCT06755541|DRUG|Fenofibrate in Combination With Ursodeoxycholic Acid|Experimental: Fenofibrate 200 mg Capsules
214492552|NCT06766617|OTHER|75 gr Glucose|75g of anhydrous glucose dissolved in 375 ml of water (Vittel) mixed with 150mg of U-13C\]-glucose (stable isotope from Eurisotope, France). will be orally taken
214492553|NCT06771310|OTHER|Endurance exercise|"The exercise-training program will be consisted of 10 minutes warming up, 30 minutes of treadmill walking, and 10 min cooling down three times per week.~Warming up: It will be in the form of stretching of muscle groups for 10 minutes (3-5 stretch for the key muscle group (iliopsoas muscle, gluteus maximus ,quadriceps ,tibialis anterior , calf muscle, hold for 20-30 seconds), before the actual aerobic training session.~Actual session: Participants will receive aerobic exercises in the form of Moderate aerobic exercise training in the form of 30 min of treadmill walking and corresponding to a target heart rate of 65% to 75% of HR max (Maximum HR = 220 - Age ) to be gradually achieved and maintained throughout the training program.~Cooling down: It will be in the form of a treadmill walking at very slow speed for ten minutes."
214680642|NCT00219336|BEHAVIORAL|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
214981371|NCT00072111|BIOLOGICAL|anakinra|
214981372|NCT04824807|OTHER|Yoga|"The yoga classes included a progression of low-impact, modified poses, stretching and isometric exercises focused on the shoulders, arms, and chest, and meditation. Breathing and poses to drain the lymphatic system were incorporated throughout the yoga practice to assist with lymphatic flow.~Exercises: sitting down badrasana, ardha navasana, dhanurasan, setu bandhasana, Urdhva Dhanurasana, Urdhvamukha Svanasana, Virabhadrasana, Warrior Virasana, Supta Virasana, Surya Namaskar, Mayurasana, Padmasana, Bharadvajasana."
214981373|NCT04824807|OTHER|Clinical Pilates|"before starting the clinical Pilates exercise program, the patients were trained on Pilates exercises and postures. During training, the patients were taught how to create lumbopelvic stability (core stabilization), which is the basis for Pilates exercises, and spinal stabilization and appropriate posture techniques.~Exercises: cork screw, toy soldier, kleopatra, the saw,breast stroke preparation, swimming, diamond press - arm openings, scapula isolations, open book, scissors, shoulder bridge."
214981374|NCT04824807|OTHER|An educational booklet|Only educational booklets will be given to the control group
214981375|NCT04422938|OTHER|Manuel chest compressions handled by clinicians|Compressions will be handled by human efforts
214981376|NCT04422938|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS-2 model piston-based mechanical chest compression device was used for mechanical chest compressions
214981377|NCT00461734|OTHER|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
214981378|NCT02236000|DRUG|Neratinib|"Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy"
214981379|NCT02236000|DRUG|T-DM1|"Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
214680643|NCT00219336|BEHAVIORAL|Informational Only|Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
214680644|NCT01869829|DRUG|Observational antifungal therapy|"Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care."
214680645|NCT00108849|DRUG|estradiol, 10 mcg|
214680646|NCT04220489|DRUG|Ketamine|Intraoperative ketamine and post operative 48 hour ketamine infusion with a standardized general anesthesia protocol.
214981380|NCT03723434|DEVICE|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
214981381|NCT03723434|DEVICE|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, St Augustin, Germany).
214981382|NCT03723434|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) will be applied at 1 and 20 Hz with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 300 rTMS pulses will be delivered during 1 and 20 Hz stimulation. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
214981383|NCT03561194|DIETARY_SUPPLEMENT|Omegaven|After the diagnosis of PNALD is made, patients who are followed by the Neonatal Intensive Care Unit, NICU, will contact Dr. Honrubia and Dr. Swarup. Cases may also include referrals of patients with PNALD from other healthcare facilities or self-referrals. If the patient's parents or guardians agree to participate in the study, informed consent will be obtained. The history of present illness and past medical history will be reviewed with the guardian and pertinent demographic and medical information will be recorded on data collection forms. This form will be used to record all laboratory results, nutritional history, and descriptions of any liver biopsies performed.
214368663|NCT06733168|DEVICE|electrical impedance tomography|"Before initiating recruitment maneuver, all patients were placed on mechanical ventilation set according to the ARDSnetwork strategy for 10 minutes, ensuring SpO2 of 88-95%, PaO2 of 55-80 mmHg, and a mean arterial pressure (MAP) ≥ 65 mmHg.~* PEEP was incrementally increased by 5 cmH2O every minute: from 10 to 15, to 20, and finally to 25 cmH2O, with a maximum pressure limit of 40 cmH2O.~* Following recruitment maneuver at the final PEEP level, the process of identifying the optimal PEEP was initiated.~* Then, PEEP will be set to 20 cmH2O and was gradually decreased by 2 cmH2O every 30 seconds until it reached 6 cmH2O or SpO2 dropped to ≤ 80%.~* Selection of optimal PEEP: The optimal PEEP was defined as the intersection point between the alveolar overdistension and collapse curves as measured by the EIT system."
215087940|NCT02541136|BEHAVIORAL|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, \< 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
215087941|NCT05589883|BEHAVIORAL|EMPOWER-Latinx|EMPOWER-Latinx will be delivered in Spanish by videoconferencing (i.e., Zoom, WebEx) with a trained study interventionist. Intervention modules will be audio- and video-recorded (videorecording optional).
214368664|NCT06733168|OTHER|Non-EIT|Patients will have PEEP set using the low FiO2-PEEP table, based on the ARDSnet protocol
214368665|NCT06733857|BEHAVIORAL|VEG2|Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants were instructed to avoid animal products for ≥6 d per wk, focusing their intake on protein-rich non-animal-derived foods (for example, mycoprotein-containing products, pulses, soy). To facilitate reaching protein intake targets, the research team provided participants with mycoprotein-containing vegan products (∼1-2 products per day) to be used as the main protein source for some meals. This group also received 105-g mycoprotein (46-g protein, 10-g carbohydrate, 13-g fat, 348 kcal), 35-g post-training, and 70-g before bed.
215087942|NCT00600769|DRUG|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
214368666|NCT06733857|BEHAVIORAL|OMNI2|Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants in OMNI2 were instructed to consume an omnivorous diet, focusing their intake on high-quality animal-derived proteins (that is, meat, milk, yogurt, cheese). To facilitate reaching protein intake targets, the research team provided participants with a weekly supply (∼1-2 products per day) of chicken or beef to be used as the main protein source for some meals. This group also received 59-g supplemental milk protein daily (47-g protein, 2-g carbohydrate, \<1-g fat, 198 kcal) 19.5-g to drink post-training and 39-g to drink before sleep.
214368667|NCT06733961|DIAGNOSTIC_TEST|SCUBE-1 and VAP-1|There is no other study comparing these biomarkers with healthy volunteers in the diagnosis of pulmonary embolism.
215087943|NCT04140201|DRUG|Simvastatin 40mg|Drugs that lower lipid level
215087944|NCT04140201|DRUG|Fenofibrate 200mg|Drugs that lower lipid levels
215087945|NCT04140201|DRUG|Omega 3 fatty acid|Drugs that lower lipid levels
215087946|NCT01066780|DEVICE|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
215087947|NCT05336825|DEVICE|CO2 laser|Mona Lisa CO2 laser
215087948|NCT05336825|DRUG|Lidocaine patch 5%|lidocaine
214981384|NCT01085643|DRUG|Lubiprostone|24mcg PO taken once
215087949|NCT04304183|PROCEDURE|total colectomy, ileorectal anastomosis|all patients underwent total colectomy and ileorectal anastomosis.The anastomosis was stapled in all patients.
214981385|NCT01085643|DRUG|Placebo|24mcg placebo capsule taken once
214981386|NCT00381628|PROCEDURE|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
214981387|NCT03122171|OTHER|Occupational Therapy Treatment|Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
214368668|NCT07073521|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss|The intervention will be an 8-week integrated group therapy curriculum combining cognitive behavioral therapy (CBT) with mindfulness practices designed for individuals adjusting to vision loss.
214981388|NCT03817281|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
214981389|NCT01612663|DEVICE|Pain relief by Acupuncture needle at non-specific site|
214368669|NCT07066228|DEVICE|tissue-engineered bone|Commercial decalcified bone scaffolds were combined with autologous bone marrow mesenchymal stem cells to form tissue engineered bone in vitro
214368670|NCT07093346|DIETARY_SUPPLEMENT|Pectin|15g of pectin with 10g of cocoa powder added as flavour were randomly allocated to eligible participants.
214368671|NCT07093346|OTHER|Cocoa Powder|10g of cocoa powder served as the control/ placebo to compare the effects observed with pectin.
214368672|NCT07093346|DIAGNOSTIC_TEST|Magnetic Resonance Imaging with Contrast|To validate MRI scans as a tool to assess intestinal wall thickness to indicate gut permeability on MASLD patients, the investigators will scan 15 healthy volunteers twice, at baseline and after 6 weeks, and then compare their results with MASLD participant results at baseline and after 6 weeks.
214368673|NCT07093138|COMBINATION_PRODUCT|Canvert-M (Produced by Alasht Pharmed co. Iran)|Canvert-M is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. At the onset of a migraine attack, an adequate amount of Canvert-M roll-on should be applied to the areas of the forehead, temporal, behind the ears, and the base of the neck. If the patient's headache persists after 30 minutes, a second dose can be used.
214368674|NCT07093164|BEHAVIORAL|Virtual visit|Patients will be provided an initial virtual health or telehealth visit instead of an in person visit.
214368675|NCT07093190|DIETARY_SUPPLEMENT|exercise following Rg1 consumption|The effect of Rg1 on exercised skeletal muscle in older women
214368676|NCT07093190|DIETARY_SUPPLEMENT|Placebo|Resistance exercise performed 1 hour following placebo consumption
214368677|NCT07093879|OTHER|STATIC HAMSTRING STRETCH|For the static stretching technique, individuals lay supine in a straight posture on the treatment table and relaxed. Then, the pelvis and thighs opposite to the lower limb to which the stretching technique was to be applied were tied with Velcro straps. With the knees extended, the foot in neutral position and the hip joint bent as much as possible within its range, the hip joints were bent more until the hamstring muscle was stretched with light, tolerable pain, and kept there for 30 seconds
214368678|NCT07092878|DIETARY_SUPPLEMENT|Chamomile (Matricaria recutita)|Participants in the intervention group will consume the chamomile with L-theanine (CTT) beverage, which contains 480 mg of chamomile extract and 200 mg of L-theanine.
214368679|NCT07092878|DIETARY_SUPPLEMENT|Chamomile|A chamomile-flavored beverage
214368680|NCT07093697|DRUG|DW5121|Participants receive DW5121, 2 tablets orally, DW51211 Placebo, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days
214368681|NCT07093697|DRUG|DW51211|Participants receive DW5121 placebo, 2 tablets orally, DW51211, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days
214368682|NCT07093697|DRUG|DW51212|Participants receive DW5121 placebo, 2 tablets orally, DW51211 placebo, 2 tablets orally, DW51212 , 1 tablets orally, 3 times a day after meals for 7 days
214368683|NCT07094191|DIETARY_SUPPLEMENT|Chicory Coffee (Caffeine-free, polyphenol-rich beverage from roasted chicory root)|"A single oral dose of 180 mL chicory coffee prepared by steeping 20 grams of roasted and ground chicory root in hot water (approximately 90°C) for 5 minutes. The beverage was administered once, exactly 45 minutes before exercise, as part of a single session within a randomized crossover design. Chicory coffee is naturally caffeine-free, and rich in inulin and polyphenols, which are standardized in each preparation. No additional ingredients (milk, sugar, or flavoring) were added.~Blood lactate, glucose, blood pressure, and oxygen saturation (SpO₂) levels were measured both before and after the exercise. In addition, venous blood samples were collected post-exercise to assess serum levels of adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and LPL."
214680647|NCT04220489|DRUG|Placebo Comparator|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure)
214680648|NCT06224699|DRUG|Toothpaste Product|Use of toothpaste with or without sodium carbonate at 67%
214680649|NCT00269074|DRUG|IDEA-070|
214981390|NCT01612663|DEVICE|Acupuncture needle|
214981391|NCT01612663|DEVICE|Acupuncture needle|
214981392|NCT01612663|DEVICE|Acupuncture needle|
214981393|NCT00465530|DRUG|Saline|Intranasal Saline
214981394|NCT00465530|DRUG|Gentamycin|Intranasal irrigation
214981395|NCT00949442|DRUG|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
214981396|NCT00949442|DRUG|Glimepiride|tablets of 1 and 2 mg
215087950|NCT04983797|DEVICE|OPTRELL Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
215087951|NCT05551676|PROCEDURE|transforaminal group|Epidural steroid injection will be applied with transforaminal approach accompanied by fluoroscopy.
215087952|NCT05551676|PROCEDURE|Lateral parasagittal group|Epidural steroid injection will be applied with lateral parasagittal approach accompanied by scopy.
214680650|NCT01841424|BEHAVIORAL|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
214680651|NCT05789264|DEVICE|Nasal Compression Device|Participants assigned to the NasaClip arm will not receive routine care as the objective of this study is to compare the NasaClip device to routine digital compression in terms of feasibility, comfort, and efficacy. Limited data previously discussed in the background section indicates that application of nasal compression devices may be superior to digital compression.
214680652|NCT05789264|DIAGNOSTIC_TEST|Routine Care|Most first aid instructions for epistaxis management tell patients to apply firm digital pressure for 10 to 20 minutes, use a topical vasoconstrictor and apply an ice pack over the nose.
214680653|NCT00408421|DRUG|Duloxetine|
214680654|NCT00408421|DRUG|placebo|
214680655|NCT02772965|DRUG|Methotrexate|"1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.~2. A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
214680656|NCT02772965|OTHER|Sugar pill (placebo)|"1. Placebo for methotrexate: The weekly dose will mimic that of methotrexate.~2. Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided to maintain blinding.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
214680657|NCT01979796|DEVICE|Ecig 24 mg nicotine|Cigalike
214680658|NCT01979796|DEVICE|Ecig 0 mg nicotine|Cigalike
214680659|NCT01979796|DEVICE|Nicotine free inhalator|Plastic CIG a Like
214981397|NCT00949442|DRUG|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
214680660|NCT01829802|DRUG|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
214680661|NCT01829802|DRUG|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
214680662|NCT01829802|DRUG|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
214680663|NCT06123208|OTHER|Whole cooked pinto bean|Meal comprised of whole cooked pinto beans
214680664|NCT06123208|OTHER|Pinto bean flour|Meal comprised of pinto bean flour
214981398|NCT02577536|OTHER|No Interventions|No Interventions will be conducted under this study.
214981399|NCT04858152|PROCEDURE|Follicular Unit Extraction via punch biopsy|Follicular unit extraction will be performed using standard 0.7mm - 1mm punch biopsies. The donor site, which will be selected as a vitiligo-free, hair-bearing area that is not visible per patient's preference, will be harvested via punch biopsies and transplanted to the recipient site, which will be the glabrous skin of the hands or feet.
214981400|NCT00310986|BEHAVIORAL|Breathing Meditation|
215087953|NCT04956029|OTHER|There are no any interventions. This is to observe and test hospital cleanliness.|There are no any interventions. This is to observe and test hospital cleanliness.
215087954|NCT04297969|DIAGNOSTIC_TEST|"objective pediatric vision screen GCK glow fixation"|2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
215087955|NCT03098225|RADIATION|Orbital radiotherapy|A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.
214981401|NCT03912389|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
215087956|NCT03098225|DRUG|Methylprednisolone|Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
215087957|NCT05536856|DRUG|a new effervescent mixture 5-florouracil formula|30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
215087958|NCT05536856|DRUG|5-Fluorouracil plain powder|30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
214680665|NCT06123208|OTHER|Control|Control meal
214680666|NCT03825289|DRUG|Hydroxychloroquine|Given PO
214680667|NCT03825289|DRUG|Trametinib|Given PO
214680668|NCT00218855|DRUG|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
214680669|NCT00218855|DRUG|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
214981402|NCT03912389|DRUG|Pemetrexed|IV infusion
214981403|NCT03912389|DRUG|Cisplatin (or carboplatin)|IV infusion
214981404|NCT03912389|OTHER|Placebo|IV infusion
214368684|NCT07094191|DIETARY_SUPPLEMENT|arabica coffee|A single oral dose of 180 mL Arabica coffee prepared by steeping 20 grams of roasted and ground chicory root in hot water (approximately 90°C) for 5 minutes. The beverage was administered once, exactly 45 minutes before exercise, as part of a single session within a randomized crossover design. Chicory coffee is naturally caffeine-free, and rich in inulin and polyphenols, which are standardized in each preparation. No additional ingredients (milk, sugar, or flavoring) were added. Blood lactate, glucose, blood pressure, and oxygen saturation (SpO₂) levels were measured both before and after the exercise. In addition, venous blood samples were collected post-exercise to assess serum levels of adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and LPL.
214981405|NCT04346953|BEHAVIORAL|Video based exercise|Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.
214981406|NCT03035162|DEVICE|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
214981407|NCT00264212|DRUG|irbesartan and irbesartan-hydrochlorothiazide|
214981408|NCT02783638|DRUG|YHD1119|2 by 2
214981409|NCT02783638|DRUG|Lyrica|2 by 2
214981410|NCT01627665|DRUG|D->R->C+R|one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
214981411|NCT01627665|DRUG|D->R->C+D|one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
214981412|NCT01627665|DRUG|R->D->C+D|RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
214981413|NCT01627665|DRUG|R->D->C+R|RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
214981414|NCT00953030|BEHAVIORAL|COACH|
214981415|NCT00953030|BEHAVIORAL|RealAge|
214981416|NCT05618223|DRUG|Dapagliflozin|Dapagliflozin 10 mg once daily in addition to standard therapy
214981417|NCT01806181|OTHER|Exercise|
214981418|NCT06448052|BIOLOGICAL|umbilical cord mesenchymal stem cell|A total of 100 million single cells were suspended in 0.9% sterile saline solution and given intravenously at a 5-ml/min rate for 45 min. All patients will get two intravenous autologous infusions on days 0 (D0) and 90 (D90).
214368685|NCT07094191|DIETARY_SUPPLEMENT|no beverage control|Participants underwent the shuttle run exercise protocol in a fasted state, without consuming any food or beverages prior to the test. Blood lactate, glucose, blood pressure, and oxygen saturation (SpO₂) levels were measured both before and after the exercise. In addition, venous blood samples were collected post-exercise to assess serum levels of adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and LPL.
214492554|NCT06771310|OTHER|Kinesiotaping|"The participants will be asked to assume standing position then to flex back to reach its maximum point.~* Two bands, 1 on each side of the lumbar spine, will be applied vertically from the lower posterior iliac crest region to the upper twelfth rib region, with inhibition technique.~* The remaining 2 bands will be attached horizontally, with space correction technique.~* All 4 bands will be placed to allow for 50% longitudinal stretching. The stretching directions for the vertical and horizontal applications were bottom-up and sideways, respectively."
214492555|NCT06775210|OTHER|supportive sleep care|sleep bundle
214492556|NCT06775210|OTHER|care bundle|sleep bundle
214492557|NCT02962973|DEVICE|CARMAT TAH|
214492558|NCT02962973|PROCEDURE|Surgical intervention|
214492559|NCT04656340|OTHER|non-medication, non-interventional therapies|non-medication, non-interventional therapies
214492560|NCT06767735|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
214981419|NCT04688632|DRUG|Ampreloxetine <Dose A>|Ampreloxetine \<Dose A\> will be administered as 1 tablet of \<Dose A\> and 3 tablets of Ampreloxetine Placebo.
214981420|NCT04688632|DRUG|Ampreloxetine <Dose B>|Ampreloxetine \<Dose B\> will be administered as 4 tablets of \<Dose A\>
214981421|NCT04688632|DRUG|Ampreloxetine Placebo|Ampreloxetine Placebo will be administered as 4 tablets of placebo. The placebo tablet will match (in appearance) the ampreloxetine \<Dose A\> tablet.
214981422|NCT04688632|DRUG|Moxifloxacin|Moxifloxacin will be administered orally as a single tablet.
215087959|NCT03826823|DEVICE|HSG cannula|a thin catheter originally designed for IUI was introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum was loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye was injected slowly and the procedure was watched on the screen and x-ray films were taken.
215087960|NCT01086176|DEVICE|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
215087961|NCT05225259|DRUG|LOXO-260|Oral
215087962|NCT00235911|DRUG|budesonide/formoterol Turbuhaler|
214981423|NCT04688632|DRUG|Moxifloxacin Placebo|Moxifloxacin placebo will be administered orally as a single tablet. The placebo tablet will match (in appearance) the moxifloxacin tablet.
214981424|NCT02909062|DEVICE|Electronic Activity Monitoring (EAM)|All registered patients will receive a wearable EAM device that will measure their physical activity. Patients will wear this device around their wrist for the designated period of assessment. The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed. For the purpose of this study the EAM data captured will focus on daily step count.
214492561|NCT06767735|DRUG|Insulin Glargine U100|Insulin Glargine U100 s.c.,once-daily，treat-to-target dose
214680670|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
214981425|NCT02909062|BEHAVIORAL|Daily Questionnaire|Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device. The questionnaire was designed specifically for the purpose of this study. It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device. The daily questionnaires will be optional; however each participant will be encouraged to complete them.
215087963|NCT03053869|DRUG|Benzodiazepine - limited use strategy|"1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
214680671|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
214680672|NCT03799926|DRUG|placebo|Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
214680673|NCT03799926|DRUG|placebo|Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
214680674|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
215087964|NCT03053869|DRUG|Benzodiazepine - Ad libitum strategy|"1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
215087965|NCT05122299|PROCEDURE|Negative control group|No intervention after extraction then delayed implant insertion at the site of extraction after three months
215087966|NCT05122299|PROCEDURE|Postive control|Application of collagen only in the socket after extraction then delayed implant insertion at the site of extraction after three months.
215087967|NCT05122299|PROCEDURE|Study group|Application of acombination of CoQ10 and collagen hydrogel in the socket after extraction then delayed implant insertion at the site of extraction after three months.
215087968|NCT05657873|RADIATION|L-SABR|L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.
215087969|NCT05657873|BIOLOGICAL|Anti-PD-(L)1 based immunotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
215087970|NCT05657873|DRUG|Platinum based chemotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
215087971|NCT06387836|DRUG|Isoflurane 0.8 MAC|Patients in this group will be anesthetized using isoflurane with the depth of 0.8\~1.0MAC during the operation.
214492562|NCT06780605|GENETIC|niPGT-A|"After being thawed following the standard lab practice, any donated blastocyst usable for the study will be washed individually to remove any trace of cumulus DNA and will be transferred to a new culture dish with a drop of 10-15µl. Day-5 blastocysts with proper re-expansion after thawing, will be cultured overnight (≈24 hours) before media collection and TE/ICM biopsies. Day-6 blastocysts will be cultured a total of 8 hours after thawing, before media collection and TE/ICM biopsies.~On day 6/7, the embryos' media will be collected with an automatic pipette for niPGT-A and additional genetic analysis. The same protocol will be used to analyze SBM and blastocyst biopsies."
214492563|NCT06780605|GENETIC|Multifocal TE biopsies and ICM biopsy|"For biopsy, blastocysts will be transferred to the biopsy dish and multi-focal TE biopsies will be performed in three locations related to the position of the ICM. ICM biopsies will be performed following a published protocol provided to the participant centers. ICM and TE sections will be aspirated with the use of micropipettes adapted to a micromanipulation and laser microscope system.~For the genetic study of the samples, the same protocol will be used to analyze embryo biopsies and SBM."
215087972|NCT06387836|DRUG|Desflurane 0.8MAC|Patients in this group will be anesthetized using desflurane with the depth of 0.8\~1.0MAC during the operation.
214492564|NCT06654947|DRUG|Surufatinib+Toripalimab+GEMOX|Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；GEMOX：Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W，Oxaliplatin：100mg/m2,ivgtt，d1，Q3W）
214492565|NCT05755204|DRUG|LA-CAB|Intramuscular LA-CAB for PrEP
214492566|NCT05755204|DRUG|TDF/FTC|Oral TDF/FTC for PrEP
214492567|NCT03777657|DRUG|Tislelizumab|200 mg intravenously (IV) on Day 1 of each 21-day cycle
214680675|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
214680676|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
214680677|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
214680678|NCT04631458|OTHER|standard of care.|Observational trial.
214680679|NCT04031170|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies for themselves; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, they learn how to be more positive and nurturing through academic, social and emotional coaching.
214981426|NCT02238366|DRUG|triptorelin|This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
214680680|NCT04031170|OTHER|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
214981427|NCT06171893|BEHAVIORAL|Wavy stress application|"The intervention consists of the application named Wavy. Wavy uses artificial intelligence and the user's feedback to detect stress increasingly more efficient over time. This provides not only real-time feedback on an individual's stress level but also helps the patient to calm down using music guided relaxation. It does so with a music filter, allowing the participant to listen to music where the stress level determines the quality of the music.~Thus, relaxing is rewarded by improving the experience. In this process, implicit learning is used to establish a habit of getting better at recognising increased stress levels and getting familiar with reducing stress levels more and more effectively."
214368686|NCT07093827|PROCEDURE|Posterior decompression surgery|\*\*Posterior decompression for thoracolumbar fractures involves a midline incision and subperiosteal exposure of the posterior spinal elements, followed by laminectomy or laminotomy to relieve neural compression. Pedicle screw-rod instrumentation is then applied above and below the fractured level under fluoroscopic guidance to restore stability, often supplemented by posterolateral fusion using bone graft. The procedure concludes with layered wound closure, providing direct neural decompression, rigid fixation for early mobilization, and reduced morbidity compared to anterior approaches in select cases. This technique is indicated for unstable fractures (e.g., AO Type B/C) or neurological deficits with posterior canal compromise, with variations based on fracture severity and surgical judgment.\*\*
214492568|NCT03777657|DRUG|Placebo|Placebo to match tislelizumab IV on Day 1 of each 21-day cycle
214981428|NCT00671268|BIOLOGICAL|AL0704rP|strict subcutaneous
214981429|NCT00671268|BIOLOGICAL|Placebo|strict subcutaneous
214492569|NCT03777657|DRUG|Cisplatin|80 mg/m² IV on Day 1 of each 21-day cycle
214981430|NCT05665868|DEVICE|integrated care mode|The information system consists of big data platform and nursing strategy platform. The system includes medical work end, patient operation end and administrator management end. The big data platform can automatically extract patient data from HIS, Medcare and other patient diagnosis and treatment systems, complete registration and establish patient health files according to the preset patient registration standards. By comparing the data input on the patient side with the database set on the platform, the system decision-making module can generate personalized measures and plans for feedback to patients, and can generate patient information overview feedback to the nurse side. Complete intelligent push of symptom management decision model
214981431|NCT05665868|DEVICE|conventional care mode|① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
214981432|NCT01033838|PROCEDURE|rectosigmoid resection|
214981433|NCT00045266|BIOLOGICAL|ziv-aflibercept|
214492570|NCT03777657|DRUG|Oxaliplatin|130 mg/m² IV on Day 1 of each 21-day cycle
214492571|NCT03777657|DRUG|Capecitabine|1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle
214492572|NCT03777657|DRUG|5-Fluorouracil|800 mg/m²/day IV using continuous infusion on Days 1 to 5 of each 21-day cycle
214492573|NCT03672201|BEHAVIORAL|Non-Pharmacological Intervention|The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.
214492574|NCT03672201|OTHER|Pharmacological Intervention|The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
214492575|NCT06704464|OTHER|Manual Dexterity|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT, 9-HPT, ABILHAND, and JTHFT.
214492576|NCT06704464|OTHER|Manual Dexterity (only MMDT)|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT on a predetermined day.
214492577|NCT06704464|OTHER|disability level|Individuals who meet the inclusion criteria will be evaluated for disability level using EDSS
214492578|NCT04104139|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214492579|NCT04104139|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214492580|NCT04104139|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214492581|NCT06802068|DIETARY_SUPPLEMENT|whole salmon oil|A minimally processed whole salmon oil
214492582|NCT06802068|DIETARY_SUPPLEMENT|Cod liver oil|Standard, processed omega-3 cod liver oil
214492583|NCT03665922|DIETARY_SUPPLEMENT|BroccoMax®|Nutraceutical neoadjuvant
214492584|NCT03665922|OTHER|Placebo|control
214492585|NCT05160012|BEHAVIORAL|Peer Comparison Message|"In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~1. If HTN control rate \<50th percentile, PCP is told they are below median~2. If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~3. If HTN control rate is between 90-100th percentile, PCP is told they are a high performer"
214492586|NCT05785221|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive general dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
214680681|NCT04247932|BEHAVIORAL|Active labor market intervention|Behavior change intervention
214680682|NCT03913286|DEVICE|Cortimo|The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
214680683|NCT00186238|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
214680684|NCT04153812|DEVICE|vagus nerve stimulation|Vagus nerve stimulation (VNS) is a new technique for stimulating the left cervical vagus nerve through implanted lead and a programmable pulse generator.
214680685|NCT01115946|DRUG|ASP1585|oral
214680686|NCT01115946|DRUG|enalapril|oral
214981434|NCT01164761|DRUG|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
214981435|NCT01164761|DRUG|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
214368687|NCT07093827|PROCEDURE|unilateral open-door laminoplasty|Posterior cervical expansive open-door laminoplasty (also known as unilateral open-door laminoplasty) is a surgical technique used to decompress the spinal cord in cervical myelopathy or spinal cord injury. The procedure involves a midline posterior cervical incision, followed by exposure of the laminae. A high-speed burr is used to create a hinged trough on one side (preserving the inner cortex) and a complete trough on the contralateral side, allowing the lamina to be gently elevated like an opening door. The opened lamina is then stabilized using sutures, miniplates, or spacers to maintain the expanded canal diameter. This approach effectively increases spinal canal space while preserving posterior elements, reducing cord compression while minimizing instability risks compared to laminectomy. It is particularly indicated for multilevel cervical stenosis with preserved cervical alignment.
214492587|NCT05785221|BEHAVIORAL|Personalized nutritional and lifestyle weight reduction intervention|Participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions and APP-connected scale will be used to monitor their weight changes during interventions.
214492588|NCT02998164|BEHAVIORAL|augmentative and alternative communication technology|
214981436|NCT02139540|DRUG|Nitrous Oxide|"Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen \[inert\]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart."
214492589|NCT02998164|BEHAVIORAL|Usual Care|No change to the therapy care received
214981437|NCT02139540|DRUG|Placebo|50% nitrogen \[inert\]/50% oxygen - otherwise completely identical administration and setup
214981438|NCT03220308|OTHER|MYmind mindfulness training|The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.
214981439|NCT03220308|OTHER|Care-as-usual for children (8-16 years old) with ADHD|According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
214981440|NCT01550133|BEHAVIORAL|Learned: Non-nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with non-nutritive sweetener everyday for two weeks.Half of these participants will then be tested against a non-nutritive beverage.
214981441|NCT01550133|BEHAVIORAL|Learned: Nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
214981442|NCT01550133|BEHAVIORAL|Learned: Nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
214981443|NCT01550133|BEHAVIORAL|Not Learned: Non-nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
214981444|NCT01550133|BEHAVIORAL|Not Learned: Nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive beverage.
214981445|NCT01550133|BEHAVIORAL|Not Learned: Non-Nutritive solid to Non-nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
214981446|NCT01550133|BEHAVIORAL|Not Learned: Non-nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
214981447|NCT01550133|BEHAVIORAL|Not Learned: Non-Nutritive solid to Non-Nutritive Solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
214981448|NCT00349336|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
214981449|NCT00349336|DRUG|XELOX|As prescribed
214981450|NCT00349336|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
214981451|NCT00349336|DRUG|FOLFOX-4|As prescribed
214981452|NCT01510405|OTHER|Tissue Collection|Tissue sample collection
214981453|NCT05470452|OTHER|The reading process is assisted by ENDOANGEL|Diagnosis of benign and malignant lesions with the help of ENDOANGEL
214680687|NCT01997567|DRUG|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
214368688|NCT07093827|PROCEDURE|Posterior lumbar discectomy with fusion|Posterior lumbar discectomy with fusion (PLDF) is a standard surgical treatment for lumbar disc herniation with instability or recurrent symptoms. The procedure involves a midline posterior approach to expose the affected vertebral level, followed by laminotomy or partial laminectomy to access the neural elements. The herniated disc material is carefully removed to decompress the nerve roots, after which pedicle screws and rods are inserted for segmental stabilization. Interbody fusion (via posterior lumbar interbody fusion \[PLIF\] or transforaminal lumbar interbody fusion \[TLIF\]) is often performed by placing a bone graft or cage in the disc space to promote bony union. The combination of neural decompression, rigid instrumentation, and interbody fusion aims to relieve radicular pain while restoring spinal stability and alignment.
214368689|NCT07093827|PROCEDURE|Surgical resection of spinal tumors|Surgical resection of spinal tumors involves a tailored approach based on tumor location, type (primary/metastatic), and spinal stability. For posteriorly accessible lesions, a midline incision exposes the affected vertebrae, followed by laminectomy to access the epidural space and decompress neural elements. Tumor resection is performed using meticulous dissection, with intraoperative neuromonitoring to minimize neurological risk. In cases requiring vertebral body involvement, a posterolateral (costotransversectomy) or combined anterior-posterior approach may be used for en bloc or piecemeal excision. Reconstruction typically involves spinal instrumentation (pedicle screws/rods) and structural support (cages/allografts) to restore stability. The goal is maximal safe resection while preserving neurological function, often supplemented by adjuvant therapies (radiation/chemotherapy) for malignant tumors.
214368690|NCT07093827|DRUG|Conservative management of ankylosing spondylitis|Conservative management of ankylosing spondylitis (AS) focuses on symptom relief, functional preservation, and slowing disease progression through a multidisciplinary approach. First-line pharmacotherapy includes NSAIDs (e.g., celecoxib) for pain and inflammation control, supplemented by TNF-α inhibitors (e.g., adalimumab) or IL-17 inhibitors for refractory cases. Physical therapy emphasizes daily spinal extension exercises, postural training, and deep breathing to maintain mobility and prevent kyphotic deformity. Patient education on ergonomic adjustments (sleeping positions, workplace modifications) and low-impact aerobic exercise (swimming, yoga) is integral. Smoking cessation is strongly advocated due to its association with worse outcomes. Regular monitoring with inflammatory markers (CRP/ESR) and imaging (MRI for early sacroiliitis) guides therapeutic adjustments, while comorbidities (uveitis, osteoporosis) require coordinated care.
214680688|NCT01997567|DRUG|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
214680689|NCT02022683|DEVICE|ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves|
214981454|NCT05470452|OTHER|No ENDOANGEL assistance during the reading process|Diagnosis of benign and malignant lesions without the help of ENDOANGEL
214981455|NCT02460016|DRUG|AK0529|AK0529 pellets for oral administration
214981456|NCT04482634|OTHER|Remote controlled exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
214981457|NCT04482634|OTHER|Home exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
214981458|NCT04346316|DRUG|SHR0302|Oral tablets taken once daily (QD)
214981459|NCT01378208|BEHAVIORAL|Intermittent fasting - the effect on glucose metabolism, body composition and cognitive function|"Each of the 10 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.~DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)~* 28 days of dietary monitoring~* 28 days measurement by pedometer DAY 1, DAY 28 \& DAY 56: Test 1~* Oral glucose tolerance test with stable isotopes~* Fat and muscle biopsies DAY 2, DAY 29 \& DAY 57: Test 2~* DXA scanning~* Resting Metabolic Rate Measurement~* VO2max test on bicycle~* Cognitive testing~* MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 \& DAY 48: Test 3~* Actiheart for 3 days~* 72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION~* Fasting from 7am - 9pm~* 28 days of dietary monitoring~* 28 days measurement by pedometer"
214981460|NCT04668417|BEHAVIORAL|Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with a direct scheduling link included, enabling the patient to directly schedule a flu vaccination only visit
214981461|NCT04668417|BEHAVIORAL|Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with no direct scheduling link included
214981462|NCT02060500|PROCEDURE|Cardiaplication|
214981463|NCT00720499|DRUG|BI 1744 CL plus tiotropium bromide|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
214492590|NCT06071130|BEHAVIORAL|Fit and Strong|Procedure: During Years 3-5, participants will be recruited in waves through our standard recruitment practices to participate in Experiments 4A at the City of Chicago park sites. We will first prescreen them via telephone to verify that potential participants meet the inclusion criteria. F\&S! classes will be offered at two pre-determined Chicago park sites. Each of the two sites will host the 8-week-long program once in the spring and once in the fall for two years for a total of four F\&S! cycles at each center (totaling 8 F\&S! cohorts). Upon consenting to be in E4A, participants will be enrolled in F\&S! at the site closest to their home or the wait-list control. In the pre-intervention phase, participants both in F\&S! and on the waitlist will come to the lab at DePaul to complete the pre-intervention measurement batter. Within one week after baseline measurements, participants will attend F\&S! for 3 sessions a week for 8 weeks.
214981464|NCT00720499|DEVICE|Respimat® Inhaler|
214981465|NCT03651141|OTHER|Neurodynamic Sliding|Subjects in the neurodynamic sliding group perform 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets. A metronome will be set at 30 beats per minute for 15 full slides per minute to standardize the amount of slides per session.
214981466|NCT03651141|OTHER|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
214981467|NCT03651141|OTHER|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
214981468|NCT05062096|OTHER|Blood samples|Blood samples at each protocol visit, T and NK cell analysis
214981469|NCT05062096|OTHER|Skin biopsy|Biopsy of the skin lesion (optional)
214981470|NCT05718349|OTHER|Biospecimen sampling|From the patients participating in the study i) blood, ii) tissue from resected material, iii) bile, iv) stool, v) urine, vi) jejunal content and vii) information on the itch severity will be collected.
214981471|NCT03021746|BEHAVIORAL|Diabetes Self Management Support (DSMS)|
214981472|NCT05171322|DEVICE|WARD|"The following monitoring devices are included in the WARD monitoring system (as intervention):~Isansys Life Touch patch: Measures heart rate (HR), respiratory rate (RR) and electrocardiogram (ECG)~Wearable, wireless Pulse Oximeter (Model 3150 WristOx from Nonin): Measures peripheral oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR)~Blood pressure monitor (Meditech BlueBP-05): Measures BP every 30 minutes during daytime and every 60 minutes during the night~All included patients are set up with the monitoring devices after surgery when they are back at their ward (with a maximum of 24 hours postoperative). Afterwards they wear the devices for up to 5 days. All measurements are sent through bluetooth to a tablet serving as a gateway which in turn sends data to a central server where the algorithmic processing ensures."
214981473|NCT04911348|OTHER|none (observational)|no intervention
215087973|NCT05828667|OTHER|Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).|CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This is done with the intent to limit the repeated number of inductions and prolonged point-by-point voltage mapping that often result in hemodynamic instability.
214368691|NCT07093827|PROCEDURE|anterior cervical discectomy/fusion|Surgical management of cervical spondylotic myelopathy (CSM) aims to decompress the spinal cord and stabilize the spine, with the approach tailored to pathology and spinal alignment. For multilevel anterior compression, anterior cervical discectomy/fusion (ACDF) or corpectomy with plating is preferred, utilizing structural grafts or cages to restore lordosis. Posterior approaches (laminoplasty or laminectomy with fusion) are indicated for multilevel stenosis with preserved cervical curvature, employing lateral mass or pedicle screws for fixation. Hybrid strategies (e.g., ACDF combined with laminoplasty) address complex cases. Intraoperative neuromonitoring (SSEPs/MEPs) minimizes neurological risks, while emerging techniques like cervical disc arthroplasty are considered in select patients to preserve motion. Surgical timing is critical, with earlier intervention correlating to better neurological recovery in progressive myelopathy.
214492591|NCT06822673|BEHAVIORAL|Mindfulness Based Intervention|The Mindfulness-Based Intervention will include techniques derived from the Mindfulness Matters Program protocol (for Children and Adolescents, 2019). It will consist of both formal and informal practices, which participants will engage in during sessions and at home. These practices will encompass body scan meditation, mindful eating, mindful sitting, walking exercises, attention-focusing activities, and more. The intervention will be delivered over eight weekly sessions, following a skill-building, educational approach.
214492592|NCT06821672|PROCEDURE|Chronobiological Group|In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
214368692|NCT07093827|PROCEDURE|anterior cervical corpectomy/fusion|Surgical management of cervical spondylotic myelopathy (CSM) aims to decompress the spinal cord and stabilize the spine, with the approach tailored to pathology and spinal alignment. For multilevel anterior compression, anterior cervical discectomy/fusion (ACDF) or corpectomy with plating is preferred, utilizing structural grafts or cages to restore lordosis. Posterior approaches (laminoplasty or laminectomy with fusion) are indicated for multilevel stenosis with preserved cervical curvature, employing lateral mass or pedicle screws for fixation. Hybrid strategies (e.g., ACDF combined with laminoplasty) address complex cases. Intraoperative neuromonitoring (SSEPs/MEPs) minimizes neurological risks, while emerging techniques like cervical disc arthroplasty are considered in select patients to preserve motion. Surgical timing is critical, with earlier intervention correlating to better neurological recovery in progressive myelopathy.
214981474|NCT06442605|DEVICE|single-channel uterine fibroid morcellation system|Conventional laparoscopic myomectomy is performed with the use of a single-channel uterine fibroid morcellation system for fragmentation and retrieval of the fibroids during the procedure.
214981475|NCT06442605|DEVICE|Multi-channel specimen retrieval bag + conventional laparoscopic uterine fibroid morcellator|In conventional laparoscopic myomectomy, a multi-channel specimen retrieval bag is used during the procedure, along with a conventional laparoscopic uterine fibroid morcellator for fragmentation and retrieval of the fibroids.
214981476|NCT01414244|DRUG|Glutamine|Drug
214981477|NCT01418443|DRUG|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
214981478|NCT01326871|DRUG|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
214981479|NCT01326871|DRUG|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
214981480|NCT01326871|BIOLOGICAL|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
215087974|NCT04870463|PROCEDURE|Maxillary and mandibular Cone Beam Computed Tomography record|A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
214492593|NCT04252235|DEVICE|Air purifier|The intervention is the placement of active HEPA air purifiers in the bedroom and living room of the true air purifier arm. These air purifiers have been shown to reduce levels of particles in the home.
214492594|NCT04252235|DEVICE|Sham air purifier|The intervention is the placement of sham HEPA air purifiers in the bedroom and living room. These purifiers look identical to real HEPA air purifiers, but do not filter the air.
214680690|NCT03120338|DIAGNOSTIC_TEST|The Development and Wellbeing Assessment|The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
214680691|NCT04157660|PROCEDURE|Oxygen application|Oxygen application Supplemental oxygen via mask
214680692|NCT04157660|PROCEDURE|Sham room air|Room air will be applied via mask
214680693|NCT03319992|DEVICE|Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)|RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
214981481|NCT03638323|OTHER|Speech therapy|During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
215087975|NCT06437626|DRUG|Mexidol|50 mg/ml IV solution, 250 mg tablets
215087976|NCT06437626|DRUG|Placebo|Placebo IV solution, Placebo tablets
215087977|NCT03452826|DEVICE|Antibiotic therapy according to the result of mPCR (device)|"* Phone call at D28 and D90, unless the patient is still hospitalized;~* Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~* Collection of an additional respiratory tract sample for biological banking in both arms."
215087978|NCT03460548|DEVICE|Remogen|instil 1 drop of the product in each eye, 4 times per day
215087979|NCT03460548|DEVICE|Cationorm|instil 1 drop of the product in each eye, 4 times per day
215087980|NCT00006268|BIOLOGICAL|cintredekin besudotox|
215087981|NCT00006268|DRUG|isolated perfusion|
215087982|NCT00006268|PROCEDURE|conventional surgery|
215087983|NCT00783081|DRUG|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
215087984|NCT00783081|DRUG|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
215087985|NCT00783081|DRUG|Placebo|Placebo BID for 26 weeks.
215087986|NCT03131596|PROCEDURE|IUB dilatation therapy|A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
215087987|NCT00434356|DRUG|bevacizumab|Intravenous repeating dose
215087988|NCT00434356|DRUG|sunitinib|Oral repeating dose
215087989|NCT00434356|DRUG|paclitaxel|Intravenous repeating dose
214680694|NCT02292381|OTHER|Isometric exercise|
215087990|NCT00734071|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
215087991|NCT00734071|DRUG|Placebo|Vortioxetine placebo-matching capsules
215087992|NCT01765725|BEHAVIORAL|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
215087993|NCT06829641|PROCEDURE|Tislelizumab Combined with Chemotherapy,|Tislelizumab Combined with Chemotherapy as Induction Therapy
215087994|NCT03143751|DRUG|NaCl20% (Continuous hyperosmolar therapy)|"Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+"
214680695|NCT01139723|DRUG|MINT1526A|Intravenous escalating dose
215087995|NCT04465968|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV, day 1
215087996|NCT04465968|DRUG|S1|80 - 120 mg/day, PO, day 1-14
215087997|NCT04465968|RADIATION|concurrent radiotherapy|66 Gy/33 Fr
215087998|NCT04465968|DRUG|Durvalumab|preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
215087999|NCT04465968|PROCEDURE|Surgery|Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
215088000|NCT04465968|DRUG|Durvalumab|"(For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1"
214680696|NCT01139723|DRUG|bevacizumab|Intravenous repeating dose
214368693|NCT07093827|DRUG|Conservative management of lumbar spinal stenosis|Conservative management of lumbar spinal stenosis (LSS) focuses on symptom alleviation and functional improvement through a multimodal approach. First-line interventions include NSAIDs or acetaminophen for neurogenic claudication pain, with consideration of epidural steroid injections for refractory radicular symptoms. Supervised physical therapy emphasizes flexion-based exercises, core stabilization, and aquatic therapy to reduce mechanical stress on neural structures. Activity modification strategies (e.g., avoiding prolonged standing) combined with assistive devices (walking frames) improve mobility. Adjuvant therapies such as gabapentinoids may be trialed for neuropathic pain, while cardiovascular conditioning (stationary cycling) counters deconditioning. Patient education on weight management and posture optimization is integral, with surgical evaluation reserved for progressive neurological deficits or failure of 3-6 months structured conservative care.
214680697|NCT01790438|DRUG|LY2605541|
214680698|NCT01790438|DRUG|Human Insulin NPH|
214680699|NCT01790438|DRUG|Oral Antihyperglycemic Medications (OAM)|
214680700|NCT01847638|DRUG|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
214680701|NCT01847638|DRUG|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
214680702|NCT01945931|OTHER|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
214680703|NCT01437631|PROCEDURE|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
214981482|NCT04245774|DRUG|Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule|7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine (1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) plus 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
214981483|NCT04245774|DRUG|Bupivacaine/Dextrose|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
214981484|NCT02510339|OTHER|Observation|Administration of two questionnairs during post operative visits.
214981485|NCT03273855|OTHER|Fecal microbiota transplantation|The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
214680704|NCT00950612|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular injection, 2 doses
214680705|NCT00950612|BIOLOGICAL|Placebo|Intramuscular injection, 2 doses
214680706|NCT02815631|DEVICE|Cardiogoniometry (CGM)|
214680707|NCT02815631|DEVICE|Fractional Flow Reserve (FFR)|
214680708|NCT05071781|DRUG|Corticotropin-release hormone|intravenous CRH (100 µg)
214680709|NCT05071781|DRUG|Corticotropin-release hormone|a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
214680710|NCT00733512|DEVICE|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
215088001|NCT02315482|PROCEDURE|pneumoperitoneum insufflation and steep trendelenburg|the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
214680711|NCT05892783|OTHER|manual treatment|soft tissue mobilization applied by the therapist on the plantar fascia of both legs and self massage and stretching using foam roller and self stretching.
214680712|NCT00900133|OTHER|immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
214680713|NCT00900133|OTHER|laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
214680714|NCT03935477|DEVICE|WellBeing catheter|Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension
214680715|NCT03275883|PROCEDURE|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
214680716|NCT01614769|DRUG|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
214680717|NCT01614769|DRUG|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
214981486|NCT03273855|OTHER|Placebo: fecal microbiota transplantation|The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
214981487|NCT01004939|DRUG|fondaparinux|fondaparinux
214981488|NCT06194916|OTHER|Education|A 4-WEEK SELF-MANAGEMENT TRAINING WILL BE PROVIDED THROUGH THE WEB-BASED TRAINING SITE.
214981489|NCT06194916|OTHER|CONTROL GROUP|THEY WILL RECEIVE THE ROUTINE CARE GIVEN TO PATIENTS WITH EPILEPSY.
214680718|NCT01614769|DRUG|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
214981490|NCT05034549|DEVICE|Noninvasive ventilation|The non-invasive ventilator at home (≥5h/ night)
214981491|NCT05544097|OTHER|Recording of the bowel sounds|Recording of the bowel sounds before and after enteral feeding three times a week with an electronical stethoscope
214981492|NCT02193841|PROCEDURE|Curettage with puncture (C & P)|A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity
214981493|NCT02193841|DEVICE|Curette|A small surgical instrument with a rounded edge designed for scraping
214981494|NCT02193841|DEVICE|Vitoss morsels|A bone substitute intended for use as a filler for voids or gaps in bones
214981495|NCT04040686|DRUG|Injection of 99mTc-NM-02|Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
214981496|NCT06894277|BEHAVIORAL|iTRAC-HERO|"iTRAC-HERO will consist of eight, approximately 45-minute, gamified digital modules of 4-6 activities (games, videos, etc.). No instruction is needed to use the program. Content will use gender- and sexuality-inclusive language and avoid heteronormative descriptions of risk. This content will include strategies for (and practice with) recognizing and managing emotions, particularly in relation to sexual health situations, to enhance the likelihood that the emotion regulation and sexual health education provided can be applied to experiences that are emotionally arousing and lead to risk."
214981497|NCT04354935|DEVICE|rTMS basic|1 session per day, for 4 or 6 weeks.
214981498|NCT04354935|DEVICE|rTMS VIIT|5 sessions per day, for 2 weeks.
214981499|NCT04354935|DEVICE|rTMS SAINT modified|8 sessions per day, for 1 week.
214981500|NCT04354935|DEVICE|rTMS SAINT|10 sessions per day, for 1 week.
214981501|NCT06339775|DRUG|Blinatumomab|"patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment.~(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg)."
214368694|NCT07093827|PROCEDURE|decompression surgery for caudal plexus disorder|Surgical intervention for caudal plexus disorders is indicated in cases of structural compression, trauma, or refractory symptoms unresponsive to conservative measures. The approach involves meticulous exposure of the lumbosacral plexus through a retroperitoneal or transabdominal route, depending on lesion location. For compressive pathologies, microsurgical decompression with intraoperative neurophysiological monitoring (IONM) is performed to minimize iatrogenic injury. In traumatic avulsions or sharp injuries, direct nerve repair, grafting, or neurolysis may be attempted to restore function. For chronic pain syndromes, dorsal root entry zone (DREZ) ablation or nerve decompression may be considered. Surgical success depends on etiology, timing of intervention, and extent of neural damage, with optimal outcomes achieved in early decompression of compressive lesions or precise repair of focal injuries.
214368695|NCT07093632|PROCEDURE|Graft dysfunction will be assessed through clinical examination and imaging follow-up to detect occlusion, pseudoaneurysm, aneurysm rupture, infection, or major amputation of the treated limb.|This study concerns adult subjects with symptomatic lower limb arterial disease who have undergone arterial bypass surgery and are included in the study cohort. Graft dysfunction will be assessed through clinical examination and imaging follow-up to detect occlusion, pseudoaneurysm, aneurysm rupture, infection, or major amputation of the treated limb.
214368696|NCT07093736|DEVICE|FW-200|Non-invasive, home-use neurostimulation device delivering transcranial fixed output, alternating current stimulation
214368697|NCT07094009|PROCEDURE|received transverse needling|received transverse needling of high-frequency microneedles
214368698|NCT07094009|PROCEDURE|received vertical needling|received vertical needling of high-frequency microneedles
214368699|NCT07094009|PROCEDURE|received mixed needling|received mixed needling of high-frequency microneedles
214368700|NCT07094464|DRUG|Maintenance Therapy with Selinexor and Azacitidine|"1. Selinexor: Oral administration in 4 cycles:~   \- Dose Escalation Phase: Cohort 1: Selinexor, 20 mg, twice a week for 2 weeks Cohort 2: Selinexor, 40 mg, twice a week for 2 weeks Cohort 3: Selinexor, 60 mg, twice a week for 2 weeks~   \- Dose Expansion: MTD/RP2D will be determined based on safety.~2. Azacitidine: 35 mg/m² for 5 days."
214368701|NCT07093515|OTHER|No intervention|No intervention
214680719|NCT01614769|PROCEDURE|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
214981502|NCT02394769|DRUG|Aspirin|
214981503|NCT02394769|DRUG|Placebo for Aspirin|
214981504|NCT05031442|DEVICE|RH1 (low waist)|Investigational product variant 1 low waist
214981505|NCT05031442|DEVICE|Reference variant 1 (low waist)|Reference product variant 1
214981506|NCT05031442|DEVICE|RC2 (high waist)|Investigational product variant 2 high waist
214981507|NCT05031442|DEVICE|Reference variant 2 (high waist)|Reference product variant 2
214981508|NCT02675205|DRUG|Clopidogrel|clopidogrel: efficacy and safety in cerebral aneurysm stenting
214981509|NCT02675205|DRUG|Ticagrelor|ticagrelor:efficacy and safety in cerebral aneurysm stenting
214981510|NCT02675205|DRUG|aspirin|
214981511|NCT05628753|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)|LUS performed 30 mins prior to and 120 minutes after planned extubation with a linear high frequency probe longitudinal approach was used in all three zones Repeated third scan will be done prior to re-intubation (if required) The ultrasound total execution cut-off time expected to be less than 5 minutes
215088002|NCT05714137|BEHAVIORAL|Evaluation of the Effect of Proximal Massage and Fist Clenching in Reducing the Risk of Phlebitis From Peripheral Venous Catheter|"Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers.~Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of 2 days a day for four days, lasting between 30 seconds - 1 minute."
214368702|NCT07094802|DRUG|Intrathecal morphine with bupivacaine|Participants will receive 100 mcg intrathecal morphine along with 2.2ml of 0.5% hyperbaric bupivacaine
215088003|NCT00151372|BEHAVIORAL|Treatment Adherence Intervention|The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
214368703|NCT07094802|DRUG|Hyperbaric Bupivicaine|0.5% hyperbaric Bupivacaine 2.2 ml
214368704|NCT07094750|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214368705|NCT07094750|PROCEDURE|Bone Marrow Collection|Undergo bone marrow assessment
214368706|NCT07094750|OTHER|Electronic Health Record Review|Ancillary studies
214368707|NCT07094750|OTHER|Questionnaire Administration|Ancillary studies
214981512|NCT04630184|BEHAVIORAL|Exposure intervention in virtual reality|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) with cognitive restructuring and VR exposure supervised by psychologists
214981513|NCT04630184|BEHAVIORAL|Exercise|Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).
214981514|NCT04630184|BEHAVIORAL|Placebo|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) Discussion around social physical anxiety, stress management (relaxation and breathing) supervised by psychologists
214981515|NCT03620513|DRUG|Decongestant (oxymetazoline 0.05%)|As described in arm/group
214981516|NCT03620513|DRUG|Anesthesia (Lidocaine 15%)|As described in arm/group
214981517|NCT03620513|DRUG|Decongestants and Anesthesia (oxymetazoline and lidocaine)|As described in arm/group
214981518|NCT03620513|DRUG|Normal saline|Spray of normal saline as premedication
214368708|NCT07092748|DRUG|HS387|HS387 tablets will be given orally
214492595|NCT06759064|DRUG|zoledronic acid plus Sintilimab intraperitoneal injection|At D-5\~D-1, drain the ascites by placing a tube in the abdominal cavity first, try to drain the ascites as much as possible according to the clinical routine, and record the amount of drainage.D1, D8, D15, D22 start the first immunocheckpoint inhibitor combined with zoledronic acid treatment, try to drain the ascites first, calculate the amount of drugs according to the patient's body weight, and then dissolve the corresponding dosage of immunocheckpoint inhibitor and zoledronic acid in 100 ml of saline and inject them into the abdominal cavity respectively, and then inject another 100 ml of saline according to the patient's tolerance. The corresponding dose of immune checkpoint inhibitor and zoledronic acid was dissolved in 100 ml of saline and injected into the abdominal cavity.
214492596|NCT06791759|OTHER|The course on technology use in nursing|Students attended in the course technology use in nursing. The course consisted of 2 hours per week over 14 weeks. The course aims to provide students with an understanding of fundamental technological developments in nursing, highlighting the importance and impact of technology in nursing education and practice.Theoretical lessons were delivered by two nurse educators over 8 weeks through PowerPoint presentations and interactive discussions. For the remaining five weeks, students were given some assignments to increase their interaction with digital technological tools. Three assignments were planned for each of the students. In this context, microsoft teams, canva, microsoft powerpoint, kahoot, mentimeter, quizlet, ed-puzzle, capcut, mobile health applications, google classroom, discord and artificial intelligence applications were used for assignments.
214981519|NCT00037986|DEVICE|Hearing Aids|Hearing aid use
214981520|NCT01296412|DRUG|sitagliptin|100 mg tablet, orally, once daily.
214981521|NCT01296412|DRUG|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
214981522|NCT01296412|DRUG|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
214981523|NCT01296412|DRUG|metformin|metformin tablets at a dose of ≥1500 mg per day
214981524|NCT04176224|DRUG|MT-1186|Suspension
214981525|NCT04454359|DIETARY_SUPPLEMENT|Multi-nutrient supplement|
214981526|NCT04454359|DIETARY_SUPPLEMENT|Placebo|
214981527|NCT00776880|OTHER|ASA scale|ASA scale evaluation before operation
214981528|NCT00776880|OTHER|PPS scale|PPS scale evaluation before operation
214981529|NCT02461212|PROCEDURE|Magnetic Resonance Imaging (MRI)|A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
214981530|NCT02632617|OTHER|Computed tomographic angiography|Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
214981531|NCT02160626|DRUG|A-101 Vehicle|Placebo control
214981532|NCT02160626|DRUG|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
214981533|NCT02160626|DRUG|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
214981534|NCT03918317|DEVICE|AirXpanders AeroFormtissue expander|The AeroFormdevice will be placed in an immediate fashion at the time of mastectomy in a submuscular, prepectoral or dual-plane approach. The tissue expander will be minimally inflated intraoperatively to minimize dead space and while facilitating tension free closure. Participants will undergo standard postoperative management, and will be given instructions on utilization of the device, including daily expansion until desired volume is reached as determined b surgeon and participant agreement.
214981535|NCT02078258|BEHAVIORAL|ABMT|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
214981536|NCT01340690|DIETARY_SUPPLEMENT|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days
214981537|NCT01340690|DIETARY_SUPPLEMENT|placebo suspension|suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
214981538|NCT04559984|DEVICE|JUVÉDERM VOLUX®|JUVÉDERM VOLUX® injectable gel
215088004|NCT00151372|BEHAVIORAL|Enhanced Care|For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
214368709|NCT07093853|OTHER|Four Locator Attachments, Four Bar Attachment System|"This study retrospectively evaluated two types of implant-retained mandibular overdenture attachment systems placed in edentulous patients over a 10-year period. All patients received four dental implants placed in the interforaminal region (lateral incisor and first premolar areas).~In the Locator group, each implant was restored with an individual Locator attachment, allowing for independent retention and easier hygiene access.~In the Bar group, the four implants were splinted together with a rigid metal bar, and the overdenture was attached using clips that engaged the bar, offering splinted support and enhanced load distribution.~Both interventions were designed to support mandibular overdentures and were compared in terms of their long-term effects on posterior mandibular ridge resorption, marginal bone loss around implants, and anterior maxillary ridge resorption."
214368710|NCT07094620|RADIATION|Non-surgical rhinoplasty|Non-surgical rhinoplasty using hyaluronic acid at baseline consultation.
214368711|NCT07093905|PROCEDURE|arthroscopy of the shoulder rotator cuff|minimally invasive surgical procedure in which a camera (arthroscope) is inserted into the shoulder joint
214492597|NCT06758674|OTHER|education|Prepared in clear language and supported with visuals in line with guidelines and studies (Kottner et al. 2019, Orhan 2017, APUPA 2011, EPUAP and NPUAP 2009, EPUAP 2019, Arıkan and vanGiersbergen 2019, Arslantaş et al. 2018) training will be given to prevent pressure ulcers. Training content will be sent to expert opinion for content validity. In the content of the training, the definition of pressure ulcers, how they develop, high-risk areas for wound formation, identification of risks, evaluation of the skin, skin care, lying positions and position changes, supporting bone protrusions with pillows, lying on a support surface, nutritional status and content, fluid intake will be discussed.
214492598|NCT06738212|OTHER|Group A aerobic exercises|"Group A will perform the aerobic exercises (such as bicycling, treadmill and running) Aerobic exercises 15min/session for each exercise, 2 times/week. Frequency: 2 times /week Intensity: Easy to moderate about 60 to 75% of maximum heart rate Type: treadmill, bicycling, running Time: 45min/session~Bicycling:~15~\- Start with gentle, low-intensity cycling and gradually increase as comfort allows - Aim for regular, consistent cycling sessions (e.g., 2-3 times a week,15min/session) - Consider incorporating other exercises, like stretching or yoga, to complement cycling.~Running~To get started with running for dysmenorrhea:~1. Start with short distances and gradually increase as comfort allows~2. Aim for regular, consistent running sessions (e.g., 2-3 times a week,15 minute/session)~3. Consider incorporating other exercises, like stretching or yoga, to complement running."
214981539|NCT02888054|DRUG|lesinurad/allopurinol 200/300 FDC tablet|
214981540|NCT02888054|DRUG|lesinurad 200 mg|
214368712|NCT07094698|OTHER|sacral stimulation|A low-frequency (2-10 Hz) current with a pulse duration of 200 μs will be applied for 30 minutes, 5 days a week, under the supervision of a physiotherapist for 6 weeks.
214492599|NCT06738212|OTHER|Group B Aviva exercises|"Group B will perform the Aviva exercises in 18 different movements. Aviva exercise intervention method is based on a carefully structured, mild-to-moderate intensity series of 18 movement sequences and aerobic exercises 30min/session, 2 times/week (20)~Aviva Methods of exercises:~These exercises are a carefully structured, intense, and methodical series of movement sequences, including a 5 min warm-up exercise at the beginning and 5 min cooling-down exercises at the end of the session. These exercises are performed in Standing, Sitting, Supine lying, prone lying"
214981541|NCT02888054|DRUG|allopurinol 300 mg|
214981542|NCT05944640|PROCEDURE|Intraocular surgery|Pars plana vitrectomy or cataract surgery.
214981543|NCT01822444|OTHER|Biomarker analysis|
214981544|NCT03451396|DRUG|Lifitegrast|All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID
214981545|NCT02172027|DEVICE|Immunomagnetic Detection|Analysis of pleural effusion through immunomagnetic detection device.
214981546|NCT04371016|OTHER|Verticalization (bed)|"The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes.~At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method"
215088005|NCT03219411|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks
215088006|NCT03219411|OTHER|placebo|Placebo administered orally as capsules three times a day over 12 weeks
214368713|NCT07094828|OTHER|AOMI with D-Wall|"The intervention group will follow routine rehabilitative activity in the morning and will perform one hour of Action Observation and Motor Imagery training with augmented visual feedback (D-Wall) in the afternoon, three times a week.~Each session will be conducted as follows: first AO (Action Observation), then MI (Motor Imagery). During the MI phase, participants will be asked to imagine the motor tasks and then perform them, receiving real-time augmented visual feedback provided by the digital mirror."
214492600|NCT05113862|BIOLOGICAL|LD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
214981547|NCT05959928|DEVICE|Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely|The HaH team will place Viture Device on the patient's armpit and train the patient and/or caregiver. They will ask to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the Home data collection notebook (HDCN)
214981548|NCT04798157|RADIATION|transcranial doppler|Transcranial Doppler ultrasonography will be done using the ultrasound machine by placing a transducer over the relatively thinner temporal and occipital bones in order to visualize and evaluate the velocities at the circle of Willis.
214981549|NCT04239924|BEHAVIORAL|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program, specific coaching content is delivered by paramedics in 1-2 hour in-home sessions and over the phone throughout a 12-month period.
214680720|NCT03960138|DEVICE|Intermittent Theta-burst stimulation (iTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
214492601|NCT05113862|BIOLOGICAL|LD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
214492602|NCT05113862|BIOLOGICAL|HD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
214492603|NCT05113862|BIOLOGICAL|HD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
214492604|NCT06361173|OTHER|BMT4me|Caregivers will pilot test a Spanish version of the BMT4me app at a single time point.
214492605|NCT06717373|DEVICE|AutoAS|AutoAS is an artificial intelligence algorithm that will be tested retrospectively on the images acquired as part of the study
214492606|NCT06708962|OTHER|Mulligan's mobilization|Mulligan mobilization isthe concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient.
214492607|NCT06708962|OTHER|corticosteroid injection for rotator cuff tendinopathy|corticosteroid injection for rotator cuff helps resolving inflammation which occur for paraplegic patients from overuse of the crutches
214981550|NCT06122558|DIETARY_SUPPLEMENT|Probiotic|Probiotic Lactobacillus plantarum at 9 log CFU/day for 8 weeks
214981551|NCT06122558|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 8-weeks)
214981552|NCT07073560|PROCEDURE|Anthropometric Measurements|"1. Assessment of the accuracy of sex determination from hand indexes using anthropometric hand measurements.~2. Assessment of the accuracy of sex determination from the length of the metacarpals using x-ray radiographs on the same hand.~3. Determination of the best and least costly method for sex identification by comparing the effectiveness of the previous two methods."
214981553|NCT00678457|DRUG|Ondansetron|ondansetron (4 μg/kg b.i.d.)
214981554|NCT00678457|DRUG|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
214981555|NCT00678457|DRUG|Placebo|placebo
214981556|NCT00502437|DRUG|GRANISETRON|
214981557|NCT00592111|DRUG|COPP/ABV|4 courses of COPP/ABV hybrid
214981558|NCT00592111|DRUG|COPP/ABV|6 courses of COPP/ABV hybrid
214981559|NCT00592111|DRUG|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
214981560|NCT04081181|PROCEDURE|Microwave ablation|CT\_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60\_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
214981561|NCT03708146|DRUG|BIA 5-1058|"25 mg and 100 mg tablets; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), BIA 5-1058 will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), BIA 5-1058 will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
214981562|NCT03708146|DRUG|Placebo|"matching placebo tablet; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), placebo will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), placebo will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
214981563|NCT04075175|DRUG|S315|Human monoclonal antibody against Diphtheria Toxin
214981564|NCT04075175|DRUG|0.9% Sodium Chloride (NaCl)|Placebo 0.9% Sodium Chloride (NaCl)
214981565|NCT03342768|OTHER|Smartphone-based messages|"For the TID arm, the messages' contents include the tobacco industry's (TI's) anti-smoking campaigns that made smoking more grown-up and more appealing to youth; the TI's role in smoking in movies; etc.~For the sugar sweetened beverage (SSB) arm, the messages' contents include the disease conditions linked to SSBs, and the interference of sugar industry in scientific research."
214981566|NCT04059250|DEVICE|Nobio composite|Nobio has developed a bactericidal composite, which does not leak out the bactericidal nano fillers
214368714|NCT07094828|OTHER|Routine physiotherapy with D-Wall|The control group will also follow routine rehabilitative activity in the morning, while in the afternoon they will perform motor training of the same duration, without Action Observation and Motor Imagery, but solely with augmented visual feedback (D-Wall), with the same weekly frequency.
214492608|NCT06822465|OTHER|P. aeruginosa using in vitro and in vivo assays|This trial will entail collecting and screening stool samples obtained from critically ill patients for their virulence inducing capabilities on laboratory strains of P. aeruginosa using in vitro and in vivo assays. The investigators also plan to isolate strains of intestinal P. aeruginosa from stool samples to determine the prevalence of intestinal P. aeruginosa in a population of critically ill patients.
214492609|NCT06613867|OTHER|Wakobotikodro|Wakobotikodro : an intervention combining (i) training matrons to identify and monitor high-risk pregnancies, (ii) integrating them into the healthcare system and (iii) using a digital decision-support application installed on a smartphone and adapted to their profile, could improve the identification and monitoring of high-risk pregnancies.
215088007|NCT02384434|DEVICE|THOR Laser System for Low Level Laser Therapy (LLLT)|Non-invasive, a cold laser output treatment.
215088008|NCT03301116|BEHAVIORAL|Healthy Moves for Aging Well (Healthy Moves)|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.
215088009|NCT03301116|BEHAVIORAL|Active Mind for Aging Well (Active Mind)|A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
215088010|NCT06208345|BEHAVIORAL|Life-Style app|The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
215088011|NCT03348995|DEVICE|Bridge-Enhanced ACL Restoration (BEAR)|In the BEAR Procedure, surgery is performed to sew the ACL back together and a scaffold is placed between the torn ends at the time of repair.
214492610|NCT06822140|DEVICE|transcutaneous auricular vagus nerve stimulation|"Stimulation parameters:~* Stimulating side: ipsilateral to the infarcted brain hemisphere~* Location of pStimulation: Cymba conchae~* Impulse shape: bi-phasic~* Impulse intensity: at least 0.5 mA (max. 2.0 mA).~* Impulse duration: 28 sec on, 32 sec off~* Impulse frequency: 20-30 Hz."
214492611|NCT06822140|DEVICE|sham-stimulation|An electrode is only attached to the ear without applying electrical impulses.
214492612|NCT06591715|OTHER|Home exercise program|The home exercise program routinely given to individuals with knee OA in addition to their medical treatment will consist of exercises routinely used in the BETY innovation.
214492613|NCT06728215|DEVICE|CRET 1|Fisiowarm 7.0 and the new capacitive/resistive electrode, for 15' at a frequency of 300 KHz (Treated Group).
214492614|NCT06728215|DEVICE|CRET 2|Classical methodology using the monopolar electrode Activ CT8 INDIBA® at a frequency of 448 KHz in both resistive and capacitive modes, for 10 min each mode with two different electrodes. (Control group).
214492615|NCT06658145|DEVICE|Vnotes surgery using fully visualised surgical instruments|Vnotes surgery using fully visualised surgical instruments
214492616|NCT06658145|DEVICE|Vnotes surgery using traditional surgical instruments|Vnotes surgery using traditional surgical instruments
214492617|NCT06183645|DEVICE|Actimyo|Participants will wear 2 Actimyos in everyday life. Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
214680721|NCT03960138|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
214981567|NCT04059250|DEVICE|traditional composite|traditional composite which has no bactericidal activities
214981568|NCT01341704|BIOLOGICAL|MSP3-LSP/AlOH|"30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)~Secondary administration (Boost):~Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1"
214368715|NCT07089836|DEVICE|ALPCO Syphilis-T|Detection of antibodies to Treponema pallidum in human serum and plasma
214368716|NCT07089836|DEVICE|ALPCO Syphilis-NT CLIA Kits|Detection of antibodies to lipoidal antigens in human serum and plasma
214368717|NCT07094763|DRUG|TNK plus standard medical treatment|Patients in the TNK treatment group will receive TNK intravenous thrombolysis and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg.
214368718|NCT07094763|DRUG|standard medical management|standard medical management
214368719|NCT07093723|DIAGNOSTIC_TEST|S100B Protein|Serum level of S100B Protein was measured on the first and third days of seizure activity by ELISA.
214368720|NCT07093723|DIAGNOSTIC_TEST|Neutrophils to Lymphocytes ratio|Neutrophils to Lymphocytes ratio was measured on the first and third day of seizure activity obtained by complete blood count.
214368721|NCT07092657|OTHER|Nursing Education Intervention|Four standardized sessions. With a duration of 40 to 60 minutes each session, once a week for a period of one month and a follow-up one month after the end of the intervention. Interventions are carried out at different times depending on the availability of the nursing professionals.
214368722|NCT07094438|PROCEDURE|Deep Brain Stimulation, DBS|Deep brain stimulation (DBS) is performed after preoperative MRI and CT images are fused in a planning system to determine the target and trajectory. Under general anesthesia, electrodes are precisely implanted into the fornix or nucleus basalis of Meynert using a stereotactic frame or neurosurgical robot. The electrodes are inserted through a burr hole in the patient's skull and connected to a pulse generator placed subcutaneously in the chest. Optimal stimulation parameters for Alzheimer's disease are not yet established. For fornix targets, settings are typically 3-3.5 V, \~130 Hz, 90 μs; for nucleus basalis targets, 2-4.5 V, 10-20 Hz, 90-150 μs, adjusted according to anatomical features and intraoperative responses.
214368723|NCT07094438|PROCEDURE|Deep cervical lymphatic-venous anastomosis, LVA|Cervical deep lymphaticovenous anastomosis (LVA) microsurgically connects deep cervical lymphatic vessels to adjacent veins, promoting drainage of brain-derived amyloid-β and tau into the venous system and potentially alleviating Alzheimer's disease symptoms. The minimally invasive neck procedure involves small incisions and high-magnification suturing of lymphatics and veins with ultra-fine (11-0 or 12-0) sutures, creating multiple anastomoses to enhance brain lymphatic outflow.
214368724|NCT07094438|DRUG|Recognized pharmacological treatments for AD.|Patients in the medication group received only the currently recognized pharmacological treatments for AD, including Memantine Hydrochloride and Donepezil.
214368725|NCT07093866|DRUG|Disitamab Vedotin (RC48)|Disitamab Vedotin 2mg/kg is administered intravenously once every 2 weeks (1 cycle)
214368726|NCT07093866|DRUG|Abiraterone + prednisone|Abiraterone 1000mg is administered orally once a day，and prednisone 5mg is administered orally twice a day.
214368727|NCT07092709|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization, and within 24 hours of stroke onset.
214981569|NCT01341704|BIOLOGICAL|Verorab Vaccine|The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.
214368728|NCT07092709|DRUG|Placebo|Matched placebo is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization, and within 24 hours of stroke onset.
214368729|NCT07092956|BEHAVIORAL|Financial Literacy Education|A structured financial literacy training program delivered by an expert in economics. The training includes topics such as budgeting, saving, opportunity cost, financial planning, and investment tools. It was provided to the experimental group over a single session, and outcomes were assessed three weeks later.
214368730|NCT07093060|DRUG|Oxytocin lower dose (24IU)|Oxytocin (24IU) will be administered as a lingual spray (6, 0.1 puffs (4IU per puff) of spray on and under the tongue)
214492618|NCT03999983|OTHER|Observational Prospective Registry|This is a prospective registry looking at patients admitted for stroke with evidence of Vertebral Artery Origin Stenosis. Patients clinical outcomes will be collected at 30 days and 1-year post-treatment and angiographic outcomes at 1-year post-treatment
214492619|NCT06761820|DEVICE|Echocardiogram|Echo : for evaluation anatomical and functional alteration LV and diastolic dysfunction and myocardial reserve measure by LVEF by M-mode before the study and follow up echo assessment 3 months after glycemic control
214680722|NCT00587418|DIETARY_SUPPLEMENT|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
214981570|NCT01341704|OTHER|0.9% NaCl/Normal Saline|0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
215088012|NCT06360341|BEHAVIORAL|Emergency Department Digital Pain Self-Management Intervention (EDPSI)|The EDPSI is a developed supplemental digital video for patients presenting to the emergency department with acute low back pain (aLBP). The content consists of self-management approaches for diverse adult patient preferences including biopsychosocial contributors to pain and clinical practice guidelines to self-management options. Highlights of the discharge instructions summary include follow-up with provider, red flag warnings, and medication safety. Actor demonstration of ergonomics and range of motion movements provide application of Physical Therapy (PT)-based preventative strategies. Combination therapies including PT counseling, complementary alternative medicine (acupuncture, massage, yoga, or Pilates), and use of and safety with ice or heat thermal therapies. Active participation, stress management, and involvement of support systems are addressed.
215088013|NCT06360341|OTHER|Routine Discharge Care|Routine Discharge Care
214680723|NCT00587418|DIETARY_SUPPLEMENT|Placebo|Placebo powder 9.2g bid for 7 days
214981571|NCT03999047|DIAGNOSTIC_TEST|PRISMA score|Screening for frailty using PRISMA-7
214981572|NCT00066456|RADIATION|3-Dimensional Conformal Radiation Therapy|
214981573|NCT00066456|DRUG|Chemosensitization/Potentiation Therapy|
214981574|NCT00066456|DRUG|Docetaxel|Given IV
214981575|NCT02097732|DRUG|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
214981576|NCT02097732|PROCEDURE|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
214981577|NCT03351270|OTHER|Standardized strength, respiratory and motor function assessments|Standardized assessments will be adjusted by the age, the ambulant status and the respiratory status of the patient. The visit frequency will also be adjusted according to the age and to the time spent in the study varying between quarterly to yearly.
214981578|NCT04675879|DEVICE|Shoulder arm bandage|Three different shoulder-arm bandage types
214981579|NCT01029756|DEVICE|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
214981580|NCT01029756|DEVICE|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
214981581|NCT00906321|BEHAVIORAL|Web-Based Decision Support|
214981582|NCT00300157|DEVICE|Percutaneous coronary intervention with Taxus stent|
214981583|NCT04562909|DEVICE|Neurocom balance master device|With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.
214981584|NCT02349438|DEVICE|senofilcon A|A soft spherical contact lens
214981585|NCT02349438|DEVICE|lotrafilcon B|
214981586|NCT01949545|DRUG|Carfilzomib|Carfilzomib was administered by IV injection over 30 minutes
214981587|NCT03029390|DIETARY_SUPPLEMENT|Berberine|"Berberine capsules, 500 mg, three per day before each meal during 14 weeks.~The patients will have a running period during two weeks:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study (14 week), they will be receive three 500 mg"
214981588|NCT03029390|DRUG|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.~The patients will have a running period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
214981589|NCT01050153|DRUG|Dalteparin sodium|Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
214981590|NCT01050153|DRUG|Dalteparin sodium/aspirin|Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
214981591|NCT00532623|DRUG|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
214981592|NCT00532623|DRUG|Sequential|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
214981593|NCT04699539|RADIATION|SBRT|SBRT: in 5-6fractions with Cyberknife.
214981594|NCT04699539|DRUG|Chemotherapy|Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) or single-agent oral S-1 (60-120 mg/ daily, d1-14) , repeat every 3 weeks.
214981595|NCT00623181|BIOLOGICAL|Fluzone: Influenza virus vaccine|0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid
214981596|NCT00623181|BIOLOGICAL|Fluzone: Influenza virus vaccine|0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid
214981597|NCT03659344|DRUG|Vicryl plus|Using vicryl sutures which coated with triclosan (antibiotic)
214981598|NCT05200169|DRUG|14C-AB1010|Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
214981599|NCT00320047|DRUG|Baclofen|Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
214981600|NCT00053326|DRUG|fenretinide|Given orally
214981601|NCT00053326|OTHER|pharmacological study|Optional correlative studies
214981602|NCT03433235|DRUG|Edoxaban|"1-3-6-12 rule\*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS \<8)~After 6 days: moderate ischemic strokes (NIHSS 8-16)~After 12 days: severe ischemic strokes (NIHSS \>16)~\- NIHSS: National Institute of Health Stroke Scales"
214981603|NCT02957201|OTHER|Blood samples|Blood samples at baseline and 3 timepoints for EPC analysis
214981604|NCT04902781|DRUG|AT-007|Treatment with AT-007 given orally
214981605|NCT04902781|OTHER|Placebo|Placebo given orally
214981606|NCT01781897|DEVICE|acupuncture|sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
214981607|NCT01781897|DRUG|mosapride|Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
214981608|NCT04936893|BEHAVIORAL|Mindfulness Practice|10-15 mins of daily mindfulness practice using HeadSpace, for 3 weeks
214981609|NCT04936893|BEHAVIORAL|Cognitive training|10-15 mins of cognitive games using Lumosity, for 3 weeks
214981610|NCT01973751|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 2 puffs (200mcg) twice a day for 8 weeks
214981611|NCT04367298|BEHAVIORAL|Chronoprevention|Preventive measures will be focused on organizational, educational and behavioural elements related to older people and healthcare professionals
214981612|NCT05241301|OTHER|one to one interviews|one to one interviews to explore the perspective of family carers of older adults of Turkish and Moroccan origin in Flanders and Brussels, Belgium, concerning advance care planning (ACP)
214368731|NCT07093060|DRUG|Oxytocin higher dose (48IU)|48IU oxytocin administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on or under the tongue)
214368732|NCT07093060|DRUG|Atosiban|150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue)
214368733|NCT07093060|DRUG|Placebo|Placebo administered as a lingual spray (6, 0.1 ml sprays one and under the tongue. Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and atosiban interventions
214368734|NCT07092982|PROCEDURE|Ultrasound Guided Suprainguinal Fascia Iliaca Block|Ultrasound Guided Suprainguinal Fascia Iliaca Block, 30 ml Bupivacain %0,25
214368735|NCT07092982|PROCEDURE|Ultrasound Guided Adductor Canal Block|Ultrasound Guided Adductor Canal Block, 15ml Bupivacain %0,25
214368736|NCT07092982|PROCEDURE|Ultrasound Guided iPACK Block|Ultrasound Guided iPACK Block, 15ml Bupivacain %0,25
214368737|NCT07093372|DEVICE|Laryngeal Mask Airway|A supraglottic airway device (i-gel) used to deliver oxygen and assist ventilation during electroconvulsive therapy (ECT) in obese patients. The device is inserted after induction of general anesthesia and removed after spontaneous respiration is restored.
214492620|NCT06762522|OTHER|Nonlinear dynamical neurofeedback (NLD)|NeurOptimal nonlinear dynamical (NLD) neurofeedback brain training works as a detection and monitoring system of changes in cortical patterns within the brain, mirroring the brain activity that can be undermining optimal brain function, providing the brain with the information it needs to make its own adjustments which over time results in the brain functioning more efficiently and effectively. Two scalp sensors at C3 \& C4 and two earclips at tops of ears (reference) and one on the earlobe (ground) are used to read EEG activity which is analyzed by the NeurOptimal software. As participants listen to music through earbuds, information is fed back to the individual by slight interruptions in the music. One session lasts 33.5 minutes.
214492621|NCT06762522|OTHER|Low energy neurofeedback system (LENS)|Low energy neurofeedback system (LENS) therapy is an EEG-based direct neurofeedback system that stimulates the brain to reset itself and achieve optimal performance. Therapy consists of delivery of a tiny electromagnetic field carrying the feedback signal down the electrode wires for only one second at each of the chosen electrode sites during every session. Generally, between one and seven of the ordinary electrode sites are utilized during each session. Therapy is adapted to the participant's reactivity/sensitivity and the response of their nervous system.
214492622|NCT06762522|OTHER|Brain Music|Chen Medimo Corp (CMC) Brain Music neurofeedback analyzes an individual's EEG brainwave patterns and translates them into orchestral music. Listening to this personalized brain music allows the individual to gain self-awareness and rewire and alter their own mental states. The Brain Music protocol requires regular in-person follow-ups for optimal results. Generally, the number of sessions varies based on individual needs and the progress made in response to the CMC Brain Music. A minimum of once a week in-person sessions is recommended for qEEG model updating to accurately track progress. Each session may last 30 minutes. Additionally, participants are advised to listen to their personalised music at least once a day, with a minimum of two listens per session. In general, participants may start to detect a change in their neurodevelopmental or cognitive function in 4-6 weeks.
214492623|NCT06762522|OTHER|Usual Care|The Usual Care control group will be followed in the Memory clinic at intervals determined by their clinician. Usual Care for individuals with mild cognitive impairment (MCI) at the The Memory Clinic consists of inter-professional assessment, diagnosis and recommendations. There are currently no drugs approved to treat MCI. Therapy is aimed at managing treatable causes and contributors including medication side effects, thyroid problems, sleep apnea, vitabim B deficiency, depression, anxiety, and unrecognized or untreated difficulties with hearing or vision. Neurofeedback is not a component of the standard of care.
214492624|NCT06761482|PROCEDURE|monitoring by dd-cfDNA|monitoring by dd-cfDNA
214492625|NCT06761482|PROCEDURE|monitoring by T-Vis|monitoring by T-Vis
214492626|NCT06761482|PROCEDURE|monitoring by dd-cfDNA+ T-Vis|monitoring by dd-cfDNA+ T-Vis
214492627|NCT06761235|DIAGNOSTIC_TEST|Standard BP intervention|Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure.
214492628|NCT06761235|DIAGNOSTIC_TEST|EVA intervention|Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure. In contrast to BP arm, EVA arm will additionally reciuve counseling about vascular age.
214492629|NCT06569914|BEHAVIORAL|Humanized care|(1) Humanized environmental care；(2) Humanized medical guidance；(3)Humanized psychological nursing；(4) Humanized and standardized management of IVGTT treatment process
214492630|NCT06570577|PROCEDURE|Inter-semispinalis Plane Block|A nerve block targeting the dorsal rami of the cervical spinal nerves can help alleviate postoperative incisional pain.
214492631|NCT06570577|DRUG|Opioids|Routine Pain Management
214492632|NCT06740799|DRUG|Quizartinib|Participants will receive a single oral dose of 30 mg
214492633|NCT06889506|PROCEDURE|skin biopsy and serum sample|skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control
214492634|NCT05629689|DRUG|GEH200520 Injection / GEH200521 (18F) Injection - Part A|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
214492635|NCT05629689|DIAGNOSTIC_TEST|Dynamic and Static - PET/CT scan|Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
214492636|NCT05629689|DRUG|GEH200520 Injection / GEH200521 (18F) Injection - Part B|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
214492637|NCT05629689|DIAGNOSTIC_TEST|Static - PET/CT scan|Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.
214492638|NCT06832709|OTHER|a program of rehabilitation|physical activities, health education, psychosocial and motivational support
214368738|NCT07093372|DEVICE|High-Flow Nasal Cannula|A heated and humidified oxygen delivery system that provides high flow oxygen through nasal prongs. In this study, it is used throughout the ECT procedure to maintain oxygenation in obese patients without the need for invasive airway insertion.
214680724|NCT02388529|DRUG|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
214981613|NCT06233786|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).
214492639|NCT06738953|BEHAVIORAL|Cognitive-Behavioral Intervention to increase Self Efficacy|Participants in the intervention group will receive a brief (6 sessions of 75-90 min each) cognitive-behavioral intervention. The intervention will be delivered in an online group format (subgroups of 8-12 participants). The courses will be structured according to well-established self-efficacy interventions with proven effectiveness (Bresó et al., 2011; Cieslak et al., 2016; Luszczynska et al., 2007), targeting Bandura's four key sources of self-efficacy (i.e., mastery experience, vicarious experience, verbal persuasion, and physiological/emotional arousal). Each session will consist of a theoretical and a practical part and be structured as follows: opening, discussion of homework (with special emphasis on participants' progress and sharing of experiences), introduction to the topic, practice, answering open questions, closing. The course sessions are accompanied by weekly homework assignments to be completed at home.
214492640|NCT06738953|BEHAVIORAL|Placebo: Weekly Recap and Group Discussion on Psychological Experiments|Participants in the control group will meet in small groups (8-12 participants per group; 6 sessions, similar to the intervention group). They will receive a brief introduction to well-known psychological experiments and findings (e.g., the Asch experiment, selective attention) and discuss their perspectives on these topics, including personal implications of the experiments. Content related to self-efficacy or cognitive-behavioral interventions will be explicitly avoided. To prevent expectancy effects and other biases, participants will not be informed that they are part of the control group. If suspicions arise, participants will be told that group leaders are not allowed to disclose this. Group sessions will be led by a psychologist. The course materials (workbook, slides, and course instructions) will be shared on OSF.
214492641|NCT06779643|DEVICE|General Anesthesia (GA)|Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
214492642|NCT06779643|DEVICE|Continuous Brachial Plexus Block|Patients were positioned supine with the head slightly turned to the contralateral side to expose the supraclavicular fossa. The injection site was prepared using standard aseptic techniques. Under ultrasound guidance, a needle was advanced to the vicinity of the brachial plexus. Aspiration was performed to confirm the absence of blood return before the slow, incremental injection of either liposomal bupivacaine \[adult dose: 133 mg (10 mL) to 266 mg (20 mL)\] or ropivacaine \[adult dose: 20 mL of 0.5% ropivacaine, administered via continuous infusion at a rate of 5-10 mL/h; pediatric dose: 0.1% ropivacaine at 0.1-0.2 mL/kg, administered via continuous infusion at 0.05-0.15 mL/kg/h\]. Patient responses were closely monitored throughout the procedure.
214680725|NCT02388529|DRUG|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
214680726|NCT02388529|DRUG|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
214680727|NCT02388529|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
214680728|NCT06034834|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
214680729|NCT00559052|DRUG|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
214680730|NCT04760314|DRUG|Lebrikizumab|Administered SC
214680731|NCT04760314|DRUG|Placebo|Administered SC
214680732|NCT04760314|DRUG|Topical Corticosteroid|Self-applied
214680733|NCT04279561|PROCEDURE|Computed Tomography|Undergo 68Ga-PSMA-11 PET/CT
214680734|NCT04279561|DRUG|Gallium Ga 68 Gozetotide|Given IV
214680735|NCT04279561|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET/CT
214680736|NCT01290484|DRUG|Sildenafil|Sildenafil oral tablet three times daily
214680737|NCT03883022|DRUG|with U-VANCO (vancomycin hydrochloride)|1 gm or 2 gm mixed with autogenous cancellous bone graft
214680738|NCT03883022|DRUG|without U-VANCO (vancomycin hydrochloride)|no vancomycin added
214981614|NCT03632824|DRUG|Tranexamic Acid|"One gram( 2 ampules ) of tranexamic acid was received by the participant intravenously twice daily for 48 hours followed by 500 mg tranexamic acid tablet three times daily for 5 days .~follow up of the patient was done by recurrence of the bleeding latter on during pregnancy . the course of treatment was repeated again ."
215088014|NCT05276310|BIOLOGICAL|IMC-002|Part 1: Dose escalation IMC-002 5, 10, 20, and 30 mg/kg over 3 hours (±30 minutes) intravenous (IV) infusion every 2 weeks Part 2: Expansion cohort IMC-002 20 mg/kg over 3 hours (±30 minutes) IV infusion at the first cycle, if the first infusion is tolerated, then over 1 to 1.5 hours (±10 minutes) IV infusion at all following cycles every 3 weeks In hepatocellular (HCC) Cohort, Lenvatinib 8 mg once daily (body weight of \< 60 kg), or 12 mg once daily (body weight of ≥ 60 kg) In triple negative breast cancer (TNBC) Cohort, Paclitaxel 175 mg/m2 IV infusion on Day 1 of each cycle, or Gemcitabine 1,000 mg/m2 followed by Carboplatin AUC 2 IV infusion on Day 1 and Day 8 of each cycle In biliary tract cancer (BTC) Cohort, Lenvatinib 8 mg once daily (body weight of \< 60 kg), or 12 mg once daily (body weight of ≥ 60 kg) In B-cell lymphoma Cohort, Rituximab 375 mg/m2 IV infusion on Day 1 of each cycle
214680739|NCT03572543|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
214981615|NCT05766241|BEHAVIORAL|Sensory Strategies Training|In SST, participants will be introduced to the concept of sensory processing in the context of PTSD and will learn about the ways in which difficulties in this area can impact their affective, cognitive, and functional outcomes. Participants will learn about the effects of PTSD symptoms on their ability to regulate stressful situations and engage in social interactions, as well as the benefits of physical activity and proper sleep hygiene. Participants will also identify functional goals (e.g., reduce sensation-avoiding, better regulate physical and emotional reactions to trauma reminders, increase sensory sensitivity, etc.) which they will aim to achieve with the knowledge and resources gained from SST. Throughout the program, participants will learn various strategies to help with movement, sleep, and interacting with others, and will have opportunities to practice the strategies identified as being relevant to their specific needs during their baseline sensory assessment.
214981616|NCT05037604|OTHER|Questionnaire about associated factors|Questionnaire about age, prolonged sun exposure, intake of anticoagulants / antiplatelets, intake of oral steroids, chronic kidney disease. Maternal age\> 40 years in their last child , time of lactation per pregnancy and cumulative time of lactation. Age of the first pregnancy and age of menopause onset.
214981617|NCT05037604|DIAGNOSTIC_TEST|Self questionnaire diagnostic tool|Self questionnaire of physical characteristics
215088015|NCT05845671|DRUG|Amivantamab 1050mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
214981618|NCT05037604|OTHER|Physical Examination|Physical Examination made by a dermatologist
214981619|NCT04576000|DRUG|Janus Kinase Inhibitor|Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)
214981620|NCT03540459|DIAGNOSTIC_TEST|sleep polygraphy|sleep polygraphy (one night) in all included patients
214981621|NCT03966989|BEHAVIORAL|Performance Feedback|Performance feedback offline that benchmarks providers' own performance to that of their peers
214981622|NCT03389165|DEVICE|Wearable hip assist robot|All participants climbed stairs from the first basement level to the fourth floor of the Proton Therapy Center, Samsung Medical Center, Korea with and without a wearable hip assist robot. During climbing stairs, the metabolic energy expenditure of all participants was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy).
214981623|NCT01621074|DIETARY_SUPPLEMENT|Sodium bicarbonate|Ergogenic effect
214981624|NCT01621074|DIETARY_SUPPLEMENT|Placebo|Placebo effect
214981625|NCT00499122|DRUG|Cyclophosphamide|
214981626|NCT00499122|DRUG|Docetaxel|
214981627|NCT00499122|DRUG|Doxorubicin|
214981628|NCT00499122|DRUG|NOV 002|
214981629|NCT03031925|OTHER|ANXA2|serum and urinary concentration
214368739|NCT07092930|DIETARY_SUPPLEMENT|BA and SB supplementation|"Assigned Interventions:~* Beta-alanine (BA)~* Sodium bicarbonate (SB)~Description:~• Participants receive beta-alanine and sodium bicarbonate~Intervention list \& supplementation details:~1. Beta-alanine (BA)~   * Form: Gelatin capsules~  * Substance: Pure beta-alanine~  * Daily dose: 6.4 g/day~  * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner)~  * Supplementation period: days 1 to 28~2. Sodium bicarbonate (SB)~   * Form: Gelatin capsules~  * Substance: Pure sodium bicarbonate~  * Daily dose: 0.3 g/kg body mass per day~  * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner)~  * Supplementation period: days 21 to 28 of BA or PL1 supplementation~Rationale:~• This group tests the combined effects of BA and SB"
214492643|NCT06759896|DEVICE|Protraction facemask|Patients assigned to intervention 1 will utilize the Petit protraction facemask, in conjunction with a rapid maxillary expansion (RME). This facemask consists of a forehead pad and chin pad linked by a sturdy steel support rod.
214492644|NCT06759896|DEVICE|Upper partial fixed appliance|Upper partial fixed appliance / 2 by 4 appliance will be used in this study by using bracket set (119-142 Unitek™ Gemini Bracket MBT™ U/L 5x5 0T-Cuspid 3Hk) with molar bands (3M™ Victory Series™ First Molar Bands) or buccal tubes (3M™ Victory Series™ Superior Fit Buccal Tubes) and upper nickel titanium archwires (3M™ Unitek™ Nitinol Heat-activated Archwire) and upper stainless steel archwires (3M™ Unitek™ Permachrome Standard Archwire) .
214492645|NCT06793761|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, 3 cycles
214492646|NCT06793761|DRUG|Cisplatin|cisplatin 75mg/m2, IV, 3 cycles
214492647|NCT06793761|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg, IV, 3 cycles
214492648|NCT06836297|DEVICE|Transcranial Magnetic Stimulation Sham|Participants will be asked to perform various behavioral tasks involving the use of action observation or motor imagery. During these tasks, transcranial magnetic stimulation will be used.
214492649|NCT05169697|DRUG|A:YH002+YH001|YH002 on CnD1,YH001 on CnD8,Q3W
214492650|NCT05169697|DRUG|B:YH002+YH001|YH002 and YH001 on same day,Q3W
214492651|NCT05169697|DRUG|YH002+YH001|A traditional 3+3 dose escalation algorithm
214492652|NCT05375851|OTHER|Digital Interventions|"The digital interventions will consist of two parts:~A) Psychoeducation videos: Five psychoeducation videos on mental health and GAD will be produced especially for the research to be watched by the patient between consultations. These videos will last approximately 3 minutes, will use animations and educational content. They will be available on +PSI app. The topics of the videos will be as follows: Normal Anxiety versus Pathological Anxiety; Sleep Hygiene; Healthy Eating and Mental Health; Physical Exercise and Mental Health; Excessive Consumption of Alcohol and Drugs.~B) GAD-7 Scale: The patient will be instructed to respond to the GAD-7 self-administered scale the day before their next scheduled appointment. This instrument will also be available free of charge on +PSI mobile app and will be used to guide clinical management."
214981630|NCT01967199|DEVICE|Everolimus-eluting balloon expandable stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
214981631|NCT01967199|DEVICE|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
214981632|NCT05285839|DRUG|Dupixent|dupilumab 300mg
214981633|NCT06201104|OTHER|Patient empowerment education|"After the pre-test is administered to the patients in the experimental group, patient empowerment training (intervention) will be given. Patients will be divided into groups of 15 people and the training will be given in a total of 6 sessions, all in one session. The Patient Empowerment Handbook prepared by the researchers will be used during the training. The training was planned to last 1 hour (45 minutes of theoretical training, 15 minutes of question and answer). The training was planned to be carried out in an interactive manner (question and answer method, sharing of patient experiences, group discussion). The Patient Empowerment Handbook will be delivered to patients after the training for them to read whenever they want. How to use the manual will be explained to patients."
214981634|NCT00299039|DRUG|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
214981635|NCT00299039|DRUG|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
215088016|NCT05845671|DRUG|Amivantamab 1400mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
215088017|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
214981636|NCT00903968|DRUG|Plerixafor|
214981637|NCT00903968|DRUG|bortezomib|
215088018|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
214368740|NCT07092930|DIETARY_SUPPLEMENT|BA and PL2 supplementation|"Participants in this intervention group will undergo chronic supplementation with beta-alanine (BA) and an inert placebo (PL2) matched to the sodium bicarbonate (SB) protocol.~* Beta-alanine (pure, in gelatin capsules) will be administered at a total daily dose of 6.4 g, divided into four servings taken with meals, over a period of 28 consecutive days.~* PL2 (placebo matched to SB, in gelatin capsules) will be administered from Day 21 to Day 28 of beta-alanine supplementation, at a daily dose of 0.3 g per kg of body mass, divided into three equal servings taken with meals.~This group allows for evaluation of the isolated effects of BA supplementation when combined with a placebo comparator to SB"
214368741|NCT07092930|DIETARY_SUPPLEMENT|PL1 and SB supplementation|"Assigned Interventions:~* Placebo matched to BA (PL1)~* Sodium bicarbonate (SB)~Description:~• Participants receive only sodium bicarbonate as the active compound and placebo capsules matching the BA protocol.~Intervention list \& supplementation details:~1. Placebo matched to BA (PL1)~   * Form: Gelatin capsules~  * Substance: Inert substance matched in appearance and dosing schedule to BA~  * Daily dose: 6.4 g/day~  * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner)~  * Supplementation period: days 1 to 28~2. Sodium bicarbonate (SB)~   * Form: Gelatin capsules~  * Substance: Pure sodium bicarbonate~  * Daily dose: 0.3 g/kg body mass per day~  * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner)~  * Supplementation period: days 21 to 28 of BA or PL1 supplementation~Rationale:~• This group tests the isolated effects of SB"
214981638|NCT00903968|DRUG|Dexamethasone|
214492653|NCT05375851|DRUG|Treatment as Usual|"The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil."
214981639|NCT00189930|BIOLOGICAL|MVA-nef|3 imm.: 5E8\_TCID50 MVA-nef, 1E8\_TCID50 MVA-nef in non-dominant upper arm
214981640|NCT00189930|BIOLOGICAL|IMVAMUNE|3 immunizations: 1E8\_TCID50 IMVAMUNE
214981641|NCT00339053|DRUG|Immunonutrition ( Impact)|
214981642|NCT05278468|OTHER|PCR test for covid-19|real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
214492654|NCT04895956|PROCEDURE|Intra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
214981643|NCT04836741|DEVICE|Micro Hand S robot|The surgeries are performed with the Micro Hand S robot
214981644|NCT04836741|DEVICE|Laparoscope|The surgeries are performed with the laparoscope
214981645|NCT02924935|DIETARY_SUPPLEMENT|L-Histidine|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
214981646|NCT01663623|BIOLOGICAL|Placebo|Placebo
214981647|NCT01663623|BIOLOGICAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg
214981648|NCT01663623|DRUG|Azathioprine|Azathioprine
214981649|NCT02251275|DRUG|Tolvaptan|Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
214368742|NCT07092930|DIETARY_SUPPLEMENT|PL1 and PL2 supplementation|"Assigned Interventions:~* Placebo matched to BA (PL1)~* Placebo matched to SB (PL2)~Description:~• Participants receive two matched placebos.~Intervention list \& supplementation details:~1. Placebo matched to BA (PL1)~   * Form: Gelatin capsules~  * Substance: Inert substance matched in appearance and dosing schedule to BA~  * Daily dose: 6.4 g/day~  * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner)~  * Supplementation period: days 1 to 28~2. Placebo matched to SB (PL2)~   * Form: Gelatin capsules~  * Substance: Inert substance matched in appearance and timing to SB~  * Daily dose: 0.3 g/kg body mass per day~  * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner)~  * Supplementation period: days 21 to 28 of BA or PL1 supplementation~Rationale:~• This serves as the control group for comparison with all active intervention arms."
214368743|NCT07092839|OTHER|transcranial electric stimulation|tTIS is an innovative non-invasive brain stimulation approach, in which two or more independent stimulation channels deliver high-frequency currents in the kHz range (oscillating at f1 and f1 + Δf). These high-frequency currents are assumed to be too high to effectively modulate neuronal activity. Still, by applying a small shift in frequency, they result in a modulated electric field with the envelope oscillating at the low-frequency Δf (target frequency) where the two currents overlap. The peak of the modulated envelope amplitude can be steered towards specific areas located deep in the brain, by tuning the positions of the electrodes and the current ratio across stimulation channels. Here, we applied tTIS via surface electrodes applying a low-intensity (2mA baseline to peak), sub-threshold protocol following the safety guidelines for low-intensity transcranial electric stimulation in humans.
214368744|NCT07094841|DEVICE|3D PRINTED herbst appliance|participants will receive treatment with herbst appliance for 4 to 5 months
214368745|NCT07094841|DEVICE|3d printed mara|participants will receive treatment with mara appliance for 4 to 5 months
214368746|NCT07093385|DRUG|Faricimab Injection|Faricimab (6 mg/0.05 mL) for three months (loading dose) in a sterile environment,
214368747|NCT07094516|BIOLOGICAL|VHB937|VHB937 solution for infusion
214680740|NCT03435991|OTHER|Validation Experience Sampling Method 'Uromate'|In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.
214680741|NCT03952897|OTHER|balneotherapy|10 days of balneotherapy with immersion techniques using Fitero spa water.
214680742|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
214680743|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
214981650|NCT01994200|OTHER|Interdisciplinary Team-Based Approach|Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
214680744|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
214680745|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
214680746|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
214981651|NCT01994200|OTHER|Usual Care Control|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
215088019|NCT05084014|OTHER|Deep Stripping|The deep longitudinal stripping can be applied on adhesions and knots in muscles. The lengthening stokes are parallel to muscle fiber and applied in an oblique direction with the help of the thumbs of hands/ elbow/ knuckles
215088020|NCT05084014|OTHER|Kneading|kneading lifts the muscle in circular movements with the help of the hands. It lifted, rolled, and squeezed muscle
215088021|NCT05432388|DRUG|remibrutinib|oral tablets
214368748|NCT07094516|BIOLOGICAL|VHB937|VHB937 solution for infusion
214368749|NCT07094516|OTHER|Placebo|Solution for infusion
214680747|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
214680748|NCT05396066|DIAGNOSTIC_TEST|Muscle evaluation|Repeated maximal voluntary contraction
214680749|NCT00211770|BEHAVIORAL|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
214680750|NCT00428506|DRUG|albumin 4 gr/L ascites removed|albumin 4 gr/L ascites removed
214680751|NCT00428506|DRUG|albumin 8 gr/L ascites removed|albumin 8 gr/L ascites removed
214680752|NCT02461914|DRUG|PEX168|200µg,injected subcutaneously,once a week.
214680753|NCT02461914|DRUG|Warfarin|5mg,oral,two times.
214680754|NCT03233490|OTHER|web course|Web course Help Brain Heart was conducted Before CPR training.
214680755|NCT03233490|OTHER|CPR training|No web course was conducted
214680756|NCT01005394|DEVICE|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
214680757|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
214680758|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
214680759|NCT01635751|DRUG|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
214680760|NCT04202562|PROCEDURE|Ab interno trabeculectomy|Ab interno trabeculectomy performed after pupil contraction and 90 degrees ablation of the nasal trabecular meshwork
215088022|NCT05432388|DRUG|placebo|oral tablets
215088023|NCT05306288|OTHER|Blood Sample Collection|Subjects enrolled in DELFI-L201 will have blood specimens collected (\~30 mL) at enrollment or up to 30 days after enrollment.
214981652|NCT03447834|OTHER|Selective intracoronary hypothermia + PPCI|Selective intracoronary hypothermia is a new technique, recently tested for safety and feasibility in the SINTAMI trial. The procedure starts by advancing a guidewire beyond the occlusion in the culprit artery, followed by an OTWB that is inflated at the location of the occlusion, at a low pressure (4 atm), to prevent reperfusion. After that, a pressure/temperature wire will be advanced along the inflated OTWB and is placed in the distal coronary artery. Then the guidewire is removed and the lumen is used for infusion of saline. During the 'occlusion phase', saline at room temperature is infused for 10 minutes with distal coronary temperature 6-8°C below body temperature. After that, the balloon of the OTWB is deflated. Simultaneously, infusion is started with saline of 4°C, the so called 'reperfusion phase'. This is continued for 10 more minutes. After that, the OTWB can be retracted and the procedure can continue not different from routine PPCI.
214368750|NCT07093242|BEHAVIORAL|Personalized Nutritional Follow-Up|Participants in the experimental arm will receive a individual nutritional follow-up based on their epigenetic hair analysis results. This includes dietary guidance, recommendations tailored to genetic markers, and periodic consultations with a nutritionist over 4 weeks and continuous availability to clarify doubts via email . The aim is to evaluate changes in genetic expression or health biomarkers after the intervention period.
214492655|NCT04895956|PROCEDURE|Extra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
214492656|NCT04895956|DEVICE|Ultrasound|To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
214492657|NCT06840678|DEVICE|Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. The investigators will use a cylindrical neodymium magnet of 60 mm diameter and 30 mm of thickness (MAG60r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the supplementary motor area (SMA) using an ergonomic helmet (MAGsv1.1, Neurek SL, Toledo, Spain).
214492658|NCT06791876|BEHAVIORAL|Nurture and Play (NnP)|"The NnP group Intervention is a group-based, manualized parenting intervention initiated during pregnancy and continued into the postnatal period until infant age seven months. The program is designed to enhance parenting abilities focusing on three domains: Emotional availability, parental reflective functioning, and the ability to regulate own emotions. During NnP, the parents are supported in enhancing their emotional availability through caring and playing activities.~The intervention has been developed in Finland by Dr. Saara Salo and colleagues and tested in a randomized controlled trial among pregnant women with depression and it is now being implemented in Finland. The results from the study showed that mothers in the intervention group showed more emotional availability and higher levels of reflective functioning and experienced fewer depressive symptoms compared to mothers in the control group."
214368751|NCT07092852|OTHER|Cheek swab for PGx testing|Pharmacogenetic test kits will be provided to each CPU residence. An order will be issued to obtain samples for the study - a cheek swab - to be collected by residence direct care providers or nursing staff, trained in the procedure for obtaining the sample, and preparing and submitting it for transport. Failures to collect and submit valid samples, the number of samples submitted that cannot be processed, and the reasons for failure, will be recorded. If a submitted sample cannot be processed, another sample can be obtained and submitted.
214368752|NCT07092852|OTHER|Medication safety review|A medication reconciliation will be performed by a GalenusRx pharmacist on all included residents. Medication data for enrolled participants will be collected by the GalenusRx pharmacist from the unique pharmacy provider and/or the medication records from the facility and a medication reconciliation will be conducted with the nurse of the residents' facility. GalenusRx pharmacists will apply a CDSS to patients' medication regimens, screening for drug interactions, assess medication related risks, and consider pharmacogenomic type and phenoconversion results in recommending appropriate drug selection and dosage to prescribing clinicians.
214492659|NCT06866782|DIAGNOSTIC_TEST|Imaging|Imaging will be done according to local protocols and/or guidelines of EAU
214492660|NCT06763458|PROCEDURE|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
214981653|NCT03447834|OTHER|Standard PPCI|PPCI per routine
214981654|NCT01272206|DRUG|NNC 0128-0000-2011|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
214981655|NCT01272206|DRUG|NNC 0128-0000-2021|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
214981656|NCT00667511|DEVICE|NxStage System One|Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
215088024|NCT04687033|DEVICE|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
214368753|NCT07094477|DRUG|CD22/CD19 CAR-T cell immunotherapy|targeted CD22/CD19 CAR-T cell immunotherapy
214368754|NCT07094451|DEVICE|Virtual Reality|Meta Quest 2 virtual reality headset. The VR experience includes an interactive, immersive environment with classical music and wrist-controlled movement to match floating visual cues to a beat. The experience is designed to be soothing and require minimal movement.
214680761|NCT04202562|PROCEDURE|Cataract|Cataract surgery with minimal clear cornea incision and phacoemulsification
214680762|NCT01279538|DRUG|bleselumab|Intravenous (IV) infusion
214680763|NCT01279538|DRUG|Placebo|Intravenous (IV) infusion
214680764|NCT04442958|OTHER|Convalescent Immune Plasma|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
215088025|NCT00541346|DRUG|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
215088026|NCT01918514|DRUG|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
215088027|NCT04341688|DRUG|Gargle/Mouthwash|"There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period."
215088028|NCT06546072|OTHER|MRI|
215088029|NCT04966923|OTHER|No intervention in this study|Analyses of pathogenic variant TP53 and variants in genetic test
215088030|NCT03755583|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.
215088031|NCT02920723|OTHER|Training|
215088032|NCT02920723|OTHER|Control|
215088033|NCT04300036|DIETARY_SUPPLEMENT|longan syrup|Subjects will take 15 ml of longan syrup once a day for 3 months
214368755|NCT07094451|PROCEDURE|Ultrasound|Ultrasound-guided (US-Guided) procedure
214680765|NCT01803399|DRUG|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
215088034|NCT04300036|DIETARY_SUPPLEMENT|Placebo syrup|Subjects will take 15 ml of placebo syrup once a day for 3 months
215088035|NCT04732949|DRUG|SNG001|SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
215088036|NCT04732949|DRUG|Placebo|Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
215088037|NCT00478790|DEVICE|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
214368756|NCT07094854|OTHER|Cention Forte alkasite bioactive restorative material|Cention forte material will be used as a final restoration for pulpotomized second primary molars
214368757|NCT07094854|OTHER|Stainless steel crown|The control group using the gold standard stainless steel crown (SSC) as a final restoration for pulpotomized second primary molars
214368758|NCT07093554|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
214368759|NCT07093554|DRUG|Ciltacabtagene Autoleucel|Ciltacabtagene Autoleucel will be administered intravenously.
214368760|NCT06924788|BEHAVIORAL|Video-Conferenced Stress Management and Relaxation Training (VSMART)|10 week stress management group discussions
214368761|NCT06443346|OTHER|Eosinophilic Esophagitis|Eosinophilic Esophagitis patients with a proper diagnosis
214368762|NCT01797679|OTHER|Strength Training|
214368763|NCT01797679|OTHER|Aerobic Exercise|
214492661|NCT06850519|GENETIC|Exome Sequencing and Sanger Sequencing|Exome Sequencing and Sanger Sequencing
214492662|NCT06763016|BEHAVIORAL|Cognitive Behavioural Theory-based group consultation|"The sessions focused on various topics, such as sexuality, sexual health, gender roles, and sexual violence. Participants were encouraged to engage in group discussions and complete weekly tasks, which allowed them to interact and reflect on the material presented. The intervention aimed to address and challenge prevalent sexual myths, encourage open discussions about sexuality, and foster healthier sexual attitudes through evidence-based counseling.~The content of the digital interventions was structured on the basis of a semi-structured interactive group counseling. It was supported by sharing content on Instagram, one of the most widely used social media tools of the generation representing.~For three days a week over six weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous consultation session was held once a week. The participants were connected to the live broadcast of the research team."
214492663|NCT06734819|BEHAVIORAL|Storytelling Video|The Living Donation Storytelling Project (LDSP) is an online video library of living donation first-person narratives aiming to inspire more people to consider LDKT (https://livingdonationstories.org/).17 As of 2020, the library has 118 stories from living donors and kidney recipients sharing their experiences with the pursuit, challenges and outcomes of transplant.18,19 Four videos were selected from the LDSP and edited to standardized duration and thematic content. Videos were cut to three minutes in length and covered the topics of 1) challenges faced when seeking LDKT, 2) life after LDKT and 3) advice for other patients considering LDKT.
214981657|NCT03096535|PROCEDURE|Cooling|Individualized cooling protocol.
214981658|NCT03096535|PROCEDURE|Thermoneutral|Thermoneutral control day.
214981659|NCT00311051|DRUG|ramatroban|
214981660|NCT00311051|DRUG|montelukast|
214981661|NCT01100385|DIETARY_SUPPLEMENT|Ateronon|Tomato extract (lycopene) capsule, taken once daily for 56 days
214981662|NCT01100385|DIETARY_SUPPLEMENT|Placebo|Matched placebo capsule, taken once daily for 56 days
214981663|NCT02222662|OTHER|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
214981664|NCT02222662|OTHER|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
214981665|NCT00004700|DRUG|insulin-like growth factor I|
214981666|NCT03147326|DIAGNOSTIC_TEST|FDG-PET-CT|scanning method
214981667|NCT03147326|DIAGNOSTIC_TEST|NaF-PET-CT|scanning method
214981668|NCT03147326|DIAGNOSTIC_TEST|Whole-body MRI|scanning method
214981669|NCT01543165|DRUG|Ketorolac and nefopam balanced analgesia|Sequential intravenous administration of ketorolac and nefopam
214981670|NCT01543165|DRUG|Balanced analgesia using ketorolac and morphine|Sequential intravenous administration of ketorolac and morphine
214981671|NCT01543165|DRUG|Pain control with single analgesics (ketorolac)|This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
214981672|NCT02817139|DEVICE|TDCS|
214981673|NCT00761098|DRUG|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
214981674|NCT00761098|DRUG|Experimental|25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
214981675|NCT05246995|DRUG|IBI325+Sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 monotherapy on Cycle 1 Day 1 ,and then receive IBI325 and sintilimab combination until progressive disease, intolerability, or other reasons leading to treatment discontinuation
214981676|NCT03738735|DRUG|Hypertonic saline|For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
214981677|NCT01381120|DRUG|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
215088038|NCT04251975|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
214981678|NCT01381120|DRUG|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
214981679|NCT04898881|OTHER|Breast Human Milk|Interventional drug is given to the neonates 2 minutes before the heel lance
215088039|NCT04831099|DRUG|Testosterone gel|The route of administration is transdermal.
214981680|NCT04898881|OTHER|24 % Sucrose|0.5 ml of sucrose given once 2 minutes prior to procedure
215088040|NCT04831099|DRUG|Placebo|The route of administration is transdermal
215088041|NCT05485142|PROCEDURE|prolotherapy|5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.
215088042|NCT00003252|DRUG|amifostine trihydrate|
214368764|NCT04073563|DEVICE|Infuse™ Bone Graft (Infuse™)|(Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))
214368765|NCT04073563|DEVICE|Intervertebral body fusion device and Medtronic posterior Fixation Systems|Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System
214368766|NCT03099330|DRUG|TQ-B3139|TQ-B3139 p.o. qd
214981681|NCT04229823|DIAGNOSTIC_TEST|Video-oculography|Eye movement parameters will be measured in all of the subjects using video-oculography device (EyeSeeCam, InterAcoustics). Measurement sessions consist of the study subject wearing a goggle attached to a camera that detects the pupil and eye position and velocity. Evaluation start with vestibulo-ocular reflex testing, with video head impulse test. Afterwards, saccades, smooth pursuit and fixation are evaluated.
214981682|NCT04229823|DIAGNOSTIC_TEST|Clinical Scales|All subjects are examined by an investigator in order to score clinical scales for ataxia, including Scale for the Assessment and Rating of Ataxia (SARA), International Co-operative Rating Scale (ICARS), Neurological Examination Scale for SCA (NESSCA), Inventory of Non-ataxia Symptoms (INAS), SCA Functional Index (SCAFI) and Composite Cerebellar Functional Severity Score (CCFS).
214981683|NCT04229823|DIAGNOSTIC_TEST|Genotyping|Individuals at 50% risk (offspring of subjects with molecular diagnosis of SCA3/MJD) will be genotyped in a double-blind manner so that they can be divided into pre-ataxic carriers and related controls (non carriers)
214981684|NCT06519058|OTHER|self-myofascial stretching|self-myofascial stretching exercise
214981685|NCT06519058|OTHER|conventional physical therapy|conventional physical therapy treatment, including exercises
214981686|NCT01812187|BEHAVIORAL|SHIFT Cognitive Behavioral Therapy|Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
214981687|NCT06013566|DEVICE|SSVEP|Non-invasive, non-interventional SSVEP EEG device
214981688|NCT04896463|RADIATION|Abdominal ultrasound (US)|abdominal examination with US device
214981689|NCT03314480|DIAGNOSTIC_TEST|Standardized physical examination|Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
214981690|NCT02891473|OTHER|Mézières Method|10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
214981691|NCT02891473|OTHER|Home based exercise program|1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
214981692|NCT04337632|DRUG|Doxorubicin Hydrochloride Liposome Injection+carboplatin|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.
214981693|NCT04337632|DRUG|paclitaxel +carboplatin|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
214981694|NCT05555680|OTHER|Ferriman-Gallwey Score|The Ferriman-Gallwey score is used to evaluate hirsutism. The examiner scores the subjects on a scale of 0-4 for terminal hair growth on eleven different body areas according to the Ferriman-Gallwey scoring system. A Ferriman-Gallwey score of 8 or more was considered diagnostic of hirsutism
214981695|NCT02730962|DRUG|Vancomycin|Vancomycin 3 times a day for 7 days
214981696|NCT02730962|OTHER|Placebo|Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic
214981697|NCT02730962|DRUG|Neomycin|Neomycin 3 times a day for 1 day
214981698|NCT02730962|DRUG|Clindamycin|Clindamycin 3 times a day for 5 days
214981699|NCT02730962|PROCEDURE|Fecal Microbiota Transplantation|FMT conducted via colonoscopy
214981700|NCT04151394|PROCEDURE|Duodenojejunostomy|Resection of duodenal lesions and reconstruction by duodenojejunostomy
215088043|NCT05691374|PROCEDURE|Ultrasound (US) examination|"Shear-Wave Elastography (SWE) measurements of operated shoulder (quality, elasticity of repaired tendon) compared to healthy contralateral side. Parameters documented by regular US: Diameter of repaired tendon/ tendon thickness (mm), Rotator cuff muscle fatty infiltration (Grade 0-4), Signs of suture cut-through (yes \| no), Signs of anchor displacement and location (lateral\|medial row), Location of defect (at the foot print\|medial cuff failure), Status of long biceps tendon (intact\|in continuity\|defect). Tissue elasticity measured by SWE in longitudinal orientation (in passive state and with active tension): Trapezius and Deltoid muscle: uninjured superficial muscle for individual patient muscle quality, SSP muscle and tendon: anterior and posterior part, SSC muscle and tendon: cranial and caudal part, ISP muscle and tendon, Biceps muscle and tendon: native (intraarticular) or subpectoral tenodesis (extraarticular)"
215088044|NCT05691374|PROCEDURE|Clinical examination|Clinical examination for shoulder range of motion and strength measurement
215088045|NCT02743455|DRUG|ISA-720|The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.
215088046|NCT02743455|BIOLOGICAL|MVA Smallpox Vaccine|Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.
214368767|NCT06038955|BEHAVIORAL|Virtual reality Based Cognitive Remediation|The main component of the intervention is a virtual reality training platform in 360° Oculus Quest 2-software in which participants train their cognitive abilities guided by the therapist. The platform includes four immersive daily-life scenarios in which patients have consistently reported that they often experience cognitive difficulties: (1) a kitchen scenario focusing on planning and cooking a meal, (2) a supermarket scenario focusing on grocery shopping, (3) a restaurant scenario focusing on remembering names and personal information and (4) an office scenario focusing on planning, initiating, and completing work assignments. The virtual reality training is supported by a psychoeducation program that focuses on application of learned cognitive strategies in daily life.
214368768|NCT06038955|BEHAVIORAL|Virtual reality control training|The virtual reality control training involves completing different virtual reality games that are available through the Oculus Quest games store.The chosen games involve no direct training of cognitive abilities such as planning skills og strategic learning, but merely involves simple reaction time and interaction with an entertaining environment that is meaningful to the participant and gives the impression of training cognitive skills.
214981701|NCT03980119|OTHER|HITSystem 3.0|The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
214981702|NCT02860936|DRUG|Lenvatinib|Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
214981703|NCT04172740|DEVICE|Radiesse (calcium hydroxylpatite)|"RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy)."
214981704|NCT00856180|DRUG|Bevacizumab|
214981705|NCT00856180|DRUG|Cyclophosphamide|
214981706|NCT00266318|DRUG|Interferon Alfacon-1 and Ribavirin|
214981707|NCT02265510|DRUG|INCB052793|Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
214981708|NCT02265510|DRUG|gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
214981709|NCT02265510|DRUG|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
214981710|NCT02265510|DRUG|dexamethasone|Dexamethasone administered orally at the protocol-specified dose and frequency.
214981711|NCT02265510|DRUG|Carfilzomib|Carfilzomib administered intravenously at the protocol-specified dose and frequency.
214981712|NCT02265510|DRUG|bortezomib|Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
214981713|NCT02265510|DRUG|lenalidomide|Lenalidomide administered orally at the protocol-specified dose and frequency.
214981714|NCT02265510|DRUG|azacitidine|Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
214981715|NCT02265510|DRUG|INCB052793|INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
214981716|NCT02265510|DRUG|pomalidomide|Pomalidomide administered orally at the protocol-specified dose and frequency.
214981717|NCT02265510|DRUG|INCB050465|INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
214981718|NCT02265510|DRUG|INCB039110|INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
214981719|NCT05376501|DIETARY_SUPPLEMENT|Astaxanthin|8 mg Astaxanthin per capsule, taken once a day with meal
214981720|NCT05376501|OTHER|Placebo|Modified food starch
214981721|NCT01515124|BEHAVIORAL|Exercise Intervention|The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
214981722|NCT01515124|BEHAVIORAL|Weight Loss Intervention|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
214981723|NCT03706846|PROCEDURE|fasting|fasting before gastrointestinal endoscopy
214981724|NCT01004614|DRUG|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
214981725|NCT01004614|DRUG|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
214981726|NCT01004614|DRUG|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
214981727|NCT01004614|DRUG|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
214981728|NCT05430906|DRUG|AK104 - Chemotherapy|AK104 10mg/kg then \[paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)\] and \[carboplatin (AUC5 or 6) or cisplatin (75mg/m²)\] of each 21-day cycle
214981729|NCT01979432|OTHER|Cardiovascular evaluation|
215088047|NCT02743455|BIOLOGICAL|MVA-BN Yellow Fever Vaccine|Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.
215088048|NCT02743455|OTHER|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
215088049|NCT02743455|OTHER|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
215088050|NCT02743455|BIOLOGICAL|YF Vax 17D Strain|Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos. Will be used as an active comparator.
215088051|NCT05264116|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
215088052|NCT02772588|DRUG|ARN-509|
215088053|NCT02772588|DRUG|Abiraterone|
215088054|NCT02772588|DRUG|Leuprolide|
215088055|NCT02772588|RADIATION|stereotactic, ultra-fractionated radiotherapy|
214981730|NCT01985178|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplement|
214981731|NCT04075448|OTHER|Control|100 grams breakfast cereal
214981732|NCT04075448|OTHER|50 g Walnut|50 grams walnuts mixed with 50 gram breakfast cereal.
214981733|NCT02130440|DRUG|Resveratrol nasal spray|
214981734|NCT02859883|DEVICE|gastroscope FUSE™|All patients undergoing a diagnostic gastroscopy are eligible. Using the FUSE endoscope with side screen, the duodenal and accessory papilla are monitored. Data are collected by each operator. Clinical examination of patients is performed before they leave the centre.
214981735|NCT02415946|PROCEDURE|Sinus floor augmentation (lateral)|
214981736|NCT02415946|PROCEDURE|Sinus floor augmentation (transcrestal)|
214981737|NCT02818543|DRUG|LYC-30937|
214981738|NCT05151913|OTHER|Exploratory|Fecal microbiome
214981739|NCT02111083|BIOLOGICAL|Insulin Lispro|LY275585 administered SC.
214981740|NCT06420739|DIAGNOSTIC_TEST|Gastric Ultrasound|Bedside Gastric Ultrasound to determine the volume and nature of gastric content in patients before their surgery.
214981741|NCT05192642|DRUG|Larotrectinib(Vitrakvi, BAY2757556)|Clinical trials
214981742|NCT05192642|DRUG|Data on other treatments|Real word data
214981743|NCT04506736|OTHER|ARM|"The ARM is performed by setting the peak inspiratory pressure to 45 cmH₂O then changing the mode of ventilation to pressure controlled ventilation (PCV) with the inspiratory pressure set to give a tidal volume equal to that given during VCV, I:E ratio of 1:1 and a PEEP of 5 cmH₂O. The PEEP level is then increased in 5 cmH₂O steps every minute till it reaches 20 cmH₂O and inspiratory pressure is increased to get an airway opening pressure (inspiratory pressure + PEEP) of 40 cmH₂O which is maintained for one minute after which the ventilation returned to the original setting except for the PEEP level which is kept at 20 cmH₂O.~The titration of individualized PEEP is done by decremental reduction of the 20 cmH₂O PEEP level in 2 cmH₂O steps every 2 minutes and measuring static compliance of the respiratory system (CRS) at each step."
214981744|NCT04506736|OTHER|spontanous ventilation|volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
215088056|NCT04603001|DRUG|LY3410738|Oral LY3410738
215088057|NCT04603001|DRUG|Venetoclax|Oral venetoclax
215088058|NCT04603001|DRUG|Azacitidine|Subcutaneous or intravenous azacitidine
214680766|NCT01803399|DRUG|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
214680767|NCT01803399|DRUG|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
214680768|NCT01803399|DRUG|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
214680769|NCT03799003|DRUG|ASP1951|Intravenously (IV)
214492664|NCT06734819|BEHAVIORAL|Standard Patient Education|Standard of care patient education materials include verbal didactic offered during the surgical consult and pamphlets produced by Vancouver Coastal Health.
214981745|NCT05540119|PROCEDURE|Surgery|Patients who undergo surgery are separately assessed
214981746|NCT01562899|DRUG|MEK162|Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
214981747|NCT01562899|DRUG|AMG 479|Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.
214492665|NCT06675019|OTHER|Manual therapy|Manual therapy group: will have manual therapy and relaxation training three times per week in addition to their medications as needed. Manual therapy will include stretching exercises, strengthening exercises, soft tissue manipulation in the form of myofascial release and deep friction massage, and postural correction.
214492666|NCT06675019|OTHER|Kinesio taping|Kinesio taping group: will have kinesio taping (KT), and relaxation exercises three times per week in addition to their medication as needed, One I-shaped tape was used to apply KT to the upper trapezius muscle that was 50 mm broad and 0.5 mm thick. The tape was measured from the acromion to the hairline in the back, and the upper trapezius fibers were stretched in the extended position, i.e., the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation positions. The band was secured to the acromion's insertion site in its first resting position. The muscle was lengthened, and the band was fixed with the initial skin shift, after which the band was fixed to the origin of the hairline from the muscle with a 10% stretch. The tape was massaged with the muscle in the extended position.
214492667|NCT06675019|OTHER|Control (Standard treatment)|The control group will just receive relaxation exercises three times per week, in addition to their medications as needed.
214492668|NCT06867263|PROCEDURE|Fulguration|Posterior urethral valve fulguration
214492669|NCT06766370|PROCEDURE|Ultrasound-guided nerve hydrodissection treatment|Under ultrasound guidance, a mixed solution of corticosteroids and local anesthetics is injected around the nerve, followed by release of the transverse carpal ligament.
214492670|NCT00129038|DRUG|modified-release dipyridamole/aspirin|
214492671|NCT00129038|DRUG|aspirin|
214981748|NCT00614835|DRUG|Docetaxel plus Gemcitabine|Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
215088059|NCT06419166|DRUG|GC012F injection|"Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.~Other Name: CD19-BCMA CAR-T cells"
215088060|NCT01073475|OTHER|There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.|"There is no intervention associated with the parent MNHR study~For the MNHR COVID sub-study, each woman will be asked to provide a blood specimen of approximately 3-5 cc at or near delivery (at delivery or 14 days after) to be tested for COVID-19 antibodies. The person collecting the specimen will be a trained member of the registry staff. The ZEUS ELISA SARS-CoV-2 IgG Test System will be used and run at each site. RTI International will provide central quality support of the analyses."
215088061|NCT05756608|DIAGNOSTIC_TEST|68Ga-FAPI and 18F-AlF-FAPI PET-MR|Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer
214492672|NCT02500576|BIOLOGICAL|Aldesleukin|Given IV or SC
214492673|NCT02500576|DRUG|Cyclophosphamide|Given IV
214492674|NCT02500576|DRUG|Fludarabine Phosphate|Given IVPB
214492675|NCT02500576|OTHER|Laboratory Biomarker Analysis|Correlative studies
214680770|NCT03799003|DRUG|pembrolizumab|Intravenously (IV)
214680771|NCT05062161|BEHAVIORAL|Sleep hygiene/extension intervention|The 60-minute sleep hygiene/extension educational session include the following: This session will consist of questionnaires, handouts, videos, and a discussion. Topic examples include information on establishing a comfortable sleep environment, including strategies on how to extend sleep duration by a maximum of 1 hour over the duration of the 8-week trial for an average of 7.5 minutes per week, not to exceed 15 minutes per week. Participants will also receive educational brochures and a sleep diary.
214680772|NCT05062161|BEHAVIORAL|Control care|The 60-minute educational session will address sleep physiology but not sleep hygiene. This session will consist of questionnaires, handouts, videos, and a discussion. Participants will receive an educational brochure.
214981749|NCT01163799|DRUG|Alefacept (ASP0485)|Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
214492676|NCT02500576|BIOLOGICAL|Pembrolizumab|Given IV
214492677|NCT02500576|OTHER|Quality-of-Life Assessment|Ancillary studies
214492678|NCT02500576|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Given IV
214680773|NCT05401773|OTHER|Real-time Quaking-Induced Conversion (RT-QuIC)|RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies.
214680774|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with vincristine and prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
214680775|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
215088062|NCT03357874|DRUG|Clopidogrel|600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).
214368769|NCT04414579|DRUG|Faster Insulin Aspart (Fiasp®)|Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.
215088063|NCT03357874|DRUG|Ticagrelor|patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).
214981750|NCT06201091|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
214981751|NCT04695561|OTHER|Self Myofascial Relaxation|Total of 12 times for 6 weeks
214981752|NCT04695561|OTHER|Instrument Assisted Soft Tissue Mobilization|Total of 12 times for 6 weeks
214981753|NCT04695561|OTHER|Only Exercise (Control)|Every day for 6 weeks
214981754|NCT03368417|OTHER|Usual Care|"Participants will be advised to measure their BP at least 3 times a week and record their results on a form. The participants will be educated on how to interpret their BP according to standard self-monitoring practice guidelines.~As part of the study, participants without a HBPM will be provided with the Omron HEM 7130. Adherence to hypertensive medicines will be monitored using the medication event monitoring system eCAP™. In addition, the participants will be asked to undertake ambulatory blood pressure monitoring (using the Welch Allyn ABPM 7100 monitor) at Baseline and Month 6 for a duration of 12 hours, during their waking hours."
215088064|NCT02808910|BEHAVIORAL|Nudged to eat less added salt and more other seasonings|
215088065|NCT02808910|BEHAVIORAL|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
215088066|NCT02808910|BEHAVIORAL|Nudged to eat more vegetables|
215088067|NCT02808910|BEHAVIORAL|Nudged to eat smaller portions|
215088068|NCT02808910|BEHAVIORAL|Nudged to eat less calorie-dense food|
215088069|NCT02220426|DRUG|Xenon|Inhalation of hyperpolarized xenon gas
215088070|NCT06034652|DEVICE|Integra® Gentrix® Surgical Matrix|Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic \& reconstructive surgery.
215088071|NCT05627219|BEHAVIORAL|Training and Education|Undergo training and education
214492679|NCT06109090|OTHER|Neuropsychological testing|"In this study, the Vineland Adaptive Behavior Scale is administered, which evaluates the child's adaptive functioning, particularly in four areas: communication, socialization, daily living skills, and motor activities. The Child Behavior Checklist (CBCL) questionnaire is also administered, which is a questionnaire given to parents that highlights elements related to internalizing and externalizing behavioral disorders.~For the assessment of executive functions, a series of tests are administered to evaluate specific functions. These tests are chosen from a list of available tests according to the document from the Italian Society of Child Neuropsychiatry, titled Assessment of attention and executive functions in developmental age: review of Italian instruments and proposal of a battery for in-depth analysis."
214492680|NCT06524804|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
214492681|NCT06524804|RADIATION|palliative radiotherapy|Undergo palliative radiotherapy
214492682|NCT06524804|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
214492683|NCT06524804|RADIATION|curative radiotherapy|Undergo curative radiotherapy
214981755|NCT03368417|OTHER|Wireless HBPM System|"BP will be monitored using the iHealth KN-550BT wireless HBPM and transmitted to the study application via the iHealth mobile application.~The Wireless HBPM System consists of:~i) Instant BP feedback: Classification of each BP reading with feedback SMS. CRC will call the patient in case of alarming BP readings.~ii) Weekly HBPM adherence feedback: Participants receive praise, encouraging, or reminder SMSes.~iii) Continuous assessment: Based on average BP over the last 4 weeks, participants will be categorized and flagged for the CRC to follow clinical protocols. Protocols include asking patients to immediately come to the clinic, checking for alarm symptoms and discussing adherence over the phone, remote titration, and cancelling 1 clinic visit in case of good BP control."
215088072|NCT05627219|OTHER|Educational Intervention|Receive educational booklet
215088073|NCT05627219|PROCEDURE|Discussion|Attend discussion with peer genetic coach
215088074|NCT06196125|OTHER|Four body positions|Physiological characteristics such as ventilation distribution and lung aeration patterns recorded by the electrical impedance tomography signals and ultrasound imaging will be measured when patients are in a initial supine position, then turned into a lateral positioning on each side then back in supine positioning.
215088075|NCT06240728|DRUG|NPX887|NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years
215088076|NCT05351216|OTHER||No intervention
215088077|NCT06392776|OTHER|Early diagnosis and treatment|Early diagnosis of previously undiagnosed asthma or COPD and subsequent treatment by a primary care practitioner
215088078|NCT06570382|OTHER|Videos: Taste messaging focused|Participants in this intervention will watch the taste focused videos.
214368770|NCT05151068|BEHAVIORAL|traditional nursing method|"①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support."
214368771|NCT05151068|BEHAVIORAL|Precise acupoint application combined with ear acupoint embedding nursing program|On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.
214368772|NCT03041779|DRUG|Diclofenac Sodium 50Mg Suppository|
214368773|NCT03041779|DRUG|Paracetamol 500Mg Suppository|
214368774|NCT04585659|OTHER|Qigong|Mind-body movement art that includes specific movements, breath exercises, stretching and meditation.
214368775|NCT00000822|DRUG|Ritonavir|
214368776|NCT00000822|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
214680776|NCT06031467|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|The laser group received mechanical therapy followed by Er;Cr;YSGG laser. Laser application was performed using the bottom-up technique. Therefore, the tip was retracted about 1 mm after it was placed on the bottom of the pocket and slowly moved in the coronal direction to the parallel to the implant surface.
214981756|NCT03368417|BEHAVIORAL|BP Monitoring Incentives|"Participants will receive an intervention identical to those in the Wireless HBPM System, with financial incentives for BP monitoring. This arm is further randomly subdivided into the Instant Reward and Health Capital arms in a 1:1 ratio.~Instant Reward sub-arm:~* Participants receive SGD 3 for each day they measure their BP, up to three times per week.~* Participants do not receive financial incentive if they do not measure their BP.~Health Capital sub-arm:~* Participants receive an initial health capital of SGD 72~* Participants' health capital increases by SGD 6 on each week where they measure their BP on at least 3 different days and decreases weekly by 10% per missing BP reading."
214680777|NCT06031467|DEVICE|Non-surgical mechanical therapy|Traditional non surgical mechanical therapy Mechanical instrumentation in all groups was made with titanium curettes.The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt.
214680778|NCT04417088|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
214981757|NCT04595058|DEVICE|Double pigtail plastic stent through lumen-apposing metal stent|Biliary drainage guided by endoscopic ultrasound: Addition or not, of a axis-orienting plastic stent, mostly, double-pigtail stent through the lumen of a lumen-apposing metal stent
214981758|NCT04595058|DEVICE|Lumen-apposing metal stent without double pigtail plastic stent|Endoscopic ultrasound-guided transmural biliary drainage is with lumen-apposing metal stent is a formal indication according to the instruction forms of the manufacturer.
214368777|NCT00000822|DRUG|Stavudine|
214368778|NCT00000822|DRUG|Didanosine|
214368779|NCT05395988|DEVICE|Digital hand washing instructions|Tablet displaying animated hand washing instructions
214368780|NCT05395988|DEVICE|Digital hand washing reward|Tablet displaying animated hand washing instructions and animated animals as reward
214680779|NCT04417088|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
214680780|NCT04650321|DRUG|Ocrelizumab at home|Patients will receive ocrelizumab infusion at home.
214680781|NCT02421120|DRUG|Ceftolozane/Tazobactam|1 hour intravenous infusion
214680782|NCT02996695|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
214981759|NCT04260633|DEVICE|Dental Monitoring assisted aligner change, 12-hour tray wear time and VPro+ are the interventions for the trial.|"The current standard of care for clear aligner use as suggested by Invisalign is unclear as to how frequently aligners should be changed. We suspect that the frequency for aligner change as determined by the orthodontist using Dental Monitoring will be variable for every participant.~Vpro+ is an adjunctive therapeutic tool for clear aligner treatment. It is proposed to deliver high frequency vibrations to reduce treatment time and pain associated with clear aligners.~Align Technology suggests 22-hour wear time for clear aligner therapy. Participants in two arms of the study will be asked to wear the trays for about half the recommended wear time to assess whether night-time aligner wear will be sufficient for successful treatment."
214981760|NCT01352039|BIOLOGICAL|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
214981761|NCT01352039|BIOLOGICAL|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
214981762|NCT00282932|DRUG|Detrol LA|
214981763|NCT02667899|DEVICE|deep brain stimulation|Deep brain stimulation means stimulate the brain with DBS.
214981764|NCT02667899|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.
214981765|NCT02667899|OTHER|Routine treatment|Means without above additional treatment.
214981766|NCT00002419|DRUG|Abacavir sulfate|
214981767|NCT00002419|DRUG|Amprenavir|
214981768|NCT00002419|DRUG|Efavirenz|
214981769|NCT00002419|DRUG|Adefovir dipivoxil|
214981770|NCT03236792|DRUG|Ixazomib|3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle
214981771|NCT03236792|DRUG|Cyclophosphamide|300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
214981772|NCT03236792|DRUG|Dexamethasone|20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
214981773|NCT02602951|OTHER|Pilot MRI program|Pilot MRI program
214981774|NCT02602951|OTHER|MRI with 4D Flow sequence|MRI with 4D Flow sequence
214981775|NCT00368550|DRUG|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
214981776|NCT00368550|DRUG|Placebo|Placebo for 14-week treatment period
214981777|NCT03489564|BEHAVIORAL|Active|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
215088079|NCT06570382|OTHER|Videos: Health messaging focused|Participants in this intervention will watch the health focused videos.
214680783|NCT02996695|DRUG|Chloroquine|4-aminoquinolone, antimalarial agent for oral administration
214680784|NCT02996695|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
214680785|NCT02996695|OTHER|Placebo|Placebo
214981778|NCT03489564|BEHAVIORAL|Sedentary|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
214981779|NCT05518721|PROCEDURE|Hallux Rigidus Treatment|Participants will receive either a synthetic cartilage implant or dermal interposition arthroplasty
214981780|NCT04376281|DRUG|Noradrenaline|Noradrenaline infusion for patients undergoing liver transplantaion from living donor .
214981781|NCT06472479|BIOLOGICAL|LCAR-M61S cells preparation|"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
214981782|NCT06472479|BIOLOGICAL|LCAR-M61D cells preparation|"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
214981783|NCT00486044|DRUG|Simvastatin|40 mg tablet each night for one month, then 80 mg for 8 months
214680786|NCT02207530|DRUG|MEDI4736|MEDI4736 monotherapy
214680787|NCT00034970|BEHAVIORAL|Mindfulness-based at therapy|
214680788|NCT01523119|DRUG|Ondansetron|Orally Disintegrating Tablets 8 mg
214680789|NCT04099056|DEVICE|Neurostimulation|"Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI).~TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.~TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates."
214680790|NCT06396039|DRUG|BMS-986374|Specified dose on specified days.
214981784|NCT00486044|DRUG|Placebo|Matching tablet each night for 9 months
214981785|NCT03072550|DEVICE|RenewalNail™ Plasma Treatment System|application of cold atmospheric plasma to a fungal infected toenail
214981786|NCT03715062|OTHER|Dialogue tool|The intervention has two parts: an educational session and a dialogue tool. The educational session consists of 75 minutes of education in diagnosing urinary tract infection. The dialogue tool consists of 1) a checking box for the most important symptoms and observations for urinary tract infection 2) an algorithm to evaluate if urinary tract infection is likely based on the present symptoms and observations 3) a list of reflection points to evaluate with a collegue 4) a specialized ISBAR (communication tool) if long-term care facility staff finds it appropriate to contact the General Practicioner
214981787|NCT01670292|OTHER|HVLA-SM|High Velocity Low Amplitude Spinal Manipulation
215088080|NCT06569953|DRUG|Liposomal bupivacaine|Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).
215088081|NCT06569953|DRUG|Bupivacaine Hydrochloride|Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)
215088082|NCT02965885|DRUG|TAS-116|TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
215088083|NCT05796973|BEHAVIORAL|Guided physical exercise|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions.
215088084|NCT05796973|DRUG|Atorvastatin|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. In addition to the exercise program they will be given atorvastatin 40 mg QD medication.
214680791|NCT03962049|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
214680792|NCT04737122|DRUG|LM-061|Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.
214981788|NCT03306199|DEVICE|Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
214981789|NCT00379106|PROCEDURE|Arm exercises.|Basic active exercise program at home.
214981790|NCT00379106|PROCEDURE|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
214981791|NCT03108612|DIAGNOSTIC_TEST|Análisis de carga de trabajo (ACT)|Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
214981792|NCT00781846|DRUG|ridaforolimus|oral tablets, daily for 5 days/week
214981793|NCT00781846|DRUG|bevacizumab|IV infusion
214981794|NCT01751282|GENETIC|Stem Cell|
214368781|NCT04112225|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
214368782|NCT00048880|DRUG|HeFi-1 Monoclonal Antibody|
214981795|NCT03194334|BEHAVIORAL|Vegetarian diet|
214981796|NCT03194334|DIETARY_SUPPLEMENT|creatine|1g creatine/day
214981797|NCT03194334|DIETARY_SUPPLEMENT|Placebo|pills
214981798|NCT03194334|DIETARY_SUPPLEMENT|Beta-alanine|0.8g beta-alanine per day
215088085|NCT05796973|OTHER|Independent exercise|The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own.
215088086|NCT04901741|DRUG|Olaptesed pegol|400 mg per week as continous infusion until progression or intolerable toxicity
215088087|NCT04901741|DRUG|Pembrolizumab|200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations
215088088|NCT04097379|DRUG|LRX712|LRX712 intra-articular injections
215088089|NCT04097379|DRUG|Placebo|Placebo intra-articular injections
215088090|NCT02448589|DRUG|TAS-119|
214368783|NCT06470074|DEVICE|Transcranial electrical stimulation|Transcranial electrical stimulation can modulate the brain functional network through weak transcranial current
214368784|NCT00819364|BEHAVIORAL|BCRI intervention program|"Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions."
214492684|NCT06134453|OTHER|Reiki/Sham Reiki|Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.
214492685|NCT06848673|OTHER|Office-Based Vergence/Accommodative Therapy with Movement (OBVAM)|Head and body movements are incorporated into some therapy procedures in Phases 3 and 4. Additional details are provided in the Overall Program Narrative. Participants undergoing office-based VAM therapy will be prescribed home therapy procedures including the HTS2 Home Vision Therapy System (https://htsvision.com/) thrice weekly to support their in-office VAM therapy. This software progressively increases fusional convergence and divergence demands, offers instant user feedback, and will allow us to track participants' usage and progress. Basic procedures like free-space fusion cards and Brock String will also be prescribed for home therapy.
214492686|NCT06841978|DRUG|Intravenous Thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
214492687|NCT06229106|DEVICE|Symfony IOL|The Symfony IOL is a lens designed to provide high quality vision up tp 26 inches reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
214492688|NCT06229106|DEVICE|Vivity IOL|The Vivity IOL is a lens that provides extended range of vision ranging from distance to near reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
214492689|NCT03399500|BEHAVIORAL|In-Person Case Management at Homeless Recovery Program|In-Person Case Management at Homeless Recovery Program
214492690|NCT03399500|BEHAVIORAL|Unlimited Smartphone|Smartphone with unlimited calls, texts, and data plan
214492691|NCT03399500|BEHAVIORAL|Smartphone Based Case Management (SPCM) app|Smartphone Based Case Management app
214492692|NCT06816706|PROCEDURE|Modified high flow tracheal oxygen-40L/min|Modified high-flow tracheal oxygen with a flow rate of 40L/min will be performed.
214492693|NCT06816706|PROCEDURE|Standard high flow tracheal oxygen-40L/min|Standard high-flow tracheal oxygen with a flow rate of 40 L/min will be performed.
214492694|NCT06816706|PROCEDURE|T-piece|T-piece will be performed.
214492695|NCT06816706|PROCEDURE|Modified high-flow tracheal oxygen-60L/min|Modified high-flow tracheal oxygen with a flow rate of 60L/min will be performed.
214492696|NCT06816706|PROCEDURE|Standard high-flow tracheal oxygen-60 L/min|Standard high-flow tracheal oxygen with a flow rate of 60 L/min will be performed.
214981799|NCT06550492|DEVICE|smoke filtering electrocautery device|A smoke-filtering electrocautery device was used during surgery.
214981800|NCT06550492|OTHER|double mask|A double-layer mask was used during the operation.
214981801|NCT04420091|DIETARY_SUPPLEMENT|Cartidyss|Oral intake of two tablets of Cartidyss 500 mg, once daily in the morning, preferably during a meal, with water, during 3 months
214981802|NCT00792181|DRUG|Midazolam|Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
214981803|NCT00792181|OTHER|Course intervention - a professional development course for caregivers.|The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
214981804|NCT00006152|DRUG|Ritonavir|
214981805|NCT00006152|DRUG|Abacavir sulfate|
214981806|NCT00006152|DRUG|Amprenavir|
215088091|NCT03737721|COMBINATION_PRODUCT|Avelumab and Radical radiotherapy|A single-arm, interventional study combining Avelumab with radical radiotherapy. Avelumab will be delivered on a 14-day cycle, with the first cycle administered 14 days in advance of the radiation therapy start date; 63-66 Gy radiation will be delivered over 30 daily fractions concurrent with an additional 4 cycles of Avelumab
215088092|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
215088093|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
215088094|NCT06508983|DRUG|SG301 Injection|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
214981807|NCT03675217|OTHER|PE|Physical exercise program for familiy caregivers. 36 session physical exercise (3 sessions/week) performed by physioterapist. It incluided exercices to improve coordination, aerobic capacity, control motor and strenght
214981808|NCT03675217|OTHER|Usual Care|Usual Programe in primary care for family caregivers. 4 session (2 session/week). It incluides: ergonomy, postural hygiene, mobilitation of patients and self-care.
214981809|NCT06207955|DRUG|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin And Botulinum Toxin Type A|TMJ Arthrocentesis I-PRF Intra-articular Injection Botulinum Toxin Type A to Lateral Pterygoid Muscle
214981810|NCT06207955|DRUG|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin|TMJ Arthrocentesis I-PRF Intra-articular Injection
214981811|NCT06207955|DRUG|TMJ Arthrocentesis|TMJ Arthrocentesis By Saline
214981812|NCT04976816|PROCEDURE|peri-levator betamethasone injection|The injection dose was 1 ml of betamethasone suspension (1 ml contains 5 mg betamethasone dipropionate \&2 mg betamethasone sodium phosphate). The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where the injection was delivered. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
214981813|NCT04976816|PROCEDURE|peri-levator triamcinolone injection|The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where 1ml (40mg/ml) triamcinolone acetate was injected. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
214981814|NCT04976816|PROCEDURE|peri-levator and retrobulbar betamethasone injection|In addition to peri-levator betamethasone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
215088095|NCT06508983|DRUG|SG301 placebo|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
215088096|NCT06508983|DRUG|pomalidomide|Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
215088097|NCT06508983|DRUG|dexamethasone|Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
214981815|NCT04976816|PROCEDURE|peri-levator and retrobulbar triamcinolone injection|In addition to peri-levator triamcinolone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
215088098|NCT02651480|DIETARY_SUPPLEMENT|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
215088099|NCT02651480|DIETARY_SUPPLEMENT|Control Group|Unrestricted diet with no instruction.
215088100|NCT05544136|DIAGNOSTIC_TEST|18F-FMISO PET/CT scan|18F-FMISO PET/CT scan (only 1 injection) that occurs 5-10 treatment days after RT start
214981816|NCT05185063|DIAGNOSTIC_TEST|Point of Care blood test|The pH will be incorporated into the MIRACLE2 score in a pre-hospital setting. The patients will continue to be treated with standard of care.
215088101|NCT05544136|RADIATION|Chemoradiation therapy|"* 18F-FMISO hypoxia negative patients complete CRT with 70Gy primary tumor and 50Gy de-escalated RT dose to gross nodes (if 50Gy is has pilot efficacy, then 44Gy to gross nodes; if 44Gy has pilot efficacy, then 40Gy to gross nodes).~* 18F-FMISO hypoxia positive patients are taken off study and complete SOC 70Gy CRT to primary tumor and gross nodes."
215088102|NCT05544136|DRUG|Carboplatin|The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil
215088103|NCT06579690|DRUG|8.4% sodium bicarbonate solution|Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.
214492697|NCT06875648|OTHER|Not applicable (observational study)|Retrospective analysis of gut microbiota in CRC patients vs. healthy controls. No interventions were administered; data were collected from archived samples and medical records.
214492698|NCT06818136|DIAGNOSTIC_TEST|Bladder EpiCheck|The participant will provide a voided urine sample, which will be tested using the Bladder EpiCheck test. The clinical care team and the participant will not be informed of the result, and the standard of care will not change.
214492699|NCT06873230|OTHER|The study will utilize the Jefferson Scale of Empathy-Health Profession Students (JSE-HPS) as the primary instrument for measuring empathy.|This cross-sectional observational study utilizes the Jefferson Scale of Empathy-Health Profession Students (JSE-HPS) as the primary instrument for measuring empathy, distinguishing itself as the first of its kind to be conducted among Dental Hygiene students and interns in Saudi Arabia. The unique focus on this specific population in the Saudi context sets this research apart from previous studies in the field.
214492700|NCT06735924|DIETARY_SUPPLEMENT|Low-oxalate fixed diet|Ingestion of a low-oxalate (\< 60 mg/day) , normal calcium (800-1200 mg/d) eucaloric diet for 5 days
214680793|NCT04737122|DRUG|Toripalimab|For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
214680794|NCT00455546|DRUG|A-002|
214680795|NCT02345161|DRUG|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
215088104|NCT06579690|OTHER|0.9% Normal Saline|The comparision group will receive 50 mls of 0.9% Normal Saline
215088105|NCT06579846|DRUG|Cytisinicline and exercise|"Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change.~Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25.~Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes."
214680796|NCT02345161|DRUG|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
214680797|NCT02345161|DRUG|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
214680798|NCT02345161|DRUG|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
214680799|NCT02345161|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
214492703|NCT06744478|DEVICE|Misight 1 Day Contact Lens|Misight 1 Day Contact Lens wearing for myopia control
214680800|NCT00230581|DRUG|DDP225|
214680801|NCT05269134|DRUG|Bacteriophage|Phage Therapy
214492704|NCT03691493|DRUG|Anastrozole|Given PO
214680802|NCT05269134|DRUG|Placebo|Placebo
214680803|NCT04012268|DEVICE|RIC|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
214680804|NCT04012268|DRUG|Aspirin|patients will accept medication guided by neurologists
214680805|NCT04151381|DRUG|Aminophylline|"the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol."
214680806|NCT00003264|DRUG|cisplatin|
214981817|NCT04142333|GENETIC|GIA|Patients receive a secure GIA link from their provider and then are able to send their relatives the link to GIA through texting, email, and/or Facebook messenger. Once a relative clicks on the provided link, GIA's platform is structured as a decision tree, allowing family members to construct a personalized conversation about their family member's test results. This can be done either on a smartphone or computer. GIA provides basic genetics education and risk assessment and connects family members with local genetic counseling resources to continue this conversation and/or go forward with genetic testing. At the end of the conversation, the family member has the option of having a transcript sent to them via email for their reference. The objective of the current study is to evaluate the application of GIA for cascade testing in newly identified high risk breast and gynecologic mutation carriers.
214680807|NCT00003264|DRUG|gemcitabine hydrochloride|
214981818|NCT00607217|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
214981819|NCT00607217|BIOLOGICAL|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
214680808|NCT04364074|DIETARY_SUPPLEMENT|Goodbelly|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.
214981820|NCT00607217|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
214981821|NCT03154086|DRUG|GSK3352589|It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
215088106|NCT06579846|DRUG|Cytisinicline|Same intervention as the experimental group without directed exercise prescription
215088107|NCT05773963|DEVICE|Irilens; Iridina; Afomill Lubricating Eye Drops|"* Irilens (with 0.4% HA as key ingredient);~* Iridina (with 0.4% HA as key ingredient);~* Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile)."
215088108|NCT06528288|PROCEDURE|Erector Spinae Plane Block|The erector spinae plane block (ESPB) is a method for injecting local anesthesia to reduce pain related to a surgical procedure. The anesthesia is theorized to spread along the paraspinal fascia and anesthetize a larger area, resulting in patients reporting less pain and using less opioids postoperatively.
214492705|NCT03691493|DRUG|Exemestane|Given PO
214492706|NCT03691493|DRUG|Fulvestrant|Given IM
214492707|NCT03691493|DRUG|Letrozole|Given PO
214492708|NCT03691493|DRUG|Palbociclib|Given PO
214492709|NCT03691493|RADIATION|Radiation Therapy|Undergo radiation therapy
214492710|NCT03691493|DRUG|Tamoxifen|Given PO
214492711|NCT06745505|PROCEDURE|Bowel Preparation|Group A received bowel preparation and Group B did not.
214492712|NCT06329245|OTHER|Do not take any interventions|Do not take any interventions
214680809|NCT04364074|DIETARY_SUPPLEMENT|Placebo|To prepare the placebo, the dietitian will first heat a water bath to 80 degrees Celsius. This removes the lactobacillus plantarum 299v from the probiotic drink
214680810|NCT00763685|DRUG|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
214680811|NCT01573208|DEVICE|Custom guides|Symbios custom guides for TKA
214680812|NCT05603624|PROCEDURE|Cervical examination to assess labor|Patients were randomized to receive cervical examinations to assess progression in labor with either sterile or clean gloves.
214680813|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm|HIV Prevention Behavioral Health Intervention delivered by Probation Staff
214680814|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm|HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
214680815|NCT00322595|DRUG|Quetiapine fumarate|
214680816|NCT00322595|DRUG|Paroxetine|
214680817|NCT02636764|OTHER|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
214680818|NCT02636764|DEVICE|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (\<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
214680819|NCT02636764|DEVICE|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
214680820|NCT02636764|DEVICE|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
214981822|NCT03154086|DRUG|Matching Placebo|It will be available across all strengths to match active drug in the form of tablet for oral administration.
214981823|NCT01603277|BIOLOGICAL|Anti-GM-CSF Monoclonal Antibody 400mg|Anti-GM-CSF Monoclonal Antibody 400mg
214981824|NCT01603277|OTHER|Placebo|Normal Saline
214981825|NCT05393596|BEHAVIORAL|Virtual Reality Software Intervention|Virtual Reality Software Intervention
214981826|NCT01925443|OTHER|Low level laser therapy|Will be performed irradiation with low-intensity laser in quadriceps muscle
214981827|NCT02936973|DEVICE|Real catgut implantation at acupoints|"1. Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~2. lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week ."
214981828|NCT02936973|DEVICE|sham catgut implantation at acupoints|"Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group."
214981829|NCT04880109|DRUG|APX-115|Oral administration of APX-115 100 mg capsule once daily for 14 days
214981830|NCT04880109|DRUG|Placebo|Oral administration of placebo capsule once daily for 14 days
214981831|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
215088109|NCT06528288|PROCEDURE|Subcutaneous Anesthesia|Subcutaneous anesthesia injection involves placement of local anesthesia under the skin around the surgical incision. This is thought to reduce pain from the incision site postoperatively.
215088110|NCT05725018|BIOLOGICAL|EB-101 Surgical application of RDEB wounds|"EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets \[LEAES\]"
215088111|NCT06463743|DRUG|metformin|metformin
215088112|NCT06463743|DRUG|Placebo|Placebo
215088113|NCT05534438|RADIATION|Stereotactic body radiotherapy|SBRT will be initiated as soon as possible, at not beyond 8 weeks of baseline measurements. Recommended dosing is per department standards for oligometastatic disease (ie, 10 Gy x 3 or 7-8 Gy x 5 fractions daily, excluding weekends and departmental holidays)
214368785|NCT00819364|BEHAVIORAL|Standard community care|"Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.~Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year."
214492713|NCT06791811|OTHER|OFA|"Prior to the induction of anesthesia the patients in OFA group will receive Dexmedetomidine loading dose 1 μg/kg i.v. infusion, and Lidocaine loading dose 1.5 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine will be prepared in a 20 ml syringe and infused over 10 minutes prior to induction.~Then after induction maintenance drugs will be infused as follow:~Dexmedetomidine 0.25-0.5 μg/kg/h (200 micogram in 50cc syrige with infusion rate 0.125-0.250ml/kg/h), and Lidocaine 2mg/kg/h (400mg in 20cc syringe with infusion rate 0.1 ml/kg/h)"
214981832|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
214981833|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
214981834|NCT00089219|BIOLOGICAL|IFA|vaccine adjuvant
214981835|NCT00089219|BIOLOGICAL|6MHP|melanoma helper peptides
214981836|NCT00089219|BIOLOGICAL|GM-CSF|vaccine adjuvant
214981837|NCT03225963|RADIATION|Chemoradiation with temozolomide|
214981838|NCT04112576|DEVICE|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
214981839|NCT03148262|DEVICE|The Comfort Flo system|The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
214981840|NCT03148262|DEVICE|The Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
214981841|NCT02950701|DEVICE|Observational data collection.|
214981842|NCT01192321|DEVICE|Toric T3 - T9|Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
214981843|NCT01192321|DEVICE|Monofocal|Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
214981844|NCT04525521|OTHER|Hand sanitizer and hand washing|All subjects will cleanse their hands with hand sanitizer, followed by hand washing with soap and water
214981845|NCT05469945|DEVICE|Compressive garments class II|Daily wearing of compressive garments, especially during prolonged standing upright or strenuous activities.
215088114|NCT05566431|OTHER|ICP|The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury
214981846|NCT01515839|DIETARY_SUPPLEMENT|Multivitamin Supplement intervention|"We recommend the following protocol:~1. 2 tablets of a high quality multivitamin BID~2. 2 capsules of omega 3 fish oil BID for a total of 3 grams daily~3. 3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg~4. Weight loss"
214981847|NCT05211934|OTHER|No intervention|No intervention
214368786|NCT06147518|DRUG|Metformin|Metformin: 1.5g/d CTPA,1g/d CTPB
214368787|NCT06147518|DRUG|Sitagliptin|Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c\>7%
214981848|NCT02522117|DRUG|Atorvastatin|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
214981849|NCT02522117|DRUG|Placebo|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
214981850|NCT02472899|OTHER|Blood sample|Non-interventional study based on blood samples taken at a single study visit
214981851|NCT00550199|DRUG|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
214981852|NCT04486664|BEHAVIORAL|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
214981853|NCT02936947|DEVICE|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation
214981854|NCT02936947|OTHER|Free breathing|Free breathing
214981855|NCT02936947|OTHER|Active Breathing Control|Active Breathing Control
215088115|NCT05566431|OTHER|CREVICE|The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
214368788|NCT06147518|DRUG|Dapagliflozin|Assess HbA1c/HBSG at 8 weeks, increase Dapagliflozin to 10 mg if HbA1c\>7%
214680821|NCT02636764|DEVICE|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
214981856|NCT04435496|DEVICE|GYN-CS|placement of the GYN-CS device
214981857|NCT04900311|DRUG|pyrotinib + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pyrotinib: 400 mg/day, orally, qd trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
214981858|NCT04900311|DRUG|pertuzumab + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pertuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 840 mg for Cycle 1, followed by 420 mg for Cycles 2-4 trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
215088116|NCT00583791|DEVICE|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
215088117|NCT02433873|DIETARY_SUPPLEMENT|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
214981859|NCT01183923|OTHER|Broccoli Sprouts|Broccoli Sprouts will be eaten daily in a sandwich form during the intervention period for broccoli sprouts.
214981860|NCT01183923|OTHER|Alfalfa Sprouts|Alfalfa sprouts will be eaten daily in a sandwich form during the intervention period for alfalfa sprouts.
214981861|NCT04494646|DRUG|Bardoxolone Methyl|Once-daily administration of bardoxolone methyl (20mg)
214981862|NCT04494646|DRUG|Placebo|Once-daily administration of matching placebo
214368789|NCT03810534|BEHAVIORAL|Connect-Home|Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
214368790|NCT04083716|DRUG|ABI-H2158 Reference Formulation|ABI-H2158 tablets Reference Formulation
214368791|NCT04083716|DRUG|ABI-H2158 Test Formulation|ABI-H2158 tablets Test Formulation
214981863|NCT05759572|DRUG|Apatinib|TKI
214981864|NCT05759572|DRUG|Dalpiciclib|CDK4/6 inhibitor
214368792|NCT02300012|PROCEDURE|Surgeons knowledge of pre-operative PBIs|Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
214368793|NCT05083195|OTHER|Home-based Telerehabilitation|Balance, walking, strengthening exercise videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
214368794|NCT05083195|OTHER|Exercise Brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
214368795|NCT00992953|BEHAVIORAL|Treatment as Usual|10 weeks of therapy and/or psychiatric medication as available
214680822|NCT02045277|DRUG|IDP-118 Lotion|Lotion
214680823|NCT02045277|DRUG|IDP-118 Monad HP Lotion|Active Comparator
214981865|NCT05759572|DRUG|Fulvestrant/AI|Endocrine therapy
214368796|NCT00992953|BEHAVIORAL|Virtual Reality Exposure with Stimulus Control|10 weeks of therapy, up to twice a week, 90 min sessions involving Virtual Reality Exposure with Stimulus Control
214981866|NCT00286182|DRUG|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
214981867|NCT00286182|DRUG|Placebo|Placebo
214981868|NCT02506920|DIETARY_SUPPLEMENT|Six different types of fat in a meal in random order|Oral fat tolerance test
214981869|NCT03818152|OTHER|Functional strength assessment|Functional strength exercises to assess strength in lower limbs.
214981870|NCT02785939|DRUG|Docetaxel|Given IV (arm II closed to accrual 12/18/2015)
214368797|NCT00113282|DRUG|Interleukin-2 (IL-2)|
214981871|NCT02785939|OTHER|Laboratory Biomarker Analysis|Correlative studies
214981872|NCT02785939|DRUG|Palbociclib|Given PO
214368798|NCT02427789|OTHER|Physical Exercise|physical exercise
214368799|NCT03586583|DEVICE|FBP|Old processing
214368800|NCT03586583|DEVICE|ISR|New processing
214368801|NCT00336739|DRUG|cinacalcet|
214981873|NCT04465422|BEHAVIORAL|Occupational therapy based on the MOHO theory|"We selected two acute wards in the Songde hospital as the intervention group and the control group. At the same time, the demographic data of the participants were collected, including gender, age, age of onset, marital status, education level, work experience, etc., and the clinical records, including assessment of mental symptoms and medication records, etc. Continuity or categorical information on Occupational performance, personal and social performance, instrumental activities daily living, and clinical performance.~OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model."
214368802|NCT00622011|DRUG|Risperidone and Zotepine for delirium|try risperidone or zotepine in the treatment of delirium
214981874|NCT04465422|BEHAVIORAL|Occupational therapy|The original Occupational therapy. OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model.
214368803|NCT00845338|DRUG|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
214368804|NCT06347094|OTHER|Personalized Dietary Plan|Prescription of dietary plans increasing the intake of (poly)phenols through consumption of foods rich in these compounds, in the context of a balanced, personalised diet
214368805|NCT06347094|DIETARY_SUPPLEMENT|Oral (Poly)phenol Challenge Test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
214368806|NCT06347094|OTHER|General Dietary Advice|Prescription of balanced dietary plans
214368807|NCT02816190|PROCEDURE|prone position|
214368808|NCT02243280|DRUG|ABT-493|Tablet
214368809|NCT02243280|DRUG|ABT-530|Tablet
214368810|NCT00605514|DRUG|VRC-EBODNA023-00-VP|
214368811|NCT00605514|DRUG|VRC-MARDNA025-00-VP|
214368812|NCT02020122|DRUG|Duloxetine|duloxetine 60mg
214368813|NCT02020122|DRUG|Pregabalin|pregabalin 150mg
214368814|NCT02020122|DRUG|Placebo|non active placebo
214368815|NCT02713711|RADIATION|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
214368816|NCT02713711|PROCEDURE|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
214492714|NCT06791811|OTHER|OA|In the opioid anaesthesia group patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h (200 micograms in 50 cc syringe with infusion rate 0.125-0.250ml/kg/h).Placebo (saline infusion) in 20 cc syringe with rate infusion rate 0.1 ml/kg/h.
214680824|NCT02045277|DRUG|IDP-118 Monad Taz Lotion|Active Comparator
214680825|NCT02045277|DRUG|IDP-118 Vehicle Lotion|Vehicle
214368817|NCT02713711|PROCEDURE|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
214368818|NCT00998400|BEHAVIORAL|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
214368819|NCT03766841|BEHAVIORAL|Facilitated Enrollment|Research coordinator will assist patients in account creation and usage of the tool.
214368820|NCT05502419|PROCEDURE|Neural slump mobilization|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
214368821|NCT05502419|PROCEDURE|Conventional Physical Therapy|Moist heat with hydro collator pack, Maitland Mobilization for Lumbar spine, Therapeutic exercise: Core stability exercises
214368822|NCT01083641|DRUG|Estradiol|10mg oral three times daily
214368823|NCT03439189|COMBINATION_PRODUCT|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
214368824|NCT03439189|DRUG|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
214368825|NCT03439189|DRUG|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
214981875|NCT02668003|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
214981876|NCT01710462|DRUG|Pantoprazole + Domperidone|
214368826|NCT05233202|DRUG|Levosimendan|Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.
214492715|NCT06820047|PROCEDURE|Laparoscopic sleeve gastrectomy|"Patients underwent SG, involving longitudinal resection of approximately 75% of the stomach along its greater curvature, with excision of the fundus and part of the body and antrum, preserving a portion of the latter and the pylorus itself. This results in a vertical tube-shaped gastric tube sleeve. After surgery, patients followed a free diet. Patients were evaluated at baseline and at 1, 3, 6, 9, and 12 months after starting the intervention."
214492716|NCT06820047|OTHER|Obesity pharmacotherapy|Patients underwent 1 month of a very low calorie diet (VLCD) with 813 kcal/day, followed by a low calorie diet (LCD) for 11 months together with intensive physical exercise (30 min/day of brisk walking plus at least 3 h/week of aerobic exercise) with 2.4 mg/week of semaglutide (Ozempic®), given once weekly as subcutaneous injections. Patients were evaluated at baseline and at 1, 3, 6, 9 and 12 months after starting the interventions.
214981877|NCT01710462|DRUG|Pantozol®|
214981878|NCT03893786|DEVICE|Robotic Rehabilitation|"Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
214981879|NCT03786640|RADIATION|3T MRI scan|A clinically indicated 3T MRI scan will be performed per standard procedures for the radiology department. Cardiac monitoring during the MRI scan is recommended to include Pulse Oximetry and/or ECG.
214981880|NCT01427140|OTHER|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
214981881|NCT01427140|OTHER|Saturated fatty acid group|Addition of saturated fatty acids to the diet in the form of pastries
214981882|NCT05033132|DRUG|Balstilimab|Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
214981883|NCT05033132|DRUG|Balstilimab + Zalifrelimab|An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
214981884|NCT05543304|DIAGNOSTIC_TEST|radiological evaluation|All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.
214981885|NCT02989974|BEHAVIORAL|KY LEADS Survivorship Care|"Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment"
215088118|NCT01345565|DRUG|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
215088119|NCT02476474|PROCEDURE|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
215088120|NCT02476474|PROCEDURE|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
215088121|NCT05302141|BEHAVIORAL|Wear 3D printing assistive device|"Wear 3D printing aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
215088122|NCT05302141|BEHAVIORAL|Wear universal cuff device|"Wear universal cuff aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
214680826|NCT03468283|OTHER|mobile application for diabetes|Intervention was mobile application and individualized regular message feedback sent by healthcare professionals.
215088123|NCT03980821|DRUG|AZD4635|AZD4635 taken orally
215088124|NCT03601559|DIETARY_SUPPLEMENT|Lactobacillus paracasei Lpc-37|Live probiotic bacteria
214368827|NCT05233202|DRUG|PLACEBO|Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction.
214368828|NCT06070584|PROCEDURE|aerobic exercises with electrical treadmill for 30 min and inspiratory muscle training for 10 minutes.,|aerobic exercises with moderate intensity in the form of walking on electrical treadmill
214368829|NCT01777321|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
214981886|NCT05461040|PROCEDURE|optic capture|optic capture of Intraocular lens without anterior vitrectomy
214981887|NCT05461040|PROCEDURE|In-the-bag implantation of Intraocular lens|in-the-bag implantation of Intraocular lens with anterior vitrectomy
214981888|NCT02415985|DRUG|Lopinavir/r will be supplied by NHSO/GPO|200/50 mg tablet LPV/rtv
214981889|NCT02415985|DRUG|Rifabutin|
214981890|NCT04287348|DRUG|Brolucizumab 6 mg solution for intravitreal injection|All consenting, enrolled patients (irrespectively of maximum recurrence-free interval under aflibercept pretreatment) will receive an intravitreal injection of brolucizumab 6 mg at baseline (week 0), at week 4 and each of the following treat and extend visits. At each visit all patients will undergo an OCT assessment. For all patients extension of treatment intervals is only possible 2-week-stepwise, e.g. 4, 6, 8 weeks etc.
214981891|NCT00394641|BEHAVIORAL|listening to music / stories via stereophonic headphones|
214981892|NCT04422067|OTHER|Fetal cephalometry|Fetal cephalometry
214981893|NCT05423951|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.
214981894|NCT05423951|DRUG|Propofol|For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.
214981895|NCT05423951|DRUG|Rocuronium|After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed
214981896|NCT05423951|DRUG|Sufentanil|During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
214981897|NCT02182804|DEVICE|Olympus|narrow band imaging with magnification
214981898|NCT02182804|DEVICE|Cellvizio|probe-based confocal laser endomicroscopy
214981899|NCT04562974|DEVICE|MRI-scanner|Only one group of 30 participants is constituted. All participants will perform perception and memory tasks inside a MRI-scanner. Functional activity (BOLD signal) will be registered, as well as anatomical and behavioural data.
214981900|NCT00941551|DRUG|levothyroxine|levothyroxine 75-125 ug/day
214981901|NCT00941551|DRUG|no levothyroxine|observation only without prophylactic levothyroxine
214981902|NCT00572832|BIOLOGICAL|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
214981903|NCT00572832|BIOLOGICAL|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
214981904|NCT00966433|PROCEDURE|Spontaneous ventilation|The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
215088125|NCT03601559|DIETARY_SUPPLEMENT|Placebo|Inert placebo matched for taste and appearance
214981905|NCT00966433|DEVICE|Pressure support Ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
214981906|NCT00966433|DEVICE|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
214981907|NCT02060409|GENETIC|spliceosome|spliceosome mutations
214981908|NCT04808102|DEVICE|IER AG|The game is a web-based single-player adventure game with 3 levels created with the RPG Maker MV. Playtime is approximately 3 hours.
214981909|NCT04808102|DEVICE|BubbleShooter|A free-to-play arcade browser puzzle game called BubbleShooter.
214981910|NCT02634255|DRUG|Rocuronium elective surgery|Rocuronium onset time in patients undergoing inguinal herniorrhaphy
214981911|NCT02634255|DRUG|Rocuronium emergency surgery|Rocuronium onset time in patients undergoing appendectomy
214981912|NCT02634255|DRUG|Propofol|
214981913|NCT02634255|DRUG|Fentanyl|
214981914|NCT02634255|OTHER|Ringer Lactate|
214981915|NCT02634255|DEVICE|Acceleromyography device|
214981916|NCT03925896|DRUG|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
214981917|NCT01258049|DRUG|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
215088126|NCT00005875|DRUG|rubitecan|
214368830|NCT01900600|OTHER|Cardiopulmonary exercise test|All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
214680827|NCT00780468|BEHAVIORAL|Existing diet plan|
214680828|NCT00780468|BEHAVIORAL|New diet plan|
214981918|NCT01258049|DRUG|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
214981919|NCT01031290|DEVICE|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
214981920|NCT05052840|OTHER|Muscle endurance training (MET)|Experimental group will be given MET Program, stretching \& strengthening exercises and Hot packs (for 15 minutes). MET program will include warm up, endurance and cool down exercises. The warm up and cool down period will be consisted of 5-minute walking, and 10 repetitions of stretching exercises. Endurance exercises will consist of 4 levels.
214981921|NCT05052840|OTHER|Conventional Treatment|"Conventional treatment group will be given hot packs (for 15 minutes) and Strengthening \& stretching exercise program including:~STRETCHING EXERCISES (lumbar extensor muscles, iliopsoas muscles, hamstring muscles, gastrocnemius muscles and pectoral muscles).~STRENGTHENING EXERCISES (rectus abdominus crunch, oblique crunch, pelvic elevation, single leg pelvic elevation, lumbal spine extension, on hands and knees position with the raise of one leg, on hands and knees position with the raise of opposite arm and leg). Each exercise will be repeated 10 times."
214981922|NCT02715908|DRUG|LBEC0101|Etanercept 50mg
215088127|NCT05001841|PROCEDURE|Lung Transplantation|Double lung transplant
215088128|NCT06089941|OTHER|circulating tumoral DNA detection|blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse
215088129|NCT01209663|OTHER|Postoperative Intermediate Care|Comparison of postoperative Intermediate Care versus Ward Care.
215088130|NCT03323736|COMBINATION_PRODUCT|Iontophoresis & tube placement|Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.
214368831|NCT01900600|OTHER|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
214368832|NCT01329354|BIOLOGICAL|Autologous effector lymphocytes expanded ex-vivo|Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
214368833|NCT01807156|DRUG|Tivozanib|Oral medication given daily. No placebo.
214981923|NCT00067834|DEVICE|Pulsing electromagnetic field (PEMF)|
214981924|NCT03735615|BEHAVIORAL|sprint interval training|Each training session will be performed 3 times per week for 3 weeks. Each session consists of 3-5x20 sec all-out cycling efforts against a load corresponding to 0.05-0.07 kg/kg body mass, separated by 3-5 min of low intensity cycling (20-50 W), on a lode bicycle ergometer (Excalibur Sport V2.0, Groningen, the Netherlands). All training sessions includes a 5 min warm-up and 3 min cool-down.
214981925|NCT03583281|DIETARY_SUPPLEMENT|Capsules containing flax oil|Capsules containing flax oil to provide 4 grams ALA per day for 4 weeks
214981926|NCT03583281|DIETARY_SUPPLEMENT|Capsules containing DHA-enriched fish oil|Capsules containing fish oil to provide 4 grams DHA per day and 0.8 grams EPA per day for 4 weeks
214981927|NCT00006022|BIOLOGICAL|aldesleukin|
214981928|NCT00006022|DRUG|bryostatin 1|
214981929|NCT00522665|DRUG|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
214981930|NCT00522665|BIOLOGICAL|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
214981931|NCT00522665|BIOLOGICAL|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
214981932|NCT03359746|DRUG|Grazoprevir/Elbasvir|Medication for treatment of patient
215088131|NCT03323736|DEVICE|Tube placement|Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.
214368834|NCT05753865|DRUG|SYHX2011|IV infusion, 260 mg/m\^2
214368835|NCT05753865|DRUG|Paclitaxel for injection (albumin-bound)|IV infusion, 260 mg/m\^2
214368836|NCT05412888|DIETARY_SUPPLEMENT|CoQ10 supplementation|Young men training endurance running will be supplemented with CoQ10
214368837|NCT05412888|PROCEDURE|Ischemic preconditioning training|Young men training endurance running will undergo IPC training
214368838|NCT05412888|DIETARY_SUPPLEMENT|IPC training combined with CoQ10 supplementation|Young men training endurance running will undergo IPC training combined with CoQ10 supplementation
214368839|NCT05412888|DIETARY_SUPPLEMENT|Sham IPC combined with placebo|Young men training endurance running will undergo sham IPC training combined with placebo supplementation
214368840|NCT01480947|DRUG|Bio-three|oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
214680829|NCT05424900|BEHAVIORAL|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
214981933|NCT04725669|DIAGNOSTIC_TEST|ELISA IgG Testkit|All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.
214981934|NCT06000644|DEVICE|Combined group|The combined group will undertake progressive treadmill walking speed while performing a cognitive task with rhythmic auditory cueing for 30 minutes per session, 3 times a week for 4 weeks.
214981935|NCT06000644|DEVICE|Cognitive group|The cognitive group will receive cognitive training while treadmill walking with a progressive speed for 30 minutes per session, 3 times a week for 4 weeks .
214981936|NCT06000644|DEVICE|Rhythmic group|The rhythmic group will hear rhythmic auditory stimulation while treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
214981937|NCT06000644|DEVICE|Treadmill group|The treadmill group will train only in progressive treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
214981938|NCT02049216|OTHER|Flexible tape|Flexible, elasticised, adhesive athletic tape
214981939|NCT02049216|OTHER|Fixomull|
214981940|NCT02049216|OTHER|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
214981941|NCT03444584|DRUG|MEDI0382|Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).
214981942|NCT03444584|DRUG|Placebo|Subcutaneous dose of placebo matched to MEDI0382.
214981943|NCT03444584|DRUG|Dapaglifozin|Oral dose of dapaglifozin 10 mg tablet.
214981944|NCT03444584|DRUG|Metformin|Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).
214981945|NCT03233074|OTHER|Bone marrow analyses|This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
215088132|NCT05632276|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
215088133|NCT01762254|PROCEDURE|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
214680830|NCT03493308|OTHER|Pain neuroscience education|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
214680831|NCT03493308|OTHER|Exercise|Exercise will be provided in different formats including general exercise, strengthening, dance.
214680832|NCT03642015|BEHAVIORAL|Music listening|listening the music 15 min
214680833|NCT06334029|DIAGNOSTIC_TEST|Functional and structural Connectome|Reconstruction of EEG derived functional relationship between brain regions (functional connectome). Reconstruction of thickness covariance across brain regions (structural connectome)
214492717|NCT06854445|DRUG|TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection|"Drug: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection;~Other Name:~Gemcitabine Hydrochloride for Injection, Zefei; Oxaliplatin for Injection, Aihen~TQB2825 injection is Cluster of Differentiation 3 (CD3) and and Cluster of Differentiation 20 (CD20) bispecific antibody; Gemcitabine hydrochloride for injection is a cell cycle-specific antimetabolite; Oxaliplatin for Injection is a platinum chemotherapy drug."
214680834|NCT04971044|BEHAVIORAL|COACH|Multi-Level Behavioral Intervention
214680835|NCT04971044|BEHAVIORAL|School Readiness Intervention|Multi-Level Language and School Readiness Intervention (Control Group)
214368841|NCT02483286|BEHAVIORAL|ICG|"Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.~The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.~Subjects are encouraged to practice study home exercise program at least twice weekly."
214492718|NCT05197530|DRUG|Indocyanine green|A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.
214680836|NCT05152160|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell Therapy|Umbilical Cord Mesenchymal Stem Cell Therapy
214680837|NCT06478758|DRUG|Ibuprofen 400 mg|The ibuprofen group (n=36) was administered 800 mg of ibuprofen . All procedures were performed with the same team. During surgery, a 20% increase in the participant's heart rate and mean arterial pressure remifentanil infusion was administered. During the postoperative period, all participants continued to receive acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4. In the recovery room, the participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
214981946|NCT03720561|DRUG|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.
214492719|NCT05197530|DEVICE|MultiSpectral Imaging System|Once the ICG is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
214492720|NCT03373552|DIAGNOSTIC_TEST|Platelet function assay|Platelet function assay
214492721|NCT06787300|BEHAVIORAL|Stories that Empowered Mother|this intervention is made by resercher for this research.
214492722|NCT06785493|DRUG|Optimized Treatment (OPT)|After the first sufficient intravenous infusion of UST (6 mg/kg), the patient's response was assessed based on PRO2 at week 8, and an individualized treatment plan was developed. At week 8, the patients with incomplete response of PRO2 (a decline of PRO2 was less than 50% from baseline or still in moderate to severe active phase of PRO2) were given one or more UST intravenous re-induction (6 mg/kg) every 4 or 6 weeks.
214492723|NCT02806570|DEVICE|Mitral valve repair|
214492724|NCT06780462|DRUG|Corticosteroids + Rivaroxaban|Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market) and Rivaroxaban
214492725|NCT06780462|DRUG|Corticosteroids alone|Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market)
214492726|NCT06786858|DEVICE|HandMate|HandMate device is used for 20 hours in 4 weeks. Device is then used in the home for 3 months at discretion of participant.
214981947|NCT01142336|DRUG|Simvastatin|Simvastatin 40mg qHS for 1 year
214981948|NCT01142336|DRUG|Placebo|Placebo 1 tablet qHS for 1 year
214981949|NCT01704261|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
214981950|NCT01704261|DRUG|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
214981951|NCT01704261|DRUG|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose \>=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
214981952|NCT01704261|DRUG|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose \>=1500 mg
214981953|NCT02061657|DRUG|Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation
214981954|NCT02061657|DRUG|Placebo( for misoprostol)|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
214368842|NCT02483286|BEHAVIORAL|MTG|MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist
214981955|NCT04845230|BEHAVIORAL|FreshRx Nourishing Healthy Starts|This is a field experiment study that incorporates referrals to public programs, food supplementation and nutrition education, or integrative care services provided by a Licensed Masters Social Worker.
214368843|NCT02483286|BEHAVIORAL|XBG|XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
214368844|NCT04377230|PROCEDURE|biliopancreatic limb length of 60cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
214368845|NCT04377230|PROCEDURE|biliopancreatic limb length of 100cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
214368846|NCT03276637|GENETIC|Whole exome sequencing|Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory on 75 enrolled individuals
214368847|NCT03484676|DEVICE|Titinium|custom made plate at one point after 3D virtual simulation and reduction of the complex using Mimics software.
214368848|NCT03464279|BEHAVIORAL|Nudge using Behavioral Economic Interventions|
214368849|NCT03464279|BEHAVIORAL|Standard Practices to Reduce Health System Antibiotic Prescription|
214368850|NCT04508452|DRUG|Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; Administered every 2 weeks.
214368851|NCT06329726|DIAGNOSTIC_TEST|Clinical examinations and clinical scales administration|Psychometric assessment of cognitive and behavioral outcomes
214368852|NCT01731743|DEVICE|AT LISA tri 839MP|
214368853|NCT00005993|DRUG|aldesleukin|
214368854|NCT00005993|DRUG|filgrastim|
214368855|NCT00005993|DRUG|recombinant human stem cell factor|
214368856|NCT00005993|PROCEDURE|peripheral blood stem cell transplantation|
214368857|NCT02056860|PROCEDURE|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
214368858|NCT02056860|PROCEDURE|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
214492727|NCT06789822|DEVICE|Invitation to wear the smartwatch|During a consultation with the psychiatrist, and after verifying the eligibility criteria, the patient will receive oral information about the study from the psychiatrist.
214492728|NCT06718192|OTHER|Bleomycin injection|Wart injection (0.2 mL \<5 mm; 0.5 mL 5-10 mm; 1ml for \>10 mm) were injected at a depth of 1.5mm, diluted with normal saline at a concentration of 3u/ml=3mg/ml, and the maximum amount of each wart was 1ml until the wart turned white
214492729|NCT06718192|OTHER|Cryotherapy|The wart was frozen by liquid nitrogen until a circle of frozen tissue appeared around the wart for about 10s, with an interval of 30s, for a total of 2 times
214492730|NCT06788301|PROCEDURE|Inferior Alveolar Nerve Block|local anesthesia administration (inferior alveolar nerve block)
214492731|NCT06788301|DEVICE|VR eyeglasses|VR eyeglasses was used to distarct patients from dental environment during inferior alveolar nerve block.
215088134|NCT01762254|PROCEDURE|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
214368859|NCT02056860|PROCEDURE|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
214368860|NCT02056860|PROCEDURE|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
214368861|NCT02056860|PROCEDURE|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
214368862|NCT00122590|DRUG|nelfinavir|
214368863|NCT00122590|DRUG|lopinavir/r|
214368864|NCT00122590|DRUG|indinavir|
214368865|NCT00122590|DRUG|ritonavir|
214368866|NCT05596084|PROCEDURE|maxillary sinus augmentation and implant placement|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides.platelet-rich fibrin prepared with titanium on the other side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared with titanium (T-PRF), the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 14 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
214492732|NCT06788301|DEVICE|Buzzy device|Buzzy device was used to distarct patients from dental environment during inferior alveolar nerve block.
214492733|NCT06794346|DRUG|Transdermal testosterone|women will receive 300mcg of transdermal testosterone in cream daily for six months
215088135|NCT00109356|DRUG|AQ4N (Chemotherapy)|
215088136|NCT00684827|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, Pirbuterol HFA MDI"
214981956|NCT05232617|OTHER|Rheumatological rehabilitation training|Online rheumatological rehabilitation training is planned. Online rheumatological rehabilitation training will be video-based via the Edpuzzle application and interactively via the zoom application. Online trainings are planned for 15-person intern physiotherapy student groups 4 days a week, 2 hours a day, for 4 weeks on a case-based basis. With the Edpuzzle application, videos will be prepared for 10 different rheumatological diseases. In each video, a case with rheumatic disease will be introduced, evaluations made from a physiotherapy perspective and their results will be included. Before the lesson, students will watch the video defined for them every day from the application called Edpuzzle, answer the questions and plan a disease-specific assessment and treatment program according to the directions in the video. Then, the assessment and treatment programs prepared by a group of 15 people through the zoom platform will be discussed during the lesson.
214981957|NCT02137798|DEVICE|Radio-frequency catheter ablation|Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude \< o.5 mV) will also be ablated.
214981958|NCT04909944|DEVICE|i-gel Supraglottic insertion|i-gel Supraglottic insertion for oxygenation
214981959|NCT04909944|DEVICE|Laryngeal Tube Suction Disposable Supraglottic insertion|Laryngeal Tube Suction Disposable Supraglottic insertion for oxygenation
214981960|NCT06243445|DIAGNOSTIC_TEST|Transthoracic echocardiography for central venous catheter tip location|Measure of time between injection of echographic contrast in the distal lumen of a central venous catheter, inserted via supra/infra clavicular right veins, and visualization, using transthoracic echocardiography, of micro bubbles in right atrium with the catheter tip positioned under transesophageal ultrasound control in four different positions: right atrium, cavo-atrial junction (CAJ), at 4 centimeters proximal to CAJ, in superior vena cava and at 8 centimeters proximal to CAJ
214981961|NCT05590338|DRUG|GSK1070806|Participants will receive GSK1070806
214981962|NCT05590338|DRUG|Placebo|Participants will receive placebo
214981963|NCT03196141|DIAGNOSTIC_TEST|StO2 and EndoPAT|"* StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~* The EndoPAT probe will be place on a finger on the same arm.~* Pulse oximeter probes will be connected to a finger on each hand."
214981964|NCT01670370|DRUG|R-GemOx|Rituximab Gemcitabine Oxaliplatin
214981965|NCT04503044|OTHER|Retrospective observational study|No intervention to occur
214981966|NCT02722967|DRUG|Aripiprazole + IEM (Ingestible Event Marker)|Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
214981967|NCT03761316|OTHER|interview regarding goals|interview regarding goals
214981968|NCT05861908|OTHER|Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
214981969|NCT05861908|OTHER|Heated Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
214981970|NCT05861908|OTHER|G-aenial™ BULK Injectable restoration|restoration of class II caries with different bulk-fill technique
214981971|NCT05861908|OTHER|Sonicfill3 restoration|restoration of class II caries with different bulk-fill technique
214981972|NCT02391337|DRUG|Bisoprolol|Drug intervention
214981973|NCT02391337|DRUG|Digoxin|Drug intervention
214981974|NCT02596048|OTHER|Iomeron|Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
214981975|NCT04294537|PROCEDURE|TAP Block|At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal oblique and transveralis fascia
215088137|NCT00684827|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. Pirbuterol HFA MDI, Xopenex HFA MDI"
215088138|NCT03353766|DEVICE|Early crossbite correction with Q-H Device|Crossbite treatment in deciduous dentition with Quad-Helix appliance
214368867|NCT05596084|PROCEDURE|Maxillary sinus augmentation with bovine bone graft|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides. Bio-oss bovine bone graft on one side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared, the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 13 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
214368868|NCT05748210|OTHER|Symptom management mobile health application with personalised support|"Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
214492734|NCT06794346|DRUG|Vaginal testosterone gel|women will receive 300mcg of vaginal gel testosterone daily for six months
214492735|NCT06794346|DEVICE|Placebo group|women will receive both vaginal gel and transdermal cream placebo for six months
214492736|NCT05733494|OTHER|Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)|the CADN will be administrated to each patient at the enrolment
214492737|NCT06809712|DRUG|Busulfan (Busulfex)|Myeloablative conditioning: Busulfan (Bu，3.2 mg/kg/d IV -8d \~-6d); Reduced intensity conditioning: Busulfan (Bu，3.2 mg/kg/d IV -7d\~-5d);
214981976|NCT04294537|PROCEDURE|LIA local infiltration|At the end of surgery 0,5% levobupivacaine 1.5 mg/kg, equally distributed between ports, injected in the skin and subcutaneous tissue during wound closure.
214981977|NCT04294537|PROCEDURE|General anesthesia|"General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv."
214981978|NCT04294537|DRUG|Postperative analgesia|"During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours."
214981979|NCT01061996|DRUG|Basiliximab|Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
214981980|NCT04054830|DRUG|Voltaren Ophtha 1 mg/ml, GSK|Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
214981981|NCT04054830|DRUG|Monopex 1 mg/ml, Théa|Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
214981982|NCT03704064|BEHAVIORAL|Stigma-Reduction Intervention|Session topics will be based on those tested in a previous pilot study, including: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to physical activity. For example, they will be given strategies to cope with anticipated stigma while exercising in public spaces (e.g., while walking), as well as to challenge self-critical beliefs (e.g., that they are lazy) which may otherwise lead them to avoid exercising. These concrete strategies, along with reducing WBI and improving self-confidence, are intended to increase participants' self-efficacy for and engagement in physical activity.
214981983|NCT03704064|BEHAVIORAL|Behavioral Weight Loss (BWL)|This intervention will be based on the Diabetes Prevention Program. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 20 weeks will include self-monitoring, stimulus control, social support, portion sizes, and goal-setting. Those during weeks 21-72 will focus on skills required for weight loss maintenance and relapse prevention. Physical activity will be begin with a prescription of 60 min/wk, and will gradually progress by 10 minutes over 2-4 week intervals until achieving 150 min/wk by week 20, 200 min/wk by week 46, and 250 min/wk by week 72. Participants will be instructed to spread the activity equally across at least 5 days in bouts that are \>10 minutes in duration. Moderate intensity will be prescribed with an emphasis on walking; the vast majority of our research participants self-select this form of activity.
214368869|NCT05748210|OTHER|Wait-list Symptom management mobile health application with personalised support|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
214492738|NCT06809712|DRUG|Cyclophosphamide (CTX)|Myeloablative conditioning: Cyclophosphamide (Cy，1.8g/m2, -5d, -4d) Cyclophosphamide is not used for reduced intensity conditioning
214492739|NCT06809712|DRUG|Fludarabine (Fludara)|Myeloablative conditioning: Fludarabine (Flu，30 mg/m2/d IV -6d \~ -2d); Reduced intensity conditioning: Fludarabine (Flu，30mg/m2 /d IV -10d\~-5d);
214492740|NCT06809712|DRUG|Semustine (MeccNU)|"For both myeloablative and reduced intensity conditioning:~Semustine (MeCCNU: 250 mg/m2 orally-3d)"
214981984|NCT01834547|DRUG|Drugs use: methylphenidate|40 mg tablets
214981985|NCT01834547|DRUG|Drug use: modafinil|40 mg tablets
214981986|NCT01834547|DRUG|caffeine|400 mg
214981987|NCT01834547|DRUG|placebo|placebo
214981988|NCT01369264|DEVICE|true left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor
214981989|NCT01369264|DEVICE|Passive sham left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The passive (inactive) coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor. An active coil will be held vertically in a mechanical holder 50 cm behind the subject head and run at 10 Hz with an intensity set to 150% of motor threshold.
214981990|NCT00773357|DRUG|guanfacine|3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.
214981991|NCT00773357|DRUG|placebo|placebo
214981992|NCT01090180|DRUG|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
214981993|NCT01090180|DRUG|Placebo (sugar pill)|inactive
214981994|NCT02378389|DRUG|Pyrotinib/Pyrotinib with Docetaxel|Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
214981995|NCT04534998|PROCEDURE|Partial nephrectomy|Partial nephrectomy for localized kidney cancer as curative treatment.
214981996|NCT06017245|DEVICE|whole-body vibration to Control|Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.
214981997|NCT04077892|DRUG|budesonide|SAR patients received treatment of a combination of budesonide and montelukast tablet or only intranasal budesonide randomly for 14 days
215088139|NCT03468972|DRUG|Immunosuppressive treatment|At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria \< 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
214368870|NCT03122119|DRUG|Platelet Rich Plasma Joint Injection|30 to 50 milliliters of venous blood will be drawn from the patients arm with a 19 gauge ¾ inch needle using universal precautions. The venous blood will be mixed with 8 milliliters of anticoagulant citrate dextrose solution-A (ACD-A). The anti-coagulated blood will then be centrifuged for 15 minutes at 3200 revolutions per minute in the office centrifuge. This will allow plasma to separate from blood cells. The portion of centrifuged blood deficient in platelets will be extracted and discarded. Once the needle is visualized entering the joint capsule via ultrasound guidance and the physician feels resistance provided by the capsule and ligaments, 3 milliliters of PRP extract will be injected (3 inch, 22 gauge needle) into the sacroiliac joint. The needles will be properly disposed.
214368871|NCT01641796|DRUG|Paromomycin|Paromomycin Topical Cream applied to all lesions once a day for 20 days
214368872|NCT01924611|PROCEDURE|Atraumatic Restorative Technique using cotton rolls|Atraumatic Restorative Technique using cotton rolls.
214492741|NCT06651814|BEHAVIORAL|Supervised Exercise Group|A supervised exercise program will consists of 10 sessions. The 1st exercise station will be a 5-minute warming up of the jaw with a heat lamp. The 2nd station will involve jaw opening-closing movements (TMJ rotation) with the mandible in a slightly protruded position for 6 minutes. The 3rd and 4th exercise stations will comprised of jaw opening and jaw protrusion, respectively, against resistance for 4 minutes each. Measurements will be done before the trial started and after 3 months.
214492742|NCT06651814|BEHAVIORAL|Home Exercise Group|Patients will received a home regime of jaw exercises. They will be instructed to do two different trainings. The 1st type of exercise will be jaw opening and closing movements daily for 5 minutes after each meal with the mandible and the head of the TMJ in a slightly protruded position. This exercise should not produce any clicking sounds. The 2nd type of exercise will be isometric exercises; this entailed jaw opening and jaw protrusion against resistance with their hand for 10 seconds with 10 repetitions each daily. All the patients will receive a training brochure with photos of the exercises and detailed information on frequency and exercise time. The brochure will include a diary. After 6 weeks, the subject and the assistant will check the performance of the exercise and the diary
214492743|NCT05599412|DRUG|Lorviqua|As provided in real world practice
214492744|NCT06805695|OTHER|No Intervention|No Intervention
214492745|NCT06750757|BIOLOGICAL|Bone marrow aspirate concentrate|145cc of BMAC/PRP/PPP injection.
214492746|NCT06750757|PROCEDURE|Hip arthroscopy|Both groups will undergo a hip arthroscopy to treat their condition. However, the control group will not receive a BMAC injection during the surgery.
214981998|NCT02361866|BIOLOGICAL|GC1107|0.5 ml, Intramuscular, single dose(day0)
214981999|NCT02361866|BIOLOGICAL|Tetanus and Diphtheria(Td vaccine)|0.5ml, Intramuscular, single dose(day0) only applicable step1
214982000|NCT01663389|DRUG|GSK1322322 1000 mg containing radioactive 14C-GSK1322322|GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
214982001|NCT01663389|DRUG|GSK1322322 1200 mg containing radioactive 14C-GSK1322322|GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
214982002|NCT04862338|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
214982003|NCT01884948|DRUG|Omegaven™|
214982004|NCT04850651|DRUG|Pyrotinib；Fluconazole|"Drug: Pyrotinib Participants received a single oral dose of Pyrotinib tablet on the morning of day1 in treatment period 1.~Drug: Pyrotinib/Fluconazole In treatment period 2, Participants received a single oral dose of pyrotinib tablet on the morning of day9, and received a loading dose of fluconazole capsule on day6 followed by single dose of fluconazole for oral administration from D7 to D18."
214982005|NCT06508086|PROCEDURE|laser ablation technique in the treatment of pilonidal sinus|group (A) will include patients with pilonidal sinus disease who will be operated by sinus tract ablation procedure using 1470 nm Diode laser
214982006|NCT06508086|PROCEDURE|Karydakis technique in the treatment of pilonidal sinus|group (B) will include patients with pilonidal sinus disease who will be operated by Karydakis technique
215088140|NCT03468972|OTHER|intensive supportive care|During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of \<130/80 mmHg, and protein restriction diet. If proteinuria does not decrease \< 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
215088141|NCT00806143|DEVICE|repetitive transcranial stimulation (rTMS)|"Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.~In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days."
214982007|NCT03779269|OTHER|meditation|meditation effect assessment using assessment tools.
214982008|NCT00563771|DRUG|Rasburicase|
215088142|NCT00806143|DEVICE|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
215088143|NCT02236416|BEHAVIORAL|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
215088144|NCT02236416|BEHAVIORAL|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
215088145|NCT04590209|OTHER|Blood sampling|Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
215088146|NCT04590209|OTHER|Skin biopsy|Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
215088147|NCT05301036|DEVICE|Diadem prototype|Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
215088148|NCT02792023|OTHER|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
215088149|NCT02792023|DEVICE|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
214492747|NCT03867201|BIOLOGICAL|Erenumab|Administered by pre-filled syringe
214492748|NCT03867201|OTHER|Placebo|Administered by pre-filled syringe
214492749|NCT06772779|DRUG|Warfarin|single oral dose
214492750|NCT06772779|DRUG|Enlicitide Decanoate|single oral dose
214492751|NCT06772779|DRUG|Lisinopril|single oral dose
214492752|NCT06848426|DRUG|Xingbaiji Formula|"Patients were randomized into two groups:~Control Group:~Non-squamous NSCLC: Sintilimab (200 mg) combined with pemetrexed + cisplatin/carboplatin, administered intravenously (IV) every 3 weeks (Q3W) for 4 cycles. After 4 cycles, maintenance therapy with sintilimab (200 mg Q3W, up to 24 months) + pemetrexed Q3W continued until disease progression, intolerable toxicity, death, or voluntary withdrawal.~Squamous NSCLC: Sintilimab (200 mg) combined with gemcitabine + cisplatin/carboplatin, IV Q3W for 4-6 cycles. Post-induction, sintilimab (200 mg Q3W) maintenance continued until progression, intolerance, or ≤2 years of treatment.~Experimental Group:~The control regimen plus Xingbaiji Formula:~Xingbaiji Granule 1: 10 g/bag, dissolved in warm water, 1 bag twice daily (morning and evening) after meals.~Xingbaiji Granule 2: 5 g/bag, dissolved in warm water, 1 bag twice daily (morning and evening) after meals."
214492753|NCT02110004|PROCEDURE|Ablation procedure|The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
214492754|NCT02110004|DEVICE|Picasso NAV Catheter|
214492755|NCT06762665|PROCEDURE|Spinal injection|Patients underwent a spinal injection procedure under CT scan
214492756|NCT06762665|OTHER|pre-operative consultation|Pre-operative consultation, in person or by teleconsultation, consists of an interview about the patient's history and symptoms. This is followed by a clinical examination and consultation of the patient's imaging file, to confirm the request for paraspinal infiltration and its location. In addition, the radiologist explains the procedure to the patient, supplementing the explanatory documents already provided at the time of the appointment, and outlines the results that may be expected and any complications.
214492757|NCT01983683|DRUG|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
214492758|NCT01983683|DRUG|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
214492759|NCT01983683|DRUG|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
214982009|NCT06478641|DRUG|Tafenoquine|Tafenoquine will be self-administered orally as 2 x 100 mg dark pink coated tablets once daily (total daily dose 200 mg) with food on Days 1, 2, 3 \& 4 then weekly thereafter (starting on day 11) until the patient has two consecutive negative PCR tests for Babesia parasites and symptoms of babesiosis have resolved.
214368873|NCT01924611|PROCEDURE|Atraumatic Restorative Technique|"Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.~This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.~This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier."
214982010|NCT00153426|BEHAVIORAL|West Virginia WISEWOMAN|Print-based tailored health communications and computer-based interactive nutrition program
214982011|NCT01763541|DRUG|leuprolide acetate|Given to both arms to induce hypogonadism
214982012|NCT01763541|DRUG|Anastrozole|Given to men to prevent conversion of administered testosterone to estradiol.
214368874|NCT00699439|OTHER|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
214368875|NCT04728308|DRUG|Bupivacain|Before closing the skin incision,Infiltration of 20ml of 0.5% bupivacaine around incision site will be done in the patients of experimental group and 20 ml of distill water will be infiltrated in the pateints of the placebo group
214368876|NCT04332523|DRUG|JNJ-53718678|Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.
214368877|NCT00970216|DRUG|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
214368878|NCT04361344|BIOLOGICAL|blood samples|Clinical examination and blood samples will be done at inclusion (day 0), at day 7 (between day 4 and exit from intensive care) and at day 60.
214492760|NCT01983683|DRUG|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
214492761|NCT05557045|DRUG|JZP815|JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.
214492762|NCT06750198|OTHER|Hip focused|"Group A will be treated with hip focused exercises and standard rehabilitation protocol.~Hip focused exercises will be comprised of following exercises in phase 1 will be Side lying hip abduction, Hip abduction in standing, Hip extension from prone, Single leg bridge, Side lying clam with resistance while exercises in phase 2 will be same with more repetitions in addition to Side lunges, Forward lunges"
214492763|NCT06750198|OTHER|Standard rehabilitation|Group B will be only be treated with standard rehabilitation protocol. When participant reach full ROM of knee, perform four sets of 20 repetitions of straight leg raising with full extension, and maintain one minute single leg balance on a solid surface with the affected side, subject can transfer to phase 2
214492764|NCT06749951|OTHER|Cognitive Behavioural Therapy for insomnia (CBT-I)|Five 60-90 minutes weekly sessions delivered by an appropriately trained cardiac nurse at a cardiology department. The CBT-I intervention will follow a manualized treatment protocol developed by Espie and colleagues (Espie et al. 2001, 2007, 2008) and evaluated in a number of published RCTs using CBT-I. The key components of this intervention include sleep hygiene advice, stimulus control, sleep restriction, relaxation training, and cognitive restructuring.
214492765|NCT06749951|OTHER|Sleep Hygiene Advice|"Sleep well is a 16-page written brochure developed by the Directorate of Health in Norway for dissemination to patients with sleep problems including insomnia. It covers general sleep hygiene advice (setting a regular bed-time, avoiding stimulants, alcohol and exercise in the evening, sleeping in a quiet bedroom, advice of practicing relaxation technique and postpone worries)."
214492766|NCT06091124|DRUG|Adebrelimab|Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
214492767|NCT06091124|DRUG|Etoposide|Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
214492768|NCT06091124|DRUG|Cisplatin|Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
214492769|NCT06091124|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed within 4-6 weeks after completion of last dose
214982013|NCT06517992|OTHER|Health education for cadre (communicated project)|The investigators perform health education to cadre in order to support their role in providing care for metastatic breast cancer living in the community using a module. The module consists of text (written information) and some videos as education medias.
214982014|NCT03961399|DEVICE|Abbott Medical® CRT device with SyncAVTM stimulation function|patients with Abbott Medical® CRT device will be randomized and SyncAVTM stimulation will be activated.
214982015|NCT03961399|DEVICE|Abbott Medical® CRT device with biventricular stimulation (BiV)|patients with Abbott Medical® CRT device will be randomized and biventricular (BiV) stimulation will be activated.
214982016|NCT05029908|DIAGNOSTIC_TEST|Jaw Functional Limitation Scale|DC/TMD Axis I TMD Pain Screener Questionnaire and TMD Symptom Questionnaire will be administered to the participants. To determine parafunctional habits and limitation of function, the DC/TMD Axis II assessment tools 'Jaw Functional Limitation Scale-8 (JFLS-8) and Oral Behavioral Checklist (OBC) will be applied. In addition, demographic data (age, gender, education level, occupation) will be questioned.
214982017|NCT04127617|OTHER|Osteopathic Manipulative Treatment|"Osteopathic treatment~Dural system:~L5-S1 decompression; sacred decompression among the iliacs; occipital-sphenoid approach; decongestion of occipital condyles~Fascial system:~fascial techniques in the abdominal region: right hypochondrium, epigastrium, left hypochondrium, right side, mesogastrium, left side, right iliac area, hypogastrium, left iliac area; relationship with corresponding vertebral levels (eg, hypogastrium); fibro scar adhesions treatment.~Biomechanical system:~diaphragm rebalancing with respect to anatomical insertions; passive mobilization of dysfunctional areas. Nursing education as described in Standard Treatment"
215088150|NCT02792023|DEVICE|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
215088151|NCT00007267|BEHAVIORAL|Cognitive behavioral therapy|
215088152|NCT00007267|BEHAVIORAL|Disease/health education|
215088153|NCT00007267|BEHAVIORAL|Self-help cognitive behavioral intervention facilitated by a psychologist|
214368879|NCT02032160|BIOLOGICAL|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
214368880|NCT02032160|BIOLOGICAL|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
214368881|NCT01519388|OTHER|Spontaneous breathing|study of the swallowing of boluses of water and yogurt under spontaneous breathing
214368882|NCT01519388|DEVICE|Elysée 150®|Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
214982018|NCT04127617|OTHER|Nursing Educational Care|"Nursing education~* assessment of the best personal evacuation strategy concerning the quality of life, individual resources, and level of autonomy;~* assessment of the correct execution of the identified evacuation manoeuvre (digital stimulation, manual removal, reflex stimulation, transanal irrigation, use of micro-enemas or suppositories;~* identification of the best postural strategies during evacuation;~* nutrition and proper hydration education;~* education in completing the evacuation diary;~* colonic massage training;~* verification of the correct hiring of any previously prescribed laxative drugs."
214982019|NCT00706563|BIOLOGICAL|Fluarix™|Single intramuscular dose on Day 0
214982020|NCT05216484|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
214982021|NCT03201991|OTHER|Resistance Exercise Program|The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
214982022|NCT04087512|OTHER|Training on perturbation treadmill|Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.
214982023|NCT04087512|OTHER|Exercises of dynamic stability under unstable conditions|The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
214982024|NCT03580018|DRUG|Tranexamic Acid Powder|Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
214982025|NCT03580018|PROCEDURE|Post-anterior cruciate ligament reconstruction (ACLR)|Post-anterior cruciate ligament reconstruction (ACLR)
214982026|NCT02246933|OTHER|PUFA Diet|The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
214982027|NCT02246933|OTHER|Control Diet|The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
214982028|NCT05244096|OTHER|No intervention|Observational study
214982029|NCT01092767|DEVICE|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
214982030|NCT05709613|DEVICE|Use of a chest compressions' feedback device|The participants will have access to a chest compressions' feedback device
214982031|NCT05907447|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
214982032|NCT01767337|DEVICE|FLUGEN 101.2 device|
215088154|NCT00649831|DRUG|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
215088155|NCT00649831|DRUG|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
215088156|NCT03908918|OTHER|Mindfulness app|Mobile app-delivered mindfulness intervention delivered over 4 weeks.
215088157|NCT02054884|DRUG|Arm A: F16IL2 in combination with paclitaxel|"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
214368883|NCT05850780|DEVICE|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) Wavelength 660 nm will be used, and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied to the surface of the pulp stumps for 60 seconds. The pulp chamber will then be filled with reinforced zinc oxide-eugenol (IRM, Dentsply, Mount Waverley, Australia) to ensure proper sealing.~Then, each tooth in both groups will finally be restored with a stainless-steel crown (SSC)40 (3M/ESPE, St. Paul, Minn., USA) in the same visit, which will be cemented onto the tooth using glass ionomer cement.~Finally, reapplication of laser with the same parameters will be done around inserted crowns to promote tissue healing and decrease post operative pain."
214368884|NCT05850780|DRUG|MTA|Three parts of MTA powder will be mixed with one part of distilled water to obtain paste. This mixture will then be placed on the radicular pulp stumps and condensed lightly with a moistened cotton pellet. then the access cavities will be sealed with glass ionomer cement
214982033|NCT06478914|DEVICE|Neuromuscular electrical stimulation (NMES)|NMES unit manufactured by Enraf-Holland was be used to administer the neuromuscular electrical stimulation (NMES) The study involved adjusting the patient's hips, knees, and ankles to achieve a comfortable position. Two electrodes of NMES were used in the first study group and a placebo in the control group. The electrodes were placed on the popliteal fossa and fibular head, and each session was conducted for 15 minutes daily for 2 months.
214982034|NCT06478914|DEVICE|low-intensity laser therapy (LILT)|"The laser unit is a small, hand-held, class III laser product manufactured by Laserex Technology Pty Ltd Australia. It offers continuous and pulsed laser therapy, with continuous therapy being the most effective. The device has a maximum average power of 5 milliwatts, a wavelength of 820 nm, and a power density of 0.39 W/cm2.~Patients were treated as outpatients, receiving full explanations about the purpose, therapeutic, and physiological benefits of low-intensity laser therapy (LILT). They were relaxed in supine position, with hips and knees adjusted. The patient was irradiated in a continuous mode and direct contact method, 3 times per week for 2 months, at 1-cm intervals and across the surface in grids. The laser applicator was applied to the surface, maintaining contact for maximum penetration."
215088158|NCT02054884|DRUG|Arm B: Paclitaxel|"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
215088159|NCT02737150|DEVICE|CoreValve Evolut R|
215088160|NCT02737150|DEVICE|Edwards Sapien 3|
215088161|NCT02737150|PROCEDURE|Local anesthesia with conscious sedation|
215088162|NCT02737150|PROCEDURE|General anesthesia|
215088163|NCT05663775|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA)
214680838|NCT06478758|DRUG|Acetaminophen 100 MG/ML|The investigators administered 1000 mg of acetaminophen to the participants in Group A. A 20% increase in the participant's heart rate and mean arterial pressure was evaluated as pain and remifentanil infusion was administered. All participants continued to receive the routine application of acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4, postoperatively.In the recovery room, participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
214680839|NCT00935142|DRUG|[18F]VM4-037|Bolus IV injection of \[18F\]VM4-037
214982035|NCT03252626|DRUG|Alprostadil|"Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects.~2ml Alprostadil injection added into 10ml 0.9% saline."
214982036|NCT03252626|DRUG|Normal saline|2ml normal saline injection added into 10ml 0.9% saline.
214982037|NCT00216372|DRUG|Lanreotide (microparticle formulation)|A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
214982038|NCT00216372|OTHER|Placebo|A single intra-muscular injection on day 0.
214982039|NCT03617302|DRUG|Experimental: Nitrate-containing|Experimental
214982040|NCT03617302|DRUG|Placebo: Nitrate-depleted|Placebo
214982041|NCT00006126|DRUG|busulfan|
214982042|NCT00006126|DRUG|cyclophosphamide|
214982043|NCT00006126|DRUG|etoposide|
214982044|NCT00006126|DRUG|fludarabine phosphate|
214982045|NCT00006126|PROCEDURE|peripheral blood stem cell transplantation|
214982046|NCT00006126|RADIATION|radiation therapy|
214982047|NCT02702544|DEVICE|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
214982048|NCT02702544|DEVICE|SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 1 min during leg elevation
214982049|NCT04673500|DRUG|Propofol lidocaine through large vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a large antecubital vein to assess pain severity on propofol injection during general anesthesia induction
214982050|NCT04673500|DRUG|Propofol lidocaine through small vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a small vein on the dorsum of hand to assess pain severity on propofol injection during general anesthesia induction
214982051|NCT03310216|PROCEDURE|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
214982052|NCT03310216|PROCEDURE|Order II of visual inspection|The participants in Group II are provided EDTRS first and AI visual inspection system later.
215088164|NCT04032301|DRUG|Ketamine|Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
215088165|NCT04032301|OTHER|Normal Saline|Six infusions of intravenous normal saline solution over 3 weeks.
215088166|NCT05490186|PROCEDURE|Total Knee Replacement|Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.
214982053|NCT03398473|DRUG|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial
214982054|NCT03398473|DRUG|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial
214982055|NCT00185315|DRUG|Ventavis (Iloprost, BAYQ6256)|Inhaled iloprost
214982056|NCT05782153|DEVICE|Intervention A (hearing aid self-fitting with direct adjustment)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using a self-fitting strategy with direct adjustment. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete a hearing screening (at 500, 1000, 2000 and 4000 Hz) called Hearing Check on the Lexie smartphone application, which will be used to tune the hearing aids according to frequency and loudness level. Participants will be able to use two wheels to change the loudness and fine-tune the hearing aids. Participants will wear the hearing aids for four weeks.
214982057|NCT05782153|DEVICE|Intervention B (hearing aid self-fitting with in-situ fitting)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using the in-situ audiometry fitting strategy. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete an in-situ audiogram on the Lexie app, which enables the measurement of hearing thresholds through the hearing aids (at 500, 1000, 2000 and 4000 Hz). The hearing aids will then be self-programmed according to the participant's in-situ audiogram with a proprietary fitting algorithm that is based on NAL-NL2. Participants will wear the hearing aids for four weeks.
214982058|NCT04030312|DIETARY_SUPPLEMENT|Bottle Supplementation--Commercially-Sterilized Donor Human Milk|Supplementation by bottle with 20-calorie-per-ounce commercially-sterilized donor human milk (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
214982059|NCT04030312|DIETARY_SUPPLEMENT|Bottle Supplementation--Standard Infant Formula|Supplementation by bottle with 20-calorie-per-ounce standard infant formula (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
214982060|NCT00747214|DRUG|CRx-102|
214982061|NCT00747214|DRUG|Placebo|
214982062|NCT00747214|DRUG|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
214982063|NCT04398836|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|Mulnourished patients will drink an enteral polymeric formula suited to their energy expenditure calculated by 25-30 kcal/kg and at least 1 gr/kg of protein, a minimum of 1500 ml (1500 kcal, 54 gr of protein). The amount of formula to achieve nutritional requirements are based on body weight, but the average intake is of 6-8 cups of formula (36-48 scoops of formula mixed with 1260-1680 ml of water to achieve a concentration of 1 kcal per ml). During this period patients will be guided to avoid eating and drinking anything but the enteral formula. The formula will be supplied to the patients by the investigators. The formula used for this study will be VITAL - suitable for people with disease-related malnutrition and malabsorption. Vital 1.5kcal is peptide-based, nutritionally complete formulation for the dietary management of active phase of Crohn's disease. VITAL includes all the nutritional macro and micronutrients and can serve as a sole source of nutrition.
214982064|NCT04398836|OTHER|High energy / protein diet.|Mulnourished patients will receive a high energy / protein diet.
214368885|NCT05742425|DRUG|Serplulimab Combined With FOLFIRI and Bevacizumab|For patients with confirmed failure to reach CC0/1, they should be treated with sullizumab combined with FOLFIRI+bevacizumab for 4-8 cycles within 3 weeks after the exploration operation. After the end of the 4th and 8th cycles, they should be evaluated with imaging and MDT. If the conversion is successful, they should be treated with a second exploration operation within 3-4 weeks, The patients with CC0/1 can be evaluated for tumor reduction surgery (CRS) combined with intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), and the follow-up treatment plan will be selected according to the clinical situation of the patients after surgery; If CC0/1 cannot be evaluated after the second exploration surgery and CC0/1 cannot be performed after the imaging evaluation, other chemotherapy and optimal supportive treatment will be performed according to the situation.
214368886|NCT00485225|DRUG|EN3270|Transdermal Therapeutic System
214680840|NCT05973994|DEVICE|intravascular lithotripsy with Shockwave coronary system|OCT acquistion is performed at baseline. Then the IVL catheter will be passed across the lesion over the guidewire. Atherectomy or cutting/scoring balloons is not permitted per protocol. The IVL procedure is considered successful when a residual stenosis \<50% by visual estimate after IVL alone is achieved. After IVL procedure, one OCT imaging acquisition must be performed. If the residual stenosis is ≥50% following IVL, noncompliant balloon dilatation will be performed prior to stenting and OCT images repeated accordingly. Subsequent stent implantation will be performed per local standard of care at the discretion of the operator. Following stent implantation, high pressure post-dilatation is recommended and OCT imaging acquisition must be performed to assess stent apposition for secondary end point.
214680841|NCT00819533|DEVICE|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
214680842|NCT03466489|DEVICE|Floraseal|FloraSeal is a cyanoacrylate-based sealant used in the prevention of surgical site infections.
214680843|NCT04388735|BEHAVIORAL|Questionnaire|Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
214680844|NCT01873664|BEHAVIORAL|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
214982065|NCT04398836|OTHER|Standard nutrition|Well nurished patients will receive a standard nutrition
214982066|NCT05673395|DEVICE|Electrolyzed alkaline reduced water generator|Participants drink water (10 mL/kg body weight) generated from the device after intensive excercise.
214982067|NCT00171093|DRUG|valsartan + simvastatin|
214982068|NCT00652444|DRUG|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
214680845|NCT04366986|OTHER|Tested for SARS-CoV-2 (regardless of the result)|This is an observational study with no intervention
214982069|NCT00652444|DRUG|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
214982070|NCT00652444|DRUG|Placebo (Unspecified)|Matching ezetimibe placebo
214982071|NCT06525467|PROCEDURE|radical nephrectomy|open radical nephrectomy and lymph node dissection.
214982072|NCT05613348|BIOLOGICAL|CD19 CAR T-Cell(CAT19T2)|Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously
214982073|NCT05125445|PROCEDURE|Implants placed at bone crest|"Mid crestal incision will be performed and full-thickness envelope flap will be elevated to expose the alveolar ridge (no releasing incisions will be made).~Implant site will be prepared according to the manufacturer's instructions under sterile copious irrigation Implants will be placed at crestal level"
214982074|NCT05125445|PROCEDURE|Implants placed 1mm Subcrestally|Implants will be placed 1mm subcrestally
214982075|NCT01457794|OTHER|School meals based on the principles of the New Nordic Diet|The study participants are provided with three daily school meals for 3 month
214982076|NCT02436863|PROCEDURE|Surgical performance|Two different surgical performances
214982077|NCT03366662|DEVICE|Monitoring of frontal electrical muscle activity|Continuous monitoring of frontal electrical muscle activity during general anesthesia simultaneous to burst suppression electroencephalogram
214982078|NCT02115100|PROCEDURE|procedure|Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
214982079|NCT06088641|DIAGNOSTIC_TEST|preoperative BNP value|preoperative BNP value
214982080|NCT04217291|DRUG|SY-004|Take orally once a day
214982081|NCT04217291|OTHER|SY-004 matching placebo|Take orally once a day
214982082|NCT00699868|OTHER|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
214982083|NCT00699868|OTHER|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
214982084|NCT01344135|DIETARY_SUPPLEMENT|Dietary supplementation|"Phase A, Rehabilitation (4 months): 3 nutritional supplements daily~Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)~Phase C, Follow-up (3 months): no supplementation"
214982085|NCT01344135|DIETARY_SUPPLEMENT|Placebo supplement|"Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily~Phase B, Maintenance (8 months): No supplementation~Phase C, Follow-up (3 months): No supplementation"
215088167|NCT02773771|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive \>3g of HMB/ day.
214368887|NCT02552290|OTHER|Upper Trapezius Stretch|Sustained stretch of upper trapezius muscle
214680846|NCT04366986|OTHER|Clinical diagnosis of COVID-19 by a health care professional|This is an observational study with no intervention
214982086|NCT01344135|BEHAVIORAL|Nutritional counselling|"Phase A, Rehabilitation (4 months): No counselling~Phase B, Maintenance (8 months): Nutritional counselling (4x)~Phase C, Follow-up (3 months): No counselling~Aim:~1. Optimising dietary intake to physical activity pattern and energy expenditure.~2. Minimize deterioration of dietary intake during acute exacerbations.~3. Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.~4. Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle."
214368888|NCT02552290|OTHER|Cervicothoracic manipulation|Manipulation to the cervicothoracic spine
214982087|NCT01344135|BEHAVIORAL|Feedback on physical activity level|"Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~1. Integration of exercise behaviour into daily routine~2. Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~3. Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle"
214982088|NCT02475369|DRUG|pancrelipase|
214982089|NCT01036802|DRUG|Warfarin|Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3
214982090|NCT01036802|DRUG|Placebo|
214982091|NCT06082440|BIOLOGICAL|Human Umbilical Mesenchymal Stem Cells|Ntra-articular injection inject a corresponding dose of cells suspension into each joint cavity according to the lesion site.
214982092|NCT06006156|PROCEDURE|Dental implants placement|surgery for placement of two one-piece trans gingival implants
214982093|NCT02204670|OTHER|Acute release of irisin after a single exercise session.|We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
214982094|NCT05965596|OTHER|a psycho educational intervention program|The program was developed by the researcher herself based on recommendations derived from a systematic review of psychoeducational interventions to improve the quality of Life and psychological outcomes in gynecological cancer patients. Also guided by the program adopted by chow et all in 2014(28) to test the feasibility of implementing a psychoeducational intervention program for gynecological cancer patients.
214982095|NCT05965596|OTHER|the routine care|the routine care provided for all gynecological cancer patients in the study setting
214982096|NCT00727129|DRUG|Divigel|
214982097|NCT03428334|DRUG|Oral roflumilast|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
214982098|NCT00004102|DRUG|FOLFOX regimen|
214982099|NCT00004102|DRUG|fluorouracil|
214982100|NCT00004102|DRUG|leucovorin calcium|
214982101|NCT00004102|DRUG|oxaliplatin|
214368889|NCT02552290|OTHER|No intervention|Wait
214982102|NCT00000363|DRUG|Antihistamine|
214368890|NCT04970199|DEVICE|laser application on acupoints|laser acupuncture
214982103|NCT00000363|DRUG|Corticosteroid|
214982104|NCT04190355|OTHER|Irrigant type|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on postoperative pain using different uniforms will be evaluated.
214982105|NCT04190355|DRUG|5.25% NaOCl|5.25% NaOCl solution
214982106|NCT04190355|DRUG|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water
214982107|NCT02526485|PROCEDURE|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
214368891|NCT01631890|PROCEDURE|Endoscopic Ultrasound assisted endoscopic glue injection|N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
214680847|NCT03066817|DRUG|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
214680848|NCT03066817|DRUG|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
214680849|NCT00909987|DRUG|Capecitabine|PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
214680850|NCT00909987|DRUG|Oxaliplatin|IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
215088168|NCT02773771|DIETARY_SUPPLEMENT|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
215088169|NCT02773771|DIETARY_SUPPLEMENT|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
215088170|NCT04886700|DRUG|SG001|Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
214368892|NCT01631890|PROCEDURE|Standard Endotherapy|Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
214368893|NCT05566808|OTHER|Autologous Costal Cartilage Graft|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
214368894|NCT05566808|OTHER|Costal Cartilage Allograft.|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
214368895|NCT03181802|DRUG|Botox|single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
214368896|NCT03181802|DRUG|Placebos|4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
214368897|NCT01512771|OTHER|CPAP|6 weeks of CPAP
214368898|NCT04070625|OTHER|Communication book group|Communication book
214982108|NCT04149717|DIETARY_SUPPLEMENT|Energy Drink Ingredients and Exercise|"Subject will ingest 500 mL of one of three test solutions:~A) sucrose (150g) B) sucrose (150g); caffeine (400 mg) C) sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg) 3. 30 min later, subject will exercise on a treadmill using the Bruce Protocol maximum exercise test (https://www.aopa.org/go-fly/medical-resources/health-conditions/heart-and-circulatory-system/bru...). For one additional session, subjects will receive test solution C without exercise.~4\. Each stage will last 3 minutes. Stage 1 = 1.7 mph at 2% Grade Stage 2 = 2.5 mph at 4% Grade Stage 3 = 3.4 mph at 6% Grade Stage 4 = 4.2 mph at 8% Grade Stage 5 = 5.0 mph at 10% Grade Stage 6 = 5.5 mph at 12% Grade Stage 7 = 6.0 mph at 14% Grade Stage 8 = 6.5 mph at 15% Grade Stage 9 = 7.0 mph at 15% Grade. The test will end when subjects reach exhaustion.~5\. 1, 2, and 4 hrs following ingestion, HR, BP, and EKG will be recorded."
214982109|NCT06265831|OTHER|Hand-fan application to the face|Hand fan application is one of the applications recommended in managing dyspnea in evidence-based guidelines. Hand fan application effectively reduces shortness of breath by stimulating cold airflow to the 2nd and 3rd trigeminal nerve branches, mucosa, and skin.
214982110|NCT04823312|DEVICE|Experimental prospective single arm evaluating the Medtronic Duo Extended Set|Subjects will be using 4 Duo extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
214982111|NCT04105179|DEVICE|Zimmer NexGen LPS-Flex|Patients will be randomly assigned to 1 of 2 devices
214982112|NCT04105179|DEVICE|Smith & Nephew Journey II|Patients will be randomly assigned to 1 of 2 devices
214982113|NCT00910234|DRUG|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
214982114|NCT00910234|DRUG|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
214982115|NCT00910234|DRUG|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
214982116|NCT05549596|DEVICE|Ceragem Master V6 Traction|Ceragem Master V6 Traction for L2\~L3
214982117|NCT05549596|DEVICE|Physical therapy with standard traction device|Physical therapy with standard traction device
214982118|NCT00948090|DRUG|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
214982119|NCT03641976|DRUG|A-FOLFOXIRI|"Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV"
214982120|NCT03641976|DRUG|Arm II (A-FOLFOX/A-FOLFIRI)|"Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV"
214982121|NCT02845674|DRUG|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
214368899|NCT04070625|OTHER|Control group|Simple speech therapy
214982122|NCT04045756|DEVICE|Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bollous of i.v. corticosteriods () is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Cirpofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
215088171|NCT01217320|DIETARY_SUPPLEMENT|creatine|5g/d throughout 12 weeks
215088172|NCT01217320|DIETARY_SUPPLEMENT|placebo (dextrose)|5g/d throughout 12 weeks
214368900|NCT00131339|BEHAVIORAL|Cognitive behavioral therapy|
214368901|NCT00131339|DRUG|D-cycloserine|
214368902|NCT05767528|DIAGNOSTIC_TEST|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing|Conducting the neoadjuvant therapy of FDA-approved drugs for patients with muscle-invasive bladder carcinoma, culturing the patient-derived tumor-like cell clusters for drug sensitivity testing simultaneously, then assess the accuracy of the diagnostic test by combination and analysis of these results
214368903|NCT05716230|OTHER|bowel function score questionnaire survey|Bowel function score(BFS, total 20 points) was approved by Rintala in 1995, and patients with a score ≥ 17 were considered to have normal bowel habits. 7 items were in BFS, including the ability to hold back defecation, feeling/reporting the urge to defecate, frequency of defecation, soiling, accidents, constipation. In December 2022, BFS questionnaire surveys were conducted on children with ARM who underwent surgical repair between January 2017 and December 2019 at Children's Hospital of Nanjing Medical University.
214368904|NCT06789484|OTHER|Probiotic|Given daily from enrollement to 28 days of life
214368905|NCT06789484|DIETARY_SUPPLEMENT|Placebo|Given daily from enrollement to 28 days of life
214680851|NCT00909987|DRUG|Bevacizumab|IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
214982123|NCT04440501|DEVICE|Virtual Reality Goggles to provide education a regarding the gluten free diet.|To watch and participate in a virtual reality educational experience regarding the gluten free diet.
214982124|NCT02139397|DRUG|DFMO|
214982125|NCT02139397|DRUG|Bortezomib|
214982126|NCT00100906|DRUG|IL-2|Immunotherapy with interleukin-2
214982127|NCT00100906|DRUG|ATRA|
215088173|NCT01676519|PROCEDURE|PCI|percutaneous coronary intervention
215088174|NCT04195386|PROCEDURE|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
215088175|NCT04195386|PROCEDURE|Dental Restoration with Resin-Modified Glass ionomer Cement|Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
214680852|NCT00909987|RADIATION|Radiotherapy|Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
214680853|NCT00909987|DRUG|Capecitabine during all Radiotherapy period|825 mg/m2 bid
214680854|NCT00909987|PROCEDURE|Total Mesorectal Excision (TME)|4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
215088176|NCT05332418|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise, Educational postural correction, and Home neck exercise program for patient
214368906|NCT06446505|OTHER|Deep Brain Stimulation Decision Aid|An online decision support tool that provides education about deep brain stimulation and the alternatives, and includes value clarification exercise.
214680855|NCT02238028|BEHAVIORAL|Wear respirator|Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
214368907|NCT05127148|OTHER|Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.|Evaluation of survival (event free survival and overall survival) and toxicities in AYA Ph-negative ALL patients treating in first line with argentinian pediatric-like protocol depending on risk category.
214368908|NCT05445154|DRUG|SKLB1028 Dose Escalation|Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin
214680856|NCT05367687|DRUG|Camrelizumab、Rivoceranib|Camrelizumab: 200 mg, intravenous infusion. Rivoceranib: 250 mg, oral.
214680857|NCT05367687|DRUG|Camrelizumab|Camrelizumab: 200 mg, intravenous infusion.
214982128|NCT03951519|OTHER|oral administration of water|Volume expansion via 500 mL of water administered by the patient's nasogastric tube
214982129|NCT03951519|OTHER|administration of saline solution|Volume expansion via 500 mL of saline (Nacl 0.9%) administered by the venous route
215088177|NCT05332418|DEVICE|Electromagenetic Field therapy|Magnetotherapy application the device will be adjusted around the neck and shoulder area at low frequency (50 Hz), with intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60) , and the application time (10 minutes)
215088178|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ) .~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radiofrequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view separated by 0,5 cm to ensure successful targeting. Then remove the needles."
214368909|NCT01493687|DRUG|CD5024|CD5024 1% Cream, once daily
214368910|NCT01493687|DRUG|Azelaic acid 15% Gel|Topical Gel applied twice daily
214368911|NCT02282397|DEVICE|Continuous Glucose Monitor|RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
214680859|NCT05217979|DEVICE|Transcutaneous pulsed radiofrequency|single treatment with transcutaneous pulsed radiofrequency, for a duration of 15 minutes, at a strength of 800 mA.
214680860|NCT05217979|DEVICE|Sham|Sham treatment by turning on the device in demo mode. No treatment delivered, but indistinguishable by sound or visual signals or sensations felt by the study participant
214680861|NCT04875819|DRUG|Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine|One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
214680862|NCT04875819|DRUG|13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine|One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
214680863|NCT05264571|DIAGNOSTIC_TEST|calscreener|The calscreener (SYMCEL®) is a new diagnostic tool to rapidly identify the presence of pathogens in biological samples based on micrometabolic activity detection. All living cells produce heat by the chemical and physical processes of life; by monitoring the heat flow over time (J/s, W) a significant amount of information can be obtained regarding the biological system.
214982130|NCT00975936|DRUG|[14C]-GSK706769|50µg \[14C\]-GSK706769 containing 250 nCi
214982131|NCT00975936|DRUG|Ketoconazole|200 mg Ketoconazole (Q12)
214982132|NCT02125552|PROCEDURE|Ultrasound guidance|The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group
214982133|NCT02125552|PROCEDURE|Traditional intravenous access|Placement by experienced nurse using standard IV techniques
214982134|NCT04329429|DRUG|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
214982135|NCT03524716|BEHAVIORAL|Fitbit and Text Messages|Physical activity tracker wristband and daily text messages delivered to the participants' phones.
214982136|NCT01450488|DRUG|masitinib|masitinib 3 mg/kg/day
214982137|NCT01450488|DRUG|masitinib|masitinib 6 mg/kg/day
214982138|NCT06491498|DIAGNOSTIC_TEST|Supraclavicular Brachial Plexus Blockade|Hemidiaphragmatic Paralysis Following Ultrasound-Guided Supraclavicular Brachial Plexus Blockade in patients undergoing upper limb surgery
214982139|NCT04541355|DRUG|Cisplatin|Given IV
214982140|NCT04541355|OTHER|Hearing Handicap Inventory for Adults - Screening|Patient self-assessment questionnaire to measure probability of hearing impairment
214982141|NCT04541355|RADIATION|Radiation Therapy|Radiation therapy will be delivered according to the standard of care
214982142|NCT04541355|DRUG|Sodium Thiosulfate|Given IV
214982143|NCT00433472|DEVICE|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2\* on MRI
214982144|NCT00218751|BEHAVIORAL|Home Visiting|
214982145|NCT01449253|DRUG|Sildenafil|20 mg initially and then increased to 20 mg TDS if there is no fall in BP
214982146|NCT01449253|DRUG|Bosentan|Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
214982147|NCT05696600|PROCEDURE|Scaling and root planing and open flap debridement|"Scaling and root planing involves removal of plaque and calculus.~Open Flap debridement involves reflection of full thickness mucoperiosteal flap, thorough debridement of the surgical site and approximation and suturing of the flap at the original position."
215088179|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency plus alcohol neurolysis|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves of the knee.~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radio-frequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view. After the radiofrequency is done at each level a 1 ml of 70% alcohol will be injected making a total of 3 ml injection to each nerve Then remove the needles."
214368912|NCT05809713|OTHER|Technology-enabled Team Care|Patients randomized to the TTC arm will receive telehealth-enabled team-based care. The team will include a physician and/or advanced practice provider, a pharmacist with Certified Pharmacist Practitioner (CPP) status or similar skills in NC, and will incorporate brief nutritionist-directed lifestyle behaviors counseling (DASH diet; exercise) initially delivered every other week by phone for two months, followed by monthly calls (once SBP values achieve individualized goal and remain stable for 14 days) over 12 months supported by cellular enabled home BP monitoring.
214368913|NCT05809713|OTHER|Enhanced Usual Care|Patients randomized to the enhanced usual care (EUC) arm will receive telehealth enabled home BP monitoring equipment including set-up and instruction and basic hypertension-specific lifestyle (diet, exercise) instruction and materials at baseline, but will not receive telehealth-enabled team-based care, active home BP monitoring by a pharmacist, or detailed DASH intensive lifestyle counseling.
214368914|NCT02088203|DIETARY_SUPPLEMENT|Dose 1|Russian Tarragon Nutrasorb 0.3 g
214368915|NCT02088203|DIETARY_SUPPLEMENT|Dose 2|Russian Tarragon Nutrasorb 1 g
214368916|NCT02088203|DIETARY_SUPPLEMENT|Dose 0|Placebo
214492770|NCT05365997|OTHER|Default Nudge|For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
214492771|NCT05954585|BEHAVIORAL|Treatment as usual|Emergency department treatment as usual
214492772|NCT05954585|BEHAVIORAL|Family Navigator|Family Navigator will speak with families about individual and systemic issues for linkage to mental health care biweekly for 3 months or until the youth's first mental health appt has been attended, whichever comes first.
214492773|NCT01644669|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
214492774|NCT06080074|DEVICE|Cardiohelp device (VA-ECMO)|In children receiving the Cardiohelp device for severe heart failure, participants will be consented to a systematic data collection to describe the safety and effectiveness of the device in children.
214492775|NCT06756516|OTHER|Feldenkrais Method and Core stabilization|Balance exercises from supine lying position using Feldenkrais style, plus core stabilization exercises.
214492776|NCT06756516|OTHER|Core stability exercises|trunk deep muscles activation and engaging using exercises as bridging, side bridging, plank, side plank and McGill Abdominal
214680864|NCT05264571|OTHER|Metabolic profile|"The cal screener allows the measure of metabolic activity of pathogens directly from a sample (here, the peritoneal fluid).~The heat production will be compared between peritoneal fluid, with or without addition of bacteria"
214680865|NCT05264571|OTHER|optical microscopy|To explain the metabolic activity, growth and yeast-to-hyphae transition will be analysed using optical microscopy and conventional culture
214680866|NCT05264571|OTHER|RTqPCR|To explain the metabolic activity, level of expression of 5 Candida albicans virulence genes (UME6, ALS3, SFL2, HWP1 and ECE1) will be address and compared between peritoneal fluid.
214680867|NCT01626183|GENETIC|RNA analysis|
214680868|NCT01626183|GENETIC|proteomic profiling|
214680869|NCT01626183|OTHER|laboratory biomarker analysis|
214982148|NCT01769547|DRUG|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
214982149|NCT05324917|DRUG|Rituximab|Chemotherapy for children with lymphoma: rituximab (375mg/m2 BSA) was added intravenously from COPADM1 regimen. once every 3 weeks to 4 weeks, combined with corresponding chemotherapy, a total of 4 times.
214982150|NCT05324917|DRUG|Rituximab (once a week)|"Rituximab (375mg/m2 BSA) was administered intravenously for lymphoproliferative diseases and EB virus-associated B lymphoproliferative diseases after hematopoietic stem cell transplantation. Once a week, a total of 4 times.~ITP and AIHA patients received rituximab (100mg/m2 BSA) intravenously once a week, a total of 4 times."
214982151|NCT05901220|BEHAVIORAL|Healthy lifestyle|An educational programme to promote healthy lifestyle will be performed.
214680870|NCT01023399|DRUG|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
214680871|NCT03777579|DRUG|JS001，an engineered anti-PD-1 antibody|JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
214680872|NCT03777579|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
214680873|NCT03777579|DRUG|Placebo|Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
214680874|NCT03554005|DRUG|PEG Interferon Alfa-2b|Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
214680875|NCT03554005|DRUG|Acetaminophen|Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
214680876|NCT02834052|DRUG|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
214982152|NCT01621009|DRUG|Active bupropion + counseling|"Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.~Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date."
214982153|NCT01621009|DRUG|Active bupropion, No counseling|"Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.~Counseling: No cessation counseling, only medication checks"
214982154|NCT01621009|DRUG|Placebo medication + counseling|"Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day."
214982155|NCT01621009|DRUG|Placebo medication, No counseling|"Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks"
214982156|NCT04150315|DIAGNOSTIC_TEST|Proteome analysis|Evaluation of specific protein levels in tissue and plasma.
214982157|NCT02084823|BIOLOGICAL|cancer stem cell vaccine|
214368917|NCT02088203|DIETARY_SUPPLEMENT|Dose 3|Russian Tarragon Nutrasorb 3 g
214368918|NCT02088203|DIETARY_SUPPLEMENT|Dose 4|Russian Tarragon Nutrasorb 10 g
214368919|NCT02088203|DIETARY_SUPPLEMENT|Dose 5|Russian Tarragon Nutrasorb 20 g
214368920|NCT02088203|DIETARY_SUPPLEMENT|Dose 6|Russian Tarragon Nutrasorb 30 g
214368921|NCT04121884|BEHAVIORAL|Accelerated Resolution Therapy|"The ART protocol first uses the technique of imaginal exposure to elicit physiological reactions associated with patient recall from beginning to end (verbally or non-verbally) of a traumatic/distressing experience. As physiological reactions emerge, the participant is directed to focus their attention on the specific body-centric reactions while laterally performing smooth pursuit eye movements which are achieved by tracking the clinician's hand which oscillates from left-to-right at a short distance from the participant's eyes. Then the participant is directed to imagine a positive way in which they prefer to recall their experience(s), including emphasis on replacing negative images in the brain with positive images. This technique is based on the process of memory reconsolidation, which allows for adding of positive material to the recall of negative, highly emotional past experiences."
214368922|NCT06373484|BEHAVIORAL|Behavioral Parent Training|Two 15-session multi-component cognitive-behavioral group treatments for children with disruptive behavior and their parents (i.e., one program for children aged 6-8 years and their parents and another for children aged 9-12 years and their parents. The programs have a child and parent group that are implemented concurrently).
214368923|NCT00705133|DRUG|Treprostinil|For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated
214680877|NCT02834052|DRUG|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"
214680878|NCT02484196|BEHAVIORAL|Questionnaires|Questionnaires
214680879|NCT02580487|PROCEDURE|appendicectomy|Appendix was removed either laparoscopically or open surgery
214680880|NCT06472700|OTHER|No intervention|No intervention
214982158|NCT04509271|DIAGNOSTIC_TEST|MicRNAs battery kits|Novel peripheral blood diagnostic biomarker for MCI due to AD.
214982159|NCT06550921|PROCEDURE|ablation of oligometastasis|The oligometastasis of hepatocellular carcinoma are ablation completely by ablation (including microwave ablation, radiofrequency ablation, and cryoablation)
214982160|NCT03661775|DRUG|Magnesium sulfate administration|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
215088180|NCT00599690|PROCEDURE|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
215088181|NCT00946907|DRUG|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
214680881|NCT02855411|DRUG|PF-04958242|Administered as specified in the treatment arm
214680882|NCT02855411|DRUG|placebo|placebo, twice daily (BID) for 12 weeks, capsule
214680883|NCT05909579|BEHAVIORAL|PelvicSense (R)|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
215088182|NCT00946907|DRUG|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
215088183|NCT00411190|DRUG|Relacatib|Subjects will administer 60 or 120 mg tablets in Session 2
215088184|NCT00411190|DRUG|Acetaminophen|Acetaminophen will be administered orally
215088185|NCT00411190|DRUG|Ibuprofen|Ibuprofen will be administered orally
214982161|NCT03463083|DRUG|Dexmedetomidine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgery an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
215088186|NCT00411190|DRUG|Atorvastatin|Atorvastatin will be administered orally
214982162|NCT03463083|DRUG|Bupivacaine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
214982163|NCT03463083|DRUG|Fentanyl|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
214982164|NCT03289078|OTHER|Spa Treatment|The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
214982165|NCT00151944|DRUG|SPD476 (mesalazine)|
214982166|NCT01625468|BEHAVIORAL|Educational print materials and a coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
215088187|NCT03710876|BIOLOGICAL|rAd-IFN|Adenovirus-Delivered Interferon Alpha-2b
215088188|NCT03710876|DRUG|Celecoxib Oral Product|400 mg twice daily
215088189|NCT03710876|DRUG|Gemcitabine|1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
215088190|NCT03481426|OTHER|Workplace intervention|The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
215088191|NCT03972878|OTHER|control snack|dry fruit snack (200 kcal) + 250 ml water
215088192|NCT03972878|OTHER|control cream|commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water
214368924|NCT03135535|DEVICE|Avex Footbeat|Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
214368925|NCT02857439|OTHER|Standard diagnostic item list|All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.
214368926|NCT02364180|DIAGNOSTIC_TEST|Electromyography (EMG)|
214368927|NCT02731664|BIOLOGICAL|GLP-1|Intravenous infusion of GLP-1
214368928|NCT02731664|BIOLOGICAL|Intravenous saline|Control
214368929|NCT03073564|DIAGNOSTIC_TEST|Endurance test for upper limbs|Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.
214368930|NCT03073564|DIAGNOSTIC_TEST|Functional test|The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
214368931|NCT04416893|DIAGNOSTIC_TEST|RT-PCR SARS-Cov2|nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR
214368932|NCT04416893|DIAGNOSTIC_TEST|Sars-Cov2 serology|A microsample of blood will be taken for serology
214368933|NCT03844022|DIAGNOSTIC_TEST|MRI|magnetic resonance imaging
214368934|NCT00107055|DRUG|REN-1654|
214368935|NCT04224324|PROCEDURE|Tonsillectomy and Adeniodectomy|pediatric patients undergoing tonsillectomy and adenoidectomy
215088193|NCT03972878|OTHER|cream version 1|commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
215088194|NCT03972878|OTHER|cream version 2|commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water
215088195|NCT03972878|OTHER|cream version 3|commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water
214982167|NCT06515288|BEHAVIORAL|Nutrition Goes To School (NGTS) Program Intervention Package|"The NGTS Program intervention package in this project consists of four components:~1. A comprehensive Nutrition Education to improve healthy eating, physical activity, and hygiene-sanitation practices.~   This is a weekly interactive and fun nutrition and health promotion with different kinds of activities.~2. Healthy School Canteen to improve the availability of healthy food in school. This is an effort to strengthen the school canteen referring to the 4 Pillars of a Healthy School Canteen, including School Commitment and Management, Human Resources, Facilities and Infrastructure, and Food Quality.~3. School Garden. This is a gardening activity as a form of school garden as a media for nutrition education, character building, and contribute to supply vegetables during cooking class sessions in school.~4. Entrepreneurship nutrition. Entrepreneurship nutrition aims to foster entrepreneurial potential and skills among school members in providing healthy food at school."
214982168|NCT06515288|BEHAVIORAL|Nutrition Education Capacity Building for Teachers and Management|The intervention schools will receive Nutrition Education Capacity Building for Teachers and School Management, before the above four NGTS components is implemented in the respective school. Three representatives from each school will be invited to attend a 5-day training that include knowledge on adolescent nutrition and health issues, as well as skills in implementing the NGTS Program.
214368936|NCT01972633|PROCEDURE|Laser|Endovenous Laser (1470nm) ablation of great or small saphenous vein
214982169|NCT03531749|DIETARY_SUPPLEMENT|HIV+ MRPJ|supplemented with (1g/d) MRPJ
214982170|NCT03531749|DIETARY_SUPPLEMENT|HIV+ ascorbic acid|Supplemented with (1g/d) AA
214368937|NCT01972633|PROCEDURE|Radiofrequency|Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
214982171|NCT01200329|DRUG|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
214982172|NCT01200329|DRUG|Busulfan|"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5."
214982173|NCT01200329|DRUG|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
214982174|NCT01200329|PROCEDURE|Stem Cell Transplantation|Infusion of stem cells on Day 0.
214982175|NCT01200329|DRUG|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
214982176|NCT04746638|DIAGNOSTIC_TEST|whole body study and SPECT with 99mTc-RM26|One single intravenous injection of 99mTc-RM26, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
214982177|NCT00677898|BEHAVIORAL|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
214982178|NCT00677898|BEHAVIORAL|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
214368938|NCT00089141|DRUG|mycophenolate mofetil|Given orally
214982179|NCT03279042|PROCEDURE|Flapless corticotomy surgical intervention will be conducted|Piezocision will be used to perform the procedure
214368939|NCT00089141|DRUG|placebo|Given orally
214368940|NCT03087344|DEVICE|Fibroscan and Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
214368941|NCT03087344|DEVICE|Fibroscan|Liver stiffness will be measured before and after a standard meal is administered
214982180|NCT03279042|PROCEDURE|Traditional corticotomy|Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
214982181|NCT01528410|DEVICE|ALFApump removal of ascites|Implanted ALFApump, removing produced ascites according to programmed schedule
214982182|NCT01528410|PROCEDURE|Large volume paracentesis for removal of ascites|Large volume paracentesis - standard of care, removing ascites according to patient need
214982183|NCT02852460|OTHER|rapid recovery|
214982184|NCT05684341|COMBINATION_PRODUCT|Connected Solution with H2S app which connects with blood glucose meter (BGM)|Combination of the Insultrate titration module software, the H2S app for participants, and the H2S platform for healthcare professionals
214982185|NCT03400449|OTHER|Video counseling|Video counseling
214982186|NCT03400449|OTHER|Conversational counseling|Conversational counseling
214982187|NCT03641508|DRUG|Triamcinolone|Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine
214982188|NCT03641508|DRUG|Dexamethasone|dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
214982189|NCT00004233|DRUG|fluorouracil|
214368942|NCT03087344|DEVICE|Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
214368943|NCT05435222|BEHAVIORAL|Male-specific psychotherapeutic program (MSPP)|The MSPP for MDD is designed to be used for the acute treatment of depression in men in 18 sessions over a period of 18 weeks. Therapy is delivered weekly with homework bridging every session. Central CBT elements (e.g. behavioral activation, cognitive restructuring) will be retained in MSPP. During implementation of typical CBT techniques, masculine role norms will be considered. One underlying topic will be the potential of multiple masculinities to coexist, being fluid and relational within one man, emphasizing positive aspects of masculinities compatible with psychotherapy for MDD.
214368944|NCT05435222|BEHAVIORAL|Cognitive beahvioral therapy (CBT)|This intervention consists of 18 sessions of manualized, standard cognitive behavioral therapy for major depression. Therapy is delivered weekly with homework bridging every session.
214982190|NCT00004233|DRUG|leucovorin calcium|
214982191|NCT00004233|DRUG|triacetyluridine|
214982192|NCT03642990|DRUG|Nicotinamide Riboside|Capsule
214982193|NCT00525837|DRUG|fixed dose varenicline|varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.
214982194|NCT00525837|DRUG|varenicline|up to 1 mg twice daily
214982195|NCT03733236|DEVICE|ISS Active Stimulation|ISS SPG stimulation and standard of care
215088196|NCT03972878|OTHER|control chocolate bar|commercial chocolate bar (200 kcal)+ 250 ml water
215088197|NCT03972878|OTHER|chocolate bar version 1|commercial chocolate bar (200 kcal), version 1+ 250 ml water
215088198|NCT03242356|OTHER|Questionnaire to assess of the application of the current French guidelines as to fasting during labor.|"Questionnaire focuses on :~* oral intake of clear fluid during the labor~* oral intake of solid meal during the labor~* fasting duration for solid and liquids~* instruction received as to fasting during labor, nature of these instructions, and who given the instruction (midwife, nurse anesthetist, …)~* discomfort related to thirst during labor~* discomfort related to hunger during labor~We will also record several medical data as to the course of pregnancy and delivery, analgesia technique, history and characteristics of the parturient."
214982196|NCT00973258|DIETARY_SUPPLEMENT|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
214982197|NCT00973258|OTHER|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
214982198|NCT00973258|OTHER|Cognitive Training|"The proposed cognitive training intervention program comprises:~1. Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~2. Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~3. Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors."
214982199|NCT00973258|OTHER|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
214982200|NCT00973258|OTHER|Placebo|Participants will receive their usual diet and placeboes.
214982201|NCT05235438|DRUG|IMM27M|IMM27M injection
214982202|NCT02717195|DRUG|Risperidone|4-6 mg/day, encapsulated tablets, orally
214982203|NCT02717195|DRUG|Olanzapine|15-20 mg/day, encapsulated tablets, orally
214982204|NCT02717195|DRUG|Lu AF35700|10 mg/day, encapsulated tablets, orally
214982205|NCT02717195|DRUG|Lu AF35700|20 mg/day, encapsulated tablets, orally
214982206|NCT03308552|RADIATION|SIB-IMRT|PTV:50.4Gy/28f, PGTV:59.92Gy/28f
214982207|NCT03308552|DRUG|Paclitaxel|45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
214982208|NCT03308552|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
214368945|NCT05455905|DIAGNOSTIC_TEST|Patient Health Questionnaire-9|The Patient Health Questionnaire-9 is a nine question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Patient Health Questionnaire-9 is scored from 0 to 27 where higher scores are associated with more severe depression.
214368946|NCT05455905|DIAGNOSTIC_TEST|Generalized Anxiety Disorder-7|The Generalized Anxiety Disorder-7 is a seven question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Generalized Anxiety Disorder-7 is scored from 0 to 21 where higher scores are associated with more severe anxiety.
214982209|NCT03308552|DRUG|Paclitaxel|150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
214982210|NCT03308552|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
214982211|NCT05437601|DRUG|Astaxanthin Oral Capsule|12 mg oral astaxanthin daily for 8 weeks
214982212|NCT05437601|OTHER|Placebo|Oral placebo identical to astaxanthin
214982213|NCT03658551|DIAGNOSTIC_TEST|Fluorescein|Measurement of intensity in the gastrointestinal mucosa after intravenous administration of fluorescein by confocal endoscopy
214982214|NCT05355558|DIAGNOSTIC_TEST|[18F]FLT-PET/MRI body scan|"\[18F\]FLT-PET/MRI body scan will be done at~* Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy.~* Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy).~At these visits:~* Obtain vital signs and weight in kg before FLT administration.~* Record the dose of FLT received and injected. (\*\*specify dose: 1mCi per 10kg. Maximum injected dose: \< 10mCi per patient.)~* Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT.~* Perform a saline flush following the FLT injection.~* Body PET/MRI will be performed after FLT injection.~* Time of injection of FLT and time of scan will need to be recorded."
214982215|NCT00855218|DRUG|Sorafenib (Nexavar, BAY43-9006)|800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. \[twice daily\], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
214982216|NCT00855218|DRUG|Placebo|4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
214982217|NCT04572373|DIETARY_SUPPLEMENT|SMOFlipid|
215088199|NCT02853435|DRUG|Gepotidacin RC Tablet|The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
215088200|NCT02853435|DRUG|Gepotidacin HSWG Tablet|The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
215088201|NCT02853435|DRUG|Gepotidacin Capsule|It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
214680884|NCT02606045|DRUG|recombinant von Willebrand factor|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
214680885|NCT02606045|DRUG|tranexamic acid|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
214680886|NCT00856271|DRUG|olmesartan medoxomil|oral tablets, once daily for 8 weeks
214680887|NCT00856271|DRUG|losartan potassium|capsules, once daily for 8 weeks
214680888|NCT00907881|DRUG|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
214368947|NCT05455905|DIAGNOSTIC_TEST|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is administered by a mental health profession and includes twenty-one questions asking about how the participant has been feeling in the past week. The Hamilton Depression Rating Scale is scored from 0 to 45 where higher scores are associated with more severe depression.
214368948|NCT05455905|DIAGNOSTIC_TEST|Hamilton Anxiety Rating Scale|The Hamilton Anxiety Rating Scale is administered by a mental health profession and includes fourteen questions asking about how the participant has been feeling in the past week. The Hamilton Anxiety Rating Scale is scored from 0 to 56 where higher scores are associated with more severe anxiety.
214680889|NCT04344405|DRUG|Vitamin D|vitamin D supplementation
214982218|NCT04063839|DRUG|Elbasvir / Grazoprevir Oral Tablet|HCV treatment according to Norwegian guidelines
214982219|NCT02283398|OTHER|without RIPC|the cuff will be placed around the left arm without being inflated
214982220|NCT02283398|PROCEDURE|RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
214680890|NCT04344405|DRUG|Steroid Drug|control
214680891|NCT06642337|OTHER|Educational program +Oral Iron therapy|The Nutritional Education Program is a structured intervention designed to enhance caregivers' understanding of nutrition and improve dietary practices for children suffering from iron deficiency anemia. The program comprises six weekly workshops lasting 1.5 hours each, focusing on essential topics such as the importance of iron in child development, identifying and preparing iron-rich foods, and practical meal planning strategies. Participants will engage in hands-on cooking demonstrations and receive educational materials, including recipe cards and meal planning tools, to support their learning. Knowledge assessments will be conducted at the beginning and end of the program to measure improvements in caregivers' nutritional knowledge.
214680892|NCT03440372|DRUG|Ozanimod|Specified dose on specified days
214680893|NCT03440372|OTHER|Placebo|Specified dose on specified days
214982221|NCT04005040|PROCEDURE|Mobile X-ray|Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
214982222|NCT01542827|OTHER|Biofreeze|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
214982223|NCT01542827|OTHER|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
214982224|NCT04352348|OTHER|blood samples|"All arms:~1 blood sample at inclusion (T0)~COVID-19 positive, severe only:~1 blood sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms, eventually, at discharge from hospital if the last blood sample was more than 3 days old, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
214982225|NCT04352348|OTHER|feces samples (COVI-BIOME ancillary study)|"All arms:~1 feces sample at inclusion (T0)~COVID-19 positive, severe only:~1 feces sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms and, eventually, at discharge from hospital"
214982226|NCT04352348|OTHER|sweat samples (COVIDOG ancillary study)|"All arms:~2 sweat samples at inclusion (T0)"
214982227|NCT04352348|OTHER|saliva samples|"All arms:~1 saliva sample at inclusion (T0)~COVID-19 positive, severe only:~1 saliva sample at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
215088202|NCT05863208|DEVICE|Artificial intelligence|ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma
215088203|NCT05863208|DEVICE|Endocuff vision|Endocuff vision (Olympus, UK) is used to help the detection of colon adenoma
215088204|NCT05863208|DEVICE|High-definition endoscope|High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma
214368949|NCT03026218|OTHER|GlucoseMama application with blood sugar monitoring and carb monitoring.|We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.
214368950|NCT03026218|OTHER|Group prenatal care for GDM.|group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
214368951|NCT03373526|OTHER|Inspiratory Muscle Training|The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.
215088205|NCT05696093|DRUG|cotrimoxazole|Use of cotrimoxazole therapy for enterobacterial VAP
214680894|NCT06527378|DIAGNOSTIC_TEST|AI in implant planning|Assessment of Current Technology for Supporting Implant Planning
214680895|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 100ug|Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.
214680896|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 10ug|Placebo dose. Minimal recommended dose.
215088206|NCT05696093|DRUG|standard antibiotic therapy|Use of standard antibiotic therapy for enterobacterial VAP
214492777|NCT06751940|COMBINATION_PRODUCT|Conventional second-line therapy|Conventional second-line therapy includes chemotherapy, targeted cancer drugs, and/or PD-1 inhibitors.The chemotherapy drugs, dosage and treatment cycle are determined by the subject's attending physician based on the subject's specific conditions. The medication, dosage and treatment cycle of targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances. The PD-1 inhibitor treatment cycle is 3 weeks, and the drug is administered by intravenous infusion on the first day (D1) of each treatment cycle. The dosage is based on the instructions.
214492778|NCT06751940|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
214982228|NCT04352348|OTHER|6 minutes walk test|"COVID-19 positive, severe only:~6 minutes walk test in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~6 minutes walk test at inclusion (T0) and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization."
214982229|NCT04352348|OTHER|Phone call|"All arms except COVID-19 negative:~1 phone call 3 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 6 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 12 months after COVID-19 infection."
214982230|NCT04352348|OTHER|Urine samples|"All arms:~1 urine sample at inclusion (T0)~COVID-19 positive, severe only:~1 urine sample at D3, at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 urine sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
214982231|NCT06036472|PROCEDURE|Standard periodontal therapy (steps 1 & 2)|participant will receive standard periodontal treatment consisting of two sessions of supra- and subgingival debridement (steps 1 and 2) under local anesthesia following current guidelines for periodontal therapy in patients with periodontitis (Herrera et al., 2022; Sanz et al., 2020). The use of chlorhexidine (0.12%) and cetylpyridinium chloride (0.05%) mouthwash will be prescribed twice a day for 15 days (Perio-Aid®, Dentaid, Barcelona, Spain). If needed, hopeless teeth might be extracted during this step.
214982232|NCT06036472|PROCEDURE|supragingival debridement with anesthesia (step 1)|periodontal treatment consisting of two sessions of supragingival debridement with anesthesia (step 1) and administration of a placebo mouthwash (FluorAid®, Dentaid, Barcelona, Spain), twice a day for 15 days.
215088207|NCT04973696|BEHAVIORAL|Toolkit for Optimal Recovery after Orthopedic Injury|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
215088208|NCT04973696|OTHER|Minimally Enhanced Usual Care (MEUC)|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
215088209|NCT03747120|DRUG|Paclitaxel|All subjects will receive Paclitaxel weekly for 12 weeks
215088210|NCT03747120|DRUG|Trastuzumab|All subjects will receive Trastuzumab every 3 weeks
215088211|NCT03747120|DRUG|Pertuzumab|Arm A and Arm B subjects will receive Pertuzumab every 3 weeks
215088212|NCT03747120|DRUG|Pembrolizumab|Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks
214492779|NCT06776198|DRUG|Chemotherapy|Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue
214680897|NCT03965988|DRUG|DHA|Docosahexaenoic acid
214680898|NCT03965988|DRUG|Placebo|Placebo
214680899|NCT00225368|DEVICE|Insecticide treated bednets|
214680900|NCT05772650|BEHAVIORAL|e-Health Program|Lifestyle modification for health and disease management using digital solutions
214680901|NCT03505697|OTHER|inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement16, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
214982233|NCT04192331|DRUG|nab-paclitaxel regimen1|nab-paclitaxel regimen1 means use abraxine with 125mg/m2 at day 1 and day 8 per 21d.
214982234|NCT04192331|DRUG|nab-paclitaxel regimen2|nab-paclitaxel regimen2 means use abraxine with 125mg/m2 at day 1 and day 8 and day 15 per 28d.
214982235|NCT04173819|BIOLOGICAL|3BNC117-LS-J|300mg
214982236|NCT04173819|BIOLOGICAL|10-1074-LS-J|300mg
214982237|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J|30mg/kg of each
214982238|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1|Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
214982239|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2|Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
214982240|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3|Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
214982241|NCT04173819|BIOLOGICAL|Placebo|0.9% Saline
214982242|NCT04173819|BIOLOGICAL|Placebo|Buffer Solution
214982243|NCT01590108|DRUG|(Pyr1)apelin-13|(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
214982244|NCT01590108|DRUG|Saline|Saline
214982245|NCT00764790|BIOLOGICAL|Fluarix|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
214982246|NCT00764790|BIOLOGICAL|Fluzone|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
214982247|NCT00405418|DRUG|Insulin glargine|Subcutaneous injection, once a day in the evening
214982248|NCT00405418|DRUG|Insulin Detemir|Subcutaneous injection, twice a day at breakfast and before dinner
214982249|NCT03191552|DEVICE|SPIO|"SPIO (stabilizing input pressure orthosis) 2 hours will receive conventional exercise therapy with the garment on during 2 hours. SPIO 6 hours group wore the SPIO 4 hours more in addition to 2 hours during therapy.~SPIO 6 hours group will wear the SPIO 4 hours more in addition to 2 hours during therapy.~(conventional exercises :range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills"
214982250|NCT03191552|OTHER|conventional exercises|range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills
214982251|NCT03847961|DEVICE|hemoperfusion with cytokine adsorption column (CA330)|Hemoperfusion treatments are performed using a perfusion machine via centrally inserted standard dialysis catheters at a prescribed blood flow rate of 100-300ml/min. In the beginning, lower flow rate is recommended, if there is no discomfort, then gradually increases. Each patient received 2 hemoperfusion treatments within 24 hours with a target duration for each treatment of 120-180 minutes (minimum of 120 minutes). The shorter the interval between the two hemoperfusion is, the better. It is suggested that the second hemoperfusion be performed within 0-5 hours after the first one.
214368952|NCT03373526|OTHER|Aerobic Training|The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
214368953|NCT04028349|DRUG|Ad26.ZEBOV/MVA-BN-Filo|Candidate Ebola Vaccine
214368954|NCT03418116|DEVICE|Argus II Retinal Prosthesis|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
214368955|NCT06496191|BIOLOGICAL|FMT|\- Single dose (30gm/90ml) of FMT will be given via upper GI gastroduodenoscope at D4
214368956|NCT06496191|OTHER|SMT|Baclofen + AUD counselling
214368957|NCT06496191|OTHER|Placebo|Placebo identical to the FMT arm.
214368958|NCT06083870|DRUG|Oba01|Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
214368959|NCT03067454|PROCEDURE|Early mobilisation|"Conservative treatment with early mobilisation~The patient is instructed to do a fist and is not allowed to leave the clinic before. Active mobilisation under control (doctor or physiotherapist) is performed until healing of the fracture is documented."
214368960|NCT03067454|PROCEDURE|Operation|Operation of the fracture. Usually open reduction and internal fixation with plates and screws or just screws within 2 weeks of injury. Immobilisation in a cast for two weeks followed by physiotherapy.
214368961|NCT01888393|DRUG|lumacaftor 200 mg q12h + ivacaftor 250 mg q12h|
214368962|NCT00508261|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection
214368963|NCT00508261|BIOLOGICAL|Infanrix™ hexa|Single dose intramuscular injection
214982252|NCT03985683|OTHER|agility tests|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
214368964|NCT00508261|BIOLOGICAL|Meningitec™|Single dose intramuscular injection
214368965|NCT00873418|BEHAVIORAL|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
214368966|NCT00972348|OTHER|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
214368967|NCT00972348|OTHER|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
214368968|NCT00180479|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214368969|NCT00180479|DEVICE|TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
214368970|NCT06181864|OTHER|NAO intervention|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Test of Emotional Vocabulary (TLE) and the Test of emotion comprehension (TEC). The tests will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 15 sessions, one per week lasting one hour and thirty minutes. the children are guided by the voice of the robot Nao. The robot guides them in carrying out practical and relaxation activities. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
215088213|NCT04467671|COMBINATION_PRODUCT|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
214368971|NCT06181864|OTHER|Traditional intervention|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Test of Emotional Vocabulary (TLE) and the Test of emotion comprehension (TEC). The tests will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 15 sessions, one per week lasting one hour and thirty minutes. The children are guided by the instructions of the operator who guides them in carrying out practical and relaxation activities. Consequently, the operator will provide feedback, to return information to the subject regarding the accuracy of the response.
214368972|NCT02336243|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
214368973|NCT02336243|DIETARY_SUPPLEMENT|Placebo (for Docosahexaenoic acid (DHA))|Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
214368974|NCT05346003|PROCEDURE|TCSP|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human BLS mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a BLS mock-up in a home environment, and after blended e-learning, they will be able to perform BLS iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice BLS in a real simulation model two weeks after the blended e-learning.
214368975|NCT02300857|BEHAVIORAL|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
214368976|NCT02300857|BEHAVIORAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
214368977|NCT02300857|BEHAVIORAL|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
214368978|NCT01945905|OTHER|Intramural|Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free
214368979|NCT01945905|OTHER|Extramural|In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
214368980|NCT01478009|DIETARY_SUPPLEMENT|Korean red ginseng|Korean red ginseng(3.0g/day) for 12 weeks
214368981|NCT01478009|DIETARY_SUPPLEMENT|Placebo|Placebo (3.0g/day) for 12 weeks
214368982|NCT00766233|OTHER|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
214368983|NCT01798394|DRUG|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
214368984|NCT01798394|OTHER|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
214368985|NCT03026023|DRUG|Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin|HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.
214368986|NCT05758831|DRUG|Perfusion of treatment Rituximab|Perfusion of treatment (Mabthera®, Truxima®, Rixathon®, Ruxience®)
214368987|NCT05758831|DRUG|Perfusion of treatment Ocrelizumab|Perfusion of treatment (Ocrevus®)
214368988|NCT01711762|DRUG|GDC-0973|Single oral dose of \[14C\]-GDC-0973
214368989|NCT05001724|BIOLOGICAL|KN046|KN046 is 5 milligram per kilogram, every 3 weeks.
214368990|NCT05001724|DRUG|Lenvatinib|Lenvatinib is RP3D milligram per day, every day.
214368991|NCT05001724|DRUG|Docetaxel|Docetaxel is 75 milligram per Square meter, every 3 weeks.
214368992|NCT01746095|DRUG|Vancomycin hydrochloride inhalation powder|There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
214492780|NCT03274297|DRUG|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
214492781|NCT03274297|DRUG|HMW PIB patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
214982253|NCT03985683|DIETARY_SUPPLEMENT|Nutritional Interventional|Athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively.T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
214982254|NCT00826553|DRUG|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
214982255|NCT00826553|DRUG|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
214368993|NCT01746095|DRUG|Placebo inhalation powder|
214368994|NCT02520167|BEHAVIORAL|Dietary and Lifestyle Counseling|Dietary and lifestyle education; Peer group support.
214368995|NCT00526630|DRUG|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
214368996|NCT00526630|DRUG|Placebo|Participants will be given placebo instead of active MPD.
214368997|NCT00116896|DRUG|OSI-7904L|
214368998|NCT00116896|DRUG|Cisplatin|
214368999|NCT04107831|OTHER|Pulmonary rehabilitation|Pre-post test design
214369000|NCT06187740|RADIATION|thoracic radiotherapy|"Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).~Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx(3 patients), then to the next dose group: 40 Gy/10 Fx(22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy."
214369001|NCT04088201|DEVICE|Glucose measurements|We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
214369002|NCT02234544|DRUG|Ezetimibe|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
214369003|NCT02234544|DRUG|Cholecalciferol|All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
214369004|NCT02234544|OTHER|Placebo|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
214369005|NCT01094132|DEVICE|Multispectral Digital Colposcope (MDC)|"The MDC has 2 components: an optical probe \& a multispectral colposcope. The optical wand makes use of fluorescence \& reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer \& healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence \& polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.~This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.~All study subjects will receive this same intervention."
214369006|NCT01007656|DIETARY_SUPPLEMENT|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
214982256|NCT04993209|BIOLOGICAL|NDV-HXP-S 1μg|NDV-HXP-S 1μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
214982257|NCT04993209|BIOLOGICAL|NDV-HXP-S 3μg|NDV-HXP-S 3μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
214982258|NCT04993209|BIOLOGICAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
214982259|NCT04993209|OTHER|Adsorbed inactivated COVID-19 vaccine (CoronaVac)|Adsorbed inactivated COVID-19 vaccine 600 SU/0.5 mL 2 doses intramuscular (deltoid) 28 days apart
214982260|NCT02958579|OTHER|No intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.|
214982261|NCT02391025|DRUG|Gallium-68 citrate|Given via IV at time of imaging
214982262|NCT02391025|PROCEDURE|Positron Emission Tomography (PET)|Imaging procedure
215088214|NCT02582281|DEVICE|intrauterine device TCu 380A|
214369007|NCT04111068|DEVICE|anodal tDCS Active Stimulation|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
214369008|NCT04111068|DEVICE|anodal tDCS Sham/Placebo Stimulation|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
214982263|NCT00632567|PROCEDURE|caesarean section|caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
214982264|NCT00632567|PROCEDURE|vaginal delivery|vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
214982265|NCT00296855|DRUG|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
214982266|NCT02187549|DEVICE|HYMOVIS|Intra-articular injection
214982267|NCT02187549|DEVICE|Placebo|Intra-Articular Injection
214982268|NCT00528307|DEVICE|HIS buldle ablation|HIS bundle ablation, followed by implant of a biventricular pacemaker
214982269|NCT03513016|DRUG|UBX0101|Investigational drug intra-articular injection
214982270|NCT03513016|OTHER|Placebo|Diluent intra-articular injection
215088215|NCT06258057|OTHER|Not applicable / database analysis|Not applicable / database analysis
215088216|NCT04172467|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
214982271|NCT03497871|DEVICE|HeartMan system|The HeartMan system uses wristband sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
214982272|NCT04195711|DIAGNOSTIC_TEST|"objective pediatric vision screen, blinq,"|hand-held birefringent screener for simultaneous foveation
214982273|NCT01265498|DRUG|obeticholic acid|25 mg daily for 72 weeks
214982274|NCT01265498|DRUG|placebo|placebo capsule, 25 mg daily for 72 weeks
214369009|NCT00320775|DRUG|VEGF Trap|"Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap."
214369010|NCT05987306|BEHAVIORAL|Weight loss plus self-compassion|A novel weight loss approach combining a standard weight loss based on the Diabetes Prevention Program and internalized weight bias intervention with self-compassion exercises.
214369011|NCT06497218|DIAGNOSTIC_TEST|Blinklab diagnostic device|Blinklab is a non-invasive diagnostic device for Autism Spectrum Disorder
214492782|NCT06758297|OTHER|AI-Powered Motivational Speech|"It is known that patients with knee prosthesis have difficulty in the first standing process due to fears of falling, not being able to walk again, and recurrence of their disease. For this purpose, a speech text that will motivate patients was prepared with the support of ChatGPT. Expert opinions were obtained from 2 orthopedic specialists and 2 specialist psychiatric nurses for this speech text. Later, the speech text was converted into an audio video with the ElevenLabs application. Thus, it was planned to make it easier for patients to listen to it again. Patients will listen to this motivational speech in their own patient rooms and using their own headphones."
214492783|NCT06173063|DEVICE|Mobility+ Enteral Feeding System|Enteral feeding using a continuous feeding, self-powered, discreet, silent enteral feeding system.
214492784|NCT04447209|OTHER|2-weekly Food baskets|2 weekly Food basket containing fresh foods or minimally processed foods.
214680902|NCT03505697|OTHER|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
214680903|NCT01671085|DRUG|LY3015014|Administered SQ
214680904|NCT01671085|DRUG|Placebo|Administered SQ
214680905|NCT00637273|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
215088217|NCT05147714|DEVICE|Surgical Pleth Index (SPI)|SPI data were recorded at one-minute intervals during the last five minutes (6 times in total) until the entropy value reached 60
215088218|NCT00439452|OTHER|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
215088219|NCT00439452|OTHER|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
215088220|NCT02878044|OTHER|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
215088221|NCT06326749|OTHER|Modified Graded Motor Imagery and Conventional Treatment Group|A modified form of graded motor imagery training and conventional rehabilitation will be applied.
215088222|NCT06326749|OTHER|Graded Motor Imagery and Conventional Treatment Group|Graded motor imagery training and conventional rehabilitation will be applied.
215088223|NCT06326749|OTHER|Conventional Treatment Group|conventional rehabilitation will be applied.
215088224|NCT03993223|BEHAVIORAL|Upper trapezius muscle fatigue|Isometric contraction of scapular elevation
215088225|NCT04118790|OTHER|Clinical Assessment|"1. Medical history and details of the vascular incident will be collected from the patient and the medical journal. (Duration: 1hr)~2. Neuropsychological measures collected using test measures and questionaries (duration approx 45-60 min)."
215088226|NCT04118790|PROCEDURE|MRI scan|1\. MRI scan session, which includes Structural, Quantitative, Functional and Diffusion MRI sequences. (maximum duration: 90 min).
215088227|NCT00518674|PROCEDURE|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
215088228|NCT04332614|BEHAVIORAL|Less-is-better|Email
215088229|NCT04332614|BEHAVIORAL|Social proof|Email
215088230|NCT04332614|BEHAVIORAL|Endowment / decision staging|Email
215088231|NCT04332614|BEHAVIORAL|Standard email|Email
215088232|NCT03041142|BEHAVIORAL|Interdisciplinary intervention|Physical Activity, nutrition and Psychological
215088233|NCT03041142|OTHER|Routine|The participants continued to maintain their routine
215088234|NCT01073917|OTHER|Spontaneous Breathing|
215088235|NCT01073917|OTHER|Pressure Controlled Ventilation|
215088236|NCT01073917|OTHER|Pressure Support Ventilation|
215088237|NCT04144959|DEVICE|Indigo Aspiration System|Indigo Aspiration System
215088238|NCT02582047|BIOLOGICAL|Influenza vaccination with PPV23|GCflu and Pneumovax-23
215088239|NCT02582047|BIOLOGICAL|Influenza vaccination with PCV13|GCflu and Prevenar-13
214369012|NCT04955834|DRUG|Insulin degludec injection|long-acting insulin
214369013|NCT04955834|DRUG|Tresiba®|long-acting insulin
214680906|NCT00637273|DRUG|sitagliptin|oral tablet, 100mg, once a day
214680907|NCT00637273|DRUG|pioglitazone|oral tablet, 45mg, once a day
214680908|NCT00637273|DRUG|placebo tablet|oral tablet, once a day
214680909|NCT00637273|DRUG|placebo once weekly|subcutaneous injection, once a week
215088240|NCT04191499|DRUG|Inavolisib|Participants will receive oral inavolisib on Days 1-28 of each 28-day cycle.
214369014|NCT03674554|PROCEDURE|titanium bases using intra oral luting cement technique|a full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
214369015|NCT03674554|PROCEDURE|transmucosal abutment|a full-arch screw-retained implant prosthesis with transmucosal abutment
214369016|NCT02107794|OTHER|Decision Aid|Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
214369017|NCT05130125|DRUG|rFSH|rFSH or HP-hMG or rFSH and HP-hMG
214982275|NCT06482164|DIAGNOSTIC_TEST|Dry Eye Disease|Corneal sensitivity in patients who also have dry eye.
214982276|NCT00968461|DRUG|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
214982277|NCT00624988|PROCEDURE|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
214982278|NCT05576311|OTHER|Focus Group|Focus Groups to capture information about the need for innovation in the diagnosis and monitoring of urinary symptoms.
214982279|NCT06359899|DRUG|AK0901 capsule|Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral
214982280|NCT06359899|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
214982281|NCT04391478|DRUG|Milrinone|milrinone lactate, 1mg/ml, for intra venous use only
214982282|NCT04391478|DRUG|Sildenafil|50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube
215088241|NCT04191499|DRUG|Placebo|Participants will receive oral placebo on Days 1-28 of each 28-day cycle.
215088242|NCT04191499|DRUG|Palbociclib|Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
214369018|NCT02437656|DRUG|Metformin|"J3 - J10 (7 days minimum) : 850 mg 2 times / day~J10 - 48h before surgery : 850 mg 3 times / day"
214492785|NCT06812546|DRUG|Vericiguat|Patients enrolled in the experimental group will receive 26 weeks of oral vericiguat on top of the standard treatment, with vericiguat at a dose of 2.5 mg once a day, doubled every fortnight to a maximum dose of 10 mg once a day at the end of week 6 of the visit, which will be maintained for the duration of the treatment.
214492786|NCT06779305|PROCEDURE|Minimally invasive surgical application of Calcanail®|The procedure involves making small incisions to insert a specialized nail into the bone to realign and stabilize the fracture. This approach minimizes damage to surrounding tissues, reduces the risk of wound complications, and allows for quicker recovery compared to traditional open surgery. after surgery, the patient will benefit from an immobilisation with a plaster boot without support for 3 weeks, followed by immobilisation with a removable walking boot for 3 weeks with partial support depending on the patient's pain.
214369019|NCT01934803|DIETARY_SUPPLEMENT|Zinc gluconate|Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
214369020|NCT01934803|DIETARY_SUPPLEMENT|Placebo|
214369021|NCT03320798|OTHER|Data record|
214369022|NCT06370910|OTHER|Low-Level Laser Therapy|The patient will be submitted to evaluation through a questionnaire, which will be the patient's evaluation form, which will be elaborated by the researcher (Appendix A). Next, pain and edema will be evaluated, using the VAS scales, Mc Gill scale and REEDA scale, after this process, the therapy will be applied, and the patient will be randomly selected for cryotherapy or LLLT. After application, the patient will be evaluated immediately and the scales applied again and after 24 hours.
214369023|NCT04500496|DRUG|INH|3 tablet of INH inserted by the patient 12 hours before the scheduled office hysteroscopy
214369024|NCT04500496|DRUG|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
214492787|NCT06779305|PROCEDURE|Immobilisation by cast boot|The patient will be immobilised in a plaster cast without support for 3 weeks, followed by immobilisation in a removable walking boot for 3 weeks with partial support depending on the pain.
214492788|NCT06779513|DIAGNOSTIC_TEST|Echocardiohraphy|Transthoracal echocardiography for diastolic function assessment
214982283|NCT04716985|DIETARY_SUPPLEMENT|MOLECULAR HYDROGEN|Magnesium Tablet
214982284|NCT04716985|DIETARY_SUPPLEMENT|PLACEBO MAGNESIUM|Magnesium carbonate tablet
214369025|NCT03518125|BIOLOGICAL|BioThrax|"Other Names:~Anthrax Vaccine Adsorbed (AVA)"
214369026|NCT03518125|BIOLOGICAL|AV7909|Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
214369027|NCT03518125|DRUG|Sodium chloride injection USP, 0.9% (placebo)|"Other Names:~Saline Solution"
214982285|NCT03477656|PROCEDURE|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption using GLYCOSORB®-ABO column
214982286|NCT03477656|PROCEDURE|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis
214982287|NCT04640922|DEVICE|Gedea Pessary pHyph|Vaginal tablet
214982288|NCT04640922|DEVICE|Placebo|Vaginal tablet
214982289|NCT00471484|BIOLOGICAL|recombinant interferon alfa-2b|
214982290|NCT00471484|DRUG|doxorubicin hydrochloride|
214982291|NCT00471484|DRUG|fluorouracil|
214982292|NCT00471484|DRUG|oxaliplatin|
214982293|NCT00471484|OTHER|diagnostic laboratory biomarker analysis|
214982294|NCT00471484|OTHER|immunoenzyme technique|
214982295|NCT00471484|OTHER|immunohistochemistry staining method|
214982296|NCT00471484|PROCEDURE|adjuvant therapy|
214982297|NCT00471484|PROCEDURE|biopsy|
214982298|NCT00471484|PROCEDURE|neoadjuvant therapy|
214982299|NCT00471484|PROCEDURE|therapeutic conventional surgery|
214982300|NCT00709332|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid|
214982301|NCT06139926|DRUG|Dexmedetomidine administered intranasally|Intranasal administration of dexmedetomidine (plain) was given at the bedside of the ward as per the pre-tested recommended dose. The patient's vital signs were maintained. On the day of surgery, 30 min before induction of anesthesia, intranasal dexmedetomidine (original solution) was administered in the operating room at the pre-tested recommended dose.
214982302|NCT00545025|BIOLOGICAL|Influenza Vaccine GSK1247446A|Single dose, Intramuscular injection
214982303|NCT00545025|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
215088243|NCT04191499|DRUG|Fulvestrant|Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.
215088244|NCT04521686|DRUG|LY3410738|Oral LY3410738
214982304|NCT05239663|DRUG|Ganglioside-Monosialic Acid|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
214982305|NCT05239663|DRUG|250ml normal saline (NS)|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus 250ml normal saline (NS)
214982306|NCT00617279|DEVICE|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
214982307|NCT00617279|PROCEDURE|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
214982308|NCT03880474|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
214982309|NCT03880474|DRUG|Saline|Sodium Chloride Placebo
214982310|NCT01738100|DRUG|Ticagrelor|
214369028|NCT03311282|DEVICE|infants bottles|"* angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;~* extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* flexors at the base to enhance elasticity and flexibility of the teat"
214369029|NCT03311282|DEVICE|Infants Bottles|"* large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.~* flexors at the base to enhance elasticity and flexibility of the teat"
214369030|NCT03311282|DEVICE|Infants Bottles|"* teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.~* flexors at the base to enhance elasticity and flexibility of the teat"
214369031|NCT06491836|DIETARY_SUPPLEMENT|oligoantigenic diet|Oligoantigenic diet that will cover recommended daily allowance (RDA) of macronutrients and micronutrients according patients' ages according to our available sources of food in our culture and the diet consists typically of meat (e.g. chicken and lamb), carbohydrate sources (e.g., potatoes and rice), fruits (e.g., bananas, pears and apples), vegetables (e.g., cucumbers, carrot, lettuce, cauliflower, turnips, cabbage and broccoli)
214369032|NCT06491836|OTHER|Food regimen without food restrictions.|Food regimen that will cover recommended daily allowance (RDA) for macronutrients and micronutrients according patients' ages without any food restriction
214369033|NCT03730285|DEVICE|Telemedicine|Installation of videotelephone with broadband in patient's home
214369034|NCT04626739|DRUG|CD19 CAR-T|CD19 CAR-T for CD19 positive R/R non-Hodgkin lymphoma
214369035|NCT04626739|DRUG|CD22 CAR-T|CD22 CAR-T for CD22 positive R/R non-Hodgkin lymphoma
214369036|NCT04626739|DRUG|CD19+CD22 CAR-T|CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma
214369037|NCT04626739|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
214369038|NCT04626739|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
214369039|NCT02167763|DEVICE|VeraCept Intrauterine Copper Contraceptive|
214369040|NCT02167763|DEVICE|TCu380 IUD|
214369041|NCT00260143|DRUG|Testosterone enanthate|
214369042|NCT00260143|DRUG|Placebo|
214369043|NCT00872040|OTHER|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
214369044|NCT02449668|DEVICE|Acupuncture|Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.
214982311|NCT01738100|DRUG|Clopidogrel|
214982312|NCT01738100|DRUG|Morphine Sulfate|
214982313|NCT01738100|DRUG|Saline|
214982314|NCT00921024|DRUG|CXA-101|intravenous
214982315|NCT00921024|DRUG|Ceftazidime|intravenous
214982316|NCT03328988|PROCEDURE|QLB|bilateral single shot block, placed under ultrasound control between the thoracolumbar fascial structures close to the quadratus lumborum muscle
214982317|NCT03412214|DEVICE|Perfusion index detected by pulse oximeter|Perfusion index detected by pulse oximeter
214982318|NCT03412214|DEVICE|AAI|The AEP Monitor/2 (Danmeter A/S, Odense, Denmark), a commercialized system for depth of anesthesia monitoring, extracts the middle latency auditory evoked potentials (MLAEP) from the EEG-signal by using an autoregressive model with an exogenous input adaptive method.
214982319|NCT00000347|DRUG|Risperidone|
214982320|NCT03225287|DRUG|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
214982321|NCT02842528|BEHAVIORAL|Diagnostic Interview for Genetic Studies|
214982322|NCT02842528|BEHAVIORAL|Family Informant Schedule and Criteria|
214982323|NCT02842528|BEHAVIORAL|Temperament and Character Inventory|
214982324|NCT02842528|BEHAVIORAL|Barratt Impulsiveness Scale|
214369045|NCT02449668|DEVICE|Sham Acupuncture|
214492789|NCT06778564|DRUG|CBD 100 mg/mL Oral Solution|Daily dose 1000mg, taken as 500mg (5ml) b.i.d for 6 weeks. For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks
214982325|NCT02842528|BEHAVIORAL|Wisconsin Card Sorting Test|
214982326|NCT02842528|GENETIC|blood sample withdrawn|
214982327|NCT00743756|DIETARY_SUPPLEMENT|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
214982328|NCT00743756|DIETARY_SUPPLEMENT|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
214982329|NCT00743756|BEHAVIORAL|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
214982330|NCT03036267|BEHAVIORAL|BREATHE|Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.
214492790|NCT06778564|OTHER|Placebo|5ml b.i.d for 6 weeks; For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks
214982331|NCT03036267|OTHER|Attention Control Condition|PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
214982332|NCT01749956|RADIATION|Radiation|
214982333|NCT01749956|DRUG|Aflibercept|
214982334|NCT01749956|PROCEDURE|Surgery|Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines
214982335|NCT01749956|DRUG|FOLFOX6|
214982336|NCT02239211|DRUG|BTT1023|IV (in the vein) Investigational Medicinal Product (IMP)
214982337|NCT05387876|DIETARY_SUPPLEMENT|Vitamin D intervention|Nordic Naturals vitamin D gummies (1000 IUs/gummie), 4 gummies per day for 12 weeks
214982338|NCT05387876|DIETARY_SUPPLEMENT|Placebo intervention|Organic gummie candies (no vitamin D), 4 gummies per day for 12 weeks
214982339|NCT06609122|OTHER|Animal Assisted Intervention|"Animal-assisted intervention (AAI) is a therapeutic approach that involves animals as part of a treatment plan to improve physical, social, emotional, or cognitive functioning in individuals. Animals such as dogs, cats, horses, and even dolphins are commonly used in AAI due to their ability to provide comfort, companionship, and motivation.~AAI can take many forms, including animal-assisted therapy (AAT), where a trained therapy animal works with a licensed healthcare professional to achieve specific treatment goals. Animal-assisted activities (AAA) involve interactions with animals in a more casual and recreational setting, such as visits to hospitals or nursing homes to provide companionship and emotional support."
214982340|NCT06612632|DRUG|research drug in combination with Toripalimab|research drug in combination with Toripalimab
214982341|NCT06612632|DRUG|Toripalimab|Toripalimab
214982342|NCT01138020|BEHAVIORAL|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
214982343|NCT01138020|BEHAVIORAL|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
214982344|NCT04258072|DRUG|Vactosertib|Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-(\[1,2,4\]triazolo\[1,5-a\]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight
214982345|NCT01383278|BEHAVIORAL|Computer-directed 5 A's intervention for smoking|Computer-directed 5 A's intervention for smoking
214982346|NCT01383278|BEHAVIORAL|Screening and resource provision|Screening and resource provision
214982347|NCT02298972|BEHAVIORAL|Nurse support and selfmanagement intervention|
214982348|NCT01916200|DRUG|Paroxetine CR|Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
214982349|NCT04610138|DRUG|CNM-ZnAg|ZnAg liquid solution
214982350|NCT04610138|DRUG|Placebo|Water
214982351|NCT05418803|DRUG|YHP1807 Tab. 2.5mg|Rivaroxaban 2.5mg
214982352|NCT05418803|DRUG|YHR1901 Tab. 2.5mg|Rivaroxaban 2.5mg
215088245|NCT04521686|DRUG|Gemcitabine|Intravenous gemcitabine
215088246|NCT04521686|DRUG|Cisplatin|Intravenous cisplatin
214492791|NCT06828536|OTHER|Gynecology consultation|Gynecology consultation M0 - M3 - M6 - M12
215088247|NCT04521686|DRUG|Durvalumab|Intravenous durvalumab
214492792|NCT06828536|OTHER|Transvaginal ultrasound|Transvaginal ultrasound
214492793|NCT06828536|OTHER|PCR Schistosoma spp|PCR Schistosoma spp Colposcopy Cervical biopsy Cervical smear
214982353|NCT02025283|PROCEDURE|Group Decompression or Group Nucleoplasty|Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith \& Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM \[ArthroCare Spine, Sunnyvale, CA\]
214982354|NCT06119165|BEHAVIORAL|Environmental nudges|Participants will view protein, frozen meal, and snack products with eco-labels applied. For each category, they will then be instructed to select 1 item from that category they wish most to purchase. Categories will be shown in random order. If a participant selects a product with a red eco-label, they will be shown a peer comparison message and will be given an opportunity to switch to a product with a yellow or green eco-label.
215088248|NCT05031065|RADIATION|Breast Cancer Radiotherapy|4000-4250 cGy in 15-16 daily fractions
215088249|NCT05627583|OTHER|Rehabilitation|Hospitalized patients with AN under treatment for rehabilitation
215088250|NCT02546089|OTHER|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
215088251|NCT02546089|OTHER|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
215088252|NCT02546089|OTHER|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
214492794|NCT06778655|DIETARY_SUPPLEMENT|5% propolis gel|5% propolis gel (prepared according to Joshy et al. 2018) Joshy A, Doggalli N, Patil K, Kulkarni PK. To Evaluate the Efficacy of Topical Propolis in the Management of Symptomatic Oral Lichen Planus: A Randomized Controlled Trial. Contemp Clin Dent. 2018 Jan-Mar;9(1):65-71.
214492795|NCT06778655|OTHER|Placebo gel|placebo mucoadhesive gel having the same flavor, consistency, and color as the propolis.
214492796|NCT06833346|OTHER|Hip belt squat exercise|Hip belt squat exercise performed twice per week for 12 weeks
215088253|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
214369046|NCT04119895|OTHER|Neuromuscular electrical stimulation and core stabilization exercise|"In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second"
214369047|NCT04119895|OTHER|Sham neuromuscular electrical stimulation and core stabilization exercise|In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
214369048|NCT02608866|RADIATION|SF-SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
214369049|NCT02608866|RADIATION|MF-SSRS|SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
214680910|NCT05240950|DRUG|Anti-CEA CAR-T Cells|"The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10\^6/kg, 3×10\^6/kg, and 6×10\^6/kg using a standard 3+3 design and preliminarily observe the efficacy."
214680911|NCT02733692|BEHAVIORAL|Understanding Reproductive Health for Ladeez (GURHL) Code|Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
214982355|NCT02107846|DRUG|PRX-112|
214982356|NCT04078009|DIAGNOSTIC_TEST|Aquagen|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
214982357|NCT04078009|DIAGNOSTIC_TEST|Grazax|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
214982358|NCT03685604|DRUG|CHX disinfection|CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
214982359|NCT03685604|DRUG|PI Disinfection|PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
214982360|NCT03429101|DRUG|Poziotinib|Poziotinib is a tablet for oral administration.
214982361|NCT03429101|DRUG|T-DM1|T-DM1 (ado-trastuzumab emtansine) is a HER2-targeted therapy for I.V. administration.
214982362|NCT04277780|DEVICE|Continuous Glucose Monitoring Sensor|Placement of continuous glucose monitor sensor for 14 days. Instructions on how to peel off the sensor and mail it back to the clinician.
214982363|NCT04277780|OTHER|Diabetes Management Instructions|Instructions on checking fingerstick blood glucose and information on the required equipment including glucose test strips, lancets, and glucometer. Instructions on how to log blood glucose values onto the blood glucose log sheet for 14 days, and how to mail it back to the clinician.
214982364|NCT01093846|DRUG|AIN457|300mg every 4 weeks
214982365|NCT01093846|DRUG|AIN457|300mg every 2 weeks
214982366|NCT01093846|DRUG|Placebo AIN457|Placebo to AIN457
214369050|NCT01791920|DRUG|Botulinum toxin type A(Botulax®)|Single administration, Day 0, 20 units
214369051|NCT01791920|DRUG|Botulinum toxin type A(Botox®)|Single administration, Day 0, 20units
214369052|NCT02417779|DEVICE|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
214369053|NCT02417779|DEVICE|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
214369054|NCT02157480|DEVICE|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
214369055|NCT02157480|DEVICE|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
214680912|NCT03471845|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
214982367|NCT03228030|DIETARY_SUPPLEMENT|Thiamine|Capsules
214982368|NCT03228030|DIETARY_SUPPLEMENT|Placebo|Identical capsules
214982369|NCT00001475|DRUG|IL-2 plus Anti-TNF or Thalidomide|
215088254|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
215088255|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube|
215088256|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes|
215088257|NCT01266317|DRUG|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
215088258|NCT00296153|DRUG|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
215088259|NCT00490776|DRUG|Panobinostat|Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
215088260|NCT01940536|DRUG|Tranexamic Acid|antifibrinolytic
215088261|NCT01940536|DRUG|Placebo|Placebo
215088262|NCT03166111|DRUG|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
215088263|NCT03166111|DRUG|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
214982370|NCT05625243|OTHER|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
214982371|NCT05625243|OTHER|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured sectional matrix systym (Saddle matrix, TORVM, Moscow, Russia)|A suitable size precontoured sectional matrix band (Saddle matrix, TORVM, Moscow, Russia) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (fixing wooden wedges, TORVM, Moscow, Russia) and a separation ring (Delta ring, TORVM, Moscow, Russia). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
214982372|NCT05625243|OTHER|Bulk-fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
214982373|NCT00000972|BIOLOGICAL|MTP-PE/MF59|
214982374|NCT00000972|BIOLOGICAL|Env 2-3|
214982375|NCT00660452|DRUG|Staloral|Sublingual immunotherapy with Staloral dust mites solution
214982376|NCT01416571|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Intramuscular (IM), two doses
214982377|NCT02820389|PROCEDURE|Optical colonoscopy|Patients with suspected colorectal cancer in this group will undergo Optical Colonoscopy as the initial imaging modality.
214982378|NCT02820389|PROCEDURE|CTC|Patients with suspected colorectal cancer in this group will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan, i.e. patients with medium to large polyps or colorectal cancer will undergo Optical Colonoscopy as the second imaging test.
215088264|NCT03591172|DRUG|Propolis|Using propolis as a final irrigation in revascularization
215088265|NCT03591172|DRUG|Nano-propolis|Using Nano-propolis as a final irrigation in revasculariztion
215088266|NCT03591172|DRUG|saline|Using saline as a final irrigation in revasculariztion
214492797|NCT03305549|OTHER|Conservative dialysis strategy|"Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~* Blood urea nitrogen \>112 mg/dL (40 mmol/L)~* Serum potassium concentration \>6 mmol/L~* Serum potassium concentration \>5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~* Arterial blood gas pH \<7.15 in a context of pure metabolic acidosis (PaCO2 \<35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate \<12 mmol/L~* Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate \>5 L/min to maintain SpO2 \>95% or requiring FiO2 \>50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy"
214492798|NCT03305549|OTHER|TIW dialysis strategy|Thrice-weekly acute intermittent hemodialysis schedule.
214982379|NCT00747877|DRUG|cyclophosphamide|Given orally
214982380|NCT00747877|DRUG|melphalan|Given IV
214982381|NCT00747877|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous hematopoietic stem cell transplantation on day 0.
214982382|NCT02059109|PROCEDURE|Hands on Assembly of Belmont Rapid Infuser|Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
214492799|NCT06654141|PROCEDURE|Alveolar ridge preservation|Alveolar ridge preservation using xenograft (Bio-Oss Collagen®) and implant placement at 2 different time intervals (3 and 6 months)
214492800|NCT05001087|OTHER|Observation|Not applicable-Observational study
214680913|NCT00012337|DRUG|gefitinib|
214680914|NCT01762293|DRUG|Famitinib|Famitinib 25 mg p.o. qd
214680915|NCT01762293|OTHER|placebo|p.o. qd
214982383|NCT06424353|PROCEDURE|Endoflas pulpectomy|obturation of root canals of primary molars with Endoflas using pressure seringe and lentilospiral files
214982384|NCT05175625|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
214982385|NCT05175625|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL); a single intramuscular injection into the deltoid muscle of the non-dominant arm
214982386|NCT03811938|PROCEDURE|Low voltage ablation|Catheter ablation of low voltage areas in the left atrium and catheter ablation aiming for the electrical isolation of the pulmonary veins.
214982387|NCT03811938|PROCEDURE|Pulmonary Vein Isolation|Catheter ablation aiming for the electrical isolation of the pulmonary veins.
215088267|NCT04401878|DRUG|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.
215088268|NCT02886871|BEHAVIORAL|Step Goal Delivery by Smartphone|
215088269|NCT04964596|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
214369056|NCT03737201|OTHER|ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
214369057|NCT03737201|OTHER|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
214369058|NCT03737201|OTHER|Control|without any cavity disinfectant
214369059|NCT00714376|DRUG|Docetaxel|75 mg/m2 iv every 3 weeks for 8 cycles
214369060|NCT03924778|BEHAVIORAL|DASH diet|brief description
214369061|NCT03924778|BEHAVIORAL|standard American diet|describe
214369062|NCT02579876|DRUG|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
214369063|NCT02579876|DRUG|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
214369064|NCT06108401|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Goat milk-based infant formula exclusively for 4 weeks at a volume depending on the infant.
214369065|NCT06108401|DIETARY_SUPPLEMENT|Cow milk-based infant formula|Regular cow milk-based infant formula that is similar in color, smell, and taste to the formula received by the experimental group.
214369066|NCT02081625|DRUG|NS-065/NCNP-01|"NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks"
214369067|NCT04077957|DRUG|Methotrexate|Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
214982388|NCT01899092|DRUG|TT-034|The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
214982389|NCT05395507|DRUG|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
214982390|NCT05395507|DRUG|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
214982391|NCT04852822|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214982392|NCT04852822|OTHER|Electronic Health Record Review|Medical records are reviewed
214982393|NCT03736018|DIAGNOSTIC_TEST|CTCA|Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
214369068|NCT04077957|DRUG|Sulfasalazine|Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.
214369069|NCT04077957|DRUG|Hydroxychloroquine|Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.
214369070|NCT04077957|DRUG|Etanercept (50mg per week, for 4 weeks)|Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.
214369071|NCT04077957|DRUG|Etanercept (50mg per week, for 2 weeks)|Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1\>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.
214369072|NCT04077957|DRUG|Etanercept (50mg per week)|Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.
214369073|NCT01933035|OTHER|Immune Thrombocytopenics|Full blood count with extended platelet parameters
214369074|NCT01933035|OTHER|Hypo-proliferative thrombocytopenics|Full blood count with extended platelet parameters
214369075|NCT01933035|OTHER|Control Population|Full blood count with extended platelet parameters
214369076|NCT00738686|DEVICE|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
214369077|NCT05287308|DRUG|doxorubicin|doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
214982394|NCT04321889|DEVICE|defurocumarinized bergamot loaded in a nanotechnological essential oil release system|Patients will be treated either with placebo cream or with defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of cream 2 times a day for 4 weeks. The subject will be monitored throughout the treatment and for at least 4 weeks after the end of the treatment.
214982395|NCT04321889|OTHER|Placebo|nanotechnological system loaded with placebo cream
214982396|NCT03816046|DRUG|botulinum toxin A|injection in hair bearing area of armpits
214982397|NCT00737178|DEVICE|CuT380A|Comparison of different timing of IUD insertion
214982398|NCT04735614|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after the surgery by our research member and will be asked to keep it on except for during showering through the whole study period.
214982399|NCT01477567|DRUG|LY3009385|
214369078|NCT05287308|DRUG|epirubicin|epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
214369079|NCT05287308|DRUG|pirarubicin|pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
214369080|NCT05287308|DRUG|cyclophosphamide|cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
214369081|NCT05287308|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.
214369082|NCT05287308|DRUG|paclitaxel|paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.
214369083|NCT05287308|DRUG|docetaxel|docetaxel 80\~100mg/m2, i.v., d1, q3w.
214369084|NCT05080062|BEHAVIORAL|Requirements and functional Schedule|An interview with the employee and the employer where the occupational worker is leading the interview and a pain rehabilitation-program
214369085|NCT05080062|BEHAVIORAL|No intervention|a pain rehabilitation-program
214369086|NCT01555788|DEVICE|Artificial Pancreas for DiaPort system with Zone-MPC algorithm|Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
214369087|NCT01551602|DRUG|AK159|transdermal administration of teriparatide acetate
214369088|NCT01551602|DRUG|MN-10-T|subcutaneous administration of teriparatide acetate
214369089|NCT01551602|DRUG|Placebo|Multiple administration of placebo AK159
214369090|NCT00639730|DIETARY_SUPPLEMENT|modified Atkins diet|High fat, low carbohydrate diet
214369091|NCT00548730|PROCEDURE|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
214369092|NCT02877602|DEVICE|MRI|
214492801|NCT05315206|DIETARY_SUPPLEMENT|Citicoline|"The patient will be given 10 ml of Citicoline oral solution (Neurotidine ®) once a day in the morning for 1 year. To patients will be given 4 bottles containing 500 ml of Citicoline and the relative instructions for administration. After 6 months, the patient will bring back the used bottles and will be given additional 4 bottles containing Citicoline (Neurotidine ®). Again at the end of this 6 month period the patient will bring back the used bottles.~Each bottle of Neurotidine will contain: water; fructose; Citicoline (500 mg per 10 ml); acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavine."
214492802|NCT05315206|DIETARY_SUPPLEMENT|Placebo|The patient will be given 10 ml of an oral solution of Placebo. Each bottle of Placebo, the solution of which will be indistinguishable from the active product in terms of appearance and flavor, will contain: water; fructose; acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavin
214492803|NCT06024473|DEVICE|rTMS|Transcranial Magnetic Stimulation
214492804|NCT06024473|DEVICE|rTMS+iVCT|Transcranial Magnetic Stimulation and immersive virtual reality
214982400|NCT01477567|DRUG|Placebo|
214982401|NCT02931461|PROCEDURE|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration|
214982402|NCT04093271|DIETARY_SUPPLEMENT|Rest-ZZZ|A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm
214982403|NCT04093271|DRUG|Active Comparator - Diphenhydramine HCl|DIN 02229960 encapsulated for blinding purposes
214982404|NCT04093271|OTHER|Placebo|No active ingredients
214982405|NCT06346158|DIAGNOSTIC_TEST|Cognitive testing|Preoperative cognitive battery test
214982406|NCT06346158|DEVICE|electroencephalogram|Preoperative 24 channel EEG
214982407|NCT06346158|DEVICE|High density electroencephalogram|preoperative 128-channel electroencephalogram
214982408|NCT06346158|PROCEDURE|General anesthesia|induction of general anesthesia using propofol 1%
214369093|NCT02877602|DEVICE|Transient Elastography|
214369094|NCT01547026|BEHAVIORAL|Implementation Intentions|In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
214369095|NCT00969397|DRUG|Topical Antiangiogenic|Topical Antiangiogenic
214369096|NCT00969397|DEVICE|Pulsed Dye Laser|Pulsed Dye Laser
214369097|NCT01681108|BEHAVIORAL|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
214369098|NCT03487536|OTHER|Nutritional assessment|BMI and cholesterol levels evaluation
215088270|NCT04964596|DIAGNOSTIC_TEST|FIT test|faecal immunochemical test
215088271|NCT04964596|DIAGNOSTIC_TEST|CT colonography|noninvasive medical imaging technique that uses computed tomography to visualize the interior of the colon and rectum especially to screen for polyps or cancerous growths
214369099|NCT02897479|DRUG|Savolitinib|Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
214369100|NCT01905930|DEVICE|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
214369101|NCT01905930|DEVICE|Anterior Cervical Discectomy and Fusion (ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
214369102|NCT00048672|DRUG|Gleevec|Starting dose of 400 mg orally daily.
214369103|NCT01359670|DRUG|Tadalafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
214369104|NCT01359670|DRUG|Sildenafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
214369105|NCT00760539|DRUG|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
214369106|NCT00760539|DRUG|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
214369107|NCT04543006|DIAGNOSTIC_TEST|serology|blood sample of 10 ml twice (6 and 12 months after the Covid-19)
214369108|NCT00106184|DRUG|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
214369109|NCT00106184|DRUG|Placebo|"Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1"
214369110|NCT00314561|DRUG|Pioglitazone, Rosiglitazone|
214369111|NCT06063720|DEVICE|Endoscreen QC|Artificial intelligence monitoring of effective withdrawal time
214369112|NCT04325113|DRUG|levobupivacaine|Patient satisfaction and pain score using a visual anagogic scale (VAS)
215088272|NCT02975726|DEVICE|Peritoneal Dialysis Catheter|Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.
214982409|NCT00901641|DEVICE|CogniFit Personal Coach®|The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
214982410|NCT00021164|BIOLOGICAL|aldesleukin|
214982411|NCT00021164|BIOLOGICAL|incomplete Freund's adjuvant|
214982412|NCT00021164|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
214982413|NCT01686893|DEVICE|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
214982414|NCT01686893|DEVICE|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
214369113|NCT02789384|OTHER|Procedure/Surgery|"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices."
214369114|NCT02560662|BEHAVIORAL|Physical activity|"Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call."
214982415|NCT04233684|DIAGNOSTIC_TEST|rapid urease test|"Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~Pathologic test for H. pylori by H\&E stain and Giemsa stain Gold standard is a immunohistochemistry."
214982416|NCT01737528|PROCEDURE|Transcatheter Aortic Valve Replacement|Minimal invasive implantation of a biological prothesis in Aortic Position
214982417|NCT02359708|PROCEDURE|Surgical hand disinfection.|Bacterial recolonization
214982418|NCT00140439|BEHAVIORAL|Emergency Department based asthma follow-up clinic|"The clinical activities of the intervention followed a fully specified protocol and provided education and care in three domains:~1. Asthma self-monitoring and management: Educators first reviewed the basic physiology of asthma with emphasis on its chronicity. After evaluating asthma severity and treatment history, the physician completed an individualized medical action plan (MAP) and provided any necessary device teaching.~2. Environmental modification and trigger control: After evaluation of potential environmental triggers in the home, each family was educated on their control. Each child was provided hypoallergenic bed encasings.~3. Linkages and referrals to ongoing primary care: Clinic staff stressed the importance of longitudinal asthma care by a PCP. A full report of the clinic visit was mailed to each child's PCP. In addition, the asthma educator scheduled a follow-up appointment with the PCP within 4 weeks"
214982419|NCT03520010|BEHAVIORAL|Externally-facilitated implementation|NHs randomized to the externally-facilitated arm will attend the same kickoff meetings and have access to the same online resources as the control arm but will also be assigned a clinical coach and will have the opportunity to participate in a series of hosted peer-to-peer learning opportunities. The clinical coach will meet regularly with NH staff to guide the facility through implementation of the Wisconsin UTI Improvement Toolkit.
214982420|NCT03520010|BEHAVIORAL|Internally-driven implementation|Study NHs randomized to the control arm will participate in kickoff meetings introducing the different UTI toolkit components. The meeting will also cover topics on how to assemble a change team, how to use the different tools in the UTI toolkit, and how to track process and outcome measures to monitor progress. NHs assigned to the control arm will have access to a web-based data tracking tool that will allow them to trend a number of study outcomes (e.g., number of monthly urine cultures and UTI treatment events) in their facility over time. Instructions and educational tools will be made available as an online resource but otherwise NHs in the control arm will be expected to implement the Wisconsin UTI Improvement Toolkit using existing internal resources.
214369115|NCT05016726|DEVICE|Intravascular Lithotripsy|Intravascular Lithotripsy and/or Rotational Atherectomy and/or Orbital Atherectomy to the target vessel prior to placing a coronary stent.
214492805|NCT05209802|OTHER|Group A: High intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
214492806|NCT05209802|OTHER|Group B: moderate intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
214492807|NCT05111600|DRUG|Transplantation|Implantation of autologous cultured grafts containing genetically modified stem cells for restoration of functional skin on pre-selected areas
214492808|NCT06269198|DEVICE|WARD-CSS|"Patients' continuously monitored vital signs will be recorded via a bedside tablet device (data not visible).~The clinical staff will have access to the continuously monitored vital signs through a mobile device (smart phone) with a purpose-built app-based GUI displaying vital sign status and summaries, alarms, and device connectivity. The GUI will alert the clinical staff (acoustic and visual signals) when any of the predefined thresholds for deviating vital signs are exceeded."
214982421|NCT02169882|DRUG|Placebo|"Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs."
214982422|NCT02169882|DRUG|Rifampicin|"Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section."
214982423|NCT02169882|DRUG|Other TB drugs|"Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
214369116|NCT04667364|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Conventional TENS will be performed using two electrodes placed on the involved extremity and with the following stimulation parameters; a frequency of 100 Hz, pulse duration 50-100 ms, and at an intensity gradually increased until the patient feels a strong, tolerable and non-painful sensation (18, 19). The intensity is incrementally increased based on patient feedback. Patients will receive guidelines on how to use the TENS device at home and will over a period of 30 days self-administer TENS as needed. Patients is to fill out a predefined schedule on paper each day to monitor dose.
214982424|NCT02169882|DRUG|Adjuvant dexamethasone|Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
214982425|NCT02280434|DRUG|CBP-307|
214982426|NCT02280434|DRUG|Placebo|
214982427|NCT01675609|DRUG|Placebo|1 drop in each eye daily for up to 35 days
214982428|NCT01675609|DRUG|Brimonidine tartrate 0.025%|1 drop in each eye for up to 35 days
215088273|NCT02975726|PROCEDURE|Large Volume Paracentesis|Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.
215088274|NCT02975726|BIOLOGICAL|25% Human Serum Albumin injection|Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.
215088275|NCT02975726|PROCEDURE|Bloodwork|Monthly bloodwork will be done as part of usual standard of care.
214369117|NCT06156722|PROCEDURE|Sperm selection by IMSI|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI)
214369118|NCT06156722|PROCEDURE|Sperm selection by IMSI and spermslow|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI) + spermslow
214492809|NCT06429228|PROCEDURE|Catheter removal after surgery|Removal of catheter placed during the procedure in first or second post-surgical days.
214982429|NCT04198168|DRUG|IV crystalloid fluid bolus|The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).
214982430|NCT00081003|GENETIC|gene expression analysis|
214982431|NCT00081003|GENETIC|protein expression analysis|
214982432|NCT00081003|OTHER|cytology specimen collection procedure|
214982433|NCT00081003|OTHER|laboratory biomarker analysis|
214982434|NCT00081003|OTHER|physiologic testing|
214982435|NCT00081003|PROCEDURE|breast duct lavage|
214982436|NCT00081003|PROCEDURE|endoscopic biopsy|
214982437|NCT00081003|PROCEDURE|study of high risk factors|
214982438|NCT00079976|DRUG|Tigecycline|
214982439|NCT06399159|PROCEDURE|Thyroidectomy and lymph node dissection|All surgical specimens of thyroidectomy and lymph node dissection were subjected to paraffin-embedded histopathological examination, and postoperative were categorized as with cervical lymph node metastasis and without cervical lymph node metastasis.
214982440|NCT00296244|DRUG|Steroids|Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
214982441|NCT00296244|DRUG|Basiliximab|Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
214982442|NCT00296244|DRUG|Tacrolimus|Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
214982443|NCT00296244|DRUG|Enteric-coated Mycophenolic acid (EC-MPA)|This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
215088276|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
215088277|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
215088278|NCT06583291|DRUG|Allogeneic dopaminergic neural precursor cell(iDAP)|Bilateral implantation
215088279|NCT06583551|DRUG|Botulinum toxin|Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.
215088280|NCT06583551|PROCEDURE|Dry needling|Dry needling (DN) is a type of acupuncture therapy, that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points (MTrPs) and muscular, and connective tissues.
215088281|NCT06583551|DRUG|Myorel|Metacarbamol (380mg), paracetamol (300mg)
215088282|NCT06583551|PROCEDURE|Manual therapy|Manual therapy (MT) entails the use of the hands to apply a force with a therapeutic intent, including techniques such as massage, joint mobilization/manipulation, myofascial release, nerve manipulation, strain/counterstrain, and acupressure.
215088283|NCT06583408|OTHER|Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)|Subjects will complete the ASA food diary for 2 weekdays and 1 weekend day
214982444|NCT03932708|BEHAVIORAL|CDC Core Elements of Outpatient Stewardship|The intervention is described above and includes components of leadership, action of policy and practice, tracking and reporting, and education and expertise.
214680916|NCT00986258|DRUG|Tapentadol Prolonged Release|"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~* if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~* if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~* if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."
214680917|NCT04585945|DIAGNOSTIC_TEST|Positive for SARS-CoV-2 infection|Patients that have a positive test for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
214680918|NCT04465370|DEVICE|Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight|A Swan-Ganz catheter, FloTrac transducer, ClearSight finger cuff and ForeSight Elite sensors will be placed prior to the start of the catheterization procedure. Intermittent cardiac output and other hemodynamic parameters will be collected throughout the duration of the procedure and analyzed according to the Statistical Analysis Plan.
214680919|NCT05919784|BEHAVIORAL|Cognitive behavioural therapy|The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
214680920|NCT05361018|OTHER|Whole Body Vibration exercise - WBV|participants will be randomised to two different training interventions
214680921|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm|Sham treatment (shock wave probe w/o energy)
214680922|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm|Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
214680923|NCT02616029|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
214680924|NCT04809727|PROCEDURE|Cervical biopsy|4 quadrant biopsy
215088284|NCT06583408|OTHER|REVEAL Questionnaire|Subjects will complete the REVEAL questionnaire form. This form includes questions about current and past medical history, including reproductive history, lifestyle specifics, and assessment of current health status.
215088285|NCT06584123|DIAGNOSTIC_TEST|18F-Fluoro-ethyl-tyrosine (FET) PET|18F-Fluoro-ethyl-tyrosine PET study of the pituitary
214680925|NCT06255977|DRUG|CN-105|Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
214982445|NCT01077557|OTHER|No Antiretroviral (ARV) Drug Exposure|No pharmacy dispensing of an ARV drug
215088286|NCT06583421|BEHAVIORAL|4-week MVPA intervention|The 4-week MVPA intervention engaged in supervised aerobic exercise, resistance training and interesting sport for 60 minutes, 3 days/week (Monday, Wednesday and Friday). As shown in Table S1, participants completed four sessions including preparation module (15 min), training module (30 min), and relaxation module (15 min). Another aerobic module (15 min) was added in each Friday.
215088287|NCT06584019|OTHER|Range Of Motion applied group|Range Of Motion was applied once a day for approximately 20 minutes for 5 days.
215088288|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (25g/d)|Participants will consume 25g soy protein powder daily for a 6 week treatment period.
215088289|NCT02180841|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
214982446|NCT01077557|DRUG|Any Antiretroviral (ARV) Drug Exposure|Pharmacy dispensing claim for any ARV drug
214982447|NCT02378272|OTHER|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
214982448|NCT01905696|DRUG|Oral N-acetylcysteine|
215088290|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (50g/d)|Participants will consume 50g soy protein powder daily for a 6 week treatment period.
215088291|NCT01670565|DRUG|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
215088292|NCT01670565|DRUG|Mycophenolate Mofetil|Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
215088293|NCT01670565|OTHER|Placebo Infusion|Infusion of normal saline
214680926|NCT04958564|DEVICE|DCP|"1. Dynamic compression plating to compress the fracture~2. Intramedullary device to share the load."
214680927|NCT02310958|PROCEDURE|Laparoscopic surgical hernia repair|Laparoscopic surgical hernia repair in children
214680928|NCT02771808|OTHER|biomarker samples|biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
214680929|NCT00003753|DRUG|dexamethasone|
214680930|NCT00003753|DRUG|floxuridine|
214680931|NCT00003753|DRUG|irinotecan hydrochloride|
214680932|NCT00003753|PROCEDURE|adjuvant therapy|
214680933|NCT00003753|PROCEDURE|conventional surgery|
214982449|NCT05793658|PROCEDURE|Standard capnography|Patients undergoing colonoscopy under sedation were randomly assigned to receive standard capnography monitoring or modified capnography monitoring which can be achieved by tucking capnography probe under the face mask.74 patients were enrolled. Patient characteristics were well balanced between the two groups 37 patients in each group.
214369119|NCT04203043|DRUG|Pycnogenol Oral Product|pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
214369120|NCT04203043|OTHER|Placebo|Placebo
214492810|NCT05464732|DEVICE|Vivity IOL emmetropia|The Vivity IOL will be implanted bilaterally in all subjects, tested with correction to bilateral emmetropia.
214492811|NCT05464732|DEVICE|Vivity IOL monovision|The Vivity IOL will be implanted bilaterally in all subjects, tested with correction to emmetropia in the dominant eye and -0.50 in the non-dominant eye.
214492812|NCT06761963|OTHER|Whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
214492813|NCT06761963|OTHER|Rehabilitation|Pulmonary rehabilitation program.
214492814|NCT06838585|PROCEDURE|infusion therapy|Monitoring patients with fluid overload and fluid accumulation
214492815|NCT06760520|DRUG|Ivonescimab (SMT112 or AK112) Injection|Eligible subjects will receive short-course radiotherapy (SCRT), 25Gy/5f/1 week. 1-2 weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK112 20 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 850-1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
214982450|NCT05793658|PROCEDURE|Modified capnography|If Respiratory rate below 14 b/m: more sedation isn't not advised and the patient may develop airway obstruction and needs airway intervention ( like jaw thrust or oral airway) If respiratory rate more than 20 b/m it means this patient is prone to awake or to move and this patient in need for incremental dose of sedative drug ( e.g 20 to 30 mg propofol) Also roughly speaking respiratory rate from 16 to 18 b/m is the target
214982451|NCT05084391|DEVICE|stereotactic ablative radiotherapy (SABR)|is safe for treating heart arrhythmias (irregular heartbeat
214982452|NCT05084391|OTHER|Standard of Treatment|Standard of care
214982453|NCT00427934|DRUG|Maraviroc|300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
214492816|NCT03400150|DEVICE|balloon|balloon implantation
214492817|NCT03400150|OTHER|Control|Control - Marking \& IMRT are standard of care for prostate cancer - there is no study-specific intervention
214492818|NCT05556746|DRUG|Bedaquiline|Daily therapy for 12 weeks
214492819|NCT05556746|DRUG|Clofazimine|Daily therapy for 12 weeks
214492820|NCT05556746|DRUG|Pyrazinamide|Daily therapy for 12 weeks
214492821|NCT05556746|DRUG|Delamanid|Daily therapy for 12 weeks
214492822|NCT05556746|DRUG|Rifampin|Daily therapy for 26 weeks
214492823|NCT05556746|DRUG|Isoniazid|Daily therapy for 26 weeks
214982454|NCT00427934|DRUG|Maraviroc Placebo|Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
214982455|NCT04168957|DRUG|Oraxol|"Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets"
214982456|NCT03673891|DEVICE|Life Flow|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
214369121|NCT06384950|BEHAVIORAL|ChatGPT|Patients receive additional education using a GPT-3.5-based educational robot on top of the traditional education.
214369122|NCT06384950|BEHAVIORAL|patient education with traditional methods.|Patients receive standard traditional education procedures.
214369123|NCT03202043|OTHER|High dose vegetable juice|High dose (13 fl oz) vegetable juice
214369124|NCT03202043|OTHER|Medium dose vegetable juice|Medium dose (10 fl oz) vegetable juice
214369125|NCT03202043|OTHER|Low dose vegetable juice|Low dose (5.5 fl oz) vegetable juice
214369126|NCT03202043|OTHER|Control bottled water|Control (12 fl oz) bottled water
214369127|NCT01032733|BEHAVIORAL|Lifestyle Counseling|In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
214369128|NCT01032733|OTHER|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
214369129|NCT05860127|BEHAVIORAL|Referral for Cognitive Stimulation Therapy|Physician will review participant eligibility for CST treatment and offer referral based on clinical judgement
214369130|NCT05860127|OTHER|No change to Standard of Care|Participants will not receive referral from a physician. They will continue with standard of care at their site.
214369131|NCT02231177|DRUG|BI 1744 CL|
214369132|NCT02231177|DRUG|BI 1744 CL/Tiotropium FDC|
214369133|NCT02231177|DRUG|Tiotropium|
214369134|NCT00087958|DRUG|XRP9881|
214369135|NCT05718843|DRUG|BI 425809|BI 425809
214492824|NCT05556746|DRUG|Ethambutol|Daily therapy for 8 weeks
214492825|NCT05556746|DRUG|Pyrazinamide|Daily therapy for 8 weeks
214492826|NCT06892457|OTHER|TMS-EEG|Evoked brain activity is measured with the help of TMS-EEG in epilepsy patients OFF and ON medication.
214492827|NCT05943522|OTHER|Asciminib|There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
214982457|NCT03355144|DIETARY_SUPPLEMENT|Daily Supplementation with Coffee|"At the beginning of study week 2 (study day 8), two coffee machines (one Nespresso Inissia and one Hamilton Beach 46205 12 Cup Programmable Coffee Maker) will be installed in the resident work rooms at each site.~Subjects will be provided with free coffee beans, milk, cream, sugar and sweetener"
214982458|NCT05676658|BEHAVIORAL|Coherent breathing|Guided audio of coherent breathing pre-recorded by trained breathwork facilitator: \~5.5bcpm (with equal inhalation/exhalation durations of \~5.5secs each) for \~10mins/day over four weeks / 28 days. Delivered remotely through audio link.
214369136|NCT05807659|DRUG|fractionated busulfan-based conditioning regimen|"Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation"
214369137|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
214369138|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
214369139|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
214982459|NCT05676658|BEHAVIORAL|Placebo coherent breathing|Same audio of coherent breathing but paced at: \~12bcpm (with equal inhalation/exhalation durations of 2.5secs each) for \~10mins/day over four weeks / 28 days.
214982460|NCT02329158|DRUG|6% hydroxyethyl starch|
214369140|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
214369141|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
214369142|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
214369143|NCT00200304|BEHAVIORAL|Internet weight loss with SlimFast and human counseling|
214369144|NCT00200304|BEHAVIORAL|Internet weight loss with SlimFast and computer counseling|
214369145|NCT00200304|BEHAVIORAL|Internet weight loss program with SlimFast|
214982461|NCT04399681|DEVICE|Bedside lung ultrasound|Point of care ultrasound will be used as bedside lung ultrasound to determine the patients if they have a COVID-19 pneumonia.
214982462|NCT05152121|OTHER|Carb and fat counting|In the 7 days leading up to the study, participants were contacted to review blood glucose levels with CGMS, food and activity diary. basal rates and insulin carbohydrate ratio and sensitivity factor were changed according to the CGMS values and normoglycemia was achieved.In the study day same meals were served which included high fat, high energy density test meal containing 80 gram carbohydrate (34%), 70 gram fat (66%) and 35 g protein (14%).The participants had to have no glucose fluctuations 2 hours before study entry based on CGMS, no correction boluses for at least 4 hours before the test meal consumption and fasting glycemia in the range of 70-180 mg/dL on both study days.The participants received the test meal calculating insulin dose by CC on the first study day and calculating insulin dose by and fat/protein counting in the second study day. The test meal consumption was completed in 20 minutes under supervision by a caregiver and a dietician of the research team
214982463|NCT03699423|DRUG|0.01% atropine eye drops|0.01% atropine sulphate
215088294|NCT01611051|DRUG|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
214369146|NCT00409682|BIOLOGICAL|Adalimumab|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
214369147|NCT00409682|BIOLOGICAL|Adalimumab|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
214492828|NCT06812455|DRUG|Rivaroxaban|Patients with RAO that will receive p.o. tabs Rivaroxaban 20 mg q.d.
214680934|NCT02148458|OTHER|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
214680935|NCT02148458|OTHER|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
214982464|NCT03699423|DRUG|0.02% atropine eye drops|0.02% atropine sulphate
214982465|NCT03699423|DRUG|0.03% atropine eye drops|0.03% atropine sulphate
214982466|NCT04996030|DRUG|SY-2101|SY-2101 will be administered per dose and schedule specified in arm description.
214982467|NCT04996030|DRUG|Arsenic Trioxide|IV ATO will be administered per dose and schedule specified in arm description.
214492829|NCT06790446|OTHER|Eccentric training group (ECC)|"The first, preparatory phase, lasts two weeks, aiming at making the participant familiar with the principles of eccentric training. Participants first experience the muscle recruitment patterns (during two sessions), then are prepared to induce protective response from the plantar flexors, conditioning these muscles for higher subsequent eccentric intensities.~The aim of the second, training phase per se, which lasts six weeks, is to induce muscular and neurological adaptations through a steady increase in work intensity to stimulate muscle plasticity until the end of the program - varying volume, load and speed.~Perceived exertion is quantified using Borg's scale (expected rating between 3 and 6) to ensure sufficient work intensity and prevent excessive fatigue. Musculoskeletal pain is assessed before and after each session through a Visual Analog Scale (0-10). Verbal encouragements and advising on correct exercise execution are provided by the therapist along each session."
214492830|NCT06790446|OTHER|Conventional therapy|The participant visits a physiotherapist depending on the prescription, as in current practice
214982468|NCT02633774|DRUG|Propafenone|AAD(antiarrhythmic drug)
214982469|NCT02633774|DRUG|Apixaban|anti-coagulation
214982470|NCT04955756|DIAGNOSTIC_TEST|mNGS|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
214680936|NCT03808272|DEVICE|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
214680937|NCT05870007|DRUG|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg
214680938|NCT05870007|DRUG|Sodium Bicarbonate 600 Mg Oral Tablet|Sodium bicarbonate would be titrated up to 1800mg per day according to metabolic acidosis severity during clinical follow-up
214680939|NCT05897138|DRUG|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle|"Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle"
214982471|NCT04955756|DIAGNOSTIC_TEST|Multiplex PCR|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
214982472|NCT00038662|DRUG|Atrasentan|
214492831|NCT06880081|DRUG|PN20 treatment|Three dose cohorts, single dose, subcutaneous injections
214492832|NCT06623357|OTHER|Pilot Training Protocol|The pilot training protocol uses principles based on evidence-based research on factors that support caregiver learning of and adherence to home-therapy techniques/recommendations.
214492833|NCT06623357|OTHER|Standard Training Protocol|The standard training protocol uses the caregiver training methods that are currently used in our clinics.
214492834|NCT06811012|DRUG|Contezolid|"This study intends to enroll 24 patients with bone and joint tuberculosis, who will be randomly divided into two groups: the contezolid monotherapy group and the linezolid monotherapy group. Patients will receive oral contezolid or linezolid monotherapy for 14 consecutive days, and data on treatment safety, pharmacokinetics, and preliminary efficacy will be collected before and after administration.~Study Medications:~Contezolid 800mg QD for 14 days; Linezolid 600mg QD for 14 days."
214982473|NCT00881166|DRUG|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
214492835|NCT06811012|DRUG|Linezolid (LZD)|Linezolid 600mg QD for 14 days.
214680940|NCT00478660|DRUG|adalimumab (Humira)|
214982474|NCT00881166|DRUG|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
214982475|NCT00881166|DRUG|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
214982476|NCT00881166|DRUG|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
214982477|NCT00881166|DRUG|MP-470 + carboplatin/etoposide|Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
214680941|NCT06035432|OTHER|Bluesky software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Bluesky software.
214680942|NCT06035432|OTHER|3D slicer software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by 3D slicer software.
214680943|NCT06035432|OTHER|OnDemand software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by OnDemand software.
214680944|NCT06035432|OTHER|Mimics software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Mimics software.
214680945|NCT04594408|DRUG|Epinephrine|1 mL of 1:1000 mixed into irrigation bag.
214680946|NCT04594408|DRUG|Tranexamic acid|1 g IV x 1 dose to be administered intraoperatively.
214982478|NCT02950389|DEVICE|PMMA filter|
214982479|NCT02950389|DEVICE|HFR17 filter|
214982480|NCT02950389|DEVICE|F7 filter|
214982481|NCT03309618|DRUG|low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)|
214982482|NCT03309618|DRUG|placebo|
214982483|NCT02638792|BEHAVIORAL|Internet-based exposure therapy (I-ET)|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
214982484|NCT02638792|BEHAVIORAL|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
214982485|NCT02305316|DRUG|BIA 9-1067 non-micronized|
214982486|NCT02305316|DRUG|BIA 9-1067 micronized|
214982487|NCT00001132|DRUG|Abacavir sulfate|
214982488|NCT04539275|DRUG|Convalescent Plasma|Convalescent plasma from persons recovered from SARS-CoV-2 is being used to treat hospitalized individuals with complicated COVID-19 infection.
214982489|NCT04539275|OTHER|Masked Saline Placebo|0.9% saline solution will be used as the Masked Saline Placebo
214982490|NCT00105430|PROCEDURE|Deep Brain Stimulation|
214982491|NCT03176914|BEHAVIORAL|prevention and management of childhood illnesses at community level|provision of critical health education and targeted promotion services to the participants in their locality
214369148|NCT00409682|BIOLOGICAL|Adalimumab|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
214369149|NCT00428467|PROCEDURE|LV Apex Compression|
214369150|NCT01944202|BEHAVIORAL|Educational intervention|Educational and feedback intervention, as described in the Arm Description.
214369151|NCT03475082|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is utilized clinically by a variety of health care professionals for the reduction of pain. The mechanisms by which TENS produces analgesia or reduces pain are only recently being elucidated. TENS is a non-invasive modality that is inexpensive, safe and easy to use with relatively few contraindications. Frequency of stimulation is broadly classified as high frequency (\>50Hz), low frequency (\<10Hz) TENS. Intensity is determined by the response of the patient as either sensory level (low-intensity) TENS strong but comfortable. With sensory level TENS, the voltage (i.e. amplitude) is increased only until the patient feels a comfortable tingling (perceived with high frequency) or tapping (perceived with low frequency) sensation without motor contraction. With strong but comfortable TENS the intensity is increased to a strong but comfortable level which may include muscle contraction.
214982492|NCT03176914|BEHAVIORAL|conventional community interventions|community health programs as the sole source of health education
214982493|NCT02243748|OTHER|Palliative Therapy|Receive individualized palliative care
214369152|NCT03375281|PROCEDURE|RFA|thermal ablation using radiofrequency for HCC
214369153|NCT02782702|DRUG|Botulism Toxin Treatment|Injection of 50 UI of botulism toxin for treated zone
214369154|NCT01087268|OTHER|questionnaire administration|
214369155|NCT01087268|PROCEDURE|gastrointestinal complications management/prevention|
214369156|NCT01087268|PROCEDURE|quality-of-life assessment|
214982494|NCT02243748|OTHER|quality-of-life assessment|Ancillary studies
214982495|NCT02243748|OTHER|questionnaire administration|Ancillary studies
214982496|NCT02318199|PROCEDURE|Anesthesia recovery after intracranial surgery|Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
214982497|NCT02474836|BIOLOGICAL|Skin Prick Test - Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
214369157|NCT05461703|BEHAVIORAL|Planet Nutrition Program|It is a 6-month school-based obesity prevention program that includes: nutrition education sessions, physical activity and family participation.
214369158|NCT02367755|DRUG|Propofol|Propofol use during therapeutic hypothermia
214982498|NCT02474836|BIOLOGICAL|Skin Prick Test - Non Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
214982499|NCT02474836|BIOLOGICAL|Skin Prick Test - Allergic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
214982500|NCT01373164|DRUG|Galunisertib|Administered orally
214982501|NCT01373164|DRUG|Gemcitabine|Administered intravenously
214982502|NCT01373164|DRUG|Placebo|Administered orally
214982503|NCT04948918|PROCEDURE|Anatomically optimized distal renal denervation|Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter
214982504|NCT00612235|DRUG|Lamotrigine|Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.
214369159|NCT02367755|DRUG|Lorazepam|Lorazepam use during therapeutic hypothermia
214369160|NCT01896869|DRUG|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
214369161|NCT01896869|BIOLOGICAL|Vaccine|5x10\^8 cells administered in 6 intradermal injections
214369162|NCT01896869|DRUG|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
214369163|NCT02260453|OTHER|Preoperative coronary angiography|If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied
214369164|NCT02260453|OTHER|Standard cardiac workup|EKG, transthoracic cardiac echocardiogram
214982505|NCT00612235|DRUG|Levetiracetam|Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.
214982506|NCT00612235|DRUG|Carbamazepine|Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.
214982507|NCT00612235|OTHER|No Intervention|No intervention was given
214982508|NCT00049231|DRUG|EF5|
214982509|NCT00049231|OTHER|immunohistochemistry staining method|
214982510|NCT00049231|PROCEDURE|biopsy|
214369165|NCT03058341|DRUG|propofol|Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
214680947|NCT04594408|DRUG|Epinephrine and Tranexamic Acid|1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
214680948|NCT03370081|DEVICE|CAPNOGRAPHY|MONITORING OF CAPNOMETRY USING ETCO2 METHOD
214982511|NCT03061942|OTHER|Arthroscopic rotator cuff repair without synovectomy|30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.
214982512|NCT03061942|OTHER|Arthroscopic rotator cuff repair with synovectomy|30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
214982513|NCT05222867|PROCEDURE|lower back massage|Lower back massage performance: In the study, Linda Kimber's massage protocol was used. First, the researcher ensured that the patient was holding the bed, squatting, or bent over on the bed, which is suitable for the massage, between two contractions. The pregnant woman was instructed to breathe deeply and exhale audibly when her contractions began. Gloves were worn during the massage and liquid Vaseline, which does not contain any active substance, was used to provide lubricity. The circular hip massage was applied at the beginning of the contraction, and lower lateral area and sacral pressure massage was applied towards the end of the contraction as per the massage protocol, and simultaneously with the inhaling sound of the pregnant woman
214982514|NCT02957552|BIOLOGICAL|Mesenchymal Stem Cells|Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
214982515|NCT02254642|PROCEDURE|Ischemic preconditioning during aortic clamping|Ischemic preconditioning during aortic clamping
214982516|NCT02254642|PROCEDURE|Procedure/Surgery: usual surgery|Procedure/Surgery: usual surgery
214982517|NCT01138241|OTHER|Tc99mDTPA renal clearance|"Tc99mDTPA renal clearance only for 200 patients~1. Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria~2. serum creatinine prior and during TDF~3. TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels~4. stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)~5. serum for cystanin C ( stored sample prior taking ARV and present time)~6. intensive 24 hours pharmacokinetic study of TDF in 20 patients"
214982518|NCT01799941|DRUG|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
214982519|NCT00843349|DRUG|Lanthanum Carbonate|Phosphorus binder
214982520|NCT00843349|OTHER|900 mg Phosphate Diet|Amount of phosphorus consumption in a day kept below 900 mg.
214982521|NCT00843349|DRUG|LC Placebo|Placebo for Lanthanum Carbonate
214369166|NCT03058341|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously (IV) for induction of general anaesthesia. Otrivin can be applied nasally at the discretion of the anaesthetist. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to keep a BIS value of 40-60. Intravenous remifentanil infusion between 0.1-0.25mcg/kg/min will be given and this will be titrated to optimal haemodynamic parameters. Muscle relaxants can be given during the operation as required.
214492836|NCT05981664|DEVICE|One Handed Video Game Controller Adapter|The one handed video game controller adapter was designed and 3D printed at Rehabilitation Centre for Children. It is a simple model that snaps onto an XBox One controller and uses a series of levers to allow access to almost all buttons of the controller from one side. There is both left and right sided versions
214492837|NCT05417321|DRUG|HB0036|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
214492838|NCT06811506|PROCEDURE|Anatomical size patella component|After the patella was resurfaced, surgeon evaluated the symmetry through haptic feedback and assessed the thickness by measuring the distance from the anterior to posterior center of the patella. An inset, single pegged patella component was cemented after milling the patella. The patella was medialized as the patella bone would allow. Synovium laying on top of the femoral component with the knee in extension was routinely excised. Lateral facetectomy and restoration of native patella thickness were performed in all knees. In the control group, anatomically sized patella components were used.
214680949|NCT06342297|DEVICE|Dermatoscopy|Dermatoscopy used in decision of surgical margin before resection of basal cell carcinoma or cutaneous squamous cell carcinoma
214982522|NCT00843349|OTHER|Ad Libitum Diet|Patients continued to eat their usual diet.
214982523|NCT02526238|DEVICE|TMS and trunk rotation|TMS and trunk rotation
214982524|NCT02526238|DEVICE|Sham TMS and trunk rotation|Sham TMS and trunk rotation
214982525|NCT01398241|DRUG|RO5267683|Multiple ascending doses
214680950|NCT03802422|DRUG|Vitamin B12|Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.
214982526|NCT01398241|DRUG|placebo|Multiple ascending doses
214982527|NCT05072808|OTHER|View PACCI-ED and referral recommendations|Results of parent completed PACCI-ED and referral recommendations
214982528|NCT03394937|BIOLOGICAL|ECI-006|ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules
214982529|NCT02120404|DRUG|Esmolol administration|"Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours."
214982530|NCT05902624|DRUG|Hepatitis B Virus Vaccine(HBV)|Hepatitis B Virus Vaccine(HBV)
214982531|NCT01605903|DRUG|Ibuprofen|Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
214982532|NCT01605903|DRUG|Acetaminophen|During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
214982533|NCT04780399|DRUG|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
214982534|NCT04780399|DRUG|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
214369167|NCT04670692|OTHER|5G-MCE examination|The endoscopist (W.Z.) manipulated the two joysticks on the remote console (based in Shanghai). Then the remote control software and remote connection software takes the endoscopist's input and translates it into a control signal. After network transmission, the patient side cart (based in Yinchuan) translates the control signal into actual instrument manipulation and mobilize the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric and duodenum examination. Meanwhile, the images captured by the capsule are simultaneously sent back to the screen of the remote console, and thus provide guidance for better control of the capsule.
214369168|NCT04670692|OTHER|MCE examination|The endoscopist (W.Z.) performs the MCE examination procedure conventionally. And communicate with the volunteer face to face in the same examination room.
214369169|NCT01919203|DRUG|Remifentanil|The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
214369170|NCT05291780|RADIATION|Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures.~Participants will SABR once a day for 5 days, Monday through Friday (around 1 week)."
214369171|NCT01287130|DRUG|Cetuximab|Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
214369172|NCT01287130|DRUG|AZD6244|Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
214369173|NCT02221167|OTHER|Donor Milk|"breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk comes in."
214492839|NCT06811506|PROCEDURE|Reduced size patella component|The same procedure of patella resurfacing as control group was done, then 3 mm reduced size patella component was used in the intervention group.
214492840|NCT02828202|OTHER|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
214492841|NCT02828202|OTHER|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
214492842|NCT02828202|OTHER|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
214492843|NCT06894706|BEHAVIORAL|Control （CON） group|Both groups were given arthroscopy and meniscoplasty. After operation, the control group received active knee flexion and extension exercise, ankle pump training, quadriceps muscle training and other routine rehabilitation training.
214492844|NCT06894706|BEHAVIORAL|Functional exercise training (FET) group|Patients in the observation group were supplemented with neuromuscular training on the basis of routine rehabilitation training, and received rehabilitation education before training. The patients were informed of the specific content, frequency, expected effect and importance of training in various forms such as on-site demonstration combined with publicity brochures and playing videos, so as to improve patient cooperation.
214492845|NCT05501600|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using an electric nerve stimulator.
214492846|NCT05501600|DRUG|Lidocaine IV|Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
214680951|NCT03802422|DRUG|Normal saline|Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
214680952|NCT05451121|DRUG|Propofol|patient sedation with a propofol (sedative agent) after cardiac surgery
214680953|NCT05451121|DRUG|Dexmedetomidine|patient sedation with dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) after cardiac surgery
214982535|NCT04780399|DRUG|Placebo|72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
214680954|NCT05451121|DRUG|Propofol and dexmedetomidine|Patients sedation with a drug combination: propofol and dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist)
214982536|NCT01559168|DEVICE|UpholdTM LITE placement|Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
214982537|NCT01068236|BEHAVIORAL|Healthy lifestyle managment|Exercise, yoga, food diaries, provider consultation
214982538|NCT00218413|BIOLOGICAL|NicVAX|100 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
214982539|NCT00218413|BIOLOGICAL|NicVAX|200 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
214982540|NCT00218413|BIOLOGICAL|NicVAX|200 μg, Formulation B, on Days 0, 21, 42m 91 \& 182
214982541|NCT00218413|BIOLOGICAL|NicVAX|300 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
214982542|NCT00218413|BIOLOGICAL|NicVAX|400 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
215088295|NCT01611051|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
215088296|NCT01611051|DRUG|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
214982543|NCT00420745|BIOLOGICAL|Rotarix™|Two-dose oral vaccination.
215088297|NCT00360932|DEVICE|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
215088298|NCT00308165|PROCEDURE|Convection-Enhanced Delivery|microinfusion pumps to deliver chemotherapy directly into brain tumors
215088299|NCT00308165|DRUG|Topotecan|chemotherapeutic drug for the treatment of brain tumors
214369174|NCT04235335|BEHAVIORAL|Indigenous Mother's Empowerment Program & Indigenous Kid's Club Program|Weekly groups administered to mothers and children simultaneously but separately for 10 weeks
214369175|NCT06437379|BEHAVIORAL|Infection control|To evaluate the effect of implementing teaching protocol on nurse's knowledge and practice regarding infection control measures for patients undergoing Percutaneous Nephrolithotomy.
214369176|NCT00286117|DRUG|Anastrozole|oral
214369177|NCT00286117|DRUG|Tamoxifen|oral
214369178|NCT01387555|BIOLOGICAL|JX-594 recombinant vaccina GM-CSF|Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
214369179|NCT01387555|OTHER|Best Supportive Care|Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
214492847|NCT06423157|OTHER|Intervention|The intervention period will last 6 weeks, with a periodicity of 2 weekly sessions of 20 minutes each. All interventions will take place at the Palacio de los Deportes de Murcia. All interventions will be carried out by the same physiotherapist, following the same protocol. The intervention of the experimental group will consist of a protocol using plyometric and stability exercises.
214369180|NCT01691833|DIETARY_SUPPLEMENT|Vitamin D|Patients that are Vitamin D deficient and randomized to the treatment group will receive a 10,000 IU dose of Vitamin D.
214492848|NCT05147909|DIETARY_SUPPLEMENT|Sodium Phosphate|Sodium Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium)
214492849|NCT05147909|DIETARY_SUPPLEMENT|Sodium Chloride|Sodium Chloride 2 capsules daily (NaCl, containing a total of 372mg of sodium)
214492850|NCT06777342|BEHAVIORAL|Cognitive behavioral therapy intervention|The cognitive behavioral intervention provides sleep-related education 7-14 days before surgery. The educational content should include the following aspects: 1) Establish a consistent bedtime and wake-up time, recommending a sleep schedule from 22:00 to 07:00, and avoid prolonged daytime naps; 2) Optimize the sleep environment by ensuring a quiet setting, turning off lights, and refraining from using mobile phones, computers, and other electronic devices 30 minutes before bedtime; 3) Manage diet by avoiding caffeinated foods such as chocolate, tea, and cola; 4) Engage in appropriate daytime activities as permitted by the patient's condition.
214492851|NCT06777342|DIETARY_SUPPLEMENT|Melatonin intervention|Patients in the melatonin intervention group are required to take an oral melatonin of 5 mg at 30-60 minutes before sleep (administered at 21:00) nightly for 7 to 14 days before surgery. The melatonin was provided by Kangenbei Pharmaceutical Co., LTD. (Hangzhou, Zhejiang, China).
214492852|NCT06777342|OTHER|Placebo intervention|Patients in the placebo group need to take oral placebos of 5 mg at 30-60 minutes (administered at 21:00) before sleep, nightly, for 7 to 14 days before surgery. The placebo is provided by Guangzhou Boji Biomedical Science Park Co., LTD. (Guangzhou, Guangdong, China).
214492853|NCT06759402|BEHAVIORAL|Family based treatment|FBT is an intensive, manualized therapy in which the parents of those affected are closely involved in a resource-oriented manner by FBT-certified therapists. FBT takes place in 3 phases: in phase 1, the parents take responsibility for their child's weight gain. Phase 2 involves the gradual transfer of responsibility for eating back to the patient. Phase 3 focuses on individual issues of the children and adolescents, e.g. catching up on important developmental steps missed due to the illness.
214982544|NCT00420745|BIOLOGICAL|Placebo|Two-dose oral administration
214982545|NCT03515408|DEVICE|rTMS|The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
214982546|NCT00818935|DIETARY_SUPPLEMENT|Low-Intermediate-Glycemic Index diets|
214982547|NCT00818935|DIETARY_SUPPLEMENT|High GI diet|
214982548|NCT04512495|OTHER|Blood samples will be collected at two times :|"* at Baseline,~* after surgery or at the time of post-chemotherapy evaluation."
214982549|NCT02037087|BEHAVIORAL|Good household prenatal practice|Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
214982550|NCT02037087|BEHAVIORAL|Care seeking|"* Danger-sign recognition~* Reminders for government projects"
214982551|NCT02037087|BEHAVIORAL|Full bank of SMS|"* Danger-sign recognition~* Reminders for government projects~* Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression"
214982552|NCT04828499|PROCEDURE|Progressive Cracking Technique|Performing the cataract surgery with our phaco chop-progressive cracking technique.
214369181|NCT01691833|DIETARY_SUPPLEMENT|Placebo|Patients that are Vitamin D deficient maybe randomized to the placebo group D.
214369182|NCT04857203|DIAGNOSTIC_TEST|Vitamin D|Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer
214369183|NCT03496519|DRUG|Dose Escalation of Durvalumab and Trabectedin|"There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.~* Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2~* Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~* Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~* Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~* Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
214369184|NCT03496519|DRUG|Dose Expansion of Durvalumab and Trabectedin|There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
214369185|NCT02826200|DRUG|Acenocoumarol|Standard of care plus oral anticoagulant therapy (acenocoumarol)
214982553|NCT04828499|PROCEDURE|Conventional Chop Technique|Performing the cataract surgery with Conventional Chop Technique.
214369186|NCT02826200|OTHER|Standard of care|Standard of care
214982554|NCT04596319|BIOLOGICAL|AP-PA02|Bacteriophage administered via inhalation
214369187|NCT04610931|BEHAVIORAL|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.~In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level."
214369188|NCT04610931|BEHAVIORAL|cognitive behavior therapy|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups."
214369189|NCT01080222|DRUG|telaprevir|tablet, 1125-mg, twice daily
214982555|NCT04596319|OTHER|Placebo|Inactive Placebo administered via inhalation
214369190|NCT01080222|DRUG|VX-222|capsule, 100-mg, twice daily
214369191|NCT01080222|DRUG|ribavirin|tablet, 1000-mg for subjects weighing \<75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
214369192|NCT01080222|BIOLOGICAL|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
214982556|NCT00247234|BEHAVIORAL|Schema Therapy|group based schema therapy
214369193|NCT01080222|DRUG|VX-222|capsule, 400-mg, twice daily
214492854|NCT06759402|BEHAVIORAL|Inpatient multimodal therapy|comprehensive, patient-oriented and multidisciplinary approach to address eating disorders following the S3 joint German treatment guidelines in specialized hospitals. Includes individual psychotherapy, family sessions, body-oriented therapy, nutritional counseling, group therapy sessions, relaxation techniques, mindfulness practices, and skills training. Targeted weight gain per week is at least 500g.
214982557|NCT00247234|BEHAVIORAL|standard care|standard psychiatric out-patient care
214982558|NCT02609490|DRUG|Azilsartan tablets|20mg/tablet
214982559|NCT02609490|DRUG|Azilsartan placebo tablets|placebo tablet
214369194|NCT03462615|DIAGNOSTIC_TEST|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
214369195|NCT03019874|DIETARY_SUPPLEMENT|Cranberry Extract|3 x Cystorenal Cranberry plus daily for 6 months (contains 300 mg Cranberry-Extract, 100 mg Pumpkin seeds-Extract, 20 mg Vitamin C und 0,47 mg Riboflavin)
214492855|NCT05589831|DEVICE|Non-invasive Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist (NAVA) is a new non-invasive ventilation mode that uses the electrical activity of the diaphragm (EAdi) to offer ventilatory assistance in synchrony with patient effort, thus potentially reducing stress and discomfort. It uses electrodes placed on a modified nasogastric feeding tube to detect the electrical activity of the diaphragm (EAdi), such that both the initiation and termination of a breath during each respiratory cycle is in synchrony with the infant's effort
214680955|NCT04328064|DRUG|Rosuvastatin calcium 40mg|Active drug -Rosuvastatin
214680956|NCT04328064|DRUG|Placebo oral tablet|40 mg placebo for 12 months
214680957|NCT06041672|BEHAVIORAL|Warm Water Hand Baths|"1. Patients in the experimental group receive warm water hand baths as an intervention on the evening before surgery.~2. The intervention is carried out in the patient's room, room temperature was adjusted to 26°C and the timing is determined based on the patient's preference.~3. The study utilizes a foldable water bucket with temperature maintenance capability.Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes in a comfortable lying position."
214680958|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
214982560|NCT02609490|DRUG|Olmesartan medoxomil tablets|20mg/tablet
214982561|NCT02609490|DRUG|olmesartan medoxomil placebo tablets|placebo tablet
214982562|NCT03437967|DEVICE|LightForce EXPi|LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
214982563|NCT01125930|DRUG|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
214982564|NCT01125930|DRUG|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
214982565|NCT04192682|DRUG|Anlotinib Hydrochloride|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
214982566|NCT04472572|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients with COVID-19 infection
214369196|NCT04951674|OTHER|High fiber diet|30 grams of fiber per day
214369197|NCT04951674|OTHER|Control diet|No diet education and change in diet
214369198|NCT03956290|BEHAVIORAL|TREAT pilot intervention|Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
214982567|NCT03051711|DRUG|GBT440|Capsules which contain GBT440 drug substance in Swedish Orange
214982568|NCT05669157|PROCEDURE|Radiography request by nurse|Intervention group with radiography requested by the IRN instead of the physician. The radiography will be interpreted by the physician afterwards, according to current practice
214982569|NCT05669157|PROCEDURE|Radiography request by physician|The physician prescribed the X-ray, the X-ray technician carries out the imagery and the physician interprets it afterwards
214369199|NCT03865966|OTHER||No intervention
214982570|NCT06470581|DRUG|Botulinum toxin A|Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin type A 75 IU mixed with 3 ml of non-preserved saline solution are injected in the patients in the control and botulinum toxin groups, respectively.
214982571|NCT02491762|PROCEDURE|respiratory function tests|FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
214982572|NCT06516224|OTHER|Liftactiv® B3 Serum|In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
214982573|NCT06516224|OTHER|Liftactiv® B3 retinol night cream|In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
214982574|NCT06516224|OTHER|Sunscreen UVAage® Inter SPF 50+|twice daily (morning and beginning of the afternoon)
214982575|NCT06516224|OTHER|Mineral 89 cream|2 drops in the morning before sunscreen application for 6 months
214982576|NCT03371550|DRUG|Docetaxel|Induction chemotherapy
214982577|NCT03371550|RADIATION|concomitant radiotherapy|Pulmonary and mediastinal radiotherapy
214982578|NCT03371550|DRUG|Cisplatin|Induction chemotherapy
214982579|NCT02934685|RADIATION|hypofraction|70 Gy in 28 fractions over 5.6 weeks
214982580|NCT02934685|RADIATION|convention|80Gy in 40 fractions over 8 weeks
214369200|NCT03319537|DRUG|pevonedistat|Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.
214982581|NCT01715831|DRUG|DMARDs|DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
214982582|NCT01715831|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
214982583|NCT02111018|DEVICE|CytoSorb Device|
214982584|NCT02111018|PROCEDURE|CVVH|
214982585|NCT04140448|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML
215094530|NCT06217419|DEVICE|Radio Frequency IDentification (RFID) device|"RFID devices monitor breathing patterns by means of temperature measurements of the respiratory airflow. The temperature gradient of the air flow in and out of the airways can be correlated to the flow-based respiratory patterns. Accordingly, a temperature-based breath monitoring can be achieved by means of on-skin RFID sensors attached below the nose. Finally, a bilateral measurement of nostrils respiratory flow can provide more information since nasal cavities do not behave in the same way during a respiratory cycle.~In this project we will evaluate the possibility to perform domestic breath flow analysis by exploiting thin, lightweight and battery-less sensing plasters directly attached under the nose. The system includes a proper external reader interrogating the face sensors that is capable to directly communicate with smartphone/pc/tablet/cloud environment."
215094531|NCT00617955|DRUG|Aprotinin|compare outcomes of Aprotinin versus Amicar
214369201|NCT03319537|DRUG|Pemetrexed and cisplatin|Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
214369202|NCT00430053|GENETIC|gene rearrangement analysis|
214369203|NCT00430053|GENETIC|polymerase chain reaction|
214369204|NCT00430053|GENETIC|proteomic profiling|
214369205|NCT00430053|OTHER|flow cytometry|
214369206|NCT00430053|OTHER|immunohistochemistry staining method|
214369207|NCT00430053|PROCEDURE|biopsy|
214369208|NCT00314314|DRUG|Intranasal Insulin|Intranasal spray; 40 IU qid; 8 weeks
214369209|NCT00314314|DRUG|Diluent|Intranasal spray; 8 weeks
214680959|NCT01505491|DRUG|BI695501|BI 695501 single s.c injection
214680960|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
214982586|NCT04140448|DEVICE|Ultra-wide Fluorescein Angiography|Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
214982587|NCT05729958|DIAGNOSTIC_TEST|CT scan|CT scan of the involved ankle
214982588|NCT03052777|BEHAVIORAL|Telephone counselling|The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
214982589|NCT03799861|OTHER|Epoch 2: HBB with NeoBeat|At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.
214982590|NCT03799861|OTHER|Epoch 3: HR-guided HBB|At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
214369210|NCT04307706|BEHAVIORAL|Acceptance and Commitment Therapy|The Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in six sessions. The duration of each session lasted on average 60-90 minutes. A session was held for each parent once a week.
214982591|NCT03804619|DEVICE|Accelerated intermittent theta-burst stimulation (aiTBS)|aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
214982592|NCT03257579|OTHER|90 Day Supply|Policy Change implementing a 90 day standardized discharge prescription form with 3 repeats for all cardiac medications available on all wards where MI patients are managed at Hamilton Health Sciences sites
214982593|NCT03257579|BEHAVIORAL|Education|Education Alone provided at St. Joseph's Hospital and Niagara Health System
214982594|NCT00150696|DRUG|Risedronate|
214680961|NCT05415956|BEHAVIORAL|Walking exercise therapy|Moderate-to-high intensity walking exercise therapy (7 weeks, 14 session) with progression in duration and intensity.
214982595|NCT03563222|DRUG|Smoflipid|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
215094532|NCT00617955|DRUG|Amicar|compare outcomes of Aprotinin versus Amicar
214369211|NCT00846105|OTHER|Rapid MRSA PCR test for screening carriers|In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
214982596|NCT03563222|DRUG|Intralipid, 20%|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
214982597|NCT03502824|DEVICE|PuraPly® Antimicrobial Wound Matrix|PuraPly® AM is a class II medical device, that has been 510(k) cleared by US Food and Drug Administration (FDA) (K051647) and is intended for the management of acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.
215094533|NCT01477008|DEVICE|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
214680962|NCT04964830|DEVICE|Orthodontic treatment with functional appliance (MAD)|Expansion plate and z-activator (MAD)
215094534|NCT01477008|PROCEDURE|Marrow Stimulation|Microfracture or Subchondral Drilling
215094535|NCT01576185|OTHER|laboratory biomarker analysis|Correlative studies
215094536|NCT01576185|DRUG|quizartinib|Via gavage
215094537|NCT01576185|DRUG|sorafenib tosylate|Via gavage
215094538|NCT04187742|BEHAVIORAL|Social Comparison Email vs. Standard Email|Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
214369212|NCT02826122|DEVICE|Pai APP|Prescription: Target 100 PAI Points per week
214369213|NCT02826122|DEVICE|FitBit APP|Prescription: Target daily 10.000 steps
214369214|NCT00779389|DRUG|Erlotinib|Erlotinib 150mg will be taken once a day for 14-21days.
214369215|NCT00779389|DRUG|Dasatinib + Placebo|Dasatinib (100 mg) once a day for 14-21 days.
214680963|NCT02629523|DRUG|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
214680964|NCT05601999|BIOLOGICAL|GNR-060|GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus
214680965|NCT05601999|BIOLOGICAL|Metalyse|Metalyse will be administered in an individual dose depending on body weight as a single intravenous bolus
214680966|NCT02759146|OTHER|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
214680967|NCT02759146|OTHER|Meditative Practices|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
214369216|NCT00779389|DRUG|Erlotinib plus Dasatinib|Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
214369217|NCT00779389|DRUG|Placebo|Placebo for 14-21 days.
214369218|NCT00779389|DRUG|Erlotinib|Erlotinib 150 mg for 14-21 days.
214369219|NCT00146250|DRUG|Nitrous oxide|Substitution of Nitrous oxide for Nitrogen as balance gas in inspired gas mixture
214369220|NCT02787707|DRUG|Persumac|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
214369221|NCT02787707|DRUG|lactose|2.7 grams Lactose every 8 hour
214680968|NCT03237832|DRUG|ARN-6039|Ascending doses per Cohort
214680969|NCT03237832|OTHER|Placebo|Placebo to match ARN-6039
214982598|NCT03502824|OTHER|SOC for Pressure Ulcers|SOC group will receive institutional standard of care which includes, but is not limited to, debridement, negative pressure wound therapy (i.e. VAC), ensuring perfusion and oxygenation, evaluating nutritional status and addressing deficits, offloading, keeping the ulcer bed moist with appropriate cleansing at the time of each dressing change. Standard dressings may include hydrocolloids, alginates, transparent film, foam, moist gauze dressings. In addition, a non-toxic topical antiseptic, may be used per NPUAP Clinical Practice Guidelines (2014) for SOC group only, if colonization is suspected.
214982599|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
214982600|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
214982601|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
214982602|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
214982603|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
214982604|NCT03098979|DRUG|Placebo|Orally once daily for 20 weeks
214982605|NCT03598296|OTHER|Large size tube|Patients in Group A are inserted the large size tube (28F).
214982606|NCT03598296|OTHER|Drainage ball|Patients in Group B are inserted the small-bore tube connects with a negative pressure ball(drainage ball).
214369222|NCT00024492|DRUG|Liposome Encapsulated Mitoxantrone (LEM)|
214982607|NCT02426684|DRUG|IdeS® (Imlifidase)|0.24mg/kg IdeS
214982608|NCT00146068|DRUG|Avonex/Zocor|
214982609|NCT05598567|OTHER|target controlled infusion - total intravenous general anesthesia|Both interventions are subtypes of general anesthesia.
214982610|NCT05598567|OTHER|sevoflurane based balanced general anesthesia|Both interventions are subtypes of general anesthesia.
214492856|NCT06513663|BEHAVIORAL|Exercise Intervention|"Eligible and consented participants randomized to the exercise arm will work with an exercise trainer three times weekly for 12 weeks. Training sessions will be delivered virtually using HIPPA Complaint IU Health Zoom. These sessions will last 60 minutes and include cardiovascular exercise, resistance training, and balance or stretching exercise. The participants will be able to use any equipment they already have at home but will be provided a heart monitor and a set of resistance bands.~All sessions will have a moderate-intensity training goal, defined as 40-80% of heart rate reserve (HRR). Cardiovascular exercise will include any at-home equipment available to the participants or follow a Tabata-style program. Resistance training will include a full body workout, emphasizing all major muscle groups. Trainers will progress or regress intensity levels based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session."
214680970|NCT06518109|OTHER|Zarit Caregiver Burden Scale|The Zarit Caregiver Burden Scale (ZCBS) is a widely used instrument for assessing the burden experienced by caregivers of individuals requiring long-term care. It consists of 22 items and the total score ranges from 0 to 88 (low/no burden to severe burden)
214982611|NCT03736967|DRUG|REGN3500|Administered subcutaneous (SC) every 2 weeks (q2w)
215094539|NCT04187742|BEHAVIORAL|Maintenance Certification Email vs. Standard Email|Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
214369223|NCT04413292|DIAGNOSTIC_TEST|ELISA assays and Westren blot analysis of survivin and fibulin-3 expression|expression analysis of biomarkers
214982612|NCT03736967|DRUG|Dupilumab|Administered SC q2w
214982613|NCT03736967|DRUG|REGN3500 + Dupilumab Combo|Administered SC q2w
214982614|NCT03736967|DRUG|Placebo|Administered SC q2w
214982615|NCT03810443|DIAGNOSTIC_TEST|Hyperventilation test|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
214982616|NCT02369653|DRUG|Apixaban|
214982617|NCT02369653|OTHER|No systemic anticoagulant prophylaxis|
214982618|NCT00259831|DRUG|CVT-E002 (Cold-FX); a natural health product|
214982619|NCT05634291|OTHER|Standard of care|Standard of care as prescribed by healthcare provider.
214982620|NCT05634291|DEVICE|Nottingham AR smartphone app with active intervention|AR software treatment delivered by smartphone app and developed by VRx Medical (VRx) using established principles of illusion therapies (e.g. mirror therapy) for pain management.
214982621|NCT05877989|DRUG|Amino Acid|Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
214982622|NCT05877989|PROCEDURE|Physical exercise|The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
214982623|NCT00194376|PROCEDURE|Continuous positive airway pressure ventilation|CPAP ventilation is a therapeutic modality which uses positive pressure of air through a sealed nasal mask to treat a condition known as sleep apnea
214982624|NCT02271178|OTHER|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
214982625|NCT02271178|OTHER|Conventional therapy|Usual therapy
214982626|NCT02419807|DRUG|Indocyanine Green Solution|Given subdermally
214982627|NCT02419807|RADIATION|Technetium Tc-99m Sulfur Colloid|Given via injection
214369224|NCT02091479|DRUG|UFH Early group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
214982628|NCT02419807|PROCEDURE|Lymphoscintigraphy|This is a method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.
214369225|NCT02091479|DRUG|UFH Late group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
214982629|NCT02419807|PROCEDURE|Axillary Lymph Node Biopsy|Undergo biopsy
214982630|NCT03847493|OTHER|Endothelial Glycocalyx|Non-invasive assessment of endothelial glycocalyx dimensions.
214982631|NCT05092087|BEHAVIORAL|nutrition counseling|nutrition counseling
214982632|NCT00883727|DRUG|Stem cell|IV infusion of stem cells
214982633|NCT00883727|DRUG|Plasmalyte A|IV infusion
214982634|NCT02623192|OTHER|Patients who have performed the ARDS pulmonary function test|
214982635|NCT04989933|PROCEDURE|Ultrasound-guided erector spinae plane block|Ultrasound-Guided erector spinae plane block with 0.25% bupivacaine
215088300|NCT05780918|OTHER|Best Case/Worst Case-ICU Communication Tool|"This intervention uses scenario planning and a daily report of the interplay between major events and prognosis to illustrate a range of long-term outcomes and treatment experiences. By using a graphic aid to illustrate what we are hoping for, what we are worried about, and the evolution of the patient's story over time, the tool aims to facilitate dialogue among older adult trauma patients, their families, and the trauma team. Because the tool delivers critical prognostic information over the longitudinal course of care, subsequent treatment decisions can be made within the context of the patient's overall health status. This information alerts patients and families to the life-limiting nature of serious injury and provides an entrée for them to consider how comfort-focused strategies might better align with patients' end-of-life goals.~All clinicians will be trained to create, use, and/or reference the graphic aids with patients depending on their roles in the trauma ICU."
215088301|NCT05871996|OTHER|Palliative Care and Oncology Survey on Terminology (POST)|Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
214369226|NCT01410955|DIETARY_SUPPLEMENT|Probiotic formula|Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
214369227|NCT01410955|DIETARY_SUPPLEMENT|Placebo|Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
214492857|NCT04092192|DEVICE|IVC filter removal|"In the clinic, it will be explained to patient that they are asked to participate in a study that would randomize them to one of two established techniques for IVC filter removal. It will be explained these are both techniques that are used by interventional radiologists normally used for IVC filter retrieval.~One technique would be the utilization of an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.~The other technique described will be the usage of a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed."
214492858|NCT04663061|BEHAVIORAL|Medical weight loss|Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight
214492859|NCT04663061|BEHAVIORAL|Diabetes education|Participants will receive standard of care diabetes education
214982636|NCT05849857|DRUG|Mosunetuzumab|Mosunetuzumab is administered as a subcutaneous injection. The first dose is 5 mg in 0,5 mL volume, subsequent doses are 45 mg in 1,0 mL volume.
214982637|NCT02650739|PROCEDURE|Macular hole surgery|Vitrectomy with internal limiting membrane removal and gas tamponade
214982638|NCT04363476|OTHER|SHRED Osteoarthritis program|Combined exercise and education intervention
214492860|NCT04663061|BEHAVIORAL|Continuous glucose monitoring|Participants will use CGM devices to track blood glucose levels in near real time
214492861|NCT06029673|DRUG|Cabergoline 1 MG|Dopamine agonist
214492862|NCT06029673|DRUG|Placebo|Placebo
214492863|NCT05357989|DRUG|buntanetap/posiphen|HPMC (vegetarian source) capsule shells
214492864|NCT05357989|DRUG|Placebo|HPMC (vegetarian source) capsule shells
214492865|NCT05694715|DRUG|Niraparib|Given orally
214492866|NCT05694715|DRUG|Irinotecan|Given intravenously (IV)
214982639|NCT00425919|DRUG|PPM-204|
214982640|NCT04732793|DEVICE|Hyruan ONE®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
214982641|NCT04732793|DEVICE|Durolane®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
214982642|NCT05510453|OTHER|Low-intensity online intervention (LiON)|"The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills.~Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for 45 minutes. Participants will attend these sessions once a week.~The control group will receive the intervention after a waiting period of 4 weeks."
214982643|NCT01655875|DRUG|AMD3100|AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
214982644|NCT01353534|BIOLOGICAL|A/H5N1 Antigen|A/H5N1 Antigen
214982645|NCT01353534|DRUG|Vaccine Enhancement Patch|Vaccine Enhancement Patch
214982646|NCT01458587|DRUG|Aminolevulinic Acid PDT (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
215088302|NCT06204159|DEVICE|TACE Catheters|"End Hole and TriNav catheters are FDA approved. This study is comparing the two for chemotherapy delivery during the TACE procedure.~This study will randomize which catheter is used for the first TACE procedure and the other catheter will be used for the second TACE procedure"
214982647|NCT01458587|DRUG|Vehicle PDT (VEH)|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
214369228|NCT02695355|DRUG|Methylphenidate (MPH)|Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.
214369229|NCT00868465|DRUG|Artemether-Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h \[+/-90 min\] after the initiation of treatment). AL is currently the first line treatment in Tanzania
214369230|NCT00868465|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
214369231|NCT01258192|DRUG|albumin-bound paclitaxel plus cisplatin|neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
214369232|NCT04150991|OTHER|Fiber intervention|Each subject will supplement his/her normal dietary intake with 35 grams of dietary fiber daily for three consecutive weeks.
214369233|NCT04150991|OTHER|Placebo treatment|Each subject will supplement his/her normal dietary intake with an 18.53-g maltodextrin placebo daily for three consecutive weeks.
214369234|NCT04336748|DRUG|Hydroxychloroquine|low dose (200mg) Hydroxychloroquine once daily for 4 weeks
214369235|NCT04336748|DRUG|Placebo|Placebo
214369236|NCT05939921|DRUG|Metformin|T2DM patients will be provided with metformin in a specified dose
214369237|NCT03389152|DEVICE|Elastography|liver stiffness measurements by shear wave-based elastography
214492867|NCT05853055|PROCEDURE|Respiratory training|Respiratory training will be included in the rehabilitation program of a subgroup of post-COVID-19 patients. The intervention group will train twice daily for the length of their rehabilitation stay using an incentive spirometer (Voldyne 5000 R, Sherwood Medical, St. Louis, USA). Subjects will be instructed to first completely exhale slowly. Then inspire slowly up to 70% of their vital capacity, producing a constant flow controlled via feedback from the device. This procedure will be repeated every 30 s (paced by a metronome) for 15 min. The training will be conducted twice a day, resulting in a total of 60 inspirations per day.
214492868|NCT02609750|OTHER|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
214492869|NCT02609750|OTHER|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
214492870|NCT05169112|DRUG|Lupron Depot|Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months
214492871|NCT06892353|DIAGNOSTIC_TEST|AI-powered fundus camera screening|All the participants will undertake an AI-powered fundus camera screening, physician/optometrist consultation, survey with questionnaires and a phone interview three months after their baseline assessment.
214492872|NCT06736587|DRUG|DWP212525 10mg|DWP212525 10mg
214492873|NCT06736587|DRUG|DWP212525 30mg|DWP212525 30mg
214492874|NCT06736587|DRUG|DWP212525 50mg|DWP212525 50mg
214492875|NCT06736587|DRUG|DWP212525 100mg|DWP212525 100mg
214492876|NCT06736587|DRUG|DWP212525 200mg|DWP212525 200mg
214492877|NCT06736587|DRUG|DWP212525 400mg|DWP212525 400mg
215088303|NCT02993042|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
214492878|NCT06736587|DRUG|DWP212525 placebo|DWP212525 placebo
214492879|NCT06818721|DRUG|Intravitreal topotecan|Patients who meet all inclusion criteria and none of the exclusion criteria will receive intravitreal topotecan (8 µg in 0.05 mL). The treatment will be administered within one week before retinal detachment surgery (pneumatic retinopexy, pars plana vitrectomy, and/or scleral buckling) and one week after surgery, for a total of two injections.
214492880|NCT06818721|PROCEDURE|Retinal detachment surgery|Standard retinal detachment surgery (pneumatic retinopexy, three-port pars plana vitrectomy, and/or scleral buckling).
214492881|NCT06664242|DEVICE|Placebo|these patients will be subjected to the same usual routine of pharmacological analgesia, consisting of the administration of 1g of dipyrone at the discretion, with escalation to tramal (dose) and physiotherapy in the hospital ICU, in addition to an application of TENS, with the device turned on, with programming on channels that are not connected to the patients, so as to generate visual and auditory feedback.
214982648|NCT03595098|BEHAVIORAL|Family Based Cognitive Behavioural Therapy|Family Based Cognitive Behavioural Therapy (FCBT) focuses on the interrelation between thought, emotion, and behaviour, Exposure and Response Prevention, family involvement, homework assignments, and formulating of specific goals for the child. The important, active components is Exposure and Response Prevention. It involves exposing the child to a feared object, situation or thought, and preventing the child from carrying out compulsions to show the child that distress/anxiety can decrease or disappear without performing rituals.
214982649|NCT03595098|BEHAVIORAL|Family Based Psychoeducation/Relaxation Training|Family-based Psychoeducation/Relaxation Training (FPRT) as an active control matches the experimental intervention as closely as possible, many elements of the control intervention are similar to FCBT. The main and intended difference between the two approaches is the absence of the Exposure and Response Prevention component, which is deemed the most effective treatment for OCD.
214982650|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
214982651|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
214982652|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
214982653|NCT03445169|DRUG|Belzutifan|Belzutifan Tablets
214369238|NCT05580848|PROCEDURE|Wrist arthroscopy|"Wrist arthroscopy is a minimally invasive endoscopic method that enables the diagnosis and treatment of certain diseases and injuries of the radiocarpal, mediocarpal and distal radioulnar joints.~Wrist arthroscopy enables a direct view of the articular surface of the wrist and the assessment and adequate treatment of articular fractures The wrist arthroscopy procedure also enables the detection and necessary treatment of associated soft tissue injuries (scapho-lunate and/or luno-triquetral ligament, i.e. triangular fibrocartilaginous complex) and/or cartilage lesions in extra-articular and articular fractures."
214982654|NCT01006629|BIOLOGICAL|palivizumab|palivizumab 15 mg/kg intramuscularly
214982655|NCT00095329|BIOLOGICAL|sirolimus|
214982656|NCT01118299|DEVICE|AMPLATZER Cardiac Plug|AMPLATZER Cardiac Plug is a percutaneous transcatheter device
214982657|NCT02090881|OTHER|Ultrasound scan|Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
214982658|NCT04148404|PROCEDURE|Normothermic group|"1. Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~2. Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP)."
214982659|NCT01228045|DRUG|Trastuzumab in Combination with TS-ONE and cisplatin|Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
215088304|NCT06318611|OTHER|sleep, chronotype|Our objectives were to compare sleep health composite dimensions, and chronotype in children and adolescents with and without T1D, and to explore relationship between sleep and glycemic variability in T1D.
215088305|NCT00795834|DIETARY_SUPPLEMENT|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
215088306|NCT00795834|DIETARY_SUPPLEMENT|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
215088307|NCT02714881|DRUG|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
214369239|NCT00816465|DIETARY_SUPPLEMENT|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
214369240|NCT00816465|OTHER|Placebo|PO Placebo pill
214369241|NCT00983632|PROCEDURE|Selective vagus nerve stimulation|"Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.~For details see detailed study description"
214369242|NCT00983632|DEVICE|selective vagus nerve stimulation|electrical vagus stimulation
214369243|NCT00218881|PROCEDURE|HIV educational video|
214369244|NCT05691257|DRUG|Roxadustat|"The initial dose of roxadustat was given according to body weight, which was more than 60kg: 100mg (three times a week); Weight less than 60kg: 70mg (three times a week); 2 weeks later, the corresponding indexes were rechecked and medication was adjusted according to hemoglobin. The target is hemoglobin 100-120g/L.~Reference for medication Method: The use of roxadustat is the same as the RCT study of roxadustat in the treatment of anemia and the drug instructions of roxadustat published by N Engl J Med in 2019."
214369245|NCT05691257|DRUG|Recombinant human eythropoietin and/or Iron agents|Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
214369246|NCT01089374|RADIATION|Partial breast radiation after lumpectomy|Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
214369247|NCT01092403|DRUG|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
214369248|NCT01092403|DRUG|Placebo|Placebo once daily by inhalation
214369249|NCT02856113|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets.
214982660|NCT06190366|PROCEDURE|Bloodletting acupuncture at the fossa poplitea|This group is treated with bloodletting acupuncture at the fossa poplitea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
214982661|NCT06190366|PROCEDURE|Bloodletting acupuncture at the regio glutaea|This group is treated with bloodletting acupuncture at the regio glutaea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
214982662|NCT05255822|DRUG|INNA-051|Liquid for intra-nasal administration
215088308|NCT02714881|RADIATION|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
215088309|NCT00623662|OTHER|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
214369250|NCT02856113|DRUG|Placebo|Alogliptin placebo-matching tablets.
214369251|NCT04601558|BEHAVIORAL|The letters with the Cochrane abstracts in the form of blog-shots|"The active intervention were letters with the remainder on participant's own cardiovascular risk factors, a participant's own count of 10-year risk of cardiovascular disease, and Cochrane abstract in the form of blog-shots and personal advice in reducing cardiovascular disease risk.~There were three Cochrane blog-shots. The first was about calcium in prevention of high blood pressure, the second was about the effect of reducing saturated fat acids in eating habits and the third consisted evidence of green and black tea for the prevention of cardiovascular diseases.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
214369252|NCT04601558|BEHAVIORAL|The letters with remainder on cardiovascular risk factors|"The passive intervention were letters with the remainder on participant's own cardiovascular risk factors and participant's own count of 10-year risk of cardiovascular disease.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
214492882|NCT06664242|DEVICE|TENS low frequence group|Patients in this group will undergo the hospital usual analgesia and physiotherapy routine, in addition to conventional TENS with a low frequency of 5 Hz and a pulse width of 250 µs.
214492883|NCT06664242|DEVICE|Conventional TENS|In this group, patients will undergo the usual routine of analgesia and hospital physiotherapy, in addition to TENS with a frequency of 140 Hz, pulse width of 50 µs.
214492884|NCT06787846|OTHER|Experimental: Group TP|Serum : Application full face, twice daily, in the morning and at bedtime for 4 months and application Tinted sunscreen SPF 50+, twice a day
214492885|NCT06787846|DRUG|Active Comparator: Group HQ: Hydroquinone 4%|Cream : Application all over the face once a day (at bedtime) and Tinted sunscreen SPF 50+, twice a day
214492886|NCT06877468|BEHAVIORAL|Associative conditioning|Child is offered a vegetable to taste with a palatable dip, over 8 occasions. Vegetable is served at home by parent/caregiver following standard script.
214492887|NCT06877468|BEHAVIORAL|Modeling|Child is offered a vegetable to taste while their parent/caregiver also tastes it and models enjoying it, over 8 occasions. Vegetable is served at home with parent/caregiver following standard scripting.
215088310|NCT00623662|OTHER|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
215088311|NCT04248894|OTHER|Exercise training of High Intensity|High intensity
215088312|NCT04248894|OTHER|Exercise training of Moderate Intensity|Moderate intensity
215088313|NCT04248894|OTHER|Untraining|Sedentary
214369253|NCT04367038|OTHER|Warm Acupressure, Cold Acupressure , Conventional Acupressure|Acupressure is non-invasive, safe and effective.
214369254|NCT00311038|DRUG|ONO-1101|
214369255|NCT03494166|BEHAVIORAL|Start with SMSH+TIPC|See arm/group descriptions
214369256|NCT03494166|BEHAVIORAL|Start with SMSH alone|See arm/group descriptions
215088314|NCT02151331|BEHAVIORAL|External Facilitation|Non-responding sites randomized to receive external facilitation
215088315|NCT02151331|BEHAVIORAL|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
215088316|NCT04566653|DRUG|Calcium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
214492888|NCT06885801|DEVICE|use of an anatomically designed nasal conformer|this study will evaluate the use of a nasal conformer that has been designed to match the internal airway anatomy of the anterior nose rather than the standard hollow, conical conformer currently available on the market
214492889|NCT06745635|OTHER|Usual Care|Usual care for immunizations.
214492890|NCT06745635|OTHER|Multifaceted intervention|The multifaceted quality improvement intervention includes: video-based training on vaccine management in SUS, an optimized Cold Chain Manual schema, technical documents on proper vaccine handling and immunization schedules, and checklists for managing post-vaccination errors and corrective procedures. Videos will focus on six key points (right person, vaccine, dose, time, route, and documentation), with each lasting about 2 minutes and accessible on-demand. The Cold Chain schema will cover storage, monitoring, transport, conservation, and handling, with checklists for each category. Standardized technical documents will align with video themes, ensuring protocol adherence. An error identification and management schema will address issues like improper vaccine administration, cold chain violations, and incorrect dosages. This schema will be reviewed by staff and made available in health units.
214492891|NCT06773455|DRUG|tralokinumab|600mg at week 0 followed by 300mg Q2W for 24 weeks
214492892|NCT03422432|PROCEDURE|HIPEC|All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.
214492893|NCT01968109|BIOLOGICAL|Relatlimab|
214982663|NCT05255822|OTHER|Placebo|Liquid for intra-nasal administration
215088317|NCT04566653|DRUG|Lokelma® 5 g/45mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
215088318|NCT04566653|DRUG|Lokelma® 10 g/45 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
215088319|NCT04566653|DRUG|Veltassa® 8,4 g/80mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
215088320|NCT04566653|DRUG|Sodium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
215088321|NCT00002506|BIOLOGICAL|recombinant interferon alfa|
215088322|NCT00002506|DRUG|isotretinoin|
215088323|NCT04271475|DRUG|Macitentan|Participants will receive Macitentan film-coated tablets orally od.
214982664|NCT04459338|BIOLOGICAL|Exendin-9,39|Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor
214982665|NCT04459338|OTHER|Saline|Placebo comparator
214982666|NCT04942600|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
214982667|NCT03157089|DRUG|Afatinib|Film-coated tablet
214982668|NCT03157089|DRUG|pembrolizumab|Solution for infusion
214982669|NCT01506076|DRUG|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
214982670|NCT02932943|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
214982671|NCT02932943|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
214982672|NCT05622903|OTHER|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
214982673|NCT05622903|OTHER|No Cash Benefit|No monthly cash benefit.
214982674|NCT04661631|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound during the screening process for SARS-CoV-2 infection in patients with an indication for urgent surgery.
214982675|NCT00487591|DRUG|Omacor (omega-3-acid ethyl esters)plus simvastatin|Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
214982676|NCT00487591|DRUG|simvastatin plus placebo|simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
214982677|NCT00255385|DRUG|Micronutrient (Zinc and Iron) fortification|
214982678|NCT00255385|DRUG|Pre and Probiotic fortification|
214982679|NCT00250484|DEVICE|Transcranial Magnetic Stimulation|1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
214982680|NCT00250484|DEVICE|Sham Transcranial Magnetic Stimulation|Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
214982681|NCT01454284|DRUG|Glargine|
214982682|NCT01454284|DRUG|LY2605541|
214982683|NCT01454284|DRUG|Insulin Lispro|
214982684|NCT03661918|BEHAVIORAL|In-Person First Session|Conduct first session in person vs. over the phone
214982685|NCT03661918|BEHAVIORAL|Second Caregiver|Have second caregiver participate in three coaching calls
214982686|NCT03661918|BEHAVIORAL|WiFi-enabled Scale|Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale
214369257|NCT05969457|DRUG|Naropeine|Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg)
214982687|NCT03661918|BEHAVIORAL|10 Core Coaching Calls Only|Participant will receive 10 core phone coaching sessions
214982688|NCT04710121|OTHER|Virtual Reality Glasses|Virtual Reality Glasses (VRG), one of the methods of distracting attention; widely used in clinical medical care to relieve symptoms by providing the opportunity to create therapeutic environments for the evaluation and treatment of medical conditions. Virtual reality is a computer simulation technique that enables individuals to hear and feel the sounds and corresponding stimuli accompanying the visual image through headphones. The most basic feature that distinguishes virtual reality (VR) glasses from similar applications is that it gives individuals a real feeling. VR has helped to distract patients from mental processing and reduce the amount of pain. Virtual reality glasses, which are inexpensive to apply and use, do not cause side effects, and can be used in the recovery of the individual, are an intervention that can be preferred in nursing practices.
214982689|NCT06327594|DIAGNOSTIC_TEST|ultrasound scan|The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by ultrasound at multiple sites of the whole body, including muscle and fat.
214982690|NCT06327594|DIAGNOSTIC_TEST|CT/MRI scan|The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by abdominal CT/MRI.
214982691|NCT06167902|OTHER|Ginseng oligopeptide (Ginseng extract）|The experimental group was given ginseng oligopeptide preparation 1.2g per day orally.
214982692|NCT06167902|OTHER|Maltodextrin|The control group was treated with placebo maltodextrin 1.2g/d
214982693|NCT02356120|OTHER|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
214982694|NCT01022333|DIETARY_SUPPLEMENT|Diindolylmethane (DIM)|300 mg per day of DIM for six weeks.
214982695|NCT03686592|OTHER|Measurement of body awareness|Questionnaires+ interviews
214982696|NCT00163592|DRUG|Tissucol®|
214982697|NCT00163592|PROCEDURE|Control: Conventional treatment, i.e. compression with swabs|
214982698|NCT00574639|DRUG|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
214982699|NCT00574639|DRUG|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
214982700|NCT02017301|OTHER|Nutritional assessment|Daily nutritional assessment with bioelectrical impedance vector analysis, phase angle and mid-arm muscle circumference
214982701|NCT06026436|BIOLOGICAL|Blood samples|12-24 hours after P2Y12 ADP receptor loading dose (LD)
214982702|NCT06026436|BIOLOGICAL|Blood samples|1 month after Percutaneous Coronary Intervention (PCI)
215088324|NCT04271475|DRUG|Placebo|Participant will receive matching placebo tablets orally od.
215088325|NCT02745847|RADIATION|Re-irradiation with SBRT|Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
214369258|NCT05969457|OTHER|questionnaires|Numerical Rating scale Questionnaire FSFI Qustionnaire SF12 Questionnaire DN4
214369259|NCT05969457|OTHER|Placebo|Injection of 20 mL of NaCl
214492894|NCT01968109|BIOLOGICAL|Nivolumab|
214492895|NCT01968109|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab
214492896|NCT06723522|DEVICE|HD-tDCS|2 mA HD-tDCS of right inferior frontal gyrus lasting for 10 days, each stimulation lasted for 20 min, with 30 s of ramp-up and ramp-down before and after the 20-min stimulation, respectively.
214982703|NCT00546442|DRUG|Metformine|850-2550 mg/daily for 48 weeks
214982704|NCT00546442|OTHER|Placebo of metformine|850-2550 mg/daily for 48 weeks
214982705|NCT05706324|BIOLOGICAL|Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation|0.2mL/dose, Inhalation using a nebulizer
214982706|NCT00421278|DRUG|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
214982707|NCT03248037|DRUG|Netarsudil|netarsudil opthalmic solution 0.02%
214982708|NCT03248037|DRUG|Placebo|Placebo eye drops
214369260|NCT06579495|OTHER|Peer involvement in Two player mode(peer involvement) in Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
214369261|NCT06579495|OTHER|Single player mode in Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
214369262|NCT06579495|OTHER|Children did not engage in any Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
214369263|NCT02605564|OTHER|Gluten Free Diet|Gluten Free Diet
214369264|NCT02605564|OTHER|Placebo|Placebo No intervention, standard T1DM diet
214982709|NCT02300610|DRUG|Enzalutamide|Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
214982710|NCT02300610|DRUG|Cisplatin|Cisplatin at 70 mg/m\^2 IV on day 1, repeated every 21 days for total of 6 cycles.
214982711|NCT02300610|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m\^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
214982712|NCT02669875|DRUG|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
214982713|NCT02669875|DRUG|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
214982714|NCT01626066|DRUG|LUM015|LUM015 assigned dose given once by IV push
214982715|NCT01653691|PROCEDURE|Pulse-Dye Laser|Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
214982716|NCT01653691|PROCEDURE|Sham|No treatment to one side of subject's scar.
214982717|NCT04245761|DIETARY_SUPPLEMENT|Sonidor®|Sonidor® triple layer release tablets are developed with a specialized process to improve stability and bioavailability of the formulation based on hawthorn, lavender and hop extracts. The hawthorn, lavender and hop extracts used to product Sonidor® have an elevated content of vitexin (3%), monoterpens (4% as linalool) and flavonoids (4%), respectively.
214982718|NCT01995383|OTHER|LS followed by NS diet condition|LS diet period followed by NS diet period
214982719|NCT01995383|OTHER|NS followed by LS diet condition|NS diet period followed by LS diet period
214982720|NCT01995383|DRUG|Placebo|Single oral administrations
214982721|NCT01995383|DRUG|Placebo|2 single oral administrations
215088326|NCT04056780|OTHER|Sample collection study|Sample collection and collection of laboratory values
215088327|NCT07040163|DRUG|ketamine|This is the experimental intervention to be used as an alternative sedation method to the other comparator intervention (fentanyl).
215088328|NCT07040163|DRUG|fentanyl|This is the traditional (comparator) intervention used in interventional radiology procedure sedation.
214492897|NCT06723522|DEVICE|Sham (No Treatment)|Received 1 min of ramping up/down without experiencing 2 mA HD-tDCS stimulation lasted for 20 min.
214492899|NCT04039113|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
214492900|NCT04039113|OTHER|Placebo|Placebo subcutaneous injection
214982722|NCT01995383|DRUG|RO6836191|Orally administered, single ascending doses
214982723|NCT01995383|DRUG|RO6836191|2 single oral doses
215088329|NCT07040163|DRUG|Midazolam|Adjuvant administered in combination with either fentanyl (comparator) or ketamine (experimental).
215088330|NCT07041996|DIAGNOSTIC_TEST|Mobile-based SARC-F screening application|SARC-F mobile application as a digital health intervention for sarcopenia risk assessment.
215088331|NCT07041463|OTHER|Psychoeducation program coordinated by an APRN|"Individual and group psycho-education programs. Each investigating center will be trained in the same tools, in order to harmonize practices:~* BREF: This is a 3-session psycho-educational program in which each family is received individually by a pair of caregivers who are not involved in the patient's care.~* PEPs Caregiver: This is a group psycho-education program in 5 2-hour sessions developed in the coordinating center."
215088332|NCT07041463|OTHER|Usual Care|"The caregiver will benefit from the interventions and referrals provided for caregivers as usual at each center."
214982724|NCT01995383|DRUG|RO6836191|Intravenous administration
214982725|NCT04422886|DEVICE|active transcranial direct current stimulation (tDCS)|20 minutes at 2.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines)
214982726|NCT04422886|BEHAVIORAL|Physiotherapy|motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
214982727|NCT04422886|DEVICE|sham transcranial direct current stimulation (sham)|1 minutes at 1.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines) and 19 minutes with unit shut off and electrodes remaining on the scalp
214982728|NCT00968162|DRUG|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
214982729|NCT03824431|DIAGNOSTIC_TEST|Endoscopic esophageal biopsies|
214982730|NCT05460884|DIETARY_SUPPLEMENT|Seaweed extract LD and white bread|109g of white bread with 0.5g of seaweed extract
214982731|NCT05460884|DIETARY_SUPPLEMENT|Seaweed extract HD and white bread|109g of white bread with 1g of seaweed extract
214982732|NCT05460884|DIETARY_SUPPLEMENT|White bread|109g of white bread
214982733|NCT05983536|DIAGNOSTIC_TEST|HIV Ag +Ab Assay Kit (Sysmex)|Using the HIV Ag +Ab Assay Kit (Sysmex) to detect the HIV antigen and antibody in serum, then verified by Human Immunodeficiency Virus (HIV 1+2) Antibody Test Kit (Immunoimprinting). The specificity of the HIV Ag +Ab Assay Kit (Sysmex) is calculated according to the specificity calculation formula.
214982734|NCT01655160|BEHAVIORAL|MT with low-intensity group (MT-LI)|The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
214982735|NCT01655160|BEHAVIORAL|MT with moderate-intensity group|The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
215088333|NCT07040293|DEVICE|Absorbable bone wax for hemostasis in the osteotomy surface of the facet joint|"Following the enrollment of patients who underwent posterior lumbar decompression, intervertebral bone graft, and internal fixation surgery, a V-shaped osteotomy was executed at the facet joint contralateral to the decompression site, with 0.5g absorbable bone wax subsequently applied to the osteotomy surface."
215088334|NCT07040293|DEVICE|Traditional bone wax for hemostasis in the osteotomy surface of the facet joint|"Following the enrollment of patients who underwent posterior lumbar decompression, intervertebral bone graft fusion, and internal fixation surgery, a V-shaped osteotomy was executed at the facet joint contralateral to the decompression site, with 0.5g traditional bone wax subsequently applied to the osteotomy surface."
214982736|NCT01655160|BEHAVIORAL|Mirror therapy with high intensity group|The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
214982737|NCT01655160|BEHAVIORAL|Control intervention group|The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
214982738|NCT00207168|BEHAVIORAL|Compliance|
214982739|NCT02943122|DEVICE|Ambulatory blood pressure monitor|
214982740|NCT04214743|DEVICE|Incident dark field videomicroscope from Braedius|It allows to look at conjunctival microcirculation
214982741|NCT04214743|DEVICE|Fundus camera from Optomed|It allows to monitor retinal microvasculature
214982742|NCT04018066|DIETARY_SUPPLEMENT|GP-SPI|grape polyphenol-soy protein isolate complex (GP-SPI)
214982743|NCT04979871|PROCEDURE|Venous bleeding|Blood samples collected 5 times with approx. 2-4 weeks interval
214982744|NCT04222491|DRUG|Peanut oral immunotherapy|Peanut oral immunotherapy for peanut allergy
214982745|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
214982746|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
214982747|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
214982748|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
214369265|NCT04605848|DIAGNOSTIC_TEST|Infrared themrography|measurement of temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test
214492901|NCT06725017|DRUG|Live SK08 powder|SK08 is an investigational live biotherapeutic product containing a nontoxigenic B. fragilis(NTBF) strain as an active ingredient.
214369266|NCT06006988|COMBINATION_PRODUCT|myoton pro|MyotonPRO is a mobile, removable handheld myotonometer. This tool is noninvasive and provides a quantitative assessment of a muscle's viscoelastic properties. These properties are characterized by various parameters such as hardness, tone and elasticity. The probe of MyotonPRO delivers a short (15 ms), low intensity (0.58 N) mechanical impact/impact on the skin on the muscle. The response of the touch then generates a recorded signal and an internal software program generates an acceleration graph. Measurements of various viscoelastic muscle properties such as stiffness, tone and elasticity are then extracted from this graph.
214492902|NCT06725017|DRUG|Placebo|Placebo
214492903|NCT05634005|BEHAVIORAL|Clinical Decision Support|In blood product order entry within the electronic health record, the ordering provider is required to select an indication for the blood product order. If the patient's laboratory values are not in line with the guideline indication selected, a clinical decision support alert will fire and be shown to the ordering provider. This alert will inform the provider that the order is outside institutional guidelines and the provider has the option to cancel the order (or bypass the order and select a reason for proceeding with the order).
214492904|NCT06752252|PROCEDURE|ultrasound guided paravertebral block|after sterilization and identifying the level of T10 ,linear ultrasound probe will be placed in the midline over the spinous process at the chosen level, then the probe will be moved laterally to view the lamina and hyperechoic transverse process ,the pleural should be visible as a bright white line .The needle should be inserted in -plane from lateral to medial and the needle tip should end in a hypoechoic triangular space. Correct needle placement should be confirmed by anterior displacement of pleura with injection of small volume of saline then 0.5 ml/kg of a mixture of 0.25 ℅ bupivacaine and 1℅ lidocaine (1:1) will be injected
214492905|NCT06752252|PROCEDURE|Ultrasound guided erector spinae plane block|After sterilization, the linear ultrasound probe will be placed over transverse process of T10 ,after optimizing the image in sagittal or transverse scanning ,A 50 mm 22-G needle will be placed under the erector spinae muscle in -in plane orientation until it contacted T8 transverse process in the cranial caudal direction ,after hydro dissection and confirmation that the tip of the needle is between the transverse process and the fascia of the erector spinae muscle group, 0.5 ml/kg of a mixture of 0.25 ℅bupivacaine and 1℅ lidocaine (1:1) will be injected
214492906|NCT06752252|PROCEDURE|control group C|will receive standard general anesthesia with pain management protocol without regional block.
214492907|NCT06825455|DRUG|Fludarabine|Intravenous infusion group:30mg/m2 x 3 days (Day-4\~-2)
214492908|NCT06825455|DRUG|Cyclophosphamide|Intravenous infusion group:500mg/m2 x 3 days (Day-4\~-2)
214492909|NCT06825455|BIOLOGICAL|B7H3 CAR-γδT cells|A single infusion of 6.0×107 CAR+ cells, 2.0×108CAR+ cells, and 6.0×108CAR+ cells
214492910|NCT06864429|PROCEDURE|Radiofrequency catheter ablation|Radiofrequency (RF) catheter ablation is a minimally invasive procedure that targets and eliminates certain types of cardiac arrhythmias. RF became effective as the first-line treatment for ventricular arrhythmias in some circumstances.
214492911|NCT06860802|DRUG|Cefoxitin|Cefoxitin 2000 mg Bolus Injection
214492912|NCT06870045|OTHER|Physical examination|The physical examination will included Timed Up and Go Test (TUG), Walking speed, Wong-Baker FACES Pain Scale, Pediatric balance scale and CHAQ (Childhood Health Assessment Questionnaire).
214492913|NCT06870045|OTHER|Dynamic Gait Index|The DGI, whose validity and reliability will be investigated, consists of 8 items: walking on level ground, walking with changing speed, walking with sideways head turns, walking with vertical head turns, walking with pivot turns, walking over obstacles, going around obstacles, and climbing stairs. Performance on each item is rated on a 4-point scale ranging from 0 (severe impairment) to 3 (normal walking ability without a walking aid). The total score is 24. Scores below 19 indicate a risk of falling, while scores above 22 define safe ambulation.
214492914|NCT06085300|BEHAVIORAL|Sentence recast|Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax .
214492915|NCT02298348|DRUG|Sorafenib|Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
214492916|NCT02298348|DRUG|Cyclophosphamide|250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
214492917|NCT02298348|DRUG|Topotecan|0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
214680971|NCT01204840|DRUG|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
214982749|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
214982750|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
214982751|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
214982752|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
214982753|NCT02779569|DRUG|decitabine|
214982754|NCT02739893|PROCEDURE|Scope Guide Assist|"Olympus has developed a new instrument which provides physicians a real-time, three dimensional visualization of position and configuration during colonoscopy. The Olympus ScopeGuide technology has received FDA clearance and can be used within the United States. The new technology called the 'scopeguide' has been developed that uses magnetic coils embedded into the scope to create a 3 D image of the shape of the entire scope inside the body that is projected onto the monitor to see. This acts as a GPS and shows the advancement of the scope through bends providing information on loops and thereby eliminating chances of loop formation, helping in loop reduction and also reducing the number of external maneuvers that may be required for the completion of colonoscopy."
214369267|NCT03376815|DIAGNOSTIC_TEST|landscape sample method|200 cases of different tumor tissues will be compared by traditional sample method and landscape sample method to testify the clinical value and significance of tumor landscape pathological diagnosis .
214982755|NCT02739893|PROCEDURE|Standard procedure for colonoscopy|
214982756|NCT02924155|DRUG|SJP002|"1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: SJP002, Topical administered one drops to each eye (Once a day)~  * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"
214982757|NCT02924155|DRUG|Placebo|"1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: Placebo, Topical administered one drops to each eye (Once a day)~  * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"
214982758|NCT01027156|BEHAVIORAL|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
214982759|NCT02230163|BIOLOGICAL|anti-CHIKV hyperimmune immunoglobulins|Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.
214982760|NCT03817528|DRUG|ITI-007|ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events
214982761|NCT06293833|RADIATION|Low-dose CT scan|Participants get an annual low-dose CT scan in UZA
214982762|NCT06293833|BEHAVIORAL|Smoking Cessation|Smoking cessation campagnes
214982763|NCT05122481|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C (also known as ascorbic acid and ascorbate) is a vitamin found in various foods and sold as a dietary supplement.Vitamin C is a water-soluble vitamin, with dietary excesses not absorbed, and excesses in the blood rapidly excreted in the urine, so it exhibits remarkably low acute toxicity. More than one gram may cause indigestion, flatulence and stomach pain.
214369268|NCT01694732|DRUG|Varenicline|
214369269|NCT01694732|DRUG|placebo|
214369270|NCT02390726|BIOLOGICAL|Fecal Microbiota Transplant|
214369271|NCT02390726|BIOLOGICAL|Placebo|
214369272|NCT01645748|DRUG|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
214369273|NCT01645748|DRUG|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
214369274|NCT01645748|DRUG|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
214369275|NCT02857426|DRUG|Nivolumab|
214369276|NCT01487980|PROCEDURE|Cord clamping|Early vs Delayed
214492918|NCT03263546|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (ICBT)|"Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks."
214982764|NCT03181308|DRUG|Carotuximab (TRC105)|Anti Endoglin Antibody
214982765|NCT03181308|DRUG|OPDIVO|Programmed Death Receptor-1
214982766|NCT04284254|DRUG|Autologous Plasmablasts|"Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.~Phase 1:~* Dose Level 1: 5 x 10e7 cells/kg on Day 0~* Dose Level 2: 1 x 10e8 cells/kg on Day 0~* Dose Level 3: 1 x 10e8 cells/kg x 2 doses on Day 0 and Day 30 +/-3 days.~Phase 2:~\- Maximum Tolerated Dose (MTD) established in Phase I"
214982767|NCT04568655|DEVICE|noninvasive ventilation|noninvasive ventilation to support the COVID-19 patients with respiratory failure
214982768|NCT00912366|PROCEDURE|Lobectomy|Assessment of VATS versus open surgery.
214982769|NCT04794257|DEVICE|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
214982770|NCT02484677|DRUG|Cisplatin|Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
214982771|NCT02484677|DRUG|Docetaxel|Taxanes. Blood sampling for pharmacokinetic evaluation
214982772|NCT02484677|DRUG|5-Fluorouracile|Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
214982773|NCT00033280|DRUG|temozolomide|
214982774|NCT00033280|PROCEDURE|neoadjuvant therapy|
214982775|NCT00033280|RADIATION|radiation therapy|
214982776|NCT05348252|OTHER|Patient Journey App|The group will receive all information and insctructions on discontinuing PPI use through the Patient Journey App which timely deliveres all information.
214982777|NCT05348252|OTHER|Information folder|The group will receive all information and instructions on discontinuing PPI use through an information folder.
214982778|NCT03530891|PROCEDURE|Computer guided lag screw fixation|Under general anaesthesia: Patient specific pre operative prefabricated surgical guide will be used intra operative for open reduction and internal fixation for anterior mandibular fracture using lag screws.
214982779|NCT03530891|PROCEDURE|Conventional lag screw fixation|Under general anaesthesia: Open reduction and internal fixation for anterior mandibular fracture utilising lag screws.
214982780|NCT05446285|OTHER|Clinical assessment|All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)
214982781|NCT03635918|DEVICE|NightOwl HSAT|Patient wears the NightOwl sensor device
214982782|NCT03177395|DRUG|PP100-01 (calmangafodipir)|PP100-01
214982783|NCT03177395|DRUG|Acetylcysteine|NAC
214982784|NCT02606812|DIETARY_SUPPLEMENT|Traditional-food|Intake of ethnic local food
214982785|NCT04078386|BIOLOGICAL|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 24 times.
214369277|NCT03782311|BEHAVIORAL|motivation and and oral hygiene instructions|Motivation and oral hygiene instructions were received OHSE-high and OHSE-low groups. After showing the modified-Bass tooth brushing technique and interdental cleaning on the model, patients were followed up while brushing and flossing their teeth to correct misapplications. It was advised to brush teeth twice a day and use the interdental cleaning devices once a day.
214982786|NCT04078386|BIOLOGICAL|RC18 240 mg|Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
214982787|NCT04078386|BIOLOGICAL|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
214982788|NCT03398096|DEVICE|Cardiac shock wave therapy|Ultrasound guided cardiac shock wave therapy (CSWT) is a new treatment method offering an alternative to revascularization by stimulating angiogenesis. Subsequent clinical trials showed that CSWT could reduce symptoms of myocardial ischemia and improve cardiac function in patients with severe coronary artery disease.
214982789|NCT05021653|OTHER|no intervention|No intervention involved
214982790|NCT01099046|BEHAVIORAL|Lifestyle|water intake, tympanic tubing, regular sleep
214982791|NCT00170443|BIOLOGICAL|rHAO Trivalent Influenza Vaccine|
214982792|NCT02360332|BEHAVIORAL|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
214982793|NCT00880126|BEHAVIORAL|Community Development Teams|CDTs bring together counties who are implementing a new practice
214982794|NCT03139500|DRUG|JNJ-61803534|Participants will receive JNJ-61803534 tablets orally.
214369278|NCT01733108|DRUG|Glyburide|One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.
214369279|NCT01733108|DRUG|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
214369280|NCT05462535|DRUG|Amosartan Plus Tab.|Amosartan Plus Tab., Once daily administered per the locally approved product information
214369281|NCT01155154|DRUG|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
214369282|NCT01155154|DRUG|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
214369283|NCT01155154|DRUG|placebo|Two placebo capsules every 6 hours for 7 days
214982795|NCT03139500|DRUG|Placebo|Participants will receive matching placebo.
214982796|NCT03139500|DRUG|Midazolam|Participants will receive single oral dose of midazolam.
214982797|NCT01259245|OTHER|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
214982798|NCT01259245|OTHER|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
214982799|NCT01146483|DRUG|Rosuvastatin, Pantoprazole|"Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study."
214982800|NCT04638062|OTHER|1.Post Isometric Relaxation|"For Upper Trapezius In supine position Neck flexion, contra-lateral full side bending followed by slight ipsilateral rotation will be provided towards the side being treated. while asking the patient to shrug the stabilized shoulder and contraction will be maintained for 7- 10s. Repeating it 3-5 times.~For Levator Scapulae Step One In supine position while lifting the patients neck in full flexion, lateral flexion and rotation with 7-10s isometric contraction away from side to be treated will be provided.~Step Two The patient will be instructed to take head backwards to the table while at the same time asking the patient to slightly shrug the shoulder and resistance will be provided. Repeating it 3-5 times.~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
215088335|NCT07040553|BEHAVIORAL|Motivational Interviewing and WhatsApp Support|This intervention consists of weekly face-to-face motivational interviews and supportive WhatsApp messages, delivered over 8 weeks. It is based on the principles of Motivational Interviewing (Miller \& Rollnick, 2012) and aims to support symptom management and emotion regulation in participants with moderate to severe premenstrual syndrome.
214680972|NCT01204840|DRUG|Patch protocol|"Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped."
214680973|NCT03695523|BEHAVIORAL|PLAY (PhysicaL ActivitY) Policy Intervention|An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
214680974|NCT02432001|PROCEDURE|Image-Guided Biopsies|
215088336|NCT07041788|DRUG|Iparomlimab and Tuvonralimab Injection|"Induction Therapy:~Spatially Fractionated Radiotherapy: Administer 10-20 Gy in a single fraction to the tumor.~Chemotherapy + Immunotherapy:~Docetaxel 75 mg/m² IV on Day 1. Cisplatin 25 mg/m² IV on Days 1-3. Iparomlimab and Tuvonralimab Injection 5 mg/kg IV on Day 1. Cycles: Every 3 weeks (Q3W) for 3 cycles.~Maintenance Therapy:~Begin 4-6 weeks after radiotherapy completion.~Iparomlimab and Tuvonralimab:~Dose: 5 mg/kg diluted in 100 mL 0.9% NaCl or 5% glucose. Administration: IV infusion over ≥20 minutes (total duration including flushing ≤60 minutes).~Cycles: Q3W for 14 cycles (maximum 1 year).~Iparomlimab and Tuvonralimab Injection:~Continue until disease progression, intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of consent, or investigator decision to discontinue.~Maximum treatment duration: 1 year."
215088337|NCT07041710|OTHER|experimental in day hospital|multidisciplinary day hospital
215088338|NCT07041710|OTHER|taste and smell disorders questionnaire|Answer to the home-made questionnaire at inclusion and at 6 months
215088339|NCT07042204|PROCEDURE|Group I (extended platelet-rich fibrin)|mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group
215088340|NCT07042204|PROCEDURE|Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)|bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)
215088341|NCT07042204|PROCEDURE|Group III (bioactive glass nanoparticles and covered by a collagen membrane)|bioactive glass nanoparticles and covered by a collagen membrane
215088342|NCT07041645|DIETARY_SUPPLEMENT|Vitamin K|each participant will recive one dose of each of the four vitamin K vitamers but in different orders (4 different orders).
215088343|NCT07040865|DRUG|Gadobutrol (Gadovist/Gadavist)|Magnetic resonance acquisition without contrast agent followed the same acquisition 60 s and 15 min after gadobutrol contrast injection.
215088344|NCT07040865|DRUG|Gadopiclenol|Magnetic resonance acquisition without contrast agent followed the same acquisition 60 s and 15 min after gadopiclenol contrast injection.
215088345|NCT07041502|OTHER|Aut-CARE|There is no intervention
215088346|NCT06736093|DRUG|Vitamin D3|Vitamin D3 60,000 IU given once weekly Pre Liver Transplant atleast for 6 weeks
215088347|NCT06736093|DRUG|Placebo|Placebo capsules once weekly for atleast 6 weeks pre liver transplant
215088348|NCT02965690|PROCEDURE|Zimmer Biomet NexGen CR|Total Knee Replacement
215088349|NCT02965690|PROCEDURE|Medacta International GMK Sphere|Total Knee Replacement
215088350|NCT06727552|BIOLOGICAL|Barzolvolimab|Subcutaneous Administration
215088351|NCT06727552|DRUG|Matching placebo|Subcutaneous Administration
214369284|NCT05602051|DEVICE|virtual reality device|mindfulness combined with virtual reality
214680975|NCT01397071|OTHER|Avocado|Fresh Avocado
214680976|NCT06012760|DRUG|Iron sucrose, Human Erythropoietin Injection, Vitamin C|The participants were administered a combined iron supplementation regimen consisting of iron sucrose,Human Erythropoietin Injection, and vitamin C, three times throughout the preoperative week.
214982801|NCT04638062|OTHER|1.Myofascial Release therapy|"For Upper Trapezius In sitting position Myofascial Release of Trapezius will be performed unilaterally with soft fist or elbow sinking and then taking up the line of tension from mid belly of Trapezius, to the acromion process, while the patient drops the head forward and will slowly rotate the head from side to side. While providing the resistance to contralateral side of rotation. Repeating for 2-3 times.~For Levator Scapulae In sitting position applying same unilateral muscle release as Trapezius, but the line of tension will be to the inferior border of Scapulae slightly laterally and will ask the patient to drop the head forward to increase resistance on Levator muscle. Repeating it 2-3 times~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
214982802|NCT00447083|DEVICE|UVB|UVB exposure by a tanning bed
214982803|NCT00447083|PROCEDURE|Non-UVB|Non-UVB exposure by a tanning bed
214982804|NCT03599960|DRUG|Chemotherapy|"* Idarubicin 12mg/m2 IV at D1~* Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):~  * Patients \<65y and albuminemia \>35 g/l and CrCl (MDRD)\>60 ml/min: 3000 mg/m²~ * Patients \<65y and albuminemia \<35 g/l and/or CrCl (MDRD) \<60 ml/min: 1000 mg/m² IV~ * Patients ≥65y and albuminemia \>35 g/l and CrCl (MDRD) \> 60 ml/min : 1000 mg/m²~ * Patients ≥ 65y and albuminemia \< 35 g/l and/or CrCl (MDRD) \< 60 ml/min : 500 mg/m²~* L-asparaginase (SPECTRILA) : 5000 units/m² IV at D2, 5, 8, 11 (switch to Erwinia asparaginase/Cirsantaspase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~* Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)"
214982805|NCT05321537|OTHER|Therapeutic exercises|A somatosensory training and an endurance-strength training protocol
214982806|NCT03442062|OTHER|Assessment Feedback Incentives and eXchange|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
214982807|NCT03442062|OTHER|Physician-to-physician engagement|Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
214982808|NCT03442062|OTHER|Active Intervention Control|Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
214982809|NCT06479902|PROCEDURE|Core stability exercise|Core stability exercises featured moves such as planks and side planks.
214982810|NCT06479902|PROCEDURE|Diaphragmatic Strengthening Exercise|. Diaphragmatic exercises included diaphragmatic breathing in various positions.
214982811|NCT05512559|DEVICE|body composition analysis|Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.
214982812|NCT05230901|OTHER|Standard of Care|Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).
214982813|NCT05230901|DRUG|Spironolactone 25mg|"Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication ."
214982814|NCT05230901|DRUG|Dihydralazine|"Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)"
214982815|NCT04361058|DRUG|Nivolumab|At Day +50 (±10 days) post-allogeneic SCT, participants will be treated with Nivolumab. Nivolumab will be administered intravenously once every two weeks for a total of 4 treatments. Participants will initially receive nivolumab at a significantly reduced starting dose of 0.25 mg/kg. This dose was determined based on the incidence of increased aGVHD, which was noted after treatment post-SCT in previous studies. Nivolumab IV will be given every 2 weeks for 4 cycles. One dose of nivolumab is equivalent to one cycle. The first administration will be at Day +50 (±10 days), assuming the participant has not had any evidence of Grade II-IV aGVHD after allogeneic SCT and does not have any current evidence of any grade of aGVHD at the day of first application of nivolumab. Depending on emerging safety data, dose escalation cohorts will explore higher dose levels of nivolumab at 0.5 mg/kg and 1 mg/kg.
214982816|NCT05185804|DRUG|Dimolegin|60 mg orally, 1 time per day
214982817|NCT05185804|DRUG|Clexane|40 mg subcutaneously, 1 time per day
214982818|NCT00822848|DRUG|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
214369285|NCT03098940|DRUG|Chewing Gum|During the study healthy subjects will receive single doses of the various strengths of dronabinol
214680977|NCT06012760|DRUG|Standard Medical Care|Standard Medical Care (SMC) for the treatment of IDA. SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
214680978|NCT06286787|OTHER|Intervention|The training programme will consist of a 3-hour lecture. The contents of the lecture will include knowledge of mountaineering in Hong Kong, country codes and care for the environment, environmental awareness when undertaking outdoor activities, hiking skills, knowledge and choice of hiking equipment and clothing, trip planning, mountain safety, map reading, the use of a compass, mountain safety, basic first aid, methods of calling for help in an emergency and sources of weather data. After completing the lecture, participants will be required to join a 6-day hiking training programme on weekends within a 3-month period (each training will be at least 5 kilometres and the duration will be at least 4 hours).
214982819|NCT00822848|DRUG|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
214982820|NCT00822848|DRUG|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
214982821|NCT00822848|OTHER|immunoenzyme technique|
214982822|NCT00822848|OTHER|immunohistochemistry staining method|
214982823|NCT00822848|OTHER|laboratory biomarker analysis|
214982824|NCT00822848|PROCEDURE|adjuvant therapy|Preoperative administration has been the preference at our institution.
214982825|NCT00822848|PROCEDURE|neoadjuvant therapy|
214982826|NCT00822848|PROCEDURE|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
214982827|NCT00822848|RADIATION|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. \*Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
214982828|NCT00424242|DRUG|Pemetrexed|Orally beginning at 500 mg/m2 every 3 weeks until disease progression
214492919|NCT03263546|BEHAVIORAL|Cognitive behavioral therapy (CBT)|"Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks."
214982829|NCT04271215|OTHER|Chemotherapy protocol used|Chemotherapy protocol used in each participating hospital
214982830|NCT06228339|DRUG|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets (Test Drug)
214982831|NCT06228339|DRUG|Xatral® XL 10 mg|Xatral® XL 10 mg (Reference Drug)
214982832|NCT00855348|OTHER|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
214982833|NCT00023231|DRUG|Daclizumab|1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8
214982834|NCT00023231|DRUG|Methylprednisolone/prednisone|Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
214982835|NCT00023231|DRUG|Mycophenolate mofetil|Solution or oral tablet taken daily. Dosage depends on body surface area.
214982836|NCT00023231|DRUG|Sirolimus|Oral tablet taken once prior to transplant. Dosage dependent on body surface area.
214982837|NCT00023231|DRUG|Bactrim|Oral tablet taken three times per week. Dosage is dependent on weight.
214982838|NCT00023231|DRUG|Ganciclovir|Oral tablet taken daily. Dosage is dependent on weight.
214492920|NCT06827288|BEHAVIORAL|SUN|The SUN helps patients initiate buprenorphine treatment in the hospital, connects patients to follow-up care by facilitating appointments at outpatient clinics, addresses barriers to care, and serves as a resource for patients and clinicians. The SUN also advocates for a harm-reduction culture, models respectful interactions with people who use drugs and provides technical assistance to hospital staff to reduce stigma and discrimination.
214492921|NCT06827288|BEHAVIORAL|SUN + Telebridge|TeleBridge consists of an immediate telehealth connection to a buprenorphine provider affiliated with the CA Bridge program who has expertise facilitating pharmacotherapy with individuals with OUD. TeleBridge addresses barriers to initiation of buprenorphine by reducing long wait times and the inability of the outpatient setting to initiate treatment on demand. TeleBridge also eliminates the need for patients to meet system-level requirements (e.g. on time for appointments during working hours while wearing appropriate attire) to obtain follow-up care. TeleBridge is a more resource-intensive form of care because it involves developing formalized relationships with outpatient providers and implementing telehealth protocols. TeleBridge is feasible based on the increased use of telehealth to expand post-ED care pathways.
214680979|NCT06286787|OTHER|Placebo|Control participants will be asked to join six day-time leisure activities on weekends within a 3-month period. Leisure activities will be organised by the Asbury Methodist Social Service and will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and eating a healthy diet, and day visits to a museum and theme park. Children in the placebo control group will receive free access to leisure activities, including visits to museums and theme parks as an incentive for his/her participation.
214680980|NCT02680223|DEVICE|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
214982839|NCT00023231|DRUG|Lipitor|Oral tablet taken daily
214982840|NCT02171624|DRUG|dabigatran etexilate|
214982841|NCT02171624|DRUG|quinidine|
214982842|NCT03164642|BEHAVIORAL|LENA with Feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.
214982843|NCT03164642|BEHAVIORAL|LENA no feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
214982844|NCT00129831|DRUG|QAB149|
214982845|NCT00217490|BEHAVIORAL|dietary counseling via computer|An interactive computer program that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
214982846|NCT00217490|BEHAVIORAL|dietary counseling via nutritionist|A one on one counseling sessions to addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
214982847|NCT00217490|BEHAVIORAL|combined computer and nutritionist|An interactive computer program plus one on one nutrition counseling that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
214982848|NCT00217490|OTHER|physical activity counseling via computer|An interactive computer program that addresses increase to physical activity, barriers to change and possible solution to barriers to develop an action plan
215088352|NCT04401345|DRUG|Glycopyrrolate 0.2 MG/ML|In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
215088353|NCT04401345|DRUG|Normal saline|In this group, the patients will receive 1 ml of 0.9% normal saline
214982849|NCT02118623|BEHAVIORAL|Moderated discussion board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone.~The discussion boards will be moderated by research staff, who will be supervised by a trained clinician (masters levels or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
214982850|NCT02118623|BEHAVIORAL|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies."
214982851|NCT02118623|BEHAVIORAL|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviours, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
214680981|NCT02680223|DEVICE|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
214982852|NCT00526617|DRUG|ABT-888|Oral capsules
214982853|NCT00526617|DRUG|Temozolomide|Oral capsules
214982854|NCT01513655|DEVICE|LTNIV|LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
214982855|NCT06403657|OTHER|An enhanced model of hepatitis B testing and linkage to care|Implementing CME sessions (\<50 attendees) at Le Van Thinh Hospital will focus on preventive strategies for hepatitis B (HBV). We'll collaborate with IT to integrate a Best Practice Advisory (BPA) system into the hospital's electronic records for hepatitis B testing reminders. The system prompts healthcare workers when a patient lacks HBV screening notes, ensuring timely education and testing. Also, we'll introduce Point-of-Care (POC) HBsAg testing using SD Bioline HBsAg WB® for efficient screening and counseling, with follow-up to ensure care linkage within two weeks.
214982856|NCT00787878|DRUG|somatropin|SGA previously treated with Norditropin®
214982857|NCT00787878|DRUG|No treatment given|Untreated SGA
214680982|NCT00002452|DRUG|L-756423|
214680983|NCT00002452|DRUG|Indinavir sulfate|
214982858|NCT00787878|DRUG|No treatment given|AGA (Average gestational age)
214982859|NCT05989425|DRUG|surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
214982860|NCT06231524|OTHER|Analyse pathologic slides|HE-stained whole slide images were used for the validation of the PSN-AI model.
214982861|NCT02861313|DEVICE|CM LOC attachment|CM LOC attachment
214982862|NCT02861313|DEVICE|ball attachment|Ball attachment
214982863|NCT03282864|DEVICE|Bedroom air filtered by an air filtration device to remove airborne pollutants|The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
214982864|NCT06179459|PROCEDURE|Endoscopic management of pancreatic fluid collections|Patients with pancreatic fluid collections will be undergoing EUS-guided drainage and/or endoscopic necrosectomy
214982865|NCT03733964|PROCEDURE|Manual therapy|Manual therapy - the mobilisation of joint segments L4-L5 and L5-S1 and mobilisation techniques for soft tissues (functional massage of soft tissues and skin relaxation using the methods of stretching).
214982866|NCT03733964|PROCEDURE|PNF|The PNF method - the movement patterns of the scapulae and the pelvis were used (anterior and posterior elevations and depression) along with the patterns of upper extremities (e.g. bending, abduction, outward rotation) and lower extremities (e.g. bending, abduction, inward rotation with bending of the knee joint).
214982867|NCT03733964|PROCEDURE|Manual therapy + PNF|Combination therapy - Manual therapy and Proprioceptive Neuromuscular Facilitation
214982868|NCT03733964|PROCEDURE|Kinesiotherapy|Traditional kinesiotherapy in the form of active slow exercises of back muscles, abdominal and gluteal muscles on a mat. The patients participated in a uniform treatment programme consisting of ten exercises. Each of the exercises was performed in a number of 20 repetitions.
214982869|NCT04272229|DIAGNOSTIC_TEST|Cognition|Cognition tests will be performed with questionnaires, which will be applied to the main investigator. Stroop Color test, digit symbol substitution test, Addenbrooke's cognitive examination 3, mini-mental state examination, Montreal Cognitive Assessment, Trail Making Test A e B and Reaction time test will be performed to check the cognition in all volunteers.
215088354|NCT03397992|OTHER|Changing dialysate temperature|Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
214680984|NCT00851734|DRUG|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
214680985|NCT02469831|DRUG|Rocuronium|
214680986|NCT01943734|BEHAVIORAL|Information passed on anthropometric assessment|Information passed on worker's anthropometric assessment.
214680987|NCT02731391|PROCEDURE|Pelvic floor reconstruction（with or without mesh）|
214680988|NCT00828087|DRUG|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
214982870|NCT04272229|DIAGNOSTIC_TEST|Sympathetic Nervous System|The sympathetic activation will be evaluated by heart rate variability. Volunteers will have their hear rate recorded by a frequencymeter and the R-R interval will be analyzed to ch check the central nervous system activation during all cognitive tests.
214982871|NCT04272229|DIAGNOSTIC_TEST|Concentratio and Attention|Concentration and attention measures will be recorded with the MindWave headset during all cognitive tests. The EEG will be recorded with the MindWave and then alfa wave will be analized to check the attention and concentration levels.
214982872|NCT04115813|BEHAVIORAL|Project YES! Youth Engaging for Success|Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
214982873|NCT02363088|OTHER|Neutral text message reminder|"Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
214369286|NCT03761303|DEVICE|active rTMS|The rTMS coil is applied tangentially to the head surface above the left DLPF (corresponding to position F3 of the international 10-20 system). For the stimulation intensity, the motor rest threshold of the patient is determined. The motor rest threshold is defined as the minimum intensity that triggers an EMG response with an amplitude\> 50 μV in the first right interosseus dorsalis muscle in at least 5 out of 10 cases. The stimulation intensity within the rTMS therapy is 80 percent of the motor rest threshold. In one session, 1,000 pulses are applied in 10 trains at a frequency of 10 Hz (1 train = 100 pulses in 10 s). Between the individual trains there is an inter-train interval of 28 seconds. The total duration of a session is 5:52 minutes. In total, the patient recieve 20 sessions.
214982874|NCT02363088|OTHER|Messenger text message reminder|"\<GP NAME\>: Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
214982875|NCT02363088|OTHER|Social Norms A reminder|"Last year in Hillingdon 7 out of 10 women took part in cervical screening. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
214369287|NCT03761303|DEVICE|sham rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
214369288|NCT03771430|BEHAVIORAL|Osteoarthritis education, exercise and CBT|"Osteoarthritis Education~1. 60-min session by AktivA trained PT)~   * Signs/symptoms, risk factors, weight control, treatment~  * Importance of physical activity~  * Appropriate activity \& training modalities~   Exercise and CBT Support~2. 60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~   * Warm-up session~  * Strengthening exercises~  * Functional exercises~  * Stretching~  * Monitoring of CBT progress~  * Review of CBT lessons learned~  * Integration of CBT skills~  * Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~* Pain causes \& prevention~* Pain management~* Health promotion \& stress reduction at home \& work~* Adapting for leisure \& work~* Controlling flare-ups~* Maintaining \& improving results"
214369289|NCT03771430|PROCEDURE|Total Knee Arthroplasty|Standard total knee arthroplasty will be performed.
214982876|NCT02363088|OTHER|Social Norms B reminder|"Last year 12000 women in Hillingdon took part in cervical screening. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
214982877|NCT02363088|OTHER|Framed Gain text reminder|"Cervical cancer screening saves 4500 lives in England every year. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
214982878|NCT02363088|OTHER|Framed Loss text reminder|"Failing to attend cervical screening could lead to 4500 avoidable deaths in England each year. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
214982879|NCT04256200|DRUG|Dienogest 2 MG Oral Tablet|Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg
214982880|NCT04256200|DRUG|Yasmin|0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
214982881|NCT02196129|DRUG|Sinbaro-3|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
214982882|NCT02196129|DRUG|Hwangryun|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
214982883|NCT03271697|DRUG|Astragalus Membranaceus|This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
214982884|NCT03271697|DRUG|Placebo|as a comparator comparing with AM group
214982885|NCT05141253|DRUG|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
214982886|NCT03689517|OTHER|placebo|participants took placebos (pills made by starch) that were told to be an effective analgesic.
214982887|NCT03689517|DEVICE|orthodontic elastic separators|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.
214982888|NCT00568971|DRUG|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
214680989|NCT00828087|DEVICE|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
214680990|NCT00139854|DRUG|Alprazolam orally disintegrating tablets|
214982889|NCT05363202|DRUG|Fluticasone propionate Inhalation Aerosol 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
214982890|NCT05363202|DRUG|FLOVENT HFA 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
214982891|NCT05363202|DRUG|Matching Placebo inhaler|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
214982892|NCT06232343|OTHER|Parachute Resistance Training|The training programmed duration is of four weeks.The groups will follow the training programmed three times a week. The daily schedule (training group) included four repetitions of maximum intensity 30 m \& 50 m dashes (4 × 30 m, 4 × 50 m). The duration of recovery time between the 30 m \& 50 m runs will be 4 and 6 minutes respectively. Between the last 30 m dash and the first 50 m dash, a 10-minute recovery will be applied. Moreover, sprint speed training should not exceed 400-500 meters in total . To this end, the training programmed of the present study consisted of 4x30m and 4x50m runs, at a frequency of 3 times a week.
214982893|NCT06232343|OTHER|Sprinters|control group perform sprinters without any external resistance training for four weeks.
214982894|NCT02346318|DRUG|Compound Kushen Injection|Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
214982895|NCT02760303|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.
214982896|NCT02760303|BEHAVIORAL|Mindfulness Based Stress Reduction|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.
214982897|NCT02760303|BEHAVIORAL|Diabetes Support and Education|Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
214982898|NCT02640560|OTHER|Food allergy questionnaire|The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
214680991|NCT03389061|DRUG|sofosbuvir/velpatasvir tablet|Single-dose SOF/VEL as a whole tablet in a fasted state.
214680992|NCT03389061|DRUG|sofosbuvir/velpatasvir crushed|Single-dose crushed SOF/VEL in a fasted state.
214680993|NCT02000986|BEHAVIORAL|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy|Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
214680994|NCT04220632|DRUG|Itacitinib|at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
214982899|NCT02640560|OTHER|Control Questionnaire|The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
214982900|NCT02833909|OTHER|surgery|
214982901|NCT06163859|BEHAVIORAL|Intervention Group|FCHVs will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. FCHVs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'.
214982902|NCT04226157|DEVICE|Home Blood Pressure Monitoring Device (Qardio Arm)|The Home Blood Pressure Device with telemonitoring capability will allow the participants and physician to monitor blood pressure over time and titrate blood pressure medications as needed for persistently elevated blood pressure.
214982903|NCT04226157|OTHER|Primary Care Provider Blood Pressure Management|Participant will follow up as would normally do with primary care provider for blood pressure management.
214982904|NCT02423408|DRUG|TNX-201|TNX-201 capsule
214982905|NCT02423408|DRUG|Placebo|Placebo capsule
214982906|NCT01462942|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
214982907|NCT01462942|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
214680995|NCT04220632|DRUG|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
214680996|NCT04220632|DRUG|Methylprednisolone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
214982908|NCT01462942|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
214982909|NCT01462942|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
214982910|NCT01462942|DRUG|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
214680997|NCT01063751|DEVICE|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell in total hip replacement.
214982911|NCT05696067|BIOLOGICAL|Corfluvec component 1 low dose|Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
214982912|NCT05696067|BIOLOGICAL|Corfluvec component 2 low dose|Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
214982913|NCT05696067|BIOLOGICAL|Corfluvec component 1 high dose|Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
214982914|NCT05696067|BIOLOGICAL|Corfluvec component 2 high dose|Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
214982915|NCT05696067|BIOLOGICAL|Corfluvec low dose|Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
214982916|NCT05696067|BIOLOGICAL|Corfluvec high dose|Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
214982917|NCT05696067|BIOLOGICAL|Placebo|Participants will receive two intranasal injections of placebo three weeks apart
214982918|NCT01027845|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
214982919|NCT01027845|BIOLOGICAL|DTPa|Subcutaneous injection, 4 doses
214982920|NCT06424808|OTHER|Consolidating content on a single website and providing access to it via QR codes in a brochure format|The group assigned to the experimental group will receive information in the same manner as current patients do, with the addition of receiving a brochure once when moving to a general ward after surgery. Afterward, they are free to use the brochure. The control group will receive information only in the manner currently provided to patients.
214982921|NCT04573270|BIOLOGICAL|PrimePro|Intravenous Injection
214982922|NCT04573270|OTHER|Placebo|Intravenous Injection
214369290|NCT03367507|BEHAVIORAL|Sub-symptom aerobic exercise|Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.
214369291|NCT05009303|DEVICE|OneStep Smartphone App and C-Mill Treadmill|OneStep technology is a smartphone application that utilizes smartphone sensors to provide ongoing gait diagnostics. Each participant will have two sessions, during which, they will walk on a C-Mill smart treadmill for up to 15 minutes (with a minimum of 2 minutes), while carrying 2 smartphones and being recorded via two video cameras. The second walking session, conducted under similar conditions, will be used for test-retest reliability.
214369292|NCT02524392|OTHER|Independent medical evaluation|The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
214369293|NCT04093674|PROCEDURE|de-epithelized (DE) SCTG|subepithelial connective tissue grafts
214369294|NCT04889001|OTHER|Simulation enhanced HBB training|Simulation enhanced HBB is a one-day course delivered using a format of Explain, Demonstrate and Facilitate practice. Compared to the standard HBB training, the simulation enhanced HBB course is designed with increased peer-to-peer feedback and scripted expert facilitator feedback at HBB practice exercises.
214492922|NCT06827288|BEHAVIORAL|ED-ITT|Enrolled patients who have not filled an outpatient buprenorphine (BUP) prescription at 30 days, return to the ED with an OUD-related event, or self-report nonadherence to the prescribed BUP are considered non-responders, and randomly assigned to a second stage intervention. For non-responders randomized to receive ongoing BUP treatment by an ED-based interim treatment team (ED-ITT), the SUN and Site PI (an ED physician with expertise in addiction medicine) will meet weekly to review the SUN's caseload, using a patient registry that has been modified for the trial. The registry: 1) prompts/documents proactive SUN outreach up to 3 additional months for non-responders, with an emphasis on prioritizing subsequent outreach to patients who have not yet engaged with outpatient care, or who are at risk of dropping out if the patient have transitioned; and 2) documents when the ED provider prescribes transitional BUP and when the patient would be due for a new prescription.
214492923|NCT06827288|BEHAVIORAL|ED-ITT + BHS|Enrolled patients who have not filled an outpatient buprenorphine (BUP) prescription at 30 days, return to the ED with an OUD-related event, or self-report to the SUN nonadherence to the prescribed BUP will be considered non-responders, and randomly assigned to a second stage intervention. For non-responders randomized to receive ongoing BUP treatment from the ED-ITT+BHS, Behavioral Health Support (BHS) will be added to ED-ITT and include a weekly caseload review with an externally-affiliated psychiatrist with expertise in addiction medicine who will make mental health and substance use treatment recommendations, both pharmacological and behavioral, to the ED provider and SUN for up to 3 months. The consultant may also ask the SUN to do a more detailed behavioral health assessment, if insufficient information is available to make treatment recommendations. All prescriptions will be written by the ED provider.
214492924|NCT06748820|BEHAVIORAL|Remote Therapeutic Patient Education (e-TPE)|TPE is a set of practices aiming at allowing a patient to acquire and preserve abilities and skills to manage actively their disease, cares, and surveillance, in collaboration with the caregivers
214492925|NCT06757114|OTHER|High altitude|High altitude is defined as a long-term residence with an altitude of 1500m and above
214492926|NCT06741592|DEVICE|EDDY Group|The EDDY activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.
214492927|NCT06741592|DEVICE|PUI Group|The passive ultrasonic activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.
214982923|NCT04568200|DRUG|Durvalumab|Durvalumab 1500mg i.v. day 1-22-43-64
214982924|NCT04568200|DRUG|Carboplatin|Chemotherapy
214982925|NCT04568200|DRUG|Paclitaxel|Chemotherapy
214982926|NCT04568200|RADIATION|Radiotherapy 23 x 1.8 Gy|Radiotherapy 23 x 1.8 Gy
214982927|NCT05612321|DEVICE|Vacuum application|vacuum-assisted delivery
214369295|NCT04788901|OTHER|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
214369296|NCT05453968|DRUG|Berotralstat|Administered orally once daily at a weight-based dose in up to 4 cohorts
214369297|NCT05634044|DEVICE|eNose Device|Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.
214369298|NCT00448890|DRUG|GSK729327|Tablets
214369299|NCT00448890|DRUG|Placebo|GSK729327 Matching placebo - Tablets
214680998|NCT00614666|DRUG|nikkomycin Z|"Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~* 50 mg BID (n=4) vs placebo capsule BID (n=1)~* 50 mg BID (n=4) vs 250 mg BID (n=4) vs Placebo capsule BID (n=2)~* 250 mg BID (n=4) vs 500 mg BID (n=4) vs Placebo capsule BID (n=2)~* 500 mg BID (n=4) vs Placebo capsule BID (n=1)~At least 4 subjects complete lower dose before randomization includes next higher dose.~Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization."
214680999|NCT00614666|DRUG|Placebo|Placebo comparator
214982928|NCT00012116|DRUG|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
214982929|NCT04020562|OTHER|Mild Resistive Expiratory Technique|"Mild Resistive Expiratory Technique (EMST150- five-week training protocol):~The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for five weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
214982930|NCT04020562|OTHER|Conventional Training|"Breathing exercise: Deep breathing 10-15 repetitions twice a day. Assistive Coughing: 5-6 repetitions twice a day. ROM Exercises: Both active and passive limb ROM exercises 10-15 repetitions twice a day.~Sustained stretching: Both upper and lower limbs, 10 repetitions, held for 5 seconds, twice a day.~Splinting: According to patient's injury level Bracing: According to patient's injury level Functional Mobility: Mobilizing patient according to injury level Tilt table standing: 10-15 minutes once a day"
214982931|NCT02891512|OTHER|ELF|Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
214982932|NCT02891512|OTHER|Xinepa®|2 tablets of Xinepa daily (morning and evening) for 1 month.
214982933|NCT02891512|OTHER|Placebo Xinepa®|2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
214982934|NCT00005925|DRUG|Muscimol|
214982935|NCT00225875|DRUG|Mabthéra|
214982936|NCT05001607|DEVICE|Bronchial Blocker|Trial of four methods of pulmonary blockade; one novel method and three published methods.
214982937|NCT01231217|OTHER|Green tea (Camellia sinensis)|Patients are recommended to drink at least 5 cups of green tea per day
215088355|NCT00733135|DEVICE|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
215088356|NCT06506006|BIOLOGICAL|Covid infection|outcome with and without covid infection
215088357|NCT04542460|PROCEDURE|PCI|"A loop recorder is implanted i all patients in both study groups to investigate:~* Prevalence and severity of cardiac arrhythmias.~* Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI.~* Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI.~* Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI.~* Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI."
214369300|NCT02110901|DRUG|PRT-201|
214369301|NCT02110901|DRUG|Placebo|
214369302|NCT05024669|COMBINATION_PRODUCT|Gluma desensitiser|Gluma desensitiser was used before restoration.
214982938|NCT01231217|OTHER|Coffee|Patients are recommended to drink as much coffee as they tolerate.
214982939|NCT00918983|DRUG|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
214982940|NCT00918983|DRUG|Placebo|Single intraprostatic injection of placebo
214982941|NCT05459415|PROCEDURE|Reducing Excision Margins|Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy
214369303|NCT05024669|COMBINATION_PRODUCT|Sheildforce Plus desensitiser|Sheildforce Plus desensitiser was used before restoration.
214369304|NCT05024669|COMBINATION_PRODUCT|Telio CS desensitiser|Telio CS desensitiser was used before restoration.
214369305|NCT06173375|DIAGNOSTIC_TEST|Cologuard|Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.
214369306|NCT06173375|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.
214369307|NCT02522143|BEHAVIORAL|Informational sessions describing BPD characteristics|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
214369308|NCT02522143|BEHAVIORAL|Condensed-DBT treatment intervention|The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
214369309|NCT05414539|OTHER|OptiCogs Online|A multicomponent intervention to rehabilitate cognitive deficits in people post-stroke
214982942|NCT01308619|DRUG|Doxycycline|doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
214982943|NCT01308619|OTHER|Placebo|Placebo, oral, one capsule daily in the morning
214982944|NCT04593381|RADIATION|Stereotactic body radiotherapy|All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.
214982945|NCT00269724|DRUG|OROS® oxybutynin|
214982946|NCT00514085|BIOLOGICAL|recombinant human interleukin-21|"Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.~Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle"
214982947|NCT00514085|OTHER|immunohistochemistry staining method|Cycle 1 Day 1 and Cycle 1 Day 29
214982948|NCT00514085|OTHER|laboratory biomarker analysis|slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody
214982949|NCT00514085|OTHER|pharmacological study|Starting dose of 50μg/kg/day as an IV push
214982950|NCT00087178|DRUG|cyclophosphamide|Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
214982951|NCT00087178|DRUG|adriamycin|adriamycin 60 mg/m2 IV every 21 days for 4 cycles
214982952|NCT00087178|DRUG|epirubicin|epirubicin 100 mg/m2 IV every 21 days for 6 cycles
214982953|NCT00087178|DRUG|fluorouracil|fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
214982954|NCT01692119|BEHAVIORAL|Regular, pharmacy based intervention|"Regular, pharmacy-based intervention conducted in cooperation with the treating physician:~* Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.~* Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician."
214982955|NCT02147626|BEHAVIORAL|Web-based educational and motivational modules|
215088358|NCT03692481|RADIATION|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
214369310|NCT00758459|DRUG|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
214369311|NCT00758459|DRUG|Placebo|Dosing to match AZD1236
214982956|NCT02147626|BEHAVIORAL|Information and Screening Group|
214982957|NCT00997893|DIETARY_SUPPLEMENT|Soy Phytoestrogen|Novasoy® pill (55 mg)
214982958|NCT00997893|DRUG|Estradiol|Estradiol pill (1 mg)
214369312|NCT04069780|PROCEDURE|Intravitreal injection (4mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Intravitreal injection (4mg/0.1ml) of triamicinolone acetonide will be done using a 30-31 gauge needle at a distance of 3.5 mm from the limbus in aphakic or pseudophakic patients, and 4 mm in phakic patients. The needle will be then removed with application of cotton tipped applicator over the entry site.~-IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups."
214492928|NCT06748014|DRUG|Aescin in Horse Chestnut|Patient will recived MPFF 3000 mg for 7 day then 1000 mg for 2 month + Aescin 60 mg for 2 month
214982959|NCT00997893|DRUG|Medroxyprogesterone Acetate (MPA)|medroxyprogesterone acetate (MPA) (10mg)
214982960|NCT00997893|DRUG|Soy Placebo|oral placebo pill (0mg Soy Phytoestrogen)
214982961|NCT00997893|DRUG|MPA Placebo|oral placebo pill (0mg MPA)
214492929|NCT06748014|DRUG|MPFF|MPFF 3000 mg 7 day then 1000 mg 2 months
215088359|NCT00159913|DRUG|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
215088360|NCT00159913|DRUG|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
215088361|NCT00159913|DRUG|Placebo|oral; 3 times a day(TID)
215088362|NCT00159913|DRUG|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
214492930|NCT06750952|DRUG|Ivonescimab Combined With Chemotherapy|Ivonescimab injection is an IgG1 subtype humanized bispecific antibody targeting human vascular endothelial growth factor-A (VEGF-A) and programmed death protein-1 (PD-1). It can bind to VEGF-A and PD-1 at the same time, and competitively block the interaction between VEGF-A, PD-1 and their ligands, exerting antitumor activity.
214492931|NCT06431113|COMBINATION_PRODUCT|Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® )|treatment for 4 months and then cross over to the other therapy
214492932|NCT05566262|DRUG|Bodewell Calming Cream|Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
214492933|NCT05786612|DEVICE|Biatain® Silicone|Wound care dressing
214492934|NCT05786612|DEVICE|Mepilex Border with Aquacel Extra Hydrofiber|Wound care dressing
214492935|NCT04926740|OTHER|Ringer's lactate|Ringer's lactate is the most commonly used balanced crystalloid. Compared to normal saline, balanced crystalloids have chloride concentrations similar to human plasma; therefore, treatment with balanced crystalloids may lead to faster DKA resolution.
214681000|NCT05912959|OTHER|photo biostimulation|the intervention is a type of wavelength around 820 nm. this method of treatment is totally safe. yet, it has many therapeutic effects on the cellular level as well as tissue and organ level. during treatment with laser, the patient does not feel any specific sensation.
214982962|NCT04970082|DIAGNOSTIC_TEST|FFR DWP|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
214982963|NCT04970082|DIAGNOSTIC_TEST|FFR|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
214982964|NCT05899530|DEVICE|Invisalign|Expansion using Invisalign versus conventional expander
214982965|NCT05899530|DEVICE|Conventional expander|conventional expander
214982966|NCT01707524|PROCEDURE|Randomized left versus right radial artery approach|Randomized left versus right radial artery approach
215088363|NCT02816203|DEVICE|Hemostatic Intra-Uterine suction cup|The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
215088364|NCT03153072|BIOLOGICAL|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
215088365|NCT00824005|BIOLOGICAL|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
214982967|NCT01244464|BIOLOGICAL|IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine|0.5 mL, at 2, 3, and 4 months; Intramuscular
214982968|NCT04283318|BEHAVIORAL|12h fasting|12h fasting (overnight)
214369313|NCT04069780|PROCEDURE|Superachoroidal injection (4 mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (4mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
214369314|NCT04069780|PROCEDURE|Suprachoroidal injection (2mg/0.1ml)|"njection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (2mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
214369315|NCT01238640|DRUG|Code STD|"2 mg Single-dose of experimental nicotine product coded STD"
214369316|NCT01238640|DRUG|Code STE|"2 mg Single-dose of experimental nicotine product coded STE"
214369317|NCT01238640|DRUG|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
214369318|NCT02415699|DRUG|Fluorouracil|
214369319|NCT02415699|DRUG|Oxaliplatin|
214369320|NCT02415699|DRUG|Leucovorin|
214369321|NCT02415699|BIOLOGICAL|DC-CIK|
214369322|NCT00892125|DRUG|paliperidone ER; Carbamazepine|
214369323|NCT00326586|DRUG|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
214369324|NCT02223884|DRUG|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
214982969|NCT04283318|BEHAVIORAL|36h fasting|36h fasting ( one day and two nights fasting)
214982970|NCT00071981|BIOLOGICAL|incomplete Freund's adjuvant|Given by injection
214982971|NCT00071981|BIOLOGICAL|melanoma helper peptide vaccine|Given by injection
214982972|NCT00071981|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given by injection
214982973|NCT00071981|BIOLOGICAL|sargramostim|Given by injection
215088366|NCT00824005|BIOLOGICAL|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
215088367|NCT02696408|DEVICE|Laser treatment|"Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.~If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only."
214369325|NCT02223884|DRUG|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
214492936|NCT04378400|PROCEDURE|Sacrocolpopexy|Sacrocolpopexy is offered to patients with symptomatic prolapse (≥stage II) of the vaginal apex (vault or cervix). The procedure involves dissection of the promontory and the vaginal vault, suturing of two meshes to the anterior and posterior aspect of the vagina using minimally three rows of sutures on each side, and one row at the apex. Thereafter the mesh is fixed with staples to the promontory and the peritoneum closed, with staples and a running suture.
214492937|NCT06119295|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants. Depending on the condition participants are in, they will be served either a portion size which consists of the amount of food they consumed in the first test session, or a reduced portion size. Within these two reduced portion size conditions, one group of participants will be made aware that their portion size has been reduced, the other will not and instead will be told that this portion size is the same as the amount of food they consumed in the previous session.
214492938|NCT06764043|OTHER|Clinical evaluation|In this study, it was aimed to measure the levels of MMP-8, MMP-20, and TGF-β1 in GCF together with the volume of GCF to investigate the effect of MIH on oral hygiene, and gingival health, and also to evaluate the relationship between MIH, and various biomarkers.
214369326|NCT00004410|DRUG|tauroursodeoxycholic acid|
214492939|NCT06762938|BEHAVIORAL|ShotBlocker|Apply ShotBlocker
214492940|NCT06764212|DIAGNOSTIC_TEST|Ultrasound|M-mode ultrasonography images of the fascia under the trapezius muscle will be recorded during 3 different movements.
214492941|NCT06765603|DRUG|Atropine 0.025%|Atropine 0.025%
214492942|NCT06765603|DEVICE|Multizonal contact lens|Multizonal CL
214492943|NCT06765603|DRUG|Placebo|Placebo
214681001|NCT05083780|DRUG|Chlorphenesin Carbamate, Hydroxychloroquine|In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.
214982974|NCT00071981|BIOLOGICAL|tetanus peptide melanoma vaccine|Given by injection
214982975|NCT04244539|DEVICE|high-intensity laser Device.|Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of \~0.1%.
214369327|NCT01780935|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
214369328|NCT00855595|DRUG|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
214369329|NCT00855595|DRUG|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
214492944|NCT06765603|DEVICE|Single vision Contact lens|Single vision contact lens
214982976|NCT00802971|DIETARY_SUPPLEMENT|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
214982977|NCT03991039|RADIATION|Gamma knife|Microvascular decompression
214982978|NCT01867255|DRUG|venlafaxine ER (extended-release) 75 mg|A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
214982979|NCT01445249|PROCEDURE|Landmark guided ankle block.|25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
214982980|NCT01445249|PROCEDURE|PNS guided block.|This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
214982981|NCT04958876|DRUG|SP-104|oral capsule once daily
214982982|NCT04958876|DRUG|Naltrexone immediate release oral capsules|oral capsule once daily
214982983|NCT00467519|BIOLOGICAL|Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|0.5 mL, IM
214982984|NCT00467519|BIOLOGICAL|DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)|0.5 mL, IM
214982985|NCT01028781|DRUG|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
214982986|NCT03448198|PROCEDURE|Total knee replacement|Primary knee gonarthrosis treated with navigated total knee replacement and computer-assisted patellar replacement.
214982987|NCT02937597|BEHAVIORAL|ePBP: eProficiency Based Progression|National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
214982988|NCT02937597|BEHAVIORAL|eS: eScenarios|National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
214982989|NCT02937597|BEHAVIORAL|HSE|National HSE e-learning programme only
214982990|NCT01123655|DRUG|APLA12|Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
214982991|NCT01123655|DRUG|Placebo|Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
214681002|NCT05895279|OTHER|Media Intervention|Watch MiCaP Research Digest video
214982992|NCT03456466|DRUG|TQB2303|375mg/m2 ，iv
214982993|NCT03456466|DRUG|Rituximab|375mg/m2 ，iv
214982994|NCT02346734|DEVICE|Multiple Sclerosis Home Automated Telemanagement (MS HAT) system|
214982995|NCT03779555|OTHER|Medication Event Monitoring System|-Microchipped bottle cap
214982996|NCT00836732|PROCEDURE|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
214982997|NCT02387086|DRUG|Thalidomide|
214982998|NCT02387086|DRUG|placebo|
215088368|NCT02696408|DEVICE|Placebo|"Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.~If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only."
215088369|NCT02223611|DRUG|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
215088370|NCT02223611|DRUG|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
214681003|NCT05895279|OTHER|Media Intervention|Watch alternate video
215088371|NCT05300685|DRUG|Standard Buccal Harvest|Our institutions current anesthetic regimen. Comparison group
215088372|NCT05300685|DRUG|Basic buccal procedure + Long acting local|Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
215088373|NCT05300685|DRUG|Basic buccal procedure + Buccal block|Addition of long-acting local anesthetic as a buccal block after oral graft harvest
215088374|NCT02933567|OTHER|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
215088375|NCT06089213|OTHER|real-time intervention|An individual exercise program will be carried out at home, supervised remotely via videoconference.
215088376|NCT02508740|DRUG|bevenopran|Single oral dose
215088377|NCT03732365|COMBINATION_PRODUCT|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
215088378|NCT03732365|DRUG|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
215088379|NCT00780637|DRUG|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
215088380|NCT01292083|DRUG|azacitidine|Given IV
214681004|NCT05895279|OTHER|Survey Administration|Complete survey
214681005|NCT00000455|DRUG|naltrexone|
214982999|NCT02387086|DRUG|Gefitinib|
214983000|NCT02387086|DRUG|Aspirin|
214983001|NCT00614510|DEVICE|CardioWest temporary Total Artificial Heart (TAH-t)|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) system is a pulsatile biventricular device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external console connected by drivelines.
214983002|NCT00815152|BEHAVIORAL|coping skills intervention training|The strategies will include ways to improve problem solving, communication skills, and managing activities.
214983003|NCT00815152|BEHAVIORAL|usual care|The ususal care at the Preston Robert Tisch Brain Tumor Center
214983004|NCT05120076|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|s. arm/group description
214983005|NCT05120076|DRUG|NaCl 0.9%|s. arm/group description
214983006|NCT06184048|PROCEDURE|Intra-Articular knee injection of LC-PRP|Blood Collection 45mL, Processed Neutrophil-Poor PRP, 2 Injections at day 0 and 3 weeks.
214983007|NCT05571111|DRUG|FE 999302|Subcutaneous injection as a single dose. 3 different doses
214983008|NCT05571111|DRUG|Ovitrelle|Subcutaneous injection as a single dose. 250 µg (0.5 mL)
214492945|NCT06359314|BEHAVIORAL|ALDER|The ALDER skills are delivered over approximately 5 weeks. A week consists of learning at least one skill and then applying that skill(s) in daily home practice throughout the week. Skill lessons and daily home practice exercises are housed on the ALDER website. Participants have the option to share their home practice responses with fellow participants by posting them to the discussion board, where they can like and comment on each other's posts.
214681006|NCT02998892|BEHAVIORAL|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 6 weeks. This intervention corresponds to the current recommendations.
214983009|NCT05571111|DRUG|Novarel|Subcutaneous injection as a single dose. 10,000 IU (1 mL)
215088381|NCT01292083|OTHER|laboratory biomarker analysis|Correlative studies
215088382|NCT01292083|OTHER|immunohistochemistry staining method|Correlative studies
215088383|NCT01292083|GENETIC|polymerase chain reaction|Correlative studies
215088384|NCT01292083|GENETIC|western blotting|Correlative studies
214492946|NCT02427724|DRUG|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
215088385|NCT01292083|GENETIC|nucleic acid sequencing|Correlative studies
215088386|NCT01292083|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
215088387|NCT02256410|DEVICE|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
215088388|NCT02256410|OTHER|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
214492947|NCT02427724|DRUG|lidocaine 7%/tetracaine 7% topical anesthetic|
214492948|NCT02427724|DRUG|placebo vehicle|
214492949|NCT02427724|DEVICE|Q-switched 532nm Laser|
214681007|NCT02998892|BEHAVIORAL|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 9 hours, 5 days/week, by brisk walking for 6 weeks.
214681008|NCT04018014|OTHER|CT angiography|CT angiography in detection of pulmonary embolism
214983010|NCT03931070|DRUG|Ramelteon|Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
214983011|NCT03931070|DRUG|Placebo - Cap|Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
215088389|NCT01874275|DEVICE|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
215088390|NCT04709484|DRUG|USG-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
215088391|NCT04709484|DRUG|Palpation-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
214983012|NCT05594082|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan, 5.4 mg/kg ivgtt q3w
214983013|NCT00833755|DRUG|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
214983014|NCT00833755|DRUG|Placebos|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
214983015|NCT02439164|DRUG|Midazolam|specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
214983016|NCT00003261|DRUG|methotrexate|
214983017|NCT00003261|DRUG|zidovudine|
214983018|NCT00003261|PROCEDURE|neoadjuvant therapy|
214983019|NCT00003261|RADIATION|radiation therapy|
214983020|NCT02343224|DRUG|Pegylated interferon alpha-2b|PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
214983021|NCT00707837|OTHER|Preterm infant formulas and discharge formulas|Preterm infant formulas to be consumed per health care provider orders
215088392|NCT03165214|DEVICE|coil|microcoils
215088393|NCT03165214|DEVICE|hystoacryl glue|hystoacryl mixed with lipidol
214983022|NCT00707837|OTHER|Preterm infant formula with added soluble lipids|Preterm infant formula to be fed per healthcare provider instructions
214983023|NCT04042831|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214983024|NCT04042831|PROCEDURE|Computed Tomography|Undergo CT
214983025|NCT04042831|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214983026|NCT04042831|DRUG|Olaparib|Given PO
214983027|NCT01776554|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
214983028|NCT00595361|DRUG|salmeterol|salmeterol 50 micrograms twice daily for 2 weeks
214983029|NCT06447636|DRUG|Surufatinib|Surufatinib: 250mg qd，d1-21, q3w
214983030|NCT06447636|DRUG|Sintilimab|Sintilimab：200mg ivdrip, d1, q3w
214983031|NCT06447636|DRUG|Oxaliplatin|130mg/m2，iv drip for 2h，d1, q3w
214983032|NCT06447636|DRUG|S1|S1：40\~60mg Bid，d1\~14, q3w
214983033|NCT00981617|DRUG|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
214983034|NCT00981617|DRUG|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
214983035|NCT00981617|DRUG|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
214983036|NCT00981617|DRUG|Placebo|Matching placebo taken once daily for 12 weeks
214983037|NCT05968105|PROCEDURE|Lateral Sagittal Infraclavicular Block|Patients will be in the supine position and after aseptic conditions are provided, the axillary artery of the patient will be visualized in the craniocaudal plane, in the infraclavicular region and in the lateral sagittal position with the help of an 8-12 mHz linear probe. After the brachial plexus cords around the axillary artery are identified, a local anesthetic mixture will be applied in-plane between the posterior cord and the artery. During the block, patients will routinely be given a mixture of 0.25% bupivacaine + 0.5% lidocaine 0.5 mL/kg.
214983038|NCT05968105|PROCEDURE|Inferior vena cava diameter >1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) < 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
214983039|NCT05968105|DIAGNOSTIC_TEST|Inferior vena cava diameter <1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) > 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
214983040|NCT06045117|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
214983041|NCT03559816|OTHER|Classification of perineal tears based on new classification|Classifications according to the American College of Obstetricians and Gynaecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) and sub classification of second-degree lacerations based on the assumption that episiotomy involves the same anatomic structures of a second-degree laceration (perineal muscle, mucosa and skin), and divides them in two sub-groups, named A (if spontaneous vaginal tear is smaller than episiotomy) and B (if spontaneous vaginal tear is bigger than episiotomy).
214983042|NCT03559816|PROCEDURE|Selective use of Episiotomy|Standardized selective use of Episiotomy as recommended by guidelines.
215088394|NCT03411109|DRUG|Hydromorphone Hydrochloride|All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
215088395|NCT01127555|DRUG|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
214369330|NCT00855595|DRUG|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
214983043|NCT01642381|BEHAVIORAL|"Full Motivational Interviewing (FMI)"|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
214983044|NCT01642381|BEHAVIORAL|"Spirit Only Motivational Interviewing (SOMI)"|Empathic and non-directive counselling based on Rogerian psychotherapy model.
214369331|NCT03792854|OTHER|EORTC QLQ C30|standardized questionaire
214983045|NCT03424135|DRUG|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
214983046|NCT03424135|DRUG|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
214983047|NCT00982345|DRUG|quetiapine (Seroquel XR)|Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
215088396|NCT00168103|BIOLOGICAL|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
215088397|NCT00168103|BIOLOGICAL|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
215088398|NCT01731730|DRUG|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
215088399|NCT01731730|DRUG|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
215088400|NCT01731730|DRUG|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
214369332|NCT03792854|OTHER|EORTC QLQ CR29|standardized questionaire
214983048|NCT03188575|BEHAVIORAL|SilverCloud Internet-delivered Cognitive Behavioural Therapy|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
214983049|NCT03188575|OTHER|Waiting List|8 week waiting list period.
214983050|NCT02101151|DIETARY_SUPPLEMENT|Vitamin D3(cholecalciferol)|
214983051|NCT02908347|DRUG|MP1032|hard gelatine capsules containing 50 mg MP1032 as active ingredient
214983052|NCT02908347|DRUG|Placebo|hard gelatine capsules without active ingredient
214983053|NCT03874611|OTHER|electrophysiological data from DBS|For each selected patient, the evaluation of cognitive or sensory-motor functions by electrophysiology will be conducted in the operating room, preoperatively the week before implantation and post-operatively within five days between the implantation of deep electrodes and the setting of the stimulator.
214983054|NCT05392400|DEVICE|Steri3X|This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the Steri3X wound dressing will have the liquid polymer applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s).
214983055|NCT05392400|OTHER|Control|"Device: Steri3X~This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the control wound dressing will have the current standard of care dressing applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s)."
214983056|NCT00393315|DEVICE|paclitaxel coated balloon catheter|
214983057|NCT02886351|DRUG|Nitrous Oxide|Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
214983058|NCT04575870|OTHER|waiting period|amount of time between clinical procedure and modified functional endoscopic exam of swallowing
214983059|NCT02760888|DRUG|Tramadol|Women will receive a oral Tramadol 100mg 1 hour before the procedure
214983060|NCT02760888|DRUG|Diclofenac|Women will receive oral Diclofenac 100mg 1 hour before the procedure
214983061|NCT02760888|DRUG|Placebo|Women will receive a Placebo 1 hour before the procedure
215088401|NCT03677479|PROCEDURE|socket preservation procedure|socket preservation of post extraction site using bone xenografts
215088402|NCT00002849|BIOLOGICAL|recombinant interferon alfa|first 2 years
214369333|NCT03962725|DRUG|Neuromuscular Blocking Agents|Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
214369334|NCT03962725|DRUG|Anesthetic Adjuncts|Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
214369335|NCT05163613|OTHER|magnetostimulation|Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.
214983062|NCT02631681|BEHAVIORAL|Group based exercise|Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
214983063|NCT02431429|DRUG|Miltefosine|
214983064|NCT00691379|DRUG|Carboplatin|Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression
214983065|NCT00691379|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression
214983066|NCT00691379|DRUG|Paclitaxel|Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression
214983067|NCT04254510|OTHER|Myofascial relaxation technique|"* Before the intervention, the number of days of the last menstrual cycle of all participants, the number of painful days throughout the cycle, pain intensity values according to the Visual Analogue Scale will be recorded, and the scores will be recorded in the participants.~* Technique of direct relaxation of fascia of both psoas muscles to the participants in the myofascial relaxation group since the end of the last cycle, 90-120 sec. It will be applied by the physiotherapist twice a week."
214983068|NCT03717571|DIAGNOSTIC_TEST|Glenohumeral translation assessment|amount of glenohumeral translation under load
214983069|NCT00306176|DRUG|Rosiglitazone|
214983070|NCT04539977|DRUG|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
215088403|NCT00002849|DRUG|dexamethasone|40 mg\*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles\*
215088404|NCT02523625|DEVICE|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
215088405|NCT02111135|BIOLOGICAL|b-OPV|
215088406|NCT02111135|BIOLOGICAL|m-OPV2|
215088407|NCT02111135|BIOLOGICAL|m-IPV HD|
214492950|NCT04538352|DRUG|Semaglutide|Medication for type 2 diabetes management
215088408|NCT02111135|BIOLOGICAL|t-IPV|
215088409|NCT00989235|DRUG|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
214983071|NCT04539977|DRUG|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
214369336|NCT05163613|OTHER|standard therapy|Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.
214369337|NCT01824615|DRUG|Sunitinib|37.5mg everyday from D1-D28
214369338|NCT02666287|DRUG|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
214369339|NCT02666287|DRUG|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
214369340|NCT02666287|DRUG|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
214369341|NCT02666287|DRUG|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
214983072|NCT01369381|PROCEDURE|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
214983073|NCT04585997|DRUG|Mepolizumab|Mepolizumab 100mg subcutaneous injection monthly for 6 months
214983074|NCT04585997|DRUG|Omalizumab|Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
214983075|NCT05441007|OTHER|Hypoxic|Hypoxic gas mixture Gas mixture of 10% O2 and 90% N2 for six minutes.
214983076|NCT05441007|OTHER|Hypercapnic|Hypercapnic gas mixture Gas mixture of 21% O2, 5% CO2 74% N2 for six minutes.
214983077|NCT05441007|OTHER|Hypoxic and Hypercapnic|Hypoxic and Hypercapnic gas mixture Gas mixture of 10% O2, 5% CO2 85% N2 for six minutes.
214983078|NCT04170413|DRUG|CeVUS|Contrast enhanced voiding urosonography
214983079|NCT02346864|BEHAVIORAL|Three-stair-position|Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest
214369342|NCT02666287|DRUG|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
214369343|NCT02533869|RADIATION|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis
214369344|NCT02533869|PROCEDURE|Laparoscopic appendectomy|All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
214369345|NCT00262795|DRUG|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
214369346|NCT00262795|DRUG|Chlorambucil|Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
214369347|NCT01726855|PROCEDURE|vascularized finger dorsal fascial flap|
214369348|NCT06162143|DEVICE|Gelsectan®|Gelsectan® is a CE-marked class II device containing xyloglucans, xylo-oligosaccharides, pea proteins, and tannins from grape seeds extract, already used in Irritable Bowel Syndrome (IBS).
214369349|NCT02571270|OTHER|Combined aerobic and resistance physical training program|
214369350|NCT05374044|DIAGNOSTIC_TEST|pelvic MRI for establishing new mrTRG method|they will received two pelvic MR examinations before and after neoadjvant therapy. The MRI before neoadjvant therapy is considered as baseline MRI, which is usually taken within 3 weeks before NAT. The MRI after neoadjvant therapy is considered as preoperative MRI, which is usually taken within 3-8 weeks before NAT.
214983080|NCT02346864|BEHAVIORAL|Head elevated tilt position group|Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
214983081|NCT03012737|DEVICE|Trilogy 100 ® (Philips Respironics)|Trilogy 100 ® (Philips Respironics) on MPV mode.
214983082|NCT02789371|PROCEDURE|the first pass is made with 5ml suction technique|the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.
214983083|NCT02789371|PROCEDURE|the first pass is made with modified wet suction technique|the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
214983084|NCT02905162|OTHER|Transitional HIV care for prison releasees|Transitional HIV care program for releasees
214983085|NCT00235261|DRUG|Pregabalin|
214983086|NCT00235261|DRUG|Dexamethasone|
214983087|NCT03798418|BEHAVIORAL|elastic band strengthening exercise|2-3days per week(150min per week)
214983088|NCT03798418|DIETARY_SUPPLEMENT|diet counseling|each patients in this group will receive4-5times diet counseling
214983089|NCT03974282|BEHAVIORAL|Psychological task|Participants will complete a psychological task that evokes antisocially- and prosocially-motivated empathic responding
214983090|NCT02174757|DRUG|Inersan|Probiotic
214983091|NCT02174757|DRUG|Doxycycline|Antibiotic
214983092|NCT01082744|DRUG|Ropivacaine + Sufentanil|Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
214983093|NCT01082744|DRUG|Ropivacaine|Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
214983094|NCT00086671|DRUG|ABT-874/Human monoclonal antibody against IL-12|
214681009|NCT03408873|DRUG|Abilify Maintena|Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.
214983095|NCT00086671|DRUG|Placebo|
214983096|NCT01880827|PROCEDURE|Roux-en-Y|Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.
214983097|NCT01880827|DRUG|GIP-infusion|Blood flow and volume during infusion
214983098|NCT01880827|DRUG|GLP-1|Blood flow and volume during infusion
215088410|NCT00989235|DRUG|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
215088411|NCT03624426|DEVICE|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
215088412|NCT05639153|DRUG|DR30303|DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
215088413|NCT04235569|DRUG|Warfarin Sodium 5 MG|warfarin sodium 5mg tablets
215088414|NCT04235569|DRUG|Warfarin Sodium 3 MG|warfarin sodium 3mg tablets
215088415|NCT04235569|DRUG|Enoxaparin Sodium 100 MG/ML Prefilled Syringe|"Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours."
215088416|NCT04909502|DRUG|EHP-101 25 mg OD|25 mg OD during the first 28 Days of the trial
214492951|NCT04538352|DRUG|Insulin Degludec|Medication for type 2 diabetes management
214983099|NCT01880827|DRUG|MMS|Blood flow and volume after meal solution
214983100|NCT01880827|PROCEDURE|Sleeve gastrectomy|as in RYGS group
214983101|NCT05056961|OTHER|Multiparametric mesurements|Multiparametric assessments will necessitate the use of a plastic belt to record electro-impedancemetry tomography data; and a nano-gatsric tube fitted with esophageal and gastric low pressure balloons
214983102|NCT00871156|DRUG|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
214983103|NCT00871156|DRUG|Placebo|Placebo
214983104|NCT04545073|DEVICE|PanOptix|Trifocal IOL with ORA in post refractive patients
214983105|NCT00183079|BEHAVIORAL|Motivationally-focused brief alcohol intervention|Brief, motivationally-focused alcohol intervention
214983106|NCT05926609|DIETARY_SUPPLEMENT|EB-PA|1 capsule to be taken after breakfast once a day
214983107|NCT05926609|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken after breakfast once a day
214983108|NCT02643875|DEVICE|Orthokeratology|It is a kind of rigid permeable lens.
214983109|NCT03710512|PROCEDURE|Bilateral sagittal split osteotomy|Bilateral sagittal split osteotomy of the mandible is a surgical procedure used to correct dentofacial discrepancies
215088417|NCT04909502|DRUG|EHP-101 25 mg BID|25 mg BID during the first 28 Days of the trial
215088418|NCT04909502|DRUG|EHP-101 50 mg OD|After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
215088419|NCT04909502|DRUG|EHP-101 50 mg BID|After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
215088420|NCT02949388|DRUG|Placebo|Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
214492952|NCT04538352|DRUG|Insulin aspart|Medication for type 2 diabetes management (rapid-acting)
214492953|NCT06222489|DRUG|89Zr-Patritumab deruxtecan|Day 1, day 3, day 6, day 11 and day 26 of first course
214492954|NCT06790225|OTHER|Glucose-dependent Insulinotropic Polypeptide (GIP)|Recombinant human GIP (1-42)
214492955|NCT06639425|DIETARY_SUPPLEMENT|Lactobacillus paracasei LC19 supplementation|Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
214983110|NCT02866656|OTHER|Conventional conservative treatment|Treatment last for 4 weeks, three times a week,
214983111|NCT02866656|DEVICE|therapeutic ultrasound|Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
214983112|NCT01589315|DEVICE|focal ECT|FEAST, ECT, unidirectional stimulation
214983113|NCT02147301|DEVICE|LC Bead|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first."
214983114|NCT04659005|OTHER|Nurse-led decision counseling|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
214983115|NCT04659005|OTHER|Usual care|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises
214983116|NCT04375163|OTHER|Isokinetic intense exercise protocol|The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.
214983117|NCT04375163|OTHER|Massage treatment|"Massage consisted of stroking (30) and petrissage (50) for muscle relaxation, then friction (10), pincement and clapping (30) to prepare muscles for the next set."
214983118|NCT03517904|PROCEDURE|IVUS-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
214983119|NCT03517904|PROCEDURE|Angiography-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
214369351|NCT06082245|PROCEDURE|TLIP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"* Patients were placed in a prone position;~* ultrasound-guided TLIP block: (1) The transducer was positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles. (2) The probe was moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. (3) the TLIP block was performed under real-time ultrasound guidance using an insulated 100-mm 22G echogenic needle which was inserted in-plane lateral to the medial direction. (4) After negative aspiration, 20-mL 0.25% ropivacaine was injected in each side bilaterally in the interface between the MF and LG muscles.~* patients received general anesthesia"
214983120|NCT01813279|OTHER|the cell therapy|the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
214983121|NCT01940965|DRUG|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
214983122|NCT01940965|DRUG|biguanide|Pharmaceutical form:tablet Route of administration: oral
214492956|NCT06639425|DIETARY_SUPPLEMENT|Placebo probiotic milk powder|Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
214492957|NCT06637969|BEHAVIORAL|mindfulness-based|The experimental group was also provided with a total of 30 minutes of mindfulness training once a day for seven consecutive days. The content included mindful breathing awareness for 8 minutes while resting and lying in bed, 10 minutes of mindfulness meditation, 12 minutes of mindfulness body scanning, and 10 minutes of mindful walking and breathing. The control group The group received routine care, and a pre-test was conducted before the implementation of the interventional measures (from 7 pm to 9 pm the day before the operation), and a post-test was conducted after the seven-day intervention (from 7 pm to 9 pm on the seventh day of the interventional treatment). Comparison between the experimental group and the control group group differences
214492958|NCT06777732|DRUG|Keverprazan|Potassium-competitive acid blocker
214983123|NCT01940965|DRUG|TZD|Pharmaceutical form:tablet Route of administration: oral
214983124|NCT01940965|DRUG|alpha-GI|Pharmaceutical form:tablet Route of administration: oral
214983125|NCT01940965|DRUG|glinide|Pharmaceutical form:tablet Route of administration: oral
214983126|NCT03087058|DRUG|Patiromer|4.2 g/day, 8.4 g/day and 16.8 g/day
214983127|NCT03087058|DRUG|Patiromer|2 g/day, 4 g/day and 8 g/day
214983128|NCT03087058|DRUG|Patiromer|1 g/day, 2 g/day and 4 g/day
214983129|NCT03912038|OTHER|No intervention.|No intervention
214983130|NCT02577029|DRUG|ARC-520|ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
214983131|NCT02577029|DRUG|entecavir|0.5 mg once daily; oral
214983132|NCT02577029|BIOLOGICAL|pegylated interferon alpha 2a|180 mcg; subcutaneous injection once weekly
214983133|NCT02577029|DRUG|tenofovir disoproxil|300 mg once daily; oral
214983134|NCT02577029|DRUG|antihistamine|All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
214983135|NCT02499016|PROCEDURE|suprapubic single-incision laparoscopic appendectomy|the approach of appendectomy
214983136|NCT00109993|BIOLOGICAL|alemtuzumab|alemtuzumab IV over 2 hours on days 4-6, 18, and 32
214492959|NCT06777732|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
214492960|NCT06777732|DRUG|Furazolidone|Antibiotic for H. pylori eradication
214492961|NCT06777732|DRUG|Colloidal Bismuth Pectin|Gastric mucosal protectant
214983137|NCT00109993|DRUG|methylprednisolone|methylprednisolone IV on days 1-3 and then orally or IV on days 4-14
214983138|NCT00109993|DRUG|tacrolimus|tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease
214983139|NCT02078817|DRUG|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
214983140|NCT02980081|OTHER|abdominal plain x-ray|Abdominal plain x-ray as prescribed by the emergency physician
214983141|NCT03500978|BEHAVIORAL|Peer CBT Intervention|Peer specialist delivery of cognitive behavioral therapy intervention over the phone.
214983142|NCT00049244|DRUG|capecitabine|
214983143|NCT00049244|DRUG|ixabepilone|
215088421|NCT02949388|DRUG|400 mg (200 mg BID)|Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
215088422|NCT02949388|DRUG|300 mg (150 mg BID)|Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
215088423|NCT05683015|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.
215088424|NCT05683015|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
215088425|NCT02266875|DRUG|hypertonic saline|
215088426|NCT02266875|DRUG|standard saline|
214983144|NCT01420536|PROCEDURE|Occlusal scheme|"Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts."
214983145|NCT01162200|RADIATION|Stereotactic Body Radiation Therapy|3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
214983146|NCT02650375|DRUG|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
214983147|NCT01208285|DRUG|VX-770|150 mg oral tablet
214983148|NCT03684746|OTHER|No Intervention|It is an observational Study with staff
214983149|NCT04505852|DEVICE|Embrace|Patients wear Embrace2 to help in seizure reporting and patient care.
214983150|NCT02539251|BEHAVIORAL|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
214983151|NCT03054428|DRUG|Dupilumab|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
214983152|NCT03054428|DRUG|Placebo|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
214983153|NCT02055586|OTHER|fluorine F 18 fluorothymidine|Undergo FLT-PET/MRI
214983154|NCT02055586|DEVICE|positron emission tomography|Undergo FLT-PET/MRI
214983155|NCT02055586|DEVICE|magnetic resonance imaging|Undergo FLT-PET/MRI
214983156|NCT01502085|DRUG|Vorinostat, Lenalinomide and Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~\* Lenalidomide dose for patients with renal impairment (CrCL\<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
214983157|NCT05171907|BEHAVIORAL|Teleobesity|Teleintervention based on Dietary Guidelines for the Brazilian Population during 8 weeks; two subsequent assessments will also be made, in 24th and 48th weeks, to assess the maintenance of weight loss.
214983158|NCT01652690|BIOLOGICAL|Denosumab|This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.
214983159|NCT03330509|OTHER|SPARK intervention|An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
214983160|NCT04050033|DEVICE|Evoke Device|Subjects will undergo treatment with Evoke Device
214983161|NCT05551390|OTHER|one-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
214369352|NCT06082245|PROCEDURE|ESP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"* Patients were placed in a prone position;~* ultrasound-guided ESP block: (1) The 12th rib was identified in the parasagittal plane, and with probe shifted caudad and medial, the L3 transverse process (TP) was identified. (2) Insulated 100-mm 22G echogenic needle was inserted from cranial to caudal direction. (3) The needle tip was identified between the L2 and L3, and 20 mL of 0.25% ropivacaine was injected in each side bilaterally in ESP.~* patients received general anesthesia"
214369353|NCT06082245|PROCEDURE|Lidocaine injection|"* patients received general anesthesia~* the expected incision was anesthetized with 15ml of 1% lidocaine mixed with 1/200,000 adrenaline on each side before surgery."
214369354|NCT02604290|DEVICE|Kinesio Taping method|"The tape is applied depending on the physical examination:~* Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~* Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~* Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
214369355|NCT02604290|DEVICE|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
214369356|NCT00166296|DRUG|Escitalopram|15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
214369357|NCT00166296|DRUG|Placebo|Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
214369358|NCT04035200|DRUG|V117957 tablets|V117957 tablets taken orally at bedtime
214369359|NCT04035200|DRUG|Placebo|Tablets to match V117957
214983162|NCT05551390|OTHER|three-times umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
214983163|NCT02799147|PROCEDURE|Allogeneic stem cell transplantation|
214983164|NCT02799147|DRUG|Fludarabine monophosphate|
214983165|NCT02799147|DRUG|Busulfan|
214983166|NCT02799147|DRUG|Bendamustine|
214983167|NCT06661473|DEVICE|Avance Solo Negative Pressure Wound Therapy|Avance Solo NPWT 7-14 days after high-risk revision TKA or THA.
214983168|NCT03434210|OTHER|LAT-treated Community Model|The subjects in experimental group is on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
214983169|NCT03434210|OTHER|care as usual|Control group will get usual community care, the treatment is identified by doctors, patients and care-giver as usual.
214983170|NCT05525260|DRUG|Limonene capsule|Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
214983171|NCT05525260|DRUG|Limonene capsules(Placebo)|Limonene capsules(Placebo)
214983172|NCT05158569|OTHER|Slow breathing exercise group|The patient will be first asked to close one nostril with a thumb and slowly breathe in completely through the other for 6 seconds. This nostril will be then closed and the patient will exhale through the other nostril over a period of 6 seconds. These steps complete one breathing cycle. An attempt will be made to keep the breathing rate is about 5-6 breaths per minute. Such alternate nostril breathing cycles will be repeated continuously for a period of about 15 minutes (3 sets of 5 minutes) in one sitting.
214983173|NCT05158569|OTHER|Diaphragmatic breathing exercise group|"Patients would be instructed to Sit or lie down in a comfortable place and put their hands on their belly.~Relax the muscles in their neck and shoulders. Breathe in slowly through the nose, keeping their mouth closed. Feel the lungs fill with air and inflate like a balloon while their belly moves outward. Such breathing cycles will be repeated continuously for a period of about 15 (3 sets of 5 minutes) minutes in one sitting."
214983174|NCT03415178|DRUG|Alirocumab SAR236553|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
214983175|NCT03415178|DEVICE|Current auto-injector device (AI)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
214983176|NCT03415178|DEVICE|New auto-injector device (SYDNEY)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
214983177|NCT03415178|DRUG|Atorvastatin|Pharmaceutical form:tablet Route of administration: oral
214983178|NCT03415178|DRUG|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
214983179|NCT01689597|DRUG|Morphine|Comparison of different dosages of drug
214983180|NCT01689597|DRUG|Placebo|
215088427|NCT02459275|OTHER|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
215088428|NCT02459275|DRUG|Metoclopramide|Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
215088429|NCT00875056|DRUG|Vorinostat|Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle
215088430|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
214369360|NCT05108649|OTHER|Nicotine Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will view nicotine corrective messaging at each in-person session or delayed control messaging at the final study session.
214369361|NCT05108649|OTHER|Cigarette Condition|After completing a 7-day period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive reduced nicotine content (RNC) cigarettes or normal nicotine content (NNC) cigarettes.
214369362|NCT06771388|DIETARY_SUPPLEMENT|Liposomal collagen drink|consume 50 g liquid drink daily for 8 consecutive weeks
214983181|NCT03062371|BEHAVIORAL|Playgroup|A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
214983182|NCT00523432|DRUG|Topotecan|Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
214983183|NCT00523432|DRUG|CCI-779 (temsirolimus)|Weekly 25mg dose via IV infusion.
214983184|NCT01872962|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
214983185|NCT01872962|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
214983186|NCT05678361|BEHAVIORAL|Sleep/Nap|Participants sleep after a maximum of three sessions of exposure therapy.
214983187|NCT03717597|BEHAVIORAL|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
214983188|NCT03335345|OTHER|maintaining calorie intake|Maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube.
214369363|NCT06771388|DIETARY_SUPPLEMENT|Non-liposomal collagen drink|consume 50 g liquid drink daily for 8 consecutive weeks
214369364|NCT06771388|DIETARY_SUPPLEMENT|Placebo drink|consume 50 g liquid drink daily for 8 consecutive weeks
214983189|NCT03335345|OTHER|maximum gastric vacuity|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its caliber permits) continuously for 6 hours before extubation
214983190|NCT01884597|DRUG|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
214983191|NCT01884597|DRUG|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
214983192|NCT02377869|OTHER|No intervantion|
214983193|NCT05401721|DIAGNOSTIC_TEST|Serum copeptin|Blood test
214983194|NCT02097823|DRUG|Olanzapine|
214983195|NCT02097823|DRUG|Aprepitant|
214492962|NCT05883358|DRUG|Clonidine, Buprenorphine|Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
214983196|NCT00747916|DEVICE|CryoSpray Ablation (TM) System|Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
214983197|NCT05817162|DRUG|Ropivacaine injection|Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the without affecting the motor ones. Ropivacaine comes as solution for injection.
214983198|NCT05817162|PROCEDURE|temporomandibular joint arthrocentesis|Temporomandibular arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ.
214983199|NCT05817162|DRUG|PRP injection|Platelet-Rich Plasma (PRP) is an orthobiological adjuvant treatment. PRP has properties to restore intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis and balances joint angiogenesis. It is often used as a viscosupplement in TMJ arthrocentesis
214983200|NCT05817162|DRUG|Ringer's Lactate solution|Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.
214983201|NCT03416348|DRUG|Aluminum Chloride 20% (deodorant)|Aluminum Chloride (deodorant)
214983202|NCT03416348|DRUG|Alcohol|Placebo
214983203|NCT06107998|OTHER|stethoscope|endotracheal tube cuff will be inflated via stethoscope guidance
214983204|NCT06107998|OTHER|Audible leak/Balloon palpation|endotracheal tube cuff will be inflated via audible leak/balloon palpation method
215088431|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
215088432|NCT01318070|DRUG|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
214492963|NCT04248335|DRUG|Pantoprazole|single-dose administration
214492964|NCT04248335|DRUG|Midazolam injection|single-dose administration
214492965|NCT05665049|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Using results from a qualitative study, we identified the following culturally grounded social transfer options that is responsive to the identified needs of new mothers. Based on the monthly Lao PDR minimum wage and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately $75 would fairly subsidize women's breastfeeding efforts. Therefore all social transfer options equate to approximately 75 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
214492966|NCT05327504|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a 5 session treatment in which individuals write about their trauma event in a specified manner.
214492967|NCT05327504|BEHAVIORAL|Neutral Topic Writing|Treatment as Usual augmented by 5 sessions of Neutral Topic Writing which involves writing about specific objects (e.g., what they have eaten over the past week) or events (e.g., what they did since yesterday) in detail without discussing thoughts or feelings.
214492968|NCT04528459|DEVICE|Stryker© ADAPT™ platform|The ADAPT system is a software platform that utilizes augmented reality to assist surgeons with implant alignment, lag screw length and positioning, and distal interlocking screw placement for cephalomedullary fixation of peritrochanteric femur fractures.
214983205|NCT06115460|DRUG|oral sitagliptin supplementation|oral sitagliptin supplementation for three months
214983206|NCT04559113|DRUG|Methylprednisolone Injectable Product|"1. 0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~2. Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day."
214983207|NCT04245969|DEVICE|Experimental: 448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the shoulder and thoracic area
214983208|NCT04245969|OTHER|Sham comparator|A simulation of 448kilohertz capacitive resistive monopolar radiofrequency will be carried out to make believe the patient to be treated through this equipment.
214983209|NCT04245969|OTHER|No intervention|These participants will be assessed at the same time than the rest of participants. They will not receive any kind of treatment.
214983210|NCT03539094|OTHER|Intermittent fasting|the subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
214983211|NCT03082729|DRUG|Apremilast|Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
214983212|NCT01662544|PROCEDURE|Oxygen delivery|
214983213|NCT04378335|OTHER|completion of questionnaire|parents have to complete 2 questionnaires: demographic questionnaire and Montréal questionnaire when they come on allergy consultation.
214983214|NCT00367926|DRUG|American ginseng root / polysaccharides|
215088433|NCT00236392|DRUG|rabeprazole|
215088434|NCT06378645|DRUG|General Anesthesia: Propofol|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Propofol will be administered intravenously using the target-controlled infusion algorithm with effect site concentrations between 1.5-4.0 µg/ml necessary."
214983215|NCT04328987|PROCEDURE|cold snare polypectomy|Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.
214983216|NCT02023827|BEHAVIORAL|RAYS Intervention|The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
214983217|NCT01683461|BEHAVIORAL|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
214983218|NCT01683461|BEHAVIORAL|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
214983219|NCT03614104|BEHAVIORAL|Mobile Health Technology (short message service)|Health education through mobile technology with Short Message Service (SMS)
214983220|NCT00313872|DRUG|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre \& Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre \& post hydration (if Mg \<WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
214983221|NCT00313872|DRUG|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
214983222|NCT03434483|PROCEDURE|Assessment of the atherosclerotic plaque in a moderate lession.|"In patients who have been successfully revascularized the artery responsible for AMI and also present an intermediate lesion (40-80%) in another coronary territory, the clinical care protocol of the Cardiology Service stipulates the need for a physiological assessment with guidance of pressure (FFR).~The thickness of the fibrous cap shall be measured using optical coherence tomography.~In addition to the FFR measurement, a complete physiological assessment with a Doppler-pressure guide. This will allow the procedure to be performed without additional risk to the patient. The physiological study will include the analysis of endothelium-dependent vascular function and endothelium-independent vascular function."
214983223|NCT03434483|GENETIC|Gene variants in atherosclerosis|From the blood samples of the patients, the total DNA will be extracted and the main functional variants identified in the literature will be genotyped
214983224|NCT03434483|OTHER|Microbiota analysis|From the samples of blood, feces, oral cavity and blood, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
214983225|NCT03434483|OTHER|Immunological analysis|A study of immunological cell populations and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
214983226|NCT03434483|OTHER|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies and questionaries for diet and exercice registration
214983227|NCT05348304|DIETARY_SUPPLEMENT|EUDIAMET|A combination of myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
214983228|NCT04650737|DRUG|single shot ESBP with dexmedtomidine|Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
214983229|NCT04650737|DRUG|continous ESPB|Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
214983230|NCT04102137|BIOLOGICAL|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
214983231|NCT04102137|BIOLOGICAL|Boostagen (TDaP BioNet)|"Boostagen (TDaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TDaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
214983232|NCT04102137|BIOLOGICAL|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
214983233|NCT01953991|DEVICE|Dentures|Removable prosthesis to replace missing teeth
215088435|NCT06378645|DRUG|General Anesthesia: Sevoflurane|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Sevoflurane will be given in gaseous form via the endotracheal tube in concentrations between 1.5-2.5% Vol."
215088436|NCT02679365|PROCEDURE|lower segment cesarean section and double lock closure of rectus sheath|
215088437|NCT02679365|PROCEDURE|lower segment cesarean section and continuous non-locking closure of rectus sheath|
215088438|NCT02956850|OTHER|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
214492969|NCT04528459|RADIATION|Traditional fluoroscopy|For patients in the control group, traditional fluoroscopy will be utilized for placement of the cephalomedullary nail.
214983234|NCT05892237|PROCEDURE|bronchial artery interventional therapy|After successful anesthesia, right femoral artery puncture was performed by Seldinger method. 5F-Yashrio catheter is chosen to locate the bronchial artery of the diseased side at the level of the thoracic aortotracheal bifurcation. Angiography was performed (Osu 300mg/ml, 3ml/s, total 8ml, 200Psi) to visualize tumor blood supply artery before infusion of chemo+PD-1 inhibitor and embolism.
214369365|NCT02417584|DEVICE|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
214369366|NCT04685590|DRUG|Dasatinib + Quercetin|D+Q will be administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
214369367|NCT04685590|OTHER|Placebo Capsules|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
214983235|NCT05892237|DRUG|Chemotherapy drug|Nano-paclitaxel 260 mg/m2, d1, ivgtt, q3w+Cisplatin 75mg/m2, d1, ivgtt,q3w.
214983236|NCT05892237|RADIATION|IMRT|60Gy/2Gy/30f
214983237|NCT05892237|DRUG|Immunotherapy|PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.
214983238|NCT03184246|DEVICE|GlideScope|videolaryngoscopy (GlideScope) will be used for intubation
214983239|NCT03184246|DEVICE|Direct laryngoscopy|direct laryngoscopy will be used for intubation
214983240|NCT05519865|DRUG|Tucidinostat|30mg orally BIW
214983241|NCT05519865|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
214983242|NCT02964871|DEVICE|Sofia Fluorescent Immunoassay Analyzer Influenza A+B|The Sofia Influenza A+B Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and influenza B viral nucleoprotein antigens.
214983243|NCT02964871|OTHER|Usual care|Our team will discuss our interest in monitoring influenza antiviral treatment and prophylaxis courses, antibiotic courses, clinician and emergency room visits, respiratory infection-related hospitalizations, all-cause hospitalizations, and deaths during the anticipated 4-month influenza season over 3 years.
214983244|NCT01866254|DRUG|Hydromorphone|Injection of 100 mcg hydromorphone into the intrathecal space
214983245|NCT01866254|DRUG|Morphine|Injection of 200 mcg of intrathecal morphine
214983246|NCT02603133|BEHAVIORAL|Three Good Things|"In this tool participants reflect on good things that happened that day during evenings across 10 days. Participants are also able to voluntarily share their good things and read other participants' good things through the nightly anonymous log. By savoring good moments from earlier that day, participants are thought to shift from the natural focus on what went poorly due to negativity bias1 to an appreciation for what went well. This shift in focus is thought to reduce rumination and depression symptoms. In prior research, 3GTs was found to increase happiness and decrease depression in internet participants.2 In prior cohorts of 3GTs, we saw improvements in burnout, depression symptoms, work-life balance, and happiness. Participants also report benefiting from viewing nightly Three Good Things logs of others."
214983247|NCT02603133|BEHAVIORAL|Gratitude|In this tool participants are offered the opportunity to cultivate gratitude toward others through a guided gratitude letter writing exercise.2 Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways. Previous research has found that gratitude interventions increase well-being in a number of ways, particularly in boosting positive affect.
214983248|NCT02603133|BEHAVIORAL|Random Acts of Kindess|In this tool, participants report kind acts that they have committed, received, and/or witnessed, each day. By committing random acts of kindness participants experience a boost of positive emotions, and report lower negative affect. Recipients of acts of kindness benefit as well.
214983249|NCT02603133|BEHAVIORAL|Awe|This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
214983250|NCT02603133|BEHAVIORAL|1 Good Chat|This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
215088439|NCT02956850|DRUG|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
214369368|NCT01908465|DRUG|Ebastine|
214492970|NCT04972292|DRUG|FDC of codeine 30 mg/dipyrone 500 mg|Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.
214983251|NCT01150682|GENETIC|RNA analysis|
214983252|NCT01150682|GENETIC|reverse transcriptase-polymerase chain reaction|
214983253|NCT01150682|OTHER|enzyme-linked immunosorbent assay|
214983254|NCT01150682|OTHER|immunohistochemistry staining method|
215088440|NCT00457444|DRUG|Pollen|
215088441|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
215088442|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
215088443|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
215088444|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
215088445|NCT01536548|PROCEDURE|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
215088446|NCT01536548|PROCEDURE|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
214369369|NCT01908465|DRUG|Placebo|
214369370|NCT05133050|DRUG|Ramipril|We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.
214492971|NCT04972292|DRUG|Tylex|Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
214492972|NCT05691192|BEHAVIORAL|Cognitive Leisure Activities|Participants in the active phase of the study will be asked to increase engagement in certain cognitive leisure activities. The activities are chosen on the basis of previous research and measures of cognitive reserve-building activities.
214492973|NCT06828367|BEHAVIORAL|Online family educational intervention and cooking workshop|Registration for the educational platform will be open for 3 months from the start of the school year. Over the first 2-3 months, the contents of each topic will be activated weekly, and family participation will be encouraged through reminders. In the following 3 months, the platform will remain open, allowing families who did not follow the weekly content to catch up. Participation reminders will continue. From the 3rd to 6th month, the cooking workshop will be held in person. Throughout the intervention, activities will promote participation, and a Q\&A channel with an expert (nutritionist) will remain open. Total intervention time: 6 months.
214983255|NCT01150682|OTHER|laboratory biomarker analysis|
214983256|NCT00303043|PROCEDURE|Mixed venous saturation monitoring|Mixed venous saturation monitoring
214983257|NCT02441647|DEVICE|KL029 Intimate Lubricant Gel|
214983258|NCT01950702|PROCEDURE|Laryngoscope assisted lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~The Macintosh laryngoscope (female: 3rd blade, male: 4th blade) was inserted into the oral cavity to provide direct view of the epiglottis and then the tip of the lightwand was placed below the epiglottis."
214983259|NCT01950702|PROCEDURE|Lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~After 2min from administration of rocuronium, the clinician holds the wand similar to a pencil, stands directly behind the patient's head, inserts the device into the side of the mouth and sweeps the tip to the midline. After confirmation of precise location via clear light source on anterior neck, endotracheal tube was inserted and withdrawn lightwand."
214983260|NCT01765322|DEVICE|ZILOS-TK IVOS Analyzer|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
214983261|NCT00068523|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin IV over 4 hours on days -2 to -1
214983262|NCT00068523|DRUG|cyclophosphamide|cyclophosphamide IV over 1 hour on days -3 to -2
214983263|NCT00068523|DRUG|cyclosporine|oral cyclosporine on days -1 to 100
214983264|NCT00068523|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
214983265|NCT00068523|DRUG|methylprednisolone|methylprednisolone (oral or IV) on days 5-15
214983266|NCT00068523|PROCEDURE|UV light therapy|Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.
214369371|NCT00946296|DRUG|Potassium Iodide|8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
214492974|NCT03911466|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
214492975|NCT03911466|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
214983267|NCT00068523|PROCEDURE|allogeneic bone marrow transplantation|
214983268|NCT00068523|PROCEDURE|peripheral blood stem cell transplantation|Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.
214983269|NCT04538105|OTHER|Control|Saline Articular Nerve Branch Block
214983270|NCT04538105|OTHER|Articular Branch Block (ABB)|0.5% Bupivacaine with epinephrine 1:200,000 (Articular Branch Block)
214983271|NCT02936999|DRUG|Cholecalciferol|Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
214369372|NCT04283448|BEHAVIORAL|Dietary Lentil|Participants in the Lentil arm of the study will consume midday meals containing 0.66 cups of lentils seven days per week for 12 weeks.
214369373|NCT04283448|BEHAVIORAL|Control|Participants in the Control arm of the study will consume midday meals containing 0.00 cups of lentils seven days per week for 12 weeks.
214369374|NCT05917977|BEHAVIORAL|Collective Motivational Interviewing plus Education Materials|The participants in the intervention group will receive IGD educational materials as well as four counseling sessions of CMI intervention.
214492976|NCT05377736|GENETIC|Molecular analyses|Collect thyroid tissue for molecular analysis from the histological specimen collected by routine surgery
214492977|NCT05028881|OTHER|blood sampling|blood sampling for determining antibody responses
214369375|NCT05917977|OTHER|Control group (Education Materials)|The participants in the control group will receive IGD educational materials.
214492978|NCT06944899|DEVICE|NO Sensor|NO sensor measuring wound characteristic data in wound bed
214492979|NCT06793293|DEVICE|High level laser|It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) in addition to High level laser for 5 minutes on days 1 st , 2 nd , and 3 rd , after cesarean section (3 sessions)
214983272|NCT00753519|DEVICE|Real iTBS|Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
214983273|NCT00753519|DEVICE|Sham iTBS|Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
214983274|NCT06197490|BIOLOGICAL|Evaluation of the parameters of the lithiasis assessment before and after KAFTRIO initiation|Collection of Uricuria, phosphaturie, calciuria, magnesuria, glycosuria, citraturia, oxaluria, before and after initiation of KAFTRIO
214369376|NCT06571448|DRUG|SR750 tablet|SR750 high dose BID orally for 6 weeks
214369377|NCT06571448|DRUG|SR750 tablet|SR750 low dose BID orally for 6 weeks
214369378|NCT06571448|DRUG|Placebo|Placebo
214369379|NCT06100419|PROCEDURE|serratus posterior superior intercostal plane block|With this newly introduced procedure added to the literature, patients undergoing breast surgeries are expected to experience reduced pain.
214369380|NCT05535049|PROCEDURE|Non-surgical periodontal treatment|Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.
214983275|NCT06197490|DRUG|Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation|Arterial pressure, glycemia, glycated hemoglobin, lipid profile, weight, serum and urinary electrolytes, hepatic check, complete blood count, calcium phosphate balance and urinary sediment analysis before and after initiation of KAFTRIO
214983276|NCT03625024|BEHAVIORAL|Cognitive-behavioral therapy|Individual cognitive-behavioral therapy, including homework and behavioral change methods.
214983277|NCT06517199|DRUG|Olanzapine 2.5 MG|olanzapine 2.5 mg/day for 28 days
214983278|NCT06517199|DRUG|Olanzapine 5 MG|olanzapine 5 mg/day for 28 days
214983279|NCT06517199|DRUG|Placebo|placebo 1 tab/day for 28 days
214983280|NCT04432480|PROCEDURE|NIPE (Newborn Infant Parasympathetic Evaluation) monitoring|Non invasive monitor connected to standard anesthesia monitor (no part of the device in contact with the patient) during anesthesia.
214983281|NCT01915316|OTHER|prostate biopsy|Measurements of Zinc concentration along fresh Specimens taken during Trans-Perineal saturated repeat Prostate Biopsy before Specimens are sent to Pathology.
214983282|NCT01136590|DRUG|Tranexamic Acid|A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.
214983283|NCT01136590|DRUG|fisiologic serum|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
214983284|NCT00959751|DRUG|NXN-188|200 mg capsules, 600 mg, PRN
214983285|NCT00959751|DRUG|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
214983286|NCT06284473|DRUG|Ketamine|Ketamine is an N-methyl-D aspartate receptor agonist
214983287|NCT06284473|OTHER|Saline|Intranasal saline flushes pollen, dust, and other debris from nasal passages. It also removes excess mucus and adds moisture
214983288|NCT00434252|DRUG|bevacizumab|15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
214983289|NCT00434252|DRUG|carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
214983290|NCT00434252|DRUG|paclitaxel|175 mg/m\^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
214983291|NCT00434252|DRUG|placebo|Administered by IV infusion on the first day of each 3-week cycle
215088447|NCT01278316|BEHAVIORAL|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
214369381|NCT05810493|OTHER|Observation|Follow-up of disease, therapeutics and evolution
214369382|NCT05556720|BIOLOGICAL|Pfizer Bivalent COVID-19 Vaccine|One or Two doses three months apart, per manufacturer's recommendations.
214983292|NCT02898467|OTHER|diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
214983293|NCT02898467|OTHER|non-diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
214983294|NCT04734613|BEHAVIORAL|Tai Chi exercise|Yang style Tai Chi 16 movements
214983295|NCT04734613|BEHAVIORAL|self management|health education and dietary counseling
214983296|NCT03950804|DRUG|Eculizumab Injection|Patients receive eculizumab as deemed necessary by the primary physician
214983297|NCT01735812|DEVICE|IceSense3 system|The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
214369383|NCT05556720|BIOLOGICAL|Moderna Bivalent mRNA vaccine|One or Two doses three months apart, per manufacturer's recommendations.
214492980|NCT06793293|DRUG|Non-steroidal anti- inflammatory drugs and antibiotics|It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) only.
214492981|NCT06795308|OTHER|Bed Position and Head Elevation|The first group will remain in the supine position for 6 hours after the Angiography procedure, and the treated leg will be kept straight and immobile. Patients will not move their legs during this period. A sandbag weighing approximately 4 kg will be placed over the catheter dressing for 6 hours to prevent bleeding and subcutaneous blood accumulation. For the first two hours, the patient will lie on his back and on a flat surface with his legs extended straight. During the remaining 4 hours, investigators will monitor the patient's bed head by raising it 15 degrees intermittently under the supervision of the doctor, and at the end of the 6th hour, the sandbag on the leg will be removed. Blood pressure, pulse rate, respiratory rate, body temperature, as well as pain level will be measured every two hours.
214492982|NCT06797323|BEHAVIORAL|Web-Based Application for Pelvic Floor Health|A user-friendly web application designed to provide educational resources, exercises, and interactive tools aimed at improving pelvic floor health in pregnant women.
214492983|NCT06940297|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214492984|NCT06940297|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214492985|NCT06940297|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214492986|NCT06940297|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214492987|NCT06940297|BIOLOGICAL|Ciltacabtagene Autoleucel|Given IV
214492988|NCT06940297|PROCEDURE|Computed Tomography|Undergo CT scan
214492989|NCT06940297|DRUG|Cyclophosphamide|Given IV
214492990|NCT06940297|DRUG|Dasatinib|Given PO
214492991|NCT06940297|DRUG|Fludarabine|Given IV
214492992|NCT06940297|PROCEDURE|Positron Emission Tomography|Undergo PET scan
215088448|NCT01278316|BEHAVIORAL|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
215088449|NCT05104619|PROCEDURE|tongue surgery|In squamous cell carcinoma of the tongue, complete surgical resection of the tumor
214983298|NCT05649501|OTHER|Proprioceptive neuromuscular facilitation techniques.|Proprioceptive neuromuscular facilitation stretching which include hold-relax and contract-relax for 6 sec hold, 10 repetitions and 2 min rest in between, for 5 day/week for 4 weeks along with conventional treatment for 40 minutes.
214983299|NCT05649501|OTHER|Traditional physical therapy|Conventional therapy (ROMs, stretching, strengthening) of lower limbs for 40 minutes.
214983300|NCT01008644|OTHER|Water|The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
214983301|NCT01008644|OTHER|Saline 3%|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
214983302|NCT02807259|BEHAVIORAL|Multi-level intervention|At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
214983303|NCT03861039|DRUG|Tirzepatide|Administered SC
214983304|NCT03861039|DRUG|Oral antihyperglycemic medication (OAM)|Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
214983305|NCT02442908|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|2 daily for 12 weeks
215088450|NCT00558532|PROCEDURE|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
215088451|NCT01743404|DIETARY_SUPPLEMENT|Inflaminat|
215088452|NCT01743404|DRUG|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
214983306|NCT02442908|DIETARY_SUPPLEMENT|Isocaloric placebo|2 daily for 12 weeks
214983307|NCT00719667|OTHER|coronary artery bypass grafting|on pump off pump
215088453|NCT00199225|DRUG|Rupatadine|
215088454|NCT00199225|DRUG|moxifloxacin|
215088455|NCT00199225|PROCEDURE|Continous electrocardiographic register|
215088456|NCT00199225|PROCEDURE|Pharmacokinetic profile|
215088457|NCT04311827|OTHER|Serratus Anterior Plane Block|Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
214492993|NCT06940297|DRUG|Quercetin|Given PO
214492994|NCT05292352|BEHAVIORAL|LFSD|"Assessment of child's usual diet to assess sugar intake in relation to the total usual diet.~Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home.~Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1."
214492995|NCT00683670|DRUG|cyclophosphamide|
214492996|NCT00683670|BIOLOGICAL|Mature dendritic cell vaccine|
214492997|NCT05854212|BEHAVIORAL|Behavioral economics-enhanced user interface|The intervention changes the ordering platform visible to food agencies using behavioral economics strategies to promote healthier food choices.
214492998|NCT05787054|OTHER|Third trimester ultrasound|Single scan versus Longitudinal scan
214492999|NCT05023434|PROCEDURE|Intraoperative Brain Simulation - Alternate Stimulation Parameters|Additional stimulation parameters outside of standard of care during intraoperative brain stimulation to aid in motor mapping.
214493000|NCT02377700|DEVICE|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
214493001|NCT00655499|DRUG|Panitumumab|6 mg/kg
214493002|NCT00655499|DRUG|Irinotecan hydrochloride|180 mg/kg
214493003|NCT00655499|GENETIC|Chromogenic in situ hybridization|
214493004|NCT00655499|GENETIC|Fluorescence in situ hybridization|
214493005|NCT00655499|GENETIC|Gene expression analysis|
214493006|NCT00655499|OTHER|Laboratory biomarker analysis|
214493007|NCT06324240|BIOLOGICAL|Ipilimumab|Given IV
214493008|NCT06324240|BIOLOGICAL|Pembrolizumab|Given IV
214493009|NCT06324240|BIOLOGICAL|Vaccine Therapy|Given TMV vaccine ID
214493010|NCT01078909|BIOLOGICAL|Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)|Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
214493011|NCT05152849|DRUG|AXA1125|AXA1125 administered BID with or without food
214493012|NCT05152849|DRUG|Placebo|Matching Placebo administered BID with or without food
214493013|NCT03140670|DRUG|RUCAPARIB|Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
214493014|NCT00569634|PROCEDURE|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always \< 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
214493015|NCT00792337|DRUG|simvastatin|10 mg per oral once daily for 8 weeks
214983308|NCT02733419|DRUG|Enfuvirtide|Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.
214983309|NCT02733419|DRUG|Optimized background antiretroviral regimen (OB)|Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
215088458|NCT02481713|BEHAVIORAL|motivational interviewing|motivational interviewing
214983310|NCT06133166|DRUG|EG017 ointment|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
214983311|NCT06133166|DRUG|EG017 ointment placebo|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
214983312|NCT02868944|DRUG|experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).|
214983313|NCT02868944|DRUG|control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.|
214983314|NCT05679986|OTHER|no intervention|no intervention
215088459|NCT02481713|BEHAVIORAL|learning style interviews|interview and feedback about learning style
215088460|NCT01920152|BIOLOGICAL|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
215088461|NCT01920152|DEVICE|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
214369384|NCT05349825|DIAGNOSTIC_TEST|Genetic analysis and Losartan plazma level measurement|20 ml of blood was collected from the enrolled patients. 10 ml of blood was stored in the tubes with ethylene diamine tetraacetic acid (EDTA) until Deoxyribonucleic acid (DNA) isolation was performed at -20 degrees and plasma level was identified. The remaining 10 ml was centrifuged at 3500 rpm for 10 min, and the plasma was separated. The resulting plasmas were stored in the eppendorf tubes at -20°C until the tandem mass spectrometry measurement. The blood samples in EDTA tubes were then transferred for DNA analysis. . To measure plasma losartan concentration, after the frozen plasma samples stored in the eppendorfs were thawed and brought to room temperature, plasma losartan and EXP3174 levels of the patients were calculated using tandem mass spectrometry
214369385|NCT03670667|OTHER|Non-Interventional|Non-Interventional
214369386|NCT03670667|OTHER|Non-Interventional|Non-Interventional
214369387|NCT03670667|OTHER|Non-Interventional|Non-Interventional
214369388|NCT01868295|BEHAVIORAL|Sleeping with denture|Sleeping with denture at night
214369389|NCT04367584|OTHER|Clinical and laboratory examination|Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
214493016|NCT00792337|DRUG|B1-6-12|1 table per day for 8 weeks
214493017|NCT02377193|DRUG|Simulect|"Simulect IV 40 mg/day D0 and D4~and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg"
214493018|NCT02377193|DRUG|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
214493019|NCT00220805|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
214493020|NCT00220805|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
214493021|NCT06454474|DEVICE|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states.
214493022|NCT01355172|BIOLOGICAL|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
214493023|NCT03351400|BIOLOGICAL|Stem cells administered to participants|Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
214493024|NCT02984345|OTHER|Mycoprotein beverage|Mycoprotein protein beverage
214493025|NCT02984345|OTHER|Milk protein beverage|Milk protein beverage
214493026|NCT02867982|PROCEDURE|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
214983315|NCT01673386|DRUG|Tivozanib|
214983316|NCT01673386|DRUG|Sunitinib|
214983317|NCT05726253|DRUG|Supportive Care + Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (7 days)
214983318|NCT05726253|DRUG|Supportive Care + Placebo (no antibiotics)|Participants will be randomized to receive oral placebo for a standard course (7 days)
214983319|NCT01026935|DEVICE|Open inguinal hernia repair|Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
214983320|NCT05252338|BIOLOGICAL|CVSQIV|Participants will receive an intramuscular injection by needle in the deltoid area.
214983321|NCT00000204|DRUG|Buprenorphine|
214983322|NCT02576600|DEVICE|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
214983323|NCT02576600|OTHER|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
215088462|NCT04082013|OTHER|Hamstring Flexibility|"The active knee extension test has been proposed as the gold standard for assessment of hamstring flexibility, as it utilizes readily available equipment and offers a quick, reliable, and low-cost alternative for measurement of hamstring flexibility (Connor et al; 2015).~* The subject will be instructed to maintain 90° hip flexion in the supine position.~* Then asked to actively extend the knee joint.~* The degree of achieving active knee extension will be measured using a universal goniometer.~* The average of three active knee extension measurements will be used as the hamstring muscle length for the data analysis (Dong-Kyu Lee, et al; 2018).~  * the procedures will be done with opposite-leg flexed, then repeated with opposite-leg extended."
215088463|NCT03755232|DIETARY_SUPPLEMENT|scFOS|Fossence™ (short chain Fructo-oligosaccharides (scFOS)
215088464|NCT03755232|OTHER|Control|water or dextrose or white bread
215088465|NCT01883648|DRUG|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
215088466|NCT01883648|OTHER|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
214983324|NCT02576600|DRUG|Propofol|TCI
214983325|NCT02576600|DRUG|Remifentanil|TCI
214983326|NCT03524001|DEVICE|Compare VVi mode versus DDD bifocal stimulation through crossover randomization|All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.
214983327|NCT01588275|DEVICE|mandibular repositioning appliance (MRA) (SomnoDent)|bibloc MRA type SomnoDent starting at 70% protrusion of the mandibula
214983328|NCT01588275|PROCEDURE|Continuous positive airway pressure (CPAP)|Proper CPAP-pressure will be set for each patient separately.
214983329|NCT00008697|DRUG|arsenic trioxide|
214983330|NCT04555447|DIETARY_SUPPLEMENT|Agavins (prebiotic fiber)|Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
214983331|NCT04555447|DIETARY_SUPPLEMENT|Placebo|Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
215088467|NCT01706042|OTHER|legume meal|
215088468|NCT01706042|OTHER|white bread|
215088469|NCT04292990|DRUG|Fentanyl|Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
215088470|NCT04292990|DRUG|Morphine|Tablets taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
215088471|NCT04841603|DEVICE|Mindshift CBT|A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
215088472|NCT04841603|DEVICE|Treatment as Usual|Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
215088473|NCT02165462|OTHER|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
215088474|NCT01777945|DRUG|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
215088475|NCT01777945|DRUG|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
215088476|NCT03490149|DEVICE|Electroconvulsive Therapy|Series of electroconvulsive therapy for major depressive disorder
214983332|NCT00895713|DRUG|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
215088477|NCT03490149|DRUG|Medication - Treatment as usual|Medication only sample - Treatment as usual
215088478|NCT04053595|DIAGNOSTIC_TEST|Dynamic parameters of fluid responsiveness protocol|Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume \>10% after fluid administration.
214983333|NCT06217471|PROCEDURE|Carotid Endoarterectomy|Surgical removal of atherosclerotic plaque from the carotid artery, collection of blood samples
214983334|NCT02880501|DEVICE|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
215088479|NCT04053595|DIAGNOSTIC_TEST|Estimated oxygen extraction protocol|Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
215088480|NCT02680210|OTHER|Questionnaires and cognitive measures|
215088481|NCT02564861|DRUG|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
215088482|NCT02564861|DRUG|Placebo|Placebo matching DS-1971a suspension
215088483|NCT01995552|DEVICE|External Loop Recorder|
214493027|NCT02867982|PROCEDURE|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
214493028|NCT02867982|DRUG|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
215094540|NCT04187742|BEHAVIORAL|Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)|Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
214983335|NCT06066775|OTHER|Observation study without intervention|Observation study without intervention
214983336|NCT02862509|DRUG|Budesonide nasal instillation|
214983337|NCT02862509|DRUG|Normal saline nasal instillation|
214983338|NCT02934178|BIOLOGICAL|Shigella sonnei Strain WRSS1 Vaccine|Live attenuated, oral Shigella WRSS1 vaccine
214983339|NCT02934178|BIOLOGICAL|Placebo|Sterile saline solution
214983340|NCT04663113|OTHER|Control Group/1st group ( standard physiotherapy|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
215088484|NCT05553275|PROCEDURE|Usual Care|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely managed with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor. Blood sugars of more than 110 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour. If blood sugar 111-140, insulin drip at 1 unit/hour will be given and continued if blood sugar is 111-140.If blood sugar is 141-180, then drip will be changed to to 1.5 unit/hour and if blood sugar is 181-220, drip will be changed to 2.0 units/hour and MD will be called if blood sugar is more than 221 mg/dl"
214983341|NCT04663113|OTHER|2nd group- Standard physiotherapy + bicycle ergometer|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given."
215094541|NCT02272179|BEHAVIORAL|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
214369390|NCT02961530|OTHER|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
214983342|NCT04663113|OTHER|3rd group- Standard physiotherapy + exercise protocol to be developed|"Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.~Portable indirect calorimetry will be used to measure the basal metabolic rates of the patients.~The basal metabolic rates of the patients will be measured before the exercise and aerobic exercise or resistant exercise will be given according to the metabolic state of the patient.~Ratings of perceived exertion (RPE) will be used as the aerobic exercise protocol and a 10-11 strength exercise will be given according to the RPE.~If resistance exercise will be given, the intensity of the exercise (12-14) will be determined according to the RPE. Sandbags attached to the ankle will be used as a resistance exercise and 9 exercises were determined. (Knee extension, knee flexion, trunk flexion, trunk extension, hip extension, hip flexion, hip abduction, shoulder flexion, shoulder abduction"
214493029|NCT02867982|DEVICE|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
214493030|NCT02867982|RADIATION|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
214493031|NCT05320094|DRUG|Mavacamten|Specified dose on specified days
214493032|NCT05320094|DRUG|Activated Charcoal with Sorbitol|Specified dose on specified days
214493033|NCT06360133|DRUG|VVN001 Ophthalmic Solution, 5%|VVN001 Ophthalmic Solution, 5%
214493034|NCT06360133|DRUG|VVN001 Ophthalmic Solution, Vehicle|VVN001 Ophthalmic Solution, Vehicle
214493035|NCT05044598|OTHER|RAFT-OS|RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) is an artificial tissue, populated with limbal epithelial cells and stromal cells.
214493036|NCT06450587|DEVICE|iCare IC1000|Measurement of Intraocular Pressure (IOP)
214493037|NCT06450587|DEVICE|iCare ST500|Measurement of Intraocular Pressure (IOP)
214493038|NCT06450587|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP)
214493039|NCT06450587|DEVICE|GAT|Measurement of Intraocular Pressure (IOP)
214493040|NCT05142215|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention using drug eluting stents and contemporary CTO PCI techniques on background of optimal medical therapy.
214983343|NCT03126149|DRUG|PF-06667272|Single ascending dose of PF-06667272
214983344|NCT03126149|OTHER|Placebo|Single dose of placebo
214983345|NCT02963324|DRUG|Ivermectin|
214493041|NCT05142215|PROCEDURE|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention procedure on background of optimal medical therapy.
214493042|NCT06579157|OTHER|Pressure-Sensing Mattresses|using ballistocardiography (BCG) for monitoring respiration and heart rate in neonates
214493043|NCT01203722|DRUG|Fludarabine|Fludarabine 30 mg/m2/day
214493044|NCT01203722|DRUG|Cytoxan|Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day
214493045|NCT01203722|RADIATION|Total Body Irradiation|400 cGy TBI administered in a single fraction
214493046|NCT01203722|PROCEDURE|Allogeneic Blood or Marrow Transplant|
214983346|NCT04323592|DRUG|Methylprednisolone|Usual standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 \> 350 mmHg or a CRP \< 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to \< 20% of normal range and/or PaO2:FiO2 \> 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient.
214983347|NCT04323592|OTHER|standard care|"usual standard of care:~* oxygen therapy (regular or high-flow) and monitoring~* empiric antibiotic therapy~* mechanical ventilation (invasive or noninvasive)~* ECMO when needed and available~* pronation when possible~* other treatment which can be used are: antivirals, chloroquine, vitamins"
214983348|NCT00542308|DRUG|Zalutumumab|Individual dose titration weekly i.v. doses
214983349|NCT00357942|DRUG|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
214983350|NCT00357942|DRUG|Placebo|Placebo mouthwash
214983351|NCT00357942|DRUG|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
214369391|NCT02961530|OTHER|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
214369392|NCT01704469|PROCEDURE|The local anesthetic injection|
214369393|NCT04639388|BEHAVIORAL|neuropsychological testing, questionnaires and experimental tasks|Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
214369394|NCT05078931|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles
214369395|NCT05078931|DRUG|Lenvatinib|Lenvatinib 20mg will be administered orally daily.
214369396|NCT06156423|OTHER|Motor control exercise|Motor control exercises include stabilization exercises for the scapula with external focus by activating the correct alignment and kinetic chain by providing verbal feedback and visual feedback.
214369397|NCT06156423|OTHER|Standard exercise|The standard rehabilitation group received a rehabilitation program via video call 3 days a week for 12 weeks.
214369398|NCT05440370|DEVICE|MegaCarti®|MegaCarti® application after microfracture through athroscopic or incision surgery
214369399|NCT05440370|PROCEDURE|Microfracture|Microfracture through athroscopic or incision surgery
214369400|NCT03019926|BIOLOGICAL|Hydroxychloroquine dosage|Blood sample from a 6 ml tube, performed in the common practice.
214369401|NCT02718274|DEVICE|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|Community based distribution of self-tests
214369402|NCT02718274|OTHER|Home-based initiation of ARVs|Home-based initiation of ARVs by study nurse linked to follow-up at clinic
214369403|NCT02303184|DRUG|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
214369404|NCT02303184|DRUG|Sham|suprachoroidal sham procedure
214369405|NCT02303184|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
214369406|NCT01422408|DRUG|Fluocinonide Cream|Given topically
214369407|NCT01422408|PROCEDURE|Management of Therapy Complications|Receive fluocinonide cream
214369408|NCT01422408|OTHER|Questionnaire Administration|Ancillary studies
214369409|NCT03185481|DRUG|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
214369410|NCT03185481|DRUG|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
214369411|NCT03185481|DRUG|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
214369412|NCT03185481|DRUG|15 mg QD PF-06649751|15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751
214493047|NCT01203722|PROCEDURE|Peripheral Blood Stem Cell Transplant|
214493048|NCT01203722|DRUG|Mycophenolate Mofetil|15mg/kg by mouth three times daily
214493049|NCT01203722|DRUG|Sirolimus|Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
214493050|NCT01203722|DRUG|Tacrolimus|Tacrolimus 1mg intravenously, daily
214493051|NCT06275464|COMBINATION_PRODUCT|BT-600|NaviCap device containing liquid formulation of Tofacitinib
214983352|NCT00357942|DRUG|Placebo|Placebo solution for injection every 3 hour for 24 hours
214983353|NCT01898078|DRUG|Alisertib|Alisertib ECT
214983354|NCT02588508|PROCEDURE|Warm packs|: The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
214369413|NCT03185481|DRUG|1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)|Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study
214369414|NCT03185481|DRUG|3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study
214493052|NCT06275464|COMBINATION_PRODUCT|BT-600 Placebo|NaviCap device containing placebo formulation
214493053|NCT06060977|DRUG|IMG-007|Intravenous Infusion
214493054|NCT06519617|DRUG|Yi Qi Yang Yin Decoction|The Yi Qi Yang Yin Decoction (Dihuang 15g, Baihe 12g, Nanshashen 15g, celery Qinghao 10g, Malt 10g, Shengma 6g, Chaihu 6g) prescription for patients eligible for qi and yin deficiency was 200 ml twice daily for 12 weeks.
214493055|NCT06519617|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.
214983355|NCT02588508|PROCEDURE|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
214983356|NCT04176523|DRUG|Carglumic Acid|Maintenance therapy with carglumic acid
214983357|NCT05226377|DIAGNOSTIC_TEST|Atherogenic Index of Plasma|\- The atherogenic index of plasma (AIP) is defined as the base 10 logarithms of the ratio of plasma triglyceride (TG) to high-density lipoprotein cholesterol (HDL-c) (17). AIP was employed as a predictor of cardiac risk (CR) with values of -0.3 to 0.1 are associated with low, values of 0.1-0.24 are associated with the medium, and values above 0.24 with high CR
214983358|NCT06440512|OTHER|Dark chocolate Intervention|The intervention involves daily consumption of 50 grams of dark chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.
214983359|NCT06440512|OTHER|White chocolate Intervention|The intervention involves daily consumption of 40 grams of white chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.
214983360|NCT00234741|DRUG|STA-5326 mesylate|
214983361|NCT05849805|PROCEDURE|Intracalvaria bone marrow injection|Intracalvaria bone marrow injection Y-3 (dose was given at 32 ug/kg), continuous medication for 3 days
214983362|NCT05849805|OTHER|Conventional treatment|standard treatment and management according to related guidelines
214983363|NCT05700864|DRUG|Cenegermin-Bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in both eyes every 3 hours 4 times daily for 4 weeks
214983364|NCT06199739|BEHAVIORAL|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
214983365|NCT00631293|DIETARY_SUPPLEMENT|lactisole|administration of lactisole followed by placebo
214983366|NCT00631293|OTHER|placebo|administration of placebo followed by lactisole
214983367|NCT00171535|DRUG|valsartan/amlodipine|
214493056|NCT06091449|OTHER|High fidelity simulation|Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).
214493057|NCT06091449|OTHER|Virtual reality|"For the virtual reality-based simulation application, students can log in to the virtual reality-based simulation program prepared in line with the Diabetes Mellitus scenario using their username and password; They will receive modular training integrated into the simulation. The expected time for students to complete the modular training is 30 minutes. Students who complete the module will be asked to take a 10-minute break and then participate in a virtual reality-based simulation application.The application of high-fidelity simulation is the same in both groups."
214493058|NCT05971875|PROCEDURE|vNOTES vs Vaginal Hysterectomy|Comparison of vNOTES vs VH
215094542|NCT02272179|BEHAVIORAL|Brite|Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.
214983368|NCT05641571|BEHAVIORAL|The home-based extremity exercise program|Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time before chemotherapy to the completion of chemotherapy.
214983369|NCT00002844|DRUG|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
214983370|NCT00002844|PROCEDURE|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
214369415|NCT03185481|DRUG|7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study
214369416|NCT03185481|DRUG|15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD|7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
214369417|NCT03401684|BEHAVIORAL|Resilient Minds|The program is designed: 1) to decrease the risk of developing a stress disorder or other mental illnesses due to workplace incidents and/or unhealthy stress; 2) to mitigate the negative impacts of mental illness and trauma through early recognition and early intervention; 3) to support the public while on the frontline; and 4) to improve the psychological health of fire staff while cultivating resilience and enhancing quality of life.
214369418|NCT06383585|DEVICE|oZTEo|An FDA approved MRI pulse sequence, oZTEo, will be added to a standard of care MRI examination. The oZTEo pulse sequence will be anonymized and sent to GE Healthcare for the application of a deep learning algorithm, 3D DL.
214493059|NCT05971875|PROCEDURE|vNOTES vs Laparoscopic Hysterectomy|Comparison of vNOTES vs LH
214493060|NCT03572803|OTHER|Group of Dry Needling|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
214493061|NCT03572803|OTHER|Group of Electrolysis|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
214493062|NCT03572803|OTHER|Control Group|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
214493063|NCT00146172|DRUG|neratinib|HKI-272
214493064|NCT01902914|PROCEDURE|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
214493065|NCT00838461|DRUG|HSD-016|
214493066|NCT00838461|DRUG|placebo|
214983371|NCT00002844|PROCEDURE|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
214983372|NCT00002844|RADIATION|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
214983373|NCT02022358|DRUG|Glucarpidase|Glucarpidase rescue (50 units/kg x 1, intravenously)
214983374|NCT02022358|DRUG|Methotrexate|Methotrexate (12 g/m2 x 1, intravenously)
214983375|NCT02022358|DRUG|Folinic Acid|Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
214983376|NCT03957993|OTHER|Occupational Therapy via Telehealth|The caregiver will be with the participant in their home environment receiving occupational therapy via Telehealth (video-calling) with the occupational therapist.
214983377|NCT03957993|OTHER|Standard of Care Occupational Therapy|The caregiver and participant will be in the clinic receiving occupational therapy in-person with the occupational therapist.
214983378|NCT00560963|DRUG|everolimus|
214983379|NCT05297357|DIETARY_SUPPLEMENT|Mediterranean Diet weaning scheme|Kids in experimental group were weaned by using fresh foods traditionally used in MD and appropriately adapted to infants including seasonal fruit and vegetables, various kinds of fresh blue fish, spices and herbs. No salt was used while a small amount of Parmesan cheese was added. No sugar was added to any meal.
214983380|NCT01140906|DRUG|Placebo|capsules, daily, orally
214983381|NCT01140906|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
214983382|NCT01140906|DRUG|Duloxetine|encapsulated capsules, daily, orally
215088485|NCT05553275|PROCEDURE|Permissive intrapartum glucose control|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely management with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor.Blood sugars of more than 180 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour.If blood sugar is 181-200, insulin drip at 1 unit/hour will be given. If blood sugar is 201-220, then drip will be changed to 1.5 units/hour. If blood sugar is 221 - 250, then drip will be changed to 2.0 units/hour and if blood sugar is more than 251 MD will be called."
215088486|NCT02606760|DRUG|P-3073|
214983383|NCT04968704|OTHER|3D photography and computer modelling|3D photography is available at our unit department of clinical photography. Photos will be taken and the associated NHS software (Canfield Imaging scientific, inc) used to sit down with the patients and model their reconstruction, thereby reducing anxiety and improving awareness of their treatment plan.
215088487|NCT02606760|DRUG|Vehicle of P-3073|
214681010|NCT03408873|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
214681011|NCT02990481|BIOLOGICAL|TRK-950|Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle
214681012|NCT02990481|BIOLOGICAL|TRK-950|"Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle~High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle"
214681013|NCT02990481|BIOLOGICAL|TRK-950|Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle
214681014|NCT01806870|DIETARY_SUPPLEMENT|Zinc and SAMe|If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
214983384|NCT01182025|OTHER|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
214983385|NCT01182025|DRUG|Xiyanping Injection|"Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor."
214983386|NCT01182025|DRUG|Xiyanping Injection with western medicine|"1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Symptomatic treatment using the same treatment methods in Xiyanpin injection group."
214983387|NCT05401175|OTHER|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemoradiotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemoradiotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
215088488|NCT02864173|GENETIC|Whole genome small nucleotide polymorphism genotyping|
215088489|NCT00353873|DRUG|Fluticasone propionate|200μg twice daily
215088490|NCT00353873|DRUG|Fluticasone propionate/salmeterol|50/100μg twice daily
215088491|NCT03109691|DRUG|bupivacaine|group 1
215088492|NCT03109691|DRUG|Dexamethasone|group 2
215088493|NCT03109691|DEVICE|ultrasound|in all groups
214681015|NCT01600131|BEHAVIORAL|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
215088494|NCT01968057|DRUG|Baricitinib|Administered orally
215088495|NCT01968057|DRUG|Ciclosporin|Administered orally
215094543|NCT02272179|BEHAVIORAL|Treatment as Usual|Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.
215094544|NCT03994315|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
215094545|NCT03994315|OTHER|Lacto-N-tetraose (LNT)|LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
215094546|NCT01472211|DEVICE|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
215094547|NCT01472211|DEVICE|placebo filter|filter purifies water
215094548|NCT01472211|OTHER|disinfection tablets|government promoted tablets disinfect water
214681016|NCT01600131|OTHER|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
214681017|NCT04772365|DRUG|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels;
214681018|NCT04772365|DRUG|Placebo|Placebo will be subcutaneously administered with different dose levels;
214983388|NCT04064268|DIETARY_SUPPLEMENT|Whey|45 g whey + 20 g maltodextrin
214983389|NCT04064268|DIETARY_SUPPLEMENT|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
214983390|NCT00703534|DRUG|AZD3355|Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
214493067|NCT05786378|BIOLOGICAL|Platelet Rich Plasma|"Sample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use.~Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~PRP activation prior to injection. PRP can be activated exogenously by calcium chloride."
214983391|NCT00703534|DRUG|Placebo|capsule. administered as a single dose twice daily for 4 weeks
214681019|NCT02961647|PROCEDURE|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
214983392|NCT00703534|DRUG|Gelusil®|Chewable tablets taken as needed
214983393|NCT06472921|BEHAVIORAL|Butylphthalide treatment initiation time|Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group (\&lt;3 hours) and a late initiation group (3-6 hours).
214983394|NCT06258252|OTHER|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
214983395|NCT04831710|DRUG|Sintilimab|Sintilimab,200mg, ivd, d1
214983396|NCT04831710|DRUG|Chidamide|Chidamide,30mg,po,biw,d1-21
215088496|NCT02819960|DRUG|Probio-Tec® BG-VCap-6.5|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
214983397|NCT02177994|DRUG|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
214983398|NCT00134134|DRUG|efalizumab|
214983399|NCT04168242|DEVICE|Scalp cooling Paxman Orbis II system|The experimental arm will have scalp cooling that starts 30 minutes before the chemotherapy, continues throughout the infusion of the chemotherapy, and lasts for 20-90 minutes more depending on the type of regimen.
214493068|NCT05786378|DRUG|local anesthesia in external auditory canal|local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
214681020|NCT00013598|DRUG|Pioglitazone|
214681021|NCT02519244|DEVICE|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
214681022|NCT03534258|DEVICE|Ceribell Rapid Response EEG, Survey|This trial will qualitatively examine how information from rapid response and conventional EEG data changes physicians' diagnostic suspicion or their treatment decisions and confidence levels. In addition, the results will examine the mean time to EEG lead placement, and ease of use.
214983400|NCT04168242|OTHER|Standard treatment|The control arm will not have scalp cooling before, during and after chemotherapy.
214983401|NCT04553419|DRUG|Cephalexin|Cephalexin capsule: TEVA Cephalexin Cephalexin suspension: LUPIN Cephalexin
214983402|NCT04553419|DRUG|Placebo|Cellulose capsules or suspension
214983403|NCT03968809|DIAGNOSTIC_TEST|CardioFlux Magnetocardiography|All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.
214983404|NCT00171275|DRUG|Fluvastatin|
214983405|NCT00666770|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
214983406|NCT00666770|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
214983407|NCT00666770|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
214983408|NCT00900562|DRUG|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
214983409|NCT03496740|PROCEDURE|Penile Block|Ultrasound guided dorsal penile nerve block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
214983410|NCT03496740|PROCEDURE|Pudendal Block|Nerve stimulation guided bilateral pudendal block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
214983411|NCT03496740|DRUG|Bupivacaine (Block Drug)|Block drug
214983412|NCT02661308|DEVICE|Litebook|
214983413|NCT03720587|OTHER|Semi-structured interviews|Semi-struuctured telephone interviews
215088497|NCT02819960|DRUG|Placebo|Maltodextrin
215088498|NCT05443282|DIAGNOSTIC_TEST|Prolidase Level|Measurement of venous blood serum level of prolidase enzyme level by ELISA method.
215088499|NCT05443282|DIAGNOSTIC_TEST|Follicle Stimulating Hormone Level|Measurement of venous blood serum level of follicle stimulating hormone level.
215088500|NCT05443282|DIAGNOSTIC_TEST|Estradiol Level|Measurement of venous blood serum level of estradiol hormone level.
215088501|NCT05443282|DIAGNOSTIC_TEST|Proline Level|Measurement of venous blood serum level of proline level.
214983414|NCT02362022|DRUG|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
215088502|NCT05443282|DIAGNOSTIC_TEST|Hydroxyproline Level|Measurement of venous blood serum level of hydroxyproline level.
215088503|NCT05443282|DIAGNOSTIC_TEST|Anti-mullerian Hormone Level|Measurement of venous blood serum level of anti-mullerian hormone level.
215088504|NCT05443282|DIAGNOSTIC_TEST|Antral Follicle Count|Ultrasonographic evaluation of antral follicle count to determine ovarian reserve.
215088505|NCT05443282|DIAGNOSTIC_TEST|Prolactine Level|Measurement of venous blood serum prolactine hormone level.
215088506|NCT05443282|DIAGNOSTIC_TEST|Thyroid Stimulating Hormone Level|Measurement of venous blood serum thyroid stimulating hormone level.
214369419|NCT04735549|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
214681023|NCT02065440|DRUG|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
215088507|NCT00506597|DRUG|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m\^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m\^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
215088508|NCT03328416|DEVICE|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
214369420|NCT04735549|DRUG|Topical hormone estriol|Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
214369421|NCT04735549|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis, Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study).
214369422|NCT04735549|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
214369423|NCT04735549|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), cytology, microbiological analysis with Gram staining (to evaluate procedure efficiency).
214369424|NCT04735549|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
214369425|NCT04735549|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
214493069|NCT05786378|PROCEDURE|Intratympanic Injection|0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.
214493070|NCT05766202|OTHER|An group intervention for multiparas with fear of childbirth|The intervention consists of 4 group meetings, three during pregnancy and once after giving birth. It also includes a phone call.
214493071|NCT00772044|DEVICE|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
214493072|NCT00772044|DEVICE|Sham Device|Sham device will be applied
214681024|NCT02065440|DRUG|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
214983415|NCT00047827|DRUG|Micafungin|IV
214983416|NCT00047827|DRUG|Liposomal Amphotericin B|IV
214983417|NCT03587636|DRUG|liposome bupivacaine|interscalene block with liposomal bupivacaine plus bupivacaine
214983418|NCT03587636|DRUG|Bupivacaine|interscalene block with bupivacaine
214983419|NCT06140134|PROCEDURE|Liver Transplant|Whole liver allotransplantation will be performed for patients on the liver transplant waiting list
214983420|NCT02499107|DIETARY_SUPPLEMENT|Rice treatment|All arms are given to all participants, in a randomized (cross over) order
214983421|NCT02499107|DIETARY_SUPPLEMENT|Pasta treatment|
214983422|NCT02499107|DIETARY_SUPPLEMENT|Boiled and mashed potato treatment|
215088509|NCT03909451|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
215088510|NCT03909451|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
215088511|NCT01363934|DRUG|GC1113|"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."
215088512|NCT01363934|DRUG|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
215088513|NCT00870194|DRUG|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
214493073|NCT06950515|PROCEDURE|Peripheral EBUS under Concious sedation|In the conscious sedation group, the procedure will be performed through the nose or mouth at the discretion of the endoscopist. The patient will remain breathing spontaneously throughout the procedure and will be administered oxygen through a nasal cannula at an initial flow rate of 2L/min. A combination of propofol, fentanyl and midazolam boluses will be used to maintain moderate sedation. At IUCPQ-UL, fentanyl and midazolam will be used as in our routine practice. The boluses will be prescribed by a doctor experienced in conscious sedation (anesthesiologist, intensivist or pulmonologist) according to the patient's state of wakefulness assessed by the Richmond Agitation-Sedation Scale (RAS) .Centers will decide, prior to initiating recruitment locally, the drug combination used to sedate patients and they will maintain the use of the same drug combination throughout the study
214493074|NCT06950515|PROCEDURE|Peripheral EBUS under General Anesthesia|In the general anesthesia group, an endotracheal tube larger than 7 will be used. The patient will be kept non-arousable to non-nociceptive stimulation (RAS = -5) by a perfusion including, at the anesthesiologist's discretion: fentanyl, sufentanyl, remifentanyl, midazolam or propofol. The sedation of this group will not be protocolized given the wide variety of practices in the participating centers, but the targeted level of sedation will be and the medication administered will be adjusted according to this target. The RAS will be evaluated every 5 minutes, or earlier if signs of arousal are present, to ensure that the intended target is maintained and adjustments to the rate of infusions as well as boluses may be made/administered by the anesthesiologist to maintain the targeted level of sedation. Patients may be paralyzed at the discretion of the anesthesiologit. The ventilatory parameters will be standardized according to the VESPA protocol
214681025|NCT02739334|BEHAVIORAL|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
214681026|NCT02739334|BEHAVIORAL|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
214681027|NCT03253198|DRUG|Saline|A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
214681028|NCT03253198|DRUG|Bupivacaine liposome|an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
214681029|NCT02713581|BIOLOGICAL|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
214681030|NCT01312428|DEVICE|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
214681031|NCT01312428|DEVICE|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
214681032|NCT04191278|DRUG|Varenicline|All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84
214681033|NCT04191278|DEVICE|Mobile phone application|Participants randomized to 2 of the 3 study groups will receive a mobile phone application designed to improve adherence to medication. The app has a number of functions, including: a) reminders to take medication; b) information about coping strategies for dealing with side effects and withdrawal symptoms; c) provision of a personalized graphical display of treatment progress (e.g., adherence, side effects); d) camera-based verification of having taken medication.
214681034|NCT04191278|BEHAVIORAL|Contingency management|Participants randomized to 1 of the 3 study groups will receive monetary reinforcement contingent upon verified medication adherence behaviors. Participants in the other 2 groups will be yoked to a participant in the CM group so that they also have a chance of earning monetary reinforcers, though not contingent upon their own behaviors.
214681035|NCT03143582|OTHER|Running|A 13-week running program where youth run for 30 minutes twice weekly.
214681036|NCT05508776|DRUG|LEO 152020|"Film-coated tablet~Route of administration: Orally~50 mg tablets"
214983423|NCT02499107|DIETARY_SUPPLEMENT|Baked french fries treatment|
214983424|NCT02499107|DIETARY_SUPPLEMENT|Fried french fries treatment|
214681037|NCT05508776|DRUG|Moxifloxacin|"Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet"
214681038|NCT05508776|DRUG|Placebo|"Film-coated tablet~Route of administration: Orally~No active ingredient"
214983425|NCT03738280|DIAGNOSTIC_TEST|Endoscopic ultrasound-fine needle biopsy|Patients with non-hypovascular solid pancreatic lesion undergo endoscopic ultrasound-fine needle biopsy
214983426|NCT04742218|DRUG|K-877|K-877 Tablet
214983427|NCT00779337|BIOLOGICAL|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
214983428|NCT04954872|BEHAVIORAL|Standard Problem Management Plus training (training as usual)|10-day training on Problem Management Plus.
214983429|NCT04954872|BEHAVIORAL|Equip-based Problem Management Plus training|Training and supervision for Problem Management Plus in which the trainers and supervisors use the EQUIP platform for competency assessment and feedback.
214983430|NCT03965585|PROCEDURE|in-office hysteroscopy|in-office hysteroscopy with miniaturized instruments
214983431|NCT03434262|DRUG|Gemcitabine|Given intravenously (IV).
214983432|NCT03434262|DRUG|ribociclib|Given orally (PO).
214983433|NCT03434262|DRUG|sonidegib|Given PO.
214983434|NCT03434262|DRUG|trametinib|Given PO.
214983435|NCT03434262|BIOLOGICAL|filgrastim|Given subcutaneously (SQ).
214983436|NCT02827539|DEVICE|LessRay|A software device has been developed that combines the benefits of reduced radiation associated with low-dose and/or pulse settings while preserving and possibly offering enhanced resolution. LessRay is a software device that is viewed on a separate monitor next to the fluro screen of the C-arm.
214983437|NCT02827539|DEVICE|Standard Fluoroscopy|For control arm, patients will receive the standard fluoroscopy for imaging.
214983438|NCT00202488|DRUG|H. pylori treatment|
214983439|NCT01503047|DIETARY_SUPPLEMENT|Tonalin®|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
214983440|NCT01503047|DIETARY_SUPPLEMENT|Placebo|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
214983441|NCT04740853|BEHAVIORAL|Sensory Integration Therapy+Special Education|Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
214983442|NCT05731596|DRUG|Rosuvastatin 20 Mg Oral Tablet|Rosuvastatin 20 mg will be administered orally once daily for 3 Months
215088514|NCT00870194|DRUG|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
215094549|NCT03234231|BEHAVIORAL|3-month supervised tooth brushing programme|One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
214681039|NCT01262261|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
214983443|NCT05731596|DRUG|Coenzyme Q10 100 MG Oral Capsule|Coenzyme Q10 100 mg will be administered orally once daily for 3 Months
214983444|NCT03161054|DRUG|Prednisone|"Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast)."
214983445|NCT03161054|DRUG|Vinorelbine|"Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast)."
214983446|NCT03161054|DRUG|Etoposide|Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
214983447|NCT03161054|DRUG|Cyclophosphamide|"Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner)."
214983448|NCT03161054|DRUG|Rituximab|Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
214983449|NCT02665117|DRUG|Potassium Magnesium Citrate (KMgCit)|KMgCit will be administer for 4 months with chlorthalidone.
214983450|NCT02665117|DRUG|Potassium Chloride (KCl)|KCl will be administer for 4 months with chlorthalidone.
214983451|NCT02665117|DRUG|Chlorthalidone|Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
214369426|NCT04735549|OTHER|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
214369427|NCT04735549|OTHER|Vulvovaginal Symptoms Questionnaire|Vulvovaginal Symptoms Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
214369428|NCT04735549|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
214369429|NCT04735549|DIAGNOSTIC_TEST|Elastography (ultrasound investigation)|Ultrasound investigation for assessing elasticity / stiffness of tissues of vulva region with Mindray device (head L14-6WU) (to evaluate procedure efficiency).
214369430|NCT04735549|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with EmbaGYN device (to evaluate procedure efficiency).
214681040|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|6.5mg patch daily for 11 weeks
214681041|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|6.5mg patch daily for 11 weeks
214681042|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|12.5mg patch daily for 11 weeks
214983452|NCT00345267|DEVICE|Integrated Care Pathway|
214983453|NCT02453607|DRUG|Infliximab|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
215094550|NCT03234231|BEHAVIORAL|oral health education talk|It is conducted by a dentist, while written materials will be delivered to the students and their carers.
215094551|NCT02351284|OTHER|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
214369431|NCT04735549|OTHER|Visual Analogue Scale (VAS)|Visual Analogue Scale will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
214369432|NCT03051971|DEVICE|Vibrating Mesh Nebulizer|short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
214369433|NCT03051971|DEVICE|Jet Nebulizer|short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
214681043|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|12.5mg patch daily for 11 weeks
214681044|NCT03474133|DRUG|Brentuximab Vedotin|brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
214983454|NCT02453607|DRUG|thiopurine|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
214983455|NCT04176913|DRUG|LUCAR-20S CAR-T cells|An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
214983456|NCT00329316|DRUG|Crinone Gel 8%|
214983457|NCT02106273|DEVICE|Bronchial blocker (Coopdech, Arndt)|Using bronchial blocker with LMA
214983458|NCT02106273|DEVICE|LMA-ProsealTM|
214983459|NCT00257452|DRUG|tiotropium 18 mcg or 54 mcg qd|
214983460|NCT00257452|DRUG|placebo matching tiotropium qd|
214983461|NCT00257452|DRUG|moxifloxacin 200 mg|
214983462|NCT01244659|DRUG|Tacrolimus from EMS|Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
214983463|NCT01244659|DRUG|Prograf|Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
214983464|NCT04453683|DEVICE|Air-Q. ILA insertion of proper size|Success of fiberoptic guided intubation throuhgh Air Q supraglottic airway device
214983465|NCT04453683|DEVICE|ILMA insertion of proper size|Success of fiberoptic guided intubation throuhgh ILMA supraglottic airway device
214983466|NCT06508814|PROCEDURE|Lower Insufflation Pressure|Participants underwent laparoscopic hysterectomy with an insufflation pressure that is lower than the standard insufflation pressure used in this type of surgery.
214983467|NCT06508814|PROCEDURE|Standard Insufflation Pressure|Participants underwent laparoscopic hysterectomy with a standard insufflation pressure.
214983468|NCT01245348|GENETIC|SULT4A1-1 genetic test|SULT4A1-1 haplotype result (+/-)
214983469|NCT05828992|OTHER|No intervention administered|Survey only to gather people's experiences, opinions and needs.
214983470|NCT00001512|DRUG|Id-KLH Vaccine|
214983471|NCT00001512|DRUG|GM-CSF|
214983472|NCT00002438|DRUG|Itraconazole|
214983473|NCT05841511|BEHAVIORAL|"Chinese handwriting intervention program for children with ASD, named Go Go Handwriting - ASD version"|"The intervention program was developed and finalized by a group of occupational therapist specialists in the pediatric field. Thirty-six 20-minute activities with twelve activities for each handwriting fundamental skill were designed in this program.~All intervention activities were designed based on the characteristic of Chinese characters and included different types of characters.~The activities designed will also be graded according to the following principle: (1) the similarities between the character given, (2) the complexity of the figure or character in the activities, and (3) the frequency and level of therapist assistance.~Furthermore, a playful and interesting intervention context will also be integratedinto the program with the design of the adventure journey of an astronaut to further facilitate the motivation and participation of the participants in our program."
215088515|NCT01986972|OTHER|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
214493075|NCT06951178|DEVICE|TMJ Total Arthroplasty System (TMJ System)|All patients treated or to be treated with the TMJ Total Arthroplasty System for TMJ reconstruction. The TMJ Total Arthroplasty System (TMJ System) is a medical device intended to restore the TMJ. It comprises two articulating components: a temporal component and a mandibular component. The TMJ System is patient-specific based on the patient's anatomy and surgical treatment. Different shape designs are possible depending on the patient's anatomy and the type of surgery performed.
214983474|NCT03720119|DRUG|Lidocaine Hydrochloride|As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.
214493076|NCT06950307|RADIATION|Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer patients|Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer will be treated with 20x3 Gray (Gy), 5 days/week
214983475|NCT02271113|DRUG|GMI-1271|
214983476|NCT02271113|DRUG|Placebo|
214983477|NCT02271113|DRUG|Enoxaparin Sodium (Lovenox®)|
214983478|NCT04587804|DEVICE|rPMS+RF|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of the device will be applied over umbilicus and visible muscle contractions along with heating of the subcutaneous fat will be induced by the device.
214983479|NCT00129337|DRUG|Bavituximab|Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
214983480|NCT03743194|DRUG|Exparel 266 MG Per 20 ML Injection|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
214983481|NCT03743194|DRUG|Placebo|Patients randomized to standard analgesia technique will be given pain medications.
214983482|NCT03414632|DRUG|99mTc-PYP|Radioisotope used in the SPECT/CT imaging
214983483|NCT01944423|DRUG|d-cycloserine|d-cycloserine is a medication thought to be associated with fear extinction.
214983484|NCT01944423|DRUG|Pill Placebo|
215094552|NCT03082014|DRUG|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
215094553|NCT03082014|DRUG|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
215088516|NCT01986972|OTHER|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
214983485|NCT01944423|DRUG|Nicotine replacement therapy|All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
214983486|NCT01944423|BEHAVIORAL|Panic and Smoking Reduction Treatment|PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
214983487|NCT02654509|BIOLOGICAL|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
214983488|NCT05665998|DEVICE|ARC-BSI Cervical system|Unilateral implantation of a 64 channel - ECoG array over the sensory motor cortex combined with an implantation of 32 channel spinal cord stimulation system over the cervical region. The system decodes the motor attempts of the participant and translates those intentions into modulation of electrical stimulation.
214983489|NCT01829347|BIOLOGICAL|ELAD|ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
214983490|NCT01829347|OTHER|Standard of Care treatment|Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
214983491|NCT01289522|BIOLOGICAL|cetuximab IV|"* Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.~* Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.~* Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.~Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy."
214983492|NCT01289522|OTHER|Biopsies|No intervention, only biopsy for translational project.
214983493|NCT06279078|DRUG|Corticosteroid|oral/inhaled corticosteroid
214983494|NCT03547609|OTHER|No arm intervention|No arm intervention
215088517|NCT02717130|DRUG|Aripiprazole|
215094554|NCT03082014|DRUG|Atenolol|blood pressure lowering agent - beta-blocker
215094555|NCT02624336|OTHER|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
215094556|NCT02624336|OTHER|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
215094557|NCT02624336|OTHER|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
215094558|NCT03597282|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
214369434|NCT04492527|BEHAVIORAL|Telehealth coaching sessions|Participants will be receiving a 2-month coaching session intervention that will be delivered via telephone or video-conferencing. Each of the 6 sessions will be 30-45minutes long and one-on-one with a student coach. In each session, coaches will review the participants' health behaviours and assess their knowledge about behavioural risks factors for chronic diseases and their current behaviours. The coaches will then provide information about the health risks of poor health behaviours, and benefits of change. Health behavioural goals will be established through a collaborative process. The coaches will then assist participants to develop readily achievable action plans that participants will follow in between coaching sessions as a means to realize their health goals. Adherence and modifications to the action plans will be discussed at the follow-up coaching session to promote health accountability.
214369435|NCT00701038|DEVICE|auto adjusting bi-level positive airway pressure device|auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
214369436|NCT03079154|OTHER|Teacher-led MBCT course|9 x 2 hour group sessions following national guidelines for mindfulness-based cognitive therapy
214493077|NCT06950307|RADIATION|Hypofractionated radiotherapy for high-risk prostate cancer patients|Hypofractionated radiotherapy for high-risk prostate cancer will be treated with 20x3.1 Gy, 5 days/week
214493078|NCT03684590|DEVICE|ANI-guided opioid administration|Intraoperative opioid will be administered guided by analgesia nociceptive index (ANI) values measured by ANI monitor (MetroDoloris Medical Systems, Lille, France)
214493079|NCT03684590|OTHER|Standard opioid administration|Intraoperative opioid will be administered according to standard practice during surgery.
215094559|NCT03597282|BIOLOGICAL|Nivolumab|monoclonal antibody against PD-1
215094560|NCT03597282|OTHER|Adjuvant|immune adjuvant
215094561|NCT03597282|BIOLOGICAL|APX005M|monoclonal agonist antibody against CD40
215094562|NCT03597282|BIOLOGICAL|ipilimumab|monoclonal antibody against CTLA4
214493080|NCT04421365|DEVICE|neurofeedback brain-computer interface (BCI)|The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
214983495|NCT05279872|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
214983496|NCT04222543|COMBINATION_PRODUCT|RGD PET/CT|Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
214983497|NCT01930591|DRUG|Ticagrelor|180 mg bolus followed by 90 mg BID
214983498|NCT01930591|DRUG|Clopidogrel|300 mg bolus followed by 75 mg OD
214983499|NCT05057520|OTHER|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
214983500|NCT05141032|PROCEDURE|Endoscopic Submucosal Dissection with Pathfinder/Overtube device|Removal of gastrointestinal polyps via ESD
214983501|NCT06399042|DEVICE|SP5M002 inj|pre-filled syringe
214983502|NCT06399042|DEVICE|Synovian inj|pre-filled syringe
214983503|NCT03113955|DEVICE|Tandem Microsphere loaded with Epirubicin|The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
214983504|NCT05890079|OTHER|Subcostal transversus abdominis plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure.
214983505|NCT05890079|OTHER|External oblique intercostal plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure. .
214983506|NCT03189082|PROCEDURE|Microbotox|Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
214983507|NCT02136381|BEHAVIORAL|LEAP intervention|"LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.~Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.~Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.~Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles"
214983508|NCT02136381|BEHAVIORAL|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.~Participants in the control group will be assessment after two months."
214983509|NCT05720637|DRUG|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
214983510|NCT05720637|DEVICE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
214983511|NCT05720637|DEVICE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
215088518|NCT04259684|DRUG|gases Nitric Oxide (gNO)|Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
215088519|NCT00554099|DRUG|Mesalamine|6 - 400 mg tablets once daily
215088520|NCT00554099|DRUG|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
215088521|NCT00554099|DRUG|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
215088522|NCT00554099|OTHER|Dietary Advice|Dietary advice
215088523|NCT00554099|DRUG|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
214493081|NCT00990808|DRUG|anacetrapib|\[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.
214983512|NCT05808985|DRUG|sodium butyrate|Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
214983513|NCT06207474|OTHER|Video + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and interactive chatbot sessions.
215088524|NCT00841399|BIOLOGICAL|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
215094563|NCT02223481|DRUG|Terbogrel low dose|
215094564|NCT02223481|DRUG|Terbogrel high dose|
215094565|NCT02223481|DRUG|Placebo|
214493082|NCT00990808|DRUG|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
214493083|NCT00990808|DRUG|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
214493084|NCT00990808|DRUG|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
214983514|NCT06207474|OTHER|Video + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and paper materials.
214983515|NCT06207474|OTHER|Paper + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of paper materials and interactive chatbot sessions.
214983516|NCT06207474|OTHER|Paper + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using paper materials.
214983517|NCT00834184|DRUG|nikkomycin Z|"Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos."
214983518|NCT00937534|DRUG|Fimasartan|Fimasartan 240mg/day
214983519|NCT03315949|DRUG|Polyethylene Glycol (PEG)|Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
214983520|NCT00600522|PROCEDURE|Ultrasound-guided hepatectomy|"After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~1. Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~2. Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~3. Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended."
214983521|NCT05069467|DEVICE|Acupuncture|For the active acupuncture group, the acupuncturist chose standard points depending on subjects' preferred positions. In addition, up to four acupuncture points were chosen on the basis of subjects' other presenting symptoms (such as fatigue, insomnia, or erectile dysfunction). The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling.
214983522|NCT05069467|DEVICE|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
214983523|NCT01771926|OTHER|potatoes|Daily intake of assigned treatment for 8 weeks
214983524|NCT01771926|OTHER|other carbohydrate|Daily intake of assigned treatment for 8 weeks
215088525|NCT03920059|DRUG|Mycophenolate Mofetil|"Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius."
214493085|NCT03718013|DEVICE|accelerated deep TMS|subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
214493086|NCT03718013|DEVICE|standard deep TMS|standard deep TMS treatment: once a day, during 4 weeks
214493087|NCT00387452|BEHAVIORAL|Aerobic Exercise and Strength Exercise|6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
214493088|NCT00387452|BEHAVIORAL|Strength training|6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
214493089|NCT04029909|DRUG|Gimatecan 0.6mg/m2/d|0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
214493090|NCT04029909|DRUG|0.8mg/m2/d|0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
214493091|NCT04029909|DRUG|0.4mg/m2/d|0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
214493092|NCT05611060|BEHAVIORAL|Building Healthy Life Skills Program|The intervention provides education and training in the long-term mental and physical health consequences of childhood adversity and emotion regulation skills.
214493093|NCT04657172|DRUG|Pilocarpine Ophthalmic|Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
214493094|NCT04657172|DRUG|Placebo|Vehicle ophthalmic solution administered with the Optejet microdose dispenser
214493095|NCT01321164|DEVICE|Full Body UV Therapy System UV 7002 plus fumaric acid esters|"Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.~Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months"
214493096|NCT01321164|DRUG|Fumaric acid esters|Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
214493097|NCT00220675|DRUG|Erythropoietin infusion|
214493098|NCT00168415|BIOLOGICAL|Botulinum Toxin Type A|100 U up to 6 times during the study depending on the response to treatment
214493099|NCT04139005|BEHAVIORAL|Awareness|The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
214681045|NCT01807507|DEVICE|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
214983525|NCT01612013|DRUG|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
214983526|NCT01612013|DRUG|Intravenous NAC plus saline|Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
214983527|NCT01612013|DRUG|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
214983528|NCT01612013|DRUG|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
214983529|NCT01612013|DRUG|NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
214983530|NCT01612013|DRUG|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
214983531|NCT04694469|PROCEDURE|Closed reduction and percutaneous pinning (CRPP)|Operated for supracondylar humeral fractures
214983532|NCT00896259|OTHER|home based exercise and education program|Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
214983533|NCT04489342|DEVICE|IMU sensor test|Measurement of maximum range of movement in the spine; Ambulatory observational data while performing standardised functional tests
214983534|NCT05244200|OTHER|Pharmaceutical care and insulin staging.|Pharmaceutical care is a patient-centered practice in which the practitioner assumes responsibility for a patient's drug-related needs and is held accountable for this commitment. Due to the progressive nature of Type 2 Diabetes Mellitus, which requires timely optimization of treatment, leading in a majority of cases to insulin therapy, so that proper use of insulin is one of the critical tools for prevention of long-term complications. From the hundred patients in this study, half of the patients will be the control group without any intervention, and pharmaceutical care and insulin staging will be applied on the remaining. In this research two strategies will be applied including pharmaceutical care process and Insulin Staging approach on patients with T2DM, those who are on end stage treatment.
214983535|NCT01102634|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Application of TENS over acupuncture points
214983536|NCT01102634|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Placebo
214983537|NCT02437292|OTHER|Ischemic compression with stretching|
214983538|NCT00922311|DRUG|Aliskiren|Titrate from 150 mg daily to 300 mg daily
214983539|NCT05188105|DEVICE|Alpha tACS (12 Hz) over the occipital cortex|Single session of alpha tACS (12 Hz) over the occipital cortex
214983540|NCT00415467|DEVICE|GliaSite Radiation Therapy System|Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
214983541|NCT03265561|DEVICE|Bone allograft|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone allograft only.
214983542|NCT03265561|DEVICE|Bone auto and allograft group|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone autograft plus bone allograft
215088526|NCT02168972|DEVICE|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
215088527|NCT04035746|OTHER|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
215088528|NCT04299763|DIETARY_SUPPLEMENT|Oat Beta-glucan as a Supplement in Type 2 Diabetics|44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
215088529|NCT03356509|BEHAVIORAL|Exercise|Exercise will be performed on a stationary bicycle ergometer.
215088530|NCT06358560|OTHER|Therapeutic exercises|Rehabilitation exercises designed to achieve the treatment goal
215088531|NCT04896203|PROCEDURE|rotational thromboelastometry|Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
215088532|NCT03386747|BEHAVIORAL|Home visits to improve parenting behaviors|Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.
215088533|NCT03386747|BEHAVIORAL|Center based parenting groups|Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
215088534|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
215088535|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
214983543|NCT01777646|BIOLOGICAL|MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF|
214983544|NCT03307135|DEVICE|single assessment with the MSPMI|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
214983545|NCT03307135|DEVICE|double assessment with the MSPMI with 7 days of interval|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
214983546|NCT03307135|DEVICE|double assessment with the MSPMI before and after treatment|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
214681046|NCT06329362|PROCEDURE|Minimally invasive implantation|Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.
214681047|NCT06329362|PROCEDURE|Open flap procedure for ridge expansion.|Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.
214681048|NCT03939130|DIETARY_SUPPLEMENT|Fructose|Consumption of 1.0g / kg of body mass / day of fructose.
214983547|NCT05998967|BEHAVIORAL|Mobile Mantram Repetition Program|Internet-based instruction in a meditation practice that involves silent repetition of a spiritual word, one-pointed attention and slowing down
215088536|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
215088537|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
215088538|NCT01443130|DRUG|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
215088539|NCT01443130|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
214681049|NCT03939130|DIETARY_SUPPLEMENT|Glucose|Consumption of 1.0g / kg of body mass / day of glucose.
214983548|NCT01980758|PROCEDURE|Laparoscopic Gastric Plication|The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
214983549|NCT04418947|OTHER|Communication type|Control letter vs. intervention letter
214983550|NCT02865161|DRUG|NISELAT|NISELAT 600MG BD
214983551|NCT04617821|DRUG|Nab paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine are given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycle.
215088540|NCT01342744|DRUG|Metformin|Metformin(850 mg) 1tab oral twice aday
215088541|NCT01342744|DRUG|Placebo|Placebo 1 tab oral twice a day
215088542|NCT02279836|DEVICE|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
215088543|NCT02768025|OTHER|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
215088544|NCT02768025|OTHER|NRT, counselling|Nicotine Replacement Therapy, counselling
214369437|NCT03079154|OTHER|Self-guided MBCT course|9 weeks of self-guided mindfulness-based cognitive therapy, following an audiobook covering the same material and exercises as the teacher-led intervention
214369438|NCT00038051|DRUG|Hum-195/rGel|Starting Dose = 3 mg/m\^2 twice weekly for 2 weeks.
214369439|NCT03023592|DRUG|Iguratimod|Iguratimod 25 mg orally twice a day for 24 weeks
214369440|NCT00473070|DRUG|Tobradex AF|
214369441|NCT05000567|OTHER|12 week nordic hamstring exercise program|12 weeks progressive eccentric strength training program targetting the hamstring muscles.
214369442|NCT04547608|OTHER|The difference of the timing of rocuronium administration after propofol injection|The difference of the timing was rocuronium was administered immediately after propofol injection or when BIS score became below 60 after propofol administration.
214369443|NCT00960180|DRUG|MR1817|
214369444|NCT00960180|DRUG|Placebo|
214681050|NCT03939130|OTHER|Fructose and exercise|Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
214983552|NCT04617821|DRUG|mFOLFIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
214983553|NCT01792232|OTHER|Allergen|Subject specific allergen is placed in the lungs on day 1 of each triad
214493100|NCT04139005|BEHAVIORAL|Connection|The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
214493101|NCT04139005|BEHAVIORAL|Insight|The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
214983554|NCT01792232|OTHER|Saline|Saline will be placed in the lung on day 1 of each triad
214493102|NCT01288443|DRUG|Alirocumab|Two SC injections in the abdomen only.
214983555|NCT05660876|PROCEDURE|standard fistulotomy|in a standard manner fistula tract was identified and laid open without doing marsupialization
214983556|NCT05660876|PROCEDURE|fistulotomy with marsupialization|in this arm fistulotomy was done in a standard manner and marsupialization was done
214983557|NCT03277131|DEVICE|DURAFIBER Ag|DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing
214983558|NCT00858286|OTHER|Spirometry, PEF measurements and diary cards to evaluate control of Asthma|No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
214983559|NCT02152007|DRUG|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
214983560|NCT02258061|PROCEDURE|DDD-80|Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
214983561|NCT02258061|PROCEDURE|DDD-60|Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
214983562|NCT03316105|DEVICE|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
214983563|NCT05569096|DIAGNOSTIC_TEST|ELIZA , Flowcytometry|CD25 , CXCL9 by ELISA. T cell population , T regulatory cells by Flow cytometry.
214369445|NCT03873948|OTHER|Evaluation of arginine serum level|correlation of serum arginine level with periodontal and cardiovascular disease
214369446|NCT04502576|DEVICE|Noninvasive respiratory support|"In both arms, the treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge.~Patients will have to undergo the allocated treatment within 1 hour from the moment of randomization and within 24 hours from admission in the intensive care unit"
214369447|NCT02469948|DRUG|Botulinum toxin type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
214493103|NCT01288443|DRUG|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
214493104|NCT01288443|DRUG|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
214681051|NCT03542240|DIETARY_SUPPLEMENT|Curcumin|500 milligram daily supplement
214681052|NCT02226094|DEVICE|DWT device dose A|Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.
214681053|NCT02226094|DEVICE|Ellex Tango SLT machine|Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
214681054|NCT02226094|DEVICE|DWT device dose B|Same as DWT device dose A except 20 second spot treatments.
214681055|NCT02226094|DEVICE|DWT sham|Same as DWT device dose A except device not applied to ocular surface.
214681056|NCT03813563|DRUG|RL|lactated Ringer's
214983564|NCT02467244|DRUG|Levothyroxine|At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
214369448|NCT00279669|PROCEDURE|Ultrasound examination|contact ultrasound examination
214369449|NCT00729404|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
214369450|NCT00729404|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
214983565|NCT00314405|DRUG|Methylene blue (1%)|
214983566|NCT00314405|DRUG|Rhenium sulfure|
214983567|NCT00314405|PROCEDURE|Surgical procedure|
214983568|NCT00314405|PROCEDURE|Anatomo-pathologic procedure|
214983569|NCT01302899|DRUG|Aliskiren|Aliskiren 150 mg (Tablet)
214983570|NCT01302899|DRUG|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
214983571|NCT01302899|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
214983572|NCT01302899|DRUG|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
214983573|NCT01302899|DRUG|Ramipril|Ramipril 10mg (Tablet)
214983574|NCT05724290|GENETIC|EGR2|We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
214983575|NCT02834975|DRUG|Pembrolizumab|Pembrolizumab on Day 1 of each cycle.
214983576|NCT02834975|DRUG|Paclitaxel|"* NACT: Paclitaxel on Day 1 of each cycle;~* ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol."
214983577|NCT02834975|DRUG|Carboplatin|Carboplatin IV on Day 1 of each cycle.
214983578|NCT06004960|DRUG|[14C]CCX168|Administered orally.
214983579|NCT01856933|DRUG|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
214983580|NCT04992247|BIOLOGICAL|COVI-MSC|"2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.~Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4~Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4~Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2~Group D: 2 MSC vials infused on D0, D2 and D4"
214983581|NCT04992247|BIOLOGICAL|Placebo|6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.
214983582|NCT06366308|PROCEDURE|Transperineal Prostate Biopsy|The investigators plan to retrospectively review data from over 10000 men receiving transperineal prostate biopsy in our center.
214983583|NCT05327582|DRUG|Durvalumab|Administered intravenously, 1000 mg on day 1 in a 3-week cycle
214983584|NCT05327582|DRUG|Lenvatinib|Administered orally, 8mg/d once daily in a 3-week cycle
214983585|NCT05327582|DRUG|Nab paclitaxel|Administered intravenously, 180-220 mg/m2 on day1 in a 3-week cycle
214983586|NCT01741077|DIETARY_SUPPLEMENT|folic acid|subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
214983587|NCT00962286|DRUG|Furosemide|"Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid."
214983588|NCT03558516|DRUG|Magnesium group|We will dilute magnesium 6 gram with 0.9% sodium chloride to 30 ml. The patient will receive magnesium sulfate 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
214983589|NCT03558516|DRUG|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
214983590|NCT05531955|DRUG|Pirfenidone Oral Capsule|pirfenidone capsules were added to patients receiving basic treatment
214983591|NCT05531955|OTHER|Placebo Oral Capsule|placebo oral capsules were added to patients receiving basic treatment
214983592|NCT05531877|DIAGNOSTIC_TEST|Penile Prosthesis Implantation|Penile measurement are taken preoperatively to serve as a guide to the surgeon to optimize post-operative penile size.
214983593|NCT03363906|DRUG|Dulaglutide (Reference)|Administered SC
214983594|NCT03363906|DRUG|Dulaglutide (Test)|Administered SC
214493105|NCT01596972|DEVICE|dBest semi-quantitative urine pregnancy test|The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
214681057|NCT03813563|DRUG|PLA|PlasmaLyte
214681058|NCT01792622|OTHER|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
214983595|NCT00676143|DRUG|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
214983596|NCT00676143|DRUG|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
214493106|NCT00042731|DIETARY_SUPPLEMENT|Lycopene|Daily administration as outlined in treatment arm(s)
214681059|NCT01792622|OTHER|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
214681060|NCT00495560|DRUG|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
214681061|NCT03799718|BIOLOGICAL|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
214983597|NCT00001011|DRUG|Zidovudine|
214983598|NCT06406504|OTHER|in-laboratory simulation group|The students in-laboratory group performed the simulation applications in the patient room in the simulation laboratory. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.
214983599|NCT06406504|OTHER|in-situ simulation group|Students in the in-situ simulation group performed the simulation practices in a patient room in a clinic at a university hospital. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.
215088545|NCT00319657|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from the living donor.
215088546|NCT00319657|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
215088547|NCT02818114|BEHAVIORAL|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
215088548|NCT02645435|PROCEDURE|hip replacement|Total hip replacement
214681062|NCT01321996|PROCEDURE|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
214681063|NCT01449019|DRUG|exendin(9-39)amide|intravenous infusion of exendin(9-39)
214681064|NCT01449019|DRUG|saline|intravenous infusion of saline
214681065|NCT01449019|OTHER|duodenal meal|duodenal perfusion of a meal
214681066|NCT01449019|OTHER|duodenal saline|duodenal perfusion of saline
214983600|NCT05541705|BEHAVIORAL|Treadmill Oscillation Walking|Each participant with stroke will partake in 18 training sessions. Training sessions will be for one hour three times a week for 6 weeks. During training, participants will walk at their self-selected walking speed on the treadmill that moves side-to-side for 1 cm in a sinusoidal pattern. The sinusoidal oscillation frequency will match each participant's natural stride frequency calculated from baseline evaluation. Subjects will be instructed to respond naturally and maintain continuous walking. Participants will wear a safety harness with no body weight support. For each training session, six 6-minute bouts of treadmill oscillation trials will be performed (Hsiao et al. 2016) and rest period will be provided between bouts. Because lower extremity muscle activity increases with increasing oscillation frequency, the treadmill oscillation frequency will be increased by 5% each week to continue to drive progressive adaptive changes (25% over 6 weeks) (Pohl et al. 2002).
214983601|NCT03862638|OTHER|Yoga Therapy|Yoga therapy is therapeutic application of yoga, specifically designed to treat the condition using physical posture, breathing exercises, guided relaxation and meditation.
214983602|NCT03764605|DRUG|Metformin|Patieny will be treated by using Metformin from 500 mg a day to 500 mg thrice a day.
214983603|NCT03764605|DRUG|Tolvaptan|Patients will be treated with tolvaptan from 45 mg + 15 mg a day to 90 mg + 30 mg a day
214983604|NCT02640079|BEHAVIORAL|Cognitive behavioral therapy|
214983605|NCT00929669|DRUG|pasireotide LAR|pasireotide LAR 80 mg IM once a month
214983606|NCT03261999|DRUG|Leuprolide Mesylate|Subcutaneous injection of 25mg Leuprolide Mesylate
214983607|NCT04582617|DIETARY_SUPPLEMENT|Cocoa Extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
214983608|NCT04582617|DIETARY_SUPPLEMENT|Cocoa Extract Placebo|Cocoa extract placebo
214983609|NCT04582617|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
214983610|NCT04582617|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
214983611|NCT04285463|DIAGNOSTIC_TEST|Transbronchial Lung Cryobiopsy (TBLC)|TBLC is a relatively new endoscopic technique used to obtain lung parenchyma specimens. It is a minimally invasive technique performed with a flexible or rigid bronchoscope under deep sedation or general anesthesia. Flexible cryoprobes of either 1.9 or 2.4 mm in diameter are introduced into a bronchoscope and a compressed gas, most commonly carbon dioxide or nitrous oxide, is released at high flow at the tip of the probe. As the tissue rapidly freezes, it adheres to the probe and is avulsed and extracted with a quick pullback movement followed by immediate extraction of samples.
214983612|NCT02714153|DEVICE|Bridge Balloon|The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
214983613|NCT01658839|DRUG|Travoprost ophthalmic solution, 0.004% (new formulation)|Travoprost ophthalmic solution, 0.004%, new formulation
214983614|NCT03749161|DEVICE|Low-add multifocal IOL|Lentis comfort, low-add multifocal, IOL
214983615|NCT03749161|DEVICE|Monofocal IOL|Lentis L-313, monofocal IOL
214983616|NCT01144832|DRUG|ebastine|20 milligram capsule once daily
214983617|NCT01144832|DRUG|placebo capsule|one capsule once daily
214983618|NCT02318264|DEVICE|Kinesio Tape|Elastic tape placed over the skin
214983619|NCT04525196|OTHER|Physical activity.|"The procedure under study (physical activity program) will include, each week for 12 months, two sessions dedicated to the development of aerobic capacity and a muscle building session.~The experimental group will therefore be offered 3 sessions of Physical Activity (PA) per week. The PA will be positioned in the first two hours after the start of the dialysis session. Each session will include 5 minutes of general warm-up, then 15 minutes of PA itself and finally 5 minutes of cool down period. The PA time itself will be increased as the sessions progress, according to the progress and improvement of physical capabilities of patients."
214983620|NCT03130413|DEVICE|Ambu Aura Gain supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
215088549|NCT02182609|DRUG|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
215088550|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of normal protein liquid diet supplementation|group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)
215088551|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of high protein liquid food supplementation|group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
215088552|NCT06141837|OTHER|Observation|No intervention: observational study
215088553|NCT04401670|OTHER|HPV screening and triage tests|The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt \[Hologic, Inc., Bedford, MA, USA\] and a visual inspection by acetic acid (VIA) by a nurse.
215088554|NCT04401670|BEHAVIORAL|HPV self-sampling|"The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler \[Preventive Oncology International, Cleveland, OH, USA\]."
215088555|NCT05874349|BEHAVIORAL|General variables|Variables evaluated: age, sex, location, extent, and phenotype of IBD according to the Montreal classification, smoking habit, therapeutic requirements (immunosuppressants, biologics, steroids, salicylates, drugs that cause enteropathy such as olmesartan, valsartan, non-steroidal anti-inflammatory drugs, etc, ...).
215088556|NCT05874349|BEHAVIORAL|Clinical activity|Clinical activity was evaluated using the Harvey-Bradshaw index (HBI) (cut-off values: \<5, remission; 5-7, mild activity; 8-16, moderate activity; and \>16, severe activity).
214983621|NCT03130413|DEVICE|Air-Q supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
214983622|NCT02065557|BIOLOGICAL|Adalimumab|Subcutaneous (SC) injection
214983623|NCT02065557|BIOLOGICAL|Placebo|Subcutaneous (SC) injection
214493107|NCT00042731|DIETARY_SUPPLEMENT|Multivitamin|Daily administration as outlined in treatment arm(s)
214493108|NCT00042731|DIETARY_SUPPLEMENT|Soy isoflavones|Daily administration as outlined in treatment arm(s)
214493109|NCT02203500|DRUG|Lacidipine|
214493110|NCT02203500|DRUG|Telmisartan|
215088557|NCT05874349|PROCEDURE|Laboratory data|Laboratory data: blood count, renal function and C-reactive protein, anti-transglutaminase antibodies, genetic study of celiac disease DQ2.5, DQ8, and DQ2.2, study of parasites, fecal calprotectin.
214493111|NCT00283205|BEHAVIORAL|Yoga|
214493112|NCT01623908|DRUG|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
214493113|NCT04327843|BEHAVIORAL|Customized Adherence Enhancement|Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.
214983624|NCT06082232|DRUG|Dexmedetomidine|Under strict aseptic conditions, a lumbar puncture will be performed with selective technique in sitting position at L2-3 or L3-4 interspaces with midline approach using a 25-G Quincke's needle. After achieving the free flow of cerebrospinal fluid, the study drug will be injected into the subarachnoid space, immediately after injection the patient will be asked for supine position.
214983625|NCT06082232|DRUG|Midazolam|1 mg midazolam intrathecal administration
214983626|NCT06082232|DRUG|Bupivacain|20 mg bupivacaine intrathecal administration
214983627|NCT00250588|BEHAVIORAL|Problem solving skills training|See description in Results
214983628|NCT00250588|BEHAVIORAL|Asthma care coordination|See description in Results
214983629|NCT00250588|OTHER|Usual Care|Usual clinical care
214983630|NCT00516646|DRUG|ALT-711|200 mg bid
214983631|NCT00516646|DRUG|Placebo|bid
214983632|NCT03453294|DEVICE|Apnoeic oxygenation using THRIVE|Apnoeic oxygenation using THRIVE
214983633|NCT03453294|DEVICE|Endotracheal intubation and mechanical ventilation|Endotracheal intubation and mechanical ventilation
214983634|NCT00485823|DRUG|Olanzapine Hydrochloride|
215088558|NCT05874349|PROCEDURE|Endoscopic and histology data|"Endoscopic signs suggestive of CD in UDT (presence of canker sores, ulcers, ...) and colon inflammatory activity was evaluated when available in patients with active disease using the Simple Endoscopic Score for CD (SES-CD: 0-2, remission; 3-6, mild endoscopic activity; 7-15, moderate endoscopic activity; and \>15, severe endoscopic activity).~Duodenal biopsies were assessed by 2 pathologists and were evaluated according to Marsh classification modified by Ensari \[Marsh 0, 1, 2 or 3\], the limit of normality for intraepithelial lymphocytes (IELs) per 100 enterocytes is set at 25, gastric biopsies (determination of H. Pylori by immunohistochemistry) and esophageal biopsies was recorded too.~Percentage of lymphocyte subpopulations are assessed by flow cytometry."
215088559|NCT02228343|OTHER|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
215088560|NCT05741047|OTHER|a2Milk skim milk powder|a2Milk skim milk powder (1L) containing A2 β-casein only
215088561|NCT05741047|OTHER|Yili skim milk powder|Yili skim milk powder (1L) containing A1 and A2 β-caseins
215088562|NCT01107561|OTHER|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
215088563|NCT01107561|DEVICE|Surgical Airway Approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
215088564|NCT06008483|DRUG|153-Sm-DOTMP (Samarium-153-DOTMP)|This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP, given as a tandemly administered pair of doses to subjects with solid tumors visible on bone scan.
214681067|NCT04730986|BEHAVIORAL|ED GOAL Nursing|A brief (\<7minutes) interview by an emergency department nurse to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
214681068|NCT00200278|BEHAVIORAL|PROJECT STRIDE|
214983635|NCT00485823|PROCEDURE|Weight Management Program|
214983636|NCT01993199|PROCEDURE|deep biopsy via ESD technique|
214983637|NCT03025204|BIOLOGICAL|Enamel Matrix Proteins|EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
214983638|NCT03025204|PROCEDURE|Open Flap Debridement|After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
214983639|NCT00706797|DRUG|etanercept (EnbrelTM)|
214983640|NCT00706797|DRUG|methotrexate|
214983641|NCT02192788|RADIATION|Stereotactic Body Radiation Therapy for Oligometastases|
214983642|NCT02330341|DIETARY_SUPPLEMENT|Artemisia dracunculus|
214983643|NCT02330341|OTHER|Placebo|
214983644|NCT02936765|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
214983645|NCT02936765|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / Squale.|Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
214983646|NCT04599231|DIAGNOSTIC_TEST|Quality of Recovery -15|The investigators plan to evaluate patients' quality of recovery at postoperative day (POD) 1, 2, and 3.
214983647|NCT02902575|PROCEDURE|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
214983648|NCT06551740|DRUG|HUC2-344|per oral
214983649|NCT06551740|DRUG|HUC2-344-R1, HUC2-344-R2|per oral
214983650|NCT02737137|PROCEDURE|Manual measurement|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic
214983651|NCT02737137|PROCEDURE|Measurement with a gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
214493114|NCT04327843|DRUG|Haloperidol Decanoate|Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
214493115|NCT02201888|BEHAVIORAL|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
214493116|NCT02201888|OTHER|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
214681069|NCT03238144|OTHER|MRF scan|MRF with or without dynamic contrast-enhanced MRI scans.
214983652|NCT02532504|OTHER|CBT|"8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;~1. Five Areas vicious circle~2. Bad thought spotter~3. Amazing Bad thought Busting Programme (ABTPB)~4. Easy 4 Step plan~5. Things you do that mess you up/Confidence sheet~6. Happy List/ Things you do that boost how you feel sheet~7. Planner and Review sheets"
214983653|NCT01869309|DRUG|Prasugrel|Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
214983654|NCT01869309|DRUG|Ticagrelor|Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
214983655|NCT03798743|DRUG|Sintilimab Combined With Docetaxel|Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w
214983656|NCT03442452|OTHER|Electronic Decision Aid Tool|The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
214983657|NCT00485303|DRUG|Abiraterone acetate|Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
214983658|NCT00485303|DRUG|Prednisone|Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
214983659|NCT05951634|DEVICE|PerQseal ELITE|"Percutaneous ELITE Arterial Closure Device~The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer."
215088565|NCT02749383|DRUG|PAC-14028 cream 0.3%|Topical application
215088566|NCT02749383|DRUG|PAC-14028 cream 1.0%|Topical application
215088567|NCT02749383|DRUG|PAC-14028 cream vehicle|Topical application
215088568|NCT00531297|PROCEDURE|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
215088569|NCT00321997|DRUG|Pegaptanib sodium|
215088570|NCT05788705|DIETARY_SUPPLEMENT|"apigenin and glycyrrhizin"|"apigenin will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
215088571|NCT05788705|DIETARY_SUPPLEMENT|"glycyrrhizin and boswellic acid"|"boswellic acid will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
214983660|NCT02738502|DRUG|darunavir monotherapy|darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.
214983661|NCT01391611|DRUG|Pazopanib|800 mg; PO
214983662|NCT04186156|DRUG|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
214983663|NCT04179682|PROCEDURE|40-hour constraint-induced movement therapy|Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.
214983664|NCT04479046|OTHER|PMMA crowns|New type of pediatric crowns
214983665|NCT06250114|OTHER|Retreatment|manual k file, carrier based technique, Xrays, tooth build up, provisional and definitive crowns. Post if necessary will be placed
214983666|NCT06250114|OTHER|extraction implant|Flapless or flapped techniques, early, delayed and immediate implant insertions. Cement retrained restorations
214983667|NCT02655874|BIOLOGICAL|Influenza vaccine|Administered at day 1
214983668|NCT02655874|BIOLOGICAL|Influenza vaccine|Administered at day 180
214983669|NCT02655874|BIOLOGICAL|Tetanus-diphtheria-pertussis vaccine|Administered at day 180
214983670|NCT02774083|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
214983671|NCT02774083|BEHAVIORAL|Adler Program|Social and emotional group program
214983672|NCT01687699|DRUG|Spironolactone|
215088572|NCT05788705|DIETARY_SUPPLEMENT|"placebo"|"Placebo capsule will be administered two times daily for 6 months"
215088573|NCT05030064|DRUG|Intestinal flora capsule|"This research group has independently researched and created a human intestinal flora capsule based on intestinal bacteria transplantation: Intestinal flora capsule, which has been declared a national invention patent (patent number: 2015103040414)."
215088574|NCT05030064|PROCEDURE|placebo capsule|Each placebo capsule is the two-layer empty capsule shell of the Intestinal flora capsule, which is made of titanium dioxide and iron oxide yellow. It is non-toxic and has the same appearance as the authentic Intestinal flora capsule.
214493117|NCT02201888|OTHER|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
214493118|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
214493119|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
214493120|NCT04502381|DRUG|Inhaled amp B deoxycholate+intravenous liposomal amp B|"Intravenous liposomal amphotericin B (beginning with 3mg/kg) along with inhaled amphotericin as below: Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited), will be dissolved in 10 mL distilled water. 2 mL of the reconstituted amphotericin B solution will be transferred into the drug chamber of a breath actuated nebulizer (Lupineb Ultra kit breath actuated nebulize which contains aeroclipse XL Reusable Breath Actuated Nebulizer and DeVilbiss 3655 compressor). 3 mL of distilled water is added to 2 mL of the reconstituted amphotericin B. The nebulization is continued till the chamber is emptied of the drug or the patient does not tolerate the therapy.~The first three doses of amphotericin B nebulization will be under the direct supervision of a physician. If tolerated, nebulization will be continued twice a day till tolerated or till response.The patient will complete a VAS score for cough after nebulization."
214493121|NCT04502381|DRUG|Intravenous liposomal amphotericin B alone|Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
214983673|NCT03820401|DEVICE|choice of dialyzer|Fiber blocking is calculated in different commercially available dialyzers
215088575|NCT00928278|DRUG|Treatment A|Inhaled, 300/150, single dose
215088576|NCT00928278|DRUG|Treatment B|Inhaled, 300/150, single dose
215088577|NCT00928278|DRUG|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
215088578|NCT00928278|DRUG|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
215088579|NCT01011933|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
215088580|NCT01011933|DRUG|Selumetinib|Given PO
215088581|NCT00180297|DEVICE|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
214681070|NCT02405052|OTHER|No intervention|Validation of the Panic Screening Score
214681071|NCT00748826|BIOLOGICAL|Infliximab|"Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of~Infliximab therapy with additional infusions of 5 mg/kg at week 2"
214681072|NCT06373081|BIOLOGICAL|Anti-CD19-CD3E-CAR-T cells|The injection of anti-CD19-CD3E chimeric antigen receptor T (CAR-T) cells, referred to as anti-CD19-CD3E-CAR-T cells. The anti-CD19-CD3E-CAR protein is composed of a murine-derived CD19 single-chain variable fragment (scFv) FMC63, CD28 hinge and transmembrane regions, the intracellular domain of CD3E, the intracellular domain of CD28, and the intracellular domain of CD3ζ, all linked in sequence.
214681073|NCT02214186|OTHER|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
214681074|NCT02754934|OTHER|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
214681075|NCT02353351|DEVICE|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
214681076|NCT05357313|DEVICE|Bright light therapy|Exposure to 10,000lux bright light for 30minutes a day for six weeks
214681077|NCT05357313|DEVICE|Inactive negative ion generator|Exposure to an inactive negative ion generator for 30 minutes a day for six weeks
214681078|NCT01651052|PROCEDURE|Heart Valve Surgery|Implant of an aortic valve, Model 11000
214681079|NCT02560701|OTHER|Patient Interview|Investigators will conduct in-depth interviews with approximately 40 commercially insured individuals with bipolar disorder or their family caregivers to explore how they navigate deductibles, copayments, and other complex insurance features. Investigators will also determine the health care services that patients most value and assess how they prioritize difficult health care cost tradeoffs.
214983674|NCT03820401|OTHER|choice of dialysis mode|Fiber blocking is calculated in different commercially available dialyzers used in different dialysis stategies
214983675|NCT03820401|OTHER|choice of anticoagulation strategy|Fiber blocking is calculated in different commercially available dialyzers using different anticoagulation strategies
214983676|NCT03820401|OTHER|preparation of dialyzer|Fiber blocking is calculated in different commercially available dialyzers either preprimed with Albumin or not
214983677|NCT00412620|DRUG|ABT-925|
214983678|NCT00412620|DRUG|Placebo|
214983679|NCT01524315|DRUG|Vitamin B1-ratiopharm|300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
214983680|NCT01524315|DRUG|Placebo|100 ml normal saline, intravenous, preoperative
214983681|NCT03646539|BEHAVIORAL|Use of smartphone application (app)|Use of a CBT-based automated conversational agent available as a mobile device smartphone application for the management of mood.
214983682|NCT03646539|OTHER|Treatment as usual|Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
214983683|NCT03073928|PROCEDURE|Interscalene Block|Regional Anesthesia procedure in the neck
214983684|NCT03073928|PROCEDURE|Paracoracoid SPB|Regional anesthesia procedure under the collar bone
214983685|NCT03073928|DRUG|Ropivacaine|Amide local anesthetic Ropivacaine will be used in same concentration (milligrams) in both active comparator and experimental group
214983686|NCT04555148|BIOLOGICAL|GC5131|COVID19 Hyper-Immunoglobulin
214983687|NCT04555148|OTHER|Placebo|Placebo
214983688|NCT05595226|PROCEDURE|RT3D-TEE-guided mitral valve repair|RT3D-TEE forms a surgical plan before surgery and 3 to 4 senior doctors with more than 50 cases of mitral valve repair perform the procedure.
214983689|NCT03644732|PROCEDURE|SEEG Group|Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
214983690|NCT05362201|PROCEDURE|therapeutic position of the anterior repositioning splints|the ADDWR paricipants will be allocated into 2 grounps and treated with anterior repositioning splints determined by traditional and digitial method respectively.
214983691|NCT05508958|PROCEDURE|Anterior approach|Anterior approach
214983692|NCT05508958|PROCEDURE|Posterolateral approach|Posterolateral approach
214983693|NCT00694772|PROCEDURE|Electrocautery-tonsillectomy|standard of care electrocautery tonsillectomy
214983694|NCT00694772|PROCEDURE|Coblation-tonsillotomy|use of Arthrocare Coblation Technology to perform tonsillotomy
214983695|NCT03017859|DEVICE|High flow nasal cannula|We shall use the Airvo 2 device to administer humidified and warmed air at high flow during sleep.
214983696|NCT02500498|DRUG|Nulojix|
214983697|NCT04158609|DIAGNOSTIC_TEST|Doppler flow indices assessment|Doppler flow indices, UA-PI, MCA-PI and CPR values, assessment performed prior to induction of labor
214983698|NCT03641027|OTHER|Increased physical activity|"Preoperatively~Individual coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week)~* decrease time spent sitting/lying~Telephone follow up one week after the intervention starts~At the hospital~-Frequent mobilization~After discharge~A telephone follow up one week postoperatively with coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week) until 8 weeks postoperatively~* decrease time spent sitting/lying~The intervention includes a prescribed FaR (Fysisk aktivitet på recept) with frequency, duration and intensity of the activity corresponding 12-15 on the BORG-RPE scale."
214983699|NCT03641027|OTHER|Standard care|
214983700|NCT02247388|BEHAVIORAL|Computerized Alcohol Screening|iPad based automated alcohol screening
214983701|NCT02247388|BEHAVIORAL|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
214983702|NCT00293592|DRUG|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
214983703|NCT06265311|PROCEDURE|IDUS examination|for patients with high risks of bile duct stones recurrence using IDUS during ERCP
214983704|NCT04861792|BEHAVIORAL|Michigan SPARC Quality Improvement Intervention|Practice facilitation, electronic health record (EHR) support, performance monitoring and feedback combined with alcohol-related continuing medical education (CME) and maintenance of certification (MOC) and tools to support alcohol related care including a decision aid for shared decision making about alcohol use disorder (AUD).
214983705|NCT02771964|OTHER|Quality of life survey|"All enrolled patients complete a survey of baseline health during their visit to the preoperative assessment clinic and then complete a follow-up survey approximately 30 days after surgery.~The intervention for this study is to compare self-reported quality of life (How would you rate your quality of life now? (better/same/worse)) to the quantitative change in their VR-12 quality of life scores between the baseline survey and 30-day follow-up survey."
214983706|NCT06039163|DRUG|HH-120|Participants randomized to active treatment in escalation phase will receive HH-120 administered via inhalation for 5 consecutive days (Day 1 to Day 5). Planned dose levels to be used for the escalation phase of the study are 50 (BID), 50 (TID), and 100 (BID) mg. The expansion phase will begin once the recommended dose for expansion phase determined, based on safety and preliminary efficacy data from the escalation phase.
214983707|NCT06039163|DRUG|placebo|Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
215088582|NCT03461406|BIOLOGICAL|Fibrin Sealant Grifols|The FE Grifols solution was applied topically via drip or spray application.
215088583|NCT03461406|BIOLOGICAL|EVICEL|The EVICEL solution was applied topically via drip or spray application.
215088584|NCT01439074|DEVICE|Mepilex Ag|Dressing
215088585|NCT01439074|DRUG|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
215088586|NCT04791059|DRUG|S-ketamine|S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.
215088587|NCT04791059|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
214493122|NCT03985774|PROCEDURE|Transcarotid revascularization|The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
214493123|NCT00176800|DRUG|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
214493124|NCT00176800|PROCEDURE|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
214493125|NCT00176800|PROCEDURE|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
214493126|NCT04633941|OTHER|Standard Care|Standard Care
214493127|NCT02446145|DRUG|Eltrombopag|"Patients will receive EPAG in addition to their background standard treatment with Decitabine/Azacitidine~\- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
214493128|NCT02446145|DRUG|Placebo|"Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~\- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
214493129|NCT00263549|BIOLOGICAL|House dust mite Novo Helisen Depot|
215088588|NCT04791059|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
215088589|NCT05050396|PROCEDURE|Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis|Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). \[16, 17\] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation \[20\]
215088590|NCT04275609|OTHER|AI generated report|After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
215088591|NCT04275609|OTHER|physicians writing report|After the endoscopic procedure, the physicians writing the report in computer according the procedure.
214983708|NCT05273983|BEHAVIORAL|Behavioural Activation|The intervention will span 6 weeks, including two intervention sessions with the primary care psychologist, and 6-weeks use of a mobile activity scheduling app (Strides). In the first intervention session, the psychologist would provide psychoeducation about depression, therapeutic rationale of behavioural activation, aid the patient in identifying their values and corresponding activities that may correspond with their values, introduce the mobile app, and help the patient schedule initial activities/goals. The second intervention session, which would be flexibly scheduled according to patient need, would focus on troubleshooting/clarification of previously discussed topics.
214983709|NCT03998631|PROCEDURE|Carbon Dioxide and Saline Flush|The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.
214983710|NCT03998631|PROCEDURE|Standard Saline Flush|Standard of care flushing of the TEVAR or TAVI device with normal saline.
214983711|NCT02668068|PROCEDURE|large volume whole-lung lavage (WLL)|Generally 1000 \~ 2000ml each time, 14 \~ 10 times totally, each side of the lung to 20 \~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
214983712|NCT02668068|BIOLOGICAL|clinical grade umbilical cord mesenchymal stem cells|10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
214983713|NCT02465450|DRUG|JBT-101 (lenabasum)|Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
214983714|NCT02465450|OTHER|Placebo|Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
214983715|NCT00610415|PROCEDURE|tumor biopsy|
214983716|NCT01687660|OTHER|acupuncture|apply acupuncture to prevent the migraine attack
214983717|NCT01836120|DRUG|Raltitrexed plus Docetaxel|"Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d~1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)"
214983718|NCT01836120|DRUG|Docetaxel|Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
214983719|NCT04026425|OTHER|Two-day cardiopulmonary exercise test|A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.
214983720|NCT00112957|BIOLOGICAL|rV-NY-ESO-1 vaccine|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10\^7 PFU) on Day 1.
215088592|NCT00002742|DRUG|amphotericin B deoxycholate|
215088593|NCT00002742|DRUG|nystatin|
214493130|NCT06367023|BEHAVIORAL|Rajyoga Meditation Practice|The intervention will be given for 3 months, For 6 days one hour per day Rajyoga meditation basic course will be provided, followed by 1 hour daily spiritual lesson, Positive thinking and motivation classes will be provided to the intervention group and in control group standard treatment will be given.
214493131|NCT02745249|BEHAVIORAL|Maternal Nutrition Behavior change|
214493132|NCT04801706|DIAGNOSTIC_TEST|Ultrasound|Association of each ultrasonographic parameter with FIGO clinical grading of placenta accreta and with histopathological diagnosis of placenta accreta in hysterectomy specimens
214493133|NCT01964300|BIOLOGICAL|peginterferon alfa-2b|Given subcutaneously (SC)
214493134|NCT01964300|OTHER|laboratory biomarker analysis|Correlative studies
214983721|NCT00112957|BIOLOGICAL|rF-NY-ESO-1 vaccine|Patients received subcutaneous injections of rF-NY-ESO-1 (7.41 × 10\^7 PFU) on Days 29, 57, 85, 113, 141, and 169.
215088594|NCT01109771|DEVICE|permanent mesh fixation|Permanent mesh fixation will be used.
215088595|NCT01109771|DEVICE|absorbable mesh fixation|Absorbable mesh fixation will be used.
215088596|NCT05251532|OTHER|Kinesio Taping|In addition to Kinesio Tex tape distortion taping, conventional rehabilitation is applied.
215088597|NCT05251532|OTHER|Conventional Rehabilitation|Conventional rehabilitation practices are carried out
215088598|NCT05504668|DIETARY_SUPPLEMENT|Turmeric Brainwave|A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
215088599|NCT01059383|DRUG|VECAM 40/300|1 capsule, orally, once daily at bedtime.
214983722|NCT06467721|DEVICE|Self-adhesive silicone gel waterproof dressing|Self-adhesive silicone gel waterproof dressing is used after artificial joint replacement surgery.
214983723|NCT06467721|DEVICE|Sterile gauze dressing|Sterile gauze dressing is used after artificial joint replacement surgery.
214983724|NCT02165527|PROCEDURE|Lunar iXDA scan|Subject will receive a total body scan taken by the Lunar iXDA. This scan will take approximately 8 minutes to complete. Following the scan, the computer of the Lunar iXDA will calculate the bone length.
214983725|NCT00870142|DRUG|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
214983726|NCT00870142|DRUG|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
214983727|NCT02366871|DRUG|Oral apixaban|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
215088600|NCT01059383|DRUG|Esomeprazole 20 mg|1 capsule, orally, once daily 30-60 min. before dinner
215088601|NCT04498351|DRUG|Control Test|"Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side."
215088602|NCT04498351|DRUG|Dexmedetomidine|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
215088603|NCT04498351|DRUG|Dexmedetomidine and magnesium sulphate|"Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side."
215088604|NCT04498351|DRUG|magnesium sulphate|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
215088605|NCT04867694|BEHAVIORAL|BCC|Behavior change communication on Nutrition, Health \& Hygiene, including (but not limited to) awareness of dietary diversification from 6 months of age and adequate complementary feeding; and raising awareness of good water and hygiene practices.
215088606|NCT04867694|DIETARY_SUPPLEMENT|Preventive supplement|Monthly delivery of a nutritional supplement: enriched flour (CSB++), at a dose of 3 kg/month/beneficiary child. The nutritional supplement is limited to \[6-11\] months old children diagnosed as non-wasted (green MUAC); or children \[12-59\] months old for 6 months after discharge from a CMAM treatment or consolidation program.
215088607|NCT04867694|DIETARY_SUPPLEMENT|MNP|Delivery of micronutrient powders to \[12-23\] months old children (30 sachets per month for 2 months, every 6 months, according to international recommendations).
215088608|NCT04867694|OTHER|Water purification input|Monthly delivery of a water purification input: bleach or flocculant/decontamination sachets for the potabilization of the water of the whole household. The water treatment input is limited to households with \[6-11\] months old children, or children \[12-59\] months old enrolled in a CMAM treatment program and for 6 months after discharge.
214493135|NCT06210659|BEHAVIORAL|Theory of Planned Behavior Based Training Program|"Theory of Planned Behavior Based Training Program will be implemented. The training program will consist of 4 sessions. First session; It will consist of the definition, symptoms and treatment approaches of primary dysmenorrhea. Content of the second session; It will consist of lifestyle interventions in dysmenorrhea. Content of the third session; It will consist of the importance of physical activity in primary dysmenorrhea. The fourth session consists of a group walk.~Students will be monitored for 3 menstrual cycles. Starting from the end of the first menstrual period after completion of the training session, students will be asked to record their daily step count using a pedometer. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated. After the training sessions are completed, students will be given an end-of-menstrual motivational interview for 3 menstrual cycles."
214493136|NCT02906657|OTHER|Medication reconciliation|The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
214493137|NCT00557492|DRUG|Avastin (bevacizumab)|10 mg/kg, days 1, 15, 29 and 43
214493138|NCT00557492|DRUG|Gemzar (Gemcitabine)|On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
214493139|NCT00557492|RADIATION|external beam radiotherapy|3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
214983728|NCT02366871|DRUG|Subcutaneous enoxaparin|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
214983729|NCT06147674|DEVICE|VQm Pulmonary Health Monitor™|"The VQm Pulmonary Health Monitor™ (may be referred to as the VQm PHM™) is a a Class IIa, Health Canada approved medical device used as an adjunct monitor and is non-life supporting, providing clinicians with measurements of pulmonary function parameters of mechanically ventilated adult patients. The measurements provided are:~* Pulmonary Blood Flow (PBF)~* Shunt Fraction (Qsi)~* Dead space (VD):~* Functional Residual Capacity (FRC)"
214983730|NCT00167700|BEHAVIORAL|Dietary counselling and placebo|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
214983731|NCT00167700|BEHAVIORAL|Dietary counselling and probiotics|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
214983732|NCT00167700|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules
214983733|NCT00167700|DIETARY_SUPPLEMENT|Probiotics|
214983734|NCT00167700|DIETARY_SUPPLEMENT|Prebiotics|
214983735|NCT02803463|PROCEDURE|open appendectomy with peritoneal closure|open appendectomy with peritoneal closure under general anesthesia for acute appendicitis
214983736|NCT02803463|PROCEDURE|open appendectomy without peritoneal closure|open appendectomy without peritoneal closure under general anesthesia for acute appendicitis
215088609|NCT04867694|BEHAVIORAL|Family MUAC|"One-time delivery of a mid-upper arm circumference (MUAC) measuring tape and training of families in its use, and actions to be taken based on the results. This will involve distributing Shakir bands to all households with \[6-59\] months old children and training mothers/guardians, or any other family members who express an interest, in screening for wasting using the MUAC criteria, and explaining the procedure to follow if the child tests positive in the family.~Formative supervision of MUAC measurement in families. The training will be carried out by the members of the care groups and at each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary."
214983737|NCT02830139|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.
214983738|NCT02830139|PROCEDURE|Radical colorectal resection|radical colorectal resection with lymphadenectomy
214493140|NCT02438137|DRUG|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
214983739|NCT02830139|DRUG|Oxaliplatin , Capecitabine|XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
214983740|NCT02830139|DRUG|Normal saline , Cisplatin , 5-Fu|
214983741|NCT04871464|DRUG|Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules|Oral
214983742|NCT04871464|OTHER|Placebo|Oral
214983743|NCT06243302|PROCEDURE|OTSC Closure After VAAFT|Under general anesthesia,the fistulas will be drained at least for 8 weeks. Then a video camera will be inserted through the external opening to fulgurate the fistula tract under direct vision. Finally the internal fistula opening will be closed water tight by a circular clip. The patients will be followed up for complications as well as short and long term recurrences
214983744|NCT05803707|BEHAVIORAL|Home-based Adapted Physical Activity|There will be 8 weekly sessions at a time defined in advance for the same group and for the 8 sessions
214983745|NCT02752477|DRUG|Opioid-free general anesthetic|An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
214983746|NCT02752477|DRUG|Traditional general anesthetic|Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
214983747|NCT05415878|DEVICE|RCW design form|"Tall RCW= a knee high removable cast walker with an offloading insole~Short RCW= an ankle high (extending up the leg just past the ankle) removable cast walker with an offloading insole, paired with an external shoe lift to be used with a diabetic shoe on the contralateral limb"
214983748|NCT02309359|BIOLOGICAL|ALX-0061|
214983749|NCT02309359|OTHER|Placebo|
214983750|NCT02309359|DRUG|Methotrexate|Stable background dose of commercially available methotrexate (not provided by the Sponsor).
214983751|NCT00092001|DRUG|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
214983752|NCT01578291|BEHAVIORAL|Parental information|An informational brochure indicating the study details
214983753|NCT01578291|BEHAVIORAL|Play therapy|Play therapy with a child life specialist
214983754|NCT05534542|OTHER|exercıse|ıntradıalıtıc core stabılızatıon
214983755|NCT05055765|PROCEDURE|Microneedling|MN will be carried out 1mm below of the gingival margin on the gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles.
214983756|NCT05055765|PROCEDURE|injectable- platelet rich fibrin|I-PRF will be prepared according to Choukroun PRF method.
214983757|NCT01242787|DRUG|LB80380|Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
214983758|NCT01242787|DRUG|Entecavir 0.5 mg|Entecavir 0.5 mg, by oral for 48 weeks
214983759|NCT00626145|PROCEDURE|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
214983760|NCT00626145|PROCEDURE|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
214983761|NCT00701363|DRUG|Lanreotide Autogel 120 mg|120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
214983762|NCT02136693|DRUG|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
214983763|NCT02136693|DRUG|Placebo|3.5 g /day of inert compound for 180 days after STARR
214983764|NCT00386061|DRUG|rimonabant (SR141716)|
214983765|NCT01981083|DIETARY_SUPPLEMENT|Egg albumin-based protein supplement|
214983766|NCT01981083|DIETARY_SUPPLEMENT|Renal-specific oral supplement|
214983767|NCT00060411|DRUG|erlotinib hydrochloride|Given IV
214983768|NCT00060411|DRUG|fluorouracil|Given IV
214983769|NCT00060411|DRUG|leucovorin calcium|Given IV
215088610|NCT04867694|BEHAVIORAL|Screening by care group|"Monthly screening by the care group volunteers of the children they follow, using the MUAC.~Referral to the health center of \[6-59\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled"
214983770|NCT00060411|DRUG|oxaliplatin|Given IV
214983771|NCT00060411|BIOLOGICAL|bevacizumab|Given IV
214983772|NCT00770406|DRUG|botulinum toxin type A|100 or 200 units intravesically
214983773|NCT03749200|OTHER|Obemat2.0 therapy|
214983774|NCT03749200|OTHER|Regular practise in primary care|
214983775|NCT00049569|DRUG|cytarabine|Given IT
214983776|NCT00049569|DRUG|methotrexate|Given IT
214983777|NCT00049569|DRUG|vincristine sulfate|Given IV
214983778|NCT00049569|DRUG|prednisone|Given PO
214983779|NCT00049569|DRUG|pegaspargase|Given IM
214983780|NCT00049569|DRUG|doxorubicin hydrochloride|Given IV
214983781|NCT00049569|DRUG|imatinib mesylate|Given PO
214983782|NCT00049569|DRUG|cyclophosphamide|Given IV
214983783|NCT00049569|DRUG|etoposide|Given IV
214983784|NCT00049569|BIOLOGICAL|filgrastim|Given SC
214983785|NCT00049569|DRUG|leucovorin calcium|Given IV
214983786|NCT00049569|DRUG|asparaginase|Given IM
214983787|NCT00049569|DRUG|therapeutic hydrocortisone|Given IT
214983788|NCT06099535|DRUG|LNK01001 Dose A|Capsules taken orally
214983789|NCT06099535|DRUG|LNK01001 Dose B|Capsules taken orally
214983790|NCT06099535|DRUG|placebo|Capsules taken orally
214983791|NCT05916209|PROCEDURE|Peripheral nerve blocks|Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.
214983792|NCT05297682|DEVICE|anesthesia with propofol|General anesthesia with propofol
214983793|NCT00290225|BEHAVIORAL|Breath Water Sound Course and Traumatic Incident Reduction|
214681080|NCT02997020|OTHER|EDSPD|The equipment \& conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
214983794|NCT01641042|BIOLOGICAL|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
214681081|NCT05748925|DRUG|dapagliflozin|The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.
214983795|NCT02595658|DIETARY_SUPPLEMENT|Meal composition|
214983796|NCT02595658|DRUG|Rapid-Acting Insulin Dose|
214983797|NCT02925468|DEVICE|Bite turbo|In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
214983798|NCT02230215|DEVICE|Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation|The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
214983799|NCT05473845|PROCEDURE|Acupressure intervention|Acupressure
214983800|NCT05473845|PROCEDURE|Reiki intervention|Reiki
214983801|NCT00863707|DRUG|Regadenoson|IV
214983802|NCT00863707|DRUG|Placebo|IV
214983803|NCT06190028|DEVICE|Iridium A Gel|IRIDIUM® A gel is a sterile, preservative free ophthalmic gel, containing Carbopol, amino acids, Echinacea and Aloe extract. IRIDIUM® A gel is indicated for the protection of the eye surface particularly at night, even in the presence of changes in histological continuity and blepharitic conditions, including those of an iatrogenic nature, following the use of hypotonic eye drops and of the preservatives contained therein.
214983804|NCT05778344|BEHAVIORAL|Teletechnology-assisted home-based pulmonary rehabilitation|The accuracy and safety of home-based pulmonary rehabilitation will be checked regularly through technology devices such as smart watch and via videotelephony (or telephone calls if indicated).
214983805|NCT06468956|DRUG|SHR-1819|SHR-1819 injection
214983806|NCT06468956|DRUG|Placebo|placebo
214983807|NCT05913362|BEHAVIORAL|IVUS based ultralow contrast PCI|IVUS based ultralow contrast PCI
214983808|NCT06351904|DRUG|RAG-01|RAG-01 is a therapeutic small activating RNA (saRNA) duplex molecule comprised of two partially chemically modified complementary oligonucleotide strands.
214983809|NCT00289276|DEVICE|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
214983810|NCT03939104|DRUG|Artemether-lumefantrine+amodiaquine|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: Amodiaquine is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
214983811|NCT03939104|DRUG|Artemether-lumefantrine+placebo|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
214983812|NCT03939104|DRUG|Artesunate-mefloquine+piperaquine|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
214983813|NCT03939104|DRUG|Artesunate-mefloquine+placebo|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
214983814|NCT05093582|DRUG|Levcromakalim|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
214983815|NCT05093582|DRUG|Saline|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
214983816|NCT02728323|DRUG|Levobupivacaine|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
214681082|NCT05748925|DRUG|placebo|Control group: will be maintained on their medication
214681083|NCT04855877|DRUG|Oral tablet|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
214681084|NCT04855877|DRUG|Placebo|Oral administration of lactose tablet (placebo)
214983817|NCT02728323|DRUG|Saline|20 ml of saline saline by intramuscular injection, at the end of surgery
214983818|NCT00001091|DRUG|Ritonavir|
214983819|NCT00001091|DRUG|Nelfinavir mesylate|
214983820|NCT00001091|DRUG|Nevirapine|
215088611|NCT04867694|BEHAVIORAL|CMAM compliance|"Weekly follow-up of \[6-59\] months old children under treatment and for 6 months after discharge from the national treatment and consolidation program : care group volunteers follow children under treatment until they recover and for the whole duration of their consolidation (for children cured of severe emaciation) through weekly home visits.~They monitor treatment adherence (i.e., families follow the planned schedule of visits and receive inputs for treatment or consolidation) and treatment compliance (i.e., the malnourished or consolidating child receives the planned dose of therapeutic or supplementary food each day)."
214983821|NCT00001091|DRUG|Lamivudine|
215088612|NCT05577949|OTHER|Structured aerobics exercise|A 12 week structured aerobics exercise program will be offered. The patient has to perform exercise five times a week , 30 minutes a day
215088613|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
215088614|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
214369451|NCT06011941|PROCEDURE|Modified laparoscopic transcystic biliary drainage|First, a needle was passed through a separate skin puncture wound 3 cm below the costal margin on the midaxillary line/posterior axillary line. Second, a lateral incision into the cystic duct was performed medially to allow insertion and embedding of the catheter. Third, a 7-Fr catheter was introduced through the abdominal wall via the cystic duct into the CBD. Fourth, if the position of the catheter inside the CBD was correct (the end of the tube reached the distal CBD but did not pass the papilla), the lateral incision of the cystic duct was closed by a V-Loc closure device using a single-layered, continuous suture in a circling manner to simultaneously cover and anchor the C-tube. After the procedure, an artificial fistula of 3 to 5 mm in length was formed.
214369452|NCT03094260|DEVICE|High intensity bright light therapy|"Treatment with light therapy in high intensity (10,000 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subject is sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
214369453|NCT03094260|DEVICE|Low intensity light therapy|"Treatment with light therapy in low intensity (\<500 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subjectis sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
214493141|NCT02438137|DRUG|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
214493142|NCT03447496|PROCEDURE|Closed reduction|The children were treated with closed reduction.
214493143|NCT03447496|PROCEDURE|Open reduction|The children were treated with Open reduction.
214493144|NCT05420480|PROCEDURE|Two-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
214983822|NCT00001091|DRUG|Stavudine|
214983823|NCT00513929|DIETARY_SUPPLEMENT|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
214983824|NCT02051868|DRUG|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
214983825|NCT02051868|DRUG|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
214983826|NCT02051868|DRUG|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
214983827|NCT02051868|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
214983828|NCT05302011|DRUG|Pembrolizumab|Pembrolizumab 200mg i.v. day 1-22-43-64
214983829|NCT05302011|DRUG|Carboplatin or Cisplatin|Carboplatin Area Under the Curve(AUC) = 4-5 i.v. day 1-22-43-64 or Cisplatin 75mg/m2 i.v. day 1-22-43-64
214983830|NCT05302011|DRUG|Docetaxel|75mg/m2 i.v. day 1-22-43-64
214983831|NCT00869960|DRUG|tenofovir|tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
214983832|NCT00869960|DRUG|emtricitabine|emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
214983833|NCT00869960|DRUG|atazanavir|atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
214983834|NCT00869960|DRUG|ritonavir|ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
214681085|NCT05942274|DIAGNOSTIC_TEST|We propose to validate these smartwatch ECG functions to support FDA submissions|1\) Obtain a simultaneous recording of a Lead I (RA-LA) ECG from the Smartwatch and a clinical standard device (GE Cardiosoft ECG). Subsequent recordings will be acquired from the other models of the Smartwatch as well as a recording utilizing the FDA-cleared KardiaMobile.
214681086|NCT00153634|DRUG|IV amikacin|5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
214681087|NCT00153634|DRUG|PO azithromycin|250 mg once daily
214681088|NCT00153634|DRUG|IV ceftazidime|50 mg/kg every 8 hours, up to 2 grams every 8 hours
214681089|NCT00153634|DRUG|PO ciprofloxacin|500 mg every 12 hours if weight \<50 kg 750 mg every 12 hours if weight ≥50 kg
214681090|NCT00153634|DRUG|IV meropenem|40 mg/kg every 8 hours, up to 2 grams every 8 hours
214681091|NCT00153634|DRUG|IV piperacillin-tazobactam|100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
214681092|NCT00153634|DRUG|IV ticarcillin-clavulanate|100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
214681093|NCT00153634|DRUG|IV tobramycin|2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
214681094|NCT05632133|DRUG|Lacosamide 50 MG Oral Tablet|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
214681095|NCT05632133|DRUG|Ibuprofen 400 mg|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
214681096|NCT01372111|DRUG|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
214681097|NCT01372111|RADIATION|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
214681098|NCT04397393|DRUG|Midazolam|Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform OPU
214983835|NCT01382550|DRUG|long-lasting OAT or 12-month OAT|"The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (\>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded."
214983836|NCT00496418|DEVICE|Mesh in permanent colostomy|
214983837|NCT01181973|DRUG|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
214983838|NCT01181973|DRUG|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
214369454|NCT01496833|DEVICE|Ankura Branched/Fenestrated Stent Graft|Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
214369455|NCT06542536|DRUG|Monlunabant|Oral monlunabant
214681099|NCT04313335|DRUG|Duloxetine|Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.
214681100|NCT04770610|DRUG|OT-101 Ophthalmic Solution|Atropine 0.01%
214681101|NCT04770610|DRUG|Vehicle|Investigational Product minus active ingredient
214681102|NCT04795713|DRUG|MT-6402|Experimental Treatment
214983839|NCT01181973|DRUG|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
214369456|NCT06542536|DRUG|Placebo (monlunabant)|Oral placebo (monlunabant)
214681103|NCT05394545|DEVICE|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
214681104|NCT03964415|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
214681105|NCT03964415|BIOLOGICAL|Clade C and Mosaic gp140 HIV bivalent vaccine|Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
214681106|NCT03964415|BIOLOGICAL|Placebo|Participants will receive matching placebo.
214681107|NCT03747172|DIETARY_SUPPLEMENT|complementary and alternative therapy|complementary and alternative therapies were grouped into five main categories: (1) biologically based therapies , (2) mind/body therapies, (3) manipulative and body-based therapies, (4) Energy therapies and (5) alternative medical systems.
214681108|NCT00596518|DRUG|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
214681109|NCT06275971|DEVICE|Dexcom G6|Glycemic control was monitored using CGM data for seven days following cardiac surgery
214681110|NCT06275971|DEVICE|SMBG or venous/arterial blood glucose|Glycemic control was monitored using SMBG or venous/arterial blood glucose data for seven days following cardiac surgery
214681111|NCT01257646|OTHER|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
214681112|NCT01734993|DRUG|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
214681113|NCT01024465|DEVICE|ReShape Duo Balloon|ReShape Duo Balloon
214681114|NCT03411213|DEVICE|diffuse optical tomography|Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
214369457|NCT03246282|DEVICE|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
214983840|NCT01181973|DRUG|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
214983841|NCT00091078|BIOLOGICAL|oblimersen sodium|Given IV
214983842|NCT00091078|DRUG|imatinib mesylate|Given orally
214983843|NCT00091078|OTHER|laboratory biomarker analysis|Correlative studies
214983844|NCT03652896|PROCEDURE|anatomical liver resection|Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
214983845|NCT03720886|BIOLOGICAL|rhPTH（1-34） 28.2μg|Administered by subcutaneous injection
214983846|NCT03720886|BIOLOGICAL|rhPTH（1-34） 56.5μg|Administered by subcutaneous injection
214983847|NCT03720886|BIOLOGICAL|teriparatide acetate(Teribone™)|Administered by subcutaneous injection
214983848|NCT02029417|DRUG|cytarabine|Given SC
214369458|NCT03246282|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of 0.9% Sodium Chloride Solution
214369459|NCT03246282|DEVICE|Peripheral Catheterization|"20-gauge 1.0 catheter"
214369460|NCT03737838|DEVICE|Atrial fibrillation ablation|High density mapping of left atrium using Rhythmia mapping system to identify gaps in conduction and wavefront discontinuities (deceleration zones)
214369461|NCT03661138|DRUG|Upadacitinib|Upadacitinib is administered orally.
214369462|NCT03661138|DRUG|Placebo for upadacitinib|Placebo is administered orally.
214369463|NCT03661138|DRUG|Topical Corticosteroids (TCS)|It is administered concomitantly with upadacitinib or placebo.
214369464|NCT01295450|DRUG|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
214369465|NCT01295450|DRUG|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
214369466|NCT01292551|DRUG|Bosentan|tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
214369467|NCT01292551|DRUG|Placebo|Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
214369468|NCT03365154|DEVICE|Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment|Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.
214369469|NCT03365154|DEVICE|Balloon Angioplasty|Low pressure balloon angioplasty may be used following atherectomy
214369470|NCT03209804|PROCEDURE|hybrid operating techniques|A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
214369471|NCT06579131|BEHAVIORAL|sitting position|The participants' seating positions will be assessed, and evaluations will be made based on this.
214369472|NCT06580431|OTHER|Saliva and serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.
214369473|NCT00386022|DRUG|GnRH|GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
214369474|NCT00386022|DRUG|NAL-GLU GnRH antagonist|A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
214369475|NCT00386022|DRUG|Estrogen patch|transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
214369476|NCT03124979|DEVICE|LNCS DBI Sensor|Noninvasive Measurement of SpO2
214369477|NCT06144866|DRUG|Dabigatran, rivaroxaban, apixaban, edoxaban|For patients who received direct oral anticoagulants (DOAC) before ischemic stroke or intracranial hemorrhage, the DOAC level upon hospital arrival will be measured.
214369478|NCT03818282|DRUG|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.
214369479|NCT06579898|OTHER|Progressive resistance exercise training|A 24-week progressive strength training programme (PRET). Divided into 4 mesocycles in which the intensity of training is built up from 60% 1RM- 80% 1RM. Training is carried out twice a week under the guidance of a physiotherapist or exercise instructor.
214369480|NCT03371082|BIOLOGICAL|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
214369481|NCT03371082|BIOLOGICAL|Lantus®|Route of administration: subcutaneous injection
214369482|NCT01064297|DRUG|Lamotrigine monotherapy|Lamotrigine monotherapy
214369483|NCT01064297|DRUG|Lamotrigine polytherapy including valproate|Lamotrigine polytherapy including valproate
214369484|NCT01064297|DRUG|Lamotrigine polytherapy without valproate|Lamotrigine polytherapy without valproate
214983849|NCT02029417|DRUG|omacetaxine mepesuccinate|Given SC
214983850|NCT02029417|DRUG|decitabine|Given IV
214983851|NCT02029417|OTHER|laboratory biomarker analysis|Correlative studies
214983852|NCT04582656|DEVICE|Targeted microwave ablation|Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
214983853|NCT01997658|DRUG|Methylprednisolone|Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.
214983854|NCT01997658|DRUG|Placebo|Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
214983855|NCT03168945|OTHER|GeneXpert MTB/RIF|Screening intervention: novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB collected and performed at point-of-contact in a mobile van
214983856|NCT03168945|OTHER|Smear microscopy|Screening intervention: routine diagnostic test (smear microscopy) for active case finding for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
214983857|NCT04056169|DRUG|high-dose rosuvastatin|rosuvastatin 20 mg once a day for 6 months
214983858|NCT04056169|DRUG|low-dose rosuvastatin plus ezetimibe|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
214983859|NCT02406820|DEVICE|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
214983860|NCT03578042|DRUG|Losartan and amlodipine and hydrochlorothiazide|this is a fixed combination containing the 3 drugs
214369485|NCT01229631|DIETARY_SUPPLEMENT|Juice plus+|Subjects in active group will be supplemented with Juice plus+ capsules (3 in the morning and 3 in the evening, for 3 months)
214369486|NCT01229631|DIETARY_SUPPLEMENT|Placebo non active capsules|Subjects will take non-active placebo capsules (3 in the morning and 3 in the evening, for 3 months)
214681115|NCT05772715|OTHER|orthosis + exercise therapy|The orthosis + exercise group receives the same orthosis and instructions as the orthosis group (see next section), supplemented by exercise therapy. This includes weekly 25-30-minute physical therapy sessions with a total of 12 sessions. Sessions include patient education on thumb positioning, functional training and home exercise instructions to improve CMC-1 stability during pinch in extension/abduction, as instability and degeneration occurs in flexion/adduction(17,19,28-31). The first phase (week 0 - week 6) comprises coordination exercises for the thumb intrinsics (except adductor pollicis), extensor pollicis brevis and first dorsal interosseous to support CMC-1 extension/abduction. The second phase (week 6 - month 3) comprises reduced orthosis usage and thenar muscle strengthening exercises(except adductor pollicis).
214681116|NCT05772715|OTHER|Orthosis|The orthosis group receives a custom-made thermoplastic orthosis immobilizing the first carpometacarpal joint (CMC-1) in extension/abduction and the metacarpophalangeal joint in flexion. Orthosis usage is 24/7 in the first two weeks, thereafter only during activities with high load until three months. Two appointments take place: one for orthosis fabrication and one for a one-week checkup.
214983861|NCT03578042|DRUG|Standard of care|any free triple combination therapy for hypertension given as 2 or 3 pills
214983862|NCT01254370|DRUG|Latanoprost|0.005%
214983863|NCT01254370|DRUG|Travatan Z|0.004%
214983864|NCT06178692|DIAGNOSTIC_TEST|Validation of miRNA-serum signatures associated with IDH1 status|Validation of miRNA-serum signatures associated with IDH1 status and prognosis, as reliable, specific and sensitive circulating diagnostic biomarkers also useful to improve prognostic stratification of patients.
214369487|NCT00276692|DRUG|irinotecan hydrochloride|
214369488|NCT01722942|PROCEDURE|ICD implantation|ventricular ICD implantation
214369489|NCT01722942|DRUG|amiodarone hydrochloride|amiodarone prescription
214369490|NCT04590534|DRUG|Chromax|Treatment of BPH by Chromax for 3 Months
214369491|NCT04590534|DRUG|Sildosin Group|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
214983865|NCT03401957|DRUG|Cetuximab|Cetuximab-based infusional 5-FU regimen as the 1st line treatment.
214983866|NCT03401957|DIAGNOSTIC_TEST|liquid biopsy|The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
214983867|NCT05856487|DRUG|NVP-2203|Take it once daily for 8 weeks orally.
214983868|NCT05856487|DRUG|NVP-2203-R1|Take it once daily for 8 weeks orally.
214983869|NCT05856487|DRUG|NVP-2203-R2|Take it once daily for 8 weeks orally.
214983870|NCT05856487|DRUG|NVP-2203-R3|Take it once daily for 8 weeks orally.
214983871|NCT05856487|DRUG|NVP-2203 Placebo|Take it once daily for 8 weeks orally.
214983872|NCT05856487|DRUG|NVP-2203-R1 Placebo|Take it once daily for 8 weeks orally.
214983873|NCT05856487|DRUG|NVP-2203-R2 Placebo|Take it once daily for 8 weeks orally.
214369492|NCT04590534|OTHER|Placebo Group|patients will receive placebo 3 times daily for 12 weeks
214369493|NCT02615964|RADIATION|Nova Flow Procedure|Evaluation of the diagnosis, and stratification of the severity of Raynaud's disorder in patients with scleroderma based on clinical and imaging data will allow creation of more precise diagnostic criteria as well as disease classification which may guide treatment practices. The study results will likely have no immediate benefit to the patients participating in the study, however may have a future impact diagnosis, stratification and ultimately treatment of patients with Raynaud's disorder. In addition, data collected in this study may provide insight into disease process and leading to future research endeavors.
214983874|NCT05856487|DRUG|NVP-2203-R3 Placebo|Take it once daily for 8 weeks orally.
214983875|NCT04873726|DEVICE|Magnetic Tape® aplication|Magnetic tape® is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
214983876|NCT04873726|DEVICE|Kinesiology Tape|Kinesiology tape is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
214983877|NCT02783911|DEVICE|MTA|Mineral Trioxide Aggregate grey paste
214983878|NCT02783911|DRUG|Ferric Sulfate|Ferric Sulfate paste
214983879|NCT05583630|DEVICE|A gap plate with the function of knee joint pressure detection|A gap plate can measure knee joint pressure by tension sensor. This is a part of routine medical care.
214983880|NCT01555593|DEVICE|Cardioline Exp'air by Medi-soft - Sorinnes (B)|FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
214983881|NCT06466239|OTHER|PNF Stretching|PNF was applied to the hamstring muscle, with a 1-day washout period in between.
214983882|NCT06466239|OTHER|Static Stretching|Static stretching was applied to the hamstring muscle, with a 1-day washout period in between.
214983883|NCT01703468|DRUG|Oxcarbazepine|
214983884|NCT05605990|DEVICE|Innovative tourniquet (Acusense Nonpneumatic tourniquet)|To use this innovative tourniquet before collecting blood samples, and setting IV catheter. We also use this innovative tourniquet to occlude the flow of blood.
214983885|NCT04382482|DEVICE|Tachidino|Web-platform delivering remote treatment of reading and spelling disorders through the (visual or auditory) presentation of words and sentences to be either decoded or corrected (reordering wrong letter sequences).
214983886|NCT00036426|BIOLOGICAL|FavId (Id-KLH) active immunotherapy|
214983887|NCT05295589|PROCEDURE|Computed Tomography|Undergo CT scan
214983888|NCT05295589|DRUG|Copanlisib Hydrochloride|Given IV
214983889|NCT05295589|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214493145|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
214983890|NCT05295589|DRUG|Olaparib|Given PO
214983891|NCT05295589|DRUG|Paclitaxel|Given IV
214493146|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
214493147|NCT00936416|PROCEDURE|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
214983892|NCT05295589|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
215088615|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
215088616|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
215088617|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
215088618|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
214369494|NCT02803554|OTHER|Plasma|Blood plasma from donors aged 25 years or younger
214369495|NCT04928105|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
214369496|NCT00986076|DRUG|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
214369497|NCT00986076|DRUG|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
214369498|NCT04371146|DRUG|Methylphenidate|35 mg methylphenidate (Ritalin®) is administered once using a randomized placebo-controlled between subject's design
214369499|NCT04371146|DRUG|Reboxetine|8 mg Reboxetine (Edronax®) is administered once using a randomized placebo-controlled between subject's design
214369500|NCT04371146|DRUG|Placebos|A placebo pill is administered once using a randomized placebo-controlled between subject's design
214369501|NCT02578979|DEVICE|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
214369502|NCT02578979|DEVICE|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
214369503|NCT05089617|DRUG|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699."
214369504|NCT03027648|PROCEDURE|Placement of levonorgestrel-releasing intrauterine system|All the patients accepted treatment of levonorgestrel-releasing intrauterine system
214369505|NCT06451900|DRUG|Fenofibrate|full-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
214369506|NCT06451900|OTHER|placebo|ull-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
214369507|NCT06185933|DRUG|Lidocaine Spray|Pharyngeal anesthesia using a topical lidocaine spray was administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
214369508|NCT06185933|DRUG|Lidocaine Viscous+Lidocane spray|Pharyngeal anesthesia using topical viscous lidocaine solution + lidocaine spray were administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
214369509|NCT06393621|DIETARY_SUPPLEMENT|KEFPEP®|Twice daily (one pack before breakfast and the other before dinner)
214369510|NCT06393621|OTHER|Placebo|Twice daily (one pack before breakfast and the other before dinner)
214493148|NCT04327752|OTHER|dermatological consultation|Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.
214493149|NCT00359606|DRUG|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
214493150|NCT00359606|OTHER|Laboratory Biomarker Analysis|Correlative Studies
214493151|NCT00359606|OTHER|Pharmacological Study|Correlative Studies
214493152|NCT00359606|DRUG|Tetrahydrouridine (THU)|Given PO and IV
214983893|NCT05295589|DRUG|Topotecan Hydrochloride|Given IV
214983894|NCT03210766|DRUG|Nabilone|
214983895|NCT03210766|DRUG|THC/CBD|
214983896|NCT05449665|OTHER|Phase 1 - Control|"Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d).~Fed to energy balance (1.5 x Resting Metabolic Rate, RMR)."
214983897|NCT05449665|OTHER|Phase 2 - High Fibre|High Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 30g/day Fibre). Fed ad libitum, contains 20g/day pectin (split over breakfast, lunch and dinner) in drinks/yoghurts which will be compulsory to consume and 10g/day fibre coming from the diet provided.
214983898|NCT05449665|OTHER|Phase 3 - Low Fibre|Low Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 10g/day Fibre). Fed ad libitum.
215094566|NCT02231385|DRUG|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
214983899|NCT00843466|OTHER|Mild, moisturizing hand cleanser|"Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water"
214983900|NCT01785381|OTHER|Added value of coordinator|Added value of coordinator
214493153|NCT02285270|DEVICE|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
214493154|NCT03753932|DEVICE|Fixed prosthodontics|The intervention takes place six months after finishing radiotherapy.
214493155|NCT02035605|DRUG|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
214493156|NCT02035605|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
214493157|NCT05708365|OTHER|Standard-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute"
214493158|NCT05708365|OTHER|Ultra-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute"
214493159|NCT00913289|BIOLOGICAL|adipose tissue derived stromal cells|dosage
214493160|NCT04868617|DEVICE|ATTRACT-I|The aim of this investigation is to evaluate the performance and safety of an ostomy baseplate with a novel skin protection technology and its ability to reduce peristomal skin complications compared to SenSura® Mio. The subject will be randomized to either test product or comparator at enrollment. The subject will wear the test product for approximately 35 days and then cross-over to the comparator (or vice-versa) for approximately 35 days. At each baseplate change, the subject will answer questions about their skin, and take pictures of their stoma and used baseplate. They will also answer quality of life questionnaires at each study visit.
214493161|NCT00192218|BIOLOGICAL|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
214493162|NCT04898569|DRUG|Ferinject|Ferric carboxymaltose injection
214493163|NCT04898569|DRUG|Normal Saline Flush|placebo
214493164|NCT03472352|BIOLOGICAL|An anticancer medication (A01) and immune cells (IC01)|The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
214983901|NCT06525792|PROCEDURE|Oxygen|Oxygen and standard therapy were given
214983902|NCT06525792|PROCEDURE|Ozone|Ozone and standard therapy were given
214983903|NCT06525792|PROCEDURE|Standard therapy|Best standard of care
214493165|NCT05994131|DRUG|IN10018|orally taken once daily
214493166|NCT05994131|DRUG|Furmonertinib|orally taken once daily
214493167|NCT00832169|DRUG|AZD1386|1 dose of oral solution
214493168|NCT03279224|BIOLOGICAL|Allogenic FMT|"Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3\. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
214493169|NCT03279224|BIOLOGICAL|Autologous FMT|"1\. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3\. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
214493170|NCT01053325|DRUG|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
214493171|NCT01053325|DRUG|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
214681117|NCT05033444|DRUG|PRV-002|"SAD portion: Eligible participants will be randomized to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomized to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.533 mg/kg (based on a 60kg participant) will be investigated.~MAD portion: Eligible participants will be randomized to receive a multiple (one dose per day for 5 consecutive days). Dose escalation will be conducted in a total of 2 cohorts. Within each cohort, 6 participants will be randomized to receive of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.266 mg/kg (based on a 60kg participant) will be investigated."
214983904|NCT04460053|PROCEDURE|Neurofilament light protein measurement in Isolated limb perfused patients|A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
214983905|NCT04194164|OTHER|Fluid intake app|Monitor fluid intake and interdialytic weight gain in patients using the fluid app
214983906|NCT04165122|BIOLOGICAL|HDIT101|i.v. Infusion
214983907|NCT04165122|DRUG|Valaciclovir|oral application of encapsulated Valaciclovir tablets
214983908|NCT04165122|BIOLOGICAL|HDIT101 placebo|i.v. Infusion
214983909|NCT04165122|DRUG|Valaciclovir placebo|oral application of encapsulated Valaciclovir placebo tablets
214983910|NCT02429050|DRUG|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
214983911|NCT02429050|DRUG|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
214983912|NCT01041859|DRUG|Tapentadol extended release (ER)|Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
214983913|NCT01041859|DRUG|Placebo|Form= tablet, route= oral use. Matching placebo twice daily.
214983914|NCT01952652|DRUG|Group N:Naproxen sodium|drug will be given 60 minutes before surgery
214983915|NCT01952652|DRUG|Group NC :naproxen sodium codeine phosphate|drug will be given 60 minutes before surgery
214983916|NCT03889392|PROCEDURE|Kidney transplantation and nephrectomy|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
214983917|NCT04367805|DIAGNOSTIC_TEST|nasopharyngeal Covid 19 RT-PCR|nasopharyngeal Covid 19 RT-PCR
214983918|NCT02075125|DRUG|Prasugrel 60 mg|Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
214983919|NCT02075125|DRUG|Ticagrelor 180 mg|Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
214983920|NCT00774085|OTHER|No intervention was given|Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
214493174|NCT05260398|BEHAVIORAL|Mightier Online Gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
214493175|NCT05416827|PROCEDURE|slow-release dexamethasone implant|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
214983921|NCT02990052|PROCEDURE|Volar plating|Open reduction and volar fixed-angle plate fixation of distal radius fracture
214983922|NCT02990052|PROCEDURE|Conservative treatment|Closed reduction \& casting of distal radius fracture
214983923|NCT06516471|DEVICE|Conventinal Navigation System Group|The preoperative planned model is projected onto the endoscopic display area in 3D using a mixed reality headset, accurately matching the actual anatomical structure and tissue displayed under the patient's endoscope to guide surgical resection of tumors.
214983924|NCT05711368|BEHAVIORAL|Distress tolerance training|It consisted of seven sessions. A 90-minute session will be conducted twice a week for four weeks. The first introductory session will be concerned with helping the student learn how to engage in distress tolerance training and define goals of distress tolerance. At the end of the 1st session, a written plan for every session (time, duration and setting) will be scheduled individually with each student.The next six training sessions will cover three core skills which comprised three sets: Crisis Survival Skills, the skills of Reality Acceptance; and the Skills When the Crisis Is Addiction. The distress tolerance training methods will include individualized interactions, demonstration, and rehearsal, psychoeducation, practice exercises and homework assignments. Follow up between sessions will done using telephone calling and messaging in order to encourage performance homework assignments, and provide help and support when needed particularly at the time of stress. .
214983925|NCT05852093|DRUG|Celecoxib+Buprenorphine Transdermal Patch|NSAIDs+narcotic analgesics
214983926|NCT05852093|DRUG|Celecoxib+Buprenorphine Transdermal Patch+Tizanidine|NSAIDs+narcotic analgesics+Skeletal Muscle Relaxant
214493176|NCT04185181|OTHER|virtual reality|wii video game based exercise
214493177|NCT04185181|OTHER|proprioceptive neuromuscular facilitation|PNF with breathing
214493178|NCT04185181|OTHER|complete decogestive therapy|pneumatic compression, manual lymph drainage, skin care and home exercise program
214493179|NCT02109575|DIAGNOSTIC_TEST|Blood Draw of up to 10 ml|In a laboratory setting, the blood will be spun for plasma and buffy coat, DNA will be extracted for processing using the diagnostic test. The results of the test are not provided back to the clinical setting.
214493180|NCT00623194|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
214983927|NCT00989222|PROCEDURE|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
214983928|NCT00989222|PROCEDURE|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
214983929|NCT01015027|BIOLOGICAL|REGN668|4 IV Cohorts (Dose 1, 2, 3, \& 4)
214493181|NCT00623194|DRUG|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
214681118|NCT05033444|DRUG|Placebo|Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
214983930|NCT05409365|OTHER|Immunohistochemical staining monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody)|Immunohistochemical staining
214983931|NCT04145063|OTHER|no stent|following uretroscopy, no stent will be placed
214983932|NCT04411615|DRUG|Omega 3|rTG form Omega-3
214983933|NCT00885118|DRUG|Placebo (middle dose)|Placebo tablets once a day
214983934|NCT00885118|DRUG|Placebo|Placebo tablets once a day
214983935|NCT00885118|DRUG|BI 10773|BI 10773 middle dose tablets once a day
214983936|NCT00885118|DRUG|BI 10773|BI 10773 high dose tablets once a day
214983937|NCT00885118|DRUG|BI 10773|BI 10773 middle dose tablets once a day
214983938|NCT00885118|DRUG|Placebo (high dose)|Placebo tablets once a day
214983939|NCT00885118|DRUG|BI 10773|BI 10773 low dose tablets once a day
214983940|NCT00885118|DRUG|Placebo (low dose)|Placebo tablets once a day
214983941|NCT02816723|BEHAVIORAL|Mindfulness-based Stress Reduction|mindfulness/meditation/movement training
214983942|NCT02816723|BEHAVIORAL|Brain Health|Brain Health Education
214983943|NCT00057135|BEHAVIORAL|Unit of use medication packaging|
214983944|NCT00057135|BEHAVIORAL|Mailed reminders to patient when medication refills are due|
214983945|NCT00057135|BEHAVIORAL|Note to Mental Health Provider when refill is overdue|
214983946|NCT00057135|PROCEDURE|Aligning all prescriptions to fall due on same date|
214983947|NCT02582476|DRUG|Bumetanide|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
214369511|NCT01085838|DRUG|Erlotinib|Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
214983948|NCT02582476|DRUG|Placebo|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
214369512|NCT02161302|DEVICE|transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
214369513|NCT02161302|DEVICE|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
214369514|NCT03943784|PROCEDURE|Endoscopic Variceal Ligation|Endoscopic varices ligation was performed with a six-shooter multiband ligator (Cook Medical, Limerick, Ireland) if medium to large varices or reddish spots, regardless of the grade of the varix, were observed. Each varix was ligated 1-2 cm above the gastro-esophageal junction, with 1 or 2 rubber bands and using no more than 5 rubber bands per session.
214983949|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 0.6 U/kg|Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
214983950|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 0.8 U/kg|Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
214983951|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 1.0 U/kg|Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
214983952|NCT03180710|DRUG|Humalog® Mix25 at 0.8 U/kg|Injection of Humalog® Mix25 at 0.8 U/kg
214983953|NCT04198935|DEVICE|Span Health Mobile Application|A 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
214983954|NCT01061372|DRUG|Placebo|Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
214983955|NCT01061372|DRUG|pregabalin|pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
214983956|NCT01061372|DRUG|pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
214369515|NCT03943784|DRUG|Non-Selective Beta-Blocking Agent|Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
214983957|NCT05442008|DRUG|Erenumab 70/140 mg s.c.|Monoclonal antibody directed against the receptor of the Calcitonin Gene Related Peptide (CGRP)
214983958|NCT05293795|BEHAVIORAL|3D printed model|Mother is given 3D printed model of fetus' face
215088619|NCT05190055|DEVICE|bone graft delivery system/wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. In the case of the device group, a novel filler tube with an integrated threaded rod, which can be connected to a surgical drill, A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
214493182|NCT06798545|DEVICE|endoscopic ultrasound with navigation system|Use of the EZ-EUS navigation system during the procedure
214493183|NCT01231438|DRUG|Renvela|800mg t.i.d. over 2 weeks
214983959|NCT05293795|BEHAVIORAL|Placebo|Mother is given a picture of 3D ultrasound of fetus
214983960|NCT00338780|DRUG|Lamivudine/ Placebo 100mg daily|
214983961|NCT01620645|RADIATION|CT scan and PA chest X-ray|"All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.~The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK."
214983962|NCT02087098|DRUG|Solifenacin|Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
214983963|NCT00013507|PROCEDURE|Falls|
214983964|NCT04421755|OTHER|Produce delivery|weekly home delivery of fresh fruits and vegetables
214681119|NCT06284928|OTHER|Gut Microbiota Analysis|This refers to the procedure of collecting fecal samples from both the hypertension group and the control group, followed by analyzing these samples to assess and compare the gut microbiota composition using methods like gene sequencing.
214681120|NCT03735693|DIAGNOSTIC_TEST|Ulstrasound|measurement of right femoral cross-section
214681121|NCT04906005|DRUG|gadopiclenol|administration by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a saline flush of at least 5 mL at the same rate to ensure complete injection of the contrast agent.The gadopiclenol administration is performed by power injecto
214983965|NCT04421755|OTHER|Cooking classes|weekly home delivery of fresh fruits and vegetables participants will be invited to participate in a Culinary Medicine cooking series. The OU Culinary Medicine cooking curriculum will involve a 3-part class series designed to build nutrition knowledge and cooking self-efficacy for preparing fresh F/Vs. Each session is \~2 hr. Core nutrition guidelines for blood pressure and blood sugar management will also be emphasized informed by an evidence-based Conceptual Model of Healthy Cooking. Classes will be conducted in small groups (\~16 participants) in an established teaching kitchen used by the culinary medicine program. Classes will be facilitated by a professional chef, a healthcare professional (dietitian, medical doctor, or trained medical student), and other support staff, including trained medical, dietetic, and public health students.
214983966|NCT06523712|BEHAVIORAL|Smile Smarts|The interactive oral health care lessons provided to participants in Arm 1 would involve activities and discussions aimed at changing behaviors such as tooth brushing frequency, brushing techniques, and the use of interdental aids. The intervention aims to educate and motivate participants to adopt and maintain optimal oral hygiene habits through behavioral change strategies.
214681122|NCT04906005|DRUG|Placebo|intravenous (IV) bolus injection at 2 mL/s, followed by a saline flush of at least 5 mL to be in the same conditions as for gadopiclenol administration.The gadopiclenol administration is performed by power injector
214983967|NCT01521000|DEVICE|Garment Sleeve|compression sleeve (20 to 30 mm of Hg)
215088620|NCT05190055|DEVICE|wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. For the control group, the bone substitutes were filled in the disc space manually using a bone grafting funnel. A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
215088621|NCT01612455|BEHAVIORAL|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
215088622|NCT03399656|DIETARY_SUPPLEMENT|Avmacol tablets|The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.
215088623|NCT03399656|DIETARY_SUPPLEMENT|Placebo tablets|MCC 90M Emcocel
215094567|NCT01362387|OTHER|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
215094568|NCT05806866|BEHAVIORAL|Cognition scores, cognitive instrumental activities of daily living scores|A detailed neuropsychological test battery will be applied. The Functional Activitites Questionnaire (FAQ) subscores will be used to define cognitive and motor instrumental activities of daily living function
214369516|NCT03069092|BEHAVIORAL|aerobic exercise|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
215094569|NCT01733433|PROCEDURE|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
215094570|NCT02299076|BEHAVIORAL|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
215094571|NCT02299076|OTHER|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
215094572|NCT02800590|DRUG|ABP-700|
215094573|NCT01969721|DRUG|fluticasone propionate|low dose
215094574|NCT01969721|DRUG|salmeterol|
215094575|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
215094576|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
215094577|NCT01969721|DRUG|tiotropium|tiotropium high dose
215094578|NCT01969721|DRUG|olodaterol|
215094579|NCT01969721|DRUG|olodaterol|
215094580|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
215094581|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
214493184|NCT01231438|DRUG|Etalpha|0.25ug o.d. for 2 weeks
214493185|NCT03502369|PROCEDURE|Anterior Quadratus lamborum block|Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.
214493186|NCT01260896|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
214493187|NCT01260896|DRUG|Effexor® XR|150 mg Extended-Release Capsule
214493188|NCT00312208|DRUG|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
214983968|NCT01311219|OTHER|Non-operative Treatment|A figure-of-8 brace will be applied to afflicted extremity in clinic. The patient will be instructed on proper application of the brace and asked to continue wearing the brace for 2 to 6 weeks, depending on the patient's level of comfort.
214983969|NCT01311219|PROCEDURE|Operative Treatment-Plate Fixation|Plate fixation of the clavicle fracture will be performed utilizing a 3.5-mm dynamic compression plate.
214983970|NCT01311219|PROCEDURE|Operative Treatment-Intramedullary Pinning|Clavicle fracture will be repaired through intramedullary pinning using The Rockwood Clavicle Pin (DePuy Orthopaedics, Warsaw, IN).
214983971|NCT05923996|DRUG|microbotox|Will be treated by single session of microbotox injection
214369517|NCT03069092|BEHAVIORAL|resistance exercise|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial
214983972|NCT05923996|RADIATION|fractional carbon dioxide laser|Two sessions of the fractional CO2 laser on this side of the face at 4-weeks intervals
214983973|NCT00688441|DRUG|Nasal CO2|Twice daily during the 14 day Treatment Period
214983974|NCT00688441|DRUG|Placebo|Use of the study drug dispenser at the same frequency as the active arm
214493189|NCT00312208|DRUG|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
214493190|NCT01094626|DRUG|Secretin|Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
214493191|NCT02098837|DRUG|Dolutegravir|Dolutegravir 50mg once daily
214493192|NCT06116929|OTHER|Morphological and functional magnetic resonance imaging (MRI)|"Patients will undergo 3 morphological and functional MRI scans (during rest and activity) on the 3T MRI scanner at St Philibert Hospital (Lille, France) at 0 (M0), 6 (M6) and 12 (M12) months.~The controls will perform a single functional MRI on the 3T MRI."
214983975|NCT05645926|PROCEDURE|Percutaneous coronary intervention (PCI)|Patients who underwent percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA), and coronary stent insertion
214983976|NCT05645926|PROCEDURE|Coronary artery bypass grafting (CABG)|Patients who underwent coronary artery bypass grafting (CABG)
214983977|NCT05298241|OTHER|Hand-grip Strength Game|Interactive Handgrip Strength Game for ICU patients receiving the game and to assess the impact on psychological.
214983978|NCT01813747|DEVICE|1440 nm wavelength laser with handpiece (Cynosure)|To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
214983979|NCT01399307|PROCEDURE|Liposuction|Elective Liposuction
214983980|NCT02629783|OTHER|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
214983981|NCT02629783|OTHER|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
214983982|NCT02629783|DRUG|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
215094582|NCT01969721|DRUG|tiotropium|tiotropium low dose
215094583|NCT01969721|DRUG|fluticasone propionate|low dose
215094584|NCT01969721|DRUG|salmeterol|
215094585|NCT03951090|OTHER|Results of the brief geriatric assessment|Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
215094586|NCT03951090|OTHER|No results of brief geriatric assessments|Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
214493193|NCT06116929|OTHER|Neuropsychological assessment|"3 neuropsychological assessments will be carried out at M0, M6 and M12, by the same neuropsychologist for all patients included.~Controls will undergo the same neuropsychological assessments, but only once."
214493194|NCT02955563|OTHER|CSDM Web-Based Tool Intervention|The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
214493195|NCT03907306|PROCEDURE|Wound healing|The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
214493196|NCT02624141|DRUG|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
214493197|NCT05570305|DRUG|Zibotentan|Zibotentan 1.5 mg once per day as a hard capsule.
214493198|NCT05570305|DRUG|Dapagliflozin|Dapagliflozin 10 mg once per day as a tablet.
214493199|NCT05570305|DRUG|Placebo|Matching placebo.
214493200|NCT05570305|DRUG|Dapagliflozin and Zibotentan|Dapagliflozin 10 mg once per day as a tablet in combination with zibotentan 1.5 mg once per day as a hard capsule.
214983983|NCT03634319|DEVICE|Beacon Aqueous Microshunt|"The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.~Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma."
214983984|NCT01628536|DIETARY_SUPPLEMENT|Black cohosh|Remifemin 20 mg tablet orally twice per day x 4 weeks
215088624|NCT01272791|BIOLOGICAL|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
215088625|NCT01272791|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
215088626|NCT05410262|OTHER|Evaluation of CT images|A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
215088627|NCT01367392|DEVICE|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
215088628|NCT02570243|DRUG|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
215088629|NCT02570243|DRUG|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
215088630|NCT00633789|DRUG|brivanib|Tablets, Oral, 800 mg, once daily, until progression
214369518|NCT03069092|BEHAVIORAL|Combined resistance and aerobic exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
214369519|NCT02080429|PROCEDURE|Passive Descent|
214369520|NCT02080429|PROCEDURE|Pushing|
214369521|NCT00032474|DRUG|Ginkgo biloba extract|
214369522|NCT06070155|OTHER|Aerobic Exercise three time a week|The participants will receive mild to moderate aerobic exercise for three weeks for 12 sessions.
214369523|NCT00329329|DRUG|satraplatin and capecitabine|satraplatin and capecitabine dose escalated per the dosing scheme
214369524|NCT01134146|RADIATION|IMRT|Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
214369525|NCT02428465|BEHAVIORAL|Purposeful Parenting|Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
214369526|NCT03189784|OTHER|mobilization with movement techniques|patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
214369527|NCT03369379|DRUG|D3 Vitamin|Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.
214369528|NCT03369379|OTHER|Placebo|Placebo pill
214369529|NCT05741957|BEHAVIORAL|Once-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve one session weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 75 min. Participants will exercise with an exercising heart rate at 6-7 metabolic equivalents (METs). Health information provided to the usual care control group will be made available to the participants in this group.
214369530|NCT05741957|BEHAVIORAL|Thrice-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve three sessions weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 25 min. Participants will exercise with an exercising heart rate at 6-7 METs. Health information provided to the usual care control group will be made available to the participants in this group.
214369531|NCT05741957|OTHER|Usual Care Control|Participants in this group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to general health and NAFLD, such as non-communicable diseases, infectious diseases, and a healthy lifestyle.
214369532|NCT04475432|DRUG|TP-03, 0.25%|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
214983985|NCT03415152|DRUG|Omacor (Omega-3-acid ethyl esters)|Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
214983986|NCT04950400|DRUG|Carrelizumab + chemotherapy + apatinib|Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
214983987|NCT05689359|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered at 600 mg po BID for 3 days prior to starting chemotherapy, continued during the course of chemotherapy, and for 7 days after chemotherapy.
215088631|NCT00633789|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, until progression
214983988|NCT03783065|DRUG|Propranolol|Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
214983989|NCT03783065|PROCEDURE|Laparoscopic splenectomy and pericardial devascularization|Including splenectomy and pericardial devascularizaion under laparoscopy
215088632|NCT01650714|OTHER|Full thickness gastric biopsy|
215088633|NCT01650714|PROCEDURE|Full thickness gastric biopsy|
215088634|NCT01634529|DRUG|V158866|Single ascending oral doses of V158866 and Placebo
215088635|NCT01634529|DRUG|V158866|Multiple ascending oral doses of V158866 and Placebo
215088636|NCT03030339|OTHER|High VA intake, recent VAS|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
215088637|NCT03030339|OTHER|High VA intake|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
215088638|NCT03030339|OTHER|Low/adequate VA intake|Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
214369533|NCT04475432|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
214369534|NCT05947929|OTHER|Aerobic excise|the treadmill exercises three times a week for 12 weeks) based on the Following protocol: Intensity exercise: determined by karvonen formula: Exercise heart rate = \[(A-B) × desired intensity\] + B \[A represents maximum heart rate (220-age) and B for resting heart rate (average of three measurements)\]. The desired intensity will be at 50- 70%. Heart rate was measured by pulse-meter to detect pulse rate before exercise (Resting HR)\].
214983990|NCT03783065|PROCEDURE|Endoscopic therapy|Either endoscopic variceal ligation (EVL) or cyanoacrylate injection was applied according to the condition of varices
214983991|NCT00584389|DRUG|rimonabant|20mg/d (oral) once daily for 12 weeks
215088639|NCT03514680|BEHAVIORAL|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
215088640|NCT05289583|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
215088641|NCT03331783|OTHER|Standard hydrocolloid adhesive patch|This patch is made of a standard hydrocolloid adhesive
214369535|NCT05947929|OTHER|acupuncture|the acupuncture needles will be inserted through the adhesive pads. The acupuncture needles used in the study are 40 mm in length and 0.30 mm in diameter and manufactured by Suzhou Hwato Medical Instruments Co. Ltd (Suzhou, China). The following acupoints will be used: DU20 (Baihui), ST36 (Zusanli), ST37 (Shangjuxu), SP6 (Sanyinjiao), ST25 (Tianshu), and LR3 (Taichong).
214369536|NCT02493296|OTHER|This observational study will not entail an intervention.|This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
214369537|NCT03427684|RADIATION|Hypo-fractionated radiotherapy|Hypo-fractionated radiotherapy with fraction \>2Gy .
214369538|NCT03427684|DRUG|S1|S-1 80mg/m2/day, orally intake on radiotherapy days.
214369539|NCT01353781|DRUG|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
214369540|NCT05753150|DRUG|Tafenoquine|Tafenoquine 300 mg (2x150 mg tablets)
214369541|NCT05753150|DRUG|Primaquine|Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)
214369542|NCT05753150|DRUG|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
214369543|NCT05660200|DIETARY_SUPPLEMENT|IBSA Iron ODF|IBSA Iron ODF is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film. IBSA Iron ODF appears as a yellow, opaque, homogeneous film, without visible particles. Once taken, it dissolves on the tongue and can be swallowed without adding water.
214369544|NCT05660200|DIETARY_SUPPLEMENT|SiderAL® FORTE|Sideral® r.m. contained in SiderAL® FORTE is an iron protected with Sucrosomial® Technology which passes through the gastric environment intact and is absorbed in the intestine, thus preventing any irritation and discomfort to the stomach. The presence of Vitamin C facilitates the absorption of iron.
214369545|NCT00095706|DRUG|Bevacizumab (drug), Herceptin (drug)|
214369546|NCT04029129|OTHER|Air filtration and building envelop modifications|Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
214369547|NCT06180304|OTHER|Exercise training|The indoor physical exercise program was carried out in a gym with weight machines. The physical exercise program was divided into four parts. Part I: playful game or shuttle run (5 to 7 minutes). Part II: aerobic training (treadmill; 10 minutes; 40% to 80% of Heart Rate Reserve; between 12 to 17 according to the Borg Rating Of Perceived Exertion Scale; between 5 to 8 according to the Borg Category-Ratio 10 Scale. Part III: strength training (more or less 25 minutes; Leg Press + Chest Press + Leg Extension + Lat Pull Down + Leg Curl + Shoulder Press; 40-80% of 3 maximum repetitions; 10-15 reps; 2-3 sets). Part IV: 4 static stretches (30 to 60 seconds each).
214369548|NCT02296554|PROCEDURE|SLAP Repair|SLAP repair for SLAP tear
214369549|NCT02296554|PROCEDURE|Biceps Tenodesis|Biceps tenodesis for SLAP tear
214369550|NCT00168038|BIOLOGICAL|Immunoglobulin Intravenous (Human)|A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
214369551|NCT01637103|BEHAVIORAL|Cognitive therapy of depression|Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
214369552|NCT01637103|BEHAVIORAL|Bright light therapy|Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
214983992|NCT00584389|BEHAVIORAL|Dietary intervention|Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
214983993|NCT04433104|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval
214983994|NCT04433104|DRUG|drug therapy according to Vietnamese MOHS procedure|Salbutamol, Terbutaline
214983995|NCT01537172|DRUG|ONO-4053|Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
214983996|NCT01537172|DRUG|Placebo|Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
214983997|NCT05767983|OTHER|Fat-free milk|Fat-free milk (500 mL, skim, 0%, Lactantia PurFiltre) will provide 180 kcal, 0 g fat, 26 g carbohydrate, and 18 g protein. Treatments matched for calories (180 kcal).
214983998|NCT05767983|OTHER|Fat-free yogurt|Fat-free yogurt (242 g, vanilla, 0% Greek, Oikos) will provide 180 kcal, 0 g fat, 23.5 g carbohydrate, and 19.4 g protein. Treatments matched for calories (180 kcal).
214983999|NCT05767983|OTHER|Low-fat cheese|Low-fat cheese (60 g, mild marble cheddar, 40% less fat, Selection) will provide 180 kcal, 10 g fat, 2 g carbohydrate, and 16 g protein. Treatments matched for calories (180 kcal).
214984000|NCT05767983|OTHER|Fruit juice|Fruit juice (450 mL, Fruité® Fruit Punch) will provide 180 kcal, 0 g fat, 46.8 g carbohydrate, and 0 g protein. Treatments matched for calories (180 kcal).
214984001|NCT05767983|OTHER|Snack skipping|Water control treatment (no caloric contribution). Matched for volume (500 mL) to fat-free milk treatment.
214984002|NCT00666237|PROCEDURE|Tube shunt surgery|The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.
214984003|NCT00666237|PROCEDURE|Trabeculectomy|The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.
214984004|NCT00666237|DRUG|Mitomycin C|A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes
215088642|NCT03331783|OTHER|LT-2|This patch is made of a new adhesive
215088643|NCT03331783|OTHER|LT-21|This patch is made of a new adhesive
214984005|NCT03321721|PROCEDURE|Suture for wound repair|Repair of wound with suture
215088644|NCT03331783|OTHER|33-20|This patch is made of a new adhesive
214369553|NCT05016583|OTHER|Paula Method|12 weeks of Paula Method of Exercises
214369554|NCT01151800|OTHER|Using IVR to maintain ACS patients on best practice guidelines|
214369555|NCT05586594|DIAGNOSTIC_TEST|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B)|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B) to look for common non-syndromic MODY in Emirati population
215088645|NCT03118830|DRUG|Triptorelin|daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
215088646|NCT03118830|DRUG|cetrorelix|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
215088647|NCT03118830|DRUG|Recombinant Follicle Stimulating Hormone|Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
215088648|NCT04226976|DEVICE|Otoband|Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
214369556|NCT01600664|BEHAVIORAL|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
214369557|NCT01600664|BEHAVIORAL|Convertible PC|Participants will be using the convertible PC without the interactive computer game
214369558|NCT03502863|DEVICE|Digital refraction|A web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone.
214369559|NCT03502863|OTHER|Manual Refraction|Manual refraction and ETDRS chart
214369560|NCT05673239|DRUG|Levocarnitine Injection|The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
214369561|NCT00914004|DRUG|Desipramine HCl 50 mg Tablets Cord Laboratories|
214369562|NCT00914004|DRUG|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc|
214369563|NCT03205657|PROCEDURE|auto transplant followed by allo transplant|patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL
214984006|NCT03321721|DEVICE|Suture for wound repair|Repair of wound with suture
214984007|NCT02615886|OTHER|Observational Control|Participants will be observed and not provided any dietary supplementation.
214984008|NCT02615886|DIETARY_SUPPLEMENT|Rice bran|Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
214984009|NCT06307262|DEVICE|T-TEER|T-TEER using the PACAL or TriClip device
214984010|NCT04005768|DRUG|Hydroxychloroquine Sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
214984011|NCT04005768|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
214984012|NCT01533259|DRUG|Stribild|Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
214984013|NCT05553405|DRUG|Intralipid Infusion|Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids. It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
214984014|NCT02062138|OTHER|continuous passive motion (CPM)|standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
214369564|NCT01974115|DEVICE|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
214984015|NCT02062138|OTHER|controlled active motion (CAM I)|Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
214984016|NCT02062138|OTHER|controlled active motion (CAM II)|Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
214984017|NCT04207671|PROCEDURE|Complete omission of chest tube|No chest tube implacement
214984018|NCT04207671|PROCEDURE|Improved drainage strategy|A two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-remove
214984019|NCT06675955|DRUG|Ocrelizumab|Ocrelizumab will be administered according to the regimen in the parent study.
215088649|NCT04226976|DEVICE|Placebo Device|Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
215094587|NCT01012323|BIOLOGICAL|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
214369565|NCT05030779|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
214369566|NCT03389568|BEHAVIORAL|singing-based music therapy program|A single 1-hour singing-based intervention is conducted with each primary caregiver of an ICU patient. The intervention is composed of three steps: 1) listening to a participant's preferred music and identifying his and her emotional states (15 minutes), (2) singing for emotional changes (30 minutes), and (3) discussing what he or she experiences during singing and identifying how they apply such experience to their personal use of music for emotional changes in his or her everyday life (15 minutes).
214369567|NCT04813380|OTHER|Sublingual immunotherapy|Sublingual immunotherapy give to allergic rhinitis patients for treatment
214369568|NCT01345630|DRUG|Maraviroc|Maraviroc tablet 150 mg once daily for 96 weeks.
214369569|NCT01345630|DRUG|Emtricitabine/tenofovir|Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
214369570|NCT01345630|DRUG|darunavir/ritonavir 800/100 mg|darunavir/ritonavir 800/100 mg
214369571|NCT01345630|DRUG|placebo for emtricitabine/tenofovir|placebo for emtricitabine/tenofovir
214369572|NCT01345630|DRUG|placebo for maraviroc|placebo for maraviroc
214369573|NCT01573806|DRUG|Exenatide|Exenatide, dosed subcutaneously every 12 hours for 4 doses
214369574|NCT01573806|DRUG|Exenatide vehicle|Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
214369575|NCT02310555|PROCEDURE|Gastric bypass|
214369576|NCT02310555|PROCEDURE|Modified gastric bypass.|
214369577|NCT02310555|PROCEDURE|Slevee Gastrectomy|
214369578|NCT01201603|DIETARY_SUPPLEMENT|orange juice|250ml of orange juice or a sugars matched orange drink
214369579|NCT04960605|PROCEDURE|Dental implants|Treatment of the toothless regions with dental implants
214369580|NCT00463827|DRUG|Atorvastatin|
214681123|NCT02948595|OTHER|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
214984020|NCT01408693|PROCEDURE|Trans-gluteal approach, CLAS|Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
214984021|NCT01408693|PROCEDURE|Anterior minimal invasive approach, AMIS|Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
214984022|NCT01788761|DIETARY_SUPPLEMENT|Probiotic Supplemented Group|
214984023|NCT01788761|DIETARY_SUPPLEMENT|Control Group|
214984024|NCT00315341|DRUG|Buprenorphine/naloxone|Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
214369581|NCT00463827|DRUG|atorvastatin|atorvastatin 40mg
214369582|NCT00463827|DRUG|matched placebo|Matched placebo
214369583|NCT04612855|OTHER|Groupwise comparison of primary and secondary outcomes|Statistical comparison of cohorts. Cfr supporting information on statistical plan.
214681124|NCT02948595|OTHER|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
214681125|NCT05394272|OTHER|Energy Therapy - Pranic Healing|Energy therapy - Non invasive non touch and non pharmacological - 100% natural complementary therapy
214681126|NCT00882869|DRUG|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
214681127|NCT00882869|DRUG|Sorafenib|Sorafenib will be administered at 400 mg BID every day
215094588|NCT02117349|DRUG|Raplixa|Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
214493201|NCT03744559|BEHAVIORAL|Retrieval Extinction Training (RET)|Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.
214984025|NCT00315341|DRUG|Methadone|Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
214493202|NCT03744559|BEHAVIORAL|Control Retrieval Extinction Training (RET)|The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
214984026|NCT02728908|DEVICE|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100
214493203|NCT03541525|OTHER|Biological sampling|Biological samples including blood, surgical remainder, urine,...
214681128|NCT00151762|DRUG|Colesevelam hydrochloride|
214681129|NCT04004507|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
214681130|NCT04004507|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
214984027|NCT06764316|DRUG|BAY 3547926|antibody conjugate with actinium-225 label
214984028|NCT06764316|DRUG|BAY 3547922|antibody conjugate without actinium-225 label as preinjection
214984029|NCT07129096|BEHAVIORAL|Applied Relaxation|Applied relaxation method developed by psychologists from progressive relaxation is used. The method is trained using a web application (Relappy.app), which contains step-by-step instructions with self-instructed exercises and exercise diaries, in which the examinee records his/her level of tension before and after the exercise (on a scale of 0-100, where 0 means a completely relaxed state, 50 a normal state (neither relaxed nor tense) and 100 maximum tenseness.
214681131|NCT02062151|OTHER|Acupuncture|Acupuncture
214984030|NCT07129096|DEVICE|Occlusal splint|The splint group is treated with occlusal splint, which is a conventional treatment method in cases where the implementation of information and self-care methods has not given a sufficient treatment response. The splint is prepared for night use and controlled according to the usual protocol.
214984031|NCT01268995|DRUG|Cyclosporine A|"Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a stop and go protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated."
214681132|NCT03919110|DIAGNOSTIC_TEST|Collection of biological samples|"Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses."
214984032|NCT01268995|DRUG|Tacrolimus|Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
214984033|NCT06894810|OTHER|Decision-aid|Decision Aids (DA) are evidence-based clinical tools developed for patients to supplement clinicians' discussions and facilitate difficult preference-sensitive decisions. They are the gold standard approach (recommended by the Australian Commission of Safety and Quality in Healthcare) to facilitate complex healthcare decisions where there is more than one reasonable choice and where patients may value benefits and risks differently.
214984034|NCT06941610|DEVICE|Erchonia GVS Laser|405nm violet and 520nm green laser light therapy.
214984035|NCT06945250|OTHER|Experimental Audio Visual|Participants in this group will receive the audiovisual presentation
214984036|NCT04240314|BIOLOGICAL|scAAV9.U7.ACCA|A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
214984037|NCT07145229|DRUG|ABP-745 Dose A|ABP-745 Dose A + Colchicine placebo - tablets (PO)
214984038|NCT07145229|DRUG|ABP-745 Dose B|ABP-745 Dose B + Colchicine placebo - tablets (PO)
214984039|NCT07145229|DRUG|Colchicine|ABP-745 placebo + Colchicine - tablets (PO)
214984040|NCT07145229|DRUG|Placebo|ABP-745 placebo + Colchicine placebo - tablets (PO)
214681133|NCT02672839|DRUG|LGD-6972 Solution|15 mg of LGD-6972
214681134|NCT02672839|DRUG|LGD-6972 Capsules|15 mg LGD-6972
214681135|NCT04256746|OTHER|Boiled Rice|
214681136|NCT04256746|OTHER|Boiled Rice+0.37 gr mulberry fruit powdered extract|
214984041|NCT06948279|PROCEDURE|The endoscopic retrograde cholangiopancreatography (ERCP) with insertion of a plastic stent.|A plastic stent was placed during the initial ERCP, with elective stone removal scheduled 8-12 weeks later.
214984042|NCT06948279|PROCEDURE|The endoscopic retrograde cholangiopancreatography (ERCP) with immediate stone extraction attempts.|Immediate ERCP for stone removal, utilizing conventional techniques such as basket, balloon, or mechanical lithotripsy as needed.
214984043|NCT01320397|DRUG|Rostafuroxin|6 microgram capsules
214984044|NCT01320397|DRUG|Rostafuroxin|50 micrograms capsules
214984045|NCT01320397|DRUG|Rostafuroxin|500 micrograms capsules
214984046|NCT01320397|DRUG|Losartan|Losartan 50 mg once a day
215088650|NCT05045170|DRUG|Influence of propofol sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
215094589|NCT02117349|DEVICE|Gelfoam|Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
214493204|NCT03032458|DRUG|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
214493205|NCT03032458|DRUG|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
214493206|NCT03032458|DRUG|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
214493207|NCT04165564|OTHER|Institutional standard of care|Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
214493208|NCT04165564|OTHER|Biosamples of airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
214493209|NCT00982644|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
214493210|NCT00982644|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
214493211|NCT02023346|BEHAVIORAL|surveys and cognitive tests|
214493212|NCT02695134|OTHER|Healing Touch|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
214493213|NCT00571298|PROCEDURE|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
214493214|NCT00571298|DRUG|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
214493215|NCT00571298|DRUG|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
214493216|NCT00571298|DRUG|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
214493217|NCT00571298|DRUG|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
214493218|NCT00571298|PROCEDURE|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
214493219|NCT00909649|PROCEDURE|fibrin glue in breast surgery|fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
214493220|NCT04994795|OTHER|Predictive models (data collection)|Machine learning predictive models
214493221|NCT00477893|DRUG|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
214493222|NCT00477893|DRUG|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
214493223|NCT03997994|DEVICE|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter coated with a proprietary coating containing the drug and carriers.
214493224|NCT00051298|DRUG|Olanzapine|
214493225|NCT00051298|DRUG|Placebo|
214493226|NCT05283408|DRUG|Dexmedetomidine infusion|Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
214493227|NCT05283408|DRUG|Co-administration dexmedetomidine and low-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
214493228|NCT05283408|DRUG|Co-administration dexmedetomidine and high-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
214493229|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management and Dietary Fiber|Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
214984047|NCT07151079|BEHAVIORAL|Trans Adolescent Group ThErapy for Alleviating Minority stress|The intervention, Trans Adolescent Group ThErapy for Alleviating Minority stress (TAG TEAM), is a group Cognitive Behavioural Therapy (CBT) program, originally developed using co-design methodology with trans and gender diverse young people. The 6 weekly, 2-hour session TAG TEAM program aims to improve mental health and wellbeing using evidence-based cognitive and behavioural strategies to target minority stressors discrimination and internalised stigma and facilitating community connection and pride. The intervention will be delivered by a psychologist facilitator and peer facilitator, who will both be trained and supervised by clinical psychologists, to groups of 8 participants from the same stratum.
215094590|NCT02117349|DRUG|Rescue treatment|Thrombin-containing hemostats included in standard care at the site
214984048|NCT07151469|OTHER|Kaltenborn mobilization|The therapist applies gentle traction to the mandible, maintained for approximately 20 to 30 seconds, to create space in the joint. This is done by pulling the jaw downward and slightly forward, which can help alleviate pressure and pain. This hand placement allowed the therapist to apply transverse force across the mandible as necessary, while at the same time allowing an anterior-inferior gliding force to the mandible on the side of restriction, while also controlling the unrestricted side inhibiting any excessive mandibular forward gliding with the other hand. The mobilization is then initiated with Grade I, which involves small-amplitude movements performed at the beginning of the range of joint play to reduce pain and muscle guarding. This is followed by Grade II mobilization, which consists of larger amplitude movements within the mid-range of joint play to enhance joint mobility and decrease pain without reaching the joint's full resistance barrier
214984049|NCT07151469|OTHER|active release technique|This deep tissue therapy technique is primarily used to break up adhesions and scar tissue on the surrounding muscle and ligaments. However, this technique has been proven to be a very effective method for treating TMD.While there are several muscles connected with the movement of the TMJ, it is thought that the major players are the digastricus, masseter, and lateral pterygoid muscles
214984050|NCT07153224|BEHAVIORAL|Peri-operative support measures [mentorship, intraoperative consult, surgical coaching, standard practice (no structured support)]|"Mentorship: Formal (assigned by an institution or via an official program) or informal (personal relationship built during the career pathway) professional guidance relationships that support early-career surgeons in clinical decision-making, technical development, and emotional processing.~Surgical Coaching: Structured, feedback-oriented discussions or sessions aimed at performance enhancement and reflective practice Intraoperative Consultation (IOC): Real-time assistance or second opinions provided by a more experienced surgeon or peers during a surgical procedure Standard practice: the surgeon performs the procedure supported by one or multiple assistants, as per internal hospital protocols and national/local regulations, receiving and providing natural feedback without a structured support system."
214984051|NCT07154628|DRUG|Lidocaine %2 ampoule|During general anesthesia, the anesthesiologist administers 1.5cc of lidocaine spraying on the vocal cords using Terumo SurfloTM I.V. Catheter 20G before intubation.
214984052|NCT07154628|DRUG|Normal Saline (0.9% NaCl)|During general anesthesia, the anesthesiologist administers 1.5cc of normal saline spraying on the vocal cords using Terumo SurfloTM I.V. Catheter 20G before intubation.
214984053|NCT07158060|BEHAVIORAL|Breathing Exercises|Breathing Exercises This intervention
214984054|NCT07155863|DEVICE|Earplugs and eye mask|Participants in the experimental group will use earplugs and eye mask during MRI. The use of these devices aims to decrease anxiety levels caused by noise and the MRI procedure. Physiological parameters and axiety scores will be monitored throughout the study.
214984055|NCT07151963|DEVICE|prolonged continuous TBS|prolonged continuous theta burst stimulation
215088651|NCT05045170|DRUG|Influence of dexmedetomidine sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
214369584|NCT02573480|BEHAVIORAL|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
214369585|NCT05284864|PROCEDURE|Stoma closure|Stoma closure after rectal surgery
214369586|NCT04233372|DRUG|Delstrigo|"Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.~1 covered tablet for day .( will be administered 28 days maximum)"
215094591|NCT00512291|DRUG|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
214493230|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management|Routine nutrition management for 12 weeks.
214369587|NCT04867837|DRUG|Octaplex|Four-factor prothrombin complex concentrate (4F-PCC)
214369588|NCT05450263|BEHAVIORAL|Interoceptive exposure|A pilot study addressing the efficacy and feasibility of an interoceptive exposure technique.
214369589|NCT05776927|DRUG|QVM149|QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®
214369590|NCT05776927|DRUG|Salmeterol Xinafoate / Fluticasone Propionate|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
214369591|NCT05776927|DRUG|Placebo to QVM149|Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®
214493231|NCT05599815|DRUG|ADX-629|ADX-629 (250 milligrams) administered twice daily
214493232|NCT00943917|OTHER|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
214493233|NCT00943917|DRUG|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
214493234|NCT00943917|OTHER|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
214681137|NCT04256746|OTHER|Boiled Rice+0.75 gr mulberry fruit powdered extract|
214984056|NCT07151963|DEVICE|20 Hz rTMS|20 Hz repetitive transcranial magnetic stimulation
214984057|NCT06052306|DRUG|BAY3546828|Intravenous (IV) infusion on Day 1 of each cycle.
214984058|NCT07167056|BEHAVIORAL|Standard of Care Psychotherapy|Participants will receive six psychotherapy sessions over the course of approximately 3 months.
214984059|NCT07167056|BEHAVIORAL|WYSA App|Participants will have access to the WYSA mental health support artificial intelligence app over the course of the 3 months that they are participating in psychotherapy sessions per standard of care. The app will contain features intended to manage symptoms of depression and anxiety in individuals with cancer. The app will include an AI-powered chatbot with Cognitive Behavioral Therapy (CBT) and mindfulness techniques, visual progress elements (a progress roadmap, a weekly progress report, etc.), and a customizable tool library. Participants are instructed to use the app whenever they feel like it, if they are in distress, or if the app prompts them to use it. App prompts (notifications) will occur once daily.
214984060|NCT00788385|DEVICE|ShuntCheck test|
214984061|NCT03139162|OTHER|Swiss RAI-HC assessment|RAI-HC assessments done by trained nurses in clinical routine
214984062|NCT05681988|PROCEDURE|Early minimally invasive image guided endoscopic hematoma evacuation|The intervention group will first receive BMT (as defined below) upon admission and early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT. Surgery will be performed within 6-24 hours after SSICH symptom onset. Surgery will be performed in an emergency operating theatre or a hybrid operation theatre equipped with intraoperative CT (in hybrid OR), neuronavigation, and neuro-endoscopy.The position and progress of the trocar towards the hematoma cavity will be monitored with neuro-navigation. The endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent) will be inserted into the trocar and tracked using neuro-navigation. Using the pre-planned trajectory, the hematoma will be entered. Using continuous suction and irrigation, the hematoma will be aspirated and/or washed out.
214984063|NCT05681988|PROCEDURE|Best medical treatment (BMT)|The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT). This involves strict blood pressure control (SBP\<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary
214984064|NCT01587313|DRUG|Isosorbide dinitrate / hydralazine capsules|Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
214984065|NCT01931605|DEVICE|Prostatic arterial embolization using BeadBlock (Terumo)|Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
214984066|NCT05367999|DIAGNOSTIC_TEST|initial Paroxysmal Event Profile|The initial Paroxysmal Event Profile (iPEP) was derived from the paroxysmal event profile (PEP) and paroxysmal event observer (PEO) to provide a diagnostic tool aiming to differentiate between the most common underlying reasons for TLOC presentations: syncope, epilepsy, and dissociative seizures. The iPEP is a 35-item questionnaire developed from the PEP and PEO.5,25 The 5-point frequency scales used in response to each symptom in the PEP and PEO have been replaced with a binary 'present'/'not present' classification in recognition of the fact that the target patient group may have experienced only one or a few episodes of TLOC.
214369592|NCT05776927|DRUG|Placebo to Salmeterol Xinafoate / Fluticasone Propionate|Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
214369593|NCT05776927|DRUG|Run-In Medication|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
214984067|NCT01950663|DEVICE|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
214984068|NCT03007940|OTHER|Coach Site Visit|The coach will conduct a one-day on site visit and will review the walk-through and DDCAT assessment results, and help the change team design an initial change project with Plan-Do-Study-Act (PDSA) cycles. The site visit will use a standardized agenda to ensure NIATx fidelity.
214369594|NCT05776927|DRUG|Rescue Medication|Salbutamol 100μg / Albuterol 90μg
214369595|NCT05776927|DEVICE|Concept 1 Device|Concept1 (Breezhaler) used for QVM149 and placebo delivery
214369596|NCT05776927|DEVICE|Girohaler|Girohaler for Comparator and Placebo delivery.
214369597|NCT06196736|DRUG|9MW2821|1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
214369598|NCT06196736|DRUG|Chemotherapy|75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.
214369599|NCT01090310|DRUG|AIN457|AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
214369600|NCT01090310|DRUG|Placebo|Matching placebo to AIN457
214369601|NCT06116838|DEVICE|Spinal motor evoked responses (sMERs)|Spinally Evoked Motor Responses (sMERs) will be obtained while stimulating with single pulses using various stimulation parameters. sMERs are the electromyograph (EMG) responses of the peripheral muscles to electrical stimulation of the spinal cord. sEMP will be used to test the integrity of the motor pathways of the spinal cord. This will be measuring by assessing the EMG responses in the lower limb muscles.
214369602|NCT06116838|DEVICE|Continuous stimulation tolerance|Participants may receive up to 45 min of locomotion training (treadmill or overground training) with transcutaneous spinal cord stimulation. The goal will be for the investigators to determine what amount of intensity at each stimulation site the individual finds to be comfortable enough that they would be able to receive without pain or discomfort
214369603|NCT00695786|DRUG|Lenalidomide|Given PO
214369604|NCT00695786|BIOLOGICAL|Rituximab|Given IV
214369605|NCT06492980|PROCEDURE|triple-branched stent graft|a triple-branched stent graft for aortic arch repairement during surgery
214369606|NCT01471132|DRUG|Oxaliplatin|Oxaliplatin 345mg/m2,43℃，30mins
214369607|NCT01471132|DRUG|Paclitaxel|Paclitaxel 260mg/m2,43℃，30mins
214369608|NCT01364922|DRUG|hydrocodone/acetaminophen extended release|
214369609|NCT01364922|DRUG|Placebo|
214369610|NCT02542839|DEVICE|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
214369611|NCT02542839|DEVICE|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
214369612|NCT02542839|OTHER|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
214984069|NCT03007940|OTHER|Walk-through|Walk-Through: Provider change teams will participate in a coach-led webinar that introduces how to conduct a NIATx walk-through from the co-occurring patient perspective and how to write up results using a standard report format. The walk-through will be conducted within two months of the initial coach site visit.
215094592|NCT00640367|OTHER|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
214369613|NCT02542839|OTHER|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
214369614|NCT02542839|OTHER|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
214369615|NCT02542839|PROCEDURE|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
214369616|NCT06247202|OTHER|Smart Phone Education (mhealth)|Nutrition and Health Education module delivered through m-health approach (smart phones)
214369617|NCT06247202|OTHER|Paper Education (conventional)|Nutrition and Health Education module delivered through conventional approach (paper)
214369618|NCT02018445|PROCEDURE|Posterolateral Fusion|
214369619|NCT02888717|PROCEDURE|'OSNA stadification during surgery'|"The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.~* Slices A and C are sent OSNA analysis~* Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.~After the analysis, the report indicates whether the node is:~* Free (-): \<250 copies~* Micrometastatic (+): 250 ≤ - \<5,000 copies,~* Macrometastatic (++): ≥ 5000 copies."
214369620|NCT00651235|DRUG|Losartan and Atenolol or Propranolol|"50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.~Losartan is 100 mg/day for adult and 50 mg/day for children."
214369621|NCT00651235|DRUG|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
214369622|NCT02775318|PROCEDURE|Stellate Ganglion Block|Under aseptic conditions, transducer is placed on the surface of the neck at the level of C6 vertebrae. The internal jugular vein, carotid artery, thyroid gland, trachea, C6 vertebrae, transverse process of C6, esophagus , longus colli with its covering prevertebral fascia and esophagus are visualized. A 25-gauge Quincke spinal needle was inserted paratracheal towards the middle of the longus colli muscle. The endpoint of the injection was the ultrasound image of the tip of the needle as it penetrates the prevertebral fascia covering the longus colli muscle. The drug is then injected and spread of drug is visualized in real time.
214369623|NCT02775318|DRUG|Bupivacaine|10 ml of 0.5% injection bupivacaine is used for giving stellate ganglion block on the side of cerebral vasospasm
214369624|NCT02775318|PROCEDURE|Transcranial Doppler|The principle on which the TCD works is that with arterial narrowing, the blood flow velocity within the vessel increases. A good correlation has been found between the TCD blood flow velocities and vasospasm. The MCA velocity greater than 120 cm/sec indicates mild vasospasm , velocity greater than 130 cm/sec indicates moderate vasospasm and velocity greater than 200 cm/sec indicates severe vasospasm.
214369625|NCT02775318|PROCEDURE|Digital Subtraction Angiography|Digital subtraction angiography is a direct method for the assessment of vessel caliber. It generates high resolution, high contrast and low artifact images using digital subtraction technology. Direct visualization using DSA is the gold standard for the radiographic diagnosis of cerebral vasospasm
214369626|NCT01787097|DRUG|Symbicort® total dose 400ug/12ug|Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose
214369627|NCT01787097|DRUG|Symbicort® total dose 800ug/24ug|Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose
214369628|NCT01787097|DRUG|Formoterol 24ug|Turbuhaler
214369629|NCT01787097|DRUG|BUD total dose 800ug|Turbuhaler
214493235|NCT02766296|BEHAVIORAL|Active Emotional Working Memory Training|This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.
214493236|NCT02766296|BEHAVIORAL|Control Working Memory Training|This training utilized a fixed dual 1-back training paradigm.
214493237|NCT05538494|OTHER|BFR intervention|"Training is applied to this group using low-load exercises with restriction of blood flow. Based on the variables used by the major part of the protocols used in studies on the ERFS, the protocol that will be applied to this group will consist of the following parameters.~* Training: 1 series of 30 repetitions followed by 3 series of 15 repetitions of squats~* Rest between series: Duration of 45 seconds.~* Workload: 30% of 1RM.~* Cadence: 2 seconds for the concentric phase and 2 seconds for the eccentric phase (2:2).~* Cuff pressure: The inflation pressure will be individualized for each individual.~A pressure equivalent to 80% of the minimum pressure necessary for the total occlusion of the femoral artery.~• Cuff placement: proximal quadriceps."
214493238|NCT05538494|OTHER|High load intervention|"A program will be applied to this group of exercise with high loads as a method of treatment in which the following will be applied parameters:~* Training: 4 series of 12 repetitions of squats.~* Rest between series: Duration 2 minutes.~* Workload: 70% of 1RM."
214493239|NCT00068458|DIETARY_SUPPLEMENT|Calcium-Rich Diet|1,200 - 2,500 mg/day. 6 month intervention
214493240|NCT00068458|OTHER|Arm 2: Exercise + Calcium-Rich Diet|Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
214493241|NCT00068458|OTHER|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|1,200 - 2,500 Calcium intake per day. 6 month intervention period.
214493242|NCT06133530|DIETARY_SUPPLEMENT|Human milk oligosaccharides|Prebiotic
214493243|NCT06133530|DIETARY_SUPPLEMENT|Maltose|Control
215094593|NCT00640367|DRUG|Alteplase IV|intravenous recombinant tissue plasminogen activator
215094594|NCT00495755|DRUG|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
215094595|NCT06412952|DRUG|68Ga-RM26|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.
215094596|NCT02452203|BEHAVIORAL|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
215094597|NCT01560299|DRUG|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
214984070|NCT03007940|OTHER|Learning Sessions|The study includes two one-day coach-led learning sessions. The learning sessions promote peer-to-peer sharing about specific goals and objectives. The agenda is tailored to specific treatment service integration issues. The first coach-led learning session teaches providers how to use NIATx process improvement strategies. Providers share walk-through results and initial change projects. Skill development activities include how to: identify change opportunities, use specific tools (e.g., flowcharting), develop PDSA cycles, effectively use data and learning successful change strategies. At the final session, providers present results, sustainment plans, and identify ways for the group to continue to interact.
214984071|NCT03007940|OTHER|Coaching|A NIATx coach leads the active 12 month implementation phase. The coach works with executive directors, change leaders and teams. After the site visit, a coach will hold individual monthly coaching calls (10 hours in total), and participate in group coaching calls (2 hours in total). In the individual calls, the coach and change team review change projects; discuss successes; and identify ideas for future change projects. Group coaching calls involve change leaders from multiple providers. On these calls, change leaders will discuss common change-related issues, progress, and exchange innovative implementation strategies with their peers. These calls provide opportunities for the coach to share new strategies and discuss implementation issues such as the development of a sustain plan.
214984072|NCT03007940|OTHER|Business as Usual|Programs in this intervention will continue with their own plans without coaching support to integrate services for individuals with co-occurring substance abuse and mental health disorders. Once the programs in the wait-list control group receive the NIATx Strategy, they will participate in all of the interventions listed above.
214369630|NCT00949884|DRUG|olmesartan medoxomil|Oral tablets, once daily, at either 20mg or 40mg daily.
214984073|NCT00389389|DRUG|AZD4877|intravenous infusion
214984074|NCT01104649|DRUG|riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
214984075|NCT01104649|DRUG|Placebo comparator|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
214984076|NCT04326374|DRUG|TransCon hGH|Once weekly subcutaneous injection
214984077|NCT04326374|DRUG|daily hGH|Once daily subcutaneous injection
214984078|NCT06229938|OTHER|Passive leg raise manoeuvre|"Stroke volume measurements are performed with the Nexfin hemodynamic monitor and the volemic state measurement is based on the principle of the classic passive leg raise test. The Nexfin monitor (Nexfin CC, Edwards Life Sciences, the Netherlands) uses a small inflatable cuff around the index finger of the right hand, to measure the blood pressure, and uses a specific algorithm to calculate the stroke volume.~First a baseline measurement is performed during supine position while the patient is lying in bed. Next, the head end will be lowered until lying flat, and the legs will be passively raised until the lower end of the bed is 30 degrees elevated. The change in stroke volume following the passive leg raise test is used to assess fluid responsiveness. An increase of 10% indicates a fluid responsive status or hypovolemia."
214984079|NCT01075048|DRUG|Tivantinib|ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
214984080|NCT01075048|DRUG|Placebo|Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
214984081|NCT01075048|DRUG|Cetuximab|Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
214984082|NCT01075048|DRUG|Irinotecan|60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
214984083|NCT05816941|PROCEDURE|Conventional Periodontal Treatment (Complete Oral Disinfection)|"Oral hygiene instructions followed by complete oral disinfection (removal of hard and soft deposits, scaling and root planing, mouth rinse with 0.2% chlorhexidine twice in one minute, pocket rinse with 0.2% chlorhexidine three times in ten minutes). Ultrasonic (Piezoled, KaVo) and hand instruments (Gracey curettes, Hu-Friedy, USA) were used for this purpose.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
214984084|NCT05816941|PROCEDURE|Adjunctive Photodynamic Therapy|"Photodynamic Therapy as adjunctive treatment in pockets with PPD ≥ 5 mm. For this purpose, a Fotona XD -2 diode laser (Fotona, Ljubljana, Slovenia) with a wavelength of 810 nm, a power of 250 mW and the photosensitizing agent indocyanine green at a concentration of 1 mg/ml was used. First, the area to be irradiated was isolated, and the photosensitizing agent was applied to the periodontal pocket. After 60 seconds, the supragingival excess of the photosensitizing agent was removed by gentle rinsing with a saline solution. This was followed by irradiation for ten seconds on each side.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
214984085|NCT00193648|DRUG|Rosiglitazone (Avandia)|oral drug administration
214369631|NCT00949884|DRUG|Placebo|placebo oral tablets once daily for two weeks
214369632|NCT00949884|DRUG|losartan potassium|losartan potassium oral tablet at either 50mg or 100 mg daily dose.
214369633|NCT02463201|BEHAVIORAL|Weight loss|
214369634|NCT01985620|BEHAVIORAL|Educational intervention|
214369635|NCT06175585|OTHER|narrative nursing|"The narrative nursing process is based on the practice of two-line system proposed by Jiang, which is carried out in a separate classroom, office or ward with sufficient space and good lighting. The environment is set to the right temperature and humidity for comfortable face-to-face conversation. This process is done in stages, depending on how often the patient is dialysis three or more times a week.~Each session lasts about 30 minutes and the whole process lasts four weeks. Adjust to the specific needs of each patient ."
214369636|NCT06175585|OTHER|traditional nursing|Patients undergoing MHD received traditional nursing interventions, encompassing various aspects such as dietary advice, instructions on medication usage, health education, emphasis on precautions during dialysis, and guidelines for vascular access care. Additionally, the nurses proactively inquired about patients' emotional well-being during the nursing shift change, actively engaged and uplifted patients experiencing low spirits, and encouraged family members to provide emotional support.
214681138|NCT04256746|OTHER|Boiled Rice+1.12 gr mulberry fruit powdered extract|
214984086|NCT00193648|DRUG|Adalimumab (Humira)|Injection of drug biweekly
214984087|NCT00547144|DRUG|Gemcitabine|1000 mg/m2 intravenoulsy once a week according to protocol schedule
214984088|NCT00547144|PROCEDURE|Dendritic Cell Immunotherapy|The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
214984089|NCT04483765|PROCEDURE|spinal anesthesia|patients undergoing transurethral resection of the prostate (TURP) and transurethral resection of the bladder (TURB) surgery under spinal anesthesia.
214984090|NCT04499885|DEVICE|Paraffin oil gastric lavage|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
215094598|NCT01560299|DRUG|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
214984091|NCT04499885|DEVICE|Gastric lavage with saline and sodium bicarbonate 8.4%|Gastric lavage with saline and sodium bicarbonate 8.4%
214984092|NCT05041686|COMBINATION_PRODUCT|CADISS® System|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5 2.~2. Reusable stainless steel noncutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
214369637|NCT02212444|DEVICE|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
214493244|NCT05150873|OTHER|CTA evaluation|Any pre-operattive CTA of the patients of the cohort will be carefully evaluated to determine the theoric anatomical feasibility of an off the shelf Endograft, particularly in patients with an angulated and short aortic neck
214493245|NCT05028933|DRUG|EPCAM CAR-T|Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion
214493246|NCT00288288|PROCEDURE|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
214493247|NCT00288288|PROCEDURE|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
214493248|NCT05093062|OTHER|Tian Jiu Therapy|
214493249|NCT01241526|OTHER|Disease Management|"* Individual, group and phone education sessions~* Telephone supporter follow-up~* LTOT monitoring"
214493250|NCT01241526|OTHER|Usual site management|"* Usual education as per site protocol~* Usual follow-up as per site protocol~* LTOT monitoring"
214493251|NCT04473703|DRUG|renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor|Patients with odd random number will treat with RASI（renin-angiotensin system inhibitors）, and those with even random number will treat with ARNI（angiotensin-receptor-neprilysin inhibitor）
214493252|NCT04030585|DEVICE|Robot|Patients with upper limb amputation using myoelectric prosthesis will done robot-assisted exercise program
214493253|NCT04030585|OTHER|Home exercise|Patients with upper limb amputation using myoelectric prosthesis will done home exercise program
214493254|NCT04640584|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
214493255|NCT04740944|BEHAVIORAL|Salutogenic Approach Based Interview|Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
214493256|NCT05443464|BIOLOGICAL|OSSM-001|Direct IV infusion of OSSM-001
214493257|NCT03948542|OTHER|Outcome|"Nerve Recovery~* NCV~* Funcional assessment"
214493258|NCT02844439|DRUG|Tesevatinib|
214493259|NCT03041155|BEHAVIORAL|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
214493260|NCT06311396|GENETIC|genetic model|Create a complete molecular-level description of the heterogeneous population of cells that are capable of giving rise to tumor transformation in the liver.
214984093|NCT04933565|DRUG|ORG-129|ORG-129 oral capsules
214984094|NCT04933565|DRUG|Placebo|Placebo oral capsules
214984095|NCT04596293|DRUG|BBT-401-1S or Placebo|Administered by 200mg capsules of BBT-401-1S or placebo
214984096|NCT02776293|BEHAVIORAL|Relaxation|
214984097|NCT02776293|BEHAVIORAL|Music|
214984098|NCT00325169|DRUG|Tiotropium + SERETIDE 50/500|
214984099|NCT01287936|BIOLOGICAL|SB623|SB623, a modified stem-cell product
214984100|NCT00681200|BEHAVIORAL|Enhanced health education|health education and social support
214369638|NCT02212444|DEVICE|Off -the-shelf triplanar orthoses|
214369639|NCT04227080|DRUG|BH4|oral administration of 20 mg/kg KUVAN (BH4)
214369640|NCT00944658|DRUG|Apremilast|10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks
214369641|NCT00944658|DRUG|Placebo (sugar pill)|twice a day
214369642|NCT01272960|DEVICE|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
214984101|NCT00681200|BEHAVIORAL|Transcendental Meditation program|The TM program plus didactic-based health education classes
215094599|NCT01560299|DRUG|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
215094600|NCT02201836|OTHER|One time music therapy|
215094601|NCT02201836|OTHER|Group music therapy|
215094602|NCT01261169|DRUG|Myfortic|Myfortic in uveitis
214984102|NCT01118676|DRUG|cilengitide, radiochemotherapy|"Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.~The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).~After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy."
214984103|NCT04512989|DIAGNOSTIC_TEST|Cognitive assesment using MOCA test|Cognitive assesment using MOCA test
214984104|NCT01269294|DRUG|TMC435|2 capsules of 75 mg once daily for 7 days in Treatment A
214984105|NCT01269294|DRUG|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment C
214984106|NCT01269294|DRUG|TMC435|2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
214984107|NCT01269294|DRUG|Placebo for TMC435|2 placebo capsules once daily for 7 days in Treatment A
214984108|NCT01269294|DRUG|Moxifloxacin|1 tablet of 400 mg on Day 7 of Treatment C
214984109|NCT01269294|DRUG|Placebo for moxifloxacin|1 placebo tablet on Day 7 of Treatments A, B and D
214984110|NCT01269294|DRUG|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment D
214984111|NCT04217759|BEHAVIORAL|Healthy lifestyle intervention|"The main goal was to provide knowledge and skills for targeted population in order for them to adapt healthy lifestyle throughout their life. At the end of intervention, participants were expected to be fully equipped with necessary knowledge and fundamental skills in adapting and maintaining healthy lifestyle throughout their life. Gradual improvements were emphasised and at least 5% loss of initial body weight was expected, aiming for at least 0.5% loss in the first month.~It was divided into three phases (preparation, implementation, maintenance) focusing on PA and diet, in which self-efficacy enhancement and self-regulatory skills were emphasised during the first month of intervention."
214984112|NCT02791269|DRUG|Peginterferon alfa-2a|180 mcg SC injection QW for 48 weeks.
214984113|NCT05729321|COMBINATION_PRODUCT|neutrox|Each ECC, after discontinuing the Parental Nutrition (NP) infusion, will be flushed with 0.3 ml saline. Subsequently, Saline will be infused at a rate of 2 ml/h for 10 minutes. The ECC will then be closed for 1 hour. At the end of the hour the ECC will be once again flushed with 0.3 ml Saline and infused with SF at the rate of 2 cc/h for 10 minutes. The difference in pressure of the two infusions, before and after catheter closure, will be evaluated.
214369643|NCT01272960|DEVICE|Interval Insertion|Insertion of Mirena 4-8 weeks post partum after vaginal delivery
214369644|NCT01837329|DRUG|Tetrathiomolybdate|"Dose Escalation - Dose level -1: 20 mg TM orally 3 x daily x 21 days in combination with carboplatin IV area under the curve (AUC) = 6 and pemetrexed IV 500/mgm2 day 1 x 1 cycle.~Dose level 1: 40 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Dose level 2: 60 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Patients in the dose-expansion cohort will continue on carboplatin and pemetrexed (without TM) at the discretion of the treating physician.~Dose Expansion - Maximum tolerated dose of TM determined from the dose-escalation cohorts combined with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 4 cycles."
214369645|NCT03312153|DRUG|Neem|A natural irrigant solution act as anti-inflammatory and anti bacterial
214369646|NCT03312153|DRUG|2.5% sodium hypochlorite|anti bacterial root canal irrigant solution
214369647|NCT04698317|PROCEDURE|open flap debridement|Open flap for removal of diseased periodontal tissues and necrotic cementum
214984114|NCT05375916|DRUG|Hydromorphone|Sustained-release hydromorphone is a long-acting preparation opioid
214984115|NCT00038285|PROCEDURE|Amputation Prevention|
214984116|NCT00176735|DRUG|Capecitabine|
214984117|NCT05224830|OTHER|Nijmegen questionnaire score|We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
214984118|NCT01327768|PROCEDURE|Olfactory ensheathing cells|Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
214369648|NCT04698317|OTHER|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate plus concentrated growth factors|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate incorporating Concentrated Growth Factors in Periodontal Defect
214369649|NCT04698317|OTHER|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone in the Intrabony Periodontal Defect
214369650|NCT00963911|OTHER|Geriatric screening tests|"The G-8 consists of eight items: patient age (\>85, 80-85, \<80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with lower scores indicating a higher risk of impairments. The cut-off value for an 'impaired' reference test score was \<=14 and the time taken to complete the test was recorded.~VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For three pre-identified centers, patients also filled in the questionnaire at the following geriatric visit. VES-13 consisted of four groups of questions: age, self-perceived health, difficulties to perform six specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score \>=3 was considered to show impairment."
214369651|NCT00963911|OTHER|Multidimensional geriatric assessment|Patients underwent a geriatric evaluation in the month following the completion of G8 and VES-13 (+/- seven days) before treatment began. The nurse completed six of the seven instruments of the MGA (MNA, Timed Get up and Go (TUG), Activities of Daily Living (ADL), Instrumental ADL (IADL), Mini Mental State Examination (MMSE), and Geriatric Depression Scale (GDS-15)), and the geriatrician rated comorbidity on the Cumulative Illness Rating Scale (CIRS-G), recorded the time required for the consultation, identified patients who needed personalized geriatric interventions, and, if necessary, proposed further geriatric evaluation (outside of the scope of this study).
214369652|NCT04962399|DIAGNOSTIC_TEST|Enzyme linked immunosorbent assay|Serum N / OFQ and IL-6 levels were detected，and the genotype and allele frequencies of rs1800796 in IL-6 gene were determined.
214984119|NCT03667521|PROCEDURE|nerve-sparing laparaoscopic sacrocolpopexy|nerve-sparing laparaoscopic sacrocolpopexy implemented after 2010
214984120|NCT01309334|PROCEDURE|PET scan|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
214984121|NCT01309334|PROCEDURE|MRI|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
214984122|NCT00336544|DRUG|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
214984123|NCT00336544|DRUG|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
214984124|NCT02397746|DEVICE|total hip arthroplasty implant|
214984125|NCT04546763|DEVICE|Study Watch|The Study Watch is a miniaturized wearable device made with biocompatible contact materials containing various sensors capable of measuring physiological and environmental metrics.
214984126|NCT04546763|DEVICE|Zio XT|The Zio XT Patch, the reference device, is a FDA-cleared single-patient use, continuously recording ECG monitor that can be worn up to 14 days.
214369653|NCT02782390|OTHER|Dental Restoration with Stainless Crown|Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans \& Innes, 2010).
214984127|NCT03711721|DIETARY_SUPPLEMENT|Food basket|
214493261|NCT04496024|DRUG|ofloxacin|ofloxacin treatment in patients with bone and joint infections
214493262|NCT04496024|OTHER|questionnaire|questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
214493263|NCT04496024|BIOLOGICAL|Ofloxacin Serum concentration|Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
214493264|NCT04614454|DEVICE|High Frequency Impulse Therapy|The home TENS unit device is an at-home transcutaneous electrical nerve stimulation unit in that it provides non-invasive transcutaneous electrical impulses to reduce pain. It is a small, wearable device that utilizes both high and low frequencies to create a nerve-block effect based on the same gating theory.
214493265|NCT04614454|DEVICE|High Frequency Impulse Therapy - Sham|This device looks like the experimental device but does not provide the electrical current.
214493266|NCT05563766|DRUG|Itraconazole|Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
214984128|NCT03711721|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food|
214984129|NCT00459017|DEVICE|Portable blood pressure wrist manometer|
214984130|NCT03592628|OTHER|Visual Aid|The visual aid was a one-sheet diagram with illustrations of important features of post-cesarean wound care.
214984131|NCT03592628|OTHER|Standard Instructions|Standard discharge instructions WITHOUT supplement of visual aid.
214984132|NCT01649765|DRUG|belimumab 10mg/kg|belimumab 10mg/kg IV monthly
214984133|NCT01649765|OTHER|placebo|Normal Saline 250 ml
214984134|NCT02188550|DRUG|everolimus and letrozole|"This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally"
214493267|NCT04612244|DEVICE|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
214493268|NCT04612244|DEVICE|RadioFrequency and Cryoballoon Ablation|Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
214493269|NCT04991831|DEVICE|Unilateral thalamotomy|Unilateral thalamotomy using focused ultrasound for the treatment of medication-refractory tremor dominant idiopathic Parkinson's Disease.
214493270|NCT05613296|DRUG|Fostamatinib|Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
214493271|NCT06239831|DEVICE|ExSpiron and ActivPAL Monitors|ExSpiron chest monitor will be placed on the chest ActivPAL accelerometer will be placed on the chest and thigh
214493272|NCT05103345|DRUG|SGN1|SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.
214493273|NCT06405841|OTHER|Survey|All patients will be asked to complete a survey at 1, 2, 4, 12 and 24 weeks from the trauma to assess their quality of life
214984135|NCT01147796|DEVICE|computed tomography|64 slices CT with iodine injection
214984136|NCT01147796|DEVICE|computed tomography|64 slices CT with iodine injection
214984137|NCT00715208|DRUG|rituximab|
214984138|NCT00715208|DRUG|cyclophosphamide|
214984139|NCT00715208|DRUG|doxorubicin|
214984140|NCT00715208|DRUG|VELCADE|
215088652|NCT05045170|DRUG|Influence of spinal anesthesia on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
215088653|NCT01615601|DRUG|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
215088654|NCT01615601|DRUG|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
214369654|NCT02782390|OTHER|Dental Restoration with Composite Resin|"Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 15 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions."
214369655|NCT05616364|DRUG|Dexmedetomidine injection|Dexmedetomidine intravenous
214369656|NCT05616364|DRUG|Tramadol|Tramadol intravenous
214369657|NCT06491251|PROCEDURE|Bilateral Subinguinal microscopic varicocelectomy|Using Leica® Microsystems , Germany. the patient was placed in a supine position after spinal anesthesia administration , The left external inguinal ring was located near the pubic tubercle by palpation, and the incision site was marked below the annulus of the left external ring. A 1.5- to 3-cm oblique incision was made along the skin line. After the tissues were dissected layer by layer, the incision was exposed until the spermatic cord became visible. the spermatic cord was lifted out with Babcock clamp and delivered though the incision and followed by the placement of a nelaton catheter 20 fr below the spermatic cord. The external spermatic vein was located and ligated. The microscopic operation was performed at 10× to 20× magnification.
214681139|NCT04256746|OTHER|Boiled Rice+1.50 gr mulberry fruit powdered extract|
214984141|NCT00715208|DRUG|prednisone|
214369658|NCT03784690|OTHER|Individualized intraoperative BP management|"In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).~Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status."
214984142|NCT01648764|DRUG|LY2334737|Administered orally
214984143|NCT05197439|DRUG|Dexmedetomidine|The 4.8ug/kg dexmedetomidine will be diluted into 100ml and pump 2ml/h at the beginning of the second of DBS and last for 48 hours.
214984144|NCT05197439|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
214984145|NCT01316614|DEVICE|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
214984146|NCT00052338|DRUG|gemcitabine hydrochloride|Given IV
215088655|NCT01615601|DRUG|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
215088656|NCT01615601|DRUG|Other antiretroviral medications|Given as per Canadian Product Monograph
215088657|NCT04503590|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
214369659|NCT03784690|OTHER|Standard intraoperative BP management|Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.
214369660|NCT00101127|BIOLOGICAL|filgrastim|
214369661|NCT00101127|BIOLOGICAL|pegfilgrastim|
214369662|NCT00101127|DRUG|docetaxel|
214369663|NCT00101127|DRUG|gemcitabine hydrochloride|
214681140|NCT04256746|OTHER|Rice Porridge|
214681141|NCT04256746|OTHER|Rice porridge+1.50 gr mulberry fruit powdered extract|
214984147|NCT00052338|DRUG|carboplatin|Given IV
214984148|NCT00052338|DRUG|bortezomib|Given IV
214984149|NCT00052338|OTHER|laboratory biomarker analysis|Correlative studies
215088658|NCT03349866|DRUG|apatinib|apatinib：250mg qd po
215088659|NCT03349866|DRUG|Capecitabine|1000mg/m2 bid d1-14
215088660|NCT03349866|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
215088661|NCT03349866|RADIATION|Radiotherapy|45Gy/25f （1.8Gy/f/d，5 f/w）
215088662|NCT00568477|DRUG|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over \>=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
215088663|NCT00272688|DRUG|Levodopa (drug), intraduodenal administration|
215088664|NCT05242666|DIAGNOSTIC_TEST|3T MR Imaging of the cervical spinal cord|Patients will undergo either Magnetic Resonance Imaging of the Spinal Cord
214984150|NCT01860209|PROCEDURE|Hemodialysis|Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
215088665|NCT05242666|OTHER|Positron Emission Tomography using [11C]PIB|Patients will undergo combination MRI/PET using a \[11C\]PIB radiotracer
214984151|NCT03427411|DRUG|M7824|Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks
214984152|NCT05307393|BEHAVIORAL|Positioning|Upon admission to labor and delivery, following an initial ultrasound to confirm fetal OP position, women in this study will be randomly assigned to one of three groups; one control (Group A), and two experimental (Groups B and C) groups. Those assigned to Group A will be allowed to remain in any position they chose during their labor and delivery course. Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement. Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
215088666|NCT05242666|OTHER|3T MR Imaging of the Brain|3T MR Imaging of the Brain
214984153|NCT05662969|DEVICE|MACHINE PERFUSION|Different outcomes of MP use in low/mid-volume and high-volume LT centres
214984154|NCT00076570|DRUG|Sirolimus|
214984155|NCT00076570|DRUG|Tacrolimus|
214984156|NCT02106507|DRUG|apalutamide|apalutamide, 240 mg/day, oral
214984157|NCT02106507|DRUG|Everolimus|5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
214984158|NCT02939352|DEVICE|Real continuous Theta Burst Stimulation|Continuous Theta Burst stimulation delivered
214984159|NCT02939352|DEVICE|Sham continuous Theta Burst Stimulation|active sham Continuous Theta Burst stimulation delivered
214984160|NCT00481663|DRUG|Sitagliptin|
214369664|NCT01038258|PROCEDURE|PET scan after course 1 and surgery after 8 courses|PET scan and surgery
214369665|NCT00297115|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
214369666|NCT00297115|DRUG|Placebo|once daily
214369667|NCT05153460|DEVICE|Telemetry and manual monitoring vs Contactless monitoring devices|"All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simultaneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device)."
214493274|NCT06405841|OTHER|Pain management|All patients will be asked about their pain management at 1, 2, 4, 12 and 24 weeks from the trauma to assess if they are under medication and what kind of medication are they taking
214493275|NCT03357926|DIAGNOSTIC_TEST|24 hour Holter ECG Monitoring|24 hour Holter ECG Monitoring
214493276|NCT06066268|DIAGNOSTIC_TEST|Critical limb ischemia: analysis of RNAs|analysis of miRNA expression levels
214984161|NCT00481663|DRUG|Placebo to sitagliptin|
214984162|NCT00481663|DRUG|Metformin|
214984163|NCT00481663|DRUG|Rescue|Patients whose FPG \>240 mg/dL from Week 16 or HbA1C \>8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently \>240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C \>8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C \>7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
214984164|NCT04548245|DEVICE|EEG|EEG
214984165|NCT00533338|BEHAVIORAL|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
214984166|NCT00533338|BEHAVIORAL|Questionnaire|Packet of questionnaires will be completed.
214984167|NCT05859230|DIETARY_SUPPLEMENT|Experimental: The probiotic drink study group|The 100 ml volume of milk drink containing 10 billion Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded by study team members and subjects. The milk drink bottles are coded by the manufacturing company.
214984168|NCT05859230|DIETARY_SUPPLEMENT|Placebo Comparator: The placebo drink study group|The 100 ml volume of milk drink without containing Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded to study team members and subjects. The milk drink bottles are coded by the manufacturing company.
215088667|NCT05242666|OTHER|7T MR Imaging of the Spinal Cord|7T MR Imaging of the Spinal Cord
215088668|NCT01859845|OTHER|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
215088669|NCT04287686|DRUG|Recombinant human angiotensin-converting enzyme 2 (rhACE2)|In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
215088670|NCT00895960|DRUG|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
215088671|NCT00895960|RADIATION|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
214984169|NCT04069858|DRUG|Switching to Generic Entecavir (Baracle®)|switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
215088672|NCT00895960|DRUG|TMZ (Temozolomide)|75 mg/m\^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles.
215088673|NCT05462808|DRUG|High viscosity glass ionomer cement|High viscosity glass ionomer cement
214493277|NCT06066268|DIAGNOSTIC_TEST|Controls: analysis of RNAs|analysis of miRNAs expression levels
214984170|NCT02186028|DRUG|Vitamin D|Vit D 400 IU vs. Vit D 200 IU
214984171|NCT04044118|BEHAVIORAL|Low Calorie Diet|Low Calorie Diet consisted of \~50% calories of a normal-calorie diet (female, 1000kcal/day; male, 1200kcal/day)
214984172|NCT00001891|PROCEDURE|Myocardial contrast echocardiography|
214984173|NCT00001891|PROCEDURE|Dobutamine echocardiography|
214984174|NCT04227912|OTHER|Transversus abdominis plane block|Before surgery, Ultrasound-guided TAP block was performed preemptively to Group TAP patients.
214984175|NCT04227912|OTHER|Local anesthetic infiltration|Before surgery, Ultrasound-guided Local anesthetic infiltration to the surgical incision line was performed preemptively to Group Local patients.
214984176|NCT04227912|OTHER|Intravenous dexketoprofen|Before surgery, 50 mg intravenous dexketoprofen was performed preemptively to Group dexketoprofen patients.
214984177|NCT04889040|DRUG|RO7496998|275 mg tablets
214493278|NCT06478667|DRUG|levosemindan|inotropic agent
214493279|NCT01934036|DIETARY_SUPPLEMENT|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
214493280|NCT01934036|DRUG|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
214493281|NCT02748226|PROCEDURE|endovascular treatment|endovascular treatment
214493282|NCT03170648|DEVICE|Acupuncture|Acupuncture has been studied in clinical trials in cancer patients and has been shown to be helpful for management of pain, nerve damage from chemotherapy, and nausea
214984178|NCT04889040|DRUG|Placebo|Matching tablets
215088674|NCT05462808|DEVICE|Stainless steel crown|Stainless steel crown
215088675|NCT05094817|OTHER|Brain Health Assessment|BHA is a free, self-administered online cognitive screening test developed in Toronto at Baycrest (www.cogniciti.com). BHA has been validated against a gold standard neuropsychological assessment for detecting amnestic MCI (aMCI) - the most common type of MCI - in community dwelling older adults. BHA has high sensitivity (.78), specificity (.78), PPV (.82), NPV (.74), and was better than MoCA for identifying aMCI. ROC curves showed an AUC of 0.75 for detecting aMCI from normal subjects. BHA measures memory and executive attention processes sensitive to subtle cognitive changes associated with normal aging and MCI. BHA can be completed from a patient's home or can be self-administered in hospital.
215088676|NCT05094817|OTHER|Demographics questionnaire|To compare the sociodemographic characteristics of patients completing Cogniciti's BHA vs. those who are not able to complete the BHA.
214493283|NCT00789542|DEVICE|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
214493284|NCT00789542|OTHER|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
214493285|NCT03500549|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214493286|NCT03500549|DRUG|Soliris|Complement (C5) Inhibitor
214493287|NCT02371512|DEVICE|MitraClip system (Abbott Vascular, Menlo Park, USA)|Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
214493288|NCT02371512|PROCEDURE|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
214493289|NCT02754596|DRUG|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
214493290|NCT02754596|DRUG|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
214493291|NCT02754596|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
214984179|NCT05522478|DEVICE|Fall risk|Fall risk, static postural balance and sensorimotor integration were assessed using the Biodex Balance System.
214984180|NCT02295137|PROCEDURE|Using pre-procedural CTA to guide advanced EVAR procedure|
214984181|NCT05500937|DRUG|UDCA|UDCA vs. placebo together with statin in ASCVD patients
214984182|NCT00128375|BEHAVIORAL|Financial incentives|
214984183|NCT04941872|DIAGNOSTIC_TEST|68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT|Each subject receive a single intravenous injection of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
214984184|NCT04796974|DEVICE|Cention|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques
214984185|NCT04660383|DEVICE|Inspiratory Muscle Training|Patients will be submitted to three weekly IMT sessions in three different intensities for a period of twelve weeks, totaling 36 sessions.
214984186|NCT02058095|DRUG|Tadalafil|"Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil."
214984187|NCT02058095|DRUG|Placebo|"Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo."
214984188|NCT03626896|DEVICE|NaviFUS System|BBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system
214984189|NCT02663700|DRUG|Artesunate|Four tablets of 50mg each, totaling 200mg will be given in a single calendar day
214984190|NCT02663700|BIOLOGICAL|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
214984191|NCT02663700|OTHER|Placebo|Placebo
214984192|NCT02253342|DRUG|WCK-2349|Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
214984193|NCT05082480|DEVICE|Hyaluronic acid (HA)|Hyaluronic acid (HA)
215088677|NCT05094817|OTHER|PHQ-2|PHQ-2 is a shortened version of PHQ-9 which is originally a component of the longer Patient Health Questionnaire. The tool incorporates DSM-IV depression criteria and other leading major depressive symptoms into brief self-reported instruments. PHQ-2 inquires about the degree to which an individual experiences depression and anhedonia (inability to feel pleasure) over the past two weeks. The tool is not for final diagnosis of depression or monitoring its severity but only for the purpose of screening for the condition.The questionnaire comprises of the first two questions from PHQ-9, each item is scored 0-3. Therefore, the PHQ-2 score ranges from 0-6.
215094603|NCT02349490|DEVICE|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
215094604|NCT04712552|PROCEDURE|deep brain stimulation|"On the day of surgery, under general anesthesia, a Fischer ZD frame will be attached to the skull. A T1-weighted 3D MRI with gadolinium will be performed.~Investigators will plan on this MRI, anatomical targets and deep brain trajectories using the NeuroInspire surgical planning software.~The patient will be attached to the base of the robot through the frame. Registration will be performed using the Neurolocate method after the acquisition of 3D CT images using the O-arm. The Neurolocate recording is based on radiographic images.The 3D MRI will be merged with the 3D tomography images taken with the O-arm to co-register the trajectories planned on the MRI in the robot space The surgical procedure will be performed as usual by milling the bone at the entry point and inserting under robotic guidance an electrode through a guide tube to the intended target."
214369668|NCT05381298|PROCEDURE|Deep Margin Elevation using resin composite|After completion of the root canal treatment of the offended tooth and comprehensive evaluation of the obtained treatment, the randomly allocated patients will undergo deep margin elevation procedure where rubber dam isolation will be accomplished Followed by proper matricing and wedging ) followed by selective enamel etching for 10 seconds then universal adhesive application following the manufacturer instructions followed by application of flowable resin composite for the first 1 mm and light cured for 20 seconds according to the manufacturer recommendations followed by application of packable bulk fill composite to elevate the margins and light cured following the manufacturer instructions.
214369669|NCT05381298|PROCEDURE|Surgical Crown Lengthening|Participants in this group will undergo surgical crown lengthening in which an internal bevel incision will be done buccally and lingually followed by full thickness flap reflection using mucoperiosteal elevator, then interproximal bone removal will be done using end cutting bur to the planned position away from the margins by 3 mm. The flap will be displaced apically with apically positioned sutures. Postoperative instructions will be given to the patient aiming to control postsurgical complications including pain and swelling. Suture removal and assessment of the surgical site will be done after two weeks
214369670|NCT02235467|BEHAVIORAL|ABA parent training|A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
214369671|NCT04916119|DRUG|IBI323|In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
214369672|NCT02789683|OTHER|Fine emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
214984194|NCT05082480|DEVICE|Saline|Saline
214984195|NCT04252729|PROCEDURE|Psychotherapy|Psychotherapy sessions based on Psychoanalytic Psychosomatics
214984196|NCT00998946|DRUG|Pralatrexate|Pralatrexate injection administered as intravenous (IV) push
214984197|NCT00998946|DIETARY_SUPPLEMENT|Vitamin B12|1 mg intramuscular (IM) injection
214984198|NCT00998946|DIETARY_SUPPLEMENT|Folic Acid|Oral 1 mg tablet
214984199|NCT00144313|BIOLOGICAL|hepatitis B vaccine|
214984200|NCT05429996|OTHER|Skin Biopsy|Skin biopsy specimens will be collected for both groups and subjected to quantitative nano histology using atomic force microscopy to assess for structural profile of a single collagen fibril
214984201|NCT01897116|DRUG|Hydroxychloroquine (HCQ)|
214984202|NCT01897116|DRUG|Vemurafenib (VEM)|
215094605|NCT03063190|DRUG|Vitamin D|patients will receive vitamin D supplementation according to guidelines
215094606|NCT03063190|DRUG|Placebo Oral Tablet|patients will receive placebo oral tablets
214984203|NCT00148798|DRUG|cetuximab + cisplatin + vinorelbine|cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
214984204|NCT00148798|DRUG|cisplatin + vinorelbine|cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
214984205|NCT03050567|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
214984206|NCT02139319|DRUG|Botulinum toxin|
214984207|NCT02139319|DRUG|Placebo|
214984208|NCT00316004|DRUG|7.5% Hypertonic Saline in 6% Dextran-70 (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
214984209|NCT00316004|DRUG|7.5% Hypertonic Saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
214984210|NCT00316004|DRUG|0.9% Normal Saline (NS)|250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
214984211|NCT01339169|DRUG|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
214984212|NCT02254655|DRUG|Puerarin injection 400 mg|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
214984213|NCT02254655|DRUG|Control|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
214984214|NCT02202252|PROCEDURE|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
215088678|NCT05094817|OTHER|AFT|AFT is a free, rapid cognitive assessment commonly used to assess semantic language ability. Language is one of the earliest functions affected by AD and naming and semantical knowledge seems to be particularly affected. The identification of language deficits may pick up signs of neurological decline preceding the appearance of clinical symptoms. Milder forms of cognitive impairment such as MCI may also show language deficits if language is one of the domains affected.
215088679|NCT05094817|OTHER|GAI-SF|GAI-SF is a 5-item questionnaire derived from the original 20-item Geriatric Anxiety Inventory (GAI).In the population of community dwelling older women GAI-SF was developed in, a cut-off score of 3 yields a specificity of 87% and sensitivity of 75%. This highly accessible questionnaire is suitable for everyday use in a range of health-care settings. It has been employed amongst older adults in primary care settings, nursing homes, geriatric psychiatry patients and amongst clinical geriatric participants with co-morbid anxiety and unipolar mood disorder and their controls.
214493292|NCT04888104|PROCEDURE|Index or revision spine surgery for complex adult spinal deformity|Adult patients receiving minimum 5 level posterior spinal fusion with pedicle screw fixation supplemented at the proximal aspect of the construct with the VersaTie System.
214493293|NCT02961868|OTHER|Abdominal and supra-aortic trunks vascular imaging|Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.
214493294|NCT02961868|GENETIC|Blood sampling (genetic)|A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.
214493295|NCT02961868|OTHER|Blood sampling (biomarkers)|A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
214493296|NCT02961868|OTHER|Urine sampling|A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
214493297|NCT03778515|DIAGNOSTIC_TEST|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
214984215|NCT02202252|PROCEDURE|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
214984216|NCT02202252|PROCEDURE|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
214984217|NCT05106569|DIAGNOSTIC_TEST|Spirometry|All study participants will undergo pulmonary function testing using conventional spirometry in clinic and portable spirometry in clinic and at home. In-clinic conventional laboratory spirometry is compared with portable spirometry and Slow vital capacity is obtained in upright and supine positions.
214984218|NCT03483428|BEHAVIORAL|Interventionist training and supervision|"Online and in-person training and weekly supervision with licensed clinical social worker while delivering the Family Check-Up to 5 families."
215088680|NCT05094817|OTHER|pain VAS|The VAS is a unidimensional measure of pain intensity. The VAS tries to measure a continuous characteristic or attitude signifying the intensity or frequency of symptoms. The scale ranges from 0-10, with 0 = no pain to 10 = worst pain.
214984219|NCT03483428|BEHAVIORAL|Behavioral parent training|"Up to 6 sessions of the Family Check-Up program, involving discussions, assessments, feedback, and skills training with a parent coach."
214984220|NCT01700803|DRUG|Povidone Iodine 10% vand cesarean section wound infections|
214984221|NCT01700803|DRUG|Povidone Iodine 7.5% vand cesarean section wound infections|
214984222|NCT03155698|COMBINATION_PRODUCT|microneedling and Platelet rich plasma|"Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~* After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days."
214369673|NCT02789683|OTHER|Coarse emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
214493298|NCT02107261|DRUG|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
214369674|NCT02789683|OTHER|Control|Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
214369675|NCT01560325|DRUG|CKD-516 inj.|CKD-516: 3.3\~13mg/m2/day
214369676|NCT02352597|DRUG|phytoestrogen|20mg of cimifuga racemosa from day 1- 12
214369677|NCT02352597|DRUG|estradiol valerate|2mg from cycle day 7 to day 11
214369678|NCT02352597|DRUG|clomiphene citrate|50 mg orally every 8 hours started from cycle day 3 for 5 days
214369679|NCT04978974|BEHAVIORAL|Stress Management Program|Stress management program includes different techniques such as relaxation technique, psycho-education, laughing, emotional freedom technique, referenting, cognitive restructuring, rational emotive imagery, time management, anger management, assertiveness and social support
214369680|NCT02832622|DEVICE|MPP|MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)
214493299|NCT02107261|DRUG|Placebo|matching placebo
214493300|NCT05461235|DRUG|Pembrolizumab|2mg/kg or 200mg,iv,q3w
214493301|NCT05461235|DRUG|Nivolumab|3mg/kg or 240mg,iv,q2w
214493302|NCT05461235|DRUG|Sintilimab|200mg,iv,q3w
214493303|NCT05461235|DRUG|Toripalimab|3mg/kg or 240mg,iv,q2w
214493304|NCT05461235|DRUG|Camrelizumab|200mg,iv,q2w or q3w;3mg/kg,iv,q3w
214493305|NCT05461235|DRUG|Tislelizumab|200mg,iv,q3w
214681142|NCT04239274|DEVICE|transcranial direct current stimulation|Subjects in this arm will receive one session of tDCS for 20 minutes at 2.0 milliamps.
214984223|NCT03155698|RADIATION|NB-UVB phototherapy|All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
214984224|NCT04287179|DRUG|Semaglutide|Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.
214984225|NCT00977197|DRUG|Pregabalin|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
214984226|NCT00977197|DRUG|Placebo|A matching placebo will be administered twice a day
214984227|NCT01961492|OTHER|Fecal microbiota transplantation|A single fecal microbiota transplantation through colonoscope
214984228|NCT02684929|DIETARY_SUPPLEMENT|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
215088681|NCT05094817|OTHER|IADL|Instrumental activities such as preparing meals or managing finances allow individuals to maintain their health while living on their own. The IADL measures the ability of older adults to manage their daily activities, as well as the impact, if any, cognitive decline would have on these activities. Scores range from 0-5 for men, and 0-8 for women, with higher sores being more independent and higher functioning.
214984229|NCT00784875|DRUG|LY2624803|1 mg, oral capsule, once nightly before bedtime
214984230|NCT00784875|DRUG|LY2624803|3 mg, oral capsule, once nightly before bedtime
214984231|NCT00784875|DRUG|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
214984232|NCT00784875|DRUG|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
214984233|NCT04345224|OTHER|Dynamic tape|A kinesiology tape will be applied to the lateral hip of the affected side to facilitate the gluteus medius muscle activation while the participant is lying down. The first third of one I-strip will begin at the posterior iliac crest without tension to provide an anchor that will not cross the target tissue. The participant will actively flex the adducted hip to allow for the application of the middle third of the tape with approximately 50 percent tension (able to visualize the wave pattern in the tape). Subsequently, with the leg in the original position, the remainder of the tape will be applied without tension, ending approximately at the greater trochanter. Afterward, the second I-strip will be applied in the same manner starting at the anterior iliac crest.
214984234|NCT04345224|OTHER|Rigid tape|The rigid tape will be applied in a standing position. The first tape will be applied from the greater trochanter to the anterior iliac crest. The second from the greater trochanter to the posterior iliac crest. Both tapes are applied with the muscle mass lifted towards the iliac crest.
214984235|NCT04345224|OTHER|Sham tape|The control group (sham tape application) will receive a single strip of a Kinesio tape across the lateral affected hip without tension in the tape or muscle stretch.
214984236|NCT03524209|DEVICE|Percutaneous instrumentation of the thoracolumbar spine|The spine is stabilized cranially and caudally of the level of spondylodiscitis. The percutaneous instrumentation consists of a rod and pedicle screw construct. The vertebrae are instrumented through minimal skin incisions using a fluoroscopic guidance or a spinal navigation system based on 3D imaging.
214984237|NCT03524209|OTHER|Brace|Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine
214984238|NCT04111315|DRUG|Metamizole Sodium|Novalgin® Oblong tablets 0,5 g 2-2-2
214984239|NCT04111315|DRUG|Ibuprofen 600 mg|Ibufen-L® tablets 500 mg 2-2-2
214984240|NCT04111315|BEHAVIORAL|Patient education|Leaflet and phone call
214984241|NCT02842866|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
215088682|NCT05094817|OTHER|FAM CAM|FAM-CAM was derived from the CAM instrument in order to screen for delirium by interviewing family members or caregivers of the patient. They are asked specific questions about any new or sudden changes in the patient's activity, behavioural or cognitive status. FAM-CAM showed good sensitivity and specificity in the original study where caregivers of elderly patients with pre-existing cognitive impairment were interviewed.
215088683|NCT05094817|OTHER|4AT|The 4AT is a rapid tool for delirium detection that has previously been used in a surgical setting. The 4Ats test for the patient's alertness, mental state, attention, and signs of acute change. Across 17 studies, the pooled sensitivity and specificity of 4AT was 0.86 and 0.89. The 4AT will be administered after the patient has completed surgery, prior to discharge.
215088684|NCT05094817|OTHER|BHA Usability Survey|The survey aims to assess system usability and acceptability based on standard questions adapted from the validated System Usability Scale. The questions evaluate satisfaction, experience with technology, and comfort level, as well as questions targeting usability concerns typically experienced by older adults, such as typeface and font size, consistent navigation, and writing style.
214493306|NCT05461235|BIOLOGICAL|NK-Cell or DC-Cell|50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10\^6 cells/Kg) was completed on day 14.
214493307|NCT02137616|DRUG|risperidone|Risperdal tablets
214984242|NCT02842866|BIOLOGICAL|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined|0.5 mL, Subcutaneous (SC), single dose on Day 0.
214984243|NCT06255483|OTHER|Osteoperiosteal pedicled clavicular flap for mandibular and facial bone reconstruction|"A clavicular flap with a vascular supply based on the transverse cervical artery which receives a reverse blood supply from the ascending cervical artery. This vascular pattern is reliable because of the existence of the sub-occipital microvascular network named the  Bosniak node ."
214984244|NCT04854746|BIOLOGICAL|VXA-GI.1.NN|GI.1 oral vaccine tablet
214984245|NCT04854746|BIOLOGICAL|Placebo Tablet|Tablets matching in number and appearance to active vaccine tablets
214984246|NCT02178514|OTHER|Formula fed with BabyNes Nutrition System|
214984247|NCT00634556|DRUG|levodopa solution 2mg/ml for i.v. use|2mg/mL in normal saline
214493308|NCT02137616|DRUG|olanzapine|olanzapine tablets
214493309|NCT02137616|DRUG|Quetiapine|quetiapine tablets
214493310|NCT02137616|DRUG|Aripiprazole|Aripiprazole tablets
214493311|NCT05297214|DIAGNOSTIC_TEST|serum creatinine and Other investigations will be done according to the case|following up AKI patients with serum creatinine,Urine out put, CBC,Serum electrolytes,renal functin test,Liver function test,urine analysisand specific investigations according to case
214493312|NCT04337931|DRUG|sotigalimab|Sotigalimab is a CD40 agonistic monoclonal antibody
214493313|NCT02431273|DRUG|TDF IVR|
214984248|NCT00634556|DRUG|placebo|normal saline
214984249|NCT04943393|OTHER|nointervention|Nointervention
214984250|NCT05316870|BEHAVIORAL|Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions|Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
214984251|NCT05316870|BEHAVIORAL|Conventional general practitioner management model|The current general practitioner anticoagulation management model was continued in the control group.
214984252|NCT04572035|BEHAVIORAL|Behavioural Coaching|behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting)
214984253|NCT04572035|BEHAVIORAL|Self-compassion psychoeducation|self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks)
214984254|NCT04572035|OTHER|Exercise|aerobic exercise program either delivered in a laboratory setting or via Zoom
214984255|NCT00470548|DRUG|Abraxane|ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
214984256|NCT00470548|DRUG|Alimta|Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
215088685|NCT05094817|OTHER|Clinical Frailty Scale|CFS is a 9-item scale that uses clinical descriptors and pictographs and is an easily applicable tool to stratify older adults according to level of vulnerability. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). It is easy to use and may readily be administered in a clinical setting, an advantage over the tools previously developed. The scale helps in objective early identification of older adults with frailty in acute care units and helps to target interventions to prevent complications and to implement effective discharge planning.
215088686|NCT00944463|DRUG|Gemcitabine+simvastatin|Gemcitabine and simvastatin
215088687|NCT00944463|DRUG|Gemcitabine+Placebo|Gemcitabine plus Placebo
214681143|NCT04239274|DEVICE|transcranial pulsed current stimulation|Subjects in this arm will receive one session of tPCS for 20 minutes at 2.0 milliamps.
214681144|NCT04239274|DEVICE|Sham-no stimulation|Subjects in this arm will receive one session of sham for 20 minutes.
214493314|NCT02431273|DRUG|TDF-FTC IVR|
214681145|NCT04440917|DRUG|Camrelizumab|200mg, iv, on day 1, 15, 29, 43
214681146|NCT04440917|DRUG|Apatinib Mesylate|250 mg po, qd, 28 days as a cycle, 2 cycles in total
214984257|NCT02215902|DEVICE|Affinity plasmapheresis|Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
214984258|NCT04496232|DEVICE|PICSI|Semen processing by density gradient centrifugation followed by sperm selection by PICSI dishes of the first ejaculate
214984259|NCT04496232|OTHER|Second ejaculate|Semen processing by density gradient centrifugation for the second ejaculate
215088688|NCT06334757|DRUG|Serplulimab|300 mg，IV，Q3W
215088689|NCT06334757|DRUG|Bevacizumab Biosimilar HLX04|7.5 mg/kg，Q3W
215088690|NCT06334757|DRUG|Pemetrexed|500 mg/m2，IV，Q3W
215088691|NCT06334757|DRUG|Carboplatin|AUC=5，IV，Q3W
214493315|NCT02431273|DRUG|TDF-FTC-MVC IVR|
214493316|NCT04086849|DIAGNOSTIC_TEST|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
214493317|NCT06140732|DRUG|camrelizumab and apatinib|camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
215088692|NCT02012686|DEVICE|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
215088693|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
215088694|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
215088695|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
214493318|NCT04436289|BEHAVIORAL|Home Link|In the Home Link intervention, a team will conduct home visits to (1) provide a structured clinical assessment; (2) reconcile medications, (3) provide psychosocial support through patient-centered counseling, and (4) assess home needs (food security). These visits will start one week after discharge and be repeated every two weeks until the participant is stabilized and ready to initiate lower intensity clinic-based services or three months have elapsed.
214493319|NCT05681234|RADIATION|18F-RD2|Patients will receive 5-10 mCi 18F-RD2
214493320|NCT00649805|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
214493321|NCT00649805|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
214493322|NCT06251674|OTHER|long-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
214493323|NCT06251674|OTHER|short-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
214493324|NCT05443945|DEVICE|Nasal Spray|3 sprays in each nostril 3 times per day
214493325|NCT02804074|OTHER|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
214681147|NCT00832715|PROCEDURE|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
214681148|NCT03145129|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
214681149|NCT00478972|DRUG|Rimonabant|Tablet, oral administration
214681150|NCT00478972|DRUG|placebo (for Rimonabant)|Tablet, oral administration
214681151|NCT00478972|OTHER|Diet and exercise|Target daily caloric intake: Ideal body weight × 25 kcal
215088696|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
214984260|NCT02517723|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
215088697|NCT02184429|DRUG|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
215088698|NCT02184429|DRUG|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
214493326|NCT02804074|OTHER|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
214493327|NCT06302842|DIETARY_SUPPLEMENT|Bioritmon Immuno Defend|Bioritmon Immuno Defend daily oral preparation for 24 days.
214493328|NCT06819449|DRUG|Dapsone|To evaluate the effect of the multi drug therapy in leprotic patients and their side effects and to assess the role of Rab 32 gene in leprosy prognosis and to know its association with the multi drug therapy.
214493329|NCT06251869|PROCEDURE|total hip arthroplasty with electrocoagulation|using normal technique
214493330|NCT06251869|PROCEDURE|total hip arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
214493331|NCT06251869|PROCEDURE|total knee arthroplasty with electrocoagulation|using normal technique
214493332|NCT06251869|PROCEDURE|total knee arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
214493333|NCT06306924|RADIATION|Radiation therapy|Subjects with metastatic cancer receive radiation therapy.
214493334|NCT04580888|PROCEDURE|early transthoracic echocardiography|In the intervention arm, echocardiography will be performed immediately and potentially repeated to confirm the need for additional fluid resuscitation up to 30 mL/kg in the presence of persisting hypovolemia, or not (e.g., severe ventricular dysfunction). A therapeutic algorithm will allow standardized impact on ongoing management according to the hemodynamic profile identified by early echocardiography. After the completion of initial fluid resuscitation up to 30 mL/kg if required, a new echocardiographic assessment will be systematically performed by the same operator to stop or not fluid resuscitation, and to potentially initiate another treatment according to both the hemodynamic profile and clinical context.
214493335|NCT04580888|PROCEDURE|standards of care|In the control arm, patients will be treated according to standards of care based on current SSC recommendations, including a fluid resuscitation of 30 mL/kg.
214493336|NCT06608446|OTHER|Telerehabilitation|"The telerehabilitation intervention will begin from 10 days post-surgery, the operation will be carried out at home from Monday to Friday via the TeleHab device (Vald Performance) up to 2 months after the surgery.~Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week. The progression of the exercises will be carried out taking into account the pain and fatigue recorded by the patient at the end of each exercise session."
214493337|NCT06608446|OTHER|Standard Care|Standard care intervention follow the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out. It consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.
214493338|NCT06153628|OTHER|Virtual reality glasses|Videos consisting of nature and undersea images will be played through virtual reality glasses, which the woman wants to watch and can change whenever she wants.
214493339|NCT06456723|DRUG|[18F]-FET-βAG-TOCA|Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA). Patients will receive a maximum injected dose of 370MBq and will subsequently undergo PET/CT imaging.
214493340|NCT05783869|DEVICE|Echocardiography|echocardiographic study of both groups
214493341|NCT00104741|DRUG|flutamide|
214681152|NCT00941772|OTHER|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
214681153|NCT01441167|BIOLOGICAL|PfSPZ|
214681154|NCT06030895|DRUG|Sorafenib Tablets|Sorafenib Tablets (200 -400 mg) twice daily
214681155|NCT02086565|BEHAVIORAL|Portal training and home visits|patient portal training and home visits by CHW to coordinate care
214681156|NCT02086565|BEHAVIORAL|Portal training|training in use of patient portal
215088699|NCT02184429|DRUG|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
215088700|NCT00612508|DRUG|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
215088701|NCT00612508|DRUG|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
214681157|NCT03591952|PROCEDURE|Suction-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
214493342|NCT00104741|DRUG|triptorelin|
214493343|NCT00104741|RADIATION|radiation therapy|
214681158|NCT03591952|PROCEDURE|Gravity-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
214681159|NCT01595750|DRUG|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
214984261|NCT02517723|BEHAVIORAL|Dialectical Behavior Therapy|"Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.~Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings."
214984262|NCT02517723|BEHAVIORAL|Standard Inpatient Care|Unspecific group therapy that is identical in both groups (music therapy etc.)
214984263|NCT02517723|OTHER|Waiting List|Treatment as usual in the community (no DBT, no exposure of trauma memories)
214984264|NCT03950882|DRUG|PXL770|Oral capsule
214984265|NCT03950882|DRUG|Placebo|Oral capsule
214984266|NCT03035019|BEHAVIORAL|Lantern|This pilot will evaluate how the availability of a virtual stress management resource can help patients reduce anxiety and improve quality of life.
214984267|NCT04182893|DIAGNOSTIC_TEST|ctDNA and Exosome Combined Detection|Through the detection and analysis of blood and alveolar lavage fluid of 300 patients with pulmonary nodules and 100 healthy population, the diagnostic efficacy of ctDNA and exosomes combined detceion will be studied.
214984268|NCT05648734|DRUG|Corticosteroids alone|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge)
214984269|NCT05648734|DRUG|Corticosteroids + Colchicine|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days)
214984270|NCT05648734|DRUG|Corticosteroids + Pirfenidone|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
214984271|NCT05648734|DRUG|Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
214984272|NCT01590615|DRUG|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
214984273|NCT02897349|DRUG|placebo|
214984274|NCT02897349|DRUG|linagliptin|
215088702|NCT03344198|BEHAVIORAL|Circuit Training exercise & Modified Mediterranean diet|Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
214681160|NCT01595750|DRUG|Placebo|Placebo 500 mcg , 12 weeks of treatment
214681161|NCT01623778|DRUG|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
214681162|NCT02116972|DRUG|FX006 32 mg|Single 5 mL IA injection
214681163|NCT02116972|DRUG|Placebo|Single 5 mL IA injection
214984275|NCT02897349|DRUG|background therapy|insulin with or without metformin
214984276|NCT00166400|DRUG|metoprolol succinate|Treatment with potent beta-blockade titrated to the maximally tolerated dose.
214984277|NCT03468504|DEVICE|Mirror Therapy|Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.
214984278|NCT03468504|DEVICE|Placebo Mirror Therapy|"Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
214984279|NCT03468504|DEVICE|Treadmill|Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
214984280|NCT01750437|DRUG|YH1885L(Revaprazan)|
214681164|NCT02116972|DRUG|FX006 16 mg|Single 5 mL IA injection
214681165|NCT03663608|PROCEDURE|WALANT Technique|pure local anaesthesia and without use of a tourniquet (WALANT Technique) for trigger finger release surger
214681166|NCT04687202|OTHER|follow up and record|None additional intervention was applied to the subjects.
214984281|NCT01750437|DRUG|Esomeprazole 20mg|
214984282|NCT01750437|DRUG|placebo|
214984283|NCT04662333|PROCEDURE|Transcrestal approach for sinus lift|After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.
214984284|NCT04662333|PROCEDURE|Xenograft application|Before implant placement, xenogenic collagen membrane and bone granules will be pushed under the Schneiderian's membrane through the surgical site.
214984285|NCT01708603|DRUG|210 mg brodalumab|210 mg brodalumab administered SC
214984286|NCT01708603|DRUG|140 mg brodalumab|140 mg brodalumab administered SC
214984287|NCT01708603|DRUG|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
214984288|NCT01708603|DRUG|placebo|Placebo administered SC
215088703|NCT02008357|DRUG|Placebo|Administered IV
215088704|NCT02008357|DRUG|Solanezumab|Administered IV
215088705|NCT06414330|BIOLOGICAL|Ringer acetate based Del Nido cardioplegia|All patients will receive hypothermia 29 - 32 ℃ and cardioplegia will be injected between the aortic valve and aortic cross clamp in a pressure not less than 50 mmHg above systolic pressure. After removal of aortic cross clamping, the heart will be monitored for ventricular arrhythmias, early recovery, and postoperative 24 hours serum troponin and new changes in echocardiography.
215088706|NCT06414330|BIOLOGICAL|HTK|Giving HTK instead of Del Nido
215088707|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
214984289|NCT01482832|BEHAVIORAL|Interpersonal therapy-based treatment|Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
214984290|NCT00001078|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
214681167|NCT01901471|DRUG|Single bolus of Placebo of CicloMulsion® (Neurovive).|"The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
214681168|NCT01901471|DRUG|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|"The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).~Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.~CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.~CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
214681169|NCT00325442|DRUG|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
214681170|NCT00325442|DRUG|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
214681171|NCT04593498|DIAGNOSTIC_TEST|Holter recording|Holter recording with Zenicor Flex ECG during 14 days.
214681172|NCT04593498|DIAGNOSTIC_TEST|Echocardiography (Echo)|Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.
214681173|NCT04593498|DIAGNOSTIC_TEST|Blood sample|Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.
214681174|NCT04593498|DIAGNOSTIC_TEST|24 hour ambulatory blood pressure monitoring And Arteriograph|To assess artery stiffness.
214681175|NCT04024683|PROCEDURE|Serratus block with ropivacaine 2mg/ml|The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
214681176|NCT04766203|BEHAVIORAL|Treatment of REDS using a holistic treatment arm|This arm aims to treat athletes with REDS symptoms by implementing a holistic, individualized nutrition intervention to improve energy availability and thus restore impaired body function due to REDS.
214681177|NCT00875784|DRUG|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
214681178|NCT00875784|DRUG|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
214681179|NCT00875784|DRUG|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
214984291|NCT06157424|OTHER|Thread Embedding Acupuncture|Thread Embedding Acupuncture is applied at acupoints including CV-12, CV-13, ST-36, PC-6, BL-17, BL-18, BL-21 on both sides of the body every 2 weeks, totaling 2 sessions over 4 weeks of intervention.
214984292|NCT06157424|OTHER|Auricular acupuncture|Auricular acupuncture is administered using adhesive patches with small needles (0.25 x 1.3 mm) placed at acupoints TF4, AH6, CO12, CO4, CO2 once a week, totaling 4 sessions over the 4-week intervention period.
214984293|NCT06157424|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
214984294|NCT05517590|DRUG|Tranexamic acid|1 gram of tranexamic acid will be diluted into 100 ml of saline solution and administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
214984295|NCT05517590|DRUG|Saline|100 ml of saline solution will be administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
214984296|NCT03456323|BEHAVIORAL|Palliative Care Consultation|The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
214984297|NCT03456323|OTHER|Usual Care|Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
214984298|NCT06275399|DIAGNOSTIC_TEST|OCT examination|OCT examination for precise evaluation of plaque morphology within the coronary stenosis.
214984299|NCT06275399|DIAGNOSTIC_TEST|Blood sampling|Blood sampling directly from coronary artery (proximal and distal segment) arteries
214681180|NCT00875784|DRUG|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
214984300|NCT06275399|DIAGNOSTIC_TEST|Assessment of vFFR and shear stress parameters|The procedure is based on non-invasive assessment of vFFR and shear stress parameters with dedicated software, deriving parameters directly from coronary angiography with the calculation based on the computational fluid dynamics
214493344|NCT03357952|DRUG|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week for 8 weeks (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).
214984301|NCT05051163|DRUG|Ceftriaxone Sodium|7 days of once daily dosing
214984302|NCT05051163|DRUG|Ampicillin|7 days of 6 hourly dosing
214984303|NCT05051163|DRUG|Gentamicin|7 days of once daily dosing
214984304|NCT00244309|DRUG|tamsulosin and/or dutasteride|
214984305|NCT06064201|OTHER|Short-chain fatty acids (SCFAs)|The SCFAs mixture contains acetate, butyrate, and propionate in a ratio of 60:20:20, and the total daily amount of SCFAs is equivalent to the fermentation of 10g of arabinoxylan oligosaccharides. Participants will be asked to consume these capsules spread at four intervals throughout the day. The nursing staff will distribute the capsules to the participants individually, supervise their intake, and monitor adherence by capsule count.
215088708|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
215088709|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
214493345|NCT03357952|DRUG|JNJ-63723283|Participants will receive JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter.
214493346|NCT06867731|PROCEDURE|Endosonographic Elastography|The patient will undergo a standard-of-care endoscopic ultrasound with liver biopsy. At the time, elastography of the liver and spleen will be performed while using the echoendoscope. Different degrees of pressure will be applied while performing elastography of the left and right lobes of the liver as well as the spleen. The E values and VsN values will be recorded and then compared to liver histology.
215088710|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
214493347|NCT06867731|DIAGNOSTIC_TEST|Endosonographic shear wave elastography|The patient will undergo an upper endoscopic ultrasound procedure. During this procedure, the patient will be put to sleep and a trained endosonographer physician will insert an echo-endoscope through the mouth and guide it down to the stomach and the duodenum. This endoscope is equipped with technology that uses sound waves to assess the stiffness of the liver and spleen. For research purposes, the doctor will also press on these organs in order to take the additional measurements.
214493348|NCT06613490|BIOLOGICAL|anti CD19 CAR NK cells|This study is a single-arm, open-label and single-center exploratory clinical study to evaluate the safety and effectiveness of anti CD19 CAR NK cells in patients with refractory antisynthetase antibody syndrome (ASyS) and rheumatoid arthritis (RA). All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by Anti-CD19 CAR NK cells infusion.
214681181|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal bupivacaine will be administered at the L3-L4 intervertebral level with 10-15 mg bupivacaine while the patient is in a sitting position.The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
214681182|NCT06298370|DRUG|Intrathecal bupivacaine and morphine|Patients will receive intrathecal bupivacaine and morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
214984306|NCT06064201|OTHER|Placebo|To serve as a placebo, microcrystalline cellulose will be included in the same type of CDCs.
214984307|NCT04054297|BEHAVIORAL|High GI/SFA diet|Subject will adhere to a 2 week high GI/SFA diet.
214984308|NCT04054297|BEHAVIORAL|Low GI/SFA diet|Subject will adhere to a 2 week low GI/SFA diet.
214984309|NCT02399332|OTHER|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
214984310|NCT00235807|PROCEDURE|Tinnitus Masking|Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.
214984311|NCT00235807|PROCEDURE|Tinnitus Retraining Therapy (TRT)|The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).
215088711|NCT00787202|OTHER|placebo|Administration via oral route twice daily for the duration of treatment
214984312|NCT00235807|PROCEDURE|Tinnitus Education (TED)|TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
214984313|NCT00388921|DRUG|Vitamin A|
214984314|NCT03620448|DEVICE|bCPAP Arm|bCPAP (Rice 360◦c low cost bCPAP device)
214984315|NCT03620448|OTHER|Oxygen Arm|Oxygen therapy from oxygen cylinders
215088712|NCT00060814|OTHER|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
215088713|NCT05544630|DEVICE|computerized dynamic posturography (sensory orgnization test)|assess of an individual's ability to maintain static and dynamic stance. The assessment is composed of a battery of tests that are similar to everyday conditions of daily living. There are four main components to CDP that are used clinically: the Sensory Organization Test (SOT),
215088714|NCT04294316|DIAGNOSTIC_TEST|Sonovue|Twice dose of 2.4ml of Sulphur hexafluoride microbubbles contrast Sonovue administration to evaluate brain microcirculation
214984316|NCT03791320|DIAGNOSTIC_TEST|Vessel Fractional Flow Reserve|FFR measurement based on coronary angiography
214984317|NCT03287544|OTHER|Combined rehabilitation|Linguistic training as well as communication training.
214984318|NCT03287544|OTHER|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
214681183|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine and morphine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal drugs. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a S22 Gauche 80 mm block needle. Subarachnoid block will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
214681184|NCT01165801|PROCEDURE|Cataract Surgery|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
214681185|NCT00277472|DRUG|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
214681186|NCT00277472|DRUG|HCTZ|25 mg taken once daily orally
214984319|NCT00906243|BIOLOGICAL|CV9103|CV9103 encodes for 4 prostate specific antigens.
214984320|NCT01027949|DRUG|Oral Treprostinil|Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
214984321|NCT01416038|BIOLOGICAL|DPX-Survivac|Vaccine targeting survivin antigen will be administered subcutaneously.
214984322|NCT01416038|DRUG|low dose cyclophosphamide (oral)|Low dose cyclophosphamide will be taken by mouth.
214984323|NCT02426697|DRUG|fentanyl transmucosal|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
214984324|NCT02426697|DRUG|Placebo|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
214984325|NCT05945407|COMBINATION_PRODUCT|Indication-extended Fertility-sparing Therapy|"Patients will receive medroxyprogesterone acetate (FARLUTAL) 250-500mg/d or megestrol acetate (YiLiZhi) 160-320mg/d orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (Mirena) and gonadotropin-releasing hormone agonist (Leuprorelin, Goserelin or Triptorelin) 3.75mg/28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (Mirena, Progesterone, Dydrogesterone, or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions."
214984326|NCT03773874|OTHER|Assessment|Evaluation
214984327|NCT03258255|PROCEDURE|penil or pudendal nerve block in circumcision|regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision
214984328|NCT03897335|DRUG|Aminophylline|Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.
214984329|NCT03897335|DRUG|Placebo|The placebo group will not receive any aminophylline treatments for the first post-op five days
215088715|NCT02584387|BEHAVIORAL|3D Video Virtual Reality Exposure Therapy|The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
214681187|NCT00216606|DRUG|topiramate|
214984330|NCT05563558|DRUG|Pembrolizumab|Included in arm/group description
215088716|NCT02479581|PROCEDURE|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
214984331|NCT05563558|DRUG|Carboplatin|Included in arm/group description
214984332|NCT05563558|DRUG|Cabazitaxel|Included in arm/group description
214984333|NCT03353077|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214984334|NCT00587665|DRUG|ketamine|Single IV dose of 0.1 mg/kg of ketamine
214984335|NCT00587665|DRUG|Placebo|Saline given of equal volume to drug
214984336|NCT03703895|DRUG|Topical AFX5931|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
214984337|NCT03703895|DRUG|Topical Placebo|Placebo Comparator, Topical Placebo.
214984338|NCT00338117|DRUG|Galantamine hydrobromide|
214984339|NCT00671749|DRUG|adapalene gel, 0.3%|Applied once daily at bedtime
214984340|NCT00671749|DRUG|clindamycin/benzoyl peroxide gel|Applied once daily in the morning
214984341|NCT05236530|DRUG|Midazolam|Midazolam 2 mg (1 mL of 2 mg/mL oral solution) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
214984342|NCT05236530|DRUG|Repaglinide|Repaglinide 0.5 mg (1 x 0.5 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
214984343|NCT05236530|DRUG|Dextromethorphan|Dextromethorphan 15 mg (10 mL of 7.5 mg/5 mL syrup) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
214984344|NCT05236530|DRUG|Metformin|Metformin 500 mg (1 x 500 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
214984345|NCT05236530|DRUG|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 4-probe cocktail co administered on the morning of Day 3.
214984346|NCT05236530|COMBINATION_PRODUCT|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
214681188|NCT00789477|PROCEDURE|Laser Photocoagulation|laser every 16 weeks as needed
214984347|NCT05236530|DRUG|Rosuvastatin|Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
214984348|NCT05236530|DRUG|Dolutegravir|Dolutegravir 50 mg (1 x 50 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
214984349|NCT05236530|DRUG|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 2-probe cocktail co administered on the morning of Day 3.
214984350|NCT05236530|COMBINATION_PRODUCT|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
214681189|NCT00789477|DRUG|Intravitreal Aflibercept Injection|
214984351|NCT00129636|PROCEDURE|Additional specific letter written to patient|
214984352|NCT02515227|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
214984353|NCT02515227|DRUG|Pembrolizumab|Humanized monoclonal antibody (mAb) specific for PD-1.
214984354|NCT00413517|PROCEDURE|Epi-Lasik|A vision correcting surgery
214984355|NCT03731013|BEHAVIORAL|Mediterranean diet (MedDiet)|Participants randomized in the Mediterranean diet group without physical activity will be instructed and supported towards adhering to principles of the Mediterranean diet, without changes in physical activity habits.
214984356|NCT03731013|BEHAVIORAL|Physical activity (PA)|Participants randomized in the group physical activity without Mediterranean diet will participate in a structured, supervised PA program to achieve 150 min of moderate PA per week, without changes in dietary habits.
214984357|NCT03731013|BEHAVIORAL|Mediterranean diet and physical activity|The combination group (MedDiet + PA) will receive the combination of both interventions.
214984358|NCT03318172|DEVICE|Spinal Cord Stimulator|Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
214984359|NCT05755126|BEHAVIORAL|Iatrosedation|Alleviating the anxiety of patients by iatrosedative interview and clinical encounter
214984360|NCT05755126|BEHAVIORAL|Musical Therapy|Patients were provided with headphones and a playlist to listen to the music of their choice for 10 minutes
214984361|NCT02023489|DEVICE|1H/ 13C and 31P Magnetic Resonance Spectroscopy|Study participants will be studied in the fasting state after an overnight fast of at least 10 h. Participants will arrive at the MR-Centre in the morning of the study. Between 6:30 and 10:00 a.m., 1H MRI (3T) will be performed for the assessment abdominal adipose tissue distribution and composition as well as myocardial functional parameters. 1H/13C MRS examinations (7T) will be performed for measurements of myocardial, skeletal muscle and liver lipid content and composition as well as glycogen content. Additionally, ATP synthesis and energy metabolism will be assessed.
214984362|NCT02023489|OTHER|Meal Tolerance Test|"A meal tolerance test meal tolerance test according to Petersen et al. (PNAS, Vol 104, 2007) will be performed. After MRI and MRS examinations subjects will be returned at our outpatients clinic, where small polyethylene catheter will be inserted in an antecubital vein for hourly blood sampling. At 10:30 a.m. and 1:30 p.m. two liquid high carbohydrate meals of equal size containing all the required daily energy (30 kcal/kg of body weight; 55% carbohydrate, 10% protein, and 35% fat) with an additional 25% of the daily energy requirements added in the form of sucrose will be served.~At 5 p.m. subjects will be returned at the MR - Centre for postprandial 1H / 13C MRS (7T) of muscle, liver and myocardial lipid and glycogen contents. Myocardial function parameters and abdominal fat distribution will be assessed again by 1H MRI (3T)."
214984363|NCT02023489|OTHER|Hyperglycemic-hyperinsulinemic clamp|"All volunteers will be admitted in the morning and basal 13C tracer enrichment will be assessed.~At 8:00a.m. (0 min) a hyperglycemic-hyperinsulinemic-pancreatic clamp test will be initiated by somatostatin (-5-300 min: 0.1 µg·kg-1·min-1, UCB Pharma, Vienna, Austria) and insulin (0 - 8 min: 80 mU·min-1·m-2 body surface area; 8 -300 min: 40 mU·min-1·m-2 body surface area) infusion. Plasma glucose will be raised and maintained at \~180 mg·dL-1 by primed (0.2 g·kg-1)-variable dextrose infusion (20%w/v) enriched with \[1-13C\]glucose (40%w/w). A second catheter will be placed into an antecubital vein of the other arm and blood samples for the measurement of glucose, insulin and c-peptide. Glucose concentrations will be analysed immediately every 5 minutes, employing a glucose analyser. Myocardial glycogen concentrations will be measured before the clamp (-60 - 0 min) and from 90 min to 180 min during the clamp employing 13C MRS."
214984364|NCT03451071|DRUG|Gardasil9|Gardasil 9
215088717|NCT02479581|PROCEDURE|ERAS group|"1. No routine bowel preparation;~2. Normal eating 1 days before the operation;~3. No drinking 2h and solid food 6h before the operation;~4. Drink 10% glucose 250ml 3h before operation ;~5. Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);"
215088718|NCT02479581|PROCEDURE|ERAS group|Emphasize the preoperative psychological preparation for patients.
214681190|NCT03908788|DEVICE|Intplex test|Blood sample at each tumor assessment
214681191|NCT04232891|DIAGNOSTIC_TEST|liquid biopsy|detection of tumor DNA alteration in cf-DNA
214681192|NCT05535673|DRUG|ThisCART19A|In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
214681193|NCT01654497|DRUG|Dexanabinol|"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg"
214681194|NCT05930925|DRUG|[phenyl-14C]ARV-471|Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth
214681195|NCT05930925|DRUG|[oxoisoindolin-14C]ARV-471|Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth
214681196|NCT00138125|DRUG|Faslodex|Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.
214681197|NCT00138125|BIOLOGICAL|Herceptin|Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly
214681198|NCT05468450|DRUG|Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant|Direct injection Foam sclerotherapy
214681199|NCT05468450|DEVICE|Endovenous Laser Ablation (EVLA)|EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
214984365|NCT06228989|PROCEDURE|Restorative therapy|Restorative treatment of first permanent molars affected with severe MIH
214681200|NCT04429425|PROCEDURE|epidural anesthesia|epidural anesthesia through epidural injection of a local anaesthetic combined with an opioid
215088719|NCT02479581|PROCEDURE|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
214681201|NCT05979129|OTHER|zero PEEP|zero end-expiratory pressure during face mask ventilation
214681202|NCT05979129|OTHER|low PEEP|4 cmH2O PEEP during mask ventilation
214984366|NCT06228989|PROCEDURE|Extraction therapy|Extraction treatment of first permanent molars affected with severe MIH
214984367|NCT01901185|DRUG|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
214984368|NCT01530919|PROCEDURE|Minimally invasive radioguided parathyroidectomy|After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
214984369|NCT04005872|DRUG|Nano Silver Fluoride|Nano silver fluoride (NSF) is a new material consisting of nano silver particles, chitosan and sodium fluoride. It is a bacteriostatic and bactericidal compound.
214984370|NCT04005872|DRUG|Calcium hydroxide|Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
215088720|NCT02479581|PROCEDURE|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
215088721|NCT02479581|PROCEDURE|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
214681203|NCT05979129|OTHER|high PEEP|8 cmH2O PEEP during mask ventilation
214681204|NCT00002056|DRUG|Pentamidine isethionate|
214681205|NCT00123526|BEHAVIORAL|Diet|Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.
214681206|NCT00123526|BEHAVIORAL|Physical Activity|The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
214681207|NCT01242020|DRUG|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
214984371|NCT04133389|OTHER|Growth mindset of personality educational intervention|This is a brief online educational intervention that teaches growth mindset of personality. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
214984372|NCT04133389|OTHER|Growth mindset of athletic ability educational intervention|This is a brief online educational intervention that teaches growth mindset of athletic ability. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
214984373|NCT01934179|OTHER|cytology specimen collection procedure|Undergo blood sample collection
214984374|NCT01934179|OTHER|laboratory biomarker analysis|Correlative studies
214369681|NCT02832622|DEVICE|BiV/MPP|MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., BiV pacing ON at some point in months 1-9 and MPP ON for months 10-12)
214681208|NCT03418402|DEVICE|Airseal®|Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
214681209|NCT03418402|DEVICE|Standard insufflator|Standard insufflator
214681210|NCT01695980|PROCEDURE|ETT with non modified retractor|adenotonsillectomy
214681211|NCT01695980|OTHER|LMA with modified retractor|LMA with modified retractor
214681212|NCT04521959|PROCEDURE|Blood flow restricted and normal aerobic exercise and resistance exercise|Interventions of the same duration and intensity will be applied to two groups.
214681213|NCT06661265|PROCEDURE|adjuvant tomotherapy +- chemotherapy after the reconstructive surgery with flaps|adjuvant treatment in locally-advanced head and neck cancers submitted to upfront surgery with flap reconstruction, evaluation of toxicity and flap status performed at San Raffaele Hospital between December 2017-December 2022.
214984375|NCT01934179|OTHER|questionnaire administration|Ancillary studies
214984376|NCT02039349|DRUG|PF-05190457|
214984377|NCT03502798|DEVICE|scanning a/LCI|Imaging of the cervical epithelium using the scanning a/LCI device.
215088722|NCT02479581|PROCEDURE|ERAS group|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~2. Goal-directed fluid management."
215088723|NCT02479581|PROCEDURE|ERAS group|"1. Infusion of Human Albumin Grifol®20% 50ml;~2. Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~3. Shorten the Cardio-pulmonary Bypass line；~4. Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)"
215088724|NCT02479581|PROCEDURE|ERAS group|Monitor urine volume closely, over 0.5ml/kg·h.
214681214|NCT00890630|PROCEDURE|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
214681215|NCT00890630|DRUG|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
214681216|NCT06539845|BEHAVIORAL|Outbreak Preparedness Intervention for the Orang Asli|"The chosen villages will be given the intervention package, which includes a workshop, simulation exercises, and a card game, in addition to educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This entire package will be delivered once, during the workshop, after they have answered the survey at T0."
215088725|NCT02479581|PROCEDURE|ERAS group|Protective ventilation strategy：Low tidal volume about 6\~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
215088726|NCT02479581|PROCEDURE|ERAS group|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia:~   * Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1\~0.4ug/kg·min, Propofol Injection 2\~6mg/kg·h, Sevoflurane 0.5\~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06\~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
215088727|NCT02479581|PROCEDURE|ERAS group|"1. Drink water after 6h, 200ml once, 2\~3 times / day，~2. early ambulation，mobilization within 48 h,~3. Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~4. Intravenous the lansoprazole 30mg q12h."
214681217|NCT06539845|BEHAVIORAL|Educational Brochures for the Orang Asli|"The chosen villages will be given educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This will be given once during the first encounter with the participant, after they have answered the survey at T0."
214681218|NCT02621268|DRUG|Indocyanine Green|Infusion of ICG 24 hours prior to surgery
214984378|NCT05850715|DIAGNOSTIC_TEST|Disability Assessment for Dementia (DAD)|The scale consists of 40 items and assesses patients' independence in basic and instrumental activities. The scale is completed by the patient's caregiver with the assistance of the assessor-therapist.
214984379|NCT02197156|DRUG|10 mg HC-ER|Single dose
214681219|NCT05837260|OTHER|Sample collection only|Sample collection only
214681220|NCT04819425|DEVICE|Elastic Adhesive Strips|Securement of Endotracheal tube with Elastic Adhesive Strips
214681221|NCT04819425|DEVICE|Lace in A Protective Sheath|Securement of Endotracheal tube with Lace in A Protective Sheath
214681222|NCT02021422|DRUG|anakinra|Dosage Route Administration 100 mg SC Every Other Day
214984380|NCT02197156|DRUG|20 mg HC-ER|Single dose
215088728|NCT02479581|PROCEDURE|Conventional control group|Routine preoperative psychological preparation for patients.
215088729|NCT02479581|PROCEDURE|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
214681223|NCT02021422|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 2-4 hours
214681224|NCT02021422|DRUG|Irinotecan|Irinotecan 180 mg/m2 90 minutes
214681225|NCT02021422|DRUG|fluorouracil|fluorouracil 2400 mg/m2 48 hours
214681226|NCT03213639|DRUG|Esomeprazole 40 mg Oral Tablet|once daily oral tablets
214681227|NCT03213639|DRUG|Placebo Oral Tablet|once daily oral tablets
214681228|NCT00775372|DRUG|Clarithromycin 250mg/5mL|
214681229|NCT03854955|OTHER|iScribes|Device-based scribing service.
214681230|NCT02185599|DEVICE|DySIS|Colposcopy performed with the DySIS digital colposcope
214681231|NCT04107012|DEVICE|Orthodontic treatment with clear aligner|Included orthodontic treatment with clear aligner (eon Aligners)
214681232|NCT02612714|DRUG|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
214681233|NCT01070355|DRUG|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
214681234|NCT01070355|DRUG|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
214681235|NCT03307447|DRUG|Secukinumab|Secukinumab 300 mg subcutaneous injection
214681236|NCT00294593|DRUG|folinic acid|
214681237|NCT05198167|OTHER|Hyperoxygenated fatty acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
214681238|NCT05198167|OTHER|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
214681239|NCT01221545|DRUG|AZD1656|3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
214681240|NCT01221545|DRUG|Placebo|Placebo
214681241|NCT01161524|DRUG|Perampanel|2 mg titrated up to 8-12 mg maximum; taken once daily.
214681242|NCT01161524|DRUG|Placebo|Matching Placebo taken once daily.
214984381|NCT02197156|DRUG|30 mg HC-ER|Single dose
214984382|NCT02197156|DRUG|40 mg HC-ER|Single dose
214984383|NCT02197156|DRUG|10 mg HC / 325 mg APAP|Single dose
214984384|NCT02197156|DRUG|Matching Placebo|Single dose
215088730|NCT02479581|PROCEDURE|Conventional control group|"1. Routine bowel preparation;~2. Liquid food eating 2 days before the operation;"
215088731|NCT02479581|PROCEDURE|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
215088732|NCT02479581|PROCEDURE|Conventional control group|"1. Induction use Sufentanil 0.5\~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2\~0.6mg/kg,Midazolam0.05\~0.1mg/kg ;~2. Maintain use Sufentanil 1\~2ug/kg·h, Propofol 4\~12mg/kg·h, Sevoflurane 1\~3(minimal alveolar concentration)， Vecuronium 0.06\~0.12mg/kg·h;"
215088733|NCT02479581|PROCEDURE|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
215088734|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
215088735|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g before the operation
214984385|NCT02914327|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
214984386|NCT00591877|PROCEDURE|Acupuncture|"Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~* ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~* PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~* CV-12: 4 finger breadths superior to the umbilicus."
215088736|NCT06390787|DRUG|Metoclopramide and Vitamin B6|We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.
215088737|NCT06390787|DRUG|Vitamin B6|We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.
215088738|NCT06390787|DRUG|Ondansetron|We gave only Zofran as a treatment for managing nausea and vomiting.
214984387|NCT00591877|PROCEDURE|Sham Acupuncture|"The acupoints for SAC are:~* LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~* GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~* UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae."
215088739|NCT06390787|DRUG|Metoclopramide|We gave only Metoclopramide as a treatment for managing nausea and vomiting.
214984388|NCT00591877|OTHER|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
214984389|NCT03835039|DEVICE|NIRS|Monitoring cerebral and perirenal perfusion using NIRS
215088740|NCT04551001|PROCEDURE|Cold forcep polypectomy|Removal of appropriate polyps using cold forceps until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
215088741|NCT04551001|PROCEDURE|Cold snare polypectomy|Removal of appropriate polyps using cold snare until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
215088742|NCT01969617|DRUG|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
215088743|NCT01969617|DRUG|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
215088744|NCT04070196|DIAGNOSTIC_TEST|Periplex|Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
215088745|NCT01442064|DRUG|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
215088746|NCT04644744|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
214369682|NCT05011643|OTHER|Moderate-intensity exercise|Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.
214369683|NCT01058538|DRUG|L19IL2|Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
214369684|NCT05001438|PROCEDURE|Hidro|Guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
214369685|NCT05001438|PROCEDURE|MUA|Movilization under anesthesia
214369686|NCT02472652|DRUG|Abilify Maintena|For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
214369687|NCT01053260|BEHAVIORAL|LEARN Program|Participants will receive weekly counseling based on the LEARN Program for Weight Management
214369688|NCT01053260|BEHAVIORAL|Contingency Management|Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
214369689|NCT00001790|DRUG|FK463|
214369690|NCT03460457|DRUG|TQB2450|Pharmacokinetics/Dynamics Study
214369691|NCT03704584|DRUG|Treatment Group: Corticosteroid injection|Subjects will receive a corticosteroid injection that is 40 mg/mL injection of Methylprednisolone or 40mg/mL injection of methylacetate injectable suspension or 40 mg/mL triamcinolone.
214369692|NCT03704584|DRUG|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .
214369693|NCT03704584|DRUG|Treatment Group: Lidocaine|Subjects will receive an injection of lidocaine (1% lidocaine HCl).
214369694|NCT03185832|DEVICE|CRT-D|This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
214369695|NCT03185832|DEVICE|ICD|This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
214681243|NCT00339079|DRUG|Fluoxetine|Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
214681244|NCT00339079|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
214681245|NCT00339079|OTHER|Supportive Therapy|The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
214984390|NCT03253822|OTHER|Decision aid|The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
214681246|NCT00339079|DRUG|Placebo|Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
214681247|NCT04211545|DRUG|Rabeprazole|Rabeprazole
214681248|NCT04211545|DRUG|CC-92480|CC-92480
214681249|NCT04946344|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
214984391|NCT00445718|PROCEDURE|computed tomography|
214681250|NCT04946344|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive phone calls/emails/texts.
214984392|NCT00445718|PROCEDURE|3-Tesla magnetic resonance imaging|
214984393|NCT00445718|PROCEDURE|Abdominal Sonogram|Sonogram of the abdomen area
214984394|NCT00156260|PROCEDURE|Ductal lavage|
214984395|NCT03341520|DRUG|Obinutuzumab Injection [Gazyva]|7x 1000mg flat dose
214984396|NCT03341520|RADIATION|Low dose radiation Therapy (LDRT)|2 x 2 Gy
214984397|NCT05439564|DRUG|Dexmedetomidine|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
214369696|NCT03185832|DEVICE|PM / CRT-P|This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
214369697|NCT03185832|OTHER|Non-device|Patient enrolled but not implanted with a Defibrillator or Pacemaker
214369698|NCT00004935|DRUG|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
214369699|NCT00004935|DRUG|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
214681251|NCT04089124|PROCEDURE|surgery of zone II cut flexor repair|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture
214681252|NCT02688010|BEHAVIORAL|Noise reduction and cycled light|Reduced noise exposure (sound levels \<45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
214681253|NCT03210285|DIAGNOSTIC_TEST|Whole exome sequencing|Whole exome sequencing
214984398|NCT05439564|DRUG|Morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
214984399|NCT05439564|DRUG|Dexmedetomidine|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
214984400|NCT00296335|DRUG|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
214984401|NCT00296335|DRUG|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
214984402|NCT03331081|OTHER|Bladder Training|The patient will participate in a class in which the physiotherapist will provide the following information: on the anatomy and function of the MAP, using figures; on bladder function; guidelines on the positioning and voiding habits and the definition and main risk factors responsible for urinary incontinence. The bladder training will consist of a program of time micturition to increase bladder capacity and the interval between urinations. Urge suppression strategies will be targeted, and include distraction, relaxation, breathing, and MAP contraction (quick flicks).
214681254|NCT02430792|BEHAVIORAL|Football|The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
214681255|NCT01011062|PROCEDURE|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
214681256|NCT01011062|DRUG|Losartan|Acute administration of losartan 200mg total prior to clamp
214681257|NCT01011062|DRUG|Saline|Infusion of Saline as a volume control intervention
214681258|NCT02764866|OTHER|Sleep testing|Home sleep testing
214681259|NCT03336840|DRUG|Metformin tablets|0.5g (1 pill) of Metformin tablets administered three times a day orally before meal
214681260|NCT03336840|DRUG|ProMetS probiotics powder|4g (2 strips) of ProMetS probiotics powder administered orally every night
214681261|NCT03336840|DRUG|1. Metformin tablets; 2. ProMetS probiotics powder|"1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
214681262|NCT03224637|PROCEDURE|radiofrequency|radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
214681263|NCT03224637|DRUG|Paracetamol (conventional)|
214984403|NCT03331081|OTHER|TMAP|There will be 36 monthly series of home training (totaling at the end of the 3 months of treatment 108 series) performed 3x / week, 3x / day. The training protocol consists of three daily TMAP series. One series consists of 8 maximum voluntary contractions, with maintenance of the contraction of 6 to 10 seconds (type I muscle fibers), with twice the rest time between contractions, followed by three to five rapid contractions (muscle fibers type II ). The protocol will total 24 contractions of MAP per day performed, which will be divided in the morning (8 contractions), late (8 contractions) and night (8 contractions).
214984404|NCT03331081|OTHER|Bladder Training + TMAP|Will perform the exercises of the bladder training group and the TMAP in an associated way.
214984405|NCT01401322|DRUG|Lenalidomide|50 mg; po
214984406|NCT05230836|OTHER|High-frequency alternating current stimulation|"For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group"
214681264|NCT03224637|DRUG|Ketorolac Tromethamine (conventional)|
214984407|NCT05230836|OTHER|Sham current stimulation|"Sham electrical stimulation will be performed with the same equipment and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) is exceeded and once the threshold is reached, the intensity will be reduced to 0 mA with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants."
214984408|NCT03980912|DIAGNOSTIC_TEST|LiverFASt|LiverFASt™ is a blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease. The test is non-invasive, simple, and less expensive than liver biopsy or liver imaging.
214984409|NCT02737722|DRUG|Bisphosphocin Nu-3|
214984410|NCT02737722|DRUG|Placebo|
214681265|NCT00564629|DRUG|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
214984411|NCT06032663|DIAGNOSTIC_TEST|PET-MRI|Patients that participate in the current study will have an extra PET-MRI scan, which will expose them to a small amount (4 - 6 mSv) of extra radiation.
214984412|NCT00518570|DRUG|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
214984413|NCT06471439|OTHER|single leg exercise intervantion in COPD|"single leg exercise intervantions~1. high intensity interval training~2. continous exercise training~3. resistance exercise training"
214984414|NCT00875316|DRUG|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
215088747|NCT04644744|DEVICE|Normothermic machine perfusion (NMP)|End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
215088748|NCT04363593|BIOLOGICAL|Serological test|Serological testing is performed for patients with confirmed COVID-19 infection by RT-PCR.
214369700|NCT02127619|DEVICE|Total knee replacement with the ROCC® knee prosthesis|replacement of an osteoarthritic knee with a total knee prosthesis operation may be for a single knee ( unilateral) or both knees of a patient ( bilateral)
214369701|NCT04563325|DRUG|Oral co-amoxiclav or oral dicloxacillin only|High dose oral treatment followed by standard dose oral treatment
214369702|NCT04563325|DRUG|IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin|IV treatment followed by standard dose oral treatment
214369703|NCT01528449|BIOLOGICAL|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
214681266|NCT00564629|DRUG|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
214681267|NCT00564629|BIOLOGICAL|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
214681268|NCT04822922|GENETIC|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4\*10\^5 cells/kg/each time, and medium dose: 8\*10\^5 cells/kg/each time, high dose 12\*10\^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.
214681269|NCT00818038|DRUG|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
215088749|NCT04363593|BIOLOGICAL|Serum test|Use of the serum taken from patients consulted for suspicion of COVID-19 before the beginning of the trial
215088750|NCT05781958|DRUG|Cadonilimab+Gem/Cis|Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m\^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m\^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine（1000 mg/m\^2 orally according to Body Surface Area (BSA)，BID，Q3W，on Days 1-14）as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.
214681270|NCT03094936|PROCEDURE|APC|Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
214369704|NCT01528449|BIOLOGICAL|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
214681271|NCT03094936|DEVICE|Endoscopic Suture Technique (OverStitch TM)|OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
214681272|NCT02828319|DRUG|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
214984415|NCT03918057|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based psychotherapeutic intervention that combines cognitive and behavioural principles. Specifically, this therapy provides psychoeducation about thoughts contributing to the maintenance of sleep problems, and instruction in behavioural techniques to help decrease sleep onset latency and promote effective sleep maintenance.
214984416|NCT03918057|OTHER|Active Control|Participants will receive regular obstetric care and will be placed on a wait-list for CBT-I treatment after their final assessment. All activities women try for improving their own sleep problems between assessments will be recorded and coded for.
214984417|NCT00318695|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
214984418|NCT00318695|OTHER|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
214984419|NCT01100424|DEVICE|Opti-Free RepleniSH|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
214984420|NCT01100424|DEVICE|ReNu MultiPlus|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
214984421|NCT01100424|DEVICE|Balafilcon A|Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.
214984422|NCT01100424|OTHER|Unisol 4|Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
214984423|NCT04527588|OTHER|Questionaire Michigan|Patient-Reported Outcome Measures (PROMs) are important clinical items for evaluating injuries and recovery of the hand. The Michigan Hand Questionnaire is one of the most important.
214984424|NCT00746005|DIETARY_SUPPLEMENT|fish oil|3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg
214984425|NCT00746005|DIETARY_SUPPLEMENT|placebo, sunflower oil|3 g of sunflower oil
214369705|NCT03881280|BEHAVIORAL|Parenting education program|"Parenting education program through the app Fammeal. It includes educational content, tailored to parents and centered on positive parenting child-feeding practices. The app will also include a virtual-pet game for children, in order to help them self-regulate their intake.~Through the app, parents will:~* Fill in a registration questionnaire, which will tailor recommendations.~* Receive information and video content recommendations.~* Set goals related to their child's lifestyle and tracking progress.~* Earn points by watching the contents.~* Invite children to play a serious game.~* Exchange messages with other users.~The investigators created a support website that connects to the main server to get data gathered from the mobile app and game."
214984426|NCT00226369|DRUG|CY-1503|
214984427|NCT01012427|PROCEDURE|percutaneous cryoablation|All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase \> 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
214369706|NCT04234724|OTHER|Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.|Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
214369707|NCT02352441|OTHER|Implementation Intentions(II)|"Implementation Intention training will include:~Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals."
214369708|NCT00003084|DRUG|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
214369709|NCT00003084|DRUG|Estramustine phosphate sodium|"Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle."
214369710|NCT00003084|DRUG|Etoposide|Oral etoposide twice daily on days 1-14.
214369711|NCT00003084|DRUG|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
214369712|NCT00003084|DRUG|Paclitaxel|IV over 1 hour on day 2.
214369713|NCT00003084|DRUG|Vinblastine|IV on days 8, 22, and 36.
214681273|NCT03826953|OTHER|Nurse Led Allergy Clinic|Project to investigate if it is feasible to establish a nurse-led primary care-based allergy clinic intervention in NHS Lothian, and to understand the acceptability and estimate the impact of this service on improving access and outcomes in patients with allergic conditions.WE will undertake a mixed-methods longitudinal evaluation of the community-based nurse-led allergy clinic.
214681274|NCT03634072|PROCEDURE|PVR|Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
214984428|NCT01841372|OTHER|Second Life|Second Life is an online virtual reality environment.
214984429|NCT01841372|BEHAVIORAL|Group Phone Conference Call|
214984430|NCT04149080|PROCEDURE|SIM + polypropylene membrane|After tooth extraction the socket will be filled with 1.2% simvastatin gel and covered with polypropylene membrane, which will be intentionally exposed.
214984431|NCT04149080|PROCEDURE|Placebo|After tooth extraction the socket will be filled with gel and covered with polypropylene membrane, which will be intentionally exposed.
214984432|NCT00622765|DRUG|placebo|Placebo capsule twice daily
214369714|NCT01750762|DRUG|Lenalidomide|
214681275|NCT02466269|PROCEDURE|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
214681276|NCT06106425|DIAGNOSTIC_TEST|EEG|diagnostic tool
214984433|NCT00622765|DRUG|R256918|5 mg capsule twice daily
214984434|NCT00622765|DRUG|R256918|10 mg capsule twice daily
214984435|NCT00622765|DRUG|R256918|15 mg capsule twice daily
214369715|NCT02421562|PROCEDURE|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
214369716|NCT02955030|BIOLOGICAL|NSV0001|sublingual
214984436|NCT02219256|DRUG|TAK-079|TAK-079 solution
214984437|NCT02219256|DRUG|Placebo to TAK-079|Placebo to TAK-079 solution
214984438|NCT02678819|DEVICE|Digital cognitive aid|Digital cognitive aid during anesthesia and intensive care crises.
214984439|NCT06233708|DRUG|Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use|Non-selective blocker including Propranolol, Carvedilol PO was prescribed
214984440|NCT03880513|DIAGNOSTIC_TEST|Cardiovascular status and quality of life|Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment
214984441|NCT00454298|DRUG|AGG-523 (Aggrecanase Inhibitor)|
214984442|NCT00998153|BEHAVIORAL|Risk Reduction through Family Therapy|Component based intervention based on existing empirically supported treatments
214984443|NCT00833326|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
214984444|NCT00833326|DRUG|Docetaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
214984445|NCT00833326|DRUG|Prophylactic growth factors; subcutaneous|standard of care
214369717|NCT02955030|BIOLOGICAL|"Influenza HA vaccine Biken HA"|subcutaneous
214369718|NCT02955030|BIOLOGICAL|Placebo|sublingual
214369719|NCT04995562|DRUG|129Xe|Inhaled contrast for MRI
214369720|NCT00087360|OTHER|counseling intervention|
214369721|NCT00087360|OTHER|physiologic testing|
214369722|NCT00087360|PROCEDURE|evaluation of cancer risk factors|
214369723|NCT04680325|DIETARY_SUPPLEMENT|Juice daily consumption|Single-service bottles of juice were provided for 15 days of daily consumption in each arm
214369724|NCT05655676|DRUG|89Zr-NY008|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
214369725|NCT01450722|PROCEDURE|bypass surgery, stent placement|bypass surgery, stent placement
214369726|NCT01450722|PROCEDURE|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
214369727|NCT01003522|OTHER|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
214369728|NCT01003522|OTHER|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
214369729|NCT01003522|PROCEDURE|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
214369730|NCT01003522|PROCEDURE|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
214369731|NCT01003522|OTHER|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
214369732|NCT01003522|OTHER|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
214369733|NCT01003522|OTHER|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
214984446|NCT00988182|OTHER|dietary intervention|whey protein
214369734|NCT05067439|DRUG|Abrocitinib|200 mg once daily (QD)
214369735|NCT05067439|DRUG|Omeprazole|single doses of 10 mg
214369736|NCT05067439|DRUG|Caffeine|single dose of 100 mg
214369737|NCT05067439|DRUG|Efavirenz|single doses of 50 mg
214369738|NCT04368650|DRUG|BMP-2|lyophilized Human Bone Morphogenetic Protein-2 was used as an active drug.
214369739|NCT04368650|PROCEDURE|PRF|For the preparation of sticky bone, the patient's venous blood is collected and centrifuged at 2400rpm for 2min which leads to two different layers in the vacutainer the upper autologous fibrin glue (AFG) and the lower RBC portion, the upper AFG is mixed with a particulate bone graft (hydroxyapatite). Within 5-10 min fibrin meshwork was formed
214369740|NCT00453011|DEVICE|posterior chamber intraocular lens|
214369741|NCT00453011|DEVICE|anterior chamber intraocular lens|
214369742|NCT01903421|DRUG|Spinal anesthesia group: bupivacaine 10-15mg|
214369743|NCT01903421|DRUG|General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|
214369744|NCT01903421|GENETIC|Blood test|DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene
214369745|NCT01903421|OTHER|Lumbar spinal tap|1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
214369746|NCT01903421|BEHAVIORAL|Montreal Cognitive Assessment (MOCA) and MMSE|
214984447|NCT00988182|OTHER|water control|
214984448|NCT00005649|DRUG|capecitabine|
214984449|NCT00005649|DRUG|paclitaxel|
214984450|NCT02667639|BIOLOGICAL|RPH-104|Anti-IL-1 Mab
214984451|NCT02667639|OTHER|Sodium chloride Sterile Injection 0.9% w/v|Sterile saline solution
214984452|NCT00598091|DRUG|gemcitabine|1000mg/m2, Days 1, 8, 15
214984453|NCT00598091|DRUG|dasatinib|50mg, PO, QD
214984454|NCT00598091|DRUG|gemcitabine|1000mg/m2, days 1, 8, 15
214984455|NCT00598091|DRUG|dasatinib|50mg, PO, BID
215088751|NCT00246506|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
215088752|NCT00246506|PROCEDURE|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
214984456|NCT05572931|DEVICE|Fu's Subcutaneous Needling(FSN)|"Insertion points are both sides of 1) inferior edge of the scapula; 2)the midpoint of inferior edge of the posterior superior iliac spine and the ischial tuberosity.~FSN (Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.) ) is a solid needle with plastic cannula tube on the outside. Add on swaying movement (SM) and reperfusion approach (RA) after the needle inserting into the subcutaneous layer. The SM is a horizontal fan sway movement with the base of the needle for the fulcrum, The SM speed is 200 times in 2 minutes. Apply RA when performing SM. RA movement is hip extension in prone position with resistance by physician's hand for 10 seconds. And then rest for 10 seconds. Repeat 3 cycles. The same RA is performed over the other three insertion point."
214984457|NCT05572931|DEVICE|fine acupuncture needle|(36G, 0.5 inch, Wujiang city cloud \& dragon medical device Co.,Ltd.) Only inserted to skin, not into the subcutaneous layer. No SM and RA.
214984458|NCT03444207|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
215088753|NCT01228994|DRUG|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
214369747|NCT02755064|DRUG|Erythromycin lactobionate|In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
214369748|NCT02755064|DRUG|Placebo IV|In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
215088754|NCT01228994|DRUG|placebo pill|placebo pill
215088755|NCT01228994|DRUG|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
214369749|NCT02755064|DRUG|[13C]-Spirulina|The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
214369750|NCT02755064|DRUG|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.
214369751|NCT02755064|DRUG|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
214369752|NCT02323646|DRUG|Placebo|Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
214369753|NCT02323646|DRUG|Telapristone Acetate|Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
214369754|NCT03362359|DRUG|Ga-68-PSMA-11|Single administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg. A 2nd administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg is possible in the unlikely case of a negative histological result (i.e. no prostate-specific membrane antigen (PSMA) expression in dissected lymph nodes) to verify if PSMA PET-positive tissue as seen on day 1 has not been removed during RP with EPLND.
214369755|NCT05709990|DRUG|Solifenacin Succinate 5 MG Oral Tablet [Vesicare]|These patients will receive solifenacin 5-10 MG daily (combined with standard urotherapy) for 8 weeks.
214369756|NCT05709990|DRUG|Vitamin D3|These patients will receive high dose vitamin D supplementation (more than 2000IU daily) (combined with standard urotherapy) for 8 weeks.
214369757|NCT05709990|BEHAVIORAL|Standard urotherapy|These patients will receive standard urotherapyfor 8 weeks.
214369758|NCT01299155|DEVICE|ReSTOR +3|Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.
214369759|NCT01299155|DEVICE|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
214369760|NCT05810207|PROCEDURE|Colorectal resection|Patients undergoing a colorectal resection with the construction of a primary anastomosis
214369761|NCT02106130|DRUG|Rebamipide|oral administration, 3 times/day
214369762|NCT02106130|DRUG|Mosapride citrate|oral administration, 3 times/day
214369763|NCT03263689|DRUG|Intrathecal morphine|ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
214369764|NCT00521144|DRUG|obatoclax mesylate|Given IV
214369765|NCT00521144|DRUG|topotecan hydrochloride|Given IV
214369766|NCT00521144|OTHER|laboratory biomarker analysis|Correlative studies
214369767|NCT01592149|OTHER|No Drug|No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
214369768|NCT01037439|DEVICE|Adaptive Servo-controlled Ventilation (ASV)|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
214369769|NCT01370525|DRUG|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
214369770|NCT04664725|DRUG|Repaglinide, Bupropion and SHR3680|Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680
214369771|NCT02614443|OTHER|Space from Depression|Delivered through the online SilverCloud platform, the program for the treatment of depression employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
214369772|NCT02614443|OTHER|Space from Anxiety|Delivered through the online SilverCloud platform, the program for the treatment of anxiety employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
214369773|NCT02614443|OTHER|Space from Stress|Delivered through the online SilverCloud platform, the program for the treatment of stress employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
214984459|NCT03444207|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
214984460|NCT04503460|DRUG|Salmeterol Xinafoate|All participants will receive inhaled salmeterol xinafoate 50 μg twice in the morning and twice in the evening for 2 weeks; this will be followed by a 2-week washout period during which time no beta-agonists will be administered. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
214984461|NCT04503460|DRUG|Salmeterol Fluticasone|Following the 2-week washout period, all participants will receive inhaled salmeterol xinafoate 50 μg combined with fluticasone propionate 250 μg twice in the morning and twice in the evening for 2 weeks. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
214984462|NCT04976374|DRUG|Dexmedetomidine and Gabapentin|Administration of intravenous dexmedetomedine for post operative analgesic purposes in combination with gabapentin
214984463|NCT04976374|OTHER|Saline|Intravenous Saline 0.9% for placebo purposes
214984464|NCT04451096|DIETARY_SUPPLEMENT|Probiotics with prebiotic|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
214984465|NCT04451096|DIETARY_SUPPLEMENT|Placebo|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
214984466|NCT02933814|DRUG|Liposomal Bupivicaine|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
214984467|NCT00454870|DRUG|MEM 3454|
214984468|NCT00004921|BIOLOGICAL|filgrastim|
214984469|NCT00004921|DRUG|carboplatin|
214984470|NCT00004921|DRUG|cyclophosphamide|
214984471|NCT00004921|DRUG|melphalan|
214984472|NCT00004921|DRUG|paclitaxel|
214984473|NCT00004921|PROCEDURE|adjuvant therapy|
214984474|NCT00004921|PROCEDURE|bone marrow ablation with stem cell support|
214984475|NCT00004921|PROCEDURE|peripheral blood stem cell transplantation|
214984476|NCT06264713|DEVICE|Immersive Virtual Reality|Patients wear a head-mounted-display and will be immersed in a virtual environment. The stimuli will be provided in the left, center and right visual fields. Eye-tracking biofeedback will be provided about the real-time performance during each exercise.
214984477|NCT06264713|DEVICE|Sham Immersive Virtual Reality|The patients performed the same protocol of the experimental group, differently to the immersive virtual reality group, from session 2 to session 8 (7 sessions), the stimuli will be provided in the center and right visual fields.
214984478|NCT02889419|DEVICE|Evaluation of underwear Selfia®|Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
214984479|NCT00284856|DRUG|montelukast sodium|montelukast 10 mg tablet once daily, 6 month treatment period
214984480|NCT00284856|DRUG|Comparator: Placebo|fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
214984481|NCT00284856|DRUG|Comparator: fluticasone|fluticasone propionate 250 mcg twice daily, 6 month treatment period
214984482|NCT00284856|DRUG|Comparator: Placebo|montelukast 10 mg Pbo tablet once daily, 6 month treatment period
215088756|NCT04082910|DRUG|Metoprolol|Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
214369774|NCT00804492|BEHAVIORAL|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
214369775|NCT05799326|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.
214369776|NCT05799326|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo.
214369777|NCT01207570|PROCEDURE|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
214369778|NCT01207570|PROCEDURE|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
214369779|NCT03376867|OTHER|Conditioned pain modulation|Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.
214369780|NCT03128424|DEVICE|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
214369781|NCT00214305|BEHAVIORAL|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
214369782|NCT00214305|BEHAVIORAL|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
214369783|NCT01705496|RADIATION|[124I]FIAU|This is a single dose study of 5 mCi \[124I\]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after \[124I\]FIAU injection.
214681277|NCT03211130|BEHAVIORAL|SystemCHANGE™|During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.
214984483|NCT03019380|DEVICE|removing cerumen from external ear (Wondertip)|The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
214681278|NCT03211130|BEHAVIORAL|Attention-Control|An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
214681279|NCT06858124|OTHER|Mulligan+TE|"Mulligan Mobilizations plus Home Therapeutic Exercise~The protocol will last 25 minutes (Mulligan protocol: 5 minutes and Home Therapeutic Exercise protocol: 20 minutes) and will include the application of the following mulligan techniques and home exercises:~* Mulligan sustained natural apophyseal glide SNAG mobilizations with overpressure with the patients in seated position.~* 4 home-based therapeutic exercises: isometric exercises for cervical regions, head retractions, thoracic spine rotation mobility exercise and diagonal cervical mobility exercise pattern."
214681280|NCT06858124|OTHER|Maitland+TE|"The participants of this group will perform the same 4 home-based therapeutic exercises as the first group. In addition, they will receive a 5-minute maitland mobilization protocol.~Maitland mobilizations will include posterioranterior glides with oscillations with the patients in prone position."
214984484|NCT06140186|DRUG|Topical Timolol|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.
214984485|NCT06140186|DRUG|Betamethasone Valerate|Betamethasone valerate 0.1% cream application twice daily
214984486|NCT05776992|DEVICE|Xbox virtual reality games|X-box balance evaluation was implemented in a completely dark and isolated room specially prepared for this treatment and evaluation
215088757|NCT04082910|DRUG|metoprolol, infliximab, etanercept, tocilizumab and/or other agents|During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
215088758|NCT00966719|OTHER|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
214984487|NCT05776992|DEVICE|Biodex balance training|the Biodex Balance System SD has been designed to meet the needs of everyone looking to improve balance, increase agility, develop muscle tone and treat a wide variety of pathologies.
215088759|NCT01341691|OTHER|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
215088760|NCT04175067|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
215088761|NCT04175067|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
215088762|NCT05478668|OTHER|visual analog scale|In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
215088763|NCT05229796|DRUG|Empagliflozin 10 mg Tab|The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
215088764|NCT06915636|OTHER|DPL|Half of the face was randomly treated with DPL, with an energy of 6-8 J/cm2, at an interval of 10 days, for a total of 8 treatments.One randomly assigned half of the face was treated with a large-spot, low-energy 1064nm laser at an energy of 0.8-1 J/cm², administered at 10-day intervals, for a total of 8 treatment sessions.
215088765|NCT04239300|BEHAVIORAL|Delivery in water|Participants delivery in water
214984488|NCT03955549|BEHAVIORAL|Insight Enhancement Program (IEP)|"IEP is comprised of 8 sessions, administered twice weekly, across a one month period. The session duration is 60-90 minutes. IEP will be administered in a group format with 8-12 patients in each group.~During sessions, different topics representing 8 different stages of illness are discussed according to a chronological schedule. These stages are presented on an Illness March Graph (IMG) and include: Stage I: Personality formation, Stage II: Pre onset confusion, Stage III: Prodroma, Stage IV: The illness, Stage V: Resistance, Stage VI: Remission, Stage VII: Maintenance, Stage VIII: Relapse. Patients actively participate through the exchange of their own experiences and interpretations, which are then reinterpreted by the therapist and by the patients themselves."
214984489|NCT03955549|BEHAVIORAL|Metacognitive Training for Psychosis (MCT)|The training consists of eight modules that are administered within the framework of a group intervention program that involves eight 1-hour group sessions with 4 to 10 patients in each group. MCT is manualized and currently available in thirty languages and can been downloaded via the following web address: http://www.uke.de/mct. Among the problematic thinking styles recognized as potential contributors to the development of delusions are attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
214984490|NCT03955549|DRUG|Treatment As Usual (TAU)|"Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
214984491|NCT00930618|DRUG|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
214984492|NCT00930618|DRUG|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
214984493|NCT01131936|DRUG|Amlodipine|Amlodipine Tablets, 10 mg
214984494|NCT04164238|DRUG|Toripalimab|Toripalimab Injection
214984495|NCT04164238|DRUG|Paclitaxel|Paclitaxel Injection
214984496|NCT04164238|DRUG|Carboplatin|Carboplatin Injection
214984497|NCT04164238|DRUG|Cisplatin|Cisplatin injection
214984498|NCT04164238|DRUG|5-fu|5-fu injection
214984499|NCT03207399|DRUG|Epclusa|Patients will be treated with this drug for 12 weeks post lung transplant.
214984500|NCT05598697|BEHAVIORAL|Life Skills Building (LSB) curriculum for males|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All male study participants attending LSB curriculum classes are married to BISP-CT clients.~For men, the MEWE intervention provides access to the LSB curriculum only."
215088766|NCT02916459|DEVICE|21G EBUS-TBNA needle|
215088767|NCT02916459|DEVICE|Flexible 19G EBUS-TBNA needle|
215088768|NCT01703065|DRUG|Cabozantinib|Given orally once a day
215088769|NCT01892761|DRUG|Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups|
215088770|NCT04267731|DIETARY_SUPPLEMENT|VMK223|Heat killed and purified Bifidobacterium breve polysaccharide-based extract
215088771|NCT04267731|DIETARY_SUPPLEMENT|Cellulose|Bulking agent in food production without probiotic properties
214369784|NCT05033782|OTHER|questionnaire|"Each included patient will be given a paper questionnaire, with the following questions:~* Zip code of patient's iterative residences since 2018, as well as the zip code of residence at the time of the 2 confinements~* Occupational status~* Occurrence of COVID infection/date needed for hospitalization~* During the COVID-19 outbreak, did the patient: avoid seeing a doctor, avoid going to health care facilities, stop background treatment for MS. If yes to any of the questions, the reason, date and duration of the cessation will be asked.~Other sources of data will be used together:~Clinical data from the OFSEP registry Pollution data from approved air quality monitoring associations Data on the circulation of influenza and gastroenteritis, produced by Santé Publique France"
214369785|NCT03653455|BEHAVIORAL|Email reminders|Patients will receive email reminders until their PROs are completed.
215088772|NCT03720600|BEHAVIORAL|MAB Intervention|The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
215088773|NCT02970526|DRUG|Oxaliplatin|Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
214681281|NCT06858124|OTHER|Control|Participants in this group will only perform the same 4 home-based therapeutic exercises as the first group.
214369786|NCT03653455|BEHAVIORAL|Pre- and Post-operative discussion|Patients will discuss with their provider the importance of PROs pre-operatively, as well as their post-operative progression in comparison to established norms.
214369787|NCT03653455|BEHAVIORAL|Incentive|Patients will receive up to $30 in amazon gift cards upon the completion of their PROs.
214369788|NCT04280653|DEVICE|NDE L68 StableFit® Punctal Plug|Tear lake evaluation of the planned study eye, prior to insertion of the Punctal Plug and then tear lake evaluation at days 7 and 28 after punctal plug insertion.
214369789|NCT00314548|DRUG|PGE1 (prostacyclin)|alprostadil nebulization
214681282|NCT04863287|BIOLOGICAL|2217LS|Fully Human Monoclonal Antibody
214984501|NCT05598697|BEHAVIORAL|Life Skills Building (LSB) curriculum for females|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs."
214984502|NCT05598697|OTHER|Cash transfer to adult females|The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
214984503|NCT05836480|PROCEDURE|mitral valve repair|conservative surgery to treat mitral regurgitation. A mitral valve plasty is performed according to the most appropriate technique
214984504|NCT00764634|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182
214984505|NCT00764634|BIOLOGICAL|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182
215088774|NCT02166541|PROCEDURE|BCSK|"The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier."
215088775|NCT02166541|PROCEDURE|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
215088776|NCT02166541|PROCEDURE|INRS|"The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy."
215088777|NCT01998191|OTHER|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
215088778|NCT01998191|OTHER|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
214369790|NCT00314548|DRUG|normal saline|nebulize for 30 mins
214369791|NCT06395610|DRUG|CHF6001 DPI|Single dose of CHF6001
214369792|NCT06395610|DRUG|Erythromycin|Repeated doses of oral Erythromycin
214369793|NCT04030858|BEHAVIORAL|Plant-based diet + nutrition education|The intervention group will adopt a nutrient-dense dietary pattern and receive nutrition education sessions specific to that lifestyle. The diet protocol is comprised of minimally-processed plant foods such as fruits, vegetables, legumes, beans, nuts and seeds. No refined sugars, added salt, or oil will be included. Dietary fat intake limited to 20% of total calories or less per day. Animal products will be eliminated. This dietary pattern is expected to improve resilience, mood, inflammation, microbiome, spirituality, and overall general health (as measured by weight, cholesterol, blood pressure). The treatment group will also receive weekly nutrition education sessions to support the diet.
214369794|NCT05428605|OTHER|Blood sample|10 mL on lithium heparinate tubes, 10 mL on EDTA tubes.
214369795|NCT06171334|DEVICE|Remote ischemic conditioning|The intervention consists in Remote Ischemic conditioning (RIC), one session of 40-minutes duration per day for 12 months. The procedure will be performed by using an electric auto-control device by SnapDx Inc (Calgary, Canada) with a blood pressure cuff that inflates up to a pressure of 200 mmHg during the ischemic period. Participant will self-administer the RIC procedure at their home. The device records and documents each RIC cycle.
214369796|NCT01719822|DEVICE|Yamax Digi-Walker CW-700|A pedometer with a daily step count target set by a physiotherapist.
214369797|NCT06219564|PROCEDURE|Peripartum total abdominal hysterectomy (p-TAH)|"Peripartum total abdominal hysterectomy (cesarean hysterectomy) refers to a surgical procedure in which a woman undergoes both a cesarean section (C-section) and a hysterectomy simultaneously.~Placenta Accreta, Increta, or Percreta: These are conditions where the placenta attaches too deeply to the uterine wall. In cases of severe attachment, it may be difficult to remove the placenta without causing excessive bleeding, and a hysterectomy may be required.~Cesarean hysterectomy is a major surgical procedure involving significant medical expertise and coordination among healthcare professionals, including obstetricians and surgeons. The decision to perform a cesarean hysterectomy is usually made in emergency situations to address life-threatening complications."
214369798|NCT06219564|PROCEDURE|Cesarean Section (C/S)|"A cesarean section (C/S) involves making an incision in the abdominal wall and uterus to deliver a baby when a vaginal delivery is not feasible or safe.~Total placenta previa refers to a condition where the placenta completely covers the opening of the cervix in the uterus. This condition can pose significant risks during pregnancy and childbirth, and it often necessitates a planned cesarean section (C/S) for delivery."
214681283|NCT04863287|OTHER|0.9% Sodium Chloride (NaCl)|Subcutaneous injection
214681284|NCT01952015|BIOLOGICAL|Secukinumab|Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
214681285|NCT02239094|DRUG|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
214681286|NCT04570891|PROCEDURE|Ultrasound-guided fascia iliaca compartment block|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
214681287|NCT04570891|PROCEDURE|Control|No regional block is provided at the end of surgery.
214984506|NCT00764634|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182
214984507|NCT00764634|BIOLOGICAL|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
214984508|NCT05047900|DIAGNOSTIC_TEST|Rapid antigen testing kit|COVID-19 Saliva Antigen Rapid Test Tigsun COVID-19 Speichel Antigen-Schnelltest
214984509|NCT01192815|DRUG|erlotinib hydrochloride|Given orally or via gastronomy tube
214984510|NCT01192815|RADIATION|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
214984511|NCT01192815|OTHER|pharmacogenomic studies|Optional correlative studies
214984512|NCT01192815|OTHER|gene expression analysis|Correlative studies
214984513|NCT01192815|RADIATION|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
214984514|NCT01192815|OTHER|biopsy|Optional correlative studies
214984515|NCT01192815|OTHER|pharmacological study|Optional correlative studies
214984516|NCT01192815|OTHER|laboratory biomarker analysis|Optional correlative studies
214984517|NCT01192815|OTHER|questionnaire administration|Optional ancillary studies
214984518|NCT01192815|OTHER|enzyme-linked immunosorbent assay|Optional correlative studies
214984519|NCT01192815|OTHER|polymorphism analysis|Optional correlative studies
215088779|NCT01998191|OTHER|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
215088780|NCT02008409|DEVICE|EndoLift Liver Retractor|"During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
215088781|NCT00002363|DRUG|Peptide Construction 3, Synthetic|
215088782|NCT01895933|DEVICE|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36\~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
215088783|NCT04161378|DIAGNOSTIC_TEST|Cardiac imaging|"* Transthoracic echocardiography~* Late gadolinium enhancement CMR"
214369799|NCT06219564|OTHER|Neonatal mortality|"Neonatal mortality refers to the death of a newborn within the first 28 days of life. This period is divided into early neonatal mortality, which covers the first seven days of life, and late neonatal mortality, which extends from the eighth to the 28th day. Neonatal mortality is a critical measure of the health and well-being of infants and is often used to assess a population's overall health and healthcare systems.~To reduce neonatal mortality, efforts are made to improve maternal healthcare, access to prenatal care, skilled attendance during childbirth, and the availability of neonatal healthcare services. Tracking and addressing factors contributing to neonatal mortality are crucial for improving the chances of survival of newborns and overall health outcomes."
214369800|NCT00964834|DRUG|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
214369801|NCT00964834|DRUG|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
214681288|NCT05295160|BEHAVIORAL|weight loss by very low energy diet intake which may differ in protein or carbohydrate content|The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss
214984520|NCT06305845|PROCEDURE|Digital crowns|crowns fabricated digitally by CAD-CAM technology
214984521|NCT06305845|PROCEDURE|zirconia crowns|crowns that are ready made for primary teeth
214984522|NCT06060470|BEHAVIORAL|Virtual reality based dance group|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
215088784|NCT04161378|DIAGNOSTIC_TEST|Laboratory analysis|"* complete blood count~* biochemistry~* hs-CRP, MMPs, IL6, NT-pro-BNP"
215088785|NCT05066945|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
215088786|NCT02635347|PROCEDURE|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
215088787|NCT02635347|DEVICE|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
214681289|NCT02917486|OTHER|blood sample|
214681290|NCT01930734|DRUG|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
214681291|NCT01930734|DRUG|Normal Saline|Normal Saline solution 0.9% Placebo Arm
215088788|NCT04835376|DEVICE|Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis|Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
215088789|NCT05158985|OTHER|phonophoresis|treatment
215088790|NCT05158985|OTHER|exercises|treatment
214984523|NCT06060470|BEHAVIORAL|Active Comparator: Control|Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
214984524|NCT04809116|DRUG|Pimavanserin|open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
214984525|NCT04668677|OTHER|On-line questionnaire|On-line questionnaire about working life, medical care, functional recovery, quality of life and psychological state.
214984526|NCT05312996|OTHER|Heart Rate Variability|Caretaker Heart Rate Variability ECG wrist monitor and chest patch.
214984527|NCT05312996|OTHER|Galvanic Skin Response (Biopac)|Galvanic Skin Response- measuring autonomic response-via perspiration
214984528|NCT00477685|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
214984529|NCT05414604|DIAGNOSTIC_TEST|3D spine CT|CT scan of the spine
214984530|NCT02500251|DRUG|belimumab|Belimumab will be administered per study protocol.
215088791|NCT02144155|DRUG|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
215088792|NCT02144155|DRUG|Placebo|placebo drug
214369802|NCT00964834|DRUG|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
215088793|NCT02482857|DRUG|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
215088794|NCT03964753|DRUG|Nab-paclitaxel and Cisplatin|Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
214369803|NCT05279781|PROCEDURE|Non surgical root canal treatment|Complete root canal treatment will be performed followed by direct restoration
214369804|NCT05279781|PROCEDURE|Pulpotomy|Full pulpotomy followed by direct restoration
214681292|NCT02260414|DRUG|Tinzaparin|single subcutaneous injection of 4500 IU tinzaparin
214681293|NCT02260414|OTHER|Blood sample|blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
214681294|NCT02573805|DEVICE|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
214984531|NCT02500251|DRUG|Bortezomib|Bortezomib will be administered per study protocol.
214984532|NCT02500251|DRUG|Rituximab|Rituximab will be administered per study protocol.
214984533|NCT02500251|DRUG|Plasmapheresis|Plasmapheresis will be administered per study protocol.
214984534|NCT03779646|DRUG|Bisoprolol Fumarate|Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate \<75bpm and systolic blood pressure \<90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
214984535|NCT03451045|DRUG|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
214984536|NCT03451045|DRUG|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
214984537|NCT03451045|OTHER|Placebo|Subjects will receive placebo twice daily.
214984538|NCT01553929|OTHER|Physical Training and cognitive activity (EPC group)|The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
214984539|NCT01553929|OTHER|Physical training (EP group)|The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
214984540|NCT01553929|OTHER|control group|no physical training and no cognitive activity
214984541|NCT04581915|DRUG|Triazavirin (Riamilovir)|Capsule - 250mg 8 hourly po
214984542|NCT04581915|OTHER|Placebo|Placebo capsule
214984543|NCT03350919|DEVICE|Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
214984544|NCT03350919|DEVICE|Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the intact field of vision. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
214984545|NCT00572845|OTHER|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
215088795|NCT03964753|PROCEDURE|surgery|surgery
215088796|NCT04988997|DRUG|Vurolenatide 50mg/PBO|Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
214681295|NCT03290638|PROCEDURE|Guided Bone Regeneration (GBR)|Teeth Extraction With Bone Grafting and Membrane
214681296|NCT01746667|BEHAVIORAL|Exposure in vivo|
215088797|NCT04988997|DRUG|Vurolenatide 100mg/PBO|Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
215088798|NCT04988997|DRUG|Vurolenatide 50/50 mg|Vurolenatide - 50 mg weekly SC administration
215088799|NCT04988997|DRUG|Placebo|PBO - weekly SC administration
214681297|NCT01746667|BEHAVIORAL|Virtual Reality Exposure Therapy|
214681298|NCT00592501|RADIATION|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
214681299|NCT00592501|DRUG|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
214681300|NCT00592501|DRUG|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
214681301|NCT00126464|DRUG|fulvestrant|
214681302|NCT00126464|DRUG|tamoxifen citrate|
214984546|NCT03879031|DIAGNOSTIC_TEST|Cluster of Clinical tests to measure lumbar stability|"All subjects will be submitted to a cluster of clinical test before the starting of the first session, and at the ending of the last session of the physical therapy program. This cluster will include:~* Aberrant Movements (AM) Test,~* Active Straight Leg Raise Test (ASLR) Test,~* Supine Bridge Test (SuBT),~* Right Side Bridge Test (RBT),~* Left Side Bridge Test (LBT),~* Prone Bridge Test (PrBT),~* Passive Lumbar Extension (PLE) Test,~* Prone Instability Test (PIT)."
214984547|NCT06374303|OTHER|NE + Meal Delivery (NE+MD) intervention|NE + Meal Delivery (NE+MD) participants received the same educational platform plus weekly meal deliveries using a commercial service that delivers premade, refrigerated meals directly to the participant's home.
214984548|NCT02291978|DEVICE|ExAblate 2100|The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
214984549|NCT00512590|BEHAVIORAL|Relaxation and Guided Imagery|"The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.~Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10."
214681303|NCT00126464|PROCEDURE|conventional surgery|
214681304|NCT00126464|PROCEDURE|neoadjuvant therapy|
214681305|NCT01051388|DRUG|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
214681306|NCT01051388|DRUG|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
214681307|NCT01051388|DRUG|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
214984550|NCT05415293|DIETARY_SUPPLEMENT|Expecta 200mg DHA|
214984551|NCT05415293|DIETARY_SUPPLEMENT|Promise 275mg DHA|
214984552|NCT00514696|DRUG|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
214984553|NCT00217230|BIOLOGICAL|CAIV-T|
214984554|NCT01745510|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Docosahexaenoic acid from algae source
214984555|NCT01745510|DIETARY_SUPPLEMENT|Placebo|Placebo was designed to mimic the color and consistence of the oil that contains DHA
214984556|NCT04142242|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection; Route of administration: Intramuscular
214681308|NCT00279500|DEVICE|Argus 16 Retinal Stimulation System|The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
214681309|NCT02014532|DRUG|Montelukast|Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
214681310|NCT02014532|DRUG|Placebo|Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
214681311|NCT02892851|DEVICE|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :~* Parameter setting~* Cross-over double-bind (ON/OFF)~* Open Phase (ON)"
214681312|NCT05777434|PROCEDURE|Conventional Physical Therapy for Chronic Neck Pain|Conventional physical therapy for Chronic Neck Pain will include hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises. After 2 weeks, functional training will be added. Sets and repetitions will be increased progressively.
214681313|NCT05777434|PROCEDURE|Scapulothoracic Stabilization Exercises|• Scapulothoracic stabilization exercises in addition to conventional physical therapy will include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance. After 2 weeks, functional training will be added. Sets aand repetitions will be increased progressively.
214681314|NCT01429012|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
214681315|NCT01429012|OTHER|Culture medium without MSC.|2 ml of culture medium.
214681316|NCT01243606|BEHAVIORAL|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
214681317|NCT01243606|BEHAVIORAL|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
214984557|NCT04142242|OTHER|Blood sample|Blood sample for assessment of antibody persistence.
214984558|NCT04140110|OTHER|Intensive BP lowering|The aim is to achieve a systolic BP level of \<120mmHg within 1 hour after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
214984559|NCT04478617|DRUG|Metronidazole Vaginal|Vaginal metronidazole 0.75% (MetroGel or Vandazole) will be inserted per vagina days 1 through 5 prior to date of surgery.
214984560|NCT03040726|DRUG|Netupitant|Given PO
214984561|NCT03040726|DRUG|Palonosetron|Given PO
214984562|NCT03040726|DRUG|Palonosetron Hydrochloride|Given PO
214984563|NCT03040726|OTHER|Placebo|Given PO
214984564|NCT03040726|OTHER|Questionnaire Administration|Ancillary studies
214984565|NCT03998072|OTHER|Five session cognitive analytic therapy (CAT) consultancy|Five session consultancy with patients and care coordinators using cognitive analytic therapy
214984566|NCT04749199|BEHAVIORAL|Enhanced mirror therapy|Participants of the enhanced mirror therapy group will perform complex, randomized, finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a 35% blurred visual feedback through the computerized mirror therapy device. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
214984567|NCT04749199|BEHAVIORAL|Standard mirror therapy|Participants allocated to this group will perform simple, sequential finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a clear image of the exercising hand. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
214984568|NCT05692440|DEVICE|Intracept Procedure|Intraosseous radiofrequency ablation of the basivertebral nerve
214984569|NCT05882877|DRUG|Rocatinlimab|Subcutaneous (SC) injection
214984570|NCT05882877|OTHER|Placebo|SC injection
214984571|NCT03630848|OTHER|Effect of Protein on Blastocyst Development|Embryo Development Related to The Protein Concentration
214984572|NCT02328612|OTHER|Intravenous infusion of cells|"The treatment administration will be infused intravenously to the subjects after randomization:~An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator."
215088800|NCT05061654|DRUG|Ceftolozane-tazobactam IV|Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
215088801|NCT01388751|PROCEDURE|night splinting|splint finger at night for 4 weeks
215088802|NCT01911312|DEVICE|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
215088803|NCT01911312|DEVICE|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
215088804|NCT00670891|PROCEDURE|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~1. Air or Gas Embolus~2. Decompression Illness~3. Carbon Monoxide poising~4. Clostridial Myonecrosis (Gas Gangrene)~5. Necrotizing Fasciitis~6. Crush Injury (Compartment syndromes)~7. Selected Problem Wounds~8. Compromised Skin Flaps or Grafts~9. Refractory Osteomyelitis~10. Exceptional Anemia due to Blood loss~11. Osteoradionecrosis~12. Thermal Burns and Radiation Tissue Damage~13. Diabetic Wounds~14. Intra-Cranial Abscess~15. Brain Injury and other Head Trauma~16. Cerebral Palsy~17. High Altitude Sickness~18. Lyme disease"
214369805|NCT05936931|BEHAVIORAL|Changes in CRC screening awareness and intentions|Using a single arm, open-label, pre-test post-test design (n=15 adult child/parent dyads), assess the impact of a young adult-mediated intervention to increase CRC screening among a paired age-eligible family member (e.g., parent/grandparent). The focus of the intervention will be on changes in CRC screening awareness and intentions among the age-eligible adult, but we hypothesize that the young adult could benefit as well. Thus, in addition to assessing feasibility and acceptability, we will assess changes in 1) CRC screening intentions among the age-eligible adults and 2) CRC health literacy and awareness of screening guidelines among the younger adult participant.
214369806|NCT03948984|BEHAVIORAL|Therapeutic Music Session|The 20 minute therapeutic music session will consist of classical music performed by a pianist with or without flute accompaniment with an individual patient's ICU room.
214681318|NCT04674852|DEVICE|Research Marker|The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.
214984573|NCT04108390|OTHER|Dry needling|For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.
214984574|NCT01948245|DEVICE|TaurolockTMHep100|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
214984575|NCT01948245|DEVICE|Heparin 100 IE/ml|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
214984576|NCT05283434|DRUG|Arnica|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the experimental group will take the recommended doses of Arnica 1M coated sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
214984577|NCT05283434|DRUG|Placebo|Sugar pill placebo
214984578|NCT02458066|OTHER|IRS: bendiocarb|carbamate insecticide
214984579|NCT02458066|OTHER|IRS: deltamethrin|Pyrethroid insecticide
214984580|NCT05615077|OTHER|Combined exercise-education intervention|"Combined exercise and education intervention by fall risk state for 12 months during intervention period.~Exercise intervention includes balance exercise and strength exercise according to protocol.~Education intervention includes medication review, nutrition intervention, and home hazard modification.~The key to medication review is paying special attention to medications known to increase the risk of falls. Reduction of these medications is recommended, and redundant psychotropic medications are withdrawn. Nutrition intervention includes investigating dietary habits and calculate insufficient protein intake to provide customized diet and high protein drink. If vitamin D necessary, supplements are prescribed. Home hazard modification includes providing instructions to reduce and modify the home hazards that increase the risk of falls."
214984581|NCT03226795|OTHER|" Information-Motivation-Behavioral skills  intervention."|"* information -\> Reminders of medication: mobile application~* Motivation -\> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients~* Behavioral skills -\> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments"
214984582|NCT01141816|OTHER|Contrast-Enhanced Ultrasound|Contrast-enhanced ultrasounds of the kidney will be performed within 7 days of routine CTs or MRIs at 3, 6, 12, 18, and 24 months post-radiofrequency ablation, with Perflutren Lipid Microsphere Injectible Suspension ('Definity') as the contrast agent.
214984583|NCT02444026|BEHAVIORAL|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
214984584|NCT06524258|DIAGNOSTIC_TEST|testicular elastography|testicular elastography for predicting non obstructive azoospermia
214984585|NCT04451083|DRUG|FOY-305|Multiple-dose of FOY-305 will be administered orally at 4 times/day.
214984586|NCT02123381|RADIATION|preoperative radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f."
214984587|NCT02123381|DRUG|cetuximab|400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
214984588|NCT03297190|BEHAVIORAL|SMS|Receipt of SMS messages on nutrition and health topics
214984589|NCT03297190|BEHAVIORAL|Interpersonal Counselling|Interpersonal counselling on health and nutrition topics
214984590|NCT00465179|DRUG|Sunitinib Malate|50 mg by mouth daily for 4 weeks, then 2 weeks off.
214984591|NCT01366716|BEHAVIORAL|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
214984592|NCT01366716|BEHAVIORAL|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
214984593|NCT01894906|DRUG|Soluble Ferric Pyrophosphate|
214984594|NCT01894906|OTHER|Placebo|
214984595|NCT00112749|BIOLOGICAL|infliximab|A single infusion of 1mg/kg will be administered.
214984596|NCT00112749|OTHER|Clinical Assessment|Medical, psychiatric, and immune evaluation.
214681319|NCT03902405|BEHAVIORAL|Active CEASAR Intervention|Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.
214681320|NCT03902405|BEHAVIORAL|Placebo CEASAR|In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.
214984597|NCT00112749|OTHER|Self-report questionnaires|Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.
214984598|NCT00112749|OTHER|Immune Assessment|Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
214984599|NCT00976339|DRUG|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
214984600|NCT04622566|DRUG|Lenvatinib, Pembrolizumab|After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
214984601|NCT01231269|OTHER|MRI|MRI scan without administration of contrast/without radiation
214984602|NCT02673749|DRUG|RP-G28|Study drug taken orally
214984603|NCT02673749|OTHER|Placebo|Placebo taken orally
214984604|NCT02857504|DEVICE|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
215088805|NCT01044316|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
215088806|NCT00514020|DRUG|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
215088807|NCT00514020|DRUG|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
215088808|NCT00514020|DRUG|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
214681321|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the morning for 12 weeks
214984605|NCT02857504|DEVICE|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
215088809|NCT00514020|GENETIC|gene expression analysis|Blood collection
214681322|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the evening for 12 weeks
214493349|NCT03786237|DRUG|Rigosertib Oral Capsules / Rigosertib Intravenous|"Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter."
214493350|NCT01371994|DRUG|solifenacin succinate|oral
214493351|NCT01371994|DRUG|Placebo|oral
214681323|NCT03880227|DEVICE|Active anodal tDCS|active anodal tDCS with behavioral tasks to assess visual attention
214681324|NCT03880227|DEVICE|Sham tDCS|sham tDCS with behavioral tasks to assess visual attention
214984606|NCT01434511|BIOLOGICAL|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
214984607|NCT02322996|OTHER|questionnaires|The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
214984608|NCT00262925|BIOLOGICAL|alemtuzumab|Given subcutaneously
215088810|NCT00514020|GENETIC|polymorphism analysis|Blood collection
215088811|NCT00514020|GENETIC|protein expression analysis|Blood collection
214493352|NCT03151798|BEHAVIORAL|Phase II: Lifestyle treatment|Subjects will undergo energy restriction and exercise training over a 9 month period.
215088812|NCT00514020|OTHER|pharmacological study|Blood collection
215088813|NCT01688921|BIOLOGICAL|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
215088814|NCT01688921|DEVICE|Needle-Syringe|
215088815|NCT01688921|DEVICE|Stratis needle-free injection device|
215088816|NCT01898104|RADIATION|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
215088817|NCT01898104|DRUG|Valproic Acid|
214493353|NCT03151798|BEHAVIORAL|Phase II: Control treatment|Subjects will receive dietary advice and receive information on a stretching program.
214493354|NCT03151798|OTHER|Phase I: Observational studies|The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
214681325|NCT03698240|BEHAVIORAL|Mindfulness-based program|The program includes 9 mindfulness-based sessions for children and their parents.
215088818|NCT01898104|DRUG|Capecitabine|
215088819|NCT03089944|DRUG|Glecaprevir/Pibrentasvir|Tablet
215088820|NCT04034940|OTHER|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
215088821|NCT03512431|DIAGNOSTIC_TEST|Micro sampling|Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
214681326|NCT05537324|OTHER|Brazil nut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 50g Brazil nuts
214681327|NCT05537324|OTHER|Coconut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 46g coconut flakes
214681328|NCT03058458|DRUG|PIN201104|IV or SC administration
214681329|NCT03058458|DRUG|Placebo|IV or SC administration
214681330|NCT01217658|BEHAVIORAL|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
214681331|NCT01217658|BEHAVIORAL|AAP Infant Colic counseling|Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
215088822|NCT00884910|DEVICE|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
214681332|NCT01185535|PROCEDURE|times of topical anesthesia for glottis|topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
214681333|NCT02986958|OTHER|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
214681334|NCT02986958|OTHER|Usual care|routine primary care
214681335|NCT05420519|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214681336|NCT02111824|DEVICE|MIMIG System|Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
214681337|NCT02111824|DRUG|Indocyanine Green (ICG)|Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
214681338|NCT02820610|DRUG|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
214681339|NCT02820610|DRUG|Magnesium Sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
214681340|NCT02820610|DRUG|Normal saline 0.9 %|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
214681341|NCT02257814|BEHAVIORAL|Incredible Years Teacher Training|
214681342|NCT02257814|BEHAVIORAL|Preschool PATHS|
214681343|NCT02257814|BEHAVIORAL|Tools of the Mind|
214681344|NCT01950481|DRUG|LDK378|Oral LDK378 750 mg once
214984609|NCT00262925|DRUG|asparaginase|Given IM
214984610|NCT00262925|DRUG|methotrexate|Given IV or orally
214984611|NCT00262925|DRUG|dexamethasone|Given orally
214984612|NCT00262925|DRUG|leucovorin calcium|Given IV
214984613|NCT00262925|DRUG|mercaptopurine|Given orally
214984614|NCT00262925|DRUG|vincristine|Given IV
214984615|NCT04543864|DEVICE|Electric intraoral welding device|welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally
214984616|NCT04543864|DEVICE|casting|casting the metal framework
215088823|NCT04064346|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
215088824|NCT04064346|DRUG|Placebo|Matching placebo
214681345|NCT02399475|DRUG|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
214984617|NCT04682301|BEHAVIORAL|Behavioral Intervention|Receive SDM intervention
214681346|NCT02399475|DRUG|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
214984618|NCT04682301|OTHER|Discussion (focus group)|Attend focus group
214984619|NCT04682301|OTHER|Discussion (feedback on SDM)|Provide feedback on SDM
214984620|NCT04682301|OTHER|Interview|Attend a telephone interview
214984621|NCT04682301|OTHER|Survey Administration|Ancillary studies
214984622|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g"
214984623|NCT00877968|DIETARY_SUPPLEMENT|Whole pea flour banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g"
214984624|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g"
214984625|NCT00877968|DIETARY_SUPPLEMENT|Whole pea flour biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g"
214984626|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat pasta|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g"
214984627|NCT00877968|DIETARY_SUPPLEMENT|Whole pea pasta|"Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g"
214984628|NCT00877968|DIETARY_SUPPLEMENT|White bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g"
214984629|NCT00877968|DIETARY_SUPPLEMENT|Boiled yellow peas|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --\> 250 g cooked Available CHO: 52.8 g"
214984630|NCT02907827|OTHER|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
214984631|NCT04369937|RADIATION|IMRT (Intensity Modulated Radiotherapy)|Radiation therapy
214984632|NCT04369937|DRUG|Pembrolizumab|A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
214681347|NCT02399475|DRUG|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
214681348|NCT02237807|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
214681349|NCT02237807|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
214984633|NCT04369937|DRUG|Cisplatin|Chemotherapy
214984634|NCT04369937|BIOLOGICAL|ISA101b|ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.
214681350|NCT02154854|DRUG|Tacrolimus targeted half-dose|
214681351|NCT02154854|DRUG|Tacrolimus targeted plain dose|
214681352|NCT06113354|DEVICE|Transcatheter mitral valve repair (MRace Implant and Delivery System)|"The MRace Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture~Other Names:~TMVr"
214681353|NCT01775046|DEVICE|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
214984635|NCT04805528|RADIATION|Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS)|Twice weekly ALTENS therapy for 12 weeks
214984636|NCT05010265|OTHER|Clinician Questionnaire|Surveys will serve to identify preferences, expectations and concerns among clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through investigative neurotechnologies which will then be systematically evaluated.
214984637|NCT05010265|OTHER|Semi Structured Interviews|Semi-structured interviews will further serve to identify preferences, expectations and concerns among patients, surrogates, clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through these investigative neurotechnologies which will then be systematically evaluated.
215088825|NCT01636713|DRUG|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
215088826|NCT01636713|DRUG|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
215088827|NCT01636713|DRUG|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
215088828|NCT05082350|DIETARY_SUPPLEMENT|black garlic|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
215088829|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up with wearable devices|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
215088830|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up in traditional ways|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
215088831|NCT03958591|DRUG|Traditionally upgrading therapy, followed up in traditional ways|The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
215088832|NCT03780959|DRUG|Etanercept|Administered twice weekly by subcutaneous injection
215088833|NCT03780959|DRUG|Placebo|Administered twice weekly by subcutaneous injection
214984638|NCT05219162|GENETIC|Gene Profile explore|The tissue and blood sample for this genetic research will be obtained from the participants at baseline(disease progression after 1L Osimertinib). Paired tissue and whole blood sample should be collected per participant for genetics during the study.
214984639|NCT06106256|DEVICE|Galvanic Vestibular Stimulation (GVS)|Four electrodes, forehead, behind both ears, and back of your neck, provide bidirectional electrical stimulation and receive information about the amplitude delivered accounting for skin impedance
214984640|NCT06106256|OTHER|Flight simulations in virtual reality (VR)|Highly immersive, 3D virtual flight simulation environment
214984641|NCT06106256|OTHER|3-DOF Bertec Portable Essential's dual-balance force plate system|Firm surface/plate to stand on while being presented disorienting visual patters of moving vertical and/or horizontal bars of alternating black and white.
214681354|NCT03574467|BEHAVIORAL|Bobath Neurodevelopmental Treatment Approach|The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.
214984642|NCT05399875|OTHER|Augmented reality virtual ruler|Use of augmented reality virtual ruler to measure catheter length
215088834|NCT04944368|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
214984643|NCT04632108|DRUG|ASKB589 Injection|ASKB589 Injection with dose escalation stage of 0.3mg/kg up to 20mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
214984644|NCT05579015|DEVICE|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz), as described previously. iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
214984645|NCT05579015|OTHER|telephone interviews|Telephone interviews will be conducted at the follow-up stage. RMDD group will receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence
214984646|NCT04154891|GENETIC|Trio Whole Genome Sequencing|WGS trio analysis will be performed using the genome data of the index case in addition to the genome data of his parents. This analysis will follow a consensus protocol that contains 3 obligatory steps: first of all, de novo variants (SNV, CNV and others SV) will be examined in the whole genome data set; then, a SNV/CNV/other SV analysis will be performed under a AR or X linked Mendelian mode hypothesis in the whole genomic regions of a OMIM extended list (that contains all genes already involved in human genetic diseases). Finally, analysis will focus on inherited pathogenic variants under an AD mode hypothesis (analysis of variations already reported as pathogenic in clinVar or HGMD pro; CNV or truncating variation in OMIM genes, etc). When these 3 steps analysis is completed then variants of interest identified at each step will be recorded until examination by a specific multidisciplinary meeting.
214984647|NCT04154891|GENETIC|Simplex Whole Genome Sequencing|This analysis will be performed using only the index case following a similar strategy than the one used for the WGS trio
214984648|NCT04154891|GENETIC|Current French Reference strategy|Actual ANPGM recommendations defined by the following analysis: Fra-X + chromosomal microarray analysis + 44GPS
214984649|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 200 J/cm\^2.
214984650|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 400 J/cm\^2.
214984651|NCT03506061|DRUG|Trikafta|Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.
214984652|NCT02143687|BEHAVIORAL|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
214984653|NCT02143687|BEHAVIORAL|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
214984654|NCT02143687|DRUG|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
214984655|NCT02143687|DRUG|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
214984656|NCT05929833|BEHAVIORAL|BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery)|The six components of BETTER include: 1) assessment of patient/family needs and referral to community-based resources; 2) patient goal setting and review of goals; 3) health care coordination; 4) availability of clinical interventionist to patient/family; 5) training on self- and family-management and brain injury coping skills; and 6) warm hand off/referral to the state-affiliated Brain Injury Association at the end of the intervention for additional resources.
215088835|NCT04944368|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
214681355|NCT01050179|OTHER|carbon dioxide|sinusoidal carbon dioxide delivery
214984657|NCT05929833|OTHER|Usual Care|Usual care discharge planning process and follow up (e.g., verbal and written discharge instructions, with guidance on medications, outpatient therapy, and follow-up appointments)
215088836|NCT06147687|DIAGNOSTIC_TEST|Self reported data collection|ML assessement of colleceted data
215088837|NCT02437604|DRUG|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
215088838|NCT02437604|DRUG|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
215088839|NCT02437604|DRUG|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
215088840|NCT02437604|DRUG|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
215088841|NCT00831701|DRUG|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
214681356|NCT01147731|BIOLOGICAL|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
214681357|NCT05427682|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule on Day 1
214681358|NCT02532868|DRUG|MK-0457|
214681359|NCT01963117|RADIATION|Combined hyperthermia and radiation therapy|
214369807|NCT01559948|BEHAVIORAL|Lumbopelvic stabilization exercise|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
214681360|NCT02313935|OTHER|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
214984658|NCT04626505|DRUG|Ziltivekimab|Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
214984659|NCT04626505|DRUG|Placebo (ziltivekimab)|Administered s.c. once every 4 weeks for 12 weeks
214984660|NCT05880719|OTHER|Computer-assisted Music remediation|"These sessions of computer-assisted music remediation last 1h and are each divide in 4 parts :~* 15 minutes of music improvisation~* 20 minutes of harmony and rythm exercices~* 20 minutes of Lesson about the software and musical interfaces~* 5 minutes of debrief."
214984661|NCT01367691|DEVICE|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
214984662|NCT02484521|DEVICE|PPI monitoring device protocol|The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.
214984663|NCT02484521|OTHER|Questionnaires|"Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.~Questionnaires what would be used are:~1. GAF- Global assessment of functioning~2. PANSS- Positive and negative syndrome scale~3. SANS- Scale for the Assessment of Negative Symptoms~4. The Calgary Depression Scale for schizophrenia~5. Demographic Questionnaire~6. Hamilton Anxiety scale"
214984664|NCT05041465|OTHER|Clay mask|Clay mask powders- French green, Rhassul and bentonite
214984665|NCT03246945|BEHAVIORAL|Instructions on taking photographs provided, see methods|Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
214984666|NCT03890965|OTHER|Reflex locomoction therapy|"The intervention of the stimulation of the reflex locomotion is carried out in this study in a sitting position in a conventional chair, an unorthodox posture in the usual treatment of Vojta therapy.~The reflex stimulation is performed by the passive pressure exerted by the weight of the wrist (pisiform) on the rubber sphere. Simultaneously the patient has to exert a slight pressure with the heel towards the ground with his foot. This foot will be the opposite of the wrist that has the sphere under the pisiform.~Alternating each diagonal 4 times, 5 minutes each. Total session 20 minutes, 2 times x day, every day according to degree of affectation."
214984667|NCT04716543|DIAGNOSTIC_TEST|ILI and COVID-19 detection|"All participants presenting with ILI symptoms will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.~All family members more than 6 months living with SARS-CoV-2 positive individuals will have will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire."
214984668|NCT02587208|DEVICE|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
214984669|NCT02587208|PROCEDURE|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
214984670|NCT05126316|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
214984671|NCT05126316|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
214984672|NCT06062992|DIAGNOSTIC_TEST|Contrast Enhanced Stereotactic Biopsy|Stereotactic breast biopsy using CEM as targeting modality
214984673|NCT00000498|BEHAVIORAL|diet, sodium-restricted|
214984674|NCT00000498|BEHAVIORAL|diet, reducing|
214984675|NCT00000498|BEHAVIORAL|alcohol restriction|
214681361|NCT02313935|OTHER|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
215088842|NCT00831701|DRUG|Placebo|One placebo pill per day for 21 days or until stone expulsion
214984676|NCT00000498|DRUG|antihypertensive agents|
214984677|NCT02466503|DRUG|Fluticasone propionate|Inhaled corticosteroid, pMDI
214984678|NCT02466503|DRUG|Salmeterol (as xinafoate)|Beta-agonist, LABA, pMDI
214984679|NCT06433284|PROCEDURE|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole"
215094607|NCT04663334|OTHER|inverse myocardial remodeling|a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment
214681362|NCT02313935|OTHER|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
214681363|NCT02313935|OTHER|VideoGrade|Active cognitive training by use of the VideoGrade software by AUTH.
214681364|NCT02682888|BEHAVIORAL|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
214681365|NCT02682888|DRUG|Oxytocin|intranasal administration of oxytocin
214681366|NCT02682888|DRUG|Placebo|intranasal administration of placebo
214681367|NCT02082067|PROCEDURE|Adductor canal|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
214681368|NCT02082067|PROCEDURE|Femoral|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
214984680|NCT06433284|PROCEDURE|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining then filling the hole with amniotic membrane hydrogel and sulfur hexafluoride (SF6) tamponade
214681369|NCT02082067|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
214681370|NCT02082067|PROCEDURE|Local anesthetic infusion|Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
214681371|NCT02082067|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
214984681|NCT04896671|BEHAVIORAL|Physical exercise (running on a treadmill)|Participants in the intervention group join a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes. In each session, every participant will be trained to run for 30 minutes on a treadmill. According to Exercise and Sports Science Australia (ESSA) exercise intensity guidelines, the intensity of running is suggested to be moderate and vigorous (alternating between the two) in this study.
214369808|NCT01559948|DEVICE|Sacroiliac joint belt|The belt should be worn low around the pelvis just above the greater trochanter and instructed to wear the belt during all waking hours of the first four weeks of the study. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
214984682|NCT00761878|PROCEDURE|Exposure to plasma energy|Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
214984683|NCT02954081|DRUG|Phase I: Fumaric acid esters. Phase II: Apremilast|Apremilast
214369809|NCT04692402|DEVICE|Solitaire™ thrombus retrieval device|After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.
214369810|NCT02231866|BIOLOGICAL|VRC-EBOADC069-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan
214369811|NCT02231866|BIOLOGICAL|VRC-EBOADC076-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire
214369812|NCT02101229|DRUG|Insulin, Asp(B28)-|"the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient"
214369813|NCT02546934|DRUG|ABX, cisplatin|ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
214681372|NCT02082067|DRUG|Ropivacaine 0,75%|
214681373|NCT02082067|DRUG|Levobupivacaine 0,5%|
214681374|NCT02082067|DRUG|Levobupivacaine 0,125%|
214681375|NCT02082067|DRUG|Ketorolac 30mg|
214984684|NCT01618877|DRUG|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
214681376|NCT02082067|DRUG|Morphine|
214681377|NCT02082067|DEVICE|stimulong sono, Pajunk, Germany|
214681378|NCT05232591|DIAGNOSTIC_TEST|The teeth diagnosed with chronic apical periodontitis|GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
214681379|NCT02309736|DEVICE|ReSure Sealant|
214681380|NCT03911544|DEVICE|BIS monitor|Participants allocated to the intervention group will receive TIVA anesthesia adjusted by the BIS monitoring in addition to clinical signs of poor anesthesia.
214681381|NCT02089386|DRUG|Tamoxifen|
214681382|NCT02089386|PROCEDURE|Endoscopy|
214681383|NCT03015350|DRUG|Sevoflurane|Measurement of blood desflurane level during one lung ventilation
214681384|NCT03015350|DRUG|Desflurane|Measurement of blood desflurane level during one lung ventilation
214681385|NCT02619240|PROCEDURE|bronchoscopy|performance of bronchoscopy with BAL
214984685|NCT01618877|OTHER|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
214984686|NCT03418519|OTHER|Constraint Induced Movement Therapy|Constraint-induced movement therapy (CIMT) is a high-dosage, efficacious, rehabilitation approach used for children with hemiplegic cerebral palsy
214984687|NCT02933853|DRUG|Faster-acting insulin aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
214984688|NCT02933853|DRUG|Insulin Aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
214984689|NCT02164292|PROCEDURE|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
214984690|NCT00001104|DRUG|Zidovudine|
214984691|NCT05637502|OTHER|Graded Motor Imagery|Graded Motor Imagery programme consisting on three stages that will be gradually implemented. (i) Implicit Motor Imagery, that will be implemented through a developed app that resembles the Recognize app but adapted for Pelvic Floor disorders, (ii) Explicit Motor Imagery, applied through several sessions of motor imagery assisted through audio recordings and (iii) Graded Exposure, also guided through audio recordings and several practical tasks to perform.
214984692|NCT02524938|DIETARY_SUPPLEMENT|Chlorogenic Acid (CGA) enriched coffee|"Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)"
214984693|NCT02524938|DIETARY_SUPPLEMENT|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
214984694|NCT01313754|PROCEDURE|Vicryl Suture|Vicryl suture material will be placed on the patients left sided incision.
214984695|NCT01313754|PROCEDURE|Dermabond|Dermabond skin glue will be placed on the patients left sided incision.
214984696|NCT01436734|OTHER|Fasting glycemia|no intervention
214984697|NCT01436734|OTHER|Hypoglycemia|Insulin induced hypoglycemia
214984698|NCT02873975|DRUG|LY2606368|
214984699|NCT03891225|PROCEDURE|Amniotic Membrane implantation|Surgical procedure will be performed with Longemire Traverso technique. At the end of all pancreatic, biliary and duodenal anastomosis, the AM will be implanted.
214984700|NCT04655417|DRUG|Sodium Tetradecyl Sulfate|DRUG WILL BE INJECTED TO ALLAPTIENTS ACCORDING TO STANDARD PROTOCOL
214984701|NCT01860196|DRUG|Meditoxin|
214984702|NCT01860196|DRUG|Normal saline|
214984703|NCT05742334|PROCEDURE|Robot-Assisted Radical Prostatectomy with MLG-COMPLETE Allograft Implantation|The intervention will be administered on an inpatient basis. Participants receiving MLG-Complete™ will have it placed around the neurovascular bundle. Placement of the graft should not take more than 5 minutes, therefore, there should be minimal impact to overall surgical time.
214984704|NCT05742334|DEVICE|MLG-COMPLETE Allograft Implantation|The MLG-Complete™ allograft will be placed on each neurovascular bundle (NVB) bilaterally as shown on the above picture after excision of the prostate prior to completing the urethrovesical anastomosis.
214984705|NCT03699748|BEHAVIORAL|Lay Health Worker Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice). The intervention is provided along with usual care as provided by Unite Here Health and local oncologists.
214984706|NCT03699748|OTHER|Usual Care|Usual care as provided by Unite Here Health and local oncologists
214984707|NCT00123344|DEVICE|AT501 pacemaker|
214984708|NCT00687700|DRUG|GSK961081|GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
214984709|NCT00687700|DRUG|GSK961081 matching placebo|GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
214984710|NCT00687700|DRUG|Propranolol|Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.
214984711|NCT00687700|DRUG|Propranolol matching placebo|Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
215088843|NCT00829491|BEHAVIORAL|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
215088844|NCT06397508|DRUG|AGMB-129|Each participant will receive 3 study interventions, 1 in each intervention period
215088845|NCT04007770|OTHER|Acupuncture|10 treatments of acupuncture over the course of 10 weeks with a +/- 7 day window
215088846|NCT04007770|OTHER|Sham Acupuncture|10 treatments of sham acupuncture over the course of 10 weeks with a +/- 7 day window. After the 16-week study concludes patients in this group will have the option of receiving up to 10 sessions of real acupuncture; however, these sessions must be completed within 6 months of study conclusion.
215088847|NCT04007770|OTHER|16 week waiting period + optional Acupuncture|Optional real acupuncture after 16 weeks waiting period. This arm is Closed to accrual.
215088848|NCT02535533|DRUG|Selenomethionine (SLM)|SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
215088849|NCT02535533|DRUG|Axitinib|Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
215088850|NCT02535533|DRUG|Selenomethionine (SLM)|Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
215094608|NCT02265796|DRUG|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
214984712|NCT01646437|DRUG|Polycap|Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
214984713|NCT01646437|DRUG|Aspirin|75 mg daily
214984714|NCT01646437|DRUG|Vitamin D|60,000 IU monthly
214984715|NCT01646437|DRUG|Matching Placebo|Matching Placebo
214984716|NCT02473497|DRUG|Crizotinib|For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
214984717|NCT03156075|BEHAVIORAL|Nutrition and exercise program|"Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn."
214984718|NCT02426099|DRUG|Low dose spironolactone|4-week add-on low dose spironolactone in resistant hypertension
214984719|NCT02426099|OTHER|Routine intensification of antihypertensive treatment|4-week guidelines oriented intensification of antihypertensive treatment
214984720|NCT04421417|PROCEDURE|Microfracture + Standard Arthroscopic Rotator Cuff Repair|drilling of rotator cuff footprint area on humerus and standard arthroscopic rotator cuff repair
214369814|NCT02546934|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
214369815|NCT04302831|BEHAVIORAL|Strength training|weight lifting to increase muscle strength
214369816|NCT04302831|BEHAVIORAL|Endurance training|treadmill walking to increase endurance
214369817|NCT04302831|BEHAVIORAL|Flexibility training|stretches to improve flexibility
214369818|NCT04302831|BEHAVIORAL|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
214369819|NCT04302831|BEHAVIORAL|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
214984721|NCT04421417|PROCEDURE|Standard Arthroscopic Rotator Cuff Repair|Standard Arthroscopic Rotator Cuff Repair
214984722|NCT01712711|DRUG|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
214984723|NCT04132765|OTHER|Drooling Impact Scale|A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.
214984724|NCT04132765|OTHER|Drooling Frequency and Severity Scale|In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)
214984725|NCT04132765|OTHER|The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)|A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').
214369820|NCT01423682|BEHAVIORAL|Eccentric exercise|Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
214369821|NCT04577677|DEVICE|brain stimulation|tDCS and peripheral nerve stimulation
214369822|NCT03056482|DRUG|Ondansetron 8mg|Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
214984726|NCT04132765|OTHER|Drooling Quotient (DQ)|DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.
214984727|NCT04132765|OTHER|Patient and caregiver visual analog scale (VAS) for drooling|Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)
214984728|NCT04132765|OTHER|Functional Oral Intake Scale (FOIS)|Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.
214984729|NCT04132765|OTHER|number of bibs daily used|Parents will be asked their children's number of bibs daily used.
214984730|NCT04132765|OTHER|number of hospital admissions per year related to respiratory infections|Parents will be asked their children's number of hospital admissions per year related to respiratory infections.
214369823|NCT03056482|DRUG|Haloperidol 0.05mg/kg|Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
214369824|NCT03056482|DRUG|Haloperidol 0.1mg/kg|Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
214369825|NCT02780232|BEHAVIORAL|Cuida tu animo / Care for your mood|"CUIDA TU ÁNIMO is an online program to adolescents that provides information, education and support related to the care of the mood.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links. The website have the following modules:~1. What is 'CUIDA TU ÁNIMO': Description and definition of the program~2. Psycho-educational information: Information about depression, its treatment, and opportunities for prevention~3. How is your mood? (Monitoring): a) Online assessment of symptoms every two weeks during three months with the PHQ-3. b) Feedback~4. Forums.~5. Blog.~6. Appointment (Chat or Phone call).~7. Contact."
214369826|NCT02391636|DRUG|Carbetocin|at delivery of anterior shoulder
214493355|NCT05689073|DEVICE|Conversational AI system|The conversational AI system based on LLM processes user queries with a sophisticated generation, decision, action, and safety framework to provide optimal feedback. The system has several key features. Firstly, it utilizes retrieval-augmented in-context learning to enhance responses generated by the LLM, sourcing information from trustworthy websites. Secondly, it includes Guardrail module that addresses potential harmful content in the LLM-generated responses by clarifying and validating the content before delivery. Furthermore, the AI system is equipped with Self-checking memory module that retains essential clinical characteristics across multi-turn dialogues, ensuring the continuity and consistency of its interactions with users. The educational content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
214493356|NCT05689073|OTHER|Printed educational Brochure|A printed brochure whose content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
214984731|NCT04132765|OTHER|Gross Motor Function Classification System (GMFCS)|The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.
214984732|NCT04132765|OTHER|Manual Ability Classification System (MACS)|The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.
214984733|NCT04132765|OTHER|Communication Function Classification System (CFCS)|The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.
214984734|NCT04132765|OTHER|Eating and Drinking Ability Classification System (EDACS)|EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.
214369827|NCT02391636|DRUG|Oxytocin|at delivery of anterior shoulder
214369828|NCT01479998|OTHER|standard care|standard care plus nicotine replacement therapy
214369829|NCT01479998|OTHER|standard care plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
214984735|NCT05844540|PROCEDURE|harvesting bone block|Under local anesthesia, a sulcular incision was performed between lower right and left second premolars with an oblique incision distal to each one. After that, a full thickness mucoperiosteal flap was elevated to expose the anterior mandible including the entire symphysis and both mental nerves. By using piezo-surgery unit (Surgic Touch, Woodpecker, China), a rectangular bone block was harvested from the symphysis about 8mm in depth and 2mm wider than the recipient site to allow for contouring. The bone cuts were performed 5mm far from the apices of the anterior teeth, mental foramina, and inferior border of the mandible. Finally, thin curved osteotomes was used to detach the bone blocks. The harvested bone block was trimmed to form L-shape block and kept in normal saline. After hemostasis, the flap was closed with 4/0 vicryl interrupted sutures.
214984736|NCT05844540|PROCEDURE|Recipient site preparation|At the maxillary recipient site, after induction of local anesthesia, a mid-crestal incision that continued in the sulcus for two teeth on either side of the defect with bilateral oblique incisions were performed. After that, the full thickness mucoperiosteal flap was elevated. While for mandibular recipient site, it was the same flap used for harvesting symphyseal bone block. For both upper or lower recipient sites, perforations (bone marrow penetration) were done to the recipient site by using a fissure surgical bur. The L-shape block graft was trimmed to obtain optimal adaptation to the recipient site, then it was fixed to the residual ridge with two 1.5mm self-tapping titanium screws. After attaining graft stability, any sharp edges were smoothed and any gap between the graft and underlying alveolar bone was filled with particulate bone curetted from the donner site.
214984737|NCT05844540|PROCEDURE|implant insertion|"Implant insertion:~After 6months, the surgical site was opened to remove fixation screws and insert dental implants, and the final restoration was done 4months after implant insertion."
214493357|NCT06699550|OTHER|Haptonomy|The session transitioned to energy work and dream visualization. The researcher and the pregnant participant placed their left hands on each other's hearts. The goal was for the participants to feel the energy flowing between them, sense their hearts, open their third eye, and prepare their hands. This exercise aimed to enhance the pregnant participant's confidence in her own emotions and body by recognizing her feelings and physical sensations. Next, the researcher and the pregnant participant placed their right hands on the participant's forehead and their left hands over their hearts. This positioning facilitated the pregnant participant in visually sensing the presence of her baby. It was intended to promote communication between the mother and her baby at both a physical and spiritual level.
215088851|NCT02535533|DRUG|Axitinib|Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
215088852|NCT02535533|DRUG|Selenomethionine (SLM)|Pilot Phase - Dosing will begin at dose level 3 (4000, 5000 or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days
215088853|NCT06402396|DRUG|bDMARDS|Patients at time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.
214493358|NCT06699550|OTHER|Mindfulness-Based Stress Reduction Program|Participants were introduced to each other and provided with information related to pregnancy. The Mindfulness-Based Stress Reduction Program (MBSR) was introduced. The participants shared their levels of well-being, stress, coping mechanisms for fear of childbirth, and their expectations from the MBSR program. Awareness of habitual behaviors was facilitated. Afterwards, breath-focused meditation and dried fruit meditation were practiced. Participants were encouraged to maintain awareness of activities performed at any time during the day. Lastly, body scan meditation was taught, and participants were instructed to repeat the practice throughout the week using audio recordings.
214493359|NCT06880107|BIOLOGICAL|blood withdrawal|blood withdrawal
214493360|NCT06888583|PROCEDURE|Transpedicular fixation|Patients underwent transpedicular sacral fixation.
214369830|NCT02984657|PROCEDURE|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.|RTP, reverse Trendelenburg positioning
214369831|NCT02984657|PROCEDURE|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.|RTP, reverse Trendelenburg positioning
214369832|NCT01222169|DRUG|NaCl 0,9%|Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
214369833|NCT05131165|BEHAVIORAL|Daily Text Messages|Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.
214369834|NCT05131165|BEHAVIORAL|Incentivization based on timely ART adherence|Participants will be eligible to draw a prize if they take their medication within +/- one hour of the stated existing routine to which pill-taking is anchored on at least 70% of days between recruitment and the 3-month study visit.
214369835|NCT03652779|DRUG|Tecarfarin 10mg|Tecarfarin 10mg tablets
214369836|NCT03652779|DRUG|Tecarfarin 20mg|two tecarfarin 10mg tablets
214369837|NCT03652779|DRUG|Tecarfarin 30mg|three tecarfarin 10mg tablets
214369838|NCT03652779|DRUG|Tecarfarin 40mg|four tecarfarin 10mg tablets
214369839|NCT04930692|DIAGNOSTIC_TEST|Contrast-enhanced CT lymphography with the periareolar injection of iopamidol|"Patients who meet the inclusion/exclusion criteria will undergo the CT lymphography with periaoreolar injection of a mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride. Computed tomographic images will be obtained 1, 3, 5, and 10 minutes after administration of the iopamidol. Following enhancement of the lymphatic duct, the first lymph node to show enhancement will be defined as the SLN.~No later than 10 days after the CT lymphography patients will receive surgical treatment. During breast cancer surgery identification of the SLN using the ICG-fluorescence method with injection of 2 ml indocyanine green into the skin of the areola and the biopsy of identified SLN will be performed. The comparison of the results of CT lymphography and SLN biopsy will be administrated by the investigator."
214369840|NCT03626779|OTHER|Prf|Take 10cc blood from patient and gain prf blug
214493361|NCT06778161|PROCEDURE|nerve block|Nerve block for providing analgesia after thoracotomy
214493362|NCT06826547|DRUG|Adjustment of insulin doses DAR|"Patients will be hospitalized at La Rabta Hospital from February 15 to February 28, 2025 for clinical (weight, BP, SF-12), biological (HbA1c, lipid profile) assessments and inflammatory markers (Interleukin 6 and TNF alfa) DAR Group: Insulin will be adjusted per DAR 2021 guidelines. Patients will track insulin doses, glycemic cycles, hypoglycemia episodes, fasting interruptions, and hospital visits in a dedicated log. They will receive weekly calls for insulin adjustments and continuous support.~During the last week of Ramadan, clinical and biological data including inflammatory markers will be collected. Two months post-Ramadan, HbA1c, fasting glucose, and lipid profile will be reassessed to evaluate glycemic control."
214493363|NCT06826547|DRUG|Adjustment of insulin doses CFT|"Patients will be hospitalized at La Rabta Hospital from February 15 to February 28, 2025 for clinical (weight, BP, SF-12) and biological (HbA1c, lipid profile) assessments and inflammatory markers (Interleukin 6 and TNF alfa) .~CFT Group: Insulin adjusted after a Carbohydrate Fasting Test. Patients will track insulin doses, glycemic cycles, hypoglycemia episodes, fasting interruptions, and hospital visits in a dedicated log. They will receive weekly calls for insulin adjustments and continuous support.~During the last week of Ramadan, clinical and biological data including inflammatory markers will be collected. Two months post-Ramadan, HbA1c, fasting glucose, and lipid profile will be reassessed to evaluate glycemic control."
214493364|NCT06892171|BIOLOGICAL|Blood sample|blood sample for genetic analysis
214493365|NCT06894459|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, 3 cycles
214493366|NCT06894459|DRUG|Cisplatin|cisplatin 75mg/m2, IV, 3 cycles
214493367|NCT06894459|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg, IV, 3 cycles
214493368|NCT06742697|BEHAVIORAL|Flexibility, Resistance, Aerobic, Movement Execution training|"Flexibility: static and dynamic stretching combined with sensory, high-frequency electrical stimulation to reduce spasticity and improve mobility.~Resistance training: core stability and lower limb strength training in conditions of instability, to improve strength, coordination, and balance.~Movement execution training: gait training according to motor learning principles.~Aerobic exercise: in the form of high-intensity interval training at the end of each session, to improve cardiovascular status and foster motor learning consolidation (probably due to the release of brain derived neurothrophic factors)."
214984738|NCT04425317|DIAGNOSTIC_TEST|Blood sample|Blood sample and endometrial biopsy on the moment of oocyte retrieval
214984739|NCT04730609|DRUG|Dexmedetomidine|Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
214984740|NCT03684408|DEVICE|RFID Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
214984741|NCT03684408|DEVICE|Wire Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
214984742|NCT03684408|DEVICE|RFID and Wire Localization|Both RFID and the standard of care wire localization will be performed for physician training.
214984743|NCT02631447|DRUG|LGX818|LGX818 450 mg p.o. od
214984744|NCT02631447|DRUG|MEK162|MEK162 45 mg p.o. bid
214984745|NCT02631447|DRUG|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
215088854|NCT00843154|DRUG|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
215088855|NCT00843154|DRUG|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
215094609|NCT02265796|DRUG|Sugar pill|"1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
215094610|NCT03382067|DIETARY_SUPPLEMENT|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
215094611|NCT03382067|OTHER|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
215094612|NCT01150643|GENETIC|gene expression analysis|
215094613|NCT01150643|GENETIC|microarray analysis|
214369841|NCT03960229|OTHER|MicroFluidic Sperm Sorting Chips|sperm selection of IVF treatment
214369842|NCT03960229|OTHER|Gradient-Density Centrifugation|sperm selection of IVF treatment
214369843|NCT01267292|DRUG|Buspirone|\[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday\]
214369844|NCT01267292|DRUG|Placebo for Buspirone|\[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\]
214984746|NCT02631447|DRUG|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
214984747|NCT04953195|DRUG|Levothyroxine Sodium Tablets|Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
215088856|NCT05365048|OTHER|Local Tailoring implementation strategy|"The local-tailored approach will be guided by a structured process involving the following: (1) convening a local HPV vaccine project team, (2) conducting a local diagnostic process to identify top barriers, (3) selecting from a menu of intervention options that will be offered in this study, categorized by core function (i.e., the forms and functions menu) that address top local barriers, and (4) deploying the selected interventions. The barrier assessment and intervention customization are key processes for the local-tailored strategy, which allow clinics to devote resources to respond to unique local barriers in addition to common barriers."
214369845|NCT01267292|DRUG|Methylphenidate|Methylphenidate serves as an acute stimulant challenge. \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
214493369|NCT04921449|OTHER|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
214493370|NCT04921449|OTHER|Usual Care|Includes any diagnostic imaging, patient education and reassurance, and administration or prescribing of analgesic medications, as per the treating physician's usual and customary practice.
214493371|NCT06736860|DRUG|Tranexamic acid (TXA) injection|All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. The 1+1 control group continued to infuse 1g TXA within 8 h.
214493372|NCT06736860|DRUG|Tranexamic acid (TXA) injection|All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. the 1+x study group was subjected to thromboelastography (TEG) without TXA for the time being, and the coagulation and fibrinolytic status of the patients was judged according to the results of TEG (LY30, EPL value), and the patients diagnosed with hyperfibrinolysis continued to be infused with 1g TXA, and the patients diagnosed with normal or reduced fibrinolysis were not infused with TXA. TEG was rechecked after 4 h, and the decision of whether to use TXA was based on the TEG results.
214493373|NCT06312514|BEHAVIORAL|LAFIYA|The Lafiya intervention is a comprehensive program designed to address the intersectional stigma and discrimination challenges faced by marginalized communities, particularly among Gay, Bisexual, and other Men who have Sex with Men (GBMSM). It aims to enhance HIV prevention, care, and treatment outcomes, with a focus on increasing HIV self-testing (HIVST) uptake among these key populations in Ghanaian urban slum settings.
214681386|NCT01605396|DRUG|Ridaforolimus|Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.
214984748|NCT01526408|DRUG|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
214984749|NCT01526408|DRUG|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
215088857|NCT05365048|OTHER|Prescribed Strategy|"The prescribed strategy is the standard implementation approach used by most health systems. Our prescribed approach will be guided by the evidence-based, award-winning 4 Pillars™ Practice Transformation Program for improving vaccination rates in the outpatient setting. The 4 Pillars™ address 4 main functions, i.e., convenience, communication, office systems, and motivation to guide the selection of interventions. For adolescent HPV vaccination, the 4 Pillars has demonstrated moderate effectiveness."
215088858|NCT05755815|PROCEDURE|retrolaminar block|A high-frequency 12 MHz linear ultrasound probe will be used, patients will receive bilateral ultrasound-guided retrolaminar plane block with 20 mL of bupivacaine 0.25%. Their spines will be palpated from the vertebra prominens caudally to T7 and point will be marked to identify the spinous processes, which will be confirmed by ultrasound through counting from T12 with the characteristic last rib attached to its transverse process upward to the T7 lamina. The linear high frequency transducer (6-13 MHz) will be placed in the parasagittal plane one cm lateral to the midline. The needle will be inserted in the in-plane view of the ultrasound probe and will be advanced from downward to upward to target the T7 posterior lamina surface at an angle of 90˚ to the skin until the needle tip will be contacted the posterior surface of targeted lamina . After negative aspiration, 20 mL of bupivacaine 0.25% will be injected. The procedure was repeated following the same steps on the other side.
214681387|NCT01605396|DRUG|Dalotuzumab|Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
214681388|NCT01605396|DRUG|Exemestane|Exemestane 25 mg tablet administered PO QD.
214681389|NCT05174052|DRUG|Dapagliflozin 10Mg Tab|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.
214984750|NCT06413966|PROCEDURE|Partially absorbable mesh|\- In this group, after bullectomy or blebectomy, partially absorbable mesh (ULTRAPRO size 15 x 15 cm, Ethicon) will be prepared and inserted into the pleural cavity through one of the working ports and placed at the apical part of the thoracic cage (over the staple line) using fixation device (ProTack™ 5 mm fixation device, Medtronic).
214984751|NCT06413966|PROCEDURE|Apical pleurectomy|\- In apical pleurectomy group, after bullectomy or blebectomy, the parietal surface from the apex to the fifth rib was dissected and abraded using a curved dissector with a diathermy scratch pad. Abrasion was done until a uniform aspect of bloody pleura was obtained.
214984752|NCT04155645|DRUG|AZD8233 subcutaneous injection|Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
214984753|NCT04155645|DRUG|Placebo|Randomized subjects will receive SC dose of placebo injection.
214681390|NCT05174052|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
214369846|NCT01267292|DRUG|Placebo for Methylphenidate|\[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
214369847|NCT05897723|DEVICE|Fractional Radiofrequency|Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.
214984754|NCT02062697|PROCEDURE|Lavage of the Cavum uteri and proximal fallopian tubes|
214369848|NCT05181293|BEHAVIORAL|Mobile Gaming App for Nutrition Intervention|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
214369849|NCT01103310|DRUG|BAY94-9392|
214369850|NCT03238898|DRUG|Botulinum toxin type A|"botulinum toxin type A injections~Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
214984755|NCT02062697|PROCEDURE|Liquid-PAP smear|
214681391|NCT02124850|DRUG|Motolimod|
214681392|NCT02124850|DRUG|Cetuximab|
214369851|NCT03238898|OTHER|Normal saline|"Normal saline injections~The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
214493374|NCT06843096|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography (CEM)|"The intervention in this study involves Contrast-Enhanced Mammography (CEM), a specialized imaging technique that combines standard mammography with contrast-enhanced imaging to detect neo-angiogenesis, which is a characteristic of malignancy. Unlike traditional mammography, CEM utilizes both low-energy and high-energy images to provide enhanced visualization of tissue vascularity, aiding in the identification of occult primary tumors, particularly in patients with Cancer of Unknown Primary (CUP) syndrome.~Patients who present with CUP syndrome, suspected of having a primary breast malignancy, will undergo CEM as part of their diagnostic workup. The CEM findings will be compared with other conventional imaging modalities, including ultrasound and MRI, to assess the diagnostic accuracy of CEM in detecting primary breast tumors. The intervention will also involve correlating the imaging results with histopathological findings from biopsy or surgical specimens.~This study aims to demons"
214984756|NCT04763993|PROCEDURE|Roux-en-Y-Gastric bypass, Sleeve gastrectomy|RYGBP consists in creating a small gastric pouch along the little curvature of the stomach, followed by the section of the small bowel. The restoration of the gastro-intestinal tract is achieved by performing a gastro-jejunal and a jejuno-jejunal anastomosis, giving this procedure the characteristic aspect of a Y. Also, for RYGBP the laparoscopic approach requires the placement of 5 trocars in the upper part of the abdomen.
214984757|NCT04763993|PROCEDURE|SG|SG consists in removing the fundus and the body of the stomach, along the greater curvature. To perform it with a laparoscopic approach, we create the pneumoperitoneum with Veress needle and place 5 trocars in the upper part of the abdomen. The first step is the dissection of the greater curvature of the stomach, that starts at 6 centimetres from pylorus and it's conducted up to the angle of His, freeing the fundus and exposing the left pillar. A 38 Fr bougie is placed inside the stomach to calibrate its section. After it is carried out, the specimen is removed from the greater trocar site.
214984758|NCT01899911|DEVICE|Vital Signs Patch (VSP)|Infrared and red absorbance measurement
214984759|NCT04223947|PROCEDURE|DIGESTIVE ENDOSCOPY|DIGESTIVE ENDOSCOPY
215094614|NCT01150643|GENETIC|polymerase chain reaction|
214493375|NCT06837779|DRUG|Fluoride Iontophoresis with Acidulated Phosphate Fluoride|Application of fluoride gel and activated with Iontophoresis electrical pole
214681393|NCT02124850|DRUG|Nivolumab|
214369852|NCT06282614|DEVICE|Mucogyne Ovule|At inclusion visit (V0), the Investigator will ask the subject to use MUCOGYNE® Ovule 2 times a week until symptoms improve during 5 weeks (D35± 3) preferably at bedtime
214369853|NCT04074421|DRUG|Rifaximin|A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.
214493376|NCT06837779|DRUG|Remineralization with sodium fluoride varnish|CASIN PHOSPHOPEPTIDE AMORPHOUS CALCIUM PHOSPHATE
214681394|NCT06671639|DEVICE|da Vinci Xi Robotic Surgery System|"The da Vinci Xi Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery. It consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument and EndoWrist Xi instruments and accessories.~The surgeon seated at the surgeon console controls all movement of the EndoWrist Xi instruments and Camera Instrument using two master controls and a set of foot pedals. The surgeon views the three-dimensional endoscopic image on a high-resolution stereo viewer (3D viewer), which provides him/her/they a view of patient anatomy and instrumentation, along with icons and other user interface features. The Vision Cart includes the supporting electronic and video processing equipment for the system."
214681395|NCT03067766|PROCEDURE|Art Therapy|Participate in a comic art creation workshop
214984760|NCT01508988|DRUG|ONO-9054|Eye drops 0.3 µg/mL both eyes on Day one
214984761|NCT01508988|DRUG|ONO-9054|Eye drops 1 µg/mL both eyes on Day one
214984762|NCT01508988|DRUG|ONO-9054|Eye drops 3 µg/mL both eyes on Day one
214984763|NCT01508988|DRUG|ONO-9054|Eye drops 10 µg/mL both eyes on Day one
214984764|NCT01508988|DRUG|ONO-9054|Eye drops 20 µg/mL both eyes on Day one
214984765|NCT01508988|DRUG|ONO-9054|Eye drops 30 µg/mL both eyes on Day one
215094615|NCT01150643|GENETIC|polymorphism analysis|
215094616|NCT01150643|OTHER|immunohistochemistry staining method|
215094617|NCT01150643|OTHER|laboratory biomarker analysis|
214369854|NCT04074421|DRUG|Probiotic Formula|A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
214369855|NCT04074421|DRUG|Placebo oral tablet|Placebo oral tablet that has no therapeutic effect
214369856|NCT02298361|OTHER|Health insurance outreach IT tools|"IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management."
214369857|NCT00598026|OTHER|Tele- follow-up|Remote transmission to the implantation centre every 3 months
214369858|NCT00598026|OTHER|Conventional follow-up|Visits at the implantation centre every 3 months
214369859|NCT05541055|DEVICE|digital CBT-I|A fully-automated and personalized digital intervention based on principles from cognitive behavioral therapy for insomnia.
214493377|NCT06739148|DEVICE|Low Level Laser Therapy|Low-level laser therapy can increase cellular energy production, making it useful as a pre-conditioning treatment to prevent muscle contraction fatigue or as a post-contraction therapy to accelerate fatigue recovery.
214493378|NCT06739148|DEVICE|blood flow restriction|Its advantage is that during training, it can surpass the \&#34;overload principle,\&#34; allowing for effective muscle cross-sectional area growth with relatively light weight training (20%-50% of 1RM or 20%-40% of MVC).
214493379|NCT06739148|DEVICE|Neuromuscular Electrical Stimulation|It is a strength training method that uses electrical currents to stimulate nerve and muscle activation, helping to maintain muscle mass, increase blood flow, and slow down or prevent muscle atrophy.
214493380|NCT06765200|BEHAVIORAL|Self-administered psychosocial intervention delivered via smartphone.|The treatment includes a smartphone-based psychosocial program designed to improve the quality of life of adolescents with chronic pain.
214493381|NCT06762704|OTHER|Video recording|Videos of rotating the blastocysts will be recorded during the preparation stage of trophectoderm (TE) biopsy. The focal plane starts from the middle plane of the blastocyst. and then moves downwards until individual TE cells and inner cell mass (ICM) are clearly visible. A biopsy micropipette is used to gently push the blastocyst and rotate the blastocyst each time by a small angle, for instance, smaller than 35° such that more than 10 images can be captured for the entire 360° rotation to achieve high-accuracy measurement. After the first 360° rotation, the second one will be conducted around the axis perpendicular to the previous axis to ensure the whole surface of the blastocyst is captured. The entire rotation process will be video recoded.
214493382|NCT06764108|BEHAVIORAL|Self-monitoring|Self-monitoring will involve completing one brief smartphone-based survey (at a fixed time) per day on suicidal thoughts and related affect states and experiences over the past day during the four weeks after psychiatric hospitalization.
214493383|NCT06764108|BEHAVIORAL|JITAI|The JITAI will involve prompts to complete additional randomly timed self-monitoring surveys throughout the day. When suicidal thoughts are reported on any self-monitoring survey, random assignment to receive or not receive a series of automated smartphone-based messages that recommend using specific coping strategies from either a personalized safety plan or general evidence-based coping strategies that others tend to find helpful.
214493384|NCT06764108|BEHAVIORAL|Self-guided SSI|The brief (10-12 minute) online self-guided SSI will help individuals identify and address barriers to using coping strategies for suicidal thoughts. It may be delivered up to three times during the four weeks after hospitalization for those who do not sufficiently respond to the initial (self-monitoring only or self-monitoring plus JITAI) interventions.
214681396|NCT03067766|OTHER|Interview|Undergo qualitative interviews
214681397|NCT03067766|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214681398|NCT03067766|OTHER|Questionnaire Administration|Ancillary studies
214681399|NCT04341844|DRUG|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
214984766|NCT01508988|DRUG|ONO-9054|Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
214984767|NCT02821533|PROCEDURE|TACE|TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
214984768|NCT02821533|DRUG|Cisplatin|Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
214984769|NCT05978167|DRUG|Methylphenidate|Oral administration of 20 mg Methylphenidate
214984770|NCT05978167|BEHAVIORAL|Memory reconsolidation|Retrieval of drug-cue memories before extinction.
214984771|NCT05978167|DRUG|Placebo|Matching placebo pill
214984772|NCT06986148|OTHER|Immediate Antibiotic Prescribing Group Instructions|Children randomized to the immediate antibiotic prescribing group will receive an antibiotic prescription with instructions to fill and administer the antibiotics.
214984773|NCT06986148|OTHER|Safety Net Antibiotic Prescribing (SNAP) Group Instructions|For children randomized to the SNAP group, their parents or guardians will receive a prescription for antibiotics, but will be told not to administer the antibiotic unless their child's symptoms show no improvement at 72 hours or worsen within 72 hours.
214984774|NCT03847402|BEHAVIORAL|The early integrated intervention for GDD|The early integrated intervention for GDD integrates developmental approaches with strategies of applied behavior analysis.
214369860|NCT05541055|OTHER|Sleep hygiene education|Participants will be provided with sleep hygiene advice which will be delivered digitally all at once upon allocation to the SHE arm. Participants will be able to revisit content during the trial as they wish.
214369861|NCT00440869|DIETARY_SUPPLEMENT|N-acetylcysteine|600 mg po bid
214369862|NCT00440869|DIETARY_SUPPLEMENT|placebo|bid oral dosing
214369863|NCT03631446|DRUG|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Combination powder for oral solution
214369864|NCT00953264|BEHAVIORAL|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
214984775|NCT03847402|BEHAVIORAL|The early integrated intervention for ASD|The theoretical underpinnings of the early integrated intervention for ASD originate from Early Start Denver Model.
214984776|NCT03847402|BEHAVIORAL|The early integrated intervention for ADHD|The methods of the early integrated intervention for ADHD includes behavior training, sensory integration training and psychological counseling
214369865|NCT05388721|OTHER|Clinical data and specimen collection|"Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible."
214984777|NCT03847402|BEHAVIORAL|community intervention for ASD|TEACCH (Treatment and Education of Autistic and related Communication- handicapped Children) intervention or ABA(applied behavior analysis) intervention
214984778|NCT03847402|BEHAVIORAL|Community intervention for GDD|community intervention based on developmental approaches
214984779|NCT03847402|BEHAVIORAL|community intervention for ADHD|School and family education
214984780|NCT01499810|PROCEDURE|Bilateral radiofrequency sympathetic renal denervation|Bilateral radiofrequency sympathetic renal denervation is performed as percutaneous transluminal radiofrequency (RF) ablation of neural pathways in the renal artery walls and surrounding tissue using standard equipment for RF ablation of cardiac electrical pathways
214984781|NCT03198845|OTHER|video game|20-min per session for 3 times per week for a 4-week duration
215088859|NCT05755815|PROCEDURE|Peritoneal block|before giving an incision for the ports, 20 ml of 0.25% bupivacaine will be infiltrated subcutaneously over the port sites (6 ml will be infiltrated around each midline port site and 4 ml will be infiltrated around at the lateral port sites) and at the end of surgery and before the removal of trocars, 20 ml of 0.25% bupivacaine diluted in normal saline will be instilled by the surgeon intraperitoneally at gallbladder bed and under domes of both diaphragms under direct vision with a separate catheter passed through one of the trocars.. The pressure of the gas insufflation was kept within 10-12 mm Hg in all patients. At the end of surgery, CO2 was evacuated, and intraperitoneal anesthetic solution was left in situ.
214369866|NCT03012464|OTHER|Pathologic and functional assessment|Random biopsies will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. Tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type I and type III, and to reveal any myopathic or degenerative changes
214369867|NCT02944084|DIETARY_SUPPLEMENT|Rice bran extract|
214369868|NCT02944084|DIETARY_SUPPLEMENT|Porridge in water|
214369869|NCT02944084|DIETARY_SUPPLEMENT|Porridge in milk|
214493385|NCT06764108|BEHAVIORAL|Clinician-delivered SSI|The clinician-delivered SSI will consist of a brief (30-minute) Zoom or phone meeting in which a study clinician will help individuals identify and address barriers to using coping strategies for suicidal thoughts. Those who do not sufficiently respond to the initial (self-monitoring only or self-monitoring plus JITAI) interventions may receive up to three clinician-delivered SSIs during the four weeks after hospitalization.
214493386|NCT06763523|PROCEDURE|arthroereisis of the subtalar joint|arthroereisis alone versus arthroereisis combined with corrective osteotomies
214493387|NCT06756659|OTHER|Center-based exercise training|All participants will undergo a spot jogging cardiopulmonary exercise test and a six-minute walking test. The outpatient center-based cardiac rehabilitation group will perform moderate-intensity stationary biking or treadmill exercise for 30 minutes, twice a week, under the supervision of a physical therapist in the outpatient cardiac rehabilitation room.
214493388|NCT06756659|OTHER|Home-based spot jogging|The home-based spot jogging cardiac rehabilitation group will receive exercise intensity guidance in the outpatient cardiac rehabilitation room for 30 minutes of spot jogging and treadmill exercise during the first, fourth, and seventh weeks. They will then perform moderate-intensity spot jogging at home for 30 minutes, twice a week, at a perceived exertion level of 13 out of 20 on the RPE scale.
214493389|NCT03280030|DRUG|Midostaurin|Midostaurin 50 mg \[two 25 mg capsules\] were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
214984782|NCT03198845|OTHER|exercise|20-min per session for 3 times per week for a 4-week duration
214984783|NCT06443827|DRUG|Amantadine Sulfate|intravenous amantadine sulphate at a single daily dose of 200 mg or physiological saline (0.9% NaCl solution)
214369870|NCT05845268|COMBINATION_PRODUCT|Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
214369871|NCT05845268|COMBINATION_PRODUCT|Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
214493390|NCT03280030|DRUG|Placebo|Placebo, two capsules, were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
214984784|NCT01042418|OTHER|Effect of breakfasts with whole vs milled rye kernels on appetite|Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
214984785|NCT05356364|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|cognitive and behavioral treatment for perinatal insomnia.
214984786|NCT05356364|BEHAVIORAL|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|Mindfulness and behavioral based therapy for perinatal insomnia.
214984787|NCT07005973|BEHAVIORAL|mobile-based mindfulness intervention|"Patients will be provided with usual care by surgeon, anesthetist and perioperative team, and they will be asked to install a validated mindfulness based mobile app during the PAS session. Orientation and teaching on the use of the mobile app will be carried out by research team. Return demonstration by patients will be performed at the end to ensure they are capable to use the app at home independently.~A minimum of 4-week intervention duration with session lengths of 1 min, 3 days per week is set for this study.~Patients will be distributed a dairy log to record the frequency and duration of mindfulness practice and submit to the researcher on the day of admission. Follow up on patient's progress through phone call or whatsapp will be provided by the researcher to ensure patient's adherence to the intervention on a bi-weekly basis."
214369872|NCT03979196|OTHER|Inpatient Management|"Admission for a minimum of three days, administration of betamethasone, and clinical reassessment by obstetrician after three days. After the initial three day admission, further management will be at the discretion of their obstetrician who will continue their care and decide if further admissions are needed.~Weekly cervical length assessment will be performed until 28 weeks and patient readmission will be decided by their Obstetrician.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
214984788|NCT03658980|BEHAVIORAL|Health Education Intervention|Face-to-face health education intervention on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminder at Day 7, 30 and 90.
214369873|NCT03979196|OTHER|Outpatient Management|"Avoid heavy lifting and core exercise, avoid intercourse, weekly assessment of cervical length by ultrasound and administration of betamethasone. Patients will continue with outpatient management for the remainder of their pregnancy with no admission unless the patient develops contractions, PPROM, bleeding, or the cervix is dilated to ≥1cm.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
214369874|NCT02560870|DRUG|Active Comparator:Aloe Vera mouthwash|mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
214369875|NCT02560870|DRUG|Active Comparator:Chlorhexidine mouthwash|mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
214369876|NCT06185998|DEVICE|low pressure tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
214369877|NCT06185998|DEVICE|plated balloon tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
214369878|NCT03372330|DRUG|Standard care for sepsis and PAD|The standard medications care for the patient with PAD included antiplatelet agents.
214369879|NCT03372330|DRUG|Standard care for sepsis|The standard care for the patient with sepsis.
214493391|NCT05933941|OTHER|Virtual reality|"This is a game set in space in which you pilot a spaceship and have to go through rings while dodging meteorites, all controlled by neck movements. Before starting the game, the assigned therapist is in charge of establishing the necessary movement parameters. In addition, the software allows you to modify the difficulty of the game. We will start the first 3 sessions in easy mode, where cervical mobility does not exceed 30º. The following 3 sessions will be configured in medium mode, reaching 60º of mobility. In the last 2 sessions, we will select the hard mode, which not only increases the speed of the spacecraft but also covers the entire range of cervical mobility."
214493392|NCT05933941|OTHER|Exercises|The patients perform mobility and strengthening exercises for the cervical region, in which they are required to complete 1 set of 10 repetitions for each exercise. The patient should rest for at least 30 seconds between exercises.
214493393|NCT06771232|PROCEDURE|Subdural pressure measurement|Subdural intracranial pressure (SDIP) will observed during an alveolar recruitment maneuver and best PEEP titatration. SDIP will be measured while mechanical ventilation is maintained using the identified best PEEP.
214681400|NCT04341844|DRUG|Placebo|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
214681401|NCT06920485|PROCEDURE|Third molar surgery|Effects of different gargles/mouth rinses/antiseptic agents applied after impacted surgical tooth extraction on postoperative wound healing and total bacterial load
214681402|NCT06920485|DIAGNOSTIC_TEST|Pain Medicine|After the extraction, patients will be given two separate forms with VAS scales for pain to mark every day for 7 days. The patient will be asked to mark the level of pain they feel on the scale. The amount of analgesic use on the home assessment form will also be recorded as part of the pain assessment. On the 7th day, healing in the wound area will also be assessed.
214681403|NCT06920485|DIAGNOSTIC_TEST|Wound healing|The degree of healing of the wound area will be checked using Landry scoring.
214984789|NCT07014137|DRUG|ABSK043 single agent|ABSK043 BID continuously for 28 day cycle
215088860|NCT05433415|BEHAVIORAL|Black Girls Move|Goal setting and monitoring. All BGM daughters will self-monitor their progress towards PA goals using a PA device, Fitbit®. Additionally, BGM daughters will self-monitor their progress towards diet goals using a mobile application, Start Simple with My Plate®. Further, all BGM mothers will use Fitbit® and Start Simple with My Plate® for self monitoring, however, mothers' data will not be analyzed for this study. Since the daughter/ mother relationship is critical to achieving behavioral change, BGM mothers will utilize Fitbit® and Start Simple with My Plate® as a mechanism to communicate, problem solve and support daughters' behavioral goals.BGM is situated within the contexts of environmental, cultural, interpersonal, and developmental factors impacted by structural racism. Intentionally engaging mothers and daughters in an asset based program provides a framework for mothers to model responses to structural racism i.e. racial socialization.
215088861|NCT00270660|BEHAVIORAL|biopsy, audiometry, ET function test, ear swab culture, DNE|
215088862|NCT03566017|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
214681404|NCT06920485|OTHER|Total bacterial load|Total bacterial load will be evaluated by microbiological analysis of sutures obtained from all groups.
214369880|NCT02459262|BIOLOGICAL|GBS-NN vaccine|Three dose levels will be administered, with and without Alhydrogel®
214369881|NCT01656330|DRUG|Rivaroxaban 20 mg twice daily|One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
214369882|NCT01656330|DRUG|Rivaroxaban 20 mg once daily|One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
214369883|NCT01656330|DRUG|Profilnine SD|Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
214369884|NCT01656330|DRUG|Beriplex P/N|Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
214369885|NCT01656330|OTHER|Saline|Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
214369886|NCT03233568|DIAGNOSTIC_TEST|Indirect calorimetry|"Indirect calorimetry will be performed by using an open-circuit calorimeter (Sensor Medics, Italy). Indirect calorimetry is the reference method for energy expenditure determination. A canopy hood covered the patient's head and expired air is extracted by a pump to be analyzed by metabolic cart sensors; flow rate is directly measured with a digital turbine flowmeter. After an overnight fast, patients will asked to lay supine in complete physical rest, not sleeping or talking for approximately 20-25 minutes, at a room temperature ranged between 22 and 24°C. The mean REE for each participant considers the last 15-20 minutes of measurements corresponding to steady state.~Software of calorimeter will be set for minute-by-minute reading report of VO2 (Oxygen flow) and VCO2 (Carbon dioxide flow) measurement.~Parameters obtained by Indirect Calorimetry will be the Resting Energy Expenditure and the Respiratory Quotient (RQ)"
214369887|NCT05168579|BEHAVIORAL|Deliberate practice|As above
214369888|NCT01302431|OTHER|Manualised nurse-led telephone support|The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
214369889|NCT00303056|DRUG|HOE140 Icatibant|
214369890|NCT00181571|DRUG|methylphenidate HCl (Concerta)|up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
214369891|NCT00181571|DRUG|Placebo|up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
214369892|NCT03107078|DRUG|Glucocorticoids|Intravenous Glucocorticoids (GCs)
214369893|NCT06363422|PROCEDURE|Epicanthoplasty|Patients with unsatisfied blepharoplasty underwent epicanthoplasty in our center
214369894|NCT01242748|DRUG|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
214369895|NCT01242748|DRUG|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
214369896|NCT00840801|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360
214369897|NCT00840801|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
214369898|NCT05542810|COMBINATION_PRODUCT|Use sports drinks as polyethylene glycol solvents|Using sports drinks as a polyethylene glycol solvent and water as a polyethylene glycol solvent in the control group, the effectiveness of intestinal preparation in the two groups was compared, and the adverse reactions, the acceptability of the solution taste, the timing of oral laxatives, and the willingness to repeat the same intestinal preparation or the willingness to recommend the same intestinal preparation to others were compared.
214493394|NCT06775600|PROCEDURE|Hip Replacement|Total Hip Arthroplasty where the Femoral Head will be used to harvest stem cells post-extrication from the individual.
214493395|NCT06310343|DRUG|Alemtuzumab|Licensed dose
214493396|NCT05301842|DRUG|Tremelimumab|Tremelimumab IV (intravenous)
214493397|NCT05301842|DRUG|Durvalumab|Durvalumab IV (intravenous)
214493398|NCT05301842|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
214493399|NCT05301842|DRUG|Lenvatinib|Lenvatinib (oral)
214493400|NCT06775054|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It is primarily used to treat depression, particularly in patients who have not responded to traditional treatments such as selective serotonin reuptake inhibitors (SSRIs) or psychotherapy. The most common target area is the dorsolateral prefrontal cortex, which is often underactive in individuals with depression. TMS devices, such as the FDA-approved Magventure system, deliver magnetic pulses to stimulate or inhibit brain activity in the targeted region. This process is believed to help reset or normalize patterns of neural activity associated with depression and other psychiatric disorders. TMS offers a promising alternative for individuals struggling with depression, providing a non-invasive approach with relatively few side effects and notable potential benefits.
214681405|NCT06896604|DEVICE|Ocular Ultrasonography for measuring Optic Nerve Sheath Diameter|In the study, the investigators measured the optic nerve sheath diameter to observe its effects on intracranial pressure and used ocular ultrasonography for this measurement.
214681406|NCT06896032|OTHER|physical therapy intervention|retro-walking and forward-walking underwater treadmill training
215088863|NCT01283308|BEHAVIORAL|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
214369899|NCT05386667|DRUG|Majezik %0.25 oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
214369900|NCT05386667|OTHER|Aftamed oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
214369901|NCT05386667|OTHER|Crystalin oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
214369902|NCT05386667|PROCEDURE|Free gingival graft harvesting|Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.
214369903|NCT05272891|OTHER|experimental group|audio book app
214493401|NCT06770374|PROCEDURE|Control group: silicone adhesive sutureless fixation device|"The standard care consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV), cyanoacrylate glue (SecurePortIV®) and silicone adhesive sutureless fixation device (3300MWA Grip-Lok®)."
214493402|NCT06770374|PROCEDURE|Intervention Group: zinc oxide sutureless fixation device|"Alternative care consisted of:~* Application of haemostasis at the insertion site for 2 minutes post-puncture or until cessation of bleeding.~* Fixation with clear polyurethane dressing (3M®-1655 Tegaderm™ IV), cyanoacrylate glue (SecurePortIV®) and zinc oxide sutureless fixation device (2200NUZA Grip-Lok®)."
214493403|NCT06770374|DEVICE|PICC|"The PICC lines used in the study will all be third-generation polyurethane and of the commercial brands:~* PowerPICC™ 4, 5 and 6 Fr from BD~* Maxflo expert™ 5 and 6 Fr from Vygon"
214493404|NCT06770374|DEVICE|Midline|"The midline lines used in the study will be second or third generation polyurethane and of the commercial brands:~* PowerMidline™ 4 Fr from BD~* Arrow® Midline 4Fr from Arrow"
214493405|NCT06770374|OTHER|Ultrasound scanner|All punctures will be performed under ultrasound guidance.
214493406|NCT06774118|OTHER|Data collection|Data collection
214493407|NCT05175404|DIAGNOSTIC_TEST|PET/CT scan F18-PSMA-11|PET/CT scan with F18-PSMA-11
214493408|NCT06777680|DIETARY_SUPPLEMENT|co-ultramicronized Palmitoylethanolamide + Luteolin (770 mg)|oral suspension, 10 ml twice a day (every 12 hours) for 7 days
215088864|NCT01283308|BEHAVIORAL|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
214369904|NCT03767166|DEVICE|Biodegradable biliary and pancreatic stents placement|Biodegradable biliary and pancreatic stents placement
214369905|NCT03724487|BEHAVIORAL|Coachman|Coachman is comprised of: TBI and nurse counseling. TBI is comprised of: 1) web-based education modules on hypertension knowledge and skills as well as behavioral lifestyle guidance, (2) Medisafe, a smartphone medication management app to support medication adherence to antihypertensives, and (3) self-monitoring blood pressure. Participants will be exposed to nurse counseling, by registered nurses from the community, affiliated with a local nurse organization that will serve as community health workers (CHWs). The CHWs will provide informal counseling, social support, as well as follow-up phone sessions on medication adherence and monitoring blood pressure.
214369906|NCT03724487|BEHAVIORAL|Enhanced Usual Care (EUC)|Standard printed education materials on hypertension management, including content on lifestyle modification and medication-taking will be provided; plus access to one web-based education (video) with information on how to self-monitoring blood pressure.
214369907|NCT00464451|DRUG|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
214369908|NCT00464451|DRUG|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
214369909|NCT05008952|OTHER|High-fat shake|All participants will be given a high-fat test meal to examine their postprandial triglyceride response.
214369910|NCT04696913|DIAGNOSTIC_TEST|Exposure: Positive COVID-19 infection|Exposure: Positive COVID-19 infection as determined by RT-PCR
214369911|NCT04696913|DIAGNOSTIC_TEST|Exposure: Negative COVID-19 infection|Exposure: Negative COVID-19 infection as determined by RT-PCR
214369912|NCT00715650|BEHAVIORAL|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
214493409|NCT06777680|OTHER|Placebo|oral suspension,10 ml twice a day (every 12 hours) for 7 days
214493410|NCT06777680|PROCEDURE|Thrombectomy|Endovascular Thrombectomy in all eligible patients, according to national acute stroke treatment guidelines
214493411|NCT06777550|OTHER|SimucaseTM|experiment group - who will receive the clinical learning method using SimucaseTM
214493412|NCT06777550|OTHER|Conventional Clinical Learning|Problem-based learning case-study case studies
214493413|NCT06762119|DRUG|CAR-T cell|CAR-T cell
214493414|NCT06760780|OTHER|Experimental|The experimental group will first be given a theoretical lesson prepared in line with the current literature on osteoporosis. At the end of the lesson, a prepared scenario example on osteoporosis will be covered.
214369913|NCT00715650|BEHAVIORAL|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
214493415|NCT06760780|OTHER|Control|The control group will only be given a theoretical lesson prepared in line with the current literature on osteoporosis. No other intervention will be made.
214984790|NCT06682416|PROCEDURE|In the context of epidural analgesia, the temperature of the local anesthetic solution is elevated to 37°C utilizing a blood transfusion and infusion warmer.|"For the observation group, after reactivating the analgesic pump's exhaust procedure to clear the air from the tubing, the output tubing of the analgesic pump is first connected to the epidural catheter. Following this, a blood transfusion and infusion warmer (manufactured by Barkey GmbH \& Co. KG., Germany, model S-line, with the national medical device registration number 20182450063) is used to preheat the output tubing of the analgesic pump until it reaches the predetermined temperature of 37°C.~For the control group, after reactivating the analgesic pump's exhaust procedure to remove air from the tubing, the output tubing of the analgesic pump is connected to the epidural catheter without preheating the output tubing using a blood transfusion and infusion warmer, maintaining room temperature (23°C)."
214984791|NCT06686420|DIETARY_SUPPLEMENT|B. longum|On the first day of the intervention period, participants will be instructed to consume two capsules of the live B. longum strain daily with a glass of water before breakfast for the next eight weeks.
214984792|NCT06686420|DIETARY_SUPPLEMENT|Placebo|On the first day of the intervention period, participants will be instructed to consume two capsules, which are without any live bacteria, daily. They should take these before breakfast with a glass of water, for the following eight weeks.
214984793|NCT07017946|DRUG|MTP-101C|MTP-101C is a freeze-dried encapsulated formulation of fecal microbiota purified from the stool of healthy donors.
214984794|NCT03244488|DRUG|Scopolamine Injectable Product|2.5 or 5 mcg/kg of scopolamine via IV
214984795|NCT03244488|DRUG|Mecamylamine Pill|10 or 20mg of mecamylamine orally
214984796|NCT01647178|PROCEDURE|TORQ assisted sternal closure|
214984797|NCT01647178|PROCEDURE|Conventional closure|
214984798|NCT06094816|DRUG|Furosemide (Diuretic)|The diuretic furosemide will be given during a 3% hypertonic saline infusion to examine blockade of the NKCC2.
214984799|NCT06094816|OTHER|Hypertonic Saline Infusion|3% Hypertonic saline infusion to acutely increase sodium and osmolality
214984800|NCT00676949|BIOLOGICAL|5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1|1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
214984801|NCT03251365|DRUG|HIPEC-gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
215088865|NCT04311398|DIAGNOSTIC_TEST|New QIAstat-Dx fully automatic multiple PCR detection platform|We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients
215088866|NCT06269705|DRUG|ZILRETTA|IA injection of 32 mg ZILRETTA
215088867|NCT06269705|DRUG|TCA-IR|IA injection of 40 mg TCA-IR
215088868|NCT06269705|OTHER|Placebo|IA injection of placebo (normal saline)
214369914|NCT01230255|PROCEDURE|Percutaneous catheter drainage|Ultrasound guided insertion of a 14 French pigtail catheter to drain free intra-peritoneal fluid or blood and thereby reduce elevated intra-abdominal pressure
214369915|NCT03962296|DRUG|Vitis vinifera extract|Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group
214369916|NCT03962296|DRUG|Calcium Dobesilate|Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group
214369917|NCT03962296|DRUG|Placebo|Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
214369918|NCT02856425|DRUG|Nintedanib|Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
214369919|NCT02856425|DRUG|Pembrolizumab|Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
214369920|NCT01288339|DRUG|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
214369921|NCT01288339|DRUG|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
214369922|NCT02946840|DEVICE|FNA with 25 G Beacon needle|
214369923|NCT02416492|BIOLOGICAL|SB623 cells|SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
214369924|NCT02416492|PROCEDURE|Sham Control|Sham Surgery
214493416|NCT06768567|PROCEDURE|effect of hemostasis time on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.|After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required and time taken to achieve hemostasis will be recorded using stop watch. Teeth in which bleeding will be controlled within 6 mins will be placed in Group A, while those in which it gets controlled between 7 to 12 mins will be included in Group B. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 12 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
214493417|NCT06767592|DIETARY_SUPPLEMENT|Bio-Kult Advanced|Bio-Kult Advanced will be provided as capsules and can be stored at room temperature. Participants will be instructed to swallow two capsules in the morning and two capsules in the evening, with food.
214984802|NCT03308669|DRUG|Lasmiditan|Administered orally
214984803|NCT03308669|DRUG|Placebo|Administered orally
214984804|NCT03308669|DRUG|Topiramate|Administered orally
214984805|NCT04291040|BEHAVIORAL|Decision Aid|Following randomization, participants will independently view the multimedia based decision aid on a provided tablet. They will also receive provider counseling. For the remainder of the pregnancy, they will receive a text message with a link to the multimedia based presentation. This will occur every 4 weeks until 12 weeks postpartum.
214984806|NCT04291040|BEHAVIORAL|Routine Care|The control arm will receive routine prenatal care including provider counselling on postpartum contraceptive options.
214984807|NCT07030088|DEVICE|Dual-Headed Manual Toothbrush|A novel toothbrush with a dual-headed design intended to clean both upper and lower buccal/ or upper and lower lingual/ palatal surfaces simultaneously. Participants were instructed to use this toothbrush on one side of the mouth only, twice daily using the Bass brushing technique. This intervention is evaluated for plaque removal efficacy, gingival health, brushing time, and patient comfort
214984808|NCT07030088|DEVICE|Conventional Single-Headed Manual Toothbrush|A standard single-headed manual toothbrush used as the active control. Participants used this toothbrush on the other side of the mouth, with the same brushing technique (Bass method), frequency (twice daily). It serves as the comparator for assessing the performance of the dual-headed design.
214984809|NCT05814107|DRUG|CT-996|Capsule of CT-996
214984810|NCT05814107|DRUG|Placebo|Capsule of placebo matching CT-996.
214984811|NCT03908411|PROCEDURE|Paratracheal pressure|Paratracheal pressure is applied by 30N force with the ultrasound transducer.
214984812|NCT03908411|PROCEDURE|Sellick's maneuver|Conventional Sellick's maneuver is applied by 30N force
214984813|NCT06324617|PROCEDURE|Treatment of failed carpal tunnel syndrome by dorsal ulnar artery perforator adipofascial flap|"Treatment of failed carpal tunnel syndrome by dorsal ulnar artery perforator adipofascial flap The previous incision is reopened and extended, Neurolysis begins proximally preserving the palmar cutaneous branch. The subcutaneous tissue is exposed, leaving part of the superficial venous plexus with the adipofascial flap. Flap elevation is begun by incising the subcutaneous tissue through the deep fascia along the radial border of FCU and ECU .~When the flap reaches a suitable length (10-12 cm from the wrist), it is cut proximally and along the ulnar side. The flap is dissected proximally to distally in continuity with the underlying fascia . When the dissected flap is (2-5) cm proximal to the wrist. Ulnar retraction of the flexor carpi ulnaris permits identification of the perforator. the pivot point of the flap is localized (2-5) cm proximal to the pisiform.~The adipofascial flap is turned 180 degrees and anchored with a few absorbable stitches around the median nerve."
214984814|NCT07034950|DRUG|Intravenous esketamine using Dixon's up-and-down sequential method|Using Dixon's up-and-down sequential method, esketamine will be titrated intravenously from an initial 0.3 mg∙kg-1 dose with 0.02 mg∙kg-1 adjustments based on intraprocedural responses to pain (Positive: purposeful somatic movement or the complaint of pain; Negative: no movement or no complaint of pain). The titration sequence will continue until six crossover inflection points are observed.
214369925|NCT05747963|DEVICE|software-delivered CBT-I|The automated software called 'resleep' incorporates all core elements of CBT-I: sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene and education, tailoring content based on each participant's reported baseline sleep function and sleep progress. The 6-week treatment includes 42 times of intervention.
214369926|NCT05747963|OTHER|online PE|Subjects in the control group will receive non-tailored information about insomnia and sleep health education content using the Wechat Official Account.
214369927|NCT00508404|DRUG|Panitumumab|Administered by intravenous infusion
214369928|NCT00508404|DRUG|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
214369929|NCT06276933|DRUG|Camrelizumab + chemotherapy+Thalidomide|"Camrelizumab + chemotherapy+Thalidomide Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: Thalidomide Thalidomide 100mg，po qd； Other Name: Thalidomide~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy"
214984815|NCT07034950|DRUG|Intravenous the dose of esketamine ED95|The intervention group will be injected with the dose of esketamine ED95.
214984816|NCT07034950|DRUG|Intravenous fentanyl 1 μg∙kg-1|The control group will be injected with fentanyl 1 μg∙kg-1.
214984817|NCT03668210|PROCEDURE|Isokinetic evaluation|Isokinetics is used to measure the peak of strength of quadriceps and hamstrings, in concentric or eccentric, at slow and fast speed to determine a hamstring / quadriceps ratio to highlight a deficit or imbalance.
214984818|NCT05947253|OTHER|Buyteko breathing technique|group A 20 participants received Buyteko breathing technique 2 session for 3 weeks
214984819|NCT05947253|OTHER|active cycle of breathing technique|Group B 20 participants received active cycle of breathing technique 2 session for 3 weeks
214984820|NCT00173628|PROCEDURE|blood drawing|
214493418|NCT06832384|PROCEDURE|intensive physiotherapy|"the dosing of the intensive physiotherapy is of 2 sessions a day, lasting 45 minutes each, administered 5 days a week, for a period of 4 weeks.~the physiotherapy is mainly addressed to the improvement of gross motor movement and balance and the training is designed according to the specific need of the subject recruited. it is not allowed the use of technological devices, excepted treadmill training."
214493419|NCT06767982|DRUG|Bacillus Calmette-Guerin (BCG)|In this study we compared the efficacy and side effects of two different strains of BCG (RIVM and RUSSIAN strains) in non muscle invasive bladder cancer patients
214493420|NCT06744868|DRUG|THDBH120 injection (SAD)|Participants received escalating single doses of THDBH120 by subcutaneous injection.
214984821|NCT03456245|DEVICE|Vision device validation|Group members had their vision tested with the following devices/methods: Eyenetra NETRA, PlenOptika Quicksee, Right Manufacturing Retinomax K Plus 3, and standard eyesight tests using eye charts, phoropters, and slit lens lamp imaging.
214369930|NCT06276933|DRUG|Camrelizumab + chemotherapy+placebo|"Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: placebo 100mg placebo 100mg，po qd；~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy"
214369931|NCT02754102|OTHER|Sunscreen Spray- Liquid (BAY987516)|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.
214369932|NCT05692622|OTHER|Whole-body exercise and respiratory exercise|The study involves an 8-week intervention involving whole-body and respiratory exercises. The whole-body exercise component will involve doing exercises while watching a total of 32 Comic Kids yoga movies. These movies have been adapted to suit the needs and abilities of the target population. For the first 7 weeks of intervention, children will be provided with 4 yoga movies for each week, providing around 67 minutes of exercise in each week. In the last week of intervention, children will have the choice to practice any 4 exercises of their choice from the 28 movies. The respiratory exercise component will involve watching a 10-minute-long movie that involves practicing different styles of breathing and breath holding. Participants will be provided a respiratory trainer to use while practicing these breathing exercises. Children will be asked to practice these breathing exercises by watching the movie at least 2 days each week.
214369933|NCT05197361|DIAGNOSTIC_TEST|Invasive coronary physiology|Estimation of guide-wire coronary physiology parameters
214369934|NCT06448429|OTHER|Usual care|Participants will have the usual diabetes care at the Grady Diabetes Clinic.
214493421|NCT06744868|DRUG|Placebo of THDBH120 injection (SAD)|Participants received single dose of placebo by subcutaneous injection.
214493422|NCT06744868|DRUG|THDBH120 injection (MAD)|Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.
214984822|NCT05328960|OTHER|Diagnosed during or not during the pandemic|We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
214984823|NCT02367300|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
214984824|NCT02649010|DEVICE|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
215088869|NCT03075124|DEVICE|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
214493423|NCT06744868|DRUG|Placebo of THDBH120 injection (MAD)|Participants received placebo once weekly for four weeks by subcutaneous injection.
214493424|NCT06831292|DIETARY_SUPPLEMENT|Diet intervention NMR|Participants will receive groceries to their homes with planned recipes. The recipes are planned by using the Nordic nutrition councils recommendations.
214493425|NCT06831487|DEVICE|Line-Field Confocal Optical Coherence Tomography (LC-OCT)|Analysis of Line-Field Confocal Optical Coherence Tomography (LC-OCT) in separate groups of patients with gingivitis, periodontitis and healthy patients
214493426|NCT02636569|DRUG|topical diclofenac daily|"Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed."
214493427|NCT02636569|DRUG|placebo|"placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
214493428|NCT04457284|DRUG|Temozolomide (TMZ)|"TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1~TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +"
214493429|NCT04457284|DRUG|Cisplatin|Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +
214493430|NCT04457284|DRUG|Nivolumab|Nivolumab 480 mg Q4W IV infusion Cycle 1 +
214984825|NCT02991001|PROCEDURE|Ultrasound-guided hydrodissection|Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
214984826|NCT02991001|PROCEDURE|Placebo ultrasound-guided injection|Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
214984827|NCT02991001|DEVICE|Ultrasound|
214984828|NCT02991001|DRUG|Normal Saline|
215088870|NCT01513681|DRUG|Lamotrigine|Lamotrigine Tablets 200 mg
215088871|NCT01513681|DRUG|Lamictal®|Lamictal® 200 mg Tablets
215088872|NCT05716204|OTHER|High force lateral distraction|High force lateral distraction on the affected hip.
215088873|NCT05716204|OTHER|Placebo distraction group|Placebo lateral distraction on the affected hip.
215088874|NCT03551756|OTHER|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
215088875|NCT00940485|DRUG|entecavir|0.5mg po daily for 8 weeks
215088876|NCT00940485|DRUG|entecavir|0.5mg po daily for 48 weeks
214369935|NCT06448429|OTHER|Collaborative care model (CoCM)|"Collaborative care will include:~* Care with a behavioral health consultant (BHC)~* Measurement-based mental health care~* Systematic caseload reviews~* Medical management of depression~The BHC will monitor depression and anxiety severity, promote behavioral change with patients through Behavioral Activation, and support the medical management of depression through participation in caseload reviews (I.e., Mental health care plans for individual patients will be reviewed monthly by a multi-disciplinary T1D clinical team and BHC). Depression treatment initiation (if warranted) by a clinician and engagement in mental health care."
214369936|NCT06162832|COMBINATION_PRODUCT|Allograft and rHPDGF-BB|At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)
214369937|NCT06162832|COMBINATION_PRODUCT|Allograft and Saline solution|This will be used as the control group
214369938|NCT03379623|OTHER|ESCAPE-pain Programme|The Enabling Self-management and Coping with Arthritic (knee) Pain using Exercise (ESCAPE-pain) is a programme of rehabilitation that integrates educational self-management and coping strategies for people with joint pain with an individualised exercise regimen for each participant. The implementation of the programme will be conducted by the researcher as a certified facilitator by using Clinician's training manual for the ESCAPE-pain programme.
214369939|NCT02819102|DRUG|BCX7353 and probes|
214493431|NCT06753084|PROCEDURE|Alloderm|the study is done to patient who lacks of keratinized mucosa width by apically positioned flap and using of FGG as gold standard and Mucoderm as compartive group
214493432|NCT04875078|DEVICE|UVA-1 Phototherapy|UVA-1 Phototherapy treatments
214493433|NCT06514664|OTHER|Using Probiotic Toothpaste|"Scaling and root planing (Phase 1 = non-surgical periodontal treatment) are performed in all patient groups.~Depending on the study groups, regular or probiotic toothpaste will be used. Toothpaste is instructed to be used twice a day"
214493434|NCT06153485|DEVICE|AutoO2|Automated Titration of Oxygen (Auto-O2) using a closed-loop system in which the oxygen flow to the participant is continuously adjusted on the basis of pulse oximetry signals to maintain a target range of oxygen saturation to meet the participant's immediate needs.
214493435|NCT06153485|OTHER|FixedO2|Fixed flow oxygen delivery administered using manual flow meters according to standard clinical procedures.
214493436|NCT06873386|DEVICE|Valera & Minaya protocol|"Valera \& Minaya protocol:~US-guided PNM with the conventional frequency of the Valera Minaya protocol, with localised location on the peripheral nerve. Stimulation of the upper gluteal nerve and lower gluteal nerve will be performed, with 10 stimulations, with 10 seconds of stimulation and 10 seconds of rest, at a frequency of 10 Hz, with a pulse amplitude of 250 μs, and of maximum intensity tolerable by the patient that causes an exacerbated muscle contraction.~The specific device used will be an electric needle stimulator, AS Super 4 Digital, Schwa-medico Holistic Health, Ehringshausen, Germany."
214493437|NCT06873386|DEVICE|High-frequency US-guided PNM|"High-frequency US-guided PNM with localised peripheral nerve location. Ten 10-second stimulations of the upper gluteal nerve and lower gluteal nerve will be performed, with frequency sweeps of 20Hz -100Hz with a pulse amplitude of 250 μs, and of maximum intensity tolerable by the patient that causes an exacerbated muscle contraction, with 10 seconds of rest between each stimulation.~The specific device used will be an electric needle stimulator, AS Super 4 Digital, Schwa-medico Holistic Health, Ehringshausen, Germany."
214493438|NCT06874088|PROCEDURE|Pulpotomy with Calcium Silicate-Based Bioceramics in Permanent Teeth|This intervention involves performing pulpotomy using calcium silicate-based bioceramic materials, MTA and Biodentine™, in both mature and immature permanent teeth diagnosed with reversible or irreversible pulpitis. The study uniquely evaluates the long-term clinical and radiographic success of these materials by assessing pulp healing, dentin bridge formation, and periapical healing over a 24-month follow-up period. Additionally, this study compares clinical survival rates between mature and immature teeth, contributing to the growing body of evidence on the efficacy of pulpotomy in cases traditionally considered for root canal treatment. Unlike conventional pulpotomy studies, this research incorporates retrospective data analysis to align with international standards, addressing gaps in existing literature.
214493439|NCT06744270|OTHER|i-PRF group|"In the i-PRF group, 10 ml of venous blood taken from the patient immediately after the SDG operation will be transferred to a tube that does not contain any anticoagulant. The collected venous blood will be centrifuged for 3 minutes at 2300 rpm in a centrifuge device and two layers will be obtained: the lower layer is red blood cells and the upper layer is i-PRF. 20-25 minutes will be waited for polymerization. After polymerization, the polymerized i-PRF will be applied to the wound surface in the donor area. Following the operation, patients will be called for check-ups on the 3rd, 5th, 7th, 14th, 21st and 30th days and their photographs will be taken and the following parameters will be evaluated.~* Pain assessment and analgesic intake~* H2O2 Foaming Test (to assess epithelialization)~* Wound healing will be assessed using the Image program from patient photographs~* Edema and erythema scores will be assessed visually."
214493440|NCT06744270|OTHER|low-dose laser group|"In the laser group, low-dose laser will be applied to the palatal donor area immediately after SDG surgery, on the 3rd, 5th, 7th and 14th days. A GaAlAs diode laser (CHEESETM, GIGAA Laser, Wuhan Gigaa Optronics Technology Co., Ltd., China) with a wavelength of 810 nm and a low-dose diode laser application tip with a fiber diameter of 950 µm will be used. A low-dose diode laser will be applied to the surgical operation area in accordance with the manufacturer's instructions, with a non-contact regional 0.3 W power and an intensity of 4 J/cm2 in continuous mode for 1 min. Following the operation, patients will be called for check-ups on the 3rd, 5th, 7th, 14th, 21st and 30th days, and their photographs will be taken and the following parameters will be evaluated. • Pain assessment and analgesic intake~* H2O2 Foaming Test (to assess epithelialization)~* Wound healing will be assessed using Image program from patient photographs~* Edema and erythema scores will be assessed visually."
214493441|NCT06784232|PROCEDURE|BARP|deep layers of collagen, medium-superficial heterologous bone graft, superficial collagen layer
214493442|NCT06784232|PROCEDURE|Modified Periosteal Inhibition Technique|Cortical lamina stabilized with human fibrin glue to preserve the buccal wall of the socket. The socket was then filled with collagen.
214493443|NCT06767189|DIAGNOSTIC_TEST|ECG monitoring|R-test or ECG patch for up to 28 days
214493444|NCT06790615|DRUG|methyl prednisolone acetate|methyl prednisolone acetate was injected after the aspiration
214493445|NCT06790615|OTHER|Silk suture|The silk suture was used for threading technique
215088877|NCT00940485|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
214369940|NCT02600884|BEHAVIORAL|Families Talking Together Plus (FTT+HPV)|Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.
214369941|NCT02600884|BEHAVIORAL|Brief motivational interviewing (BMI)|Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
214369942|NCT04230057|DIETARY_SUPPLEMENT|Antitumor B|Single dose 2400 mg
214369943|NCT06427655|DEVICE|SALAD intubation|SALAD suction during intubation
214369944|NCT00796250|BIOLOGICAL|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
214369945|NCT00796250|DRUG|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
214369946|NCT00796250|DRUG|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
214369947|NCT00796250|DRUG|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
214493446|NCT06838390|DEVICE|Microcurrent Therapy|The study uses a four-channel microcurrent therapy device to treat pressure ulcers. The treatment involves applying four electrodes to the area around the ulcer, ensuring microcurrent passage throughout the wound bed. The treatment is done three times a day, lasting 35-40 minutes. The microcurrents are delivered in a monophasic, pulsed, square-form wave pulse with a voltage of 21 mV, an intensity of 42 µA, and a current density of 4.2 µA/cm.
214493447|NCT06838390|DEVICE|Transcutaneous electrical nerve stimulation|The study aimed to treat ulcers with TENS using a two-channel device, delivered three times a day, for 8 weeks. The device induced peripheral vasodilation and activate local blood flow, potentially promoting wound healing. The treatment was delivered using a pulse train duration of 300 ms, with an internal frequency of 100 Hz and a burst frequency of 2 Hz.
214493448|NCT06838390|OTHER|physical therapy program|The physiotherapy program included circulatory circulatory exercises, stretching exercises, and ROM exercises.
214984829|NCT02511301|DEVICE|Cyrcadia CBR™ device placement for abnormality screening|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.
214984830|NCT03798314|BIOLOGICAL|Nivolumab|Given IV
214984831|NCT03798314|DRUG|Pomalidomide|Given PO
214369948|NCT00796250|DRUG|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
214369949|NCT00796250|BIOLOGICAL|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
214369950|NCT06579352|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)|Umbilical cord-derived mesenchymal stem cells administered intravenously.
214493449|NCT06838390|DRUG|medial treatment|patients was given their drugs from their physicians
214493450|NCT06655610|DEVICE|External Trigeminal Nerve Stimulation|Active eTNS will be provided by applying single, bipolar pulses of 0.5 milliseconds duration at a frequency of 125 hertz, with an active period of 30 seconds on/off. Stimulation current will range from 0.2 mili ampere (mA) to 10 mA. The level of current, which is noticeable, yet within the level of comfort, will be identified for each patient by titration at baseline. Depending on the perception of stimulation, the level of current may be altered during the four weeks of treatment, by either the guardian or adolescent in control of the settings.
214984832|NCT01585883|BEHAVIORAL|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
214984833|NCT02273167|DRUG|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
214984834|NCT02273167|DRUG|NER1006,1-Day Morning Split-Dosing|"The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid."
214984835|NCT02273167|DRUG|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
214369951|NCT01591382|DRUG|Ketamine|Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
214369952|NCT01591382|DRUG|Placebo|Patients who received ketamine-matching placebo were given saline infusions
214369953|NCT01591382|DRUG|Hydromorphone PCA|Intravenous hydromorphone PCA
214369954|NCT05506748|OTHER|pantients undergoing pancreaticoduodenectomy|The study includes all the cases who underwent pancreaticoduodenectomy for carcinoma head of the pancreas, distal cholangiocarcinoma, periampullary and duodenal cancer.
214369955|NCT03550833|BEHAVIORAL|Questionnaire|Questionnaire
214369956|NCT03550833|BIOLOGICAL|blood sample|7 ml whole blood for Peripheral blood
214984836|NCT04670120|DRUG|Pyrifazimine (TBI-166)|"The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
215088878|NCT05785182|PROCEDURE|Open Fracture|Patients 18 years of age or older with open fracture. Provision of informed consent.
214369957|NCT06379191|BEHAVIORAL|Nutrition intervention model based on WeChat applets|"We recorded the full nutritional management plan for ovarian cancer chemotherapy patients obtained through evidence-based in the previous period into the applet developed by our team - Good Nutrition. At the first chemotherapy admission assessment, patients were instructed to search for the applet on WeChat and add it to My applet. The patient was introduced to the main functional sections of the applet and the content settings for each section. The patient was instructed to turn on the applet notification permission and set it to receive new content alerts. Patients were invited to join our nutrition management group chat. They were informed that throughout the intervention phase, we would be sending evidence-based scientific articles to the group chat for independent study, and that they were allowed to ask questions, share personal experiences, and discuss lifestyles within the group."
214369958|NCT03170375|BEHAVIORAL|Performance of WHEELS-I in promoting DASH/SRD adoption|All participants will receive motivational interviewing (MI) based counseling. Participants in the MI + WHEELS-I arm will also receive the WHEELS-I electronically-delivered tailored messaging.
214369959|NCT03587246|DIAGNOSTIC_TEST|3DTVUS : Uterine peristaltic frequencies|Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
214369960|NCT04040309|BIOLOGICAL|PRGF injection|Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
214369961|NCT04040309|DRUG|Lidocaine injection|1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
214493451|NCT06655610|DEVICE|Sham device|The stimulator and patches will be identical in appearance to the active treatment. The guardian/the adolescent will be informed to administer the device in the same fashion as with active treatment. The sham device will however be programmed to only apply stimulation for 30 seconds every hour during sleep, optimally at a frequency of maximum 2 Hz. As with the active eTNS, the sham stimulation current will range from 0.2 to 10 mA. Such settings have previously been considered to induce the sensation of a current applied to the forehead as seen with active treatment, yet without it being therapeutically effective. Stimulation will be directed through an internal resister, which ensures draining of batteries and need for recharging after each session. The manufacture of the eTNS device (Neurosigma) will oversee the programming the sham device.
214493452|NCT06762223|DRUG|Henagliflozin 10 mg daily|Henagliflozin (SHR3824) is a hypoglycemic agent classified as an SGLT2i, which has been independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (China) and Shanghai Hengrui Pharmaceutical Co., Ltd (China). It received marketing authorization in China on December 31, 2021 (ID: H20210053).The prescribed dosage of Henagliflozin is 10 mg per day, as indicated on the drug label, with administration recommended in the early morning. In instances where a participant forgot to take the medication in the morning, they were permitted to do so until 12:00 PM on the same day.
214493453|NCT06762223|DRUG|Metformin 1700 mg daily|The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company. This formulation of metformin is available in a dosage of 0.85 grams per tablet, necessitating that patients administer two tablets daily to acquire the dose of 1.7g daily, to be taken within thirty minutes prior to breakfast and dinner respectively. However, adjustments to the metformin dosage were not permitted during follow-up visits.
214493454|NCT06762223|OTHER|Placebo of Henagliflozin|The placebo was supplied by the pharmaceutical company responsible for Henagliflozin, ensuring that both the placebo and Henagliflozin were indistinguishable in terms of appearance, taste, and odor, while lacking any significant pharmacological effect. Administration of the placebo was recommended to occur in the early morning.
214493455|NCT06762249|OTHER|CIMT + Brunnstrom therapy + routine physical therapy|this therapy will be given for 5 days per week for 4 weeks.
214493456|NCT06762249|OTHER|CIMT + routine physical therapy|this therapy will be given for 5 days per week for 4 weeks
214493457|NCT06773351|DRUG|Sevoflurane 0 + different doses of ciprofol|Sevoflurane 0% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.6mg/kg, respectively.
214493458|NCT06773351|DRUG|Sevoflurane 0.7% + different doses of ciprofol|Sevoflurane 0.7% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.5mg/kg, respectively.
214493459|NCT06773351|DRUG|Sevoflurane 1.0% + different doses of ciprofol 0.05|Sevoflurane 1.0% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.
214493460|NCT06773351|DRUG|Sevoflurane 1.5% + differnet doses of ciprofol|Sevoflurane 1.5% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.
214493461|NCT06773351|DRUG|Sevoflurane 2.0% + different doses of ciprofol|Sevoflurane 2.0% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.
214369962|NCT05725252|DRUG|NVP-2203|NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
214369963|NCT05725252|DRUG|NVP-2203-R|administration of active comparator
214369964|NCT01227603|DRUG|Nifedipine-candesartan FDC (BAY 98-7106)|Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
214369965|NCT01227603|DRUG|Nifedipine GITS (Adalat LA, BAYA1040)|Single oral dose of 1 tablet of nifedipine GITS 60 mg
214369966|NCT01227603|DRUG|Candesartan (Atacand)|Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
214369967|NCT03883815|OTHER|Active Video Games Therapy|"Interventions were completed in 1-week periods, after 3 clinical visits. All individuals underwent both neurodevelopmental therapy and active video games therapy. Demographic data of individuals were recorded and muscle tone and gross motor functions were evaluated at the first visit. The games determined by the physiotherapist were explained and experienced by individuals. During the second visit, individuals played 4 games that were previously determined and experienced for about 45 minutes. On the last visit, individuals underwent neurodevelopmental therapy. During both treatment sessions, the accelerometer was fitted on a flexible belt by attaching it to the dominant wrist. Individuals were instructed not to remove the device during both treatment sessions.~One session individuals treated with exercises which weight transfer and postural reactions were facilitated.~Other session they played Nintendo Wii games in accordance with their current level and skills."
214369968|NCT00855062|DRUG|minocycline|100 mg capsule every 12 hours by mouth
214369969|NCT00855062|DRUG|minocycline placebo capsule|1 capsule every 12 hours by mouth
214369970|NCT01550484|DRUG|18F-AV-133|222 MBq (6 mCi)
214369971|NCT03474302|BEHAVIORAL|Physical Activity|Aerobic, strength training, balance, flexibility
214369972|NCT03474302|OTHER|Successful Aging|Healthy aging education
214369973|NCT01522534|DRUG|Mepivacaine|mepivacaine 1% 20 ml corresponding to 200 mg
214369974|NCT01522534|DRUG|Morphine|Morphine alone with a placebo nerve block
214369975|NCT01320332|DRUG|ASP3291|Oral tablets
214493462|NCT06773351|DRUG|Sevoflurane 2.5% + different doses of ciprofol|Sevoflurane 2.5% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.
214493463|NCT06773351|DRUG|Ciprofol 0 + different end-expiratory concentration of sevoflurane|Ciprofol 0 combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5%, respectively.
214984837|NCT00860275|DRUG|BMS-708163|Capsule, Oral, 50 mg, once, Day 1
214984838|NCT00860275|DRUG|BMS-708163 + Ketoconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
214984839|NCT00860275|DRUG|Ketoconazole|Tablet, Oral, 400 mg, daily, 16 days
215088879|NCT05785182|PROCEDURE|Infected Fracture|Patients 18 years of age or older with infected fracture. Provision of informed consent.
215088880|NCT04877236|DEVICE|Green Sun Medical Brace|"All patients in the study will receive the Green Sun Medical Whisper Brace. Each GSM brace will be custom-fabricated via computer-assisted design using the 3D torso scans and a treatment plan (e.g. placement of corrective forces) devised by the treating orthotist as inputs. The brace components are then assembled. Once fabricated, the GSM brace will be fit to the subject by representatives of the manufacturer and in consultation with the treating orthotist.~The GSM brace will be prescribed for the same number of hours per day as was the TLSO (generally 18-22 hours per day, individualized based on patient characteristics). Subjects and the family will be shown how to don and doff the brace, how to clean the brace cover, how to remove the temperature monitor, and how to remove the iButton and how to replace batteries in the GSM sensor board."
215088881|NCT00606983|DRUG|Tamsulosin|oral administration of Tamsulosin
214369976|NCT01320332|DRUG|Placebo|Oral tablets
214369977|NCT00530062|DRUG|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
214369978|NCT00530062|DRUG|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
214369979|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation of the left ventricular pacing lead will be performed by cannulating one of the tributaries of the coronary sinus using delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed for biventricular pacing.
214493464|NCT06773351|DRUG|Ciprofol 0.05mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.05 mg/kg combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5 %, respectively.
214493465|NCT06773351|DRUG|Ciprofol 0.1mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.1mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.
214493466|NCT06773351|DRUG|Ciprofol 0.2 mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.2 mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.
214493467|NCT06773351|DRUG|Ciprofol 0.3 mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.3 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.
215088882|NCT06562595|BEHAVIORAL|Education Intervention|Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.
215088883|NCT06175351|DRUG|9MW1911|Participants will receive IV 9MW1911 every 4 weeks.
214681407|NCT03725046|OTHER|Optimized information transmission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
214984840|NCT00860275|DRUG|Fluconazole|Tablet, Oral, 1 day 400 mg then 3 days 200 mg
214984841|NCT00860275|DRUG|BMS-708163 + Fluconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
214984842|NCT01220284|DRUG|Satraplatin in combo with vinorelbine|"* Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~* Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks."
214984843|NCT06448962|DRUG|AD-2021|PO, Once daily(QD), 8weeks
214984844|NCT06448962|DRUG|AD-2022|PO, Once daily(QD), 8weeks
214984845|NCT06448962|DRUG|AD-2021 Placebo|PO, Once daily(QD), 8weeks
214369980|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation to the left bundle branch will be performed by using special delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed left bundle branch pacing.
214369981|NCT03050502|DEVICE|Chest tube drain|This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
214369982|NCT03050502|OTHER|Expectant management|This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
214681408|NCT01292772|PROCEDURE|contract-enhanced MRI|Patients will have contrast-enhanced MRI of the breasts.
214369983|NCT01376323|DRUG|GSK256073 1mg|GSK256073 1mg capsule
214369984|NCT01376323|DRUG|GSK256073 5mg|GSK256073 5mg capsule
214681409|NCT01292772|RADIATION|Unilateral Adjuvant Radiation Therapy|The study group will consist breasts receiving post-operative radiation, and the control group will consist of the patient's breasts on the non-radiated side. In this way, patients will act as their own control.
214681410|NCT04083040|PROCEDURE|transcatheter aortic valve implantation|"1. Tilt angle.~2. Depth of implantation of the valve.~3. Type of the valve.(Medtronic core valve self expandable valve ,Edwards sapient balloon expandable valve"
214681411|NCT01059604|DRUG|Sumatriptan|Sumatriptan
214681412|NCT01059604|DRUG|Naratriptan|Naratriptan
214681413|NCT01059604|DRUG|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
214681414|NCT05248087|DEVICE|The bonded McNamara-type appliance|The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.
214681415|NCT05248087|DEVICE|The removable palatal expansion appliance|The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
214369985|NCT01376323|DRUG|GSK256073 10mg|GSK256073 10mg capsule
214369986|NCT01376323|DRUG|GSK256073 25mg|GSK256073 25mg capsule
214369987|NCT01376323|DRUG|Placebo|placebo capsule
214681416|NCT01324583|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution~Route of administration: intravenous"
214984846|NCT06448962|DRUG|AD-2022 Placebo|PO, Once daily(QD), 8weeks
214984847|NCT06417970|DIAGNOSTIC_TEST|Shoulder Proprioception, Palmar Touch Sensation and Psychometric Parameters|"Shoulder Proprioception: Proprioception will be measured with isokinetic device. The measurement reference angles are 30° and 60°.~Palmar Touch Sensation: Palmar tactile sensation will be measured with the Semmes-Weinstein Monofilament.~Psychometric Parameters: Athlete Psychological Strain Questionnaire, Tampa kinesiophobia questionnaire"
214984848|NCT04539990|BEHAVIORAL|Behavioral treatment for sleep difficulties|"This intervention is mediated by the parents. Parents are educated regarding sleep hygiene and instructed to follow simple rules which create a reliable evening routine and reduce exposure to stimulating factors that delay sleep onset (e.g., caffeine or exercise). In addition, parents are asked to initiate a fading behavioral protocol whereby they teach their child to fall asleep independently, with less parental attention. This requires parents to limit their interaction with their child after the children are put to bed so as not to interfere with sleep onset. This includes limiting conversations and lying in bed with the child. This behavioral approach is applied gradually and is expected to reduce the time it takes children to fall asleep."
214984849|NCT04079504|PROCEDURE|Ligation of indirect hernia sac|Indirect inguinal hernia sac will be separated from the spermatic cord and contents of the sac will be reduced before ligating it at the deep inguinal ring.
214984850|NCT04079504|PROCEDURE|Non-ligation of Indirect Inguinal hernia sac|the indirect inguinal hernia sac will be separated from the spermatic cord and reduced/inverted in to the peritoneal cavity through the deep inguinal ring along with its contents.
215088884|NCT06175351|DRUG|Placebo|Participants will receive IV placebo every 4 weeks.
215088885|NCT01549119|BIOLOGICAL|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
214369988|NCT01376323|DRUG|Sitagliptin 100mg|Sitagliptin 100mg capsule
214369989|NCT03406546|DRUG|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
214369990|NCT03406546|DRUG|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
214369991|NCT03406546|DEVICE|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
214369992|NCT01209637|BEHAVIORAL|exercise training|exercise training min. 4 times a day for at least 30 min
214681417|NCT01324583|DRUG|prednisolone|"Pharmaceutical form:tablet~Route of administration: oral"
214681418|NCT04221906|DRUG|BOS-475|topical cream
214681419|NCT04221906|DRUG|Active ingredient-free vehicle cream|topical cream
214681420|NCT04221906|DRUG|Daivonex cream (calcipotriol 0.005%)|topical cream
214681421|NCT04221906|DRUG|Betnesol-V cream (betamethasone 0.1%)|topical cream
214681422|NCT02205567|DIETARY_SUPPLEMENT|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
214681423|NCT04415216|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
214681424|NCT05092581|DRUG|casirivimab+imdevimab|Single dose weight-based equivalent administered intravenously (IV)
214681425|NCT02797366|RADIATION|Proton radiotherapy|
214681426|NCT05034783|DRUG|[68Ga]Ga-HBED-CC-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-HBED-CC-exendin-4. Tracer doses of \[68Ga\]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.
214369993|NCT01209637|BEHAVIORAL|Intensive exercise training|Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
214369994|NCT00433303|BEHAVIORAL|Correlation between early delivery and coital activity|
214984851|NCT00763360|DEVICE|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
214984852|NCT00763360|DRUG|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
214984853|NCT00763360|DRUG|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
214984854|NCT03404245|BEHAVIORAL|Education, Fitbit/self-management app, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.
214984855|NCT03404245|BEHAVIORAL|Same intervention with a 6 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
214984856|NCT04066374|DEVICE|Peripheral Nerve Stimulation|Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
214984857|NCT03011996|DRUG|CLR 500mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
214984858|NCT03011996|DRUG|CJ-12420 100mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
214984859|NCT03011996|DRUG|CJ-12420 50mg|Cohort 2: bid for 7 days
214984860|NCT03011996|DRUG|AMX 1g|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
214984861|NCT03011996|DRUG|Pantoprazole 40mg|Cohort 2: bid for 7 days
214984862|NCT02323074|PROCEDURE|Brain Computer Interface|
214984863|NCT00576511|DRUG|prucalopride|4 mg o.d.
214984864|NCT00576511|DRUG|placebo|Placebo o.d.
214369995|NCT05671640|DEVICE|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
214984865|NCT03311867|OTHER|Ethibond Suture|Cerclage placement with ethibond
214984866|NCT03311867|OTHER|Prolene Suture|Cerclage placement with prolene
214984867|NCT04724746|BEHAVIORAL|Written Exposure and Cognitive Behavioral Therapy|Intervention involves writing details about a recent sexual assault and coping skills for substance use.
214984868|NCT02781324|PROCEDURE|Posterior Spinal Fusion|
214984869|NCT02781324|DEVICE|Ultrasonic Bone Scalpel|
214984870|NCT01989858|OTHER|peri-operative cht|"CHT treatment have to be chosen between the following associations:~Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or~Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line."
214984871|NCT01989858|OTHER|post-operative CHT|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line."
214984872|NCT01989858|OTHER|peri-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
214984873|NCT01989858|OTHER|post-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
214984874|NCT05750758|DRUG|rivaroxaban|rivaroxaban 2.5mg bid for 1m
214984875|NCT00834041|DRUG|Aliskiren 3.125 mini-tablets|Oral mini-tablets (3.125 mg) of aliskiren once each morning
214984876|NCT04913831|DRUG|Cerebrolysin|Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration
214984877|NCT04913831|DRUG|Placebo|physiological saline 100ml, 8-35 days, once/day, intravenous administration
214984878|NCT02523352|PROCEDURE|Non-Invasive Ventilation|Progressive increase in airway pressure to open lungs atelectatic regions.
214369996|NCT02551523|DRUG|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
214369997|NCT02551523|DRUG|Standard of care combinational antiretroviral therapy|
214369998|NCT01960725|BIOLOGICAL|RV5 (Pentavalent Rotavirus Vaccine)|
214369999|NCT00487058|DRUG|Gimatecan|
214370000|NCT00006825|BIOLOGICAL|trastuzumab|
214370001|NCT00006825|DRUG|pegylated liposomal doxorubicin hydrochloride|
214370002|NCT03306901|PROCEDURE|Esophagectomy|Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy
214370003|NCT03306901|DRUG|5-fluorouracil|3,200 \~ 4,000mg/m2 intravenously for 4 to 5 days.
214370004|NCT03306901|DRUG|Cisplatin|45\~60mg intravenously over 1 hour on day 1
214984879|NCT02523352|PROCEDURE|Esophageal catheter positioning|The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
214370005|NCT03306901|RADIATION|Radiation therapy|45 Gy irradiation (5 days a week for 5 weeks)
214370006|NCT02387892|DIETARY_SUPPLEMENT|Cheese & yogurt + Vitamin D|cheese \& yogurt with added 420 IU cholecalciferol
214370007|NCT02387892|DIETARY_SUPPLEMENT|Cheese & yogurt|Cheese \& yogurt without added vitamin D
214370008|NCT03092284|BIOLOGICAL|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Direct intramyocardial injection of CSCC\_ASC
214370009|NCT03092284|BIOLOGICAL|Placebo|Saline
214370010|NCT05392023|OTHER|Relaxation Exercises and Scapular Stabilization exercise program|Scapular Stabilization Program (3 sets of 10 reps each/day). This exercise program is for muscles affecting scapular alignment due to chronic neck pain. A specialized program of non-resistive scapular upward rotation, wall facing arm lift, backward rolling arm lift, overhead arm raise, shoulder abduction in scapular plane above 120˚, shoulder shrugs, levator scapulae and pectoralis minor stretching. Hot pack (10 min) and relaxation exercises including myofascial release and stretching of neck and scapular region muscles. A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long-term effects at the end of 6th week.
214370011|NCT05392023|OTHER|Relaxation Exercises of cervico- scapular region|Relaxation exercises of the cervico-scapular region including neck stretches of scapular muscles and myofascial release will be given to patients three times a week on alternate days for 3 weeks. Assessment will be done at baseline, at the end of the 3rd week, and for long-term effects at the end of the 6th week.
214984880|NCT04606758|PROCEDURE|PCNL under fluoroscopic control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance
214984881|NCT04606758|PROCEDURE|PCNL under ultrasound control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance
214984882|NCT02832778|DRUG|Efavirenz|Efavirenz 400mg
214984883|NCT02832778|DRUG|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
214984884|NCT02832778|DRUG|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
214984885|NCT02832778|DRUG|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
214370012|NCT02634788|DRUG|Buprenorphine|Buprenorphine sublingual spray delivered via single 100 μL spray
214370013|NCT02634788|DRUG|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
214370014|NCT05103163|OTHER|Foot Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applie
214370015|NCT06347510|DIAGNOSTIC_TEST|Suppression of tumorigenicity 2 (ST2)|Suppression of tumorigenicity 2 (ST2) is a member of the interleukin-1 (IL-1) receptor family. The ligand and soluble versions are its two isoforms. It was first isolated in 1989. It was found to function as an IL-33 ligand in 2005. The IL-33-ST2L ligand complex\&#39;s creation offers protection against heart fibrosis and hypertrophy. The formation of this complex is inhibited by soluble ST2, which removes the cardioprotective effect. Unlike NT pro BNP, it is unaffected by age, body mass index, creatinine, hemoglobin, and albumin levels, according to studies performed on individuals. with heart failure.
214370016|NCT04402463|OTHER|Global Postural Reeducation|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~In the treatment 3 of the therapeutic postures of GPR method to will carry out following Souchard's principles of Global Postural Reeducation"
214370017|NCT04402463|OTHER|Exercise Therapeutic|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~The treatment will be divided into 3 phases, where it initially starts with phase 1 (3 treatments) and progresses to phase 2 (3 treatments) until reaching stage 3 (2 treatments)."
214493468|NCT06773351|DRUG|Ciprofol 0.4 mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.4 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.
214984886|NCT02832778|DRUG|Rifinah or local generics|Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)
214370018|NCT03760770|PROCEDURE|corneal collagen crosslinking|Crosslinking in patients with progressive keratoconus.
214493469|NCT03981380|DRUG|11C-PIB|Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of \[11C\]PiB (over 5-10 seconds).
214493470|NCT06765018|DEVICE|Tongue Brush (Orabrush)|Patients in this group uses the Tongue Brush (Orabrush) 2 times a day for a duration for 3-5 days until the follow-up-screening takes place.
214493471|NCT06749691|DRUG|Liposomal Irinotecan and Apatinib|Liposomal Irinotecan in Combination With Apatinib
214493472|NCT06748326|PROCEDURE|Laparoscopy|Intussusception reduction by laparoscopy in children in failed non surgical procedures and in recurrence
214681427|NCT05034783|DRUG|[68Ga]Ga-NOTA-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-NOTA-exendin-4. Tracer doses of \[68Ga\]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.
214984887|NCT05441189|PROCEDURE|Resection|radical R0 resection of pancreatic adenocarcinoma
214984888|NCT05502029|BEHAVIORAL|Extended translation|Translation extended beyond the preoperative area
214984889|NCT05502029|BEHAVIORAL|Standard translation|Translation in the preoperative area
214984890|NCT03795415|BEHAVIORAL|Gundo So|"Gundo-So was adapted from a program established in quebec. It has been implemented in Mali following 3 phases: 1) cultural adaptation; 2) validation using a pre-post intervention evaluation; 3) scale-up~The programm consists on 9 group meetings group spread over 9 weeks (for 8 WLHIV + 2 trained community-based leaders). Each meeting has some particular thematics with adapted tools."
214984891|NCT01001741|OTHER|Cell phone text message|We will use cellular text messages to remind patients of impending drug prescription refills and scheduled visits to their healthcare provider.
214984892|NCT03353220|DRUG|Belviq|Belviq is an oral drug
214984893|NCT03353220|DRUG|Placebo|The placebo is made to mimic Belviq, but does not contain any active drug
214984894|NCT03680027|DIETARY_SUPPLEMENT|Walnut-enriched Group|All subjects supplemented with 40 g/day of walnuts for 6 weeks.
214984895|NCT05862012|DRUG|ISB 2001|Participants will receive escalating doses of ISB 2001
214984896|NCT05862012|DRUG|ISB 2001|Participants will receive injection of ISB 2001 as determined in Part 1.
214370019|NCT05892666|OTHER|On-site recruitment (information and consent) following a random sampling recruitment schedule|A trained research assistant in collaboration with local clerks at each site will screen eligible patients after on-site registration or online scheduling, but prior to assessment by a physician, based on included presenting complaints. The research assistant or member of the care team, depending on the local rules, will approach the potentially eligible participants and present them the research project and information consent form. If the patient agrees to participate and is eligible, they will sign the information and consent form and the research assistant will take their vital signs (for onsite participants only).
214493473|NCT06749158|PROCEDURE|spontaneous bone regeneration|"stage 1 surgery:~1. after administration of Local anesthesia (articaine hydrochloride 68 mg/1.7 ml + adrenaline 0.017 mg/1.7 ml injectable solution), sulcular incision will be done , extending two teeth beyond the area of interest followed by two oblique incisions on either side of the flap~2. after flap elevation, enucleation of the cystic lesion and extraction of the non-restorable teeth related to the lesion will be done.~3. titanium mesh will be tailored with 3 mm overlap at the edges to cover the bone window completely and fixed to the bone using mono-cortical titanium screws.~This will be followed by:~* proper decompression of soft tissue to achieve tension-reduced suture.~* Primary closure will be performed using 4-0 vicryl sutures.~* Sutures will be removed one week postoperatively. stage 2 surgery(after 6 months):~  1. titanium mesh and screws will be removed.~ 2. core biopsy will be obtained for histological assessment~ 3. implant/s placement."
214493474|NCT06749158|PROCEDURE|guided bone regeneration|"stage 1 surgery after cyst enucleation and extraction of the non-restorable teeth related to the lesion, The intra-bony defect will be filled with Deproteinized Bovine Bone.~* Titanium mesh will be tailored with 3mm overlap at the edges to cover the bone window completely and fixed to the bone using mono-cortical titanium screws. This will be followed by:~* proper decompression of soft tissue will be applied to achieve tension-reduced suture.~* Primary closure will be performed using 4-0 vicryl sutures.~* Sutures will be removed one week postoperatively. stage 2 surgery(6 months later) :~  1. titanium mesh will be removed.~ 2. core biopsy will be obtained for histological assessment.~ 3. implant/s placement."
214493475|NCT06762743|DRUG|Brivaracetam Oral Solution (Test Formulation)|The drug is manufactured by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
214493476|NCT06762743|DRUG|Brivaracetam Oral Solution (Reference Formulation)|The drug is manufactured by UCB Pharma S.A. under the trade name Briviact®. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
214493477|NCT06769698|DRUG|FDC fianlimab+cemiplimab|Fixed-Dose Combination (FDC) Administered per the protocol
214493478|NCT06769698|DRUG|Cemiplimab|Administered per the protocol
214493479|NCT06769698|DRUG|Placebo|Administered per the protocol
214681428|NCT01134887|OTHER|Informational Guide for Patients|"Veterans received a copy of the NIA guide for Talking with Your Doctor. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
214681429|NCT01134887|BEHAVIORAL|Video-Assisted Coaching|Physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients, but before seeing them for follow-ups. The main goal of this video-assisted coaching session was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management.
214681430|NCT01134887|OTHER|Monograph for Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians. The Four Habits provided practical evidence-based advice for improving patient-physician communication."
214681431|NCT01134887|BEHAVIORAL|Educational Coaching|an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor \[Coaching\]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management.
214984897|NCT06908317|OTHER|floor rise training using backward chaining method|"Each session lasts for 40 minutes starting with a five minutes warming-up including flexibility exercises and ends with a five minutes cooling-down consisting of stretching and breathing exercises. Warming-up is followed by the practicing of getting up floor taught with BMC involving the following 7 steps:~Step 1: descending from a standing position to half kneeling on a wedge pillow. Step 2: descending from a standing position to half kneeling on the floor. Step 3: Like step 2, then descending both knees to the floor into a high kneeling position. Step 4: Like step 3, then descending both hands to the floor one at a time, to come to a prone kneeling position. Step 5: Like step 4, then descending of the body to half sitting. A pillow can be positioned under the hip to soften the floor surface. Step 6: Like step 5, then descending of the body to side lying position. Step 7: Like step 6, then turning from side-lying to supine"
214984898|NCT06908083|OTHER|Analytical Treatment Interruption|Participants will stop their ART (Antiretroviral therapy) on Week 0 and will remain off of their ART for up to 48 weeks or until they meet restart criteria.
214984899|NCT02868567|DRUG|dalfampridine|Pill open label
214681432|NCT01134887|OTHER|Control|"The primary care providers randomly assigned to the Control-Physicians arm did not receive any additional coaching or resources and conducted their practice as usual."
214681433|NCT01686984|OTHER|Altered breath|
214681434|NCT06438276|BEHAVIORAL|Psychiatric outreach nurse service|Mental health service provided by psychiatric outreach nurses for 12-16 year old students in secondary schools
214681435|NCT02795988|BIOLOGICAL|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
214984900|NCT07091032|OTHER|Treatment as Usual|This is the comparison condition, in which participants will receive treatment as usual for their conditions at the clinic.
215088886|NCT01549119|BIOLOGICAL|Placebo|Comparison with experimental vaccine
214370020|NCT05892666|OTHER|First phone call 1-3 days after the initial visit|Once the patient has been discharged, a research assistant will call the patient within 72 hours following the initial visit. This phone call will allow to i) ensure that gender, ethnicity, comorbidities and disposition plans are fully documented; and ii) use our patient-reported experience measure tool and administer a questionnaire on motivation for choosing one care setting over the other. Motivation will be classified in the 6 domains of the Conceptual Model of Emergency Department Use (Uscher-Pines et al. 2019). Participants will be asked to specify whether their choice of care setting was based on accessibility, convenience, their perception of the severity of illness, their beliefs and knowledge regarding these care settings, referral/advice from a care professional or an acquaintance, or on costs.
214493480|NCT06754826|OTHER|AI-generated questions and feedback as a spaced repetition|Participants in the intervention group will undergo structured learning sessions consisted of AI-generated questions and feedback as a spaced repetition.
214493481|NCT06809569|DRUG|Allyl Isothiocyanate (AITC)|Topical administration
214493482|NCT06809569|DRUG|Capsaicin|Intradermal administration
214493483|NCT06809569|OTHER|Vehicle for AITC|Topical administration
214493484|NCT06809569|OTHER|Vehicle for Capsaicin|Intradermal administration
214493485|NCT06764082|DIETARY_SUPPLEMENT|high MCT formula|"Energy Intake: The tube-feeding formula was a special medical-purpose formula food with high MCT and deep hydrolyzed milk protein (Alfare, Nestlé, Switzerland), which contained hydrolyzed whey protein, maltodextrin, vegetable oil, and MCT, etc. At a high-calorie concentration, each 1000 mL could provide 800 kcal, 15.8 g MCT, and 21.5 g protein (osmotic pressure 227 mOsm/kg).~Feeding Procedure: On the basis of 130 - 150% DRI, a high-calorie formula feeding amount of 160 ml/kg/d could provide 2.7 g/kg/d MCT. After the operation, starting from when oral nutrition was feasible, the amount gradually increased from the initial amount until the expected amount was reached, and this continued until 6 months after the operation. The difference between the estimated feeding amount and the actual feeding amount could be selectively supplemented with enteral nutrition (nasogastric tube)."
214493486|NCT06764082|DIETARY_SUPPLEMENT|normal oral intake of the traditional formula|For the children in the control group, there were no special restrictions before the operation. After they were able to have a normal diet postoperatively, they were encouraged to have a normal oral intake of the traditional formula. The recommended energy input for the formula was 130 - 150% of the reference intake (DRI) based on age and gender as per the World Health Organization (WHO). The final dosage and schedule were determined by the children and their parents or caregivers. The feeding route and the schedule for complementary feeding were the same as those in the experimental group.
214493487|NCT06765135|BEHAVIORAL|Clinician Survey|At the conclusion of the intervention period, practice stakeholders, including survey providers and practice managers in the intervention sites will be surveyed to identify their degree of satisfaction with the intervention and suggestions for improvement.
214984901|NCT07091032|BEHAVIORAL|Building Connections Intervention|The combined Building Connections intervention incorporates three areas. Participants take part in those for which they are eligible. The obesity/weight management intervention offers coaching and support for education on evidence-based anti-obesity medications (AOM) and a lifestyle behavioral intervention offered by Community Health Workers focused on diet and physical activity. The cancer screening intervention focuses on developing workflows and systems to offer a CHW-delivered population-based intervention to improve colorectal and cervical cancer, focusing on newer screening modalities and monitoring adherence for individuals with a positive screening test result. The mental health intervention uses the evidence-based Strong Minds intervention, a 10-session psychoeducational program provided by trained community health workers with clinical supervision. The skills-based intervention uses an integrative approach aimed at improving depression, anxiety, and trauma-related symptoms.
214984902|NCT02996383|DEVICE|Internal fixation|Internal fixation of the fracture with a Targon FN implant (BBraun Ltd, Germany)
214984903|NCT02996383|DEVICE|Cemented Hemiarthroplasty|Replacement of the femoral head with a cemented hemiarthroplasty
214681436|NCT02795988|DRUG|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.|Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
214681437|NCT06097195|DEVICE|BioEP|When a consenting participant has their first electroencephalogram (EEG), they will be assigned with a unique participant study identifier before being uploaded. The centre will convert the EEG to European Data Format (EDF) format (or upload the total file) and upload this to the Neuronostics platform. The EEG will be stored on the Neuronostics database management system, within which the computational and mathematical analysis will be carried out. This study involves data analysis and mathematical modelling of the EEG recordings of each patient individually to generate a computational analysis score (BioEP).
214681438|NCT00956241|PROCEDURE|j-pouch coloanal anastomosis|
214984904|NCT06315283|DRUG|TV-44749|Administered subcutaneously (sc)
214984905|NCT06315283|DRUG|Oral olanzapine|Administered orally
214984906|NCT07136441|DIAGNOSTIC_TEST|Lower Limb Neurodynamic Test (LLNT) with Shear Wave Elastography|"Participants underwent sciatic nerve stiffness assessment using shear wave elastography during two distinct sequences of the lower limb neurodynamic test. Each participant received:~Proximal-to-distal sequence: Starting with hip flexion, followed by knee extension, then ankle dorsiflexion with toe extension.~Distal-to-proximal sequence: Starting with ankle dorsiflexion and toe extension, followed by knee extension, then hip flexion."
215088887|NCT06080100|DRUG|Xenon|inhalation of xenon in a sub-narcotic dosage
215088888|NCT06080100|OTHER|premedication hydroxyzine 25 mg|taking anxiolytic 30 minutes before surgery
215088889|NCT06585709|DEVICE|Active repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS will be delivered with a MagVenture MagPro X100 rTMS device with a Cool-B65-AP coil. rTMS will be applied to a personalized treatment target within the Left-Dorsolateral Prefrontal Cortex using a Localite Neuronavigation device.
214984907|NCT06891820|OTHER|Physical effort|The examined athletes will be subjected to an effort on a rowing ergometer, covering a designated distance in the shortest possible time.
214984908|NCT06928116|BEHAVIORAL|Heat therapy|At home lower body heat therapy
214984909|NCT06928116|BEHAVIORAL|Sham Control|Sham Thermoneutral
214984910|NCT06928116|BEHAVIORAL|Walking|Walking intervention
214984911|NCT02707042|DRUG|Amoxicillin|7-day therapeutic oral course of twice daily amoxicillin
214984912|NCT02707042|DRUG|Azithromycin|5-day oral course of once-daily azithromycin
214370021|NCT05892666|OTHER|Second phone call 8-14 days after the initial visit|A follow-up phone call will be made to all participants 8 days after the initial visit to evaluate primary and secondary outcome metrics. Patient-reported outcome (primary) and cost measures will be completed by the participants at this moment.
214370022|NCT00000986|DRUG|Zidovudine|
214370023|NCT00000986|DRUG|Aldesleukin|
214370024|NCT02565719|DRUG|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
214370025|NCT02565719|DRUG|Pegasys|immunotherapy
214493488|NCT06765135|BEHAVIORAL|Focus Group|Prior to installing the device in each primary care practice, trained moderators will conduct focus groups with clinicians and practice staff to to elicit provider perceptions of POC testing for respiratory pathogens, including feasibility and acceptability of integration of testing into routine workflows.
214493489|NCT06765135|DIAGNOSTIC_TEST|Biofire Spotfire Respiratory (R) panel|Eligible patients will be offered testing with the BioFire Spotfire Respiratory (R) Panel, which is an FDA-cleared, CLIA waived test. This is a multiplexed polymerase chain reaction (PCR) test intended for use with the BioFire Spotfire System for the simultaneous, qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal (NP) swab specimens obtained from individuals with signs and symptoms of respiratory tract infection, including COVID-19. This testing will be made available in participating practices along with clinical guidance about use and interpretation. Clinicians will administer the tests to patients who agree to be tested. Results will be shared with patients, who can discuss the results with their clinicians. Clinicians can use the test results to guide their treatment decisions.
214493490|NCT06765135|BEHAVIORAL|Patient Survey|During the intervention period, patients who undergo POC RPP testing will be surveyed soon after their visit to elicit their opinions about the test.
214493491|NCT06766786|DRUG|Magnesium Sulfate high dose|Patients undergoing simultaneous pancreas-kidney (SPK) transplantation who gave their consent were given an intravenous magnesium supplement at a dose of 45-50 mg/kg over the course of an hour during the procedure.
214493492|NCT06765239|DIETARY_SUPPLEMENT|Hayfever Care|"Powdered natural food supplement provided as a decoction, to be taken twice daily.~Personalized Diet and Nutrition Guidance along with Lifestyle Advice"
214493493|NCT06765239|OTHER|Wait-list Control|Personalized Diet and Lifestyle Advice
214493494|NCT06766903|BEHAVIORAL|Exercise training|"All subjects will participate of 8-weeks of exercise training intervention of concurrent training of high-intensity interval training (HIIT) using stationnaire bikes plus resistance training (RT) using free weight under lab conditions.~The exercise program will be monitored by 8-weeks, adapted individually to each participants in terms of exercise intensity an volume."
214493495|NCT06774508|OTHER|HIFE+cog|Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Simultaneous cognitive exercises are added to static and dynamic balance exercises. Relative exercise intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.
214984913|NCT02707042|OTHER|Control|A group of volunteers will receive no antibiotics and will serve as study controls.
214984914|NCT06908707|DRUG|LAE102 SC|A single dose of LAE102 will be administered subcutaneously
214984915|NCT06908707|DRUG|Placebo SC|A single dose of placebo administered subcutaneously
214984916|NCT06908707|DRUG|LAE102 IV|A single dose of LAE102 administered intravenously
215088890|NCT06585709|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS in an identical fashion to the active-rTMS condition will be delivered via the built-in e-sham system in the MagVenture device.
214370026|NCT02565719|DRUG|Viread|HBV RT polymerase inhibitor
214370027|NCT02565719|DRUG|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
214370028|NCT02831257|DRUG|AZD2014|
214681439|NCT00956241|PROCEDURE|side-to-end coloanal anastomosis|
214681440|NCT02341014|DRUG|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .
214984917|NCT06908707|DRUG|Placebo IV|A single dose of placebo administered intravenously
214984918|NCT06649409|DRUG|Vamorolone|vamorolone 20 mg/kg single dose on Day 2
214984919|NCT06649409|DRUG|Eplerenone|Eplerenone 200 mg single dose on Day 2
214984920|NCT06649409|DRUG|Fludrocortisone|"Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm."
214984921|NCT06188208|DRUG|VVD-130850|Oral tablets
214984922|NCT06188208|DRUG|Pembrolizumab|IV infusion
215088891|NCT06585709|DIAGNOSTIC_TEST|High Ventral Striatal Reactivity|We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define high ventral striatal reactivity as having \>mean voxels in the ventral striatum activate
215088892|NCT06585709|DIAGNOSTIC_TEST|Low Ventral Striatal Reactivity|We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define low ventral striatal reactivity as having \<mean voxels in the ventral striatum activate
215088893|NCT05572398|BEHAVIORAL|STAC-T|Middle school participants will complete online modules to learn about anti-bullying techniques and bystander intervention.
215088894|NCT06797895|BEHAVIORAL|VR assisted mobility|Commercially-based VR experience used to help move upper extremities to music, similar to dancing or Tai-Chi.
214984923|NCT07103889|BEHAVIORAL|Spartacus Test|The Spartacus test was conducted on a 750 m (75 × 10 m) rectangular course marked with cones at regular intervals to indicate different speeds (from 7 to 18 km/h). Each participant began running at 7 km/h, with speed increasing by 1 km/h every three minutes.During the 3-minute intervals (for each speed stage), participants had 15 seconds to reach the corresponding marker, followed by 15 seconds of rest. Participants had to adjust their running pace to reach the target cone in synchrony with an audio signal. The test ended when a participant failed to reach the next cone within the given time. This test is validated for assessing maximal aerobic capacity (MAS) in obese adolescents. During the Spartacus test, maximal heart rate (HRmax) was recorded using a heart rate monitor (S810; Polar, Kempele, Finland).
214984924|NCT04224974|OTHER|Usual Care|The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial
215088895|NCT06098534|BEHAVIORAL|Hospi'Senior|The Hospi'Senior room is equipped with conventional furnishings (same bed and same armchair as a conventional room) to which have been added technological innovations and innovations in furnishings. Innovative technologies cover bed equipment, patient mobility (autonomous and assisted), lighting, communication and social space.
215088896|NCT06098534|BEHAVIORAL|Conventional room|"The conventional room is a classic hospital room not equipped with the innovative technologies found in the Hospi'Senior room.~The room is equipped with a bed, bedside table, adjustable bed table with castors and an armchair."
215088897|NCT05621239|BIOLOGICAL|BNT162b2|BNT162b2 half dose and full dose
215088898|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
215088899|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
215088900|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)\*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
215088901|NCT06981273|PROCEDURE|Robotic pancreatoduodenectomy|A Robotic approach pancreatoduodenectomy is performed on patients
214370029|NCT00615186|DRUG|Neuradiab + Radiotherapy + Temozolomide|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
214370030|NCT00615186|DRUG|Radiation Therapy + Temozolomide|"Prior Surgery: Gross total resection (\< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
214493496|NCT06774508|OTHER|HIFE|Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Relative exercises intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.
214493497|NCT06763172|DRUG|Caffeine (200 mg)|Caffeine (200mg) will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
214493498|NCT06763172|DRUG|Placebo|Lactose tablet will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
214493499|NCT05296187|DEVICE|TEAS|Transcutaneous electrical acupuncture stimulation
214493500|NCT06753513|OTHER|99mTc-FDPH46 SPECT/CT Imaging|99mTc-FDPH46 SPECT/CT Imaging
214493501|NCT06775223|OTHER|Cardiac implantable electronic devices|validity and reliability study
214493502|NCT06797427|DRUG|DPH001|100 mg
214493503|NCT06797427|DRUG|Nexavar (Sorafenib)|200 mg
214493504|NCT00747565|DEVICE|Tecnis ZM900 Multifocal Intraocular Lens|Investigational intraocular lens
214493505|NCT00747565|DEVICE|CeeOn 911A monofocal IOL|Monofocal Control IOL
214493506|NCT05008276|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
214493507|NCT05008276|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
215088902|NCT06981273|PROCEDURE|open pancreatoduodenectomy|An open approach for pancreatoduodenectomy is performed
215088903|NCT06980844|OTHER|No intervention: no treatment|translationnal study: Only blood sampling and imaging will be performed on two groups of ILD patients.
215088904|NCT06980103|BEHAVIORAL|Decision Aid|The study intervention is a web-based decision aid (DA) developed by the study team. The Radioactive Iodine Decisions decision aid is designed as an educational tool to help patients have information about Radioactive Iodine and encourage them to talk with their medical team about this treatment decision.
215088905|NCT06980103|BEHAVIORAL|Usual Care|Patients randomized in the Usual Care Condition arm will receive a link for the American Cancer Society website on Radioactive Iodine (Radioiodine) Therapy for Thyroid Cancer as our comparison.
215088906|NCT06815003|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
215088907|NCT06815003|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214493508|NCT05008276|DRUG|Dextran 40|Diagnostic aid/agent used to measure glomerular size and selectivity
214681441|NCT02341014|DRUG|Romidepsin|
214681442|NCT02341014|DRUG|Lenalidomide|
214681443|NCT00041236|DRUG|exatecan mesylate|
214370031|NCT02621346|BEHAVIORAL|Imagery|Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.
214370032|NCT02621346|BEHAVIORAL|Muscle Maintenance|Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth
214370033|NCT02621346|BEHAVIORAL|Bicep Curls|Control group participants will complete a bicep exercise at a maintenance training intensity.
214681444|NCT05054933|OTHER|ultrasound capsule endoscopy|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
214681445|NCT01511289|DRUG|Imatinib|400mg/Tab, QD
214370034|NCT01860469|PROCEDURE|vancomycin-soaked mesh|
214370035|NCT01860469|PROCEDURE|plain mesh|
214370036|NCT03041844|DEVICE|Low Frequency, Low Intensity Ultrasound|Therapeutic ultrasound (20 kHz, \<100 mW/cm2 spatial peak-temporal peak)
214370037|NCT03041844|DEVICE|Sham Applicator|Sham ultrasound applicator
214370038|NCT00571766|DRUG|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
214493509|NCT06851520|PROCEDURE|Anterior Quadratus Lumborum Block (QLB)|A regional anesthesia technique where local anesthetic is injected anterior to the quadratus lumborum muscle under ultrasound guidance for postoperative pain management.
214493510|NCT06851520|PROCEDURE|Posterior Quadratus Lumborum Block (QLB)|A regional anesthesia technique where local anesthetic is injected posterior to the quadratus lumborum muscle under ultrasound guidance for postoperative pain management.
215088908|NCT06815003|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214493511|NCT06809218|DRUG|Inhaled isoflurane administered by Sedaconda ACD-S|Intervention: isoflurane
214493512|NCT06809218|DRUG|Intravenous infusion of propofol|Intervention: propofol
214681446|NCT01511289|DRUG|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
214681447|NCT00390780|DRUG|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
214681448|NCT00390780|DRUG|Clotrimazole|10mg troches administered Five Times a Day for 14 days
215088909|NCT06815003|PROCEDURE|Computed Tomography|Undergo CT
215088910|NCT06815003|DRUG|Cyclophosphamide|Given IV
214493513|NCT06262776|BIOLOGICAL|Recombinant zoster vaccine adjuvanted (SHINGRIX)|2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.
214493514|NCT03673280|PROCEDURE|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
214493515|NCT05014178|DIAGNOSTIC_TEST|Sodium-23 MRI|Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.
214493516|NCT05275686|DRUG|Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray|Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
214681449|NCT01710228|DRUG|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
214681450|NCT04302883|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE)|Ultrasound of heart chambers via esophagus
214681451|NCT04302883|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
214681452|NCT03360981|DRUG|Incretins|after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
214681453|NCT03664986|DRUG|Liposomal Bupivacaine|The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
214681454|NCT03218293|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
215088911|NCT06815003|PROCEDURE|Echocardiography|Undergo ECHO
215088912|NCT06815003|DRUG|Fludarabine|Given IV
214370039|NCT00571766|DRUG|Placebo|Placebo 2 g twice a day for 14 weeks
214370040|NCT01281202|DRUG|Vigabatrin|Tablets
214370041|NCT01281202|DRUG|Matching Placebo|Tablets
214370042|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 200 mg, twice daily, 7 days.
214370043|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 300 mg, twice daily, 8 days.
214370044|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 400 mg, twice daily, 9 days.
214370045|NCT00894673|BIOLOGICAL|Heparin sodium Hipolabor|Heparin sodium Hipolabor 5.000 UI/mL
214370046|NCT00894673|BIOLOGICAL|Heparin sodium APP|Heparin sodium APP 5.000 USP
214370047|NCT01984580|DRUG|zinc gluconate|26.6 mg zinc BID (as zinc gluconate)
214370048|NCT01488565|DRUG|Azacitidine and eltrombopag|Standard: azacitidine D1-5, 8\&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
214370049|NCT06296823|BEHAVIORAL|Simulated jetlag protocol|16 hours of wakefulness and an 8 hour scheduled sleep opportunity in a simulated jetlag protocol where you will go to bed and awaken earlier than usual.
214681455|NCT05469932|DEVICE|Rexon device|Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
214681456|NCT05228652|OTHER|Questionnaire|Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.
214681457|NCT04997837|DRUG|PD-1 inhibitor|Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
214681458|NCT04997837|DRUG|Oxaliplatin|"CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off."
215088913|NCT06815003|DRUG|Melphalan|Given IV
215088914|NCT06815003|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215088915|NCT06815003|OTHER|Questionnaire Administration|Ancillary studies
215088916|NCT06815003|DRUG|Tacrolimus|Given IV or PO
215088917|NCT06815003|BIOLOGICAL|Vedolizumab|Given IV
214984925|NCT04224974|BEHAVIORAL|EASE-psy|"All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT).~-EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms."
214984926|NCT04709276|DRUG|Nivolumab|360 mg intravenously every 3 weeks
214984927|NCT04709276|DRUG|Ipilimumab|1 mg/kg intravenously every 6 weeks
214984928|NCT04709276|DRUG|Carboplatin|"AUC 4 mg/ml per minute intravenously every 3 weeks for up to 10 cycles.~Subjects will also receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving carboplatin."
214984929|NCT04709276|DRUG|Cabazitaxel|"20 or 25 mg/m2 intravenously every 3 weeks for up to 10 cycles.~Subjects will also take prednisone by mouth at a dose of 10 mg daily and receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving cabazitaxel."
214984930|NCT07101445|DRUG|Acetaminophen|Given by mouth (PO).
214984931|NCT07101445|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214984932|NCT07101445|DRUG|Dexamethasone|Given intravenously (IV).
214984933|NCT07101445|OTHER|Electronic Health Record Review|Ancillary studies
214984934|NCT07101445|DRUG|Famotidine|Given by mouth (PO).
214984935|NCT07101445|DRUG|Loratadine|Given by mouth (PO).
214370050|NCT02087436|DEVICE|Taperloc Complete Microplasty|Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
214370051|NCT02087436|DEVICE|Taperloc Complete Standard|Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
214493517|NCT05275686|OTHER|Placebo Nasal Spray|The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day
214984936|NCT07101445|DRUG|Methylprednisolone|Given intravenously (IV).
214984937|NCT07101445|DRUG|Montelukast|Given by mouth (PO).
214493518|NCT05802264|COMBINATION_PRODUCT|ABCI|Subjects will receive ABCI via oral inhalation
214493519|NCT05802264|COMBINATION_PRODUCT|Placebo|Subjects will receive ABCI via oral inhalation
214493520|NCT06812845|OTHER|eye investigations|BY data entry ,measuring the visual acuity ,measuring IOP, doing refraction and recording eye investigations results to reach the final diagnosis
214493521|NCT06764433|PROCEDURE|GONPRF|GON PRF treatment, which we apply by imaging the target nerve and surrounding structures with the proximal technique (at C2 level) under USG guidance in patients who do not respond to conservative treatments for cervicogenic headache.
214493522|NCT06764433|PROCEDURE|Proximal GONPRF|Ultrasound-guided pulsed radiofrequency treatment of the greater occipital nerve at the C2 level
214493523|NCT06734273|DRUG|Mounjaro|In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.
214493524|NCT06734273|PROCEDURE|Sleeve Gastrectomy|Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.
214681459|NCT04997837|DRUG|Capecitabine|CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
214681460|NCT04997837|DRUG|Tegafur-gimeracil-oteracil potassium|SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
214681461|NCT04997837|DRUG|5-FU|FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
214681462|NCT04997837|RADIATION|Radiotherapy|1.8 Gy/Fx, 45-50.4 Gy
214681463|NCT04997837|DRUG|Chemotherapy|Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
214681464|NCT02567344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
214984938|NCT07101445|DRUG|Motixafortide|Given subcutaneously (SC).
214984939|NCT07101445|PROCEDURE|Pheresis|Undergo apheresis
214984940|NCT07101445|OTHER|Questionnaire Administration|Ancillary studies
214984941|NCT07101445|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Give Granulocyte Colony-Stimulating Factor (G-CSF).
214984942|NCT06690281|BIOLOGICAL|KRAS TCR-Transduced PBL|Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine)
214984943|NCT06690281|DRUG|Aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 3 doses)
214984944|NCT06690281|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 4 days
214984945|NCT06690281|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 30 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 7.5 mg/kg/day over 1 hour x 2 days
214984946|NCT04895436|DRUG|Venetoclax|Oral tablet
214984947|NCT04895436|DRUG|Obinutuzumab|Intravenous (IV) infusion
214984948|NCT04138719|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
214984949|NCT04138719|DRUG|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；
214370052|NCT02276924|DEVICE|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
214984950|NCT06662409|OTHER|Nature-based healing meditation (NBHM) intervention|6 nature-based healing meditation (NBHM) auditory modules available via the study website to facilitate bereavement (grief) recovery and assessed on parameters of directed attention, grief, and QOL (including parameters of depression/anxiety)
214984951|NCT07112443|BIOLOGICAL|NVD003|Bone correction and grafting surgery
214984952|NCT07112443|PROCEDURE|Iliac Crest Bone Graft|"Either a single-stage Grafting Surgery with internal fixation and cross-union or the 2-stage induced membrane Grafting Surgery approach, depending on the surgeon's own standard of care."
214370053|NCT03044522|OTHER|Opioid Education|
214370054|NCT03763643|DRUG|Rituximab|Rituximab 375mg/m2 intravenous on day 0 or -1 prior to kidney transplant
214370055|NCT03763643|PROCEDURE|Plasmapheresis|1.5 volume exchange plasmapheresis with fresh frozen plasma replacement
214681465|NCT02567344|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
214984953|NCT00195741|DRUG|divalproex sodium|
214984954|NCT02617095|DEVICE|T2762|One drop in each eye 3 to 6 times daily
214984955|NCT02617095|DEVICE|Optive|One drop in each eye 3 to 6 times daily
214984956|NCT05417750|DRUG|TIL therapy|A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.
214984957|NCT01022606|OTHER|Arterial sampling|Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
214681466|NCT03389126|DRUG|Avelumab|Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
214681467|NCT00028366|DRUG|Fosamprenavir|
214681468|NCT00028366|DRUG|Lopinavir/Ritonavir|
214984958|NCT04941274|DRUG|Abemaciclib|An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.
214681469|NCT00028366|DRUG|Ritonavir|
214681470|NCT00028366|DRUG|Tenofovir disoproxil fumarate|
214984959|NCT06952998|DRUG|Topical application of Plasma Rich in Growth Factors (PRGF)|Topical application of PRGF will be maintained each time the patient undergoes the conventional treatment. The frequency of conventional treatment will be determined by the health specialist according to the evolution of the ulcer. The treatment will be maintained until complete wound closure or until the end of the follow-up period (6 months).
214984960|NCT06952998|PROCEDURE|Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).|"Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic). The TIME dynamic wound closure strategy will be followed, which summarizes the four key points to stimulate the natural healing process: control of non-viable tissue, control of inflammation and infection, control of exudate and stimulation of the edges. After healing, chlorhexidine spray will be applied topically to these patients. The frequency of conventional treatment will be determined by the health specialist according to the evolution of the ulcer. Treatment will be maintained until complete wound closure or until the end of the follow-up period (6 months)."
214984961|NCT04765904|PROCEDURE|SDF|1)Dry with cotton to affected tooth surfaces 2) Apply the SDF material 3)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
214370056|NCT06488092|OTHER|Cesarean Risk Calculator|The cesarean risk calculator will be incorporated into routine care at the site
214370057|NCT03138733|DRUG|Ceftobiprole medocaril|Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion
214370058|NCT03138733|DRUG|Daptomycin|Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam
214370059|NCT06502665|OTHER|Women having had second ovulation induction after failed oocyte pick-up|IVF success is defined by the number of retrieved oocytes. Identifying women at risk of failed oocyte pick-up at the first oocyte pick-up and optimizing their ovulation induction could enhance outcomes
214370060|NCT05688059|OTHER|Absorbable Suture and Permanent Suture|Absorbable Suture and Permanent Suture
214370061|NCT06527183|DIAGNOSTIC_TEST|Skin punch biopsy to demonstrate small fiber neuropathy|Skin punch biopsy to assess intrapidermal nerve fiber density
214370062|NCT05867160|OTHER|ASM as adjunctive therapy|ASM approved as adjunctive therapy
214370063|NCT01364051|DRUG|Cediranib|Given PO
214370064|NCT01364051|DRUG|Cediranib Maleate|Given PO
214370065|NCT01364051|OTHER|Laboratory Biomarker Analysis|Correlative studies
214370066|NCT01364051|OTHER|Pharmacological Study|Correlative studies
214370067|NCT01364051|DRUG|Selumetinib|Given PO
214984962|NCT04765904|PROCEDURE|Hall technique|Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up
214370068|NCT01364051|DRUG|Selumetinib Sulfate|Given PO
214370069|NCT05107960|DRUG|Azilsartan (TAK-536)|Azilsartan Tablets, Azilsartan Granules
214370070|NCT05585684|OTHER|Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection|Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
214370071|NCT04417595|DRUG|Fish Oil (Containing Omega-3 Acids)|Fish Oil Supplement
214370072|NCT04417595|DRUG|Olive Oil|Olive Oil Supplement
214370073|NCT03182075|BEHAVIORAL|Computerized Training|OCD and hoarding disorder participants will receive 14 sessions of training via computer within 3 weeks.
214681471|NCT01585961|DEVICE|Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)|Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.
214681472|NCT01670513|DRUG|IDP-118 Low Strength|8 weeks
214681473|NCT01670513|DRUG|IDP-118 High Strength|8 weeks
214370074|NCT06289192|BEHAVIORAL|C-Raven Virtual Tobacco Cessation Counseling|A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.
215088918|NCT06981312|BEHAVIORAL|Acceptance and Commitment Therapy|Participants receive a 9-week internet-delivered intervention: 2 weeks of Pain Neuroscience Education (PNE) based on the PSE curriculum, followed by 7 weeks of Acceptance and Commitment Therapy (ACT) targeting psychological flexibility. In addition to value-oriented behavioral activation, the ACT content includes classical exposure. The treatment is mainly text-based, supported by multimedia content, and delivered on a secure digital platform. Communication with a clinician occurs at least weekly. Parents receive a parallel program based on PSE, ACT, and behavioral principles to support flexible and effective parenting.
215088919|NCT06981312|BEHAVIORAL|Pain Science Education|Participants receive 9 weeks of internet-delivered Pain Science Education (PSE), based on the PSE curriculum but with more detailed content, including extended examples, reflection exercises, and behavioral experiments. The aim is to reduce the threat value of pain by promoting a reconceptualization of pain. Parents receive a parallel program with tailored content. The intervention is text-based with multimedia components and delivered via a secure platform. Clinician support is provided asynchronously at least once weekly.
215088920|NCT06979908|DRUG|Fruquintinib+Sintilimab+Chidamide|"Fruquintinib: 5 mg orally once daily on days 1-14 of each 21-day cycle (Q3W).~Sintilimab (anti-PD-1): 200 mg intravenously on day 1 of each cycle (first infusion over 60 minutes, subsequent infusions over 30-60 minutes, Q3W).~Chidamide: 30 mg orally twice weekly (BIW; e.g., Monday \& Thursday or Tuesday \& Friday, with ≥3 days between doses), taken 30 minutes after meals."
214370075|NCT06289192|DRUG|Nicotine Replacement Product|Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
214370076|NCT06289192|OTHER|Community Health Worker|A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.
214370077|NCT06289192|OTHER|Lung Cancer Screening|Eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
214370078|NCT04573023|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
214370079|NCT04573023|DRUG|Idursulfase|IV infusion
214370080|NCT04573023|DRUG|JR-141 or Idursulfase|"The subjects who have achieved the pre-specified criteria\* are able to change the drug.~\*If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141.~If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase."
214370081|NCT06207630|DEVICE|Dressing Device|Use of a dress at the end of surgery in the operating room, making sure not to stick it on the openings of the chest drains.
214370082|NCT04578678|OTHER|Steering|Fine tuning of the STN-DBS settings
214370083|NCT02974725|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
214370084|NCT02974725|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
214370085|NCT02974725|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
214370086|NCT02974725|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
214370087|NCT00439712|DRUG|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
214370088|NCT00439712|DRUG|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
214370089|NCT04605562|DRUG|GP+DDP|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
214370090|NCT04605562|DRUG|Palbociclib|Administered orally
214370091|NCT04605562|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
214370092|NCT04605562|DRUG|PD-1 blocking antibody|Administered every 3 weeks
214370093|NCT04605562|DRUG|Galunisertib|Administered orally
214370094|NCT05964608|BEHAVIORAL|Behavioral Therapy|"Structured interviews, consisting of a total of 6 sessions, were held once every two weeks for men with premature ejaculation problems. Behavioral therapy took place once every two weeks for a total of six 45-minute sessions. The stop-start technique was the therapy used. Behavioral therapy interviews were conducted at the urology outpatient clinic of the hospital. Post-tests were administered to men with premature ejaculation (PEDT) and their spouses (FSFI and SQOL-F) immediately after the 6th session was completed."
214370095|NCT01276925|DRUG|Ropivacaine|7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
214370096|NCT01276925|DRUG|Ropivacaine|7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
214370097|NCT01276925|DEVICE|Ultrasound|All nerve blockades will be performed with ultrasound guidance.
214370098|NCT01276925|PROCEDURE|Peripheral nerve blockade|All patients will receive injections around the three nerves before surgery.
214370099|NCT01276925|DRUG|Saline|Isotonic. 10 ml for the femoral nerve.
214370100|NCT01276925|PROCEDURE|Total hip arthroplasty|All patients undergoes total hip arthroplasty.
214370101|NCT01276925|DRUG|Bupivacaine|5 mg/ml. 3 ml for spinal anaesthesia.
214370102|NCT03346603|OTHER|urine culture and susceptibility testing|All patients will have a urine culture and susceptibility test ordered per standard care. Results of tests will identify which patients have antimicrobial-resistant organisms.
214370103|NCT02440633|DRUG|14C-OPS-2071|Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
214370104|NCT01172002|DRUG|Leflunomide|"Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
214370105|NCT01172002|DRUG|Azathioprine|"Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
214984963|NCT05502887|DIAGNOSTIC_TEST|Sublingual in vivo microscopy with the Glycocheck microscope|For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
214984964|NCT02987868|DRUG|Amino acid supplement first day|An orally administered supplement of the proprietary amino acid derivative
214984965|NCT02987868|DRUG|Placebo first day|A non-active orally administered supplement of the proprietary amino acid derivative
214984966|NCT02987868|DRUG|Amino acid supplement second day|An orally administered supplement of the proprietary amino acid derivative
214984967|NCT02987868|DRUG|Placebo second day|A non-active orally administered supplement of the proprietary amino acid derivative
214984968|NCT03286790|OTHER|Data collection on pneumonia events|
214984969|NCT00479752|DRUG|FOLFOX4 (Oxaliplatin), Cetuximab|"Arm A FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².~Arm B FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
214984970|NCT00322322|DRUG|L-Carnitine|L-Carnitine
214984971|NCT04363814|BIOLOGICAL|Bactek-R|BACTEK-R is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
214370106|NCT05085626|DRUG|fluzoparib+chidamide|Arms A will be treated with fluzoparib in combination with cedaramide
214984972|NCT00498550|DRUG|Clozapine|Clozapine up to 550mg per day
214984973|NCT00498550|DRUG|Treatment as usual|Remain on pre-study antipsychotic treatment
214984974|NCT02918344|OTHER|Hydroset|Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.
214984975|NCT02918344|PROCEDURE|Standard sagittal split osteotomy|The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.
214984976|NCT02530840|BEHAVIORAL|medical team|Lowering HbA1c by behavioral changes in meetings with the medical team.
214984977|NCT02530840|BEHAVIORAL|peers group|Lowering HbA1c by behavioral changes in meetings with the peers group.
214984978|NCT02530840|BEHAVIORAL|SMS notification|Lowering HbA1c by behavioral changes in meetings with the SMS notification
214984979|NCT06425640|BEHAVIORAL|24-hour movement behavior|Cross-sectional observational study investigating the 24-hour movement behaviors and glucose control
214984980|NCT02711137|DRUG|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
214984981|NCT02711137|DRUG|Gemcitabine|Standard of Care (SOC) agents
214984982|NCT02711137|DRUG|Paclitaxel|Standard of Care (SOC) agents
214984983|NCT02711137|DRUG|Rucaparib|Standard of Care (SOC) agents
214984984|NCT02711137|DRUG|Abiraterone|Standard of Care (SOC) agents
214984985|NCT02711137|DRUG|Ruxolitinib|Standard of Care (SOC) agents
214984986|NCT02711137|DRUG|Azacitidine|Standard of Care (SOC) agents
214370107|NCT05085626|DRUG|fluzoparib+camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
214370108|NCT01274052|OTHER|Meal test|Liquid meal test
214370109|NCT04841941|DEVICE|G4 Multifocal soft contact lens with a 54% water content for presbyopia|"The participants must agree to wear lenses from a trial set with the fit assessed according to the Fitting Guide. Prescription lenses will then be ordered from the manufacturer."
214370110|NCT01210430|DRUG|Losartan|Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
214984987|NCT01855022|BEHAVIORAL|MI + IVR|Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
214370111|NCT01210430|DRUG|Ascorbic Acid (Vitamin C)|Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
214370112|NCT01210430|DRUG|Normal Saline|Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
214370113|NCT05773118|DEVICE|orthokeratology lens|Subjects will wear orthokeratology lens at night. Axial length elongation over a period of 12-month will be recorded.
214370114|NCT05773118|DEVICE|multifocal soft contact lens|Subjects will wear multifocal soft contact lens during the day time. Axial length elongation over a period of 12-month will be recorded.
214370115|NCT05773118|DEVICE|Single vision spectacles|Subjects will wear single vision spectacles during the day. Axial length elongation over a period of 12-month will be recorded.
214984988|NCT05096377|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
214984989|NCT03549026|DRUG|Duloxetine|The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption
214370116|NCT00490256|PROCEDURE|Modified Selective Cerebral Perfusion|Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
214984990|NCT03549026|DRUG|placebo|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
214984991|NCT01212510|OTHER|Blood sampling|blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA
214370117|NCT02472210|DRUG|Botulinum Toxin|An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
214370120|NCT02827006|PROCEDURE|corrective osteotomy distal radius|Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
214370121|NCT03687801|BEHAVIORAL|Online hearing support|The intervention group will follow an online hearing support for five weeks
214984992|NCT04571489|DRUG|Gimatecan|Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.
214984993|NCT04571489|DRUG|tegafur, gimeracil and oteracil potassium|Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.
214984994|NCT04571489|DRUG|gemcitabine|Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
214984995|NCT04800796|OTHER|Audiovisual|Receive blended learning before and reading the Standard operating procedure
214370122|NCT03687801|BEHAVIORAL|Standard care|The control group will follow standard care during the time the intervention group receives online haring support
214370123|NCT04430751|BEHAVIORAL|Medical QiGong training|"The study intervention consisted of a 12-week training program that introduced students to a progressive series of 10 QiGong forms that are designed to build upon each other to restore balance and function and to enhance well-being. These forms involve both physical movement and visualization."
214370124|NCT00438880|DRUG|Agatolimod Sodium|Given IV
214370125|NCT00438880|RADIATION|Indium In-111 Ibritumomab Tiuxetan|Given IV
214370126|NCT00438880|OTHER|Laboratory Biomarker Analysis|Correlative study
214370127|NCT00438880|PROCEDURE|Radionuclide Imaging|Undergo imaging scans
214370128|NCT00438880|BIOLOGICAL|Rituximab|Given IV
214370129|NCT00438880|PROCEDURE|Single Photon Emission Computed Tomography|Undergo imaging scans
214370130|NCT00438880|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
214370131|NCT05385120|PROCEDURE|Temporary Portocaval Shunt|In Temorary Portocaval Shunt Group (TPCS group), Hilar dissection( division of Hepatic artery, Bileduct) is followed by temporary portocaval shunt formation during recipient Hepatectomy.
214370132|NCT04461743|OTHER|No intervention|No intervention, regular therapy
214370133|NCT05582005|DEVICE|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children 3 year old and younger, scheduled for elective MRI, that are not intubated or require higher oxygen support and with no parents/guardians refusal will be placed on an electrocardiogram during post-anesthesia recovery. The NIPE monitor will be connected to the patients monitor in the PACU. Values will be recorded from the time of patient awaking until the patient meets the discharge criteria from PACU not before 1 hour.
214370134|NCT05559957|BEHAVIORAL|observation of delivery and neonatal outcomes|MONITORING THE DELIVERY MODE EITHER CESAREAN OR VAGINAL, BESIDE THE NEONATAL OUTCOME AND MORBIDITIES IN BOTH GROUPS
214370135|NCT02168530|DRUG|placebo|matching placebo administered daily orally
214370136|NCT02168530|DRUG|vismodegib|vismodegib 150 mg administered daily orally
214370137|NCT00228605|DRUG|OraVescent Fentanyl|
214370138|NCT05365243|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center and at home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
214984996|NCT00750269|RADIATION|SBRT 40.0 Gy|SBRT delivered in 5 fractions of 8.0 Gy/fraction over 1.5 to 2 weeks for a total of 40.0 Gy
214984997|NCT00750269|RADIATION|SBRT 42.5 Gy|SBRT delivered in 5 fractions of 8.5 Gy/fraction over 1.5 to 2 weeks for a total of 42.5 Gy
214984998|NCT00750269|RADIATION|SBRT 45.0 Gy|SBRT delivered in 5 fractions of 9.0 Gy/fraction over 1.5 to 2 weeks for a total of 45.0 Gy
214984999|NCT00750269|RADIATION|SBRT 47.5 Gy|SBRT delivered in 5 fractions of 9.5 Gy/fraction over 1.5 to 2 weeks for a total of 47.5 Gy
214985000|NCT00750269|RADIATION|SBRT 50.0 Gy|SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
214370139|NCT01032655|DRUG|susceptibility test guided sequential therapy|"susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~1. Klaricid, 500 mg, bid~2. Cravit, 250 mg, bid~3. Tetracycline, 500 mg, bid"
214985001|NCT00750269|RADIATION|SBRT 52.5 Gy|SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
214985002|NCT00750269|RADIATION|SBRT 55.0 Gy|SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
214985003|NCT00750269|RADIATION|SBRT 57.5 Gy|SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
214985004|NCT00750269|RADIATION|SBRT 60.0 Gy|SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
214985005|NCT02983123|PROCEDURE|1-hour hs-cTnT|
214985006|NCT01799889|DRUG|Entospletinib MM|Entospletinib MM tablet administered orally
214985007|NCT01799889|DRUG|Entospletinib SDD|Entospletinib SDD tablet administered orally
214985008|NCT04858464|OTHER|Survey study|Patients will complete the mentioned questionnaires.
214985009|NCT03380156|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
214985010|NCT03380156|DEVICE|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
214985011|NCT06426745|PROCEDURE|Bowel preparation|to compare bowel cleanliness, compliance, tolerability, and patient satisfaction of a single regimen versus a split regimen for colonoscopy.
214985012|NCT05759871|OTHER|GnRH antagonist|The GnRH antagonist in the control group (standard therapy) is administered from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day and is injected each time immediately after the injection of FSH.
214985013|NCT00185159|DRUG|Olmesartan medoxomil|tablets
214985014|NCT00185159|DRUG|Placebo Tablets|Tablets
214985015|NCT03069664|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
214985016|NCT03069664|DEVICE|Covered Self-expandable Metal Stent|Pancreatic duct stent
214985017|NCT04156659|BIOLOGICAL|Tisagenlecleucel|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
214985018|NCT05105256|DRUG|Prednisolone|Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
214985019|NCT05105256|DRUG|Platelet-rich plasma|Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
214985020|NCT03944616|BEHAVIORAL|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
214985021|NCT03944616|BEHAVIORAL|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
214985022|NCT01614652|DEVICE|CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)|CardioKinetix Parachute implant and all appropriate medical therapy
214985023|NCT05707221|OTHER|cleaning removable acrylic appliance with denture brush and chlorhexidine toothpaste|mechanical cleaning of removable appliance by the patient for 7 days before bedtime for one minute
214985024|NCT05707221|OTHER|cleaning removable acrylic appliance with cleansing tablet|chemical cleaning by patient for 7 days with cleansing tablet
214370140|NCT00018135|DRUG|calcium acetate|
214985025|NCT05707221|OTHER|combination of mechanical and chemical cleaning|cleaning the appliance with denture brush and CHX toothpaste followed by the cleansing tablet
214985026|NCT01721798|DEVICE|Mirena levonorgestrel IUD|Intrauterine contraception system
214985027|NCT01721798|DEVICE|Copper T-380a IUD|intrauterine contraception system
214985028|NCT01308515|DEVICE|Vanguard Knee System with AS Bearing|FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
214985029|NCT01308515|DEVICE|Vanguard Knee System with PS Bearing|FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
214985030|NCT00478621|BIOLOGICAL|GSK Biologicals' HPV vaccine (GSK1674330A)|Intramuscular administration, 5 different formulations
214370141|NCT00018135|DRUG|aluminum hydroxide|
214370142|NCT00018135|DRUG|Sevelamer|
214370143|NCT06252103|DRUG|Ferrous Gluconate 300 MG|iron salt one tab 300 mg contain 35 mg of elemental iron given 2 doses 600 mg per day
215088921|NCT06981286|OTHER|A dataset comprising participants withT2D will be used to evaluate the classification performance of various machine learning techniques.|A dataset comprising participants with T2D will be used to evaluate the classification performance of various machine-learning techniques.
214370144|NCT06252103|DRUG|ferrous gluconate with lactoferrin|Lactoferrin is a glycoprotein from the transferrin family consist of 691 amino acids,Lactoferrin is a protein found in cow milk and human milk
214985031|NCT00478621|BIOLOGICAL|Cervarix TM|Intramuscular administration
214985032|NCT00090532|DRUG|AG-013,958|
214985033|NCT02144909|BEHAVIORAL|Partners in Care with Semi-Structured Support Group|
214985034|NCT06450288|BEHAVIORAL|GO|"Green Oasis wellness program: include physical exercises, gardening, interaction with the developed website. Participants' general health status and website evaluation will be measured at T0 (baseline), T1 (3 months), T2 (9 months), using standardized questionnaires.~Study Design: pre-post study, 50 participants will be recruited from the Concordia Tsat Sing Kong transitional housing estate."
215088922|NCT04319627|DRUG|Rosuvastatin Calcium|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
215088923|NCT04319627|DRUG|Placebo Oral Tablet|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
214985035|NCT06833697|PROCEDURE|erector spinae plane block|"the ESP block will be administered after surgery but before the patient is awakened, under sterile conditions and ultrasound guidance.~Patient Positioning: The patient will be placed in the lateral position with the surgical side up, and a sterile ultrasound probe cover will be used.~Ultrasound Imaging: A high-frequency (11-12 MHz) linear probe will be placed transversely at the T5 thoracic vertebra.~Anatomy Identification: The erector spinae muscle and transverse processes will be visualized.~Needle Insertion: Using an in-plane technique, the needle will be advanced to the transverse process.~Injection: After confirming the needle position with 1-2 mL saline, 30 mL of 0.25% bupivacaine will be injected between the erector spinae muscle and transverse process, with spread monitored via ultrasound."
215088924|NCT06981000|BEHAVIORAL|Locally adapted nature-based health intervention|"The locally adapted NBHIs are organized according to the following structure:~* Duration of the program: Minimum 10 weeks, once a week, 1.5-2.5 hours per session~* Group composition: Across conditions: mild to moderate anxiety, depression, and/or stress~* Group size: 8-12 participants in a closed group~In the locally adapted programs, activities in nature are based on three main mechanisms of change (nature interaction and sensory experiences, social communities, and physical activity and movement)."
214681474|NCT01258348|DRUG|Drug: LY573636-sodium|"Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression."
214681475|NCT01258348|DRUG|Sunitinib|"37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression."
215088925|NCT06825910|DEVICE|LMA igel|adults allocated to the LMA igel group, an LMA igel device will be inserted intraoperatively
215088926|NCT06825910|DEVICE|LMA protector|adults allocated to the LMA protector group, an LMA protector device will be inserted intraoperatively
215088927|NCT06174116|DRUG|Lumateperone|Subject will take lumateperone (Caplyta) for 12 weeks, in addition to their regular medications.
214370145|NCT02475252|PROCEDURE|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
214370146|NCT05815654|DEVICE|Warm Palace Analgesic Point Sticker|The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
214370147|NCT03733405|BEHAVIORAL|Postpartum Visit at 6 Weeks|The patient will be scheduled for a routine postpartum visit at the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
214370148|NCT03733405|BEHAVIORAL|Postpartum Visit at 2 Weeks|The patient will be scheduled for an earlier postpartum visit in addition to the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
214370149|NCT01299519|BEHAVIORAL|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
214370150|NCT01299519|BEHAVIORAL|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
214370151|NCT00944047|DRUG|nab-paclitaxel|100 MG/M2 IV over 30 minutes once a week for 12 weeks
215088928|NCT06174116|DRUG|Placebo|Subject will take placebo for 12 weeks, in addition to their regular medications.
215088929|NCT06980142|BIOLOGICAL|CM512|Administered SC
215088930|NCT06980142|DRUG|Placebo|Administered SC
214370152|NCT00944047|DRUG|trastuzumab|4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
214370153|NCT00944047|DRUG|Doxorubicin|60 MG/M2 every two weeks for a total of 4 cycles
214370154|NCT00944047|DRUG|cyclophosphamide|600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
214370155|NCT00944047|BIOLOGICAL|Growth Factor Support|"* All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.~* Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician."
214370156|NCT00944047|PROCEDURE|Surgery|"* After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.~* All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection."
214370157|NCT05203484|DEVICE|Multielecotrde Mapping|Multielectrode Mapping with Pentaray/Octaray
214370158|NCT05203484|DEVICE|Point-by-point mapping|Point-by-point mapping with QDot
214370159|NCT01857401|OTHER|No intervention, observational study only|No intervention. We are collecting blood for an ex vivo study
214681476|NCT02704728|OTHER|Thetanix|Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
214681477|NCT02704728|OTHER|Placebo|Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
214681478|NCT00003982|DRUG|sabarubicin|
214681479|NCT03452553|DEVICE|LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin|Drug Eluting Beads loaded with chemotherapy
214681480|NCT04387058|DEVICE|TIPS|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is an interventional radiology method that creates an anastomosis between the portal venous network and the hepatic venous network.
214681481|NCT01090089|DRUG|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
214681482|NCT01090089|DRUG|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
215088931|NCT03887559|BEHAVIORAL|Group-based stabilization and skill training in addition to individual treatment|"Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'."
215088932|NCT03887559|OTHER|Treatment as usual|Treatment as usual: conventional individual treatment (outpatient). Not standardized.
215088933|NCT06997887|OTHER|CH2 vaginal gel|12-week intervention with CH2 vaginal gel
215088934|NCT06997887|OTHER|vaginal rehabilitation exercises|12-week intervention with vaginal rehabilitation exercises
214370160|NCT01752673|OTHER|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
214370161|NCT01752673|OTHER|Didactic review lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
215088935|NCT02092402|OTHER|Fecal transplantation|
214370162|NCT02108379|DEVICE|Rhinix Nasal Filters|
214493525|NCT05687292|DEVICE|Clinical decision support system (CDSS) for ventilator weaning|A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.
214493526|NCT06791512|DRUG|mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody|Participants in the experimental group will receive the neoadjuvant therapy regimen of mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody. And the first five doses received the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) combined with sintilimab (200 mg, intravenous) and Bevacizumab (5 mg/kg, intravenous), and the sixth dose received the same regimen of mFOLFOX6 and PD-1 monoclonal antibody but not plus bevacizumab, in order to allow sufficient withdrawal time of Bevacizumab for surgery.
214493527|NCT06791512|DRUG|mFOLFOX6|Participants in the control group will receive the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) alone.
214493528|NCT06426329|BEHAVIORAL|Therapeutic Touch|Therapeutic touch, as meaningful touch, is included in complementary medicine in the literature. It provides physical, emotional and spiritual relief, improves physiological health, makes the person feel valuable, gives confidence, peace, calmness and increases self-confidence.
214493529|NCT06832774|PROCEDURE|Local treatment|For bone lesions, radiotherapy or orthopedic surgery may be selected. For lymph node lesions, radiotherapy or high-energy focused ultrasound (HIFU) maybe selected. The specific treatment plan will be determined by the researcher and based on the patient's clinical condition.
214681483|NCT03928834|BEHAVIORAL|Adapted Nzira Itsva|Adolescents will be provided an enhanced adherence package consisting of VL testing using DBS, including the NI intervention and low-cost genotyping and drug resistance monitoring. Participants receiving the intervention will have their first session after recruitment and enrollment, and will schedule up to 4 additional booster sessions at a time convenient for them spaced approximately 1 month apart. This may be modified after the formative assessment.
214681484|NCT04050007|OTHER|Preventive initiation of fluid removal|"Preventive initiation of fluid removal will be started right after the randomization with intravenous diuretics according to a predefined algorithm based on the urine output every three hours.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
214681485|NCT04050007|OTHER|Curative initiation of fluid removal|"The initiation of fluid removal will be considered by the attending physician only in case of failure to the spontaneous breathing trial with a clinical suspicion of weaning induced pulmonary edema.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
214681486|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
214681487|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
214681488|NCT02829086|OTHER|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
215088936|NCT06102811|OTHER|Low Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.075% (50 mL)
215088937|NCT06102811|OTHER|High Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.25% (50 mL)
215088938|NCT07007364|DRUG|Adebrelimab Combined With Albumin Paclitaxel|Eligible patients received neoadjuvant low-dose radiotherapy combined with Adebrelimab and monotherapy with albumin paclitaxel for two cycles. Radical surgical resection is planned to be carried out 3 to 4 weeks after neoadjuvant therapy. Patients who obtain PCR after evaluation by the researchers after the operation will be maintained for 6 cycles of immunomonotherapy
215088939|NCT05425810|DEVICE|Apply ENABLE sensing pad|The developed ENABLE system is integrated into the standard prosthetic liner and measures the pressure distribution during locomotion. Using the ENABLE system may lead temporary increase in the temperature inside the prosthetic socket and it is expected that the total exposition during the experimental procedure will be less than 10 min.
215088940|NCT05425810|DEVICE|Insert small pads at pressure tolerant locations|To change the pressure distribution inside the socket, four fitting conditions are introduced by adding small pads at patella tendon (PT), lateral tibial crest (LTC), medial tibial crest (MTC), and popliteal fossa (PF) respectively. Including the no pads scenario, totally of five fitting conditions are simulated.
214370163|NCT04589533|OTHER|educational program|The educational program will be based on: a outreach visit (a 3-h face-to-face meeting between a trained diabetes specialist from outside the Center and the staff of the Center itself) and a distance learning (FAD).The educational programme will be focused on current Diabetes Guidelines recommendations and based on possible deviations from the best clinical practice observed during phase1
214370164|NCT04060875|DEVICE|Karuna Labs Virtual Reality Software|The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
214370165|NCT02612064|DEVICE|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
214370166|NCT02612064|OTHER|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
214370167|NCT03580889|DRUG|Atropine|Comparison between atropine, glycopyrrolate and Normal Saline
214370168|NCT03580889|DRUG|Glycopyrrolate|Comparison between glycopyrrolate, atropine and Normal saline
214370169|NCT03580889|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Comparison between Normal saline, atropine and glycopyrrolate
214370170|NCT00269802|DRUG|OROS methylphenidate HCl|
214985036|NCT06833697|PROCEDURE|serratus posterior superior intercostal plane block|"In Group 3, SPSIP block will be administered after surgery but before the patient is awakened, under sterile conditions and ultrasound guidance.~Patient Positioning: The patient will be placed laterally with the surgical side up, using a sterile ultrasound probe cover.~Ultrasound Imaging: A high-frequency (11-12 MHz) linear probe will be positioned sagittally at the scapula's upper corner to visualize the rhomboid major, trapezius, serratus posterior superior muscles, and the third rib.~Anatomy Identification: The third rib and serratus posterior superior muscle will be identified.~Needle Insertion: Using an in-plane technique, the needle will be advanced between the serratus posterior superior muscle and the third rib.~Injection: After confirming the needle position with 1-2 mL saline, 30 mL of 0.25% bupivacaine will be injected into the space, with spread monitored via ultrasound."
214985037|NCT06833697|DRUG|0.25% bupivacaine|0.25% bupivacaine
214370171|NCT00269802|DRUG|Ritalin|
214370172|NCT00269802|DRUG|Placebo|
214370173|NCT02674217|PROCEDURE|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
214370174|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
214985038|NCT01294046|DEVICE|Deep Brain Stimulation of SPG for Migraine|Deep Brain Stimulation of SPG for Migraine
214985039|NCT04897620|OTHER|Scanning the blood test results|"Participants' age, gender, duration of low back pain (days), if evaluated, conditions associated with low back pain in cases with subacute/chronic pain, ESR, CRP, RDW, MPV, neutrophil count, lymphocyte count, eosinophil count and platelet count in blood tests at admission examinations were recorded. NLR was calculated by dividing the number of neutrophils by the number of lymphocytes, PLR by dividing the number of platelets by the number of lymphocytes, ELR by dividing the number of eosinophils by the number of lymphocytes, and SII by the formula platelet numberxneutrophil number/lymphocyte number"
214985040|NCT04319224|DRUG|Vopratelimab|Specified dose on specified days
214985041|NCT04319224|DRUG|Ipilimumab|Specified dose on specified days
215088941|NCT06687824|OTHER|Black Tea Extract|Sterile gauze is impregnated into 5ml of black tea-extract solution with tannin concentration 18.67mg/ml
214370175|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
214370176|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
214370177|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
214370178|NCT04716699|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor samples
214370179|NCT04716699|DRUG|Lidocaine|Given IV
214370180|NCT04716699|PROCEDURE|Resection|Undergo surgical resection per standard of care
214370181|NCT01669798|DRUG|BIBF 1120|PO 200mg BID
214370182|NCT02080975|OTHER|Data Collection During Atrial Flutter Ablation|All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
214370183|NCT03125005|DEVICE|Rainbow Universal Pulse Oximeter Sensor|
214370184|NCT04876040|DEVICE|SSO2 Downstream System|60-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting.
214370185|NCT04876040|PROCEDURE|PCI + Impella|Standard of Care Intervention
214370186|NCT03367039|PROCEDURE|ProDisc-C vivo|Total Disc Replacement using ProDisc-C vivo.
214370187|NCT03367039|PROCEDURE|Anterior cervical discectomy fusion|Anterior Cervical Discectomy and Fusion
214985042|NCT04319224|DRUG|Nivolumab|Specified dose on specified days
214985043|NCT04319705|DRUG|Azithromycin|Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
214985044|NCT04319705|DRUG|Placebo oral tablet|capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
214985045|NCT05105685|DRUG|recombinant human growth hormone|RhGH treatment was started at 0.1 IU/kg once daily
214985046|NCT05105685|DRUG|Saline|Saline was started at 0.1 IU/kg once daily as the placebo
214985047|NCT00312442|DRUG|Treatment with WST09 Vascular Photodynamic therapy|
214370188|NCT01445405|DRUG|Bortezomib (Velcade, PS-341)|
214493530|NCT06832774|DRUG|Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).|"The intervention contains gonadotropin releasing hormone analog (GnRHa) and novel hormone therapy. For GnRHa, there are 3 options available. 1. Leuprorelin/Prostap or Staladex. 2. Goserelin/Zoladex. 3. Triptorelin /LiverTox. For novel hormone therapy, there are also 3 options available. 1. Abiraterone/ ZYTIGA®. 2. Apalutamide/ERLEADA®. 3. Rezvilutamide/ARIANE®. The specific treatment plan will be designed according to patients' clinical conditions based on EAU guidelines."
214493531|NCT06752486|DRUG|Giving post photorefractive keratectomy for pain relief|We plan to conduct a randomized prospective study to assess the efficacy and safety of oral Gabapentin versus oral Diclofenac Potassium for postoperative analgesia in adults undergoing surface ablation. The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours. The drugs will be administered starting from the first day postoperative.
214493532|NCT06804408|BEHAVIORAL|Qigong|12-week training of Baduanjin (or named Eight-Section Brocades), with two sessions per week. Each session lasts for 60 min.
214493533|NCT06804408|BEHAVIORAL|Mindfulness-based training|12-week training of mindfulness-based breathing, walking, and stretching practices, with two sessions per week. Each session lasts for 60 min.
214493534|NCT06804408|BEHAVIORAL|Low-to-moderate intensity physical exercise|12-week training of stretching, flexibility exercise, and balance exercise, with two sessions per week. Each session lasts for 60 min.
214493535|NCT06810700|DEVICE|MiniMed 780G|patients aged \>12 years old with T1DM who are on MiniMed 780G
214493536|NCT06806163|BEHAVIORAL|EHR-Embedded Elevated-Risk Flag|Clinicians seeing patients at elevated predicted risk will see a flag on the EHR 'storyboard' during in person or telephone encounters indicating the patient is at elevated predicted risk of opioid overdose. The clinician will have the option of including this information into their decision-making process when providing care. There will be no best practice alerts/behavioral nudges in this arm.
214493537|NCT06806163|BEHAVIORAL|EHR-Embedded Elevated-Risk Flag with Behavioral Nudges|"Clinicians seeing patients at elevated predicted risk for opioid overdose will see a flag on the EHR storyboard indicating that the patient is at elevated predicted risk.~Clinicians will also receive up to 4 best practice alerts/behavioral nudges during an in-person or telephone primary care encounter with elevated risk patients when certain requirements are met: 1) if the patient does not have an active naloxone prescription on their medication list, the clinicians will receive an active choice alert during any medication ordering to encourage naloxone prescription; 2) if the patient's opioid dosage is \>50 MME, OR they are ordered a new opioid prescription, OR they have an overlapping opioid and benzodiazepine prescription order, the clinicians will receive an accountable justification alert when the relevant order is entered."
214493538|NCT06806163|BEHAVIORAL|Usual Care|Patients in the practices randomized to the Usual Care arm will receive standard care practice without change.
214493539|NCT06843187|DRUG|Lemborexant|Dayvigo (lemborexant compound) is an orexin antagonist that acts on the arousal and sleep neural networks of the brain to regulate sleep-wake cycles and is used in the treatment of insomnia characterized by difficulties with sleep.
214493540|NCT06843187|OTHER|Placebo|The placebo is an inactive sugar pill that looks and tastes identical to the lemborexant pill.
214493541|NCT06808178|DEVICE|Low Level Laser Therapy|"The device has the following treatment parametes :~* Maximum average power \> 500 milli watts~* Wave length combined (904-808) nm~* Maximum repition rate (1-2000) Hz~* Energy density : 4:6 J per cm per session"
214681489|NCT02829086|OTHER|Family Stress and Conflict Management|Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
214681490|NCT02829086|OTHER|Financial Management|Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
214681491|NCT03904446|DRUG|Methylergonovine|0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
214681492|NCT03904446|DRUG|Normal Saline (placebo)|1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
214681493|NCT05857202|DRUG|Analgesics, Opioid|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
214370189|NCT01445405|DRUG|Cetuximab|
214370190|NCT01445405|DRUG|Cisplatin|
214370191|NCT01445405|PROCEDURE|Radiation Therapy|
214370192|NCT06256289|DRUG|Canagliflozin 100mg Tab|Canagliflozin 100mg once daily combined Metformin 1000mg twice daily
214370193|NCT06256289|DRUG|Metformin Hydrochloride|Metformin 1000mg twice daily
214370194|NCT05381935|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
214370195|NCT05381935|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
214370196|NCT04914611|OTHER|No intervention|No intervention
214370197|NCT01865916|DRUG|Polyethylene Glycol (PEG) and 15 mg Bisacodyl|Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl
214370198|NCT01865916|DRUG|Polyethylene Glycol (PEG) + ascorbic acid|Subjects will be asked to take split dose of 2L PEG and vitamin C
214370199|NCT06558929|BEHAVIORAL|Occupational Therapy|Participants will redesign their daily routine with support from occupational therapists and an online health management platform.
214370200|NCT06558929|OTHER|Conventional Treatment|Participants will receive conventional treatment and education on sleep hygiene.
214370201|NCT06102057|RADIATION|standard Radiotherapy|standard FDG-PET-based radiotherapy
214370202|NCT06102057|DRUG|Chemotherapy|concurrent standard of care chemotherapy
214681494|NCT05857202|DRUG|Analgesics, Non-Narcotic|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
214681495|NCT04367116|PROCEDURE|Spinal Cord Stimulation|Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.
214370203|NCT06102057|DRUG|Immunotherapy|standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
214985048|NCT04111302|OTHER|IV-PCA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h.
214985049|NCT04111302|OTHER|IV-dezocine|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.
214985050|NCT04111302|OTHER|IV-PCA+AA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h. And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
214985051|NCT04111302|OTHER|IV-dezocine+AA|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
214985052|NCT05642676|OTHER|Clinics remodeling|changes to the clinics will be planned based on baseline surveys
214985053|NCT05769816|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
214985054|NCT05769816|DRUG|NAs|Once/day, 1 capsule/time, oral
214985055|NCT00174824|DRUG|Insulin glargine|
214985056|NCT02204943|DEVICE|Biomarker analysis|Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples
214985057|NCT02204943|DRUG|Administration of radium-223|Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
214985058|NCT02574585|BIOLOGICAL|Autologous mesenchymal cells transplantation|Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
214985059|NCT00634478|RADIATION|Pre-lemniscal Radiation Deep Brain Stimulation|
214985060|NCT01286129|PROCEDURE|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
214985061|NCT04071379|BIOLOGICAL|Recombinant Hepatitis B + DTP-HB-Hib|1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib
214370204|NCT06102057|RADIATION|Experimental Radiotherapy|FDG-PET-based small volume accelerated radiotherapy
214370205|NCT05458648|PROCEDURE|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients participating in the study will undergo a cardiac ablation for the treatment of persistent atrial fibrillation.
214985062|NCT04071379|BIOLOGICAL|Hep B + Pentabio (registered)|1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
214985063|NCT06098508|OTHER|Osteopathic Manual Treatment|This study will be using osteopathic manual therapy as the primary intervention. Osteopathic manual therapy (OMT) is a hands-on treatment that is performed by a specially trained physician known as a Doctor of Osteopathic Medicine (DO). This treatment can be used to diagnose and treat somatic dysfunctions, which are palpable areas of tightness, misalignment, and/or restricted motion within the musculoskeletal system and its related vascular and neural structures. A combination of myofascial release, strain/counterstain, soft tissue, balanced ligamentous release, facilitated positional release and muscle energy techniques will be used for the OMT treatment.
215088942|NCT06687824|OTHER|0.5% Povidone Iodine Impregnated Sterile Gauze|Diluted povidone-iodine act as negative control is added into sterile gauze to color blind the involved subject and the operator
215088943|NCT06396221|DRUG|Estetrol 15 mg/Drospirenone 3 mg (24/4)|Completing a pack (28 pills) of Estetrol 15 mg/Drospirenone 3 mg (24/4), starting on day 7-9 of menstrual cycle
214370206|NCT06084858|OTHER|Dialysate bicarbonate modification|Dialysate bicarbonate prescription will be modified from low (27 mmol/l) to high (37 mmol/l) in a step-wise fashion
215088944|NCT06396221|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
215088945|NCT02596191|OTHER|Clinical evaluation|
214370207|NCT02414191|BEHAVIORAL|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
214370208|NCT02414191|BEHAVIORAL|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
214370209|NCT00717860|DRUG|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
214370210|NCT00717860|DRUG|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
214370211|NCT02917707|OTHER|normal colorectal tissues|The investigators will extract total protein, DNA and RNA from these groups.
214370212|NCT06013254|DIETARY_SUPPLEMENT|sour liquid|applying lemon juice
214985064|NCT06098508|OTHER|Sham Treatment|The sham treatment will include a hands-on evaluation typically used to diagnose somatic dysfunctions, but no treatment will be performed. The sham treatment will assess the upper extremities/scapulae, ribs, cervical spine, thoracic spine, thoracic inlet, and occipital-atlantal regions.
215088946|NCT02596191|OTHER|electrophysiological record|
215088947|NCT02596191|OTHER|Muscle MRI|
214370213|NCT04866212|BEHAVIORAL|Beery- Buktenica Developmental Test of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
214370214|NCT04866212|BEHAVIORAL|Jebsen Taylor Hand Function Test|Investigation of hand skills by Jebsen Taylor Hand Function Test
214370215|NCT04866212|DIAGNOSTIC_TEST|Participation and Environment Measure - Children and Youth|Investigation of participation by Participation and Environment Measure - Children and Youth
214370216|NCT03538015|DRUG|Carvedilol 3.125 mg|Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period
214370217|NCT03538015|DRUG|Carvedilol 2.5 mg|Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period
214493542|NCT06808178|OTHER|kinesio taping|"* the material used is 100%acrylic,latex free and heat activated with 10-15% stretch.~* It is made of 100% cotton to allow quickening of the drying process.~* Ability to stretch to 120-140% of its original length~* Recoil back to the anchor that is applied without stretch~* Heat-activated adhesive~* Hypoallergenic dyes that make the tape safe for most users~* Latex-free~* Drying time after being wet is about 5-10 minutes~* Can be worn for several days"
214493543|NCT05120856|BEHAVIORAL|AAT-App|Participants will receive the active AAT-App on their smartphone, which includes ApBM training, and prompted to engage with the app during the 28-day intervention period.
214493544|NCT05120856|BEHAVIORAL|Minimal AAT-App|Participants will receive the minimal version of AAT-App, which does not include ApBM training, on their smartphone and prompted to engage with the app during the 28-day intervention period.
214681496|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
214681497|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
214681498|NCT01218932|DRUG|A|Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
214681499|NCT01218932|DRUG|B|Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
214681500|NCT04065230|DRUG|Tenofovir Alafenamide Fumarate tablets|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
214681501|NCT06360874|DRUG|ND-003 40mg|Participants receive 40mg ND-003 tablets once.
214681502|NCT06360874|DRUG|ND-003 placebo 40mg|Participants receive placebo tablet matching to receive 40mg of ND-003.
214681503|NCT06360874|DRUG|ND-003 80mg|Participants receive 80mg ND-003 tablets once.
214681504|NCT06360874|DRUG|ND-003 placebo 80mg|Participants receive placebo tablet matching to receive 80mg of ND-003.
214681505|NCT06360874|DRUG|ND-003 160mg|Participants receive 160mg ND-003 tablets once.
214985065|NCT05785169|BEHAVIORAL|All-facility Training|The HP+ curriculum includes total-site training and co-facilitation via participatory modules. To change clinic culture, a multi-level approach that includes the whole facility and reaches all parties is required. The intervention aims to modify top-down mechanisms of influence. The training is modeled on these principles and supports the development of multiple stigma-reduction strategies to improve patient and staff wellbeing.
214985066|NCT00466830|OTHER|questionnaire administration|
214985067|NCT00466830|PROCEDURE|management of therapy complications|
214985068|NCT00466830|PROCEDURE|psychosocial assessment and care|
214985069|NCT00466830|PROCEDURE|quality-of-life assessment|
214985070|NCT06546345|DEVICE|KeriFlex®|The KeriFlex® finger joint prothesis MCP is designed to replace a damaged metacarpophalangeal (MCP) joint and the KeriFlex® finger joint prothesis PIP is designed to replace a damaged proximal interphalangeal (PIP) joint.
214370218|NCT03538015|DRUG|Placebo capsule|Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
214370219|NCT05663424|OTHER|rTMS-PTi|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus immediate rehabilitation programs
214370220|NCT05663424|OTHER|rTMS-PTd|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus delayed rehabilitation programs (\>2hr)
214370221|NCT05663424|OTHER|rTMSs-PT|10 daily sessions of sham rTMS (to vertex) plus rehabilitation programs
214370222|NCT00698646|DRUG|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
214493545|NCT06302452|BEHAVIORAL|Adopting Comprehensive Training for FireArm Safety in Trauma Centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
214493546|NCT06750887|OTHER|Normal condition|The normal condition IS measured as a lumbar extension without VR until the onset of pain.
214493547|NCT06750887|OTHER|Understated condition|It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% less movement in the VR (understated visual feedback)
214681506|NCT06360874|DRUG|ND-003 placebo 160mg|Participants receive placebo tablet matching to receive 160mg of ND-003.
214681507|NCT06360874|DRUG|ND-003 240mg|Participants receive 240mg ND-003 tablets once.
214681508|NCT06360874|DRUG|ND-003 placebo 240mg|Participants receive placebo tablet matching to receive 240mg of ND-003.
214681509|NCT06360874|DRUG|ND-003 300mg|Participants receive 300mg ND-003 tablets once.
214681510|NCT06360874|DRUG|ND-003 placebo 300mg|Participants receive placebo tablet matching to receive 300mg of ND-003.
214681511|NCT06360874|DRUG|MAD_ND003_Dose 1|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
214681512|NCT06360874|DRUG|MAD_placebo_Dose 1|Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 1
214985071|NCT02398773|PROCEDURE|Computed Tomography|Undergo PET/CT
214985072|NCT02398773|DRUG|F-18 16 Alpha-Fluoroestradiol|Given IV
214985073|NCT02398773|OTHER|Laboratory Biomarker Analysis|Correlative studies
214370223|NCT00698646|DRUG|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
214370224|NCT00698646|DRUG|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
214370225|NCT05844813|DRUG|Doxorubicin+Ifosfamide+Anlotinib(AI+A)|Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles
214370226|NCT05844813|PROCEDURE|Radical Surgery|Radical sarcoma resectional surgery
214370227|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose|50μg/dose
214370228|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose|100μg/dose
214370229|NCT05550142|DRUG|Placebo|Saline solution
214370230|NCT04642508|PROCEDURE|Prepectoral reconstruction|Immediate prepectoral breast reconstruction in women requiring a mastectomy
214493548|NCT06750887|OTHER|OVERSTATED CONDITION|It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% more movement in the VR (understated visual feedback)
214493549|NCT06747520|DRUG|ET-26HCl|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
214493550|NCT06618950|BEHAVIORAL|physical activity|The key factor that distinguishes this study from others is its comprehensive examination of the effects of regular physical activity on late adolescents, not only in terms of physical health but also regarding healthy lifestyle behaviors, self-esteem, and psychological well-being. While other studies typically focus on the benefits of physical activity for physical health, this research considers the broader psychological and social development of adolescents, offering a wider perspective. Additionally, its emphasis on the sustainability of a planned and structured physical activity regimen, along with its approach to transforming physical activity into a lifestyle, represents a significant difference.
214985074|NCT02398773|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214985075|NCT02816359|OTHER|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
214985076|NCT04128917|DRUG|Tegoprazan|Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral
215088948|NCT02596191|OTHER|blood samples analysis|
215088949|NCT06111729|DEVICE|HabitAware group|A device that provides gentle vibration when the motion of nail biting is sensed will be provided to all participants. Participants will use an app that connects to the device to track the frequency of their nail biting over the study period.
215088950|NCT07032623|PROCEDURE|Spinal Manipulation|The spinal manipulation will target the sacroiliac joint using the global pelvic manipulation technique. Participants will be positioned in lateral decubitus with the ACL-reconstructed limb placed uppermost. The therapist will apply progressive rotation and flexion at the hip and knee joints to increase tissue tension. To establish contact, the therapist's knee will be placed against the participant's flexed knee. A high-velocity, low-amplitude thrust will then be delivered to optimize joint motion, with cavitation being monitored throughout the procedure.
214370231|NCT05907824|OTHER|Histopathological review, long-term prognosis and quality of life follow-up|Histopathological review, long-term prognosis and quality of life follow-up
214493551|NCT06770114|DRUG|Cetylpyridinium Chloride and Zinc Lactate Mouthwash|0 .075 % cetylpyridinium chloride and 0 .28 % zinc lactate
214493552|NCT06770114|DRUG|PhosFlur Mouthwash|0 .044 % sodium fluoride
214493553|NCT03133195|DRUG|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)
214493554|NCT03133195|DRUG|Placebo|Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
214493555|NCT03133195|DIETARY_SUPPLEMENT|Calcium supplement|1000 mg/day of elemental calcium
214493556|NCT03133195|DIETARY_SUPPLEMENT|Vitamin D|20,000 IU/week of vitamin D2
214493557|NCT06583759|PROCEDURE|Full coverage Crowns|The crown will be prepared accordingly. Try in of the best fitted crown will be done and cementation.
214370232|NCT02739282|OTHER|Systematic therapeutic drug monitoring|Blood samples with antiepileptic drug level measurement
214370233|NCT03651648|DEVICE|SENSITACT System|the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
214370234|NCT03651648|DEVICE|SENSITACT System|the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
214985077|NCT04128917|DRUG|RAPAE01|RAPAE01/Clarithromycin/Amoxicillin BID peroral
214985078|NCT00998569|BEHAVIORAL|Neurocognitive Enhancement|Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
214985079|NCT00998569|BEHAVIORAL|Wait List|Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
215088951|NCT07033026|DRUG|NGM120 Q4W|NGM120 given subcutaneously every 4 weeks
215088952|NCT07033026|DRUG|NGM120 Q8W|NGM120 given subcutaneously every 8 weeks
215088953|NCT07033026|DRUG|Placebo given|Placebo given subcutaneously every 4 weeks
214370235|NCT02808364|BIOLOGICAL|Personalized cellular vaccine|Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
214370236|NCT03381768|BIOLOGICAL|PD-L2 peptide|100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.
214370237|NCT03381768|BIOLOGICAL|PD-L2 and PD-L1 peptide|100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.
214370238|NCT00319540|BEHAVIORAL|Control with depression course (CWD)|
215088954|NCT07033351|PROCEDURE|Dental implant placement without PRF|Standard dental implant placement procedure with flap elevation and suturing, without the application of any PRF membrane over the implant site.
215088955|NCT07033351|BIOLOGICAL|Single-layer PRF membrane application|PRF membrane prepared via centrifugation is applied as a single layer over the implant site following implant placement before flap closure.
214681513|NCT06360874|DRUG|MAD_ND003_Dose 2|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
214681514|NCT06360874|DRUG|MAD_placebo_Dose 2|Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 2
214681515|NCT06360874|DRUG|MAD_ND003_Dose 3|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
215088956|NCT07033351|BIOLOGICAL|Triple-layer PRF membrane application|Three autologous PRF membranes prepared via centrifugation are stacked and applied as a 3-layer membrane over the implant site before flap closure.
214370239|NCT04000295|DRUG|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d
214370240|NCT04000295|DRUG|Etoposide|Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
214370241|NCT04000295|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
214370242|NCT04663022|OTHER|Dunn's sensory profile questionnaire|all children will complete the Dunn Sensory Profile questionnaire
214370243|NCT01531452|DRUG|Oxaliplatin|130mg/m2 d1,repeated q21d
214370244|NCT01531452|DRUG|s1|80mg/m2/d, d1-14,repeated q21d
214370245|NCT00279201|DRUG|Insulin glargine|Subcutaneous injection daily
214370246|NCT00279201|DRUG|Lispro Low Mix|Subcutaneous injection twice daily.
214985080|NCT00477009|DEVICE|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
214985081|NCT05720598|PROCEDURE|Sentinel Node Assessment|The SN assessment will be conducted similarly to the method proposed by Märkl et al. All LNs will be stored in a -80 °C freezer, immediately after retrieval. Within 1 to 3 days, each LN will be individually measured and weighed. Small LNs (\<5 mm in short diameter) will be bisected, and half of the node will be processed for histological evaluation while the remaining half will be used for OSNA analysis. For intermediate-sized LNs (5-10 mm), a middle slice of about 2 mm thickness will be cut out for the histology, and the remaining parts of the node will be processed by OSNA. In large LNs (\>10 mm), at least two slices will be cut out for histology, and the remaining parts of the node will be analyzed by OSNA.
215088957|NCT07036068|DEVICE|IceMagic™ CryoAblation Catheter|IceMagic™ CryoAblation Catheter is available in two diameters: 23 mm and 28 mm. Each diameter has two types of balloon outer surfaces: with or without multi-channel tissue temperature measurement function. The catheter length is 140 cm, and the tube diameter is 10.5 F. Doctors can choose according to the size of the target pulmonary vein.
215088958|NCT07039032|DEVICE|FireMagic™ Magbot Ablation Catheter 、FireMagic™ TrueForce™ Ablation Catheter|"1. The pressure-sensing catheter primarily consists of electrodes, a catheter body, and a control handle. The catheter body comprises a high-torque body and a flexible tip, divided into an adjustable bending segment and a main segment. By pushing or pulling the handle at the proximal end of the catheter, the internal traction wire at the catheter tip can be activated to control the bending of the tip. The adjustable bending segment is fixed with four electrodes at regular intervals, including one tip electrode and three ring electrodes.~2. The disposable star-shaped magnetoelectric positioning catheter is specifically designed for cardiac electrophysiological mapping. The distal end of the catheter has multiple 3F branches, each with multiple platinum-iridium electrodes for collecting cardiac electrophysiological signals. The distal end of the catheter features an adjustable bend design; pushing the button on the catheter forward will cause the distal end of the catheter to bend."
214370247|NCT00279201|DRUG|Lispro Mid Mix|Lispro Mid Mix subcutaneous injection 3 times daily.
214370248|NCT00279201|DRUG|Lispro|Lispro subcutaneous injection 3 times daily.
214370249|NCT01391221|DRUG|Duloxetine|Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
214370250|NCT02413164|OTHER|A multimodal physiotherapy programme|"Intervention: individualised Multimodal Physiotherapy Programme of therapeutic exercises with education healthy-style-of-life based.~Groupal sessions two times per week during 12 weeks. Each session 60 minutes: 10 minutes of warm up, 20 minutes of strength and muscular endurance, 20 minuts of aerobic training, 10 minutes of cold-down.~Intensity aerobic training: The training heart rate will be calculated according to recommendations of the American College of Sport Medicine (ACSM), it must oscillate between 55/65% and 90% of the HRmax. Initial four weeks: moderate intensity (55-69% HRmax); Following weeks according to each response, to higher level of training (70-89% HRmax). Strength training: individualised working with the principal muscular groups. 3 sessions using a weight which can repeat the exercise 10-15 times, increasing to a weight at which they can repeat the exercise 8-12 times."
214370251|NCT00680927|OTHER|46 hrs Holter ECG recording|Maximum of 2 46 hrs external Holter ECG recordings are required.
214681516|NCT06360874|DRUG|MAD_ placebo_Dose 3|Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 3
214681517|NCT06360874|DRUG|Food effect_Cohort 1|Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
214681518|NCT06360874|DRUG|Food effect_Cohort 2|Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
214370252|NCT01274091|OTHER|PUFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
214370253|NCT01274091|OTHER|SAFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
214370254|NCT01444859|DIETARY_SUPPLEMENT|Trenev Trio®/Healthy Trinity®|Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
214370255|NCT01444859|DIETARY_SUPPLEMENT|Placebo|Daily placebo for 10 weeks
214370256|NCT01717781|PROCEDURE|Thunderbeat technology|
214681519|NCT02519075|OTHER|No intervention|Observational study
214985082|NCT05720598|PROCEDURE|Staging laparoscopy|Pneumoperitoneum (10-12mmHg) will be obtained with Veress needle or 10mm trocar after minilaparotomy. Peritoneal cavity will be thoroughly assessed after insertion of two additional trocars. In cases of macroscopic dissemination, peritoneal cancer index (PCI) will be determined. After switching the optical camera into near-infrared / indocyanine green fluorescence mode, the primary tumor will be visualized, followed by assessment and possible dissection of sentinel lymph node with a high-energy device. The lymph node will be retrieved with a sterile bag, and the area of dissection will be marked with a clip. Trocars will be removed under visual assistance, and the pneumoperitoneum will be released through trocars in order to prevent port-site metastases.
214370257|NCT01717781|PROCEDURE|Standard bipolar electrosurgery|
214370258|NCT04598867|DRUG|CD-008-0045|CD-008-0045 20 mg capsules
214985083|NCT05720598|PROCEDURE|Gastroscopy with indocyanine green (ICG) injection|Patients will undergo gastroscopy one day prior to staging laparoscopy. The ICG powder contains 0.125 mg/ml. Two milliliters of ICG (0.125mg/ml) solution is injected in the submucosa with into four peritumoral sites, 0.5 ml for each site.
215088959|NCT07040137|DRUG|KPS-0373|Oral administration
215088960|NCT07040137|DRUG|Placebo|Oral administration
214370259|NCT04598867|DRUG|Placebo|Placebo capsules
215088961|NCT00293436|DRUG|celecoxib|
215088962|NCT00293436|DRUG|erlotinib hydrochloride|
214985084|NCT02373267|BIOLOGICAL|Technozyme|determination of ADAMTS13 activity
214370260|NCT04598867|DRUG|Afobazol|Afobazol 10 mg tabletes
214370261|NCT03281473|OTHER|Strategy 1|PEEP titration according to transpulmonary-end-expiratory pressure
214370262|NCT03281473|OTHER|Strategy 2|PEEP titration according to chest wall elastance measurement
214370263|NCT03113474|OTHER|Food palatability|Food palatability is modulated
214370264|NCT04980118|BEHAVIORAL|Control group|A nutritional intervention program that consisted of two individual nutritional consults.
214493558|NCT06767085|DRUG|Lidocaine-Prilocaine Topical|lidocaine-prilocaine spray on the cervix and cervical canal 5-7 minutes prior to the procedure
214493559|NCT06767085|DRUG|Saline spray|saline spray on the cervix and cervical canal 5-7 minutes prior to the procedure
214370265|NCT04980118|BEHAVIORAL|Nutrition and physical activity group|A nutritional and physical activity intervention program that consisted of two individual nutritional consults and five nutritional group lectures.
214370266|NCT06166693|DEVICE|"MINDLiNG Digital Mental Health Intervention"|The intervention was delivered on an online platform set up separately for the study, which was accessible via the web browser and application. The psychological intervention program for maladaptive personality traits (Mindling) is based on the principles of CBT, psychological schema therapy, acceptance-commitment therapy, and mindfulness-based cognitive therapy, and is aimed primarily at adults to prevent and overcome psychological difficulties
214370267|NCT00162695|DRUG|Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide|
214370268|NCT00316173|DRUG|topotecan|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
214370269|NCT00316173|DRUG|CARBOPLATIN|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
214370270|NCT05857787|DEVICE|Ultrasound with nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use this feature to educate subjects before seeking brachial plexus and median nerve.
214493560|NCT06763185|OTHER|Dietary Supplement: conventional cow's milk consumption, and then A1PF milk consumption|Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.
214493561|NCT06763185|OTHER|Dietary Supplement: A1PF milk consumption, and then conventional cow's milk consumption|Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.
214681520|NCT04776356|DEVICE|QuickFix Small Staple (Arthrex)|The Arthrex QuickFix Small Staple enables the surgeon to perform a wedge osteotomy of the first phalanx (Akin). The device is made of stainless steel and designed with barbed leg tips. The staple sizes are 8 and 10 mm wide with a 1 mm diameter.
214985085|NCT04134039|DEVICE|Polyurethane (PU) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
214985086|NCT04134039|DEVICE|Natural Rubber Latex (NRL) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
215088963|NCT00293436|PROCEDURE|adjuvant therapy|
215088964|NCT07041749|DRUG|Bleomycin|);will be treated with combination of microneedling and topical bleomycin .
215088965|NCT07041749|DEVICE|Microneedling alone|' Microneedling will be performed on each wart using dermapen supplied with 12 needles arranged in rows. Topical anesthetic cream will be applied for 60 min before the procedures. Microneedling will be performed on each wart using dermapen. The penetration depth will be adjusted at 2-mm, endpoint is pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the warts.
215088966|NCT07041749|DRUG|5 fluorouracil|);will be treated with combination of microneedling and topical 5-flurouracil .
215088967|NCT07040449|BEHAVIORAL|Montreal Imaging Stress Task|Psychosocial stress procedure consisting of completing sections of mental arithmetic that are 5.5 minutes in length, during which the individual receives neutral and negative evaluative feedback about their performance relative to their peers.
214370271|NCT05857787|DEVICE|Ultrasound without nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use ultrasound alone without this feature to educate subjects before seeking brachial plexus and median nerve.
214370272|NCT03497455|DEVICE|Barco NV Digital Dermatoscope device images|Images taken by Clinician in consultation OR in Dermatology department theatres OR images taken in medical photography suite - in the latter case, images can be taken by medical photographer or Research nurse or Dermatologist
214370273|NCT03497455|DEVICE|Standard medical photographs including dermoscopy images|Images taken by medical photographer as part of standard care in the medical photography suite.
214370274|NCT03497455|OTHER|Clinic proforma completion|This is part of standard care and will be undertaken by the clinician who is responsible for the patient
214370275|NCT04207827|BEHAVIORAL|xSmoker app|xSmoker - mHealth intervention consisted of using the app xSmoker
214370276|NCT04207827|BEHAVIORAL|SMS|Text messages with content based on the Motivation and Problem Solving approach and informed by our prior work.
214370277|NCT04207827|OTHER|Usual Care|Usual postnatal care
214985087|NCT04113135|OTHER|Yoga|Participants will be lead through a series of yoga poses by a licensed physical therapist with advanced training in yoga. Participants in this group will also receive education related to MS as well as SMART goal setting, journaling and guided meditation. Modifications will be offered as needed.
214370278|NCT05260996|OTHER|Pilot Group|12 Weeks, 1-1 Hour Session Per Week for 10 Total Curriculum Sessions,including 1 Week of Orientation and 1 Week of Debriefing/Program Graduation.
214370279|NCT01172769|BIOLOGICAL|Temsirolimus|"After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.~Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered."
214985088|NCT04113135|OTHER|Control|Participants in this group will receive education related to MS as well as SMART goal setting, journaling, and guided meditation.
214985089|NCT03911531|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
214985090|NCT03911531|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
214370280|NCT02390531|DRUG|Bevacizumab|Varying dosages in 10µl
214370281|NCT01911377|DRUG|Botulinum Toxin Type A|
214370282|NCT01911377|DRUG|Normal Saline for Injection|
214370283|NCT00511875|DRUG|doxycycline monohydrate|50mg once daily for 24 months
214370284|NCT00511875|DRUG|placebo|placebo taken once daily for 24 months
214370285|NCT00221910|PROCEDURE|Ultrasound|
214370286|NCT06350890|DRUG|HTD1801|HTD1801 1000 mg administered orally BID as four capsules
214985091|NCT03860688|DRUG|TED + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
215088968|NCT07040449|BEHAVIORAL|Trier Social Stress Test for Children|Psychosocial stress procedure in which the individual tells a story for 5 minutes in front of two neutral judges and performs mental arithmetic in front of the judges for 5 minutes.
214370287|NCT06350890|DRUG|Placebo|Matching placebo administered orally BID as four capsules
214370288|NCT00784394|DRUG|diindolylmethane|Given PO
214370289|NCT00784394|OTHER|placebo|Given PO
214370290|NCT00784394|OTHER|pharmacological study|Correlative studies
214370291|NCT00784394|OTHER|laboratory biomarker analysis|Correlative studies
214370292|NCT00784394|OTHER|quality-of-life assessment|Ancillary studies
214370293|NCT00002538|PROCEDURE|laparoscopic surgery|
214370294|NCT02618616|DRUG|ZPL-3893787|
214370295|NCT02618616|DRUG|Placebo|
214370296|NCT01458470|DRUG|Memantine|oral tablet, 1 BID, 24 weeks
214370297|NCT01458470|OTHER|Placebo|oral tablet, 1 BID, 24 weeks
214370298|NCT04272502|DRUG|CKD-348 F1, CKD-348 F2, CKD-828, D326, D337|Each arm has a different order for taking IP
214681521|NCT02795351|DRUG|Sildenafil|Single oral administration of active or placebo one week apart
214681522|NCT02795351|DRUG|Placebo|
214370299|NCT01996579|DIETARY_SUPPLEMENT|Lactoferrin|Lactoferrin is an 80 kilodalton (kD) naturally occurring multifunctional glycoprotein of the transferrin family which is an important component of the human innate immune system. Lactoferrin is distributed widely in humans with the main sources of production being exocrine glands and specific granules of neutrophils. It is present in virtually all human secretions. The highest concentrations are found in milk and colostrum. Lactoferrin has multiple biological functions which make it of interest as a therapeutic agent in the critically ill. These include the ability to bind iron, antimicrobial activity including antibacterial, antifungal, antiviral properties, the ability to bind endotoxin, promotion of beneficial bacteria in the gastro-intestinal tract and immunomodulatory activity.
214681523|NCT00423410|DRUG|EPC2407 (crinobulin)|IV infusion 1 to 4 hours
214681524|NCT05822895|DEVICE|CADe enabled programme (GI Genius)|CADe enabled programme (GI Genius)
214370300|NCT01996579|OTHER|Placebo|Sterile water will be utilized as the placebo control in this double blind randomized-controlled trial.
214370301|NCT00002832|BIOLOGICAL|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
214370302|NCT00002832|DRUG|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
214370303|NCT00002832|DRUG|Decitabine|IV for 6 hours every 12 hr for 5 days.
214370304|NCT00002832|PROCEDURE|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
214370305|NCT00002832|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
214985092|NCT06298734|BEHAVIORAL|Exercise Program|A high-intensity interval training, aerobic exercise program virtually supervised, home-based, and appointment-based program under direct one-on-one supervision by a trained oncology exercise specialist. Sessions will be conducted via the Zoom platform. Participants will be provided with home stationary bike, heart rate monitor, blood pressure monitor. For participants who do not have a smart device, a Wi-Fi enabled tablet will be provided.
214985093|NCT06298734|BEHAVIORAL|Diet Program|A virtual dietary consultation program supervised by trained research staff. Appointments will be conducted via the Zoom platform. Participants will receive an education handout at the baseline visit.
214985094|NCT05578053|DRUG|Dalpiciclib|a new, orally administered, selective CDK4/6 inhibitor
215088969|NCT07042113|DRUG|new formulations of 611|Subjects will receive new formulations of 611 300mg once subcutaneous injection on D1
214985095|NCT06646302|OTHER|Personalized 40 Hz Broadband Stimulation|Broadband acoustic stimulus (125 Hz-12 kHz) amplitude-modulated at 40 Hz with a 50% duty cycle. A polynomial regression and FFT-based algorithm applies individualized frequency weighting, combining population data (70%) and patient-specific responses (30%). Delivered for 60 seconds at 10 dB above the individual minimum masking level (MML).
214985096|NCT06646302|OTHER|40 Hz Pure Tone Stimulation|Pure tone stimulus at the optimized frequency (matched to tinnitus characteristics or high-frequency carrier), amplitude-modulated at 40 Hz with a 50% duty cycle. Delivered for 60 seconds at 10 dB above MML.
215088970|NCT07042113|DRUG|existing formulations of 611|Subjects will receive existing formulations of 611 300mg once subcutaneous injection on D1
215088971|NCT07041385|DRUG|Aspirin Tablets|This study aims to evaluate the effectiveness of 75 mg aspirin versus 150 mg aspirin in preventing preeclampsia among individuals with high risk for the condition.
214370306|NCT03034343|BEHAVIORAL|Mindfulness|
214370307|NCT04310553|PROCEDURE|Irreversible electroporation|Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology will receive nano knife treatment if the target lesion is not suitable for surgical resection or the target lesion is suitable for surgical resection but patients give up surgery and choose nano knife combined with chemotherapy. Patients who have not previously received first-line chemotherapy will receive systemic chemotherapy for 4-6 cycles of treatment. Imaging evaluation will be performed every 6-8 weeks (± 7 days) during chemotherapy.
214681525|NCT05884788|OTHER|free interview, and questionnaires in a second time|"After inclusion in the study, patients will be met for a free interview. The interview will be conducted using an open-ended interview method with the patients to allow free expression of their life history, using open and broad questions to avoid the influence of the interviewer as much as possible.~Each interview will be conducted by the same person to allow for better interpersonal reproducibility.~After the interview, the patients will be seen again to complete two questionnaires:~* An attachment questionnaire: Relationship Scales Questionnaire~* A questionnaire on symptoms: Distress thermometer"
214370308|NCT01216930|OTHER|Observation|Observation
214370309|NCT04225988|DRUG|Extended-release tacrolimus|Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.
214370310|NCT04225988|DRUG|Immediate-release tacrolimus|Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.
214370311|NCT05752799|DRUG|Opioid Free Anaesthesia|"* 40 mg/kg magnesium sulfate in 100 ml N/S infusion~* 0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~* 0.3 mg/kg ketamine in 10 ml volume~* 0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~* 0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding."
214370312|NCT05752799|DRUG|Opioid based anesthesia|"* 2 mcg/kg fentanyl in 10 ml volume~* 0.2 mL/kg/h remifentanil infusion~* 0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding."
214370313|NCT04490746|OTHER|with no intervention, Collect samples|only with observation,there is no need to intervene
214681526|NCT05690412|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary neoplasm
214370314|NCT00419822|PROCEDURE|Acupuncture|6 Acupuncture visits
214370315|NCT00419822|PROCEDURE|Sham Acupuncture|6 Acupuncture visits with sham procedure
214370316|NCT00419822|OTHER|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
214370317|NCT06670664|OTHER|No intervention|No intervention. This is a single-group study.
214370318|NCT05320731|PROCEDURE|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
214681527|NCT06045546|PROCEDURE|5-5-5-8 technique|the new technique of 5-5-5-8 for laparoscopic cholecystectomy
214681528|NCT06045546|PROCEDURE|10-10-5-5 technique|the standard technique of 10-10-5-5 for laparoscopic cholecystectomy
214681529|NCT05721950|DRUG|Brigatinib|Brigatinib Tablets
214985097|NCT06646302|OTHER|Continuous Broadband Noise|Continuous broadband noise spanning 125 Hz-12 kHz without 40 Hz modulation. Delivered for 60 seconds at 10 dB above MML as an active control condition.
214985098|NCT02837926|OTHER|questionnaire|
214985099|NCT02837926|BIOLOGICAL|Gardasil vaccine|
214985100|NCT02837926|BIOLOGICAL|Cervarix®|
214985101|NCT06046950|OTHER|Treatment target DAS28CRP-LDA|Aiming for DAS28CRP-low disease activity
214985102|NCT06046950|OTHER|Treatment target SDAI-remission|Aiming for SDAI-remission
214985103|NCT01862042|OTHER|Follow-up diary and questionnaire|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
214985104|NCT06075953|DRUG|Tamoxifen|"For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose).~For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen."
214985105|NCT06075953|DRUG|Exemestane|For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
214985106|NCT06075953|DRUG|Letrozole|For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.
214985107|NCT06075953|DRUG|Anastrazole|For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.
214985108|NCT06075953|DRUG|Testosterone + Anastrazole|Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
214370319|NCT05320731|PROCEDURE|Atomization with lidocaine|A simple atomization device as a modification of the McKenzie technique will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
214370320|NCT00379132|DRUG|131-I-TM-601 (chlorotoxin)|"Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.~Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)"
214370321|NCT02630134|OTHER|These patients receive the Baeta device and take it home|
214985109|NCT06075953|DRUG|Elacestrant|Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.
214985110|NCT06075953|DRUG|Z-endoxifen|Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.
214985111|NCT05263193|DRUG|Caplacizumab|as in real world practice
214985112|NCT05150691|BIOLOGICAL|DB-1303/BNT323|Administered IV
214985113|NCT05150691|DRUG|Pertuzumab Injection|Administered IV
214985114|NCT05150691|DRUG|Ritonavir|Administered oral
214985115|NCT05150691|DRUG|Itraconazole|Administered oral
214985116|NCT03993912|DRUG|Daratumumab SC in combination with Lenalidomide|"Daratumumab SC 1800 mg~* once every week for 8 weeks~* then once every other week for 16 weeks~* thereafter once every 4 weeks, until progression"
214985117|NCT03993912|DRUG|Lenalidomide PO (25mg)|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
214985118|NCT03993912|DRUG|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
214985119|NCT06271642|BEHAVIORAL|Bluetooth Haptic Device (Experimental Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with experimental Frequency placed on their arm and randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
214985120|NCT06271642|BEHAVIORAL|Bluetooth Haptic Device (Control Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with control frequency placed on their arm. They will be randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
214985121|NCT06255457|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement of mitral regurgitation
214985122|NCT04485949|COMBINATION_PRODUCT|IGV-001 Cell Immunotherapy|IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.
214985123|NCT04485949|COMBINATION_PRODUCT|Placebo|Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.
214985124|NCT04485949|PROCEDURE|Standard of Care (SOC): Radiation Therapy|Radiation therapy administered per institutional standards.
214985125|NCT04485949|DRUG|SOC: Temozolomide|Temozolomide administered orally.
214985126|NCT02310542|DEVICE|MARS albumin dialysis system|
214985127|NCT02310542|DEVICE|SPAD albumin dialysis system|
214985128|NCT06293248|OTHER|musical application|Rast, Acemasiran, and Huseyni from Classical Turkish Music modes were optionally offered to the patients in the music group, and the patient's preferred music was listened to through headphones for 15-20 minutes before the CAG procedure. Following the interviews, musical genres were arranged as instrumental, without words, at 70 decibels in terms of rhythm and duration, at approximately 60 metronomes per minute, and were played according to the person's preference. Instrumental music was loaded onto the portable MP3 player provided by the researchers.
214985129|NCT06217302|DRUG|Sotagliflozin|Oral sotagliflozin (200 mg per day)
214985130|NCT06217302|DRUG|Placebo|Inactive tablets identical to sotagliflozin tablets
214985131|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Open Label Pilot|"As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype."
214370322|NCT06724276|PROCEDURE|balloon angioplasty and stenting of lower extremity vessels + fibroblasts|A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest. After surgery, fibroblasts will be applied to the wound for 24 hours.
214370323|NCT06724276|PROCEDURE|balloon angioplasty and stenting of lower extremity vessels|A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest.
214370324|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using NuSmile Zirconia crowns|Prefabricated pediatric Zirconia crowns offer an excellent alternative to full-coverage crowns when restoring deciduous teeth with a sizeable carious defect. These crowns have high flexural strength, allowing them to resist crack propagation. The additional benefits of these crowns are the ability to replace metals due to extremely high strength and toughness, higher resistance to chemicals, and superior erosion resistance
214370325|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using BioFlx crowns|The Bioflex crown has been introduced in pediatric practice as a synthetic crown that will provide better adaptation, durability, and ease of handling with improved aesthetic properties compared to conventional crowns. The Bioflex crown may provide a promising result in terms of the clinician's and parental satisfaction as aesthetic is a prime concern for parents and children in this era. The limitations of the studies on this type of crowns will require more studies with more detailed clinical observation and larger sample size to provide more rigorous results.
214370326|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using Digital VITA ENAMIC crowns (CAD/CAM blanks)|is a hybrid ceramic with a dual network structure that combines the best characteristics of ceramic and composite. Fast and efficient CAM fabrication; for minimally invasive reconstructions, tooth-like material properties.
214370327|NCT06733870|PROCEDURE|guided immediate implant surgery|fully guided immediate implant placement and loading
214370328|NCT06732206|OTHER|Short Solution Focused Approach Program|It will be a psychoeducational approach aimed at developing preventive and protective properties against addiction.
214370330|NCT06209281|DRUG|Lower dose atropine sulfate eye drops|Administer to eyes
214370331|NCT06209281|DRUG|Low dose atropine sulfate eye drops|Administer to eyes
214370332|NCT06209281|DRUG|placebo|Administer to eyes
214370333|NCT06735651|DIETARY_SUPPLEMENT|Wild Blueberry|Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 6 weeks
214370334|NCT06735651|DIETARY_SUPPLEMENT|Placebo|Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 6 weeks
214370335|NCT07061080|DRUG|Tarlatamab|Tarlatamab as a standalone treatment through intravenous infusion at 10 mg dose every 14 days (i.e. 2 weeks)
214370336|NCT07061080|DRUG|standard of care second-line chemotherapy (FOLFIRI)|FOLFIRI:: irinotecan intravenously 180 mg/m2 on day 1, followed by 400 mg/m2 folinic acid or 200 mg/m² levofolinate in a 2-h infusion, a 10-min bolus of 400 mg/m2 5-FU, and 2400 mg/m2 5-FU over 46 hours; every 14 days).
214370337|NCT07061509|OTHER|Battery of Physical and Psychological Assessments|Participants in this observational study will not receive any therapeutic intervention. Instead, all individuals will undergo a series of standardized non-invasive assessments for data collection purposes. These include the Exercise Dependence Scale-21 (EDS-21) to classify exercise addiction status, the Drive for Muscularity Scale (DMS) to evaluate body image and muscle-related attitudes, and the Extended Nordic Musculoskeletal Questionnaire to determine the presence and severity of musculoskeletal symptoms. Cardiovascular risk will be assessed using the SCORE Risk Assessment System, which incorporates blood pressure, cholesterol, blood glucose, smoking status, and demographic data. Additional measurements will include oxygen saturation and heart rate using pulse oximetry, and blood pressure using a sphygmomanometer. These evaluations are intended solely for comparative analysis between exercise-dependent and non-dependent groups.
214370338|NCT01265199|DRUG|AT-406 in combination with daunorubicin and cytarabine|Oral AT-406 (capsule) given once daily on days 1-5 of induction therapy with daunorubicin 90 mg/m2 I.v. on days 1-3 and cytarabine 100 mg/m2 i.v. by continuous infusion on days 107 of induction therapy.
214493562|NCT06747221|OTHER|Systems Analysis and Improvement Approach (SAIA)|"SAIA is a 5-step implementation strategy that is repeated every 4-6 weeks for continuous quality improvement. It will be implemented by Kenyan public health workforce and frontline clinical care personnel to systematically identify and address bottlenecks to develop and implement solutions to delivery of HIV Testing Services during emergency department (ED) interactions.~Step 1: Understanding the cascade of ED patient flow from triage through care conclusion with focus on HTS opportunities. This will support identification of bottlenecks where patients are missed and provides data on potential increases in efficiency if misses are addressed.~Step 2: Use process mapping to identify modifiable bottlenecks.~Step 3: Define and implement workflow adaptations to mitigate modifiable bottlenecks.~Step 4: Monitor changes in performance.~Step 5: Repeat the analysis and improvement cycle (steps 1-4)."
214985132|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Randomized Control Trial|As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
214985133|NCT04657185|OTHER|OR PathTrac Feedback Optimization|OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
214370339|NCT07093658|OTHER|High fall injury group|High fall injury group
214985134|NCT06823037|OTHER|HAPPI software|"We will enroll 15 community pharmacies. These 15 pharmacies will continue to provide birth control services as normal for several months (control).~Then, we will introduce the intervention: the HAPPI software. The pharmacies will continue to provide birth control services while using the HAPPI software in place of any paper or electronic processes that they were previously using. The results will then be compared between the control and the intervention period."
214985135|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal /SARS-CoV-2 mRNA Dose 1|A Flu mRNA vaccine composition in combination with Dose 1 of a COVID-19 component will be administered.
214985136|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal /SARS-CoV-2 mRNA Dose 2|A Flu mRNA vaccine composition in combination with Dose 2 of a COVID-19 component will be administered.
214985137|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal mRNA|An investigational mRNA Flu Seasonal vaccine will be administered.
214985138|NCT06680375|COMBINATION_PRODUCT|SARS-CoV-2 mRNA Dose 1|Dose 1 of an investigational mRNA COVID-19 vaccine will be administered.
214985139|NCT06680375|COMBINATION_PRODUCT|SARS-CoV-2 mRNA Dose 2|Dose 2 of an investigational mRNA COVID-19 vaccine will be administered.
214985140|NCT06680375|COMBINATION_PRODUCT|Licensed Flu Seasonal|A licensed Flu Seasonal vaccine will be administered.
214370340|NCT07093840|DEVICE|AmblyoPlay Digital Visual Therapy|AmblyoPlay is a home-based, app-delivered multimodal visual therapy program designed for children with amblyopia. The therapy consisted of 30-minute sessions, performed 5 days per week over a 6-month period. Exercises included gamified visual tasks targeting oculomotor control, visual acuity, stereopsis, visual-motor integration, and postural coordination. The software automatically adjusted task difficulty based on individual performance. Therapy was performed on a tablet or computer with red-green anaglyph glasses provided to participants
214370341|NCT07093840|OTHER|control group|Participants in this group were healthy children who did not receive any therapeutic intervention during the 6-month study period. They were age- and gender-matched with participants in the intervention group to ensure baseline comparability. Assessments were performed only at baseline and at the 6-month follow-up and included measurements of visual acuity, oculomotor function, stereopsis, visual-motor integration, and postural control.
214370342|NCT07092475|DRUG|Methadon|A long-acting synthetic opioid with a pharmacologic profile that potentially offers more stable and longer-lasting pain relief.
214370343|NCT07092813|DRUG|sulopenem etzadroxil and probenecid|single dose of 500 mg of sulopenem etzadroxil and 500 mg of probenecid given orally as a bilayer tablet.
214370344|NCT07094022|DIETARY_SUPPLEMENT|Nutrilite Protein MetX Pro|A total of 4 cans (460 g/can) of study products (Nutrilite Protein MetX Pro) are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
214370345|NCT07094022|DIETARY_SUPPLEMENT|Placebo Product|A total of 4 cans (460 g/can) of placebo products are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
214370346|NCT07093151|OTHER|Target SBP <160mmHg|For subjects assigned to the SBP \<160 mmHg group, an SBP target order will be placed to guide the neuro-intensive care team to treat the patient with antihypertensive medications as needed to achieve an SBP \<160 mmHg. Selection of the antihypertensive medication and administration route is at the discretion of the treating team. Patients will undergo regular and frequent blood pressure measurements using the arterial line placed during surgery, or through a non-invasive blood pressure measurement method if no arterial line is present.
214370347|NCT07093151|OTHER|Target SBP <140 mmHg|For subjects assigned to the SBP \<140 mmHg group, an SBP target order will be placed to guide the neuro-intensive care team to treat the patient with antihypertensive medications as needed to achieve an SBP \<140 mmHg. Selection of the antihypertensive medication and administration route is at the discretion of the treating team. Patients will undergo regular and frequent blood pressure measurements using the arterial line placed during surgery, or through a non-invasive blood pressure measurement method if no arterial line is present.
214370348|NCT07094048|DRUG|Target trough IgG level of 8-10 g/L|Target trough IgG level of 8-10 g/L
214370349|NCT07094048|DRUG|Target trough IgG level 4-6 g/L|Target trough IgG level of 4-6 g/L
214493563|NCT06208904|OTHER|Intravenous infusion of GIPRA|Intravenous infusion of GIP(3-30)NH2 in a concentration of 1,000 pmol/kg/min during experimental days
214493564|NCT06208904|OTHER|Intravenous infusion of saline|Intravenous infusion of isotonic saline 9 mg/ml added 0,5% human serum albumin during experimental days
214493565|NCT06776900|PROCEDURE|Supine position|"An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved."
214985141|NCT06680375|COMBINATION_PRODUCT|Licensed COVID-19 mRNA|A licensed mRNA COVID-19 vaccine will be administered.
214985142|NCT06680375|DRUG|Placebo|A placebo will be administered.
214985143|NCT06827236|DRUG|BNT323|Intravenous infusion
214985144|NCT06827236|DRUG|BNT327|Intravenous infusion
214985145|NCT06510504|DRUG|225 mg BNC210|225 mg BNC210
214985146|NCT06510504|DRUG|Placebo|Placebo
214985147|NCT06850922|DRUG|RO7446603|Participants will receive RO7446603 as an IVT injection per the schedule described in the treatment arms.
214985148|NCT06850922|DRUG|Aflibercept|Participants will receive aflibercept as an IVT injection per the schedule described in the treatment arm.
214985149|NCT06850922|DRUG|Faricimab|Participants will receive faricimab as an IVT injection per the schedule described in the treatment arms.
214985150|NCT01739140|BEHAVIORAL|Yoga|
214985151|NCT02187783|DRUG|LEE011|Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
214985152|NCT03622567|BEHAVIORAL|Smartphone push notifications|The purpose of this study is to assess how smartphone push notifications can impact the overall score, accuracy and reaction time of participants using the Brain Power Score application (app). Push notification quantity will be varied and counter-balanced.
214985153|NCT02283879|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
214985154|NCT03010072|DRUG|low-dose sucroferric oxyhydroxide|250 mg suroferric oxyhydroxide
214985155|NCT03010072|DRUG|high-dose sucroferric oxyhydroxide|2000 mg suroferric oxyhydroxide
214985156|NCT00121056|DRUG|Enbrel®|
214985157|NCT00121056|DRUG|Kineret®|
214985158|NCT00997945|DRUG|ZD4054 (Zibotentan)|10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15
214985159|NCT05334394|OTHER|Mulligan Technique|Mulligan suggested that injuries or sprains can cause a minor positional error in a joint, thereby causing limitations in physiological movement. Unique to this concept is mobilization of the spine while weight bearing and directing the mobilization parallel to the spinal facet planes. Although it includes various mobilization techniques, one of the most important techniques, motion co-mobilization, is the SNAG's technique, which includes the application of accessory passive gliding to the lumbar vertebra while the patient performs active movement simultaneously.
214985160|NCT05334394|OTHER|Exercise Therapy|Exercise is recommended by physical therapists for most chronic low back pain patients.
214370350|NCT07094048|DRUG|No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L|If, during follow-up, the patient presents recurrent or severe infections and/or total IgG level less 4 g/L, crossover to group A or B
214370351|NCT07088315|DEVICE|TECAR therapy|TECAR therapy was applied to the lower limbs of patients diagnosed with lipedema using the BTL-6000 TR-Therapy PRO device (BTL, Turkiye). All treatment sessions were performed by a physiotherapist with specific experience in TECAR therapy. The device operated at a frequency of approximately 500 kHz and employed three types of electrodes: active, neutral, and static application electrodes. Two types of active electrodes -capacitive and resistive- were utilized and applied directly to the treatment area. The neutral electrode, serving as a reference point, was placed in proximity to the target region to ensure effective energy transfer.
214985161|NCT00888875|DEVICE|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
214985162|NCT00888875|DEVICE|ILMA|Insertion after Induction. Insertion of tracheal tube over device
214370352|NCT07088315|OTHER|compression|All participants were provided with individually fitted compression garments (either pantyhose-type or thigh-high models, in class I \[18-21 mmHg\] or class II \[23-32mmHg\] depending on symptom severity and tolerance), and were instructed to wear them during waking hours for a minimum of 8 hours per day. Adherence to garment usage was monitored through patient diaries and reinforced at follow-up visits.
214370353|NCT07088315|OTHER|Exercise|All patients were advised to engage in a structured walking program, consisting of moderate-intensity walking (perceived exertion level 11-13 on the Borg scale), for at least 20 minutes per session, three times per week.
214370354|NCT07087990|DEVICE|Virtual Reality Glasses|articipants in the VR group used virtual reality glasses during coronary angiography to reduce anxiety and pain and improve satisfaction.
214370355|NCT07087990|OTHER|Stress Ball|articipants in the stress ball group used a stress ball during coronary angiography to evaluate its effects on anxiety, pain, and satisfaction.
214370356|NCT07094282|OTHER|Acupuncture|Integrative Medicine: Acupuncture treatment
214370357|NCT07094282|OTHER|myofascial therapy|Integrative Medicine: myofascial therapy to include transverse abdominus teaching, rectus abdominus release, functional neuromyofascial techniques, cupping, gua sha, active needling.
214370358|NCT07094282|OTHER|microcurrent therapy|Integrative Medicine: Microcurrent
214370359|NCT07094282|OTHER|LASER|Integrative Medicine: LASER
214370360|NCT07094282|OTHER|extracorporeal shockwave therapy|Integrative Medicine: Extracorporeal shockwave therapy
214370361|NCT07094282|OTHER|Pulsed electromagnetic therapies|Integrative Medicine: Pulsed electromagnetic therapies
214493566|NCT06776900|PROCEDURE|Lateral position|"An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved."
214493567|NCT06836934|DEVICE|soft knee brace|A commercially available soft brace (orthomedics ser. number 86) plus traditional physiotherapy
214493568|NCT06836934|DEVICE|lateral wedge foot insole|Wearing Lateral wedge insole 5mm for 8 weeks Standardized non-customized laterally wedged insoles were evaluated. Insoles were made of high-density ethyl vinyl acetate, were wedged approximately 5°
214493569|NCT06836934|PROCEDURE|convential physical therapy program|"Strengthening Exercises:~* Quadriceps Strengthening: Exercises like straight leg raises, quadriceps sets, and seated knee extensions help strengthen the quadriceps muscle, which supports the knee joint.~* Hamstring Strengthening: Hamstring curls and bridges target the hamstrings to enhance stability and support for the knee.~* Hip Strengthening: Exercises such as hip abductions, adductions, and clamshells strengthen the hip muscles (each 3 sets, 10 reps). (Deyle et al ., 2005)~Flexibility Exercises:~* Hamstring Stretch: Gentle stretching of the hamstrings can alleviate tension around the knee.~* Quadriceps Stretch: Stretches like the standing quadriceps stretch help maintain flexibility in the front of the thigh.~* Calf Stretch: Stretching the calf muscles can prevent tightness (J. D. Deyle et al 2005) TENS (Transcutaneous Electrical Nerve Stimulation): Helps manage pain by sending electrical impulses to the affected area."
214985163|NCT00471497|DRUG|nilotinib|Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
214370362|NCT07094282|OTHER|Miscellaneous integrative medicine|other integrative medicine modalities
214370363|NCT07093996|PROCEDURE|Endoscopic pancreatic duct stent placement|Endoscopic pancreatic duct stent placement will be performed with a 5Fr Boston Scientific pancreatic stent (3-4 cm in length) within 24 hours from the randomization procedure. The stent will be removed on the 5th day after installation.
214681530|NCT05520996|BEHAVIORAL|Cyberball|Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence
214681531|NCT06286098|DRUG|Alpha lipoic acid|THIOTACID 600 MG ORIGINAL ® Tablets manufactured by EVA PHARMA
215088972|NCT07040215|DEVICE|Freewalk lower limb Robotic Assistive Gait Training|"Participants in this group will receive robotic-assisted gait training three times per week (every other day) for 30 minutes per session, using the FREE Walk exoskeleton device (FREE Bionics, Taiwan). The device assists with walking, standing, and sitting. A physical therapist will help the participant wear the exoskeleton and supervise the training, adjusting the level of robotic support and intensity based on the participant's ability. In addition to RAGT, participants will receive conventional stroke rehabilitation therapy (including sit to stand, balance and gait training) on the remaining weekdays (2 days/week), 30 minutes per session.~Intervention Duration: 4 weeks."
214370364|NCT07093996|DRUG|Conventional treatment of acute pancreatitis in early phase|Infusion therapy, pain relief, nutritional support and surgical procedure if needed
214370365|NCT07093606|DRUG|Eltrombopag|ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
214370366|NCT07093918|OTHER|V-echo|Imaging system
214370367|NCT07093918|OTHER|L-echo|Imaging system
214370368|NCT07094100|DEVICE|Tissue engineered cartilage|Cartilage constructed by autologous bone marrow mesenchymal stem cells
214370369|NCT07092696|DRUG|Toripalimab|"Induction chemo-immunotherapy (platinum-based tri-weekly regimen)~* Paclitaxel 175 mg/m² IV on day 1~* Cisplatin 50 mg/m² IV on day 1 or carboplatin AUC 4-5 IV on day 1~* Toripalimab 240 mg IV on day 1, administered immediately before each chemotherapy infusion Cycle length: every 3 weeks Number of cycles: 2 Concurrent chemoradiotherapy (weekly regimen)~* Radiation therapy delivered according to institutional protocol~* Cisplatin 40 mg/m² IV once weekly~* Toripalimab 240 mg IV on day 1 of every 3-week cycle, given before chemotherapy Cycle length: every 3 weeks during radiotherapy~Maintenance immunotherapy~• Toripalimab 240 mg IV on day 1 every 3 weeks (Q3W) Duration: 1 year (total 13 cycles)"
214370370|NCT07092696|RADIATION|Pelvic External-Beam Radiotherapy (EBRT)|"* PTV: 6 MV photons, 1.80 Gy per fraction × 28 fractions = 50.4 Gy.~* PGTVnd: 6 MV photons, 2.14 Gy per fraction × 28 fractions = 59.92 Gy. Brachytherapy:Dose prescriptions~* Dose: 7.00 Gy per fraction × 4 fractions = 28.0 Gy."
214370371|NCT07093255|DRUG|FLQ-101|"The invervention comprises 3 Groups:~* Group 1: Low Dose~* Group 2: Middle Dose~* Group 3: High Dose"
214370372|NCT06008496|PROCEDURE|Day case surgery|Operation, surgical group, magnitude of surgery, anaesthetic type.
214370373|NCT05471102|PROCEDURE|Study group: lower segment resection with ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
214370374|NCT05471102|PROCEDURE|Control group: lower segment resection without ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
214370375|NCT07092683|OTHER|anemia|preoperative anemia
214370376|NCT07092683|OTHER|nonanemia|preoperative nonanemia
214370377|NCT05303493|BIOLOGICAL|Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI|Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma
214370378|NCT06920186|PROCEDURE|Analgesia|1-Adductor canal block + surgical infiltration
214370379|NCT06920186|PROCEDURE|Analgesia|2-Adductor canal block + femoral-cutaneous block + obturator block + IPACK block
214370380|NCT06931652|DRUG|Epcoritamab|Epcoritamab Investigational Medicinal Product (IMP): Epcoritamab will be used during induction phase and Maintenance phase.
214370381|NCT07094061|DEVICE|fMRI|Participants will have an MRI to scan participants brains and will wear skin conductance electrodes on the hand and fill out questionnaires. Scanning will take approximately 90 minutes. While lying in the scanner, participants will be asked to perform some tasks. The tasks will be presented to participants visually on a screen in the scanner and eye movements will also be tracked during some of these tasks. Participants will respond to stimuli with button presses that are recorded by computer.
214370382|NCT07094061|BEHAVIORAL|Questionnaires and surveys|Participants will have multiple visits during this study and fill out various surveys at these visits.
214370383|NCT07094061|BEHAVIORAL|Behavioral tasks and eye tracking|Participants will perform behavioral tasks while having eye-tracking hardware monitor participants eye movements. A video camera will be used to record eye movements during the behavioral tasks.
214493570|NCT06885398|OTHER|treatment|"* Endotracheal Tube Ventilation with an endotracheal tub~* Laryngeal tube Ventilation with a laryngeal tube~* Laryngeal mask Ventilation with a laryngeal mask~* I-Gel-Laryngeal Mask Ventilation with an I-Gel-laryngeal mask"
214493571|NCT03682172|DRUG|GLP-2 (1pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
214493572|NCT03682172|DRUG|GLP-2 (10pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min
214493573|NCT03682172|DRUG|Placebo|Four hour intravenous infusion with saline water
214681532|NCT06286098|OTHER|Placebo|Placebo identical Tablets are manufactured by EVA PHARMA containing the same excipients without Alpha Lipoic Acid.
214681533|NCT01848821|DEVICE|OASIS Ultra|Porcine derived intestinal submucosa
214370384|NCT06932783|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|"Participant will apply TEA at home twice a day (approximately 45 minutes am/pm) for 8 weeks. The top electrode will be placed at ST36 (via acupuncture point) and the electrode patch will be placed vertically.~Additionally, participants will agree to allow medical records to be collected, complete various surveys and have follow-up after treatment (approximately 9-10 weeks)."
214370385|NCT06932783|DEVICE|Sham Transcutaneous Electrical Acustimulation (TEA)|"Participant will apply sham TEA at home twice a day (approximately 45 minutes am/pm) for 8 weeks. Sham TEA will be performed via one point on the leg and not on any meridian or acupoints that were used in previous gastrointestinal studies and did not yield any significant effects.~Additionally, participants will agree to allow medical records to be collected, complete various surveys and have follow-up after treatment (approximately 9-10 weeks)"
214370386|NCT06104956|DRUG|HFNO weaning protocol|Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
214493574|NCT06765629|DEVICE|Non-invasive Percutaneous Tibial Nerve Stimulation (TTNS) group|After obtaining informed consent from the subjects, the researchers screen the subjects based on the inclusion and exclusion criteria. The wearable non-invasive percutaneous tibial nerve stimulator is placed on the area where the tibial nerve runs at the medial malleolus of the subjects. Once the wearable stimulator is properly fitted, stimulation parameter programming and treatment record management are conducted through the programming software running on the mobile phone.
214493575|NCT06561555|DRUG|RC48|RC48 at a dosage of 2mg/kg administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
214681534|NCT01848821|DEVICE|Wound VAC Standard Therapy|Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
214681535|NCT00050349|DRUG|EPO906 epothilone B|
214681536|NCT00483249|DEVICE|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
214985164|NCT00471497|DRUG|imatinib|Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
214370387|NCT06104956|DRUG|HFNO Standard of care|Weaning methods will be left to the free choice of the practitioner.
214370388|NCT06932809|DRUG|18F-JSS20-183A PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 18F-JSS20-183A.
214985165|NCT00309517|DRUG|Fluourouracil|
214985166|NCT00309517|DRUG|Leucovorin|
214985167|NCT00309517|DRUG|MAb 17-1A|
214985168|NCT01654276|DRUG|Febuxostat|One 40 mg tablet once a day for 6 months
214985169|NCT04163874|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
214985170|NCT04163874|DRUG|Pramlintide Acetate|Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
215088973|NCT07040215|OTHER|Physiotherapy|Participants in this group will receive conventional stroke rehabilitation therapy (including sit to stand, balance and gait training) 5 days/week, 30 minutes per session. Intervention Duration: 4 weeks.
215088974|NCT07038980|OTHER|Observational Assessment|"Participants in both groups undergo a one-time diagnostic evaluation consisting of:~Smartphone Addiction Scale - Short Form (SAS-SF)~Neck Disability Index (NDI)~MyotonPRO measurement of cervical muscle tone, stiffness, and elasticity~Pressure pain threshold measurement using a handheld algometer~Social Media Addiction Scale (SMAS)~No therapeutic or behavioral intervention is applied. All procedures are non-invasive and conducted for observational purposes only."
215088975|NCT07041060|DIETARY_SUPPLEMENT|EOLO|Eolo, a nutraceutical blend of sodium alginate, sodium bicarbonate, palmitoylethanolamide (PEA), and herbal extracts
214370389|NCT06932809|DIAGNOSTIC_TEST|Brain MRI|MRI scan of the brain.
214370390|NCT06932809|DIAGNOSTIC_TEST|Amyloid PET|PET scan with Florbetaben F18 or 11C-PiB.
214370391|NCT06932809|BEHAVIORAL|Neurological Assessments|Neurological assessments, including a video interview.
214681537|NCT03552705|DRUG|Tranexamic Acid|5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
214681538|NCT03552705|DRUG|Placebos|5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
214681539|NCT01495546|OTHER|Early loading|Patients stepping down immediately after THA
214681540|NCT01495546|OTHER|Late loading|Patients stepping down after three weeks of HTA
214681541|NCT00019513|DRUG|fluorouracil|
214681542|NCT00019513|DRUG|gemcitabine hydrochloride|
214681543|NCT00019513|DRUG|leucovorin calcium|
214681544|NCT01266707|BIOLOGICAL|antiangiogenic paptide vaccine|for drugs include administration time frame
214681545|NCT06031480|DRUG|Anlotinib and TQB2450|"Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent."
214985171|NCT04163874|DRUG|Placebo|Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
215088976|NCT07041060|DRUG|PPI (proton pump inhibitor)|Received a half-dose of PPIs for 24 weeks
214985172|NCT04163874|DEVICE|Artificial Pancreas|Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
214985173|NCT06492629|DRUG|Toripalimab|Intravenous infusion, 240mg, administered once every 3 weeks, until the subject has been treated for 2 years, disease progression occurs, intolerable toxic reactions are experienced, or treatment is discontinued for other reasons.
214985174|NCT06492629|DRUG|chidamide|Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses (such as on Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), to be taken 30 minutes after meals.
214985175|NCT03904654|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
214985176|NCT04334369|DEVICE|Proclear Single Vision Contact Lenses manufactured by CooperVision|FDA approved single vision contact lenses.
214985177|NCT04334369|DEVICE|Proclear Multifocal Contact Lenses manufactured by CooperVision|FDA Approved Multifocal Contact Lenses
214985178|NCT05054634|BEHAVIORAL|Psycho-oncological Intervention Based on Counselling (PIBC)|Patients in EG received a psycho-oncological intervention based on Counselling (PIBC) following the scheme proposed by Arranz and Cancio in addition to the standard treatment. The evolution of anxiety and depression was evaluated using Hospital Anxiety and Depression Scale (HADS). The aim of the study was to evaluate the effectiveness of a PIBC in reducing anxiety and depression of patients with DTC. Other QoL relevant items were also evaluated using the Short Form-36 Health Survey (SF-36) and Psychological General Well-Being Index (PGWBI) scales.
214370392|NCT06936241|OTHER|Circuit weight training|"The Circuit Training protocol will be performed as follows:~wall push-up, bridge on floor, single leg bridge, bird dog, windshield wiper, march in place, ball squat, squat with an overhead press, reverse pendulum, jumping rope, and spinal twist, 30-35 minutes, 3 times a week for 8 weeks"
214370393|NCT06936241|OTHER|Traditional physical therapy program|The participants will receive traditional physical therapy program in the form of therapeutic exercises to keep daily living activity by restoring the strength of flexors and abductors of the shoulder joint using the shoulder wheel and ladder. It will be performed 3 times per week for eight weeks
214370394|NCT06940336|DRUG|Tafamidis Meglumine Soft Capsules|20 mg orally once daily for 72 weeks
214370395|NCT07093593|OTHER|Mandatory biological samples (blood and sell)|"At cycle 1 and Cycle 3 :~* Stool sample collection~* Blood sample collection (5 EDTA tubes)"
214370396|NCT07094308|BEHAVIORAL|Learn Intestinal Failure Tele-ECHO Program|LIFT-ECHO (Learn Intestinal Failure Tele-ECHO) is a virtual tele-education program designed to improve the knowledge and clinical decision-making of non-specialist clinicians managing patients with chronic intestinal failure (CIF) on parenteral nutrition (PN). The intervention consists of eight 60-90-minute sessions delivered over 2-4 months. Each session includes the presentation of anonymized real-world CIF cases and a didactic lecture by an expert in intestinal rehabilitation. Participating physicians may also complete baseline and follow-up surveys, and optionally participate in focus groups or appreciative inquiry workshops.
214370397|NCT07094308|BEHAVIORAL|Standard of Care|Participants will receive routine clinical care for chronic intestinal failure from their usual providers. No additional educational programming or intervention is delivered during this period.
214370398|NCT07092761|DEVICE|GS3 CGM|Wearing CGM for a consecutive 14 days
214493576|NCT06782984|OTHER|Organoid-based drug sensitivity test|"The intervention in this study involves utilizing glioblastoma organoids (GBOs) to perform an organoid-based drug sensitivity test (DST) and retrospectively comparing the results with clinical outcomes. Notably, no interventions will be applied to participants based on GBO-DST results; the study is limited to retrospective analysis.~The GBO-DST is conducted by performing a drug response assay with temozolomide to determine the half-maximal inhibitory concentration (IC50), which serves to classify GBOs as TMZ-sensitive or TMZ-resistant. This classification is further validated through GBO cell survival analysis."
214493577|NCT06808490|BEHAVIORAL|Moderate Intensity Exercise|Participants randomized to the moderate intensity exercise condition will complete a 30 min session on a motor driven treadmill. Participants will complete a 3-minute warm-up at low speed on a treadmill. Speed and incline will be increased in 3-minute increments until moderate-intensity exercise, defined as the goal of participants staying within a target zone of 50-70% AAMHR while briskly walking and/or jogging depending on current fitness status.
214493578|NCT06808490|BEHAVIORAL|Light Intensity Stretching|Participants randomized into the light stretching condition will complete a 30-minute video, tailored for 9-17-year-olds. This video leads participants through a series of seated arm, torso, leg, knee and shoulder stretches on a yoga mat. Participants will be monitored throughout the stretching session by a trained research assistant, and HR and perceived exertion will also be measured throughout. The research assistant may make modifications to the poses in real-time to ensure that AAMHR is kept below 40%.
214493579|NCT06808490|BEHAVIORAL|Seated Meditation|Participants randomized into the meditation condition will complete a 30-minute video, tailored for 9-17-year-olds. This video leads participants through a seated guided meditation on a yoga mat. This includes a series of breathing, visualization, and body awareness exercises. Participants will be monitored throughout the meditation session by a trained research assistant, and HR and perceived exertion will also be measured throughout, to ensure that AAMHR is kept below 30%.
214493580|NCT06736964|DEVICE|Giomer|based on Pre-reacted glass ionomer (PRG)
214493581|NCT06628843|OTHER|cesarean section rate|Incidence of cesarean sections in the two periods, Rate of adverse outcomes within vaginal and cesarean deliveries
214493582|NCT06888128|DRUG|Psilocybin 15mg|Each participant will have a low dose (15 mg) psilocybin session to establish basic skills with session format, psilocybin effects, and continue to build rapport with session facilitators. Given the potential intensity of the psilocybin and the reality of experiencing significant trauma memories, the purpose of the first psilocybin session is to familiarize participants with the drug effects that may be encountered at a higher dose of psilocybin. The first psilocybin session will also allow for assessment of both the suitability of each participant to the study procedures and drug effects, and the safety of administering a higher dose to each participant.
214493583|NCT06888128|DRUG|Psilocybin 25mg|The second psilocybin session will utilize a high dose (25mg) and take place approximately 2 weeks after the first psilocybin session.
214370399|NCT02977559|DEVICE|Laryngeal Tube Suction Disposable|Device for ventilation
214493584|NCT06809920|PROCEDURE|Group 1 ACL reconstruction with quadruple flexor tendons and conventional physiotherapy|Group 1 will undergo conventional ACL reconstruction with quadruple flexor tendons (double gracilis and semitendinosus). All the participants will receive conventional physiotherapy.
214493585|NCT06809920|PROCEDURE|Group 2 ACL reconstruction with quadruple flexor tendons + ALL reconstruction|Group 2 will undergo conventional ACL reconstruction with quadruple flexor tendons (double gracilis and semitendinosus) + ALL reconstruction. All the participants will receive conventional physiotherapy.
214493586|NCT06787183|RADIATION|Short course radiotherapy|CTV 25Gy/5Fx.
214493587|NCT06787183|DRUG|Capecitabine|1000mg/m2, d1-14，bid, q3w, 2 cycles.
214493588|NCT06787183|DRUG|Oxaliplatin|130mg/m2, d1, q3w, 2 cycles
214985179|NCT02243657|DRUG|ASP3652|oral
214985180|NCT02243657|DRUG|Placebo|oral
214985181|NCT03332537|BEHAVIORAL|Personalized IBS Pain SM|
214370400|NCT02977559|DEVICE|Laryngeal Mask Airway AuraGain|Ventilation device
214370401|NCT04499859|DRUG|Ezetimibe 10mg + Rosuvastatin 5mg|Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin
214370402|NCT04499859|DRUG|Rosuvastatin 20mg|20mg of Rosuvastatin as a standard treatment for AMI patients
214370403|NCT06211296|DEVICE|Shortcut|Splitting bioprosthetic aortic valve leaflets
214370404|NCT01546467|BEHAVIORAL|Cognitive remediation|Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
214370405|NCT00766675|DRUG|Tramadol hydrochloride|Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
214370406|NCT00766675|DRUG|Acetaminophen|Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
214370407|NCT05795413|PROCEDURE|Mastectomy with PECS blocks|Approximately half of patients recruited will receive a PECS block with Liposomal bupivacaine and half will not receive a block.
214370408|NCT05795413|DRUG|Liposomal bupivacaine|All of the PECS blocks performed at this institution have liposomal lupivacaine as the anesthetic. Investigators will examine quality of recovery and pain control in patients who receive a PECS block versus those who do not receive one.
214370409|NCT05613790|DEVICE|Active High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
214370410|NCT05613790|DEVICE|Sham High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
214370411|NCT01747564|DRUG|YM178 (mirabegron)|oral
214493589|NCT06787183|DRUG|QL1706|5.0 mg/kg, q3w
214493590|NCT06868160|BEHAVIORAL|Rehabilitation|"Two cycles of dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises.~Three 1-hour sessions per week for 6 weeks. Cycle repeated after 8-week washout period."
214493591|NCT06868160|DEVICE|SHAM tDCS|SHAM stimulation will be performed using the same montage used for transcranial and spinal stimulation, however an initial current is delivered and programmed to fade off in a brief period of time.
214493592|NCT06868160|DEVICE|tDCS|Anodic tDCS with the anode placed on the of the left DorsoLateral Prefrontal Cortex. Patients will undergo 30 minutes tDCS session preceding rehabilitation
214493593|NCT06868160|DEVICE|tsDCS (first cycle)|Anodic spinal cervical stimulation with anode electrode placed on the spinous process of C3 vertebra and cathode placed on T3. Patients will undergo 30 minutes stimulation session preceding rehabilitation during the first cycle (6 weeks)
214493594|NCT06868160|DEVICE|tsDCS (second cycle)|Anodic spinal cervical stimulation with anode electrode placed on the spinous process of C3 vertebra and cathode placed on T3. Patients will undergo 30 minutes stimulation session preceding rehabilitation during the second cycle (6 weeks after 8-week washout)
214681546|NCT02261870|DEVICE|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
214681547|NCT04143542|PROCEDURE|trunk blocks|Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
214985182|NCT03966066|DRUG|erythromycin|3-5mg/kg.d orally for 6 months
214493595|NCT06868160|DEVICE|SHAM tsDCS (first cycle)|SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation during the first cycle (6 weeks)
214493596|NCT06868160|DEVICE|SHAM tsDCS (second cycle)|SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation during the second cycle (6 weeks after 8-week washout)
214493597|NCT06868160|DEVICE|SHAM tsDCS|SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation
214681548|NCT04438603|DRUG|Intervention for incipient patients at low risk of disease progression|Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of \< 130/80 mm Hg
214681549|NCT04438603|DRUG|Intervention for patients at high risk of disease progression|"BP-lowering goal of \< 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:~1. If GFR\>60 ml/min/1.73m\^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.~2. If GFR is 30-60 ml/min/1.73m\^2, intravenous cyclophosphamide (CTX) 750 mg per month per m\^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks."
214681550|NCT04205370|DEVICE|Deactivated Pregnancy Coach|Naturalistic monitoring of their typical sleep patterns and behaviors
214681551|NCT04205370|DEVICE|Active Pregnancy Coach|The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
214681552|NCT04162964|BEHAVIORAL|Virtual Chair Yoga|8-week virtual chair yoga program for one hour per week. Chair yoga is an effective way to offer modified yoga postures and relaxation techniques to individuals with limited mobility and/or advanced age for whom mat-based classes may not be accessible. The weekly yoga classes will be lead on the software Zoom by a certified instructor in English and French.
214985183|NCT03832556|OTHER|CT scan|CT scan with biphasic injection of contrast product
214985184|NCT03832556|OTHER|MRI examination|MRI with injection of contrast
215088977|NCT07041060|DIETARY_SUPPLEMENT|Group C: Eolo|Eolo, a nutraceutical blend of sodium alginate, sodium bicarbonate, palmitoylethanolamide (PEA), and herbal extracts for 24 weeks
214370412|NCT05467579|DEVICE|Device: orthodontic - mandibular advancement clear aligner|Intervention orthodontic - mandibular advancement: mandibular retrognathia correction with a mandibular advancement using a step-wise approach with clear aligner.
214985185|NCT02844595|BEHAVIORAL|Standard cognitive-behavioural smoking cessation treatment|"Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
214985186|NCT02844595|BEHAVIORAL|Standard cognitive-behavioural smoking cessation treatment and behavioural activation|"Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
214985187|NCT00236626|DRUG|topiramate|
214985188|NCT04683575|DRUG|Selenium Yeast|oral medication
214370413|NCT00969475|DEVICE|Lumenis fractional carbon dioxide laser|intra-operative laser resurfacing at time of wound closure
214370414|NCT00385411|DRUG|valproate microgranules|20 to 30 mg/kg/day
214370415|NCT04606784|BIOLOGICAL|Ampion|Ampion, nebulized for inhalation
214370416|NCT04606784|OTHER|Standard of Care|Standard of Care
214370417|NCT04700501|OTHER|Enjoy Your Bump - CBT life skills learning programme|Antenatal use of an online Cognitive Behavioural Therapy life skills learning programme to improve maternal feelings of anxiety and low mood.
214370418|NCT00820274|PROCEDURE|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
214370419|NCT05323617|DRUG|Romiplostim|Administered as a subcutaneous injection.
214985189|NCT04683575|DRUG|Placebo|oral medication
215088978|NCT07040995|OTHER|Swift follow-up|Swift and structured follow-up on-demand for 6 months at a disease-specific outpatient clinic following hospitalization for heart failure among older adults
214370420|NCT05323617|DRUG|Antithymocyte Globulin|Horse or rabbit antithymocyte globulin administered as an intravenous infusion.
214493598|NCT06792383|DIAGNOSTIC_TEST|quality of life|"The following assessment tools will be proposed to patients:~* Quality of Life in Epilepsy (QOLIE-31)26~* Dissociative Experience Scale (DES)27~* Symptom Checklist-90 (SCL-90)28~* Irritability Questionnaire (I-EPI)29~* Beck Depression Inventory II (BDI-II)30~* State-Trait Anxiety Inventory Y-1 e Y-2 (STAI)31~* Epilepsy Stigma Scale modificata32 These assessment tools are validated and used universally, and will allow the collection of information on the psychological and psychiatric functioning of the patients."
214493599|NCT06866639|BEHAVIORAL|Cognitive behavioral therapy|The CBT is based on the treatment manual written by Fennell (1997). The patients receiving CBT will be treated for 8 sessions, with weekly session of 45-60 minutes duration.
214493600|NCT06866639|BEHAVIORAL|Metacognitive therapy|The meta-cognitive treatment program is based on Wells's metacognitive therapy (Wells, 2013). The patients receiving meta-cognitive therapy will be treated for 8 sessions, with weekly session of 45-60 minutes duration.
214493601|NCT06779812|PROCEDURE|Carpal Tunnel Surgery|Carpal tunnel surgery is performed endoscopically, using smaller incisions. Endoscopic surgery is a minimally invasive method that allows for faster and less painful recovery
214493602|NCT06779812|OTHER|real auricolothery|3 days before the intervention, patients will have an auriculotherapy session with an experimental group
214493603|NCT06779812|OTHER|sham auriculotherapy|3 days before the intervention, patients will have an auriculotherapy session with an sham group
214985190|NCT01991795|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
214985191|NCT01991795|DRUG|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
215088979|NCT07042087|BEHAVIORAL|Mindfulness Yoga|A structured 9-month program integrating physical yoga postures (asanas), breathing techniques, sound, and meditation. Sessions are conducted twice weekly (90 minutes each) and focus on enhancing physical health, stress regulation, and cognitive performance. Delivered by certified instructors.
214370421|NCT05323617|DRUG|Cyclosporine A|Administered orally.
214370422|NCT05773560|DEVICE|virtual reality rehabilitation|All patients will receive VR-assisted rehabilitation. The VR-assisted rehabilitation is proceed with SyncVR® (Padualaan, Netherlands ) equipment, which is composed of a head set (PICO NEO 3) and one dashboard (TABLET), enabling the patients to receive stepwise rehabilitation program with 360° videos activities (SyncVR Medical Platform). The VR-assisted rehabilitation will be performed two times per day, 30 minutes per training. The first training will start on the second post-operative day.
214370423|NCT02044627|DRUG|[14C-ETC-1002]|
214370424|NCT01048892|BIOLOGICAL|Seneca Valley virus-001|
214370425|NCT01048892|DRUG|cyclophosphamide|
214370426|NCT01048892|OTHER|laboratory biomarker analysis|
214370427|NCT01048892|OTHER|pharmacological study|
214370428|NCT01331460|BEHAVIORAL|RBT|"Intervention for Injection Drug Using Women:~Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors."
214681553|NCT05653778|DEVICE|Scrambler therapy|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
214370429|NCT01331460|OTHER|Case-Management|"Standard Intervention:~Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs"
214370430|NCT03610763|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a portable neurostimulation method that modulates cortical excitability. The technique involves placing two saline-soaked electrodes (anode and cathode) on the scalp and passing a small direct current (1.5 milliamps; mA) between them. Cortex underlying the anode is more easily excited due to lowered thresholds for depolarization of glutamatergic neurons, while thresholds are increased in neurons beneath the cathode, making them less excitable. Sham stimulation is easily implemented, and the technique can be effectively double-blinded.
214370431|NCT03610763|BEHAVIORAL|Modified Constraint Induced Movement Therapy|In CIMT, patients are required to wear a mitt that restricts use of the unaffected limb while they practice structured tasks and also engage in activities of daily living.
214985192|NCT03318458|OTHER|Pilates|The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
214985193|NCT04618913|DRUG|Apixaban|Anticoagulant
214370432|NCT05513326|OTHER|Exercises and education|"Exercises: 3 training sessions per week that will last for 30 minutes. Sessions will start with 5 minutes of activation (walking on a treadmill or cycling). Then, participants will be asked to complete 5 exercises targeting lower limb strengthening (time: 18 minutes) followed by 2 exercises designed to improve balance and 3 stretching exercises for the lower limb (time: 7 minutes).~Education: Two one-on-one sessions (during week 2 and week 4 assessments) during which participants will receive information directly related to LSS and NC using illustration and videos. Participants will also be invited to ask their questions."
214985194|NCT04618913|DRUG|Rivaroxaban|Anticoagulant
214985195|NCT04618913|DRUG|Edoxaban|Edoxaban
214985196|NCT04618913|DRUG|Dabigatran|Dabigatran
214985197|NCT04618913|DRUG|VKA|Vitamin K antagonist
214985198|NCT04618913|DRUG|LMWH|Low Molecular Weight Heparin
214985199|NCT02644746|DEVICE|acupuncture|Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57), Taixi (KI3) acupoints will be used. For bilateral Dachangshu (BL 25), the needle will be inserted vertically at approximately 40-70 mm until participants got a electric shock feeling downward to calves, then the needle should be elevated up 2 mm, without rotating or lifting. For other four acupoints (BL23, BL40, BL57, KI3), they will be inserted 10 to 15 mm in depth with three times light amplitude rotation and lift to induce a sensation of soreness. The manipulations will be performed 3 times in total during 1 session (every 10 min). There are 24 treatment sessions after baseline, 3 times a week, and the patients will undergo a 30-min treatment each session.
214985200|NCT02644746|DEVICE|placebo needle|Acupuncturists will use blunt tip needles (Huatuo, Suzhou, China) that cannot penetrate skin and stimulate deep tissues, and the thrusting and twisting motions will be used by acupuncturists to simulate the treatment and blind the patients. Each placebo needle consists of four parts: needle handle, needle body, blunt tip and adhesive pad. The chosen of acupoints, treatment duration, and frequency of sessions will be the same as the acupuncture group. To guarantee blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk among groups.
214370433|NCT05513326|OTHER|Education alone|Education: Two one-on-one sessions (during week 2 and week 4 assessments) during which participants will receive information directly related to LSS and NC using illustration and videos. Participants will also be invited to ask their questions.
214370434|NCT06325423|COMBINATION_PRODUCT|neoadjuvant chemotherapy|platinum-based chemotherapy before radical cystectomy or bladder preservation
214493604|NCT06623370|DRUG|methylprednisolone|Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
214985201|NCT05949840|OTHER|Expressive Interviewing|Automated computer system designed to engage participants in discussion about challenges faced during the COVID-19 pandemic.
214985202|NCT06301438|DRUG|dalpiciclib|dalpiciclib oral day 1-21, every 28 days
214985203|NCT03344757|BEHAVIORAL|Cultural CBSM|The Culturally Adapted Cognitive Behavioral Stress Management (C-CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own. The delivery of C-CBSM places a greater emphasis on salient sociocultural determinants of symptom burden and Health Related Quality of Life (HRQoL) in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo).
214985204|NCT03344757|BEHAVIORAL|Standard CBSM|The standard Cognitive Behavioral Stress Management (CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own.
214985205|NCT04511013|DRUG|Binimetinib|Given PO
214985206|NCT04511013|DRUG|Encorafenib|Given PO
214985207|NCT04511013|BIOLOGICAL|Ipilimumab|Given IV
214985208|NCT04511013|BIOLOGICAL|Nivolumab|Given IV
214985209|NCT06851858|DRUG|AZD6234|Weekly SC injections of AZD6234
214985210|NCT06851858|DRUG|Placebo to match|Weekly SC injections of matching placebo
214985211|NCT06666283|DRUG|AP303 150μg|AP303 Tablet 150μg QD
214985212|NCT06666283|DRUG|Placebo 150μg|Placebo Tablet 150μg QD
214985213|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg single dose
214985214|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 15mg single dose
214985215|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 20mg single dose
214985216|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg\*2 single dose
214681554|NCT05653778|DEVICE|TENS treatment|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
214681555|NCT06036446|PROCEDURE|Cervical cerclage|Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.
214681556|NCT06036446|DRUG|Vaginal Suppository Progesterone|Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
214370435|NCT06495203|DRUG|anti-VEGF treatment|Follow clinical practice/administration
214370436|NCT02240108|DRUG|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
214370437|NCT02240108|DRUG|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
214370438|NCT04799379|DRUG|microporous polysaccharide hemospheres (MPH) agent in rectal surgery|Use of microporous polysaccharide hemospheres (MPH) agent in patients after rectal surgery to avoid pelvic collections and the use of any drain
214370439|NCT03808779|PROCEDURE|Radiofrequency Ablation|Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
214370440|NCT03808779|PROCEDURE|Conventional Surgery|Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
214370441|NCT00533104|PROCEDURE|BM-MNC preparation|"For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
214370442|NCT00533104|PROCEDURE|PB-MNC preparation|"Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
214985217|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 25mg single dose
214985218|NCT06020508|DEVICE|Group 1 - Lumoptik BrightPoint Epidural Device|Participants will undergo a neuraxial procedure to measure loss of resistance with saline in conjunction with the Lumoptik BrightPoint Epidural Device.
214370443|NCT03994042|DEVICE|Mental imagery neurofeedback training|Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
214370444|NCT00744094|DIETARY_SUPPLEMENT|protein drink|250 ml protein hydrolysate solution
214681557|NCT02538237|DRUG|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
214681558|NCT02538237|DRUG|Ibuprofen 2% mouthwash|
214681559|NCT04316689|BIOLOGICAL|S-488210|S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).
214681560|NCT04316689|BIOLOGICAL|S-488211|S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).
214681561|NCT02184416|OTHER|observational|The study is non interventional. All drugs will be prescribed
214985219|NCT06105749|DEVICE|contrast-enhanced mammography|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
214985220|NCT04047264|PROCEDURE|Microdialysis|Undergo microdialysis
214985221|NCT04047264|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214985222|NCT06622187|DRUG|Desmopressin (DDAVP)|Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure
214985223|NCT06622187|DRUG|Sodium Chloride|Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure
214985224|NCT04931342|DRUG|Ipatasertib|Ipatasertib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)
214985225|NCT04931342|DRUG|Cobimetinib|Cobimetinib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length=28 days)
214985226|NCT04931342|DRUG|Trastuzumab Emtansine|Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
214985227|NCT04931342|DRUG|Atezolizumab|Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
214985228|NCT04931342|DRUG|Bevacizumab|Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
214985229|NCT04931342|DRUG|Paclitaxel|Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)
214985230|NCT04931342|DRUG|Giredestrant|Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)
214985231|NCT04931342|DRUG|Abemaciclib|Abemaciclib will be administered by mouth twice a day during each 28-day cycle
214985232|NCT04931342|DRUG|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle
215088980|NCT07042087|BEHAVIORAL|Time-Restricted Eating with nutritional counseling promoting a flexitarian dietary pattern|Participants follow a 16:8 time-restricted eating schedule (16 hours fasting / 8 hours eating window) for 9 months, with nutritional counseling promoting a flexitarian dietary pattern. The intervention is designed to support metabolic health and reduce risk factors for neurodegeneration.
215088981|NCT07042087|BEHAVIORAL|Cognitive Training|A 9-month structured program of twice-weekly cognitive training sessions (90 minutes each), targeting memory, attention, executive function, and social cognition using both paper-based and computer-based tasks. Supervised by trained therapists.
215088982|NCT07042087|BEHAVIORAL|Stretching|A twice-weekly stretching routine performed over 9 months (90-minute sessions), led by physiotherapists. This intervention provides low-intensity physical activity to control for physical engagement across study arms.
215088983|NCT07041112|DRUG|Biologic therapy for psoriasis|Exposure to systemic biologic drugs for psoriasis, including TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab), IL-12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). Treatments were prescribed as part of routine clinical care.
215088984|NCT07041346|OTHER|Education|"1. Objectives of the Training Program To increase students' knowledge and awareness of gender concepts, gender roles, and gender inequality.~   To help students develop more conscious and critical thinking skills regarding social norms and gender-based discrimination.~   To promote the development of gender-sensitive attitudes and contribute to positive attitude changes following the training.~2. Duration and Structure of the Training Total Duration: 2 weeks~   Weekly Duration: 2 hours~   Training Format: In-person~   Training Methods: Presentations, group discussions, surveys, brainstorming, Q\&A sessions, debates~3. Training Content and Modules Week 1 Topic 1: Fundamental Concepts, Gender Roles, and Inequality~Introduction and Training Objectives~Gender and Social Norms: Definition of gender norms and their impact on individuals"
214370445|NCT00744094|BEHAVIORAL|Resistance training|12 weeks resistance training, 3 days per week
214985233|NCT04931342|DRUG|Palbociclib|Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle
214985234|NCT04931342|DRUG|Letrozole|Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle
214985235|NCT04931342|DRUG|Olaparib|Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle
214985236|NCT04931342|DRUG|Luteinizing Hormone-Releasing Hormone (LHRH) Agonists|LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.
214370446|NCT00148226|BEHAVIORAL|Decision Aid|
214370447|NCT04660422|OTHER|VitalTalk communication skills training|Clinicians will receive VitalTalk intensive communication skills training via highly structured Zoom conference. They will learn skills relevant to discussions about ACP and COVID-19 including delivering serious news, eliciting goals of care, and managing difficult conversations via telehealth platforms.
214370448|NCT04660422|OTHER|ACP Decisions Video Program|All clinicians will also be trained remotely on the ACP Decisions Video Program using the ACP app. Training will instruct clinicians on how to: 1. Introduce the COVID-19 videos to patients and caregivers; 2. Select the appropriate video(s) from the entire suite according to patients' needs; and, 3. Prescribe videos for patients and caregivers using the electronic platform. The suite of ACP videos is designed to address common ACP decisions confronting patients at risk or with COVID-19 and the caregivers.
214370449|NCT04660422|OTHER|Intervention training:|Training will instruct the clinicians on how to: i. more effectively communicate with patients regarding COVID- 19, ii. have ACP conversations with patients, iii. introduce the videos to patients and families, iv. use the videos as an adjunct to ACP counseling by clinicians, v. select the appropriate video(s) from the entire suite as according to patients' needs, and, vi. use the app or electronic platform for prescribing videos to be seen at home (telehealth visits), or to be viewed in clinic with an iPad.
214493605|NCT06623370|OTHER|Saline (NaCl 0,9 %) (placebo)|Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
214493606|NCT06619574|DEVICE|3D Analysis Group|Dental Compass and Dental Compass software used for therapeutic splint fabrication
214493607|NCT06619574|OTHER|Manual Analysis Cohort|Manual methods used for therapeutic splint fabrication
214985237|NCT04931342|DRUG|Cyclophosphamide|Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
214985238|NCT04931342|DRUG|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle
214985239|NCT04270838|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 1x10\^10 and 5x10\^10
214985240|NCT04270838|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units
214370450|NCT04660422|OTHER|Medical Record Review|13,000 (total) patients aged 65 or older for our primary (completed advance care plans) outcome. ACP can include designating a health care proxy, discussion of advance directives, goals-of-care discussions, CPR discussions, palliative care discussions and referrals, as well as hospice. Each of these ACP outcomes will also be compared in secondary analyses using NLP. These data will be obtained from the EHR. All patient participants will only be included for medical record review.
214985241|NCT06973863|DRUG|PEP08|PEP08 is an oral, potent, MTA-cooperative PRMT5 inhibitor.
214681562|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability|The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.
214681563|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability of healthy subject|The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
214985242|NCT05948579|DRUG|Intervention B Vilazodone Hydrochloride (HCl)|Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
214493608|NCT06783777|DEVICE|Esophageal pressure monitoring|Esophageal pressure and Tracheotomy tip pressure were measured simultaneously in patients with off-line tracheotomy to verify the correlation
214985243|NCT05948579|DRUG|Intervention B Placebo|A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
214985244|NCT01316718|DRUG|Mesalazine|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
214985245|NCT01316718|DRUG|Placebo|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
214985246|NCT02970383|BEHAVIORAL|Initial prescription for 10 narcotic tabs|Reduced number of pills in initial prescription post-operatively
215088985|NCT07040813|DRUG|CGRP mAbs and onabotulinumtoxin A|CGRP mAbs given subcutanously every 4th week and onabotulinumtoxin A 155 given once intramuscularly according to adjusted PREEMPT protocol in the 12 week period of study intervention.
215088986|NCT07040813|DRUG|CGRP mAbs and placebo|CGRP mAbs given subcutanously every 4th week and placebo once intramuscularly according to adjusted PREEMPT protocol in the 12 week period of study
215088987|NCT07040280|DRUG|Sulforaphane (broccoli sprout extract)|Sulforaphane - Three tablets of Avmacol® Extra Strength \[Nutramax\] by mouth, once daily, for 12 months.
215088988|NCT07040280|DRUG|Placebo|Three tablets by mouth, once daily, for 12 months
215088989|NCT07040280|DEVICE|Derma-AI|Photographs of lesions as part of the clinical exam at baseline, three (3) months, and twelve (12) months. These photographs will be submitted for assessment by a software called Derma-AI, which tracks moles over time for changes in size, number, and appearance
214370451|NCT05739669|DEVICE|EEG recording with the comparator device Micromed Brain Quick|Each patient will undergo a visit in a clinic, during which a 15 minutes long EEG trace with a CE-certified wet electrode EEG Device (Micromed Brain Quick) will be recorded by specialized staff.
214370452|NCT05739669|DEVICE|"EEG recording with the investigational device Atlas with dry electrodes clinic/specialized staff"|"During the same visit when the wet electrode EEG is recorded, the patient will be subjected to a second 15 minutes long EEG recording with the investigational device Atlas with dry electrodes, which will be conducted by specialized staff"
215088990|NCT07040982|DRUG|Asciminib|Given PO
214370453|NCT05739669|DEVICE|"EEG recording with the investigational device Atlas with dry electrodes home/lay people"|"The patients will record their own EEGs at home daily for 14 days, using the investigational device Atlas with dry electrodes"
214370454|NCT02222480|DRUG|Fimasartan|
214370455|NCT02222480|DRUG|Hydrochlorothiazide|
214370456|NCT02222480|DRUG|Placebo|
214370457|NCT06303154|DEVICE|Mobiderm Intimate Bra group|At the conclusion of the surgical operation, MOBIDERM Intimate bra will be placed on the patient by the medical team. It will be recommended for the patients to wear MOBIDERM Intimate Bra during day and night for 3 weeks after the surgery, and as much time as the patients tolerate the device during the rest of the study, until 6 months after radiotherapy
214493609|NCT06783777|DEVICE|Tracheotomy tip pressure|Esophageal pressure and tracheotomy tip pressure were measured simultaneously in patients with off-line tracheotomy to verify the correlation
214370458|NCT06135311|DEVICE|Pulse Width 260us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 260us, intensity setting to patient's tolerance, duration 30 days
214370459|NCT06135311|DEVICE|Pulse Width 50us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 50us, intensity setting to patient's tolerance, duration 30 days
214493610|NCT06854575|DIETARY_SUPPLEMENT|Dietary Supplement|Oral dietary supplement
214493611|NCT06854575|OTHER|Placebo|Placebo pill
214493612|NCT02405169|DEVICE|4 vs 6 implant treatment in the maxilla|
214370460|NCT01641263|BEHAVIORAL|Sleep Education Therapy|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
214370461|NCT01641263|BEHAVIORAL|Cognitve Behavioral Therapy for Insomnia|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
214370462|NCT00150774|DRUG|Levetiracetam|
214370463|NCT02163590|OTHER|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
214493613|NCT05686668|OTHER|assessment by scales|Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2
214493614|NCT06893367|DEVICE|IMU and RealSense Cameras|Each participant will perform the FMA-sens, with their most affected hand, followed by the FMA-sens with the less affected hand.
214681564|NCT03938376|DIAGNOSTIC_TEST|Micro-Ultrasound guided biopsy|High-resolution imaging device
214681565|NCT00695084|BEHAVIORAL|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
214985247|NCT02970383|BEHAVIORAL|Inital prescription for 30 narcotic tabs|
214985248|NCT02121210|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
214681566|NCT01518608|DRUG|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|"Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.~Pentothal 4mg/kg Rocuronium 0.6 mg/kg"
214681567|NCT06410781|OTHER|Radial Extracorporeal Shockwave|Treatment procedure will be initiated by palpation to locate the painful area around the lateral femoral condyle and the lateral side of the thigh. The therapist uses the principle of clinical focusing where the patient guides the therapist to the most painful area. The area will be treated in a circumferential pattern, starting at the point of maximum pain. At each of the session a total of 4600 pulses will be applied. RESWT will start with 500 pulses at (2 Bar) with the frequency of 15 Hz to the lateral femoral condyle to adjust to treatment.An additional 2000 pulses will be applied at (2- 4 Bar), 15 Hz, depending on pain tolerance. in addition,stretching exercise, manual therapy, and ultrasound on the iliotibial band.
214370464|NCT02163590|OTHER|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
214370465|NCT02163590|OTHER|Placebo|Intervention that mimics the experimental procedures
214370466|NCT04437420|DRUG|injection of BEP 800|injection of BEP 800
214370467|NCT04437420|OTHER|Control|no injection of BEP 800
214370468|NCT00673062|DRUG|SCH 900538|(4X50mg Capsules)
214370469|NCT00673062|DRUG|Pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
214370470|NCT00673062|DRUG|Placebo Capsules|Placebo
214370471|NCT02481284|DEVICE|Laser Doppler perfusion imaging|LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
214985249|NCT01356420|DIETARY_SUPPLEMENT|Cholesterol supplementation|Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
214985250|NCT02664675|PROCEDURE|Crown lengthening|After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.
214985251|NCT02664675|PROCEDURE|Open Flap Debridement|"After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.~Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap."
214985252|NCT02642705|OTHER|High intensity interval training N|Exercise training and ambient air breathing
214985253|NCT02642705|OTHER|High intensity interval training H|Exercise training and hypoxic breathing
214681568|NCT06410781|OTHER|traditional therapy|the patients will receive traditional therapy in the form of stretching exercise, manual therapy and ultrasound on iliotibial band.
214985254|NCT02642705|OTHER|Constant load exercise training N|Exercise training and ambient air breathing
214370472|NCT01514214|DEVICE|WInged perimeter biliary stent insertion (Viaduct)|Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
214985255|NCT02642705|OTHER|Constant load exercise training H|Exercise training and hypoxic breathing
214985256|NCT02642705|OTHER|Hypoxic conditioning at rest|Hypoxic breathing at rest
214493615|NCT06889519|BEHAVIORAL|MBT Lighthouse Parenting Program|Lighthouse Parenting Programme, a 12-week intervention for parents, focusing on enhancing mentalizing abilities. It includes weekly group sessions (2hrs) led by 3 trained MBT psychotherapists for 8-12 parents, and fortnightly individual parenting sessions (1hr) with a practitioner. The programme, rooted in Mentalization-Based Treatment (MBT) skills, explores parents mentalizing and their childrens mentalizing and attachment styles through a variety of interactive methods, including multimedia resources and creative activities to stimulate mentalizing. Central to the programme is the metaphor of the parent as a lighthouse, guiding their child. Training for practitioners spanned 4 days, covering MBT and Lighthouse Parenting skills, with an emphasis on experiential learning and self-reflection. Ongoing weekly group supervision will ensure the quality and fidelity of the intervention. Delivered in person at University Diego Portales.
214493616|NCT06889519|BEHAVIORAL|Psychoeducational cards|They will receive weekly information on parenting in the first 3 years of life. They will have direct contact (via WhatsApp) with a child psychologist to ask questions about the material and to refer to specialized support if needed.
214985257|NCT02642705|OTHER|Normoxic conditioning at rest|Normoxic breathing at rest (placebo)
214985258|NCT04108078|BEHAVIORAL|Health Policy Plus (HP+)|HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility.
214985259|NCT04108078|BEHAVIORAL|Many Men Many Voices (3MV)|3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana.
215088991|NCT07040982|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215088992|NCT07040982|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214370473|NCT01514214|DEVICE|traditional polyethylene stent insertion (Cotton Huibregtse)|insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
214370474|NCT06240052|BEHAVIORAL|Conditioning and active avoidance paradigm (CAAP)|On day 1 subjects will undergo image viewing, fear conditioning, and avoidance learning. Subjects will be instructed to passively view the images from 3 categories on the screen, with 2 of the 3 categories being paired with a mild shock to the subjects' foot. Then they will see a picture of a button on the screen together with all three categories. If they press the button, they may prevent the shock from occurring. Pressing the button for one of the conditioned categories will prevent the shock from happening. Pressing the button to the other conditioned cue will not prevent the shock .Pressing the button to the third category does nothing. On day 2, subjects will be given $5 and will be told that they can press a button to avoid a shock. The number of times the button was pressed will be counted and if it is less than the number by another randomly selected participant then the participant will get to keep the money.
214370475|NCT06219889|BEHAVIORAL|Frequency of neurochecks|the frequency with which a patient is awakened to perform serial examinations
214370476|NCT05177510|DRUG|Mifepristone|Progestin Antagonist
214370477|NCT05177510|DRUG|Placebo|Placebo
215088993|NCT07040982|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215088994|NCT07040982|PROCEDURE|Echocardiography Test|Undergo echocardiography
214370478|NCT06229457|BEHAVIORAL|Girls PLAY program|Girls PLAY program (8-12 weeks) will include 1) a series of in-person sessions, led by Boys and Girls Clubs staff at the Boys and Girls Club sites, and 2) take-home activities. In-person sessions (60-75 min; 2-3x/week) will center around a different developmentally appropriate sport each week. Lesson plans will outline games/activities in which youth engage in fundamental, sport-specific movement skills. Lesson plans will be delivered by Boys and Girls Club leaders using acts of instruction derived from Self-Determination Theory. Take home activities will 1) summarize and add on to the week's in-person sessions and 2) be adapted for delivery by parents and/or self-guided participation by youth. Take-home activities will provide information for engaging in the past week's activities as well as additional activities that parents and youth can participate in together.
214493617|NCT06887855|PROCEDURE|Neuromuscular Electrical Stimulation|NMES is a modality for stimulating muscles through electrical pulses, is used widely in the rehabilitation of stroke patients with pharyngeal dysphagia. It reinforces the strength of the muscles for swallowing and smooths the swallowing reflex through sensory stimulation. Clinically, NMES is applied to depolarize nerve fibers at the point of engagement, involving muscle contraction (Park et al. 2019). NMES includes the placement of electrical stimuli to the skin around the face and neck through surface electrodes. Stimulation intensity can be diverse depending on the treatment objectives. Low-intensity (sensory) NMES lets patients feel the tingling sensation on the skin, whereas high-intensity (motor) NMES can stimulate muscle contractions (Cheng et al. 2022).
214493618|NCT06887855|PROCEDURE|Neuromuscular Taping|NMT is similar to kinesiology taping but specifically focuses on neuromuscular re-education and it is a commonly used therapy approach for various neuromuscular problems. The neuromuscular tape can be easily applied to skeletal muscles to induce or inhibit muscle activity and to support the stabilization of structures such as joints and ligaments. The elasticity and adhesion properties of NMT can be used to restrain the anterior-upward movement of the hyolaryngeal complex during spontaneous swallowing. This effect increases the load on the suprahyoid muscles and consequently, the patient spends more effort to overcome this movement while swallowing. Resistance exercises provided with NMT activate the suprahyoid muscle and contractions for the muscles of the tongue.
214985260|NCT04108078|BEHAVIORAL|HIV Education, Empathy and Empowerment (HIVE3)|The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana.
214985261|NCT04609514|DEVICE|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
214985262|NCT04609514|BEHAVIORAL|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
214985263|NCT04609514|DRUG|Nicotine patch|All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
214985264|NCT04609514|BEHAVIORAL|Smartphone coaching|All participants will partake in over-the-phone smartphone coaching lead by the PI or a research assistant. This will be a time for participants to bring up any technical issues they are experiencing with the study smartphone or app.
214985265|NCT04054401|DEVICE|DRG Neurostimulation with Spinal Fusion|Surgeons will implant a neurostimulator during the same open back procedure as fusion devices (spinal fusion hardware and interbody cage) and begin neurostimulation in a short time following surgery (24 hours).
214985266|NCT00909870|DEVICE|Dermagraft(R)|Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
214985267|NCT00909870|DEVICE|Profore|Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
214985268|NCT03070873|DEVICE|Perigee and Apogee Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
214985269|NCT03070873|DEVICE|Gynecare Prolift Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
214985270|NCT03070873|PROCEDURE|Traditional Surgery|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
214985271|NCT02923765|OTHER|Aerobic training by a stepper|Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
214985272|NCT00000320|DRUG|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
214985273|NCT02590458|PROCEDURE|Short Breast MRI (SBMRI)|One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.
214985274|NCT02590458|BEHAVIORAL|Questionnaire|After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
214985275|NCT01316575|DEVICE|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
214985276|NCT01316575|DEVICE|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
214985277|NCT00943436|OTHER|Exercise Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Exercise Session will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
214985278|NCT00943436|OTHER|Rest Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Rest Session will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
215088995|NCT07040982|OTHER|Survey Administration|Ancillary studies
214985279|NCT05830760|BIOLOGICAL|Myocardium biopsy|The expression of SGLT2 on small myocardium specimens harvested during aortic valve replacement operation in patients with aortic stenosis
214493619|NCT06887855|PROCEDURE|Swallowing exercise (Expiratory Muscle Strength Training)|IN EMST the patients blow into a one-way spring-loaded apparatus calibrated to a percentage of maximum expiratory pressure until the valve opens with adequate effort. Four to eight weeks of EMST exercises increased the maximum expiratory pressure (MEP), maximum hyoid displacement, suprahyoid muscle action, and swallowing safety in patients with amyotrophic lateral sclerosis, stroke, and neck cancer.
214985280|NCT02102555|DRUG|IV acetaminophen|Single dose of one gram of IV acetaminophen given in pre-operative area
214985281|NCT02102555|DRUG|placebo|placebo (IV normal saline)
214985282|NCT00053625|PROCEDURE|deep brain stimulation|Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
214985283|NCT03728569|OTHER|Vanicream Moisturizing Skin Cream|Vanicream Moisturizing Skin Cream daily application
214985284|NCT03728569|OTHER|Vanicream Cleansing Soap|Vanicream Cleansing Soap daily use
214985285|NCT03137810|PROCEDURE|placental cord drainage|"In the study group a of total number of 90 women placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.~Blood loss in the third stage will be measured using a Kelly's pad which will be used during delivery and the blood lost will be collected in a clean metal bowl which will be kept at the tail end of Kelley's pad."
214985286|NCT03137810|PROCEDURE|non placemtal cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
214985287|NCT01565213|BEHAVIORAL|CBT|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
214985288|NCT01565213|BEHAVIORAL|MMI|group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
214985289|NCT01565213|BEHAVIORAL|CAU|Care as usual by the GPs
214985290|NCT01232283|DRUG|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
215088996|NCT07040618|PROCEDURE|Ultrasound-guided Rhomboid Intercostal Block|This intervention involves an ultrasound-guided injection of 20-25 mL of 0.25% bupivacaine into the fascial plane between the rhomboid major and intercostal muscles. The patient is positioned laterally, and the block is performed at the T5-T6 level using a high-frequency linear ultrasound probe. The goal is to anesthetize the lateral cutaneous branches of the intercostal nerves to provide postoperative thoracic analgesia.
215088997|NCT07040618|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|This intervention consists of an ultrasound-guided injection of 20-25 mL of 0.25% bupivacaine into the plane deep to the erector spinae muscle at the T4-T5 transverse process level. The patient is positioned sitting or in lateral decubitus, and the procedure uses a curved or linear ultrasound probe. This block targets the dorsal and ventral rami of thoracic spinal nerves to manage postoperative pain after thoracotomy.
215088998|NCT07041138|BEHAVIORAL|cognitive behavioural programme with physical training|Participants will receive 7 sessions of cognitive behavioural programme over 8 weeks and have physical training at home for 8 weeks.
215088999|NCT07041138|BEHAVIORAL|health education with physical training|Participants will receive 7 sessions of health education over 8 weeks and have physical training at home for 8 weeks.
214370479|NCT03938454|DRUG|Crizanlizumab|Crizanlizumab is a concentrate for solution for infusion, IV use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
215089000|NCT07041138|BEHAVIORAL|Usual Care|Participants will maintain their usual life and activities for 8 weeks.
214370480|NCT05954156|OTHER|Injectable restorative resin composite|The introduction of injectable composites, according to available literature, offers a simple and efficient solution for the cementation of veneers. This versatile, injectable restorative composite unites easy handling, high physical properties and excellent aesthetics. Generally used as a restorative material, it can also be used for the cementation of veneers and some inlays/onlays, thus considered as good alternative to preheated composite. (Alajrash MM et al., 2020)
214370481|NCT05954156|OTHER|Dual cured resin cement|Resin cements are widely used due to their strong adhesion, and compatibility with various restorative materials, including ceramics and zirconia. They bond to enamel and dentin through functional monomers such as MDP, and 4-META, forming a stable hybrid layer. Based on their bonding mechanism, resin cements are classified as adhesive or self-adhesive, while their polymerization method -chemical, light, or dual-cure-allows for versatility in clinical applications
214370482|NCT05438030|DIAGNOSTIC_TEST|Cardiac MRI scan|Undertaken at the radiology department at Hammersmith Hospital. The scan will be performed by the MRI radiographers, under the supervision of a consultant radiologist or cardiologist.
214370483|NCT05438030|DIAGNOSTIC_TEST|Echocardiogram scan|Undertaken at the Peart Rose research unit, by a British Society of Echocardiography accredited sonographer.
214370484|NCT03354728|OTHER|Laboratory Biomarker Analysis|Correlative studies
214370485|NCT03354728|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
214370486|NCT06326710|BEHAVIORAL|mHealth|"Participants receive 4 sessions of face-to-face or online delivered workshop on how to use the mobile app Outdoor Rehab-Fit to support their daily PA level. In addition to the workshop, participants have to go to public parks to practice what they have learnt from the mobile app."
214370487|NCT06326710|BEHAVIORAL|Health Talk|Participants receive 4 sessions of face-to-face or online delivered health talks on the benefits different types of modified exercises for frail older adults (chair yoga, seated eight-section brocades, Otago and seated multi-component exercise). Each talk has an experiential session.
214370488|NCT01142388|BIOLOGICAL|Cixutumumab|Given IV
214370489|NCT01142388|OTHER|Laboratory Biomarker Analysis|Correlative studies
214370490|NCT01142388|DRUG|Paclitaxel|Given IV
214370491|NCT01142388|OTHER|Pharmacological Study|Correlative studies
214370492|NCT06051539|DEVICE|MR-001|MR-001 is an autonomous neurorehabilitation system based on the principles of Rhythmic Auditory Stimulation intended to improve walking and ambulation in adult chronic stroke patients. MR-001 is intended to be a prescription use only device for use at home/community. The user operates the MR-001 System autonomously and the therapy progresses automatically once a user engages in a session. The MR-001 system consists of two foot sensors that measure walking, a touchscreen device preloaded solely with a proprietary software application, a headset, and charging equipment. The electronic components are powered by lithium-ion rechargeable batteries. Participants are asked to walk with the device for 3 times per week for 12 weeks. Each walking session is 30 minutes in length.
214985291|NCT01232283|DRUG|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
214985292|NCT01232283|OTHER|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (\< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
214370493|NCT00877578|DIETARY_SUPPLEMENT|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
214370494|NCT00877578|DIETARY_SUPPLEMENT|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
214370495|NCT06053814|DRUG|NS-050/NCNP-03|NS-050/NCNP-03 solution for IV infusion.
214370496|NCT06053814|DRUG|Placebo|NS-050/NCNP-03 placebo-matching solution for IV infusion.
214493620|NCT06887855|PROCEDURE|Swallowing exercise (Chin Tuck Against Resistance)|CTAR exercise is performed by an inflatable 12 cm rubber ball. The patients are directed to sit upright on a chair and hold the rubber ball between the base of the chin and the manubrium sterna. This exercise is composed of isometric and isotonic movements. The isometric movement will be performed for 10 seconds, whereas the isokinetic movement will be successively repeated 10 times to strengthen the suprahyoid and infrahyoid muscles (Kagaya \& Inamoto, 2022).
214493621|NCT06688903|BEHAVIORAL|App-based diabetes management and community-based health coaching|All participants will use the EMPOWER+ app and a Fitbit wearable. They will also received community-based health coaching and/or other prescribed structured programmes.
214493622|NCT06687941|DRUG|AST-201|AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.
214985293|NCT01226329|BEHAVIORAL|Right Question Project - Mental Health (RQP-MH)|"The RQP-MH trainings each take approximately 45 minutes to complete and are delivered approximately three weeks apart. The manualized intervention uses a Question Formulation Technique (QFT) and a Framework for Active Decision-Making (FADM). The QFT consists of asking patients to generate and revise questions to obtain more informative answers from their providers. The FADM teaches participants to identify questions that will help them consider their role in a decision, the process of decision-making, and the reasons behind a decision. All intervention sessions will be taught by a bachelors-level Care Manager."
214370497|NCT03592225|BEHAVIORAL|Educational workshop|the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
214493623|NCT06751303|OTHER|Patients that are HRP are given a decision aid for PARPi use|Study created patient decision aid if the first for HRD tested Ovarian Cancer patients
214493624|NCT00319020|DRUG|Bosentan|32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
214493625|NCT06877559|OTHER|balloon-assisted enteroscopic treatment for phytobezoar|The endoscopists applied balloon-assisted enteroscopy for the treatment of the phytobezoar
214493626|NCT06819059|BEHAVIORAL|Pediatric Cardiac Telerehabilitation|The program was entirely virtual except for pre and post program cardiopulmonary exercise testing. Patients were provided a stationary bicycle, hand weights, and resistance training bands. They exercised over zoom with a physical therapist or exercise physiologist weekly and were also asked to exercise independently 2x per week. Electrocardiograms (ECGs) were provided to the patients as a single lead monitor and results were shared with the study team after each session or during sessions if the patient reported symptoms. Compliance and activity data were recorded using Fitbit activity trackers.
214985294|NCT01226329|BEHAVIORAL|Pamphlet|"Participants in this group receive a handout called Managing Your Mental Health (available in Spanish and English) that provides tips on how to manage mental health through the proper maintenance of physical health and stress."
214985295|NCT04534751|BIOLOGICAL|Fibrinogen + PCC|"Patients randomized to the intervention group will receive 4g of Fibryga and 2000 IU Octaplex will be released as part of the first and second MHP packs, if requested.~If a third MHP pack is required, and thereafter, FC will be administered if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units)."
215089001|NCT07041476|OTHER|Exercise|Tele-rehabilitation methods can provide an important advantage for patients who cannot receive hospital services due to pain, mobility limitations, and distance to the hospital
214370498|NCT01960595|PROCEDURE|IV fentanyl PCA|
214370499|NCT01960595|PROCEDURE|local bupivacaine infiltration and post-OP IV fentanyl PCA|
214370500|NCT01960595|PROCEDURE|Nerve Blocks and post-OP IV fentanyl PCA|
214370501|NCT00286000|DRUG|Administration of high dose simplified folfiri|
214370502|NCT03027414|DRUG|Transcranial Magnetic Stimulation Sham|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
214370503|NCT03027414|DEVICE|Transcranial Magnetic Stimulation|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
214370504|NCT02200263|DIETARY_SUPPLEMENT|Lutein plus Zeaxanthin|dose: two softgels once a day with a meal
214370505|NCT02200263|DIETARY_SUPPLEMENT|Placebo|two softgels once-daily with a meal
214681569|NCT01829035|OTHER|Conventional Transarterial Chemoembolization (cTACE)|"Concurrent use of the following material/drug is defined as cTACE in this trial.~* Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~* Anti-tumor drug:~  1. Unapproved drug/embolization material from each regulatory agency should not be used.~ 2. To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"
214370506|NCT05064787|BEHAVIORAL|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
214370507|NCT03007784|DEVICE|transcranial direct current stimulation (tDCS) / Comparison of current intensities|
214370508|NCT04117269|DEVICE|External shoe lift|Height compensation will be made with cork or EVA (polyurethane + Ethylene Vinyl Acetate) depending the characteristics of the shoe. It will be made by the same orthophaedic technician. The prescription of the heigh of the lift will be made with the patient in a barefoot standing position, a calibre will be used to mark the femoro-tibial joint in both lower limbs in order to rule out the asymmetry. After this, the patient will shod the offloading device in the ulcerated feet and their conventional footwear in the other foot (with the use of their own foot orthosis). 5 millimeters splints will be added under the non affected footwear until the previous mark in both limbs been balanced. The difference in the heigh between limbs will be assessed measuring all the splints used previously
214370509|NCT06178783|DRUG|Brensocatib|Brensocatib oral solutions will be expectorated following the tasting.
214370510|NCT01936896|DRUG|Alpha 1-Antitrypsin|
214370511|NCT04244396|DEVICE|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)|TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.
214370512|NCT05286944|OTHER|Mobile phone alarm reminder|Patients are reminded to take their INCS using a mobile phone alarm set to ring daily
214370513|NCT05794555|BEHAVIORAL|Enhanced Usual Care|Patients will be provided and counseled on two methods which will enhance care. The first is a handout on nutrition recommendations and protein supplementation. This will include the recommendation of both high protein snacks during the daytime (e.g., protein bars) and a high-protein night-time snack (e.g., peanut butter and crackers). The second will be to counsel participants on falls prevention methods that can be enacted in day-to-day life. All participants will be provided with a standard hand-out of Centers for Disease Control and Prevention (CDC)-endorsed fall-risk reduction measures.
214493627|NCT06819059|BEHAVIORAL|Fitness Tracker Only|Control participants were provided fitness trackers and weekly text messaging from the study team to synch their devises but no formal exercise training. They were allowed to enroll in the exercise training after completing 3 months as a control.
214493628|NCT00227266|DRUG|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
214493629|NCT00227266|DRUG|Placebo|
214493630|NCT04584983|DRUG|usual prescribed intralipid (UL) regimen|Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
214493631|NCT04584983|DRUG|restricted prescribed intralipid (RL) regimen|Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
214493632|NCT05971602|DRUG|Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)|D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
214985296|NCT04534751|BIOLOGICAL|Frozen Plasma|"4U FP will be released as part of the first and second MHP packs.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units).~Patients randomized to the control group may receive FC if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods. FC dosing in MHP packs 3 and above will be site-specific and at the discretion of the treating clinician."
215089002|NCT07041476|OTHER|telemedicine|Tele-rehabilitation will be achieved through a video conference (VC) via the internet platform Zoom at the time and day 29 decided upon with the therapist
214370514|NCT05794555|DRUG|Lactulose|"Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2."
214493633|NCT05971602|DRUG|Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)|P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
214493634|NCT05971602|DRUG|Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)|Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
214493635|NCT05971602|DRUG|Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)|X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration
214493636|NCT05971602|DRUG|Isoniazid and Rifampicin (HR)|Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
214370515|NCT05794555|BEHAVIORAL|Investigator recommended exercise|Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.
214370516|NCT05794555|BEHAVIORAL|TeleTai-Chi (virtual)|TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.
214370517|NCT02597907|DRUG|aprepitant|aprepitant 80 mg is given to all patients before surgery
214370518|NCT02597907|DRUG|palonosetron|palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
214681570|NCT00166010|DRUG|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
214681571|NCT00679159|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
214681572|NCT00679159|BIOLOGICAL|Prevenar|Streptococcus pneumoniae vaccine
214681573|NCT02013024|OTHER|cryopreservation technique|
214681574|NCT03397797|DRUG|Rocuronium|In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
214681575|NCT04419064|DIAGNOSTIC_TEST|Point of care ultrasound|Tracheal and lung ultrasonography
214681576|NCT02433288|OTHER|Smart phone based patient support tool|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
214681577|NCT02433288|OTHER|Control application: only for data collection|the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
214681578|NCT05858294|BEHAVIORAL|Cognitive Behavioral Therapy programme|This mobile application comprised CBT-based therapy for social anxiety based on the Clark and Wells model
214681579|NCT04314167|DRUG|Lowering cholesterol concentrations by PCSK-9 inhibitor|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
214681580|NCT01073956|PROCEDURE|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
214681581|NCT01073956|PROCEDURE|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
214681582|NCT01073956|PROCEDURE|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
214681583|NCT06504173|PROCEDURE|diced cartilage|In reconstructions using DC management of IMVES, the surgical nurse processed the removed cartilage into DC using a dermatome blade. Cartilage pieces of approximately 0,5-1 mm were used. After microvascular anastomosis (coupler device for venous anastomosis; Synovis MCA, Birmingham AL, USA), all DC was placed back into the rib removal zone using a blunt dissector. The vessels were embedded and stabilized in cartilage paste according to the desired orientation.
214681584|NCT03862079|OTHER|Best Practice|Given standard of care
214681585|NCT03862079|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
214681586|NCT03862079|DRUG|Nystatin|Given PO
214370519|NCT02597907|DRUG|Ramosetron|ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
214370520|NCT02063100|DRUG|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
214681587|NCT03862079|DRUG|Piperacillin-Tazobactam|Given PO
214681588|NCT00367640|DRUG|100 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
214681589|NCT00367640|DRUG|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
214681590|NCT00367640|DRUG|500 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
214681591|NCT00367640|DRUG|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
214681592|NCT05288634|OTHER|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
214681593|NCT01695057|DRUG|vorinostat|Given PO
214681594|NCT01695057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214681595|NCT01695057|OTHER|laboratory biomarker analysis|Correlative studies
214681596|NCT06641323|OTHER|Ozonized gel|Administration of Ozonized Gel GeliO3
214681597|NCT06641323|DEVICE|Ozonized water|Admininstration of Gaseous ozone (Healozone X4)
214681598|NCT02409784|DIETARY_SUPPLEMENT|Pre-KD|Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
214681599|NCT02409784|DIETARY_SUPPLEMENT|Post-KD|After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
214681600|NCT05808348|OTHER|Scales and questionnaires|"We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively."
214681601|NCT04362579|DEVICE|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing or in the home setting
214681602|NCT02812433|DRUG|Sildenafil|sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
214985297|NCT03181152|DIAGNOSTIC_TEST|Impulse Oscillometry|"1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result."
214985298|NCT02776566|OTHER|Patient Self-Monitoring vs Anticoagulation Clinic|"Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
215089003|NCT07040891|BEHAVIORAL|Just ASK training|"Just ASK™ is a web-based training designed to help providers understand the impact of assumptions about their patients' interest in cancer clinical trials. The training framework aims to increase clinical trial discussions with all cancer patients."
214985299|NCT05911217|DRUG|CT041 autologous CAR T-cell injection|Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion
214985300|NCT01219023|DRUG|sildenafil citrate|Subjects will be given 2 types of topical creams, one containing 1% sildenafil and one containing placebo control. Subjects will be randomized to apply sildenafil cream to either the right or left hand/foot; placebo cream will be applied to the opposite hand/foot. The cream will be supplied to subjects with proper labeling to indicate right and left application assignment. Cream will be applied to each affected hand/foot two times per day.
214985301|NCT04393649|OTHER|ESOGER|Questionnaire
214985302|NCT05906849|BEHAVIORAL|ACT for anxiety disorders|A twelve session Acceptance and Commitment Therapy (ACT) for anxiety disorders, applied individually and remotely (through videoconference) to participants fulfilling inclusion criteria (i.e., participants included in the SAD and GAD Experimental Groups).
214985303|NCT00402831|BIOLOGICAL|ProQuad®|Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
214985304|NCT02986464|DEVICE|Virtual Reality Prototype|VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
214985305|NCT02986464|OTHER|Standard Pharmacological Treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and the pain clinic nurse.
214985306|NCT06477978|DIAGNOSTIC_TEST|Hand grip function testing|The use of Bio-impedance to measure the skeletal muscle mass
214985307|NCT02483884|DRUG|[68Ga]RM2|\[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
215089004|NCT06887296|OTHER|women answer a questionnaire|Sexual Function and Distress Assessment in Women with Polycystic Ovary Syndrome (PCOS) Using Standardized Questionnaires
215089005|NCT07041827|DIAGNOSTIC_TEST|Cardiovascular assessment|A cardiovascular assessment will be performed to screen for (sub)clinical cardiovascular diseases and to compare the prevalences in survivors of non-Hodgkin lymphoma and a control group.
215089006|NCT07040631|DEVICE|Endotra Gel|Endotra Gel is a hyaluronic acid-based, water-soluble wound dressing gel approved by the Korean Ministry of Food and Drug Safety. In this study, it is applied to the cuff of the endotracheal tube before intubation to evaluate its effect on reducing postoperative sore throat and hoarseness.
215089007|NCT06721299|DRUG|Clenbuterol|Beta-Agonist
214370521|NCT02063100|DRUG|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
214370522|NCT02063100|DRUG|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
214985308|NCT02483884|PROCEDURE|PET/CT|Patients received \[68Ga\]RM2 undergo PET/CT 60 min p.i. for at least 20 min
214985309|NCT03662412|DRUG|Sirolimus|Oral solution of sirolimus, 2mg, once a day.
214985310|NCT03068104|OTHER|No intervention|
214985311|NCT02203266|DEVICE|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
214985312|NCT02203266|BEHAVIORAL|Education|Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
214985313|NCT04773028|OTHER|matrix metalloproteinase enzymes 2 and 9|concentration of matrix metalloproteinase 2 and 9 enzymes
214985314|NCT03122795|PROCEDURE|Microbiome transplant|A raw microbiome, collected from a donor without any sinonasal health problems, as a nasal lavage.
215089008|NCT06924177|OTHER|Telehealth with dietician|9 weeks of telehealth visit with dietician using the DPP diet modules
214370523|NCT02063100|DRUG|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
214985315|NCT03927170|COMBINATION_PRODUCT|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
214985316|NCT03927170|COMBINATION_PRODUCT|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
214370524|NCT02063100|DRUG|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
214370525|NCT01478711|OTHER|Clinical Decision Support Tool|A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
214370526|NCT01879423|DRUG|Lamotrigine Dispersible/Chewable tablets 5mg*5|Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15
214985317|NCT01725672|DRUG|Metformin, 500 mg extended release tablet|In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
214985318|NCT01725672|DRUG|Metformin, 1000 mg extended release tablet|In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
214985319|NCT01725672|DRUG|Glimepiride, 1 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
214985320|NCT01725672|DRUG|Glimepiride, 2 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
214985321|NCT01725672|DRUG|Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
214985322|NCT01725672|DRUG|Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
214985323|NCT01725672|DRUG|Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
215089009|NCT07041970|OTHER|Exergame|The training program will focus on strength and functional movements. It requires a Nintendo Switch console, a Ring-Con (a Pilates ring that the user holds or ring holder), wireless Joy-Con controllers (the right Joy-Con, connected to the Ring-Con; and the left Joy-Con, attached to the strap around the player's thigh) and a screen. In adventure mode, women will move through the game by performing physical activities such as jogging or doing squats. To minimize risk, knee-assist mode will be used, which makes the game more accessible. Activating knee assist mode provides support when women perform exercises that require walking, kneeling or squatting, making these activities easier for pregnant women, increasing the fitness benefits of the game. In battle mode women will perform aerobic activities, strength training and yoga exercises that involve the whole body to advance in the game.
214370527|NCT01879423|DRUG|Lamotrigine Compressed tablet 25mg|Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15
214370528|NCT04458584|PROCEDURE|Trapeziectomy with ligament reconstruction (I; LRTI)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)
214370529|NCT04458584|PROCEDURE|Trapeziectomy with suture suspensionplasty (II; SS)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)
214370530|NCT04458584|PROCEDURE|Arthroscopic Trapeziectomy (III; AT)|Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
214370531|NCT05464381|DRUG|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
214370532|NCT05464381|DRUG|Placebo|Placebo
214370533|NCT03897062|DRUG|Suvorexant 20 mg|Placebo controlled double blind suvorexant vs placebo
214370534|NCT03897062|OTHER|placebo|Placebo controlled double blind suvorexant vs placebo
214370535|NCT00926510|BEHAVIORAL|Language toolkit|Simple toolkit of interactive things to stimulate language.
214681603|NCT02812433|DRUG|Ora-Blend|Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
214370536|NCT00926510|BEHAVIORAL|Safety counseling|Smoke detector and general safety counseling
214370537|NCT04536246|PROCEDURE|Bone Quadriceps Tendon (BQT) arthroscopic-assisted ACL reconstruction|New intervention method deployed in Indonesia to gain better clinical outcome for ACL--deficient patients requiring surgical treatment
214370538|NCT04536246|PROCEDURE|Single-Bundle Hamstring Tendon (SBHT) arthroscopic-assisted ACL reconstruction|Comparator for New Reconstruction Technique
214370539|NCT04978714|PROCEDURE|Cystocele repair|Fascial repair for endopelvic fascia and anterior colporrhaphy
214370540|NCT05760157|OTHER|Possible risk factors of heart failure|Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.
214370541|NCT00335452|DRUG|Clopidogrel|oral administration
214370542|NCT00335452|DRUG|acetylsalicyclic acid (ASA)|oral administration
214370543|NCT06096480|PROCEDURE|gabapentin + bilateral spine erector block|preoperative, ultrasound-guided, bilateral ESP block (administration of a local anesthetic mixture of ropivacaine 0.375% and lidocaine 1%) and a 100mg dose of oral gabapentin 4 nights daily before surgery and 2 weeks postoperatively.
214370544|NCT01969422|PROCEDURE|observation|intervention is the contact with online question answering serice ad subseudd
214681604|NCT03982771|DRUG|Bortezomib|-Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
214370545|NCT02031367|DRUG|Triamcinolone Acetonide|Corticosteroid arm
214370546|NCT02031367|OTHER|Platelet Rich Plasma|Platelet Rich Plasma
214370547|NCT03486028|OTHER|Adherence to ASAM protocols|ASAM Counties. These counties are requiring their providers to use ASAM criteria to assess patients and to determine level of care. These counties also use ASAM to determine the ongoing need for high-intensity services, such as residential, and approve those services for Medicaid payment.
214985324|NCT01725672|DRUG|Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
214370548|NCT03486028|OTHER|Non-adherence to ASAM protocols|These counties are not implementing the ASAM criteria to assess patients and determine the level of care.
214370549|NCT03933475|DEVICE|Virtual reality game|Use of virtual reality games on television screens
214370550|NCT03088709|DRUG|Cyclophosphamide|IV medication given for prevention of graft versus host disease.
214370551|NCT03088709|DRUG|Tacrolimus|IV medication given for prevention of graft versus host disease.
214370552|NCT03088709|DRUG|Mycophenolate mofetil|IV medication given for prevention of graft versus host disease.
214370553|NCT03088709|OTHER|Haploidentical Stem Cell Transplantation|A stem cell transplant that involves matching a patient's tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related donor.
214370554|NCT01904864|DRUG|elemental iron (NovaFerrum®)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
214370555|NCT01904864|DRUG|elemental iron (Ferrous Sulfate)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
214370556|NCT01163643|DRUG|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
214370557|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
214370558|NCT01163643|DRUG|Placebo Comparator: Vehicle|Placebo Comparator: Vehicle BID for 12 weeks.
214370559|NCT01163643|DRUG|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
214370560|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension AM|2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
214370561|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension PM|Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
214370562|NCT01152775|OTHER|This group of patients will be exposed to multimedia|This group of patients will be exposed to multimedia
214370563|NCT01152775|OTHER|No Media|This group will not be exposed to multimedia
214370564|NCT03880630|OTHER|Inspiratory muscle training|Patients will perform 3 inspiratory loading tests (15%, 30%, and 50% of maximum inspiratory pressures) on 3 separate days with the sequence will be randomized. Patient will then be trained with individualized IMT program based on the results of 3 inspiratory loading tests.
214370565|NCT00959101|DRUG|repaglinide and metformin combination tablet|Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
214370566|NCT00959101|DRUG|repaglinide and metformin combination tablet|Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
214370567|NCT00959101|DRUG|repaglinide|Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
214370568|NCT00959101|DRUG|metformin|Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
214370569|NCT01719107|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 chewable tablets|2 chewable tablets with breakfast for 4 weeks
214370570|NCT01719107|DIETARY_SUPPLEMENT|Placebo chewable tablets|2 chewable tablets with breakfast for 4 weeks
214370571|NCT00691808|DRUG|LX6171 High Dose|A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
214370572|NCT00691808|DRUG|LX6171 Low Dose|A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
214370573|NCT00691808|DRUG|Placebo|Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
214370574|NCT06171230|OTHER|Eye Movement Desensitization and Reprocessing|Using the LEC and PCL-5, emotionally charged images are selected at the onset of the EMDR intervention. Initially, events meeting the criteria for PTSD (A-criterion worthy events) are processed. Subsequently, pain-related experiences, including any distressing images, are addressed. If the emotional charge of the events diminishes (SUD=0) before the completion of the six EMDR sessions, the participant is categorized as an 'early completer,' and the post-assessment is conducted immediately. The duration of each EMDR session is 90 minutes.
214370575|NCT06171230|OTHER|Attention control phase|Prior to EMDR, there is a two-week attention control phase. During this phase, the participant is asked to daily record their activities, emotions, and thoughts when experiencing pain. This information is further explored and evaluated in two sessions lasting 45 minutes each, involving in-depth discussions with the participant.
214370576|NCT05333406|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"
214370577|NCT05333406|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"
214370578|NCT03687190|BEHAVIORAL|Tai chi|participants were required to receive hospital-based Tai chi training at least once a month, and home-based Tai chi exercise at least three times a week over the next 9 months
214370579|NCT03687190|DRUG|conventional medicine|participants without Tai chi training still received routine conventional medicine
214370580|NCT02714855|DRUG|Apixaban|
214985325|NCT03553147|OTHER|SARC-F score, handgrip test and impedancemetry|Participation in the study will be offered to any patient admitted to the geriatric ward, those who meet the inclusion criteria and do not have exclusion criteria will have to complete the SARC-F questionnaire during their stay, and to do the handgrip test and impedancemetry performed by a third party. Biological data (albumin, pre-albumin and C-Reactive Protein) and anthropometric data will be collected and analyzed to determine if the patient is malnourished or not, and the results of SARC-F will be compared between these 2 groups.
214370581|NCT05516277|BEHAVIORAL|Behavioral Sleep Education Intervention|Manual-based education program focusing on behavioral sleep techniques provided in individual 60-minute sessions for 5 weekly sessions.
214370582|NCT03685838|OTHER|Compression Stockings|Class II above knee compression stockings
214370583|NCT02115867|DIETARY_SUPPLEMENT|Probiotic|Symprove probiotic
214370584|NCT01928966|OTHER|Pumpkin Seeds|Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
214370585|NCT03168568|DRUG|Valsartan/Sacubitril or placebo|tablet (double dummy)
214370586|NCT03168568|DRUG|Valsartan or placebo|tablet (double dummy)
214370587|NCT01750879|DRUG|Peanut Flour|Peanut Flour
214370588|NCT01750879|DRUG|Oat Flour|Oat Flour
214370589|NCT00809692|PROCEDURE|validated techniques for histamine response|the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
214370590|NCT00809692|PROCEDURE|new technique for histamine response|laser Dopper technique and genotyping
214370591|NCT05993702|DRUG|regorafenib|(TAS102): Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; (TKI: regorafenib: regorafenib capsules administered at a dose of 80 mg (2 tablets, each containing 40 mg regorafenib) once daily for a 28-day cycle)
214493637|NCT06765408|OTHER|facial yoga exercise program|An exercise programme consisting of basic yoga movements such as swan neck exercise, fist exercise, hand to head exercise, jowl drawer exercise, tongue and palate exercise, lip curling exercise, ceiling kissing exercise, namaste exercise, balloon inflation, spider and fish exercise, lip spray, Chinese moustache, binocular exercise, gaze exercises and lion pose was applied. Each session was approximately 30 minutes and all exercises were accompanied by breathing exercises on the basis of exercising all facial muscles. The exercise programme was performed for 8 weeks, 2 days a week face-to-face and 5 days at home, for a total of 16 sessions face-to-face and 40 sessions at home. Participants were given verbal, written and video explanations and instructions about the exercise protocol. Every day in a WhatsApp group where all participants take part, Assist. Prof. Dr. Hazel Çelik Güzel provided information and reminders and ensured the continuity of the exercises. Participants were al
214985326|NCT05354297|DEVICE|Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Expert guidance via coaching
214985327|NCT05354297|DEVICE|Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Fitness and wellness guidance
214985328|NCT05354297|DEVICE|Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Behavioral weight loss program
214985329|NCT05354297|DEVICE|Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app|Multi condition support
214370592|NCT05993702|DRUG|fruquintinib|TAS102: Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; or Fruquintinib: a dose of 3mg/dose administered orally once daily, continuously for 28 days as a cycle.
214370593|NCT00001785|DRUG|Recombinant human interferon beta-1a|
214370594|NCT00019058|DRUG|chemotherapy|
214370595|NCT00019058|DRUG|hydroxyurea|
214370596|NCT00019058|DRUG|pentoxifylline|
214370597|NCT00019058|RADIATION|radiation therapy|
214370598|NCT02421666|BEHAVIORAL|PNMI|Eligible patients received patient navigator led plus mobile phone text messaging intervention (PNMI) or standard care. Bilingually trained patient navigators were recruited from our existing patient navigator training network, received intensive training on HBV prevention, diagnosis and treatment management, and served as a liaison with respective clinical partners. The PNMI intervention offered three education sessions on HBV management and weekly CHB patient-designed educational phone-based text messages for five weeks.
214681605|NCT03982771|DRUG|Cyclophosphamide|-Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
214370599|NCT00455585|DRUG|nevirapine, stavudine, lamivudine|
214370600|NCT04976803|OTHER|Determination of ATM alteration status.|ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
214370601|NCT05877950|DEVICE|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
214370602|NCT05877950|OTHER|Home-based speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
214370603|NCT04647032|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4
214370604|NCT00317889|PROCEDURE|Bone preparation technique: compaction|
214370605|NCT00317889|PROCEDURE|Bone preparation technique: broaching|
214370606|NCT01041014|BEHAVIORAL|Professional medical interpreter|All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
214370607|NCT06153043|OTHER|Women patients with classical congenital adrenal hyperplasia|The Easily and Médifirst medical files of these patients will be studied in order to collect the desired variables. If the files are incomplete, and if data concerning fertility, pregnancy, and the characteristics of the newborn are missing, patients will be contacted to ask them to answer the questionnaire to obtain this information.
214681606|NCT03982771|DRUG|Dexamethason|Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
214681607|NCT05631327|DRUG|JZP341|JZP341 will be administered as a single, intravenous infusion over 2 hours.
214985330|NCT03043053|DRUG|oxytocin nasal spray|oxytocin intranasal spray
214985331|NCT03043053|DRUG|Placebo|Placebo nasal spray
214985332|NCT01577797|BEHAVIORAL|Text messages|Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
214370608|NCT00290602|DRUG|Methylprednisolone sodium succinate|
214370609|NCT05968222|OTHER|Vibration exercise|Each training session on the vibrating platform is composed of 6 exercises with a duration of 60 seconds with 60-second pauses between exercises and a warm-up exercise
214370610|NCT04424784|BIOLOGICAL|5% O2|5% oxygen will be used during oocyte retrieval, fertilization check and embryo grading
214370611|NCT03708588|DRUG|Ticagrelor|Chewed
214370612|NCT03708588|DRUG|Ticagrelor|Integral
214370613|NCT01722760|PROCEDURE|measurements|
214370614|NCT01936701|PROCEDURE|bilateral cataract surgery|same-day bilateral cataract surgery with implantation of intraocular lens
214370615|NCT02093663|DRUG|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.
214370616|NCT02093663|DRUG|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
214370617|NCT04009590|OTHER|Educational Intervention|Read educational booklet
214370618|NCT04009590|OTHER|Questionnaire Administration|Ancillary studies
214370619|NCT04009590|BEHAVIORAL|Smoking Cessation Intervention|Utilize Quit4Health
214370620|NCT00239564|DRUG|IPX054 100 mg|IPX054 containing 25 mg carbidopa and 100 mg levodopa
214370621|NCT00239564|DRUG|IPX054 150 mg|IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
214370622|NCT00239564|DRUG|IPX054 200 mg|CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
214370623|NCT00239564|DRUG|IPX054 250 mg|CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
214370624|NCT00239564|DRUG|IPX054 300 mg|CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
214370625|NCT06233643|DRUG|Phloroglucinol|The active comparators will be treated with 40 mg of Phloroglucinol in the form of a single intramuscular injection.
214370626|NCT06233643|COMBINATION_PRODUCT|Acupuncture Combined Intradermal Sterile Water|Acupuncture was applied to a seated patient using the urinary bladder meridian points and combianed Intradermal Sterile Water in costovertebral area where the patient's pain was located (Sterile water of 0.5 ml was injected as intradermal into 4 points at a depth of 1-3 mm to form papules)
214370627|NCT06130878|OTHER|Rhythmic exercise|"A multicomponent rhythmic physical training will be carried out, with a predominance of QMT, following the principles of Animal Flow \[46\] and including the following components: wrist mobilizations; activations; specific stretching positions; special locomotor movements or traveling forms; interruptions and transitions with dynamic movements and choreographic sequences of Flow. Aspects related to the control of intensity, volume and progression strategy have yet to be defined."
214370628|NCT04204369|OTHER|Ultrasound education curriculum|"Participants were enrolled in a musculoskeletal ultrasound course including 2 components:~* An online course (1-2 hours) to be done before the practical session. The videos were made available one (1) month prior to the practical course. This component reviewed the basics of ultrasonography, as well as the normal and abnormal appearance of relevant musculoskeletal structures (bone, tendon, ligaments, muscles, bursas, and nerves), and the ultrasound anatomy of high yield regions of the musculoskeletal system (shoulder, elbow, knee, ankle)~* A practical session (4-6 hours) done during one of the usual academic days of the orthopedic residency program. This session covered the use of the ultrasound; the examination of the shoulder, elbow, knee, and ankle; ultrasound-guided musculoskeletal injections and aspirations; and ultrasound-guided distal radius fracture reductions. Ample practice time was given to the residents using means such as phantom models, cadavers, and real patients."
214370629|NCT06386003|DRUG|Psilocybin|Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.
214370630|NCT03662074|DRUG|Gemcitabine|Given IV
214370631|NCT03662074|BIOLOGICAL|Nivolumab|Given IV
214370632|NCT02781948|DEVICE|Optical Coherence Tomography|
214681608|NCT03329040|OTHER|No Intervention.|No intervention.
214985333|NCT00808223|BIOLOGICAL|alefacept|IM injection
214985334|NCT04405752|DEVICE|12-mm metallic biliary stent|Metallic biliary stent, covered or uncovered,KEBOMED HILZO 12mm in diameter (length 4 or 6 cm).
214370633|NCT00846638|BEHAVIORAL|Brief Intervention|Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up
214370634|NCT00846638|BEHAVIORAL|Diagnostic assessment|Single session diagnostic assessment with 12 month followup
214370635|NCT01566331|DEVICE|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
214370636|NCT03090867|OTHER|Relatives or surrogates are encouraged to perform care|"The relative or surrogate will perform at least two cares a week among feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~The relative or surrogate will give his opinion by completing the study questionnaires."
214370637|NCT03090867|OTHER|Conventional ,care|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
214370638|NCT06362980|DRUG|BPI-1178|200 or 300 mg, oral, QD
214370639|NCT06362980|DRUG|Osimertinib|80mg, oral, QD
214681609|NCT01512641|OTHER|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
214681610|NCT01512641|OTHER|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
214681611|NCT04279912|DEVICE|Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis|The intervention is MRIgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
214985335|NCT04405752|DEVICE|10-mm metallic biliary stent|Biliary, metallic, covered or uncovered stent, COOK EVOLUTION 10mm in diameter (length 4 or 6 cm)
214985336|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of nominal strength|Sodium Chloride (0.9%)
214985337|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of low strength (upper limit)|Sodium Chloride (0.9%)
214985338|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of low strength (lower limit)|Sodium Chloride (0.9%)
214985339|NCT01535924|DRUG|gemcitabine hydrochloride|Given IV
214985340|NCT01535924|DRUG|bendamustine hydrochloride|Given IV
214370640|NCT03685396|BIOLOGICAL|Platelet rich fibrin ( PRF)|"Venous blood was collected with a butterfly needle in two 10 mL tubes without anticoagulants or other chemicals. The tubes were immediately centrifuged at 3000 rpm for 10 minutes.~At the end of centrifugation a fibrin clot (PRF) was obtained in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. The PRF clot was taken from the tube and the red cells portion at the base of the clot was eliminated with sterile scissors Then the PRF was enveloped in sterile gauzes and positioned between two glass plates: the compression drove out the serum from the clot obtaining PRF membranes that were ready to be used in the surgical site."
214370641|NCT03685396|DRUG|hemostatic agents with oxidized and regenerated cellulosa|In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
214370642|NCT05177445|COMBINATION_PRODUCT|Phototherapy|"Prior to the beginning of the procedure the patient will be administered a nasal decongestant. Second to this, the patient will be advised to blow his/her nose. This step allows the physician a better view and allows the light exposure to reach the majority of the nasal mucosa(9).~To start the intervention the physician will introduce the phototherapy device inside the patient's nasal cavity as the patient sits in an upright condition. As the procedure is ongoing the physician will slightly rotate the device in order to minimize dryness and to irradiate all the nasal cavity. After the intervention the patient will be administered an emollient/moisturizing drug to further hydrate the nasal mucosa(9).~The intervention will have a crescent duration, the first one will be only two minutes and the following ones will increase 15 seconds each until a plateau is reached at 3 minutes in the 5th intervention."
214370643|NCT05177445|COMBINATION_PRODUCT|OT+Corticosteroids|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
214370644|NCT00148382|DRUG|ATL-962|
214370645|NCT01422135|DRUG|AG200-15|A transdermal contraceptive delivery system for levonorgestrel (LNG) and ethinyl estradiol (EE). . A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
214370646|NCT02295566|DRUG|Nitric Oxide|Not required
214370647|NCT02295566|DRUG|Control|Not required
214370648|NCT04786314|OTHER|Hot Water Application|Pregnant women will apply hot water to their legs before going to sleep for a week.
214370649|NCT04786314|OTHER|Cold Water Application|Pregnant women will apply cold water to their legs before going to sleep for a week.
214370650|NCT02162680|DRUG|1% lidocaine|
214370651|NCT02162680|DRUG|bacteriostatic normal saline (BNS)|
214370652|NCT04836221|BEHAVIORAL|Support|"Community Health Workers will conduct weekly phone calls to monitor blood pressure or blood glucose, to check in on patient need for social, practical or emotional supports, and to encourage healthy lifestyle modification.~Participants will also have access to a mobile app to support chronic disease management (Either diabetes or hypertension)."
214370653|NCT02809144|PROCEDURE|Nerve block|Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
214370654|NCT00705302|BEHAVIORAL|Group training with self-help group|Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
214370655|NCT00705302|BEHAVIORAL|Group training|Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
214370656|NCT05343338|DRUG|Sivelestat sodium|After dissolving sivelestat sodium with 0.9% sodium chloride injection, dilute the 1-day dose (4.8 mg/kg) with 50 mL of 0.9% sodium chloride injection and continue intravenously at a rate of 0.2 mg/kg/h for administration. The start time of administration was after induction of anesthesia, and at the same time, the extracorporeal circulation circuit is prefilled with 100 mg. The end time is 48 hours after admission to the ICU.
214493638|NCT06775990|OTHER|Blood sample|Children were not given any medication in the study. Peripheral blood samples from the children were collected, centrifuged and stored in the biochemistry laboratory in deep freezers at -80 degree celcius. From stored serum samples leptin, leptin receptor (LEPR), ghrelin, acylated ghrelin, deacylated ghrelin, ghrelin receptor (GHSR), kisspeptin (KISS1), kisspeptin receptor (KISS1R), preptin, Peroxisome proliferator-activated receptor gamma (PPAR γ), nod-like receptor pyrin domain-containing 3 (NLRP3), interleukin-18 (IL-18) levels were determined by ELISA in thirty obese and thirty healthy children.
214493639|NCT06760221|RADIATION|stereotactic body raiotherapy|Neoadjuvant stereotactic body radiation therapy followed by radical surgery for soft tissue sarcoma.
214985341|NCT01737736|DEVICE|Neurokeeper stroke detector|Electrophisoloigcal monitoring
214985342|NCT04721418|RADIATION|11C-UCB-J|11C-UCB-J PET scan
214985343|NCT05916547|PROCEDURE|pancreatic extracorporeal shock wave lithotripsy|Pancreatic extracorporeal shock wave lithotripsy is based on the principle of shock wave energy. Whenever energy is abruptly released in an enclosed space, shock waves are generated and then cross to the surface of pancreatic duct stones to cause further fragmentation.
214985344|NCT00848497|DRUG|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
214985345|NCT00848497|OTHER|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
214985346|NCT00848497|DRUG|Viagra®|Viagra 25mg was the dose given to the patient which he started.
214370657|NCT05951088|PROCEDURE|Cardio2U follow-up|During the follow-up period, participants will have access to the application and will be able to explore the different modules. At fixed time points, the application will allow them to fill in questionnaires about the application's usability and patient satisfaction. App user data will track how long and how often patients visit the application and which aspects are mostly used. In addition, at different time points during the study, patients will be asked to complete clinical questionnaires regarding e.g. patients' knowledge and self-care abilities. The results of these questionnaires can be used in a more clinical way as they will be accessible to doctors and nurses in the healthcare provider dashboard and can support targeted patient follow-up and guidance
214370658|NCT05889806|OTHER|Observational Study Only. NO Intervention.|Observational Study Only. NO Intervention.
214985347|NCT02066571|DRUG|Droxidopa|Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.
214985348|NCT02066571|DRUG|sugar pill|Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
214985349|NCT03647592|DRUG|Erlotinib/Gefitinib combined with Bevacizumab|Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months
214985350|NCT05149339|DRUG|Cholecalciferol 2800 I.U. ml oral drops|"(Cholecalciferol 2800 I.U. ml) Oral Drops 15 ml. supplied with a dropper.~* Composition:~Each 1 ml (= 28 drops) of oral solution contains: Vitamin D3 (Cholecalciferol) 2800 I.U., (each drop contains 100 IU of vitamin D3)."
214985351|NCT00469131|DRUG|tacrolimus + steroid|
214985352|NCT00469131|DRUG|tacrolimus + mycophenolate mofetil|
214985353|NCT01114724|DEVICE|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
214985354|NCT05313308|DRUG|Midazolam|Midazolam oromucosal solution
215089010|NCT07040384|DEVICE|Knee Extensors Activation (KEA) Device|A portable, non-electric device consisting of an inflatable cushion, pressure gauge, and digital counter. It provides objective feedback during isometric quadriceps exercises after ACL reconstruction. The device encourages full contraction by only counting repetitions that exceed a preset pressure threshold and return to baseline.
215089011|NCT07040384|OTHER|Conventional Towel-Based Exercise|Standard rehabilitation method using a rolled towel under the knee during quadriceps setting exercises. Patients perform isometric contractions without feedback or objective measurement. Repetitions are manually counted by the physiotherapist.
215089012|NCT07040410|PROCEDURE|Aromatherapy|Fifteen minutes before the PD session and during the first outflow and inflow phases, aromatherapy will be administered via inhalation. Five drops of 100% pure organic lavender oil
215089013|NCT07040410|PROCEDURE|Music Therapy|Fifteen minutes before the PD session and during the first outflow and inflow phases, music chosen by the child or parent will be played. Pain and vital signs will be assessed as in the control group.
215089014|NCT07040410|PROCEDURE|Control|"Peritoneal dialysis treatment will be started with discharge first, and then the amount of dialysate fluid determined by the physician's request will be filled. In the clinical routine, nonpharmacological pain treatment method is not applied during excretion and filling. Nonpharmacological pain treatment method will not be applied to the control group. The Wong-Baker Facial Expressions Rating Scale and Life Signs Evaluation Form will be filled in by the researcher at the 0th and 1st minutes of the first discharge and at the 0th and 1st minutes of the first filling."
215089015|NCT07041255|PROCEDURE|Cold endoscopic mucosal resection|3-4 ml of solution is injected into the submucosal layer under the formation. The formation with the surrounding mucous membrane (at least 1 mm from the edge of the formation) is captured with a specialized or standard polypectomy loop available to the operator (depending on the randomization result). The formation is removed by mechanical cutting without using electric current.
214493640|NCT06780774|DIETARY_SUPPLEMENT|Caffeine, Vitamins, Minerals and Botanical Blend|"Blend containing 120mg of caffeine, vitamins, minerals and botanical extracts in capsule form.~Other Names: Active Treatment"
214493641|NCT06780774|DIETARY_SUPPLEMENT|Placebo|Blend containing 17mg Marigold Extract and Brown rice flour. Other Names: Placebo Treatment
214985355|NCT02342626|BEHAVIORAL|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
214985356|NCT01990326|DRUG|XAF5 Gel|
214370659|NCT04918368|BEHAVIORAL|Behavioral scales were used|Women's Health Initiative Sleeplessness Scale (WHISS) and State Anxiety Scale (SAS), were applied.
214370660|NCT02291523|BIOLOGICAL|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
214985357|NCT01990326|DRUG|Placebo Gel|
214985358|NCT00646724|BIOLOGICAL|cotransplantation of islet and mesenchymal stem cell|islet of allograft and MSCs of autograft
214985359|NCT04538508|DEVICE|Diathermy|10 sessions of 12 minutes of radiofrequency diathermy at the anterior surface of the knee, in constant movement
214985360|NCT04538508|OTHER|Supervised knee exercises|Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.
214985361|NCT00176449|DRUG|Bupropion SR|150mg twice a day (starting with 150mg once a day for three days)
214985362|NCT00176449|DRUG|Placebo Oral Tablet|Comparable placebo
214985363|NCT03406520|DEVICE|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated sponge, named biopatch, is a protective disk (2.5 cm x 0.7 cm), which is hydrophilic polyurethane absorptive foam with chlorhexidine gluconate, in average of 86.8mg per disk
214985364|NCT02966834|DRUG|Placebo|GSK2330672 matching placebo will be supplied as white film-coated tablets.
214985365|NCT02966834|DRUG|GSK2330672|GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
214985366|NCT04929015|PROCEDURE|Biospecimen Collection - blood and tissue sample collection|The original tissue sample from each patient will be obtained at time of surgery or prior to surgery. Plasma for ctDNA will be obtained at baseline, pre-surgery, post-surgery and every 3 months up 2 years
214985367|NCT04929015|OTHER|Electronic Health Record Review|Medical record reviewed
214985368|NCT02450643|OTHER|Test extensively hydrolyzed formula|extensively hydrolyzed formula made with a new enzyme
214985369|NCT02450643|OTHER|Control extensively hydrolyzed formula|commercially available extensively hydrolyzed formula
214985370|NCT01430377|PROCEDURE|SB predilatation|Initial SB \[predilatation.
214985371|NCT01430377|PROCEDURE|No SB predilatation|Without SB predilatation
214985372|NCT04139252|OTHER|No intervention|No intervention
214985373|NCT05858983|GENETIC|FT-001 Low Dose|Comparison of different dosages of FT-001
215089016|NCT07041255|PROCEDURE|Hot endoscopic mucosal resection|"3-4 ml of solution is injected into the submucosal layer under the formation. The formation with the surrounding mucous membrane (at least 1 mm from the edge of the formation) is captured with a specialized or standard diathermic polypectomy loop available to the operator (depending on the randomization result). The formation is removed using electric current in the Endocat mode (or its analogue, providing alternating cutting and coagulation under the control of a processor built into the electrical unit).~After the formation is removed, the resection site is examined in white light, then virtual chromoscopy (NBI), and then an examination with magnification. The examination results are recorded in the scientific protocol separately, and are assessed as a whole. The criteria for visual removal of the formation within healthy tissues are the absence of visible fragments of the formation. The time of complete cessation of capillary bleeding is recorded."
215089017|NCT07040579|DEVICE|transcatheter closure of outlet VSDs with bioabsorbable occluders|Transcatheter closure of outlet ventricular septal defects using a bioabsorbable occluder (Shape Memory Alloy Ltd, Shanghai, China). Implantation is performed via femoral/transthoracic approach under echocardiographic guidance following standard interventional protocols.
215089018|NCT06726863|DRUG|Vamifeport IRF|Vamifeport IRF will be administered orally as per the dosing levels and formulations for respective treatment periods.
214370661|NCT02732613|DEVICE|Laryngeal Mask Airway|If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.
214370662|NCT01403025|DRUG|liraglutide|Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
214370663|NCT04800419|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|The term 'mindfulness' refers to mindful awareness as a way of being - a knowing and experiencing of feelings, thoughts, and perceptions as they arise and pass away each moment. It is a way of relating to all experiences in an open, receptive way, without judging experiences as good or bad (grasping at them or pushing them away). Mindfulness employed two styles of meditations: concentrative meditation involves intentionally focusing attention on a chosen object (e.g. the sensations of breathing) in a sustained way, while receptive meditation involves monitoring the content of experience (e.g. sensations, emotions, thoughts, sounds, etc.) in a non-reactive and non-judgmental way, from moment to moment, with the goal being to recognize the nature of emotional and cognitive patterns. Mindfulness-based stress reduction (MBSR) is an 8-week, standardized group intervention consisting of mindfulness meditation and gentle yoga that is designed to have applications for stress, pain, and illness
214370664|NCT03683797|OTHER|Post-discharge call|Patients will receive a call 1-3 days after they were discharged from the hospital to make sure their healthcare needs are being met.
214985374|NCT05858983|GENETIC|FT-001 Mid Dose|Comparison of different dosages of FT-001
214985375|NCT05858983|GENETIC|FT-001 High Dose|Comparison of different dosages of FT-001
214985376|NCT01700491|DRUG|Epidural Catheter 0.2% ropivacaine|0.2% ropivacaine into epidural space and saline into paravertebral space
214985377|NCT01700491|DRUG|Paravertebral Catheter 0.4% ropivacaine|0.4% ropivacaine into paravertebral space and saline into the epidural space
214985378|NCT00287430|DRUG|Growth Hormone|
214985379|NCT00287430|PROCEDURE|Whole body Protein Turnover Study|
214985380|NCT00287430|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
214985381|NCT01542762|DRUG|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
214985382|NCT00333528|DRUG|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
214985383|NCT00333528|DRUG|Placebo: Normal saline|Intramuscular administration
214985384|NCT02493959|BIOLOGICAL|PYY1-36 infusion|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
214985385|NCT02493959|BIOLOGICAL|PYY1-36 + sitagliptin|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
214985386|NCT02493959|BIOLOGICAL|PYY3-36 infusion|0.8 pmol/kg/min infusion of PYY3-36.
214985387|NCT02493959|BIOLOGICAL|placebo|Infusion of saline for 2 hrs.
214985388|NCT06377423|PROCEDURE|Direct technique|The composite was placed directly using free-hand technique
214985389|NCT06377423|PROCEDURE|Indirect technique|The ceramic was placed using indirect method via laboratory casts
214985390|NCT00800046|DEVICE|AccuCinch® Ventriculoplasty System|Mitral valve repair due to functional disease
214985391|NCT06389617|DRUG|supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous administered dexamethasone|Comparing the onset of sensory, motor block, duration of motor block and analgesic duration
214985392|NCT00864110|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
214985393|NCT00864110|RADIATION|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
214985394|NCT00864110|RADIATION|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
214370665|NCT02929433|OTHER|Cycloergometer|Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
214370666|NCT02153138|DEVICE|Endo-pat 2000|"The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:~1. The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.~2. The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution"
214370667|NCT02153138|DEVICE|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
214370668|NCT02153138|DEVICE|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
214370669|NCT05147610|DIAGNOSTIC_TEST|Intraocular pression|"First, measurement of the eye pressure by air-puff tonometry and estimation of the pachymetries with the TONOREF III.~Secondly, measurement of the eye pressure by GAT. Thirdly, measurement of the eye pressure by Icare 200."
214370670|NCT05633875|OTHER|MRI|Patients will undergo MRI without contrast agent
214370671|NCT03996057|DRUG|Methenamine Hippurate 1000 MG|Discussed in arm/group description
214370672|NCT03996057|DRUG|Vaginal estrogen|Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
214370673|NCT03996057|DIETARY_SUPPLEMENT|D-mannose|Powder or tablet, depending on what patient is already using.
214370674|NCT06579053|DRUG|Spironolactone Tablets (Test)|Take one test tablet each period
214370675|NCT06579053|DRUG|Spironolactone Tablets (Reference)|Take one reference tablet each period
214370676|NCT00369538|DRUG|losartan, hydrochlorothiazide|Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months
214370677|NCT00369538|DRUG|hydrochlorothiazide, losartan|One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
214985395|NCT00914368|DRUG|Clopidogrel|Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
214985396|NCT03883386|DRUG|Loratadine|10 mg in a capsule
214370678|NCT00053495|BIOLOGICAL|Vaccinia virus: ACAM2000 smallpox vaccine|Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml
215089019|NCT06726863|DRUG|Vamifeport PR1|Vamifeport PR1 will be administered orally as per the dosing levels and formulations for respective treatment periods.
215089020|NCT06726863|DRUG|Vamifeport PR2|Vamifeport PR2 will be administered orally as per the dosing levels and formulations for respective treatment periods.
214370679|NCT00053495|BIOLOGICAL|vaccinia virus (calf lymph): Dryvax|Group 5 dose: 1.0x10-8th PFU/ml
214370680|NCT01670981|BIOLOGICAL|ixmyelocel-T|12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
214370681|NCT01670981|OTHER|Placebo|12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
214370682|NCT03483987|DRUG|Sof+Ledi+R arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
214370683|NCT03483987|DRUG|Sof+Ledi+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
214370684|NCT03483987|DRUG|Sof+Dacla+R arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
214370685|NCT03483987|DRUG|Sof+Dacla+R+Peg-IFN arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
214370686|NCT03483987|DRUG|Sof+Velpa+R arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
214681612|NCT02003560|RADIATION|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
214681613|NCT00077805|DRUG|Enoxaparin sodium|
214985397|NCT03883386|DRUG|Placebo|Administered via capsule
214985398|NCT02814526|BEHAVIORAL|Aerobic exercise|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
214985399|NCT02814526|BEHAVIORAL|Stretching/balance/range of motion exercise|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
214985400|NCT00720135|BIOLOGICAL|DI-Leu16-IL2 immunocytokine|Given IV
215089021|NCT07041879|PROCEDURE|maxillary anterior teeth atraumatically extracted with piezotome extraction kit, and subsequent immediate implant placement|piezotome extraction kit,
215089022|NCT07041879|PROCEDURE|maxillary anterior teeth atraumatically extracted with periotome, and subsequent immediate implant placment|periotome
214985401|NCT00720135|BIOLOGICAL|rituximab|Given IV
214985402|NCT00720135|OTHER|flow cytometry|Correlative studies
214370687|NCT03483987|DRUG|Sof+Velpa+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
214493642|NCT04234646|BEHAVIORAL|Patient Navigation (PN) 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
214985403|NCT00720135|OTHER|immunohistochemistry staining method|Correlative studies
214985404|NCT00720135|OTHER|pharmacological study|Correlative studies
215089023|NCT07041671|DEVICE|ColdZyme|"ColdZyme is a medical device classified as a Class III device, certified according to the European Medical Devices Regulation (2017/745/EU) (MDR). It has been CE-marked since 2013.~ColdZyme is a mouth spray that protects against upper respiratory tract viruses causing common cold and flu-like symptoms. ColdZyme forms a protective moisturizing barrier on the mucous membrane of the oral cavity and throat. The viscous barrier catches the virus and thereby the contact between the virus and the epithelial cells are reduced and avoided, thus the barrier disables the viruses' ability to spread and multiply."
214370688|NCT03630822|BEHAVIORAL|Psychiatric Advanced Directive|The patient completes a questionnaire to express in advance his wishes regarding his future care in psychiatry.
214493643|NCT04234646|BEHAVIORAL|One-on-one Patient Navigation (PN)|The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
214493644|NCT04452097|BIOLOGICAL|Human umbilical cord mesenchymal stem cells + best supportive care|hUC-MSC product will be administered intravenously in addition to the standard of care treatment.
214493645|NCT04452097|OTHER|Placebo control + best supportive care|Placebo control will be administered intravenously in addition to the standard of care treatment.
214493646|NCT05544045|DEVICE|Surpass Streamline Flow Diverter System|The Surpass Streamline FDS is indicated for use in the endovascular treatment of adults (age 18 years or older) with unruptured large (≥ 10 mm) saccular, wide-neck (neck width ≥ 4 mm or dome/neck ratio \< 2 mm) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm to ≤ 5.3 mm.
214493647|NCT05239793|DRUG|NJOY e-cigarette|NJOY e-cigarette with Virginia Tobacco flavored 5% nicotine pods
214493648|NCT04153890|BEHAVIORAL|FamPALcare|Intervention participants will receive standard care plus five weekly coaching sessions with telephone follow-up to reinforce HF palliative home care.
214493649|NCT06782828|OTHER|observe results of FNAC|observe results of FNAC and compare it with results of histopathological examination to detect accuracy of FNAC in diagnosis of thyroid nodules.
214493650|NCT06653062|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|"Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients.~Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence."
214493651|NCT06894940|BEHAVIORAL|Active Comparator #1|task oriented rehabilitation
214493652|NCT06894940|BEHAVIORAL|Placebo|passive rehabilitation
214493653|NCT06894940|BEHAVIORAL|Experimental|rehabilitation with virtual reality
214493654|NCT06498661|PROCEDURE|Biospecimen Collection|Undergo collection of cervical samples by clinician
214493655|NCT06498661|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy conducted by clinician
214493656|NCT06498661|PROCEDURE|Colposcopy|Undergo colposcopy conducted by clinician
214493657|NCT06498661|OTHER|Electronic Health Record Review|Ancillary studies
214985405|NCT00720135|OTHER|laboratory biomarker analysis|Correlative studies
214370689|NCT03630822|BEHAVIORAL|Standard care|standardized maintenance with the patient
214493658|NCT06498661|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage conducted by clinician
214493659|NCT06498661|PROCEDURE|Excision|Undergo cervical excisional procedure conducted by clinician
214681614|NCT04635696|DRUG|Ethyl chloride|Pressurized vapocoolant developed for acute, mild pain relief.
214681615|NCT04635696|OTHER|Tissue culture grade water|Pressurized water mist
214985406|NCT00720135|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214985407|NCT00720135|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
214370690|NCT02017054|OTHER|Cath|No intervention - registry
214370691|NCT03262740|DRUG|BMS-986195|Oral administration of specified dose on specified days
214370692|NCT03262740|DRUG|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
214985408|NCT00889304|DEVICE|Position HTO system|open wedge high tibial osteotomy
214985409|NCT02723240|DRUG|NUC-3373|
214985410|NCT03002402|BEHAVIORAL|Internet-based CBT-I|Internet-based cognitive-behavioral treatment for insomnia
214370693|NCT06384248|DRUG|LTC004|LTC004,45μg/kg,IV,Day 1,Q3W;
214370694|NCT05354843|DRUG|ET0038|ET0038 for oral administration
214370695|NCT03513406|DRUG|Sugammadex|Sugammadex is indicated for the reversal of neuromuscular blockade.
214370696|NCT03513406|DRUG|Neostigmine|Neostigmine is indicated for the reversal of neuromuscular blockade.
214370697|NCT03513406|DRUG|Glycopyrrolate|Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
214370698|NCT03797482|PROCEDURE|Intra-operative Tumor Tissue Biopsy|The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.
214370699|NCT01572779|DEVICE|BSM device with bio-feedback|A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).
214370700|NCT01572779|DEVICE|BSM device with no bio-feedback|The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
214370701|NCT01893385|DRUG|Vitamin D (drug)|
214370702|NCT00908089|DRUG|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
214370703|NCT00908089|DRUG|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
214370704|NCT02770651|DEVICE|Everolimus-Eluting stent|Everolimus-Eluting stent with bioabsorbable polymer
214370705|NCT02770651|DEVICE|Zotarolimus-Eluting stent|Zotarolimus-Eluting stent with permanent polymer
214985411|NCT06088693|OTHER|Electroacupuncture and Standard Therapy|Acupuncture Needle Insertion with Electroacupuncture machine.
214985412|NCT05782517|DEVICE|Supraglottic Airway Device|Placement of an I-gel Supraglottic Airway Device.
214985413|NCT05782517|DEVICE|Endotracheal Tube|Placement of an Endotracheal Tube.
214985414|NCT03945630|PROCEDURE|anterior Quadratus Lumborum Block|Interfascial plane block
214985415|NCT03945630|PROCEDURE|Standard of Care|No QLB
214985416|NCT01409668|DIETARY_SUPPLEMENT|L. Amylovorus|L. Amylovorus
214985417|NCT01409668|DIETARY_SUPPLEMENT|L. Fermentum|L. Fermentum
214985418|NCT00908934|DRUG|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
214985419|NCT00908934|DRUG|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
214985420|NCT00908934|DRUG|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
214370706|NCT06273943|DRUG|Cabotegravir Tablets, for oral use.|Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.
214985421|NCT00908934|DRUG|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
215089024|NCT07040371|OTHER|Health Promotion Behavior Intervention Program|The intervention program is structured around a three-step framework: ① building motivation and providing opportunities; ② reinforcing motivation, enhancing capabilities, and providing opportunities; and ③ sustaining motivation, strengthening capabilities, and providing opportunities. The process involves assessing the current state of health-promoting behaviors among elderly migrants, implementing interventions to promote these behaviors, and evaluating the effectiveness of the interventions. The program spans 12 weeks and is carried out by a team of researchers and nursing students. Key intervention components include: ① helping elderly migrants recognize their health issues, analyzing the impact of migration on health-promoting behaviors, and emphasizing the importance of such behaviors through comparisons of negative and positive case studies; ② conducting thematic training on health habits, dietary nutrition, exercise safety, oral hygiene, and other topics through health lectures,
214370707|NCT06273943|DRUG|Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.|Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.
214493660|NCT06498661|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal samples
214493661|NCT06498661|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal samples and cervical samples
214493662|NCT06498661|OTHER|Questionnaire Administration|Ancillary studies
214985422|NCT00251758|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
214985423|NCT00251758|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
214493663|NCT06498661|OTHER|Survey Administration|Ancillary studies
214493664|NCT04579952|DEVICE|transcranial Direct Current Stimulation|The current stimulation will be applied using 35 squares cm wide sponge electrodes
214493665|NCT05044845|BEHAVIORAL|Interview|Semi structured interview will be conducted virtually using an online video-conferencing platform, phone or in person.
214493666|NCT06059651|PROCEDURE|Metabolic & Bariatric Surgery|Roux-en-Y metabolic and bariatric surgery
214985424|NCT00251758|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
214985425|NCT04596904|OTHER|Lavender oil application group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
214985426|NCT04596904|OTHER|Distilled water application group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
214985427|NCT05650502|DRUG|saisonal malaria chimoprevention|Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection
214985428|NCT01576614|BEHAVIORAL|Remote physician rounding|Use of Remote physician rounding using Remote Telepresence Robotics
214370708|NCT06273943|DRUG|Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use|"* Daily regimen: a single tablet of TDF/FTC every 24 hours, regardless of sexual activity. If PrEP was stopped, resume with two pills of TDF/FTC followed by one pill every 24 hours.~* On-demand regimen: a loading dose of two pills of TDF/FTC 2 to 24 hours before sexual intercourse, a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourse, participants will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills. If the last dose of TDF/FTC was taken less than one week prior, a leading dose with a single pill of TDF/FTC is sufficient."
214370709|NCT06273943|PROCEDURE|Rectal Biopsies|"This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm."
214370710|NCT01945749|DRUG|Intraarticular steroid|1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided.
214370711|NCT01945749|DRUG|Intraarticular saline|1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
214985429|NCT05076734|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
214985430|NCT03252158|BEHAVIORAL|Availability of healthier vs. less healthy foods|"Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2\&3 and 5\&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7)."
214985431|NCT00966368|DRUG|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
214985432|NCT00966368|DRUG|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
214985433|NCT03514953|BEHAVIORAL|Reduced Physical Activity|"Preliminary Phase (Baseline to Day 7): Subjects will begin wearing an accelerometer for 7 days to track physical activity and sleep patterns.~Experimental Phase 1 (Day 7 to Day 21): Participants will be required to reduce their step count by 5,000 steps per day and engage in no moderate-vigorous physical activity during this timeframe. Every 7 days subjects undergo the blood draw, vascular health measures and questionnaire assessments.~Experimental Phase 2 (Day 21 to 28): During the week of assessment, subjects will be asked to return to their normal physical activity patterns."
214985434|NCT01518062|DRUG|somatropin|4 IU/m\^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
215089025|NCT07040371|OTHER|receiving routine community care and management only|It primarily included distributing health manuals, conducting regular health education sessions, and performing follow-ups. Researchers and community nurses collected and addressed health-related inquiries raised by the elderly migrants. Additionally, to ensure scientific rigor and equity in the study, compensatory interventions (such as providing equivalent intervention opportunities or distributing relevant intervention materials) were offered to participants based on their actual needs upon completion of the research project.
215089026|NCT06732453|OTHER|Seated Yoga Skills Training in Functional Dyspepsia and Gastroparesis (FD-GP)|Two one-hour chair-based yoga sessions that will include gentle movements, breathing practices, and meditation, along with home practice.
215089027|NCT06823297|OTHER|Total mesorectal excision|Direct surgery without receiving neoadjuvant chemoradiotherapy
215089028|NCT06823297|OTHER|Neoadjuvant Chemotherapy followed by total mesorectal excision|Neoadjuvant chemoradiotherapy treatment regimens (including conventional chemoradiotherapy/radiotherapy/chemotherapy regimens or total neoadjuvant chemoradiotherapy regimens) before surgery
215089029|NCT06718140|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound to one of the 4 brain locations
214370712|NCT01945749|OTHER|Exercise therapy|"The exercise is commenced 2 weeks after injection.~The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.~In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities."
214370713|NCT02660801|PROCEDURE|Spinal manipulation|A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
214370714|NCT02660801|PROCEDURE|Spinal mobilization|Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
215089030|NCT07041801|DRUG|hUC-MSCs treatment (low dose)|patients will receive conventional therapy plus low dose hUC-MSCs treatment,The dosage is 1E6 cells/kg.
214370715|NCT03076372|DRUG|MM-310|MM-310
214370716|NCT03057743|DEVICE|Positron emission tomography (PET/CT) imaging|
214370717|NCT03057743|DEVICE|radiotracer [18F]ISO-1|
214370718|NCT02415348|DEVICE|Fibroscan|
214370719|NCT05999786|BEHAVIORAL|early rehabiliation swallowing program|not receiving early rehabilitation swallowing program from before and after surgery
214370720|NCT05999786|BEHAVIORAL|not receiving early rehabilitation swallowing program|the Taiwan Dysphagia Society's publicly shared swallowing exercises for dysphagia, which is from before and after surgery
214493667|NCT05120947|RADIATION|42 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.2 Gy.
214493668|NCT05120947|RADIATION|39 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.875 Gy.
214493669|NCT05120947|RADIATION|32.5 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 6.5 Gy.
214493670|NCT02334865|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
214493671|NCT02334865|OTHER|Laboratory Biomarker Analysis|Correlative studies
214493672|NCT02334865|DRUG|Lenalidomide|Given PO
214493673|NCT02334865|BIOLOGICAL|Sargramostim|Given SC
214493674|NCT02334865|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
214985435|NCT01518062|DRUG|somatropin|Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
214985436|NCT01518062|DRUG|somatropin|Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface, the second year and finally 8 IU/m\^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
214985437|NCT01518062|DRUG|oestrogen|Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
214985438|NCT00102323|DRUG|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
214985439|NCT00102323|BIOLOGICAL|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
214681616|NCT03252496|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
214681617|NCT03252496|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
214985440|NCT06807346|DIETARY_SUPPLEMENT|Kids Plus Multi & Omega|Participants will be instructed to take two gummies of Kids Plus Multi and Omegas with or without food once daily for the duration of the study starting on Day 1 with a recommendation to consume in the morning for consistency.
214493675|NCT06688409|DIAGNOSTIC_TEST|awake ABPM|Comparison of a BP measured with the home BP devices and the average awake ABPM performed immediately after
214493676|NCT04728295|DEVICE|Exablate 4000|Exablate Pallidothalamic Tractotomy
214493677|NCT05386316|OTHER|Multilevel intervention for racial disparities in severe maternal morbidity and mortality|"In addition to standard enhance prenatal care (EPC) services, the following will be offered.~Community level. We will make EPC services (i.e., MIHP and Healthy Start) available via telehealth with flexible hours to women who are eligible for Healthy Start (primarily minority women) who decline traditional (i.e., home visiting) services.~Provider/practice level. We will provide actionable maternal health-focused anti-racism training to health system administrators, physicians, residents, midwives, nurses, front desk staff, schedulers, public health officers, EPC staff, doulas, WIC staff, and lactation consultants.~System level. Counties will implement equity focused community care maternal safety bundles. Community care is care provided by outpatient, EPC, community-based organizations, and linkages between hospital care and these settings."
214493678|NCT05386316|OTHER|Standard Enhanced Prenatal Care (EPC) services|"Pregnant women in comparison counties will receive whatever EPC services (MIHP and/or Healthy Start) they naturalistically choose to receive.~Maternal Infant Health Program (MIHP). All women in Michigan who are Medicaid insured are eligible for MIHP. MIHP offers monthly home visiting and care coordination to supplements regular care during pregnancy and up to 12 months post birth. MIHP offers care coordination; risk assessment; individual care plan; evidence-based interventions; transportation; education; and referrals.~Healthy Start. Health Start is a federally funded program for minority women that offers more intensive EPC services delivered by race/ethnicity matched community health workers. Community health workers offer peer support; resilience and problem solving; risk assessment; facilitating provider-client communication; collaborative care; system navigation, including transition from prenatal care to postnatal primary care; and supportive referrals."
214681618|NCT03252496|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
214681619|NCT03252496|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
214681620|NCT03252496|RADIATION|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
214985441|NCT06807346|DIETARY_SUPPLEMENT|Placebo|Participants will be instructed to take two gummies of placebo with or without food once daily for the duration of the study starting on Day 1 with a recommendation to consume in the morning for consistency.
214985442|NCT04562376|OTHER|High-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes twice a week (group A) during 12 weeks
214985443|NCT04562376|OTHER|Low frequency of high-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes once a week (group B) during 12 week
214985444|NCT00006362|DRUG|bortezomib|
214985445|NCT01471626|DEVICE|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
214985446|NCT01387269|DRUG|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
215089031|NCT07041801|BIOLOGICAL|hUC-MSCs treatment (medium dose)|patients will receive conventional therapy plus medium dose hUC-MSCs treatment,The dosage is 3E6 cells/kg.
214681621|NCT03252496|DRUG|250 mL Colloid over 5 minutes|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
214681622|NCT03252496|DRUG|250 mL Crystalloid over 5 minutes|Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
214681623|NCT03252496|DRUG|500 mL Crystalloid over 55 minutes|Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
214681624|NCT03252496|DRUG|250 mL Colloid over 60 minutes|After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
214681625|NCT03252496|DRUG|250 mL Crystalloid over 60 minutes|After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
214985447|NCT01387269|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
214985448|NCT01066572|DRUG|Lisinopril|5-10 mg Lisinopril per day for seven days, depending on blood pressure.
214985449|NCT01066572|DRUG|Placebo|Matched placebo; identical tablets to Lisinopril.
214370721|NCT02788630|BEHAVIORAL|Sleep hygiene counseling|The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
214370722|NCT05863130|DRUG|BI 764198 (C-14) (approach 1)|BI 764198 (C-14) (approach 1)
214370723|NCT05863130|DRUG|BI 764198 (C-14) (approach 2)|BI 764198 (C-14) (approach 2)
214370724|NCT03360630|BIOLOGICAL|Anti-PD-1 plus DC-CIK|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal. DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
214370725|NCT03360630|BIOLOGICAL|Anti-PD-1 alone|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
214370726|NCT00500721|DRUG|HCV-796|HCV-796 500mg BID x 14 days
214370727|NCT00500721|DRUG|Desipramine|"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."
214370728|NCT00325325|DRUG|everolimus and tacrolimus|
214370729|NCT02252432|DRUG|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
214370730|NCT02252432|DRUG|Methadone|A single dose of IV methadone (0.2 mg/kg) preinduction.
214985450|NCT00851149|DEVICE|Sangvia blood sampling system|Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
214985451|NCT04058509|COMBINATION_PRODUCT|Focused shockwave therapy|3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.
214370731|NCT02252432|DRUG|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
214370732|NCT04345159|OTHER|Questionnaire by phone call|"2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in Suggestive of a COVID-19 infection or Not suggestive of COVID-19 infection by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake."
214370733|NCT04513613|DEVICE|Procedure/Surgery: Robotic-PVI|Robotic-assisted (CorPath GRX System) percutaneous vascular interventions.
214370734|NCT03224221|DRUG|Apatinib|Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days
214370735|NCT03224221|DRUG|fluorouracil and platinum|the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
214370736|NCT02712125|DRUG|isosorbide mononitrate|20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .
214370737|NCT02712125|DRUG|Placebo|placebo vaginal tablets once daily until delivery
214370738|NCT00521703|DRUG|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
214370739|NCT00521703|DRUG|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
214370740|NCT02265614|GENETIC|PGS|
214370741|NCT00133536|BIOLOGICAL|Influenza A/H5N1 Vaccine|Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.
214370742|NCT00133536|DRUG|Placebo|Normal saline administered intramuscularly.
214370743|NCT02481492|DEVICE|No flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
214370744|NCT02481492|DEVICE|Flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
214370745|NCT01154478|OTHER|Diet rich in omega-3 fatty acids|fish at least 3 times per week, large leaf vegetables
214370746|NCT01154478|OTHER|Diet rich in polyphenols|extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
214985452|NCT01222299|DRUG|bepotastine besilate nasal product - low dose|sterile nasal product
214985453|NCT01222299|DRUG|bepotastine besilate nasal product - medium dose|sterile nasal product
214985454|NCT01222299|DRUG|bepotastine besilate nasal product - high dose|sterile nasal product
214985455|NCT01222299|DRUG|placebo comparator nasal product|sterile nasal product
214985456|NCT03999255|PROCEDURE|combined respiratory support (CRS)|combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
214985457|NCT06018090|OTHER|The presence and rate of MES measured by TCD monitoring|TCD monitoring within 24 hours from the last known well time. Bilateral M1 segments of middle cerebral artery were insonated at a single depth with 2-MHz transducers secured by a probe-holder.
214985458|NCT01981616|DRUG|Vedolizumab|Vedolizumab for intravenous infusion
214370747|NCT01154478|OTHER|Control diet|low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)
214370748|NCT01154478|OTHER|diet rich in omega-3 and polyphenols|Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
214370749|NCT00170222|DRUG|doxycycline|
214370750|NCT02659917|OTHER|Glass ionomer|Application of preventive agent
214370751|NCT02659917|OTHER|Glass ionomer cement|Application of preventive agent
214493679|NCT06473974|DRUG|Test cosmetic product|"Test cosmetic product: Test cosmetic product will be applied to affected hyperpigmented areas twice daily at AM and PM.~Cleanser and sunscreen: A facial cleanser will be used twice daily (morning and evening) by gently rubbing it on face and neck, then rinse and pat dry. Sunscreen of SPF 50, apply evenly on face and neck, 20 minutes before stepping out."
214493680|NCT05927194|BEHAVIORAL|Using the Connect|Using the Connect (UTC) is an innovative, game-based intervention for youth to develop skills in adulthood preparation topics such as communication, decision making and accessing information.
214681626|NCT03252496|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
214985459|NCT01981616|DRUG|Placebo|Placebo intravenous infusion
214985460|NCT01981616|BIOLOGICAL|Hepatitis B vaccine|
214985461|NCT01981616|BIOLOGICAL|Oral cholera vaccine|
214985462|NCT03619278|OTHER|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 doses of 10-1074 antibodies and 3 doses of romidepsin
214985463|NCT03619278|OTHER|placebo|Participants will receive 5 vaccines of placebo of HIVACAR01, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
214985464|NCT04092413|DEVICE|Dermoscope|It is a non invasive tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic dermatopathology .
214985465|NCT06269835|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
214985466|NCT06269835|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
215089032|NCT07041801|BIOLOGICAL|hUC-MSCs treatment (high dose)|patients will receive conventional therapy plus high dose hUC-MSCs treatment,The dosage is 5E6 cells/kg.
215089033|NCT07041801|DRUG|Placebo|patients will receive conventional therapy plus Placebo
214370752|NCT02659917|OTHER|-Glass ionomer-|Atraumatic Restorative Treatment
214370753|NCT02659917|OTHER|-Glass ionomer cement-|Atraumatic Restorative Treatment
214370754|NCT02277990|DEVICE|TYRX™ Absorbable Antibacterial Envelope|
214370755|NCT04711603|DRUG|MR13A9|Intravenous administration
214370756|NCT04711603|DRUG|Placebo|Intravenous administration
214370757|NCT05541510|BIOLOGICAL|AD17002 + Formulation buffer|Intranasal innate immune modulator
214370758|NCT05541510|BIOLOGICAL|Placebo|Formulation buffer
214370759|NCT06499285|BIOLOGICAL|KER-050|KER-050 administered subcutaneously every 4 weeks
214370760|NCT06499285|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks
214681627|NCT03252496|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
214681628|NCT04453839|DRUG|ZYESAMI (aviptadil acetate)|Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
214681629|NCT01524445|OTHER|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
214370761|NCT05887908|DRUG|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam
214370762|NCT05887908|DRUG|co-administration of aztreonam and nacubactam|2 g aztreonama and 1 g nacubactam
214370763|NCT05887908|DRUG|imipenem/cilastatin|1 g imipenem/1 g cilastatin
214370764|NCT06319846|DRUG|Tirofiban|Initial infusion of tirofiban 0.4μg/kg body weight/minute for 30 minutes (a maximum dose of 1mg) within 24 hours of symptom onset, followed by a continuous infusion of tirofiban 0.1μg/kg body weight/minute for 48 hours.
214370765|NCT06319846|DRUG|Placebo|Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.
214681630|NCT04729088|DRUG|Isosorbide mononitrate|Intra-anal application performed by the study physician of 2 g of the study drug
214985467|NCT06269835|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
214985468|NCT02160938|OTHER|3-year follow-up|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~* The Vineland-II Adaptive Behavior Scale (VABS)~* Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~* Children will also be photographed (for review by the study dysmorphologist)"
214985469|NCT01924598|DEVICE|DBS to nucleus accumbens/anterior limb of internal capsule|deep brain stimulation followed by 12 month post switch on followup
214985470|NCT00513214|DRUG|XOMA 052|"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
214985471|NCT00513214|DRUG|Placebo|"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
214985472|NCT01132508|DEVICE|Norian Drillable Bone Void Filler|Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
214985473|NCT01213238|DRUG|Oxaliplatin|140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.
214985474|NCT01213238|DRUG|Capecitabine|Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
214985475|NCT01213238|DRUG|Bevacizumab|10 mg/kg by vein on day 1 of a 21 day cycle.
214985476|NCT02344823|DRUG|Vardenafil|per oral intake of 10mg Vardenafil once daily
214985477|NCT02344823|PROCEDURE|HVPG (Hepatic venous pressure measurement) baseline|HVPG measurement day 1
214985478|NCT02344823|PROCEDURE|HVPG (Hepatic venous pressure measurement) day 7|HVPG measurement day 7
214985479|NCT02344823|BEHAVIORAL|IIEF 5 (International Index of Erectile Function) questionaire baseline|IIEF 5 questionaire to define level of erectile dysfunction at baseline
214985480|NCT02344823|BEHAVIORAL|IIEF 5 (International Index of Erectile Function) questionnaire at study phase end|IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
214985481|NCT02344823|DRUG|Placebo intake once daily|
214985482|NCT06380283|DEVICE|Virtual reality headset|Use of a virtual reality headset during pediatric dental care
214985483|NCT01367041|PROCEDURE|vibration|Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
214985484|NCT01020123|DRUG|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
214985485|NCT01020123|DRUG|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
214985486|NCT01020123|DRUG|Glipizide|Glipizide administered to 1 group of patients
214985487|NCT01911741|DRUG|MDV3100|Oral
214985488|NCT01716273|OTHER|Granulated Sugar|30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
214985489|NCT01716273|OTHER|Debridement Dressing|1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
214985490|NCT01178788|DRUG|17 alpha-hydroxy progesterone caproate|weekly injection of 17 P
214370766|NCT03871088|DIETARY_SUPPLEMENT|Omega-3 fatty acids|12-week double-blind, randomized controlled trial
214370767|NCT02557490|DRUG|oxaliplatin and raltitrexed|"TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)"
214370768|NCT06959524|DEVICE|Drug Eluting Balloon|AGENT DCB
214370769|NCT06959524|DEVICE|Drug eluting stent|Any commercially available DES used for standard of care.
214985491|NCT01178788|DRUG|micronized Progesterone|daily administration of vaginal progesterone
214370770|NCT06959524|PROCEDURE|Plain old balloon angioplasty|Bifurcation side branch - POBA
214985492|NCT01178788|PROCEDURE|Control|
214985493|NCT00336908|DRUG|a combination of MCT, LCT , and Fish Oil|
214985494|NCT01576848|DIETARY_SUPPLEMENT|Protein|"Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
214985495|NCT01576848|DIETARY_SUPPLEMENT|Protein + carbohydrate|"subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
214985496|NCT05287815|BEHAVIORAL|training/observation|In the study, elderly individuals who met the sampling criteria and accepted to participate in the study were 30 in the experimental group and 30 in the control group, using the stratified randomization method to control and balance the effects of age (65-75 years, 76 and over) and gender (female and male) variables. It will be planned to be an elderly individual. Computer-assisted randomization, which is one of the simple randomization methods, was assigned to the groups according to the determined.
214985497|NCT06257888|OTHER|patient navigation|two trained patient navigators will admit breast cancer patients to HCM, navigate them from admission to commencement of first treatment and will collect all pertinent epidemiological data and variables
214985498|NCT04660045|DRUG|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
214985499|NCT04646382|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
214985500|NCT04646382|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose
214985501|NCT01141608|OTHER|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
214985502|NCT01141608|OTHER|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
214370771|NCT06960070|DEVICE|Saremco print resin|The teeth were restored with Saremco print resin via Asiga Max printer according to the manufacturer's instructions.
214370772|NCT06960070|DEVICE|Varseosmile Crownplus resin|The teeth were restored with Varseosmile Crownplus resin via Asiga Max printer according to the manufacturer's instructions.
214370773|NCT06960070|DEVICE|Varseosmile TriniQ resin|The teeth were restored with Varseosmile TriniQ resin via Asiga MAx printer according to the manufacturer' instructions
214370774|NCT05497219|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VF)|A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
214370775|NCT06029270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214370776|NCT06029270|PROCEDURE|Bone Scan|Undergo bone scan
214370777|NCT06029270|DRUG|Carboplatin|Given IV
214370778|NCT06029270|DRUG|Cisplatin|Given IV
214370779|NCT06029270|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214370780|NCT06029270|DRUG|Gemcitabine|Given IV
214370781|NCT06029270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214985503|NCT01376219|OTHER|asthma control test|results of asthma control testing collected
214985504|NCT00175227|DRUG|intravenous saline hydration + mannitol + furosemide|500 mls half-normal saline + 25g mannitol + 100 mg furosemide
214985505|NCT00175227|DRUG|intravenous saline hydration|500 mls half-normal saline
214985506|NCT04434508|PROCEDURE|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
214370782|NCT06029270|BIOLOGICAL|Nivolumab|Given IV
214370783|NCT06029270|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214681631|NCT04998045|BEHAVIORAL|Screening and brief intervention for substance use|Screening will be done using the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST). The brief intervention will be delivered based on ASSIST risk scores: low risk - verbal positive reinforcement and brief advice on harmful consequences of substance use (ii) moderate risk - brief motivational interviewing (BMI) (iii) high risk - BMI and referral to child psychiatry out-patient clinic. The BMI will be delivered in a single session (approximately 15 minutes) using Feedback Listen Options model (15): (i) providing feedback on screening results (ii) exploring pros and cons of substance use, enquiring about importance of change (iii) exploring options for change.
214681632|NCT00406315|DRUG|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
214681633|NCT02512263|PROCEDURE|Home-based training program|A home-based training program of 8 exercises to do 5 times a week during 9 weeks
214681634|NCT06397872|DRUG|100 mg Resmetirom Tablet|Once daily oral dose for 6 days
214985507|NCT04434508|PROCEDURE|Open right hemicolectomy with CME and central v|Open right hemicolectomy with CME and central v
214370784|NCT06029270|BIOLOGICAL|Relatlimab|Given IV
214370785|NCT06048081|DRUG|zolbetuximab|"intravenous infusion~mFOLFOX6 or CAPOX (used at physician discretion) will be used in combination with zolbetuximab"
214370786|NCT04026529|OTHER|walking on incline or walking at increasing speed|"Subjects will be prepared for data collection by wearing a form-fitting suit (i.e., wrestling singlet) and obtaining height and body weight. Retro-reflective markers will be placed bilaterally on anatomical locations of the feet, legs, and hips.~Subjects will be outfitted with the portable metabolic cart and oximeter as in the previous visit. One of two treadmill trials will be performed: 1) at the speed and 2) at the slope +speed determined in the previous visit. Trial order will be randomized among subjects and across visits 3 \& 4. For each trial, subjects will be asked to walk on a treadmill for up to 6 minutes. Speed or slope will be increased every 30 seconds and they will be asked to walk for one minute at that speed or slope."
214370787|NCT05646485|DIAGNOSTIC_TEST|Urinalysis|"Urine analysis (every 6 months for 2 years); Patients with \<3 red blood cells (RBCs) per high-powered field (HPF) will repeat screening at 6-month intervals for an average of 2 years.~If RBCs are 3-25 RBSc/HPF- subjects will undergo- \[cystoscopy + Upper tract imaging\] or \[urine marker cancer testing with Cxbladder triage + Upper tract imaging\].~If \>25 RBCs, subjects will get - \[cystoscopy + Upper tract imaging\]."
214370788|NCT06135727|DEVICE|Maestro2 OCT|3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
214370789|NCT05982873|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
214370790|NCT02514681|DRUG|Trastuzumab|
214370791|NCT02514681|DRUG|Pertuzumab|
214370792|NCT02514681|DRUG|Docetaxel|
214370793|NCT02514681|DRUG|Paclitaxel|
214370794|NCT02514681|DRUG|Nab-paclitaxel|
214370795|NCT02514681|DRUG|Vinorelbine|
214370796|NCT02514681|DRUG|Eribulin|
214370797|NCT02514681|DRUG|Capecitabine|
214370798|NCT02514681|DRUG|Gemcitabine|
214370799|NCT02969837|DRUG|Elotuzumab|Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15
215089034|NCT07041801|BIOLOGICAL|hUC-MSCs treatment （Double dose）|Double dosing is selected by the investigators and the sponsor based on the data from the single-dose part of the study. One superior dose is chosen for multiple dosing (tentatively set at 3E6 cells/kg, administered twice with an interval of 4 weeks; the actual dose, frequency and interval of multiple dosing can be adjusted according to the available data). During the trial, stable standard treatment is allowed.
215089035|NCT07040904|BEHAVIORAL|mindfulness|MBSR: Mindfulness Program A novel and culturally-adapted version of the well-validated mindfulness-based stress reduction (MBSR) course will be used for the intervention. The adapted program curriculum embeds core MBSR principles and practices within a culturally responsive didactic framework developed directly from community focus-group feedback. The course will be delivered via a group meeting across 8 weeks, with weekly classes held at a local community center. All classes will be held in hybrid format, with most participants attending in person, but with a live-stream option offered via Zoom.
214985508|NCT02638532|PROCEDURE|Foot Fat Pad Grafting|Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
214985509|NCT06039202|DRUG|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim)
215089036|NCT07041372|DIAGNOSTIC_TEST|FDG-PET|The participants undergo whole-body FDG PET once their neurological status has stabilized after stroke.
214370800|NCT02969837|DRUG|Carfilzomib|Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond
214370801|NCT02969837|DRUG|Lenalidomide|Lenalidomide will be given on days 1-21 for all cycles.
214370802|NCT02969837|DRUG|Dexamethasone|"Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22"
214370803|NCT02956499|DRUG|APX001 single dose 1|
214985510|NCT06039202|DRUG|TAS-102|TAS-102 is a cytotoxic combination treatment of 2 drugs: trifluridine, a thymidine-based nucleoside analogue, and tipiracil an inhibitor of thymidine phosphorylase.
214985511|NCT06039202|BIOLOGICAL|Bevacizumab|Bevacizumab recombinant humanized monoclonal antibody that binds and neutralizes circulating vascular endothelial growth factor (VEGF)-A.
214985512|NCT06422533|DRUG|Ceftolozane/tazobactam|Ceftolozane/tazobactam 1.5 g tid IV infusion for 1 hour during 5 to 7 days
215089037|NCT07041229|PROCEDURE|EMR|"3-4 ml of high-osmolar solution or saline solution stained with indigo carmine are introduced into the submucosal layer under the formation. The formation and the surrounding mucous membrane (at least 5 mm from the edge of the formation) are removed using a standard diathermic polypectomy loop available to the operator. The formation is removed using electric current in the EndocatQ mode. After the formation is removed, the resection site is examined in white light, then virtual chromoscopy (NBI), and then examined with magnification. If residual tissue of the formation is detected, it is removed using the same technique. If the removal of residual tissue of the formation was performed by another method, indicate which one and why.~The removed formation is extracted using a snare loop; if it is removed in parts, then all fragments, if possible, are extracted through the aspiration channel of the endoscope; for large fragments, a snare loop is used."
214370804|NCT02956499|DRUG|APX001 single dose 2|
214493681|NCT06758648|DIAGNOSTIC_TEST|Dynamic retinal vessel analysis (DVA)|"Dynamic retinal vessel analysis (DVA) is an established, non-invasive technique for evaluating the responsiveness of retinal vessels to flickering light stimuli. This technique allows for the measurement of changes in retinal vessel diameter in response to changes in blood flow, providing insight into the microcirculatory function of the retina. In the case of DVA, patients will asked to focus on a needle, and one arteriole and venule diameter were automatically and continuously recorded. Arteriole and venule segments between 0.5 to 1 mm will be analyzed approximately 2-disc diameters away from the optic nerve in a lower-temporal direction. The baseline recording will be 50 seconds, followed by a flickering phase of 20 seconds and then a recovery period of 80 seconds. Three of these cycles were performed.~Based on this, we will calculate the percentage of maximum arteriolar (aFID) and venular dilation (vFID) to baseline."
214493682|NCT06758648|DIAGNOSTIC_TEST|Biochemistry and immune phenotyping|Collection of blood samples from participants for the purpose of performing clinical chemistry analysis. Peripheral blood mononuclear cells (PBMCs) will be isolated from the collected blood samples using standard techniques, such as density gradient centrifugation, and will be analyzed using fluorescence-activated cell sorting (FACS)
214985513|NCT06422533|DRUG|Piperacillin/tazobactam|Piperacillin/tazobactam 4.5 g qid IV infusion for 30 minutes during 5 to 7 days
215089038|NCT07041229|PROCEDURE|ESD|After assessing the boundaries of the formation, a mark is made at least 5 mm from the edge, then a circular or semicircular incision of the mucosa is made, after which the formation is removed by dissection of the submucosal layer using a scarecrow knife, a knife with a ceramic head at the end in EndocutQ mode, spray-coag swift-coag. The EDPS technique - a tunnel method, will also be used where feasible. The essence of the technique is a semilunar incision of the mucous membrane, retreating from the marks, and creating a tunnel under the formation to the proximal edge of the marks, with subsequent cutting off of the formation along the edges. The removed neoplasm is extracted and stretched on a plate. After removal, the edges and bottom of the wound are assessed, if necessary, prophylactic coagulation of visible vessels and clipping are performed.
214370805|NCT02956499|DRUG|APX001 single dose 3|
214370806|NCT02956499|DRUG|APX001 single dose 4|
214370807|NCT02956499|DRUG|APX001 single dose 5|
214370808|NCT02956499|DRUG|APX001 single dose 6|
214370809|NCT02956499|DRUG|APX001 multiple dose 1|
214370810|NCT02956499|DRUG|APX001 multiple dose 2|
214370811|NCT02956499|DRUG|APX001 multiple dose 3|
214370812|NCT02956499|DRUG|APX001 multiple dose 4|
214370813|NCT02956499|DRUG|Matching Placebo|
214370814|NCT06200155|DRUG|Psilocybin|Given by PO
214370815|NCT06200155|OTHER|Niacin|Given by PO
214985514|NCT02339337|OTHER|Abbreviation of treatment duration|
214985515|NCT02866643|DRUG|Etonogestrel-Immediate|The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
214985516|NCT02866643|DRUG|Etonogestrel-Delayed|The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
215089039|NCT06893107|PROCEDURE|Intentional Replantation|The intervention involves intentional replantation (IR) of periodontally compromised single-rooted teeth. Patients are selected based on criteria ensuring no vertical root fractures and potential for restoration. Preoperative preparation includes radiographic evaluation (CBCT/periapical), scaling, and root planing, along with antibiotic prophylaxis. The tooth is extracted non-traumatically using periotomes to preserve the periodontal ligament (PDL). After extraction, the tooth is stored in a sterile medium and granulation tissue is excised. Optional modifications (apical resection, retrograde filling, or surface treatment) may be performed. The tooth is then replanted into the socket, secured with a non-rigid splint, and occlusal adjustment is made. Postoperative care includes analgesics, antibiotics, and chlorhexidine rinse. Follow-ups are scheduled at 1 week, 4 weeks, and 9 months for evaluation of healing, survival, and patient-reported outcomes.
214681635|NCT04860713|DRUG|aspirin and ketamine|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
214985517|NCT04919707|BEHAVIORAL|Header Session|Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.
214985518|NCT04919707|PROCEDURE|MRI Session|Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.
214985519|NCT03721354|OTHER|NAVA vs PSV - TCCD|"Patients will be submitted to 3 different 30 minutes ventilation trials: the first one in PSV mode, the second one in NAVA mode and the third one in PSV mode again. PSV will have PEEP setted by clinician and pressure support set in order to obtain Vt 6-8 ml/kg. NAVA will have the same PEEP as PSV and NAVA level will be set to obtain the same Peak of Inspiratory Pressure) of PSV.~Trans cranial doppler technique will be performed to evaluate the blood cerebral flow speed (average/systolic speed) at the end of every ventilation trial. At the end of each trial, ABGs will be performed. Traces of flow, airways pressure (Paw) and electric diaphragmatic activity (EAdi) will be recorded and acquired through a dedicated ventilator software called NAVA tracker."
214985520|NCT05769972|DEVICE|Immersive Virtual Reality (Parkinson's disease)|This tool involves placing sensors in the space where it will be used, wearing virtual reality glasses, and using controllers to create realistic fictional spaces and interact with them. The program used for the study consists of an interface and a set of tasks designed specifically for the type of cognitive process deficits related to frontal function (executive functions) that are predominantly presented by patients with cognitive impairment associated with Parkinson's disease. This is due to the effect of the disease's pathophysiology on a series of brain circuits and structures that range from the basal ganglia to the frontal lobe. The affected functions correspond to the individual's ability to plan, sequence, organize, make decisions, be flexible, abstract, conceptualize, inhibit, among others.
214985521|NCT05769972|DEVICE|Computer-based cognitive rehabilitation (Parkinson's disease)|This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
214681636|NCT04860713|DRUG|Nurtec (Rimegepant)|Drug: 75 mg of ODT
214681637|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
215089040|NCT03756311|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|
215089041|NCT06736132|DEVICE|High-flow nasal oxygen|In this study, we will use high-flow nasal oxygen for preoxygenation in patients undergoing elective anaesthesia. Preoxygenation with high-flow nasal oxygen is most often performed at flow rates of \<50 l/min. In this study, patients will be randomised to preoxygenation using high-flow nasal oxygen and flow rates of 45 l/min, 70 l/min or 95 /min.
215089042|NCT06756256|DEVICE|Customized insole|Participants will wear the produced customized insoles during daily activities and interventions for six weeks under the guidance of physical therapists working at Miso Hospital in Iksan City. As their continuation of their rehabilitation program, they will receive a conservative physiotherapy treatment five times a week for six weeks.
215089043|NCT06748703|DEVICE|CPAP Treatment|CPAP therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
214681638|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
214681639|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
214681640|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
214681641|NCT02786355|OTHER|Frova bougie|Squeezing an Ambu bag and delivering air through a Frova bougie. Measuring mean volumes of air delivered and peak pressures generated.
214681642|NCT05015400|OTHER|Plain Water|To increase water fluid intake, an additional 1.89 L, during phase 1 of the menstrual cycle (days 1-5).
214681643|NCT00023985|BIOLOGICAL|autologous tumor cell vaccine|
214681644|NCT00023985|BIOLOGICAL|therapeutic autologous dendritic cells|
214681645|NCT00023985|PROCEDURE|conventional surgery|
214681646|NCT02183025|DRUG|Meloxicam 7.5 mg|
214681647|NCT02183025|DRUG|Meloxicam 15 mg|
214681648|NCT02183025|DRUG|Mefenamic acid 500 mg|
214681649|NCT02183025|DRUG|Placebo matching 7.5 mg meloxicam|
214681650|NCT02183025|DRUG|Placebo matching 15 mg meloxicam|
214681651|NCT02183025|DRUG|Placebo matching 500 mg mefenamic acid|
214985522|NCT05769972|DEVICE|Computer-based cognitive rehabilitation (Huntington's disease)|This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
214985523|NCT05769972|BEHAVIORAL|Music-therapy (Huntington's disease)|The process used in each session will be standardized, while the content will be flexible, administering the guidelines according to the mood of the patients and their needs at that time. The therapist's clinical experience will guide them, providing sufficient space for flexible adaptation within the treatment guideline. While the sessions will be standardized, without limiting the music therapist in their interactions, the intervention itself will be applied during the experimental period, using all of the cognitive music therapy exercises detailed below in all groups: auditive perception training, musical sensorial orientation, control of musical attention, training of musical executive function, training in musical mnemotecnia and associative training of mood and musical memory
214985524|NCT01531426|DEVICE|near infrared spectroscopy (INVOS®, Covidien)|Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
214985525|NCT03523637|BEHAVIORAL|Interoceptive Exposure|The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. This psychological technique is about focusing attention on pain, 'staying with the pain' without trying to escape it.
214493683|NCT06758648|DIAGNOSTIC_TEST|Questionnaires (Patient reported outcomes)|This study involves a comprehensive evaluation of life quality, pain, and gastrointestinal (GI) symptoms using a set of established and validated questionnaires. The tools employed include the SF-36 (Short Form-36 Health Survey) to assess overall health-related quality of life across multiple domains, the COMPASS-31 (Composite Autonomic Symptom Score) to evaluate autonomic dysfunction symptoms, and the Brief Pain Inventory (BPI) to measure pain severity and its impact on daily activities. Additionally, the Gastrointestinal Symptom Rating Scale (GSRS) is used to quantify the severity and frequency of GI symptoms, covering dimensions such as reflux, abdominal pain, indigestion, diarrhea, and constipation. Together, these questionnaires provide a multidimensional assessment of the patient's physical, emotional, and symptomatic experiences, allowing for a robust understanding of their health status and quality of life.
214985526|NCT03007875|BIOLOGICAL|high-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
214985527|NCT04711005|DRUG|(2R,6R)-Hydroxynorketamine hydrochloride|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.
214985528|NCT04711005|DRUG|Placebo|Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
215089044|NCT05888662|PROCEDURE|Endo-epicardial ablation|Endo-epicardial ablation of ventricular tachycardia
214493684|NCT06758648|DIAGNOSTIC_TEST|Cardio MRI|Cardiovascular magnetic resonance imaging (CMR or cardio MRI) will be utilized in patients with Fabry disease. This imaging technique will enable detailed assessment and monitoring of key cardiac abnormalities, including thickening of the heart walls, left ventricular hypertrophy, and decreased blood flow in the coronary vessels. Additionally, T1 relaxation time measurement will be conducted, offering a non-invasive means to detect myocardial tissue abnormalities such as fibrosis and sphingolipid accumulation, which are hallmarks of Fabry disease. Together, these measures provide a comprehensive evaluation of cardiac structure, function, and tissue characteristics in affected patients.
214985529|NCT05576896|DRUG|Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab|"Prior to starting therapy, patients will have a pretreatment cross-sectional scan. Patients will then begin with encorafenib 300 mg daily starting with Cycle 1 day 1; then patients will receive IV cetuximab weekly, with 400 mg/m2 on C1D1 as a loading dose and 250 mg/m2 on all other days.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
214985530|NCT03024567|DIETARY_SUPPLEMENT|Salt|10 capsules daily for 14 days
214985531|NCT03024567|DIETARY_SUPPLEMENT|Placebo|10 capsules daily for 14 days
214985532|NCT02753881|DRUG|whole liver lobe cTACE doxorubicin|Doxorubicin CTACE administered in a whole liver lobe manner.
215089045|NCT05888662|PROCEDURE|endocardial ablation only|endocardial-only catheter ablation of ventricular tachycardia
215089046|NCT05055310|DIAGNOSTIC_TEST|MicRNAs test|plasma micRNAs concentration
214493685|NCT06758648|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive, high-resolution imaging technique that utilizes low-coherence light to capture cross-sectional images of the ocular fundus. Based on the principle of interferometry, OCT employs low-coherence light, which is scattered by the tissue, to produce detailed, high-resolution images of the retina and its layers. This technology enables precise visualization of the different retinal layers, including the nerve fiber layer, the ganglion cell layer, and the inner and outer plexiform layers. Additionally, OCT can be used to detect and monitor subtle structural changes in the retina, offering critical insights into retinal microarchitecture and potential manifestations of systemic diseases such as Fabry disease.
214370816|NCT02098538|DRUG|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
214985533|NCT02753881|DRUG|superselective cTACE doxorubicin|Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
214370817|NCT04252742|DRUG|Erenumab|140 mg, 2 consecutive injections of 70 mg
214370818|NCT04252742|DRUG|Placebo|2 consecutive injections
214370819|NCT05997407|BEHAVIORAL|Organic Conceptions mindset management program|"Organic Conceptions is a theoretical model and corresponding 9-step cognitive-based therapy program that enables people to understand where they are in their fertility journey, and provides them with coping strategies to reframe the painful emotional side effects of infertility. In addition to the 9-step program, there are mini-classes on the key triggers that people face when dealing with infertility.~The intervention consists of a series of assignments that participants in the intervention group will complete for a ten-week period. These assignments will take approximately three hours per week to complete. In addition, participants will complete biweekly live support group sessions led by certified coaches and will have the option to join a Facebook support group."
214370820|NCT06304389|OTHER|electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration|Recording of the electrical activity of the brain, of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
214370821|NCT06304389|OTHER|transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration|Transcutaneous vagus nerve stimulation will be performed in helathy subjects, as well as the recording of the electrical activity of the brain, and of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
214370822|NCT05317416|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
214370823|NCT05317416|DRUG|Lenalidomide|Immunomodulatory drug
214370824|NCT05317416|DRUG|Lenalidomide|Immunomodulatory drug
214370825|NCT05317416|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
214370826|NCT04121026|OTHER|External validation of the PAANTHER TB treatment decision algorithm|"The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:~* history of contact~* suggestive TB symptoms~* tachycardia~* chest radiography~* abdominal ultrasound~* Xpert MTB/RIF Ultra.~A score of \>100 is highly predictive of TB. In children with a score \>100, anti-TB treatment will be initiated immediately. In children with a score of \<100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up."
214370827|NCT06644560|BEHAVIORAL|Prehabilitation Intervention|The intervention involves a 3-week prehabilitation program during the participant's preoperative window before cancer surgery. During the intervention, patients will be asked to consume 60 grams of walnuts daily, participate in two 60-minute individualized supervised physical activity training sessions per week, meet with a nutritionist for a 30-60 minute session, and conduct 30 minutes of independent walking per day. The participants will be given pre-portioned walnuts for daily consumption, a pedometer, and educational materials. The participants will track their completion of tasks with a daily log and the study coordinator will also track their attendance at scheduled nutrition and fitness sessions. In addition, the study coordinator will check-in with participants twice weekly and send text reminders about their required activities.
214370828|NCT05572944|OTHER|LDCT lung cancer screen, immediately|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test and chest X ray~5. Arrenge chest CT right away, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~6. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
214681652|NCT06250530|PROCEDURE|High tibial osteotomy using TOMOFIX|TOMOFIX: A guidepin is placed to determine the level and length of the osteotomy with an appropriate hinge position selected. The oscillating saw is then used along with osteotomes to complete the osteotomy under image intensifier guidance. This is opened to the desired width of correction with a trapezoidal gap noted when using laminar spreader in the posterior position to avoid slope change. The plate is then applied and secured as per manufacturers operative technique.
214985534|NCT00506675|DEVICE|Patching|42 hours per week of patching
214985535|NCT00506675|DRUG|Atropine|daily atropine (1%)
214985536|NCT00506675|DEVICE|Patching|two hours of daily patching for 4 weeks, then no treatment
214985537|NCT00506675|DRUG|Atropine|once weekly atropine for 4 weeks, then no treatment
214985538|NCT05672875|DIAGNOSTIC_TEST|Anthrax LF Dx System|Lateral flow immunoassay for the detection of the LF biomarker in whole blood samples.
214985539|NCT02858908|DRUG|Tideglusib|Tideglusib for oral suspension,
214985540|NCT04236778|DRUG|VE303|The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
214985541|NCT04236778|DRUG|Oral Vancomycin|Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
214370829|NCT05572944|OTHER|LDCT lung cancer screen, later|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test.~5. Arrange AI-asisted chest X-ray right away.~6. Arrange chest CT three years later, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~7. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
214370830|NCT06517563|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
214370831|NCT06517563|DRUG|Rivaroxaban|FXa Inhibitor
214370832|NCT06517563|DRUG|UFH|Unfractionated Heparin
214370833|NCT06517563|DRUG|Enoxaparin|Low Molecular Weight Heparin
214370834|NCT06020014|DRUG|AZD4604|AZD4604
214370835|NCT06020014|OTHER|Placebo|Placebo
214370836|NCT05370781|BEHAVIORAL|Peer Led Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
214370837|NCT05370781|BEHAVIORAL|Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.
214370838|NCT06262997|OTHER|Pilates|Pilates training will be given to groups of 3 people for 8 weeks, 2 days a week. Exercises will start with 10-12 repetitions and the number of repetitions will be increased to 20 starting from the 4th week. Before the Pilates training, basic principles such as breathing, concentration, focusing on the center, control, precision and fluid movement will be taught in a special session to inform individuals about the training principles and exercises. Each exercise will be demonstrated by the physiotherapist and cues such as tactile, verbal and imagery will be used to control the participants throughout the training. The difficulty level of Pilates training will be progressed by changing body positions, exercise ball and band use according to the performance of the patients and Pilates principles. The exercise program will start with warm-up exercises and end with 40 minutes of basic Pilates exercises followed by cooling exercises.
214370839|NCT06262997|OTHER|Pilates and Kinesiotape|Patients in the Pilates and Kinesiotape group will receive exactly the same Pilates training as in the Pilates group. At the end of each exercise session, Kinesio Tex Gold FP elastic tape (5 cm) will be applied with mechanical correction technique for postural correction and the tape will be renewed in each session. Waterproof, porous, adhesive, 0.5 mm thick tape will be applied to the upper trapezius.
214370840|NCT06199934|BIOLOGICAL|Vaccination|BNT162b2 vaccination
214370841|NCT04270747|DRUG|ABP 938|Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
214370842|NCT04270747|DRUG|Aflibercept|Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
214370843|NCT06239519|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
214370844|NCT04862676|DRUG|Hyperbaric oxygen|The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes are spent during the compression and decompression phases and subjects have 5-10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
214370845|NCT03672539|DRUG|Gemtuzumab Ozogamicin|Given IV
214370846|NCT03672539|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
214370847|NCT03672539|OTHER|Quality-of-Life Assessment|Ancillary studies
214370848|NCT06636565|OTHER|No intervention|No intervention
214370849|NCT06796764|DEVICE|the COMBO Endoscopy Oropharyngeal Airway Group|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
214370850|NCT06796764|DEVICE|Regular Nasal Cannula|Using regular nasal cannula for oxygenation.
214370851|NCT03459287|DEVICE|INTERCEPT|Pathogen reduced RBCs
214370852|NCT03459287|DEVICE|Control|Conventional RBCs
214370853|NCT04138277|DRUG|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
214370854|NCT04138277|BIOLOGICAL|ATB200|Enzyme Replacement Therapy via intravenous infusion
214370855|NCT04189354|DEVICE|Transcranial direct current stimulation (t-DCS) device|t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.
214370856|NCT01784068|DRUG|Nilotinib followed by treatment-free|Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
214370857|NCT04877288|BIOLOGICAL|Belatacept|Specified dose on specified days
214370858|NCT04877288|DRUG|Tacrolimus|Specified dose on specified days
214370859|NCT04877288|DRUG|Cyclosporine A|Specified dose on specified days
214370860|NCT04877288|DRUG|Mycophenolate Mofetil|Specified dose on specified days
214370861|NCT04877288|DRUG|Enteric Coated Mycophenolate Sodium|Specified dose on specified days
214370862|NCT04877288|DRUG|Corticosteroids|Specified dose on Specified days
214985542|NCT03524378|BEHAVIORAL|Ergonomic and movement modifications|Introduction of basic ergonomic and self-management principles, participants will review video clips of the prioritized and revised solutions. Adjustments in work tasks, movement strategies or self-management techniques will be self selected by workers after an educational session using videotapes of work processes.
214985543|NCT06355349|DRUG|Reference Drug or Test Drug|Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration
214985544|NCT05212298|DIETARY_SUPPLEMENT|The gel contains a mixture of glucose and maltodextrin|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
214681653|NCT06250530|PROCEDURE|High tibial osteotomy using BodyCAD|BodyCAD: The patient specific cutting block is applied to the proximal tibia and secured in placed. The osteotomy is then created with sequential drills and osteotome and opened to the predetermined correction as per the manufacturer's guidelines. The plate is applied and secured with the supplied screws.
214985545|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound low-dose|The total amount of herbal compound capsules is 557 mg.
214985546|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound high-dose|The total amount of herbal compound capsules is 1114 mg.
214985547|NCT06395727|DRUG|Fentanyl|traditional fentanyl dose
214985548|NCT06395727|DRUG|Lidocain|lidocaine nebuliser and lidocaine spray targeting difficult swallowing
214370863|NCT03178552|DRUG|Alectinib|Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
214985549|NCT03279575|BEHAVIORAL|Night Shift|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.
214370864|NCT03178552|DRUG|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
214370865|NCT03178552|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
214370866|NCT03178552|DRUG|Cisplatin|Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
214681654|NCT03140800|DEVICE|intrauterine device|a method of contraception inserted in the uterus
214985550|NCT03279575|BEHAVIORAL|Graveyard Shift|Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.
214985551|NCT03279575|BEHAVIORAL|Educational program|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.
214985552|NCT03279575|BEHAVIORAL|Control|Physicians in this arm will serve as a no-contact control group.
214370867|NCT03178552|DRUG|Carboplatin|Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
214681655|NCT02273154|DRUG|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
214681656|NCT02273154|DRUG|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
214985553|NCT03846375|BEHAVIORAL|Psychotherapy|DBT is a well-established treatment for recurrent self-harm and suicidal thoughts. The program is principle-based, but the skills training follow a manualized curriculum.
214985554|NCT03846375|OTHER|Pre-intervention testing|Pre-intervention testing for baseline measures.
214985555|NCT01800370|DRUG|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
214985556|NCT01800370|DRUG|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
214985557|NCT01800370|OTHER|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds."
214370868|NCT03178552|DRUG|Gemcitabine|Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
214370869|NCT03178552|DRUG|Entrectinib|Participants will receive entrectinib 600 mg orally QD.
214370870|NCT03178552|DRUG|Cobimetinib|Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
214370871|NCT03178552|DRUG|Vemurafenib|Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
214370872|NCT03178552|DRUG|Bevacizumab|Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
214370873|NCT03178552|DRUG|Divarasib|Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.
214370874|NCT03178552|DRUG|Docetaxel|Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
214681657|NCT05921006|DRUG|RJ4287|Oral，tablets，Once daily for 14 days
214681658|NCT05921006|DRUG|Placebo|Oral，tablets，Once daily daily for 14 days
214681659|NCT00848692|DRUG|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
214681660|NCT00848692|DRUG|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
214681661|NCT01142219|DRUG|L-arginine|L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
214681662|NCT01142219|DRUG|Placebo|Mannitol was administered orally at a dose of 01 g/kg/day for six months.
214681663|NCT00819624|OTHER|Interactive Voice Response System (IVRS)|Telephone based system
214985558|NCT01800370|PROCEDURE|Blood Draws|Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
214985559|NCT01800370|OTHER|Fasting procedure|Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
214985560|NCT06500702|DRUG|frexalimab|frexalimab treatment
214370875|NCT06079203|BEHAVIORAL|Emergency Care Redesign (ECR)|"Care Process Redesign: Care process redesign with a shared structured worksheet for data gathering, standardized assessment and referral. Education of all providers (Physician, Nurse, and Social Work Champion) on new processes at huddles and via on-line training, smart phone-compatible animated videos, faculty meetings, e-mail and from ED champions on shift~CDS System: Alerts and new workflow to refer the dyad to social work or care manager. Continued use throughout study period and beyond~Follow up: Within 72 hours of ED visit if discharged home Social Work Champion will have a single phone call. Triadic telephone encounter to ensure understanding of discharge plan, medication management and connection to community services"
214985561|NCT06500702|DRUG|SAR442970|SAR442970 treatment
214985562|NCT06500702|DRUG|rilzabrutinib|rilzabrutinib treatment
214370876|NCT06079203|BEHAVIORAL|Nurse-led Telephonic Care (NLTC)|Telephonic support for dyad for safe ED to home care transition, and to enhance knowledge and management of AD/ADRD and co-morbid conditions. First call to dyad within 72 hours of index ED visit from Registered nurses. Each call \~30 minutes depending on needs and willingness of dyad. Calls also occur at 14 days, and at least monthly thereafter for 6 months. Dyad or nurse can initiate additional as-needed calls and coordinate care and care needs with other providers
214370877|NCT06079203|BEHAVIORAL|Community Paramedic-led Transitions Intervention (CPTI)|Community paramedics to provide coaching with dyad to improve medication management, outpatient follow up, understanding of red flags necessitating medical care. Home visit within \~5 days of index ED visit. One home visit and three telephone encounters over 30 days
214370878|NCT06807437|PROCEDURE|Biospecimen Collection|Undergo blood sample and pancreas fluid collection
214370879|NCT06807437|PROCEDURE|Distal Pancreatectomy|Undergo distal pancreatectomy
214985563|NCT06500702|DRUG|placebo|placebo treatment
214985564|NCT03824561|DRUG|Vedolizumab|Vedolizumab IV infusion
214370880|NCT06807437|DRUG|Lanreotide|Given SC
214370881|NCT06807437|OTHER|Questionnaire Administration|Ancillary studies
214370882|NCT06807437|OTHER|Saline|Given SC
214370883|NCT00520390|DRUG|EZN-2208|
214370884|NCT05845814|BIOLOGICAL|Coformulated favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
214493686|NCT06758648|DIAGNOSTIC_TEST|Echocardiography|Detection of signs of left ventricular hypertrophy, diastolic dysfunction, and valvular disease, which are common cardiac complications associated with Fabry disease, will be a key focus of the assessment. These abnormalities are indicative of the progressive cardiac involvement characteristic of the disease. Left ventricular hypertrophy reflects the thickening of the heart muscle, often caused by sphingolipid accumulation, while diastolic dysfunction highlights impaired relaxation and filling of the left ventricle. Valvular disease, including regurgitation or stenosis, further contributes to the cardiac burden in Fabry disease. Identifying and monitoring these conditions are essential for timely intervention and effective management of cardiac manifestations in affected patients.
214493687|NCT06758648|DIAGNOSTIC_TEST|24 hour pulse wave analysis|Pulse wave analysis (PWA) is a non-invasive method used to assess the cardiovascular system. It uses a sensor to measure the pressure waves generated by the heart's contraction and the subsequent blood flow through the peripheral vessels. By analyzing these pressure waves, PWA can provide information about the elasticity of the arterial walls, the blood flow in the peripheral vessels, the blood pressure, and the arterial stiffness.
214493688|NCT06758648|DIAGNOSTIC_TEST|24-hour blood pressure measurement|Blood pressure measurement to asses cardiovascular risk.
214493689|NCT06758648|DIAGNOSTIC_TEST|1 hour ECG|One hour ECG to asses autonomic dysfunction in patients with Fabry disease.
214493690|NCT06758648|DIAGNOSTIC_TEST|Ophthalmological consultation|Evaluation and monitoring of ocular manifestations of Fabry disease.
214493691|NCT06758648|DIAGNOSTIC_TEST|Static retinal vessel analysis (SVA)|"Comparable to DVA, SVA is a non-invasive and quick tool to examine the retinal microvasculature. SVA pictures will be analyzed using Vesselmap 2® (IMEDOS Systems GmbH, Jena, Germany). One eye will be examined, and three images will be taken with a focus on the optic disc at an angle of 50°. Roughly one disc diameter away from the optic disc, retinal veins and arterioles segments will be semi-automatically labeled. The Paar-Hubbard formula averages the central retinal arteriolar (CRAE) and central venular (CRVE) equivalents.~The arteriolar-venular ratio will be calculated as CRAE/CRVE."
214493692|NCT06886620|DRUG|Cilostazol 200 mg|Provided as 1# placebo tablet in the morning and 1# PMR 200 mg/tablet in the evening, orally, for 24 weeks.
214681664|NCT00819624|OTHER|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
214985565|NCT05771402|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
214370885|NCT05845814|BIOLOGICAL|Coformulated vibostolimab/pembrolizumab|Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
214370886|NCT05845814|COMBINATION_PRODUCT|EV|1.25 mg/kg IV infusion
214370887|NCT05845814|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
214370888|NCT00743561|DEVICE|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
214493693|NCT06886620|DRUG|Cilostazol 100 mg|Provided as 1# Pletaal® 100 mg/tablet, orally twice a day, for 24 weeks.
214493694|NCT06779227|BEHAVIORAL|Hospital family transitional nursing intervention|The intervention group received a transitional care intervention mainly focused on the transitional care model (TCM).
214493695|NCT05954481|OTHER|Stress echocardiography|After a rest trans thoracic echocardiography (usual follow-up), eligible patients will have a stress ultrasound echocardiography on a dedicated cycle ergometer
214493696|NCT06920433|BIOLOGICAL|UCAR T-cell group|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
214681665|NCT03868007|DEVICE|RIC|The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
214985566|NCT05771402|DRUG|NAs|Once/day, 1 capsule/time, oral
214985567|NCT05771402|DRUG|Peg-IFNα|Once/week, 180μg/time, subcutaneous injection
214985568|NCT07133828|DRUG|BIIB142|Administered Orally
214985569|NCT07133828|DRUG|BIIB142-Matching Placebo|Administered Orally
214985570|NCT06095999|BEHAVIORAL|Perfect Fit intervention: virtual coaching intervention to quit smoking and increase physical activity|The intervention, delivered through a virtual coach, has a personalized duration and intensity, but will last on average 16 weeks. The intervention has three phases: preparation, execution (including \[re\]lapse) and closing. By having chat conversations with the Perfect Fit virtual coach (using the mobile application 'NiceDay'), the user will be guided through the different phases of the intervention. In each phase, the user has chat conversations with the virtual coach (e.g. about goal setting, weekly reflection) and, in addition, receives exercises and educational video material to support smoking cessation and PA promotion. Additionally, a smartwatch is used to objectively assess PA. It allows participants to monitor their PA and the data (on the number of steps) is used to give automatic, personalized PA advice to the user.
214985571|NCT01773928|BIOLOGICAL|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
214985572|NCT01773928|BIOLOGICAL|VCIV manufactured with the current manufacturing process (VCIV current)|
214985573|NCT01773928|BIOLOGICAL|Fluzone®, licensed trivalent influenza vaccine (TIV)|
214985574|NCT06978127|BEHAVIORAL|Technology Assisted Stepped Collaborative Care|The TĀCcare 2.0 intervention will provide pharmacotherapy recommendations and/or CBT for pain, fatigue and depression. A stepped-treatment approach will be used to intensify treatment. CBT will be provided through 12 weekly telehealth sessions (done during dialysis treatment or from home) with the behavioral specialist. Booster sessions will be used to enhance the maintenance of effect following the initial intervention to complete a total 12 month intervention. A collaborative care approach will be used so that patients' symptom management will be integrated with their dialysis treatment. Throughout the study, participants will be asked to complete phone surveys about their symptoms and health.
214985575|NCT06978127|OTHER|Usual Care Arm|Participants in the Usual Care Arm will continue with their usual care.
214985576|NCT06428175|BEHAVIORAL|Focused Dose Hospital-to-Home Transitional Care Interventions|Focused dose H2H-TCIs will consist of a one-time post-discharge phone call completed within 72 hours post-hospital discharge by a clinical interventionist (e.g., nurse care coordinator or care manager). Calls will follow a structured template that provides empirically supported core H2H-TCI functions (follow-up care access, contingency planning, medication review, family education). The interventionist will also conduct a pre-hospital discharge clinical needs assessment with the parent.
214985577|NCT06428175|BEHAVIORAL|Extended Dose Hospital-to-Home Transitional Care Interventions|Extended dose H2H-TCIs will include a pre-discharge clinical needs assessment and initial phone call within 72 hours post-discharge, similar to the focused arm. After the initial contact, the dose of the extended H2H-TCI will increase as subjects receive high-intensity support during weekly post-discharge phone contacts through 30 days post-discharge. All contacts in the extended dose arm will be completed by a transition coach interventionist (e.g., nurse care coordinator or care manager) who will be formally trained on pillars of the Care Transitions Intervention© (CTI), a multi-faceted H2H-TCI that is the basis for the extended dose arm.
214985578|NCT05105347|DRUG|Adalimumab plus different doses of oral glucocorticosteroid|A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
214370889|NCT00743561|DEVICE|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
214370890|NCT04108052|RADIATION|Low CT scanner without injection dose|CT scan acquisition will be performed at 140 kVp (kilovolt peak), 10 mAs(milliampere), CTDI 1.3 mGy with an irradiation dose 0.51 mSv (milliSievert). The CT image will be reconstructed and analyzed in parenchyma window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
214370891|NCT04108052|RADIATION|Ultra-low dose CT scanner without injection|CT acquisition will be performed at 80 kVp for patient with a body mass index\<30, and 100 kVp with a body mass index\>30, 10 mAs, CTDI 0.3 and 0.6 mGy with an irradiation dose 0.15-0.30 mSv. The CT images will be reconstructed and analyzed in mediastinal window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
214370892|NCT06455371|OTHER|Decision support tool|Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.
214370893|NCT06465186|COMBINATION_PRODUCT|Efinopegdutide|Efinopegdutide is given as a subcutaneous injection using a single-use prefilled syringe, once per week for 28 weeks
214370894|NCT06465186|COMBINATION_PRODUCT|Placebo|Placebo is given as a subcutaneous injection using a single-use prefilled syringe once per week for 28 weeks.
214370895|NCT03726788|DRUG|Botulinum Toxin Type A 100U|one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI
214370896|NCT03726788|DRUG|Botulinum Toxin Type A 200U|one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI
214370897|NCT03726788|DRUG|Triamcinolone Hexacetonide Inj Susp 20 MG/ML|one intra-articular injection of 2 ml Triamcinolone Hexacetonide
214370898|NCT00344058|DRUG|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
214370899|NCT05902234|BEHAVIORAL|interdiciplinary treatment|Normal interdiciplinary treatment path
214370900|NCT05434858|OTHER|Dual-energy CT (DECT) and ultrasound|DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.
214681666|NCT03868007|DEVICE|sham-RIC|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
214681667|NCT06250127|DEVICE|Modified 3D printed facemask|modified 3D printed customized maxillary protraction facemask will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
214681668|NCT06250127|DEVICE|Conventional facemask appliance|Conventional facemask appliance will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
214681669|NCT02446054|DIETARY_SUPPLEMENT|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
214681670|NCT03407924|OTHER|Aerobic Exercise (AER)|Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.
214985579|NCT06001879|OTHER|Simulation in basic life support training (SBLST)|The interventional tools, simulation in basic life support training (SBLST), were prepared in English. The researcher will use an already established BLS training from the American Guidelines 2020, a simplified two-part; PowerPoint presentation, and clinical simulation training.
214985580|NCT06001879|OTHER|standard treatment by using an AHA-BLS 2020 brochure|The participants will read and understand this brochure over 30 minutes, including a brief guideline about basic life support guidelines, and after these 30 minutes, the participants will move to the post-test
214985581|NCT03879070|DEVICE|Ankle active and passive mobilization using an Ankle mobilization device|The treatment consists in 20 rehabilitation sessions, 5 times/week for 4 weeks. The device is capable of generating ankle dorsi/plantarflexion movements using two activation modes: passive and assistive. In the passive mode the device generates a movement pattern which the patient follows passively without exerting any force on the device. During the assistive mode, the device follows the active movement of the patient. During the intervention, these two modes will be alternated.
214370901|NCT00209924|DRUG|Gaboxadol|
214370902|NCT01864239|OTHER|Medicines Advice Service|"The intervention consists of:~1. Telephone consultations with a pharmacist~2. Follow-up tailored written information~3. A medicine reminder chart"
214370903|NCT02137525|DRUG|Morphine 6 mg|Intravenous infusion - delivering morphine 6 mg
214370904|NCT02137525|DRUG|Fentanyl 100 µg|Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
214370905|NCT02137525|DRUG|Fentanyl 200 µg|Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
214370906|NCT02137525|DRUG|Fentanyl 400 µg|Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
214370907|NCT02137525|DRUG|Placebo Sublingual Spray|Matching sublingual spray - single unit delivering 0 µg fentanyl
214370908|NCT02137525|DRUG|Intravenous Placebo|Matching intravenous infusion - delivering 0 mg morphine
214370909|NCT01348750|OTHER|Healing Touch & Guided Imagery|"Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and the energy centers which control the flow of energy to the physical body.~HT complements traditional health care and is used together with other approaches to health and healing.~Guided Imagery (GI) is a form of focused relaxation used to create harmony between the mind and body. Positive mental imagery can promote relaxation, reduce stress and improve mood as well as alter heart rate, blood pressure and breathing."
214370910|NCT06190795|OTHER|AMPLIFY Smartphone Application|AMPLIFY Smartphone Application enables prescription and progression of exercises/functional activities, while offering immediate feedback on upper limb movement performed, real-time logging and monitoring of adherence through virtual platform
214370911|NCT06190795|OTHER|Hardcopy Manual|Hardcopy Manual
214681671|NCT03407924|OTHER|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
214681672|NCT02142894|DEVICE|CST001|
214681673|NCT00904241|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214681674|NCT00904241|OTHER|Laboratory Biomarker Analysis|Correlative studies
214985582|NCT03092752|DRUG|oral antidiabetic drugs|OADs usage conditions and dose selection in T2DM patients
214985583|NCT03567681|DRUG|Extended release oxcarbazepine vs Immediate release oxcarbazepine|Extended release oxcarbazepine vs Immediate release oxcarbazepine
214985584|NCT00217945|BEHAVIORAL|Shared-Decision Making|
214985585|NCT05784051|DRUG|Experimental group|medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain \>10% after 2 lines of AAD treatment).
214985586|NCT05784051|DRUG|Control group|patients of this group have no therapeutic or no treatment modification such as drug therapy
214985587|NCT00486681|DEVICE|Accu Chek Inform and Cobas IT 1000|period II (warning activated)
214985588|NCT01420159|DRUG|Methoxyflurane|Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
214985589|NCT05058989|DIAGNOSTIC_TEST|Advanced ultrasound measurements (Duplex ultrasound (DUS) and Vector flow imaging (VFI)|PPG is a non-invasive method used to evaluates the severity venous reflux by measuring the venous refiling time (VRT).The principal of PPG works by using a small light source and a photoelectric cell attached to the skin in the medial supramalleolar area of the leg (the distal lower medial area of the leg).
214985590|NCT05058989|OTHER|Clinical interventions and procedures|"First trimester (0-13 weeks):~* Consent~* Clinical data collection~* Blood samples (genomic+ hormonal)~* Duplex ultrasound~* Vector flow imaging (advanced ultrasound software)~* Truncated cone tool (measuring leg circumference using a tape measure)~* PPG~* AVVQ (Aberdeen varicose veins questionaire)~Second trimester (14-26 weeks):~* Clinical data collection~* Blood sample (hormonal only)~* DUS~* VFI~* Truncated cone tool~* PPG~* AVVQ~Third trimester (27-40 weeks):~Same as second trimester~Three months after giving birth:~Same as second trimester"
214370912|NCT05855226|OTHER|OTHER-intervention (Occupational Therapy at Home E-Rehabilitation)|The occupational therapist will use activity monitoring and coaching techniques with videoconference during OTHER.
214370913|NCT05034432|PROCEDURE|Intra-Op Prophylactic VT ablation|For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping
214681675|NCT03454139|PROCEDURE|Subcostal transversus abdominis plane block|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
214681676|NCT03074448|DEVICE|Aquanet|Aquanet bowel cleansing devices
214681677|NCT03074448|DRUG|Sodium Picosulfate|Sodium Picosulfate solution (Picoprep)
214985591|NCT02284100|BEHAVIORAL|animal assisted therapy|"For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.~The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions."
214985592|NCT04987047|BIOLOGICAL|Blood collection|A blood sample will be collected at enrollment to perform pharmacogenetics analyses.
214985593|NCT04987047|OTHER|Questionnaires|Several questionnaires will be filled by the participants or by the clinicians at every study visits: Hospital anxiety depression scale (HAD), Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), Quick inventory of depressive symptomatology - self rated (QiDS), Beck's Anxiety Inventory (BAI), World Health Organization Quality Of Life (WHOQOL-BREF), EuroQol Group questionnaire (EQ5D), Frequency, intensity, burden of side effects rating (FIBSER), Udvalg for Kliniske Undersøgelser - Side Effects Rating Scale - for Patients (UKU-SERS-PAT), Clinical Global impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS).
214985594|NCT04987047|OTHER|Cognitive test battery (optional)|"For patients participating in the ELAN ancillary study : the participants will undergo a battery of neurocognitive tests assessing motivation (élan vital in French)."
214985595|NCT04499703|DEVICE|RHMS-RTM|Assessment of retinal thickness
214985596|NCT04499703|DIAGNOSTIC_TEST|SD-OCT|Assessment of retinal structure
214985597|NCT03397017|OTHER|Transfusion|
214985598|NCT04092478|OTHER|Spinal Anesthesia Position|The patient positions during the spinal anesthesia
214985599|NCT01586052|DRUG|Erythropoietin|250 IU/kg, Twice a week for 4 weeks
214985600|NCT06804824|DRUG|VVD-159642|Oral capsules
214985601|NCT06804824|DRUG|Sotorasib|Oral tablets
214985602|NCT06804824|DRUG|Trametinib|Oral tablets
214985603|NCT06593938|DRUG|HRS-5965 capsule|HRS-5965 capsule for 24 weeks
214985604|NCT06593938|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
214985605|NCT01706562|DRUG|Itraconazole|Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
214370914|NCT05034432|OTHER|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
214681678|NCT02898025|DEVICE|Active Interferential Current|Involves the application of medium frequency alternating currents
214681679|NCT02898025|DEVICE|Active Laser|Involves the application of low level laser over the knee
214681680|NCT02898025|DEVICE|Placebo Interferential Current|It is a sham interferential therapy
214681681|NCT02898025|DEVICE|Placebo Laser|It is a sham laser therapy
214985606|NCT00792285|BEHAVIORAL|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
214985607|NCT03393182|PROCEDURE|TLDG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
214985608|NCT03393182|PROCEDURE|LADG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
214985609|NCT03485599|DIAGNOSTIC_TEST|ELIZA , Westron blot|Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done
214985610|NCT04887649|DRUG|Morphine|morphine 3 mg
214985611|NCT04887649|DRUG|saline solution|4 cc of saline solution in epidural cateter in postpartum
214985612|NCT04887649|DRUG|Morphine|morphine 2 mg for epidural cateter in postpartum
214985613|NCT05724758|PROCEDURE|Breast-conserving surgery|"Following oncoplastic surgeries are performed at the Brust-Zentrum in Zurich:~* Oncoplastic reconstruction with round-block technique~* Oncoplastic reconstruction using J-Plastic~* Oncoplastic reconstruction using V-Plastic~* Oncoplastic reconstruction using Grisotti~* Oncoplastic reconstruction using Batwing~* Oncoplastic reconstruction using Mammareductionplasty (Wise Pattern, Vertical)~* Oncoplastic perforator flap surgery"
214985614|NCT01549665|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.
214985615|NCT04400266|DRUG|Buspirone|Buspirone 15mg once daily
214985616|NCT04400266|DRUG|Mealatonin|Melatonin 3mg once nightly
214370915|NCT04290130|OTHER|Measurement of brain activity using electrodes.|We will present audiovisual speech and record neural responses.
214681682|NCT05924100|DRUG|Luspatercept Injection [Reblozyl]|"Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit."
214985617|NCT05408364|DIETARY_SUPPLEMENT|probiotic or natural yoghurt|Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt
214985618|NCT05408364|PROCEDURE|SRP|Scalling and root planing
214985619|NCT05745623|DRUG|ICP-723|ICP-723 tablet administered orally，once a day，for every 28 days as one cycle
214985620|NCT06983743|DRUG|ERAS-0015|ERAS-0015 Administered orally
214681683|NCT05490953|DRUG|Pentoxifylline|Patients will be treated pentoxifylline during the first two chemotherapy cycles of their respective treatment.
214681684|NCT05490953|DRUG|Placebo|Patients will be treated with placebo during the first two chemotherapy cycles of their respective treatment.
214370919|NCT04605731|BIOLOGICAL|Durvalumab|Given IV
214370920|NCT04605731|BIOLOGICAL|Tremelimumab|Given IV
214370921|NCT05614089|DRUG|Insulin Glargine|"Formulation: Available as a clear liquid in a glass cartridge (1 cartridge =3ml=300 units).~Route: Reusable pen~Amount of each dose: varies depending on baseline basal insulin needs~Dose escalation scheme: Participants randomly assigned to glargine will start with a dose that is generally equal to 80% of their total basal human insulin dose prior to the switch (per ISPAD guidelines and the switching guide developed by Life for a Child with the guidance of Dr. Ragnar Hanas and two other ISPAD members familiar with less-resourced settings).~Frequency of dose: once per day (usually administered before bedtime)~Duration of therapy: 12 months"
214370922|NCT05614089|DRUG|NPH or premixed 70/30 (human insulin)|"Formulation: Available as a liquid in a glass cartridge (3ml=300IU) or as liquid in a prefilled, disposable pen (3ml=300IU).~Route: Bangladesh = reusable pens; Tanzania = disposable pens~Amount of each dose: varies depending on baseline basal insulin needs (per usual care or treating clinician)~Frequency of dose: once or twice per day (per usual care or treating clinician)~Duration of therapy: 12 months"
214493697|NCT06022081|DIAGNOSTIC_TEST|Lung ultrasound to detect pneumothorax.|Within a maximum of two hours after chest tube removal, the sonographic exam will be performed with an ultrasound device to assess residual PNX using a portable ultrasound device. The examination will require patients to lie face upward and will be performed at three different sites on both sides of the patient's chest. Each chest site will be imaged for approximately 10-20 seconds, allowing a complete examination of each side in approximately 30-60 seconds. The total study time for the LUS exam is approximately 2 minutes. The results of this assessment will be compared to the standard chest x-ray performed by a radiologist who is unaware of the study.
214493698|NCT05220332|BEHAVIORAL|Heart to Heart|The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.
214681685|NCT06024928|DEVICE|Control-IQ use in Type 2 Diabetes under basal insulin injections|Testing the safety and feasibility of using Automated Insulin Delivery (AID) in people with Type 2 Diabetes under basal insulin injections to achieve safe and fast basal insulin titration.
214985621|NCT06983743|DRUG|ERAS-0015 in combination|ERAS-0015 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.
214985622|NCT06606002|BEHAVIORAL|Group schema therapy|Group schema therapy based on the model by Farrell and Shaw, which is complemented with separate group sessions for the participants\&#39; parents
214985623|NCT06606002|BEHAVIORAL|Treatment as Usual (TAU)|TAU typically comprises visits at the outpatient clinic with variable frequency and content
215089047|NCT06776549|PROCEDURE|Temperature control|Procedure: Temperature control at 33-34 °C In the hypothermia group, patients receiving ECPR will be immediately cooled to 33ºC-34ºC with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be kept at 33ºC-34°C. The maintenance phase will end 24 h after reaching this targeted temperature. Subsequently, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
215089048|NCT06776549|PROCEDURE|Temperature control|Procedure: Temperature control at 36 °C In the normothermia group receiving ECPR, the temperature of 36ºC will be immediately reached with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be maintained at 36ºC. The maintenance phase will end 24 h after reaching this targeted temperature. Then, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
215089049|NCT06609928|BIOLOGICAL|FOLR1 CAR T-cells|Given IV
214370923|NCT05587712|DRUG|Sotatercept|SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
214370924|NCT06432686|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is a safe, relatively cheap, and non-painful stimulation of the peripheral sensory and motor nerves. The stimulator is easy to operate and pwMS can apply the stimulation themselves at home. This makes TENS an interesting tool to augment sensory input. A high frequency and long pulse duration is used.
214370925|NCT06432686|BEHAVIORAL|Movement|Participants are instructed to perform plantar- and dorsi-flexion contraction in a relatively slow tempo. The movement of the ankle is measured by an MRI-compatible potentiometer and participants receive feedback of this movement on the screen inside the scanner.
214370926|NCT03809273|DRUG|Yangxinshi|Yangxinshi pill 3 pills /tid
214370927|NCT03809273|DRUG|Trimetazidine|Trimetazidine 20mg/tid
214370928|NCT03809273|DRUG|Yangxinshi mimic|Yangxinshi mimic tablets 3 pills /tid
214370929|NCT03809273|DRUG|Trimetazidine mimic|Trimetazidine mimic tablets 20mg/tid
214370930|NCT05038930|DEVICE|Mobilisation using the Sara Combilizer|The mobilisation with the Sara Combilizer, will be done one time either 24 or 48 hours after stable intracranial pressure
214370931|NCT05656040|BIOLOGICAL|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
214985624|NCT03974464|DIAGNOSTIC_TEST|copeptin, PS100|"Age, sex and time between dizziness onset and ED visit were collected using Resurgences® software. PS100 concentrations were measured on serum samples by electro-chemiluminescence assay. Copeptin concentrations were measured on serum samples by the Kryptor method. The positivity threshold for copeptin was set at strictly above 10 pmol/L and that of PS100 was set at strictly above 0.105 μmol/L.~And after, we compared results with results of brain imaging: Magnetic Resonance Imaging alone, CT scan alone or both. Depending on clinical presentation, the imaging tests were performed during ED stay, during hospitalization or externally. Presence or absence of stroke was established on diffusion-weighted brain MRI . In case of normal contrast CT alone, a specialized opinion should exclude the need for diffusion-weighted MRI according to clinical presentation."
214985625|NCT06604442|DRUG|Flotufolastat (18F)|Positron emission tomography (PET)
215089050|NCT06609928|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
215089051|NCT06609928|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215089052|NCT06609928|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214370932|NCT05656040|DRUG|Placebo|Normal saline administered subcutaneously
214370933|NCT04273542|OTHER|liquid biopsy|Blood sample collection during follow-up of the three cohorts of patients
214370934|NCT06356220|OTHER|Gluten-Free Diet Education|The two groups will receive different gluten free diet education interventions. Currently, virtual GFD education classes are the standard of care for educating children with CeD and their families about GFD at Boston Children's Hospital. Thus, all diet education (including GFFG intervention) will be provided virtually by Registered Dietitians with expertise in GFDs. .
214370935|NCT01712477|DRUG|Intravenous sedation using propofol|Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
214370936|NCT01712477|DRUG|Intravenous sedation with midazolam|patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
214493699|NCT05220332|BEHAVIORAL|Money Smart|The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
214493700|NCT05397457|DEVICE|low-level light therapy|"Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks."
214985626|NCT06604442|DRUG|piflufolastat (18F)|Positron emission tomography (PET)
215089053|NCT06609928|DRUG|Cyclophosphamide|Given IV
215089054|NCT06609928|PROCEDURE|Echocardiography|Undergo ECHO
215089055|NCT06609928|DRUG|Fludarabine|Given IV
215089056|NCT06609928|PROCEDURE|Pheresis|Undergo apheresis
214370937|NCT04875286|OTHER|Electronic Health Record Review|Medical records reviewed
214370938|NCT04875286|OTHER|Questionnaire Administration|Complete questionnaires
215089057|NCT06609928|PROCEDURE|Positron Emission Tomography|Undergo PET
215089058|NCT00623168|DRUG|Ribavirin|7 Day multiple dosing regime based on weight and dosage day
215089059|NCT06226805|DRUG|BB-031|Solution for injection
214370939|NCT06370481|OTHER|Telemedicine|Routine care administered via telemedicine
214370940|NCT06370481|OTHER|Standard of care|Standard of care, as received in HIV clinic settings
214370941|NCT05183672|PROCEDURE|Telecare consultation|Using Zoom to communicate with patients
214370942|NCT05183672|PROCEDURE|Usual face-to-face consultation|Face-to-face communication with patients
214370943|NCT04072952|DRUG|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
214370944|NCT04072952|DRUG|ARV-471 in combination with palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
214370945|NCT03627013|DRUG|Custodiol-N Solution|Perfusion
214370946|NCT03627013|DRUG|Custodiol HTK Solution|Perfusion
214370947|NCT05470101|DRUG|ITI-333|ITI-333 oral solution
214370948|NCT06256614|OTHER|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive three doses of WMT for T1DM.
214370949|NCT05861674|BIOLOGICAL|HH-003(20mg/kg)|20 mg/kg Q2W intravenously for 48 weeks
214370950|NCT05861674|BIOLOGICAL|HH-003(10mg/kg)|10 mg/kg Q2W intravenously for 48 weeks
214370951|NCT05861674|DRUG|TAF|TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
214493701|NCT00593840|RADIATION|Intensity modulated radiation therapy|
215089060|NCT06226805|DRUG|Placebo|0.9% sodium chloride for injection
215089061|NCT03921554|DRUG|Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
215089062|NCT06900543|DRUG|NRT6003 Injection|Patients will be administered NRT6003 Injection via Intra-arterial infusion, and subsequently they will be assessed by PET/CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.
214370952|NCT04086329|DEVICE|Nanosensor|"The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA.~The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue."
214370953|NCT04176848|DRUG|CFI-400945|CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily
214370954|NCT04176848|DRUG|Durvalumab|Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)
214985627|NCT06819891|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
214985628|NCT06819891|DRUG|Placebo|Placebo matching IV afimkibart.
214985629|NCT06818825|BEHAVIORAL|Automated interactive messages|High ED utilizers will be sent SMS text messages guiding them through ED-alternative resources, with different guidance (including a follow-up phone call from a healthcare worker) depending on patient responses.
214985630|NCT06818825|BEHAVIORAL|Live outreach|High ED utilizers will be called (and possibly visited) by a CHW/CMA guiding them through ED-alternative resources.
214985631|NCT06984627|DRUG|Rilzabrutinib dose 1|Pharmaceutical form:Tablet-Route of administration:Oral
214985632|NCT06984627|DRUG|Rilzabrutinib dose 2|Pharmaceutical form:Tablet-Route of administration:Oral
214985633|NCT06331351|OTHER|control group|2 times a day, 1 sachet each time.
214985634|NCT06331351|OTHER|Jing Si herbal tea liquid packets|2 times a day, 1 sachet each time.
215089063|NCT06900543|DRUG|cTACE|Patients will receive cTACE treatment. And the investigators will select one or more chemotherapy drugs in combination with embolic materials for administration, based on the specific condition of the patient.
214370955|NCT05995821|OTHER|Collection of biological specimens|Collection of tumor, blood, lymph nodes, white blood cells, mouth cells (buccal smears) scraped from the inside of your cheek, urine, saliva, or other tissue samples.
214985635|NCT04399642|PROCEDURE|Arthroplasty|All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision
214985636|NCT06819878|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
214985637|NCT06819878|DRUG|Placebo|Placebo matching IV afimkibart. Placebo matching SC afimkibart.
214985638|NCT04259138|BIOLOGICAL|Treatment Algorithm A|Participants who are not on UC treatment at screening (or who have only used topical therapy) will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (azathioprine, 6-mercaptopurine, or methotrexate), with optional oral corticosteroid up to a maximum of 30 mg or prednisone or equivalent, will be initiated.
214985639|NCT04259138|BIOLOGICAL|Treatment Algorithm B|"Participants who are taking oral 5-ASA, immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), and/or oral corticosteroid at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
214985640|NCT04259138|BIOLOGICAL|Treatment Algorithm C|"Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
214985641|NCT06822738|DEVICE|XEN63 Glaucoma Treatment System|Gel Stent
214985642|NCT03573297|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily
215089064|NCT02818348|DRUG|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
215089065|NCT02818348|DRUG|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
214370956|NCT03652259|GENETIC|SRP-9003|SRP-9003 will be administered through a single systemic injection.
214370957|NCT01849263|DRUG|Ibrutinib|Given PO
214370958|NCT01849263|OTHER|Laboratory Biomarker Analysis|Correlative studies
214985643|NCT03573297|DRUG|Placebo|Matching placebo capsules, oral administration, once daily
214985644|NCT03501251|DRUG|Moxidectin 8mg|Participants will receive the tablet with clean water and a package of biscuits.
214985645|NCT03501251|DRUG|Moxidectin 8 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
214985646|NCT03501251|DRUG|Moxidectin 16 mg|Participants will receive the tablets with clean water and a package of biscuits.
214985647|NCT03501251|DRUG|Moxidectin 16 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
215089066|NCT06194955|DRUG|GIP(1-42)|Infusion
215089067|NCT06194955|DRUG|GLP-1|Infusion
215089068|NCT06194955|DRUG|GLP-2|Infusion
215089069|NCT06194955|OTHER|Placebo|Saline
215089070|NCT03395301|DEVICE|Coil|Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
215089071|NCT04104685|COMBINATION_PRODUCT|FCD105|Experimental combination
214370959|NCT02272049|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
214370960|NCT05721235|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
214370961|NCT05543616|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
214370962|NCT05543616|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
214370963|NCT05543616|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
214985648|NCT03501251|DRUG|Moxidectin 24 mg|Participants will receive the tablets with clean water and a package of biscuits.
214370964|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose|Injection in the muscle
214370965|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose|Injection in the muscle
214985649|NCT03501251|DRUG|Moxidectin 24 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
214985650|NCT03501251|OTHER|Placebo|Participants will receive the tablet with clean water and a package of biscuits.
214985651|NCT06296511|BEHAVIORAL|Exercise|60 min of treadmill exercise performed at 70% of peak oxygen uptake.
215089072|NCT04104685|DRUG|3% Minocycline Foam|Active Comparator
215089073|NCT04104685|DRUG|0.3% Adapalene Foam|Active Comparator
215089074|NCT04104685|OTHER|Vehicle Foam|Placebo
215089075|NCT02836782|PROCEDURE|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
215089076|NCT05203367|DRUG|BAR502|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."
214370966|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose|injection in the muscle
214370967|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose|Injection in the muscle
214493702|NCT06758570|DIETARY_SUPPLEMENT|Pectin dosages|15 individuals were provided with increasing doses of pectin: 5g for 2 weeks 10g for 2 weeks 15 for 2 weeks
214493703|NCT06742203|DIETARY_SUPPLEMENT|Whey Protein Milk-Derived EVs|WPMDE1 - Whey Protein Milk-Derived EVs, is a white powder obtained by filtration, concentration, and dehydrating whey solution, with the addition of sweeteners and flavorings to balance the taste. The WPMDE1 contains a known concentration of EVs (also known as milk exosomes).
214493704|NCT06771778|OTHER|Survey using a questionnaire.|A Qualtrics link was provided for current and former NICU RDNs to complete a 10-minute online survey that provided an optional gift card for completion. Part 1 of the survey had eight questions, and part 2 had eleven additional questions.
214493705|NCT06789497|DRUG|Lovastatin 60 MG|Participants were given lovastatin 60 mg/day for three consecutive days.
214493706|NCT06789497|DRUG|Placebo|Participants were given placebo 60 mg/day for three consecutive days.
214493707|NCT05011721|DEVICE|Activity tracker|"Participants will receive a Withings Steel HR activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the NeoFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure NeoFit space."
214493708|NCT06936475|DRUG|Povidone-Iodine|5% povidone iodine
214493709|NCT06936475|DRUG|Chlorhexidine Gluconate|0.5% chlorhexidine
214493710|NCT06939842|OTHER|Menthol ice|When patients are brought from the operating theatre to the surgical clinic, patients will be waited until they are able to communicate. In the first stage, after filling in the Patient Identification Form before the intervention, thirst status with Perioperative Thirst Discomfort Scale (PTDS) and sore throat status with the Numerical Pain Scale (NPS) will be evaluated. In the second stage, evaluation will be made according to the Safety Protocol for the Management of Immediate Postoperative Thirst and menthol ice will be applied if the patients meet the criteria in the protocol. Thirst will be re-evaluated with PTDS and sore throat will be re-evaluated with NPS at 30th and 60th minutes after the first application. Immediately after this evaluation, menthol ice will be applied for the second time. After the second application, thirst will be re-evaluated with PTDS at 30th and 60th minutes and sore throat will be re-evaluated with NPS.
214493711|NCT06939842|OTHER|Frozen saline|When patients are brought from the operating theatre to the surgical clinic, patients will be waited until they are able to communicate. In the first stage, after filling in the Patient Identification Form before the intervention, thirst status with Perioperative Thirst Discomfort Scale (PTDS) and sore throat status with the Numerical Pain Scale (NPS) will be evaluated. In the second stage, evaluation will be made according to the Safety Protocol for the Management of Immediate Postoperative Thirst and frozen saline will be applied if the patients meet the criteria in the protocol. Thirst will be re-evaluated with PTDS and sore throat will be re-evaluated with NPS at 30th and 60th minutes after the first application. Immediately after this evaluation, frozen saline will be applied for the second time. After the second application, thirst will be re-evaluated with PTDS at 30th and 60th minutes and sore throat will be re-evaluated with NPS.
214681686|NCT05789446|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
214681687|NCT04392011|DRUG|Midazolam HCl|Oral syrup, 2 mg/mL
215089077|NCT05203367|DRUG|Placebo|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
215089078|NCT04006301|DRUG|JNJ-74699157|Participants will receive JNJ-74699157 orally.
215089079|NCT03446053|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
215089080|NCT03446053|OTHER|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
214370968|NCT05387603|DRUG|177Lu-DOTATOC|"The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing."
214370969|NCT05387603|DRUG|Capecitabine|Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
214370970|NCT05701995|DRUG|Deucravacitinib|Specified dose on specified days.
214985652|NCT06983249|PROCEDURE|Rhomboid intercostal and Sub-serratus nerve block in nephrectomy|That block was performed when the patient was in the lateral position. A high frequency linear ultrasound transducer was placed longitudinally on the patient's back, just 2 cm medial to the medial scapular border. Then, the probe was slightly rotated to obtain an oblique parasagittal plane. The following landmarks were identified: the trapezius muscle, rhomboid major muscle, intercostal muscles, pleura, and lungs (from superficial to deep in order of appearance). Under ultrasound guidance, a 22 mm gauge spinal needle was directed to the plane by using high frequency ultrasound guidence (Sono SiteTM, Inc., Bothell, WA 98021, USA) between the rhomboid major and the underlying intercostal muscles and 15 ml bupivacaine (0.25%) was delivered into that plane (after repeated negative aspiration of blood), and its spread was manifested by the hydrodissection and widening of the plane visualized by ultrasound
214985653|NCT06983249|PROCEDURE|Quadratus lumborum nerve block in nephrectomy|"Ultrasound guided posterior quadrates lumborum block was done in lateral decubitus position and linear probe according to the depth was placed in the midaxillary line in the transverse plane immediately above the iliac crest and then it was slided dorsally until the Shamrock sign was clearly identified. In Shamrock sign The quadratus lumborum (QL) muscle is seen as a superior leaf of the Shamrock at the apex of the transverse process (TP) of L4"
214985654|NCT02714933|OTHER|MRI sequence Advanced ZTE|Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
214985655|NCT06193889|DRUG|Standard of Care Treatment|Standard of Care Medications Optional Crossover to receive KYV-101 treatment
214985656|NCT06193889|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
214985657|NCT06193889|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
214985658|NCT02262806|DRUG|Metreleptin|A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.
214985659|NCT06983678|BEHAVIORAL|Smoking as usual fMRI session|Participants in this condition will continue smoking as usual prior to the fMRI session
214985660|NCT06983678|BEHAVIORAL|Abstinent fMRI session|Participants in this condition will be asked to abstain from smoking or using any other tobacco products for 24 hours prior to the fMRI session
214985661|NCT06664567|BEHAVIORAL|Colorectal cancer screening test|delivery of colorectal cancer screening test by GP
214985662|NCT04715087|OTHER|Blood sample (Day -42 to Day -28, Day 3),Skin swab sampling (Day -42 to Day -28, Day 0, Day 13) , patch test application (Day 0) , skin biopsies (Day 13)|A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at screening and Day 3. Bacteriological samples from AD patients will be performed by swabbing the skin at screening visit (Day -42 to Day -28). Each sample will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be re-applied (via patchtest) to AD patient. A well-characterized S. epidermidis lab strain will be also applied to AD patients. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healed or improved area as defined by a lesional score ≤ 1 or a 2-point change from the baseline lesional score. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application.
214493712|NCT06939842|OTHER|No Interventions|When patients are brought from the operating theatre to the surgical clinic, patients will be waited until they are able to communicate. In the first stage, after filling in the Patient Introduction Form before the intervention, thirst status with Perioperative Thirst Discomfort Scale (PTDS) and sore throat status with Numerical Pain Scale(NPS) will be evaluated. Patients in the control group will be waited for approximately 10 minutes, taking into account the application times in the intervention groups. No intervention will be applied during the waiting period. After 10 minutes of waiting time, thirst will be re-evaluated with PTDS and sore throat will be re-evaluated with NPS at 30th and 60th minutes. Considering the 2nd application time in the intervention groups, it will be waited again for approximately 10 minutes without any intervention. After the waiting period, thirst will be re-evaluated with PTDS at 30th and 60th minutes and sore throat will be re-evaluated with NPS.
214493713|NCT06401759|BEHAVIORAL|Podcast|Routine maintenance will be applied.
214493714|NCT06072092|DEVICE|BIS Monitor|No interventions will be administered, but in addition to the standard of care according to the Guidelines of the European Resuscitation Council 2021, a frontal EEG-monitoring (BIS), a CPRMeter and a FlowMeter will be installed. The study will be observational only; the readings of the BIS monitor will be blinded to the treating PRU team.
214493715|NCT05254496|BEHAVIORAL|Dietary Intervention Classes|Participants will attend classes once per week for 6 months and then bi-weekly for 6 months.
214493716|NCT03130452|DRUG|Lansoprazole 30mg|lansoprazole 30 mg tablet
214493717|NCT03130452|DRUG|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
214493718|NCT03130452|DRUG|Clarithromycin 500mg|Clarithromycin 500mg tablet
214493719|NCT03130452|DRUG|Metronidazole 500 mg|Metronidazole 500 mg tablet
214493720|NCT06941753|OTHER|Off-script diagnosis & differential diagnosis (D&D) training|"1. Training Timeline: Must be completed within 72 hours post-randomization; Requires standardized structured off-script D\&D analysis.~2. Structured Analysis Framework: 1)Epidemiology: Incidence, mortality, and disability rates; 2) Etiologic Classification: TOAST classification system; 3) Vascular Mechanisms: Culprit vessel, vascular territory, pathophysiology; 4) Differential Diagnosis: Stroke mimics and stroke subtype differentiation; 5) Acute Management: Hyperacute interventions (thrombolysis/EVT), secondary prevention strategies, and evidence-based case analysis; 6) Patient Education: Stroke prevention education for patients/public; 7) Research Gaps: Current limitations and future directions.~3. Presentation Requirements: 1)Mandatory off-script delivery (no prepared text); 2) Time limit: 15+3 minutes for complete analysis."
214493721|NCT06773468|BEHAVIORAL|stress management|These different stress management modalities have been developed to ensure equivalent content across: (a) psychoeducation and strategy introduction; and (b) skills-based practice of strategies. Stress management strategies touched on 4 main areas which included (a) pause/break; (b) positive awareness; (c) kindness to self; and (d) social support.
214493722|NCT06767527|DRUG|AK112|AK112 via intravenous (IV) infusion
214681688|NCT04392011|DRUG|Dextromethorphan HBr|Oral liquid capsules, 15 mg
214985663|NCT04715087|OTHER|Blood sample (Day 0 ,Day 3),Skin swab sampling (Day 0,Day 13), patch test application (Day 1), skin biopsies (Day 13)|"A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at Day 0 and Day 3.~Each bacteriological sample from AD patients performed by swabbing the skin at screening visit will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. A well-characterized S. epidermidis lab strain will be also applied to healthy volunteers. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healthy skin. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application"
214985664|NCT06986590|BEHAVIORAL|ADHINCRA Program|The ADHINCRA Program is a nurse-led intervention that includes the use of home blood pressure monitoring, a mobile health app, lifestyle counselling, and a simplified hypertension treatment protocol to achieve blood pressure control among people diagnosed with hypertension.
214985665|NCT00161655|DRUG|Etanercept|
214985666|NCT00161655|DRUG|Methotrexate|
214985667|NCT06513260|PROCEDURE|Surgical extraction of impacted lower third molars.|Surgical extraction of impacted mandibular third molars in the mesioangular position, according to the Tetsch and Wagner classification
214985668|NCT06861244|RADIATION|Radiotherapy (RT)|Undergo RT
214985669|NCT06861244|DRUG|Chemotherapy Drug, Cancer - Physician's Choice|One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.
214985670|NCT06861244|PROCEDURE|Non-Investigational Surgical Resection|Undergo surgery directly before study enrollment as part of planned care.
214985671|NCT06861244|DRUG|Temozolomide|Participants assigned to or whom receive optional RT will receive concurrent temozolomide
214985672|NCT06861244|PROCEDURE|Tumor Tissue Sample|Tumor tissue will be collected for correlative studies
214985673|NCT06861244|PROCEDURE|Blood Sample|Blood samples will be collected for correlative studies
214985674|NCT06861244|PROCEDURE|Cerebrospinal Fluid (CSF) Sample|CSF samples will be collected for correlative studies
214370971|NCT05701995|OTHER|Placebo|Specified dose on specified days.
214985675|NCT06993038|DRUG|adenosine|IV adenosine at standard doses for SVT (6 mg, 12 mg)
214985676|NCT06993038|DRUG|diltiazem|IV diltiazem at standard doses for SVT (0.25 mg/kg)
214985677|NCT06996301|DIAGNOSTIC_TEST|Treatment guided by the PCR results|Patients receive treatment prescribed by a blinded clinician, based solely on the PCR diagnostic results
214985678|NCT06996301|DIAGNOSTIC_TEST|Treatment guided by the C&S results|Patients receive treatment prescribed by a blinded investigator (clinician), based solely on the C\&S diagnostic results.
214985679|NCT06994299|RADIATION|Radiation Therapy|Hypofractionated radiotherapy - 8Gy x3 fractions (week 0)
214985680|NCT06994299|DRUG|Tremelimumab|Tremelimumab - single dose of 300 mg IV (week 0).
214985681|NCT06994299|DRUG|Durvalumab|Durvalumab-500 mg IV every 4-weeks (weeks 0-3) prior to hepatic resection
214985682|NCT06994299|PROCEDURE|Surgery|Hepatic resection
214985683|NCT05056207|OTHER|Cohort I (patients receiving annual lymphedema screening|patientns who previously underwent preoperative perometer lymphedema screening
214985684|NCT05056207|OTHER|Cohort II (patients followed intensively for lymphedema)|patients who have recently undergone ALND
214985685|NCT06664853|DRUG|Dexamethasone sodium phosphate|Dexamethasone Sodium Phosphate encapsulated in autologous erythrocytes and administered via intravenous (IV) infusion
214985686|NCT02256865|DRUG|Ketoconazole|Ketoconazole is taken 4 times a day
214985687|NCT02256865|DRUG|Hydrocortisone|Hydrocortisone is taken 3 times a day
214985688|NCT02256865|DRUG|Testosterone|Testosterone gel is applied once a day
214985689|NCT02256865|DRUG|Placebo for ketoconazole|Placebo for ketoconazole
214985690|NCT02256865|DRUG|Placebo for hydrocortisone|Placebo for hydrocortisone
214985691|NCT02256865|DRUG|Placebo for testosterone|Placebo for testosterone
214985692|NCT06673628|DRUG|Pembrolizumab plus Lenvatinib|"One course is fixed at 21 days, and the length of course is not extended or shortened.~Participants receive 200 mg of pembrolizumab injection intravenously over approximately 30 minutes on day 1 of each course, and take 20 mg of lenvatinib capsules orally once daily, preferably at the same time each day.~Treatment with pembrolizumab and lenvatinib will be continued for up to 35 courses unless the criteria for termination of protocol treatment are met."
214985693|NCT07001800|DRUG|Ataciguat|Ataciguat will be administrated daily for up to 156 weeks
214985694|NCT07001800|DRUG|Placebo|Placebo will be administrated daily for up to 156 weeks
215089081|NCT02340390|DEVICE|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
214370974|NCT06368115|OTHER|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
214370975|NCT05750654|DEVICE|Small Phlebotomy Tube Group|"In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU."
214370976|NCT05750654|DEVICE|Standard Phlebotomy Tube Group|In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
214370977|NCT06340217|OTHER|washed microbiota transplantation|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive two doses of WMT for DGP.
214681689|NCT04392011|DIETARY_SUPPLEMENT|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
214681690|NCT01765647|OTHER|AGY|AGY is a natural health product produced in egg yolks
214681691|NCT06387238|DIAGNOSTIC_TEST|PSMA PET/CT|pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy.
215089082|NCT02340390|DEVICE|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
215089083|NCT02098811|DEVICE|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
215089084|NCT02098811|DEVICE|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
214681692|NCT05463679|DRUG|Enzastaurin|500 mg QD orally in the form of four 125 mg tablets with background standard of care
214681693|NCT05463679|DRUG|Placebo|Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
215089085|NCT01063842|DRUG|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
215089086|NCT01063842|DRUG|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
215089087|NCT02458547|DRUG|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8\~1.0
215089088|NCT02458547|DRUG|Propofol|Total intravenous anesthesia with propofol target controlled infusion
214681694|NCT01704248|DEVICE|Eye Drop Guide technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~5. Then place the upper lip down to cover the whole orbital rim area.~6. Tilt the head back if seated or standing.~7. Insert the bottle in the device all the way. Hold the bottle gently.~8. Look upward.~9. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~10. Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward."
214681695|NCT01704248|BEHAVIORAL|Routine self-instillation technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Lie down or tilt the head back if seated or standing.~5. Using the other hand, pull the lower lid down.~6. Hold the bottle over the eye and look up.~7. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~8. Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye."
215089089|NCT02458547|DRUG|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
215089090|NCT05004506|DRUG|Adductor Canal Block|The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
215089091|NCT05004506|DRUG|Intra-articular Injection|receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
214370978|NCT06340217|OTHER|placebo|A carrier fluid with matching volume and consistent appearance to the infusion of washed microbiota.
214370979|NCT04130802|DRUG|OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL|OCS-01 eye drops
214370980|NCT04130802|DRUG|Placebo|Vehicle eye drops
214370981|NCT06064890|PROCEDURE|Intrathalamic AAV.PGRN administration|One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain
214681696|NCT06322823|PROCEDURE|direct thawing|Vitrified blastocysts will be thawed directly into 1ml G-TL medium
214681697|NCT06322823|PROCEDURE|Vitrification|Vitrified blastocysts will be thawed using commercially available one-step media.
214681698|NCT02096393|DEVICE|Zimmer Patient specific instruments|A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
214681699|NCT02096393|DEVICE|Standard instrumentation|Standard instrumentation will be used during total knee replacement surgery.
214681700|NCT00506051|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
214681701|NCT00506051|DRUG|pemetrexed|intravenous infusion
214681702|NCT00506051|DRUG|ZD6474 (vandetanib) 300mg|
214681703|NCT01252797|RADIATION|Stereotactic Radiosurgery (15 Gy)|"Group A will start at dose level II: 15 Gy~Group B will start at dose level I: 12 Gy"
214681704|NCT01252797|RADIATION|Stereotactic Radiosurgery (12 Gy)|Group B will start at Dose Level I: 12 Gy
215089092|NCT03283150|DRUG|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
215089093|NCT03283150|DRUG|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
215089094|NCT03283150|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
215089095|NCT01604655|PROCEDURE|Coronary CT Angiography|CCTA
215089096|NCT01604655|PROCEDURE|Stress Test|Stress Test
215089097|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
215089098|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
214370982|NCT06064890|GENETIC|Intrathalamic AVB-101|AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
214370983|NCT04073745|OTHER|Quality-of-Life Assessment|Ancillary studies
214985695|NCT04719897|BEHAVIORAL|FIRST: Repairing Thoughts|"This intervention uses the Repairing Thoughts cognitive restructuring module of the FIRST (Feeling Calm, Increasing Motivation, Repairing Thoughts, Solving Problems, Trying the Opposite) cognitive behavioral therapy protocol. This psychotherapy module teaches adolescents that thoughts are linked to feelings and behaviors, and that thoughts are often guesses to interpreting the world around us. Adolescents are taught to notice their thoughts in real-time and evaluate the evidence that supports or contradicts the thoughts and interpretation. Adolescents are then taught strategies to re-interpret thoughts in a more realistic manner and notice changes in emotional and behavioral responses. Clinicians are provided with examples to enhance learning, and between-session practice is assigned as homework."
214985696|NCT05382897|OTHER|Plant-based fasting-mimicking diet|Participants will be on a low caloric plant-based diet or a caloric-sufficient plant-based diet for 3 x 5 day cycle each month followed by 3 weeks of eating normally for a total period of 3 months.
214985697|NCT02144558|OTHER|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
214985698|NCT04804553|DRUG|Apremilast|Participants will receive apremilast orally.
214985699|NCT04804553|DRUG|Placebo|Participants will receive the matching placebo orally.
214985700|NCT06868186|DEVICE|RUS NE|The RUS NE is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the intra-abdominal surgical environments, allowing for the visualization of tumor, vascular structures and intra-abdominal organs during the surgical planning process and the operation. RUS NE utilizes preoperative CT images of the patients to segment tumor, organs, and blood vessels and reconstructs them into a 3D model. Although there is no direct intervention on the patient, the surgeon uses RUS NE as a surgical navigation tool to simulate the surgery before performing the actual procedure.
214985701|NCT06624085|DRUG|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days)
214985702|NCT06624085|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
214985703|NCT06624085|DRUG|Obinutuzumab|Participants will receive IV obinutuzumab pretreatment
214985704|NCT06624085|DRUG|Gemcitabine|Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days)
214985705|NCT06624085|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days)
214985706|NCT06870838|DIAGNOSTIC_TEST|7T MRI scan|MRI-scanning of the brain using a 7T MRI scanner
214985707|NCT06870838|DIAGNOSTIC_TEST|CSF|CSF collection via lumbar puncture
214493723|NCT06767527|DRUG|Nab-paclitaxel|Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
214985708|NCT06870838|DIAGNOSTIC_TEST|Blood withdrawal|Blood is collected by doing a blood withdrawal
214985709|NCT06870838|DIAGNOSTIC_TEST|Neuropsychological assessment|Tests for memory, language, attention, executive functions, praxis, social cognition, visuoconstructive skills
214985710|NCT06870838|DIAGNOSTIC_TEST|Clinical measures|Medical history, neurological assessment, neuropsychiatric inventory
214370984|NCT04073745|OTHER|Questionnaire Administration|Ancillary studies
214370985|NCT04073745|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214370986|NCT01042015|COMBINATION_PRODUCT|Emergency preservation and resuscitation|This involves the induction of profound hypothermia using a flush of ice-cold saline into the aorta. Once hypothermia is achieved, the subject would undergo rapid operative interventions to control bleeding followed by resuscitation/rewarming with cardiopulmonary bypass.
214985711|NCT00275652|DRUG|LdT (Telbivudine) and lamivudine|
214985712|NCT06428825|DRUG|BAY3283142|oral administration
214985713|NCT06428825|DRUG|Placebo to BAY3283142|oral administration
214985714|NCT07011459|BEHAVIORAL|Cooking class|3-month community teaching kitchen-based culinary education of MedDiet
214370987|NCT01042015|OTHER|Standard resuscitation|Standard resuscitation includes an emergency department thoracotomy, open cardiac massage, and fluid resuscitation.
214370988|NCT03083288|DRUG|[18F]FluorThanatrace|\[18F\]FluorThanatrace is a radiotracer for PET/CT
214493724|NCT06767527|DRUG|Placebo|Placebo via IV infusion
214493725|NCT05372549|OTHER|Oxidative stress|Oxidative stress occurs as soon as there is an imbalance between pro- / antioxidants, and molecules exhibiting antioxidant properties are at the forefront of fertility treatment and preservation. Oxidated stress will be measured by blood sample
214493726|NCT05372549|OTHER|cf-DNA|cfDNA, extracted from blood plasma in samples collected will uncover the potential role of cfDNA as a stress signal released in response to oxidative stress
214493727|NCT05372549|OTHER|MAGENTA AI|Non-invasive technique analyzing images of oocytes that can differentiate oocytes with a higher reproductive potential reflective of their quality
214985715|NCT07011459|OTHER|Standard of care|Participants will continue to receive clinical care recommendations from their physicians
214985716|NCT01721538|OTHER|Weight reduction program|
214985717|NCT01721538|OTHER|Lecture on healthy nutrition|
214985718|NCT00505635|DRUG|Temozolomide|250 mg/m\^2 By Mouth Every 4 Hours x 3 Doses On Day 1
214985719|NCT00505635|DRUG|Velban|1.5 mg/m\^2 By Vein Over 15-30 Minutes On Days 1-4
214985720|NCT00505635|DRUG|Cisplatin|20 mg/m\^2 By Vein Over 45-120 Minutes On Days 1-4
214985721|NCT00505635|DRUG|Interleukin-2|9 MIU/m\^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
214985722|NCT00505635|DRUG|Intron-A|5 mu/m\^2 Subcutaneously (Under the skin) Daily On Days 1-5
214985723|NCT00505635|DRUG|Thalidomide|400 mg By Mouth Daily
214985724|NCT03000946|DRUG|Somatostatin|Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
214985725|NCT03000946|DRUG|Octreotide|Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
215089099|NCT05389501|BEHAVIORAL|Social policy intervention to support women of reproductive years|"The project team will attempt to address this challenge by delivering the following interventions through social workers in underdeveloped primary healthcare settings to promote maternal and child health:~1. Developing a database on a digital app of participants in the study and use the data for development of an Index for Maternal Health and Wellbeing~2. Conducting a Community Assessment Needs~3. Conduct a psychosocial needs assessment~4. Develop interprofessional health workforce collaboration~5. Measure basic clinical health indicators~6. Provide health awareness and literacy training to participants"
215089100|NCT02515201|DRUG|Taurolidine|taurolidine in central catheter lumen
214370989|NCT06659029|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
214370990|NCT04858269|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle
214370991|NCT04858269|DRUG|Carboplatin|Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle
214370992|NCT04858269|DRUG|Paclitaxel|Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.
214493728|NCT05271331|DRUG|ESP block with saline|Bilateral ultrasound guided injection of saline in the erector spinae plane (below erector spinae plane muscle group and above the transverse process of the vertebra)
214493729|NCT05271331|DRUG|Wound infiltration with saline|Blinded injection of saline in the skin, subcutaneous tissue and muscles at the site of surgical incision
214985726|NCT06753396|PROCEDURE|Platelet rich fibrin|The injectable platelet rich fibrin will be integrated into the tissue by subgingival and submucosal application to the keratinized gingiva of the implant sites with insufficient peri-implant soft tissue phenotype. Then, the prepared injectable platelet rich fibrin will be injected into the mucogingival junction apical to the keratinized gingival site. This procedure will be repeated 3 times in total, 1 time in 30 days for 3 months.
214985727|NCT02634177|GENETIC|Assay-guided treatment (AGT)|The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
214985728|NCT02634177|OTHER|Treatment-as-usual (TAU)|Subjects are treated-as-usual without the aid of the assay.
215089101|NCT02515201|DRUG|Heparin|heparin in central venous catheter lumen
214370993|NCT03004287|DRUG|Carfilzomib|Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
214370994|NCT03004287|DRUG|Thalidomide|Given by mouth at bedtime: days 1-4 of Induction
214370995|NCT03004287|DRUG|Dexamethasone|Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
214370996|NCT03004287|DRUG|Daratumumab|Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
214493730|NCT05271331|DRUG|ESP block with local anesthetic|Bilateral ultrasound guided injection of local anesthetic (ropivacaine 0.35%, 40ml) in the erector spinae plane (below erector spinae plane muscle group and above the tranverse process of the vertebra)
214493731|NCT05271331|DRUG|Wound infiltration with local anesthetic|Blinded injection of local anestetic (ropivacaine 0.35%, 40ml) in the skin, subcutaneous tissue and muscles at the site of surgical incision.
214493732|NCT06796413|PROCEDURE|Loop Resection or Cold-cup biopsy|Loop Resection or cold-cup biopsy of bladder tumor base - thus after the tumor has been resected and the deep muscle specimen needed to be obtained, the Loop Cautery or Lowsley Forceps (for cold-cup biopsy) was used to obtain the deep muscle specimen
214493733|NCT06046690|DEVICE|Mechanical Ventilation Device|"During the first week of training, ventilator trigger sensitivity will be initiated at 20% of the patient's baseline MIP (NIF). Patients will train for 5 minutes twice a day for the first days. As the training progresses, the triggering sensitivity will be gradually increased to 30% and 40% of the initial MIP and the duration will be increased up to 30 minutes. During the training sessions, participants will be elevated to a position similar to the Semi-Fowler position at an angle of approximately 45°. Vital signs will be monitored regularly.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
214681705|NCT01848964|DEVICE|Clinical and instrumented measurements|"Clinical examination will include stump pain, wound, scar and unusual shape.~Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)~After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.~Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.~Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate."
214681706|NCT00733356|DRUG|Vyvanse|Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
214370997|NCT03004287|DRUG|Cisplatin|Given by vein: days 1-4 (continuous infusion) of Induction
214370998|NCT03004287|DRUG|Adriamycin|Given by vein: days 1-4 (continuous infusion) of Induction
214681707|NCT00004284|DRUG|potassium citrate|
214681708|NCT00004284|DRUG|potassium phosphate|
215089102|NCT04065633|DRUG|P3-Fast|200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
215089103|NCT04065633|DRUG|Comm-Fast|200 mg PF-04965842 commercial tablet formulation under fasted conditions
214985729|NCT05831878|DRUG|Disitamab vedotin|2.0mg/kg, iv, day1, every 2 weeks
214681709|NCT02836990|DEVICE|Prevena Incision Management System|A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
214985730|NCT07069426|DIETARY_SUPPLEMENT|20 grams protein|20 grams of whey protein provided as beverage
214985731|NCT07069426|DIETARY_SUPPLEMENT|40 grams protein|40 grams of whey protein provided as beverage
214985732|NCT07062679|OTHER|Maitland Oscillatory Glides/Mobilization|"Hot pack for 15 minutes Ultrasound for 5 minutes Maitland Mobilization Oscillatory Glides inferiorly during normal abduction. Glenohumeral caudal glide mobilization was given at the rate of 2-3 glides per second for 30 seconds for each glide, 5 sets were given.~(3 sessions per week for 4 weeks)"
214985733|NCT07062679|OTHER|Mulligan Mobilization with Movement (MWM)|"Hot pack for 15 minutes Ultrasound for 5 minutes Mobilization with Movement (MWM) Patient sitting with therapist posterolateral to him/her. Therapist places the Mulligan belt across the humeral head and to his waist. Patient movement (Flexion, extension, \& abduction respectively) combined with therapist-applied joint gliding (postero-lateral Glide) MWM will be performed.~3 sets of 10 reps per session (30 seconds rest between sets)~(3 sessions per week for 4 weeks)"
214985734|NCT06805175|DEVICE|vestibular implant|vestibular implant
215089104|NCT04065633|DRUG|Vari-Fast|200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
214370999|NCT03004287|DRUG|Cyclophosphamide|Given by vein: days 1-4 (continuous infusion) of Induction
214371000|NCT03004287|DRUG|Etoposide|Given by vein: days 1-4 (continuous infusion) of Induction
214493734|NCT06046690|DEVICE|External Device|"The IMT (Inspiratory Muscle Training) with device will commence at 20% of the value obtained from the NIF (Negative Inspiratory Force) measurement or the lowest pressure setting, depending on the patient's tolerance. The duration and intensity will be gradually increased. Once the participants are disconnected from the mechanical ventilator, the IMT device will be connected to the T-tube via a catheter mount with a Catheter Mount. Patients will be instructed to breathe against the resistance set on the IMT device. After completing 8 repetitions, the patient will be allowed to rest for a few minutes. This routine will be repeated for a total of 3 sets of 8 repetitions.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
214681710|NCT02836990|DEVICE|Dermabond|A surgical skin adhesive used to prevent surgical wound infections
214681711|NCT03917719|DRUG|Edasalonexent|100 mg/kg/day
214681712|NCT05967988|DEVICE|Immersive atmospheric projection|Projection of computer-generated videos or videos of real moving landscapes on the walls of the examination room
214985735|NCT06717308|DEVICE|Comfort Release® NPWT drape|Comfort Release® NPWT drape- painless and trauma-free removal, as compared to the control NPWT drape.
215089105|NCT04065633|DRUG|Comm-Fed|200 mg PF-04965842 commercial tablet formulation under fed conditions
215089106|NCT05140551|DEVICE|COMPASS: digital CBT|COMPASS is an evidence based digital CBT intervention with guided therapist support, tailored to treat anxiety and/or depression in long term conditions (LTCs). The intervention consists of eleven modules/sessions in which CBT techniques are taught. Users of COMPASS receive guided therapist support from a trained therapist. The guided support aims to help patients identify and apply the CBT skills outlined in COMPASS to meet their individual needs and experiences of living with LTC(s). The support can occur through in-site messaging or via the telephone.
214681713|NCT05967988|DEVICE|Minimal atmospheric projection|Projection of a colors on the walls on the walls of the examination room
214681714|NCT02277132|DRUG|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
214985736|NCT07080775|DRUG|human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection|5.0×10\^7 cells/mL, injection, once, 12 months
214985737|NCT06765980|GENETIC|VV-14295|VV-14295 will be administered as a single suprachoroidal injection.
215089107|NCT04097496|BEHAVIORAL|Act Out! Intervention|Data included in the description of the intervention arm.
215089108|NCT01376570|BEHAVIORAL|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.
214371001|NCT03004287|DRUG|Melphalan|Given by vein: days -4 - -1 of Transplant(s)
214371002|NCT03004287|PROCEDURE|ASCT|day 0 of Transplant(s)
214371003|NCT03004287|DRUG|Lenalidomide|Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
214371004|NCT03004287|DRUG|Bortezomib|Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
214371005|NCT03056794|OTHER|No intervention|This is an observational study. The investigators will collect data about exposure to responses to dietary supplements, medications, and the ketogenic diet.
214371006|NCT03006770|BIOLOGICAL|PLX-PAD|Local intramuscular (IM) injections of PLX-PAD in the index leg.
214371007|NCT03006770|BIOLOGICAL|Placebo|Local intramuscular (IM) injections of Placebo in the index leg.
214371008|NCT04987762|DRUG|Adhansia XR|Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)
214681715|NCT02277132|DRUG|Placebo|Placebo tablets three times daily orally from randomization until delivery
214681716|NCT05814770|DRUG|Finerenone|The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
214371009|NCT02044991|DRUG|Corticosteroid|40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
214371010|NCT02044991|DRUG|Placebo Injection|A placebo injection
214371011|NCT02954523|DRUG|Dasatinib|oral every day
214371012|NCT02954523|DRUG|Osimertinib|oral every day
214371013|NCT01760850|OTHER|educational intervention|Engage in the Esperanza y Vida educational information session for breast and cervical cancer
214371014|NCT01760850|OTHER|educational intervention|Engage in an educational information session for diabetes
214371015|NCT01760850|OTHER|questionnaire administration|Ancillary studies
214371016|NCT00685958|DRUG|enoxaparin (XRP4563)|14 days of treatment
214493735|NCT05664243|BIOLOGICAL|Autologous genetically modified gamma-delta T cells|Arm A: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance
214681717|NCT05814770|DRUG|Spironolactone|The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
214681718|NCT04617340|OTHER|Multifaceted clinical pharmacy intervention|"1. Assessing patient and caregiver preferences~2. Medication reconciliation on admission~3. Performing a comprehensive medication review before discharge~4. Promoting safe transition~4.a. Compiling a patient friendly medication list~4.b.Optimizing communication with healthcare providers in primary care:~4.b.i.Providing a copy of the medication list for the community pharmacist~4.b.ii. Contacting the general practitioner by phone~4.b.iii. Contacting, if applicable the home care nurse or the nurse from the nursing home by phone.~5.A motivation interview will take place before discharge with patients and caregivers~6.Post-discharge follow-up: 6.a.Follow-up call to discuss potential drug therapy issues, therapy adherence and to resolve any pending issues 6.b.A telepharmacology service will be provided to primary healthcare professionals as a means to consult the ward-based clinical pharmacists and/or research team after discharge."
214681719|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS training|After the PSS and TBW are calculated with the standard TOJ paradigm, 100 training trials are provided where the SOA is set to a PSS slightly greater than what was the mean calculated for normal subjects, with the goal of shifting the PSS in a direction associated with better clinical vestibular parameters and vestibular precision measurements (e.g. standard rotational testing VOR time constant, lower DHI, higher FGA score) . Then the TOJ task will be repeated but every 10 testing trials will be followed by 10 training trials (SOA = PSS desired or mean normal PSS), and this pattern will be repeated 10 times to 100 more training trials interspersed with the Post TOJ data. Subjects will respond after all trials and testing and training will not be distinguished. After this is completed, the new PSS and TBW are calculated. Sham PSS training will be identical to the above except that the 'training' period will consist of random SOAs rather than a series of fixed SOAs.
214493736|NCT05664243|BIOLOGICAL|Allogeneic genetically modified gamma-delta T cells|"Phase 1b and Arm B: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with D1 of TMZ 150mg/m2~Arms C: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance"
214371017|NCT06279325|BEHAVIORAL|Computerized cognitive stimulation program|"* The cognitive stimulation (CS) program, for the IG, will be previously designed by 2 Occupational Therapy (OT) of the team, and adapted to the computerized format through a platform specialized in cognitive neurorehabilitation. The activities will be designed under OT models: human occupation model and cognitive-perceptual model, so that the different professions, interests and roles are represented, and allow to express different levels of complexity, according to the level of Cognitive Reserve (CR).~* The cognitive aspects to be worked on are: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.~* In addition, reinforcement, EF, episodic memory, attention and information processing speed activities will be designed, also according to the CR level."
214371018|NCT06279325|BEHAVIORAL|Face-to-face training-explanatory session|The CG will undergo a group and face-to-face training-explanatory session, where the importance of maintaining the usual level of cognitive activity will be emphasized.
214371019|NCT05763069|OTHER|Home surveillance of pregnancies at risk|Offer women with pregnancies at risk home surveillance instaed of more frequent hospital out-patient visits and/or hospitalisation: cardiotocographia (CTG), patient measurements of CRP, temperature, blood pressure, and clinical signs of infection or severe forms of preeclampsia.
214371020|NCT03633942|DEVICE|LMA Supreme|Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
214371021|NCT06170164|DIAGNOSTIC_TEST|Diagnostic accuracy|The aim of the study is to evaluate whether the pathological stage of the disease, Gleason score, age at diagnosis, serum PSA value and PET parameters (SUV, MTV) are predictive factors of choline PET examination.
214371022|NCT04549610|DIETARY_SUPPLEMENT|HMB supplementation|Group taking oral HMB supplementation in a blinded capsule form.
214371023|NCT04549610|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.
214371024|NCT06131580|DRUG|Intervention/Treatment|"Drug: osilodrostat~\- osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint."
214371025|NCT02259738|DRUG|Human Urinary Kallidinogenase|
214371026|NCT02259738|DRUG|Shuxuening injection|
214493737|NCT05836025|DRUG|Rapamycin|5mg/week of rapamycin orally for 12 weeks
214493738|NCT05836025|OTHER|Placebo|5mg/week of placebo orally for 12 weeks
214493739|NCT06947317|PROCEDURE|Arthroscopic anterior talofibular ligament repair|This intervention involves an isolated all-inside arthroscopic repair of the anterior talofibular ligament (ATFL) without addressing the coexisting osteochondral lesion of the talus. It is intended for patients with chronic ankle instability and a concomitant talar osteochondral lesion, where only the ligamentous injury is treated. Patients follow a standard rehabilitation protocol with return to sports allowed after 3 months.
214371027|NCT05842226|OTHER|Micro-teaching enriched with standard patient|The practice group will be shared the 4 most common symptoms in palliative care nursing: pain, fatigue, respiratory distress and loss of appetite. The practice group will be 5 groups and there will be 4 students in each group. During the practice, each student will provide patient education about only one symptom. The standard patient will participate in the intervention in the application laboratory and the students will participate in the intervention in the computer environment. Video recordings will be taken while the students are giving education. After watching the experts, peers and their own video with the micro-teaching group evaluation form, the student himself/herself will make an evaluation. At the same time, a lecturer from outside the research will fill in the Standard Patient Check-List Evaluation Form. The application will be repeated one week later.
214371028|NCT04162093|PROCEDURE|uretero ileal anastomosis in single trough|
214371029|NCT00504426|DRUG|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
214371030|NCT03872479|DRUG|EDIT-101|Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.
214371031|NCT01602406|DRUG|LJM716|LJM716
214493740|NCT06947317|PROCEDURE|Talar chondral lesion treatment using microfracture technique|This intervention consists of an arthroscopic debridement and microfracture of a symptomatic osteochondral lesion of the talus. Postoperative rehabilitation is extended due to the cartilage procedure, delaying return to sports until 4 months.
214493741|NCT04692181|BIOLOGICAL|SYN-004, Ribaxamase or Placebo|SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
214493742|NCT06048380|DRUG|Ripasudil|"Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil."
214493743|NCT06048380|OTHER|Placebo|Saline eye drops
214493744|NCT06946602|PROCEDURE|Bu/Flu/Cy/ATG|The Bu/Flu/Cy/ATG conditioning regimen consists of the following components: Ara-C (2 g/m²/day, injected i.v.) on days-10 and-9; Bu (0.8 mg/kg, q6h, injected i.v.) on days -8 to -6; Flu (30 mg/m²/day, injected i.v.) from day-6 to day-2; Cy (1.0 g/m²/day, injected i.v.) on days-5 and-4; and ATG (2.5 mg/kg/day) on days-5 to -2.
214493745|NCT06946602|PROCEDURE|Bu/Cy/ATG|The Bu/Cy/ATG conditioning regimen consists of the following components: Ara-C (4 g/m²/day, injected i.v.) on day-9; Bu (0.8 mg/kg, q6h, injected i.v.) on days -8 to -6; Cy (1.8 g/m²/day, injected i.v.) on days-5 and-4; and ATG (2.5 mg/kg/day) on days-5 to -2.
214681720|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS adaptation with VI stimulation|The adaptation will utilize the same approach used in non-implanted patients. The investigators will provide a repeated, fixed SOA with either the CI or VI leading the other stimulus by 220 ms. After the training period, which will match the number of stimuli pairs provided to our normal vestibular-auditory control subjects undergoing PSS adaptation, the TOJ study is repeated to recalculate the PSS and TBW.
214681721|NCT04196933|BEHAVIORAL|Chronic Motion-modulated Stimulation|To provide 8 hours of 'physiologic' CI and VI inputs during normal activities, the investigators will employ standard motion-modulated stimulation with the VI. This requires pre-adaptation to a 200 pps tonic stimulation rate (to emulate the push-pull design of the native vestibular system allowing modulating stimulation upward or downward with opposite directions of motion). The three electrodes are connected to the head-mounted prosthetic circuit, which consists of three angular velocity sensors (one aligned with the sensitive axis of each canal) such that head rotations in the plane of the given canal modulate the stimulation rate of the corresponding electrode, upward (for ipsi) or downward (for contralateral) head rotations, thereby simulating normal canal-mediated modulations.
214681722|NCT01455428|DRUG|Lyrica (pregabalin)|Capsule, 300 mg/d, BID, 8 weeks treatment
214681723|NCT01455428|DRUG|Placebo|Capsule, 300 mg/d, BID, 8 weeks treatment
214681724|NCT05545813|DIETARY_SUPPLEMENT|Probiotic|Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.
214681725|NCT05545813|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
214681726|NCT00828386|PROCEDURE|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
214681727|NCT03303339|DRUG|Onvansertib|Onvansertib orally
214371032|NCT01602406|DRUG|Trastuzumab|Trastuzumab
214371033|NCT02701894|DIETARY_SUPPLEMENT|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
214371034|NCT02605226|PROCEDURE|Cryoablation therapy|Cryoablation therapy
214681728|NCT03303339|DRUG|Cytarabine|subcutaneously
214681729|NCT03303339|DRUG|Decitabine|intravenously
214681730|NCT03718104|OTHER|Pharmacokinetic analysis|Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
214681731|NCT03718104|OTHER|Safety and Efficacy|Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).
214985738|NCT06682013|DEVICE|Virtual agent|"The virtual agent is an interactive audio agent that is similar to voice agents that interact with callers in many industries today. They create a very human-like interaction in contrast to more traditional virtual call agents that can only respond to menu options (e.g. choose 1 for appointments, choose 2 for questions about your bill, etc.). The virtual agent is engineered to accomplish the very specific task of onboarding the patient on use of the RPM devices. It is trained to understand normal human English speech, detects emotional tone and frustration of callers, and is trained to deescalate when appropriate."
214985739|NCT06682013|OTHER|Human agent|The human agent will onboard the patient on use of the RPM devices.
214985740|NCT07080619|DRUG|SC-101|Receive 7.5 mg/m² of SC-101 intravenously once weekly (QW).
214371035|NCT02605226|RADIATION|External beam radiation therapy|External beam radiation therapy
214493746|NCT06948643|OTHER|Play the Oculus Quest 2|Every three to four days (roughly 72 to 96 18 19 hours), a session was held. Students were required to use the Oculus Quest 2 and touch controllers to play immersive exergames for thirty minutes during each session. In each session, they were asked to play the games Dance Central (https://www.dancecentral.com/ ) and CREED: Rise to Glory (which the researchers loaded into the Oculus Quest 2) via the Meta Quest Gaming platform (https://www.meta.com/tr-tr/experiences/creed-rise-to27 glory-championship-edition/2366245336750543/ ).
214681732|NCT03718104|GENETIC|Genetic and epigenetic analysis|Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.
214985741|NCT06903104|OTHER|Mindfulness closed program|MAEva program will be proposed with meditative practices and three different themes will be addressed (one theme per session): Meditation, Acceptance and Commitment to values.
214681733|NCT03718104|OTHER|Breast milk analysis|Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
214681734|NCT02857023|BEHAVIORAL|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
214681735|NCT05692193|BEHAVIORAL|pain education|Pain education was given to the experimental group for 20-30 minutes on the day of hospitalization.
214681736|NCT00036205|DRUG|sumanirole|
214681737|NCT06150209|DEVICE|Vendaje|Dehydrated Human Amniotic Membrane
214681738|NCT00469235|DRUG|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
214681739|NCT00785746|OTHER|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
214985742|NCT06903104|DIAGNOSTIC_TEST|Quality of life evaluation|The assessment will be carried out at inclusion and after completion of the program.
214681740|NCT00940927|DRUG|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
214493747|NCT04599036|DEVICE|MARK|EMG controlled arm orthosis
214681741|NCT00604448|OTHER|Dietary advise|Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.
214681742|NCT00604448|OTHER|Diet enriched with a meal containing pulses|Subjects in pulse group will consume the commercially available pulses for 8 weeks
214681743|NCT05384743|DRUG|Rituximab Monotherapy|Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
214681744|NCT01299597|DRUG|Atorvastatin|20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
214681745|NCT01299597|DRUG|Simvastatin|10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
214681746|NCT01299597|DRUG|SB649868|20mg daily given for 14 days.
214985743|NCT06903104|DIAGNOSTIC_TEST|Perceived Stress Scale|The assessment will be carried out at inclusion and after completion of the program.
214985744|NCT06903104|DIAGNOSTIC_TEST|Multidimensional Psychological Flexibility Inventory|The assessment will be carried out at inclusion and after completion of the program.
214371036|NCT02605226|DRUG|bicalutamide|bicalutamide
214371037|NCT02605226|DRUG|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
214371038|NCT01303081|BEHAVIORAL|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
214371039|NCT01303081|BEHAVIORAL|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
214493748|NCT06950801|BEHAVIORAL|outdoor-horticultural therapy|Students are randomly assigned to the Outdoor Horticultural Therapy group, where they will receive outdoor horticultural therapy for eight weeks
214985745|NCT06903104|OTHER|satisfaction questionnaire and semi-structured interview|The assessments will be carried out after completion of the program.
214493749|NCT06950801|BEHAVIORAL|indoor-Horticultural Therapy group|Students are randomly assigned to the indoor horticultural therapy group, where they will receive indoor horticultural therapy for 8 weeks
214985746|NCT06924541|DIETARY_SUPPLEMENT|Choline|Each subject gets one of two oral choline doses or placebo on each of three study days, 550 mg, 1100 mg, and placebo
214985747|NCT06924541|DIETARY_SUPPLEMENT|Placebo|Each subject gets one of two oral choline doses or placebo on each of three study days, 550 mg, 1100 mg, and placebo
214985748|NCT06846606|DRUG|AUTX-703|AUTX-703 administered orally
214985749|NCT02912130|DIETARY_SUPPLEMENT|Protein Supplementation|1.2-1.5g/kg/body weight per day
214985750|NCT02912130|OTHER|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
214985751|NCT02912130|OTHER|Resistance Exercise|60 minutes per week of progressive resistance training
214985752|NCT06776159|OTHER|Active Control|Patients in the control group will receive the usual practice of subcutaneous LMWH injection administered by nurses.
214985753|NCT06776159|OTHER|Standardized injection protocol|Nurses administer LMWH according to the standardized evidence-based protocol.
214985754|NCT07086820|DRUG|Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks|Weekly isoniazid and rifapentine for 12 weeks (3HP regimen) will be provided to all participants.
214985755|NCT07086820|DRUG|Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks|Weekly isoniazid and rifapentine for 12 weeks (3HP regimen) will be provided only to participants with a positive IGRA result at baseline.
214371040|NCT01303081|BEHAVIORAL|Chosen Deposits|Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
214371041|NCT01303081|BEHAVIORAL|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
214985756|NCT07084948|DRUG|Flavonoid|"The daily maintenance, Tenofovir 150mg + SB Flavon 1345mg dose is to be taken 2 times a day, 1 tablet each time.~The composition treats acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma at an early stage. The product is Acid ascorbic, L-Arginine hydrochloride, Kaempferol, Urinariaflavone, 5,6-dihydroxy-7,8,4'-trimethoxy-flavone, Quercetin, Rutin.~Use these ingredients to protect liver cell membranes, preventing the growth of HBV in the body."
214985757|NCT07084948|DRUG|Tenofovir|"The daily maintenance, Tenofovir 300mg dose is to be taken 1 time a day, 1 tablet each time.~The composition treats acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma."
214985758|NCT06902077|BEHAVIORAL|low carb diet|diet based on low carb with max 50-80 grams of carbohydrates daily
214371042|NCT01303081|BEHAVIORAL|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
214371043|NCT01530230|DRUG|oxytocin|Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
214371044|NCT04050774|DEVICE|Balance boards|The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
214371045|NCT06517667|DRUG|Icross tear substitute|Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.
214371046|NCT06517667|DRUG|Hyabak tear substitute|Patients were instructed to instill 1 drop of 0.15% hyaluronic acid substitute into each eye 3 times per day for 3 months.
214493750|NCT06950801|BEHAVIORAL|General Psychological Group Counselling Team|Students were randomly assigned to general group groups to participate in an 8-week mental health group activity
214493751|NCT06950723|OTHER|Chest Physical Therapy (CPT) modalities , Medical Treatment|Chest Physical Therapy (CPT) modalities in the form of postural drainage, percussion and vibration.
214985759|NCT06902077|BEHAVIORAL|diabetic diet|Balanced diet based on standard of care recommendations for type 2 diabetes
214985760|NCT06907667|OTHER|Vaccine injection|Injection of the vaccine in chronic renal insufficiency patients.
214493752|NCT06950138|DRUG|Triticum aestivum|During the intervention period, the aim is to evaluate changes in the patient's vascular function.
214493753|NCT06950138|DRUG|calcined magnesia|During the intervention period, the aim is to evaluate changes in the patient's vascular function.
214493754|NCT06950203|DIETARY_SUPPLEMENT|Very Long Chain Polyunsaturated Fatty Acids|Fish oil with DHA and VLCPUFA
214985761|NCT06906809|DRUG|BGB-16673|Administered orally
214985762|NCT06906809|DRUG|Itraconazole|Administered orally
214985763|NCT06906809|DRUG|Phenytoin|Administered orally
214985764|NCT06742801|DEVICE|Onyx™ Liquid Embolic System|The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
214371047|NCT01395108|DRUG|Nemonoxacin|oral once daily
214371048|NCT03988166|PROCEDURE|Chronic Total Occlusion Revascularization|Teleflex's series of study guidewires and catheters will be used to facilitate the safe and effective crossing of de novo CTOs and placement of conventional guidewires beyond the lesion via either a true lumen or subintimal pathway.
214371049|NCT03988166|DEVICE|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
214371050|NCT02459730|PROCEDURE|ART with GIC containing 1.25% CHX.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
214371051|NCT02459730|PROCEDURE|ART with GIC.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
214493755|NCT06950203|DIETARY_SUPPLEMENT|Comparator arm (DHA)|Oil containing equal DHA content to active arm
214493756|NCT05774002|BEHAVIORAL|Aims to Decrease Anxiety and Pain Treatment (ADAPT)|One pre-operative and 4 post-operative sessions of cognitive behavioral therapy (CBT) treatment in the first two months, beginning 2-3 weeks after surgery, will be completed.
214681747|NCT03524365|PROCEDURE|RYGB|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.
214681748|NCT03524365|PROCEDURE|SG|The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.
214681749|NCT03524365|OTHER|Intensive Lifestyle Modification|"Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF."
214681750|NCT00397228|DRUG|ALTROPANE®|ALTROPANE® SPECT imaging
214371052|NCT00992680|DEVICE|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
214681751|NCT01747330|DRUG|Pancreatin|Doses of Pancreatin \<2500 lipase u/kg/feed or \<4000 lipase U/g fat/intake or \<10000 lipase U/kg/day given orally are used
214681752|NCT01588574|BIOLOGICAL|MT10109|Botulinum toxin type A
215089109|NCT01376570|BEHAVIORAL|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
214371053|NCT05960825|COMBINATION_PRODUCT|injectable platelet rich fibrin versus microosteoperforation|injectable platelet rich fibrin which is second product of blood versus microosteoperforation which is surgical procedure
214371054|NCT05488275|PROCEDURE|Surgery|MPFL reconstruction
214371055|NCT01068808|PROCEDURE|skin prick test|skin prick test to aeroallergen
214371056|NCT06170671|DRUG|Non interventional study|CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection
214681753|NCT01588574|BIOLOGICAL|BOTOX(Registered trade mark)|Botulinum toxin type A
214985765|NCT07091422|DEVICE|Etch-Free Adhesive|A self-adhesive orthodontic bonding material applied directly to enamel without prior phosphoric acid etching or primer application. Brackets are bonded following the manufacturer's instructions.
214985766|NCT07091422|DEVICE|Conventional Etch-and-Bond Adhesive|A standard orthodontic bonding protocol using 35-37% phosphoric acid etching, primer application, and a conventional light-cure adhesive. Brackets are bonded following the manufacturer's recommended procedure.
215089110|NCT06243055|OTHER|questionnare|laval questionnare
214371057|NCT00002180|DRUG|Tenofovir|
214371058|NCT06007690|DRUG|Bel-sar|Bel-sar via suprachoroidal administration followed by laser application.
214371059|NCT06007690|DEVICE|Suprachoroidal Microinjector|Suprachoroidal injection device
214371060|NCT06007690|DEVICE|Infrared Laser|Laser application
214493757|NCT06954688|OTHER|dry needling|Dry Needling: The puncture is intramuscular and is performed with a non-beveled, filiform, solid needle, similar to those used in acupuncture, which has been shown to produce less damage at the muscle level. It does not infiltrate any substance. As many entries as necessary are made until the local twitch response (LTR) is exhausted.
214493758|NCT06953700|DIAGNOSTIC_TEST|Test of hearing function|These are measurements of hearing acuity and spatial hearing.
215089111|NCT06243055|OTHER|questionnare|Obese-Specific Quality of Life
214371061|NCT06007690|DEVICE|Sham Infrared Laser|Sham laser application
214371062|NCT06007690|DEVICE|Sham Microinjector|Sham injection device
214371063|NCT06566326|DRUG|Propofol and ketamine|Patients received IV sedation using prepared mixture of propofol and ketamine in ratio (4:1). It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation. The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.
214493759|NCT06952556|DRUG|ACB|15 mL of 0.25% Bupivacaine block of the saphenous nerve injected under ultrasound guidance via adductor canal.
214493760|NCT06952556|DRUG|IPACK block|IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee
214493761|NCT06953232|DIETARY_SUPPLEMENT|Whey protein-enriched milk fat globule membrane supplement|Participants will consume a high-fat, mixed meal containing approximately 75 g of test fat (refined palm oil), supplemented with a whey protein-enriched milk fat globule membrane (providing \~5 g of milk polar lipids) powdered ingredient. The experimental and placebo meals will be isoenergetic and protein-matched, and will be administered in a randomised order, with a washout period of at least 21 days between sessions.
214985767|NCT02670707|DRUG|Cytarabine|Cytarabine 100 mg/m\^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
214493762|NCT06953232|DIETARY_SUPPLEMENT|Whey protein-based supplement|Participants will consume a high-fat, mixed meal containing approximately 75 g of test fat (refined palm oil) supplemented with a whey protein-based powdered ingredient without milk fat globule membrane (placebo) The experimental and placebo meals will be isoenergetic and protein-matched, and will be administered in a randomised order, with a washout period of at least 21 days between sessions.
214681754|NCT00257192|DRUG|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
215089112|NCT06243055|OTHER|questionnare|SF-12 Quality of Life scale
214681755|NCT00257192|DRUG|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
214681756|NCT01058174|DRUG|micafungin|intravenous infusion
214493763|NCT06765148|OTHER|Retrospective radiologic study|Retrospective radiologic study
214681757|NCT01058174|DRUG|fluconazole|intravenous infusion
214681758|NCT01058174|DRUG|liposomal amphotericin B|intravenous infusion
214681759|NCT01058174|DRUG|caspofungin|intravenous infusion
214681760|NCT00004081|DRUG|docetaxel|
214681761|NCT00060086|DIETARY_SUPPLEMENT|pomegranate juice|Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
214681762|NCT01120327|DRUG|Placebo|Placebo
214493764|NCT06955819|OTHER|Placebo Intervention|Subjects will be given a blank matrix powder with the same appearance as the products in the experimental groups, which does not contain probiotics or herbal powder. The dosage, frequency, and administration method are exactly the same as those in Experimental Group. Intervention duration will be 12 weeks, carried out synchronously with the experimental groups to ensure the consistency of research conditions.
214493765|NCT06955819|DIETARY_SUPPLEMENT|Probiotic Intervention|Subjects will take Zhigu Zhijian (QingzhiningTM) probiotic powder, 2g per sachet, twice a day, one sachet after breakfast and one after dinner, taken with lukewarm water (water temperature ≤ 30℃). Intervention duration will also be 12 weeks, for parallel comparison with other groups.
214493766|NCT06955819|DIETARY_SUPPLEMENT|Probiotic with Herbal Powder Intervention|Subjects in this group will be given Zhigu Zhijian (QingzhiningTM) probiotic powder and Zhigu Zhijian (QingzhiningTM) herbal powder. The probiotic powder is 2g per sachet, taken twice a day, one sachet after breakfast and one after dinner, and should be taken with lukewarm water (water temperature ≤ 30℃). The herbal powder is 15g per sachet, taken once every other day before breakfast, and should be taken after being brewed with boiling water. Intervention duration will be last for 12 weeks to ensure sufficient time to observe the long - term effects on defecation and gut microbiota.
214493767|NCT06953037|OTHER|acupressure|The application will be made to the women in the acupressure group after applying the data collection forms (Personal Information Form, STAI-1 and Physiological Parameters and Fetal Heart Rate Chart) 1 hour before the cesarean section. The application will be made to the women in the acupressure group by manually pressing the SP6 and HT7 points with the index or middle finger for 5 seconds to a depth of 1-1.5 cm in the order determined by lot, then resting for 2 seconds and continuing the application for 2 minutes. Anxiety, physiological parameters and fhr will be measured again 40 minutes after the application. The data collection forms (descriptive characteristics form, loss, physiological parameters, fhr) will be applied to the women in the control group 1 hour before the cesarean section. No intervention will be made to the women in the control group. Anxiety, physiological parameters and fhr will be measured again 40 minutes later.
214493768|NCT06953830|DEVICE|Vibration-controlled transient elastography|Liver and spleen stiffness measurements using vibration-controlled transient elastography
214493769|NCT06952946|OTHER|0.5 lt/dk fresh gas flow|Fresh gas flow will be set to 0.5 l/min in the low flow anesthesia group.
214493770|NCT06952946|OTHER|2 lt/dk fresh gas flow|Fresh gas flow will be set to 2 lt/min in the medium flow anesthesia group.
214493771|NCT06952946|OTHER|4 lt/dk fresh gas flow|Fresh gas flow will be set to 4 lt/min in the high flow anesthesia group.
214493772|NCT06954389|OTHER|Hyperbaric oxygen therapy|Patients received hyperbaric oxygen therapy using a monochamber hyperbaric chamber in addition to conventional rehabilitation.
214493773|NCT06954389|OTHER|Conventional rehabilitation|Patients received conventional rehabilitation alone.
214493774|NCT06953869|DRUG|Tasimelteon Oral Suspension|Single daily dose, weight-based liquid suspension formulation.
214681763|NCT01120327|DRUG|Amlodipine|Amlodipine
214681764|NCT00570739|DRUG|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
214681765|NCT00570739|DRUG|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
214681766|NCT00570739|DRUG|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
214681767|NCT00570739|DRUG|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
214681768|NCT04554030|BEHAVIORAL|Evaluate sperm count before and after immunotherapy|Evaluate sperm count before and after immunotherapy
214681769|NCT03774017|PROCEDURE|one-staged hybrid operation|An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
214681770|NCT03774017|PROCEDURE|Traditional microsurgical operation|The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
215089113|NCT04912323|DEVICE|Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold|Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
215089114|NCT02674425|DEVICE|Dark Adaptometer|
214985768|NCT02670707|DRUG|Vinblastine/prednisone|"Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m\^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m\^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m\^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
214985769|NCT07098169|BEHAVIORAL|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities. i
214985770|NCT07098169|BEHAVIORAL|Active Control|Behavioral: Mobile cognitive tests will be administered to control subjects. Participants will receive feedback regarding their performance but not on the accuracy of their self-ratings. Coaching will also be coupled with mobile cognitive tests and will include goal-setting without specific mention of Introspective Accuracy (IA). in place of content related to IA, participants will receive psychoeducation about the benefits of sleep, physical activity, and social connection to overall cognitive health
214493775|NCT06953869|DRUG|Placebo|Placebo comparator.
214493776|NCT06949163|OTHER|Homemade formula|Patients will receive enteral feeding with a polymeric formula made from blended natural foods (apple, chayote, cookie, chicken and olive oil), adjusted to meet their nutritional requirements (energy: 25 kcal/kg, protein: 1.3 g/kg).
214493777|NCT06949163|DIETARY_SUPPLEMENT|Commercial formula|Patients will receive enteral feeding with a commercial polymeric formula, adjusted to meet their nutritional requirements (energy: 25 kcal/kg, protein: 1.3 g/kg).
214493778|NCT06952075|DRUG|GR1803|D1 given at a dose of 10ug/kg, D4 given at a dose of 30ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
214493779|NCT06954610|OTHER|No intervention|No intervention
214493780|NCT06946511|DRUG|Peptide PMS-001 Intravenous Injection|Participants will receive intravenous injections of PMS-001.
214493781|NCT06946511|DRUG|Placebo|The control group will receive a placebo, which is the blank excipient (mannitol) of the injectable PMS-001.
214493782|NCT06950437|DEVICE|active iTBS|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.
214493783|NCT06950437|DEVICE|Sham iTBS|Participants will undergo three sham iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.
214493784|NCT06950437|BEHAVIORAL|speech therapy|Speech therapy will be delivered between iTBS/sham sessions. Two 30-minutes trainings every day.
214493785|NCT06951607|OTHER|Coban wrap|A Coban bandage or wrap is a self-adhering elastic wrap that sticks to itself but not to skin or clothing. It is commonly used as a wrap on limbs due to its ability to adhere to itself and not loosen. Coban is often used as a compression bandage
214493786|NCT06951607|OTHER|Neoprene sleeve|Neoprene sleeve is an innovative treatment approach, it consists of a synthetic rubber-like material used to provide compressive support. Neoprene sleeves can provide protection, light compression and mild extension support while allowing full finger flexion.
214493787|NCT06954649|DIETARY_SUPPLEMENT|Plant based extract rich in phytosterols and phytostanols resveratrol and hydroxytyrosol.|Individuals will take two capsules daily of the phytosterol-rich extract for 56 days. Two capsules will be taken daily in the evening, after dinner
214493788|NCT06954649|OTHER|Placebo|Individuals will take two capsules daily of the placebo capsule for 56 days. Two capsules will be taken daily in the evening, after dinner
214493789|NCT06953024|DIAGNOSTIC_TEST|INSTI HIV/syphilis Point of Care Self-Test Administration|The INSTI Human Immunodeficiency Virus (HIV)/syphilis POCT is a rapid, single-use, flow-through immunoassay that is Health Canada-approved as a screening test for detecting antibodies to HIV1/2 and syphilis using a fingerstick blood sample.
214493790|NCT06951451|BEHAVIORAL|smartphone application (MED-AD)|"1. Medication Reminders: The oral medication list of the patient (names, doses, times, and frequency of administration) will be entered manually in the application by the RA in agreement with the patient during the medication prescription refill. This application will then send reminders, as notifications and voice notes, to take medications. An example of the reminder is take lisinopril, one tablet, 10 mg at 9:00 am. The reminders will be categorized as normal, urgent \& critical. Normal is a reminder sent on the normal medication timing. An urgent reminder is when the patient misses confirming a reminder more than once, which will be set as an alert on the phone. Critical reminder is when the patient misses confirming a reminder multiple times, which will be as an alert or an alarm on the phone. In addition, the application will notify a family member in case of urgent and critical reminders.~2. Medication Adherence Report: The application will generate a weekly report on medication"
214493791|NCT06951451|BEHAVIORAL|Short Text-message Reminders|"Participants will receive short text message (SMS) reminders to remind them to take medications as prescribed ONCE daily. However, the SMS will be general and not specify taking particular medicine compared to the application reminders. An example of the SMS message will be Remember to take your medicines of the day? The research team will pilot the MED-AD application on the same population and modify it before the implementation of the study."
214493792|NCT06953531|DEVICE|Cold Application (Local Skin Cooling Device)|Immediately before the blood collection procedure, cold application will be made to the area with a local skin cooling device.
214493793|NCT06953531|BEHAVIORAL|Distraction Method (Bubble Machine)|A bubble machine will be used to distract children during the blood collection process.
214493794|NCT06953531|BEHAVIORAL|Distraction Method (Simulative Toy)|A simulative toy will be used to distract children during the blood collection process.
214493795|NCT05551507|DRUG|IN10018 in combination with PLD|IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
214985771|NCT06928324|PROCEDURE|Erector Spinae Plane block|The Erector Spinae Plane Block (ESPB) is a technically simple and safe form of regional anesthesia that can provide effective analgesia for 12 hours in patients with acute postoperative pain
214985772|NCT06928324|PROCEDURE|Control|No intervention
214985773|NCT07095075|BIOLOGICAL|LUCAR-DKS1 NK cells|Prior to the infusion of the LUCAR-DKS1 cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
214985774|NCT06842485|OTHER|Telerehabilitation|The experimental group will be given a tailored program of telerehabilitation consisting of stretching and strengthening exercises for six weeks (three times per week)
214985775|NCT06842485|OTHER|Patient education|Patient education will be given to both the experimental and control groups. Patient education and telerehabilitation will be given to the experimental group. To the control group, patient education alone will be provided
214985776|NCT06826768|DRUG|REGN5678|Given by IV infusion
214493796|NCT06523270|RADIATION|Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI)|"All adult (≥18 y.o) subjects (until 50000 individuals) presenting to the U.O of Radiologia DiMer Advanced Imaging for Personalized Medicine to be submitted to imaging study on advanced scanner"
214493797|NCT03610971|DRUG|Ruxolitinib|Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
214493798|NCT03610971|DRUG|BCR-ABL Tyrosine Kinase Inhibitor (TKI)|The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
214493799|NCT05370612|DEVICE|Dexcom G6 CGM|"Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data.~Experimental Group will wear CGM for the duration of their pregnancy.~Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy."
214493800|NCT05370612|OTHER|Participant Finger Stick Glucose Monitoring|Standard of care for individual participant
214493801|NCT02755896|RADIATION|Arm 1 600 cGY x 5 fractions|Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
214493802|NCT02755896|RADIATION|Arm 2 800 cGY x 3 fractions|Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
214493803|NCT04036812|PROCEDURE|Superficial cervical plexus block|superficial cervical plexus nerve block will be performed under the guidance of ultrasound
214493804|NCT04036812|OTHER|Control group|ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
214493805|NCT04557501|DIAGNOSTIC_TEST|PSMA PET/CT guided intensification of therapy|PSMA PET/CT prior to treatment.
214493806|NCT04557501|OTHER|Control Arm|Control - Treatment without PSMA PET/CT
214493807|NCT05246709|DEVICE|Cyanoacrylate glue|"Adhesive to be applied on the PICC line site prior to usual standard film dressing over the site, such as SecurePortIV® Catheter Securement Adhesive by Adhezion Biomedical® Cyanoacrylate adhesive that is FDA-approved for securement of vascular access devices.~Securement method that provides microbial protection by sealing the insertion site."
214493808|NCT05246709|DEVICE|Standard transparent film dressing|A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.
214493809|NCT05699564|OTHER|Early biomarker-based cardiological assessment|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
214493810|NCT06342973|DEVICE|Xenograft and allograft|For the guided bone augmentation procedure, a crestal incision with one or two vertical incision will be made and a full thickness mucoperiosteal flap will be elevated. Decortication will be performed and the patient will receive grafting with DFDBA with a buccal overlay of xenograft. A bi-layered native collagen membrane will be used and fixed with tacks or sutures. Periosteal incisions will be made to get tension free primary closure. The flap will be closed with sutures. Patients will be prescribed antibiotics, analgesics and mouth rinses as appropriate.
214493811|NCT05458258|DEVICE|Bioelectrical Impedence Analysis Device|A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.
214493812|NCT05458258|OTHER|6 Minute Walk Test|Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.
214493813|NCT05458258|DIAGNOSTIC_TEST|Computed Tomography Scans to Measure Skeletal Muscular Index|Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).
214493814|NCT05458258|DIAGNOSTIC_TEST|Blood Test/Blood Draw|Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.
214493815|NCT05458258|OTHER|Hand Grip Strength Test|Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.
214493816|NCT05863234|DRUG|PPMX-T003|The therapeutic agent is administered continuously intravenously
214493817|NCT01739244|DRUG|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
214493818|NCT01739244|DRUG|Placebo|Ocular topical administration of placebo for 14 consecutive days
214493819|NCT04129203|DEVICE|Versi Retriever thrombectomy|Mechanical thrombectomy using Versi Retriever
214985777|NCT06826768|DRUG|Cemiplimab|Given by IV infusion
214985778|NCT06410534|DRUG|nivolumab|Nivolumab will be dosed at 3 mg/kg and given as an IV over 30-60 minutes on day 1 of each cycle. It will be administered every 3 weeks (21 days) for up to 8 cycles
214681771|NCT03268174|OTHER|AO+Mist|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
214371064|NCT06566326|DEVICE|Modified Oropharyngeo-esophygeal Topical Anesthesia by OPETA Prototype tool|Topicalization was done for anterior tonsillar pillar on both sides and posterior 1/3 of tongue and posterior pharyngeal wall using xylocain gel 5 % on tip of his index or middle finger then after 5-7 min. patient inserted his middle finger deeply into his mouth as a test for tolerability before insertion of OPETA tool. While head tilted forward, Lubricated OPETA device, soaked with 10 ml lidocaine 2 % mixed with adrenaline 1/200000 was gradually placed by patient with assistance from anesthetist \& patients swallowing into esophagus. To ensure effective topical anesthesia and patient tolerance, pack was left in place for 3-5 min. before being moved up, down, clockwise \& anti-clockwise.. If necessary, increments of 5 ml of 2% lidocaine/adrenaline mixture was injected through device until patient is comfortable. Maximum LA dose was kept at 5 mg/kg.
214371065|NCT06579820|COMBINATION_PRODUCT|tubular bandage|The experimental group consisted of the group in which a tubular bandage was applied over the PIC, which was routinely applied.
214985779|NCT06410534|DRUG|ipilimumab|Ipilimumab will be dosed at 1 mg/kg and given as an IV over approximately 30 minutes on day 1 of every other cycle (every 6 weeks or 42 days) for up to 4 doses
214371066|NCT01756911|DEVICE|MFM|Implantation of the MFM
214371067|NCT03760536|BEHAVIORAL|16-week Exercise Rehabilitation Program for Breast Cancer Survivors|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
214985780|NCT05441306|DEVICE|Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).
214371068|NCT04876079|OTHER|Test to induce a decline in plasma glucose|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.
214985781|NCT05441306|DEVICE|Epic®MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
214493820|NCT05106842|OTHER|Hydrotherapy|Aquatic therapy was performed in a swimming pool (depth 125-140 cm, temperature 28-31°C) supervised by a physiotherapist. Patients were asked to kneel or sit to submerge both shoulders to perform exercises consisting of progressive passive and active motion of the shoulder for 4-6 weeks, then strengthening exercises in a swimming pool for 2-4 months.
214493821|NCT05106842|OTHER|Land-based Therapy|Land-based therapy was performed at a rehabilitation center supervised by a physiotherapist. Patients performed progressive passive and active-assisted motion of the shoulder for 4-6 weeks, then strengthening exercises for 2-4 months.
214985782|NCT06116136|DRUG|S095029|Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).
214985783|NCT06116136|DRUG|pembrolizumab 200 mg (KEYTRUDA ®)|Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
214985784|NCT07103941|DEVICE|AM Aligner|"Intervention Name: AM Aligner (Interocclusal Aligner) Type: Device Manufacturer: (AM Aligner; TAP Sleep Care, Texas, USA)~Description:~The AM Aligner is a prefabricated, commercially available thermoplastic appliance designed to help patients return their mandible to a normal resting position after nighttime use of a Mandibular Advancement Device (MAD). In this study, the aligner will be used each morning immediately after removing the MAD. The participant will bite into the warmed aligner for 2-5 minutes to promote realignment of the mandible and occlusion. This approach aims to minimize or prevent occlusal changes, including posterior open bite and anterior shift, associated with prolonged MAD therapy.~This intervention is distinct from the alternative study arm, which uses a set of guided jaw exercises instead of a physical appliance to achieve the same goal.~The AM Aligner used in this study is a standard-of-care option and is FDA-cleared for this use. It is not investigational."
214985785|NCT07103941|BEHAVIORAL|Exercise|"Participants in this arm will perform a standardized set of jaw exercises for 5 minutes each morning immediately after removing their Mandibular Advancement Device (MAD). The exercises are intended to assist in reestablishing the natural occlusal relationship following overnight mandibular advancement.~This routine includes the following movements:~Side-to-side jaw movements Backward pressure to the chin (similar to a thinker's pose) Gentle simulated clenching~The exercises are performed once daily and take approximately 2-3 minutes to complete. This approach represents a standard-of-care method for minimizing occlusal changes associated with MAD therapy."
214985786|NCT07117968|OTHER|Standard-of-care|Management of the first year post-CI follow-up according to current center practices
214985787|NCT07117968|OTHER|Experimental hybrid care pathway|First year post-CI follow-up including early activation of the implant and hybrid follow-up, including remote or in-center monitoring visits, adjustable according to the evolution of their hearing performance and comfort. In this new care pathway, compared with the Standard-of-care, the 2-week visit and the 9-month visit are omitted, due to early activation and remote follow-up. Visits at 1 and 6 months are the same as those in the conventional, on-site routine. Visits at 3 and 12 months will be carried out remotely by default via the remote monitoring application.
214985788|NCT07118046|DEVICE|Pulmonary vein isolation|Pulsed field ablation for pulmonary vein isolation in atrial fibrillation ablation
214371069|NCT04876079|DEVICE|Dexcom G6|Participants will have to wear a Dexcom G6 during study interventions
214371070|NCT04876079|OTHER|Dex4|When the glycemic threshold is reach, participants will be given 16g of Dex4
214493822|NCT01884805|DEVICE|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
214681772|NCT03268174|OTHER|Placebo|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
214681773|NCT04738045|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
214681774|NCT04738045|DRUG|Lopinavir/ Ritonavir and Remdesivir combination|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
214681775|NCT02481960|PROCEDURE|CM-BC2 Irinotecan drug-eluting bead|
214681776|NCT02289755|DRUG|ALLN-177|ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
214681777|NCT03809065|DRUG|Nitroglycerin|Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
214681778|NCT03809065|DRUG|Labetalol|Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
214681779|NCT02020343|BEHAVIORAL|taste tests|"Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling."
214985789|NCT06919991|DRUG|Casdatifan|Administered as a single dose in treatment Periods 1, 2, and 3
214985790|NCT06919991|DRUG|Itraconazole|Administered as multiple doses in treatment Period 2
214985791|NCT06919991|DRUG|Phenytoin|Administered as multiple doses in treatment Period 3
214371071|NCT04876079|DRUG|Insulin|A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
214371072|NCT03248375|RADIATION|Radiation Segmentectomy|The administration of radioactivity in a branch of an artery of the liver
214371073|NCT03763162|DRUG|Bortezomib|Given SC
214681780|NCT01206595|DRUG|SKY0402|Single dose of SKY0402 administered as a nerve block
214681781|NCT01206595|DRUG|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
214681782|NCT03327922|DEVICE|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
214681783|NCT02535949|DRUG|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
214681784|NCT02535949|OTHER|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
214681785|NCT05438485|OTHER|Registry|Observational (Registry)
214371074|NCT03763162|BIOLOGICAL|Daratumumab|Given IV
214371075|NCT03763162|DRUG|Dexamethasone|Given IV or PO
214371076|NCT03763162|DRUG|Ixazomib|Given PO
214493823|NCT04394897|COMBINATION_PRODUCT|Remifentanil-Propofol admixture|
214493824|NCT01645124|DRUG|Hydroxyurea|
214493825|NCT01645124|PROCEDURE|Phlebotomy|
214681786|NCT01461954|DRUG|FST-100|FST-100
214681787|NCT01461954|DRUG|FST-100 Vehicle|FST-100 Vehicle
214681788|NCT00884182|BIOLOGICAL|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
214371077|NCT03763162|OTHER|Quality-of-Life Assessment|Ancillary studies
214371078|NCT04992546|DRUG|PRN473 (SAR444727)|White to off-white gel suspension
214371079|NCT04992546|DRUG|Placebo|White to off-white gel suspension
214371080|NCT06275893|BIOLOGICAL|IC14|recombinant monoclonal antibody directed against cluster of differentiation 14 (CD14) antigen
214985792|NCT06655246|DRUG|ziftomenib|menin inhibitor
214985793|NCT06655246|DRUG|imatinib mesylate|kinase inhibitor
214985794|NCT07117058|DIAGNOSTIC_TEST|New rapid screening tool for anxiety and depressive disorders|New rapid screening tool for anxiety and depressive disorders completed by patient during a regular follow-up consultation
214985795|NCT07117058|DIAGNOSTIC_TEST|SCARED-R-51 (Screen for Child Anxiety Related Emotional Disorders-Revised)|Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 7-14 years old.
214985796|NCT07117058|DIAGNOSTIC_TEST|HADS (Hospital Anxiety and Depression Scale)|Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 15-25 years old.
215089115|NCT04700956|PROCEDURE|primary abdominal closure|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
214681789|NCT01921270|DRUG|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units"
214681790|NCT02427594|DRUG|Sodium bicarbonate|Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
214681791|NCT02427594|OTHER|Controlled diet|Diet without sodium bicarbonate supplementation
214371081|NCT04419649|DRUG|KER-050|KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
214681792|NCT04579055|OTHER|1-min STS test: adjusted|Individually adjusted chair seat height of 90° knee joint flexion
214371082|NCT04506775|DEVICE|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
214371083|NCT04506775|PROCEDURE|Radial artery catheterization|Radial artery catheterization is the standard of care for measuring blood pressure continuously throughout surgery.
214371084|NCT04996758|DRUG|Toripalimab and Anlotinib|Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.
214371085|NCT05759988|DEVICE|Outpatient Foley catheter|Outpatient Foley catheter placement for induction of labor
214371086|NCT06265285|OTHER|Home Health Encounter|Receive in-home visits by a home health nurse
214371087|NCT06265285|BIOLOGICAL|Nivolumab|Given SC
214371088|NCT06265285|PROCEDURE|Patient Monitoring|Undergo remote patient monitoring
214371089|NCT06265285|OTHER|Questionnaire Administration|Ancillary studies
214371090|NCT05989698|DEVICE|C-mo System|Patients will use C-mo System for a period of 24h, to assess cough characteristics.
214493826|NCT05917015|DIETARY_SUPPLEMENT|Treatment|Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
214493827|NCT05917015|OTHER|Placebo|Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
214493828|NCT01637402|DRUG|Abiraterone Acetate|"Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration"
214493829|NCT01637402|DRUG|Prednisone|5 mg, twice daily, oral administration
214493830|NCT02436174|DEVICE|novel device|novel device being used to measure shivering
214493831|NCT00202436|PROCEDURE|Phlebotomy|Removal of 500 ml whole blood
214493832|NCT00202436|PROCEDURE|Erythrocytapheresis|machinal removal of erythrocytes
214493833|NCT00862706|DRUG|Telbivudine/LDT600A|Oral once daily
214681793|NCT04579055|OTHER|1-min STS test: standardized|Standardized chair seat height of 46 cm
214985797|NCT07126535|DIAGNOSTIC_TEST|Radiofrequency ablation alone|If there is no evidence of nodularity, these patients will undergo RFA. Clinical biopsies utilizing a large-capacity biopsy forceps (Radial Jaw 4, Boston Scientific, Marlborough, MA) are obtained. RFA may be delivered through several devices under the BarrX RFA System (Medtronic USA, Minnetonka, MN), including a circumferential balloon catheter (Halo 360; figure 1), or over the scope focal catheter (Halo 90 or 60). The Halo 360 treats a circumferential 4 cm segment at a time, whereas the focal catheters treat a 1.3x2 cm (Halo 90) or 1.0x1.5 cm (Halo 60) area.
214985798|NCT02177500|DRUG|Telmisartan + hydrochlorothiazide|
214681794|NCT01883128|DEVICE|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
214985799|NCT02177500|DRUG|Telmisartan|
214985800|NCT02177500|DRUG|Placebo|
215089116|NCT04700956|DEVICE|abdominal closure with prophylactic mesh|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
215089117|NCT01299571|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
214371091|NCT05901610|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
214371092|NCT05901610|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive past events.
214371093|NCT05901610|DEVICE|Low-intensity Focused Ultrasound|A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.
214371094|NCT05901610|DEVICE|Sham Low-intensity Focused Ultrasound|All of the same actions done during LIFU will be performed, but the device will be inactive.
214681795|NCT01883128|PROCEDURE|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
214493834|NCT02512250|OTHER|Registry|
214493835|NCT02111096|DRUG|LY2409021|Administered orally
214493836|NCT02111096|DRUG|Sitagliptin|Administered orally
214493837|NCT02111096|DRUG|Placebo|Administered orally
214493838|NCT02111096|DRUG|Metformin|Administered orally
214493839|NCT02111096|DRUG|Sulfonylurea|Administered orally
214681796|NCT01883128|PROCEDURE|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
214681797|NCT06300970|DRUG|Amodiaquine-artesunate (ASAQ)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
214681798|NCT06300970|DRUG|Artemether+Lumefantrine (AL)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
214985801|NCT07133607|OTHER|education about pain and physical excersice|"The sessions will be conducted in groups of 10 to 15 patients.~* 4 pain science education sessions, each lasting 1.5 hours (6 hours), with one session per week, for 4 weeks.~* 12 therapeutic physical exercise program sessions, each lasting 1 hour, to be conducted over 6 weeks (12 hours), with two sessions per week. Although the intervention is group-based, individual instructions will be given to patients. Reference will be made to the content learned in the neuroeducation sessions. The exercise dose must be adjusted to the patient's condition, keeping in mind that, due to the inhibition of the descending pain modulation system, they may experience an initial increase in pain during the first sessions, so as not to alarm the patient and prevent the activity from being discontinued. The main objective is to increase the patient's functionality, an aspect that will be constantly reinforced.~The session structure will be as recommended by the American College of Sports Medicine, with se"
214681799|NCT06321744|OTHER|adapted physical activity program (APA Program)|"Content of the APA program:~* Strengthening of the lower limbs: Exercises alternating different regimes of muscular contractions (eccentric, concentric and isometric), with the use of elastics, balls or even body weight. These exercises will mainly work the quadriceps and hamstrings.~* Upper limb strengthening: Exercises focused on eccentric and concentric contraction regimes, in a global movement approach (as opposed to a segmental approach), with the use of elastics, dumbbells, weighted balls, etc. These exercises will work the muscles of the biceps, triceps, pectorals, deltoids and lats.~* Walking: In the room and/or in the corridor, with technical assistance (cane/walker, etc.) or human work~* Balance and proprioception: Balance work in a bi- and uni-pedal situation, statically and dynamically (eyes open and closed) will be offered with the use of proprioception boards and/or mats combining if possible work in dual task."
214681800|NCT00808691|OTHER|Critical care|Standard care for each group of patients
214681801|NCT00865254|BEHAVIORAL|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
214681802|NCT00865254|BEHAVIORAL|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
214681803|NCT00865254|BEHAVIORAL|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
214681804|NCT00854932|OTHER|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
214681805|NCT06415578|OTHER|ergonomics training|In this training; What is ergonomics, the importance of ergonomics, the purpose of ergonomics, risk factors for musculoskeletal disorders that can be seen in e-sports players, ergonomic arrangements that can be made in the working environment and methods of protection from musculoskeletal injuries, posture disorders and various ergonomic arrangements that can be made for posture disorders and chair selection, screen selection. selection and rest breaks were included. Participants will be trained twice in total, on the first day of the study and at the end of the 4th week. The training will be carried out interactively, supported by videos and visuals. Training will be done individually and will last approximately 2 hours.
214681806|NCT06415578|OTHER|Exercises|The exercise training program will be implemented for 8 weeks, 3 days a week, lasting an average of 45 minutes. All participants will be given information about the exercises before the exercise training. The exercise protocol was designed as 3 parts: warm-up, exercise and cool-down. Stretching exercises, mobility and strength exercises will be applied. A rest period of 30-45 seconds was given between sets and 2-3 minutes between exercises. Participants will be given dynamic and static stretching, nerve stretching, postural strength and functional exercises for the upper extremity. Relevant movements will be modified according to the exercise capacity of the participants. Exercise content will also include median, ulnar and radial nerve stretching, neck and thoracic mobility exercises, and functional strength exercises for the shoulder, arm, hand and wrist. Exercise tracking will be checked regularly through online conversations.
214681807|NCT03388125|DRUG|Injection Sclerotherapy|5% ethanolamine oleate group
214681808|NCT03388125|DRUG|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
214681809|NCT00455858|DRUG|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
214681810|NCT04713358|DRUG|Nalmefene|Immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
215089118|NCT00088283|DRUG|pegaptanib sodium|
215089119|NCT00864851|BIOLOGICAL|Replagal|Intravenous (IV) infusion for 12 months
214681811|NCT04713358|DRUG|normal Saline|Immediately Intravenous injection of normal saline 1ml after surgery
214681812|NCT00198159|DRUG|ZD1839 Iressa|
214681813|NCT02375698|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).
214681814|NCT02375698|BIOLOGICAL|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
215089120|NCT02124954|DRUG|TA-8995|
215089121|NCT02124954|DRUG|Midazolam|
215089122|NCT02124954|DRUG|Digoxin|
214681815|NCT02402192|DRUG|Corifollitropin alfa|
214371110|NCT04683848|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
214371111|NCT04683848|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
214371112|NCT06968741|DEVICE|Artificial Urinary Sphincter (AUS)|AUS implant
214371113|NCT06821997|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214371114|NCT06821997|PROCEDURE|Computed Tomography|Undergo CT
214681816|NCT06598007|DRUG|CT3001|CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.
214681817|NCT02273310|BEHAVIORAL|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
214371115|NCT06821997|DRUG|Fluorouracil|Given IV
214371116|NCT06821997|DRUG|Irinotecan Sucrosofate|Given IV
214681818|NCT00489983|DRUG|pemetrexed|
214681819|NCT00489983|DRUG|gemcitabine|
214681820|NCT00555945|PROCEDURE|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
214681821|NCT00555945|PROCEDURE|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
214681822|NCT00363025|PROCEDURE|Two post-remission strategies|
214681823|NCT00363025|DRUG|Idarubicin versus daunorubicin|
214681824|NCT03611309|OTHER|Surgeon-palliative care team co management|Surgeon-palliative care team co management includes surgeon alone care and palliative care specialist team
215089123|NCT03166644|DEVICE|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
215089124|NCT01203358|DRUG|Exosurf|Infants received up to four intratracheal doses of the surfactant.
215089125|NCT01203358|DRUG|Survanta|Infants received up to four intratracheal doses of the surfactant.
215089126|NCT00140699|BEHAVIORAL|Balance|
215089127|NCT04152434|DRUG|Erenumab Auto-Injector|Assess synergy of add on medication to Erenumab
215089128|NCT04764734|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
215089129|NCT03147313|DEVICE|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
215089130|NCT03147313|DEVICE|Sham|Extracorporeal shock wave treatment will be faked.
214371117|NCT06821997|DRUG|Leucovorin Calcium|Given IV
214371118|NCT06821997|DRUG|Oxaliplatin|Given IV
214371119|NCT06821997|PROCEDURE|Surgical Procedure|Undergo surgical resection
214371120|NCT06082960|DRUG|GS-9911|Tablets administered orally
214371121|NCT06082960|DRUG|Zimberelimab|Administered intravenously
214371122|NCT06822400|PROCEDURE|corrective surgery within 28 days of birth|"Participants will be randomized into two groups with a 1:1 allocation:~Intervention Group: Neonates undergoing surgical correction of TOF within 28 days of birth."
214371123|NCT06822400|PROCEDURE|corrective surgery between 3-6 months of age|"Participants will be randomized into two groups with a 1:1 allocation:~Control Group: Infants undergoing surgical correction of TOF between 3-6 months of age"
214371124|NCT02175355|DRUG|Low dose of Micardis®|
214371125|NCT02175355|DRUG|Medium dose of Micardis®|
214371126|NCT02175355|DRUG|High dose of Micardis®|
214371127|NCT02175355|DRUG|Hydrochlorothiazide|
214371128|NCT02175355|DRUG|Placebo|
214371129|NCT04540432|OTHER|Stool collection at the patient's home.|Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
214371130|NCT04540432|DIAGNOSTIC_TEST|Blood test|7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
214371131|NCT04255628|DIAGNOSTIC_TEST|FDG PET|Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.
214371132|NCT06066437|DRUG|Arm A: 177Lu rhPSMA-10.1|Participants will receive 177Lu rhPSMA-10.1 alone.
214371133|NCT06066437|DRUG|Arm B: 177Lu rhPSMA-10.1 plus Degarelix|Participants will receive 177Lu rhPSMA-10.1 alone. Participants will receive 177Lu rhPSMA-10.1 with Degarelix
214371134|NCT02254226|DRUG|Salmeterol Diskus low|
214371135|NCT02254226|DRUG|Salmeterol Diskus high|
214371136|NCT02254226|DRUG|Salmeterol MDI low|
214371137|NCT02254226|DRUG|Salmeterol MDI high|
214371138|NCT00633464|DRUG|ixabepilone|"injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria."
214371139|NCT00633464|DRUG|ixabepilone + cetuximab|"Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.~Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Cetuximab 400 mg/m\^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m\^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria."
214371140|NCT03794076|DRUG|Cromoglycate|Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray
214371141|NCT03794076|DRUG|Placebo|Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
214681825|NCT03611309|OTHER|Surgeon team alone management|The surgeon and surgical team will manage
214681826|NCT04111822|DRUG|red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate|Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
214681827|NCT04111822|DRUG|on crystalloid fluid and Tranexamic acid|Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
214681828|NCT01100021|DRUG|Tamsulosin and avanafil|tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
214681829|NCT01100021|DRUG|Doxazosin and avanafil|doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
214681830|NCT03836638|DRUG|30 Units of botulinum toxin|30 Units of botulinum toxin to upper face
214681831|NCT03836638|DRUG|50 Units of botulinum toxin|50 Units of botulinum toxin to upper face
214681832|NCT00881829|DEVICE|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
214681833|NCT01595646|DRUG|Saline|Saline, administered intranasally twice per day for a 16 week duration
214681834|NCT01595646|DRUG|Insulin detemir|20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
214681835|NCT01595646|DRUG|Insulin|20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
214985802|NCT07133607|OTHER|education about pain and physical excersice with somatosensorial treatment|"Patients assigned to this group will receive, in addition to the same intervention as the AADC study group intervention type 2 (education about pain), somatosensory and body schema treatment for the changes observed in an initial assessment during the 4 weeks prior.~The prescribed treatment will be repeated daily at home. To facilitate~the progress of the treatment, it is recommended that a companion participate in the first session, when possible, where the daily intervention to be performed at home will be explained.~If the participation of a companion is not possible, the patient will attend the Health Center's physiotherapy room once a day to be accompanied by the physiotherapist and offered the same treatment opportunities.~As a control and monitoring measure, the patient will attend the physiotherapy room once a week and will be called again weekly to verify that the treatment is being performed correctly. They will also be provided with a form to record their home treatment."
215089131|NCT02196480|BIOLOGICAL|anti-TNF|Anti-tumor necrosis factor therapy
215089132|NCT03425721|OTHER|No Intervention|No Intervention is administered in this study.
215089133|NCT03972410|BEHAVIORAL|EMDR|2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
215089134|NCT03972410|BEHAVIORAL|SEDP|2-4 sessions individual 60-min-long treatment sessions of SEDP
215089135|NCT02389205|OTHER|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
214371142|NCT06161311|DEVICE|DIMS lenses|Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children
214493840|NCT01780649|PROCEDURE|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
214371143|NCT04044222|BIOLOGICAL|Sintilimab|IV
214493841|NCT01780649|PROCEDURE|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
214493842|NCT02307396|DRUG|Olanzapine|
214371144|NCT04044222|DRUG|Carboplatin|IV
214371145|NCT04044222|DRUG|Etoposide|IV
214371146|NCT04044222|DRUG|Ifosfamide|IV
214493843|NCT02307396|DRUG|Amisulpride|
214371147|NCT04044222|DRUG|Placebo|IV
214371148|NCT04044222|DRUG|Carboplatin|IV
214371149|NCT04044222|DRUG|Etoposide|IV
214493844|NCT02307396|DRUG|Risperidone|
214493845|NCT02307396|DRUG|Haloperidol|
214371150|NCT04044222|DRUG|Ifosfamide|IV
214371151|NCT04671979|DIAGNOSTIC_TEST|Lactate Dehydrogenase|All the patients that arrived at the hospital with symptoms of mesenteric ischemia, had a registered lactate dehydrogenase. We compared the value with the patient's outcomes.
214371152|NCT04754412|OTHER|Behavioral, Psychological or Informational Intervention|Write about stress and coping, emotional disclosure, and benefit finding
214371153|NCT04754412|OTHER|Behavioral, Psychological or Informational Intervention|Write about positive thoughts and feelings regarding their breast cancer experience
214371154|NCT04754412|OTHER|Best Practice|Write about facts regarding their cancer diagnosis and treatment
214493846|NCT02307396|DRUG|Quetiapine|
214371155|NCT04754412|OTHER|Quality-of-Life Assessment|Ancillary studies
214371156|NCT04754412|OTHER|Questionnaire Administration|Ancillary studies
214493847|NCT02307396|DRUG|Perphenazine|
214493848|NCT02307396|DRUG|Sulpiride|
214493849|NCT02307396|DRUG|bromperidol|
214493850|NCT02307396|DRUG|Zuclopenthixol|
214493851|NCT02307396|DRUG|Thioridazine|
214493852|NCT02307396|DRUG|Paliperidone|
214493853|NCT02307396|DRUG|Ziprasidone|
214493854|NCT02307396|DRUG|Benperidol|
214493855|NCT02307396|DRUG|Fluspirilene|
214681836|NCT01237548|OTHER|Smoking Narghile for 30 min|No Other intervention will be used
214681837|NCT04706546|OTHER|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
214681838|NCT04706546|OTHER|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
214681839|NCT05600712|DEVICE|REDAPT Sleeved Stem|The REDAPT Sleeved Stem is designed to provide secondary proximal support to the distal fixation and enhance implant stability.
214681840|NCT00003139|DRUG|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
214681841|NCT00003139|OTHER|Placebo|
214681842|NCT05615714|OTHER|Paresthesia-free Peripheral Nerve Field Stimulation|High frequency and sub-paresthesia threshold intensity parameters will be used for paresthesia-free stimulation of trigeminal nerve branches.
214681843|NCT05615714|OTHER|Sham stimulation|Stimulation will be turned off.
214985803|NCT07133607|OTHER|Classic physiotherapy treatment with physical exercise, analgesic electrotherapy and thermotherapy|The patients will receive the usual physiotherapy treatment provided in Primary Care Physiotherapy units, supported by the current Primary Care Physiotherapy protocols of Castilla y León, since Andalusia does not currently have any published. The patient will receive 12 sessions of thermotherapy (Infrared/Microwave) and analgesic electrotherapy (analgesic Tens currents) in the painful area(s), and will be prescribed exercises recommended by the Spanish Society of Physical Medicine and Rehabilitation (SERMEF). The learning and execution of the exercises will be supervised by a Primary Care physiotherapist. The sessions will be with a frequency of 2 per week on alternate days for 6 weeks.
214985804|NCT07130786|DRUG|Levetiracetam (Keppra)|Patients will be randomized to receive levetiracetam/ASM or to receive no ASM therapy
214985805|NCT07129486|DEVICE|CPAP|Continuous positive airway pressure (CPAP) is the standard treatment for moderate to severe OSA in clinical practice.
214681844|NCT03029962|BEHAVIORAL|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
214681845|NCT02946229|DEVICE|Ultrasound scan|Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
214985806|NCT06934785|PROCEDURE|IUI or intercourse|5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland) and 50 milligrams CC (Duinum 50 milligrams, Medochemie, Cyprus) or 5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland) will be started on the second to the fourth day of the cycle, for five consecutive days. An ultrasound will be carried out three days after the last dose of medicine (day 8 of OI) to evaluate ovarian follicles' growth and the endometrium's thickness. If the follicular diameter reach ≥14 millimetres, check-up will be planned every two days until it reaches 18 millimetres. If there is the appearance of at least one follicle reaching 18 millimetres or more, a human chorionic gonadotropin (hCG) injection (IVF-C 5000 IU, LG Life Science, Korea) will be administered on the same day of the ultrasound in order to induce ovulation. IUI will be scheduled 36 - 38 hours after hCG injection or intercourse will be scheduled in the next day.
214985807|NCT06928246|DRUG|Onabotulinum Toxin Type A - Phase 1b|The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.
214681846|NCT02227407|DEVICE|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
214681847|NCT03177577|DEVICE|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
214681848|NCT03177577|DEVICE|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
214681849|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
214681850|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
214681851|NCT05846386|BEHAVIORAL|Resistance training|moderate-intensity resistance training: three sessions per week for one month. Participants had been instructed to perform exercises at a 4:2:4 tempo; that is, four sets of concentric contraction, two sets of isometric hold, and four sets of eccentric contraction. Participants had been instructed to complete a single set until volitional fatigue or been instructed to stop by the physiotherapist when the technique falters
214681852|NCT05846386|BEHAVIORAL|Aerobic training|"The exercise program consisted of ten minutes warm-up, 45 minutes of moderate aerobic exercises upper extremity aerobic bulk muscles training and arm ergometer and cool-down in five minutes, respectively. That was done as 3 sessions/week for 4 weeks."
214371157|NCT03245138|PROCEDURE|Endoscopic Third Ventriculostomy|patients receive an endoscopic third ventriculotomy as surgical procedure
214371158|NCT03245138|PROCEDURE|Ventriculo-Peritoneal Shunting|patients receive an ventriculo-peritoneal shunt as surgical procedure
214371159|NCT04230421|DEVICE|The Monsenso system with feedback|See description under intervention
214371160|NCT04230421|DEVICE|The Monsenso system without feedback|See description under intervention
214681853|NCT04346823|DRUG|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3minutes. Then, parturients breath 1% of sevoflurane in a mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min.~Thirty seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure.The duration of ECV in addition to the level of difficulty estimated by obstetricians will be recorded. Usually, the duration of ECV does not exceed 10 minutes.~The intervention will be stopped if the woman reported severe pain, if version could not be achieved readily, or if prolonged fetal bradycardia, uterine bleeding or placental abruption occurred.~Parturient will be kept in Post Anesthesia Care Unit (PACU) for 45minutes. CTG will be monitored during PACU stay."
214681854|NCT05504330|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|First of all, ICAS patients were given health education to exhort them to reduce the risk factors of exposure to stroke and get rid of their unhealthy lifestyles. Secondly, for patients in need, standardize their dosage and course of treatment, mainly including antiplatelet drugs and statins. In addition, patients with diabetes and hypertension urge rational medication to control blood pressure and blood glucose level.
214681855|NCT00231062|DEVICE|Sinuplasty|
214681856|NCT03467022|DRUG|Vitamin C|Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
214681857|NCT02242539|BEHAVIORAL|Height measurement poster|Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.
214681858|NCT02242539|BEHAVIORAL|Community-based monitoring|"Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of Yummy Soy powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day."
214681859|NCT00803244|DRUG|300 IR|300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
214681860|NCT00803244|DRUG|Placebo|Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
214681861|NCT05102201|DEVICE|Paro (social robot) intervention|Participants in the Paro group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks
214681862|NCT02277210|OTHER|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
214681863|NCT03488810|OTHER|Radiation Therapy|Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
214681864|NCT03488810|DRUG|Apalutamide|240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
214681865|NCT03488810|DRUG|Luteinising Hormone Releasing Hormone analog agonist (LHRHa)|2 injections of a three-monthly LHRH agonist depot
214681866|NCT03488810|DRUG|Non-steroidal anti-androgen|Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
214681867|NCT00024297|DRUG|warfarin|
214681868|NCT00200148|PROCEDURE|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
214681869|NCT00200148|PROCEDURE|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
214681870|NCT00616239|DRUG|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
214681871|NCT00616239|DRUG|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
214371161|NCT04230421|DEVICE|CAG Bipola and mood monitoring only|See description under intervention
214681872|NCT02696512|DRUG|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
214681873|NCT02696512|DEVICE|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
214681874|NCT02696512|DIETARY_SUPPLEMENT|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
214681875|NCT02696512|OTHER|Standard of Care|Standard of Care treatment
214681876|NCT05386433|DRUG|Paxlovid|"Paxlovid contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir \[PF-07321332\] is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.~Ritonavir is co-administered with nirmatrelvir to help slow its metabolism in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus."
214681877|NCT05386433|DRUG|standard-of-care|standard-of-care of COVID-19
214681878|NCT02873715|BEHAVIORAL|Family-based treatment|Family based treatment as the invention to randomized participants. Family Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
214681879|NCT02873715|BEHAVIORAL|Usual Care|Usual care is a treatment that is normally provided to patients in pediatric offices by a pediatrician, physician assistant, or other primary care staff.
214681880|NCT03514472|DIETARY_SUPPLEMENT|Dried Moringa oleifera leaves|
214681881|NCT03596125|DRUG|N-acetylcysteine|N-acetylcysteine supplementation
214681882|NCT03596125|DRUG|Placebo|per os: jelly tablets Intravenous Route: Glucidion G5
214681883|NCT01955174|DRUG|Esophageal endoscopic injection of botulinum toxin|Endoscopic injection of botulinum toxin in the esophageal muscle : one hundred units of type A botulinum toxin (Botox®, Allergan) diluted in 10 mL of normal saline and injected at the lower third of the esophageal wall in 10 sites between 2 and 10 cm above the Z-line.
214985808|NCT06928246|DRUG|Onabotulinum Toxin Type A - Phase 2|The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 75 units per patient.
214681884|NCT01955174|OTHER|No injection of botulinum toxin|Upper gastro-intestinal endoscopy without any injection
214681885|NCT02021812|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
214681886|NCT03241173|DRUG|INCAGN01949|In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
214681887|NCT03241173|DRUG|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
214985809|NCT00661388|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
214985810|NCT07140770|DEVICE|Fitbit|"You will wear the tracker on your wrist like a watch and it will continuously (non-stop) monitor your activity, sleep, and heart rate.~Functional testing will be completed with a research team member and will consist of 2 tests: testing your grip strength by having you squeeze a measuring device 3 times with your dominant hand and measuring how many minutes it takes for you to walk 15 feet."
214985811|NCT07140770|OTHER|Questionnaire|Complete questionnaires at 3 timepoints, at the time of enrollment on the day of allogeneic hematopoietic cell transplantation, 8 days after allogeneic hematopoietic cell transplantation, and 7 days after hospital discharge.
214985812|NCT05162742|DRUG|Colchicine|ATC: M04AC01
214985813|NCT05162742|DRUG|Placebo|Placebo tablets
214985814|NCT06507553|BIOLOGICAL|Trivalent-Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214985815|NCT06507553|BIOLOGICAL|Augment-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214371162|NCT05632939|DRUG|ASKB589 +CAPOX+Sintilimab/Tislelizumab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab/Tislelizumab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~ASKB589 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
214371163|NCT03675152|OTHER|Soft spinal brace|Soft thoracolumbar brace worn 23 hours a day.
214985816|NCT06507553|BIOLOGICAL|TIV-2X Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214985817|NCT06507553|BIOLOGICAL|Trivalent-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
214371164|NCT03675152|OTHER|thoracolumbar orthosis|Hard thoracolumbar orthosis done individually molded, Worn 23 hours a day.
214371165|NCT03675152|OTHER|Excersice restriction|Patients are only allowed to do isometrical excersices adviced by a physiotherapist.
214681888|NCT03241173|DRUG|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
214681889|NCT04246229|DIAGNOSTIC_TEST|Transcutaneous bilirubinometry|use of transcutaneous bilirubinometry a non-invasieve measurement of skin bilirubin levels
214681890|NCT04246229|DIAGNOSTIC_TEST|Serum bilirubin|use of blood draws to measure serum bilirubin level
214681891|NCT02147938|DRUG|Tacrolimus|oral
214681892|NCT02229149|DRUG|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
214681893|NCT02229149|DRUG|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
214681894|NCT02229149|DRUG|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
214681895|NCT00050713|DRUG|Sirolimus|
214681896|NCT02698423|DEVICE|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
214985818|NCT06941194|DEVICE|PICO 14|PICO 14 application after neoadjuvant radiotherapy followed by surgery
214985819|NCT05998135|DRUG|Atovaquone|Given PO
214985820|NCT05998135|PROCEDURE|Biopsy|Undergo biopsy
214985821|NCT05998135|PROCEDURE|Computed Tomography|Undergo CT
214985822|NCT05998135|PROCEDURE|Paracentesis|Undergo paracentesis
214985823|NCT07146698|BEHAVIORAL|daily Interruption of Sedation|The patients will be managed by DIS. Richmond agitation and sedation score (RASS) will be used for monitoring the depth of sedation
214985824|NCT06952699|DRUG|TAK-360|TAK-360 tablet.
214985825|NCT06952699|OTHER|Placebo|TAK-360 matching placebo tablet.
214985826|NCT07157163|BEHAVIORAL|Phase 1: standardized nudge messages|Participants receive uniform messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake.
214985827|NCT07157163|BEHAVIORAL|Phase 1: personalized nudge messages + chatbot|Participants receive tailored messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake. Additionally, they have access to an interactive chatbot to address questions and provide decision-making support for influenza vaccination.
214985828|NCT07157163|BEHAVIORAL|Phase 2: motivational Interviewing|Unvaccinated participants engage in one-on-one motivational interviewing sessions with a trained interviewer.
214985829|NCT07158216|DEVICE|TMS|Active TMS + sham tDCS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
214985830|NCT07158216|DEVICE|tDCS|sham TMS + active tDCS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
214985831|NCT07158216|DEVICE|Sham TMS|Sham TMS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
214985832|NCT07158216|DEVICE|Sham tDCS|Sham tDCS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
214371166|NCT04387864|DEVICE|Whole-body Vibration Device|Power Plate® (pro5TM; Power Plate North America, Inc., Northbrook, IL, USA)
214371167|NCT05278130|OTHER|Additional vaginal swabs|Every 2 weeks from 16 weeks gestational age to 34 weeks gestational age
214371168|NCT06558851|BEHAVIORAL|High intensity endurance training|12 weeks of high intensity endurance training three times a week. Two of the weekly sessions are supervised.
214493856|NCT02307396|DRUG|Pimozide|
214493857|NCT02307396|DRUG|Perazine|
214493858|NCT02307396|DRUG|Fluphenazine|
214493859|NCT02307396|DRUG|Flupentixole|
214493860|NCT02307396|DRUG|Sertindole|
214493861|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
214493862|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
214493863|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
214493864|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
214493865|NCT00692120|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule once daily for 12 months
214493866|NCT00936182|DRUG|Fluconazole|Fluconazole daily for 30 days
214493867|NCT03709706|DRUG|Lete-cel|lete-cel will be administered to eligible participants.
214493868|NCT03709706|DRUG|Pembrolizumab|Pembrolizumab will be administered to eligible participants.
214493869|NCT06397196|OTHER|Laser guided proprioceptive exercises|Participants will receive Laser guided Proprioceptive exercises on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
214493870|NCT06397196|OTHER|Routine Physical therapy|Participants will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
214493871|NCT00442637|DRUG|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
214493872|NCT00442637|OTHER|observation|observation after induction treatment
214493873|NCT00649272|DRUG|Oxybutynin Chloride Extended-Release Tablets, 15 mg|15mg, single dose fasting
214493874|NCT00649272|DRUG|Ditropan XL® Extended-release tablets, 15 mg|15mg, single dose fasting
214493875|NCT01575015|DEVICE|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
214493876|NCT01575015|PROCEDURE|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
214493877|NCT03222934|DEVICE|multislice computed tomography|radiological diagnosis of the status and variations in the sphenoid sinus
214493878|NCT03779672|DRUG|Memantine Hydrochloride 10 mg|"* Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps"
214493879|NCT03454113|DEVICE|Ellipsys Vascular Access|The Ellipsys Vascular Access System comprises the Ellipsys Catheter, Ellipsys Crossing Needle and Ellipsys Power Controller. The Ellipsys Crossing Needle is used to facilitate access between the artery and the vein. The Ellipsys Catheter is placed percutaneously into the selected vein in close proximity to the selected artery. The Ellipsys Catheter is actuated at the selected anastomosis site, and the vein and artery are approximated. Once the vessels are in the appropriate relative positions the catheter is connected to the Ellipsys Power Controller to create the anastomosis after which the Ellipsys Catheter is removed, and the access site is closed using standard percutaneous closure techniques.
214681897|NCT02698423|OTHER|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
214681898|NCT00282490|DEVICE|Nerve stimulator|
214681899|NCT01193725|BEHAVIORAL|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
214681900|NCT01193725|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
214681901|NCT01193725|BEHAVIORAL|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
214681902|NCT01187212|DRUG|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
214681903|NCT01187212|DRUG|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
214681904|NCT04390698|PROCEDURE|paravertebral block|Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.
214681905|NCT04390698|DRUG|opioid free anesthesia|propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
214681906|NCT04390698|PROCEDURE|sham block|Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.
214681907|NCT04390698|PROCEDURE|opioid general anesthesia|propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
214681908|NCT02307526|DRUG|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
214681909|NCT02307526|DEVICE|Tilt table test|After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
214681910|NCT00991627|DRUG|Bupivacaine|10 mg of a 5 mg/ml hyperbaric solution, intrathecally
214681911|NCT00991627|DRUG|Morphine|200 µg of a 100 µg/ml solution, intrathecally
214371169|NCT06068218|OTHER|Biopsy for the patient group|The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet. For vitiligo patients, the biopsies will be taken on a non-depigmented skin.
214681912|NCT00991627|DRUG|Lactated Ringer's solution|25 ml/min intravenously
214681913|NCT00991627|DRUG|Ephedrine, continuous infusion|37.5 mg/h intravenously
214681914|NCT00991627|DRUG|Ephedrine, bolus|"6.25 mg IV bolus prn.~Hypotension defined according to study protocol for each arm."
214985833|NCT07149727|OTHER|Standard Care|Environmental temperature control, preoperative psychological counseling, and parent-guided distraction.
214985834|NCT07149727|BEHAVIORAL|Immersive Game Experience (IGE)|Standard care plus immersive game experience, including role-playing scenarios (e.g., using dolls to simulate IV puncture), parent-child interactive games, environmental adjustments (children's music, colorful objects), and post-intervention rewards (cartoon stickers).
215089136|NCT03653572|DEVICE|Ultrasound exam|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
215089137|NCT05041569|OTHER|MRI sequences|perform additional sequences added by research
214371170|NCT06068218|OTHER|biopsy for the volunteer group|A publicity in the hospital will announce the study, and will be use to recruit the healthy volunteers. The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet.
214371171|NCT04058353|DRUG|ELX/TEZ/IVA|FDC tablet for oral administration.
214371172|NCT04058353|DRUG|IVA|Mono-tablet for oral administration.
214371173|NCT04058353|DRUG|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
214371174|NCT04956302|DRUG|Bortezomib|Given SC
214371175|NCT04956302|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
214371176|NCT04956302|DRUG|Dexamethasone|Given PO or IV
214371177|NCT04956302|DRUG|Panobinostat Lactate|Given PO
214371178|NCT02792465|DRUG|CFI-402257|
214371179|NCT02792465|DRUG|Fulvestrant|
214371180|NCT00583986|DRUG|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
214681915|NCT00991627|DRUG|Atropine|"0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values."
214681916|NCT03271008|DEVICE|Direct laryngoscopy|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.
214681917|NCT03271008|DEVICE|Vividtrac videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.
214681918|NCT03271008|DEVICE|KingVision videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
214681919|NCT01651260|OTHER|Experimental ET Tube Securement Device|Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
214681920|NCT05275829|OTHER|Tele simulation|Interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform).
214681921|NCT00296283|BEHAVIORAL|integrative behavior couples therapy|
214681922|NCT03177876|PROCEDURE|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement
214681923|NCT03177876|PROCEDURE|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
214681924|NCT03792269|DRUG|Irinotecan|intraperitoneal
214681925|NCT03792269|DRUG|Oxaliplatin|intravenous
214371181|NCT00769548|DRUG|flutamide|Drug used for TAS.
214371182|NCT00769548|DRUG|goserelin acetate|Drug used for TAS.
214371183|NCT00769548|RADIATION|low-LET photon therapy|radiation therapy
214371184|NCT04511754|BEHAVIORAL|Experiential Psychotherapy Skill Training|The Experiential Training intervention will include components of training not usually included in standard clinical training experiences; such components include opportunities for deliberate practice of the skills trained, live supervision and feedback, and discussion with a trainer focused on the skills taught and the trainees' performance.
214681926|NCT03792269|DRUG|Capecitabine|
214371185|NCT04511754|BEHAVIORAL|Standard Psychotherapy Skill Training|Standard didactic training with research support, examples, and opportunities to ask questions.
214371186|NCT01536132|DRUG|Levosimendan|0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
214371187|NCT01536132|DRUG|Placebo|Placebo (same appearance than active drug) is administered with the same dosing regime
214371188|NCT03951454|BEHAVIORAL|Conexiones|5 Conexiones telephone sessions
214681927|NCT02134704|OTHER|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
214681928|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
214681929|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
214681930|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #3|"Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable."
214681931|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
214985835|NCT07153913|OTHER|Intensive growth support|For women in the intervention group, we will develop a nutritional plan for the child in collaboration with the mother. Mothers will then receive a visit every other week - during this visit, children's health and nutrition will be discussed, and height and weight will be measured by field officers. Detailed food recommendations will be made based on national and international infant and young child feeding guidelines. To ensure appropriate foods are available, field workers will drop off local foods on a weekly basis.
214371189|NCT03951454|BEHAVIORAL|Taking Time|1 Taking Time telephone session
214371190|NCT05322148|DRUG|Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free|A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.
214371191|NCT04022967|DRUG|dolutegravir|One daily tablet (50mg) during 96 weeks
214371192|NCT04022967|DRUG|atazanavir boosted with ritonavir|One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
214371193|NCT04022967|DRUG|tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir|One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
214371194|NCT04022967|DRUG|Lamivudine|One daily tablet (300mg) during 96 weeks
214371195|NCT06272422|PROCEDURE|hip arthroplasty|resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty.
214371196|NCT03861910|DIETARY_SUPPLEMENT|hypoallergenic formulas|hypoallergenic formulas used for cow milk allergy treatment
214371197|NCT05089838|BIOLOGICAL|CMV-TCR-T cells|Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
214371198|NCT01349920|DRUG|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
214681932|NCT02112604|DEVICE|Ventilator|Mechanical ventilator used to replace or assist spontaneous breathing.
214681933|NCT02112604|DEVICE|Alice PDx|Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
214681934|NCT02112604|OTHER|Pulmonary function test|The pulmonary function tests are used to study upper airway patency.
214681935|NCT02112604|OTHER|Muscle strength tests|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
214681936|NCT02112604|OTHER|Grip strength measurement|Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
214681937|NCT02112604|DRUG|Sedatives and muscle relaxants given in the ICU|Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
214681938|NCT00300872|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
215089138|NCT05592496|PROCEDURE|Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.|After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
214681939|NCT00300872|DEVICE|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
214681940|NCT04052958|DEVICE|IMT - inspiratory muscle training|respiratory strength or indurance training with respiratory therapy device
214681941|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject
214681942|NCT00317941|DRUG|Rebif|44ug administered with Rebiject II
214681943|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject light
214681944|NCT06096233|OTHER|Bouts of Exercise|The participants will run on the treadmill for 10 minutes (short) or 30 minutes (prolonged).
215089139|NCT05592496|DEVICE|Catheter insertion technique by using special tube t|By using special tube, it is possible to locate the catheters in retromuscular space, where they are close to cutaneous nervs
214371199|NCT00812279|OTHER|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
215089140|NCT05592496|PROCEDURE|"Connection of catheters bilateraly to easy pump system,"|"Connection of catheters, which are inserted in to retromuscular space, to ensure continuous receiving of Bupivacaine fluid for analgesia. Easy pump system provides continous receiving of bupivacaine fluid infusion speed - 5ml per hour"
214371200|NCT00812279|OTHER|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
214371201|NCT00812279|OTHER|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
214681945|NCT01259297|DRUG|Aliskiren|Aliskiren 150/300 mg once daily
214681946|NCT01259297|DRUG|Amlodipine|Amlodipine 5 mg
214681947|NCT01259297|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
214681948|NCT01259297|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
214681949|NCT01259297|DRUG|Placebo for Amlodipine|Placebo for Amlodipine
214681950|NCT01259297|DRUG|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
214681951|NCT05022992|OTHER|Resistance Training|Both groups will perform a resistance training session consisted of 10 reps x 3 set of upper- and lower-body resistance exercises.
214681952|NCT01276015|DRUG|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
214681953|NCT02991820|DEVICE|Miller|Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope
214681954|NCT02991820|DEVICE|Macintosh|Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
214681955|NCT02991820|DEVICE|C-MAC|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope
214681956|NCT02991820|DEVICE|GlideScope|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope
214681957|NCT01750476|DRUG|Mirena|
214681958|NCT01750476|DRUG|Oral contraception|
214681959|NCT01750476|DRUG|Depo-Provera|
214681960|NCT03543891|OTHER||
214681961|NCT00004865|BIOLOGICAL|cetuximab|
214681962|NCT00004865|DRUG|cisplatin|
214681963|NCT00004865|DRUG|fluorouracil|
214681964|NCT00004865|DRUG|paclitaxel|
214681965|NCT03335631|BEHAVIORAL|Exercise|Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
214681966|NCT01810146|OTHER|Digestive functions investigations|
214371202|NCT04167605|OTHER|Bone metastasis|Collection of waste tissue samples during surgery and immediate immersion of the same in 10% Neutral buffered formalin. The samples will be send to the laboratory where they will be processed (decalcification, inclusion in paraffin, sectioning etc.) for subsequent analyzes.
214985836|NCT07158801|BEHAVIORAL|Project EMPOWER-OCD|"Project EMPOWER-OCD is a web-based intervention for caregivers that takes about 20-25 minutes to complete that reduces accommodation. The program is drawing from an empirically supported intervention, Project EMPOWER, and will be adapted for the OCD population pending stakeholder input during phase 1 and include 5 elements: (1) an introduction to the program's rationale; (2) psychoeducation around OCD-driven avoidance, along with how caregiver accommodation can inadvertently maintain these avoidance patterns; (3) information on how caregivers can better identify patterns of avoidance, validate, and encourage approach behaviors instead; (4) creation of an action plan to promote approach behavior and reducing avoidance; (5) a vignette exercise in which caregivers read about another case and provide possible solutions based on what they learned. Resources for finding mental health treatment for OCD are presented at the end."
215089141|NCT05592496|DIAGNOSTIC_TEST|VAS scale for pain control|By using Visual Analog scale of pains, the pain score is fixed
214681967|NCT00053846|DRUG|buspirone hydrochloride|The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
214681968|NCT00053846|DRUG|Placebo|Placebo
214681969|NCT01219244|BEHAVIORAL|caloric restriction|6 months of caloric restriction (15 %)
214681970|NCT01219244|BEHAVIORAL|omega-3 supplementation|6 months of omega-3 supplementation
214681971|NCT01219244|BEHAVIORAL|resveratrol supplementation|6 months of resveratrol supplementation
214681972|NCT01219244|BEHAVIORAL|Placebo|6 months of placebo intake
214371203|NCT04167605|OTHER|Breast cancer metastatic to bone|Patients will be assisted in the recovery of samples (slides) related to surgery on primary tumor (breast cancer responsible for metastatic disease).
214371204|NCT04049318|OTHER|Education+ exercise (delivered digitally)|The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.
214371205|NCT04656379|PROCEDURE|spine surgery|Risk factors for postoperative delirium in elderly patients underwent spine surgery will be evaluated.
214371206|NCT00637286|DRUG|Zolmitriptan|5mg Nasal Spray
214371207|NCT01552564|PROCEDURE|Index of microvascular resistance|
214371208|NCT01552564|OTHER|Cardiac magnetic resonance|
214371209|NCT01552564|OTHER|Blood markers|
214371210|NCT02568631|OTHER|serious game JeStiMulE|The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.
214371211|NCT02568631|OTHER|control video game|The patients will play 6 sessions of one hour with the control video game
215089142|NCT05588037|PROCEDURE|FLACS +PPV+IOL + air|The procedures are combined the FLACS +PPV+IOL + air.
215089143|NCT05588037|PROCEDURE|FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex|The procedures are combined the FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex.
215089144|NCT05588037|PROCEDURE|FLACS + PPV+IOL + internal limiting membrane peeling + air|The procedures are combined the FLACS + PPV+IOL + internal limiting membrane peeling + air.
214371212|NCT01005342|OTHER|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
214371213|NCT01005342|OTHER|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
214371214|NCT01005342|OTHER|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
214371215|NCT01005342|OTHER|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
214371216|NCT01005342|OTHER|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
214371217|NCT01005342|OTHER|Control|No fiber was added to control meal (250 g black-currant beverage)
214681973|NCT01219244|BEHAVIORAL|2nd step: intervention + physical / cognitive training|most effective dietary intervention plus physical and cognitive training
214681974|NCT01219244|BEHAVIORAL|2nd step: intervention + control|most effective dietary intervention plus control
214681975|NCT01856946|DIETARY_SUPPLEMENT|4,000 IU vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
214681976|NCT04927988|OTHER|Ringer's Lactated|Using of Ringer's Lactated In Autologous Blood Cell Transfusion
214681977|NCT06511856|DEVICE|ARROW|Patients included in the study are patients operated with one or more shoulder medical device fabricated by FH ORTHO. Medical devices of interest are CE marked and include ARROW and ARROW prosthesis, Telegraph Evolution humeral nail and STRAPFLEX strapping system.
215089145|NCT05588037|PROCEDURE|FLACS + PPV+IOL|The procedures are combined the FLACS + PPV+IOL.
215089146|NCT03059771|BEHAVIORAL|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
215089147|NCT03059771|BEHAVIORAL|Control|The control group will only engage in a goal-setting session.
214371218|NCT00895986|BEHAVIORAL|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
214371219|NCT00895986|BEHAVIORAL|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
214371220|NCT00333164|DRUG|Asprin, Cilostazol|
214371221|NCT04636489|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 8 weeks
214371222|NCT04636489|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
214681978|NCT03074175|RADIATION|radiotherapy|The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 \<25%, lung V30 \<18%, spinal cord \<36 Gy.
214681979|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
214681980|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
214371223|NCT03660579|OTHER|HIIT-AB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer with 5.4% alcohol.
214371224|NCT03660579|OTHER|HIIT-NAB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%).
214985837|NCT07158801|BEHAVIORAL|Project CARE|To evaluate the effects of Project EMPOWER-OCD, we will compare it to an active psychoeducation-based SSI that provides general information on caregiving and caregiver mental health. The intervention includes 5 elements that mirror Project EMPOWER: (1) introduction to the rationale for the program; (2) introduce the concept of caregiving across relationships and situations; (3) present broad information on typical development processes; (4) helping caregivers identify their own role and reflect on how caregiving looks like in their life (5) vignette exercise where caregivers identify caregiving roles, prompting reflection on roles. This active comparator intentionally does not include any psychoeducational components explicitly designed to reduce accommodation of anxiety, OCD, and its related disorders.
214371225|NCT03660579|OTHER|HIIT-SW Group|Group that performed HIIT and consumed the same amount of sparkling water (0.0%).
214985838|NCT07155070|DRUG|Kera Sol Eye Drops|Eye drops
214985839|NCT07168265|DRUG|androgen replacement therapy|intramuscular testosterone
214371226|NCT03660579|OTHER|HIIT-ASW Group|Group that performed HIIT and consumed sparkling water with the same amount of alcohol than the pre-established beer (5.4%).
214371227|NCT04063774|DIAGNOSTIC_TEST|Dengue calculator|Clinical diagnostic algorithms of dengue generated by discrete and continuos Bayes formulas installed in a mobile device
214985840|NCT05360290|DEVICE|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
214681981|NCT00690937|DRUG|Colesevelam Cholestagel|Drug comparator
214493880|NCT04163237|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti- autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
214493881|NCT04163237|DRUG|Sorafenib|Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
214493882|NCT05121142|DRUG|Ruxolitinib|Ruxolitinib will be given by mouth or enteral tube (if applicable).
214493883|NCT05145205|PROCEDURE|Sleeve gastrectomy|"Bougie was applied over the lower curvature to adjust the gastric tube then longitudinal amputation of the stomach was performed for about 4 to 6 cm per pecker of the pylorus to the corner of His. No supportive materials were used, and over-suturing of the basic line performed only over the points of bleeding.~All resected specimens were sent to histopathology laboratory for examination."
214681982|NCT00690937|DRUG|Placebo|Placebo
214681983|NCT00690937|DRUG|Placebo|Placebo
214985841|NCT06348147|BIOLOGICAL|Daratumumab|Daratumumab is a CD38-directed cytolytic antibody indicated for the treatment of adults with multiple myeloma. 1800 mg will be given subcutaneously according to its standard package insert schedule.
214371228|NCT06088524|OTHER|Social Media Fatigue|Mental Fatigue creation protocol: It has been reported that at least 30 minutes of social media use causes mental fatigue and impairs lower extremity and decision-making performance (Fortes et al., 2021). For mental fatigue with social media, participants will be created with 45 minutes of continuous use of social media (instagram, facebook, twitter, youtube) on smartphones by concentrating with headphones.
214371229|NCT04467957|DRUG|Initiation of CFTR Modulator|Inhaled contrast for MRI occurring at each visit
214371230|NCT04467957|DRUG|Hyperpolarized Xenon 129|Inhaled contrast for MRI occurring at each visit
214371231|NCT00653458|DRUG|Ondansetron|ODT, 8 mg, single-dose, fed conditions
214371232|NCT00653458|DRUG|Zofran|ODT, 8 mg, single-dose, under fed conditions
214371233|NCT04849286|DRUG|HTL0016878|Oral solution
214371234|NCT00026143|BIOLOGICAL|recombinant interleukin-12|Given IV
214681984|NCT02692053|BIOLOGICAL|blood sampling|additional blood sampling (volume: 18 mL)
214681985|NCT01563588|BEHAVIORAL|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
214681986|NCT02033551|DRUG|Veliparib|
214681987|NCT02033551|DRUG|Carboplatin|
214681988|NCT02033551|DRUG|Paclitaxel|
214681989|NCT02033551|DRUG|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
214681990|NCT00064662|PROCEDURE|Burch Modified Tanagho|The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
214681991|NCT00064662|PROCEDURE|Autologous Fascia Sling|The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
214371235|NCT00026143|BIOLOGICAL|recombinant interferon alfa|Given SC
214371236|NCT00026143|OTHER|laboratory biomarker analysis|Correlative studies
214371237|NCT03323879|RADIATION|LDR/HDR|Focal LDR to dominant lesion with whole gland 19 Gy HDR
214371238|NCT00542880|DRUG|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
214371239|NCT00542880|DRUG|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
214371240|NCT00652223|BIOLOGICAL|CYT005-AllQbG10|Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
214371241|NCT01778348|DEVICE|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
214371242|NCT01778348|DEVICE|Real-time CGM alone|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
214371243|NCT01690091|DRUG|Metformini hydrochloridum (Siofor 1000 tbl, Berlin)|"Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
214681992|NCT02987673|PROCEDURE|MGB/OAGB|
214681993|NCT02987673|PROCEDURE|LSG|
214371244|NCT01690091|DRUG|placebo|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
214371245|NCT03497650|DEVICE|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair with a standard mirror placed between both legs with the reflective side of the mirror facing the non-affected leg. The patient is instructed to observe the reflection of the non-affected limb during the sessions. The patient was not given any instruction on the use of the affected limb.
214493884|NCT05145205|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|An antecolic and antegastric RYGB become executed with a 150 cm alimentary limb with both a linearly or circularly kink (25 mm) gastrojejunostomy in step with the desire of the surgeon. A 50-cm-lengthy biliopancreati
214493885|NCT04132167|PROCEDURE|perturbation training|exercises for body stability in different positions (bridge, sitting, quadrupedal, half- kneeling, kneeling, standing, monopodalic) performed with visual biofeedback; transfers training performed in front of a mirror; ambulation training with courses drawn on the ground in a straight line and with more complex tracks with visual controlin particular using the protocols seated balance/strength training, standing bal- ance/weight-bearing training, mobility training and closed-chain training;
214371246|NCT03497650|OTHER|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected leg of each stroke patient.
214371247|NCT05101525|PROCEDURE|Ultrasound|Ultrasound to visualize the intra tendinous marker. If this is in place, healing is effective. On the other hand, if it has migrated, there is no scarring.
214371248|NCT02642198|DEVICE|Surveyor S12 and S19 patient monitor|Non-invasive blood pressure measurement
214493886|NCT00609869|DRUG|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
214681994|NCT02471131|DEVICE|WATCHMAN Device implantation|The implantation of the device will be done into the left atrial appendage according to the guidelines.
214681995|NCT04384640|OTHER|Change of posture after Intra Tympanic injection|Seating position after Intra Tympanic injection
214681996|NCT03242096|COMBINATION_PRODUCT|Sirolimus coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
214681997|NCT03242096|COMBINATION_PRODUCT|Paclitaxel coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
214681998|NCT03008590|DRUG|Naltrexone|One 4.5 mg capsule each evening
214681999|NCT03008590|DRUG|Placebo|One capsule each evening
214985842|NCT06348147|DRUG|Lenalidomide|Lenalidomide will be administered, once daily orally on Days 1-21 of a 28-day
214985843|NCT06348147|DRUG|Bortezomib|Bortezomib is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma, will be given subcutaneously once weekly on days 1, 8, and 15 of every 28 day cycle.
214985844|NCT06348147|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid.
214985845|NCT05539131|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) suppresses excitability and regulates excitability of neurons by injecting a small amount of current through electrodes attached to the scalp.
214985846|NCT03386981|OTHER|blood and saliva tests|Blood and saliva will be tested for: bone turnover markers, cytokines, chemokines, adipokines, myokines and hormones regulating bone and energy metabolism
214371249|NCT00696384|DRUG|Azilsartan medoxomil|"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and \<130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit."
214985847|NCT04211714|BIOLOGICAL|EXG34217|Single infusion
214985848|NCT03370172|DRUG|BAX 888|Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1 and 2 Day 0.
214985849|NCT05896332|DEVICE|Active, Open Label iTBS-rTMS|Participants in this group will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total)
214371250|NCT00696384|DRUG|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
214985850|NCT06814730|DRUG|THN391|THN391, IV infusion, 3\*Q4W (every 4 weeks)
214985851|NCT06814730|DRUG|Placebo|Placebo for comparison with THN391, IV infusion, 3\*Q4W
214493887|NCT00609869|DRUG|Rituximab|Rituximab was administered at 375 mg/m\^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
214493888|NCT04775810|DEVICE|The device is an algorithm designed to enhance speech intelligibility of speech-in-noise signals|Normal-hearing and hearing-impaired subjects will listen to speech-in-noise audio files that are either unprocessed or processed in order to increase speech intelligibility.
214493889|NCT00505336|DRUG|Eplerenone|oral Eplerenone titrated to 50mg for duration of 12 months
214493890|NCT00505336|OTHER|No additional treatment|normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
214493891|NCT00505336|DRUG|Atorvastatin|oral Atorvastatin 40mg
214985852|NCT03694171|OTHER|Any cancer treatment|
214985853|NCT06952153|PROCEDURE|Phacoemulsification with Goniosynechialysis|This procedure involves standard phacoemulsification cataract surgery combined with goniosynechialysis, which mechanically separates peripheral anterior synechiae to open the anterior chamber angle. It aims to both remove the cataractous lens and restore aqueous outflow in patients with primary angle-closure glaucoma.
214985854|NCT06952153|PROCEDURE|Trabeculectomy with 5FU|Trabeculectomy is a glaucoma filtration procedure designed to lower intraocular pressure by creating a new drainage pathway from the anterior chamber to the sub-conjunctival space. It is considered the standard surgical intervention for medically uncontrolled glaucoma.
214493892|NCT03588832|DIAGNOSTIC_TEST|Evaluation Upper Extremity patterns.|The procedure involves evaluating subjects who meet the eligibility criteria and agree to participate in the study by signing informed consent. The study includes a measurement, applying a registration form, the Barthel scale and the FIM scale.
214493893|NCT04242212|BEHAVIORAL|Misoprostol sourced from clinics|One cohort of women using misoprostol sourced from clinics
214493894|NCT04242212|BEHAVIORAL|Misoprostol sourced from PMVs|One cohort of women using misoprostol sourced from PMVs
214493895|NCT01627561|BIOLOGICAL|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.
214493896|NCT01627561|BIOLOGICAL|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.
214985855|NCT05954312|DRUG|VVD-130037|Oral tablets
214985856|NCT05954312|DRUG|Docetaxel|IV infusion
214985857|NCT05954312|DRUG|Paclitaxel|IV infusion
214985858|NCT04639440|OTHER|Adipose tissue|Adipose tissue sampling
214985859|NCT02382302|DEVICE|Telemedicine system|The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
214985860|NCT00067340|DRUG|Chlorhexidine mouth rinse|women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
214985861|NCT00067340|OTHER|Xylitol chewing gum|Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
214985862|NCT00863122|DRUG|lapatinib|1500 mg lapatinib by mouth per day for 10 days
214985863|NCT01171534|DEVICE|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
214985864|NCT01171534|DEVICE|Vessel loop|Vessel loops and staples for fasciotomy closure
214985865|NCT03991975|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
214371251|NCT00696384|DRUG|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
214493897|NCT01627561|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.
214493898|NCT00856700|DRUG|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
214985866|NCT03991975|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214985867|NCT04861298|DRUG|standard of care for COVID-19 as per the hospital guidelines|Hospital standard of care treatment for COVID-19
214985868|NCT04861298|DIETARY_SUPPLEMENT|Quercetin Phytosome (QP)|Daily dose of 600 mg of Quercetin for 1st week and then 400 mg for the 2nd week
214985869|NCT00849056|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
214985870|NCT00849056|DRUG|placebo|placebo weekly subcutaneous injection
214371252|NCT01445808|BEHAVIORAL|Psychodynamic Motivation and Training Program (PMT)|The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
214371253|NCT01445808|BEHAVIORAL|Advice in Exercise Training (+Ex)|Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
214371254|NCT01445808|OTHER|Treatment as usual (TAU)|Usual care by family doctor, cardiologist
214371255|NCT04984057|DRUG|PS is stopped when the pressure is equal between bPDA and aPDA.|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
214371256|NCT04984057|DRUG|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
214371257|NCT03117348|OTHER|Enteral nutrition|Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.
214371258|NCT04552743|DRUG|MGTA-145|A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.
214371259|NCT04552743|DRUG|Plerixafor|An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).
214371260|NCT02129101|DRUG|Azacitidine|Given SC or IV
214371261|NCT02129101|DRUG|Decitabine|Given IV
214371262|NCT02129101|OTHER|Laboratory Biomarker Analysis|Correlative studies
214371263|NCT02129101|OTHER|Quality-of-Life Assessment|Ancillary studies
214371264|NCT02129101|DRUG|Sonidegib|Given PO
214371265|NCT03544892|OTHER|Low carbohydrate diet|60-80 g total carbohydrate per day
214371266|NCT03544892|OTHER|Standard of care diet|\> 150 g total carbohydrate per day
214493899|NCT03661463|DRUG|Aspirin|Drug
214493900|NCT03422549|DEVICE|Drager VN500 Ventilator|This ventilator is capable of providing both CPAP and NHFOV support.
214493901|NCT03516370|DRUG|Saccharomyces Boulardii 250 MG|all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
214493902|NCT06371456|PROCEDURE|epidural catheter placement|after sterilization of the back, local anesthesia injection (xylocaine 5 ml) at lumbar 4-5 level, then advancing the epidural needle till loss of resistance by air occurs and the epidural catheter inserted then aspiration through the catheter will be done to confirm that no accidental cerebrospinal fluid or blood are aspirated and to observe the dew sign inside the outer portion of the epidural catheter near the back of the patient
214493903|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 60mj|
214493904|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 120mj|
214493905|NCT02358005|PROCEDURE|non extracorporeal shock wave therapy|
214493906|NCT00382941|DEVICE|Red and near infrared LED phototherapy device|
214493907|NCT04221659|DEVICE|Transcranial Direct Current Stimulation|Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². The cathode, reference electrode (5x7cm), will be positioned in the occipital region. These parameters are within the safe limits established in previous human studies.
214493908|NCT05892562|OTHER|No intervention|As this study is purely observational, no intervention is involved.
214493909|NCT00890591|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
214493910|NCT05694832|BEHAVIORAL|Expressive Writing|Creative writing, discussion and social support, in a group setting via videoconference
214493911|NCT00914641|DRUG|Apixaban IR|immediate release tablet, 10 mg, single dose
214493912|NCT00914641|DRUG|Apixaban MR1|modified release tablet 1, 10 mg, single dose
214493913|NCT00914641|DRUG|Apixaban MR2|modified release tablet 2, 10 mg, single dose
214493914|NCT00914641|DRUG|Apixaban MR3|modified release tablet 3, 10 mg, single dose
214493915|NCT01281657|DRUG|fingolimod|
214493916|NCT05031923|PROCEDURE|SMV and antimicrobial photodynamic therapy|Application of SMV and antimicrobial photodynamic therapy in intrabony defects
214493917|NCT05031923|PROCEDURE|SMV application|Application of SMV without antimicrobial photodynamic therapy in intrabony defects
214493918|NCT03294967|DIETARY_SUPPLEMENT|Caffeine|As in group descriptions
214493919|NCT03294967|DIETARY_SUPPLEMENT|Vitamin E|As in group descriptions
214493920|NCT05357677|DRUG|SR419|SR419 capsule
214985871|NCT05608434|BEHAVIORAL|Floreo Virtual Reality application|Floreo VR is a novel VR-based cognitive training therapy for ADHD. It incorporates multiple learning modules, each of which targets a neuropsychological domain relevant to ADHD (inhibitory control, working memory, temporal processing, processing speed). The demands of the training intervention adapt to the subject s practice-driven improvements in performance. Specifically, when the subject is deemed to perform adequately well at a given level of difficulty, the training adapts by presenting a more challenging difficulty. This adaptation to the subject s performance is designed to allow for continued incremental improvements in the trained domains. The VR games take place in a spaceship themed environment. The VR training is designed to be used at home, under the supervision of a parent.
215089148|NCT05601661|DEVICE|Active VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)
215089149|NCT05601661|DEVICE|Sham VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)
214371267|NCT02027402|PROCEDURE|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
214371268|NCT05692505|DIAGNOSTIC_TEST|QuadQuik|Invitro diagnostic device
214371269|NCT01767168|OTHER|comprehensive preoperative testing for risk factors of persistent postoperative pain|nociceptive reflex threshold, pain threshold, CPM-effect of hot water bath, pain sensitivity questionnaire, STAI, BDI, fear of surgical consequences
214371270|NCT03513757|DRUG|propofol|propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
214371271|NCT03513757|DRUG|Dexmedetomidine|single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg
214371272|NCT03513757|DRUG|Glycopyrrolate|4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group
214371273|NCT03513757|DRUG|Lidocaine 1% Injectable Solution|1 mg/kg intravenous administration prior to propofol administration
214371274|NCT03513757|DRUG|Nitrous Oxide|Inhalation of nitrous oxide may be used for IV placement
214371275|NCT03513757|DRUG|Sevoflurane|Inhalation of sevoflurane may be used for IV placement
214371276|NCT02513069|OTHER|Nicotine gum|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
214371277|NCT02513069|BEHAVIORAL|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided reinforcement for videos that suggest smoking abstinence.
214371278|NCT02513069|BEHAVIORAL|Telephone counseling|Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
214371279|NCT02513069|OTHER|Nicotine patch|Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
214493921|NCT00259792|DRUG|Budesonide/formoterol Turbuhaler|
214493922|NCT02867956|DRUG|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
214493923|NCT02867956|DRUG|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
214493924|NCT01023698|PROCEDURE|laser photocoagulation|Laser photocoagulation
214493925|NCT03455985|OTHER|Discharge Order Set (DOS)|In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.
214493926|NCT03455985|OTHER|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
214493927|NCT01579318|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
214493928|NCT01579318|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
214493929|NCT02797132|DRUG|LUM/IVA|
214682000|NCT02512016|OTHER|Study Procedures|"* Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)~* Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.~* Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.~* Measures of strength and body habitus:~  8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index~  1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod~* Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings."
214682001|NCT04292119|DRUG|Lorlatinib|"Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days."
214371280|NCT02513069|OTHER|Nicotine lozenge|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
214371281|NCT02513069|OTHER|Smart phone|Participants in the experimental condition will be loaned a smart phone to use during the mobile contingency management intervention period. The phone will be used to record videos of carbon monoxide readings to determine smoking abstinence.
214371282|NCT02513069|OTHER|Carbon monoxide monitor|Participants in the experimental condition will be loaned a CO monitor to use during the mobile contingency management intervention period. The monitor will be used to determine carbon monoxide content in the breath as a measurement of smoking.
214682002|NCT04292119|DRUG|Crizotinib|"Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days."
214682003|NCT04292119|DRUG|Binimetinib|Binimetinib will be taken orally twice daily for 28 days.
214682004|NCT04292119|DRUG|TNO155|TNO155 will be taken orally once daily for 14 days.
214682005|NCT05181917|BEHAVIORAL|STUDIA app|STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
214682006|NCT04615390|BEHAVIORAL|Early rehabilitation|The intervention is primarily focused on the recovery of mobility and functional autonomy. The treatment sessions are dependent on the patient's exercise tolerance.
214682007|NCT04615390|BEHAVIORAL|Subacute rehabilitation|Comprehensive intensive rehabilitation in the hospital
214682008|NCT04615390|BEHAVIORAL|Mindfulness training|The home mindfulness training consists of 2 parts: 1) explanation and reflection of the Mindfulness practice 2) formal and informal practice.
214682009|NCT04615390|BEHAVIORAL|Personalized ambulatory training|Low-intensity walking exercises at home
214985872|NCT03770819|PROCEDURE|Photodynamic therapy|"Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam."
214985873|NCT06964815|DIETARY_SUPPLEMENT|Silibinin as STAT3 inhibitor|Sillbrain will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Each 3.7 g sachet of Sillbrain contains 500 mg silibinin. Every patient will assume 2 sachets/day for a total of 1 g/day of silibinin.
214371283|NCT04945148|DRUG|Metformin|Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.
214371284|NCT04945148|RADIATION|Radiation IMRT|2 Gy x 5 days for 6 weeks to be started 7 days after first administration of Metformin and by 7 weeks after histological diagnosis
214371285|NCT04945148|DRUG|Temozolomide|75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles
214371286|NCT01949779|DEVICE|TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
214371287|NCT02859402|DRUG|Busulfan|intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)
214371288|NCT02859402|DRUG|Fludarabine|intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
214371289|NCT00002892|BIOLOGICAL|recombinant interferon alfa|
214371290|NCT05174663|OTHER|Almond-enriched diet - 1.5 oz|Participants will receive 1.5 oz of almonds consumed as a snack daily for 16 weeks.
214371291|NCT05174663|OTHER|Almond-enriched diet - 2.5 oz|Participants will receive 2.5 oz of almonds consumed as a snack daily for 16 weeks.
214371292|NCT05174663|OTHER|Control snack|Participants will receive a control snack daily for 16 weeks.
214371293|NCT01048814|OTHER|ChemoFx|Chemoresponse Marker Assay
214371294|NCT03169218|OTHER|Mirror therapy|The treatment proposed for the mirror group consisted of 8 weeks of treatment, performing a series of exercises 2 times a day / 4 times a week. The first 4 weeks the treatment was done in the hospital next to the physiotherapist for 2-3 days a week, and the next 4 weeks the patient performed the exercises following the same guidelines at home.
214371295|NCT03169218|OTHER|Placebo group|The treatment was the same than proposed in inference group but with a mirror covered to avoid the reflexion on the hand and looking at the hand that did not remain hidden.
214985874|NCT06964815|OTHER|Placebo|Placebo will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Every patient will assume 2 sachets/day for a total of 1 g/day of placebo.
214985875|NCT03427892|DRUG|Brexpiprazole|Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.
214493930|NCT06372340|PROCEDURE|Personalized pelvic floor rehabilitation program generated by the intelligent diagnosis and treatment system.|Utilizing machine learning to process and analyze vast amounts of previously collected data, the investigators will establish an intelligent system that can generate personalized pelvic floor exercise prescription by matching factors such as general clinical information and pelvic floor muscle strength data. The experimental group will receive tailored program, including pelvic floor muscle training with diverse intensity and frequency, electrical stimulation, magnetic stimulation, biofeedback and other treatments. The results will ultimately be compared with those taking standardized pelvic floor muscle training only.
214493931|NCT06372340|PROCEDURE|Standard pelvic floor muscle training(PFMT) program|Participants will be given handbooks with detailed training program: the basic regimen consists of 3 sets of 8 to 12 contractions sustained for 8 to 10 sec each, performed 3 times a day. Patients should try to do this every day and continue for at least 15 to 20 weeks.
214493932|NCT05161000|OTHER|Oral Nutritional Supplement|ONS plus dietary counseling
214493933|NCT05161000|OTHER|Dietary counseling|dietary counseling
214493934|NCT02435485|DEVICE|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
214493935|NCT02435485|OTHER|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
214493936|NCT04239768|DEVICE|MonoDermà HA gel combined to a low level laser|"Two intradermal injections of the filler were performed during the basal and after 1 month, on the middle and inferior third of the face (1ml for each face side) using a needle (30G).~Immediately after both injection procedures, LLLT session were performed on the same face area for a total of 8 minutes, using three different wavelengths (450 nm, 650 nm and 1064 nm) simultaneously."
214493937|NCT03239704|BEHAVIORAL|Telemedicine Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
214493938|NCT03239704|OTHER|Telemedicine Monitoring|Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
214493939|NCT03239704|BEHAVIORAL|30 Day Comprehensive Questionnaire|Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
214493940|NCT03388840|BIOLOGICAL|Adipose derived stem cells suspention|application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
214493941|NCT03388840|BIOLOGICAL|Platelet rich plasma|application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
214493942|NCT01215747|DRUG|KIACTA (eprodisate disodium)|Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.
214493943|NCT01215747|DRUG|Placebo|Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
214493944|NCT02347332|DRUG|Vinflunine|
214493945|NCT02347332|DRUG|Methotrexate|
214493946|NCT02705976|OTHER|Experimental|The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
214493947|NCT02705976|OTHER|Active Comparator|Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
214493948|NCT02977832|DIETARY_SUPPLEMENT|Odyliresin|Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
214493949|NCT02977832|DRUG|Alfuzosin|10Mg Oral Tablet, Extended Release
214493950|NCT04574466|BEHAVIORAL|Problem Management Plus|Problem Management Plus (PM+) is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
214493951|NCT03267537|BEHAVIORAL|Telemedicine CBT-I|Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
214493952|NCT03267537|BEHAVIORAL|Conventional office-based CBT-I|Conventional office-based CBT-I
214493953|NCT01970007|DEVICE|Zilver Vena Venous Self-Expanding Stent|stenting
214493954|NCT04996407|DEVICE|survival thermal blanket|patients were given a thermal blanket
214493955|NCT04996407|DEVICE|draping fabric|Patients were given a draping fabric
214493956|NCT03941106|DEVICE|Accelerated repetitive transcranial magnetic stimulation|Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
214493957|NCT00278928|DRUG|Liposyn III 20% (lipid infusion)|
214493958|NCT00278928|DRUG|Intralipid 20% (lipid infusion)|
214493959|NCT03878979|DRUG|Nivolumab 480mg and surgical resection|One dose of Nivolumab 480mg given four weeks prior to surgical resection.
214371296|NCT00661739|DRUG|Bendamustine|Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
214371297|NCT05369715|OTHER|Exercise|Aerobic exercise
214371298|NCT02832206|PROCEDURE|hybrid ablation|Surgical thoracoscopic epicardial ablation (box-lesion) and left atrial appendage occlusion , followed (after 2-3months) by electrophysiological examination, and catheter ablation (completion of the box-lesion, cavotricuspid isthmus ablation and other ablation if indicated)
214682010|NCT04895059|DRUG|Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose|Form: Tablets Dosage: 20 mg Adminstration way: Oral
214682011|NCT04895059|DRUG|Rosuvastatin 20mg|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
214682012|NCT04895059|DRUG|Ezetimibe 10mg|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
214985876|NCT00548327|DRUG|Atomoxetine|Comparison between Atomoxetine and Placebo
214682013|NCT04222127|OTHER|EUS guided injection of gastric varices by CYA|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate \& lipidol using 19G EUS-FNA needle
214682014|NCT04222127|OTHER|Direct endoscopic injection of gastric varices by CYA|Direct endoscopic injection of gastric varix by CYA
214682015|NCT03292627|DEVICE|Portable Noninvasive Hemodynamic Monitor|A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.
214682016|NCT04736524|OTHER|Rapid antibody test|Serial serology tests on day 21, 90, 180 and 365 following the first dose of the COVID-19 vaccine to detect the temporal trend of the IgM and IgG production in response to the vaccination.
214682017|NCT00192517|DRUG|MEDI-522|4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
214682018|NCT00192517|OTHER|Placebo|4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
214682019|NCT04499508|DEVICE|Optima Coil System|Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
214682020|NCT02665442|DEVICE|Esophageal Stylet - EsoSure|The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
214682021|NCT03567499|DRUG|GSK3039294|GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.
214682022|NCT03567499|DRUG|Placebo|Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
214985877|NCT00548327|PROCEDURE|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
214985878|NCT00548327|PROCEDURE|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
214985879|NCT00548327|DRUG|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
214682023|NCT01713400|DRUG|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
214985880|NCT00362232|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
214682024|NCT01713400|DRUG|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
214985881|NCT00362232|DRUG|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
214682025|NCT01713400|DRUG|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
214682026|NCT01713400|DRUG|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
214682027|NCT04254237|PROCEDURE|Infraumbilical Hasson trocar incision|Infraumbilical Hasson trocar incision
214985882|NCT00362232|DRUG|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
214985883|NCT00362232|DRUG|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
214985884|NCT00534651|DRUG|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
214985885|NCT06209918|DEVICE|bioptron light therapy|patient will be sitting on comfortable chair with the hand placed on an armrest in an extended and supinated position. Firstly, the skin over the wrist area will be exposed and cleaned by alcohol to achieve maximal penetration of light. Then, the bioptron device will be held perpendicular to the surface of the treated area, at a distance of 10 cm.
214371299|NCT03688061|BIOLOGICAL|ChAd3-hliNSmut|Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV
214371300|NCT03688061|BIOLOGICAL|MVA-hliNSmut|Modified Vaccinia Ankara (MVA) vectored vaccine against HCV
214371301|NCT01865955|PROCEDURE|Ultrasound|Ultrasound applied to the lumbar region to determine spinal needle placement.
214371302|NCT01865955|DEVICE|The spinal needle|
214371303|NCT04092725|DRUG|DAB|Single oral 150-mg dose of DAB on Day 1 AM.
214371304|NCT04092725|DRUG|SCY-078 plus DAB|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
214682028|NCT04254237|PROCEDURE|Supraumbilical Hasson trocar incision|Supraumbilical Hasson trocar incision
214682029|NCT03172546|GENETIC|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
214682030|NCT01651182|DRUG|No tranexamic acid|Control
214682031|NCT01651182|DRUG|Tranexamic Acid|
214985886|NCT06209918|DEVICE|wrist brace|will keep the wrist in a neutral position, not bent back or bent down too far
214985887|NCT00274456|DRUG|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
214371305|NCT03018964|PROCEDURE|Solo surgery|Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
214493960|NCT05643521|OTHER|Dietary composition of macronutrients and calories|Carbohydrate restriction
214493961|NCT04813991|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg for breakthrough pain.
214493962|NCT04813991|DRUG|OxyCODONE 5 Mg Oral Capsule|OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
214493963|NCT04569188|BIOLOGICAL|Convalescent plasma|COVID-19 elderly patients treated with convalescent plasma
214493964|NCT04559633|OTHER|cognitive and behavioral therapy (CBT)|"The CBT program is delivered by a multidisciplinary team with 4 half day hospitalization that includes individual, group CBT and education time (2 hours per day delivered by the teacher). Participants have homework to do in their own time at home.~CBT is a manualized program with anxiety psychoeducation, stress management, cognitive restructuration, problem solving techniques, progressive exposure, assertiveness exercises and self-esteem work."
214493965|NCT04890938|COMBINATION_PRODUCT|Sputum-guided management and comprehensive care management|Those in the intervention group will have their treatment determined by the presence and type of airway inflammation whether during AECOPD or as part of clinic optimization. Corticosteroids are given for airway eosinophilia (sputum eosinophils \>3%), and antibiotics for airway neutrophilia (sputum neutrophils ≥65% and total cells \>10 million cells/gram) or a positive sputum culture. Specialized stains to identify aspiration (Oil Red O; (3)) and left ventricular dysfunction (Perl's Prussian blue; (4)) will guide swallowing assessment and cardiac work-up, respectively. If a sputum sample is not produced as an outpatient spontaneously, then sputum induction will be pursued 8 weeks after discharge. If there are no sputum samples to guide inhaler regimen, then it will be determined by the study physician guided by the Canadian Thoracic Society guidelines (2) if a sputum-guided regimen has not already been established.
214493966|NCT04890938|OTHER|Usual Care|As per previous, this group will receive three follow-up visits with study pulmonologist and clinic personnel interventions.
214493967|NCT06199115|PROCEDURE|Photobiomodulation|"In oncology, photobiomodulation is used to help heal damaged tissues, improve immune response, reduce inflammation, and prevent or treat certain side effects of treatments such as chemotherapy. Photobiomodulation is also the subject of recent clinical studies to expand its indications (peripheral neuropathies induced by certain chemotherapies.~Patients in the experimental group will receive 3 photobiomodulation sessions per week during their oxaliplatin treatments (6 months), for a total of 72 sessions. Exposition to laser light is 30 minutes for each session."
214493968|NCT00362960|DRUG|Olmesartan medoxomil|
214493969|NCT00362960|DRUG|Losartan|
214493970|NCT01847456|DRUG|human insulin as nasal spray|
214493971|NCT01847456|DRUG|Placebo|
214493972|NCT06700720|DRUG|Dose 1 YN001|Dose 1 YN001 will be administered on Day 1 and Day 5 of each week from Week 1 to Week 12, and on Day 1 of Week 13, 25 times in total.
214493973|NCT06700720|DRUG|Dose 2 YN001|Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
214493974|NCT06700720|DRUG|Evolocumab|Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
214493975|NCT01331499|DEVICE|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
214493976|NCT01331499|PROCEDURE|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
214493977|NCT03078205|OTHER|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
214493978|NCT03078205|OTHER|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
214493979|NCT01816971|DRUG|dexamethasone|Given IV or PO
214371306|NCT03018964|PROCEDURE|operation with a camera operator in SILC|conventional single incision laparoscopic cholecystectomy with a scopist
214371307|NCT02660814|OTHER|Non-surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
214371308|NCT02660814|OTHER|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
214371309|NCT04251884|PROCEDURE|Local anesthetic (ropivacaine)|Patients randomized in the treatment arm will receive a sonography-guided pudendal nerve block
214371310|NCT04179721|BEHAVIORAL|PES-4-BPSD Model|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks training the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
214493980|NCT01816971|DRUG|carfilzomib|Given IV
214493981|NCT01816971|DRUG|lenalidomide|Given PO
214493982|NCT01816971|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
214493983|NCT01816971|OTHER|laboratory biomarker analysis|Correlative studies
214985888|NCT00274456|DRUG|Docetaxel|Docetaxel dosed q3w at 100 mg/m\^2
214682032|NCT02796404|DEVICE|Homebased cardiac rehabilitation program|homebased cardiac rehabilitation program with monitoring vest Nuubo
214682033|NCT02796404|OTHER|Traditional cardiac rehabilitation program|multidisciplinary intervention in cardiac rehabilitation gym
214682034|NCT04452812|BIOLOGICAL|Convalescent plasma|"Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
214682035|NCT06512038|RADIATION|DEXA Scan|If the participant consents to take part in the trial, they will have an additional DEXA scan.
214682036|NCT03102775|OTHER|Comprehensive follow-up program for low-income families|The main follow-up areas within the HOLF-program is to improve employment, housing, financial situation of the children. Beside manuals, family coordinators participate in five seminars with home-based tasks in between. Alo a comprehensive supervision structure is implemented that follow the train the trainer model. Coordinators ought to work directly with th families, but also with other actors important to the family, such as child-welfare and school. Coordinators should use specific tools improving the quality of the meetings, such as forms for preparation of meetings, being goal-focused and empowering.
214985889|NCT02314546|DRUG|Midazolam|"Study participants will be randomly assigned to one of three treatment groups:~* Group 1 - Placebo - Control patients will receive intranasal saline.~* Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.~* Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam."
214985890|NCT02314546|DRUG|xylocaine|Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
214985891|NCT02314546|DRUG|saline placebo|Placebo - Control patients will receive intranasal saline.
214985892|NCT00629577|GENETIC|microarray analysis|
214985893|NCT00629577|OTHER|flow cytometry|
214985894|NCT00629577|PROCEDURE|biopsy|
214985895|NCT00629577|PROCEDURE|colposcopy|
214985896|NCT03255187|DIETARY_SUPPLEMENT|Fish oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA \[24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)\].
214985897|NCT03255187|DIETARY_SUPPLEMENT|Sunflower seed oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
214985898|NCT03231176|DRUG|Varlitinib|oral tablets, twice daily
214682037|NCT03102775|OTHER|local family projects|The control group offices will develop local family projects, depending on local needs. they will also recruit and follow-up families.
214682038|NCT06020859|DEVICE|undergo NaviEC-2000Pro Gastro Scan mode|Patients undergo NaviEC-2000Pro Gastro Scan mode.
214682039|NCT06020859|DEVICE|NaviEC-2000Pro Routine gastric examination|Patients undergo NaviEC-2000Pro Routine gastric examination mode.
214682040|NCT06020859|DEVICE|NaviEC-1000 Routine gastric examination|Patients undergo NaviEC-1000 Routine gastric examination mode.
214985899|NCT03231176|DRUG|Capecitabine|oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
214985900|NCT02664688|OTHER|Lumbar stabilization exercises|"The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)"
214682041|NCT02270632|DRUG|F8IL10|F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
214682042|NCT02270632|DRUG|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
214682043|NCT02270632|DRUG|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
214682044|NCT04523285|DRUG|TQB3728|TQB3728 tablets is a small molecule oral drug.
214682045|NCT03653715|DEVICE|Clerio Vision LIRIC-modified Bifocal Contact Lens|Within this arm the investigational acofilcon B material bifocal contact lens, which has been modified with the laser and is the focus of the study, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
214682046|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens|Within this arm the control etafilcon A material bifocal contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
214682047|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Contact Lens|Within this arm the control etafilcon A material single vision contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
214682048|NCT03653715|DEVICE|Clerio Vision Single Vision Contact Lens|Within this arm the control acofilcon B material single vision contact lens, the material of which is commercially available from Contamac Ltd, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
214682049|NCT06115577|DIAGNOSTIC_TEST|endometrial tissue and peripheral blood mononuclear cells receptivity|Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.
214682050|NCT02527876|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training
214371311|NCT04179721|BEHAVIORAL|The attention control condition|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to train the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
214371312|NCT02268695|DRUG|Cisplatin|
214985901|NCT02664688|OTHER|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
214371313|NCT02268695|DRUG|5-Fluorouracile|
214371314|NCT02268695|DRUG|Docetaxel|
214493984|NCT04416321|DEVICE|Surgery with the Keos Lumbar Interbody Fusion Device|All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis
214493985|NCT06432192|DIAGNOSTIC_TEST|APO-Easy|Testing for the APOE genotype using the APO-Easy Genotyping test
214985902|NCT00375752|DRUG|Letrozole|2.5 mg.tablet.
214985903|NCT00375752|DRUG|Zolendronic Acid|4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
214493986|NCT00110552|DRUG|Salvia officinalis (sage)|oral dosage
214985904|NCT06094036|BEHAVIORAL|Structured and personalized program of physical exercise|"In line with the most recent guidelines, exercise prescription will require the clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.~This intervention will be accompanied by a nutrition program aiming for proper dietary habits in terms of both quantity and quality."
214985905|NCT03369782|DRUG|Rocuronium|rocuronium is administered in bolus and continuous infusion
214371315|NCT02268695|DRUG|Cetuximab|
214371316|NCT02268695|DRUG|granulocyte colony-stimulating factor (G-CSF)|
214371317|NCT01989143|DRUG|PF-06480605|Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
214493987|NCT00435318|PROCEDURE|Iontophoresis|
214493988|NCT00436631|BEHAVIORAL|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
214493989|NCT05845515|PROCEDURE|laparoscopic orchiopexy|laparoscopic or open orchiopexy and comparison between the two groups
214493990|NCT05551286|OTHER|A rehabilition programme for young adult cancer survivors|The programme consists of 22 sessions focusing on; 1) everyday life (energy conservation, cognitive challenges, fatigue); 2) Physical activity; 3) psychological issues; 4) work and study d; 5) sexuality and relationship; 7) rights and finance, and 8) goal setting. The sessions include both education, workshops, and engagement in different activities and will be delivered by a multidisciplinary team.
214371318|NCT01989143|DRUG|Placebo|Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
214371319|NCT01989143|DRUG|PF-06480605|Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
214371320|NCT01989143|DRUG|Placebo|Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
214371321|NCT01989143|DRUG|PF-06480605|Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
214371322|NCT01989143|DRUG|Placebo|Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
214371323|NCT03613805|DEVICE|Dexcom G5-Eversense|Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered
214493991|NCT04544982|OTHER|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
214682051|NCT02527876|BEHAVIORAL|Moderate Intensity|Moderate Intensity Training
214985906|NCT03369782|DRUG|Sugammadex|Sugammadex is administered just before reduction of the joint
214985907|NCT03369782|DRUG|Placebo|"Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex"
214682052|NCT02527876|BEHAVIORAL|Delayed Control|Delayed Control
214682053|NCT02527876|DEVICE|FitBit Flex|Use to measure increase in Physical Activity
214985908|NCT02034006|DRUG|Ranibizumab|All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
214985909|NCT01259999|DIETARY_SUPPLEMENT|Calogen extra strawberry|A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
215089150|NCT05601661|OTHER|Arm rehabilitation|. The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
215089151|NCT06421272|BEHAVIORAL|APP-based emotion recognition intervention|ASD children were asked to play emotion recognition-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
214682054|NCT00207376|DEVICE|Solysafe Septal Occluder|
214682055|NCT00897520|BIOLOGICAL|recombinant interferon alfa|
215089152|NCT06421272|BEHAVIORAL|APP-based memory intervention|ASD children were asked to play memory-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
215089153|NCT01790555|DRUG|Namisol|
214371324|NCT03613805|DEVICE|Eversense-Dexcom G5|"Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously"
214371325|NCT01405625|OTHER|Pictogram-based asthma action plan|Asthma action plan using plain language, pictograms, and photographs
214371326|NCT01405625|OTHER|AAAAI standard of care written action plan|
214371327|NCT01696448|DIETARY_SUPPLEMENT|CAR-191|Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
214493992|NCT04544982|OTHER|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
214493993|NCT00802126|DRUG|"Combination therapy IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
214493994|NCT04678375|DIAGNOSTIC_TEST|Retinal diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
214493995|NCT00002381|DRUG|Nelfinavir mesylate|
214493996|NCT00002381|DRUG|Nevirapine|
214493997|NCT00002381|DRUG|Stavudine|
214493998|NCT06515678|DRUG|arm A - angiotensin converting enzyme inhibitors (ACEi)|"Patients with ACEi monotherapy before or within 6 months following debulking surgery.~ACEi will be defined as any drugs from the Anatomical Therapeutic Classification C09AA with an indication for hypertension, including but not limited to: captopril, enalapril, lisinopril, perindopril, ramipril, quinapril"
214493999|NCT06515678|DRUG|arm B - calcium channel blockers (CCBs)|"Patients with CCB monotherapy before or within 6 months following debulking surgery.~CCBs will be defined as any drugs from the Anatomical Therapeutic Classification C08CA with an indication for hypertension, including but not limited to: amlodipine, felodipine, isradipine, nicardipine, nifedipine"
214494000|NCT06515678|DRUG|arm R - angiotensin receptor blockers ARB|"Patients with angiotensin receptor blocker (ARB) before or within 6 months following debulking surgery.~ARBs will be defined as any drugs from the Anatomical Therapeutic Classification C09CA with an indication for hypertension, including but not limited to: losartan, valsartan, irbesartan, candesartan or olmesartan medoxomil."
214494001|NCT00954668|PROCEDURE|immediate angiography and revascularization|immediate angiography \< 2 hours after randomization
214494002|NCT00954668|PROCEDURE|early invasive angiography|early invasive angiography 12-72 h after randomization
214682056|NCT00897520|GENETIC|proteomic profiling|
214682057|NCT00897520|OTHER|immunoenzyme technique|
214682058|NCT00897520|OTHER|laboratory biomarker analysis|
214682059|NCT01417780|DRUG|AB103|AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion
214682060|NCT01417780|DRUG|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
214682061|NCT02776280|OTHER|Meal|Typical Brazilian meal consisting of rice, beans and meat with vegetables
214682062|NCT06339229|OTHER|proteinuria|dipstick proteinuria values negative, trace, 1+, and ≥2+
214682063|NCT00876980|DEVICE|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
214682064|NCT06024330|DIAGNOSTIC_TEST|VAN assessment|An investigator assesses the VAN scale when a patient arrives at ED triage with a suspected stroke.
214682065|NCT06024330|DIAGNOSTIC_TEST|VES assessment|An investigator assesses the VES scale when a patient arrives at ED triage with a suspected stroke.
214682066|NCT06024330|DIAGNOSTIC_TEST|LARIO assessment|An investigator assesses the LARIO scale when a patient arrives at ED triage with a suspected stroke.
214682067|NCT05975567|OTHER|Three-dimensional imaging of the collected cardiac specimens|The cadaveric coronary artery segments will first be scanned with intravascular imaging modalities, namely optical coherence tomography (OCT) and intravascular ultrasound (IVUS), and then with micro-computed tomography (micro-CT) and light sheet fluorescence microscopy (LSFM). The thrombotic specimens aspirated from patients with ST-elevated myocardial infarction, will also be scanned using micro-CT. The surgically removed aortic valves will undergo scanning with micro-CT and LSFM. Traditional histopathological assessment will also be performed on the scanned specimens.
214682068|NCT00828867|DRUG|100 mg GSK investigational drug|
214985910|NCT03042546|DRUG|Calcium Sulfate|Calcium Sulfate with abx will be used in the defect
214985911|NCT03042546|DRUG|PMMA|PMMA with abx will be used in the defect
214985912|NCT03042546|OTHER|No treatment|The defect will not be treated
214985913|NCT00109343|BIOLOGICAL|Comparator: ProQuad™ (V221)|0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)
214985914|NCT00109343|BIOLOGICAL|Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)|0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
214682069|NCT00828867|DRUG|200 mg GSK investigational drug|
214682070|NCT00828867|DRUG|400 mg GSK investigational drug|
214682071|NCT00828867|DRUG|800 mg GSK investigational drug|
214985915|NCT06469086|OTHER|Clinical data collection|The clinical significance of appendicoliths in the conservative management of acute complicated appendicitis with abscesses.
214371328|NCT01696448|OTHER|Placebo|Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
214985916|NCT05528952|DRUG|Atezolizumab|1200 mg IV every 3 weeks until disease progression or unacceptable toxicity
214985917|NCT05528952|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity
214985918|NCT05528952|DRUG|UCPVax|UCPVax vaccine (combined with Montanide ISA51 as adjuvant) at 0.5 mg subcutaneously
214985919|NCT06784193|DRUG|OP-3136|OP-3136
214371329|NCT01738880|DRUG|SVV|During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
214371330|NCT01738880|DRUG|CVP|Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
214371331|NCT00256958|PROCEDURE|total knee replacement|
214371332|NCT03637244|BEHAVIORAL|Decision Support Aid and PrEP for Black Canadians|Ottawa Decision Support Framework Adaptation.Investigators will use the inputs from the qualitative findings, CDC public health guidance and the tenofovir + emtricitabine product monograph to tailor the ODSF for use in the C5TM PrEP decision support web-app.
214985920|NCT06784193|DRUG|Fulvestrant|Fulvestrant
214371333|NCT00265135|DRUG|CNTO 328|Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
214371334|NCT05403099|OTHER|Hyaluronic acid|immediate placement of dental implant after topical application of hyaluronic acid on implant surface
214371335|NCT05403099|OTHER|conventional implant placement|immediate placement of dental implant without application of hyaluronic acid on implant surface
214494003|NCT03484910|OTHER|Exercise therapy|Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
214494004|NCT00557596|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
214682072|NCT00828867|DRUG|2000 mg GSK investigational drug|
214682073|NCT00828867|DRUG|1500 mg GSK investigational drug|
214682074|NCT00828867|DRUG|800mg fed GSK investigational drug|
214985921|NCT00070434|DRUG|capecitabine|825mg/m2 BID, PO, daily
215089154|NCT01790555|DRUG|Diazepam/placebo|
214682075|NCT00828867|DRUG|3000mg GSK investigational drug|
214682076|NCT00828867|DRUG|4000mg GSK investigational drug|
214682077|NCT04174131|DEVICE|Restylane + Lidocaine|Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.
214682078|NCT04174131|DEVICE|Restylane® Lyft|Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).
214682079|NCT01345786|DRUG|Commercial NOMAC-E2|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
214682080|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch A"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods"
214985922|NCT00070434|DRUG|fluorouracil|Bolus + IV for 46 hrs on Day 1
214985923|NCT00070434|DRUG|irinotecan hydrochloride|IV infusion over 90 min on Day 1
214985924|NCT00070434|DRUG|leucovorin calcium|200mg/m2 IV 2 hour infusion on Day 1
214985925|NCT00070434|DRUG|oxaliplatin|85mg/m2 IV infusion for 90minutes on Day 1
215089155|NCT04035096|DRUG|Ascorbic Acid|"1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
215089156|NCT04035096|OTHER|Control group|"1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~2. Usual care"
214985926|NCT00070434|RADIATION|radiation therapy|Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
214985927|NCT00070434|DRUG|Pyridoxine|50mg TID, PO daily
214985928|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
214985929|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Mepore Pro dressing after hip surgery.
215089157|NCT05805748|BEHAVIORAL|serious game rehabilitation|The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).
214371336|NCT02624739|DEVICE|Reassure Non-Contact Respiration Monitor|Reassure uses a specially-designed, non-contact motion sensor to monitor body movement and continuous respiratory rate (CRR) during sleep. Reassure is used to monitor, over a prolonged period, the sleep patterns and respiration rate while the patient is asleep.
214371337|NCT02651935|DEVICE|Intellivent ASV|Automated Invasive mechanical ventilation and weaning strategy
214371338|NCT06477640|BEHAVIORAL|Exercise|The intervention group will receive daily activity messages sent through SMS text message or email.The messages will provide daily exercises with heart rate guidance.
214985930|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Mepilex Border dressing after hip surgery.
215089158|NCT02663141|DRUG|Losartan|
214371339|NCT06477640|BEHAVIORAL|Standard of Care|"The control group will receive daily non-descript messages to help with blinding and to eliminate the confounding variable of daily contact. The messages will not include activity tasks and will include phrases such as I hope you have a good day."
214371340|NCT06634225|DIAGNOSTIC_TEST|Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test|Patients will receive the care they need, in line with HAS recommendations. They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).
214371341|NCT06634225|DIAGNOSTIC_TEST|Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test|They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).
214371342|NCT00158665|BIOLOGICAL|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
214371343|NCT05361655|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
214371344|NCT05361655|DRUG|Aromatase inhibitor|Aromatase inhibitor therapy
214371345|NCT06249828|DEVICE|MegaCarti^®|MegaCarti® application after microfracture through athroscopic or incision surgery
214371346|NCT06249828|PROCEDURE|Microfracture|Microfracture through athroscopic or incision surgery
214371347|NCT01984697|BIOLOGICAL|V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
214371348|NCT03308825|BIOLOGICAL|Fluzone Quadrivalent vaccine|0.25 mL, Intramuscular
214371349|NCT03308825|BIOLOGICAL|Fluzone Quadrivalent vaccine|0.5 mL, Intramuscular
214371350|NCT03308825|BIOLOGICAL|Fluzone High-Dose vaccine|0.5 mL, Intramuscular
214371351|NCT00001579|DRUG|5-Fluorouracil|
214371352|NCT00001579|DRUG|Ethynyluracil|
214371353|NCT00001579|DRUG|Leucovorin|
214371354|NCT04236193|DIAGNOSTIC_TEST|Ultrasound Shoulder and Immunological Phenotyping by FACS|Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements
214371355|NCT00000844|DRUG|Interferon alfa-n3|
214371356|NCT00000844|DRUG|Interferon alfa-n1|
214371357|NCT06487091|DIAGNOSTIC_TEST|Analysis of platelet function|Blood withdrawal, platelet separation and analysis of the expression levels of markers of platelet function
214371358|NCT01332396|DRUG|Lapatinib|
214985931|NCT01131273|DRUG|methadone|12 weeks of methadone maintenance with counseling
214985932|NCT01131273|DRUG|buprenorphine-naloxone (Suboxone) for 12 weeks|12 weeks of maintenance with counseling
214985933|NCT02705430|DIETARY_SUPPLEMENT|EPA and DHA capsules of 2 g/day|EPA and DHA capsules of 2 g/day
214985934|NCT02705430|BEHAVIORAL|Stress management phone application (Eco Fusion Mentally)|Stress management phone application (Eco Fusion Mentally)
214371359|NCT04737109|DRUG|Ipatasertib|Ipatasertib
214371360|NCT04737109|DRUG|Darolutamide|Darolutamide
214371361|NCT04737109|DRUG|Androgen Deprivation Therapy|ADT per institutional standards
214371362|NCT06832683|DRUG|Sevoflurane|For Group S, 8% sevoflurane was administered for induction via the procedural oxygen mask for 2 minutes through the external output of the anesthesia machine. The concentration was then reduced to 2%. If any undesired movements occurred, they were recorded, and the sevoflurane concentration was increased by 0.5%.
214985935|NCT02705430|BEHAVIORAL|life style program using a mobile phone (Eco Mentally and NewMe)|life style program using a mobile phone (Eco Mentally and NewMe)
215089159|NCT02663141|DRUG|Intravitreal bevacizumab|
215089160|NCT02663141|DRUG|Placebo|
215089161|NCT05810714|OTHER|Best Practice|Receive usual care
215089162|NCT05810714|OTHER|Fecal Immunochemical Test|Receive FIT kit
215089163|NCT05810714|BEHAVIORAL|Health Education|Receive audio brochure
215089164|NCT05810714|BEHAVIORAL|Health Education|Receive video brochure
214985936|NCT02705430|DEVICE|mobile phone|mobile phone
214985937|NCT01859039|BIOLOGICAL|Administration of Live attenuated influenza vaccine|
214985938|NCT05024448|DRUG|Prednisone|oral administration, 60mg/d for 10d
214371363|NCT06832683|DRUG|Propofol|In Group P, 1.0 mg/kg propofol as a bolus. In the event of undesired movements, an additional 0.5 mg/kg of propofol was administered, and all additional doses were recorded.
214371364|NCT06832683|DRUG|Ketamine|In Group P, 1 mg/kg, single dose ketamine was administered intravenously and all additional doses were recorded.
214494005|NCT06398600|PROCEDURE|Caudal|In the prone position , linear transducer will be first positioned transversely on the middle line. The two sacral cornua appear as two hyperechoic structures ,two hyperechoic band structures are present between the two sacral cornua. The superficial is the sacrococcygeal ligament (SCL) and the deep is the dorsal surface of the sacrum. The sacral hiatus is a hypoechoic area between two band-like hyperechoic structures. In longitudinal view, the block needle will be inserted using the in plane technique .The block needle can be visualized in real time piercing the SCL entering the hiatus but cannot be visualized beyond the apex of the hiatus. It is therefore proposed to limit the extension of the needle tip beyond the tip of the sacral hiatus to 5 mm to avoid perforating the dura mater. After the needle is inserted in the caudal canal, 20 ml of 0.25% bupivacaine will be injected.
214494006|NCT06398600|PROCEDURE|Quadratus lumborum plane block|The patient is placed in the prone position , under aseptic conditions with the sterile convex probe is placed in a transverse view at the triangle of the QL muscle and the middle thoracolumbar fascia. The projected needle path is advanced in-plane until the needle tip is visualized between the middle thoracolumbar fascia and the QL muscle . After confirming the location of the needle with 2-3 ml of saline and then aspiration, 20 ml of 0.25% bupivacaine is injected in this plane with confirmation by visualizing hydro dissection . the procedure is applied to the opposite side using the same dose to achieve bilateral block.
214494007|NCT05692817|DEVICE|Low-Intensity Pulsed Ultrasound|"The total sample will be randomly divided into two equal groups (according to method of application of the lipus on the intervention side)as follows: ■ Group I: will include 8 patients who will receive lipus with maxillary canine retraction that will be performed every (3 weeks) on intervention 6 sides according to a standardized protocol.~▪ Group II: will include 8 patients who will receive lipus that will be performed every (1 week) on intervention sides according to a standardized protocol."
214494008|NCT02362139|DRUG|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
214494009|NCT06562907|DRUG|GS-4571|Administered orally
214494010|NCT06562907|DRUG|Placebo|Administered orally
214494011|NCT06562907|DRUG|Omeprazole|Administered orally
214985939|NCT05240690|BIOLOGICAL|Umbilical Cord Blood Derived MAK Immune Cells|Intravenous drip
214985940|NCT02348333|DRUG|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
214371365|NCT01799460|DRUG|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|"①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily."
214371366|NCT01799460|DRUG|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
214371367|NCT01166490|DRUG|ASG-5ME|0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
214371368|NCT02060591|DRUG|Exparel|
214371369|NCT02060591|DRUG|Marcaine|
214371370|NCT06259565|DRUG|Dexmedetomidine|Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation (IMV) that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium
214371371|NCT06259565|OTHER|Placebo Control|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
214371372|NCT02198495|DRUG|Supplementation of ferric carboxymaltose|
214371373|NCT02198495|DRUG|Supplementation of iron sucrose|
214371374|NCT02259517|DRUG|Guanfacine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
214494012|NCT01834846|PROCEDURE|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
214494013|NCT01834846|PROCEDURE|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
214494014|NCT00874536|DIETARY_SUPPLEMENT|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
214494015|NCT00874536|DIETARY_SUPPLEMENT|Placebo|
214494016|NCT05435794|DEVICE|CPAP|Fixed-pressure CPAP device for the treatment of sleep apnea with optional humidification and heated circuit. This device is a Class II device. It has a remote monitoring function allowing service providers to track the use of the device.
214985941|NCT02348333|DRUG|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
214985942|NCT01104844|DRUG|Full Dose Strength|Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
215089165|NCT05810714|OTHER|Scheduled Notification|Receive scheduled reminder
214682081|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch B"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods"
214985943|NCT01104844|DRUG|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
214985944|NCT01104844|DRUG|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
214371375|NCT02259517|DRUG|Lisdexamfetamine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
214494017|NCT05435794|DEVICE|MAD|mandibular device orthosis made to measure from the dental impressions of patients, made by the specialist in the masticatory apparatus for the treatment of sleep apnea.
214494018|NCT02839395|OTHER|No intervention- base line|the subject will sited in a dim light room. No screen light illumination.
214494019|NCT02839395|OTHER|Acute|The subject will be sited in front of computer screen light illumination for 2 hours.
214494020|NCT02839395|OTHER|Chronic|The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
214494021|NCT00112359|DRUG|AZLI 75 mg three times a day (TID)|
214494022|NCT00112359|DRUG|Placebo three times a day (TID)|
214494023|NCT02576275|DRUG|Duvelisib|Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
214494024|NCT02576275|DRUG|Placebo|Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
214494025|NCT02576275|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
214494026|NCT02576275|DRUG|Bendamustine|IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
214494027|NCT01467128|OTHER|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
214494028|NCT01467128|OTHER|No Intervention|Normal hospital pharmaceutical care
214494029|NCT02530190|DEVICE|intermittent pneumatic compression|20 minutes of intermittent pneumatic compression to lower extremities
214494030|NCT02530190|PROCEDURE|massage|20 minutes of massage to lower extremities
214494031|NCT06196749|PROCEDURE|Perform distal radial arterial cannulation using modified ultrasound-guided dynamic needle tip positioning technique|This study employs a modified ultrasound-guided dynamic needle tip positioning technique for distal radial arterial cannulation. The technique uses an ultrasound probe with two wires to create an acoustic shadow, improving needle tip visibility. Real-time dynamic tracking assists in precise needle placement within the distal radial artery through the nose-horn region. This method is used for coronary angiography and potential percutaneous coronary interventions, aiming to increase success rates and reduce complications like hematoma, nerve injury, and arterial spasm, thus enhancing safety and efficiency.
214494032|NCT06196749|PROCEDURE|Palpation guided puncture|Perform distal radial arterial cannulation under palpation guidance
215089166|NCT05810714|OTHER|Survey Administration|Ancillary studies
214371376|NCT06197555|OTHER|Sodium Monofluorophosphate|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
214494033|NCT05985408|DEVICE|left ventricular septal pacing|For left bundle branch pacing (LBBP) failure cases, use left ventricular septal pacing instead of LBBP; others were same as traditional CRT.
214494034|NCT05985408|DEVICE|right ventricular apical pacing|For left bundle branch pacing (LBBP) failure cases, use right ventricular apical pacing instead of LBBP; others were same as traditional CRT.
214494035|NCT05430087|DRUG|Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.|All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.
214494036|NCT01961609|BIOLOGICAL|Secukinumab (AIN457)|Secukinumab was supplied in 150mg pre-filled syringes.
214494037|NCT01988402|DRUG|allopurinol|
214682082|NCT00053820|BIOLOGICAL|aldesleukin|
214682083|NCT00053820|BIOLOGICAL|recombinant interferon alfa|
214682084|NCT00053820|DRUG|fluorouracil|
214682085|NCT02145767|DRUG|Progesterone|
214682086|NCT02145767|DRUG|Placebo|
214682087|NCT03953586|DIAGNOSTIC_TEST|Bubble suction test and tubal peristalsis|Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)
214682088|NCT02096939|PROCEDURE|Adrenal extirpation|
214682089|NCT02096939|DRUG|Antihypertensive medication|
214682090|NCT00141635|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|
215089167|NCT05291559|DIETARY_SUPPLEMENT|Enterade|Enterade is a glucose-free, amino acid-based medical food containing specific amino acids (aspartic acid, valine, serine, threonine and tyrosine) in addition to electrolytes and a non-sugar sweetener.
215089168|NCT05291559|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical product to Enterade except without added amino acids.
215089169|NCT06194500|DRUG|[14C]-LY3549492|Administered as oral solution.
215089170|NCT06194500|DRUG|LY3549492|Administered orally.
215089171|NCT06194500|DRUG|[14C]-LY3549492|Administered as IV infusion.
214682091|NCT05725798|DRUG|Sitagliptin|Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.
214682092|NCT03575091|OTHER|Non-individualized|Comparing two experimental interventions with standard care
214682093|NCT03575091|OTHER|Individualized|Comparing two experimental interventions with standard care
214371377|NCT06197555|OTHER|Stannous Fluoride|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
214371378|NCT06197555|OTHER|Nano-Hydroxyapatite|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
214371379|NCT06197555|OTHER|8% Arginine & Calcium Carbonate|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
214494038|NCT01988402|DRUG|Placebo (sugar pill)|
214494039|NCT05566444|DEVICE|Heat stimulus|Contact heat pain stimulus with a termode set at 46 degrees and contact warm stimulus with a termode set at 40 degrees
214494040|NCT01462799|BEHAVIORAL|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
214494041|NCT01462799|BEHAVIORAL|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
214494042|NCT03402854|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during the first 20 min of bimanual training.
214494043|NCT03402854|BEHAVIORAL|bimanual training|Participants will engage in movements that use both hands, by playing with toys and games.
214371380|NCT02540694|DEVICE|Endosonography|
214371381|NCT03496974|DRUG|Bermekimab Monoclonal Antibody 200 mg|200 mg subcutaneous injection
214371382|NCT03496974|DRUG|Bermekimab Monoclonal Antibody 400 mg|400 mg subcutaneous injection
214494044|NCT04755504|DIAGNOSTIC_TEST|EEG behind the ear|2 additional electrodes behind each ear will record EEG
214494045|NCT02766946|DEVICE|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
214494046|NCT02766946|DEVICE|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
214494047|NCT02766946|OTHER|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
214494048|NCT02766946|OTHER|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
214494049|NCT03132688|DRUG|Propofol|Intravenous administration with dose of 100-200mcg/kg/min
214494050|NCT01262339|DRUG|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
214682094|NCT00246883|PROCEDURE|Exercise|
214682095|NCT01145027|OTHER|Breakfast tray|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
214682096|NCT03179098|OTHER|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
214985945|NCT01104844|DRUG|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
214985946|NCT01104844|DRUG|Ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
214985947|NCT01104844|DRUG|Ibuprofen high dose|Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
214985948|NCT01104844|DRUG|Placebo|2 placebo tablets
214985949|NCT04040699|BIOLOGICAL|KN026 combined with KN046|KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
214371383|NCT06452056|DEVICE|Rapid Antigen Screening Test|A point-of-care Rapid Antigen Screening Test (RAST) using a lateral flow immunoassay platform with our partner, BioMedomics Inc. The BioMedomics RAST is a lateral flow immunoassay that detects the nucleocapsid protein (NP) antigen of SARS-CoV-2 using a double antibody sandwich assay. The test cassette contains one detection line (T) fixed with anti-SARS-CoV-2 NP antibody and one quality control line (C) fixed with control antibody. When the test sample is treated with lysis buffer and added to the sample well of the test cassette, the fluid will move forward along the test strip via capillary action. If the sample contains NP antigen at levels higher than the limit of detection, the antigen will bind to the NP capture antibody as well as the immobilized detection antibody on the membrane forming a red T line, indicating a positive result. A positive signal at C line provides assurance that the fluid containing the sample material has moved laterally in an appropriate fashion.
214494051|NCT03664882|DRUG|Fexofenadine M016455|Pharmaceutical form: tablet Route of administration: oral
214494052|NCT03664882|DRUG|Placebo|Pharmaceutical form: tablet Route of administration: oral
214494053|NCT04373694|PROCEDURE|vaginoscopy|vaginal distension with hysteroscope for hysteroscopy morcellation (without speculum or tenaculum forceps)
214682097|NCT03179098|OTHER|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
214985950|NCT06265025|DRUG|GM103 (Part A)|dose escalation of GM103 as monotherapy, conducted in 12-24 patients. Part A will include a screening period of up to 28 days, a dose limiting toxicity (DLT) evaluation period of the first 2 cycles, and a treatment period from cycles 3-12 (each cycle will consist of 14 days \[2 weeks\]).
214985951|NCT06265025|DRUG|GM103 (Part B)|dose expansion study of GM103 as monotherapy, conducted in up to 40 patients (a minimum of 20 patients per target disease \[HNC, CRC\]). Part B of the study will include a screening period of up to 28 days, and 1 to a maximum of 12 treatment cycles (each cycle will consist of 14 days \[2 weeks\]).
214682098|NCT03179098|OTHER|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
214682099|NCT04149327|DRUG|amoxicillin 500 mg + metronidazole 500 mg|500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
214682100|NCT04149327|PROCEDURE|non-surgical periodontal and peri-implant treatment|"Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned."
214682101|NCT01891747|DRUG|Bevacizumab|bevacizumab at 10mg/kg IV every 14 days (Phase I \& phase II)
214985952|NCT06265025|DRUG|GM103 and Pembrolizumab (Part C)|dose-escalation and dose-expansion of GM103 in combination with pembrolizumab, conducted in approximately 61 patients. Part C of the study will include a screening period of up to 28 days, a safety run-in period of 2 cycles (it consists of 2 cohorts and the first 1 cycle for the DLT assessment period of each cohort is included, each cycle will consist of 21 days \[3 weeks\]), and a dose expansion period from cycle 3 to a maximum of 12 treatment cycles (of 21 days \[3 weeks\]).
214985953|NCT05781802|OTHER|Level of pressure support|"Patients will be evaluated in two different conditions sequentially. The first condition will be at a clinically selected level of pressure support under stable clinical conditions.~This condition will be labeled according to P0.1:~* In case of P0.1\<2, the clinically selected level of pressure support will be considered High Pressure support.~* In case of P0.1\>2, the clinically selected level of pressure support will be considered Low Pressure support.~After data collection at clinically selected level of pressure support, pressure support level will be transiently increased or decreased (i.e. from high to low/ from low to high) to the lowest/highest clinically tolerated level, aiming at the predefined P01 thresholds, and then kept for 20 minutes under stable clinical conditions. Data collection will be repeated and then the clinically selected level of pressure support restored."
214494054|NCT04373694|PROCEDURE|standard hysteroscopy|speculum, paracervical block before hysteroscopy morcellation
214494055|NCT00582972|DRUG|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
214371384|NCT03644901|PROCEDURE|nonsurgical periodontal treatment|patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.
214371385|NCT04607655|DRUG|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
214371386|NCT04607655|DRUG|Placebo|Placebo is administered as inhalation once a day
214371387|NCT03401892|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
214494056|NCT05305391|OTHER|Dietary intervention|The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.
214494057|NCT02206815|DRUG|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
214494058|NCT02206815|DRUG|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
214494059|NCT00588406|DRUG|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
214494060|NCT00588406|DRUG|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
214494061|NCT00588406|DRUG|Ipratropium bromide|2.5 mg, one dose
214494062|NCT00588406|DRUG|Prednisone|60mg PO
214371388|NCT03401892|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
214371389|NCT03401892|DEVICE|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
214371390|NCT01870752|PROCEDURE|Transplantation of previously cryopreserved ovarian tissu|
214371391|NCT04682119|DRUG|LY3526318|Administered orally.
214494063|NCT03342820|PROCEDURE|Muscle fatigue|Isokinetic quadriceps muscle fatigue of the paretic lower limb
214494064|NCT01566890|DRUG|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
214494065|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
214494066|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
214494067|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
214494068|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
214494069|NCT03983434|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
214494070|NCT06387576|BEHAVIORAL|Behaviorally informed pre-discharge iPad video scheduling|The iPad video scheduling process will occur prior to patient discharge from the hospital. This intervention harnesses behavioral principles, such as commitment (patient committing to scheduled appointment), social accountability (patients feeling more accountable after scheduling their appointment via the video visit), and social support (patients feeling more supported after engaging in this conversation with a scheduler via video).
214494071|NCT03934528|DEVICE|Virtual environment activity|Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
214494072|NCT05559801|DRUG|Bone marrow-derived mesenchymal stromal cells (MSCs)|Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.
214494073|NCT00588471|DRUG|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
214494074|NCT00588471|DRUG|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
214494075|NCT05780762|OTHER|IMPACT Program|"care at 3 levels:~(1) co-definition of the health situation, (2) co-planning of care and co-actions, and (3) co-assessment with the patient and with the team caring for him or her, and incorporating evidence-based measurement tools."
214494076|NCT05780762|OTHER|usal care|usual management with a Nurse in Advanced Practice.
214494077|NCT04004325|DRUG|FT-4101|FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
214494078|NCT04004325|DRUG|FT-4101 placebo|FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
214494079|NCT04004325|OTHER|Deuterated Water|Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
214494080|NCT03589625|OTHER|Solar Suitcase|"The intervention is a Solar Suitcase. The Solar Suitcase comes with: 2 LED lights, 1 battery, 1 aluminum glass 100 watt solar panel, 2 rechargeable LED headlamps, 1 universal cell phone charger, 1 USB adapter, 1 fetal Doppler, 1 AA/AAA battery charger and expansion box (provides 2 additional lights).~Installers will teach health workers how to use and maintain the Solar Suitcase on the day of installation. Within one week following installation, the contractor will contact the facility over the phone and/or in-person to check if there are any problems with the Suitcase. Additional checks will be made to ensure the solar suitcase is functioning and being used properly."
214494081|NCT01970553|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
214494082|NCT01970553|DRUG|Gemcitabine|1000 mg vial, powder for injectable solution
214494083|NCT01357512|DEVICE|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
214682102|NCT01891747|DRUG|Temozolomide|150 mg/m2/day for a 5-day regimen per month (Phase I \& Phase II)
214682103|NCT01891747|DIETARY_SUPPLEMENT|Vitamin C|250 mg vitamin C once a day (oral) - Phase I \& Phase II
214682104|NCT01929044|DRUG|654-II (anisodamine)|10mg injection
214371392|NCT04682119|DRUG|Placebo|Administered orally.
214371393|NCT06212648|DRUG|SPC1001 High|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
214371394|NCT06212648|DRUG|SPC1001 Mid1|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
214371395|NCT06212648|DRUG|SPC1001 Mid2|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
214371396|NCT06212648|DRUG|SPC1001 Low|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
214371397|NCT06212648|DRUG|SPC3001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
214371398|NCT06212648|DRUG|SPC4001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
214985954|NCT02397616|OTHER|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
214985955|NCT06216340|DRUG|Henagliflozin|10mg of Henagliflozin and diet-exercise therapy
214682105|NCT01929044|DRUG|Buscopan® (hyoscine butylbromide)|20mg injection
214682106|NCT01080989|OTHER|diagnosis, treatment and education|"Drug:~anti-intestinal parasitic drugs:~1. mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)~2. albendazole(400 mg bid \* 7days) or Ivermectin(200 mcg/kg/day \* 2 days) (For Strongyloidiasis).~Behavior:~1. Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.~2. Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents."
214682107|NCT03555539|DRUG|Danicopan|Oral tablet.
214682108|NCT01974674|PROCEDURE|Allogeneic transplantation of intrahepatic islet|
214682109|NCT00063648|BIOLOGICAL|EBV-specific autologous CTL|
214682110|NCT03907722|OTHER|Long pentraxin 3|Primary PCI
214371399|NCT06212648|DRUG|SPC4002|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
214371400|NCT06212648|DRUG|Placebo|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
214371401|NCT01808625|OTHER|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
214371402|NCT03928028|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition.
214371403|NCT03928028|BEHAVIORAL|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
214371404|NCT02802501|DRUG|Tafenoquine|This intervention is provided as tablet containing 150 mg of tafenoquine. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
214371405|NCT02802501|DRUG|Matched-Placebo for Tafenoquine|This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
214494084|NCT05088798|DRUG|18F-Fluoro Dopa PET/MRI Imaging|The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
214494085|NCT05325541|DEVICE|Visual Biofeedback Therapy|Visual Biofeedback intervention will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
214494086|NCT05325541|BEHAVIORAL|Conventional Balance exercise|Conventional Balance exercises will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
214494087|NCT03117582|OTHER|Stool specimen|"The following stool specimen will be collected for this study:~1. 4, 3mL stool specimen from patient~2. 1, 25mL stool aliquot from donor"
214682111|NCT03268304|OTHER|VR-based training including AO and MI|Virtual Reality-based training intervention including Action Observation and Motor Imagery using the YouGrabber® training device
214985956|NCT06216340|DRUG|Placebo|Placebo and diet-exercise therapy
214985957|NCT00577408|DRUG|depot naltrexone|On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
214985958|NCT00577408|DRUG|Oral Naltrexone|For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
214494088|NCT05246943|DIAGNOSTIC_TEST|D-dimer and lower limb venous duplex|D-dimer blood test- The D-dimer assay detects the presence of fibrin degradation products, which can indicate the breakdown of a fibrin clot Lower Limb Venous Duplex- Using an ultrasound to visually look for a clot
214494089|NCT05605925|DRUG|Artemether/lumefantrine|4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
214494090|NCT05605925|DRUG|Ivermectin|IVN 600 mcg/kg/day for 3 days
214682112|NCT04037358|DRUG|Radium-223|Radium-223 plus SABR will be within two weeks.
214682113|NCT04037358|RADIATION|stereotactic ablative radiotherapy (SABR)|SABR 1-5 fractions
214682114|NCT02788916|OTHER|No Intervention|
214682115|NCT04436510|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily"
214682116|NCT04436510|DRUG|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
214682117|NCT02807454|DRUG|Daratumumab|
214682118|NCT02807454|DRUG|Durvalumab|
214682119|NCT02807454|DRUG|Pomalidomide|
214682120|NCT02807454|DRUG|Dexamethasone|
214682121|NCT02769572|OTHER|real moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
214682122|NCT02769572|DRUG|placebo gel|4 grams per knee, 4 times per day, for 4 weeks
214682123|NCT02769572|DRUG|diclofenac sodium gel|4 grams per knee, 4 times per day, for 4 weeks
214682124|NCT02769572|OTHER|sham moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
214682125|NCT03739944|PROCEDURE|Laparotomic radical hysterectomy|Laparotomic radical hysterectomy for patients without fertility requirement
214371406|NCT02802501|DRUG|Primaquine|This intervention is provided as over-encapsulated tablet containing 15 mg of primaquine. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
214371407|NCT02802501|DRUG|Matched-Placebo for Primaquine|This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
214494092|NCT04491201|OTHER|Customized questionnaire|A customized questionnaire will be delivered by the social software WeChat to the specific hospital which has been randomly sampled, and all physicians of Obstetrics and Gynecology in this hospital will fill the questionnaire anonymously.
214494093|NCT04291027|OTHER|Land Based Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
214494094|NCT04291027|OTHER|Aquatic Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
214682126|NCT03739944|PROCEDURE|Laparotomic radical trachelectomy|Laparotomic radical hysterectomy for patients with fertility requirement
214682127|NCT03739944|PROCEDURE|Laparoscopic radical hysterectomy|Laparoscopic radical hysterectomy for patients without fertility requirement
214494095|NCT06150833|BIOLOGICAL|Boya IVIG|"The initial dose and other dose changes will be determined by the investigator on a case-by-case basis aiming to prevent infection and minimum serum IgG levels of 5 g/L. The total number of doses administered will depend on the treatment regimen and run-in period:~* Between 16 and 20 intravenous injections for participants receiving infusions every 28 days, or;~* Between 21 and 25 intravenous injections for participants receiving infusions every 21 days"
214682128|NCT03739944|PROCEDURE|Laparoscopic radical trachelectomy|Laparoscopic radical hysterectomy for patients with fertility requirement
214682129|NCT05182502|DEVICE|Tixel|Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
214682130|NCT01165203|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
214985959|NCT03613298|DEVICE|HIFU (Focal One®)|Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
214371408|NCT02802501|DRUG|Dihydroartemisinin-piperaquine (DHA-PQP)|This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing \>=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
214682131|NCT01165203|BIOLOGICAL|Placebo|intramuscular injection
214682132|NCT02205385|PROCEDURE|Targeted Muscle Reinnervation|
214682133|NCT02205385|PROCEDURE|Traction Neurectomy|
214682134|NCT03070977|OTHER|Interprofessional clinical training unit|"In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.~A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.~The training unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions."
214682135|NCT01652378|DRUG|ondansetron, lidocaine|"Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion)."
214985960|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution|Participants will receive Human interferon alfa 1b inhalation solution orally for a single dose.
214985961|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution placebo|Participants will receive Human interferon alfa 1b inhalation solution placebo orally for a single dose.
214985962|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution|Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
214985963|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution placebo|Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution placebo administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
214985964|NCT01625767|BEHAVIORAL|AAT experiment|Smokers and nonsmokers complete AAT experiment
214682136|NCT05913557|BEHAVIORAL|Radically Open Dialectical Behavior Therapy (RO DBT)|Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
214371409|NCT02802501|DRUG|ACT plus PQ (Rescue medication)|Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
214682137|NCT04885244|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
214371410|NCT02802501|DRUG|PQ (End of study treatment)|Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
214371411|NCT02239497|PROCEDURE|Femoral block by ultrasound and neurostimulation|
214371412|NCT02239497|DRUG|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
214371413|NCT01670448|PROCEDURE|PECBLOCK under echoguidance|Performance of block under echography
214371414|NCT03895554|PROCEDURE|cardiac PET stress test|Volunteers will undergo cardiac PET stress testing
214371415|NCT02966145|OTHER|Observational Study|
214371416|NCT03559088|OTHER|Migraine App|Smart phone app used to report migraine burden to the EHR.
214371417|NCT03326960|DRUG|Sevoflurane|Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
214371418|NCT03326960|DRUG|Propofol|Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
214371419|NCT03326960|DRUG|Desflurane|Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
214371420|NCT00146614|DRUG|Sirolimus|
214371421|NCT00146614|DRUG|Tacrolimus|
214371422|NCT00146614|DRUG|Methotrexate|
214494096|NCT01211184|DIETARY_SUPPLEMENT|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
214494097|NCT01211184|DIETARY_SUPPLEMENT|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
214494098|NCT01211184|BEHAVIORAL|Fasting.|The patient is fasting from midnight before the surgery.
214985965|NCT05009550|PROCEDURE|Group ESP|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group
214371423|NCT00146614|PROCEDURE|Stem Cell Transplantation|
214371424|NCT06835725|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|prostate stereotactic ablative radiotherapy
214371425|NCT05918302|DRUG|177Lu-edotreotide|6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
214371426|NCT05918302|DRUG|Everolimus|10 mg orally once daily (QD)
214371427|NCT05234307|DRUG|Adenosine A2B Receptor Antagonist PBF-1129|Given PO
214371428|NCT05234307|PROCEDURE|Biospecimen Collection|Correlative studies
214371429|NCT05234307|BIOLOGICAL|Nivolumab|Given IV
214371430|NCT03622788|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214371431|NCT03622788|DRUG|Cyclophosphamide|Given IV
214371432|NCT03622788|BIOLOGICAL|Cytokine-treated Veto Cells|Given IV
214371433|NCT03622788|DRUG|Fludarabine|Given IV
214371434|NCT03622788|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
214371435|NCT03622788|RADIATION|Total-Body Irradiation|Undergo TBI
214371436|NCT04669600|DRUG|SAR445088 (BIVV020)|Pharmaceutical form:solution for injection
214371437|NCT06254183|DRUG|Gabapentin|"Gabapentin is a drug that is commonly used to treat neuropathic pain, epilepsy, and other neurological disorders. According to some studies, gabapentin may affect the Wnt signaling pathway.~In this study Gabapentin will be given by a dose of 1200 mg 1 hour before a laparoscopic sleeve gastrectomy(LSG) to decrease postoperative pain and opioid consumption. As acute kidney injury is a common condition following LSG , and as gabapentin has a positive effect on decreasing AKI induced in animal studies, we assess the effect of gabapentin on the AKI status following LSG"
214494099|NCT00822120|BIOLOGICAL|bleomycin sulfate|
214371438|NCT06254183|DRUG|Placebo|A placebo is a sham medical treatment that appears to be a real medical intervention but has no therapeutic effect. It is often used in clinical trials to compare the effects of a new treatment to those of a placebo. Common examples of placebos include inert tablets (like sugar pills), inert injections (like saline), and even sham surgery or other procedures. Placebos are typically made of inactive substances such as starch or sugar and are designed to be indistinguishable from the actual treatment
214494100|NCT00822120|BIOLOGICAL|filgrastim|
214494101|NCT00822120|DRUG|ABVD regimen|
214494102|NCT00822120|DRUG|BEACOPP regimen|
214494103|NCT00822120|DRUG|cyclophosphamide|
214494104|NCT00822120|DRUG|dacarbazine|
214494105|NCT00822120|DRUG|doxorubicin hydrochloride|
214494106|NCT00822120|DRUG|etoposide|
214494107|NCT00822120|DRUG|prednisone|
214494108|NCT00822120|DRUG|procarbazine hydrochloride|
214494109|NCT00822120|DRUG|vinblastine sulfate|
214494110|NCT00822120|DRUG|vincristine sulfate|
214494111|NCT03765658|DRUG|GRT0151Y dose escalation|Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)
214682138|NCT00231985|BEHAVIORAL|Habit reversal therapy|Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
214985966|NCT05009550|OTHER|Non-blocked Group|This Group is received no intervention.Patients will be sedated as standard and radiofrequency procedure will be applied.
214985967|NCT03400189|DRUG|Sulthiame|Single dose (50, 100, 200 mg)
214371439|NCT04589468|OTHER|Exercise|Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
214371440|NCT06423963|BEHAVIORAL|Physical Activity|Each participant will receive a Fitbit device with instruction and encouragement to self-monitor physical activity using step counts.
214371441|NCT06423963|BEHAVIORAL|Nutrition Counseling|Participants will receive nutritional counseling with a registered dietician.
214371442|NCT06423963|BEHAVIORAL|Resistance Training|Participants will engage in progressive, full-body resistance training based on American College of Sports Medicine (ACSM) guidelines.
214682139|NCT00231985|BEHAVIORAL|Supportive therapy|Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
214371443|NCT06802601|OTHER|Manual Therapy and Exercise|Manual Therapy and Exercise
214371444|NCT06802601|OTHER|Manual Therapy, Exercise and Visio-Vestibular Exercise|Manual Therapy, Exercise and Visio-Vestibular Exercise
214371445|NCT04808505|BIOLOGICAL|Cipaglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
214371446|NCT04808505|DRUG|Miglustat|65 mg oral capsules
214371447|NCT01544998|DRUG|Nesiritide|10 ug/kg
214371448|NCT01544998|DRUG|Tadalafil|5 mg
214371449|NCT01544998|DRUG|Placebo|The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
214371450|NCT01544998|DRUG|Saline load|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
214371451|NCT03379194|BEHAVIORAL|Antibiotic stewardship program|Routine feedback on antibiotic prescriptions in addition to evidence based guidelines for the management of acute respiratory and urinary tract infection and patient leaflets for using antibiotics wisely
214371452|NCT05842213|BIOLOGICAL|AVT05 (proposed biosimilar to golimumab)|AVT05 is a recombinant human IgG1қ mAb developed as a subcutaneous injection
214371453|NCT05842213|BIOLOGICAL|Simponi (Golimumab)|Simponi (Golimumab) is a recombinant human IgG1қ mAb developed as a subcutaneous injection
214371454|NCT01713543|OTHER|physical therapy|Tailored physical therapy sessions to modify impairments in balance and/or gait and to transition high-risk participants to an evidence-based group exercise program.
214371455|NCT00710606|DRUG|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
214494112|NCT03765658|DRUG|Matching placebo|Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
214494113|NCT03491540|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
214494114|NCT03491540|DRUG|Oral Gentamycin|"Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials"
214494115|NCT03491540|DRUG|Oral Ornidazole|"Oral ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
214494116|NCT03491540|DRUG|Oral Placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
214494117|NCT03491540|DRUG|Oral Placebo Ornidazole|"Placebo for oral ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablets per day) on day -2 and day -1"
214494118|NCT05462067|DEVICE|AT LARA IOL|EDOF IOL for treatment of cataract
214494119|NCT05462067|DEVICE|AT LISA Tri IOL|Trifocal IOL for treatment of cataract
214494120|NCT06461390|DRUG|Norepinephrine|NE Group (Fluid loading with early norepinephrine administration group) NE Group will receive ringer lactate bolus 20 ml/kg along with norepinephrine infusion at 0.1 mcg/kg/minute until MAP\&gt;5 percentile. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed, with or without continued norepinephrine infusion according to the treatment group
214494121|NCT06461390|DRUG|Ringer's Lactate|Fluid Group will receive ringer lactate bolus 20 ml/ kg only. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed
214494122|NCT01324310|DRUG|Romidepsin|Romidepsin 8 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
214494123|NCT01324310|DRUG|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
214494124|NCT00291954|BIOLOGICAL|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
214494125|NCT00291954|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
214494126|NCT02582424|OTHER|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
214682140|NCT05077917|DRUG|Cromolyn Sodium|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
214494127|NCT02582424|OTHER|placebo|placebo
214371456|NCT00710606|DRUG|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
214371457|NCT00022230|BIOLOGICAL|aldesleukin|
214371458|NCT00022230|BIOLOGICAL|filgrastim|
214371459|NCT00022230|BIOLOGICAL|sargramostim|
214371460|NCT00022230|BIOLOGICAL|therapeutic autologous lymphocytes|
214494128|NCT00255307|DRUG|CVT-E002 ginseng extract|
214494129|NCT00008242|DRUG|dexamethasone|
214682141|NCT05077917|OTHER|Placebo|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
215089172|NCT05356338|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families enrolled in WIC|"A 6-month intervention based on the use of 5 components: 2 educational videos, provision of a water-promotion toolkit, a mobile phone application (app), a series of 14 computerized interactive voice response (IVR) phone calls to parents and 2 counseling sessions by a WIC nutritionist to compare families' SSB's consumption behaviors"
215089173|NCT02177019|OTHER|Personalized health plan|
215089174|NCT01842581|DRUG|Rifaximin|Rifaximin will be administered per the dose and schedule specified in the arms.
215089175|NCT01842581|DRUG|Lactulose|Laculose will be administered per the schedule specified in the respective arm.
215089176|NCT03028987|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
215089177|NCT03028987|BIOLOGICAL|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
215089178|NCT03420105|OTHER|Neuropsychological, psycho-pathological and quality of life assessments|Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
215089179|NCT03420105|DRUG|Hormonotherapy|Adjuvant hormone therapy
215089180|NCT00940784|DRUG|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
214371461|NCT00022230|DRUG|cyclophosphamide|
215089181|NCT00940784|DRUG|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
214371462|NCT00022230|DRUG|doxorubicin hydrochloride|
214371463|NCT00022230|DRUG|paclitaxel|
214494130|NCT00008242|DRUG|doxorubicin hydrochloride|
214371464|NCT05891769|DRUG|18Fluorocholine|18F Fluorocholine 5 mCi ± 20% administered intravenously.
214371465|NCT05316129|DRUG|Follicle Stimulating Hormone Receptor T Cells|Participants will receive an infusion of autologous t cells genetically modified ex vivo to express the FSHR-specific 4-1BB/CD3ζ CER.
214371466|NCT02128646|DRUG|EXPAREL|
214371467|NCT02128646|DRUG|Ketorolac|
214371468|NCT02128646|PROCEDURE|laparoscopic abdominal hernia repair|
214371469|NCT02128646|PROCEDURE|an open surgery for abdominal hernia repair|
214494131|NCT00008242|DRUG|thalidomide|
214494132|NCT00137098|DRUG|Caffeine|
214494133|NCT02999763|DEVICE|SlimShape|SlimShape radiofrequency treatment to the abdomen
214494134|NCT02192242|OTHER|acute ischemic pain|acute ischemic pain was induced by treadmill exercise
214494135|NCT04060212|OTHER|Tuna fish|Six meals of tunafish (\~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
214494136|NCT04060212|DIETARY_SUPPLEMENT|prebiotic|Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.
214494137|NCT06162702|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
214494138|NCT03095872|DEVICE|CO2-laser|Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
214494139|NCT03095872|DRUG|Vaseline|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home."
214494140|NCT03095872|DRUG|Bepanthen|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home."
214494141|NCT02505191|DRUG|St. John's wort prolonged-release tablet 500 mg|
214494142|NCT02505191|DRUG|St. John's wort film coated tablets 250 mg|
214494143|NCT03954275|OTHER|no intervention|no intervention
214494144|NCT03447457|DEVICE|High-flow oxygen|HFNC is continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min and a FiO2 adjusted to maintain a pulse oxymetry at least 92%
214494145|NCT03447457|DEVICE|Standard oxygen|nasal cannula, face mask or non-rebreathing reservoir mask
214494146|NCT00708045|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer to assess brain tumor metabolism
214494147|NCT00115011|DRUG|Escitalopram|
214494148|NCT05489913|OTHER|cardiac rehabilitation support program|First of all, a preliminary interview was made with the patients in the experimental group, and their information needs were evaluated individually. Which trainings he should receive and his priorities were determined with the patient. After the training requirements were determined, the general introduction of the website was made and they were allowed to register. Experimental group patients received both training on the website and counseling over the phone for 12 weeks after they started working. A total of 3 phone calls were made with the patients in the first week, 4th and 8th weeks. The interviews lasted an average of 20 minutes. In each phone call, patients were informed and reminded. When patients needed, an average of 2-3 more phone calls were made and information was provided on the subjects they needed.
214494149|NCT05374642|BEHAVIORAL|cognitive training|tablet-based cognitive training for 12 weeks, 30 minutes each time, at least 5 times a week
215089182|NCT00940784|DRUG|Aspirin|81-100 mg qd
214371470|NCT06679010|OTHER|Online group counseling|The program progresses as one weekly group session over 10 weeks, each with its own topic. The core components of the program include psychoeducation, training self-compassion and acceptance, cognitive restructuring, interpersonal skills training, systems and management of daily life activities, prevention of conflicts, and the mother-baby relation. Participants will meet online as a group together with the instructor, a consultant from the ADHD Association, who will lead and facilitate the sessions. Before each session, there is a podcast episode that covers the topic of each session. The 10 podcasts feature interviews with clinicians, researchers, and women with ADHD, focusing on the themes from the program's sessions.
214682142|NCT03721081|DRUG|Lidocaine 1%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
214682143|NCT03721081|OTHER|Na Cl 0.9%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
214682144|NCT00907140|PROCEDURE|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
214985968|NCT03797053|PROCEDURE|Biological sample|"Biological sample performed :~* before treatment~* 1 months after the beginning of treatment~* every tumoral assessment"
214985969|NCT05737511|DRUG|Hydroxyzine|Oral tablet of hydroxyzine 25mg at night which could be increased to TID or QID
214985970|NCT05737511|DRUG|Escitalopram Oxalate|The treatment as usual can include first-line, second-line and third-line recommendations
214985971|NCT00656617|DRUG|Idarubicin|12 mg/m\^2 IV over 1 hour daily for 3 days (days 4 to 6)
215089183|NCT05736939|OTHER|Out-patient Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
215089184|NCT00967759|DRUG|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
215089185|NCT00967759|DRUG|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
215089186|NCT00967759|DRUG|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
215089187|NCT01287195|DRUG|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
214371471|NCT03462329|DRUG|Antibiotics (preferentially oral doxycycline 100 mg bid)|Patients will be treated with antibiotics for Lyme disease.
214371472|NCT06472076|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
214371473|NCT06472076|BIOLOGICAL|Belrestotug|Belrestotug will be administered.
214371474|NCT06472076|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
214371475|NCT06472076|DRUG|Placebo|Placebo will be administered.
214494150|NCT05374642|BEHAVIORAL|active control|tablet-based cognitive training tasks with weak or no difficulty changes, 5 times a week, 30 minutes each time for 12 weeks
214494151|NCT01974843|DRUG|Levobupivacaine|in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
214494152|NCT01974843|DRUG|Bupivacaine|in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
214682145|NCT01149278|DRUG|maintain mean arterial pressure between 80-85 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
214371476|NCT04903314|DRUG|Xcopri|Xcopri will be administered orally not to exceed 400mg/day adult equivalent
214371477|NCT03339479|DIAGNOSTIC_TEST|dielectric property test|Test the dielectric property of resected lung nodules/mass through a touching probe after the lung tissue with nodules/mass has been resected and cut open, which usually takes only 1-5 minutes.
214682146|NCT01149278|OTHER|maintain mean arterial pressure between 65-70 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
214682147|NCT00002141|DRUG|Abacavir sulfate|
214682148|NCT02639117|DRUG|Vismodegib|Vismodegib 150 mgs po qd for 3 months
214682149|NCT01070784|DRUG|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
214682150|NCT01070784|DRUG|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
214682151|NCT03204838|GENETIC|IDH mutation test performed at diagnosis|Observation of the test result
214985972|NCT00656617|DRUG|Cytarabine|1.5 g/m\^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
214985973|NCT00656617|DRUG|Vorinostat|Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
214985974|NCT01544036|DRUG|perflutren|Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
214985975|NCT03997877|OTHER|Physical activity|Increase physical activity Balanced diet
214985976|NCT01604772|DRUG|Akt Inhibitor MK2206|Given PO
214985977|NCT01604772|OTHER|Laboratory Biomarker Analysis|Correlative studies
214985978|NCT03931564|PROCEDURE|PRESERFLO Microshunt implantation|The intervention consists of the microshunt implantation augmented with mitomycin C application.
214682152|NCT05769803|DIAGNOSTIC_TEST|Nasal and mouth swab|"Whinin 7 days from diagnosis, the subjects will be requested to sample another two specimens i.e. nasal swab and mouth swab, that will be tested for the presence of SARS-CoV-2 RNA. Results, expressed as cycle threshold will be then compared to analyze viral loads from the two different sites.~Moreover, an aliquot will be retro-transcribed into cDNA and sequenced by Next Generation Sequencing (NGS) to obtain the virus entire genome sequence or evaluated by RT-PCR for variantdetermination."
214682153|NCT03693287|DRUG|Standardized-parenteral nutrition (S-PN)|NUMETA G13%E 300 mL is a triple-chamber (lipid emulsion, amino acids solution with electrolytes, and glucose solution), ready-to-use parenteral nutrition product available to treat preterm infants (less than 37 weeks gestational age).
214371478|NCT03339479|DIAGNOSTIC_TEST|frozen pathological examination|And after the dielectric property test, the lung tissue will be sent for frozen pathological examination.
214371479|NCT03339479|DIAGNOSTIC_TEST|final pathological examination|All of the lung nodules/mass will be diagnosed by final pathological examination and recognized as the final diagnosis after surgery.
214371480|NCT02347644|BEHAVIORAL|Brief Motivational Interview|"Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:~* No perception of any alcohol consumption problem~* Realization of alcohol consumption problem with no corresponding action"
214371481|NCT04029701|DRUG|Ruyizhenbao Pill|Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
214371482|NCT04029701|DRUG|Placebo of Ruyizhenbao Pill|Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
214371483|NCT04292782|PROCEDURE|anterior Quadratus lumborum block|ultrasound anterior quadratum lumborum block with 1 ml/kg 0.2% ropivacaine
214371484|NCT04292782|PROCEDURE|caudal block|ultrasound guided caudal block with 1 ml/kg 0.2% ropivacaine
214371485|NCT00514683|DRUG|low dose BIBF1120 once daily|low dose BIBF1120 once daily
214682154|NCT03693287|DRUG|Personalized-parenteral nutrition (P-PN)|"Intravenous glucose will be dextrose 50%, amino acids (AA) will be Primene® and lipids (FAT) will be Clinoleic®.~Parenteral nutrition bags will be prepared by the hospital pharmacy according to the prescription of the attending neonatologist."
214371486|NCT00514683|DRUG|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
214371487|NCT00514683|DRUG|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
214371488|NCT00514683|DRUG|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
214371489|NCT00514683|DRUG|placebo|placebo
214494153|NCT03959813|OTHER|Psychomotricity by touching and passive mobilizations|"The patient will have a first psychomotricity session. It will be carried out remotely from the drug catches to avoid bias induced by their administration having effects on the symptoms studied.~Before and after the session, two evaluations will be offered to the patient and performed by a nurse:~* A questionnaire, based on the physical experience,~* The ESAS scale will be administered to the patient to assess the importance of symptoms (pain, depression, anxiety, discomfort) During the session, a touch treatment will be offered to promote awareness of the body. Passive mobilizations at the level of the members and the axis will then be proposed, to promote the pleasure of being in motion. A touch treatment will be done again to promote relaxation.~A questionnaire can be offered to the patient after 4 sessions to assess his perception of psychomotricity."
214494154|NCT01009424|DRUG|R7103|escalating inhaled dose
214494155|NCT05282966|DIAGNOSTIC_TEST|QSant-TM Urine Test|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
214985979|NCT03931564|PROCEDURE|Trabeculectomy|The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.
214985980|NCT02236377|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems
214985981|NCT04782141|PROCEDURE|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
214371490|NCT00664898|DRUG|bortezomib|Escalating intravenous repeating dose
214371491|NCT00664898|DRUG|SGN-40|Escalating intravenous repeating dose
214371492|NCT04894526|OTHER|Alternating Energy Intake|To alternate between caloric overconsumption (130% of usual total energy needs) and caloric underconsumption (70% of usual total energy needs) on a daily basis for 6 days/week followed by one ad libitum day for 4 weeks.
214371493|NCT04894526|OTHER|Regular Energy Intake|To consume the usual energy intake (100% of total energy needs) on a daily basis for 6 days/week, also followed by one ad libitum day for 4 weeks.
214371494|NCT02417103|DRUG|GLP-1 (Liraglutide)|GLP-1 Analogon
214371495|NCT02417103|DRUG|Placebo|Placebo
214371496|NCT01410370|RADIATION|6MV-X ray|3Gy/time, 5 times/week, a total of 10 times
214371497|NCT01410370|DRUG|Endostar|7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
214985982|NCT04782141|PROCEDURE|hand motor coordination in a supine position with the upper extremity positioned perpendicularly to the trunk|motor tasks carried out in starting positions: supine with the upper extremity positioned perpendicularly to the trunk; the upper limb in adduction and flexion in the humeral joint, elbow extension, forearm in the intermediate position; elbow, wrist, hand free from stabilization.
214985983|NCT04782141|PROCEDURE|hand motor coordination in a supine position with adduction in the humeral joint, elbow flexion in the intermediate position|In the supine position, the upper limb was held beside the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
214985984|NCT02349386|DRUG|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
214985985|NCT02349386|DRUG|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
214371498|NCT05868915|BIOLOGICAL|HV-101|"Biological: HV-101~HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification.~Drug: IL-2~Following cell infusion, the patient receives intravenous IL-2.~Drug: Fludarabine~Part of the non-myeloablative lymphocyte-depleting preparative regimen.~Drug: Cyclophosphamide~Part of the non-myeloablative lymphocyte-depleting preparative regimen."
214371499|NCT05320055|PROCEDURE|robotic repair|robotic assisted retromuscular hernia repair
214371500|NCT02736825|DEVICE|Ulthera System with standard transducer|Focused ultrasound energy delivered below the surface of the skin using commercially available transducer to deliver one line of treatment at a time
214371501|NCT02736825|DEVICE|Ulthera System with prototype 2 simulines transducer|Focused ultrasound energy delivered below the surface of the skin using new transducer to deliver two lines of treatment simultaneously
214371502|NCT02943941|OTHER|Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.|Cardiac Monitor with LINQ™ HF Investigational RAMware download
214371503|NCT00790452|DRUG|Aspirin|325 mg daily by mouth
214371504|NCT00790452|DRUG|Placebo|Tablet daily by mouth
214371505|NCT00182962|BEHAVIORAL|Geriatric Resources for Assessment & Care of Elders (GRACE)|
214371506|NCT02103621|BEHAVIORAL|Unified Protocol (UP)|
214371507|NCT02103621|BEHAVIORAL|Taper and Monitoring (TAP-M)|
214371508|NCT03394066|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-eight TMS coil. An MRI compatible version of the figure-of-eight coil will be used inside the MRI scanner with an appropriate TMS coil holder.
214371509|NCT05199363|OTHER|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
214494156|NCT02540369|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
214494157|NCT01074359|DRUG|A0001 (alpha-tocopherolquinone)|28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
214494158|NCT01074359|DRUG|Placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
214494159|NCT00231504|PROCEDURE|Blood samples|Blood samples
214494160|NCT04881409|DEVICE|Respiratory support with nasal high-flow (NHF)|Patient with AECOPD is treated with NHF.
214494161|NCT04881409|DEVICE|Respiratory support with non-invasive ventilation (NIV)|Patient with AECOPD is treated with NIV.
214494162|NCT02356055|BEHAVIORAL|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
214494163|NCT04027439|DRUG|Part A: RPL554|1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
214494164|NCT04027439|DRUG|Part B: RPL554|Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
214494165|NCT04027439|DRUG|Placebos|"Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A."
214494166|NCT03664011|DRUG|BI 730357 mixed with [C-14]BI 730357 BS|Oral Solution
214494167|NCT01693822|DRUG|Axitinib|"Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
214494168|NCT03450460|BEHAVIORAL|Peer support|The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
214494169|NCT06298266|BIOLOGICAL|infusion of GPRC5D-CD19 CAR T injection|Infusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10\^6 /kg±20 % CAR-T ，3.0×10\^6 /kg±20%、6.0×10\^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214985986|NCT03423771|DRUG|NPF-08|Drug: NPF-08 Arms: NPF-08 oral sulfate solution
214985987|NCT01712178|BIOLOGICAL|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
214985988|NCT01712178|BIOLOGICAL|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
214985989|NCT00091819|DRUG|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
214985990|NCT00091819|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
215089188|NCT01287195|DRUG|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
214371510|NCT05199363|OTHER|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
214371511|NCT05199363|OTHER|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers"
214371512|NCT00650195|DRUG|Metolazone Tablets 10 mg|10mg, single dose fasting
215089189|NCT03562793|BEHAVIORAL|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
215089190|NCT04033094|DRUG|MorphaBond ER|This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
215089191|NCT04033094|DRUG|Comparator Drug|This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
215089192|NCT02006069|DEVICE|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
214371513|NCT00650195|DRUG|Zaroloxyn® Tablets 10 mg|10mg, single dose fasting
214371514|NCT00267410|BEHAVIORAL|Healthy Relationships|"Healthy Relationships, grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts."
214371515|NCT05905250|BEHAVIORAL|an empirically supported protocol, further refined with evidence-based strategies|The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.
214371516|NCT05905250|BEHAVIORAL|Health education|Health education regarding maintaining a healthy weight, physical activity, and nutrition, based on American Cancer Society and NCI guidelines/recommendations.
214371517|NCT04563650|BIOLOGICAL|blood sample|Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
214371518|NCT03536364|BEHAVIORAL|Food Order|carbohydrate (ciabatta bread ) first, followed 10 minutes later by protein (grilled chicken) and vegetables
214371519|NCT03536364|BEHAVIORAL|Carbohydrate Last|protein and vegetables first, followed 10 minutes later by carbohydrate
214371520|NCT03536364|BEHAVIORAL|Vegetables first|vegetables first, followed 10 mins later by protein and carbohydrate.
214371521|NCT04035837|DRUG|pegylated interferon-alfa|All the patients in this study will receive pegylated interferon for all course.
214371522|NCT05408728|PROCEDURE|Endoscopic biopsy|Upper small intestinal biopsies from patients undergoing BS will be collected during routine standard of care screening EGD and again from the same patients at 1 year during routine standard of care surveillance EGD (esophageal reflux screening/surveillance). Biopsy-derived enteroid cultures and tissue samples from pre- and one-year post BS will be examined for expression level of sugar transporters and gluconeogenic enzymes; glucose and fructose absorption
214494170|NCT06424652|OTHER|Blood draws|After passing the screening, participation in the research study will be approximately three weeks. The participant will have seven study visits all at the Pennington Center. On five occasions, the participant will have a five-hour visit in the inpatient unit. At the study visit blood will be drawn. The total amount of blood drawn during the study is approximately 12 fluid ounces.
214682155|NCT02371733|OTHER|Upper extremity aerobic exercise training|"Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
214371523|NCT04035213|BEHAVIORAL|Behavior of Sleep Course|The current study will evaluate whether a semester-long course focused on sleep improves college students' sleep patterns over one semester compared to students completing a similar-level course in the same department (Psychology) at the same university.
214371524|NCT01564368|PROCEDURE|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
214371525|NCT03021135|PROCEDURE|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection
214371526|NCT03021135|PROCEDURE|Underwater Endoscopic Mucosal Resection|Underwater Endoscopic Mucosal Resection
214371527|NCT00500864|DRUG|Magnesium Sulfate 2 grams|
214371528|NCT03960632|DIAGNOSTIC_TEST|Abbott SD Bioline Malaria Pf Plus (05FK150) and Abbott SD Bioline Malaria Pf/Pv Plus (05FK160))|Qualitative in vitro tests for the detection of Plasmodium antigens
214371529|NCT03183102|DIETARY_SUPPLEMENT|Flaxseed|2 months of dietary flaxseed supplementation
214371530|NCT06347796|PROCEDURE|Conventional Surgery|Conventional surgery is surgical drainage through burr holes or craniotomy.
214682156|NCT02371733|OTHER|Alternative upper extremity exercises|"Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
214682157|NCT05493956|RADIATION|chemoradiation|Radiation dose of 54 Gy will be given alongwith concurrent capecitabine
214985991|NCT03582683|BEHAVIORAL|Chronic Pain Self-Management Program (CPSMP)|Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program. The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
214371531|NCT06347796|DEVICE|Middle Meningeal Artery Embolization (MMAE)|Particle embolization of the middle meningeal artery with micron variants of the Embosphere Microspheres or CONTOUR Embolization Particles device.
214371532|NCT01402596|DRUG|Midazolam|0,4 mg per kg - intranasal midazolam - once
214371533|NCT01402596|DRUG|Chloral Hydrate|50 mg per kg, rectal
214371534|NCT06738368|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
214371535|NCT06738368|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214371536|NCT06738368|PROCEDURE|Bone Marrow Collection|Undergo bone marrow sample collection
214371537|NCT06738368|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214371538|NCT06738368|DRUG|Cyclophosphamide|Given IV
214371539|NCT06738368|DRUG|Doxorubicin|Given CIV
214494171|NCT06424652|OTHER|Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test|This procedure measures how the body responds to insulin. Insulin is normally produced by the body during meals and helps the body use sugar. There will be two IV lines, one in the participant's arm and one in the participant's hand on the opposite side. Small amounts of glucose and insulin will be infused into the participant's arm. The participant's blood sugar level will be checked every 5-10 minutes from the IV in the hand to determine how much glucose the participant should have to keep blood sugar at a normal level. The participant's hand will be placed inside a warming box to increase skin temperature to about 105 degrees Fahrenheit. The temperature will be warm, but not uncomfortable. During the IV procedure, a small amount of the participant's own blood (less than 1 teaspoon) will immediately be returned into the vein through the IV after each specimen is collected.
214494172|NCT06424652|OTHER|Resting Metabolic Rate (RMR)|After the participant rests for 30 minutes, a clear plastic hood will be placed over the participant's head and chest area. The hood is ventilated with fresh air. The participant's oxygen intake and carbon dioxide output will be measured for 30 minutes to determine how many calories the participant burns during the time they are being tested.
214371540|NCT06738368|DRUG|Etoposide|Given CIV
214371541|NCT06738368|BIOLOGICAL|Filgrastim|Given SC
214371542|NCT06738368|BIOLOGICAL|Pegfilgrastim|Given SC
214371543|NCT06738368|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214371544|NCT06738368|DRUG|Prednisone|Given PO
214371545|NCT06738368|BIOLOGICAL|Rituximab|Given IV
214371546|NCT06738368|DRUG|Vincristine|Given CIV
214371547|NCT00111748|DRUG|Velcade, Thalidomide, Dexamethasone|"Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14~This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit."
214682158|NCT03502759|BEHAVIORAL|CHICA SUDEP module|CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
214682159|NCT01888354|DRUG|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
214682160|NCT06191354|GENETIC|SKG0201 Injection|SKG0201 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
214682161|NCT04316572|BEHAVIORAL|mental health specialist video consultation|"The consultations will be based on a psychodynamic understanding with a solution-oriented stance and will follow a manual:~Session 1: Getting familiar with the telemental health setting, building a working alliance and deepening diagnostics.~Session 2: Clarification of the task/objective, focus building, motivational interviewing if necessary.~Session 3-4: Focused brief interventions e.g. psychoeducation, promotion of social resources, activation of health-promoting lifestyles (sleep hygiene, eating diary, relaxation etc.), work on personal problems and, if necessary, initiation of further specialised treatment.~Session 5: Ending the intervention, stabilisation, subsequent treatment plan and communicating a case summary to the general practitioner"
214682162|NCT06276972|OTHER|no intervention|there's no intervention. it's a cross sectional study correlation study
214985992|NCT05510492|OTHER|EDUCATION|THE EXPERIMENT GROUP WAS GIVEN THEORETICAL AND APPLIED EDUCATION,
214371548|NCT04562961|OTHER|Schizophrenia caregivers qualitative interview|"The semi-structured qualitative interview will be carried out in a focus group or individually for a period of 1 hour. Focus groups are a group interview technique, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on a limited number of pre-defined questions. In this study we foresee groups of 4 to 5 subjects. Focus groups will be privileged because they allow a better elaboration of the participants and therefore a better collection of data. If the focus group is not possible, the visit will be done individually. This interview will be framework-guided and recorded in their entirety and anonymously using a dictaphone and then transcribed the objective verbatim on a computer using word processing software. These transcriptions will be called the verbatims. The source data recorded using a dictaphone will be stored in secure, locked cabinets located within the investigation center."
214371549|NCT04565171|DRUG|Yimitasvir Phosphate Capsule|DAG181 100 mg (100 mg Capsule) administered orally
214682163|NCT02515591|OTHER|Bronchoalveolar Lavage validation study|Bronchoalveolar lavage involved the washing out of the right middle lobe of the lung of a healthy volunteer with 200mls of warmed normal saline with or without sedation.
214985993|NCT05510492|OTHER|APPLIED EDUCATION|"the injection was applied on the model by the researcher with the demonstration method according to the Procedure Steps of Intramuscular Injection with the Z Technique from the Ventrogluteal Region. This process was first ensured by the nurses, and then"
214985994|NCT05306704|OTHER|placebo Oil|participants will receive placebo(olive oil) orally in all visits from visit 1 to visit 4
214985995|NCT05306704|DRUG|25-Hydroxyvitamin D|Participants will receive vitamin D (100000IU) orally during all visits i.e. from visit-1 to visit-4
214985996|NCT00091429|DRUG|Ranolazine|
214985997|NCT04772443|DRUG|DWJ1506|DWJ1506
214371550|NCT04990128|COMBINATION_PRODUCT|Aspire Needle + Emcyte PureBMC|The Aspire Needle will be utilized to extract the bone marrow and the Emcyte PureBMC will be used to concentrate bone marrow aspirate. The final concentrate will be injected into the hip.
214371551|NCT04990128|DRUG|Triamcinolone|40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.
214371552|NCT02462902|DRUG|5% albumin Infusion|colloid, 5% albumin (250 ml over 15 to 30 minutes).
214371553|NCT02462902|DRUG|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
214371554|NCT00832767|PROCEDURE|SILS™ port laparoscopic cholecystectomy|This interventional arm will have a single incision laparoscopic cholecystectomy procedure.
214371555|NCT00832767|PROCEDURE|Four Port Laparoscopic Cholecystectomy|This interventional arm will have a traditional four port laparoscopic cholecystectomy procedure.
214371556|NCT03850652|DIETARY_SUPPLEMENT|Prebiotic (Synergy-1) + Iron supplement|In addition, participants will be required to take one 7 g sachet of prebiotic food supplement daily. In addition, participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
214371557|NCT03850652|DIETARY_SUPPLEMENT|Placebo (Maltodextrin) + Iron Supplement|participants will be required to take one 7 g sachet of placebo (maltodextrin) daily. In addition, participants will be required to take an iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
214371558|NCT01373931|DRUG|LY2216684|Administered orally
214371559|NCT01373931|DRUG|Ortho Cyclen|35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally
214371560|NCT01373931|DRUG|Placebo|Administered orally
214371561|NCT05177406|OTHER|Aimovig|patients newly initiating Aimovig therapy
214371562|NCT05747456|DEVICE|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
214371563|NCT05747456|DEVICE|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
214371564|NCT04857034|DRUG|Deucravacitinib|Specified dose on specified days
214371565|NCT04857034|DRUG|Placebo|Specified dose on specified days
214371566|NCT02940574|DRUG|Syntocinon (Oxytocin)|Syntocinon nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
214371567|NCT02940574|OTHER|Placebo (Physiological water (solution of sodium chloride (NaCl) in water))|Placebo nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
214371568|NCT02798510|RADIATION|Concurrent Chemoradiotherapy|
214371569|NCT02798510|DRUG|capecitabine|
214371570|NCT02798510|DRUG|gemcitabine|
214682164|NCT00620620|DRUG|Inhaled placebo|Inhaled Staccato Placebo
214682165|NCT00620620|DRUG|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
214682166|NCT00620620|DRUG|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
214682167|NCT00620620|DRUG|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
214682168|NCT00620620|DRUG|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
214985998|NCT04772443|DRUG|DWJ1507|DWJ1507
214985999|NCT04772443|DRUG|DWC202011|DWC202011
214986000|NCT04772443|DRUG|DWJ1177|DWC202011
214986001|NCT01655836|RADIATION|Brachytherapy|Undergo high dose rate brachytherapy
214986002|NCT01655836|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
214986003|NCT01655836|PROCEDURE|Quality-of-life assessment|Ancillary studies
214371571|NCT06132555|OTHER|Online questionnaire survey|"The investigators have made an electronic questionnaire through the questionnaire star, and send the link or two-dimensional code of the electronic questionnaire to the subjects through WeChat or SMS to remind them to fill in the answer on the mobile phone or computer.~The questionnaire consisted of four parts: (1) basic information of the interviewees, (2) drug abuse of the interviewees, (3) drug treatment interventions received by the interviewees, and (4) problems encountered by the interviewees when they return to society."
214371572|NCT06132555|OTHER|In-depth personal interview|The in-depth personal interview was conducted in a semi-structured way. The outline of the interview was formulated from seven aspects: drug use history, drug abstinence history, relapse situation, living conditions, physical and mental health status, return to society status, and active drug abstinence willingness of the drug abstinence personnel. The aim was to understand the needs of drug addicts in terms of family relationship, peer relationship, history of drug use, history of drug withdrawal, employment, economy, social support network, psychology, and assistance.
214371573|NCT06132555|OTHER|Colloquia|"The colloquia were carried out in the form of group interviews, 1-2 people from each different institution were selected to participate, and the number of people in each colloquium was controlled to be between 6 and 12.~The colloquia mainly focused on: ① The status quo of the implementation of the local drug drug treatment policy, ② the status quo of the compulsory isolation drug treatment work, ③ the status quo of the work of social workers for drug drug treatment, ④ the status quo of the work of community health centers, ⑤ the operation of various mechanisms in the work of various units, and ⑥ what content in the drug control work needs assistance from other departments and what external resources are needed."
214371574|NCT00387894|DRUG|erlotinib hydrochloride|Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
214986004|NCT01655836|OTHER|Questionnaire administration|Ancillary studies
214682169|NCT01031758|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
214986005|NCT04120818|PROCEDURE|secondary IOL implantation|reopened the fibrotic, closed capsular bag and achieve IOL placement
214371575|NCT03580590|DRUG|oral Diltiazem|Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
214371576|NCT03580590|DRUG|IV Tranexamic Acid|Tranexamic acid inhibits fibrinolysis, which reduces blood loss
214371577|NCT03580590|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
214371578|NCT04235907|OTHER|Telerehabilitation|Internet-guided rehabilitation with weekly phone calls from a physical therapist.
214494173|NCT06487507|BEHAVIORAL|Low fat diet|Prior to surgery, participants complete diet records for 7 days. After, participants will receive one shipment containing prepared meals (refrigerated, frozen and fresh) low fat Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
214986006|NCT04120818|PROCEDURE|primary IOL implantation|lensectomy and anterior vitrectomy and primary IOL implantation
214371579|NCT04235907|OTHER|Standard rehabilitation|Prescription for physical therapy and a printed list of exercises to complete.
214371580|NCT00659490|DRUG|AZD1940|800ug oral administration
214494174|NCT06487507|BEHAVIORAL|Lower carbohydrate diet|Prior to surgery, participants complete diet records for 7 days. After, participants will receive one shipment containing prepared meals (refrigerated, frozen and fresh) lower carbohydrate Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
214494175|NCT05690945|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
214494176|NCT05690945|DRUG|Tilesizumab|Tilesizumab will be administered by IV infusion at 200mg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
214494177|NCT06298253|BEHAVIORAL|Behavioral economics-enhanced SWAP implementation|Intervention will include behavioral nudges at baseline and over 12 months to promote use of the SWAP nutrition program for pantries.
214494178|NCT06298253|BEHAVIORAL|Basic SWAP implementation|Intervention will include basic information about the SWAP program and encouragement to obtain SWAP toolkits.
214682170|NCT02582749|DRUG|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
214682171|NCT02582749|DRUG|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
214682172|NCT02582749|RADIATION|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
214682173|NCT02815397|DRUG|Metformin|given in addition to standard of care treatment
214682174|NCT06499753|OTHER|high molecular weight HA-based artificial tears|use of high molecular weight HA-based artificial tears three times per day
214682175|NCT02518620|BIOLOGICAL|ALX-0061|Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
214682176|NCT00176566|DRUG|Lozenge Intake|of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
214682177|NCT01452074|OTHER|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, \~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
214682178|NCT01452074|OTHER|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
214371581|NCT00659490|DRUG|Naproxen|500mg oral administration
214371582|NCT00659490|DRUG|Placebo|Placebo given pre-surgery
214371583|NCT01887470|DRUG|Full dose preparation|
214494179|NCT06355063|DEVICE|CellFX® nsPFA™ Cardiac Surgery System|Adult patients presenting to the investigational center that are to undergo non-emergent concomitant cardiac surgical procedure(s), scheduled to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, ascending aortic aneurysms, or coronary artery bypass procedures with history of documented atrial fibrillation within one year prior to enrollment will be evaluated for eligibility and participation in the study.
214494180|NCT05884164|PROCEDURE|Thoracic erector spinae plane block|After induction of general Anaesthesia,a high frequency ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinal muscle and the transverse processes are identified, spinal needle will be inserted after standard skin disinfection in a caudal to cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep to the erector spinal muscle. After hydrolocalization with ml normal saline, this plane will be opened and 20 ml of 0.25 %bupivacaine will be administered for block performance
214682179|NCT05652374|DEVICE|Ialuril 50ml Prefill|50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months
214682180|NCT05652374|DRUG|Nitrofurantoin|nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
214682181|NCT00085540|DRUG|depsipeptide|Given IV
214682182|NCT03819803|BIOLOGICAL|Fecal microbiota transplantation|200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
214682183|NCT02285764|OTHER|Nutritional Supplement|Modified carbohydrate
214682184|NCT02285764|OTHER|Standard of Care|As determined by the study site
214682185|NCT01360164|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
214682186|NCT01175070|DRUG|Intravitreal injection of pegaptanib sodium|Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.
214371584|NCT01887470|DRUG|Split dose preparation|
214371585|NCT02341508|BIOLOGICAL|0.5 mg/kg Lpathomab|
214371586|NCT02341508|BIOLOGICAL|1.0 mg/kg Lpathomab|
214682187|NCT02025738|DEVICE|MAGNET APPLICATION|
214682188|NCT02025738|DEVICE|REPROGRAMING|
214371587|NCT02341508|BIOLOGICAL|3.0 mg/kg Lpathomab|
214371588|NCT02341508|BIOLOGICAL|10 mg/kg Lpathomab|
214371589|NCT02341508|BIOLOGICAL|20 mg/kg Lpathomab|
214371590|NCT02341508|OTHER|Saline solution for intravenous infusion|
214371591|NCT04196998|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
214371592|NCT04196998|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
214371593|NCT04196998|DRUG|Tenofovir alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
214371594|NCT04137354|OTHER|Intermittent placebo iron supplement|Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
214682189|NCT02025738|DEVICE|NO ACTION|
214682190|NCT02058199|DRUG|rivaroxaban|Single dose pharmacodynamic study
214682191|NCT00978445|OTHER|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
214682192|NCT03736837|DRUG|Anlotinib Plus Icotinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
214682193|NCT03124615|DRUG|Enzalutamide|Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
214682194|NCT00903461|BIOLOGICAL|EGFR Antisense DNA|"* Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~* EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
214371595|NCT04137354|OTHER|Intermittent iron supplement|Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
214371596|NCT04137354|OTHER|Placebo Vitamin A|Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
214371597|NCT04137354|OTHER|High-dose Vitamin A supplement|Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
214371598|NCT04719039|BEHAVIORAL|Restorative Yoga Internvention|Participants in the intervention group will receive links to two 60-min videos per week for 8 consecutive weeks. Each video will include a yoga practice guided by a certified yoga instructor. The intervention group is required to perform the yoga practice at least two times per week. If preferred, they can do additional sessions with the videos and record their total hours of self-practice.
214371599|NCT01375270|PROCEDURE|Glucotoxicity|Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.
214682195|NCT02380430|OTHER|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
214682196|NCT04652492|DRUG|Tislelizumab in combination with cTACE|On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
214986007|NCT05254379|DEVICE|tDCS|"tDCS is a painless brain stimulation treatment that uses direct electrical currents (at a constant, low-intensity level) to stimulate specific parts of the brain and help modulate neuronal activity. Participants will receive a series of tDCS treatments during the Intensive Outpatient Program (IOP) coupled with blood and saliva collections.~Participants will administer a stimulation session via the Soterix 1x1 tDCS mini-CT Stimulator, after being provided a single-use code to unlock the device by the research staff once proper contact quality is achieved. After the participant enters the unlock code, the screen on the device will show a timer that counts down the minutes until the end of the session. After 20 min, the device will turn off automatically and the study staff will instruct the participant to remove the headset and discard the sponges and to store safely all materials for the next session."
214682197|NCT03331172|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
214682198|NCT06693427|PROCEDURE|Peripheral Nerve Block|Femoral and Sciatic Nerve Blocks
214682199|NCT01795040|DIETARY_SUPPLEMENT|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
214986008|NCT04960267|DEVICE|Use of pre-peritoneal drainage after rTAPP|Use of pre-peritoneal drainage after rTAPP
214682200|NCT01663740|DRUG|Valganciclovir|Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
214682201|NCT01958034|DIETARY_SUPPLEMENT|Bilberry extract|
214682202|NCT04446585|DEVICE|Automated External Defibrillator (AED)|Deployment of AEDs
214371600|NCT01375270|PROCEDURE|Lipotoxicity|Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
214371601|NCT00827541|DRUG|Tigecycline|Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
214371602|NCT01171092|DRUG|bortezomib and G-CSF|"Bortezomib injection:~1.3mg/m2 11 days before and 8 days before the stem cell collection~G-CSF injection:~10mcg/kg on days -4 to day -1 once daily"
214371603|NCT04294992|DRUG|Ondansetron 8mg|Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
214371604|NCT06782919|OTHER|Trunk control training|Four sessions of biofeedback trunk movement training, provided once per week.
214371605|NCT05318924|DRUG|Ghrelin|Participants will receive an infusion that is intended to raise ghrelin level up to a steady plateau.
214371606|NCT05318924|OTHER|Placebo|Participants will receive a saline infusion as the placebo control condition.
214371607|NCT05715203|DEVICE|Pulsotonometry|Evaluation of arterial stiffness
214682203|NCT04446585|OTHER|Training in cardiopulmonary resuscitation and AED use|Residents will undergo 30-minute courses at study start and if needed during the trial period. During the course they will also be recruited as citizen responders
214682204|NCT04446585|OTHER|Activation of citizen responders|Citizen responders will be activated in case of suspected cardiac arrest through the heart runner app.
214682205|NCT05254522|OTHER|not aplicable since it is a Registry|not aplicable since it is a registry
214682206|NCT05688267|OTHER|Continuous Mobility Training|The continuous mobility training adopted 5 grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists.
214371608|NCT00520975|BIOLOGICAL|Bevacizumab|Given IV
214371609|NCT00520975|DRUG|Carboplatin|Given IV
214682207|NCT05688267|OTHER|Usual Care|Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training.
214682208|NCT04207112|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
214682209|NCT04207112|DRUG|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
214682210|NCT04207112|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
214682211|NCT04207112|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
214682212|NCT04207112|DRUG|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
214682213|NCT04207112|DRUG|Standard Drugs|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
214682214|NCT01271478|DRUG|captopril plus placebo|This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
214682215|NCT01271478|DRUG|telmisartan plus placebo|Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
214682216|NCT01271478|DRUG|Telmisartan plus Captopril|Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
214682217|NCT01271478|DRUG|Placebo|Patients in this group will receive 2 tablets of placebo (starch) twice a day.
214682218|NCT06925438|PROCEDURE|Computer-guided zygomatic implant system|Preoperative digital planning (DICOM data) to fabricate guides with metal sleeves for drill alignment
214682219|NCT06925438|PROCEDURE|free-hand zygomatic implant placement|Standard placement using sequential drills (2.8-3.6mm) under saline irrigation
214986009|NCT03581006|DIETARY_SUPPLEMENT|Low-Calorie Mediterranean Diet|Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity
214986010|NCT03581006|COMBINATION_PRODUCT|Technology based monitoring and behavioral participation|Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary
214371610|NCT00520975|DRUG|Paclitaxel|Given IV
214371611|NCT00520975|OTHER|Placebo|Given IV
214371612|NCT00520975|BIOLOGICAL|Trastuzumab|Given IV
214371613|NCT01548430|DRUG|TTP4000|
214371614|NCT01548430|DRUG|Placebo|
214371615|NCT03268239|DEVICE|Additional MRI sequences|"Due to the participation in the study, the following sequences are added to the imaging protocol:~* 3D T1 GRE after injection (Gradient-Recalled Echo)~* 3D T1 TSE before injection (Turbo Spin Echo)~* 3D fGATIR PSIR after injection (fast Gray Matter Acquisition T1 Inversion Recovery Phase-Sensitive Inversion Recovery)~Sequences will be performed in a random order to avoid the bias induced by different time intervals between injection and acquisition."
214371616|NCT03384264|OTHER|Physical activity|The suspension device was securely attached to a fixed beam. The suspension programme included an initial 10 min warm-up with very low-intensity joint mobility exercises. The central part of the program had a duration of 40 min and included six exercises in which the level of intensity was based on the inclination of the body. The exercises were performed in a split routine, alternating by segment to prevent joint overload. Finally, participants performed 10 minutes of stretching.
214371617|NCT05476055|GENETIC|NGS|In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
214371618|NCT03707288|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will not receive the intervention of an exercise program. The interventional group (Group B) will be asked to keep the standardised exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain, without having received any intervention.
214371619|NCT03707288|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine exercise program will be provided in a handout and given only to the intervention group (Group B), and will include simple basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study.
214682220|NCT03953638|DIAGNOSTIC_TEST|Next Generation Sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
214682221|NCT06722352|BEHAVIORAL|Palliative Care Training|Teaching about caring for individuals with
214682222|NCT03607682|PROCEDURE|Tumor Treating Fields (TTF) Therapy|Undergo TTF therapy
214682223|NCT03607682|DEVICE|NovoTTF-200A Device|Undergo TTF therapy
214682224|NCT03607682|OTHER|Quality-of-Life Assessment|Ancillary studies
214682225|NCT01770353|DRUG|Ferumoxytol|Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
214682226|NCT01770353|DRUG|MM-398|MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
214682227|NCT02202681|DEVICE|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
214682228|NCT00376688|OTHER|Laboratory Biomarker Analysis|Correlative studies
214371620|NCT04810221|OTHER|Controlled desaturation study|Measure of SpO2 and Heart Rate by BrOxy M device and reference device in a controlled desaturation study.
214682229|NCT00376688|DRUG|Temsirolimus|Given IV
214682230|NCT02556645|OTHER|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
214682231|NCT02556645|OTHER|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
214986011|NCT03581006|OTHER|Usual care group|Control group, who will receive no dietary or behavioral intervention during the trial
214986012|NCT04789122|OTHER|Attitude assessment|The study covered a representative group of 1000 people. Own questionnaire and standardized tools sent online via the Statistical Research and Analysis Office, in compliance with the privacy policy and personal data protection of the General Data Protection Regulation.
214371621|NCT03017417|OTHER|Exercise Intervention|Various exercise tests
214371622|NCT03017417|OTHER|standard of care|standard treatment
214371623|NCT00264979|PROCEDURE|Simultaneous surgery|Simultaneous surgery of colorectal cancer and synchronous liver metastases
214371624|NCT00264979|PROCEDURE|Sequential surgery|Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
214371625|NCT03642938|BEHAVIORAL|Walking Exercise|Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.
214371626|NCT03642938|BEHAVIORAL|Control|The Control group will perform 30 minutes of quiet rest.
214494181|NCT05884164|PROCEDURE|Thoracic paravertebral plane block|After induction of general Anaesthesia ,with the probe in the longitudinal paramedian position, it is then moved from medial to lateral direction to appreciate the saw tooth appearance of the facet joints close to the midline which changes to long finger-like shadow of the transverse process as the probe is moved slightly laterally. Repositioning the probe over the transverse process ensuring the space of interest is in the middle of the probe once again one should appreciate the intercostal muscles and the dense bright white line of the pleura in between the shadows of the transverse processes. The needle is then introduced at the caudal end of the probe in plane in a caudal to cranial direction aiming for the angle between the bottom of the transverse process and the pleura. Once position is confirmed, 20 ml of 0.25% bupivacaine will be administered for the block performance.
214494182|NCT00317720|DRUG|Trastuzumab|"Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose."
214371627|NCT04643925|DRUG|Ovitrelle|Ovitrelle 260 IE once daily for 8 weeks prior to IVF/ICSI
214494183|NCT00317720|DRUG|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
214494184|NCT06166836|DRUG|D1553|D1553 orally taken，600mg twice a day
214494185|NCT06166836|DRUG|IN10018（Ifebemtinib）|IN10018 orally taken once daily at approximately the same time each day
214494186|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
214682233|NCT06736483|DRUG|Dexmedetomidine|Intravenous administration of 1 µg /kg of dexmedetomidine in 10 ml of 0.9% sodium chloride at the time of incision.
214682234|NCT06736483|DRUG|Placebo administration|Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision
214682235|NCT06736483|OTHER|Face Legs Activity Cry Consolability scale|The pain will be assessed on admission and every 15 minutes until discharge from the PACU
214682236|NCT06736483|OTHER|Post-Hospitalization Behavior Questionnaire|The Post-Hospitalization Behavior Questionnaire will be completed at day 1 and at day 7
214682237|NCT06736483|OTHER|Postoperative pain measure|The Postoperative pain measure will be completed by parents at day 1, day 7, 3 months and 6 months
214986013|NCT02059837|PROCEDURE|recurrent pterygium excision and following grafting|The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
214986014|NCT03609463|BEHAVIORAL|Small change intervention|The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.
214986015|NCT03609463|BEHAVIORAL|Well-being intervention|The well-being intervention is a coaching intervention aimed at motivating people in making lifestyle changes by reducing levels of stress through the promotion of psychological well-being. It will consists in 4 weekly sessions to be held before starting the small change intervention. Each session will last about an hour and will be administered in an individual setting.
214371628|NCT01042028|DRUG|Everolimus, Cetuximab, Irinotecan|Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
214371629|NCT01042028|DRUG|Capecitabine, Oxaliplatine|Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
214371630|NCT05236946|RADIATION|Stereotactic radiosurgery/whole brain radiotherapy|SRS/ WBRT for asymptomatic brain metastases depending on the number of brain metastases
214371631|NCT05236946|DRUG|Tyrosine kinase inhibitor|TKI
214371632|NCT01925625|BIOLOGICAL|Early CDT Lung blood test|The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
214371633|NCT02671201|OTHER|Education|Different methods in education of emergency ultrasound
214371634|NCT04570917|BEHAVIORAL|Online educational intervention to reduce ageism|Participants in this group will go over multiple short videos covering the following content:1). Myths about aging, 2). Ageism and its negative effects, 3). Distorted views about aging among young adults, 4). Ageism during the COVID-19 pandemic, and 5). importance of reducing ageism among healthcare professionals. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
214371635|NCT04570917|BEHAVIORAL|Online educational intervention to enhance cultural competance|Participants in the control group will go over multiple short videos covering the following content: 1). Myths about cultural competence, 2) Cultural competence for health care professionals including dietitians, 3). Connecting culture and food, and 4). Importance of cultural competence in sports dietitians. At the end of the lesson, they will be asked to briefly write what they learned. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
214371636|NCT06273111|DRUG|5% simvastatin ointment|5% simvastatin ointment will be applied directly on IH lesion twice per day for 24 weeks
214371637|NCT05675449|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
214371638|NCT05675449|DRUG|Carfilzomib|proteasome inhibitor
214371639|NCT05675449|DRUG|Maplirpacept|CD47-SIRP alpha-directed
214371640|NCT06775834|DRUG|HRS-1893|HRS-1893 tablets.
214371641|NCT00105235|DRUG|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
214371642|NCT00105235|DRUG|Cyclosporine|Oral immunosuppressant
214371643|NCT00105235|DRUG|Mycophenolate mofetil|Oral immunosuppressant
214371644|NCT00105235|DRUG|Tacrolimus|Oral immunosuppressant
214371645|NCT00105235|PROCEDURE|Liver transplant|Occurs at study entry
214371646|NCT00105235|PROCEDURE|Immunosuppression withdrawal|Beginning no earlier than Year 1
214371647|NCT00361959|DRUG|Tiotropium bromide 18mcg|
214371648|NCT00361959|DRUG|Fluticasone propionate/ salmeterol combination 50/500mcg|
214371649|NCT03440502|PROCEDURE|spinal anaesthesia|Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine
214371650|NCT01956422|DEVICE|Continuous Positive Airway Pressure(CPAP)|
214371651|NCT01956422|DEVICE|Venturi Mask FiO2 40%|
214371652|NCT03826290|OTHER|EHR-integrated diabetes dashboard|The diabetes dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface.
214371653|NCT04340310|DIAGNOSTIC_TEST|Home respiratory polygraphy|Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission
214682238|NCT06736483|OTHER|Post-operative quality of life questionnaire|The Post-operative quality of life questionnaire pedQL will be completed at 3 and 6 months
214371654|NCT01964326|DRUG|Atorvastatin calcium 10 mg|Atorvastatin calcium 10 mg tablet to be administered orally every day
214371655|NCT01995539|BEHAVIORAL|therapy regimen|Subjects will be recommend changes in therapy regimens.
214371656|NCT05764343|OTHER|Immediate smoking cessation support|Smoker patients with chronic airway diseases (asthma and/or COPD and/or bronchiectasis) will be evaluated for the inclusion criteria. Afterwards they will be randomized as routine support arm (as the current procedure of the care) and immediate support arm (intensive brief cessation advices following by the immediate arrangement of the appointment from the same clinic's smoking cessation service). Both arms will be followed remotely at first week and third months of the randomization regarding their quit status as well as their use of evidence based cessation treatments.
215089193|NCT06103318|BEHAVIORAL|ICOgnition|"The ICOgnition intervention for breast cancer patients consists of three levels:~Level 1: Monthly assessments using FACT-Cog PCI and Cognifit. Scores \<54 (PCI) or ≤250 (Cognifit) escalate to Level 2.~Level 2: Specialized content includes Cognitive Psychoeducation, validating experiences and improving health literacy; Behavioral Guidance, offering practical strategies for daily tasks; and Embracing Cognitive Deficits, promoting self-compassion and acceptance through mindfulness and metaphors.~Level 3: Online cognitive training focuses on enhancing cognitive skills through gaming exercises, completing the comprehensive intervention approach."
214682239|NCT03466320|BIOLOGICAL|NKR-2|This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
214682240|NCT01255397|PROCEDURE|Male Infertility Protocol|"1. Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~2. Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~3. When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~4. 35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~   1. If the follicle has collapsed than IUI will be performed~  2. It the total motile sperm count is above 5 million sperm/ml then IUI will be done~  3. If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6\) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple."
214682241|NCT06738836|DRUG|[14C]-EDG-7500|Oral liquid suspension
214682242|NCT02875522|OTHER|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
214682243|NCT05574504|DRUG|avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin|"Avelumab 800 mg IV q 2 weeks (days 1,15, and 29 every 6 week cycle ) (premedication includes a H1 blocker, H2 blocker and Tylenol) Lurbinectedin 3.2 mg/m2 administered as a 1-h intravenous infusion once every 3 weeks (day 1 and 22 every 6 week cycle )~1 cycle= 6 weeks~Premedication for lurbinectedin:~* Corticosteroids (dexamethasone 8 mg intravenously or equivalent)~* Serotonin antagonists (ondansetron 8 mg intravenously or equivalent) Granulocyte-colony stimulating factor (G-CSF) or equivalent per ASCO guidelines per investigator discretion"
214682244|NCT06768268|PROCEDURE|Voluven-assisted Indocyanine green fluorescence guided sentinel lymph node biopsy for breast cancer|The procedure includes: (1) preparation of specific formula of ICG:Voluven solution (2) injection of ICG solution at subarelar area or peri-tumoral area (3) observation of fluorescent lymphatic drainage and retrieval of sentinel lymph nodes
214682245|NCT06768268|DRUG|Mannitol (20%)|Adding Mannitol into Voluven and used as solvent of ICG
214682246|NCT06801314|OTHER|aerobic exercise using cycle ergometer in addition to usual care|"aerobic exercise group):Patients in this group will be received usual care and cycle ergometer aerobic exercise Mood of exercise: continuous aerobic exercise~* Modality of exercise: cycle ergometer~* Intensity of exercise: low to moderate intensity and HR (calculated as recommended by the American College of Sports Medicine (ACSM) and tolerated up to 20-30 bpm above the resting HR), BP, SpO2 and rate of perceived exertion through the Borg Scale (10-13) will be monitor during cycling~* Duration: 15-20 min including 5 min warm up and 5 min cool down and working phase from 5-10 min~* Frequency: daily until discharge aerobic exercise group guided by wearable artificial intelligence ECG monitor to real-time support, guide and stop exercise when there is any adverse events will occur."
214682247|NCT06801314|OTHER|resisted exercise using weights and dumbbells in addition to usual care|"resisted exercise group): Patients in this group will be received usual care and resisted exercise~* Mode: resisted exercise~* Modality: dumbbells or sand bags tied around main groups of muscles for upper and lower limbs Intensity of exercise: the load that the patient can lift for 10-12 repetition at RPE of 10-13 and 1-2 sets resisted exercise group guided by wearable artificial intelligence ECG monitor to real-time support, guided and stop exercise when there is any adverse events will occur."
214682248|NCT06801314|OTHER|usual care using mobilization and breathing exercise|mobilization and breathing exercise
214682249|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
214682250|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
214682251|NCT06930430|PROCEDURE|Non-Surgical Periodontal Therapy (NSPT)|Scaling and root planing was performed using hand instruments under local anesthesia, if necessary. Oral hygiene instructions were provided using the modified Bass technique. GCF samples were collected from the same sites at baseline, 1 month, and 3 months to measure levels of IL-1β and S1P using ELISA.
214682252|NCT06929858|OTHER|cognitive-behavioral strategies training|"A structured training program focused on cognitive-behavioral strategies tailored to the challenges of caring for children with ASD. Examples include:~Techniques to manage stress (e.g., relaxation exercises). Cognitive reframing to address negative thoughts. Coping skills to enhance resilience in a demanding work environment."
214682253|NCT06929650|PROCEDURE|Radiofrequency ablation|"Radiofrequency energy is delivered to the thyroid nodule via the medical device. This device is a system consisting of 3 main components:~1. VIVA combo RF system (generator and pump)~2. single foot switch~3. electrode (5mm, 7mm, 10mm, or adjustable)."
215089194|NCT05700253|DEVICE|Cooled Radiofrequency Ablation|Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF\* CRFA; Avanos Medical).
214682254|NCT06930508|BEHAVIORAL|Patient participant screening|Patient participants will be provided with the standardized PrEP screening and initiation protocol.
214682255|NCT06930508|BEHAVIORAL|Physician participant training|Physician participants will be trained in the investigators' standardized PrEP screening and initiation protocol.
214682256|NCT06930287|OTHER|250 mg Nimbus shoe|lightweight shoe
214682257|NCT06100432|DRUG|DLBS5055 200mg|1x1 caplet
215089195|NCT05700253|DEVICE|Hyaluronic Acid Injection|Synvisc-One (\[Hylan G-F 20\]; Sanofi) will be administered as a single intra-articular dose (6 mL).
215089196|NCT02474537|DRUG|INC280|Single 200 mg dose INC280
214371657|NCT02564302|DEVICE|MUSE Headband|MUSE Headband will help patients with mindfulness.
214371658|NCT06452953|DRUG|suanzaoren decoction|The Suanzaoren decoction is a Chinese herbal formula known for nourishing the blood, calming the mind, and nourishing the heart and liver
214371659|NCT06452953|DRUG|Eszopiclone 1 mg|Eszopiclone is used in the treatment of various types of insomnia.
214371660|NCT06072222|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
214371661|NCT06072222|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
214371662|NCT06072222|DEVICE|ventilator|ventilator
214371663|NCT05886491|DRUG|GDX012|GDX012 suspension for IV infusion.
214371664|NCT05886491|DRUG|Chemotherapy Agents|Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
214371665|NCT05648968|BIOLOGICAL|Ianalumab|i.v. infusion, prepared from concentrate solution
214371666|NCT05648968|DRUG|Placebo|i.v. infusion, prepared from matching placebo
214371667|NCT04864002|OTHER|No intervention. only observational cross sectional study|No intervention done. only observational cross sectional study
214371668|NCT06573671|DIAGNOSTIC_TEST|Chitotriosidase|The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
214371669|NCT06573671|DIAGNOSTIC_TEST|Mass spectrometry|to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
214371670|NCT06573671|DIAGNOSTIC_TEST|scanning electron microscope with energy-dispersive X-ray spectroscopy|to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
214682258|NCT06100432|DRUG|Placebo DLBS5055|1x1 caplet
214682259|NCT06100432|DRUG|Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)|1x2 caplets
214682260|NCT06100432|DRUG|Placebo Multivitamin|1x2 caplets
214682261|NCT04963179|DEVICE|Womed Leaf|"Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated. It is degraded and discharged naturally through the cervix and vagina."
214682262|NCT04749862|OTHER|Online symptom reporting|Online symptom reporting questionnaire with linked self-management advice
214682263|NCT03079739|DIAGNOSTIC_TEST|fractional flow reserve|assessment with FFR in at least one coronary lesion
214986016|NCT03609463|OTHER|Treatment as usual|The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
214986017|NCT05337761|BEHAVIORAL|Peer-led training on lifejacket wear|Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters
214986018|NCT04824001|OTHER|exercise stress echocardiography|Stress echocardiography test. The standardized exercise test was conducted by 50-W semi-recumbent cycling for 3 min. Stress echocardiograph images were acquired at the third minute of cycling to ensure that subjects had reached a steady-state HR.
214986019|NCT01408069|DRUG|MIGRANE|1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
214371671|NCT06573671|DIAGNOSTIC_TEST|Fluorescence microscopy|to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
214371672|NCT06573671|DIAGNOSTIC_TEST|Transcriptomics|To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples
214682264|NCT04975269|DRUG|Acetazolamide|Target dose: 500 mg / day
214371673|NCT05609968|BIOLOGICAL|Sacituzumab Govitecan|IV infusion
214371674|NCT05609968|BIOLOGICAL|Pembrolizumab|IV infusion
214371675|NCT06831136|DRUG|Neoadjuvant Chemotherapy (NAC)|Participant will undergo 8 weeks of NAC (treating physician's choice). Possible regimens are either mFOLFIRINOX or NALIRIFOX or Gemcitabine Nab-Paclitaxel ± Cisplatin (GA+/-Cisplatin) or Capecitabine (Xeloda).
214371676|NCT06831136|DRUG|Immunotherapy (pembrolizumab)|2-12 weeks after initial chemotherapy and after the first EUS-RFA treatment, patients will receive 400 mg every 6 weeks of pembrolizumab via infusion. Participants will be administered standard of care chemotherapy and pembrolizumab every 6 weeks.
214371677|NCT06831136|DEVICE|Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)|After 2-12 weeks of chemotherapy, patients will undergo EUS-RFA treatment 1 session every 6 weeks. Each RFA treatment will be for up to 5 cycles at 30W for 20 seconds or until there is an increase in measured impedance. After the 5th EUS-RFA, if there is clinical benefit, then patients will continue with EUS-RFA treatments until no active tumor is seen. During each session, the therapeutic gastroenterologist will evaluate if there is any tumor to undergo RFA. If no active tumor seen, then will abort RFA
214371678|NCT00261495|DRUG|OROS hydromorphone HCl|8 to 32 mg once daily for 52 weeks (flexible dosing)
214371679|NCT00261495|DRUG|Oxycodone|10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
214371680|NCT01968525|BIOLOGICAL|pre-oxygen|3 min of preoxygenation before anesthesia induction.
214371681|NCT05383417|DEVICE|EndoClip|Clip attached to mid portion of the endotracheal tube.
214682265|NCT04975269|DRUG|Placebo|Placebo
214682266|NCT06541730|DRUG|DA-302168S|Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
214682267|NCT06541730|DRUG|Placebo of DA-302168S|Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
214682268|NCT04061980|DRUG|Binimetinib|Given PO
214986020|NCT01408069|DRUG|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
214986021|NCT00047762|DRUG|Erlotinib (aka Tarceva or OSI-774)|
214986022|NCT00047762|DRUG|Bevacizumab (aka Avastin or Rhu MAb VEGF)|
214371682|NCT04969835|DRUG|AVA6000|AVA6000 is a FAP-activated doxorubicin.
214494187|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
214682269|NCT04061980|DRUG|Encorafenib|Given PO
214986023|NCT05986110|PROCEDURE|A training intervention on clinical ultrasound|To train 20 primary care family doctors in clinical ultrasound so that they have greater power of resolution and allow them to limit the diagnostic and surgical times on the waiting lists of their patients.
214986024|NCT02373527|OTHER|No Fasting prior to catheterization|No restriction for oral intake
214986025|NCT04832035|OTHER|"coordinated and peer supported mental health care"|Health services, coordination of services, method to support utilization
214986026|NCT04832035|BEHAVIORAL|"standard psychotherapeutic care in the public healthcare system"|Psychotherapeutic services that are financed by the public health insurance system.
214986027|NCT02844478|BEHAVIORAL|SBP English|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.
215089197|NCT01560052|DRUG|methylprednisolone|"Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
215089198|NCT01560052|DRUG|Placebo|"Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
215089199|NCT04425785|OTHER|Physical Exercise Program|A structured exercise program
215089200|NCT04425785|BEHAVIORAL|Cognitive Behavioural Therapy|A structured cognitive behavioural therapy program
214494188|NCT05779761|BEHAVIORAL|Online, Self-Directed Health & Wellness Education Training with Coaching Support|The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
214371683|NCT06226766|DRUG|JSKN033 Injection|JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
214371684|NCT03953898|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214371685|NCT03953898|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214371686|NCT03953898|DRUG|Olaparib|Given PO
214371687|NCT05934747|DEVICE|DBS|Deep Brain Stimulation
214371688|NCT06388889|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
214371689|NCT01963338|DEVICE|Intradermal injection in the forearm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device.
214371690|NCT01963338|DEVICE|Intradermal injection in the upper arm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device in the upper arm (deltoid region).
214494189|NCT02787005|BIOLOGICAL|Pembrolizumab|Intravenous infusion
214494190|NCT04259047|BEHAVIORAL|Diabetes Regulation for Eyesight and Memory|Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.
214494191|NCT04259047|BEHAVIORAL|Enhanced Usual Care|Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
214682270|NCT04061980|BIOLOGICAL|Nivolumab|Given IV
214682271|NCT03484299|PROCEDURE|Irreversible Electroporation (IRE)|Non-thermal ablation of tumor
214682272|NCT03484299|DRUG|Gemcitabine|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
214682273|NCT03484299|DRUG|FOLFIRINOX|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
214682274|NCT04267562|DEVICE|Minitouch System|The investigational treatment (endometrial ablation) will be performed utilizing the Minitouch System
214371691|NCT01963338|DRUG|Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)|This injection is conducted by needle and syringe in the upper arm (deltoid region).
214494192|NCT04199338|OTHER|The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis|"In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test."
214986028|NCT02844478|BEHAVIORAL|SBP SPANISH|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
214986029|NCT02474186|RADIATION|Radiation therapy|Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
214986030|NCT02474186|DRUG|Xeloda|chemotherapy agent daily for two weeks
214986031|NCT02474186|DRUG|paclitaxel|chemotherapy agent weekly for two weeks
214682275|NCT06830980|DEVICE|intermittent theta burst stimulation (iTBS)|iTBS is an excitatory TMS paradigm that delivers 1800 pulses to the left dlPFC. Participants will receive 2 iTBS sessions separated by 50 minutes.
214682276|NCT06830980|DEVICE|continuous theta burst stimulation (cTBS)|cTBS is an inhibitory TMS paradigm that delivers 1800 pulses to the frontal pole. Participants will receive 2 iTBS sessions separated by 50 minutes.
214682277|NCT06830980|DEVICE|Sham TMS|Sham TMS delivered with the MagVenture B65 A/P coil
214682278|NCT06831968|DIAGNOSTIC_TEST|Enlighten|"The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results (elevated risk or low risk) at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point."
214682279|NCT06313164|DIETARY_SUPPLEMENT|enhanced glutathione|L-glutathione (in combination with tannin, low molecular weight chitosan and polyethylene glycol)
214682280|NCT06313164|OTHER|placebo comparator|placebo group
214986032|NCT02597608|BEHAVIORAL|CLP: Livelihoods|Capital for purchase of income generating asset, physical infrastructure (plinths, latrines, tubewells), livelihood maintenance stipend, monthly asset maintenance cost stipend, agricultural livelihood training, non-agricultural livelihood training, financial training, health and nutrition training.
214371692|NCT01373216|DRUG|Exenatide|Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
214371693|NCT04034108|PROCEDURE|Surgical intervention combined with weight-supported ambulation training|"Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months."
214494193|NCT00137800|DRUG|OSI-774 (Tarceva)|Once daily without interruption as long as there is no disease progression or serious side effects experienced.
214371694|NCT06330584|DRUG|Placebo Nasal Spray 0 mg/spray|"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0 mg midazolam/spray) in each nostril, i.e., no active compound"
214371695|NCT06330584|DRUG|Midazolam Nasal Spray 0.45 mg/spray|"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.45 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 0.9 mg"
214494194|NCT05985499|PROCEDURE|"Suturing of ileostomy using Dumpling suture method"|"Suturing of ileostomy using Dumpling suture method"
214494195|NCT05985499|PROCEDURE|Suturing of ileostomy using Traditional suture method|Suturing of ileostomy using Traditional suture method
214494196|NCT04531800|PROCEDURE|Concentrated growth factor|In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.
214494197|NCT04531800|PROCEDURE|Non-concentrated growth factor|In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
214494198|NCT01785446|DRUG|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
214494199|NCT01785446|DRUG|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
214494200|NCT06440226|BEHAVIORAL|Eye Movement Technique|Participants were instructed to move their eyes as much as possible with their eyes closed just before falling asleep. This technique aimed to mimic the Rapid Eye Movement (REM) sleep phase, which is often associated with more vivid and memorable dreams.
214682281|NCT05396456|PROCEDURE|Muscle Fiber Fragment (MFF) Injections|The participant will be treated with an injection of muscle fiber fragments into the external anal sphincter at 3, 6, 9 and 12 o'clock using a 21-gauge needle to a depth of 1-2 cm from the external skin using equal amounts in each quadrant.
214682282|NCT05938738|DEVICE|PEP-buddy|PEP-buddy
214682283|NCT03920410|OTHER|serotonergic stimulation|Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.
214682284|NCT03920410|OTHER|no serotonergic stimulation|Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
214682285|NCT05885997|BEHAVIORAL|Supported HBPM program plus multifaceted implementation strategy|"Supported HBPM Program:~* Patients are loaned a wireless home BP device or use their own device~* Navigator or app support for onboarding and engaging patients in HBPM~* Nursing or app support for monitoring and triaging home BP data for extreme readings~* EHR integration of order for program and home BP data, with weekly feedback of home BP results to clinicians within the EHR~Multifaceted implementation strategy:~* Clinician education about the benefits of the program as well as training in how to refer and manage patients who are enrolled~* Prompts and reminders to increase clinician referrals~* Instructional materials for patients and clinicians~* Problem-solving meetings to tailor implementation for individual practices"
214682286|NCT05885997|OTHER|Usual care|Usual care
214371696|NCT06330584|DRUG|Midazolam Nasal Spray 0.9 mg/spray|"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.9 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 1.8 mg"
214371697|NCT05639543|DRUG|INT-787|Blinded Study Drug
214494201|NCT06440226|BEHAVIORAL|Memory Recall of Previous Night's Thoughts|Another intervention involved asking participants to recall and think about their thoughts or events from the previous night before going to sleep. This method engaged cognitive processes related to memory and reflection, potentially setting the stage for increased awareness during sleep.
214371698|NCT05639543|DRUG|Placebo|Placebo
214371699|NCT04226222|DIAGNOSTIC_TEST|TEP-TDM FDG|Semi-quantitative PET-TDM FDG Data and Texture Analysis
214371700|NCT06250491|DEVICE|Deep active rTMS with Hesed coil|This brain neurostimulation method targets the motor cortex bilaterally
214371701|NCT06250491|DEVICE|Sham rTMS with Hesed coil|This brain sham neurostimulation method targets the motor cortex bilaterally
214371702|NCT03822572|OTHER|endurance exercise|defined exercise program
214371703|NCT03822572|OTHER|control|habitual physical activity before the diagnosis
214371704|NCT06843512|OTHER|GLP-1 Medication Initiation|One visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits.
214371705|NCT05130801|DIAGNOSTIC_TEST|pHLIP® ICG NIRF imaging|"Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery).~In Phase I, we propose to investigate 4 different doses:~Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg~In Phase IIa, the researchers propose to administer selected in Phase I dose of pHLIP® ICG. In Phase IIa, the researchers propose to administer pHLIP® ICG at DL2, DL3 or DL4 at different time points prior to surgery ranging from 12-110 hours, with targeted enrollment of 12 patients. Next, the selected optimal dose and timing will be used with targeted enrollment of 28 patients. The total number of subjects in Phase IIa study is 40."
214371706|NCT03911505|BIOLOGICAL|Cipaglucosidase Alfa|Enzyme Replacement Therapy via intravenous infusion
214371707|NCT03911505|DRUG|Miglustat|Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)
214371708|NCT05181553|OTHER|Whole-food plant based diet (WFPB diet)|28-day fully controlled dietary intervention during which participants will receive a whole food plant-based diet that reflects the recommendations of Canada's Food Guide.
214371709|NCT05181553|OTHER|Standard North American diet (SAD diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the eating habits of Canadians.
214371710|NCT06202222|OTHER|rehabilitation|The patient undergoes a daily session on the cycloergometer (Am3i Ergometer). The patient is instructed to pedal at a heart rate ranging from 60% to 80% of their maximum heart rate (calculated as 220 minus their age) for a duration of 20 minutes. These sessions can be conducted with oxygen therapy for patients dependent on oxygen. The sessions are maintained until the patient is discharged from the department.
214371711|NCT06386432|BEHAVIORAL|Smartphone App-delivered Smoking Cessation Intervention|Receive access to EQQUAL-NM (Program A) intervention
214371712|NCT06386432|BEHAVIORAL|Smartphone App-delivered Smoking Cessation Intervention|Receive access to EQQUAL-NM (Program B) intervention
214371713|NCT06386432|OTHER|Health Promotion and Education|Receive text message reminders, motivational messages and prompts via SMS text messages (Program A)
214494202|NCT06440226|BEHAVIORAL|Recall of Previous Lucid Dreams|Participants were also asked to recall their lucid dreams from previous nights. This intervention seemed to activate memory and awareness related to dreaming, which significantly increased the likelihood of experiencing lucid dreams the following night.
214371714|NCT06386432|OTHER|Health Promotion and Education|Receive text message reminders, motivational messages and prompts via SMS text messages (Program B)
214371715|NCT06386432|OTHER|Biospecimen Collection|Complete at-home saliva sample collection
214371716|NCT06386432|OTHER|Questionnaire Administration|Ancillary studies
214371717|NCT01932697|DRUG|Docetaxel|Given IV
214371718|NCT01932697|RADIATION|Hyperfractionation|Undergo hyperfractionated IMRT
214371719|NCT01932697|RADIATION|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
214371720|NCT01932697|OTHER|Laboratory Biomarker Analysis|Correlative studies
214371721|NCT01932697|OTHER|Quality-of-Life Assessment|Ancillary studies
214371722|NCT05703893|DIAGNOSTIC_TEST|Supine resting (REST) and active standing (STAND)|Analysis of baroreflex sensitivity
214494203|NCT06091995|BEHAVIORAL|impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)|Evaluate the clinical impact of administering one dose of belatacept on eGFR at one-year post-transplant, patient and graft survival outcomes, graft rejection, and incidences of BK virus, EBV and CMV infections.
214494204|NCT05615623|DEVICE|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
214494205|NCT05615623|DRUG|Doxorubicin|Doxorubicin infusion
214682287|NCT05529706|OTHER|Brain Health Program|The Brain Health Program employs 1-hour/week group-based training and education regarding modifiable Alzheimer's disease dementia risk factors delivered over a 12-week period. Participants will be assigned into a group of up to 20 participants, and participants will engage the Brain Health Program collaboratively, as administered by the program content leader (instructor), while also being monitored and supported by the tech leader (in accordance with the Diabetes Prevention Program model).
214682288|NCT06796946|DRUG|Deprescription of Antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram)|Deprescription of Antidepressants Reduction or elimination of the dose of antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram) taken by patients
214682289|NCT06794437|OTHER|Questionnaire|Translate and culturally adapt the original English version of the Mobile Device Proficiency Questionnaire
214682290|NCT06249503|DRUG|platelet rich plasma|The patients hand will be facing upwards and slightly extended, the Median nerve will be identified at the inlet of the carpal tunnel. Ultrasound guided injection will be done with the use of the ulnar in-plane technique. with a 25-gage needle will be introduced from the ulnar side of the wrist between carpal tunnel and median nerve.
214371723|NCT04575935|DRUG|Chemotherapy|Receive standard of care chemotherapy
214371724|NCT04575935|PROCEDURE|Laparotomy|Undergo laparotomy
214371725|NCT04575935|PROCEDURE|Minimally Invasive Surgery|Undergo MIS
214371726|NCT04575935|OTHER|Quality-of-Life Assessment|Ancillary studies
214371727|NCT04575935|OTHER|Questionnaire Administration|Ancillary studies
214494206|NCT03652493|DRUG|Carboplatin|Tumoral evaluation every 3 cycles
214494211|NCT06032377|BEHAVIORAL|cognitive behavioral therapy for sleep, anxiety, and depression|This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.
214371728|NCT05557695|DRUG|Acalabrutinib|Acalabrutinib
214371729|NCT05064852|DRUG|Surufatinib|The study is a real-world study. According to the actual medical history of patients, the usage of Surufatinib was collected.
214371730|NCT04023864|DIETARY_SUPPLEMENT|Platycodon Grandiflorus Extract(GCWB107)|Once-daily, once a tablet, after meals, for 12 week
214371731|NCT04023864|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 week
214371732|NCT01815788|DEVICE|Use of a personal sound amplifying device = TeoFirst|
214371733|NCT02274454|DRUG|Oxytocin|Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment
214371734|NCT02274454|DRUG|Calcium|Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
214371735|NCT00234650|PROCEDURE|Colonoscopy|
214371736|NCT03649555|DRUG|[18F]-FTC-146|Two 5 mCi \[18F\]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
214371737|NCT05911568|PROCEDURE|Endovascular Stroke Treatment|Patients who receive endovascular stroke treatment when they are admitted into the hospital, as determined by their clinical care team. Endovascular stroke treatment consist of catheter-based treatment for the blood clot causing the acute ischemic stroke
214371738|NCT05911568|OTHER|Medical Management|Patients who receive MMM when they are admitted into the hospital, as determined by their clinical care team. MMM may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care. Specifically, this treatment does not involve endovascular stroke treatment.
214371739|NCT03156933|OTHER|Assessment of splicing variants|This is a biological study with primary samples without any intervention on patients.
214371740|NCT00161590|DRUG|CHOP and alemtuzumab|
214682291|NCT05695911|BEHAVIORAL|Limb Load Biofeedback Training Intervention|Loadsol data will be used to inform the EXP telehealth sessions, as the interventionist guides the participant to self-monitor their movement, problem solve movement patterns that promote asymmetrical limb loading, and create weekly action plans for improving limb load symmetry. Weekly goals will be made in the context of functional task progression over the 40-week intervention.
214682292|NCT05695911|OTHER|Attention Control|The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group. The CTL group sessions will include a review of the standard of care home-exercises, a summary of healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use, home safety).
214682293|NCT01570400|BEHAVIORAL|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
214682294|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 1|"Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
214371741|NCT06335420|DIETARY_SUPPLEMENT|Carrot juice from Yellowstone carrots cultivars|Consumption of 100 ml of carrot juice daily for 1 year
214371742|NCT06335420|DIETARY_SUPPLEMENT|Placebo juice|Consumption of 100 ml of placebo juice daily for 1 year
214682295|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 2|"Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
214682296|NCT05443672|DEVICE|Yizhun BUSMS|During the breast scanning, Yizhun BUSMS uses different color box to identify the breast lesion, and the box color indicates the risk grade of the lesion.
215089201|NCT00487643|PROCEDURE|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
215089202|NCT03897894|BEHAVIORAL|Child Friendly Space|Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
215089203|NCT04049929|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
215089204|NCT03837288|PROCEDURE|Cerclage|Cervical cerclage under effect of spinal anaesthesia
214682297|NCT02590445|DEVICE|deep brain stimulation system|
214371743|NCT06246500|OTHER|No intervention|No intervention
214371744|NCT02908308|PROCEDURE|Targeted temperature management to 33°C|Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.
214371745|NCT02908308|PROCEDURE|Standard care with early treatment of fever|Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C
214494212|NCT06032377|BEHAVIORAL|education about healthy nutrition habits and communication in older age|This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings
214494213|NCT03736564|COMBINATION_PRODUCT|68Ga-DOTATATE PET/CT|Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein. Subjects will rest for approximately 50 minutes, after which approximately a 30 minute image of subjects body will be completed via PET/CT scan.
214494214|NCT06648265|DRUG|Tranexamic Acid (Topical)|Add 250 mg of TXA per liter of Klein\&#39;s Tumescent solution for arm liposculpture
214494215|NCT06648265|DRUG|Tumescent solution with dilute lidocaine and epinephrine|Arm infiltration with traditional Klein\&#39;s tumescent solution
215089205|NCT02893124|DRUG|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
214371746|NCT05029752|DEVICE|Vendys II Device|Using the device
214371747|NCT01597830|OTHER|Mobility shoe|flat, specialized shoe
215089206|NCT00955149|DRUG|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
215089207|NCT00110487|DRUG|ERB-041|
214371748|NCT01597830|OTHER|control shoe|control shoe
214371749|NCT06378853|OTHER|no intervention|no intervention
214371750|NCT00797979|DEVICE|Skull Grip bone fixation|Skull Grip bone fixation
214371751|NCT00797979|DEVICE|sutures|Standard skull bon flap fixation, sutures
214371752|NCT03325244|OTHER|EEG monitor|sleep patterns will be monitored using EEG monitor
214494216|NCT04068506|DRUG|Gabapentin 600 mg Tab|Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
214682298|NCT00873769|DRUG|Inhaled Loxapine 10 mg|Staccato Loxapine 10 mg, single dose
214986033|NCT02597608|DIETARY_SUPPLEMENT|CLP: Nutrition|Counseling on breastfeeding and complementary feeding; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children 7-23 months dosage of 120 sachets per year; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester; identification and referral of acute malnutrition; facilitation of government campaigns on nutrition.
214986034|NCT02597608|BEHAVIORAL|Shiree: Livelihoods|Financial training; input support for livelihoods (cropping, livestock, poultry, fishing, bamboo working, small businesses, tailoring etc.); capacity building (mobilising Self Help Groups, facilitating community based organizations (CBOs), skills transfer); innovation support (market linkage and access to value chains); credit and savings groups; support in mobilizing communities to advocate for their needs.
214682299|NCT03785886|BEHAVIORAL|Walking group|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β-blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
214682300|NCT03785886|BEHAVIORAL|Chinese square dancing group|"Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study.~Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13."
214682301|NCT03785886|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
214682302|NCT03009539|BEHAVIORAL|eHealth Familias Unidas Primary Care|"The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family."
214682303|NCT05158452|PROCEDURE|Discussion|Attend a focus group
214682304|NCT02309164|PROCEDURE|Acupuncture|10 acupuncture sessions of 30 minutes each, twice a week
214682305|NCT02309164|BEHAVIORAL|Orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
214682306|NCT03151148|BIOLOGICAL|TMT Lotion|TMT product and Vegetable glycerin-Cetaphil®
214682307|NCT03151148|DRUG|Placebo Lotion|Cetaphil® moisturizing lotion and vegetable glycerin
214682308|NCT04550793|DRUG|Botulinum toxin injection|Botulinum toxin injection at affected brachialis and/or biceps brachials.
214682309|NCT01986218|DRUG|BMS-986115|
214682310|NCT05239897|DEVICE|Continuous theta burst stimulation (cTBS)|Patients assessed for postoperative delirium will be treated by consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions.
215089208|NCT00506194|DRUG|Insulin|
215089209|NCT00506194|DRUG|OAD|Gliclazide-MR, Metformin, Glimepiride
215089210|NCT04367467|OTHER|Kidney Function Test|Cystatin-C measurement
215089211|NCT01189305|BEHAVIORAL|Behavioral Couples Therapy|Behavioral Couples Therapy
214682311|NCT03338751|DIAGNOSTIC_TEST|cognitive testing with HAD (PockeTalker) First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
215089212|NCT01189305|BEHAVIORAL|Individual Drug Counseling|Individual Drug Counseling
214371753|NCT03325244|OTHER|FitBit|activity levels will be monitored
214371754|NCT02157025|DEVICE|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry|
214371755|NCT02157025|OTHER|Usual Care procedures during Humphrey perimetry for children|
214371756|NCT05340959|DEVICE|Devices: Osstell®, Periotest® and AnyCheck®.|"1. Osstell®: is a device that measure implant stability and based on resonance frequency analysis (RFA). Due to stiffness in the interface between the implant surface and the bone smart peg will vibrates accordingly. the more dense bone the higher stability, the higher frequency and higher Implant Stability Quotient (ISQ) value which is from 1-100.~2. Periotest®: is a device used to assess osseointegration of dental implants, so it measure implant stability . it is based on damping effect of implant. Showing the measurement digitally on a scale from -8 (low mobility) to 50 (high mobility) PTV units.~3. AnyCheck®: this is an implant stability meter that measures the stiffness of alveolar bone-implant interface through a tapping motion. Showing the measurement on a scale from 30 (low stability) to 85 (high stability)."
214371757|NCT01493505|DRUG|AMG 386|AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
214371758|NCT01493505|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
214371759|NCT01493505|DRUG|AMG 386 Placebo|AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
214371760|NCT01493505|DRUG|Carboplatin|Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
214682312|NCT03338751|DIAGNOSTIC_TEST|Cognitive testing without HAD First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
214371761|NCT04617548|COMBINATION_PRODUCT|tDCS and CO-OP Group|Transcranial direct current stimulation modulates the excitability of targeted brain regions, and is thought to facilitate or inhibit neuroplasticity. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
214371762|NCT06221423|DRUG|Fruquintinib Combined With TAS-102|Fruquintinib Combined With TAS-102
214371763|NCT00794638|DRUG|SyB L-0501|The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
214682313|NCT00494871|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] \>= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
214371764|NCT00794638|DRUG|Rituximab|The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
214494217|NCT06279793|DRUG|Fish Oil|"Omegaven® is a 10% fish oil emulsion with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids.~Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose.~Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL).~Timeframe: Day -1: 0.20 g fish oil/kg BW/d (the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion); intraoperative day 0: no dose; postoperative day 0: 0.20 g fish oil/kg BW/d; postoperative days 1 to max. 7): 0.20 g fish oil/kg BW/d"
214494218|NCT06279793|DRUG|Intravenous 0.9% Sodium Chloride|Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d) provided at the same timepoints as the intervention.
214494219|NCT01858285|GENETIC|Exome and/or whole genome sequencing|
214494220|NCT02496325|PROCEDURE|Ultrasound guided transperineal pudendal nerve block|Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
214494221|NCT00979121|DRUG|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
214494222|NCT00979121|DRUG|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
214494223|NCT00933257|DRUG|LACTIC ACID(ND)|Treatment duration 5 weeks
214494224|NCT03836222|DRUG|PCS499|MR tablet
214494225|NCT03836222|DRUG|Trental|comparator tablet
214494226|NCT05835570|DIAGNOSTIC_TEST|PET/CT scans|Diagnostic Test: For 68Ga-Trivehexin PET/CT, no special preparation was required. Approximately 50 min after an i.v. administration of \[68Ga\]Ga-Trivehexin with a dose of 1.85-2.22 MBq/kg, and the PET acquisition time was 2.5 min per bed.
214682314|NCT00494871|DRUG|Warfarin|Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients \>70 years and 2.0-3.0 for patients \<70 years)
214682315|NCT00494871|DRUG|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
214682316|NCT00494871|DRUG|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
214682317|NCT01908621|DRUG|G-CSF (filgrastim)|
214682318|NCT01908621|DRUG|Cytosine arabinoside + G-CSF (filgrastim)|
214682319|NCT00688168|BEHAVIORAL|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
214682320|NCT00688168|BEHAVIORAL|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
214682321|NCT00688168|BEHAVIORAL|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
214682322|NCT04543955|DRUG|Telotristat (Low-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.
214682323|NCT04543955|DRUG|Telotristat (High-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
214682324|NCT02084836|OTHER|Functional Magnetic Resonance Imaging|
214682325|NCT03544554|BEHAVIORAL|a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program|The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
215089213|NCT03946865|OTHER|Reiki Therapy|Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.
214371765|NCT06181110|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|This intervention is a non-pharmacological approach that targets various factors contributing to sleep and circadian problems. It incorporates evidence-based elements such as CBT for insomnia, IPSRT, chronotherapy, and motivation enhancement. The treatment consists of 8 sessions with 4 cross-cutting modules: case formulation, sleep and circadian education, motivational interviewing, and goal setting. Participants also receive 4 core modules addressing sleep-wake regularity, daytime functioning, correcting beliefs, and maintaining behavioral change. Additionally, 6 optional modules cater to specific sleep-wake patterns, addressing sleep efficiency, excessive time in bed, delayed/advanced sleep phase, sleep-related worry, complex sleep environments, and nightmares. Modules are delivered based on individual needs. Sessions include agenda setting, homework review, treatment content delivery, goal assignment, and session summarization.
214371766|NCT01119768|DRUG|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
214371767|NCT01119768|DRUG|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
214371768|NCT05057689|DRUG|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.
214371769|NCT05057689|DRUG|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
214371770|NCT05057689|DRUG|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
214371771|NCT00714922|PROCEDURE|PRK|Laser refractive surgery
214682326|NCT05345886|BEHAVIORAL|Hippotherapy|Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
214682327|NCT05436899|OTHER|LapSim training|Complete 4 courses, each of 12 weeks, of virtual reality simulation on LapSim surgical simulator.
214682328|NCT05436899|OTHER|LapSim exam|Completed at the beginning and at the end of each of the 4 courses the corresponding exam task.
214682329|NCT05502471|DIAGNOSTIC_TEST|Zonulin|Serum zonulin level
214682330|NCT05502471|DIAGNOSTIC_TEST|Occludin|Serum occludin level
214371772|NCT00714922|PROCEDURE|SBK|Laser refractive surgery
214371773|NCT01059643|DRUG|LY2523355|Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
214371774|NCT01059643|DRUG|pegfilgrastim|6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
214371775|NCT04360850|BEHAVIORAL|online survey|A brief survey for therapists to fill out
214682331|NCT05824845|PROCEDURE|Hip/Knee Replacement|Hip/Knee Replacement
214682332|NCT04470492|COMBINATION_PRODUCT|Doctormate®+Medical Management|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) twice daily and conventional medication for 3 months.
214682333|NCT04470492|DRUG|Medical Management|Patients will be treated with conventional medication for 3 months.
214682334|NCT06029959|DEVICE|Continuous positive airway pressure (CPAP)|Eligible participants with a diagnosis of OSA will be set up with autotitrating CPAP by the study's sleep technologist. The CPAP device includes an auto-titrator that adjusts the delivered pressure between 5 to 15 cm of water to eliminate obstructive events.
214682335|NCT06029959|BEHAVIORAL|CPAP technical support intervention|SCOUTS 3 sleep technologists (ST) will make mask type/size or device adjustments, as needed, and provide training to participants and CPAP partners to improve skills involved with mask placement and device maintenance. For participants with non-acceptance of CPAP over the first night, a standardized desensitization program will be implemented. Persistent problems with CPAP use or mask fit, or any high residual respiratory events will be discussed between the sleep technologist and the study's board-certified sleep medicine physician.
214682336|NCT06029959|BEHAVIORAL|Motivational Enhancement Therapy (MET)|In-person Motivational Enhancement Therapy (MET) sessions by a trained sleep coach will occur within a week of starting CPAP and, with permission, conducted with a CPAP partner, when available. The MET session recordings will be uploaded into the HIPAA compliant Lyssn platform for evaluation, including feedback to the sleep coach. The goal will be 5 total MET sessions, either in-person or by phone, spanning the inpatient and then outpatient settings.
214371776|NCT05254184|DRUG|Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides|administering the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab
214682337|NCT06029959|BEHAVIORAL|Mobile Health intervention|Study participants will be assisted in registering for and trained on the ResMed myAir app. Participants will also receive mobile health messages based on Self-Determination Theory.
214682338|NCT00962065|DRUG|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
214682339|NCT00962065|DRUG|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
214682340|NCT00962065|DRUG|Placebo|Matching placebo dosing with daily oral intake for 28 days
214682341|NCT02951546|DIETARY_SUPPLEMENT|Mediterranean diet|In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol \<300 mg/day, dietary fiber 25 g/day.
214682342|NCT02951546|DIETARY_SUPPLEMENT|Low fat diet|In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
214371777|NCT00886028|DRUG|Liposomal doxorubicin|"Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
214371778|NCT00886028|DRUG|Cisplatin|"Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
214371779|NCT03128866|PROCEDURE|Hemipelvectomy|Undergo hemipelvectomy
214682343|NCT02951546|OTHER|Aerobic exercise|"A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type)."
214371780|NCT03128866|DRUG|Tranexamic Acid|Given IV
214371781|NCT06425731|OTHER|Fasting|Participants (Dance for PD, in-person only) will engage in one of their routine weekly dance sessions while a portable indirect calorimeter is used for energy expenditure analysis. Before this session, participants will be asked to fast for at least 4-hours. In this way, participants in this study arm will engage in a self-controlled study design wherein they complete a 4-hour fast before engaging in an oxygen uptake assessment during their routine dance classes. During the 4-hour fasting period, participants will be asked to refrain from eating any food and drinking any beverages except for water.
214371782|NCT06425731|OTHER|No Intervention|No Intervention
214371783|NCT03525548|DRUG|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
214682344|NCT02528669|DEVICE|RX Navigait|The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
214371784|NCT03525548|DRUG|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
214494227|NCT06048055|OTHER|Transcutaneous auricular vagus nerve stimulation|Patients in this group will be treated with 12 sessions of transcutaneous auricular nerve stimulation, three sessions per week for four weeks. The stimulation of the left auricular branch of the vagus nerve will be performed by conventional transcutaneous electrical nerve stimulation (TENS) through a Gamna Duo 200 electrotherapy device with one channel and two electrodes (5mm diameter disposable adhesive stimulation electrodes). The TENS parameters will be used: 30 30-minute treatment time, a pulse width of 200 milliseconds, and a pulse frequency of 20 hertz. The intensity of stimulation will be individually adjusted according to the patient's perceptual threshold. The perceptual threshold (PT) is defined as the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. The stimulation intensity will be set at super-threshold levels, such as 200% of the patient's perceptual threshold.
214494228|NCT06048055|OTHER|selected physical therapy program|The selected physical therapy program session will be from 25 to 30 minutes, three sessions per week for four weeks. The program will be selected mainly for stretching for shortened upper limb muscles, strengthening for weak upper limb muscles, occupational therapy for hand, trunk, and pelvic control exercises, and gait training.
214682345|NCT05137522|DRUG|Chidamide combines with VP-16 and methylprednisolone|Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
214682346|NCT01823822|DIETARY_SUPPLEMENT|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
214682347|NCT01823822|DIETARY_SUPPLEMENT|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
214682348|NCT02025972|PROCEDURE|Allogeneic umbilical cord blood therapy|
214494229|NCT03759678|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
214494230|NCT02016872|DRUG|18F-FMISO|
214682349|NCT03762525|RADIATION|ECG gated CTA|"Routine care consists of a preoperative and several postoperative CTA scans. In A. The preoperative and first postoperative CTA will be replaced by ECG-gated CTA imaging and in B. the scheduled imaging will be replaced by an ECG-gated CTA.~General information: The protocol is based on the ECG gated cardiac protocol using abdominal parameter settings."
214682350|NCT03564665|DIETARY_SUPPLEMENT|400mg Magnesium Glycinate BID|400mg Magnesium Glycinate BID for 8 weeks.
214682351|NCT03564665|OTHER|Placebo|Placebo BID for 8 weeks.
214682352|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY DORSAL APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . LISTER TUBERCULA WITH 3 CM PROXIMAL AND 3 CM DISTAL IN INCISION MADE UNDER THE SKIN. 2,3 EXTENSOR COMPARTMENTS RADIAL 4. THE EXTENSON COMPARTMENT IS EARTHED TO ULNAR A AND THE WRIST JOINT CAPSULE IS REACHED. THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision ON DISTAL UNDER RADIUS metaphyseal area of 2CM. 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
214494231|NCT02016872|OTHER|PET/CT|
214371785|NCT03525548|DRUG|IVA|Participants received IVA orally once daily in the evening.
214371786|NCT03525548|DRUG|Placebo|Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
214371787|NCT03525548|DRUG|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
214371788|NCT05246449|OTHER|individualised treatment plan (VitalCare) and associated remote medical monitoring|VitalCare is a treatment plan to help in the personalisation of patient care.
214986035|NCT02597608|DIETARY_SUPPLEMENT|Shiree: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
214682353|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY VOLAR APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . İNCİSİON STARTS 2 CM RADİAL TO SCAPHOİD TUBERCULE EXTENTS ITS 3 CM PROXİMAL . AFTER PASİNG SUBCUTANEOUS TİSSUE , FCR AND RADİAL ARTERY ARE İDENTİFİED AND DİVİDED SEPERATLY THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision WİTH PASSİNG PRONATOR QUADRATUS MUSCLE , ON DISTAL UNDER 2 CENTİMETER OF RADIUS metaphyseal area . 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
214986036|NCT02597608|BEHAVIORAL|UPPR: Livelihoods|Monetary support for communities to improve infrastructure (drains, footpaths, latrines and water dwells, access to roads and markets); financing for apprenticeships; grants for small businesses; education grants for girls; grants for urban food production activities; financial training; establishment of savings and credit groups; support for communities in advocating for their needs; microcredit; improving access to health facilities; improving housing conditions; provision of plinths.
214371789|NCT06770491|DRUG|Y-3 for injection|"The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution).~Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."
214371790|NCT06770491|DRUG|Placebo|"The placebo consists of two parts: placebo (lyophilized powder) and Solvent for Y-3 for injection(concentrated solution).~Name: Placebo Strength: 0 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Solvent for Y-3 for injection Strength: 3 mL (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."
214371791|NCT04441281|PROCEDURE|Traction of the cervix for IUD insertion|Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).
214371792|NCT02032212|OTHER|EVP unflavoured|
214371793|NCT02032212|OTHER|EVP flavoured|
214371794|NCT02032212|OTHER|Nicotine inhalator|15 mg nicotine Nicorette
214371795|NCT02032212|OTHER|Conventional cigarette|
214371796|NCT03404102|DEVICE|Cu-IUD|Copper Intra-uterine device used as contraceptive method
214371797|NCT06443242|DEVICE|Low-Dose Laser Acupuncture (LLA)|The intervention utilizes the xS-998D06 semiconductor laser acupoint therapeutic device specifically designed for targeted acupoint therapy. This device is critical in delivering precise low-dose laser therapy at a controlled wavelength and power. The laser treatment is directed towards enhancing neurological function and potentially alleviating symptoms of insomnia and depression by stimulating specific acupoints associated with mental health and sleep.
214371798|NCT06443242|DEVICE|Sham Laser Acupuncture (SLA)|Sham laser acupuncture serves as a control to assess the placebo effect of the laser treatment. It involves the same procedure as LLA but uses a non-emitting laser probe. This intervention is designed to mimic the LLA setup without delivering actual laser therapy, allowing for an evaluation of the psychological and physiological effects of the placebo compared to the active laser treatment.
214371799|NCT06437236|DRUG|ondansetron|"Group A will receive ondansetron 4mg diluted in normal saline,The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block"
214494232|NCT06698978|OTHER|Simplified protocol (PS)/Conventional protocol (PC)|Complete removable denture according to the simplified protocol (PS) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the conventional protocol (PC) in period 2 (3 months).
214494233|NCT06698978|OTHER|Conventional protocol (PC)/Simplified protocol (PS)|Complete removable denture according to the conventional protocol (PC) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the simplified protocol (PS)in period 2 (3 months).
214494234|NCT06146556|PROCEDURE|catheter based ablation|electrophysiological catheter based ablation of ventricular arrhythmia
214371800|NCT06437236|DRUG|granisetron|"Group B will receive granisetron 1mg diluted in normal saline.The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block"
214371801|NCT04538365|DRUG|Triclosan 0.5 % Topical Solution|Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
214371802|NCT04538365|DRUG|propanolol|Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
214371803|NCT03889626|DRUG|Apatinib|Apatinib: 500mg qd po, q4w
214371804|NCT03889626|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-14, q3w
214371805|NCT02834637|DRUG|bivalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
214371806|NCT02834637|DRUG|nonavalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
214494235|NCT03029286|BEHAVIORAL|Usual Care Arm|Health information provided by the American Cancer Society Website
214494236|NCT03029286|BEHAVIORAL|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
214986037|NCT02597608|DIETARY_SUPPLEMENT|UPPR: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
214371807|NCT05627063|DRUG|ABSK121-NX|In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.
214371808|NCT00643123|DRUG|Allopurinol|300-600 mg/day over a 6 week period
214371809|NCT00643123|OTHER|Placebo|Inactive substance
214371810|NCT05596890|DRUG|Paclitaxel-albumin|260mg/m2, ivdrip, d1
214371811|NCT05596890|DRUG|Cisplatin|60mg/m2, ivdrip, d1
214371812|NCT05596890|DRUG|Carboplatin|AUC=4-6, ivdrip, d1
214371813|NCT05596890|DRUG|Tislelizumab|200mg, ivdrip, d1
214371814|NCT05596890|RADIATION|VMAT or IMRT|15Gy/5F (d43-d50, d57-d64), 5 times a week
214371815|NCT05596890|PROCEDURE|Esophagectomy|Minimally-invasive or open McKeown and Ivor-Lewis esophagectomy
214371816|NCT03631225|DIAGNOSTIC_TEST|Vectra|Each arm will have the Vectra test however, scores will not be provided for the Usual Care Arm until end of study (12 month time point)
214371817|NCT03117595|DRUG|Bupivacaine-fentanyl|Dosages as previously written
214371818|NCT03117595|DRUG|Bupivacaine-fentanyl morphine|Dosage as previously written
214494237|NCT06773715|DEVICE|KindVR Aqua Program|For this study, patients will be introduced to a virtual reality software program called Aqua, created by the company KindVR. This software program was designed specifically for use in pediatric patients. The software has been programmed into the Pico Neo 3 headset and provides an immersive 3D experience during which the patients explore a virtual underwater world inside a submarine with a goal of providing more color to treasure and different sea animals that they will engage with along their journey. The VR experience itself lasts approximately 15 minutes
214494238|NCT06789250|BEHAVIORAL|Internet-based cognitive behavior therapy|The intervention within this study is based on cognitive behavioral therapy principles and adapted to target harmful alcohol use and mild to moderate alcohol use disorder co-occuring with psychological symptoms of depression, anxiety, stress and/or sleeping disorder. The 10 weeks of individually tailored treatment include psycho-educational texts as well as examples and exercises supported by a therapist.
214494239|NCT06829823|DRUG|N-803 and BCG|Combination therapy N-803 plus BCG
214494240|NCT06829823|DRUG|N-803 and Gemcitabine|Combination therapy N-803 plus Gemcitabine
214494241|NCT02793492|DEVICE|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
214494242|NCT06764862|DRUG|HSK44459 dose 1|HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
214494243|NCT06764862|DRUG|HSK44459 dose 2|HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
214494244|NCT06764862|DRUG|Placebo|Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
214986038|NCT02597608|OTHER|UPPR: Control|No interventions provided.
214371819|NCT02150720|DRUG|Tranexamic Acid|1g intra-articular before closing the wound surgery
214371820|NCT02150720|DRUG|Fibrin glue|5mL intra-articular before closing the wound surgery
214371821|NCT02150720|PROCEDURE|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
214371822|NCT05929443|OTHER|END-IT intervention for nursing homes|Complex intervention, as described in the arm/group descriptions
214371823|NCT02905383|OTHER|Exercise|A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
214494245|NCT06792123|OTHER|pre-op VR application group|VR application group during preoperative process
214494246|NCT06792123|OTHER|intra-op VR application group|VR application group during intraoperative process
214494247|NCT06772142|DEVICE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation
214986039|NCT03528941|DRUG|Lamivudine|Patients who received lamivudine to prevent hepatitis B
214986040|NCT03528941|OTHER|No prophylaxis|Patients who did not receive any prophylaxis to prevent hepatitis B
214986041|NCT03889288|DEVICE|Medical device - electronic-pain killer|Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.
214986042|NCT02827526|DRUG|Ketamine|
214986043|NCT02827526|DRUG|Control|
214986044|NCT01963871|OTHER|Yoga|Twice weekly one hour sessions of Hatha Yoga for 12 weeks
214986045|NCT00382356|DRUG|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
214986046|NCT03601676|OTHER|Integration of electronic clinical decision support|Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
214986047|NCT03659630|BEHAVIORAL|MyCompass|Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.
214986048|NCT03659630|BEHAVIORAL|Comparison group|An email containing a brief text on general tips regarding mental health was sent out once a week.
214986049|NCT04443192|DRUG|ZF874|ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.
214986050|NCT04443192|DRUG|Placebo|Placebo to ZF874
214986051|NCT02421042|DRUG|Lenvatinib|5- or 10-mg single oral dose of E7080, depending on their hepatic status \[Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)\].
214986052|NCT03716960|OTHER|Pumpkin Seed Oil|This intervention consisted of 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner).
214986053|NCT03716960|OTHER|Placebo|This intervention consisted of 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
214682354|NCT06259955|OTHER|Mindfulness|In the hybrid education process, the group that received their first year education online realized their first face-to-face clinical practice this year. In the fall semester, internal medicine nursing course and practice, and in the spring semester, surgical diseases nursing course and practice. These two practice areas, which have a high tendency to make medical errors, require clinical decision-making skills and increase stress levels, constitute the beginning of clinical practice. Studies show that the most stressful period for students is the second year of their education (Alzayyat \& Al- Gamal, 2014; White, 2011; Coram, 2015). This is because their professional knowledge and skills are not yet fully developed and they are not sufficiently prepared to meet the demands for higher level knowledge and skills (Alzayyat \& Al- Gamal, 2014; Coram, 2015). Based on the results of these studies, our study group consisted of second-year students.
214682355|NCT02433210|DEVICE|ELISIO-15H|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
214371824|NCT03819582|DEVICE|EyeCee One intraocular lens|Hydrophobic aspheric monofocal intraocular lens
214371825|NCT06529666|BEHAVIORAL|Didatic Session 1: Core Foundation Course|A 45-minute foundational presentation covering key Weight Management Counseling (WMC) concepts, obesity bias, and cultural humility facilitated by a trained clinician-educator at the residency program delivered at baseline.
214371826|NCT06529666|BEHAVIORAL|The 3Ps Program|"6 email modules delivered over months 2-8). Each 3P module will allow the resident to:~(1) Prepare: Review relevant concepts and demonstration videos sent via an email to prepare for completing the VCA vignettes; (2) Practice: Respond to brief vignettes of various 5As WMC challenging scenarios by audio recording their spoken response on the VCA tool; and (3) Process: Reflect on actionable expert and crowdsourced analogue patient feedback on the quality of their responses to each VCA vignette."
214371827|NCT06529666|BEHAVIORAL|Didactic session 2|(months 8-10): This 45-minute session will discuss key barriers to WMC adoption in clinical practice using real-world cases captured from residents facilitated by a trained clinician-educator at the residency program.
214371828|NCT06529666|BEHAVIORAL|Email reinforcement|2 emails in months 10-12 covering key concepts in the preceding components.
214494248|NCT06768294|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib is a JAK1/JAK2 inhibitor approved for use in Rheumatoid Arthritis. It is under investigation for use in several inflammatory diseases, including Psoriasis and Psoriatic Arthritis, Atopic Dermatitis, Inflammatory Bowel Disease and Systemic Lupus Erythematosus, with encouraging results. As IL-6 plays a central role in CPPD inflammatory process, a broad spectrum of interleukins and other proinflammatory proteins (including interferons) could be involved. A drug that acts by blocking more than one proinflammatory cytokine could be a promising treatment for a multifaceted disease such as CPPD.
214682356|NCT02433210|DEVICE|Revaclear|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
214682357|NCT02433210|DEVICE|Optiflux|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
214682358|NCT03119038|DRUG|Bupivicaine + epinephrine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
214682359|NCT03119038|DRUG|Bupivacaine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
214682360|NCT03119038|DRUG|Ropivacaine|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
214682361|NCT03119038|DRUG|Ketorolac|Intraoperative periarticular injection of 30 mg
214986054|NCT03163966|DRUG|CR6086|oral CR6086 capsules
214682362|NCT03119038|DRUG|Clonidine Injection|Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
214682363|NCT05055739|DEVICE|Rigid plate X steel wires|Compare the sternal alignment between the fixation with rigid plate X steel wires.
214371829|NCT06529666|BEHAVIORAL|PowerPoint of the foundational course|Residents will receive a core foundation slides on weight management counselling
214371830|NCT06328166|PROCEDURE|Sono-guided injection with ES135|Sono-guided injection with ES135 between carpal tunnel and median nerve
214371831|NCT06328166|PROCEDURE|Sono-guided injection with placebo|Sono-guided injection with placebo between carpal tunnel and median nerve
214371832|NCT06381323|DRUG|Finerenone|All eligible subjects enter a 2-week enrollment phase and only take stable doses of controlled-release nifedipine. After completing baseline examinations, subjects with SBP \<180 and ≥140 mmHg and DBP \<120 and ≥90 mmHg enter the follow-up phase of the treatment period. Eligible subjects receive a starting dose of 20 mg qd of Finerenone. If the blood pressure is still ≥140/90 mmHg at week 4, serum potassium is \<5.0 mmol/L, and eGFR has decreased \<30% compared to baseline, the Finerenone dose is adjusted to 40 mg qd.
214682364|NCT00747890|PROCEDURE|Modified tonsillectomy|"* Tonsillectomy~* Uvulectomy~* Soft palatal resection~* Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
214682365|NCT00747890|OTHER|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
214682366|NCT03206944|DRUG|acetylsalicylic acid|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
214682367|NCT03206944|DRUG|Tomato Fruit Extract|Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
214986055|NCT03163966|DRUG|Methotrexate|oral Methotrexate tablets
214986056|NCT03163966|DRUG|Placebo|oral CR6086 Placebo capsules
214986057|NCT05813561|DRUG|DWP14012|DWP14012 40mg
214986058|NCT05094427|PROCEDURE|Preoperative fluoroscopically-guided dorsal ramus block placed by the operative neurosurgeon|Patients received bupivicaine injections delivered via 22-gauge spinal needle to the junction of the facet and transverse process or ala at multiple spinal levels (2.5-5 cc per injection of 0.25% or 0.5% bupivacaine).
214986059|NCT00110708|DRUG|Oralgam (human immunoglobulin)|
214682368|NCT04171544|DEVICE|Streamline Occipito-Cervico-Thoracic Spinal Fixation System|Spinal Fixation
214682369|NCT02731040|DRUG|Bisphosphonate|
214682370|NCT00399269|DRUG|Recombinant Human Erythropoietin alpha|
214682371|NCT03574896|OTHER|Computer model predictions of acute kidney injury|Comparison of the performances of AKIpredictor and physicians in predicting AKI stage 2 or 3 in the 7 days following ICU admission
214986060|NCT02739126|PROCEDURE|Radial EBUS biopsy|Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.
214682372|NCT02090114|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
214682373|NCT02090114|DRUG|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
214682374|NCT02090114|DRUG|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
214682375|NCT02090114|DRUG|Enzalutamide|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
214682376|NCT02782455|DRUG|Flavonoids|Daflon is administered
214986061|NCT02739126|DEVICE|Types of Radial Ultrasound probes|The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.
214371833|NCT06564844|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
214682377|NCT02782455|DRUG|CDobi|Calcium dobesylate is administered
214682378|NCT02298517|PROCEDURE|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
214682379|NCT02298517|PROCEDURE|inspiratory load equipment|Threshold and Power breathe
214682380|NCT02099916|DRUG|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
214682381|NCT02099916|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
214682382|NCT03046472|OTHER|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day."
214371834|NCT06564844|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
214371835|NCT06564844|DRUG|Carboplatin|Carboplatin IV (intravenous), Active Comparator
214371836|NCT06564844|DRUG|Cisplatin|Cisplatin IV (intravenous), Active Comparator
214682383|NCT02306772|DRUG|TP05 Coating A|One radio-labelled tablet given to subjects
214682384|NCT02306772|DRUG|TP05 Coating B|One radio-labelled tablet given to subjects
214682385|NCT03823937|OTHER|Sniffin' Sticks test and Taste strips|"Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth."
214682386|NCT00926055|DRUG|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
214682387|NCT00926055|DRUG|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
214682388|NCT04220528|DRUG|Capecitabine/Tiggio|"Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2)."
214682389|NCT01806077|DRUG|PZ-128|Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
214682390|NCT03781882|PROCEDURE|Platelet rich plasma infiltration in the wound edges|platelet rich plasma will be injected in the wound edges
214986062|NCT05100563|DRUG|50 mg naltrexone|Medication combined with twice a week psychotherapy
214986063|NCT06113978|PROCEDURE|Thoracoscopic sympathectomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathectomy.
214986064|NCT06113978|PROCEDURE|Thoracoscopic sympathotomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, who underwent thoracoscopic bilateral simultaneous sympathotomy.
214682391|NCT03781882|PROCEDURE|Closure of wound without platelet rich plasma infiltration|No infiltration of platelet rich plasma is done
214682392|NCT03018782|OTHER|Brief Pain Inventory Short Form|Brief Pain Inventory Short Form
214986065|NCT06113978|PROCEDURE|Thoracoscopic sympathetic chain clipping|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, treated by thoracoscopic bilateral simultaneous sympathetic chain clipping.
214986066|NCT06412822|OTHER|Blood sampling|Blood sampling
214986067|NCT06412822|OTHER|Urine sampling|Urine sampling
214986068|NCT00453687|DRUG|GSK233705|investigational drug
214371837|NCT06564844|DRUG|Etoposide|Etoposide IV (intravenous), Active Comparator
214371838|NCT06564844|DRUG|Pemetrexed|Pemetrexed IV (intravenous), Active Comparator
214371839|NCT06564844|DRUG|Vinorelbine|Vinorelbine IV (intravenous), Active Comparator
214371840|NCT06564844|DRUG|UFT|UFT Oral route of administration, Active Comparator
214682393|NCT00773760|OTHER|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
214682394|NCT02941107|DRUG|Rotarix (RV1)|ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P\[8\] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.
214682395|NCT02941107|DRUG|Placebo|The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
214682396|NCT02269111|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
214682397|NCT02269111|PROCEDURE|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
214682398|NCT02269111|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
214682399|NCT02269111|PROCEDURE|dynamic susceptibility contrast-enhanced magnetic resonance imaging|Undergo DSC-MRI
214682400|NCT02401750|DRUG|Oxycodone Naltrexone (a)|
214682401|NCT02401750|DRUG|Oxycodone Naltrexone (b)|
214682402|NCT02401750|DRUG|Placebo|Matches both experimental drugs
214682403|NCT01989546|DRUG|BMN 673|Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
214682404|NCT01560546|DRUG|Testosterone|50 mg/dose/day for 24 weeks
214682405|NCT01560546|DRUG|Placebo|placebo on the skin for 24 weeks
214682406|NCT01924546|OTHER|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
214682407|NCT03252704|OTHER|resistant starch (high fiber muffin top)|Muffin top contained 11 g of fiber per portion
214682408|NCT03252704|OTHER|control (low fiber muffin top)|Muffin top contained 1 g of fiber per portion
214682409|NCT00002572|BIOLOGICAL|aldesleukin|
214682410|NCT00002572|BIOLOGICAL|muromonab-CD3|
214682411|NCT00002572|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
214682412|NCT00002572|PROCEDURE|conventional surgery|
214682413|NCT00624572|DRUG|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
214682414|NCT02654704|BIOLOGICAL|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
214682415|NCT02392039|DRUG|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
214682416|NCT02392039|DRUG|Loratadine|"Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
214682417|NCT02392039|OTHER|Placebo|"Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
214682418|NCT02392039|BEHAVIORAL|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
214682419|NCT03161639|OTHER|Pulpectomies|Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
214682420|NCT01290172|DRUG|Administration of Somatostatin|"6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days."
214986069|NCT05493631|BIOLOGICAL|MG1113|MG1113 subcutaneous (SC) injection
214986070|NCT04777513|PROCEDURE|CCTA (Coronary Computed Tomography Angiography)|Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
214986071|NCT04777513|PROCEDURE|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
214986072|NCT04777513|PROCEDURE|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
214986073|NCT04777513|DEVICE|CNBP measurement|Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
214986074|NCT04777513|DEVICE|Cardiolens FFR-CT Pro|Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
214986075|NCT00896831|DRUG|L-ornithine-L-aspartate|L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
214986076|NCT00896831|DRUG|placebo|Placebo: 5 g (1 sachet) three times per day for 60 days
214371841|NCT06177158|BEHAVIORAL|oral hygiene instructions|"Standardized motivation and oral hygiene instructions regarding the tooth brushing will be demonstrated to all three groups using modified bass technique and a standardized brush, medium bristled brush with toothpaste, the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily. For interdental cleaning aids each patient will be instructed to use the suitable methods regarding the space between teeth.~clinically for each patient to ensure that the patients understood the instruction sessions. Before receiving oral hygiene instructions and motivation, the salivary sample will be collected and clinical periodontal parameters will be measured at a base line visit then, after 3 weeks, saliva will be collected and the same clinical measurements will be taken."
214371842|NCT04323956|DRUG|Cyclophosphamide|Given IV
214371843|NCT04323956|DRUG|Doxorubicin Hydrochloride|Given IV
214371844|NCT04323956|DRUG|Parsaclisib|Given PO
214371845|NCT04323956|BIOLOGICAL|Pegfilgrastim|Given SC
214371846|NCT04323956|DRUG|Polatuzumab Vedotin|Given IV
214371847|NCT04323956|DRUG|Prednisone|Given PO
214371848|NCT04323956|BIOLOGICAL|Rituximab|Given IV
214371849|NCT04323956|DRUG|Vincristine Sulfate|Given IV
214494249|NCT06768294|DRUG|Methylprednisolone (Corticosteroid)|The initial dosage of methylprednisolone may vary depending on the entity of inflammation and the patient's comorbidities. Usually in CPPD a short-term administration of methylprednisolone starts with 16 mg per day after breakfast decreasing the initial dosage in small decrements at appropriate time intervals until discontinuation, in about 2 weeks. Methylprednisolone will be given in combination with gastroprotective agents such as proton pump inhibitors.
214494250|NCT06768294|DRUG|Colchicine 1 MG Oral Tablet|1 or ½ tablet (depending on individual tolerance) daily after breakfast
214494251|NCT06768294|DRUG|Hydroxychloroquine 200 mg|1 tablet daily after lunch
214494252|NCT06768294|COMBINATION_PRODUCT|Methotrexate + Folic Acid|MTX 2.5 mg tablets, from 2 to 4 tablets (5-10mg), depending on disease severity, to be administered once weekly after dinner, always in the same day of the week. One tablet of folic acid (folina 5 mg) will be administered the day after MTX administration, after breakfast, to reduce and prevent the common side effects of MTX.
214371850|NCT05184322|DRUG|T2026|Once daily for 15 days.
214371851|NCT05184322|DRUG|Placebo|Once daily for 15 days.
214371852|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 6 weeks.
214371853|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily and titrated up in concentration to once every week during maintenance period.
214371854|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
214371855|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
214371856|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
214371857|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
214371858|NCT05184322|DRUG|T2026|Once daily for 6 weeks.
214494253|NCT06769087|DEVICE|Immediate urinary catheter removal|A urinary catheter is removed immediately after surgery and before general anesthesia wears off in the operating room.
214371859|NCT05184322|DRUG|Placebo|Once daily for 6 weeks.
214371860|NCT05184322|DRUG|T2026|Once daily to once weekly for 12 weeks.
214371861|NCT05184322|DRUG|Placebo|Once daily to once weekly for 12 weeks.
214371862|NCT02923739|BIOLOGICAL|Bevacizumab|Given IV
214371863|NCT02923739|BIOLOGICAL|Emactuzumab|Given IV
214371864|NCT02923739|OTHER|Laboratory Biomarker Analysis|Correlative studies
214371865|NCT02923739|DRUG|Paclitaxel|Given IV
214494254|NCT06769087|DEVICE|urinary catheter removal within postoperative 1day|The urethral catheter will be removed in the ward within 1 day after surgery (within 24 hours after surgery).
214371866|NCT02923739|OTHER|Pharmacological Study|Correlative studies
214371867|NCT04313959|DRUG|Ropivacaine 0.2% Injectable Solution|Single-shot ultrasound-guided erector spine plane block of 0.2% ropivacaine
214371868|NCT04313959|DRUG|Ropivacaine 0.2% + Dexamethasone|Addiction of 5 mg/ml dexamethasone in 0.2% ropivacaine solution
214371869|NCT06152042|DRUG|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
214371870|NCT02701335|DEVICE|Neural mobilization|The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.
214371871|NCT02701335|DEVICE|Gloreha device|Robotic assisted passive mobilization.
214371872|NCT02701335|DEVICE|Standardized exercise|9 exercises: active range of motion, strengthen grip and pinch
214371873|NCT02179502|DRUG|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
214371874|NCT02179502|DRUG|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
214371875|NCT02179502|DRUG|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
214371876|NCT02179502|DRUG|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
214371877|NCT06094556|DRUG|SHR-1826|dose is calculated based on the subjects' baseline weight.
214371878|NCT03471169|DRUG|Desirable TEG|"Change the type and dose of antithrombotic therapy and obtain desirable TEG results.~Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol."
214371879|NCT03471169|DRUG|Undesirable TEG|Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
214682421|NCT01290172|DRUG|Administration of placebo|"The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy."
214682422|NCT04645472|DEVICE|CT-Ultrasound|For patients with kidney stones who are planning to undergo PCNL, perform a preoperative simulated CT-ultrasound fusion examination to further clarify the condition of the kidney stones and simulate and optimize the puncture route. Apply CT- Ultrasound fusion precise positioning to guide the intraoperative PCNL puncture process.
214371880|NCT03297203|BEHAVIORAL|Blood sample|The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
214371881|NCT06412627|PROCEDURE|4°C frozen normal saline gauze|Soak two 4x4 gauze pads in 15 ml of normal saline, refrigerate at 4°C, and then apply in the oral cavity for 15 minutes before removal.
214371882|NCT03526601|DIAGNOSTIC_TEST|NT-proBNP, echocardiography|screening
214371883|NCT00243542|DRUG|ACZONE Gel, 5%|
214371884|NCT00243542|DRUG|Vehicle|
214371885|NCT02573402|DEVICE|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
214494255|NCT06768762|BEHAVIORAL|Phone Coaching|Participants will receive 11 coaching calls with a health coach. Calls will occur weekly during the first month, twice/month during months 2-3, and once/month during months 4-6. Each call is expected to last 10-15 minutes.
214494256|NCT06768762|BEHAVIORAL|Progress reports to providers|Progress reports on physical activity and program adherence will be sent to participants providers at 3 and 6 months.
214494257|NCT06768762|BEHAVIORAL|'Hear from Others' Videos|Participants will receive monthly 'Hear From Others' videos. The videos will include other adults with knee replacement discussing the challenges they have faced and strategies to overcome barriers to activity.
214494258|NCT06768762|BEHAVIORAL|Individualized Feedback|Participants will receive individualized feedback from a coach via email. The feedback will specifically focus on participant responses to the 'Apply Your Knowledge' activities and will correspond with the video lessons. Feedback will be weekly during months 1-3 and monthly during months 4-6.
214682423|NCT00244699|BEHAVIORAL|MI Alone or Plus Mindfulness-Based Skills Training|
214682424|NCT03174717|BEHAVIORAL|Music performance|residents of LTC will learn and perform songs with musicians from the community
214682425|NCT06022913|BEHAVIORAL|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
214682426|NCT05545527|DRUG|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
214682427|NCT05545527|DRUG|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
214682428|NCT05545527|DRUG|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
214682429|NCT06467305|DEVICE|continuous theta-burst stimulation (cTBS)|Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.
214682430|NCT06467305|BEHAVIORAL|Adaptation|Auditory adaptation in speech
214682431|NCT01818791|BEHAVIORAL|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
214371886|NCT02573402|DEVICE|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
214494259|NCT06768762|BEHAVIORAL|Online exercise program|MOST Energized! Online Exercise Program
214371887|NCT02623855|BEHAVIORAL|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
214371888|NCT02623855|BEHAVIORAL|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
214371889|NCT02623855|DEVICE|Pedometry|Participants will record their daily pedometry.
214371890|NCT02623855|BEHAVIORAL|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
214371891|NCT02009670|DIETARY_SUPPLEMENT|13C inulin|Oral 13C inulin
214371892|NCT02009670|OTHER|Placebo|Oral maltodextrin
214371893|NCT00883038|OTHER|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
214371894|NCT00883038|OTHER|low-fat vegetarian diet|The low-fat vegetarian diet (\~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
214371895|NCT06578884|DEVICE|877PTY|IOL implantation with 6-month follow-up period Monocular UDVA/CDVA Manifest Refraction (SPH, CYL, SEQ) Optical Biometry, Keratometry (K1, K2, AXL, ACD) IOL axis orientation determination Visual function questionnaire Glistening evaluation Tonometry Slit-Lamp examination Fundus visualization
214371896|NCT01166516|DEVICE|Treatment with HUD IBV Valve System|Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
214371897|NCT01059630|DRUG|Obinutuzumab|IV infusion.
214371898|NCT01059630|DRUG|Bendamustine|IV infusion.
214986077|NCT04908501|OTHER|Intervention|The program intervention has three focuses : the prioritization of appropriateness indicators, the automation and visualization of the prioritized indicators, and support for practice analysis groups (PAG) based on e-feedback from automated indicators
214986078|NCT03980678|DIETARY_SUPPLEMENT|Mineral Rich Algae|Lithothamnion species is rich in calcium, magnesium (Mg) and 72 other trace elements absorbed from sea-water during the organisms life. Mineral-rich 'fronds' break off from the living organism, fall to the ocean floor and are harvested (AquaminF). The mineral extract in soluble form contains \~13.1% Calcium, \~1.04% Magnesium and measurable levels of 72 other trace minerals. Following or prior to a washout period (crossover intervention), participants will consume the Aquamin Soluble equivalent of 1000mg Calcium in 250 ml of orange flavored water for a 7 day loading period.
214371899|NCT03221855|DRUG|Domperidone|Capsules 10mg orally each 8 hours for 7 days.
214371900|NCT03221855|DRUG|Placebo|Capsules 10mg orally each 8 hours for 7 days.
214371901|NCT00109044|DRUG|Escitalopram|
214371902|NCT06403579|DEVICE|virtula reality goggles|no intervention
214371903|NCT05515419|BIOLOGICAL|Allogeneic cord blood treatment|Allogeneic cord blood treatment
214371904|NCT03357614|DRUG|Sulopenem|Antibiotic therapy for complicated UTI
214371905|NCT03357614|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic therapy for complicated UTI
214371906|NCT03357614|DRUG|Ertapenem|Antibiotic therapy for complicated UTI
214986079|NCT03980678|DIETARY_SUPPLEMENT|Orange flavoured water with maltodextrin as the placebo|Following or prior to a washout period (crossover intervention), participants will consume 250 ml of orange flavoured water (containing 20mg of Calcium with maltodextrin) for a 7 day period.
214986080|NCT05267717|OTHER|Non-interventional study, all patients being tested with AG Pregnolia System to assess the values of the Cervical Stiffness|Non-interventional study,
214986081|NCT00167791|DRUG|rituximab|Rituximab 375mg/m2 IV weekly times 4 weeks
214986082|NCT01902069|DIETARY_SUPPLEMENT|Phospholean|"Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).~PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994)."
214986083|NCT01902069|DIETARY_SUPPLEMENT|Placebo|Placebo consists of rice flour
214986084|NCT02749825|DRUG|Trelstar|As labeled
214371907|NCT03357614|DRUG|Ciprofloxacin|Antibiotic therapy for complicated UTI
214371908|NCT03357614|DRUG|Amoxicillin-clavulanate|Antibiotic therapy for complicated UTI
214371909|NCT00763958|DRUG|Placebo|Placebo to match buprenorphine administered for 3 months
214371910|NCT00763958|DRUG|Buprenorphine|Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
214371911|NCT02637934|DRUG|[18F]FluorThanatrace|
214371912|NCT02637934|RADIATION|PET/CT imaging sessions|
214371913|NCT01116492|OTHER|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
214371914|NCT01116492|OTHER|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
214371915|NCT03043001|DRUG|Memantine|All the subjects will receive add-on memantine for 12 week
214371916|NCT03203655|BEHAVIORAL|CareMessage™|Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
214986085|NCT02749825|DRUG|Lupron|As labeled
214986086|NCT02749825|DRUG|Zoladex|As labeled
214986087|NCT00390715|DRUG|chemotherapy|
214986088|NCT06072482|DRUG|Avacopan|Administered orally.
214986089|NCT06072482|DRUG|Placebo|Administered orally.
214986090|NCT06072482|DRUG|Standard of Care|All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
214682432|NCT01818791|BEHAVIORAL|Making Proud Choices AND Getting To Outcomes|"In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality-i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors."
214682433|NCT04524936|DIAGNOSTIC_TEST|blood sample|
214682434|NCT00976768|DRUG|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
214682435|NCT02692820|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
214682436|NCT02692820|OTHER|Placebo Comparator|The placebo contains excipients alone in a gelatin capsule
214682437|NCT01958671|DRUG|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
214682438|NCT01958671|DRUG|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
214682439|NCT01958671|DRUG|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
214682440|NCT01958671|DRUG|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
214371917|NCT03203655|BEHAVIORAL|Control Condition|Control condition will receive an initial talk about weight loss but will not be enrolled in any program or intervention.
214371918|NCT03738202|BEHAVIORAL|Multifaceted intervention package|"Multifaceted intervention package will comprise following strategies:~1. Initial training for all workers and managers on occupational health and safety (OHS)~2. Follow-up refresher sessions every three months~3. Formation of workplace committees (including worker representatives) to draw up, agree and promote a health and safety plan that includes wet mopping, safe disposal of cotton dust, and the use of simple face masks, as well as further publicity about the risks from cotton dust.~4. Provision of adequate supplies of face masks to support the health and safety plan"
214371919|NCT04681729|DRUG|Dupilumab SAR231893|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
214986091|NCT03185078|DEVICE|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system
214986092|NCT03185078|OTHER|Placebo ESWT|In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.
214986093|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
214371920|NCT04681729|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
214371921|NCT04681729|DRUG|Non sedating H1-antihistamine|Pharmaceutical form: Tablet Route of administration: Oral
214371922|NCT00365586|DRUG|Ketoprofen Topical Patch , 20%|
214371923|NCT04772846|DRUG|Oral tablet|Oral 250mg chloroquine tablets
214371924|NCT04772846|DRUG|Placebo|Oral placebo tablets
214371925|NCT03978325|OTHER|Control|The control group will receive standard pre-operative care. This involves standard pre-operative advice and a moderate intensity preoperative exercise programme.
214371926|NCT03978325|OTHER|Exercise - HIIT Intervention|"The HIIT intervention will take the form of a supervised programme, completed for at least two weeks, up to 5 days per week preoperatively. The HIIT intervention will be performed on a cycle ergometer. Exercise sessions will be individually supervised and scheduled at a time of convenience for each participant. Each exercise session will last 40 minutes and will include warm-up, exercise training and cool-down components. Lactate threshold, measured during the baseline CPT, will be used to determine the exercise intensity.~The training protocol will prescribe 15 second intervals of exercise and passive recovery. The highest resistance reached during the baseline CPET (measured in watts) will be recorded as the peak power output (PPO). During training, participants will undergo a 5-minute warm-up at 50% PPO, followed by up to 30 minutes of HIIT with intervals of 15 seconds at 100% PPO with 15 second recovery periods at 0 watts."
214371927|NCT02470494|DEVICE|Sound amplification provided via the EarLens CHD|Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
214371928|NCT03834103|BEHAVIORAL|Self-rehabilitation program and protein supplement|"Participants follow a home-based self-rehabilitation program consisting of the realisation of a set of physical exercises using an elastic band. The exercises have to be performed 3 times a week, and are associated with a protein supplementation.~The rehabilitation follow-up by the physician is planned once a week, by phone, and with face-to-face appointments at inclusion, 6 weeks and 3 months follow-up."
214371929|NCT04995848|OTHER|Telepalliation|Telepalliation platform Telepal.dk
214682441|NCT01958671|DRUG|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
214682442|NCT01958671|DRUG|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
214682443|NCT04864535|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
214682444|NCT04813237|OTHER|n a|the participants are not subjected to any type of intervention
214682445|NCT04964024|DIAGNOSTIC_TEST|SARS-CoV-2 antibodies|Analysis of the results of the serological response to COVID-19 and/or Vaccine
214682446|NCT00914199|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
214682447|NCT03800706|DRUG|TQB2450|TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
214986094|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
214371930|NCT02535364|BIOLOGICAL|JCAR015 (CD19-targeted CAR T cells)|"Part A: Following leukapheresis and concurrent with generation of JCAR015, participants received, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.~Part B: Participants who were eligible for treatment in Part B received two IV doses of JCAR015 CAR T cells separated by 14 to 28 days. JCAR015 infusion was preceded by lymphodepleting chemotherapy with cyclophosphamide alone or cyclophosphamide + fludarabine."
214371931|NCT05357014|DIAGNOSTIC_TEST|echocardiography|evaluation of cardiac function hn children on regular heamodialysis by echocardiography
214371932|NCT00284063|PROCEDURE|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
214371933|NCT00284063|PROCEDURE|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
214494260|NCT02112214|DRUG|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
214371934|NCT00284063|PROCEDURE|MRI|Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
214371935|NCT01078857|OTHER|Skin biopsy|A 3-mm-diameter skin biopsy punch was taken at the lateral side of the distal leg and fixed in 4% paraformaldehyde overnight. Sections of 50 m perpendicular to the dermis were cut on a sliding microtome, quenched with 1% H2O2 in methanol, and blocked with 5% normal goat serum. Sections were incubated with rabbit antiserum to protein gene product 9.5 (PGP 9.5, UltraClone, Isle of Wight, UK, 1:1000) overnight. PGP 9.5 is a ubiquitin carboxyl hydrolase, which labels myelinated and unmyelinated nerve fibers in the peripheral nervous system. Sections were then incubated with biotinylated goat anti-rabbit immunoglobulin G (Vector, Burlingame, CA) for 1 h and the avidin-biotin complex (Vector) for another hour. The reaction product was demonstrated using chromogen SG (Vector).
214371936|NCT02464683|DIETARY_SUPPLEMENT|VitaminD|200 International Units (oral dose) daily of 60 days
214494261|NCT02112214|OTHER|Placebo|Placebo for bismuth-based quadruple therapy
214494262|NCT06831032|RADIATION|Adaptive radiotherapy using SBRT|Adaptive External beam radiotherapy using SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25 Gy in 5 fractions ENI to PA nodes (+ common iliac nodes)
214494263|NCT05702281|DEVICE|ReLARC|ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.
214494264|NCT06785701|PROCEDURE|Upper Gastrointestinal Endoscopy|After Entering to emergency based on time of hemetemsis and based on presentation to ER , patient will be assessed and based on hemodyamic stability patient can be taken Early/Emergent endoscopy.
214494265|NCT06248762|OTHER|Adappt|An app to support parents of children with a NDD
214494266|NCT04823650|DEVICE|COHORT A: Actigraph|The ActiGraph CentrePoint Insight Watch is a small worn activity monitor designed for documenting physical movement associated with applications in physiological monitoring.
214682448|NCT05299203|DRUG|Sapropterin dihydrochloride tablets|dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
214682449|NCT01993329|DRUG|Gefapixant 50 mg|Gefapixant 50 mg tablet administered orally
214682450|NCT01993329|DRUG|Gefapixant 300 mg|Gefapixant 300 mg tablet administered orally
214682451|NCT01993329|DRUG|Placebo to mimic 50 mg tablets|Sugar pill manufactured to mimic gefapixant 50 mg tablets
214682452|NCT01993329|DRUG|Placebo to mimic 300 mg tablets|Sugar pill manufactured to mimic gefapixant 300 mg tablets
214682453|NCT00592150|DRUG|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
214682454|NCT00592150|DRUG|Placebo|Placebo infusion for 3 hours
214682455|NCT02948777|DRUG|Evolocumab|
214682456|NCT03908138|DRUG|RDD|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
214682457|NCT03908138|DRUG|VDD|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
214682458|NCT06512818|DIETARY_SUPPLEMENT|Psiguavin|A purified guava extract will be used, enriched in psiguavin
214682459|NCT06512818|DRUG|Placebo|Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound
214682460|NCT02311478|DEVICE|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
214986095|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
214682461|NCT03242928|DRUG|AFQ056|50 mg and 100 mg tablets taken orally
214371937|NCT06479616|GENETIC|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
214494267|NCT04823650|DEVICE|Panoramic Bracelet and GENEActiv|"Panoramic Bracelet:~The Panoramic Digital Health Bracelet is a wearable inertial measurement unit intended for use by researchers and healthcare professionals for high frequency or continuous collection of physical data in home and professional healthcare settings during research studies. It includes a 3 axis accelerometer and gyroscope, as well as magnetometer, pressure, and temperature sensors. The bracelet has no interface or screen for participants to interact with.~GENEActiv:~The GENEActiv device is a wearable inertial measurement unit designed for public health research and clinical trials. The device is a circular unit with attachable wrist-bands, and has no interface or screen for participants to interact with. The GENEActiv device is FDA 510(k) exempt. The device records acceleration data and can collect data remotely for up to 1 month."
214371938|NCT02489110|BEHAVIORAL|Webnovela|
214682462|NCT03242928|DRUG|Placebo|Matching placebo tablets taken orally BID
214682463|NCT00830661|PROCEDURE|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
214494268|NCT03477175|DRUG|E7080|Oral Administration.
214494269|NCT03477175|DRUG|Comparator Drug|Per parent study.
214371939|NCT02489110|BEHAVIORAL|Information|
214682464|NCT00830661|PROCEDURE|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
214682465|NCT04531319|DIAGNOSTIC_TEST|Flow cytometric analysis|Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
214682466|NCT01099839|DRUG|ASP1941|oral
214682467|NCT01099839|DRUG|Miglitol|oral
214986096|NCT04278313|PROCEDURE|PRP - Platelet Rich Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube to leave 2.5 ml of Platelet Rich Plasma in the tube. The tube is inverted several times to suspend the platelet pellet. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
214371940|NCT02293746|DEVICE|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
214371941|NCT04766086|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
214371942|NCT04766086|BIOLOGICAL|Tetanus, diphtheria, and acellular pertussis vaccine|Tetanus, diphtheria, and acellular pertussis vaccine
214371943|NCT04766086|BIOLOGICAL|Placebo|Saline control
214371944|NCT01572025|DRUG|Dehydroepiandrosterone|"Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
214494270|NCT03477175|DRUG|Comparator Drug: Sorafenib|Per parent study.
214494271|NCT06655714|OTHER|No intervention|No intervention
214494272|NCT06631586|BIOLOGICAL|MTP-101C|MTP-101C composed of double-encapsulated freeze-dried healthy donor microbiota. The fecal microbiota is frozen in the presence of a lyoprotectant (trehalose), freeze-dried, and double encapsulated into hypromellose capsules (Lonza, Morristown, NJ). Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
214371945|NCT01572025|DRUG|Placebo|"Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
214682468|NCT05078333|OTHER|dry needle|dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
214682469|NCT05078333|DEVICE|high intensity laser therapy|High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
214682470|NCT02822339|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-030)
214682471|NCT01555112|DRUG|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
214682472|NCT02379234|OTHER|simulation|Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
214682473|NCT05915754|OTHER|Hip abductors stretching and strengthening exercises|Treatment consist of four stretches for the ITB including: ITB stretch with trunk side bend, ITB stretch with trunk side bend and upward lateral reach, trunk side bend with downward lateral reach and side lying leg adduction and Strengthening exercise plan involving the gluteal muscle groups. These exercises include clams, side-lying abduction, reverse clams and supine bridge
214371946|NCT00735865|PROCEDURE|Punctal plugs, punctal cautery|25 subjects(20 silicone punctal plugs, 5 punctal cautery) The procedure will be based on clinical indication. Randomized one eye for study. Baseline cultures of lid margin \& tarsal/inferior fornix conjunctiva obtained \& plated according to protocol
214371947|NCT00735865|PROCEDURE|Punctal Plug, Punctal thermocauterization|"Up to 5 subjects. Subjects in need of punctal occlusion(No preference for punctal thermocauterization or punctal occlusion by silicone plug). Randomize one eye to silicone punctal plug occlusion, the other eye to punctal thermocauterization.~This group ONLY, cultures will be obtained of the lid margin \& conjunctiva/inferior fornix of BOTH eyes"
214371948|NCT00735865|PROCEDURE|Silicone plug or thermodynamic hydrophobic acrylic plug|"Up to 5 subjects. Subjects in need of punctal occlusion(not preference for punctal occlusion by silicone plug or by the thermodynamic hydrophobic acrylic plug). Randomize one eye to silicone punctal plug occlusion, the other eye to acrylic punctal plug occlusion.~In this group ONLY cultures will be obtained of the lid margin and conjunctiva/inferior fornix of BOTH eyes"
214494273|NCT06631586|BIOLOGICAL|MTP-101S|MTP-101S contains identical healthy donor microbiota double encapsulated in VCaps Plus (Lonza). These capsules are also composed of hypromellose but disintegrate in the proximal small bowel. Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
214682474|NCT05915754|OTHER|Posterior oblique sling strengthening exercises|Treatment consists of treatment A plus the intervention program of POSS consisted of four different exercises utilizing activation of the POSS. The intervention program focuses on one specific exercise each week that will progress in difficulty over the 4 weeks. The equipment used in the exercise progression included a blue, latex-free, medium-resistance theraband (TB), and the final exercise of the progression will include the use of a step stool. The TB will be used to increase the activation of the latissimus dorsi while simultaneously performing lower-extremity exercise to increase gluteal muscle involvement. The exercises are to be used in the 4-week progression.
214682475|NCT05679687|DRUG|Treatment|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
214682476|NCT05817773|DEVICE|breastfeeding cradle|Mothers with postop mobile cesarean section should be breastfed with a nursing cradle for 30 minutes every 2-3 hours, even if the baby does not cry, until after mobilization (for 6 hours after coming to the service) every time the baby cries.
214494274|NCT06856031|DRUG|Optimized Treatment (OPT)|After induction therapy with intravenous vedolizumab (300 mg) at weeks 0, 2, and 6, PRO2 was assessed to determine the patient's response and an individualized treatment plan was formulated: vedolizumab was reinfused intravenously (300 mg) every 4 weeks if PRO2 was reduced by \<50% from baseline or was still in the moderately-severe active phase of PRO2.
214682477|NCT05076851|OTHER|placebo|placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
214682478|NCT05076851|DRUG|Proxalutamide|Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
214682479|NCT05804305|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue
214682480|NCT05804305|DRUG|Placebo|Placebo contained substance that has no therapeutic value.
214682481|NCT01430429|DRUG|NI-0801|
214682482|NCT05678790|OTHER|Passive Stretching|Sustained passive stretching of hamstring, tendo-achilles, and adductors 10 (30 s, with three repetitions, five times per week)
214986097|NCT04278313|PROCEDURE|PPP - Platelet Poor Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube. The prepared plasma will be transported to the procedure room. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
214986098|NCT03186664|DEVICE|Lokomat training|The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.
214986099|NCT03186664|DRUG|Sativex|"Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.~Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient."
214986100|NCT04042792|OTHER|pharmacokinetics (PK) measurement|two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
214494275|NCT06753409|DEVICE|Processed electroencephalography (pEEG) Guided General Anesthesia|"Processed electroencephalography (pEEG) can guide the optimization of anesthesia depth, potentially preventing overly deep anesthesia and, in turn, reducing the incidence of IOH and the need for vasopressors .~Depth of anesthesia will be managed based on pEEG monitoring using Entropy with a target range of 40-60."
214986101|NCT00961415|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3-week cycle
214986102|NCT00961415|DRUG|cisplatin|75mg/m2 iv on day 1 of each 3-week cycle
214494276|NCT06753409|DEVICE|Non-pEEG-Guided General Anesthesia (with blinded pEEG monitoring)|Depth of anesthesia will be managed based on clinical judgment, informed by clinical perception and vital signs.
214494277|NCT06749093|OTHER|Filtered Air (FA)|Exposure to HEPA filtered air, as a control
214682483|NCT05678790|OTHER|Mobilization|Grade four mobilizations is a stretching motion performed at the talocrural joint with anterior-posterior gliding. Mobilization was performed once a day, 6 times a day, and 5 times a week, only on both deformed feet of the older sibling
214986103|NCT00961415|DRUG|pemetrexed|500mg/m2 iv on day 1 of each 3-week cycle
214986104|NCT02424695|DRUG|Gabapentin Enacarbil (GEn)|"HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:~600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc."
214986105|NCT02424695|DRUG|Placebo|
214986106|NCT00808925|OTHER|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
214986107|NCT01560117|DRUG|Rituximab|Rituximab 375 mg/m2 i.v. every 2 months for 24 months
215089214|NCT03625752|DEVICE|Active Comparator: Active tDCS + Active TUS|Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
214494278|NCT06749093|OTHER|Wood Smoke (WS)|Wood smoke (WS) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
214494279|NCT06749093|OTHER|Diesel Exhaust (DE)|Diesel exhaust (DE) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
214494280|NCT06749093|OTHER|Diesel Exhaust and Wood Smoke (DEWS)|Combined diesel exhaust and wood smoke standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
214494281|NCT06762587|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered on the first day following the close contact's enrollment in this study. Participants weighing ≤80 kg will receive 40 mg of baloxavir marboxil, while those weighing ≥80 kg will receive 80 mg.
214494282|NCT06762587|DRUG|Oseltamivir|Oseltamivir will be administered once daily for 5 consecutive days following the close contact's enrollment in this study. Participants will receive 75 mg of oseltamivir once each day.
214494283|NCT06772350|PROCEDURE|examinations|Echo-Doppler and blood samples
214494284|NCT06776094|OTHER|One-legged-knee extensor exercise|1 hour of one-legged-knee-extensor exercise followed by 4 hours of rest
214494285|NCT06776094|PROCEDURE|Insulin infusion|"The hyperinsulinemic-euglycemic clamp is a well-established and recognized method for determining glucose uptake at a specific insulin infusion rate. It is a technique with which we have 25 years of uncomplicated experience. During the clamp, insulin (human recombinant insulin) is infused (1.42 mU/kg/min) into an arm vein (antecubital vein), while glucose (20% solution) is administered in an amount adjusted to maintain blood glucose (plasma glucose concentration) at basal levels.~The amount of insulin administered raises the participant's plasma insulin concentration (blood concentration) to approximately 100 μU/mL, which is considered within the physiological range. Blood samples are collected and analyzed continuously for glucose content, allowing for the determination of glucose uptake at the whole-body level and across the legs.~Later, these blood samples will also be analyzed for relevant metabolites and proteins, including insulin, to assess the metabolism of these substances."
214494286|NCT06776094|PROCEDURE|Muscle Biopsy Medication: Lidocaine|"During supine rest, the skin on the outer thigh, approximately 15 cm above the knee, is disinfected with chlorhexidine alcohol. Subsequently, 3-4 mL of local anesthetic (lidocaine 20 mg/mL) is administered into the skin, subcutaneous tissue, and the upper portion of the muscle using a very thin needle. A pinprick test is performed after a few minutes to ensure the anesthetic is effective.~A small incision is then made in the skin and subcutaneous tissue to allow the biopsy needle to pass through to the muscle. Using the biopsy needle, a small sample of muscle tissue (approximately 150 mg) is collected. This may cause some discomfort but is very brief (\~1-2 seconds). The needle is removed, a sterile dressing is applied, and the participant can leave the facility after completing the study.~The biopsy may result in mild muscle soreness for 2-3 days, similar to a minor muscle bruise. Regular physical activities can be resumed after the biopsy. However, it is advised to avoid swimming."
214494287|NCT06776094|OTHER|Exercise|The participants' maximal oxygen uptake is determined through a test on a cycle ergometer before the start of the experiment. The test begins with a 20-minute warm-up at two different low workloads, after which the workload is gradually increased until the predetermined cadence can no longer be maintained, or the participant indicates exhaustion. During the test, the participant's exhaled air is collected. After completing the warm-up, it typically takes between 4 and 7 minutes to complete the test.
214494288|NCT06739616|BEHAVIORAL|AUTOSIB across time|Intervention will be in place across increasing time frames.
214986108|NCT01045278|DRUG|Pegylated interferon-alfa-2b and ribavirin|Pegylated interferon-alfa-2b 1.5 microg/kg subcutaneously once weekly plus weight based ribavirin 800-1200 mg PO for a variable period depending on their HCV genotype and response to treatment.
214986109|NCT00544271|BIOLOGICAL|INFANRIX|
214986110|NCT00544271|BIOLOGICAL|BOOSTRIX|
214986111|NCT00544271|BIOLOGICAL|HAVRIX|
214986112|NCT05354934|OTHER|quetionnaire|"The questionnaire includes the following modules~* Demography and socio-economic conditions~* Screening and modalities of discovery and announcement of HIV infection~* Time and modalities of introduction of antiretroviral drugs after diagnosis~* Knowledge of HIV infection~* The perception of follow-up in the health care service~* Experiences of stigma~* Barriers to accessing care~* Periods of loss of sight and reasons for this~* Perceived health status, mental health (PHQ4), chronic illness, functional limitations~* Addictions~* Social network and support~* Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
214371949|NCT00735865|OTHER|Previous subjects with Punctal occlusion|"Up to 20 subjects(15 subjects with silicone punctal plug closure and 5 subjects with punctal closure by thermocauterization)Subjects who have previously had punctal occlusion who have symptoms and/or signs thought to be secondary to punctal occlusion.~Lid margin and conjunctiva/inferior fornix of eye with greatest sign or symptoms will be cultured/plated according to standard protocol."
214371950|NCT05285462|BEHAVIORAL|VR Pain Education|pain education delivered via VR headset, up to 12 sessions
214371951|NCT05285462|BEHAVIORAL|Usual Care Physical Therapy|Normal course of PT without influence by study team on frequency or duration
214371952|NCT03467932|DRUG|Cohort A: ORMD-0801|"Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
214371953|NCT03467932|DRUG|Placebo oral capsule|Placebo provided QHS, BID, TID
214682484|NCT05678790|OTHER|Muscle strengthening|Abdominal muscle strengthening exercises were given to both siblings once a day, 10 times a day, 5 times a week. In the supine position, the patients were asked to lie on their knees with the knees flexed. The hip extensors were trained in the prone position on the bed by resisting hip extension
214682485|NCT05678790|OTHER|Balance and Coordination|"The following exercises were applied 5 times a week, with 1o repetition once a day.~* Standing on one leg in front of the mirror,~* Tandem walking,~* Rhythmic Dynamic Stabilization,~* Swiss ball sitting (eyes open and closed),~* Counting the alphabet or numbers while marching"
214682486|NCT02834403|DRUG|L-NMMA|Nitric oxide synthase inhibitor
214682487|NCT02834403|DRUG|Docetaxel|Mitotic inhibitor, cytotoxic
214682488|NCT02834403|DRUG|Amlodipine|Long-acting calcium channel blocker
214371954|NCT03467932|DRUG|Cohort B: ORMD-0801|"Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
214371955|NCT05685992|OTHER|no intervention|no intervention
214371956|NCT06306014|DRUG|EXL01|"Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period"
214371957|NCT06306014|DRUG|EXL01|"Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period"
214371958|NCT06306014|DRUG|Placebo|"Following a at least 10-days vancomycin treatment:~Oral placebo including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period"
214371959|NCT00723099|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo umbilical cord blood transplant
214371960|NCT00723099|DRUG|Cyclophosphamide|Given IV
214371961|NCT00723099|DRUG|Cyclosporine|Given IV
214371962|NCT00723099|DRUG|Fludarabine Phosphate|Given IV
214371963|NCT00723099|OTHER|Laboratory Biomarker Analysis|Correlative studies
214682489|NCT02834403|DRUG|Pegfilgrastim|Colony-stimulating factor
214682490|NCT02834403|DRUG|Enteric-coated aspirin|non-steroidal anti-inflammatory drug
214682491|NCT02021123|DRUG|Anidulafungin 100mg single dose iv|Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
214682492|NCT02438436|DIETARY_SUPPLEMENT|simo decoction|
214682493|NCT02438436|OTHER|gum chewing|
214682494|NCT00004297|DRUG|diazepam|
214682495|NCT00004297|DRUG|lorazepam|
214986113|NCT06119529|DRUG|LY3872386|Administered either IV or SC.
214986114|NCT06119529|DRUG|Prednisone|Administered orally.
214986115|NCT06119529|DRUG|Placebo|Administered either IV or SC.
214986116|NCT00300729|DRUG|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
214986117|NCT00300729|DRUG|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
214986118|NCT01543191|DRUG|PUR118|low dose and high dose for 3 doses, BID
214371964|NCT00723099|DRUG|Mycophenolate Mofetil|Given IV or PO
214371965|NCT00723099|RADIATION|Total-Body Irradiation|Undergo TBI
214682496|NCT01157871|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
214682497|NCT01157871|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intramuscular"
214986119|NCT02912052|DRUG|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
214986120|NCT02912052|DRUG|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
214986121|NCT04410393|PROCEDURE|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
214371966|NCT00723099|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
214371967|NCT04018248|DRUG|BR101801 (Phase Ia)|Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
214682498|NCT05222347|DIETARY_SUPPLEMENT|Olive Leaf Tea|Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently \[22, 23\]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects \[24, 25\]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .
215089215|NCT03625752|DEVICE|Sham|Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
214371968|NCT04018248|DRUG|BR101801 (Phase Ib)|Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
214682499|NCT03691623|DRUG|EDP-938 Dose 1|Oral suspension for 5 days
214682500|NCT03691623|DRUG|EDP-938 Dose 2|Oral suspension for 5 days
214682501|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
214682502|NCT03691623|DRUG|EDP-938 Dose 3|Oral suspension for 5 days
214371969|NCT02693821|DRUG|Gabapentin|gabapentin 300 mg per day, orally during 30 days
214682503|NCT03691623|DRUG|EDP-938 Dose 4|Oral suspension for 5 days
214682504|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
214371970|NCT02693821|DRUG|Placebo|Placebo 300 mg per day, orally during 30 days
214371971|NCT00916461|DRUG|Minocycline|Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
214371972|NCT00916461|DRUG|Placebo|Placebo + treatment as usual.
214682505|NCT02816710|DRUG|Conbercept|Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
214682506|NCT02136823|DRUG|sugar pill|
214682507|NCT02136823|DRUG|Riluzole|
214682508|NCT02136823|DRUG|Isradipine|
214682509|NCT02136823|DRUG|Memantine|
214682510|NCT02136823|PROCEDURE|Therapeutic muscle stretching|
214682511|NCT00005999|DRUG|arsenic trioxide|
214371973|NCT02496767|DRUG|Tirasemtiv|
214371974|NCT02496767|DRUG|Placebo tablets|
214682512|NCT00273858|OTHER|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
214371975|NCT02203708|OTHER|Supportive Program for Mother with BPD (SuPMother-B).|"The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.~Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids."
214371976|NCT01939886|DRUG|Mefloquine - Artesunate|
214371977|NCT01939886|DRUG|Artemether-lumefantrine combination|
214371978|NCT01241383|DRUG|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
214682513|NCT01564290|DIETARY_SUPPLEMENT|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
214682514|NCT01564290|DRUG|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
214682515|NCT02232516|DRUG|romidepsin|Given IV
214682516|NCT02232516|DRUG|lenalidomide|Given PO
214682517|NCT02232516|OTHER|laboratory biomarker analysis|Correlative studies
214682518|NCT00824486|BEHAVIORAL|Injury prevention education (TIPP)|using TIPP materials
214682519|NCT00824486|BEHAVIORAL|Injury prevention education (safe home)|using safe home model
214682520|NCT01070550|DRUG|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
214682521|NCT03532945|DEVICE|Bioactive Glass-Ceramic Spacer|
214682522|NCT03532945|DEVICE|Titanium cage|
214682523|NCT03271931|BEHAVIORAL|Active choice|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
214682524|NCT03271931|BEHAVIORAL|Passive choice|EHR passive alert to cardiologists about prescribing a statin
214682525|NCT04794699|DRUG|IDE397|IDE397 dosed orally
214682526|NCT04794699|DRUG|Docetaxel|Intravenous infusion
214682527|NCT04794699|DRUG|Paclitaxel|Intravenous infusion
214682528|NCT04794699|DRUG|Sacituzumab govitecan|Intravenous infusion
214682529|NCT04964063|OTHER|Potassium Nitrate + Sodium Fluoride|Potassium Nitrate 5% weight/weight (w/w) and Sodium Fluoride 0.15% weight/volume (w/v) fluoride ion.
214682530|NCT00779727|PROCEDURE|Placement of drainages|
214986122|NCT04258956|DRUG|Axitinib|"Avelumab 10 mg/kg will be administered every two weeks. Avelumab is administered as a 1-hour iv infusion, diluted with 0.9% saline solution; Axitinib 5 mg should be taken orally twice daily approximately 12 hours apart with or without food. They should be swallowed whole with a glass of water. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~The duration of treatment cycle is 28 days."
214986123|NCT02841046|DEVICE|cardiac index|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.
214371979|NCT02450630|BEHAVIORAL|Strenghtened referral of children|Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated \& severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
214682531|NCT04906239|PROCEDURE|Erector Spinae Plane Block|A high-frequency ultrasound linear probe, covered with a sterile sheath, will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After showing the T 4-5 transverse process and the erector spinae muscle on top of it, a 22-gauge, 80 mm insulated quincke type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal, using the in-plane technique. When the transverse process is touched, the needle will be pulled out and after a negative aspiration test with 0.5 mL of normal saline and after the demonstration of a hypo-echogenic image and hydro dissection, a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.
214682532|NCT02021500|DRUG|ABI-007|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
215089216|NCT03255876|DIETARY_SUPPLEMENT|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
215089217|NCT03255876|DIETARY_SUPPLEMENT|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
215089218|NCT02257723|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
215089219|NCT02257723|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
215089220|NCT02257723|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
215089221|NCT02257723|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214682533|NCT03350750|DEVICE|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
214371980|NCT05680454|BIOLOGICAL|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|For Low-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.
214371981|NCT05680454|BIOLOGICAL|Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine|A 3-dose regimen administered at months 0, 2 and 6.
214494289|NCT06739616|BEHAVIORAL|AUTOSIB diminished reinforcement|Intervention will be in place with decreasing levels of reinforcement
214494290|NCT06765473|DRUG|Misoprostol|preoperative vaginal and postoperative sublingual administration of misoprostol (800 μg) to reducing the amount of blood loss during and 24 hours after CS to determine the optimum time for drug administration.
214494291|NCT04532970|BEHAVIORAL|Cessation Counseling|Two different types of smoking cessation counseling
214494292|NCT06825182|DRUG|Outpatient newly diagnosed type 2 diabetes subjects|Outpatient newly diagnosed type 2 diabetes subjects, who have signed the informed consent form, meet the inclusion and exclusion criteria, and have their demographic data collected, including height, weight, systolic and diastolic blood pressure, and calculation of the body mass index (BMI) = weight/height\^2 (kg/m\^2). Fasting and postprandial 120-minute glucose, insulin (INS), C-peptide (Cp), and glucagon (GCG) levels are measured, or an Oral Glucose Tolerance Test (OGTT) is performed, measuring glucose, INS, Cp, GCG at 0, 30, and 120 minutes, and renal function and HbA1c are tested, with eGFR calculated. Type 2 diabetes patients are treated with GLP-1RA for three months, and then the aforementioned indicators are retested to complete the study.
214494293|NCT06825182|DRUG|Inpatient newly diagnosed type 2 diabetes subjects|Demographic data are collected. Fasting and postprandial 120-minute glucose, insulin (INS), C-peptide (Cp), and glucagon (GCG) levels are measured, or an Oral Glucose Tolerance Test (OGTT) is conducted, measuring glucose, INS, Cp, GCG at 0, 30, and 120 minutes, and renal function and HbA1c are tested. During hospitalization, if hypoglycemic symptoms occur or peripheral blood glucose or continuous glucose monitoring is ≤3.9 mmol/L, immediate venous blood is drawn for glucose, GCG, adrenocorticotropic hormone (ACTH), cortisol (Cor), growth hormone (GH), and Cp testing. Patients are treated with GLP-1RA for three months, then the aforementioned indicators are retested to complete the study and hypoglycemia (including hypoglycemic clamp and hypoglycemia tests) is assessed for glucose and GCG, with additional tests for ACTH, Cor, GH, and Cp if conditions permit, to complete the study.
214494294|NCT05561673|COMBINATION_PRODUCT|GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide|Three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide administered intramuscularly in the non-dominant arm, one each at Day 1, Day 31 and Day 181.
214371982|NCT05174481|OTHER|Early warning system for emergency department overcrowding|In this study, no interventions are performed.
214371983|NCT05207930|DEVICE|GAmified HOme-based COgnitive-Nutrition training (GAHOCON)|"A home-based tablet game training, in which participants are expected to apply the nutrition knowledge they learn from the centre-based nutritional education and their cognitive functions.~Participants in the intervention group are expected to engage in the home-based training regularly during those 8 weeks. A team of registered social workers working in the elderly community centre will monitor the progress, remind, set goals, and provide supports to the participant remotely on WhatsApp."
214371984|NCT05207930|DEVICE|Centre-based online open-source cognitive games|During the 8 weeks in which the intervention group receives GAHOCON treatment, the control group will be introduced to some online open-source cognitive games (e.g. CogniFit) and are encouraged to play those games at the elderly community centre. However, the content of these games are unrelated to nutrition and the training is gamified to a less extent compared to GAHOCON. They will have free access to these online open-source cognitive games at the elderly community centre.
214371985|NCT02889133|DRUG|Iron-dextran|Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
214371986|NCT02889133|DRUG|Saline|Salt water IV - 500 mL, one pint normal saline.
214371987|NCT02889133|PROCEDURE|Blood Donation|Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
214371988|NCT02889133|PROCEDURE|24-hour PTR|"The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation."
214371989|NCT04888091|PROCEDURE|Cotton swab|Removal of the cervical mucus with a cotton swab before embryo transfer.
214371990|NCT04888091|PROCEDURE|Cannula|Removal of the cervical mucus with a cannula before embryo transfer.
214494295|NCT05561673|BIOLOGICAL|GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system|Two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
214494296|NCT05561673|BIOLOGICAL|GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system|Two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
214494297|NCT05561673|BIOLOGICAL|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
214494298|NCT05561673|BIOLOGICAL|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
214494299|NCT03593226|DRUG|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
214494300|NCT06775366|DRUG|Remimazolam|Remimazolam 6mg/kg/h was pumped intravenously for 2.5 min, Sufentanil 0.5 μg/kg and rocuronium 0.6mg/kg were injected intravenously, and endotracheal intubation was performed 3 minutes later. Remimazolam was then pumped at 1 mg/kg/h, the BIS was kept in the range of 40-60 through general anesthesia, and the remimazolam infusion rate was adjusted (0.5-3 mg/kg/h).If the BIS cannot be maintained at ≤ 60 or there are signs of potential inadequate anesthesia (such as cough, sweating, and patient movement), and the maximum infusion dose of remimazolam has been given, supplemental sedation with the remedial drug sevoflurane or propofol is used and the case is dismissed.
214494301|NCT06775366|DRUG|propofol|Propofol (2-3mg/kg), Sufentanil (0.5μg /kg), rocuronium (0.6mg/kg) were injected intravenously, and endotracheal intubation was performed for 3 minutes. Subsequently, propofol was pumped at 4-10mg/kg/h to maintain the BIS in the range of 40-60.
214494302|NCT06810921|PROCEDURE|lateral sinus lift|"A rectangular shaped osteotomy was performed using a low-speed surgical handpiece and round diamond bur, with copious cooled normal saline irrigation.~The Schneiderian membrane (SM) was gently elevatated using Frios Sinus Set elevators for implant placement"
214494303|NCT06754540|DRUG|Azacitidine (AZA)|Azacitidine 32mg/m2
214494304|NCT06814158|DRUG|Ivonescimab Combined With Chemotherapy|Ivonescimab 20mg/kg + CT Q3W, 3cycles
214494305|NCT06763887|OTHER|No Interventions|No intervention
214494306|NCT03767348|BIOLOGICAL|RP1|Genetically modified herpes simplex type 1 virus
214494307|NCT03767348|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
214494308|NCT06816160|PROCEDURE|tru-cut biopsy|needle biopsy from the tumor
214494309|NCT06037980|DRUG|Gemcitabine|◦ Gemcitabine 800 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
214494310|NCT06037980|DRUG|Nab paclitaxel|◦ Nab-paclitaxel 100 mg/mq, day 1 and 8 of 21-day cycles, for 3 cycles
214494311|NCT06037980|DRUG|Cisplatin|◦ Cisplatin 25 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
214494312|NCT06037980|PROCEDURE|Curative Surgery|Curative surgery on primary tumor
214494313|NCT06037980|DRUG|Capecitabine|1250 mg/m2 given orally twice daily on days 1 to 14 of a 3 weekly cycle for a total of 8 cycles
214494314|NCT04567680|BEHAVIORAL|Acceptance and Commitment Therapy to Improve Social Support for Veterans with PTSD|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
214494315|NCT04567680|BEHAVIORAL|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
214682534|NCT01572532|OTHER|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
214682535|NCT01849250|DRUG|Docosahexaenoic Acid|Given PO
214682536|NCT01849250|OTHER|Placebo|Given PO
214682537|NCT02772354|PROCEDURE|Radiofrequency catheter ablation|Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool
214986124|NCT02841046|DEVICE|Stroke Volume Variation|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
214682538|NCT02772354|DRUG|Metoprolol|"Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg"
214682539|NCT02772354|DRUG|Verapamil|Verapamil 20-240 mg
214371991|NCT01555801|DEVICE|submucosal injection needle ; EUS|The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
214682540|NCT02772354|DEVICE|NAVI-STAR® RMT ThermoCool|
214371992|NCT01555801|DEVICE|ordinary endosonography(EUS)|These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
214371993|NCT01440686|DRUG|Somatropin|A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
214371994|NCT01440686|DRUG|Placebo|Tablets, oral administrations
214371995|NCT03991117|BEHAVIORAL|resistance exercise|unilateral knee extensions until fatigue with varying load and speeds of contraction
214371996|NCT00405457|DRUG|Restasis, Optive Tears|Restasis and Optive Tears use twice daily more frequently if needed
214371997|NCT05278052|RADIATION|Local consolidative radiation therapy|Local consolidative radiation therapy (LCRT) to all oligo-metastatic sites in addition to primary disease site
214371998|NCT05278052|DRUG|Standard maintenance therapy as decided by the treating medical oncologist|Standard maintenance therapy/Observation
214371999|NCT05024474|OTHER|Inspiratory muscle training (IMT)|Inspiratory muscle training (IMT) at 20-50 % of maximal inspiratory pressure (MIP), 2 x 30 repetitions, twice a day for 8 weeks.
214372000|NCT05024474|OTHER|Physical exercise|A physical exercise program at least two times a week for 8 weeks. Including strength, aerobic and mobility exercises.
214372001|NCT03203109|BEHAVIORAL|Postural Assessment Scale for Stroke (PASS)|Postural Assessment Scale for Stroke (PASS)
214372002|NCT03488693|RADIATION|Radiation|Radiotherapy given
214372003|NCT03488693|OTHER|No Radiation|No radiotherapy given
214372004|NCT06222372|DRUG|Rifampin|antibiotic
214372005|NCT01587352|OTHER|Laboratory Biomarker Analysis|Correlative studies
214372006|NCT01587352|DRUG|Vorinostat|Given PO
214372007|NCT05451004|OTHER|Lymphatic Mapping with SPECT-CT|Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
214372008|NCT05451004|RADIATION|Ipsilateral and Contralateral Neck|Radiotherapy
214372009|NCT06500559|PROCEDURE|PRP injection|PRP (0.7 ml = 70 unit) will be injected submucosal disto-buccal and disto-palatal to the maxillary canine like the local anesthesia injection in group I experimental sides
214682541|NCT03174821|DEVICE|Insulin pump|Blood glucose management device
214682542|NCT05581589|PROCEDURE|Lymphadenectomy|Undergo pelvic lymph node dissection
214682543|NCT05581589|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
214682544|NCT05581589|BIOLOGICAL|Sacituzumab Govitecan|Given IV
214986125|NCT02852759|PROCEDURE|Selective Cold|The volunteers of intervention group will undergo Selective Cold treatment below 10 degree celsius to neck, supraclavicular interscapular regions for 2 hours daily for 8 weeks. The electroacupuncture is conducted by commercially available device. Hyperinsulinemic euglycemic clamp, glucose tolerance test, blood parameter measurements, and PTC-CT scans will be conducted before and after the intervention. The participants will be instructed to maintain their normal behavior and calorie intake.
214986126|NCT02852759|DEVICE|Electroacupuncture|Electroacupuncture (EA) is an add-on treatment and it is applied when starting the cold treatment at the cold treated region to patients.The device is Huatuo SDZ-II model made by Suzhou Medical Appliance Factory, China.
214986127|NCT01379612|OTHER|Ultrasonic Elastography|Non-invasive
214986128|NCT03638791|BEHAVIORAL|Exposure and response inhibition|Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder
214986129|NCT02678533|DRUG|G-CSF|D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)
214986130|NCT02678533|DRUG|Plerixafor|D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
214986131|NCT01414296|DRUG|PSMA ADC|PSMA ADC administered IV
214986132|NCT05545501|DIETARY_SUPPLEMENT|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
214986133|NCT05545501|DIETARY_SUPPLEMENT|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
214986134|NCT05545501|DIETARY_SUPPLEMENT|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
214986135|NCT02548546|DEVICE|ECHO|Imaging
214372010|NCT06500559|PROCEDURE|Combined decortication and PRP injection|Experimental sides will receive PRP injection after performing decortication. After administration of local anesthesia, two-line flap will be performed from the mesial surface of the maxillary second premolar to the distal surface of the maxillary canine Mucoperiosteal flap will be reflected in the buccal side. Two millimeters of marginal crestal bone will be held intact and using a high-speed drill and a round carbide bur (1mm diameter) under copious saline irrigation, the cortical wall will be penetrated to reach marrow spaces. Multiple perforations (10 holes for standardization) in the cortical bone will be created. The surgical site will then rinsed, and the flap will be repositioned and sutured.
214372011|NCT06251739|DRUG|Ivermectin 6 Mg Oral Tablet|A cumulative dose of 60 mg Oral Ivermectin monotherapy (12 mg/day) on five consecutive days (day 1 - day 5) for three consecutive months (180 mg in total)
214372012|NCT06251739|DRUG|Miltefosine Oral Capsule|Oral Miltefosine monotherapy for 12 weeks. 50 mg in the morning and 50 mg in the evening with meal x 84 days (Total 100 mg/day)
214372013|NCT06238141|OTHER|Expressive writing|"According to the writing prompts, online expressive writing focuses on stressful events and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.~Writing prompts are developed based on Emotional Processing Theory (EPT) and Cognitive Adaptation Theory (CAT)."
214372014|NCT06238141|OTHER|Neutral writing|According to the writing prompts, online neutral writing focuses on immediate surroundings and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.
214372015|NCT04024631|OTHER|75g glucose beverage (Glucola, Trutol, or similar brand)|Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
214372016|NCT04024631|OTHER|DXA, whole body|Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
214372017|NCT06453187|DEVICE|Urinary Bladder Matrix (UBM) sheet device for Venous Leg Ulcers|Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214372018|NCT06453187|DEVICE|Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot Ulcers|Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214372019|NCT06453187|DEVICE|AmnioExcel Plus for Venous Leg Ulcers|Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214372020|NCT06453187|DEVICE|AmnioExcel Plus for Diabetic Foot Ulcers|Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214372021|NCT06453187|PROCEDURE|Standard of Care|Participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214372022|NCT05995717|DIETARY_SUPPLEMENT|PKU UP|"PKU UP is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in children aged from one (1) to ten (10) years.~PKU UP is a neutral-flavoured, ready-to-drink, low-phenylalanine protein substitute containing a blend of glycomacropeptide (GMP) isolate, essential and non-essential amino acids, fat, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA)."
214372023|NCT05687032|DRUG|inotuzumab ozogamicin|Given IV
214372024|NCT03821337|DEVICE|repetitive Trans Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that is able to alter cortical excitability and is FDA-approved to treat Major Depressive Disorder. Magnetic fields pass unimpeded through the scalp, skull and meninges, and can directly excite cortical areas.
214682545|NCT02541838|OTHER|Muscle power|
214682546|NCT02541838|OTHER|balance perturbation|
214682547|NCT02541838|OTHER|aerobic exercise|
214682548|NCT02688842|DEVICE|Rapamycin target-eluting coronary stent systems (38mm)|
214682549|NCT03121872|PROCEDURE|Root Coverage Surgery with T-PRF|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
214682550|NCT03121872|PROCEDURE|Root Coverage Surgery with CTG|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
214986136|NCT02548546|DEVICE|ECG-gated MRA|Imaging
214986137|NCT03443648|PROCEDURE|External fixator assisted plaing|The plate length is marked on the skin. Limb reconstruction system (LRS) with one swivel clamp or Taylor Spatial frame (TSF) is used in all cases. The fixator is put in a plane parallel to that of the deformity. Two tapered pins are placed on either side of the planned osteotomy site and passed at a distance from the osteotomy so that they will not impede the subsequent internal fixation. Swivel clamps or the struts of the TSF are aligned in such a way that full correction is achieved. After osteotomy, swivel clamp is loosened and angular correction is achieved. Translation is carried out according to preoperative planning. If readjustment is required the swivel clamps or TSF struts are loosened and further correction is carried out. Once desired correction is achieved, the clamps or struts are tightened. Definitive internal fixation is carried out while external fixation holds the fragments. For internal fixation, locked T plate will be used.
214986138|NCT04502316|DEVICE|Barostim™ System|Implantation of the Barostim™ System
214986139|NCT01151436|DEVICE|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
214372025|NCT03821337|DEVICE|Sham TMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real rTMS. This type of sham has been demonstrated to be indistinguishable from real rTMS, has been well tolerated (George et al., 2010; George et al., 2014) and successfully used in other clinical trials (Borckardt et al., 2008; Arana et al., 2008). During each session of rTMS the investigators will present a series of opioid related images, including those utilized in previous studies (Garland et al., 2015; Garland \& Howard, 2014).
214372026|NCT05239741|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
214372027|NCT05239741|DRUG|Oxaliplatin|85 mg/m\^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
214372028|NCT05239741|DRUG|Leucovorin|400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
214372029|NCT05239741|DRUG|5-fluorouracil|400 mg/m\^2 given as an IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for a total dose of 2400 mg/m\^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
214372030|NCT05239741|DRUG|Irinotecan|180 mg/m\^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
214372031|NCT05239741|BIOLOGICAL|Bevacizumab|IV infusion
214494316|NCT06838052|OTHER|Strong Woman, Safe Life Training Program Supported by Laughter Yoga|The training program consists of 8 modules, each module consists of two sessions. A session will last 45 minutes. The program includes the following topics: Self-Awareness and Importance of Communication (Module 1), Stress and Coping Techniques (Module 2), Gender (Module 3), Women's Empowerment (Module 4), Violence and Its Effects on Women's Health (Module 5), Non-Violent Communication (Module 6), Combating Violence (Module 7), Psychological Health (Module 8). In addition, a laughter yoga session will be held in the second session of each module.
214494317|NCT06744569|DRUG|CU-10101|0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo
214494318|NCT06752564|BEHAVIORAL|Goal-Oriented Care Model|"The experimental group : Goal-Oriented Care (GOC) The concept of Goal-Oriented Care (GOC) was first introduced by Mold et al. in 1991, addressing the limitations of problem-oriented care, which focuses on eradicating diseases and preventing death. GOC is defined as a process of reaching a consensus on health-related goals between the healthcare team and the patient (Vermunt et al., 2017). It is based on patients' core values and priorities within a clinical context, guiding medical interventions and specific treatment decisions (Secunda et al., 2020).~Healthcare professionals using GOC aim to help patients achieve their maximum personal health potential, aligning care with individual goals. The clear direction provided by GOC fosters teamwork and interdisciplinary collaboration (Gray et al., 2020). When establishing long-term goals with patients, it is crucial to revisit and adjust these goals, considering realistic survival timelines, as time plays a vital role in goal-setting."
214986140|NCT02038192|BEHAVIORAL|Living with Hope Program|"The Living with Hope Program is based on the research team's grounded theory study Hope and Connection. The film  Connecting with Hope reflects the findings of the grounded theory study. Stories of the Present has been utilized in the team's previous research with family caregivers of persons with advanced cancer."
214986141|NCT02038192|BEHAVIORAL|Stories of the Present|Stories of the Present is a directed journaling activity in which participants write in a journal at the end of the day their challenges, hope and hope for tomorrow
214986142|NCT06462287|DRUG|Aprepitant 125 and 80Mg Oral Capsule|Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)
214986143|NCT06462287|DRUG|Placebo|Placebo:1 oral capsule time a day for 4 days
214986144|NCT05247320|DRUG|Sotalol Injection|Standard of care IV sotalol infusion for atrial arrhythmias
214986145|NCT06291363|DRUG|Esmolol Hydrochloride|Patients in the experimental group will receive esmolol during general anesthesia
214986146|NCT06291363|DRUG|Saline|Patients in the standard of care group will receive saline as placebo during general anesthesia
214986147|NCT03454035|DRUG|Ulixertinib|Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
214986148|NCT03454035|DRUG|Palbociclib|Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
215089222|NCT02257723|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
215089223|NCT04254029|DIETARY_SUPPLEMENT|MOROLSTEVER1|The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days.
215089224|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
214372032|NCT05239741|BIOLOGICAL|Cetuximab|IV infusion
214372033|NCT05464121|BEHAVIORAL|• Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.|"The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention."
214372034|NCT01351909|DRUG|Cyclophosphamide|Given PO
214372035|NCT01351909|OTHER|Laboratory Biomarker Analysis|Correlative studies
214372036|NCT01351909|DRUG|Veliparib|Given PO
214372037|NCT05369052|DRUG|contezolid acefosamil (IV)/contezolid (PO)|Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
214372038|NCT05369052|DRUG|Linezolid (IV and PO)|Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
214372039|NCT06384261|DRUG|Cusatuzumab|CD70 monoclonal antibody
214372040|NCT06384261|DRUG|Venetoclax|BCL-2 inhibitor
214372041|NCT06384261|DRUG|Azacitidine|Hypomethylating agent
214372042|NCT02729922|DEVICE|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
214372043|NCT03604406|BIOLOGICAL|Varicella Zoster Vaccine|live-attenuated vaccine to prevent herpes zoster
214682551|NCT04412954|BEHAVIORAL|Smartphone + Text Messaging with Health Coach|The program includes (1) use of a free commercially available smartphone application program for 12 months, (2) a wearable Fitbit Charge device that will be provided by the study to monitor active minutes, and (3) one 45-minute behavioral counseling session focused on healthy eating and exercise and (4) personalized text messaging for 6 months by a health coach. The health coach will not send feedback during months 6-12. The intervention will be fully self-directed in these months, as there will be no contact between the 6 months visit and 12-month visit.
214682552|NCT04775212|DRUG|Desﬂurane|compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.
214682553|NCT04775212|DRUG|Sevoflurane|Sevoflurane
214682554|NCT05208424|DIAGNOSTIC_TEST|Coronary angiography|Invasive coronary angiography
214682555|NCT03235570|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered once daily.
214682556|NCT01615224|DRUG|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
214682557|NCT04554849|OTHER|Gender dysphoria psychosocial health|Retrospective analysis of medical records
214986149|NCT00696033|DRUG|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
214986150|NCT00696033|DRUG|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
214986151|NCT00696033|DRUG|placebo|lorazépam placebo or Diazépam placebo
214986152|NCT05470504|DRUG|Pegvisomant|30 mg subcutaneously every day for 4 weeks.
214986153|NCT05469490|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT is specialize radiation that is effective for ablating tumors at primary and metastatic locations that increases antigen uptake/processing/presentation.
214986154|NCT05469490|DRUG|navoximod|A small molecule inhibitor with potent inhibition of IDO1 enzymatic activity as shown both in vitro and in vivo. As the main function of IDO1 is the regulation of acquired immune tolerance, and its expression in tumor- and dendritic cells in tumor draining lymph nodes negatively correlates with cancer prognosis and survival, navoximod-mediated IDO1 inhibition may restore immune reactivity towards tumors.
214986155|NCT05469490|DRUG|NLG802 (indoximod Prodrug)|An anti-tumor immunomodulator with the active ingredient of 1-methyl-D-tryptophan (NSC- 721782, 1-MT), which is an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that increases the bioavailability of indoximod by leveraging existing mechanisms of absorption, increasing the exposure of indoximod.
215089225|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
215089226|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
214372044|NCT03604406|OTHER|Placebo Injection|Saline solution injection
214372045|NCT03604406|BIOLOGICAL|Varicella Zoster Vaccine|non-live vaccine to prevent herpes zoster
214682558|NCT05870644|OTHER|Cycling exercise in room temperature at 25 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 25 degree Celsius.
214682559|NCT05870644|OTHER|Cycling exercise in room temperature at 34 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 34 degree Celsius.
214682560|NCT04075201|BIOLOGICAL|One dose of investigational vaccine|One dose of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd.
214682561|NCT04075201|BIOLOGICAL|One dose of control vaccine|One dose of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
214682562|NCT04075201|BIOLOGICAL|Three doses of investigational vaccine|Three doses of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd. on the schedule of month 0,1,2
214682563|NCT04075201|BIOLOGICAL|Three doses of control vaccine|Three doses of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
214682564|NCT05888428|DEVICE|MyoTrain|MyoTrain is a virtual prosthesis control training system. From a hardware perspective it consists of an Apple iPad tablet computer and an eight-channel EMG armband, based on the Element electrode platform, which interfaces with the tablet via Bluetooth™. From a software perspective, MyoTrain was developed in the cross-platform Unity 4.0 game development environment.
214682565|NCT05888428|BEHAVIORAL|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
215089227|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
214682566|NCT01525849|DEVICE|Balloon Sinus Dilation|Balloon sinus dilation using the XprESS Multi-Sinus Dilation Tool or the FinESS SInus Treatment
214682567|NCT01525849|PROCEDURE|Functional Endoscopic Sinus Surgery|Endoscopic sinus surgery, specifically, maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy
214682568|NCT05631015|OTHER|AI recongnize disease and generate recommendations|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
214682569|NCT00339183|DRUG|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
214986156|NCT04249843|DRUG|BGB-3245|administered orally (PO)
215089228|NCT01767272|DRUG|fexofenadine|fexofenadine brand name
215089229|NCT00073463|GENETIC|tgAAVCF|
215089230|NCT00763945|OTHER|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
215089231|NCT02184832|DRUG|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
215089232|NCT02184832|OTHER|Low tryptophan diet|
215089233|NCT02184832|OTHER|High tryptophan diet|
214372046|NCT02747888|GENETIC|•Referral to Genetic Counselor, if indicated|
214372047|NCT04490785|PROCEDURE|MRI|1 MRI 5 days after surgery (-1; +4 days), with intravenous administration of gadolinium
214986157|NCT04764292|DEVICE|Contrast-enhanced mammography|supplemental breast cancer screening with contrast-enhanced mammography
214372048|NCT04490785|BIOLOGICAL|Postoperative dosage of released troponin|Dosage of troponin I Hs H4, H8, H12, H24, H48, and H72 after the aortic cross-unclamping.
214372049|NCT06461338|PROCEDURE|acupuncture|Acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).
214372050|NCT06461338|PROCEDURE|Sham acupuncture|Sham acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with sham electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).
214682570|NCT00339183|DRUG|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.
214682571|NCT00793819|DRUG|silodosin|α1-adrenergic antagonist
214682572|NCT00004880|BIOLOGICAL|dendritic cell vaccine therapy|
214682573|NCT00004880|PROCEDURE|conventional surgery|
214682574|NCT00078962|BIOLOGICAL|GTI-2040|Given IV
214682575|NCT00078962|DRUG|gemcitabine hydrochloride|Given IV
214682576|NCT00078962|OTHER|laboratory biomarker analysis|Correlative studies
214372051|NCT05479604|DEVICE|SinuSonic|Handheld device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion. The device is held over the nose and creates vibrations similar to humming.
214372052|NCT05479604|DEVICE|Sham Device|Device looks exactly like study device but does not emit the same pressure or make the same noise as the study device
214372053|NCT03723343|DRUG|GP+IMRT|Gemcitabine 1000 mg/m2 intravenously, d1\&d8 +Cisplatin 80 mg/m2 intravenously, d1 21\~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
214372054|NCT03723343|DRUG|TPF+IMRT|Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1\~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1\~d521\~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
214372055|NCT05108207|OTHER|Prevention software|The software is installed on an Alcatel OneTouch Pixi-3 10 tablet and is delivered every day to each patient between 9:00 am and 8:00 pm, with nighttime pickup (8:00 pm to 09:00 am), so the patient can rest and to charge the device. The first day, a previously trained health professional delivers the tablet and trains the older adults in its use, taking 10 to 15 minutes. The day after the tablet is delivered, the same person goes to the patient's room to check if he or she has any doubts or problems with its use. Both groups are advised to use the tablet 3 times a day, at least 10 minutes each time.
214372056|NCT05108207|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
214372057|NCT05108207|OTHER|Implement a program of non-pharmacological interventions to prevent delirium|Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.
214372058|NCT04062552|OTHER|Behavioral, Psychological or Informational Intervention|Receive ENABLE palliative care information
214372059|NCT04062552|OTHER|Educational Intervention|Participate in VLC group-based learning sessions
214372060|NCT04062552|OTHER|Educational Intervention|Participate in consultation with ENABLE/TA expert
214372061|NCT04062552|PROCEDURE|Medical Examination Assessment|Undergo palliative care assessment
214372062|NCT04062552|OTHER|Quality-of-Life Assessment|Ancillary studies
214372063|NCT04062552|OTHER|Survey Administration|Complete surveys
214372064|NCT04062552|BEHAVIORAL|Telephone-Based Intervention|Receive monthly phone calls
214372065|NCT05889689|BEHAVIORAL|Relationship Smarts Plus & Mind Matters|18.5 hours long intervention that combines the Relationship Smarts Plus teen pregnancy prevention curriculum with lessons from the Mind Matters trauma-coping skills curriculum
214372066|NCT05889689|BEHAVIORAL|Relationship Smarts Plus alone|14-hour-long curriculum that addresses pregnancy prevention within the context of teaching relationship skills for young teens.
214682577|NCT00078962|OTHER|pharmacological study|Correlative studies
214682578|NCT00446446|DRUG|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
214682579|NCT05944991|OTHER|Olive oil message|Message of olive oil 2 times daily
214682580|NCT01488318|DRUG|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
214682581|NCT01488318|DRUG|Dasatinib|Dasatinib 150 mg po
214682582|NCT03421002|DRUG|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
214682583|NCT04520022|DRUG|Human Umbilical Cord Blood-derived Mesenchymal Stem Cells|3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks
214682584|NCT04912570|PROCEDURE|Manual Thrombus Aspiration|Manual thrombus aspiration using one of the FDA approved aspirators will be done.
214682585|NCT04912570|PROCEDURE|Standard PCI|Standard PCI according to the most recent guidelines
214682586|NCT00639301|BEHAVIORAL|Questionnaires|The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
214682587|NCT00003342|BIOLOGICAL|filgrastim|
214682588|NCT00003342|DRUG|carboplatin|
214682589|NCT00003342|DRUG|doxorubicin hydrochloride|
214682590|NCT00003342|DRUG|gemcitabine hydrochloride|
214682591|NCT00003342|DRUG|paclitaxel|
214682592|NCT05276713|DRUG|Tucidinostat|Tucidinostat in combination with endocrine drugs
214986158|NCT04764292|DRUG|Iodinated Contrast Media (ICM)|supplemental breast cancer screening with contrast-enhanced mammography
214986159|NCT02547831|OTHER|Observational approach|Patients will be placed under wait and see approach without any specific treatment
214682593|NCT00539630|DRUG|Docetaxel|
214682594|NCT04506606|PROCEDURE|Afferent block|Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
214682595|NCT04776291|RADIATION|4D PET-CT Scan|The recruited patients will have a 4d PET-CT scan that is additional to the usual care.
214682596|NCT05309226|OTHER|Cannabis use in pregnancy or cannabis exposure in utero|Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).
214682597|NCT03433287|DIAGNOSTIC_TEST|18F-NaF-PET/MRI|PET/MRI scan after injection of 18F-labelled sodium fluoride
214682598|NCT02806765|DIETARY_SUPPLEMENT|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol every day for 6 months
214682599|NCT02806765|OTHER|Control|Placebo in Softgel form
214682600|NCT02110134|DEVICE|Revlite Laser System with hydroquinone skin care regimen|Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma
214682601|NCT02110134|OTHER|Hydroquinone skin care regimen|Hydroquinone skin care regimen for the Treatment of Melasma
214682602|NCT03202069|OTHER|Even protein|Intake of even protein 5 day rotating menu
214682603|NCT03202069|OTHER|Skewed protein|Intake of skewed protein 5 day rotating menu
214682604|NCT00818142|BEHAVIORAL|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
214682605|NCT05697939|DIAGNOSTIC_TEST|NSite 3D Scanning|"Three separate users will enter the exam room and use the NSite application to scan the patient in the bending position. These users may include research coordinators, physicians, or other authorized staff.~The NSite application will have a user tutorial on how to scan patients that users are instructed to watch prior to conducting a scan.~All participants are asked to remove clothing above the waist but may keep a bra or tight-fitting shirt on during the scanning procedures. The patient will be asked to assume a forward bending position. One user will capture a scan of the patient's back in this position. The user will calibrate the device and then walk around the patient while scanning per app directions. Once this user captures the scan, it will be processed by the application. New scans will then be obtained by the two other users. Once all users have captured a scan, the scanning process and patient participation will be completed."
214682606|NCT03968445|DRUG|[18F]DPA-714-PET/MRI|\[18F\]DPA-714-PET/MRI
214682607|NCT00477451|DRUG|Inhaled placebo|Inhaled Staccato Alprazolam Placebo
214682608|NCT00477451|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato Alprazolam 1 mg
214682609|NCT00477451|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato Alprazolam 2 mg
214682610|NCT00477451|DRUG|IV doxapram|0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
214682611|NCT01719081|PROCEDURE|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
214682612|NCT04440241|PROCEDURE|regenerative treatment periimplantitis|"Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps."
214372067|NCT05889689|BEHAVIORAL|Preparing Adolescents for Young Adulthood (PAYA).|A financial literacy curriculum
214372068|NCT03653546|DRUG|AZD3759|AZD3759 200mg PO BID.
214372069|NCT03653546|DRUG|Erlotinib|SoC EGFRTKI Erlotinib 150 mg PO Q.D
214372070|NCT03653546|DRUG|Gefitinib|SoC EGFRTKI Gefitinib 250 mg PO Q.D
214372071|NCT06376760|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of intravenous anesthetic drug during digestive endoscopy between insomnia group and normal sleep group.
214682613|NCT03415074|BEHAVIORAL|Protein restriction|In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
214682614|NCT01757704|PROCEDURE|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
214682615|NCT01757704|PROCEDURE|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
214682616|NCT05329181|BEHAVIORAL|Integrated cognitive behavioral treatment|Integrated cognitive behavioral treatment adapted specifically for homeless individuals and developed to treat substance use and depressive symptoms simultaneously
214682617|NCT00724035|DRUG|Midazolam|"Procedural sedation before the execution of the block.~* 0.03 mg/kg iv bolus"
214682618|NCT00724035|DRUG|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
214682619|NCT00724035|DRUG|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
214682620|NCT00724035|PROCEDURE|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
215089234|NCT03624452|OTHER|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
215089235|NCT03624452|OTHER|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
215089236|NCT00025116|DRUG|gefitinib|
215089237|NCT00106691|DRUG|Toremifene 20 mg|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
215089238|NCT00106691|DRUG|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
215089239|NCT02122809|DRUG|Chiauranib|Take orally
215089240|NCT00530920|DRUG|tipranavir|
215089241|NCT00530920|DRUG|ritonavir|
215089242|NCT04432805|DEVICE|Performing of lung ultrasound|Performing of lung ultrasound at bedside in labor ward or in COVID unit
215089243|NCT04320511|DEVICE|CT-V|CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
214372072|NCT06160986|BEHAVIORAL|Horizons Group Intervention|The Horizons Group intervention in English or Spanish language (per participant preference) contains 8 weekly group sessions delivered via video conference by a bone marrow transplant clinician and behavioral health specialist, over approximately 8 weeks, approximately 1.5 hours per session every week. The intervention pairs state-of-the-science information about survivorship and chronic graft versus host disease with self-management strategies. Intervention sessions will be delivered via video conference (Zoom), which participants may access by computer, laptop, tablet, or smart phone. As part of the intervention, participants will have access to an intervention manual and audio-recorded relaxation exercises to support learning and skills practice.
214372073|NCT06834113|PROCEDURE|Dorsogluteal intramuscular injection|"The injection is carried out on the dorsogluteal intramuscular site, without virtual reality headset~The injection is carried out on the ventrogluteal intramuscular site, without virtual reality headset~The injection is carried out on the dorsogluteal intramuscular site, with virtual reality headset~The injection is carried out on the ventrogluteal intramuscular site, with virtual reality headset"
214372074|NCT05449691|PROCEDURE|One-stage immediate breast reconstruction|One-stage mesh assisted implant breast reconstruction
214372075|NCT05335928|DRUG|Abatacept plus|"Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC"
214372076|NCT05335928|DRUG|Placebo|Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
214372077|NCT05539729|DRUG|Vancomycin|A marketed antibiotic (Study Drug) supplied by Amerisource Bergen, by the Mount Sinai Investigational Drug Services (IDS), and encapsulated in red coating to match the placebo.
214372078|NCT05539729|DRUG|Placebo|Placebo created by the IDS and encapsulated in red coating to match the Study Drug.
214372079|NCT06849050|BEHAVIORAL|Acute continuous exercise|Exercise, which will involve 60 minutes of brisk walking, or jogging, at 60% of peak oxygen uptake. Participants will be asked to wear a face mask, which will measure their oxygen consumption during the exercise session.
214494319|NCT06752564|BEHAVIORAL|standard health education|The control group received standard health education. The content of the standard health education included verbal instructions provided by nurses during the general hospital stay, as well as the distribution of educational pamphlets. These instructions covered topics such as the frequency of dialysis and dietary control. The standard health education was generic, without a specific schedule or structured content.
214494320|NCT06752720|DRUG|Stem cell Transplantation|Manufactured autologous mescenchymal stem cell (HUNS001-01) in our cell processing center will be injected into the brain, totally 4 x 10\^7 cells, in 2 brain sites.
214494321|NCT06763731|DRUG|Systane COMPLETE|Preop dry eye management using Systane COMPLETE can help to optimize the ocular surface.
214494322|NCT06758817|OTHER|MedDiet+ intervention|Study arm will consume a Mediterranean like style diet enriched in fermented foods for 12 weeks
214494323|NCT06758817|OTHER|General dietary recommendations|Study arm will be given general healthy eating advice at baseline.
214494324|NCT06758466|PROCEDURE|Prostate surgery|Prostate removal
214494325|NCT06753006|DEVICE|Neurorehabilitation simulator|The participant must complete a mental task - imagine the movement of his arm. If successful, the robotic simulator moves the paralyzed limb.
214494326|NCT06753006|PROCEDURE|Standard course|The participant receives a standard course of intervention as prescribed by the attending physician in accordance
214494327|NCT06776354|BEHAVIORAL|GPT-based training|GPT-based training whether could improve the ability of students to develop effective hypertension management plans
214494328|NCT06776354|BEHAVIORAL|traditional training|traditional teaching methods
214494329|NCT06771271|DRUG|RO7200220|RO7200220 was administered as IVT injection.
214494330|NCT06771271|DRUG|Ranibizumab|Ranibizumab was administered as IVT injection.
214682621|NCT00724035|PROCEDURE|Axillary brachial plexus nerve block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose."
214682622|NCT00724035|PROCEDURE|Infraclavicular brachial plexus block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks."
214682623|NCT03700476|DRUG|Sintilimab|Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
214682624|NCT03700476|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
214682625|NCT03700476|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
214682626|NCT03700476|RADIATION|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
214682627|NCT02890199|DRUG|Bupivacaine liposomal|
214682628|NCT02890199|DRUG|Lidocaine|
214682629|NCT04381819|DIAGNOSTIC_TEST|SARS-CoV-2 PCR|SARS-CoV-2 E gene
214986160|NCT05728411|OTHER|Remote foot temperature monitoring system|"Remote temperature monitoring involves a thermometric mat that can detect hot spots on the plantar surface of the foot. The mat has embedded cellular connectivity so that data can be transmitted from the patient's home to the company, where the temperature data can be analyzed. The company has a team of health coaches that work with patients and providers to detect signs of damage early in order to prevent ulceration."
214986161|NCT05728411|OTHER|Enhanced usual care|"Usual care is based on the VA's amputation prevention program (PAVE - Preventing Amputation in Veterans Everywhere - VHA Directive 1410), which provides a model of care for patients at risk for amputation as well as patients who have already undergone an amputation.~Usual care will be enhanced by providing resources (e.g., information through written newsletters) relevant to a population of Veterans with diabetes, including information on nutrition and cooking, physical activities, and whole health opportunities"
214372080|NCT05950945|DRUG|Trastuzumab Deruxtecan|Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
214372081|NCT04938817|BIOLOGICAL|coformulation pembrolizumab/quavonlimab|Intravenous (IV) infusion
214372082|NCT04938817|DRUG|lenvatinib|Oral administration
214372083|NCT04938817|BIOLOGICAL|MK-4830|IV infusion
214682630|NCT01052987|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
214682631|NCT01052987|DRUG|Allopurinol|Allopurinol tablets 300 mg, QD
214682632|NCT01052987|DRUG|Combination - Tranilast and Allopurinol|Tranilast, 300 mg QD; Allopurinol 300 mg QD
214682633|NCT01052987|DRUG|400 mg Allopurinol|400 mg Allopurinol administered once daily for 7 days
214682634|NCT01052987|DRUG|High dose combination|Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
214682635|NCT05164861|DIETARY_SUPPLEMENT|kombucha-based beverage|"kombucha-based beverage: drinking water, black tea, kombucha, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%\*), vitamin B1 - 0.4 mg (29%\*), B2 - 0.21 mg (13%\*), B6 - 0.48 mg (24%\*), niacin - 2.74 mg (15%\*), folic acid - 24.0 mcg (12%\*). Energy value/Caloric content - 54 kilojoules/13 kcal (\* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011). Flavours, identical by nutrient's content and nutrients density: black currant berries \& juniper berries, or strawberries \& lime leaves, or passion fruit \& mango.~Portion's volume - 220 ml. Daily intake: 1 portion"
214372084|NCT04938817|BIOLOGICAL|coformulation favezelimab/pembrolizumab|IV infusion
214372085|NCT04938817|BIOLOGICAL|R-DXd|IV Infusion
214372086|NCT05400005|OTHER|Dietary protein|"Intervention of the study include consuming a higher protein diet. Depending on the group allocation, this is done by asking the subjects to follow My Healthy Plate diet and consumption of 20g of protein isolates (casein or soy)."
214372087|NCT00210171|PROCEDURE|Toxicity : Time to progression, 1 and 2 years survival|
214372088|NCT05887947|DEVICE|Electronic Cigarette with 5% Nicotine Concentration|Electronic cigarette in 5% nicotine concentration (Vuse Alto), provided for free.
214372089|NCT05887947|DEVICE|Electronic Cigarette with 1.8% Nicotine Concentration|Electronic cigarette in 1.8% nicotine concentration (Vuse Alto), provided for free.
214372090|NCT06398652|BIOLOGICAL|CMAB015|Patients would receive 300 mg CMAB007 subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg CMAB007 subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.
214372091|NCT06398652|BIOLOGICAL|Secukinumab|Patients would receive 300 mg secukinumab subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg secukinumab subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.
214372092|NCT05800743|DEVICE|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
214682636|NCT02242890|BEHAVIORAL|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
214682637|NCT04891250|DRUG|Ivermectin|Treatment of SARS Cov-2 patients with Ivermectin
214682638|NCT04891250|OTHER|Prophylaxis|Treatment of high risk population with Ivermectin as prophylaxis
214682639|NCT03575520|DRUG|Pegfilgrastim|A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
214372093|NCT05800743|DEVICE|GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)|Endovascular aortic repair of the ascending aorta/aortic arch
214372094|NCT05800743|PROCEDURE|Surgery|Open surgical repair of the ascending aorta and/or the aortic arch
214372095|NCT03896568|BIOLOGICAL|Oncolytic Adenovirus Ad5-DNX-2401|Given IA
214372096|NCT03896568|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214372097|NCT04327973|BIOLOGICAL|ATB200|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
214372098|NCT04327973|DRUG|AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
214372099|NCT05952856|DRUG|Enlicitide Decanoate|Oral tablet
214372100|NCT05952856|DRUG|Placebo|Oral tablet
214372101|NCT05544708|BEHAVIORAL|Wellness Engagement Intervention|Train for, recruit participants into, and lead a 12-week lifestyle intervention delivered via weekly group meetings
214372102|NCT03305523|DEVICE|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medical, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
214372103|NCT05624450|DRUG|Tozorakimab|Single IV dose of tozorakimab on Day 1.
214372104|NCT05624450|DRUG|Placebo|Single IV dose of matching placebo on Day 1.
214372105|NCT06251375|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
214372106|NCT06251375|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
214682640|NCT03575520|DRUG|Doxorubicin/Cyclophosphamide(AC) treatment|"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."
214986162|NCT04126525|DRUG|Pyrotinib|dual HER2 blockade in the neoadjuvant setting
214986163|NCT04759131|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV
214986164|NCT06568237|DRUG|TEV-56286|TEV-56286 capsules administered orally
214986165|NCT06568237|DRUG|Placebo|Matching placebo administered orally
214682641|NCT04311476|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy|Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
214986166|NCT06793215|DRUG|Divarasib|Divarasib will be administered orally QD
214372107|NCT06576128|DEVICE|ultrasound|In additional to local anesthesia, 10 ml lidocaine (2%) (Lidon, Onfarma, Turkey ), TAPB will be performed under ultrasound imaging..
214372108|NCT06576128|PROCEDURE|parenteral local anesthesia|As routine procedure; the cardiologist will palpate the right or left femoral artery under sterile conditions and apply approximately 10 ml lidocaine (2%) to this area as local anesthesia (Lidon, Onfarma, Turkey ). Then, a puncture will be made on the anterior wall of the femoral artery with an 18 G needle . Approximately 3-4 mm skin incision will be made with the number 11 scalpel tip and the Seldinger technique will be continued. 6F femoral sheath to be placed, cardiac The catheterization process will begin.
214372109|NCT05311033|OTHER|Exacyl|Healthy males with at risk of post-inflammatory hyperpigmentation have a skin samples for evaluate the activity of tranexamic acid.
214682642|NCT04311476|DRUG|0.9% Sodiun Chloride|0.9% Sodiun Chloride in control group
214682643|NCT00146705|PROCEDURE|blood samples are taken once|
214372110|NCT02958852|DRUG|Letrozole|Daily orally
214372111|NCT02958852|DRUG|Letrozole and atorvastatin|Daily orally
214372112|NCT02958852|DRUG|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
214372113|NCT01375829|DRUG|Ixabepilone|Given IV
214372114|NCT01375829|OTHER|Pharmacological Study|Correlative studies
214372115|NCT01375829|DRUG|Temsirolimus|Given IV
214372116|NCT00554918|DRUG|docetaxel|
214372117|NCT00554918|DRUG|prednisolone|
214372118|NCT00554918|DRUG|zoledronic acid|
214372119|NCT00554918|PROCEDURE|quality-of-life assessment|
214372120|NCT00554918|RADIATION|strontium chloride Sr 89|
214372121|NCT04445480|PROCEDURE|Popliteal block|Sciatic nerve block at popliteal fossa would perform before the participant undergoing angioplasty in experimental arm.
214682644|NCT04539301|DIAGNOSTIC_TEST|Estimated anticoagulant level (conversion factor x anti-Xa activity)|Estimated anticoagulant level (conversion factor x anti-Xa activity)
214682645|NCT05785117|DEVICE|Vagal Stimulation|ear clips were placed in the ear region (auricular concha) at the stimulation site. The following stimulation settings were used: 1) density wave set to 20 Hz with a wave width of less than 1 ms; 2) intensity tuned to the patient's tolerance (4-6 mA)
214682646|NCT05785117|OTHER|Circuit training program|The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks
214682647|NCT05801926|DEVICE|Heel2Toe[TM] sensor|Heel2Toe is a new generation of wearables that provides real-time auditory feedback when the person takes a good step, one in which the step is initiated with a strong heel strike.
214682648|NCT03404414|DRUG|18F-FDG|"Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans"
214682649|NCT02691247|BIOLOGICAL|CLBS03 Low Dose|
214682650|NCT02691247|BIOLOGICAL|CLBS03 High Dose|
214682651|NCT02691247|BIOLOGICAL|Placebo|
214986167|NCT06793215|DRUG|Pembrolizumab|Pembrolizumab will be administered via IV infusion Q3W
214986168|NCT06793215|DRUG|Pemetrexed|Pemetrexed will be administered via IV infusion Q3W
214986169|NCT06793215|DRUG|Carboplatin|Carboplatin will be administered via IV infusion Q3W
214986170|NCT06793215|DRUG|Cisplatin|Cisplatin will be administered via IV infusion Q3W
214682652|NCT03554538|BEHAVIORAL|Web app exercises program|Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence
214986171|NCT05144945|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine (RIV4)|Solution for intramuscular injection
214986172|NCT05144945|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV4)|Suspension for intramuscular injection
214986173|NCT04497961|DRUG|Lenalidomide|dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle.
214986174|NCT04497961|DRUG|Daratumumab|1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36
214372122|NCT04445480|OTHER|Control|Sciatic nerve at popliteal fossa would be scanned with the ultrasound. The toothpick would be applied to simulate the procedure of nerve block.
214372123|NCT06358157|DEVICE|Ladera LBC System|Use of the Ladera LBC System to close the femoral arteriotomy
214494331|NCT06775119|OTHER|Test of neuromuscular fatigue and associated hemodynamic responses|"Baseline measurements of neuromuscular function and hemodynamic responses will be done. Investigators will then assess the mechanoreflex activation using the experimental technique of passive leg movement (PLM).~Following the PLM and the neuromuscular function baseline assessments, participants will perform four consecutive blocks, each consisting of a fatigue task followed by post-exercise circulatory occlusion (PECO). Neuromuscular function, assessed through maximal voluntary contraction (MVC) and quadriceps twitch techniques, will be measured before the fatigue task and after PECO in each block. Participants will perform 2-minutes isometric quadriceps sustained contraction at 20% MVC to induce exercise-induced neuromuscular fatigue. Hemodynamic responses will be measured during the PECO to isolate to the metaboreflex by inflating a cuff over the right thigh for a 2 minutes duration. After the PECO, the thigh cuff will be deflated, and neuromuscular function will be reassessed."
214372124|NCT01678131|DRUG|Vaniprevir 600 mg|Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.
214372125|NCT01678131|BIOLOGICAL|Peg-IFN alfa-2b|Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21
214372126|NCT01678131|BIOLOGICAL|Ribavirin|Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight
214372127|NCT01678131|PROCEDURE|Liver samples from FNA|Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.
214372128|NCT01678131|DRUG|Vaniprevir 300 mg|Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
214372129|NCT01678131|PROCEDURE|Liver samples from CNB|Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.
214494332|NCT06852573|BIOLOGICAL|ZM001 Injection|ZM001 injection, 2.5× 10\^7 CAR-T cells, 5× 10\^7 CAR-T cells, 1× 10\^8 CAR-T cells and 2× 10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
214494333|NCT05077748|OTHER||
214494334|NCT06831097|BEHAVIORAL|"Comidas Para Salud (Food for Health), Pasos Para Salud (Steps for Health), Jardines Para Salud (Gardens for Health)"|"Comidas Para Salud (Food for Health), Pasos Para Salud (Steps for Health), Jardines Para Salud (Gardens for Health)~Description: Arm Description: Comidas Para Salud (Food for Health), will focus on assisting young children to learn skills in healthy eating. The Bienestar Preschool Curriculum is home-based and directed to both the primary caregivers as well as the child participants. The Pasos Para Salud (Steps for Health), which will use IVG/exergaming to increase children's physical activity level and reduce their sedentary behavior. Jardines Para Salud (Gardens for Health), will involve planting gardens in the HS settings and supervised home gardening projects for the preschool participants and their parents/guardians. This will instill the value of gardening and gardening skills in promoting a healthy lifestyle."
214682653|NCT03554538|BEHAVIORAL|Exercise program|Exercise on an evidence based program for shoulder pain
214682654|NCT05336968|DRUG|Triamcinolone acetonide-Ketorolac-Ropivacaine|Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
214682655|NCT01844700|DRUG|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
214682656|NCT01844700|DRUG|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
214682657|NCT03471091|DEVICE|NIV with the integrated tele-monitoring management program|Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
214986175|NCT04497961|BEHAVIORAL|Questionnaires|EORTC QLQ-C30, EORTC QLQ-MY20, PRO-CTCAE)
214986176|NCT04497961|OTHER|Dietary Intervention|The intervention, consisting of fully prepared whole foods plant based (WFPBD) meals and behavioral coaching provided by Daily Harvest. Patients receive self-selected WFPBD meals (lunch/dinner) for 12 weeks, along with guidance for snacks and breakfast. Behavioral counseling will be provided by health coaches and a research dietitian. The first 15 participants on each arm interested in this intervention will be enrolled on C13D1 or C25D1.
214986177|NCT02365779|PROCEDURE|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
214986178|NCT02365779|DEVICE|endomicroscopy Cellvizio® system|
214682658|NCT01669369|DRUG|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
214372130|NCT06069050|PROCEDURE|sequential adolesent left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
214372131|NCT02252419|DRUG|Dexamethasone|Dexamethasone will be administered.
214682659|NCT01669369|DRUG|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
214682660|NCT06255561|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
214682661|NCT05742464|BEHAVIORAL|RUBI|"RUBI teaches caregivers a range of skills to support the building of a behavioral management toolbox. The intervention emphasizes: 1) tailoring the intervention to the child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice (i.e., targeting what is driving the behavior, instead of the behavior itself); 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g. use of visual supports), reinforcement, and functional communication strategies as the means to modify behaviors. RUBI uses a behavioral skills training approach, which includes direct instruction, modeling, role-play and practice with feedback in order to train caregivers in the various RUBI skills. Sessions also have accompanying video vignettes that are used to illustrate skills or test parental understanding of session materials."
214986179|NCT05960695|OTHER|Stretching|"Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds. The exercises will be done online by the physiotherapist.~The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises."
214682662|NCT03339648|BEHAVIORAL|Professional Development Enhancement|Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
214682663|NCT02680847|DRUG|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
214986180|NCT05960695|OTHER|Relaxation|Diaphragmatic breathing will be taught as a relaxation exercise. The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.
214986181|NCT06470438|DRUG|JNJ-88998377|JNJ-88998377 will be administered.
214372132|NCT02252419|DRUG|Paracetamol|Paracetamol will be administered.
214372133|NCT03450902|COMBINATION_PRODUCT|Chinese herb & acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
214494335|NCT06129942|DEVICE|Bright light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The experimental group is treated with 10,000 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
214986182|NCT06511076|DRUG|Zilucoplan|Participants will receive a single sc injection of zilucoplan in the pre-specified sequence.
214494336|NCT06129942|DEVICE|Dim Light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The control group is treated with 300 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
214494337|NCT06294990|DRUG|Testosterone gel|Two years treatment with testosterone
214494338|NCT06294990|OTHER|Placebo|Two years treatment with placebo
214494339|NCT06463015|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
214494340|NCT06333457|DEVICE|VR Cue-Exposure Therapy|Standard VR Cue Exposure Therapy (VR-CET) for the treatment of alcohol dependence
214986183|NCT03692312|DRUG|Tideglusib|Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
214986184|NCT03692312|DRUG|Placebo|Matching placebo formulation
214986185|NCT05138562|DRUG|Placebo Comparator: Placebo|4 x placebo capsules, QD
214986186|NCT05138562|DRUG|Active Comparator: TU2670 320mg|320mg (80mg x 4), QD
214986187|NCT05138562|DRUG|Active Comparator: TU2670 240mg|240mg (80mg x 3 + placebo x 1), QD
214986188|NCT05138562|DRUG|Active Comparator: TU2670 120mg|120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
214986189|NCT05567341|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff is inflated to 200 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
214682664|NCT00170248|DEVICE|computer-based decision support for asthma management|The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
214682665|NCT06219928|PROCEDURE|Control Group|After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline
214682666|NCT06219928|PROCEDURE|Ketamine Group|After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.
214682667|NCT06219928|PROCEDURE|Dexmedetomidine|After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.
214682668|NCT03786692|DRUG|Arm A|Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
214682669|NCT03786692|DRUG|Arm B|Carboplatin + Pemetrexed + Bevacizumab
214682670|NCT06609616|DEVICE|Motion Sensor|The motion sensor is the 10-axis Bluetooth Gyro Inclinometer by Wit Motion and is marketed for rehabilitation exercises, workplace injury prevention, patient care, and healthy shortrange wireless motion measurements.
214682671|NCT06609616|DEVICE|Incentive Spirometer|a device that measures the volume of the air inhaled into the lungs during inspiration.
214682672|NCT05930249|BEHAVIORAL|Personalized multidomain intervention|"1. Patients will complete personalized cognitive training based on baseline fNIRS on APP (20-30 mins/day, 3-4 days/week, 6 months).~2. Shared decision-making on risk factor of stroke between doctors and patients~3. Social support by grouping patients online to ensure close interaction with other patients in the same arm"
214682673|NCT01288040|BEHAVIORAL|Split Belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
214986190|NCT05567341|PROCEDURE|Sham-control|A blood pressure cuff is inflated to 0 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
214986191|NCT05914376|BIOLOGICAL|Recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
214986192|NCT05595577|OTHER|Exercise with Trainerize application|1-2 sessions per week consisting of slow 15 minute aerobic warm, 20 minutes of strength training, 15 minutes progressive intensity aerobic exercise and 10 minute cool down (stretching/toning) with elastic bands.
214986193|NCT05595577|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Maximal peak VO2 (to monitor the body's oxygen consumption) and 6-minute exercise walking test.
214986194|NCT05595577|DIAGNOSTIC_TEST|MRI scan|Images of the heart will be taken.
214986195|NCT05595577|BEHAVIORAL|Quality of Life Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
214986196|NCT05595577|BEHAVIORAL|Cognitive and Brain Function Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
214986197|NCT05595577|OTHER|Blood draws|Approximately 2 teaspoons of blood withdrawn from either a vein in your arm or a currently placed central line port-a-cath. A portion of blood from each visit will be used to collect information about blood cell count.
214986198|NCT05196386|BEHAVIORAL|Admission conciliation interview|Previous treatment conciliation at hospital admission
214986199|NCT05196386|BEHAVIORAL|Discharge conciliation interview|Allocated treatment during hospital stay
214986200|NCT05196386|BEHAVIORAL|Targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
214986201|NCT02745106|PROCEDURE|Radiofrequency pulmonary artery denervation|Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
214682674|NCT03356314|OTHER|MRI between 30-35 GA|MRI between 30-35 GA
214682675|NCT03356314|OTHER|Pediatric surgeon meeting|Pediatric surgeon meeting
214682676|NCT03356314|OTHER|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal
214682677|NCT03356314|OTHER|+/- prophylactic surgery|+/- prophylactic surgery
214682678|NCT02090582|OTHER|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
214682679|NCT02090582|OTHER|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
214372134|NCT03450902|COMBINATION_PRODUCT|Chinese herb & sham acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
214372135|NCT03450902|COMBINATION_PRODUCT|Placebo & acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
214372136|NCT03450902|OTHER|Placebo & sham acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
214372137|NCT05582187|DRUG|Fosmanogepix|a single dose of fosmanogepix administered by mouth under fasted conditions
214372138|NCT06425848|DEVICE|Observational|We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.
214372139|NCT00112580|BIOLOGICAL|ipilimumab|
214372140|NCT04602884|DIAGNOSTIC_TEST|Breath biopsy sampling using the ReCIVA Breath Sampler|Breath biopsy sampling using the ReCIVA Breath Sampler
214682680|NCT01965548|PROCEDURE|Treatment of splenic injury|"There are four possible treatments of splenic injury in this study:~* splenectomy~* splenic artery embolisation~* non-operative management~* any combination of the three treatments mentioned"
214372141|NCT01521962|DRUG|Alogliptin|Alogliptin tablets
214372142|NCT01521962|DRUG|Insulin|Insulin injection
214372143|NCT00426725|DEVICE|EasyLabour|According to the trial protocol
214372144|NCT03466918|DEVICE|SAPIEN 3 THV with the Commander delivery system|Edwards SAPIEN 3 Transcatheter Heart Valve is implanted using the Commander delivery system
214372148|NCT01969110|DIETARY_SUPPLEMENT|Oral IMPACT|Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
214372149|NCT00652782|DRUG|rolofyline|rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days
214372150|NCT00652782|DRUG|Comparator Placebo (unspecified)|Matching placebo for rolofyline IV QD; 3 days
214372151|NCT00983086|DRUG|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
214372152|NCT02036957|PROCEDURE|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
214494341|NCT05162352|DRUG|Donafenib+sintilimab|"Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle.~Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.~Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity."
214494342|NCT06753019|OTHER|survey assessment tools|Functional and psychological status and the level of somatosensory amplification in patients with knee osteoarthritis will be evaluated with questionnaires.
214494343|NCT06762067|OTHER|mirror therapy|Participants will undergo physiotherapy exercises in a mirror alongside post-surgery care. The program includes palming exercises, eye exercises, pencil push-ups, Brock string exercises, thumb exercises, and proprioceptive neuromuscular facilitation exercises. The first exercise warms up extra ocular muscles, the second improves eye coordination, the third motivates the lazy eye, the fourth strengthens eye muscles, and the fifth involves a near-distance jump for oblique muscles.
214682681|NCT02113748|OTHER|Downhill walking training|Walk on a treadmill with a negative inclination.
214682682|NCT02113748|OTHER|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
214682683|NCT00299884|DRUG|Lipitor 20 mg|A/A for 6 weeks
214372153|NCT02036957|PROCEDURE|PLACEBO ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
214682684|NCT00299884|DRUG|Combination Ezetrol 10 mg and Lipidil Supra 160 mg|a/a for 6 weeks
214986202|NCT02745106|DEVICE|Ablation catheter|4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
214372154|NCT03424434|OTHER|Survey diffusion|The study consists in a survey diffusion during several weeks by emailing each practitioner and resident and inviting them to participate to a questionnaire about occupational blood exposure. This survey is strictly anonymous. No identity data is required, only age, gender, function, surgical or medical specialty, work quota and hospital group they belong. This survey is diffused in four UHC (Lyon, Grenoble, Clermont-Ferrand and Saint-Etienne) in France.
214494344|NCT06762067|OTHER|traditional therapy|The patients within the control group will receive traditional care post-strabismus operation as eye glasses and eye drops and regular exercise
214494345|NCT06774833|BEHAVIORAL|Self-initiated perturbation-based balance training|This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be required to recover their balance upon self-initiated perturbation.
214494346|NCT06774833|BEHAVIORAL|Conventional balance training|This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be instructed to perform balance and strength training. The same training duration and format will be used as the Self-initiated perturbation-based balance training group.
214494347|NCT06764667|PROCEDURE|Spinal anesthesia adjuvant|Patients in this arm will receive 10 mg 0.5% hyperbaric Bupivacaine, 100 mcg Morphine, 100 mcg Sulfas Atropine, and 0.9% normal saline to total volume of 4 ml before induction of anesthesia.
214494348|NCT06764667|PROCEDURE|Quadratus Lumborum Block (QLB)|Patients in this arm will receive quadratus lumborum block with 20-30 ml of 0.25% Bupivacaine after induction of anesthesia and after operation.
214494349|NCT06764667|PROCEDURE|General Anesthesia|The subject will undergo preoxygenation with 100% oxygen for 3 minutes. Following preoxygenation, anesthesia induction will be performed using lidocaine at a dose of 1.5 mg/kg, fentanyl at 1.5 mcg/kg, and propofol at 2.0 mg/kg. Once the subject is adequately sedated, baseline neuromuscular monitoring using the train-of-four (TOF) technique will be conducted, followed by the administration of rocuronium at a dose of 0.8 mg/kg. Endotracheal intubation will be performed using direct laryngoscopy once the TOF value reaches 0, utilizing an appropriately sized endotracheal tube (ETT). Ten milligrams of intravenous dexamethasone is administered after induction.
214494350|NCT04779697|DRUG|GLP-1 analogue - semaglutide|GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
214494351|NCT04779697|OTHER|Placebo|Placebo - administered once weekly for a total of 12 weeks
214494352|NCT05857397|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
214494353|NCT06238908|DRUG|NGGT003|Single intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg)
214494354|NCT03417336|RADIATION|prostatic boost in brachytherapy with high dose rate (HDR)|prostatic boost in brachytherapy with high dose rate (HDR)
214494355|NCT00545545|BIOLOGICAL|Imprime PGG 2 mg/kg|Infusion of 2mg/kg on Day 1 of each week for 6 weeks (one cycle) Number of Cycles: until progression or unacceptable toxicity develops.
214494356|NCT00545545|BIOLOGICAL|Imprime PGG 4 mg/kg|Infusion of 4mg/kg on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
214494357|NCT00545545|BIOLOGICAL|Cetuximab|Infusion 400 mg/m2 over 2 hours on Day 1, then 250 mg/m2 over 1 hour on Days 8, 15, 22, 29, and 36 of each 6-week treatment cycle;
214494358|NCT00545545|DRUG|Irinotecan|Infusion 125 mg/m2 i.v. over 1.5 hours on Days 1, 8, 15, and 22 of each 6-week treatment cycle
214494359|NCT00545545|BIOLOGICAL|Imprime PGG 6mg/kg|Infusion of 6mg/kg on Day 1 of each week for 6 weeks (one cycle) Number of Cycles: until progression or unacceptable toxicity develops.
214494360|NCT06744153|PROCEDURE|Space Maintainer|Fabrication of KOS\&MET functional space maintainer and its cementation.
214494361|NCT06891079|DIAGNOSTIC_TEST|Videodensitometric guided|"In the experimental arm, a TAVI device is implanted according to the local practice. Immediately after implantation, aortography is performed to quantitatively assess the aortic regurgitation (qAR). The aortography is analyzed using CAAS A-Valve (Pie-Medical, Maastricht, The Netherlands).~•If qAR is \>17%, we recommend that corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed and angiography is repeated for the assessment of aortic regurgitation. If the qAR ≤17%, whether corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed is left to the discretion of the operators. Inform operators of the results of qAR and the threshold criteria. Continuous qAR was stratified into categorical variables according to the following pre-determined threshold criteria: (1) none or trace (qAR \<6%); (2) mild (6% to ≤17%); and (3) moderate or severe (\>17%).~At discharge, all the patients will undergo Cardiac magnetic resonance, the Car"
214494362|NCT06891079|DIAGNOSTIC_TEST|Stand of care guided|"In the control arm, a TAVI device is implanted according to local practice. Immediately after implantation, TEE/TTE or aortography is performed as a part of usual practice.~* The requirement of post-dilatation or any additional procedure is left to the discretion of the operator.~* The operator judges the sufficient procedural outcome to end the procedure according to local practice.~At discharge, all the patients will undergo Cardiac magnetic resonance, the Cardiac magnetic resonance-derived regurgitation fraction (CMR-RF) will be analyzed as the primary endpoint."
214494363|NCT04338399|DRUG|Buparlisib & Paclitaxel|Investigation drug plus paclitaxel
214494364|NCT06772935|BEHAVIORAL|Electro-acupuncture|A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body.
214986203|NCT02745106|DEVICE|Swan-Ganz catheter for right heart catheterization|"Standart procedure of right catheterization:~* punction of right jugular vein with Seldinger technique, introducer placement~* insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~* positioning of swan-ganz catheter in pulmonary artery~* direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~* calculating of indirect parameters (pulmonary vascular resistance)"
214986204|NCT04908787|DRUG|BD0801|Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
214682685|NCT02165540|OTHER|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
214372155|NCT04781738|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|"CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages~Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test.~SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items).~Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state)."
214372156|NCT04723095|OTHER|Follow-Up|Receive follow up
214372157|NCT04723095|OTHER|Medical Chart Review|Review of medical records
214372158|NCT06083415|OTHER|Environmental health measures|MRI will be used to confirm the presence of breast buds, to measure the size of the ovaries and uterus, as well as the fraction of fat mass (abdominal, subcutaneous, liver and bone marrow). The bood and urine tests will allow to measure different biological and metabolic parameters. The presence of endocrine disruptors will be determined in the hair. The bone age x ray will be estimate the maturity of the child's skeletal system. Photographs of the teeth will also be taken to be studied by pediatric odontology researchers on the on molar and incisor hypomineralization, known as MIH.
214986205|NCT04908787|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
214986206|NCT04908787|DRUG|Placebo|Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
214986207|NCT04908787|DRUG|Topotecan|Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
214986208|NCT04908787|DRUG|doxorubicin liposome|Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
214372159|NCT06982300|OTHER|[68Ga]Ga-DOTA-TOC PET imaging|"Patients will undergo \[68Ga\]Ga-DOTA-TOC PET imaging before and 3 weeks after start of standard of care treatment with induction chemotherapy or CRT, unless the baseline scan shows no tracer uptake in the tumor, in that case the scan will not be repeated.~Patients will receive 120 MBq \[68Ga\]Ga-DOTA-TOC intravenously and will be scanned up to 20 minutes, 60 minutes after tracer injection, after acquisition of a low dose CT for attenuation correction.~The investigators will use archival tissue of the diagnostic biopsy for SSTR2 staining. If there is not sufficient tumor tissue available, a new biopsy will be performed after the baseline PET scan.~Blood samples will be drawn before the start, during and after finishing therapy at 3 or 4 different time points, depending on the treatment schedule."
214372160|NCT04500548|PROCEDURE|Biospecimen Collection|Undergo collection of tissue samples
214494365|NCT06797492|DIAGNOSTIC_TEST|Shoulder Physical Examination|shoulder physical examination is conducted to assess the patient's musculoskeletal condition and to track progress throughout the rehabilitation phases
214494366|NCT06797492|PROCEDURE|Shoulder Rehabilitation in a Virtual Environment|The rehabilitation protocol for shoulder disorders is executed using a Virtual Reality (VR) system, where patients perform customized exercises tailored to their physical characteristics.
214494367|NCT06797492|OTHER|Usability assessment and presence and co-presence evaluation|The usability of the VR system, along with the sense of presence and co-presence during rehabilitation, is assessed using validated scales
214372161|NCT04500548|BIOLOGICAL|Ipilimumab|Given IV
214372162|NCT04500548|BIOLOGICAL|Nivolumab|Given IV
214372163|NCT06820593|BEHAVIORAL|Digital Asthma Intervention|The intervention consists of two main components-the mHealth app and sensors that is part of the Adherium's Hailie® Solution-and the remote patient monitoring (RPM), conducted in this intervention by an asthma coordinator.
214372164|NCT06820593|BEHAVIORAL|Comparison Group|Participants in the comparison group will receive the sensors for their ICS inhalers and a limited version of the app that only collects the sensor information by Bluetooth, without app features, and sends the information to the Hailie web portal. This passive adherence data collection will allow for comparison of the two groups' adherence rates without the mHealth app self-management support or RPM.
214494368|NCT06795789|DIETARY_SUPPLEMENT|Vitals+ (combined multivitamin and polyphenol supplement)|Multivitamin with 19 essential nutrients combined with Bilberry polyphenols
214494369|NCT06712901|BEHAVIORAL|Median Ranked Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study.
214494370|NCT06712901|BEHAVIORAL|Overall Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study.
214494371|NCT06712901|BEHAVIORAL|Black American Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study.
214494372|NCT06712901|BEHAVIORAL|White American Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants.
214682686|NCT04967755|DRUG|Jing-Si-Herbal-Tea|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
214682687|NCT01373905|PROCEDURE|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
214682688|NCT01373905|PROCEDURE|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
214682689|NCT00538382|DRUG|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
214682690|NCT00894530|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
214682691|NCT00894530|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
214986209|NCT04762186|DRUG|human SARS-CoV 2 specific T lymphocytes|"In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19."
214986210|NCT06468358|DRUG|LB1410|anti-PD-1/TIM3 bispecific antibody
214986211|NCT06468358|DRUG|LB4330|anti-claudin18.2/IL-10 fusion protein
214986212|NCT01072591|DRUG|MEDI-578|intravenous infusion, once
214682692|NCT04016363|OTHER|ProbeFix|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
215089244|NCT04825067|DEVICE|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
215089245|NCT05117021|DRUG|Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg|Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
215089246|NCT00139763|PROCEDURE|Educational Materials|
215089247|NCT00771121|DRUG|urea/lactic acid|new emulsion type
215089248|NCT00771121|DRUG|Placebo|only emulsion base
215089249|NCT05489900|DRUG|Dexmedetomidine Hydrochloride|"Dexmedetomidine is a specific and potent α2-adrenergic agonist. By acting directly on the sympathetic nervous system, they can exert beneficial effects on the immune system through neuroimmune interactions. Its administration can induce an anti-inflammatory response due to different central (increase parasympathetic tone, promoting control of the inflammatory condition) and peripheral effects (stimulating innate immunity).(MILLER, 2015).~Venous blood samples were collected at three times (T1, T2 and T3): Before anesthetic induction with collection in the preoperative environment on the day of surgery or during venoclysis before anesthetic induction (sample 1, T1); 6 hours after starting orifice closure and completion of drug or placebo infusion (sample 2, T2); and the last blood sample will be collected by me on the morning after the postoperative period, close to hospital discharge - 24h (sample 3, T3)."
214682693|NCT04016363|OTHER|Manual hold|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
214682694|NCT03950102|RADIATION|SBRT|Radiation dose of 27.5-50Gy in 5 fractions over 5-14 days with a radical dose as high as achievable based on mean liver dose (MLD), while fulfilling the dose constraints of OARs
214682695|NCT03005782|DRUG|REGN3767|
214682696|NCT03005782|DRUG|cemiplimab|
214682697|NCT06667284|PROCEDURE|Roux en y procedure|subtotal gastrectomy en bloc with Roux-en-Y reconstruction, using TA 90 and GIA staplers. The length of the biliopancreatic limb was 50 cm, while the alimentary limb was 80 cm
214986213|NCT01072591|DRUG|Placebo for MEDI-578|Intravenous infusion, once
214682698|NCT06667284|PROCEDURE|Omega brown procedure|Gastrojejunal anastomosis with jejunojejunal anastomosis
214682699|NCT05138120|BEHAVIORAL|Common Elements Toolbox|An unguided online single-session intervention with four modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.
214682700|NCT02144220|OTHER|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
214682701|NCT04051567|DRUG|Aspirin 100mg|In LDA group, patients were asked for taking 100mg aspirin per night;
214986214|NCT03456934|OTHER|Modified infant formula|Test formula with lower protein content than standard formula
214986215|NCT03456934|OTHER|Standard infant formula|Standard infant formula
214986216|NCT06760819|DRUG|BAY2927088|tablet, oral
214986217|NCT00000965|DRUG|Zidovudine|
214682702|NCT02077049|DEVICE|serious games|"Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.~The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.~This serious games program is instructed individually by experienced physiotherapists."
214682703|NCT02077049|OTHER|Conventional self-training|Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
214372165|NCT04979312|DEVICE|LabClasp|Subjects will complete up to 10 measurements per day with potentially more before and during their OGTT using the LabClasp
214682704|NCT03959618|OTHER|dietary supplements questionary|Patient Questionary Patient to be carried out at the last cure
214682705|NCT03648996|OTHER|Low-fructose diet, isocaloric|6 month of consumption a low fructose diet
214682706|NCT03648996|DRUG|Allopurinol|6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
214682707|NCT03648996|DRUG|Placebo|6 months of placebo treatment
214682708|NCT03648996|OTHER|Low-fructose, hypocaloric|6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
214682709|NCT00590681|DRUG|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
214682710|NCT05604612|PROCEDURE|Corticision|Incisions in the cortical plate of maxillary bone
214682711|NCT03961919|DRUG|Fludarabine|Fludarabine i.v. 30 mg/m²/d day -6 to -2
214682712|NCT03961919|DRUG|ARA-C|Cytarabine i.v. 2 g/m²/d day -6 to -2
214682713|NCT03961919|DRUG|Treosulfan|Treosulfan i.v. 10 g/m²/d day -6 to -4
214682714|NCT03961919|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3"
214682715|NCT06295510|OTHER|No interventions.|It's only observational study.
214682716|NCT06309810|RADIATION|Radiotherapy|"The treatment will be administered with a TrueBeam™ (Varian Medical Systems, Palo Alto, CA, USA) linac, equipped with a Millenium 120-leaves MLC.~The target will be represented by 5 mm of the specific spinal nerve responsible for the spams. A lateral~1 mm margin will be added to the target to generate the corresponding planning treatment volume (PTV). The prescribed dose will be 45-60 Gy in a single fraction. The treatment dose will be chosen based on patients' general condition, and possibility to respect the dose limits (constraints) for the organs at risk (OARs)."
214682717|NCT01095952|DEVICE|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
214682718|NCT03207828|BEHAVIORAL|Behavioral activation|The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, \& Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
214682719|NCT03207828|OTHER|Usual care|Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
214372166|NCT04119388|OTHER|Adapted sports practices|Adapted sports practices for 30 minutes twice a week
214372167|NCT05619003|DEVICE|Biatain Silicone Sacral dressing|Biatain Silicone Sacral dressing will be applied over the bony prominence of the sacral area as part of a PIP (Pressure Injury Prevention) protocol in patients at risk
214372168|NCT06980428|DRUG|AZD4954|AZD4954 will be administered orally.
214682720|NCT04791397|PROCEDURE|Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
214682721|NCT04791397|PROCEDURE|Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
214372169|NCT06980428|DRUG|Placebo|Placebo will be administered orally.
214372170|NCT00693251|PROCEDURE|Crush technique|Crush technique
214372171|NCT00693251|PROCEDURE|provisional T stenting|Provisional T stenting
214372172|NCT05366764|DRUG|SAR443765|solution for injection
214372173|NCT05366764|DRUG|Placebo|solution for injection
214372174|NCT05366764|DRUG|Salbutamol or levosalbutamol|metered dose inhaler
214372175|NCT06863961|DRUG|Afimkibart|Afimkibart will be administered as SC injection.
214372176|NCT06863961|DRUG|Placebo|Placebo will be administered as SC injection.
214372177|NCT03901235|BIOLOGICAL|Mesenchymal Stromal Cells|Suspension of mesenchymal stromal cells for intratissular injection
214372178|NCT06865339|DRUG|Cemiplimab|Human IgG anti-PD-1 monoclonal antibody approved for treatment of advanced NSCLC with PD-L1 TPS ≥ 50% as monotherapy and in combination with chemotherapy
214372179|NCT06865339|DRUG|Fianlimab|Human IgG anti-lymphocyte activation gene 3 (LAG-3) monoclonal antibody, which is expressed by various immune cells, and regulates effector T-cell activation and responses. LAG-3 inhibition restores the effector function of exhausted T cells, enhancing their ability to attack tumor cells. Fianlimab is currently under investigation in several clinical studies involving NSCLC (NCT05800015, NCT03916627, NCT05785767).
214372180|NCT06865339|RADIATION|Radiotherapy|Thoracic radiotherapy. Conventionally fractionated 1.8-2.0 Gray (Gy) per day. Adaptive radiotherapy will not be performed unless difficulty with patient setup or changes in internal patient anatomy require repeating the CT simulation procedure
214372181|NCT06865339|DRUG|Platinum Doublet Chemotherapy (PDC)|Acceptable histology-specific PDC regimens include carboplatin plus paclitaxel or nab-paclitaxel (any histology), carboplatin/cisplatin plus pemetrexed (nonsquamous), carboplatin/cisplatin plus etoposide (any histology), and carboplatin/cisplatin plus docetaxel or gemcitabine (squamous). Carboplatin can be used instead of cisplatin after cycle 1 in cases of cisplatin-induced neuro-/oto-/nephrotoxicity as long as the patient remains eligible for chemoradiotherapy. Weekly radiosensitizing PDC will be recommended for PD-L1 TPS \<50% patients during RT but is not required.
214372182|NCT06066333|RADIATION|Ablative Radiotherapy|All participants will first undergo ablative RT
214372183|NCT06066333|DRUG|Pembrolizumab|After completion of ablative RT, all subjects may begin pembrolizumab treatment
214494373|NCT06712901|BEHAVIORAL|Control|There will be no message content of cancer screening and sharing intentions in this arm.
214372184|NCT06829667|DEVICE|Arthrex InternalBrace|Arthrex InternalBrace is composed of a polyethylene/polyester suture tape and knotless bone anchors to provide ligament repair bridging and reinforce ligament strength. There have been conflicting results surrounding the clinical efficacy of its use in lateral ligament reconstruction.
214494374|NCT06890962|DIETARY_SUPPLEMENT|Energy drink consumption|Participants will consume an energy drink (or placebo) and then undergo experimental testing after a 40 minute rest period following drink consumption.
214494375|NCT06760494|DIAGNOSTIC_TEST|the MAPUSE model|Using the MAPUSE model to predict MVI status before surgical resection for HCC patients
214494376|NCT05507970|DRUG|MMV367|Single dose dispersed in sterile water, fasted.
214372185|NCT05037760|DRUG|KER-050 monotherapy|KER-050 administered (SC) for up to 13 cycles. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
214494377|NCT05507970|DRUG|Placebo|Single Dose dispersed in sterile water, fasted.
214372186|NCT05037760|DRUG|KER-050 in combination with ruxolitinib|KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
214372187|NCT04884334|DEVICE|VAC-Stent®|treatment with the VAC-Stent®
214372188|NCT03920228|DRUG|PTX-022|PTX-022 QTORIN
214372189|NCT03920228|DRUG|Placebo|Placebo topical
214372190|NCT06059105|DEVICE|Immediate Implant Surgery|Inverted Co-Axis 12º Southern Implants
214372191|NCT06059105|DEVICE|Immediate Implant Surgery|Internal Conical (Deep Tapered Conical) South Implants
214372192|NCT00199719|DRUG|Ribavirine|
214372193|NCT06723158|OTHER|Virtual reality (VR) glasses with relaxation module|The relaxation module will include immersive video and audio components as a distraction from the medical procedures.
214494378|NCT05507970|DRUG|MMV367 (Fed 440mg)|Single dose dispersed in sterile water with a high fat meal.
214494379|NCT05507970|DRUG|MMV367|Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
214494380|NCT05507970|DRUG|Placebo|Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
214986218|NCT06390345|OTHER|FOCuSEd Integrated Intervention|"Participants randomized to the intervention will receive an integrated telehealth-delivered, remote lifestyle intervention that promotes healthy eating and 150 minutes per week of moderate-intensity physical exercise. This intervention will include a core curriculum during the first 3 months that includes: 1) a 12-session video based program; 2) goal setting and self-monitoring using a Fitbit tracker and MyFitnessPal; 3) lifestyle coaching; and 4) three tele-pulmonary rehab sessions and an additional 60-75 minutes of gradually increasing self-directed exercise per week. At the end of 3 months, we will offer to enter a recommendation for weight loss medications to intervention participants with a BMI of ≥ 27 kg/m2. In the post-core period (months 4-12), participants will continue to have as-needed access to the lifestyle coach."
214372194|NCT07043790|OTHER|Radical cystectomy with pelvic lymphadenectomy|"Gtoup A : Radical cystectomy group Radical cystectomy included surgical removal of the bladder, adjacent organs, and regional lymph nodes. In males, it included removal of urinary bladder, prostate, and seminal vesicles whereas in females, it included removal of urinary bladder and reproductive organs (ovaries, fallopian tubes, uterus, and anterior vagina).~Standard pelvic lymph node dissection was performed to all patients in this group."
214372195|NCT07043790|RADIATION|Trimodal therapy|"Group B : trimodal therapy group~the patients underwent maximal TURBT, where as much tumor as possible was completely resected using bipolar resectoscope. The goal was to remove all visible tumor including the underlying muscle layer and tumor edges.~This was followed by radio-sensitizing chemotherapy and radiotherapy..~Chemotherapy consisted of weekly administration of iv infusion of cisplatin (40mg/m2).~Radiotherapy delivered as EBRT aimed at delivering approximately 44- 46 Gy to the urinary bladder and pelvic lymphnodes.followed by additional boost to the bladder 54 GY and a final boost to the tumor 64-65 GY"
214986219|NCT06390345|OTHER|Enhanced Usual Care|"Participants in the enhanced usual care group will be referred to MOVE! (VA's weight loss management program) and pulmonary rehabilitation in coordination with their primary care provider."
214494381|NCT05507970|DRUG|MMV367 (Fasted 440mg)|Single dose dispersed in sterile water fasted.
214494382|NCT06806059|BEHAVIORAL|Physical Activity|The intervention group will engage in increased physical activity, aiming for a daily step count of at least 8,000, with a target of 10,000 steps, over a four-week preoperative period. Weekly supervised phone consultations will be conducted to provide guidance and support.
214494383|NCT06759285|BEHAVIORAL|Experimental (cradle position)|The newborn in cot bed was swaddled freely with the help of a thin blanket during feeding. Then, the nurse, wearing a box apron, took the baby in her arms and gave it a cradle position. The baby's physiological parameters and Comfort Scale were filled in before feeding began. The baby was kept in a cradle position on the researcher's lap during feeding. Immediately after feeding, without changing the baby's position, the physiological parameters and Comfort Scale were evaluated a second time, and again 15 minutes after feeding, without changing the position, the physiological parameters and Comfort Scale were evaluated a third time and recorded. Then, the baby was gently and slowly laid down on the denim bed as usual (right lateral).
214494384|NCT06849362|DRUG|Bevacizumab|"Bevacizumab is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody used in combination with chemotherapy or immunotherapy for the treatment of metastatic colorectal cancer (CRC). In this study, bevacizumab is administered as part of combination therapy in certain patient groups to assess its impact on treatment efficacy in MSS/MSI-L/pMMR advanced colorectal cancer.~Patients receiving bevacizumab will be evaluated for treatment response, survival outcomes, and potential biomarkers predictive of therapeutic efficacy. The study will compare the clinical benefits of immunotherapy alone, immunotherapy + bevacizumab, and immunotherapy + chemotherapy + bevacizumab to determine the optimal treatment strategy.~The dose and administration schedule of bevacizumab will follow standard clinical guidelines as per institutional protocols."
214494385|NCT06866223|BEHAVIORAL|Sentence recast|Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax
214494386|NCT06667661|BEHAVIORAL|Shining Star mHealth App|The Shining Star mHealth App Intervention is a 12-week mobile health program designed to improve adherence to the 24-Hour Movement Guidelines (physical activity, screen time, and sleep) among preschool-aged children (3-4 years old). The intervention delivers weekly behavior-related goals and educational lessons to parents through a mobile app, including concise messages (\&lt;500 characters) and links to additional resources. The app also includes gamification features, behavior trackers, and a \&#34;Kids Corner\&#34; for child-friendly content. Parents receive reminders and can engage with other participants through an optional chat forum.
214494387|NCT06768450|BEHAVIORAL|Online mindfulness meditation|"The mindfulness meditation program is adapted from the Breathwork Mindfulness for Stress program. However, it uses shorter meditations designed for individuals who cannot sit for 40 minutes. The mindfulness meditation program encourages greater self-acceptance, kindness, and compassion toward oneself. It builds on this concept by helping participants find pleasure in life despite suffering, fostering kindness and compassion toward others, and increasing social connections to counteract the social isolation common among individuals with chronic and long-term illnesses.~The program will be led by a well-trained Breathwork mindfulness instructor and conducted remotely via Microsoft Teams once a week for 8 weeks. Each session will last 2 to 2.5 hours and consist of body scans, mindful movements, and various meditations, introducing new ideas every week."
214494388|NCT00902044|GENETIC|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
214682722|NCT04134104|PROCEDURE|Surgery for Colorectal malignant diseases either LAR or APR|Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
214682723|NCT00023907|DRUG|paclitaxel|
214682724|NCT01696409|DIETARY_SUPPLEMENT|400 IU vitamin D3|Take 400 IU once/day for 2 months
214682725|NCT01696409|DIETARY_SUPPLEMENT|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
214682726|NCT03469193|PROCEDURE|internal PUC implanted with mechanical ancillary|The control group consists of patients operated with a mechanical ancillary (reference surgery in our department). In this technique, bone sections are made with a standardized ancillary (manually adjusted bone cutting guides), according to preoperative radiological planning. The positioning of the implants is done manually and controlled by the placement of test implants.
214682727|NCT03469193|PROCEDURE|Internal PUC implanted with robotic assistance|Patients are operated by robotics (surgery that we want to develop systematically in our service). 3D modeling of the knee allows the operator to perform a dynamic planning taking into account the reducibility of the deformation and the model of the implant. The operator can position the implants in three dimensions of the space without difficulty. This makes it possible to visualize, before the bone resections, the angular correction obtained between 0 and 130° flexion and alignment of the prosthesis by visualizing the contact points between the two implants. Bone resections will be performed using a guided retro bone drill. The system retracts more or less the cutter according to the bone thickness to be removed. This technique requires the insertion of two threaded plugs in the tibia and two in the femur to position the sensors that will allow the acquisition of anatomical landmarks of the lower limb and then 3D modeling
214682728|NCT00002191|DRUG|Albendazole|
214682729|NCT00504166|DRUG|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
214682730|NCT00504166|OTHER|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
214372196|NCT06723912|OTHER|Health Action Process Approach-Based Program|Health Action Process Approach-Based Program: The program is planned for six weeks (six sessions). Sessions will be held once a week for 30-45 minutes. Within the scope of the program, care - structured nursing care plans based on the Health Action Process Approach will be made -, education and counseling will be provided. Sessions will be held in a quiet, calm environment in the hospital, and if such an environment cannot be provided, they will be held at the patient's home. The day, time and place of the sessions will be decided together with the participant after each interview or session. At the beginning of each session, the previous session will be briefly recalled and the homework (SWOT analysis, treatment adherence tracking chart or SMART goal plan) given in the previous session will be evaluated. At the end of each session, the evaluation of that day's session will be carried out briefly.
214372197|NCT06723314|PROCEDURE|Vestibular Subperiosteal Tunnel Access vista|CAF procedures were performed (Split-Full-Split flap), following the anesthetic agent, the sulcular incision was performed by a full thickness vertical incision till the muccogingival junction• Split thickness releasing incision was made at the flap base with full thickness flap reflection till the muccogingival junction.
214682731|NCT06070623|DEVICE|US|We use elastography and color Doppler from US machine and compare results with CT
214682732|NCT04743414|DRUG|CTP-543|Itraconazole in solution dosage form
214682733|NCT02229864|DEVICE|Coronary artery stenting: Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm"
214682734|NCT01227915|DRUG|Tobracort|tobramycin 0.3% + dexamethasone 1%
214682735|NCT01227915|DRUG|Tobradex|tobramycin 0.3% + dexamethasone 1%
214682736|NCT03704792|DEVICE|FibroScan 530 Compact|The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
214494389|NCT00902044|DRUG|Fludarabine|"Fludarabine will be administered for 5 days prior to the T cells~The dose:~\>10 kg: 25 mg/m2/day;~\<10 kg: 1 mg/kg/day IV over 30 minutes"
214682737|NCT05527704|DRUG|Salbutamol|Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
214494390|NCT00902044|DRUG|Cyclophosphamide|"Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~\>10 kg: 25 mg/m2/day; \<10 kg: 1 mg/kg/day IV over 30 minutes"
214682738|NCT05527704|DRUG|0,9% Chloride Sodium|3 mL nebulized 0.9% NaCl administered for 30 min.
214682739|NCT05090410|DRUG|filgotinib 200mg/day|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
214986220|NCT06401603|DRUG|Decitabine|Given by IV
214986221|NCT06401603|DRUG|Listaftoclax|Given by PO
214986222|NCT06401603|DRUG|Olverembatinib|Given by PO
214986223|NCT05555732|DRUG|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
214986224|NCT05555732|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
214986225|NCT05555732|DRUG|Pemetrexed|Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
214986226|NCT05555732|DRUG|Carboplatin|Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
214986227|NCT05555732|DRUG|Cisplatin|Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
214494391|NCT00902044|GENETIC|Autologous CAR Positive T cells|Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.
214682740|NCT05090410|DRUG|subcutaneous tocilizumab 162mg/biweekly|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
214682741|NCT02458612|OTHER|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
214682742|NCT02458612|OTHER|intervention group|"Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
214372198|NCT03444376|DRUG|GX-188E|GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device
214986228|NCT02484248|DRUG|Ketotifen|Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
214372199|NCT03444376|DRUG|KEYTRUDA®|pembrolizumab(100mg/4mL/vial), Intravenous administration
214986229|NCT02484248|DRUG|Placebo|The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
214372200|NCT06724991|PROCEDURE|Lower Dose Therapy|The group receiving the lower-dose therapy consists of 5 units of Actrapid (insulin) with 25cc of Dextrose 50%. This intervention is the focus of the clinical trial and is being investigated to determine if it achieves a comparable reduction in potassium levels with fewer potential complications. The aim is to establish it as a non-inferior alternative to conventional-dose therapy in the management of mild and moderate hyperkalemia.
214986230|NCT04226170|DRUG|DAS-001|ondansetron + pyridostigmine
215089250|NCT01483209|DRUG|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
215089251|NCT04957758|DRUG|OC-01 (varenicline) nasal spray 1.2 mg/ml|OC-01
214372201|NCT06724991|PROCEDURE|Conventional Dose Therapy|The group receiving the conventional-dose therapy, consisting of 10 units of Actrapid (insulin) with 50cc of Dextrose 50%, which is currently in use as a standard practice in emergency departments for managing mild and moderate hyperkalemia. This dosing regimen aligns with established clinical guidelines and is widely accepted as an effective approach in controlling potassium levels.
214372202|NCT06724757|OTHER|Health questionnaire|The intervention involves the completion and analysis of an online questionnaire designed to assess the health (mental, physical, social) of caregivers aged 50 and over in Quebec. This assessment is based on a combination of questionnaires (CARE, 4-item Zarit scale, 4-item GDS, 3-item UCLA loneliness scale, etc.).
214372203|NCT07050758|BEHAVIORAL|Pain Reprocessing Therapy|"Each PRT session will take 45-60 minutes and includes psychoeducation about the association between pain and the brain, mindfulness, and exposure- and acceptance-based concepts. Through PRT, participants will learn about how pain can emerge from 'stuck patterns' in neural circuits in the brain. Through reflections of their own pain experiences, the patient explores evidence for whether this applies to their own pain. Patients will acquire corrective experiences in which their brain learns not to respond with pain (false alarm) in situations that are safe. One central reprocessing exercise is 'somatic tracking', in which participants explore their pain sensations in a context of safety. This includes interoceptive exposures and situational exposures to activities they fear will trigger pain. Exploring these sensations and situations through a lens of safety and curiosity allows the participants to reinterpret bodily sensations previously associated with threat or pain, as safe."
214372204|NCT06566742|DRUG|Olutasidenib|Given by PO
214372205|NCT06465199|DRUG|Eflornithine (DFMO)|Oral DFMO capsules
214372206|NCT06465199|DRUG|AMXT 1501 Dicaprate|Capsule
214372207|NCT07060495|DEVICE|RADA16 hydrogel|Application of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.
214372208|NCT07071532|DRUG|ABBV-932|Oral Capsule
214494392|NCT06766526|BEHAVIORAL|Internet-based cognitive behavioral therapy|An eight week ICBT treatment. The treatment is modular and tailored to the problem profile of the participant. One module will be administered every week during the treatment phase.
214494393|NCT06766526|BEHAVIORAL|Non-directive support|Participants randomized to this condition will receive weekly support and contact with a therapist via the treatment platform. They will not have access to the treatment modules during the treatment phase.
214682743|NCT01581112|BIOLOGICAL|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
214682744|NCT01531218|DRUG|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
214682745|NCT01531218|DRUG|Placebo|
214682746|NCT02650284|DEVICE|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
214682747|NCT02650284|DEVICE|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
214986231|NCT04228289|DRUG|Oxytocin|40 IU intranasal spray
214986232|NCT04228289|OTHER|Placebo|matching intranasal spray
214986233|NCT06525935|DRUG|Placebo|Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
214986234|NCT06525935|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
214986235|NCT02580812|OTHER|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
214986236|NCT06209242|PROCEDURE|Percutaneous pinning|Using k- wire percutaneous pinning with local anesthesia with one-day surgery protocol
214986237|NCT06209242|PROCEDURE|Cast immobilization|Using sugar tong slab and then replace to short arm casting within 1 week
215089252|NCT04957758|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle)
215089253|NCT00487448|DRUG|Fludarabine|
215089254|NCT00487448|DRUG|Cytarabine|
215089255|NCT00487448|DRUG|G-CSF|
215089256|NCT00487448|DRUG|Idarubicin|
215089257|NCT00487448|PROCEDURE|Peripheral blood stem cell transplantation|
215089258|NCT00487448|PROCEDURE|Bone marrow transplantation|
215089259|NCT01901965|BEHAVIORAL|Neuromuscular electrical stimulation|
215089260|NCT01901965|BEHAVIORAL|eccentric training|
215089261|NCT00707746|DRUG|mipomersen|
215089262|NCT00707746|DRUG|placebo|
214372209|NCT07071532|DRUG|Itraconazole|Oral Capsule
214372210|NCT04584905|DIETARY_SUPPLEMENT|dietary supplements for CKD patients|follow up and assessment of nutritional status of CKD patients
214682748|NCT06314906|DEVICE|Electroacupuncture|Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz
214986238|NCT06961877|BEHAVIORAL|Cannabis Conversation Skills for Families (CCSF)|The purpose of the intervention is to train family members in communication skills that may increase contemplation of change in their loved one with first episode psychosis to reduce cannabis use, decrease conflict surrounding these discussions, and provide skills to understand when and how to approach their loved one about cannabis use and encourage treatment. Because families report confusion from the mixed messages they receive about cannabis and also desire research-based information, CCSF will involve psychoeducation on the risks and relationship of cannabis to psychosis to increase participants motivation to engage in the intervention. frequency of cannabis use as it relates to psychosis treatment outcomes.
214682749|NCT06314906|DRUG|Antiemetic Therapy|Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
214986239|NCT03692949|DRUG|LY3451838|Administered IV Part A
214372211|NCT06701812|DRUG|Digoxin|2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.
214372212|NCT04729387|DRUG|Alpelisib|Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
214494394|NCT06734962|PROCEDURE|Apical surgery procedure using A-PRF|Participants will undergo an apical surgery procedure using A-PRF. Before the surgery and at follow-ups, patients will undergo comprehensive evaluation using clinical, radiological, and ultrasonographic techniques.
214494395|NCT06734962|PROCEDURE|Apical surgery without using A-PRF|Participants will undergo an apical surgery procedure without using A-PRF. Patients will undergo comprehensive evaluation before the surgery and at follow-ups using clinical, radiological, and ultrasonographic techniques.
214494396|NCT06780280|OTHER|Overground Walking|Overground walking with an exoskeleton
214494397|NCT06758102|BEHAVIORAL|Dance Program|A 12-week, virtual dance program consisting of seated and standing choreography and contemporary style elements will be taught by a certified dance instructor. Sessions will be conducted by the HIPAA-compliant, video-conferencing platform, Zoom.
214494398|NCT06892262|OTHER|Athletes|The group was included in strength assessment using an isokinetic dynamometer and postural stability evaluation. (high level training group)
214494399|NCT06879704|OTHER|Imaging assessment|The patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan
214494400|NCT06089915|BEHAVIORAL|Standard occupational therapy|Standard occupational therapy as part of inpatient rehabilitation
214986240|NCT03692949|DRUG|LY3451838|Administered IV Part A
214986241|NCT03692949|DRUG|LY3451838|Administered IV Part A
215089263|NCT03802045|PROCEDURE|Electroacupuncture|"The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3."
215089264|NCT03802045|DEVICE|Needle|Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
215089265|NCT03802045|DEVICE|Adhesive Moxa|In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
215089266|NCT00435526|BIOLOGICAL|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
215089267|NCT06055816|DRUG|Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
215089268|NCT02322190|PROCEDURE|Extracorporeal Photopheresis (ECP)|Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment.
215089269|NCT02322190|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
215089270|NCT00495378|DRUG|epoetin alfa|
215089271|NCT01259453|BIOLOGICAL|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
215089272|NCT04787068|BEHAVIORAL|Occupational Therapy support|Intervention include (a) didactic education about diseases; (b) the use of errorless techniques to improve assistance for CR's Activities of Daily Living (ADL), Instrumental ADL, and communication tasks; (c) the use of incentives (e.g., providing a favorite scented shampoo); (e) use of a schedule/calendar on a computer, cell phone and/or blackboard in CR's home to coordinate caregiving tasks for family members; (f) suggesting more frequent PACE daycare visits or use of a nearby PACE, having a snack or short game to prevent going to bed right after dinner); (d) use of the Buffalo Functional Exercise for strengthening ( a home-based exercise developed for PACE by the PI and shown to be effective in preventing falls)
215089273|NCT00252460|DEVICE|Computed Tomography Scan and Magnetic Resonance Imaging|
214372213|NCT04729387|DRUG|Olaparib|Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
214372214|NCT04729387|DRUG|Paclitaxel|Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter
214372215|NCT04729387|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered at 40-50 mg/m2 (physician discretion) as an intravenous infusion once every 28-days in a 28 day treatment cycle, starting on Cycle 1 Day 1
214372216|NCT06008756|DRUG|Enlicitide Decanoate|Enlicitide Decanoate 20 mg tablet taken by mouth.
214682750|NCT06314906|DEVICE|Sham electroacupuncture|Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group
214682751|NCT06314906|DRUG|Antiemetic Therapy|They will also receive the same antiemetic medications as the experimental group.
214986242|NCT03692949|DRUG|LY3451838|Administered IV Part A
214986243|NCT03692949|DRUG|LY3451838|Administered IV Part A
214986244|NCT03692949|DRUG|LY3451838|Administered IV Part A
214986245|NCT03692949|DRUG|LY3451838|Administered SC Part B
214986246|NCT03692949|DRUG|Placebo|Administered IV in Part A and SC in Part B
214494401|NCT06089915|DEVICE|Robot-assisted exercise using Amadeo device and Armeo Spring exoskeleton|Exercise for fingers and hand using Amadeo device plus gross-motor exercise using Armeo Spring exoskeleton
214986247|NCT06425237|OTHER|music therapy|standard patient care in interventional radiology associated with a well-being atmosphere with the implementation of music therapy (soothing sound environment) in the preparation box and in the examination room.
214494402|NCT06785857|OTHER|mHealth Supportive Care Program|On the basis of monthly home visits in the control group, a weekly mHealth supportive care intervention program was added through the medium of Xiamen iHealth, with one supportive care item every two weeks for 12 weeks, for a total of 12 online interventions, as well as the provision of online consulting and booking services for caregivers at any time.
214494403|NCT06785857|OTHER|Offline supportive care|"This was done routinely in accordance with the requirements of public health services for chronic diseases in the community elderly. In addition, health education on diabetes mellitus and dementia was provided to the caregivers during their monthly home visits.~① the content of diabetes health education: the researcher gave the caregivers education and training on the care of diabetes patients: the main points of care in diet, sleep, exercise, etc.~② The content of dementia health education: the researcher gave the caregivers education and training related to the care of dementia patients: instructing the caregivers in the basic life care skills of patients' diet, sleep, exercise, etc."
214986248|NCT06425237|OTHER|aromatherapy|standard patient care in interventional radiology associated with a well being atmosphere with the implementation of aromatherapy (essential oil of Ylang Ylang) in the preparation box and in the examination room.
214986249|NCT00937196|DRUG|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
214986250|NCT00937196|DRUG|Histaminum hydrochloricum globuli|
214494404|NCT06893120|OTHER|BETY|The cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) will be applied for 24 one-hour sessions, two days a week.
214494405|NCT04787341|DRUG|Regorafenib|"regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
214986251|NCT03454620|DRUG|irinotecan|GC1118 combination with irinotecan
214372217|NCT06008756|DRUG|Placebo|Placebo tablet matched to enlicitide decanoate taken by mouth.
214372218|NCT06388421|OTHER|Prospective study assessments|Patients will complete prospective assessments at 6- and 12-month intervals for up to 5 years. There will be 1 check in at the first 3 months of enrollment. Follow up visits will include a ±45 day visit window. If an assessment is performed within 45 days of the visit window as part of the patient's standard of care, those values will be used in place of a prospective assessment.
214682752|NCT05296421|PROCEDURE|Biopsy|Undergo biopsy
214986252|NCT03454620|DRUG|FOLFIRI|GC1118 combination with FOLFIRI
214986253|NCT06065540|DRUG|Cagrilintide|Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached.
214372219|NCT04852562|PROCEDURE|Modified radical endoscopic sinus surgery|Modified radical endoscopic sinus surgery was performed to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate.
214372220|NCT04852562|PROCEDURE|functional endoscopic sinus surgery|Full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
214372221|NCT03916432|DEVICE|HELIOS biodegradable polymer sirolimus-eluting stents|HELIOS biodegradable polymer sirolimus-eluting stents
214372222|NCT05885659|OTHER|Control group (waiting list)|T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet. Participants assigned to this control group will participate in the scheduled assessments (pre- and post-treatment, 1-month, 6-months and 12-months follow-ups) but without receiving any of the intensive treatments previously described (CBT vs. CBT+DiME-SALUD2 protocol).
214986254|NCT06065540|DRUG|Semaglutide|Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
214986255|NCT06065540|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
214986256|NCT06065540|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
214986257|NCT06274827|DIAGNOSTIC_TEST|Superficial Electromyography|For all MVICs, five seconds of each repetition were included in the analysis and the maximum value of three repetitions was taken. For all exercises, the middle 3 seconds of the 5 second data collection period were included in the analysis and the average muscle activation level of the three repetitions was recorded. The average signal amplitude of each exercise was divided by the MVIC of each muscle of interest to obtain the %MVIC value.
214986258|NCT04855136|BIOLOGICAL|BB2121|CAR T Cell Therapy
214372223|NCT05885659|BEHAVIORAL|Cognitive Behavioral Treatment (CBT) for smoking cessation|CBT for smoking cessation will be implemented in group-based sessions of four to six patients, once a week over an eight-week period (Becoña, 2007), and includes three different components: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards. This modality of treatment also includes the following components, among others: Therapeutic contract, self-monitoring and graphical representation of tobacco consumption, psychoeducation about tobacco and specific characteristics of smoking behavior, stimulus control, strategies for coping with nicotine withdrawal symptoms, physiological feedback of consumption (using CO and cotinine in urine levels), social reinforcement when meeting nicotine reduction and abstinence goals, training in alternative behaviors to consumption and strategies for the prevention of relapses.
214372224|NCT05885659|BEHAVIORAL|CBT for smoking cessation + DiMeSALUD2 protocol|In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation). CBT plus DiMe-SALUD2 protocol will be developed as in the precedent group, but with the addition of a psychoeducational protocol for monitoring nicotine fading and abstinence specifically designed to address the particular needs of T2DM smokers. The main components of this protocol will be focused on strengthening healthy lifestyle habits as well as structured around the following core elements: dietary control and healthy nutrition, physical exercise, and glycemic control through daily self-registration of both glycemic variability and nicotine fading or abstinence. If necessary, the therapist will adapt these guidelines according to the established medical advice that the smokers receive from their own endocrinologist, so that this program is developed in accordance with their usual medical care.
214372225|NCT04803201|DRUG|Cyclophosphamide|Given IV
214372226|NCT04803201|DRUG|Doxorubicin|Given IV
214372227|NCT04803201|DRUG|Vincristine|Given IV
214494406|NCT04787341|DRUG|Panitumumab|"panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
214494407|NCT06750991|DRUG|CDR-CHOP|Rituximab 375 mg/m2 D1 Cyclophosphamide 750 mg/m2 D2 Doxorubicin 50 mg/m2 D2 Vincristine 1.4 mg/m2 D2 Prednisone 69 mg.m2 D2-6 Chidamide 20 mg/d D1,4,8,11 Decitabine 10 mg/m2 D-5 - -1
214494408|NCT06532396|DRUG|QRL-101|Multiple-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
214494409|NCT06532396|DRUG|Placebo|Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.
214494410|NCT06756555|DIAGNOSTIC_TEST|efficacy of Incentive spirometer|The main objective of this research is to check the efficacy of Incentive spirometer on pulmonary complication after bariatric surgrey
214494411|NCT06756334|DRUG|[18F]AlF-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]AlF-PSMA-N5, and undergo PET/CT imaging within the specificed time.
214494412|NCT06756334|DRUG|[18F]F-DCFPyL|Each subject receive a single intravenous injection of \[18F\]F-DCFPyL, and undergo PET/CT imaging within the specificed time.
214494413|NCT06756919|BEHAVIORAL|Music intervention|Music therapy ( nature sounds) during the endoscopy procedure
214494414|NCT06736834|OTHER|Babao Congee and Youtiao(deep-fried dough sticks) with different cooking conditions|Babao Congee and deep-fried dough sticks with different cooking conditions
214494415|NCT06767384|RADIATION|X-ray|To determine diagnostic accuracy of x-ray KUB in diagnostic renal and ureter calculi keeping CT scan KUB as a gold standard.
214494416|NCT06766734|PROCEDURE|Tendon Dry Needling|Tendon dry needling procedure is that repetitively passing the needle though the area of supraspinatus tendon. Tendon dry needling was performed under sterile conditions with real-time imaging guidance using an ultrasound probe. The supraspinatus tendon was scanned from anterior to posterior, and tendon dry needling was applied to the identified lesion (tendinozis or partial tear) area. This treatment method was applied twice, with a one-month interval between sessions.
214494417|NCT06766734|PROCEDURE|Sham Tendon Dry Needling|In this treatment subcutaneous sham tendon dry needling was performed by randomly holding the ultrasound probe in the area corresponding to the same anatomical localization. Sham tendon dry needling performed to subcutaneus tissue not tendon.
214372228|NCT04803201|DRUG|Prednisone|Given PO
214986259|NCT04855136|DRUG|CC-220|Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)
214986260|NCT04855136|DRUG|BMS-986405|gamma secretase inhibitor (GSI)
214682753|NCT05296421|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214682754|NCT05296421|OTHER|Uniformly-labeled [13C]glucose|Given IV
214372229|NCT04803201|DRUG|Etoposide|Given IV or PO
214372230|NCT04803201|DRUG|Duvelisib|Given PO
214372231|NCT04803201|DRUG|Oral azacitidine|Given PO
214986261|NCT00621101|DRUG|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
214986262|NCT00621101|DRUG|1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
214986263|NCT00621101|DRUG|1 tablet Ezetrol(R) + 1 tablet Rapamune(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
215089274|NCT04167215|PROCEDURE|superior gluteal artery flap and lumbar artery falp|Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
214372232|NCT04081220|DRUG|IMG-7289|Single starting dose with individualized dose titrations throughout
214372233|NCT05787561|DRUG|Avutometinib (VS-6766)|3.2 mg PO, twice weekly
214372234|NCT05787561|DRUG|Defactinib|200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
214372235|NCT07081074|DRUG|Amino acid-derived lipids|Amino acid-derived lipids are applied to the treatment area, once daily during radiotherapy.
214372236|NCT07081074|BEHAVIORAL|standard of care|Standard of care
214372237|NCT05891171|DRUG|AB598|Administered as specified in the treatment arm
214372238|NCT05891171|DRUG|Zimberelimab|Administered as specified in the treatment arm
214372239|NCT05891171|DRUG|Fluorouracil|Administered as specified in the treatment arm
214372240|NCT05891171|DRUG|Leucovorin|Administered as specified in the treatment arm
214372241|NCT05891171|DRUG|Oxaliplatin|Administered as specified in the treatment arm
214986264|NCT01032928|BEHAVIORAL|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
214986265|NCT05966103|OTHER|Exercises|For control group; Cervical conventional exercises. For treatment group; scapulothoracic exercises including strengthening, proprioceptive and stabilization exercises in addition to cervical conventional exercises
215089275|NCT04167215|PROCEDURE|The gluteal pocket|pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
215089276|NCT04167215|PROCEDURE|infragluteal dermal lifiting flap|dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
214372242|NCT06058039|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
214372243|NCT06058039|DRUG|Placebo|Placebo will be administered orally
214372244|NCT07093931|DRUG|lobaplatin|30mg / m2 i.v. q3w
214372245|NCT07093931|DRUG|carboplatin|AUC 5-6 i.v. q3w
214372246|NCT07093931|DRUG|Docetaxel or albumin paclitaxel|Docetaxel ( 75 mg / m2 i.v. d1, q3w ) or albumin paclitaxel ( 260 mg / m2 i.v. d1, q3w )
214372247|NCT07093931|DRUG|Trastuzumab|6 cycles of treatment, according to the instructions recommended dosage.
214372248|NCT07093931|DRUG|pertuzumab|6 cycles of treatment, according to the instructions recommended dosage.
214372249|NCT07093099|BEHAVIORAL|Enhanced Education Package for Bowel Preparation|"a multifaceted intervention was designed to improve mechanical bowel preparation (MBP) in patients undergoing colonoscopy. It included:~Structured face-to-face counseling on the importance of bowel prep, potential complications of poor prep, and how to follow instructions.~A 6-minute instructional video explaining step-by-step dietary and medication instructions.~A printed booklet with visual aids summarizing key steps.~A mobile phone app delivering interactive reminders, tracking tools, and preparation guidance.~All participants used the same polyethylene glycol-based bowel cleansing agent."
214372250|NCT07093099|OTHER|Standard Education Leaflet|Participants in this arm received a standard hospital-issued bowel preparation instruction leaflet. The document provided written instructions on dietary modifications, timing and dosage of the bowel cleansing agent, and day-of-procedure guidance. No personalized counseling, video support, or reminder tools were provided. This reflects the routine care practice at the study hospitals.
214372251|NCT07092969|DEVICE|Treadmill Exercise|Participants in this group will perform an aerobic exercise using the Bruce Protocol on a treadmill. The test involves walking or running with gradually increasing speed and incline in predefined stages to assess cardiovascular endurance. Heart rate, blood pressure, and fatigue levels will be recorded at each stage. The session will conclude with a low-intensity cool-down phase.
214494418|NCT06210243|BIOLOGICAL|C752|C752 will be administered on Day 0
214494419|NCT06619327|BEHAVIORAL|Resilient Together for Dementia|RT-D has been developed based on feedback from couples and dementia clinicians as well as prior successful dyadic interventions. RT-D was developed based on the Recovering Together (RT) dyadic intervention for acute neurological illnesses and is being adapted to address the needs of couples navigating new dementia diagnoses.
214494420|NCT06619327|BEHAVIORAL|MEUC|The MEUC condition was also developed based on the comparison trial in the Recovering Together dyadic intervention, and was adapted based on feedback from prior studies. The program is self-guided and provides educational information similar to the RT-D condition, but with no skills practice or weekly sessions with a therapist.
214494421|NCT06117111|DEVICE|PaMo monitoring device|Comparison of the device to standard monitoring
214986266|NCT05213780|OTHER|No intervention is involved|No intervention is involved
214986267|NCT01449565|DRUG|Naltrexone|3 monthly intramuscular injections of naltrexone 380 mg (extended release)
214986268|NCT01449565|DRUG|Placebo|3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
214986269|NCT02749409|DRUG|Parecoxib|
214986270|NCT02749409|DRUG|Morphine|
214986271|NCT01850316|RADIATION|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
214372252|NCT07092969|DEVICE|Bicycle Exercise|The Wingate Anaerobic Test will be conducted using an ergometer bike. After a standardized warm-up, participants will pedal all-out for 30 seconds against a preset resistance, aiming to evaluate their anaerobic performance. Physiological parameters including power output, heart rate, and oxygen saturation will be monitored throughout the test.
214372253|NCT07093268|DRUG|Intrathecal Riluzole|Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.
214986272|NCT04836377|OTHER|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention
214986273|NCT02592824|DRUG|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
214986274|NCT02592824|DRUG|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
214372254|NCT07092735|BEHAVIORAL|Neuro-Athletic Training|Participants receive a structured 8-week NAT program including oculomotor, vestibular, and proprioceptive drills, 3 sessions/week (35-45 minutes each).
214372255|NCT07092735|OTHER|Standard Training|Participants continue their standard in-season football training program without any NAT components.
214682755|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
214682756|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement with reference|blood glucose measurement with reference method using finger tip capillary blood
214682757|NCT03611400|DIETARY_SUPPLEMENT|Probiotic|This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10\^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10\^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
214682758|NCT03611400|DIETARY_SUPPLEMENT|Placebo|The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
214986275|NCT04074811|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will use the Figure of 8 coil, which affects \~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on \>50% of trials.
214986276|NCT04290104|DRUG|1gr oral ampicillin/sulbactam group|Group prescribed 1 g oral ampicillin/sulbactam 2 times a day.
214986277|NCT05266768|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
215089277|NCT03854890|DRUG|Indocyanine Green|Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
215089278|NCT00990145|DRUG|EDP-322|
215089279|NCT05978635|BEHAVIORAL|Group A Standard 4 deep breaths measured in milliliters from the ventilator.|Tidal volume breath measured in milliliters
215089280|NCT05978635|BEHAVIORAL|Group B Coached 4 deep breaths measured in milliliters from the ventilator|Coached tidal volume breath measured in milliliters
215089281|NCT03304067|BEHAVIORAL|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
215089282|NCT01656629|DRUG|Teriparatide|20 mcg subq daily for 3 months
215089283|NCT01656629|DRUG|Alendronate|70 mg weekly for 3 months
215089284|NCT01656629|DIETARY_SUPPLEMENT|calcium and vitamin D|
215089285|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
214372256|NCT07094074|OTHER|Walk tests|"* 200 m walk test~* 2-minute walk test~* 6-minute walk test"
214372257|NCT07094074|OTHER|Functional testing|Timed Up and Go test (TUG), Berg Balance Test (BBT), Choice Stepping Reaction Time (CSRT), Functional Reach Test (FRT)
214372258|NCT07094074|OTHER|Balance analysis|Balance analysis
214372259|NCT07094074|OTHER|Quantified analysis of walking|On flat ground, even on slopes and stairs
214372260|NCT07094074|OTHER|Questionnaires|Houghton, Prosthetic Profile of the Amputees-Locomotion Capabilities Index (PPA-LCI), Activities-specific Balance Confidence scale (ABC), quality of life assessed by the SF-12
214682759|NCT03711552|OTHER|ObsQoR-11|Quality of recovery questionnaire
214682760|NCT03711552|OTHER|QoR-15|Quality of recovery questionnaire
214682761|NCT00000637|DRUG|Zidovudine|
214682762|NCT00000637|DRUG|Didanosine|
214986278|NCT02559167|DRUG|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
214986279|NCT04971655|OTHER|Music therapy|Music therapy will be applied throughout diabetes education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered to individuals as an option and will be listened to throughout the process. Instrumental works will be uploaded to the computer by the researchers and will be played on the loudspeaker during the training.
214986280|NCT00490308|DRUG|Treatment with estradiol valerate|
214372261|NCT07093333|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
214372262|NCT06932614|PROCEDURE|Lyophilized self growth factor|Knee Intraarticular injection with Lyophilized self growth factor
214372263|NCT06932614|PROCEDURE|Platelet-Rich Plasma(PRP)|Knee Intraarticular injection with Lyophilized self growth factor
215089286|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
214372264|NCT06932614|PROCEDURE|Placebo|Knee Intraarticular injection with normal saline
214494422|NCT06137638|DRUG|ENA-001|ENA-001 will be prepared in Ringer's lactate solution. A loading dose will be administered for 20 minutes followed by continuous infusion until the patient meets the criteria for PACU discharge (≥ 9 Aldrete score) or ABG reveals PaCO2 \< 30 mmHg with pH in the normal range. ENA-001 is for IV injection ready for use per subject by the investigational pharmacy, according to the randomization schedule.
214494423|NCT04007796|BEHAVIORAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
214494424|NCT04007796|BEHAVIORAL|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
214682763|NCT00564707|BEHAVIORAL|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
214682764|NCT00564707|PROCEDURE|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
214682765|NCT03435653|OTHER|OFD with DFDBA|Control Group Open flap debridement with DFDBA Periodontal surgery will be performed in the form of open flap debridement along with placement of demineralized freeze dried bone allograft at the defect site.
214372265|NCT07139587|DRUG|Iparomlimab/Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-bound paclitaxel|Iparomlimab/Tuvonralimab : 5.0mg/kg, D1, Q3W Albumin-bound paclitaxel: 260mg/m², D1, Q3W
214494425|NCT05958030|DEVICE|Placebo|The placebo device consists of the same hardware as GyroGlove: aesthetically it looks the same, weight same and produces the same noise as GyroGlove. Participants will interact with Placebo on the day of baseline visit (i.e. Day 0).
214494426|NCT05958030|DEVICE|GyroGlove|GyroGlove is a patented wearable device containing high-performance, miniaturised, gyroscopes designed for individuals diagnosed with essential tremor. Participants will interact with GyroGlove on the day of baseline visit (i.e. Day 0), 2-week Home use and on the day of follow-up visit (i.e Day 14).
214494427|NCT05019742|DRUG|SPH3127|SPH3127 - selective renin inhibitor
214494428|NCT05019742|DRUG|Placebo|Placebo
214494429|NCT06411132|OTHER|observational study|observational study
214494430|NCT01297166|DRUG|LEO 27989 ointment|once daily application, 3weeks
214494431|NCT01297166|DRUG|Calcipotriol plus LEO 27989 ointment|once daily application, 3weeks
214494432|NCT01297166|DRUG|Calcipotriol ointment|once daily application, 3weeks
214494433|NCT01297166|DRUG|Vehicle ointment|once daily application, 3weeks
214494434|NCT03978637|DRUG|Itacitinib|Itacitinib administered orally at the specified dose.
214494435|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment, DCOOP Product, Hydroxytyrosol extract|Intervention group will receive a nutritional formula from DCOOP (Spain).
214494436|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment,Indukern product, Curcumin and selenium extract|Intervention group will receive a nutritional formula from Indukern (Spain).
214494437|NCT05472753|OTHER|Control Treatment|Control group will receive a placebo (product loading substance)
214682766|NCT03435653|OTHER|OFD with decortication and DFDBA|Test Group Open flap debridement with decortication and demineralised freeze dried bone allograft Open flap debridement with decortication and placement of demineralized freeze dried bone allograft at the defect site.
214682767|NCT00021853|BEHAVIORAL|constraint-induced movement therapy|
214682768|NCT00509873|DRUG|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
214682769|NCT00509873|DRUG|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
214682770|NCT04877548|OTHER|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
214682771|NCT04877548|OTHER|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
214682772|NCT04877548|OTHER|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
214682773|NCT03753568|DEVICE|Electronic medicine reminder system|Electronic surveillance device is attached to the participants push through pill sheet and the smart phone application reminds the participants to take their medicine if they are about to take their daily dosage.
214682774|NCT05639920|COMBINATION_PRODUCT|Scoreing|Validation of Emergency surgery score in predicting mortality and mortality in Egyptian patients undergoing Emergency laparotomy
214372266|NCT05550064|OTHER|Structured contraceptive counseling|"1. Educational video - healthcare providers (Medical doctors and nurse-midwives)present available contraceptives that could be used after delivery, with emphasis on effectiveness, how they should be used, mechanism of action and health benefits.~2. The four key questions are to be asked to all pregnant women to make them reflect on factors that highly affects choice of contraceptives.~3. A tiered effectiveness chart will be used to visualize the effectiveness of different contraceptives, and guide the prospective user in her choice depending on the answers to the key questions~4. The box of contraceptive models are used for the prospective user to inspect, hold, feel the different contraceptives, as this has been shown to decrease fear regarding specific methods."
214372267|NCT06747715|PROCEDURE|Serial Fat Grafting Fresh followed by Cryopreserved Fat|The therapeutic intervention is a two stage surgical procedure (with a third stage biopsy for research purposes in this trial) in which a primary traumatic or post-surgical craniofacial deformity is treated first with autologous fat grafting using freshly harvested adipose tissue. A second fat grafting procedure is performed at 3.0 months after the first procedure using autologous adipose tissue that had been cryopreserved during the first procedure.
214372268|NCT07142850|DRUG|HRS-9190|HRS-9190
214372269|NCT06945120|BEHAVIORAL|ACT Lung Health Intervention|An Asian culture-tailored lung health intervention, which includes individual counseling sessions, family coaching, provision of nicotine replacement therapy (NRT) in the form of patches, lozenges, or chewing gum, and educational materials about low-dose computed tomography (LDCT) for lung cancer screening. The eight weekly, counseling sessions with study staff will be conducted via phone call or the Zoom web-conferencing platform.
214372270|NCT06944522|BIOLOGICAL|bemdaneprocel|Investigational cell therapy comprising midbrain dopaminergic neuron progenitors derived from human embryonic stem cells
214682775|NCT06549686|BIOLOGICAL|CLS2901C (human [allogeneic] chondrocyte sheets)|CLS2901C (human \[allogeneic\] chondrocyte sheets)
214682776|NCT05868967|DRUG|[14C]DWP14012|Each subject will receive a single oral dose of \[14C\]DWP14012 suspension (containing approximately 40 mg/80 μCi \[14C\]DWP14012) under fasting conditions.
214372271|NCT06944522|PROCEDURE|Sham surgery|Sham surgery will be performed on Day 0
214372272|NCT06940154|COMBINATION_PRODUCT|Rademikibart in prefilled syringe|Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
214372273|NCT06940154|DRUG|Matching placebo in prefilled syringe|Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
214372274|NCT07146893|DRUG|Selpercatinib|"Patients will be instructed to take selpercatinib orally (PO) twice daily (BID), approximately every 12 hours. While on study, they will undergo weight measurements and regular blood draws every 4 weeks. At the 16-week post-treatment follow-up, patients will return to the clinic for a weight assessment to evaluate potential changes in body weight.~Patients will be administered assessments including, Functional Assessment of Anorexia Cachexia Therapy (FAACT), administered at screening, at 12 weeks post-discontinuation of the study drug, and again at the 16-week follow-up."
214372275|NCT07146893|OTHER|Strength Assessment|Several strength assessment will be conducted at baseline and at 12 weeks end-of-treatment, which will include measurements such as grip strength, hallux strength, timed chair stands, leg press, and localized ultrasound of the quadriceps.
214682777|NCT03528044|PROCEDURE|Bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
214682778|NCT02755740|OTHER|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
214682779|NCT00554294|BEHAVIORAL|environmental and behavioral change|In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
214986281|NCT04388423|OTHER|simulated puncture training|The residents are trained of simulated puncture : 1.the location puncture; 2. finding fixed-point needle on the model for 5 times, each time for 30 minutes.
214986282|NCT04388423|OTHER|traditional bedside teaching|The residents are trained by traditional bedside teaching
214986283|NCT00820378|OTHER|No special interventioin|Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels:
214986284|NCT01781247|BEHAVIORAL|Minimal behavioral intervention|The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
214372276|NCT07145437|DIAGNOSTIC_TEST|Radio-induced Lymphocyte Apoptosis (RILA) Assay|peripheral blood sample processed via the RILA assay to quantify apoptotic CD8+/CD4+ T cells following ex vivo irradiation.
214372277|NCT07145437|RADIATION|Stereotactic body radiotherapy (SBRT)|SBRT delivered to the prostate with image guidance, respecting dose constraints for organs at risk;
214372278|NCT07154953|DIAGNOSTIC_TEST|Serum Surfactant Protein-D|Several studies support the use of SP-D as a marker of systemic inflammation and lung tissue damage in COPD.Measuring serum SP-D could provide a valuable tool for early detection, monitoring progression, and personalizing management of COPD patients.Surfactant protein D (SP D) as a prognostic biomarker needs further studies to validate its clinical applicability
214372279|NCT07164235|OTHER|Patients diagnosed with spondylodiscitis|Patients admitted to the Infectious Diseases Department of the University Hospital of Alessandria between January 1, 2017, and December 31, 2024, who were diagnosed with spondylodiscitis
214682780|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
214682781|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
214986285|NCT01781247|BEHAVIORAL|Control intervention|"The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided."
214986286|NCT01840631|BEHAVIORAL|Nutritional Counseling|Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.
214986287|NCT05868161|DEVICE|Pounce Thrombectomy System|Non-surgical removal of thrombi and emboli from the peripheral arterial vasculature with the Pounce Thrombectomy System.
214986288|NCT03163732|GENETIC|Blood and tumor samples|Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel
214986289|NCT04704050|DRUG|dronedarone 400 mg Oral Tablet|"Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV.~Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks."
214986290|NCT04704050|DRUG|Placebo|Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
214682782|NCT01877330|PROCEDURE|Interscalene block for shoulder arthroscopy|
214682783|NCT02645448|OTHER|Resistance Exercise|"Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect"
214986291|NCT03426878|OTHER|Modified genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive modified genetic counseling to help them understand the results.
215089287|NCT06013280|OTHER|Progresive Muscle Relaxation and Breathing Exercise|"Intervention protocol contains 40 minuntes sessions, which involved tensing and relaxing the body along with deep breathing.~Protocol consisted with; Warm-up (5 minutes breathing exercise) Progressive Muscle Relaxation Exercises (The participants performed PMR for each body part in a particular order, beginning with the face muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet. This muscle tensing and relaxing procedures were performed in accompaniment with deep breathing.) Cool-down (5 minutes breathing exercise)"
214372280|NCT07164924|BIOLOGICAL|blood sample to analyse AMH level on the serum|Evaluation of MS/NMOSD inflammatory activity on the serum AMH level (ng/ml)
214372281|NCT07165548|DIETARY_SUPPLEMENT|Experimental Bar (Formulation 1) + Hypocaloric diet (10% energy restriction)|Participants will consume three satiating compound-enriched bars (formulation 1) daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
214372282|NCT07165548|DIETARY_SUPPLEMENT|Experimental Bar (Formulation 2) + Hypocaloric diet (10% energy restriction)|Participants will consume three satiating compound-enriched bars (formulation 2) daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
214494438|NCT06814015|DEVICE|Hands-free exoskeleton|"A device trainer specialist from the investigation site will deliver training sessions with the exoskeleton to pair of participants (a pair corresponds to an individual with SCI and his/her companion). The device trainer will follow the progression of the pair through the training program and ensure they learn all the device basic skills. Each training session lasts an average of 1.5 hours, variations according to the user's learning pace and tolerance. During the sessions with the exoskeleton, the participants will engage in mobility activities on different surfaces and perform Activities of Daily Living in simulated environments such as kitchen, bathroom, elevators and outdoor spaces."
214494439|NCT04827615|BEHAVIORAL|Ambuja Cement Foundation's Non Communicable Disease Program|"Government level: Strengthening linkages with Govt; Ensuring availability \& affordability of NCD diagnostics and treatment; Establishing a follow-up mechanism with patients to ensure continuity of care \& medication compliance~Provider level: Capacity building of frontline workers; Promotion of interface between community \& service provider~Community level: Screening of hypertension \& diabetes for all adults ≥30 years in the village in coordination with Govt under 'population based screening'; Create awareness of modifiable risk factors and lifestyle change among high-risk population; Community mobilization \& active participation in various health marker days; Formation of support groups, women's groups, self help groups, with involvement of people living with NCDs~Individual level: Behavior change communication with messages on NCD risk factors; Nutrition awareness on healthy and unhealthy food practices"
214494440|NCT00463983|DRUG|octreotide|
214494441|NCT03959423|DEVICE|AHCL insulin pump system|670G 4.0 system with GS3; 780G system with G4S (continued access phase);
214682784|NCT06171880|DRUG|JLP-1901|administration of JLP-1901
214682785|NCT06171880|DRUG|JC-001(active comparator)|administration of JC-001(tenofovir)
214682786|NCT04408092|DRUG|Granulocyte Macrophage Colony Stimulation Factor|Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
214682787|NCT04185324|BEHAVIORAL|Standard zippering vest|Standard zippering vest used to teach zippering
214682788|NCT04185324|BEHAVIORAL|Modified zippering vest|Modified zippering vest used to teach zippering, along with related story
214682789|NCT02526615|DRUG|Rosiglitazone|Patients received either placebo, metformin or rosiglitazone
214682790|NCT02526615|DRUG|Metformin|Patients received either placebo, metformin or rosiglitazone
214682791|NCT02526615|DRUG|Placebo|Patients received either placebo, metformin or rosiglitazone
214372283|NCT07165548|DIETARY_SUPPLEMENT|Experimental Bar (Formulation 3) + Hypocaloric diet (10% energy restriction)|Participants will consume three satiating compound-enriched bars (formulation 3) daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
214372284|NCT07165548|DIETARY_SUPPLEMENT|Placebo Bar + Hypocaloric diet (10% energy restriction)|Participants will consume three placebo bars daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
214372285|NCT07165990|BEHAVIORAL|Food is Medicine (FIM) Intervention|"Intensive intervention phase - this phase starts at enrollment (\<=14 weeks) through 28 weeks of gestation (or at the time of GDM diagnostic test) and women i) receive a bi-weekly home delivery of a mixed box consisting of fresh produce, lean protein, and whole grains combined with culinary medicine-based nutrition education available in English and Spanish.~Maintenance phase - this phase starts at 29 weeks through 12 weeks postpartum, and women will receive biweekly deliveries of about 10-15 pounds of fresh produce (8-10 different kinds of produce) plus standard nutrition education. The box will be curated for prenatal nutrients needs and following American Diabetes Association guidelines."
214372286|NCT07165990|BEHAVIORAL|Standard of Care|Standard medical care provided at Harris Health for high-risk pregnant women, plus a voucher equal to the value of the produce and meals provided in the Food is Medicine (FIM) Intervention.
214494442|NCT06786000|DEVICE|Anodal tDCS combined with mCIMT|20 minutes of anodal tDCS followed by 1 hour of the mCIMT program. The anodal electrode will be placed over the ipsilesional M1 (primary motor cortex, C3 or C4 according to EEG 10/20 system), and the cathodal electrode over the contralateral supraorbital area (Fp1 or Fp2) ). Leading to subthreshold depolarization to promote cortical excitation. And twelve different oriented tasks will be used during the 1-hour training period.
214494443|NCT06786000|DEVICE|Cathodal tDCS combined with mCIMT|20 minutes of cathodal tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the contralesional M1, and the anodal electrode over the contralateral supraorbital area (Fp1 or Fp2). leading to subthreshold polarization to promote cortical inhibition. And twelve different oriented tasks will be used during the 1-hour training period.
214494444|NCT06786000|DEVICE|Bihemispheric tDCS combined with mCIMT|20 minutes of Bihemispheric tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the primary motor cortex (M1) of the contralesional hemisphere and the anodal electrode will be placed above the ipsilateral M1 position (C3 or C4 positions, according to the 10/20 EEG system). And twelve different oriented tasks will be used during the 1-hour training period.
214494445|NCT06786000|DEVICE|Sham tDCS combined with mCIMT|20 minutes of sham tDCS followed by 1 hour of the mCIMT program. the same stimulation place and parameters will be used as in the anodal group. However, after 30 seconds of stimulation, the stimulator will switch off. This provides the participants with the experience of the initial itchy sensation that occurs during tDCS, which is required for efficient masking. And twelve different oriented tasks will be used during the 1-hour training period.
214494446|NCT06341647|DRUG|AB-201|NK Cell Therapy
214494447|NCT06341647|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214682792|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
214682793|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
214682794|NCT01517789|DEVICE|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|"Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.~Flash and steady state visual evoked potential are measured during the surgical procedure at different times."
214682795|NCT04578717|PROCEDURE|Air-abrasion|A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm
214682796|NCT04578717|PROCEDURE|Adhesive application - Etch&rinse|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .
214682797|NCT04578717|BIOLOGICAL|Adhesive application - Self-etch|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
214372287|NCT07166744|OTHER|Biological : blood sampling|will be collected from the patient
214986292|NCT03426878|OTHER|Traditional genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive traditional genetic counseling to help them understand the results.
214986293|NCT05910398|DRUG|pyrotinib|an irreversible anti-HER2 tyrosine kinase inhibitor
214372288|NCT07166744|OTHER|nasopharyngeal swab|will be collected from the patient
214372289|NCT07166744|OTHER|Procedure : Lumbar puncture|will be collected from the patient
214372290|NCT07166744|OTHER|Behavioral : clinical, functional, cognitive and psychiatric evaluations|will be collected from the patient
214372291|NCT07166744|OTHER|MRI|will be done on the patient
214682798|NCT04637659|PROCEDURE|Root Canal Treatment|Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
214372292|NCT07166783|DRUG|Tolvaptan|single dose oral administration of 7.5mg Tolvaptan
214372293|NCT07164781|BIOLOGICAL|Bacillus clausii|The (Test group) will receive bacillus clausii (Enterogermina) 4 billion every 12h.
214372294|NCT07164781|OTHER|Sugar tablets|The (Control group) will receive placebo (sugar tablets).
214372295|NCT07164625|BEHAVIORAL|Telerehabilitation Physiotherapy|Delivered via real-time video sessions focusing on strengthening and mobility exercises.
214372296|NCT07164625|BEHAVIORAL|In person physiotherapy|face-to-face, including hands-on treatments like tactile feedback and joint mobilization.
214372297|NCT07165366|DIAGNOSTIC_TEST|Hydrogen Peroxide|
214494448|NCT06341647|DRUG|Fludarabine|Lymphodepleting chemotherapy
214494449|NCT06745258|OTHER|External Facilitation|Multi-component facilitation strategy to address identified implementation needs
214682799|NCT01193790|PROCEDURE|Coblation channeling|"The combination of the energy and the fluid creates a plasma field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation."
214682800|NCT01629485|BEHAVIORAL|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
214986294|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children|The UP-C is administered in-person to parents and children over the course of up to 15 weekly group sessions, which last approximately 90 minutes each.
214372298|NCT06321575|DEVICE|Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)|Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.
214372299|NCT06052904|BEHAVIORAL|mHealth-delivered music breathing therapy|"Parental caregivers in the intervention group will receive individual home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, by a qualified music therapist based on a standardized and validated music breathing instruction manual. The music breathing therapy comprises four breathing phases, namely Discovery Breathing, Triangular Breathing, Silent Breathing, and Music Breathing. In each session, participants will practice breathing for approximately 20-25 minutes in silence or with music in a sitting position. Thereafter, the participants will be instructed to create a Mandala drawing to visualize the effects of breathing on their mental body image, emotions, and thoughts. Each session will end with a debriefing session, which will serve to verbally integrate and reflect the participants' experiences and mental states."
214372300|NCT06052904|BEHAVIORAL|Online educational modules|Participants in the control group will receive eight weekly online educational modules via email for 2 months. The content of the online educational modules will include medical information and advice about caring for a child who has been newly diagnosed with cancer.
214372301|NCT01980407|DRUG|S-1, leucovorin, oxaliplatin|S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
214372302|NCT06115330|DEVICE|Press Needle Acupuncture|Ear acupuncture using Pyonex press needles were installed with a diameter of 0.17mm, 0.9mm deep. The needles were retained for three days and stimulated at the installation site of the patch needle by means of pressure on the acupuncture point ears that have been attached needles on both sides, 1 minute at each point, four times a day, for 3 consecutive days and the patch was removed on the 3rd day
214494450|NCT06763796|OTHER|Postural Decryption Technique|"Assessment:~PDT begins with visual inspection and palpation to check postural alignment and identify joint or muscle imbalances. Evaluations proceed distal to proximal, examining the spine and shoulder complex in coronal, sagittal, and transverse planes to assess symmetry and neutral positioning.~Treatment Process:~PDT applies the 4R Technique:~1. Reposition - Correct joint alignment.~2. Restore - Release muscle tension and adhesions.~3. Reinforce - Strengthen stabilizing muscles.~4. Retrain - Improve movement patterns and posture.~Key Techniques:~1. Spinal and Shoulder Adjustments: Manual traction, mobilizations, and stretches.~2. Joint Mobilization: Multi-directional gliding within pain-free ranges.~3. Trigger Point Therapy: 5-10 seconds of pressure to relieve localized pain.~4. Proprioception Training: Balance challenges to improve stability and control."
214682801|NCT01629485|BEHAVIORAL|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
214682802|NCT01629485|BEHAVIORAL|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
214682803|NCT02572661|RADIATION|radiation in Squamous Head and Neck Cancer|
214682804|NCT00002677|DRUG|chemotherapy|
214682805|NCT00002677|DRUG|tributyrin|
214682806|NCT06361277|DRUG|Reference Drug or Test Drug|Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
214682807|NCT00698126|DRUG|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
214682808|NCT00698126|DRUG|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
214682809|NCT06554626|DRUG|Dexamethasone|Glucocorticoids
214682810|NCT06554626|DRUG|Blinatumomab|Bi-specific anti CD19/CD3 antibody
214682811|NCT06554626|DRUG|Venetoclax|BCL-2 inhibotor
214682812|NCT06554626|DRUG|Inotuzumab ozogamicin|a humanized monoclonal antibody-drug conjugate targeting CD22
214682813|NCT06554626|DRUG|Methotrexate|antifolate antineoplastic drug
214372303|NCT00175344|PROCEDURE|Scar massage.|To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
214494451|NCT06763796|OTHER|Traditional Chinese Medicine (TCM) Massage Therapy|"Definition:~A manual therapy based on Traditional Chinese Medicine (TCM) principles, using techniques like kneading, pressing, rolling, and stretching to relieve pain, improve circulation, and enhance mobility.~Key Features:~1. Techniques: Soft tissue manipulation, joint mobilization, and acupressure.~2. Focus: Pain relief, joint function recovery, and muscle relaxation.~Treatment Plan:~4 weeks, 5 sessions per week, 40 minutes per session."
214494452|NCT06744075|OTHER|Blood assessment|ctDNA collection (venous blood draw) will occur at baseline, mid-treatment, and at the end of treatment
214682814|NCT06554626|DRUG|Pegaspargase|antitumor drug
214986295|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents|The UP-A is administered to parents and teens over the course of approximately 15-24 weekly individual sessions, which last approximately 50 minutes each. Sessions can be administered in-person or online, with at least one session occurring in person.
214986296|NCT03417960|DEVICE|iTBS|"The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold.~In study 1, the accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. In study 2, the accelerated paradigm will consist of 12 sessions per day for 5 total treatment days. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method."
214986297|NCT02679846|OTHER|Standardized protocol|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
214986298|NCT02610010|DRUG|Cisplatin|Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.
214986299|NCT02610010|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
214372304|NCT00658437|DRUG|CY-503|solution for subcutaneous injection, 350 ng twice weekly
214372305|NCT01837160|PROCEDURE|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
214986300|NCT05563324|GENETIC|DNA extraction and genotyping of candidate genetic polymorphisms|
214986301|NCT05563324|OTHER|self-assessment questionnaires|
214372306|NCT01837160|RADIATION|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
214372307|NCT01837160|PROCEDURE|Echocardiogram|Echocardiography.
214494453|NCT06748027|OTHER|Fasting|Long-term fasting (\&gt;3d)
214494454|NCT04731558|DRUG|enoxaparin or tinzaparin or dalteparin|Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
214494455|NCT04731558|DRUG|No intervention|No preoperative thromboprophylaxis.
214682815|NCT06554626|DRUG|Cytarabine|Pyrimidine, antimetabolites
214682816|NCT04691596|BEHAVIORAL|Non-cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day
214682817|NCT04691596|BEHAVIORAL|Cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue
214682818|NCT04691596|BEHAVIORAL|Habit Coaching|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
214682819|NCT04691596|BEHAVIORAL|App use instructions|Received a basic training with the StepUp app
214682820|NCT04072237|BIOLOGICAL|MarzAA (marzeptacog alfa [activated])|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
214682821|NCT05971290|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure administered by face mask
214682822|NCT05971290|DEVICE|Ambient air|Air (fraction of inspired oxygen) at 14000 feet in elevation
214682823|NCT04420481|DRUG|Somatropin|Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.
214682824|NCT04420481|DRUG|Placebo|Placebo
214682825|NCT03431675|DRUG|Ciprofloxacin|Single-dose oral ciprofloxacin
214682826|NCT01328288|DRUG|standard ART according to the Thai Ministry of Public Health national guidelines|Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
214682827|NCT00004778|DRUG|betamethasone|
214682828|NCT00004778|DRUG|dexamethasone|
214986302|NCT05667441|COMBINATION_PRODUCT|Standard lifestyle recommendations + dietary supplementation|refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula
214372308|NCT01837160|RADIATION|CT-coronary angiogram scan|CT-coronary angiogram following CT-PET scan. Standard protocol.
214372309|NCT01837160|PROCEDURE|Aortic Valve Replacement|For AVR (already scheduled prior to enrollment)
214372310|NCT04215016|BIOLOGICAL|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
214372311|NCT00209807|DRUG|escitalopram|escitalopram 10 mg/d for 6 weeks
214372312|NCT00209807|DRUG|Reboxetine|Reboxetine 8 mg/d for 6 weeks
214372313|NCT00209807|OTHER|No intervention|This group of healthy volonteers will receive no drug and will be a healthy comparator.
214372314|NCT03350334|DRUG|Duloxetine|Peri-operative Duloxetine administration
214986303|NCT05667441|COMBINATION_PRODUCT|Risk profiling|Personalized risk profiling for lifestyle and genetics.
214372315|NCT03350334|DRUG|placebo|Placebo administration
214372316|NCT03070496|BIOLOGICAL|Blood sampling|Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
214372317|NCT03070496|PROCEDURE|ECG|ECG will be performed at 6 months after myocardial infarction
214372318|NCT03070496|DEVICE|MRI|MRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.
214372319|NCT03070496|OTHER|Quality of life questionnaire|Patients will pass a quality of life questionnaire at 12 months after myocardial infarction
214986304|NCT05667441|BEHAVIORAL|Coaching|Coaching
214372320|NCT02384564|DEVICE|Ambu King Vision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
214372321|NCT02384564|DEVICE|Direct Laryngoscopy via Miller Straight Blade|At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
214494456|NCT05986318|DIETARY_SUPPLEMENT|N-Acetyl cysteine|NAC capsules
214494457|NCT05986318|DRUG|Dexamethasone Oral|Dexamethasone tablets
214494458|NCT05986318|DIETARY_SUPPLEMENT|N-Acetyl cysteine Placebo|Matching placebo for NAC capsules
214494459|NCT05986318|DRUG|Dexamethasone Placebo|Matching placebo for dexamethasone tablets
214494460|NCT05986318|RADIATION|Radiation Therapy|All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.
214494461|NCT06889181|OTHER|Plasma Rich in Growth Factors (PRGF)|using prgf with closing primary cleft palate - isolated cleft palate Minutes before the surgery, 10-20 ml of venous blood from each patient. -The blood is centrifuged to obtain PRGF. -Fixed between nasal and palatal mucosa
214494462|NCT06889181|OTHER|Placebo|primary closing cleft palate-isolated cleft palate
214494463|NCT06662123|DRUG|Anifrolumab|Participants will receive a single SC or IV dose of anifrolumab at day 1
214494464|NCT03184922|PROCEDURE|Adjustable versus fixed suspensory loop femoral side graft fixation|A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
214494465|NCT04056013|DEVICE|Vicryl Rapide absorbable suture|"In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own."
214494466|NCT06749626|OTHER|progressive relaxation exercise|Relaxation exercises CD developed by the Turkish Psychologists Association; It consists of muscle exercises, rhythmic breathing and music recital. The CD content, which includes relaxation exercises accompanied by music, was prepared by Psychologist Elif Kabak and voiced by Tülay Bursa. The CD, which includes deep breathing and muscle relaxation exercises, consists of three parts. The first section includes the definition of deep relaxation, the purpose of relaxation exercises and the rules to be considered in exercise practice. In the second part; There are relaxation exercises with audio instructions accompanied by streaming sounds. The third part contains relaxation music without instructions. After the information in the first part of the CD is explained to the patients in the experimental group, the second part, which lasts only approximately 30 minutes, will be administered under the supervision of the researcher. However, since the patients have undergone abdominal surgery, the
214494467|NCT06147076|BEHAVIORAL|Social Support Network Counseling Intervention|Social support counseling intervention for kidney transplant candidates along with their social support networks.
214494468|NCT06754072|OTHER|Virtual Keyboard (VK) System|Participants underwent a 4-week training program comprising 12 one-hour sessions to enhance finger individuation and motor control using a virtual reality platform.
214682829|NCT00004778|DRUG|thyrotropin-releasing hormone|
214682830|NCT00918528|PROCEDURE|Internal urethrotomy|
214682831|NCT00918528|DRUG|Mitomycin C - local injection|
214682832|NCT01780389|DRUG|Open-label flexibly dosed milnacipran|
214986305|NCT02803489|DEVICE|medical device intervention|
214986306|NCT02607813|DRUG|LXH254|pan-RAF inhibitor
214986307|NCT02607813|DRUG|PDR001|Biological: PDR001 anti-PD1 antibody
214372322|NCT05763641|PROCEDURE|Target Axillary Dissection|TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
214372323|NCT03178279|OTHER|Physical Health Plan|Use of a Physical Health Plan by service users
214372324|NCT01755442|OTHER|Placebo|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
214372325|NCT01755442|DRUG|AMG 151|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
214372326|NCT01313143|DRUG|AOP200704|Comparison of AOP200704 with Esmolol
214372327|NCT01313143|DRUG|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
214372328|NCT04384016|BIOLOGICAL|Skyvaricella Injection|"The main target is evaluating the safety of SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection.~The secondary target is to Assess the immunogenicity of SKYVaricella inj. in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
214372329|NCT06096545|PROCEDURE|Axillary sentinal lymph node biopsy|"For SLNB evaluation, multiple sections of the excised lymph node were stained with hematoxylin and eosin (H\&E) at a thickness greater than 2 mm. Lymph nodes with metastasis greater than 2 mm were defined as positive SLNB. Macroscopic metastasis was considered positive in the evaluation for the axilla, while benign histological characteristics were considered negative. The presence of micrometastasis and isolated tumor cells was also noted. The size and diameter of the metastatic lymph node were considered in the evaluation.~SLNB technique using isosulfan blue dye was performed for axillary evaluation, and all patients had the clipped lymph node excised under ultrasound guidance with a guide wire placed preoperatively."
214372330|NCT06320626|OTHER|Emicizumab - PK-guided dose reduction|PK-guided dose reduction emicizumab targeted at a Ctrough of 30μg/mL.
214372331|NCT06320626|OTHER|Emicizumab - Dosis continuation group|Continue on their current dose regimen
214494469|NCT06757803|PROCEDURE|rertrolaminar block|"Positioning~The patient is positioned in a lateral decubitus position with the affected side up. The patient's arm on the affected side is placed behind the head. The patient's spine is aligned and the shoulder is elevated to expose the paravertebral space.~\*Ultrasound imaging~A high-frequency linear ultrasound probe (5-12 MHz) is placed in a paramedian sagittal plane at the desired level of block. The probe is oriented so that the transverse processes are visualized on the lateral side of the screen and the vertebral laminae are visualized on the medial side of the screen. The interlaminar space is visualized as a hypoechoic region between the laminae.~\*Needle insertion~A short bevel block needle (20-22 G) is inserted through the skin at the caudal end of the ultrasound probe, aiming cephalad. The needle is advanced under real-time ultrasound guidance until the tip of the needle contacts the lamina. The needle is then slightly withdrawn and the local anesthetic is injected into t"
214494470|NCT06757803|PROCEDURE|paravertebral block|"* Patient Preparation~* Place the patient in the lateral decubitus position with the side of the block facing up.~* Position the patient's arm so that it is resting comfortably on the operating table.~* Prepare the skin over the block site with an antiseptic solution.~* Sterilely drape the area.~* Ultrasound Imaging~* Place the ultrasound probe in a transverse plane at the level of the desired block.~* Identify the following anatomical landmarks:~* Vertebral body~* Transverse process~* Pleura~* Intercostal space~* Needle Insertion~Use a sterile ultrasound-guided needle. Insert the needle in-plane from a lateral to medial direction, aiming for the apex of the paravertebral space.~The needle should be advanced until it is just beyond the transverse process.~\*Test Aspiration~Aspirate to ensure that the needle is not in a blood vessel.~* Local Anesthetic Injection~* Inject the local anesthetic slowly, aspirating frequently.~* The local anesthetic should be injected int"
214494471|NCT06762821|PROCEDURE|Single-visit revascularization|Revascularization protocol will be performed in single visit
214986308|NCT04634188|DIAGNOSTIC_TEST|Procalcitonin|Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
214986309|NCT03504618|DRUG|FOLFOXIRI|"Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day"
214986310|NCT03028311|PROCEDURE|Angiography|Undergo angiography
214986311|NCT03028311|PROCEDURE|Computed Tomography|Undergo SPECT-CT
214986312|NCT03028311|PROCEDURE|Planar Imaging|Undergo planar imaging
214986313|NCT03028311|RADIATION|Radioembolization|Undergo radioembolization
214372332|NCT06320626|OTHER|Emicizumab - Dose adjustment group|Adjusted in dosing regimen according to local protocol
214372333|NCT00768508|DRUG|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy|Ondansetron 4 ug/kg b.i.d.for 12 weeks
214372334|NCT00768508|DRUG|Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Naltrexone 50 mg/day for 12 weeks
214372335|NCT00768508|DRUG|Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
214372336|NCT00768508|OTHER|Placebo + Cognitive Behavioral Therapy|Placebo comparator
214372337|NCT02024672|OTHER|Immediate postpartum placement of IUD|pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
214372338|NCT03265054|BIOLOGICAL|Analysis of plasma samples|Measuring microparticles (MPs) in Human Plasma Samples
214372339|NCT00685945|DRUG|Control (bradykinin)|Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
214372340|NCT00685945|DRUG|L-NMMA + bradykinin|Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
214372341|NCT00685945|DRUG|Isosorbide + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
214372342|NCT00685945|DRUG|Sildenafil + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
214372343|NCT03183388|BEHAVIORAL|BE-SMART|Participants will take part in 12 therapy sessions, at a rate of about 1 session every one to two weeks. Sessions are anticipated to last about 1 hour each. Sessions may be focused on teaching skills to regulate emotions or regularize sleep and activity. These therapy sessions may be videotaped and audiotaped (only with the expressed written consent of the participant, and when appropriate, the participant's parent or guardian). Participants will be asked to complete worksheets and practice the skills learned from these sessions and will be asked questions about feelings. There will be an interview, assessments and scanning performed prior to treatment and at the midpoint and end to assess progress. The intervening 9 sessions may be by video telecommunication. Participants may be given devices to track actigraphy and ecological momentary assessments.
214372344|NCT02772003|BIOLOGICAL|Electroporation-Mediated Plasmid DNA Vaccine Therapy|Undergo electroporation
214372345|NCT02772003|BIOLOGICAL|HCV DNA Vaccine INO-8000|Given IM
214372346|NCT02772003|OTHER|Laboratory Biomarker Analysis|Correlative studies
214494472|NCT06762821|PROCEDURE|Multiple-visit revascularization|Revascularization protocol will be performed in multiple visit
214682833|NCT03715569|DIAGNOSTIC_TEST|Vestibular function|Vhit, Caloric test
214494474|NCT06828146|OTHER|a quasi-experimental one-group pretest-posttest design to evaluate the effectiveness of Freirean dialogue-based critical pedagogy in fostering social justice advocacy among nursing students.|a quasi-experimental one-group pretest-posttest design to evaluate the effectiveness of Freirean dialogue-based critical pedagogy in fostering social justice advocacy among nursing students.
214682834|NCT03715569|DIAGNOSTIC_TEST|OAE/WBT|Oto acoustic emissions Wide Band Tympanometry
214682835|NCT03715569|DIAGNOSTIC_TEST|Biomarker|Biomarker examination
214682836|NCT03715569|DIAGNOSTIC_TEST|MOCA, eGOS|Cognitive tests
214682837|NCT03715569|DIAGNOSTIC_TEST|Audiometry|Hearing test
214986314|NCT03028311|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT
214986315|NCT03028311|RADIATION|Technetium Tc-99m Albumin Aggregated|Given via arterial catheter
214682838|NCT05641376|DRUG|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. Treatment will be stopped when the nebulizer began to sputter. At end of nebulizer administration, they will be observed for 30 min before induction of general anaesthesia. then the children will be transferred to the operation room and will receive intravenous (IV) normal saline 0.9% in 10 ml volume over 10 minutes after anesthesia induction.
214682839|NCT05641376|DRUG|Intravenous Dexmedetomidine|Children will receive nebulized 3 ml of 0.9% normal saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. then the children will be transferred to the operation room and will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
214682840|NCT02778776|DRUG|Metformin|Metfomin in tablet presentation of 500 mg
214682841|NCT02778776|DIETARY_SUPPLEMENT|Agave inulin|Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
214682842|NCT02778776|OTHER|Placebo of agave inulin|Calcinated magnesia powder
214682843|NCT02778776|OTHER|Metformin placebo|Calcinated magnesia tablet
214682844|NCT05663086|BIOLOGICAL|One dose group|The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
214682845|NCT05663086|BIOLOGICAL|Two doses group|The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
214682846|NCT05663086|BIOLOGICAL|Aged 18-59 years|The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
214682847|NCT05663086|BIOLOGICAL|Aged 60 years old and above|The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
214986316|NCT03028311|OTHER|Yttrium Y 90 Resin Microspheres|Given via arterial catheter
214682848|NCT05725369|BEHAVIORAL|Combined Lifestyle Intervention (CLI)|In the Netherlands, the combined lifestyle intervention (CLI, in Dutch: gecombineerde leefstijlinterventie (GLI)) is available for all Dutch citizens with a BMI ≥ 30 mg/kg2 or a BMI between 25 and 30 mg/kg2 and an increased risk of diabetes or cardiovascular disease. The CLI aims to realize health benefits for people with a moderate weight-related health risk and consists of a two-year program with advice and counseling to improve health-related behavior such as physical activity and diet.
214682849|NCT02058355|BEHAVIORAL|Consequences List Feedback|
214682850|NCT02058355|BEHAVIORAL|Personalized Normative Feedback|
214682851|NCT01519570|OTHER|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
214682852|NCT00228488|DRUG|Gefitinib|
214372347|NCT02772003|OTHER|Quality-of-Life Assessment|Ancillary studies
214372348|NCT02772003|BIOLOGICAL|Rocakinogene Sifuplasmid|Given IM
214372349|NCT00847405|DRUG|Sumatriptan Succinate|100 mg Tablets
214682853|NCT04330235|OTHER|Healthy Default Kids' Beverage Policy|The healthy default kids' beverage policy requires that all restaurants serve only healthy beverages (water, milk, or 100% juice) instead of sugary beverages as the default beverage with children's meals. The policy has been enacted in New York City and Philadelphia and will go into effect in April 2020.
214372350|NCT00847405|DRUG|Imitrex®|100 mg Tablet
214372351|NCT02820805|OTHER|Meal Skipping|No meal
214682854|NCT00778752|DRUG|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
214494475|NCT06861205|OTHER|This is an observational study|This is an observational study
214682855|NCT02013193|DEVICE|Ranger DCB|After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
214682856|NCT02013193|DEVICE|uncoated PTA balloon|The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
214682857|NCT04013581|DRUG|TZD group|Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
214682858|NCT04013581|DRUG|SGLT-2 group|Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
214682859|NCT00175175|BEHAVIORAL|"Allied health professional-run osteoporosis service (case-management)"|
215089288|NCT00586443|DRUG|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~* 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~* 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~* 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~  1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~ 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\*~     * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
215089289|NCT00866671|DRUG|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
215089290|NCT05006209|OTHER|One visit root canal treatment|
215089291|NCT05006209|OTHER|Two visit root canal treatment|
214372352|NCT02820805|OTHER|French fries|50g of available carbohydrates meal
214372353|NCT02820805|OTHER|Mashed potatoes|50g of available carbohydrates meal
214372354|NCT02820805|OTHER|Hash browns|50g of available carbohydrates meal
214372355|NCT02820805|OTHER|Rice|50g of available carbohydrates meal
214494476|NCT06615505|OTHER|VIA Disc NP|Participants will receive a single dose, intradiscal injection of 100 mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered to the affected level(s), L1-S1 (1 or 2 levels).
214494477|NCT06615505|OTHER|Sham Injection|"Participants will receive the sham procedure at 1 or 2 levels.~The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc."
214494478|NCT06770621|DIAGNOSTIC_TEST|Insulin-induced hypoglycemia test|For these tests, multiple blood samples will be collected during insulin-induced hypoglycemia (stage 1 hypoglycemia is defined as a blood glucose level below 70 mg/dL, while stage 2 corresponds to values below 54 mg/dL). The tests will be conducted on patients who have fasted for at least 12 hours and will be supervised by a medical staff member trained to manage severe hypoglycemia.
214494479|NCT06770621|DIAGNOSTIC_TEST|Glucagon profile|The subject must fast before the consultation and follow a specific diet the day before; after an initial blood draw (P1), the patient will have breakfast and take any required insulin, followed by two additional blood draws 1.5 hours after breakfast (P2) and 1.5 hours after P2 (P3)
214372356|NCT02820805|OTHER|Beans|50g of available carbohydrates meal
214372357|NCT06788444|PROCEDURE|The colonoscopy|"Both groups continued to receive the usual standard of gastroenterology care throughout the study period. The patients undergo preoperative preparation according to the requirements of colonoscopy. After entering the endoscopy room, the routine monitoring including electrocardiogram, heart rate, noninvasive blood pressure (BP), respiratory rate, and oxygen saturation (SpO2) are applied for patients. All monitoring data including HR, BP and SpO2 will be recorded at intervals of 3min. Safety assessments will be performed throughout the the research process. As a risk mitigation measure, esketamine should not be administered in patients with systolic blood pressure (SBP) \> 140 mmHg or diastolic blood pressure (DBP) \>90 mmHg prior to administration.~After the right upper limb venous access is opened, the patients is placed in the left lateral position. The oxygen mask is placed near the patients' nose and oxygen is provided by the mask for 6L/min during the colonoscopy."
214372358|NCT06788444|DRUG|Esketamine|The propofol is administered until the patients loss of consciousness (loss of the eyelash refex). The 0.2 mg/kg esketamine is then administered by the anesthesiologist, but should be discontinued if the SBP ≥200 mmHg or the DBP ≥110 mmHg. After the administration of the 0.2 mg/kg esketamine is completed, the endoscopist will begin the colonoscopic procedure.
214682860|NCT00692900|DRUG|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
214986317|NCT06115174|DRUG|Pentoxifylline|"Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy \[15\].~The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) \[16\]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes \[17\]."
214372359|NCT04614883|DEVICE|Volatile Organic Compounds analysis|VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.
214372360|NCT04614883|OTHER|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
214372361|NCT01728792|BIOLOGICAL|TDV|TDV IM or SC injection
214986318|NCT06115174|RADIATION|FOLFOX|(leucovorin, fluorouracil, oxaliplatin)
214372362|NCT02080182|DRUG|Acetylcysteine|
214372363|NCT02080182|DRUG|placebo acetylcysteine|
214372364|NCT00071721|DRUG|Valproate|250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
214372365|NCT00071721|DRUG|Placebo|Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
214372366|NCT05417984|DEVICE|Restoris MCK|During this study the Restoris MCK will be placed using robotic-assisted surgery. At the time of surgery tantalum markers will be placed in the tibia and femur. With these markers migration of the prothesis can be measured over time using RSA radiographs.
214372367|NCT02359643|DRUG|Aspirin|"This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:~1. Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).~2. Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year)."
214372368|NCT04277455|DEVICE|Laser ablation of benign thyroid nodule|Ablating symptomatic benign thyroid nodules using laser
214372369|NCT02962856|DRUG|BAY987517|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. (Formulation: Z43-078)
214372370|NCT02962856|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
214372371|NCT02294825|PROCEDURE|various surgical procedures in endometriosis|Shaving, disc excision and colorectal resection; ureterolysis or ureter resection; bladder resection; ablation of endometriomas using plasma energy; excision and ablation of deep and superficial lesions
214372372|NCT00546325|DRUG|Rimonabant|White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
214372373|NCT00546325|DRUG|Placebo|Matching placebo tablets. Once daily before breakfast
214986319|NCT06115174|RADIATION|XELOX|(oxaliplatin + capecitabine)
214986320|NCT06115174|DRUG|Monoclonal antibodies (target therapy)|target therapy (Bevacizumab).
214986321|NCT00465517|DRUG|Ganaxolone|Oral suspension 200-500 mg 3x/day
214986322|NCT00465517|OTHER|Placebo|non-active placebo
214372374|NCT05432908|BEHAVIORAL|Orofacial exercises and oropharyngeal functions|Oropharyngeal exercises (derived from speech-language pathology) to the tongue and facial muscles exercises as well stomatognathic functions.
214372375|NCT04834700|OTHER|online group|In terms of teaching ultrasound, video lectures will be conducted rather than hands-on, which is the traditional method.
214372376|NCT04581421|OTHER|High Carb Low Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
214372377|NCT04581421|OTHER|Low Carb High Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
214372378|NCT06285669|OTHER|kinesiotaping application|kinesiotaping application
214372379|NCT02422719|DRUG|Radotinib|Radotinib 400mg bid
214372380|NCT06155383|DRUG|Capecitabine|1000 mg/m2, Bid orally, D1-14, every 3 weeks
214372381|NCT06155383|DRUG|oxaliplatin|130 mg/m2, intravenous infusion, D1, every 3 weeks
214372382|NCT06155383|DRUG|Disitamab Vedotin|2.5 mg/kg, intravenous infusion, D1, every 2 weeks
214372383|NCT06155383|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
214494480|NCT06770621|OTHER|Biological sample once|The exome of each patient will then be analyzed from the blood sample taken beforehand.
214494481|NCT06770621|OTHER|Observation-questionnaire|only the answer to a questionnaire
214494482|NCT06487572|DRUG|Risankizumab|Intravenous (IV) Infusion
214494483|NCT06487572|DRUG|Risankizumab|Subcutaneous (SC) Injection
214494484|NCT06783855|PROCEDURE|suspension uretheroileal technique|The suspension technique is reported as the puboprostatic ligaments that attach the prostate to the symphysis pubis. After the ligating the complex, including both the dorsal vein complex and the puboprostatic ligaments, this complex was sharply divided anteriorly from the prostate with a safe distance (1-2 mm), and the urethra is defined and divided. After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra
214372384|NCT03244722|DIETARY_SUPPLEMENT|Very-low energy Diet (VLED)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
214372385|NCT03244722|OTHER|Standard of care (SOC)|Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women
214372386|NCT04959630|BEHAVIORAL|Clinical decision making based on visualizing liver 3D models in Virtual Reality (VR) environment or via a Desktop Interface (DI)|Visualizing 3D models of livers for preoperative surgical planning via two different environment: DI and VR in sequential order
214372387|NCT03135561|BEHAVIORAL|pedometer-plus-email|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. During the intervention period, patients will receive 8 counselling emails based on behavioural techniques.
214372388|NCT03135561|BEHAVIORAL|pedometer-only|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. There will be no further interaction during the intervention period unless they fail to upload data, in which case they will be offered technical support.
214682861|NCT00692900|DRUG|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
214372389|NCT00949715|DEVICE|Medtronic or Vitatron Dual-Chamber Pacemaker|A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability
214372390|NCT00949715|DEVICE|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
214682862|NCT03014661|OTHER|Quality of life under or after therapy with Pollinex quattro|To measure Quality of life using the DLQI-index in year one, year two, year three or six month after therapy with Pollinex quattro plus.
214682863|NCT03464708|DIETARY_SUPPLEMENT|HMB|Powder form
214682864|NCT03464708|OTHER|Lactose (placebo)|Powder form
214682865|NCT01796353|OTHER|sexual rehabilitation|exercise plus psycho-education
214682866|NCT01796353|OTHER|Usual care|usual care
214372391|NCT04672096|DEVICE|Neuronoff BASMATI Injectrode|The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.
214682867|NCT03785717|PROCEDURE|ROG|Bone width augmentation using bone grafting and membrane non cross linking.
214682868|NCT03785717|PROCEDURE|ROG & ESWT|Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
214682869|NCT04722393|OTHER|Exercise|Exercise training
214682870|NCT03388177|BEHAVIORAL|Yoga-based therapy|
214682871|NCT03388177|OTHER|Treatment as usual|
214372392|NCT00844740|DRUG|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
214372393|NCT03090581|PROCEDURE|Biopsies CP|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
214682872|NCT01593748|DRUG|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
215089292|NCT04904809|DEVICE|Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System|The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
214372394|NCT03090581|PROCEDURE|Biopsies FC|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
214372395|NCT03853356|DEVICE|Orthoss|Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
214372396|NCT06349018|OTHER|Dietary Supplement: High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
214372397|NCT06349018|OTHER|Dietary Supplement: No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
214372398|NCT01950065|DEVICE|iovera|
214682873|NCT01593748|DRUG|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
214682874|NCT02207192|OTHER|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position."
214682875|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 5600 IU (800 IU per day)
214682876|NCT00911664|DRUG|No supplementation|Control
214682877|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 11,200 IU (1600 IU per day)
214682878|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
214682879|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
214682880|NCT03664817|BEHAVIORAL|social capital intervention|The social capital intervention will focus on developing skills and group-work that culminate in participant-derived photovoice projects. Each group of YBMSM will be encouraged to complete a 30 day photovoice challenge. The 30 day challenge is based on a prior community action project done as a part of our Centers for AIDS Research (CFAR)-funded research, which was a Photovoice project conducted by Dr. Hussen. Photovoice is a participatory action research methodology in which groups of individuals from a population of interest are given cameras to document events, people and places of significance in their lives.
214682881|NCT03664817|BEHAVIORAL|group-based health promotion intervention|"The control arm will participate in a health education intervention that will be delivered in a group, but without a specific goal of creating group cohesion or social capital. The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)."
214682882|NCT03366740|OTHER|GB mixed full strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
214682883|NCT03366740|OTHER|Full strength rice suji Alone|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
214372399|NCT05385094|DIAGNOSTIC_TEST|S Creatinine concentration|
214372400|NCT05385094|DIAGNOSTIC_TEST|Serum Cystatin C concentration|
214372401|NCT05385094|DIAGNOSTIC_TEST|Urinary Creatinine Clearance|
214682884|NCT03366740|OTHER|3/4th strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
214682885|NCT02272322|DEVICE|cystocele repair with biomesh soft prolaps and endofast reliant|
214682886|NCT06472258|DRUG|IV Artesunate|IV artesunate with a weight-appropriate dosage at 0, 12, 24, and 48 hours and continued 12-hourly for a maximum duration of seven days, with each dose diluted in normal saline and given as an infusion.
214682887|NCT06472258|DRUG|IV Quinine Hydrochloride|IV Quinine hydrochloride in accordance to weight with loading dose 20mg salt/kg in 10% dextrose infusion followed by 10mg salt/kg infusion 8 hourly for 2 days and for 12 hourly onwards for a maximum of 7 days.
214682888|NCT03156556|BEHAVIORAL|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
214682889|NCT05925816|BEHAVIORAL|Video|Video uses BA techniques for approximately 5 minutes
214986323|NCT01657396|PROCEDURE|Standard Oral Hygiene|Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
214986324|NCT01657396|PROCEDURE|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
214986325|NCT01657396|PROCEDURE|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
214986326|NCT04737733|OTHER|The dementia friendly program|Implementation of a systematic screening and risk modification and management plan, to identify and enhance the management of patients with cognitive impairment and risk of delirium.
214986327|NCT03735823|OTHER|No intervention, just collect blood samples and CSF samples|No intervention
214986328|NCT06277674|DRUG|Cadonilimab plus Pemetrexed and Anlotinib|Cadonilimab was administered intravenously at a dose of 10 mg/kg every 3 weeks. Pemetrexed was administered intravenously at a dose of 500 mg/m² every 3 weeks Anlotinib was taken at doses of 10mg orally once daily for two weeks on a one-week-off schedule.
214986329|NCT04486261|OTHER|High-intensity strength training|The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
214986330|NCT04390165|OTHER|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
214986331|NCT00713076|OTHER|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
214986332|NCT02111200|DRUG|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
215089293|NCT01778322|PROCEDURE|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
215089294|NCT05558215|OTHER|Otago Exercise Program|"The Otago Exercise Program (OEP) is a CDC endorsed evidence-based falls prevention program for older adults. It has not been well studied with individuals with dementia. It is comprised of a brief warm up/flexibility series, lower extremity strengthening, and balance exercises. The same menu of exercises is used for all participants, but exercises are progressed based upon individual performance. For the purposes of this study, three 25-minute video recorded versions of OEP will be rotated for use, all of which include brief flexibility activities, strengthening, and balance exercises. Strengthening exercises will be limited to body weight resistance for ease of instruction, safety, and consistency. Balance exercises involve changes in base of support in static and dynamic contexts, with challenge progressively increased by decreasing arm support during training (from 2-hands, to 1-hand, to no hands)."
214372402|NCT06063122|DEVICE|smallTalk NICU Active|The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold.
214372403|NCT05677932|DEVICE|Bright light therapy|Exposure to bright light therapy for 30mins a day for two weeks
214682890|NCT05925816|BEHAVIORAL|Active game|Game provides positive feedback in response to decisions made by participants
214682891|NCT05925816|BEHAVIORAL|Neutral game|Game without feedback
214372404|NCT05677932|DEVICE|Dim red light therapy|Exposure to 50lux dim red light therapy for 30mins a day for two weeks
214682892|NCT06671522|OTHER|Survey|It is a qualitatative research. Only a survey.
214682893|NCT00027040|DRUG|Selegiline hydrochloride|
214682894|NCT02960932|DEVICE|ultrasound scanner|Ultrasound scanner used to the SSI technical reproducibility.
214682895|NCT05021536|OTHER|Placebo|Matching Placebo Comparator
214682896|NCT05021536|DRUG|AMX0035|Proprietary formulation of taurursodiol and sodium phenylbutyrate
214682897|NCT05185752|PROCEDURE|SIFP Block Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by SIFP block: lateral and anterior cutaneous branches of the 2nd-6th Intercostal Nerves.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
215089295|NCT03939078|RADIATION|CO2 fractional ablative laser|3 intravaginal fractional ablative CO2 laser sessions, with one month interval between them.
215089296|NCT02675335|DRUG|Sitagliptin|
215089297|NCT02675335|DRUG|Placebo|
215089298|NCT01685983|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
215089299|NCT01685983|DRUG|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
214372405|NCT05963152|BEHAVIORAL|Habitual Physical Activity|Participants will be asked to maintain their normal activity levels
214372406|NCT05963152|BEHAVIORAL|Morning Exercise|Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
214372407|NCT05963152|BEHAVIORAL|Afternoon Exercise|Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
214682898|NCT05185752|PROCEDURE|PECS II block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by PECS-II: Lateral Pectoral Nerve and Medial Pectoral Nerve Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
214682899|NCT05185752|PROCEDURE|ESP block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by ESP Block: dorsal and ventral branch block of the spinal nerves; white and gray communicating branches of the sympathetic nerves that go to the thoracic sympathetic chain.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
214682900|NCT03026543|PROCEDURE|Pulmonary Recruitment Maneuver|
214682901|NCT03026543|PROCEDURE|Laparoscopic cholecystectomy|
214682902|NCT03026543|DEVICE|Ventilator|
214682903|NCT06011005|OTHER|Ethyl Chloride spray (group A)|Cold test spray
214682904|NCT06011005|OTHER|Benzocaine gel 20% (group B)|Topical analgesia
214682905|NCT05509205|OTHER|Turkish Validity and Reliability of The PSS Scale|This study is about validation of the Pound Satisfaction Scale to Turkish. The level of satisfaction with the rehabilitation service and treatment of 130 stroke patients undergoing stroke rehabilitation will be evaluated with the Pound satisfaction scale.
214682906|NCT02566525|DEVICE|CytoSorb|Cytosorb device use during cardiopulmonary bypass
214682907|NCT00337467|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
214682908|NCT04035135|DRUG|ANX005|investigational drug
214682909|NCT04035135|DRUG|Intravenous immunoglobulin|investigational drug
214682910|NCT01881035|PROCEDURE|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
214682911|NCT02488759|DRUG|Nivolumab|
214682912|NCT02488759|DRUG|Ipilimumab|
214682913|NCT02488759|DRUG|Relatlimab|
214682914|NCT02488759|DRUG|Daratumumab|
214682915|NCT06671990|DRUG|Vericiguat|Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
214682916|NCT06671990|DRUG|Placebo|Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
214682917|NCT06673121|DRUG|Traditional Chinese Medicine|Received treatment with traditional Chinese medicine
214682918|NCT06671860|OTHER|Exercise|"Individuals were randomly assigned to the REP (Routine Exercise Program) group and the OHP group. The REP group received the traditional exercise protocol and the OHP group received oculomotor exercises and myofascial release techniques in addition to the traditional exercise. The groups were evaluated before the treatment and at the end of the 6-week treatment sessions. Patient education was given to the patients before both programs. Patient education included information about nonspecific chronic neck pain, symptoms, and complications, as well as assessment methods, parameters, tests, and exercises.~The first group, the REP group (n=19), received routine exercises, and the second group, the OHP group (n=19), received oculomotor exercises and myofascial relaxation techniques in addition to the routine exercise program. The treatments were applied for six weeks, three sessions per week, under the supervision and guidance of a physiotherapist in the clinic."
214372408|NCT02287350|DRUG|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
214372409|NCT00615862|OTHER|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
214494485|NCT06783855|PROCEDURE|conventional radical cystectomy and ileal neobladder|After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra, including the mucosa and muscularis of the neobladder neck, ensuring mucosa-to-mucosa anastomosis
214494486|NCT06791200|DIAGNOSTIC_TEST|biochemical indices|some biochemical indices for prediction of Acute kidney Injury
214494487|NCT04328532|DEVICE|MRI|MRI examination (45 min max) with potential oxygen delivery for 10 min
214494488|NCT06740084|BEHAVIORAL|Y-MIND Intervention|All participants in the intervention arm will receive the EUC plus the Y-Mind intervention. Y-Mind intervention will be delivered by trained and supervised Guidance and Counselling Coordinators (GCC) at schools in 6 sessions. The six sessions will include a) psychoeducation on depression, b) behavioural activation (helping the participant see the connection between their behaviour, daily activities, and low mood and activity scheduling) and c) problem-solving therapy (the GCC helps the participant identify and define a specific problem to work on, evaluate the potential solutions to the problem, and carry out the selected solution(s)).
214682919|NCT06671158|BEHAVIORAL|Psychotherapy|Individual psychotherapy for weekly 12-sessions
214682920|NCT06672367|PROCEDURE|Balance training group|"It includes participants receiving balance training for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously."
214682921|NCT06672367|PROCEDURE|Balance training combined with gaze stability exercises|"It includes participants receiving balance training combined with gaze stability exercises for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously.~Gaze stability exercises~Visual tracking exercises"
214682922|NCT06671431|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy with or without radiotherapy
214682923|NCT01723280|DRUG|Oxygen|During and 2 hrs after surgery
214986333|NCT02111200|DRUG|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
214986334|NCT00346437|GENETIC|Ad5FGF-4 vs. Placebo|Intracoronary infusion
214986335|NCT05033041|DRUG|Study drug metoclopramide|Intravenous administration of 10 mg metoclopramide
214986336|NCT05033041|DRUG|Study drug placebo administration|Intravenous administration of placebo (sterile normal saline)
214372410|NCT01934413|BEHAVIORAL|Technology-Enhanced Transitional Palliative Care|The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.
214372411|NCT01934413|OTHER|Usual Standard of Care|Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
214372412|NCT01303120|DRUG|Femoral Nerve Block|Preoperative Bupivacaine 0.5%, perineurally as single shot
214494489|NCT06740084|OTHER|Enhanced Usual Care|Enhanced Usual Care (EUC): Guidance and counselling coordinators in the schools provide some counselling to students who need it. Building on the existing structure, enhanced usual care in the Y-mind programme, will be enhanced in three ways: 1) Teaching staff will receive basic training on common mental health conditions affecting youth in Ghana with an emphasis on depression and suicidal symptoms and treatment. The WHO guidelines for school health services will form the basis for the training for teachers. 2) Nurses in all schools and other relevant local health care professionals will be trained in mental health, substance-use and self-harm including guidelines on when and where to refer young people for psychiatric care. The World Health Organization (WHO) Mental Health Gap intervention guide (mhGAP) will be used for training of nurses and other health care professionals . 3) The study team will provide a letter for the Guidance and Counselling Coordinators for the participant.
214682924|NCT04581681|BEHAVIORAL|Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA)|"The 6-session group CBT intervention for perinatal anxiety has been formalized with session guides for the facilitators and a workbook, Overcoming Anxiety in Pregnancy and Postpartum (Furer \& Reynolds, 2015), developed by members of our Anxiety Disorders Clinic. There are 6 core modules covered over the 6 treatment sessions, including: (1) Understanding anxiety during pregnancy and postpartum, (2) self-care, (3) setting goals and facing fears, (4) nurturing the developing relationship with baby, (5) coping with negative thoughts and worries, and (6) relapse prevention. Content is based on general principles of CBT for anxiety but specific themes and examples are geared towards the pregnancy and postpartum periods. Distorted cognitions are also explored, with an additional focus on beliefs about motherhood and perfectionism. Due to the COVID-19 pandemic, the intervention will be conducted via a hospital-approved video-conferencing platform."
214494490|NCT06222346|BEHAVIORAL|CommonGround|"Through collaboration with people living with LTCs, clinicians, academics, and web design experts, we have co-designed an online peer support and psychoeducation platform to help people with physical health conditions connect, support others, share experiences, and receive evidence-based information and advice on self-management. The web-based platform offers users access to peer support forums with embedded psychoeducation content.~The following components are key features of the platform:~* A discussion forum~* A private My Garden page that stores posts from other users and psychoeducation content that the user has decided to 'save'.~* A resources page giving access to evidence-based psychoeducation material on the mind-body link~* A 'Crisis and Further Support' page, where users can find further organisations and sources of support, particularly for crisis situations. The peer support platform does not offer one-to-one or crisis support."
214682925|NCT04581681|OTHER|No treatment (waitlist control)|Patients in this condition are randomly assigned to a waitlist control condition before receiving treatment.
214682926|NCT04083222|DRUG|Placebo|ISIS 757456-matching placebo solution administered as SC injection.
214682927|NCT04083222|DRUG|ISIS 757456|ISIS 757456 administered as SC injection.
214682928|NCT00308295|DRUG|Fish oil capsules|
214682929|NCT00308295|DRUG|matched placebo capsules|
214682930|NCT00972998|DRUG|Phenyephrine|Phenyephrine coated suppositories
214682931|NCT01418222|DRUG|5-FU|Intravenous repeating dose
214682932|NCT01418222|DRUG|FOLFOX regimen|Intravenous repeating dose
214682933|NCT01418222|DRUG|Placebo|Intravenous repeating dose
214682934|NCT01418222|DRUG|bevacizumab [Avastin]|Intravenous repeating dose
214682935|NCT01418222|DRUG|leucovorin|Intravenous repeating dose
214682936|NCT01418222|DRUG|onartuzumab [MetMAb]|Intravenous repeating dose
214682937|NCT05894993|DEVICE|transient elastograghy|is a non-invasive method proposed for the assessment of hepatic fibrosis in patients with chronic liver disease by measuring liver stiffness. It can be easily performed at the bedside or in the outpatients clinic with immediate results and good reproducibility.
215089300|NCT05947630|DEVICE|Ankle Foot Orthosis (AFO)|3D treatment (AFO will be printed) versus traditional made AFO
215089301|NCT05947630|DEVICE|Knee Ankle Foot Orthosis (KAFO)|3D treatment (KAFO will be printed) versus traditional made KAFO
215089302|NCT03430271|OTHER|Physical Activity Intervention|Participants in this arm will complete exercise sessions 1 time per week for 24 weeks. An optional, second PA session will also be offered to PA participants. The exercise sessions will be multimodal and involve walking, lower extremity strengthening exercises, flexibility and balance training.
215089303|NCT03430271|OTHER|Healthy Aging Intervention|Participants will attend health education workshops on topics of relevance to older adults. Workshops will be offered weekly in a group setting, and participants will be required to attend biweekly.
215089304|NCT00189943|BIOLOGICAL|MVA-BN|
214372413|NCT01303120|DRUG|Combined nerve blocks|Preoperative Bupivacaine 0.5%, perineurally as single shot
214682938|NCT05196997|OTHER|Mobility and Functional Assessments|"The first evaluation was made on the day the patient was discharged from the intensive care unit. DEMMI, Bartel Index, Katz Activities of Daily Living Rating Scale and MRC Muscle Strength Test were performed to the patient, respectively.~De-Morton Mobility assessment for test-retest reliability was performed again on the 1st day of the patient's service."
214372414|NCT01303120|DRUG|Patient-controlled analgesia|Patient controlled analgesia with morphine
214372415|NCT03091673|DRUG|Glucagon|0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
214682939|NCT00360022|OTHER|Joint visits|Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
214682940|NCT02944799|DRUG|Placebo|Discontinuation of alendronate treatment
214682941|NCT02944799|DRUG|Alendronate|
214682942|NCT02944799|DRUG|Calcium|Daily dietary supplement of 800mg calcium
214682943|NCT02944799|DRUG|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
214682944|NCT05050630|DRUG|TR2-ICE|Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
214682945|NCT04151017|OTHER|Autologous fibrin glue|Conjunctival graft fixation with autologous fibrin glue
214372416|NCT05636150|DRUG|Fruquintinib in Combination with S-1|"Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
214372417|NCT00610974|BEHAVIORAL|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
214682946|NCT04151017|OTHER|Suture|Graft fixation using 10.0 mononylon
214682947|NCT06671964|OTHER|Anthropometric measurements|Anthropometric measurements of the students, including weight, height, muscle mass, fat quantity, and waist circumference, were measured. The WHO BMI charts were utilized for classification. Stratified Random selection
214372418|NCT00610974|BEHAVIORAL|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
214372419|NCT05699122|OTHER|Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day."
215089305|NCT03301064|BEHAVIORAL|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
215089306|NCT03301064|OTHER|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
215089307|NCT00685373|DRUG|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
214682948|NCT06671964|OTHER|Questionnaire|"The collection of data was performed using the Atlas questionnaire (Al-Hazzaa et al., 2011) and nutrition knowledge and healthy lifestyle behavior questionnaire (Kalender et al., 2011) with additional questions related to self-efficacy and dietary practices adapted from the literature (Becher, 2009; Voss et al., 2017; Kowalski et al., 2004). Stratified Random selection"
214682949|NCT06671964|OTHER|Educational sessions|The topics that covered included a healthy eating lifestyle, energy balance, food portion control, healthy snacking, the importance of physical activity and healthy eating, dietary practices, and nutrition-related self-efficacy.
214682950|NCT06673251|OTHER|motor and sensory assessments, surveys|It does not include any intervention. Only evaluation will be made.
214682951|NCT06809361|BEHAVIORAL|Obesity prevention program|The Obesity Prevention Program was developed based on a literature review. Expert opinions (Public Health Nursing, Pediatric Nursing, Physical Therapy and Rehabilitation, Nutrition and Dietetics) were obtained for the educational content, and the final version was formulated. The training program is planned in eight sessions. The program will be scheduled at times convenient for students after prior discussion with the school administration. Two sessions per week will be conducted, with each session expected to last approximately 30-40 minutes. Students will utilize school computers and projectors during the training. The program will include verbal presentations, PowerPoint slides, brainstorming, exercises, games, written and visual materials, video screenings, and Q\&A sessions. Adolescents will try on weighted T-shirts of different weights, fruit plates will be distributed during sessions, and bookmarks, magnets, and brochures will be provided at the end of the sessions.
214682952|NCT06809361|BEHAVIORAL|Social media messages|In addition to the program, a total of 36 short messages will be sent three times a week to the Education + Social Media Supported group.
214682953|NCT06862596|DRUG|Mexiletine hydrochloride|Mexiletine hydrochloride 300 mg is administered orally divided into three times a day after meals for 12 weeks.
214682954|NCT06862596|OTHER|Placebo|Placebo is administered orally divided into three times a day after meals for 12 weeks.
214682955|NCT06672354|PROCEDURE|Otago Exercise Program|"1- Otago Exercise Program: i) This exercise program will consist of strengthening, balance exercises and walking plan. The OEP will be performed according to the following: 5 min warm-up, 10 min resistance training and 15 min balance exercises.~ii) The strength training protocol targets, on hip abductors, knee flexors, knee extensors, plantarflexors, and dorsiflexors.All exercises will be performed for 10 repetitions. This protocol recommends strength training 3 days per week.~iii) The balance retraining protocol incorporates various exercises. The exercises progress in difficulty through four levels, with Level 1 being the easiest and Level 4 the most challenging. Balance exercises will progress from holding onto a stable supporting structure such as heavy furniture to perform the exercises independent of the support. The protocol recommends participants to carry out balance exercises 3 days a week.~iv) Participants will be instructed to walk at their usual pace for 30 minutes, twice"
214682956|NCT06672354|PROCEDURE|Non-Immersive Virtual Reality Training|In this interventional group, VR training exercises will be performed by using Xbox Kinect, which includes a Kinect sensor.-The monitor or Tv screen will recognize the movements of participants via camera and infra-red motion sensors.-In order to perform simulated exercises in each session, the participant will be positioned at 1.5-2 meter from the monitor or TV screen.-The virtual reality training exercises will include Kinect Adventure games (Rally Ball, 20,000 leaks, Reflex Ridge) and Sports pack 1 games (Super Saver, Target Kick, Body ball).-Exercises will be continued for 30-45 minutes each session, for 3 alternate days per week for a total period of 12 weeks.
214682957|NCT04075227|DRUG|0.2% loteprednol etabonate|Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
214682958|NCT04075227|DRUG|0.1% dexamethasone|Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
214682959|NCT02887144|DEVICE|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
214372420|NCT05699122|OTHER|Gentle intimate hygiene and skin protective barrier application - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution."
214986337|NCT05259709|DRUG|89Zr˗DFO˗REGN5054|Administered by intravenous (IV) infusion during Part A and B.
214682960|NCT02887144|DEVICE|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
214682961|NCT05710874|OTHER|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
214682962|NCT05710874|OTHER|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.
214682963|NCT05710874|OTHER|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
214986338|NCT05259709|DRUG|cemiplimab|Administered by IV infusion every 3 weeks (Q3W).
215089308|NCT00084175|BEHAVIORAL|Behavior Therapy|
215089309|NCT01016314|DEVICE|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
215089310|NCT01016314|DEVICE|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
214494491|NCT06222346|BEHAVIORAL|NHS Mental Health|"Participants in the control arm will be directed towards the Mental Health webpage(s), an online resources page provided by the NHS. These resources are not specifically targeted at people living with LTCs. They include information sheets and mental health support on topics such as advice for life situations and events. Additionally, it hosts a self-help section that includes guides, tools, and activities to support mental health, but does not include any interactive or peer support elements."
214494492|NCT06863506|DRUG|befotertinib|Befotertinib will be administered orally at an initial dose of 75 mg once daily for 21 days, with escalation to 100 mg if tolerated. Treatment continues until disease progression, unacceptable toxicity, or withdrawal.
214494493|NCT06807320|DRUG|MTA pulp dressing material|MTA powder ( ProRoot; Dentsply ⁄ Tulsa Dental, Tulsa, OK,USA) was added to sterile water. The mixture was left to achieve a sandy consistency for about thirty seconds. Then, the material was applied to the cavity using a ball condenser.
215089311|NCT02642965|DRUG|Cytarabine|Given IT or IV
215089312|NCT02642965|BIOLOGICAL|Filgrastim|Given SC or IV
214682964|NCT05710874|OTHER|Conventional|Twice daily use of conventional toothpaste.
214682965|NCT02832440|OTHER|Exercise programmes|
214682966|NCT02559232|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
214986339|NCT04497116|DRUG|RP-3500 (camonsertib)|Oral ATR inhibitor
214986340|NCT04497116|DRUG|Talazoparib|Oral PARP inhibitor
214986341|NCT04497116|DRUG|Gemcitabine Injection|Gemcitabine
215089313|NCT02642965|DRUG|Fludarabine Phosphate|Given IV
215089314|NCT02642965|OTHER|Laboratory Biomarker Analysis|Correlative studies
215089315|NCT02642965|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
215089316|NCT02642965|OTHER|Pharmacological Study|Correlative studies
214986342|NCT05233761|DRUG|Defined CBD|300 mg CBD and 8 mg Terpenes administered as two small capsules.
214986343|NCT05233761|DRUG|Placebo|Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
214986344|NCT06802445|OTHER|Self-Management Therapy|Participants in this group will receive self management therapy. The self-administered therapy programme will consist of prevention of parafunctional activities, information about sleep hygiene and home exercise programmes, the effectiveness of which has been reported in the literature and is in line with the International Delphi Guidelines. Home exercises will start with 2 times a day, 8 repetitions and progress will be made weekly according to the patient's condition.
215089317|NCT01950585|DRUG|Hydroxyurea|
215089318|NCT04214886|DRUG|Fludarabine|Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
214682967|NCT03580577|DEVICE|thromboelastography|thromboelastography will assess all coagulation abnormalities including platelets function in cirrhotic group with venous thromboembolism , and guide us about is there increased thrombosis risk or not, for that a fresh blood sample will be withdrawn from each patient before starting any treatment
214682968|NCT02457351|DRUG|Roniciclib (BAY 1000394)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose"
214986345|NCT06802445|DEVICE|Placebo Non-Invasive Vagal Nerve Stimulation|Participants in this group will receive self managemenet therapy and placebo vagal nerve stimulation. For Placebo Non-Invasive Auricular Transcutaneous Vagal Nerve Stimulation, the technique will be similar to active stimulation. The VaguStim device will be set to 0 Hz by the practitioner, indicating that no actual stimulation is being delivered. Patients will be told that they will not be able to feel the current due to its lower intensity during the intervention, without explaining the true nature of the placebo stimulation.
214682969|NCT02457351|DRUG|Itraconazole (Sporanox)|Part 1 \& Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
214682970|NCT02816762|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
214682971|NCT02816762|DRUG|Pharmacological treatment|Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
214682972|NCT02816762|OTHER|Diet|Conventional anti-diabetic diet recommendations
214682973|NCT02411812|DEVICE|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
214682974|NCT02411812|DEVICE|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
214372421|NCT05699122|OTHER|Low Level Laser Therapy - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
214372422|NCT05699122|OTHER|Low Level Laser Therapy - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
214372423|NCT06397274|BIOLOGICAL|Stemchymal|Patients will receive Stemchymal® through intravenous infusion
214372424|NCT06397274|BIOLOGICAL|Placebo|Patients will receive Placebo through intravenous infusion
214372425|NCT05194189|DRUG|Vitamin C|12 g vitamin C (48 ml) will be intravenously injected by a infusion pump every 12 h for 4 days or at ICU discharge
214372426|NCT05194189|DRUG|5% glucose injection|5% glucose solution 48 ml every 12 h for 4 days or at ICU discharge.
214372427|NCT03812211|DIETARY_SUPPLEMENT|Active Supplement|Examine the effects of a multi-faceted supplement comprised of vitamins, minerals and naturally occurring and plant extracts approved for consumption of in overweight/obese men and women
214372428|NCT03812211|DIETARY_SUPPLEMENT|Placebo supplement|Examine the effects of a placebo supplement in overweight/obese men and women, compare to the active supplement
214682975|NCT02411812|DEVICE|Twin-Block appliance|Group treated with Twin-Block appliance
214682976|NCT06688084|OTHER|Molecular epidemiology of the collection|Next-generation genomic sequencing (MICRO\&BIO platform, MiSeq, Illumina) and bioinformatics analyses. After validating data quality, genomes will be re-assembled using Spades software (version 3.15.4) and CLC® (Qiagen), then compared with the National Center for Biotechnology Information GenBank database. They will also be analysed on the online Type-Strain Genomes Server platform to accurately identify the bacteria. Genome annotation will be done using the DDBJ Fast Annotation and Submission Tool. Single nucleotide polymorphisms (SNP) analysis based on the alignment of whole genomes and core-genomes will be carried out using version 7 of MAFFT (multiple alignment using fast Fourier transform) software, then quantified using snp-dists (version 0.6.3). This approach will enable the molecular epidemiology of the collection of strains in France and other European countries to be clarified, and the main circulating clades to be assessed, particularly depending on the origin of samples.
215089319|NCT04214886|DRUG|Cyclophosphamide|Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
215089320|NCT04214886|BIOLOGICAL|CD19-CD34 CAR transduced T cells|CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
215089321|NCT05236985|DRUG|Oxytocin bolus or oxytocin infusion|"On the day of surgery, the patients will be randomized to either bolus or infusion administration of oxytocin.~On the day of the procedure, periprocedural data and patient satisfaction (single question) will be recorded."
215089322|NCT02145871|OTHER|standard fluid management|
214372429|NCT01784432|DEVICE|Low-level laser therapy and training|
214372430|NCT01784432|OTHER|Training|
214372431|NCT04872244|DEVICE|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele for postmenstrual spotting and do not have desire for fertility
214372432|NCT04872244|DRUG|Levonorgestrel Drug Implant Product|intrauterine administration
214372433|NCT00771303|OTHER|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
214372434|NCT02675478|DRUG|AC220|
214986346|NCT06802445|DEVICE|Non-Invasive Vagal Nerve Stimulation|Participants will receive Non-Invasive Vagal Nerve Stimulation and self management therapy. : Non-Invasive Auricular Transcutaneous Vagal Nerve Stimulation, CE certified (CE No: 2460) non-invasive stimulation device will be applied with. The application will be performed with 3 different sized electrodes (small, medium, large) specially designed according to the size of the inner ear. The stimulation will be delivered bilaterally from the symba concha and tragus regions innervated by the auricular branch of the n.vagus, which guarantees effective and targeted vagal modulation. With reference to the studies in the literature; VaguStim application frequency will be 25 Hz, pulse width 250 µs, current level 0.5 mA with biphasic waveform. The treatment will continue 3 days a week for a total of 6 weeks, with each session lasting 20 minutes.
214372435|NCT05890625|OTHER|On going treatment|No additional attempts will be made by the investigator on the cases in the control group. These cases will only benefit from the services in the clinic.
214372436|NCT05890625|OTHER|InT-mAp|InT-mAp, the content of which will be created as a result of the evaluation of the nursing needs of infertile women, consists of a web-based training and online consultancy platform. The treatment plan specific to each participant will be entered into the web base individually, and the participants will be able to follow and manage the treatment protocols and appointments under their own control. InT-mAp is a guide that helps breakers about the intended use, effects, side effects of the drugs under treatment and how to self-administer, especially for women.
214986347|NCT05685342|DRUG|Acetaminophen/Ibuprofen fixed-dose combination|Intravenous administration of Acetaminophen (1000 mg)/Ibuprofen (300 mg) fixed-dose combination (total 100 ml)
215089323|NCT02145871|OTHER|fluid management guided by the EV1000|
215089324|NCT01167907|DEVICE|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
215089325|NCT01167907|DRUG|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
215089326|NCT02880813|OTHER|Infusion|infusion of nutrients
214372437|NCT01807806|BEHAVIORAL|Role-playing game|Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
214372438|NCT03657498|PROCEDURE|Combined orthodontic-orthognathic treatment|combined treatment including orthodontics and orthognathic surgery
215089327|NCT00239954|DRUG|Escitalopram|
215089328|NCT06026956|OTHER|Tele-Assessment|Tele-Assessment
215089329|NCT01603381|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
215089330|NCT00857948|DRUG|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
214372439|NCT03657498|PROCEDURE|Standard orthodontic treatment|treatment with standard orthodontic procedures
214372440|NCT02357030|DRUG|Methyl-P plus GWI Nutrient Formula|"Week 1:~* One tablet of Methyl-P (5mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily~Week 2 to Week 12 :~* Two tablets of Methyl-P (10mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily"
214372441|NCT01352585|DRUG|Anagrelide hydrochloride|0.5 mg hard capsules, dosing decisions will be made by the treating physician
214372442|NCT00605202|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
214372443|NCT00605202|DIETARY_SUPPLEMENT|Licorice|Licorice candy 32 grams a day for 14 days.
214372444|NCT01126827|BEHAVIORAL|Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy|12 weekly group therapy sessions
214372445|NCT02276066|DIAGNOSTIC_TEST|GFR by Iohexol|Participants may receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected and measured to determine glomerular filtration rate measurements. This test will be repeated in one year.
214494494|NCT06807320|DRUG|Calcium Hydroxide (Ca(OH)2)|For Group I patients, Calcium hydroxide (Dycal\_ Ivory,Dentsply Caulk, Dentsply, L.D. Caulk, Milford, DE,USA ) was used. The catalyst and paste were mixed as per the manufacturer's recommendations.
214494495|NCT04588038|BIOLOGICAL|Efineptakin alfa|Given via intramuscular injection
214494496|NCT06877338|OTHER|Loaded breathing on stable and unstable surfaces|Participants will be instructed to perform 10 loaded breaths via a threshold inspiratory load device on both a stable surface (sitting on a chair, Protocol 1) and an unstable surface (sitting on a soft pad, Protocol 2) in random order. The inspiratory load/resistance will be set at 50% of the maximum inspiratory pressure (MIP).
214494497|NCT06839352|DRUG|Vitamin K1|10 mg intravenous infusion daily for three days
214494498|NCT04725110|DRUG|Instilled T3|The first dose of T3 (50 micrograms in 10 mls volume BID) will be instilled by an investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. T3 doses will be given in 50 mcg doses twice daily for 4 days.
214494499|NCT04725110|OTHER|Placebo Therapy|A placebo therapy will be instilled into the lungs by the investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. Doses will be given twice daily for 4 days.
214494500|NCT02125149|OTHER|Exercise Intervention|
214494501|NCT06894823|OTHER|Creation of a laboratory network|Creation of a laboratory network in Central-Southern Italy capable of performing complex genomic analyses.
214494502|NCT06894823|OTHER|Mapping of genomic alterations|Mapping of genomic alterations aimed at precision medicine and personalized diagnostic and therapeutic approaches.
214494503|NCT06894823|OTHER|Creation of a bioinformatics network among the participating institutions.|Creation of a bioinformatics network among the participating institutions.
214494504|NCT06894823|OTHER|Development of a platform for the collection of clinicopathological and genetic-molecular data.|Development of a platform for the collection of clinicopathological and genetic-molecular data.
214494505|NCT06894823|OTHER|Identification of prognostic and predictive factors for the implementation of precision oncology strategies based on genomic profiling.|Identification of prognostic and predictive factors for the implementation of precision oncology strategies based on genomic profiling.
214494506|NCT06762834|COMBINATION_PRODUCT|Ginger tea|determine the optimal dosage of ginger tea that produces significant blood pressure reduction without adverse effects.
214494507|NCT06762834|COMBINATION_PRODUCT|self administred Ginger tea|To identify consumption and its correlation with blood pressure outcomes using a self- reported diary and periodic clinical assessments.
215089331|NCT00857948|DRUG|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
215089332|NCT00701636|DRUG|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
214372446|NCT02276066|DIAGNOSTIC_TEST|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration. This test will be repeated in one year.
214372447|NCT02276066|DIAGNOSTIC_TEST|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine results. This test will be repeated in one year.
215089333|NCT00900185|GENETIC|mutation analysis|
215089334|NCT00900185|GENETIC|polymerase chain reaction|
215089335|NCT00900185|GENETIC|polymorphism analysis|
215089336|NCT03026478|DRUG|Betamethasone Dipropionate|
215089337|NCT03026478|DRUG|Clobetasol Propionate|
215089338|NCT04580706|OTHER|this is an observational study with none intervention|this is an observational study with none intervention
215089339|NCT05801406|DEVICE|Tornado (Cook)|Fiducial marker endobronchial positioning under augmented fluoroscopy to mark ground glass opacities.
215089340|NCT00004705|DRUG|amiloride|
215089341|NCT00004705|DRUG|uridine|
214372448|NCT06948396|BIOLOGICAL|Tezepelumab|Tezepelumab is indicated as an add-on maintenance treatment in adult and adolescent ≥12 years patients with severe uncontrolled asthma despite high-dose inhaled corticosteroids plus long-acting β-agonists
214372449|NCT04148014|BEHAVIORAL|An Adjunctive Emotion Regulation Skills Training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 5 weeks to young adults with eating disorders together with treatment as usual
214494508|NCT06111872|DRUG|Ketamine|Administration described in arm/ group description
214494509|NCT06111872|DRUG|Midazolam|Administration described in arm/ group description
214494510|NCT06111872|DRUG|Pethidin|Administration described in arm/ group description
214494511|NCT06596317|PROCEDURE|Chromoendoscopy|Patients will undergo chromoendoscopy with spraying indigo carmine.
214494512|NCT06596317|PROCEDURE|Conventional colonoscopy|Patients will undergo conventional colonoscopy.
214494513|NCT06114498|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography at rest: with determination of epicardial fat tissue thickness, intensity of mitral regurgitation.
215089342|NCT02635334|DRUG|Montelukast 10 mg orally|
215089343|NCT02635334|OTHER|Placebo|
215089344|NCT03077698|DRUG|Sodium Cridanimod|The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
214494514|NCT06114498|DIAGNOSTIC_TEST|Bioimpedance|Bioelectrical impedance analysis research
214494515|NCT06114498|DIAGNOSTIC_TEST|Immunoassay|Enzyme immunoassay of heat shock proteins in blood serum
214494516|NCT06114498|DIAGNOSTIC_TEST|Routine biochemistry|Measuring of routine biochemical parameters (glucose, total protein, creatinine, urea, uric acid, total bilirubin, direct bilirubin, total cholesterol, triglycerides, low and high density lipoprotein cholesterol, Lactate dehydrogenase, creatine phosphokinase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium and special (C-reactive protein, N-terminal pro b-type natriuretic peptide)
214494518|NCT05818319|OTHER|12 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting 12 hours.
214494519|NCT05818319|OTHER|36 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 36 hours.
214494520|NCT05818319|OTHER|60 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 60 hours.
214494521|NCT02549352|DRUG|LEO43204 gel|
214494522|NCT02549352|DRUG|Vehicle gel|
214494523|NCT06778629|PROCEDURE|Transversalis Fascia Plane Block|After the wound closure is completed and the patient is still under general anesthesia the TFPB will be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed longitudinally, 2-3 cm laterally, just above the iliac crest at the mid-axillary line. After the external oblique, internal oblique, and transversus abdominis muscles are distinguished, the common aponeurosis of the transversus abdominis and the internal oblique muscle will be found. The block needle will be directed from anterior to posterior, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine, Polifarma ®) will be applied between the transversus abdominis muscle and transversalis fascia.
214494524|NCT06778629|PROCEDURE|Post Operative Pain Management|Acetaminophen 1 gr (Paracerol, Polifarma®) intravenous (IV), and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be administered to all patients 30 minutes before wound closure. After surgery, Acetaminophen (Paracerol, Polifarma®) 1 gr IV, and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be given three times a day. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV pethidine (Aldolan, Liba Laboratory ®) 0,5 mg/kg will be given as a rescue analgesic.
214494525|NCT06778629|PROCEDURE|Port Site Infiltration|A total of 20 ml of 0.25% bupivacaine ( (Buvicaine, Polifarma ®) will be applied to the trocar entry points by the surgeon at the beginning of the operation, before entering the trocars.
214494526|NCT06767137|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Cognitive Behavioral Therapy for Insomnia (CBT-I) is a gold-standard, evidence-based treatment combining techniques to improve the clinical symptomatology of insomnia. Delivered in six 90-minute group sessions over six weeks, it includes: sleep education (i.e. understanding sleep mechanisms and influencing factors), bedtime restriction (i.e. aligning bedtimes with reported sleep duration), stimulus control (i.e. getting out of bed when unable to sleep), cognitive therapy (i.e. addressing dysfunctional sleep beliefs), relaxation techniques (i.e. using methods like progressive muscle relaxation).
214682977|NCT06688084|OTHER|Study of the resistome of the S. pettenkoferi population|The resistome will be assessed by identifying known and described resistance genes in staphylococci using bioinformatics analyses of sequenced complete bacterial genomes. A search for plasmids will also be made using various specific software packages (ResFinder, CARD, PointFinder, Plasmidfinder, in-house pipeline).
214682978|NCT06688084|OTHER|Study of the virulome of the S. pettenkoferi population|The virulome of the strains will be studied based on the genomic sequencing data obtained and with reference to the literature on Staphylococci. Various specific software packages (Pathogenfinder, Virulencefinder, in-house pipeline) will be used for this purpose.
214682979|NCT06688084|OTHER|Study of the resistance profiles of all S. pettenkoferi isolates|Antibiotic resistance will be assessed using a Sensititer® plate (Thermo ScientificTM, Illkirch) to evaluate the minimum inhibitory concentration of isolates against a series of antibiotics commonly used for S. pettenkoferi infections, including new molecules currently on the market or in development, such as Ceftaroline, Ceftobiprole, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Minimum inhibitory concentration values will be interpreted in accordance with the recommendations of the Antibiogram Committee of the Société Française de Microbiologie (https://www.sfm-microbiologie.org/2021/04/23/casfm-avril-2021-v1-0/).
214372450|NCT01073670|DRUG|Indomethacin|Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
214372451|NCT01073670|DRUG|Acetaminophen & Indomethacin|Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
214372452|NCT01073670|DRUG|Acetaminophen|Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
214494527|NCT06767137|BEHAVIORAL|Bedtime restriction (BRT)|"Bedtime Restriction Therapy (BRT): A behavioral intervention aimed at improving the clinical symptomatology of insomnia by aligning time spent in bed with reported sleep duration. Participants attend four 60-minute group therapy sessions over six weeks. The intervention includes: setting individualized sleep windows based on sleep diaries, regular adjustment of sleep schedules to enhance sleep pressure, group discussions to address implementation challenges and maintain motivation.~BRT focuses exclusively on bed time restriction without additional cognitive or relaxation components, making it a simplified, resource-efficient approach to treating insomnia."
214682980|NCT06688084|OTHER|Selection of strains for in-depth phenotypic study|"Different strains of S. pettenkoferi isolated from foot osteitis in diabetic patients and non-diabetic osteitis will be selected according to the clades identified and phenotypically characterised by further analysis:~* Observation of culture characteristics (culture requirements, growth time, colony size and haemolytic capacity), (n=20)~* Determination of growth curves by measuring absorbance at 600 nm using the Infinite M Mano automatic absorbance reader (TECAN, Lyon), (n=20)~* Study of the ability to form biofilm in the presence (antibiofilmogram) (n=85) or absence (BioFilm Ring® test, Biofilm Control, St Beauzire) (n=85) of various antibiotics commonly used for the treatment of S. pettenkoferi infection during osteitis."
214372453|NCT04479033|OTHER|Multidisciplinary collaborative model of community care management|An individualised care plan is developed for PLWDs-caregiver dyads who meet/communicate weekly with various members of the HMDCS team depending on the nature of their needs. Each dyad's care plan involves the diagnosis of problems (eg: memory problems, family conflicts, poor nutrition, fall risk, medication compliance, lack of long-term care arrangements), establishment of treatment goals (eg: caregiver education, awareness of long-term care planning, stabilising medical care at home, improving emotional support), and indicating specific interventions (eg: referrals to counsellors, specialist doctors, day rehabilitation centres; consultations at GP clinic; coordination of advanced care planning; installation of home safety devices; training caregivers to detect acute deterioration in PLWDs). Monitoring of the dyads' statuses and updating of care plans are performed throughout the duration of the programme.
214372454|NCT05050578|DEVICE|Lehfilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
214372455|NCT05050578|DEVICE|Senofilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
214372456|NCT05050578|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
214494528|NCT06660836|DEVICE|Mouthguard|After the participants' records are taken with intraoral scanners, custom mouthguards will be prepared from soft EVA sheets in a dental laboratory setting.
214682981|NCT06688084|OTHER|Selection of strains (n=3) for the virulence study|"Three strains of S. pettenkoferi isolated from foot osteitis in diabetic patients will be selected on the basis of the clades identified and the study of the virulome in order to be analysed on :~* In vitro cell culture models of macrophages (RAW 264.7) and osteoblasts (MC3T3-E1) to assess the invasion potential of these isolates by measuring internalisation rates (TECAN, Lyon) and LDH release (CyQUANT LDH Cytotoxicity kit), a sign of cellular toxicity of the isolate.~* An in vivo wound model on diabetic zebrafish (Dario rerio) with evaluation of their survival at 48h in the presence of the isolates by immersion.~These models were developed at the MICRO\&BIO Platform and the INSERM 1047 VBIC unit."
214682982|NCT04947566|DRUG|Comparison of Efficacy of Naproxen versus Ibuprofen|Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis
214682983|NCT01764646|RADIATION|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
214682984|NCT01764646|RADIATION|Volumetric modulated arc therapy|Highly conformational dose distribution
214682985|NCT01764646|RADIATION|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
214682986|NCT01782599|OTHER|Dual nicotine patch and electronic cigarette|
214494529|NCT06660836|OTHER|Performance test|Participants will undergo the Yo-Yo performance test both while using and not using mouthguards prepared with a digital workflow.
214682987|NCT01168804|DRUG|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
214682988|NCT04227977|DEVICE|JuxtaFlow System|The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
214372457|NCT01558310|DRUG|Ustekinumab|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
214372458|NCT01558310|DRUG|Placebo|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
214372459|NCT00172354|DRUG|Hydrocortisone|
214372460|NCT05519384|DRUG|JK500 cell injection，cyclophosphamide，Fludarabine|After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/㎡/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.
214372461|NCT02691195|DRUG|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
214372462|NCT02691195|DRUG|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
214986348|NCT05073705|BEHAVIORAL|Empowerment and personal transformation intervention|The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
214986349|NCT02118285|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 IV on days -6 through -2 from NK cell infusion
214986350|NCT02118285|DRUG|Cyclophosphamide|Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
214986351|NCT02118285|BIOLOGICAL|NK cells|CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
214986352|NCT02118285|BIOLOGICAL|IL-2|IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
214986353|NCT02118285|DRUG|INCB024360|INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
214986354|NCT01604785|DRUG|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
214986355|NCT01604785|DRUG|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
214986356|NCT02793986|DRUG|propofol|For patients in Group P, the sedation was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
215089345|NCT03077698|DRUG|progestin therapy|The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
214372463|NCT01073904|DRUG|Levonorgestrel Emergency Pill (BAY86-5028)|Single dose of 1.5 mg coated tablet
214372464|NCT01073904|DRUG|Postinor 2|Single dose of 1.5 mg tablet
214372465|NCT03386032|DRUG|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
214372466|NCT03386032|DRUG|0.05% Desonide|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
214372467|NCT03386032|OTHER|Placebo Cream|Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
214494530|NCT06801964|OTHER|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
214494531|NCT06801964|DIETARY_SUPPLEMENT|Protein and Fish Oil|milk/carbohydrate mixture and supplementation of 3.5g of EPA+DHA (7g of fish oil)
214494532|NCT06801964|DIETARY_SUPPLEMENT|Protein and Olive Oil|milk/carbohydrate mixture with olive oil
214494533|NCT06801964|DIETARY_SUPPLEMENT|Carbohydrate and Olive Oil|carbohydrate mixture with olive oil
214494534|NCT05681156|OTHER|N/A- There is no intervention.|There is no intervention.
214494535|NCT06750419|DRUG|89Zr-TLX250 PET/CT|"89Zr-TLX250, is a chimeric monoclonal antibody (INN name: girentuximab) with specificity for the CAIX (carbonic anhydrase 9) antigen, radiolabelled with the positron emitting radiometal zirconium- 89. Girentuximab has a CAS number of 916138-87-9. The chemical formula, without the 89Zr and the desferrioxamine, is C6460H1006N1718O2018S48 with a molecular mass of 146.5 kg/mol.~89Zr-TLX250 is formulated as a solution for IV administration in glass vials at the nominal dosage strength of 37 MBq (±10%) for single IV use. The mass dose of 89Zr-TLX250 to be used in this Phase 3 study will be 10 mg, labelled with 37 MBq (±10%) 89Zr per dose."
214494536|NCT04483115|DRUG|TPN171H|Tablets; Oral; Single dose
214494537|NCT04483115|DRUG|Placebo|Tablets; Oral; Single dose
214494538|NCT04483115|DRUG|Tadalafil|Tablets; Oral; Single dose
214494539|NCT05985850|DRUG|Aurora 1:1 Drops (Indica)|Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.
214494540|NCT05985850|DRUG|Placebo|Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).
214494541|NCT06827301|DEVICE|Non Invasive vagus nerve stimulation|Transcutaneous Auricular Vagus Nerve Stimulation
214494542|NCT06379750|OTHER|Nurse-delivered care using WelTel check-ins and BCC SMS|Nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management (through NIMONCD) using WelTel check-ins and BCC SMS
214494543|NCT06379750|OTHER|Community-based peer-support model|Community-based peer- support model using Weltel check-ins and BCC SMS and facilitated group self monitoring
215089346|NCT06430190|DRUG|Peginterferon α-2b injection|Participants receive CO2 laser treatment followed by local injection of 36mcg of Peginterferon α-2b directly into the base of each treated wart, repeated weekly for 12 weeks, and then followed for another 12 weeks.
214372468|NCT01003457|OTHER|ultrasonography|transvaginal ultrasonography of bladder wall thickness
214372469|NCT03753295|DIAGNOSTIC_TEST|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation.~The test will be performed twice, and the higher value between the two measurements will be selected.~The subjects will be allowed a rest time of more than 5 minutes after the first measurement to avoid examiner bias and to decrease physical stress"
214372470|NCT05362552|OTHER|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
214372471|NCT03364348|DRUG|Utomilumab|Given IV
214372472|NCT03364348|DRUG|Trastuzumab|Given IV
214372473|NCT03364348|DRUG|Ado-Trastuzumab Emtansine|Given IV
214372474|NCT00004884|DRUG|cisplatin|
214372475|NCT00004884|DRUG|docetaxel|
214372476|NCT00004884|DRUG|gemcitabine hydrochloride|
214372477|NCT04532723|DEVICE|ExoAtlet II|ExoAtlet II is the second version of an exoskeleton that ExoAtlet has manufactured
214372478|NCT01772784|OTHER|Phenolic acids|Phenolic acids
214372479|NCT04896333|OTHER|Interaction and exposure with the Robot EBO|The participants will interact with the Robot EBO. The robot will be control by an operator that will conduct a dialogue. The dialogue will include questions related to the social, leisure, activities of daily living and informative areas.
214372480|NCT05966402|OTHER|Virtual Reality|Immersion in Virtual Reality
214372481|NCT04379193|BEHAVIORAL|Neuroproprioceptive facilitation and inhibition physical therapy|All groups underwent two months' therapy, 16 face-to-face sessions (1 hour, twice a week for two months).
214372482|NCT05022095|OTHER|Questionnaires|Diverse questionnaires have to be filled in.
214372483|NCT01042509|DRUG|Alemtuzumab and rituximab|Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25
214372484|NCT06138249|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D
214372485|NCT02710292|DEVICE|Delefilcon A contact lenses|
214372486|NCT02710292|DEVICE|Narafilcon A contact lenses|
214372487|NCT01074892|DRUG|Provera (medroxyprogesterone/progestin)|10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
214682989|NCT05106972|DRUG|UC-MSC infusion|UC-MSC infusion by introvenus
214372488|NCT01074892|DRUG|Provera (medroxyprogesterone)|10 mg per oral tablet. One tablet per day for 6 months
214372489|NCT01074892|DEVICE|Mirena (levonorgestrel)|Inserted in the uterine cavity and kept in situ for 6 months
214372490|NCT02016404|OTHER|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
214372491|NCT02016404|OTHER|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
214372492|NCT03594539|OTHER|Withholding standard phosphate binder|In this trial, placebo represents the intervention and not the control. Standard therapy for hyperphosphatemia in end-stage renal disease includes treatment with a phosphate binder. In this trial the intervention will be to withhold the phosphate binder and use placebo instead. In this way the effect of a higher serum phosphate can be evaluated.
214372493|NCT05485363|DIAGNOSTIC_TEST|ultrasonographic measurement of the optic nerve sheath diameter|Assessing the optic nerve sheath diameter as an indicator of intracranial pressure during different positions and on specific time intervals in patients undergoing laparoscopic sleeve gastrectomy
214372494|NCT04525547|DRUG|Nintedanib|Nintedanib
214494544|NCT06817616|BIOLOGICAL|Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell|"Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Low dose: 2.5X10 cells/0.5mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   \- High dose: 5X10 cells/1mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator"
214494545|NCT03680456|DRUG|Ferric carboxymaltose|maximum of 750mg in U.S. is given, maximum of 1000mg in EU
214494546|NCT03680456|DRUG|Crystalloid|an equivalent volume dose of Natriumchlorid is administered
214682990|NCT03103750|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
214682991|NCT03103750|DRUG|PHNO|Used as a tracer for in vivo imaging.
214682992|NCT03103750|DIETARY_SUPPLEMENT|calcitriol|three 0.5 mcg capsules
214682993|NCT03103750|DRUG|Placebo oral capsule|three 0.5 mcg capsules
214682994|NCT03103750|PROCEDURE|high-resolution research tomography|A functional imaging technique that is used to observe metabolic processes in the body.
214682995|NCT03103750|DRUG|Dextro Amphetamine|Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
215089347|NCT06430190|DRUG|Peginterferon α-2b injection|Participants undergo CO2 laser treatment and then receive a weekly subcutaneous injection of 180mcg of Peginterferon α-2b for 12 weeks, and then followed for another 12 weeks.
214372495|NCT02628002|DEVICE|Antigravity treadmill (Alter-G)|Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
214682996|NCT05657977|OTHER|nonpharmacologic intervention (swaddling)|Swaddling method;The newborn will be placed on a square fabric blanket in the flexion and abduction position and will be loosely swaddled with a blanket.
214372496|NCT02628002|DEVICE|Conventional treadmill/regadenoson|Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
214372497|NCT03117283|PROCEDURE|Laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach|Patients with advanced posterior gastric wall cancer including in the laparoscopic total gastrectomy (LTG) with bursectomy group will undergo laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach.
214372498|NCT03117283|PROCEDURE|Laparoscopic D2 radical total gastrectomy without bursectomy|Patients who are included in the laparoscopic total gastrectomy (LTG) without bursectomy group will undergo laparoscopic D2 radical total gastrectomy without bursectomy in a conventional manner.
214682997|NCT00517686|OTHER|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
214372499|NCT06395155|DRUG|DHP2306R1|100mg per capsule, BID
214372500|NCT06395155|DRUG|DHP2306R2|75mg per Tab, BID
214372501|NCT02531763|BEHAVIORAL|Social incentive intervention|Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
214372502|NCT06100302|OTHER|no-intervention|no-intervention
214372503|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
214372504|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
214372505|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
214494547|NCT04214210|OTHER|Adapted Family Gene Toolkit|Five web-based modules designed to increase knowledge of cancer genetics (Module 1); provide decisional support for genetic testing (Module 2); increase active coping to common challenges faced by HBOC families (Module 3); provide a five-steps, skills-building communication training (Module 4); increase knowledge about management of hereditary cancer risk based on the most updated recommendations from the National Comprehensive Cancer Network (Module 5).
214494548|NCT04214210|OTHER|Targeted intervention|The comparison website will provide targeted information about HBOC and enable sharing genetic test results.The Korean team will define the contents of the comparison website that will mimic the structure and function of a website already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and three Swiss national languages. The tailored and the targeted platform will be technically implemented in the same system, to track access and usage of the platform and provide a user-friendly experience.
214682998|NCT00807547|BIOLOGICAL|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
214372506|NCT00518635|DRUG|Nutropin|Nutropin 0.1 mg/day self-administered once a day
214372507|NCT05411432|DRUG|68Ga labeled HER2 Affibody|inject the tracer to subjects and perform PET/CT scans
214494549|NCT04559581|DRUG|Nintedanib|Capsules
214494550|NCT05061316|DIETARY_SUPPLEMENT|Nestlé Impact Advanced Recovery|Immunonutrition drink that helps support the immune system: reduces risk of prolonged hospital stay and complications after surgery.
214494551|NCT06827223|DEVICE|computer-controlled Starpen Automatic Injection Device|using computer-controlled Starpen Automatic Injection Device during inferior alveolar nerve block anesthesia and extraction of mandibular primary molars
214372508|NCT04803448|BEHAVIORAL|Benefit statement|"The participant reads this statement after asked one of eight health questions~1. What is your height in inches?~2. What is your weight in pounds?~3. How many days out of the last 2 weeks did you drink alcohol?~4. How often a month do you use other substance such as marijuana, cocaine, ecstasy, or other drugs~5. How often a month do you use Rx or non-Rx medications to excessive amounts?~6. When was the last time you smoked a cigarette?~7. How many days in the last 2 weeks did you engage in more than 30 min exercise?~8. How many times did you engage in sexual activity in the last month with another individual? . The statement reads: Accurately answering this will increase the likelihood of a correct diagnosis.~An example of this with one of the 8 health questions is... What number of days in the last 2 weeks you engaged in \>30 minutes of exercise? Accurately answering this will increase the likelihood of a correct diagnosis."
214494552|NCT06827223|DEVICE|Traditional Syringe|nerve block anesthesia and extraction of mandibular primary molars using Traditional Syringe
214494553|NCT04261855|DRUG|Avelumab|All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
214494554|NCT04261855|RADIATION|External Beam Radiation Therapy (EBRT)|Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
214682999|NCT03158545|DIETARY_SUPPLEMENT|Olive oil Placebo|olive oil
214683000|NCT03158545|DIETARY_SUPPLEMENT|EPA-rich|EPA-rich omega-3 oil
214683001|NCT03158545|DIETARY_SUPPLEMENT|DHA-rich|DHA-rich omega-3 oil
214683002|NCT06692413|OTHER|Questionnaire|Users who consent to the study will receive a questionnaire every 3 months
214683003|NCT01128972|DRUG|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
214683004|NCT01128972|DRUG|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
214683005|NCT01128972|DRUG|Sterile water|Sterile water rinse
214986357|NCT02793986|DRUG|dexmedetomidine|For patients in Group D, the sedation was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h. The depth of sedation was considered enough when patient was unresponsive to voice.
214372509|NCT04803448|BEHAVIORAL|Risk Statement|"The participant reads this statement after being asked one of eight health questions.~The statement reads: Inaccurately answering this will increase the likelihood of an incorrect diagnosis."
214372510|NCT04803448|BEHAVIORAL|Privacy Statement|"The participant reads this statement after being asked one of eight health question for example. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
214683006|NCT04624932|BEHAVIORAL|RR Digital Tool|This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.
214683007|NCT04624932|BEHAVIORAL|Position Statement on Active Outdoor Play|This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
214372511|NCT04803448|BEHAVIORAL|Benefit + Privacy|"The statement reads Accurately answering this will increase the likelihood of a correct diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
214372512|NCT04803448|BEHAVIORAL|Risk + Privacy|"The statement reads Inaccurately answering this will increase the likelihood of an incorrect diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
214372513|NCT00800202|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
214372514|NCT00800202|DRUG|carboplatin|AUC6 iv every 3 weeks for 6 cycles
214372515|NCT00800202|DRUG|erlotinib [Tarceva]|150mg/day po
214372516|NCT00800202|DRUG|paclitaxel|200mg/m2 iv every 3 weeks for 6 cycles
214494555|NCT04261855|RADIATION|Lutetium-177 (177Lu)-DOTATATE|"Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart.~This treatment arm is now closed to recruitment."
214494556|NCT06739707|DRUG|MD-18|MD-18 administered subcutaneously to healthy individuals with overweight or obesity.
214494557|NCT06811311|BEHAVIORAL|Ericksonian Hypnotherapy|Ericksonian hypnotherapy is a therapeutic approach that utilizes indirect suggestion, storytelling, and metaphorical language to induce a trance state and facilitate psychological change. This intervention aims to reduce anxiety symptoms, improve emotional regulation, and alter neurophysiological responses as measured by EEG. Participants will undergo 12 individual sessions, each lasting 90 minutes, over a period of 12 weeks.
214683008|NCT03809572|BEHAVIORAL|Mindfulness Based Cognitive Therapy|See Arm description
214683009|NCT04661618|DEVICE|Gym Tonic programme and Gym equipment|12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
214683010|NCT06246825|DIAGNOSTIC_TEST|Polysomnography|Patients with a high likelihood of having obstructive sleep apnea will undergo a polysomnography, as recommended by the guidelines
214683011|NCT06711835|OTHER|Whole-body vibration and Jumping|The subjects were first asked to jump in place 20 times, as if they were jumping rope. Then, whole-body vibration was applied. While the participants stood upright on the whole-body vibration device, low-amplitude (1.2 mm) vibrations were applied at eight different frequencies (25, 27, 29, 31, 33, 35, 37, 39 Hz), each lasting for 10 seconds, with a 5-second rest period in between.
214372517|NCT04425902|DRUG|GSK3640254 200 mg|GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.
214683012|NCT03806595|DRUG|Lidocaine 2% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
214683013|NCT03806595|DRUG|Normal Saline Flush, 0.9% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
214683014|NCT02429427|DRUG|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
214372518|NCT04425902|DRUG|Caffeine 200 mg|Caffeine will be available as oral tablets at unit dose strength of 200 mg.
214372519|NCT04425902|DRUG|Metoprolol 100 mg|Metoprolol will be available as oral tablets at unit dose strength of 100 mg.
214372520|NCT04425902|DRUG|Montelukast 10 mg|Montelukast will be available as oral tablets at unit dose strength of 10 mg.
214372521|NCT04425902|DRUG|Flurbiprofen 100 mg|Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.
214372522|NCT04425902|DRUG|Omeprazole 40 mg|Omeprazole will be available as oral capsules at unit dose strength of 40 mg.
214372523|NCT04425902|DRUG|Midazolam 5 mg (2.5 mL)|Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).
214372524|NCT04425902|DRUG|Digoxin 0.25 mg|Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.
214494558|NCT06774287|BEHAVIORAL|Karman Line memory strategy training|The memory strategy training consists of six weekly face-to-face treatment sessions. After sessions 3-5, the participant will play 8 levels in total of the Karman Line memory game on their computer or mobile device. In these levels they practice the strategies that are introduced in the face-to-face treatment in a safe digital environment. Also, the Karman Line memory app is provided.
214494559|NCT06774287|BEHAVIORAL|Treatment as usual|Treatment as usual contains ten sessions, with nine obligatory sessions supplemented with 1 (of five) non-obligatory sessions. Which non-obligatory sessions is chosen is dependent on the patients treatment goals.
214494560|NCT05856396|BIOLOGICAL|Triaxis® (Pertussis-containing vaccine)|"Triaxis® (Pertussis-containing vaccine) will be administered:~* in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation~* in Pregnant women between 16 and 29 weeks of gestation."
214683015|NCT02429427|OTHER|Placebo|Two capsules once daily with food
214494561|NCT05856396|BIOLOGICAL|Vaxelis® (Pertussis-containing vaccine)|Vaxelis® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.
214683016|NCT00906256|DRUG|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
214683017|NCT00906256|DRUG|Placebo|Placebo
214683018|NCT03397485|DIETARY_SUPPLEMENT|Growing milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
214986358|NCT02938780|OTHER|placebo text message|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
214986359|NCT02938780|OTHER|nutrition physical activity text message|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message arrival over a 10 am to 7 pm time frame. The American Cancer Society recommends a set of exercise and nutrition behaviors for cancer survivors based upon developed expert evidence. These behaviors have been structured to achieve healthier lifestyles, improve quality of life and reduced mortality. The intervention will provide via text messaging exemplars and social norms designed to improve compliance with this advice.
214683019|NCT03397485|DIETARY_SUPPLEMENT|Fortified milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
214683020|NCT03697967|PROCEDURE|supine or prone position|"Before delivery, a sealed enveloppe is opened by the physician or nurse present at delivery. Immediately at birth the team in charge of delivery place the newborn in skin to skin contact on the mother's chest where he is dried. Umbilical cord clamping is delayed in both intervention arms to 1 minute after birth.~The newborn is placed in the prone or in the supine position depending on allocation. The nurse in charge of the newborn uses a stopwatch to check the time at which clamping was accomplished.~All subsequent nursery care are conducted according to hospital protocol."
214683021|NCT06854315|BEHAVIORAL|ChatGPT-Based Digital Counseling|Participants in this group received standard clinician-led chemotherapy education plus access to ChatGPT-based digital counseling. They could submit up to 10 personalized questions regarding their treatment, side effects, and supportive care. Oncology specialists reviewed ChatGPT-generated responses for accuracy. This intervention aimed to assess whether AI-assisted counseling could reduce anxiety and depression levels in newly diagnosed cancer patients.
214683022|NCT06854315|BEHAVIORAL|Standard Clinician-Led Education|Participants in this group received only standard clinician-led chemotherapy education, delivered by oncology physicians and nurses. The education covered key aspects of chemotherapy, including potential side effects, treatment schedules, and supportive care recommendations. Unlike the ChatGPT group, these participants did not receive AI-assisted counseling or additional interactive educational tools.
214683023|NCT06929377|OTHER|IPPON warm-up programme|The IPPON intervention is an injury prevention programme designed specifically to reduce injuries in judo athletes. The trainer-supervised IPPON intervention mainly focuses on preventing musculoskeletal injuries of the shoulder, knee and ankle. The IPPON intervention consists of 36 exercises divided into (1) flexibility and agility, (2) balance and coordination and (3) strength and stability. Each category consisted of 12 exercises with 3 levels of difficulty. Athletes performed 4 exercises per category and thus 12 exercises at the start of the training at least two times per week.
214986360|NCT03084237|BIOLOGICAL|HLX02|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
214986361|NCT03084237|BIOLOGICAL|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
214986362|NCT03084237|DRUG|docetaxel|75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
214986363|NCT01332825|OTHER|saline nasal irrigation|subjects irrigate with nasal saline daily for one week
214372525|NCT04425902|DRUG|Pravastatin 40 mg|Pravastatin will be available as oral tablet at unit dose strength of 40 mg.
214372526|NCT01920282|DRUG|Nebivolol|
214372527|NCT01920282|OTHER|Lifestyle Modification|
214372528|NCT01920282|OTHER|Nebivolol plus Lifestyle Modification|
214494562|NCT04444778|DEVICE|CPAP|Continuous positive airway pressure
214372529|NCT02803125|BEHAVIORAL|Psychosocial intervention|This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
214494563|NCT06780124|DRUG|ZE63-0302 or placebo|The participants will receive ZE63-0302 or placebo
214494564|NCT06773650|OTHER|Completion of online survey|The online survey aims to reach a representative sample of the Italian population to identify their knowledge regarding LI
214494565|NCT06780631|OTHER|Web-based diabetic foot education based on health promotion model|The first group can access the training at any time and repeat the training thanks to web-based training.
214494566|NCT06780631|OTHER|Face to face diabetic foot education based on health promotion model|Individuals with Type 2 diabetes in the face-to-face training group will receive face-to-face diabetic foot training in line with the training booklet for approximately 45 minutes, one by one.
214683024|NCT06930313|BEHAVIORAL|Brief Compassion-Based Intervention (BCI)|"The intervention program is based on Compassion-Focused Therapy (CFT) and incorporates evidence-based compassion exercises.Drawing on insights from the literature, the program includes:Session 1: Introduction to caregiving challenges and emotional systems. Includes a soothing breathing exercise and group discussion on caregiving stress.~Session 2: Cultivating self-compassion. Includes reflecting on emotions, guided meditation, and a compassionate body scan practice.~Session 3: Transforming self-criticism into self-compassion. Caregivers explore self-critical thoughts, practice reframing, and engage in compassionate dialogue.~Session 4: Building resilience and connections. Focuses on gratitude, setting boundaries, and loving-kindness meditation, ending with daily intention setting."
214683025|NCT06930313|BEHAVIORAL|Telephone-Based Support and Education (TSE)|The session will address their questions and concerns, provide psychological support for managing difficult emotions (e.g., anxiety, fear, sadness, and guilt), and emphasize the importance of self-care, encouraging them to take time for themselves and seek support when needed.
214986364|NCT05646914|OTHER|Complex training exercises|Squats and drop jumps, Barbell step-ups and hops, Bench press and plyometric press-up, Barbell lunge and box jumps were performed.
214986365|NCT05646914|OTHER|Plyometric training exercises|Drop Jumps, Hops, Plyometric press-up, Box Jumps were performed.
214986366|NCT05398627|DEVICE|Amygdala Neurofeedback|real-time feedback on the hemodynamic response of the amygdala during positive autobiographical memory recall
214372530|NCT02803125|BEHAVIORAL|Support group control|The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
214372531|NCT00027924|DRUG|busulfan|
214372532|NCT00027924|DRUG|cyclosporine|
214372533|NCT00027924|DRUG|fludarabine phosphate|
214372534|NCT00027924|DRUG|methotrexate|
214372535|NCT00027924|PROCEDURE|peripheral blood stem cell transplantation|
214372536|NCT02916602|DRUG|HCP1401|amlodipine, Losartan, Chlorthalidone FDC
214494567|NCT06827977|DRUG|PRIM-DJ2727|"For oral administration, each dose will contain the number of capsules needed to deliver the lyophilized intestinal bacteria powder derived after lyophilization of 60 g of filtered stool in 300 mL 0.85% NaCl and 2% mannitol. Participants will take the capsules (5-6 capsules twice weekly) from week 2 through week 10. Capsules will be taken over a period of up to one hour to maximize tolerance and ensure the capsules are not expelled by vomiting.~For administration via retention enema, which will be done at baseline and week 11, 50 g of filtered, frozen stool in 250 mL of 0.85% sodium chloride (NaCl) will be used."
214494568|NCT06827977|DRUG|Placebo|Placebo will be administered as capsules from week 2-10 and as enema at baseline and week 11.
214494569|NCT02754583|BEHAVIORAL|Water, sanitation, and hygiene (WASH) intervention|WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction and maintenance, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
214372537|NCT02916602|DRUG|HCP0605|amlodipine, Losartan FDC
214494570|NCT02754583|BEHAVIORAL|Standard of care WASH intervention|Stand of care WASH arm
214494571|NCT02754583|DRUG|Azithromycin|20mg/kg
214372538|NCT02584348|DEVICE|Gastric ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed for each children admitted for emergency surgery
214372539|NCT04943198|DRUG|Vemurafenib|20 mg/kg/day
214372540|NCT02564679|PROCEDURE|Laparoscopic Sleeve gastrectomy (LSG)|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated."
214494572|NCT02754583|DRUG|Tetracycline|Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
214494573|NCT02754583|OTHER|Control|The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
214683026|NCT06930196|OTHER|Counterstrain|Subjects were first analyzed for tissue texture changes with the SA201 then given an osteopathic treatment and analyzed post treatment with the SA201 to analyze for tissue texture changes.
214986367|NCT01563783|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is being used for the treatment of symptomatic uterine fibroids
214372541|NCT02564679|BEHAVIORAL|Lifestyle Intervention|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment."
214372542|NCT01768832|BEHAVIORAL|Treadmill|
214986368|NCT01563783|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
214372543|NCT01768832|BEHAVIORAL|Tango|
214372544|NCT01768832|BEHAVIORAL|Stretching|
214372545|NCT05917704|OTHER|Guitar then physical therapy|See arm/group descriptions
214372546|NCT05917704|OTHER|Physical therapy then guitar|See arm/group descriptions
214986369|NCT01563783|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
214986370|NCT02960451|OTHER|PRIME care|Specialist medication, cognitive behavior therapy, family-focused therapy
214986371|NCT02960451|OTHER|Usual care|Medication and psychotherapy as available form community providers
214986372|NCT00327327|DRUG|imexon|30-60 minutes IV, days 1,8,15 every 28 days
214986373|NCT00327327|DRUG|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
214986374|NCT05579132|DRUG|MK-1045|MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first. Each 4 week treatment cycle is followed by a 2-week treatment-free interval
214986375|NCT06524375|DRUG|Venetoclax|Venetoclax tablets will be administered as per the schedule specified in the arm.
214986376|NCT06524375|DRUG|cBTKi Monotherapy|Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
214986377|NCT03202303|DRUG|Cannabidivarin|Weight-based dosing of 10 mg/kg/day of CBDV
214986378|NCT03202303|DRUG|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo
214986379|NCT06486883|DRUG|Trastuzumab deruxtecan (T-DXd, DS-8201a)|Patients will receive T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on Day 1 (D1) of each 21-day cycle. The initial dose will be administered as a 90-minute IV infusion.
214986380|NCT06486883|DRUG|CDK4/6i plus ET|Patients will receive physician's choice of CDK4/6 inhibitor (CDK4/6i) including palbociclib, ribociclib, and abemaciclib; physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane.
214986381|NCT03789877|OTHER|Physical Activity|Participate in home-based walking program
214986382|NCT03789877|OTHER|Questionnaire Administration|Ancillary studies
214986383|NCT03789877|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
214986384|NCT03789877|PROCEDURE|Sham Intervention|Undergo sham rTMS
214372547|NCT00336843|DRUG|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
214372548|NCT03710525|OTHER|Own-Price Elasticity|The price of vegetables will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
214372549|NCT03710525|OTHER|Cross-Price Elasticity|The price of vegetables will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
214372550|NCT01461382|OTHER|Treadmill Desks|Treadmill Desk were installed in subjects personal workspace.
214372551|NCT01461382|OTHER|Treadmill Desks|Treadmill desks were installed in subjects personal workspace six months after phase I started.
214372552|NCT01875354|DIETARY_SUPPLEMENT|Dietary Supplements and TR90 Eating Plan|Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
214372553|NCT01875354|DIETARY_SUPPLEMENT|Placebo and Low Fat Eating Plan|
214494574|NCT06775418|PROCEDURE|Ultrasound erector spinae plane block|"Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group U (15 patients):will receive bilateral US guided single shot ESPB, 30 ml of bupivacaine 0.25% on each side after induction of anesthesia."
214494575|NCT06775418|PROCEDURE|dexamedotomidine infusion after induction of anesthesia|"Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group D (15 patients):will receive the study drug infusion (Dexmedetomidine) after induction of anesthesia."
214494576|NCT05182008|OTHER|Decision aid|Online interactive decision aid on method of early abortion
214494577|NCT05182008|OTHER|Usual care|Patients will be directed to the abortion clinic website
214494578|NCT05048394|DEVICE|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
214494579|NCT05048394|DEVICE|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
214494580|NCT06922279|RADIATION|Radiation Therapy + standard sistemic therapy (chemoteraphy)|Standard systemic therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist considers most useful) + combination of RT on the primary gastroesophageal Gross Tumor Volume (GTV) + SBRT on each of the distal lesions for oligometastatic or limited metastatic spread patients (to be delivered prior to initiation of systemic therapy).
214494581|NCT06922279|DRUG|Standard systemic therapy (chemotherapy)|The patients will go to standard therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist that the oncologist considers most useful.) without RT/SBRT combination
214494582|NCT04871594|DRUG|Nivolumab|On day 1, 22, and 43 240mg
214494583|NCT03636607|DIAGNOSTIC_TEST|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
214986385|NCT05049122|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
214986386|NCT01745588|DRUG|Pomalidomide|
214986387|NCT01745588|PROCEDURE|stem cell|
214986388|NCT01745588|DRUG|Dexamethasone|
214986389|NCT01745588|DRUG|Clarithromycin|
214986390|NCT05295719|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA)
214986391|NCT05295719|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
214683027|NCT06930196|OTHER|Muscle Energy|Subjects were first analyzed with the Ultralign SA201/Spineliner, then treated with an osteopathic technique, and then reassessed with the SA201 for tissue texture changes.
214372554|NCT00204984|DRUG|oral hydralazine and intravenous nesiritide|vasodilators
214372555|NCT00462254|DRUG|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
214683028|NCT06930196|OTHER|High Velocity Low Amplitude|Subjects were first analyzed for tissue texture changes with the SA201 then given an osteopathic treatment and analyzed post treatment with the SA201 to analyze for tissue texture changes.
214372556|NCT00462254|DRUG|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
214372557|NCT02376621|DIETARY_SUPPLEMENT|PronovaPure 150:500 triglycerides|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
214494585|NCT06758713|BIOLOGICAL|CAR-T|CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies.
214494586|NCT06808945|OTHER|Prehabilitation program|Participants will be subjected to an eight week home-based multimodal prehabilitaiton program. The program consists of an exercise program, nutritional support, smoking cessation and psychological counselling.
214683029|NCT06930196|DEVICE|The Ultralign SA201 used for measuring tissue texture changes|The Ultralign SA201 was used for diagnostic purposes to measure the tissue texture changes of the paraspinal cervical muscles pre and post treatment
214683030|NCT06930196|DEVICE|IsoTouch|The IsoTouch is a palpation monitoring system that uses capacitance pressure sensors in the pads of gloves to measure the palpation pressures used for both diagnosis and treatment using OMT. No sensation is felt by either the subject or operator other than a feeling of a glove being used during treatment. No electrical impulses are sent or should be experienced by either party as the sensors are merely pads that sense pressure.
214683031|NCT06834815|DRUG|Probiotic with Prebiotic|"After assigning the patients , all patients will submit an unstimulated salivary sample of 1ml will in sealed test tubes then stored in a deep freezer until microbiological evaluation, then they'll receive an oral prophylaxis session.~* The patients will receive probiotics for 14 days given to them in a sealed box.~* All patients will be followed up after 14 days and another salivary sample will be collected and sent for microbiological assessment."
214683032|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
214986392|NCT05295719|DIETARY_SUPPLEMENT|Safflower oil|4 grams safflower oil (AlaskOmega®) per day
214986393|NCT05295719|BEHAVIORAL|Low-intensity training|A low-intensity training exercise program 3 days/week for 4 weeks. This will include consistently cycling at 50% HRmax for 30 min.
214986394|NCT00769769|BEHAVIORAL|Psychotherapy|Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
214372558|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-048|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
214372559|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-037|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
214372560|NCT02376621|DIETARY_SUPPLEMENT|PronovaPure 500:200 TG|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
214494587|NCT06813794|BEHAVIORAL|Gain- Framed Messages|Patients will be recruited to whatsapp group based on gain framing about diabetic foot care skills. Gain framing messages and videos will be delivered to patients via whatsapp 3 times a week for 3 months.
214494588|NCT06813794|BEHAVIORAL|Lost Framed Messages|Patients will be included in whatsapp group based on Lost framing about diabetic foot care skills. Patients will receive loss framing messages and videos 3 times a week for 3 months via whatsapp.
214494589|NCT06516497|OTHER|Group using traditional method in long bone deformity correction|Osteotomy will be performed from the deformity center after two coring wires are placed in the same plane from the proximal and distal of the determined osteotomy line to the femur or tibia of the patients in the control group with deformity. While the degree of deformity is corrected, the determination will be made after the amount of deformity determined preoperatively is determined visually.
214683033|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
214372561|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-047|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
214372562|NCT02581332|BEHAVIORAL|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
214372563|NCT01055925|DEVICE|modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)|
214372564|NCT01055925|DEVICE|Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing|
214372565|NCT03319511|OTHER|spinal group|plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.
214372566|NCT03319511|OTHER|paravertebral group|plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
214372567|NCT02145325|DRUG|Expanded Tregs|
214494590|NCT06516497|DEVICE|Group using computer-aided sensors in long bone deformity correction|After 2 wires are placed in the same plane from the proximal and distal parts of the osteotomy line determined on the deformed femur or tibia of patients who underwent general anesthesia during the surgery, motion sensors will be placed on the wires. Osteotomy will be performed on the bone with deformity from the deformity center. When correcting the degree of deformity, the detection will be performed after the correction is achieved by the amount of deformity determined preoperatively.
214372568|NCT01124721|BEHAVIORAL|Cognitive training|Cognitive computerized training for several days per week.
214372569|NCT01124721|BEHAVIORAL|Cognitive training-placebo|Cognitive training that only minimally increases in difficulty
214372570|NCT03117725|DRUG|Melatonin adminstration|The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
214372571|NCT03117725|DRUG|placebo administration|the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
214372572|NCT00327002|DRUG|LY518674|
214372573|NCT03852238|OTHER|Blood test and self-administrated questionnaires|
214494591|NCT05662397|DRUG|HST-1011|HST-1011 given orally
214494592|NCT05662397|BIOLOGICAL|Cemiplimab|Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally
214372574|NCT06833476|OTHER|EVOQUE|This is a retrospective, non-randomized study. The decision to intervene by TTVR with the EVOQUE device is made by the heart team.
214372575|NCT03323619|PROCEDURE|anesthesia type|No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice
214494593|NCT06812559|DRUG|Progesterone|compare the use of the progesterone-primed ovarian stimulation protocol versus GnRH antagonist protocol in women with polycystic ovarian syndrome (PCOS) regarding the number of oocytes retrieved, percentage of MII oocytes, and the rate of good quality blastocysts available for cryopreservation.
214494594|NCT06812559|DRUG|GnRH antagonist (Cetrorelix)|Subcutaneous injection
214986395|NCT00769769|BEHAVIORAL|Psychotherapy|Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
214986396|NCT06520891|DRUG|Statin and SGLT2i|Statin as atrovastatin SGLT2i as dapagliflozin
214986397|NCT06422208|BIOLOGICAL|Autologous midbrain dopamine neurons|The autologous midbrain dopamine neurons are a experimental cryopreserved cell product derived from human autologous induced pluripotent stem cells. The autologous midbrain dopamine neurons will be surgically administered into the putamen, unilaterally, in a single surgical session.
214986398|NCT03547570|OTHER|Progressive heavy shoulder resistance training|The training programme includes five exercises identified in literature to target scapular and rotator cuff muscles.
214986399|NCT05905835|DEVICE|Synaptic Cryoablation System|The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).
214986400|NCT00560404|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
214986401|NCT00560404|DRUG|Epoetin alfa|As prescribed
214986402|NCT05716893|BEHAVIORAL|Adaptive Aerobic Training/AT Dosing|o In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
214986403|NCT05716893|BEHAVIORAL|Standard (fixed) Aerobic Training/AT dosing|In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
214986404|NCT03609047|DRUG|Palbociclib|CDK4/6 inhibitor
214986405|NCT03609047|DRUG|Docetaxel / cyclophosphamide|Adjuvant Chemotherapy
214986406|NCT03609047|DRUG|doxorubicin/cyclophosphamide|Adjuvant Chemotherapy
214986407|NCT03609047|DRUG|epirubicin/cyclophosphamide|Adjuvant Chemotherapy
214986408|NCT03609047|DRUG|paclitaxel|Adjuvant Chemotherapy
214986409|NCT04155307|DEVICE|Anal EndoFLIP®|Anal EndoFLIP® measure to evaluate anal compliance
214986410|NCT04155307|DIAGNOSTIC_TEST|Anal Manometry|Anal Manometry done in standard care
214372576|NCT03873220|DEVICE|Wrist Actigraphy Devices|A watch-like wearable sensor
214372577|NCT03873220|DEVICE|Sleep Monitor|Remote Sensor
214494595|NCT06759012|OTHER|EyeTeacher|Participants randomized to the intervention group will receive access to the EyeTeacher system, along with their username, password, and a user manual, one week before the start of the course. They will follow instructions on the website and complete a quiz before and after each course. After completing the EyeTeacher curriculum, they will take the first examination (Examination 1) and complete a set of questionnaires. A classroom will be provided for study purposes, but no restrictions will be imposed on the study location. Following the EyeTeacher section, participants will attend the ophthalmology course in the regular training program, with support from the EyeTeacher system. They will be evaluated according to the ophthalmology posting's evaluation criteria (Examination 2).
214494596|NCT04713033|DIAGNOSTIC_TEST|surface electromyogram (sEMG)|A device that measures electrical signals from your skin will be connected to those stickers and will make a graph that is characteristic to your vocal function.
214372578|NCT03873220|DEVICE|Polysomnography|Sleep Monitor
214372579|NCT03873220|DEVICE|Videography|Thermal Camera
214372580|NCT01170338|DRUG|Varenicline 100 mg by mouth twice daily|this is an active drug to help smoking cessation
214372581|NCT01170338|DRUG|control|this is the placebo that will help us maintain a blinded study
214494597|NCT04713033|DIAGNOSTIC_TEST|flexible laryngoscopy|"A device that examines the throat and nasal passages. The flexible laryngoscope or scope consists of an eyepiece and a fiber-optic light enclosed in a thin, flexible tube. The scope looks like a strand of black spaghetti with a tiny light on the end of it. The scope is inserted through the nose, and can be moved around to help the doctor see all areas of the nasal passages and throat."
214494598|NCT02645851|DRUG|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
214494599|NCT02645851|DEVICE|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
214494600|NCT02645851|DEVICE|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
214494601|NCT02645851|OTHER|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
214494602|NCT06795776|DRUG|Eschscholzia tablets|"The intervention will be provided as swallowable Eschscholzia tablets (1.0 g) containing 0.503g Eschscholzia californica Herba rec. tinct. conc. as the active pharmaceutical ingredient (API) corresponding 600 mg powdered herbal material."
214494603|NCT06795776|DRUG|Placebo Tablets|A placebo tablet will be provided that matches the verum in its optical and sensorial properties and posology. Contains: microcrystalline cellulose, Colloidal anhydrous silica, glycerol distearate, caramel couleur and colorants.
214494604|NCT06775106|OTHER|There is no intervention in this observational study|No direct intervention will be done to patients eligible for the study. There will be a shunt placed to divert 5-15% of exhaled breath into a collection tube. This will not affect the patient's existing standard medical care.
214494605|NCT06767878|BEHAVIORAL|PORTiSOFIE|"This treatment is based on the Clark and Wells model of social phobia, and it is constituted by 9 modules:~1. Introduction of the program and overview of social anxiety disorder and symptoms~2. Negative automatic thoughts~3. Challenging negative automatic thoughts~4. Behavioral experiments~5. Exposure~6. Exposure and self-focus attention~7. Exposure and get closer to fears~8. Social skill training~9. Maintenance plan"
214494606|NCT04895917|DRUG|daratumumab and pomalidomide|Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
214986411|NCT04155307|DIAGNOSTIC_TEST|Defecography|Defecographydone in standard care
214986412|NCT04155307|DIAGNOSTIC_TEST|Electromyogram|Electromyogram done in standard care
214986413|NCT05468307|BIOLOGICAL|Membrane Bound Cytokine Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous TIL engineered with membrane-binding cytokine to patients i.v. in 30-120 minutes.
214372582|NCT06043986|DEVICE|novel nurse call system|"Inavya Ventures Ltd (Inavya) has developed a medical-grade artificial intelligence enabled mobile system (AVATR) to support out-of-hospital healthcare. AVATR is approved as a UK Government official supplier of healthcare technology on the UK Digital Marketplace for cloud-based solutions (G Cloud). AVATR in hospital, will connect to the existing AVATR outpatient service building on existing AVATR technology, which is regulated CE-mark Grade 1 (EU/UK). The research team will create, deploy and test a novel ward-based AI technology innovation to transform current nurse call systems to patient-centred mobile technology assets at bedside, thus reducing the need for unproductive visits by nurses to the bedside, which takes away time and attention where it is otherwise best served.~Having mobile connection to the patients, would improve patient experience and saving nursing staff time, thereby improving quality of care, and saving money."
214372583|NCT00958763|BEHAVIORAL|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
214986414|NCT06271590|DEVICE|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
214372584|NCT00958763|BEHAVIORAL|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
214372585|NCT00958763|OTHER|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
214372586|NCT01533363|PROCEDURE|Stapled hemorrhoidopexy|
214372587|NCT01533363|PROCEDURE|Milligan Morgan|
214986415|NCT06271590|DEVICE|Drug eluting stents (DES)|For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES (ZES or EES) and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.
215089348|NCT06430190|OTHER|CO2 laser|On the day (baseline), CO2 laser treatment was performed to remove all warts, and the treatment range was 0.2cm around the lesion and the depth was up to the dermis. Wound disinfection after laser. Participants are treated with CO2 laser therapy only and are observed for 12 weeks, followed by another 12-week observation period without any additional adjuvant therapy.
214372588|NCT01910623|OTHER|Health Related Quality of Life (HRQOL) measures|
214372589|NCT04358692|DEVICE|Aixplorer Mach30|To measure myocardial stiffness by ShearWave elastography on not beating heart
214372590|NCT06075563|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation (TLI) 6Gy by tomotherapy as part of conditioning treatment before haploidentical hematopoietic stem cell transplant
215089349|NCT00220493|DRUG|Ritalin|
214372591|NCT00122564|BIOLOGICAL|HIV-1 gp 160|
214372592|NCT00122564|BIOLOGICAL|DC-Chol|
214372593|NCT05435924|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants by two examiners separately.~4. Second application of the scales to the participants by one examiner.~5. Statistical analysis and scaling"
214372594|NCT06029855|OTHER|Kabat Therapy|The participants of group A will receive Kabat Rehabilitation with routine physical therapy. The protocol will be given to the participants for three sessions/week for six weeks. Each session will be of 30 minutes.
214372595|NCT06029855|OTHER|Mime Therapy|The participants of group B will receive Mime Therapy in addition to routine physical therapy. The protocol will be given to the participants once a week for six weeks, while physical therapy will be given on alternate days. Each session will be of 30 minutes.
214372596|NCT02901626|DEVICE|Arabin Cervical Pessary|"The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:~Pessary Size upper diameter, lower diameter~1. Nulliparous 65 mm, 32 mm~2. Multiparous 70 mm, 32 mm~3. Alternative 70 mm, 35 mm"
214372597|NCT06176599|DRUG|Shenxiao Yuning decoction|Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
214494607|NCT06769009|BEHAVIORAL|Educational intervention measures on iodine, iodine deficiency and iodine intake|The intervention consist of an educational intervention which will educate the young women on the importance of iodine, the consequences of iodine deficiency, dietary iodine sources and the iodine in pregnancy. The educational intervention consist of four intervention components: an iodine feedback tool, and educational iodine conversation with a healthcare professional, an iodine factsheet and an iodine video. The healthcare professionals who carry out the educational conversation will receive a specially designed training program.
214494608|NCT06781372|BIOLOGICAL|Development and characterization of PDOs|An amount of tissue of approximately 2-3 cm3, if available, will be allocated to the study. The specimen will be divided in three parts (depending on the volume of the biopsy) and used to: a) obtain PDOs according to established procedures (Chadwick, et al., 2020; Gamboa, et al., 2021); b) flash-frozen for molecular analysis of original tissue; c) used to isolate GSCs by flow-cytometry cell sorting. Only PDOs characterized by histological and molecular conformity with primary tumors will be used. The mutational status of genes frequently associated with GBM onset and progression will be analyzed in PDOs, and compared with data derived from tumor DNA, in order to assess their representation of the genetic heterogeneity of original tumors. These studies will allow us the set up a reliable procedure for the ex-vivo establishment of pre-clinical models of GBM.
214494609|NCT06781372|BIOLOGICAL|Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs|PDOs and GSCs representing different GBM molecular subtypes will be treated with epigenetic modulators , with spliceosome inhibitors or with drugs that indirectly target the splicing machinery, such as PRMT5 inhibitors. These drugs will be tested for their ability to suppress growth and/or induce cell death, when administered either alone or in combination with standard chemotherapy. Furthermore, the investigators will perform RNA sequencing experiments to identify TE-derived transcripts and splice variants induced by the treatments. By employing a computational pipeline developed in our laboratory (Pieraccioli and Sette, unpublished), the investigators will also characterize the affinity for MHC-I and immunogenicity of neoepitopes encoded by the treatment-induced TE-derived transcripts and splice variants. The results of these analysis will allow to identify neoepitopes to be used for designing immunotherapy approaches.
214494610|NCT06773234|OTHER|Questionnaire|DREEM Tool
214494611|NCT05496829|BEHAVIORAL|Multicomponent Adherence Intervention|The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
214683034|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
214683035|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
214683036|NCT05519761|DEVICE|Implantation of veinous access ports|"The surgeon, anaesthetist and interventional radiologist should be thoroughly familiar with the surgical procedure, instruments, and device characteristics prior to performing the implantation.~The nurse has also to be familiar with the implantable port since he/she intervenes in it at the time of the Huber needle puncture and solution injection."
214683037|NCT05419154|PROCEDURE|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
214683038|NCT01395485|DRUG|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
214683039|NCT03334578|DRUG|Gastrografin|Gastrografin group
214683040|NCT06488326|DRUG|Mulberry leaf extract 6 mg capsule|Take one capsule of the sample one time.
214683041|NCT06488326|DRUG|Mulberry leaf extract 12 mg capsule|Take one capsule of the sample one time.
214683042|NCT06488326|DRUG|Mulberry leaf extract 18 mg capsule|Take one capsule of the sample one time.
214683043|NCT06488326|DRUG|Placebo capsule|Take one capsule of the sample one time.
215089350|NCT03710239|DEVICE|Dilapan-S|Synthetic osmotic dilator
214372598|NCT06176599|DRUG|Symptomatic treatment|(i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
214683044|NCT03660904|BIOLOGICAL|home made vitrification & thawing kit|home made vitrification was made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
214372599|NCT05751031|DRUG|Raltegravir|Raltegravir exposure in pregnant women living with HIV in routine clinical care. No study intervention administrated.
214372600|NCT00654810|BEHAVIORAL|Walking Exercise|Intermittent treadmill walking to near maximal claudication pain three days per week
214372601|NCT03504098|BEHAVIORAL|nutrition consult|Post-lung cancer operation diet pattern
214372602|NCT02301351|OTHER|Graphic Warning Label|All packs provided will include FDA-approved graphic warning labels
214372603|NCT02301351|OTHER|Text Warning Label|All packs provided will include standard text warning labels
214372604|NCT00331344|DRUG|mitoxantrone hydrochloride|Given IV
214372605|NCT00331344|DRUG|ixabepilone|Given IV
214372606|NCT00331344|DRUG|prednisone|Given orally
214372607|NCT01945151|OTHER|Group 2 (G2) NMES is applied in the spastic muscle (gastrocnemius).|The G2 apply NMES in the gastrocnemius motor point and the rest will be done during stretching of the gastrocnemius muscle (autogenic inhibition). Five consecutive sessions will be held in the morning and afternoon in the laboratory of Sensory Motor Rehabilitation Engineering.
214372608|NCT05273970|OTHER|Behavioral testing under intracranial monitoring|After standard of care surgery to implant the electrodes is complete and patients have have recovered satisfactorily from the procedure, they will be asked to perform some computer based tasks to answer questions about pretend financial decisions, pay attention to certain images, watch videos, look at images, listen to sounds, or move a joystick.
214683045|NCT03660904|BIOLOGICAL|commercially made vitrification & thawing kit|commercially available vitrification \& thawing kit were made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
214683046|NCT05551299|DRUG|Photosensitizer|A photosensitizer, which is absorbed preferentially by tumour cells, is administered 24 - 48 hours prior to PDT. Light of a particular wavelength is then applied during endoscopic retrograde cholangiopancreatography (ERCP) to kill primarily cancer cells locally within the stenosis. Immediately after PDT treatment, new stents are inserted into all treated segments if needed.
215089351|NCT03710239|DEVICE|Laminaria|Seaweed-based osmotic dilator
214683047|NCT05551299|PROCEDURE|Radiofrequency ablation (RFA)|RFA is also carried out as part of an ERCP. The RFA-probe is placed within the tumour stenosis and electrical current is applied. New stents are inserted into all treated segments if needed.
214372609|NCT03396029|BEHAVIORAL|Individually tailored lifestyle feedback|The written, standardized individually tailored lifestyle feedback includes feedback on consumption of fruit, berries and vegetables and alcohol, physical activity, smoking and body mass index.
214372610|NCT03396029|BEHAVIORAL|Standard leaflet|The leaflet is The Norwegian Cancer Society's one-page information brochure on healthy lifestyle behaviours for low cancer risk, including non-smoking, healthy body weight, physical activity, diet, moderate alcohol consumption, moderate sun exposure etc.
214372611|NCT01774747|DRUG|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
214372612|NCT01774747|DRUG|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
214372613|NCT05378984|OTHER|before - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
214494612|NCT05496829|OTHER|Usual Care|Receipt of usual care from providers
214494613|NCT05701150|OTHER|Minimal documentation|Minimal data documentation only of patients without targeted therapy based on NGS results
214494614|NCT05701150|OTHER|Extended documentation|Extended data documentation of patients with targeted therapy based on NGS results
214494615|NCT06752759|DRUG|nebulized ketamine|The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
214494616|NCT06935799|PROCEDURE|One minute intercostal nerves cryoanalgesia|One-minute cryoanalgesia will be applied bilaterally to each of the intercostal nerves from Th3 to Th7
214494617|NCT06935799|PROCEDURE|Two minutes intercostal nerves cryoanalgesia|Two-minutes cryoanalgesia will be applied bilaterally to each of the intercostal nerves from Th3 to Th7
214494618|NCT06949475|DIAGNOSTIC_TEST|Single Task (Box and Block Test)|The test requires a wooden box divided into two compartments and 150 blocks (2.5 cm tall). When administering the test, the evaluator should be aware of whether the child's fingertips move from one compartment to the other. The number of blocks passed from one side of the box to the other in one minute determines the level of the skill. It is done separately for right and left hand. The number of cubes thrown in 1 minute gives the score.
214494619|NCT06949475|DIAGNOSTIC_TEST|Single Task (Nine Hole Peg Test)|The 9-hole peg test is a standardized test that measures fine dexterity against time. It is simple to administer and is a valid and reliable method of assessment. Both hands are tested in the assessment. The child is first asked to place 9 sticks of 3.2 cm in length into the holes on the platform as quickly as possible with the dominant hand and the time from the start command until the last stick is placed is recorded. Then, with the same hand, he/she is asked to pick up the sticks in order and the time to remove all the sticks is recorded in seconds. The same procedure is repeated with the other hand.
214494620|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Box and Block Test-Kognitif Task)|Box Block Test-for the cognitive task assessment, the individual will be asked to count animal names while performing the test.
214494621|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Nine Hole Peg Test-Kognitif Task)|9 Hole Peg Test-for the cognitive task assessment, the individual will be asked to count backwards from 20 one by one while performing the test
214494622|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Box and Block Test-Motor Task)|For the Box Block Test-motor task assessment, the individual will be asked to keep a rhythm by tapping the table with the fingers on the other side while performing the test. The number of blocks passed from one side to the other side of the box divided into two in one minute will be determined and recorded.
214494623|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Nine Hole Peg Test-Motor Task)|9 Hole Peg Test-for motor task assessment, the individual will be asked to bend and unbend the other elbow while performing the test.
214494624|NCT06949475|DIAGNOSTIC_TEST|ABILHAND-Kids|The Abilhand Kids Hand-Related Ability Scale will be used to assess the use of upper extremities in Activities of Daily Living (ADL). The scale includes 21 sub-items. Sub-items are scored as 0; cannot do, 1; has difficulty in doing and 2; can easily do. The questions are usually answered by the parent, but can also be answered by the child if the child is old enough and cognitive level is appropriate.
214683048|NCT06226285|DEVICE|TechQoL4Carers Platform|"The TechQoL4Carers platform is a technological solution that has been designed and developed by the research team in collaboration with the end users. A website and a mobile application integrate the platform. The services offered are: summary of the person's state of health; training content, advice and personalised recommendations based on their situation in terms of quality of life, provision of care, occupational balance, self-management of health and empowerment. It also allows synchronisation with the Xiaomi Smart Band 7/8 activity wristband.~The intervention has a duration of three months. Participants will use the services of TechQoL4Carers and wear the Xiaomi Smart Band 7/8 wristband on a regular basis.~It is expected that caregivers will access and use the TechQoL4Carers platform, at least once a week, to answer the weekly questionnaire and they will consult, at least once a month, the training contents for self-care and for the provision of care."
214683049|NCT01012193|DRUG|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
214683050|NCT06552442|DRUG|Methylprednisolone|High-dose intracoronary glucocorticoid methylprednisolone to abrogate no-reflow: a unique study for restoration of infarct-related artery patency and reduction of ischemia-reperfusion injury
214372614|NCT05378984|OTHER|after - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
214372615|NCT03366922|DIETARY_SUPPLEMENT|Artemisia Annua, Moringa oleifera|As described above
214372616|NCT01556126|DEVICE|Amphilimus Eluting Stent (CRE8)|Sirolimus formulated coronary eluting stent
214372617|NCT04573543|DIAGNOSTIC_TEST|Evaluation of the degree of fibrosis and steatosis|The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.
214683051|NCT05294822|PROCEDURE|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|Islet transplantation was completed using percutaneous transhepatic portal vein puncture. After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
214683052|NCT02160379|OTHER|standard test meal|
214683053|NCT01446952|DRUG|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
214683054|NCT00625521|DRUG|ASF 1096 0.5 % cream applied twice daily|
214494625|NCT06949475|DIAGNOSTIC_TEST|Functional Mobility Scale (FMS)|The child's walking ability is assessed at 3 different distances (5 meters (home), 50 meters (school), 500 meters (community)). The assessment at all three distances is graded on a scale of 1-6, with wheelchair mobilization 1 and independent ambulation 6. It is indicated as (C) if the distance can be covered by crawling and (N) if the distance cannot be covered by any other means. The assessment is done through an interview with the family. The child is not observed.
214683055|NCT00625521|DRUG|Cream vehicle for ASF 1096 cream applied twice daily|
214683056|NCT02078713|BEHAVIORAL|Contraceptive Decision Support Tool|"The decision support tool:~* Provides an educational session about different aspects of contraception~* Elicits patient preferences about different aspects of contraception~* Identifies potential contraindications to certain contraceptive methods~* Allows the patient to view details about and compare available contraceptive methods~* Suggests methods most appropriate based on the patient's preferences~* Collects questions the patient may have for her provider~* Generates a printout the patient can bring to her contraceptive counseling visit"
214683057|NCT00094341|DRUG|Etanercept|
214494626|NCT06949475|DIAGNOSTIC_TEST|Myelomeningocele Functional Classification System (MMFC)|The Myelomeningocele Functional Classification System (MMFC) is a 4-level system that classifies individuals with myelomeningocele according to their functional capacity. The functional status of children in Level 1 is more inadequate than in other levels. Functional status improves as the level increases.
214494627|NCT06949475|DIAGNOSTIC_TEST|Modified Mini Mental Test (MMMT)|The Modified Mini Mental Test (MMMT) is used to screen for cognitive dysfunctions in children, to assess the severity of impairments and to determine changes over time. It has been reported that the test is a suitable tool for examining cognitive functions in children from the age of 4 and can be easily included in general neurological examinations of children. The test, which takes 5 to 10 minutes to administer, assesses 5 cognitive domains, including orientation, memory, concentration, language function and measures of structural ability. The total score in this test reaches a plateau at approximately 9-10 years of age. In children over 10 years of age, scores below 27 out of a total of 35 points are indicative of mental retardation.
214494628|NCT06847737|DIAGNOSTIC_TEST|perfusion index|To compare the incidence of hypotension after spinal anesthesia and the values of perfusion index, pleth variability index, tissue oxygen saturation and tissue hemoglobin index between those who developed hypotension and those who did not develop hypotension over time.
214494629|NCT06766279|PROCEDURE|Osteopathic Manipulative Treatment|"The OMT intervention in this study will be comprised of an occipitoatlantal (OA) decompression and treatment of the nasal Chapman point. The OA decompression will be applied for 2 minutes with 12N of pressure as this pressure has been determined to produce the greatest effect. Treatment at this level reduces congestion of nasal mucosa. The suboccipital decompression technique is generally considered to bear minimal risks and is perceived by most patients as a pleasant experience. This technique is considered to be a basic skill among osteopathic physicians. It is usually taught within the first semester of the first year at Colleges of Osteopathic Medicine.~The other intervention technique will be addressing the nasal Chapman points that are found at the tip of the transverse process of C1 and the costochondral junction of the first rib on each side. Both techniques are performed while the subject is supine."
214494630|NCT06766279|PROCEDURE|Sham treatment|The sham intervention will consist of the subject lying supine with the investigator's hands resting gently on both sides of subject's neck for 5 minutes.
214494631|NCT05453695|DRUG|Intravenous DNase I|Dose-escalating intravenous infusion of DNase I
214494632|NCT06952920|DEVICE|electroacupuncture|The acupuncturist applied needles at four acupoints: Zusanli (ST36), Neiguan (PC6), Hegu (LI4), and Zhaohai (KI6), with insertion depths of approximately 20 mm, 15 mm, 20 mm, and 5 mm respectively. Electrical stimulation was delivered in continuous wave mode at 2 Hz frequency with current intensity ≤10 mA (adjusted according to patient tolerance), administered for 30 minutes per session.
214494633|NCT06952920|DRUG|standard quadruple antiemetic therapy|Olanzapine 2.5 mg orally daily on days 1 to 4; dexamethasone 10 mg intravenously on day 1, and 7.5 mg intravenously on days 2 to 3; palonosetron 0.25 mg intravenously on day 1, or ondansetron 8 mg intravenously on day 1, or tropisetron 5 mg intravenously on day 1; and fosaprepitant 150 mg intravenously on day 1, or aprepitant 130 mg intravenously on day 1, or aprepitant 125 mg orally on day 1 followed by 80 mg orally on days 2 to 3.
214494634|NCT06952920|DEVICE|sham electroacupuncture|The same acupoints as the electroacupuncture group were referenced, but with sham acupuncture (minimal insertion at non-acupoint locations) and sham electrical stimulation, while maintaining the same treatment duration and course as the electroacupuncture group.
214683058|NCT02096861|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
214683059|NCT02096861|BIOLOGICAL|Remicade|Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
214683060|NCT05050409|BEHAVIORAL|Brief mindfulness|A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.
214683061|NCT05050409|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|An 8-session intervention. Sessions involve: 1) mindfulness training to reduce pain and increase self-regulation over opioid use, 2) cognitive reappraisal to decrease psychological distress, and 3) savoring to augment natural reward processing, positive emotion, and esprit de corps.
214683062|NCT05050409|OTHER|Standard care|Preoperative Standard Care. Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. Postoperative standard care includes (1) pain medications to minimize opioid use, including acetaminophen, lyrica, meloxicam/naproxen and celebrex, and (2) anticoagulants for 3-6 weeks postoperatively, as well as (3) ambulatory care with assistive devices 1-6 weeks after surgery. Patients see their surgeon postoperatively 2-6 weeks after surgery, 3-6 months, and yearly.
214372618|NCT04573543|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|"Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome."
214372619|NCT04573543|DIAGNOSTIC_TEST|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
214494635|NCT06952920|DRUG|standard quadruple antiemetic therapy|Olanzapine 2.5 mg orally daily on days 1 to 4; dexamethasone 10 mg intravenously on day 1, and 7.5 mg intravenously on days 2 to 3; palonosetron 0.25 mg intravenously on day 1, or ondansetron 8 mg intravenously on day 1, or tropisetron 5 mg intravenously on day 1; and fosaprepitant 150 mg intravenously on day 1, or aprepitant 130 mg intravenously on day 1, or aprepitant 125 mg orally on day 1 followed by 80 mg orally on days 2 to 3. All the antiemetic drugs used are the same as those in the true acupuncture group.
214494636|NCT06953999|DRUG|Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine|"Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV).~AK117: a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."
214494637|NCT06953999|DRUG|Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine|"Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV).~AK117 Placebo: a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."
214494638|NCT06953999|DRUG|Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine|"Ivonescimab Placebo : a specified dose and frequency administrated by intravenous infusion (IV).~AK117 Placebo : a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."
214683063|NCT03383718|PROCEDURE|Revascularisation|Percutaneous coronary intervention or coronary artery bypass surgery
214986416|NCT06015490|OTHER|Sucrose drink|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
214683064|NCT03383718|OTHER|Optimal Medical Treatment/OMT|Standard of care in stable coronary artery disease or after acute myocardial infarction.
214683065|NCT00696657|DRUG|semaglutide|0.1 mg, once weekly, s.c. injection
214683066|NCT00696657|DRUG|semaglutide|0.2 mg, once weekly, s.c. injection
214683067|NCT00696657|DRUG|semaglutide|0.4 mg, once weekly, s.c. injection
214683068|NCT00696657|DRUG|semaglutide|0.8 mg, once weekly, s.c. injection
214683069|NCT00696657|DRUG|semaglutide|0.8 mg with titration, once weekly, s.c. injection
214683070|NCT00696657|DRUG|semaglutide|1.6 mg with titration, once weekly, s.c. injection
214683071|NCT00696657|DRUG|placebo|0.1 mg, once weekly, s.c. injection
214683072|NCT00696657|DRUG|placebo|0.2 mg, once weekly, s.c. injection
214683073|NCT00696657|DRUG|placebo|0.4 mg, once weekly, s.c. injection
214683074|NCT00696657|DRUG|placebo|0.8 mg with titration, once weekly, s.c. injection
214683075|NCT00696657|DRUG|placebo|1.6 mg, once weekly, s.c. injection
214683076|NCT00696657|DRUG|liraglutide|1.2 mg with titration, once daily, s.c. injection
214683077|NCT00696657|DRUG|liraglutide|1.8 mg with titration, once daily, s.c. injection
214372620|NCT04573543|DIAGNOSTIC_TEST|Identification of semaphorin gene polymorphisms|Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
214372621|NCT05674890|DIAGNOSTIC_TEST|SmartSystem VR Headset perimeter|Patients will undergo visual field testing with the head-mounted SmartSystem VR Headset perimeter.
214683078|NCT00649376|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fasting
214683079|NCT00649376|DRUG|Allegra® Tablets 180 mg|180mg, single dose fasting
214683080|NCT04914832|BIOLOGICAL|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.
214683081|NCT01368731|PROCEDURE|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
214683082|NCT03027817|PROCEDURE|Prone Positioning|Noninvasive cardiac output monitoring parameters were recorded before and after prone positioning.
214683083|NCT04634058|DRUG|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 monoclonal antibody combined with CTLA-4 monoclonal antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
214683084|NCT04527224|DRUG|AstroStem-V|Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
214683085|NCT01488825|BEHAVIORAL|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
214683086|NCT02454218|DEVICE|Transcranial Direct Current Stimulation|"The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions."
214683087|NCT01180413|DRUG|Amlodipine|5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
214683088|NCT01180413|DRUG|Ramipril|5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.
214494639|NCT06766825|DRUG|Plitidepsin 1.5 mg/day|"Receive 1.5 mg/day of plitidepsin intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion."
214683089|NCT01180413|DRUG|Lercanidipine|Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
214683090|NCT01180413|DRUG|Losartan|Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
214683091|NCT03750032|PROCEDURE|Stapler appendectomy|The patients randomised for this intervention will undergo stapler appendectomy.
214683092|NCT03750032|PROCEDURE|Endoloop|The patients randomised for this intervention will undergo appendicular stump closure using Endoloop.
214683093|NCT03750032|PROCEDURE|Hem-O-Lock|The patients randomised for this intervention will undergo appendicular stump closure using Hem-O-Lock.
214683094|NCT03239756|BIOLOGICAL|TK006|Subcutaneous injection
214683095|NCT01589068|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
214683096|NCT01589068|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
214986417|NCT06015490|OTHER|Glucose drink|Participants will consume flavored beverage solutions containing 110 calories of glucose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
214986418|NCT06015490|OTHER|Fructose drink|Participants will consume flavored beverage solutions containing 110 calories of fructose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
214986419|NCT04340076|DRUG|Secukinumab|Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
214986420|NCT04340076|DRUG|Ixekizumab|Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
215089352|NCT05482659|BEHAVIORAL|Health education on healthy nutrition and regular physical activity based on the transtheoretic model|An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
214372622|NCT02228967|BEHAVIORAL|SBIRT|"SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk."
214494640|NCT06766825|DRUG|Placebo|"Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion."
214372623|NCT05891626|BEHAVIORAL|Group intervention|"An enhanced electronic reminder mechanism specialized on vaccines and actively highlight vaccine standing orders in the system.~Set up a data benchmarks, so clinic managers or providers are able to aggregate immunization data, red flag missed opportunities, and facilitate modifying vaccine promotion plans.~Other components:~1. missed opportunities and doubts/hesitancy about immunization as a whole;~2. specific questions with regard to specific vaccines;~3. health conditions and socioeconomic/demographic vulnerabilities (insufficient resources in health literacy, linguistic or cultural considerations); and~4. challenges in patient-clinician interactions. These components will be addressed through team training/meetings, pamphlets, physician-led speech in online videos, and group messages via MyChart on the clinic level."
214372624|NCT04141631|DRUG|EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value"
214986421|NCT04340076|DRUG|Brodalumab|Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
214372625|NCT04699955|BEHAVIORAL|Deviance Regulation Theory|In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.
214494641|NCT06766825|DRUG|Placebo and Plitidepsin 1.5mg/day|"Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during two treatment periods and receive plitidepsin 1.5mg/day during the last two treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion."
214683097|NCT00541892|OTHER|Medium with no human serum albumine added|See above
214683098|NCT00541892|OTHER|Conventional medium|See above
214683099|NCT04688346|DRUG|HemeRX epinephrine pellets|Racemic Epinephrine Pellet
214683100|NCT00157092|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
214683101|NCT05308225|BIOLOGICAL|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
214683102|NCT06291181|DIAGNOSTIC_TEST|antibiotic sensitivity test|"Disc diffusion method using modified Kirby-Bauer technique on Muller Hinton agar (MHA) will be carried out for antimicrobial susceptibility of S. aureus isolates. The following antibiotics will be tested: cefoxitin (30 µg ), Tetracyclin 30 µg (TE), Chloramphenicol 30 µg (C), Gentamycin 10µg (CN), Erythromycin 15µg(E),Clindamycin 2 µg (DA), Ciprofloxacin 5 µg (CIP), Trimethoprim/sulphamethoxazole 1.25/23.75 µg (SXT), Rifampin 5µg (RA), Linezolide 30µg (LZD); cefoxitin disc (FOX 30 g)~zone diameters interpretation will be done according to Clinical and Laboratory Standard Institute (CLSI 2018),"
214683103|NCT03664622|DRUG|Ketamine|Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
214683104|NCT03664622|DRUG|Morphine|a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
214986422|NCT04340076|DRUG|Guselkumab|Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
214986423|NCT04340076|DRUG|Risankizumab|Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
214986424|NCT04340076|DRUG|Tildrakizumab|Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
214986425|NCT04340076|DRUG|Bimekizumab|Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
214986426|NCT05519254|DIETARY_SUPPLEMENT|Lactoferrin|Caregivers of children will be instructed to provide 1.5g of lactoferrin with 40g of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
214986427|NCT05519254|DIETARY_SUPPLEMENT|Lysozyme|Caregivers of children will be instructed to provide 41.5g of Lysosure daily mixed with 125 mL of porridge or other complimentary food.
214986428|NCT05519254|COMBINATION_PRODUCT|Lactoferrin + Lysozyme|Caregivers of children will be instructed to provide 40g of Lysosure with 1.5 grams of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
214986429|NCT05519254|OTHER|Placebo|Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
214986430|NCT04352673|DIAGNOSTIC_TEST|Elbow flexion and extension strength measurements using a hand-held dynamometer|Elbow flexion and extension strength of the participants will be measured in both arms in the supine, prone, and sitting positions using a hand-held dynamometer.
214986431|NCT05605353|DIAGNOSTIC_TEST|Faecal microbiota sampling and blood sampling|There is no intervention in this study. We will obtain faeces and blood from the recruited patients and assess the microbiota and their metabolites therein. This is an observational work
214986432|NCT05074901|BEHAVIORAL|digital behavioral intervention|interaction with a conversational agent to implement physical and cognitive programs
214986433|NCT01631942|DRUG|NNC172-2021|"Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation."
214986434|NCT00605020|DRUG|insulin detemir|
214986435|NCT00605020|DRUG|insulin aspart|
214986436|NCT00605020|DEVICE|biphasic insulin aspart|
214986437|NCT02339688|OTHER|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
215089353|NCT03693313|BEHAVIORAL|CrossFit Kids exercise program|Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
215089354|NCT05639322|DRUG|Ketamine Hydrochloride|Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.
215089355|NCT05639322|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12
214372626|NCT00001444|DRUG|7-hydroxystaurosporine (UCN-01)|
214494642|NCT06954519|OTHER|Mental imagery|The principle of guided mental imagery and helping students to mentally represent the key stages of a process, using an animated slideshow full of evocative elements, which we created specifically for this study. The mental imagery will be repeated by the students several times independently until the evaluation simulation at 6 months based on reminders via messages from investigators.
214494643|NCT06954519|OTHER|Cognitive aid reading|Participants of the control group will only read the cognitive aid on neonatal resuscitation at the same intervalls than the experimentation group
214494644|NCT06953349|PROCEDURE|Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis|The use of combination Phacoemulsification, OMNI Canaloplasty and Hydrus microstent successfully lowers IOP in ethnically-diverse patients with Open Angle Glaucoma
214494645|NCT06953102|OTHER|Survey using a questionnaire.|Survey was conducted to collect their responses to PSQI and BAI questionnaires.
214494646|NCT06952621|DRUG|3 cycles (Toripalimab + chemotherapy)|Toripalimab: 240mg, intravenous infusion, on Day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; Nab-paclitaxel: 125mg/m², intravenous infusion, on Day 1 and Day 8, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; Cisplatin: 75mg/m², intravenous infusion, on Day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment;
214494647|NCT06952621|DRUG|3 cycles（DCF）|Docetaxel: 70mg/m², intravenous infusion, on day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; Cisplatin: 70mg/m², intravenous infusion, on day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; 5-FU (5-fluorouracil): 750mg/m², intravenous infusion, on day 1 to day 5, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment
214494648|NCT03561818|OTHER|Hospital-based pulmonary rehabilitation|The patients who undergo two days pulmonary rehabilitation under supervision in our clinic and three days a week at home during two months will taken as hospital group. The exercises include breathing exercises, treadmill (15sc), cycle training (15sc), arm ergometer training (15sc), peripheral muscle training and stretching exercises with free weights.
214494649|NCT03561818|OTHER|Home-based pulmonary rehabilitation|The patients who follow a home-based pulmonary rehabilitation program for two months comprising breathing exercises, training in chest hygiene techniques, peripheral muscle strengthening training and self-walking for 5 days in a week for two months. An exercise follow-up form will give to the patients to record their daily exercises. A similar form will fill by physiotherapist once a week during phone call.
214494650|NCT05419726|DRUG|Semaglutide Injectable Product (not provided by the study)|"Study Procedure:~Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall."
214494651|NCT06524089|OTHER|Pilate training|Pilates based training exercises group will perform Pilates divided into two levels (beginner and intermediate). Each level will last for six sessions.
214494652|NCT06524089|OTHER|eccentric training|eccentric trunk training exercises group:The course of the intervention period is 12 sessions total, exercises performed for two to three sets with 10 to 15 repetitions each set and 2 min rest between each set
214683105|NCT00429039|DRUG|L-leucyl-L-leucine methyl ester (LLME)|
214494654|NCT04530487|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
214494655|NCT04530487|DRUG|Cyclosporine|Given IV and PO
214494656|NCT04530487|DRUG|Etoposide|Given IV
214494657|NCT04530487|DRUG|Fludarabine Phosphate|Given IV
214494658|NCT04530487|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
214494659|NCT04530487|DRUG|Melphalan|Given IV
214494660|NCT04530487|DRUG|Mycophenolate Mofetil|Given IV or PO
214494661|NCT04530487|DRUG|Tacrolimus|Given IV and PO
214494662|NCT04530487|DRUG|Thiotepa|Given IV
214494663|NCT06380517|DEVICE|Luminopia|dichoptic movies/shows shown through a virtual reality headset
214494664|NCT06380517|OTHER|Eye Patch|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye
214372627|NCT01383889|OTHER|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
214372628|NCT00407199|DRUG|quetiapine|
214372629|NCT05374499|DRUG|Liposomal bupivacaine|Dosage: 3 mL Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
214372630|NCT05374499|DRUG|0.5% bupivacaine with 1:100,000 epinephrine|Dosage: 3 mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine (2:1 ratio of saline to standard bupivacaine) Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
215089356|NCT05639322|OTHER|Ketamine + Cognitive Behavioral Therapy|Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.
215089357|NCT00005647|DRUG|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
215089358|NCT00005647|DRUG|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
215089359|NCT00023751|DRUG|fluorouracil|
215089360|NCT00023751|DRUG|leucovorin calcium|
214372631|NCT01271569|DRUG|Fospropofol disodium|Fospropofol disodium： 0.5g
214372632|NCT03600675|OTHER|No intervention element, observational study.|No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.
214372633|NCT05356754|DEVICE|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals.
214372634|NCT05751512|DRUG|MRG003|Administered intravenously
214372635|NCT05751512|DRUG|Cetuximab injection|Administered intravenously
214372636|NCT05751512|DRUG|Methotrexate Injection|Administered intravenously
214372637|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
214372638|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
214494665|NCT04926324|DRUG|Niraparib|Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
214494666|NCT04926324|DRUG|Dostarlimab|Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.
214494667|NCT04926324|RADIATION|Short course radiation|Participants will be treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimize mean dose to femoral, pelvic, and lumbar bone marrow. The entire mesorectum will be treated to a total dose of 25 Gy.
214683106|NCT03648281|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
214683107|NCT00029848|DRUG|Rimonabant (SR141716)|
214986438|NCT00392223|DRUG|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
214986439|NCT00392223|DRUG|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
214986440|NCT00392223|DRUG|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
214986441|NCT00392223|DRUG|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
214986442|NCT04926168|OTHER|Delay of TMZ|Delay of TMZ to analyze the current standard of care practice of prescribing TMZ post combination (RT and TMZ).
214986443|NCT04926168|OTHER|Standard of Care (SOC) Adjuvant TMZ (no intervention|SOC in Adjuvant Setting no intervention
214986444|NCT00003858|DRUG|mitoxantrone hydrochloride|
214372639|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
214494668|NCT04356729|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.
214494669|NCT04356729|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
214494670|NCT01595451|PROCEDURE|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
214494671|NCT06326788|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|"Participants will start soleus pushups in sitting positions. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Soleus push-ups will be performed with moderate intensity using weights which will be placed on their laps.~Participants will perform this activity till 60-70% of their maximum heart rate is achieved and maintained."
214683108|NCT01913249|PROCEDURE|LIFT|Ligation of intersphincteric fistula tract
214683109|NCT04739657|DEVICE|Insight Lifetech IVUS System|The Insight Lifetech IVUS System is intended for examination of coronary intravascular pathology only, including TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
214683110|NCT04739657|DEVICE|Boston Scientific IVUS System|The Boston Scientific IVUS System is intended for the examination of coronary intravascular pathology only, including Opticross IVUS diagnostic catheter and iLAB IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
214683111|NCT03877120|DRUG|Dexmedetomidine 0.004 MG/ML|Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.
214372640|NCT00642902|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
214372641|NCT06464588|BIOLOGICAL|Allogeneic Neonatal mesenchymal stromal cells (nMSCs)|nMSCs will be administered intravenously in the predefined dose per each group. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels.
214372642|NCT00947726|DRUG|CeraVe|Using OTC cream on foot twice daily for two weeks.
214986445|NCT01492959|DRUG|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
214986446|NCT01763229|PROCEDURE|transthoracic echocardiography|
214986447|NCT06024460|PROCEDURE|non-pharmacological treatment strategy|Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
214986448|NCT06024460|PROCEDURE|pharmacological treatment strategy|"Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.~This group is treated using the above treatment strategies, and no drug is specified."
214683112|NCT03877120|DRUG|Diazepam Injectable Solution|diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.
214372643|NCT03762343|DRUG|ultrasound guided Greater occipital nerve block|ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
214494672|NCT06326788|BEHAVIORAL|SUSTAINED SOLEUS PUSH-UPS|"Participants will start soles push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum 4-minute break time after every 90 mins intervention. In the meantime, their blood sample will be collected."
214494673|NCT06098105|PROCEDURE|Ultrasound-guided transversus abdominis plane block|This group will receive ultrasound-guided transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL as a control group.
214683113|NCT04534439|DRUG|APX-115|oral administration of APX-115 400mg capsule once daily for 12 weeks
214683114|NCT04534439|DRUG|Placebo|oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
214494674|NCT06098105|PROCEDURE|Laparoscopic-assisted transversus abdominis plane block|Patients will receive laparoscopic-assisted transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL.
214683115|NCT05465603|DEVICE|ETDNO (Elastic Tension digital neoprene orthosis)|A bespoke orthosis created from neoprene.
214683116|NCT01419275|DRUG|Xenon contrast agent|
214683117|NCT01419275|DEVICE|Magnetic Resonance Imaging|Arterial spin label sequence for the purpose of measuring collateral flow
214683118|NCT00059215|DRUG|Prasugrel (CS-747)|Administered orally
214683119|NCT00059215|DRUG|Clopidogrel|Administered orally
214683120|NCT02645656|DRUG|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
214683121|NCT04439838|DRUG|BI 1595043|BI 1595043
214683122|NCT04439838|DRUG|Placebo|Placebo
214683123|NCT01044238|DRUG|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
214372644|NCT03762343|DRUG|control group C|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
214494675|NCT06098105|PROCEDURE|Laparoscopic-assisted intraperitoneal instillation|This group will receive laparoscopic-assisted intraperitoneal instillation by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL will be instilled into the peritoneal cavity immediately after gas insufflation.
214494676|NCT06098105|DRUG|Bupivacaine|bupivacaine
214683124|NCT01044238|DRUG|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
214683125|NCT03898336|OTHER|broad-spectrum micronutrient|daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
214986449|NCT03854110|DRUG|GP-2250|GP-2250 monotherapy for pharmacokinetics and safety; GP-2250 plus gemcitabine for safety, tolerability, pharmacokinetics, and biomarker assessments
214372645|NCT04387981|DRUG|[14C]-orvepitant|Oral solution of \[14C\]-orvepitant
214372646|NCT01538472|DRUG|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
214372647|NCT01538472|DRUG|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
214372648|NCT01538472|DRUG|Rituxan|"250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8."
214372649|NCT01538472|DRUG|BCNU|300 mg/m2 by vein on Day -6.
214683126|NCT03898336|OTHER|placebo|daily intake of capsules
214683127|NCT04985799|DEVICE|Gynecare TVT Exact Continence System|Participants will have placement of Gynecare TVT Exact sling.
214683128|NCT04985799|DEVICE|Neomedic KIM (Knotless Incontinence Mesh)|Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
214683129|NCT04789642|OTHER|blood pressure measurement whatsapp educational program|educational
214683130|NCT02523664|DRUG|Hydrocortisone|effects of hydrocortisone on memory while fMRI
214683131|NCT02523664|DRUG|Placebo|
214683132|NCT01274442|OTHER|anamnesis|To update the anamnesis.
214683133|NCT01274442|PROCEDURE|oral examination|A brief clinical oral examination will be performed.
214683134|NCT01274442|PROCEDURE|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
214683135|NCT06072001|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
214683136|NCT06072001|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
214683137|NCT04494633|OTHER|Clinical Encounters Medical School 3D Simulation|A 3D simulation related to coping with the stresses of medical school and burnout.
214683138|NCT05764018|DIETARY_SUPPLEMENT|Caffeine|Negligible amount of maltodextrin in flavoured drink solution containing 6 mg/kg body mass caffeine provided 45 minutes before exercise
214683139|NCT05764018|OTHER|Hypoxia|Participants will be breathing from a hypoxic gas mixture (13% O2) for the duration of the exercise bout. This will simulate an altitude of approximately 3500 m.
214683140|NCT05764018|OTHER|Placebo|Negligible amount of maltodextrin in flavoured drink solution provided 45 minutes before exercise.
214683141|NCT05764018|OTHER|Normoxia|Participants will be breathing from ambient air (\~21% O2) for the duration of the exercise bout. This will provide no hypoxic stimulus as the laboratory is located relatively near sea level (295 m)
214683142|NCT03196271|DIETARY_SUPPLEMENT|Ketocal 2.5:1|A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
214372650|NCT01538472|DRUG|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
214683143|NCT06491628|BEHAVIORAL|Avoiding the risk factors|Exercise, Salt and lipid reduction in diet, smoking cessation
214683144|NCT02736292|BEHAVIORAL|Mindfulness Practices for Healthcare Professionals|
214683145|NCT00414310|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days.
214683146|NCT00414310|DRUG|Valproic Acid|50 mg/kg orally daily for 7 days
214986450|NCT06472739|DRUG|GM-CSF|GM-CSF mouthwash four times per day at radiotherapy initiate, during the whole radiotherapy phase
214986451|NCT03989544|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
214986452|NCT01413802|PROCEDURE|Continuous nerve monitoring|Continuous nerve monitoring is performed during thyroid surgery.
214986453|NCT02323243|DEVICE|"Allium  Bulbar Urethral Stent  (BUS) system"|
214986454|NCT06472622|DEVICE|Thermal Pain Stimulation|Thermal pain will be administered during fMRI neuroimaging via a thermal stimulation device (Medoc Ltd., Advanced Medical System, Israel; 510K: K052357; K041908; K922052) to examine brain activity corresponding to the experience of this stimulus. This device and associated system carries an FDA 510 (K) clearance.
214986455|NCT06472622|DEVICE|Physical Effort Stimulation|Physical effort will be administered during fMRI neuroimaging via a hand dynamometer attachment for a physiological monitoring system (BIOPAC Systems, Inc., Goleta, CA, USA) to examine brain activity corresponding to the experience of this stimulus. This device has not received pre-marked approval or 510 (K) clearance by the FDA.
214372651|NCT01538472|DRUG|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
214372652|NCT01538472|DRUG|Melphalan|140 mg/m2 by vein on Day -1.
214372653|NCT01538472|PROCEDURE|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
214372654|NCT01538472|DRUG|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
214372655|NCT02309112|OTHER|Yoga|A mind-body therapy that includes specified breathing, meditation and physical postures.
214372656|NCT02539836|DIETARY_SUPPLEMENT|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
214372657|NCT02539836|DIAGNOSTIC_TEST|MRI in quantifying liver fat with MRS|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
214372658|NCT02873130|BEHAVIORAL|Telepractice Global Voice Prevention Model|
214683147|NCT06258525|RADIATION|Standard of care oxaliplatin-based chemotherapy|mFOLFOX6 or CAPOX
214683148|NCT06258525|DIETARY_SUPPLEMENT|S-adenosylmethionine (SAMe) supplement|(400 mg tablet): 2 tablets taken orally AM and 1 tablet PM daily (total 1,200 mg daily) prior to surgical resection
214372659|NCT02873130|BEHAVIORAL|In-person Global Voice Prevention Model|
214372660|NCT02873130|BEHAVIORAL|Telepractice, Vocal Hygiene and Vocal Education|
214372661|NCT03223103|DRUG|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
214372662|NCT03223103|DEVICE|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
214372663|NCT03223103|BIOLOGICAL|Peptides|synthetic long peptides (SLP) as vaccine substrate
214372664|NCT03881319|DRUG|Conventional gynecologic treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
214683149|NCT06258525|PROCEDURE|Surgery|At 1-Month
214683150|NCT04542798|DEVICE|Radiofrequency COSMAN|Radiofrequency ablation and neuromodulation
214683151|NCT01568190|BIOLOGICAL|AVANZ MITE|Immunotherapy Dermatophagoides mix
214683152|NCT01254604|DRUG|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
214683153|NCT01254604|DRUG|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
214683154|NCT03862534|PROCEDURE|CAF|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession
214683155|NCT03862534|PROCEDURE|CAF + CTG|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
214683156|NCT03074162|DRUG|Diclofenac Sodium|twice daily
214683157|NCT03074162|DRUG|Diclofenac & Capsaicin|twice daily
214683158|NCT03074162|DRUG|Diclofenac Sodium Topical Gel|twice daily
214683159|NCT05687201|DIAGNOSTIC_TEST|Non-enhanced CT scan、Nuclear Magnetic Resonance (MRI)|Non-surgical patients were followed up by CT on days 1 and 5-7 after ICH, and by CT or MRI on day 5-7. Surgical patients were followed up by CT before surgery and then transferred to the operating room. The first postoperative follow-up CT scan was performed on the second day after surgery, and the second postoperative CT scan was performed on the third day after surgery. Some patients need a third or even a fourth CT follow-up after surgery. The CT scan can be repeated at any time if the patient has neurologic deterioration.
214683160|NCT03402867|PROCEDURE|Deep dry needling|Insertion of a filiform needle in the active trigger point of musculoskeletal muscle
214683161|NCT04439630|DIETARY_SUPPLEMENT|Nopal fractions|Nopal flour were divided in two fractions and mixed in two different test breads
214986456|NCT05397496|BIOLOGICAL|PIT565|Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
214986457|NCT06241313|DRUG|Atogepant|Oral Tablet
214986458|NCT06241313|DRUG|Placebo for Atogepant|Oral Tablet
214986459|NCT06119854|BEHAVIORAL|Attitudinal inoculation|A brief video focused on bolstering resistance to mis/disinformation about the COVID vaccine. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
214986460|NCT06119854|BEHAVIORAL|Cognitive-behavioral therapy-informed intervention|A brief video using a CBT-informed approach and focused on addressing barriers to COVID-19 vaccination. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
214986461|NCT06119854|BEHAVIORAL|Conventional public health messaging|A brief video conveying conventional public health messaging adapted from a review of public health public service announcements with no inoculation messaging. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
214683162|NCT04439630|DIETARY_SUPPLEMENT|Test product without the active components|Test product without the active components
214683163|NCT03532971|OTHER|Symptom index questionnaire|A survey administered to identify the symptoms of the patient
214372665|NCT03881319|DEVICE|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
214372666|NCT03881319|DEVICE|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner Pass(PC6) 、Supreme Rush(LR3) 、Joining Valley(LI4) 、Supreme Stream(KI3) 、Uterus(EX-CA1) 、Leg Three Miles(ST36)
214683164|NCT03532971|DIAGNOSTIC_TEST|BK polyomavirus PCR|quantitative PCR testing
214683165|NCT03532971|OTHER|quality of life questionnaires|Standard questionnaires validated for HCT recipients
214683166|NCT04769583|DRUG|metronidazole based quadriple therapy|patient randomized in QC will be treated by a double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day)
214683167|NCT04769583|DRUG|placebo based quadriple therapy|patient randomized in TT will be treated by double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), clarithromycin (500 mg x 2 per day) and a placebo of metronidazole.
214372667|NCT06409221|OTHER|Non-interventional study, Observational only|Observational study only, there are no planned interventions.
214372668|NCT05046496|DIAGNOSTIC_TEST|Intra-arterial digital subtraction angiography|Invasive intra-arterial angiography, with intra-arterial stent placement if a stenosis is confirmed
214372669|NCT00004902|DRUG|tocladesine|
214372670|NCT01416870|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
214372671|NCT01416870|DRUG|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
214372672|NCT01861314|DRUG|Bortezomib|Given SC
214372673|NCT01861314|DRUG|Decitabine|Given IV
214372674|NCT01861314|OTHER|Laboratory Biomarker Analysis|Correlative studies
214372675|NCT01861314|OTHER|Pharmacological Study|Correlative studies
214683168|NCT04339946|DIAGNOSTIC_TEST|Three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
214986462|NCT04887688|DEVICE|exciflex|untethered electronic bandage with all the components of a surface stimulation system mounted on a flexible substrate.
214986463|NCT06473532|BEHAVIORAL|TEXT4HF|In addition to usual care, participants in the intervention group will receive 5 TMs/week for 12 weeks at a time of their preference. Tailoring of the TMs is performed based on participants' responses to validated questionnaires (health beliefs scales, HF-knowledge scale, and self-efficacy about HF self-care scale), administered at baseline and 4 weeks. They will also receive an AHA HF discharge informational packet.
215089361|NCT00023751|PROCEDURE|conventional surgery|
215089362|NCT00023751|RADIATION|radiation therapy|
214372676|NCT01861314|DRUG|Sorafenib Tosylate|Given PO
214372677|NCT05297448|DRUG|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
214494677|NCT06411041|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT) and yoga|The experimental group participants will be instructed to perform the practice session four days a week. The four days per week practice times (PFMT 15 minutes/day; yoga 40 minutes/day.) will result in weekly practice times for pelvic floor muscle training (PFMT) of 60 minutes and for yoga of ≥150 minutes.
214372678|NCT05297448|DRUG|Placebo|Placebo Twice Daily
214372680|NCT06014502|DRUG|IMGS-001|Every 2 weeks
214494678|NCT00091689|DRUG|852A|
214494679|NCT06030258|DRUG|IN10018|orally taken once daily
214494680|NCT06030258|DRUG|Tislelizumab|200mg D1, Q3W, intravenously
214494681|NCT06030258|DRUG|Carboplatin|AUC 5 mg/ml/min, D1, Q3W, intravenously
214494682|NCT06030258|DRUG|Etoposide|Etoposide 100 mg/m2, D1-D3, Q3W, intravenously
214683169|NCT04339946|DIAGNOSTIC_TEST|Two-dimensional rectal water contrast transvaginal ultrasonography (2D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution.
214372681|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
214372682|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
214372683|NCT03815019|DRUG|Megestrol Acetate|The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.
214494683|NCT05677269|PROCEDURE|Laparoscopic excision of endometriosis, including colorectal endometriosis|Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.
214494684|NCT05677269|PROCEDURE|In vitro fertilisation or intracytoplasmic sperm injection|IVF/ICSI treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill. One IVF/ICSI cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.
214683170|NCT04211610|DIAGNOSTIC_TEST|Blood and urine sampling|"* Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin."
214683171|NCT03144141|OTHER|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
214683172|NCT01825590|OTHER|Dialysate and serum sodium concentration aligned|
214986464|NCT06968637|OTHER|care recommendations|Provision of specific care recommendations for diabetes management. Based on existing guidelines, when any DR is present, the PIS will prompt diabetologists to check, and if necessary, change medicines to optimize, blood sugar, blood pressure and lipids.
214986465|NCT06194825|DRUG|Eplontersen|Eplontersen by subcutaneous injection
214683173|NCT01560728|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Individual psychotherapeutic approach occurring once per week for 12 to 20 weeks
214683174|NCT03041116|DRUG|Fosmetpantotenate|Daily dosing
214683175|NCT03041116|DRUG|Placebo|Daily dosing
214683176|NCT04949880|DEVICE|Neurovascular Drug-Eluting Balloon Dilatation Catheter|The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
214683177|NCT00003546|DRUG|gemcitabine hydrochloride|given IV
214683178|NCT00003546|RADIATION|radiation therapy|1.8 Gy to tumor bed
214372684|NCT03815019|BEHAVIORAL|iKanEat Behavioral Intervention|"The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating.~Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding."
214372685|NCT03550391|DRUG|Memantine|20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:
214372686|NCT03550391|RADIATION|Hippocampal-avoidant (HA-WBRT) Radiotherapy|30Gy in 10 fractions
214372687|NCT03550391|PROCEDURE|Stereotactic Radiosurgery (SRS)|18-20 or 22 Gy in single fraction
214372688|NCT06796647|DIAGNOSTIC_TEST|ESAT6/CFP10 skin test|Each recruited participant would be offered standard tuberculin skin test (TST) and ESAT6/CFP10 (C-TST) skin test on the same day or setting of clinical visit. TST and C-TST would be performed by the Mantoux technique with intradermal injection of 2U purified protein derivative-RT23 on one forearm and 5U (1.0µg/0.1 ml) of recombinant fusion protein ESAT6-CFP10 on the other forearm respectively.
214372689|NCT05373342|DEVICE|iCount system assembled with swabs|Designed as single use. Intended purpose - To be used to count swabs and tampons after childbirth in an objective manner. This is intended to be used in women during and after childbirth.
214986466|NCT06194825|DRUG|Placebo|Eplontersen-matching placebo by subcutaneous injection
214683179|NCT04987541|DEVICE|intermittent theta burst stimulation|stimulatory protocol
214683180|NCT00683956|DEVICE|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
214372690|NCT03961971|DRUG|MBG453|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214494685|NCT03876457|DEVICE|Endovascular Thrombectomy|Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
214683181|NCT00683956|DRUG|Propofol|
214683182|NCT03097328|DRUG|TAK-228|TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
214683183|NCT02734589|OTHER|Fecal transplantation|Transplantation of fecal bacteria from a healthy individual into a recipient- ulcerative colitis patient via colonoscopy and enemas
214683184|NCT02734589|OTHER|Unique novel Diet for UC and Unique novel Diet for the donor + FMT|A developed unique diet that is geared to induces remission and decreases inflammation in patients with active UC. Also a conditioning diet for healthy subjects to be used by the donor prior to transplantation- a developed unique diet for two weeks.
214683185|NCT02734589|OTHER|Unique novel Diet for UC|A developed diet that is geared to induces remission and decreases inflammation in patients with active UC.
214683186|NCT03272854|OTHER|No intervention performed, the study is observational|
214683187|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
214683188|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
214683189|NCT02436577|DRUG|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
214986467|NCT05135091|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
214986468|NCT05135091|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
214986469|NCT05135091|PROCEDURE|Sham Comparator|Sham Comparator
214986470|NCT03958877|DRUG|BIIB017 (peginterferon beta-1a)|Administered as specified in the treatment arm
214986471|NCT03958877|DRUG|Interferon beta type 1a|Administered as specified in the treatment arm
214986472|NCT06851533|PROCEDURE|Standard Analgesia (No Block)|Participants receive standard perioperative analgesia (including intravenous paracetamol/tramadol), but no additional regional block is applied.
214986473|NCT06851533|PROCEDURE|Thoracolumbar Interfascial Plane (TLIP) Block|In addition to standard perioperative analgesia, a TLIP block is performed under sterile conditions and ultrasound guidance, after the surgical procedure is completed but before the patient is awakened. A total of 30 mL of 0.25% bupivacaine is injected into the thoracolumbar fascial plane, and spread is confirmed via ultrasound.
214986474|NCT06851533|PROCEDURE|Quadro Iliac Plane Block|In addition to standard perioperative analgesia, a Quadro Iliac Plane Block is performed under sterile conditions and ultrasound guidance, after the surgical procedure is completed but before the patient is awakened. A total of 30 mL of 0.25% bupivacaine is injected into the quadro iliac plane at the level of the iliac crest, and spread is confirmed via ultrasound.
214986475|NCT05942885|OTHER|anxiety questionnaire|Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session
214986476|NCT06395012|DRUG|LY3985297|Administered either IV or SC.
214986477|NCT06395012|DRUG|Placebo|Administered either IV or SC.
214986478|NCT06061952|BEHAVIORAL|Customized Adherence Enhancement for Schizophrenia (CAE-S)|6-session series spaced out over approximately 6-10 weeks
214986479|NCT06061952|OTHER|Enhanced Treatment as Usual (eTAU)|eTAU participants will view a pre-taped series of 6 videos
214683190|NCT06552585|OTHER|12-weeks weight prevention program|Twice a week, over 12-weeks, the weight program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with two weights Domyos with 1, 2, 3, 4, or 5 kg.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
214372691|NCT05463692|BEHAVIORAL|Camelia Cohort|Through the HealthMpowerment (HMP) app tailored for women, we will be able to provide informational content, access to resources, PrEP locators and additional gamification features to optimally engage and retain our cohort, which may support linkage to PrEP care.
214986480|NCT06970080|DRUG|Inhaled corticosteroid (ICS)|In Phase I, participants will receive additional same dose of extra-fine particle ICS (i.e., their ICS would be doubled) for 12-weeks.
214986481|NCT06970080|DRUG|Oral Corticosteroid (OCS)|In phase II, participants will receive add-on oral prednisone (30mg/day) for one-week.
214986482|NCT06554665|BEHAVIORAL|High-intensity Interval Training|There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.
215089363|NCT06073639|PROCEDURE|Autogenous dentin graft|Dentin graft is made from the participant extracted tooth by using Kometa Smart Dentin Grinder
215089364|NCT02926092|DIAGNOSTIC_TEST|Observation|Observation of progression of disease over time
215089365|NCT00137826|DRUG|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
215089366|NCT00137826|DRUG|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
215089367|NCT01175200|DRUG|Clopidogrel|antiplatelet agent
215089368|NCT01175200|DRUG|Prasugrel|antiplatelet agent
215089369|NCT01175200|DRUG|Lansoprazole|proton pum inhibitor
214494686|NCT03876457|OTHER|Medical Management|Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
214494687|NCT01184326|DRUG|pazopanib|
214494688|NCT01184326|DRUG|everolimus|
214372692|NCT06469944|BIOLOGICAL|Pembrolizumab|Administered via intravenous (IV) infusion.
214372693|NCT06469944|BIOLOGICAL|Sacituzumab Tirumotecan (sac-TMT)|Administered via IV infusion.
214372694|NCT06469944|DRUG|Capecitabine|Administered via oral tablet.
214372695|NCT06469944|DRUG|Leucovorin|Administered via IV infusion.
214372696|NCT06469944|DRUG|Levoleucovorin|Administered via IV infusion.
214372697|NCT06469944|DRUG|5-FU|Administered via IV infusion
214372698|NCT05495737|BEHAVIORAL|Meaning-Centered Psychotherapy/MCP-PC Training|Two-Day MCP-PC Training for Nurses (including mock patient/simulation with actor) with a Pre- and Post-Training Assessment
214372699|NCT05495737|BEHAVIORAL|Meaning-Centered Psychotherapy/MCP-PC|3 sessions, completed over the course of 3-6 weeks in the participant's home
214494689|NCT01036724|DEVICE|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX\[TM\]) and measuring the amount of radiation exposure duration for each.
214372700|NCT05495737|BEHAVIORAL|Treatment As Usual/TAU|"Research team will provide:~1. feedback about level of distress at time of screening~2. local referral for psychological care"
214372701|NCT04462419|RADIATION|Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography|Undergo PET-MRI imaging
214372702|NCT04462419|OTHER|Fluciclovine F18|Given IV
214372703|NCT03383770|PROCEDURE|Regional Anesthesia Touhy|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A touhy cannula is used.
214372704|NCT03383770|PROCEDURE|Regional Anesthesia Facet|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A facet cannula is used.
214372705|NCT05221931|PROCEDURE|Percutaneous coronary intervention|1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent \[Boston Scientific, USA\], Prevail \[Medtronic, USA\], or SeQuent Please, SeQuent Please NEO \[B-Braun, Germany\])
214372706|NCT05827237|DIAGNOSTIC_TEST|Clinical decision rule|Clinical decision rule for acute chest pain, consisting of the Marburg Heart Score (5 questions) combined with a high-sensitive troponin I point of care test
214372707|NCT03759834|DEVICE|Cochlear promontory stimulation|Promontory stimulation is an established otologic procedure that was initially developed as a diagnostic tool to assess patient candidacy for cochlear implantation. Promontory stimulation is most commonly performed in the outpatient setting on an awake patient by placing a single insulated probe through a topically anesthetized tympanic membrane and applying monopolar current for several seconds to minutes. The initial session of promontory stimulation will define optimal stimulation parameters (i.e., location, current level, pulse-width, phase polarity), where maximal tinnitus suppression occurs with minimal or no auditory percept. Additional stimulation testing visits will confirm these findings.
214372708|NCT01881503|BIOLOGICAL|HBOC-201|HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
214372709|NCT05753774|BIOLOGICAL|FMT|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut. FMT was given 1-3courses, 3-6 times per courses
214683191|NCT06552585|OTHER|12-weeks elastic band prevention program|Twice a week, over 12-weeks, the elastic band program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with an elastic band Bodytone Power Band with 10, 15, 20, 25, or 30 kg weights Domyos.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
214683192|NCT06552585|OTHER|sham intervention|The control group performed a sham intervention, twice a week, for 12-weeks. This intervention consisted of 2 sets of 10 repetitions of 5 shoulder mobility exercises, without preventive aim, normally carried out in warm-up before training: shoulder maximum flexion and extension, horizontal abduction and adduction starting from 90º of shoulder abduction, maximum internal/external rotation starting from 90º of shoulder abduction, circumduction of the shoulder in a clockwise direction and circumduction of the shoulder in a counterclockwise direction. There was no progression after 6-weeks of this sham intervention. The coach of the respective team checked the execution of the exercises, but there was no individualized monitoring with a regular exercise technique correction by a physiotherapist.
214683193|NCT03333057|DRUG|NOV03|Perfluorohexyloctane
214683194|NCT03333057|DRUG|Placebo|Saline solution (0.9% sodium chloride solution)
214683195|NCT01675011|DEVICE|Embozene® Microspheres|
214683196|NCT01675011|DEVICE|Embosphere®|
214683197|NCT01815333|DRUG|Feraheme|6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.
214683198|NCT01815333|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.
214372710|NCT05753774|DRUG|Conventional drugs|Conventional drugs include probiotics and omeprazole, and cyproheptadine and moxapride
214494690|NCT02863315|DEVICE|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
214494691|NCT03755752|PROCEDURE|Phacoemulsification with and without Trypan Blue capsule staining|Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.
214683199|NCT03851276|RADIATION|Multi-sliced computed tomography (MSCT)|Surgery planning done based solely on MSCT.
214683200|NCT01336179|PROCEDURE|Salvadora persica|twice daily use, two minutes interval
214683201|NCT01336179|PROCEDURE|Toothbrush|Twice daily use two minutes interval
214683202|NCT04006899|DEVICE|Bioelectrical Impedance Monitor|Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
214683203|NCT05126368|OTHER|Cataract surgery|During cataract surgery the Eyhance toric II intraocular lens will be implanted in one eye of the patient
214683204|NCT03955887|BIOLOGICAL|bronchoalveolar lavage fluid (BAL)|Recovery of a 10 mL volume of BAL fluid, performed as part of patient care
214986483|NCT06554665|BEHAVIORAL|Moderate-Intensity Continuous Training|There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.
214986484|NCT06554665|BEHAVIORAL|Stretching|There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.
214986485|NCT05787574|DRUG|Emapalumab|Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.
214683205|NCT03955887|BIOLOGICAL|Venous blood|Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
214683206|NCT06424873|RADIATION|PET/CT with FDG or FES|The study consists of an additional 50 minutes of imaging during the radiotracer's uptake phase prior to their clinical scan (standard of care).
214683207|NCT01622920|OTHER|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
214986486|NCT05787574|DRUG|Fludarabine and Dexamethasone|Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.
214986487|NCT05787574|PROCEDURE|Stem Cell Transplant|Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.
214986488|NCT06971445|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids (PUFA n-3)|1280 mg of omega-3 polyunsaturated fatty acids (650mg EPA, 450mg DHA, and 179mg ALA) per day for 8 weeks
215089370|NCT01175200|DRUG|Placebo|placebo comparator similar to lansoprazole
214683208|NCT03743662|RADIATION|Re-irradiation (RT)|Re-RT will start on day 28 +/- 5 days for 5 fractions of 600cGy every other day over a 2-week period.
214683209|NCT03743662|DRUG|Bevacizumab|Bevacizumab if deemed beneficial by the investigator, will be started at the initiation of re-RT and continued for three doses in the medical arm. Patients in the surgical arm will omit the first bevacizumab dose to assure adequate wound healing after surgery and receive two doses. Bevacizumab will be dosed at 10mg/kg and given intravenously on day 28 (medical arm only), day 42 and day 56. Following day 56, further bevacizumab doses can be given every two weeks at the discretion of the treating physician.
214683210|NCT03743662|DRUG|Nivolumab|"Nivolumab will be started at enrollment and each patient will receive two doses of nivolumab prior to radiation.~Nivolumab will be dosed at 3mg/kg given intravenously before re-RT (day 1 +/- 5 and 14 +/- 5) and when given with bevacizumab if deemed beneficial by the investigator, (day 28 +/- 5 (medical arm only), day 42 +/- 5, and day 56 +/-5). Nivolumab will be dosed based on body weight while combined with re-radiation and bevacizumab for safety considerations to reduce adverse events. Single agent nivolumab will be given at 240mg flat dose every 2 weeks thereafter until disease progression, withdrawal, adverse event, or death."
214372711|NCT05557487|DIAGNOSTIC_TEST|Low dose computed tomography|"1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc.~5. Check pulmonary function test."
214372712|NCT06721065|OTHER|Remote Simultaneous Medical Interpreting/RSMI|"Remote Simultaneous Medical Interpreting (RSMI), UN-style simultaneous interpreting applied to the medical encounter, which holds tremendous promise for closely approximating a same language encounter, decreasing interpreting errors, and improving outcomes."
214372713|NCT06721065|OTHER|Remote Consecutive Medical Interpreting/RCMI|"Remote Consecutive Medical Interpreting (RCMI; audio consecutive), is the most commonly utilized remote interpreting"
214372714|NCT06721065|OTHER|Remote Consecutive Video Medical Interpreting/RCVI|"Remote Simultaneous Medical Interpreting (RSMI), UN-style simultaneous interpreting applied to the medical encounter"
214372715|NCT06577337|BIOLOGICAL|M5542|Participants will receive single ascending dose of M5542 subcutaneously on Day 1 in Part A. Participants will receive loading dose of M5542 followed by maintenance doses in Part B.
214372716|NCT06577337|BIOLOGICAL|Placebo|Participants will receive placebo matched to M5542 in Part A and Part B.
214372717|NCT06348199|DRUG|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
214372718|NCT06348199|DRUG|Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
214683211|NCT03743662|PROCEDURE|Re-resection|Re-resection will be performed in the surgical arm at day 14 (+/- 5 days).
214372719|NCT02886065|DRUG|Hiltonol|Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
214372720|NCT02886065|DRUG|Citarinostat|Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
214372721|NCT02886065|DRUG|Lenalidomide|Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.
214372722|NCT02886065|BIOLOGICAL|PVX-410|PVX-410 Biweekly (0.8 mg) via subcutaneous injection
214372723|NCT03937219|DRUG|Cabozantinib|Specified dose on specified days.
214372724|NCT03937219|BIOLOGICAL|Nivolumab|Specified dose on specified days.
214372725|NCT03937219|BIOLOGICAL|Ipilimumab|Specified dose on specified days.
214986489|NCT06971445|DIETARY_SUPPLEMENT|Olive oil (placebo)|Softgels containing extra virgin olive oil, with a similar appearance to the experimental group, were given to participants for 8 weeks.
214986490|NCT06431841|DRUG|Atropine 0,025%|Atropine 0,025% (1 drop per day)
214683212|NCT05741944|OTHER|Care with the use of PERSARC|PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options
214683213|NCT05741944|OTHER|standard care|All patients in control condition receive usual care.
214986491|NCT06431841|DEVICE|DIMS Lenses|Use of peripheral defocus lenses with DIMS technology, the design of which simultaneously introduces myopic defocus and provides clear vision to the wearer at all viewing distances.
214986492|NCT06431841|DEVICE|Monofocal lenses|Use of monofocal lenses.
214372726|NCT03937219|DRUG|Cabozantinib-matched placebo|Specified dose on specified days.
214494692|NCT01048476|DIETARY_SUPPLEMENT|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
214494693|NCT01048476|DIETARY_SUPPLEMENT|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
214494694|NCT01048476|DIETARY_SUPPLEMENT|placebo|Dietary Supplement: placebo; daily supplementation one year
214494695|NCT01048476|DRUG|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
214494696|NCT01617369|DEVICE|Hypertonic Saline|2.8% NaCl x 4ml via nebulizer
214494697|NCT04689178|OTHER|Invitation letter + GP reminder|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test, AND GPs will receive the list of their 40-65 year-old patients who did not perform a PAP test over the last 3 years
214494698|NCT04689178|OTHER|Invitation letter|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test. GPs will NOT receive any list of their non-adherent patients.
214494699|NCT03555175|OTHER|Eccentric exercise|The group make hamstring eccentric exercise. The participants have to do 12 serie of 6 repeats
214986493|NCT05837195|DEVICE|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
214683214|NCT04302610|DEVICE|Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,|A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments
214683215|NCT04302610|DEVICE|Sham treatment|Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
214683216|NCT04598581|RADIATION|Low Dose Radiation Therapy (LD-RT)|Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray
214372727|NCT04953130|BIOLOGICAL|Gardasil® HPV vaccine|Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).
214372728|NCT04987268|GENETIC|clonal hematopoiesis of indeterminate potential|Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)
214372729|NCT06216821|DRUG|standard DAPT|standard DAPT with aspirin and a P2Y12 inhibitor for 12 months after DES implantation.
214372730|NCT06216821|DRUG|OPT-CAD score guided DAPT de-escalation|De-escalation DAPT at 3 months for moderate to high risk patients and de-escalation DAPT at 1 month for low risk patients.
214372731|NCT06848231|DRUG|YA-101|"Drug: YA-101~• YA-101 taken BID"
214372732|NCT06848231|DRUG|Placebo|Placebo taken BID
214372733|NCT06851481|DEVICE|Ladera LBC System|Use of the Ladera LBC System to close the femoral arteriotomy
214372734|NCT03483974|DIAGNOSTIC_TEST|hyperspectral imaging|using hyperspectral detector for evaluation excreta pattern
214494700|NCT03555175|OTHER|Proprioception|The group have to do three kinds of exercise in a inestable area during 15 second in 2 repeats for each one
214494701|NCT03555175|OTHER|Control group|Any exercise
214494702|NCT06232681|BEHAVIORAL|Progressive relaxation exercise|The intervention group will take one month progressive relaxation exercise starting from the hospitalisation to the clinic
214372735|NCT05167266|BEHAVIORAL|Psychoeducation|Psychoeducation refers to the process of providing education and information to those seeking or receiving mental health services.
214372736|NCT04803214|DEVICE|ReActiv8|Market-approved ReActiv8 device implanted
214372737|NCT03501303|PROCEDURE|No touch technique|Veins for CABG is harvested with the no touch technique
214372738|NCT03501303|PROCEDURE|Control technique|Veins for CABG is harvested with the Control technique.
214372739|NCT03059758|OTHER|fMRI|All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
214372740|NCT02957929|DRUG|APX001 single IV dose|
214372741|NCT02957929|DRUG|APX001 single oral dose 1|
214372742|NCT02957929|DRUG|APX001 single oral dose 2|
214372743|NCT02957929|DRUG|APX001 single oral dose 3|
214372744|NCT02957929|DRUG|APX001 single oral dose fasted|
214372745|NCT02957929|DRUG|APX001 single oral dose fed|
214372746|NCT02957929|DRUG|APX001 multiple oral doses 1|
214372747|NCT02957929|DRUG|APX001 multiple oral doses 2|
214372748|NCT02957929|DRUG|APX001 multiple oral doses 3|
214372749|NCT02957929|DRUG|Cytochrome P450 substrates|
214372750|NCT02957929|DRUG|Matching placebo control|
214372751|NCT05125471|DRUG|Cobimetinib|Adult dosing (\>/= 18 years old) will be 60 mg orally once daily (tablet formulation); Pediatric dosing (\<18 years old) will be 1 mg/kg/dose (maximum 60 mg per dose) orally once daily (oral suspension formulation).
214372752|NCT05059236|DRUG|Darolutamide (BAY1841788, Nubeqa)|300 mg per tablet, oral administration with food
214372753|NCT05059236|OTHER|ADT|LHRH agonist/antagonist or orchiectomy
214372754|NCT05983965|DRUG|Tazemetostat|Treatment: On day 1 and day 15 of the first cycle, and day 1 of all following cycles, the subject will have office visit with physical exam, vital signs, and lab tests. The subject will take tazemetostat twice a day by mouth continuously as an outpatient. If continuing on the treatment for more than 6 cycles, visits change to every 3 months.
214372755|NCT00482820|BEHAVIORAL|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
214494703|NCT01887275|DEVICE|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
214494704|NCT01887275|DRUG|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
214372756|NCT06501014|OTHER|Action Observation Therapy-Experimental Group|Patients will be asked to watch the exercises before doing them.For each exercise, patients will first watch the relevant video and do the exercise after the video ends.
214372757|NCT06501014|OTHER|Conventional Exercises-Control Group|Patients will be asked to perform exercises that are described verbally and/or shown through pictures.
214372758|NCT06445972|BIOLOGICAL|Ramucirumab|8 mg/kg IV Infusion
214372759|NCT06445972|DRUG|Paclitaxel|80 mg/M\^2 IV infusion
214372760|NCT06445972|BIOLOGICAL|Sacituzumab Tirumotecan|3 mg/kg or 4 mg/kg IV Infusion
214372761|NCT06445972|DRUG|Rescue Medications|Participants receive rescue medications according to each approved drug's product label. Recommended rescue medications include antihistamines (histamine-1 and histamine-2 receptor antagonists), acetaminophen or equivalent, dexamethasone or equivalent infusion, and steroid mouth wash (dexamethasone or equivalent).
214494705|NCT03001440|OTHER|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
214494706|NCT05429164|OTHER|Self Myofascial Release|In the self-myofascial release technique, a tennis ball will be placed on the 4th rib on the shoulder side to be applied on the wall, and the participants will be asked to move the ball using their body along the pectoralis minor.
215089371|NCT02679625|DEVICE|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
214372762|NCT02987257|DRUG|Harmonized supportive care|Harmonized supportive care with and etanercept placebo days 1 and 4
214372763|NCT02987257|DRUG|Etanercept 50 mg sc day 1 and day 4|Harmonized supportive care with placebo
214372764|NCT04374630|DRUG|Paclitaxel|Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.
214372765|NCT04374630|DRUG|Afuresertib|"Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)"
214372766|NCT06559956|OTHER|Daytime titration polysomnography|A titration polysomnography assesses the device settings and, if necessary, the stimulation strength will be adjusted based on observed respiratory events and/or snoring. Patients in the daytime titration PSG cohort were instructed to refrain from sleeping during the night, and in the morning, they were permitted to sleep in a soundproof room without daylight at the sleep lab.
214683217|NCT04598581|OTHER|Sham irradiation|Sham irradiation
214683218|NCT04903548|PROCEDURE|SIRT with Y-90 resin microspheres|Selective internal radiation therapy (SIRT) with Y-90 resin microspheres (Y-90 resin SIRT) is an intra-arterial, catheter-based locoregional therapy that has been used to treat patients with unresectable HCC
214683219|NCT05730829|OTHER|pain informed movement|group classes twice weekly for 8 weeks of neuromuscular exercise in combination with mind-body techniques such as breath regulation, muscle tension regulation, relaxation, mindfulness, awareness of pain related thoughts and emotions.
214372767|NCT05278156|DRUG|CPL500036 - low dose|CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
214372768|NCT05278156|DRUG|CPL500036 - high dose|CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
214372769|NCT05278156|DRUG|Placebo|Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
214372770|NCT06650761|DRUG|CDX-622|Up to 4 infusions of one of seven dosages of CDX-622 or up to 1 dose by subcutaneous injection of one of three dosages of CDX-622
214372771|NCT06650761|DRUG|Normal Saline|Up to 4 infusions or 6 SC injections of normal saline
214372772|NCT01814592|PROCEDURE|coronally partial thickness flap plus connective tissue|The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
214372773|NCT01814592|PROCEDURE|coronally mucosal thickness flap|The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
214372774|NCT06976736|OTHER|Observational|Long Term Follow-Up for participants treated with TSC-100 or TSC-101 TCR-T products
214372775|NCT06344390|DRUG|Pentoxifylline|Take pentoxifylline 0.4 g twice daily
214372776|NCT04012684|DEVICE|Transcranial magnetic stimulation|For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
214372777|NCT04012684|DEVICE|Sham|For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
214372778|NCT03764072|DRUG|VX-150|Capsules for oral administration.
214372779|NCT03764072|DRUG|Placebo|Capsules for oral administration.
214494707|NCT05429164|OTHER|Myofascial Release|A slight caudal force will be applied by the physiotherapist until the pectoralis minor muscle meets the comfortable elastic limit of the soft tissue.
214494708|NCT05429164|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization will be performed with the specified instruments for the pectoralis minor muscle.
214494709|NCT04255316|PROCEDURE|Modified method of eversion carotid endarterectomy|Mini approach for CCA bifurcation - Clamping ICA, ECA and CCA - ICA is cut off with a scalpel at the mouth itself - Dissection of the ICA and ECA in the distal direction to the distal border of the atherosclerotic plaque - Endarterectomy - Performing of a new bifurcation of the CCA with prolene 7/0
214494710|NCT04255316|PROCEDURE|Standard method of eversion carotid endarterectomy|standard eversion technic
214494711|NCT03871439|DRUG|PF-05221304 Formulation A|50mg
214494712|NCT03871439|DRUG|PF-05221304 Formulation B|50mg
214494713|NCT04826822|DRUG|Spironolactone + Dexamethasone|Low doses of orally administered spironolactone and dexamethasone
214494714|NCT04826822|DRUG|Standard-of-care SARS-CoV-2 treatment|Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
214494715|NCT00557284|DRUG|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
214494716|NCT00557284|DRUG|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
214494717|NCT02432300|BEHAVIORAL|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
214494718|NCT05995795|DEVICE|ARTHROSCOY|arthroscopy
214494719|NCT06094166|DIAGNOSTIC_TEST|MRI|Quantitative imaging MR parameters
214494720|NCT05136066|OTHER|massage with peppermint oil|Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
214494721|NCT03827200|DRUG|Ambrisentan|Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
214494722|NCT01266369|DRUG|masitinib|
214494723|NCT01006772|OTHER|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
214494724|NCT05106049|DIAGNOSTIC_TEST|serum Adiponectin|serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
214986494|NCT06022354|DRUG|SIM0278 Injection/Placebo|SIM0278 Injection/Placebo
214494725|NCT01792557|DRUG|Crystallized phenol|Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
214683220|NCT05730829|OTHER|standard neuromuscular exercise|group classes twice weekly for 8 weeks of neuromuscular exercise.
214372780|NCT03390387|DRUG|Dexamethasone continuous|6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.
214372781|NCT03390387|DRUG|Dexamethasone intermittent|6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.
214494726|NCT01792557|PROCEDURE|Limberg Flap|Limberg Flap surgery for pilonidal disease treatment
214986495|NCT06684990|OTHER|POC testing|POC testing for HbA1c and cystatin C
214986496|NCT01581450|DRUG|Nitrous Oxide|35%
214986497|NCT01581450|DRUG|Nitrous Oxide|50%
214986498|NCT03104374|DRUG|Placebo|Oral tablet
214986499|NCT03104374|DRUG|Upadacitinib|Oral tablet
214986500|NCT06079424|OTHER|high-precision carotid echo-tracking|evaluation of vascular aging parameters and baroreflex sensitivity
214494727|NCT01792557|PROCEDURE|Modified Limberg Flap|Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
214494728|NCT01792557|PROCEDURE|Karydakis Flap|Karydakis Flap surgery for pilonidal disease treatment
214683221|NCT05730829|OTHER|Pain Neuroscience Education (PNE)|The pain neuroscience education (PNE) will be delivered in videos addressing concepts such as the purpose of pain, neurophysiological changes of pain, movement guidelines when pain persists, and self-care techniques to impact neurophysiology and support moving with ease that include breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness.
214683222|NCT05730829|OTHER|Standard osteoarthritis (OA) education|The standard osteoarthritis (OA) education will address the following topics, OA prevalence, risk factors, symptoms, diagnosis, treatment, role of exercise, surgery, self-management
214683223|NCT05886244|DRUG|Eculizumab|Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
214683224|NCT04750070|DRUG|Blood and Dopamine|Children in this group will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. They will also receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
214986501|NCT04210284|DIETARY_SUPPLEMENT|Ensure|"Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains:~* 160 Calories, 20 from fat~* 2g Total fat~* 0.5g Saturated fat~* 20mg Cholesterol~* 135mg Sodium~* 170mg Potassium~* 19g Total carbohydrate~* \<1g Fiber~* 4g Sugar~* 16g Protein~Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously.~Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control (NO ENSURE) and oral supplementation (ENSURE) arms for the aforementioned baseline and perioperative variables"
214986502|NCT05899023|OTHER|Telehealth Bridge Visits|Patients will be scheduled for a telemedicine visit staffed by a family or internal medicine trained physician who will assess their understanding and answer any questions about the new diagnosis of diabetes, start initial conversations about how to improve their habits around diet and exercise, and discuss medication options for diabetes and, if appropriate, initiate treatment. At the end of the telemedicine visit, providers will attempt to address any difficulties that patients are experiencing in accessing primary care by providing an alternative contact for care or reaching out to a primary care doctor as necessary. If the patient experiences difficulties accessing a primary care provider based on their first telemedicine visit, then an additional telemedicine visit can be scheduled for the patient.
214372782|NCT03390387|DRUG|Dexamethasone|"Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.~Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
214986503|NCT05899023|OTHER|Standard of Care|Standard of care currently includes calls from the site's follow-up center to see if patients received their HbA1c result, understood what their result meant, had any problems accessing medications prescribed or any difficulty scheduling an outpatient follow-up visit.
214986504|NCT03686124|BIOLOGICAL|IMA203 Product|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
214986505|NCT03686124|BIOLOGICAL|IMA203 product- flat dose|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells
214986506|NCT03686124|BIOLOGICAL|IMA203CD8 Product|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
214986507|NCT03686124|DRUG|Nivolumab|Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.
214683225|NCT04750070|DRUG|Blood and adrenaline|Children in this group will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. They will also receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
214986508|NCT03686124|DEVICE|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.
214986509|NCT04233866|DRUG|Fluorouracil|Given IV
214683226|NCT06723028|BEHAVIORAL|Regulation of craving training|"Participants randomized into the active mROC-T intervention (mROC-T+ or mROC-Tc) will: 1. Read a brief essay about either the social justice benefits of eating healthy foods (POSITIVE, mROCT+) or critical of social justice aspects of unhealthy foods (CRITICAL, mROC-Tc). 2. Participants complete six free-response questions to ensure that they understood the essays.~3\. Participants are instructed to use the information from the essay. They are shown a cue matching the essay they read either: Think Positive or Think Critically.~4\. They are shown an image of a healthy food (no added sugar and \< 2g/serving saturated fat) OR an image of an unhealthy food (contain added sugar and/or \>4.5g/serving saturated fat). 5. Finally, the participant is asked to rate how strong their craving is for the pictured food. The participant indicates their craving on a VAS from 1 (No craving at all) to 5 (Very high craving)"
214986510|NCT04233866|DRUG|Gemcitabine|Given IV
214986511|NCT04233866|DRUG|Gemcitabine Hydrochloride|Given IV
214372783|NCT03390387|DRUG|Methylprednisolone|"Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely.~Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
214372784|NCT03390387|DRUG|Daunorubicin|Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
214372785|NCT03390387|DRUG|Idarubicin|Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
214372786|NCT03390387|DRUG|Bortezomib|1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).
214372787|NCT03390387|DRUG|Second phase of induction|Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour - days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)
214494729|NCT01211106|BEHAVIORAL|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
214494730|NCT01211106|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
214494731|NCT02387606|DRUG|Placebo|Participants will receive placebo once daily.
214494732|NCT02387606|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
214683227|NCT05951972|OTHER|nutritional|participants will receive 2 pairs of food items to consume - pair A - Bananas and Apples, pair B - cucumbers and peanuts.
214683228|NCT04653922|DEVICE|LinkCor Bioengineered Corneal Implant|Intrastromal implantation of a bioengineered corneal equivalent device
214683229|NCT05041218|OTHER|Neural Interfaces Electroencephalogram measurement on Operators|Electroencephalogram based neural interfaces acquired during the interventional procedure and during alpha attenuation protocols (AAP) and psychometric questionnaires. AAP and psychometrics are acquired at the beginning of the shift, before and after each procedure performed.
214683230|NCT00135434|DRUG|Atazanavir/Ritonavir/Lopinavir/ritonavir|
214372788|NCT03390387|DRUG|Standard induction therapy|Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)
214683231|NCT05716607|DRUG|OD dual-release Hydrocortisone|Treatment with once-daily dual-release hydrocortisone
214986512|NCT04233866|DRUG|Leucovorin|Given IV
214986513|NCT04233866|DRUG|Leucovorin Calcium|Given IV
214986514|NCT04233866|DRUG|Liposomal Irinotecan|Given IV
214986515|NCT04233866|DRUG|Nab-paclitaxel|Given IV
214986516|NCT04233866|OTHER|Quality-of-Life Assessment|Ancillary studies
214986517|NCT04233866|OTHER|Questionnaire Administration|Ancillary studies
214986518|NCT04802057|DRUG|SAR445088|"Pharmaceutical form: solution for injection~Route of administration: IV and SC (Part 1) IV (Part 2)"
214986519|NCT04622345|DRUG|VSJ-110|ophthalmic solution
214986520|NCT04622345|DRUG|Placebo|ophthalmic solution
214986521|NCT06193200|DRUG|Dexamethasone sodium phosphate|Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion
214986522|NCT06193200|OTHER|Placebo|Placebo encapsulated in autologous erythrocytes and administered via IV infusion
214683232|NCT05716607|DRUG|TID Hydrocortisone|Treatment with thrice-daily conventional immediate-release hydrocortisone
214683233|NCT04449068|OTHER|Neurological and neuropsychological Follow-up after deep brain stimulation|Investigation of tic severity, psychiatric co-morbidities, quality of life, and neuropsychologcial measures until the 5-year after deep brain stimulation (DBS)
214372789|NCT03390387|DRUG|Standard consolidation therapy|Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)
214494733|NCT05362942|DRUG|Venetoclax, Decitabine, Azacytidine, Cytarabine|Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
214494734|NCT06314932|OTHER|MD high in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of UPF, as defined by the NOVA system (e.g., flavored yogurt, breakfast cereals with added sugar, processed meat).
214683234|NCT04933006|DIAGNOSTIC_TEST|Pulsevelocity|arterial stiffness evaluation with pulsewave velocity
214683235|NCT00931892|DIETARY_SUPPLEMENT|Gluten|3g
214372790|NCT04285255|DRUG|Fentanyl|opioids anaesthesia
214494735|NCT06314932|OTHER|MD low in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of products from the same food group, but non-UPF (e.g., plain yogurt, breakfast cereals with no added sugar, unprocessed meat)
214494736|NCT04425980|OTHER|Modified Constraint-Induced Movement Therapy|intensive use of more affected arm in structured setting
214683236|NCT00931892|DIETARY_SUPPLEMENT|Gluten|10g
214372791|NCT04285255|DRUG|Ketamine|ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia
214372792|NCT04285255|DRUG|Dexmedetomidine Injection [Precedex]|alpha 2 agonist with sedative, analgesic effect
214372793|NCT04285255|PROCEDURE|Oblique subcostal transversus abdominis plane block|Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane
214372794|NCT04285255|DRUG|Lidocaine|infusion of lidocaine 2%(1mg/kg/h)
214372795|NCT01342705|PROCEDURE|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
214372796|NCT06286605|PROCEDURE|A-oss and autogenous bone|Horizontal ridge augmentation in one stages approach will be performed using a mix of A-Oss and autologenous bone.
214372797|NCT06286605|PROCEDURE|A-oss an LCR-A|Horizontal ridge augmentation in one stages approach will be performed using OssMem with A-Oss and LCR-A
214372798|NCT04858698|DEVICE|Ultrasound / Echocardiography|Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
214494737|NCT00395759|DRUG|Optiva artificial tear by Allergan|
214683237|NCT01876732|DRUG|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
214683238|NCT03704597|OTHER|cryotherapy|Cooling of oral mucosa
214683239|NCT04462848|BIOLOGICAL|anti-SARS-CoV-2 human convalescent plasma|Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.
214683240|NCT00964548|DRUG|Dantrolene|1.25 mg/kg IV once over 60 min
214683241|NCT00964548|DRUG|Dantrolene|2.5 mg/kg IV once over 60 min
214683242|NCT02531373|BIOLOGICAL|V114 Medium Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
214683243|NCT02531373|BIOLOGICAL|V114 High Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
214683244|NCT02531373|BIOLOGICAL|V114 Medium Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
214683245|NCT02531373|BIOLOGICAL|V114 High Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
214683246|NCT02531373|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
214683247|NCT06381518|OTHER|Switch to SC CT-P13.|all patients in the study will switch from IFX to SC CT-P13
214683248|NCT00536731|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
214683249|NCT00536731|DRUG|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
214683250|NCT00536731|DRUG|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
214683251|NCT06382974|PROCEDURE|Cyst enucleation and bone grafting|cyst enucleation followed by bone grafting the residual bone defects using Atorvastatin combined with β-TCP.
214683252|NCT03899194|DIETARY_SUPPLEMENT|fish oil capsules|fish oil capsules(1000mg，EPA 180mg；DHA 120mg)
214372799|NCT05438654|DIAGNOSTIC_TEST|Point of care ultrasound|"Abdominal PoCUS use according to the following protocol:~PoCUS assessment of the right lung base PoCUS assessment of Morrison's pouch PoCUS assessment of gallbladder PoCUS assessment of right kidney (comparison to left kidney acceptable) PoCUS assessment of small bowel"
214494738|NCT05025813|DRUG|Pembrolizumab|Delivery of neo-adjuvant Pembrolizumab
214494739|NCT04213807|BIOLOGICAL|MAA868 Cohort 1|Subcutaneous injection: low dose
214683253|NCT03899194|DRUG|escitalopram|escitalopram 10-20 mg/d
214986523|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
214986524|NCT06455449|OTHER|Placebo|Matched placebo delivered subcutaneously, once weekly for 52 weeks
214494740|NCT04213807|BIOLOGICAL|MAA868 Cohort 2|Subcutaneous injection: high dose
214494741|NCT04213807|BIOLOGICAL|MAA868 Cohort 3|Subcutaneous injection: Dose to be determined.
214494742|NCT04213807|OTHER|Placebo|Subcutaneous injection: Placebo
214494743|NCT03142672|PROCEDURE|pulpotomy|vital endodontic procedure
214494744|NCT03142672|PROCEDURE|tooth filling|tooth filling
214494745|NCT01574716|DRUG|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
214494746|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
214494747|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
214494748|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
214494749|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
214494750|NCT01574716|DRUG|Placebo|
214494751|NCT02208596|DRUG|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
214494752|NCT02208596|DRUG|propofol|
214494753|NCT02208596|DRUG|Etomidate|
214494754|NCT01411137|DRUG|IPX066|"Subjects were converted from their current treatment to IPX066 over a 6-week period.~Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules"
214494755|NCT02802488|PROCEDURE|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care."
214494756|NCT01678079|DIETARY_SUPPLEMENT|Encapsulated Calcium|The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
214494757|NCT01678079|DIETARY_SUPPLEMENT|Non-capsulated Calcium|The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg). This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
214683254|NCT00152815|DRUG|antioxidant vitamin E|Vitamin E 800IU per day for 12 months
214683255|NCT00152815|BEHAVIORAL|weight reduction and exercise|Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
214683256|NCT01675531|DRUG|Targin|Single arm for Targin
214683257|NCT05602441|BEHAVIORAL|VALID - diabetes supportive clubs|"The VALID - diabetes supportive clubs comprised diabetes classes and diabetes clubs, to highlight two prominent aspects of diabetes self-management: education and peer support.~The diabetes club meeting was held twice a month during a 9-month intervention, consisting of a focused delivery of the knowledge and discussion following the topic in the monthly class. Club meetings also included dedicated time for blood glucose testing and sharing experiences to deal with the difficulties of the periodic insurance examinations process. Finally, the club meetings provided the participants with emotional support to deal with the stigma and sadness in their daily lives.~Core messages aimed to strengthen daily self-management and boost the spiritual bond between individuals with T2D toward a healthy, happy life with T2DM. In addition, the intervention aimed to strengthen the capacities of grassroots health care workers in diabetes consultations and communication in rural communities."
214683258|NCT00623467|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
214683259|NCT02874690|DRUG|Methylphenidate|single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg
214494758|NCT01558908|BIOLOGICAL|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
214683260|NCT02874690|DRUG|Placebo|Placebo pill identical in appearance to methylphenidate
214986525|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all study participants on anifrolumab or placebo will receive open label anifrolumab once weekly for an additional 52 weeks
214986526|NCT06578416|DIAGNOSTIC_TEST|Standardized assessments of speech and language abilities|Standardized and observational assessment of speech and language abilities
214372800|NCT00084370|DRUG|celecoxib|Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
214372801|NCT00084370|PROCEDURE|oophorectomy|
214372802|NCT01965210|OTHER|Rye + high dose inulin + low dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
214494759|NCT02969759|OTHER|Skin Biopsy|
214494760|NCT03784170|DEVICE|FemPulse System|Device therapy with the FemPulse System
214494761|NCT03658915|DEVICE|Smartphone application (Goniometer Pro )|Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
214494762|NCT00279981|DEVICE|Diagnostic|
214494763|NCT02809755|DRUG|4% Lidocaine|
214494764|NCT02809755|OTHER|Saline|
214372803|NCT01965210|OTHER|Rye + equal doses of inulin & gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
214372804|NCT01965210|OTHER|Rye + low dose inulin + high dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
214372805|NCT01965210|OTHER|Large non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
214372806|NCT01965210|OTHER|Small non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
214372807|NCT01965210|OTHER|Refined wheat bread|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
214372808|NCT02498834|BEHAVIORAL|Educational Video and Question Prompt List|Educational Video and Question Prompt List
214372809|NCT04794231|OTHER|Standard dressing|a standard breathable, hypoallergenic, transparent dressing (TegadermTM 1635 \[8.5 x 10.5cm\] or 1633 \[7 × 8.5 cm\] depending on patient size; 3M, Neuss, Germany)
214372810|NCT04794231|OTHER|Chlorhexidine gluconate -impregnated dressing group|A chlorhexidine gluconate -gel impregnated transparent dressing (TegadermTM CHG 1660R \[7 x 8.5 cm\] or \[11.5 x 8.5 cm\] depending on patient size; 3M, Neuss, Germany).
214372811|NCT01896401|DEVICE|InSeal's Vascular Closure Device|
214372812|NCT00161239|DRUG|Doxil, Methotrexate, L-Asparaginase, Prednisone|
214372813|NCT03534310|DRUG|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)|
214372814|NCT03534310|OTHER|lifestyle modification|
214683261|NCT02597673|OTHER|Home Exercise Program (HEP)|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. This program includes sessions with the study coordinator. A handout and given a demonstration of the daily exercises to be performed at home and weekly communication from the study coordinator regarding compliance with the exercises.
214683262|NCT02597673|DEVICE|NMES|To ensure consistent interventions across participants, a specified percentage of baseline maximal voluntary contraction (% MVC) will be used to determine the intensity of the training contraction. The electrical amplitude to obtain the desired intensity will be determined for each participant. Participants will train at 20-30% of MVC during weeks 1-3, 30-40% of MVC during weeks 3-6, and 40-50% of MVC during weeks 6-9. Incremental increases will be made at the 3 and 6 week clinic visits. Individualized instructions for adjusting the amplitude dial settings, with a return demonstration, will be used to maintain the appropriate percentage of MVC. During the home training sessions, participants will adjust the amplitude required to achieve the desired goal, as tolerated.
214683263|NCT02597673|DEVICE|TENS|The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
214683264|NCT05483816|COMBINATION_PRODUCT|VR+TENS|The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality
214372815|NCT03534310|OTHER|sleeve gastrectomy|
214372816|NCT00194051|PROCEDURE|gastric bypass surgery|
214372817|NCT01646593|DRUG|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
214372818|NCT01636999|DRUG|50% Nitrous Oxide/50% Oxygen|The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
214372819|NCT06328764|GENETIC|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
214372820|NCT00558064|DRUG|telmisartan+amlodipine|
214372821|NCT00558064|DRUG|amlodipine|
214372822|NCT04618666|PROCEDURE|laparoscopic and open surgery intervention|laparoscopic and open surgery to remove an inflammed appendix in chronic appendicitis
214372823|NCT05959343|BEHAVIORAL|Enhanced Recovery After Surgery program for Oblique Lumbar Interbody Fusion|In the ERAS CP group, the components of the ERAS are protocolized and implemented as a clinical pathway
214372824|NCT06081764|OTHER|Exercise|Doing Otago Exercise Program, which lasting 3 days a week and an average of 30 minutes per day under the supervision of a physiotherapist. Also doing walking exercise for 30 minutes a day, 2 days a week for total of 12 weeks.
214494765|NCT02503397|DEVICE|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
214372825|NCT02801539|DEVICE|RMT therapy using modified RMT device|The exercises provided by the RMT device is intended to strengthen breathing muscles.
214372826|NCT02801539|DEVICE|Sham-RMT therapy using modified RMT device|The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
214372827|NCT04604080|OTHER|service of questionnaire|Respondents will be given a survey form only and after filling this will be collected back
214372828|NCT02219984|DRUG|Anticoagulants|
214372829|NCT04204200|DIETARY_SUPPLEMENT|liposomal vitamin C|The intake of liposomal vitamin C at 500 mg, in the morning and evening, one week before surgery, one during the day of surgery and lastly, during the first 21 post operation days.
214372830|NCT04204200|DIETARY_SUPPLEMENT|standard vitamin C|The intake of traditional vitamin C with a daily intake of 500 mg in the morning and evening for 28 days (starting 7 days before the operative procedure, on the day of the surgery and ending twenty-one days after surgery).
214683265|NCT04109625|DIAGNOSTIC_TEST|Demonstrator MAGIA|test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.
214986527|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
214986528|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
214683266|NCT02676076|DRUG|CHF 5993 100/6/12.5 µg|
214683267|NCT02676076|DRUG|CHF 1535 100/6 µg|
214683268|NCT06351748|DRUG|Semaglutide|Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.
214683269|NCT04143971|OTHER|intermittent fasting diet|intermittent fasting diet
214683270|NCT04143971|OTHER|low calorie diet|continuous low calorie diet
214683271|NCT03819244|DEVICE|940 nm Gallium Aluminum Arsenide Diode Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.
214683272|NCT03819244|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
214986529|NCT02330952|DRUG|Prednisone|40mg/day per os for 5 days
214986530|NCT02330952|DRUG|Placebo|40mg/day per os for 5 days
214986531|NCT05012124|OTHER|Collaborative care|Receive u-CoCM
214494766|NCT00692913|DRUG|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
214494767|NCT00692913|DIETARY_SUPPLEMENT|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day)."
214986532|NCT05012124|OTHER|Interview or Focus Group|Participate in an interview or focus group
214986533|NCT05012124|OTHER|Media/technology Intervention with collaborative care|Use t-CoCM digital platform with collaborative care
214494768|NCT00692913|OTHER|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
214494769|NCT05673109|DRUG|AC176|AC176 will be given orally (PO) on a 28-day cycle.
214494770|NCT03513692|DEVICE|Fill-Up composite resin|2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
214494771|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
214494772|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
214494773|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
214494774|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
214683273|NCT05501444|OTHER|Topical antiperspirant|The participants will be instructed to use topical antiperspirant (aluminum chloride, 15 percent every evening for four weeks. The PI will contact the participants every week. If the participant experiences that antiperspirant have an effect, the use of antiperspirant will be reduced from daily use to 3 times a week.
214683274|NCT03808714|BEHAVIORAL|TOUCHDOWN|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
214683275|NCT03808714|BEHAVIORAL|Control Group|Alabama Quitline
214683276|NCT03241797|PROCEDURE|EUS-FNA|Once the lesion was evaluated by EUS, the echoendoscopist would select the shortest pathway, while avoiding blood vessels, to reach the lesion. Under real-time visualization, slow-pull technique and suction technique were used to punctured each lesions. The specimens were expelled onto glass slides, and then prepared for histological and cytological examinations.
214683277|NCT04667195|OTHER|Clinical assessment|"Within 4 hours of admission to the emergency department, clinical assessment will include:~* Demographics,~* comorbidity,~* symptoms,~* objective findings,~* triage at admission,~* blood test results,~* urine test results"
214683278|NCT03384849|DIAGNOSTIC_TEST|MRI examination|The part of the body that is being scanned and the time of the MRI examination are not relevant.
214683279|NCT04705597|DRUG|BGE-175|Drug
214683280|NCT04705597|OTHER|Placebo|Placebo
214683281|NCT03797950|BEHAVIORAL|Voice Reminder (Group A)|Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.
214683282|NCT03797950|BEHAVIORAL|Cash Incentive (Group B)|Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
214986534|NCT05012124|OTHER|Survey Administration|Complete surveys
214986535|NCT05678738|DIETARY_SUPPLEMENT|Antioxidant Berry Supplementation|Participants who opt-in will be instructed to consume 300mL of the bioactive (antioxidant berry) supplement every morning and afternoon during days of participation.
214986536|NCT05678738|OTHER|Acute and Chronic Exercise-Heat Stress|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.
214986537|NCT05678738|DIETARY_SUPPLEMENT|Placebo (non-juice) Supplementation|Participants who opt-in will be instructed to consume 300mL of the placebo (non-juice) supplement every morning and afternoon during days of participation.
214986538|NCT04393701|PROCEDURE|Additional blood sampling|Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program
214986539|NCT05385497|OTHER|Aerobic Exercise|Participants will perform a 30-minute exercise protocol (5 minutes warm-up and cool-down each and 20 minutes moderate intensity exercise) on a StepOne™ recumbent stepper
214372831|NCT04204200|DIETARY_SUPPLEMENT|placebo|The intake placebo was taken daily in the morning and the evening for 28 days (7 days before surgery, on the day of surgery and twenty-one days after the surgical procedure).
214372832|NCT01834508|DRUG|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks|
214372833|NCT05696210|OTHER|Transfusion rate of red blood cells|Transfusion rate of red blood cells greater than 7
214372834|NCT03152084|DRUG|Dapagliflozin|The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
214986540|NCT05385497|DEVICE|Virtual Reality|Participants will interact with the virtual environment and view the gaming environment on a flat-screen TV placed in front of them at a suitable distance. The participants will play four games (50 repetitions/game divided into three blocks with 1-2 minutes rest between blocks), with the order of the games randomized in every session.
214986541|NCT04421573|PROCEDURE|BCPHD with D5W|D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
214986542|NCT04421573|PROCEDURE|Waiting period with usual care|Same as previous group description
214372835|NCT00765596|OTHER|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
214372836|NCT04284345|PROCEDURE|Saline Pd/Pa|"Use of a ≥6F guiding catheter and the Verrata pressure guidewire. Administration of intracoronary nitroglycerin.~Verrata normalisation and placement of the Verrata sensor ≥3 vessel-diameter beyond the stenosis.~Whole cycle resting Pd/Pa and resting iFR measurements.~Measurement of contrast FFR: record 5 baseline heart beats, injection of contrast media, 10 ml in the left coronary system, 8 ml in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Adenosine FFR: measurement: record 5 baseline heart beats, injection of intracoronary adenosine, 200 mcg in the left coronary system, 100 mcg in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Saline-induced Pd/Pa measurement: record 5 baseline heart beats, injection of saline using the ACIST system during 5 heart beats, measure minimal Pd/Pa under stable hyperaemia.~Perform pressure guidewire pullback and check for drift: drift ±0.02 is accepted, if ≥0.03, repeat measurement."
214372837|NCT05354232|DEVICE|2 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 2mA condition, the investigators will assist the administration of a 2mA current stimulation from the device.
214372838|NCT05354232|DEVICE|1 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 1mA condition, the investigators will assist the administration of a 1mA current stimulation from the device.
214372839|NCT05354232|DEVICE|Sham transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the sham condition, the investigators will assist the administration of a sham stimulation from the device.
214372840|NCT03915639|PROCEDURE|Peri-incisional injection|The surgeons are planned to inject the cocktail mixture or ropivacaine to muscles and the subcutaneous tissue beneath the fixation sites and incision site using a 22-gauge needle in a sterile fashion prior to skin incision.
214494775|NCT06330298|BEHAVIORAL|Treatment social cognition and emotion regulation (T-ScEmo)|T-ScEmo is a multifaceted treatment protocol that has the overall aim to improve social cognition, regulation of social behaviour and social participation in everyday life (Westerhof et al., 2017; 2019). The treatment includes, in addition to practicing social cognitive skills throughout the treatment, close involvement of a significant other, and homework assignments. The treatment consists of three modules that address 1) perception of social information including facial expressions of emotions, 2) perspective taking and understanding of social information and 3) regulation of social behaviour. The treatment contains 15-one hour live treatment sessions with a neuropsychologist and 5 online practice sessions, once or twice a week. In the online sessions, the patient can practice the information at home as a neuropsychologist is available for questions. When patients find it too difficult to practice individually at home, there is a opportunity to offer these sessions as live sessions
214986543|NCT05370391|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|The CBIT (or CBIT-JR) intervention consists of a minimum of 6 sessions of 50-minutes each week in an individual or group setting.
214494776|NCT00000234|DRUG|Buprenorphine|
214494777|NCT02917512|DRUG|HU00701|Cyclosporine 0.01% + 3% trehalose
214494778|NCT02917512|DRUG|HU007|Cyclosporine 0.02% + 3% trehalose
214494779|NCT02917512|DRUG|Restasis|Cyclosporine 0.05%
214986544|NCT03207997|OTHER|unenhanced MR sequences|2 additional unenhanced MR sequences
214986545|NCT06279013|OTHER|Counseling|Receive TIPC
214372841|NCT00982930|DRUG|Tobramycin inhalation powder|Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
214494780|NCT02917512|DRUG|Placebo|Vehicle
214494781|NCT04334317|DRUG|TAK-071|TAK-071 tablet.
214494782|NCT04334317|DRUG|Placebo|TAK-071 placebo-matching tablet.
214494783|NCT02993211|DEVICE|Bipolar transurethral standard resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
214494784|NCT02993211|DEVICE|Bipolar transurethral en bloc resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
214683283|NCT05413499|OTHER|Biomarkers research|For a part of the included population, the children with a mTBI and without indication of CT scan, a non-routine blood sample will be planned
214683284|NCT02284399|OTHER|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
214683285|NCT03685799|DIAGNOSTIC_TEST|Pathological revision|Pathological revision
214372842|NCT05788302|BEHAVIORAL|Prolonged Exposure|\- Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
214683286|NCT02902016|DRUG|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
214683287|NCT03751995|BEHAVIORAL|Mindfulness meditation|"Participants in the intervention group will have their choice of two commercially available mindfulness programs, HeadspaceTM and eMindful for 6 weeks.~The Headspace program provides progressive guided mindfulness meditation instruction via a website and mobile app to help users learn the skills of mindfulness for use in everyday life. Sessions last 3-20 minutes. Videos encourage the integration of mindfulness into daily life.~eMindful offers an online virtual classroom where participants can participate in synchronous, 1-hour mindfulness classes 1-2 times per week. The program is modeled after the mindfulness-based stress reduction (MBSR) program. eMindful also offers a cancer-specific meditation course that participants may choose to participate in."
214683288|NCT03616080|BEHAVIORAL|soccer play program|once a week for an hour of a soccer program for 8 weeks
214683289|NCT01286844|DRUG|GSK2190915A 5mg|Oral powder for dispersion in water
214683290|NCT01286844|DRUG|GSK2190915A 10mg|Oral powder for dispersion in water
214683291|NCT01286844|DRUG|GSK2190915A 25mg|Oral powder for dispersion in water
214683292|NCT01286844|DRUG|GSK2190915A 50mg|Oral powder for dispersion in water
214986546|NCT06279013|BEHAVIORAL|Health Education|Receive handbook
214986547|NCT06279013|OTHER|Interview|Ancillary studies
214986548|NCT06279013|OTHER|Medical Chart Review|Ancillary studies
214986549|NCT06279013|OTHER|Monitoring|Receive IVR symptom monitoring
214986550|NCT06279013|OTHER|Questionnaire Administration|Ancillary studies
214986551|NCT04405336|DRUG|tab block|injection of tab block to women who are doing cs
214986552|NCT04405336|DRUG|PCA|giving women PCA
214986553|NCT04405336|DRUG|women who will not receive tab block or PCA|no tab block or PCA will be given
214986554|NCT03043196|DRUG|SRP plus Rosuvastatin gel|SRP followed by Rosuvastatin placement into intrabony defect
214986555|NCT03043196|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
214683293|NCT01286844|DRUG|GSK2190915A 100mg|Oral powder for dispersion in water
214683294|NCT06094296|DRUG|BMS-986315|Specified dose on specified days
214683295|NCT06094296|DRUG|Nivolumab|Specified dose on specified days
214683296|NCT06094296|DRUG|Pemetrexed|Specified dose on specified days
214683297|NCT06094296|DRUG|Cisplatin|Specified dose on specified days
214683298|NCT06094296|DRUG|Carboplatin|Specified dose on specified days
214683299|NCT06094296|DRUG|Paclitaxel|Specified dose on specified days
214683300|NCT06323356|DRUG|TAK-279|Specified drug on specified days.
214683301|NCT05280704|PROCEDURE|Volar digital block with lidocaine|Volar digital block with lidocaine
214683302|NCT05280704|PROCEDURE|Volar digital block with saline|Volar digital block with saline
214683303|NCT05280704|PROCEDURE|Dorsal digital block with lidocaine|Dorsal digital block with lidocaine
214683304|NCT05280704|PROCEDURE|Dorsal digital block with saline|Dorsal digital block with saline
214683305|NCT03439865|DRUG|Ivacaftor|150 mg tablet PO BID x 14 days
214683306|NCT03439865|DRUG|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics x 14 days
214683307|NCT03332667|RADIATION|131I-MIBG|Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration
214683308|NCT03332667|DRUG|Dinutuximab|Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.
214683309|NCT03332667|DRUG|Vorinostat|Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.
214683310|NCT03332667|DRUG|Sargramostim|Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2
214683311|NCT03332667|DRUG|Potassium Iodide|Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45
214683312|NCT03508752|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery dose is based on the largest tumor size
214683313|NCT05893537|DRUG|Active Comparator CT1812|123 participants will receive a single daily dose of CT1812 (200 mg)
214683314|NCT05893537|DRUG|Placebo Comparator|123 participants will receive a single daily dose of placebo
214986556|NCT06195644|DEVICE|Galvanic vestibular stimulation|galvanic current generated by Gymna DUO 200 and delivered through conductive medium (electrode gel) by two small carbon rubber electrodes 3 cm 2 each bilaterally over two mastoid processes for 30 minutes, two times per week for 12 weeks .
214986557|NCT06195644|DEVICE|MovAlyzeR® software from Neuroscript|MovAlyzeR® movement analysis software from Neuroscript turns a pen tablet or mouse into a high-quality system for examining movements by a pen, mouse or finger. Hence, it can train and analyze hand dexterity and handwriting using pen tablets such as sentence parameters.
214683315|NCT05551351|DIAGNOSTIC_TEST|Cardiac CT with photon counting detector|Cardiac CT including the coronary arteries. The cardiac CT is performed in routine care for the included patients.
214683316|NCT04160286|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)"
214372843|NCT02764710|DRUG|Amoxicillin-Potassium Clavulanate Combination|"Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.~Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7."
214372844|NCT00941798|DRUG|QMF149 Twisthaler®|Once daily via multi-dose dry-powder inhaler
214372845|NCT00941798|DRUG|Mometasone Twisthaler®|Once daily via multi-dose dry-powder inhaler
214372846|NCT06492798|DRUG|umbilical cord mesenchymal stem cell|intravenous infusion of umbilical cord mesenchymal stem cell
214372847|NCT04484025|DRUG|Ebselen|Glutathione peroxidase mimetic
214372848|NCT04484025|DRUG|Placebo|Matching placebo containing excipients
214372849|NCT02546414|OTHER|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
214372850|NCT05749848|DRUG|[¹⁴C]-LY3372689|Administered orally.
214494785|NCT03621735|DEVICE|Burst-SCS/sham SCS|"The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
214494786|NCT03621735|DEVICE|Sham SCS/Burst-SCS|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
214494787|NCT00147719|DRUG|Colesevelam hydrochloride|
214494788|NCT03035084|DRUG|Vitamin D3|Single oral dose of 50,000 IU of vitamin D3
214683317|NCT01035606|BEHAVIORAL|training in goal-directed attention regulation|training in goal-directed attention regulation
214372851|NCT06076720|DEVICE|New head-mounted visual aids|New head-mounted visual aids such as Beyes, HOLA, Acesight and OXSIGHT are the latest wearable electronic visual aids
214372852|NCT00110370|DRUG|Lispro Mixture Therapy|
214372853|NCT00110370|DRUG|Glargine Basal-Bolus Therapy|
214372854|NCT01356680|DRUG|BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|
214372855|NCT01356680|DRUG|ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|
214372856|NCT01356680|RADIATION|30Gy IF-RT (Involved-Field Radiotherapy)|
214372857|NCT01356680|RADIATION|30Gy IN-RT (Involved-Node Radiotherapy)|
214372858|NCT01489189|OTHER|Prompt Panretinal Photocoagulation|Panretinal photocoagulation alone at baseline (full session completed within 56 days).
214494789|NCT03035084|DRUG|Vitamin D2|Single oral dose of 50,000 IU of vitamin D2
214372859|NCT01489189|DRUG|0.5-mg Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
214372860|NCT01489189|OTHER|Deferred panretinal photocoagulation|PRP is deferred until failure/futility criteria for intravitreal injection are met.
214372861|NCT02537639|DEVICE|Transesophageal echocardiography simulator|
214372862|NCT04327141|BEHAVIORAL|P-IF|Protein pacing and intermittent fasting
214372863|NCT04327141|BEHAVIORAL|HH|Heart Healthy
214372864|NCT02822625|DRUG|QUTENZA®|
214372865|NCT02822625|OTHER|hypnotic message|
214372866|NCT02822625|OTHER|music therapy|
214494790|NCT03035084|DRUG|Placebo oral capsule|Placebo oral capsule
214494791|NCT02747394|OTHER|Working Memory Training|
214494792|NCT00724399|BEHAVIORAL|Survey on womens health Issues.|Cardiovascular health.
214683318|NCT01035606|BEHAVIORAL|brain health education|brain health education workshops
214683319|NCT01035606|BEHAVIORAL|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
214683320|NCT02120651|PROCEDURE|Fibrin monomer|Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
214683321|NCT02120651|PROCEDURE|Hemostatic sponge|Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
214683322|NCT06116461|DRUG|Nivolumab|Participants receive three reduced doses of 240 mg every four weeks
214683323|NCT01809262|DRUG|single dose of 5 mcg|solution for inhalation
214683324|NCT01809262|DRUG|single dose of placebo|solution for inhalation
214683325|NCT01809262|DRUG|single dose of 40 mcg|solution for inhalation
214683326|NCT01809262|DRUG|single dose of 20 mcg|solution for inhalation
214372867|NCT05597722|BEHAVIORAL|Digital cognitive behavioral intervention-RxWell|RxWell is a coach enhanced digital behavioral health intervention that teaches techniques to help manage emotional distress, which may improve cognitive fog and/or depression. Participants will have access to this app for three months.
214372868|NCT05597722|DRUG|Amphetamine-Dextroamphetamine|Participants randomized to this arm will be prescribed 10mg of amphetamine-dextroamphetamine to take as needed to help with cognitive fog. Participants in this arm will be contacted at 2 and 6 weeks to assess for any side effects from taking the medication.
214372869|NCT03675932|OTHER|Rapid Cadence Cycling on a Solo-Rider Spin Bicycle|Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
214372870|NCT03588793|OTHER|Two Point Discrimination|Validity of mechanism in phantom limb pain i.e. cortical reorganisation to be tested using comparison of data from interventions above
214372871|NCT01489943|DRUG|GSK1605786 500 mg|Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.
214372872|NCT01489943|DRUG|Midazolam 3 mg|Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.
214372873|NCT01489943|DRUG|Pioglitazone 15 mg|Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.
214372874|NCT01489943|DRUG|Omeprazole 40 mg|Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.
214372875|NCT01489943|DRUG|Rosuvastatin 10 mg|Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
214372876|NCT01018225|DRUG|darifenacin|7.5 or 15 mg darifenacin, once a day for 6 weeks
214372877|NCT01018225|DRUG|Placebo|Placebo pill, once a day, for six weeks
214372878|NCT02013310|DRUG|HT-0712|
214372879|NCT02013310|DRUG|Placebo|
214372880|NCT04987125|BEHAVIORAL|Dyspnea Neuroscience education|"Patients will follow an online therapeutic education course about dyspnea. Education about the cognitive and emotional aspects of dyspnea processing, with the goal of changing maladaptive cognitions and behaviors.~The course will be group-based (5 participants). The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour."
214372881|NCT04987125|BEHAVIORAL|Usual care|General health advice, physiotherapy treatment. The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.
214372882|NCT02026323|OTHER|acupuncture|acupuncture
214372883|NCT04108000|BEHAVIORAL|SPIRIT-Dementia|"The interventionist will begin the SPIRIT-dementia session by assessing the patient's and surrogate's cognitive, emotional, and spiritual/religious representations of the patient's illness, prognosis, and end-of-life care. Individualized information will be provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the patient will examine their values about life-sustaining treatment at the end of life. The interventionist will help the surrogate prepare for end-of-life decision-making and for the emotional burden of decision-making. A Goals-of-Care document will be completed at the end of the session. The delivery of SPIRIT-dementia incorporates enhanced consent techniques, such as reducing information load by proceeding in manageable segments, offering repetition of material, opportunity for rehearsal, and using targeted questioning to verify adequate comprehension prior to eliciting preferences for goals of care."
214683327|NCT01809262|DRUG|single dose of 2 mcg|solution for inhalation
214372884|NCT04108000|BEHAVIORAL|Usual Care|As required by Centers for Medicare and Medicaid Services (CMS) written information on advance directives is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an advance directive.
214372885|NCT04166825|DIAGNOSTIC_TEST|fibrin clot properties|Assessment of thrombin generation and efficiency of fibrinolysis.
214372886|NCT02765919|RADIATION|HDR Brachytherapy of 9 Gy in 2 fractions|Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
214683328|NCT01809262|DRUG|single dose of 10 mcg|solution for inhalation
214372887|NCT02765919|RADIATION|HDR Brachytherapy of 7 Gy in 3 fractions|Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
214372888|NCT06253845|BIOLOGICAL|CG0070|CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with DDM and normal saline.
214372889|NCT02536014|DRUG|Dexmedetomidine|Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum
214683329|NCT00906022|DEVICE|Astron Pulsar Stent|Stenting with Astron Pulsar
214683330|NCT00906022|DEVICE|PTA alone|Balloon angioplasty alone
214683331|NCT02791789|OTHER|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
214683332|NCT02610556|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
214683333|NCT02610556|DRUG|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
214683334|NCT02610556|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
214986558|NCT06195644|DEVICE|BODYFIT Mini Portable Pedal Home Exerciser (cyclic ergometer)|stationary upper body pedaling as a moderate intensity aerobic training
214986559|NCT02600260|DRUG|Enoxaparin|Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
214986560|NCT02600260|OTHER|No intervention|Hospitalized patients that score less than three are not prescribed enoxaparin.
214986561|NCT00094445|DRUG|Curcumin|Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to \</= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with \</= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.
214986562|NCT01714115|DRUG|Aflibercept|2.0 mg Intravitreal Injection, every 2 to 4 weeks
214986563|NCT03962829|DRUG|mCPP|Healthy participants administrate one capsule of mCPP (30mg)
214372890|NCT02536014|DRUG|Saline|Saline infusion during the same time period
214372891|NCT05347758|DRUG|HRS-7535|Drug: HRS-7535
214372892|NCT05347758|DRUG|Placebo|Drug: Placebo
214372893|NCT01058317|DRUG|Propranolol|Propranolol 2mg/kg divided twice daily
214372894|NCT01330810|DRUG|curcumin|standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
214372895|NCT00876538|DRUG|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
214372896|NCT00876538|DRUG|Placebo Control|Placebo Control 2 capsules once day with the noon meal
214372897|NCT03243162|BEHAVIORAL|CBPT-ACLR|The CBPT-ACLR program focuses on improving sports function and return to sport. CBPT-ACLR sessions cover realistic expectations, relaxation strategies, problem-solving training, cognitive restructuring, and behavioral self-management (i.e., graded activity, goal setting, managing setbacks and symptom management plans). Each session builds upon the content of the previous session using an action plan and weekly homework is personally tailored based on patient goals. The program consists of one preoperative telephone session and six postoperative telephone sessions with a physical therapist. Each patient randomized into the CBPT-ACLR program will receive a manual to follow along with the study therapist.
214683335|NCT02610556|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
214683336|NCT06101394|DRUG|Cetuximab-IRDye800|Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab-IRDye800 over 30 minutes to 1 hour.
214683337|NCT02942095|DRUG|Ixazomib|"Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase"
214683338|NCT02942095|DRUG|Erlotinib|Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.
214683339|NCT00331786|DRUG|nitric oxide-releasing acetylsalicylic acid derivative|
214683340|NCT00331786|OTHER|laboratory biomarker analysis|
214683341|NCT00331786|PROCEDURE|biopsy|
214683342|NCT02404155|DRUG|Clozapine|
214683343|NCT02064439|DRUG|BAY 59-7939|10 mg tablet once daily for 12 months
214683344|NCT02064439|DRUG|BAY 59-7939|20 mg tablet once daily for 12 months
214683345|NCT02064439|DRUG|ASA|100 mg tablet once daily for 12 months
214372898|NCT03243162|OTHER|Education|The education program focuses on postoperative ACLR recovery. Sessions address benefits of physical therapy, proper biomechanics during sports and other functional activity, importance of early exercise after surgery, and ways to promote healing. Education on stress reduction, sleep hygiene, energy management, communication with health providers, and preventing future injury are also provided. The Education program is matched to the CBPT-ACLR treatment in terms of session frequency, length and contact with the study therapist. Each patient randomized into the Education program will receive a manual to follow along with the study therapist.
214372899|NCT06624644|BIOLOGICAL|LNS8801|G protein-coupled estrogen receptor (GPER) agonist
214372900|NCT06624644|BIOLOGICAL|Pembrolizumab|Recombinant monoclonal antibody (anti-PD1)
214372901|NCT06624644|DRUG|Chemotherapy (dacarbazine or temozolomide)|chemotherapy (dacarbazine, temozolomide)
214372902|NCT06624644|BIOLOGICAL|Immunotherapy (Pembrolizumab)|pembrolizumab
214372903|NCT06624644|BIOLOGICAL|Immunotherapy (nivolumab and relatlimab)|nivolumab and relatlimab
214372904|NCT06624644|BIOLOGICAL|Immunotherapy (ipilimumab and nivolumab)|ipilimumab and nivolumab
214372905|NCT06681857|PROCEDURE|Sinus lifting|The implant osteotomy will be initiated by pilot drill entries followed by sequential drills via the radiographic stent's sleeves to position the fixtures precisely into the pre-determined recipient sites. The Implant stability quotient (ISQ) will then be measured using an Osstell device after attaching intelligent implant pigs. Finally, the mucoperiosteal flaps will be sutured in place with 4-0 Prolene.
214372906|NCT05211323|BIOLOGICAL|Atezolizumab|Given IV
214372907|NCT05211323|BIOLOGICAL|Bevacizumab|Given IV
214683346|NCT01815892|DRUG|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
214683347|NCT01815892|DRUG|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
214683348|NCT06018584|OTHER|Tooth extraction|Tooth extractions were performed by a single physician. Topical anesthesia (Xylo-caine, Astra, Södertalje, Switzerland) was applied to the dried mucosa in the area to be lo-calized with the help of an ear stick for 1 minute. Posterior-superior-alveolar nerve block anesthesia and palatal anesthesia were applied for the upper primary molars; Inferi-or-alveolar nerve block anesthesia and lingual anesthesia (Ultracain, Aventis Pharma, Is-tanbul, Turkey) were applied for the lower primary molars. After anesthesia control was achieved, a randomly selected tooth was extracted. Tooth extraction on the other side was performed two weeks later. During the shootings, attention was paid to the traumatic ap-proach. After the control of bleeding was achieved, data were recorded for each group.
214683349|NCT02615535|DEVICE|EEG neurofeedback-assisted meditation|meditation with auditory feedback regarding EEG status
214683350|NCT02615535|DEVICE|Non-EEG feedback-assisted meditation|meditation without auditory feedback regarding EEG status
214683351|NCT00985855|DRUG|cisplatin, vinorlebine, cetuximab|patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
214683352|NCT00985855|DRUG|cisplatine, etoposide, cetuximab|patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
214494793|NCT04752072|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|"The first (formulation) session enables linking present difficulties and traumatic events, identifying current issues/concerns, and collaboratively agreeing on the order of modules based on symptom severity and client readiness.~The PTSD module provides narrative exposure to the traumatic memories and targets re-experiencing, avoidance and hyperarousal symptoms. The AD module focuses on identifying and labelling feelings, emotion management, distress tolerance, acceptance of feelings and experiencing positive emotions. The NSC module focuses on staying in the present moment and combating dissociation; self-compassion and mindfulness skills; challenging thinking patterns and developing a balanced view of self. The DR module focuses on exploring and revising maladaptive schemas; effective assertiveness; awareness of social context; and flexibility in interpersonal expectations and behaviours displayed in social interactions."
214683353|NCT05428748|OTHER|1 serving of test product|Participants will consume 1 serving/day of the test product for 28 days
214683354|NCT05428748|OTHER|2 servings of test product|Participants will consume 2 servings/day of the test product for 28 days
214683355|NCT05428748|OTHER|3 servings of test product|Participants will consume 3 servings/day of the test product for 28 days
214683356|NCT05428748|OTHER|Placebo|Participants will consume 1 serving/day of the placebo for 28 days
214683357|NCT01834144|OTHER|Exercise Training|
214683358|NCT01120093|DRUG|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
214683359|NCT01120093|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
214494794|NCT04752072|BEHAVIORAL|Treatment as usual|The first session will involve a mental health assessment by either a psychiatrist or psychologist. A treatment package will be developed based on the information collected during the assessment. Details of the interventions delivered to each participant receiving TAU, which will include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, will be recorded.
214494795|NCT06026800|BIOLOGICAL|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
214494796|NCT02523170|DEVICE|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
214494797|NCT00143130|DRUG|Pregabalin|Pregabalin
214494798|NCT03614663|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
214494799|NCT03614663|OTHER|Placebo Transdermal Gel|Placebo formulated as a clear gel (transdermal delivery)
214494800|NCT04039906|DEVICE|Removal of needle with using ANDYs|"1. ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~2. Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~   Identify the number of syringes processed by ANDY.~3. After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary."
214494801|NCT01128595|DRUG|FF/GW642444M|
214494802|NCT01128595|DRUG|GW642444M|
214494803|NCT01128595|DRUG|Fluticasone Furoate|
214494804|NCT01128595|DRUG|Placebo|
214683360|NCT01120093|DRUG|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
214683361|NCT01120093|DRUG|Placebo|Placebo via inhalation in the morning and evening for 7 days
214683362|NCT01120093|DRUG|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
214683363|NCT01880268|DEVICE|BCI-controlled neurorehabilitation device|"Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)"
214683364|NCT01880268|BEHAVIORAL|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
215089372|NCT03839836|OTHER|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
214683365|NCT00003636|DRUG|carboplatin|
214683366|NCT00003636|DRUG|cisplatin|
214683367|NCT00003636|PROCEDURE|conventional surgery|
214683368|NCT00003636|PROCEDURE|neoadjuvant therapy|
214683369|NCT04436627|DEVICE|Amadeo-assisted training-1|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
214683370|NCT04436627|DEVICE|Amadeo-assisted training-2|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).
214683371|NCT04436627|DEVICE|Amadeo-assisted training-3|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
214683372|NCT04116814|DIAGNOSTIC_TEST|wall-to-lumen ratio measurement|wall-to-lumen ratio measurement in patients with renal insufficiency
214683373|NCT02631135|DRUG|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
214683374|NCT02631135|DRUG|Propofol|BIS values were arranged 40-60 until the end of operation
214372908|NCT05211323|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
214372909|NCT05211323|DRUG|Cisplatin|Given IV
214372910|NCT05211323|PROCEDURE|Computed Tomography|Undergo CT
214683375|NCT02631135|DRUG|Dexmedetomidine|0.5 microgram/kg infusion, no changes
214683376|NCT02631135|DRUG|Rocuronium|0.5 mg/kg iv for intubation, no changes
214683377|NCT03677687|BEHAVIORAL|Mindfulness for Physical Activity|The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
214683378|NCT03306134|DIAGNOSTIC_TEST|Dysphagia|"An overall assessment is going to be carry out by a multidisciplinary team during the visit.~Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire \[4\]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.~All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)"
214683379|NCT00385268|DRUG|acamprosate|1998 mg/dau fpr 8 weeks
214683380|NCT00385268|DRUG|placebo|placebo pills
214683381|NCT04770337|DEVICE|STARSTIM device|Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
214683382|NCT04770337|DEVICE|Sham Device|Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp
214683383|NCT01975779|DRUG|Cohort A1: Lu AE58054 or placebo|One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
214683384|NCT01975779|DRUG|Cohort A2: Lu AE58054 or placebo|One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
214683385|NCT01975779|DRUG|Cohort B1: Lu AE58054|Two single oral doses 60 mg with \>=7 days washout.
214683386|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
214683387|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
214372911|NCT05211323|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo MRI
214372912|NCT05211323|DRUG|Gemcitabine Hydrochloride|Given IV
214372913|NCT05524571|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
214372914|NCT05524571|DRUG|Placebo|Matching Placebo
214372915|NCT06172582|BEHAVIORAL|12-week lifestyle intervention|A 12-week lifestyle intervention delivered via weekly group meetings in the House Chat Leaders (HCL's) homes
214683388|NCT02173496|OTHER|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
214683389|NCT02529761|DRUG|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
215089373|NCT02467920|DRUG|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
215089374|NCT02467920|DRUG|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
215089375|NCT01829282|BEHAVIORAL|Risk Reduction|
215089376|NCT01309022|DRUG|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
215089377|NCT01309022|DRUG|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
214372916|NCT04756726|DRUG|cemsidomide|oral cemsidomide
214372917|NCT04756726|DRUG|Dexamethasone Oral|oral dexamethasone \[ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; \>75 Years old: 20 mg QW on days 1, 8, 15, and 22\]
214372918|NCT06638398|PROCEDURE|Computed Tomography|Undergo standard of care Computed Tomography
214372919|NCT06638398|DEVICE|Diagnostic Procedure|Receive a Virtual Nodule Clinic radiomic prediction score obtained in Optellum software.
214372920|NCT06638398|OTHER|Best Practice|Receive standard of care lung nodule management
214372921|NCT06638398|OTHER|Electronic Health Record Review|Ancillary Studies
214372922|NCT06284564|DRUG|Evolocumab|Given by SC
214372923|NCT06284564|DRUG|Nivolumab|Given by IV
214372924|NCT06036238|BEHAVIORAL|Healthy Living Intervention (HLI)|The Healthy Living Intervention (HLI) is a brief alcohol counseling intervention developed using the Information, Motivation, and Behavioral skills (IMB) model, a framework in which information, motivation, and behavioral skills are key determinants of health behavior. Participants initiating PrEP will be randomized to either HLI or standard of care alcohol counseling.
214683390|NCT02529761|PROCEDURE|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
214683391|NCT02710266|DRUG|Preoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
214683392|NCT02710266|DRUG|Intraoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
214683393|NCT02710266|DRUG|hepatectomy with dextrose water|Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
214372925|NCT06036238|BEHAVIORAL|Standard of Care|Participants who are randomized to the control arm will receive basic alcohol counseling through the Ministry of Health if it is provided as standard of care.
214372926|NCT05009082|DRUG|Carboplatin|Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
214372927|NCT05009082|DRUG|Paclitaxel|175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
214494805|NCT00605306|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
214494806|NCT00605306|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
214683394|NCT02389816|DRUG|Placebo|Placebo tablets
214683395|NCT02389816|DRUG|Vortioxetine|Vortioxetine tablets
214986564|NCT03962829|DRUG|Placebo oral tablet|Healthy participants administrate one capsule of placebo (containing lactose)
214986565|NCT04368169|DIETARY_SUPPLEMENT|Teramune Botanical Extract|Combination blend of aromatic plant extracts in an emulsifier carrier.
214986566|NCT04368169|OTHER|Placebo|Emulsifier carrier without active supplement ingredients.
214986567|NCT05981846|BIOLOGICAL|BIMERVAX|One dose of booster vaccine
214986568|NCT05981846|BIOLOGICAL|SIIV|One dose
214986569|NCT03665870|BEHAVIORAL|Hypoglycemia Education|Two in-person visits to the home of the participant and 4 phone calls will be conducted to provided education on prevention of hypoglycemia.
214986570|NCT00117416|PROCEDURE|controlling the MAP|
215089378|NCT01309022|DRUG|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
214494807|NCT03980613|OTHER|Triage|Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
215089379|NCT01309022|DRUG|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
214494808|NCT06444984|OTHER|Fasting Trial|Participants will report fasted and consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles) in the morning.
215089380|NCT02419170|PROCEDURE|Standard of care surgery|
214372928|NCT05009082|DRUG|Bevacizumab|7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year starting from Cycle 7 Day 1
214372929|NCT05009082|DRUG|Niraparib|200 or 300 mg capsules once daily for up to a total of 3 years starting from Cycle 7 Day 1
214372930|NCT04579523|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
214494809|NCT06444984|OTHER|Fed Trial|Participants will report fasted and first consume a high-fat meal (Jimmy Deans) in the morning. After a three-hour break, participants will consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles).
215089381|NCT02419170|PROCEDURE|Apheresis|
214683396|NCT04713566|OTHER|oral rinces|natural and commercial oral rinses were compared for efficacy
214372931|NCT04579523|BIOLOGICAL|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
214372932|NCT04579523|DRUG|Cyclophosphamide|Given IV
214372933|NCT04579523|DRUG|Fludarabine Phosphate|Given IV
214372934|NCT04579523|RADIATION|Total-Body Irradiation|Undergo TBI
214494810|NCT00372775|DRUG|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
214494811|NCT05854446|OTHER|Survey|In this survey, The experts will be asked open-ended questions based on the literature research and patient surveys carried out by the researchers in the first round to identify key themes related to myofascial pain syndrome, including the disease burden, patient journey, and unmet diagnosis and treatment needs. In subsequent rounds, the experts will rate the importance of each theme and provide additional feedback.
214494812|NCT04805736|PROCEDURE|Microwave Ablation|Image-guided microwave ablation 7-10 days prior to surgery
214494813|NCT04805736|DRUG|Camrelizumab|Camrelizumab 200 mg was given a few days after microwave ablation
214494814|NCT04805736|PROCEDURE|Breast Surgery|Standard of care breast conserving surgery or radical mastectmoy
214494815|NCT00575016|BIOLOGICAL|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U \> Week 12; injection into the detrusor
214494816|NCT00575016|BIOLOGICAL|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
214683397|NCT02417233|BEHAVIORAL|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
214683398|NCT02417233|BEHAVIORAL|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
214683399|NCT05169307|DRUG|CPX-351|This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.
214683400|NCT02235116|OTHER|Survey|
214683401|NCT03649321|DRUG|Bemcentinib|200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
214683402|NCT03649321|DRUG|Nab-paclitaxel|25 mg/m\^2 Day 1 /8 every 21 days or 28 days.
214683403|NCT03649321|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days
214683404|NCT03649321|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days
214683405|NCT04175704|DRUG|UB-221|Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
214683406|NCT01026701|DRUG|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
214683407|NCT05009316|OTHER|Questionnaires|Online-based questionnaires
214986571|NCT05063240|BEHAVIORAL|Mobile phone text messaging plus prospective motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviewing at study follow up visits
214986572|NCT05063240|BEHAVIORAL|Standard infant feeding counselling|Standard infant feeding counselling as part of routine practice at primary healthcare facility
215089382|NCT02419170|DRUG|Cyclophosphamide|
215089383|NCT02419170|BIOLOGICAL|Personalized mature dendritic cell vaccine|
215089384|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/CT|Imaging scan
215089385|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/MR|Imaging scan
214372935|NCT04579523|PROCEDURE|Biospecimen Collection|Undergo blood collection
214372936|NCT04579523|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
214683408|NCT04778267|DRUG|Bupivacaine Hydrochloride|We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
214683409|NCT04778267|DRUG|Dexamethasone phosphate|used as additive to bupivacaine
214683410|NCT04310150|DRUG|Collastat|hemostatic agent that combine porcine-derived collagen thrombin
214683411|NCT04310150|DEVICE|Floseal|hemostatic agent that combine bovine-derived gelatin
214683412|NCT02709434|BEHAVIORAL|Psychoeducational programme|Activity diary analysis and a structured programme of intervention
214683413|NCT02709434|OTHER|Standard care|Usual IBD management
214683414|NCT00415714|DEVICE|Portable Biofeedback|
214683415|NCT00204425|DIETARY_SUPPLEMENT|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
215089386|NCT01480011|DRUG|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
215089387|NCT05953012|DRUG|PMC-403|PMC-403 will be administered Intravitreal.
215089388|NCT02845076|OTHER|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
215089389|NCT05324423|DRUG|Colchicine|Colchicine0.5 mg Oral Tablet Day-7\~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
214372937|NCT04579523|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214372938|NCT04579523|PROCEDURE|X-Ray Imaging|Undergo chest x-rays
214372939|NCT04649385|DRUG|BGB-15025|Administered orally once or twice daily (QD or BID)
214372940|NCT04649385|DRUG|Tislelizumab|Administered 200 mg intravenous (IV) infusion
214372941|NCT01676337|OTHER|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
214372942|NCT01665664|OTHER|Hypocaloric feeding|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
214372943|NCT06457633|BEHAVIORAL|Experiential FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.) carried out experientially.
214372944|NCT06457633|BEHAVIORAL|Traditional FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.)
214372945|NCT06457633|BEHAVIORAL|Online FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.) performed virtually.
214372946|NCT00486421|BIOLOGICAL|Rituximab|375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
214372947|NCT00486421|DRUG|Prednisone|1mg/kg/d PO, taper to off by 8 weeks
214372948|NCT06361901|DEVICE|Zenicog;language rehabilitation program|This program is an AI-based computerized cognitive and language training program.
214372949|NCT06361901|PROCEDURE|Conventional language rehabilitation|Conventional language rahabilitation therapy will apply for all participants with speech impairement
214372950|NCT04386525|DIETARY_SUPPLEMENT|Omega-3 fish oil|soft gels,1000gm, 84% of DHA and EPA
214372951|NCT05110196|DRUG|Capmatinib 150 mg|Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
214372952|NCT05110196|DRUG|Capmatinib 200 mg|Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
214494817|NCT00575016|BIOLOGICAL|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
214494818|NCT00575016|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
214494819|NCT04257487|DRUG|Sulodexide|2 soft capsules of Vessel® 250 LSU BID for 12 months
214494820|NCT04257487|DRUG|Sulodexide and placebo|1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
214372953|NCT05874804|DEVICE|Carry Life UF|A 5-hour treatment with the Carry Life UF used with a 1.36% glucose PD fill.
214372954|NCT05874804|DRUG|2.27% glucose peritoneal dialysis dwell|A 5-hour CAPD dwell with a 2.27% glucose PD fluid.
214494821|NCT04257487|DRUG|Placebo|Sugar pill manufactured to mimic sulodexide 250 LSU
214494822|NCT01149759|DRUG|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
214683416|NCT01954303|OTHER|Progress of CHD|
214683417|NCT02356406|RADIATION|Celiac Plexus Radiosurgery|"5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis."
214683418|NCT05139368|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
214683419|NCT01702363|DRUG|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
214683420|NCT02531789|OTHER|Observation|C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
214683421|NCT03951857|OTHER|Resistance exercise with a gym stick|Exercise intervention: The resistance exercise intervention is performed with a gym stick for 3 times a week for 12 weeks. Exercise load is gradually increased by the number of times the band is wound and the speed of motion by dividing into three stages in 1-4 weeks (1st stage), 5-8 weeks (2nd stage) and 9-12 weeks (3rd stage).
214683422|NCT04629989|OTHER|Standard Oxygen Delivery System|The standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
214683423|NCT04629989|OTHER|Double-Trunk Mask|The Double-Trunk Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
214683424|NCT04629989|OTHER|Surgical Mask|The Surgical Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
214683425|NCT01881594|PROCEDURE|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
214683426|NCT01293032|PROCEDURE|Neoadjuvant Therapy|Undergo neoadjuvant therapy
214683427|NCT01293032|PROCEDURE|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
214683428|NCT01293032|OTHER|Laboratory Biomarker Analysis|Correlative studies
214683429|NCT01293032|GENETIC|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
214683430|NCT01293032|DRUG|Systemic Chemotherapy|Undergo chemotherapy
214683431|NCT01293032|DRUG|Tamoxifen Citrate|Undergo hormonal therapy
214683432|NCT01293032|DRUG|Aromatase Inhibition Therapy|Undergo hormonal therapy
214372955|NCT06337370|BEHAVIORAL|Chronic Disease Self Management Program|"Experimental Intervention (Self-Management Program):~In addition to standard care from a rheumatology specialist, the intervention group will receive the Chronic Disease Self-Management Program (CDSMP). This program is a group intervention that provides education on self-managing chronic diseases. The program consists of six weekly sessions, each lasting two and a half hours (including time for breaks and refreshments), for a total of six weeks. Each group will consist of 12 to 16 participants, and the sessions will follow a standardized, scripted format. Two group leaders, who have received training from a Master Trainer certified by Stanford University in how to implement the program, will lead the activities. For this study, the principal investigator and a nurse experienced in health education will undergo training from a CDSMP Master Trainer to ensure fidelity to the intervention."
214372956|NCT06337370|BEHAVIORAL|Conventional Intervention- Standard care|"Conventional intervention (standard care):~The control group will receive standard care provided by a rheumatology specialist. This approach emphasizes clinical and clinimetric evaluations of rheumatoid arthritis. It includes applying validated disease activity indices (e.g., DAS28, CDAI, or SDAI), making therapeutic decisions, and adjusting medications according to current clinical practice guidelines. It also includes the standard clinical counseling provided during routine medical consultations. No additional self-management strategies or structured interventions beyond those already incorporated into routine healthcare practice will be included."
214683433|NCT01665326|OTHER|Observational|This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
214372957|NCT05716906|DIETARY_SUPPLEMENT|Melatonin|5mg gummy 30 min before bedtime for 2 consecutive nights
214372958|NCT06808984|DRUG|BMS-986368|Specified dose on specified days
214683434|NCT05365893|COMBINATION_PRODUCT|Paricalcitol, Hydroxychloroquine, Losartan|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
214683435|NCT05365893|OTHER|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
214683436|NCT05987293|DEVICE|Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure.|A flexible film sensor with a thickness of 0.11mm is placed between the tongue and the tracheal tube to measure the distribution, join force and dynamic changes of pressure at different site of the tongue. Five channels of pressure values will be recorded separately: (Ch1) the tip of the tongue, (Ch2) the middle of the tongue, (Ch3) the base of the tongue, (Ch4) the right side at the base of the tongue, (Ch5) the left side at the base of the tongue. The pressure values at the following points during the operation will be recorded: (t1) after intubation, (t2) highest pressure during patient positioning, (t3) after position fixed, (t4) at the end of surgery, (t5) before extubation.
214683437|NCT04911101|DEVICE|Excision with 7G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
214683438|NCT04911101|DEVICE|Excision with 10G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
214683439|NCT00260572|BEHAVIORAL|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
214683440|NCT00260572|BEHAVIORAL|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
214683441|NCT00260572|BEHAVIORAL|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
214372959|NCT06808984|DRUG|Placebo|Specified dose on specified days
214372960|NCT04411849|OTHER|Best Practice|Receive usual care
214683442|NCT00260572|BEHAVIORAL|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
214683443|NCT01666080|DRUG|Busulfan|0.4 mg/kg (0.5 mg/kg if \<4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
215089390|NCT06376071|DIAGNOSTIC_TEST|functional endoscopic sinus surgery|functional endoscopic sinus surgery for diagnosis the disease
214372961|NCT04411849|PROCEDURE|HPV Self-Collection|Receive HPV self-testing intervention
214683444|NCT01666080|DRUG|Fludarabine|40 mg/m\^2 intravenously (IV) over 1 hour on days -6 through -2.
214683445|NCT01666080|RADIATION|Total body irradiation|200 cGy on Day -1
214683446|NCT01666080|BIOLOGICAL|Stem cell transplant|stem cell infusion on day 0
214683447|NCT01666080|DRUG|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
214683448|NCT02243527|OTHER|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
214683449|NCT02243527|OTHER|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
215089391|NCT03123614|DRUG|Loteprednol Etabonate 0.5% Oph Gel|
215089392|NCT03123614|DRUG|Prednisolone Acetate 1% Oph Susp|
215089393|NCT03167489|BEHAVIORAL|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
214372962|NCT04411849|OTHER|Informational Intervention|Receive information about cervical cancer
214372963|NCT04411849|BEHAVIORAL|Patient Navigation Program|Receive telephone-based patient navigation
214372964|NCT06365346|BEHAVIORAL|Dyadic video-assisted gamified group-based music breathing therapy|Dyadic video-assisted gamified music breathing therapy comprising six 75-min weekly sessions delivered in a group size of 6-8 (first sessions: parents only; reminding 5 sessions: parent-child dyads).
214372965|NCT06365346|BEHAVIORAL|Online educational modules|Six weekly educational modules on ADHD and its management via email.
214372966|NCT06979375|DRUG|CDR132L|Administered intravenous infusion of CDR132L once every 4 weeks for 48 weeks.
214372967|NCT06979375|DRUG|Placebo|Administered intravenous infusion of placebo once every 4 weeks for 48 weeks.
214372968|NCT03091257|DRUG|Dabrafenib|Administered Orally BID
214372969|NCT03091257|DRUG|Trametinib|Administered Orally once daily
214372970|NCT06977100|BEHAVIORAL|Gratitude|Participants in this group will receive a gratitude journal where they will be asked to write down three things they are grateful for each day and reflect why they are grateful for these things. Journaling will take place from the comfort of their home on three days of their choice per week, for a total duration of two weeks.
214372971|NCT06977100|OTHER|General Wellness|Participants in this group will receive a general wellness journal where they will be asked to reflect on three things that happened, or they did during the day (daily activities). Journaling will take place from the comfort of their home on three days of their choice per week, for a total duration of two weeks.
214683450|NCT02936505|DRUG|Cyclosporine|"Cyclosporin A (Sandimmun Neoral® or similar):~* Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~* Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; \>12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily."
215089394|NCT04109833|DRUG|ABT|any antibiotic therapy in the first week of life
214372972|NCT07128303|DRUG|GS-5319|Administered orally
214683451|NCT02936505|DRUG|Mycophenolate mofetil (MMF)|"MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly."
214683452|NCT02936505|DRUG|Rabbit Anti thymocyte globulin|Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).
214683453|NCT02936505|DRUG|Corticosteroids|"Corticosteroids:~* Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~* From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg \> 6 months."
214683454|NCT02936505|DRUG|Tacrolimus|"* Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.~* Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, \>12 months 6-8 ng/ml. Tacrolimus will be administered once daily."
214683455|NCT01841658|DIETARY_SUPPLEMENT|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
214683456|NCT00870948|DRUG|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
214683457|NCT05399706|DIAGNOSTIC_TEST|CTA Aorta|Computed Tomography Angiography - Aorta Whole
214372973|NCT06512558|PROCEDURE|Additional MRI with gadolinium injection and 3D camera imaging|The study includes an additional MRI with gadolinium injection, performed in addition to standard practice. In addition, 3D camera images will be acquired at the time of surgery.
214372974|NCT05985694|DRUG|AD17002|The dosing days of AD17002 are: Days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32.
214683458|NCT02237495|DRUG|dexmedetomidine|dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
214372975|NCT05985694|DRUG|Placebo|Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.
214372976|NCT06655324|BIOLOGICAL|V350A|Vaccination administered via intramuscular injection
214372977|NCT06655324|BIOLOGICAL|V350B|Vaccination administered via intramuscular injection
214372978|NCT06655324|BIOLOGICAL|Placebo|Vaccination administered via intramuscular injection
214683459|NCT02237495|DRUG|placebo|The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
214683460|NCT04664920|DEVICE|exergame|motor-cognitive training device
214683461|NCT01540188|BEHAVIORAL|Family Intervention to Address Drug Use and HIV in Vietnam|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
214683462|NCT02520804|DRUG|sterofundin|sterofundin for shock patients in the first 72 hours
214683463|NCT02520804|DRUG|normal saline|Normal saline for shock patients in the first 72 hours
214372979|NCT06979401|OTHER|Exercise|After obtaining informed consent to participate in the study, all participants will be evaluated by an experienced physiotherapist before group allocation. All participants will receive diabetic foot training. Then, the experimental group and the control group will be formed by a sequential random method. Foot sensory training will be applied to the experimental group and no intervention will be made to the control group. However, after the study is completed, sensory training will be provided to the participants in the control group who wish to do so. Foot sensory training will be performed by the researcher physiotherapist. Foot sensory training sessions will be planned for 6 weeks, 3 days a week. An initial assessment will be made before the sessions begin and a final assessment will be made after the 6-week foot sensory training program.
214372980|NCT04296487|OTHER|autologous chondrocytes|autologous chondrocytes implantation (ACI)
215089395|NCT00973102|DRUG|Premarin IV|One time dose of Premarin IV
214372981|NCT01325025|OTHER|High-field MRI (3 Teslas)|"* anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence"
214372982|NCT01325025|OTHER|High-field MRI (3 Teslas)|"* anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence"
214372983|NCT06884176|DEVICE|Ultrasound Guided Central Venous Catheter|Patients randomized to this arm will receive an ultrasound guided central venous catheter. The catheter is 20cm in length.
214372984|NCT06884176|DEVICE|Ultrasound Guided Midline Catheter|Patients randomized to this arm will receive an ultrasound guided midline catheter. The catheter is 8-10cm in length.
214372985|NCT04015180|DRUG|Eylea (Aflibercept, BAY86-5321)|Treatment administered in 20090. Solution in a sterile glass vial, Dose A, IVT injection.
214372986|NCT04015180|PROCEDURE|Laser photocoagulation|Treatment administered in 20090. Transpupillary conventional laser ablative therapy
214372987|NCT06628622|DRUG|BI 1356225|BI 1356225
214372988|NCT06628622|DRUG|Placebo|Placebo
214372989|NCT06491953|DRUG|SGLT-2 inhibitors|SGLT-2 inhibitors use or not use； the duration of SGLT-2 inhibitors use
214372990|NCT06173531|DRUG|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
214372991|NCT06173531|DRUG|Placebo|Placebo given TID, identical in appearance respective to carbetocin treatment
214494823|NCT00733811|DRUG|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
214494824|NCT00733811|DRUG|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
214494825|NCT02132559|DRUG|DHEA|
214494826|NCT02350400|DEVICE|DEBIRI|DEBIRI TACE
214494827|NCT04147637|COMBINATION_PRODUCT|FreeStyle Libre with MiaoMiao|Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms
214494828|NCT04147637|DEVICE|FreeStyle Libre alone|Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning
214494829|NCT05220111|PROCEDURE|Cardiac surgical operation (valve, aorta, coronary arteries)|Quality of life assessment using EQ-5D-3L
214494830|NCT01841671|BIOLOGICAL|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
214494831|NCT01841671|BIOLOGICAL|bOPV|As indicated
214494832|NCT01841671|BIOLOGICAL|mOPV type 2|Administered at 28 weeks of age to all study participants
214494833|NCT01841671|BIOLOGICAL|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
214494834|NCT00635869|BEHAVIORAL|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
214494835|NCT00635869|BEHAVIORAL|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
214494836|NCT00635869|BEHAVIORAL|Placebo|didactic education sessions on physical assessment
214494837|NCT01064999|DRUG|Oxaliplatin|CRT:50mg/m2,IV,weekly\*5 cycle CT: 130mg/m2,IV,d1,q 21 day
214494838|NCT01064999|DRUG|Capecitabine|CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
214494839|NCT01064999|RADIATION|Radiotherapy|High intensity group:55Gy Low intensity group:50Gy
214494840|NCT01064999|PROCEDURE|Surgery|Lower anterior resection or abdominoperineal resection
214494841|NCT06151301|DIAGNOSTIC_TEST|serum procalcitonin|predicting the severity of intoxication
214494842|NCT06151301|DIAGNOSTIC_TEST|C-reactive protein|predicting the severity of intoxication
214494843|NCT05141136|PROCEDURE|Ultrasound probe sagittal group|Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.
214494844|NCT05141136|PROCEDURE|Ultrasound probe transverse group|Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.
214494845|NCT00336505|DRUG|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
214494846|NCT00336505|DRUG|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
214494847|NCT01624493|DRUG|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
214494848|NCT01624493|DRUG|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
214494849|NCT01624493|DRUG|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
214494850|NCT01624493|DRUG|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
214494851|NCT01624493|DRUG|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
214494852|NCT01939691|DRUG|Difluprednate|Difluprednate 0.05% - corticosteroid eyedrop
214494853|NCT01939691|DRUG|Nepafenac|Nepafenac 0.1% - NSAID eyedrop
214494854|NCT01939691|DRUG|Prednisolone acetate|prednisolone acetate 1% - corticosteroid eyedrop
214372992|NCT06807775|OTHER|Dietary Intervention (time-restricted feeding model (16:8))|Time-Restricted Feeding (16:8 model): Participants can consume food in any amount during an 8-hour window (08:00-16:00), but no food or energy-containing drinks are allowed during the remaining 16-hour fasting period.
214372993|NCT06807775|OTHER|Dietary Intervention (energy restricted dietary intervention)|Participants' daily energy needs are calculated based on their basal metabolic rate and physical activity. The energy intake is then reduced by 15-25%. The diet plan consists of 3 main meals and 2-3 snacks, with the daily intake of carbohydrates, proteins, and fats making up 50-60%, 15-20%, and 25-30% of the total daily energy, respectively.
214372994|NCT06979154|DEVICE|tACS (aperiodic)|Individualized tACS waveform based on aperiodic EEG activity will be delivered.
214372995|NCT03750006|BEHAVIORAL|Short session HIIT|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
214372996|NCT04965350|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)|sterile solution for intramuscular injection
214372997|NCT03534973|OTHER|Caffeine intake|Cataract surgery in eyes with prior caffeine intake
214372998|NCT03534973|OTHER|No caffeine intake|Cataract surgery in eyes without prior caffeine intake
214372999|NCT00449280|DRUG|Sorafenib|400mg BID (200 mg twice daily)
214373000|NCT00449280|DRUG|Rapamycin|30mg once weekly
214373001|NCT00449280|DRUG|Rapamycin|3mg once daily
214373002|NCT04722445|DIAGNOSTIC_TEST|Early ultrasound measurement of quadriceps shortening during neuromuscular electrical stimulation (NMES)|NMES will be applied to the quadriceps muscle to generate muscle contraction. Ultrasound measurement of the quadriceps thickness will be provided during contraction and rest, and the shortening of the quadriceps muscle will be measured. A second measurement using Shear-wave elastography measurement will also be undertaken. The measures will be undertaken at day 1 of neuromuscular blockers liberation (if any) as well as at day 3 and day 7 for the patients that will still be received mechanical ventilation at that time.
215089396|NCT00973102|DRUG|Placebo|One time dose of placebo.
215089397|NCT03378648|DRUG|CHF6366|"Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366"
215089398|NCT03378648|DRUG|Placebo CHF6366|"Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366"
215089399|NCT03378648|DRUG|umeclidinium bromide and vilanterol trifenatate|Part 3 Single dose
215089400|NCT03375372|PROCEDURE|Scaling and Root Planing (S&RP)|dental Scaling and Root Planing and oral hygiene regimen
215089401|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
215089402|NCT00853840|DRUG|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
215089403|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
214373003|NCT06816901|DRUG|Depo Medroxyprogesterone acetate|Initiation of injectable depo medroxyprogesterone acetate (DMPA) contraception within 48 hours after birth
214373004|NCT06658730|DEVICE|Endovascular|TEVAR - thoracic endovascular aortic repair
214373005|NCT06825871|DEVICE|Smart Inhaler Monitoring Platform for Asthma Management|"The intervention utilizes the aflo™ digital platform, a comprehensive system designed to improve asthma management through advanced technology. It integrates the following components:~1. Electronic Inhaler Sensor: The sensor attaches to a metered-dose inhaler (MDI) and a spacer (if applicable) to automate and provide feedback on the six critical steps of proper inhaler technique, such as shaking the inhaler, breathing out, inhaling slowly, and holding the breath. The sensor also records and stores medication usage data securely.~2. Mobile Application: The app delivers real-time notifications and feedback on inhaler technique, sends reminders for daily controller medication, tracks asthma symptoms, and provides monthly Asthma Control Test (ACT) assessments. It also offers reminders for spacer cleaning and customizable alerts for caregivers.~3. Clinician Portal: Data collected from the sensor and app is accessible via a secure clinician portal, enabling healthcare providers to monitor pa"
214373006|NCT06605612|DIAGNOSTIC_TEST|FBIndex|There will be no intervention.
214494855|NCT01185041|DIETARY_SUPPLEMENT|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
214494856|NCT03067857|BIOLOGICAL|Stem Cells|Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
214494857|NCT05535959|DRUG|VX-121/TEZ/D-IVA|FDC tablet for oral administration.
214494858|NCT02005159|OTHER|Microbiological studies|
214494859|NCT04169256|DRUG|HYR-PB21|HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen
214494860|NCT04169256|DRUG|Liposomal bupivacaine|Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen
214494861|NCT04169256|OTHER|Normal Saline|Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
214494862|NCT02379000|DRUG|Triamcinolone Acetonide|Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
214494863|NCT02379000|PROCEDURE|Transpupillary thermotherapy|We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
214494864|NCT03648190|DIAGNOSTIC_TEST|Flowcytometry analysis of platelets surface receptors|"BD FACSCalibur flowcytometry instrument.~Platelet flow cytometry is an emerging tool in diagnostic and therapeutic hematology. It is eminently suited to study the expression of platelet surface receptors both qualitatively as well as quantitatively.~Flow cytometry rapidly measures the specific characteristics of a large number of cells in suspension. Typically, the cells are labeled with fluorescently conjugated monoclonal antibodies (mAbs)."
214494865|NCT05706246|DIAGNOSTIC_TEST|diagnostics|Serum tryptase levels were evaluated in all suspected children with perioperative hypersensitivity
214373007|NCT06596265|BEHAVIORAL|Fit2Lead Group 1-2|"Each park serves anywhere from 2 to 9 feeder schools within these neighborhoods (a target population of 34 000 youth residents aged 12-17 years), and transportation from schools to parks is provided at no cost within a 3-mile radius of a program park. Fit2Lead participants can also enroll in the MDPROS youth summer camp at no charge.~Work assignments support MDPROS operations and recreation staff. Interns in Phase II rotate every 8 weeks for exposure to different job opportunities, supervisors, and mentors.~Duke is conducting a secondary data analysis on data collected as part of the Fit2Lead study."
214373008|NCT06603077|DRUG|AVTX-009 Regimen 1|AVTX-009 will be administered as a subcutaneous injection every 4 weeks.
214683464|NCT05224622|DIAGNOSTIC_TEST|VOX|Breath exhalation into the mouthpiece of the VOX breath diagnostic device.
214373009|NCT06603077|DRUG|AVTX-009 Regimen 2|AVTX-009 will be administered as a subcutaneous injection every 2 weeks.
214373010|NCT06603077|DRUG|Placebo|Matching placebo will be administered as a subcutaneous injection every 2 weeks.
214373011|NCT06051890|DRUG|Extended-Release Buprenorphine (XRB)|XRB (Sublocade) will be delivered as a pre-filled 2cc subcutaneous monthly injection, using a 300mg starting dose in most cases (100mg starting doses are available per the study team's clinical judgement). XRB consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades. Prior to an initial injection, the participant must be stable for several days or longer on sublingual buprenorphine (SLB) at doses of 8mg/day or higher. Participants will receive at least one XRB monthly injection prior to release, which investigators anticipate to usually be the 300mg dose. Some participants will be recruited earlier during the incarceration (or experience delayed release dates and then longer than anticipated incarcerations); XRB will be continued monthly from the time of induction to the day of release.
214373012|NCT06051890|DRUG|Sublingual Buprenorphine (SLB)|Maintenance of existing SLB prescription (treatment as usual).
214373013|NCT04854304|DIAGNOSTIC_TEST|Fast Breast Abbreviated Magnetic Renounce Imaging|Fast Breast MRI Imaging
214373014|NCT04239573|PROCEDURE|Computed Tomography|Undergo CT
214373015|NCT04239573|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
214373016|NCT04239573|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214683465|NCT02191202|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
214683466|NCT02262039|DEVICE|Valveless recirculating insufflation (VTI)|10 mmHg target pressure
214683467|NCT02262039|DEVICE|Conventional pressure|15 mmHg target pressure
214986573|NCT00769561|BEHAVIORAL|Biofeedback-Based Cognitive Behavioral Treatment|The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
214986574|NCT00769561|DEVICE|Dental treatment with occlusal splint (OS)|Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
214986575|NCT04646278|DRUG|Hyperemic stimuli|Hyperemic simuli of coronary flow by adenosine or nicorandil injection
214986576|NCT03349307|DEVICE|Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)|Patients scheduled for a lobectomy will be recruited to this study and approached for informed consent. At the time of surgery, once the lobe has been removed, the TCP-EBUS will be inserted through a bronchial stamp for brief operability evaluations and image acquisition. Once this data has been captured standard of care will continue.
214373017|NCT04239573|OTHER|Quality-of-Life Assessment|Ancillary studies
214373018|NCT04239573|OTHER|Questionnaire Administration|Ancillary studies
214373019|NCT06668064|DRUG|EYP-1901|Intravitreal Injection
214373020|NCT06668064|DRUG|Aflibercept (2.0 mg)|Intravitreal Injection
214373021|NCT04766944|OTHER|No intervention|No intervention
214373022|NCT03851133|OTHER|Blood Sample Collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).
214373023|NCT03851133|OTHER|Tumor Sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.
214373024|NCT03851133|OTHER|Data Collection|Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
214683468|NCT04174638|OTHER|Motivational Interviewing and Education Based on Watson's Theory of Human Caring|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
214683469|NCT02184143|BEHAVIORAL|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
214683470|NCT02184143|OTHER|Education|Patient education
214986577|NCT04585893|DRUG|Rituximab|375 mg/m\^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.
215089404|NCT00853840|DRUG|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
214683471|NCT04506827|PROCEDURE|Maxillary Sinus Augmentation|Biomaterial Graft into the Maxillary Sinus
214683472|NCT04506827|DEVICE|Maxillary Sinus Graft with ABBM|The maxillary sinuses in the control group are grafted with ABBM
214683473|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP|The maxillary sinuses in the test1 group are grafted with TCP
214373025|NCT06610526|DRUG|Dapagliflozin|Dapagliflozin by oral administration
214683474|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP + HA|The maxillary sinuses in the test1 group are grafted with TCP + HA
214683475|NCT00543751|DRUG|MK0767|
214683476|NCT00745485|DRUG|zoledronic acid|
214683477|NCT02364193|DEVICE|MRI|"Cardiac MRI for LVEF and segmentation.~* Phase-contrast MRI for CO in aorta and each pulmonary vein.~* DCE-MRI for bolus kinetic parameter analysis."
214683478|NCT02364193|DRUG|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
214683479|NCT02364193|DEVICE|BIS ImpediMed™ SFB7|"BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).~Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.~Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds."
214683480|NCT02364193|DEVICE|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
214373026|NCT04932564|DRUG|Leflunomide tablet|"Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.~The dosing for children will be as follows:~1. \<20 kg - 100 mg x 1 day followed by 10 mg every alternate day~2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily~3. \>40 kg - Usual adult dose.~This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD."
214373027|NCT06990399|DRUG|KSI-101|Intravitreal injection
214373028|NCT06990399|OTHER|Sham Comparator|Sham injections
214373029|NCT04105231|DRUG|Cannabidiol|Cannabidiol oral suspension
214683481|NCT03636776|OTHER|Quality of life in metastatic BC|"1 month after metastatic stage diagnosis, patients complete their 1st therapeutic sequence evaluation visit (T1) within the recommended standard time frames. If the disease remains stable or if a response to treatment is observed then patients continue their follow-up in the same therapeutic sequence (T1).~If progression occurs, treatment is modified and patients move on to the next therapeutic sequence (T2).~And so on as many times as necessary. Before each evaluation visit with investigator, patients complete the questionnaires QLQ-C30, BR23, STAI, BDI II"
214494866|NCT01561300|OTHER|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
214494867|NCT01561300|OTHER|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
214494868|NCT00018096|BIOLOGICAL|LPS endotoxin, saline, HDM|instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
214683482|NCT00602316|DRUG|gadolinium-chelate|
214683483|NCT00602316|PROCEDURE|conventional surgery|
214683484|NCT00602316|PROCEDURE|magnetic resonance imaging|
214683485|NCT00602316|PROCEDURE|magnetic resonance spectroscopic imaging|
214683486|NCT03491722|OTHER|risk factors and revascularization procedures|arterial revascularizations needed since index procedure
214683487|NCT06367868|PROCEDURE|After 5 ml CSF Drainage|Optic Nerve Sheath Diameter and Intracranial Pressure measurements will be after 5 ml CSF drainage
214683488|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
214683489|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
214683490|NCT00321984|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
214683491|NCT03560193|DRUG|2%Chlorhexidine-70%Isopropanol|2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
214373030|NCT04105231|DRUG|Risperidone|Risperidone, encapsulated tablet.
214683492|NCT03560193|DRUG|5%Povidone Iodine- 69%Ethanol|5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
214683493|NCT02627131|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
214373031|NCT04323189|DRUG|Sitagliptin 100mg|Sitagliptin will be administered daily for 7 days, with a study day on day 7.
214373032|NCT04323189|DRUG|Placebo Oral Tablet|Placebo will be administered daily for 7 days, with a study day on day 7.
214373033|NCT06602024|BIOLOGICAL|mRNA-1010|Intramuscular (IM) injection
214373034|NCT06602024|BIOLOGICAL|Fluarix®|IM injection
214373035|NCT06602024|BIOLOGICAL|Influsplit® Tetra|IM injection
214373036|NCT06602024|BIOLOGICAL|Fluarix Tetra|IM injection
214373037|NCT06602024|BIOLOGICAL|Alpharix® Tetra|IM injection
214683494|NCT03434964|DIAGNOSTIC_TEST|the intraoperative effectiveness of the AIFIB software in real time in the detection of atrial fibrillation drivers during an ablation procedure.|Real-time validation by an expert operator of the correct detection of atrial fibrillation driver
214986578|NCT04585893|DRUG|Etoposide|Subjects with high-risk disease will receive 100 mg/m\^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
214986579|NCT06615908|DRUG|Psilocybin|See treatment arm description.
214986580|NCT03942770|BEHAVIORAL|Contingency Management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
214683495|NCT04929262|BEHAVIORAL|Supporting Anxious Youth: Strategies for Caregivers|The outreach presentation will last 75 minutes with an additional 15 minutes for caregiver questions. The presentations will occur in the evening via Zoom. The presentation will include information about identifying anxiety disorders, strategies for caregivers to help their youth with anxiety, evidence-based practices to treat youth anxiety, and strategies for finding a therapist who uses cognitive behavior therapy with exposures. The text on the presentations is written at a 5.3 grade reading level. Presentations will incorporate stigma reduction strategies, such as education to dispel myths, and behavioral decision-making tools to elicit hope, empowerment, and motivation.
214683496|NCT00757939|OTHER|MRI|During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.
214373038|NCT05596448|PROCEDURE|Coccygeal nerve radiofrequency ablation|During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
214373039|NCT02417532|DEVICE|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
214683497|NCT00757939|OTHER|FDG-PET|2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
214683498|NCT01593683|BEHAVIORAL|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
214494869|NCT01943305|BIOLOGICAL|Japanese Encephalitis vaccine|IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
214494870|NCT01943305|BIOLOGICAL|Yellow Fever vaccine|STAMARIL, 1 dose (0.5 ml)
214494871|NCT02620449|OTHER|Diet|Participants will be fed a low-additive diet as the primary intervention
214494872|NCT06250868|DEVICE|Kerato-Refracto Tonometer|measures pressure inside the eye and thickness of the cornea.
214494873|NCT04936386|BEHAVIORAL|Survey|The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
214494874|NCT01099566|DRUG|Prasugrel|Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
214494875|NCT01099566|DRUG|Placebo|A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
214494876|NCT03194659|DIETARY_SUPPLEMENT|Choline|Choline chloride is a water soluble choline salt that will be provided in a juice solution to participants to be consumed daily. The intervention will increase dietary choline intake by 500mg/day.
214494877|NCT04773145|PROCEDURE|Hemiarthroplasty with hydroaxyapatite coated stem|Hemiarthroplasty with non cemented femoral stem, using the hydroxyapatite-coated femoral stem Pharo
214494878|NCT03234374|COMBINATION_PRODUCT|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
214494879|NCT03234374|DRUG|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
214494880|NCT00724126|DRUG|Rifaximin|
214494881|NCT00724126|DRUG|Placebo|
214494882|NCT06498817|BEHAVIORAL|Standard Recommendation|Standard recommendation given by government of Bangladesh on the use of oral rehydration solution (ORS) and a flyer on water treatment and handwashing with soap given at the health facility during the time of diarrhea patient treatment.
214683499|NCT01387295|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
214373040|NCT02316379|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
214373041|NCT02316379|DEVICE|MRI|
214373042|NCT05388500|DRUG|Paclitaxel + Trastuzumab|"Regarding neoadjuvant treatment :~\- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SubCutaneous (SC) (600mg fixed dose) every 3 weeks + weekly Paclitaxel IV : 80 to 90 mg/m2~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
214683500|NCT04746612|DRUG|HH30134|HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors
214683501|NCT04336046|PROCEDURE|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
214683502|NCT04336046|PROCEDURE|sham bilateral ultrasounded guided erector spinae block|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
214683503|NCT04336046|DRUG|normal saline|using 1 mg /kg normal saline
214683504|NCT04336046|DRUG|Bupivacaine|bupivacaine
214683505|NCT01847664|DRUG|Rifamycin SV-MMX® 400 mg b.i.d.|
214683506|NCT01847664|DRUG|Rifamycin SV-MMX® 600 mg t.i.d.|
214683507|NCT01847664|DRUG|Rifamycin SV-MMX® Placebo|
214683508|NCT02641236|DRUG|Vancomycin-polymyxin B|
214683509|NCT02985450|BIOLOGICAL|Engerix-B|Hepatitis B Vaccine
214373043|NCT05388500|DRUG|Trastuzumab|"Regarding neoadjuvant treatment :~\- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SC (600mg fixed dose) every 3 weeks~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
214373044|NCT05901038|DEVICE|Wearing heart rate monitors|Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.
214373045|NCT00811382|DEVICE|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
214373046|NCT00811382|DEVICE|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
214373047|NCT06999694|RADIATION|Proton radiotherapy|"* 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 66 CGE in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart."
214373048|NCT06999694|DRUG|Tremelimumab|Tremelimumab 300 mg will be administered as an IV infusion for one dose
214373049|NCT06999694|DRUG|Durvalumab|"Durvalumab 1500 mg will be administered as an IV infusion every 4 weeks.~Treatment Duration Guidelines:~* Complete Response (CR): Patients who achieve a CR within one year of treatment will continue durvalumab for a total duration of two years.~* Partial Response (PR): Patients who achieve a PR should continue durvalumab until achieving CR, disease progression (PD), or for a total duration of two years.~* Stable Disease (SD): Patients with SD will receive duvalumab for a total of 6 doses."
214373050|NCT07001150|DRUG|levodopa-carbidopa|Carbidopa/levodopa is a combination of two medications: carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease. The main and most effective treatment strategy for motor symptoms in Parkinson's disease relies on replenishing dopamine levels through the use of L-dopa.
214373051|NCT07001150|DRUG|Silymarin|Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, is employed clinically for managing hepatic disorders. Its antioxidant effects are primarily attributed to its ability to scavenge free radicals.
214373052|NCT06998628|DRUG|Methotrexate|Methotrexate (MTX) is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for including breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Methotrexate is also used to treat rheumatoid arthritis and other inflammatory conditions.
214373053|NCT06998628|DRUG|Pentoxifylline|Pentoxifylline (also known as oxpentifylline) is a methylxanthine derivative with strong hemorrheologic effects. In the United States, it is primarily used to treat intermittent claudication. Studies in both humans and animals have demonstrated that pentoxifylline therapy induces various physiological changes at the cellular level
214683510|NCT03392155|BEHAVIORAL|Training & Nutrition|Exercise at moderate to high intensities and diet education/counseling
214683511|NCT00816907|DRUG|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
214683512|NCT00816907|DRUG|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
214683513|NCT00431847|PROCEDURE|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
214683514|NCT00431847|PROCEDURE|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
215089405|NCT01521910|DIETARY_SUPPLEMENT|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses \>= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
214683515|NCT02524860|DEVICE|Focal-Fusion Bx|The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
214683516|NCT04081935|DEVICE|Virtual Reality|virtual reality (VR) as a distracting intervention could reduce pain and fear during an IV placement for school-age children in the emergent department.
214683517|NCT01469013|DRUG|Placebo|
214683518|NCT01469013|DRUG|Baricitinib|
214683519|NCT01469013|DRUG|Baricitinib|
214683520|NCT01469013|DRUG|Baricitinib|
214683521|NCT01469013|DRUG|Methotrexate|Administered orally as background therapy
214683522|NCT01350349|BEHAVIORAL|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
214683523|NCT01350349|BEHAVIORAL|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
214683524|NCT04686006|DRUG|Potassium Iodide|
214683525|NCT00002663|BIOLOGICAL|Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
215089406|NCT01521910|DIETARY_SUPPLEMENT|normal protein diet|"The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period."
215089407|NCT03571165|BEHAVIORAL|My Tools 4 Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
215089408|NCT03099148|DRUG|Reference Formulation (R)|Administered PO
214373054|NCT07001371|BEHAVIORAL|Emotional Brain Training|Emotional Brain Training (EBT) is a structured, neuroscience-based behavioral intervention that focuses on rewiring the brain's stress-related circuits to promote emotional resilience, self-regulation, and lasting behavioral change. This behavioral intervention has not been implemented in addiction treatments in the past. Unlike traditional therapies that primarily target cognitive processes or symptom management, EBT directly addresses the physiological and emotional root causes of maladaptive behaviors by engaging the brain's natural neuroplasticity mechanisms. EBT integrates rapid emotional processing tools, peer-to-peer support, clinician-facilitated sessions, and mobile app-based self-care to systematically transition brain circuits from stress-reactive to stress-resilient states.
214373055|NCT07001371|OTHER|Standard addiction counseling and medical therapy|Participants will receive standard counseling (including but not limited to cognitive behavioral therapy, motivational interviewing, etc.), which does not include EBT, in addition to medications for addiction treatment (including but not limited to buprenorphine, naltrexone, bupropion, etc.).
214373056|NCT06013748|BEHAVIORAL|VR-VOICES|7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.
214373057|NCT06013748|OTHER|Treatment as usual|Treatment as usual as provided by the mental health centers
214373058|NCT05072548|BEHAVIORAL|The ABCs of SLEEPING|"The intervention is comprised of three components. The first is a sleep check-in which is a questionnaire that is evidence based and evaluates what areas of sleep parents can work on. The second component is the sleep report which summarizes to the parent what areas they're doing well in (i.e., within the ABCs of SLEEPING mnemonic described above) and what areas they can improve on. The third component of this intervention are the sleep tips which are sleep recommendations that are customized based on the identified areas of sleep the parents are suggested to work on."
214683526|NCT01351766|DRUG|Transdermal Nicotine Patch|Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
214683527|NCT02040194|DRUG|AM-101|AM-101 gel for intratympanic injection
214683528|NCT02040194|DRUG|Placebo|Placebo gel for intratympanic injection
214683529|NCT00002250|DRUG|CD4-IgG|
214683530|NCT03085706|BIOLOGICAL|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
214683531|NCT02000570|PROCEDURE|Sitting position (neurosurgery)|
214683532|NCT03106493|OTHER|None (observational)|None (observational)
214683533|NCT00148733|DRUG|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
214683534|NCT03721185|COMBINATION_PRODUCT|Dr.K. Treatment|Overweight and obesity treatment response
214683535|NCT01603641|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
214683536|NCT05889494|OTHER|Autologous Whole Blood Management|Intraoperative high volume autologous whole blood withdrawal with re-transfusion following weaning from CPB.
214683537|NCT05889494|OTHER|Standard Care involving allogenic and/or derivative transfusion.|Therapeutic treatment of CPB-induced coagulopathy using donated allogenic blood products including plasma, platelets, and cryoprecipitate and/or derivative administration using prothrombin complex and fibrinogen concentrates.
214683538|NCT04131309|DRUG|Daratumumab|As of Protocol Amendment 1, all new subjects are dosed with daratumumab subcutaneous injection (SC) co-formulated with recombinant human hyaluronidase rHuPH20. Subjects who already began treatment with daratumumab intravenous (IV) infusion (i.e., prior to Am 1) switch to SC on the next administration date according to the protocol schedule. Subjects receive daratumumab IV at a dose of 16 mg/kg and daratumumab SC at a fixed dose of 1800 mg for the first 8 weeks (Cycles 1 and 2) of treatment and then every 2 weeks for 4 cycles (Cycles 3 to 6) and then every 4 weeks until progression of disease (according to MOD-PFS), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total. All treatment cycles are 4 weeks (28 days) in length.
214683539|NCT04131309|DRUG|Bortezomib Injection|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib at a dose of 1.3 mg/m2 weekly for a maximum of 6 cycles as a subcutaneous injection
214683540|NCT04131309|DRUG|Dexamethasone oral tablet|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab low dose dexamethasone at a maximum total dose of 20 mg weekly.
214683541|NCT02255851|DEVICE|SENTINEL (Cerebral Protection System)|
214986581|NCT03942770|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
214683542|NCT00000461|DRUG|pravastatin|
214683543|NCT00000461|DRUG|niacin|
214683544|NCT00000461|DRUG|cholestyramine|
214683545|NCT00000461|DRUG|gemfibrozil|
214683546|NCT00000461|DRUG|fatty acids, omega-3|
214683547|NCT06534346|DRUG|15 mg DA-302168S tablet|"Qualified subjects will be randomly assigned to one of two dosing sequences in a 1:1 ratio. Either DA-302168S tablet with food on Day 1 and DA-302168S tablet without food on Day 6 (treatment sequence fed/fasted), or DA-302168S tablet without food on Day 1 and DA-302168S tablet with food on Day 6 (treatment sequence fasted/fed).~Each administration sequence consists of two cycles, with one administration per cycle and a 5-day washout period between each administration."
214683548|NCT03161678|DRUG|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
214986582|NCT05614063|DRUG|XEN1101|XEN1101 Capsules
214986583|NCT05614063|DRUG|Placebo|Placebo Capsules
215089409|NCT03099148|DRUG|LY3337641 (T1)|20 mg PO
215089410|NCT03099148|DRUG|LY3337641 (T2)|20 mg PO
214373059|NCT06673394|DRUG|Complement protein C5 inhibitor|Investigational arm: eculizumab (900 mg) will be administered intravenously once per week for a total of four doses (days 1, 8, 15, and 22) in conjunction with IVMP and oral prednisone (60mg, 5mg weekly decline). Terminal complement complex inhibition by eculizumab predisposes patients to infections by encapsulated bacteria, especially N meningitidis. Meningococcal vaccination will not be effective in this timeframe; instead, all enrolled patients will receive antibiotic prophylaxis against N meningitidis from the time of the first dose of the study drug to 8 weeks after the last administration.
214373060|NCT06673394|DRUG|IVMP|IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics
214683549|NCT03161678|DRUG|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
215089411|NCT03455439|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
214683550|NCT05782101|DIAGNOSTIC_TEST|Integrated proteomic HPLC-ESI-MS analysis of salivary peptides|A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
214683551|NCT01154972|PROCEDURE|Preoperative sentinel lymph node identification and marking|SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
214373061|NCT06752668|DRUG|ORX750|ORX750 capsule.
214373062|NCT06752668|DRUG|Placebo|ORX750 matching placebo capsule.
214373063|NCT06868108|DEVICE|Flexible Suturing System with Anchors (FSSA)|Surgically repaired full-thickness rotator cuff tendon tears with the Flexible Suturing System with Anchors (FSSA).
214373064|NCT06770738|OTHER|There is no intervention in this study.|This study is planned as a retrospective cross sectional cohort study. Only the information of the patients will be used.
214683552|NCT04141644|DRUG|Ipilimumab|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
214683553|NCT04141644|DRUG|Osimertinib|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
214683554|NCT04859127|OTHER|effects of neck pain|Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.
214683555|NCT05632497|BIOLOGICAL|Stool and blood samples|Stool and blood samples
214683556|NCT01895010|DEVICE|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
214683557|NCT01895010|DRUG|tropisetron|only tropisetron 6mg before TACE
214373069|NCT04817007|DRUG|BMS-986158|Specified dose on specified days
214373070|NCT04817007|DRUG|Ruxolitinib|Specified dose on specified days
214373071|NCT04817007|DRUG|Fedratinib|Specified dose on specified days
214373072|NCT06624202|BEHAVIORAL|COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) Intervention|COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) includes use of practice plans and a resource booklet aligned with the National Federation for High School guidelines for contact in practice. Coaches will also attend a pre-season coaches' clinic and be paired with a peer mentor during the season.
214373073|NCT06606340|DRUG|Eteplirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
214373074|NCT06606340|DRUG|Golodirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
214373075|NCT06606340|DRUG|Casimersen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
214373076|NCT06867107|DRUG|SAT-3247|AAK1 inhibitor
214683558|NCT00814840|DEVICE|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
214683559|NCT00814840|DEVICE|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
215089412|NCT05122117|DEVICE|Methylene blue mediated Photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
214373077|NCT07010575|DRUG|New TETA 4HCl Formulation|Individual patient doses will depend on the Standard of Care (SOC) therapy at study entry and guided by recommended dosing switch schedule outlined in the study protocol. The dose may subsequently be titrated based on clinical response per the investigator's judgement.
214373078|NCT07010575|DRUG|Standard of Care|Patients will be returned to their approved Wilson's Disease SOC therapy (dose and frequency) at study entry as prescribed by their treating Wilson's Disease physician.
214373079|NCT06871943|OTHER|Incremental Shuttle Walk Tests|The participants will walk on the flat around cones placed 9 meters apart inline with the procedure for the incremental shuttle walk test. They will also walk at a matched speed to the incremental shuttle walk test on a treadmill. This will be performed in a counter balanced procedure to reduce any benefit of a learning effect.
214373080|NCT07006818|DEVICE|Direct current stimulation|Direct current stimulation will be applied at 2 mA for 20 minutes.
214683560|NCT03962998|DRUG|Lactulose/Rhamnose solution|Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine
214683561|NCT03962998|DRUG|MB-102|MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
214683562|NCT05648344|BEHAVIORAL|WW|"WW assigns foods to a point value calculated through a proprietary algorithm that accounts for the food's caloric value, saturated and unsaturated fat, sugar, fiber, and protein. Members are encouraged to track their food and beverage intake, with the goal of staying within their personal points targets assigned based in an individual's sex, age height, weight, goals, and activity. The program also has Zero Point Foods (list of healthy foods with no point value) and can be eaten freely. In addition to the personal points, participants will be asked to attend WW coach-led virtual workshops conducted over Zoom, engage with peer- support, and WW-trained behavior change experts via 24/7 chat."
214494883|NCT06498817|BEHAVIORAL|CHoBI7 Scale-Up Program|Health promoter delivery of handwashing with soap, water treatment, and safe water storage module in the health facility to diarrhea patients and the patient's household members during the time of treatment. This module includes video testimonials from diarrhea patient households on how the patient benefits from adhering to the promoted behaviors, and a demonstration on how to construct homemade handwashing washing stations. This in-person module is reinforced by weekly voice, interactive voice response, and text messages for three months sent to the mobile phones of diarrhea patient household members from a doctor at diarrhea ward at local hospital.
214494884|NCT04869605|DIAGNOSTIC_TEST|1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin ratio|the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes
214494885|NCT01929291|BIOLOGICAL|Boostrix|Single intramuscular injection
214494886|NCT01929291|OTHER|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
214494887|NCT04353050|PROCEDURE|Non-invasive adhesive system (patch)|The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice
214494888|NCT00253266|DRUG|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
214494889|NCT00253266|DRUG|Quetiapine|Quetiapine up to 200 mg/d for four weeks
214494890|NCT02502526|DEVICE|Centurion® Vision System, 45° Balanced Tip|
214494891|NCT02502526|DEVICE|Centurion® Vision System, 45° MFK Tip|
214494892|NCT02502526|DEVICE|lnfiniti® Vision System, 45° MFK Tip|
214494893|NCT02502526|DEVICE|INTREPID® Ultra infusion sleeve|
214494894|NCT02502526|DEVICE|Ultra infusion sleeve|
214683563|NCT05648344|BEHAVIORAL|Control|Usual care with information from myplate.gov
214683564|NCT04501653|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic compound produced by psilocybin mushrooms, and has been shown to have antidepressant and anti-anxiety effects after one dose of 25 mg. Common side effects are slight elevations in blood pressure and heart rate. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
214683565|NCT04501653|DRUG|Methylphenidate|Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is used as an active control for this study because it is metabolized similarly to psilocybin and has similar effects on heart rate and blood pressure. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
214683566|NCT03656887|DEVICE|Continuous interstitial glucose sensor|Installing and removing the sensor
214683567|NCT03656887|OTHER|Sensor Scan|Scan of the sensor, using the Freestyle Pro free version reader, at installation then before removal after 14 days.
214373081|NCT07015918|DRUG|[14C] PF-07976016|\[14C\] PF-07976016 liquid (oral) formulation
214373082|NCT07015918|DRUG|PF-07976016|PF-07976016 liquid (oral) formulation
214373083|NCT07015918|DRUG|[14C] PF-07976016|\[14C\] PF-07976016 intravenous (IV) formulation
214373084|NCT07014488|DRUG|HRS-5041 Tablets|HRS-5041 tablets.
214373085|NCT07014488|DRUG|Rifampicin Capsule|Rifampicin capsule.
214373086|NCT00140205|DRUG|r-metHuLeptin|r-metreleptin was given in 3 different dose in fed and fasting states
214373087|NCT02938351|BEHAVIORAL|Collaborative care|Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
214373088|NCT05068869|OTHER|Dignio Digital Remote Care intervention group|"The intervention consists of Dignio Prevent (for healthcare professionals) and MyDignio (for patients). The system is CE marked and the system satisfies all regulatory requirements for privacy and information security. Various components can be added for an individualized follow-up of the patients.~Elements of the digital outpatient service in Dignio include patient reported outcomes and other questionnaires, tasks, objective measures, reminders and information, in addition to a chat function for asynchronous contact with healthcare personnel and video consultations for real-time consultations."
214373089|NCT05068869|OTHER|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
214373091|NCT07016880|BEHAVIORAL|Virtual Reality Relaxation Session|A 20 minute virtual reality session using visual and auditory stimuli for relaxation before surgery. Delivered via VR headset.
214373092|NCT05025020|OTHER|interactive 3D tool|The study tool displays 3-dimensional step-by-step animations of autologous and implant-based breast reconstruction procedures.
214373093|NCT05025020|OTHER|BREAST-Q Reconstruction Module|The BREAST-Q Reconstruction Module1-3 has 6 domains that cover various aspects of patient satisfaction and quality of life. BREAST-Q is part of our standard of care for patients treated for breast cancer and referred for reconstruction.
214373094|NCT05025020|OTHER|DQI|The DQI has 3 domains that cover decision-specific questions about what it is like for a patient to make decisions about reconstruction after breast cancer treatment.
214373095|NCT05025020|OTHER|Ottawa Decision Regret Scale|The validated Decision Regret Scale measures distress or remorse after a health care decision by the use of 5 items to indicate the extent to which the respondent agrees or disagrees with the statements in the regret scale.
214373096|NCT06683742|DRUG|EYP-1901|Intravitreal Injection
214373097|NCT06683742|DRUG|Aflibercept (2.0 mg)|Intravitreal Injection
214373098|NCT07021742|DEVICE|BioHealx|Subjects will have their anal fistula treated with the BioHealx Anal Fistula Device, a bioabsorbable implant designed to securely close the fistula internal opening, preventing reinfection, while allowing for drainage through the external opening during healing.
214373099|NCT07021898|DRUG|ERAS-4001|ERAS-4001 Administered orally
214373100|NCT07021898|DRUG|ERAS-4001 in combination|ERAS-4001 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.
214373101|NCT00000657|DRUG|Zidovudine|
214373102|NCT00000657|DRUG|Didanosine|
214373103|NCT07025577|DRUG|Immunoglobulin G|Participants will receive SC administrations of IgG
214373104|NCT07024823|DRUG|AZD4248|AZD4248 will be administered orally.
214373105|NCT07024823|DRUG|Placebo|Placebo will be administered orally.
214373106|NCT07024823|DRUG|AZD4248|AZD4248 will be administered via IV infusion.
214373107|NCT07024823|DRUG|Placebo|Placebo will be administered via IV infusion.
214683568|NCT00599430|DIETARY_SUPPLEMENT|Placebo|Inert excipient
214683569|NCT00599430|DIETARY_SUPPLEMENT|Lactobacillus acidophilus NCFM|1e10 CFU/day
214373108|NCT06701435|DEVICE|Cold Compression|Cold compression was applied to the athletes with the Game Ready (Game Ready; Global, UK) device. The Game Ready (GR) device applies cooling to the tissue by continuous circulation of ice water with intermittent pneumatic compression. The GR consists of a sleeve that surrounds the affected tissue, a tank containing the ice water and a hose connecting the two. There are chambers inside the sleeve and the air pumped through these chambers and the broken ice pieces and water surround the tissue. The pressure settings are no compression (0 mmHg), low compression (5 to 15 mmHg), medium compression (5 to 50 mmHg) and high compression (5 to 75 mmHg). The ice water passes through the sleeve in 3-minute inflation and deflation cycles. The temperature of the water inside the device can be adjusted by adding ice and water. The temperature to be applied to the tissue is set with the screen on the device.
214494895|NCT03604809|OTHER|OT Guided Cognitive Interventions|"RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission."
214683570|NCT00599430|DIETARY_SUPPLEMENT|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
214683571|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 1|Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
214373109|NCT07021963|DRUG|HRS-1893 Tablet|HRS-1893 tablet.
214373110|NCT06137157|DRUG|ATR12-351|Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
214373111|NCT04793035|DEVICE|Omega-Cuff|An omega-shaped nitinol device to be placed and secured on the Lower Esophageal Sphincter area
214494896|NCT04261309|OTHER|Usual care|Since this is an observational study there will be no interference with the care given by the primary healthcare providers. However, the usual care provided by these and other healthcare utilization used by the patients during follow-up will be recorded during the follow-ups.
214683572|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 2|Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
214986589|NCT04697797|OTHER|Device Programming|Intervention includes (1) pacemaker reprogramming (2) echocardiographic parameters acquisition (3) ECG recording
214373112|NCT04226365|DRUG|Nortriptyline|10mg capsule Nortryptyline
214373113|NCT04226365|DRUG|Placebo|10mg capsule Thick-It filler
214986590|NCT06814275|BEHAVIORAL|ARTEMIS|The ARTEMIS intervention includes 5 sessions delivered individually over Zoom across 3 months. The intervention teaches 9 positive affect skills: noting and capitalizing on positive events, gratitude journaling, formal and informal mindfulness, positive reappraisal and problem solving coping skills training, focusing on personal strengths, setting achievable goals, and small acts of kindness. Each session consists of a didactic portion with in vivo skills practice, and participants are asked to complete daily home practice of the skills between sessions.
214986591|NCT06814275|BEHAVIORAL|Contingency management for Antiretroviral (ARV) adherence|All participants will received the contingency management (CM) intervention to support ARV adherence. They will use the Spotlight by Scene Health platform, a HIPAA-compliant mHealth application for directly observed therapy, to upload videos of ART adherence. The app records and uploads time-stamped videos of medication doses, which staff verify asynchronously. Participants will be paid for each verified dose and receive a weekly bonus if they complete 6 doses.
214986592|NCT02396667|OTHER|5D ultrasound|Measure the femur length by 5DLB to calculate fetal weight
214986593|NCT07004764|DRUG|Nitroglycerin Ointment 2%|Patients will have pre- and post-nitropaste tissue perfusion measurement with the LA-ICG system.
214986594|NCT04467021|OTHER|Best Practice|Receive usual blood pressure management
214986595|NCT04467021|OTHER|Blood Pressure Measurement|Undergo blood pressure measurement
214986596|NCT04467021|OTHER|Clinical Management|Undergo intensive systolic BP management
214986597|NCT04467021|OTHER|Quality-of-Life Assessment|Ancillary studies
214986598|NCT04467021|OTHER|Questionnaire Administration|Ancillary studies
214986599|NCT04826341|DRUG|Berzosertib|Berzosertib will be supplied as 20 mg/mL M6620 to be diluted with 5% dextrose in water solution before intravenous infusion.
215089413|NCT05122117|PROCEDURE|Non-surgical periodontal therapy|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
215089414|NCT03618914|BIOLOGICAL|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
215089415|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
215089416|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
214494897|NCT03910855|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
214494898|NCT03910855|OTHER|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
214494899|NCT05652075|PROCEDURE|pericapsular nerve group and lateral femoral cutaneous nerve block|Will undergo pericapsular nerve group block (PENG) combined with lateral femoral cutaneous nerve under ultrasound guided block with 20 mL of 0.25% bupivacaine.
215089417|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
215089418|NCT01439126|DRUG|clonidine hydrochloride|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
215089419|NCT01439126|DRUG|Placebo|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
214494900|NCT05652075|PROCEDURE|lumbar plexus block|Will undergo Lumbar plexus block (LPB) under ultrasound guided block with 20 mL of 0.25 % bupivacaine.
215089420|NCT02156817|OTHER|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
214494901|NCT05100797|DEVICE|Vyntus CPX|To study the validity, precision and accuracy of the Vyntus CPX metabolic cart using both, in-vitro and in-vivo (i.e., human study) measures.
214494902|NCT00571649|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
214494903|NCT00571649|DRUG|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
214494904|NCT00571649|DRUG|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
214494905|NCT00571649|DRUG|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
214494906|NCT01421667|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
214494907|NCT01421667|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion
214494908|NCT00503906|DRUG|Avastin|
214494909|NCT00503906|DRUG|Gemcitabine|
214494910|NCT00503906|DRUG|Abraxane|
214494911|NCT01951807|BEHAVIORAL|Psychotherapy|
214494912|NCT03617315|DRUG|Hylauronic Acid|Schirmer Test, BUT test and OSDI test. Previous and After treatment
214494913|NCT06622057|DRUG|D07001-Softgel Capsules|D07001-softgel capsule is an oral gemcitabine.
214494914|NCT06622057|DRUG|Placebo|Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)
214494915|NCT06622057|COMBINATION_PRODUCT|Capecitabine|Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.
214494916|NCT00694655|BIOLOGICAL|Yellow Fever Vaccine|Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.
214494917|NCT03598946|DEVICE|Urinary test|Women use a home urinary test themselves
214494918|NCT02631668|DRUG|ferrous succinate and vitamin C|As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
214494919|NCT02631668|DRUG|ferrous succinate|As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
214494920|NCT02631668|DRUG|ferrous succinate|As another active comparator, patients take the tablets of ferrous succinate with double dosage
214494921|NCT01077700|DRUG|ABT-288 Low Dose|
214494922|NCT01077700|DRUG|Placebo|inactive substance
214494923|NCT01077700|DRUG|ABT-288 High Dose|
214494924|NCT03960099|BEHAVIORAL|Pictograph in Banner and Verification Alert|Patient Pictograph will be displayed in the banner at the top of the screen in the electronic health record AND patient Pictograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
214986600|NCT04826341|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles.
214986601|NCT06040619|BEHAVIORAL|Therapy Together|8-week caregiver-led pediatric constraint-induced movement therapy program
214986602|NCT06040619|BEHAVIORAL|Usual Care|8 weeks of usual care received in an early intervention therapy program
214986603|NCT06901297|DRUG|Raphamin|Oral administration
214986604|NCT06901297|DRUG|Placebo|Oral administration
214986605|NCT06735469|OTHER|Discrete choice experiment|Participants will state their preferences for 1) return of full versus limited results to participants (trust/personal benefit), 2) balancing a study's participant burden with the study's ability to address multiple research aims (burden/knowledge generation), 3) incentivizing clinical assessments vs. conducting home-based assessments (personal benefit/burden), and 4) results generalizable to specific social groups versus the broader population. Participants will evaluate these attributes within a hypothetical trial to prevent chronic diseases.
214986606|NCT06755736|DRUG|superficial cervical plexus block|In anterior cervical discectomy surgeries, superficial cervical block will be used for analgesia.
215089421|NCT05088993|OTHER|Antigravity treadmill training|This group received antigravity treadmill training 100% weight bearing
215089422|NCT05088993|OTHER|Conventional exercise program|This group received the conventional exercise program only.
215089423|NCT02721108|BEHAVIORAL|Mindfulness meditation|The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
215089424|NCT02721108|BEHAVIORAL|Relaxation app|The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
215089425|NCT05677503|DIAGNOSTIC_TEST|CBC|measurement of CBC will be performed at the time of admission and by the time of discharge
215089426|NCT05677503|DIAGNOSTIC_TEST|(NT-proBNP)|measurement of serum NT-proBNP levels will be performed at the time of admission and by the time of discharge
214494925|NCT01231971|DRUG|Florbetapir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
214494926|NCT01231971|DRUG|Flortaucipir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
214494927|NCT04817020|OTHER|%2 Klorheksidin|Effect on phlebitis
214494928|NCT05461885|BEHAVIORAL|Supervised exercise|The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down. Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic. The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
214494929|NCT05176392|DEVICE|Active rTMS|Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.
214494930|NCT05176392|BEHAVIORAL|Headache Management Therapy|Therapy will be provided on headache management.
214494931|NCT05176392|DEVICE|Sham rTMS|Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.
214494932|NCT05176392|BEHAVIORAL|Headache Education Control|In the control, educational sessions on headaches will be provided.
214494933|NCT05784194|PROCEDURE|Intervention for correct discharge medication list|As above
214494934|NCT04116372|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
214494935|NCT00516477|BIOLOGICAL|voretigene neparvovec-rzyl|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
214683573|NCT05203302|OTHER|Single-Electrode Pulse Train|AIM 2 - Stimuli will be presented on one of three electrodes (apical, middle, and basal) at an amplitude between 10 and 100% dynamic range in µAs in 10% dynamic range steps. Stimulation will be delivered at a rate of 1000 pps. The process will be repeated in random order until 20 loudness estimates are obtained for each stimulus (3 electrodes x 2 rates x 10 amplitudes) for each subject. The dynamic range will be determined by measuring the maximum acceptable loudness (MAL) and threshold for each of the stimuli. MAL will be measured by slowly raising the current level for each stimulus until the subject reports that it is as loud as they are willing to accept without becoming uncomfortably loud.
215089427|NCT05677503|DIAGNOSTIC_TEST|(cTnT)|measurement of cTnT levels will be performed at the time of admission and by the time of discharge
215089428|NCT03715192|BIOLOGICAL|LY3462817 IV|Administered IV
214373114|NCT06872268|BEHAVIORAL|Therapeutic photography and expressive writing|Therapeutic photography, unlike phototherapy, consists of a set of photography-based activities that are initiated independently as part of an organised group or project, but in which no formal therapy is taking place within a psychotherapeutic setting. This approach, too, can be used as a routine practice in treatment pathways. The subject deepens his or her self-awareness to improve the sense of being: images become a way to express oneself, to communicate what one is unable to verbalize. Therapeutic photography can be done independently and individually, or in the presence of other professionals (nurses, sociologists, teachers, facilitators, psychologists) who accompany the individual to the understanding and production of the activity.
214373115|NCT06872268|BEHAVIORAL|Expressive writing|Expressive writing is a technique that helps to understand and manage one's experiences and emotional tensions, contributes to mental and physical well-being, decreased stress, improved relationships, and the strengthening of the immune system.
214373116|NCT07028177|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of etomidate during digestive endoscopy between insomnia group and normal sleep group.
214373117|NCT06685861|DEVICE|a digital product based on CBT|The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.
214373118|NCT06698458|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|DaRT source will be inserted using endoscopy into the tumor. The sources release by recoil into the tumor short-lived alpha-emitting atoms
214494936|NCT04896736|OTHER|Multisite tissue oxygenation-guided care|"The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase \>/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity"
214494937|NCT04896736|OTHER|Usual care|Usual care in this study means the standard perioperative care. Patients who are meant to receive usual care will receive both cerebral and muscular tissue oxygen saturation monitoring; however, the monitor screen will be covered and the monitoring data will not be used to guide clinical care.
214494938|NCT02246075|DRUG|EVP-6124|
214494939|NCT01387516|BEHAVIORAL|Motivational Intervention|The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
214494940|NCT01387516|BEHAVIORAL|Relaxation Therapy|The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.
214494941|NCT01387516|BEHAVIORAL|Cognitive Behavioral Therapy|The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
214494942|NCT01387516|BEHAVIORAL|Self-Help Programming|"The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
214494943|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's Parent Toolkit 2.0|Parent Toolkit 2.0 is designed to equip parents and caregivers with skills to talk to their teens about sex and contraception and ultimately influence their teens' decision-making and behaviors around sex. The Georgia Campaign for Adolescent Power \& Potential (GCAPP) developed the Parent Toolkit intervention. Morehouse School of Medicine's (MSM) Health Promotion Research Center tested and adapted it through an OPA Innovation Network grant, creating Parent Toolkit 2.0.
214494944|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's General Health Guide|General Health Guide provides information to parents on how to promote health in their families.
214494945|NCT04694365|DRUG|Fluzoparib|A single oral dose of 50 mg Fluzoparib will be administered.
215089429|NCT03715192|BIOLOGICAL|LY3462817 SC|Administered SC
215089430|NCT03715192|DRUG|Placebo|Administered IV
215089431|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection|9MW1411 injection
215089432|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection placebo|9MW1411 injection placebo
215089433|NCT03048838|BEHAVIORAL|Risk reduction behavioral intervention|
215089434|NCT03048838|BEHAVIORAL|Wellness Promotion Intervention|
215089435|NCT04254874|DRUG|Abidol hydrochloride|0.2g once, 3 times a day,two weeks
214373119|NCT03684148|OTHER|Motor imagery practice|In detail, they were advised to imagine maximal voluntary isometric contractions (MViC). MViC imagery practice was planned in a progressive manner. Thus, it was performed in two sets of 25 repetitions with 2 minutes of inter-sets rest period, for two weeks, and 10 additional repetitions were added on week three and four, respectively. Each MViC repetition was sustained for 5 seconds, followed by 5 seconds of inter-repetition rest periods. Additionally, after every fifth contraction, participants had a 20 seconds of rest. Following 5 days of MI practice, the participants were advised to take a break from MI for two consecutive days. After hospital discharge, the participants in the MIp group were supplied with an audio description of the exercises to be performed.
214373120|NCT07028190|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of ciprofol during digestive endoscopy between insomnia group and normal sleep group.
214373121|NCT07030933|DRUG|Travesol 10%|Travesol 10% (Baxter) will be administered to the post-intervention participants at a dose of 2g per kilogram of ideal body weight for up to 3 days or until the participant's discharge from the intensive care unit.
214683574|NCT05203302|OTHER|Modulation Detection Threshold (MDT) and Gap Detection Tasks|AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.
214373122|NCT06412146|BEHAVIORAL|Peer Support Group|Participation in an Online Peer Support Group
214373123|NCT07032688|DRUG|SHR-3167 Injection|SHR-3167 injection.
214373124|NCT07032688|DRUG|Insulin Degludec Injection|Insulin Degludec injection.
214373125|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
214373126|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
214373127|NCT07138040|BEHAVIORAL|Stage 1 Written Information|Stage 1 WI: consists of a letter from the survivorship care team with information about long-term follow-up care and relevant contacts to schedule an appointment.
214373128|NCT07138040|BEHAVIORAL|Stage 1 Low Touch Intervention|Stage 1 LTI: consists of the WI stage 1 letter, a copy of their treatment summary with instructions for creating their own survivorship care plan, and one text message per week with information to schedule a follow-up care appointment.
214494946|NCT03249142|DRUG|ARM A Durvalumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : the tremelimumab 75 mg IV will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. Durvalumab 1125 mg IV (with one cycle of tremelimumab 75 mg IV post S3) will be pursued in maintenance treatment, up to 1 year or until disease progression, unacceptable toxicity or patient withdrawn."
214683575|NCT05203302|OTHER|Sound coding strategy.|Aim3 - Spectral-temporally modulated ripple test (SMRT), Quick Spectral Modulation Detection (QSMD), Modulation Detection, Gap Detection. CNC words will be set in quiet and Az-Bio/BabyBio sentences in quiet and multi-talker babble (+10 and +5 dB SNR) using both the subject's clinical map and the new reduced channels map. Tests will be presented in the soundfield at 60 dB SPL
214986607|NCT07073963|BEHAVIORAL|Virtual Mindfulness Based Cognitive Therapy Group|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week, group-based psychological intervention that integrates principles of cognitive behavioral therapy (CBT) with training in mindfulness meditation. The intervention is designed to help participants develop greater awareness of thoughts, emotions, and bodily sensations, with the goal of preventing depressive relapse and reducing psychological distress. Each weekly session includes guided mindfulness practices (e.g., body scan, sitting meditation, mindful movement), group discussion, and cognitive-behavioral exercises focused on recognizing and disengaging from unhelpful thought patterns. Participants are assigned daily home practice using audio recordings and written materials. The MBCT intervention will be delivered over a video platform for this trial.
215089436|NCT04254874|DRUG|Abidol Hydrochloride combined with Interferon atomization|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
215089437|NCT03033953|DIETARY_SUPPLEMENT|Native whey|
215089438|NCT03033953|DIETARY_SUPPLEMENT|Milk|
215089439|NCT03033953|OTHER|Strength training|
215089440|NCT02460341|DRUG|ondansetron|Ondansetron 8mg, 16mg, 24mg
214373129|NCT07138040|BEHAVIORAL|Stage 2 Written Information|Stage 2 WI: consists of a letter from the survivorship care team with information about what to expect at a long-term follow-up care appointment.
214373130|NCT07138040|BEHAVIORAL|Stage 2 Low Touch Intervention|Stage 2 LTI: consists of the WI stage 2 letter, a copy of their treatment summary with instructions for creating their own survivorship care plan, and two to three non-tailored (generic) text messages per week related to scheduling an appointment, overcoming barriers to follow-up care, and health self-management.
214494947|NCT03249142|DRUG|ARM B Durvalumab/Tremelimumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV + tremelimumab 75 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : patients will be treated according to investigator choice."
215089441|NCT02460341|DRUG|placebo|placebo pill
214986608|NCT07073963|BEHAVIORAL|Virtual sarcoidosis support group|Participants attend a once-monthly, virtual support group via secure video conferencing. Each session includes a brief didactic presentation on topics relevant to living with chronic illness (e.g., symptom management, coping strategies, navigating healthcare) followed by a facilitated group discussion. The discussion emphasizes peer support, shared experiences, and emotional processing in a safe, respectful environment. Groups are led by an experienced facilitator with experience in chronic illness care. No home practice is required.
214986609|NCT06603155|BEHAVIORAL|Time restricted eating (TRE)|TRE is defined as limiting daily food intake to 10 hour period with a nightly fasting period of 14 hours.
214986610|NCT07075159|DEVICE|Hydrocolloid Wound Dressing|one time hydrocolloid dressing application
214986611|NCT06939036|DRUG|225Ac-SSO110 + SoC|Dose Level -2-7
215089442|NCT02559661|OTHER|Training on a virtual simulator in eye surgery|
215089443|NCT02845778|DRUG|Melatonin|Each sachet contains 0.5 g
215089444|NCT00755469|PROCEDURE|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
215089445|NCT03205904|DIETARY_SUPPLEMENT|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
215089446|NCT02654418|PROCEDURE|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
215089447|NCT00566865|DRUG|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
215089448|NCT00566865|DRUG|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
214373131|NCT07138040|BEHAVIORAL|Stage 2 High Touch Intervention|Stage 2 HTI: consists of personalized mobile-friendly dashboard containing the WI letters, their treatment summary, survivorship care plan, and a growing discover section with helpful tailored resources. They will also receive four to six text messages per week with personalized messages related to their chosen health goal, personal barriers to attending cancer-related follow-up care, treatment-related risks, information about scheduling their long-term follow-up appointments, health self-management, and fun texts consisting of celebrity quotes, memes, and altruistic messages.
214373132|NCT07121712|DEVICE|Mapsd Continuous Theta Burst Stimulation|A non-invasive brain stimulation technique using a MagStim Rapid2 stimulator with a 70mm air-cooled figure-of-eight coil. The stimulation target is the left auditory association cortex (MNI: -62, -40, 10), located using a Brainsight neuronavigation system. The cTBS protocol consists of 3-pulse 50 Hz bursts repeated at a 5 Hz frequency for a total of 600 pulses, delivered at 100% of the individual's resting motor threshold (RMT).
214494948|NCT04755920|DRUG|SGM-101|Fluorescence-guided surgery
214494949|NCT04793100|OTHER|Ophthalmologic exam at inclusion and 12 months after CRVO|"As part of routine care : OCT-B (Optical coherence tomography-B), OCT-angiography (Optical coherence tomography and fluorescein angiography after pupillary dilatation (at inclusion only)~Added by the study :~* Assessment of best corrected visual acuity in letters read and validated using the ETDRS scale ;~* The shooting of a 10 second infrared movie by the Heidelberg Spectralis device centered on the head of the optic nerve (at inclusion only)~* A measurement of the eye tension with an air tonometer (at inclusion only)~* A blood pressure measurement (diastolic and systolic) and pulse measurement (at inclusion only)~* A color retinophotography (Optos) with autofluorescence images~* A color Doppler ultrasound of the optic nerve of both eyes will be performed, for patients treated at the Foundation A de Rothschild Hospital only."
214494950|NCT04793100|DRUG|Treatment standardization with aflibercept|For patients requiring intravitreal injection
214494951|NCT06463977|OTHER|Survey|The study consisted of a 3 × 3 online factorial experiment employing a survey instrument hosted via Qualtrics presenting describing three patient vignettes. The three patient vignettes varied by various clinical characteristics including age, gender, performance status, smoking history, extent of disease, symptoms and molecular status. Each patient had advanced non-small cell lung cancer (aNSCLC). Each vignette had two parts: Part 1 described the case history for one of the three patients, after which prognostic estimates and medical decision-making was assessed (i.e. 1, 2, 3). Part 2 immediately followed and described the same vignette from the same patient with added information from a hypothetical ML predictive algorithm (i.e. A, B, C). The order of the vignettes in each survey was randomized with regard to presentation strategies for the ML risk predictions, so that there were 6 versions of the survey to which each participant was randomized.
214494952|NCT06623305|DEVICE|Photobiomodulation|Light therapy will be administered using the cluster probe on the external cheeks bilaterally and intraorally using the lollipop probe for patients ≥7 years of age. Patients \&lt; 7 years of age will not receive intraoral treatment with the lollipop. Instead, they will be asked to open their mouth while the covered cluster probe is held externally to treat their intraoral membranes. Each treatment (both external cheeks and intraoral buccal region) will be administered over 1 min with a Modulation Frequency 2.5Hz, Skin Conduction nS 001, and Beam Power mW 000, for a total treatment time of 3 minutes.
214494953|NCT03956628|BEHAVIORAL|stay safe program|Prevention consist of 5-6 lessons having topics about learning safety skills which includes identifying touch, safe and unsafe environment/events, bullying, the good or bad secrets and strangers.
214494954|NCT01208116|OTHER|Cardiovascular events|"* Coronary intervention~* Infarction~* Congestive heart failure~* Stroke~* Cardiac death"
214494955|NCT01913314|DRUG|[^14C]-LY2835219|Administered as oral solution
214986612|NCT06939036|DRUG|Atezolizumab|Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)
214986613|NCT06939036|DRUG|Durvalumab|Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)
214986614|NCT06939036|DRUG|Avelumab|Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
214986615|NCT06939036|DRUG|Pembrolizumab|Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
214986616|NCT06939036|DRUG|Retifanlimab|Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
215089449|NCT01887119|DRUG|Eplerenone|
215089450|NCT01887119|OTHER|Placebo|Eplerenone-matched placebo
215089451|NCT00200538|DRUG|memantine|
215089452|NCT04861246|DEVICE|Laser|The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.
215089453|NCT04861246|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.
214986617|NCT06943859|DRUG|Treatment with Ketamine|Participants will receive four doses of ketamine spaced 1-6 days apart of 0.75 mg/kg intramuscular ketamine (n=25) for two weeks (first ketamine session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.
215089454|NCT04861246|DEVICE|VISIA®|The device is skin analysis system and will be used to obtain before and after images of laser treatment.
214683576|NCT05203302|OTHER|Electric-only spectral resolution|Aim 1- Spectral resolution will be tested using frequency allocations consisting of the full default clinical range as well as the subject's clinical frequency allocation if they differ. For Hybrid electrode users in which electrode contacts are closer in proximity in the cochlea, maps with a frequency allocation of 938-7938 Hz will also be tested in that it will closely approximate the frequency spacing of a Nucleus Contour Advance electrode array. Spectral resolution will be measured with three repetitions of the SMRT and one repetition of the QSMD test. Testing will be presented at 60 dB SPL in the soundfield with the acoustic ear plugged and muffed.
214683577|NCT01270646|DEVICE|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|"Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping."
214683578|NCT03919253|COMBINATION_PRODUCT|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
214373133|NCT07121712|DEVICE|Sham Navigated Continuous Theta Burst Stimulation|A placebo procedure using an inert sham coil that is identical in appearance and sound to the active coil but does not deliver a significant magnetic field to the cortex. All other aspects of the procedure, including neuronavigation, coil placement, duration, and sound, are identical to the active intervention to maintain the blind.
214373134|NCT07122843|DEVICE|VR Guided Meditation|Patients will wear a VR headset for approximately 15 minutes. The headset fully covers the eyes, immersing users in a calming, 3D virtual environment. Once the headset is on, patients will engage in a guided meditation experience, set in a nature-themed scene of their choice; options include a lake, beach, mountains, desert, forest, space, and more. An AI-powered guide will lead the meditation, offering real-time, personalized support based on the patient's age and the pain-related information provided during the hospital intake process. The AI is designed to promote relaxation by helping patients focus, breathe deeply, and feel more at ease. The intervention will be standardized for all participants, with each receiving the same duration of exposure in the VR headset and access to an identical selection of nature scenes. The patients will fill our pre and post intervention pain and anxiety surveys. The pre and post surveys will take between 5-10 minutes each to complete.
214373135|NCT07038538|BEHAVIORAL|Evidence-based gastric placement|Establish an enteral nutrition management team and develop standardized procedures through a quality improvement project. Conduct a 3-month quality improvement initiative, during which regular training sessions will be provided to nurses on gastrointestinal tube placement and maintenance. These training sessions will include various formats such as lectures, group discussions, operational demonstrations, and scenario simulations, along with regular reviews of practical issues.
214373136|NCT06705270|BEHAVIORAL|Response-focused education|Once participants recover from sedation, they will receive education that is focused on their response to treatment.
214373137|NCT06705270|BEHAVIORAL|Diagnosis-focused education|Once participants recover from sedation, they will be provided education that is focused on their diagnosis of major depressive disorder.
214494956|NCT00359658|DRUG|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
214494957|NCT00359658|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
214683579|NCT00739297|DRUG|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
214494958|NCT00359658|DRUG|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
214494959|NCT05743205|BEHAVIORAL|voluntary consultative wellness session|Professional wellness counseling sessions provided to health care professionals through voluntary enrollment. Consultative sessions will conducted throughout the course of 1 year and number of subsequent sessions will be determined by the participant.
214494960|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 1 for 32 weeks、level 2 for 20 weeks
214494961|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 2
214494962|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 3
214494963|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 4
214494964|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks、HRS9531 injection level 2 for 20 weeks
214494965|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks、HRS9531 injection level 2 for 20 weeks
214494966|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks、HRS9531 injection level 2 for 20 weeks
214494967|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks、HRS9531 injection level 2 for 20 weeks
214494968|NCT00859781|DRUG|177Lu-J591|177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
214494969|NCT00859781|DRUG|Ketoconazole|Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
214494970|NCT00859781|DRUG|Hydrocortisone|Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
214683580|NCT00739297|DRUG|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
214683581|NCT06401655|BEHAVIORAL|Financial Coaching for People living with Acquired Brain Injury (FC-ABI)|This is an individualized, in-person 10-session financial coaching intervention program. Each session is 45-minutes. In total, participants will be asked to participate in up to 7 hours and 30 minutes of intervention time with a trained Occupational Therapist. Each session will happen 1-1.5 weeks apart and the financial coaching program will last over 3-4 months. The financial coaching sessions will only be offered in-person (at MBIA Winnipeg location, in their home, at the University of Manitoba/Banntyne Campus, or other community locations acceptable/consented by the participant).
214373138|NCT06880770|DRUG|Plozasiran|ARO-APOC3 injection
214373139|NCT06880770|DRUG|Placebo|sterile normal saline (0.9% NaCl)
214683582|NCT05579093|COMBINATION_PRODUCT|Cognitive test + Pupillary measure|"Patients will be put into a quiet room with a computer and a webcam for a five minute assessment with the NeuroTrack™ testing. Study personnel will stay in the room, and be available for answering questions about using the online testing tool.~After Neurotrack, pupillary responses will be recorded with the pupillometer with the PLR -3000TM. In brief, an eye cup attached to a pupillometer will be placed over one eye to allow measurement of the pupillary response to light. Once the eye cup is properly positioned, the reading takes approximately 5 seconds, after which time the eye cup will be removed. The reading will then be taken in the contralateral eye."
214683583|NCT04933279|DIETARY_SUPPLEMENT|iodine-containg spareribs soup|administrated a 150 ml - 200 ml of iodine-containg spareribs soup delivering ≈ 600 µg or 1200 µg iodine
214373140|NCT06726200|DRUG|Buprenorphine + naloxone (Suboxone)|Participants randomized to sublingual buprenorphine naloxone will initiate treatment based on clinical guidelines/standard of care
214683584|NCT04933279|DIETARY_SUPPLEMENT|intrinsic iodine in natural kelp|administrated 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine). The natural kelp will be approximately produced in an experimental barn feeding supplementary iodine to reach a final iodine intake of ≈ 600 µg or 1200 µg. The iodine intake of natural kelp will be adjusted to the required dose by determing iodine content in the natural kelp.
214373141|NCT06726200|DRUG|Buprenorphine Injection|Participants randomized to injectable buprenorphine naloxone will receive a 300mg injection after receiving/tolerating a single 4/1 mg sublingual buprenorphine/naloxone dose
214373142|NCT07046572|DRUG|Methoxyflurane - Penthrox|3ml of Methoxyflurane via a Penthrox inhaler
214683585|NCT02005601|DRUG|Placebo|Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
214683586|NCT02005601|DRUG|Duloxetine 60mg|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
214373143|NCT07046572|OTHER|Placebo Penthrox inhaler|3ml of normal saline via an identical placebo Penthrox inhaler
214373144|NCT07044544|DRUG|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
214373145|NCT07044544|DRUG|Decitabine|Decitabine is a hypomethylating agent.
214373146|NCT07044544|DRUG|Venetoclax|Venetoclax is a selective inhibitor of BCL-2 protein.
214494971|NCT00859781|DRUG|111In-J591|111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
214494972|NCT01219790|RADIATION|external radiotherapy|All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
214494973|NCT01219790|DRUG|Acide zoledronic|The administration of zoledronic acid as defined under the Authorisation on the Market.
214494974|NCT06696599|PROCEDURE|Serum and corporal irisin|measure serum and corporal irisin
214494975|NCT06698692|DRUG|Trilaciclib Injection [Cosela]|Trilaciclib Combined chemoradiotherapy
214494976|NCT06698848|DRUG|ketamin|Participants in this study will have been diagnosed with major depressive episode (MDE) and have not received any psychiatric treatment for at least 2 weeks (5 weeks if on fluoxetine).Patients will receive intravenous ketamine as the only study drug treatment for the 2 weeks of the study. Magnetic Resonance Imaging (MRI) will be used to measure effects of ketamine on brain structure, function and chemistry, in addition to a soft-nasal brushing procedure to obtain olfactory sensory neurons which will provide the ability to profile in vivo how neurons may react to KET treatment in depressed patients.
214494977|NCT06798025|PROCEDURE|Punctal dilation|Patients were treated with punctal dilatation only.
214494978|NCT06798025|DRUG|Punctal dilation and topical medication|Patients were treated with a combination of punctal dilation and topical medication in the form of preservative-free steroid eye drops based on dexamethasone sodium phosphate (0.1%) and preservative-free artificial tears based on sodium hyaluronate, polyethylene, and propylene Glycol.
214494979|NCT06798025|DRUG|Triamcinolone acetonide|Patients were treated with a peri-punctual injection of Triamcinolone acetonide.
214494980|NCT05966064|DRUG|Denosumab 120 Mg/1.7 Ml Inj|Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label
214494981|NCT05966064|DRUG|Placebo|placebo randomized at baseline and after 3 months
214494982|NCT06698588|DIETARY_SUPPLEMENT|Omega 3 Fish Oil supplements|Wileys Easy Swallow Mini Softgel capsules, dose 3 caps/day, providing 945mg/day long-chain omega-3 (540mg EPA, 405mg DHA).
214494983|NCT06698588|DIETARY_SUPPLEMENT|Placebo|Placebo: high-oleic sunflower oil (which broadly matches the overall fatty acid composition of typical UK diet), matched with active treatment for appearance and taste.
214373147|NCT06886477|OTHER|Mediterranean Diet|Mediterranean Diet foods will be provided for 4 weeks.
214373148|NCT06886477|OTHER|Usual Diet|Participants will consume their typical at home-diet.
214373149|NCT05019248|BIOLOGICAL|Most recent vaccine to seasonal influenza|Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).
214373150|NCT03881696|DRUG|Omalizumab|Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
214494984|NCT06879067|DRUG|Placebo|Placebo nasal spray
214494985|NCT06879067|DRUG|Foralumab Nasal|foralumab nasal spray
214373151|NCT03881696|DRUG|Placebo for Omalizumab|Placebo contains the same ingredients as the omalizumab formulation, excluding omalizumab. Placebo will be supplied in pre-filled syringes (PFS). PFS of placebo will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
214373152|NCT03881696|DRUG|Multi-Allergen Oral Immunotherapy|"Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours).~A prescription for each participant for the appropriate dose of each of the allergens will be prepared. The pharmacist will compound the appropriate allergens and dispense the Multi-allergen OIT dose in a blinded (masked) fashion. The Clinical Research Unit (CRU) staff will administer food flour to the participant orally in an age-appropriate food vehicle (e.g., applesauce, pudding, etc.). Dosage will be administered according to the study protocol."
214683587|NCT01623817|DRUG|Vancomycin HCL|"Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.~Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day."
214683588|NCT03014219|DRUG|Only 1 arm: treatment with MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
214683589|NCT01337011|OTHER|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
214683590|NCT02549911|OTHER|HIPEC,Chemotherapy AND surgery|"1. HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~2. chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~3. surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~4. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
214683591|NCT00375882|PROCEDURE|hypothermia|
214683592|NCT00375882|PROCEDURE|cochlear implantation with mild hypothermia|
214373153|NCT03881696|DRUG|Placebo for Multi-Allergen Oral Immunotherapy|Oat flour will be used for placebo for Multi-allergen OIT. Route: by mouth/oral. Dosage will be administered according to the study protocol.
214683593|NCT03885739|OTHER|Continuous Pericapsular Nerve Group block|Continuous Pericapsular Nerve Group block to standardize the approach. Injections were performed using a curvilinear low-frequency ultrasound probe (3.5- to 5-MHz). The lateral border of iliopsoas tendon in an oblique axial plane at level of iliopectineal eminence provides target for needle placement. Toggling the transducer was necessary to optimize visualization of the iliopsoas tendon secondary to anisotropy. Injections were performed using an 18-gauge Tuohy needle under sterile conditions. Then, 10 mL 0.25% bupivacaine was administered and a 20-G polyamide catheter (connect to a filter) was advanced into the space. The end point of the catheter placement was the direct visualization of microbubbles in a peritendinous distribution using a bolus of agitated saline applied through threaded catheter connected to not purged filter. After catheter placement patients received a 0.1% bupivacaine continuous infusion at a constant rate.
214986618|NCT06943859|DRUG|Treatment with Active Placebo|Participants will receive four doses of an active placebo (diphenhydramine 50 mg) (n=25) spaced 1-6 days apart for two weeks (first placebo session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.
214986619|NCT06943963|BEHAVIORAL|Self Stigma Tailored Cognitive Behavioral Therapy on Gambling Disorder|"The Self Stigma Tailored Cognitive Behavioral Therapy for Gambling Disorder (SSCBT) is a novel intervention designed specifically for this study and has not been previously used or named in existing literature. This 4-session protocol can be integrated into any part of GD treatment. Each session was accompanied by materials specifically designed for that session's content, and assignments related to the session's topics were given at the end of each session.~Session 1: Gambling Disorder from a bio-psycho-social perspective, stigma and self-stigma, CBT introduction, cognitive-behavioral model of self-stigmatization, impact of emotions and cognitive distortions.~S. 2: Self-stigmatizing thoughts and behaviors, identifying automatic thoughts with cognitive techniques, cognitive awareness, and restructuring with evidence examination.~S. 3: Aligning behaviors with values, cognitive restructuring, behavior change, and self-awareness.~S. 4: Prevention strategies, relapse prevention planning."
214373154|NCT03881696|OTHER|Double-Blind Placebo-Controlled Food Challenge Based Treatment|"Each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods. A treatment plan will include instructions for one of the following:~* Long-term follow-up with dietary consumption of a food; or~* Long-term follow-up with avoidance of a food; or~* Rescue OIT for a food. The treatment plan for each food may change depending on a participant's response to prescribed treatment over time."
214986620|NCT06943963|DRUG|standart pharmacotherapy|All participants continued to receive standard pharmacotherapy from their respective psychiatrists.
214986621|NCT06943963|BEHAVIORAL|motivational intervention|All participants continued to receive the standard motivational interviewing intervention for addiction from their psychiatrist.
214986622|NCT06949774|BEHAVIORAL|Daily Text Messages|Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.
214986623|NCT06949774|BEHAVIORAL|Incentivization based on timely ART adherence|Participants will be eligible to (draw a prize in monthly prize group) or get a monthly prize (monthly escalated group) if they take their medication within +/-one hour of the stated existing routine to which pill-taking is anchored on at least 80% of days for 3-months.
214986624|NCT07150884|DIETARY_SUPPLEMENT|Lactase|The lactase drops that will be used in the study will be Delictase®, which is a dietary supplement that helps the proper digestion of lactose through its breakdown. Delictase® lactase drops offer an exogenous source of the lactase enzyme, which is essential for the proper absorption and digestion of lactose, can be administered from birth, mixed into the administered milk and contain high levels of lactase (\>3,000 ALU\*). The supply of Delictase® lactase preparations will be carried out by Galenic Pharmacy, every 2 months at the study site.
214986625|NCT07155096|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS): Participants will each receive Default Mode Network-targeted continuous theta burst stimulation (cTBS) administered at 100% Active Motor Threshold
214986626|NCT07157176|BEHAVIORAL|Daily 3-Minute Laughter Practice (Laughie Prescription)|"The intervention will consist of 3-minutes of laughter (joyful and natural laughter is recommended) per day. Each day participants will laugh for one minute in a group (virtual and/or actual) guided by a professional laughter practitioner who is not going to be involved in the analysis of the data. That laughter will be recorded. The recording (the Laughie) will then be prescribed for participants to laugh with (with others - family, friends, colleagues, or alone) twice a day. This will result in 3 minutes of laughter per day (the first in a group, the second two prompted by the Laughie)"
214986627|NCT07156760|DIAGNOSTIC_TEST|Ultrasound diagnostics|Non-invasive ultrasound evaluation of the upper limb on the hemiplegic side (Ekipomed Portable Ultrasound) to determine its pathological morphology (thickness, fiber orientation, and echogenicity) using the modified Heckmatt scale. This procedure will be performed by a physician who is an expert in muscle ultrasound.
214986628|NCT07168252|DRUG|Rocuronium dosing|Rocuronium doses of 0.6ng/kg, 1.2mg/kg, 1.6mg/kg and 2.0 mg/kg will be compared for onset speed of muscle relaxation and information on speed, cardiac output and patient body size entered into a computer model
214986629|NCT07169201|DIAGNOSTIC_TEST|Angiography based RWS and OCT based plaque characteristcis|Angiography based RWS and OCT based plaque characteristcis
214986630|NCT07169019|DRUG|Probiotics and methotrexate|weekly oral methotrexate 15-25 mg/week, along with an oral daily dose of probiotics.
214494986|NCT06829732|DEVICE|closed-loop oxygen control (CLOC)|HAMILTON-C6 (Hamilton Medical, Bonaduz, Switzerland) ventilators will be used. It allows for O2 Assist software, that will be installed on all C6 ventilators before the start of this study. Automatic Oxygen management sets the Oxygen control according to the patient's measured SpO2 and the operator-set SpO2 target range. The Oxygenation controller will be activated for 4h and adjusts the Oxygen according to patient's measured SpO2.
214986631|NCT07169019|DRUG|Methotrexate|weekly oral methotrexate 15-25 mg/week
214494987|NCT06829732|DEVICE|2. manual oxygen titration (MOT)|O2 will be manually set according to SpO2 target during a 4h period.
214494988|NCT05844982|DRUG|Faricimab|6.0 mg intravitreal injection at randomization and every 3 months
214494989|NCT05844982|DRUG|fluocinolone acetonide|0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
214494990|NCT06776939|DEVICE|Oxygen therapy|All patients are subject to both oxygen therapy groups in this randomized cross-over study. Study measurements are performed during several different disconnection sessions. Disconnection sessions can either be short (\<90 min) or long (12 hours). Both short and long disconnection sessions are performed twice; once with conventional oxygen, and once with high-flow tracheal oxygen as respiratory support.
214494991|NCT06850441|OTHER|Psychoeducation|"The education is a group psychoeducation. Education methods such as role-play, discussion, demonstration, and narration will be applied. The education will be held once a week and will be completed in 7 weeks.~Psychoeducation topics include adaptation to stigma in type 1 diabetes, coping, diabetes management, social life, self-esteem, roles in life and impact on life. Concepts such as stigma, blame, judgment, discrimination, shame and stereotyped thoughts will be included."
214494992|NCT06738225|DIAGNOSTIC_TEST|certain serum MicroRNA biomarkers (miR-15b and miR-21)|miR-15b and miR-21 as diagnostic biomarkers of colorectal cancer
214494993|NCT06759922|DRUG|Tab Metformin + Tab Glimepiride|Tab Metformin 500mg+ Tab Glimepiride 2mg (FDC) once per orally for 90 days.
214494994|NCT06759922|DRUG|Tab Metformin + Tab Empagliflozin|Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) once per orally for 90 days.
214494995|NCT06759922|DRUG|Tab Metformin +Tab Sitagliptin|Tab Metformin 500mg+Tab Sitagliptin 50mg (FDC) once per orally for 90 days.
214494996|NCT06759922|DRUG|Tab Metformin + Tab Empagliflozin + Tab Sitagliptin|Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) + Tab Sitagliptin 50mg once per orally for 90 days.
214683594|NCT06536985|BEHAVIORAL|treatment group|Researchers will collaborate with participants to develop personalized intervention plans, which include physical exercise, oral function training, basic dietary guidance, and detailed oral health knowledge directly related to oral health behaviors. To facilitate better communication and management, a WeChat group will be created to encourage participants to share their daily exercise achievements. In the first week, face-to-face oral function training sessions will be organized for the intervention group at the nursing home activity center. Concurrently, once a week, the intervention group will gather at the nursing home activity center to practice together using illustrated videos. On Wednesdays, educational articles and videos about oral health are sent via text message. On Fridays, a group communication activity is organized to enhance their social connections. Additionally, we will guide elderly participants to master essential internet skills, enabling them to use smartphones to
214683595|NCT06536985|BEHAVIORAL|Contral group|Participants in the control group will receive general lifestyle advice via text message once or twice a week.They will not participate in the intervention\&#39;s fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group\&#39;s complaints or questions will always be answered with basic health information and suggestions. Researchers won\&#39;t ask for individual advice or comments from other professionals.
214683596|NCT02583789|DRUG|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
214373155|NCT07064330|DRUG|Cemiplimab|350 mg IV every 3 weeks as per standard of care. Patients are observed prospectively for biomarkers of response and toxicity during cemiplimab treatment.
214373156|NCT07072728|DRUG|Psilocybin therapy|Following a screening period, eligible participants will undergo one cycle of psilocybin-assisted psychotherapy (PAP). Non-responders at Week 10 who continue to meet eligibility criteria will be offered a second PAP cycle at the 25 mg PEX010 dose. A maximum of two PAP cycles may be given. Long-term follow-up will include a visit at Month 3 following the final PAP cycle.
214373157|NCT06773013|DEVICE|Acoustic Resonance (Sound) Therapy|Sonu consists of an acoustic Vibrational Headband worn circumferentially at the level of the forehead; and a Smartphone App, paired to the Headband. The App determines acoustic resonant frequencies of the subject's nasal cavity (using the facial image) and delivers treatment through bone conduction transducers in the headband
215089455|NCT02258555|DRUG|GS-9901|GS-9901 tablets administered orally
215089456|NCT04239183|DEVICE|Stomatherapy|Demonstrate improvement of quality of life (difference of at least 5 points in the StomaQoL questionnaire (21)) among descending colostomy patients, establishing the following comparisons.
215089457|NCT03110445|BIOLOGICAL|rVV-740CTA|non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
215089458|NCT01083498|DEVICE|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
215089459|NCT03781219|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
215089460|NCT03781219|DRUG|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
214373158|NCT06680037|DRUG|Azercabtagene zapreleucel (azer-cel)|IV infusion
214373159|NCT07165054|OTHER|atheroma plaque|Before the endarterectomy procedure, samples will be collected for study from some of the atheroma plaques routinely taken for pathology from patients.
214373160|NCT07165054|OTHER|Dental plaque|Subgingival plaque samples will be collected from patients before the endarterectomy procedure.
214373161|NCT07165626|DEVICE|Subtreshold micropulse laser therapy|Laser-treated group will receive additional subthreshold micropulse laser therapy (SMLT) 1 month after pars plana vitrectomy (PPV), using a 577 nm solid-state yellow diode laser applied to the macular area (thirty 5 × 5 spot sizes of 160 µm, zero-spot spacing, including the fovea; fixed power 250 mW; exposure time 200 ms; micropulse mode, 5% duty cycle). Control group (nonlaser group) will not receive additional laser treatment.
214373162|NCT07165626|PROCEDURE|Pars plana vitrectomy|Both groups will undergo pars plana vitrectomy (PPV) with epiretinal membrane (ERM) and internal limiting membrane (ILM) peeling prior to allocation to study arms.
214373163|NCT07165717|OTHER|No Intervention: Observational Cohort|Obsercational study
214373164|NCT07166367|DRUG|ASLAN001|400mg of Oral ASLAN001 is administered twice daily, every day of each 21-day cycle
215089461|NCT03159364|BIOLOGICAL|pathogen-specific CTLs|Patients will receive approximately 1x10\^5\~1x10\^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
214373165|NCT07166367|DRUG|Capecitabine|1000mg/m\^2 of Oral Capecitabine is administered twice daily, on Days 1-14 of a 21-day cycle
214373166|NCT07164300|DRUG|Tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h|Group 1: administration of tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h
214373167|NCT07164300|DRUG|Tranexamic acid at a dose of 20 mg/kg|Group 2: administration of tranexamic acid at a dose of 20 mg/kg
214373168|NCT07164300|DRUG|Tranexamic acid at a dose of 30 mg/kg|Group 3: administration of tranexamic acid at a dose of 30 mg/kg
214373169|NCT07166003|PROCEDURE|Pneumonectomy|Patients will receive pneumonectomy after neoadjuvant treatment
214373170|NCT07166003|PROCEDURE|lobectomy|Patients will receive lobectomy after neoadjuvant immunotherapy.
214373171|NCT07166003|RADIATION|radiotherapy|Patients will receive radiotherapy after neoadjuvant immunotherapy.
214373172|NCT07166003|DRUG|Anti-Tumor Drugs|Patients will receive anti-tumor drugs.
214495004|NCT06817122|BEHAVIORAL|Let's Talk Tech|Let's Talk Tech is a self-administered dyadic education and communication tool delivered as a web application to support shared decision making about technology use.
214495005|NCT05963165|BEHAVIORAL|Non-phonatory exercises|Muscle exercises that favor glottic adduction without vocal emissions
214495006|NCT06777927|OTHER|Exercise|The participants would be playing exergames using XBOX-360 Kinect. Multiple games would be selected for the participants to play. The player would be upgraded to next levels of games after completing the initial levels.
214495007|NCT06777927|OTHER|Exercise|The subjects would be doing treadmill training within moderate intensity target heart rate.
214495008|NCT06777927|OTHER|No intervention|The subjects would not be given any intervention and would be used as controls.
214495009|NCT06745596|PROCEDURE|cataract surgery 1|Cataract with limited anterior pars plana vitrectomy
214495010|NCT06745596|PROCEDURE|cataract surgery 2|cataract without limited anterior pars plana vitrectomy
214495011|NCT06750705|OTHER|PechaKucha|The PechaKucha format consists of 20 slides, each displayed for 20 seconds, focusing on vital signs measurement skills. The method emphasizes a fast-paced, engaging, and visual learning experience designed to enhance retention and improve students' practical knowledge and skills in measuring vital signs.
214495012|NCT06750705|OTHER|PowerPoint|The PowerPoint presentation will cover the same vital signs measurement content but in a more conventional, linear format. The intervention will aim to reinforce students' understanding of vital signs through text and images, with a slower pace compared to the PechaKucha method.
214495013|NCT06754748|OTHER|Caffeinated coffee|11 g caffeinated coffee made with 200 ml water was given to participants.
214495014|NCT06754748|OTHER|Decaffeinated coffee|11 g decaffeinated coffee made with 200 ml water was given to participants.
214495015|NCT06754748|OTHER|Water|200 ml water was given to participants.
214495016|NCT04057820|OTHER|Finnegan Neonatal Abstinence Scoring Tool|The FNAST is a scoring system used in neonatal units to initiate and guide therapy in infants of opiate-dependent mothers.
214495017|NCT04057820|OTHER|Eat, Sleep, Console (ESC) care tool|The ESC care approach emphasizes parental involvement, simplifies the assessment of infants with NOWS and focuses interventions on non-pharmacologic therapies.
214683597|NCT02583789|DRUG|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
214683598|NCT06224894|OTHER|Music Therapy|Music Therapy
214683599|NCT06224894|OTHER|antiemetic treatment|antiemetic treatment
214683600|NCT02041351|DRUG|Docetaxel|evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
214683601|NCT02401555|DEVICE|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
214683602|NCT00420394|PROCEDURE|Chemotherapy|
214683603|NCT00420394|PROCEDURE|surgery|
214683604|NCT00420394|PROCEDURE|radiotherapy|
214683605|NCT01933191|BEHAVIORAL|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
214683606|NCT01933191|BEHAVIORAL|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
214683607|NCT00860340|DRUG|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
214373173|NCT07166510|OTHER|Yoga and meditation|For 12 months, with no restrictions or imposed frequency, as often as the participant feels the need. They can take individual or group video-guided 15-minute breaks to do tailored yoga exercises targeting areas affected by repetitive movements, fatigue, and stress (hands, wrists, shoulders, and back), or mindfulness meditation sessions focused on managing fatigue, transitioning at the end of a shift, and post-shock relaxation.
214373174|NCT07166796|DRUG|singe dose 15mg|succesfule screened subject, take single dose of 15mg Tolvaptan tablet with no feeding.
214373175|NCT07166796|DRUG|single dose 30mg|succesfule screened subject, take single dose of 30mg Tolvaptan tablet with no feeding.
214373176|NCT07166796|DRUG|single dose 60mg|succesfule screened subject, take single dose of 60mg Tolvaptan tablet with no feeding.
214373177|NCT07166796|DRUG|single dose 120mg|succesfule screened subject, take single dose of 120mg Tolvaptan tablet with no feeding.
214373178|NCT07166796|DRUG|multi dose 30mg|radomize 24 healthy adult male to 2 groups, 12 subjects each. One group take 30mg Tolvaptan. First day, with no feeding, take single 30mg dose, then start from day 3rd, take medication for 7 days. 8 days treatment in total.
214373179|NCT07166796|DRUG|multi dose 60mg|radomize 24 healthy adult male to 2 groups, 12 subjects each. One group take 60mg Tolvaptan. First day, with no feeding, take single 60mg dose, then start from day 3rd, take medication for 7 days. 8 days treatment in total.
214373180|NCT02582346|PROCEDURE|MRI acquisition - no contrast agent|No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
214373181|NCT06426017|OTHER|High Protein Low Calorie Dietary Intervention|High Protein Diet: Diet consisting of 40-60% total energy from proteins, \<20% total energy from carbohydrates and \<30% total energy from fats.
214683608|NCT01882998|BEHAVIORAL|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
214683609|NCT02946879|BIOLOGICAL|AAV OPTIRPE65|comparison of different doses of AAV RPE65
214683610|NCT06484530|DRUG|N acetyl cysteine|1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.
214683611|NCT05545267|PROCEDURE|Angioplasties|Transluminal angioplastie
214986632|NCT07168629|BEHAVIORAL|Community health worker delivered outreach, shared decision-making, tobacco treatment, and navigation|The CHW will perform: 1) patient outreach 2) patient-centered shared-decision making, 3) smoking cessation counseling, and 4) navigation of logistical barriers
214986633|NCT07168629|OTHER|Enhanced Usual Care|After randomization, the control group will receive the same mailed LCS educational materials as the intervention group and encouraged to discuss screening with their PCP, the typical pathway through which patients enter the LCS program.
215089462|NCT05586698|PROCEDURE|Auricular acupressure|We conducted auricular acupressure at zero acupoints on the left ear with Vaccaria ear seed (Group A) or removed seed (Group B) in 20 minutes, with 2 times of auricular acupressure. The stimulation was performed for 30 seconds each time, with two pressure movements per second, resulting in a total of 60 pressure movements per stimulation.
214683612|NCT00088582|DRUG|Pasireotide (SOM230), Octreotide (Sandostatin)|
214683613|NCT06114953|DRUG|Mizoribine|Mizoribine+glucocorticoid+tacrolimus after kidney transplantation
214683614|NCT06114953|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation
214683615|NCT00694512|DIETARY_SUPPLEMENT|Low fat diet|20% fat diet
214683616|NCT00694512|DIETARY_SUPPLEMENT|High fat diet|40% fat diet
214683617|NCT00694512|DIETARY_SUPPLEMENT|MCT diet|Medium chain triglyceride diet
214683618|NCT02749721|DRUG|vortioxetine|Open-label vortioxetine
214683619|NCT00002887|DRUG|cisplatin|
214683620|NCT00002887|DRUG|etoposide|
214683621|NCT00002887|DRUG|hydroxyurea|
214683622|NCT00002887|DRUG|vinblastine sulfate|
214683623|NCT00002887|DRUG|vindesine|
214683624|NCT00002887|DRUG|vinorelbine tartrate|
214683625|NCT00002887|PROCEDURE|drug resistance inhibition treatment|
214683626|NCT00806780|PROCEDURE|on table cholangiography|x-ray imaging of common bile duct
214683627|NCT05986539|OTHER|Observational|This study is only observational in nature and will not include an intervention.
214683628|NCT02137772|DRUG|Letermovir|Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
214683629|NCT02137772|DRUG|Placebo|Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
214683630|NCT01146067|DRUG|Rivastigmine|Rivastigmine capsules 1.5 mg
214373182|NCT04794426|DRUG|Silver diamine fluoride|Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)
214373183|NCT04794426|DEVICE|Hall Technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
214373184|NCT04082884|BEHAVIORAL|Very Low Carbohydrate Diet|A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 11% of total daily caloric intake.
214373185|NCT05801731|OTHER|Intervention|"The low GI snack is a biscuit with a Glycemic Index of 23.8 ± 3.3. The low GI snack contains plain flour, fibre, plant-based protein, vegetable oil and a low GI sweetener.~The interventional snacks (control, experimental) are matched for caloric content."
214373186|NCT05801731|OTHER|Control|The normal GI snack is a biscuit with a Glycemic Index of 54.4 ± 6.3. The control snack is formulated using basic ingredients for a biscuit recipe consisting of all-purpose flour, butter, sugar, vanilla flavour, baking soda, egg and salt.
214495018|NCT06809348|BEHAVIORAL|PRECISE|"PRECISE includes aspects of several evidence-based approaches, such as Safety Planning and DBT to manage and reduce suicide risk. During the initial visit, staff train participants how to complete EMAs. Participants then complete two weeks of five-times per day EMAs regarding their emotions, emotion regulation strategies as well as SITBs. Following an initial learning period, participant data is analyzed via GIMME to determine the within-person correlates of SITBs. Data is processed through a real-time pre-programmed data cleaning and analysis script. Coaches then teach a selection of skills in collaboration with the client."
214495019|NCT04517435|DRUG|ME-401|ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
214495020|NCT04517435|DRUG|Rituximab|"375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines."
214495021|NCT04517435|DRUG|Cyclophosphamide|750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
214495022|NCT04517435|DRUG|Doxorubicin|50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
214683631|NCT05416931|DRUG|ACD440 Gel 14mg/g|Topical application to painful area
214683632|NCT05416931|DRUG|Placebo Gel|Topical application to painful area
214683633|NCT02607969|OTHER|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
215089463|NCT01710527|DRUG|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
214683634|NCT02053220|BIOLOGICAL|Colo-Ad1|Oncolytic virus
214683635|NCT00326105|DRUG|Quetiapine fumarate|
214373187|NCT04709172|DRUG|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
214373188|NCT00002420|DRUG|Emivirine|
214373189|NCT00002420|DRUG|Hydroxyurea|
214373190|NCT00002420|DRUG|Delavirdine mesylate|
214495023|NCT04517435|DRUG|Vincristine|1.4 mg/m2 (max 2 mg) IV Vincristine
214495024|NCT04517435|DRUG|Prednisone|100mg PO Prednisone Days 1-5 of 21-day cycle
214495025|NCT06754306|OTHER|normal diet (100% energy)|Daily intake of 100% energy requirements, adjusted individually based on each participant's basal metabolic rate (BMR).
214495026|NCT06754306|OTHER|16+8 time-restricted eating group (100% energy)|Participants will consume 100% energy within an 8-hour eating window and fast for the remaining 16 hours.
214495027|NCT06754306|OTHER|16+8 time-restricted eating group (75% energy)|Participants will consume 75% of their energy requirements within the 8-hour eating window.
214495028|NCT06754306|OTHER|Alternate-day fasting group (75% energy)|"Participants alternate between feeding days (125% energy requirements) and fasting days (25% energy requirements)."
214495029|NCT06754306|OTHER|5+2 intermittent fasting group (75% energy)|Participants consume 95% energy requirements for 5 consecutive days and 25% energy requirements for 2 fasting days.
214495030|NCT06754306|OTHER|Low-calorie diet group (75% energy)|Participants will reduce daily caloric intake to 75% of energy requirements, consumed evenly across three meals.
214495031|NCT06754306|OTHER|Very low-calorie diet group (45% energy)|Participants will reduce daily caloric intake to 45% of energy requirements (\~800 kcal/day)
214495032|NCT06753773|DEVICE|Repeated Low-Level Red-Light|All participants will receive a video guide of the Repeated Low-Level Red-Light device. Eligible subjects will receive daily treatment for 14 days, with each treatment lasting for 3 minutes twice a day, with a minimal interval of 4 hours.
214683636|NCT04841382|OTHER|Supporting information.|CardioSolv Software System is a software-based medical device meant which creates a patient-specific 3D heart model that provides physiologic information.
214683637|NCT04611295|PROCEDURE|Teleneurological evaluation and support|The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
214683638|NCT04848116|DRUG|Nivolumab|Nivolumab is an investigational drug in this study.
214683639|NCT04848116|DRUG|HuMax-IL8|HuMax-IL8 is an investigational drug in this study.
215089464|NCT01710527|DRUG|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
214373191|NCT00002420|DRUG|Stavudine|
214373192|NCT00002420|DRUG|Didanosine|
214373193|NCT02742298|DEVICE|Muscle ultrasound|Ultrasound images of limb muscles will be collected.
214495033|NCT06755398|OTHER|Exercise|During the exercises based on the protocol developed by the Royal Dutch Society for Physical Therapy (KNGF) following anterior cruciate ligament (ACL) surgery, additional cognitive tasks will be assigned to the patients.
214495034|NCT06755398|OTHER|Exercise|The protocol developed by the Royal Dutch Society for Physical Therapy (KNGF) will be applied following anterior cruciate ligament (ACL) surgery.
214683640|NCT04962321|BEHAVIORAL|Wellness Education|Psychoeducation on relationships between mood, anxiety, eating, and exercise behaviors. One one-hour session each week for 8 weeks.
214683641|NCT00002118|DRUG|Zalcitabine|
214683642|NCT02564159|OTHER|Measure of quadriceps thickness with ultrasonography and albumin/prealbumin levels|"* Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ;~* Biospecimen collection: Blood samples (prealbumin levels, C-reactive protein, Interleukin-1, Interleukin-6, TNF-alpha and PATROL test™)collection of albumin and prealbumin levels"
214683643|NCT01912040|DRUG|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
214683644|NCT00984230|OTHER|BSF|feeding amount according to individual baby need
214683645|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
214683646|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
214373194|NCT02742298|OTHER|Electrical Impedance Myography|A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
214495035|NCT06818149|DIAGNOSTIC_TEST|Biomarker Analysis for Severity Assessment|Blood samples will be collected at baseline and at follow-up time points (3 days, 7 days, and before discharge). Traditional myocardial injury biomarkers, iron metabolism-related biomarkers, and immunological biomarkers will be tested.
214495036|NCT06868745|DRUG|Experimental: melatonin treatment group|Each participant received melatonin 5 mg for a period of 30 days
214495037|NCT06868745|DRUG|Placebo comparator: placebo treatment group|Each participant received placebo for a period of 30 days
214495038|NCT04968964|DEVICE|DiviTum® TKa assay|-Determines serum enzymatic activity of TK1
214683647|NCT03940573|DEVICE|Eclipse Insert|Rectal Control System.
214683648|NCT06220344|BIOLOGICAL|Honey Dressing|Honey Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
214683649|NCT06220344|DRUG|Iodine Dressing|Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
214683650|NCT01347567|OTHER|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
214683651|NCT01253460|DRUG|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
214683652|NCT01253460|DRUG|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
214683653|NCT01253460|DRUG|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
214373195|NCT00813852|BEHAVIORAL|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
214495039|NCT04968964|OTHER|Study Care Plans|-Study Care Plans will be completed prior to and post release of serum DiviTum® TKa value
214495040|NCT06793345|OTHER|Moderate intensity intermittent walking training|The intensity of the training is 60 to 80% of 6MWTdistance.
214495041|NCT06767826|BEHAVIORAL|Salutogenesis Models|On the basis of the Salutogenesis Model, this study is based on the development of individuals' internal and external resources for game addictions and strengthening their sense of integrity. It has been determined that digital game addiction and problematic internet use in adolescents form the basis of seven problems. These problems have been identified as mental health, vision, pain, sleep and rest patterns, nutrition, social contact and physical activity. Encouraging behavioral changes regarding internet use and teaching adolescents how to deal with these problems becomes a necessity in today's technology. In the literature, counseling has been provided for families and adolescents to prevent digital game addiction in adolescents.
214683654|NCT06274346|OTHER|Multiangular Isometric exercise|already were described in arm descriptions
214683655|NCT00754429|DRUG|losartan|losartan 50mg qd for 30 weeks.
214683656|NCT00754429|DRUG|amlodipine|amlodipine 5 mg q.d for 30 weeks.
214683657|NCT02856789|OTHER|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
214683658|NCT02856789|OTHER|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
214683659|NCT02856789|OTHER|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
214683660|NCT02856789|OTHER|Specialized hemostasis tests|Coagulation factors
214683661|NCT01494961|BEHAVIORAL|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
214373196|NCT06785181|DIAGNOSTIC_TEST|Active standing|a session at resting state in supine position, a session during autonomic challenge obtained via active standing evoking reflex sympathetic activation, and a session of emotional elicitation via the administration of videos
214495042|NCT05337826|DEVICE|Continuous Glucose Monitor|Participants will enroll in a series of remote educational visits conducted by CDCES to assess readiness and barriers to CGM initiation and utilization, with the goal to sustain use of CGM Technology over time in older populations on complex insulin regimen.
214495043|NCT06844799|DRUG|HS-20137|HS-20137 200mg injection at week 0, 4, 8 and then every 8 or 12 weeks.
215089465|NCT00579046|DRUG|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections"
215089466|NCT01707589|DEVICE|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
214683662|NCT03553238|DRUG|Chidamide|Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
215089467|NCT02995044|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)
215089468|NCT02995044|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
215089469|NCT02124772|DRUG|Trametinib|Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
215089470|NCT02124772|DRUG|Dabrafenib|Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
215089471|NCT03467672|OTHER|Diagnosis of bacterial infection|use of eosinopenia in the diagnosis of bacterial infection
215089472|NCT06135363|DRUG|SC1011|SC1011 tablet
215089473|NCT06135363|DRUG|Placebo tablet|SC1011-matching placebo tablet
215089474|NCT05530889|DEVICE|TEST Lens|ACUVUE® Theravision® with Ketotifen
215089475|NCT05530889|DEVICE|CONTROL Lens|1-DAY ACUVUE® MOIST.
215089476|NCT02718014|OTHER|scaling and root planing (srp)|
214495044|NCT06844799|DRUG|Placebo&HS-20137|Placebo injection at week 0, 4, 8, and then HS-20137 200mg injection at week 16, 20, 24, and every 8 or 12 weeks thereafter
214495045|NCT06837610|PROCEDURE|Inverted T trabeculectomy|"* Fornix-based conjunctival incision along with the opening of Tenon's capsule and dissection along the area of the potential bleb.~* A 4 x 4 mm limbal-based scleral flap was fashioned using a crescent knife. Dissection was carried out up to the clear cornea.~* A longitudinal tunnel was made through the scleral bed, starting from the limbus and extending 1 mm beyond the end of the scleral flap. Afterwards, the horizontal limb of the Inverted T was created. (Figure 2)~* A paracentesis was made using an MVR blade.~* The anterior chamber was entered using an MVR blade. Kelly's punch was used to excise 1.5 x 1.5 mm of scleral bed at the limbus at the base of the vertical limb of the figure (T), and then a peripheral iridectomy was performed using Vannas scissors.~* The scleral flap was then closed using two fixed 10/0 Nylon sutures, one at each corner."
214495046|NCT06846177|OTHER|Graded Activity Training|"4 types of progressive activities of 2 hour session two times/week with resting periods of 30 mins. Activities consist of treadmill walk ,walk on floor, core muscles exercises ,home tasks .~To ensure the proper heart rate and loads during the exercises, measurements of individual heart rate and muscle strength are taken during the first session (baseline) with HR Tracking portable device and also during the session to continuously monitor HR of the Patient. To withdraw or adjust the training intensity for each patient Borg's Scale of Perceived Exertion is used throughout the session for monitoring Training intensity of endurance, muscle training, individual's effort and exertion level."
214683663|NCT03553238|DRUG|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
214683664|NCT03553238|DRUG|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
214683665|NCT03553238|DRUG|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
214683666|NCT03553238|DRUG|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
214683667|NCT03553238|DRUG|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
214683668|NCT03553238|DRUG|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
215089477|NCT02609945|DRUG|zolmitriptan|Oral Tablet and Nasal Spray
215089478|NCT02609945|DRUG|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
214373197|NCT02014818|DEVICE|CoCr-EES|
214373198|NCT06448338|BEHAVIORAL|MyDiaMate|MyDiaMate program
214373199|NCT03200106|DEVICE|Alfapump|Alfapump implant
214373200|NCT01649232|DEVICE|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
215089479|NCT01617447|DRUG|Placebo of Aripiprazole|administered orally once daily
214683669|NCT03553238|DRUG|Methotrexate|Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
214683670|NCT03553238|DRUG|6-Mercaptopurine|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
214683671|NCT03553238|DRUG|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
214683672|NCT03553238|DRUG|Cytarabine|AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
214683673|NCT03553238|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
214373201|NCT01927679|DRUG|Vitamin E|
214683674|NCT03553238|PROCEDURE|Intrathecal injection|Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
214373202|NCT01927679|DRUG|Eucerin|Control
214495047|NCT06846177|OTHER|Task-Oriented Training|4 task oriented physical fitness activities which include walk on floor, walk on inclined surface using treadmill ,sit to stand , stair climbing and descending for duration of 2 hour session with frequent breaks. Each treatment session began with 10 minutes of warm-up exercise, which consisted of passive stretching of the calf muscles, hamstring, and hip adductors. The level of difficulty and frequency for each task were gradually increased during the 6 weeks with the patients consent.10 minutes of cool down at the end of each treatment session.
214495048|NCT06729255|DEVICE|EpiZact-assisted epidural placement|The standard epidural kit used with the EpiZact device to place a midline epidural using the landmark technique between the L2 and L5 vertebral bodies. The patient's back will be sterilized with a 2% chlorhexidine/70% isopropyl alcohol applicator. The epidural will be placed with a 17-gauge 3.5-inch Tuohy needle. Once the Tuohy needle is appreciated to be engaged in ligament the EpiZact device will be filled with sterile and attached to the Tuohy via a Luer connector. The green button on the EpiZact device will then be pressed to prime the device. The EpiZact device and Tuohy needle will be advanced as a unit in continuous fashion or with intermittent advancement. Upon sensing a loss of resistance, the EpiZact device will provide a visual and tactile signal, halting needle advancement and signaling that the epidural catheter should be threaded through the Tuohy needle.
214495049|NCT06850311|DRUG|herbal ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 4 weeks
214495050|NCT06850311|DRUG|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 4 weeks.
214683675|NCT03553238|RADIATION|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
214683676|NCT03553238|GENETIC|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
214683677|NCT03553238|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
214683678|NCT03553238|DIAGNOSTIC_TEST|Flow-MRD|Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
214373203|NCT03517592|OTHER|EMDR|The EMDR SUD Protocol consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol and a further specific protocol for SUD that is focused on the concept of addiction memory.
214495051|NCT04110340|DRUG|Ciprofloxacin|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
214683679|NCT03553238|DIAGNOSTIC_TEST|FISH|FISH will be performed in PDT-ETP-ALL for bone marrow samples.
214683680|NCT03553238|DIAGNOSTIC_TEST|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.
214683681|NCT03553238|DIAGNOSTIC_TEST|Karyotyping|Karyotyping will be performed in PDT-ETP-ALL protocol.
214683682|NCT02644083|DRUG|Dimethyl fumarate|
214683683|NCT00443430|DRUG|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
214683684|NCT00443430|DRUG|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
214683685|NCT00898144|OTHER|Papanicolaou test|
214683686|NCT00898144|OTHER|laboratory biomarker analysis|
214683687|NCT03616769|DRUG|antiplatelet drugs ,statins ,antihypertensive drugs|According to the international guidelines, we treated patients who suffered from different disease.
214683688|NCT04954469|BIOLOGICAL|CoVAC-1|Peptide vaccination should be started as soon as possible after the screening visit.
214683689|NCT01300780|DRUG|Etoricoxib|Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
214683690|NCT01300780|OTHER|Placebo|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
214683691|NCT00418262|DRUG|Atomoxetine|Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
214683692|NCT01818557|BEHAVIORAL|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
215089480|NCT01617447|DRUG|Aripiprazole|Flexibly dose administered orally once daily
215089481|NCT00005053|DRUG|glufosfamide|
215089482|NCT02986113|BEHAVIORAL|MAPS tailored multimedia patient activation program|
215089483|NCT02986113|BEHAVIORAL|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
215089484|NCT02986113|BEHAVIORAL|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
215089485|NCT02986113|BEHAVIORAL|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
214373204|NCT03517592|OTHER|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
214373205|NCT06294119|PROCEDURE|Major Cardiac surgery|From a clinical perspective, MANCAVA will especially target neuro-cardiovascular health and mood disorders such as depression
214373206|NCT01713725|BIOLOGICAL|Omalizumab|"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
214373207|NCT01713725|BIOLOGICAL|Placebo|"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
214373208|NCT03114202|OTHER|intensive nutritional counseling|Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.
214495052|NCT04110340|DRUG|Streptomycin|"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
214495053|NCT04110340|DRUG|Gentamicin|"Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."
214495054|NCT04194424|OTHER|Multidisciplinary weight loss program|Diet and behavioral therapy,and supervised exercise sessions
214683693|NCT03488940|DEVICE|24-hours group|"Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
214495055|NCT04194424|OTHER|Standard Care|General lifestyle tips
214495056|NCT04194424|DRUG|Metformin Hcl 850Mg Tab|1 tablet, twice daily
214495057|NCT02235857|DEVICE|LIPOSORBER® LA-15 System|LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
214495058|NCT06846801|PROCEDURE|Balloon Dilation Under Portable X-ray System|"* All the esophageal dilation procedures will be performed using rigid hypopharyngoscope and / or oesophagoscope with endotracheal intubation under general anesthesia by experienced surgical and anesthesia team.~* The rigid hypopharyngoscope / oesophagoscope (Storz, germany) will be introduced through the mouth to whole through examination to localize the site of the stenosis then a contrast material will be injected via the endoscope and picture taken with X-DR portable x-ray system.~* After that a guide wire 0.035mm will be passed through the endoscope till the stomach. The guide wire site will be confirmed by with X-DR portable x-ray system and then a suitable size balloon catheter will be passed over the guide wire (Boston Scientific, Cork, Ireland), then the balloon catheter will be advanced through the stricture confirmed by taking a photo by the x-ray system. The balloon will be inflated with radiopaque contrast solution using EncoreTM 26 inflation device."
214495059|NCT06850142|PROCEDURE|Discopexy to external ear cartilage|stabilizing the articular disc within the temporomandibular joint (TMJ) in patients experiencing TMJ disorders (TMD) to external ear cartilage
214683694|NCT03488940|DEVICE|16-hours group|"Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
215089486|NCT00280345|PROCEDURE|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
215089487|NCT00280345|PROCEDURE|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
215089488|NCT00280345|PROCEDURE|Cataract surgery|Removal of the cataract from the eye
215089489|NCT01075971|DRUG|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
214373209|NCT03114202|OTHER|Standard care|Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
215089490|NCT01075971|DRUG|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
215089491|NCT02995551|PROCEDURE|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
215089492|NCT02995551|BEHAVIORAL|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
215089493|NCT02713529|BIOLOGICAL|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
215089494|NCT00780273|DEVICE|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
214495060|NCT06850142|PROCEDURE|Discopexy to temporal fascia|stabilizing the articular disc within the temporomandibular joint (TMJ) in patients experiencing TMJ disorders (TMD) to temporal fascia
214495061|NCT06844786|OTHER|Physical activity program|SCORE! Club is offered twice a week for enrolled participants. Modules will include soccer, arts and health, Sportball, and nature-based activities.
214373210|NCT02331602|DRUG|Rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
214373211|NCT02331602|DRUG|Dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
214373212|NCT03083938|PROCEDURE|Omental Roll-up|Using omentum roll-up pancreato-jejunal anastomosis
214495062|NCT06844786|OTHER|Navigation|Participants will have access to a navigator from the study team who will help them access resources relating to recreation and physical activity in their communities. For example, the navigator will help direct families with low income to the recreation assistance program if they are interested in such a service.
214495063|NCT06844786|OTHER|Health promotion|Health promotion messaging will be provided to participants via social media and other physical methods (i.e., flyers). Topics will include diet, sleep, physical activity, and other related items.
214495064|NCT06849518|DIAGNOSTIC_TEST|Circulogene liquid biopsy testing|A Circulogene liquid biopsy testing for plasma NGS ctDNA and plasma cfRNA PD-L1 expression.
214495065|NCT03936790|OTHER|Ropivacaine|In case of successful spinal anaesthesia, the dose of spinally administered ropivacaine will decrease by 0.375 mg for the next participant.In case of unsuccessful spinal anaesthesia, the dose of spinally administered ropivacaine will increase by 0.375 mg for the next participant.
214495066|NCT03936790|OTHER|Fentanyl|A fix dose of fentanyl (15 mcg) will be co-administered spinally to all participants.
214495067|NCT06447272|OTHER|sham inspiratory muscle training|This group will receive conventional treatment + sham IMT (with 10% MIP as the training intensity)
214495068|NCT06447272|OTHER|target inspiratory muscle training|This group will receive conventional treatment + target IMT (the IMT identified as optimal intensity based on the results of our undergoing study).
214495069|NCT01173341|DIAGNOSTIC_TEST|Echocardiography|Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
214495070|NCT01173341|OTHER|Blood Collection|Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
214495071|NCT01173341|OTHER|Symptoms Questionnaire|Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
214495072|NCT05537142|DRUG|BV100|Rifabutin for Infusion
215089495|NCT00780273|DEVICE|Biomet 3i Prevail Implants|
215089496|NCT05565768|DRUG|HZN-457|HZN-457 will be given in one subcutaneous administration
215089497|NCT05565768|DRUG|Placebo|Placebo will be given in one subcutaneous administration
215089498|NCT02367391|BEHAVIORAL|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
214373213|NCT03430193|OTHER|FIRM|"FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward.~PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided."
214373214|NCT03430193|OTHER|Conventional rehabilitation|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
214373215|NCT05118633|BEHAVIORAL|Device and app system designed for participant to self-administer Habit Reversal Training and Stimulus Control|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training and Stimulus Control. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania, as well as receive stimulus control reminders.
214373216|NCT05118633|BEHAVIORAL|Reminder bracelet and journaling app control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull. They will also be instructed to journal in an app on their phone several times per day.
214373217|NCT02347657|DRUG|VX-661 Plus Ivacaftor Combination|FDC tablet, oral use
214373218|NCT02347657|DRUG|Ivacaftor|Tablet, oral use
214373219|NCT02347657|DRUG|VX-661 Plus Ivacaftor Combination Placebo|FDC tablet, oral use
214373220|NCT02347657|DRUG|Ivacaftor placebo|Tablet, oral use
214373221|NCT03417947|DIETARY_SUPPLEMENT|Vitamin D bolus|One single oral liquid vitamin D3 supplement of 300 000 IU
214373222|NCT03417947|DIETARY_SUPPLEMENT|Placebo|Placebo identical in taste and appearance to the vitamin D bolus
214373223|NCT01036308|DIETARY_SUPPLEMENT|pure fibre-product|The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
214495073|NCT05376462|DIAGNOSTIC_TEST|Quantra System with the QStat Cartridge|Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.
214495074|NCT06384976|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
214495075|NCT06384976|DRUG|Standard lymphodepletion regimen|CYC/FLU
214495076|NCT06384976|DRUG|Anti-CD20 mAB|Anti-CD20 mAB
214495077|NCT06405113|COMBINATION_PRODUCT|Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy|Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab
214495078|NCT05958940|PROCEDURE|Bright Light Therapy|In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
214495079|NCT05958940|DEVICE|Blue Light Blocking Glasses|Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
214495080|NCT06850740|DRUG|Ondansetron 8mg|Patients will receive 8 mg of ondansetron (ZOFATRONE®, 8 mg/4 mL, EVA Pharma, Egypt)
214495081|NCT06850740|DRUG|Normal Saline|Patients will be managed by administering 100 ml of normal saline solution as placebo
214495082|NCT03875144|PROCEDURE|PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks
214495083|NCT03875144|DRUG|Cisplatin|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
214495084|NCT03875144|DRUG|Pemetrexed|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
214373224|NCT01036308|DIETARY_SUPPLEMENT|reference fibre|The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
214373225|NCT01271348|DRUG|Etoricoxib|Etoricoxib film tablet, 90 mg, q.d.
214373226|NCT01271348|DRUG|placebo|Placebo tablet, q.d.
214373227|NCT02127086|OTHER|Intervention Group|The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
214373228|NCT06030401|DEVICE|Transthoracic Ultrasound|Sonar of The Chest
214373229|NCT04078737|DRUG|Ticagrelor and Aspirin|"Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg"
214373230|NCT04078737|DRUG|Clopidogrel and Aspirin|"Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day"
214373231|NCT05358678|DIAGNOSTIC_TEST|cs niche group|"A niche is formally defined by the European Niche Taskforce as an indentation of the uterine myometrium of at least 2 mm at the site of the CS scars. A niche can be sub classified as follows:~1. Simple niche~2. Simple niche with one branch~3. Complex niche (with more than one branch).~The following measurements will be taken:~* Length.~* Depth.~* Width.~* RMT (residual myometrium thickness).~* AMT (adjacent myometrium thickness).~* Distance between the niche and the VV (vesico-vaginal) fold.~* Distance between the niche and the external os. We will also comment on the position of the uterus (AVF or RVF), presence or absence of intra cavitary fluid and its thickness."
214373232|NCT00873236|BIOLOGICAL|bevacizumab|Given IV
214373233|NCT00873236|BIOLOGICAL|recombinant interferon alpha-2a|Given SC
214495085|NCT06811220|DRUG|Hespiridin and Diosmin|Daflon® (50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet)
214373234|NCT00291902|DRUG|SB-681323|
214373235|NCT05865613|DEVICE|Pulsed electromagnetic field|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
214683695|NCT03488940|DEVICE|intermittent group|"Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
214683696|NCT03731416|PROCEDURE|GBR by xenograft and autogenous bone|Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
214373236|NCT06474897|OTHER|Ozone therapy|Ozone therapy will be practiced to study group. Inject 10 ml of ozone gas (O2-O3) at a concentration of 10 µg/ml 3 times at one week intervals. All injections will be performed by the same experienced specialist doctor.
214683697|NCT03855917|DRUG|Sofosbuvir 400mg [Sovaldi]|Four weeks.
214373237|NCT06474897|OTHER|Mulligan Mobilization|Mulligan mobilization will be practiced to control group. Mobilizations will be performed once a week for 3 consecutive weeks. The first one is a seated position with the patient's arm in approximately 90° abduction. The patient will be asked to abduct the arm and at the same time the physiotherapist will perform posterio/lateral gliding of the shoulder head with the left hand.
214495086|NCT02415127|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
214495087|NCT02415127|DRUG|Placebo|The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
214495088|NCT06811974|PROCEDURE|Impacted lower wisdom tooth extraction|One of the most frequently performed procedures in maxillofacial surgery is impacted wisdom tooth surgery. An impacted tooth is defined as a tooth that is not fully or partially erupted and is blocked from eruption by another tooth, bone, or soft tissue, and thus has a low probability of eruption. The tooth is blocked from eruption by adjacent hard or soft tissue, including bone or dense soft tissue. The most common complications after impacted wisdom tooth surgery are pain, edema, trismus, and alveolar osteitis.
214683698|NCT03855917|DRUG|Glecaprevir/pibrentasvir (300mg/120mg)|Four weeks.
214683699|NCT03519308|DRUG|Nivolumab|Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3
214683700|NCT03519308|DRUG|Nab-Paclitaxel|Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
214683701|NCT03519308|DRUG|Gemcitabine|Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
214683702|NCT03519308|DRUG|Paricalcitol|Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
214373238|NCT02871960|PROCEDURE|Robotic and Laparoscopic Colectomy|
214683703|NCT00933335|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
214683704|NCT04196036|PROCEDURE|Day of vitrification|Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5
214683705|NCT02480075|OTHER|Observational|Observational Study only
214683706|NCT03568006|OTHER|Specific passive mobilization|Specific passive mobilizations for the shoulder
214683707|NCT03568006|OTHER|Standardized treatment (standard protocol)|Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene
214683708|NCT00739778|OTHER|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
214683709|NCT00739778|OTHER|food vehicle blank|water blank
214683710|NCT00739778|OTHER|food - sweetener, positive control|4.7% sucrose in water
214683711|NCT00739778|OTHER|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
214683712|NCT03688646|DIETARY_SUPPLEMENT|Intensive Nutrition Intervention|
214683713|NCT03065673|PROCEDURE|Potassium oxalate 5% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
214683714|NCT03065673|PROCEDURE|Placebo gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
214683715|NCT05754827|DIAGNOSTIC_TEST|RDW to platlet count ratio|RDW to platlet ratio will be measured for all patients and results will be compared between groups
215089499|NCT02367391|BEHAVIORAL|Control|Usual Care. All participants receive the active medication, Varenicline.
215089500|NCT05606991|OTHER|CPAP Withdrawal|Complete withdrawal of continuous positive airway pressure (CPAP) therapy for a 2-week period.
215089501|NCT04214431|BEHAVIORAL|Mindfulness-Based Childbirth Education|8-week mindfulness-based childbirth education
215089502|NCT00487123|DRUG|Valsartan+/- Hydrochlorothiazide|
215089503|NCT03504566|DRUG|Linagliptin|Linagliptin
215089504|NCT03504566|DRUG|Empagliflozin|Empagliflozin
215089505|NCT03504566|DRUG|Telmisartan|Telmisartan
215089506|NCT03504566|DRUG|Sulodexide|Sulodexide
214986634|NCT07167355|PROCEDURE|POEM|Children randomised to POEM arm will undergo a single session of POEM following an overnight fast. The procedure will be done in supine position under general anaesthesia. A gastroscope (Olympus GIF-HQ190) with a transparent tapered cap fit at its distal end will be used. A mucosal bleb will be created using a 21G sclerotherapy needle and a solution of saline with indigo-carmine dye. A posterior approach will be followed in all patients. A small mucosal incision (2-3mm) will be made using a needle knife and enlarged using an insulated tip knife (2-3cm). The submucosal tunned will then be entered and the submucosal fibres will be cleared using a triangular tip knife (TriangularTipKnife J, Olympus). Full thickness will be performed in all patients. Length of the myotomy will be \~3cm in the oesophagus and \~2cm in the cardia of the stomach. Minor bleeding will be controlled using coagulation forceps. Mucosal injury and resistance at the gastroesophageal junction will be examined. Mucosal i
215089507|NCT05497856|OTHER|Integrated neuromuscular inhibition technique|Ischemic compression will be applied for 90 seconds followed by the SCS technique with a reduction in pain of at least 70%. it will be held for 20-30 sec followed by the Muscle energy technique in which the isometric contraction will be held for 7-10 sec and then the stretch will be held for 30 sec. This will be repeated 5 times per session with a 30-second rest interval in between each repetition Session will be held 3 times per week for 2 consecutive weeks
215089508|NCT05497856|OTHER|Myofascial Release|Deep sustained pressure on the trigger points will be applied with thumb in 5-7/10 pain tolerance and maintained for 60 seconds and then will be released in a vertical direction followed by stretch of the rhomboid muscle held for 30 sec. This Sustained manual pressure will be applied for 3 times each followed by a stretch per session with a 30 sec rest interval in between .Session will be held 3 times per week for 2 consecutive weeks.
214373239|NCT00704301|DRUG|Rivastigmine|Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
215089509|NCT02061046|DEVICE|CPAP therapy|8 weeks of CPAP therapy
215089510|NCT04418336|PROCEDURE|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
214373240|NCT00704301|DRUG|Placebo|Placebo, 2 times a day
214373241|NCT06569875|DEVICE|iCARE|iCARE is an internet-based cognitive behavioral therapy program designed for women experiencing symptoms of postpartum depression, including anxiety, irritability, and sadness. The program offers digital therapy through an online platform tailored to mothers with mild to moderate postpartum depression. The program consists of 7 modules, each with its own theme, incorporating cognitive behavioral therapy, a well-established therapeutic approach for depression. The content includes text, images, audio files, and short films, supplemented with small tasks to provide knowledge and tools to understand and manage one's situation. The treatment course is self-directed, allowing participants to engage with the content at their own pace and at times that are most convenient for them
214495089|NCT05085886|BEHAVIORAL|DepCare|Primary Care Provider (1) One-time presentation or video with education and motivational messaging around collaborative care, functionality of the DepCare patient tool and optimal management of depression and comorbid anxiety (2) Quality improvement/ implementation team meetings on optimizing mental health treatment in primary care and DepCare (i.e., multi-level, multi-component intervention) implementation (3) Automatically-generated decisional support on individual patient treatment preferences (i.e., for every patient who receives the DepCare patient tool) Patient: Tool comprised of enhanced depression and anxiety screening (includes option for voice-over questions, point-and-click responses), and for those who screen positive for depressive symptoms (with or without comorbid anxiety), diagnosis recognition support, psycho-education, videos promoting patient engagement in treatment, and personalized medication selection support.
214495090|NCT05085886|BEHAVIORAL|Enhanced Usual Care|Clinic-level (1) Quality Improvement Support and education around valid depression screening (2) Local technical support for mental health treatment optimization
214495091|NCT06593392|DRUG|Difelikefalin|The study includes a screening period of up to 4 weeks (including a 7-day run-in period during the week prior to enrolment), a study treatment period of 12 weeks, and a safety follow-up visit at 7 (up to 10) days after EoT. Total study duration for a single participant is up to 17 to 18 weeks.
214495092|NCT06740734|BEHAVIORAL|Stress ball|Sterile Stress ball for pregnant women during mediolateral episiotomy repair. Participants in the stress ball group will be asked to squeeze and loosen the stress ball in their hands.
214495093|NCT06740734|BEHAVIORAL|Expressive touch applications|During the mediolateral episiotomy repair, expressive touch will be applied to one hand of the mother by the researcher, lasting approximately 15-20 minutes
215089511|NCT05628051|PROCEDURE|ultrasonographic measurement of carotid artery corrected flow time (FTc)|Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 \~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+\[1.29× (HR-60)
215089512|NCT00979355|DEVICE|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
215089513|NCT02225912|OTHER|PrevinC|
215089514|NCT02225912|DRUG|placebo|
215089515|NCT00430001|DRUG|docetaxel|
215089516|NCT00430001|DRUG|vinorelbine|
215089517|NCT00430001|DRUG|trastuzumab|
215089518|NCT00024310|DIETARY_SUPPLEMENT|folic acid|
215089519|NCT00024310|DRUG|lometrexol|
215089520|NCT00024310|DRUG|paclitaxel|
214986635|NCT07167355|PROCEDURE|BALLOON DILATATION|"Children randomised to BD arm will undergo BD of 30mm (Rigiflex II, Achalasia balloon dilators, Boston Scientific) following an overnight fast. The balloon will be positioned at the gastroesophageal junction and inflated to a diameter of 30mm with a pressure of 5psi initially and gradually the pressure will be increased to a maximum of 15 psi till the disappearance of waist fluoroscopically. A note will be made at the pressure at which the waist disappears and will be maintained for 1 minute. One month after the initial session, if the Eckardt score \>3 or if the TBE shows a barium column of \>5cm at 5 minutes, a second session of BD will be done using a 35mm balloon.~These children will be kept nil per oral for 4 hours post procedure. They will be observed for signs of perforation (crepitus, hemodynamic instability, chest pain). If they are stable, a clear liquid (water) will be provided. If there is no pain, they will be discharged with an advise to follow soft diet for a day"
214986636|NCT07167485|OTHER|Assessment of sleep quality|Sleep quality will be assessed each night in intensive care using a Richards-Campbell sleep questionnaire and an intensive care sleep questionnaire, completed by the patient.
214986637|NCT07168200|DRUG|SHR-1316 Injection|SHR-1316 injection.
214986638|NCT07168200|DRUG|Cisplatin Injection|Cisplatin injection.
214986639|NCT07168200|DRUG|Carboplatin Injection|Carboplatin injection.
214373242|NCT04034394|OTHER|Electromoxibustion|Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
214373243|NCT04034394|OTHER|Knee health education|Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
214373244|NCT04412044|DRUG|Mepolizumab Injection [Nucala]|Patients receive monthly injection with 100 mg mepolizumab
214373245|NCT00236171|DRUG|Protopic, Advantan|
214373246|NCT00236171|PROCEDURE|Blood and Urine Test|
214373247|NCT00236171|PROCEDURE|coherence tomography|
214495094|NCT06745895|BEHAVIORAL|MATCHES|"Participants will be asked to complete a survey with specific topics including Hepatitis C (HCV) and Colorectal (CRC) knowledge and health beliefs, screening intentions and demographic characteristics.~Participants will be provided with education intervention materials (for example, a booklet) either in-person or via mail, access to free stool-based CRC screening, and access to free HCV screening.~Approximately 1-2 weeks after receiving the education materials, participants will be asked to complete a post-intervention survey about the same specific topics (for example, HCV and CRC knowledge, HCV and CRC health beliefs, HCV and CRC screening intentions, healthcare experiences, perceptions of the educational materials) over the phone with a trained study staff.~Participants with a positive HCV screening and/or CRC screening result will be navigated to follow-up care as needed."
214495095|NCT05308121|OTHER|Evaluation of biomechanics and viscoelastic properties of Achilles tendon|The biomechanical and viscoelastic properties of the Achilles tendon will be measured in the side lying position. Measurements will be taken from two different points with the ankle in the neutral position.
214495096|NCT05308121|OTHER|Evaluation of foot characteristics|The mobility of foot, morphological changes of foot and foot posture will be evaluated
214495097|NCT03291522|PROCEDURE|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
214495098|NCT06891339|OTHER|mobile application|The aim is to evaluate whether a patient-centered mobile application with smartphone-based systematic follow-up assessment during the perioperative period can improve surgery-related anxiety, complications, comfort, and patient satisfaction compared to standard care. This thesis will be one of the pioneering studies in this field.
214986640|NCT07168200|DRUG|Paclitaxel Injection|Paclitaxel injection.
214986641|NCT07168200|DRUG|SHR-1316 Placebo Injection|SHR-1316 placebo injection.
214986642|NCT07167004|BEHAVIORAL|Marketing Nudges Only|Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives
214683716|NCT06242340|OTHER|Preterm group bathing 24 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
214986643|NCT07167004|BEHAVIORAL|Marketing Nudges + Dynamically Adapted Financial Incentives|Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives, plus personalized financial incentives with individual incentive amounts optimized weekly based on prior whole grain purchasing behavior and engagement
215089521|NCT05666232|DIAGNOSTIC_TEST|renal resistive index and myocardial performance index|"Transthoracic echocardiography and transabdominal ultrasonography will be performed before induction of anesthesia, after termination of operation and before transmission to ICU and then daily for the early seven postoperative days.~RRI = (peak systolic velocity - end diastolic velocity) ∕ peak systolic velocity: Then, we will obtain the mean RRI from the above three measurements.~We will consider RRI ≥0.7 as abnormal and define it as subclinical AKI.~Myocardial performance index (using tissue doppler) =~(isovolumetric contraction time + isovolumetric relaxation time) / ejection time. We will consider MPI ≥0.4 as abnormal and define it as subclinical LV dysfunction."
214373248|NCT00621543|DEVICE|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
214373249|NCT02740322|PROCEDURE|Hum Test|The subject will be brought into an exam room. The subject will then be asked to hum for a few seconds in a low pitch. They will then be asked if the nose was heard more so in one ear compared to the other. The subject will then be asked to hum for a few seconds in a high pitch. They will then be asked again if the noise was heard more so in one ear compared to the other.
214373250|NCT02740322|PROCEDURE|Weber Test|Using a 512 Hz tuning fork, the tuning fork will be vibrated and placed on the subject's glabella (forehead landmark). The subject will then be asked if the vibration was heard more so in one ear compared to the other.
214373251|NCT02740322|DEVICE|Audiogram|A standard audiogram will be administered by an audiologist.
214373252|NCT00307749|DRUG|Placebo|once daily for 24 weeks
214373253|NCT00307749|DRUG|MCC-257|20mg, once daily for 24 weeks
214373254|NCT00307749|DRUG|MCC-257|40mg, once daily for 24 weeks
214373255|NCT00307749|DRUG|MCC-257|80mg, once daily for 24 weeks
214373256|NCT02146313|DRUG|DMUC4064A|Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
214373257|NCT02206217|DEVICE|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
214373258|NCT01567358|BIOLOGICAL|Infliximab|100mg/vial
214373259|NCT01567358|BIOLOGICAL|Infliximab|100mg/vial
214373260|NCT02709005|DRUG|5% Monolaurin Vaginal Gel|Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
214373261|NCT02709005|OTHER|Placebo|The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
214373262|NCT06346314|OTHER|Scapular retraction exercise|Participant lies prone with hands superior to the head on a treatment plinth and lifts their elbows 10 repetitions for three sets with 30 seconds of rest between each set.
214373263|NCT04307433|BEHAVIORAL|Storytelling narrative videos on tablets|The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.
214373264|NCT03532308|DRUG|Fermented Soy|Two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.
214373265|NCT03532308|OTHER|Placebo|A placebo compliment to the active intervention with identical packaging and labeling will be used.
214373266|NCT03720938|OTHER|Active Video Games|Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
214373267|NCT02767063|DRUG|Pioglitazone|PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade \>1 related AE.
214373268|NCT02767063|DRUG|Avelumab|10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
214373269|NCT06107595|BEHAVIORAL|Placebo|Participant take 1 dose placebo (odor or pill) on post-op day 0 (POD 0) and 3 placebo dose from POD 2 to POD 17
214495099|NCT06889792|OTHER|Theory of planned behaviour|This theory holds that an intention to engage in a health-related behaviour is determined by the proximal factors of attitudes, subjective norms, and perceived behavioural control. Attitudes represent individuals perceived likelihood of performing and appraisal of the consequences of performing a health-promoting behaviour. Subjective norms are the social pressure perceptions to either perform or not perform a health-promoting behaviour. Finally, perceived behavioural control is an individual's perception of control regarding performing the behaviour.
214373270|NCT01874457|BIOLOGICAL|MMR (Mumps, Measles and Rubella)|MMR (Mumps, Measles and Rubella)
214373271|NCT03960671|DRUG|Midazolam/diazepam/propofol|Therapeutic drug monitoring of anxiolytics
214373272|NCT01630720|DIETARY_SUPPLEMENT|vitamin C or vitamin D|vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
214373273|NCT04975022|DRUG|N11005|oral insulin N11005, 300IU, p.o.
214495100|NCT06889792|OTHER|Foot-in-the-door technique|The foot-in-the-door technique, which was introduced by Freeman and Fraser, emphasises the notion that individuals who initially comply with a small, easy request are more likely to later comply with a larger request. Compliance with the first request or target increases the individual's confidence and alters their self-perceived capability and willingness regarding further requests or targets. This technique can facilitate the recruitment process and enhance compliance.
214683717|NCT06242340|OTHER|Preterm group bathing 48 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
215089522|NCT04445623|DRUG|Prasugrel Hydrochloride 10 MG Oral Tablet|administration of prasugrel daily for 15 days
215089523|NCT04445623|DRUG|Placebo|administration of placebo daily for 15 days
214683718|NCT06242340|OTHER|Early term group bathing 24 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
214373274|NCT04975022|DRUG|Novolin R|reference preparation Novolin R, 0.1 IU/Kg, i.h.
214683719|NCT06242340|OTHER|Early term group bathing 48 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
214683720|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN0 breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy
214683721|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN+ breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy Lymph node region: 5 x 5.4Gy
214373275|NCT04193501|DRUG|Melatonin 3 mg|Melatonin dose: 3mg/OD Melatonin is a hormone made by the pineal gland; its biosynthesis is initiated by the uptake of the essential amino acid tryptophan and is an important inducer of sleep. Abnormality in melatonin has been shown in several studies on patients of IBS and functional constipation.
214373276|NCT04193501|OTHER|Placebo|Similar looking placebo
214683722|NCT00632034|OTHER|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
214683723|NCT04621123|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT plasma|Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
214683724|NCT04621123|OTHER|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
215089524|NCT05549310|DEVICE|CPAP|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
214373277|NCT05319106|OTHER|stem cell preparation combined with silver ion dressing|The dosage range of each cm2 ulcer wound is (1～5)×10\^6. The dosage of human umbilical cord mesenchymal stem cells for the second treatment is determined according to the severity of the ulcer. Each patient is treated for 2 consecutive times, and the interval between each treatment is 3 days.
214373278|NCT05319106|PROCEDURE|silver ion dressing|fter wound debridement, a silver ion dressing suitable for the size of the wound was cut and covered on the wound bed. Sterile gauze was covered on the silver ion dressing and fixed with adhesive tape.
214373279|NCT00206557|DRUG|Raloxifene|
214373280|NCT00206557|DRUG|Estradiol/dyhydroprogestrone|
214373281|NCT04293263|COMBINATION_PRODUCT|2gether app used by trained personal|"each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.~Musical partner - A person trained in the program's work plan, which includes contact with empathic listening and the use of a dedicated application developed for it. A musical partner will meet with the same elderly person throughout the study period.~Empathetic listening - a situation in which a person listens to music with another person, while the music enables contact and deepening the connection between people."
214373282|NCT03839654|DEVICE|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
214373283|NCT04012515|DEVICE|Electrode Pads|Participants wear six electrode pads in total; three different types of pad, worn in the same positions on both sides of the face. The pads on the left-hand side of the face are replaced daily, and those on the right-hand side are replaced every other day. The pads do not administer a medical treatment or perform any other active function. The purpose of the intervention is to determine which combination of pad and replacement regime maximises the tolerability of wear over a 30-day period.
214683725|NCT05941884|DIAGNOSTIC_TEST|Immunohistochemistry staining,|"Tissue samples:~* Histopathological examination: Hematoxylin and Eosin slides will be prepared and examined.~  * The only dependable criterion for the diagnosis of bilharzial infestation is the microscopic detection of Bilharzia ova in pathological sections.~ * Pathology (cystitis- cancer and its grade staging will be reported in accordance with the 2022 World Health Organization Classification of Tumors of the Urinary System (17).~* To quantify levels of Nuclear factor kappa B and protein kinase c α:~  * Immunohistochemistry according to the manufacturer's instructions."
214683726|NCT05941884|DIAGNOSTIC_TEST|microscopic examination of urine|"Urine samples:~* Mic roscopic examination (detection of S. haematobium egg - egg counting)~* Detection of HSP 70 Measurements: indirect ELISA will be used to quantify HSP concentrations in urine."
214373284|NCT00006422|PROCEDURE|current standard of care treatments|
214373285|NCT05160324|PROCEDURE|Removal of axillary lymph nodes.|Axillary dissection in patients with positive sentinel lymph node
214683727|NCT00002442|DRUG|Indinavir sulfate|
214683728|NCT00002442|DRUG|Nelfinavir mesylate|
214373286|NCT05160324|PROCEDURE|Preservation of axillary lymph nodes|Preservation of axillary lymph nodes in patients with positive sentinel lymph node
214373287|NCT05313386|DRUG|BXCL501|BXCL501 is given in a film form
214683729|NCT00002442|DRUG|Lamivudine|
214683730|NCT00002442|DRUG|Stavudine|
214683731|NCT03105154|OTHER|Prevena Dressing|Prevena dressing is applied on one groin
214683732|NCT03105154|OTHER|Conventional Dressing|Conventional dressing is applied on the contralateral groin
214683733|NCT05022004|DRUG|Brinzolamide ophthalmic suspension|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
214683734|NCT05022004|DRUG|Azopt®|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
214683735|NCT01461863|DIETARY_SUPPLEMENT|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
214683736|NCT01461863|DIETARY_SUPPLEMENT|multivitamin|Standard multivitamin
214683737|NCT02084134|DRUG|hydrocortisone|100mg at the time of surgery
214373288|NCT05313386|DRUG|Placebo film|Placebo is given in a film form
214373289|NCT01865305|DRUG|insulin degludec/insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
214373290|NCT01865305|DRUG|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
214495101|NCT06889792|OTHER|Self-determination theory|"According to self-determination theory, behavioural regulation is more autonomous when it is internalised, as opposed to being regulated by external factors. Compared with external regulation, autonomous regulation is associated with increased self-efficacy, greater behavioural persistence, longer-term behavioural changes and more positive health behaviour. Autonomy is another influential determinant of behaviour that is emphasised by freedom of choice. There is some evidence that people who have greater autonomy demonstrating greater competence and self-efficacy in achieving behavioural change compared with those with less autonomy. As a result, increased autonomy will facilitate a gradual change in risky behaviours.~Our intervention aims to first change the participants' attitudes and their subjective norms through risk communication. Using foot-in-the-door technique and self-determination theory, it will then increase participants' willingness to adopt a healthy lifestyle."
214495102|NCT06889792|OTHER|Follow-up booster intervention|Staff will send WhatsApp/WeChat messages approximately once a week to remind the participants to adhere to their desired health-related lifestyle for the first 6 months. In addition, during the first week, the RA will send participants a link via WhatsApp/WeChat to a 1-minute video developed by the research team comprising content relevant to their selected health-related lifestyle. Four separate 1-minute videos will be compiled, each focusing on a different healthy lifestyle. These videos will indicate the health hazards of continuing this health risk behaviour and the benefits of adopting a healthy lifestyle. Moreover, the RA will encourage the participants to watch the video and ask any questions regarding the video content via WhatsApp/WeChat.
214495103|NCT06889792|OTHER|Practical Resource Hub for Healthy Life leaflet|The participants will be provided a Practical Resource Hub for Healthy Life leaflet containing information on various applications, including (i) 'Move Your Body', (ii) 'Eat Healthy', (iii) 'Live Alcohol Free', and (iv) 'Stay Away from Tobacco', which were developed by the Hong Kong Department of Health
214495104|NCT06889792|OTHER|a brief intervention using the Ask, Warn, Advise, Refer and Do-it- again (AWARD) model|The participants will receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it- again (AWARD) model : (1) Ask about and assess health-risk behaviours; (2) Warn about the high morbidity and mortality risks associated with health-risk behaviours; (3) Advise on adopting healthy lifestyles to improve the participant's health; (4) Refer to hotline services, such as those for smoking cessation and alcohol treatment or the nearest district health centre to follow up their health status; and (5) Do it again if participants have not adopted a healthy lifestyle at follow-ups.
214495105|NCT06751160|OTHER|Dry Needling|"Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Dry Needling will be given to group A along with baseline treatment through following protocol:~Patient will be in prone lying. Sterilized disposable dry needles of 0.25\*60mm will be used. Dry needling will be performed on three points on Hamstring muscle for one minute each. We considered a line between ischial tuberosity and head of fibula to target long head of bicep femoris (60% of line) and short head of bicep femoris (30% of line). Semitendinosus and Semi Membranosus were targeted at a point of 60% of line from ischial tuberosity to medial epicondyl of femur.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks."
214683738|NCT02084134|DRUG|dexamethasone|0.5mg every 6 hours for a total of four doses
214683739|NCT02436486|DRUG|Placebo|Capsules, orally, single dose
214683740|NCT02436486|DRUG|ldalopirdine 120 mg|Two 60 mg encapsulated film-coated tablets, orally, single dose
214683741|NCT02436486|DRUG|Idalopirdine 360 mg|Four 90 mg encapsulated film-coated tablets, orally, single dose
214683742|NCT02436486|DRUG|Moxifloxacin 400 mg|Encapsulated tablets, orally, single dose
214683743|NCT02456116|DEVICE|acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
214683744|NCT02456116|DEVICE|sham acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
214683745|NCT02456116|OTHER|PCA/NSAID|standard boli of morphine by pressing a button of PCA
214683746|NCT02385461|DRUG|Low Molecular Weight Heparins (LMWHs)|
214683747|NCT05474040|DRUG|Morphine versus multimodal analgesia for post elective craniotomy pain|To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
214683748|NCT05544825|DIETARY_SUPPLEMENT|Ice plant group|Ice plant extract 2,000 mg/day for 12 weeks
214683749|NCT05544825|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
215089525|NCT05549310|DEVICE|high-flow nasal canula oxygen therapy|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
214373291|NCT01865305|DRUG|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
214373292|NCT01865305|DRUG|insulin degludec|Single dose administrated subcutaneously (s.c., under the skin).
214373293|NCT01865305|DRUG|insulin aspart|Single dose administrated subcutaneously (s.c., under the skin).
214373294|NCT01865305|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin) as comparator.
214373295|NCT01865305|DRUG|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
214373296|NCT01865305|DRUG|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
214373297|NCT01865305|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
214373298|NCT04850404|PROCEDURE|abdominal nerve block|All Patients of group A-M will be administered with rectus abdominis block combined with TAPB after anesthesia. Rocuronium was infused continuously (concentration: 1 mg/ml) when TOF recovered to 1. The starting rate was 0.3mg/kg/h, and the TOF count was maintained between 1\~3 (moderate NMB) and recorded during the operation. Whether and how to add rocuronium was based on TOF count and request of surgeons. When TOF Watch- SX showed 4 or ratio, the investigators increased the speed of rocuronium pump infusion and record the score at the time of shallow NMB. When the chief surgeon thought the vision could not satisfy the needs of the operation, rocuronium 0.1mg/kg in bolus was added as a rescue. Then, the pump speed was lowered or even decreased to 0 to make the TOF count recover to 1\~3 as soon as possible.
214373299|NCT03260530|OTHER|Locomotor evaluation|collection of parameters associated with walking and balance in patients with their usual prosthesis and then equipped with the new prosthesis
214373300|NCT03260530|OTHER|Questionnaires|Houghton's scale, PPA-LCI, ABC, QEP, SF-12, SAT-PRO, ESAT
214373301|NCT03715400|BEHAVIORAL|Positive Virtual Reality Training|Participants will undergo 7 45 minute sessions of positive virtual reality training over the course of four weeks. All assessments will be completed online at home following initial orientation to the program.
214373302|NCT04299516|PROCEDURE|Two-team simultaneous bilateral total knee arthroplasty|Bilateral total knee arthroplasty can be performed in three different ways: single-stage, two-team simultaneous bilateral total knee arthroplasty; single-stage, one-surgeon, and two-stage bilateral total knee arthroplasty. Two surgeons will operate simultaneously on one side for two-team SBA.
214373303|NCT04299516|PROCEDURE|Single-team simultaneous bilateral total knee arthroplasty|One surgeon will operate sequentially on both sides for one-surgeon SBA
214373304|NCT02346019|PROCEDURE|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
214373305|NCT00499863|DRUG|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
214683750|NCT04591314|BEHAVIORAL|Neurofeedback|The intervention by neurofeedback (NF) will consist in providing the subjects with a feedback on their EEG Theta / Beta activity in real time Each subject will perform 8 sessions of neurofeedback (1h30 / session, 40 min of effective training by neurofeedback) at an average rate of 1 to 2 sessions per week.
214683751|NCT05251935|OTHER|Foot Muscle Exercise Protocol|Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program
214683752|NCT05251935|COMBINATION_PRODUCT|Arch Support Insole and One Leg Balance Activities|Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
215089526|NCT02607540|OTHER|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
215089527|NCT02607540|OTHER|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
214683753|NCT02244359|BEHAVIORAL|Training|
214683754|NCT02244359|BEHAVIORAL|Usual care|
214683755|NCT04869956|OTHER|Dietary pattern : High-fiber diet rich in PUFA|High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
214683756|NCT04869956|OTHER|Dietary pattern: Standard diet|standard nutritional recommendations
214683757|NCT03262493|DEVICE|Interventional Group|Use of the feeding tube attachment device (FTAD).
214373306|NCT00499863|DRUG|Placebo|Placebo patch
214683758|NCT05518344|DEVICE|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."
214683759|NCT01283191|BEHAVIORAL|Behavioral Incentives|Vouchers for complying with target behavior of treadmill walking
214683760|NCT01283191|BEHAVIORAL|Education Control|Education class
214683761|NCT01512394|PROCEDURE|standard bowel prep|standard bowel prep
214683762|NCT01512394|PROCEDURE|no bowel prep|no bowel prep
214683763|NCT03395340|DRUG|Ruxolitinib 1.5% cream|Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
214683764|NCT03395340|DRUG|vehicle cream|Matching vehicle cream applied as a thin film
214373307|NCT03949790|PROCEDURE|ESPB and Intercostal nerve block|Erector spinae plane block + Intercostal nerve block
214373308|NCT03949790|PROCEDURE|Intercostal nerve block|Intercostal nerve block
214373309|NCT06484270|OTHER|Simulation based safety mobilization program|"Nurse participants experienced safe patient mobilization with a simulation-based learning method with a standardized patient for 4 weeks.~Patient participants were mobilized safely under the supervision of a nurse and the care results were measured."
214373310|NCT03184584|DRUG|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily
214683765|NCT04790006|DRUG|TG103|Administered SC
214683766|NCT04790006|DRUG|Placebo|Administered SC
214683767|NCT01293396|DRUG|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
214683768|NCT01293396|DRUG|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
214683769|NCT01293396|DRUG|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
214683770|NCT05399758|DEVICE|NOL monitor|NOL monitor data will be acquired, as well as clinical assessment of pain and fentanyl dosage.
215089528|NCT02607540|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
215089529|NCT02358044|DRUG|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
215089530|NCT02358044|BIOLOGICAL|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
215089531|NCT02358044|DRUG|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
215089532|NCT02358044|DRUG|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
214373311|NCT02121678|OTHER|Resistance training|"Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~* Week 0-4: 70-80 % of 1-RM~* Week 5-8: 75-86 % of 1-RM~* Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~* MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~* CIDP patients train knee (flexion/extension) and elbow (flexion/extension)"
214373312|NCT02121678|OTHER|Aerobic training|"Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data."
214373313|NCT04792125|BEHAVIORAL|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT)|"Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.~While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week."
214373314|NCT04792125|BEHAVIORAL|External electrical stimulation|Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.
214373315|NCT04792125|BEHAVIORAL|Pelvic floor muscle training (PFMT)|While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.
214373316|NCT02138643|PROCEDURE|Endoscopic surgery|These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
214683771|NCT01266798|BEHAVIORAL|Portal|"The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.~1. A checklist for critical assessment of health information~2. Access to research databases for health information and an introduction to research methods and principles of science~3. A checklist to the consultation"
214683772|NCT03059303|DRUG|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
214683773|NCT03059303|DRUG|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
214683774|NCT03059303|DRUG|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
215089533|NCT02761577|DRUG|Sodium bicarbonate|3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
215089534|NCT02761577|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
215089535|NCT00114023|DRUG|Imiquimod 5% cream|
214373317|NCT02138643|PROCEDURE|Laparoscopic surgery|These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
214373318|NCT00571701|DRUG|celebrex (celecoxib)|Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight \>25 kg
214373319|NCT00571701|DRUG|placebo|similar appearing capsules containing inert ingredients
214373320|NCT01247428|DEVICE|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
214373321|NCT01119430|DRUG|DU125530|20mg/twice a day
214373322|NCT01119430|DRUG|Placebo|Similar pill as active comparator twice a day
214373323|NCT01112228|PROCEDURE|Bariatric surgery|Bariatric surgery: Gastric bypass, Sleeve gastrectomy, or Gastric banding
214683775|NCT03059303|DRUG|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
214683776|NCT03059303|DRUG|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
214683777|NCT03059303|DRUG|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
214683778|NCT03059303|DRUG|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
214683779|NCT00493116|DRUG|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
214683780|NCT00493116|DRUG|methylprednisolone|dosage and frequency as per Biogen Idec protocol
215089536|NCT05492760|DEVICE|cryoballoon ablation|Patients with AF will accept cryoballoon ablation.
215089537|NCT03291262|OTHER|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
215089538|NCT01007422|BEHAVIORAL|telephone-based intervention|
215089539|NCT01007422|OTHER|communication intervention|
215089540|NCT01007422|OTHER|intervention by caregiver|
215089541|NCT01007422|OTHER|medical chart review|
215089542|NCT01007422|OTHER|survey administration|
215089543|NCT01007422|PROCEDURE|end-of-life treatment/management|
215089544|NCT01007422|PROCEDURE|pain therapy|
215089545|NCT01007422|PROCEDURE|psychosocial assessment and care|
214683781|NCT01641315|BIOLOGICAL|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
214373324|NCT05927974|DIAGNOSTIC_TEST|Passive testing|Passive testing includes baseline recordings or behavioral tasks without stimulation. Examples include language tasks, cognitive, and motor tasks. Passive testing typically takes 30-60 minutes and does not require presence of an epileptologist as the tasks are of minimal or no risk.
214373325|NCT05927974|DIAGNOSTIC_TEST|Active testing|"Active testing includes any study activity in which stimulation occurs. The most frequent paradigm consists of delivering small amounts of electrical stimulation through the implanted grid/strip/depth electrodes. This will be either continuous stimulation or patterned stimulation such as intermittent theta-burst . Stimulation will range between 1-8 mAmp. The duration of these pulses will last between 2-5 seconds.~Subjects may be asked to rest quietly or to perform behavioral tasks during stimulation. Since there is a risk of evoking seizure activity with active testing, presence of an epileptologist is required. Active testing will only occur once the PI/staff has communicated with the epileptologist regarding safety, feasibility, and timing of active testing. Active testing will typically take 60-90 minutes and is only performed once patients are back on their anti-seizure medications."
214373326|NCT03737786|OTHER|Tight control of end-tidal CO2 levels|The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
214373327|NCT06029556|OTHER|Mobility out of Bed|Active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conduct on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low-intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned
214373328|NCT06029556|OTHER|Ergometry in Bed|Ankle pumps (5\*2), knee extension (5\*2), breathing exercises with elbow flexion and extension(5\*2), spirometry and progressive early ambulation (from bed to wheelchair and wheelchair to standing and from standing to few steps), and conventional chest physical activity (5 minutes on precursor)
214373329|NCT01846000|PROCEDURE|low-level laser treatment|A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
214373330|NCT03540875|DEVICE|Closed loop anesthesia|"Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia."
214373331|NCT03540875|DRUG|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
214373332|NCT03540875|DRUG|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
214373333|NCT01210521|DRUG|Vitamin D|Vitamin D, (2000IU) will be administered orally, once a day, for one month.
214683782|NCT04495361|OTHER|E-learning portal|An online learning portal for the identification and management of pneumonia in under five children
214683783|NCT00854763|DRUG|olmesartan|olmesartan
214683784|NCT00933205|DRUG|Tipranavir|
214683785|NCT04985773|DEVICE|Lacrosse NSE ALPHA coronary dilatation catheter|The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
214683786|NCT00830427|DRUG|PF-00610355|100 mcg, QD, dry powder inhaler
214683787|NCT00830427|DRUG|PF - 00610355|600 mcg, QD, dry powder inhaler
214683788|NCT00830427|OTHER|Placebo|QD, dry powder inhaler
214683789|NCT00830427|DRUG|PF - 00610355|300 mcg, QD, dry powder inhaler
214683790|NCT00607646|DRUG|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
214683791|NCT00607646|DRUG|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
214986644|NCT07168239|BEHAVIORAL|ENHANCING VASCULAR ACCESS SELF-CARE IN HEMODIALYSIS PATIENTS|A set of health education sessions were developed for patients who did not exhibit fully adequate behaviour in the first assessment of the Scale of Assessment of Self-Care with AVF in HD. The sessions were conducted individually through an expository method and providing an informative leaflet. The sessions focused on the areas presented by the scale, i.e. prevention of thrombosis and infection, signs and symptoms of intra/interdialytic complications, haemostasis care, protection of the AV limb and correct assessment of signs and symptoms suggestive of complications with the AVF, evaluation of AVF functionality and detection of thrombosis, changes in colour and sensitivity of the hand corresponding to the AV, pain in the AV limb
214986645|NCT07169500|BIOLOGICAL|CAR-T|Chimeric antigen receptor T cells (car-t) are genetically engineered MHC independent tumor specific killer cells.
215089546|NCT01484379|PROCEDURE|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
215089547|NCT03202108|DIETARY_SUPPLEMENT|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian."
214373334|NCT01452646|OTHER|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
214683792|NCT02588274|DEVICE|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
214373335|NCT03279835|OTHER|Classic evaluation of neurocognitive functions|Symbol Digit Modalities Test (SDMT)
214373336|NCT03279835|OTHER|New evaluation of neurocognitive functions|Cognitive Speed Computerized Test (CSCT)
214373337|NCT04580563|DRUG|OctaplasLG®|Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
214373338|NCT04580563|DRUG|0.9% NaCl|Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
214373339|NCT03390530|DRUG|Thyroxine|8 µg/kg/day divided into two doses intravenous every 12 hours
214373340|NCT03390530|DRUG|Placebo|Placebo
214373341|NCT04903171|OTHER|INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN|Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
214373342|NCT03140501|DEVICE|"Mobile application (app)"|"The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues."
214373343|NCT03163914|DRUG|Epinephrine|Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
214373344|NCT03163914|DRUG|Norepinephrine|Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
214373345|NCT03163914|DRUG|Phenylephrine|Phenylephrine infusion rate will adjust 30 ml/h (100µg/ ml )
214495106|NCT06751160|OTHER|Soft Tissue Mobilization|"Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Soft Tissue Mobilization will be given to Group B along with Baseline treatment.~Subject will be in prone lying position with knee bent at 30 to 60 degrees. Soft tissue mobilization will be applied on hamstring muscle through Graston technique. Massage cream will be applied on hamstring muscle and Graston Instrument will be rubbed from gluteal line to politeal fossa 30 times for 60 seconds.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks."
214495107|NCT06748404|DRUG|Tricalm Hydrogel|TriCalm Hydrogel® is a topical gel that allows rapid administration to areas of the skin. TriCalm Hydrogel® is available over-the-counter and contains the active ingredient, aluminum acetate 0.2%, and inactive ingredient, strontium chloride hexahydrate.
214495108|NCT06748404|DRUG|Triamcinolone acetonide 0.1% cream|Triamcinolone acetonide 0.1% cream is a topical steroid cream that will be applied directly to the skin.
214495109|NCT02423629|DEVICE|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
214495110|NCT06743386|DEVICE|Therapeutic procedure combines EUS-Guided Radiofrequency Ablation (RFA)|It will be performed under general anesthesia with intubation, using a sectorial probe echoendoscope to target pancreatic tumors. Prophylactic measures, including intrarectal Diclofenac and antibiotics, are used to prevent complications. A high-frequency monopolar electrode needle is inserted into the lesion under ultrasound guidance, avoiding critical structures like pancreatic and biliary ducts. Energy is delivered until specific safety parameters are met, with multiple applications to maximize tumor coverage. RFA sessions are scheduled before, midway, and after chemotherapy cycles, and progress is monitored with routine imaging. Post-procedure care includes fasting, pain management, and standard blood tests. Patients are typically discharged the day after the procedure if no complications occur. Further treatment plans, including continuation or modification of chemotherapy and RFA, are determined based on disease progression observed in follow-up scans.
214495111|NCT06754410|DRUG|Tamsulosin|group A take tamsulosin once daily
214495112|NCT06754410|DRUG|Cetirizine|give cetirizine once dailly
214495113|NCT06754410|COMBINATION_PRODUCT|Cetirizine + Tamsulosin|both once daily
214495114|NCT06754410|OTHER|Placebo|once dailly
214683793|NCT02588274|DEVICE|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
214373346|NCT03163914|DRUG|Saline|saline infusion will apply till the end of the surgery
214373347|NCT05326763|DRUG|Platelet Rich Plasma|Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle. A local subcutaneous anesthesia (2 ml of 1% lidocaine) will be finished by the orthopedist.
214373348|NCT05326763|DRUG|Dextrose 50%|The group will use 4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
214986646|NCT07168148|DRUG|Oxymetazoline + Triamcinolone|"Participants will be stratified according to this usage and placed into a titration schedule.~* Titration 1: 0.05% 5x/day,~* Titration 2: 0.05% 4x/day,~* Titration 3: 0.05 3x/day,~* Titration 4: 0.05% 2x/day.~Participants with twice daily use, will then be placed in a titration schedule for oxymetazoline concentration which will stop when the oxymetazoline concentration is set to zero.~* Titration 5: 0.0375% Afrin/Nasacort 2x/day,~* Titration 6: 0.025% Afrin/Nasacort 2x/day,~* Titration 7: 0.0125% Afrin/Nasacort 2x/day,~* Titration 8: 0.0% Afrin/Nasacort 2x/day."
214683794|NCT00708994|DRUG|THC|"* Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~* Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
214683795|NCT00708994|DRUG|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
214683796|NCT01037374|OTHER|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
214683797|NCT03921281|OTHER|scalp acupuncture treatment|"The parameters for scalp acupuncture are set as follows:~1. Scalp acupoint selection: The Motor Area of Jiao's Scalp acupuncture and Si shencong (EX-HN1).~2. Acupuncture manipulation: Disposable stainless steel needles will be manually inserted in at an approximately 15-degree angle to a depth of 1.5-2.0 cm respectively along the upper point and middle point of the motor area on the scalp. The acupuncture direction of Si shencong (EX-HN1) acupoint is toward the Baihui (GV20) acupoint. the needles will be rotated for at least 200 revolutions per minute for 1 minute every 20 minutes for a total of 60 minutes.~3. Treatment course: three times a week, 12 weeks in total."
214683798|NCT03921281|OTHER|Rehabilitation Treatment|The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
214373349|NCT01069081|DRUG|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
214373350|NCT01069081|DRUG|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
214373351|NCT01069081|DRUG|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
214373352|NCT04045821|DRUG|AMD3100|Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
214373353|NCT04045821|DRUG|Normal saline|Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
214373354|NCT04045821|PROCEDURE|dilation and curettage|all participants will undergo routine D\&C procedure
214373355|NCT00052676|DRUG|patent blue V dye|
214495115|NCT06751277|DRUG|QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706|QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
214373356|NCT00052676|PROCEDURE|radionuclide imaging|
214373357|NCT00052676|PROCEDURE|sentinel lymph node biopsy|
214495116|NCT06766240|DEVICE|MRI on lumbosacral spine|MRI imaging on lumbosacral spine using Philips Achieva1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea1.5T MRI device (Siemens Healthineers, Germany). the sequences used are Axial T2W; Sagittal T1W, T2W, Sagittal STIR, Coronal STIR and post gadolinium if needed.
214373358|NCT00052676|RADIATION|technetium Tc 99m sulfur colloid|
214495117|NCT04566887|DRUG|Acalabrutinib|Administered as 100mg tablets.
214683799|NCT01095250|DRUG|AIN457|
214683800|NCT01095250|DRUG|AIN457|
214683801|NCT01095250|DRUG|AIN457|
214986647|NCT07168915|BIOLOGICAL|V118E|IM administration
214986648|NCT07168915|BIOLOGICAL|PREVNAR 20™|IM administration
214986649|NCT07168915|BIOLOGICAL|Saline|IM administration
214986650|NCT07167342|DRUG|Clostridium butyricum capsules, Live|Oral Clostridium butyricum capsules, Live: take 3 capsules twice daily (bid) for the first 3 months after adenoma resection, then continue with 3 capsules once daily (qd) until 3 years post-resection (each capsule contains ≥6.3 × 10⁶ CFU of Clostridium butyricum).
214373359|NCT00021814|DRUG|Doxazosin|
214373360|NCT00021814|DRUG|Finasteride|
214373361|NCT00021814|DRUG|Doxazosin placebo|
214373362|NCT00021814|DRUG|Finasteride placebo|
214373363|NCT04988802|DIETARY_SUPPLEMENT|Prenatal Nutrients Solgar|Patients will take dietary supplement Prenatal Nutrients from Solgar
214373364|NCT04988802|OTHER|Placebo|Placebo capsules based on starch.
214495118|NCT04566887|DRUG|R-CHOP chemotherapy|R-CHOP chemotherapy
214495119|NCT06550687|OTHER|Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis|Phase 1: Observation of doctor-patient consultations Phase 2: Adaptation of information tools Phase 3: Assessment of understanding of information tools
214495120|NCT06502418|OTHER|Acupuncture therapy|7 acupuncture points will be used to managed pain and improved patient's experience
214683802|NCT01095250|DRUG|Placebo|
214683803|NCT05951764|DIAGNOSTIC_TEST|Non-invasive measurement of arterial stiffness by Pulse Wave Velocity (PWV)|For all patients PWV in (cm/s) will be collected from D-30 to D-1 before the procedure and at D3 postoperatively.
214683804|NCT01323673|DRUG|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
214986651|NCT07167342|OTHER|Control (placebo)|Placebo capsules containing corn starch, with identical appearance, weight, and administration method as the treatment group.
215089548|NCT05749354|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through."
215089549|NCT03303118|OTHER|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
214373365|NCT04072341|DRUG|Propolis Period (Green Propolis 250mg/day)|Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.
214373366|NCT04072341|OTHER|Control Period|In the control period they will only follow standard treatment for their comorbidities.
214373367|NCT04692792|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50 mL) per day for 8 weeks
215089550|NCT03481712|DIAGNOSTIC_TEST|Diagnostic tests|"Head-to-head comparison between:~* CADScor and Diamond-Foster score~* Rb PET and 3T CMRI~* QFR and ICA-FFR"
215089551|NCT06497335|DIAGNOSTIC_TEST|non invasive hemoglobin measure|non invasive hemoglobin measure
215089552|NCT02001896|DRUG|gemcitabine; cisplatin or carboplatin; erlotinib|
214373368|NCT04692792|DIETARY_SUPPLEMENT|Dai Dai flower drink|consume 1 bottle (50 mL) per day for 8 weeks
214373369|NCT03281122|DRUG|Placebo|Specified dose on specified days
214373370|NCT03281122|DRUG|BMS-986224|Specified dose on specified days
214373371|NCT02475135|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
214373372|NCT02475135|DRUG|Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
214373373|NCT02475135|DRUG|Darunavir|A tablet containing Darunavir (DRV) 800 mg will be administered.
214495121|NCT06588673|OTHER|Art Thrapy|Art therapy at Art Therapy Studio, a well-established recommended art therapy leader since 1967 with extensive experience in virtual therapy for patients with medical needs. Cheryl Pete, MA ATR-BC, a board-certified art therapist and the Clinical Director will complete the art therapy sessions. The art therapy will be a 1-hour sessions, once a week for a total of 8 weeks (or 8 sessions). Cheryl Pete's role will solely involve providing a service. Chery will complete the Art Therapy according to her standard practices. Cheryl's Art Therapy will not be altered in any way as a part of this research study. Cheryl will not collect any research data. As research participants are referred to Cheryl for the Art Therapy, the research participant's name and contact information will be shared.
214495122|NCT06855966|OTHER|250 ml crystalloid bolus infusion|In thoracic surgical setting, restrictive fluid replacement is widely accepted. However, goal directed fluid therapies can provide a more precise and tailored fluid replacement for each patient. Although ERAS protocols emphasize otherwise, patients still arrive in the operating room with certain deficite, due to prolonged fasting or advanced age. PLR is used as a reversible fluid challenge since the blood which is pooled in the lower extremities as well as splancnic area. End tidal carbon dioxide is monitorized at each patient per American Society of Anesthesia Guideline. In this study, we aimed to assess the feasibility of end tidal carbondioxide changes as a response to passive leg raise maneuer (PLR) for preload optimization in thoracic surgical practice.
214495123|NCT06753526|DRUG|NSAID|For 1st group of patients
214495124|NCT06753526|DRUG|L-Arginine, 500 Mg Oral Capsule|group 2by twice dose
214495125|NCT06753526|DRUG|Tamsulosin 0.4 mg QD|group 3 by once per day
214495126|NCT06754436|BIOLOGICAL|Determination of blood drug concentration|Collecting blood samples from patients and determining blood drug concentrations. Patients were intravenously titrated after 3 doses of maintenance dose titration of L-AmB. The time points of sample collecting were 30 minutes before and 1, 2, 3, 6, 9, 12, 16, 20, 24 hours after administration. Then, the blood concentrations were determined according to the established method.
214495127|NCT06753786|DRUG|Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission.|Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
214495128|NCT06753786|DRUG|Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission.|Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
214495129|NCT06764329|BIOLOGICAL|Mesenchymal Stem Cells|allogeneic bone marrow-derived mesenchymal stem cells therapy
214495130|NCT06764329|OTHER|0.9 % saline|0.9% Saline as placebo
214495131|NCT06789263|DIETARY_SUPPLEMENT|Collagen hydrolyzed peptides|Dissolved in flavoured water, single dose, 10 g
214495132|NCT06789263|OTHER|Placebo|Single dose
214495133|NCT06780345|DRUG|Placebo|Mechanically ventilated neonates will receive the usual protocol of sepsis and a placebo without vitamin C.
214495134|NCT06780345|DRUG|Vitamin C|Mechanically ventilated neonates will receive the usual protocol of sepsis plus vitamin C with a loading dose of 0.5 gm /kg and a maintenance dose of 0.5 gm /kg/hour adjusted for six hours for 7-10 days.
214495135|NCT06773091|BIOLOGICAL|NK042|NK042 is an allogeneic, off-the-shelf cellular therapy derived from healthy donors and enriched with NKR+ NK cells.
214495136|NCT06773091|DRUG|Fludarabine (FLU)|Fludarabine (FLU) is administered as a lymphodepletion regimen prior to NK042 infusion.
214495137|NCT06773091|DRUG|Cyclophosphamide (CTX)|Cyclophosphamide (CTX) is administered as a lymphodepletion regimen prior to NK042 infusion.
214495138|NCT06829225|DRUG|Tulisokibart|SC Injection or IV Infusion
214495139|NCT06829225|DRUG|Placebo|Tulisokibart-matched Placebo SC Injection or IV Infusion
214495140|NCT06826586|DIAGNOSTIC_TEST|Measuring the microplastics|Measuring the type, nature, and abundance of microplastics in stomach, liver, feces, and blood
214373374|NCT02475135|DRUG|Emtricitabine/Tenofovir alafenamide (FTC/TAF)|A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
214373375|NCT02475135|DRUG|Cobicistat|A tablet containing cobicistat (COBI) 150 mg will be administered.
214683805|NCT01323673|DRUG|Vehicle / Placebo|2 times a day, 14 total days of study treatment
214683806|NCT03677089|BEHAVIORAL|12 ECHO Autism telehealth clinics|Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
214986652|NCT07169175|DRUG|SNUG01|AAV (adeno-associated virus) Gene therapy
214986653|NCT07169383|DRUG|Melatonin tablet|Group A will receive oral melatonin 5mg every night for 3 months
214986654|NCT07169383|DRUG|Tranexamic Acid (TXA)|Group B will receive oral tranexamic acid 250mg twice daily for 3 months.
214986655|NCT07168304|DRUG|S. boulardii|Participants received zinc plus S. boulardii supplementation according to the World Health Organization recommendations.
214986656|NCT07168785|DRUG|[18F]-AraG radiotracer|\[18F\]-AraG radiotracer, which occurs on the first and sixteenth day of treatment.
214986657|NCT07168785|DRUG|Chemotherapy|Concurrent chemoradiotherapy (CRT) with weekly doses of cisplatin.
214986658|NCT07168785|DEVICE|Radiotherapy|Concurrent chemoradiotherapy (CRT) of 70Gy of radiation dose in 33 fractions.
215089553|NCT02001896|DRUG|erlotinib|
214373376|NCT02475135|OTHER|High-fat Breakfast|High-fat breakfast will be administered.
214373377|NCT02475135|OTHER|Standardized Regular Breakfast|Standardized regular breakfast will administered.
214373378|NCT02872948|GENETIC|Diagnostic|
214373379|NCT03180671|DEVICE|Deprogramer Sliding Guide|Use of the intraoral device.
214373380|NCT03180671|DEVICE|Deprogrammer Dawson B-Splint|Use of the intraoral device.
214373381|NCT03180671|DEVICE|Deprogrammer Kois|Use of the intraoral device.
214373382|NCT00466102|DRUG|RAD001|Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
214373383|NCT00466102|DRUG|Placebo|2 tablets are taken once daily during study therapy
214373384|NCT00829686|DRUG|Septra|(800/125) PO BID X 7 days
214495141|NCT05139225|DRUG|TTI-622|"(-2) 0.4 mg/kg (-1) 0.8 mg/kg~(1 ) 1.2 mg/kg (2) 2 mg/kg (3) 4 mg/kg (4) 8 mg/kg (5) 12 mg/kg~The appropriate dose of TTI-622 will be administered IV over 60 minutes, however, can be extended up to 4 hours to mitigate Infusion-related reactions."
214495142|NCT05139225|DRUG|Daratumumab Hyaluronidase-fihj|Daratumumab hyaluronidase-fihj SC 1800 mg days 1, 8, 15, and 22.
214495143|NCT06770907|OTHER|Blood, stool and saliva collection|Blood, stool and saliva collection
214495144|NCT06770907|OTHER|Questionnaire completion|"Questionnaire on:~* Hospital Anxiety and Depression Score (HADS) for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Patient Health Questionnaire 12 (PHQ-12) Somatic Symptom scale"
214495145|NCT06770907|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) and Breath test|MRI scans and breath test samples collected after drink test with sucrose
214495146|NCT05305664|DRUG|Pelacarsen (TQJ230) 80 mg s.c.|Pelacarsen (TQJ230) 80 mg s.c. Q4W
214495147|NCT05305664|DRUG|Corresponding Placebo|Placebo to Pelacarsen
214373385|NCT05797831|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
214373386|NCT05797831|DRUG|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
214373387|NCT04748016|OTHER|3D printed (3DP) bone models + CT imaging|In addition to CT-MPR and CT-3DR, 3DP models will be used for surgical planning and intraoperative visualization.
214373388|NCT04748016|OTHER|CT imaging|CT-MPR and CT-3DR used for surgical planning and intraoperative visualization.
214495148|NCT06604364|DEVICE|hypno VR|pre-surgery sedation using virtual reality headset
214495149|NCT06792045|OTHER|Physiotherapist assessment|"* Tongue motor skills (Tongue pressures and tongue mobility, assessed through the Iowa Oral Performance Instrument and the Motricité Bucco-Linguo-Faciale tongue subscore, respectively)~* Tongue restriction of mobility due to its frenulum (assessed through the Quick Tongue-Tie assessment tool)~* Breathing Pattern (questionnaire from Abreu RR, Rocha RL, Lamounier JA, Guerra AF. Etiology, clinical manifestations and concurrent findings in mouth-breathing children. J Pediatr (Rio J). 2008;84(6):529-535.)."
214495150|NCT06792045|OTHER|ENT assessment|Data from the ENT appointment will be collected (e.g., sex, height, weight)
214495151|NCT06792045|DIAGNOSTIC_TEST|Drug-Induced Sleep Endoscopy|A Drug-Induced Sleep Endoscopy will be performed, recorded, and evaluated by two blinded raters using the IPSES scale.
214495152|NCT03987009|DEVICE|Without RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning without RAMP device
214495153|NCT03987009|DEVICE|With RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning with RAMP device
214495154|NCT03987009|DEVICE|Without RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning without RAMP device
214495155|NCT03987009|DEVICE|With RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning with RAMP device
214495156|NCT03574493|PROCEDURE|TME with LAR|Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME
214495157|NCT06821789|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
214986659|NCT07167251|DRUG|Low-dose corticosteroids for immune-related hepatitis grade 3|Prednisolone 0.5-1 mg/kg orally for grade 3 IR-hepatitis; adjusted based on liver function; treatment per local standard of care.
215089554|NCT03400631|DRUG|Dextrose 0|Dextrose injection at time 0
215089555|NCT03400631|DRUG|Aspiration 0|Aspiration only at time 0
215089556|NCT03400631|DRUG|Dextrose 1|Dextrose injection at week 1
215089557|NCT03400631|DRUG|Aspiration 1|Aspiration only at week 1
214683807|NCT04598165|BEHAVIORAL|Interactive two-way SMS dialogue|We will utilize Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated theoretically grounded SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day for the remaining four weeks. Women who experience pregnancy or infant loss will be enrolled into an infant loss track where they will receive messages of support.
214373389|NCT02304276|RADIATION|18F-Fluoride PET-CT|Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
214683808|NCT02269059|DRUG|MK-7680|MK-7680 10 mg and 100 mg capsules
214683809|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
214683810|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
214683811|NCT02151409|DRUG|placebo|A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
214683812|NCT00426751|DRUG|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
214683813|NCT00426751|DRUG|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
214683814|NCT00400933|BEHAVIORAL|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
214683815|NCT03682796|DRUG|TRPH-222|administered by IV, 21-day Cycle
214373390|NCT02304276|RADIATION|CT calcium score of aortic valve|CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
214373391|NCT01644201|DIETARY_SUPPLEMENT|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
214373392|NCT01644201|DIETARY_SUPPLEMENT|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
214373393|NCT03670225|DEVICE|Invia Motion Endure|NPWT Invia Motion Endure
214373394|NCT00339690|OTHER|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
214683816|NCT04708964|DRUG|Flurbiprofen|Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
214683817|NCT04708964|DRUG|saline solution|Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
214986660|NCT07167251|DRUG|Low-dose corticosteroids for immune-related hepatitis grade 2|Hold immunotherapy and reassess liver function at the treating physician's discretion. If liver function tests persistently worsen or continue to rise, consider administering prednisolone at 0.5 mg/kg body weight
214683818|NCT01554202|BEHAVIORAL|assessment of memory|
214373395|NCT00345163|DRUG|bevacizumab|Intravenous repeating dose
214373396|NCT00345163|DRUG|irinotecan|Intravenous repeating dose
214373397|NCT02989272|DRUG|Sulfate, Magnesium|magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
214683819|NCT01554202|BIOLOGICAL|circulating tPA dosage|
214683820|NCT01554202|GENETIC|ApoE4|
214683821|NCT01554202|OTHER|Brain imaging examination MRI and PET examinations|
214986661|NCT07167420|PROCEDURE|RISE (Revolute Insert Side-End ileocecal valve reconstruction)|After performing a conventional right hemicolectomy, an additional step is carried out in which sutures are used to artificially reconstruct an ileocecal valve structure at the ileal stump before proceeding with the ileocolic anastomosis.
214373398|NCT02989272|OTHER|saline group|saline group (30 patients) who will receive pretreatment by saline solution
214683822|NCT00540722|DRUG|R-(-)-gossypol acetic acid|Given PO
214683823|NCT00540722|OTHER|laboratory biomarker analysis|Correlative studies
214683824|NCT01724736|DRUG|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
214986662|NCT07168902|DRUG|BL1107 Low dose|Dosed twice daily for 28 days.
214683825|NCT01724736|DRUG|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
214683826|NCT00307593|DRUG|Infliximab|Infliximab
214986663|NCT07168902|DRUG|BL1107 High dose|Dosed twice daily for 28 days.
214986664|NCT07168902|DRUG|Timolol maleate 0.5%|Dosed twice daily for 28 days.
214986665|NCT07169253|OTHER|GAP Index|For each patient in the IPF, fibrotic HP, and non-fibrotic HP groups, the GAP index was calculated based on age, gender, FVC, and DLCO values. According to the GAP index, patients were classified as Stage 1 (0-3 points), Stage 2 (4-5 points), and Stage 3 (6-8 points).
214986666|NCT07169253|OTHER|ILD-GAP Index|In addition to the GAP parameters, the index was calculated to include the ILD subtype as well.
214683827|NCT00307593|DRUG|Rituximab|Rituximab
214373399|NCT04956328|DRUG|Obeticholic Acid Tablets|Obeticholic Acid：Once a day (QD) by mouth (PO).
214683828|NCT02504892|DRUG|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
214683829|NCT04034979|BEHAVIORAL|decision aid|One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
215089558|NCT01739803|BEHAVIORAL|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
215089559|NCT04933760|DIAGNOSTIC_TEST|Cytovale IntellipSep test|The Cytovale IntelliSep test measures a series of physical properties that indicate activation of leukocytes obtained from a venous K2-EDTA anti-coagulated whole blood sample.
215089560|NCT01428336|PROCEDURE|1 ug ACTH stimulation test|1 ug cortrosyn dose
215089561|NCT01428336|PROCEDURE|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
215089562|NCT01428336|PROCEDURE|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
215089563|NCT01428336|PROCEDURE|Insulin tolerance test|subjects will undergo an insulin tolerance test
215089564|NCT02230371|DRUG|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
214683830|NCT03633071|OTHER|Web-knee brace|Web -Knee Brace
214683831|NCT03549624|OTHER|Standardised protocol for the perioperative management in patients in need of an acute laparotomy|A standardised protocol for the perioperative management of patients including early start of antibiotics and swift surgical intervention as well as an emphasis on repeated monitoring of physiological parameters pre- and post-operatively.
214683832|NCT04229446|BEHAVIORAL|Music based caregiving|The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement.
214683833|NCT02984826|OTHER|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
215089565|NCT02230371|DRUG|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
214373400|NCT04956328|DRUG|UDCA|UDCA：continue prestudy dose
214373401|NCT04956328|DRUG|Placebo|Placebo
214373402|NCT01570530|PROCEDURE|Cardiac surgery|Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
214373403|NCT01570530|PROCEDURE|Cardiac surgery|Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
214373404|NCT03352934|DRUG|Avelumab|Avelumab will be administered as intravenous infusion at 10 mg/kg once every two weeks until documented disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawal are met.
214373405|NCT00179790|PROCEDURE|Extracorporeal Photopheresis|Patient will undergo ECP treatment pre and post stem cell transplant infusion
214373406|NCT02124148|DRUG|Prexasertib|Administered IV
214373407|NCT02124148|DRUG|Cisplatin|Administered IV
214373408|NCT02124148|DRUG|Cetuximab|Administered IV
214373409|NCT02124148|DRUG|G-CSF|Administered SC
214373410|NCT02124148|DRUG|Pemetrexed|Administered IV
214373411|NCT02124148|DRUG|Fluorouracil|Administered IV
214373412|NCT02124148|DRUG|LY3023414|Administered PO
214373413|NCT02124148|DRUG|Leucovorin|Administered IV
214373414|NCT03351738|DRUG|MEDI5884|Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.
214373415|NCT03351738|DRUG|Placebo|Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
214373416|NCT04191447|DRUG|Flamboyant 200/12|Flamboyant 200/12 capsule
214373417|NCT04191447|DRUG|Budesonide / Formoterol 400/12|Budesonide / Formoterol 400/12 capsule
214373418|NCT04191447|OTHER|Flamboyant 200/12 Placebo|Flamboyant 200/12 Placebo capsule
214373419|NCT04191447|OTHER|Budesonide / Formoterol 400/12 Placebo|Budesonide / Formoterol 400/12 Placebo capsule
214373420|NCT03997513|BEHAVIORAL|Pulmonary Telerehabilitation|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
214373421|NCT04310917|OTHER|blood lipoprotein (a) test|research specific blood sample
214683834|NCT02984826|OTHER|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
214373422|NCT02322541|OTHER|Garlic Intervention|Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
214373423|NCT06427122|BEHAVIORAL|EMD Protocol for Urge|During the EMD-U sessions, the patient is asked to focus on the spot on his/her skin where the urge to scratch is highest. The patient is asked to rate the level of urge to scratch this spot on a 10-point scale and to imagine that they scratch this spot as they would like. At the same time eye movements are offered for 30 seconds. This procedure is repeated until the level of urge to scratch has become nihil. This procedure is repeated for all other skin parts where the patient experiences an urge to scratch, until there are no skin parts left. As a homework assignment straight after the first session, the patient is instructed and encouraged to practice the same intervention at home. The two EMD-U sessions and two phone calls, take place in the first three weeks of the study. In the five following weeks, patients are phoned twice to ask for their experiences with the practicing at home.
214373424|NCT06427122|OTHER|Care as Usual|Patients in the control group receive care as usual (CAU), which is the standard care of the dermatologist. In addition to completing the questionnaires at T0, 1, 2, 3, and 4 these patients are not offered any additional treatment or support aimed at their scratching behaviour.
214373425|NCT01375205|OTHER|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
214986667|NCT07169253|OTHER|Composite Physiologic Index (CPI)|"The CPI (Composite Physiologic Index) was calculated using the following formula:~CPI = 91 - (0.65 × %DLCO) - (0.53 × %FVC) + (0.34 × %FEV1).~DLCO: Diffusing Capacity of the Lung for Carbon Monoxide FVC: Forced Vital Capacity FEV₁: Forced Expiratory Volume in One Second"
214986668|NCT07168811|PROCEDURE|Hyaluronic Acid (HA)|"• After achieving complete hemostasis:~1. Mix HA (0,5% gengigel teething) with ZO powder until a mixture, then apply it on pulp stumps.~2. all teeth will be restored with glass ionomer (Prevest Denpro Micron Superior Limited, India),then a stainless steel crown (3M, ESPE, USA) to ensure proper coronal seal and long-term success, which was cemented by glass ionomer cement(Prevest Denpro Micron Luting Limited, India)"
215089566|NCT01248871|DRUG|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
215089567|NCT01248871|DRUG|volatile agent only during reperfusion|Active Comparator
215089568|NCT01248871|DRUG|propofol-remifentanil/sufentanil|Active Comparator
215089569|NCT02423122|DRUG|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
215089570|NCT05045677|OTHER|digital DBT skills intervention|The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.
215089571|NCT05045677|OTHER|Standard Care|Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
215089572|NCT05363540|PROCEDURE|pre-incisional parasternal intercostal block|LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
214373426|NCT01375205|OTHER|Standard of Care|Subjects will apply Johnson\&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson\&Johnson cleanser.
214373427|NCT01120158|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
214373428|NCT01120158|DRUG|Paclitaxel|Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
214373429|NCT02260128|OTHER|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
214495158|NCT06821789|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
214495159|NCT05184504|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
214495160|NCT06783257|DRUG|Vonorasan fumarate injection1|40 mg (20 mg bid, 6 hours apart, Day1) + 20 mg (Day2\&3, q24h), ivd, 30 min, administered for 3 days
214495161|NCT06783257|DRUG|Vonorasan fumarate injection2|40mg（Day1）+20mg（Day 2\&3），ivd，30min，q24h，administered for 3 days
214495162|NCT06783257|DRUG|Esomeprazole sodium for injection|80mg，iv，30±3min； Followed by 8 mg/h, ivd, 71.5 h
214495163|NCT06828458|OTHER|Biological sampling|"Whole blood on EDTA sample 2 tubes (5mL) PAXgene sample 1 tube (2.5 mL) Rectal swab Skin swab (1 swab for 5 anatomically burned sites)~At day 0, day 3, day 7, day 14, day 21"
214495164|NCT05956795|DIAGNOSTIC_TEST|Ultrasound|Sonographic imaging will be performed of lymph node basins
214495165|NCT06739512|PROCEDURE|Extensive Electro-Anatomical Guided Ablation|Ablation using PFA. Combination of anatomical and electrogram-guided ablation techniques.
214495166|NCT06739512|PROCEDURE|Anatomical Guided Ablation|Ablation using PFA. Guided by anatomical landmarks without potential mapping
214495167|NCT06739512|PROCEDURE|Electrogram Guided Ablation|Ablation using PFA. Guided by real-time electrogram characteristics from a multi-electrode catheter.
214495168|NCT06763315|DRUG|Selumetinib|Use of the internationally recommended standard dose and low dose of the same drug
214495169|NCT05268237|DRUG|Liraglutide|Sublingual or subcutaneous liraglutide
214495170|NCT05268237|DRUG|Placebo|Sublingual placebo
214495171|NCT06637800|DEVICE|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)|The Seraph 100 is part of the Seraph platform technology that was developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens, bacteria, viruses, fungus, and other sepsis mediators from the bloodstream. In addition, it has been demonstrated that Seraph 100 is also capable of removing circulating tumor cells from the whole blood.
214495172|NCT06763159|DRUG|HS-20124 (Phase Ia：Dose escalation )|Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
214986669|NCT07168811|PROCEDURE|TheraCal|"• After achieving complete hemostasis:~1. TheraCal L.C will be applied directly to the radicular pulp by a disposable syringe tip and light cure will be done for 20 seconds.~2. all teeth will be restored with glass ionomer (Prevest Denpro Micron Superior Limited, India),then a stainless steel crown (3M, ESPE, USA) to ensure proper coronal seal and long-term success, which was cemented by glass ionomer cement(Prevest Denpro Micron Luting Limited, India)"
214373430|NCT01750736|OTHER|Augmented Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
214373431|NCT01750736|OTHER|General Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
214373432|NCT02993887|BEHAVIORAL|Resourcefulness Training|This intervention will include a one time face to face instruction on Resourcefulness Training that entails 8 self-help and help-seeking skills plus viewing short video vignettes of caregivers describing application of the resourcefulness skills. In addition, participants will use daily journaling to describe application of the resourcefulness skills in their daily caregiving with their technology-dependent child.
214373433|NCT02993887|BEHAVIORAL|Mindfulness|The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
214373434|NCT02143037|BEHAVIORAL|prize contingency management for attending treatment|
214373435|NCT02143037|BEHAVIORAL|usual care|
214373436|NCT05542290|PROCEDURE|Capsular tension ring implantation|Capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
214373437|NCT05542290|PROCEDURE|No capsular tension ring implantation|No capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
214683835|NCT01676376|DEVICE|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
214683836|NCT01676376|OTHER|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
214373438|NCT05529758|BEHAVIORAL|Internalized Weight Bias Intervention|ACT-based programs and self-compassion have shown promise throughout research for lowering IWB (Berman et al., 2016; Levin et al., 2018; Lillis et al., 2009; Palmeira, Cunha, \& Pinto-Gouveia, 2017; Palmeira, Pinto-Gouveia, \& Cunha, 2017; Forbes et al., 2020). Therefore, using techniques from prior ACT- and self-compassion based programs, a weight bias reduction intervention will be administered. Session topics will include psychoeducation and coping for weight bias and internal weight bias, and these topics will be viewed through a self-compassionate and ACT-based lens (for example, participants may defuse from internal critical thoughts rather than challenge them). Sessions will also cover acceptance, cognitive defusion, mindfulness, committed action, and the dialectical behavioral therapy (DBT) DEARMAN skill.
214373439|NCT01954368|DRUG|Placebo|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
214683837|NCT03527615|OTHER|Clinical Pharmacist Medication Review|Programmatic review of physician orders for direct anticoagulants by clinical pharmacists.
214683838|NCT00002263|DRUG|Zidovudine|
214683839|NCT00002263|DRUG|Sargramostim|
214683840|NCT00416767|DRUG|fluorouracil|
214373440|NCT01954368|DRUG|Sufentanil|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
214683841|NCT00416767|DRUG|irinotecan hydrochloride|
214683842|NCT00416767|DRUG|leucovorin calcium|
214683843|NCT06228183|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214683844|NCT06228183|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
215089573|NCT05363540|PROCEDURE|post-incisional parasternal intercostal block|LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
214683845|NCT06228183|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
215089574|NCT02248740|PROCEDURE|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
215089575|NCT02645617|DRUG|Varnish|Topical application to the teeth
215089576|NCT05451680|DEVICE|Negative pressure device|Negative-pressure therapy postoperatively on the full-thickness skin graft
214683846|NCT02284334|OTHER|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
215089577|NCT05451680|PROCEDURE|Conventional care|Conventional dressing postoperatively on the full-thickness skin graft
214683847|NCT03186404|DRUG|Atorvastatin|Atorvastatin 40mg OD
214986670|NCT07168811|PROCEDURE|Mineral Trioxide Aggregate|"• After achieving complete hemostasis:~1. mix MTA with sterile saline and put on pulp stumps. A moist cotton pellet was placed for initial setting.~2. all teeth will be restored with glass ionomer (Prevest Denpro Micron Superior Limited, India),then a stainless steel crown (3M, ESPE, USA) to ensure proper coronal seal and long-term success, which was cemented by glass ionomer cement(Prevest Denpro Micron Luting Limited, India)"
215089578|NCT04988282|DRUG|Methylprednisolone Tablet|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
215089579|NCT02525094|BIOLOGICAL|MEDI9929|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
215089580|NCT02525094|BIOLOGICAL|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
214986671|NCT07167368|DRUG|Standardized Basic Drug Therapy for HFrEF with Chronic Kidney Dysfunction|Participants receive standardized basic drug therapy for HFrEF and chronic kidney dysfunction in accordance with clinical practice guidelines. Medications include but are not limited to angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and diuretics, with dosage adjustments based on individual patient conditions.
215089581|NCT00699218|DEVICE|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
215089582|NCT04433013|DRUG|Lianhua Qingwen|The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
215089583|NCT04433013|DRUG|Placebo|The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
215089584|NCT05301738|OTHER|Plyometric Exercises|The plyometric exercise group received a 12-week plyometric training program. Each session lasted 45 minutes and was repeated two times a week. The training was conducted in conformity with the National Strength and Conditioning Association guidelines and American Academy of Pediatrics safety standards. The plyometric exercise program consisted of ten unilateral and bilateral lower limb plyometrics in the form of hopping/bounding/jumping activities. The Iplyometric workout was proceeded by a 5-minute warm-up and ended up with a 5-minute cool-down
214393816|NCT03900312|BEHAVIORAL|Asdzaan Be'eena' Program|The program will consist of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices. The program will be conducted over 2.5-3 months with one session occurring every week for 11 weeks.
214683848|NCT03186404|DRUG|Placebo oral tablet|Placebo
214683849|NCT04561388|PROCEDURE|Electrocochleography|"Electrocochleographic responses will be evoked using different pure tone sounds delivered through an insert placed in the external auditory duct. The responses will be recorded with the electrodes of the cochlear implant connected to a dedicated interface.~Electrocochleographic responses will be collected continuously during the electrode-array insertion at the implantation surgery using 500Hz pure tone and after suturing with 250, 500, 750 and 1000Hz pure tones. Then, electrocochleographic responses to pure tones from 125 to 8000HZ (according to the subject residual hearing) will be recorded 2 weeks, 1 month, 2 months and 4 months after implantation."
214683850|NCT04561388|OTHER|Pure Tone Audiometry|"The perception thresholds to 125, 250, 500, 750, 1000, 2000, 4000 and 8000 Hz pure tones will be measured within the month preceding the implantation using the same insert t.~Pure tone audiometry with the same frequencies will be done 2 weeks, 1, 2 and 4 months after the implantation."
215089585|NCT05301738|OTHER|Standard Physical Therapy|The control group received their usual physical rehabilitation program for 45 minutes, twice/week for 12 consecutive weeks. The program comprised advanced balance training, and gait training exercises, postural and flexibility exercises, strength training exercises.
215089586|NCT03024138|RADIATION|Repeat CT scan|
215089587|NCT02242981|DRUG|LY2623091|Administered orally
215089588|NCT03858504|OTHER|Exercise|The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
215089589|NCT03481621|DEVICE|Acupuncture|Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).
214683851|NCT04561388|OTHER|Speech audiometry|The speech perception will be assessed in silence and in noise in free field 1 and 4 months after implantation. The speech perception in silence will be assessed using monosyllabic words 60 dB SPL. Speech in noise will be assessed using an adaptative test with fixed noise level (60 dB SPL).
214986672|NCT07167368|BEHAVIORAL|Home-based Personalized Exercise Rehabilitation|On the basis of basic drug treatment, participants in the exercise rehabilitation group receive personalized home-based exercise prescriptions. Prescriptions are developed according to cardiopulmonary exercise test results (using heart rate at anaerobic threshold) or 6MWT (for those unable to complete cardiopulmonary exercise tests). The 6-month exercise program includes aerobic exercises (e.g., brisk walking, cycling), with intensity, duration, and frequency adjusted based on individual tolerance and progress.
214683852|NCT06671470|DRUG|YZJ-1139 tablets|Oral dose 20 mg
214683853|NCT06671470|DRUG|Ticagrelor Tablets|Oral dose 90 mg twice daily
214986673|NCT07167849|BEHAVIORAL|UKADO Content - problem-focused|UKADO is a digital ultra-brief intervention intended to reduce symptoms of depressive disorders and anxiety disorders. Content is either problem-focused or resource-focused. This version is problem-focused
214683854|NCT05847270|PROCEDURE|Anterior and posterior treatment strategy|Before surgery, a large weight traction of 1/6 body weight was used to determine the reversibility of atlantoaxial dislocation. After determining that it is difficult to restore the dislocation, a technique of anterior oral release and posterior fixation fusion was used for reduction, with sequential release of the longus colli and longus capitis, the anterior longitudinal ligament, the blitateral lateral mass joints, the contracted soft-tissue mass between the odotiod and the anterior C1 tubercle, and the peri-odontoid ligaments (i.e., the alar ligaments and the apical ligament), followed by posterior internal fixation and bone grafting was used between C1 and C2 lamina.
215089590|NCT03481621|OTHER|Standard care|PT, pain medications, nerve block, etc
215089591|NCT04462991|DIAGNOSTIC_TEST|corneal topography|In all patients, TCT will be measured first by WaveLight® Oculyzer™II Pentacam HR and second by The Optovue AS-OCT .
214393817|NCT04182607|PROCEDURE|kidney transplant|Clinical data will be collected from electronic medical records (EMRs) on donors and recipients who underwent a minimally invasive kidney transplantation procedure
214393818|NCT02561715|BEHAVIORAL|Questionnaires|Pre and post deep brain surgery questionnaires
214393819|NCT05554146|OTHER|Receipt of Coupon for Placebo Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
214495173|NCT06763159|DRUG|HS-20124 (Phase Ib: Dose expansion)|Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
214495174|NCT06756958|OTHER|No intervention (observational study)|No intervention (observational study: The study participants were inpatient and were given robot-assisted gait training routinely.)
214495175|NCT06894264|BEHAVIORAL|Emotion regulation|The intervention is an adapted version of skills training that stems from DBT. The text has been simplified, and illustrations have been added to facilitate learning. In addition, metaphors have been removed, making it more user-friendly for the targeted populations. It consists of 12 modules that are delivered during 12 weeks, one module per week. A licensed psychologist are responsible for each individual treatment. Care givers or relatives are encouraged to participate and help the study participant to complete their homework assignments.
214495176|NCT04632810|OTHER|Ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 75g (25E%), protein 60 g (20E%), fat 73 g (55E%) in 8 weeks
214495177|NCT04632810|OTHER|non-ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 180g (60E%), protein 60 g (20E%), fat 27 g (20E%), in 8 weeks
214495178|NCT05742269|DIAGNOSTIC_TEST|89Zr-atezolizumab PET/CT|All patients undergo a 89Zr-atezolizumab PET/CT. Allocation to chemotherapy + atezolizumab in case of a PD-L1 positive tumor (on IHC and/or PET)
214495179|NCT05310786|OTHER|Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)|This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.
214495180|NCT04399473|BEHAVIORAL|Pain Neuroscience Education (PNE)|Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
215089592|NCT05450627|DRUG|Pancreatic Enzyme|Registry of pancreatic enzyme therapy prescribed to included patients
215089593|NCT04720768|DRUG|Binimetinib|MEK inhibitor
215089594|NCT04720768|DRUG|Encorafenib|BRAF inhibitor
215089595|NCT04720768|DRUG|Palbociclib|CDK4/6 inhibitor
215089596|NCT02437786|DRUG|GRAZAX|GRAZAX
215089597|NCT02301481|RADIATION|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
215089598|NCT02301481|DRUG|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
215089599|NCT02301481|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
215089600|NCT02301481|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
214393820|NCT05554146|OTHER|Receipt of Coupon for High THC Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
214495181|NCT06750978|BEHAVIORAL|Self-reflection|Participants will be guided to identify goals of daily PSU reduction. o Participants will be guided to actively review their smartphone usage data each day.
214495182|NCT06750978|BEHAVIORAL|Self-reflection + Alternative activity engagement|Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will be guided to develop a plan for alternative activity engagement and confirm their engagement in the alternative activities as planned.
214683855|NCT05847270|PROCEDURE|Simple posterior approach treatment strategy|Preceding the surgical procedure, an assessment was conducted utilizing 1/6 weight traction to ascertain the reducibility of atlantoaxial dislocation. Upon confirmation of IAAD, the chosen approach involved the utilization of a specially designed spreader, tailored to the patient's atlanto-axial joint morphology. Upon entering the joint space, the spreaders were skillfully maneuvered to gently open the joint through rotational and prying actions. Subsequently, two cages, pre-filled with autogenous bone grafts, and designed with the appropriate angle and height, were meticulously placed between the Atlanto-axial joints via a posterior approach. This procedure facilitated direct distraction and reduction of the dislocated joint. In the final step of the surgical process, stabilization was achieved by securing the atlas and axis with screws and rods. This surgical approach was selected to address the unique challenges posed by IAAD, with the aim of achieving optimal patient outcomes.
214683856|NCT06671275|BIOLOGICAL|Cell therapy|Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
214683857|NCT03659747|DIETARY_SUPPLEMENT|Probiotic|\- 6 g sachet containing probiotic powder (1.8 x 10\^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
214683858|NCT03659747|DIETARY_SUPPLEMENT|Lactrase|\- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
214683859|NCT03659747|OTHER|Placebo|\- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
214683860|NCT01223976|OTHER|Tuberculin skin test and Quantiferon -TB Gold test|"TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.~QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions."
214683861|NCT06047301|BEHAVIORAL|Pathways|Delivered by a nurse or other healthcare provider, includes 2 in-person sessions, and phone check-ins, and occurs primarily during infusion visits. Includes a Pathways Toolkit with handouts on values and goal setting, as well as resources on symptom management, lung cancer stigma, communication strategies, and other cancer center resources.
214683862|NCT06047301|BEHAVIORAL|Enhanced Usual Care|Pathways Toolkit handouts on symptom management, lung cancer stigma, communication strategies, and other cancer center resources provided to participants. The Toolkit will be reviewed with patients in person to orient them to its purpose and contents.
214986674|NCT07167849|BEHAVIORAL|UKADO Content - resource-focused|UKADO is a digital ultra-brief intervention intended to reduce symptoms of depressive disorders and anxiety disorders. Content is either problem-focused or resource-focused. This version is resource-focused.
214986675|NCT07167849|BEHAVIORAL|Human support|Human support is provided as two weeks of guidance for study participants
214986676|NCT07167849|BEHAVIORAL|Expectation fostering elements|Patient in the expectation-fostering condition receive elements in UKADO that are meant to foster expectations.
214986677|NCT07169552|DRUG|HC010|HC010 Q3W intravenous infusion
214986678|NCT07168668|PROCEDURE|Transarterial chemoembolization|"1. Targeting 1-3 prognostically relevant tumor nodules.~2. Administration of anti-cancer drugs (doxorubicin 20 mg in each section of TACE).~3. Embolization with Drug-Eluting Beads (doxorubicin 20 mg loaded Hepasphere 20 mg of TACE)~4. Embolization was done when there was a slight decrease in blood flow for each tumor feeder."
214986679|NCT07168668|DRUG|durvalumab and tremelimumab|Combine TACE with immunotherapy
214986680|NCT07167290|BEHAVIORAL|Focused Acceptance and Commitment Therapy|Focused Acceptance and Commitment Therapy will be delivered following a facilitators guide. The intervention is adapted for Spinal Cord Injury patients and is to be delivered on an inpatient neurorehabilitation setting over the course of 1-3 sessions.
214683863|NCT00248313|DRUG|Rapamune®|
214683864|NCT03398018|DRUG|repository corticotropin injection|80 units twice per week as a subcutaneous injection
214683865|NCT05633576|DRUG|steroid eye drops|Self-administration of steroid eye drops three times a day for four consecutive weeks.
214683866|NCT05633576|DRUG|Placebo|Self-administration of placebo eye drops three times a day for four consecutive weeks.
214683867|NCT03912922|OTHER|Activity regime|Activity regime of 4 days followed by a test day.
214683868|NCT01321294|PROCEDURE|laparoscopic anti-reflux surgery|
214683869|NCT06673693|DRUG|Tislelizumab|SBRT
214986681|NCT07167277|DIETARY_SUPPLEMENT|Whey Protein|24g of whey protein will be given to the participant to be consumed daily. Participants will be asked to consume 1 serving per day for 3 months.
214986682|NCT07167277|DIETARY_SUPPLEMENT|Placebo|A calorie matched serving of carbohydrate powder will be given to participants to consume daily. Participants will be asked to consume 1 serving per day for 3 months.
214683870|NCT02419183|OTHER|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
214683871|NCT02419183|OTHER|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
214683872|NCT01415622|DEVICE|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
214683873|NCT01415622|PROCEDURE|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
214683874|NCT01745627|DEVICE|755nm Alex laser|
214683875|NCT01052597|DRUG|curcumin|Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
214683876|NCT06094777|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
214683877|NCT06672757|DEVICE|CV_AID|"Upon arrival at the scene, the paramedic utilizes a mobile app with an integrated camera to aid in conducting the National Institutes of Health Stroke Scale (NIHSS) assessment. The app assists in scoring the patient\&#39;s responses according to NIHSS criteria to determine the severity of stroke symptoms.~If the app assessment indicates a high likelihood of stroke, transport can be initiated without a conference with the neurovascular centre. The app shares the recorded NIHSS assessment and video of the patient with the neurovascular centre for review.~While en route, the paramedic confer with the neurovascular centre to discuss the patient\&#39;s condition and determine appropriate course of action. If the neurovascular centre decides not to treat the patient, transport can be diverted to the nearest hospital.~The paramedic documents all assessment findings, interventions, and communications related to the stroke patient in the patient care record. U"
214683878|NCT04384263|BEHAVIORAL|Tai Chi|Participants in the Tai Chi group will practice a Yang style, 8-form Tai Chi routine. Specifically, the routine will incorporate slow, deep breathing and mental relaxation by utilizing Tai Chi movements which: 1) are slow and smooth; 2) without break or pause; and 3) have minimal muscular force and exertion. In addition, investigators will emphasize the breathing techniques of Tai Chi exercise. Investigators will adopt methods of progression to enable the participants learn and safely adapt to the Tai Chi routine and improve skills of practicing, specifically: 1) Tai Chi forms will be taught one at a time; 2) participants will receive instructional videos with step-by-step instructions of how to perform the new Tai Chi form that has been taught in the live online Tai Chi exercise session. Participants will be encouraged to practice Tai Chi offline between live online Tai Chi exercise sessions; however, no time requirement will be proposed.
214683879|NCT05901597|DEVICE|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer
214986683|NCT07167602|BEHAVIORAL|Positional Release Therapy|A manual therapy technique applied to the medial and lateral hamstrings after conventional physiotherapy. In PRT, the affected muscle is placed in a position of maximal comfort and relative shortening, while gentle pressure and controlled joint movements are applied. This position is held for approximately 30 seconds and repeated three times per session. The method aims to decrease neuromuscular tension, reduce pain, and promote muscle relaxation through a reflexive response. Distinct from Active Release Therapy, PRT does not involve active contractions or longitudinal tension but instead relies on positioning and relaxation to achieve therapeutic effects.
214986684|NCT07167602|BEHAVIORAL|Active Release Therapy|A manual therapy technique applied to the hamstrings after conventional physiotherapy. ART combines therapist-applied longitudinal tension with patient movement and brief isometric contractions of both hamstrings and quadriceps. The limb is guided through specific ranges of motion to break down adhesions, restore tissue mobility, and improve flexibility. Unlike Positional Release Therapy, ART is an active technique requiring patient engagement through contractions and controlled movement against resistance, targeting scar tissue and myofascial restrictions.
214495183|NCT06750978|BEHAVIORAL|Self-reflection + Contingency management|Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will receive an incentive ($8) if they meet the daily PSU reduction goal.
214495184|NCT04032106|OTHER|Best Practice|Receive standard information about HPV and HPV vaccine
214495185|NCT04032106|OTHER|Informational Intervention|Receive Outsmart HPV intervention
214683880|NCT05482646|BEHAVIORAL|Tai Chi|The Tai Chi intervention will be prescribed as a 3-month program with two 1.5-h sessions weekly instructed by qualified Tai Chi instructors.
214683881|NCT05482646|BEHAVIORAL|Conventional exercise|The conventional exercise intervention will be prescribed as a 3-month program with two 1.5-h sessions of generic fitness training weekly instructed by qualified instructors.
214683882|NCT05482646|BEHAVIORAL|Health Education Control|Participants in the control group will participate in a health education program delivered by research personnel.
214683883|NCT05329155|DRUG|Heparin Sodium Injection|Heparin Sodium Injection (100U/Kg body weight)
214986685|NCT07167602|OTHER|Conventional Physiotherapy|Hot pack, TENS, hamstring stretching, ankle pumps (common to both groups).
214986686|NCT07168434|DRUG|Saccharomyces Boulardii 250 MG|Saccharomyces boulardii CNCM I-745, 250 mg, 2 capsules/day
214986687|NCT07168434|DRUG|Placebo 250 mg|Placebo, 250mg, 2 capsules/day
214986688|NCT07168421|DRUG|Landiolol|The main dose range is 1-40 mcg/kg/min, titrated to the effect on heart rate aiming for a heart rate of below 90 beats per minute throughout. This dose can be decreased to 0 if heart rate stays below target.
214495186|NCT04032106|OTHER|Questionnaire Administration|Ancillary studies
214495187|NCT04032106|BEHAVIORAL|Text Message-Based Intervention|Receive unidirectional text message vaccine reminders
214495188|NCT04032106|BEHAVIORAL|Text Message-Based Intervention|Receive interactive text message vaccine reminders
214495189|NCT06255171|BEHAVIORAL|Reading journalistic posts and articles on social media on nature|Reading journalistic posts and articles, published on social media, regarding nature.
214495190|NCT06255171|BEHAVIORAL|Reading journalistic posts and articles on social media on deaths by suicide|Reading journalistic posts and articles, published on social media, regarding deaths by suicide.
214495191|NCT06255171|BEHAVIORAL|Reading journalistic posts and articles on social media on traffic-related deaths|Reading journalistic posts and articles, published on social media, regarding traffic-related deaths
214495192|NCT06435663|OTHER|Different methods of efficacy evaluation|When the treatment method remains unchanged, compare the accuracy data of the effectiveness evaluation between the two groups, and verify that the ultra-fine blood flow imaging technology (SMI) is superior to the organ contrast-enhanced ultrasound evaluation method in the efficacy evaluation after HIFUA treatment.
214495193|NCT06847321|DRUG|LHP588|25 mg
214495194|NCT06847321|DRUG|LHP588|50 mg
215089601|NCT01329744|DRUG|mecasermin|a subcutaneous injection twice a day
215089602|NCT01329744|DRUG|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
215089603|NCT00123773|PROCEDURE|Positron Emission Tomography|
215089604|NCT02610491|DIETARY_SUPPLEMENT|Hesperidin|Citrus peel extract
215089605|NCT02610491|DIETARY_SUPPLEMENT|Placebo|Cellulose
215089606|NCT02210091|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
215089607|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
215089608|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
215089609|NCT01613352|OTHER|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
215089610|NCT01268215|DRUG|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
215089611|NCT01268215|DRUG|Pulmicort|Endotracheal instillation, once per week for three weeks
215089612|NCT01268215|OTHER|Sham|None instilled through the endotracheal tube
215089613|NCT01730404|DRUG|CHF6001 DPI|
215089614|NCT01730404|DRUG|Roflumilast|
215089615|NCT01730404|DRUG|Placebo|
215089616|NCT02290938|BEHAVIORAL|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
215089617|NCT02290938|OTHER|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
214393821|NCT05554146|OTHER|Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
214495195|NCT06847321|DRUG|Placebo Drug|Placebo
214495196|NCT06789055|OTHER|Cold Spray|Before the capillary blood glucose measurement, cold spray will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.
214495197|NCT06789055|OTHER|Placebo|Before the capillary blood glucose measurement, placebo will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.
214495198|NCT06829212|DEVICE|WRS|WRS is a minimally invasive, wireless brain-machine interface system, consisting of a wireless implanted neural signal collector(Model: WRS64), data energy transmitter(Model: DTC01/02), and a brain function information management platform software(Model: SW01).
214495199|NCT02898610|DRUG|Colchicine|
215089618|NCT03362697|DIETARY_SUPPLEMENT|Probiotics|The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
215089619|NCT03362697|DRUG|Antibiotics|Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
215089620|NCT06385535|BEHAVIORAL|Habit Reversal Training (HRT)|Habit Reversal Training (HRT) is a multicomponent treatment package developed to treat a repetitive behaviors. HRT includes (1) increasing awareness of discrete occurrences of tics and associated premonitory urges (PMUs; i.e., awareness training), (2) teaching the patient to suppress tics by engaging in behaviors that are physically incompatible with target tics (i.e., competing response \[CR\] training), and (3) prompting and reinforcing between-session patient engagement with therapeutic techniques and homework (i.e., providing social support).
215089621|NCT02578342|DEVICE|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
215089622|NCT00906269|DRUG|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
215089623|NCT00906269|DRUG|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
215089624|NCT06377709|OTHER|ProACTive|ProACTive intervention, a talking therapy utilising acceptance and commitment therapy (ACT) techniques.
215089625|NCT04507165|PROCEDURE|Paravertebral block+Anterior serratus plane block|"Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure."
214373441|NCT04597710|GENETIC|utility of whole genome sequencing (WGS) to aid clinical decision making in patients referred for liver resection|All participants will attend their planned outpatient surgery appointment.The consultant will document the intended treatment plan for each participant in line with their usual care pathway.Following this, participants will be required to attend three dedicated study visits:The results of the MRI scans from Study Visit 1 will be analysed into a LiverMultiScan report.A report will be sent to the consultant who will review their original documented care plan alongside the LiverMultiScan report.The consultant may update the intended care plan as a result of the LiverMultiScan report, in line with the device CE-marking.Any changes to the care plan will be documented.The patient will then undergo their planned treatment.The tumour explant will be collected and samples will be stored, transported and processed for genetic sequencing and digital histopathology.Study Visit 2 will be performed remotely 12 months following their planned treatment,where patient reported outcomes will be collected
214373442|NCT06163053|DRUG|Immunotherapy|Immune checkpoint inhibitors in approved indications
214683884|NCT06327321|DRUG|Deucravacitinib|Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
214683885|NCT06327321|OTHER|Volunteer without treatment|Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
214683886|NCT05579704|BEHAVIORAL|Web-based wellness platform|A web-based wellness platform is based on preventive self-care and contains tools to monitor nutrition, physical activity, and mental wellbeing.
214373443|NCT06339060|COMBINATION_PRODUCT|Experimental: Arm 1 Organ preservation|"Arm 1 patients will undergo clinical response evaluations (CREs) after neoadjuvant therapy(A+B+C）, If cancer is detected, surgery will be performed. Patients with clinical complete response （cCR） are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer.Postoperative adjuvant therapy will follow the NCCN guideline.~A: Camrelizumab 200mg IV on days 1 and 22 B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~A+B+C=Neoadjuvant therapy"
214683887|NCT05579704|BEHAVIORAL|Healthcare professional-facilitated online support group|Participants will take part in weekly group video conferencing sessions with various health professionals (registered dietitian, mental health therapist, and exercise professional). The sessions will occur once per week for 1 hour each. The group sessions will contain cohorts of approximately 10 individuals.
214683888|NCT05647811|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
214683889|NCT01893840|DEVICE|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
214986689|NCT07169487|DRUG|Methylene Blue|Intravenous infusion of methylene blue once daily for 3-5 consecutive days at doses of 1 mg/kg, 2 mg/kg, or 3 mg/kg, administered over 20 minutes, following CAR-T or bispecific antibody infusion in patients who develop Grade ≥1 CRS or ICANS.
214373444|NCT06339060|COMBINATION_PRODUCT|Active Comparator: Arm 2 Surgery|"Arm 2 patients will undergo surgery after neoadjuvant therapy(B+C）.Postoperative adjuvant therapy will follow the NCCN guideline.~B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week."
214373445|NCT02192775|DRUG|MV-NIS|one dose in conjunction with a 4 day course intravenously
214495200|NCT05489289|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 16 cycles
214495201|NCT05489289|BIOLOGICAL|placebo|Subjects will receive placebo until disease progression or for a maximum of 16 cycles
214495202|NCT04466150|DRUG|Ocrelizumab|open label biomarker study
214495203|NCT06789146|PROCEDURE|Serratus posterior superior intercostal plane block|"Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
214495204|NCT06789146|PROCEDURE|Thoracic Paravertebral Block|"Thoracic paravertebral block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
214495205|NCT04846881|DRUG|Iclepertin|Iclepertin
214495206|NCT04846881|DRUG|Placebo|Placebo
214495207|NCT06735599|DIETARY_SUPPLEMENT|Wild Blueberry|Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks
214495208|NCT06735599|DIETARY_SUPPLEMENT|Placebo|Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks
214495209|NCT03005652|BEHAVIORAL|Mindfulness weekly courses for 8 weeks|The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
214683890|NCT01752569|DRUG|Selumetinib|"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
214683891|NCT02995343|PROCEDURE|Hypogastric and/or uterine artery ligation|
214683892|NCT03335852|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
214986690|NCT07166926|DEVICE|Mobile CT|SOMATOM On.site
214683893|NCT06082557|DRUG|T60c injection|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion."
214986691|NCT07166991|DRUG|Volatile anesthetic|"In the volatile anesthetic group, sevoflurane will be administrated during the organ procurement procedure. Administration will be initiated progressively after moving in the operating room and will be pursued until aortic clamping (targeted end-expiratory concentration suggested between 1 and 2%).~No opioid agent (or intravenous hypnotic agent) will be allowed in this group."
214986692|NCT07166991|DRUG|Opioid Anesthesia|In the opioid anesthetic group, intravenous sufentanil will be administrated during the organ procurement procedure. Continuous administration will be initiated after moving in the operating room (suggested dosage : 0,3 µg/kg/h) with supplemental dose if needed (at the discretion of the anesthesia team) and will be pursued until aortic clamping. No hypnotic drug administration will be allowed in this group.
214683894|NCT05523063|OTHER|Quality of life questionnaire|"The quality of life questionnaire will be performed in routine practice by the CAMI during the initial assessment.~The 3-month visit is part of the routine patient visit to CAMI. During this visit, the quality of life questionnaire will be completed a second time by the patients, through a phone call given by the investigator."
214986693|NCT07166991|OTHER|Intraoperative brain-dead donor management|"In all groups (experimental and control groups), neuromuscular blocking agents will be administered during the entire procedure, according to national guidelines. In all groups, hemodynamic management (use of vasoactive agents as vasopressors or anti-hypertensive drugs) will be done according to the discretion of the anesthesia team.~In all groups, all the others aspects of the donor management will be not modified by the study protocol."
214683895|NCT00747617|DRUG|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
214683896|NCT00988741|DRUG|ARQ 197|The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.
214683897|NCT00988741|DRUG|Placebo|The placebo is provided in a capsule form.
214683898|NCT02279524|DRUG|Aramchol|"Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study."
214683899|NCT00518219|DRUG|TW|TW,120mg/d
214683900|NCT01746732|DRUG|Ortho-Cyclen|Oral administration
214683901|NCT01746732|DRUG|Evacetrapib|Oral administration
214683902|NCT03509207|DRUG|Vorinostat Oral Capsule|Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
214683903|NCT02817555|DRUG|Epoetin Alfa|"The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin \> 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
214683904|NCT02817555|DRUG|Darbepoetin alfa|"The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin \>150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
214986694|NCT07167511|OTHER|This study is a retrospective study, and all data have been collected in advance with no active intervention required.|This study is a retrospective study, and all data have been collected in advance with no active intervention required.
214986695|NCT07167771|OTHER|No intervention|There is not intervention in these patients, appart from their normal dental check-up visits.
215089626|NCT04507165|DRUG|opioid free anesthesia|"Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h)."
214683905|NCT05390450|DEVICE|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block. Prior to Popliteal plexus block, the proximal end of the adductor canal will be identified. The transducer will be slid distally along the femoral artery until the artery deviated away from the sartorius muscle in the distal part of the adductor canal towards the adductor hiatus. The nerve block needle will be inserted from the anterolateral end of the transducer and advanced in-plane through the medial vastus muscle. The endpoint of injection will be inside the distal end of the adductor canal close to the adductor hiatus. The injection will be adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle. The Popliteal plexus block will be carried out with 10 mL of local anesthetic mixture, containing 50 mg of bupivacaine and 0.05 mg of epinephrine.
214683906|NCT05390450|DEVICE|Ultrasound-Guided Fascia Iliaca block|Patients will be placed in a supine position, and the skin will be cleaned aseptically. The inguinal ligament from the anterior superior iliac spine to the pubic tubercle will be drawn on the skin and divided into 3 parts. The injection point was 1 cm caudally from the point where the lateral and middle part of the inguinal ligament met. The skin and deep tissues were infiltrated with 1% lidocaine. A 18G nerve block needle will be inserted into the skin perpendicularly until the first (fascia lata) and second loss of resistance (fascia iliaca) will be felt. Following aspiration to exclude intravascular injection, 40 mL of 0.25% bupivacaine (1-1.5 mg/kg), which will be prepared under aseptic conditions, and then injected. Sensorial block will be evaluated using the pinprick test 20 minutes after injection for areas of the thigh innervated by the femoral, lateral cutaneous and obturator nerves.
214683907|NCT01838174|DRUG|ACTHAR Gel (ACTH)|15 days of daily injections
214683908|NCT01838174|DRUG|IV methylprednisolone (steroids)|3 days of intravenous methylprednisolone followed by 11 days of oral taper
214683909|NCT05275738|DIETARY_SUPPLEMENT|Nicotinamide|Study tablets for nicotinamide are produced by Blackmores Ltd.
214683910|NCT05275738|OTHER|Placebo|Study tablets for placebo are produced by Blackmores Ltd.
214683911|NCT06106321|PROCEDURE|Transalveolar crest maxillary sinus floor lift|Transalveolar crest maxillary sinus floor lift + bone grafting + implant implant is used
214683912|NCT06106321|PROCEDURE|transalveolar crest parietal maxillary sinus floor secondary lift|Transalveolar crest parietal maxillary sinus floor secondary lift + bone grafting + implant implantation were used body
214683913|NCT00137436|DRUG|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
214683914|NCT00137436|DRUG|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
214683915|NCT00137436|DRUG|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
214495210|NCT03005652|BEHAVIORAL|Health education weekly courses for 8 weeks|The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
214683916|NCT05745116|DEVICE|Notal Vision Home OCT|Optical Coherence Tomography (OCT) was originally developed in 1991 as a non-invasive imaging technology to generate cross-sectional imagery of ocular tissues in vivo1. Cross-sectional visualization of the retina has proven to be a valuable tool in the identification and assessment of structural abnormalities that are not visible with ophthalmoscopic or biomicroscopic examination. OCT has become eye care professionals' leading diagnostic tool in the detection, diagnosis and treatment of retinal diseases and conditions, including age-related macular degeneration (AMD), Diabetic Macular Edema (DME), and Retina Vein Occlusion (RVO). Notal Vision, Inc. (Manassas, VA) is developing a Home Optical Coherence Tomography (OCT) System to allow OCT images to be captured on an OCT device placed in the patients' homes for daily scanning of eyes diagnosed with DME. This Home OCT allows visualization of retinal fluid in the central 10 degrees and is currently for investigational use only.
214373446|NCT03056534|DEVICE|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
214373447|NCT00563225|DRUG|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
214373448|NCT01163890|BEHAVIORAL|Work and Health Initiative|Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
214373449|NCT01163890|BEHAVIORAL|Usual Medical or Behavioral Intervention|Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
214373450|NCT02661100|DRUG|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
214373451|NCT02661100|BIOLOGICAL|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
214495211|NCT06745817|DIAGNOSTIC_TEST|Assessement of nutritional status|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
214495212|NCT06745817|DIAGNOSTIC_TEST|Dermis density and thickness|Dermis density and thickness will be measured using ultrasonography with Cortex DermaLab 20 MHz US probe.
214495213|NCT06745817|DIAGNOSTIC_TEST|Skin elasticity|Skin elasticity will be measured using Cortex DermaLab elasticity probe.
214495214|NCT06745817|DIAGNOSTIC_TEST|Body composition measurement|Body composition will be measured using Biostat Multiscan 5000.
214495215|NCT06745817|DIAGNOSTIC_TEST|Screening questionnaire|Screening questionnaire: assessment of socio-demographic parameters, use of food supplements, health status, dietary habits
214495216|NCT06734442|OTHER|Video-Assisted Thoracoscopy with blebectomy and pleural abrasion|Thoracoscopic management of pneumothorax
214683917|NCT00443378|BEHAVIORAL|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
214373452|NCT02661100|BIOLOGICAL|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
214373453|NCT03133559|OTHER|Observational|We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.
214373454|NCT03775460|DRUG|Methotrexate|Participants in the intervention group will receive methotrexate along side prednisolone
214373455|NCT03775460|DRUG|Placebo|Participants in the control arm will receive placebo along side prednisolone
214373456|NCT03775460|DRUG|Prednisolone|Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
214373457|NCT02063828|DEVICE|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 12 weeks.
214373458|NCT02063828|DEVICE|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 12 weeks.
214373459|NCT02063828|DEVICE|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 12 weeks.
214373460|NCT05277844|RADIATION|Local Consolidative Radiation Therapy|Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
214373461|NCT05277844|DRUG|TKI|TKI
214373462|NCT03654742|PROCEDURE|tonsillectomy|removal of tonsil tissue as described in the study arms
214495217|NCT06765720|OTHER|Intermittent feeding method with nasogastric tube|"30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding.~5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding.~Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding.~Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool."
214683918|NCT00165646|DRUG|E3810|E3810 5mg: once daily orally for 4 weeks
214683919|NCT00165646|DRUG|E3810|E3810 10mg: once daily orally for 4 weeks
214683920|NCT00165646|DRUG|Placebo|Placebo: once daily orally for 4 weeks
214683921|NCT04743245|DEVICE|TherOx DownStream System|SSO2 Therapy with Therox downstream System after Percutaneous Coronary Intervention (PCI)
214683922|NCT04743245|DEVICE|PCI|Standard Care of PCI
214683923|NCT05412719|BEHAVIORAL|THE EFFECT OF FINGER PUPPET MANIPULATION ON PAİN AND PHYSİOLOGıCAL PARAMETERS DURING URINARY CULTURE WITH URINARY CATHETERIZATION IN INFANTS|the effect of finger puppet manipulation on pain and physiological parameters during urinary culture with urinary catheterization
214683924|NCT02975440|DRUG|Rifampicin|11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
214683925|NCT02975440|DRUG|Midazolam|2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
214373463|NCT06822426|DRUG|(taurolidine and heparin) catheter lock solution|for central venous catheter installation use
214683926|NCT02975440|DRUG|BAY1002670_Vilaprisan|2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
214683927|NCT02600026|DEVICE|DriveCam|Video event monitoring device
214683928|NCT02600026|BEHAVIORAL|Feedback|Video feedback intervention
214683929|NCT05263128|OTHER|Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome|To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey
214683930|NCT00738543|OTHER|WHOLE GROUP OF 48 VOLUNTEERS|Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
214683931|NCT03609658|BEHAVIORAL|Nurse Navigator Pathway|In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.
214373464|NCT06822426|DRUG|Heparin|Heparin
214373465|NCT06205485|DRUG|Leucovorin|400 mg/m2
214373466|NCT06205485|DRUG|Oxaliplatin|85 mg/m2 or 130 mg/m2 on day 1
214373467|NCT06205485|DRUG|Fluoruracil|bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2
214373468|NCT06205485|DRUG|Capecitabine|1,000 mg/m2 twice daily for 14 days
214373469|NCT06205485|RADIATION|Radiation|54 Gy (27-30 fractions)
214373470|NCT03484598|DEVICE|SPEAC System|A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
214373471|NCT03334500|DEVICE|[18F]FluorThanatrace|Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.
214683932|NCT03609658|BEHAVIORAL|Usual Care|In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
214373472|NCT03334500|DRUG|Poly(ADP Ribose) Polymerase 1|Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
214373473|NCT06521502|OTHER|Blood collection|"Blood will be collected from a catheter (IV) that is already in place or using a needle stick into a vein.~Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort)."
214373474|NCT06521502|OTHER|Urine Collection|"Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.~Urine will be collected in hospital only (Cohorts A, B)"
214373475|NCT06521502|OTHER|Nasal, oral, and rectal swabs|"Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.~Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B)."
214495218|NCT06765720|OTHER|Intermittent feeding method with orogastric tube|"30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding.~5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding.~Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding.~Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool."
214495219|NCT04363827|DRUG|Hydroxychloroquine|Hydroxychloroquine
214495220|NCT06844591|OTHER|Conditioning Exercises/ Aerobic Interval Training|Aerobic interval training (AIT), which included rest intervals in between sessions of aerobic activity on a stationary bike and treadmill, was administered to the control group. A 10-minute warm-up, or a maximum of 50% to 60% of HR, preceded the program. The next activity round consisted of six x six-minute intervals of cycling and walking/uphill running on a treadmill at 60% to 85% of THR, separated by three minutes of rest/recovery. A ten-to fifteen-minute cool- down period followed the session.
214683933|NCT02726932|OTHER|No intervention, merely observational|
214683934|NCT01132677|DEVICE|Hylan G-F 20 (Synvisc One)|Single IA injection of 6cc's. Injections will be administered as outlined on the company label.
214683935|NCT01132677|DRUG|Methylprednisolone (Corticosteroid)|Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
214683936|NCT06384924|DEVICE|Raman Spectroscopy handheld probe (EmVision, FL, USA)|The probe is approximately the size of a pen or pencil. The handheld probe is connected to the laser source using a cable. The probe is placed in light contact with the skin. The features of the laser light after it bounces off the skin is collected. This measurement can allow us to see tissue characteristics. This is a single session that will take approximately 15 minutes.
214683937|NCT06384924|DEVICE|Raman Spectroscopy laser source (Hubner Photonics Inc, CA, USA)|This light source will create the laser light that will pass through the cable and through the handheld probe onto the skin.
214683938|NCT04765800|BEHAVIORAL|weekly, biweekly, or twice a week sessions of face-to-face outpatient psychotherapy|according to the German Psychotherapy Guidelines (Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie)
215089627|NCT04507165|DRUG|opioid based anesthesia|"Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively."
214683939|NCT00912015|DRUG|Tramadol OAD|
214683940|NCT00912015|DRUG|Tramadol OAD|
214683941|NCT00912015|DRUG|Tramadol OAD|
214683942|NCT00912015|DRUG|Tramadol OAD 100mg|
214683943|NCT03550326|PROCEDURE|airway management|patients will be intubated or will be placed an airway device
214683944|NCT05647057|COMBINATION_PRODUCT|A: gelofusine + ringers|750 milliliter (mL) modified fluid gelatin (Braun Melsungen, Germany), 650 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
214683945|NCT05647057|COMBINATION_PRODUCT|B: albumine + ringers|200 mL human albumin (20%, Sanquin, Amsterdam, Netherlands), 1200 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
214683946|NCT05647057|COMBINATION_PRODUCT|C: ringers + retrograde autologous priming|"1400 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands) with retrograde autologous priming.~Retrograde autologous priming (RAP) is applied using clinical parameters such as Central Venous Pressure, Mean Arterial Pressure (MAP), and intra cardiac filling pressure based on Trans Esophageal Echo as guidance to the amount of fluid displaced. RAP is applied to a maximum volume of 475 mL provided that systolic blood pressure will remain \>90 millimeter of mercury (mmHg). Phenylephrine can be administered up to 200 mcg to keep the system hemodynamics stable during RAP. In case of a body surface area \<1.7m2, a maximum volume of 375 mL is desired. Once the desired amount of prime is displaced, the transfusion bag is clamped and CPB is started. If additional fluids are needed during CPB to maintain optimal perfusion, the displaced prime is used prior to the vasoplegia protocol."
214683947|NCT01109901|PROCEDURE|anterior subcutaneous transposition|transposition of ulnar nerve into subcutaneous bed
214495221|NCT06844591|OTHER|Resistance Interval Training|Resistance interval training for post-coronary artery bypass grafting (CABG) patients requires careful consideration and should be conducted under the supervision of healthcare professionals, such as cardiac rehabilitation specialists or physiotherapists. Exercise programs for individuals recovering from cardiac surgery must be tailored to their specific needs, taking into account their overall health, medical history, and current fitness level. Before beginning any exercise program, it's essential to obtain clearance from a healthcare provider. The workout lasted thirty to forty minutes in total. To fit the training load, resistance and intensity were gradually raised. For six weeks, this supervised training program was adhered to three times a week on alternate days
214495222|NCT06762860|DRUG|Dexmedetomidine|label sticker
214683948|NCT01109901|PROCEDURE|Anterior submuscular transposition|transposition of ulnar nerve into muscular tissue
214683949|NCT04114994|DIAGNOSTIC_TEST|Boston Cognitive Assessment (BoCA)|"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.~BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.~After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts."
214683950|NCT00568789|DRUG|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
214495223|NCT06762860|DRUG|Granisetron|label sticker
214495224|NCT06762860|OTHER|Placebo|label sticker
214495225|NCT06766565|DRUG|QYJD Compound Preparation|The intervention group was treated with 2 capsules (g) of expelling stasis and QYJD compound preparation orally for 4 days before thoracoscopic radical surgery for lung cancer, 3 times a day. The blank control group had no oral drug treatment before surgery.
214495226|NCT05064293|BEHAVIORAL|Navigation Arm|Families will be offered a formal assessment to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to the navigator for connection to care or study-provided tele-video visits. Navigators will outreach families monthly during the 6-month study period. The navigator will inquire about the child's status and re-evaluate barriers to access. When barriers exist, the navigator will help in facilitating specialty treatment initiation and assess appropriateness of tele-video therapy sessions until ongoing MH services can be arranged. Families/patients reporting that index symptoms have resolved will be offered a 'watchful waiting' approach. Subjects accepting 'watchful waiting' will be outreached quarterly, but not beyond the end of the 6-month follow-up period.
214495227|NCT05064293|BEHAVIORAL|Control Arm|Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders (e.g., substance use). After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider. Control arm participants do not receive navigation.
214495228|NCT04109950|DRUG|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
214683951|NCT03978494|DRUG|Advagraf®|Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
214683952|NCT03978494|DRUG|Generic tacrolimus|Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
214683953|NCT03445013|DRUG|SB414 6%|Twice daily
214683954|NCT03445013|DRUG|Vehicle|Vehicle Comparator
214683955|NCT05791318|DRUG|VYD222|Monoclonal antibody
214683956|NCT05791318|OTHER|Placebo|Matching Placebo
214683957|NCT01356602|DRUG|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
214683958|NCT01356602|DRUG|Canakinumab lyophilized powder|Canakinumab lyophilized powder
214683959|NCT01356602|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide
214683960|NCT01356602|DRUG|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
214683961|NCT05232942|OTHER|Headache calendar completion|The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
214683962|NCT02146807|DEVICE|Picosecond Laser system|Picosecond Laser System for the Treatment of Unwanted Tattoos
214986696|NCT07169305|PROCEDURE|Deep Margin Elevation|The tooth preparation is performed using conventional diamond burs. The extent of caries decides the group into which the participant falls. A precontoured sectional matrix (Palodent) with a properly sized plastic diamond wedge (Bioclear Matrix Systems) is applied and stabilized using a separating ring to ensure closure of deep cervical margins, adaptation of the matrix cervically and attain contact tightness. A 37% phosphoric acid etch gel is used for Selective Enamel Etching technique for 15-20 seconds. Two coats of adhesive are applied to both enamel and dentin using a microbrush and light cured. Flowable bulkfill composite (SDR plus, Dentsply, Sirona) restorative composite is placed using teflon coated hand instruments to perform DME till the level of CEJ and light cured for 20s. Further build up of proximal box is done using packable composite. The restoration is finished using fine grit yellow coded tapered diamond stones. Polishing done by using Composite Polishing kits.
215089628|NCT06113575|DEVICE|NeuroStar TMS|NeuroStar TMS treatment - 90-120% of Observed MT, 3 pulses/burst, 5 bursts/sec, 2 sec stimulation, 20 msec interval, 20 trains, 600 total pulses/session for 36 treatments in 5 days. 6 treatments on day 1, 8 treatments on days 2, 3, and 4, 6 treatments on day 5.
215089629|NCT05069207|OTHER|POWER breathe K5|Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
215089630|NCT05794711|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
215089631|NCT01231815|RADIATION|15O-H2O PET -|Assessment of coronary reserve using PET
214373476|NCT06521502|OTHER|Stool collection|"Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.~Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort)."
214373477|NCT06521502|OTHER|Heat Moisture Exchange Filter collection|"An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.~HME filters will be collected in hospital on intubated patients only (Cohorts A, B)."
214373478|NCT06521502|OTHER|Tracheal Aspirate sample collection|"Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.~Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)"
214373479|NCT06521502|PROCEDURE|Non-bronchoscopic bronchoalveolar lavage (NBBAL)|"The NBBAL procedure involves putting a flexible rubber tube through the breathing tube into the airway of one of the lungs. A small amount of fluid is injected into the lung and then a gentle suction is used to collect fluid. Only patients who pass a safety screen showing that they are not at high risk for complications will have the NBBAL procedure performed.~NBBAL will be performed in hospital on intubated patients only (Cohort A)"
214495229|NCT04882917|DRUG|M4076|M4076 was administered orally.
214986697|NCT07167459|DEVICE|ndividualized Stereotactic Body Radiotherapy (SBRT) System|The individualized SBRT system employs advanced image-guided radiation delivery to deliver highly conformal, ablative doses to early-stage peripheral non-small-cell lung cancer while minimizing exposure to surrounding normal tissues. Treatment is delivered via a state-of-the-art robotic radiosurgery platform (e.g., CyberKnife M6) according to patient-specific fractionation schedules based on tumor size and proximity to critical structures, following standard indications and institutional protocols for medically inoperable or surgically refused cases.
214495230|NCT04950764|DRUG|Seladelpar 10 mg|Seladelpar 10 mg single oral dose
214495231|NCT04950764|DRUG|Seladelpar 10 mg or less|Seladelpar 10 mg or less, once daily for 28 days
214986698|NCT07167927|BEHAVIORAL|Decision support tool|Decision support tool developed for patients, parents, and providers of children with neuromuscular scoliosis
214986699|NCT07169474|PROCEDURE|Isolated trapeziometacarpal arthroplasty with double mobility|Isolated trapeziometacarpal arthroplasty with double mobility in all cases, using a MAIA or TOUCH prosthesis depending on the operator's habits.
214986700|NCT07168070|OTHER|physical therapy and exercise|"Participants will receive one-on-one physiotherapy sessions, 45 minutes each, three times per week for 6 weeks. Sessions will include range of motion, strengthening, balance, and gait training.~Home-based Exercise Participants will be instructed to perform a structured home exercise program to complement in-clinic sessions."
214986701|NCT07168070|BEHAVIORAL|group physical therapy vs individualized physical therapy|group physical therapy vs individualized physical therapy
214373480|NCT06521502|OTHER|Surveys|Participants will be contacted by email, text, and /or phone to give updates about their health. These surveys will ask questions about quality of life, mental health, return to work, and re-admission to the hospital. (Cohort A)
214495232|NCT06192615|DRUG|Intravenous Dexmedetomidine|Intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg)
214495233|NCT06192615|DRUG|Sublingual Dexmedetomidine|Sublingual dexmedetomidine (120 μg)
214495234|NCT06192615|DRUG|Intravenous Placebo|Intravenous placebo of 0.9% saline administered over 40 minutes
214495235|NCT06192615|DRUG|Sublingual Placebo|Inert sublingual film
214495236|NCT06865469|DRUG|Dexmedetomidine|dexmedetomidine will be administered by i.v. infusion at 0.4 μg/kg/h
214495237|NCT06865469|DRUG|Lidocaine Hydrochloride 2%|lidocaine hydrochloride 2% (400 mg/20 mL) 1.5 mg/kg/h by i.v. infusion.
214495238|NCT06892912|OTHER|Diaphragmatic ultrasound|"Sample:~Given the observational nature of the study, a convenience sample will be obtained from all patients admitted to the emergency services and/or ICU with respiratory failure over the course of 1 year.~Inclusion Criteria:~* Age ≥ 18 years~* Hypoxemic respiratory failure (SpO2 \< 88% - PaO2 \< 60 mmHg) or hypercapnic (PaCO2 \> 40)~* Need for NIMV and/or HFNC.~Exclusion Criteria:~* Neuromuscular disease~* Pregnancy~* Tracheostomy~* Rib fractures~* Cervical injuries~* Diaphragmatic paralysis~* Diaphragmatic malformations~* Hemodynamic instability~* Morbid obesity (BMI \> 35)~* Use of sedation and neuromuscular relaxants~* Pneumothorax or pneumomediastinum~* Poor acoustic window~* Critically ill patients with a prognosis of less than 24 hours of life~* Patients receiving palliative interventions."
214495239|NCT06836336|BEHAVIORAL|Hybrid therapy|Hybrid intervention that combined face-to-face educational sessions with the integration of technological advancements. They attended weekly 40-minute interactive educational sessions over the course of a month. The educational materials encompass information regarding the components of a healthy balanced diet and an active lifestyle.Throughout the intervention, participants were provided with a range of behavior change techniques to support participants in applying the educational content to improve their dietary and lifestyle habits. The employed behavior change techniques were SMART (specific, measurable, achievable, relevant, time-bound) goal setting, reviewing behavioral goals, problem-solving and environmental restructuring. The technological support for this intervention included the use of a smartphone diet tracker app called MyFitneesPal as well as communication with the interventionists via WhatsApp.
214495240|NCT06836336|BEHAVIORAL|Fully digital|Fully digital intervention, where they received the same educational materials through WhatsApp twice a week over the course of one month. The educational materials were presented through easily understandable posters, brief videos, and followed by short quizzes to reinforce the acquired knowledge. Additionally, the digital intervention incorporated the same behavior change strategies that were utilized in the hybrid group. Participants were also introduced to MyFittnessPal application in order to help them track their dietary habits and monitor their progress since it is considered a tool for self-monitoring and promoting healthy dietary behaviors throughout the intervention period.
214495241|NCT06769880|OTHER|Ultrasound and Educational Intervention|This will include the educational intervention combined with a point-of-care ultrasound
214495242|NCT06769880|OTHER|Educational Intervention Alone|This will include only the educational intervention (without ultrasound)
214683963|NCT05904405|OTHER|quationaire|"Data will be collected through a semi-structured interview administered questionnaire which includes:~1. Socio-demographic characteristics of women~2. Family planning practice: This will include number of living children, current use of FP method and its type, and suggested causes of discontinuation of FP, previous contraceptive use, and reason for the visit 3-Facility factors such as gender of providers, qualification of providers, type of the health facility.~4-Quality of contraceptive counseling (QCC) scale: it is a 22-item scale which measures the quality of care received by women during family planning visits. It includes : 1) information exchange, 2) interpersonal relations, and 3) disrespect and abuse in contraceptive counseling. The information exchange subscale consists of ten items, the interpersonal relationship subscale consists of seven items, and the disrespect and abuse subscale consists of five items."
214683964|NCT02887534|DRUG|SPARC1401-low dose|SPARC1401- low dose
214683965|NCT02887534|DRUG|SPARC1401-mid dose|SPARC1401- mid dose
214683966|NCT02887534|DRUG|SPARC1401-high dose|SPARC1401-high dose
214373481|NCT06521502|OTHER|Short physical performance battery|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort)~Chair Stand Test: For this test the participant will sit in a chair. They will then stand as quickly as possible without using their upper body to assist them.~Balance Test: For this test the participant will stand unsupported for 10 seconds with their feet in 3 different positions.~4-meter walk: For this test the participant will walk 4 meters as quickly as possible."
214373482|NCT06521502|OTHER|Hand grip strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will squeeze a machine called a hand-held dynamometer 3 times with all their strength."
214373483|NCT06521502|OTHER|CNS Vital Signs|"At visits 3, 6, and 12 months following hospitalization (Cohort A - Long-term Outcomes Cohort):~The participant will sit at a computer and follow the prompts on the screen. This test takes about 45 minutes."
214373484|NCT06521502|OTHER|Muscle Ultrasound|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo ultrasound on the quadriceps muscle on the dominant side of their body."
214373485|NCT06521502|OTHER|Muscle Strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~A dynamometer will be used to measure muscle strength in the dominant leg."
214373486|NCT06521502|OTHER|Spirometry|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip placed on their nose and will be given a plastic mouthpiece that is connected to a machine called a spirometer. They will place their lips tightly around the mouthpiece and take in as big and deep of a breath as possible and then blow out as hard and fast as they can."
214373487|NCT06521502|OTHER|Lung Diffusion Testing (DLCO)|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip on their nose. They will put their mouth over a mouthpiece that is attached to a machine. This machine will deliver a small amount of carbon dioxide when they breathe in and will also record the results of the test. They will then take a few normal breaths. Next they will inhale deeply and exhale completely. They will breathe in quickly through their mouth and hold their breath for 10 seconds or as long as they can. Then they will breathe out."
214373488|NCT06521502|RADIATION|Chest CT Scan|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo a Chest Computed Tomography (CT) scan which uses special X-ray equipment to take detailed pictures of the lungs."
214373489|NCT04494945|PROCEDURE|Biospecimen Collection|Undergo collection of saliva sample
214373490|NCT04494945|OTHER|Genetic Counseling|Receive genetic counseling if testing results are positive
214683967|NCT02887534|DRUG|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
214373491|NCT04494945|OTHER|Genetic Testing|Undergo genetic testing
214373492|NCT04494945|OTHER|Survey Administration|Complete a survey
214373493|NCT06515821|DIAGNOSTIC_TEST|ONCOSCREEN|Subjects samples will be tested with diagnostic tests.
214495243|NCT06769191|BIOLOGICAL|CD7 CAR-T cells injection|Intravenous infusion, single dose
214495244|NCT06769191|PROCEDURE|Allo-HSCT|allogeneic hematopoietic stem cell transplantation
214495245|NCT06769191|PROCEDURE|Kidney Transplantation|Kidney Transplantation
214495246|NCT06752291|DEVICE|water flosser|A water flosser will be provided for use throughout the study, with participants instructed to use it once daily, specifically at the end of the day before bedtime.
214495247|NCT06070857|DRUG|LV232|Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
214495248|NCT06070857|DRUG|Placebo|Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
214495249|NCT06747728|DRUG|Bevacizumab|Patients were enrolled and given bevacizumab on days 1 and 15, administered by intravenous infusion at 5 mg/kg.
214495250|NCT06782477|DRUG|STAR-0310|STAR-0310 will be administered as a subcutaneous bolus injection.
214495251|NCT06782477|DRUG|Placebo|Placebo will be administered as a subcutaneous bolus injection.
214495252|NCT06776042|OTHER|Nasal brushing of the olfactory cleft|Nasal brushing of the olfactory cleft
214495253|NCT06776042|OTHER|Smell testing|Smell testing using the Sniffin' Sticks Test
214683968|NCT02887534|DRUG|Placebo1401|Placebo
214683969|NCT00887718|BIOLOGICAL|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
214683970|NCT04990245|DIAGNOSTIC_TEST|endoscopic biopsies|patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests
214683971|NCT05142657|OTHER|diet survey|Dietary survey applied to all participants
214683972|NCT01115569|DRUG|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
214683973|NCT01707069|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."
214683974|NCT04346134|PROCEDURE|mini-PNL|Percutaneous nephrolithotomy using miniature nephroscope. The procedure will be performed under general or spinal anesthesia under fluoroscopy guidance.
215089632|NCT01231815|RADIATION|MRI|Assessment of coronary reserve using MRI
215089633|NCT02170909|DRUG|BIBR 1048 MS low dose|
214683975|NCT04346134|PROCEDURE|SWL|Extracorporal shockwave lithotripsy using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
214683976|NCT00704743|DEVICE|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
214683977|NCT00704743|DEVICE|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
214683978|NCT00704743|DEVICE|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
214393822|NCT05554146|OTHER|Receipt of Coupon for High CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
214683979|NCT03811223|DRUG|Evolocumab Auto-Injector [Repatha]|Evolocumab 140 mg every 2 weeks for 12 weeks
214683980|NCT03811223|DRUG|Placebos|Placebo subcutaneous injection every 2 weeks for 12 weeks
214683981|NCT03451864|PROCEDURE|Vaginal delivery|classic vaginal delivery
214683982|NCT03451864|PROCEDURE|Cesarean Section|routine lower segment cesarean scetion
214683983|NCT00527215|DRUG|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
214683984|NCT02850887|OTHER|general endotracheal anesthesia|sedation with the use of endotracheal intubation
214683985|NCT02850887|OTHER|deep sedation without endotracheal intubation|deep sedation without endotracheal airway management.
214683986|NCT01931462|DEVICE|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
214683987|NCT02819310|DRUG|BLI400 Laxative|oral laxative
214683988|NCT00511407|DEVICE|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
214683989|NCT02046265|BEHAVIORAL|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
214683990|NCT02046265|BEHAVIORAL|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
214683991|NCT02046265|BEHAVIORAL|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
214683992|NCT02046265|BEHAVIORAL|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
214683993|NCT01152008|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
214683994|NCT01241851|BEHAVIORAL|Aerobic exercise|
214683995|NCT01241851|BEHAVIORAL|Resistance exercise|
214683996|NCT02266901|PROCEDURE|endoscopic drainage|Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
214683997|NCT04345991|DRUG|Transfusion of COVID-19 convalescent plasma|Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient
214683998|NCT01790893|DRUG|aflibercept|
214683999|NCT06239909|OTHER|24-h pad-weight test|The patients will be asked to perform the 24-h pad-weight test
214684000|NCT06239909|OTHER|Patient Global Impression - Improvement Questionnaire|The patient-reported outcome, as measured by PGI-I (Patient Global Impression - Improvement Questionnaire)
214684001|NCT02427256|DEVICE|Topcon Specular Microscope SP-1P|
214986702|NCT07168070|OTHER|Group Physical therapy|Participants will attend group physiotherapy sessions, where several patients receive treatment at the same time. Each session lasts 45 minutes, three times per week for 6 weeks, and includes range of motion, strengthening, balance, and gait training.
214986703|NCT07167303|OTHER|VR Training)|Participants were first introduced to the VR simulator and briefed on the current scenario. Through the VR headset, nurses experienced the CPR scenario in real time in an interactive environment. Each nurse had sufficient time to practice the skill steps in the given scenario. Participants used the scenario-based VR CPR training game until they felt ready (approximately 30 minutes)
214986704|NCT07167303|OTHER|Traditional Training|Nurses in the control group received traditional training in a hospital training room using an adult plastic CPR manikin
214986705|NCT07169227|DRUG|Lidocaine %2 ampoule|Patients who were administered 40 mg lidocaine.
214986706|NCT07169227|DRUG|Dexmedetomidine|Patients who were administered 0.25 mg/kg dexmedetomidine.
214986707|NCT07169227|DRUG|paracetamol|Patients who were administered 50 mg paracetamol.
214986708|NCT07167160|DRUG|Camrelizumab combined with chemotherapy|Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery
214986709|NCT07168499|BEHAVIORAL|Diet Management|Visit with IBD dietician for diet management specifically for IBD
214986710|NCT07168499|BEHAVIORAL|Stress Management|Visit with IBD GI psychologist for stress management
214986711|NCT07169409|DRUG|Telemedicine Buprenorphine Treatment|With this NIDA-funded grant, the study team will identify app-based treatment workflows that are demonstrably effective in low-resource settings: namely, telehealth services that are accessible without high-speed internet and deliberately helping patients transition into OUD care from relevant health and community system settings. An intentional focus on rural areas and Black and Hispanic demographics will help enhance health equity, and support solutions for payors.
215089634|NCT02170909|DRUG|BIBR 1048 MS medium dose|
214684002|NCT02427256|DEVICE|Konan Specular Microscope CELLCHEK XL|
214684003|NCT05623904|PROCEDURE|Carotid Revascularization|Carotid Artery Stenting/Carotid Endarterectomy
214373494|NCT05637203|BEHAVIORAL|THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)|"THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls."
214684004|NCT05623904|DRUG|Medical Treatment|"Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment."
214684005|NCT01333267|DRUG|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
214684006|NCT01333267|DRUG|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
214684007|NCT01333267|DRUG|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
214684008|NCT04243135|DEVICE|ESWT|Extracorporeal shock wave therapy
214684009|NCT03169829|DIETARY_SUPPLEMENT|Standard Diet|"Adapted from National Kidney Foundation guidelines for HD1~* Animal only Protein~* Refined only Grains~* Limit Dairy~* Low-k only"
214684010|NCT03169829|DIETARY_SUPPLEMENT|Low-k|"•¼ Animal, ¾ Plant Proteins~•½ Refined, ½ Whole Grain~* Limit Dairy, provide Soymilk Dairy~* Low-k only Fruit and Vegetables"
214684011|NCT03169829|DIETARY_SUPPLEMENT|Standard|"•¼ Animal, ¾ Plant Proteins~* Refined, ½ Whole Grain~  •Limit Dairy, provide Soymilk Dairy~* Low-k, Fruit and Vegetables~* High-k Fruit and Vegetables"
214684012|NCT01449552|DRUG|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
214684013|NCT01449552|PROCEDURE|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
214684014|NCT01449552|OTHER|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
215089635|NCT02170909|DRUG|BIBR 1048 MS high dose|
215089636|NCT01390207|OTHER|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
215089637|NCT04608734|DRUG|Buccal midazolam|The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
214684015|NCT01449552|OTHER|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
214684016|NCT00344617|DRUG|Bevacizumab (tradename: Avastin)|
214684017|NCT00743600|OTHER|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
214684018|NCT00743600|OTHER|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
215089638|NCT04608734|DRUG|Intranasal midazolam|Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
215089639|NCT01831817|DRUG|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
215089640|NCT01831817|DRUG|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
215089641|NCT01831817|DRUG|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
215089642|NCT01831817|DRUG|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
215089643|NCT00911573|DRUG|Tigecycline|50 mg IV every 12 hours up to 14 days
215089644|NCT00911573|DRUG|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
215089645|NCT05505604|PROCEDURE|PENG|patients will receive an ultrasound-guided Pericapsular Nerve Group Block with 20mL of 0.25% bupivacaine (not to exceed 2mg/kg)
215089646|NCT05505604|PROCEDURE|FICB|Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block with 20 mL of 0.25% bupivacaine (not to exceed 2 mg/kg) diluted to total volume of 40 mL of injectate
214373495|NCT05637203|BEHAVIORAL|Discharge / Safety Planning|"* A written safety plan completed with the person~* Mental health appointment scheduled within seven days~* One phone follow-up call within 30 days"
214373496|NCT00532155|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
214986712|NCT07169461|DEVICE|The blue MY MASK-E|"Device-Specific Protocol Blue MyMask® LLLT (Espansione): Emits monochromatic photobiomodulation therapy at 633 nm, distinct from conventional red or near-infrared LLLT used in other studies.~Espansione IPL: Uses a patented Optimal Power Energy (OPE®) system with a polychromatic spectrum of 590-1200 nm, allowing sub-threshold energy pulses for selective thermal effects on abnormal telangiectasia and Demodex-related inflammation."
214986713|NCT07169461|DEVICE|IPL|"IPL : The Eye-light device (Espansione Marketing S.p.A., Bologna, Italy,waveleggths 1,200-1,500 nm, Delivery system 12cm2) (Thai FDA No 66-2-2-2-0012685) :~* Protective eye shields~* 5 flashes of light were applied for each eye (3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim)~* Therapeutic energy level (10-16 joules/ cm2) based on the degree of skin pigmentation."
214986714|NCT07169461|PROCEDURE|Mechanical with pharmacological treatment|"Mechanical with pharmacological treatment : Warm compression 15 minutes + Lid hygiene + 1% TTO 2 times per day for 90 days~1%TTO : OCuSOFT Oust Demodex Eyelid Cleanser Foam Bottle 50ml (OCuSOFT, Richmond, TX) is the only commercially available medication in Thailand that contains 1% tea tree oil."
214986715|NCT07169461|DEVICE|ShamIPL|the Eye-light device (Espansione Marketing S.p.A., Bologna, Italy) - Protective eye shields, 5 time for each eye with flashes of light off , but flashes sound on.
214986716|NCT07169461|DEVICE|ShamLLLT|the MY MASK-E (Espansione Marketing S.p.A., Bologna, Italy) - No eye shields, applying a power off special mask for 15 minutes but light on , once a week for 4 weeks
214684019|NCT04067765|BEHAVIORAL|Cue Exposure|Participants will undergo a validated in-scanner alcohol cue and neutral cue exposure protocol involving passive viewing of images of alcohol beverages (beer, wine, or liquor) and neutral beverages (water).
214986717|NCT07167069|RADIATION|Radiation Therapy|Standard of Care Chemoradiation for Cervical cancer patients in India.
214684020|NCT03395171|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Supplementation of subjects who meet the inclusion criteria and test to have below the threshold of vitamin D in their blood.
214684021|NCT06579170|BEHAVIORAL|Cyanobacteria exposure during water contact|Cyanobacteria levels in beach water among participants who report water contact in the beach survey
214684022|NCT02776696|DEVICE|Advanced Hybrid Closed Loop System|
214986718|NCT07168759|OTHER|VR game -based education program|The schoolchildren in the intervention group participate in an innovative VR game-based educational programme featuring: (1) Web-based health education on (i) SARS-CoV-2 and Influenza virus transmission, (ii) proper hand and respiratory hygiene practices and (iii) the importance of rapid screening and vaccination in the prevention of upper respiratory tract infections.
214986719|NCT07167498|BEHAVIORAL|Intermittent midwife absence during remote monitoring of remifentanil PCA in labour|"Midwife absence during remifentanil PCA for labour analgesia.~We aim to include a total of 80 participants. All will receive remifentanil PCA for labour analgesia and be monitored with remote monitoring equipment. First a group of 40 parturients will be included, and the attending midwife will not be allowed to leave the parturient (Group 1). A following group of 40 parturients will then be included and the attending midwife can leave the room in intervals up to 10 minutes (Group 2)."
214986720|NCT07167680|PROCEDURE|Individualized reduction of falls (iROLL)|The iROLL program is a 6-week fall prevention and management program for people living with spinal cord injury (SCI) and multiple sclerosis (MS) who use wheelchairs and scooters. The program's overall goals are to reduce fall frequency, improve functional mobility skills, decrease fear of falling, increase quality of life, and increase community participation. It uses many active learning strategies such as: goal setting, journaling, small group discussions, practicing skills, and homework to apply content to one's daily life.
214373497|NCT00532155|DRUG|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
214373498|NCT00532155|DRUG|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
214373499|NCT00532155|DRUG|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
214373500|NCT05303532|DRUG|Durvalumab|Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.
214373501|NCT03483038|DRUG|Liposomal Irinotecan|Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
214373502|NCT03483038|DRUG|FOLFOX regimen|Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
214373503|NCT02134925|OTHER|Laboratory Biomarker Analysis|Correlative studies
214373504|NCT02134925|BIOLOGICAL|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
214373505|NCT02134925|OTHER|Quality-of-Life Assessment|Ancillary studies
214373506|NCT02134925|OTHER|Saline|Given SC
214373507|NCT04545762|DRUG|Fludarabine|Given intravenously (IV)
214373508|NCT04545762|DRUG|Cyclophosphamide|Given intravenously (IV)
214373509|NCT04545762|BIOLOGICAL|anti-CD19 CAR-T cells|Single infusion
214684023|NCT02776696|DEVICE|Hybrid Closed Loop System|
214684024|NCT00159744|DRUG|Asenapine|Asenapine, 3 weeks
214684025|NCT00159744|DRUG|Olanzapine|Olanzapine, 3 weeks
214684026|NCT00159744|DRUG|Placebo|placebo, 3 weeks
214684027|NCT03175393|DEVICE|coronary angiography|per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
214684028|NCT02752867|DRUG|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
214373510|NCT05823142|BEHAVIORAL|CB Sleep|The CB-sleep intervention is a cognitive behavioral intervention guided by principles and practices from motivational interviewing and the psychology of behavior change, primarily drawing on self-efficacy and action planning theory. The goals of CB-sleep are for participants to achieve adequate sleep duration (7-9 hours per night), adequate sleep efficiency (≥ 85%), and regular sleep timing (\<60-minute differences in bed and wake times). The intervention components include improving sleep knowledge (hygiene), developing a nightly routine, addressing competing activities, modifying environmental conditions, lifestyle (avoiding caffeine and vigorous exercise before bed), technology (limiting or avoiding screens for at least one hour before bed), basic stress-management (progressive muscle relaxation and guided imagery), and self- monitoring.
214373511|NCT05411029|DIAGNOSTIC_TEST|24 hour blood pressure (BP) monitoring|24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
214373512|NCT05411029|DIAGNOSTIC_TEST|Polysomnography|Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
214373513|NCT06464185|DRUG|Bispecific antibody-based combined with CAR-T cell therapy|"lymphocytes collection, and bispecific antibody-based therapy will be performed after successful Lymphocytes collection: Obinutuzumab:1000mg, cycle 1 day 1(C1D1) ,IV.~Glofitamab: 2.5 mg, C1D8; 10 mg,C1D15 ; 30 mg,C2D1 and C3D1, IV. It can be combined with other Immunization therapy during the use of bispecific antibodies according to the patient's condition.~On C4D1, the patient will be pretreated with fludarabine and cyclophosphamide (FC) regimen, and then infused with CART cells at a specific dose of 4 \* 1000000/Kg. Bispecific antibody maintenance therapy will be initiated on month 1/2/3 after CART infusion. In Phase1 bispecific maintenance therapy will be divided into three dose groups, using a 3 + 3 dose escalation design. In Phase 2, bispecific maintenance therapy will be used at the MTD dose of Phase 1."
214495254|NCT06454669|DRUG|Dronabinol|Eligible subjects will be randomized (2:1) to dronabinol or placebo, administered orally. The dose of dronabinol will be titrated such that on Day 1, subjects will take 2.5 mg, twice. On subsequent days patients may gradually increase the total number of doses, by one dose each day, as needed and tolerated until either the optimal dose is achieved, or the dose reaches 30 mg THC per day.
214495255|NCT06454669|DRUG|Placebo|Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.
214495256|NCT06750029|OTHER|Medical clown visits|The intervention is 15-minute visits from MCs twice daily during the first two days of admission. The clowns use various techniques to relax the patients (e.g. music, singing, playing, humor, guided imagination) and helpe encourage children to begin drinking and eating on their own.
214495257|NCT02678689|BIOLOGICAL|BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
214684029|NCT02752867|OTHER|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
214986721|NCT07167680|PROCEDURE|Stopping Elderly Accidents, Deaths & Injuries (STEADI)|The CDC's Stopping Elderly Accidents, Deaths \& Injuries (STEADI) initiative is a coordinated approach to fall prevention for older adults. It focuses on helping healthcare providers implement clinical fall prevention strategies, including screening for fall risk, assessing modifiable risk factors, and intervening to reduce risk.
214684030|NCT04040062|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
214684031|NCT01798784|BEHAVIORAL|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
214684032|NCT01798784|BEHAVIORAL|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
214684033|NCT01798784|BEHAVIORAL|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
214684034|NCT02844101|DEVICE|GT3X Actigraph accelerometer.|
214986722|NCT07169565|DRUG|Ibrutinib|Oral Bruton's tyrosine kinase (BTK) inhibitor administered at a fixed dose of 420 mg once daily. Capsules must be swallowed whole with water; do not open, break, or chew. If a dose is missed by ≤6 hours, take immediately; if \>6 hours, skip the dose and resume normal schedule the next day. Avoid grapefruit and Seville oranges (moderate CYP3A inhibitors). Treatment duration: 3 cycles (28 days/cycle) or until disease progression/unacceptable toxicity. Dose reduction is mandated for specific toxicities: 420 mg → 280 mg → 140 mg → discontinuation (per protocol-specified criteria). Use with caution in hepatic impairment (Child-Pugh A: reduce to 80 mg/day; Child-Pugh B/C: contraindicated).
214495258|NCT02678689|DEVICE|Intracerebroventricular access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
214684035|NCT03282201|OTHER|Transfusion|Transfusion of red blood cells, fresh frozen plasma, platelets
214684036|NCT01244334|DRUG|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
214684037|NCT01244334|DRUG|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
214684038|NCT00779090|PROCEDURE|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
214684039|NCT03613090|DRUG|Collagen-hydroxyapatite scaffold (Syn-Oss)|The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot
214373514|NCT05485792|DIAGNOSTIC_TEST|18F-FAPI PET/CT and 18F-FDG PET/CT|Each subject undergo both 18F-FDG and 68Ga-FAPI PET/CT scans within 1 week
214373515|NCT00242372|DRUG|Tesaglitazar 0.5|
214684040|NCT03613090|DRUG|Collagen Scaffold (Colla-Plug)|Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
214684041|NCT02725892|OTHER|NIS observational stud|NIS observational study : Epidemiologic registry
214684042|NCT05272917|OTHER|Sensorial tests|Patients will be included in the study between 3 to 6 months after the end of treatment and go to the Paul Bocuse Research Institute to perform several sensorial tests. The same sensorial tests will be completed by healthy volunteers to compare.
214684043|NCT05272917|BEHAVIORAL|food preferences questionnaires|Patients will be included in the study between 3 to 6 months after the end of treatment and go at Institut Paul Bocuse to complete food preferences questionnaires. The same questionnaires will be completed by healthy volunteers to compare.
214684044|NCT05070429|OTHER|Clinic-based audiological rehabilitative service delivery|Participants will have scheduled clinic-based visits at 6 and 12 months post-randomization to reinforce self-management strategies and perform hearing aid checks.
214684045|NCT05070429|OTHER|Telehealth audiological rehabilitative service delivery|Participants' scheduled clinic-based visits will be complemented with asynchronous and synchronous telehealth that will allow for routine troubleshooting of communication challenges, hearing aid technical issues, and reinforcement of self-management support strategies. At an initial session, participants will be instructed in the use of a study-provided, internet-enabled tablet device for telehealth sessions, re-introduced to the hearing loss toolkit for self-management and C2Hear Reusable Learning Objects within the context of the telehealth platform, re-evaluated on the Client Oriented Scale of Improvement (COSI) goals. Two remote follow-up sessions will be scheduled 3 and 6 weeks later to confirm participants' comfort with the telehealth platform and then completed every 6 months, in addition to scheduled 6-month clinic-based visits.
214684046|NCT00854529|DRUG|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
214684047|NCT04541849|OTHER|Critical Care|Critical care in the intensive care units
214684048|NCT01270672|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
214684049|NCT01270672|DRUG|carvedilol|50 mg per os, single dose
214684050|NCT01270672|DRUG|placebo|capsules identical to MDMA or carvedilol
214684051|NCT00200525|DRUG|apomorphine HCl injection|
214684052|NCT01399801|PROCEDURE|Doppler flow measurement|use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement
214684053|NCT01399801|PROCEDURE|standard implantation of the LV lead|Standard implantation of the LV lead with measurements of flow
214986723|NCT07169565|DRUG|Bendamustine|Intravenous alkylating agent dosed via a 3+3 dose de-escalation design (70 mg/m² → 60 mg/m² → 50 mg/m²). Infused over 60-120 minutes on Days 1-2 of each 28-day cycle for 3 cycles. Starting dose: 70 mg/m² (Dose Level 1); dose reduction triggered by Dose-Limiting Toxicity (DLT) events per protocol. In the dose-expansion phase, all subjects receive the MTD/RP2D established in Part 1. Concomitant live vaccines are prohibited. Dose delays (≤4 weeks) and reductions are required for Grade ≥3 hematologic/non-hematologic toxicities.
214373516|NCT00242372|DRUG|Insulin at least 30 units/day|
214373517|NCT03508739|DRUG|Sacubitril/Valsartan 200mg (blinded)|study day 2 for AB and study day 3 for BA
214373518|NCT03508739|DRUG|Valsartan 160mg (blinded)|study day 3 for AB and study day 2 for BA
214373519|NCT06579105|DRUG|Placebo (placebo matching AZD5004 film-coated tablet)|Placebo film-coated tablet (matching AZD5004)
214373520|NCT06579105|DRUG|AZD5004|AZD5004 film-coated tablet, once daily during 26 weeks
214373521|NCT06579105|DRUG|Semaglutide|3-14 mg tablets of Semaglutide
214373522|NCT05631795|DRUG|Alpelisib|Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
214373523|NCT05631795|DRUG|Fulvestrant|Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
214373524|NCT02184754|PROCEDURE|Magnetic endoscope imaging (MEI)|
214393823|NCT05921721|DEVICE|EOS|This modality simultaneously captures biplanar radiographs (anteroposterior and lateral images) through the whole-body slot scanning with patients in standing position with ultralow irradiation
214393824|NCT02941068|DRUG|fluconazole and caspofungin|
214684054|NCT00708604|PROCEDURE|Islet Transplantation|Islet Transplantation
214684055|NCT00708604|BIOLOGICAL|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
214684056|NCT01742624|DRUG|Advagraf|oral
214684057|NCT01742624|DRUG|Prograf|oral
214684058|NCT01742624|DRUG|Corticosteroid|oral
214684059|NCT01742624|DRUG|Mycophenolate mofetil|oral
214684060|NCT03381924|OTHER|Educational programme|In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
214684061|NCT03381924|OTHER|Routine clinical practice|Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
214684062|NCT05257720|DIAGNOSTIC_TEST|GFAP, S100B|It is planned to measure serum GFAP and S100 B protein levels by ELISA method.
214684063|NCT02697955|DRUG|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
214684064|NCT02697955|OTHER|Placebo|9 mg sodium chloride pr. ml (0,9 %)
214684065|NCT05640713|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B Cell Malignancy .
214684066|NCT05640713|DRUG|Fludarabine Pill|Fludarabine is used for lymphodepletion.
214684067|NCT05640713|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
214684068|NCT05640713|DRUG|VP-16 Protocol|VP-16 is used for lymphodepletion.
214684069|NCT05372068|OTHER|Concrete household floor|Household soil floors will be replaced with concrete floors
214495259|NCT06777199|PROCEDURE|Microscopic Selective Dorsal Neurectomy (SDN)|"Selective dorsal neurectomy (SDN) involves microsurgical dissection and partial transection of the dorsal penile nerves to reduce glans sensitivity.~The procedure is performed under spinal anesthesia or local anesthesia with 1% lidocaine.~A midline or dorsal sub-coronal incision is made 1 cm proximal to the coronal sulcus.~The skin is retracted, exposing the Dartos fascia and Buck's fascia to reach the neurovascular bundle (two dorsal penile nerves lateral to two dorsal penile arteries).~Every other nerve on either side of the corpora cavernosa is transected to damage approximately 50% of the nerve supply to the glans.~Suturing is done using 7-0 or 8-0 prolene sutures, and the incision is closed. Patients are evaluated at 1 month and 3 months post-procedure for IELT, AIPE, and PEDT scores to determine success."
214684070|NCT00461955|PROCEDURE|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
214373525|NCT02492854|DEVICE|PICO Single-Use Negative Pressure Dressings|Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith\&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
214684071|NCT01893944|OTHER|virtual reality|customized applications using virtual and augmented reality to be developed.
214684072|NCT00835887|DIETARY_SUPPLEMENT|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
214684073|NCT05741723|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
214986724|NCT07169565|DRUG|Rituximab|Intravenous anti-CD20 monoclonal antibody administered at a fixed dose of 375 mg/m² on Day 0 of each 28-day cycle for 3 cycles. Initial infusion starts at 50 mg/hour; if tolerated, increase by 50 mg/hour every 30 minutes (maximum: 400 mg/hour). Subsequent infusions start at 100 mg/hour with the same escalation. Premedication with acetaminophen and an antihistamine is required prior to each infusion. Permanently discontinue for Grade 4 infusion-related reactions or severe/life-threatening toxicity.
214684074|NCT00055822|BIOLOGICAL|oblimersen sodium|
214684075|NCT00055822|DRUG|fluorouracil|
214684076|NCT00055822|DRUG|leucovorin calcium|
214684077|NCT00055822|DRUG|oxaliplatin|
214684078|NCT00943319|DRUG|Busulfan|Daily intravenous dosing to target AVC
214684079|NCT00943319|DRUG|Fludarabine|Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
214684080|NCT00943319|DRUG|Campath|All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
214684081|NCT00943319|PROCEDURE|Stem Cell Transplant|Infusion of bone marrow and donors(related/ unrelated).
214373526|NCT02492854|OTHER|Sterile Gauze Dressings|Current standard-of-care dressings used to cover surgical wounds post-operatively.
214373527|NCT06067633|OTHER|Triple-Masked|Eligible manuscripts in the triple-masked editorial process arm will be masked electronically before being entered in the trial by the editorial assistant
214373528|NCT06067633|OTHER|Usual Procedures|Articles will be processed by the editors with identifiable/unmasking content of cover page and letters.
214684082|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
214684083|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
214684084|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
214684085|NCT06103695|DRUG|Tapinarof|Add on Vtama (tapinarof) to biololgic therapy
214684086|NCT00151060|DRUG|Estramustine|
214684087|NCT00151060|DRUG|Etoposide|
214684088|NCT00151060|DRUG|Paclitaxel|
214684089|NCT04804722|DEVICE|18F-FDG PET-CT (fluorodesoxyglucose positron emission tomography)|18F-FDG PET-CT exams during 30 minutes with injection of radiopharmaceutical product
214684090|NCT02653976|DRUG|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
214684091|NCT02932722|OTHER|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
214684092|NCT02932722|DRUG|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
214684093|NCT02932722|DRUG|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
214684094|NCT02023164|DRUG|JDP-205 Injection|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
214684095|NCT02023164|DRUG|Diphenhydramine|Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
214684096|NCT00883558|DRUG|Insulin Lispro|
214684097|NCT00883558|DRUG|regular human insulin|
214684098|NCT00883558|DRUG|recombinant human hyaluronidase PH20|
214684099|NCT00883558|DRUG|Insulin glargine|
214684100|NCT04772183|DEVICE|SpO2 and SaO2 comparison|"Several pulse oximeter will be place on patient find few minutes before arterial blood gases.~During an arterial blood sample, all SpO2 will be recorded"
214684101|NCT03219749|BEHAVIORAL|exercise training|Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
214986725|NCT07167537|BIOLOGICAL|OL-CD19-GDT|OL-CD19-GDT will be given through IV bolus with ascending dose levels to determine the RDE and RP2D as specified in the protocol
214684102|NCT03284619|DEVICE|Magnetic resonance imager linear accelerator|The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
214986726|NCT07168486|BIOLOGICAL|CD19.20.22 CAR T cells|CAR19.20.22 is a type of immunotherapy known as a chimeric antigen receptor T-cells (CAR T-cells).
214684103|NCT00169494|BIOLOGICAL|HPV-16/18 L1/AS04|
214684104|NCT01598857|DRUG|Blisibimod|
214684105|NCT01598857|DRUG|Placebo|
214684106|NCT02038296|PROCEDURE|transarterial chemoembolization|
214684107|NCT06552520|DRUG|TQH2722 injection|Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody
214684108|NCT06552520|DRUG|Placebo of TQH2722 injection|Placebo without drug substance
214684109|NCT06553339|DRUG|Oral HS-10516|Oral HIF-2α inhibitor
214684110|NCT03703375|DRUG|Azacitidine|Azacitidine
214684111|NCT03703375|DRUG|Romidepsin|Romidepsin
214684112|NCT03703375|DRUG|Gemcitabine|Gemcitabine
214684113|NCT00137852|DRUG|Cisplatin|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
214684114|NCT00137852|DRUG|Irinotecan|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
214684115|NCT00137852|DRUG|Celecoxib|Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
214684116|NCT00137852|PROCEDURE|Radiation Therapy|5 days a week for 5-6 weeks
214684117|NCT00137852|PROCEDURE|Esophagectomy|Within 4-8 weeks of chemoradiation therapy
214684118|NCT05160077|DIAGNOSTIC_TEST|Multispectral optoacoustic tomography (MSOT)|MSOT Acuity Echo, iThera medical, Munich
214684119|NCT01003561|PROCEDURE|spinal anesthesia for surgery|spinal anesthesia (T10) for elective TURP surgery
214684120|NCT01821170|DRUG|Methylphenidate|Patient will take treatment during two months
214986727|NCT07168486|DRUG|Fludarabine and Cyclophosphamide|Lymphodepletion with Flu-Cy prior to CAR T cell therapy
214986728|NCT05800015|DRUG|fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
214986729|NCT05800015|DRUG|cemiplimab|Administered IV Q3W
214986730|NCT05800015|DRUG|Pemetrexed|IV Infusion, Q3W
214986731|NCT05800015|DRUG|Paclitaxel|IV Infusion, Q3W
214986732|NCT05800015|DRUG|Carboplatin|IV Infusion, Q3W
214986733|NCT05800015|DRUG|Cisplatin|IV infusion, Q3W
214986734|NCT05800015|DRUG|Placebo|IV infusion, Q3W
214986735|NCT04585750|DRUG|rezatapopt|First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
214986736|NCT04585750|DRUG|pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
214986737|NCT05621668|DRUG|Cyclophosphamide|Given by IV (vein)
214986738|NCT05621668|DRUG|attIL2-T cells|Given by IV (vein)
214986739|NCT06472362|DIAGNOSTIC_TEST|HRCT biomarkers|HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis
214986740|NCT06385041|OTHER|Multicomponent training group|Additional exercise program with balance and strength trainings will include 3 times/week. Patients will get an individualized exercise program for frailty syndrome, which will include strength exercises (with elastic resistance bands and weights up to 2kg 30-50% 1RM) and balance training (with unstable surfaces). The program will be performed by 3 sets with 10 repetitions 3 times/week 30-45 minutes.
214986741|NCT06385041|OTHER|Computer-based interactive training group|Additional exercise program with balance and strength trainings will include 3 times/week 30-45 minutes. Patients will get an individualized program for frailty syndrome, with interactive technologies: gait training with Biodex GaitTrainerTM3 with visual, audio feedback and incline up to 10-15 min, Zebris FDM-T, with virtual barriers, thus simulating real environment for the patient, while performing a cognitive task up to 10-15 min, for balance training investigators used a computerized Biodex board. Exercises will be performed with the programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training. For strength training investigators used equipment HUR based on pneumatic (air pressure) technology. For strength training intensity 30-50% 1-RM, 10 repetitions with 3 sets. Leg press, leg extension, leg abduction, leg adduction will be performed with pneumatic technology.
214986742|NCT04799288|DRUG|Teriflunomide|Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.
214986743|NCT05852860|OTHER|Clinician Nudge|"The clinician nudge will use the BPA functionality within the electronic medical record to deliver a message with a defaulted option to refer to the health system's tobacco treatment program. Changing the default to no referral will require an explanation using the options provided or by entering free text."
214986744|NCT05852860|OTHER|Patient Nudge|The patient nudge will deliver a message within 72 hours of a patient's next scheduled clinic visit. The message will be delivered through the Penn patient portal (MyPennMedicine) or by text with security measures for privacy.
214986745|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
214986746|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
214373529|NCT01062503|DRUG|Zoledronic acid|ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
214986747|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
214684121|NCT01821170|DEVICE|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
214684122|NCT01821170|BEHAVIORAL|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
214684123|NCT01821170|OTHER|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
214684124|NCT00003243|BIOLOGICAL|aldesleukin|
214684125|NCT00003243|BIOLOGICAL|filgrastim|
214684126|NCT00003243|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214684127|NCT00003243|DRUG|cyclophosphamide|
214986748|NCT02414126|DEVICE|CPAP|
214986749|NCT06514989|DIETARY_SUPPLEMENT|Low-residue full nutrition formula podwer|The day before the colonoscopy, subjects were given a low-residue full nutrition formula podwer instead of a traditional self-prepared low-residue diet. Subjects were given 6 packs (60g/pack) pre-packaged FNFP and asked to use the FNFP according to individual needs. The 2 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 1 liter taken 3-5 hours before the colonoscopy.
214986750|NCT06514989|DIETARY_SUPPLEMENT|Self-prepared low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liter taken 4-6 hours before the colonoscopy.
214373530|NCT01091948|DEVICE|Intubation with Fiberoptic laryngoscope|Subjects will be intubated with the Fiberoptic laryngoscope.
214373531|NCT01091948|DEVICE|GlideScope® Video Laryngoscope|Patients will be intubated with the GlideScope® Video Laryngoscope.
214986751|NCT03729362|BIOLOGICAL|Cipaglucosidase Alfa|Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).
215089647|NCT04114799|PROCEDURE|Hemodynamic management based on invasive fluid responsiveness parameters|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
214373532|NCT03681574|DRUG|Placebo Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive placebo concentrate.
214373533|NCT03681574|DRUG|GABA 15mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 15mg/kg.
214684128|NCT00003243|DRUG|etoposide|
214684129|NCT00003243|DRUG|pegylated liposomal doxorubicin hydrochloride|
214684130|NCT04860284|DRUG|Hydroxychloroquine tablets|Hydroxychloroquine tablets 400mg given orally 12 hourly on day 1 and 200mg 12 hourly on day 2 to 5
214684131|NCT04477824|DIAGNOSTIC_TEST|Diagnostic imaging|Ultrasonography, computerized tomography, magnetic resonance imaging
214684132|NCT02969317|DRUG|Tiotropium|Fixed dose combination
214684133|NCT02969317|DRUG|Olodaterol|Fixed dose combination
214684134|NCT04417777|GENETIC|Blood Test|Blood analysis
214684135|NCT01781429|DRUG|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
214684136|NCT03740607|DEVICE|Virtual reality|Healthcare virtual reality software implemented during peripheral intravenous catheter placement
214684137|NCT03740607|PROCEDURE|Peripheral intravenous catheter placement|Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.
214684138|NCT03533140|DEVICE|DUCEST Neurostimulator V Group A|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively to stimulate the R.auricularis of the vagus nerve located at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates the device. (The stimulation intensity can be adjusted from 0,05mA to 1,2mA, default value is 0,4mA). The starting stimulation intensity will be adjusted to 1mA and takes place at 1Hz continuously for 40 minutes, followed by a 20 minute break. The built-in 3V battery lasts for approx. 14 days. After 7 days the electrodes are replaced and applied to the other ear of the patient. A plaster with a plastic mounting clip is attached on the shoulder of the patient. The Neurostimulator is connected to the mounting clip. After 14 days or at hospital discharge of the patient, the device is unmounted and the needle-electrodes are removed.
214684139|NCT03533140|DEVICE|DUCEST Neurostimulator V Group B|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates only the signal lamp but not the device.
214684140|NCT04397406|DRUG|levobupivacaine|The patients will receive 15 ml of 0.125% levobupivacaine.
214684141|NCT04397406|DRUG|Dexmedetomidine|The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.
214684142|NCT04397406|DRUG|Fentanyl|The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
214684143|NCT01368289|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of large sessile colonic polyps.
214684144|NCT02678741|DRUG|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
214986752|NCT03729362|DRUG|Miglustat|Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
214986753|NCT03729362|BIOLOGICAL|Alglucosidase Alfa|Participants received an IV infusion dose over a 4-hour duration Q2W.
214986754|NCT03729362|DRUG|Placebo|Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
214986755|NCT01113749|OTHER|Feeding Options in Dementia Decision Aid|Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
215089648|NCT04114799|PROCEDURE|Hemodynamic management based on noninvasive cardiac output and SVV measurement|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
215089649|NCT05578638|COMBINATION_PRODUCT|Aloe Vera rosemary tropical application|10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
214684145|NCT00903032|BEHAVIORAL|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
214684146|NCT00903032|BEHAVIORAL|Usual care|Usual care following ACS hospital discharge.
214684147|NCT02481336|OTHER|Questionnaires|EORTC CIPN20 and EQ-5D-3L
214684148|NCT02481336|PROCEDURE|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
214684149|NCT02481336|GENETIC|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
214684150|NCT01766297|RADIATION|Proton Radiotherapy|
214684151|NCT04523064|DRUG|Empagliflozin 25 MG|Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
215089650|NCT05578638|COMBINATION_PRODUCT|aloevera tropical application|10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
215089651|NCT05578638|COMBINATION_PRODUCT|rosemary tropicalapplication|10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
215089652|NCT04787380|DEVICE|Heartfelt device|"The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition."
214986756|NCT05702632|DEVICE|1- Reciprocal electrical stimulation|A specialized programmable electrical stimulation device was used (Uniphy is the manufacturer of Phyaction787; Uniphy, Eindhoven, the Netherlands). The device has two channels that can alternatively stimulate two opposing groups of muscles (reciprocate).
214373534|NCT03681574|DRUG|GABA 30mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 30mg/kg.
214373535|NCT01326858|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.7%|Treatment A
214986757|NCT05702632|DEVICE|TheraTogs orthotic treatment|A sleeveless top vest and two pairs of shorts with two thigh cuffs and limb cuffs each make up the TheraTogs strapping system which is applied to the children in the TheraTogs group. The TheraTogs suit is providing breathable, comfortable- Latex over the torso and thigh, as well as free toileting. For infection control and size fitting problems, participants are not allowed to share their TheraTogs with other patients. TheraTog's orthotic undergarment and strapping system were worn under their regular clothes, so it was neither distracting nor irritating.
214986758|NCT05702632|PROCEDURE|traditional physical therapy program|Facilitation of balance and gait training
215089653|NCT05296980|BEHAVIORAL|REMINDER|The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.
215089654|NCT05296980|BEHAVIORAL|Brain health Psychoeducation|Delivery of psychoeducation sessions about dementia modifiable risk factors, brain health solutions and lifestyle change tips.
215089655|NCT00206934|DRUG|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
214986759|NCT04134390|DRUG|Cabozantinib|Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation
215089656|NCT00206934|DRUG|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
215089657|NCT06064773|DIAGNOSTIC_TEST|thoracic USG|the confirmation of double lumen tube placement with thoracic USG in thoracic surgery operations with one lung ventilation.
214373536|NCT01326858|DRUG|Olopatadine hydrochloride ophthalmic solution vehicle|Treatment B, inactive ingredients used as placebo
214373537|NCT01326858|DRUG|Ketotifen fumarate ophthalmic solution, 0.025%|Treatment C
214373538|NCT04104451|DRUG|Corlicyte|expanded umbilical cord lining mesenchymal stem cells
214373539|NCT02158884|DEVICE|IDEO brace|All participants will receive the IDEO brace.
214373540|NCT00035074|DRUG|Methotrexate|
214373541|NCT06236867|OTHER|KaleidoscopeGroup|The group consists of 34 people. Pain level was measured during 3 dialysis sessions.In order for the patients in the kaleidoscope group to recognize the device and increase their compliance during the procedure, a practice was performed using the device before the AVF cannulation procedure. Kaleidoscope application was performed during cannulation.
214393825|NCT03039543|DRUG|Rocuronium|Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
214986760|NCT04723862|DRUG|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
214986761|NCT04723862|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
214373542|NCT06236867|OTHER|Ice Application Group|The group consists of 34 people. Pain level was measured during 3 dialysis sessions. Before, during and after AVF cannulation, VAS pain scores will be evaluated after cannulation without any intervention.Ice application application was made with non-melting ice molds to the area where the index finger and thumb of the hand with fistula are joined (HOKU point)
214373543|NCT06236867|OTHER|Control Group|The group consists of 34 people. Pain level will be measured during 3 dialysis sessions. In the control group, the vital signs of the patients before AVF cannulation will be recorded.
214373544|NCT02932046|DIETARY_SUPPLEMENT|Standardized noon meal|"The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa."
214986762|NCT04431544|DEVICE|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
214986763|NCT04429542|DRUG|BCA101|EGFR/TGFβ fusion monoclonal antibody
214986764|NCT04429542|DRUG|Pembrolizumab|anti-PD-1
214986765|NCT01691651|PROCEDURE|Subcutaneous injection of botulinum toxin type A|Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
214986766|NCT01691651|DRUG|Botulinum Toxin Type A|2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
214986767|NCT01043419|DRUG|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
214393826|NCT03039543|DRUG|Sugammadex|Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
214393827|NCT03821415|DRUG|RP101|17β-oestradiol-3-phosphate ophthalmic sterile solution
214393828|NCT04266171|BEHAVIORAL|Diet education based on CGMS data|Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.
214495260|NCT06777199|PROCEDURE|Pulsed Radiofrequency (PRF) Nerve Ablation|"Pulsed radiofrequency (PRF) nerve ablation aims to reduce sensitivity of the dorsal penile nerves using low-energy radiofrequency pulses.~Under sterile conditions, a 22-gauge RF cannula (5-cm-long, 10-mm active tip) is inserted into the flaccid penile skin at the 1-o'clock position for the right dorsal penile nerve.~Sensory stimulation testing is performed at 50 Hz to identify the point of maximum glans sensitivity.~Pulsed radiofrequency is applied at an energy output of 45 V for 180 seconds at 42°C (using the NeuroTherm generator).~The procedure is repeated at the 11-o'clock position for the left dorsal penile nerve, ensuring both sides are treated.~The goal is to ablate sensation over as large an area of the glans as possible without causing permanent nerve damage.~Post-procedure, patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores."
214495261|NCT06777199|PROCEDURE|Intraglanular Hyaluronic Acid (HA) Injection|"Intraglanular hyaluronic acid (HA) injection involves administering HA gel into the glans penis to reduce its sensitivity.~The circumference of the glans penis is divided into three circles (1 cm apart, starting from the base), and each circle is further divided into quarter circles.~Topical anesthetic cream (Emla®, lidocaine 25 mg + prilocaine 25 mg) is applied for 30 minutes to numb the glans.~Using two prefilled syringes of HA gel (Hyabell Ultra® 24 mg/ml with 0.3% lidocaine), 12 injections are administered into the deep dermis of the glans using a 27-G needle.~Each injection site receives 0.25 ml of HA gel following the multiple puncture technique.~Patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores to assess efficacy."
214495262|NCT06111248|OTHER|Training|Staff training on the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
214495263|NCT05973630|BIOLOGICAL|ATA-200|single intravenous infusion
214495264|NCT06774599|DEVICE|music combined with lavender essential oil group|listening of 30 mins ocean wave music, aromatherapy of lavender essential oil, and eye masks and earplugs.
214495265|NCT06774170|BEHAVIORAL|structured follow-up intervention|"The intervention has been created in light of the studies including type 1 and type 2 diabetes patients and experiences of the project team with patients after PD. Theoretical background of the intervention is based on the interventions developed for glucose management in type 1 and type 2 diabetes patients and the effect of the intervention will be evaluated by using the plan-do-check-act model."
214495266|NCT06765538|OTHER|Video consultation|Preanaesthetic videoconsultation
214986768|NCT04262349|BEHAVIORAL|sleep education|As a training program to increase sleep, pregnant women will be given 2 training sessions per week for two weeks and four sessions in total for 60 minutes.
214684152|NCT04906993|DRUG|camrelizumab； famitinib malate|Camrelizumab intravenously ; Famitinib Orally
214373545|NCT03970239|DRUG|Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)|"Imaging of the serotoninergic system with Positron Emission Tomography using \[11 Carbon\]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (\[11C\]-DASB) and \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg) of \[11C\]-DASB immediately prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 2.1 milliSievert (mSv).~On a separate day, subjects will receive a single intravenous administration of approximately 3.7 MBq/kg of \[18F\]-altanserin for 120 minutes prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 8.4 mSv."
214373546|NCT03970239|DRUG|Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)|Imaging of the serotoninergic system with Positron Emission Tomography using \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 3.7 Megabecquerel/kilogram (MBq/kg) of \[18F\]-altanserin 120 minutes prior to imaging using Positron Emission Tomography. The effective dose in human body is about 8.4 mSv.
214373547|NCT05651776|OTHER|Physical Therapy, Exercise|Outpatient physical therapy intervention incorporating golf related assessment of skills and prescribed exercises including postural, balance, and club swing
214373548|NCT00770926|BEHAVIORAL|Live Well, Be Well|Lifestyle change program using personal contact and telephone counseling
214373549|NCT02524041|DEVICE|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
214373550|NCT02524041|OTHER|blood specimen|blood specimen
214373551|NCT05802368|OTHER|virtual reality group|a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.
214373552|NCT05802368|OTHER|exercise group|Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
214373553|NCT05205902|OTHER|Low-dose total-skin electron-beam therapy|Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
214373554|NCT05205902|OTHER|Phototherapy|"Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy."
214373555|NCT03349164|DIAGNOSTIC_TEST|acute PE survivors|Patients from this group will be assessed by cardiologist, echocardiography and VQ scanning
214373556|NCT04113954|DRUG|Mepivacaine Injection|Injection of 0.375% mepivacaine in nerve block
214373557|NCT04113954|DRUG|Mepivacaine Injection|Injection of 1.5% mepivacaine in nerve block
214393829|NCT04266171|BEHAVIORAL|Conventional diet education|Control group will receive conventional diabetes diet education without CGMS data.
214393830|NCT01394250|DEVICE|Buzzy|Cold, Vibrational Device
214495267|NCT06765213|DIAGNOSTIC_TEST|Open Ended Oral Food Challenge|Allergens determined to be sensitized will be brought in for an oral challenge to that food.
214495268|NCT06765213|OTHER|Early Introduction|Infants that are not sensitized will have the food introduced to their diet at regular intervals.
214495269|NCT06564454|OTHER|No intervention|Assessment of knowledge, attitude and practice of green Dentistry
214393831|NCT01394250|DRUG|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
214393832|NCT00634322|DRUG|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
214495270|NCT03160885|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
214495271|NCT03160885|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
214495272|NCT04081428|RADIATION|Stereotactic Body Radiotherapy|Daily collection of breath and blood before and after each of the 5 radiotherapy treatment sessions. Before and after daily cone beam CT image collection
214495273|NCT03404778|DEVICE|Biomet Comprehensive Reverse Shoulder|Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
214684153|NCT04906993|DRUG|platinum-based chemotherapy|Physician's choice chemotherapy
214986769|NCT04167813|DRUG|Ondansetron 8mg or matched placebo tablets|"Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase"
214986770|NCT01933724|DRUG|5 mg prednisone|Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
214393833|NCT00634322|DRUG|leucovorin|IV or po given every 6 hours
214393834|NCT00783120|OTHER|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
214986771|NCT01933724|DRUG|0 mg prednisone|Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
214986772|NCT03729284|DRUG|Cymbalta Capsules|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
214986773|NCT03729284|DRUG|Duloxetine Hydrochloride Capsules|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
214986774|NCT01447966|BEHAVIORAL|Cognitive Behavioral Therapy|Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
214986775|NCT03227588|DIAGNOSTIC_TEST|Fractional Flow Reserve|This is a prospective data collection study for patients that have undergone FFR.
214393835|NCT00783120|OTHER|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
214495274|NCT04040452|DRUG|Continuous ketorolac|Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
214495275|NCT06619600|DRUG|Dapagliflozin|Dapagliflozin 10 mg qd
214495276|NCT06619600|DRUG|Placebo|Matched placebo qd
214495277|NCT03117946|OTHER|Biological samples|blood and tumor tissue sample
214495278|NCT03499691|DEVICE|Theranova 500 medium cut-off dialyzer|The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.
214684154|NCT04510194|DRUG|Metformin|Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.
214684155|NCT04510194|DRUG|Placebo|placebo; appearance and size are exact matching to the three study drugs.
214684156|NCT04510194|DRUG|Fluvoxamine|An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14
214684157|NCT04510194|DRUG|Ivermectin|An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
214684158|NCT04820452|BIOLOGICAL|Low dose IBI302|Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection
214684159|NCT04820452|BIOLOGICAL|High dose IBI302|High dose IBI302 intravitreal injection given as every other month after three loading monthly injection
214684160|NCT04820452|DRUG|Aflibercept|Intraocular injection
214684161|NCT05588674|DIETARY_SUPPLEMENT|Probiotic Supplement|8.5 week supplementation period. One capsule daily.
214684162|NCT05588674|OTHER|Placebo Capsule|8.5 week supplementation period. One capsule daily.
214684163|NCT05968352|DEVICE|Sacral Anterior Root Stimulation (SARS)|Comparison of High frequency versus low frequency stimulation
214986776|NCT03889132|PROCEDURE|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
214986777|NCT03186352|PROCEDURE|photoactivated disinfection|"After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying"
214986778|NCT04084704|DEVICE|Cingal|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
214986779|NCT01679470|DEVICE|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
214986780|NCT05054387|DRUG|Agalsidase beta|Powder for concentration into a solution Intravenous (IV) infusion
214986781|NCT05596175|BEHAVIORAL|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise, nutritional support and optimisation of AF-related clinical risk factors.
214986782|NCT00297011|DRUG|valacyclovir+clobetasol gel|
214986783|NCT03625674|BEHAVIORAL|explanation when prescribing psychoactive medicine|explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
214986784|NCT02746861|BEHAVIORAL|Peer-Supported DSMS|Phone, SMS/text, and smartphone-based intervention.
214986785|NCT05848284|DEVICE|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
214986786|NCT05514990|DRUG|Bortezomib|Given SC or IV
214986787|NCT05514990|DRUG|Dexamethasone|Given PO, IV, or IM
214986788|NCT05514990|BIOLOGICAL|Pelareorep|Given IV
214986789|NCT05514990|BIOLOGICAL|Pembrolizumab|Given IV
214986790|NCT05530018|BEHAVIORAL|Brief contact intervention|The brief contact intervention (BCI) will send out text messages to the participants. The text messages will include caring messages, reminders of appointments, and a link to a web page. The web page is anticipated to include safety planning, volitional helpsheet, and resources information. The text messages are anticipated to send out to the participants on a weekly base for 6 weeks in a row, and then change to monthly reminders. The monthly reminders are anticipated to include caring messages, reminders of appointments, and invitations to encourage the participants to click the previous web links again. The monthly reminders are anticipated to send out to the participants three times in a row. In the final reminder, the participants will be told that this intervention is going to end. In total, the participants will receive 9 texts within 5 months.
214986791|NCT04638244|BEHAVIORAL|Music|Brief Online Music
214986792|NCT04638244|BEHAVIORAL|Reading messages|Reading psychoeducational messages
214986793|NCT06492837|DRUG|Mosunetuzumab in combination with Zanubrutinib|Combinations of Mosunetuzumab and Zanubrutinib as salvage strategy in patients with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
214986794|NCT05425979|DRUG|Mepivacaine|Up to two 30 ml vials of mepivacaine 1.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
214986795|NCT05425979|DRUG|Bupivacaine|Up to two 30 ml vials of bupivacaine 0.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
214986796|NCT02967029|DRUG|Esmolol Hydrochloride|the influence of brevibloc as a hypotensive agent on rSO2
214986797|NCT02967029|DRUG|Remifentanil Hydrochloride|the influence of remifentanyl as a hypotensive agent on rSO2
214684164|NCT06648161|OTHER|Labor Mirror|The labor mirror used in the second stage of labor allows the mother and midwife to observe the descent and birth of the baby during vaginal delivery and provides instant visualization of progress for the mother and midwife, especially in water births or water births
214684165|NCT02071134|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
215089658|NCT00507273|OTHER|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
215089659|NCT03716752|PROCEDURE|Modified connective tissue graft wall with wing technique|the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
215089660|NCT03985007|DRUG|CDIAG regimen|Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
215089661|NCT06054256|BEHAVIORAL|Group CBT-I|The group-based intervention will consist of 6 weekly sessions (90-min, 5-8 pregnant women in each group). The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia with the followings: psycho-education about sleep and sleep hygiene (e.g., psychoeducation about sleep during pregnancy and normal development and patterns of infant sleep, psychoeducation on ways of improving infant sleep, strategies to limit the development of unwanted sleep associations, etc.), stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
215089662|NCT06054256|BEHAVIORAL|App-based CBT-I|The smartphone app-based intervention will consist of 6 weekly sessions. The app-based intervention will involve a self-paced, fully automated digital programme with interactive components. The structure of the app involves six sequential modules (comparable to the six treatment sessions delivered in groups) with different elements to engage the users, such as animated videos, case vignettes, narration, quizzes, and homework assignment. Each module will be unlocked and released to the participants every week after the previous module has been completed. Personalised feedback will be provided by the app following the completion of sleep diary each week. Automated messages will be sent to the participants regularly via phone to remind them of implementing learned strategies after each module, as well as timely completing the treatment modules and sleep diaries.
214684166|NCT02880319|DRUG|Stereotactic Body Radiation Therapy (SBRT)|
214684167|NCT02880319|DEVICE|Stereotactic Linear Accelerator|
214684168|NCT05919108|PROCEDURE|Endocrine Therapy|Undergo endocrine therapy
214684169|NCT05919108|PROCEDURE|Biopsy of breast|Undergo breast biopsy
214684170|NCT05919108|DRUG|Neratinib|Taken by mouth
215089663|NCT06054256|OTHER|Health related psychoeducation|The control group will receive 6 sessions of group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components.
215089664|NCT02155530|DRUG|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
215089665|NCT02155530|DRUG|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
215089666|NCT00337584|PROCEDURE|Pre-surgical screening|
215089667|NCT03507075|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
215089668|NCT03507075|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
215089669|NCT06229054|DRUG|Dexmedetomidine|Dexmedetomidine (DEX), an α2-agonist with more promising pharmacokinetic and pharmacodynamic characteristics than clonidine has been proved to have a positive effect on postoperative pain intensity and to reduce opioid consumption
215089670|NCT06229054|DRUG|Bupivacaine Hydrochloride|local anesthesic which works through blocking sodium channels
215089671|NCT04215432|DEVICE|Gel containing propolis extract, nanovitamin C and nanovitamin E|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.
215089672|NCT04215432|DEVICE|Placebo|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.
214684171|NCT05919108|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214986798|NCT04155554|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function
214986799|NCT04155554|DRUG|Dolutegravir/lamivudine/abacavir|Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function
214986800|NCT02361931|DRUG|A hydrogel containing erythropoietin|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
214684172|NCT05919108|PROCEDURE|Mammogram|Undergo Mammogram
214684173|NCT05919108|PROCEDURE|Magnetic Resonance Imaging|Undergo breast Magnetic Resonance Imaging
214684174|NCT05919108|PROCEDURE|Breast Surgery|Undergo Breast Surgery
214684175|NCT05919108|PROCEDURE|Ultrasound|Undergo Ultrasound
214684176|NCT06828796|DRUG|Tacrolimus|Begins Day -1 and continues to Day +90 or Day +180 after transplant
214684177|NCT06828796|DRUG|Cyclophosphamide|Given Days +3 and +4 after transplant
214684178|NCT06828796|DRUG|Mycofenolate mofetil|Given Day 0 to Day +35 after transplant
214684179|NCT06301373|DRUG|Methotrexate Combined With Tofacitinib|Methotrexate Combined With Tofacitinib
214684180|NCT06301373|DRUG|Methotrexate|Methotrexate
214684181|NCT02678156|DEVICE|Lyoplant Onlay|
214373558|NCT03872752|BEHAVIORAL|FL lay leader training and workshop implementation|Intervention components will include a training course for community lay leaders, enabling them to acquire the skills to lead food literacy workshops. This includes raising their knowledge about nutrition recommendations and food labels, raisin self efficacy, and improving nutrition related organization and preparation skills.
214373559|NCT04484974|OTHER|Pecan snack|Under this condition, each participant will consume a mid morning snack of pecans followed by an ad libitum lunch.
214373560|NCT04484974|OTHER|Tortilla chip snack|Under this condition, each participant will consume a mid morning snack consisting of an iso-caloric (equal to the pecan snack) snack of tortilla chips followed by an ad libitum lunch.
214373561|NCT06065566|DIETARY_SUPPLEMENT|L-alanyl-L-glutamine dipeptide|"1\. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~A. Study group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the dipeptide L-alanyl-L-glutamine, at a dose of 0.4 g / kg of weight 6 hours before the surgical intervention."
214495279|NCT03499691|DEVICE|Hemodiafiltration|The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
214495280|NCT05164601|OTHER|No Intervention - Observational Only|Clinical Follow-Up
214495281|NCT02994459|OTHER|Weight Loss|Diet-induced weight loss (obese only)
214495282|NCT02761187|OTHER|No Intervention|As this was an observational study, no intervention was administered.
214495283|NCT05128513|DEVICE|DELP|The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
214684182|NCT03500133|RADIATION|No radiotherapy if CR at the end of chemotherapy.|Adapted chemotherapy without radiotherapy
214684183|NCT03500133|DRUG|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
214684184|NCT03500133|DRUG|Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
215089673|NCT06422637|DIAGNOSTIC_TEST|Liquid Biopsy Early Screening|An early screening model for lung cancer aids in identifying individuals with early-stage lung cancer. Those with positive indications of lung cancer will subsequently undergo confirmatory clinical assessments using Low-Dose Computed Tomography (LDCT) in sequence. Ultimately, a definitive diagnosis of lung cancer is established through surgical and pathological examination.
215089674|NCT06484361|DRUG|68Ga-PSMA|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
215089675|NCT06484361|DRUG|68Ga-RM2|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
215089676|NCT01286571|DRUG|BI 135585|one oral single dose per subject
215089677|NCT01286571|DRUG|BI 135585|one oral single dose per subject
215089678|NCT05007977|DRUG|ZT-01 low dose|Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
215089679|NCT05007977|DRUG|ZT-01 high dose|Single SC injection of ZT-01 20 mg during hypoglycemic clamp
215089680|NCT05007977|DRUG|Placebo|Single SC injection of placebo during hypoglycemic clamp
215089681|NCT02162966|DRUG|High Dose Colistin|High Dose Colistin
215089682|NCT02162966|DRUG|Standard Dose Colistin|Standard Dose Colistin
215089683|NCT02174744|OTHER|numeric pain rating scale|
215089684|NCT01651091|OTHER|Meditation Awareness Training|Psychotherapy Intervention
215089685|NCT01651091|OTHER|Treatment as usual|
215089686|NCT00126984|BIOLOGICAL|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
215089687|NCT00126984|BIOLOGICAL|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
215089688|NCT00126984|BIOLOGICAL|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
214373562|NCT06065566|OTHER|Placebo|"1\. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~B. Control group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the placebo in the form of saline solution in a volume similar to the control 6 hours before the surgical intervention."
214495284|NCT05979116|OTHER|myofascial release|MFR in its simplest form targeted restoration of mobility of myofascial and fascial layers from within, and with the surrounding structure. MFR techniques utilized with the cases include different variations of application: 1. Muscle was stroked in a long
214684185|NCT03500133|RADIATION|IN 30Gy RT in case of PR at the end of chemotherapy|Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT
215089689|NCT00126984|BIOLOGICAL|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
215089690|NCT01858753|BIOLOGICAL|Autologous fibroblasts|
215089691|NCT01858753|BIOLOGICAL|placebo sterile saline|
215089692|NCT00083486|DRUG|epoetin alfa|
214373563|NCT05659225|DEVICE|Electronic Stethoscope|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the electronic stethoscope group will be instructed to install the electronic stethoscope developed by our team and its accessories, then they will be trained by investigators on how to use the electronic stethoscope.
214373564|NCT05659225|OTHER|Standard treatment according to GINA(2019)|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the control group will receieve standard treatment according to GINA(2019).
214373565|NCT03204955|DRUG|Sodium chloride /sodium acetate (16.4%)|"Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy."
214373566|NCT03204955|DRUG|Sodium chloride (23.4%)|Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
214373567|NCT03204955|DRUG|PlasmaLyte|PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
214495285|NCT06758154|DEVICE|"TXJN electro-acupuncture"|Firstly, EA treatment will be administered at the Neiguan (PC6, bilateral), Shenting(GV23), Yingxiang(LI20, bilateral), Yintang(GV29) acupoints. Disposable stainless-steel needles (0.25 mm × 25 mm; Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Suzhou City, China) will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensations of achiness, heaviness, and numbness (known as de qi) at all above-mentioned acupoints. Following needle manipulations, EA instruments (SDZ-V, Hwato brand, Suzhou Medical Supplies Factory Co., Ltd., Suzhou City, China) will be used to attach the needle handles at PC6, GV23, LI20, GV29, with a dilatational wave of 5 Hz and a current intensity of 2 \~ 4 mA depending on the patient's tolerance. The needles will be removed after 30 min. Participants will receive 24 sessions over 8 weeks at a frequency of 3 times per week.
214684186|NCT03500133|DRUG|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
214684187|NCT03500133|DRUG|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
214684188|NCT03500133|DRUG|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
214684189|NCT03500133|DRUG|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
214684190|NCT03500133|DRUG|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
214684191|NCT01482026|OTHER|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
214684192|NCT01482026|OTHER|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
214986801|NCT02361931|DRUG|Hydrogel (as a part of SOC)|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
214986802|NCT03417297|DEVICE|High Intensity Focused Ultrasound|Participants will undergo high intensity focused ultrasound surgery utilizing magnetic resonance (MR) imaging guidance using a 3 Tesla scanner.
214684193|NCT01990521|PROCEDURE|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
214684194|NCT01990521|DEVICE|MS3TMRI / TRUS Guided Biopsy|"Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.~A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished)."
214684195|NCT05014776|DRUG|Tadalafil|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.
214684196|NCT05014776|DRUG|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
214684197|NCT05014776|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
214684198|NCT05014776|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 \[1 × 10\^9 colony forming units (CFU) in 100ml NS\] will be administered IV on Day 2 of Cycles 1-6.
214684199|NCT06275126|OTHER|CONSYDER decision aid|Web-based breast cancer surgery decision aid
214684200|NCT06226883|DRUG|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
214684201|NCT06226883|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
214684202|NCT05673603|DRUG|Brensocatib|Oral tablet
214684203|NCT05586581|DRUG|SV2A PET|SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain
214684204|NCT05586581|DRUG|TSPO PET|TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status
214684205|NCT05889702|BEHAVIORAL|KATR Linkage Strategy|"The Kentucky ATR (KATR) strategy is a 25-county program that links county residents at or below the 200% national poverty level who have an illicit SUD and are in treatment or early recovery to evidence-based RSSs such as recovery housing, and to other RSSs.~The KATR linkage approach uses vouchers as a linkage strategy for individuals in SUD treatment who have no other funding options to acquire critical RSSs. As such, KATR's linkage through vouchers is a last resort approach for linking to RSSs."
215089693|NCT05490966|OTHER|isometric trunk extensor muscles fatigue|Participants will perform three sets of intermittent isometric efforts between 50 and 60 percents of their maximal isometric strength. A padded force sensor will be placed approximately at the level of the 7th thoracic vertebrae. The first two sets will last six minutes each, while the third set will last three minutes. Between each set participants will rest for two minutes.
215089694|NCT00048113|DRUG|Alicaforsen|
214373568|NCT05059379|RADIATION|Entire supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
215089695|NCT03341455|BEHAVIORAL|Capacity building to support families affected by IPV & substance misuse|Training targeted groups (mothers, fathers, preschool teachers, community officers managing preschools) separately with the aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.
215089696|NCT06258590|DEVICE|Transcutaneous auricular vagus nerve stimulation|Patients will receive non invasive vagus nerve stimulation via electrodes attached to the ear.
215089697|NCT05226078|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral treatment of insomnia
215089698|NCT05065190|DRUG|Nintedanib|Soft gelatin capsule
214373569|NCT05059379|RADIATION|Medial supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
214373570|NCT03984370|DRUG|ZP4207|Abdominal SC administration
214684206|NCT06332625|DIAGNOSTIC_TEST|Brain quantitative magnetic resonance imaging|Identification and predictability of early structural and metabolic markers from 3T and 7T quantitative magnetic resonance imaging (qMRI)
214684207|NCT00174746|DRUG|AVE2635A|
214684208|NCT03819179|OTHER|Burt's Bees Serum|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.
214684209|NCT03819179|OTHER|Burt's Bees Serum with Biulin|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).
214684210|NCT03819179|OTHER|Burt's Bees Serum with Bonicell|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).
215089699|NCT05065190|DRUG|Placebo|Soft gelatin capsule
215089700|NCT05669872|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 20Ml|ferric carboxymaltose 1000mg, fixed dose for intervention group
215089701|NCT05669872|DRUG|RBC|pack RBC transfusion
215089702|NCT02108314|BEHAVIORAL|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
215089703|NCT05971446|DEVICE|Visual Evoked Potential (VEP)|Small gold-cup electrodes will be placed on the participant's head using a small dot of adhesive paste. The handheld device is then connected to the electrodes, and the participant's eyes are exposed to a light flicker. Each eye will be tested separately, and while testing one eye, the other eye may be patched.
214684211|NCT03819179|OTHER|Burt's Bees Serum with Berenew Complex|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).
214684212|NCT03819179|OTHER|Burt's Bees Serum with Ecoskin|This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
214684213|NCT02983981|DRUG|Topicort Topical Spray|open label Topicort spray
214684214|NCT01224353|DRUG|lipoic acid|Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
214684215|NCT01224353|OTHER|Placebo|Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
215089704|NCT05971446|DEVICE|Electroretinogram (ERG)|Skin electrodes will be placed under each eye. Eyes will then be exposed to a flashing light. Each eye will be tested separately and while testing one eye, the other eye may be patched.
215089705|NCT05039892|DRUG|3D185|All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.
214373571|NCT03984370|OTHER|Placebo (saline)|Abdominal SC administration
214373572|NCT00462280|DRUG|lovastatin|Given PO
214373573|NCT00462280|OTHER|placebo|Given PO
215089706|NCT05006833|BEHAVIORAL|Brief Provider Training - Bundled Approach|At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).
215089707|NCT05006833|BEHAVIORAL|Brief Provider Training - Benefits Approach|At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.
215089708|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Bundled Approach|Text messages sent to parents will focus on receiving all three adolescent vaccines.
215089709|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Benefits Approach|Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
215089710|NCT04938037|PROCEDURE|US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine|nerve block
215089711|NCT03350906|DRUG|n3-PUFA|The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).
215089712|NCT03350906|DRUG|Placebo|Looks exactly like the study drug but contains soybean oil with no active ingredient.
215089713|NCT03350906|PROCEDURE|Biopsy|Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.
214373574|NCT00462280|PROCEDURE|biopsy|Correlative studies
214373575|NCT00462280|PROCEDURE|laboratory biomarker analysis|Correlative studies
214373576|NCT03210155|DEVICE|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
214373577|NCT03210155|DEVICE|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
214373578|NCT01313286|DRUG|LY2608204 Reference|Administered orally
214495286|NCT06758154|DEVICE|sham acupuncture|Firstly, EA treatment will be administered at the non-acupoints near above-mentioned real acupoints. Disposable stainless-steel needles (0.25 mm × 25 mm; Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Suzhou City, China) will be used. After skin disinfection, the acupuncturists will take the needle into the acupoints without the sensations of de qi. Following needle manipulations, EA instruments (SDZ-V, Hwato brand, Suzhou Medical Supplies Factory Co., Ltd., Suzhou City, China) will be used to attach the needle handles at non-acupoints without the current. The needles will be removed after 30 min. Participants will receive 24 sessions over 8 weeks at a frequency of 3 times per week.
214495287|NCT06806969|DEVICE|Decision support|Patients will digitally fill out forms, which will go into the decision support tool integrated in the electronic health record journal, which predicts outcome of surgery for the patient, to inform shared decision making.
214373579|NCT01313286|DRUG|LY2608204 Test|Administered orally.
214373580|NCT04859582|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
214373581|NCT04859582|DRUG|Cisplatin|Administered as an IV infusion on Day 1 Q3W
214684216|NCT03115489|DRUG|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
215089714|NCT03350906|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
215089715|NCT06580314|BIOLOGICAL|Bevacizumab|Given IV
214684217|NCT03115489|DRUG|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
215089716|NCT06580314|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215089717|NCT06580314|PROCEDURE|Computed Tomography|Undergo CT
215089718|NCT06580314|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215089719|NCT06580314|DRUG|Olaparib|Given PO
215089720|NCT03320330|OTHER|Laboratory Biomarker Analysis|Correlative studies
215089721|NCT03320330|BIOLOGICAL|Pepinemab|Given IV
215089722|NCT03320330|OTHER|Pharmacological Study|Correlative studies
215089723|NCT00556179|DRUG|Lactoserum (Dermacyd Femina®)|Once a day during three months
214373582|NCT04859582|DRUG|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
214373583|NCT04859582|DRUG|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
214373584|NCT04859582|DRUG|Capecitabine|Administered orally BID on Days 1 to 14 Q3W
214373585|NCT04859582|DRUG|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
214684218|NCT03177837|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
214684219|NCT03177837|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
214373586|NCT05794633|OTHER|Acupuncture|"The patients will be recieved two days a week for 8 sessions with sterile 25\*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
214373587|NCT05794633|OTHER|Placebo acupuncture|"The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
214684220|NCT02690480|DRUG|PD-0332991 (Palbociclib)|"Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
214684221|NCT02690480|DRUG|Fulvestrant|"Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
214373588|NCT04436315|DEVICE|Motor-cognitive training device|Motor-cognitive training device
214373589|NCT04436315|OTHER|Active control condition|Physical activity program
214373590|NCT01552590|DRUG|Tolvaptan|
214373591|NCT01552590|DRUG|Placebo|
214373592|NCT01226901|DRUG|MK-4827|MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
214495288|NCT06768333|DIETARY_SUPPLEMENT|45 grams Voom Pocket Rocket Electro Energy|Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
214495289|NCT06768333|DIETARY_SUPPLEMENT|45 grams Maurten Gel 160|Participants will be required to consume 45 grams (in carbohydrates) of the Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
214684222|NCT02690480|DRUG|Placebo|"Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs"
214684223|NCT02927808|BEHAVIORAL|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
214684224|NCT05170893|DIETARY_SUPPLEMENT|Coenzyme Q10|Oral capsules
214684225|NCT05170893|OTHER|Placebo|Oral capsules
214684226|NCT00377065|DRUG|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
214684227|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
214684228|NCT01703286|DRUG|Linagliptin|given once daily for 28 days
214684229|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
214986803|NCT03588624|DEVICE|TearCare|The TearCare procedure includes the delivery of thermal energy to the external surface of the eyelids for 15 minutes, immediately followed by manual expression of each eyelid.
214373593|NCT02034708|DRUG|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
214373594|NCT02034708|DRUG|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
214495290|NCT06768333|DIETARY_SUPPLEMENT|45 grams SIS Go Isotonic Energy Gel|Participants will be required to consume 45 grams (in carbohydrates) of the SIS Go Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
214684230|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
214684231|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
214684232|NCT01703286|DRUG|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
214684233|NCT06112990|DIETARY_SUPPLEMENT|creatine monohydrate|Creatine is part of the phosphagen system and plays a critical role in energy metabolism. Creatine monohydrate supplementation increases availability of creatine and phosphocreatine in the skeletal muscle. Increased phosphocreatine enables greater buffering of adenosine triphosphate, an organic compound providing energy to cells, enhancing training volume (e.g., an individual can work-out harder and longer).This augmentation in exercise capacity amplifies training adaptations. Additionally, creatine monohydrate supplementation reduces levels of inflammatory markers, which are associated with severe muscle loss.
214684234|NCT06112990|OTHER|Placebo|Placebo supplementation consists of a flavorless, colorless, dextrose powder and will be supplied in concealed, unlabeled packaging.
214986804|NCT05138575|DRUG|Empagliflozin + Potassium Chloride|"Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control."
215089724|NCT00203021|DRUG|Glatiramer acetate|Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
214373595|NCT02335190|PROCEDURE|Radiofrequency ablation|RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
214373596|NCT02335190|PROCEDURE|Sensory block|Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
214373597|NCT02335190|DRUG|Lidocaine|
214373598|NCT00597948|BEHAVIORAL|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
214986805|NCT05138575|DRUG|Empagliflozin + Potassium Nitrate|Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
214373599|NCT00446069|DRUG|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
214986806|NCT05138575|DRUG|Potassium Chloride + Placebo for Empagliflozin|Active control.
214373600|NCT01209065|DRUG|GSK1349572|GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
214373601|NCT01209065|DRUG|Fosamprenavir|Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
214373602|NCT01209065|DRUG|Ritonavir|Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
214373603|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)|0.5 mL, Intramuscular
214373604|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)|0.5 mL, Intramuscular
214373605|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)|0.5 mL, Intramuscular
214373606|NCT00654901|BIOLOGICAL|Infanrix Hexa™|0.5 mL, Intramuscular
214373607|NCT03773367|DRUG|Fluorouracil|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
214373608|NCT03773367|DRUG|Oxaliplatin|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
214373609|NCT03773367|DRUG|Irinotecan|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
214373610|NCT06461416|BEHAVIORAL|ActiveHeal|Participants will have 6 group activity sessions and six individualized sessions from home, all focused on optimizing persistence in performance of specific selected activities.
214373611|NCT05375539|DRUG|AGN-CognI.Q|Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.
214495291|NCT06817421|BIOLOGICAL|Pneumococcal conjugate vaccine|10-valent pneumococcal polysaccharide conjugate vaccine at a dosage of 2μg for each serotype polysaccharide for 1, 5, 6A, 7F, 9V, 14, 19A, 19F, 23F, and 4μg for serotype 6B, conjugated to a carrier protein (CRM197), polysorbate 20 and aluminium phosphate as an adjuvant. Administered as an intramuscular injection of 0.5mL.
214495292|NCT06817421|BIOLOGICAL|Typhoid conjugate vaccine|Typhoid conjugate vaccine at a dosage of 25μg purified Vi capsular polysaccharide of Salmonella typhi Ty2 conjugated to Tetanus Toxoid with preservative (2-Phenoxyethanol). Administered as an intramuscular injection of 0.5mL.
214495293|NCT05972525|BEHAVIORAL|Shared decision-making supported by an in-consultation PtDA to patients with severe osteoarthritis in their hip or knee|The intervention group has been involved in the development process of the PtDA. After receiving a training course in SDM and the use of a PtDA, the surgeons will practice SDM supported by an in-consultation PtDA during the consultations with the participant.
214986807|NCT05051839|PROCEDURE|Implant surgery and restoration|Implants with two different transmucosal neck configuration are placed.
214986808|NCT04060836|DRUG|Xyntha|Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.
214986809|NCT04060836|DRUG|Recombinant Coagulation Factor VIII Injection|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
214986810|NCT04823104|OTHER|Home visitation|Home visitation for pregnancy follow-up
214986811|NCT05188508|DRUG|Pembrolizumab|Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.
214986812|NCT05188508|COMBINATION_PRODUCT|Olaparib and Temozolomide|Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.
214986813|NCT02871596|OTHER|Placebo|A combination of maltodextrins and red and blue food colors.
214986814|NCT02871596|DIETARY_SUPPLEMENT|Flavonoids|A combination of blueberry extract, black current extract, and black rice extract.
214986815|NCT02871596|DIETARY_SUPPLEMENT|Flavonoids+Prebiotics|A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
214373612|NCT06115252|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing with peer dyads starts with an open-ended exploration of the dyad's hazardous drinking behavior via personal stories about alcohol use. It includes a values clarification task and age-matched norms along with personalized feedback regarding the dyad's alcohol use. The goal of the session is to engage the dyad in a thoughtful conversation about drinking and the implications it may have on their lives, with an eye to bolstering and supporting inherent drive for behavior change.
214373613|NCT00895700|BEHAVIORAL|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
214986816|NCT06422780|OTHER|Maternal Role Preparation Training|Maternal Role Preparation Training: Maternal Role Preparation Training (MRHE) is an occupational training programme aimed at increasing the competence of first-time mothers regarding motherhood. In this four-session programme, pregnant women will be provided with written materials, face-to-face talks and practical training covering topics related to their babies (maternal attachment, training on the sensory and developmental abilities of babies) and themselves (training on adopting a new role as a mother).The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions.
214986817|NCT06422780|OTHER|Awareness Centred Occupational Therapy Group|Awareness Centred Occupational Therapy (FME); In FME, areas that affect the occupational performance of pregnant women in their daily lives will be identified and appropriate occupational therapy interventions will be applied. Awareness training on the applications will be given before starting the sessions. The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions. Awareness training will be given before starting the sessions.
214986818|NCT06721247|DRUG|Magnesium|oral intake of magnesium for asthmatic patients with dose 200 mg per day for one year in addition to usual asthmatic treatment according to GINA guidelines 2024
214986819|NCT06721247|DRUG|ICS+LABA|inhaled corticosteroids with long acting Beta 2 agonist are given to control group patients twice daily
214986820|NCT02340676|PROCEDURE|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
215089725|NCT01877577|DIETARY_SUPPLEMENT|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
215089726|NCT06583681|OTHER|The measuring of the sagittal curvatures of the spine|Research tool was Baseline Bubble inclinometer.
214373614|NCT03626090|BIOLOGICAL|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
214373615|NCT00724464|BIOLOGICAL|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
214495294|NCT06651567|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
214495295|NCT06651567|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
214495296|NCT06702124|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
214495297|NCT06702124|DRUG|Placebo|Placebo administration for 24 weeks
214986821|NCT02340676|DRUG|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
214986822|NCT04533581|DRUG|ME-401|In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
214495298|NCT06731777|PROCEDURE|Scaling and root planing plus PHTALOX® oral gel vehicle|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (PHTALOX® oral gel vehicle) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
215089727|NCT05178381|DEVICE|Continuous theta burst transcranial magnetic stimulation|Participants will receive cTBS (50Hz stimulation at 80% AMT for 40 seconds). Stimulation will be applied to either the target area (frontal pole or IFG) or control area (vertex). Targeting of each region will be achieved using a frameless neuronavigation system with a Polaris Spectra infrared camera that enables stimulation to be centered on specific coordinates in Montreal Neurological Institute space. We will use coordinates \[x,y,z\] = \[35,50,15\] for frontal pole and \[x,y,z\] = \[56,16,22\] for right IFG based on the location of our activations in the young pilot group (Figure 4). The vertex control site is defined as the Cz position of a 10-20 EEG system. After receiving TMS, participants will stare at a white wall for 1 minute before performing the Horizon Task for 45 minutes.
215089728|NCT05036707|DEVICE|Xenodiagnosis Ticks|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors.
215089729|NCT05036707|PROCEDURE|skin biopsy|2-3 mm skin punch biopsies will be performed.
215089730|NCT05036707|PROCEDURE|blood draw|Peripheral blood draws will be performed.
215089731|NCT05915442|DRUG|Quemliclustat|100mg IV once every two weeks
215089732|NCT05915442|DRUG|Etrumadenant|150 mg orally (PO) once a day (QD)
214986823|NCT06074835|DEVICE|Gamete preparation, ICSI, embryo culture and vitrification robot assistant|Patients undergoing an assisted conception treatment with medical indication to perform ICSI may be recruited in this study. The study will follow a sibling-oocyte and/or sibling embryo study design where oocytes and/or embryos obtained from a specific patient or couple will be randomly distributed across two groups (test and control) and undergo one or more elements of an automated assisted conception laboratory workflow (for the test group) or a standard assisted conception laboratory workflow (for the control group). Before distributing the samples, an embryologist will slightly blur the vision of the samples so that their morphology can no longer be clearly assessed. Robotic automation may include any of the following steps: robotic sperm preparation, robotic oocyte selection and denudation, robotic sperm injection, automated embryo culture, and automated cryopreservation. The resulting embryos may be employed for embryo transfer.
214986824|NCT06074835|OTHER|Routine Manual ICSI Workflow|Routine Manual Icsi Workflow
214986825|NCT06233461|DRUG|TAK-279|TAK-279 capsules.
214986826|NCT06233461|DRUG|Placebo|TAK-279 placebo-matching capsules.
215089733|NCT05915442|DRUG|Zimberelimab|240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT
215089734|NCT05915442|RADIATION|Stereotactic Body Radiation Therapy|Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat
215089735|NCT04460859|OTHER|Specific lung recruitment maneuvers|Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.
215089736|NCT05796115|PROCEDURE|Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS on the basis of Procalcitonin and Presepsin values measured within the first 3 hours of life.
215089737|NCT05796115|PROCEDURE|Antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS.
214495299|NCT06731777|PROCEDURE|Scaling and root planing plus 0.12% chlorhexidine oral gel|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (0.12% chlorhexidine oral gel) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
214495300|NCT06731777|PROCEDURE|Scaling and root planing plus PHTALOX® oral gel|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (PHTALOX®) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
214495301|NCT04160507|OTHER|Biorepository|To collect and store biological samples (whole blood and urine), along with relevant medical information, from adult inpatients and outpatients. Buffy coats will also be received from H3Africa Kidney Disease Research Network.
214495302|NCT06644196|DEVICE|Acquisition of images/videos of the bilateral fundus with the holographic doppler laser|Acquisition of images/videos of the bilateral fundus with the holographic Doppler laser
214495303|NCT06044324|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Participants in the active stimulation group will receive the high frequency rTMS to left middle temporal visual area. The left middle temporal visual area will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 100% of RMT.~Stimulation will be delivered to the left middle temporal visual area using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
214495304|NCT06837441|PROCEDURE|Atrial Fibrillation Termination|Pursuing Atrial Fibrillation Termination as a Procedural Endpoint
214495305|NCT06837441|PROCEDURE|Prespecified Ablation|Prespecified Ablation Strategy Followed by Cardioversion
214495306|NCT06662136|BEHAVIORAL|motivasional intereview|No application will be made to the participants in the control group
214495307|NCT04015700|BIOLOGICAL|Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics|-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.
214495308|NCT04015700|DEVICE|CELLECTRA®2000 EP Device supplied by Geneos Therapeutics|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
214495309|NCT04015700|DRUG|Plasmid encoded IL-12|The INO-9012 vials will be supplied by Geneos Therapeutics
214495310|NCT06791603|OTHER|Standardized chemotherapy education + video|Videos will be provided with patients and they will watch videos during the visit. The information regarding the prevention and management of side effects and further instructions when to visit hospital. Patients will have access to videos and watch videos after leaving the hospital for the entire treatment course
214495311|NCT06749262|OTHER|walking on incline or walking at increasing speed for 36 visits|Subjects will be prepared for data collection by wearing an exercise suit and obtaining height and body weight. Breathing sensors and foot switches will be worn to measure breathing and walking performance.
214495312|NCT06750744|RADIATION|chest x ray|chest X ray identify severity of pneumonia
214495313|NCT06750744|RADIATION|chest X ray|chest radiological evaluation via x ray
214495314|NCT06750744|DRUG|Tigecycline (Tygacil)|selective antibiogram
214495315|NCT06816550|OTHER|Doing Interviews with the patients admitted to emergency department to detect whom are on chronic use of nonsteroidal anti inflammatory drugs|detection of patients on chronic use of nonsteroidal anti inflammatory drugs among total patients admitted to emergency department in Alexandria Main University Hospital
214986827|NCT06471010|OTHER|Blended Dynamic Interpersonal Therapy (B-DIT)|The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp (http://www.onlinepsyhulp.be), integrates FTF therapy and online modules into a cohesive treatment program for clients with personality pathology. Both FTF and online treatment components are anchored in the Dynamic Interpersonal Therapy (DIT) framework (Lemma et al., 2011).The program spans three phases: an individual phase lasting approximately two months, followed by a five-month group phase, concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases. Both verbal psychotherapy and art therapy are offered as treatment modalities in the face-to-face treatment sessions. The program is implemented by a multidisciplinary team.
214986828|NCT03746496|DIAGNOSTIC_TEST|point-of-care laboratory analysis|POC analysis with i-STAT POC analyser from the intraosseous and arterial blood
215089738|NCT05924477|PROCEDURE|Sulcus tube placement|GDD implantation surgery with tube placement in the ciliary sulcus
215089739|NCT05924477|PROCEDURE|Anterior chamber (AC) tube placement|GDD implantation surgery with tube placement in the anterior chamber
215089740|NCT03694873|DRUG|Tramadol Hydrochloride|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
214495316|NCT06817655|BEHAVIORAL|PaRole OncO France : Individual peer support|"Following the development of the peer support program PaRole OncO France, we are now proceeding with its implementation and evaluation through a pilot study. This study aims to derive both implementation-related and clinically relevant results.~Prior to their assignment, all peer helpers undergo a comprehensive training course to ensure they are well-equipped for their role.~Patients receive individual peer support during their treatment visits, providing real-time assistance and support within the clinical setting.~The study incorporates three key measurement time points:~1. Baseline measurement (before the intervention)~2. After the intervention~3. Follow-up measurement (1months after the first intervention)~4. Follow-up measurement (6 months after the first intervention)~At each time points, participants will complete a set of standardized questionnaires. These instruments are designed to capture relevant outcomes and experiences related to the peer support intervention."
214495317|NCT06820229|PROCEDURE|Enucleation|The entire cyst lining was radically enucleated, followed by thorough curettage of the cavity with meticulous evaluation of any residual daughter cyst lining followed by reduction of lingual and buccal walls bony undercuts to remove any residual cystic epithelium
214373616|NCT00724464|DRUG|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
214373617|NCT04199260|DEVICE|papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
214373618|NCT04309084|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
215089741|NCT03694873|DRUG|Celecoxib 200mg|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
214684235|NCT06112990|BEHAVIORAL|Home-based, telehealth|Home-based, individualized, whole-body RT program, supervised via the telehealth platform within the electronic medical record system. The RT program consists of 12 resistance exercises, focusing on all major muscle groups including upper and lower body, core, and whole-body. Exercises within each participant's individualized RT program progress with a periodization model as recommended by the American College of Sports Medicine. In addition, the cancer exercise trainer will inquire about space availability in the home for completing resistance prior to developing the personalized prescription. This logistical information is key to ensure feasibility of completing the exercises prescribed. Participants will be provided with beginner and advanced sets of elastic resistance bands to enable progression throughout the 52-week study.
214684236|NCT06121947|PROCEDURE|The DBS electrodes are implanted into MLR.|MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
214684237|NCT06121947|PROCEDURE|The electrodes are implanted into the patient's vagus nerve|A pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
214684238|NCT01744847|DEVICE|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
214684239|NCT01984346|DEVICE|AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax|Convergent Epicardial Endocardial Ablation Procedure
214684240|NCT01984346|DEVICE|Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering|Endocardial Catheter Ablation Procedure
214684241|NCT02973529|DEVICE|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
214684242|NCT02973529|DEVICE|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
214684243|NCT06245018|BIOLOGICAL|iNK Injection|Subjects will receive about 4 cycles of iNK
214684244|NCT04150874|DIAGNOSTIC_TEST|Lumason®|Hepatic artery embolization using standard of care radioembolization and assessment of tumor and hepatic parenchymal perfusion kinetics before, during and after treatment with standard of care iodinated contrast (at the time of Y90 radioembolization treatment) and standard of care follow-up with multiphase CT or MRI with the addition of study agent Lumason microbubbles for contrast-enhanced ultrasound (which will be performed concurrently with standard evaluation).
214684245|NCT06086639|OTHER|Online Occupational Therapy Group Training|In this study, a 4-week online occupational therapy group training was conducted by an occupational therapist specialized in the field of nutrition. The content of the training, which takes place one hour a week, is given below; Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs
214684246|NCT06428643|OTHER|Chlamydia, gonorrhea, syphilis, and HIV screening|Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.
214684247|NCT06528938|DEVICE|Theta Burst Stimulation|Cool B70 coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
214684248|NCT00427388|DRUG|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
214684249|NCT00427388|OTHER|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
214986829|NCT00668616|DRUG|Cyclophosphamide, Epirubicin, Paclitaxel|4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
214986830|NCT00668616|DRUG|Epirubicin, Paclitaxel, Filgrastim|cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
214373619|NCT05699421|OTHER|screening programme|CMV screening during the first trimester of pregnancy and neonatal
214373620|NCT05669950|DRUG|Lu AG13909|Solution for infusion
214373621|NCT05873452|DEVICE|Kaitoh Atherectomy System|The Kaitoh Atherectomy System is a handheld device which initiates mechanical rotation of the blade to debulk atherosclerotic lesions.
214373622|NCT06804122|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients are counseled how to do endurance training and strenght training at home by a trained physiotherapist.
214373623|NCT04869553|OTHER|Management pain with distraction methods ABC|"Every patient will receive :~* The usual pain management of their ward (Treatment A),~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)"
214373624|NCT04869553|OTHER|Management pain with distraction methods BCA|"Every patient will receive :~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)"
214373625|NCT04869553|OTHER|Management pain with distraction methods CAB|"Every patient will receive :~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)~* The usual pain management of their ward with a hypnosis session (Treatment B)"
214373626|NCT06247735|DRUG|K-808 (Dose A)|Administered orally once daily
214373627|NCT06247735|DRUG|K-808 (Dose B)|Administered orally once daily
214373628|NCT06247735|DRUG|Placebo|Administered orally once daily
214373629|NCT05741385|DRUG|Caffeine|Caffeine
214373630|NCT05741385|DRUG|Warfarin sodium|Warfarin sodium
214684250|NCT06960252|DEVICE|OPTRELL™ Mapping Catheter|PVI plus substrate modification of LA chamber coexisting with low unipolar voltage (\< 3.0 mv) or bipolar voltage (\< 0.5 mv) in SR and stable (STD \< 30), fast AF CL detected by CLM module and OPTRELL™ Mapping Catheter.
214684251|NCT03301766|DRUG|lidocaine 5% patch|transdermal patch
214986831|NCT04037605|DRUG|Ketoconazole Pill (also known as nizoral)|Ketoconazole pill is taken 4 times per inpatient visit
214684252|NCT03301766|DRUG|standard therapy|Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
214684253|NCT03301766|DRUG|Non-medicated patch|non-medicated patch
214684254|NCT03165513|BEHAVIORAL|mhGAP-IG|psychosocial interventions
214684255|NCT05197595|BEHAVIORAL|Attachment-based compassion therapy|Compassion program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
214684256|NCT05197595|BEHAVIORAL|Relaxation program|Relaxation program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
214684257|NCT04738513|PROCEDURE|Vertical preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.
214684258|NCT04738513|PROCEDURE|Conventional Preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
214684259|NCT06077968|BIOLOGICAL|Prior standard of care receipt of Pfizer's ABRYSVO vaccine|Participants will receive Pfizer's ABRYSVO vaccine as part of standard of care. Vaccine is not administered in this study.
214373631|NCT05741385|DRUG|Omeprazole|Omeprazole
214495318|NCT06820229|PROCEDURE|cyst enucleation|"The entire cyst lining was radically enucleated, followed by thorough curettage of the cavity with meticulous evaluation of any residual daughter cyst lining followed by reduction of lingual and buccal walls bony undercuts to remove any residual cystic epithelium.~Using coarse round surgical carbide burs under copious normal saline irrigation, peripheral ostectomy was done for all bony walls to remove any microscopic daughter cyst, with isolation, retraction, and preservation of the lingual and inferior alveolar bundle. The bony septa were removed using rotary Lindemann fissure burs in case of multilocular lesions.~After enucleation and peripheral ostectomy a sterile radiopaque gauze coated with 5-fluorouracil cream 5% and put into the surgical cavity."
214495319|NCT05927350|OTHER|Survey|Survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community
214495320|NCT05240924|BEHAVIORAL|Exposure and Response Prevention|ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.
214684260|NCT04644419|OTHER|none (observational study)|This is an observational study and does not include intervention delivery.
214684261|NCT00682825|BEHAVIORAL|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
214373632|NCT05741385|DRUG|Metoprolol|Metoprolol
214373633|NCT05741385|DRUG|Midazolam|Midazolam
214373634|NCT05829083|DEVICE|Asymmetric nasal cannula - DUET|"DUET asymmetric nasal high flow interface that fits best to the patients' nostrils (size: one nostril of the patient should be fully occluded)~Patients will be crossed-over between the 2 interventions"
214373635|NCT05829083|DEVICE|Conventional nasal high flow cannula|"Well-established conventional nasal high flow cannula (size: medium)~Patients will be crossed-over between the 2 interventions"
214684262|NCT00682825|BEHAVIORAL|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
214684263|NCT03652415|DEVICE|Artificial tears (classified by MHRA as a medical device)|Use of artificial tears
214684264|NCT01279135|RADIATION|Conventional Radiation|Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
214684265|NCT01279135|RADIATION|Tomotherapy based IGRT|Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
214684266|NCT00491114|DRUG|Gemcitabine|
214684267|NCT04793672|OTHER|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
214684268|NCT02440178|DRUG|Micafungin|
214684269|NCT01837147|BEHAVIORAL|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
214684270|NCT01837147|BEHAVIORAL|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
214986832|NCT04037605|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per inpatient visit
214986833|NCT04037605|DRUG|Dexamethasone Pill|Dexamethasone pills is taken twice per inpatient visit
214986834|NCT04037605|DRUG|Dexamethasone injection|Dexamethasone IV injection is given twice per inpatient visit
214986835|NCT04037605|DRUG|Cosyntropin Injectable Product|Cosyntropin injection is given twice per inpatient visit
214986836|NCT04037605|DRUG|Recombinant Human Luteinizing Hormone (also known as luveris)|Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
214986837|NCT04037605|DRUG|Hydrocortisone Injection (also known as solu-cortef)|Hydrocortisone IV push is given twice per inpatient visit
214684271|NCT00863785|DRUG|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
214684272|NCT05552378|DEVICE|Multi-Gyn FloraFem|Vaginal gel packed in 5 single use plastic tubes.
214684273|NCT01532700|DRUG|Ofatumumab with GSK2110183|"* GSK2110183 125mg OD continuously~* Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
214684274|NCT02549690|DRUG|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
214684275|NCT02549690|DRUG|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
214684276|NCT05058664|BEHAVIORAL|A-F texting component|Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.
214684277|NCT05058664|BEHAVIORAL|P-F texting component|Over the course of the 6 week intervention, parents will receive between 1-2 messages, depending on randomization (in addition to A-F component messages)
214684278|NCT03182205|OTHER|IME|The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.
214684279|NCT03182205|OTHER|Sham IME|The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
214684280|NCT05635162|DRUG|Zanubrutinib|Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
214684281|NCT05635162|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle
214684282|NCT03845036|BEHAVIORAL|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
214684283|NCT03845036|BEHAVIORAL|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
215089742|NCT01744717|OTHER|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~* TURNING / POSITIONING (moving side to side or up or down in bed)~* ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~* NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
214684284|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant IB160|H7N9 monovalent (fragmented and inactivated)
215089743|NCT01410812|BEHAVIORAL|Control|Receive weekly emails asking participants about their exercise and receive cash.
215089744|NCT01410812|BEHAVIORAL|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
215089745|NCT01410812|BEHAVIORAL|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
214684285|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant SE|H7N9 monovalent (fragmented and inactivated)
214684286|NCT03330899|BIOLOGICAL|H7N9 antigen without adjuvant|H7N9 monovalent (fragmented and inactivated)
214684287|NCT03330899|BIOLOGICAL|Placebo (PBS)|Placebo (Phosphate Buffered Saline -PBS)
214684288|NCT01004783|GENETIC|DNA methylation analysis|
214684289|NCT01004783|GENETIC|gene expression analysis|
215089746|NCT05455502|DRUG|VX-548|Tablet for oral administration.
215089747|NCT00697437|DRUG|Docetaxel|70mg q3wx 1 dose
215089748|NCT00697437|DRUG|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
215089749|NCT02936284|BEHAVIORAL|Music Enhancement|
215089750|NCT02936284|BEHAVIORAL|Play Date|
215089751|NCT06433999|DRUG|Brepocitinib|Oral Brepocitinib PO QD
215089752|NCT05825235|DRUG|Pramipexole|6 months of treatment with add-on Pramipexole
214684290|NCT01004783|GENETIC|loss of heterozygosity analysis|
214684291|NCT01004783|GENETIC|microarray analysis|
214684292|NCT01004783|GENETIC|mutation analysis|
214684293|NCT01004783|GENETIC|polymerase chain reaction|
214684294|NCT01004783|GENETIC|reverse transcriptase-polymerase chain reaction|
214684295|NCT01004783|OTHER|laboratory biomarker analysis|
214684296|NCT06038097|PROCEDURE|Radiofrequency Pallidotomy|Radiofrequency bilateral simultaneous pallidotomy
214684297|NCT00184249|PROCEDURE|Bipolar radiofrequency ablation|Ablation using CE marked bipolar ablation devices
214684298|NCT06295055|PROCEDURE|Ridge augmentation with semi-rigid shell barrier system|The semi-rigid shell, fixed to the outside cortex by tacks, acts as a bone wall. Bone particles are placed in the gap and covered with the semi-resorbable covering membrane, serving as a barrier membrane.
214684299|NCT03696069|OTHER|Non-Interventional|Non-Interventional
214684300|NCT00748059|PROCEDURE|Standing or upright tilt|stand upright or tilt table test
214684301|NCT00748059|PROCEDURE|Microneurography|Recording from sympathetic nerve
214684302|NCT00748059|PROCEDURE|QSweat|quantitative sweat testing
215089753|NCT05740566|DRUG|Tarlatamab|Tarlatamab will be administered as an IV infusion.
215089754|NCT05740566|DRUG|Lurbinectedin|Lurbinectedin will be administered per local SOC.
215089755|NCT05740566|DRUG|Topotecan|Topotecan will be administered per local SOC.
214373636|NCT05365477|BEHAVIORAL|Empiric Therapy: Diet|Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to \<2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to \<100 mg/day
214684303|NCT00748059|DEVICE|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
214684304|NCT00748059|DRUG|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
214986838|NCT04037605|DRUG|Gonadorelin (also known as Lutrepulse)|Gonadorelin IV injection is given twice per inpatient visit
214986839|NCT04037605|DRUG|Corticorelin (also known as Acthrel)|Corticorelin IV injection is given twice per inpatient visit
214684305|NCT00748059|DRUG|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
214986840|NCT04037605|DRUG|Placebo oral tablet|Placebo for Ketoconazole are given 4 times per inpatient visit
214986841|NCT04037605|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
214684306|NCT00748059|PROCEDURE|BodPod|Determination of body composition
214684307|NCT00748059|PROCEDURE|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~1. 0.5% proparacaine (Alcaine, Allergan, Inc)~2. Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~3. 0.5%, 1% tropicamide (Mydriacyl, Alcon)~4. Over-the-counter preservative-free artificial tears~5. 0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~6. 1% cyclopentolate hydrochloride (Alcon)"
214684308|NCT00748059|PROCEDURE|Sleep study|Recording of sleep pattern overnight
214684309|NCT00748059|PROCEDURE|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
214986842|NCT04037605|DRUG|Saline solution for injection|Saline Solution (placebo) for ganirelix subcutaneous injection
214684310|NCT00748059|PROCEDURE|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
214684311|NCT00748059|PROCEDURE|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
214986843|NCT06478212|DRUG|Vorasidenib|To be taken by mouth once daily in 28-day cycles with no break between cycles
214373637|NCT05365477|DRUG|Empiric Therapy: Drug|Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.
214684312|NCT00748059|PROCEDURE|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
214986844|NCT06478212|DRUG|Temozolomide (TMZ)|To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
214684313|NCT02871180|DIETARY_SUPPLEMENT|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
214986845|NCT04804644|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214986846|NCT04804644|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214986847|NCT04804644|DRUG|Memantine Hydrochloride|Given PO
214986848|NCT04804644|OTHER|Neurocognitive Assessment|Ancillary studies
214986849|NCT04804644|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214986850|NCT04804644|OTHER|Survey Administration|Ancillary studies
214986851|NCT04804644|RADIATION|Whole-Brain Radiotherapy|Undergo HA-WBRT
214986852|NCT01528085|DRUG|Nilotinib|Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)
214986853|NCT06958042|OTHER|Questionnaire and Physical Exam|\- St George Respiratory Questionnaire (SGRQ): The SGRQ developed by Jones (2000), which is used specifically for respiratory diseases, consists of 50 questions. In the questionnaire, there are three categories in which symptom, activity and the effect of the disease on quality of life are questioned and each category is evaluated within itself and there is an evaluation scale between 0-100 points. In the evaluation, high scores indicate an inadequate and low quality of life.
214684314|NCT02871180|OTHER|No late night snack|Patient consumed no nutrients at late night.
214684315|NCT02752529|DRUG|Tacrolimus（FK506）|
214684316|NCT00397969|OTHER|counseling intervention|
214684317|NCT00397969|PROCEDURE|screening colonoscopy|
214684318|NCT06413173|COMBINATION_PRODUCT|Active tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with active tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
214684319|NCT06413173|COMBINATION_PRODUCT|Sham tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with sham tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
214684320|NCT00972244|DRUG|Dapagliflozin|once daily, 12 weeks
214684321|NCT00972244|DRUG|Placebo|once daily, 12 weeks
214684322|NCT04421196|OTHER|Exclusion of opioid analgesics|The intervention involves removing the option of patients having an opioid analgesic at any time point during the perioperative period.
214684323|NCT00366730|DRUG|Nitazoxanide|
214684324|NCT00038688|BEHAVIORAL|Peer HIV Education Program|
214495321|NCT05240924|OTHER|Stress Management Training|The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
214495322|NCT06764290|OTHER|pedal walking|Pedal walking is a challenging walking task that can be used as a form of physical therapy for stroke participants.
214684325|NCT05582811|DRUG|Dose Riociguat 2,5 or 5mg|A selective stimulator of soluble guanylate cyclase (sGC)
214684326|NCT05582811|DRUG|Riociguat|A selective stimulator of soluble guanylate cyclase (sGC)
214495323|NCT06764290|OTHER|visual occlusion|Walking with eyes-covered is a challenging walking task that can be used as a form of physical therapy for stroke participants.
214684327|NCT05582811|DRUG|Placebo|Placebo
214684328|NCT01597557|DRUG|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
214684329|NCT01597557|OTHER|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
214684330|NCT05897346|OTHER|'Learning while serving' training program|The training program will involve training workshops, hands-on sessions, and a smoker referral competition.
214986854|NCT03174639|PROCEDURE|Inverted and free ILM insertion|ILM was peeled and the ILM flap was inverted and inserted into the macular hole, followed by insertion of free ILM flap.
214986855|NCT06150820|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
214684331|NCT05897346|OTHER|Usual care|A 3-hour training workshops in the control group are regarded as usual care since the training workshops are also conducted regularly to other secondary or tertiary schools.
214684332|NCT05201859|DRUG|Sintilimab|Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
214684333|NCT05201859|DRUG|Capecitabine|An oral anticancer agent that can be converted into 5-Fu in vivo.
214684334|NCT03086200|BEHAVIORAL|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
214684335|NCT03480282|OTHER|Prognosis information and Provider Scripts|An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.
214986856|NCT00219609|DRUG|UK-390,957|
214986857|NCT03821129|DEVICE|PFO closure with GORE® CARDIOFORM Septal Occluder|PFO closure with GORE® CARDIOFORM Septal Occluder in patients with ischemic stroke
214986858|NCT03328065|OTHER|Interviews|Semi-directed interviews, recorded and transcribed for analysis
214986859|NCT03328065|OTHER|Questionnaires|economic and psycho-social questionnaires
214986860|NCT00961064|DRUG|Eltrombopag|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
214684336|NCT01966562|BEHAVIORAL|WHOLE-BODY VIBRATION TRAINING|The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
215089756|NCT05740566|DRUG|Amrubicin|Amrubicin will be administered per local SOC.
215089757|NCT06176768|DRUG|LY3972406|Administered orally
214986869|NCT00574314|OTHER|No Intervention|Participants will be consented.
214986870|NCT02397525|DRUG|LIPO-202|
214986871|NCT00576758|DRUG|obinutuzumab (RO5072759)|1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
214986872|NCT00576758|DRUG|rituximab|375 mg/m\^2 rituximab IV infusion once a week for 4 weeks.
214986873|NCT01262586|DRUG|Vildagliptin|
214986874|NCT01262586|DRUG|Glimepiride|
214986875|NCT02166112|PROCEDURE|Permacol mesh placement|All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
214986876|NCT00026130|DRUG|fluorouracil|200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
215089758|NCT06176768|DRUG|Placebo|Administered orally
215089759|NCT04461418|DRUG|Glucocorticoid therapy|The study intervention is defined as treatment with either prednisone or dexamethasone as palliative therapy for the control of neurological symptoms; patients with symptomatic brain metastases with a requirement for glucocorticoid therapy will be treated with an available, standard-of-care immune checkpoint inhibitor regimen.
214986877|NCT00026130|DRUG|gemcitabine hydrochloride|200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
214986878|NCT00026130|RADIATION|radiation therapy|4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
214684337|NCT01966562|BEHAVIORAL|MULTICOMPONENT TRAINING|This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
214684338|NCT02912000|BEHAVIORAL|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
214684339|NCT00285298|DRUG|Pentoxifylline|
214684340|NCT00285298|DRUG|Placebo|
214684341|NCT03897270|PROCEDURE|Photoacoustic Imaging|Undergo photoacoustic imaging of the breast
214684342|NCT02077075|BEHAVIORAL|Web-based weight loss program|A 4-week web-based wellness program.
214986879|NCT05721313|PROCEDURE|root resection|It will be carried out under local anestesia. Intra-crevicular or para-marginal gingival incision will be carried out and full-tickness mucoperiostal flaps will be raised to expose the affected roots. Whit the use (if possible) of a surgical stent an incision will be performed on the root to be removed. Biodentine will be used for retrogade obturation. The flaps will be sutured.
214986880|NCT00761319|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
214986881|NCT00761319|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
214986882|NCT02556749|DIETARY_SUPPLEMENT|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
214986883|NCT02556749|DIETARY_SUPPLEMENT|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
215089760|NCT06602063|PROCEDURE|surgery/chemotherapy|secondary cytoreductive surgery followed by 6 cycles of post-operative chemotherapy
215089761|NCT06602063|DRUG|Iparomlimab/Tuvonralimab|Iparomlimab/tuvonralimab will be administered at a dose of 5 mg per kilogram IV every 21 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity or withdrawal of consent.
215089762|NCT06981130|DEVICE|FebriDx Point of Care Test|Patients self-referring to their GP practice with symptoms of acute respiratory infection (ARI) will receive the FebriDx point-of-care test during their clinical consultation.
214684343|NCT02077075|BEHAVIORAL|On-line health coaching|A 4-week web-based wellness program with weekly personalized on-line health coaching.
214684344|NCT02446730|DEVICE|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
214684345|NCT02446730|DRUG|Prasugel|
214684346|NCT02446730|DRUG|Clopidogrel|
214986884|NCT00123136|DEVICE|foot energizer|
214986885|NCT06074510|DRUG|Piflufolastat F 18 Intravenous Solution [PYLARIFY]|Participants will receive a single dose of 333 MBq (9 mCi) \[296 MBq-370 MBq (8 mCi - 10 mCi)\] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing
214684347|NCT02424955|DRUG|perflutren lipid microspheres|
214684348|NCT02424955|DIAGNOSTIC_TEST|3D ultrasound|
214684349|NCT03871517|DRUG|Indobufen|Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.
214684350|NCT03871517|DRUG|Aspirin|Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
214684351|NCT04374305|DRUG|Brigatinib|Oral daily per predetermined dosage per protocol.
214684352|NCT04374305|DRUG|Neratinib|Oral daily per predetermined dosage per protocol.
214684353|NCT01492647|DRUG|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
214684354|NCT01492647|DRUG|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
214986886|NCT00623610|PROCEDURE|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
214373638|NCT05365477|BEHAVIORAL|Selective Therapy: Diet|"Diet:~Volume \<2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume~Calcium \>250mg male, \>200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to\<2000mg/d, avoid vitamin D + calcium supplements~Oxalate \>40mg Reduce dietary oxalate intake to \<100 mg/d; increase fiber intake to 25-35 g/d~Citrate \<450mg male, \<550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~pH\<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Uric acid \>800mg male, \>750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Sodium \>150mmol Reduce sodium intake to \<2000mg/d~Sulfate \> 80mEq or urine urea nitrogen \>14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d"
214373639|NCT05365477|DRUG|Selective Therapy: Drug|"Drug(s):~For calcium \>250mg male, \>200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate \<450mg male, \<550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH\<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid \>800mg male, \>750mg female: allopurinol 300mg.~If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID"
214373640|NCT06451978|OTHER|Nature-based intervention|The nature-based intervention is a manualised, caregiver-led intervention consisting of a physical manual comprising of 8 sessions of 8 different nature-based activities. It is designed for the person living with dementia or mild cognitive impairment and their caregiver to carry out the sessions together, either in their own home or out in a local area of nature.
214373641|NCT06341868|DEVICE|KneeStim|Participant will be randomized to either be in control or experimental group
214373642|NCT03275974|BIOLOGICAL|Carbon C 11 Glutamine|Given by IV
214986887|NCT06098183|OTHER|Whey Protein Isolate|Whey protein isolate essential amino acids (25 g), 5.5 grams of branched-chain amino acids (BCAAs), and 2.7 grams of Leucine per serving
214684355|NCT01492647|DRUG|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
214684356|NCT02561000|DRUG|PZ-128|
214684357|NCT02561000|DRUG|Placebo|
214684358|NCT06224348|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
214684359|NCT06224348|DRUG|Placebo|Pharmaceutical form: injection solution Route of administration: SC injection
214684360|NCT06224348|DRUG|Topical corticosteroids|Pharmaceutical form: Topical formulation Route of administration: Topical
214684361|NCT06224348|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical formulation Route of administration: Topical
214684362|NCT06781099|DEVICE|Low-volume continuous veno-venous haemodialysis with MEX-CD1 use|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. Intervention includes 3 low-volume continuous veno-venous hemodialysis for a duration of 4 hours each. For non-hospitalized patients, the treatment is performed on an outpatient basis.
214684363|NCT06379789|DRUG|REGV131|Single dose administered via intravenous (IV) infusion before LNP1265
214684364|NCT06379789|DRUG|LNP1265|Single dose administered via IV infusion following REGV131
214684365|NCT01234402|BIOLOGICAL|Ramucirumab DP|"10 mg/kg I.V.~Day 1 of every-21-day cycle"
214684366|NCT01234402|BIOLOGICAL|IMC-18F1|"12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle"
214986888|NCT06098183|OTHER|Non-caloric Placebo water|Non-caloric placebo
214986889|NCT04922281|DEVICE|Insertable Cardiac Monitor or external non-invasive LT-ECG patch|"Implantable device that provides accurate daily transmission. Patients without an existing CIED who prefer to use noninvasive LT-ECG monitoring will be offered to use the Carnation Ambulatory Monitor (CAM™; Bardy Diagnostics) the CAM™ patch approved for LT-ECG monitoring applied to the skin over the chest for a time-period of 7-days every 2 months for cardiac electrical data for arrhythmia detection."
214684367|NCT01234402|DRUG|Capecitabine|"1000 mg/m\^2 orally~Twice a day for 14 days"
214684368|NCT06473623|DEVICE|vagus nerve stimulation|Non-invasive Auricular Fiber Vagus Nerve Stimulation (afVNS)
214684369|NCT04283890|DRUG|Ipilimumab and nivolumab|The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
214373643|NCT03275974|BIOLOGICAL|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given by IV
214373644|NCT03275974|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214373645|NCT03275974|PROCEDURE|Blood Draw|Undergo venous blood draws
214684370|NCT04283890|DRUG|Melphalan chemosaturation via percutaneous hepatic perfusion|The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
214684371|NCT02758717|DRUG|Brentuximab Vedotin|Given IV
214684372|NCT02758717|BIOLOGICAL|Nivolumab|Given IV
214684373|NCT05401877|PROCEDURE|therapies for breast cancer|the type of tumor removal surgery, combined therapy
214684374|NCT04212494|PROCEDURE|Thrombus aspiration|Percutaneous Coronary Intervention with manual aspiration thrombectomy
214684375|NCT04212494|PROCEDURE|PCI Alone|Percutaneous Coronary Intervention without manual aspiration thrombectomy
214684376|NCT05423899|BEHAVIORAL|Grace Robot|The Grace robot was designed by Awakening Health/Hanson Robotics for healthcare settings and to interact with the elderly and those isolated by the COVID-19 pandemic. Grace is a robot with a human-like appearance, which can move, actively listen, engage in conversation and react appropriately to human emotions. Intervention activities will mostly consist of active listening and general discussions about topics of interest (e.g. hobbies, music). The participant will also have the option of other types of interactions with the robot, including robot-led meditation, robot-led light exercise, listening to music and singing. Because loneliness is a subjective experience and does not have a standardized solution, this is a personalized intervention approach. We anticipate that each older adult participant will have different needs and wishes when interacting with the robot, which will allow for a more natural interaction with the robot.
214373646|NCT04917809|DRUG|Erdafitinib|Participants will receive erdafitinib at a dose of 6 mg orally once daily for the first 14 days (±3 days). Serum phosphate levels will be assessed on day 14 (±3 days) and the dose of erdafitinib may be lowered based on the serum phosphate level. Treatment with erdafitinib at a dose of 6 mg orally once daily, or at a lower dose level for another 14 days (±3 days) until the day of their standard-of-care TURBT/biopsy. Standard-of-care TURBT/biopsy will be performed after approximately 28 days (±5 days) from the start of treatment with erdafitinib, and biologic and pathologic tumor response will be assessed. All participants will then be followed up for recurrence or progression in accordance with the standard of care.
214373647|NCT04741997|DRUG|Encorafenib Pill|Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles
214373648|NCT04741997|DRUG|Binimetinib Pill|Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles
214986890|NCT00197743|DIETARY_SUPPLEMENT|Vitamin A + Beta Carotene|one daily oral dose of 30 mg beta-carotene + 5000 IU preformed vitamin A
214684377|NCT05423899|BEHAVIORAL|Treatment as Usual|The treatment as usual active control group will not receive the robot intervention. The investIgators have deliberately chosen the participating long-term care (LTC) homes due to their high frequency of social interactions for their clients as part of their routine care (e.g. one-on-one and group activities, family interaction, exercise groups) compared to most LTC homes settings, making TAU an active control.
214684378|NCT01552356|OTHER|Laboratory Biomarker Analysis|Correlative studies
214684379|NCT01552356|DRUG|Pazopanib Hydrochloride|Given PO
214684380|NCT01552356|OTHER|Pharmacological Study|Correlative studies
214684381|NCT05172271|DEVICE|MagPro TMS Stimulator and coil|TMS measurements of cortical excitability pre and post study intervention
214684382|NCT05172271|DEVICE|Thymatron(R) System IV|The Thymatron(R) System IV (Somatics LLC, Venice, FL, USA) is an FDA 510(k)-cleared ECT device. For TESt, we will be using it in a non FDA-approved manner--stimulating without intending to induce seizures.
214684383|NCT05172271|DEVICE|Magnetic Resonance Imaging Scanner|Conventional MRI studies in this protocol are considered non-significant risk (NSR) devices. While operated in research mode, the MRI will be under the International Electrotechnical Commission (IEC) 60601-2-33 First Level Controlled Operating Mode, which allows for research pulse sequences to be used within the FDA/IEC safety limits for MRI devices.
214684384|NCT05172271|OTHER|ECT device without stimulation|Anesthesia alone
214986891|NCT00197743|DIETARY_SUPPLEMENT|Multivitamins|one daily oral dose of 20 mg thiamine (vitamin B-1), 20 mg riboflavin (vitamin B-2), 25 mg vitamin B-6, 100 mg niacin, 50 ug cobalamin (vitamin B-12), 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid
214986892|NCT00197743|OTHER|Placebo|Placebo pill
214986893|NCT02335281|PROCEDURE|FMT|Standardized FMT once
214373649|NCT04741997|DRUG|Nivolumab|Nivolumab will be administered at a dose of 480 mg IV infusion over 30 minutes every 4 weeks.
214373650|NCT01057238|OTHER|Intensive Communication System|Regular family meetings once a week, using a standard protocol
214495324|NCT04615260|DEVICE|NanoBone|Nanobone® Synthetic Bone Graft is a nanocrystalline hydroxyapatite imbedded in a silica gel matrix. The nanocrystalline structure accurately replicates autologous hydroxyapatite and the silica gel matrix that rapidly transforms into an osteogenic matrix post-implantation. NanoBone promotes remodeling by acting as a strong osteoinductive material. NanoBone® is available as a putty.
214495325|NCT06795464|DEVICE|Immersive Virtual Reality|"Participants in the experimental group will follow a treatment program that combines standard care with an immersive virtual reality (IVR) intervention. During the first 4 weeks, participants will undergo the IVR intervention, followed by the same standard treatment as the control group for the subsequent 8 weeks.~IVR Intervention Protocol:~Sessions and Equipment: Participants will attend up to 12 IVR sessions using a head-mounted device (HMD), the Meta Quest III, equipped with a hand-tracking system (Meta VR, Facebook, California) to enable interaction with the therapeutic software Dynamics PainRehab (Dynamics VR Rehab, Seville, Spain). The Meta Quest III HMD is chosen for its commercial availability, widespread use, minimal visual latency, and user-friendly interface. The software application, Hombro PainRehab, features multisensory inputs (vision and sound), high-quality graphics, head and hand tracking, and provides a highly immersive experience. The IVR intervention incorporate"
214495326|NCT06795464|PROCEDURE|Exercise|Participants assigned to the control group will receive standard treatment for rotator cuff-related shoulder pain. This will consist of standardized therapeutic exercise performed for 25 minutes, 3 times per week, over a 12-week period. The exercise regimen will be individualized based on intensity, utilizing the Rate of Perceived Exertion (RPE) scale, with the goal of achieving intensity levels of 6-8 on a scale of 0 to 10.
214495327|NCT06766578|RADIATION|Neoadjuvant Therapy(5×3Gy radiotherapy)|Radiotherapy: 5×3Gy. The preoperative radiotherapy target was outlined by radiotherapy physicians according to the NCCN Guidelines for Gastric/esophagogastric Junction Tumor 2024 edition and the surgeon's opinions. The first and third cycles were 5×3Gy.
214684385|NCT02003742|DRUG|NX-1207|Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
214684386|NCT02003742|DRUG|Tamsulosin|1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
214684387|NCT04655105|DEVICE|root canal rotary files|post operative pain evaluation using different rotary file system
214684388|NCT04156750|DRUG|LY3556050|Administered orally.
214684389|NCT04156750|DRUG|Placebo|Administered orally.
214684390|NCT04156750|DRUG|Iohexol|Administered IV.
214684391|NCT04156750|DRUG|Metformin|Administered orally.
214684392|NCT02080689|OTHER|Decipher|
214986894|NCT02335281|DRUG|Mesalazine|2g Po perday
214986895|NCT03890575|PROCEDURE|Airway stent implantation|The airway stents modified with 3D printing were implanted to treat malignant stricture involving carina and bronchi distal to carina.
214986896|NCT05127460|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
214986897|NCT00407875|PROCEDURE|Intensity Modulated External Beam Radiation Therapy|
214986898|NCT01902667|PROCEDURE|Magnetic Resonance Imaging|
214986899|NCT00559260|DEVICE|Passive monitoring with pulse-oximetry, NIBP and ECG|
214373651|NCT02522936|DRUG|Biotene oral spray|Biotene oral spray will be provided to participants.
214373652|NCT04173455|DRUG|HZ-A-018|"In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort."
214373653|NCT01089231|DIETARY_SUPPLEMENT|Fish oil|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
214373654|NCT01089231|DIETARY_SUPPLEMENT|Placebo (corn oil)|corn oil (6 capsules per day)
214373655|NCT03464487|DIETARY_SUPPLEMENT|Low Glycemic Index Therapy Diet|Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.
214373656|NCT01764087|DRUG|KX2-391 and Paclitaxel|"A treatment cycle in phase I will consist of 28 days, according to the following schedule:~KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated~A treatment cycle in phase II will consist of 28 days, according to the following schedule:~KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle."
214373657|NCT04174248|OTHER|BCSMS App|Breast Cancer Using a Self-Management Support mHealth Application
214373658|NCT04425005|OTHER|Home-based exercise|Home-based exercise training, supervised by videoconference.
214373659|NCT04278625|DRUG|Acetaminophen|IV acetaminophen given as part of standard of care.
214373660|NCT04241094|BEHAVIORAL|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
214495328|NCT06766578|DRUG|Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)|The first and third cycles are 5×3Gy radiotherapy D1 to 5, intravenous administration for tirelizumab 200 mg D6, intravenous administration for oxaliplatin 130 mg/m2 D6, and oral administration twice a day for S-1 40 mg/m2 D6 to 19. The second and fourth cycles are intravenous administration for tirelizumab 200 mg D1, intravenous administration for oxaliplatin 130 mg/m2 D1, and oral administration twice a day for S-1 40 mg/m2 D1 to 14. Every treatment cycle is spaced 1 week apart.
214986900|NCT00861081|BEHAVIORAL|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
214986901|NCT00861081|BEHAVIORAL|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
214684393|NCT02046343|BEHAVIORAL|Health education|Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
214495329|NCT06766578|PROCEDURE|Surgical treatment|Surgical treatment is completed within 3-5 weeks after the end of neoadjuvant therapy.
214684394|NCT02046343|BEHAVIORAL|Telephone Counseling|Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
214684395|NCT02046343|OTHER|Newsletter|Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
214986902|NCT05165784|PROCEDURE|femoral vein identification|Femoral vein identification using V technique
214986903|NCT05165784|PROCEDURE|femoral vein identification|Femoral vein identification using palpation technique
214373661|NCT01610310|DEVICE|BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
214373662|NCT01610310|DEVICE|BIIB017 (peginterferon beta-1a) Autoinjector|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
214373663|NCT00079001|DRUG|zoledronic acid|Given IV
214373664|NCT00079001|OTHER|placebo|Given IV
214495330|NCT06766578|DRUG|Adjuvant therapy(SOX chemotherapy)|Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
214495331|NCT02307682|DRUG|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection
214495332|NCT02307682|DRUG|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection
214684396|NCT02046343|OTHER|Environmental Change|Create a site atmosphere that promotes PA and increases the number of PA program offerings.
214986904|NCT02472405|DEVICE|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
214986905|NCT02472405|DEVICE|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
214986906|NCT00080054|DRUG|Motexafin Gadolinium Injection|
214986907|NCT05226429|BIOLOGICAL|UNAIR Inactivated COVID-19 Vaccine|UNAIR Inactivated Covid-19 Vaccine contains S protein of SARS-CoV-2 virus, Aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005% Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
214986908|NCT05226429|BIOLOGICAL|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
214373665|NCT00079001|DRUG|androgen deprivation therapy|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
214373666|NCT00079001|DRUG|GnRH agonist|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
214373667|NCT00079001|DIETARY_SUPPLEMENT|Calcium supplement|Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
214373668|NCT00079001|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
214684397|NCT02413125|DEVICE|ChitoRhino irrigation solution|ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
214684398|NCT02413125|DRUG|Normal saline|Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
214373669|NCT05674760|DEVICE|Trancutaneous CO2 monitoring (using TCM5 device)|Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)
214373670|NCT05674760|OTHER|Arterial Blood Gas (ABG) sampling|Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
214684399|NCT01744509|DEVICE|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
214986909|NCT06452550|DIAGNOSTIC_TEST|Logistic regression (LR) prediction models|Logistic regression model was used to establish a model to distinguish different levels of intestinal inflammation.
214373671|NCT04423822|OTHER|stress test|endurance capacity
214373672|NCT05397535|BEHAVIORAL|Baduanjin|"Participants in Baduanjin group will receive health education on hypertension and attend a 4-hour class to learn Baduanjin before receiving the interventions after the randomization. Baduanjin exercise protocol is based on the Fitness Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Badaunjin exercise session will last at least 30 minutes and be conducted at least 5 days per week for 52 weeks. These participants will be required to practice Baduanjin regularly, and the researchers will monitor their adherence to practice and provide reminders if needed."
214373673|NCT05397535|BEHAVIORAL|Brisk walking|Participants in this group will receive health education on hypertension and practice brisk walking on their own for at least 30 minutes, at least 5 days per week for 52 weeks. These participants will be required to do brisk walking regularly, and the researcher will monitor their adherence to practice and provide reminders if needed.
214373674|NCT01938651|PROCEDURE|high field strength magnetic resonance imaging|Undergo 7T MRI
214373675|NCT01938651|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo 31P MRS
214373676|NCT01938651|PROCEDURE|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
214373677|NCT01938651|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
214373678|NCT01938651|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
214373679|NCT00681304|OTHER|ultrasound scan|The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
214373680|NCT03205228|DRUG|Omeprazole|A capsule of Omeprazole 20 mg \& 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
214373681|NCT03205228|BEHAVIORAL|psychoeducation|Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
214373682|NCT03205228|DRUG|Flupentixol +Melitracen|A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg \& a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
214373683|NCT01082562|DRUG|BMS-844421|"Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
214684400|NCT01594476|DRUG|Levonorgestrel IUS|20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
214986910|NCT03332342|OTHER|Eye wash|Research subjects will perform a wash of their ocular surface with phosphate buffered saline
214373684|NCT01082562|DRUG|0.9% sodium chloride injection solution|"Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
214495333|NCT04272827|PROCEDURE|Liposuction|"Liposuction treatment will be performed according to the study protocol using the wet technique depending on the amount of fat to be removed, if necessary in several sessions."
214495334|NCT05929118|OTHER|Aquatic Rehabilitation|Reviewing the existing literature studies and related books, and combining the post-operative rehabilitation process of ACLR with the opinions of experts from the China Aquatic Rehabilitation Association, the Aquatic rehabilitation program of this study was designed.
214495335|NCT05929118|OTHER|Land-based Rehabilitation|Peking University Third Hospital Anterior Cruciate Ligament (ACL) Postoperative Rehabilitation Guidelines.
214495336|NCT03431818|OTHER|Nasal cannula flow rate|This is a crossover study where observations will be obtained at five nasal cannula flow rates: 0.5, 1, 2, 4 and 6 liters per minute.
214986911|NCT02882971|BEHAVIORAL|Pain Assessment|To create an objective observational pain scoring system and validate.
214986912|NCT00732914|DRUG|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
214373685|NCT02565563|OTHER|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
214373686|NCT02565563|DEVICE|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
214373687|NCT05720923|DEVICE|Analysis with Ergometer|The analysis with the ergometer aims at assessing neuromuscular function
214373688|NCT01559233|DEVICE|FPlus RF device for wrinkles and rhytide reduction|Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
214373689|NCT00165425|PROCEDURE|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
214373690|NCT05271786|OTHER|Decannulation|retrospective evaluation of decannulation
214373691|NCT03843918|DRUG|LAE001|LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
214373692|NCT05831696|OTHER|Powered Microprocessor-controlled Knee (PMPK)|A microprocessor-controlled Knee with standardized commercial prosthetic foot
214373693|NCT06033274|DEVICE|Transcatheter Tricuspid Valve Replacement|All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease
214373694|NCT03094624|OTHER|Neuropsychological and neurophysiological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
214373695|NCT03094624|OTHER|Experiment 1|Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
214373696|NCT03094624|OTHER|Experiment 2|Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
214373697|NCT03094624|OTHER|Experiment 3|Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
214495337|NCT06028334|BEHAVIORAL|GetUp&Go|A behavioral treatment combining personalized activity planning and a mobile health application for supporting adherence to activity plans.
214495338|NCT06028334|BEHAVIORAL|GetUp&Go with 10-Week Delay|No assigned treatment during the waitlist phase. Participants in the WL group will be offered the GetUp\&Go intervention, which combines personalized activity planning and a mobile health application, after collection of the primary outcome measure.
214495339|NCT06305364|DEVICE|Gixam|Participants will be required to extend their tongue in the Gixam device. Six images will be obtained and analyzed by the artificial intelligence (AI) model generating a prediction score for the presence of colorectal adenoma.
214495340|NCT06444152|OTHER|Sample analysis|This study is analyzing stored samples
214495341|NCT04909268|DIAGNOSTIC_TEST|HIV testing|serology for HIV testing
214495342|NCT04683250|DRUG|TAS0953/HM06|Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
214495343|NCT04683250|DRUG|TAS0953/HM06|Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
214495344|NCT06889259|BEHAVIORAL|CBT based digital therapeutics|The mobile-based digital therapeutic intervention integrated video education, thought record sheets, and sound therapy. This comprehensive treatment was administered five times weekly. The program consisted of a total of 30 sessions.
214495345|NCT06889259|BEHAVIORAL|Conventional CBT|The cognitive behavioral therapy program for tinnitus, based on a paper manual, was administered five times per week. The treatment regimen consisted of a total of 30 sessions,.
214495346|NCT06867393|DRUG|HL-003 tablet Placeco|100mg、250mg、500mg、1000mg、1500mg，SAD
214495347|NCT06867393|DRUG|HL-003 tablet|25mg、100mg、250mg、500mg、1000mg、1500mg，SAD
214495348|NCT06862102|BIOLOGICAL|HPV vaccine|vaccine administration
214495349|NCT06740786|DRUG|Dapagliflozin Treatment Group|"This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.~Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day)."
214495350|NCT06817200|DRUG|Amantadine (100mg) as add on therapy.|Amantadine will be administered at the dose of 100 mg t.i.d or b.i.d. (if t.i.d. is not tolerated) over 12 weeks, after a period of 3 weeks of titration.T he study treatment will be stopped after a dose decrease of 100 mg / day every 3 days.
214495351|NCT06817200|DRUG|Placebo|Placebo tablets will be also administered b.i.d. or t.i.d over 12 weeks after a period of 3 weeks of titration. Placebo tablets will be indistinguishable from amantadine ones.
214495352|NCT06778707|PROCEDURE|External Oblique Intercostal Block|In group E, a needle will be used to pierce the skin, subcutaneous tissue then external oblique muscle to hydrodissect the fascial plane between external oblique muscle and intercostal muscles with 25 ml bupivacaine 0.25 % and 4 mg dexamethasone added to it.
214373698|NCT03094624|OTHER|Experiment 4|"Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners."
214373699|NCT06975969|DEVICE|Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter|The Versus Pulmonary Artery Catheter is a dual-tip, infusion catheter. Two lumens access and deliver physician-specified fluids, including thrombolytics, into the pulmonary arteries of each lung via a single access site. The Secondary Catheter tip telescopes independently to facilitate infusion into the contralateral lung. The device may allow for assessment of a patient's hemodynamic condition through direct intracardiac and pulmonary artery pressure monitoring. Pressure is measured through an interface between the catheter's fluid lumen and an externally located, FDA-cleared, pressure transducer. The device may include an additional lumen that is in communication with a distal flow-directed balloon.
214986913|NCT00732914|DRUG|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
214986914|NCT03831022|OTHER|Capillary refill time and skin mottling score measurement at the admission to the emergency department|Patients who meet the inclusion criteria and none of the non-inclusion criteria will benefit from capillary refill time and skin mottling score measurement at the admission to the emergency department (ED) and followed during their hospital stay to precise the destination after ED (home, ICU, ward) and 30- and 90-days mortality after hospital admission.
214373700|NCT06576219|BEHAVIORAL|Group Music Therapy|My Life Is Music group therapy model
214373701|NCT03948074|DRUG|Cannabis|Medicinal Cannabis Oil
214495353|NCT06778707|PROCEDURE|Subcostal Transversus Abdominis Plane Block|In group T, a needle will be used to pierce the skin, subcutaneous tissue then rectus muscle and 25 ml of 0.25 % bupivacaine with 4 mg dexamethasone will be injected between rectus muscle and transversus abdominis muscle.
214495354|NCT06760286|DIETARY_SUPPLEMENT|Lung Care Solution|"Participants in the Breathe-Easy group received the food supplement solution designed to improve lung health and respiratory function. The supplement includes natural ingredients known for their potential to reduce inflammation, improve oxygen utilization, and support overall lung capacity.~Participants used 1 teaspoon of the supplement, prepared as a tea decoction, twice daily."
214495355|NCT06760286|OTHER|Support treatment|Participants in this group engaged in guided lifestyle modifications aimed at improving respiratory health. This included dietary recommendations as part of clinical practice.
214495356|NCT06830824|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
214495357|NCT06830824|OTHER|Placebo|A pack of unsweetened almond powder milk will be administered daily for 8 weeks
214495358|NCT06808412|DRUG|sintilimab combined with bevacizumab and XELOX|Patients with locally advanced low rectal cancer receiving sintilimab combined with bevacizumab and XELOX as a neoadjuvant regimen during the perioperative period.
214495359|NCT06771349|PROCEDURE|sigmoidopexy|"Both Sigmoidectomy and sigmoidopexy can be used for the treatment of sigmoid volvulus. The former is the treatment of sigmoid volvulus by removing a portion of the sigmoid colon, and depending on the patient's condition, a bowel reconstruction or anastomosis may be performed to reattach the healthy bowel segment. The procedure may result in long-term bowel changes and may even require an stomy. sigmoidopexy is a procedure that immobilizes the sigmoid colon to the abdominal wall or pelvic structure, preventing it from twisting again.~The goal of sigmoidectomy is primarily to remove damaged or necrotic portions of the sigmoid colon and to treat complications resulting from sigmoid volvulus, especially when the volvulus results in intestinal necrosis, ischemia, or other serious complications. The goal of sigmoidopexy is to prevent the sigmoid from re-twisting by immobilizing the sigmoid, and it is suitable for those cases of sigmoid torsion without severe ischemia or necrosis."
214495360|NCT06666439|DIAGNOSTIC_TEST|circulating tumor DNA (ctDNA)|Signatera is based on a custom-designed multiplex polymerase chain reaction (mPCR) assay for each patient, targeting up to 16 mutations found in the patient's tumor during whole exome sequencing (WES) to create a unique tumor mutation signature.
214495361|NCT06773312|BIOLOGICAL|BC001+Sintilimab+XELOX|patients will be given : BC001 8mg/kg, 12mg/kg or 16mg/kg intravenously once every three weeks; Sintilimab 3mg/kg（body weight\<60kg）or 200mg（body weight≥60kg）intravenously once every three weeks; Oxaliplatin 130mg/m2 intravenously once every three weeks; Capecitabine 1000mg/m2 orally once daily in the first two weeks of each three-week treatment cycle.
214495362|NCT03656081|DRUG|inhaled Ambisome®|inhaled liposomal amphotericin B = inhaled LAmB
214495363|NCT03656081|DRUG|inhaled placebo|inhaled isotonic saline
214495364|NCT03656081|DRUG|Itraconazole|Itraconazole tablet
214495365|NCT05874492|OTHER|Thermal cure with a primary dermatological indication|The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
214495366|NCT06235905|DRUG|NV-5138|NV-5138 is a novel , orally bioavailable, activator of mTORC1
214495367|NCT05630833|DRUG|Gepotidacin|Gepotidacin will be administered.
214495368|NCT05630833|DRUG|Nitrofurantoin|Nitrofurantoin will be administered.
214495369|NCT05630833|DRUG|Placebo|Placebo will be administered.
214495370|NCT04568473|OTHER|PRG Barrier Coat (By SHOFU Inc., Japan)|PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
214495371|NCT04568473|OTHER|EMBRACE™ Varnish by (Pulpdent Corporation, USA)|5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
214373702|NCT04929769|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
214373703|NCT04929769|OTHER|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
214373704|NCT02332590|DRUG|Sarilumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
214373705|NCT02332590|DRUG|Adalimumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
214373706|NCT02332590|DRUG|Placebo (for sarilumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
214373707|NCT02332590|DRUG|Placebo (for adalimumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
214373708|NCT00916032|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
214373709|NCT02591134|OTHER|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
214373710|NCT02591134|OTHER|Control|Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
214373711|NCT05152173|BIOLOGICAL|EN3835|Participant will receive a maximum dose of up to1.8mg of EN3835 injection
214373712|NCT05152173|OTHER|Placebo|Participant will receive a maximum dose of up to1.8mg of Placebo injection
214373713|NCT01111357|BIOLOGICAL|Collect of 10 ml of peripheric blood for DNA extraction|After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)
214373714|NCT00000431|DRUG|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
214373715|NCT01995487|DEVICE|BioNIR|drug-eluting stent
214986915|NCT04044508|DIETARY_SUPPLEMENT|Ketocal 4:1 liquid Nutricia (intervention)|Modified ketogenic diet
214986916|NCT04044508|DIETARY_SUPPLEMENT|Fortini multifibre Nutrica (placebo)|Placebo diet
214986917|NCT01724268|DRUG|Pred + Meth|PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
214986918|NCT01724268|DRUG|Anti TNF + Meth|
214373716|NCT01995487|DEVICE|Resolute|drug-eluting stent
214373717|NCT01975155|OTHER|food questionnaire|
214373718|NCT01975155|OTHER|Urinary mycotoxin test|
214373719|NCT04035057|OTHER|Behaviorally Enhanced Training|Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.
214373720|NCT04035057|OTHER|Standard Didactic Training|Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
214373721|NCT01592331|DRUG|Placebo|Single oral dose
214373722|NCT01592331|DRUG|RO5508887|Single oral dose
214373723|NCT06267885|PROCEDURE|Cannulated screws vs wagner's technique|Fixation of fracture neck of femur by cannulated screws or wagner's technique
214373724|NCT06380699|DRUG|QHRD106 Injection|PEG-tissue kallikrein-1
214373725|NCT06380699|DRUG|Human Urinary Kallidinogenase|tissue kallikrein-1
214373726|NCT06380699|DRUG|placebo|placebo
214373727|NCT04534257|DEVICE|SELUTION Sirolimus DCB|Suitable lesions will be treated with SELUTION Sirolimus DCB
214373728|NCT01637779|BEHAVIORAL|Fact sheet|fact sheet about pain management during immunization
214986919|NCT01451658|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
214986920|NCT01620424|DRUG|biphasic insulin aspart 30|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
214986921|NCT01620424|DRUG|biphasic insulin aspart 50|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
214373729|NCT04509895|PROCEDURE|Lateral extensile approach in calcaneal fractures fixation|The standard extended lateral approach with L-shaped incision was made in this group, which originated vertically from 5 cm over lateral malleolus or the midpoint between the fibula and Achilles tendon and ended on the base of the fifth metatarsal . The incision is made directly to the bone at the corner to create a full-thickness flap. Attention must be paid to protect the sural nerve and peroneal tendons as well.
214495372|NCT05214391|DRUG|Zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
214495373|NCT06620276|BEHAVIORAL|Acceptance and Commitment Therapy|8 sessions of one hour of Acceptance and Commitment Therapy delivered one on one by a licensed psychologist with experience and training in this intervention.
214495374|NCT06323460|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214495375|NCT06323460|DRUG|Carboplatin|Given IV
214495376|NCT06323460|DRUG|Cisplatin|Given IV
214495377|NCT06323460|PROCEDURE|Computed Tomography|Undergo PET/CT
214495378|NCT06323460|RADIATION|External Beam Radiation Therapy|Undergo external beam radiotherapy
214495379|NCT06323460|DRUG|Paclitaxel|Given IV
214373730|NCT04509895|PROCEDURE|Minimally invasive sinus tarsi approach in calcaneal fractures fixation|An incision is made from the tip of the lateral malleolus toward the base of the fourth metatarsal bone. The incision lies in a plane between the superficial peroneal nerve and the sural nerve. Care is taken to bluntly dissect after the skin incision to protect the sural nerve or branches of the superficial peroneal nerve. By mobilizing the sinus tarsi fat pad dorsally, the incision was deepened. The extensor digitorum brevis muscle is sharply elevated off of the anterior process with the lateral root of the inferior extensor retinaculum and reflected dorsally and distally. The peroneus brevis and peroneus longus tendons are split, allowing exposure to the sinus tarsi and visualization of the posterior facet of the subtalar joint.
214373731|NCT04309916|DRUG|Tegoprazan|Tegoprazan 50mg tablet
214373732|NCT04309916|DRUG|Esomeprazole|Esomeprazole 40mg tablet
214373733|NCT02259504|OTHER|PHASE 1- HyperSoft® 3D and HyperSoft® Helical Coils|Framing with HyperSoft® 3D or any FDA-approved bare platinum coil. Must fill and finish the the aneurysm with HyperSoft® 3D and/or HyperSoft® helical coils.
214495380|NCT06323460|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214684401|NCT01106534|DRUG|placebo + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
214684402|NCT01106534|DRUG|clopidogrel + aspirin OR prasugrel + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
214986922|NCT06522425|OTHER|mindfulness-based serious games|The intervention consists of a single session using a digital serious game designed to teach mindfulness techniques for pain management. In addition to explaining mindfulness concepts, the game provides a variety of mindfulness exercises to help users manage and reduce pain perception. For example, it involves relaxation through breathing or becoming aware of the state of one's body and mind. Additionally, it includes various interaction elements such as touch, voice, and motion controls to increase user immersion.
214986923|NCT02995148|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-104)
214986924|NCT02995148|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
214986925|NCT00674726|OTHER|Observation and measurement of axilo-rectal temperature|Measurement of axilo-rectal temperature
214373734|NCT02259504|OTHER|PHASE 2 - HydroSoft® 3D and HydroSoft® Helical Coils|Framing with HydroFrame® or HydroSoft® 3D coils. Must fill the aneurysm with HydroFrame®, HydroSoft® (3D and/or Helical), and/or HydroFill® Coils and finish with HydroSoft® (3D and/or Helical) Coils.
214373735|NCT04725344|OTHER|ACTIV'DOS group|ACTIV'DOS group use ACTIV'DOS application (with smartphone) to do the self rehabilitation each day (15 minutes per day) during 6 weeks. There are 7 exercices.
214373736|NCT04725344|OTHER|Usual practise|Control group uses a standard sheet of paper to do the self-rehabilitation (15 minutes per day) during 6 weeks. There are 7 exercises.
214373737|NCT00606190|PROCEDURE|Retrograde brain perfusion|observational
214373738|NCT00606190|PROCEDURE|Antegrade brain perfusion|observational
214495381|NCT06323460|OTHER|Questionnaire Administration|Ancillary studies
214495382|NCT06826469|DEVICE|Temporal Interference Stimulation|During the treatment period, all subjects were treated with a fixed time interference stimulation (TI) device at a frequency of 30 minutes twice a day, 5 days a week, for a total of 10 treatments. The output current intensity during treatment is 3.64 mA+4.36 mA.
214495383|NCT05567692|DIAGNOSTIC_TEST|OGTT|Oral Glucose Tolerance Test
214495384|NCT05567692|OTHER|HbA1c|HbA1c measurement
214495385|NCT05567692|OTHER|Questionnaire|Follow-up questionnaire
214495386|NCT03905694|DRUG|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
214495387|NCT06833489|OTHER|ARN extraction from muscle biopsies|"There will be no visits from participants, so we will be using samples already in the Biological Resources Centre (CRB).~RNA will be extracted from muscle biopsies taken as part of the treatment. RNAseq libraries will be sequenced by the Genomics and Bioinformatics Platform (GBiM) at Marseille Medical Genetics (MMG, U1251, AMU). Sequencing will be performed in paired-end (2\*100 bp) on Illumina's Novaseq 6000 system (50 million clusters per sample, 100 M paired-end reads) and then analysed by bioinformatics."
214684403|NCT01106534|DEVICE|XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
214684404|NCT04067531|DRUG|treatment of BV with first Deqularum and then direkt after with vaginal clindamycin|All patients will get the same treatment
214684405|NCT04734756|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
214684406|NCT05699616|PROCEDURE|Repair of perforated peptic ulcer|Repair of perforated peptic ulcer either open or laparoscopic.
214684407|NCT03067662|OTHER|Aerobic exercise|
214684408|NCT00049959|DRUG|verteporfin PDT|
214684409|NCT00022711|DRUG|temozolomide|150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
214986926|NCT00815529|DEVICE|Acupuncture, Pak-sham needle|25\*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
214986927|NCT01715298|DRUG|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
214986928|NCT01715298|DRUG|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
214986929|NCT05764499|OTHER|Physiotherapy Scoliosis Specific Exercise (PSSE)|Patients completed 120 hours of group based PSSE over a four week time frame. Monday - Friday, 10.00-17.00.
214373739|NCT03438695|PROCEDURE|Motorized Spiral Enteroscopy|Motorized Spiral endoscope will be inserted and advanced with the assistance of motorized clockwise spiral rotation, After reaching the cecum or if no further advancement of the endoscope can be achieved depth of insertion required for patient treatment or diagnosis, the endoscope will be withdrawn using motorized counter-clockwise spiral rotation, also controlled by the foot pedal. If no total enteroscopy was achieved, a submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde peranal enteroscopy is then performed on one of the following days.
214373740|NCT02919722|BEHAVIORAL|Music Therapy|The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
214373741|NCT05208684|OTHER|Breast stimulation|Breast stimulation by the Elvie Pump to trigger prolactin release.
214373742|NCT02699879|DRUG|Pirfenidone|Pirfenidone will be administered according to the physician discretion as part of standard care.
214373743|NCT07135375|OTHER|Rehabilitation protocol|The modified protocol will be implementen based on available scientific evidence and guided by the consensus remaches with the traumatologist at the physiotherapy center
214373744|NCT06699758|OTHER|CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.|CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors. These cells will be administered intranasally.
214684410|NCT02275026|PROCEDURE|Functional magnetic resonance imaging|Diffusion tensor imaging
214373745|NCT05180708|DRUG|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% rapamycin anhydrous gel
214495388|NCT05711550|DEVICE|Real Neurofeedback|Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
214495389|NCT05711550|DEVICE|Sham Neurofeedback|The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
214495390|NCT06826573|DIAGNOSTIC_TEST|Intraocular pressure|Intraocular pressure will be measured and recorded at 1 day, 1 week, 1 month, 3 months, 6 months postoperatively, and before silicone oil removal.
214495391|NCT06826573|DIAGNOSTIC_TEST|retinal recovery status|Measure and record the retinal recovery status 1 day, 1 week, 1 month, 3 months, 6 months after surgery and before silicone oil removal.
214684411|NCT02974062|OTHER|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
214684412|NCT05883267|DEVICE|Virtual reality glasses|"PICO model neo 2 VR glasses"
215089763|NCT06981182|OTHER|Faith-placed intervention to promote breast, cervical, bowel, and AAA screening uptake in Black communities.|The intervention includes a two-hour workshop, delivered in person to the entire congregation, that aims to promote the uptake of breast, cervical, bowel, and AAA screening among Black communities in the North East of England, Leeds and Scotland. However, we will only include effectiveness data (i.e., surveys and screening uptake) from those who meet the study eligibility criteria. The intervention will be a peer-led, multidimensional community workshop. It will incorporate multiple components that tackle barriers to screening and that are present in the existing IMCAN and PROCAN-B interventions, if the PICE group believe these are helpful, such as health education about breast, cervical, bowel and AAA screening delivered by a healthcare provider with an opportunity to ask questions, personal testimonials through survivors' stories, as well as members of the community discussing experiences of screening, and utilising community and peer support and religious leaders.
215089764|NCT06980467|OTHER|Large Language Model|An artificial intelligence system generating clinical recommendations using prompts, designed to simulate clinical advisory outputs. The protocol focuses on structured medical language generation.
214373746|NCT05180708|DRUG|Vehicle|Matching vehicle (QTORIN anyhydrous gel)
214373747|NCT06716749|DRUG|Morphine|10 mg morphine in 10 mL normal saline
214495392|NCT04597671|DRUG|Durvalumab|Durvalumab is used as standard of care
214495393|NCT04597671|RADIATION|low-dose PCI|PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
214684413|NCT05883267|DEVICE|Vocal-guided affective imagery|Audio via telephone
214684414|NCT01728272|DRUG|blood concentration of metoprolol|measure blood concentration of metoprolol
214684415|NCT05468086|DEVICE|VR Solace|Participants will use the VR audio and visual head-mounted device. The device is a standalone VR headset. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
214684416|NCT05415202|DRUG|Remimazolam 20 MG [Byfavo]|Remimazolam will be administered for sedation and efficacy and safety will be recorded
214684417|NCT04098952|OTHER|Group 1: Manual Therapy|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
214684418|NCT04098952|OTHER|Group 2: Interferential massage plus Manual Therapy|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
214684419|NCT04559906|OTHER|Spray and Stretch technique (Ethyl chloride)|"Group A receive spray and stretch technique (Ethyl chloride) with conventional treatment.~The upper trapezius muscle stretches on the basis of the Technique originally described by Simons. The subject is seated in a relaxed position on their homolateral hand for anchoring the distal end of the studied muscle. Initially, 3 to 5 parallel sweeps of ethyl chloride spray is applied covering the Upper trapezius muscle. Then, the muscle are positioned in a maximal but tolerable stretch and lengthened until the Physical Therapist felt the muscle tension barrier. This procedure repeated 2 or 3 times."
214373748|NCT06716749|DRUG|Vancomycin|500 mg Vancomycin in 100 mL of normal saline
214373749|NCT03387553|BIOLOGICAL|Dendritic Cell Vaccine (DC1)|"Study Vaccine:~Lead In Phase - Weekly as outlined in each treatment Arm.~Expansion Phase - At the optimal schedule determined at the end of the Lead In Phase.~Pre-surgery - Booster Vaccine at week 25 prior to receiving surgery.~Post-surgery - Participants will receive a series of 3 booster intranodal study vaccines given once every 6 months."
214373750|NCT03387553|DRUG|Neoadjuvant Chemotherapy|Upon completion of the 3 week series of vaccinations participants will then undergo neoadjuvant chemotherapy treatment with the TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen given intravenously once every 3 weeks for up to 6 cycles. The treating physician will have the discretion to delay, modify, or shorten the neoadjuvant chemotherapy as per routine practice guidelines and physician discretion.
214373751|NCT03387553|PROCEDURE|Curative Surgery|Planned definitive curative surgery at 26 to 28 weeks.
214373752|NCT06733610|BIOLOGICAL|universal allogeneic anti-CD19/BCMA CAR T-cells|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells.
214373753|NCT04739761|DRUG|Trastuzumab Deruxtecan|Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
214373754|NCT07047235|PROCEDURE|Pulmonary vein reisolation|The pulmonary veins will be checked electrically and further ablation will be undertaken if they are not isolated.
214373755|NCT07047235|PROCEDURE|Ganglionic plexi ablation|Sites where ganglionix plexi have been found will be ablated.
214373756|NCT07047235|PROCEDURE|Substrate ablation|Areas of rate dependent conduction velocity slowing will be targeted using cathether ablation
214495394|NCT06759038|DEVICE|C-MAC blade D video laryngoscope|C-MAC blade D Video Laryngoscope is used for difficult intubation and for better glottic view
214373757|NCT05604716|OTHER|observational study|observational study
214373758|NCT06734611|DIETARY_SUPPLEMENT|Fortified Iodized Salt with Folic Acid (FISFA)|Addition of folic acid to iodized salt for daily consumption to assess folate levels.
214373759|NCT00242281|DRUG|APC-111 MP Tablet, 775 mg|
214373760|NCT02584725|DRUG|Tranexamic Acid|Comparison of 3 different doses of the drug
214373761|NCT07050082|PROCEDURE|Bladder dissection after filling with 200 cc saline solution|Bladder filling after entering peritoneal cavity, then bladder dissection done to avoid bladder injury
214373762|NCT07050082|OTHER|Bladder dissection with empty bladder|After entering peritoneal cavity, bladder dissection done with empty bladder
214373763|NCT06746285|DIETARY_SUPPLEMENT|Synbiotic Supplement|Participants will be given 1g of a synbiotic product each day, containing 4 microbial strains isolated from an infant gut (total of 1 billion cfu) and a mixture of 4 human milk oligosaccharides. Parents will administer the product by dissolving in breast milk, formula, or water, or mixing with food.
214373764|NCT06746285|DIETARY_SUPPLEMENT|Lactose (inactive placebo)|Participants will be given 1g of lactose as a placebo. Parents will administer the product by dissolving in breast milk, formula, or water, or mixing with food.
214495395|NCT06759038|DEVICE|Macintosh Laryngoscope|Macintosh Laryngoscope is conventional laryngoscope used generally for intubations
214495396|NCT05783908|COMBINATION_PRODUCT|With non-magnetic screen|Radiotherapy treatment with Linac MRI is performed with a non-magnetic screen that will guide the patient to block the breathing
214684420|NCT04559906|OTHER|Sustain pressure release|"Group B receive sustain pressure release with conventional treatment. Progressive pressure release are considered in two stages. The initial step is to recognize and find the trigger in upper fiber of trapezius, utilizing trigger point palpation. Trigger point felt as firm and restricted hyperirritable knots with in gut of the muscle.~The second step is to applying pressure release ranging from eight to twelve second for each pressure, then it increases gradually for maximum of twenty seconds. The total duration of pressure is five minutes or more until the discharge is felt by the fingers."
214986930|NCT06249971|PROCEDURE|Dermal subsitute Glyaderm + skin graft|A human donor-derived dermal substitute will be implanted together with a skin graft
214373765|NCT07052214|DRUG|68Ga-PSMA-11|The radioconjugate 68Ga-PSMA-11 is composed of a human PSMA-targeting ligand peptide conjugated via the acyclic radiometal chelator, N, N'-bis \[2-hydroxy-5-(carboxyethyl)benzyl\] ethylenediamine-N, N'-diacetic acid (HBED-CC) to the radioisotope Gallium68 ( 68Ga); which binds to PSMA on the surface of cells expressing PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. 68Ga is a β+ (beta) ray emitting radionuclide that allows precise imaging via PET.
214373766|NCT07051577|OTHER|Exercise Group|"Participants in the neuromuscular exercise group will undergo a training program supervised by the researcher, conducted twice a week for 6 weeks. This group will receive gaze stabilization training, core stabilization training, scapular stabilization training, balance training, and NeuroTracker training.~The exercises provided to the neuromuscular exercise group are structured in three phases and progressively intensified based on phase transition criteria."
214373767|NCT07051577|OTHER|control group|There are standard exercise programs consisting of scapular stabilization and balance exercises.These exercises are commonly used in clinical rehabilitation and will not include any additional neurosensory or visual components.
214373768|NCT05751941|DRUG|Abiraterone|1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
214373769|NCT05751941|DRUG|Enzalutamide|160 mg of Enzalutamide will be given orally daily ending at week 4
214986931|NCT06249971|PROCEDURE|Skin graft alone|Skin graft alone with no dermal substitute
214986932|NCT00953433|DEVICE|Endoflex tube|Size decided upon gender.
214986933|NCT00953433|DEVICE|Polyvinyl chloride endotracheal tube with a stylet|Size decided upon gender.
214986934|NCT00187434|DEVICE|Infant Flow System|
214986935|NCT00187434|DEVICE|Bubble CPAP|
214986936|NCT02508792|DEVICE|LASER|Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
214986937|NCT02508792|DEVICE|LASER PLACEBO|The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
214986938|NCT06076590|DRUG|maintenance fluid|Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.
214684421|NCT00279903|DRUG|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
214684422|NCT00279903|DRUG|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
214373770|NCT05751941|DRUG|Apalutamide|240 mg of Apalutamide will be given orally daily ending at week 4
214373771|NCT05751941|DRUG|Sipuleucel-T|Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
214373772|NCT05259527|DRUG|Ergocalciferol Capsules|Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
214373773|NCT05259527|DIETARY_SUPPLEMENT|Cholecalciferol Capsules|Vitamin D3 5,000IU by mouth daily
214373774|NCT06897007|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of ciprofol during digestive endoscopy between insomnia group and normal sleep group.
214373775|NCT07058311|OTHER|Manual Therapy|Various soft tissue and joint mobilizations, intramuscular stretches, trigger point treatments, and intraoral applications for the temporomandibular joint were performed in 15 randomly selected bruxism patients. Manual therapy was applied twice weekly over eight weeks, each session lasting approximately 45 minutes. Techniques included trigger point therapy, myofascial release, intraoral mobilizations to the masseter, medial and lateral pterygoid, and temporalis tendons, post-isometric relaxation for masticatory muscles, cervical traction, and suboccipital and cervical fascial release. The manual therapy procedure, which was applied in the supine position and lasted approximately 40 minutes for 8 weeks
214373776|NCT07058311|OTHER|Home Exercise Therapy|The exercise group consisted of 15 randomly selected bruxist individuals and aimed to reduce pain, decrease involuntary contractions of masticatory muscles, increase their nutrition, flexibility and coordination, and strengthen weak muscles with exercise therapy. The exercise program included Rocabado exercises, stretching of the platysma, masticatory and cervical muscles, resistance training (mouth opening, protrusion, and lateral mandibular movements), and postural exercises. Exercises were performed while sitting in a chair with back support in front of a mirror. Each exercise was repeated 10 times. The duration of each session was 25-30 minutes. repeat the home exercises three times a week for 8 weeks. Weekly phone calls were made to encourage compliance. In addition, a video explaining the exercises in detail was shared with all participants in the group in order to ensure that the exercises were not forgotten and to achieve accuracy and standardization among the participants.
214373777|NCT03707574|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue
214373778|NCT06861933|OTHER|Physiotherapy and rehabilitation|It is reported in the literature that scapulohumeral rehabilitation applied in primary shoulder pathologies is effective. In neurological diseases, a study was found in which scapulohumeral rehabilitation was applied to individuals diagnosed with stroke and reported that it was effective. However, when the literature was examined, no study was found in which scapulohumeral rehabilitation was applied to individuals diagnosed with PD. Therefore, our aim is to compare the effectiveness of the scapulohumeral rehabilitation program to be applied for shoulder dysfunction, which is thought to be one of the early findings in PD and is reported to be related to other main findings in PD, with the upper extremity neurorehabilitation program.
214373779|NCT06764940|DRUG|Utidelone|Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle.
214373780|NCT06764940|DRUG|Utidelone in combination with capecitabine|UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
214373781|NCT06764940|DRUG|Utidelone in combination with capecitabine|Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
214684423|NCT02494349|DRUG|JLP-1207|The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
214684424|NCT02494349|DRUG|Solifenacin 5mg+Tamsulosin 0.2mg|The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
214684425|NCT01937208|RADIATION|intensity modulated radiation therapy in both arms|
214684426|NCT01937208|DRUG|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
214684427|NCT00374907|DRUG|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
214684428|NCT00374907|DRUG|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
214986939|NCT04554251|OTHER|Survey|invited questionnaire
214986940|NCT05733338|OTHER|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 5 days.
214986941|NCT05733338|OTHER|Sham Intermittent Hypoxia|The sham intermittent hypoxia protocol refers to 55 minutes normoxia inhaling, which is performed twice a day (at least 6 hours apart) in 5 days.
214986942|NCT03415880|BEHAVIORAL|Interactive workshops LiPAT intervention group|Workshops include practical behavior change strategies and address barriers to movement, awareness of the immediate benefits of movement and implementation-intentions. Participants will be encouraged to cultivate a learning mind-set in order to better tolerate potential set-backs and to apply strategies such as pre-planning their week to incorporate physical activity, engaging their social network, and setting up systems and habits. Participants' progress in changing their physical activity patterns which will be compared and discussed.
214986943|NCT03415880|DEVICE|Wrist-worn feedback physical activity monitor|Participants receive the feedback monitor (Fitbit inspire®; commercially available consumer product (https://www.fitbit.com/inspire)
214986944|NCT03415880|DEVICE|Smartphone application LiPAT|With a cloud-based platform the iHealth data is synchronized with a mobile phone app developed by the research team. The app is designed to help the participant to self-monitor their physical activity levels and includes information on total activity and number of steps taken.
214373782|NCT06764940|DRUG|Utidelone in combination with capecitabine|Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
214373783|NCT07054320|OTHER|Observational procedures|Patients at the Hoskinson Health and Wellness Clinic qualifying for treatment with Rapamune (Sirolimus) receive a prescription from their physician during clinic visits as part of their standard health care. This study will evaluate the safety, monitor the adverse reactions and observe the preliminary effectiveness of physician-prescribed medical treatment with oral rapamycin \[Rapamune (Sirolimus)\] in a total of 15 adults, 18 years and older toward preventing and lowering the severity of infectious disease or infection-related illness.
214373784|NCT06100822|DRUG|Metformin|500 mg capsules of Metformin Extended Release
214373785|NCT06100822|DRUG|Placebo|500 mg capsules of placebo pills
214373786|NCT06753123|BEHAVIORAL|A workplace-based depression intervention for low-wage hospital workers|This intervention is a remotely delivered workplace-based depression intervention that is tailored to the specific social and behavioral needs of low-wage hospital service workers. The intervention involves assessment of depression-related work impairment, work-focused cognitive behavioral therapy, work coaching, social needs screening and referral, and text message support for mood and physical activity.
214373787|NCT06772285|OTHER|Albert Health app|Test an existing digital health app, called Albert Health, designed to support patients with a newly inserted feeding tube to use and manage their tube care, in a feasibility study.
214373788|NCT04334226|OTHER|Interview|Interviews will explore the patient's and caregiver's experiences and perceptions of ostomy surgery prior to the Bootcamp and after the Bootcamp from a physical, psychological, social, and spiritual perspective
214986945|NCT03415880|BEHAVIORAL|Telephone Coaching|participants in the intervention group will receive telephone coaching during the first 3 months of the intervention. Telephone coaching will be conducted twice in the first month and once each in months two and three. The researcher will enquire about the progress with increasing LiPA, about the experiences of applying the strategies discussed during workshops, and about the experience with Fitbit Inspire® and the corresponding app. If needed, the coach will offer suggestions to improve goal adherence.
214373789|NCT06714864|DRUG|(taurolidine and heparin) catheter lock solution|for central venous catheter instillation use
214373790|NCT06714864|DRUG|Standard of Care|Site specific standard of care
214373791|NCT06772181|BEHAVIORAL|IM@Home Program|Participate in the IM@Home program delivered via Zoom
214373792|NCT06772181|OTHER|Medical Device Usage and Evaluation|Wear a FitBit activity tracker
214373793|NCT06772181|OTHER|Questionnaire Administration|Ancillary studies
214373794|NCT06772181|OTHER|Interview|Ancillary studies
214373795|NCT06746597|OTHER|Walking intervention on plantar skin thickness and stiffness|Walking intervention in three different air-insole pressures (80 mmHg, 160 mmHg, 240 mmHg) in two different walking durations (10 and 20 minutes).
214495397|NCT06746584|BEHAVIORAL|benson relaxation exercise|BRT is one of the behavioural intervention techniques developed by Herbert Benson in 1975. BRT is based on the principle of deep breathing and relaxing all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it. This exercise, which has no side effects on patients and can be applied for patients of all age groups, is more widely used because it is a simple and easy-to-learn method compared to other relaxation methods all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it.
214495398|NCT04013152|OTHER|Clinical database|Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
214495399|NCT03170349|DEVICE|Mitral Valve Repair|Minimal Invasive Transcatheter Mitral Valve Repair
214495400|NCT05661136|DEVICE|Warm air blower|Lower body blanket with warm air blower set at 44 deg c started after spinal anesthesia when patient placed in supine/left lat position
214495401|NCT05661136|OTHER|Control: Lower body blanket not attached to warm air blower|Control: Lower body blanket placed, not attached to warm air blower
214495402|NCT04789070|DRUG|Sirolimus|Sirolimus is a currently licensed drug primarily used for immunosuppression post-kidney transplantation to prevent organ rejection. Sirolimus was initially considered as a treatment in IBM for its immunosuppressive action and beneficial effects in an experimental myositis mouse model.(11) Transfer of effector T cells from affected to healthy animals resulted in myositis, but the presence of Treg cells were protective against development of myositis. As Sirolimus, which acts to deplete effector T cells but preserving the Treg cells, was effective in this mouse model of myositis, it was therefore postulated that it may also be effective in IBM, not only for its effects on effector T cells and Treg cells, but also for its additional effects on protein degradation.
214495403|NCT04789070|DRUG|Placebo|Placebo
214495404|NCT06779552|DEVICE|CardioMEMS HF System|PA Pressure Sensor
214495405|NCT06038032|BEHAVIORAL|Digital wellness platform|A digital wellness platform based on preventive self-care that contains tools to monitor nutrition, physical activity, and mental wellbeing will be accessed daily for 24 weeks.
214495406|NCT06038032|BEHAVIORAL|Online healthcare professional support|Individual sessions with a registered dietitian, an exercise professional, and a mental health therapist for 16 weeks.
214495407|NCT06798415|DRUG|Metronidazole|"Intralesional metronidazole (5 mg/ml, 100 ml, Flagyl®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia will be added. The solutions will be injected intralesionally and not subcutaneously."
214495408|NCT06829654|OTHER|Step 1|Cryopreservation of ovarian tissue
214495409|NCT06829654|OTHER|Step 2|Analysis of tumor markers in the primary tumor
214495410|NCT06829654|OTHER|Step 3|Search for neoplastic cells in cryopreserved ovarian tissue
214986946|NCT03415880|BEHAVIORAL|Workshops control group LiPAT|During the first 6 months of the study (the intervention period) participants in the control group will attend 4 workshops in which the benefits of physical activity and the health-risks of sedentary behavior will be discussed. Additionally, information will be provided on healthy lifestyle for patients with type 2 diabetes.
214373796|NCT06750094|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
214373797|NCT06750094|BIOLOGICAL|Cetuximab|Cetuximab will be administered.
214373798|NCT06750094|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered.
214373799|NCT06750094|DRUG|5-fluorouracil|5-fluorouracil will be administered as chemotherapy regimen.
214373800|NCT06750094|DRUG|Leucovorin calcium/Levoleucovorin|Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
214373801|NCT06750094|DRUG|Irinotecan|Irinotecan will be administered as chemotherapy regimen.
214373802|NCT06770387|BEHAVIORAL|mhealth|mobile application for postoperative period
214373803|NCT02998229|DEVICE|Artisse™ Intrasaccular Device|Intrasaccular Device
214373804|NCT04008706|DRUG|Acalabrutinib|Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.
214373805|NCT04546399|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214373806|NCT04546399|PROCEDURE|Biospecimen Collection|Undergo blood, urine and cerebrospinal fluid collection
214495411|NCT06829654|OTHER|Step 4|Cryopreserved ovarian tissue autotransplantation
214373807|NCT04546399|BIOLOGICAL|Blinatumomab|Given IV
214495412|NCT06813898|PROCEDURE|Computed Tomography|Undergo PET/CT
214495413|NCT06813898|OTHER|Electronic Health Record Review|Ancillary studies
214495414|NCT06813898|OTHER|Flotufolastat F-18 Gallium|Given IV
214495415|NCT06813898|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214495416|NCT04888338|OTHER|Data Capture|Treatment related data is collected
214495417|NCT04888338|OTHER|Electronic Medical Record|Medical records are reviewed
214495418|NCT05486507|DIETARY_SUPPLEMENT|Montmorency tart cherry|US grown Montmorency tart cherry 60ml per day for 6 weeks.
214495419|NCT05486507|DIETARY_SUPPLEMENT|Placebo|Taste matched placebo.
214495420|NCT05995860|BEHAVIORAL|Intervention group triads|The intervention consists of a rapid (less than 10-minute) communication intention elicitation exercise (via Freelisting), which is conducted independently with the patient, caregiver, and provider immediately prior to the outpatient oncology encounter. Patients, caregivers, and providers will not be instructed to endorse the Freelist responses that were generated by the intervention prior to the outpatient encounter-leaving the decision to discuss elicited communication intentions during the encounter up to individuals as the conversation naturally occurs. As with the control group, post-encounter survey data will also be collected independently from the patient, caregiver, and the provider, followed by a post-encounter qualitative interview conducted jointly with the patient and caregiver.
214495421|NCT05929339|DRUG|Oxytocin|Intravenous oxytocin
214495422|NCT04551066|DRUG|parsaclisib|parsaclisib will be administered QD orally
214495423|NCT04551066|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
214684429|NCT00374907|DRUG|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
214684430|NCT00374907|DRUG|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
214684431|NCT03558932|DIAGNOSTIC_TEST|pleural biopsy|diagnostic sampling
214373808|NCT04546399|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214495424|NCT04551066|DRUG|placebo|placebo will be administered QD orally
214373809|NCT04546399|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214373810|NCT04546399|DRUG|Calaspargase Pegol|Given IV
214373811|NCT04546399|DRUG|Cytarabine|Given IT
214373812|NCT04546399|DRUG|Dexamethasone|Given PO or IV
214373813|NCT04546399|DRUG|Hydrocortisone Sodium Succinate|Given IT
214373814|NCT04546399|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214373815|NCT04546399|DRUG|Mercaptopurine|Given PO
214373816|NCT04546399|DRUG|Methotrexate|Given IT, PO, and IV
214373817|NCT04546399|BIOLOGICAL|Nivolumab|Given IV
214373818|NCT04546399|DRUG|Pegaspargase|Given IM or IV
214373819|NCT04546399|DRUG|Pegcrisantaspase|Given IM or IV
214373820|NCT04546399|DRUG|Vincristine Sulfate|Given IV push or via infusion
214373821|NCT06849791|DRUG|ABBV-932|Oral Capsule
214373822|NCT06849791|DRUG|ABBV-932|Oral tablet
214373823|NCT04266886|OTHER|Best Practice|Receive usual care
214373824|NCT04266886|PROCEDURE|Hypnotherapy|Receive self-hypnosis guided relaxation
214373825|NCT04266886|OTHER|Quality-of-Life Assessment|Ancillary studies
214373826|NCT04266886|OTHER|Questionnaire Administration|Ancillary studies
214495425|NCT05529992|DRUG|Velaglucerase Alfa|VPRIV intravenous infusion every other week for 60 minutes.
214495426|NCT06836895|BEHAVIORAL|HIIT and IMT|The HIIT protocol involved four intervals, each lasting 4 minutes, beginning at 70% of maximum power and building to a target intensity of at least 85% HRmax. The IMT sessions included 2-3 sets of 30 breaths (totaling 60-90 breaths per session), with a two-minute rest between sets, three days per week starting with 30% of PImax and reaching 60% of PImax.
214495427|NCT06836895|OTHER|walking|30-min walking
214684432|NCT03280732|DEVICE|Lung Ultrasound|A Mindray-DC-T6 ultrasound machine equipped with a linear probe with frequencies ranging from 7.5 to 12 MHz will be use. LUS examination will consist of both longitudinal and transversal sections according to the methodology described by Copetti and colleagues.
214684433|NCT01892254|DRUG|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
214684434|NCT01892254|DRUG|Placebo|Placebo (to metformin)
214684435|NCT01108809|DRUG|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
214986947|NCT05080985|PROCEDURE|TPVB|20 ml 0.375 % bupivacaine was injected between superior costotransverse ligament and pleura.
214986948|NCT05080985|PROCEDURE|ESPB|20 ml 0.375 % bupivacaine was injected between deep fascia of the erector spinae muscle and transverse process.
214986949|NCT05080985|DRUG|Bupivacain|20 ml 0.375 % bupivacaine was injected
214986950|NCT03424304|DEVICE|Excel V™ Laser With Green Genesis|Subject(s) will receive treatments with a Cutera Excel V™ Laser
214986951|NCT00635713|DRUG|Fulvestrant|125mg
214986952|NCT00635713|DRUG|Anastrozole|ARIMIDEX
214986953|NCT00635713|DRUG|Fulvestrant|250mg
214684436|NCT04736511|OTHER|Star Excursion Balance Test|"The subject will be in unipodal support (only one foot on the ground) on the tested lower limb in the center of the platform. Three lines forming a Y will be arranged according to the lower limb in charge in three directions : anterior (ANT), posteromedial (PM) and posterolateral (PL). The goal is then to reach the longest distance possible in all three directions with the tip of the foot in relief before returning to the starting position. The subject will have 4 training trials per direction on each lower limb then 3 trials will be recorded in order to keep the average."
214684437|NCT04736511|OTHER|Single leg Drop Vertical Jump|The subject will drop from a step and land on one leg, then jump as high as possible and stabilize again on the same leg. The height of the step is 30 cm. The subject will perform 3 consecutive jumps in the strictest respect of the instructions: drop to the level of the mark on the ground and bounce as high as possible while spending a minimum of time on the ground. The subject must stabilize for 3 seconds during the second contact with the ground so that the instructions and measurements are reproducible.
214684438|NCT04736511|OTHER|Unplanned sidestep cutting manoeuvre|"The objective is to create an unanticipated playing situation, close to the daily actions of the subjects in the practice of handball. The subject will make sidestep cutting manœuvre in front of an opponent simulated by a dummy used during usual training.~The subject will sprint in a straight line and then at the force platform will make a rapid change of direction on the side of his shooting arm or will continue his run in a straight line. A light signal randomly will indicate to the player the direction in which he must carry out his manoeuvre. A computer reconstruction of the kinematics and dynamics (knee moment) will be performed."
214684439|NCT04736511|OTHER|Tendon vibration|The subject will be asked to stand, motionless in bipodal (both feet on the ground) support on a stable and unstable ground (foam). A tendon vibration (80Hz) will be randomly applied to the subject in the Achilles tendons or paravertebral muscles. This vibration will cause an alteration of proprioceptive information in the vibrated area leading to a disruption of postural balance. Thus, according to the amount of displacement of the center of pressure (CoP), the proprioceptive weighting ratio (dRPW) is calculated to deduce therefrom the weight assigned by the CNS to the various proprioceptive inputs during the postural task.
214684440|NCT04815629|RADIATION|Radiotherapy|Radiotion therapy squamous cell carcinoma in cancer bladder
214684441|NCT06069557|OTHER|Respiratory exercise|This group will undergo intervention. The participants will be assessed in terms of abdominal distension and shoulder pain in preoperative period. Respiratory exercise training will be given in the preoperative period. At the 1st, 2nd, 3rd, 4th, 5th, 4th, 5th, and 6th hours postoperatively, 10 deep breathing exercises will be performed in semi fowlers 45º position. During this 6-hour period, the patient will be asked to give 10 deep breaths into the incentive spirometer every 2 hours. Patients will be evaluated for abdominal distension and shoulder pain at the 1st, 2nd, 3rd, 4th, 5th, and 6th hours postoperatively and mobilization times will be measured in the first 6 hours.
215089765|NCT07041086|PROCEDURE|Extracorporeal membrane oxygenation (ECMO)|In extracorporeal membrane oxygenation (ECMO), blood is pumped outside of the body to a heart-lung machine. The machine removes carbon dioxide and sends oxygen-rich blood back to the body. Blood flows from the right side of the heart to the heart-lung machine. It's then rewarmed and sent back to the body.
214684442|NCT00393289|BEHAVIORAL|Calcium controlled diet|
214373827|NCT07087353|DEVICE|Edra PRO|Remote monitoring software
214373828|NCT05653882|BIOLOGICAL|etakafusp alfa (AB248)|Intravenous infusion of etakafusp alfa (AB248): CD8+ T cell selective interleukin-2 investigational drug
214373829|NCT05653882|BIOLOGICAL|pembrolizumab|Intravenous infusion of pembrolizumab
214373830|NCT03211793|DRUG|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
214373831|NCT03211793|OTHER|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
214373832|NCT06848205|OTHER|OFF Parkinson's Medication(s)|Participants will be asked to withhold Parkinson's medications 12 hours prior to their testing visit (if extended-release Parkinson's medications are taken by the participant, they will be asked to withhold these for 24 hours prior to their testing visit).
214373833|NCT06848205|OTHER|OFF Deep Brain Stimulation|Participants will have their deep brain stimulation turned off at the beginning of their testing visit.
214373834|NCT06546995|DRUG|NMRA-323511|Participants will receive NMRA-323511 orally.
214373835|NCT06546995|DRUG|Placebo|Participants will receive matching placebo tablets orally.
214373836|NCT06393465|DRUG|Tafamidis|61 milligrams under real world conditions
214373837|NCT07102901|DRUG|SHR2554 Tablets|Oral SHR2554 tablets.
214373838|NCT07102901|DRUG|SHR-A1811 Injection|SHR-A1811 for injection.
214373839|NCT07102901|DRUG|SHR-A1904 Injection|SHR-A1904 for injection.
214373840|NCT07102901|DRUG|SHR-1701 Injection|SHR-1701 injection
214373841|NCT03868670|DEVICE|responsive neurostimulation|The RNS® System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to continuously monitor brain electrical activity, detect abnormal electrical activity and respond by delivering imperceptible levels of electrical stimulation to normalize that activity before an individual experiences seizures. This is an Early Feasibility Study determining the safety and efficacy of NAc-RNS in the treatment of LOC eating in treatment-refractory obesity.
214373842|NCT07111039|OTHER|Airway Pressure Release Ventilation|APRV
214373843|NCT07111039|OTHER|Conventional Mechanical Ventilation|CMV
214373844|NCT06918665|DRUG|ivermectin infant formula preparation|The ivermectin infant formula preparation is produced by micronizing the standard 3mg ivermectin tablet and then blending it with Stage 1 infant formula (Blackmores brand) to produce a homogenous powder. This powder blend of ivermectin and infant formula is then filled into food grade clear capsules.
214373845|NCT06918665|DRUG|Standard ivermectin 3mg tablet|standard 3mg ivermectin tablet
214373846|NCT07130344|PROCEDURE|TAP CT-scan|Patient in the SOC arm will be followed by TAP CT-scan every 3 months, until progression or new treatment initiation or until 2 years whichever occurs first.
214373847|NCT07130344|PROCEDURE|Bone scintigraphy|Patient in the SOC arm will be followed by bone scintigraphy every 3 months, until progression or new treatment initiation or until 2 years whichever occurs first.
214373848|NCT07130344|PROCEDURE|18F-FDG PET-CT|Patient in the experimental arm will be followed by 18F-FDG PET-CT every 3 months, until progression or new treatment initiation or until 2 years whichever occurs first.
214373849|NCT07136545|DRUG|HCB101|QW
214373850|NCT07136545|DRUG|Pembrolizumab|200 mg IV on Day 1, cycled every 21 days;
214373851|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
214373852|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
214373853|NCT06950905|BEHAVIORAL|Feeding your demons practice|The Feeding Your Demons (FYD) is a contemplative practice based on the Tibetan Buddhist tradition, adapted in a secular form. The intervention is online and lasts a total of 8 weeks. During this period, participants will engage in weekly home practice of the FYD method using guided audio. The intervention includes 3 expert-facilitated sessions: an initial individual session, a group session at week 4, and a final group session at week 8.
214373854|NCT06950905|BEHAVIORAL|Mindfulness practice|The control group will undergo an online mindfulness meditation intervention, lasting a total of 8 weeks. It includes 3 expert-facilitated sessions: an initial individual session, a group session at week 4, and a final group session at week 8. Participants will engage in weekly home practice of mindfulness meditation using guided audio.
214373855|NCT06946368|PROCEDURE|Intra-articular Posteromedial Surgeon Administered (IPSA) Block of EXPAREL|"Patients in this group will receive IPSA block and Local Infiltration Analgesia (LIA).~IPSA block is a pain numbing medication given by surgeon and injected inside the back and inner side of the knee joint. Local Infiltration Analgesia is a pain numbing medication injection given by the surgeon around the surgical knee area. The medications used in the procedure will be EXPAREL, and Bupivacaine HCL."
214684443|NCT05926986|OTHER|Exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
214684444|NCT05926986|OTHER|control|No additional treatment will be practiced to the control group.
214684445|NCT01968044|DRUG|Gemigliptin|
214684446|NCT01968044|DRUG|Placebo to Linagliptin|
214373856|NCT06946368|PROCEDURE|Adductor Canal Block (ACB) and Local Local Infiltration Analgesia of EXPAREL|ACB is a pain numbing injection given by anesthesiologist near the adductor canal, a passage in the mid-thigh that contains nerves connecting the knee region. Local Infiltration Analgesia is a pain numbing medication injection given by the surgeon around the surgical knee area. The medications used in the procedure will be EXPAREL, and Bupivacaine HCL.
214373857|NCT06946368|PROCEDURE|Local Infiltration Analgesia (LIA) of EXPAREL|Local Infiltration Analgesia is a pain numbing medication injection given by the surgeon around the surgical knee area. The medications used in the procedure will be EXPAREL, and Bupivacaine HCL.
214373858|NCT06952803|DRUG|Saruparib|Saruparib will be administered orally.
214373859|NCT06952803|DRUG|Placebo|Matching placebo to saruparib will be administered orally.
214373860|NCT06952803|DRUG|Abiraterone + Prednisolone/Prednisone|Abiraterone will be administered orally in combination with prednisone/prednisolone.
214373861|NCT06952803|DRUG|Androgen Deprivation Therapy (ADT)|Standard of care ADT will be administered.
214684447|NCT00034112|PROCEDURE|osteopathic manipulative treatment|
214684448|NCT05379023|BEHAVIORAL|Face-to-face evaluation (FF)|The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
214684449|NCT05379023|BEHAVIORAL|TeleNP evaluation|The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
214684450|NCT00354549|DRUG|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
214684451|NCT00354549|DRUG|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
214986954|NCT00667264|PROCEDURE|perineural ropivacaine|Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
214986955|NCT04454502|OTHER|Oral colostrum administration|In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered into the cheek and on the tongue for the infants weighing between 1001-1500 g.
214495428|NCT06945783|DEVICE|Kinesiology Taping|Kinesiology taping was applied to the lumbar area of the participants in the intervention group. The taping aimed to improve posture, reduce pain, and enhance balance and functional performance.
214495429|NCT06945783|OTHER|Physiotherapy|The physiotherapy program included therapeutic exercises and physical modalities (such as stretching, strengthening, and posture training) tailored for individuals with nonspecific low back pain.
214495430|NCT06954207|DEVICE|Non interventional. Data collection concerns routine procedures and monitoring devices|Non interventional. Physiological parameters under general anesthesia are collected (arterial pressure, heart rhythm, bispectral index, NOL index, temperature, total dose of remifentanil infusion, analgesic drugs infusions). After surgery, pain scores (NRS), motor function and time to ambulation are also collected.
214495431|NCT06953856|OTHER|occlusal reduction|Occlusal reduction is a procedure that applied patients for different aims. One of these aims is pain relief after endodontic treatment and there are some studies about this topic however, there is no consensus about it. This discrepency could be related to differences of the inclusion criteria for this reason this study aimed to get a reliable result.
214684452|NCT03230175|BIOLOGICAL|TTAX01|TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
214373862|NCT07148271|DIETARY_SUPPLEMENT|Dietary Supplement Product|Participants will receive a dietary supplement product administered orally once daily for 8 weeks. The supplement is provided in capsule form and taken with water. The intervention is designed to modulate gut microbiota composition and diversity, with the potential to influence ocular surface outcomes in patients with dry eye disease. The regimen will be self-administered at home, with adherence monitored at study visits. Stool samples will be collected at baseline and week 8 for metagenomic sequencing, and ocular surface parameters will be assessed at the same time points. Safety will be evaluated by monitoring for adverse events throughout the intervention period.
214373863|NCT07147946|DRUG|TQC3721 Suspension for inhalation|TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor
214373864|NCT07147946|DRUG|Placebo of TQC3721 Suspension for Inhalation|Placebo without drug substance
214684453|NCT03230175|PROCEDURE|Surgical resection and debridement|"Perform surgical sharp debridement in the OR, to remove:~* infectious agents and biofilms (purulence),~* all debris, eschar, callus and macerated non-viable tissue from the wound base, and~* dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge.~Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate."
214684454|NCT03230175|DRUG|Systemic antibiotics|Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
214684455|NCT03230175|DEVICE|Off-loading|Provide off-loading device appropriate to the location of wound with full length boot or total contact cast
214684456|NCT02422043|OTHER|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
214373865|NCT07145099|OTHER|PT Group|Exercise, Manual Therapy, and education
214373866|NCT07145099|OTHER|Usual Care|Education
214684457|NCT02807909|DRUG|BMS-986177|
214684458|NCT02807909|DRUG|Itraconazole|
214684459|NCT02807909|DRUG|Diltiazem ER|
214684460|NCT04014153|PROCEDURE|Iodinated contrast media|Percutaneous coronary intervention with iodinated contest media
214373867|NCT07144956|BIOLOGICAL|Cilostazol (Pletal®) 100 mg Tablets|100 mg orally or via feeding tube twice daily for 14 days, starting within 96 hours after aneurysmal subarachnoid hemorrhage onset. Tablets may be crushed for enteral administration.
214373868|NCT07144956|DRUG|Placebo|Oral or enteral placebo, visually identical to cilostazol, twice daily for 14 days, starting within 96 hours after hemorrhage onset.
214373869|NCT07144956|DRUG|Nimodipine group|Administered orally, enterally, or intravenously for 21 days as part of standard of care. Dose, route, and duration determined by treating physician according to clinical condition and guidelines.
214373870|NCT07145801|DIAGNOSTIC_TEST|Lumason|Following baseline ultrasound imaging, CEUS will be performed using dual B-mode and CEUS mode. For the first injection using Lumason the approximate tumor mid-line will be imaged during breath hold until complete tumor enhancement is achieved followed by imaging sweeps through the tumor. Intermittent imaging will be performed after that. Following a 10 minute Lumason wash-out period, participants will then receive a bolus injection of Sonazoid with identical imaging protocol to Lumason for the first 60 seconds to evaluate arterial phase enhancement. Imaging sweeps of the tumor will then be obtained at 1 and 2 minutes to evaluate enhancement within the late vascular phase to detect early washout. After visualization in the late phase, imaging will resume to evaluate the Kupffer phase of contrast enhancement. Following completion of the exam, patients will be monitored for at least 30 minutes before being discharged and all data will be exported for later off-line analysis
214373871|NCT07145801|DIAGNOSTIC_TEST|Sonazoid|Participants will receive a bolus injection up to (0.12 µl of MB/kg) of Sonazoid, followed by 5-10 ml of normal saline. Imaging of Sonazoid will be identical to the protocol described above for the first 60 seconds to evaluate arterial phase enhancement. Imaging sweeps (5-10 seconds) of the tumor will then be obtained in at 1 and 2 minutes to evaluate enhancement within the late vascular phase and detect early washout. After that imaging will resume to evaluate the Kupffer phase of contrast enhancement. Kupffer phase imaging (also called the postvascular phase) starts approximately 8-10 mins after injection when the free circulating microbubbles have been eliminated from the vasculature with Kupfer-cell enhancement persisting for up to 2 hours. Sonazoid CEUS will be performed in all patients after Lumason clearance from the circulation, usually within 15 min after injection.
214684461|NCT02553720|OTHER|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
214684462|NCT02553720|OTHER|aquatic activity plus conventional management|walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
214684463|NCT01129791|BEHAVIORAL|Raw Milk|Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
214684464|NCT01129791|BEHAVIORAL|Pasteurized Milk|Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
214684465|NCT01129791|BEHAVIORAL|Non-dairy milk|Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
214986956|NCT00726453|DEVICE|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
214373872|NCT07149948|BEHAVIORAL|THRIVE Integrated Care Program|The THRIVE Integrated Care Program is a psychoeducational behavioral intervention for adolescent mothers that combines reproductive health education and mental health support. It includes seven biweekly in-person or virtual sessions covering topics such as sexual health, parenting, mental health, substance use prevention, social support, and professional development. The intervention is delivered by trained medical students and staff using interactive learning modules and assessments.
214373873|NCT02204228|DEVICE|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
214373874|NCT07153237|DEVICE|STYLAGE® HydroMax|3 injection sessions : Group A: at week 0 (V1a), week 3 (V2a), and week 24 (V5a). Group B: at week 6 (V3b), week 3 from V3b (V4b), and week 24 from V3b (V7b)
214373875|NCT07153107|OTHER|Local Heat Therapy|"This will use a simple device provided to participants named jaw bra, which is a head wrap with straps that goes around the chin and head that holds heated gel packs over the cheeks area"
214373876|NCT07152834|DIAGNOSTIC_TEST|Blood Sampling|"For AAT Level: Residual serum from routine blood samples drawn for standard clinical care will be aliquoted into polypropylene cryotubes.~For Genetic Testing: A separate capillary blood sample will be obtained via finger prick using a sterile lancet and collected on a designated filter paper."
214373877|NCT07153003|DRUG|Oxycodone|"Patients will receive oral Oxycodone only to treat post-operative pain:~Oxycodone 5mg~* Patients ≤75 years old: 5mg or 10 mg PO every 4 hr as needed~  * 5 mg for pain rated 4-6~ * 10 mg for pain rated 7-10~* Patients \>75 years old and/or sensitive to opioids or sedatives: 2.5mg or 5mg every 4hr as needed~  * 2.5mg for pain rated 4-6~ * 5mg for pain rated 7-10"
214373878|NCT07153003|DRUG|Tramadol and Oxycodone|"Patients will receive a combination of Tramadol and Oxycodone to take orally to treat post-operative pain:~Tramadol 50mg~* Patients ≤75 years old: 50 mg for pain rated 4-6; 100 mg for pain rated 7-10~* Patients \>75 years old and/or sensitive to opioids or sedatives; use 50 mg~* Dosing is every 8 hours as needed. Cumulative dose not to exceed 400mg in 24 hours~Oxycodone 5mg~* Patients ≤75 years old: 5mg or 10 mg PO every 4 hr as needed if still having pain after maximum tramadol administration~  * 5 mg for pain rated 4-6~ * 10 mg for pain rated 7-10~* Patients \>75 years old and/or sensitive to opioids or sedatives: 2.5mg or 5mg every 4 hr as needed if still having pain after maximum tramadol administration~  * 2.5 mg for pain rated 4-6~ * 5 mg for pain rated 7-10"
214373879|NCT07152847|OTHER|Psychosexual education app with artificial intelligence|"Development of the App will contain the following features:~1. A basic Mac for iphone Operating System development~2. General Data Protection Regulation compliance legal certification~3. Hosting and cloud services~4. Security Features: for encryption and secure authentication user sign in~5. Analytics Integration: for integrating app analytics tools~6. Push Notifications: incorporated into the app~7. Legal and Compliance additional General Data Protection Regulation certified~8. Custom Artificial Intelligence Models Interactive Learning Tools Artificial Intelligence will create interactive educational materials on sexual function and dysfunction~9. Artificial Intelligence cloud services~10. Natural Language Processing. Artificial Intelligence will process textual data from the feedback questions to identify emerging topics and concerns in sexual function and participants' experiences using the app."
214495432|NCT06953193|PROCEDURE|General Anesthesia|"Patients will undergo balanced general anesthesia for pancreatoduodenectomy. Induction will include: fentanyl 4 mcg/kg, lidocaine 1 mg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg.~Anesthesia maintenance will be achieved with sevoflurane (variable concentration as per anesthesiologist discretion) and continuous fentanyl infusion according to the attending anesthesiologist's judgment.~No epidural catheter will be placed."
214495433|NCT06953193|PROCEDURE|Combined General Anesthesia (Thoracic Epidural)|"Patients will undergo combined general anesthesia (thoracic epidural) for pancreatoduodenectomy.~Induction will include: fentanyl 4 mcg/kg, lidocaine 1 mg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg.~A thoracic epidural catheter will be placed at the best palpable intervertebral space between T6-T9 by the attending anesthesiologist.~Anesthesia maintenance will include sevoflurane (variable concentration), fentanyl infusion at the anesthesiologist's discretion, and continuous infusion of 0.25% bupivacaine via the epidural catheter throughout the surgery."
214684466|NCT04187222|OTHER|Mechanical debridements|Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.
214684467|NCT04187222|BIOLOGICAL|Bifidobacterium animalis subsp. lactis|Capsules containing Bifidobacterium animalis subsp. lactis were chubby and subsequently ingested twice a day for 12 weeks.
214684468|NCT01123239|BEHAVIORAL|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches, who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care."
214684469|NCT01123239|BEHAVIORAL|Standard Diabetes Education|Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
214373880|NCT07154329|BEHAVIORAL|Internet-Based EMDR-Flash Program|"Self-guided, internet-based EMDR-Flash program (SKY-Flash) tailored to reduce test anxiety in university students. Delivered via a secure web platform with no live therapist involvement. The intervention comprises six \~40-minute modules completed independently during the study. Each module includes brief psychoeducation and step-by-step EMDR-Flash procedures (focus on a positive engaging image with brief flash cues), guided practice, and in-platform exercises. Gamification (progress tracking, badges) and automated prompts support adherence. Unlike CBT-based online programs or clinician-delivered EMDR, this is a fully automated, low-intensity Flash protocol adapted to exam-related distress. Safety messaging and referral resources are embedded; access is via individual login and usage is recorded for adherence."
214373881|NCT07160400|DRUG|Placebo|Single dose placebo IBI3032 administered orally
214986957|NCT04128553|BEHAVIORAL|Intervention motivational interview group|"Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.~In the present study, an effort was made to help the IG to realize the dilemmas of individuals in the precontemplation stage about exercising, and individuals in the contemplation stage to produce their own solutions. In this direction, techniques such as decision balance, importance, and trust technique were applied, thus enabling them to reveal their feelings, thoughts, and reactions regarding the benefits/harms of doing/not doing exercise. They were supported to raise awareness about the consequences and solutions of the causes."
214373882|NCT07160400|DRUG|IBI3032 tablets|Single dose of IBI3032 administered orally
214986958|NCT03507101|OTHER|No intervention|No particular intervention or exposure is of particular interest
214986959|NCT05570422|DRUG|KRC-01|KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.
214684470|NCT03037957|DEVICE|ARIES Group A Strep Assay|
214684471|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.5 mL|Solution for intramuscular injection Сhildren were vaccinated with the Flu-M vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
214684472|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.5 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
214373883|NCT07157514|DRUG|131I-apamistamab|Iodine-131 radiolabeled anti-CD45 monoclonal antibody (apamistamab). Administered IV as a dosimetric dose followed by treatment dose.
214373884|NCT07157514|DRUG|Fludarabine|Fludarabine phosphate, 30 mg/m² IV daily on Days -6 through -2.
214684473|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.25 mL|Solution for intramuscular injection Children were vaccinated with the Flu-M vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
214684474|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.25 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
214684475|NCT00003771|BIOLOGICAL|therapeutic estradiol|
214684476|NCT00003771|DRUG|norethindrone acetate|
214684477|NCT00585299|OTHER|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
214684478|NCT00585299|OTHER|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
214684479|NCT01984593|OTHER|Yoga|"The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.~The two yoga exercises were:~1. Left nostril breathing - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and~2. Spinal flex - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes)."
214684480|NCT01221675|DRUG|Antibody TF2|preciblage with an antibody
214684481|NCT01221675|RADIATION|IMP-288-Lutetium|Internal Radiation
214684482|NCT01221675|RADIATION|IMP-288-Indium|Imaging
214684483|NCT05869851|OTHER|Pavlik Harness|The Pavlik harness is an abduction brace used for treatment of hip dysplasia in infants. It keeps the hips in proper alignment to allow for appropriate growth and development of the joint.
214684484|NCT00004747|DRUG|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
214373885|NCT07157514|DRUG|Cyclophosphamide|Cyclophosphamide
214373886|NCT07157514|RADIATION|Total Body Irradiation (TBI)|TBI, 200 cGy on Day -1 prior to HSCT.
214373887|NCT07157514|BIOLOGICAL|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Unmodified, G-CSF-mobilized donor stem cells infused on Day 0.
214373888|NCT07155031|DEVICE|Pathogen reduced red blood cells|pathogen reduced red blood cells with biotin labeled aliquots will be transfused as part of routine care red cell exchange procedures
214373889|NCT07165795|BEHAVIORAL|Transcendental Meditation|Standard TM instruction by certified TM teachers, including 4 days of initial training (60-90 min/day), then follow-up sessions (60-90 min) every 2-4 weeks.
214373890|NCT07165210|OTHER|No Intervention: Observational Cohort|no intervention was applied in this cohort
214373891|NCT07164729|OTHER|PNF Stretching|Dynamic stretching of the quadriceps will be performed using walking lunges. This exercise dynamically stretches the quadriceps and hip flexors while also improving balance and coordination. During the exercise, participants stand upright, step one leg forward, and lower their body by bending the knee. They then step forward with the other leg to complete the movement. Ten steps will be performed for each leg.
214986960|NCT05570422|RADIATION|External Beam Radiation Therapy|"* Target definition for EBRT will be based on 3D imaging by computed tomography, positron emission tomography with computed tomography, or MRI.~* Intensity-modulated radiotherapy (IMRT) must be used.~* IMRT should be given once daily Monday-Friday, 5 fractions per week."
214373892|NCT07164729|OTHER|Dynamic Stretching|"The Hold-Relax technique will be applied. Hold-Relax PNF stretching is based on the principle of isometric contraction of the muscle followed by passive stretching. This technique is effective for increasing muscle flexibility and reducing muscle tension. The medial and lateral parts of the quadriceps will be stretched by Flexion-Adduction-External Rotation and Flexion-Abduction-Internal Rotation patterns3. During the exercise, participants will lie prone with the knee flexed. They will be asked to attempt knee extension while the movement is resisted by the physiotherapist. The contraction will be maintained for 10 seconds, after which the participant will be instructed to relax. Following relaxation, the knee flexion angle will be increased. Ten repetitions will be performed for each leg."
214373893|NCT07165600|OTHER|Yoga|Physical activity
214986961|NCT05570422|DRUG|cisplatin|"* Weekly concomitant cisplatin (40 mg/m2) during EBRT~* Neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/m2) are not allowed.~* Adjuvant chemotherapy (after completion of EBRT+BT) is not allowed."
214684485|NCT00783705|OTHER|placebo|Given orally
214373894|NCT07165743|DIAGNOSTIC_TEST|40-Minute Real-Time First-Trimester Ultrasonography|A one-time midsagittal ultrasound performed between 11 +0 and 14 +0 weeks. Bladder emptying time and post-void longitudinal bladder diameter are recorded. No invasive procedures are performed.
214684486|NCT00783705|DRUG|inositol|Given orally
214986962|NCT05570422|RADIATION|brachytherapy|"* BT treatment planning will be based on 3D-image-guided BT by MRI.~* Low-dose-rate, pulsed-dose-rate, or high-dose-rate BT"
214373895|NCT07165145|DIETARY_SUPPLEMENT|Organic Fruits and Vegetables|Dietary Intervention
214373896|NCT07165145|DIETARY_SUPPLEMENT|Conventional Fruits and Vegetables|Dietary Intervention
214986963|NCT03951389|OTHER|Non-interventional|Non-interventional
214684487|NCT04857398|DRUG|insulin icodec|"Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin.~The study will last for 15 to 22 weeks."
214684488|NCT06058780|PROCEDURE|Implantable Collamer Lens (ICL)|Phakic intraocular lenses (pIOL) have proven to be a great alternative to corneal refractive surgery in certain situations. They offer several advantages over corneal techniques, such as being suitable for high myopes and causing relatively fewer higher-order aberrations
214684489|NCT06058780|PROCEDURE|Implantable Intraocular Lens (IPCL)|The IPCL offers a distinct economic advantage as the cost of the IPCL implant is only 2. times that of the ICL implant. Moreover, the IPCL can correct higher degrees of myopia, up to -30. D, compared to the maximum correction of -18. D provided by the ICL.
214373897|NCT07165457|DIETARY_SUPPLEMENT|Probiotic group|Daily consumption of one capsule containing a probiotic for 15 days
214684490|NCT05242276|DEVICE|USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY|The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. . It is inserted vaginally through the cervical canal into the endometrial cavity. The uterine manipulator facilitates the uterus mobilization during the surgery, generating tension on the main supporting elements of the uterus to improve surgical field exposure and provide a landmark for the colpotomy.
214684491|NCT03854591|OTHER|No intervention|No intervention
214684492|NCT04162886|OTHER|Exercise|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
214373898|NCT07166406|BIOLOGICAL|Atezolizumab|Given IV
214684493|NCT01800227|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
214684494|NCT06385964|DRUG|SHR-4597|SHR-4597 by dry powder inhalation
214986964|NCT06535659|DEVICE|VitaFlow Liberty™ Transcatheter Aortic Valve System|"Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System.~Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care."
214373899|NCT07166406|BIOLOGICAL|Bevacizumab|Given IV
214373900|NCT07166406|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214373901|NCT07166406|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
214373902|NCT07166406|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214373903|NCT07166406|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214373904|NCT07166406|OTHER|Questionnaire Administration|Ancillary studies
214684495|NCT06385964|DRUG|Placebo|Placebo by dry powder inhalation
214684496|NCT01563627|OTHER|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
214684497|NCT01563627|DEVICE|Magnetic Resonance Imaging|
214684498|NCT04363086|BEHAVIORAL|iFightDepression online self-help tool|Computerized cognitive behavior therapy
214684499|NCT04363086|BEHAVIORAL|Treatment as Usual|TAU
214684500|NCT04363086|BEHAVIORAL|phone call|phone call
214684501|NCT01142986|BEHAVIORAL|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
214986965|NCT02865291|DEVICE|ForConti device|
214986966|NCT05572918|DIAGNOSTIC_TEST|Urodynamics aka filling cystometry|Participants will be undergoing a routine diagnostic test to characterise bladder function and volume
214986967|NCT05876065|DRUG|XC|Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
214684502|NCT01142986|BEHAVIORAL|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
214684503|NCT00763204|DRUG|AN2728 Cream, 2%|
214684504|NCT00763204|DRUG|AN2728 Cream, 1%|
214684505|NCT00763204|DRUG|AN2728 Cream, 0.3%|
214684506|NCT00763204|DRUG|AN2728 Cream Vehicle|
214684507|NCT00763204|DRUG|Betnesol®-V Creme, 0.1%|
214684508|NCT04376268|DRUG|Chlorhexidine mouthwash|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
214684509|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
214684510|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
214986968|NCT05876065|DRUG|TPC|Any physician's choice as maintenance therapy (except for XC regimen)
214986969|NCT03171259|OTHER|care as usual|The investigators will be following patients with critical limb ischemia and documenting the usual care that the participants receive.
214986970|NCT01611675|DRUG|Vemurafenib|take orally, twice daily
214986971|NCT01611675|DRUG|Leflunomide|take orally, once daily
214986972|NCT03750565|DRUG|TD-1473 - Dose A|oral capsule/tablet, QD
214986973|NCT03750565|DRUG|TD-1473 - Dose B|oral capsule/tablet, QD
214986974|NCT03750565|DRUG|TD-1473 - Dose C|oral capsule/tablet, QD
214986975|NCT03750565|DRUG|Placebo|oral capsule/tablet, QD
214986976|NCT03310840|OTHER|others|others
214986977|NCT05707676|DRUG|LB4330|LB4330
214986978|NCT01395719|OTHER|Remote ischemic conditioning|Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
214986979|NCT01374386|BEHAVIORAL|Exergaming|Participants will have access to Exergaming equipment (video games that require physical activity)
214986980|NCT00355641|DRUG|Ropinirole Extended Release (XR)|Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
214373905|NCT07166406|BIOLOGICAL|Tremelimumab|Given IV
214373906|NCT07166406|BIOLOGICAL|Durvalumab|Given IV
214373907|NCT07166406|BIOLOGICAL|Nivolumab|Given IV
214373908|NCT07166406|DRUG|Ipilimumab|Given IV
214373909|NCT07166406|RADIATION|Stereotactic Body Radiation Therapy|Undergo liver SBRT
214373910|NCT07166406|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214373911|NCT07166757|DRUG|human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection|5.0×10\^7 cells/mL, injection, once, 12 months
214373912|NCT07164690|RADIATION|Low Dose Radiation Therapy|"A dose of 2 Gy/1Fx will be delivered to all currently visible lesions. Lesions in different anatomic sites may be irradiated separately, but the entire course must be completed within one week.~* Esophageal primary tumor management: If the investigator judges there is a risk of fistula or bleeding from the esophageal lesion, palliative radiotherapy at 40-50 Gy may be added.~* Immunotherapy: The original PD-1/PD-L1 inhibitor regimen will be resumed immediately after LDRT is completed and continued as maintenance therapy.~* Chemotherapy: At the investigator's discretion, standard second-line chemotherapy per the current CSCO guidelines for esophageal cancer may be administered."
214986981|NCT05301634|PROCEDURE|infraorbital block|the patients will receive bilateral infraorbital block
214986982|NCT05301634|PROCEDURE|topical intranasal bupivacaine|the patients will receive topical intranasal application of bupivacaine
214986983|NCT00795340|DRUG|carboplatin|Given IV
214373913|NCT07166250|PROCEDURE|Quadratus Lumborum Block|Ultrasound-guided quadratus lumborum block performed preoperatively using local anesthetic injection at the thoracolumbar fascia for postoperative analgesia in lumbar disc herniation surgery.
214373914|NCT07166250|PROCEDURE|Retrolaminar Block|Ultrasound-guided retrolaminar block performed preoperatively using local anesthetic injection into the retrolaminar space for postoperative analgesia in lumbar disc herniation surgery
214373915|NCT07166341|DEVICE|Observational|The study objectives require placement of a jugular venous bulb catheter and radial arterial line placement with ultrasound guidance. Two INVOS™ sensors (PMSENS71-A) will be placed bilaterally on the subject's forehead and two on the calf. The INVOS™ device will be evaluated for a targeted range of 70-100% SpO2 levels. Hypoxic mixtures of gas are delivered, and data are collected at approximately (\~) 5-minute intervals during steady periods of increasing and decreasing oxygen concentration.
214986984|NCT00795340|DRUG|cediranib maleate|Given orally
214986985|NCT00795340|DRUG|paclitaxel|Given IV
214986986|NCT00795340|OTHER|placebo|Given orally
214986987|NCT01963806|BEHAVIORAL|Smartphone-supplemented iCBT|"The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support."
214986988|NCT01963806|BEHAVIORAL|Therapist support|The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.
214986989|NCT01963806|OTHER|Active waiting list|Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
214986990|NCT01432951|DRUG|Enzastaurin|Administered orally
214986991|NCT01345799|DRUG|TRK-170|
214986992|NCT01345799|DRUG|Placebo|
214986993|NCT03969537|OTHER|Telemedicine follow-up visit|Study participants will experience two telemedicine (live audio/video) visits.
214373916|NCT07164508|BEHAVIORAL|Sitting Light Volleyball Intervention|16-week intervention centered around Sitting Light Volleyball, an adaptive sport developed by the Project Coordinator specifically for adults with physical disabilities.
214373917|NCT07164508|BEHAVIORAL|Group Seated Dance Intervention|16-week intervention program for adults with physical disabilities centered around para dance in a group setting of various dance styles.
214986994|NCT04464460|DRUG|TAK-671|TAK-671 intravenous infusion.
214495434|NCT06765746|PROCEDURE|Ventricular tachycardia ablation|"All ventricular tachycardia (VT) ablation procedures will be performed under general anesthesia. An epicardial approach will be performed, if clinically needed, when a detailed endocardial mapping during VT fails to reveal the complete VT critical isthmus. In case of epicardial mapping, the pericardium will be accessed percutaneously using the method described by Sosa et al.~VT activation mapping will be performed and the critical isthmus will be defined as the diastolic pathway.~Ablation will be performed at 50 W (temperature limit of 43 °C) using an irrigated ablation catheter (TactiFlex, Abbott, MN). Ablation will be aimed at VT isthmus transection. Substrate modification will be added if the patient is still inducible or in the absence of any inducible/tolerated VT. Substrate ablation will be performed based on sinus rhythm mapping, aiming at non-inducibility of any VT. At the end of procedure, programmed ventricular stimulation will be repeated."
214986995|NCT04464460|DRUG|TAK-671 Placebo|TAK-671 placebo-matching intravenous infusion.
214986996|NCT00853385|DRUG|CP 690,550|tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
214986997|NCT00853385|DRUG|CP-690,550|tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
214986998|NCT00853385|OTHER|Placebo|placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
214986999|NCT00853385|OTHER|Placebo|tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
214987000|NCT00853385|BIOLOGICAL|Biologic TNFi|placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
214987001|NCT01951950|DRUG|Nicardipine|
214987002|NCT01951950|DRUG|Esmolol|
214373918|NCT07164651|OTHER|Accelerated MRI scanning|"All patients underwent MRI scans of the abdominal and pelvic regions on the uMR 790 scanner at Tongji Hospital's Optical Valley Campus. The scanning protocol included multiplanar ACS T2WI sequences, TACS T2WI sequences, and conventional T2WI sequences.~ACS T2WI sequence: Used for preliminary motion artifact correction. TACS T2WI sequence: Employed for advanced motion artifact correction and provided dynamic images of organ movement.~Conventional T2WI sequence: Served as the standard reference for comparison."
214987003|NCT00915525|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
214987004|NCT06436859|BEHAVIORAL|stress ball group|"According to randomization, pregnant women in the intervention group will receive stress ball therapy during labor."
214987005|NCT00176046|DRUG|viscum album pini|s.c. injection of 0,001-20 mg 3 times per week
214987006|NCT00176046|DRUG|viscum album pini|s.c. injection 0,001-20 mg 3 times per week
214987007|NCT00941928|DRUG|Epratuzumab|360 mg/m\^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
214987008|NCT00941928|DRUG|Fludarabine|25 mg/m\^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
214987009|NCT00941928|DRUG|Cyclophosphamide|60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
214987010|NCT00941928|DRUG|Mesna|12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
214987011|NCT00941928|PROCEDURE|Infusion of NK cells|Transplant of Haploidentical NK cells by vein on Day 0.
214987012|NCT00941928|DRUG|Interleukin-2|Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
214987013|NCT02690129|DRUG|Vaginal Progesteron|
214373919|NCT07166536|OTHER|Provocation Test for Symptoms Using Mental Imagery|"• The mental imagery task will be guided by the examiner through continuous verbal instruction (the examiner will provide ongoing instructions throughout the entire task, not just at the beginning). During the instruction, the examiner will direct the participant's attention to visual, auditory, and proprioceptive aspects of the imagined movement or scenario. Example: Close your eyes, and without moving your head or body at all, try to imagine that you are moving your head from side to side quickly and easily, while noticing the sensation of motion, seeing the rotation through your eyes, and feeling the acceleration of your head as it moves from side to side..."
214495435|NCT06954155|DRUG|Tenecteplase (0.25mg/kg)|Each vial of tenecteplase is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. Calculate the total amount of drug according to the subject's actual body weight and measure the required drug volume. The maximum dose should not exceed 25mg. Tenecteplase should be given as a single, intravenous bolus (within 5-10 seconds).
214987014|NCT03562130|DRUG|Teduglutide|Daily sub cutaneous injection 0,05 mg/kg/day
214987015|NCT05550181|BEHAVIORAL|intraoperative mechanical ventilation with hypocapnia (etCO2 < 35 mm Hg)|A patient is considered 'hypocapnic' if the etCO2 was \< 35 mm Hg at any point during surgery, from start of the study till end of the study and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
214495436|NCT06954155|DRUG|Standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.
214684511|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
214684512|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
214684513|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
214987016|NCT02955927|DRUG|0.01% atropine eye drops|
214987017|NCT02955927|DEVICE|ortho-k|
214987018|NCT00126945|BIOLOGICAL|Meningococcal Vaccine|
214373920|NCT07165652|DRUG|NKF-INS(L)|Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.
214373921|NCT07165652|DRUG|US-Humalog®|Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.
214373922|NCT07165652|DRUG|EU-Humalog®|Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.
214495437|NCT06953271|DRUG|Methenamine Hippurate|Drug: Methenamine hippurate 1 gram by mouth twice daily for three days.
214495438|NCT06953271|DRUG|Typically prescribed oral antibiotic prophylaxis|Drug: typically prescribed oral antibiotic prophylaxis following intradetrusor BOTOX-A injections. This includes, but is not limited to, antibiotic medications such as nitrofurantoin, amoxicillin/clavulanic acid, and trimethoprim/sulfamethoxazole. Dosage will be determined per usual care. Duration of treatment will be standardized to three days.
214987019|NCT05250869|DIAGNOSTIC_TEST|HPLC/MS|Quantification of MTX and its metabolites by HPLC/MS under various preanalytical conditions
214987020|NCT05164211|OTHER|Didgeridoo|the children will have 6 didgeridoo lessons given by a teacher spread over 3 months.
214987021|NCT02650817|DRUG|RAD1901|RAD1901, a novel selective ER degrader (SERD)
214987022|NCT05716464|BEHAVIORAL|Lifestyle medicine intervention|The lifestyle medicine intervention includes six weekly sessions (i.e., participants will receive the intervention once per week) that are related to the following topics: (a) lifestyle psychoeducation, (b) physical activity, (c) dietary recommendation, (d) stress management, (e) sleep management and (f) motivation and goal-setting techniques. Each topic will be delivered during each face-to-face session and the duration of each session will be around 120 minutes.
214495439|NCT06950970|BEHAVIORAL|Tion-Emo therapy and technique for depression and anxiety Improvement|From 10 a 12 sessions once a week and one hour each session , for a positive result and development it is necessary to practice the technique
214684514|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
214987023|NCT05716464|BEHAVIORAL|Cognitive-behavioral therapy for depression (CBT-D)|The group-based CBT-D therapy includes six weekly sessions (i.e., participants will attend one 120-minute, face-to-face group therapy per week, and will be asked to practice taught-skills every day, for 42 days) that are related to the following topics: (a) psychoeducation, (b) cognitive restructuring, (c) behavioral activation, (d) self-care and relapse prevention.
214987024|NCT03006120|PROCEDURE|Retroperitoneal hematoma due to cardiac catheterization|
214987025|NCT03587597|PROCEDURE|socket shield technique|socket shield technique with immediate temporization
214987026|NCT03587597|PROCEDURE|conventional immediate implant placement with immediate temporization|conventional immediate implant placement with immediate temporization
214373926|NCT07165522|BEHAVIORAL|Transformative and Restorative Engagement Circle (TREC)|TREC will be co-developed in Phase 1, to focus on ensuring the presence of at least 3 key components: 1) a listening phase (focused on unconditionally hearing the experiences of autistic participants), 2) an acknowledgement phase (in which the experiences, including but not limited to harms and trauma, of autistic participants will be expressly addressed and acknowledged), 3) a negotiation/priority-setting phase, in which participants will collaboratively identify goals for future CER.
214373927|NCT07165522|BEHAVIORAL|Stakeholder Engagement in quEstion Development and prioritization (SEED)|The SEED Method is a PCORI-supported multilevel stakeholder engagement model, using a participatory framework to develop stakeholder priorities. The core premise of SEED is creating a level playing field for stakeholders, wherein participants learn how to collaboratively identify their own community's priorities, and then refine them together. It involves convening participatory Topic Groups of stakeholders, assembled based on their experience and knowledge of the area of focus (in this case, autism and ABA). It also involves additional consultative stakeholder participants to fill in key gaps in representation; this element may or may not be present in thi SEED iteration, based on the CAC-led adaptation. SEED participants convene over a period of time (adapted to the needs of the specific group, and will be matched to the length of TREC here) to conceptualize (i.e., learn how to build a conceptual model and conduct exercises to do so), generate questions (i.e., review the conceptual m
214495440|NCT06954129|DRUG|Vancomycin|Vancomycin is a glycopeptide antibiotic used to treat infections caused by Gram-positive bacteria, including those due to methicillin-resistant Staphylococcus aureus. Dosing of vancomycin will follow standard of care procedures, including the use of individualized dosing regimens developed in consultation with clinical pharmacists, based on participant body weight and renal function, and dosage titration guided by therapeutic drug monitoring. Vancomycin is administered via intermittent intravenous infusions of 60-90 minutes.
214495441|NCT06954129|DRUG|Piperacillin-tazobactam|Piperacillin-tazobactam is an anti-pseudomonal penicillin with a dose range of 2.25 g or 4.5 g and frequency of every 6 or 8 hours based on a participant's body weight, renal function, and clinician discretion. Piperacillin-tazobactam is administered via extended-duration (4 hours) intravenous infusions
214495442|NCT06954129|DRUG|Cefepime|Cefepime is an anti-pseudomonal cephalosporin with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 8, 12, or 24 hours based on a participant's body weight, renal function, and clinician discretion. Cefepime is administered via extended-duration (4 hours) intravenous infusions
214495443|NCT06950632|DIETARY_SUPPLEMENT|Pepppermint oil inhalation|Participants in the experimental group will inhale five drops of 100% pure peppermint essential oil placed on a cotton ball inside a container for ten minutes before each chemotherapy session and every two hours during the chemotherapy infusion.
214495444|NCT06950632|DIETARY_SUPPLEMENT|Placebo|The control group will follow the same procedure using five drops of distilled water placed on a cotton ball inside a container for ten minutes before each chemotherapy session and every two hours during the infusion
214987027|NCT04247971|PROCEDURE|Blood draw|23 ml of blood collected
214987028|NCT04247971|PROCEDURE|Sputum collection|Induced sputum sample collected
214987029|NCT04247971|PROCEDURE|Pulmonary function test|Pulmonary function testing
214987030|NCT01055912|DRUG|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
214987031|NCT01055912|DRUG|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
214987032|NCT02337582|OTHER|Opportunistic Breast cancer screening|Opportunistic breast screening offered to women attending clinics for non-breast health issues
214987033|NCT02337582|OTHER|Usual Care|No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
214987034|NCT00869180|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
214987035|NCT00869180|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
214987036|NCT06317974|BEHAVIORAL|Breastfeeding education based on the Health Belief model|Training was given face to face with the participant, lasting approximately 40 minutes. One week after the training presentation, three short messages about the training were sent to the couples (both the pregnant woman and her partner) every other day. Two weeks after the training was given, a phone call was made for feedback. Post-test data were taken four weeks later.
214987037|NCT06551844|DRUG|Molnupiravir 400 mg|"This is an antiviral drug (an RNA dependent RNA polymerase inhibitor, with broad spectrum antiviral activity) currently approved for use in treatment for COVID-19 patients.~In this trial, its antiviral effectiveness on the early phase of dengue virus infection will be assessed."
214987038|NCT06551844|DRUG|VIS513 (a monoclonal antibody)|VIS513 is an engineered humanised monoclonal antibody produced by recombinant DNA technology in a mammalian cell (i.e. Chinese hamster ovary) line. It was discovered in the USA by Visterra Inc and subsequently technology for manufacturing and further development was transferred to Serum Institute of India Pvt. Ltd., Pune, India. It has shown potent, specific neutralization of all four serotypes of DENV.
214684515|NCT04376268|PROCEDURE|Boric acid mouthwash (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
214684516|NCT05005208|OTHER|rehabilitation program with the support of the technological platform SI-ROBOTICS|"A 16-treatment session will be conducted, divided into 2 training sessions per week, for 8 weeks. The therapy sessions last 60 minutes; each session will involve 2 patients at time. Cardiac and respiratory activity monitoring is planned during robotic treatments in order to detect the heart rate during physical activity. Individual participants must complete at least 80% of the sessions. Recovery of 2 sessions will be possible.~Each session involves the following activities:~* Breathing, relaxation and postural harmonization exercises;~* Active mobility and stretching exercises;~* Irish dance with the SI-ROBOTICS system;~* Relaxation exercises."
214684517|NCT02379923|DEVICE|Crossing of Coronary Artery CTO|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires"
214684518|NCT05148208|DEVICE|Creatine supplementation to dialysate|Creatine supplementation to dialysate
214684519|NCT01043523|DRUG|Gadoxetic Acid Disodium (Eovist, BAY86-4873)|Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
214684520|NCT02558881|PROCEDURE|Virtual colonoscopy|
214684521|NCT02558881|PROCEDURE|Colon capsule|
214373928|NCT07165496|BEHAVIORAL|Text message-based intervention|Participants received weekly text messages to promote health and HIV testing and were followed and supported by trained healthcare counselors through two-way communication over a 12-week period. They were able to schedule a free HIV testing appointment at any time up to six months after enrollment.
214373929|NCT07165574|OTHER|No intervention as the study is observational|As this is an observation study, participants are not assigned an intervention as part of the study
214373930|NCT07166458|DIETARY_SUPPLEMENT|Kefir Peptide|Oral supplementation with kefir-derived bioactive peptides given daily in addition to standard care.
214373931|NCT07166458|OTHER|Standard Care (in control arm)|Standard fracture management including immobilization, pain control, and routine follow-up care.
214373932|NCT07164872|RADIATION|preoperative radiotherapy|preoperative radiotherapy
214373933|NCT07165067|DRUG|AP601|AP601 is a fully human bispecific antibody designed for the treatment of CD73-expressing solid tumours. Participants will receive a single infusion of AP601 once every 2 weeks (14 days) (Q2W) for up to 12 months. All doses of AP601 will be admistered intraveneously. The infusion time for all doses of AP601 in each patient will be approximately 60 to 120 minutes.
214373934|NCT07165405|OTHER|Shower|Participants in this group will receive a shower administered by their partner on their back, abdomen, or entire body while standing or sitting, with the water temperature maintained between 32-37°C (the woman's preferred temperature will be applied) for at least 20 minutes upon admission to the labor room (when dilation is 4-5 cm). This will be performed under the observation of the researcher midwife. The application will be repeated when dilation reaches 7-8 cm.
214684522|NCT00100373|DRUG|RSV challenge material|
214684523|NCT04005092|DEVICE|hCPAP versus HFNC|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
214684524|NCT00005022|DRUG|cisplatin|
214684525|NCT00005022|DRUG|etoposide|
214684526|NCT00005022|RADIATION|radiation therapy|
214684527|NCT00156546|DRUG|antibiotic to reduce the recurrence of infection|
214373935|NCT07165405|OTHER|Massage|Sacral Massage Application will be performed using 20x20 cm pouches filled with cherry pits. Like the shower application, massage will be performed upon admission to the delivery room (when dilation is 4-5 cm) and repeated when dilation reaches 7-8 cm. Unless the pregnant woman requests otherwise, massage will be performed while she is in the left lateral position.
214373936|NCT07165405|OTHER|Midwifery Care|Care provided by a midwife in the delivery room
214684528|NCT04458038|OTHER|driving simulator|For this study a driving simulator is being used which is an internationally approved method. Besides the driving simulator following tests are done: COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), a clock drawing test and a continuous reaction time test (CRT). A CardioRespiratory Monitor (CRM), NOX T3TM, is used to measure if the patients have moderate to severe OSA. Furthermore, following tests are done: Epworth Sleepiness Scale (ESS).
214684529|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
214684530|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
214684531|NCT02811484|DRUG|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%
214684532|NCT02811484|BEHAVIORAL|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
214684533|NCT03679208|DEVICE|Investigational device coded KIO014|Innovative chitosan-based biomaterial intended for intraarticular injection.
214684534|NCT03679208|DEVICE|Durolane(r) as control device|Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
214684535|NCT01830153|DRUG|RAD001|
214373937|NCT07164807|DRUG|Methylene Blue (0.3%) with Ropivacaine Hydrochloride (0.75%)|Perianal subcutaneous injection of 0.3% methylene blue solution (Formulation: 1.5 mL of 1% methylene blue with 3.5 mL ropivacaine hydrochloride injection).
214373938|NCT07164807|DRUG|Methylene Blue (0.1%) with Ropivacaine Hydrochloride (0.75%)|Perianal subcutaneous injection of 0.1% methylene blue solution (Formulation: 0.5 mL of 1% methylene blue with 4.5 mL ropivacaine hydrochloride injection).
214684536|NCT01618955|DEVICE|VIBEX MTX|Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
214684537|NCT05431413|DRUG|Control group: Fluoxetine and Placebo|Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
214684538|NCT05431413|DRUG|Experimental group: Fluoxetine and ATP|Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
214684539|NCT05431413|DRUG|Control group: Fluoxetine and Phosphocreatine|Cap Fluoxetin 20mg OD for four weeks and injection Phosphocreatine 1g in NS BD for two weeks.
214684540|NCT01200511|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
214684541|NCT05901714|DRUG|Afimetoran|Specified dose on specified days
214684542|NCT05901714|DRUG|Phenytoin|Specified dose on specified days
214684543|NCT05901714|DRUG|Midazolam|Specified dose on specified days
214684544|NCT05915819|OTHER|Plyometric Training|Exercise prescription according to weeks, sets and repetition. Weeks 1 and 2 1-2 sets / 10 repetitions Double leg jump Medicine ball(MB) stuffer flutter MB overhead throw MB single leg dip, Arrow cone drill Figure 8 drill Weeks 3 and 4 1-2 sets / 8 repetitions Ankle jumps Lateral cone hops Zigzag jump drill MB chest pass Jump \& turn 90° High-5 drill MB split squat Power skipping Clock drill T-drill Weeks 5 and 6 1-2 sets / 6 repetitions Dot drill Single leg cone hops Long jump and sprint Single leg zigzag drill MB lunge chest pass Jump and turn 180° Split squat jump Alternate bounding X-drill Shuttle drill
214684545|NCT05915819|OTHER|Eccentric Training|The eccentric training will be Pull-ups 3-5 sets X 6-8 reps Glute-ham raise 3-5 sets x 10rep Manual glute-ham raise 3-5 sets x 10rep single-leg Romanian dead lift or good morning(barbell or dumbbell) 3-5 sets x 10rep Glute-bridge and hip thrust (can also perform single leg movement) 3-5 sets x 10rep Half-kneel-bottom-up press-eccentric only. 3-5 sets x 8rep The eccentric exercise technique will be 2/1 technique, Two-movement technique, Slow/super slow, Negative (supramax)
214684546|NCT00661752|DEVICE|quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
214684547|NCT00661752|DEVICE|quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
214684548|NCT00424580|DRUG|Montelukast (10mg) and Desloratadine (5mg)|
214684549|NCT03403491|OTHER|patientMpower application|electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms
214684550|NCT03403491|OTHER|sham application|dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms
214987039|NCT05799950|DEVICE|AcrySof single-piece IOL|Acrylic single-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
214987040|NCT05799950|DEVICE|AcrySof multi-piece IOL|Acrylic multi-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
214987041|NCT05207358|DRUG|Rituximab|2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15.
214987042|NCT05207358|DRUG|Mycophenolate Mofetil|Patients will receive Mycophenolate Mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months.
214373941|NCT07166029|OTHER|russian current|russian current will be is applied in 50Hz sinusoidal bursts with a duty cycle of 50% (10ms on/10ms off). Russian Stimulation (at 2500Hz or 2.5kHz) has been shown to be effective in increasing muscle strength and torque generation through stimulation of type II muscle fiber. The stimulation will be given for duration of 10 minutes on followed by 50 sec off and again 10 sec on, three tims per week plus selsected physical therapy program.
214373942|NCT07166029|OTHER|selected physical therapy program|the patients will receive selected physical therapy program in the form of TENS for 15 min, US for 5 min and exercise for 20 min
214373943|NCT07166263|DRUG|NK510|NK510 will be administered through intravenous infusion, once a week for a total of six times.
214373944|NCT07166263|DRUG|NK510|NK510 will be administered through intraperitoneal perfusion on D1, D4, and D7 of the first week for a total of 3 times, with each 3-week cycle constituting a total of 2 cycles.
214373945|NCT07165184|OTHER|no intervention was applied as observation study|no intervention was applied as observation study
214684551|NCT03516292|DIAGNOSTIC_TEST|Urinary Nerve Growth Factor|The subjective patient's discomfort regarding the vaginal prolapse problems and urinary incontinency symptoms will be assessed through the following questionnaires: (a) ICIQ-OAB (b) ICIQ FLUTS (c) ICIQ-VS. Determination of the bladder neck of urethra in midsagittal plane using a transvaginal two-dimensional ultrasound machine at lithotomy position in rest (point OA) and on Valsalva maneuver (point OB). Bladder Neck Mobility is defined as the difference from point OA to OB. BWT is determined and measured as the hypoechoic layer between two hyperechoic layers that is recognized as the urothelium and the perivesical tissue using a transvaginal two-dimensional ultrasound machine at lithotomy position. The measurement is performed with a bladder volume \<30 ml and is taken place in 3 different bladder sites: (a) the thickest part of the bladder triangle, (b) the dome of the bladder in the midline, (c) the anterior wall of the bladder. NGF will be measured in urine sample.
214684552|NCT05380414|BIOLOGICAL|Tumor samples (archival FFPE) and blood samples|Molecular screening
214684553|NCT03544671|DIETARY_SUPPLEMENT|Vitamin D|
214684554|NCT02329795|RADIATION|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
214684555|NCT02329795|DRUG|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
214684556|NCT03130101|OTHER|Change in their basal insulin rate|Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
214684557|NCT00576693|DEVICE|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl).
214684558|NCT00576693|OTHER|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl)
214684559|NCT00073593|DRUG|Bivalirudin|250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) \>300 seconds (s).
214684560|NCT00073593|DRUG|Heparin|: Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of \>300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
214684561|NCT00073593|DRUG|Protamine|Per institutional practice. Batches from hospital stock.
214684562|NCT00812071|BIOLOGICAL|RiVax|vaccine
214373946|NCT07164482|BIOLOGICAL|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive allogenic HB-adMSCs through intravenous infusion only, with a treatment duration of 16 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1, infusion 2 and infusion 3, and 4 weeks between the remaining infusions.
214684563|NCT02596347|PROCEDURE|Blood draw|We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
214684564|NCT02596347|PROCEDURE|bronchoscopy|CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
214684565|NCT00003667|DRUG|cyclophosphamide|
214684566|NCT00003667|DRUG|dexrazoxane hydrochloride|
214684567|NCT00003667|DRUG|disaccharide tripeptide glycerol dipalmitoyl|
214684568|NCT00003667|DRUG|doxorubicin hydrochloride|
214684569|NCT00003667|DRUG|vincristine sulfate|
214684570|NCT00003667|PROCEDURE|surgical procedure|
214684571|NCT00003667|RADIATION|radiation therapy|
214684572|NCT04291417|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
214373951|NCT07166328|DEVICE|BACKSCNR , measure the deviations of frontal and axial back asymmetry in AIS|BACKSCNR is a non-invasive surface topography device designed to assess spinal deformities, particularly scoliosis. It uses optical scanning technology to capture the three-dimensional shape of the back without radiation exposure.
214373952|NCT07165834|BEHAVIORAL|"Treatment group. Take your sexuality back"|The intervention is trauma-sensitive and focus both on traumatized sexuality and positive sexuality. It incorporates regulatory skills to prevent re-traumatization when addressing sex-positive themes, thus accommodating a wide range of trauma-related symptoms, sexual shame, sexual dysfunctions, and regulation difficulties. The intervention integrates psychoeducation, exercises, reflections and sharing.
214684573|NCT04045249|DIETARY_SUPPLEMENT|Home based food|Home based food is compare able to RUTF
214684574|NCT05305638|OTHER|Exercise|Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.
214373953|NCT07166419|BIOLOGICAL|Autologous Anti-CD19/CD20/CD22 CAR T-cells|Given IV
214373954|NCT07166419|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214373955|NCT07166419|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214373956|NCT07166419|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214373957|NCT07166419|PROCEDURE|Computed Tomography|Undergo PET/CT
214373958|NCT07166419|DRUG|Cyclophosphamide|Given IV
214373959|NCT07166419|PROCEDURE|Echocardiography Test|Undergo echocardiography
214373960|NCT07166419|DRUG|Fludarabine|Given IV
214373961|NCT07166419|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214373962|NCT07166419|PROCEDURE|Pheresis|Undergo apheresis
214373963|NCT07166419|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214373964|NCT07165873|PROCEDURE|Erector Spinae Plane Block|30 mL of 0.25% bupivacaine was injected deep to the erector spinae muscle.
214373965|NCT07165873|PROCEDURE|Serratus anterior plane block (SAP)|10 mL was injected into the superficial plane and 20 mL into the deep plane, for a total of 30 mL of 0.25% bupivacaine.
214373966|NCT07165873|PROCEDURE|Serratus posterior superior intercostal plane block|30 mL of 0.25% bupivacaine was injected into the plane between the serratus posterior superior muscle and the rib.
214373967|NCT07164326|DRUG|Dexmedetomidine|Nebulization of dexmedetomidine
214373968|NCT07164326|DRUG|Saline|Nebulization of normal saline
214373969|NCT07164833|DRUG|BX-001N Experimental group 1|Each participant will receive BX-001N at a weight-based low dose via IV injection once daily for a total of three administrations.
214373970|NCT07164833|DRUG|BX-001N Experimental group 2|Each participant will receive BX-001N at a weight-based high dose via IV injection once daily at the same time during hospitalization, for a total of three administrations.
214495445|NCT06950580|OTHER|abdominal massage|In addition to routine physiotherapy, abdominal massage will be applied by the physiotherapist. The patient is positioned supine. The abdominal muscles are stroked three times, followed by colon stroking performed three times, and colon kneading performed three times. The massage is concluded by repeating the colon and abdominal stroking techniques in the same manner. Patients hospitalized in the intensive care unit will routinely receive abdominal massage twice daily by the physiotherapist
214373971|NCT07164833|DRUG|Placebo|Each participant will receive Placebo at a weight-based dose via IV injection once daily at the same time during hospitalization, for a total of three administrations.
214373972|NCT07164794|DRUG|Memantine Hydrochloride|"Memantine Hydrochloride is administered orally, once daily, in combination with the patient's ongoing standard of care treatment for metastatic castration-resistant prostate cancer (mCRPC).~The dosing follows a weekly titration schedule for the first three weeks to reach the maintenance dose.~Week 1: 5 mg once daily. Week 2: 10 mg once daily. Week 3: 15 mg once daily. Week 4 and onwards: 20 mg once daily. This intervention is being studied to evaluate its potential to reduce neuroendocrine differentiation and correct castration resistance in advanced prostate cancer."
214373973|NCT07165912|BEHAVIORAL|Health Education Program|An informative leaflet will promote a healthy lifestyle with WHO guidelines to reduce cognitive decline, recommending a balanced diet, physical activity, social engagement, cognitive games, good sleep, stress management, hydration, and avoiding smoking and excessive alcohol.
214373974|NCT07165912|BEHAVIORAL|Individual Cognitive Training Program|The cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
214373975|NCT07165912|BEHAVIORAL|Group training program|The group cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
214373976|NCT07165847|DRUG|Iparomlimab and Tuvonralimab|q3w Iparomlimab and Tuvonralimab 5mg/kg on day 1 of each cycle
214373977|NCT07165847|DRUG|Oxaliplatin|130mg/m2 on day 1 of each cycle
214373978|NCT07165847|DRUG|Tegafur|\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid
214373979|NCT07165847|RADIATION|Radiotherapy|30 Gy/10 fractions
214373980|NCT07164274|OTHER|Questionnaire|An online questionnaire that will be shared via online platforms for medical students and interns in the Middle East countries to fill.
214373981|NCT07166432|OTHER|observational diagnostic model development|observational diagnostic model development
214495446|NCT02631733|DRUG|Ferumoxytol|Given IV
214495447|NCT02631733|DRUG|Irinotecan Sucrosofate|Given IV
214495448|NCT02631733|OTHER|Laboratory Biomarker Analysis|Correlative studies
214495449|NCT02631733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214495450|NCT02631733|DRUG|Veliparib|Given PO
214495451|NCT06124820|DEVICE|Deka SmartXide Touch C60 (MonaLisa Touch)|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)
214373982|NCT07164599|BEHAVIORAL|strength training|A 12-week strength training program designed for college dancesport athletes. Training is performed three times per week, 60 minutes per session, in addition to participants' regular dancesport training. Exercises include multi-joint resistance movements (e.g., squats, lunges, deadlifts, jumps) following NSCA guidelines with progressive overload based on 1RM. After the 12-week intervention, participants continue with an 8-week detraining phase without supplemental strength sessions and dance training.
214373983|NCT07165249|BEHAVIORAL|Positional release technique (PRT)|Group A (PRT): Patients lay prone for the application of the hot pack. PRT was then applied to the erector spinae muscles. The therapist identified tender points and passively positioned the patient into a position of comfort, typically involving lateral trunk flexion toward the symptomatic side. Each session involved three 90-second holds per tender point. PRT procedures followed standardized positioning principles as described in previous literature.
214373984|NCT07165249|BEHAVIORAL|Muscle energy technique|Group B (MET): Following the hot pack application, patients were assessed for segmental dysfunction via palpation of lumbar transverse processes in prone position. MET was applied using isometric contractions aimed at correcting lumbar rotational or side-bending dysfunctions. Each contraction was held for 7-10 seconds, followed by a passive stretch. The technique was repeated for 3-5 cycles per session.
214373985|NCT07165821|BEHAVIORAL|Interpersonal Communication Skills Training Program|This program was developed based on DeVito's communication theory and integrated with the positive reinforcement-based interpersonal communication training developed by Thiengwiriyakul et al.(11) This program was evaluated by a panel of three experts-a psychiatrist, a psychiatric nurse, and a psychiatric nursing academic-who assessed content relevance, appropriateness, and language clarity. After revisions based on their feedback, the program achieved a Content Validity Index (CVI) of 0.93, exceeding the acceptable threshold.
214373986|NCT07165821|BEHAVIORAL|Usual care|Received routine psychiatric nursing care
214373987|NCT07166887|DRUG|Tolvaptan|One dose on the first day and one dose on days 3-9, for a total of eight doses.
214373988|NCT07164963|OTHER|upper cervical translatoric mobilisation|(UC-TSM) is defined as a system of manual techniques using straight-line forces delivered in a parallel or perpendicular direction to an individual vertebral joint or motion segment there is also increasing in body of evidence supporting the its clinical effectiveness and safety in the management of patients with cervical impairments.
214373989|NCT07164963|OTHER|sub occipital muscle energy technique|Muscle Energy Technique (MET) is another form of a gentle manual therapy intervention that primarily targets the soft tissues, though it also contributes significantly to joint mobilization. It has been reported that, adding MET to exercise program resulted in better improvement in CVA and FHP than exercise group only
214373990|NCT07164963|OTHER|traditional physical therapy|hot pack and kendel exercise
214373991|NCT07164209|PROCEDURE|"Excision of the mesentery: the mesentery is fully dissected and excised to the limit of macroscopic fat wrapping, where mesenteric fat is inflamed and extends beyond its normal anatomical distribut"|The resection of mesentery could take off the inflammatory tissue who may increase the risk of anastomotic recurrence The Kono anastomosis achieves a column of support (made with the bowel ) located immediately behind the posterior wall of the anastomosis providing a rigid and stable support to prevent mechanical deformation and functional constriction of the lumen of the anastomosis being a barrier between anastomosis and mesentery
214373992|NCT07164209|PROCEDURE|Kono S Anastomosis|ono-S anastomosis: the mesentery is not removed but cutted close to the bowel. The bowel is then divided transversely by placing a linear stapler perpendicular to the intestinal lumen and the mesentery. The corners of the two staple lines are reinforced and the two stumps are approximated using 5-7 sutures to create the column. If the caliber of the two intestinal segments differs significantly, the sutures should be spaced to evenly distribute the surplus tissue of the larger segment, in order to achieve good approximation and stable support for the anastomosis. To create the anastomosis, an antimesenteric longitudinal enterotomy (or colostomy) is performed on each stump to allow a transverse lumen of 7 cm in diameter for the small bowel or closer to 8 cm for the colon. In this way the supporting column is located immediately behind the posterior wall of the anastomosis providing a rigid and stable support to prevent mechanical deformation and functional constriction of the lum
214684575|NCT02805868|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214684576|NCT02805868|OTHER|Laboratory Biomarker Analysis|Correlative studies
214684577|NCT02805868|BIOLOGICAL|Siltuximab|Given IV
214684578|NCT04438746|BEHAVIORAL|Emotion discussion|General discussion of emotions; no therapy or training is offered
214684579|NCT04438746|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger
214684580|NCT00398619|DRUG|INCB13739|
214684581|NCT00059436|BEHAVIORAL|Mental effort in muscle strengthening|
214684582|NCT01570985|DRUG|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
214684583|NCT01570985|DRUG|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
214684584|NCT00921856|OTHER|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
214684585|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension|topical suspension
214684586|NCT00804193|DRUG|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
214987043|NCT05207358|DRUG|Cyclophosphamide|All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.
214987044|NCT05207358|DRUG|Corticosteroids|3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment.
214987045|NCT04571593|BEHAVIORAL|Yoga Nidra|The practice of Yoga Nidra, is a scripted and reproducible, guided meditation technique that promotes mental, emotional and physical relaxation while also facilitating the transition between waking and sleeping.
215089766|NCT04284813|BEHAVIORAL|CRAFT-FT|CRAFT-FT will be delivered via telemedicine. Topics include building motivation, self-care, communication, understanding patterns of behavior, positive reinforcement, and negative consequences. The intervention will be tailored to families of individuals experiencing psychosis and substance use who are enrolled in first episode psychosis outpatient services. Participants will be asked to completed assessments at pre-treatment, mid-treatment (approximately week 3), post-treatment, and a follow-up assessment approximately 3 month post-treatment.
215089767|NCT07035405|DRUG|Colchicine 0.5 mg|Oral colchicine will be initiated with a dose of 0.5 mg per day.
214373993|NCT07166497|OTHER|Cosmetic product RV4660C CY0203|The product was applied once a day, in the evening, on the whole body/ off face on previously cleansed skin. The product was warmed in the hands before being applied in wide movements.
214373994|NCT07164469|DRUG|Fludarabine|Given by IV
214373995|NCT07164469|DRUG|Cyclophosphamide|Given by IV
214373996|NCT07164469|DRUG|CD70.CAR NK Cells|Given by IV Infusion
214373997|NCT07164469|DRUG|Rimiducid (AP1903)|Given by IV Infusion
214373998|NCT07166107|OTHER|EVOLV-Rx dashboard|Using the TheraDoc® platform, the investigators will deploy a custom-designed EVOLV-Rx dashboard that incorporates all 18 components of the EVOLV-Rx metric. \[Within TheraDoc®, the dashboard will display an automated report in the form of a patient list that includes the names, locations, and specific LVP practices to which Veterans under their care are subject. Pharmacists will then query specific patients on the list as part of their required medication review. The dashboard will provide detailed clinical decision support by identifying the specific EVOLV-Rx LVP criteria met by each flagged medication and provide access to the patient's full medication list, problem list, and laboratory or testing data contained within VISTA.\] Pharmacists may use the EVOLV-Rx dashboard to track Veterans' receipt of LVP practices and quickly document actions related to the intervention, such as patient and family caregiver engagement, deprescribing LVP practices, or any other medications discontinued.
214373999|NCT07166068|OTHER|Manual Therapy (Mobilization with Movement)|A continuous glide to the tibia will be a combined simultaneously by whether medial, lateral, anterior, posterior, or rotational-during active knee flexion and extension repeated movement as applied by Mulligan.
214374000|NCT07166068|OTHER|Exercise|standard care (exercise program to strengthen the musculature of the knee)
214495452|NCT06124820|DEVICE|Sham|Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
214374001|NCT07166068|OTHER|sham mobilization|The therapist will simulate MWM by performing slight external rotation of the skin only. This mimics the tactile sensation of true MWM without affecting the underlying joint mechanics.
214374002|NCT07166692|OTHER|Prof. Valmed|Prof Valmed. decision support system.
214374003|NCT07164287|DRUG|Lysergic Acid Diethylamide (LSD) or psilocybin|Psychedelic-assisted psychotherapy with LSD or psilocybin as a part of a clinical routine in our department
214374004|NCT07165353|BEHAVIORAL|Virtual Walking|This virtual walking therapy uses a life-sized video avatar of the participant walking through a forest environment. A green screen setup combines a live video of the participant's upper body with pre-recorded walking legs, creating a full-body walking illusion. The participant is seated in a modified wheelchair that tilts 2° to each side to mimic pelvic movement during walking. This approach differs from the sham condition (Group 2), which displays only the moving forest without an avatar or wheelchair tilt, and from the standard care group (Group 3), which receives no virtual walking therapy.
214374005|NCT07165353|BEHAVIORAL|Sham Virtual Walking|Participants view a moving forest environment on a large projection screen for 10 sessions over 2 weeks (each up to 20 minutes). No avatar of the participant is displayed, and the wheelchair tilt function is disabled. This differs from the experimental intervention (Group 1), which includes a life-sized walking avatar and wheelchair tilt to mimic pelvic movement, and from the standard care group (Group 3), which receives no virtual walking therapy.
214374006|NCT07166705|OTHER|Metaverse-Based Education Group|"As part of this intervention, participants will receive palpation skills training in a metaverse-based virtual learning environment. The training consists of three modules, each of which will cover the palpation of a different anatomical region:~* Module 1: Cervical region palpation~* Module 2: Thoracic region palpation~* Module 3: Lumbo-pelvic region palpation The training will be delivered in a three-dimensional virtual classroom environment using avatars. Participants will engage in interactive exercises based on scenarios structured on the metaverse platform and, under the guidance of an instructor, will practice palpation techniques on virtual patient models.~Sessions will be conducted in a group format, allowing students to interact with each other in real-time. Voice communication, motion tracking, and virtual feedback mechanisms will be used throughout the training."
214495453|NCT05628207|OTHER|Observational|There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
214495454|NCT05628207|OTHER|Observational-control|There is no intervention, the hospitals will not use the CDS system.
214495455|NCT05831254|OTHER|Health education:Interactive group training|"1. To introduce e-pulse software, which is a personal health record system, to show its use, to provide training materials such as video-brochures about e-pulse. This program will be done as interactive group training~2. Six modular interactive group training, each of which includes the steps of the European Health Literacy Scale of 90 minutes."
214495456|NCT05831254|OTHER|Health education: Individually training|To introduce e-pulse software, which is a personal health record system, to provide training materials such as video-brochures about e-pulse. This education will be done individually.
214495457|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40\& of the contralateral MVIC.
214495458|NCT03626857|OTHER|Eccentric Exercise (ECC)|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum
214495459|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES) placebo|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.
215089768|NCT07035405|DRUG|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.
214374007|NCT07166705|OTHER|Distance/Online Education Group|"As part of this intervention, a palpation skills course will be delivered to participants online via the Microsoft Teams application. The training consists of three modules, each of which will cover the palpation of different anatomical regions.~Module 1: Cervical region palpation Module 2: Thoracic region palpation Module 3: Lumbo-pelvic region palpation The training will utilize theoretical information, visual materials, and live/pre-recorded practice videos. Participants will attend the course as a group and participate in structured learning sessions guided by the instructor in each module."
214495460|NCT03626857|OTHER|Eccentric Exercise (ECC) placebo|4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
214495461|NCT06817408|OTHER|Observation|One additional blood draw in the Emergency Department as part of their standard of care visit.
214495462|NCT05737108|DIETARY_SUPPLEMENT|Bilberry capsule product|A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
214495463|NCT05737108|DIETARY_SUPPLEMENT|Placebo(starch)|30 days of placebo or Bilberry capsule product with crossover to the other.
214495464|NCT05879068|DRUG|PM8002|IV infusion
214495465|NCT05879068|DRUG|Paclitaxel|IV infusion
214495466|NCT05820711|DRUG|MSC|"Injection of MSCs into submandibular glands at pre-specified dose level:~* Dose -1: 5 (4 - 6) x10\^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml)~* Dose 0: 10 (8 - 12) x10\^6 MSCs per gland (1 ml)~* Dose 1: 20 (16 - 24) x10\^6 MSCs per gland (2 ml)"
214684587|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
214684588|NCT00206115|DRUG|Seroquel Sustained Release (SR)|
214987046|NCT01107015|DEVICE|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
214684589|NCT00206115|DRUG|Seroquel Immediate Release (IR)|
214684590|NCT00206115|DRUG|Placebo|
214684591|NCT02352051|DRUG|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
215089769|NCT07042061|DEVICE|Mobile external automated defibrillator|A single-use, hand-held, chocolate bar sized portable AED
214684592|NCT02352051|DRUG|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
214684593|NCT05784909|DEVICE|rezum|"Technique With the patient in a lithotomy position, after cystoscopy, an RF current is applied to. Water vapour is delivered through a retractable vapor needle via emitter holes in the transurethral device. This is done in 9-second bursts to the transition zone of the prostate, where, via convection, it diffuses evenly throughout the target tissue. The depth of the needle penetrating is approximately 10 mm.~Upon contact with body-temperature tissue, the water vapour then condenses. This phase shift to a liquid state dispenses concentrated energy onto the cell membranes of the target tissue, triggering instant cell necrosis. Overlapping injection sites can be established with repeated applications in order to fully target areas of hypertrophy. Saline flush irrigation is used to both cool the urethra and to promote visualization.~At the end of the procedure Urethral catheter is fixed for 1-3 days."
214684594|NCT00757562|DRUG|desloratadine|desloratadine syrup: 1.25 mg (2.5 mL) for subjects \>=2 to \<6 years, 2.5 mg (5 mL) for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
214684595|NCT00757562|DRUG|Placebo|placebo syrup: 2.5 mL for subjects \>=2 to \<6 years, 5 mL for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
214684596|NCT01617434|DRUG|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
214684597|NCT01617434|DRUG|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
214684598|NCT01987986|BIOLOGICAL|Collagenase Clostridium Histolyticum|injectible intervention
214684599|NCT01987986|BIOLOGICAL|Placebo|
214684600|NCT00705224|BIOLOGICAL|Pegylated Interferon|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
214684601|NCT00705224|DRUG|Ribavirin|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
214684602|NCT03283163|BEHAVIORAL|Exercise Testing and Training|The study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
214684603|NCT00659919|DRUG|Placebo|
214684604|NCT00659919|DRUG|Trazodone|
214987047|NCT01107015|DEVICE|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
214684605|NCT05774912|OTHER|Ultrasound evaluation|Fetal ultrasound evaluation will be collected longitudinally during the prenatal period from the weeks 14 every 4-5 weeks, for a total of maximum 6 ultrasound scans
214684606|NCT03881917|DIAGNOSTIC_TEST|Cystatin c and beta 2 microglobulin kits|Kits for measurement concentration
214684607|NCT06671847|DEVICE|THERABand resistance exercise bands|The training will be performed using THERABand resistance exercise bands.Participants will be instructed to perform the exercises twice per week at home, for the 24 weeks duration. Each exercise session will entail 1 set of 15 repetitions of 9 different exercises
214684608|NCT06672562|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy|NECT-Y consists of 14 90-minute sessions over the course of 14 weeks. The intervention combines psychoeducation, cognitive therapy, narrative therapy, goal-setting and peer support. Each group meeting includes educational materials, reflections, and active exercises that participants are guided through to personalize the content to their experiences. Participants will be provided with a workbook which allows them to follow the activities easier.
215089770|NCT06887387|DEVICE|Wearable device|This is an observational study that does not impact routine clinical care for participants
215089771|NCT07042074|BEHAVIORAL|Augmented Reality (AR) / Virtual reality (VR) Exposure Therapy + Cognitive Behavioral Therapy (CBT) Exposure Therapy|AR/VR (Apple Vision Pro or Meta Quest 3) will be used together with Cognitive Behavioral Therapy (CBT) Exposure Therapy
214374008|NCT07166705|OTHER|Traditional Face-to-Face Education Group|"As part of this intervention, participants will be taught palpation skills in a face-to-face classroom setting using traditional teaching methods. The training consists of three modules:~Module 1: Palpation of the cervical region Module 2: Thoracic region palpation Module 3: Lumbo-pelvic region palpation Throughout the training, the instructor will conduct structured theoretical presentations, demonstrations, and face-to-face practice sessions. Students will observe palpation techniques through live demonstrations by the instructor and then have the opportunity to practice one-on-one."
214374009|NCT07166354|DRUG|CS-002|CS-002 Topical Treatment
214684609|NCT06672562|OTHER|Usual care|Standard usual care. No study-specific care, but participants will be provided with information on community resources and support, and will also be encouraged to speak to their clinician if they are interested in learning about other services.
214684610|NCT04372329|BEHAVIORAL|CPAP4HealthySleep system|Tailored multimedia messages and tailored feedback messages delivered via web-based system to participants' phones to motivate them to use their CPAP therapy
214684611|NCT06672835|BEHAVIORAL|eBASIS|eBASIS is an online, optimized, and evidence-based practice agnostic implementation strategy that addresses the behavioral component often missing from standard evidence-based practice training and consultation. It relates to motivation before and volition after the evidence-based practice training and targets behavioral intentions by improving attitudes, subjective norms, and self-efficacy. The implementation strategy is designed to be designed to be delivered within the Preparation/Adoption phase immediately prior to the Action implementation in the EPIS model.
214684612|NCT06672835|BEHAVIORAL|eAttention Control|eAC is an online control for eBASIS. Providers assigned to eAttention Control (eAC) will receive pre- and post-training experiences designed to mirror those received in eBASIS. These training experiences will be delivered on the same platform and be approximately the same length as the eBASIS but will not contain any eBASIS content or mechanisms of change. The eAC pre-training experience will define, describe, and advocate for evidence-based practice implementation in schools. Content in eAC will be didactic similar to a typical professional development training for providers.
214684613|NCT00038259|DRUG|Aldesleukin|
214684614|NCT01686022|OTHER|Immunoblot|serum specific IgE binds to grass extract by immunoblot
214684615|NCT00231920|BIOLOGICAL|Fluzone|
214684616|NCT06671743|PROCEDURE|Root canal treatment|"History of presenting illness will be recorded and vitality testing will be done in addition to pre-operative radiograph.~Patient will read and sign the consent form. Pre-operative pain score will be recorded using visual analogue scale. The patient will take the preoperative medication 1 hour prior to the procedure.~The patient will receive 1 cartridge of LA with inferior alveolar nerve block (2% lidocaine 1:80000) and a rubber dam will be used for isolation.~Access cavity will be prepared and working length will be determined. Cleaning and shaping of the root canal system will be performed followed by obturation using a standardized protocol followed by final coronal restoration.~Postoperative pain score will be recorded at the 6, 12, 24, and 48 hours using visual analogue pain scale."
214684617|NCT00000650|DRUG|Ditiocarb sodium|
214684618|NCT06671418|PROCEDURE|Primary percutaneous stenting (PPS)|PPS bridging malignant hilar biliary obstruction with self-expandable uncovered metal stents without crossing the ampulla and without leaving an external drain. The procedure is performed by an interventional radiologist who has performed at least 5 PPS procedures.
214684619|NCT06671418|PROCEDURE|Endoscopic biliary drainage|EBD according to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines of 2021. The procedure is performed by a gastro-enterologist who is experienced in performing EBD in patients with a MHBO.
214684620|NCT06672770|OTHER|Functional Inspiratory Muscle Training|"The functional inspiratory muscle training group will perform basic inspiratory muscle training in the first four weeks of the study and the following exercises with the Powerbreath device in muscle training in the following four weeks:~1. Diaphragmatic breathing exercises~2. Warm-up exercises~3. Trunk strength and lumbopelvic stability exercises~4. Dynamic trunk exercises~5. Postural control exercises~6. Cool-down exercises"
214374010|NCT07166354|DRUG|Placebo Topical Solution|Placebo Topical Solution
214374011|NCT07164456|OTHER|Education sessions|Remote and In person sessions
214374012|NCT07164456|OTHER|Questionnaire|Questionnaires given a 3,6,12 mouth follow ups
214684621|NCT06672770|OTHER|Basic Inspiratory Muscle Training|The basic inspiratory muscle training group will do muscle training with the POWERbreathe device for eight weeks.
214684622|NCT00387387|DRUG|Pazopanib|Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases
214684623|NCT00387387|DRUG|FOLFOX 6|FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2), IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours on Day 1 of every 14-day cycle.
214684624|NCT00387387|DRUG|CapeOx|CapeOx treatment consists of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m\^2 twice daily.
214684625|NCT00787696|BEHAVIORAL|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
214684626|NCT04833985|PROCEDURE|LAAC combined with radiofrequency ablation|Each patient received the same group of patients with simple radiofrequency ablation and LAAC
214684627|NCT02756715|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation.
214684628|NCT02756715|DRUG|Desflurane group|Patient will be anesthetized by using desflurane inhalation during operation.
214684629|NCT04238663|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
214684630|NCT04238663|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
214684631|NCT04238663|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
214684632|NCT06000722|OTHER|eDelphi method|This is a Delphi technique-based study using a purposive sample of convenience. Consensus development methods will be used to generate clinical guidelines, endorsed by key clinical groups, on the use of SGLT2i's in patients with diabetic foot ulcer disease, including acknowledgement of specific scenarios or patient characteristics that may influence these guidelines.
214684633|NCT02510729|DEVICE|Neurostimulation|
214374013|NCT07165223|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
214684634|NCT02510729|DEVICE|Sham stimulation|
214684635|NCT04388280|DIAGNOSTIC_TEST|Echocardiography|Functional assessment of coronary artery disease
214684636|NCT04388280|DIAGNOSTIC_TEST|CT angiography|Anatomical assessment of coronary artery disease
215089772|NCT07042074|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Exposure Therapy|Participant will experience the traditional CBT exposure therapy only
215089773|NCT07040878|BEHAVIORAL|Antigravity Treadmill Training|Antigravity treadmill training uses air pressure to reduce effective body weight during walking, minimizing joint load while preserving gait mechanics. The 6-week intervention includes five sessions per week within a 120-minute daily kinesitherapy program. Treadmill speed is individualized at baseline and increased by 0.5 km/h every two weeks. Unloading is progressively reduced: 60% support in weeks 1-2, 40% in weeks 3-4, and 20% in weeks 5-6, allowing gradual adaptation to full weight-bearing.
215089774|NCT07040878|BEHAVIORAL|Body Weight-Supported Treadmill Training|Body weight-supported treadmill training uses a harness-based system to partially offload body weight, promoting safe ambulation and gait normalization in early postoperative rehabilitation. The 6-week intervention includes five sessions per week within the 120-minute daily kinesitherapy program. Treadmill speed is individualized at baseline and increased by 0.5 km/h every two weeks, depending on tolerance. The unloading level remains constant and is individually adjusted to ensure safety.
215089775|NCT07040878|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilitation follows standard postoperative protocols after hip or knee arthroplasty. The 6-week program includes five weekly sessions. Gait training is conducted in hospital corridors under physiotherapist supervision, using assistive devices as needed (crutches, walkers). Daily therapy includes 120 minutes of kinesiotherapy (general exercises and gait training), 30 minutes of ergotherapy to improve functional independence, and three individualized physical therapy procedures (laser therapy, magnetic therapy, or electrotherapy) tailored to patient needs.
215089776|NCT07042178|OTHER|Meditation video at the beach|A virtual reality video consisting of a 5 minute meditation video at te beach.
214374014|NCT07165223|DRUG|Insulin Icodec group|insulin Icodec s.c., once-weekly，treat-to-target dose
214374015|NCT07165678|DIAGNOSTIC_TEST|CTCA|Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
214374016|NCT07166809|OTHER|Pelvic Floor Muscle Training (PFMT)|A structured pelvic floor muscle training program delivered remotely for 8 weeks, including exercises designed to strengthen and improve the endurance, coordination, and control of the pelvic floor muscles.
214374017|NCT07166809|OTHER|Pelvic Floor Muscle Training combined with Dynamic Neuromuscular Stabilization (PFMT+DNS)|Participants received the same 8-week remotely monitored pelvic floor muscle training program as the PFMT group, in addition to supervised Dynamic Neuromuscular Stabilization exercises three times per week. DNS exercises aimed to enhance core stability, postural control, and coordination to support pelvic floor muscle function.
214374018|NCT07164976|DRUG|Ribociclib 400mg|phase 1b cohort 1
214374019|NCT07164976|DRUG|Ribociclib 600mg|Phase 1b cohort 2
214374020|NCT07164976|DRUG|Ribociclib 600mg|phase 2
214374021|NCT07164547|DIETARY_SUPPLEMENT|Tribulus terrestris extract|625 mg oral capsule (40% saponins), single dose
214374022|NCT07164547|OTHER|Cellulose capsule (placebo)|Oral cellulose capsule, identical in appearance
214374023|NCT07165470|DIETARY_SUPPLEMENT|pre-packaged low-residue diet for bowel preparation|Participants will be provided with 6 sachets of pre-packaged low-residue diet one day prior to colonoscopy
214374024|NCT07165392|OTHER|Neuromodulation|The application of neuromodulation therapy will be carried out with the support of ultrasound visualization on the anatomical area of the target nerve, seeking a motor and/or sensory response with its stimulation.
214374025|NCT07165392|OTHER|Physical Exercise|The therapeutic physical exercise will consist of 3 periods of isometric contraction of 30 seconds, with a rest period of 1 minute, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
214374026|NCT07165392|OTHER|Stretching|To stretch the muscles involved, 3 periods of maximum tolerable stretching without pain will be performed, lasting 20 seconds and resting for 30 seconds.
214684637|NCT04356755|DRUG|AdMSC|At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks
214684638|NCT04356755|DRUG|Placebo|At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
214684639|NCT01833273|DRUG|PolyMVA|Subjects will take 8 tsp/day of PolyMVA over a 26 week period while receiving standard of care from his/her neuro-oncologist. Subjects will begin taking the study compound after maximal surgical resection of the tumor and receiving an initial treatment of radiation therapy. Subjects will not take study compound on days when they receive chemotherapy.
214987048|NCT01107015|DEVICE|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
214684640|NCT05998993|RADIATION|Stereotactic Body Radiation Therapy SBRT|This is a non-randomized Phase II study in which all patients receive the experimental treatment with Stereotactic Ablative Radiotherapy (SABR) to residual tumor lesions (up to 5 residual metastatic lesions in a maximum of 2 organs) following 12 weeks of systemic treatment with Osimertinib. The study aims to enroll 35 patients diagnosed and treated at CTIC Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo.
214684641|NCT05057585|BEHAVIORAL|Turning in bed, arm and leg exercises|Exercises (arm and leg exercises, turning in bed) were applied only to the experimental group. It was applied for 15 minutes 12-24 hours before the operation.
214684642|NCT04039685|OTHER|Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
214684643|NCT04039685|OTHER|Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
214684644|NCT04039685|OTHER|Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
214987049|NCT01608594|DRUG|administration of ipilimumab10mg/kg|"Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
214987050|NCT01608594|DRUG|administration of ipilimumab 3mg/kg + HDI|"Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
214684645|NCT03596177|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
214684646|NCT03596177|DRUG|Placebo|Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
214684647|NCT02177851|DIETARY_SUPPLEMENT|Single oral iron dose of 120 mg per day for 3 consecutive days|
214684648|NCT02177851|DIETARY_SUPPLEMENT|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days|
215089777|NCT07042178|OTHER|Rollercoaster video|A virtual reality video consisting of a five minute rollercoaster ride.
214684649|NCT03569111|DEVICE|Bronchoscopic ablation catheter|The Emprint™ Ablation Catheter Kit with Thermosphere™ Technology is deployed endoscopically and will be used to conduct bronchoscopic ablations in the lung using the superDimension™ navigation system.
214684650|NCT00968253|DRUG|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
214684651|NCT00968253|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
214684652|NCT00968253|DRUG|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
214684653|NCT00968253|DRUG|Doxorubicin|50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
214374027|NCT07166848|DEVICE|Electrodes with Currents|Electrodes will be placed on the cheeks and forehead, and treated with an amplitude of 300 µA for 30 mins
214987051|NCT05598970|OTHER|Digital application supported CHW Parenting Intervention|"All pregnant women served by the trained CHW will be invited to participate in the Parenting program, from when the mother is at least 20 weeks pregnant and less than 32 weeks pregnant with the target child for a period of 15 months. CHWs will visit pregnant women at least 3 times during their pregnancy and at least 16 times following delivery. In addition to the individual home visits, the CHWs will organise bi-weekly in-community group sessions for children aged 6-12 months and their primary caregivers, focusing on caregiver-child interaction and stimulation activities.~The immediate supervisors Health Care Workers (HCWs) of the CHWs will be trained to closely monitor CHWs activities and progress made. HCWs and CHWs will in turn be supervised and supported by district level Council Health Management Team (CHMT).~Parenting services will be provided to all target children of these eligible caregivers, irrespective of their learning or physical abilities."
214684654|NCT00968253|DRUG|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
214684655|NCT00968253|DRUG|Mesna|600 mg/m\^2 IV continuous infusion daily for 24 hours days 1-3.
214684656|NCT00968253|DRUG|Methotrexate|200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.
214684657|NCT00968253|DRUG|Ara-C (Cytarabine)|3 gm/m\^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
214374028|NCT07166848|DEVICE|Electrodes without Currents|Electrodes will be placed on the cheeks and forehead, and treated with an no amplitude for 30 mins
214374029|NCT07164560|BIOLOGICAL|Anti-TRBC1 CAR-T cells|lentiviral vector-transducted peripheral blood-derived T cells to express anti-TRBC1 CAR
214374030|NCT07164898|DEVICE|Test patches|Patches (incontinence product cut outs) either dry, 50% saturated with water or 100% saturated with water applied to the forearm and worn for 2 hours
214374031|NCT07166445|OTHER|None intervention|this study is retrospective based on the CT images, which dose include any intervention.
214374032|NCT07165808|OTHER|Nicotine pouch: Low dose|Nicotine pouch: 3-4 mg
214374033|NCT07165808|OTHER|Nicotine pouch: High dose|Nicotine pouch: 6-8 mg
214374034|NCT07165808|OTHER|Low pH|Nicotine pouch with low pH level \[\<8.5\]
214374035|NCT07165808|OTHER|High pH|Nicotine pouch with high pH level \[\>8.5\]
214684658|NCT00968253|DRUG|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
214374036|NCT07165769|DRUG|Induction Therapy|"All enrolled patients will receive the ZGR regimen (zanubrutinib, obinutuzumab, and lenalidomide) for induction therapy. Each cycle lasts 28 days, up to 6 cycles, followed by maintenance therapy. Patients experiencing disease progression during induction will discontinue the trial drugs but remain under survival follow-up.~1. Zanubrutinib: 160 mg twice daily, administered orally continuously.~2. Obinutuzumab: 1000 mg via intravenous infusion, administered on Days 1, 8, and 15 of Cycle 1 and subsequently on Day 1 of Cycles 2-6.~3. Lenalidomide: 25 mg once daily, taken orally on Days 1-21 of each 28-day cycle until disease progression. Doses should be taken at approximately the same time daily."
214374037|NCT07165769|DRUG|Maintenance Therapy|"Maintenance therapy consists of zanubrutinib plus lenalidomide:~Lenalidomide is continued for 1 year. Zanubrutinib is continued for 2 years. Treatment continues until disease progression, intolerability, or completion of 2 years. For patients who do not achieve complete remission (CR), therapy may continue until progression or intolerability.~1. Zanubrutinib: 160 mg twice daily, administered orally continuously.~2. Lenalidomide: 10 mg once daily, taken orally on Days 1-21, followed by a 7-day rest period, constituting a 28-day cycle."
214374038|NCT07164222|DIAGNOSTIC_TEST|Glycated haemoglobin and triglycerides level|Follow up with triglycerides and glucose index and ratio on diabetic type 2
214374039|NCT07165418|DRUG|Vorolanib Tablets+Everolimus|Subjects received oral vorinib 200 mg once daily (QD) plus everolimus 5 mg once daily (QD), administered within 30 minutes after breakfast daily. Treatment cycles lasted 28 days and continued until disease progression.
214374040|NCT07165418|DRUG|Sunitinib|Subjects received oral sunitinib 50 mg once daily (QD) in a 4-week on, 2-week off regimen or a 2-week on, 1-week off regimen until disease progression.
214374041|NCT07164638|PROCEDURE|lung ultrasound (LUS)|Serial lung ultrasound will be performed to patients enrolled in this study before the beginning of the surgery, every 15 minutes in the first 30 minutes, and then every 30 minutes for the rest of the operation.lung ultrasound will be used as a tool for monitoring of EVLW to identify early the subclinical pulmonary edema and ensure timely and correct diagnosis and appropriate management.
214374042|NCT07164638|PROCEDURE|IVC collapsibility index|Serial assessment of IVC collapsibility will be used as a monitoring of volume overload in patients enrolled in this study. Basal IVC scanning using ultrasound will be performed before the start of the operation and serial IVC scanning will be done during the procedure every 15 minutes in the first 30 minutes, and then every 30 minutes for the rest of the operation.
214374043|NCT07164846|DEVICE|Therapy Sessions|You will complete up to 12 sessions using the Neuro20 suit under the direct supervision of study staff. Each session will be 1-2 hours in duration. Each session, you will change into the suit and then receive no more than 105 minutes of electrical stimulation, and then change out of the suit and have a skin check. The suit has 20 electrodes that will stimulate muscles in your upper arm (above the elbow), upper leg (above the knee), chest, abdominals, and back. Stimulation levels will be adjusted to your comfort. You will likely feel tingling and/or muscle contractions. The timing and intensity of each type of activity will depend on your individual needs and will be prescribed by the study doctor.
214374044|NCT07166575|DIAGNOSTIC_TEST|B-mode ultrasonography|Thickness and cross-sectional area of upper trapezius muscle
214374045|NCT07165886|DRUG|Sirolimus for injection (albumin bound)|Sirolimus for injection (albumin bound), ivgtt., Q2W
214374046|NCT07165886|DRUG|Octreotide long-acting injection|SC, Q2W
214374047|NCT07165886|DRUG|Everolimus|Oral, once a day
214374048|NCT07165899|BEHAVIORAL|EEG-Guided Binaural Beat Audio|30-minute audio session with dynamic frequency adjustments based on real-time EEG feedback
214374049|NCT07165899|BEHAVIORAL|Sham Control|30-minute audio session with identical tones presented to both ears (no binaural beat), EEG monitored but not used for frequency adjustment
214374050|NCT07166315|OTHER|observational study|This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.
214684659|NCT00968253|DRUG|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
214495467|NCT05036291|DRUG|NB004 tablets|"Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA ."
214684660|NCT01267097|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
214987052|NCT05598970|OTHER|Unconditional Cash Transfer only Intervention fixed amount|The fixed cost for delivering the Parenting only Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer fixed amount' treatment arm, the transfer will be 109,000 TZS (32,000 TZS + 77,000 TZS).
214684661|NCT01267097|BEHAVIORAL|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
214684662|NCT03680794|OTHER|sampling of ophthalmic liquid|aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
214684663|NCT05599126|DRUG|Mianserin|Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
214684664|NCT05599126|DRUG|Lorazepam|Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
214374051|NCT07165119|OTHER|Interdisciplinary group|For 12 weeks, the subjects in the interdisciplinary group participated in 45 minutes of clinical Pilates three times a week, as in the clinical Pilates group, and 45 minutes of nurse coaching once a week, as in the nurse coaching group.
214374052|NCT07165119|OTHER|Clinical Pilates Group|Clinical Pilates was applied by a certified physiotherapist for 12 consecutive weeks. with 45-minute sessions 3 times a week and was delivered to small groups of participants (3-5). The Pilates program has been developed in accordance with the extant literature to cultivate strength, balance, and coordination in a range of body positions, including the supine, seated, kneeling, and standing positions. Participants were instructed to perform each movement with control and precision, focusing on proper breathing patterns (exhaling during flexion, inhaling during extension) and engaging their core muscles throughout the exercise The load level and progression were determined using the Borg CR10 scale: Borg ≤ 2 = light load; Borg \> 2 - \< 5 = moderate load; Borg ≥ 5 - \< 7 = heavy load; Borg ≥ 7 = near-maximum load. During the sessions, the effort level was generally maintained at a moderate intensity (Borg 3-4). Each time the intensity of the exercise was changed, the new loa
214374053|NCT07165119|OTHER|Nurse Coaching group|Training and follow-up was carried out with nurse coaching for 12 weeks lasting 45 minutes once a week .
214684665|NCT01736202|BIOLOGICAL|fat orally|Oral ingestion of palm oil or canola oil or water at timepoint zero
214684666|NCT02731508|DEVICE|Bihemispheric transcranial direct current stimulation|5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
214684667|NCT04775797|DRUG|AB-836|Capsules or Tablets
214374054|NCT07165314|PROCEDURE|Free positioning|Participants are not given instructions on how to position for intubation using direct laryngoscopy.
214374055|NCT07165314|PROCEDURE|"Sitting cross-legged (Lotus position)"|Participants are requested to sit cross-legged for intubation using direct laryngoscopy.
214374056|NCT07165262|DRUG|Fentanyl (IV)|Fentanyl, Intravenous bolus administration at a dose of 1 microgram per kilogram of body weight administered once before spike stimulation and another time after resection of epileptic foci for spike stimulation.
214374057|NCT07165262|DRUG|Ketamine (0.5 mg/kg)|Ketamine, Intravenous bolus administration at a dose of 0.5 milligram per kilogram of body weight administered once before spike stimulation and another time after resection of epileptic foci for spike stimulation.
214684668|NCT04775797|DRUG|Placebo|Capsules of Tablets
214374058|NCT07164521|BEHAVIORAL|Music Listening (Relaxing Classical Music)|Participants listened to a standardized playlist of relaxing classical instrumental music (e.g., Mozart, Vivaldi, Debussy) for 15 minutes every hour, beginning at the 24th postpartum hour until the 48th hour. The intervention aimed to reduce postpartum anxiety and pain perception.
214684669|NCT04775797|DRUG|AB-836|Tablets
214684670|NCT04775797|DRUG|Placebo|Tablets
214684671|NCT04775797|DRUG|Nucleos(t)ide Analogue|Tablets
214684672|NCT03839147|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
214684673|NCT05052775|OTHER|Chlorhexidine Mouthwash|Patients were given chlorhexidine mouthwash 2 times per day for 15 days
214987053|NCT05598970|OTHER|Unconditional Cash Transfer Intervention|Families will receive from 5-7 months pregnancy over a period of 15 months a bi-monthly unconditional cash transfer, which equals the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under Tanzania Social Action Fund (TASAF), i.e., Tanzania's National Cash Transfer program.
214987054|NCT05598970|OTHER|Unconditional Cash Transfer only Intervention vary amount|The rationale for the levels of the varying UCT amounts is to keep them comparable with i) the bi-monthly cost of the parenting program per family, ii) the bi-monthly cash transfers disbursed under TASAF, and iii) the sum of the bi-monthly cost of the parenting program and the bi-monthly cash transfer disbursed under TASAF. The fixed cost for delivering the Parenting Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer only vary amount' group, each of the amounts vary individually (32,000 TZS; 77,000 TZS; 109,000 TZS).
214684674|NCT05052775|OTHER|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
214684675|NCT05052775|OTHER|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
214684676|NCT00110656|OTHER|Observations|This is a non-interventional study- only observational.
214374059|NCT07164534|DIETARY_SUPPLEMENT|Sodium-copper-chlorophyllin, a semi-synthetic derivative of chlorophyll, is made up of a mixture of sodium copper salts.|Oral adjuvant sodium-copper-chlorophyllin 750mg given once daily given on an empty stomach for 3 months, starting within 2 weeks of RT completion
214374060|NCT07165613|OTHER|Kinesiotape|Kinesiotape is applied
214374061|NCT07165613|OTHER|Dynamic tape|dynamic tape applied
214374062|NCT07166835|DIETARY_SUPPLEMENT|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Nootropic drink containing Anthrocyanins, L-theanie and Enzogenol
214374063|NCT07166835|DIETARY_SUPPLEMENT|Placebo|Taste- and appearance-matched placebo beverage without active ingredients.
214987055|NCT03409965|DEVICE|Lutronic Infini System|A microneedle radiofrequency device
214374064|NCT07165132|DRUG|RYZ401|Ac-225
214987056|NCT03409965|DEVICE|Lutronic LaseMD System|A fractional thulium laser device
214987057|NCT06518291|DRUG|Nitrofurantoin 100 MG|Comparing two drugs in UTI treatment
214495468|NCT04550169|OTHER|Intensive Care Coordination|"Intensive care coordination will include:~* Discharge instructions and contacts for following up on care and treatment~* Referral information~* Appointment scheduling~* Medication instructions~* Intensive care coordination by a social worker, case manager, nurse, or care coordinator to connect Medical Assistance (MA) recipient to a primary care provider or to a managed care organization~* Information about other health and social resources, such as transportation and housing~* Sharing of information (discharge instructions, medication information, and care plan information) with managed care organization in which patients are enrolled, if applicable"
214987058|NCT06518291|DRUG|Fosfomycin|treatment of UTI
214684677|NCT01916122|DRUG|Fluorestradiol (FES)|
214684678|NCT01916122|PROCEDURE|PET/CT Imaging|
214684679|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
214684680|NCT01301742|DRUG|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
215089778|NCT07041593|OTHER|Inspiratory Muscle Training and Traditional Physiotherapy|Participants in this group will undergo inspiratory muscle training (IMT). The resistance to be applied at the start of IMT has been set at 30% of the maximum inspiratory pressure (MIP) value. The MIP value will be remeasured every week, and the training load will be updated according to 30% of the new value obtained. IMT will be carried out twice a week with a physiotherapist and on the remaining days as a home programme, for a total of eight weeks, five days a week, 15 minutes a day. Participants in the experimental group will receive traditional physical therapy treatments for cerebral palsy in the same manner as the control group. In this context, traditional physical therapy methods based on neurodevelopmental principles will be applied and designed according to the individual's needs.
214374065|NCT07165288|OTHER|Continuous midwife support care|Primiparous pregnant women are provided with continuous and individual midwife support starting from the 36th week until the postpartum period.
214495469|NCT05741112|DEVICE|Wearable device|The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
214495470|NCT05458323|DEVICE|Free near and Distance Vision glasses|Intervention Description: All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction.Glasses will be provided at the time of enrolment in the study.
214684681|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
214684682|NCT02614872|DRUG|GLASSIA® and Institution standard of care (SOC)|Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)
214684683|NCT00013624|DRUG|IV Levodopa|
214684684|NCT04666324|DRUG|Simethicone Solution|Oral daily treatment for four weeks
214684685|NCT04666324|DIETARY_SUPPLEMENT|Multilac Baby|Oral daily treatment for four weeks
214684686|NCT05196243|OTHER|Patients diagnosed as gastrointestinal mucosal lesions|Patients diagnosed as gastritis, gastric cancer, intestinal polyps and colorectal cancer
214684687|NCT02551367|DRUG|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
214684688|NCT02551367|DRUG|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
214684689|NCT02551367|DRUG|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
214684690|NCT01072864|OTHER|Walnuts|Consumption of 5 g of walnuts.
214684691|NCT01072864|OTHER|Walnuts|Consumption of 20 g of walnuts.
214684692|NCT01072864|OTHER|Walnuts|Consumption of 30 g of walnuts.
214987059|NCT03104413|DRUG|placebo for risankizumab IV|placebo for risankizumab administered as intravenous (IV) infusion.
214987060|NCT03104413|DRUG|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
214374066|NCT07165288|OTHER|Pilates ball usage|Primiparous pregnant women were provided with educational support starting from the prenatal period to the postnatal period. In addition, depending on the preferences of the pregnant woman, at least one of the above-mentioned practices was chosen with the accompaniment of a midwife at the time of birth.
214684693|NCT01072864|OTHER|Walnuts|Consumption of 40 g of walnuts.
214684694|NCT04180410|DEVICE|EIT|Electrical Impedance Tomography is performed before extubation, during follow-up visits of extubation and 48H after extubation. Follow-up visits are shortened in case of extubation failure.
214684695|NCT00390364|DRUG|everolimus|
214684696|NCT00390364|PROCEDURE|antiangiogenesis therapy|
214684697|NCT00390364|PROCEDURE|biopsy|
214684698|NCT00390364|PROCEDURE|diagnostic procedure|
214684699|NCT00390364|PROCEDURE|gene expression analysis|
214684700|NCT00390364|PROCEDURE|immunohistochemistry staining method|
214684701|NCT00390364|PROCEDURE|laboratory biomarker analysis|
214684702|NCT00390364|PROCEDURE|mutation analysis|
214684703|NCT00390364|PROCEDURE|protein tyrosine kinase inhibitor therapy|
214684704|NCT00390364|PROCEDURE|reverse transcriptase-polymerase chain reaction|
214684705|NCT05582577|COMBINATION_PRODUCT|Intravitreal bevacizumab injection with subthreshold micropulse laser|Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser
214684706|NCT05582577|DRUG|Intravitreal bevacizumab injection alone|Group B: Intravitreal injection of Bevacizumab alone
214374067|NCT07165288|OTHER|warm shower|It was generally applied to the majority of our pregnant women within the scope of training.
214684707|NCT02630277|DRUG|Aflibercept|Intravitreal Aflibercept Injection 2.0 mg
214684708|NCT03228251|OTHER|Stroke team simulation training|"The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin."
214684709|NCT03201653|PROCEDURE|Stump closure using NU-KNIT SURGICEL|We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
214684710|NCT02994589|OTHER|Tegaderm™(Absorbant, 3M)|3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
214374068|NCT07165379|OTHER|Neuromodulation|The application of neuromodulation therapy will be carried out with the support of ultrasound visualization on the anatomical area of the target nerve, seeking a motor and/or sensory response with its stimulation.
214684711|NCT02994589|DEVICE|OASIS® wound matrix|OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
214684712|NCT02994589|OTHER|Xeroform™|Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
214684713|NCT04027465|DIETARY_SUPPLEMENT|Egg allergy oral desensitization|Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
214684714|NCT06672029|OTHER|combining pattern-specific manual therapy, Schroth Best Practice exercise, and Gensingen brace application|"* The pattern-specific manual therapy: It was developed by our author. This therapy was done immediately before each SBP (Schroth Best Practice) exercise session, targeting both the spine and extra-spinal regions.~* The Schroth Best Practice exercises: It contains following 6 components: The physio-logic® program for sagittal profile correction, education on activities of daily living (ADLs), the 3D made easy program, the new Power Schroth program, the rehabilitation of walk, and neuromobilization.~* The Gensingen brace application: it was made according to the patients' Lehnert Schroth Classifications. the investigators recommended the patients to wear the brace for 21-23 hours per day during the first year. As the bone maturation reached Risser 4 to 4.5, the daily brace wearing time was gradually reduced."
214684715|NCT05585411|PROCEDURE|Left bundle branch area pacing|"LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~1. RBBB configuration observed during unipolar tip pacing~2. One of the following should be met:~   1. Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 \[LV activation time\]) of \>10ms during increasing output~  2. Short and constant stim-LVAT and the shortest stim-LVAT \<75ms in non-LBBB and \<85ms in LBBB~  3. Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~  4. LBB potential (LBB-V interval of 15 to 35ms)~  5. Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP)."
214684716|NCT05585411|PROCEDURE|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
214684717|NCT05582837|DRUG|nortriptyline + topiramate|nortriptyline (7.5mg) + topiramate (10mg) taken 1x per day and escalate weekly as needed for 8 weeks
214987061|NCT03104413|DRUG|risankizumab IV|risankizumab administered as intravenous (IV) infusion.
214987062|NCT02765035|DEVICE|C-Leg 4|Microprocessor Controlled Knee
214987063|NCT02765035|DEVICE|C-Leg 3|Microprocessor Controlled Knee
214684718|NCT06693596|DIAGNOSTIC_TEST|Group 2: Conservative management (follow-up)|"A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the adnexal mass is seen and if the decision is to manage the adnexal mass conservatively, the patient will be re-scanned at 6 weeks (maximal range 6-8 weeks), 3 months (+/- 2 weeks) and 12 months (maximal range 10-14 months)"
214374069|NCT07165379|OTHER|Physical Exercise|The therapeutic physical exercise will consist of 3 periods of isometric contraction of 30 seconds, with a rest period of 1 minute, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
214374070|NCT07165379|OTHER|Stretching|To stretch the muscles involved, perform three periods of maximum tolerable stretching without pain, lasting 20 seconds and resting for 30 seconds.
214495471|NCT05804032|DRUG|Isatuximab|IV isatuximab will be administered weekly in the first cycle (Cycle 1) on days 1, 8, 15, 22, 29, and biweekly on the 2 subsequent cycles at days 1, 15 and 29, at the dose of 10 mg/kg.
214684719|NCT06693596|PROCEDURE|Group 1: Surgical management|"A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the patient requires surgery, no further ultrasound scans will be required."
214684720|NCT06693453|OTHER|Electroacupuncture and Dry cupping|This group will perform electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
214684721|NCT06693453|OTHER|Electroacupuncture and Sham Dry cupping|This group will perform Electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and Sham Dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
214684722|NCT01173627|DRUG|Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
214495472|NCT05804032|DRUG|Isatuximab|SC isatuximab will be administered on days 1, 8, 15, 22, 29 of cycle 1, and on days 1, 15 and 29 of cycles 2-3, at the dose of 1400 mg
214495473|NCT05804032|DRUG|Lenalidomide|Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3
214495474|NCT05804032|DRUG|Bortezomib|Both arms: 1.3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
214495475|NCT05804032|DRUG|Dexamethasone|20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3.
214684723|NCT01173627|DRUG|Actiq 400 mcg|Actiq 400 mcg administered as a single dose under fasted conditions
214684724|NCT06786286|DRUG|[14C]-ITI-1284|\[14C\]-ITI-1284 20 mg oral solution (not more than 22 μCi), subcutaneous administration
214684725|NCT00358618|DRUG|Propofol|See Detailed Description.
214987064|NCT01575990|BEHAVIORAL|Making A Decision About CRC Screening|"Targeted by age and gender with 3 components.~1. Educational component~2. Values clarification exercise~3. Individualized decision making worksheet~The intervention or control condition is administered before the index visit with the patient's provider."
214684726|NCT02468089|DRUG|Carbepenem|
214684727|NCT02468089|DRUG|Albumin|
214684728|NCT02468089|DRUG|GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .|
214374071|NCT07165730|BEHAVIORAL|Virtual Health Coaching with Artificial Intelligence (DIACOACH)|Participants in the intervention group will receive a 12-week virtual health coaching program using the DIACOACH application. The program includes adaptive digital education on diet, physical activity, and medication adherence, personalized reminders, daily self-monitoring, and feedback powered by artificial intelligence. The intervention is designed to improve self-care adherence and glycemic control (FBG, HbA1c, RBG) among adults with type 2 diabetes mellitus in primary care settings.
214374072|NCT07165730|BEHAVIORAL|Standard Diabetes Education|Participants in the control group will receive standard diabetes education usually provided in primary health care centers. This includes routine counseling sessions, printed educational materials, and general advice on diet, physical activity, and medication adherence, without the use of the DIACOACH application.
214495476|NCT03672058|OTHER|Fitness tracker with goal setting and text message feedback|Participants provided with a Fitbit and this will also be linked to Fitabase. The physiotherapist will discuss the participants' baseline physical activity levels and individual patient centred short and long-term goals will be set with each participant. Every week participants will be contacted via text message by their CF physiotherapist. The physiotherapist will review their online data and will provide feedback and encouragement on their progress. Goals will be reviewed for each participant.
214495477|NCT03672058|OTHER|Fitness Tracker only|"Participants will be provided with the Fitbit and educated on how to use it. This will be linked to Fitabase, an online monitoring system for data collection purposes, with the consent of the participants. However no goal setting will be completed and no feedback will be provided to the participants on their physical activity levels"
214495478|NCT03801434|DRUG|Ruxolitinib|Given PO
214684729|NCT02945449|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
214987065|NCT01575990|BEHAVIORAL|Drivers 65 Plus|This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
214987066|NCT02301455|BEHAVIORAL|Text messaging|persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
214374073|NCT07164391|BEHAVIORAL|Digital Intervention for Vietnamese-American Storytelling (VIDAS)|The intervention consists of 4 brief stories about HPV vaccine, created by Vietnamese mothers
214374074|NCT07164391|BEHAVIORAL|HPV Educational Video Intervention|The intervention consists of 4 brief informational videos about HPV and the vaccine
214374075|NCT07164391|BEHAVIORAL|Teen General Health|This intervention consists of 4 brief videos on general teen health topics, such as mental health, social media usage.
214987067|NCT05684107|PROCEDURE|IPACK block|the probe is applied to the popliteal fossa for identification of the popliteal artery and femur. Then, the probe is slid distally for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared. a spinal needle 22G x 3.5 inches is advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reached the medial edge of the femur, nearly at the level of the popliteal artery, negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
215089779|NCT07041593|OTHER|Traditional Physiotherapy|Participants in the control group will undergo a neurodevelopmental-based traditional physiotherapy programme for 8 weeks, with two 40-minute sessions per week under the supervision of a physiotherapist; on other days, they will be asked to continue the exercises taught to their families at home.
215089780|NCT07041073|DEVICE|Active swLORETA Z-score Neurofeedback|Participants receive 10 sessions (25 minutes each, twice per week for 5 weeks) of EEG-based neurofeedback using the NeuroGuide® software and a 24-channel EEG recording system (eego™, ANT Neuro). The neurofeedback protocol is based on real-time swLORETA Z-score training targeting brain regions involved in emotion regulation. Feedback is provided via gamified visual displays when EEG activity moves toward normative patterns. This is an operant conditioning-based protocol designed to enhance emotional self-regulation.
215089781|NCT07041073|DEVICE|Yoked-sham swLORETA Z-score Neurofeedback|"Participants receive 10 sessions identical in appearance and duration to the active neurofeedback condition. However, the feedback provided is not based on their own EEG activity. Instead, it is pre-recorded data from a matched participant in the active group (yoked design), ensuring no real-time neurophysiological modulation occurs. The same EEG equipment and visual feedback interface are used to maintain blinding."
215089782|NCT07042126|DRUG|611|Double blind treatment period : 611 600 mg/450 mg at day 1，then 300 mg subcutaneous injection Q2W thereafter until week 16 Maintenance treatment period : 611 300 mg subcutaneous injection Q2W/Q3W until week 52.（The subjects in the placebo group during the double-blind treatment period need to be given a loading dose at week 16.）
215089783|NCT07042126|DRUG|Matching placebo|Double blind treatment period : placebo subcutaneous injection Q2W until week 16.
214374076|NCT05836571|PROCEDURE|Biopsy Procedure|Undergo biopsy
214374077|NCT05836571|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine sample
214374078|NCT05836571|DRUG|Cabozantinib|Given PO
214374079|NCT05836571|PROCEDURE|Computed Tomography|Undergo CT
214374080|NCT05836571|BIOLOGICAL|Ipilimumab|Given IV
214374081|NCT05836571|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214374082|NCT05836571|BIOLOGICAL|Nivolumab|Given IV
214374083|NCT01332890|OTHER|Sequence 1|Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
214374084|NCT01332890|OTHER|Sequence 2|Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
214374085|NCT01332890|OTHER|Sequence 3|Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
214374086|NCT01332890|OTHER|Sequence 4|Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
214374087|NCT01332890|OTHER|Sequence 5|Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
214374088|NCT01332890|OTHER|Sequence 6|Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
214374089|NCT01582789|DEVICE|enfilcon A|enfilcon A daily wear soft contact lens
214374090|NCT01582789|DEVICE|senofilcon A|senofilcon A daily wear soft contact lens
214495481|NCT05551104|DRUG|Oral Nifedipine|Administration of oral nifedipine to control postpartum hypertension.
214495482|NCT05551104|DRUG|Oral Labetalol|Administration of oral labetalol to control postpartum hypertension.
214495483|NCT03955991|BEHAVIORAL|R-CBSM|10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.
214495484|NCT03955991|BIOLOGICAL|Influenza vaccine|Standard of care Influenza vaccine for that given year.
214495485|NCT05278104|DRUG|Zentiva®|Zentiva®
214495486|NCT05278104|DRUG|Placebo|Placebo
214495487|NCT04207736|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
214495488|NCT04207736|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
214495489|NCT03674372|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E \< 25%; O/E LHR \< 30 %) and right CDH (O/E LHR \< 45%).
214374091|NCT04861870|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho was a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engaged men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focused on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
214374092|NCT05377359|DEVICE|Recordings of Hearing Aids with Open Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled to open domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
214374093|NCT05377359|DEVICE|Recordings of Hearing Aids with Closed Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with closed domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
214374094|NCT05377359|DEVICE|Recordings of Hearing Aids with Novel State 1|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its first state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
214495490|NCT06432998|OTHER|Perineal massage|The technique will be applied for approximately twenty minutes and will be carried out as follows: the vaginal dilator is introduced progressively using crescent-shaped movements. Once the dilator is fully inserted, movements will be made from bottom to top and from one side to the other, and then continue with the crescent-shaped movements.
215089784|NCT07040462|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|CPP is a structured, evidence-based dyadic therapy designed for children aged 0-6 exposed to trauma and their caregivers. The intervention involves weekly joint sessions emphasizing safety, emotional expression, and caregiver reflective functioning. Delivered by trained psychologists either online or in person.
214495491|NCT06432998|OTHER|Standard treatment|The treatment will consist of the use of vaginal dilators according to the gold standard proposed in the literature. It will consist of introducing the same dilators as for the experimental group, with the same time schedule, but without massage, only introducing the dilator and keeping it in the vagina for 20 minutes.
214495492|NCT06352632|DRUG|Standard-dose intravenous tenecteplase|Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation
214684730|NCT00931788|DRUG|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
214495493|NCT06352632|DRUG|Low-dose intravenous tenecteplase|Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation
214495494|NCT06352632|OTHER|No intravenous tenecteplase|No intravenous tenecteplase only in subjects on direct oral anticoagulant (DOACs) or those planned for emergency endovascular thrombectomy (EVT)
214684731|NCT00931788|OTHER|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
215089785|NCT07040436|DRUG|OPM-101|"OPM-101 will be administered in combination with an authorized regimen of Pembrolizumab.~Pembrolizumab will be administered by IV infusion either at a dose of 200 mg every 3 weeks or at a dose of 400 mg every 6 weeks, as per Principal Investigator's decision."
215089786|NCT07040709|OTHER|Opioid Analgesic (tramadol hydrochloride)|For postoperative pain management, a patient-controlled analgesia (PCA) pump will be routinely applied to the patient in our clinic. An infusion of an opioid (tramadol hydrochloride) at an appropriate dose will be administered via intravenous route through the pump, and the patient will be provided with detailed information about its use. Instead of continuous infusion, the device will deliver intermittent bolus doses when the patient's numeric rating scale (NRS) score is 4 or higher.
214684732|NCT06929689|PROCEDURE|three dental implants|fixed detachable prosthesis
214684733|NCT06930144|DRUG|active folate|Daily oral intake of active folate 800ug combined with basic diabetic treatment
214684734|NCT06930144|DRUG|Placebo|take oral placebo daily combined with basic diabetic treatment
214684735|NCT06930742|DEVICE|Cognitive-Motor Dual-Task Training|"Participants perform physical exercises using the balance training system and isokinetic muscle strength training system while simultaneously completing cognitive tasks to improve motor-cognitive coordination. The training follows a task-segmentation approach:~Balance Task Module: Participants perform dynamic balance training on the balance training system while engaging in cognitive tasks (e.g., digit span, arithmetic, or word fluency tasks).~Strength Task Module: Participants conduct isokinetic strength training while performing corresponding cognitive tasks.~Task difficulty is progressively adjusted based on participant performance."
214684736|NCT06930742|OTHER|Mindfulness Training|Guided by a professional mindfulness instructor, participants engage in mindfulness meditation to enhance attention, emotional regulation, and cognitive readiness. The training includes breath awareness, body scan, and present-moment awareness, delivered through guided meditation.
214684737|NCT06930742|DEVICE|Single-task Training|Participants perform physical exercises using the balance training system and isokinetic muscle strength training system without any concurrent cognitive tasks. The training follows a task-segmentation approach, including dynamic balance training and isokinetic strength training to enhance motor function.
214684738|NCT06930742|OTHER|Quiet Rest|Participants remain seated in a quiet environment without engaging in mindfulness training or cognitive tasks.
214684739|NCT03740542|PROCEDURE|Esophagectomy|Surgical removal of part of esophagus
214684740|NCT03740542|PROCEDURE|Pyloroplasty|pyloric drainage procedure
214684741|NCT05725148|DEVICE|CART-I plus|CART-I plus is a ring-type medical device that continuously monitors Atrial Fibrillation, heart rate, oxygen saturation, and blood pressure using PPG and ECG signals.
214684742|NCT04497246|OTHER|Questionnaire|Data collection by means of various questionnaires
214684743|NCT03434132|PROCEDURE|Open or robotic radical cystectomy|"ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed."
214684744|NCT02004652|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
214684745|NCT02004652|DRUG|Placebo|Vitamin, 50mg, tablet.
215089787|NCT07040709|OTHER|Prophylactic analgesia (intravenous paracetamol)|All patients will receive routine prophylactic analgesia with 1 gram of intravenous paracetamol every 6 hours (which may be skipped if the patient's pain score is 2 or below and they do not request pain relief).
214374095|NCT05377359|DEVICE|Recordings of Hearing Aids with Novel State 2|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its second state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
214374096|NCT04425343|GENETIC|16s RNA Metagenomics sequencing|The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.
214374097|NCT05673590|DRUG|Utidelone Injection|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle. The dose of dexamethasone and diphenhydramine can be halved by the physician based on patient's condition in the following day through the fifth day in each cycle, as detailed in the protocol.~Dexamethasone 8 mg per oral, bid, one day prior to docetaxel iv drip for 3 days.~The treatment group will be treated with Utidelone Injection at 40 mg/m2/d intravenously once daily on days 1-5 in a 21-day cycle until disease progression or an occurrence of intolerable toxicities."
214495495|NCT06352632|OTHER|Conservative Blood Pressure Control|No or minimal Systolic Blood Pressure (SBP) control; SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP (≥180mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
214495496|NCT06352632|OTHER|Moderate Blood Pressure Control|SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP (150-160mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
214495497|NCT06352632|OTHER|Intensive Blood Pressure Control|SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher after endovascular thrombectomy (EVT); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
214495498|NCT06352632|OTHER|Placebo|100 mL of 0.9% normal saline, administered as a single IV infusion with a 20-minute dosing duration.
214495499|NCT06352632|DRUG|NoNO-42|NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration
214495500|NCT06352632|OTHER|No deferoxamine mesylate and no colchicine|No deferoxamine mesylate and no colchicine
214495501|NCT06352632|DRUG|Deferoxamine mesylate only|Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
214495502|NCT06352632|DRUG|Colchicine only|0.5mg of oral colchicine daily for 30 days
214495503|NCT06352632|DRUG|Both deferoxamine mesylate and colchicine|Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days
214495504|NCT06230510|BEHAVIORAL|Introduction of Milk Type|Beginning at approximately age 2, milk (equivalent to 2 cups/day) will be provided at no cost to the family for one year.
214495505|NCT06230510|BEHAVIORAL|Child Nutrition Counseling|Parent/caregivers will receive quarterly phone-based counseling by a Registered Dietitian (RD) on how to introduce the toddler to the assigned milk and the importance of continuing to drink the assigned milk for the one year.
214495506|NCT01823406|PROCEDURE|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
214495507|NCT01823406|PROCEDURE|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
214495508|NCT00083590|DRUG|Huperzine A|
214495509|NCT00773500|OTHER|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
215089788|NCT07040709|OTHER|Rescue analgesia (intramuscular diclofenac sodium)|If the pain persists despite the administered analgesics and the patient's pain score remains 4 or above, rescue analgesia with intramuscular diclofenac sodium, which is routinely used in our clinic, will be administered.
214684746|NCT00436670|BIOLOGICAL|AMG 317 75 mg|75 mg SC weekly injection
215089789|NCT07041190|DRUG|Abrysvo|Maternal RSV Vaccine (MV). RSV bivalent recombinant vaccine with subgroup A and B stabilised prefusion F antigens, single intramuscular injection of 0.5 mL, administered once, in pregnancy.
214374098|NCT05673590|DRUG|Docetaxel Injection|"Pretreatment: Dexamethasone should be administered orally for 3 days at 16 mg per day (8 mg twice daily), starting one day before the start of Docetaxel.~The control group will be treated with Docetaxel Injection at 75 mg/m2/d, administered intravenously once on day 1. Patients in this group will be treated in 21-day cycles until disease progression or intolerable toxicities occurs."
214374099|NCT06182566|PROCEDURE|Convergent ablation|Staged hybrid ablation with CONVERGENT epicardial ablation with ablation of the ligament of Marshall and left atrial appendage clip, followed in second stage by endocardial catheter ablation including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
214987068|NCT05684107|PROCEDURE|adductor canal block|"the transducer is placed anteromedially, approximately at the junction between the middle and distal third of the thigh or somewhat lower.~The saphenous nerve block should be performed at the most distal level where the artery still lies immediately deep to the sartorius muscle, thus minimizing the amount of motor nerve block of the vastus medialis; an adductor canal nerve block is typically performed more proximally, around the mid-thigh level. The needle is inserted in-plane in a lateral-to-medial orientation and advanced toward the femoral artery. Once the needle tip is visualized anterior to the artery and after careful aspiration, 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn"
215089790|NCT07041190|DRUG|Nirsevimab|Infant RSV monoclonal antibody (mAb). For infants \<5kg: 50mg (0.5mL in pre-filled syringe), for infants ≥5kg: 100mg (1mL in pre-filled syringe), administered as a single intramuscular injection.
214374100|NCT06182566|PROCEDURE|Catheter ablation|Pulmonary vein isolation using commercially available catheters; including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
214374101|NCT01031901|DRUG|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
214374102|NCT01031901|DRUG|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
214374103|NCT01031901|DRUG|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
214374104|NCT02012192|DRUG|Ganetespib|
214374105|NCT02012192|DRUG|Paclitaxel|
214495510|NCT06253299|OTHER|marble stone|"Marble stones with dimensions of 4x5 cm will be used for cold application. When placed in the freezer compartment of the refrigerator at -10°C (Celsius) for 4 minutes, they cool down to 11°C. Subsequently, in 1 minute, the temperature rises to 12°C when held in the palm. After being placed on a table at room temperature, it reaches 18°C in 5 minutes."
214495511|NCT03956095|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition Shake supplements|Three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
214495512|NCT03956095|OTHER|Daily Food Intake form|On the day of surgery, the patient will return her Daily Supplement/Food Intake Forms and complete the Day of Surgery Intake Form can also be completed the day before surgery and the Daily Supplement/Food Intake Forms can be returned at the patient's postoperative appointment.
214495513|NCT06033105|DEVICE|ELISA|Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.
214495514|NCT04094519|DRUG|enzalutamide|oral
214495515|NCT04094519|DRUG|enzalutamide Placebo|oral
214495516|NCT04094519|DRUG|digoxin|oral
214495517|NCT04094519|DRUG|rosuvastatin|oral
214495518|NCT01630902|DRUG|Torrent's Felodipine Extended-Release Tablets|
214495519|NCT04515667|BEHAVIORAL|Mindfulness|Participants will view a brief mindfulness video
214495520|NCT04515667|BEHAVIORAL|Video|Participants will view a control video
214495521|NCT05747014|DEVICE|Novapak Nasal Sinus Packing and Stent|Potential subjects will have the need to undergo nasal/sinus surgery using a space-occupying stent and will perform daily self-saline nasal irrigations.
214495522|NCT02896907|DRUG|Oxaliplatin|Given IV
214495523|NCT02896907|DRUG|Irinotecan Hydrochloride|Given IV
214495524|NCT02896907|DRUG|Leucovorin Calcium|Given IV
214495525|NCT02896907|DRUG|Fluorouracil|Given IV
214495526|NCT02896907|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
214495527|NCT06074744|OTHER|SSNB + IPACK|already included in arm/group description
214495528|NCT06074744|OTHER|FNB + IPACK|already included in arm/group description
214495529|NCT03933371|DEVICE|Colon Capsule Endoscopy|The capsule endoscopy will be ingested by the participant. This device captures images along the large bowel. This images are stored in an external memory and afterwards they are downloaded in a computer
214495530|NCT00536120|BIOLOGICAL|BG00002 (natalizumab)|
214495531|NCT00536120|BIOLOGICAL|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
214495532|NCT00536120|BIOLOGICAL|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
214495533|NCT03737487|PROCEDURE|Multidisciplinary fall risk and geriatric comprehensive assessment|"* Complete blood count, serum electrolytes, C-Reactive Protein, transaminases and gamma-glutamyl transferase, thyroid-stimulating hormone, and 25OH vitamin D.~* Calculation of BMI~* A 40-min assessment of balance, walking speed, muscle strength, activity, and functional status by a physiotherapist~* A 40-min assessment by an occupational therapist, including a detailed questionnaire on social support, living situation and home environment, fear of falling, and cognitive function~* A 20-min assessment by a podiatrist including an examination of the patient's feet and footwear.~* A 60-min assessment by a geriatrician including assessment of circumstances of the previous fall(s), review of current medications and medical history, and an in-depth examination of the patient to detect possible contributors or risk factors for falling~* A 20-min review meeting with the 4 healthcare professionals in order to prioritize recommendations to be provided."
214684747|NCT00436670|BIOLOGICAL|AMG 317 150 mg|150 mg SC once weekly injection
214374106|NCT00959062|DRUG|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
214987069|NCT05684107|PROCEDURE|sciatic nerve block|patient in a supine position with the hip and knee on the operated side flexed and the leg externally rotated at approximately 45 degrees. The ultrasound transducer is first positioned perpendicular to the skin approximately 8 cm distal to the inguinal crease. The location is then scanned by sliding and tilting the transducer until a clear transverse image of the hyperechoic sciatic nerve located posterior and medial to the lesser trochanter is obtained. a spinal needle 22G x 3.5 inches is advanced parallel and in line with the ultrasound transducer while the sciatic nerve is kept in the middle of the screen. The needle is advanced slowly under real-time ultrasound guidance until it is near the nerve then negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
214987070|NCT04147156|PROCEDURE|Epley's Maneuver|Treatment with Epley's Maneuver in the ROTUNDUM-chair
214987071|NCT04147156|PROCEDURE|Semont Maneuver|Treatment with the Semont Maneuver in the ROTUNDUM-chair
214987072|NCT04147156|PROCEDURE|360 degree vertical rotation|Treatment with 360 degree vertical rotation in the ROTUNDUM-chair
214987073|NCT04772976|OTHER|Observational study, not applicable|Observational study, not applicable
214374107|NCT00959062|DRUG|placebo|Preparation visually identical to clonidine.
215089791|NCT06733558|PROCEDURE|Electroconvulsive Therapy|Electroconvulsive therapy (ECT) is a medical treatment that uses controlled electrical stimulation to induce a brief, generalized seizure in the brain. This intervention is performed under general anesthesia with muscle relaxants to ensure patient comfort and safety. ECT is typically used to treat severe depression, bipolar disorder, and other mental health conditions when other treatments, such as medication and psychotherapy, have not been effective.
215089792|NCT06893978|DRUG|Placenta organoids treatment|Placenta organoids in vitro treatment with heparin, aspirin, IVIG, filgrastim and metformin
215089793|NCT06747455|DRUG|BCG for Therapeutic Use|After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were given intravesical infusion (experimental drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.
215089794|NCT06747455|DRUG|BCG for Therapeutic Use ( BI SAI JI )|After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were administered intravesical infusion (control drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.
214374108|NCT02985762|DRUG|EXPAREL|
214374109|NCT01746043|DRUG|Armodafinil|150 mg by mouth once a day for 6 weeks.
214374110|NCT01746043|OTHER|Placebo|1 capsule by mouth 2 times a day for 6 weeks.
214374111|NCT01746043|DRUG|Minocycline|100 mg by mouth 2 times a day for 6 weeks.
214495534|NCT05724966|DEVICE|mHealth app|We wish to examine the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before.
214495535|NCT05935969|PROCEDURE|ERCP(Endoscopic retrograde choangiopancreatography), ETGBD(endoscopic transpapillary gallbladder drainage)|For transpapillary gallbladder drainage, biliary cannulation was performed with a duodenoscope (JF-260V or TJF-260V; Olympus Optical). After successful deep cannulation of the CBD, we checked the cholangiogram, performed endoscopic sphincterotomy, and removed the CBD stone using a memory basket and/or retrieval balloon. Cholangiography was then performed again to locate the cystic duct orifice, and a guide wire (Jagwire; Boston Scientific, Marlborough, Massachusetts, USA or Visiglide; Olympus, Tokyo, Japan) was inserted into the gallbladder with different types of catheters (standard catheter, pull-sphincterotome, or rotating sphincterotome) under fluoroscopic guidance. After placement of the guide wire into the gallbladder, contrast dye was injected to confirm good entry into the gallbladder. Once the gallbladder was selected and the guidewire was coiled in the GB, a 7Fr 12-15cm double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Winston-Salem, NC) was inserted into the GB.
214495536|NCT01419808|PROCEDURE|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
214374112|NCT01746043|BEHAVIORAL|Questionnaires|Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
214374113|NCT04761276|DEVICE|Surgical implantation of intra ocular lens|Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.
214374114|NCT01191840|DRUG|Vancomycin|Duration
214374115|NCT01191840|DRUG|Vancomycin|Duration
214374116|NCT03271476|BEHAVIORAL|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
214374117|NCT05912140|OTHER|TRACE 2|"The first version of TRACE2 will be retrospectively verified through its application by experts on 150 photos of scoliosis patients who agreed to use the material produced for clinical use for retrospective research. Both intra-operator and inter-operator repeatability will be evaluated and a first Rasch analysis will be performed.~The new version of TRACE2 (TRACE2.2) obtained following the retrospective validation on the photos will be verified prospectively through its application by the experts on 150 patients in specialist medical examination. Both intra-operator and inter-operator repeatability will be evaluated and further Rasch analysis will follow. On the basis of the results obtained from the analysis, the new TRACE2 scale (TRACE2.3) will then be applied to a further 150 patients, its intra- and inter-operator repeatability will be calculated and a final Rasch analysis will be performed to arrive at the final version of the scale (TRACE2.4)."
214684748|NCT00436670|BIOLOGICAL|AMG 317 300 mg|300 mg weekly SC injection
214684749|NCT00436670|BIOLOGICAL|Placebo|Placebo SC once weekly injection
214684750|NCT01556399|OTHER|Tissue Sampling|A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
214684751|NCT06212232|PROCEDURE|Piezoelectric surgery|Application of a new piezoelectric technique in third molar surgery
214987074|NCT00255580|DRUG|Smoked cannabis|
214374118|NCT01392300|DRUG|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
214374119|NCT01392300|DRUG|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
214684752|NCT05117086|BEHAVIORAL|DASH diet|Nutrition education and counseling on DASH diet, behavioral and lifestyle modifications
214684753|NCT04958096|DEVICE|Standard Therapeutic Deep Brain Stimulation|DBS to the standard subcortical targets (anterior limb of the internal capsule- ALIC) will be used to treat OCD
214374120|NCT00118781|DRUG|iseganan hydrochloride|
214495537|NCT01419808|PROCEDURE|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
214495538|NCT02760654|DEVICE|Proactive Self Management Program for Effects of Cancer Treatment|
214495539|NCT00130546|DEVICE|Paclitaxel-eluting TAXUS(TM)|TAXUS(TM) Paclitaxel-eluting stent
214987075|NCT04104971|DIAGNOSTIC_TEST|blood tests , abdominal US and doppler|
214495540|NCT00130546|DEVICE|Sirolimus eluting Cypher Select(TM)|Sirolimus eluting Cypher Select(TM) stent
214495541|NCT05562427|BEHAVIORAL|Gold-Standard Online Behavioral Obesity Treatment|Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
214495542|NCT00206986|DRUG|clonidine|Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
214495543|NCT00206986|DRUG|clonidine|0.15 mg of clonidine will be administered to 20 healthy male volunteers
214495544|NCT03238261|RADIATION|Chemotherapy and concomitant radiotherapy|Radiotherapy (teletherapy + high or low rate brachytherapy)
214495545|NCT01078285|BEHAVIORAL|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
214684754|NCT04958096|DEVICE|Cortical Stimulation for PFC|Patients enrolled in this study will have a second pair of leads placed in the prefrontal cortex (PFC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
214684755|NCT04958096|DEVICE|Cortical Stimulation for ACC|Patients enrolled in this study will have a second pair of leads placed in the anterior cingulate cortex (ACC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
214987076|NCT02278653|OTHER|Questionnaires for the evaluation of Quality of Life|"1. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score~2. Short Form (36) health survey~3. EORTC CR38~4. Vaizey score~5. Low Anterior Resection Syndrome (LARS) score~6. International Index of Erectile Function for men~7. International Prostate Symptom Score for men~8. Female Sexual Function Index for women"
214987077|NCT02278653|OTHER|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
214987078|NCT05270356|OTHER|MRI|Magnet Resonance Imaging of the Brain without Contrast
214987079|NCT05844423|BIOLOGICAL|0.5 ml dose of 1.1 mcg VAX-24|24 valent pneumococcal conjugate vaccine
214987080|NCT05844423|BIOLOGICAL|0.5 ml dose of PCV20|20 valent pneumococcal conjugate vaccine
214987081|NCT05844423|BIOLOGICAL|0.5 ml dose of 2.2 mcg VAX-24|24 valent pneumococcal conjugate vaccine
214987082|NCT05844423|BIOLOGICAL|0.5 ml dose of 2.2/4.4 mcg VAX-24|24 valent pneumococcal conjugate vaccine
214987083|NCT05031351|DRUG|Withania somnifera|Nuclear Factor Kappa Beta Inhibitor
214987084|NCT05031351|DRUG|Placebo|Placebo Comparator
214987085|NCT03879330|DEVICE|NIRS monitoring|aSAH patients will be given continuous NIRS and blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring of 4 hours. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
214987086|NCT00984867|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 48 weeks
214987087|NCT00984867|DRUG|Placebo|Matching placebo tablet
214987088|NCT02900716|DRUG|DTRMWXHS-12|DTRMWXHS-12
214987089|NCT02900716|DRUG|DTRM-505|DTRMWXHS-12 and everolimus
214987090|NCT02900716|DRUG|DTRM-555|DTRMWXHS-12 and everolimus and pomalidomide
215089795|NCT04505267|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or intranodally
215089796|NCT04505267|RADIATION|Radiation Therapy|Undergo RT
214495546|NCT01078285|BEHAVIORAL|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
214495547|NCT02967458|DRUG|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
214495548|NCT05866536|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
214495549|NCT05866536|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
214495550|NCT06515873|DEVICE|Virtual Reality Headset|The virtual reality headset, which will display one of the 3 available scenarios, will be placed on the patient head during a surgery under spinal anesthesia.
214495551|NCT04715269|DRUG|Alprazolam|Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency
214495552|NCT04715269|OTHER|Placebo|Empty capsule
214495553|NCT03500822|PROCEDURE|Metronome-paced tachypnea|three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2
214495554|NCT03500822|PROCEDURE|Expiratory-stenosis breathing|three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm
214495555|NCT02482701|DEVICE|Captivator™ EMR|The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.
214495556|NCT00003867|DRUG|capecitabine|
214987091|NCT05115396|OTHER|Mirror therapy|The patient shall be seated in a chair with a table in front of him/her. On the table there is a mirror in the sagittal plane between the two upper extremities. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the procedure, patients will be instructed to concentrate on the hand reflected in the mirror.
214987092|NCT05115396|OTHER|Cross-education treatment|Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
214495557|NCT00003867|DRUG|irinotecan hydrochloride|
214495558|NCT03039296|PROCEDURE|Endoscopic rhizotomy|Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
214495559|NCT04480385|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch
214495560|NCT01292863|OTHER|Active Comparator: Conventional peritoneal dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
214495561|NCT01292863|OTHER|Experimental: Novel biocompatible dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
214495562|NCT00963092|GENETIC|DNA analysis|
214495563|NCT00963092|GENETIC|RNA analysis|
214987093|NCT05664906|DRUG|Chinese Medicine Oral Rinse Formula-I (CMORF-I)|"* Prescription of Chinese Medicine Oral Rinse Formula-I (CMORF-I)~* Instruction to rinse:~  1. The above amount of concentrated CM granules will be divided and packed in 4 bags per day.~ 2. Dissolve 1 bag of concentrated CM granules with 150ml 80'C boiled hot water, and wait for 20 mins to cool down.~ 3. Clean the mouth thoughtfully by rinsing with 150ml of distilled water for 2 minutes.~ 4. Rinse the mouth thoughtfully with one-third of the dissolved and cooled CM oral rinse, gargle, expel after 3 minutes, do not swallow and repeat twice.~ 5. To ensure better contact of the CM oral rinse in all parts and folds of the oral cavity, our research assistant and CMP will guide the patients to fully agitate the mouth, use the tongue to stir repeatedly among the teeth, cheeks and palate surface, and to raise the tip of the tongue for a moment and tilt the head back.~ 6. 4 times a day (half an hour after every meal, half an hour before sleep), from baseline to 2 weeks after RT."
214987094|NCT05664906|OTHER|Standard Care|• Standard care including normal saline or medical mouthwash, optional analgesics and antibiotics will be offered by hospital.
214987095|NCT05664906|OTHER|Placebo|Placebo granules, instruction is the same as CMORF-I.
214987096|NCT00275613|DRUG|Rituximab|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
214987097|NCT01503424|DRUG|Olanzapine|Olanzapine Tablets, 5 mg
214987098|NCT01516099|OTHER|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).
214987099|NCT01516099|OTHER|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
214987100|NCT02682758|DRUG|Xenon|Wash-in of xenon for maintenance of anaesthesia
214987101|NCT05668559|PROCEDURE|repetitive transcranial magnetic stimulation|"The rTMS mode consists of a cluster stimulus delivered every 0.2 seconds (5 Hz), with each cluster stimulus consisting of three burst stimuli with a 50 Hz body frequency. The duration of a single stimulus was approximately 40 seconds, for a total of 600 pulses. Stimulation takes place bilaterally in the dorsolateral prefrontal cortex (DLPFC).~All enrolled patient in the rTMS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes on postoperative day 1 to 5 after the surgery."
214987102|NCT05668559|PROCEDURE|Sham Stimulation|Shaman stimulation uses the same protocol (600 pulses per session, 3 sessions per set, ISI≥30 min, 3 sets) with the coil set at 90 against the skull on postoperative day 1 to 5 after the surgery.
214987103|NCT00879216|DRUG|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
214987104|NCT00879216|DRUG|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
214987105|NCT03273972|OTHER|Written Informed Consent|To be completed prior to conducting any study related procedures
214374121|NCT02938169|BEHAVIORAL|exercise|"* stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)"
214374122|NCT04539457|BEHAVIORAL|Desktop helper|The 'Desktop Helper (version 10)' is a user-friendly information sheet developed by the IPCRG. This 'Desktop Helper (version 10)' has been developed in co-operation with several clinicians and experts in the field of COPD. These practical guidance and support are a tool for clinicians working in primary care. The 'Desktop Helper (version 10)' contains specific advice to prevent clashes. The specific advice of the 'Desktop Helper (version 10)' will be elaborated in decision trees. These will be integrated and implemented into the MedicomSmart system by Stichting Healthbase. Subsequently, these decision trees will provide GPs to conduct case-finding of COPD patients with 'medication-comorbidity clashes'. These are based on the 'Desktop Helper (version 10)' . Case finding will be done by the GP or the practice nurse (POH).
214495564|NCT00963092|GENETIC|microarray analysis|
214684756|NCT06417762|BEHAVIORAL|Science Communication Curriculum Cohort 1|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
214684757|NCT06417762|BEHAVIORAL|Science communication curriculum Cohort 2|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
214987106|NCT03273972|OTHER|Inclusion/Exclusion check|Eligibility check
214987107|NCT03273972|OTHER|Full Clinical Chemistry and Haematology Bloods|Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
215089797|NCT06664866|DIAGNOSTIC_TEST|EchoNet-LVH Assessment|The AI algorithm is previously described (Duffy et al. JAMA Cardiology 2022) and will remain unchanged throughout the course of the study. A pre-determined threshold based on prior experiments and analysis has been decided prior to the study. From each site, approximately 100,000 echocardiogram studies will be reviewed by EchoNet-LVH for approximately 500 patients to be flagged.
214495565|NCT00963092|GENETIC|protein analysis|
214495566|NCT00963092|OTHER|cytology specimen collection procedure|
214495567|NCT00963092|OTHER|laboratory biomarker analysis|
214495568|NCT00963092|OTHER|questionnaire administration|
214987108|NCT03273972|OTHER|Serum sample for systemic markers and lipid sub-fractions|Serum samples may be stored for later analysis.
214987109|NCT03273972|OTHER|Pregnancy Test|If applicable for women of child bearing potential
214987110|NCT03273972|OTHER|12 Lead ECG|participant resting supine
214987111|NCT03273972|OTHER|Blood Pressure and Heart Rate|Measured in the seated position after 5 minutes rest
214987112|NCT03273972|OTHER|Arterial Stiffness|Measure of functional and structural changes which accompanies cardiovascular disease
214987113|NCT03273972|OTHER|Central Haemodynamics|Measure of functional and structural changes which accompanies cardiovascular disease
214987114|NCT03273972|OTHER|Carotid Intima Media Thickness|Measurements will be repeated three times, and the average of the median values will be recorded
214987115|NCT03273972|OTHER|Forearm blood flow studies|Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
215089798|NCT06930677|DEVICE|embolization therapy|MSK embolization
214495569|NCT05328258|DRUG|Triptorelin Embonate|"11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug."
214495570|NCT05328258|DRUG|Sodium Chloride solution 0.9%|One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
214495571|NCT05538000|OTHER|Face to face and telephonic interviews|"face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment.~Telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment."
214495572|NCT06162182|DIAGNOSTIC_TEST|electrical impedance device,|The electrical resistance of the residual dentine underneath each measurement point was determined between an electrode and the crown pulp (Prepometer, Hager \& Werken, Duisburg, Germany). Assigning the electrical resistance of the dentin. high values are considered to represent more residual dentine than low values.
214987116|NCT03273972|OTHER|Concomitant medication check|Review of medication taken by the participant
214374123|NCT04539457|BEHAVIORAL|E-learning|The e-learning module will be explanatory to the 'Desktop Helper (version 10)' how to perform the case-finding and in what way the case-finding can be beneficial to the patients with COPD and their (co)morbidities. This e-learning module will include several example cases and how to deal with the case-finding and the next steps in the process to reduce the (co)morbidity clashes with the medications of COPD. Together with the decision trees as inferred from the 'Desktop Helper (version 10)', the e-learning module is aimed at inducing a behavioral change in prescribing medication to a patient suffering from COPD and one or more (co)morbidities.
214374124|NCT04143984|DRUG|Induction chemotherapy|Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.
214495573|NCT06162182|DIAGNOSTIC_TEST|Reference test: Digital Radiographic examination|A digital periapical radiograph using paralleling technique was taken
214495574|NCT02113826|DRUG|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
214495575|NCT00701259|DRUG|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
214495576|NCT00701259|DRUG|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
214987117|NCT03273972|OTHER|Medication compliance check (Pill count)|Ensure prescribed statin has been taken
214684758|NCT06417762|BEHAVIORAL|Science communication curriculum Cohort 3|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
214684759|NCT05664971|BIOLOGICAL|Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection|200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
214987118|NCT03273972|OTHER|Physical examination|Check overall health
214987119|NCT03273972|OTHER|Medical history|Review of volunteers medial history
215089799|NCT00534287|DRUG|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
214684760|NCT05664971|BIOLOGICAL|Toripalimab|240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
214684761|NCT05664971|DRUG|Docetaxel|60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression
214684762|NCT05664971|DRUG|Pemetrexed|500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed
214684763|NCT05664971|DRUG|Cisplatin|75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
215089800|NCT00534287|DRUG|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
214495577|NCT00701259|DRUG|placebo|
214495578|NCT06509828|BIOLOGICAL|AVB-114|AVB-114 is a mesenchymal cell substrate system comprised of autologous mesenchymal cells incubated with a 3-dimensional bioabsorbable substrate. The drug substance is expanded, pure mesenchymal stem cells (MSC) which are known to modulate local inflammation and orchestrate tissue healing. By incubating cells with a 3-dimensional bioabsorbable substrate designed for anal fistula geometry, cells are locally delivered into the fistula tract to promote healing.
214495579|NCT00290537|DRUG|ZD6474|ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
214495580|NCT00290537|DRUG|Carboplatin|6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
214374125|NCT04143984|RADIATION|Carbon-ion radiotherapy|Accelerated carbon-ion beam with pencil beam scanning technique.
214495581|NCT00290537|DRUG|Paclitaxel|200 mg/m\^2 IV Over 3 Hours On Day 1
214495582|NCT02593760|OTHER|Placebo|Placebo will be administered PO QD for up to 48 weeks.
214495583|NCT02593760|DRUG|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
214495584|NCT02593760|DRUG|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
214495585|NCT03067974|DRUG|Ketamine Hcl 100Mg/Ml Inj|10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation
214987120|NCT03273972|OTHER|AE/SAE review & reporting|Monitor safety from the point of consent
214987121|NCT03273972|DRUG|Dosing|To be performed at the end of the visit following completion all other study visits
214987122|NCT00919672|DEVICE|Sacral nerve stimulation|The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
214987123|NCT02112201|BEHAVIORAL|Integrated intervention for parents and adolescent girls|The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
214987124|NCT00513799|DRUG|Mupirocin ointment|Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.
214495586|NCT06130228|DIETARY_SUPPLEMENT|Multi-ingredient supplement (PDT-MIS)|Supplementation with active PDT-MIS daily
214684764|NCT05664971|DRUG|Carboplatin|AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
214684765|NCT05664971|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
214495587|NCT06130228|DIETARY_SUPPLEMENT|Placebo (PLA)|Supplementation with inactive placebo
214495588|NCT05097638|DIAGNOSTIC_TEST|spirometry|Patient do spirometry
214495589|NCT01911156|DRUG|Continue NA treatment|Prescribed NA during the 72 week study period
214495590|NCT01911156|DRUG|Discontinue NA Treatment|Discontinue NA Treatment
214495591|NCT02097381|DRUG|Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir|"Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day)."
214495592|NCT00955162|DRUG|Buprenorphine (Subutex)|Sublingual tablet
214495593|NCT00955162|DRUG|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
214495594|NCT00945321|DRUG|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
214495595|NCT00945321|DRUG|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
214495596|NCT00945321|DRUG|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
214495597|NCT00945321|DRUG|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
214495598|NCT02633215|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
214495599|NCT06461585|OTHER|Sprint interval training|Group A the Interventional group will receive SIT . Group A will perform SIT 3 times a week for 30-second sprints on a cycle ergometer with 4 minutes of rest between each sprint, complete session will be for 30 -40 minutes. Group B will receive the aerobic exercise. Group B will perform the aerobic exercise for 30-40 minutes of moderate-intensity continuous exercise on a treadmill and stationary cycle
214495600|NCT05891405|PROCEDURE|Cardiac surgery|Operations for congenital heart diseases
214495601|NCT04017611|DEVICE|INVSENSOR00038|Noninvasive regional oximeter
214495602|NCT03987243|BEHAVIORAL|Structured Pressure Ulcer Prevention Education|Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.
214495603|NCT03987243|OTHER|Mobile Seat Interface Pressure Mapping System (IPM)|This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
214495604|NCT02291913|DRUG|Everolimus|
214495605|NCT02291913|DRUG|Exemestane|Anti-estrogen therapy
214495606|NCT02291913|DRUG|Tamoxifen|Anti-estrogen therapy
214495607|NCT02291913|DRUG|Fulvestrant|Anti-estrogen therapy
214495608|NCT02291913|DRUG|Anastrozole|Anti-estrogen therapy
214495609|NCT02291913|DRUG|Letrozole|Anti-estrogen therapy
214495610|NCT02291913|DRUG|Toremifine|Anti-estrogen therapy
214684766|NCT05664971|DRUG|Etoposide|100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles
214684767|NCT05895513|DRUG|Pimavanserin 34 mg|5HT-2a receptor antagonist
214684768|NCT05895513|DRUG|Placebo|Inactive Comparator
214684769|NCT04838275|BEHAVIORAL|12-week mHealth home exercise prescription|3x/week home walking protocol, 2x/week resistance exercise program
214684770|NCT04307134|DRUG|Inotuzumab ozogamicin|R/R ALL who treated with Inotuzumab ozogamicin
214987125|NCT00513799|GENETIC|Chlorhexidine showers|Apply Clorhexidine wash to entire body once daily for 5 days.
214987126|NCT00513799|PROCEDURE|Bleach baths (dilute)|Pour 2 ounces of bleach into water-filled bath tub. Soak in bath for 15 minutes. Apply once daily for 5 days.
214987127|NCT00513799|BEHAVIORAL|Intensive education on personal hygiene|Repeat hygiene methods for 5 days.
214987128|NCT01922453|OTHER|Music and Sound|
214987129|NCT03655431|OTHER|Telerehabilitation|Participants complete a standard physical therapy evaluation in-person. They are then provided telerehabilitation equipment for the telerehabilitation intervention. This intervention utilizes an Xbox Kinect sensor and tablet-based exercise software called Jintronix. The Jintronix exercise library includes an array of exercise activity options for varying functional levels. Exercise activities could be completed in sitting or standing postures and includes activities which focused on active range of motion, strength, balance, or calisthenic movements. Each activity requires the participant to complete a goal-directed game or replicate movements of an on-screen avatar. The therapist will adjust and progress the home exercise program using information provided by the Jintronix and the participant's verbal reports during clinical video teleconferencing. At the end of the intervention, the therapist will complete in-person discharge assessments.
214987130|NCT03655431|OTHER|Standard treatment|Participants complete standard in-person physical therapy evaluation, follow-up, and treatment. Therapeutic exercise and activities will be prescribed to participants to perform at home between standard follow-up treatment appointments. At the end of the intervention, the physical therapist will complete in-person discharge assessments.
214684771|NCT06362057|OTHER|Subperiosteal implant framework|"A 3D image of an edentulous maxilla bone will be derived from a computed tomography scan of an adult patient and saved as stl data. The solid geometry of the maxilla, including the cortical and spongious bone, was rebuilt from the stl data into the Digital Imaging and Communications in Medicine (DICOM) format with 3D-Doctor (Able Software Corp., MA, USA).~With the Boolean method, force loading will be achieved between prosthetic parts, subperiosteal implant screws and bone tissues"
214684772|NCT05983146|DRUG|HRS-7053 Injection|HRS-7053 is administered by intravenous (IV) infusion once a week (QW) for one treatment cycle every 4 weeks
214684773|NCT04094350|OTHER|ACF with a seed-and-recruit model|The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
214684774|NCT04094350|OTHER|ACF targeting household and neighborhood contacts|In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
214684775|NCT04094350|OTHER|ACF targeting the older population using mobile screening units|The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
214684776|NCT04094350|OTHER|Passive case finding|Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
214684777|NCT03111134|PROCEDURE|modified component separation technique|a new abdomen closure technique based on component separation technique
214684778|NCT00668655|DRUG|Metronidazole Gel|Topical, Once daily for 2 weeks
214684779|NCT03671824|OTHER|Measurements|Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.
214374126|NCT04143984|DRUG|Camrelizumab|An anti-PD-1 antibody.
214374127|NCT02923063|BEHAVIORAL|Combined Aerobic and Resistance Exercise via videoconferencing|Combined aerobic and resistance exercise session thrice weekly for 12 weeks
214374128|NCT06783374|PROCEDURE|Neuromodulation|A protocol of posterior tibial nerve electrostimulation will be implemented, inducing retrograde electrostimulation through the pelvic nerves, which are connected to the spinal cord via the sacral plexus at segments S2 and S3. It is recommended to conduct an average of 10 sessions to evaluate the efficacy of the treatment, within a range of 6 to 16 sessions, each lasting 30 minutes, completing a treatment period of 3 months.
214495611|NCT02549807|DEVICE|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
214495612|NCT04703283|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
214495613|NCT02246946|DEVICE|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
214495614|NCT02246946|OTHER|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
214495615|NCT02246946|PROCEDURE|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
214495616|NCT00083967|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
214495617|NCT05835375|OTHER|EQ-778|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
214495618|NCT05835375|OTHER|Placebo|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
214495619|NCT04980638|BIOLOGICAL|ER004|Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26
214495620|NCT01768793|BEHAVIORAL|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
214495621|NCT01768793|BEHAVIORAL|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
214374129|NCT06783374|PROCEDURE|Exercise|Participants will engage in a 60-minute exercise session, divided into two blocks: Block 1 will comprise 10 to 12 repetitions per set, aiming to achieve a perceived exertion level of 7 to 10 on the rating of perceived exertion (RPE). Block 2 will utilize the 5P® LOGSURF Method, termed Proprioceptive Perineal Postural Reeducation, which employs unstable positions to promote postural adjustment and continuous balance. This approach facilitates the activation of the abdominopelvic muscles, enhancing control and strengthening of the pelvic-perineal region.
214374130|NCT06783374|PROCEDURE|Exercise control group|Exercise The control group engages in specific pelvic floor exercises, which are less complex in terms of neuromuscular processing, such as Kegel's exercise. The protocol for these exercises is standardized and conducted individually, comprising 8 to 12 sessions of 20-40 minutes each, performed twice weekly.
214374131|NCT06783374|PROCEDURE|Sham Neuromodulation|A needle with a retractable handle will be used, commonly employed in experimental research with Streitberger and Kleinhenz placebo needles. This creates the appearance of insertion without penetrating the skin and allows the needles to remain in place for the duration of the intervention.
214374132|NCT03799068|OTHER|suprazygomatic maxillary nerve block|bilateral Suprazygomatic maxillary nerve block is performed before surgery in anaesthetized children, after aseptic preparation of the skin. The patient is in supine position with the head in neutral position. The puncture site is at the frontozygomatic angle, at the junction of the upper edge of the zygomatic arch and the frontal process. A 24G needle is attached to a syringe containing the local anaesthetic. It is advanced to reach the greater wing of sphenoid at approximately 20 mm depth, then withdrawn a few millimetres and redirected toward the nasolabial fold in a 20° forward and 10° downward direction. The progression in the pterygopalatine fossa is 35 to 45 mm. Loss of resistance after passing through the temporalis muscle assisted in determining the puncture depth. After a negative blood aspiration test, the calculated dose of the local anaesthetic is injected on each side.
214374133|NCT03799068|OTHER|surgical site infiltration|peri-incisional infiltration of bupivacaine around the incision site given by the surgeon on an anesthetized patient before the incision is done.
214374134|NCT01341002|PROCEDURE|Transfusion|Red Blood Cells (RBC) Transfusion if SCVO2 \< 70% and guidelines
214374135|NCT01341002|PROCEDURE|Transfusion|transfusion based on guidelines
214374136|NCT00980317|PROCEDURE|Restored Kidney Transplant Between Third Parties|Tumor part of the donor kidney is surgically removed and the kidney is restored and transplanted to a third party recipient
214374137|NCT01802437|DRUG|Fluoxetine|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
214374138|NCT01802437|BEHAVIORAL|Increased Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increased dose of interpersonal psychotherapy (4 extra therapy sessions) or fluoxetine.
214495622|NCT00351299|DRUG|Dexmedetomidine|dexmedetomidine infusion titrated to effect
214495623|NCT00351299|OTHER|Standard of Care|Standard of care per treating physician preference
214495624|NCT04876417|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
214495625|NCT04876417|DEVICE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
214495626|NCT03394534|OTHER|CGA group|CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
214495627|NCT04095884|PROCEDURE|blood sampling|observational study and no intervention will be given. only blood samples collected and treated with iron supplements
214495628|NCT02866942|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
214495629|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol - duration 3 weeks|Standard metabolic integrated rehabilitation protocol
214495630|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol + respiratory exercises - duration 3 weeks|Standard metabolic integrated rehabilitation protocol + respiratory exercises (12 sessions \[5 sessions/week for 3 weeks\])
214684780|NCT01073527|DRUG|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
214495631|NCT04463875|DIETARY_SUPPLEMENT|magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10|Supplementation per os
214495632|NCT03287713|DRUG|oxygen therapy|conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
214495633|NCT05359536|BEHAVIORAL|Training Early Childhood educators in PA|The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
214495634|NCT02127749|DRUG|Endotoxin|Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
214495635|NCT02127749|DRUG|Vancomycin, Metronidazole, Ciprofloxacin|ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
214495636|NCT00439270|DRUG|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
214495637|NCT00439270|DRUG|Docetaxel|Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.
214495638|NCT04316936|DRUG|Omidria|phenylephrine 1% and ketorolac 0.3% intraocular solution
215089801|NCT02703688|BEHAVIORAL|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
215089802|NCT02703688|OTHER|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
214684781|NCT01073527|DRUG|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
214684782|NCT03398369|DIAGNOSTIC_TEST|CMR/CTA Guidance for CRT|The intervention is the use of CMR and CTA to determine the optimal pacing site in the left ventricle for cardiac resynchronization therapy (CRT) and guide left ventricular lead placement.
214684783|NCT02867345|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
215089803|NCT06903286|DRUG|SPG302|Open label SPG302 to be self-administered daily by eligible participants for 52 weeks.
214684784|NCT02867345|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
214684785|NCT02867345|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
214684786|NCT01204619|BEHAVIORAL|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
214374139|NCT01802437|BEHAVIORAL|Continue to Receive Initial Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be assigned to continue initial dose of interpersonal psychotherapy.
214374140|NCT04025151|BEHAVIORAL|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
214374141|NCT04025151|BEHAVIORAL|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
214374142|NCT04025151|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
214374143|NCT04025151|BEHAVIORAL|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
214495639|NCT04316936|DRUG|Dextenza (dexamethasone ophthalmic insert) 0.4mg|intracanalicular dexamethasone insert
214495640|NCT04316936|DRUG|Dexycu, 9% Intraocular Suspension|dexamethasone intraocular suspension
214495641|NCT04316936|DRUG|Prednisolone Acetate 1%|standard postoperative ophthalmic drop regimen
214495642|NCT01268306|DEVICE|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch \& Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
214495643|NCT00294736|DRUG|Tarceva|Dose Escalation: 150-350+ mg/day
214495644|NCT00804219|BIOLOGICAL|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
214495645|NCT02854241|PROCEDURE|Biannual ultrasonography|Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.
214495646|NCT02854241|PROCEDURE|Annual noncontrast liver MRI|"Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.~DWI using multishot and T2 map are not included for initial MR reading."
214495647|NCT02854241|PROCEDURE|Contrast enhanced liver CT|In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
214684787|NCT02222038|OTHER|skin biopsy|
214684788|NCT06177054|BEHAVIORAL|Rotation guided by ultrasound|Instruction to avoid areas with hyperechogenicity - after two weeks observation
214684789|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Contour® Next One|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
214684790|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Accu-Chek® Aviva Connect|
214684791|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing FreeStyle Freedom Lite|
214684792|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing OneTouch® Verio|
214684793|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing GlucoMen® areo|
215089804|NCT03787810|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of left ventricular dysfunction
214374144|NCT04025151|BEHAVIORAL|General health through SMS|After baseline, they will receive regular e-message through SMS with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
214374145|NCT04025151|BEHAVIORAL|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
214374146|NCT04131270|BEHAVIORAL|Planning + Education|"Planning: Participants will fill in the planning forms that efer to replacing sedentary behavior with physical activity.~The following behavior change techniques are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all behavior change techniques would include references to planning."
214684794|NCT06496321|PROCEDURE|Conventional Saphenous vein harvest|The conventional one involves harvesting only the vein, without perivascular tissue or the nerve.
214684795|NCT06496321|PROCEDURE|No touch Saphenous vein harvest|"During the extraction of the saphenous vein using the no touch technique, it is sectioned with the perivascular adipose tissue and the saphenous nerve of the leg."
214684796|NCT06286436|OTHER|Dual-task training|The intervention will consist of three different tasks that participants have to carry out while performing mental calculations (counting backwards from 100 by ones, twos, and threes). The three tasks will be as follows: grouping blocks of different colours into groups according to colour; picking up beans with a spoon and carrying them to a specific place; opening and closing a bottle cap with the affected hand. The total duration of the intervention will be 12 sessions, divided into three days per week for four weeks.
214684797|NCT04875039|DRUG|Dexamethasone|dexamethasone 2 mg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
214684798|NCT04875039|DRUG|Dexmedetomidine-Dexamethasone|A mixture of dexamethasone 2mg with dexmedetomidine 50mcg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
214684799|NCT03416686|DEVICE|Radiofrequency (RF star electrode electrode_Fixed)|"The radiofrequency will be performed under ultrasound control after local anesthesia by a trained operator, after finding the lesion to be treated by the operator.~Medical device used: RF star electrode electrode\_Fixed (Starmed Co,Gyeonggi-do, Korea, French representative Cosysmed)."
214684800|NCT00827996|DRUG|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
214987131|NCT02214810|DRUG|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
214987132|NCT05432817|BEHAVIORAL|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
214987133|NCT01451073|BIOLOGICAL|Autologous cultured dermal and epidermal cells|Two pieces of occipital scalp are taken from the subject, three weeks apart. The dermal and epidermal cells from these tissues are expanded in culture. The cells are then harvested and, for certain types of product, combined. On the day the cells are harvested after manufacture, they are then injected into the balding area of the scalp of the original subject within a certain time period.
214684801|NCT01093924|BEHAVIORAL|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
214684802|NCT01158833|OTHER|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
214684803|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day,|
214495648|NCT06458179|PROCEDURE|Ultrasound-guided proximal greater occipital nerve radiofrequency ablation|In the prone position with the head slightly flexed and the US probe was placed in the neck transversely and then was located the bifid spinous process of C2 and the probe was lateralized (toward the affected side). At this level, the GON is located above the obliquus capitis inferior muscle and deeper than the semispinalis capitis muscle. The in-plane approach from medial to lateral was employed to treat the nerve with a 21 G 5-mm active tip radiofrequency needle. Sensory stimulation was administered at 50 Hz for 1 ms to induce paresthesia, pain, or irritation. A motor stimulus was applied at 2 Hz for 1 ms and up to 2 volts to see if fasciculation was absent. Then 1 mL of 2% lidocaine was administered through the RF cannulas to alleviate procedure related pain. Conventional RFA was conducted for 60 seconds at a temperature of 60 degrees. Following the procedure, 2 mg of dexamethasone was administered per lesion site.
214684804|NCT00200694|DRUG|ramipril 10 mg + valsartan 160 mg/day,|
214684805|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
214684806|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
214684807|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
214684808|NCT04657016|DRUG|Tirzepatide|Administered SC
214684809|NCT04657016|OTHER|Placebo|Administered SC
214987134|NCT03482024|DRUG|Tirzepatide|Administered SC.
214987135|NCT05224375|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System
215089805|NCT03859739|DRUG|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
214374147|NCT04131270|BEHAVIORAL|Education|The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.
214374148|NCT03168295|DRUG|Dapagliflozin 10mg then Placebo Oral Tablet|SGLT2 inhibitor - Dapagliflozin then Placebo
214374149|NCT03168295|DRUG|Placebo Oral Tablet then Dapagliflozin 10mg|Placebo then SGLT2 inhibitor - Dapagliflozin
214374150|NCT02427659|BEHAVIORAL|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
214374151|NCT02427659|BEHAVIORAL|Audio (sound of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care."
214374152|NCT02427659|BEHAVIORAL|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
214374153|NCT01519492|DRUG|AFN-12520000|Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
214374154|NCT02945332|BEHAVIORAL|Required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
214374155|NCT02945332|BEHAVIORAL|Non-required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
214374156|NCT02945332|DEVICE|Fitbit Flex|
214374157|NCT03756584|DEVICE|Theta-burst stimulation|iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)
214374158|NCT04194203|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
214374159|NCT04194203|DRUG|Placebo|Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
214374160|NCT04194203|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
214374161|NCT04194203|DRUG|Paclitaxel|Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.
214374162|NCT04194203|DRUG|Pemetrexed|Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.
214374163|NCT04194203|DRUG|Carboplatin|Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
214495649|NCT01290003|DRUG|Piperacillin-Tazobactam and Amikacin|Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
214987136|NCT03727165|OTHER|Continuous enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 24 hours per day
214987137|NCT03727165|OTHER|Cyclic enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 16 hours per day
214374164|NCT01342458|OTHER|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
214374165|NCT01177514|DRUG|Gabapentin|Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
214374166|NCT01177514|DRUG|Sugar pill|Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
214374167|NCT05138445|BEHAVIORAL|FAME-W self-management intervention|FAME-W is an occupational therapy led, four-week group based self-management intervention. It focuses on providing people with IA skills and confidence to manage demands of their employment and daily life through education on IA, self-management techniques, managing symptoms of fatigue, pain and stress and managing physical and mental health.
214374168|NCT05138445|BEHAVIORAL|FAME-W Handbook|Individuals in this arm receive a self-guided FAME-W handbook containing the same information as that covered in the four week FAME-W program
214495650|NCT05804994|DEVICE|Elgydium Clinic Sensileave Gel (V063B - DP3003)|Tested product is applied/used only once a day before whitening tray wear.
214495651|NCT00188045|DRUG|Propranolol - Spironolactone|
214495652|NCT01521169|OTHER|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
214495653|NCT01521169|OTHER|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
214987138|NCT01456923|OTHER|Treatment with chemotherapy|
214987139|NCT01456923|OTHER|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
214987140|NCT01456923|PROCEDURE|surgery|
214987141|NCT01873144|DRUG|Epinephrine 1/1000|Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
214987142|NCT01873144|DRUG|HSS 3%|Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
214987143|NCT01873144|DEVICE|HHHFNC|Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age
214987144|NCT01873144|DRUG|NS (0.9%)|Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
214987145|NCT02036918|DRUG|Sipuleucel-T|
214987146|NCT02036918|PROCEDURE|Lymph Node Biopsy|
214684810|NCT04771052|OTHER|COVID Rehabilitation Program for the Elderly (CORE)|In the intervention unit, two teams (core team: physiotherapists and service healthcare workers; specialized team: occupational therapist, registered dietician, social worker) are dedicated to the patients hospitalized in COVID-19 unit. To prevent malnutrition, caused by disease-associated inflammation, the Nutrition as Medicine program (prescribed small doses (30 or 60 mL; 2 kcal/mL) of oral nutrition supplement dispensed with medication pass, 1 to 4 times a day), has been systematically implemented (collective prescription). To improve muscle strength, balance and tissue oxygenation and concomitantly reduce immobilization and risk of falls, each patient has a private pedal exerciser, resistance elastic bands and free weights to perform a progressive, monitored and individualized rehabilitation program thrice a day.
214987147|NCT00469794|PROCEDURE|stress test|
214374169|NCT01682213|DRUG|Dabrafenib|Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
214684811|NCT01182623|OTHER|Observation of surface patterns of polyps|examination of the surface patterns of polyps using FICE and indigo carmine dye spray
214684812|NCT03810690|BIOLOGICAL|mRNA-3704|mRNA-3704 dispersion for intravenous (IV) infusion
214684813|NCT01755195|DRUG|Cabozantinib|Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
214374170|NCT05838001|PROCEDURE|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the breast lesion
214374171|NCT05838001|PROCEDURE|marker clip localization|Positioning marker clip in the center of the breast lesion
214374172|NCT05570643|DRUG|LPS|This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.
214374173|NCT05570643|DRUG|Placebo|Injection of NaCl 0.9%.
214374174|NCT01891448|OTHER|WebCONSORT tool|Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
214374175|NCT01891448|OTHER|Modified WebCONSORT tool|Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
214374176|NCT03645902|DIAGNOSTIC_TEST|Magnetic resonance imaging|
214495654|NCT01521169|OTHER|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
214495655|NCT00990600|OTHER|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
214684814|NCT02139995|BEHAVIORAL|RBC transfusion based on different protocols|transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
214987148|NCT03518684|DRUG|Natalis|"A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping"
214987149|NCT02104102|OTHER|Mirror Therapy|Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.
214987150|NCT02104102|OTHER|Kinesiotherapy|Hands movements.
214374177|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
214374178|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
214374179|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
214495656|NCT03600844|BEHAVIORAL|Community distribution of SP for IPTp|SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
214374180|NCT02388503|DIETARY_SUPPLEMENT|no added fruit extract|
214374181|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
214374182|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
214374183|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
214374184|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
214495657|NCT00862043|DRUG|Sildenafil Citrate|40 mg t.i.d.
214495658|NCT00862043|DRUG|Placebo|Placebo t.i.d.
214495659|NCT03420196|OTHER|Supervised exercise program|"It will consist in a supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
214684815|NCT04452162|DIAGNOSTIC_TEST|MRI|You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
214684816|NCT00419913|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA 25 mg tid
214684817|NCT04980833|DRUG|Alpelisib|Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
214684818|NCT05710887|DRUG|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
214684819|NCT05710887|DRUG|Placebo|Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
214374185|NCT05687955|OTHER|Hip Exercise Program|The exercise intervention is being implemented 3 times per week. Two sessions can be completed at home by the participant, and one session per week will be attended by a physiotherapist that will monitor exercise technique and progress the exercise program for each participant. The exercise protocol has been specifically designed to focus on hip rehabilitation appropriate for circus performance. The exercise program will involve hip strength exercises in the sagittal, coronal and transverse planes using weights and elastic bands (Theraband). It will also include trunk strength and postural correction exercises to address swayback posture which is a common clinical presentation in those with hip dysplasia.
214374186|NCT00742079|DRUG|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
214374187|NCT00742079|BEHAVIORAL|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
214374188|NCT02267005|DIETARY_SUPPLEMENT|Creapure|Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
214374189|NCT02267005|DIETARY_SUPPLEMENT|Glucose Tablet|Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
214495660|NCT03420196|OTHER|Non supervised exercise program|"It will consist in a non supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
214495661|NCT02085772|OTHER|Blood samples at 37-38 Weeks of amenorrhea|
214495662|NCT02085772|OTHER|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
214495663|NCT02085772|OTHER|Blood samples at the time of delivery|
214495664|NCT02084420|DRUG|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
214495665|NCT02084420|DRUG|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
214495666|NCT00002236|DRUG|Indinavir sulfate|
214495667|NCT00002236|DRUG|Delavirdine mesylate|
214495668|NCT00002236|DRUG|Zidovudine|
214495669|NCT04359017|DRUG|Lidocaine 1% Injectable Solution|The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
214495670|NCT05604755|DRUG|HQP1351( Olverembatinib dimesylate)|HQP1351 was initiated at a dose of 40mg every two days
214495671|NCT06275659|DEVICE|CT-100-004-A|Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to strengthen inhibitory control. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
214495672|NCT06275659|DEVICE|CT-100-004-B|The CT-100-D-004-B Processing speed training component uses implicit training targeting processing speed. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
214495673|NCT01970410|DRUG|teriflunomide|14 mg oral teriflunomide daily
214684820|NCT05429736|BEHAVIORAL|Motor Skill Training (MST)|During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
215089806|NCT00970450|DRUG|Paracetamol|Paracetamol 1 g i.v. once
215089807|NCT00970450|DRUG|Tropisetron|Tropisetron 5 mg i.v. once
215089808|NCT00970450|DRUG|Placebo|Saline
214374190|NCT06453655|BEHAVIORAL|Nursing Process|In the first step of the nursing process, nursing diagnoses NANDA-I and nursing outcomes (NOC) appropriate to the needs of the individual were selected. Immediately afterwards, the baseline measurements of NOCs were made. In the second stage, nursing interventions were determined in line with the selected diagnoses and started to be implemented. Instructions for the implementation of the selected NICs were reminded by phone 3 days before the procedure appointment and compliance with colonoscopy preparation instructions was monitored. In the third stage, after measurement of the NOCs were performed on the day of the procedure. In addition, the BBPS scores calculated by the endoscopist during the procedure were taken from the patient file and recorded in the data collection form and the stages of the nursing process were completed.
214684821|NCT05429736|DEVICE|Transcutaneous Spinal Stimulation (TSS)|TSS will be delivered using a commercially available neuromuscular electrical stimulator. The active electrode will be positioned directly over the spine at the T11/T12 spinous interspace, and the reference electrode will be positioned over the umbilicus. Stimulation intensity will be gradually increased until paresthesia of the lower legs and feet is achieved or to the highest level each participant can tolerate. Stimulation will be delivered for a total duration of 30 min after paresthesia/ maximum tolerability is reached.
214684822|NCT04686318|DIAGNOSTIC_TEST|Biomarkers for acute pyelonephritis|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~* Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~* Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~* Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection."
214684823|NCT00479024|DRUG|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
214374191|NCT03767179|DIAGNOSTIC_TEST|study|procalcitonin, sedimentation, CRP, leukocyte identification
214374192|NCT03963154|BIOLOGICAL|Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)|Implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE))
214495674|NCT03443700|DEVICE|EKSO-GT|Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).
214495675|NCT03443700|PROCEDURE|Standard neurorehabilitation locomotor training|Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
214495676|NCT02568215|BIOLOGICAL|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
214495677|NCT02568215|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
214495678|NCT05953363|DEVICE|BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes|Insertion of a BD NRFit™ spinal needle and optional BD NRFit™ Spinal Introducer Needle using a BD NRFit™ Syringe to perform the neuraxial procedure.
214495679|NCT02691169|DRUG|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
214495680|NCT02403375|DEVICE|Accu-Chek Insight Pump System|Continuous subcutaneous insulin infusion pump
214495681|NCT00201149|BEHAVIORAL|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
214495682|NCT03085433|DEVICE|Microfluidic Sperm Sorting|Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.
214495683|NCT03085433|PROCEDURE|in vitro fertilization|ivf/icsi
214495684|NCT04900467|BIOLOGICAL|Pfizer|BNT162b2 (Comirnaty®), Pfizer/BioNTech, mARN vaccine,
214684824|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer relaxing acupressure
214684825|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer sham acupressure
214684826|NCT06442891|OTHER|Internet-Based Intervention|Receive access to acupressure mobile app
214684827|NCT06442891|OTHER|Interview|Ancillary studies
214684828|NCT06442891|OTHER|Medical Device Usage and Evaluation|Receive an AcuWand
214684829|NCT06442891|OTHER|Questionnaire Administration|Ancillary studies
214684830|NCT00772512|DRUG|PF-04802540|5 mg capsule, single dose
214684831|NCT00772512|DRUG|PF-04802540|15 mg capsule, single dose
214374193|NCT01181726|DRUG|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
214374194|NCT01181726|DRUG|Activella®|1 mg/0.5 mg Tablets
214374195|NCT01638247|DRUG|Tamoxifen|25 mg daily.
214374196|NCT01638247|DRUG|Tamoxifen and GnRH analogue|"25 mg Tamoxifen daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
214374197|NCT01638247|DRUG|Exemestane and GnRH analogue|"25 mg Exemestane daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
214684832|NCT00772512|DRUG|Placebo|Placebo capsule, single dose
214684833|NCT01447173|DRUG|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
214684838|NCT01740622|OTHER|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
214987151|NCT04226443|DRUG|Midazolam intravenous injection|The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.
215089809|NCT05665400|DEVICE|Bloomlife Lovelace FT|Bloomlife Lovelace FT is a non-invasive, wireless, external measurement system used to measure accelerometer and electrophysiological signals on pregnant women with a singleton pregnancy, by acquiring biopotential signals from abdominal surface electrodes.
215089810|NCT01882517|DIETARY_SUPPLEMENT|Yogurt that contains plant stanol esters|
215089811|NCT01882517|DIETARY_SUPPLEMENT|Placebo yogurt|
214374198|NCT03606356|DRUG|Onabotulinum toxin A|Cranial Subcutaneous Injections
214374199|NCT03219385|DEVICE|Mirabilis System|The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
214374200|NCT04687735|OTHER|Intervention after nerve block|Brachial plexus block + Physical therapy
214495685|NCT04900467|BIOLOGICAL|Moderna|mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular
214495686|NCT02987218|DRUG|Propofol|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
214495687|NCT02987218|DRUG|Desflurane|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
214495688|NCT03406169|DRUG|Sildenafil 25 MG Oral Tablet|twice a day dosing
214495689|NCT03406169|DRUG|Pentoxifylline|400mg twice a day
214495690|NCT03406169|OTHER|Placebo|placebo twice a day
214495691|NCT04720612|BIOLOGICAL|Omalizumab|Single subcutaneous dose of 375mg of omalizumab and standard of care.
214495692|NCT04720612|OTHER|Placebo|Single subcutaneous dose of normal saline in a syringe identical to that of the omalizumab arm and standard of care.
214495693|NCT00073372|DRUG|Abciximab|
214495694|NCT01319838|DRUG|Isotretinoin|\>12 kg: 160 mg/m2/day, given PO, divided BID \<=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
214495695|NCT04155905|PROCEDURE|fistulotomy and marsupialization of wound edges|after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\\0 sutures
214495696|NCT04155905|PROCEDURE|fistulotomy|after defining the fistulous track it was laid open (marsupialization)
214495697|NCT05909670|BEHAVIORAL|Family Advice and Support Text and Telephone (FASTT) program|The Family Advice Support Text and Telephone (FASTT) service is a telehealth model that provides on-demand, evidence-based advice and support to reduce child behavior problems, address concerns about child development, and help manage stress for caregivers of children with DD. By using text and telephone, which are widely available without disparities in access by race, ethnicity, or socioeconomic status, FASTT overcomes barriers associated with videoconferencing which requires dependable Internet and familiarity with technology use. FASTT allows support to be delivered at times and locations that are convenient for the caregiver.
214495698|NCT02105259|BEHAVIORAL|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for patients social anxiety disorder
214684839|NCT03588767|DRUG|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
214684840|NCT03588767|OTHER|No Vitamin D3 + anabolic substance|Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
214684841|NCT04921722|DRUG|Percutaneous sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In experimental group, we administrate percutaneous sirolimus. Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
214684842|NCT04921722|DRUG|Oral sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In active comparator group, we administrate oral sirolimus. Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
214684843|NCT05901831|DRUG|Finerenone|Dose A, Dose B, oral
214684844|NCT05901831|OTHER|Placebo|Oral
214684845|NCT02545296|OTHER|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
214684846|NCT03067896|DRUG|Bupivacaine|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
214684847|NCT03067896|DRUG|Dexmedetomidine|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline
214684848|NCT03067896|DRUG|Magnesium Sulfate|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline
214684849|NCT05293132|DRUG|Montelukast Sodium 10 mg|Film coated tablets containing 10 mg montelukast
214374201|NCT00509418|DIETARY_SUPPLEMENT|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
214374202|NCT00509418|OTHER|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
214684850|NCT05293132|DRUG|Co-Enzyme Q10|Capsules contain 210 mg Co-Enzyme Q10
214374203|NCT02000830|DRUG|Stannsoporfin|Stannsoporfin administered by intramuscular (IM) injection
214374204|NCT02000830|DRUG|Placebo|Matching placebo administered by IM injection
214374205|NCT03688152|DRUG|INCB053914|"Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
214495699|NCT02105259|OTHER|Waiting list|Waiting list, where participants wait for delayed treatment
214495700|NCT00199056|DRUG|Dexamethasone / Prednisolone|
214495701|NCT00199056|DRUG|Cyclophosphamide|
214495702|NCT00199056|DRUG|Methotrexate|
214495703|NCT00199056|DRUG|Vincristine / Vindesine|
214495704|NCT00199056|DRUG|Daunorubicin|
214495705|NCT00199056|DRUG|Asparaginase|
214495706|NCT00199056|DRUG|G-CSF|
214495707|NCT00199056|DRUG|Cytarabine|
214495708|NCT00199056|DRUG|6-Mercaptopurine|
214495709|NCT00199056|DRUG|VP16|
214495710|NCT00199056|DRUG|Adriamycin|
214495711|NCT00199056|DRUG|Thioguanine|
214987152|NCT04226443|DRUG|Remifentanil intravenous bolus dose|A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
214495712|NCT00199056|DRUG|VM26|
214495713|NCT00199056|DRUG|Idarubicin|
214495714|NCT00199056|DRUG|Fludarabine|
214495715|NCT00199056|DRUG|Ifosfamide|
214495716|NCT00199056|PROCEDURE|CNS irradiation|
214495717|NCT00199056|PROCEDURE|Mediastinal irradiation (if residual tumor)|
214495718|NCT00199056|PROCEDURE|stem cell transplantation|
214495719|NCT00547066|BIOLOGICAL|veltuzumab|hA20 will be administered intravenously in two doses over two weeks
214495720|NCT02221505|DRUG|LOP628|
214495721|NCT00246805|DEVICE|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
214684851|NCT05293132|DRUG|Standard Treatment|Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
214684852|NCT02460588|DRUG|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
214684853|NCT02460588|DRUG|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
215089812|NCT05366491|DIAGNOSTIC_TEST|Il-38 serum level|measurement of serum levels of IL-38
214495722|NCT05923190|DRUG|Enfortumab vedotin|EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
214495723|NCT05923190|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of a 21-day cycle
214495724|NCT00409799|DRUG|I-0401 (a new bone graft substitute)|1 time application
214495725|NCT02379936|DEVICE|The Neo Hilda|"This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.~Point of care method"
214495726|NCT02379936|PROCEDURE|Traditional evaluation|Traditional way of evaluation
214495727|NCT02379936|DEVICE|iPhone 4S|
214495728|NCT00930306|DRUG|AZD2066|12 doses, Given as capsule, 2 mg \& 8 mg
214495729|NCT00930306|DRUG|Caffeine|2 doses, Given as Tablet, 2x50 mg
214495730|NCT00930306|DRUG|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
214495731|NCT00930306|DRUG|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
214495732|NCT00930306|DRUG|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
214495733|NCT02476435|DEVICE|Active rTMS|Strong electromagnetic fields (\~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
214495734|NCT02476435|DEVICE|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
214495735|NCT02920710|DRUG|Repository Corticotropin Injection|"* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
214495736|NCT00293397|DEVICE|Drug-eluting beads loaded with doxorubicin hydrochloride|Doxorubicin eluting beads
214495737|NCT05142046|DRUG|Fluid balance|The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
214495738|NCT02162225|DRUG|beet juice (Unbeetable)|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
214495739|NCT03058445|DEVICE|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
214495740|NCT03058445|DEVICE|CVC|Injection of 5 ml of saline
214495741|NCT02189174|DRUG|CLR457|
214684854|NCT02460588|DRUG|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
214684855|NCT05027646|DRUG|Sancuso - Part 1|Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
214684856|NCT05027646|DRUG|Sancuso - Part 2|Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
214374206|NCT03688152|DRUG|INCB050465|"Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
214374207|NCT06257368|DEVICE|Coloplast TFL Drive|Thulium Fiber laser
214374208|NCT01264380|DRUG|RO5185426|Single oral dose, fasted
214374209|NCT01264380|DRUG|RO5185426|Single oral dose, with high fat meal
214374210|NCT01264380|DRUG|RO5185426|Continuous administration, orally twice daily
214374211|NCT04269018|BEHAVIORAL|Cancer specific Mobile text message|The intervention is cancer specific lifestyle mobile text messages daily for 2 months
214374212|NCT04269018|BEHAVIORAL|General health messages|Daily text related with general health message
214374213|NCT01611584|DRUG|ALA-induced Fluorescence|ALA Dose- 20 mg/kg
214374214|NCT01147822|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
214374215|NCT01147822|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
214374216|NCT02070900|DEVICE|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
214374217|NCT02070900|OTHER|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
214374218|NCT01860586|DRUG|Bevacizumab|Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
214374219|NCT06288061|DEVICE|Non-invasive Neuromodulation|"This intervention group will receive neuromodulation treatment two days a week for a total of six sessions.~The patient is placed in the supine position with a cushion under the knees. The physiotherapist will be positioned behind the patient's head on the side to be treated. The technique will be applied on both anterolateral sides of the neck, where the Phrenic nerve passes in front of the anterior Scalene, between the Subclavian arteries and veins. Neuromodulation will be applied with a Pointer Excel II. It will be applied with negative polarity, at a frequency of 2 Hertz (HZ) and with a current intensity varying between 0 and 45 milliamperes (mA). The intensity shall be increased progressively until the patient's diaphragmatic contraction can be observed without pain. The technique shall be applied on each side for a total of 8 minutes, divided into intervals of 10 seconds of stimulation and 20 seconds of rest."
214495742|NCT02540824|DRUG|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
214495743|NCT01611493|DEVICE|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
214495744|NCT01611493|DEVICE|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
214495745|NCT04017793|BEHAVIORAL|Mindfulness Based Stress Reduction|Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.
214495746|NCT04017793|BEHAVIORAL|Relaxation Group|8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
214495747|NCT00674752|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
214495748|NCT00674752|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
214495749|NCT00674752|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
214495750|NCT04688060|DIAGNOSTIC_TEST|Falls Efficacy Scale-International (FES-I)|The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
214495751|NCT03830567|OTHER|Pharmacist prescription|Pharmacist prescribed hormonal contraception (initiation or continuation).
214495752|NCT03830567|OTHER|Clinician prescription|Clinician prescribed hormonal contraception (initiation or continuation).
214495753|NCT04623489|BEHAVIORAL|¡Vivir Mi Vida! Lifestyle Intervention|
214495754|NCT00698113|PROCEDURE|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
214495755|NCT00698113|OTHER|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
214495756|NCT06299670|DRUG|Thalidomide|Patients will get only Thalidomide
214684857|NCT01287234|OTHER|Echocardiogram/SonR|All patients will have an echocardiograph and SonR sensor readings
214684858|NCT00820703|DRUG|Nexagon®|
214684859|NCT00820703|DRUG|Nexagon® vehicle|
214987153|NCT02921165|DRUG|analgesic mouth rinses (dissolved Aspirin)|Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
214987154|NCT02921165|DRUG|Normal saline rinses.|Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
214987155|NCT05207501|BEHAVIORAL|Exercise|Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.
214987156|NCT06393231|OTHER|acupuncture|Acupuncture is applied to ST8, GB14, BL12, SJ23, ST2, SI18, ST4, ST7, RN24, Ex-HN16, SJ17 and LI4 on the affected side and needles are retained for half an hour.Add infrared irradiation therapy in the same time
214495757|NCT06299670|DRUG|Hydroxy Urea|Patients will get only Hydroxyurea
214495758|NCT06299670|DRUG|Combinations|Combination Of Thalidomide \& Hydroxyurea
214495759|NCT01218009|DRUG|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
214495760|NCT01218009|DRUG|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
214495761|NCT02095717|DRUG|Curcumin|
214495762|NCT02095717|DRUG|Placebo|
214495763|NCT02095717|DRUG|Taxotere|
214495764|NCT06512181|OTHER|Conservative/Expectant Management|At time of caesarean section, participants will not have a hysterectomy, but will be treated clinically to preserve their uterus.
214495765|NCT02540031|DRUG|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
214684860|NCT01150877|DRUG|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
214684861|NCT05482269|OTHER|no intervention|no intervention
214684862|NCT02423824|BIOLOGICAL|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
214495766|NCT02540031|DRUG|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
214495767|NCT02631369|DEVICE|Heidelberg Spectralis OCT device|
214495768|NCT00336349|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
214684863|NCT04116632|DRUG|BMS-963272|Single dose with varying frequency among groups
214684864|NCT04116632|DRUG|Placebo|Specified dose on specified days
214684865|NCT01003028|DRUG|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
215089813|NCT03023254|OTHER|Hydrotherapy|3-week Avène hydrotherapy
215089814|NCT03062618|DRUG|PRCL-02|Oral tablet(s) administered with water
215089815|NCT03062618|DRUG|Placebo Oral Tablet|Administered with water
215089816|NCT01146652|DRUG|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214374220|NCT06288061|OTHER|Cervico-dorsal Massage|"This intervention group will receive manual therapy two days a week for a total of six sessions.~The patient shall be placed prone position with a cushion under his or her feet. This group will receive manual therapy on the entire posterior cervical and dorsal region, the area between the occipital bone, the shoulders and the scapulae. The massage will be carried out with a little oil or cream for about 20 minutes."
214374221|NCT04457830|DRUG|F520|3mg/kg every 3 weeks
214374222|NCT06232720|DEVICE|Q300 QART Medical|The Q300TM Imaging system includes a Quantitative Phase Microscope. Q300TM uses a low intensity coherent light source, in a uniquely configured interferometer, which measures light delay as it passes different locations across the sperm cell. The amount
214374223|NCT04762329|OTHER|Manage My Pain (MMP) digital pain app group|To evaluate the extent of patient engagement with the Manage My Pain (MMP) digital application when used in a clinical setting
214495769|NCT00174252|DRUG|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
214495770|NCT05298371|BEHAVIORAL|Corrected Sitting postures|Change after being in Corrected Sitting postures
214495771|NCT05298371|BEHAVIORAL|Natural / relaxed sitting postures|Change after being in relaxed sitting postures
214495772|NCT05298371|BEHAVIORAL|Corrected Standing posture|Change after being in Corrected Standing posture
214495773|NCT05298371|BEHAVIORAL|Natural / relaxed standing postures|Change after being in relaxed standing postures
214495774|NCT06395571|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Goat milk-based infant formula fed at age appropriate quantities for 24 weeks
214495775|NCT06395571|DIETARY_SUPPLEMENT|Cow's milk-based infant formula|Cow's milk-based infant formula formula fed at age appropriate quantities for 24 weeks
214684866|NCT01003028|DRUG|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
214684867|NCT06551077|PROCEDURE|POSTERIOR RECTUS SHEATH HIATAL AUGMENTATION (PORSHA)|Use of a novel permanent autologous vascularized biologic fascial flap to reconstruct the diaphragmatic hiatus following standard hiatal hernia repair in selected patients. This technique is called a posterior rectus sheath flap hiatal augmentation or PoRSHA.
214684868|NCT03312777|DRUG|Omnitram|Omnitram tablets overencapsulated
215089817|NCT06876896|DEVICE|Accuryn Foley catheter device|Accuryn foley catheter placed on all subjects after consent who are having treatment for atrial flutter or atrial fibrillation
215089818|NCT00941369|DRUG|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
215089819|NCT03919227|PROCEDURE|empty bladder before inserting UAS|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS, so that we can see if the empty bladder is easier for inserting UAS.
214374224|NCT03592472|DRUG|Pazopanib|All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
214684869|NCT03312777|DRUG|Tramadol|Tramadol tablet overencapsulated
214684870|NCT03312777|DRUG|Placebo|Microcrystalline powder overencapsulated
214684871|NCT00595699|DRUG|escitalopram|10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
214684872|NCT00595699|DRUG|placebo|Placebo
215089820|NCT03919227|PROCEDURE|do not interfere with the filling degree of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS, so that we can see if the filling degree of bladder has impact on the insertion of UAS.
215089821|NCT01711281|DEVICE|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
214374225|NCT03592472|DRUG|Abexinostat|The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
214374226|NCT03592472|OTHER|Placebo|The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
214374227|NCT04382924|DRUG|NP-120 (Ifenprodil)|Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID
214374228|NCT06834672|DRUG|IBI354|intravenous infusion of 12 mg/kg on Day 1 of each 3-week treatment cycle
214495776|NCT04544319|DRUG|Zemiglo 50mg and Forxiga 10mg|Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD
214374229|NCT06834672|DRUG|paclitaxel/Gemcitabine/Liposomal doxorubicin|paclitaxel：- Usage and dosage: 80 mg/m2 administered as an intravenous infusion on Day 1 of each weekly treatment cycle。 Gemcitabine：Usage and dosage: intravenous infusion at 1000 mg/m2 on Days 1, 8 of each 3-week treatment cycle。 Liposomal doxorubicin：Usage and dosage: intravenous infusion of 40 mg/m2 on Day 1 of each 4-week treatment cycle
214374230|NCT06214078|DIETARY_SUPPLEMENT|nicotinamide mononucleotide|Nicotinamide mononucleotide (NMN), a bioactive substance found in a variety of foods, is a precursor for the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ plays a crucial role in a variety of biological processes including cell death, senescence, gene expression, neuroinflammation, and DNA repair.
214374231|NCT06214078|OTHER|placebo|The placebo mimicked the appearance and properties of nicotinamide mononucleotide(NMN) enteric-coated capsules. The specifications, usage and dosage of placebo were the same as those of NMN.
214374232|NCT05644223|DRUG|edaravone dexborneol|intravenous edaravone dexborneol 37.5mg twice daily
214374233|NCT01683760|DRUG|Fluconazole|Prophylactic fluconazole administration in VLBW infants
214374234|NCT00530803|DRUG|EMLA Cream|60 minutes x1
214374235|NCT00530803|COMBINATION_PRODUCT|Synera Patch|20 minutes x1
214374236|NCT04210414|OTHER|Embryo transfer|Transfer of only one embryo
214374237|NCT02405260|DRUG|TTP399 400 mg|once daily
214374238|NCT02405260|DRUG|TTP399 800 mg|once daily
214374239|NCT02405260|DRUG|Sitagliptin 100 mg|once daily
214374240|NCT02405260|DRUG|Placebo|once daily
214374241|NCT02013388|DRUG|N91115|Given PO daily for 14 days
214495777|NCT04544319|DRUG|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
214495778|NCT04737291|DEVICE|drug coated balloon|use of drug coated balloon in treatment of critical limb ischemia
214495779|NCT03170882|DRUG|Ixazomib|Ixazomib capsules
214495780|NCT03170882|DRUG|Pomalidomide|Pomalidomide capsules
214374242|NCT02013388|DRUG|Placebo|Given PO daily for 14 days
214374243|NCT02013388|DRUG|N91115|Given PO only on Day 1
214374244|NCT02013388|DRUG|Placebo-Day 1 only|Given PO- only on Day 1 (single dosed to match single dose treatments)
214495781|NCT03170882|DRUG|Dexamethasone|Dexamethasone tablets
214495782|NCT05823818|DEVICE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
214684873|NCT01605071|DRUG|Estradiol|"1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo"
214684874|NCT00392171|DRUG|Temozolomide|Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression
214684875|NCT04792853|BEHAVIORAL|Tab-G|Participants receive a tablet preloaded with Tab-G application and an accelerometer.
214684876|NCT03499808|BIOLOGICAL|Isatuximab|Given IV
214684877|NCT03499808|OTHER|Laboratory Biomarker Analysis|Correlative studies
214684878|NCT03470922|BIOLOGICAL|Relatlimab|Specified dose on specified day
214684879|NCT03470922|BIOLOGICAL|Nivolumab|Specified dose on specified days
214684880|NCT04423926|DRUG|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
214684881|NCT04423926|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
214684882|NCT04423926|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 d1
214684883|NCT04423926|DRUG|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
214684884|NCT04423926|DRUG|Prednisolone|Prednisolone 60mg/m2 d1-5
214684885|NCT02340819|DRUG|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
214684886|NCT03987412|BEHAVIORAL|Lifestyle intervention with APP|The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
214684887|NCT03830008|BEHAVIORAL|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
215089822|NCT03373032|OTHER|Stiper|"Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes."
214374245|NCT03420924|DEVICE|Thermal suit|Forced-air warming device will be connected to the trouser legs of the thermal suit.
214374246|NCT03420924|DEVICE|Conventional hospital clothes|The warming mattress and a forced-air warming blanket for the lower body will be used intraoperatively.
214374247|NCT05356598|OTHER|Authority-delivered Health promotion video|A video delivered by a US Army Lieutenant Colonel (authority figure) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
214374248|NCT05356598|OTHER|Peer-delivered Health Promotion Video|A video delivered by a US Army ROTC cadet (peer) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
214374249|NCT05356598|OTHER|Control Group Video|Video of a US Army First Lieutenant squatting, bench pressing, and deadlifting with voiceover. No mention of musculoskeletal injuries or help-seeking behavior.
214374250|NCT06235658|BEHAVIORAL|Gentle Yoga|Participants will attend two virtual 60-minute gentle yoga sessions per week for 12 weeks. Each session will be conducted via videoconference using the Zoom platform, with participants joining from their homes.
214374251|NCT05434845|OTHER|Blood draw|An additional 8 mL of blood will be drawn during routine lab collection
214684888|NCT03587675|DIAGNOSTIC_TEST|EVH test|
214374252|NCT01153139|DEVICE|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)|intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
214374253|NCT00429663|DEVICE|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
214374254|NCT00429663|DEVICE|locking periarticular plate|Standard of care device for femur fractures
214374255|NCT04000620|PROCEDURE|surgery|treatment intent surgery
214374256|NCT04000620|PROCEDURE|punture|diagnostic punture
214374257|NCT04207840|COMBINATION_PRODUCT|Epinephrine (0.125 mg/inhalation)|Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.
214374258|NCT04207840|COMBINATION_PRODUCT|Epinephrine Injection Auto-Injector (0.3mg/0.3mL)|Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.
215089823|NCT03373032|OTHER|Acupuncture|Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.
215089824|NCT03373032|OTHER|Exercise|Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
215089825|NCT03373032|OTHER|Follow Up|Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.
215089826|NCT03373032|OTHER|Observation|The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
215089827|NCT04485689|DRUG|Capsaicin Topical - alone|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours
214374259|NCT04207840|COMBINATION_PRODUCT|Albuterol Sulfate (0.09 mg/inhalation)|Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.
214374260|NCT03590600|DRUG|BTZ-043|Powder and solvent for oral suspension
214374261|NCT03590600|DRUG|Placebo|Matching placebo: powder and solvent for oral suspension
214374262|NCT03446014|DEVICE|Fitbit Sub-Study|
214374263|NCT05409989|DEVICE|FRED™ X™|The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.
214374264|NCT04947163|DEVICE|Inspiratory Muscle Training|Participants will perform home-based IMT twice daily \[once in the morning (between 7:00 and 12:00 am) and once in the evening (between 16:00 and 21:00 pm)\], for 8 consecutive weeks, using a mechanical pressure threshold loading device. In addition, participants in this group will try to increase the inspiratory resistance when the participants feel that 30 breaths are achievable with ease or if the participants could reach 35 consecutive breaths.
214374265|NCT04947163|DEVICE|Sham IMT|Participants will perform 60 slow breaths once daily at a load setting of 0 (corresponding to \~15% \[baseline\] MIP), using the same device as the IMT group. For the sham group, the ability to adjust the training load will be prevented using sticky tape applied to the device's load adjuster.
214374266|NCT00735501|DRUG|insulin detemir|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
214374267|NCT00542048|DRUG|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
214374268|NCT00901888|DRUG|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
214374269|NCT00901888|DRUG|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
214374270|NCT03243422|OTHER|Successful aging health education intervention|"The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over approximately 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization."
214374271|NCT03243422|OTHER|Hearing intervention|The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
214374272|NCT02466646|DRUG|Klorhex® Gel, rinse and spray|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
214374273|NCT02466646|PROCEDURE|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
214495783|NCT01233934|DRUG|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
214495784|NCT01233934|DRUG|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
214495785|NCT00154115|DRUG|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
214495786|NCT00154115|DRUG|placebo|Placebo
214495787|NCT02958800|OTHER|Intervention|"The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A."
214495788|NCT03802994|DRUG|23 valent pneumococcal polysaccharide vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.
214495789|NCT03802994|BIOLOGICAL|13 valent conjugated pneumococcal vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.
214495790|NCT03802994|OTHER|Peripheral blood sample|Peripheral blood samples (30-60 mL) will be collected at day 0 (pre-immune), day 7, and day 30 (4 weeks post-PPV23) for groups 1-4 and at days 366, 373 and 396 for group 5. In addition, day 5, and 10 blood samples will be obtained from a limited (n=10) number of elderly RT participants to determine the optimal time point for circulation of PPS-specific B cells. Yearly blood samples will be obtained thereafter for serum antibody and OPA analyses to test longevity of antibody and OPA responses. Samples obtained from days 0, 30 and yearly samples will be used for antibody titers and opsonophagocytic assays. Samples from day 0 (day of vaccination with PCV13) and day 7 will be used for flow cytometric analysis.
214374274|NCT02466646|PROCEDURE|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
214495791|NCT02620306|DRUG|Fimsartan 60mg~120mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
214495792|NCT02620306|DRUG|Fimsartan 60mg~120mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
214495793|NCT02620306|DRUG|Losartan 50mg~100mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
214495794|NCT02620306|DRUG|Losartan 50mg~100mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
214684889|NCT03640806|OTHER|PHYSICAL ACTIVITY|3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
214684890|NCT02258009|DRUG|Ranibizumab|0.5 mg intravitreal injections
215089828|NCT04485689|DRUG|Placebo - alone|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
214684891|NCT02258009|DRUG|Aflibercept|2 mg intravitreal injections
214684892|NCT04141787|DRUG|Ceftriaxone|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
214684893|NCT04141787|DRUG|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
214684894|NCT00004285|DEVICE|Standard dose, low flux hemodialysis|
214684895|NCT00004285|DEVICE|Standard dose, high flux hemodialysis|
214684896|NCT00004285|DEVICE|High dose, low flux hemodialysis|
214684897|NCT00004285|DEVICE|High dose, high flux hemodialysis|
214684898|NCT03779425|OTHER|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
214684899|NCT01743586|OTHER|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
214684900|NCT02656992|DEVICE|Inspiratory muscle training group|
214684901|NCT02053389|BEHAVIORAL|DVD Decision Aid|"The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation."
214684902|NCT02053389|BEHAVIORAL|Written decision aid|"A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer."
214684903|NCT02361762|BEHAVIORAL|Computerized executive control training|"Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.~Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.~A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks."
214684904|NCT03940924|OTHER|Training program|High Intensity Interval Training + Resistance Training (HIIT + RT)
214684905|NCT01880255|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
214374275|NCT00624611|PROCEDURE|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
214374276|NCT00624611|PROCEDURE|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
214374277|NCT06537011|DRUG|AK112|"1. The patients are given AK112 combined with AP regimen every 3 weeks for 3 cycles before operation.~2. After the neoadjuvant therapy ,the patients will be assessed and be commanded surgery.~3.4-6 weeks after the surgery, the patients will be given chemoradiotherapy or radiotherapy alone decided on the conditon after surgery.~4.The participants will receive AK112 for 14 cycles after surgery."
214374278|NCT03261271|BEHAVIORAL|Weight Loss Program|Program involves one-on-one coaching, diet meal plan, and physical activity plan.
214684906|NCT01452958|BIOLOGICAL|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
214684907|NCT01452958|BIOLOGICAL|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
214684908|NCT01383395|DRUG|simvastatin/cilostazol|
214684909|NCT03415919|OTHER|no intervention will be given to patients.|samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
215089829|NCT04485689|DRUG|Capsaicin Topical - ice|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
215089830|NCT04485689|DRUG|Placebo - ice|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
214684910|NCT04811521|BEHAVIORAL|Primary care follow-up|Those randomized to primary care and enhanced primary care coordination will receive the minimal intensity treatment that includes: (1) assistance in identifying a primary care provider for participants who do not have one, (2) sharing results of diagnostic testing (including anxiety screening) with the primary care provider (results sent via EMR note, mailed letter, or delivered by participant at appointment); and (3) an educational brochure on anxiety and treatment.
215089831|NCT05562349|DRUG|Clavulanic Acid Only Product|Drug will be given in 250mg capsules
215089832|NCT05562349|DRUG|Placebo|Capsule with no active medication - identical to drug capsule
215089833|NCT05908968|DIETARY_SUPPLEMENT|ELO water|Drinking 1.5 litres daily of ELO water for 12 weeks
215089834|NCT03476876|COMBINATION_PRODUCT|Dermacell|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
214374279|NCT03261271|BEHAVIORAL|Standardized educational flyer|"The American Institute for Cancer Research handout Nutrition and the Cancer Survivor will be provided to participants."
214374280|NCT03261271|BEHAVIORAL|Weight Maintenance Program|Post-surgery program involves group support sessions, phone check-ins, and diet and exercise monitoring.
214374281|NCT05897632|BEHAVIORAL|Outpatient Evaluation|Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.
214374282|NCT05897632|BEHAVIORAL|Hospitalization Evaluation|Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
214374283|NCT05440513|DEVICE|Renal Pelvic Denervation (bilateral)|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
214374284|NCT04897425|DEVICE|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"Hardware and software for myoelectric pattern recognition and sensory training developed at the Center for Bionics and Pain Research.~tES by Neuroelectrics"
214495795|NCT00949364|DRUG|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
214495796|NCT05909072|DRUG|Hyaluronic acid combined with tranexamic acid microneedling|1 ml of TXA, available as a 500 mg/5 ml ampoule, will be applied on the right side of the face after microneedeling and left to dry
214987157|NCT01687803|BEHAVIORAL|Physical Activity|Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to \~60 min/day for 6 days/week (\~360 minutes per week).
214987158|NCT01687803|BEHAVIORAL|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
214987159|NCT03937778|BEHAVIORAL|Deep pressure block|Apply deep pressure block by using blood pressure cuff.
214374285|NCT00949481|OTHER|Pregnancy Test|Free pregnancy test strips will be supplied to family planning clinics
214374286|NCT00949481|OTHER|Job aid|"A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.~Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)"
214374287|NCT05856214|BEHAVIORAL|Couple-Based Violence Prevention education(CBVPE)|Couples in the intervention group will receive training on violence against women including intimate partner violence, types, and consequences of intimate partner violence during pregnancy, managing triggers of intimate partner violence, healthy relationships, the role of male partners during pregnancy, and couples communication and problem-solving skills. Training will be provided every fourth week by trained health extension workers for consecutive six months.
214374288|NCT04585438|DRUG|Diclofenac Potassium|The drug will be used as a transparent disc applied to the mucosa
214374289|NCT02875405|PROCEDURE|Posterior left pericardiotomy|Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
214374290|NCT02173054|OTHER|Adapalene gel with Eucerin|Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
214374291|NCT02173054|OTHER|Adapalene gel|Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
214374292|NCT02173054|OTHER|Adapalene gel with placebo moisturizer|Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
214374293|NCT00147940|PROCEDURE|Acoustic rhinometry (procedure)|
214374294|NCT03270917|PROCEDURE|Parenchymal preserving postero-superior liver segment resection|Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
214495797|NCT05909072|DRUG|tranexamic acid microneedling|On the left side of face, 0.5 ml of HA 3.5% will be used 1st followed by microneedling then 1 ml of TXA will be applied
214495798|NCT06308406|DRUG|Bevacizumab； HRS-1167|Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
214374295|NCT05073042|BEHAVIORAL|Morning exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 AM and 10 AM each day.
214374296|NCT05073042|BEHAVIORAL|Evening exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 PM and 10 PM each day.
214987160|NCT01513499|DRUG|Oxytocin|Intranasal oxytocin 24 IU single-dose administration
214987161|NCT01513499|DRUG|Placebo|Intranasal Placebo single-dose administration
214987162|NCT04909723|COMBINATION_PRODUCT|NOV-001|NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.
214987163|NCT04909723|BIOLOGICAL|NB1000S|A recombinant live biotherapeutic product.
214987164|NCT04909723|DRUG|NB2000P|A botanically derived polysaccharide.
214987165|NCT04909723|DRUG|Placebo|Placebo
214374297|NCT05073042|BEHAVIORAL|Time of choice exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes at a time of their choice each day. This time can change day-to-day.
214684911|NCT04811521|BEHAVIORAL|Online Self-Administered Anxiety Management Program plus Peer Support Guidance|Individuals randomized to the online Cognitive Behavioral Therapy (CBT) + peer support guidance arm will receive access to six online, evidence-based CBT modules in the This Way Up Generalized Anxiety Course to be completed weekly or bi-monthly. Individuals who screen positive on the PHQ panic measure will complete 2 additional panic-specific homework assignments applying exposure therapy to panic (in addition to Generalized Anxiety Disorder) experiences aligned with content from the This Way Up Panic Course.
214374298|NCT01288274|OTHER|Community Based administration of DMPA|Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
214374299|NCT01079559|DEVICE|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
214495799|NCT05206240|OTHER|Radial extracorporeal shock wave therapy and conventional physical therapy|"The conventional physical therapy program will consist of verticalization strategies, range of motion exercises, muscle stretching and strengthening exercises, stance and balance training, core stability exercises, gait training, functional training, cryotherapy or local heat for 1h/day, 5 days/week for 2 weeks.~Regarding the rESWT delivery, 2000 shots will be applied on the triceps surae myotendinous junction with a frequency of 10 Hz and an energy density of 60 mJ, 7 min/session, 1 session/week for 2 weeks."
214495800|NCT03418610|DRUG|Azelaic Acid foam 15%|mild to moderate rosacea
214495801|NCT05680857|OTHER|Placebo|Product doesn't have active ingredients i.e. marine collagen peptide and Coenzyme Q10.
214495802|NCT05680857|OTHER|Product containing marine collagen peptide and Coenzyme Q10.|Product containing marine collagen peptide and Coenzyme Q10.
214495803|NCT02614911|OTHER|Biological sampling|Biological sampling including blood, feces, biopsies...
214495804|NCT03865004|DRUG|Paracetamol+Morphine|1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
214495805|NCT03865004|DRUG|Dexketoprofen plus Morphine|Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
214495806|NCT03865004|DRUG|Placebo plus Morphine|100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
214495807|NCT05480540|BEHAVIORAL|Serious game|According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.
214495808|NCT03960359|OTHER|Clinical, microbiological and inflammatory phenotype|Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.
214495809|NCT05729503|DRUG|Lidocaine 2% Injectable Solution|Cotton tip applicator pre-soaked with lidocaine
214495810|NCT05729503|DRUG|Placebo|Cotton tip applicator pre-soaked with saline
214495811|NCT03738709|BEHAVIORAL|Falls prevention and education giving a demonstration of the usage of technical assistance.|"* Ecological trail to work on balance and walking.~* Technical assistance presentation and try-outs within the therapeutic apartment.~* Discussion on the perceived feelings over the exercises and the technical assistance submitted.~* Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours."
214495812|NCT04023175|OTHER|Telemedicine preoperative counseling|The telemedicine visit will be completed using an Atrium Health approved virtual visit platform.
214495813|NCT04023175|OTHER|In office preoperative counseling|This includes our standard preoperative counseling located at the Women's Center for Pelvic Health
214987166|NCT02699164|DEVICE|DRX 9000, Axiom Worldwide, Tampa, Florida|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
214987167|NCT02699164|OTHER|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
214987168|NCT02699164|OTHER|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
214987169|NCT00089388|DRUG|cilengitide|Given IV
214987170|NCT04816344|PROCEDURE|Outpatient Anesthesia|The inclusion criteria were children aged between 2 and 10 years, undergoing outpatient anaesthesia for elective MRI under sedation, and classified as American Society of Anesthesiologists (ASA) grade I-II. The study exclusion criteria were defined as difficult airway, allergies to the study drugs, asthma, severe central nervous system disease (eg, brain tumour, uncontrolled seizures), mental motor retardation, the application of another procedure after MRI sedation, and those whose parents declined to participate in the study.
214987171|NCT03748667|DIAGNOSTIC_TEST|White light endoscopy (WLE)|Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.
214987172|NCT03748667|DIAGNOSTIC_TEST|NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)|Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
214987173|NCT00819039|DRUG|Aprepitant|Aprepitant administered orally or intraveously.
214684912|NCT04811521|BEHAVIORAL|Therapist-Administered Cognitive Behavioral Therapy|Individuals randomized to therapist-led CBT via telehealth will receive 8 one-hour sessions over the course of 8 to 10 weeks via telehealth (HIPAA compliant software such as Zoom Health or AmWell) or telephone. Therapists will be master's-degreed or eligible clinicians trained in CBT by our study psychologist. Therapists will follow a manualized protocol for delivering CBT for anxiety, specifically, with a primary focus on anxiety and worry management. Individuals who screen positive on the PHQ panic measure will have training in exposure therapy added to CBT. Although many CBT trials have a standard length of 12 sessions, brief CBT lasting 4-8 sessions is equally efficacious.
215089835|NCT03476876|COMBINATION_PRODUCT|Integra|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
214495814|NCT06843824|DEVICE|a custom-made graphene therapy cap|The GFII involved the use of a custom-made graphene therapy cap. The cap consisted of 3 parts: the main body of the cap, the thermostat and the power adapter. One end of the thermostat was connected to the main body of the cap, and the other end was connected to the power adapter; the adapter was plugged into a 220 V household power outlet. This turned on the cap, and the temperature could be adjusted. The light energy conversion rate of the graphene coating material used in the cap reached 90%, generating a temperature of 40 °C. Five caregivers were responsible for providing care for the elderly individuals. We will provided standardized training on the GFII to their caregivers. Each caregiver was responsible for assisting with the intervention of the elderly individuals that they usually cared for.
214684913|NCT01557608|PROCEDURE|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
214684914|NCT01557608|PROCEDURE|Placebo treatment|"For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment."
215089836|NCT02499692|DEVICE|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
214684915|NCT02147704|DIETARY_SUPPLEMENT|High-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets"
214684916|NCT02147704|DIETARY_SUPPLEMENT|low-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. Low sodium intake : 50 mmol/day by diet"
215089837|NCT02181478|DRUG|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
215089838|NCT02181478|DRUG|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
215089839|NCT02181478|RADIATION|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
215089840|NCT02181478|DRUG|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
215089841|NCT02181478|DRUG|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
214684917|NCT02218658|DRUG|WE941 OD tablets|
214684918|NCT02218658|DRUG|Brotizolam|
215089842|NCT02181478|PROCEDURE|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
215089843|NCT02181478|PROCEDURE|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).
214684919|NCT03483324|BIOLOGICAL|Unmanipulated Umbilical Cord Blood (UCB)|Human leukocyte antigen (HLA) matched umbilical cord blood
214684920|NCT03483324|BIOLOGICAL|AB-110|Expanded cord blood stem cells and engineered human endothelial cells
214684921|NCT03238586|BEHAVIORAL|WELL Program|
214684922|NCT05655637|OTHER|Exercise|There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
214684923|NCT06530602|OTHER|3 D SPA (shoulder complex pain alignment) Moblization|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
214495815|NCT06843824|DEVICE|A regular cap that generates heat|The rest of the procedure is the same as the GFII group, but the cap used is a regular cap that can heat up to 40°C.
214684924|NCT06530602|OTHER|Shoulder Moblization (KaltenBorn)|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
214684925|NCT00028002|PROCEDURE|Conventional Surgery|Undergo surgical resection
214495816|NCT01753999|DEVICE|Standard CPAP|Use of the REMstar Auto A-Flex in standard CPAP therapy mode
214684926|NCT00028002|DRUG|Imatinib Mesylate|Given orally
214987174|NCT00819039|DRUG|Ondansetron|Ondansetron administered intravenously.
214495817|NCT01753999|DEVICE|CPAP - Flex|Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
214684927|NCT05787353|OTHER|Exercise programme|Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.
214684928|NCT01793051|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
214684929|NCT01793051|OTHER|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
214684930|NCT01793051|BEHAVIORAL|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
214684931|NCT02826733|DEVICE|Electroencephalogram (EEG)|
214684932|NCT02826733|DEVICE|Near Infra Red Spectroscopy (NIRS)|
214684933|NCT02826733|DEVICE|magnetic resonance imaging (MRI)|
214684934|NCT01972880|DRUG|ASP1941|Oral
214684935|NCT03209180|DRUG|CarVeDilol-SR (Slow Release)|patients will receive slow-release carvedilol (SR) once daily
214987175|NCT01693952|BIOLOGICAL|blood draw|
214987176|NCT03310047|DRUG|Infusion, Lidocaine, 0.5%, 5 mL|A catheter-based perineural infusion of 5 mL Lidocaine 0.5%
214987177|NCT03310047|DRUG|Infusion, Lidocaine, 0.5%, 10 mL|A catheter-based perineural infusion of 10 mL Lidocaine 0.5%
214987178|NCT00375661|DRUG|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
214987179|NCT04985162|OTHER|Intervention group|Differential learning based physiotherapy to improve torso control, balance and gait
214987180|NCT04985162|OTHER|Control group|Ordinary physiotherapy program
214987181|NCT02494024|DRUG|Single dose C2N-8E12|C2N-8E12 is a humanized recombinant anti-human tau antibody.
214987182|NCT02494024|DRUG|Single dose placebo|Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
214987183|NCT01240694|DRUG|CEP-33457|CEP-33457 will be administered subcutaneously per dose specified in the arm description.
214987184|NCT05902065|DEVICE|AVR Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill with AVR applications. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. The patient will be supervised by a physical therapist and asked not to use lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance. Progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'; progression in difficulty: the protocol has 5 levels for each AVR application, and the transition among levels will be set at 80% success achievement.
214987185|NCT05902065|DEVICE|Conventional Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill without AVR applications, walking on the treadmill. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. All sessions will be supervised by a physical therapist, who will give guidance and standardized cues on walking patterns (e.g., step length). The patient will be asked not to use the lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance: progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'.
214987186|NCT04636047|OTHER|The method of gene mutation detection|All samples were detected by NGS CGP panel.
214987187|NCT02819128|OTHER|Swabs skin, pharyngeal, and blood sample|Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).
214987188|NCT02819128|OTHER|Collection of body lice|For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.
214987189|NCT00251472|DRUG|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
214374300|NCT01079559|DEVICE|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
214374301|NCT03967769|DEVICE|High Flow nasal Cannula|Apnoeic Oxygenation by High Flow Nasal Cannulae
214374302|NCT04671238|DEVICE|SPECT CT|SPECT/CT scan of the spine as part of a vertebroplasty
214374303|NCT01674309|DRUG|FOLFORINOX|INTRAVENOUS administration
214374304|NCT04419402|DRUG|Lu-PSMA|"Patients will be given 7.5 GBq of Lu-PSMA in 4 doses. Dose 1 and 2 on Days 15 and 57. Doses 3 and 4 (Days 113 and 169) will be given following result of 68Ga-PSMA PET/CT at Day 92.~Treatment administered every 6 weeks, x 4 cycles."
214374305|NCT04419402|DRUG|Enzalutamide|160 mg (four 40 mg capsules) daily.
214374306|NCT01271998|DRUG|TR-701 FA|200 mg, oral, once daily for 3 days.
214374307|NCT02609217|OTHER|Questionnaires and interviews|
214374308|NCT01939873|BEHAVIORAL|KRISTELLER|
214374309|NCT00192309|BIOLOGICAL|CAIV-T|Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
214495818|NCT04717544|BEHAVIORAL|Intervention Arm|The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
214495819|NCT02392234|DRUG|VX-661/Ivacaftor|Fixed dose combination tablet, oral use
214987190|NCT01881425|PROCEDURE|Glaucoma Surgery|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure."
215089844|NCT06521073|BEHAVIORAL|education|"Patient Information Form (HBF): This form, prepared by scanning the literature, includes the patient\&#39;s age, gender, marital status, education level, profession, social security, place of residence, presence of caregivers in the family, from whom he/she receives care, chronic diseases, the side on which knee prosthesis is applied, knee prosthesis. It is a form consisting of questions about your training status, who you received your training from, and your satisfaction with the training.~Barthel Index (BI): Barthel activities of daily living index is an evaluation scale used to measure an individual\&#39;s performance in daily living activities. The index is used for activities of daily living in 10 domains. The Turkish validity and reliability of the Barthel index, developed by Barthel and Mahoney (1965), was determined by Küçükdeveci et al. (17)."
214374310|NCT00192309|BIOLOGICAL|TIV|TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
214374311|NCT00192309|BIOLOGICAL|Placebo|Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
214374312|NCT03298230|BEHAVIORAL|REmotely SuPervised Exercise Training|As described in the Arms section.
214374313|NCT03298230|BEHAVIORAL|Supervised Exercise Training|As described in the Arms section.
214495820|NCT02392234|DRUG|Ivacaftor|Tablet, oral use
214495821|NCT02392234|DRUG|Placebo matched to VX-661/ ivacaftor|Fixed dose combination tablet, oral use
214495822|NCT02392234|DRUG|Placebo matched to Ivacaftor|Tablet, oral use
214495823|NCT02402569|DEVICE|32 channels Deep Brain Stimulator|
214495824|NCT00948168|DRUG|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
214495825|NCT00112034|DRUG|Methotrexate|
214495826|NCT00112034|DRUG|IV methylprednisolone|
214495827|NCT02029235|DRUG|Acetaminophen/Ibuprofen|Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
215089845|NCT01198457|DRUG|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
214495828|NCT02029235|DRUG|Acetaminophen/Hydrocodone|Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
214495829|NCT02911441|BEHAVIORAL|Cognitive Behavioral Therapy|
214684936|NCT03209180|DRUG|Carvedilol IR (Immediate Release)|patients will receive immediate release carvedilol (IR) twice daily
214684937|NCT00782015|DIETARY_SUPPLEMENT|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
215089846|NCT01300351|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
215089847|NCT01300351|DRUG|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
215089848|NCT04453813|DRUG|Toripalimab plus concurrent chemo-radiotherapy|"1. Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
215089849|NCT04453813|DRUG|Concurrent chemo-radiotherapy|"1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
215089850|NCT03481803|DRUG|MS1819-SD|Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.
215089851|NCT05256420|DEVICE|Kinesiotape|Application of a kinesiotape bandage on the knee.
215089852|NCT05256420|DEVICE|Sham Bandage|Application of a sham bandage on the knee.
215089853|NCT00431951|DRUG|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
215089854|NCT00431951|DRUG|Placebo|Capsules to match experimental drug
215089855|NCT05618886|OTHER|Education|The education about urinary incontinence, PFM and PFMT together with lifestyle behavior modifications such as using the knack, maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure will be provided along with the PFMT instruction.
215089856|NCT05618886|OTHER|Education and PFMT|Along with education twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant's will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participant's will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary.
215089857|NCT01547312|DRUG|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
215089858|NCT01547312|PROCEDURE|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
215089859|NCT01547312|PROCEDURE|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
214495830|NCT06615232|BEHAVIORAL|Vaginal washing cessation|Participants will attend weekly small group (\~10 women per group) sessions that are structured using the transtheoretical model of behavioral change to promote vaginal washing cessation.
215089860|NCT01547312|PROCEDURE|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
215089861|NCT01547312|DRUG|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
215089862|NCT01547312|DRUG|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
215089863|NCT01547312|DRUG|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
215089864|NCT01547312|PROCEDURE|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
215089865|NCT01976858|DRUG|PEX168|A injection administered subcutaneously
215089866|NCT02707211|BIOLOGICAL|Anti-oxLDL IgM antibody|Immunization
214495831|NCT05948449|DRUG|S-1, Oxaliplatin, Cadonilimab|3 cycles of neoadjuvant therapy will be administered: S-1: 40\~60mg Bid，d1\~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
214495832|NCT01715194|DEVICE|Telemedicine intervention|Patients undergoing telemedicine intervention
215089867|NCT01651832|BEHAVIORAL|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
214495833|NCT02190149|BIOLOGICAL|ADVATE (Antihemophilic Factor [Recombinant])|
214495834|NCT02190149|BIOLOGICAL|RIXUBIS (Coagulation Factor IX [Recombinant])|
214495835|NCT05784259|BEHAVIORAL|Transdiagnostic single-session treatment|Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
214495836|NCT05960539|PROCEDURE|surgical training|surgical residency focussed on visceral robotic procedures
214495837|NCT06509529|OTHER|Motivational Interviewing Based on the COM-B Model|Motivational Interviewing Based on the COM-B Model will be applied to the women in the experimental group.
214684938|NCT00782015|DIETARY_SUPPLEMENT|Placebo Comparator:|NCEP Step 2 diet
214684939|NCT01300468|DRUG|PHA-848125AC|
214684940|NCT03478319|DRUG|ACE-2494 or placebo|Recombination fusion protein
214684941|NCT02668107|OTHER|Hammock positioning|Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
214684942|NCT03572439|DIAGNOSTIC_TEST|Sensory block level check using ice|Patients are asked to report when the ice feels as cold as it does on the forehead.
214684943|NCT01141634|OTHER|Homeopathic Remedies|Homeopathic remedies prepared according to the standards as set out by Health Canada
214987191|NCT01881425|DEVICE|InnFocus MicroShunt|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure."
215089868|NCT00343863|DRUG|palonosetron hydrochloride|Given IV
214374314|NCT01083654|BEHAVIORAL|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
214374315|NCT01083654|BEHAVIORAL|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
214374316|NCT04050241|DEVICE|Glidescope intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Glidescope videolaryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
214374317|NCT04050241|DEVICE|Mcintosh intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Mcintosh laryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
214495838|NCT05916768|OTHER|Pelargonium sidoides extract EPs® 7630|Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).
214495839|NCT05916768|OTHER|usual care|symptomatic treatments
214495840|NCT05931627|PROCEDURE|Patients undergoing ACL reconstruction with or without a tourniquet|Patients undergoing ACL reconstruction with or without a tourniquet
215089869|NCT00343863|DRUG|cyclophosphamide|Given orally
215089870|NCT00343863|DRUG|dexamethasone|Given orally or IV
214495841|NCT03335397|DEVICE|M-learning application|Mobile application with interactive contents available for android platform and Apple's operating system.
214495842|NCT03335397|OTHER|Traditional learning process|Traditional content available in university library.
215089871|NCT00343863|DRUG|doxorubicin hydrochloride|Given IV
215089872|NCT00343863|PROCEDURE|quality-of-life assessment|Ancillary studies
214374318|NCT01559454|DRUG|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
214374319|NCT01559454|DRUG|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
214495843|NCT04251442|DEVICE|OrthoSensor Verasense Technology|IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
214495844|NCT00928824|DIETARY_SUPPLEMENT|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
214495845|NCT05461313|OTHER|Constrained Liner|Subjects in this arm will receive a constrained liner with one of the following implants: Freedom Constrained Acetabular Liner (Zimmer Biomet), G7 Freedom Constrained Acetabular Liner (Zimmer Biomet) or Lubinus Acetabular Cup with a safety ring (LINK)
214987192|NCT06351176|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
214684944|NCT03044015|BEHAVIORAL|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
214684945|NCT03044015|BEHAVIORAL|as usual|
214987193|NCT06351176|DIAGNOSTIC_TEST|Biochemical tests|The investigators perform blood and urine tests in every participant.
215089873|NCT00343863|PROCEDURE|nausea and vomiting therapy|Given IV
215089874|NCT00343863|PROCEDURE|management of therapy complications|Given IV
214495846|NCT05461313|OTHER|Dual Mobility|Subjects in this arm will receive a dual mobility cup with the following implant: Avantage Dual Mobility Cup (Zimmer Biomet)
214495847|NCT00756067|BIOLOGICAL|Pneumococcal vaccine GSK2189241A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
214495848|NCT00756067|BIOLOGICAL|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
214684946|NCT04489485|BEHAVIORAL|Teen Depression Module used for care|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, and treatment using the Teen Depression Module and offered a depression chabot. Suicide screening will be conducted.
215089875|NCT00343863|DRUG|ondansetron hydrochloride|Given IV
215089876|NCT00343863|OTHER|survey administration|Ancillary studies
215089877|NCT04790487|DRUG|CPM|one spray dose (\~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
215089878|NCT04790487|DRUG|Placebo|Saline
215089879|NCT03697044|PROCEDURE|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
214684947|NCT04907539|DRUG|RXC004|"RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules."
214374320|NCT06304350|DRUG|Combination of pembrolizumab and platinum containing dual drugs|After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab immunomaintenance therapy continued after surgery
214374321|NCT02543255|DRUG|Abiraterone acetate with prednisone|Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
214374322|NCT02543255|DRUG|Leuprolide|Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
214374323|NCT02543255|DRUG|Cabazitaxel with peg-filgrastim|Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.
214374324|NCT00615732|PROCEDURE|Qigong|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
214374325|NCT00615732|PROCEDURE|exercise therapy|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
214374326|NCT03065296|BEHAVIORAL|Musculoskeletal (MSK) Prescription Didactic Lectures|In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
214374327|NCT03065296|OTHER|Musculoskeletal (MSK) home exercise hand-outs|In between phase 1 and phase 2, residents will use home exercise hand-outs readily available and educate their patients in regards to those.
214374328|NCT01114204|DRUG|Ferumoxytol|IV Ferumoxytol
214374329|NCT01114204|DRUG|Iron Sucrose|IV Iron Sucrose
214495849|NCT03920592|BEHAVIORAL|Virtual Reality of Bullying|"Immersive videos (360º) filmed by 12-14 year old pupils who, guided by professional actors, represented the subjective experience of bullying.~Eight different potential situations designed depending on the sex of the pupil were filmed:~Girls:~1. Classmates steal her personal diary~2. Classmates tear her clothing~3. Classmates insult her and steal her belongings~4. Classmates deliberately exclude her in class~Boys:~1. Classmates exclude him while playing with a ball~2. Classmates bother him in the dining room~3. Classmates insult and steal him in class~4. Classmates insult him and steal his belongings"
214495850|NCT01039155|DRUG|Azacitidine|Given IV
214374330|NCT00808574|BEHAVIORAL|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
214374331|NCT00854282|PROCEDURE|Staging surgery or debulking surgery|Staging surgery or debulking surgery
214495851|NCT01039155|OTHER|Laboratory Biomarker Analysis|Correlative studies
214495852|NCT01039155|DRUG|Oxaliplatin|Given IV
214374332|NCT05771779|BIOLOGICAL|Oral Cholera Vaccine (OCV)|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
214374333|NCT05771779|BIOLOGICAL|Typhoid Conjugate Vaccine (TCV)|Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT
214374334|NCT05771779|BIOLOGICAL|Measles and Rubella (MR)|Live attenuated vaccine
214684948|NCT04907539|BIOLOGICAL|Nivolumab|Nivolumab will be administered via IV infusion, 480 mg q4w.
214684949|NCT04907539|BIOLOGICAL|Denosumab|"Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic"
214684950|NCT05055232|DRUG|XZP-3621|tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
214684951|NCT05862792|DRUG|Liposomal bupivacaine|We will inject liposomal bupivacaine into the surgical bed.
215089880|NCT00005056|DRUG|bryostatin 1|
214374335|NCT05786729|OTHER|Aerobic Exercise (AER)|Aerobic exercise will be performed by utilizing aerobic exercise equipment 3 times per week.
214374336|NCT05786729|OTHER|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
214374337|NCT04156165|DIETARY_SUPPLEMENT|VLCD-Active|Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.
214374338|NCT04156165|OTHER|Maintenance-Active|Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.
214374339|NCT04156165|DIETARY_SUPPLEMENT|VLCD-Control|Lighter life VLCD products
214374340|NCT04156165|OTHER|Maintenance-Control|Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
214374341|NCT06524011|BIOLOGICAL|Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone|Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
214374342|NCT06118723|PROCEDURE|Supramaximal resection|Supramaximal resection. Tumor resection continues until either the FLAIR abnormalities have been resected based on the neuronavigation (after updating the navigation intraoperatively), or when subcortical tracts are identified with intraoperative stimulation.
214374343|NCT06118723|PROCEDURE|Maximal safe resection|Maximal safe resection. Tumor resection continues until maximal safe resection has been achieved as by the neurosurgeon's opinion.
214374344|NCT03476629|OTHER|Physical activity|Effects of different physical activity programs
214374345|NCT05582304|DEVICE|Test Lens|ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter
214374346|NCT05582304|DEVICE|Control Lens|ACUVUE OASYS 1-Day with HydraLuxe Technology
214374347|NCT02273830|DRUG|oxygen|Oxygen administered after adjustment during a waking test or at 3L/min
215089881|NCT00895687|DRUG|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
215089882|NCT00895687|DRUG|Bortezomib|Beginning dose of 1. mg/m\^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
215089883|NCT00714766|PROCEDURE|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
215089884|NCT04536922|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
215089885|NCT04536922|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
214374348|NCT04943224|DRUG|Trametinib|\< 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,
214374349|NCT03716375|DRUG|Intrapleural Medications|urokinase
214374350|NCT00002488|DRUG|cisplatin|
214495853|NCT01039155|OTHER|Pharmacological Study|Correlative studies
214374351|NCT00002488|DRUG|cyclophosphamide|
214495854|NCT05296772|BIOLOGICAL|JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody|Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years
214495855|NCT05296772|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|200 mg, once every three weeks until disease progression, withdrawal or up to two years
214495856|NCT03874819|DEVICE|Medium cut-off dialyzer|Treatment using a Medium Cut-Off Dialyzer
214495857|NCT03874819|DEVICE|High-flux dialyzer|Treatment using a high-flux dialyzer
214495858|NCT02867072|PROCEDURE|Open appendectomy|
214684952|NCT04940871|DRUG|Favipiravir HU 200 mg hard capsules|Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
214374352|NCT00002488|DRUG|etoposide|
214374353|NCT03848702|DEVICE|Distal radius fracture brace|The distal radius fracture brace is constructed from biocompatible materials (like polylactic acid; PLA) and the skin is protected by commercially available and approved waterproof padding (like Aquacast®). The major brace components are connected and reinforced with carbon rods and plastic bolt-nut connections. PLA is extensively used, for example in surgical implants, but also as biological alternative for plastics. Aquacast® is approved and used as waterproof padding in swim plaster. The biomechanical function of the distal radius brace has been tested successfully in an ex vivo setting (results to be published). The DRFB includes the distal forearm, wrist an base of the hand. The thumb and fingers are free and the DRFB provides more movement than classical casting.
214374354|NCT02311205|PROCEDURE|Conventional Transarterial Chemoembolization (TACE)|On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
214374355|NCT02311205|DRUG|sorafenib|Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
214374356|NCT00816179|PROCEDURE|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
214374357|NCT01435811|BIOLOGICAL|Norovirus challenge pool (GII.4, CIN-1)|Norovirus challenge pool (GII.4, CIN-1)
214374358|NCT03005509|OTHER|TQIM checklist|"The intervention phase will include an intense training period covering:~1. Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.~2. Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist."
214374359|NCT05842655|PROCEDURE|The wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth|A novel digital technique to analyze the wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth as antagonist
214374360|NCT01916655|BEHAVIORAL|Self-Management Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
214374361|NCT01916655|BEHAVIORAL|Self-Management Mobile Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
214374362|NCT01916655|BEHAVIORAL|Usual Care|standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
214495859|NCT02867072|PROCEDURE|Laparoscopic appendectomy|
214495860|NCT01138254|DEVICE|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
214495861|NCT01138254|OTHER|no intervention|no intervention
214495862|NCT05599282|DRUG|Amino Acid Supplement|Four capsules of Amino Acid Supplement will be taken once a day for 90 days.
214495863|NCT05599282|OTHER|Placebo|Four capsules of Placebo will be taken once a day for 90 days.
214495864|NCT01435252|DRUG|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
214495865|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 100 mg/day
214495866|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 150 mg/kg/ twice daily
214684953|NCT04940871|DRUG|Placebo HU|Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules
215089886|NCT04536922|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
215089887|NCT04536922|DRUG|Pembrolizumab (KEYTRUDA(R))|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
214374363|NCT03420781|DRUG|Placebo|Placebo injected twice daily
214374364|NCT03420781|DRUG|Relamorelin|Relamorelin 10 μg injected twice daily
214374365|NCT02862379|BEHAVIORAL|home-based program|The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
214495867|NCT01821989|DIETARY_SUPPLEMENT|Placebo|in form of distilled water
214495868|NCT01738438|DRUG|Cabozantinib|
214495869|NCT04210037|DRUG|APG-1252|APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.
214684954|NCT02304783|DRUG|Piroxicam|Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
214684955|NCT02304783|DRUG|Placebo|Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
214374366|NCT02768610|DRUG|Dexmedetomidine|
214374367|NCT02768610|DRUG|Normal Saline|
214374368|NCT03036384|DRUG|HB Prilocaine 2% (varying dose)|Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
214374369|NCT03036384|DRUG|HB Prilocaine 2%|The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
214374370|NCT03036384|DRUG|Sufentanil|2.5µg sufentanyl
214374371|NCT03036384|DRUG|Morphine|100 µg Morphine
214374372|NCT03076541|DEVICE|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
214374373|NCT05093387|DRUG|Carboplatin|Given IV
214495870|NCT04210037|DRUG|Paclitaxel|80 mg/m˄2 on days 1 and 8 of a 21-day cycle
214495871|NCT03323203|DEVICE|FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA|Tissue oxygenation was monitored using a tissue oximeter based on near-infrared spectroscopy (FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA). The oximeter had four cables with each cable connected to an adhesive probe.
214495872|NCT01511159|DRUG|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
214495873|NCT01511159|DRUG|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
214495874|NCT01511159|DRUG|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
214495875|NCT01511159|DRUG|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
214495876|NCT01511159|DRUG|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
214495877|NCT01511159|DRUG|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
214495878|NCT01511159|DRUG|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
214495879|NCT06321952|DEVICE|ROSA robotic assist TKA|total knee replacement with ROSA robotic assist
214495880|NCT06321952|PROCEDURE|iassist TKA|total knee replacement with iassist
214684956|NCT02304783|DRUG|paracetamol|Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
214684957|NCT04449783|OTHER|pre-operative screening|reported symptoms plus nose and throat swabbing 48 hrs prior to surgery
214684958|NCT04449783|OTHER|telephone consult|telephone consult 14 days (+/- 2 days) to assess for any COVID-19 symptoms
214374374|NCT05093387|BIOLOGICAL|Pembrolizumab|Given IV
214374375|NCT05093387|GENETIC|Transferrin Receptor-Targeted Liposomal p53 cDNA|Given IV
214374376|NCT02489032|BEHAVIORAL|SBIRT Training & Support Tool|Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
214374377|NCT02489032|OTHER|Waitlist Control|3-month wait-list and then provided access to the SBIRT training program
214374378|NCT03291743|DEVICE|Capsule endoscopy|PillCam(TM) CROHN'S CAPSULE
214374379|NCT06328582|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing."
214374380|NCT06328582|PROCEDURE|Acupuncture Technique for Restoring Consciousness combined with Scalp Acupuncture|"Acupuncture Technique for Restoring Consciousness:~Main acupoints: Neiguan (bilateral), Renzhong, Sanyinjiao (affected side) Additional acupoints: Fengchi, Wangu, Yifeng (bilateral), and posterior pharyngeal wall needling.~Scalp Acupuncture Method:~Based on the standard treatment lines for scalp acupuncture \[17\], select the anterior oblique line of vertex-temporal region, posterior oblique line of vertex-temporal region, and anterior line of temporal region (bilateral)."
214374381|NCT00215540|DRUG|Lucinactant 175 mg/kg|Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
214374382|NCT00215540|DRUG|Lucinactant 90 mg/kg|Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
214374383|NCT00215540|DRUG|Placebo|Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
214374384|NCT00817999|DIETARY_SUPPLEMENT|Grapefruit juice|Participants received grapefruit juice during 1 of the 2 periods.
214374385|NCT00817999|DRUG|Clopidogrel 75 mg/day|
214684959|NCT03425942|BEHAVIORAL|Internet Cognitive Behavioral Therapy for insomnia (ICBT-i)|This intervention lasts for five weeks. The intervention is internet-based and mainly consists of the most potent CBT technics i.e. sleep restriction and stimulus control. Weekly feedback is provided by master students supervised by clinical psychologists.
214684960|NCT03425942|BEHAVIORAL|Internet Applied Relaxation Techniques (IART-i)|This intervention lasts for five weeks. The intervention is internet-based and consists of different common applied relaxation exercises and treatments. Weekly feedback is provided by master students supervised by clinical psychologists.
214374386|NCT00817999|DRUG|Clopidogrel 300 mg|
214374387|NCT00777907|DEVICE|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
214374388|NCT00777907|DEVICE|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
214374389|NCT03766256|BEHAVIORAL|Shared decision-making with pharmacists|Pharmacist will engage patient with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
214374390|NCT02526355|BEHAVIORAL|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
214374391|NCT03850080|DRUG|Autologous Conditioned Serum|"Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. 50mL of whole blood were taken using a special syringe containing CrSO4-coated grade glass beads in order to promote IL-1ra synthesis and aggregation.The incubation period lasted 7 hours after which, the blood-filled syringes were centrifuged and the serum supernatant was filtered and aliquoted into four 3mL portions. The aliquots were stored at -20oC until their use was necessary.~Patients received 1 intra-articular injection for 4 consecutive weeks at the site of OA."
214374392|NCT04242693|BEHAVIORAL|Mobile goal-setting intervention|This intervention applied two constructs from the goal setting theory-self-monitoring and goal setting. Briefly, all participants were asked to take photos of all their meals and upload them with descriptions to an online platform. The participants in the experimental group were taken through two additional processes that represented these two constructs. Self-monitoring was operationalized by asking those in the experimental group to count the number of times they ate red/orange vegetables using a counting checklist. Goal setting was operationalized as asking them to set a goal to eat red/orange vegetables one more time tomorrow.
214684961|NCT01881620|DEVICE|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
214684962|NCT02647762|DRUG|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
214684963|NCT02647762|DRUG|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
215089888|NCT04536922|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
215089889|NCT00313547|DRUG|Quinapril 40 mg|
215089890|NCT00313547|DRUG|Quinapril 10 mg and amlodipine 5 mg|
215089891|NCT00673881|DRUG|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
215089892|NCT00096018|DRUG|fludarabine phosphate|Given IV
214374393|NCT03983122|PROCEDURE|Laparoscopic sleeve gastrectomy|Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.
214374394|NCT05210829|DIAGNOSTIC_TEST|stationary and trait anxiety scale|survey
214374395|NCT04191629|COMBINATION_PRODUCT|EO1404|
215089893|NCT00096018|DRUG|thalidomide|Orally
214374396|NCT04191629|PROCEDURE|Endothelial brushing or Descemet stripping|
214495881|NCT04437641|OTHER|Tobacco questionnaire|"A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact."
214987194|NCT06351176|DIAGNOSTIC_TEST|DXA scan with TBS and VFA|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) including trabecular bone score (TBS) and Vertebral Fracture Assessment (VFA) in every participant.
214374397|NCT05777148|DEVICE|super high-flux hemodialysis|Super high-flux hemodialysis (SHF-HD) is hemodialysis using Super high-flux dialyzer for 24 week then crossover to post dilution online HDF (wash out period 4 weeks)
214374398|NCT05777148|DEVICE|postdilution online hemodiafiltration|hemodialysis by post dilution online HDF technique for 24 week then crossover to super high-flux HD (wash out period 4 weeks)
214374399|NCT03479021|DIAGNOSTIC_TEST|Welch-Allyn Spot Vision Screener|photograph of the eye
214495882|NCT03486600|OTHER|Fluid Resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
214495883|NCT02673216|OTHER|No intervention|
214684964|NCT02647762|DRUG|Placebo|Placebo tablets, 1mg BID for 12 weeks
214987195|NCT06351176|DIAGNOSTIC_TEST|AGEReader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
214987196|NCT00521495|DEVICE|neodymium permanent magnet|"3/4 diameter by 1/8 thick permanent magnet"
214987197|NCT00521495|DEVICE|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
214987198|NCT00521495|DEVICE|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
215089894|NCT05302362|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea)
215089895|NCT00252772|DRUG|Tesaglitazar|
215089896|NCT00252772|BEHAVIORAL|Dietary and Lifestyle counseling|
215089897|NCT02510183|DEVICE|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
215089898|NCT02510183|DEVICE|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
215089899|NCT04927793|DRUG|EDP-938|\[14C\]EDP-938
215089900|NCT00337792|DRUG|oxycodone + lorazepam versus fentanyl + midazolam|
215089901|NCT00386555|DRUG|docetaxel|
215089902|NCT00386555|DRUG|CP-868,596 + docetaxel|
215089903|NCT00386555|DRUG|AG-013736 + docetaxel|
215089904|NCT00386555|DRUG|CP-868,596 + AG-013736 + docetaxel|
215089905|NCT04373473|DRUG|PRIM-DJ2727|Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
215089906|NCT04373473|DRUG|Placebos|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
215089907|NCT02526108|OTHER|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
215089908|NCT01545973|OTHER|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
215089909|NCT00689793|DRUG|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
215089910|NCT00689793|DRUG|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
215089911|NCT01186107|DEVICE|Endeavor Resolute stent|zotarolimus-eluting stent
215089912|NCT01186107|DEVICE|Cypher stent|sirolimus-eluting stent
215089913|NCT02212171|OTHER|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~1. Administrative staff:~   Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~2. Nursing staff:~   They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~3. GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
214987199|NCT06456307|BEHAVIORAL|Integrated Perinatal Mental health program (systematic screening for PMAD, PM+ and tele-psychiatry)|The intervention includes systematic screening for PMAD symptoms using PHQ-2 and GAD-2, non-specialist delivery of PM+ for participants with likely depression (PHQ-9≥10) or anxiety (GAD-7≥10) and in-facility tele-linkage to mental health specialist for participants with severe depressive symptoms (PHQ-9≥15), those who endorse suicidality, or non-responders to PM+
214987200|NCT00397579|DRUG|DT388IL3|Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
214987201|NCT03421587|BEHAVIORAL|Processing of social olfactory and tactile stimuli|Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.
214374400|NCT00745706|DEVICE|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
214374401|NCT00053001|BIOLOGICAL|epoetin alfa|
214374402|NCT00053001|DRUG|thalidomide|
214374403|NCT00895882|DRUG|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
214374404|NCT00895882|DRUG|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
214374405|NCT00895882|DRUG|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
214374406|NCT00895882|DRUG|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
214374407|NCT00895882|DRUG|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
214374408|NCT00228293|DEVICE|investigational monitor/defibrillator with CPR feedback|
214374409|NCT04567264|DEVICE|StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).|"Regimen 1 (weeks 0-12): one stimulation every 2 days, for a duration of 30 minutes each.~Regimen 2 (weeks 12-24): Three stimulation treatments per week, for a duration of 30 minutes each."
214987202|NCT00351247|PROCEDURE|Postconditioning|
214374410|NCT02319226|OTHER|Transplantation from an HLA-identical sibling donor|The study will include a cohort of 60 patients transplanted from an HLA-identical sibling donor.
214374411|NCT00229957|BEHAVIORAL|Occupational therapy|
214374412|NCT00229957|BEHAVIORAL|Physiotherapy|
214987203|NCT00620906|PROCEDURE|Manipulation|HVLA manipulation to Sacroiliac Joint
214495884|NCT05751161|OTHER|conventional gait training|The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
214495885|NCT00111683|DRUG|MK0457|
214495886|NCT05769413|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
214495887|NCT05492604|OTHER|Clinical examination|Cinical examination carried out during a consultation for the follow-up of the patient
214684965|NCT02647762|DRUG|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
214684966|NCT03539172|DRUG|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course
214684967|NCT03217617|BIOLOGICAL|Direct intravenous injection of ivlv-X1 lentiviral vector|ivlv-X1 LV intravenous injection at a dose of \~1x10e9/kg body weight.
214987204|NCT00034632|DRUG|Posaconazole oral suspension|
214987205|NCT02524119|DRUG|LEE011|600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
214374413|NCT00229957|BEHAVIORAL|Self-management|
214374414|NCT02317055|OTHER|imaging|
214374415|NCT04837872|OTHER|Multimodal Physical Therapy (MPT)|Individualized physical therapy and static progressive splint (flexion with or without extension splint).
214374416|NCT00338598|DRUG|Glycine|Glycine, 0.8 gr per kg given in two daily doses
214374417|NCT00338598|DRUG|placebo|
214374418|NCT03161457|BIOLOGICAL|JHL1101|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
214374419|NCT03161457|BIOLOGICAL|MabThera|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
214374420|NCT02799472|DRUG|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
214374421|NCT02799472|DRUG|Placebo|0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.
214374422|NCT02799472|DRUG|MTX|Capsule, tablet or liquid administered orally or as SC injection.
214374423|NCT02799472|DRUG|Folic (or folinic) acid|Capsule, tablet or liquid and will be administered orally.
214374424|NCT01368848|DRUG|Bevacizumab|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W -\> Bevacizumab Q3W until progression"
214374425|NCT01368848|DRUG|Cisplatin|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"
214374426|NCT01368848|DRUG|Docetaxel|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"
214374427|NCT01226511|DRUG|Duloxetine|Administered orally
214374428|NCT01226511|DRUG|Placebo|Administered orally
214684968|NCT05858138|OTHER|Jing-Si Herbal Tea|patient will receive twice in a day for 24 weeks
214684969|NCT05858138|OTHER|Placebo Jing-Si Herbal Tea|Placebo Jing-Si Herbal Tea
214684970|NCT03750201|DEVICE|Direct Selective Trabeculoplasty|Laser surgery by automated direct automated SLT device to lower intraocular pressure
214684971|NCT03750201|DEVICE|Selective Trabeculoplasty|Laser surgery by standard SLT device to lower intraocular pressure
214684972|NCT04841499|DRUG|BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)|take 2 capsules orally each day for 7 days
214684973|NCT04803708|BIOLOGICAL|TP-102|One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).
214684974|NCT06579040|DEVICE|Monoplace Hyperbaric Chamber (Class III medical device)|Participants in the intervention group will be triaged to the closest hyperbaric facility to their address and treated with 40 HBOTs (2 ATM for 90 mins, scheduled daily from Monday to Friday). As HBOT is not a service currently offered at Sunnybrook Hospital, all HBOT treatments will be provided at three collaborating outpatient facilities, Halton Hyperbaric Unit, Restore Hyperbaric Oxygen \& Medical Centre (CPSO-certified Level-II OHP), and Rouge Valley Hyperbaric Medical Centre. All three facilities have the exact same hyperbaric chambers, run by anesthesiologists with advanced training, thus treatments will be identical at all sites.
214684975|NCT03070730|DRUG|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
214684976|NCT03070730|DRUG|Atenolol|Atenolol: 50 mg Q.D.
214684977|NCT03070730|DRUG|Placebos|Placebo: t.i.d
214374429|NCT00628797|RADIATION|UVA1|intraindividual half body irradiation
214684978|NCT04511078|DRUG|Panitumumab-IRDye800|single dose infusion of panitumumab-IRDye800CW
214684979|NCT03237260|DRUG|Vedolizumab|Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
214374430|NCT00628797|OTHER|UVA1|60 J/cm2 at least 36 tx
214374431|NCT04177225|PROCEDURE|Trans thoracic Ultrasound Examination|Ultrasound examination of cardiac function before and after induction of general anesthesia.
214495888|NCT05492604|OTHER|Functional scales|The Clinical scales are as follows : MRC (Medical Research Scale), ONLS (Overall Neuropathy Limitations Scale), R-ODS (Rasch-built Overall Disability Scale) , INCAT (Inflammatory Neuropathy Cause and Treatment) The functional scales are used as part of the usual care of the patient in the neurology department
214495889|NCT05492604|DIAGNOSTIC_TEST|Walking test|Walking test over 10 metres at a comfortable speed on the GAITRITE® walkway, fitted with FEETME® soles at the same time. The 10-metre test will be repeated 5 times, with a 2-minute break between each test.
214495890|NCT03137836|BEHAVIORAL|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
214495891|NCT01183767|DRUG|Epigallocatechin-Gallate|EGCG in a dosage of up to 10mg/kg body weight
214495892|NCT01183767|DRUG|Placebo|
214495893|NCT01180231|DRUG|Moxonidine (Physiotens)|Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
214684980|NCT06021652|DEVICE|MindCotine Virtual reality|Virtual reality platform
215089914|NCT03793491|OTHER|TCI scale|TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.
215089915|NCT03793491|OTHER|PDQ-39 scale|PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.
215089916|NCT04799691|PROCEDURE|Invasive ventilation strategy|Use of an invasive ventilatory support strategy
215089917|NCT04799691|PROCEDURE|Non-invasive ventilation strategies|Use of non-invasive ventilatory support strategies
214374432|NCT04177225|OTHER|Intravenous fluid administration|Intravenous fluids will be administered as a bolus in response to standard clinical indications
214374433|NCT01222195|DRUG|Lenalidomide|10 mg/day by mouth on days 1-21 of every 28 day cycle.
214495894|NCT01180231|OTHER|Dietary intervention|Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
214495895|NCT02928172|DEVICE|qCON-qNOX|Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
214495896|NCT02928172|DEVICE|BIS|Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
214684981|NCT04743037|BEHAVIORAL|iSMART|This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
215089918|NCT04767165|DIAGNOSTIC_TEST|MRI|Dynamics of Bone marrow fat fraction by mDixon-quant (%)
214374434|NCT01222195|DRUG|Darbepoetin alfa|200 mcg subcutaneously every 2 weeks of a 28 cycle.
214684982|NCT04467164|OTHER|exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)|Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
214684983|NCT04467164|OTHER|Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)|Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
214684984|NCT03209544|BEHAVIORAL|Online self-help intervention|The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, \& Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
214684985|NCT02369835|DRUG|Dakin's solution|Apply modified Dakin's solution (0.005 to 0.01%) topically
214684986|NCT02369835|OTHER|Placebo|Applied topically
215089919|NCT02990507|OTHER|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
215089920|NCT02990507|OTHER|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
215089921|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
215089922|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
215089923|NCT04533230|BEHAVIORAL|Educational intervention with prescription feedback|Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
214374435|NCT00335582|DRUG|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
214374436|NCT03424590|DEVICE|Clearblue Connected Ovulation Test System|Urinary LH test to predict ovulation
214684987|NCT00690716|DRUG|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
214374437|NCT01718093|DRUG|Sitagliptin|up to 50 mg twice a day
214374438|NCT01718093|DRUG|Metformin|up to 1000 mg twice a day
214374439|NCT01718093|DRUG|Sitagliptin + Metformin|up to 50/1000 mg twice a day
214374440|NCT03333798|BEHAVIORAL|Cognitive-Behavioral Intervention|"A Cognitive-Behavioral intervention will be delivered by psychologists with LPCWs support. LPCWs who will be under the supervision and guidance of psychologists.~Volunteers will receive 11 weekly sessions of which six will be provided by psychologists and five by LPCWs.~The Cognitive-Behavioral component will be delivered through a set modules that will cover the following components:~* The Cognitive-Behavioral model~* Tackling traumatic events~* Cognitive reprocessing~* Relaxation techniques~* Prevention of revictimization~* Behavioral reactivation for the start of a new life The intervention will be given within the health system and volunteers will be seen if necessary by an interdisciplinary team including social workers, general physicians and psychiatrists."
214495897|NCT02282657|DEVICE|ECCO2R will be initiated during the 2-hour run-in time|"A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).~Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.~Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.~Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation."
214684988|NCT00690716|DRUG|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
214684989|NCT03940651|DRUG|Spinal Anesthesia|Patients will be randomized to type of anesthesia
214684990|NCT03940651|DRUG|General Anesthetics|Patients will be randomized to type of anesthesia
214684991|NCT04420871|DRUG|150 mg of Xeloda®|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.
214684992|NCT04420871|DRUG|150 mg of capecitabine|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
214684993|NCT05149937|OTHER|interprofessional, person-centered care concept|interprofessional, person-centered care concept
214987206|NCT02524119|PROCEDURE|Chemoembolization|Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
215089924|NCT04533230|BEHAVIORAL|Information on treatment guidelines|Written information on treatment guidelines.
214374441|NCT03333798|BEHAVIORAL|Standard psychosocial care|"The active control group will receive standard psychosocial care for intimate partner violence, provided by the participating health centers. Standard care is delivered by psychologists, social workers, general physicians and psychiatrists. Additionally, patients receive extramural support which includes telephone calls or domiciliary visits from a variety of health professionals (doctors, nurses, social workers and nursing assistants).~Psychology consultations typically occur every four weeks in each health center. Psychologists use a variety of approaches according to their personal preferences, including humanist, psychoanalytic, psychodynamic and cognitive-behavioral approaches. At the end of the intervention psychologists will be asked which approach or approaches they used."
215089925|NCT04763187|PROCEDURE|Tooth extraction|Tooth extraction and alveolus regeneration with autologous blood concentrate.
214374442|NCT05605210|DEVICE|Electric stimulation|Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.
214684994|NCT03865017|BIOLOGICAL|Regulatory T cells|The trial will be carried out in Alzheimer's disease patients. The investigators will isolate CD4+CD25+ Tregs from these patients, expand and injection.
214495898|NCT02282657|OTHER|Neuromuscular blocking agents (NMBA)|Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician
214684995|NCT03865017|OTHER|Saline|Saline+cell suspension solution infusion
214684996|NCT03924674|OTHER|Education, clinical decision support tools|"Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing"
214684997|NCT01761955|OTHER|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
214684998|NCT05488561|DIAGNOSTIC_TEST|CBC with differential ,ESR ,CRP, Amyloid level , FMF gene|leucocytosis , high ESR and CRP ,amyloid level indicates inflammation positive FMF gene indicates having the disease .
214684999|NCT04008433|DRUG|Lidocaine|Advanced intravenous injection of lidocaine before the propofol injection
215089926|NCT02940782|PROCEDURE|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
214495899|NCT02282657|DEVICE|Ventilation|Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.
214685000|NCT04177056|RADIATION|SBRT|Patients will received a single fraction of 15-20 Gy to bone metastases causing pain. Planning and delivery will be conducted using a volumetric modulated arc therapy (VMAT) approach on the Varian TrueBeam platform. Patients will be CT simulated, with vac-lock immobilization. Use of 4-dimensional CT will be dependent on the area being treated. Daily image guidance will be performed using cone beam CT aligning to relevant bony anatomy.
214495900|NCT02282657|OTHER|Level of carbon dioxide released at the end of expiration|EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction
214495901|NCT02282657|OTHER|Respiratory Rate|RR will be kept what it was at baseline
214495902|NCT02282657|OTHER|Sweep gas flow|Sweep gas flow will be adapted to maintain the same EtCO2
214495903|NCT02282657|OTHER|Ventilation will be adapted|If PaCO2\> 75 mmHg and/or pH \< 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
214495904|NCT02282657|OTHER|Respiratory rate will be adapted|If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
214685001|NCT01701583|DRUG|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
214685002|NCT05863689|DIAGNOSTIC_TEST|Spectralis SD-OCT|Optical Coherence Tomography
214685003|NCT01441440|DRUG|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
214495905|NCT03484949|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
214495906|NCT03468634|DIAGNOSTIC_TEST|endoscopy|Oesophageal endoscopy with biopsy
214495907|NCT02961634|DEVICE|Nailner 2 in 1|Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.
214495908|NCT02961634|DRUG|Ciclopirox 8%|Ciclopirox 8% is a glaze used in the treatment of onychomycosis
214495909|NCT03611088|OTHER|Kangaroo Position.|The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
214495910|NCT04066075|BEHAVIORAL|Low Vision Rehabilitation|Low Vision Rehabilitation for use of magnification devices for near reading tasks
214495911|NCT00327119|DRUG|ABX-EGF (panitumumab)|
214495912|NCT04801199|DRUG|CPL-2009-0031 140 mg|Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
214495913|NCT04801199|DRUG|Sitagliptin 100mg|Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
214495914|NCT00309166|BIOLOGICAL|Cervarix vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
214495915|NCT00309166|BIOLOGICAL|Engerix-B vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
214685004|NCT01441440|DRUG|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
214685005|NCT01441440|DRUG|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
214685006|NCT03879148|OTHER|Erector spinae plane block|Erector spinae plane block was performed to the patients under aseptic conditions
214685007|NCT00589888|DRUG|Intralipid 20% @ 20cc/hour|In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
214685008|NCT00589888|DRUG|Intralipid 20%@ 40cc/hour|In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
214685009|NCT00589888|DRUG|Normal Saline|In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
215089927|NCT02940782|PROCEDURE|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
215089928|NCT02940782|DEVICE|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
215089929|NCT01100528|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously (SC) 3 times a week for 24 weeks
215089930|NCT01100528|DRUG|dacarbazine|Given IV on days 1 and 29
215089931|NCT01100528|OTHER|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
215089932|NCT03083184|DRUG|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
215089933|NCT03083184|DRUG|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
215089934|NCT02391376|OTHER|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
215089935|NCT02391376|OTHER|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
215089936|NCT02391376|OTHER|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
215089937|NCT03184610|DEVICE|OCT-scanning|All participants will be scanned with a OCT-device
215089938|NCT03968159|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
214685010|NCT00589888|DIETARY_SUPPLEMENT|32-gram oral fat load|In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
214685011|NCT00589888|DIETARY_SUPPLEMENT|64-gram oral fat load|In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
214685012|NCT00490373|DRUG|pemetrexed|
214685013|NCT05814393|DRUG|Treatment Period(JW0201)|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
214685014|NCT05814393|DRUG|Treatment Period(Placebo)|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
214685015|NCT05814393|DRUG|Extension Period(JW0201)|JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)
214685016|NCT00742443|DRUG|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
214685017|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
214374443|NCT05777967|BIOLOGICAL|human autologous synovial stem cells|A single injection of 1.5 to 9.0 x 10\^7 human autologous synovial stem cells under arthroscopy
214374444|NCT00674570|DRUG|Hydrocortisone|25 mg/oral one hour prior to extinction task
214374445|NCT00674570|DRUG|D-Cycloserine|50 mg/oral one hour prior to extinction task
214374446|NCT00674570|DRUG|Placebo|One hour prior to extinction task
214374447|NCT05982665|OTHER|Molecular hydrogen|Hydrogen gas, purity \>99.9%, flow rate 300 ml/min.
214374448|NCT05982665|OTHER|Placebo|Ambient air, flow rate 300 ml/min.
214374449|NCT00402571|DRUG|acetaminophen|
214374450|NCT01995448|BIOLOGICAL|Blood test|Residue of blood further to NFS.
214374451|NCT04302376|DIAGNOSTIC_TEST|Cather-related thrombosis ultrasonography|Doppler and compression ultrasound to detect catheter-related thrombosis
214374452|NCT03077984|COMBINATION_PRODUCT|Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
214685018|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
214685019|NCT01031524|BIOLOGICAL|PfCS102|Antigen of the sporozoite protein
214685020|NCT01031524|BIOLOGICAL|Montanide ISA 720|adjuvant alone
214685021|NCT00004735|BIOLOGICAL|Tetanus toxoid|
214685022|NCT00004735|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
214685023|NCT02854137|DRUG|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
214374453|NCT02850822|DRUG|Demethylation drug|Demethylation drug,such as Decitabine
214374454|NCT02850822|DRUG|Chemotherapy regimen|Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
214685024|NCT02854137|DRUG|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
214685025|NCT02750813|DEVICE|Delefilcon A contact lenses|
214685026|NCT02750813|DEVICE|Senofilcon A contact lenses|
214987207|NCT04640896|DRUG|Trigger point injection with bupivacaine|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
214374455|NCT01337986|DRUG|Dalfampridine/Placebo|Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
214374456|NCT01337986|DRUG|Placebo/Dalfampridine|Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
214374457|NCT02835872|OTHER|dietary fiber|Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
214685027|NCT02908958|BIOLOGICAL|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
214685028|NCT02908958|BIOLOGICAL|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
214685029|NCT03025048|BEHAVIORAL|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
214685030|NCT01935908|DRUG|levetiracetam|
214685031|NCT03276936|DRUG|FMX103 1.5%|FMX103 1.5% minocycline foam
214685032|NCT04953949|DEVICE|NU-MAX®|Topical Hemostat
214685033|NCT05255055|OTHER|Physical Therapy|A manual therapy protocol and a therapeutic exercise protocol
214495916|NCT04310514|DIETARY_SUPPLEMENT|Fructose/glucose/xylitol/saccharose|"1. Intervention: rehydration with glucose solution. Glucose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~2. Intervention: rehydration with fructose solution. Fructose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~3. Intervention: rehydration with xylitol solution. Xylitol will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~4. Intervention: rehydration with sucrose solution Saccharose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m."
214495917|NCT04861805|DEVICE|Vienna Aortic Valve SE System|Vienna Aortic Valve SE system for TAVI.
214495918|NCT05827796|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
214495919|NCT05827796|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
214685034|NCT03125746|DRUG|LXI-15029|The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
214685035|NCT03125746|DRUG|LXI-15029+Exemestane|The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
214685036|NCT03279783|DEVICE|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
214685037|NCT01798134|DEVICE|TANDEM™|
214685038|NCT03725995|DRUG|Midazolam|Patients received 0.5 mg/kg midazolam, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
214685039|NCT03725995|DRUG|Lidocaine-Midazolam|Patients received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg midazolam, with a maximum dose of 10 mg. , Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
214685040|NCT03725995|DRUG|Placebo|Patients received saline 9% (placebo), 0.5 mg/kg, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
214685041|NCT04041076|PROCEDURE|Major surgical operation|Surgical operation with magnitude defined as major or ultra-major
215089939|NCT03968159|DRUG|Placebo|Placebo (2×placebo tablets \[size- and color-matched to pimavanserin\]) administered orally as a single dose once daily
215089940|NCT04438876|OTHER|Functional Power Training|The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
215089941|NCT04438876|OTHER|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
215089942|NCT05203159|OTHER|Ocean sound|The experimental group will listen to ocean sound, starting at the 1st minute before the ROP examination and ending at the 5th minute after the ROP examination.
215089943|NCT05203159|OTHER|Routine|No sound will be played before, during and after the ROP examination.
215089944|NCT05881720|DRUG|Sacubitril / Valsartan Oral Tablet|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
214495920|NCT05827796|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
214495921|NCT05827796|DRUG|KN046|KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
214495922|NCT04177147|OTHER|Clinical decision support via alert tool|The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
214495923|NCT03492866|DRUG|Gentamicin Sulfate|Topical treatment of 1 side of the scalp twice daily during 6 months
214495924|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Cyclophosphamide: 250 mg/m\^2 IV q4w after Myozyme infusion for 6 months.
215089945|NCT05881720|DRUG|Valsartan 80 mg|group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
215089946|NCT00004864|DRUG|GEM 231|
215089947|NCT00004864|DRUG|docetaxel|
214987208|NCT04640896|DRUG|Trigger point injection with normal saline|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
214374458|NCT01578863|OTHER|Intervention program for obese children|The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
214374459|NCT03885037|DRUG|Infliximab [infliximab biosimilar 3]|\<Rheumatoid arthritis\> The usual dose is 3 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks. This drug should be given in combination with methotrexate.
214374460|NCT03833635|OTHER|osteopathic manipulative treatment|OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect
214374461|NCT03833635|OTHER|Sham|the sham intervention consists in a stable skin-to-skin contact with the participant
214374462|NCT01815528|DRUG|Catumaxomab|"Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~1. 10 µg on day 0~2. 20 µg on day 3~3. 50 µg on day 7~4. 150 µg on day 10"
214374463|NCT00032890|DRUG|glucosamine|
214374464|NCT00032890|DRUG|chondroitin sulfate|
214374465|NCT00032890|DRUG|glucosamine and chondroitin sulfate combined|
214374466|NCT00032890|DRUG|celecoxib|
214374467|NCT05416255|DIAGNOSTIC_TEST|Measuring synovial fluid components|Using speialized techniques to measure S.F. components
214374468|NCT00141739|DRUG|Etanercept|"Etanercept 0.4 mg/kg per dose \[maximum dose 25 mg\] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.~Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant."
214374469|NCT00944723|DIETARY_SUPPLEMENT|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
214495925|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m\^2 IV weekly beginning the day after Myozyme infusion for 4 weeks (an optional additional 2nd cycle could be administered at the discretion of the investigator); Methotrexate: 15 mg/m\^2 subcutaneous qow on the day after Myozyme infusion for 6 months.
214495926|NCT06048588|DRUG|YN001|In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.
214374470|NCT00944723|DIETARY_SUPPLEMENT|Zinc supplement|Liquid supplement with zinc
214374471|NCT00944723|DIETARY_SUPPLEMENT|Non-fortified bread|Daily consumption of non-fortified bread
214374472|NCT00944723|DIETARY_SUPPLEMENT|Placebo supplement|Daily intake of placebo supplement
214374473|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 500mg per day(once a day)
214374474|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 1000mg per day(twice a day)
214374475|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 2000mg per day(three times a day)
214374476|NCT01499225|DRUG|INSADOL[Zea mays L. extract] 35mg Tab|"\[Initiation dose : 4weeks after administraion\] INSADOL\[Zea mays L. extract\] 210mg TAB per day~\[Maintain dose : Between 4weeks and 8weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day~\[Maintain dose : Between 8weeks and 12weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day"
214374477|NCT01499225|DRUG|DENTISTA[Doxycycline hyclate] 20mg Cap|DENTISTA\[Doxycycline hyclate\] Cap 40mg per day
214374478|NCT01499225|DRUG|Placebo|Placebo
214374479|NCT01391923|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214374480|NCT00698386|DIETARY_SUPPLEMENT|Zinc supplement|Zinc miconutrient supplements have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.Each micronutrient capsule contains 50mg zinc (as zinc sulphate) in a lactose matrix.In this clinical trial one tablet of zinc as oral supplement will be given everyday during the entire course in line with the directly observed treatment, short-course (DOTS) strategy recommended by the World Health Organization.
214374481|NCT00698386|DIETARY_SUPPLEMENT|Placebo|Placebo have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.The placebo consisted of lactose alone. Supplement and placebo capsules were indistinguishable in appearance both externally and internally.
214374482|NCT06449092|DIAGNOSTIC_TEST|Lipid profile|carotid intima media thickness
214495927|NCT06048588|DRUG|Placebo for YN001|The injection solution to mimic the YN001
214987209|NCT04640896|DRUG|Lidocaine skin wheal|"Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.~However, this skin wheal is not considered a trigger point injection."
214987210|NCT02821845|BEHAVIORAL|Untrained and Trained SCI Hip or Knee|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of hip control or knee control, members of this group will be trained at slow to moderate gait speeds,
214987211|NCT01928849|DRUG|Valproic Acid|"Intervention patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital."
214987212|NCT01928849|OTHER|Cherry Syrup|Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
214987213|NCT02237664|PROCEDURE|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
214987214|NCT02237664|PROCEDURE|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
214987215|NCT03704077|BIOLOGICAL|Relatlimab + Nivolumab|Specified dose on specified days
214987216|NCT03704077|BIOLOGICAL|Nivolumab|Specified dose on specified days
214987217|NCT03704077|DRUG|Paclitaxel|Specified dose on specified days
214987218|NCT03704077|DRUG|Ramucirumab|Specified dose on specified days
214987219|NCT06022575|PROCEDURE|Telehealth integrated care|Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
214374483|NCT04498325|DRUG|NT-I7|Supplied by study
214987220|NCT06022575|PROCEDURE|Conventional health care|Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
214987221|NCT04383678|DEVICE|Extracorporeal membrane oxygenation|Veno-venous or veno-arterial extracorporeal oxygenation
214987222|NCT01200355|DRUG|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
214374484|NCT04498325|DRUG|Placebo|Supplied by study
214374485|NCT04498325|PROCEDURE|Blood for research purposes|Prior to injection (Day 0), Day 7, and Day 14
214374486|NCT04498325|PROCEDURE|Blood for pharmacokinetic samples|-Phase I only: 1-2 hours prior to dosing, 6 hours after dosing, 24 hours after dosing, Day 7, Day 14, and Day 21
214374487|NCT04498325|PROCEDURE|Nasopharyngeal, oropharyngeal, or saliva swab|-Prior to study treatment, Day 4(optional), Day 7, and Day 14
214374488|NCT04498325|PROCEDURE|Blood for anti-drug antibody (ADA)|Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline
214374489|NCT04461795|DRUG|Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]|225 MG/1.5 ML Subcutaneous Solution
214495928|NCT06048588|DRUG|rosuvastatin calcium tablets|In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days
214495929|NCT06648837|PROCEDURE|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy, additional tubes of blood drawn during normal clinical vist.
214495930|NCT06648837|OTHER|Collection of relevant information|Collect relevant information to ensure potential participant meets all inclusion/exclusion criteria.
214495931|NCT03664635|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
214495932|NCT06610162|OTHER|Eucalaloric feeding|Participants will complete a 3-day diet run-in followed by an 24-hr in-patient visit in the room calorimeter. The energy content of the diet will be REE x 1.5 (30% fat, 55% carbohydrate, 15% protein). On the study day, will arrive at 7 AM and an IV catheter will be placed for blood draws, as described in the research plan. Participants will then enter the calorimeter at 0800, exit at 0700 the following day. Participants will be instructed to engage in primary sedentary behaviors. The energy content of the diet will be 1.3 x REE (\~30% fat, 55% carbohydrate, and 15% protein at each meal). Breakfast will account for \~25% and lunch and dinner \~30-35% of total energy needs. Meals will be provided at 0900, 1300, and 1800, and a light snack will be provided at 2000.
214495933|NCT06610162|OTHER|Acute Fasting|Participants will complete a 3d diet run-in followed by an 24h in-patient visit in the room calorimeter. The energy content of the diet will be REE x 1.5 (30% fat, 55% carbohydrate, 15% protein). On the study day, will arrive at 7 AM and an IV catheter will be placed for blood draws, as described in the research plan. Participants will then enter the calorimeter at 0800, exit at 0700 the following day. Participants will be instructed to engage in primary sedentary behaviors. Participants will complete a 24 hour fast while in the calorimeter. They will be permitted to consume non-caloric beverages (i.e., water, non-caloric and non-caffeinated soft drinks, caffeine-free tea, or decaffeinated coffee) but refrain from consuming any caloric food or beverages. Upon exiting the calorimeter, participants will be provided a meal from the University of Colorado Hospital Patient Kitchen.
214495934|NCT06610162|OTHER|Acute Overfeeding|Participants will complete a 3d diet run-in followed by an 24h in-patient visit in the room calorimeter. The energy content of the diet will be REE x 1.5 (30% fat, 55% carbohydrate, 15% protein). On the study day, will arrive at 7 AM and an IV catheter will be placed for blood draws, as described in the research plan. Participants will then enter the calorimeter at 0800, exit at 0700 the following day. Participants will be instructed to engage in primary sedentary behaviors. The energy content of the diet will be 200% of energy requirements, based on EE measured during the eucaloric condition. Macronutrient intake will be 3% protein, 51% carbohydrate, and 46% fat. Breakfast will account for \~25% and lunch and dinner \~30-35% of total energy needs. Meals will be provided at 0900, 1300, and 1800, and a light snack will be provided at 2000.
214374490|NCT03634618|OTHER|Mirror Therapy|Mirror therapy is the treatment method in which mental performance of movements is performed by observing the movements of the healthy extremities. In the case of mirror treatment, the mirror box is placed on a fixed floor. The mirror is positioned so that the patient's body can be fully centered and the mirror image can be seen. While the affected limb is placed on the rear side of the mirror, the firm extremity is opposite to the mirror. The patient focuses on the mirror image of the moving healthy hand and, through artificial visual feedback, perceives the affected limb as moving. The exercises are as follows: flexor tendon gliding exercises, median motor exercises, wrist and forearm ROM exercises and function-oriented exercises.
214495935|NCT03224481|OTHER|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
214987223|NCT01200355|DRUG|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
214987224|NCT00724776|BIOLOGICAL|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
214987225|NCT01490710|OTHER|collection of clinical and biological parameters|Investigation focal lies in hemodynamic monitoring during the last 10 minutes (Cardiac Index Assessment and clinico-biological parameters as: ventilatory and respiratory parameters, NIRS, GDS, Omega Score, heart rate, blood pressure, lactate, BNP, perfusion coefficient…)
214987226|NCT01490710|OTHER|assign optimal ventilatory mode|End of study: At the end of the second session, clinician will assign optimal ventilatory mode regarding patient clinical response.
214987227|NCT05489575|DEVICE|Active CPAP|Continuous positive airway pressure (CPAP) is applied at 8, 10, or 12 cm H20. The active CPAP level will be determined during a CPAP titration trial
214685042|NCT06546124|OTHER|Deep Fascia Dry needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating subcutaneously to the deep fascia. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
214685043|NCT06546124|OTHER|Intramuscular Trigger Point Dry Needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating through the deep fascia into the upper trapezius muscle. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
214685044|NCT01151995|OTHER|Remote source document verification|Remote access to electronic medical records of the 5 participating sites
214685045|NCT01151995|OTHER|On-site source document verification|Study monitor will perform on-site source document verification during routine visit to the five participating sites
214685046|NCT04066816|OTHER|Walnuts|Participants will consume 2 ounces of walnuts for 21 days
214685047|NCT01133210|DRUG|Maraviroc|dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
214685048|NCT01133210|OTHER|placebo|subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
214987228|NCT05489575|DEVICE|Sham CPAP|Sham continuous positive airway pressure applied at \<4 cm H2O
214987229|NCT05489575|OTHER|Sleeping in a head-up tilt (HUT) position|Sleeping with the whole bed tilted head-up by 10 degrees or with the head elevated by 13-14 inches.
214987230|NCT04991584|DRUG|Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
215089948|NCT01342549|DRUG|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
215089949|NCT01342549|DRUG|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
215089950|NCT03577392|DRUG|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
215089951|NCT03577392|DRUG|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
215089952|NCT01848470|DRUG|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
215089953|NCT01848470|DRUG|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
214685049|NCT06128005|BEHAVIORAL|knowledge translation in nursing for pressure injury care|Pressure injury's knowledge and healing of wound.
214685050|NCT04022811|DRUG|0.1% bromfenac|the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
214685051|NCT00625365|DRUG|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
214374491|NCT03634618|OTHER|Convantional Physiotherapy|The first two weeks involve only immobilisation with plaster. The next 4 weeks, patients do the exercises which follows: 15 minutes water bath, scar tissue massage, flexor tendon gliding exercises, median motor exercises, wrist flexion-extention, median nerve gliding exercise (in addition, one week after plaster removal), hand wrist stretching exercise (in addition, 2 weeks after plaster removal).
214374492|NCT02344446|OTHER|Skilled Therapy|Active physical therapy treatment
214374493|NCT04308902|OTHER|VLBW|Participants previously enrolled in the Bovine vs. Human Milk-Based Fortifier Study
214495936|NCT06842342|PROCEDURE|Lumber plexus block|LPB Group: All members of this group will receive ipsilateral lumber plexus after induction of general anesthesia. The LPB will be performed by using 30 ml mixture of lidocaine 2% (10 ml), bupivacaine 0.25%(10 ml) and 10-mL normal saline will be injected at that point after repeated negative aspiration.
214495937|NCT06842342|PROCEDURE|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|ESB Group: All members of this group will receive ipsilateral sacral erector spinae block after induction of general anesthesia. The ESB will be performed by using 30 ml mixture of lidocaine 2% (10 ml), bupivacaine 0.25%(10 ml) and 10-mL normal saline will be injected at that point after repeated negative aspiration.
214495938|NCT06842342|PROCEDURE|PENG Block|PENG block: All members of this group will receive PENG block in the supine position after general anesthesia, The PENG will be performed by using 40 ml mixture of, 20 mL of 0.5 bupivacaine,10 mL of 2% lidocaine, and 10 mL of normal saline.
214495939|NCT06816251|DRUG|HRS-1893|HRS-1893 tablet.
214495940|NCT06816251|DRUG|HRS-1893 placebo|HRS-1893 tablet placebo.
214685052|NCT06024772|PROCEDURE|ultiparametric Magnetic Resonance Imaging|Undergo mp-MRI
214685053|NCT06024772|DRUG|Perflutren lipid microsphere|Given IV
214685054|NCT06024772|PROCEDURE|Transrectal Ultrasound|Undergo transrectal mp-US
214685055|NCT06024772|PROCEDURE|Biopsy of Prostate|Undergo prostate biopsies
214987231|NCT06436417|DEVICE|Analgesia Nociception Index (ANI) Monitor|Non-invasive monitoring of HRV to evaluate autonomic nervous system activity using the indices of Energy (SDNN) and ANI (HFnu).
214374494|NCT04308902|OTHER|Term-born Comparison|Children born \>=37 weeks gestation and weighing more than 2500g
214374495|NCT03113084|BIOLOGICAL|Sodium Heparin UQ subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
214685056|NCT06186882|BEHAVIORAL|Action Video-Game|Thanks to their specific characteristics (presentation of multiple peripheral, rapidly moving, spatio-temporally unpredictable stimuli), Action Video-Games improve reading skills through their effects on the Magnocellular-Dorsal stream. Training will consist of 20 days of Action Video-Games sessions of 1 hour each, three times per week.
214685057|NCT05149794|OTHER|Calisthenic Exercises|Bunny Jumps, Bear Crawls, Bear Crawls, Bird Dog . these intervention were used
214685058|NCT02673593|DRUG|DS102|
214685059|NCT02673593|DRUG|Placebo|
214685060|NCT01152333|DRUG|Exendin-(9-39) Acetate|Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
214685061|NCT01152333|DRUG|Saline 0.9%|Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
214685062|NCT02245568|DRUG|LMTM|The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
214685063|NCT02215421|BEHAVIORAL|Mommio|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
214987232|NCT06436417|BEHAVIORAL|Trimodal Prehabilitation|Program of physical exercise, nutritional supplementation, and psychological support according to the RICA guidelines of the Spanish Group for Multimodal Rehabilitation.
214987233|NCT06192732|BEHAVIORAL|A more plant-based diet during weight loss|Participants receive dietary counseling on a more plant-based diet during weight loss. They will be counseled by a dietician to increase their plant-based protein intake up to 60%, focusing on 1.2 grams of protein per kg body weight.
214987234|NCT02191501|PROCEDURE|Pyloric restriction|"The Apollo Overstitch Suturing Device is FDA approved for suturing in the gastrointestinal tract.~However, the suturing device has never been used for suturing the pylorus in humans before. This procedure is not standard medical care. The safety and effectiveness of this procedure are being tested."
214987235|NCT05526768|DEVICE|VITLS Device|VITLS remote vital sign monitoring device will be applied to consented patients so data obtained by the device can be compared to data obtained by traditional inpatient hospital monitoring devices.
214987236|NCT02572154|OTHER|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
215089954|NCT01848470|DRUG|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
214685064|NCT06629675|DEVICE|Music walking application BeatClearWalker (BCW)|The music walking application (BCW) is a smartphone application that can monitor the walking pace and allow individuals to listen to music and give immediate feedback so they can correct their walking pace to match their target walking speed, as prescribed by the healthcare professional. The application provides real-time audio feedback in the form of music; the music sound quality will reduce whenever the walking speed drops below or exceeds the participant\&#39;s target walking speed. Simply, the application will work to supervise service users while exercising walking. The investigators are trying to assess the feasibility of this application with service users during their Pulmonary Rehabilitation programme (at the hospital/ home) to find out how participants interact with listening to music while exercise walking and how well they're able to keep to their target speed.
214685065|NCT02739022|BEHAVIORAL|Early Psychological Support for the Critically Ill (EPSCI)|early psychological support based on positive therapeutic suggestion
214685066|NCT04762108|OTHER|Standard of care|Patients will be given standard of care as per their clinical needs
214685067|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
214685068|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
214685069|NCT03515434|PROCEDURE|ESP Block|ESP block will be performed at the finishing of surgery under spinal anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 2-3 cm lateral to T10 spinous process. The erector spinae muscles will be identified superficial to the tip of T10 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
214685070|NCT03515434|PROCEDURE|TAP Block|TAP block will be performed at the finishing of surgery under spinal anesthesia. A linear ultrasound transducer will be placed to lateral aspect of abdomen. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane between transversus abdominis and internal oblique muscles..A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
214685071|NCT03515434|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
214374496|NCT03113084|BIOLOGICAL|Sodium Heparin FK subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
214685072|NCT02150187|DIETARY_SUPPLEMENT|HCap Formula|Pill should be taken every other day during the treatment phase.
214685073|NCT02150187|DIETARY_SUPPLEMENT|Placebo|Similar pills without active ingredients
214685074|NCT01252134|DEVICE|Biotrue multipurpose solution|Contact lens care solution
214685075|NCT01252134|DEVICE|Sauflon Synergi multipurpose solution|Contact lens care solution
214374497|NCT00058422|BIOLOGICAL|darbepoetin alfa|
214374498|NCT00058422|BIOLOGICAL|filgrastim|
214374499|NCT00058422|BIOLOGICAL|rituximab|
214685076|NCT01252134|DEVICE|OTE Elements multipurpose solution|Contact lens care solution
214374500|NCT00058422|DRUG|cyclophosphamide|
214374501|NCT00058422|DRUG|doxorubicin hydrochloride|
214374502|NCT00058422|DRUG|prednisone|
214374503|NCT00058422|DRUG|vincristine sulfate|
214374504|NCT00058422|RADIATION|indium In 111 ibritumomab tiuxetan|
214374505|NCT00058422|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214374506|NCT00185640|DRUG|Cyclosporine|Starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
214374507|NCT00185640|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
214374508|NCT00185640|DRUG|Mycophenolate mofetil (MMF)|Begins on day 0 after HCT at a dose of 15 mg/kg. Transplant recipients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
214374509|NCT00185640|DRUG|Filgrastim|"* Donors mobilized with 16 µg/kg/day filgrastim.~* As needed, myelosuppression in transplant recipients will be managed with subcutaneous filgrastim 5 µg/kg/day"
214495941|NCT06783400|BEHAVIORAL|SASA! Together|"SASA! Together is a community mobilisation approach that engages communities to create positive and sustainable changes around norms and behaviors that perpetuate violence against women. Some new features in this revision of SASA! include a distinct focus on IPV, including sexual decision-making; three strategies aligned to the socio-ecological model that reach across the whole community (individuals, groups, and institutions); and more support to get organisations and communities started and to sustain change.~The evidence- and theory-based SASA! approach is grounded in: (1) benefits-based activism, (2) a gender-power analysis, (3) four phases of change (start, awareness, support, action) according to the stages of behaviour change, (4) holistic community engagement, (5) local activism, (6) community leadership, and (7) institutional strengthening."
214685077|NCT01252134|DEVICE|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
214987237|NCT02442128|DRUG|propofol /Fentanyl|fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
214987238|NCT02442128|DRUG|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
214987239|NCT01242007|OTHER|Supine spirometry|In addition to the current upright lung function evaluation we performed a supine spirometry
214987240|NCT00937807|DRUG|xenon|Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
214987241|NCT00937807|DRUG|sévoflurane|Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
214987242|NCT05584345|OTHER|Conventional Treatment and manual therapy|Cold pack, ultrasound, TENS, finger ladder, Codman, shoulder wheel, and Wand exercises, as well as stretching and capsule exercises, will be used in addition to conventional physiotherapy. There will be 30 repetitions in each direction of the Codman exercises. 5 days a week, for a total of 30 sessions, the afflicted shoulder will get 6 minutes of daily US treatment, with complete contact to the shoulder area and at a right angle. All patients will receive manual stretching in the shoulder flexion, abduction, extension, external rotation, and internal rotation directions. In addition, participants will receive manual therapy techniques, including Glenohumeral joint (GH) distraction, glenohumeral joint inferior gliding, anterior gliding, and posterior gliding, scapulothoracic joint distraction, scapulothoracic joint superior, inferior, medial, and lateral gliding. Each manual therapy technique was performed with 10 repetitions per participant
214374510|NCT00185640|RADIATION|Total Lymphoid Irradiation (TLI)|0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
214374511|NCT00548132|DEVICE|Chlorhexidine-impregnated foam dressing|Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
214987243|NCT05584345|OTHER|Manual therapy and Respiratory Exercises|In addition to the treatment program applied in conventional therapy and manual therapy,, participants in this group also will perform diaphragmatic breathing exercises, pursed-lip breathing exercises, and relaxation breathing exercises. Each breathing exercise will be performed with 10 repetitions under physiotherapist supervision. Participants were also asked to continue the breathing exercises at home, performing them three times a day with 10 repetitions per session for a duration of six weeks.
214374512|NCT00641914|DRUG|budesonide|
214374513|NCT00641914|DRUG|Placebo|
214374514|NCT00970125|BEHAVIORAL|video|outline of the goals of care
214374515|NCT03830203|DRUG|BAT1806|8 mg/kg
214374516|NCT03830203|DRUG|Actemra(EU-licensed)|8 mg/kg
214374517|NCT00273702|DRUG|N-Acetyl Cysteine|
214374518|NCT03707639|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
214374519|NCT03707639|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
214374520|NCT04061590|DRUG|Cisplatin|Given IV
214374521|NCT04061590|BIOLOGICAL|Pembrolizumab|Given IV
214374522|NCT04061590|DRUG|Pemetrexed|Given IV
214374523|NCT04061590|DRUG|Pemetrexed Disodium|Given IV
214374524|NCT04061590|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214374525|NCT01839422|BEHAVIORAL|Memory assessment|Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
214374526|NCT01839422|OTHER|Brain imaging examination MRI|Brain imaging examination : Structural and functional MRI to compare differences between each sample.
214374527|NCT01520402|DRUG|Warfarin|Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
214374528|NCT05285384|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
214374529|NCT02878928|GENETIC|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
214374530|NCT00925405|PROCEDURE|Breast MRI|Magnetic resonance imaging (MRI) scans of the breasts once per year
214374531|NCT00925405|PROCEDURE|Mammogram|Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
214374532|NCT03773458|DEVICE|An artificial system for the screening of scoliosis|An artificial intelligence to make evaluation of scoliosis using back images
214495942|NCT06767930|BEHAVIORAL|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities|The HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) program is an intensive rehabilitation therapy designed to improve motor functions and promote functional independence. Participants in this arm will engage in 6.5 hours of structured activities per day for two weeks (10 days). The therapy focuses on bimanual coordination combined with constant stimulation of the trunk and/or lower extremities, using task-oriented exercises tailored to individual goals. Each participant will be supported by one or two therapists and supervised by a trained team to ensure the program is delivered effectively and safely. The therapy emphasizes engaging, play-based activities to maximize motivation and active participation.
214374533|NCT00079638|DRUG|Niacin|
214374534|NCT00079638|DRUG|Atorvastatin|
214374535|NCT00079638|DRUG|Simvastatin|
214374536|NCT00079638|DRUG|Ezetimibe|
214374537|NCT00079638|DRUG|Rosuvastatin|
214374538|NCT00805090|DRUG|Sporanox|200 mg
214374539|NCT00805090|DRUG|Diclofenac Sodium|37.5 mg
214495943|NCT06767930|BEHAVIORAL|Conventional intervention|Participants in the control group will continue their usual care, which includes conventional physical and occupational therapy, for a duration of two weeks. They will follow their regular therapy schedules without any changes to their routines or treatment habits. This approach ensures that the control group reflects standard rehabilitation practices, allowing for a direct comparison with the intervention group.
214495944|NCT04322305|DRUG|Pregabalin|Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
214685078|NCT03463941|BEHAVIORAL|Peer Support Dyad Intervention|"Phase I: At baseline and at post-intervention, participant height, weight, BMI, fruit and vegetable intake and exercise habits will be measured. Participants will complete surveys and meet each week to learn about nutrition and exercise.~Phase II: Dyads will attend a communication training session to discuss 1) benefits of working with a partner; 2) supportive communication tips; and 3) expected activities for the next 8 weeks, including filling out daily logs. After the training session, the dyads will work together to achieve their health goals. The dyads will return to the church for two check in sessions. At these sessions, participants will turn in their logs, and be weighed. At the end of the intervention, BMI will be reassessed, and surveys and interviews will be completed."
214685079|NCT03650452|DRUG|TAK-935|TAK-935 tablets or mini-tablets.
214685080|NCT03650452|DRUG|Placebo|TAK-935 placebo-matching tablets or mini-tablets.
214685081|NCT03257930|DRUG|ethanol injection|inject ethanol in cystic thyroid nodule and follow up until complete recovery
214685082|NCT05281783|DEVICE|percutaneous radiofrequency ablation (RFA)|We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
214685083|NCT02273050|DRUG|Saxagliptin 5 mg|Tablet, Oral, 5 mg, Once daily in the morning
214685084|NCT02273050|DRUG|Placebo 5 mg for Saxagliptin|Tablet, Oral, 5 mg, Once daily in the morning
214685085|NCT02273050|DRUG|Placebo 500 mg for metformin (with titration)|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
214685086|NCT02273050|DRUG|Metformin 500 mg with titration|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
214685087|NCT00556218|BEHAVIORAL|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
214987244|NCT03083041|BIOLOGICAL|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
214374540|NCT04711356|DRUG|Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection|Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
214374541|NCT05181514|OTHER|20% Intralipid|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of 20% fat emulsion (Intralipid 20%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
214374542|NCT05181514|OTHER|Normal Saline|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of normal saline (Sodium Chloride 0.9%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
214495945|NCT04322305|OTHER|Placebo|Placebo capsules will be provided twice daily over 8 weeks and one week taper..
214495946|NCT06840665|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
214495947|NCT06840665|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
214495948|NCT06840665|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
214495949|NCT06842030|DIAGNOSTIC_TEST|Darwin OncoTarget and OncoTreat|Darwin OncoTarget and OncoTreat predict potential drugs with early markers of efficacy in early human clinical trials. Specifically, OncoTarget identifies high-affinity inhibitors of master regulator proteins, while OncoTreat identifies tumor-checkpoint module inhibitors that modulate the transcriptional activity of hyper-connected master regulators. These tests are now commercially available with Clinical Laboratory Improvement Amendments (CLIA) approval through Columbia Presbyterian Medical Center.
214685088|NCT00556218|BEHAVIORAL|No Meditation|No meditation; usual care.
214685089|NCT06296017|OTHER|Experimental: Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart.
214685090|NCT06296017|OTHER|Trigger Finger Splint|A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
214374543|NCT05404425|PROCEDURE|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
214495950|NCT06855173|DEVICE|Active external rewarming device|Electrical heating blanket
214495951|NCT06855173|DEVICE|Active external rewarming device 2|Electrical heating blanket
214495952|NCT06855173|DEVICE|Active external rewarming device 3|Electric heating blanket
214495953|NCT06855173|DEVICE|Active external rewarming device 4|Electric heating blanket
214685091|NCT06296017|OTHER|Extracorporeal Shock Wave Therapy+ Trigger Finger Splint|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart. Also, A trigger finger splint that immobilizes the MCF joint will be recommended.
214685092|NCT06567470|DRUG|CIT-013 low dose|Subcutaneous injection
214685093|NCT06567470|DRUG|CIT-013 high dose|Subcutaneous injection
214685094|NCT06567470|DRUG|Placebo|Subcutaneous injection
214685095|NCT06567470|DRUG|CIT-013 medium dose|CIT-013 medium dose
214685096|NCT05763199|DIETARY_SUPPLEMENT|AHCC|AHCC is the cultured mycelia of Lentinula edodes mushrooms from the Basidiomycetes family.
214685097|NCT05763199|DRUG|Chemotherapy|Chemotherapy will be administered per standard of care.
214685098|NCT05763199|OTHER|Placebo|Dextrin
214685099|NCT02297438|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
214685100|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
214685101|NCT02297438|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
214685102|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
214987245|NCT03083041|DRUG|Apatinib|Apatinib tablet will be administered orally,once daily until progression
214987246|NCT03185208|DRUG|Lithium Carbonate|See lithium carbonate arm
214685103|NCT06511713|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
214685104|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|
214685105|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
214987247|NCT03185208|DRUG|Placebo oral capsule|See placebo arm
214987248|NCT05364424|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab for up to 3 cycles.
214685106|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
214685107|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 100 ms intervals|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
214685108|NCT06831838|BEHAVIORAL|Cognitive Behavioral Therapy based Pain Management Program|Subjects will participate in a two-day structured class that will focus on Cognitive-Behavioral skills and strategies to improve pain control, fatigue, sleep disturbance, cognitive symptoms, and stress while educating patients on the efficacy of Aromatase Inhibitors in prolonging cancer-free survival with the goal of eliminating non-adherence.
214685109|NCT03997539|DRUG|Pyrotinib|Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
214685110|NCT03997539|DRUG|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
214685111|NCT03997539|DRUG|vinorelbine|vinorelbine
214987249|NCT05364424|DRUG|Obinutuzumab|Participants will receive IV obinutuzumab on Cycle 1 Day 1.
214987250|NCT05364424|DRUG|Tocilizumab|Participants will receive IV tocilizumab as necessary to manage cytokine release syndrome (CRS) events.
214987251|NCT05364424|DRUG|Rituximab|Participants will receive up to 2 doses of IV rituximab.
214685112|NCT02042404|DEVICE|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
214987252|NCT05364424|DRUG|Ifosfamide|Participants will receive IV ifosfamide for up to 3 cycles.
214987253|NCT05364424|DRUG|Carboplatin|Participants will receive IV carboplatin for up to 3 cycles.
214987254|NCT05364424|DRUG|Etoposide|Participants will receive IV etoposide for up to 3 cycles.
214495954|NCT06072703|DEVICE|Magstim Rapid2 System|"The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction."
214495955|NCT06743555|OTHER|Observation without surgery|Patients randomized to this arm will forego standard-of-care thoracic surgery and will undergo strict surveillance based on serial radiological follow-up and ctDNA monitoring
214495956|NCT06743555|PROCEDURE|Standard-of-care surgery|Patients randomized to this arm will undergo standard-of-care thoracic surgery and undergo post-operative surveillance with serial radiological follow-up and ctDNA monitoring
214495957|NCT06742060|DIAGNOSTIC_TEST|serum copeptin levels|For children who met the entry criteria, the blood samples were collected preoperatively (T0), 1h postoperatively (T1), 1 day postoperatively (T2), 2 days postoperatively (T3), 3 days postoperatively (T4), 4 days postoperatively (T5), 5 days postoperatively (T6) to test serum and peptide levels.
214987255|NCT04541121|BEHAVIORAL|3D printed model|Mother is given 3D printed model of fetus' face
214987256|NCT04541121|BEHAVIORAL|Placebo|Mother is given a picture of 3D ultrasound of fetus
214685113|NCT05699746|DRUG|Capecitabine tablets|Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
214685114|NCT05699746|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
214987257|NCT00573924|DRUG|Proton pump inhibitor (lansoprazole)|"1. 120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~2. 90 mg IV bolus followed 9 mg/hr infusion for 24 hrs"
214987258|NCT02141932|PROCEDURE|Bed-side pocket size ultrasound imaging|
214374544|NCT05404425|PROCEDURE|Control|For patients randomized in the control group, the evaluation is performed by the Emergency Medical Call Center physician only by pone call
214685115|NCT00290576|DIETARY_SUPPLEMENT|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
214685116|NCT04257162|OTHER|Tumor and Blood sample collection|"This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.~Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.~Tumor sample and blood sample will be collected within the framework of HER2-Predict Study"
214685117|NCT03834129|DRUG|Dexmedetomidine|Two administrations, before anesthesia and during surgery, by intravenous infusion of dexmedetomidine 1 μg/kg in 250 ml of physiological serum for 30 minutes
214374545|NCT03823222|DIETARY_SUPPLEMENT|Duckweed protein|20 grams isolated protein
214374546|NCT03823222|DIETARY_SUPPLEMENT|Whey protein|20 grams isolated protein
214374547|NCT03258424|DRUG|PTI-428|PTI-428 or placebo will be given QD for 14 days.
214374548|NCT03258424|DRUG|Placebo|PTI-428 or placebo will be given QD for 14 days.
214374549|NCT06284863|DIETARY_SUPPLEMENT|Natritional Education Program In Hemodialysis Patients|Impact Of Natritional Education Program In Hemodialysis Patients Interventional Study
214495958|NCT06741982|BIOLOGICAL|Lysogenic HSV virus.|Lysosomal HSV virus injection (divided into a dose-escalation phase and a dose-expansion phase; in the dose-escalation phase, Group 1 took 106 pfu/mL and Group 2 took 108 pfu/mL, and in the dose-expansion phase the dose of lysosomal HSV virus with the highest MPR of the escalation phase was taken.) .. The dose of intralymph node injection of lysosomal HSV virus in patients was determined according to the size of metastatic lymph nodes, (diameter less than or equal to 1.5 cm, maximum 1 mL; diameter 1.5-2.5 cm, maximum 2 mL; diameter greater than 2.5 cm, maximum 4 mL). Two injections were given per patient, with each dose separated by 2 weeks.
214495959|NCT06741982|DRUG|Tislelizumab|200mg IV Q3W
214495960|NCT06741982|DRUG|Afatinib|30mg PO QD
214987259|NCT02141932|DEVICE|GE Ultrasound Vscan|
215089955|NCT01848470|DRUG|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
215089956|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
215089957|NCT01848470|DRUG|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
215089958|NCT01848470|DRUG|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
214374550|NCT01027975|PROCEDURE|laparoscopic Nissen/laparoscopic Thal|
214374551|NCT01722162|DRUG|Bevacizumab|
214374552|NCT01722162|DRUG|Capecitabine|
214685118|NCT03834129|DRUG|sodium chloride 0.9%|Two administrations, before anesthesia and during surgery, by intravenous infusion of 250 ml of physiological serum for 30 minutes
214685119|NCT06721338|DEVICE|Mechanical thrombectomy via blood flow reversal using BOBBY balloon guide catheter|After 2 min. of mechanical thrombectomy (MT), the side port of a BOBBY balloon guide catheter will be flushed again with heparin and the balloon deflated. A follow up angiogram will be performed to determine whether to proceed with another MT pass using the same procedure or to stop if successful recanalization has been achieved. At the end of the procedure, multiple angiograms will be performed and used to record the final TICI score. Angiograms of neck vessels will be used to rule out complications. Groin angiograms will evaluate the puncture site before closure. The catheters will then be removed, allowing hemostasis to be achieved in the groin. An angioseal closure device will be used on the arterial site if not contraindicated and a venous Vascade for the venous side.
214685120|NCT04753203|DRUG|Alpelisib plus Capecitabine combination|Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation
215089959|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
214374553|NCT01722162|DRUG|Levocetirizine|
214374554|NCT04215263|OTHER|Questionaire|Patient was assessed using mini international neuropsychiatric interview
214374555|NCT03124199|DRUG|Rifaximin|Rifaximin 400 mg/8 h added to the standard triple therapy
214374556|NCT06281353|DRUG|Curcumin Oral Capsule|Curcumin oral capsule in nano-sized particle.
214374557|NCT06281353|DRUG|Trichloroacetic acid|TCA 90%
214374558|NCT06281353|PROCEDURE|Blood sample collection|HIV and CD4+ 4th generation.
214374559|NCT06281353|PROCEDURE|Cotton swab|Cotton swab for collecting sample from AGW lesions.
214374560|NCT02893306|BIOLOGICAL|MSCs|origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
214374561|NCT04116697|OTHER|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
214685121|NCT01037504|DRUG|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
215089960|NCT03345524|OTHER|Peer-Buddy System|"2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed"
215089961|NCT03345524|OTHER|Usual Care|"Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)"
214987260|NCT03834350|OTHER|BREATHES Program|Participants will complete inhaler education using the virtual education module at the baseline visit of the study. Additionally, they will be asked to complete the lesson at least once before their 30 day follow-up visit on their personal device once they have been discharged from the hospital. At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
214987261|NCT03834350|DEVICE|BREATHES SpiroPD or Propeller Health|At the time of their initial study visit, study participants may be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
214685122|NCT01037504|DRUG|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
214987262|NCT02410629|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
214374562|NCT04116697|OTHER|Aromatherapy|Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
214374563|NCT04550663|DRUG|KD-025 CAR-T cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
214374564|NCT02849275|OTHER|Lactose Free 1% Milk|isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
214374565|NCT02849275|OTHER|Probiotic Treatment|Probiotic treatment, consumed once daily, over 4-5 weeks.
214374566|NCT02221102|DRUG|Aspirin|non-steroidal anti-inflammatory drugs
214374567|NCT02221102|DRUG|edoxaban|orally active direct factor Xa inhibitor
214374568|NCT02221102|DRUG|placebo|
214374569|NCT03651102|DRUG|Thalidomide and Hydroxyurea|Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day
214374570|NCT00730379|DRUG|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
214374571|NCT03649620|DIETARY_SUPPLEMENT|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
214374572|NCT03649620|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
214374573|NCT05492526|DEVICE|Ki Monitor without feedback|Physical activity Monitor - No feedback
214374574|NCT05492526|DEVICE|Ki monitor with contextualised data feedback|Physical activity monitor and feedback
214374575|NCT00732186|BIOLOGICAL|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
214374576|NCT04074590|DRUG|LYS006|capsule for oral use
214495961|NCT06751771|OTHER|comprehensive correcting exercise program|Group A will be treated with comprehensive correcting exercise program (three times a week for 6 weeks) into 3 phases with different intensity and frequency
214374577|NCT04074590|DRUG|Placebo|capsule for oral use
214374578|NCT01355458|DRUG|CD07805/47 gel|applied topically once daily
214495962|NCT06751771|OTHER|McKenzie's method of exercises|Group B will receive the McKenzie's method of exercises that include Deep neck flexor (chin tucks), Shoulders shrug McKenzie exercise for neck, Repeated shoulder flexion/Extension, Neck flexion McKenzie exercises
214495963|NCT06776055|BIOLOGICAL|HPV-16/18 vaccine|Recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast)
214495964|NCT06776055|BIOLOGICAL|Placebo|Placebo containing the same formulation as the active vaccine (Type 16 and 18 L1 proteins, Yeast) but without the active substance.
214495965|NCT06740513|PROCEDURE|Endovascular Treatment|Medical Therapy plus Stent/Balloon Angioplasty
214495966|NCT06774092|OTHER|Data collection|Data collection
214495967|NCT02510625|PROCEDURE|Anatomic Glenoid Reconstruction|Distal tibia bone graft
214495968|NCT02510625|PROCEDURE|Arthroscopic bankart Repair|Arthroscopic bankart Repair
214495969|NCT06832839|PROCEDURE|Revascularization|Revascularization
214495970|NCT04520217|DRUG|4% Imipramine Cream|4% Imipramine Cream
214495971|NCT04520217|DRUG|Base Cream|Base Cream
214495972|NCT03654716|DRUG|ALRN-6924|ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.
214495973|NCT03654716|DRUG|Cytarabine|Cytarabine belongs to the category of chemotherapy called antimetabolites. Antimetabolites are very similar to normal substances within the cell. When the cells incorporate these substances into the cellular metabolism, they are unable to divide
214495974|NCT06496490|DRUG|TQB2102 for injection|HER2 dual-antibody-drug Conjugate (ADC).
214495975|NCT06496490|DRUG|TQB2102 for injection combined with Benmelstobart injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC); Benmelstobart injection is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
214495976|NCT06833164|DIAGNOSTIC_TEST|endoplasmic reticulum Aminopeptidase 1 and 2|endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA
214495977|NCT06833164|DIAGNOSTIC_TEST|endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA|endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA
214495978|NCT05360849|BEHAVIORAL|Practice Facilitation|Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs
214374579|NCT01355458|DRUG|Placebo|applied topically once daily
214685123|NCT02076555|BEHAVIORAL|Education - Diabetes and Social Issues|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Social Issues was created. The module covers specific and detailed aspects of the topic social issues such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible."
214685124|NCT01902082|DRUG|Mesenchymal stem cells|
214495979|NCT04516720|OTHER|data collection|Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death
214495980|NCT03789110|DRUG|Nivolumab|Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
214495981|NCT03789110|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
214495982|NCT06265740|OTHER|vaginal swab|Any pregnant woman attending the obstetrics department of Clermont-Ferrand University Hospital who requires a vaginal swab (VS) for her clinical situation (routine care) will be offered the study. If the participant accepts, the usual swab will be doubled and performed simultaneously in a single procedure using two swabs. The first swab will be sent to the laboratory and used for diagnosis. The second swab will be used for microbiota analysis.
214495983|NCT05162326|BIOLOGICAL|BC-101|Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.
214495984|NCT06805526|BEHAVIORAL|Intermittent Islamic fasting with lifestyle modification|"Both groups followed a healthy lifestyle for 6 months including:~Diet: The participants' habitual total energy expenditure was estimated using the standard Harris-Benedict equation. To achieve a reduction of over 500 kcal/day, a daily intake of 1,200 to 1,500 kcal is typically recommended for women and 1,500 to 1,800 kcal for men .~Physical Activity: Moderate physical activity is advised. This includes engaging in exercise for 30 to 60 minutes, five days a week. Additionally, incorporating resistance training is recommended twice a week .~* stress management How to cope with stress, relaxation technique, quality and quantity of sleep,~* Drinking enough water 30-40ml/kg/day. Followed Intermittent Islamic fasting which meant fasting two days per week (Monday and Thursday) with fasting (13, 14, 15) middle of lunar months. (during Intermittent Islamic fasting caloric requirement was distributed as 30-40~For Group I (intervention group) only, Followed Intermittent Islamic fasting wh"
214685125|NCT01902082|DRUG|Placebo|
214685126|NCT03417011|DEVICE|Medtronic CoreValve™ Evolut™ PRO System (Evolut™ PRO System)|Transcatheter Aortic Valve Replacement with Medtronic Evolut PRO system
214685127|NCT06452537|DRUG|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone.
214685128|NCT06452537|DRUG|Prednisone|Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage
214685129|NCT03838250|BIOLOGICAL|Cellgram™ (Bone marrow-derived MSCs)|Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
214685130|NCT00331825|DRUG|Risperidone and Olanzapine|
214685131|NCT01947049|OTHER|Rapid Influenza Testing with Xpert Flu|Participants with recieve rapid influenza testing with Xpert Flu
214374580|NCT04504201|OTHER|Focus Group|Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
214374581|NCT02504125|DRUG|Tranexamic Acid|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
214374582|NCT02504125|DRUG|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
214374583|NCT01770210|DRUG|Patients on atorvastatin treatment|Statins Therapy
214374584|NCT02093455|DIETARY_SUPPLEMENT|Chardonnay Seed Flour (CSF)|CSF is made from wine grape skins and seeds.
214374585|NCT02093455|DIETARY_SUPPLEMENT|Placebo|
214685132|NCT01163162|DRUG|Paricalcitol|2 mcg oral Paricalcitol once per day for 7 days
214685133|NCT04719065|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.
214685134|NCT00878917|DRUG|Dorzolamide 2 % eye drops solution|1 drop into eye(s) three times a day for the duration of each treatment phase
214374586|NCT06303076|DRUG|Tizanidine Hcl 4Mg Tab|"Initial Dose Administration:~Patients will start by taking an initial dose of 2 mg of Tizanidine at bedtime (HS).~Dose Titration Process:~Every 4 days, the dose of Tizanidine will be increased by 2 mg. This titration is based on the patient's response to the medication and their tolerability of it.~Maximum Dose Limit:~The dose titration will continue until reaching the maximum dose of 0.1 mg/kg/HS, or until the maximum tolerated dose is identified, whichever comes first.~Monitoring and Adjustment:~Throughout the titration process, patients will be closely monitored for any adverse effects and for the effectiveness of the medication.~Adjustments to the dosing schedule may be made based on the clinician's assessment of tolerability and therapeutic response."
214374587|NCT06303076|DRUG|Zolpidem Tartrate 10 mg|"nitial Dose Administration:~Participants will start by taking an initial dose of Zolpidem 5 mg orally at home before bedtime (HS).~Response Evaluation and Dose Adjustment:~If there is no response to the initial 5 mg dose and it is tolerated well by the participant, the dose will be increased to 10 mg.~Monitoring and Adjustment:~Participants will be monitored for their response to the medication as well as for any adverse effects.~The decision to increase the dose to 10 mg will be based on the absence of a therapeutic response to the initial dose and the participant's tolerability of Zolpidem.~Dose Maximization and Safety:~The increase to a 10 mg dose is aimed at maximizing therapeutic efficacy while ensuring the safety and tolerability of the medication in participants who do not respond to the lower dose."
214374588|NCT03708640|OTHER|Digital Activity Tracker|Group wears physical activity tracker and receives physical activity feedback information informed by the tracker
214685135|NCT04150497|BIOLOGICAL|UCART22|Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
214685136|NCT04150497|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
214685137|NCT04752813|DRUG|BPM31510|Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.
214685138|NCT04752813|OTHER|Vitamin K1|Subjects will receive prophylactic Vitamin K1 at a recommended dose of 10 mg subcutaneously prior to the beginning of each week of BPM31510 therapy.
214685139|NCT04752813|DRUG|Temozolomide (TMZ)|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for up to 12 cycles post BPM31510 treatment.
214374589|NCT03708640|OTHER|Smart Text Messaging|"Group receives personalized, health coaching via smart text messages"
214374590|NCT03708640|OTHER|Physical Activity Counseling|Group receives baseline counseling on physical activity
214374591|NCT03223532|DEVICE|PrePex Day 7 FRP|Standard PrePex procedure, foreskin and device are removed 1 week after device application.
214374592|NCT03223532|DEVICE|PrePex Day 0 FRP|Removal of the foreskin shortly after device application, the device is removed 1 week later
214374593|NCT00828308|DRUG|Ixabepilone|Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
214374594|NCT00828308|PROCEDURE|Prostatectomy|Prostatectomy 2-8 weeks after completion \*\*\*this was standard of care and not a part of the study\*\*
214495985|NCT06805526|BEHAVIORAL|Lifestyle modification only|"The participants' habitual total energy expenditure was estimated using the standard Harris-Benedict equation. For men, the formula is: BMR = 66.4730 + 13.7516 × weight (kg) + 5.0033 × height (cm) - 6.7550 × age (years). For women, the formula is: BMR = 655.0955 + 9.5634 × weight (kg) + 1.8496 × height (cm) - 4.6756 × age (years) \[27\]. To achieve a reduction of over 500 kcal/day, a daily intake of 1,200 to 1,500 kcal is typically recommended for women and 1,500 to 1,800 kcal for men \[28\].~Physical Activity: Moderate physical activity is advised. This includes engaging in exercise for 30 to 60 minutes, five days a week. Additionally, incorporating resistance training is recommended twice a week \[29\].~* stress management How to cope with stress, relaxation technique, quality and quantity of sleep,~* Drinking enough water 30-40ml/kg/day."
214495986|NCT05786157|OTHER|Alcohol Administration|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
214495987|NCT03912194|BEHAVIORAL|cognitive-behavioral withdrawal regulation strategies|Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
214685140|NCT04752813|RADIATION|Radiation|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent standard RT for 42 days.
214685141|NCT06077071|RADIATION|ViewRay MRIdian Stereotactic Radiosurgery|Participants will undergo stereotactic radiosurgery of the spinal cord on the ViewRay MRIdian, a hybrid MRI-linac platform, with 40 Gy in 5 fractions prescribed to the planning target volume (PTV).
214685142|NCT05945290|PROCEDURE|Biospecimen Collection|Undergo blood and leftover tissue sample collection
214685143|NCT05945290|OTHER|Electronic Health Record Review|Medical records are reviewed
214987263|NCT02410629|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
214987264|NCT04909788|BEHAVIORAL|a long-distance running (over 3 km)|Complete a long distance running（over 3 km） within the specified time (30 minutes)
214987265|NCT04121143|BIOLOGICAL|IL-17A Antagonist|SHR-1314 subcutaneous injection
214987266|NCT04121143|BIOLOGICAL|Placebos|placebo subcutaneous injection to maintain consistency and to prevent blindness
214987267|NCT05675800|DRUG|Psilocybin|Psilocybin administered with psychological support
214685144|NCT03667664|DIAGNOSTIC_TEST|Multidimensional assessments|"Evaluation carried out during a day hospital at T0 (initial assessment) and T3 following the exercise program including:~1. Clinical assessment by a geriatrician~2. Nutritional assessment~3. Physical capacity assessment~Following initial assessment (T0), older adults are included in the multicomponent exercise program if they present mobility disability risk factors including :~* At least pre-frailty regarding Fried frailty criteria AND/OR~* At least probable sarcopenia regarding EWGSOP2 algorithm AND/OR~* The presence of at least an intermediate fall risk AND/OR~* The presence of a fear of falling Following the exercise program (T3), all participants are re-assessed in the same way as T0. Investigators then set goals in physical activity with participants to maintain benefits and foster self-engagement in an healthy lifestyle. Additionnally, participants are orientated to exercise facilities and received an individualized booklet of exercises for home-based training."
214374595|NCT05834114|OTHER|Mckenzie protocol|"In this group 20 participants will receive McKenzie protocol with conventional physical therapy. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). Subsequently, the participant will be requested to return to the original position while the therapist one hand's forefinger placed alongside the participant's mandible (to stabilize the head at full retraction position), and the heel of the other hand placed on the first or second dorsal vertebra (to provide posterior-anterior force). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week."
214685145|NCT03667664|OTHER|Multicomponent group-based and supervised exercise program|The intervention consists in a progressive multicomponent exercise training protocol. There are 2 sessions per week of 1 hour each for a total of 12 weeks. Sessions involve functional, resistance and balance exercises. Intensity is based on rating perceived effort (Borg's scale CR1-10) and volume towards 1 to 3 sets of 6 to 15 repetitions. Progressiveness in intensity and volume was based on effort tolerance, contraction regimen, velocity and load. Training schedule is described elsewhere (Delaire et al, 2023 ; doi.org/10.3390/nu15194100). Participants are allocated to an homogenous group based on functional status and cardiorespiratory comorbidities. Trained kinesiologists supervised the exercise program. Participants used free weights and elastic bands.
214495988|NCT03912194|BEHAVIORAL|relaxation strategies|Participants will generate and refine relaxation techniques with the aid of a therapist
214495989|NCT03912194|BEHAVIORAL|early withdrawal exposure|Exposure to the first 4 hours of abstinence across 4 separate sessions
214685146|NCT03667664|OTHER|Follow-up at T3 + 6 months and T3 + 12 months|"Follow-up at T3+6 months:~Investigators interviewed participants for 30 minutes. During the interview, data collection include:record of undesirable events in the interval T3 / T3+6 (falls, unscheduled hospitalization, illness, institutionalization), medication changes, ADL, IADL, FES-I, and RAPA. Goal-settings at T3 are adjusted if not reach. Finally, investigators stimulate intrinsic motivation for PA.~Follow-up at T3 + 12 months:~Investigators re-assessed physical capacity, physical activity level, quality of life, fall risk and frailty for the last visit. Data collection include:~* SPPB~* Handgrip test and maximal isometric strength of the quadriceps~* Questionnaires : SarQoL©, FES-I, RAPA~* Gait quality analysis using inertial sensors~* Undesirable events in the interval T3+6 / T3+12 (falls, unscheduled hospitalization, illness, institutionalization)~* Medication changes~* Body mass index~* ADL and IADL At last, goals in physical activity are adjusted if they are still not reach"
214685147|NCT05430568|PROCEDURE|robot-assisted surgery|"1. traditional sternotomy for coronary bypass graft or valvular replacement~2. robot-assisted surgery for coronary bypass graft or valvular replacement"
214685148|NCT06008626|DEVICE|Cryosa Procedure|Cryotherapy
214685149|NCT03952468|DEVICE|Transcranial Magnetic Stimulation|Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
214685150|NCT03952468|OTHER|Brief Cognitive Behavioral Therapy|BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
214685151|NCT03932201|DRUG|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
214685152|NCT02948140|PROCEDURE|MRI|
214685153|NCT02948140|PROCEDURE|Abdominal scanner|
214495990|NCT04686877|PROCEDURE|STAPLE|Stereotactic aspiration plus urokinase clot irrigation
214495991|NCT06716333|OTHER|Experimental Group (12-Week Wrestling Training)|The intervention consists of a structured 12-week intensive wrestling training program designed specifically for male wrestlers aged 12-14 years. This program was conducted at athlete training centers equipped with international standard facilities, and led by professional coaches. The training included 5 sessions per week, each lasting approximately 80 minutes, with a total weekly duration of 400 minutes. Each session consisted of 20 minutes of gymnastic warm-up, 50 minutes of basic technical and strength exercises (e.g., squats, push-ups, deadlifts), and 10 minutes of stretching.
214495992|NCT06748560|OTHER|Neurodynamics|Following Castellote-Caballero et al., the neurodynamic sliding technique (NST) was applied to the dominant leg's sciatic nerve in the NST and ETNST groups. The technique involves alternating stress proximally and distally to promote nerve sliding. Participants performed two sets of movements-cervical flexion with knee and ankle flexion, and cervical extension with knee and ankle extension-repeated actively for 60 seconds, five times per session. Over six weeks, both groups underwent three supervised sessions per week led by an experienced researcher.
214495993|NCT06748560|OTHER|Eccentric training|The Nordic exercise served as the foundation for the intervention, focusing on eccentric loading as participants resisted falling forward. To minimize DOMS and ensure adherence, a two-week preparatory phase of mixed concentric/eccentric leg curls using a stability ball was implemented. Following this, the gradual progression outlined by Mjolsnes et al. led to a four-week Nordic hamstring curl regimen. Weekly supervision ensured proper technique and compliance throughout the program.
214685154|NCT06667999|DRUG|Albumin|Albumin should be used for the following indications: 1. During circulatory failure in addition to crystalloids (resuscitation). 2. For substitution in case of: suspected or overt albumin loss OR P-albumin levels below or equal to 25 g/L. Decisions around timing, volume, and concentration of albumin, and its use for other indications, are at the clinician's discretion. P-albumin should be measured according to local practice.
214685155|NCT06667999|OTHER|No albumin use|Albumin should not be used. In case of the following special circumstances, albumin may be considered: 1. Large ascites drainage (i.e., equal to or more than 1 L tapped) 2. Spontaneous bacterial peritonitis 3. Hepatorenal syndrome.
214685156|NCT02992522|DRUG|Lenalidomide|Given PO
214374596|NCT05834114|OTHER|Rhythmic Stabilization technique|In this group participants will receive Rhythmic stabilization, with Conventional physiotherapy treatment the flexion , extension exercises performed. During flexion pattern the experimenter stood at the right side of patient and used his tip of fingers at chin. The experimenter then put his left hand at anterior side of head to apply resistance. then extension pattern is resisted and asked patient to match my resistance. The experimenter provided resistance against right rotation and lateral flexion provided during the exercise in order to induce strong muscle contractions. 3 sessions of 45 minutes a week, over a period of 10 weeks.
214374597|NCT03522805|DEVICE|High-intensity non-invasive ventilation|Single night of high-intensity non-invasive ventilation
214374598|NCT03748511|OTHER|fibroscan and stool sample|patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
214495994|NCT06759636|DRUG|Romiplostim N01|3.0 µg/kg, subcutaneous injection, once a week. Afterwards, refer to the platelet count evaluated during the visit before the next dosing cycle: ① If the platelet count is less than 50×10\^9/L, increase by 1-2μg/kg once a week; ② If the platelet count is between 50-99×10\^9/L, increase by 1μg/kg once a week. According to platelet count and symptoms, investigators can adjust the dosage to the maximum dosage of 10μg/kg once a week.
214495995|NCT06759636|DRUG|Recombinant Human Interleukin-11 (rhIL-11)|25-50μg/kg, subcutaneous injection, once a day
214495996|NCT01855750|DRUG|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
214685157|NCT02992522|BIOLOGICAL|Obinutuzumab|Given IV
214685158|NCT02992522|DRUG|Venetoclax|Given PO
214685159|NCT04459273|PROCEDURE|Computed Tomography|Undergo PET/CT
214685160|NCT04459273|DRUG|Gallium Ga 68 FAPi-46|Given IV
214374599|NCT04879459|OTHER|Practical sessions to learn CUS exclusively on volunteers presenting a healthy gallbladder|The study days are 1 day apart for CG and IG but follow the exact same organization. Studytake place on day 0-10-30 (+/-2days). Practical sessions to learn CUS are organized either on volunteers presenting a healthy gallbladder or a pathological gallbladder (sludge, gallstones) (CG), either exclusively on volunteers presenting a healthy gallbladder (IG).
214685161|NCT04459273|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214685162|NCT04459273|RADIATION|18F-FDG|Given IV
214685163|NCT02774759|DEVICE|Accelerometer|Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
214685164|NCT02774759|BEHAVIORAL|Questionnaires|"Questionnaires completed at baseline regarding quality of life and diet.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
214685165|NCT02774759|BEHAVIORAL|Fitness Test|Fitness test given covering various physical activities at baseline and at 6 month visit.
214685166|NCT02774759|BEHAVIORAL|Resistance Training|Physical activity guidelines workbook distributed along with activity monitor. Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member. Information from wireless scale and Fitbit sent to Fitbit website to monitor levels.
214685167|NCT02774759|BEHAVIORAL|Aerobic Exercise|Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor.
214685168|NCT02774759|BEHAVIORAL|Telephone Coaching/Phone Calls|Participants called 4 times during the first month, 2 times during the second month, and 1 time per month for the rest of the study. Participants also receive a follow-up call at the end of the study.
214685169|NCT02774759|BEHAVIORAL|Video Chat Sessions|Video chatting between the research team and participants occurs 2 times per month during the first and third months, when new exercises are introduced. Video chatting offered monthly as needed by participants during months 2, 4, 5, and 6.
214685170|NCT06388122|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214374600|NCT00691132|DRUG|phenethyl isothiocyanate|Given orally
214374601|NCT00691132|OTHER|placebo|Given orally
214374602|NCT01460498|DRUG|Azacitidine (AZA)|Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.
214495997|NCT01855750|DRUG|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
214495998|NCT01855750|DRUG|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
214495999|NCT01855750|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
214496000|NCT01855750|DRUG|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
214496001|NCT01855750|DRUG|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
214496002|NCT01855750|DRUG|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
214496003|NCT04300023|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
214496004|NCT06747702|OTHER|Injury prevention workout|The injury prevention workout consisted on engaging on a prevention program from 1 day to 8 weeks where the participants will develop functional sport exercises to prevent shoulder injuries or pain in overhead sports.
214496005|NCT06761222|OTHER|The use of ultrasound in central blocks|Ultrasonography was conducted using a convex probe in the paramedian and transverse planes.
214496006|NCT05633836|PROCEDURE|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreduction surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
214685171|NCT05224206|DEVICE|Theta burst stimulation|Cool B65 active/placebo coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
214685172|NCT05224206|DEVICE|Theta burst stimulation|Cool B70 coil (left DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
214374603|NCT01460498|DRUG|Tyrosine kinase inhibitor (TKI)|Continuation of dose already receiving during previous 6 months.
214374604|NCT01460498|DRUG|Azacitidine|75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
214496007|NCT03328663|OTHER|CARE|Promote effective coping and reduce caregiving burden.
214496008|NCT03328663|OTHER|Standard Transplant Care|Standard cared administered by the hospital.
214496009|NCT06757335|DRUG|HP568|In the I/II stage: HP568 administered QD or BID for 28 day cycles.
214496010|NCT06757335|DRUG|HP568 in combination with palbociclib|In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.
214496011|NCT06772844|DIAGNOSTIC_TEST|fecal DNA methylation testing|Three rounds of screening were performed. In the first year, colonoscopy was conducted along with concurrent fecal DNA testing performed prior to the colonoscopy. In the second year, fecal DNA testing was performed only if no polyps were detected during the colonoscopy in the first year; otherwise, both colonoscopy and fecal DNA testing were conducted. In the third year, a colonoscopy was performed with concurrent fecal DNA testing conducted before the procedure
214496012|NCT06753344|BEHAVIORAL|Intervention app|The app-based intervention, co-designed with the V-YAC, aims to introduce life skills and self-management skills to promote general mental well-being and resilience among Vietnamese youth. With this app, youth users will have a fun and safe space to learn and practice six life skills areas (Problem-solving, Social Media and Well-being, Communication and Interpersonal Skills, Realistic Thinking, Coping with Emotions and Stress, and Goal Setting). Lessons (in the form of short texts) and activities (ex. multiple choice activities, blank worksheets, reflection questions) were adapted from evidence-based interventions developed in other contexts to be culturally appropriate to the Vietnamese youth context. Youth users are free to explore the app at their own pace. Gamification features will also allow youth users to collect points in the app for completing each lesson, activity, or challenge.
214496013|NCT06742528|DRUG|Ferrous sulfate|ferrous sulphate in a dose of 6mg/kg/day of elemental iron once daily for 8 weeks orally in syrup form.
214496014|NCT06742528|DRUG|Iron Polymaltose Complex|Iron Polymaltose complex in a dose of 6mg/kg/day of elemental iron once daily orally for 8 weeks.
214685173|NCT06409013|OTHER|Non-Interventional Study|Non-interventional study
214685174|NCT04457089|DRUG|Simvastatin 40mg|Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
214685175|NCT06182774|DRUG|Daratumumab|Dose determined at enrollment
214685176|NCT06182774|DRUG|Lenalidomide|Dose determined at enrollment
214685177|NCT06182774|DRUG|Dexamethasone|Dose determined at enrollment
214685178|NCT05770505|BEHAVIORAL|Exercise training using an e-health tool|Experimental: Exercise training will be guided by using the e-health tool MIA Health, with the possibility for digital communication between the participants and study personnel The participants will receive wearables that record heart rate. Participants will be encouraged to achieve 100 Personal Activity Intelligence (PAI) equivalents per week Control: No follow-up
214374605|NCT05568875|OTHER|e-self-management intervention (Happy Hands app)|"The 12-week intervention consists of 30 short informational videos addressing the themes prioritized by the patient research partners. These themes are further operationalized into the following categories: Information on hand OA, Hand exercises, Use of assistive devices and orthoses, Medication and surgical alternatives, and Self-management of the disease. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The intervention group will additionally receive treatment as usual."
214374606|NCT05568875|OTHER|Treatment as usual|Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.
214374607|NCT06155084|DRUG|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
214374608|NCT06155084|DRUG|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
214374609|NCT06155084|DRUG|HP518 -Dose Expansion|Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
214374610|NCT01291537|DRUG|Duodopa|
214374611|NCT01291537|DRUG|best médical treatment|
214374612|NCT01351298|DRUG|0.05% xylometazoline hydrochloride with 1% lidocaine hydrochloride|Decongestant with local anesthetic
214374613|NCT01351298|DRUG|0.05% xylometazoline hydrochloride|Decongestant
214374614|NCT01351298|DRUG|Isotonic normal saline|Placebo
214374615|NCT01856530|DRUG|Oxytocin|Liquid metered-dose nasal spray, 24 IU, administered once
214685179|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
214685180|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
214685181|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
214685182|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
214374616|NCT01856530|DRUG|Placebo|Matched placebo nasal spray
214374617|NCT01899456|DEVICE|Catheter-based renal denervation|
214374618|NCT05375123|DEVICE|Ultrasound image acquisition|"Echocardiography: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS.~Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester (20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-41 weeks of gestation), 6 weeks and 3-6 months after delivery.~Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester (20 to 24 weeks of gestation)."
214374619|NCT06150781|DRUG|erenumab-aooe|Dose and treatment duration will be advised by the HCP
214374620|NCT06499623|DIAGNOSTIC_TEST|Blood test|Albumin, C-Reactive Protein, Cholesterol, Urea, Creatinine, Vitamin D
214374621|NCT06499623|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|Total Impedance, Segmental Muscle Analysis, Segmental Fat Analysis, Absolute Muscle Mass Value, Muscle Mass Index, Total Body Fat Percentage, Total Body Water, Phase Angle Measurement
214685183|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
214685184|NCT05262400|DRUG|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
214685185|NCT05262400|DRUG|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
214685186|NCT05262400|DRUG|PF-07104091 + PF-07220060 + letrozole dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with letrozole
214374622|NCT06499623|OTHER|Nutritional Risk Assessment Questionnaire|Fill in the Questionnaire of the Working Group on Nutritional Care in Oncology and get nutrition risk score. The objective data includes weight loss in 6 months, current BMI and food tolerance, and oncological diagnosis including ongoing anti-cancer treatment.
214374623|NCT06362512|BEHAVIORAL|Dual-task training|participants receive three 60-minute COGMOTION dual-task exercise sessions per week for six consecutive weeks.
214374624|NCT06362512|BEHAVIORAL|Single-task training|participants receive 30-minute single motor tasks with 30-minute single cognitive tasks three times per week for six consecutive weeks.The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately.
214374625|NCT06362512|BEHAVIORAL|Upper limb strengthening exercise|participants receive upper limb strengthening exercise for 30 minutes and flexibility exercises for 30 minutes three times per week for six consecutive weeks. The training is performed in sitting or standing position and no cognitive load will be added.
214374626|NCT05642429|BIOLOGICAL|AV-1959D|Three doses of AV-1959D administered as a sterile suspension via intradermal injection
214374627|NCT05642429|BIOLOGICAL|Placebo|Three doses of Placebo administered as a sterile suspension via intradermal injection
214685187|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
214685188|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
214685189|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
214685190|NCT06283771|OTHER|Heated socks to be developed with wearable technology|The study group will wear heated socks to be developed with wearable technology
214374628|NCT01887080|OTHER|Exercise|"This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
214374629|NCT01887080|DEVICE|Microcurrent|"This group had the exercise program after electrolipolysis, thrice a week for eight weeks.~The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).~Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
214374630|NCT01887080|OTHER|Cardiovascular Risk Factors|It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
214374631|NCT02329548|OTHER|Alizarin Red|An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
214374632|NCT02934074|OTHER|No intervention|
214374633|NCT00703690|DRUG|MK0767|MK0767 2.5, 5, and 10 mg/day supplied as tablets
214374634|NCT00703690|DRUG|Comparator: fenofibrate|fenofibrate 200 mg supplied as capsules
214496015|NCT06685744|DEVICE|Telerehabilitation_TRsA|Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach.
214496016|NCT06685744|BEHAVIORAL|Educational treatment|Home rehabilitation indications according to a conventional approach, customized according to the disease.
214496017|NCT06685744|DEVICE|Telerehabilitation_TRcA|Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: a combination of exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach together with exercises aimed at recovering muscle strength (resistance) and improving endurance (endurance) using an Impairment-oriented approach.
214496018|NCT06747143|DIETARY_SUPPLEMENT|Lactobacillus casei DN-114001|Probiotic
214496019|NCT03219879|BEHAVIORAL|Telephone-administered continuation therapy|The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
214496020|NCT03219879|OTHER|Usual care|Usual care without any study-related intervention
214496021|NCT06668402|DEVICE|Utilizing a smartwatch to gather data on individuals receiving treatment for rectal neoplasm.|Employing a smartwatch to monitor steps, sleep quality, intense physical activity, and vital signs in persons undergoing treatment for rectal carcinoma.
214496022|NCT04449146|DIAGNOSTIC_TEST|Scapular positioning in Standing position using Sonography|The localizer ultrasound of the shoulder is performed in an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer.
214496023|NCT05525572|DEVICE|Shockwave Therapy (SWT)|"Shockwave Therapy (SWT):~720 shocks will be administered administered in every session to each treated region (left and right corpora cavernosa and crura). Each session will last approximately 20 minutes. A total of 3600 shocks will be administered over 5 weekly sessions."
214496024|NCT05525572|DRUG|Autologous Platelet-Rich Plasma (PRP)|"Autologous Platelet Rich Plasma (PRP):~5 mL PRP will be administered via intra-cavernous penile injection with a 30 ± 7 day treatment interval."
214496025|NCT01181544|PROCEDURE|Heparin dose titration|Patients will begin the study using their currently prescribed heparin doses - both bolus and constant infusion - for three treatments to establish a baseline and provide information on inter-treatment variability in dialyzer clotting. Subsequently, the bolus and infusion rates will be titrated either upward or downward based on the Robbins-Monro process and an evaluation of dialyzer clotting during the preceding treatment. Heparin doses will be adjusted for a total of 30 dialyses.
214685191|NCT05761444|DRUG|Atozet 10/40 mg or 10/80 mg|Atozet 10/40 mg or 10/80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
214685192|NCT05761444|DRUG|Lipitor 40 mg or 80 mg|Lipitor 40 mg or 80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
214685193|NCT02055521|PROCEDURE|Blood sample, biopsy|
214374635|NCT00703690|DRUG|Comparator: Placebo (unspecified)|matching placebo will be supplied as tablets/capsules.
214374636|NCT00361439|DRUG|Mometasone|2 puffs in each nostril once daily of nasal spray
214374637|NCT00361439|DRUG|Placebo|2 puffs in each nostril once daily of nasal spray
214374638|NCT01659892|DRUG|Montelukast|5 mg Chewable Tablet
214374639|NCT01659892|DRUG|Singulair|5 mg Chewable Tablet
214374640|NCT00846872|DRUG|GHRP-3 low dose|0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
214374641|NCT00846872|DRUG|GHRP-3 high dose|0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
214374642|NCT00846872|DRUG|Saline|5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
214685194|NCT03461653|OTHER|Telemedicine counselling|women on web counselling
214685195|NCT02652858|PROCEDURE|Non-invasive blood pressure oscillometer (NIBP) implementation|Implementation of two additional NIBP on humeral and femoral sites.
214685196|NCT06798714|DRUG|NSAID|standard CABG without performing pericardial fenestration intraoperatively
214685197|NCT06798714|DRUG|Colchicine 0.5 MG|Colchicine will be prescribed in a dose of 500 micrograms 4 hours before surgery and 500 micrograms 2 times a day for 10 days after surgery with pericardial fenestration
214374643|NCT04247659|DRUG|sodium aescinate|The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
214374644|NCT06285513|DIAGNOSTIC_TEST|Cardiac ultrasound|Cardiac ultrasound : determination of impairment of cardiac function by echocardiographic analysis (at V1, V3 and V4), Glycocheck : automatic analysis of sublingual microcirculation, Indirect calorimetry : determining the increase in energy expenditure in patients with septic shock
214374645|NCT00755040|DRUG|cyclosporine ophthalmic emulsion|Given as eye drops
214374646|NCT00755040|OTHER|placebo|Given as eye drops
214496026|NCT06247254|BEHAVIORAL|Intensive Clinic Management|Blood pressure management at in-person follow-up visits occurring every 2 months when systolic blood pressures are at target (i.e., \< 130 mmHg), and monthly when systolic blood pressure is ≥ 130 mmHg. Participants will also receive low-touch health promotion messaging via text messaging, with reminders focused on medication adherence, healthy diet, and physical activity and a tailored Blood Pressure Care Plan for managing stroke recovery. Participants will be encouraged to monitor their blood pressure at home and record values in logs.
214496027|NCT06247254|BEHAVIORAL|Intensive Tailored Telehealth Management|Tailored Blood Pressure Care Plan and health coaching contracted through INTERVENT.
214374647|NCT02716337|DIETARY_SUPPLEMENT|Addition of human milk fortifiers according to human milk analysis|
214374648|NCT06293209|DEVICE|3M cold pack|3M cold pack
214374649|NCT06293209|DEVICE|Perskindol cold spray|Perskindol cold spray
214374650|NCT06293209|DEVICE|Placebo|Placebo
214374651|NCT03790761|BEHAVIORAL|PREP 8.0 Curriculum|The PREP 8.0 curriculum is an experiential curriculum designed to be implemented in a workshop or educational setting. Using techniques of cognitive-behavioral marital therapy and communication-oriented marital enhancement, PREP aims to help couples achieve high levels of relationship functioning and prevent marital problems. The PREP approach is based on research in the field of relational and marital health and success conducted at the University of Denver.
214374652|NCT01957501|OTHER|MDDScoreTM|The child will receive a single blood draw (about 10 mL).
214374653|NCT03347916|DRUG|Strawberry juice as (placebo)|Patients received strawberry juice 5 ml volume, one hour before induction.
214374654|NCT03347916|DRUG|Gabapentin Oral Solution [Neurontin]|Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
214374655|NCT00683709|BEHAVIORAL|Counselling as Usual|5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.
214496028|NCT06746701|DRUG|Peg-IFNα-2b combined with NA|From baseline day 1, take NA orally once daily until the drug can be discontinued. Concurrently, combine with Peg-IFN α-2b 180μg, administered subcutaneously once a week for 48-96 weeks (if the surface antigen is not converted to negative at week 48, continue Peg-IFN α-2b treatment, but the course of treatment should not exceed 96 weeks). Discontinue Peg-IFN α-2b (while maintaining continuous oral administration of NA), and continue taking NA orally.
214496029|NCT06746701|DRUG|Nucleotide Analogues|Starting from the first day of enrollment, take NA orally once a day.
214685198|NCT05302063|DEVICE|Spinal Cord Stimulation (SCS)|Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
214685199|NCT04609592|DRUG|Lutathera|4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T
214685200|NCT04609592|DRUG|Gallium 68 Dotatate|Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)
214685201|NCT04609592|PROCEDURE|Computed Tomography (CT)|Medical Imaging
214685202|NCT04609592|PROCEDURE|Magnetic Resonance Imaging (MRI)|Medical Imaging
214685203|NCT04609592|PROCEDURE|PET/CT|Medical Imaging
214685204|NCT03802604|BIOLOGICAL|Talimogene laherparepvec|Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10\^6 PFU/mL. On week 3 (i.e. 21 days \[± 2\] days), a second talimogene laherparepvec injection will be administered at a dose of 10\^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 \[± 2\] days). The maximum volume for each injection will be 4.0 mL.
214685205|NCT03802604|DRUG|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 \[± 2\] days), for a total of 4 treatment courses.
214685206|NCT04694846|DRUG|Nicotine Replacement|Given NRT via trans-dermal patch, gum, nasal spray, inhaler or lozenges
214685207|NCT04694846|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
214685208|NCT04694846|DRUG|Varenicline|Given PO
214685209|NCT04694846|OTHER|Tobacco Cessation Counseling|Receive counseling
214685210|NCT04694846|OTHER|Questionnaire Administration|Ancillary studies
214685211|NCT04694846|OTHER|Quality of Life Assessment|Ancillary studies
214374656|NCT00683709|BEHAVIORAL|CBT|45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.
214374657|NCT03292848|DRUG|Brexpiprazole|Tablet
214374658|NCT03682835|DIETARY_SUPPLEMENT|FDGard|capsule containing peppermint oil and caraway oil
214374659|NCT03682835|OTHER|Placebo|Placebo capsule containing cellulose
214374660|NCT02701010|BEHAVIORAL|Structured training and leaflet|"The patients who were given both explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB by continence nurse and the educational leaflet were included in this group."
214685212|NCT04694846|OTHER|Best Practice|Receive standard treatment
214374661|NCT02701010|BEHAVIORAL|Structured training|"The patients who were given only explanatory verbal instructions of the educational leaflet on the structured behavioural therapy by continence nurse were included in this group."
214374662|NCT02701010|BEHAVIORAL|Leaflet|"The patients who were given only educational leaflet were included in this group."
214496030|NCT06758739|DRUG|Curcumin (Turmeric)|Curcumin Capsule will be given two per day for three months. Patient Recovery progress will be monitored month on month basis for consecutive three month.
214685213|NCT05786742|RADIATION|grade and compare reported side effects between groups|"Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~* Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~* median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~* IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment."
214685214|NCT06154369|BEHAVIORAL|JoyPop|Participants will be asked to use the app at least twice daily for the first 4 weeks with no further instructions on feature usage or time spent using the app.
214685215|NCT02889081|OTHER|maternal biological folate level|supplementation status and serum level
214685216|NCT02889081|OTHER|maternal biological Vitamin D level|supplementation status and serum level
214374663|NCT02701010|BEHAVIORAL|Control Group|Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
214374664|NCT04419844|PROCEDURE|Tar with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect with Botox injection .
214374665|NCT05476835|COMBINATION_PRODUCT|respiratory exercises - incentive spirometer - walking|respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
214374666|NCT05211271|DEVICE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by visual inspection with diluted acetic acid (VIA) presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
214496031|NCT06758739|DRUG|Intralesional Steroid Injection|Intralesional Steroid Injection (1cc), one per week, will be administered in the fibrous bands wherever formed in the oral cavity. Patient recovery progress will be monitored on monthly basis for three months.
214496032|NCT04057131|DRUG|Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
214685217|NCT06533865|DRUG|Romosozumab|Six monthly subcutaneous injections. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
214685218|NCT06533865|DRUG|Placebo|Identical to romosozumab but inactive. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
214685219|NCT06533865|DRUG|Zoledronic acid|One intravenous infusion
214685220|NCT06303648|DRUG|Methylone|Oral dose of methylone
214685221|NCT06303648|DRUG|Placebo|Placebo to match methylone
214685222|NCT04502407|RADIATION|Cisplatin-based Radiation Therapy|"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive radiation dose of 50 Gy in 25 fractions over 5 cycles on Days 1, 8, 15, 22, and 29 of radiation treatment.~* All other patients will receive radiation dose of 30 Gy in 15 fractions over 3 cycles on Days 1, 8 and 15 of radiation treatment."
214685223|NCT04502407|DRUG|Cisplatin Chemotherapy|"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~* All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation."
214685224|NCT04716933|BIOLOGICAL|Pembrolizumab|IV infusion Q3W
214685225|NCT04716933|DRUG|Carboplatin|IV infusion Q3W
214374667|NCT01146314|BEHAVIORAL|Family Focused Lifestyle Intervention|The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
214374668|NCT03350100|DIETARY_SUPPLEMENT|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
214374669|NCT02766621|BIOLOGICAL|PF-06823859|Comparison of different dosages of PF-06823859 to placebo
214374670|NCT02766621|DRUG|Placebo injection SC/IV|Comparison of Placebo to different doses of PF-06823859
214374671|NCT04392063|DRUG|Melatonin 3 mg|The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
214374672|NCT03091686|BEHAVIORAL|HAPA SB Intervention Slideshow|In the experimental condition, participants will receive sedentary behaviour and diabetes information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. For the experimental group, the intervention material will target risk perceptions (RP) related to sitting by presenting evidence supported by research on sedentary behaviour and diabetes risk; outcome expectancies (OE) by presenting research on the effectiveness of breaking up sedentary time for improving blood sugar and insulin levels; and self-efficacy (SE) by providing strategies on how to reduce and break up sitting time.
214374673|NCT03091686|BEHAVIORAL|HAPA MVPA Attention-Control Slideshow|In the attention-control, participants will receive information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. The attention-control slide show will take the same approach as the Experimental group slideshow but the slides will be geared towards meeting moderate-vigorous physical activity guidelines.
214374674|NCT06510725|DEVICE|Mutitarget tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to DLPFC and M1 alternately for ten consecutive weekdays, with each target stimulated for 5 sessions.
214374675|NCT06510725|DEVICE|Single-target tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to M1 for ten consecutive weekdays.
214374676|NCT06510725|DEVICE|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Ramps up and down will be applied for 15 seconds each at the beginning and end of the session. The current will be 0 mA during the interval between the initial and final ramps. Subjects will undergo stimulation once a day for ten consecutive weekdays.
214374677|NCT04077255|DRUG|Anti-EGFR antibody in combination with weekly paclitaxel|Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
214374678|NCT03472222|BEHAVIORAL|Arsha Vidya program|Integrated intervention program includes counselling and supportive care with the support of Arsha Vidya program
214685226|NCT04716933|DRUG|Cisplatin|IV infusion Q3W
214685227|NCT04716933|DRUG|Pemetrexed|IV infusion Q3W
214685228|NCT04716933|DRUG|Lenvatinib|Oral capsule once daily
214685229|NCT04716933|DRUG|Placebo matching lenvatinib|Oral capsule once daily
214685230|NCT06164028|OTHER|cognitive interview|Participants will take part in a semi-structured qualitative interview (\~1 hour).
214685231|NCT01334021|PROCEDURE|Biopsy|Undergo tumor biopsy
214685232|NCT01334021|PROCEDURE|Conventional Surgery|Undergo surgery
214685233|NCT01334021|OTHER|Genetic Testing|Undergo genetic testing
214374679|NCT00666432|OTHER|This is an observational study model that is family based|This is an observational study model that is family based
214685234|NCT06272968|DIAGNOSTIC_TEST|Neuropsychological Testing|Neuropsychological Testing via Cambridge CANTAB Connect
214374680|NCT05670925|DRUG|Camrelizumab plus Famitinib with/without nab-Palitaxel|After enrollment confirmed, the regimen of Camrelizumab Combined with Famitinib will be conducted for 2 cycles (8 weeks). Patients of CR or PR after 2 cycles (8 weeks) will enter dual-therapy maintenance phase until disease progression and will be recorded as PFS-1α. Patients of PD after 2 cycles (8 weeks) will be recorded as PFS-1β. Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.
214685235|NCT05478018|BEHAVIORAL|High Intensity Interval Training (HIIT)|Supervised high-intensity interval training for 12 weeks three times per week
214685236|NCT06448260|OTHER|Questionnary|Data from theses patients will be collected in our personnal data base with ask of consent according to the law Then each patient alive will have questionnary to answer by phone or during a visit.
214685237|NCT04807504|DRUG|Ropivacaine|All patients receive erector spinae plane blocks with ropivacaine.
214685238|NCT04686305|DRUG|T-DXd|T-DXd: administered as an IV infusion
214685239|NCT04686305|BIOLOGICAL|Durvalumab|Durvalumab: administered as an IV infusion
214685240|NCT04686305|DRUG|Cisplatin|Cisplatin: administered as an IV infusion
214685241|NCT04686305|DRUG|Carboplatin|Carboplatin: administered as an IV infusion
214685242|NCT04686305|DRUG|Pemetrexed|Pemetrexed: administered as an IV infusion (drug not used)
214685243|NCT04686305|DRUG|Volrustomig|Volrustomig: administered as an IV infusion
214685244|NCT04686305|DRUG|Rilvegostomig|Rilvegostomig: administered as an IV infusion
214685245|NCT05524272|OTHER|This study aims to evaluate the effects of colour by number mandala in decreasing the stress of children hospitalized due to their chronic disease.|Colour by number Mandala in different sizes includes pictures and numbers. The child has to find the colour specified in the number and colour it with the specified colour. Colourful pictures emerge as a result of colouring
214685246|NCT04717843|OTHER|4D Flow MRI|Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.
214685247|NCT04717843|OTHER|Medical consultation with 12 leads ECG|Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.
214685248|NCT04717843|OTHER|Holter ECG|48 hours ECG recording
214685249|NCT04717843|OTHER|Trans thoracic echocardiography|Trans thoracic echocardiography with standard measures performes in the core lab.
214685250|NCT04717843|BIOLOGICAL|Blood sample|Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.
214685251|NCT04717843|OTHER|Standard MRI|Acquisitions of MR imagining
214374681|NCT04961866|DIETARY_SUPPLEMENT|parenteral protein 1 g/kg|patients received 1 g/ kg of protein
214374682|NCT04961866|DIETARY_SUPPLEMENT|Parenteral nutrition 2 g/kg|Patients received 2 g/ kg of protein
214374683|NCT03931681|DRUG|OKI-179|OKI-179 single agent
214374684|NCT05801575|DRUG|Chinese Herbal Medicine (CHM) teabag|Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.
214374685|NCT03169803|DEVICE|NeuroTronik CANS Therapy™ System|The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
214374686|NCT00231907|BIOLOGICAL|FluMist|Live attenuated influenza vaccine (LAIV) containing approximately 10\^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.
214685252|NCT02540252|OTHER|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
214374687|NCT00231907|BIOLOGICAL|Fluzone|Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
214374688|NCT02719990|DRUG|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
214374689|NCT02010632|DRUG|Generic clopidogrel product Apolets®|"* Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
214685253|NCT05151770|OTHER|Measure of glycemia levels and comparison to algorithm predictions|The study aims to evaluate the efficacy of a new algorithm in predicting the evolution of glycemia levels after a full meal. Glycemia levels measured during and after a full meal will be compared to the values predicted by the algorithm. Composition of the meals will also be collected.
214685254|NCT01005719|DRUG|Zegerid|Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
214685255|NCT01005719|DRUG|Prevacid®|Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
214685256|NCT05593497|DRUG|Capivasertib|400 mg (2 tablets) BID given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week (4 days on, 3 days off). Treatment will be given in combination with abiraterone for 16 weeks duration (+/- 1 week for surgery window).
214685257|NCT05593497|DRUG|abiraterone acetate|"Administered orally as tablets at a dosage of 1000 mg daily. To be administered with prednisone 5mg po daily.~Subjects will be on concurrent GNRH agonist therapy (leuprolide, administered as standard of care). Intensified androgen deprivation (iADT) consisting of abiraterone and leuprolide will be administered for a 4 week run-in prior to addition of capivasertib."
214987268|NCT02751229|BEHAVIORAL|Honest Open Proud (HOP)|"five lessons in three modules, two for each two-hour session~1. Considering pros and cons of disclosing:~   * hurtful and helpful attitudes about mental illness~  * identify beliefs participants hold about themselves~  * explore five-step process to challenge their personally hurtful beliefs~  * weigh pros and cons of coming out in order to facilitate a decision on whether to disclose~2. Different ways to disclose:~   * different levels of (non-) disclosure and how to weigh the cons and pros~  * disclosure via social media versus disclosing face to face~  * how to find people that are better to disclose to than others and how to 'test them out'~  * participants will discuss how others might respond to their disclosure and how that will affect them~3. Telling your story:~   * how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt"
214987269|NCT04698434|DRUG|Esketamine|each group was given a single intravenous dose of the corresponding esketamine.
214987270|NCT03365180|DEVICE|Starter Kit Algorithm|Long acting insulin titration to target
214987271|NCT02765165|DRUG|USL311|Administered once weekly in a 21-day cycle
214374690|NCT02010632|DRUG|Original clopidogrel product Plavix®|"* Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
214374691|NCT03886259|OTHER|Neuromuscular exercises (NEMEX-TJR) and pain neuroscience education|"60min. of neuromuscular exercises (NEMEX-TJR) training two times a week for 3 months (12 weeks, 24 sessions). Physiotherapists will instruct and supervise the participants during the neuromuscular exercises. The aim of the neuromuscular exercise program is to restore normal movement, improve sensorimotor control, re-establishing normal motor program strategies and muscle activation.~60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function."
214374692|NCT03886259|OTHER|Pain neuroscience education|60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function.
214374693|NCT01875939|DRUG|Oral WCK2349|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
214987272|NCT02765165|DRUG|USL311|Administered once daily in a 21-day cycle
214987273|NCT02765165|DRUG|USL311|Administered once daily in a 42-day cycle
214987274|NCT02765165|DRUG|Lomustine|Administered once every 6 weeks in a 42-day cycle
214987275|NCT03732378|DIETARY_SUPPLEMENT|Omega-3 capsule|Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)
214374694|NCT01875939|DRUG|IV WCK771|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
214374695|NCT03066401|PROCEDURE|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
214374696|NCT00070135|BIOLOGICAL|filgrastim|Given SC
214374697|NCT00070135|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
214374698|NCT00070135|DRUG|busulfan|Given IV
214374699|NCT00070135|DRUG|fludarabine phosphate|Given IV
214374700|NCT00070135|DRUG|methotrexate|Given IV
214374701|NCT00070135|DRUG|tacrolimus|Given PO or IV
214374702|NCT00070135|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
214374703|NCT02947438|DRUG|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
214374704|NCT02947438|DRUG|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
214374705|NCT01448694|OTHER|No treatment|No treatment, only collecting observational data.
214374706|NCT05098093|DIETARY_SUPPLEMENT|SBE|Hard-shell capsule
214374707|NCT05098093|DIETARY_SUPPLEMENT|DBE|Hard-shell capsule
214374708|NCT05098093|DIETARY_SUPPLEMENT|BP|Hard-shell capsule
214374709|NCT01121042|DRUG|Ondansetron|8mg per day oral capsule
214374710|NCT01121042|DRUG|Placebo|daily oral capsule matched to active study medication. Made form 100% lactose powder
214374711|NCT03769779|DIETARY_SUPPLEMENT|FloraGLO Lutein|Lutein (FloraGLO™) in safflower oil
214374712|NCT03769779|DIETARY_SUPPLEMENT|Safflower Oil|Safflower Oil
214374713|NCT04308564|DIAGNOSTIC_TEST|Blood test|Blood test for the identification of biomarkers
214374714|NCT05115448|OTHER|Bevel Position|During 6 dialysis sessions, cannulation was applied to the patients with the direction of the arterial needle in the antegrade direction and the conical tip facing upwards. In the next 6 dialysis sessions, cannulation was applied to the patients in an antegrade direction and with the conical tip facing down.
214374715|NCT01016301|OTHER|Pharmacist service|Medication Review, medication report
214374716|NCT00818961|BIOLOGICAL|alemtuzumab|43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)
214374717|NCT00818961|BIOLOGICAL|graft-versus-tumor induction therapy|curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL
214374718|NCT00818961|BIOLOGICAL|rituximab|in patients with Cd20+ malignancies: rituximab 375 mg/m\*2 day -13. rituximab 1000 mg/m\*2 on days, -6, +1, +8.
214374719|NCT00818961|DRUG|busulfan|For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
214374720|NCT00818961|DRUG|cyclophosphamide|750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
214374721|NCT00818961|DRUG|fludarabine phosphate|For patients with CLL, NHL \& HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.
214374722|NCT00818961|DRUG|methotrexate|5 mg/m2 administered on days +1, +3 and +6
214374723|NCT00818961|DRUG|tacrolimus|0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO
214374724|NCT00818961|PROCEDURE|allogeneic bone marrow transplantation|Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
214374725|NCT00000280|DRUG|Nimodipine|
214374726|NCT03547401|DEVICE|Ankle Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the arm (model IntelliVue M8105a MP5 Phillips, calibrated).
214374727|NCT03547401|DEVICE|Arm Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the ankle (model IntelliVue M8105a MP5 Phillips, calibrated).
214374728|NCT01530672|DEVICE|MBIO POC combined HIV syphilis test ( SnapEsi)|Venipuncture for routine ANC screening plus additional for device validation purposes.
214374729|NCT00424125|BEHAVIORAL|Enhanced Pharmacy Care|"Participants randomized to Enhanced Pharmacy Care will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.~Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to enhanced care will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers."
214987276|NCT01206764|DRUG|RAD001|
214374730|NCT00424125|BEHAVIORAL|Control|Usual care.
214374731|NCT00286793|DRUG|AT-101|Oral
214374732|NCT04151225|DRUG|GSK2330811|GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
214374733|NCT04151225|DRUG|Placebo|Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
214987277|NCT02528448|DRUG|Plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
214685258|NCT01869010|OTHER|Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls|This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
214685259|NCT05548127|DRUG|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until the recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
214685260|NCT05548127|DRUG|Abemaciclib|Daily oral dosages of Abemaciclib continuously, cycles lasting 28 days
214685261|NCT01465698|BEHAVIORAL|Exercise|"The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.~The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study"
214685262|NCT01465698|BEHAVIORAL|Counseling|Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
214685263|NCT01465698|BEHAVIORAL|Exercise and counseling|Participants take part in both exercise and counseling as described in the separate interventions.
214685264|NCT01465698|OTHER|Control group|Participants in the control group take part only in measurements of NURSE-RCT.
214374734|NCT05861128|DRUG|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
214374735|NCT03619590|OTHER|Data Collection|When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
214374736|NCT04658641|DEVICE|Boston Scientific: Study tool computer|Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
214374737|NCT05601401|DRUG|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
214685265|NCT03179592|DRUG|Ultravist 370Mg I/Ml Solution for Injection|Reduced contrast-volume injection protocols based on patient specific tube voltage.
214685266|NCT02778750|PROCEDURE|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
214374738|NCT06387472|DEVICE|AI algorithm to evaluate photographs of skin test patch regions|Interpretation of skin test patch regions via artificial intelligence (AI)
214374739|NCT06387472|DEVICE|Allergen Patch|Contains dime-sized disks which have different substance to which a person may be allergic. Two different patches were used due to the number of allergens being tested. Each patch can only hold 10 allergens and 14 allergens were tested in patients.
214374740|NCT05208138|DEVICE|Senhance Surgical System from Asensus|Bariatric operation with the Senhance Surgical System
214685267|NCT01570712|OTHER|HOUSING FIRST PROGRAM|"Realization of a psychosocial organic evaluation and a citizen;~* Support in the development and the maintenance of the housing;~* Support in the diverse steps (administrative, judicial, financiers, etc.);~* Support around addictions / alcohol;~* Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)~* to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration."
214685268|NCT01570712|OTHER|traditional French services|"The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\\or the restoring, but this by means of the existing devices"
214685269|NCT06312956|DEVICE|Continuous Positive Airway Pressure Ventilotherapy|Breathing support device during sleeping
214685270|NCT01255748|RADIATION|Proton Therapy, Photon Therapy, SRS, Brachytherapy|Outcomes Tracking
214685271|NCT06435442|DRUG|Epaminurad, Naproxen|Period 1: Epaminurad 6mg -\> Epaminurad 9mg -\> Epaminurad 9mg +Naproxen Period 2: Naproxen
214685272|NCT06435442|DRUG|Epaminurad|Epaminurad
214685273|NCT06435442|DRUG|Epaminurad placebo|Epaminurad placebo
214685274|NCT06449677|DEVICE|iLet Bionic Pancreas System (BP)|The iLet Bionic Pancreas System (BP) consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a CGM sensor.
214987278|NCT02528448|DRUG|0,9% saline|Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
214374741|NCT02650869|DIETARY_SUPPLEMENT|Probiotics|probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)
214374742|NCT02650869|DIETARY_SUPPLEMENT|Breast milk|Normal breast milk will be given as part of standard care
214685275|NCT06449677|DEVICE|Usual Care (UC)|Usual Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump.
214685276|NCT06535139|BEHAVIORAL|Brief training|Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.
214685277|NCT06535139|BEHAVIORAL|Parent-targeted motivational aids|Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.
214685278|NCT06535139|BEHAVIORAL|Healthcare access|Healthcare access will involve three components coordinated by UF Health Cancer Center Community Outreach and Engagement Office: transportation assistance to a participating clinic or mobile vaccination clinic, UF mobile vaccination clinic scheduling, and connection to health insurance navigators.
214987279|NCT01186770|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
214987280|NCT01186770|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
214374743|NCT02239380|DRUG|Lorazepam|"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to \< 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
214374744|NCT02244255|DRUG|FLOMAX® capsules|
214374745|NCT02244255|DRUG|Ascending doses of HYTRIN® capsules|
214987281|NCT02567188|OTHER|MIRCERA|
214987282|NCT06414863|DEVICE|IPE|"Invisalign palatal expander system:~The Invisalign® Palatal Expander System (AlignTechnology, inc.) is 3D-printed orthodontic device for maxillary expansion."
214374746|NCT06196450|DIETARY_SUPPLEMENT|Vivomixx|Vivomixx is a commercially available probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis.
214496033|NCT06762535|DEVICE|repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 10 sessions of rTMS, stimulation protocol included 10 sessions within 14 days (once a day, 5 days/week, 2 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
214987283|NCT06414863|DEVICE|HE|"Hyrax expander:~The Hyrax-type maxillary expander will include a midline self-locking screw. The expansion screw is connected to the conventional molar bands or printed clasps, which are cemented on the maxillary first molars (or on the maxillary primary second molars), via 0.9 mm stainless-steel wire. The framework is soldered to the bands and extends on the palatal side to the primary canines or canines. The expander will be fabricated by a qualified laboratory technician"
214987284|NCT05893238|PROCEDURE|Natural cycle In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) without hormonal stimulation
214987285|NCT05893238|DIAGNOSTIC_TEST|Blood samples for analysis|Test hormone levels in serum
214987286|NCT05893238|DIAGNOSTIC_TEST|Follicular fluid for analysis|Test hormone levels in follicular fluid Test Oxidation-reduction potential
214685279|NCT03768570|DRUG|Durvalumab|1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
214685280|NCT04329039|DRUG|Somatostatin analog|Somatostatin analog plus perioperative antibiotics Placebo plus perioperative antibiotics
214685281|NCT05387720|PROCEDURE|Manual diaphragmatic facilitation (PNF) technique|"Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs."
214685282|NCT05387720|PROCEDURE|Trigger sensitivity adjustment on mechanical ventilation|The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP
214987287|NCT05893238|DIAGNOSTIC_TEST|Sperm samples for analysis|Oxidation-reduction potential
214987288|NCT05893238|PROCEDURE|Conventional In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) with conventional hormonal stimulation
214987289|NCT05342571|OTHER|Behavioral, Psychological or Informational Intervention|Participate in ABC session
214987290|NCT05342571|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214987291|NCT05342571|OTHER|Electronic Health Record Review|Medical records reviewed
214496034|NCT06762535|DEVICE|Sham repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 10 sessions of rTMS, stimulation protocol included 10 sessions within 14 days (once a day, 5 days/week, 2 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session).But there's no real pulse output,Just set the same conditions.
214987292|NCT05342571|OTHER|Informational Intervention|Receive patient guidebook
214374747|NCT06196450|DIETARY_SUPPLEMENT|Microcrystalline maltose|Microcrystalline maltose as placebo
214685283|NCT05387720|PROCEDURE|concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique|Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
214685284|NCT00963521|BIOLOGICAL|therapeutic autologous dendritic cells|
214987293|NCT05342571|OTHER|Survey Administration|Complete surveys
214987294|NCT01033136|BEHAVIORAL|Multiple Channel Exposure Therapy - Veterans|MCET-V offers individual therapy that provides psychoeducation about panic attacks and trauma and involves behavioral and cognitive exposure exercises.
214374748|NCT05897255|DEVICE|Surface EMG Biofeedback|Surface EMG activity will be recorded from the left and right abdominal muscles while the exercises will be performed in different positions. Electrical signals in the muscle are measured and displayed on the screen and are amplified into sounds that the patient can hear. This feedback increases patient effort and participation and provides the data and documentation required to measure patient outcomes and quantify progress. Electrical activity from Rectus Abdominis muscle, External Oblique muscle and Transversus Abdominis muscle will be recorded with their specific exercises. SEMG Biofeedback protocol of a series of ten second contractions, each contraction preceded by a ten second rest period will be followed. Starting with shorter work/rest periods as needed to build-up to these intervals are acceptable; for example, starting with 3-second contractions and 6-second rest periods, and then gradually increasing the duration of each.
214374749|NCT03917784|DRUG|Curcumin|Oral supplementation with curcumin 500 mg oral dosing for 3 months
214374750|NCT03917784|DRUG|Starch|Oral supplementation with starch 500 mg oral dosing for 3 months
214987295|NCT01033136|BEHAVIORAL|Cognitive Processing Therapy|CPT offers individual therapy that targets trauma and PTSD symptoms via cognitive restructuring.
214987296|NCT00774917|DEVICE|Numen|Numen Co-Cr coronary stent implant
214987297|NCT03052686|OTHER|Childbirth with uterine rupture|No intervention. Follow-up of women with rupture uterine at the childbirth.
214987298|NCT02502370|DRUG|observation alone|
214987299|NCT02502370|DRUG|LV5FU2|
214987300|NCT02502370|DRUG|FOLFOX|
214987301|NCT02427009|OTHER|Prone position for 1 hour after blood patch|After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.
214987302|NCT02427009|PROCEDURE|Blood patch|And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
215089962|NCT01897545|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
215089963|NCT01897545|PROCEDURE|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
215089964|NCT02418988|DRUG|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
215089965|NCT02418988|DRUG|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
214374751|NCT04539314|DRUG|Bupivacain|We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%
214496035|NCT06843603|BEHAVIORAL|culturally informed care coordination intervention|Culturally Informed Care Coordination Strategies
214496036|NCT06843603|OTHER|No Intervention - Usual Care Group|No Intervention - Usual Care Group
214496037|NCT06495372|DRUG|Experimenta group (standard of care + Methoxyflurane).|standard of care + Methoxyflurane
214496038|NCT06495372|DRUG|control group (standard of care + placebo).|standard of care + placebo
214496039|NCT05424055|BEHAVIORAL|Multicomponent exercise|The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance-training and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening). The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L., Madrid, Spain) combined with balance and gait retraining exercises that will progress in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
214496040|NCT06757517|DRUG|Oxytocin nasal spray|Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).
214496041|NCT06757517|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline intranasal placebo comparator
214496042|NCT05554510|OTHER|Observational|No interventions planned. Observational data collection only.
214374752|NCT04539314|DRUG|Dexmedetomidine o.5 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 0.5 μg / kg
214374753|NCT04539314|DRUG|Dexmedetomidine 1 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 1 μg / kg
214374754|NCT02236065|PROCEDURE|Umbilical cord blood therapy|
214685285|NCT06302569|DRUG|Pembrolizumab + Enfortumab Vedotin|"* Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab are eligible for up to 1 year of additional pembrolizumab (second course) upon experiencing disease progression.~* Enfortumab Vedotin will be given for a maximum of 3 cycles on day 1 and day 3 each 3 weeks. EV treatment could be re-started in case of Progressive Disease RECIST v1.1 during pembrolizumab monotherapy treatment."
214685286|NCT06239467|DRUG|OKI-219|Oral twice daily
214987303|NCT03384199|RADIATION|Dose escalation to prostate focal lesion|For each patient the radio-opaque marker (used for treatment verification) will be inserted by ultrasound guidance \& local anaesthetic with an 17ga x 30cm brachytherapy needle that has 1.2mm x 3mm one gold marker. The ultrasound probe (as used for transrectal biopsy) will be introduced rectally with the patient in the left lateral position. After measuring the volume of the prostate and determining the desired position (preferably in the corpus of prostate), three gold markers will be inserted as follows: one into right side, one into left side of the base and the third in the apex of the prostate
214374755|NCT02236065|BIOLOGICAL|Filgrastim|
214374756|NCT02904876|RADIATION|Diffusion Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
214496043|NCT06828250|DEVICE|intradermal needle therapy|In addition to conventional treatment, patients in the treatment group received intradermal needle therapy after returning to the ward safely. Bilateral Hegu (LI4) and Zusanli (ST36) acupoints were selected for this therapy. Patients were positioned in a supine position, and after locating the acupoints, the skin of the acupoint areas was sterilized with 75% ethanol using a medical cotton swab. The intradermal needle was then removed along with the adhesive tape, inserted into the acupoints, and pressed every 4 hours for approximately 60 presses each time, excluding nighttime sleep. The pressure was applied until an acid, swelling, or numb sensation was felt at each acupoint. The intradermal needle therapy was administered only once and continuously pressed for 3 days.
214496044|NCT06584682|OTHER|Sub-occipital muscle inhibition technique|Therapist puts finger pads just beneath the superior nuchal line (below the occiput and above the C2 vertebra), and lifts the patient head slightly and apply an anterior force with cephalic traction on cervical spine this area. Then straighten the fingers to press the finger tips into muscle and hold until relaxation(30 sec) and then drop the head into palm in new position, give this technique in 10 rep/2 sets (each set have 5 repetitions).hot packs for 15 minutes prior to session, cervical muscle stretching,cervical mechanical traction for 8-10 minutes, force is applied 1/6th of the patient body weight, for C1-C2 at 0 degree of cervical flexion and for below C2 at 20 degree of cervical spine flexion and cervical muscle METs
214496045|NCT06584682|OTHER|conventional therapy|stretching of hamstring muscle, METs, sciatic nerve glides, lower limb neurodynamics.
214496046|NCT06786026|DRUG|bevacizumab|bevacizumab
214496047|NCT06786026|DRUG|QL1706|Bispecific antibody (bsAB) targeting PD-1 and CLTA-4
214496048|NCT06786026|DRUG|Nab paclitaxel|albumin-bound paclitaxel
214496049|NCT06815419|OTHER|spiritual care education program|The spiritual care education program to improve nurses ability to provide spiritual care. Education includes; Program orientation, an introduction to spiritual care, the concepts of spiritual care, the significance of spiritual care, the theoretical underpinnings of spirituality in mental health, practical strategies for integrating spiritual care in psychiatric nursing, reflective practice, and self-care for enhancing personal spirituality were all covered in the program's weekly two-hour sessions.
214496050|NCT06740864|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current will be delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) are used throughout the stimulation.
214496051|NCT06740864|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current will be delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) are used throughout the stimulation.
214496052|NCT06740864|DEVICE|Sham Transcranial alternating current stimulation|Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
214374757|NCT05276167|DEVICE|hyperthermic intravesical perfusion|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
214374758|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
214374759|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
214685287|NCT06239467|DRUG|Fulvestrant|Intramuscular injection
214685288|NCT06239467|DRUG|Trastuzumab|Intravenous (IV)
214685289|NCT06239467|DRUG|Tucatinib|Oral twice daily
214685290|NCT06239467|DRUG|Atirmociclib|Oral twice daily
214685291|NCT06239467|DRUG|Ribociclib|Oral once daily continuous for 21-days followed by 7 days off
214685292|NCT03683433|DRUG|Azacitidine|Given SC or IV
214685293|NCT03683433|DRUG|Enasidenib Mesylate|Given PO
214374760|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
214374761|NCT03062462|DRUG|Clopidogrel|double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 5-7 days
214685294|NCT04431154|BEHAVIORAL|Provision of HIV self-screen kit with incentives and linkage promotion|This arm will receive a HIV self-screen kit and additional incentives to promote adherence and linkage to care
214685295|NCT05437341|BIOLOGICAL|bi-4SCAR PSMA/CD70 T cells|Infusion of bi-4SCAR PSMA/CD70 T cells at 10\^6 cells/kg body weight via IV
214685296|NCT05279612|RADIATION|Short-term neoadjuvant chemoradiotherapy|Short-term radiotherapy ( 25 Gy, 5f ) + XELOX regimen was performed before operation for two cycles. After the condition was evaluated by enhanced CT, whether the patients belonged to PD, SD, PR and CR was analyzed (reference RECIST 1.1). Surgery was performed four weeks after chemotherapy.
214685297|NCT01940016|BEHAVIORAL|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
214685298|NCT01940016|BEHAVIORAL|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
214685299|NCT02833610|DRUG|Denosumab Q4W|
214685300|NCT00496522|PROCEDURE|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
214685301|NCT04430738|DRUG|tucatinib|For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.
214685302|NCT04430738|DRUG|trastuzumab|Cohorts 1A and 1B: a 6 mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 Day 1, followed by a dose of 4 mg/kg IV every 2 weeks starting on Cycle 2 Day 1. Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B: an 8 mg/kg loading dose will be administered IV on Cycle 1 Day 1, followed by a dose of 6 mg/kg IV every 3 weeks thereafter.
214374762|NCT03062462|DRUG|ticagrelor|half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 5-7 days
214685303|NCT04430738|DRUG|oxaliplatin|85 mg/m\^2 given IV every 2 weeks for cohorts using FOLFOX. For cohorts using CAPOX regimen, 130 mg/m\^2 given every 3 weeks.
214685304|NCT04430738|DRUG|leucovorin|200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m\^2 given IV every 2 weeks. Part of FOLFOX regimen.
214374763|NCT05660590|OTHER|complex decongestive physiotherapy with low pressure compression bandage|both group received complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with low bandage interface pressure (20-30 mmHg)
214374764|NCT05660590|OTHER|complex decongestive physiotherapy with high pressure compression bandage|complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with high bandage interface pressure (45-55 mmHg)
214374765|NCT06492824|BEHAVIORAL|Enjoyable Activities Condition|Participants complete an introduction video about the intervention. They will then take a pre-intervention survey, after which they will choose five enjoyable activities from a large list. Daily text message reminders will be sent to BA participants in the morning to remind them to do their enjoyable activities for the day, as well as a link to a checklist where they will report how frequently they have completed any of their five activities from the previous day (example text message in documentation). At the end of the month, they will complete a follow-up survey consisting of the same measures from the pre-intervention survey.
214374766|NCT06492824|BEHAVIORAL|Healthy Activities Condition|They will take a pre-intervention survey and choose five enjoyable activities from the same list; however, active control participants will not explicitly be asked to complete these activities for the intervention. Participants in the active control condition will be promoted to complete tasks such as drinking more water, going to bed early, brushing their teeth, showering or bathing for that day, and eating well balanced meals. Daily text reminders will be sent about these healthy living activities in the morning. In that same message, they will receive a link to a checklist where they will report about their completed healthy living activities for the previous day (example text message in documentation). At the end of the month, they will also complete a follow-up survey consisting of the same measures from the pre-intervention survey.
214685305|NCT04430738|DRUG|fluorouracil|400 mg/m\^2 (IV bolus after leucovorin) and/or 2400 mg/m\^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.
214685306|NCT04430738|DRUG|capecitabine|1000 mg/m\^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.
214685307|NCT04430738|DRUG|pembrolizumab|400 mg given by IV on day 1 of cycle 1, then every 6 weeks.
214685308|NCT02834312|DRUG|Estetrol|All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
214685309|NCT02834312|DRUG|Placebo|1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
214685310|NCT05653739|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|MBSR is Mindfulness based intervention designed by Kabat-Zinn (1990) in order to deal with the stress and other psychological issues among individuals. This has been very effective intervention across different cultures . In this 8 week intervention participants will be given some home tasks to practice for at least 40 minutes a day.
214685311|NCT06533293|DEVICE|Neck Brace Device|"The neck brace device will be manufactured in the Mechanical Department at Columbia University. The device measures head motion and EMG by electronic sensors, passively supports the head in certain configurations by springs, and actively assists head movement by motors.~Motor learning principles will be combined with robotics to apply gentle forces on the head-neck during training."
214685312|NCT06221969|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
214685313|NCT06221969|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
214685314|NCT06221969|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
214685315|NCT06966453|DRUG|Disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks.
214374767|NCT05632835|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in endoscopic spinal surgeries to help to reduce intra-operative radiation, puncture time, etc..
214685316|NCT04380987|BIOLOGICAL|Biological sampling|For every symptomatic adult tested positive by RTqPCR, up to 45 mL of blood will be taken, nasopharyngeal and oropharyngeal swab will be performed, an induced sputum and a stool samples will be recovered at the inclusion. As follow-up, 3 weeks after inclusion, up to 45 mL of blood will be taken and a new induced sputum will be recovered.
214685317|NCT01956409|DRUG|18F-FCH|
214987304|NCT06002191|BEHAVIORAL|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
214374768|NCT05632835|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
214987305|NCT06002191|BEHAVIORAL|Questionnaires of Online Experiences|Adolescents will receive brief questionnaires related to their online experiences and the impact those experiences have had on their stress level.
214987306|NCT02372461|DRUG|Placebo|This is an non inferiority trial, the intervention is a placebo
214987307|NCT02372461|DRUG|Amoxicillin|Amoxicillin Liquid
214987308|NCT00366496|DEVICE|Acrysof single piece (SA60AT)|
214987309|NCT00366496|DEVICE|Acrysof IQ (SN60WF)|
214987310|NCT04793945|COMBINATION_PRODUCT|topical steroid and 308nm-Excimer light therapy|applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata
214374769|NCT05496374|DRUG|Placebo|Placebo-matching capsules will be administered orally.
214374770|NCT05496374|DRUG|SPR720 500 mg|SPR720 500 mg (250 mg × 2 capsules) will be administered orally.
214374771|NCT05496374|DRUG|SPR720 1000 mg|SPR720 500 mg (250 mg × 4 capsules) will be administered orally.
214374772|NCT02465840|PROCEDURE|custom-made dynamic hand splint|custom-made dynamic splinting with more early active exercises intervention.
214374773|NCT02465840|PROCEDURE|custom-made protective hand splint|Immobilization splint with gentle ROM exercises
214374774|NCT02465840|OTHER|physical therapy and occupational therapy|both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
214374775|NCT06184828|BIOLOGICAL|Whole blood transfusion|The transfusion of whole blood units
214374776|NCT06184828|BIOLOGICAL|Blood components transfusion|The transfusion of blood components units rather than whole blood
214374777|NCT07073820|DRUG|PF-07868489|Participants will receive subcutaneous doses of PF-07868489 every 4 weeks
214374778|NCT06029439|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
214496054|NCT06889103|OTHER|Observation|observation during eating
214496055|NCT05972772|DRUG|Doxycyclin|100-mg film-coated tablets; Pfizer
214496056|NCT05972772|DRUG|Azithromycin|250-mg capsules; Pfizer
214496057|NCT06726993|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty (TKA) is a common orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic
214496058|NCT06765460|BEHAVIORAL|Medical prescription of exercise|MPE consists of dedicating a specific time to establish a specific and individualized exercise plan for the patient, with the premises of fully assessing their physical fitness, motivation, adaptability to change and the possibility of exercising within their social environment, as well as the achievement of specific objectives within an agreed follow-up period
214496059|NCT06765460|BEHAVIORAL|Health Advice|HA consists of providing the patient with information and motivation in line with general international recommendations to try to increase PA levels in their daily life. This advice can be given in a short period of time (up to three minutes) during any medical consultation
214496060|NCT06766760|DEVICE|Da Vinci SP Surgical System, Model SP1098|The da Vinci SP Surgical System is intended to assist in the accurate control of the da Vinci SP endoscope and instruments during minimally invasive endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, and breast surgical procedures. The system is indicated for adult use. It is intended to be used by trained physicians in an operating room environment.
214496061|NCT05611632|DEVICE|Multi-cancer early detection test (Galleri test)|Blood collection and multi cancer early detection testing with return of positive test results.
214496062|NCT06769360|PROCEDURE|PMI-targeted PSV setting|The pressure support is adjusted according to PMI between 0 and 2 cmH2O. After application of PSV mode in mechanically ventilated patients, the initial PS level was first set based on respiratory rate (RR) \<35 beats/min and 6-8 ml/Kg tidal volume (Vt) per predict body weight (PBW), and then modified according to PMI at a frequency of twice a day (morning and afternoon bedside rounds)# 1) Perform three end- inspiratory occlusions, with at least 1 minute between each measurement, and calculate the mean PMI. 2) Determine whether the PMI is within the target range (0≤PMI≤2cmH2O). 3) If the PMI is not within the target range, adjust the PS level up or down by 1-3 cmH2O and balance for 3-5 minutes. 4) Repeat the above steps until PMI reaches the target. 5) Additional: During PS adjustment, if Vt≤4ml/Kg, respiratory acidosis, respiratory distress, Vt≥8ml/Kg, respiratory alkalosis occurs, return to the safe PS level before adjustment and optimize other treatments.
214496063|NCT06769360|PROCEDURE|VT/RR-targeted PSV setting|Standard of care: the pressure support is adjusted to obtain a VT between 6 and 8 ml/kg PBW and RR between 20 and 35 breaths/min.
214496064|NCT06856525|DRUG|Hyperpolarized Xe129|Determine the impact of e-cigarette use on pulmonary gas exchange capacity in interstitial tissues and capillaries using hyperpolarized xenon-129 MRI.
214496065|NCT06856525|DIAGNOSTIC_TEST|Cardiopulmonary Stress Test|Exercise stress test to evaluate cardiac and pulmonary fitness.
214496066|NCT06856525|DIAGNOSTIC_TEST|Pulmonary Function Test|Standard clinic pulmonary function test to evaluate lung function
214496067|NCT06856525|DIAGNOSTIC_TEST|Chest CT|Clinical standard chest computer tomography to evaluate any lung tissue scars or air movement.
214496068|NCT06750874|BEHAVIORAL|Acceptance and Commitment Therapy|One day workshop + telephone booster
214374779|NCT06779123|DEVICE|Transauricular vagus nerve stimulation.|TRAVAGUS is a portable electrical vagus nerve stimulator device that non-invasively activates the auricular branch of the vagus nerve in the left ear. The system consists of two units, the electrical stimulator and the ear electrodes that are mounted in a headset. The electrical signals are delivered transcutaneously to the ear via two separate cables connected to two aluminium electrodes. There is no need for electrode gel application on the auricular skin, since the conductivity of the two metallic electrodes is fully sufficient for functional electrical contact. The device is powered by 4 x 1,5V AAA batteries. The electrical source is a CE-marked tens unit termed STIM-PRO X9+, AXION GmbH, Leonberg, Germany. The investigational headset with auricular electrodes is designed and manufactured by taVNS AB in Saltsjö-Duvnäs, Sweden. Stimulation will be performed for 5 min twice daily for 12 weeks.
214374780|NCT06779123|DEVICE|transauricular vagus nerve non-stimulation|TRAVAGUS is a portable electrical vagus nerve stimulator device that non-invasively activates the auricular branch of the vagus nerve in the left ear. The system consists of two units, the electrical stimulator and the ear electrodes that are mounted in a headset. The device is placed to the ear but no stimulation will occur. The procedure is performed for 5 min twice daily for 12 weeks.
214685318|NCT01956409|DRUG|Magnevist|
214685319|NCT00756587|DEVICE|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
214685320|NCT00756587|DEVICE|Bottle Feeding|receiving all feeding by bottle
214685321|NCT00633438|OTHER|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
214685322|NCT00633438|DRUG|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
214685323|NCT04460378|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy with Focus on guided exposure
214374794|NCT06243029|DEVICE|ECG Patch|Wearable ECG Patch designed to record and transmit physiological parameters to a mobile device or a data cloud. The device stores data locally in a memory cache designed for \>96 hours of continuous data. It continuously records a one-lead ECG and has a three-axis accelerometer. On-board algorithms use those data to compute heart rate, heart rate variability, RR-interval, respiratory rate, and an activity level indicator. The company also provides optional arrhythmia detection and reporting services, the results of which may be delivered to healthcare professionals.
214374795|NCT07086638|DRUG|Photo-responsive nanozyme|The nanozyme scavenges ROS at the site of dermatitis and simultaneously responds to NIR light to generate mild heat, thereby promoting the healing of radiation-induced skin injury.
214374796|NCT05401110|DRUG|Osimertinib|Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
214374797|NCT05401110|DRUG|Carotuximab|Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
214374798|NCT06859424|DRUG|Conditioning Regimen A|"Busulfan and fludarabine~Recommended schedule as below:~* Days -6 to -3: Busulfan ≥ 9 mg/kg total dose (IV or PO) with pharmacokinetic (PK) monitoring recommended as per institutional practice to achieve a daily area under the curve (AUC) target of 4800-5300 μM\*min47 or busulfan plasma exposure units (BPEU) 19.7-21.75 mg x h/L48.~* Days -6 to -2: Flu 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion (maximum cumulative dose, 150 mg/m2)."
214374799|NCT06859424|DRUG|Conditioning Regimen B|"Fludarabine and TBI The recommended fludarabine plus TBI regimen is the following:~* Days -7, -6 and -5: Flu (30 mg/m2/day, maximum cumulative dose, 90 mg/m2), IV~* Days -4 to -1: TBI (150 cGy administered twice daily, 1200 cGy total dose)~  * Radiation sources, dose rates, and shielding follow institutional practice.~ * Although not required, it is recommended that palifermin be used to mitigate the risk of mucosal toxicity with this regimen."
214685325|NCT03606252|OTHER|Blood sampling|6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
214685326|NCT03606252|OTHER|urine sampling|2 urine sample (1 at J0 and 1 at J7)
214685327|NCT05526794|PROCEDURE|Analgesic consumption|1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.
214685328|NCT00946946|DRUG|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
214685329|NCT00946946|DRUG|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
214685330|NCT00946946|DRUG|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
214685331|NCT00946946|DRUG|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
214685332|NCT03825276|DIETARY_SUPPLEMENT|Mango consumption|Daily consumption of 280 g of frozen mangos during 8 weeks. The daily dose in equivalent to a 2-cups serving.
214987311|NCT02411643|DRUG|topical calcipotriene 0.005% ointment|Affected area will be treated twice daily for 3 months
214987312|NCT00321763|BIOLOGICAL|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
214987313|NCT00321763|BIOLOGICAL|Fluarix TM|Single dose, Intramuscular injection
214987314|NCT00267540|BEHAVIORAL|cholecalciferol (D3) (vitamin)|
214685333|NCT06576011|BEHAVIORAL|Gamified Social Norms Marketing Campaign|This intervention is a gamified social norms marketing campaign (SNMC) primarily disseminated via advertisements on Instagram. These advertisements will invite students to participate in a game about student life at their university, during which misperceived alcohol norms will be corrected. The gamified SNMC spans the first full six weeks of students' first fall semester in college and includes three rounds of play. Round one occurs during the first two weeks, round two during the third and fourth weeks, and round three during the fifth and sixth weeks. In the game, participants are asked to identify whether normative facts related to a variety of topics are true or false. Correct feedback is then provided, intended to reinforce accurate norms related to alcohol use, which are embedded alongside other facts about college life.
214496069|NCT04077346|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions"
214685334|NCT06576011|BEHAVIORAL|Social Norms Marketing Campaign|This intervention is a social norms marketing campaign that is primarily delivered via advertisements on Instagram. These advertisements will contain normative facts related to student life at their university, during which misperceived alcohol norms will be corrected.
214685335|NCT04336241|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
214496070|NCT04077346|OTHER|Transcutaneous Spinal Stimulator + Activity Based Locomotor Training|Participants will receive a combination of Activity-based locomotor training (AB-LT)+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
214496071|NCT03425682|OTHER|ViBone|Viable Bone Allograft
214496072|NCT05140902|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
214496073|NCT04003480|DEVICE|FRAME|External support for vein grafts in peripheral bypass surgery
214496074|NCT06391853|DRUG|Insulin|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
214496075|NCT06391853|DRUG|Placebo|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
214496076|NCT06303687|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
214685336|NCT04336241|BIOLOGICAL|nivolumab|Programmed death receptor (PD-1) blocking antibody
214685337|NCT05478343|BIOLOGICAL|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
214685338|NCT05187013|BEHAVIORAL|mHealth for Hypertension in Homeless Persons|SMS text messages sent to participants' mobile phones
214685339|NCT06391294|PROCEDURE|Focal cortical cooling|Focal cortical cooling will be applied
214987315|NCT00481039|PROCEDURE|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
214374800|NCT06859424|DRUG|Conditioning Regimen C|"Fludarabine and busulfan (Flu/Bu)~The recommended Flu/Bu regimen is the following:~* Days -6 to -2: Flu (30 mg/m2/day, recommended total dose of 150 mg/m2, but not exceeding 180 mg/m2), IV Busulfan options~* Days -5 to -4: Busulfan without PK - Busulfan 3.2 mg/kg/day IV or oral equivalent; total dose of 6.4 mg/kg IV or oral equivalent respectively~* Days -5 to -4: Busulfan with PK - target doses to AUC of 4000 μMol/min or BPEU of 16.43 mg x h/L (total BPEU of 65.72 mg x h/L) or less is allowed."
214374801|NCT06859424|DRUG|Conditioning Regimen D|"Fludarabine and melphalan (Flu/Mel)~The recommended Flu/Mel regimen is the following:~* Days -7 to -3: Flu (30 mg/m2/day or 25 mg/m2/day, total dose of 125-150 mg/m2), IV~* Day -1: Mel (100-140 mg/m2 IV for recipients aged 18-59; dose of melphalan cannot exceed 100mg/m2 if age 60 or older or calculated glomerular filtration rate (GFR) is \<60 ml/min), IV"
214374802|NCT06859424|DRUG|Conditioning Regimen E|"Fludarabine/cyclophosphamide/total body irradiation (Flu/Cy/TBI)~The recommended Flu/Cy/TBI regimen is the following:~* Days -6 to -5: Cy (14.5 mg/kg/day IV, total dose of 29 mg/kg, or single dose 50 mg/kg on Day -6 \[Minnesota regimen\])~* Days -6 to -2: Flu (30 mg/m2/day, total dose of 150 mg/m2) IV~* Day -1: TBI 200 cGy single dose Hydration and Mesna may be administered per institutional standards. For recipients of RIC/NMA AND donors matched at \<7/8, consider the addition of TBI 200-300cGy for the Flu/Bu and Flu/Mel regimens to mitigate the risk of primary graft failure."
214374803|NCT06859424|PROCEDURE|Hematopoietic Cell Transplantation|"* On Day 0, the donor PBSC graft is infused.~* Donor PBSC will be collected per NMDP/donor registry policies with a target viable CD34+ cell dose of at least 4 × 106 /kg recipient weight (actual, ideal, or adjusted ideal per institutional practice).~* Dose of CD34+ cells/kg and CD3 cells/kg infused will be recorded.~* If the donor PBSC graft is cryopreserved prior to the start of conditioning, follow institutional practices to ensure a sufficient cell dose is available for infusion after thawing.~* The graft cannot be manipulated ex vivo to deplete T cells."
214374804|NCT06859424|DRUG|PTCy (50 mg/kg D3, D4)|"Cyclophosphamide (50mg/kg ideal body weight (IBW); \[if actual body weight (ABW) \< IBW, use ABW\]) will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day 4 post HCT (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an intravenous (IV) infusion over 1-2 hours (depending on volume), or according to institutional standards. Hydration pre- and post- cyclophosphamide and Mesna administration will be given per institutional standards.~No systemic immunosuppressive agents are given until at least 24 hours after the completion of the PTCy. This includes corticosteroids as anti-emetics but excludes any drugs listed in section 7.9.1.~Azoles (e.g., posaconazole or voriconazole) must be delayed from beginning of conditioning through completion of Day 4 PTCy dose to avoid potential drug-drug interactions with cyclophosphamide that could lead to increased toxicity."
214685340|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 1|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
214987316|NCT00405769|DRUG|red yeast rice|600 mg 3 caps bid
214987317|NCT00405769|DRUG|placebo|3 caps bid
214987318|NCT00410163|DRUG|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
215089966|NCT05157347|OTHER|Robot-assisted Training|The gait training in this study uses an exoskeletal wearable robot (Product name: ANGEL LEGS M20, Angel robotics, Co., Ltd.) consisting of a wearable part, a hip or knee joint gear providing the auxiliary force, and a controller backpack. This product is a powered orthopedic device for gait rehabilitation and treatment such as the lower limb muscle reconstruction and joint motion recovery in patients or handicapped individuals. The product consists of a power part, a controller part and a gear part, while the device is powered by an electric motor and the device motion induces the gait posture to support the lower limbs and allow the gait training to be performed.
215089967|NCT05157347|OTHER|Conventional Therapy|The conventional gait rehabilitation has been performed as a 1:1 training session between the therapist and a stroke patient.
214496077|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 0.8 mg/kg|Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
214496078|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 3.2 mg/kg|Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
214496079|NCT02673476|DRUG|ALS-008176|ALS-008176 tablets
214496080|NCT02673476|DRUG|Placebo|Identical placebo tablets
214987319|NCT00410163|DRUG|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
214987320|NCT00410163|DRUG|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
214987321|NCT00410163|DRUG|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
214987322|NCT03147963|DRUG|Docetaxel|Docetaxel will be given until progression or patient intolerance
214987323|NCT00742937|DIETARY_SUPPLEMENT|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
214987324|NCT00742937|DIETARY_SUPPLEMENT|Placebo|second capsule with vitamin E, eight days after delivery.
214987325|NCT00021242|DRUG|docetaxel|Continuous IV infusion
214987326|NCT03612219|DRUG|Apatinib mesylate tablet|Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.
214987327|NCT03612219|RADIATION|Intensity-modulated radiation therapy (IMRT)|Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.
214987328|NCT03612219|DRUG|Cisplatin|Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
214987329|NCT05824026|DEVICE|Gelling fiber wound dressing with silver|intervention involving a wound dressing with silver
214374805|NCT06859424|DRUG|PTCy (25 mg/kg D3, D4)|"Cyclophosphamide (25mg/kg ideal body weight (IBW); \[if actual body weight (ABW) \< IBW, use ABW\]) will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day 4 post HCT (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an intravenous (IV) infusion over 1-2 hours (depending on volume), or according to institutional standards. Hydration pre- and post- cyclophosphamide and Mesna administration will be given per institutional standards.~No systemic immunosuppressive agents are given until at least 24 hours after the completion of the PTCy. This includes corticosteroids as anti-emetics but excludes any drugs listed in Table 4 and Table 5 in Section 7.1.~Azoles (e.g., posaconazole or voriconazole) must be delayed from beginning of conditioning through completion of Day 4 PTCy dose to avoid potential drug-drug interactions with cyclophosphamide that could lead to increased toxicity."
214374806|NCT06859424|DRUG|Post-transplant Tacrolimus|Tacrolimus will be given per institutional practices, at a dose of 0.05 mg/kg per os (PO) or an IV dose of 0.03 mg/kg of IBW starting on Day + 5. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-12 ng/mL. If subjects are on medications which alter the metabolism of tacrolimus (e.g., concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper is recommended to be initiated at 100 days post HCT if there is no evidence of active GVHD and ended by Day + 180 post HCT.
214374807|NCT06859424|DRUG|Post-transplant Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg 3 times daily (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day + 5 and continue until Day + 35 post-transplant, at which time it should be discontinued (no taper necessary). Study site investigators may modify dose/taper early if clinically indicated for the study subject. Dose rounding may be done per institutional practice.
214374808|NCT06859424|DRUG|Post-transplant Abatacept|Abatacept will be given at a dose of 10 mg/kg with a maximum of 1000 mg.
214374809|NCT06859424|DRUG|Post-transplant Ruxolitinib|Ruxolitinib will be given at a dose of 5 mg/kg twice daily starting at Day 30 post HCT, provided both the absolute neutrophil count (ANC) is \> 1000/μl and platelet count is \>30,000/μl.
214374810|NCT06859424|DRUG|Supportive Care: Growth Factors|Granulocyte colony-stimulating factor (G-CSF) to accelerate neutrophil recovery should be administered starting at Day +5 with dose, route of administration, formulation, and duration of administration following institutional guidelines. Filgrastim biosimilars are permissible, but granulocyte-macrophage colony-stimulating factors are not permissible.
214374811|NCT06859424|PROCEDURE|Supportive Care: Blood Products|Transfusion thresholds for blood product support will be consistent with standard institutional guidelines. All blood products must be irradiated.
214374812|NCT06859424|OTHER|Supportive Care: Infection Prophylaxis|"Subjects should receive infection prophylaxis according to institutional guidelines and in accordance with the Center for Disease Control (CDC) guidelines49. Infection prophylaxis will include, but is not limited to, agents or strategies (e.g., polymerase chain reaction \[PCR\] screening and preemptive therapy) to reduce the risk of bacterial, viral (e.g., adenovirus, CMV, EBV, herpes simplex), opportunistic (e.g. Pneumocystis jirovecii, Toxoplasma gondii) and fungal (yeast and mold) infections.~Infection risk should assess patient-, pathogen-, and immune-related factors that increase susceptibility to infection. Minimal parameters requiring prophylaxis include but are not limited to neutropenia (ANC≤500/μL), lymphopenia (ALC≤500/μL), and exposure to immunosuppression or GvHD. Use of intravenous immunoglobulin (IVIG) should be considered for total IgG\<400 mg/dL during exposure to immunosuppression and/or GvHD."
214374813|NCT06859424|OTHER|Supportive Care: Intravenous immune globulin (IVIG)|Intravenous immune globulin (IVIG) administration will be according to local institutional standard practice for hypogammaglobulinemia but is generally not recommended.
214374814|NCT06859424|DRUG|Supportive Care: Seizure prophylaxis|Subjects will receive busulfan seizure prophylaxis with levetiracetam, fosphenytoin, or lorazepam per institutional guidelines.
214496081|NCT06587659|DEVICE|Transcranial Magnetic Stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
214496082|NCT06587659|DEVICE|Robotic Arm|This robotic system is based on a commercially available collaborative robot. The robot is mounted on a cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
214496083|NCT06734247|DIAGNOSTIC_TEST|Coronary computer tomography angiography (CCTA)|Use of standard equipment for usual care
214496084|NCT06734247|OTHER|Photoplethysmography (PPG) and single-lead ECG|Physiological data acquisition equipment
214685341|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 2|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
214685342|NCT05742802|COMBINATION_PRODUCT|Placebo|Participants previously randomised to placebo in one of the predecessor studies will be re-randomised in a 1:1 ratio to the active dose of Tozorakimab or placebo.
214685343|NCT04488822|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
214685344|NCT06822530|OTHER|Best Practice|Receive usual care CRC screening program navigation
214685345|NCT06822530|OTHER|Educational Intervention|Receive QR code and link to video addressing fears of colonoscopy
214685346|NCT06822530|OTHER|Electronic Health Record Review|Ancillary studies
214685347|NCT06822530|OTHER|Interview|Ancillary studies
214685348|NCT06822530|OTHER|Supportive Care|Receive rideshare transportation home after colonoscopy
214685349|NCT06822530|OTHER|Survey Administration|Ancillary studies
214685350|NCT03838367|DRUG|350 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
214685351|NCT03838367|DRUG|525 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
214685352|NCT03838367|DRUG|700 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
214685353|NCT03838367|DRUG|AUC 5 Carboplatin|Carboplatin is an anticancer drug chemotherapy drug.
214685354|NCT03838367|DRUG|Maximum Tolerated Dose (MTD) of leronlimab|The decision on the MTD will be made following the results obtained from Phase I studies
214685355|NCT03406104|GENETIC|GS010|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
214685356|NCT03406104|OTHER|Sham Intravitreal Injection|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
214685357|NCT03277729|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD20 CAR T cell IV
214374815|NCT06859424|OTHER|Supportive Care: Monitoring and management of CRS|The use of HLA-mismatched PBSC has been associated with greater risk of CRS relative to bone marrow. Following the infusion of MMUD PBSC on Day 0, subjects should be monitored daily through Day 14 for the development of CRS. High index of suspicion is urged, particularly in the few days following infusion. Many sites have successfully intervened with tocilizumab in order to avoid severe or prolonged CRS. Supportive care is encouraged for CRS Grades 1-2 and tocilizumab (or alternative) is recommended for CRS grade 3-4 where subject outcome may be impacted (Appendix G - CRS Guidance and Management).
214374816|NCT06859424|OTHER|Supportive Care: Prophylaxis against infections|"Consider monitoring for EBV reactivation during abatacept treatment and continue for six months following HCT.~Consider monitoring and prophylaxis for CMV infection/reactivation during abatacept treatment and for six months following HCT."
214685358|NCT03277729|DRUG|Cyclophosphamide|Given IV
214685359|NCT03277729|OTHER|Laboratory Biomarker Analysis|Correlative studies
214685360|NCT03277729|PROCEDURE|Leukapheresis|Undergo leukapheresis
214685361|NCT03277729|DRUG|Fludarabine Phosphate|Given IV
214685362|NCT04734990|DRUG|Azacitidine|Given IV or SC
214374817|NCT06859424|DRUG|Supportive Care: Prophylaxis against infections|For participants receiving ruxolitinib, the recommended maximum dose of fluconazole daily is 200 mg.
214374818|NCT06859424|OTHER|Supportive Care: Lipid elevations|Assess lipid levels 8-12 weeks from start of therapy with ruxolitinib and treat as needed.
214374819|NCT06859424|OTHER|Study treatment compliance|The administration of study agents must be recorded in the subject's medical chart for verification of study treatment compliance.
214374820|NCT06859424|OTHER|Prohibited Concomitant Therapy|"Prophylactic anti-viral cellular therapies and/or co-enrollment on studies using therapies for the prevention of GVHD is prohibited.~Subjects reported to have received prohibited therapy while on this study will be withdrawn and will not be included in the primary and secondary analyses.~No concomitant systemic immunosuppressive agents can be administered during PTCy (Day 3 and Day 4). If needed, administer at least 24 hours after completion of Day 4 PTCy.~It is crucial that no systemic immunosuppressive agents are given until at least 24 hours after completion of the Day +4 dose of PTCy. This includes corticosteroids as anti-emetics but excludes tacrolimus and MMF. Steroid use is permitted as pre-medication prior to start of conditioning but is prohibited from Day 0 through 24 hours post Day 4 PTCy administration.~If prohibited therapies are administered, these data must be reported in the study EDC on the Concomitant Medications form."
214496085|NCT06734247|DEVICE|Brachial single cuff-based arterial stiffness|Use of standard equipment
214496086|NCT06854705|OTHER|Continuity of Midwifery care model|The intervention group will receive a continuity of midwifery care model organized by a team of qualified midwives. In this model, antenatal, intrapartum, and postnatal care will be provided by a named (or primary) midwife, who works within a small team (4-8) of CoMC midwives to their cohort of women and will refer or consult an obstetrician in case of complications that requires specialized care. Each named midwife will be backed up by a partner midwife and other team colleagues. The CoMC team comprises 8 whole-time equivalent midwives, including an experienced senior midwife, who leads the team. Following a training needs assessment by the team leader, midwives will receive specialist training, provided by a team of clinical experts and educators, on how to work in midwife continuity models. Pregnant women receive their entire antenatal, intrapartum, and postnatal care from one of the participating CoMC midwives.
214685363|NCT04734990|DRUG|Seclidemstat|Given PO
214685364|NCT05358964|BEHAVIORAL|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
214685365|NCT04397068|PROCEDURE|phaco-vitrectomy|phaco-vitrectomy. No other involvement drug or device. Standard of care procedure
214685366|NCT05090150|OTHER|Home delivery of ART|Home ART refill and monitoring, adherence support
214685367|NCT05090150|OTHER|Smart Lockers (Pele boxes)|Decentralized ART refills and monitoring, adherence support
214685368|NCT05090150|OTHER|Best clinic practices + conditional lottery incentives|Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART
214685369|NCT05090150|OTHER|Best clinic practices|Continue with best clinic practices
214685370|NCT05703802|DIAGNOSTIC_TEST|Procalcitonin-variants ELISA-Assay|Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.
214685371|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
214685372|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
214685373|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
214685374|NCT02944071|DEVICE|Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter|
214685375|NCT06973434|DEVICE|intubation|intubation
214685376|NCT01684397|BIOLOGICAL|Bevacizumab|Given IV
214685377|NCT01684397|OTHER|Laboratory Biomarker Analysis|Correlative studies
214685378|NCT01684397|DRUG|Pazopanib Hydrochloride|Given PO
214685379|NCT01684397|OTHER|Pharmacological Study|Correlative studies
214685380|NCT04801849|DRUG|Vitamin E|Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks
214685381|NCT04801849|DRUG|Placebo|Participants will take a placebo vitamin E capsule daily for 24 weeks
214685382|NCT05836220|DRUG|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
214987330|NCT01610518|DIETARY_SUPPLEMENT|oat beta-glucan|4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
214685383|NCT05836220|DRUG|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
214685384|NCT05836220|DRUG|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
214685385|NCT05421858|DRUG|Fosmanogepix|IV infusion
214685386|NCT05421858|DRUG|Fosmanogepix|Oral tablet
214685387|NCT05421858|DRUG|Caspofungin|IV infusion
214374821|NCT06859424|OTHER|Permitted Concomitant Therapy|"Pre-medication and/or treatment for possible AEs related to PTCy are permitted. Subjects may continue all medications in compliance with local treatment center and local institutional guidelines, except those described in Section 7.9.1. If GVHD or infection occurs, enrollment on a clinical trial to treat infection or GVHD is permissible. At time of relapse, patients are permitted to enroll on a clinical trial or receive disease targeted therapy.~The following medications/therapies must be reported on the study EDC Concomitant Medications form:~* Medications taken to treat adverse events that have been reported on the study EDC Adverse Event form.~* Antimicrobial prophylaxis (viral, bacterial, fungal, parasitic).~* Antimicrobial pharmaceutical and cellular therapies used to treat grade II-III infections per BMT CTN grading criteria (Appendix D - BMT CTN Infection Grading).~* Post HCT, primary malignant disease-directed pharmaceutical and cellular therapies.~* Planned maintenance therapy"
214374822|NCT06859424|OTHER|Prohibited Concomitant Therapy|"Treatment with any other Investigational Medicinal Product (IMP) is not allowed while on study treatment. An IMP is defined as any medication without any known FDA-approved indications.~No other investigational drugs for GVHD are allowed."
214374823|NCT06859424|OTHER|Permitted Concomitant Therapy|Premedication and/or treatment for possible adverse events (AE)s related to abatacept are permitted.
214374824|NCT06859424|OTHER|Prohibited Concomitant Therapy|"Treatment with any other Investigational Medicinal Product (IMP) is not allowed while on study treatment. An IMP is defined as any medication without any known FDA-approved indications.~Concomitant use of ruxolitinib with fluconazole doses of greater than 200 mg daily should be avoided.~No other investigational drugs for GVHD are allowed."
214496087|NCT06854705|OTHER|Standard care model|Pregnant women who receive antenatal, intrapartum, and postnatal care following standard practice in Ethiopia will be assigned to the control group. An established practice followed the shared model of care in which responsibility is shared among different staff members, including midwives, nurses, health officers, and medical doctors. Midwives and other health care providers worked conventional eight-hour shifts and handed over care to the next health care provider coming on duty during the next shift. In this model of care, each unit of care had its staff working independently. Besides, the health care provider assigned to the postnatal ward will be responsible for immediate postnatal care. After discharge, each woman in this group become the responsibility of a different group of healthcare providers (usually midwives or nurses) in the family planning and immunization room.
214496088|NCT06817187|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)|Administer 0.5ml of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed) separately at different locations upon enrollment. Both vaccine were immunized according to the 0, 1, and 2 month procedures (calculated as 30 days per month).
214987331|NCT01610518|DIETARY_SUPPLEMENT|Placebo|Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
214496089|NCT06817187|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)|Vaccination with 15-Valent Pneumococcal Conjugate Vaccine with a 7-day interval (+15 day window period) followed by vaccination with Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed). Both vaccine were immunized according to the 0, 1, and 2 month procedures (calculated as 30 days per month).
214685388|NCT05421858|DRUG|Fluconazole|Fluconazole oral capsule
214685389|NCT05421858|DRUG|Placebo|Matching placebo for caspofungin (IV infusion)
214685390|NCT05421858|DRUG|Placebo|Matching placebo for fluconazole (oral capsule)
214496090|NCT06817187|BIOLOGICAL|Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)|Only administer the Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed) and according to the 0, 1, and 2 month procedures (calculated as 30 days per month).
214496091|NCT05551754|DIETARY_SUPPLEMENT|Ketone Supplement|Drink a single dose of ketone supplement 25g
214496092|NCT05551754|OTHER|Alcohol Beverage|Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%
214496093|NCT05332093|DIAGNOSTIC_TEST|skin biopsy|4mm skin biopsy
214496094|NCT05332093|DIAGNOSTIC_TEST|venous blood sample (plasma, PBMC, WB)|venous blood sample to acquire plasma, PBMCs and whole blood
214685391|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (IV infusion)
214685392|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (oral tablet)
214685393|NCT06665425|DRUG|Epaminurad 9 mg|Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
214685394|NCT06665425|DRUG|C2406|Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
214685395|NCT05635084|DRUG|YN001|Dose ranges from 2-90mg
214685396|NCT05635084|DRUG|Placebo for YN001|5% dextrose injection to mimic the YN001
214685397|NCT05640999|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids
214685398|NCT05640999|RADIATION|Adjuvant radiotherapy (EBRT +/- brachytherapy)|Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
214685399|NCT05640999|OTHER|Observation|Observation
214685400|NCT03036592|BEHAVIORAL|Early OGTT|Oral glucose tolerance test using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
214987332|NCT05109715|PROCEDURE|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
214374825|NCT06859424|OTHER|Permitted Concomitant Therapy|Premedication and/or treatment for possible AEs related to ruxolitinib are permitted.
214685401|NCT03036592|BEHAVIORAL|Late OGTT|Oral glucose tolerance test using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
214685402|NCT05471843|DRUG|BGB-11417|Administered orally
214685403|NCT06562543|DRUG|Fruquintinib|Oral capsules
214987333|NCT05109715|PROCEDURE|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
214987334|NCT06579300|DRUG|ABBV-1088|Oral Capsule
214987335|NCT06579300|DRUG|Placebo for ABBV-1088|Oral Capsule
214987336|NCT06579300|DRUG|Itraconazole (ITZ)|Oral Capsule
214685404|NCT05407714|DEVICE|SpaceOAR Treatment|"SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
214685405|NCT05915351|DRUG|Enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg on D1, D8, D15 every 28 days
214685406|NCT02499146|DRUG|Palbociclib|125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
214685407|NCT02499146|DRUG|Letrozole|2.5 mg , orally once daily (continuously)
214685408|NCT06313190|RADIATION|Stereotactic body radiotherapy|Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.
214987337|NCT03534674|DIETARY_SUPPLEMENT|vitamin D3|a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
214685409|NCT06313190|DRUG|Sintilimab|Patients received sintilimab 200 mg every 3 weeks for up to 6 cycles, with the first dose within 1 week after the completion of SBRT.
214685410|NCT05776758|DRUG|cisplatin based neoadjuvant chemotherapy|cisplatin based neoadjuvant chemotherapy
214685411|NCT05776758|PROCEDURE|Radical cystectomy alone|RC alone
214685412|NCT05638711|DEVICE|Built-in calculator to calculate Filtration fraction|A calculator built in electronic CVVH prescription system to calculate Filtration fraction
214987338|NCT05287789|OTHER|Squatting position by footstool|"Before the study, the height of the toilet bowls in the patient rooms was measured as 42 cm. The stools to be used for the study are manufactured by ordering laminated with white medium density fiberboard and synthetic resin resistant to harsh chemicals. Stools are made of high quality non-slip materials for patient safety.~After the first postoperative ambulation, stable patients whose bowel movements resumed met their initial defecation needs with the squatting position created using a stool at the appropriate height on the water closet type toilet.~The patients used footstools throughout a week after discharge at home and in the hospital for defecation."
214987339|NCT05215288|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
214987340|NCT03428373|DRUG|Rivaroxaban|Rivaroxaban 10mg daily
214987341|NCT03428373|DRUG|ASA|ASA 81mg
214374826|NCT03871348|DRUG|SAR441000|"Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral"
214987342|NCT03171090|OTHER|sphenopalatine block with local anesthetic|bilateral ultrasonic guided sphenopalatine ganglion block using local anesthetic after induction of general anesthesia in maxilofacial cancer surgeries
214374827|NCT03871348|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
214496095|NCT05332093|GENETIC|venous blood sample (HLA)|venous blood sample used for HLA typing
214496096|NCT05332093|GENETIC|skin slit|genome sequencing of parasite DNA that is extracted from the skin slit
214496097|NCT02331979|DEVICE|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
214496098|NCT06098118|BEHAVIORAL|MyMammogram decision aid|An online breast cancer screening decision aid that includes personalized risk assessment, information on benefits and risks of mammography screening, values clarification, outcome expectancies, and a summative document with participant responses.
214496099|NCT03654001|BIOLOGICAL|Albumin|Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
214496100|NCT03654001|OTHER|Balanced|Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
214496101|NCT06822114|DRUG|Methoxyethyl Etomidate Hydrochloride|The dose is 50 μCi/48 mg，in the fasting state, a single intravenous injection was given slowly
214496102|NCT06828614|DRUG|Chemotherapy|"The present approved ethics committee includes the conduct of two studies. In the first one, a cross-sectional study, breast cancer patients will be distributed in the study groups according to the moment of their chemotherapy treatment (group 1: pre-chemotherapy, group 2: during chemotherapy, group 3: post-chemotherapy). Each patient will undergo a single evaluation session, which will include the variables detailed in the following section.~In the second, a longitudinal study, patients from the previous study in group 1 (pre-chemotherapy) will be followed up. Patients will receive three assessments of the variables detailed in the following section: 1) during the time prior to the start of chemotherapy (assessment that will coincide with study 1), 2) assessment during chemotherapy treatment and, 3) assessment after the end of chemotherapy treatment."
214496103|NCT04046692|OTHER|Hospital School Experience, point of view of the children|Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.
214496104|NCT04046692|OTHER|Hospital School Experience, point of view of the hospital teachers|operators interview hospital teachers and make them complete a questionnaire (CEESQ)
214496105|NCT04046692|OTHER|Hospital School Experience, point of view of the non hospital teachers|operators interview the teachers and make them complete a questionnaire (CEESQ)
214496106|NCT04046692|OTHER|Hospital School Experience, point of view of parents|Operators interview parents
214685413|NCT03970447|DRUG|Temozolomide|Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
214685414|NCT03970447|DRUG|Lomustine|Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
214685415|NCT03970447|DRUG|Regorafenib|Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
214685416|NCT03970447|RADIATION|Radiation|60 Gy
214685417|NCT03970447|DRUG|Paxalisib|Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
214987343|NCT03171090|OTHER|sphenopalatine block with saline|bilateral ultrasonic guided sphenopalatine ganglion block using saline after induction of general anesthesia in maxilofacial cancer surgeries
214987344|NCT06369688|OTHER|IDEAL SKIIN CARES bundles|The investigators developed a specialized PIP care bundle, named IDEAL SKIIN CARES, through extensive review of literature and expert insights, which will be utilized for training WSNs and patients in the intervention group. This comprehensive bundle comprises 15 key components aimed at effectively preventing PIs: (1) Incontinence care status; (2) Dehydration status; (3) Elevate at-risk surfaces; (4) Attention to attached devices to skin; (5) Lotion use; (6) Skin assessment; (7) Keeping repositioning; (8) Individualized up-to-date knowledge; (9) Individualized medical devices selection; (10) Nutrition status; (11) Caregiver (formal and informal) participation; (12) Activity assessment; (13) Reducing friction/shear forces; (14) Evaluate hemodynamic instability; (15) and Scrutinizing comorbidities.
214685418|NCT03970447|DRUG|VAL-083|Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
214685419|NCT03970447|DRUG|VT1021|"Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration."
214685420|NCT03970447|DRUG|Troriluzole|Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
214685421|NCT03970447|BIOLOGICAL|ADI-PEG 20|Dosage Form: Solution for intramuscular injection Strength: 11.5 ± 1.0 mg/ml Standard Regimen: For newly diagnosed patients, 36mg/m2. For recurrent disease patients, dose as confirmed through the dose finding phase intramuscularly once a week
214685422|NCT03970447|DRUG|AZD1390|Standard Regimen Newly Diagnosed: Given once daily on days of radiation and once daily for 14 consecutive days after completion of radiation.
214685423|NCT06038617|BIOLOGICAL|mRNA COVID-19 Vaccine|ACIP Recommended Vaccine
214685424|NCT06038617|BIOLOGICAL|Routine Childhood Vaccinations|ACIP Recommended Vaccines
214685425|NCT06339996|DIETARY_SUPPLEMENT|Male supplement|Participants will be administered supplements for a three-month treatment period
214987345|NCT06369688|OTHER|IDEAL SKIIN CARES bundles workshop|IDEAL SKIIN CARES bundles will be explained in detail by a trained research assistant in a workshop. This workshop is different from clinical training and following up about the IDEAL SKIIN CARES bundles.
214987346|NCT06369688|OTHER|Respiratory care workshop|An unrelated topic, specifically respiratory care will be held in a workshop. This training will involve the distribution of educational pamphlets, brochures, and visual posters outlining key aspects of respiratory care
214685426|NCT06048003|OTHER|No specific intervention|No specific intervention
214685427|NCT01847144|DRUG|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
214685428|NCT01847144|DRUG|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
214685429|NCT01879618|DRUG|Fragmin|variable dosing regimen
214685430|NCT03075397|OTHER|blood sample|A sample of HIV-1 infected patients's blood is collected
214685431|NCT03075397|OTHER|sperm sample|A sample of HIV-1 infected patients's sperm is collected
214987347|NCT04677257|PROCEDURE|PCI, invasive coronary physiology and CMR|Patients with acute STEMI will undergo invasive assessment of coronary physiology (IMR and CFR) following successful primary PCI and CMR within a week of the acute event
214987348|NCT04375046|DRUG|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV
214685432|NCT06841627|OTHER|Osteopathic Manipulative Therapy|Evaluation looking for Somatic Dysfunction (SD) involving the head, neck, upper thoracic spine, rib cage and sacroiliac joint. OMT techniques will include a mix of the following: Osteopathic Cranial Manipulative Medicine, Muscle Energy Technique, Facilitated Positional Release, Indirect Myofascial Release, and Counterstrain.
214685433|NCT02496728|BEHAVIORAL|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
214685434|NCT02496728|BEHAVIORAL|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
214685435|NCT02496728|BEHAVIORAL|Social Support|Participants may interact with each other through a private Facebook group.
214685436|NCT02496728|BEHAVIORAL|Educational Materials|Educational materials regarding healthy behaviors.
214685437|NCT00138099|DRUG|Fragmin (dalteparin sodium)|
214685438|NCT06589713|DRUG|Enpatoran|Participants will receive a single oral dose of enpataron tablets once daily.
214685439|NCT04040712|OTHER|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
214685440|NCT04040712|OTHER|Sham FMT|Sham fecal microbiota transplantation
214685441|NCT02890329|DRUG|Decitabine|Given IV
214685442|NCT02890329|BIOLOGICAL|Ipilimumab|Given IV
214685443|NCT05517447|OTHER|Observational cohort study|Observational cohort study
214374828|NCT04724330|BEHAVIORAL|Healthy for Two/Healthy for You|\~10 month (early pregnancy to 12 weeks postpartum), remotely-delivered, behavioral lifestyle intervention including health coach contacts (via phone, videoconference, and email/MyChart) and an interactive web-based platform.
214374829|NCT07085611|OTHER|Sample collection (blood and optional nasal swab)|Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur
214374830|NCT07096843|DRUG|budoprutug|Single IV dose of study product on Day 1, Day 15, Day 169 and Day 183
214374831|NCT04919226|DRUG|177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
214374832|NCT04919226|DRUG|CAPTEM (Capecitabine and Temozolomide)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
214374833|NCT04919226|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
214374834|NCT04919226|DRUG|Everolimus|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
214374835|NCT04919226|DRUG|FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
214685444|NCT05517447|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
214685445|NCT01212328|OTHER|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
214685446|NCT01212328|OTHER|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
214685447|NCT02177669|OTHER|quick Contrast Sensitivity Function test|
214685448|NCT02729454|OTHER|Mental practice and physical therapy|
214987349|NCT04369417|BEHAVIORAL|Relaxation Response Resiliency Program for Siblings of Children with ASD|Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
214987350|NCT05936307|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 2 mA for a duration of 25min. The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task.
214685449|NCT02729454|OTHER|physical therapy|
214685450|NCT03829189|DIETARY_SUPPLEMENT|inulin|prebiotic supplement
214685451|NCT03829189|DIETARY_SUPPLEMENT|maltodextrin|placebo supplement
215089968|NCT03024645|BEHAVIORAL|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
214374836|NCT04296604|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
214374837|NCT04776278|BEHAVIORAL|Brief Alcohol Intervention (BAI)|This session includes a discussion related to harm reduction and the participant's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the participant's perception of how much he or she drinks and actual norms, (b) a comparison of the participant's alcohol consumption vs. norms, (c) an estimate of the participant's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
214685452|NCT00995735|PROCEDURE|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
214685453|NCT00995735|PROCEDURE|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
214685454|NCT02911363|DEVICE|Captivator cassette|The Captivator tissue cassette has an effect on the preservation of tissue histology.
214685455|NCT02911363|OTHER|Standard of Care|The specimen will be processed following the College of American Pathology Standards.
214685456|NCT01585129|DRUG|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
214685457|NCT01585129|DRUG|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
214685458|NCT00841295|DRUG|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
214685459|NCT00841295|DRUG|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
214685460|NCT02549677|DRUG|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
214685461|NCT02549677|DRUG|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
214685462|NCT02549677|DRUG|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
214685463|NCT01270893|DRUG|Nilotinib|400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
214685464|NCT01010841|DIETARY_SUPPLEMENT|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
214685465|NCT01010841|OTHER|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
214685466|NCT01926379|BEHAVIORAL|Combination intervention components|"The CIP will contain programmatic, structural, and psychosocial components, including:~1. use of a clinical algorithm by providers;~2. identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);~3. review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;~4. reimbursement of transportation costs for monthly clinic visits; and~5. real-time adherence support using IVR via mobile phones and trained Peer Educators."
214685467|NCT01926379|DRUG|Isoniazid Prevention Therapy|Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
214987351|NCT05936307|PROCEDURE|High-definition transcranial direct current (HD-tDCS), placebo condition|"Participants will receive a session of placebo HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 2mA during the 30 first seconds at the beginning of the 25-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task"
214987352|NCT00797563|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
214987353|NCT03776279|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
214987354|NCT05378503|DRUG|Qsymia 3.75Mg-23Mg Extended Release Capsule|From W0 to W2, once a daily.
215089969|NCT03024645|OTHER|Treatment as usually (TAU)|performed in primary care settings
214987355|NCT05378503|DRUG|Qsymia 7.5Mg-46Mg Extended Release Capsule|"1. From W2 to W14, once a daily.~2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily."
214987356|NCT05378503|DRUG|Qsymia 11.25Mg-69Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
214987357|NCT05378503|DRUG|Qsymia 15Mg-92Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
214987358|NCT05378503|DRUG|Placebo|From W0(Randomisation) to W56(the End of visit) once a daily.
214987359|NCT00688597|DRUG|Duvoglustat|Powder in a bottle for dissolution in water for oral administration
214987360|NCT05209919|DIAGNOSTIC_TEST|Transthoracic Echocardiography|All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)
214987361|NCT00259103|DRUG|Serelaxin|
214987362|NCT00259103|DRUG|Placebo|
214987363|NCT04524156|OTHER|Physiology|"Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method)."
214987364|NCT03756675|OTHER|haplotype PBSCT|"haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system"
214987365|NCT01355965|BIOLOGICAL|Autologous T cells|
214987366|NCT05347628|DRUG|PLB1004|PLB1004 is a capsule in the form of 10mg and 40mg.
214987367|NCT06638125|DEVICE|3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping|All patients in Phase I and those randomized to Intervention in Phase II will have preoperative 3D VR reconstructions of their pulmonary anatomy with the target lesion created using the Elucis platform. Segment identification and confidence rating will be collected before and after visualizing the 3D VR reconstruction. Intraoperatively, the surgeon will use this 3D VR model as a guide to determine which inflow and outflow vessels to the involved segment need to be removed. After vascular ligation, a 8mL bolus of ICG solution will be injected into a peripheral vein catheter by anesthesia. The surgeon will mark out the segmental plane based on the fluorescence pattern seen on the infrared mode of the robotic camera. The surgeon will then perform the pulmonary resection and the resected non-fluorescent lung segment will be extracted from the body cavity. Study patients will receive routine postoperative care as non-study patients and will be followed until the 3-4-week mark.
215089970|NCT03090347|OTHER|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
215089971|NCT05231447|OTHER|Environmental survey|"Exposure to environmental factors, drugs or individual toxicity during the periconceptional period and at the beginning of the pregnancy will be investigated by means of a questionnaire administered to the parents. This questionnaire, drawn up by the Aquitaine Reproduction Enfance Maternité et Impact Santé-environnement (ARTEMIS) centre and completed by both members of the couple, will constitute an initial assessment that will make it possible to collect environmental exposures for the parents of cases identified by the register."
215089972|NCT04218071|DRUG|Ruxolitinib|Ruxolitinib at protocol-specified doses for given platelet count
215089973|NCT04218071|DRUG|9-ING-41|9-
215089974|NCT05260333|DEVICE|Butterfly iQ transperineal ultrasound exam|Transperineal ultrasound
214685468|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of bupivacaine|270 ml of 0.5 % bupivacaine. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
214685469|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of saline|270 mL of normal saline. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
214685470|NCT05579561|OTHER|Diet|Participants, in both groups, will be required to eat a diet that is very low in carbohydrates, moderate in protein, with added healthy fats. They will also have to breath in the device to estimate the level of different exhale gaz.
214374838|NCT04776278|BEHAVIORAL|Substance-free Activity Session (SFAS)|The SFAS session includes : a) discussion of life goals, b) discussion of associations between alcohol and drug use, goals, and substance-free activities; c) a graph depicting the participant's ratings of the relative importance of various aspects of their life and how their actions in the past week have been consistent with these priorities; d) personalized feedback on recent time allocation to activities across life domains, and a discussion of any changes the participant would like to make; e) feedback on symptoms of stress, anxiety and discussion of adaptive coping strategies; f) discussion of enjoyable substance-free activities and hobbies and substance-free recreational activity suggestions tailored to individual's interests and neighborhood; g) a goal setting exercise for specific behavior change plans; h) a Future Thinking Writing Exercise. Participants will receive weekly text-message based booster prompts for four weeks after their SFAS session.
214374839|NCT04776278|BEHAVIORAL|Relaxation Training (RT)|The clinician will begin by establishing the credibility of the session by providing the participant with the rationale that developing relaxation or mindfulness training strategies can reduce stress and enhance wellness. The clinician will then lead the participant through a diaphragmatic breathing exercise, followed by a progressive muscle RT protocol, and then a brief breath-counting (mindfulness) exercise. The session will conclude with a brief discussion of additional stress and anxiety management strategies (e.g., apps to monitor heartrate and breathing). Participants will be asked about their reaction to the techniques and, if interested, encouraged to commit to a specific plan for practicing these techniques.
214374840|NCT04776278|OTHER|Education Control|This condition will not include any clinical contact other than a brief (2-3 minute) discussion with the research assistant (RA) who completed the assessment session and who will describe the educational handout. This condition is meant to approximate a low-threshold public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or MI/clinical contact. Thus, participants will receive information on risks associated with alcohol and drug misuse, strategies for reducing use/problems, and strategies for managing stress and setting and follow-through with achievable goals. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact.
214374842|NCT07100418|DRUG|HRS-7249 Injection|HRS-7249 injection.
214374843|NCT07100418|DRUG|Sodium Chloride Injection|Sodium chloride injection.
214374844|NCT06909500|BEHAVIORAL|Smartphone app|Receive access to the ACT on Vaping app
214496107|NCT06827444|OTHER|Placebo|Participants will be provided with a chest strap for heart rate measurement (the strap will be washed and disinfected after each session), connected to the Polar Beat app downloaded by the researcher. Subsequently, each participant will perform an initial 10-minute baseline warm-up session (a cadence of 70-80 RPM will be requested). From the cycle ergometer display, values for watts (the amount of work done per second), power (the amount of work done over a certain period of time), and speed (expressed in kilometers per hour) will also be extracted. During the test, no visual or verbal feedback will be provided. Participants will be blind to the cycle ergometer screen, so the data will not influence their behavior. Heart rate will be continuously recorded throughout the exercise period and during the participant's recovery. Participants will then be randomized to one of the following manipulations.
214496108|NCT06459973|DRUG|intravenous (IV) infusion|YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
214496109|NCT03384238|PROCEDURE|Fluorescence Imaging|Undergo fluorescence imaging
214496110|NCT03384238|BIOLOGICAL|Panitumumab|Given IV
214496111|NCT03384238|DRUG|Panitumumab-IRDye800|Given IV
214496112|NCT03436992|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
214496113|NCT03436992|DIETARY_SUPPLEMENT|Resveratrol|1500 mg trans-resveratrol
214496114|NCT03436992|OTHER|Placebo|placebo
214685471|NCT00001262|DRUG|Copper Histidine|
214496115|NCT06812130|OTHER|This is a non-interventional study.|This is a non-interventional study.
214685472|NCT06245577|DEVICE|interdisciplinary mesh sacro colpopexy with resection rectopexy|surgical reconstruction of the middel pelvic compartment with the above mentioned meshes combined with a resection rectopexy in a simultaneous interdisciplinary procedure
214685473|NCT01818167|DRUG|10% Benzoyl Peroxide Topical Body Wash|
214685474|NCT01818167|DRUG|Provodine Topical Cream|
214685475|NCT04516486|OTHER|retrospective metagenomics on clinical samples collected during hospitalization|Massive sequencing of respiratory samples (restrospective)
215089975|NCT06246071|DRUG|TYK-00540|TYK-00540 PO, BID
215089976|NCT06179316|PROCEDURE|Robot Assisted Radical Prostatectomy|Performing radical prostatectomy operation using robotic equipment while preserving bilateral nerve bundles
215089977|NCT00686842|DRUG|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
215089978|NCT00686842|GENETIC|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
214987368|NCT06638125|DEVICE|3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping|The patients that are randomized to Control in Phase II will undergo the same intervention as above, but instead of using Elucis for 3D VR reconstructions, Synapse 3D will be used for 3D reconstructions.
214374845|NCT06909500|BEHAVIORAL|Smartphone app|Receive access to the ACT on Vaping app
214496116|NCT06575530|DRUG|Remimazolam Besylate|patients will be sedated with remimazolam via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if remimazolam fails to achieve a satisfactory RASS score (0 to -2 points) within its upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).
214987369|NCT06182709|BEHAVIORAL|online psychoeducation video + modeled exposure|Participants will watch a short psychoeducation video online. This will be followed by a modeled exposure online. In this modeled exposure participants watch a film of an exposure treatment (about 45min) conducted with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).
214987370|NCT06182709|BEHAVIORAL|live psychoeducation video + modeled exposure|Participants will watch a short psychoeducation video. This will be followed by a live modeled exposure. In this modeled exposure participants watch an exposure treatment (about 45min) conducted live with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).
214987371|NCT06182709|BEHAVIORAL|group exposure|Exposure training in the group is conducted live (1 spider per participant, one therapist and co-trainers). In this group exposure participants complete exposure training (about 45 min) with five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to three times: 2,4,5).
214685476|NCT04227249|PROCEDURE|no lymph node dissection|do not undergo lymph node dissection
214685477|NCT00194636|PROCEDURE|nerve block|
215089979|NCT00686842|GENETIC|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
215089980|NCT00686842|GENETIC|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
215089981|NCT00686842|OTHER|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
214496117|NCT06575530|DRUG|Dexmedetomidine Hydrochloride|patients will be sedated with dexmedetomidine hydrochloride via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if dexmedetomidine fails to achieve a satisfactory RASS score (0 to -2 points) within the upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).
214496118|NCT02778425|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
214496119|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
214685478|NCT00758927|DRUG|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
215089982|NCT00686842|OTHER|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
215089983|NCT00686842|OTHER|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
214374846|NCT06909500|OTHER|Text Message|Receive incentivized text messages to access vaping status
214685479|NCT00758927|DRUG|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
214374847|NCT06909500|OTHER|Text Message|Receive intervention text messages
214374848|NCT06909500|OTHER|Survey Administration|Ancillary studies
214374849|NCT06910358|DRUG|Placebo|Oral dose, once a day for 24 weeks
214374850|NCT06910358|DRUG|DISC-1459|Oral dose, once a day for 24 weeks
214374851|NCT05885334|OTHER|Control|Caregivers will not receive any educational solution different than what is done by routine in centers. After six months, performance in caregivers tasks will be video recorded.
214374852|NCT05885334|OTHER|Virtual Reality|Caregivers will receive a educational solution of virtual reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
214374853|NCT05885334|OTHER|Augmented Reality|Caregivers will receive a educational solution of augmented reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
214685480|NCT00878072|DRUG|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
214987372|NCT06182709|BEHAVIORAL|mental retrieval cue|Before the group exposure, participants are asked to remember the modeled exposure they had observed the day before. Therefore, the participants are asked to recall the location where they have been during the modeled exposure and the reaction of the patient during the exposure (e.g., fear decline).
214685481|NCT01954121|DRUG|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~* Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~* Down-titration Period (Week 30 up to Week 33)"
214685482|NCT01954121|DRUG|Carbamazepine|"Immediate release tablets at a strength of 200 mg.~* Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~* Down-titration Period (Week 30 up to Week 33)"
214987373|NCT05806658|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
214987374|NCT06252480|DEVICE|tDCS|4 variance of different intensities of tDCS (0.5mA, 1 mA, 1.5mA and 2mA). At F3 and F4, tDCS was applied to the desired region. Electrodes were put in using the 10-20 EEG technique throughout the parietal cortex, with the current electrode being set on F3 area and control electrode being positioned on the F4 area. For 20 minutes over three days per week for up to three weeks, current intensities of 0.5mA for group A, 1.0mA for group B, 1.5mA for group C, and 2.0mA for group D were administered. when engaging in dual-task cognitive processes. The groups are going to receive 9 sessions of tDCS treatment.
215089984|NCT00686842|PROCEDURE|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
215089985|NCT06441292|PROCEDURE|AI-assisted|utilize advanced deep learning models that integrate multi-modal image fusion from multi-parameter ultrasound and MRI to guide the biopsy process
215089986|NCT06441292|PROCEDURE|Non-AI-assisted|undergo standard prostate biopsy procedures without additional technological assistance
214374854|NCT06239545|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
214374855|NCT01061333|DRUG|Nedocromil|Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge
214374856|NCT01061333|DRUG|Comparator: Montelukast|Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge
214374857|NCT01061333|DRUG|Comparator: Mometasone|Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge
214374858|NCT01061333|DRUG|Placebo|Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
214374859|NCT07112053|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
214374860|NCT07112053|DRUG|Capecitabine|Given SOC capecitabine
214374861|NCT07112053|PROCEDURE|Computed Tomography|Undergo CT or ultrasound-guided biopsies
214496120|NCT02778425|PROCEDURE|beta blockers|A standard dose of NSBB (propranolol) was applied to the primary prevention patients according to the Baveno VI recommendations if there were no contraindications.
214496121|NCT02778425|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
214374862|NCT07112053|DRUG|Cyclin-Dependent Kinase 4 Inhibitor|Given SOC CDK4/6i
214374863|NCT07112053|DRUG|Cyclin-Dependent Kinase 6 Inhibitor|Given SOC CDK4/6i
214374864|NCT07112053|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo FES PET
214496122|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
214496123|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
214496124|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy+PSE|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
214496125|NCT05704725|DRUG|ABP 938|IVT injection
214496126|NCT05704725|DRUG|Aflibercept|IVT injection
214496127|NCT05902325|DRUG|Mepolizumab 100 MG Injection|Patients will receive Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections, no placebo) at the hospital. The IMP will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction. Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas) or the upper arms. Background therapy will be assured with mometasone furoate nasal spray (200µg BID) daily throughout the study.
214496128|NCT04180267|DEVICE|Low-magnitude High-frequency Vibration|35Hz, 0.3g, 20min/day, at least 3 times/week
214496129|NCT04384367|DRUG|Rizatriptan 10 mg + Naproxen 550mg|oral - single dose
214496130|NCT04384367|DRUG|Maxalt 10Mg Tablet|oral - single dose
214496131|NCT04384367|DRUG|Flanax 550mg|oral - single dose
214496132|NCT04384367|DRUG|Placebo oral tablet|oral - single dose
214496133|NCT06826872|DRUG|SPC 1001 Mid2|low-dose combination therapy
214496134|NCT06826872|DRUG|SPC 2002|low-dose combination therapy
214496135|NCT06826872|DRUG|SPC 2003|low-dose combination therapy
214496136|NCT06826872|DRUG|SPC 2004|low-dose combination therapy
214685483|NCT03844633|DRUG|Depo-Provera Injectable Product|Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
214374865|NCT07112053|DRUG|Hormone Therapy|Given SOC ET
214374866|NCT07112053|PROCEDURE|Positron Emission Tomography|Undergo FES PET
214374867|NCT07112053|PROCEDURE|Ultrasound Imaging|Undergo CT or ultrasound-guided biopsies
214374868|NCT07112053|PROCEDURE|Biopsy Procedure|Undergo CT or ultrasound-guided biopsies
214374869|NCT07112053|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214374870|NCT07106437|OTHER|"Basel Model: Measure of total waste after completion of the procedure"|For each included case, the total waste generated will be measured in kilograms immediately after completion of the procedure and physically recorded by category in accordance with four predefined waste types: (i) paper and cardboard, (ii) regular waste (i.e., municipal solid waste or general trash), (iii) regulated medical waste (requiring specialized incineration including sharpsafe), and (iv) recyclable plastic
214374871|NCT07106437|OTHER|"Standard Model: Measure of total waste after completion of the procedure"|Simulation of a hypothetical but common practice in many hospitals, in which all waste generated during interventional procedures is disposed of as regulated medical waste, without separation.
214496137|NCT06821217|DEVICE|NALU Endo Flow App|NALU Endo Flow App is a mobile application for women with endometriosis. The App provides educational information through videos, audios, and texts. Women learn about endometriosis in general with its symptoms, diagnosis, and therapy options such as lifestyle and mindset modification, endometriosis-specific diets, physical and mindfulness exercises. The App includes a diary to track the menstrual cycle and symptoms. Furthermore, access to a WhatsApp community of people with endometriosis is provided and a peer-group call is performed once monthly, as well as one additional monthly Q\&A (Question\&Answer) call moderated by certified health coaches.
214496138|NCT06757296|PROCEDURE|Endoscopic SASI|Endoscopic conversion to sleeve gastrectomy to SASI
214685484|NCT03844633|DRUG|Placebos|Placebos -- Shot administered within 48 hours of childbirth
214685485|NCT05964725|DEVICE|Receive traditional medical therapy and transcranial direct current stimulation|Equipment used: Bricon tDCS stimulator, high-precision electrode stimulation method Stimulant dose: 1.5mA Stimulation time: 20 minutes/time, continuous treatment for 5 days Stimulation course: 5 days/course Stimulation target: left auditory cortex area, i.e., under system 10-20, left T3 position.
214685486|NCT05964725|DEVICE|Receive traditional medical therapy and sham stimulation|By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
214685487|NCT00122746|RADIATION|Radiotherapy alone|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
214685488|NCT00122746|RADIATION|Radiotherapy with cisplatin|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
214685489|NCT02372903|DRUG|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
214685490|NCT03901287|OTHER|dual energy CT scans|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
214374872|NCT05680155|DRUG|Ecnoglutide|Subcutaneous Injection
214374873|NCT05680155|DRUG|Placebo|Subcutaneous Injection with matched volume
214374874|NCT06921720|DIAGNOSTIC_TEST|intra-muscular ATP values in phosphate diabetes|intra-muscular ATP values \[ATPi\] (measured by 31P-MRS / Phosphorus-31 nuclear magnetic resonance) at rest and during standardized exercise in patients with phosphate diabetes.
214374875|NCT06921720|DIAGNOSTIC_TEST|intra-muscular phosphate values in phosphate diabetes|intra-muscular phosphate values (measured by 31P-MRS) at rest and during standardized exercise in patients with phosphate diabetes.
214374876|NCT05693142|GENETIC|RGX-202|RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
214374877|NCT07118072|BEHAVIORAL|Internet-Delivered Skills Training in Affective and Interpersonal Regulation|Internet-Delivered Skills Training in Affective and Interpersonal Regulation (i-STAIR) is a psychological intervention that is focused on applying skills to improve emotion regulation difficulties and reduce interpersonal problems over two months (eight sessions; one session per week). i-STAIR also significantly reduces PTSD symptoms without direct discussion of the trauma and may be used alone or adjunctively to boost the effects of trauma-focused therapies.
214685491|NCT02588248|DRUG|Peppermint Oil|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640 mg of L-Menthol).
214685492|NCT02588248|OTHER|Placebo|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 80 ml of Solution B, also has 0 mg of L-Menthol).
214685493|NCT01492114|DIETARY_SUPPLEMENT|Resveratrol|"Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
214987375|NCT05439655|DEVICE|Brain Interchange System|The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
215089987|NCT00612625|DRUG|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
214374878|NCT07118072|BEHAVIORAL|Online general psychoeducation|Online general psychoeducation will focus on the teaching the link between adverse childhood experiences and depression, as well as teaching healthy lifestyle changes involving diet, exercise, and sleep. The online general psychoeducation will involve engaging presentations, active discussions, and self-directed homework activities.
214496139|NCT06763926|DRUG|Subcutaneous Triptorelin|"Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the control group, 200 mcg subcutaneous triptorelin will be administered 34-36 hours prior to planned oocyte collection."
214685494|NCT01492114|DIETARY_SUPPLEMENT|resveratrol|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
214685495|NCT03553017|DEVICE|Binocular OCT|Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
214685496|NCT03921229|BEHAVIORAL|Tele-coaching|"Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s)."
214685497|NCT05329467|OTHER|Validation of Faces Thermomether Scale|Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
214374879|NCT06923592|COMBINATION_PRODUCT|PvSeroTAT|Two rounds (month 0 and month 6) of serological screening for antibodies against P. vivax in the blood of all eligible cluster inhabitants. In the clusters in the PvSeroTAT arm, participants with a positive P. vivax serology at baseline or month 6 will be treated with 7 days of primaquine 0.5mg/kg/day and a three-day course of either chloroquine (Ethiopia) or artesunate-amodiaquine (Madagascar).
214374880|NCT06923592|DIAGNOSTIC_TEST|Control|Two rounds (month 0 and month 6) of serological screening for antibodies against P. vivax in the blood of a subset of eligible cluster inhabitants. Serological status will be assessed at a later stage (months later) and will not lead to treatment of sero-positive individuals.
214685498|NCT00571363|PROCEDURE|standard surgery|excision with 4 mm margins
214685499|NCT00571363|PROCEDURE|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
214685500|NCT06175507|DRUG|Naltrexon|Naltrexone 50mg orally once daily will give for 12 weeks
214685501|NCT06175507|DRUG|Baclofen|Baclofen 10mg orally thrice daily will give for 12 weeks
214685502|NCT01413178|DRUG|Busulfan|Test dose (32 mg/m\^2) on day -9 then 130 mg/m\^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
214685503|NCT01413178|DRUG|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
214685504|NCT01413178|OTHER|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
214685505|NCT01413178|DRUG|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
214685506|NCT01413178|DRUG|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
214685507|NCT01413178|PROCEDURE|Stem cell transplant|Stem cell infusion on Day 0.
214987376|NCT05091190|OTHER|Blood draws|"Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration."
214987377|NCT04850105|OTHER|Data Collection|"Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice."
214987378|NCT05186480|DIETARY_SUPPLEMENT|Neo Mune|"Neo-mune is a nutritional formula used in enteral feeding for critically ill patients. It's mainly indicated in cases of malnutrition, post surgeries and traumas and immunocompromisation.~Its composition:~Composition in approximate %w/w Maltodextrin 42.44% Sodium caseinate 18.25% MCT oil 6.28% Arginine 5.21% Polydextrose 4.00% Corn oil 3.48% Glutamine 2.61% Fish oil 2.32% Minerals 1.96% Vitamins 0.86% Artificial flavor (vanilla)"
214987379|NCT05719961|DRUG|INS062 injection|Part I: A single dose of 1.2noml/kg is administered.
214987380|NCT05719961|DRUG|Insulin Aspart|Part I: A single dose of 0.2U/kg is administered.
214987381|NCT05719961|DRUG|HR20014 injection|Part II: Ascending single doses at three dose levels
214685508|NCT00657761|DRUG|Enfuvirtide|90 mg/12h sc for 7 days
214987382|NCT05719961|DRUG|Insulin Aspart 30 Injection|Part II: A single dosewas administered
214987383|NCT00844311|DRUG|rFSH|150 iu/day of rFSH
214685509|NCT00657761|DRUG|Placebo|0.9% saline solution/12h sc for 7 days
214685510|NCT04053179|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
214685511|NCT03356158|BIOLOGICAL|CPGJ602|Injection, q.w., 20 mg: 100 ml
214685512|NCT03356158|BIOLOGICAL|Cetuximab|Injection, q.w., 20 mg: 100 ml
214685513|NCT03782740|DRUG|Melatonin 10 mg|Melatonin capsule
214685514|NCT03782740|DRUG|Placebo|Sugar pill manufactured to mimic Melatonin capsule
214685515|NCT03782740|DRUG|Melatonin 20 mg|Melatonin capsule
214987384|NCT00844311|DRUG|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
214987385|NCT00844311|DRUG|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
214987386|NCT00844311|DRUG|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
214987387|NCT06546306|DEVICE|TOUCH® CMC 1|TOUCH® prosthesis is a total CMC 1 (1st Carpo-metacarpal) joint replacement prosthesis.
214685516|NCT05657288|OTHER|Breathing mixtures of O2 and N2 and monitoring SpO2 on finger and left wrist|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
214685517|NCT01831557|OTHER|Blood samples will be taken for gene sequencing|
214685518|NCT04838691|BEHAVIORAL|interpersonal counseling|In the intervention group, it will be administered for 40 minutes for 8 weeks to people with symptoms of premenstrual syndrome.
214685519|NCT00543829|DRUG|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
214685520|NCT00543829|DRUG|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
214374881|NCT06522971|BEHAVIORAL|High-intensiy interval training|All participants undergo physical capacity tests before the onset of NAC and after the last course of NAC but before the breast cancer surgery. A treadmill protocol consisting of twenty-one 1-minute stages, with speed and/or grade increments at each stage, is used to obtain VO2 peak (the highest amount of oxygen consumed at peak exercise) data. The HIIT intervention consists of 2 to 3 exercise sessions per week for 6 months. The HIIT session starts with a 6-minute warm-up period at about 65-70% of maximal heart rate (HRmax) followed by 4 X 4-min high-intensity intervals (85%-95% of HRmax) combined with 3 min period of active recovery (55-70% of HRmax).
214685521|NCT01675804|OTHER|Computerized cognitive rehabilitation|\- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
214685522|NCT01675804|DRUG|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
214685523|NCT01675804|OTHER|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
214685524|NCT03960710|OTHER|Anonymized CT examinations|The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.
214685525|NCT03960710|OTHER|Training (1)|"An initial training phase of the artificial intelligence network will be carried out :~\- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals"
214685526|NCT03960710|OTHER|Training (2)|"An initial training phase of the artificial intelligence network will be carried out :~\- Use of computer data to drive the artificial intelligence network."
214685527|NCT03960710|OTHER|Validation (1)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~\- Carried out by an intern at the Lyon hospitals"
214685528|NCT03960710|OTHER|Validation (2)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~\- Carried out by the neural network"
214374882|NCT07123727|DRUG|Anktiva|600ug of NAI administered subcutaneously
214374883|NCT07129382|DRUG|CS32582 capsule（low dose） or matched placebo|CS32582 capsule（low dose） or matched placebo，4 weeks
214685529|NCT00237796|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
214685530|NCT00237796|BEHAVIORAL|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
215089988|NCT00612625|DRUG|Saline|continuous infusion of saline
214374884|NCT07129382|DRUG|CS32582 capsule（high dose） or matched placebo|CS32582 capsule（high dose） or matched placebo，4 weeks
214374885|NCT07129382|DRUG|CS32582 capsule（low dose）|CS32582 capsule（low dose），12 weeks
214685531|NCT05060510|DIAGNOSTIC_TEST|Take home saliva kit|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
214685532|NCT06672965|DIETARY_SUPPLEMENT|anti-stress supplement|The anti-stress supplement was developed to provide relief from anxiety and depression levels.Subjects were given 60 capsules of calming supplement (30-day supply) and instructed to take two capsules each day orally with water.
214685533|NCT06672965|DIETARY_SUPPLEMENT|Placebo|Subjects were given 60 capsules of placebo (30-day supply) and instructed to take two capsules each day orally with water.
214374886|NCT07129382|DRUG|CS32582 capsule（medium dose）|CS32582 capsule（medium dose），12 weeks
214374887|NCT07129382|DRUG|CS32582 capsule（high dose）|CS32582 capsule（high dose），12 weeks
214374888|NCT06934291|DEVICE|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
214685534|NCT05438680|DIETARY_SUPPLEMENT|The bovine colostrum ( trade name : baby steps sachets, 300mg )|"The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally."
214685535|NCT05438680|DIETARY_SUPPLEMENT|Placebo|distilled water with no bovine colostrum
214685536|NCT06672653|DRUG|"The monoterpenoid zinc tetra-ascorbo-camphorate (C14)"|The trial phase will consist of hospital administration by vaginal syringe of 5ml of 1% C14, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13). Gynaecological follow-up with HPV molecular testing and cervical smear will be performed two days after each course of treatment at S2, S6, S10, S14 and 2 weeks after the last course of treatment (S16). Unprotected sexual intercourse will not be permitted during each course of treatment, and for at least 72 hours before each genital swab.
214685537|NCT06672653|DRUG|Distilled water group|Instead of C14, distilled water will be administered in this group.
215089989|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intracoronary)
215089990|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intravenous)
214685538|NCT06672887|OTHER|MiLES|The MiLES intervention is an open access website, accessible via an URL, but not traceable through any online search engine during the study period. Tailored for specific preferences and needs of different employees with cancer, the MiLES intervention consists of interactive videos, conversation checklists, tips and information regarding RTW guidance of employees with cancer, and an overview of involved stakeholders and relevant legislation. The MiLES intervention intends to optimize the RTW support the employer provides to the employee with cancer by enhancing the willingness and ability to implement the employer actions. The MiLES intervention focuses for example on fostering effective communication between the employer and employee, while disregarding assumptions based on previous experiences.
214685539|NCT04680286|DRUG|Methadone Hydrochloride|Single dose, intravenous bolus, 0,1 mg/kg administered at induction of anesthesia.
214374889|NCT06934291|DEVICE|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
214374890|NCT06933160|BEHAVIORAL|PromPT-MS|The experimental intervention is a 24-week progressive exercise intervention in which participants are supported through six physical therapy visits and are provided with educational material based on social cognitive theory. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of 2-3 moderate aerobic activity sessions and two strength-training sessions per week. There are no drugs involved in the intervention.
214374891|NCT06931210|OTHER|Sedentary behavior|Patients in the control group will maintain their sedentary lifestyle unchanged.
214374892|NCT06931210|BEHAVIORAL|Exercise intervention|The intervention will include a combination of aerobic and resistance exercises, performed three times per week. Each session will last 80 minutes. Aerobic and resistance training will include cycling, chest press, rowing, abdominal and back muscle exercises, as well as leg strength training.
214685540|NCT04680286|OTHER|Placebo|Single dose, intravenous bolus. Administered as the experimental arm.
214374894|NCT05748314|OTHER|Questionnaire|KINDL-R; Morisky Medication Adherence Scale;
214374895|NCT06942936|DRUG|AZD5004|AZD50004 is administered orally as a tablet.
214374896|NCT06942936|DRUG|Itraconazole|Itraconazole is administered orally as a capsule.
214496140|NCT06763926|DRUG|Intranasal nafarelin|"Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the experimental group, 800 mcg intranasal nafarelin will be administered 34-36 hours prior to planned oocyte collection."
214496141|NCT06831214|OTHER|(pericardial) collagen membrane|bone gain following composite graft rehabilitation of horizontal maxilla atrophy with sausage technique utilizing (pericardial) collagen membrane
214496142|NCT06831214|OTHER|periosteal Membrane harvested from anterior iliac bone|The choice of comparators in clinical studies involving guided bone regeneration (GBR) often includes both nonresorbable and resorbable membranes. Resorbable membranes have demonstrated better soft tissue compatibility compared to nonresorbable options, making them a preferred choice in many cases. For instance, studies have shown that using an organic bovine bone-derived mineral (ABBM) in conjunction with a rapidly resorbing natural collagen membrane is effective for horizontal ridge augmentation, as evidenced by positive histologic outcomes.
214496143|NCT05843786|DRUG|Interferon gamma|Daily subcutaneous administration of Interferon gamma during 5 days
214685541|NCT03344601|BEHAVIORAL|physical activity|The program will consist of 18 face-to-face coaching sessions (\~1 hour) over 12 months. The timing of these sessions will be decided between participant and coach. A coaching manual will be used to provide a structured approach to coaching sessions, focussing on physical activity engagement (specifically aerobic and strengthening exercise) and adherence to exercise. The intervention will take place in the participant's home or in a rehabilitation facility at the research site. Each participant will be provided with a choice of exercise equipment options (e.g. exercise bike, weights, therabands), gym membership or use of online exercise resources. Participants will develop physical activity goals that will be monitored and adjusted throughout the program. Physical activity diaries will be completed to record the amount and type of physical activity involvement. Wearable activity monitors will also be used to facilitate/monitor physical activity and sedentary behaviours.
214685542|NCT06130696|OTHER|Clamshell exercises|Group A will receive treatment with Clamshell exercises Change sides and do 3 sets. Total of 6 session were given.
214685543|NCT06130696|OTHER|Isometric and muscle strengthen exercise|"group B will receive simple exercises also with clamshell 10 to 20 times. Change sides and do 3 sets.~Total 6 session were given"
214685544|NCT01635556|BEHAVIORAL|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
214987388|NCT05077800|DRUG|FOLFIRNINOX|Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion
214987389|NCT05077800|DRUG|Losartan|Taken Orally
214987390|NCT05077800|DRUG|9-ING-41|Administered by intravenous infusion
214987391|NCT05146336|DEVICE|CytoSorb|Sorbent hemoperfusion system
214987392|NCT05853120|DRUG|Doxycycline|Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
214987393|NCT05834179|OTHER|cold endotracheal tube|patients who were intubated with an ETT which kept in the fridge.
214374897|NCT06942936|DRUG|EE/LNG|EE/LNG is administered orally in the form of tablet.
214374898|NCT07142135|OTHER|There is no intervention, only clinical description|There is no intervention, only clinical description
214496144|NCT05843786|DRUG|Placebo|Placebo during 5 days
214496145|NCT03227861|DRUG|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
214496146|NCT03078010|DRUG|Piperacillin-tazobactam|piperacillin-tazobactam (4.5 gm IV q 6 hrs)
214496147|NCT03078010|DRUG|cefepime|(2 gm IV q 8 hrs)
214496148|NCT06534710|DEVICE|electronic moxibustion apparatus|The experimental group used the electronic moxibustion instrument every day on the basis of the control group
214496149|NCT06065800|DEVICE|STEELEX® Sternum Set|Sternal Closure with stainless steel suture (STEELEX®) in patients undergoing cardiac surgery
214685545|NCT02004756|OTHER|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
214685546|NCT03860844|DRUG|Isatuximab|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
214685547|NCT03860844|DRUG|Dexamethasone or equivalent|Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
214685548|NCT03860844|DRUG|Fludarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214685549|NCT03860844|DRUG|Cytarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214685550|NCT03860844|DRUG|Liposomal daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214496150|NCT06891586|DIAGNOSTIC_TEST|echocardiographic evaluation and blood phoenixin-14 level|For participants who provide consent, blood samples will be collected at 6 hours postpartum. Additionally, infants included in the study will undergo an echocardiographic evaluation by a pediatric cardiologist between postnatal days 3 and 5.
214496151|NCT04318717|DRUG|Pembrolizumab|Pembrolizumab is commercially available
214496152|NCT04318717|RADIATION|Hypofractionated radiation therapy|It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.
214496153|NCT05319496|DEVICE|Intermittently scanned continuous glucose monitor (isCGM)|"A wearable sensor the size of 2 stacked quarters, that allows individuals to scan their glucose levels on demand. No fingerstick is required. The device measure interstitial glucose through a filament that is inserted under the skin. The application process is painless, and each sensor lasts 90 days. Sensors can be scanned with certain smart phones. This device is marketed as the FreeStyle Libre 2 glucometer (Abbott Laboratories, IL)."
214496154|NCT05319496|BEHAVIORAL|Education and coaching|Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.
214685551|NCT03860844|DRUG|Daunorubicin (nonliposomal)|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
214685552|NCT03860844|DRUG|Idarubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214685553|NCT03860844|DRUG|Filgrastim or equivalent|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214987394|NCT04159142|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
214987395|NCT04159142|DRUG|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles；
214987396|NCT05612594|DRUG|Bexagliflozin 20 mg|15mg once daily
214987397|NCT05612594|DRUG|Placebo|matching placebo once daily
214987398|NCT05933083|BEHAVIORAL|In-person cardiac rehabilitation|In-person exercise training, health education, and counseling
214987399|NCT05933083|BEHAVIORAL|Telehealth cardiac rehabilitation|Telehealth exercise training, health education, and counseling
214987400|NCT05689645|DRUG|F573 for injection|"The first stage:the first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg, and the subsequent 9 patients with CHB were given doses of 2.0 mg/kg, with an administration volume of 2 mL and intramuscular injection (IM) according to the efficacy and safety test results of the first 16 patients. The dose was given once a day for 7 days and calculated according to the weight of the last visit.~The second stage:According to the results of Phase I efficacy and safety trials, the dosage was determined to be 0.5 mg/kg and 2.0 mg/kg, the dosage volume was 2 mL, intramuscular injection (IM), once a day for 14 days, and the dosage was calculated according to the weight of the latest visit.~The third stage:The dosage was determined according to the results of the first and second phase efficacy and safety trials. The dosage volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days, and the dosage was calculated according to the weight of the latest ."
214987401|NCT05689645|DRUG|Sterilizing water for injection|"The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days."
214987402|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level|Sodium Zirconium Cyclosilicate (SZC) Dose: Paediatric dose based on body weight equivalent to an adult 2.5 g
214987403|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)|Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g
214987404|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g
214987405|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 15 g
214987406|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase|A 28-day period during which SZC is administered orally once daily (QD) to maintain normokalaemia. A dose titration regimen starting with QD administration of the dose of SZC the participants received TID in the CP will be studied in the MP and continued in the LTMP. The maximum dose that can be used is the calculated body weight equivalent to the 15 g adult dose
214987407|NCT04431206|DRUG|Oxytocin|Oxytocin, 8.2 IU, administered by 30minute IV infusion starting at time 0
214987408|NCT03570788|PROCEDURE|Amputation|Major amputation defined as at or above ankle
214987409|NCT05774951|DRUG|Camizestrant|Camizestrant. Experimental. Administered orally
214987410|NCT05774951|DRUG|Tamoxifen|Tamoxifen. Comparator. Administered per local approved label
214374899|NCT07146464|OTHER|Self-Assembling Peptide P11-4 Self-Assembling Peptide P11-4 is a biomimetic material applied topically to white spot lesions on the enamel. It diffuses into the lesion body and forms a three-dimension|"Intervention: Self-Assembling Peptide P11-4~Intervention Description:~Self-Assembling Peptide P11-4 (SAP P11-4) is a synthetic peptide designed to mimic natural enamel matrix proteins. It is applied to cleaned, etched enamel surfaces with white spot lesions. The peptide diffuses into the subsurface lesion and self-assembles into a 3D scaffold that promotes nucleation and growth of hydroxyapatite crystals. In this study, it is applied at baseline and re-applied after 3 months. The product used is Curodont™ Repair.~Intervention: Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)~Intervention Description:~CPP-ACP is a milk-derived peptide complex that stabilizes calcium and phosphate ions in an amorphous form. When applied to enamel surfaces, it delivers these ions to promote remineralization of white spot lesions. In this study, MI Varnish™ is used as the source of CPP-ACP. The varnish is stirred and applied as a thin, uniform layer to cleaned tooth surfaces at baseline and"
214374900|NCT06949124|DRUG|SHR7280 Tablets|SHR7280 tablets.
214374901|NCT06949631|DIETARY_SUPPLEMENT|Resistant Potato Starch|Active Ingredients: 3.5 g potato starch Inactive ingredients: 3.5 g corn starch
214374902|NCT06949631|OTHER|Placebo|Active Ingredients: N/A Inactive Ingredients: 7 g corn starch
214374903|NCT07143383|BEHAVIORAL|Social Prescribing|SP is a person-centered approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and Link Workers (LWs), based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have a good knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioral activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that match their preferences.
214374904|NCT07143383|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of a CAMHS clinician or researcher meeting with YP identified and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
214374905|NCT07148726|DIETARY_SUPPLEMENT|Pyrrole Quinoline Quinone (PQQ)|Subjects will be provided with 84 capsules of the PQQ or the placebo supplement. Both supplements were in capsule form and identical in size, shape and color. The PQQ content per capsule was 10 mg. The indication was to take two capsules every evening for 6 weeks. The duration of the supplementation protocol was assessed based on a previous study (Hwang et al., 2020), while the dose was chosen according to EFSA recommendations (Turck et al., 2017).
214374906|NCT07148726|OTHER|Placebo|Subjects were provided with 84 capsules of placebo. The indication will be to take two capsules every evening for 6 weeks.
214374907|NCT06520358|OTHER|Acute Intermittent Hypoxia (AIH)|Acute intermittent hypoxia refers to brief (acute), repetitive (intermittent) episodes of breathing oxygen-deprived air (hypoxia) alternating with breathing ambient room air.
214374908|NCT06520358|BEHAVIORAL|Task specific Airway Protection Training|The vLVC maneuver involves training participants to volitionally prolong closure of the laryngeal vestibule during swallowing, beginning with swallow onset and sustaining closure for at least 2 seconds.
214374909|NCT06520358|OTHER|Sham AIH|Sham AIH will be delivered using methods identical to AIH, except a normoxic gas mixture (\~21% O2) will be delivered. The gas mixture with normoxic air will effectively serve as a sham.
214374910|NCT07151391|DRUG|Guarana|500 mg oral medication daily
214374911|NCT07151391|DRUG|Placebo|Oral medication daily
214496155|NCT02622581|OTHER|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
214496156|NCT06358612|OTHER|Stress Balls|Patients in the experimental arm will receive a foam stress ball to squeeze during their biopsy procedure.
214685554|NCT03860844|DRUG|Mitoxantrone|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214685555|NCT03860844|DRUG|Doxorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214987411|NCT05774951|DRUG|Anastrozole|Anastrozole. Comparator. Administered per local approved label
214987412|NCT05774951|DRUG|Letrozole|Letrozole. Comparator. Administered per local approved label
214987413|NCT05774951|DRUG|Exemestane|Exemestane. Comparator. Administered per local approved label
214987414|NCT06555796|DRUG|Xaluritamig|IV infusion
214987415|NCT05692726|OTHER|Patients|Patients will get study-specific measurements within first 5 days of standard of care treatment of hyponatremia or until discharge
214987416|NCT05791643|BEHAVIORAL|Personalized internal and external coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies and external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
214987417|NCT05791643|BEHAVIORAL|Personalized internal coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies from the participant's personalized safety plan.
214987418|NCT05791643|BEHAVIORAL|Personalized external coping strategies|A series of interactive, automated messages will recommend use of the external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
214987419|NCT05791643|BEHAVIORAL|General internal and external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal and external coping strategies for suicidal thoughts.
214374912|NCT07166614|DRUG|dexmedetomidin|Dexmedetomidine is a highly selective α2-adrenergic receptor agonist with sedative, anxiolytic, and analgesic properties. Unlike many other sedatives, it provides sedation without significant respiratory depression, though it may cause bradycardia and hypotension
214374913|NCT07166614|DRUG|Propofol|Propofol is a short-acting intravenous anesthetic agent widely used for induction and maintenance of anesthesia as well as procedural sedation. It provides rapid onset and recovery, but is associated with respiratory depression and hypotension
214374914|NCT07166172|DEVICE|Fetal Treatment Arm (FETO Group)|Participants will undergo FETO surgery between 27 weeks 0 days to 29 weeks 6 days gestation. The FETO intervention involves two procedures: (1) inserting a balloon into the fetal trachea, and (2) removing the balloon before delivery. After the first FETO procedure, participants will be monitored weekly by ultrasound. Removal of the balloon will be performed at 34 weeks 0 days to 34 weeks 6 days. Planned delivery will occur after 37 weeks. The follow-up phase will be conducted from birth to 24 months of age.
214374915|NCT07166627|PROCEDURE|surgical excision of cesarean section scar ectopic pregnancy|surgical excision by laparotomy.
214374916|NCT07166627|PROCEDURE|ultrasound guided evacuation of cesarean section scar ectopic pregnancy|ultrasound guided evacuation of cesarean section scar ectopic pregnancy trans-cervically.
214685556|NCT03860844|DRUG|Vincristine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214374917|NCT07165561|BEHAVIORAL|Smartphone App|This intervention is a mobile app co-created with adolescents who have experienced suicidal thoughts. It is specifically designed for youth aged 12-17 and includes a Safety Plan, tools such as a HopeBox, and psychoeducational content for young people, their loved ones, and care providers. Furthermore, there is a 'Help' button, offering direct access to crisis support. Unlike existing apps for adults, this app is tailored to the developmental needs and lived experiences of adolescents. Access is restricted to study participants to ensure controlled evaluation.
214496157|NCT05211115|PROCEDURE|Split thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the split thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a micro-blade, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
214685557|NCT03860844|DRUG|Pegaspargase (PEG) Asparaginase|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
214496158|NCT05211115|PROCEDURE|Full thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the full thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a fine periosteal elevator, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
214685558|NCT03860844|DRUG|Cyclophosphamide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
214685559|NCT03860844|DRUG|Etoposide|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
214685560|NCT03860844|DRUG|Methotrexate|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
214685561|NCT03860844|DRUG|L - Asparginase|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
214685562|NCT03860844|DRUG|Hydroxyurea|Pharmaceutical form: Solution for injection Route of administration: PO
214685563|NCT03860844|DRUG|L - Asparaginase (Erwinase)|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
214685564|NCT07021573|DEVICE|KINEVO 900 S with BLUE 400|The investigational device consists of a CE marked (MDR) surgical microscope KINEVO 900 S by Carl Zeiss Meditec AG, including the BLUE 400 fluorescence option. This microscope is equipped with an additional component (CALLAO), provided by the Carl Zeiss Meditec AG, that allows for extended, multispectral, image acquisition in the operating room. CALLAO consists of an optical setup with additional cameras, that can be mounted on the main system KINEVO 900 S, and a second light source for specific illumination during image acquisition with the CALLAO cameras.
214685565|NCT06632327|PROCEDURE|Surgical Procedure|undergo surgery
214685566|NCT06632327|DRUG|Cisplatin|Give cisplatin
214987420|NCT05791643|BEHAVIORAL|General internal coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal coping strategies for suicidal thoughts.
214987421|NCT05791643|BEHAVIORAL|General external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) external coping strategies (i.e., sources of social support/distraction) for suicidal thoughts.
214685567|NCT06632327|DRUG|Carboplatin|Give Carboplatin
214685568|NCT06632327|DRUG|Pemetrexed|Give Pemetrexed
214685569|NCT06632327|DRUG|Gemcitabine|Give Gemcitabine
214685570|NCT06632327|DRUG|Docetaxel|Give Docetaxel
214685571|NCT06632327|DRUG|Vinorelbine|Give Vinorelbine
214685572|NCT06632327|DRUG|Nivolumab|Give Nivolumab
214685573|NCT06632327|DRUG|Pembrolizumab|Give Pembrolizumab
214685574|NCT06632327|DRUG|Atezolizumab|Give Atezolizumab
214685575|NCT06632327|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
214987422|NCT05791643|BEHAVIORAL|General internal coping strategies, relaxation|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, relaxation-based) coping strategies for suicidal thoughts.
214685576|NCT06632327|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214685577|NCT06632327|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214685578|NCT06693180|OTHER|HBOT|Hyperbaric Oxygen Therapy
214685579|NCT00968578|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
214685580|NCT00968578|DRUG|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
214685581|NCT05814406|DRUG|JW0201|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
214685582|NCT05814406|DRUG|Placebo|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
214987423|NCT05791643|BEHAVIORAL|General internal coping strategies, distraction|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, distraction-based) coping strategies for suicidal thoughts.
214987424|NCT05791643|BEHAVIORAL|General internal coping strategies, physical activity|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, physical activity-based) coping strategies for suicidal thoughts.
214374918|NCT07164716|OTHER|plantar fascia recovery training group|plantar fascia recovery training group: Gliding massage,Soft tissue mobilization,Metatarsophalangeal Joint Stretching,Foam roller
214374919|NCT07164703|DRUG|Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.|Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.
214374920|NCT07166874|BEHAVIORAL|Gluten Free Diet|Patients in the experimental arm will received a gluten-free diet for 8 weeks.
214685583|NCT06693206|OTHER|Evaluation of aerobic capacity|A stepwise protocol will be used in which the load increases gradually with the bicycle ergometer. In these protocols, the load increases continuously in small amounts throughout the exercise.
214374921|NCT07164352|BEHAVIORAL|Breathing Exercises|Diaphragmatic and pursed-lip breathing exercises supervised by a physiotherapist.
214374922|NCT07164352|BEHAVIORAL|Informational Brochure|A brochure providing education about breathing exercises for cancer patients.
214374923|NCT07166666|DEVICE|atomizer|use atomizer to provide the medication in procedure sedation
214374924|NCT07166666|DRUG|rescue medication|will be used as rescue if the atomizer medication not fully sedated
214685584|NCT07035106|DEVICE|Wearable Health Monitoring|Participants receive a Garmin Vivosmart 5, Garmin Index S2 Smart Scale, and Garmin Index BPM blood pressure monitor for daily health tracking. Devices sync to the Fitrockr mobile application.
214685585|NCT07035106|BEHAVIORAL|Digital Health Summary and Lifestyle Counseling|Participants receive bi-weekly health summaries via email generated from wearable data and may opt in to monthly video-based lifestyle consultations with trained study staff.
214685586|NCT06713213|OTHER|Flow-regulated nasal oxygen delivery system (FRNDS)|"FRNDS is a novel cannula device that can both measure tidal volume (VT) in real time while simultaneously delivering air to the test subject.~After collecting data without any flow through the FRNDS cannula for 2 minutes, varying amounts of medical air ( 21% Fio2) starting with 2 Liters for two minutes , 4 liters for 2 minutes, 6 liters for two minutes and 8 liters for two minutes would be delivered while monitoring and recording data previously described with the FRNDS device."
214685587|NCT06926062|OTHER|Best Practice|Provide vaccinations per usual care
214685588|NCT06926062|OTHER|Educational Intervention|Review messages on safety and side effects
214685589|NCT06926062|OTHER|Educational Intervention|Review messages on vaccine effectiveness
214685590|NCT06926062|OTHER|Educational Intervention|Review messages on sexual activity
214685591|NCT06926062|OTHER|Educational Intervention|Review messages on HPV vaccine for boys
214685592|NCT06926062|OTHER|Educational Intervention|Review message on age to start vaccine
214685593|NCT06926062|OTHER|Educational Intervention|Review messages on school entry requirements
214685594|NCT06926062|OTHER|Interview|Ancillary studies
214685595|NCT06926062|OTHER|Questionnaire Administration|Complete a survey
214374925|NCT07166666|DRUG|Midazolam|Intranasal administration for procedural sedation.
214374926|NCT07166666|DRUG|fentanyl|Intranasal administration for procedural sedation.
214685596|NCT06926062|OTHER|Questionnaire Administration|Ancillary studies
214685597|NCT06926062|BEHAVIORAL|Training and Education|Receive interpersonal communication training
214685598|NCT06926062|BEHAVIORAL|Training and Education|Receive the vaccination workflow training
214685599|NCT06926062|PROCEDURE|Vaccination|Provide vaccinations using the interpersonal communication strategy
214685600|NCT06926062|PROCEDURE|Vaccination|Provide vaccinations using the vaccination workflow training strategy
214374927|NCT07166666|DRUG|Dexmedetomidine|Intranasal administration for procedural sedation.
214374928|NCT07166666|DRUG|Placabo|use atomizer to provide the placebo in procedure sedation
214374929|NCT07164417|OTHER|e-PRF membrane will be used with xenograft simultaneously with implant placement.|Peripheral blood is collected in plain tubes and centrifuged (700-2000 g, 8 min) to separate plasma from red cells. The first 2-4 mL of platelet-poor plasma (PPP) is withdrawn and heated at 75 °C for 10 minutes to form albumin gel, then cooled for 1-2 minutes. Meanwhile, the remaining blood fractions (buffy coat, liquid PRF, red cells) are kept cooled to prevent premature clotting.
214374930|NCT07164417|OTHER|PRF membrane will be used with xenograft simultaneously with implant placement|Peripheral blood is collected in 9-10 mL additive-free tubes and centrifuged horizontally at 700-2000 g for 8 minutes.
214374931|NCT07164170|DRUG|ABSK043 in combination with Glecirasib|"Dose escalation cohort( Part A) ABSK043 150 mg BID in combination with Glecirasib 200 mg QD will be selected as the starting dose.~Based on the accumulated safety data and PK profile, the Safety Review Committee (SRC), composed of the investigator and the sponsor, may discuss and agree to allow exploration of other possible doses.~Dose confirmation cohort (Part B) and Expansion cohort Patients in dose confirmation cohort and expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity.~All patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study."
214685601|NCT06926062|PROCEDURE|Vaccination|Provide vaccinations using both the interpersonal communication strategy and the vaccination workflow training strategy
214685602|NCT06703190|BIOLOGICAL|Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated|Non-interventional observed exposure of the receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation) ≥14 days before testing for SARS-CoV-2
214685603|NCT06703190|BIOLOGICAL|Not vaccinated with 2024-2025 formulated COVID-19 vaccine|The reference group will be no receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation), or any other 2024-2025 formulated COVID-19 vaccine, ≥14 days before testing for SARS-CoV-2.
214685604|NCT04379804|PROCEDURE|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery (ITA).
214685605|NCT04379804|PROCEDURE|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN was identified at the point of entry both visually and with hand held stimulation probe
214685606|NCT06715982|DRUG|JAK Inhibitor|JAK inhibitors for 28 days
214685607|NCT01678807|BIOLOGICAL|MK-8237 6 DU|
214685608|NCT01678807|BIOLOGICAL|MK-8237 12 DU|
214685609|NCT01678807|BIOLOGICAL|Placebo|
214374932|NCT07164586|DIAGNOSTIC_TEST|Respiratory Pattern Monitoring|Respiratory pattern assessment and continuous monitoring will be conducted utilizing the Respiratory Diagnostic Assistant, a device capable of providing comprehensive quantitative evaluation of respiratory variables including frequency, volume, flow rates, inspiratory/expiratory timing parameters, and respiratory entropy analysis, as well as qualitative analysis of respiratory pattern curves for volume and flow dynamics, incorporating entropy measurements for assessment of respiratory pattern complexity and variability.
214374933|NCT07164586|DIAGNOSTIC_TEST|Diaphragmatic Excursion|"Diaphragmatic mobility assessment will be conducted using diaphragmatic ultrasonography, a method capable of providing comprehensive quantitative evaluation of diaphragmatic excursion parameters including range of motion, contraction velocity, muscle thickening during inspiration and expiration, as well as qualitative analysis of diaphragm muscle morphology and echogenicity, incorporating craniocaudal displacement measurements for assessment of contractile function and early detection of diaphragmatic dysfunction."
214374934|NCT07164586|DIAGNOSTIC_TEST|Respiratory muscle electrical activity|espiratory muscle electrical activity assessment will be conducted using surface electromyography, a method capable of providing comprehensive quantitative evaluation of muscle activation parameters including electrical signal amplitude, firing frequency, muscle recruitment patterns during inspiration and expiration, as well as qualitative analysis of synchronization and coordination between respiratory muscles, incorporating Root Mean Square (RMS) measurements and spectral analysis for assessment of respiratory neuromuscular function and detection of muscle fatigue.
214374935|NCT07164586|DIAGNOSTIC_TEST|Respiratory Muscle Strength|Respiratory muscle strength assessment will be conducted using manovacuometry, a method capable of providing comprehensive quantitative evaluation of respiratory muscle force parameters including maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), as well as qualitative analysis of contractile capacity and muscle endurance, incorporating peak pressure measurements and performance indices for assessment of global respiratory muscle function and early detection of muscle weakness
214374936|NCT07164586|DIAGNOSTIC_TEST|Pulmonary Function Assessment|"Pulmonary function assessment will be conducted using spirometry, a method capable of providing comprehensive quantitative evaluation of respiratory function parameters including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio, and forced expiratory flow 25-75% (FEF25-75%), as well as qualitative analysis of flow-volume and volume-time curves, incorporating lung capacity and volume measurements for assessment of respiratory mechanics and early detection of obstructive and restrictive ventilatory disorders."
214374937|NCT07164586|OTHER|Data Acquisition System|The PowerLab C is a biomedical data acquisition system used as an auxiliary tool for physiological monitoring. In this study, it will be employed to collect respiratory signals and diaphragmatic excursion data through specific sensors, integrated with LabChart software for data visualization and analysis. The device is not considered an investigational intervention, but a supporting tool for data collection.
214685610|NCT04805567|DEVICE|endocuff|The Endocuff is a device that can be mounted on the tip of an endoscope and may assist to inspect a greater surface of the colonic mucosa by pulling backwards, flattening, and stretching the colonic folds as the endoscope is gradually withdrawn.
214685611|NCT04527172|DIAGNOSTIC_TEST|neuromuscular ultrasound|ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies
214685612|NCT03306069|OTHER|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
214685613|NCT03306069|OTHER|HIIT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).~HIIT:~* 2 sessions per week~* 5x1 min at 80-95% HRmax~* time-effort per week: \~30 min"
214685614|NCT03306069|OTHER|MIIT-HR|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).~MIIT-HR:~* 2 sessions per week~* 5x1 min at 65-79% HRmax~* time-effort per week: \~30 min"
214987425|NCT03331380|DEVICE|MRI scan - obj 1|For objective 1 (protocol optimization), healthy volunteers undergo imaging using an investigational low SAR CMR scanner for up to two hours, some without and some with administration of intravenous gadolinium based contrast agents (GBCAs).
214987426|NCT03331380|DEVICE|MRI scans - obj 2|For objective 2 (comparative scanning of normals), healthy volunteers undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
214987427|NCT03331380|DEVICE|MRI scans - obj 3|For objective 3 (comparative scanning of patients), subjects with known stable cardiovascular disease undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
215089991|NCT02300597|OTHER|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
215089992|NCT01335750|OTHER|Multipurpose Solution #1|B\&L Renu Fresh Multipurpose Solution
215089993|NCT01335750|OTHER|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
215089994|NCT01335750|OTHER|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
215089995|NCT01335750|OTHER|Multipurpose Solution #4|Saline Solution
215089996|NCT05364736|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks
214374938|NCT07164586|OTHER|Nijmegen Questionnaire|The Nijmegen Questionnaire is a standardized self-report instrument designed to assess symptoms related to dysfunctional breathing and hyperventilation. In this study, it will be administered to evaluate respiratory symptoms and their impact on participants' daily life. The questionnaire is used solely for data collection and is not considered a therapeutic intervention.
214374939|NCT07164586|OTHER|System Usability Scale (SUS)|The System Usability Scale (SUS) is a standardized questionnaire used to evaluate the usability and user experience of systems and devices. In this study, it will be applied to assess participants' perceptions of the usability of an intelligent respiratory monitoring system. The SUS will be used solely as a data collection tool and does not constitute a therapeutic intervention.
214374940|NCT07164586|OTHER|Borg Scale|The Borg Scale is a standardized self-report instrument used to assess perceived exertion and breathlessness during physical activity. In this study, it will be applied to evaluate participants' perception of respiratory effort. The scale is used solely for data collection and is not considered a therapeutic intervention.
214374941|NCT07164586|OTHER|Patient Identification Questionnaire|The Patient Identification Questionnaire is a standardized form used to collect sociodemographic and basic clinical information from participants, such as age, sex, and medical history. In this study, it will serve solely for data collection and will not constitute a therapeutic intervention.
214374942|NCT07164586|DIAGNOSTIC_TEST|Peak Expiratory Flow (PEF) Measurement|Peak Expiratory Flow (PEF) measurement is a rapid and noninvasive method to assess the maximum expiratory volume a participant can achieve after a full inhalation. In this study, participants will be seated upright and use a mouthpiece connected to a peak flow meter. After a deep inspiration, they will exhale forcefully, and three measurements will be taken with at least one minute between attempts; the highest value will be recorded. PEF values provide an objective measure of airflow limitation, correlate with asthma symptoms, and will be used solely for data collection, not as a therapeutic intervention
214374943|NCT07166484|OTHER|Cosmetic product RV2666C LA2984|The product is applied, according to randomization, on an area located on the anterior side of the forearm, following the laser YAG act, once a day and under occlusion from Day 1 to Day 3 included. Then it is applied twice a day in an open way from Day 4 until Day 18 included.
214374944|NCT07165691|BEHAVIORAL|TELESCOPE, Remote Decision Coaching with Navigation Intervention|The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
214374945|NCT07165665|OTHER|Bobath (Neurodevelopmental Treatment) approach|The control group will receive only the standard Bobath (Neurodevelopmental Treatment, NDT) approach.
214374946|NCT07165665|DEVICE|Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS)|The intervention group will receive the standard Bobath (Neurodevelopmental Treatment, NDT) approach combined with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS).
214374947|NCT07165197|DEVICE|Phacoemulsification with implantation of an extended depth of focus intraocular lens|Comparison of two different Extended depth of focus intraocular lenses
214374948|NCT07166822|BEHAVIORAL|Experimental group using BumptUp mobile exercise app|This BumptUp app has been developed specifically for pregnancy with safety and screening feature. This intervention will be unique since the researchers will evaluate the cardiovascular health outcomes following the 8 weeks of intervention.
214374949|NCT07164885|RADIATION|Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)）|RAPART technology is a special combination of ART and RAPRT, with a total course limit of no more than 30 exposures. The entire course of treatment can be divided into two stages: the first stage is completely the same as the conventional radiotherapy group, with a total of 23 doses of 2 Gy per session. The second stage is the combination of ART and PAPRT. ART uses a CT or PET/CT localization simulation to be performed again during the course of treatment (usually after completing the first part of 17-19 exposures) to generate a new adaptive plan, and after completing the first stage of 23 exposures, treatment is carried out according to the new adaptive plan. RAPAT uses ERCC1/2 biomarkers to predict the patient's radiation sensitivity and determine individualized radiation dose accordingly. ERCC1/2 biomarkers divided patients into 5 different radiosensitivity groups, corresponding to 5 different radiation doses (74, 66, 62, 54, and 50 Gy).
214374950|NCT07164885|RADIATION|Conventional radiotherapy|conventional radiotherapy
214374951|NCT07165080|DEVICE|smART+ REE|The two study devices will be used simultaneously: the patient's respiratory equipment will be connected directly to the smART+ REE module, and then the COSMED Q-NRG+ will be connected just downstream of that. See the diagram and key below:
214374952|NCT07165925|BEHAVIORAL|Gamified music training|Instrumental musical training will progress from basic (playing simple notes) to advanced levels (playing an entire song). Key training elements will include fundamental music knowledge and skills, music improvisation, rhythm, and pitch identification exercises. In particular, the core concepts of resilience will be incorporated into the training process through various gamified music activities.
214496159|NCT05211115|PROCEDURE|Autogenous sub epithelial connective tissue graft|Harvest of a sub epithelial connective tissue graft using a double incision technique, approximately 2-3 mm apical to the palatal gingival margins of the first and second premolars. Graft dimension standardised as 10mm (mesio-distally) by 6-8mm (apico-coronally) by 1,5mm (thickness). Graft stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
214496160|NCT05211115|PROCEDURE|Volume stable collagen matrix|Geistlich Fibro-Gide® matrix shaped at a standardised dimension of 10mm (mesio-distally) by 6-8mm (apico-coronally) by 6mm (thickness). Matrix stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
214496161|NCT06824610|DEVICE|capnography|measurment of end-tidal carbon dioxide
214685615|NCT03306069|OTHER|MIIT-LT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).~MIIT-LT:~* 2 sessions per week~* session 1: 2x4 min / session 2: 5x1 min, each at 105% LT~* time-effort per week: \~30 min"
214685616|NCT02645305|BIOLOGICAL|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
214374953|NCT07165925|BEHAVIORAL|Active placebo intervention|Participants in the active placebo control group will participate in weekly 1-hour group-based indoor community leisure activities for 6 months. These activities will include (i) drawing, (ii) drama workshops, (iii) cartoon film screenings, (iv) handcraft workshops, (v) board games, and (vi) exercise classes. Each activity will span for four sessions, that is, totally 24 sessions and will be delivered by trained staff at the study centres of the collaborating non-governmental organisations.
214374954|NCT07166055|OTHER|Therapeutic dance|The protocol includes two sessions per week of therapeutic dance, during the months of October to May.
214374955|NCT07165964|BEHAVIORAL|Personal interventions in Climateric|"The intervention group (IG) will participate in the climacteric care program. Each participant will receive a personal access code to a Moodle-based virtual campus, where they will find specially designed podcasts and videos, provided in addition to standard care. These digital pills have been developed by subject matter experts to support self-care during the climacteric stage and to promote positive mental health (PMH). Each resource is followed by a short quiz to assess engagement, knowledge acquisition, and adherence. A final satisfaction survey will also be included. IG participants will have two months of access to explore the content, complete the quizzes, and interact with the platform.~The intervention includes the following modules:~MODULE 1: INTRODUCTION TO THE CLIMACTERIC/MENOPAUSE MODULE 2: DIETARY HABITS AND PHYSICAL ACTIVITY MODULE 3: PSYCHOEMOTIONAL MANAGEMENT"
214374956|NCT07166146|OTHER|Surgical interventions|By leveraging a wide array of surgical interventions - including endoscopic surgery, minimally invasive surgery combined with urokinase, and craniotomy - the TORCH registry intends to provide a granular view of early hematoma evacuation surgical interventions and their impact on patient recovery and quality of life.
214374957|NCT07165782|BEHAVIORAL|Brief Videos Delivered by Text Message|"The intervention consists of brief videos delivered by text message, designed to deliver psychoeducation, coping strategies, and social support guidance for youth with PTSD. The focus is to reduce avoidance behaviors, increase exposure, change cognitions and enhance social support.~The text messages will follow a six-module curriculum, covering key PTSD recovery topics:~1. Psychoeducation on PTSD - Understanding symptoms, trauma responses, and brain plasticity.~2. Reducing Avoidance - Encouraging gradual engagement with feared thoughts and situations.~3. Cognitive Coping Strategies - Introducing cognitive restructuring techniques.~4. Behavioral Coping Strategies - Teaching relaxation techniques (e.g., deep breathing, grounding).~5. Social Support - Highlighting the role of social support and strategies to strengthen connections.~6. Maintenance and Relapse Prevention - Preparing for setbacks and reinforcing progress."
214374958|NCT07164365|BEHAVIORAL|Interdisciplinary Shared Decision-Making Consultation|One additional face-to-face consultation with a team (oncologist, palliative care, psychologist), following a six-step shared decision-making process.
214374959|NCT07165171|PROCEDURE|Innovative periodontal monitoring (SuP innovative)|"Different types of SMS messages will be sent alternately.~* Type 1 SMS: SMS providing targeted medical information specifically for diabetic patients.~* Type 2 SMS: Interactive SMS text messages written in the form of questions.~* Type 3 SMS: Before each scheduled periodontal follow-up visit (every 3 months), a reminder SMS will be sent with the date, time, and location of the appointment.~The SMS messages are intended for patients in the experimental group. Over these 24 months, the following are planned per patient:~* 1 Type 1 SMS/week (medical advice or information);~* 1 Type 2 SMS/month (interactive with suggested answers);~* 1 Type 3 SMS every 3 months (appointment reminder): 1 per visit. The various text messages will be scheduled from the beginning of the periodontal follow-up."
214374960|NCT07165327|DEVICE|Injection Port for Insulin Administration|For two weeks, participants will use an injection port device for all prescribed insulin doses during pregnancy. The port is inserted and replaced approximately every 3 days. Insulin is delivered through the port using standard syringes or insulin pens, eliminating the need for multiple daily needle sticks.
214374961|NCT07165327|DEVICE|Single-Use Insulin Needles|For two weeks, participants will use standard single-use disposable needles for all prescribed insulin doses during pregnancy. A new sterile needle will be used for each injection, consistent with routine clinical practice.
214374962|NCT07165431|DIETARY_SUPPLEMENT|Postbiotic + nutritional recommendations|Study participants will consume daily one gummy containing a postbiotic formulation, along with adherence to healthy nutritional recommendations for 12 weeks.
214374963|NCT07165431|DIETARY_SUPPLEMENT|Placebo + nutritional recommendations|Study participants will consume daily one gummy containing a placebo formulation, along with adherence to healthy nutritional recommendations for 12 weeks.
214374964|NCT07166653|BEHAVIORAL|HaH education|"The intervention consists of the online NorDigHE HaH education with tailored implementation tools em-bedded in the WHO Fast-IM. The education is delivered online and asynchronously, combining e-learning, simulations, reflection exercises, and practical task training.~The trial has adopted the evidence-based WHO Fast-track Implementation Model (WHO Fast-IM) as a framework to support the effectiveness and reporting of the implementation, and the tailored implementation tools embedded in the model will be provided as part of the intervention to support in-tegration into daily clinical routines. The tailored toolbox consists of workshops, introductory meetings, written guides, and access to a hotline staffed by project specialists to facilitate implementation."
214374965|NCT07166276|OTHER|coffee|The type of coffee consumed, the daily amount of coffee, and the frequency of consumption were measured.
214374966|NCT07165509|DIETARY_SUPPLEMENT|T-2 Nutritional Supplement|"Nutritional supplement labeled T-2; dose 23 g twice daily, as specified in the protocol. Used only in the arm T-2 Supplement + Structured Diet."
214987428|NCT03331380|DEVICE|MRI scans - obj 4|For objective 4 (comparative scanning of patients), subjects with known or suspected disease, including neurological, musculoskeletal disease, abdominal or lung disease, will undergo two MR examinations on two different MRI scanners (investigational low SAR CMR and conventional MR).
214987429|NCT06386601|OTHER|Ergonomics Knowledge|Participants will participate in a lecture/module on surgical ergonomics
214987430|NCT06386601|OTHER|Ergonomics Feedback/Guided Practice|Participants will practice minimally invasive surgical skills while receiving feedback on ergonomic positioning/practice
214987431|NCT04512105|DRUG|Pitavastatin|Given PO
214987432|NCT04512105|DRUG|Venetoclax|Given PO
214987433|NCT05642208|DRUG|Dupilumab step-down|step down dupilumab injections
215089997|NCT05364736|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
214374967|NCT07165509|BEHAVIORAL|Structured Dietary Program|"Rigorous, structured dietary intervention applied according to the study protocol. Used in the arms T-2 Supplement + Structured Diet and Structured Diet Only."
214374968|NCT07164196|OTHER|Angiopoietin-like protein-4 (ANGPTL4) Peritoneal Fluid Level|Measurement of peritoneal fluid levels of Angiopoietin-like protein-4 (ANGPTL4) level by ELISA method.
214987434|NCT01512654|DEVICE|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
214685617|NCT06929455|OTHER|Flavor additives|Various flavors will be added to API samples. The particular APIs and flavor additives to be studied will be determined in part by on-going in work using in vitro taste models (cell systems expressing taste receptor proteins), so there is no full prespecified list.
214685618|NCT06930924|BEHAVIORAL|Parent self-help psychological resource|A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet. Parents will also attend a 60-minute online peer support and information workshop
214685619|NCT06930235|DRUG|Weaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine|• Patients in group I will receive midodrine (10 mg orally every 8 hours) in addition to administered concurrently with ongoing intravenous norepinephrine after being on norepinephrine for more than 24 hrs.
214685620|NCT06930235|DRUG|Weaning critically ill patients from norepinephrine without use of midodrine as an adjuvant|Patients in group II with ongoing intravenous norepinephrine only
214685621|NCT06929728|DEVICE|blood pressure measurments devices|measure arterial blood pressure by arm cuff devises
214987435|NCT01512654|DEVICE|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
214685622|NCT06926023|DEVICE|1550nm non-ablative fractional laser|Treatment with the 1550nm non-ablative fractional laser for female pattern hair loss to the frontal and crown of scalp.
214987436|NCT05934019|DEVICE|EMPATIA 1|The internet-program EMPATIA is hosted on a secure website https://selfhelp.psy.unibe.ch run by the Faculty of Human Sciences and is accessible from any regular internet browser. The software is not CE-marked as it has been developed for research purposes only. EMPATIA consists of 8 sessions and 1 booster session 3 weeks after the last session. It targets transdiagnostic mechanisms that have been identified in several mental disorders in adolescents: behavioral avoidance, repetitive negative thinking including intolerance of uncertainty, emotion, self-critical perfectionism and rejection sensitivity. The contents of EMPATIA are evidence-based and well-established cognitive-behavioral interventions dedicated to the respective transdiagnostic mechanism. The self-help program consists of psychoeducation, cognitive restructuring, relaxation and acceptance-based interventions, exposure and behavioral experiments and behavioral activation as treatment components.
214987437|NCT05305859|DRUG|venetoclax combining chidamide and azacitidine (VCA)|information already included in arm/group descriptions
215089998|NCT05766033|OTHER|Enamel conditioning with a novel etchant paste|The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
215089999|NCT00332865|BEHAVIORAL|Swallowing Exercises|Daily exercises
215090000|NCT02023021|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
215090001|NCT02023021|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
215090002|NCT04478032|DEVICE|deep transcranial magnetic stimulation with H7 coil|low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
215090003|NCT01328340|OTHER|High-speed power training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
215090004|NCT01328340|OTHER|Slow-speed strength training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
214374969|NCT07164196|OTHER|Cancer Antigen 125 (CA-125) Serum Level|Measurement of venous blood serum level of CA-125 level by ELISA method.
214374970|NCT07164196|OTHER|Angiopoietin-like protein-4 (ANGPTL4) Serum Level|Measurement of venous blood serum level of Angiopoietin-like protein-4 (ANGPTL4) Level level by ELISA method.
214374971|NCT07164378|PROCEDURE|Lens-Exchange|The existing IOL will be removed and replaced by implanting SING IMT™ device in the sulcus
214374972|NCT07164378|PROCEDURE|Add-on|The SING IMT™ device will be placed in front of the existing IOL and implanted in the sulcus.
214374973|NCT07165587|DIAGNOSTIC_TEST|Bilateral duplex ultrasonography|Bilateral duplex ultrasound screening performed during hospitalization to detect symptomatic and asymptomatic deep vein thrombosis in patients with pelvic and acetabular fractures.
214374974|NCT07166679|PROCEDURE|root canal treatment with 2% taper|root canal treatment with 2%taper
214374975|NCT07166679|PROCEDURE|root canal treatment with 4% taper|root canal treatment with 4 %taper
214374976|NCT07166679|PROCEDURE|root canal treatment with 6 %taper|root canal treatment with 6 %taper
214374977|NCT06262165|OTHER|Patients with Anorexia Nervosa|Patients with Anorexia Nervosa hospitalized for malnutrition
214685623|NCT06926023|DEVICE|1927 thulium fractional laser|Treatment with the 1927 thulium fractional laser for female pattern hair loss to the frontal and crown of scalp.
214685624|NCT03245632|OTHER|Carbapenem-Resistant Klebsiella pneumoniae|no intervention, this is an obervational study.
214987438|NCT06546332|DEVICE|KeriFuse®|The intramedullary arthrodesis Implant (KeriFuse®) is indicated for consolidation or bone fusion (arthrodesis) of degraded or arthritic distal interphalangeal (DIP) of hand digits or interphalangeal (IP) joint of the hand thumb.
214685625|NCT06679231|BEHAVIORAL|Stress Ball|After the initial measurements of the participants assigned to the experimental group, the students involved in the project will accompany the patient and prepare the patient for the gynecological examination. To make the patient feel more comfortable during the gynecological examination, she will be given two stress balls. The patient will be asked to count each time she squeezes the stress ball during the examination. During the gynecological procedure, the participant will be administered the first EC-3. The stress ball intervention will help to reduce the participant's anxiety level and make the examination process more tolerable. In addition, the student's support to the patient will make the examination more comfortable and contribute to the participant's psychological well-being.
214374978|NCT05398367|DIETARY_SUPPLEMENT|Galactagogue Supplement for Treatment of Low Milk Supply|Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply
214374979|NCT05650164|DRUG|avelumab|as provided in real world practice
214685626|NCT00370149|DEVICE|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
214374980|NCT05650164|DRUG|axitinib|as provided in real world practice
214374981|NCT02044848|DRUG|Secukinumab|
214685627|NCT00370149|DEVICE|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
214685628|NCT01704872|DRUG|ch14.18/CHO|
214685629|NCT04389801|DRUG|Desferal 500 MG Injection|iron chelating agent
214685630|NCT03103269|BEHAVIORAL|Challenge! Small Group Intervention|The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.
214685631|NCT03103269|OTHER|Challenge! Environmental Intervention|The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.
214685632|NCT02719483|DEVICE|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
214685633|NCT02719483|PROCEDURE|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
214685634|NCT03344497|OTHER|VC Group|VC (Conventional Consultation/Video) Group
214685635|NCT00195559|DRUG|Levonorgestrel/Ethinyl Estradiol|
214685636|NCT05295615|DEVICE|ECHS AD Device|Pulsed electromagnetic therapy device
214987439|NCT06486844|DRUG|Vericiguat (Verquvo, BAY1021189)|Vericiguat was given following routine clinical practice.
214987440|NCT04230434|BEHAVIORAL|Safety Plan Intervention|The SPI has 6 key steps: (1) identify personalized warning signs for an impending suicide crisis; (2) determine internal coping strategies that distract from suicidal thoughts and urges; (3) identify family and friends who are able to distract from suicidal thoughts and urges and social places that provide the opportunity for interaction; (4) identify individuals who can help provide support during a suicidal crisis; (5) list mental health professionals and urgent care services to contact during a suicidal crisis; and (6) lethal means counseling for making the environment safer (Stanley \& Brown, 2012)
214685637|NCT04973345|DRUG|Terbutaline|management of asthma symptoms
214374982|NCT02044848|DRUG|Placebo|Placebo
214374983|NCT00045708|DRUG|ixabepilone|Given IV
214685638|NCT02158221|DRUG|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
214685639|NCT00413569|PROCEDURE|cervical spine surgery|
214685640|NCT01461577|DRUG|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
214987441|NCT05691543|PROCEDURE|sacrospinous fixation Using Posterior Vaginal wall flap|"* Identification of the sacro spinous ligament.~* Insertion of the sacrospinous stitch. Using a long - handled needle holder, a J - shaped Ethibond suture is placed 2 - 3 cm medial to the right ischial spine. Using posterior vaginal wall flap (rectangular flap )will be incised and retracted Superior to the right , the stitch of sacro spinous ligament will be attached to the flap not the vault after adjusting its size , then the sit . The stitch should be placed through and not around the ligament. The application of firm traction to the suture length will test the correctness of its placement. A second suture is inserted for additional support. We may do it directly or by using an alternative surgical instruments for placement of the suture include the knee scorpion. Per rectum examination should be undertaken to check for misplaced sutures.~* Attachment of the sutures to the vaginal flap . The two sutures are then secured to the upper posterior aspect of the vaginal flap ,"
214374984|NCT00045708|OTHER|pharmacological study|Correlative studies
214374985|NCT00045708|DRUG|Anticonvulsant|Drugs that induce hepatic Metabolic enzymes
214374986|NCT03114371|DRUG|Oxytocin|The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.
214685641|NCT05110742|DRUG|Fludarabine Phosphate|Given by IV
214685642|NCT05110742|DRUG|Cyclophosphamide|Given by IV
214685643|NCT05110742|DRUG|CAR.5/IL15-transduced CB-NK cells|Given by IV
214374987|NCT03114371|DRUG|Placebo|Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
214374988|NCT03114371|DRUG|Oxytocin|Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.
214374989|NCT01679236|BEHAVIORAL|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
214685644|NCT03272334|DRUG|HER2 BATs with Pembrolizumab|8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
214685645|NCT03404336|BEHAVIORAL|Well-Being Therapy|Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.
214685646|NCT03404336|OTHER|Control condition|Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
214685647|NCT04883437|DRUG|Acalabrutinib|Given PO
214987442|NCT02763566|DRUG|Abemaciclib|Administered orally
214987443|NCT02763566|DRUG|Anastrozole|Administered orally
214374990|NCT01679236|BEHAVIORAL|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
214374991|NCT01266447|BIOLOGICAL|Filgrastim|Given SC
214374992|NCT01266447|OTHER|Laboratory Biomarker Analysis|Correlative studies
214685648|NCT04883437|BIOLOGICAL|Obinutuzumab|Given IV
214987444|NCT02763566|DRUG|Letrozole|Administered orally
214987445|NCT02763566|DRUG|Placebo|Administered orally
214987446|NCT02763566|DRUG|Fulvestrant|Administered intramuscularly
215090005|NCT01473095|DRUG|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
214374993|NCT01266447|BIOLOGICAL|Pegfilgrastim|Given SC
214374994|NCT01266447|DRUG|Topotecan Hydrochloride|Given IV
214374995|NCT01266447|DRUG|Veliparib|Given PO
214987447|NCT01837745|DRUG|rhTSH stimulation|Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
214987448|NCT01837745|DRUG|I131|An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
214987449|NCT01837745|OTHER|Follow up|"* 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~* 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~* 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 4 years (+/- 2 months) after randomization: a serum Tg/LT4~* 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
214987450|NCT06552260|DRUG|Troriluzole|Tripeptide prodrug of Riluzole, 100 mg capsule, taken orally per protocol.
214987451|NCT02855268|DRUG|lademirsen (SAR339375)|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
214987452|NCT02855268|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
214374996|NCT02057289|DRUG|Micafungin|Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
214987453|NCT03008044|DEVICE|FiberSense system|A novel CGM system based on a FiberSense system placed through the dermis of the patient.
214987454|NCT02309021|OTHER|Sport|
214987455|NCT02309021|OTHER|Non-sport activities|
214374997|NCT02890914|OTHER|Transvaginal Ultrasound Educational DVD|"American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®"
214374998|NCT02935049|PROCEDURE|Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD
214374999|NCT05578625|OTHER|plasma circulation DNA methylation sequencing|10 mL of peripheral blood will be drawn from 60 multiple myeloma patients at diagnosis, 4 months post-induction, and at relapse, and cell-free DNA is then extracted and undergo bisulfite methylation sequencing.
214375000|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 0.25 mg, Once daily, 28 days
214375001|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 1.0 mg, Once daily, 28 days
214375002|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 2.5 mg, Once daily, 28 days
214375003|NCT01651273|DRUG|Placebo|Capsules, Oral, 0 mg, Once daily, 28 days
214375004|NCT01369238|DEVICE|Bee Venom Acupuncture Therapy|1:4000, SC 1cc/day, 2\~3days/wk, for 1 month
214375005|NCT01369238|DRUG|zaltoprofen|80mg/Tab, per os 1Tab tid, for 2 months
214685649|NCT04883437|OTHER|Quality-of-Life Assessment|Ancillary studies
214685650|NCT04883437|OTHER|Questionnaire Administration|Ancillary studies
214685651|NCT05914649|OTHER|IV normal saline (999 mL infusion)|999 mL of IV normal saline will be infused intravenously
214685652|NCT05914649|OTHER|IV normal saline (50 mL infusion)|50 mL of IV normal saline will be infused intravenously as a placebo control.
214987456|NCT02823886|OTHER|MRI at D7|The infarct size measured on MRI at 7 days.
214685653|NCT05875038|OTHER|video system|The video surveillance system will analyze the position of subjects in real time using algorithms based on artificial intelligence. The system works continuously without video capture and sends an alert with a photo if a person is lying down after a fall. The alert is confirmed after an operator has checked the photo capture on a dedicated platform.
214685654|NCT05875038|OTHER|Tele-alarm|Tele-alarm
214987457|NCT02823886|BIOLOGICAL|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
214987458|NCT05146739|DRUG|Cytarabine|Given IV and IT
214375006|NCT01025622|BIOLOGICAL|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
214987459|NCT05146739|DRUG|Fludarabine|Given IV
214987460|NCT05146739|DRUG|Leucovorin|Give PO or IV
214987461|NCT05146739|DRUG|Triple Intrathecal Chemotherapy|Given IT
214375007|NCT06203652|OTHER|Real-world regimen|The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
214685655|NCT06785025|BEHAVIORAL|Group-Based Dance Fitness Intervention|This group-based intervention will be conducted with women only. Women enrolled in the study and assigned to the intervention condition will complete 2 30-minute classes per week for 6 weeks. All classes will be held on a university campus and take place during the lunch hour (12:30-1pm). All classes will be led by a certified group fitness leader who is a member of the research team.
214685656|NCT06248593|DRUG|Continuous infusion of Norepinephrine|The rate of norepinephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
214987462|NCT05146739|DRUG|Uproleselan|Given IV
214987463|NCT03142893|DRUG|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
215090006|NCT05890378|OTHER|Testing water|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
215090007|NCT00494559|DRUG|Pioglitazone|Actos 15mg once a day before breakfast
215090008|NCT00494559|DRUG|Placebo|Placebo drug with the same appearance as actos
214375008|NCT00445198|DRUG|ABT-263|"Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~\- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.~Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~\- 40 patients with SCLC"
214375009|NCT01500564|DEVICE|anodal tDCS (device) Eldith DC-Stimulator|tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
214375010|NCT01500564|DEVICE|Sham tDCS|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
214987464|NCT03142893|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
214987465|NCT03142893|DRUG|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
214987466|NCT03142893|DRUG|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
214987467|NCT03142893|DRUG|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
214987468|NCT03142893|DRUG|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
214987469|NCT03142893|DRUG|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
214987470|NCT03142893|DRUG|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
214987471|NCT03142893|DRUG|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
214987472|NCT03142893|DRUG|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
214987473|NCT03142893|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
214987474|NCT03142893|DRUG|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
214987475|NCT06693765|DRUG|AZD4144|AZD4144 will be administered orally.
214987476|NCT04555005|OTHER|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
214987477|NCT05570253|DRUG|Eribulin|Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
214987478|NCT05570253|DRUG|SDX-7320|SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis
214685657|NCT06248593|DRUG|Continuous infusion of Phenylephrine|The rate of phenylephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
214685658|NCT04400318|DRUG|Dupilumab|solution for injection subcutaneous
214987479|NCT05570253|OTHER|Placebo|Placebo
214685659|NCT04400318|DRUG|Placebo|Solution for injection subcutaneous
214685660|NCT06315556|DRUG|Aflibercept (Eylea)|Eylea 40 mg/mL solution for injection in pre-filled syringe.
214987480|NCT06338566|OTHER|Follow-up|Follow-up at D45, 3 months and 6 months, with scoring, radiological monitoring and assessment of wound healing
214987481|NCT03864081|DEVICE|Phase Signal Recorder|The Phase Signal Acquisition (PSAQ) System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms. The PSAQ System consists of two components that work together to acquire and transmit the phase signals and patient specific data to a secured, cloud-based repository. The PSAQ System is comprised of: 1) the Phase Signal Recorder (PSR) which is a portable instrument, and 2) the Phase Signal Data Repository (PSDR) which is a cloud based data repository. Data collected during this study will not be used to guide treatment.
214375011|NCT01988363|PROCEDURE|GON injection at C2 location|GON will be identified at the novel, proximal C2 location on the symptomatic side via ultrasound guidance. Prior to injection, an independent examiner will perform a sensory exam of the involved dermatome. A 25 gauge spinal needle will be inserted into the symptomatic side after locating the GON via ultrasound at the C2 level. Subjects will be injected with treatment medication. Thirty minutes after injection, an independent examiner will test for anesthesia over the desired dermatome. VAS will be assessed pre-injection, 30 post-injection, 2 weeks post-injection and 1 month post-injection. The 2 week and 1 month assessments will be conducted by telephone.
214375012|NCT03861858|BEHAVIORAL|DBT-A|DBT-A is a multimodal therapy which consists of weekly individual therapy, weekly multifamily skills groups, as needed phone coaching, and weekly consultation team for the therapists.
214375013|NCT02166450|DRUG|Nystatin|100 000 IU every 6 h as a suspension
214375014|NCT03237858|DEVICE|HeartLogic ON|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned OFF
214685661|NCT05512130|DRUG|Empagliflozin 25 mg|Participants will take empagliflozin daily for 2 weeks.
214685662|NCT05512130|DRUG|Placebo|Participants will take a placebo daily for 2 weeks. The placebo will be identical to empagliflozin in appearance.
214685663|NCT05871268|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale response are shared with their physician.
214685664|NCT05871268|OTHER|Usual Care|The patients' pre-visit Control Preference Scale response are not shared with their physician.
214685665|NCT05517525|DRUG|Brensocatib|Oral tablet.
214685666|NCT01096446|DRUG|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
214685667|NCT05784948|OTHER|Virtual Reality Mindfulness Treatment|once a week for 30 minutes, over 8 weeks
214685668|NCT05784948|OTHER|Experience relaxing scenery and music|once a week for 30 minutes, over 8 weeks
214685669|NCT03355599|OTHER|3d camera|3 D camera and associated software that introduces measurement and monitoring of wounds as a specific intervention
214685670|NCT00136773|DRUG|amlodipine/benazepril|
214685671|NCT00913718|DRUG|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
214685672|NCT00913718|DRUG|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
214685673|NCT05836532|PROCEDURE|Central edge-to-edge|Suture of free margins of the mitral leaflets in central position to restore coaptation
215090009|NCT03923582|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, LGBT and sexual violence, clinical skills training, ethics and policy writing, and community resources and cultural considerations."
215090010|NCT04533399|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
215090011|NCT04533399|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
214375015|NCT03237858|DEVICE|HeartLogic OFF|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned ON
214496162|NCT06793735|DEVICE|Telerehabilitation with Virtual Reality|Participants assigned to the experimental group will engage in a six-week telerehabilitation program utilizing two non-immersive Virtual Reality (VR) applications, NeuroNation and The Sims Mobile. These apps are designed to enhance cognitive performance and social cognition skills through interactive and scientifically validated exercises. NeuroNation focuses on improving memory, attention, reasoning speed, and mental flexibility, while The Sims Mobile engages participants in realistic social scenarios that challenge their empathy, communication, and problem-solving abilities. The intervention involves three 30-minute sessions per week, which participants will complete remotely using smartphones or tablets. Therapists will provide weekly virtual check-ins to monitor progress, address questions, and ensure adherence to the protocol. This program aims to create an engaging and accessible rehabilitation experience while promoting real-life application of cognitive and social skills improv
214496163|NCT06793735|OTHER|Traditional Cognitive Rehabilitation|Participants in the control group will follow a traditional rehabilitation protocol that relies on paper-based cognitive exercises. This program targets cognitive domains such as attention, memory, and executive functions through tasks like puzzles, memory challenges, and problem-solving activities. The intervention also spans six weeks, with participants completing three 30-minute sessions per week. During an initial session, participants will receive all necessary materials and instructions for completing the exercises independently at home. Therapists will provide weekly remote support via phone or video to track progress and address any concerns. This conventional approach serves as a baseline for comparison with the innovative telerehabilitation method in the experimental group.
214685674|NCT06260644|PROCEDURE|VertiseTM flowable composite (Kerr,USA)|self adhesive flowable resin composite restoration.
214685675|NCT04251208|OTHER|Observational Study|No intervention will be administered.
215090012|NCT03776773|OTHER|Pollution exposure|Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
214375016|NCT01475695|DRUG|14C GSK2251052|1500 mg iv dose GSK2251052
214375017|NCT03812861|OTHER|CAMDS bundle|Cognitive aids for the assessment and management of deteriorating surgical patients (CAMDS). This bundle contains instructions for doctors and nursing staff to assess, manage and escalate care of deteriorating surgical patients. These management instructions will be derived from best practices that are linked with improved mortality and morbidity in surgical patients.
214375018|NCT01160484|DRUG|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
214375019|NCT00803101|BIOLOGICAL|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
214375020|NCT00803101|BIOLOGICAL|Fresh frozen plasma|Intravenous infusion, dosage depending on baseline INR and body weight
214375021|NCT01782742|DRUG|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
214375022|NCT01782742|DRUG|Placebo|
214685676|NCT04721236|OTHER|hyperimmune plasma|plasma collected from convalescent Covid-19 donors with titre 1:80 or more
214685677|NCT06342804|DRUG|4-MUST, 2 tablets, fasted|2 tablets (256 mg), fasted
214685678|NCT06342804|DRUG|4-MUST, 2 tablets, after meals|2 tablets (256 mg), after meals
214685679|NCT04002154|DEVICE|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
214685680|NCT01810198|PROCEDURE|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
214685681|NCT01810198|PROCEDURE|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
214685682|NCT00092040|DRUG|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
214685683|NCT00092040|DRUG|Comparator: risedronate / Duration of Intervention: 12 mo|
214685684|NCT00000728|DRUG|Zidovudine|
214685685|NCT00000728|DRUG|Aldesleukin|
214685686|NCT00003207|DRUG|pegylated liposomal doxorubicin hydrochloride|
214685687|NCT00003207|DRUG|PSC 833|
214685688|NCT00246467|BIOLOGICAL|Alhydrogel|
214685689|NCT00246467|BIOLOGICAL|rF1 and rV protein antigens|
214685690|NCT06200987|DEVICE|Penile vibrator|In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
214685691|NCT01043185|DRUG|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
214685692|NCT01043185|DRUG|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
214685693|NCT01043185|DRUG|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
214685694|NCT01043185|DRUG|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
214685695|NCT01043185|DRUG|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
214685696|NCT05214781|PROCEDURE|modified radical mastectomy|excision of the whole breast tissue including nipple and skin with axillary clearance
214685697|NCT01996306|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
214685698|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
214685699|NCT01996306|DRUG|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
214685700|NCT01996306|DRUG|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
214685701|NCT01996306|DRUG|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
214685702|NCT01996306|BIOLOGICAL|bevacizumab|7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
214685703|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
214685704|NCT01996306|DRUG|Capecitabine|1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
214685705|NCT03165591|BIOLOGICAL|V3-P|one tablet of V3-P given once daily for 2 months
214685706|NCT03971084|OTHER|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
214685707|NCT03971084|OTHER|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
214685708|NCT02242227|DRUG|Salmeterol xinafoate|
214987482|NCT02687802|OTHER|mechanical ventilation|we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
214393836|NCT04142463|OTHER|Care pathway|A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
214987483|NCT00213681|DEVICE|Boussignac CPAP - bilevel ventilation support|
214987484|NCT02244632|DRUG|Modufolin (arfolitixorin)|IV injection every second week for 8 weeks.
214987485|NCT02244632|DRUG|Fluorouracil|IV injection every second week for 8 weeks.
214987486|NCT02244632|DRUG|Oxaliplatin|IV infusion every second week for 8 weeks.
214393837|NCT05473091|OTHER|no intervention|retrospective analysis
214685709|NCT02242227|DRUG|Serevent® Diskus®|
214685710|NCT02242227|DRUG|Placebo (HandiHaler®)|
214685711|NCT02242227|DRUG|Placebo (Diskus®)|
214685712|NCT04077307|DRUG|Karonudib|First part of the study - four different dose cohorts Extension part of the study - karonudib BID (twice a week) and Idarubicin days 1-3.
214685713|NCT01697527|BIOLOGICAL|aldesleukin|Given SC
214685714|NCT01697527|DRUG|fludarabine phosphate|Given IV
214685715|NCT01697527|DRUG|cyclophosphamide|Given IV
214685716|NCT01697527|OTHER|laboratory biomarker analysis|Correlative studies
214685717|NCT01697527|BIOLOGICAL|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
214685718|NCT01697527|BIOLOGICAL|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
214685719|NCT01697527|RADIATION|fludeoxyglucose F 18|Undergo PET scan using \[18F\] FDG tracer
214685720|NCT01697527|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F18 PET
214685721|NCT00082706|DRUG|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
214685722|NCT00082706|DRUG|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
214685723|NCT00082706|DRUG|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
214685724|NCT00082706|DRUG|Gemcitabine|Day: 1 \& 5 Dose: 200 mg/m2 (Two doses only)
214685725|NCT01104558|DRUG|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
214685726|NCT02211976|DRUG|Bisacodyl|
214685727|NCT02211976|DRUG|Simeticone|
214685728|NCT03766724|DRUG|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD
214685729|NCT03766724|DRUG|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin|Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD
214685730|NCT03766724|DRUG|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD
214987487|NCT02244632|DRUG|Irinotecan|IV infusion every second week for 8 weeks.
214987488|NCT02244632|DRUG|Bevacizumab|IV infusion every second week for 8 weeks.
214987489|NCT02016326|DEVICE|HD Colon|High Definition White Light
214987490|NCT02016326|DEVICE|I-scan 1|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
214375023|NCT03578614|OTHER|Physical Activity|"3 physical activity sessions are planned by week, 2 supervised and 1 non-supervised conducted over 6 months. On the first 2 months, the supervised sessions have 10 minutes of warm-up + 5 minutes active pause (balance, agility and coordinative exercises) + 15 minutes walking + 5 minutes active pause (resistance exercises - 1 series of 12 repetitions~\- 3 callisthenic exercises) + 15 minutes walking + 5 minutes flexibility (1 series of 10 seconds in 3 different postures). The aimed intensity in these first two months is 12/13. Between the 2nd and the 4th months, the duration of the walking period increases, as well as the intensity, RPE 13/14. Between the 4th and the 6th months, again the duration of the walking period increases, as well as the intensity, RPE 14/15. To measure the intensity level of the physical activity, the Borg Rating of Perceived Exertion (RPE) ranging from 6 (rest) to 20 (maximum effort) is used."
214496164|NCT06751004|OTHER|BALLISTIC SIX EXERCISES|Ballistic six exercises will be given to group A and exercises of 3 sets of 10-20 repetitions will be completed, with each series offering 30-60 seconds of rest. The ballistic Six exercise uses resistance-band latex tube and fitness balls.
214496165|NCT06751004|OTHER|RESISTANCE-BAND EXERCISES|Resistance-band exercises will be given to group B and the duration of training sessions will be 3 sets of 10-20 repetitions
214496166|NCT05843708|DRUG|Vorasidenib 40 mg Oral Tablet|"Single oral dose of 1×40 mg vorasidenib tablet administered :~* under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~* or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)"
214987491|NCT02016326|DEVICE|I-Scan 2|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
214987492|NCT00797758|OTHER|Cord blood transplantation|Umbilical cord blood transplantation after reduced intensity conditioning
214685731|NCT03766724|DRUG|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin|Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD
214685732|NCT05131880|OTHER|Gait Re-education Program Using the Fisior® Mat Sequential Training System in Subjects with Parkinson's Disease|"Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR®- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition."
214685733|NCT06490315|BEHAVIORAL|OkeyMind intervention|The intervention group will receive a one-month mobile psychoeducation program (OkeyMind), which includes both psychoeducation and meditation components, with all content fully automated.
214987493|NCT00914069|DEVICE|RIVS vascular access|Access to peripheral vasculature
214987494|NCT00914069|DEVICE|Conventional vascular access|Vascular access using conventional venous access device
214685734|NCT06490315|BEHAVIORAL|Wait-list control|Participants in the waiting list control group will withhold access to the OkeyMind intervention until after the 3-month follow-up assessment.
214685735|NCT03395197|DRUG|Talazoparib with enzalutamide|Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
214685736|NCT03395197|DRUG|Placebo with enzalutamide|Placebo plus enzalutamide 160 mg/day
214987495|NCT00639509|BIOLOGICAL|cixutumumab|Given IV
214987496|NCT00639509|PROCEDURE|computed tomography|Undergo contrast-enhanced computed tomography
214987497|NCT00639509|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced magnetic resonance imaging
214987498|NCT00557232|DRUG|bevacizumab|1.25mg/month
214987499|NCT00295802|DEVICE|Integrated Imaging High Intensity Focused Ultrasound|
214987500|NCT00295802|DEVICE|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
214987501|NCT04773132|OTHER|Low Protein|Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
214987502|NCT00683137|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
214987503|NCT00683137|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
214987504|NCT00683137|DRUG|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
214987505|NCT04087772|BEHAVIORAL|Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH)|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
214987506|NCT04087772|BEHAVIORAL|Racial/Ethnic Discrimination Interventions (RED)|Racial/Ethnic Discrimination Interventions are a set of components to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
215090013|NCT04306289|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.
214987507|NCT05818787|BEHAVIORAL|Roll Tilt Training|The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a three second period of rest will be given. Each day of training will include four blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Insert earbuds (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
215090014|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - ALS|"ALS patients will be administered the following TBCS tests:~* ALS Cognitive Behavioral Screen-Phone Version;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Caregiver Behavioral Questionnaire;~* ECAS-Carer Interview."
215090015|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD|"AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory."
214375024|NCT05040022|DRUG|Pneumoperitoneum pressure 10 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
214375025|NCT05040022|DRUG|Pneumoperitoneum pressure 14 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
214375026|NCT00184483|PROCEDURE|Lichtenstein's operation|Lichtenstein's operation to repair primary unilateral inguinal hernia
214375027|NCT00184483|PROCEDURE|Prolene Hernia System|Prolene Hernia System to repair primary unilateral inguinal hernia
214375028|NCT03091647|BEHAVIORAL|acupressure intervention|Women in the acupressure intervention group will learn how to press three chief energy acupoints on each side of the body through an 11-minute Chinese-language video and press three acupoints (1 minute per acupoint) on both sides of the body every day for a total of 6 minutes per day for an 8-week intervention period and record their practice on daily logs. Women will be asked to return the logs every week by email or self-addressed envelopes.
214375029|NCT03091647|BEHAVIORAL|usual care|Women in the usual care group will receive primary and oncology care from their doctors as usual, and complete daily logs recording their fatigue and daily functioning levels. They also need to return the logs every week by email or self-addressed envelopes.
214375030|NCT05085821|DEVICE|HEART|In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
214496167|NCT05843708|DRUG|Ciprofloxacin 500 mg Oral Tablet|Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
214496168|NCT05843708|DRUG|Vorasidenib 10 mg Oral Tablet|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
214496169|NCT06831721|BEHAVIORAL|Unstable Strength Training|Sixty-two participants were divided into an experimental group and a control group. 31 participants in the experimental group were in an unstable condition, with the help of unstable equipment such as BOSU balls, balance capsules and Swiss balls. The training program was designed according to the actual situation and characteristics of the participants to meet the characteristics of the volleyball sport. The remaining 31 participants in the control group underwent a conventional strength training routine.
214496170|NCT06765278|OTHER|Interscalene brachial plexus block|Patients will receive an Interscalene brachial plexus block.
214496171|NCT06765278|OTHER|Anterior glenoid nerve block|Patients will receive an anterior glenoid nerve block.
214496172|NCT06765278|OTHER|Pericapsular nerve group block|Patients will receive a pericapsular nerve group (PENG) block.
214496173|NCT04041050|DRUG|Navitoclax|Tablet; Oral
214496174|NCT04041050|DRUG|Ruxolitinib|Tablet; Oral
214496175|NCT04041050|DRUG|Celecoxib|Capsule; Oral
214496176|NCT06773988|DIAGNOSTIC_TEST|Monitoring of NIV at home|Monitoring of NIV at home
214496177|NCT06779656|DEVICE|General Anesthesia (GA)|Following administration of the regional anesthesia, general anesthesia with endotracheal intubation will be performed. Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
214496178|NCT06779656|PROCEDURE|Paravertebral Block (PVB)|The patient will be positioned in the lateral decubitus position with the operative side up. A high-frequency ultrasound probe (6-13 MHz) will be used to visualize the transverse processes, ribs, and pleura adjacent to the thoracic transverse processes on the operative side. Under ultrasound guidance, a needle will be inserted from posterior to anterior, advancing just superior to the tip of the transverse process, 1-2 mm, avoiding the pleura, and entering the paravertebral space. For ropivacaine, either 0.375% or 0.5% will be administered at a dose of 3-5 mL per segment, according to the patient's height and the extent of surgery. The block will target the T2-T6 nerve distribution, with a total dose not exceeding 20 mL. Alternatively, for liposomal bupivacaine (10-26.6 mg/mL), the dose will be determined based on the patient's weight and surgical extent, typically a total dose of 100-200 mg, diluted with normal saline to a total injection volume of 10-20 mL.
214685737|NCT05137041|DEVICE|ITP FIRTECH|Infrared Therapy Patch
214685738|NCT05946135|DRUG|Lansoprazole|taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks
214987508|NCT05818787|BEHAVIORAL|Translation Training|The participants will be translated and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject responds, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the translation stimulus. After each trial, a three second period of rest will be given. Each day of training will include four blocks of one hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Insert earbuds (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
215090016|NCT06337578|BEHAVIORAL|Telephone-based and in-person cognitive screening - NIs|"NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners:~* Mini-Mental State Examination~* Montreal Cognitive Assessment~* In-Person Telephone Interview for Cognitive Status in person."
215090017|NCT03518346|BEHAVIORAL|Virtual Reality|Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
215090018|NCT03518346|BEHAVIORAL|Standard of Care|Books, movies, TV
215090019|NCT03217032|BIOLOGICAL|YUVA-GT-F801|Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
214496179|NCT06779656|PROCEDURE|Rhomboid Intercostal and Subserratus Plane Block (RISS)|The patient will be positioned in the lateral decubitus position with the operative side up. A high-frequency ultrasound probe will be used to locate the medial border of the scapula and identify the rhomboid, intercostal, and serratus anterior muscles. Under ultrasound guidance, the needle will be advanced into the plane between the rhomboid and intercostal muscles, or the plane between the intercostal and serratus anterior muscles. Ropivacaine 0.25% will be administered with an injection volume of 15-20 mL. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered according to the manufacturer's recommended dosage, usually a total dose of 100-200 mg, with an injection volume of 15-20 mL.
214496180|NCT06779656|PROCEDURE|Pectoral Nerves Block II (PECS II)|The patient will be placed in the supine position with the operative side arm slightly abducted. A high-frequency ultrasound probe will be used to locate the pectoralis major, pectoralis minor, and serratus anterior muscles. Under ultrasound guidance, the needle will be advanced into the plane between the pectoralis minor and serratus anterior muscles. Ropivacaine 0.25% will be administered with an injection volume of 20-30 mL. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered according to the manufacturer's recommended dosage, usually a total dose of 100-200 mg, with an injection volume of 20-30 mL.
214496181|NCT06779656|PROCEDURE|Intercostal Nerve Block (INB)|The patient will be positioned in the lateral decubitus or supine position. A high-frequency ultrasound probe will be used to locate the ribs and intercostal muscles. Under ultrasound guidance, the needle will be advanced to the inferior margin of the rib, in the intercostal muscle plane. Ropivacaine 0.25% will be administered at a dose of 2-5 mL per intercostal space, typically targeting 3-5 intercostal spaces. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered at a dose of 2-5 mL per intercostal space, with a total dose not exceeding 200 mg, and a total injection volume of 5-20 mL.
214685739|NCT05946135|DRUG|Fexuprazan Hydrochloride|taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks
214685740|NCT02856581|DRUG|Varenicline|Given PO
214685741|NCT02856581|DRUG|Placebo|Given PO
214685742|NCT02856581|OTHER|Tobacco Cessation Counseling|Complete counseling session
214685743|NCT01041690|DRUG|Bevacizumab|
215090020|NCT02350387|PROCEDURE|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
215090021|NCT02350387|PROCEDURE|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
215090022|NCT02827500|DRUG|ivabradine|Active Comparator: ivabradine
215090023|NCT02827500|OTHER|Usual Care|Placebo Comparator: usual care
215090024|NCT04947306|DEVICE|Tetragraph® (Senzime, Uppsala, Sweden)|The Tetragraph® is a recently marketed electromyographic neuromuscular monitor that uses a disposable electrode array (TetraSens) that combines stimulating and recording electrodes
215090025|NCT04947306|DEVICE|TOF Watch® SX (Organon Teknika B.V., Boxtel, Holland)|The TOF Watch® SX is a common used neuromuscular monitor
215090026|NCT04139720|BEHAVIORAL|e-book|sexual harassment prevention via education e-book
215090027|NCT00913614|DRUG|Eplivanserin (SR46349)|Oral administration
215090028|NCT02032342|DEVICE|Endobronchial double lumen tube|Endobronchial double lumen tube for one lug ventilation
215090029|NCT02032342|DEVICE|Arndt® blocker|Arndt® blocker for selective lobar deflation
215090030|NCT02032342|DEVICE|Cohen blocker|Cohen blocker for selective lobar deflation
215090031|NCT02032342|DEVICE|Fuji Uni-blocker|Fuji Uni-blocker foe selective lobar deflation
215090032|NCT00990912|DRUG|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
214987509|NCT05818787|BEHAVIORAL|Both Tilt and Translation Training|The participants will be equally tilted and translated and asked to indicate their perceived direction of self-motion (e.g., left or right) . Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject responds. After each trial, a three second period of rest will be given. Each day of training will include four blocks; 2 blocks of roll tilt and 2 blocks of translation - one hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Insert earbuds (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
214685744|NCT02073435|BEHAVIORAL|Donor pain management|"The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~* Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~* Bowel preparation (e.g. Colace or Golytely)~* Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~* Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~* I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is \> 500cc)~* I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~* NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~* Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression"
214685745|NCT05039580|DRUG|PD-1 monoclonal antibody|PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.
214685746|NCT03742401|PROCEDURE|Surgery|Traditional open excisional surgery
214685747|NCT03742401|DEVICE|HIFU (Echopulse)|High intensity focused ultrasound (HIFU) non invasive intervention
214685748|NCT03046628|DEVICE|TcPO2|
214685749|NCT03046628|DEVICE|Green laser (at 532nm) and a fast camera|
214685750|NCT01710111|DEVICE|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
214685751|NCT06128798|DIETARY_SUPPLEMENT|Oral Impact|A serving of 74 gm (containing 309 kcal ) of oral impact mixed with 250 ml of water. Each participant will receive total of 3 servings daily for 7 days pre operatively .
214685752|NCT06128798|DIETARY_SUPPLEMENT|Nutren Optimum|A serving of 66.8 gm ( containing 304 kcal ) of nutren optimum mixed with 300 ml of water.Each participant will receive total of 3 servings daily for 7 days pre operatively .
214685753|NCT00510224|DRUG|Sandostatin|Sandostatin 30mg intramuscular every 28 days
214987510|NCT05818787|BEHAVIORAL|Placebo Control|Participants will complete home-based exercises that are not associated with improving vestibular perception or balance (e.g. saccades, smooth pursuit). Participants will sit in a comfortable chair facing out into a living space. They will then find a stationary object to the right and to the left of themselves as well as above and below their line of sight. Without moving their heads, they will look back and forth and up and down between the objects. Participants will complete a total of 400 eye motions per day for six days.
214987511|NCT06003400|DEVICE|Study treatment administration (TriO FITT)|Patients will be treated with the study device 2-3 times per week (determined by their wagner score) for an hour at each visit. treatment will include a combination of methods (the exact details is patented by the company and can not be elaborated).
214987512|NCT06003400|DIAGNOSTIC_TEST|Physical Examination|physical examination will include an overall examination of the patient's body for any iregular findings and or physical changes from baseline.
215090033|NCT00990912|DRUG|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
215090034|NCT00990912|DRUG|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
215090035|NCT04451824|DEVICE|CL-100|Red Light LED device for circumferential reduction
214987513|NCT06003400|DIAGNOSTIC_TEST|Vital Signs|vital signs measurement will include blood pressure, pulse and oral temperature as well as hight and weight.
214987514|NCT06003400|DIAGNOSTIC_TEST|Hematology Blood Tests|complete CBC, coagulogram (PT, aPTT); D-dimer; C-reactive protein;; Ferritin; fibrinogen,
214987515|NCT06003400|DIAGNOSTIC_TEST|Biochemistry Blood Test|urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides).
215090036|NCT04488744|DRUG|Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s|Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
215090037|NCT00138112|DRUG|Empirical Vancomycin|
215090038|NCT00138112|DRUG|Prophylactic Vancomycin|
215090039|NCT04498377|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
215090040|NCT04498377|BIOLOGICAL|Placebo|Placebo administered intravenously
214375031|NCT05085821|DEVICE|Placebo|In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
214375032|NCT00002635|BIOLOGICAL|filgrastim|
214375033|NCT00002635|DRUG|aminocamptothecin|
214375034|NCT02757924|OTHER|Infant formula supplemented with prebiotics|Sole source nutrition
214375035|NCT00012038|DRUG|irofulven|
214375036|NCT00133757|DRUG|Bupropion SR|
214685754|NCT01585935|DRUG|SMOFLIPID|target dose: 3g/kg/d
214685755|NCT01585935|DRUG|INTRALIPID|target dose: 3g/kg/d
214685756|NCT01666418|DRUG|Pazopanib/Paclitaxel|
214685757|NCT05372341|OTHER|descriptive|posotcovid patients will be elective surgery postoperative outcomes
214685758|NCT03281772|OTHER|Clinical Decision Software - provider portal|As noted in Arms
214685759|NCT03281772|OTHER|Clinical Decision Software - patient portal|As noted in Arms
214685760|NCT04798261|DEVICE|Indigo Aspiration System|Indigo Aspiration System
214685761|NCT01808118|BIOLOGICAL|adalimumab|40 mg every other week
214685762|NCT01808118|BIOLOGICAL|Placebo|every other week
214685763|NCT06629142|BEHAVIORAL|Default Order|A specialist PC consult is automatically ordered for patients meeting a certain threshold of 1-year mortality risk (dependent on arm). An EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
214685764|NCT06629142|BEHAVIORAL|Accountable Justification|An EHR-based Our Practice Advisory alert asks generalist clinicians to self-report whether they have provided primary PC by clicking which of 4 key PC domains they have addressed or to provide a brief justification as to why not.
214685765|NCT06629142|BEHAVIORAL|Standardized Usual Care|Moderately high-risk patients (e.g., with a 1-year mortality risk between 60% and 94%) will receive usual care. For very high-risk patients (e.g., with a 1-year mortality risk of ≥ 95%), an EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
214987516|NCT06003400|DIAGNOSTIC_TEST|Wound Digital Photography|3 photographs of the wound taken before wash, after wash and after treatment.
214685766|NCT00921505|DRUG|Ibuprofen|Tablet ibuprofen 400 mg oral single dose (1 tablet)
214685767|NCT00921505|DRUG|Ibuprofen|Tablets (2 x 600 mg) oral single dose (2 tablets)
214375037|NCT04705064|DIAGNOSTIC_TEST|Prediction of postoperative acute kidney injury using an artificial intelligence|The performance of an artificial intelligence model to predict postoperative acute kidney injury will be tested prospectively.
214496182|NCT06779656|PROCEDURE|Serratus Anterior Plane Block (SAPB)|The patient will be positioned in the lateral decubitus or supine position with the operative side arm slightly abducted. A high-frequency ultrasound probe will be used to locate the serratus anterior muscle. Under ultrasound guidance, the needle will be advanced either superficial or deep to the serratus anterior muscle. Ropivacaine 0.25% will be administered with an injection volume of 20-30 mL. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered according to the manufacturer's recommended dosage, usually a total dose of 100-200 mg, with an injection volume of 20-30 mL.
214496183|NCT06779656|PROCEDURE|Epidural Block|The patient will be positioned in the sitting or lateral decubitus position. The area will be prepped and draped using standard aseptic technique. Either the thoracic or lumbar region will be selected, with the T4-T5 level often chosen. An epidural needle will be inserted into the epidural space, and an epidural catheter will be placed, using standard epidural techniques. Ropivacaine 0.1% or 0.083% will be administered as an initial bolus of 5-10 mL, followed by a continuous infusion at a rate of 5-10 mL/h. Alternatively, bupivacaine 0.1% or 0.0625% will be administered as an initial bolus of 5-10 mL, followed by a continuous infusion at a rate of 5-10 mL/h. These can be used in combination with opioid medications such as fentanyl or sufentanil to enhance analgesia.
214496184|NCT06757738|DRUG|TRX-100|CEN inhibitor, dosage form - capsules, dosing regimen - QD
214496185|NCT06757738|DRUG|Placebo|Placebo, dosage form - capsules, dosing regimen - QD
214496186|NCT06636487|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 3 - 5 patients who exercise at home and communicate via tablet-camera. Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks.~Specific exercises are evidence-based; been used in several intervention studies on patients with CRD (eg. COPD). Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations. The education sessions consist of dialogue, reflections around empowerment and better living with CRD. Every sixth education session consists of 25 min Mindfulness exercises developed for CRD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
214685768|NCT00921505|DRUG|Paracetamol (acetaminophen) 1000 mg|Tablets (2 x 500 mg) oral single dose (2 tablets)
214685769|NCT00921505|DRUG|Paracetamol + ibuprofen|Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
214685770|NCT02929095|DRUG|dexmedetomidine|
215090041|NCT02308488|RADIATION|Intensity-modulated radiation therapy (IMRT)|Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
214375038|NCT01437150|DEVICE|Anatomical locking plate|This is a new fixation treat for acetabular posterior wall fracture.
214685771|NCT02929095|DRUG|midazolam|
214685772|NCT02929095|DRUG|remifentanil|\- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
214685773|NCT03074513|DRUG|Atezolizumab|Given IV
214685774|NCT03074513|BIOLOGICAL|Bevacizumab|Given IV
214685775|NCT03074513|OTHER|Laboratory Biomarker Analysis|Correlative studies
214685776|NCT03074513|OTHER|Pharmacological Study|Correlative studies
214375039|NCT01437150|PROCEDURE|The Reconstructive Plate|Reconstructive plate was used very common in treatment of acetabular fracture.
214375040|NCT04889235|PROCEDURE|Major liver resection|All patients undergo Major hepatic resection, differences between sarcopenia and no-sarcopenia groups will be observed
214375041|NCT04490135|BEHAVIORAL|Group psychotherapy|As described above
214685777|NCT01102153|DEVICE|Coolgard|invasive cooling via femoral ICY-catheter
214685778|NCT01102153|DEVICE|ArcticSun|non-invasive surface cooling by saline-cooled thermo-vest
214987517|NCT06003400|DIAGNOSTIC_TEST|Urine pregnancy test|for women with childbearing potential
214987518|NCT06003400|OTHER|Visual Analogue Scale|Visual Analogue Scale - visual scale scoring 1-10 measuring pain, 10 being worst pain.
214987519|NCT06003400|OTHER|SF-36|SF-36 - quality of life questionnaire scaling from 0-100, 100 being best quality of life.
214987520|NCT06003400|DIAGNOSTIC_TEST|Wounds evaluation|including size measurements and visual description.
214987521|NCT06511778|DRUG|Hemoblast Bellows application|Hemoblast bellows is a hemostatic agent clinically proven effective on the validated SPOT GRADE scale for minimal, mild, and moderate bleeding. Patients will have the Hemoblast bellows applied during on pump sternotomy surgery.
214685779|NCT02752425|DEVICE|Visual feedback|Use of ultrasound echography for tongue articulatory visual feedback
214496187|NCT06636487|BEHAVIORAL|Home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle endurance based exercise; 3-days/weekly for 10-weeks. Exercises are evidence based; used in several intervention studies on patients with CRD (eg. COPD) and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of access to mindfulness exercises and an educationbook. The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to CRD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
214987522|NCT03275506|DRUG|Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
214987523|NCT03275506|DRUG|Chemotherapy - Bevacizumab|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
214987524|NCT05729347|BEHAVIORAL|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
214987525|NCT02504164|DRUG|midazolam 0.02mg/kg|
214987526|NCT02504164|DRUG|No premedication|No premedication before sedation for endoscopic submucosal dissection
214987527|NCT02325778|PROCEDURE|CTI ablation Timing|The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
214987528|NCT03039075|DRUG|Metformin SR Tablet|Metformin SR Tablet made in Conquer pharmaceutical co., LTD
214987529|NCT05735340|BEHAVIORAL|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
214987530|NCT05735340|BEHAVIORAL|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
214987531|NCT06458530|BEHAVIORAL|Vivo|Participants will meet virtually twice a week with their small group and certified trainer for 45 minutes exercise sessions for a 12-week period.
214685780|NCT06253286|DEVICE|clear aligner treatment for orthodontics patients|patient are instructed to wear aligners
214685781|NCT02306707|PROCEDURE|Endoscopic Mucosal Resection|
214685782|NCT04631120|OTHER|Integrated Dementia Practice Unit Design|"* Dementia Central: monthly review of participant progress~* Dementia Mobile: monthly nurse/lay health educator visits for assessments, education and coaching~* Dementia Link: communication between Dementia Central and Dementia Mobile using the eTransX mHealth platform and HealthStream educational interface for care providers and the patient/caregiver dyad."
214685783|NCT04631120|OTHER|Standard of Care|Standard clinical practices of the physician and institution including an initial assessment, Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard patient- and caregiver-centered educational material. Two phone sessions with a study nurse post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment.
214685784|NCT05883592|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
215090042|NCT01541917|BEHAVIORAL|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
214496188|NCT06636487|BEHAVIORAL|Control|Receive usual care; medication, scheduled follow up visit and possible phone contact with GP and the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered. If a patient changes their decision and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
214496189|NCT06477536|DRUG|HB0034|300mg, i.v. Q4W
214496190|NCT06117436|DRUG|Cilostazol|Cilostazol 100 MG oral tablet once daily antiplatelet, Selenium 200mcg tablet once daily, anti oxidant
214685785|NCT00615290|DRUG|tipranavir|
214987532|NCT06285825|DRUG|Emapalumab|Given by Infusion
214987533|NCT06154278|DRUG|Imdusiran (AB-729)|60mg subcutaneously, every 8 weeks, for a total of 4 doses
215090043|NCT01541917|BEHAVIORAL|Online disease education|"The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease."
214496191|NCT06117436|DRUG|Selenium|Selenium 200 mcg oral tablet once daily
214496192|NCT06830421|DRUG|R-MP and Procarbazine maintenance|Firstline systemic treatment with conventinal immunochemotherapy (3 cycles of Rituximab-MTX-Procarbazine) followed by Procarbazine maintenance
214685786|NCT02778516|DIETARY_SUPPLEMENT|Sodium Restriction|
214685787|NCT02220348|DRUG|linaclotide|
214685788|NCT02684019|DRUG|Dexmedetomidine|added to propofol sedation
214685789|NCT02684019|DRUG|Magnesium Sulphate|added to propofol sedation
215090044|NCT00047619|PROCEDURE|Pulsatile Lavage|pulsatile lavage to wound bed
215090045|NCT00047619|OTHER|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
215090046|NCT00659503|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
215090047|NCT00659503|DRUG|Placebo|placebo
215090048|NCT02421913|DRUG|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
214375042|NCT02098408|BEHAVIORAL|Cognitive remediation|"Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.~The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients."
214375043|NCT02098408|BEHAVIORAL|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
214375044|NCT02767583|DEVICE|Exams|Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
214375045|NCT02623816|DRUG|Optimal Dosing of Omeprazole|Omeprazole 20 mg
214375046|NCT01679301|DEVICE|Pulse Dose (Sleep Mode)|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
214375047|NCT01679301|DEVICE|Continuous Dose|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
214375048|NCT02852122|DRUG|C-11 choline|This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA \> 20 ng/mL, or Gleason score 8-10, or clinical stage \>T2c) would be included.
214375049|NCT06286124|PROCEDURE|Hybrid Surgery|Hybrid incisional hernia repair, as described by Van den Dop et al. (2021)
214375050|NCT02646215|DEVICE|Threshold inspiratory muscle training|Inspiratory muscle training
214375051|NCT05384665|DRUG|Remifentanil|REMIFENTANIL, 5 µg/cc, solution for injection, 0.5 µg/kg, parenteral (intravenous) route, injection delay of 30 seconds, once only
214375052|NCT05384665|DRUG|Sufentanil|SUFENTANIL, 5 µg/cc, solution for injection, 0.2 µg/kg, parenteral (intravenous) route, bolus over 5 seconds, once
214375053|NCT05384665|DRUG|Placebo|PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
214685790|NCT05781815|PROCEDURE|dynamic hip screw|using dynamic hip screw in treatment of trochanteric fracture and dynamic hip screw with trochanteric stabilizing plate
214685791|NCT02524652|DRUG|Ropivacaine 0.5% 20 mLs|Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
215090049|NCT01653899|DRUG|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
215090050|NCT06034756|OTHER|TMJ dysfunction|Fonseca's Anamnestic Questionnaire (FAQ) was used for TMJ dysfunction. The diagnostic accuracy of the FAQ was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
215090051|NCT06034756|OTHER|Maximum pain-free mouth opening (MMO)|The maximum pain-free mouth opening was recorded using a 15 cm ruler
215090052|NCT06034756|OTHER|Forward head posture|Forward head posture was evaluated by CVA using a goniometer. CVA was measured in degrees as the angle between the horizontal plane, the seventh cervical vertebra and the ear hole
215090053|NCT06034756|OTHER|Tongue strength and endurance|Tongue strength and endurance were evaluated with IOPI (Medical LLC, Redmond, WA), which has been clinically validated and reliable
214375054|NCT04858802|DEVICE|PROPEL Contour Sinus Implant|370 mcg mometasone furoate-coated sinus implant
215090054|NCT06034756|OTHER|Static endurance evaluation of the trunk muscles|The Trunk Flexors Endurance Test and the Biering Sorenson Test were used. These static tests are measurements targeting the local core muscles.
215090055|NCT06034756|OTHER|Dynamic endurance evaluation of the core muscles|The Sit-ups and the Modified Push-ups Tests were used. These dynamic tests are measurements targeting the global core muscles.
214375055|NCT04858802|PROCEDURE|Balloon Sinus Dilation Alone|No PROPEL Contour Sinus Implant
214375056|NCT00110253|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
214375057|NCT02827318|DIETARY_SUPPLEMENT|Isomaltulose|75g Isomaltulose (low glycaemic load intervention)
214375058|NCT02827318|DIETARY_SUPPLEMENT|Glucose|75g Glucose (high glycaemic load intervention)
214375059|NCT02827318|DIETARY_SUPPLEMENT|Sweetened water|Sweetened water will be used as a control
214375060|NCT02026232|DRUG|Hydroxychloroquine|200mg twice daily
214685792|NCT02979886|DRUG|GnRH-a|the hormone reaction to the down regulation of the patients
214685793|NCT02979886|DRUG|Human Menopausal Gonadotropins|the effects on the serum LH level of day of HCG
214685794|NCT02227017|DRUG|TPV capsule|
214375061|NCT02026232|OTHER|Hydroxychloroquine Placebo|200mg placebo twice daily
214375062|NCT01529008|DRUG|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
214685795|NCT02227017|DRUG|TPV solution|
214685796|NCT02227017|DRUG|RTV capsule|
214685797|NCT02227017|DRUG|RTV solution|
214685798|NCT02227017|OTHER|standard meal|
214685799|NCT03017248|DRUG|Ketamine|ketamine
214685800|NCT03017248|DRUG|Placebos|0.9% normal saline
214685801|NCT03017248|DRUG|Morphine|Morphine
214685802|NCT03157154|OTHER|Non interventional study|A query form to all concerned patients by each investigating centre will be send
214685803|NCT03073655|OTHER|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
214375063|NCT01529008|DRUG|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
214375064|NCT03077464|BEHAVIORAL|Behavioral nutrition education|Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.
214375065|NCT00147901|DRUG|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
214375066|NCT02556437|DRUG|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
214375067|NCT02556437|DRUG|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
214375068|NCT01776021|OTHER|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
214375069|NCT01776021|OTHER|placebo beverage|placebo beverage at a dose of one 8 oz. beverage per day for six months
214375070|NCT04402528|BEHAVIORAL|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers/childcare providers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
214375071|NCT00668135|DRUG|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg orally on demand prior to intercourse
214375072|NCT00668135|DRUG|Placebo|Matching placebo
215090056|NCT03220607|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
214375073|NCT00315913|DRUG|Propranolol|IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg
214375074|NCT00315913|OTHER|IV Placebo|IV Saline Solution
215090057|NCT04965961|DRUG|EPO|Please refer to the arm description
215090058|NCT04965961|OTHER|Control group - saline injection|Please refer to the arm description
215090059|NCT01014455|BEHAVIORAL|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
214393838|NCT05781386|DRUG|SIM1811-03 or in combination with Sintilimab injectiont|"SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)"
214393839|NCT04376697|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment will be delivered by trained medical personnel.
214393840|NCT01759680|DEVICE|Vibrosphère device|Vertical Sinusoidal vibration
214393841|NCT03230864|DRUG|Lu AF35700|10 mg/day, encapsulated tablets, orally
214393842|NCT03230864|DRUG|Risperidone|4-6 mg/day, encapsulated tablets, orally
214393843|NCT03230864|DRUG|Olanzapine|15-20 mg/day, encapsulated tablets, orally
214496193|NCT06830421|DRUG|R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT|Firstline systemic treatment with age-adjusted MTX based induction (2 cycles of Rituximab-Methotrexate-Cytarabin) followed by consolidating aged-adapted high-dose chemotherapy and autologous stem cell transplantation
214496194|NCT04233190|DRUG|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg|one inhalation, twice daily
214496195|NCT06830512|PROCEDURE|Echocardiography-guided percutaneous radiofrequency ablation for cardiac tumors|In the parasternal long-axis section, the cardiac puncture guide line was used to locate the puncture, and the best puncture path through the chest wall was selected. The coaxial biopsy needle was punctured through the guide frame, and then through the skin and subcutaneous tissue into the heart tumor tissue to take 2-10 biopsy samples, which were sent for pathological examination. The biopsy needle was extracted, and the radiofrequency electrode needle was punctured along the coaxial sheath to the planned ablation site of the heart tumor. The radiofrequency ablation device was started and the ablation treatment was performed.
214496196|NCT06827639|PROCEDURE|blood collection|Blood sampling is performed during Scrrening / visit 1 for patients enrolled in cohort 1, cohort 2 and cohort 3
214496197|NCT06827639|PROCEDURE|tissue specimen collection|In Cohort 1- patients with solid tumor undergoing surgery, fresh tissue specimen is collected during surgery
214496198|NCT03750331|OTHER|Ap'Telecare|an internet application on a computer, tablet or smartphone
214496199|NCT03750331|OTHER|traditional schedule|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule
214496200|NCT03086421|BEHAVIORAL|Questionnaires|Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
214496201|NCT06830486|OTHER|No intervention|No intervention is performed. Participants who have been treated with either a SERM or aromatase inhibitor are recruited and analyzed in separate groups, but the study design for all participants is identical.
214496202|NCT05466396|BEHAVIORAL|smoking|Smoking history and spirometry are used to define groups
214496203|NCT06827821|DRUG|18F-CP6A|For pharmacokinetics, healthy volunteers underwent PET imaging targeting α-synuclein. Blood samples were collected at before and 2 ± 1, 5 ± 2, 10 ± 2, 30 ± 5, 60 ± 5, 90 ± 5, and 120 ± 10 min after imaging agent injection, and urine specimens were collected at before and 0-1.5, and 1.5-3 h after injection to measure radioactivity in blood and urine. PET/MR and PET/CT scans were performed at 0 ± 10, 30 ± 10, 60 ± 10, and 100 ± 10 min after injection to understand distribution for healthy volunteers and synucleinopathy patients. A separate 10-minute PET scan of the brain is required of each acquisition. Blood tests, liver and kidney function, and other biochemical markers must be performed one week prior to and after imaging.
214987534|NCT03869268|DRUG|Aspirin|Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
214987535|NCT03869268|DRUG|Ticagrelor|Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
214987536|NCT06234228|BEHAVIORAL|Bluetooth Haptic Device (BHD)|The BHD will deliver constant low-frequency vibration (CF).
214987537|NCT06234228|BEHAVIORAL|BHD synced with mobile game|The BHD delivers a constant low-frequency vibration as well as tactile feedback from the game (GF).
215090060|NCT01014455|BEHAVIORAL|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
215090061|NCT01529736|PROCEDURE|High torque insertion|Osseotite implant placed with high insertion torque forces
214375075|NCT03594903|BEHAVIORAL|video intervention (therapy expectation violation)|The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).
214375076|NCT03594903|BEHAVIORAL|video intervention (symptoms+ expectation)|Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
214375077|NCT04191070|DEVICE|infrazygomatic miniscrew|class II correction by distalization using infrazygomatic crest miniscrew
214375078|NCT04191070|DEVICE|zygomatic miniplate|class II correction by distalization using zygomatic miniplate
214375079|NCT05079815|DIAGNOSTIC_TEST|CBC and serum ferritin|take blood sample for CBC and serum ferritin
215090062|NCT01529736|PROCEDURE|Low torque insertion|Osseotite implant placed with low insertion torque forces
214375080|NCT02561143|DIETARY_SUPPLEMENT|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients will be given 100 grams of Improved Atta (to make unleavened bread) everyday for consumption for six months.
214375081|NCT02561143|DIETARY_SUPPLEMENT|Wheat flour|Whole wheat flour 100 grams (to make unleavened bread) will be given everyday for consumption for six months to the patients.
214393844|NCT00464035|BEHAVIORAL|high calcium intake|
214393845|NCT03679013|DRUG|Oral Gabapentin and Intravenous Acetaminophen (IV APAP)|Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.
214496204|NCT06550934|PROCEDURE|Fracture stabilization|isolated posterior surgical fracture stabilization vs. combined anterior-posterior surgical fracture stabilization
214496205|NCT03868943|DRUG|Soliramfetol|Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
214393846|NCT03679013|DRUG|Opiate based pain regimen.|Standard of care opiate based pain regimen.
214496206|NCT05429138|OTHER|biological sampling|Biological sampling: blood and semen
214496207|NCT06425900|DRUG|Winlevi (Clascoterone) cream 1%|Dosed twice daily (BID)
214496208|NCT06074575|BEHAVIORAL|Emotion induction|The participants will receive different emotion inductions through short video clips.
214496209|NCT00833742|BEHAVIORAL|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
214496210|NCT06830070|OTHER|subjective pain score assessment|a questionnaire assessing subjective pain during surgery, using the Visual Analogue Scale with values from 0 to 10
214496211|NCT03516942|OTHER|Quality-of-Life Assessment|Ancillary studies
214496212|NCT03516942|OTHER|Questionnaire Administration|Ancillary studies
214496213|NCT04957342|DEVICE|amnion-chorion membrane|allograft to be placed on palate
214496214|NCT04957342|PROCEDURE|Sutures|Sutures (e.g. interrupted, crisscross compression) to be placed on palate
214496215|NCT06222099|DEVICE|Heartfelt Device installed|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
214496216|NCT06222099|OTHER|Standard care|RPMPs in regular contact with patients and collecting health monitoring data as per their standard operating procedures.
214496217|NCT06222099|DEVICE|Heartfelt-guided care|Volume measurements and health alerts transmitted to the RPMP for review. RPMPs follow a pre-specified alert protocol, potentially following up with the patient.
214987538|NCT06109922|DIETARY_SUPPLEMENT|Active|40g bio-active whey protein concentrate powder containing phospholipids
214375082|NCT02561143|BEHAVIORAL|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
214375083|NCT02561143|OTHER|Nutritional counseling|Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
214375084|NCT05396092|BEHAVIORAL|Integrated mindfulness-based Tai Chi Chuan|MBTCC will integrate components from both the MBI and TCC groups. The entire intervention consists of eight weekly sessions of two-and-a-half to three hours each.
214375085|NCT05396092|BEHAVIORAL|Mindfulness-based intervention|The MBI group is mainly based on the basic theory and research of the foundational mindfulness-based stress reduction program. The intervention consists of eight weekly sessions of two to two-and-a-half hours each.
214375086|NCT05396092|BEHAVIORAL|Tai Chi Chuan|TCC is mainly based on a nine-form Yang-style form of TCC, which is a brief and modified version of 64-form Yang-style TCC. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
214375087|NCT05396092|BEHAVIORAL|Sleep Hygiene Education|SHE is based on principles used in stimulus control and sleep hygiene education, which has previously been used as the control group in sleep-related research. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
214375088|NCT04591535|DRUG|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
214375089|NCT04496869|OTHER|Online questionnaire|the investigators sent by email a Googleform online questionnaires to women followed in ART center of HFME (Hospital Femme-Mère-Enfant) . Questions are about demographic characteristics, ART history, feeling during the lockdown. To evaluate psychological impact, the investigators use PSS10 and HADS scales. Both scales are worldwide validated and used in recent COVID19's research. the investigators add some quantitative questions about de feeling during the look down, ART interruption, pregnancy desire.
214375090|NCT02950857|DRUG|EPEG|(Pegylated erythropoeitin)
214375091|NCT02225379|DEVICE|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
214375092|NCT02305381|DRUG|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
214375093|NCT02305381|DRUG|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
214375094|NCT02571322|DEVICE|HyperVibe Whole Body Vibration training device|Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.
214375095|NCT02571322|OTHER|Aerobic Exercise|Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
214375096|NCT00657514|DRUG|Ranolazine|500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
214496218|NCT06222099|OTHER|Questionnaires|Patients were presented with one or more optional questionnaires (some validated, some bespoke)
214496219|NCT05236699|COMBINATION_PRODUCT|DEB-TACE combined with Surufatinib and Camrelizumab|"1. All patients will be treated with standard DEB-TACE on the first day (D1).~2. After DEB-TACE, if the liver function is Child-PughA grade, they will be treated with Camrelizumab on the same day, 200mg/ times, intravenous injection, once every 3 weeks.~3. Surufatinib capsule will be given orally to 250mg within 1 hour after breakfast on the second day (D2) after the first DEB-TACE. The drug will be given continuously once a day and stopped on the same day of each DEB-TACE.~4. The combination of drugs for 3 weeks is a cycle.The treatment will continue until the patient developed the disease or met the other criteria for terminating the study."
214496220|NCT05580770|DRUG|Mirdametinib|Mirdametinib administered orally
214496221|NCT05580770|DRUG|BGB-3245|BGB-3245 administered orally
214685804|NCT03073655|OTHER|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
214685805|NCT03073655|OTHER|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
214987539|NCT06109922|DIETARY_SUPPLEMENT|Placebo|Around 40g pea protein powder not containing phospholipids
214496222|NCT04782232|OTHER|No intervention|No intervention due to observational design
214496223|NCT06284252|OTHER|Virtual Gaming Simulation|Two-dimensional virtual game simulations that can be played on computers will be developed using the recorded videos. Games will focus on physical examination of the heart, abdomen and respiratory system. The developed games will be played to the intervention group.
214987540|NCT05388591|OTHER|Musicotherapy|Music listening with the application Music Care (style of music chosen by the patient) during wound suturing
214987541|NCT04513366|DRUG|SEL-212 low-dose|IV infusion of SEL-212 low-dose every 28 days for a total of up to 12 infusions
214987542|NCT04513366|DRUG|SEL-212 high-dose|IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions
214987543|NCT04513366|OTHER|Normal Saline|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
215090063|NCT05981937|DRUG|ICG solution|ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
215090064|NCT03674099|DRUG|Imatinib Mesylate|Tablets 400 mg
214987544|NCT05768646|BEHAVIORAL|Neuropsychological instruments|Neuropsychological instruments assessing cognitive (including counterfactual abilities), behavioural and psychopathological features
214987545|NCT00892021|DRUG|NSA-789|
214987546|NCT00892021|DRUG|Placebo|
214987547|NCT02835716|DRUG|roflumilast|DALIRESP is used in adults with severe chronic obstructive pulmonary disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations
214987548|NCT02835716|BIOLOGICAL|ustekinumab|STELARA is approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body
214987549|NCT04745728|DRUG|Prednisone|1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.
214987550|NCT04745728|DRUG|Cyclophosphamide|1-2mg/kg/d p.o. with a target accumulated dose of 12g.
214987551|NCT04745728|DRUG|Rituximab|1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count\>5/ul.
214987552|NCT01426581|BEHAVIORAL|Teach-To-Goal|"Participants observe a demonstration on the use of each inhaler, with corresponding verbal step-by-step instructions (demonstration, verbal instruction), then participants 'teachback or re-demonstrate the steps; cycles are repeated are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)"
214987553|NCT01426581|BEHAVIORAL|Brief Intervention|Participants are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
214987554|NCT02750722|DEVICE|Flutter®|Acute exercise with Flutter® breathing therapy.
215090065|NCT03674099|DRUG|Methylprednisolone|1 g tablets or infusion
215090066|NCT05896852|BEHAVIORAL|physical activity|Participants will increase their physical activity through walking.
214375097|NCT00657514|DRUG|Placebo|1 tablet po bid up to 2 tablets po bid if tolerated
214375098|NCT04389333|DEVICE|non-contact magnetically-controlled capsule endoscopy|The novel non-contact magnetically-controlled capsule endoscopy (MCE) system (Ankon Technologies, Wuhan, China) (Figure 1) added a remote control workstation and an audio-visual exchange system to the original well-establish MCE system, which consisted of a robotic magnetic arm, a workstation (currently bypassed) and a capsule endoscope.
214375099|NCT02964455|DRUG|Docetaxel|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
214496224|NCT06257537|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
214496225|NCT06257537|DEVICE|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
214496226|NCT06257537|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
214496227|NCT06257537|OTHER|SAM Patch|Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.
214496228|NCT06826885|RADIATION|Postoperative radiotherapy|Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed. A tumor bed boost will be provided to patients with high-risk factors following breast-conserving surgery, at the discretion of the radiation oncologist. The tumor bed boost regimen may consist of a sequential boost of 10-16 Gy (RBE) in 5-8 fractions, or 10-13.35 Gy (RBE) in 4-5 fractions or 10.4 Gy (RBE) in 2 fractions, or a simultaneous integrated boost of 48-49.5 Gy (RBE) in 15-16 fractions.
214496229|NCT06826885|RADIATION|Preoperative Radiotherapy|Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed.
214496230|NCT06826885|RADIATION|Definitive Radiotherapy|Radiotherapy was delivered using IMPT or IMRT. The target volume encompassed the ipsilateral whole breast and regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions was preferred. Alternatively, a conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions was permitted. Dose escalation was applied in high-risk areas, resulting in a total prescribed dose exceeding 66 Gy (RBE) when calculated as equivalent doses in 2-Gy fractions (EQD2), with an α/β ratio of 4.
214496231|NCT05662371|DEVICE|Nociception Level monitor (NOL)|NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuously monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics, and avoiding overdose or underuse of these drugs. The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation).
214987555|NCT02750722|DEVICE|No Flutter®|Acute exercise without Flutter® breathing therapy.
214987556|NCT02713672|OTHER|Dose adjustment according to genotype|Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
214987557|NCT03424278|OTHER|Motor control exercises|Motor control exercises for the deep trunk muscles in patients with chronic low back pain is based on evidence of motor control dysfunction, including delayed onset of activity in the transversus abdomens and internal oblique abdominal muscles and segmental hypertrophy of the lumbar multifidus muscle.
215090067|NCT01544452|PROCEDURE|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
215090068|NCT01544452|PROCEDURE|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
215090069|NCT03256786|BEHAVIORAL|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
215090070|NCT06230978|BEHAVIORAL|Habit workup|The patient and pharmacist will work together to specify a cue to help them take their medicine every day (e.g. brushing teeth, getting dressed, eating breakfast, making coffee, alarms, visual reminders etc).
215090071|NCT06230978|BEHAVIORAL|Standard Medication Counseling|The pharmacist provides standard counseling on the new medication
215090072|NCT04323293|OTHER|Cold Water Bath|immersion of the hand for 2-5min in 2-10°C water
215090073|NCT04323293|OTHER|Neutral Water Bath|immersion of the hand for 2-5min in 32±2°C water
214375100|NCT02964455|DRUG|Nedaplatin|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
214375101|NCT02964455|RADIATION|chest radiation|continuous chest radiation at 64 Gy/32f
214375102|NCT03040882|OTHER|cotton sock|Application of a cotton sock in the immediate postoperative period before applied the Walker
214375103|NCT03040882|OTHER|Elastic Compression Wraps|Application of an Elastic Compression Wraps in the lower limb in the immediate postoperative period before applied the Walker (standard care)
215090074|NCT06150794|DEVICE|Excimer laser|Excimer laser will be started at a dose of 300 mj/cm2 and increases 50-100 mj/cm2 each session. The aim of treatment is to deliver a dose that induces visible redness in the psoriatic lesion (supra-erythematous dose), but not induce a blister.
215090075|NCT06150794|DRUG|Methotrexate Injection|A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit, followed by a 2.5-mg intramatrical methotrexate injection into each side of the nail at a point 2.5 mm proximal and lateral to the junction of proximal and lateral nail folds.
215090076|NCT00094107|DRUG|Axitinib [AG-013736]|VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
215090077|NCT04942223|DEVICE|guided bone regeneration|After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
215090078|NCT00951756|OTHER|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
215090079|NCT04058704|DRUG|Icotinib|125mg Tid/375mg per day
215090080|NCT04058704|RADIATION|SRS/WBRT/HA-WBRT/SMART|\>3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
215090081|NCT05942794|DEVICE|Screening examination|"After an initial clinical visit, all three operators will wear the tissue autofluorescence detection device (GOCCLES®), reporting both observations on their operator-module."
215090082|NCT00525824|DRUG|Rosuvastatin (Crestor)|10mg and 20 mg
215090083|NCT00525824|DRUG|Ezetimibe|10 mg
215090084|NCT00525824|DRUG|Simvastatin|40mg and 80 mg
215090085|NCT00143780|BIOLOGICAL|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
215090086|NCT00143780|BIOLOGICAL|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
215090087|NCT06508684|DRUG|BTK inhibitor|BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
215090088|NCT04175925|DRUG|BMS-986322|Specified Dose on Specified Days
215090089|NCT04175925|OTHER|BMS-986322 Placebo|Specified Dose on Specified Days
215090090|NCT04175925|DRUG|famotidine|Specified Dose on Specified Days
215090091|NCT02610244|OTHER|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
215090092|NCT03699137|OTHER|No interventions|No interventions
215090093|NCT03379142|BEHAVIORAL|Faith-Based messages|We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
215090094|NCT06176508|DRUG|HS-10374|Administered orally QD for 16 weeks
215090095|NCT06176508|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 16 weeks
215090096|NCT06176508|DRUG|Tofacitinib 5Mg Tab,Oral|Administered orally BID for 16 weeks
215090097|NCT00801047|DRUG|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
215090098|NCT00801047|DRUG|Remifentanil|40-50 mic per 1-2 min via PCA
215090099|NCT01694719|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|
215090100|NCT01694719|BEHAVIORAL|Cognitive Control Training|
214375104|NCT04581148|DIAGNOSTIC_TEST|Blood test antibodies against SARS-CoV-2|Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2
214375105|NCT06089252|DRUG|walnut extract|Four times a day over a 10-day period
214375106|NCT02320032|DRUG|Aripiprazole Lauroxil|Gluteal IM injection, given once every 4 to 8 weeks
214375107|NCT03590340|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
214375108|NCT03590340|OTHER|Normal saline|Normal saline is 0.9% sodium chloride
214685806|NCT03135587|PROCEDURE|Loading level|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
214685807|NCT04058119|BEHAVIORAL|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
214685808|NCT02584933|DRUG|ceritinib|hard gelatin capsule or hard tablet for oral use up to 750 mg
215090101|NCT04728594|BEHAVIORAL|Social Proof|Email
215090102|NCT04728594|BEHAVIORAL|Reframing|Email
214685809|NCT00294502|DRUG|Gentamycin/citrate, Minocycline/EDTA|
214685810|NCT03951688|OTHER|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
214685811|NCT01184404|DRUG|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
214685812|NCT02145923|PROCEDURE|Peripheral blood stem cell mobilisation and collection|
214685813|NCT02145923|DRUG|High-dose chemotherapy|High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
214685814|NCT02145923|DRUG|Bone marrow derived allogeneic MMSCs infusion|
214685815|NCT02145923|PROCEDURE|Autologous peripheral blood stem cells infusion|
214685816|NCT01591226|DIETARY_SUPPLEMENT|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
215090103|NCT04728594|BEHAVIORAL|Scarcity Message|Email
215090104|NCT03791853|DIAGNOSTIC_TEST|Light-CT|Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
215090105|NCT02249494|OTHER|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
215090106|NCT02249494|OTHER|nutritional counseling|Performing routine nutritional counseling in their clinical practice
215090107|NCT02249494|DEVICE|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
215090108|NCT02337699|DEVICE|Implantation with the commercially available Axium neurostimulator|
215090109|NCT02337699|PROCEDURE|QST Testing|
215090110|NCT00049777|DRUG|Drotrecogin Alfa (Activated)|
215090111|NCT00049777|DRUG|Unfractionated heparin|
214685817|NCT01591226|DIETARY_SUPPLEMENT|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
214685818|NCT01591226|DIETARY_SUPPLEMENT|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
214685819|NCT01591226|DIETARY_SUPPLEMENT|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
214685820|NCT02044159|DRUG|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
214685821|NCT02044159|OTHER|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
214685822|NCT01795898|DRUG|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
214685823|NCT05359445|BIOLOGICAL|IMA401 (Phase Ia)|Intravenous infusions in escalating dose levels
214685824|NCT05359445|BIOLOGICAL|Pembrolizumab (Phase Ia)|Intravenous infusions in escalating dose levels for combination of IMA 401 and Pembrolizumab
214987558|NCT03424278|OTHER|Resistance training exercises|A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
214987559|NCT03774446|DRUG|Seliciclib|Drug: Seliciclib
214375109|NCT03590340|BIOLOGICAL|PfSPZ Challenge (for CHMI)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
214375110|NCT01042743|PROCEDURE|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
214375111|NCT01042743|PROCEDURE|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
214375112|NCT02582489|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.
214987560|NCT02657551|DRUG|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
214987561|NCT05898412|DRUG|Andexanet alfa|Patients treated with andexanet alfa
214987562|NCT05227716|DRUG|Perioperative magnesium sulfate|Administration of magnesium sulfate as an adjunct in anesthesia
214987563|NCT06200103|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214987564|NCT06200103|PROCEDURE|Bone Scan|Undergo bone scan
214987565|NCT06200103|OTHER|Clinical Observation|Undergo active monitoring
215090112|NCT00049777|DRUG|Low molecular weight heparin|
215090113|NCT02786680|BEHAVIORAL|stroop test in condition DBS off|Patients were evaluated in DBS Off
215090114|NCT02786680|BEHAVIORAL|stroop test in condition DBS on|Patients were evaluated in DBS On
215090115|NCT04363450|DRUG|Hydroxychloroquine|Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
214375113|NCT02582489|PROCEDURE|Standard Meniscectomy|All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
214375114|NCT00981851|DRUG|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
214375115|NCT00981851|DRUG|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
214375116|NCT04174703|OTHER|Self-compassionate letter-writing intervention|Participants in this condition will be asked to engage in an online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks.
214375117|NCT04851262|BEHAVIORAL|Exercise|The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted.
214685825|NCT05359445|BIOLOGICAL|IMA 401 (Phase Ib)|Treatment at recommended dose for extension (RDE)
214685826|NCT06374342|DEVICE|Bone defect|Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.
214987566|NCT06200103|PROCEDURE|Computed Tomography|Undergo SPECT/CT or PET/CT
214987567|NCT06200103|OTHER|Gallium Ga 68 Gozetotide|Given IV
214987568|NCT06200103|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
214987569|NCT06200103|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214987570|NCT06200103|OTHER|Questionnaire Administration|Ancillary studies
214987571|NCT06200103|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214987572|NCT06360484|DIAGNOSTIC_TEST|investigations for Hepatitis D virus|Investigations included liver function tests, abdominal ultrasounds to identify features of chronic liver disease, and evidence of decompensation. ELISA for Ant-HDV-IgG was conducted.
214987573|NCT01498549|DRUG|Atomoxetine|Atomoxetine 40mg and 80mg compared to the sugar pill
214987574|NCT01498549|DRUG|Sugar Pill|Sugar pill compared to Atomoxetine 40mg and 80mg.
214987575|NCT04478266|DRUG|Amcenestrant-matching placebo|Pharmaceutical form: Tablets Route of Administration: Oral
214987576|NCT04478266|DRUG|SAR439859|Pharmaceutical form: Tablets Route of Administration: Oral
214987577|NCT04478266|DRUG|Palbociclib|Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
214987578|NCT04478266|DRUG|Letrozole|Pharmaceutical form: Capsules Route of Administration: Orally
214987579|NCT04478266|DRUG|Goserelin|Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
214987580|NCT04478266|DRUG|Letrozole-matching placebo|Pharmaceutical form: Capsules Route of Administration: Orally
214987581|NCT05385770|DRUG|AZM X mg + AML Y mg|tablet, single dose, QD, oral administration
214987582|NCT05385770|DRUG|AZM X mg + AML Y' mg|tablet, single dose, QD, oral administration
214987583|NCT05385770|DRUG|AZM X' mg + AML Y mg|tablet, single dose, QD, oral administration
214987584|NCT05385770|DRUG|AZM X' mg + AML Y' mg|tablet, single dose, QD, oral administration
214987585|NCT05385770|DRUG|AZM X mg|tablet, single dose, QD, oral administration
214987586|NCT05385770|DRUG|AZM X' mg|tablet, single dose, QD, oral administration
214987587|NCT05385770|DRUG|AML Y mg|tablet, single dose, QD, oral administration
214987588|NCT05385770|DRUG|AML Y' mg|tablet, single dose, QD, oral administration
214987589|NCT06123117|PROCEDURE|single transversus abdominis laparoscopy-guided plane block|please see arm/group descriptions
214987590|NCT06123117|PROCEDURE|local trocar site ropivacaine infiltration|please see arm/group descriptions
214987591|NCT01937468|OTHER|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
215090116|NCT04363450|DRUG|Placebo|Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
215090117|NCT01260545|DRUG|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
215090118|NCT05052619|DRUG|Preventive use of advanced antibiotics|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
214685827|NCT06374342|DEVICE|Spine fusion|Spinal fusion is a surgery procedure that reinforces your back structure and stability by linking two vertebrae together
214375118|NCT06013046|BEHAVIORAL|Intensity-controlled physical activity training (IPAT)|The IPAT group will receive 40 (90 minute) one-on-one, intensity-controlled, exercise sessions by trained staff over 14 weeks. The initial 2-week period will include dedicated education on topics including physical activity guidelines and the benefits of achieving them, the feeling of moderate-to-vigorous physical activity intensity levels, and the appropriate exercises for achieving desired intensity levels. Tailored sessions will be created for each participant based on their physical fitness, goals, preferred exercise equipment and results from their baseline assessment. Each session can include vitals, pain assessment, warm-up, aerobic training, strength exercises and a cool-down. The participants will be monitored to ensure they are achieving at least 150 minutes of moderate-to-vigorous intensity physical activity weekly. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. The overall goal is to improve cardiorespiratory fitness.
214375119|NCT06013046|BEHAVIORAL|Education and Access (EA)|The EA group will receive an initial 60 minute educational session, during which they will receive information on the adapted exercise equipment in the Orthwein Center, education on the physical activity guidelines and the health benefits of achieving them, and access to the Orthwein Center accessible gym. They will then complete a 14-week independent workout program with the goal of meeting physical activities guidelines. They will have access to Orthwein Center staff to help with minimal setup and guidance, but sessions will be self-directed. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. Participants will be asked to complete a log for each session to report pain, details of the activities they completed during their workout, the RPE for each activity, and how long each activity lasted.
214375120|NCT05975606|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS will be applied to primary motor cortex of the brain.
214375121|NCT05975606|DEVICE|functional electrical stimulation (FES) cycling|FES will be applied to muscles associated in cycling: quadriceps, hamstrings, tibialis anterior, gastrocnemius, soleus.
214375122|NCT04003779|OTHER|Room configuration|Adjust distance, handrails, degrees of turn for participant
214375123|NCT06196216|RADIATION|MSCT|Enhanced CT chest
214375124|NCT04545996|OTHER|Suboccipital Inhibition Technique|Suboccipital Inhibition Technique For 2min And Conventional Treatment Hot Pack For 10 To 15 Mints And Muscle Energy Technique(Post Facilitation Stretch) 5 Reps × 1 Set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
214375125|NCT04545996|OTHER|Cranio Cervical Flexion Exercises.|Cranio cervical flexion exercises10 repetitions for 10 seconds and conventional treatment hot pack for 10 to 15 mints and muscle energy technique(post facilitation stretch) 5 reps × 1 set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
214375126|NCT02026180|DEVICE|Micropuncture Access|Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
214375127|NCT04863625|BEHAVIORAL|a peer-led educational intervention based on theory of planned behavior on substance use intentions and behaviors|The intervention will be a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).The intervention aims to encourage anti-substance attitudes and beliefs; foster perceptions of normative support for anti-substance behavior; increase perceptions of control/self-efficacy to resist substance use, increase knowledge and risk perceptions on substance and decrease in intention to use substance and actual substance use behaviors. Six education sessions will be delivered, with one session occurring each week. Each session will be lasted 40-55 minutes. The intervention will be conducted in 30 groups of selected students from grade 9-12, a pair of peer educators will educate a 30 sized group weekly (30 students /group)/ classrooms at pre-assigned time during class periods. The six sessions will be guided by four student training modules.
214375128|NCT06081595|DRUG|Fluzoparib|Fluzoparib 100mg bid
214375129|NCT06081595|DRUG|Apatinib|Apatinib 375mg qd
214496232|NCT05662371|DEVICE|Standard care|Hemodynamic changes outside of the normal range i.e., hypertension (systolic blood pressure greater than 140 mm Hg), tachycardia (heart rate greater than 90 min-1) and hypotension (mean arterial pressure less than 60 mm Hg) will be first assessed using the guidance of Bispectral index and Train of four monitors. Sufentanil in doses of 2.5 to 5 mcg (maximum of 0.6-1.2 mic/kg for the entire surgery) is administered if the Bispectral index and Train of four monitor values are within normal range and if required vasopressor infusion is used. Vasoconstrictors may be given as a continuous infusion of norepinephrine, or bolus doses of ephedrine or phenylephrine. Only when blood pressure remains, low additional crystalloids will be given. Finally, in case of bradycardia (heart rate less than 30 min-1), atropine may be given
214496233|NCT06338293|DRUG|Inclisiran sodium|The patients in Inclisiran group were given drugs three times in total. The first needle was injected subcutaneously with 284mg(1.5ml solution) after entering the group, the second needle was injected three months later and the third needle was injected at the ninth month.
214496234|NCT06338293|DRUG|Rosuvastatin|Rosuvastatin
215090119|NCT05052619|OTHER|Routine|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
214496235|NCT06831045|PROCEDURE|Bikini Incision|Participants will receive the bikini incision in person during THA. A one-time incision will be made along the groin line before standard of care THA surgery. The surgery takes approximately two hours.
214685828|NCT06374342|DEVICE|Cage filling|Intervertebral fusion with cages is a surgical procedure used to stabilize the spine by fusing adjacent vertebrae. The cages, typically made of materials like titanium or plastic, and pre-filled with bone graft substitutes are placed between the vertebrae to maintain the proper spacing and alignment.
214987592|NCT01937468|DRUG|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
214987593|NCT05190770|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide is a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. It is applied topically.
214987594|NCT05190770|DRUG|Oleogel-S10|Oleogel-S10 consists of birch bark extract (TE): 10 mg/100 mg; Sunflower oil, refined: 90 mg/100 mg. It is applied topically.
214375130|NCT03725540|DEVICE|I-gel|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
214375131|NCT03725540|DEVICE|Baska_mask|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
214375132|NCT05056870|DEVICE|ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism|TEST
214375133|NCT05056870|DEVICE|ACUVUE Oasys 1-Day with HydraLuxe Technology|CONTROL
214375134|NCT05044325|DRUG|GSK3884464|GSK3884464 will be administered
215090120|NCT01283490|DEVICE|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
215090121|NCT01283490|DEVICE|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
215090122|NCT01378429|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
215090123|NCT01378429|DRUG|Placebo|Placebo
215090124|NCT00316420|DRUG|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
215090125|NCT00316420|DRUG|Gemcitabine|750 mg/m2 IV Days 1 \& 8 q 21 days
215090126|NCT04142190|DRUG|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
215090127|NCT04142190|DRUG|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
214375135|NCT05044325|DRUG|Placebo|Placebo to match GSK3884464 will be administered.
214375136|NCT06339580|DEVICE|Volume-targeted non-invasive ventilation|A target tidal volume is set on the ventilation device, and the device will then automatically adjust delivered pressures to reach this target tidal volume.
214375137|NCT02587026|OTHER|Blood sample collection|
214375138|NCT02587026|OTHER|Tumor tissue sample collection|
214375139|NCT04558190|DRUG|Intralipid, 20% Intravenous Emulsion|Lipid infusion
214375140|NCT04558190|DIETARY_SUPPLEMENT|MitoQ|Oral administration of MitoQ capsules
214375141|NCT04558190|DRUG|Salbutamol|Beta2-agonist infusion
214375142|NCT02418247|DRUG|I131|
214375143|NCT02418247|DRUG|I123|
214375144|NCT05182645|BEHAVIORAL|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of crohn's disease patients.
214496236|NCT06831045|PROCEDURE|Longitudinal Incision|Participants will receive the longitudinal incision in person during THA. A one-time linear incision will be made along the thigh before standard-of-care THA surgery. The surgery takes approximately two hours.
214496237|NCT06621511|BEHAVIORAL|OurSleepKit|OurSleepKit is developed as an app including a patient version and a partner version, to be downloaded on the patient's or partner's mobile devices at home. The goal of OurSleepKit is to coach mutual engagement and model positive partner involvement in CPAP treatment, thus motivating greater CPAP adherence. Using OurSleepKit, both the patient and partner will complete periodic assessments tracking various aspects of their sleep and CPAP use. The assessment data are then processed by OurSleepKit to provide customized and dynamically updated support content consisting of brief story-telling videos featuring real-life couples' experiences emphasizing positive dyadic coping and problem-solving strategies. OurSleepKit delivers timely tailored prompts through push notifications on the users' mobile devices' screens, linked to relevant support content, to facilitate positive conversation in the dyad and offer in-the-moment support for CPAP use.
214496238|NCT05630183|DRUG|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
214496239|NCT05630183|DRUG|Gemcitabine|Standard-of-care chemotherapy administered intravenously.
214496240|NCT05630183|DRUG|Nab-paclitaxel|Standard-of-care chemotherapy administered intravenously.
214496241|NCT05079399|OTHER|Blood draw|Blood samples will be collected via venipuncture
214496242|NCT03877653|DEVICE|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
214496243|NCT06808243|PROCEDURE|connective tissue graft|10 patients received mVIP-CTG
214496244|NCT06808243|DEVICE|xenogenic collagen membrane|10 patients received XCM
214496245|NCT06780618|OTHER|RICE|150 g of brown rice from Aek Sibundong variant at once
214496246|NCT06780618|OTHER|rice wheat (placebo)|150 g of white rice from Setra Ramos variant at once
214496247|NCT06891287|COMBINATION_PRODUCT|RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity|RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity.
214496248|NCT06891287|DRUG|PG-102|PG-102 is a drug for the treatment of obesity.
214496249|NCT06891287|OTHER|Placebo|The placebo is the RaniPill with saline instead of a drug.
214496250|NCT04372914|DIETARY_SUPPLEMENT|BRB Lozenges|Each lozenge is made from 1 gram of freeze-dried black raspberry powder (equivalent to \~5 black raspberries) in the form of a dissolvable slow-release lozenge.
214496251|NCT03289949|DRUG|Psilocybine|Oral dose of psilocybine.
214496252|NCT03289949|DRUG|Ketanserin|Oral dose of ketanserin.
214496253|NCT05644275|OTHER|Data collection (demographic, clinical, functional and biomechanical outcomes in patients after ACL injury (conservative therapy and/or surgery) in patients of different ages and healthy controls)|Analysis of existing data from previous research projects MechSens (EKNZ 2019-01315) and RetroBRACE I and II (EKNZ 2019-00491 and EKNZ 2020-00551) as descriptive statistics (mean, standard deviation, range) for all parameters (for female or male patients with ACL injury and healthy subjects).
214496254|NCT06917703|OTHER|E-learning|in experience group
214496255|NCT00961792|DRUG|Ethanol|Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
214496256|NCT00961792|DRUG|Placebo|Beverage containing 0.0 g/kg alcohol to act as placebo
214496257|NCT00961792|DRUG|Diphenhydramine|Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
214685829|NCT06413485|BEHAVIORAL|Level of recreational water contact activities|We will examine a graded classification of this exposure based on individuals' minimum level of water contact: 1) no water contact; 2) minimal contact; 3) body immersion; 4) swallowed water. Minimal contact is defined as water contact that does not result in body immersion (e.g., wading below one's waist, boating, fishing). Body immersion is defined as entering the water above one's waist (e.g., swimming, surfing, snorkelling), and swallowing water as ingestion of any amount of water.
215090128|NCT04878744|BEHAVIORAL|Shmapped|Novel app-based intervention to improve wellbeing in patients with common mental health problems.
214685830|NCT04085445|DEVICE|AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter|To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese patients.
215090129|NCT01018095|DRUG|Metronidazole|2 gm single dose versus 7 day 500 mg BID dose
214375145|NCT05182645|BEHAVIORAL|waiting control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
215090130|NCT01195688|DRUG|BI 638683 or placebo|oral doses given to 6 subjects per dose group
215090131|NCT01195688|DRUG|Placebo solution|oral doses given to 2 subjects per dose group
214375146|NCT02034825|OTHER|Decipher Questionnaire|Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
214375147|NCT02243202|DRUG|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
215090132|NCT04064645|DEVICE|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
215090133|NCT01676623|BEHAVIORAL|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
214375148|NCT02243202|DRUG|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
214375149|NCT02243202|DRUG|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
214375150|NCT02243202|DRUG|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
214496258|NCT00961792|DRUG|Caffeine|Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
214496259|NCT03420404|OTHER|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
214496260|NCT00085982|DRUG|Metreleptin|Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
214685831|NCT06236698|DIAGNOSTIC_TEST|24-hour urinary aldosterone measurement|Collect 24-hour urine sample from each participant and complete the detection of urinary aldosterone content.
214685832|NCT05008913|DRUG|[14C]Adavosertib|Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.
214685833|NCT04486443|BEHAVIORAL|music therapy|patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist from the Conservatory Department in the Ege University, using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour.
214685834|NCT02455791|PROCEDURE|Ultrasound-Guided Biopsy|Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
214375151|NCT02378558|DEVICE|MagneMarker|The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
214375152|NCT04728178|OTHER|Crystalloid solution|Crystalloid solution is a true solution and is able to pass through a semipermeable membrane.
214375153|NCT04728178|OTHER|Colloid solution|Colloid solution is a heterogeneous mixture whose particle size is intermediate between those of a solution and a suspension.
214685835|NCT05826275|DRUG|TGN-S11|Small Molecule
214685836|NCT05826275|DRUG|Pembrolizumab|PD-1 checkpoint blockade
214685837|NCT01523808|DRUG|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
214685838|NCT00390000|DRUG|vatalanib|Given orally
214685839|NCT00390000|DRUG|pemetrexed disodium|Given IV
214685840|NCT00390000|OTHER|pharmacological study|Correlative study
214685841|NCT00390000|PROCEDURE|ultrasound imaging|Correlative study
214685842|NCT00878163|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214685843|NCT00878163|DRUG|Erlotinib Hydrochloride|Given PO
214685844|NCT00878163|DRUG|Gemcitabine Hydrochloride|Given IV
214685845|NCT00878163|DRUG|Vismodegib|Given PO
214375154|NCT03361995|DEVICE|Cooling Procedure using the ZOLL Thermogard XP3 IVTM System|Cooling Procedure with ZOLL Thermogard XP3 IVTM System before and after Percutaneous Coronary Intervention (PCI)
214375155|NCT03361995|DEVICE|PCI|Standard of Care for PCI
214375156|NCT04773210|DEVICE|Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment
214375157|NCT04773210|DEVICE|Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment
214496261|NCT06759818|DEVICE|transcutaneous vagus nerve stimulation|①The first adjustment requires electrical stimulation to break through the skin barrier. The first intervention is the day before the operation. The initial electrical stimulation frequency is 30Hz and the pulse width is 300μs. The frequency and pulse width are adjusted according to the individual feelings of the subject until they are tolerated by the subject. Maximum current stimulation without discomfort and lasting for 30 minutes; ② second time For the intervention, the subject is connected to the monitor after entering the surgery room. After observing that the subject\&#39;s vital signs are within the normal range, the same stimulation frequency as the first time is immediately given for 30 minutes; ③ The third intervention is after the subject\&#39;s surgery is completed. The same stimulation frequency was given in the resuscitation room until the patient was extubated and resuscitated.
214496262|NCT06759818|DEVICE|Sham stimulation group|① The first intervention is also the day before the operation. The frequency and pulse width are adjusted three times without turning on the machine, and the subject is asked if they have any feelings. After adjusting the frequency three times, no operation is performed for 30 minutes; ② The second intervention For the first intervention, after the monitor is connected in the operating room, the frequency and pulse width are not set, and it lasts for 30 minutes before being taken out; ③ For the third intervention, after the subject\&#39;s surgery, earplugs are inserted in the recovery room, and the frequency and pulse width are not set. Remove the earplugs after extubation resuscitation is completed.
214685846|NCT04378023|DRUG|Neoadjuvant Chemo-radiotherapy|Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
214685847|NCT04378023|PROCEDURE|Liver Transplantation|If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
214685848|NCT06187402|DRUG|LM-24C5|Administered intravenously
214987595|NCT05710575|BIOLOGICAL|probiotic|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
214987596|NCT05710575|OTHER|placebo|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
214987597|NCT06222697|DRUG|Damoctocog-alfa-pegol (Jivi, BAY94-9027)|Follow clinical practice/administration. No drug is provided to participants due to the observational nature of the study.
215090134|NCT01676623|BEHAVIORAL|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
215090135|NCT01676623|BEHAVIORAL|Mass media campaign|Alive \& Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
214375158|NCT02337517|OTHER|Laboratory Biomarker Analysis|Correlative studies
214375159|NCT02337517|DRUG|Vismodegib|Given PO
214375160|NCT04374396|PROCEDURE|Real ultrasound-guided single shot erector spinae plane block (ESP B)|"ESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~After negative aspiration, 0.3 mL/kg- of bupivacaine 0.25% will be injected confirming correct position by visualizing the solution lifting the ESM off the transverse process .Spread of LA between the L1 and L4 transverse processes will be thereafter visually tracked with the transducer. In the control group, no local anesthetics will be injected."
214496263|NCT06864130|DRUG|Alendronate 70mg weekly|The intervention is discontinuation of Alendronate
214685849|NCT06847022|PROCEDURE|US-guided transversalis fascia plane block|US-guided bilateral transversalis fascia plane block, using Sonotap 110 mm and 0.25% bupivacaine 20 ml on each side, will be done after wound closure.
214685850|NCT01072097|DRUG|Atorvastatin|Atorvastatin 20mg/day for 6 months
214685851|NCT01072097|DRUG|Placebo|Placebo for 6 months
214685852|NCT04893564|BIOLOGICAL|bone marrow sample|8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.
214685853|NCT04893564|BIOLOGICAL|blood sample|20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.
214685854|NCT04263285|DEVICE|rTMS|The study team will deliver rTMS five days a week for four weeks, according to a specific and approved protocol for participant positioning, motor threshold determination, and dosing.
214375161|NCT04374396|RADIATION|Sham ultrasound-guided single shot erector spinae plane block (ESP B)|"EESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~No local anesthetics will be injected"
214375162|NCT01356953|OTHER|Aerobic exercise|Intensity of aerobic exercise
214375163|NCT06251713|OTHER|VeXUS score guided fluid management strategy|"During the first 3 postoperative days, the VeXUS score is estimated daily by ultrasound. If VeXUS score \>1, diuretic-induced fluid removal will be administred (target diuresis: 2-4mL/kg/h). The diuretic administration protocol is derived from the CARRESS HF study: bolus followed by a continuous administration of Furosemide with thiazide added based on preoperative diuretic administration status.~To prevent hypokalaemia and dysnatremia, a protocol for potassium supplementation and intravenous administration of chloride serum or hypotonic perfusion is planned.~Fluid removal will be suspended if severe metabolic disturbance (pH\>7.55 with HCO3-\>40mmol/L or serum K+ \<3 mmol/L or serum Na\>150 mmol/L) or haemodynamic instability (hypoperfusion) with fluid responsiveness occurs. Regardless of the VeXUS score, diuretics will be introduced in case of pulmonary oedema.~Haemodynamic status will be every 12 hours to detect side effects attributable to diuretic-induced fluid removal."
214496264|NCT03704662|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214987598|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 1|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
214375164|NCT06251713|OTHER|Usual care|Fluid management will be at the discretion of attending physician, who will be blinded to the patient's VeXUS score status.
214496265|NCT03704662|RADIATION|Preoperative Fractionated Radiation Therapy and Chemotherapy|Conventional concurrent chemotherapy and radiation therapy.
214496266|NCT04160455|BIOLOGICAL|expression of a panel|Quantify, by droplet digital PCR, the expression of a panel of 7 genes (+ GALIG) involved in autophagy2 on sub-populations (CD4+ and CD8+ lymphocytes and monocytes) after their sorting using magnetic bead cell then RNA extraction Evaluate, on a functional test (as previously described1), whether the observed expression dysregulation is associated with a deregulation of the autophagic function, whether constitutive or induced.
214685855|NCT06846697|OTHER|Home-based Exercise|The subjects in this group will be given the exercises included in the Physical Activity guideline of the Ministry of Health as a home programme.
214685856|NCT06846697|OTHER|Hatha Yoga Group|The sessions will begin with the classic sun salutation series (Suryanamaskar) consisting of 12 basic poses of yoga. The sun salutation series will be used as a warm-up for 10 minutes. After warming up, postures aimed at stretching the front group muscles of the body and strengthening the back group muscles will be preferred. In the cooling phase, the session will be ended by relaxing with Savasana pose for 10 minutes.
214685857|NCT06846697|OTHER|Reformer Pilates Group|Exercise sessions will start with the foot series and the starting position on the back will be preferred. This series, which is progressed by maintaining the body composition, is considered as a warm-up exercise of the body. Then, the body is continued with exercise series targeting the thoracic region and core region.
215090136|NCT04890587|DRUG|AL8326 tablets|Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
215090137|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
214496267|NCT05787795|OTHER|biological samples|blood draw, oral swab, optional stool samples, spinal fluid sample, fat biopsy, tonsil biopsy, lymph node tissue sample, MRI
214685858|NCT05438875|DRUG|all-trans retinoic acid|ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.
215090138|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)
215090139|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)
214496268|NCT06778473|DEVICE|Active Intradermal Acupuncture|"Depending on acupoints' location, φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Insert the Active IA vertically into the acupoint and retain it in the skin.~Active IA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be required to press the Active IA 4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours."
214496269|NCT06778473|DEVICE|Sham Intradermal Acupuncture|Sham intradermal acupuncture will be attached to the acupoints and retained for 72 hours with a day's rest after removal. During the period of sham needle retention,pressing times and frequencies are identical to those in the active intradermal acupuncture group.
214685859|NCT05438875|DRUG|Eltrombopag|The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
214685860|NCT06138431|BEHAVIORAL|CBT|Virtual CBT groups
214685861|NCT06422234|OTHER|Exergame|Video-based game exercises will be performed 3 days a week for 6 weeks. Participants will be taught how to play the games before starting the game called Ring Fit Adventure, one of the Nintendo Switch games. Among the games within Ring Fit, games that aim to increase lower extremity muscle strength, core stabilization and balance have been selected, and game types and number of repetitions are changed every week.
214987599|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 2|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
214987600|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 3|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
214987601|NCT04798027|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: Liquid Route of administration: Intramuscular injection
215090140|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
214496270|NCT06778473|OTHER|Guided self-rehabilitation management program|Self-rehabilitation techniques are taught in individual sessions of about 40 minutes at each outpatient clinic visit, as detailed below: Analysis of the problem, Education, Massage, Facial muscles exercise,Synkinesis or spasticity management, Homework. Participants are requested to perform daily facial muscle exercises as prescribed by the therapist and keep the written diary on a daily basis. The therapists retrieve and evaluate the diaries at each visit.
214987602|NCT06967454|OTHER|Water|Participants will receive 600ml water with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
214987603|NCT06967454|OTHER|Semi-skimmed milk|Participants will receive 600ml semi skimmed milk with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
214987604|NCT06967454|OTHER|Whey permeate|Participants will receive 600ml whey permeate with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
214987605|NCT06967454|OTHER|'Low dose' water|Participants will receive 150ml water with a strawberry flavour, across 30 minutes
214987606|NCT06222762|OTHER|Experimental arm|Personalized follow-up in adapted physical activities
214987607|NCT01842295|OTHER|Blood and sperm samples|Blood and sperm samples will be done in each visit
214987608|NCT03915431|BIOLOGICAL|NCS-01|single infusion
214987609|NCT05203185|OTHER|Pulmonary Embolism Risk Kalculator (PERK)|Nudges are applications of behavioral science, defined as positive reinforcement and indirect suggestions that have a non-forced effect on decision making. Nudges will be to the PE CALC CDS tool to develop the new CDS tool, PERK.
214987610|NCT06086795|OTHER|Whole eggs|3 large whole eggs per day for 4 weeks
214987611|NCT06086795|OTHER|Egg yolks|3 large egg equivalent of egg yolks per day for 4 weeks
214987612|NCT06086795|OTHER|Egg whites|3 large egg equivalent of egg whites per day for 4 weeks
215090141|NCT01579487|DEVICE|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
215090142|NCT06942598|BEHAVIORAL|Produce prescription|Participants randomized to this arm will receive $10 worth of fruits and vegetables from Help Our People Eat (H.O.P.E) of Winston Salem each week. H.O.P.E is a local non-profit that distributes nutritious meals and fruits and vegetables to neighborhoods throughout Forsyth County to help families with FI. H.O.P.E also collaborates with local farmers to provide a Neighborhood Produce Market that provides low-cost produce. Participants will have the produce delivered to their home each week for 3 months.
215090143|NCT06942598|BEHAVIORAL|Medically tailored meals|Medically-tailored meals will be provided by Second Harvest Food Bank of Northwest NC. During the 3 months, participants will receive 10 medically-tailored refrigerated or frozen meals (5 lunches and 5 dinners) delivered to their home weekly. All meals are planned by a registered dietitian. Meals have minimal preparation time, can be heated by stove, oven, or microwave. Because the meals are medically-tailored, participants are asked not to share them.
215090144|NCT05744726|BIOLOGICAL|A-PRF|0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.
215090145|NCT05744726|COMBINATION_PRODUCT|Bone-wax|0.5 to 1g of Bone-wax for each dental socket
214496271|NCT06778473|OTHER|Health Education|Health education knowledge about the disease such as etiology, pathology,clinical symptoms of Bell's palsy, Bell's palsy diagnosis and role of medical tests;medication education;complications and sequelae,etc
214496272|NCT06464861|BIOLOGICAL|CD19-CAR-NK/T|Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T
214496273|NCT06504979|OTHER|Telehealth follow-up of post-intensive care syndrome|Using a telehealth platform for the detection of the emotional, neuropsychological and physical PICS-related sequelae along 12 months in ICU survivors
214496274|NCT01371045|OTHER|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
214496275|NCT05859750|DRUG|AK104|AK104 (6mg/kg) on day 1, IV, Q2W
214496276|NCT05859750|DRUG|AK104|AK104 (10mg/kg) on day 1, IV, Q2W
214496277|NCT05859750|DRUG|Gemcitabine|Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
214496278|NCT05859750|DRUG|Nab-Paclitaxel|Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
214496279|NCT05859750|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate|liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h
214496280|NCT05859750|DRUG|Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin|oxaliplatin, 85 mg/m²; irinotecan, 180 mg/m²; leucovorin, 400 mg/m²; and fluorouracil, 400 mg/m² given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks
214496281|NCT00490139|DRUG|Lapatinib|Small molecule inhibitor
214496282|NCT00490139|BIOLOGICAL|Trastuzumab|Antibody
214496283|NCT06024785|PROCEDURE|Vertebropexy|microsurgical (i.e., the use of a microscope or magnifying glasses during decompression) lumbar laminotomy with partial removal of the medial facet joint by preserving the midline structures (supraspinous-interspinous ligament complex); approach: bilateral or ipsilateral with cross-over to the contralateral side. Additional stabilization of the spine with a ligament (for instance semitendinosus donor allograft), which connect the postoprior structures (Proc. Spinosus and/or Lamina) of the vertebrae . Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia)
214496284|NCT06751901|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
214496285|NCT06751901|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
214685862|NCT06422234|OTHER|Game-free Exercise|All activities in the exergame group were done without games and screens. The progression of the exercises proceeds in the same way as the other group.
214375165|NCT04526002|DEVICE|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses, as done routinely by others. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 70-120%\* resting motor threshold (RMT) (The ideal %RMT will be determined first in a pilot study). In part two, stimulation intensity for patients will be 120% RMT (titration to full therapeutic dose over the first three days), as approved by the FDA in the U.S. (Blumbeger et al. 2018). The stimulation site will be the same as in the concurrent TBS/fNIRS stimulation (see above).
214375166|NCT00991341|BIOLOGICAL|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
214375167|NCT00991341|BIOLOGICAL|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
214375168|NCT00644202|BEHAVIORAL|Counseling Sessions|Counseling Sessions at each study visit around diet and physical activity from a registered dietician
214375169|NCT00644202|BEHAVIORAL|Specialized Website|Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants
214987613|NCT06420271|DEVICE|Real (real iTBS/tACS + exergaming)|Stimulation will be applied to the cerebellum. The tACS session duration will be 190 seconds with a frequency of 5 Hz coupled with iTBS (coil positioned tangentially with respect to the scalp)(600 pulses consisting of bursts of 3 stimuli at 50 Hz, repeated at intervals of 200ms, with an intensity of 80% of active motor threshold -AMT-) (Huang et al., 2005) for a total duration of 190 seconds. The exergaming will be performed with an adaptive system, comprising a force platform connected to a computer. The system is designed to enhance standard balance rehabilitation programs by guiding the user's performance of prescribed physical exercises through a video interface. Patients will perform 3 different exercises (10 minutes of training for a total of 30 minutes): 1) latero-lateral load shift; 2) antero posterior load shift; 3) omnidirectional displacement (combined latero-lateral and antero-posterior loading).
214987614|NCT06420271|DEVICE|Sham (sham iTBS/tACS + exergaming)|Stimulation will be applied to the cerebellum. The tACS session duration will be 10 seconds with a frequency of 5 Hz coupled with sham iTBS (coil positioned perpendicularly with respect to the scalp)(600 pulses consisting of bursts of 3 stimuli at 50 Hz, repeated at intervals of 200ms, with an intensity of 80% of active motor threshold -AMT-) (Huang et al., 2005) for a total duration of 190 seconds. The exergaming will be performed with an adaptive system, comprising a force platform connected to a computer. The system is designed to enhance standard balance rehabilitation programs by guiding the user's performance of prescribed physical exercises through a video interface. Patients will perform 3 different exercises (10 minutes of training for a total of 30 minutes): 1) latero-lateral load shift; 2) antero posterior load shift; 3) omnidirectional displacement (combined latero-lateral and antero-posterior loading).
214987615|NCT03114150|BEHAVIORAL|Cardiorespiratory fitness training|Physical exercise of moderate intensity designed to improve cardiorespiratory fitness
215090146|NCT00494715|DRUG|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
214987616|NCT03114150|BEHAVIORAL|Functional fitness training|Physical exercise of light intensity designed to improve functional fitness
214987617|NCT02659865|DRUG|Placebo|Administered orally
214987618|NCT02659865|DRUG|LY3039478 Capsule Formulation (Formulation 3)|Administered orally
214987619|NCT02659865|DRUG|LY3039478 Drug-in Capsule (Reference, Formulation 1)|Administered orally
214987620|NCT02659865|DRUG|LY3039478 Formulated Capsule (Test, Formulation 3)|Administered orally
214987621|NCT00133796|DRUG|Herceptin|IV
214987622|NCT06502158|DRUG|Mifepristone|200 milligrams (mg)
214987623|NCT06502158|DRUG|Misoprostol|600 micrograms (ug)
214987624|NCT05172960|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
214987625|NCT04669197|DRUG|Paclitaxel protein bound|combination therapy
214375170|NCT00644202|BEHAVIORAL|Telephone Counseling Calls|5 telephone calls with a health counselor, lasting 15-20 minutes each.
214375171|NCT00246337|DRUG|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
214987626|NCT04669197|DRUG|Gemcitabine|combination therapy
214496286|NCT06751901|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
214496287|NCT06776497|DEVICE|VIRTUAL REALITY GLASSES (VRG)|Individuals who met the inclusion criteria and signed the informed consent form were assigned to the study groups based on a list which was numbered and generated in the computer environment before the arteriovenous fistula (AVF) procedure. According to the results given by the computer programme, the individuals were assigned to the control group and the virtual realitiy group (VRG)group. While the control group included patients who underwent AVF procedure with the standard method, the virtual reality headset group included patients who underwent AVF procedure during the VRG application.
214987627|NCT04669197|DRUG|Cisplatin|combination therapy
214987628|NCT04669197|DRUG|Hydroxychloroquine|combination therapy
214496288|NCT06775197|PROCEDURE|partial meniscal replacement with Spongioflex®|for any surgical procedure, the patient receives an antibiotic shot NIMP) just before surgery. The patient will be arthroscopically treated via the arthroscopic portal with implantation of a demineralized bone block (IMP: Spongioflex ®, appropriate size (DIZG gGmbH, Berlin, Germany)) as a partial meniscus substitute. The block will be adapted to the defect size and secured with 2-4 inside-out sutures (Etibond 0, Ethicon, Somerville, NJ). No dosing, the IMP has no systemic effect. The surgery (Intervention) will last between 60-90 minutes. The hospital stay is between 2-3 days after surgery. Follow-up visits: at the end of the hospital stay, after 6 weeks, after 6, 12 and 24 months and after 5 years for the operated group.
214496289|NCT06840795|OTHER|conventional physiotherapy|Conventional physiotherapy methods will be applied. Pain relief, electrotherapy, hot applications, ultrasound etc.
214496290|NCT06840795|OTHER|Vibration Massage Therapy|The device-assisted massage therapy will be applied by the physiotherapist with its gun-shaped form that massages through vibration.
214496291|NCT06950866|BEHAVIORAL|Home-based executive function training therapy|Parents receive a 2-week, 20-session online child executive function training program, delivered by a systematically trained and supervised therapist.
214496292|NCT06950866|BEHAVIORAL|Home-based executive function training therapy|After the postintervention data collection, parents in the waitlist group receive a 2-week, 20-session online child executive function training program, delivered by a systematically trained and supervised therapist.
214685863|NCT05902741|BEHAVIORAL|RiSE|RiSE provides participants with a platform to share the emotional impact of race-based stress and to offer supportive listening to their peers. Participants explicitly discuss the experiences they have as African American women, taking into account the ways which the interaction between their racial and gender identities shapes their experiences. Facilitators review difficulties associated with addressing racism and unique experiences of Black women at interpersonal and structural levels, and provide evidence of strategies to promote effective communication and internal emotional regulation regarding experiences of racism. Facilitators provide psychoeducation on intersectionality, structural racism, overt racism, microaggressions, and internalized racism. Following this education, facilitators help participants utilize cognitive-behavioral strategies to understand consequent thoughts, feelings, and actions associated with such experiences.
214496293|NCT06953011|OTHER|music application|Patients were met within 1 hour preoperatively. Vital signs, pain score, blood glucose were checked and state anxiety scale was applied. Music was played through headphones and speakers for at least 20 minutes according to the type of music preferred by the patients and the preferred way of listening to music, and the state anxiety scale was applied again. Patients' questions were answered and they were encouraged to share any concerns. Patients were prepared for surgery and transferred to the operating room. Considering the patient's recovery from anesthesia, patients were visited again the day after surgery, vital signs, pain score, blood glucose were checked and the perianesthesia comfort questionnaire (PCQ) was applied.
214496294|NCT06954363|PROCEDURE|Mulligan Mobilization|Mulligan Mobilization involves manual tibial glides (medial and lateral) using a mobilization belt. The patient lies supine with the knee flexed between 30°-45°. The therapist applies a sustained glide while the patient actively moves the knee into flexion and extension. The treatment is delivered in 3 sets of 10 repetitions per session, 5 days per week for 3 weeks, along with a conventional physical therapy protocol.
214496295|NCT06954363|PROCEDURE|Muscle Energy Technique (MET)|Muscle Energy Technique involves the application of post-isometric relaxation targeting hamstring muscles. The therapist applies a 10-second isometric contraction at the resistance barrier, followed by a 20-second passive stretch, progressing into a new range of motion. This technique is applied 3 times per session, 5 days per week for 3 weeks, in combination with a conventional physical therapy protocol.
214685864|NCT05902741|BEHAVIORAL|HEP|The HEP group will consist of classes focusing on wellness promotion. Expert speakers provide the HEP classes (e.g dietician, pharmacist).
214685865|NCT01480154|DRUG|Akt Inhibitor MK2206|Given PO
214685866|NCT01480154|DRUG|Hydroxychloroquine|Given PO
214685867|NCT01660971|DRUG|Dasatinib|Given PO
214685868|NCT01660971|DRUG|Erlotinib Hydrochloride|Given PO
214685869|NCT01660971|DRUG|Gemcitabine Hydrochloride|Given IV
214685870|NCT01764178|DRUG|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
214685871|NCT01764178|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
214685872|NCT05482126|DIAGNOSTIC_TEST|Intraoperative Behavioral Testing|During DBS surgery, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.
214987629|NCT05633550|DIAGNOSTIC_TEST|Flexion-extension radiographs|Participants will undergo (regular) flexion-extension radiographs.
214987630|NCT05518162|DEVICE|InBloom|The Rose Program (RPv2) application will be built for iOS and Android devices (including tablets) and will feature a video-based Learning Management System (LMS) which provides resources for people with postpartum depression to improve their wellbeing. Each InBloom session will contain 4-5 video modules with specific themes contained in each ROSE session which are 3-5 minutes each.
214987631|NCT05518162|BEHAVIORAL|ROSE|"ROSE will be offered as a psychoeducational course on adjusting to parenthood by a health professional embedded in the obstetric clinics. There are five 90-minute group sessions which provide interpersonal rationale for the program, a review of the course outline, ground rules for the group, and the signs and symptoms of baby blues and postpartum depression, stress management skills. managing role transitions with an emphasis on transition to motherhood and the development of a support system, identifying types of interpersonal conflicts common around childbirth and techniques for resolving them, skills for resolving interpersonal conflicts and an opportunity to review and reinforce the content of the previous sessions."
214685873|NCT05482126|DIAGNOSTIC_TEST|Behavioral Testing|In the lab, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.
214375172|NCT00246337|DRUG|MK0974|MK0974 25 mg; one orally-administered dose
214496296|NCT06953804|OTHER|Antimicrobial stewardship activities delivered through Virtual Network|"Participants will receive online self-paced education modules regarding antimicrobial interventions, guided self-audit and reflection regarding intervention use, and reinforcement podcasts (\~7 hours).~Participants in the Virtual Newtwork arm will primarily receive these interventions online."
214496297|NCT06953804|OTHER|Antimicrobial stewardship activities delivered through Integrated Network activities|"Participants will receive online self-paced education modules regarding antimicrobial interventions, guided self-audit and reflection regarding intervention use, and reinforcement podcasts (\~7 hours).~Participants in the Integrated Network arm will primarily receive these interventions face-to-face and active online activities."
214496298|NCT06950268|DEVICE|ICAMS Splinting Protocol|The ICAMS protocol consisted of a daytime yoke splint maintaining the injured finger in 20° more extension than adjacent fingers, combined with a nocturnal static splint in the intrinsic plus position. The splinting was applied for 4 weeks following extensor tendon tenorrhaphy.
214496299|NCT06950268|DEVICE|Classic Plaster Immobilization|Participants received a classic plaster splint in the intrinsic plus position worn continuously for 4 weeks following extensor tendon tenorrhaphy.
214496300|NCT03301467|DRUG|Avacopan|Orally administered
214685874|NCT00369434|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|
214987632|NCT02602262|OTHER|HIV-infected deceased donor organ|HIV-infected deceased donor organ transplant
214987633|NCT05479461|OTHER|Digital Hypertension Management System|Mobile health technology using physician- directed, semi-automated management of hypertension
214987634|NCT05479461|OTHER|Usual Care|The participants will receive usual care
214987635|NCT03637543|DRUG|Nivolumab|Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer
214987636|NCT06110624|OTHER|Survey|A survey study will be conducted to evaluate if GHCPs have the Intention to Use (IU) MuSt-PC in daily practice.
214685875|NCT00003068|DRUG|amifostine trihydrate|
214685876|NCT00003068|DRUG|cyclophosphamide|
214987637|NCT05833035|DRUG|BI 1291583 mixed with [C-14] BI 1291583|BI 1291583 mixed with \[C-14\] BI 1291583
214685877|NCT00003068|DRUG|mitoxantrone hydrochloride|
214987638|NCT06784934|DEVICE|NeuroSky Mindfulness-Based Neurofeedback|NeuroSky will monitor participants' brain response to the intervention and provide feedback based on the participants' performance. Neurofeedback Intervention: When practicing the mindfulness-based intervention, NeuroSky will provide instructions before beginning the sessions. Dr. Saul will assist with set up and answer any questions. The apps audio and visual feedback will assist the participants as they practice mindfulness meditation. Participants in the experimental group will practice for 10 minutes in the lab during Sessions 1 and 5 and then at home for 10-20 minutes daily for 4 weeks with weekly 10-minute virtual check-ins with Dr. Saul to ensure acceptability and feasibility. Dr. Saul will also monitor participants' progress using the secure participant portal and de-identified usernames available through NeuroSky.
214496301|NCT03301467|DRUG|Avacopan Matching Placebo|avacopan matching placebo
214496302|NCT05042973|DRUG|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
214496303|NCT05042973|DRUG|Placebo|Placebo matches the active drug in appearance, odor and labelling.
214496304|NCT03243175|DRUG|Apixaban 5 MG|Apixaban 5mg x 2 during 24 months
214496305|NCT03243175|DEVICE|left atrial appendage closure|left atrial appendage closure
214496306|NCT05989659|OTHER|Exposure: Home dialysis or facility-hemodialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
214685878|NCT00003068|DRUG|thiotepa|
214685879|NCT00003068|PROCEDURE|peripheral blood stem cell transplantation|
214685880|NCT01002534|DRUG|Vardenafil|Nasal instillation of Vardenafil
214987639|NCT02967445|DEVICE|Arabin Pessary|Arabin silicon pessary
214375173|NCT00246337|DRUG|MK0974|MK0974 50 mg; one orally-administered dose
214375174|NCT00246337|DRUG|MK0974|MK0974 100 mg; one orally-administered dose
214375175|NCT00246337|DRUG|MK0974|MK0974 200 mg; one orally-administered dose
214375176|NCT00246337|DRUG|MK0974|MK0974 300 mg; one orally-administered dose
214375177|NCT00246337|DRUG|MK0974|MK0974 400 mg; one orally-administered dose
214375178|NCT00246337|DRUG|MK0974|MK0974 600 mg; one orally-administered dose
214375179|NCT00246337|DRUG|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
214375180|NCT00494533|DRUG|Remodulin (treprostinil sodium)|
214375181|NCT02547870|DRUG|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
214685881|NCT01002534|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
214375182|NCT02547870|DRUG|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
214375183|NCT02547870|DRUG|Aged RPV-LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
214375184|NCT00113932|PROCEDURE|High-Dose Density Therapy|Dexamethasone 40mg po 1-4, Thalidomide 200 mg po 1-6hrs then daily after transplant; Cisplatin\* 10 mg/m2 Continuous infusion 1-4;Adriamycin 10 mg/m2 Continuous infusion 1-4;Cyclophosphamide 400 mg/m2 Continuous infusion 1-4; Etoposide 40 mg/m2 Continuous infusion 1-4; Pegfilgrastim 6 mg subcutaneously 6 and 13; Darbepoetin 200μg subcutaneously Between -6 to-1 +12, \& every 2 weeks until HB \>12 gm/dl\*\*\*; Lovenox (or other LMWH) 40 mg subcutaneously Daily until Pltcount \<30,000/μl
214375185|NCT04411602|DRUG|SARS-CoV-2 plasma|To determine feasibility of convalescent plasma for treating patients in the ICU with COVID-19.
214375186|NCT03818789|BEHAVIORAL|Mindfulness and acceptance training|A breathing mediation, body scan, talking about acceptance, and presence activity are used. All are low-impact and expected to cause no distress
214375187|NCT03818789|BEHAVIORAL|Study skills video|A YouTube video describing study skills and suggested habits is used as a control condition.
214987640|NCT02967445|DEVICE|Cervical cerclage|
214987641|NCT01701310|DRUG|Ferric carboxymaltose|A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
215090147|NCT00494715|DRUG|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
214375188|NCT04642963|RADIATION|Cardiac Radiosurgery|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate.
214375189|NCT04447430|DEVICE|bright light|treat patients with bright light, 30 min per day, 7 times per week, over 6 weeks
214375190|NCT04447430|DEVICE|dim red light|treat patients with dim red light, 30 min per day, 7 times per week, over 6 weeks
214375191|NCT03611244|DEVICE|Portable seat device devised to maintain lumbar lordosis|"The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained."
214375192|NCT00259064|DRUG|Gefitinib|
214375193|NCT00259064|OTHER|Placebo|
214375194|NCT01966003|DRUG|Carboplatin|Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
214375195|NCT01966003|DRUG|Paclitaxel|Administered 200 mg/m² IV Q3W
214375196|NCT01966003|DRUG|ABP 215|Administered 15 mg/kg Q3W by IV infusion
214375197|NCT01966003|DRUG|Bevacizumab|Administered 15 mg/kg Q3W by IV infusion
214375198|NCT04366063|BIOLOGICAL|Cell therapy protocol 1|Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment.
214375199|NCT04366063|BIOLOGICAL|Cell therapy protocol 2|Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.
214375200|NCT04574830|OTHER|No Intervention|No Intervention
214375201|NCT01840384|DIETARY_SUPPLEMENT|Multi-micronutrients|
214375202|NCT01840384|DIETARY_SUPPLEMENT|Maltodextrin and Lactose|
214375203|NCT05147948|BEHAVIORAL|iACT for PTSD and Chronic Pain|The participants will go through internet-based Acceptance and Commitment Therapy which mainly involves: 1) Exercises focused on developing acceptance, defusion, and mindfulness skills; 2) Identification of personal values as well as valued steps and feared situations to approach during the program 3) Written exposure exercises focusing on the traumatic memory adapted from Written exposure therapy (WET) using an ACT-based framework. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
214375204|NCT02094014|BEHAVIORAL|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
214375205|NCT02094014|BEHAVIORAL|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
214496307|NCT02798471|DRUG|Edoxaban|15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
214496308|NCT02798471|DRUG|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
214987642|NCT01701310|DRUG|Ferrous Sulphate|(Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
214987643|NCT05413317|OTHER|Color Doppler Ultrasound|Comparison with conventional diagnosis strategy including a clinical probability score, D-dimers and chest imaging.
214987644|NCT02287428|RADIATION|Radiation Therapy|Standard radiotherapy (approximately 60 Gy over 6 weeks)
214987645|NCT02287428|BIOLOGICAL|Personalized NeoAntigen Peptides|NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
214987646|NCT02287428|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a flat dose of 200 mg intravenously. Pembrolizumab should be administered as a 30 minute IV infusion (Pembrolizumab treatment cycle intervals may be increased due to toxicity per protocol).
214987647|NCT02287428|DRUG|Temozolomide|Concurrent Temozolomide (TMZ) = 75 mg/m2/day for 6 weeks, administered with XRT
214685882|NCT06241599|DRUG|GP/PFLL+AK104|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks)."
214685883|NCT06241599|DRUG|GP/PFLL+placebo|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks)."
214375206|NCT02094014|BEHAVIORAL|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
214375207|NCT00571961|DRUG|Kaletra (lopinavir/ritonavir)|4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
214375208|NCT00571961|DRUG|buprenorphine|Buprenorphine will be obtained through prescription at the subject's drug treatment program.
214375209|NCT00571961|OTHER|Clinical evaluations/Blood draws|Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
214685884|NCT00257387|DRUG|Cyclosporine|
214685885|NCT03957109|PROCEDURE|general anesthesia|
214375210|NCT04264793|BEHAVIORAL|Behavioral Lifestyle Intervention|In addition to usual care in the health center, the intervention included 7 visits with the health center dietitian for individual nutrition counseling, invitation for group nutrition education (5 sessions), individual counseling for physical activity, invitation for a 6-weekly structured group physical activity, DVD on physical activity to perform physical activity at home.
214375211|NCT04264793|BEHAVIORAL|Usual Care|Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
214496310|NCT06063746|DRUG|Vidutolimod|
214685886|NCT06144528|OTHER|QT robot|In a single session each child will be video-recorded while performing the task. The participant subjects will perform the same task at two different times, once with the human operator and once with the Qt robot. Both tasks will have a duration of approximately 4 minutes. During the first minute, both the operator and the Qt will introduce themselves and ask four questions to the child to deepen the acquaintance. In the second minute, the operator/Qt will tell a story. In the third minute, the operator/Qt will ask to imitate 4 motor movements, while in the fourth minute, the operator/Qt will ask to imitate 4 facial expressions.
214685887|NCT05662137|BEHAVIORAL|Emotions Recognition and Expression|Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.
214685888|NCT03566524|DIETARY_SUPPLEMENT|Citrulline|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
214685889|NCT03566524|DIETARY_SUPPLEMENT|Alanine|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
214375212|NCT00917163|DEVICE|Supralimus(R) Sirolimus-Eluting Coronary Stent System|Drug eluting stent implantation in the treatment of coronary artery disease.
214375213|NCT00917163|DEVICE|Xience V™ Everolimus Eluting Coronary Stent|Drug eluting stent implantation in the treatment of coronary artery disease
214987648|NCT02287428|DRUG|Temozolomide|Adjuvant Temozolomide (TMZ) = 150 mg/m2/day on days 1-5 of each 28-day cycle for up to 6 adjuvant cycles
214987649|NCT02287428|BIOLOGICAL|Poly-ICLC|NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
214987650|NCT04475276|DRUG|Placebo|Lifestyle modification with placebo for 12 weeks
214375214|NCT03158363|OTHER|LPS, 36 hour immobilization and fast|LPS endotoxin is administered on study day 1 and immobilization and fast continue throughout study day 1 and 2.
214375215|NCT05974995|PROCEDURE|Robot-assisted surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymphnodes staging using DaVinci Xi
214987651|NCT04475276|DRUG|Alphalipoic acid|Lifestyle modification with Alphalipoic acid for 12 weeks
214375216|NCT05974995|PROCEDURE|Laparoscopic surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymph nodes staging using standard laparoscopic approach
214375217|NCT03327584|PROCEDURE|Arthrocentesis|Athrocentesis
214375218|NCT06020625|GENETIC|Diagnostic Test|"In order to proceed with molecular characterization, the tumor sample already taken for histological diagnosis will undergo DNA and RNA extraction, which will be analyzed for qualitative and quantitative evaluation. Based on the quantitative data, the method to be used for profiling will be decided.~Multigenic genomic profiling will be performed for each patient on already taken tumor tissue using different panels depending on the quality and quantity of nucleic acids, in particular the following will be used: comprehensive Genome Profiling (CGP, ≥500 genes), if at least 40 ng of material is available; Profiling with identification of actionable mutations by targeted sequencing with panels of size \>50 genes, if \<40 ng material available."
214496311|NCT05293717|DRUG|Ruxolitinib|1.5% Ruxolitinib cream
214496312|NCT05848674|OTHER|CArdiac Brief INtervention (CABIN)|CABIN is designed as a brief intervention with a facilitated discussion between a patient and a nurse, with the provision of a short leaflet that summarises information and acts as an aide memoir. The discussion takes place in a quiet area and is intended to last 15-20 minutes. CABIN involves a nurse listening to the patient and recognising any concerns he / she may have and / or identifying erroneous beliefs. It also provides the patient with personalised education on coronary artery disease and cardiac rehabilitation (i.e., information about stenting, stent placement, medication, and purpose / potential benefits of cardiac rehabilitation), along with facilitating psychological and emotional support discussions with a nurse (i.e., explaining causes of a STEMI, discussing support / treatment options, and exploring methods of improving health).
214496313|NCT05848674|OTHER|Refined version of CABIN|Participants of the control group will receive a refined version of CABIN, which excludes psychological and emotional support discussions with a nurse and details some standard discharge information (information about coronary artery disease and stenting / stent placement).
214496314|NCT02731612|DRUG|lurasidone|Atypical Antipsychotic
214496315|NCT02731612|OTHER|Placebo|Inactive substance
214685890|NCT06231199|OTHER|gastrocnemius release|The patient will be prone to lying and the therapist will stand at the side of the patient's leg. The therapist uses both hands in cross-hand pattern (Figure 10a and 10b). Myofascial Release will be performed for 20 repetitions, then gastrocnemius release by foam roller;This involved long sitting, with the affected leg will be extended on the foam roller and foot relaxed. The non-affected leg will be flexed at knee so that the foot will be rested on the floor. The participants will be instructed to use their arms and non\_affected foot to propel their body back and forth from the popliteal fossa to Achilles tendon in continuous motion. then patients perform plantar fascia realise from standing by foam roller
214685891|NCT06231199|OTHER|conventional treatment|the patients will receive conventional treatment in the form of ultrasound therapy (continuous mode/1MHZ) followed by plantar fascia stretch and inctruction
214685892|NCT05394584|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive stimulation therapy is a non-pharmacological intervention for people with dementia at mild to moderate stages. Group cognitive stimulation therapy is a 14-session intervention delivered twice every week for 7 weeks. In each session, mentally stimulating activities are conducted around a specific themed, such as current affairs, word association, categorising objects, and number game. Each group consists of eight people with similar levels of cognitive impairment, facilitated by two group leaders who lead the activities according to 18 key principles of the therapy, including new associations, opinions rather than facts, implicit learning, and person-centred.
214496321|NCT06525129|OTHER|Cerebellar stimulation group (CbSG)|Anodal transcranial direct current stimulation was given using a portable battery-driven brain stimulator (The Brain Stimulator v3.0 Deluxe tDCS Kit, using Professional 3x3 inches Amrex Sponge Electrodes). Skin was prepared before application of electrodes by cleaning the skin surface using alcohol swabs. In cerebellar stimulation group (CbSG) a stimulation intensity of 2mA for duration of 20 minutes. In order to avoid sudden initiation and termination of the stimulation the first and last 10 seconds of anodal tDCS application, current will gradually fade in/fade out to avoid any sudden starting or stopping of the stimulation. For the CbSG active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right buccinator muscle.
214496322|NCT06525129|OTHER|Cerebral (M1) Stimulation group (MSG)|In the M1 Stimulation Group (MSG) a similar intensity of current with 2mA was applied for a period of 20 minutes. Skin was cleaned with alcohol swab ahead of placing the electrodes. The anode was positioned over the lesioned M1 motor cortex area (C3, International 10-20 system) while the cathode was placed over the contra-lateral supraorbital area. Due to the large size of electrodes, the active electrode covered the area of M1 for the hand, arm, trunk, and the LL. Ten sessions of anodal tDCS were applied over a duration of 2 weeks. The stimulation was applied during active participation of patients in Biodex balance training.
214496323|NCT06525129|OTHER|Sham Stimulation group (SSG)|In Sham Stimulation group (SSG) Ten sessions of anodal tDCS were applied over a duration of 2 weeks having same intensity i.e., 2 mA stimulation was used for a period of 30 seconds and then gradually ramped-down and turned off for the rest of the treatment time of 20 minutes. The same procedure for skin preparation was used as in the other two groups. Electrode placement for SSG was same as in MSG for half of the patients i.e. 8 participants; anode will be placed over the left (dominant) lesioned M1 whereas the cathode will be positioned over the right (contralateral) supraorbital area. For the other 8 participants the stimulation montages were similar to cerebellar stimulation group. The active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right Buccinator Muscle.
214496326|NCT05615337|BEHAVIORAL|MBSR|"The MBSR is an eight-week group-based psychoeducational program. It is performed in weekly group sessions with the duration of 2.5 hours and a half-day retreat of 4 hours.~The program involves focused attention, consisting of body scan, yoga, and meditation. This program trains participants to be attentive to their thoughts, emotions, and sensations. There are also discussions on relevant topics related to the physiology of stress and strategies of coping. Materials for home practice are provided."
214375219|NCT05976425|DEVICE|ModPG3 Investigational Device|"* Connex Vital Sign Monitor with ModPG3~* Laptop~* Data Collection Software~* USB cable~* Power strip~* Welch Allyn FlexiPort Disposable Blood Pressure Cuffs"
214375220|NCT05976425|DEVICE|Invasive Reference Equipment|"* Surveyor S12/S19~* Hill-Rom ICU Medical data collection cable DIR 60119852~* Hill-Rom Edwards data collection cable DIR 60119853"
214375221|NCT01837004|BEHAVIORAL|CORTEX|2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task \& cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
214375222|NCT00137943|BEHAVIORAL|Full Parent communication intervention|
214375223|NCT00137943|BEHAVIORAL|Brief Parent Communication Intervention|
214375224|NCT00137943|BEHAVIORAL|Control Parent Intervention|
214375225|NCT00856674|BIOLOGICAL|OPL-CCL2-LPM|"CCL2-LPM~intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg~2 doses one week apart"
214375226|NCT03633929|OTHER|KIOS OUD|Study Participants will evaluate software known as KIOS-OUD
214987652|NCT05024929|PROCEDURE|Whole body scan|"Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor."
214987653|NCT06088979|DRUG|TOUR006 - 20 MG|TOUR006 20 MG
214375227|NCT04699435|OTHER|Control|"All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the Control group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
214375228|NCT04699435|OTHER|PreOx_3min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx\_3min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the PreOx\_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
214375229|NCT04699435|OTHER|PreOx_6min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx\_6min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 6-minute pre-oxygenation for the PreOx\_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
214375230|NCT03645967|DEVICE|ReadyCleanse Cloths|ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
214496327|NCT05615337|BEHAVIORAL|HPP|The HPP has the same structure of MBSR, including different components such as music, nutrition, cognitive enhancement, risk factors for dementia, and physical activity. During the half-day retreat participants are involved in watercolor painting activities. Materials for home practice are also provided.
214496328|NCT04926597|DIETARY_SUPPLEMENT|nutritional supplement|daily use of one or more specific oral nutritional supplement with high energy/protein content (i.e., Resource Ultra, Resource 2.0 (Fibre), Resource Ultra Fruit).
214496329|NCT04926597|OTHER|individualized nutritional guidelines|nutritional plan supervised by an experienced study dietician based on the usual home nutrition with possibility to increase intake by adaptation to patient preferences, between meal snaking and food enrichment/fortification. Every 2-4 weeks phone call by unblinded study dietician to follow nutritional intervention.
214496330|NCT04926597|OTHER|general nutritional information|general information about health food behavior upon hospital discharge
214496331|NCT04989816|DRUG|Trastuzumab Deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
214496332|NCT05902845|DRUG|RD13-02 cell infusion|CAR-T cells
214496333|NCT05716113|DRUG|RD13-02 cell infusion|CAR-T cells
214496334|NCT05982522|DRUG|IN10018|orally taken once daily
214496335|NCT05982522|DRUG|Nab-paclitaxel|125 mg/m2 D1, 8 Q3W, Intravenously
214987654|NCT06088979|OTHER|Placebo|Placebo
214375231|NCT03304002|OTHER|Breast Cancer Surgery Decision Aid|We use a standard decision aid collaboratively developed by Health Dialog and the Informed Medical Decisions Foundation
214496336|NCT05982522|DRUG|Tislelizumab|200mg Q3W, Intravenously
214496337|NCT04956887|BEHAVIORAL|AKL-T01|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
214496338|NCT04956887|OTHER|Control Group|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning
214496339|NCT01982682|RADIATION|Total-Body Irradiation (TBI)|Undergo TBI
214496340|NCT01982682|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
214496341|NCT01982682|DRUG|Cyclophosphamide|Given IV
214496342|NCT01982682|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo CD34+ selected allogeneic HSCT
214987655|NCT06088979|DRUG|TOUR006 - 50 MG|TOUR006 - 50 MG
214987656|NCT00121875|DRUG|somatropin (rDNA)|"Form/Strength: 10 mg aqueous suspension; 5 mg/ml~Dosage/Frequency: 0.35 mg/kg/week, daily divided doses~Duration: 6 months with 3-month washout period"
214987657|NCT03740893|DRUG|AZD6738|"PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle.~AZD6738 was removed as intervention under investigation as of 06 August 2024 (due to formal closure of cohort B)"
214987658|NCT03740893|DRUG|Olaparib|"PART 1 (cohort C, and cohorts E-G): Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2 (cohort C, and cohorts F and G): 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle.~Cohort C was formally closed to recruitment since 06 August 2024."
214496343|NCT01982682|DRUG|Mycophenolate mofetil|Given IV
214685893|NCT03615547|DRUG|Clomifene Citrate|"After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day."
214685894|NCT03615547|OTHER|Placebo|The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
214685895|NCT06182631|DEVICE|Buzzy Bee|The Buzzy is a vibrating palm-sized device with removable ice wings developed by MMJ Labs Atlanta, GA. It uses Melzack and Wall's Gait Control theorywhich asserts that activation of non-nociceptive fibers can interfere with signals from pain fibers thereby inhibiting pain.
214685896|NCT06182631|DRUG|Vapocoolent|Vapocoolent is a volatile refrigerated liquid, ie ethyl chloride, which is supposed to feel like the skin is numb before insertion of the IV.
214685897|NCT06182631|OTHER|Placebo|A band will be placed on the arm before IV insertion for placebo effect.
214685898|NCT03685019|RADIATION|Valgus Stress|Valgus stress radiograph
214685899|NCT03685019|RADIATION|Varus stress|Varus stress radiograph
214685900|NCT03685019|RADIATION|0 degree flexion radiograph|0 degree flexion radiograph
214685901|NCT03685019|RADIATION|20 degree flexion radiograph|20 degree flexion radiograph
214685902|NCT03685019|RADIATION|45 degree flexion radiograph|45 degree flexion radiograph
214685903|NCT04289129|DIAGNOSTIC_TEST|Myotonometric evaluation|Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.
214987659|NCT03740893|DRUG|Durvalumab|"PART 1 (cohort D): Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2 (cohorts A and D, and cohorts F and G): 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle.~Cohorts A and D were formally closed to recruitment since 06 August 2024."
214987660|NCT01636843|DRUG|NNC0109-0012|Administered subcutaneously (s.c., under the skin), once weekly.
214987661|NCT01636843|DRUG|placebo|Administered subcutaneously (s.c., under the skin), once weekly.
214987662|NCT03471819|DIAGNOSTIC_TEST|Serum serotonin level|blood sample will be obtained to evaluate serum level of serotonin
214987663|NCT00662337|DRUG|Diphenhydramine hydrochloride|After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
214375232|NCT05673629|DRUG|Utidelone Injection in combination with AC|"The treatment group will be treated with Utidelone Injection at 30 mg/m2/d administered intravenously once daily on days 1-5 of each cycle, and Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily on day 1 of each cycle. One treatment cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
214375233|NCT05673629|DRUG|Docetaxel Injection in combination with AC|"The control group will be treated with Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered intravenously once on day 1 of each cycle. One cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
214375234|NCT03152955|DRUG|Ketamine|Ketamine will be applied in patient-controlled analgesia.
214375235|NCT03152955|OTHER|scalp nerve block|Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
214375236|NCT03152955|DRUG|ondansetron|Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
214375237|NCT03152955|DRUG|Sufentanil|Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
214685904|NCT04126603|DRUG|Semaglutide|0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks
214685905|NCT04126603|DRUG|Placebos|Placebo injection
214685906|NCT00788515|DRUG|Volinanserin (M100907)|2 mg tablets QD
214685907|NCT00788515|DRUG|Lormetazepam|1 mg tablets (overencapsulated) QD
214685908|NCT06014554|OTHER|Low-risk subgroup|Self-managed exercise programme.
214685909|NCT06014554|OTHER|Medium-risk subgroup|Education, goal-orientated mobility programme, and enhanced discharge planning.
214685910|NCT06014554|OTHER|High-risk subgroup|Education, enhanced assessment, orientation, and goal-orientated activities of daily living training programme.
214685911|NCT06014554|OTHER|Control group|Usual care entails physiotherapy and occupational therapy from the day after surgery to the point of discharge, with a focus on discharge planning and sufficient recovery of activities of daily living and mobility for safe return to prefracture residence.
214987664|NCT01499407|DEVICE|ClearWay RX catheter|
214987665|NCT01499407|DRUG|Abciximab|
214987666|NCT04294823|DIAGNOSTIC_TEST|Helicobacter Pylori Diagnostic|"Helicobacter Test INFAI with standard test Meal (1g citric acid as test meal and 75 mg C\^13 urea)~\+ The C\^13 UBT with the new test (REFEX). All patients will take Nexium mups (40 mg) orally once daily 30 min before breakfast from day 1 to 28."
214685912|NCT05374408|BEHAVIORAL|Aim 2: BounceBack Now (BBN) for Trauma Informed Care Deployment|"Brief explanation of BounceBack Now (BBN) will be provided. Participants will be directed to areas of the application that are congruent with treatment focus identified during their standard of care appointment.~Participants will complete a baseline survey by either going online or being contacted by a member of the investigational team. The investigative assistant will contact all participants in 2-3 days to help the participant navigate the BBN and complete the baseline survey, if needed.~The participant will continue to meet with their behavioral health provider (BHP) as determined by the standard of care interactions. BHP will highlight features contained in BBN for participant to use in between appointments.~Follow-up phone calls will be scheduled for 2 weeks and 6 weeks after initial visit. During these phone- calls the participant will be contacted by a member of the investigational team to complete follow-up surveys."
214685913|NCT05374408|BEHAVIORAL|Aim 1 Participant Focus Groups|"At the beginning of the focus group the patients will be asked to download BBN on their smartphone device with the assistance of the research team, if they have not already done so. A basic tutorial of the BBN and the developed educational materials will be conducted/reviewed with the participants.~After the tutorial and education has been provided the participants will be asked to try some of major features of the app. Then, they will be asked to review the patient education materials. They will be asked to discuss strengths and weaknesses of the materials. They will be also asked whether there is any content missing from the education material."
214685914|NCT05374408|BEHAVIORAL|Aim 1 BHP Focus Groups|"At the beginning of the focus group the BHPs will be asked to download BBN on their smartphone device with the assistance of the research team, if they have not already done so. A basic tutorial of the BBN and the developed educational materials will be conducted/reviewed with the BHPs.~After the tutorial and education has been provided the participants will be asked to try some of major features of the app. Then, they will be asked to review the patient education materials. They will be asked to discuss strengths and weaknesses of the materials. They will be also asked whether there is any content missing from the education material."
214685915|NCT05374408|BEHAVIORAL|Aim 2: BHP, Provider, Staff and Admin Focus Groups|Semi-structured interviews will be conducted with BHPs, Clinical Staff, Providers and Administration They will ask questions to BHPs, Clinical Staff, Providers and Administration about feasibility, acceptability, and usability of BBN and overall clinical protocol.
214685916|NCT05374408|BEHAVIORAL|Aim 2 : Participant Focus Group|Semi-structured interviews will be conducted with Participants to assess the feasibility, acceptability, and usability of BBN.
214375238|NCT00993239|DRUG|Birinapant (TL32711)|30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
214685917|NCT06534905|OTHER|E-cigarette|Each participant assigned to the e-cigarette group will given a rechargeable NJOY Ace e-cigarette that is either tobacco or mint-flavored (based on their preference). Participants will also be given disposable pods prefilled with nicotine. When the pod is empty, the participant will throw it away and replace it with a new pod provided by the study staff. Participants will be asked to use as little or as much of the e-cigarette during their study participation, including choosing not to use the product. Participants will also be given information on the relative harms of nicotine and tobacco products as recommended by the American Society of Addiction Medicine.
214685918|NCT06534905|BEHAVIORAL|Control/Standard Advice|Brief advice to quit according recommendations from the American Society of Addiction Medicine
214375239|NCT05301504|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
214375240|NCT03484455|DEVICE|Hypothermic machine perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
214375241|NCT03484455|DEVICE|Static cold storage|Static cold storage (standard of care)
214375242|NCT01491139|DRUG|olaparib|Given twice daily. Exposure will escalate by daily dose and duration.
214496344|NCT05930197|DRUG|Bismuth subsalicylate|BSS is a commonly used, widely available, OTC medication for a variety of gastrointestinal GI symptoms. It is available in the generic form, but also under the more commonly known brands: Bismatrol; Diotame; Geri-Pectate; Kao-Tin; Peptic Relief; Pepto-Bismol; Pink Bismuth and Stomach Relief. It received approval by the US Food and Drug Administration (FDA) in 1939.
214496345|NCT06514391|PROCEDURE|compressive single piece dental implant|4 inter-foraminal single piece compressive dental implants were placed in the mandible via flapless protocol by the aid of stereolithographic surgical guide
214496346|NCT03259269|OTHER|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
214496347|NCT00224432|DRUG|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
214496348|NCT00609050|BEHAVIORAL|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
214375243|NCT01491139|DRUG|cisplatin|Dose will be 35mg/m2 i.v. once weekly.
214375244|NCT01491139|RADIATION|Intensity Modulated Radiotherapy|Total dose will be 70Gy in 35 fractions over 7 weeks.
214375245|NCT04119453|DRUG|Rivoceranib|Film-coated tablets
214375246|NCT01495884|DRUG|non-pegylated liposomal doxorubicon (Myocet™)|
214375247|NCT01495884|DRUG|Lapatinib (Tyverb™)|
214375248|NCT00379119|OTHER|diagnostic laboratory biomarker analysis|
214375249|NCT00379119|OTHER|flow cytometry|
214375250|NCT00379119|OTHER|physiologic testing|
214375251|NCT00379119|PROCEDURE|computed tomography|
214685919|NCT06960083|OTHER|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is an FDA-approved non-invasive brain stimulation technology. It is currently used for treating depression. Applications to other disorders such as OCD and anxiety using TMS are currently under investigation. TMS will be administered for 25 minutes.
214685920|NCT00109187|DRUG|Xolair (omalizumab)|
214685921|NCT00004879|BIOLOGICAL|panitumumab|
214685922|NCT02594475|PROCEDURE|Endoscopic retrograde cholangiopancreatography|"1. Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~2. Selective bile duct cannulation is performed using wire-guided cannulation.~3. In case of difficult cannulation, precut is performed using a needle-knife.~4. After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed."
214685923|NCT02172521|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
214685924|NCT05100316|OTHER|Screening Platform|Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.
214685925|NCT05401240|BEHAVIORAL|information reveal|the experimental group will be informed that there will be an important examination about his/her cardiopulmonary fitness condition at the outpatient department (OPD)
214685926|NCT04491942|DRUG|Cisplatin|Given IV
214685927|NCT04491942|DRUG|Elimusertib|Given PO
214685928|NCT04491942|DRUG|Gemcitabine Hydrochloride|Given IV
214685929|NCT04523727|DRUG|ferric citrate|oral tablets
214685930|NCT06432582|DIAGNOSTIC_TEST|hepatomiR|hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).
214685931|NCT05954676|OTHER|CareOrbit|CareOrbit is a third-party organization that provides a HIPAA-compliant, patient-centered digital engagement platform that helps create, organize, and update content to educate and serve the patient and caregivers through their entire treatment journey.
214987667|NCT04294823|DEVICE|Vital signs measurments|No description;
214987668|NCT04294823|DIAGNOSTIC_TEST|endoscopy|Upper endoscopy where 6 biopsy samples will be obtained . Two biopsies will be taken from antrum and corpus for histology. The biopsies will be stained with Haematoxylin \& Eosin and Giemsa stains, and gastritis wilt be scored using the Updated Sydney System 12,13 Two biopsies will be taken from antrum and corpus for rapid urease test (RUT) and two biopsies will be taken from antrum and corpus for culture. All biopsy samples will be analysed in the local laboratory of the centre.
214987669|NCT04294823|DRUG|Nexium Pill|patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast Nexium mups 40 mg will be discontinued after Day 28.
214375252|NCT05976204|PROCEDURE|ToF primary repair|ToF primary repair for patients with ToF
214375253|NCT00170833|DRUG|Everolimus|
214375254|NCT03331484|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily
214375255|NCT03331484|DRUG|Rivaroxaban|Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
214375256|NCT05701514|PROCEDURE|Elective surgical resection of CPAM between 6 and 9 months of age|Surgical resection of the CPAM between 6 and 9 months of age
214375257|NCT03933111|DIAGNOSTIC_TEST|local sound velocity measurement|All patients are scanned by Fuji film su-9000 ultrasonic system. After the lesions are found, local sound velocity measurement technology will be used to measure the sound velocity in the lesions.Pathology diagnosis or clinical follow-up results will be regard as diagnostic gold standard divide the patients into pancreatic cancer and pancreatic cancer group.
214375258|NCT00632957|DIETARY_SUPPLEMENT|Omega-3 Fatty acid (with SRP or OHI)|1000mg capsules three times daily, duration 28 weeks.
214375259|NCT00632957|DIETARY_SUPPLEMENT|Placebo|corn/soybean oil capsules 1g/three times daily
214375260|NCT02465502|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
214375261|NCT00336141|DRUG|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
214375262|NCT00237939|DRUG|Aripiprazole|
214375263|NCT04835714|DRUG|BI 1701963|BI 1701963
214375264|NCT04835714|DRUG|BI 3011441|BI 3011441
214375265|NCT02809898|PROCEDURE|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
214375266|NCT02437825|DRUG|octreotide|Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
214375267|NCT02437825|OTHER|placebo|placebo ( saline) act as comperator in this study.
214375268|NCT01390714|DRUG|E3710|"Arm A:~1. E3710 40 mg→RPZ 10 mg→E3710 20 mg~2. RPZ 10 mg→E3710 20 mg→E3710 40 mg~3. E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration."
214375269|NCT01390714|DRUG|E3710|"Arm B:~1. E3710 40 mg→E3710 80 mg→EPZ 40 mg~2. E3710 80 mg→EPZ 40 mg →E3710 40 mg~3. EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration."
214375270|NCT04774133|DIAGNOSTIC_TEST|Blood sample|Pazients will undergo to blood samples at predefined times
214375271|NCT01134601|PROCEDURE|Radiation Therapy|
214375272|NCT01134601|DRUG|Capecitabine|
214375273|NCT01134601|DRUG|AZD6244|
214987670|NCT00938938|OTHER|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
214375274|NCT03725839|DEVICE|F&P Interface|F\&P Interface to be used for OSA therapy
214375275|NCT00577018|DRUG|Prucalopride|4 mg o.d.
214375276|NCT00577018|DRUG|Prucalopride|1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
214375277|NCT00577018|OTHER|Placebo|o.d.
214987671|NCT01889381|DRUG|Bone marrow cell-based therapy & 1-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
214685932|NCT04451590|OTHER|VR-based simulation|Participants will experience a novel interactive and immersive VR full size trauma bay with an adult patient and healthcare professionals. Immersed in the environment, learners undertake the decision-making steps in managing the medical care for a patient with an airway injury. Learners are first given the case scenario from which they form their own learning goals/plans. They then navigate through the scenario that will provide feedback depending on their actions in the form of either the patient's hemodynamic changes or prompts from healthcare avatars in the scenario. These feedback processes are built-in and designed to promote reflection and reorganization of the learner's decision-making strategies. As learning progresses, fewer prompts will be given. At the end of the scenario, evaluation algorithms pre-programmed into the VR-based simulation will be displayed.
214685933|NCT04451590|OTHER|Mannequin-based simulation|Participants will experience a mannequin-based scenario practice which is the current gold standard in medical education. The trauma airway management scenario will match the VR environment and sequence of events.
214685934|NCT04461639|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice
214685935|NCT06638151|DRUG|aspirin + clopidogrel|Enrolled patients with acute ischemic stroke will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2-day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).
214987672|NCT03117127|BEHAVIORAL|Resistance Exercise|Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
214987673|NCT03117127|OTHER|Whole Eggs|Participants will ingestion whole eggs immediately after resistance exercise
214987674|NCT03117127|OTHER|Egg Whites|Participants will ingestion whole eggs immediately after resistance exercise
214987675|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.
214987676|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.
215090148|NCT00494715|DRUG|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
214375278|NCT00005625|DRUG|trabectedin|
214375279|NCT04396041|DEVICE|Microvascular Plug (MVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Microvascular Plugs.
214375280|NCT04396041|DEVICE|Amplatzer Vascular Plug (AVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Amplatzer Vascular Plugs.
214375281|NCT04396041|DEVICE|Detachable coils|Patient's Pulmonary AVM(s) treated via transcatheter embolization with detachable coils.
214375282|NCT04492358|DRUG|Colchicine|Colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)
214375283|NCT04492358|DRUG|Prednisone tablet|Prednisone 60 mg/day, in a single dose, during 3 days
214375284|NCT04492358|DRUG|standard of care|The standard treatment used in each site will be administered to the patients assigned to the control group.
214375285|NCT02287584|DRUG|DSP-5423P Placebo|DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
214375286|NCT02287584|DRUG|DSP-5423P 40mg|DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily
214375287|NCT02287584|DRUG|DSP-5423P 80mg|DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily
214375288|NCT02287584|DRUG|DSP-5423P Placebo-to-Flex|"DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
214987677|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.
214987678|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
214987679|NCT04896775|BEHAVIORAL|NiteCAPP CARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.
215090149|NCT00581451|DRUG|bifeprunox|oral tablet once daily
215090150|NCT01751776|DRUG|Placebo matching BI 655064|Placebo matching BI 655064 injected subcutaneous.
215090151|NCT01751776|DRUG|BI 655064|BI 655064 injected subcutaneous
214685936|NCT06638151|DRUG|Aspirin|Aspirin 81 mg once daily alone
214375289|NCT02287584|DRUG|DSP-5423P Active-to-Flex|"DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
214987680|NCT04896775|BEHAVIORAL|NiteCAPP SHARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
214375290|NCT05347901|DIAGNOSTIC_TEST|Echocardiography, Genomics NGS sequencing|The inner diameter of left main coronary artery, anterior descending branch, circumflex branch and right coronary artery was measured by echocardiography. Blood samples were send for genomics NGS sequencing
214987681|NCT01237730|DRUG|cefuroxime|Use the cefuroxime as prophylaxis.
214987682|NCT01237730|DRUG|Tailored antibiotic|Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
214987683|NCT02939391|DRUG|KW-6356|Oral administration
214375291|NCT02269371|OTHER|Auricular Acupuncture|Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
214375292|NCT02269371|OTHER|Sham Acupuncture|Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
214375293|NCT01817374|DIAGNOSTIC_TEST|2D US grayscale plus quantitative VCEUS|This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
214375294|NCT03841955|DEVICE|PICC with high pressure tolerance|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the experimental group and given the intervention.
214375295|NCT03841955|DEVICE|rontine central venous catheter|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the control group and given the intervention.
214375296|NCT00496002|DRUG|Clevudine|
214375297|NCT00496002|DRUG|Adefovir|
214375298|NCT03264885|OTHER|Incentive Care|ICS is a novel intervention that incorporates patient education, social support, and financial assistance to assist individuals.
214375299|NCT03182140|DRUG|Kyleena|Kyleena - intrauterine delivery system containing 19.5 mg LNG
214496349|NCT00609050|BEHAVIORAL|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
214496350|NCT00609050|BEHAVIORAL|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
214375300|NCT03389139|DEVICE|Near infrared spectroscopy (spinal anesthesia)|effect of spinal anesthesia on regional renal and cerebral oxygen saturation in newborns
214496351|NCT05188066|DIAGNOSTIC_TEST|Histology|Collect the placenta and fetal membranes and perfor either tissue culture or fixation for further analyses
214496352|NCT06566339|DEVICE|Robotically Aligned Eye Imaging System|Robotically Aligned Eye Imaging System is a non-contact, micrometer scale imaging technique that provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D. The study team will develop hardware systems and software algorithms necessary for acquiring ocular anterior segment images for those seeking eye care in emergency department settings.
214496353|NCT01505712|GENETIC|gene expression analysis|
214685937|NCT06642402|DIAGNOSTIC_TEST|Kidney biopsy|Patient refered to kidney biopsy independent of the presented study
214987684|NCT02939391|DRUG|KW-6356|Oral administration
214987685|NCT02939391|DRUG|Placebo|Oral administration
214987686|NCT03628326|OTHER|Pulmonary arterial tree|The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
214987687|NCT01544881|DRUG|Technosphere Insulin Inhalation Powder|Inhalation Powder using the Gen2C inhaler
214987688|NCT01544881|DRUG|Rapid Acting Analog|Subcutaneous Injection
214987689|NCT02857920|DRUG|Bevacizumab|7.5 mg/kg, i.v, once every 3 weeks (continuous)
214987690|NCT02857920|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v.
214987691|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
214375301|NCT03389139|DEVICE|Near infrared spectroscopy (general anesthesia)|effect of general anesthesia on regional renal and cerebral oxygen saturation in newborns
214375302|NCT04942301|DRUG|Endostar|This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed
214496354|NCT01505712|OTHER|laboratory biomarker analysis|
214496355|NCT06135922|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10\^6/kg to 1×10\^8/kg EBV-TCR-T cells per dose.
214685938|NCT06642402|DIAGNOSTIC_TEST|Urinary extracellular vesicle testing|Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease
214685939|NCT06642402|DIAGNOSTIC_TEST|Autoimmunity in plasma|Expected autoimmunity in plasma isolated from blood samples
214685940|NCT06639074|PROCEDURE|Biopsy|Undergo biopsy
214987692|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
214685941|NCT06639074|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214685942|NCT06639074|PROCEDURE|Computed Tomography|Undergo CT
214375303|NCT04942301|DEVICE|use the vein pump to pump drugs|During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.
214685943|NCT06639074|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
214987693|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
214987694|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
214987695|NCT02686255|OTHER|complete blood count|complete blood count during follow up in the heart institute
214375304|NCT04942301|COMBINATION_PRODUCT|combination therapy|Combination therapy with chemotherapy drugs was used
214375305|NCT03015506|OTHER|Bread|
214375306|NCT06449716|OTHER|12-week progressive power-oriented resistance exercise program|2x/week, 35-45 min sessions, on leg press machine
214375307|NCT02118480|OTHER|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
214987696|NCT05767970|BEHAVIORAL|Integrated Stress Toolbox for Healthcare Providers (ISTH)|The ISTH is a 12-week meditation-based well-being training. In weeks 1-8, participants engage in weekly 2-hour class sessions that are recorded and posted on a private Youtube channel for one week. There is a final two-hour session at week 12. In-class learning is augmented and extended through content in a special version of the Healthy Minds Program smartphone app that participants are asked to use on a daily basis throughout the intervention.
214987697|NCT01527669|DRUG|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
214496356|NCT01501617|BIOLOGICAL|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
214496357|NCT01501617|DEVICE|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
214496358|NCT06402552|DIAGNOSTIC_TEST|bp-MRI prostate|Biparametric MRI is considered less comprehensive compared to multiparametric MRI (mp-MRI), which includes additional parameters like dynamic contrast-enhanced MRI (DCE-MRI). However, bp-MRI offers a simpler, faster, and often less expensive alternative that still provides critical diagnostic information, particularly in the detection of clinically significant prostate cancer. It's commonly used where less comprehensive assessment is sufficient or in situations where contrast use is contraindicated.
214987698|NCT01527669|DRUG|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
214987699|NCT02100631|BIOLOGICAL|PXVX0200|
214987700|NCT02100631|BIOLOGICAL|Placebo|
214375308|NCT02118480|OTHER|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
214375309|NCT03248609|OTHER|Milano grapes|Milano grapes to test post-prandial glycemic response
214375310|NCT03248609|OTHER|Table grapes|Table grapes to test post-prandial glycemic response
214375311|NCT03248609|OTHER|Grape juice|Grape juice to test post-prandial glycemic response
214375312|NCT03248609|OTHER|Glucose beverage|Standardized glucose beverage to test post-prandial glycemic response
214496359|NCT06402552|DIAGNOSTIC_TEST|mp-MRI prostate|Multiparametric MRI is highly valued for its ability to improve the detection and characterization of clinically significant prostate cancer, aid in biopsy guidance, and help in treatment planning and monitoring. Its comprehensive approach provides crucial insights that are not as readily available through simpler imaging modalities like biparametric MRI (bp-MRI).
214685944|NCT06639074|PROCEDURE|Leukapheresis|Undergo leukapheresis
214375313|NCT04693676|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
214375314|NCT00221143|GENETIC|Autologous peripheral blood CD34 positive cell therapy|
214375315|NCT02766816|BIOLOGICAL|Part 1 study - BBio bOPV|A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.
214685945|NCT06639074|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214375316|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 1|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
214685946|NCT06639074|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
214685947|NCT06639074|DRUG|Placebo Administration|Given ID
214685948|NCT06639074|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Given IM
214685949|NCT01661361|PROCEDURE|blood levels|
214685950|NCT04318743|DRUG|Glepaglutide|GLP-2
214685951|NCT06643130|DRUG|JW0104+C2402|For 8 weeks(PO (Per Oral), QD)
214987701|NCT04786574|DRUG|Tolvaptan (OPC-41061)|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 2 years.
214987702|NCT03000972|PROCEDURE|Cement augmentation|
214987703|NCT03000972|PROCEDURE|PFN-A Nail|
214987704|NCT01446185|DEVICE|Oncotype DX breast cancer test|The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.
215090152|NCT03033342|DRUG|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
215090153|NCT03033342|DRUG|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
214375317|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 2|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
214375318|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 3|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
214375319|NCT02766816|BIOLOGICAL|Part 2 study - Licensed bOPV|Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
214375320|NCT02766816|BIOLOGICAL|Part 1 study - Licensed bOPV|A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
214987705|NCT03705325|DEVICE|Spirobank Smart spirometer|The spirometer is a compact, portable, home-based spirometer that pairs with a smartphone app. Exhaled air flow causes the turbine to rotate, generating a voltage analogous to the rate of air flow across the turbine. The spirometer measures Forced expiratory volume in 1 second (FEV1), or the volume of air that is exhaled in the first second. The device prompts the user to perform a minimum of three expiratory maneuvers in and records the best of the three maneuvers. The information generated is then transmitted to the VitalFlo App (password protected) on the user's iPhone. The user is alerted, by the App, if their expiratory effort is inadequate (such as early termination of exhalation) and is provided coaching for proper technique.
214375321|NCT04219098|PROCEDURE|Butterfly IQ|10ml of solution with .5cc (or one drop) sterile methylene blue will be injected intra-articularly under ultrasound guidance after a sterile prep. The remaining 20ml will be injected into the periarticular tissues after prosthesis implantation before closure.
214496360|NCT01240707|OTHER|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
214987706|NCT05049005|BEHAVIORAL|Simplified dietary tracking|Mobile-delivered nutrition program using simplified dietary monitoring with a focus on weight loss.
214987707|NCT00113165|DRUG|LAMICTAL extended-release|
214987708|NCT02071537|DRUG|Chloroquine|Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
214987709|NCT02071537|DRUG|Carboplatin|Administered day 1 of each 21 day cycle for 4-6 cycles.
214987710|NCT02071537|DRUG|Gemcitabine|Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
214987711|NCT01082471|DRUG|Morphine 6-glucuronide|
214987712|NCT01082471|DRUG|Morphine|
214987713|NCT01242319|BEHAVIORAL|HeartAge intervention|Computerized kiosk in waiting room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence
214987714|NCT04065308|DRUG|Drug Combinations|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response \<CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~1. dexamethasone :40mg/day D1-4, intravenous~2. cyclophosphamide: 400mg/m2 D1-4, intravenous~3. etoposide: 40mg/m2 D1-4, intravenous~4. cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
214987715|NCT02564341|BEHAVIORAL|Collaboration with an IT enabled nurse care manager|The nurse care manager at each site will collaborate with intervention physicians to implement key essential elements of guideline driven care, namely opioid treatment agreements, urine drug testing, random pill counts and periodic checking of on-line Prescription Monitoring Programs. The nurse care manager will use an electronic registry to retrieve pain medication information from the electronic medical record (EMR). Registry data will be collected on the patients of the intervention group providers. The nurse care manager will be able to use the registry to generate reports that will allow him/her to monitor those patients who are receiving opioids for chronic pain.
214375322|NCT04219098|OTHER|Standard of Care|The entire volume will be injected into the periarticular tissues after prosthesis implantation before closure.
214375323|NCT03154281|DRUG|niraparib|Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
214496361|NCT00564421|DRUG|epinastine nasal spray, low concentration, low dose volume|2 sprays in each nostril, dosed twice a day
214987716|NCT02564341|BEHAVIORAL|Education and academic detailing|All intervention participants will receive a 60 minute group didactic session by a national expert on opioid prescribing for pain. Physicians will receive two academic detailing sessions, and will be given the option of having a third, booster academic detailing session if desired.
215090154|NCT03033342|DRUG|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
214496362|NCT00564421|OTHER|placebo nasal spray|2 sprays in each nostril, dosed twice a day
214496363|NCT00564421|DRUG|epinastine nasal spray, low concentration, high dose volume|2 sprays in each nostril, dosed twice a day
214496364|NCT00564421|DRUG|epinastine nasal spray, high concentration, low dose volume|2 sprays in each nostril, dosed twice a day
214496365|NCT00564421|DRUG|epinastine nasal spray, high concentration, high dose volume|2 sprays in each nostril, dosed twice a day
214496366|NCT00065182|DRUG|Topotecan/Docetaxel combination|
214496367|NCT00065182|DRUG|Docetaxel|
214496368|NCT04684095|BEHAVIORAL|electronic patient report outcome|ePRO was conducted every two weeks in addition to routine follow-up
214496369|NCT01946594|OTHER|Acetaminophen|
214496370|NCT01946594|OTHER|Placebo|
214496371|NCT04707807|DIAGNOSTIC_TEST|IIEF-5|IIEF-15 form will be filled out by all participants
214496372|NCT05596331|OTHER|eye-tracker|Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
214987717|NCT02564341|BEHAVIORAL|Facilitated access to a specialist in addictions|The nurse care manager will encourage and arrange referral of challenging patients with potential abuse or dependence to prescription opioids to an addiction specialist.
214987718|NCT04260165|PROCEDURE|Proximal Row Carpectomy|Excision of the proximal carpal row - the scaphoid, lunate and triquetrum
214987719|NCT04260165|PROCEDURE|Four-corner fusion|Scaphoid excision and four-corner fusion with cannulated headless compression screws/dorsal plate
214987720|NCT02480296|DRUG|MYK-461|
214987721|NCT02480296|DRUG|Placebo|Placebo comparator
214987722|NCT04753801|BEHAVIORAL|Thinking, writing and imagination|All participants are asked to take some time to think and write about the respective intervention group's content. In some groups (after the writing exercise (approx. 15min)), participants are also asked to imagine that content or engage in a mindfulness activity or recall task for about 5 minutes.
214987723|NCT04023968|BEHAVIORAL|YESplus workshop|"See description in Arms section."
215090155|NCT03033342|DRUG|Oral single doses of placebo|Single doses of placebo to match MRX-4
214685952|NCT06643130|DRUG|JW0104+C2403|For 8 weeks(PO, QD)
214685953|NCT06643130|DRUG|C2402|For 8 weeks(PO, QD)
214685954|NCT06644534|DRUG|TTI-0102|(cysteamine-pantetheine disulfide)
214987724|NCT04023968|BEHAVIORAL|WOW! workshop|"See description in Arms section."
214987725|NCT02456311|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
214987726|NCT04265001|DRUG|Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash|Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
214987727|NCT00726245|BIOLOGICAL|PRGF|3-6mg IM (to area of muscle tear)
214987728|NCT00726245|BIOLOGICAL|Placebo|3cc IM of physiological saline
214987729|NCT02866981|OTHER|Observation|
214987730|NCT00279929|PROCEDURE|DHEA Replacement|
214987731|NCT05530005|OTHER|Manual Therapy|Manual Therapy according to Kaltenborn Evjenth method. Exercises with PT resistance, massage.
215090156|NCT03033342|DRUG|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
215090157|NCT03033342|DRUG|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
215090158|NCT02483949|BEHAVIORAL|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
215090159|NCT06448819|OTHER|Diet|Patients received Crohn's disease exclusion diet or Mediterranean diet
214685955|NCT06644534|DRUG|Placebo|Pearlitol® 100 SD (mannitol)
214685956|NCT06013605|BEHAVIORAL|Walking Exercise and Leg Straightening|Participants performed the exercise on the day agreed upon with the researcher. Respondents did walking exercises 3 times per week for 4 weeks with a duration of 10 minutes of warm-up, 30 minutes of walking exercises, and 10 minutes of cooling down. Respondents also did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
214685957|NCT06013605|BEHAVIORAL|Leg Straightening|Respondents did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
214685958|NCT06358859|OTHER|Food is Medicine|Regularly distributed fruit and vegetable produce boxes and nutrition education materials.
214685959|NCT00972478|DRUG|Cyclophosphamide|Given IV
214685960|NCT00972478|DRUG|Doxorubicin Hydrochloride|Given IV
214987732|NCT02764736|DRUG|Atorvastatin|Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
214987733|NCT01687439|DRUG|Endostar|7.5mg/m2, D1-14
214987734|NCT01687439|DRUG|Vinorelbine|25-30mg/m2, D1,8
214987735|NCT01687439|DRUG|Cisplatin|25 mg/m2, D1-3
214685961|NCT00972478|OTHER|Laboratory Biomarker Analysis|Correlative studies
214685962|NCT00972478|DRUG|Prednisone|Given IV
214685963|NCT00972478|BIOLOGICAL|Rituximab|Given IV
214685964|NCT00972478|DRUG|Vincristine Sulfate|Given IV
214685965|NCT00972478|DRUG|Vorinostat|Given PO
214685966|NCT05662280|DEVICE|Active Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
214685967|NCT05662280|DEVICE|Sham Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
214685968|NCT06701071|DRUG|Clomiphene Citrate|Clomiphene citrate is an estrogen receptor antagonist that leads to pituitary FSH release and prevention of the LH surge.
214987736|NCT01687439|RADIATION|Radiotherapy|
214987737|NCT01443884|DIETARY_SUPPLEMENT|Grape powder, followed by placebo powder|For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
214987738|NCT01443884|DIETARY_SUPPLEMENT|Placebo powder followed by grape powder|For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
214987739|NCT02232230|DRUG|Provenge|
214987740|NCT00872118|BEHAVIORAL|Brief Intervention for Socially Anxious Drinkers (BISAD)|integrated alcohol and social anxiety individual intervention
214987741|NCT00872118|BEHAVIORAL|Enhanced Alcohol Skills Building and Education Program|alcohol-focused group intervention
215090160|NCT02220114|DRUG|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"* first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~* second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~\- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
215090161|NCT05219669|DRUG|Nalmefene Hydrochloride|30 mg/mL solution
214987742|NCT04454606|DEVICE|Fit test|"Bitrex Fit Test The Bitrex test uses a person's ability to test a bitter solution to determine whether a respirator fits properly\[11\]. Each subject was given a taste-threshold screening test prior to each fit test to ensure that he or she could taste. This process was done without subject wearing a respirator. After passing the sensitivity test, the subject will process to 7 steps of fit test as following~* Breathe normally~* Breathe deeply~* Head side to side~* Head up and down~* Bent over wrist, jogging~* Talking~* Breath normally Each step took 60 seconds and the Bitrex solution was refilled into the hood every 30 seconds with half dosage of the amount of the previously test. We asked the participant if he / she could taste the solution during each steps of the test . The test was considered a failure, otherwise, a pass."
214375324|NCT03154281|DRUG|everolimus|Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
214496373|NCT03117426|DEVICE|SYMFONY IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
214987743|NCT04454606|DEVICE|Filtration Test|"Respirator Performance~The real time respirator performance test method was developed using MT-05U machine (SIBATA model, Saitama, Japan), which measure particle concentrations of diameter 0.03 - 0.06 µm using and particle generator laser beam scattering particle counter that measure particles outside and inside the mask. The ratio between these two values reflected % leak as following:~* leak=((Paticle inside the filter))/((Paticle inside the filter)) x 100 And calculate % filter performance = 100 - % leak We tested at the airflow rate of 40L/min which is 3-4 times higher than normal physiology, assuming that there should be no leakage through the filter. We tested 2 types of filter is CareStar and SafeStar that was incorporated with the silicone mask. CareStar is limited for 24 hour usage and SafeStar is for 72 hour duration.~Study protocol"
214987744|NCT03758508|DEVICE|High Flow Oxygen nasal cannula|High Flow Oxygen nasal cannula
214987745|NCT03758508|DEVICE|Noninvasive ventilation|In this arm, participants receive noninvasive ventilation through an interface (such as full face mask or oro-nasal mask) alternated with continuous high flow oxygen though humidified nasal cannula
214987746|NCT00300053|BIOLOGICAL|CLBS14 (low-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 1 x 10\^5 (=100000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
214496374|NCT03117426|DEVICE|AT LISA tri 839MP IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
214987747|NCT00300053|BIOLOGICAL|CLBS14 (high-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 5 x 10\^5 (=500000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
214987748|NCT00300053|BIOLOGICAL|placebo injection|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Placebo will be delivered in 10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma into the target areas of myocardial ischemia.
214987749|NCT02101567|DRUG|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head|In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
214496375|NCT01608568|DEVICE|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
214987750|NCT02101567|DRUG|Oxytocin 5 IU iv infusion and Methtergine 0.2 mg iv|In the second group of patients oxytocin 5 IU will be given iv infusion and Methergine 0.2 mg iv
214987751|NCT00744341|DRUG|SLV320|1.25mg i.v. bid
214375325|NCT02751918|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.
214496376|NCT05343494|BEHAVIORAL|Lifestyle Intervention|"The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom."
214496377|NCT00754325|DRUG|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
214496378|NCT00754325|DRUG|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
214987752|NCT00744341|DRUG|SLV320|3.75mg i.v. bid
214987753|NCT00744341|DRUG|SLV320|7.5mg i.v. bid
214987754|NCT00744341|DRUG|SLV320|15.0mg i.v. bid
214987755|NCT00744341|DRUG|Placebo|
214987756|NCT05243706|DRUG|Loratadine|Intervention is given to study its' effect on vinca alkaloids induced neuropathy
214375326|NCT02751918|DRUG|Pegylated Liposomal Doxorubicin|Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.
214375327|NCT04484714|BEHAVIORAL|Exercise|Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises.
214375328|NCT03663764|DRUG|Thymosin a1|All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
214496379|NCT03964740|OTHER|Mobile App intervention|The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
214496380|NCT01146522|DRUG|LCQ908|
214685969|NCT03385473|GENETIC|Pharmacogenomic index|All patients will have a blood sample drawn at randomization visits for PG analysis. For patients in the PA arm, the sample will be processed immediately to obtain the PG results and the subsequent index within 10 days. As soon as the results are available, the project team will contact the attending physician to propose the dosing adequation according to the pharmacogenomic index. PG analysis will be performed once for each patient.
214685970|NCT03385473|DIAGNOSTIC_TEST|Therapeutic drug monitoring|The patients included in the Pharmacological Adequation arm will have a TDM according to this schedule: day +14 (±3), +28 (±3), and +168 (±3). If there is an abnormal value (out of the therapeutic range), we will proceed to adjust the prescription.
214685971|NCT05641519|BEHAVIORAL|SERVE OC Intervention|"SERVE OC intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment and discussing prevention/risk reduction 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations such as local churches, parks, community centers, or grocery stores (for field trips) They will also receive messages from them throughout the duration of the study using their preferred method of contact (text, email, webportal/app, phone call) for reinforcement and scheduling meetings"
214685972|NCT05641519|BEHAVIORAL|Enhanced Standard Intervention|Enhanced Standard Intervention will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care
214685973|NCT00525720|DRUG|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
214685974|NCT00525720|BEHAVIORAL|Questionnaire|Questionnaires taking 30 total minutes.
214685975|NCT05391061|DRUG|Abrocitinib|Tablets
214685976|NCT04510597|PROCEDURE|Cytoreductive Nephrectomy|Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization
214685977|NCT04510597|DRUG|Active Comparator|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
214685978|NCT01522976|DRUG|Azacitidine|Given SC or IV
214375329|NCT03663764|RADIATION|hypofractionated radiotherapy|HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.
214496381|NCT01146522|DRUG|Placebo|
214496382|NCT02359929|BIOLOGICAL|Autologous mesenchymal stromal cells (MSCs)|Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
214496383|NCT01441284|DRUG|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
214496384|NCT01441284|DRUG|placebo|placebo
214496385|NCT03155113|OTHER|blood drawing|Before starting therapy a blood sample will be collected from any subject.
214496386|NCT01143142|BEHAVIORAL|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
214496387|NCT03901989|DEVICE|zeolite|given for a period of 12 months
214496388|NCT03901989|DEVICE|cellulose|given for a period of 12 months
214685979|NCT01522976|OTHER|Laboratory Biomarker Analysis|Correlative studies
214685980|NCT01522976|DRUG|Lenalidomide|Given PO
214685981|NCT01522976|DRUG|Vorinostat|Given PO
214685982|NCT06138639|GENETIC|SGT-003|Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)
214685983|NCT04889144|OTHER|Communication Intervention|Participate in PLAN intervention
214685984|NCT04889144|OTHER|Best Practice|Receive usual care
214685985|NCT04889144|OTHER|Questionnaire Administration|Ancillary studies
214685986|NCT00815412|BEHAVIORAL|Counseling in use of health care|
214685987|NCT00815412|BEHAVIORAL|Counseling in diet, exercise|
214685988|NCT00815412|OTHER|Control|
214987757|NCT05243706|DRUG|Diosmin/ Hesperidin|Intervention is given to study its effect on vinca alkaloids induced neuropathy
214987758|NCT02934594|OTHER|Palliative Decompression|palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
214987759|NCT05739071|DIETARY_SUPPLEMENT|JING SI HERBAL TEA|JING SI HERBAL TEA is a food, contain with herbal extracts
214987760|NCT05739071|DIETARY_SUPPLEMENT|Placebo|Placebo will have the same appearance as JING SI HERBAL TEA
214685989|NCT03368742|GENETIC|SGT-001|AAV9 vector containing muscle-specific promoter and microdystrophin construct
214685990|NCT06336005|DRUG|NNC6022-0001|Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.
214685991|NCT06336005|DRUG|Placebo (NNC6022-0001)|Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts
214685992|NCT05756764|DRUG|Semaglutide|Medication for weight loss
214685993|NCT05756764|DRUG|Phentermine-Topiramate combination|Medication for weight loss
214375330|NCT03663764|DRUG|concurrent chemoradiotherapy|All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
214375331|NCT04515121|DEVICE|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
214496389|NCT06337058|BEHAVIORAL|Experimental group (motivational interview)|"For the menopausal women with sexual dysfunction in the experimental group, pre-test data were obtained by applying the 'Personal Information Form', the 'Sexual Quality of Life Scale-Woman' and the 'Sexual Self-Efficacy Scale' before starting the motivational interviews. After the pre-test data were obtained, a total of 4 sessions of motivational interviews were provided, one session per week for four weeks. At the end of four weeks, post-test data were obtained by applying the Arizona Sexual Experiences Scale, Sexual Quality of Life Scale-Women and Sexual Self-Efficacy Scale.~The researcher received a training on motivational interview techniques before implementing the intervention for menopausal women in the experimental group."
214685994|NCT05756764|DRUG|Phentermine|Medication for weight loss
214685995|NCT05756764|DRUG|Tirzepatide|Medication for weight loss
214685996|NCT05756764|DRUG|Topiramate|Medication for weight loss
214685997|NCT05756764|DRUG|Diethylpropion|Medication for weight loss
214685998|NCT05756764|DRUG|Naltrexone/Bupropion|Medication for weight loss
214685999|NCT05756764|DRUG|Liraglutide|Medication for weight loss
214496390|NCT06031116|PROCEDURE|depigmentation|gingival depigmentation
214686000|NCT05107674|DRUG|NX-1607|Oral NX-1607
214686001|NCT05107674|DRUG|Paclitaxel|Paclitaxel IV
214686002|NCT05313633|OTHER|Occupational therapy|Both groups received a designed occupational therapy program for 30 minutes
214987761|NCT01060462|DRUG|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
214987762|NCT02834273|BEHAVIORAL|stroke education workshops|
214987763|NCT03246178|OTHER|MSD-HSCT|"1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day -1 and was tapered off after 1 months if no aGVHD was observed."
214496391|NCT00862030|PROCEDURE|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
214496392|NCT00001968|DRUG|Amprenavir|
214496393|NCT00001968|DRUG|Ritonavir|
214496394|NCT00001968|DRUG|Abacavir|
214496395|NCT00001968|DRUG|Lamivudine|
214686003|NCT05313633|OTHER|Plyometric training|The designed plyometric training program basically focuses on upper extremity strength training and is developed according to the guidelines of the National Strength and Conditioning Association.
214686004|NCT05313633|OTHER|Wii training|The dose of Wii training was 40 minutes, three times a week for 12 weeks which is an interactive motion-based device.
214686005|NCT00280189|PROCEDURE|Radiofrequency ablation of pulmonary malignancies|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
214686006|NCT00280189|BEHAVIORAL|Quality of life assessment|Quality of life assessment is administered prior to the Radiofrequency ablation procedure and every 3 months for 1 year following the procedure.
214686007|NCT00280189|BEHAVIORAL|Assessment of pain|Pain scores are obtained prior to the procedure, daily X 7 starting on the day of surgery, and then every 3 months for 1 year.
214686008|NCT04075266|DRUG|Ocrelizumab|"Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg"
214686009|NCT06582056|PROCEDURE|Investigational Procedure|It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.
214686010|NCT06111235|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
214686011|NCT06111235|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
214686012|NCT05132569|DRUG|Tolebrutininb|Pharmaceutical form: Film-coated tablet Route of administration: Oral
214686013|NCT05132569|DRUG|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral
214686014|NCT04102098|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
214686015|NCT04102098|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
214686016|NCT06158958|DRUG|ABBV-303|Intravenous (IV) Infusion
214686017|NCT06158958|DRUG|Budigalimab|IV Infusion
214686018|NCT04042961|OTHER|Reactive balance training|A variety of tasks will be included to induce external or internal perturbations. External perturbations will be caused by forces outside participants' control (e.g. a push or pull from the physiotherapist). Internal perturbations are when the participant fails to control the centre of mass-base of support relationship during voluntary movement; e.g., 'agility' tasks such as kicking a soccer ball. Each session will include a five-minute warm-up, at least 60 perturbations, and a five-minute cool-down. The difficulty of the task will be set such that participants will 'fail' to recover balance \~50% of the time; 'failure' is defined as use of an upper extremity response, use of external assistance (i.e. from the overhead harness or physiotherapist), or taking more than 2 steps to regain stability. Training tasks will progressed by increasing the perturbation magnitude, including cognitive or movement tasks, or imposing sensory or environmental challenges (e.g. eyes closed, obstacles).
214686019|NCT04042961|OTHER|Aerobic and strength training (AST)|"AST sessions will consist of 30 minutes of aerobic and 30 minutes of strength training.~Aerobic training: Aerobic training will be done using treadmill walking or combination of modalities (e.g. cycling or recumbent stepping) for those unable to maintain the target heart rate with walking. The heart rate that occurred at the ventilatory threshold (V̇O2VT) during the cardiopulmonary exercise test will be used to prescribe intensity. In the absence of a discernible V̇O2VT a combination of the following will be used: 60-80% of heart rate reserve, peak oxygen uptake, and rating of perceived exertion of 11-16 (Borg 6-20 scale). Prescriptions will be initially progressed by increasing duration to ≥20 minutes and then increasing intensity to target heart rate.~Resistance training: Participants will be prescribed 1-2 sets of 8 exercises per session (squat, heel raise, ankle dorsiflexion, knee extension and flexion, abdominal curl-up, wall push up, bicep curl), at 70% of 1 repetition maximum."
214686020|NCT00138710|DRUG|Letrozole (Femara)|
214686021|NCT04969016|PROCEDURE|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
214686022|NCT04969016|PROCEDURE|stapler|surgical wound closure with stapler
214686023|NCT04070313|DRUG|S-1|Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
214686024|NCT04627415|BEHAVIORAL|Promoting Engagement with ADHD Pre-Kindergarteners|Optimism Training includes the following strategies: 1) Identifying situations and associations 2) Determining consequences of beliefs 3) Use distractions to interrupt negative thinking 4) dispute current thinking 5) substitute positive, productive thoughts 6) practice skills to recognize/modify self-talk 7) Maintain positive changes in self-talk
214686025|NCT05680870|DRUG|Omeprazole|Omeprazole 40 mg 3 times daily for 5 days ..to start 2 days before chemotherapy cycles
214686026|NCT04742907|DRUG|TU-100|Treatment with investigational product
214686027|NCT04742907|DRUG|Placebo|Treatment with placebo product
214686028|NCT04372953|PROCEDURE|Positive End-Expiratory Pressure (PEEP)|"PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV)."
214686029|NCT04258111|BIOLOGICAL|IBI310 (anti-CTLA-4 antibody)|Specified dose on specified days
214686030|NCT04258111|BIOLOGICAL|Sintilimab(anti-PD-1 antibody)|Specified dose on specified days
214686031|NCT06226233|OTHER|Juniver program|The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evidence-based curriculum, interactive tools, and moderated peer support groups.
214375332|NCT04515121|DEVICE|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
214375333|NCT04515121|OTHER|Lower limb rehabilitation|Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
214375334|NCT00086541|DRUG|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
214375335|NCT05537558|DRUG|Antidepressant|Antidepressant (AD) monotherapy or complex psychopharmacology such as two ADs or AD plus augmentation (second generation antipsychotics, mood stabilizers, lithium, FT3/FT4). Combination with diverse types of ongoing psychotherapy will be accepted, if commenced prior to baseline
214375336|NCT02884414|DEVICE|Cutaneous stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
214686032|NCT04889872|DEVICE|SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA|Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve
214686033|NCT04209296|DRUG|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.
214686034|NCT02280291|DRUG|Ankle SSB|general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
214686035|NCT02280291|DRUG|Ankle OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
214686036|NCT02280291|DRUG|DR SSB|general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
214987764|NCT03246178|OTHER|HFD-HSCT|"1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day -3 and was tapered off after 2 months if no aGVHD was observed."
214987765|NCT02381691|OTHER|maternal breast milk odor|
214686037|NCT02280291|DRUG|DR OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
214686038|NCT05665465|DRUG|Nicotine nasal spray 0.5 mg|Participants will be administered nicotine nasal spray and provide subjective reactions
214987766|NCT02381691|OTHER|no odor|
214987767|NCT02631057|DRUG|Dabigatran|Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day
214987768|NCT02631057|DRUG|Warfarin|Warfarin tablet (adjustment by each patients)
214987769|NCT04841889|DIAGNOSTIC_TEST|Associated factors with decannulation|All factors potentially associated with successful tracheostomy removal will be prospectively collected: severity factors related to the ICU stay, ventilatory factors, respiratory and extra-respiratory factors. Lung and diaphragm ultrasound, swallowing, muscles and functional assessment will be performed.
214686039|NCT05665465|DRUG|Placebo|Participants will be administered placebo nasal spray and provide subjective reactions
214686040|NCT06357715|OTHER|"slumpposition"|"neurodynamic sliding mobilisation in the slump position"
214987770|NCT06293820|DRUG|TL-925|TL-925 is an eye drop.
214375337|NCT05058209|DRUG|Triamcinolone acetonide extended-release injectable suspension|Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
214686041|NCT06357715|OTHER|"no slump position"|placebo
214686042|NCT06416657|OTHER|Different anesthesia methods, namely local anesthesia and general anesthesia|"Patients in the local anesthesia group received only local anesthesia at the femoral artery puncture site without anesthesia drugs such as conscious sedation.~Patients in the general anesthesia group received not only local anesthesia at the femoral artery puncture site, but also fast-induction anesthesia with tracheal intubation or laryngeal mask insertion using isoproterenol, remifentanil, and muscle relaxants."
214987771|NCT06293820|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
214987772|NCT02934646|DEVICE|Robotic treatment|Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
214987773|NCT03261401|DRUG|M5717|Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
214987774|NCT03261401|DRUG|Placebo|Participants received placebo matched to M5717
214987775|NCT03261401|DRUG|M5717|Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
214686043|NCT06455462|DRUG|Tezepelumab|tezepelumab treatment initiated between 1st January 2023 and 31st March 2024
214686044|NCT04763109|OTHER|Whole-body Magnetic Resonance Imaging|Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
214686045|NCT03585621|RADIATION|SBRT|Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.
214987776|NCT06305481|DEVICE|P200TE|SLO and OCT imaging
214987777|NCT03808246|OTHER|using the demo version of a self-injector pen|Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.
214987778|NCT03173339|PROCEDURE|Endotracheal intubation using laryngoscope|Endotracheal intubation was done using laryngoscope for general anesthesia.
214987779|NCT03173339|DRUG|High remifentanil|Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
214987780|NCT03173339|DRUG|Low remifentanil|Remifentanil was administered as 0.1 mcg/kg/min.
214686046|NCT05264298|OTHER|VIRTUAL|At the time of discharge, stroke survivors in the VIRTUAL arm will receive a package containing an iPad and a remote BP monitoring device that allows transmission of BP to the study team.The first telehealth visit will occur 7-14 days after discharge. Patient will be counseled on the importance of BP monitoring, salt reduction, and the importance of diet and exercise for stroke prevention. Medications, side effects and interactions will be reviewed. The social worker will refer the patient to specific resources according to social needs abd patient will be referred to a primary care provider if they do not have one. Subsequent video visits will be 1-month (30 days +/- 7) , 3 months (90 days +/- 14), and 5 months (150 days +/- 14) days after enrollment.
214375338|NCT05058209|DRUG|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension|Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
214375339|NCT02798211|DRUG|Secukinumab 300 mg|150 mg x 2 s.c. injection
214375340|NCT02798211|DRUG|Secukinumab 150 mg|150 mg s.c. injection
214375341|NCT02798211|OTHER|Placebo|Placebo
214375342|NCT01982435|DRUG|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
214987781|NCT03173339|DRUG|High sevoflurane|Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
214987782|NCT03173339|DRUG|Low sevoflurane|Sevoflurane was administered as 0.5 MAC.
214987783|NCT01366391|DRUG|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
214987784|NCT04610775|OTHER|Order of cuff sizes during blood pressure measurements|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the cuff sizes are used.
214375343|NCT01982435|DRUG|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
214375344|NCT05292534|DEVICE|hearing aid amplification|Hearing aid will be fit to prescribed participant hearing loss.
214375345|NCT05292534|DEVICE|hearing aid amplification with an added sound|Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated.
214375346|NCT03844243|DRUG|NGF|Intramuscular injection
214375347|NCT03844243|DRUG|Isotonic-saline|Intramuscular injection
214987785|NCT00599001|DRUG|SD-101|Single subcutaneous escalating dose
214375348|NCT03126864|PROCEDURE|Leukapheresis|After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10\^9 (expected range 5 x 10\^8 - 5 x 10\^10), for up to two days.
214496396|NCT02672891|DEVICE|condom balloon catheter|"The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed."
214496397|NCT00145587|PROCEDURE|Stem Cell Transplantation|An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
214496398|NCT00145587|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
214496399|NCT00145587|DRUG|Systemic chemotherapy and antibodies|"Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis."
214496400|NCT05001659|OTHER|computer simulator and mannequin simulator|compared two different training simulators with respect to training effectiveness in ACLS training.
214987786|NCT00599001|DRUG|placebo|placebo
214496401|NCT00470314|DRUG|L-Ornithine L-Aspartate|
214987787|NCT02965482|DEVICE|Wright Nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
214987788|NCT02965482|DEVICE|Aerogen Solo Nebulizer|Aerogen Ltd., Galway, Ireland
214987789|NCT03873584|OTHER|Fatigue|Iron deficiency anemia with fatigue symptoms
214987790|NCT01115270|OTHER|Non-invasive measures|assessment of cerebrovascular fluid movement
214987791|NCT02503046|OTHER|Estimation of Pentraxin3|5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
214987792|NCT02503046|GENETIC|Estimation of P.Gingivalis levels|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
214375349|NCT03126864|DRUG|Fludarabine|25 mg/m2 administered by vein on Days -5 to -3.
214375350|NCT03126864|DRUG|Cyclophosphamide|900 mg/m2 administered by vein on Day -3.
214375351|NCT03126864|BIOLOGICAL|CD33-CAR-T Cell Infusion|CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is \> 1.5 x 105/kg but ≤ 4.5 x 105/kg.
214375352|NCT00002093|DRUG|Daunorubicin (liposomal)|
214375353|NCT00002093|DRUG|Bleomycin sulfate|
214375354|NCT00002093|DRUG|Vincristine sulfate|
214375355|NCT00002093|DRUG|Doxorubicin hydrochloride|
214375356|NCT04887948|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
214375357|NCT04887948|BIOLOGICAL|BNT162b2|RNA-based SARS-CoV-2 vaccine (BNT162b2)
214375358|NCT04887948|OTHER|Saline|Normal saline for injection
214987793|NCT00193635|DRUG|mycophenolate mofetil|oral drug administration
214987794|NCT00910975|DRUG|Peg-interferon-alfa2a (Pegasys)|Peg-interferon-alfa2a 180 µg per week
214987795|NCT00910975|DRUG|Ribavirin (Copegus)|Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
214987796|NCT00454077|PROCEDURE|radioiodine therapy after rhTSH|
214987797|NCT03208153|PROCEDURE|Invasive|Coronary angiogram and revascularization if anatomically feasible
214987798|NCT03208153|PROCEDURE|Conservative|Conservative
214987799|NCT03837847|BEHAVIORAL|Health Coaching Calls|Participants in this group will receive 12 weekly health coaching calls
214987800|NCT03837847|BEHAVIORAL|Control|Participants in this group will receive 6 educational guides
214987801|NCT00442793|DRUG|Epoetin beta|As prescribed, 3 times weekly
214987802|NCT00442793|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv every 2 weeks
214987803|NCT01160302|DRUG|Microgranular Curcumin C3 Complex®|4 grams twice daily for 21-28 days
214987804|NCT00793975|BIOLOGICAL|IMC-1121B|"Cohort 1~2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
214987805|NCT00793975|BIOLOGICAL|1121B|"Cohort 2~4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
214496402|NCT03311360|DEVICE|drug-coated balloon|Orchid and Dahlia DCB
214496403|NCT03311360|DEVICE|bare metal stent|any type of bare metal stent
214496404|NCT01750684|DRUG|AC105|
214496405|NCT01750684|OTHER|Placebo|
214496406|NCT00702884|DRUG|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
214496407|NCT02185794|DRUG|Voxilaprevir|Voxilaprevir tablets administered orally once daily
214496408|NCT02185794|DRUG|Placebo to match voxilaprevir|Placebo to match voxilaprevir tablets administered orally once daily
214686047|NCT05264298|OTHER|Standard care|Participants randomized to standard care will receive an educational packet and a blood pressure monitor prior to hospital discharge. They will be contacted by a social worker to determine if they received their medications and appointments. The stroke practitioner will evaluate the patients at 7-14 days and then follow up according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities. The pharmacist will contact patients at 1-month (30 +/- 7 days) days over the telephone to review BP logs and will make recommendations to their primary care provider to adjust BP medications. Subsequent pharmacist calls will occur monthly until 6 months and recommendations for medication adjustments will be communicated to their primary care provider.
214987806|NCT00793975|BIOLOGICAL|1121B|"Cohort 3~6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
214987807|NCT00793975|BIOLOGICAL|1121B|"Cohort 4~8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
214987808|NCT00793975|BIOLOGICAL|1121B|"Cohort 5~10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
214987809|NCT00793975|BIOLOGICAL|1121B|"Cohort 6~13 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
214987810|NCT00793975|BIOLOGICAL|1121B|"Cohort 7~16 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
214987811|NCT06042075|OTHER|Questionnaire on congenital birthmarks|Questions will be put to health professionals on representation using a semi-quantitative questionnaire.
214987812|NCT03259893|OTHER|AliveCor mobile ECG cardiac monitor|AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
214686048|NCT04771806|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214987813|NCT03259893|BEHAVIORAL|AF Program|The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
214987814|NCT03259893|OTHER|Standard of care|Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.
215090162|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
214496409|NCT02185794|DRUG|SOF/VEL|400 mg/100 mg FDC tablet administered orally once daily
214496410|NCT03793413|PROCEDURE|Lingual frenotomy|A lingual frenotomy will be performed using a CO2 laser - using the NFANT bottle feeding system, the intervention arm will be compared against the observation arm to determine if there are changes in lingual mobility parameters during bottle feeding.
214496411|NCT04407884|DEVICE|Soovu Labs Inc. Pain Relief System|Longnitual follow-up
214496412|NCT00005921|DRUG|L-743,872|
214496413|NCT01092416|DEVICE|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
214496414|NCT00428805|BEHAVIORAL|classroom curriculum|"classroom curriculum for 3 \& 4 year old children includes activities to increase intake of fruits, vegetables, \& whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum."
214987815|NCT03815513|OTHER|brain MRI|both case and control groups received brain MRI to evaluate cerebrovascular reactivity
214987816|NCT02145819|DRUG|hCG|
214987817|NCT02145819|OTHER|LH peak|
214987818|NCT03629301|BEHAVIORAL|ID-DPP group|This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
214987819|NCT03629301|OTHER|Wait-list Group|This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
214987820|NCT06109298|OTHER|Cold spray|Cold spray was applied for 5 seconds at a distance of 15 cm to an area of approximately 5 cm2 at the site of the procedu
214987821|NCT06109298|OTHER|Refrigerated gel ice|Refrigerated gel ice was applied for 5 minutes at 2 cm above the area to be treated.
214987822|NCT04652089|DRUG|Simvastatin 20mg|Simvastatin 20mg once a day for 7 days
214987823|NCT04652089|DRUG|Placebo|Placebo once a day for 7 days
214987824|NCT00846599|OTHER|Omega-3 study meal|Participant will eat a study meal high in omega-3 fatty acids.
214987825|NCT00846599|OTHER|Saturated fat study meal|Participant will eat a study meal high in saturated fat.
214987826|NCT01283347|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG"
214375359|NCT06542237|DRUG|YCT-529|"In the Phase 1b portion of the study (Part 1), 4 dosing cohorts and one optional 5th cohort with 4 participants in each cohort will be evaluated (approximately 20 participants): 15, 30, 90 and 180 mg.~In the Phase 1b portion of the study (Part 2), 4 dosing cohorts with 4 participants in each cohort will be evaluated (approximately 16 participant): dose to range from 30 mg upto 180 mg.~In the Phase 2a portion of the study (Part 3), up to 3 cohorts of up to 10 participants (approximately 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion."
214375360|NCT06066281|BEHAVIORAL|Neuropsychological assessment|All participants who will meet the inclusion criteria will be adminstered a pencil-paper neuropsychological tests battery including: the Digit Span Backward Task, the Brief Repeatable Battery of Neuropsychological Tests and the CST. After 15 days from the baseline evaluation the CST will be re-administrated to all subjects.
214375361|NCT01637701|PROCEDURE|PkEP|Plasmakinetic enucleation of the prostate
214496415|NCT00428805|BEHAVIORAL|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
214987827|NCT03860753|DRUG|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.
215090163|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.
215090164|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
215090165|NCT01122108|DRUG|Cholestyramine|Cholestyramine 12 grams, one time dose
214375362|NCT01637701|PROCEDURE|B-TURP|Bipolar transurethral resection of the prostate
214375363|NCT02438943|OTHER|Audit|An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
214375364|NCT02438943|OTHER|Physician Intervention|Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
214375365|NCT02167217|DRUG|Prednisolone|Prednisolone (5mg per kg) will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
214375366|NCT03600896|DRUG|CYT107|"Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~* 5 mcg/kg/dose for 3 doses~* 10 mcg/kg/dose for 3 doses~* 20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II."
214496416|NCT00428805|BEHAVIORAL|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
214496417|NCT00428805|BEHAVIORAL|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
214987828|NCT03860753|DRUG|Placebo|Pill capsules will look same as that of active drug.
214987829|NCT01668043|DRUG|Antibody UB-421|UB-421 is administered by intravenous infusion
214987830|NCT01653418|DRUG|Bortezomib|
214987831|NCT01653418|DRUG|Carmustine|
214987832|NCT01653418|DRUG|Etoposide|
214987833|NCT01653418|DRUG|Cytarabine|
214987834|NCT01653418|DRUG|Melphalan|
214987835|NCT01653418|PROCEDURE|Stem cell infusion|
214987836|NCT02331732|BEHAVIORAL|Virtually Observed Treatment|
214987837|NCT02331732|OTHER|Directly Observed Treatment|
214987838|NCT03773783|DEVICE|Button and Bead appliance|Button and Bead appliance
214987839|NCT03773783|DEVICE|Twin Block appliance|Twin Block appliance
215090166|NCT01122108|DRUG|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
215090167|NCT01902459|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
215090168|NCT01902459|OTHER|Standard of Care|Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
214496418|NCT00428805|BEHAVIORAL|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
214496419|NCT00428805|BEHAVIORAL|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
214496420|NCT00428805|BEHAVIORAL|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
214496421|NCT02877641|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
214496422|NCT02877641|OTHER|Laboratory Biomarker Analysis|Correlative studies
214496423|NCT02877641|DIETARY_SUPPLEMENT|Multivitamin|Given PO
214496424|NCT02877641|OTHER|Placebo|Given PO
214496425|NCT02877641|OTHER|Questionnaire Administration|Ancillary studies
214375367|NCT03086018|DEVICE|Successor hearing aid to Juna|The participants will all be experienced hearing instrument device users and will be switched from their current (control) devices to the new test device which succeeds the Juna device.
214375368|NCT02775422|BIOLOGICAL|Serological Test s for the Virus Chicken Pox Virus|
214686049|NCT04771806|OTHER|Neurocognitive Assessment|Undergo neurocognitive testing
214375369|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous (IV): saline
214686050|NCT04771806|OTHER|Quality-of-Life Assessment|Ancillary studies
214686051|NCT04771806|OTHER|Questionnaire Administration|Ancillary studies
214686052|NCT04331353|BEHAVIORAL|Comparator 1 (tailored approach)|Tailored to a child's sensitization status. Components include, education, cockroach baiting, mattress and bed covers, high efficiency particulate air (HEPA) vacuum cleaner, air purifier.
214375370|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline
214375371|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline
214375372|NCT01782872|PROCEDURE|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
214375373|NCT05508386|OTHER|MATLAB-based interface, showing 50 EEG traces, classification of the EEG-pattern as Burst Suppression possible, yes, no.|A software environment (MATLAB) was developed, that allows the international experts to access the data set and score the traces pseudonymously. This MATLAB-based interface shows 50 EEG traces. A representative dataset was composed, consisting of definite Burst Suppression patterns (positive control), intraoperative EEG without Burst Suppression patterns (negative control), and patterns indicating different manifestations of a possible Burst Suppression-like pattern.
214375374|NCT06399367|DIAGNOSTIC_TEST|MSOT|The MSOT system used consists of a laser in the visible near-infrared and far-infrared wavelength range (660nm-1300nm) and an ultrasonic sensor connected to a computer. Using optical components, the area to be measured is illuminated with ultra-short light pulses of selectable wavelength. The light is absorbed to varying degrees inside the object - depending on the properties of the tissue. The absorption of light leads to local microscopic volume fluctuations and thereby emits pressure waves in the ultrasonic range (photoacoustic effect). MSOT enables non-invasive, non-ionizing 2D imaging with high spatial resolution (80 μm), which enables specific visualization of endogenous tissue pigments such as collagen fibers, fat, melanin, oxyhemoglobin and deoxyhemoglobin.
214987840|NCT02856217|PROCEDURE|tunneling|In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
214375375|NCT05731089|PROCEDURE|Phacoemulsification with IVI of aflibercept|IVI was either before or after cataract surgery
214375376|NCT01892345|DRUG|Eculizumab|Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
214375377|NCT01892345|DRUG|Placebo|Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
214375378|NCT00638235|DEVICE|AMS Apogee™ with IntePro|Mesh implant for posterior wall pelvic organ prolapse
214375379|NCT00638235|DEVICE|AMS Apogee™ with Intexen LP|Graft implant for posterior wall pelvic organ prolapse
214375380|NCT00638235|DEVICE|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
214375381|NCT00638235|DEVICE|AMS Perigee™ with IntePro Lite|Mesh implant for anterior wall pelvic organ prolapse
214375382|NCT00638235|DEVICE|AMS Apogee™ with IntePro Lite|Mesh implant for posterior wall pelvic organ prolapse
214686053|NCT04331353|BEHAVIORAL|Comparator 2 (insecticidal bait)|Cockroach bait
214686054|NCT05876377|BIOLOGICAL|Pfizer-BioNTech COVID-19 mRNA vaccine|Pfizer-BioNTech COVID-19 Vaccine, is FDA licensed or authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.
214987841|NCT02856217|PROCEDURE|non-tunneling|In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
214987842|NCT04275037|OTHER|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
214987843|NCT04275037|OTHER|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
214987844|NCT02332642|OTHER|Immuno-monitoring|
214686055|NCT04145297|DRUG|Ulixertinib|"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"
214686056|NCT04145297|DRUG|Hydroxychloroquine|Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
214686057|NCT06238817|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
214686058|NCT06238817|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
214686059|NCT03508622|BEHAVIORAL|Telehealth group sessions|Telehealth sessions will utilize an online meeting platform and will be conducted by RDs, PTs, psychologists, and MDs, to deliver weight management information/counseling, to group of 5-6 14-18 yos with obesity.
214686060|NCT03508622|BEHAVIORAL|Empower clinic|Empower visits for the retrospective control group were multi-disciplinary in nature, occurred at CHLA outpatient clinic, and were intended to be monthly (though actual adherence to recommended attendance was variable). Teen and minimum of one family member were asked to attend monthly visits, as per our standard clinical care.
214375383|NCT00638235|DEVICE|AMS Elevate™ Apical & Posteiror with IntePro Lite|Mesh implant for apical and posterior wall pelvic organ prolapse
214375384|NCT00638235|DEVICE|AMS Elevate™ Apical & Posteiror with IntXen LP|Graft implant for apical and posterior wall pelvic organ prolapse
214375385|NCT00638235|DEVICE|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Mesh implant for anteiror and apical wall pelvic organ prolapse
214686061|NCT04404660|BIOLOGICAL|AUTO1|Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a total target dose of 410E+6 of CD19-positive CAR T cells as a split dose on Day 1 and on Day 10 (±2 days).
214686062|NCT03727555|GENETIC|Intrathecal and intravenous LV gene therapy|Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 multiplicity of infection/ml which carry normal ABCD1 gene
214686063|NCT06503900|BIOLOGICAL|mRNA COVID-19 vaccine|ACIP-CDC recommended vaccine
214686064|NCT06503900|BIOLOGICAL|IIV4 (quadrivalent inactivated influenza vaccine)|ACIP recommended vaccine
214686065|NCT05175261|DIAGNOSTIC_TEST|Prolocor pFCG test|Perform pFCG test on patients admitted with myocardial infarction to assess prognosis
214686066|NCT00210158|PROCEDURE|Air|Patients undergo long-term morphine treatment and vertebral cementoplasty. During the procedure, patients are ventilated with a mixture of air and oxygen.
214686067|NCT00210158|PROCEDURE|Protox|Patients undergo long-term morphine treatment and vertebral cementoplasty. During the procedure, patients are ventilated with a mixture of oxygen and nitrous oxide.
214686068|NCT03214562|DRUG|Cytarabine|Given IV
214686069|NCT03214562|BIOLOGICAL|Filgrastim|Given SC
214686070|NCT03214562|DRUG|Fludarabine|Given IV
214686071|NCT03214562|DRUG|Idarubicin|Given IV
214686072|NCT03214562|BIOLOGICAL|Pegfilgrastim|Given SC
214686073|NCT03214562|DRUG|Venetoclax|Given PO
214686074|NCT05029570|DEVICE|Conduction System Pacing (pacemaker implantation)|Conduction System Pacing (pacemaker implantation) and Atrioventricular node ablation
214686075|NCT05832931|DRUG|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
214686076|NCT05832931|DRUG|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
214375386|NCT00638235|DEVICE|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)|Mesh implant for anteiror and apical wall pelvic organ prolapse
214375387|NCT02601898|DEVICE|Lipoic acid|Vaginal capsules (medical device) containing 10 mg of lipoic acid (1 per day)
214375388|NCT02601898|DRUG|Progesterone|Vaginal capsules (drug) containing 200 mg of progesterone (2 per day)
214375389|NCT02696044|DRUG|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
214375390|NCT06009640|DEVICE|Intraoperative neurophysiological monitoring with Nicolet Endeavor IOM Machine|Integration of intraoperative neurophysiological monitoring (IONM) into laparoscopic decompression surgery to protect pelvic nerves by continuously monitoring when they are at risk during surgery.
214686077|NCT05832931|DRUG|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
214686078|NCT03036228|DRUG|Karonudib|Dose escalation of administration with Karonudib.
214686079|NCT04233749|DRUG|Tranexamic acid tablets|325mg of tranexamic acid twice daily for six months
214686080|NCT05774392|OTHER|Observational|Observational
214686081|NCT01750567|DRUG|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
214686082|NCT06402994|OTHER|Electrophysiological experiment|Neural envelope tracking to conversational speech at different intensities
214686083|NCT06402994|BEHAVIORAL|Speech audiometry|Speech perception assessment at different intensities
214686084|NCT05754944|DIAGNOSTIC_TEST|ABI/TBI|ABI/TBI to be performed after surgery while patient is still admitted at the hospital.
214686085|NCT05754944|OTHER|Questionnaires|PAD symptoms questionnaire to be administered at baseline before surgery. mLEFS (included in PAD symptoms questionnaire) and WIQ to be administered at baseline before surgery. mLEFS and WIQ will be administered 1 month, 3 months, 6 months after surgery and every 6 months after that for a goal of at least 1 year.
214686086|NCT05781321|RADIATION|Accelerated Hypofractionated Radiation Therapy|Undergo short course RT
214686087|NCT05781321|PROCEDURE|Computed Tomography|Undergo CT simulation
214686088|NCT05781321|DRUG|Fluorodopa F 18|Given IV
214686089|NCT05781321|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214686090|NCT05781321|PROCEDURE|Positron Emission Tomography|Undergo PET
214686091|NCT05781321|OTHER|Quality-of-Life Assessment|Ancillary studies
214686092|NCT05781321|OTHER|Questionnaire Administration|Complete questionnaires
214686093|NCT05781321|RADIATION|Radiation Therapy|Undergo standard course RT
214686094|NCT05781321|DRUG|Temozolomide|Given PO
214686095|NCT05781321|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214686096|NCT06585033|DEVICE|Spinal cord stimulation|Stimulation off
214686097|NCT06585033|DEVICE|Spinal cord stimulation|Stimulation on
214686098|NCT03909763|DRUG|Berberine plus danazol|Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
214686099|NCT01244542|OTHER|unpleasant stimuli|
214686100|NCT02660424|DRUG|VX-150|
214686101|NCT02660424|DRUG|Placebo|
214686102|NCT00041223|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|
214686103|NCT00145548|DEVICE|Intra Bronchial Valve|
214686104|NCT03196505|DRUG|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
214686105|NCT03196505|DRUG|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
214686106|NCT01911624|DRUG|direct thrombin inhibition|
214375391|NCT02714101|OTHER|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
214375392|NCT05763758|OTHER|No intervention|No intervention involved in this study
214375393|NCT05970302|DRUG|Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine|Use the above medications on a regular basis.
214375394|NCT04731415|DEVICE|Optical coherence tomography and optical coherence tomography angiography (Optovue®)|"Optical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks"
214375395|NCT04929093|BIOLOGICAL|Novel dose adjustment of Alutard SQ|novel dose adjustment schedule means directly reaching dose of Vial 4, 10,000 SQ
214686107|NCT01911624|DRUG|enoxaparin|
214375396|NCT04929093|BIOLOGICAL|conventional dose adjustment of Alutard SQ|conventional dose adjustment schedule means restarting from dose of Vial 1, 10 SQ
214375397|NCT04929093|BIOLOGICAL|Routine continuous cluster of Alutard SQ|Patient receiving continuous cluster SCIT for DM during the same period
214375398|NCT05688735|OTHER|Isosorbide Diester Moisturizer|Isosorbide Diesters (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5% ointment
214375399|NCT05688735|OTHER|Control Moisturizer|Topical vehicle (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5 % ointment
214375400|NCT02074046|BIOLOGICAL|cancer stem cell vaccine|
214375401|NCT01336881|GENETIC|RNA analysis|
214375402|NCT01336881|GENETIC|gene expression analysis|
214686108|NCT02032537|DRUG|Callmax cream application over affected skin|Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
214686109|NCT02032537|DRUG|Placebo|Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
214686110|NCT03879317|DEVICE|Continuous NIRS monitoring|Septic shock patients who have continuous NIRS and blood pressure monitoring at same time will be included. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
214686111|NCT06018922|BEHAVIORAL|Psychological treatment|The treatment is module-based, and the clinician are supposed to choose a small number of modules to work with depending on the patients need. The individual CBT modules are: 1) Behavioral activation, 2) Accepting thought, 3) Emotion regulation, 4) Impulse control, 5) Procrastination, 6) Relationships, 7) Problem-solving skills, 8) Structuring everyday-life, 9) Diet-Exercise-Sleep, and 10) Social anxiety. The family therapy modules are: 1) Psychoeducation about gaming, 2) Encourage other activities, 3) Positive time together, 4) Expectations and the patients abilities, 5) Making agreements in the family, 6) Emotional validation, and 7) Conflict management.
214686112|NCT05747690|DEVICE|KIO015|Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection
214686113|NCT06623461|DRUG|Standard of Care Immune Checkpoint Blockade|Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment
214686114|NCT06623461|DRUG|LND101|Approximately 40 capsules (total of 80-100g of processed fecal material) taken by mouth 7 days prior to the ICG agent(s) administered following bowel preparation.
214686115|NCT04735978|BIOLOGICAL|RP3|Genetically modified HSV-1
214686116|NCT04735978|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
214686117|NCT06052072|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
214686118|NCT00969111|RADIATION|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE|Postop High Risk
214686119|NCT00969111|RADIATION|Proton (prostate bed) to 70.2 CGE|Salvage Non-High Risk
214375403|NCT01336881|GENETIC|microarray analysis|
214375404|NCT01336881|GENETIC|nucleic acid sequencing|
214375405|NCT01336881|OTHER|diagnostic laboratory biomarker analysis|
214375406|NCT03759613|OTHER|Gait Analysis|"Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented."
214375407|NCT02475317|DRUG|Placebo|Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.
214375408|NCT02475317|DRUG|Maralixibat|Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.
214375409|NCT02475317|DRUG|Volixibat|Participants will receive volixibat in 10 mg and 20 mg doses.
214375410|NCT02748694|DRUG|TAK-041|TAK-041 tablets or oral suspension.
214375411|NCT02748694|DRUG|TAK-041 Placebo|TAK-041 placebo-matching suspension or tablet.
214375412|NCT01473381|DRUG|Vilazodone|Vilazodone was supplied as film-coated tablets.
214375413|NCT01473381|DRUG|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
214375414|NCT01473381|DRUG|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
214375415|NCT01473381|DRUG|Citalopram|Citalopram was supplied as encapsulated tablets.
214686120|NCT00969111|RADIATION|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE|Salvage High Risk
214686121|NCT00969111|RADIATION|Proton to 66.6 CGE|Post-Op Non High Risk
214987845|NCT03564262|OTHER|Low Sodium Meal (138 mg sodium)|One Low Sodium Meal
214987846|NCT03564262|OTHER|High Sodium Meal (1,495 mg sodium)|One High Sodium Meal
214987847|NCT04130087|DRUG|Selegiline Hydrochloride 10 MG|Single 10mg tablet of Selegiline Hydrochloride
214686122|NCT05544422|OTHER|The Timed Up & Go Test and 30second Chair-Stand Test'|"Evaluation of the participants will be carried out in the following order; 1) traditional assessment, 2) tele-assessment, 3) post-test. In the final test, only tele-assessment of the tests will be made.~During testing sessions, the results of each TUG and 30s-CST trial will be recorded on a standard test paper. TUG and 30s-CST will be tested in two different ways, traditional and tele, as 2 sessions every other day. Participants will rest for five to ten minutes between trials and an hour between sessions. During the one-hour rest between two test sessions, participants will rest in a chair, wheelchair or bed. Assessors will not know the TUG and 30s-CST results scored by each other."
214686123|NCT05955586|DRUG|SPR720|SPR720 1000 mg (250 mg\*4 capsules) will be administered orally.
214686124|NCT01226420|DRUG|Alefacept|Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
214686125|NCT05590793|DRUG|Triptorelin pamoate (embonate) salt|Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.
214686126|NCT02978118|DEVICE|Immune cell and CTC detection procedures|Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)
214686127|NCT04653545|DIAGNOSTIC_TEST|HbA1c|"Blood will be taken as per requirement for patients being admitted to hospital. A small sample will be sent to the biochemistry department for measurement of HbA1 (by HPLC method).~All patients who are diagnosed with diabetes (or known to have diabetes) will have a foot examination and retinal and renal screening and cardiovascular assessment for diabetes complications."
214375416|NCT03575533|DIAGNOSTIC_TEST|Bayesian network 'Sherlock'|Primary objective is to validate the Bayesian Hemodynamics model 'Sherlock'. Criterion for validation is a match between Sherlock's estimate of the Hemodynamic status of a patient and a ground truth based on a cardiologist's judgement.
214496426|NCT04046159|DRUG|Low-dose tamoxifen|Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
214496427|NCT04046159|RADIATION|Whole breast radiotherapy|Ipsilateral breast tumor recurrence and side effect
214686128|NCT06526169|OTHER|Food Frequency, Social, Lifestyle, Demographic Questionnaires and Blood Collection|Questionnaires on food frequency, social, lifestyle, and demographics will be administered to participants and will be correlated with the presence of chemical hazards in the blood. The chemical hazards analyzed will be referenced from Singapore's Total Diet Study, based on the prioritized chemical hazards of interest to investigate the distribution of risk in the population.
214686129|NCT06565416|BEHAVIORAL|Implementation Strategies|Culturally centering screening and brief intervention for chronic pain and opioid misuse/opioid use disorder among American Indian/Alaska Native clients
214686130|NCT06519929|PROCEDURE|ESP block with catheter using ropivacaine (bolus followed by continuous infusion)|A total of ropivacaine 75mg will be injected into the plane via the needle, followed by placement of a catheter 3-5 cm into the plane. A continuous infusion of ropivacaine 0.2% will be started at 8 mL/h and may be titrated up to a maximum of 10mL/h. Bolus doses of 5 mL using ropivacaine 0.2% will be permitted for breakthrough pain (pain score ≥ 7/10) and may be administered no more frequently than every 6 hours. Patients will be assessed for LAST twice daily by asking about tinnitus, perioral numbness, or metallic taste. Any patient who responds positively to these symptoms will have infusion stopped for 2 h and then restarted at a rate 2 mL/h lower. If the symptoms occur again, the catheter infusion will be stopped and the catheter removed. After the 72-hour study period the ESP catheter may remain in place if the patient has ongoing analgesia needs or if analgesia is controlled with oral medication the catheter may be removed at request of the treating team.
214686131|NCT06519929|DRUG|Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h|A bolus of 1 mg/kg based on ideal body weight will be given over 10 minutes with a physician present and infusions will be started at 1 mg/kg/h based on IBW. Infusions will run continuously for the first 72 h and can be continued beyond that at the discretion of the treating team if pain persists. Patients will be assessed for LAST twice daily. Any patient with suspected LAST will have lidocaine infusion stopped and a lidocaine plasma level will be sent. If symptoms resolve, the lidocaine infusion can be restarted at a rate 25% lower. If pain is refractory to the lidocaine infusion and multimodal adjuncts, the infusion may be increased to a maximum of 1.5 mg/kg/h (during first 24 h only). The actual duration of the infusion as well as total lidocaine dose given in mg will be recorded. Stopping criteria for lidocaine will include the occurrence of new EKG changes for which an alternative explanation is not more likely as well as LAST symptoms.
214686132|NCT06969001|DRUG|SCAI-005 0.04% or placebo|axitinib 0.014mg or placebo
214375417|NCT02302131|OTHER|SAPIEN XT|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
214375418|NCT06013501|BEHAVIORAL|puppet show|puppet show to the child before and during subcutaneous application
214375419|NCT00214825|DRUG|eplerenone|50 mg daily for 6 weeks with placebo
214496428|NCT05465018|DEVICE|Happy Flow / Baseline|Baseline (without make-up or mask)
214496429|NCT05465018|DEVICE|Make-up|To test device on participant who is wearing facial make-up
214496430|NCT05465018|DEVICE|Sunglasses|To test device on participant who is wearing sunglasses
214686133|NCT06969001|DRUG|SCAI-005 0.08% or placebo|axitinib 0.028mg or placebo
214686134|NCT06969001|DRUG|SCAI-005 0.08% or placebo 2drops|axitinib 0.056mg or placebo
214686135|NCT06442761|DRUG|Motixafortide|Given Subcutaneously (under the skin).
214686136|NCT06968390|DEVICE|Transcranial Magnetic Stimulation|Non-invasive form of brain stimulation.
214686137|NCT05278962|DRUG|SGLT2i|empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
214686138|NCT05278962|OTHER|No SGLT2i|No SGLT2i
214375420|NCT00214825|DRUG|Hydrochlorothiazide|HCTZ 12.5 mg with potassium (10 mEq) daily for 6 weeks
214375421|NCT02922894|PROCEDURE|Acute episodic hypoxia|The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.
214375422|NCT02922894|PROCEDURE|Supplemental oxygen|Supplemental oxygen therapy for 6 weeks
214375423|NCT02922894|DRUG|Trazodone|100mg before bedtime
214496431|NCT05465018|DEVICE|Face mask|To test device on participant who is wearing a facial mask
214496432|NCT05465018|DEVICE|Minimum requirements camera|To test the minimum requirements of the camera
214686139|NCT04272216|DEVICE|Treatment with HydroPearl via radial access|This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
214686140|NCT03015610|DRUG|commercially available lansoprazole|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily lansoprazole for 24 weeks
214686141|NCT03015610|DRUG|matched placebo|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
214496433|NCT05465018|DEVICE|Worst case hardware|To test if software still works with an older smartphone
214686142|NCT05174039|DRUG|Miglustat 100 milligrams (mg) Oral Capsule|Subjects will initiate miglustat at Week 1 and dosing will be escalated until 600mg/d. If a subject has not reached the maximum dose (600 mg/d) by Week 8, the Week 8 dose will be subject's MTD.
214686143|NCT04687774|DEVICE|ExaltTM Model D Single-Use Duodenoscope|The Exalt™ Model D Single-Use Duodenoscope is a sterile, single-use endoscope that facilitates access to the duodenum, delivery of accessories, and live video when connected to an Exalt™ Controller.
214686144|NCT06969261|BEHAVIORAL|Penny COPILOT|The Penny COPILOT chatbot is an interactive short messaging system (SMS) program that provides educational and supportive content for postpartum individuals. The chatbot has been adapted to include information relevant to opioid use disorder recovery in order to decrease the risk of returning to use among people who use drugs. Messages are sent at specified intervals relevant to the postpartum course and the chatbot allows for two way messaging with an interactive lens.
214686145|NCT02941783|DRUG|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)|Treatment parameters following the physician's decision based on the summary of product characteristics.
214686146|NCT02598349|RADIATION|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
214686147|NCT02598349|DRUG|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
214686148|NCT02598349|PROCEDURE|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
214686149|NCT06227754|PROCEDURE|Angiography-guided PCI group|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.
214686150|NCT06227754|PROCEDURE|Optical coherence tomography-guided PCI group|"\[Stent Optimization\]~1. Stent Expansion:~   Visually assess residual angiographic diameter stenosis \<10% AND~   ① In non-LM lesions: In-stent minimal lumen area (MSA) \>80% of the average reference lumen area OR \>4.5 mm2~   ② In LM lesion: MSA\>7 mm2 for distal LM and \>8 mm2 for proximal LM~2. Stent Apposition:~   No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall~3. Edge Dissection:~No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as \>60° of the circumference of the vessel at site of dissection and/or \>2 mm in length of dissection flap)"
214686151|NCT06400472|DRUG|LY4170156|Intravenous
214987848|NCT04130087|DRUG|Placebo|Single Placebo Tablet, identical appearance to experimental tablet.
214987849|NCT01067391|DRUG|tadalafil|20 mg tablet, administered once per study protocol
214987850|NCT01067391|DRUG|placebo|placebo tablet administered once per study protocol
214987851|NCT03049566|OTHER|preoperative questionnaires|no intervention, cross-sectional survey in a single group
214987852|NCT01905072|OTHER|Education Home Visits|"Intervention will include educational home visits on:~1. Growth monitoring and feedback~2. Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.~3. Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.~4. Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.~5. Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby."
214987853|NCT01021384|BEHAVIORAL|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
214987854|NCT05413642|DRUG|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
214987855|NCT05413642|DRUG|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
214496434|NCT05465018|DEVICE|Damaged lens|To test if software is still working when the lens of the smartphone is damaged
214496435|NCT05465018|DEVICE|Face or chest outside test frame|To test software if the participants face or chest is outside the test frame
214496436|NCT03916341|OTHER|EC with nicotine|Use an EC with nicotine for up to 30 minutes
214496437|NCT03916341|OTHER|EC without nicotine|Use an EC without nicotine for up to 30 minutes
214496438|NCT03916341|OTHER|control|sham control
214496439|NCT03916341|OTHER|TC with nicotine (own brand)|smoke a TC
214496440|NCT03916341|OTHER|research TC with very low level nicotine|smoke a research TC with very low level nicotine
214686152|NCT06400472|DRUG|Bevacizumab|IV
214686153|NCT06400472|DRUG|carboplatin|IV
214686154|NCT05557279|DRUG|500 mg NDS-446|All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
214686155|NCT05987449|DRUG|NXT007|Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
214686156|NCT04948736|COMBINATION_PRODUCT|Combined exercise and nutrition intervention|"Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks).~Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol.~Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink."
214686157|NCT04948736|OTHER|Conventional medial care|"Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein-rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
214686158|NCT02781467|BIOLOGICAL|PNK-007|
214686159|NCT02781467|DRUG|Cyclophosphamide|
214686160|NCT02781467|DRUG|Fludarabine|
214686161|NCT02781467|DRUG|Human recombinant Interleukin-2 (rhIL-2)|
214686162|NCT05692154|DRUG|Fexofenadine|Fexofenadine oral tablet
214686163|NCT05692154|DRUG|Placebo|Fexofenadine matching placebo oral tablet
214686164|NCT05711407|GENETIC|Gene Polymorphisms of MMP-8|Saliva Samples
214686165|NCT04408521|OTHER|NEUROFEEDBACK|EEG recording during alpha-related TV viewing
214686166|NCT04408521|OTHER|CONTROL|EEG recording during passive TV viewing
214686167|NCT00759473|DRUG|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
214686168|NCT00759473|DRUG|Placebo|
214686169|NCT01225406|DRUG|Tenofovir|
214686170|NCT05994846|DEVICE|RISES-T System|The RISES-T system is a hardware and software platform that has been designed and developed to help people living with movement impairment due to Spinal Cord Injury (SCI) to improve and/or restore mobility. The hardware consists of a functional electrical stimulation device that delivers stimulation to the skin through surface electrodes; a series of wearable sensors that collect kinematic (IMU) data and muscle activity (EMG) data, and RISES Software, which incorporates algorithms that utilizes the streaming IMU and EMG sensor data to inform the electrical stimulation parameters and enables real-time visualization of the sensor data and stimulation parameters via Graphical User Interface (GUI).
214686171|NCT02059421|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"\- Therapy session administered by a clinical psychologist using web-based video conferencing software.~Therapy sessions will include:~* Sleep restriction therapy~* Stimulus control instructions~* Sleep hygiene education"
214686172|NCT02059421|OTHER|Johrei therapy|"* Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.~* Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.~* Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.~* Therapy will be administered without physical contact.~* During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient."
214375424|NCT02922894|DRUG|Placebo|One placebo pill before-bedtime
214375425|NCT02922894|PROCEDURE|Sham|Room air will be administered instead of episodic hypoxia or supplemental oxygen..
214375426|NCT03166371|DIETARY_SUPPLEMENT|Liposomal Glutathione (GSH)|Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
214987856|NCT01983930|BEHAVIORAL|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
214987857|NCT01983930|BEHAVIORAL|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
214686173|NCT04023591|PROCEDURE|Surgery/Occupational Therapy|Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
214686174|NCT01787500|BIOLOGICAL|Cetuximab|Given IV
214686175|NCT01787500|DRUG|Irinotecan Hydrochloride|Given IV
214686176|NCT01787500|OTHER|Laboratory Biomarker Analysis|Correlative studies
214375427|NCT03166371|OTHER|Placebo|Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
214686177|NCT01787500|OTHER|Pharmacological Study|Correlative studies
214686178|NCT01787500|DRUG|Vemurafenib|Given PO
214686179|NCT06494059|OTHER|Intermittent theta burst stimulation (iTBS)|iTBS is a magnetic stimulation applied using a magnetic coil that is placed on top of the participants head to activate the brain. It consists of three very rapid bursts of electrical pulses at a frequency of 50 Hz (per burst) delivered at a rate of 5 per second for 2 seconds (10 bursts). The burst of pulses will be repeated every 10 seconds for a total duration of about 3 minutes. The stimulation will be applied to activate the brain regions that control upper limb, lower limb or trunk muscles. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
214686180|NCT06494059|OTHER|Functional electrical stimulation (FES)|FES is applied using electrodes that stick to the skin over the muscles or nerves. It will will be applied using an electrical stimulator to produce movements of the hand, leg or the trunk. The stimulation intensity will be determined by gradually increasing strength from 20-100 hertz (hz) until the right amount of movement is obtained. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
214686181|NCT06494059|OTHER|Transcutaneous spinal cord stimulation (TSCS)|TSCS is applied using electrodes that stick to the skin over the spinal cord to activate spinal cord. Mild electrical stimulation will be applied to make sure the nerves on the back are activated (switched on). Different stimulation intensities (strength) will be tested at different frequencies (pulses per second) to determine the best setting for activating the nerves on the back. The stimulus current strength will be adjusted between 0-250 milliamperes (mA) and will remain within the self-reported tolerance limit of each participant. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
214987858|NCT00869596|DRUG|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
214987859|NCT00869596|DRUG|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
214987860|NCT00869596|DRUG|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
214375428|NCT00615381|DRUG|Insulin|insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
214375429|NCT00361101|DRUG|AMD11070|200 mg PO BID (by mouth two times per day) for 10 days.
214987861|NCT00869596|DRUG|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
214987862|NCT04686331|DIAGNOSTIC_TEST|Biomarkers for pneumonia|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of surfactant protein D, Krebs von den Lungen (KL-6), and YKL-40. Laboratory staff will be blinded to participant diagnosis and outcome. None of the biomarkers will be available to the treating physician.~* Diagnostic test of surfactant protein D - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of KL-6: will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of YKL-40 - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis"
214987863|NCT03403049|RADIATION|Carbon Ion|Study subjects will receive carbon ion radiotherapy (CIRT), with daily fraction sizes of 3 GyE. The total CIRT dose will increase with each dose level. Subjects in dose level 1 and 2 will receive photon radiotherapy as well.
214686182|NCT06494059|OTHER|Sham Intermittent theta burst stimulation (iTBS)|Subjects will be fitted with a magnetic coil that is placed on top of the head that does not deliver any stimulation to the brain. Each subject is expected to participate longitudinally at least 9 times over 2 months.Each visit will take approximately 2-3 hours.
214686183|NCT00733382|DRUG|dexamethazone|injection form, 8 miligram, injected once
214686184|NCT06808321|DRUG|Benidipine Hydrochloride|The safety and efficacy of a dihydropyridine calcium channel blocker for the treatment of high blood pressure and/or angina pectoris
214686185|NCT06842680|BEHAVIORAL|Control|Products do not carry ultraprocessed warning label. To match the current Chilean legislation, products carry octagonal nutrient labels when applicable.
214686186|NCT06842680|BEHAVIORAL|Ultraprocessed warning label|Products carry ultraprocessed warning label. To match the current Chilean legislation, products carry octagonal nutrient labels when applicable.
214375430|NCT04397484|DRUG|0.5% Levobupivacaine|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
214496441|NCT04214756|PROCEDURE|Acute Pancreatitis|All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
214686187|NCT03647371|PROCEDURE|Macintosh laryngoscopy|intubation with MAcintosh laryngoscopy after anesthetic induction
214496442|NCT02326181|DEVICE|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
214686188|NCT03647371|PROCEDURE|McGrath MAC video laryngoscopy|intubation with McGrath MAC videolaryngoscopy after anesthetic induction
214686189|NCT00938327|BIOLOGICAL|Rotarix™|Two doses of oral vaccine.
214686190|NCT04740268|DEVICE|Straberi|"The patient's entire face will be treated with the Straberi microneedling devise.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
214686191|NCT05298033|DRUG|Crisaborole 2 % Topical Ointment|Twice daily crisaborole 2% topical ointment
214686192|NCT05298033|DRUG|PF-07038124 0.01% topical ointment|Twice daily PF-07038124 0.01% topical ointment
214686193|NCT05298033|DEVICE|NBUVB phototherapy|Home narrow band UVB phototherapy exposure sessions 3 times per week
214686194|NCT05298033|DEVICE|Sham phototherapy|Non-NBUVB visible light radiation exposure sessions 3 times per week
214686195|NCT05298033|DRUG|Vehicle|Twice daily vehicle ointment
214686196|NCT05384158|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy
214686197|NCT05384158|BEHAVIORAL|valuation with instruction|repeat laboratory sessions of computerized learning game
214686198|NCT05384158|BEHAVIORAL|valuation without instruction|repeat laboratory sessions of computerized learning game
214686199|NCT00931671|OTHER|Exercise training|aerobic exercise training
214686200|NCT03147144|OTHER|Ultrasonographic imaging|Ultrasound pelvic scan
214686201|NCT02902705|OTHER|Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)|The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).
214686202|NCT05903833|DRUG|Pembrolizumab|400 mg Q6W
214686203|NCT05903833|DRUG|Lenvatinib|20 mg QD
214686204|NCT05366816|DRUG|Sunitinib|37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.
214375431|NCT04397484|DRUG|2% Xylocaine with adrenaline 1:200,000|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
214375432|NCT05157659|DIAGNOSTIC_TEST|[18F]F-AraG PET-scan|\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
214375433|NCT02442635|BEHAVIORAL|Yoga|Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
214375434|NCT04343586|DEVICE|Blue light phototherapy|Phototherapy- Wavelength: 417±15 nm
214375435|NCT04268901|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE to be used in this study is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
214375436|NCT04268901|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
214496443|NCT02326181|DEVICE|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
214496444|NCT00570388|DRUG|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
214496445|NCT04383067|PROCEDURE|Tumor Infiltrating Lymphocytes (TIL)|Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
214496446|NCT04383067|DRUG|Proleukin|high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
214496447|NCT00366249|DRUG|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
214496448|NCT00366249|DRUG|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
214496449|NCT03188341|OTHER|vascular surgery procedure|"* an elective open vascular surgery procedure~* ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)"
214496450|NCT05600387|DRUG|Empagliflozin 10 MG|subjects in Empagliflozin group take 10mg Empagliflozin per day
214496451|NCT03239301|PROCEDURE|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
214496452|NCT03239301|PROCEDURE|Robotic REhabilitation|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
214496453|NCT00777049|DRUG|Panobinostat|Hard gelatine capsule - 5mg and 20mg
214496454|NCT02765594|DRUG|Hydroxychloroquine Sulfate|200mg bid
214496455|NCT02765594|DRUG|Valsartan|160mg qd
214496456|NCT00051584|DRUG|SGN-15 (cBR96-Doxorubicin Immunoconjugate)|
214496457|NCT00051584|DRUG|Gemzar (Gemcitabine)|
214496458|NCT01912300|BEHAVIORAL|experimental condition: Passvice Video game; Avtive Video game; Exercise|
214496459|NCT01310166|DRUG|Fingolimod|
214496460|NCT00009932|DRUG|cisplatin|
214496461|NCT00009932|DRUG|fenretinide|
214496462|NCT00009932|DRUG|paclitaxel|
214496463|NCT03478969|DEVICE|Accu-Chek® Solo micropump system|Medical device for subcutaneous delivery of insulin in a personalized way.
214496464|NCT03478969|DEVICE|mylife™ OmniPod® Insulin Management System|A patch pump system delivering insulin.
215090169|NCT05654701|DRUG|Palopegteriparatide (TransCon PTH)|The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
215090170|NCT02303899|DRUG|Gemcitabine|infusion drug
214375437|NCT04268901|DEVICE|Oculus Go|Participants 7-21 years can use the Oculus Go. The visual a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a handheld remote. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
214375438|NCT00586599|OTHER|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
214375439|NCT01005303|DRUG|Placebo|1 Tablet Daily
214375440|NCT01005303|DRUG|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
215090171|NCT02303899|DRUG|Imatinib mesylate|oral drug
215090172|NCT03216759|PROCEDURE|Ischemic preconditioning|After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
214375441|NCT03552302|BEHAVIORAL|Yoga|"1. Yoga stretch warm-up exercise for 15 minutes.~2. Five kinds of yoga correction method for 30 minutes (abdominal breathing, throat breathing, wind box breathing, nasal alternating breathing, buzzing breathing).~3. Great rest for 15 minutes"
214375442|NCT05897801|DIAGNOSTIC_TEST|MeMed BV®|One blood sampling of 3ml will be drawn on the first day for the performance of the MeMed BV® test. Two rectal swabs will be taken for determining the MDRO gut colonization. Patient information regarding the specific respiratory tract infection and the treatment regimen being prescribed will be recorded in the eCRF made specifically for this trial.
214375443|NCT06497400|OTHER|Brazilian Jiu Jitsu|Instruction of two classes each week for ten weeks of Brazilian Jiu Jitsu
214375444|NCT06497400|OTHER|Hatha Yoga|Instruction of two classes each week for ten weeks of Hatha Yoga
214375445|NCT06497400|OTHER|Waitlist|Participant will waitlist for 5 weeks and then be allowed to decide which intervention they want to do Group A/ Jiu Jitsu or Group B/Yoga for ten weeks..
214375446|NCT01562535|OTHER|Pronation|"In this technique the arm is flexed 90 degrees and a gentle pronation is applied to the arm; then the arm is further flexed to 45 degrees until the clinician feels a click in the elbow meaning the re-accommodation of the radial head has been accomplished."
215090173|NCT03216759|DRUG|Dexmedetomidine|At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
215090174|NCT03216759|PROCEDURE|Patient-controlled epidural analgesia|Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
215090175|NCT02072395|PROCEDURE|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
215090176|NCT02274259|DRUG|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
215090177|NCT02274259|DRUG|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
215090178|NCT03472690|BIOLOGICAL|QBECO-SSI|Subcutaneous injection
215090179|NCT03472690|OTHER|Placebo|Subcutaneous injection
214375447|NCT01562535|OTHER|Supination|"The affected arm is in a 90 degrees flexion. The clinician will hold the arm by the elbow and then makes a gentle supination of the affected arm and flexion of the elbow until feeling the click and the child is able to move the arm without pain."
214375448|NCT04492150|DRUG|Dextrose 5%/Nacl 0.3% Inj_#3|250 mL/hour of dextrose 5% intravenous drip
214375449|NCT04492150|DRUG|Saline|250 mL/hour of normal saline intravenous drip
214496465|NCT03478969|OTHER|Multiple Daily Injections (MDI) therapy|Injecting insulin as per participant's need.
214496466|NCT04325217|DRUG|Nintedanib|Capsules
214496467|NCT01185600|BIOLOGICAL|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
214496468|NCT01185600|BIOLOGICAL|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
214496469|NCT03673566|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
214496470|NCT04246866|BIOLOGICAL|GEM103|GEM103
214496471|NCT05749224|DIAGNOSTIC_TEST|Helkimo Index|Helkimo Index is comprised of five items, with each assessment having three possible answers, scored as 0, 1 or 5. The first item is related to the limitation in the range of jaw movement. The second item evaluates the alterations of joint function that produce deviations, sounds and/or joint locks or blockages; the third item evaluates the presence of pain when performing some movements; the fourth item evaluates muscular pain in the masticatory muscles; and the fifth item evaluates the presence of discomfort or pain in the prearticular area of the temporomandibular joint (TMJ) through palpation. From the sum of the 5 items, we identify no TMJ involvement if the score is 0, mild TMJ involvement when the score ranges from 1 to 9, moderate TMJ involvement if the score ranges between 10 and 19 and severe TMJ involvement for a score between 20 and 25.
214496472|NCT01164488|DRUG|danoprevir|Repeated daily doses
214686205|NCT05366816|DRUG|Regorafenib|120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.
214686206|NCT01220648|DRUG|Nilotinib, interferon-alfa|
214686207|NCT01379534|DRUG|TKI258|
214686208|NCT05730712|PROCEDURE|Biopsy|Undergo biopsy
214686209|NCT05730712|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214686210|NCT05730712|PROCEDURE|Computed Tomography|Undergo CT
214686211|NCT05730712|PROCEDURE|Echocardiography|Undergo ECHO
215090180|NCT06064123|DIAGNOSTIC_TEST|Cell-free DNA|Donor-derived cell-free DNA relation to recipient-derived cell-free DNA is compared to histopathological rejection grade from the same time frame.
215090181|NCT02840786|DEVICE|plaque excision system|
214375450|NCT05661721|OTHER|Sweet licorice|Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.
214375451|NCT05661721|OTHER|Salty licorice|A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.
214375452|NCT05007145|DRUG|PD-1 inhibitor|PD-1 Inhibitor 200mg D1 Q3W
214375453|NCT05007145|DRUG|Albumin-Bound Paclitaxel|125 mg/m\^2 D1/D8 Q3W
214375454|NCT05007145|DRUG|Cisplatin|75 mg/m\^2 D1 Q3W
214375455|NCT05007145|RADIATION|Radiation|40Gy/2.0Gy
214375456|NCT00069602|DEVICE|Continuous Glucose Monitoring System (CGMS)|
214375457|NCT00069602|DEVICE|GlucoWatch G2TM Biographer (GW2B)|
214496473|NCT01164488|DRUG|ketoconazole|Repeated daily doses
214496474|NCT01164488|DRUG|ritonavir|Repeated daily doses
214496475|NCT04638738|DEVICE|SensiumVitals wearable patch sensor|Wearable sensor which measures heart rate, respiratory rate, and temperature continuously.
214496476|NCT05089266|DRUG|CAR T cells|αPD1-MSLN-CAR T Cells
214496477|NCT05886972|BEHAVIORAL|Awareness about propofol injection induced pain|The aim of the study is to observe the effect of patient awareness about the possibility of occurrence of pain during propofol injection on the rate of incidence and severity of pain during injection as a primary goal as the pain score of propofol injection pain is the main end point of the study .
214496478|NCT04955951|DEVICE|polarized light|A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute
214496479|NCT04955951|DRUG|Topical corticosteroid ointment|corticosteroid 1 %.
214496480|NCT03281603|DEVICE|CAD/CAM complete denture|complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
214496481|NCT02146469|BIOLOGICAL|2 doses with an 3 months interval|varicella vaccination
214496482|NCT02146469|BIOLOGICAL|A second dose with an 1 year interval|varicella vaccine
214496483|NCT02146469|BIOLOGICAL|A second dose with an 3 year interval|varicella vaccine
214496484|NCT02146469|BIOLOGICAL|A second dose with an 5 year interval|varicella vaccine
214496485|NCT02146469|BIOLOGICAL|1 dose Varicella vaccine and 1 dose MMR given at the same time|varicella vaccine and MMR
214496486|NCT02146469|BIOLOGICAL|1 dose MMR|MMR
214496487|NCT02941549|OTHER|Placebo capsules|
214496488|NCT02941549|DRUG|Epeleuton|
214496489|NCT02994407|DRUG|turoctocog alfa pegol|"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."
214496490|NCT01214759|DRUG|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
214496491|NCT01214759|DRUG|Raltegravir|Raltegravir 400mg twice a day
214496492|NCT01436175|DRUG|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
214496493|NCT01540500|DRUG|Tasimelteon|5.66 mg dose on Day 1 and Day 8
214496494|NCT01540500|DRUG|Fluvoxamine|50 mg Dose on Days 2-8
214496495|NCT00661336|DRUG|buthionine sulfoximine|
214496496|NCT00661336|DRUG|melphalan|
214496497|NCT00661336|GENETIC|microarray analysis|
214496498|NCT00661336|OTHER|high performance liquid chromatography|
214496499|NCT00661336|OTHER|laboratory biomarker analysis|
214496500|NCT00661336|OTHER|pharmacological study|
214496501|NCT00661336|PROCEDURE|biopsy|
214496502|NCT05179265|DRUG|recombinant human serum albumin|10 g/bottle (20%, 50 mL)
214496503|NCT05179265|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
214496504|NCT05981352|PROCEDURE|mineral trioxide aggregate pulpotomy|"* After achieving hemostats, Mineral trioxide aggregate powder will be mixed with saline.~* Then Mineral trioxide aggregate will be placed directly on the pulp stumps."
214496505|NCT05981352|PROCEDURE|Dehydrated amniotic membrane pulpotomy|"* After achieving haemostasis, a double layer of sterile processed human allograft tis¬sue (dehydrated dual-layer dental amni¬on patch) will be trimed and soaked in saline for a minute.~* Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjust¬ed to the entire floor of the pulp chamber."
214496506|NCT05981352|PROCEDURE|Hyaluronic acid pulpotomy|"* After achieving haemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) .~* The cavities of all pulpotomy molars will be sealed with a layer of reinforced zinc oxide and eugenol ."
214496507|NCT01410409|OTHER|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
214496508|NCT01410409|DRUG|Paracetamol|1 g x 4/day
214496509|NCT01410409|DRUG|Burana|400 mg x 3/day for three weeks
214496510|NCT01410409|DRUG|Pantoprazol|20mg x 1/day for three weeks
214686212|NCT05730712|DRUG|Enzalutamide|Given PO
214686213|NCT05730712|DRUG|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
214686214|NCT05730712|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214686215|NCT05730712|OTHER|Questionnaire Administration|Ancillary studies
215090182|NCT02840786|DEVICE|balloon and Stent|
215090183|NCT02030990|DRUG|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
215090184|NCT02030990|DRUG|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
215090185|NCT02909855|OTHER|No intervention|Participants in this study will not receive any interventions as part of the study.
215090186|NCT05275530|BEHAVIORAL|Active FIT Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a FIT, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
214496511|NCT01410409|BEHAVIORAL|Dietary counseling|For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
214496512|NCT01410409|BEHAVIORAL|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
214496513|NCT01410409|PROCEDURE|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
214496514|NCT01410409|OTHER|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
214496515|NCT05201599|DEVICE|Flexible ureteroscope with intelligent control of renal pelvic pressure|After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.
214496516|NCT00055991|DRUG|bexarotene|This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
214496517|NCT01702376|DRUG|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
214496518|NCT01702376|DRUG|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
214496519|NCT01702376|DRUG|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
214496520|NCT01702376|DRUG|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
214496521|NCT03856619|DRUG|TERIFLUNOMIDE HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
214496522|NCT03577106|DEVICE|Transcranial magnetic stimulation (TMS)|Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
214496523|NCT03148652|OTHER|Enhanced Intervention Condition|The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
214496524|NCT01584466|DRUG|Paliperidone|"The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.~Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary."
214496525|NCT03387540|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
214496526|NCT04132154|PROCEDURE|Convective Forced-Air Active Warming|Underbody Blanket Model 585 of the 3M BairHugger Series
214496527|NCT06017700|BEHAVIORAL|Interpersonal Psychotherapy Group|IPT is a psychological intervention that focuses on four common problems that trigger depression: grief, disputes, role transitions and social isolation. Using techniques and strategies such as linking mood to event and event to mood, role play and skill-building, IPT encourages the individual to analyse and improve their interpersonal relationships context. IPT was developed in the USA to treat depressed adults but it has also been used to treat other mental disorders and among different age groups.
214375458|NCT03680664|DEVICE|Active tDCS|Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
214375459|NCT03680664|OTHER|sham tDCS|The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
214375460|NCT03680664|BEHAVIORAL|MBSR|After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
214987864|NCT03403049|DRUG|Gemcitabine + Cisplatin|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
214686216|NCT06983405|OTHER|Physical Therapy Program for MDD|PT program for hospitalized adults with MDD: twice-weekly, 45-min sessions integrating: 1) Active joint mobility (gentle movements for ROM). 2) Progressive strength (bodyweight/bands, low-mod intensity, major muscles). 3) Balance (stability exercises, adapted difficulty). 4) Progressive muscle relaxation (end of session). Includes health education: exercise \& mental health link (biological/psychological mechanisms), benefits of each exercise type (mood, function, QoL), post-discharge activity strategies, self-assessment, community resources in Zaragoza. Delivered by trained PTs, adaptable to individual needs.
214686217|NCT04994821|DEVICE|transcranial direct current stimulator (tDCS)|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
214686218|NCT04994821|BEHAVIORAL|Cognitive Reappraisal|Emotion regulation therapy
214686219|NCT03628469|BEHAVIORAL|Proactive Health Support|Active listening, coaching and counselling
214686220|NCT04086563|OTHER|Action observation|look at a clip of a hand doing neurodynamic exercises.
214987865|NCT03403049|DRUG|Gemcitabine + Capecitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
215090187|NCT05275530|BEHAVIORAL|Active Colonoscopy Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about colonoscopy as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
215090188|NCT05275530|BEHAVIORAL|Active Dual Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT Kit and Colonoscopy screening. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with either a FIT or Colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
215090189|NCT03984630|BEHAVIORAL|Dietary Fiber Intervention|Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
215090190|NCT03241004|OTHER|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
214375461|NCT03107819|DIAGNOSTIC_TEST|Plasma and urine metabolomics|Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.
214375462|NCT02487810|BEHAVIORAL|Cognitive load|Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.
214375463|NCT02487810|BEHAVIORAL|Deliberative instructions|Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
214686221|NCT04086563|OTHER|Mirror therapy|With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
215090191|NCT02728531|DRUG|Bendamustine|
215090192|NCT02728531|DRUG|Rituximab|
215090193|NCT02728531|DRUG|Cytarabine|
215090194|NCT02728531|DRUG|Pegfilgrastim|
215090195|NCT02728531|PROCEDURE|Leukapheresis|
215090196|NCT02728531|DRUG|Filgrastim|
215090197|NCT02728531|PROCEDURE|Autologous stem cell transplant|
214375464|NCT06003465|DRUG|LY3437943|Administered SC
214375465|NCT06003465|DEVICE|Test|Used to administer LY3437943 SC
214375466|NCT06003465|DEVICE|Reference|Used to administer LY3437943 SC
214686222|NCT04086563|OTHER|Neurodynamic exercises|active movement of the dominant hand. Do neurodynamic exercises.
214686223|NCT04086563|OTHER|Strength|Execute a short strength training for the dominant hand
214987866|NCT03403049|DRUG|Gemcitabine + Erlotinib|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
214987867|NCT03403049|DRUG|Gemcitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
214987868|NCT03403049|RADIATION|Photon|During this study, the prescribed dose shall be administered according to the dose escalation shown in the table, starting with dose level 1. The carbon ion dose shall be gradually escalated while gradually reducing the dose of photons until eventually administering a full dose of 56 GyE/14 Fx carbon ions (fractional dose of 4 GyE). Dose escalation will be performed in parallel for two patient groups: patients whose pancreatic tumors are greater than 5 mm from the duodenum (Group A) and those whose tumors are within 5 mm of the duodenum (Group B). Enrolled patients will be monitored for 90 days after radiotherapy starts for any acute toxic reaction and to explore the maximum tolerated dose, in addition to being observed for any related long-term toxic reactions in accordance with the protocol.
215090198|NCT02704611|DEVICE|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
215090199|NCT02704611|DEVICE|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
215090200|NCT01813123|BEHAVIORAL|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
215090201|NCT01910870|DRUG|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
215090202|NCT01910870|DRUG|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
214375467|NCT03953963|DEVICE|HydraSolve T2D™|The HydraSolve T2D™ System will be used to perform the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery. All patients will receive standard nutritional counseling and their medications will be adjusted to achieve target levels of blood glucose control.
214375468|NCT00853164|BEHAVIORAL|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
214375469|NCT00853164|BEHAVIORAL|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
214375470|NCT00853164|BEHAVIORAL|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
214375471|NCT03237273|OTHER|HEAD-US scoring system|HEAD-US scoring system - Ultrasound scan performed by a non-imaging specialist to assess for joint bleed or damage
214375472|NCT01889186|DRUG|ABT-199 (Main Cohort)|Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
214375473|NCT01889186|DRUG|ABT-199 (Safety Expansion Cohort)|Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
214375474|NCT01760421|DRUG|Hydroxychloroquine|Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
214375475|NCT00314067|PROCEDURE|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
214375476|NCT00314067|PROCEDURE|Physician training|
214375477|NCT00314067|PROCEDURE|Practice team training|
214686224|NCT02552355|DRUG|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
214686225|NCT02552355|DRUG|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
214686226|NCT02552355|DIETARY_SUPPLEMENT|Carbohydrate Beverage|Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
214987869|NCT01788514|OTHER|Videogame|Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
214987870|NCT02805998|BEHAVIORAL|Web-based CBT-I|
214987871|NCT02805998|OTHER|Treatment as Usual|
214987872|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and C. Xanthorrhiza"|Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
214987873|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and placebo"|Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
214987874|NCT01478646|OTHER|conventional breathing therapy|duration: 60 minutes.
214686227|NCT02552355|DIETARY_SUPPLEMENT|Protein Beverage|Supervised aerobic exercise 3 days per week followed by a protein drink
214686228|NCT01519245|DRUG|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
214686229|NCT01519245|DRUG|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
214686230|NCT06605144|DRUG|1- Vasopressor - Mean arterial pressure 56-60|Vasopressor(s) will be titrated according to 56-60 range.
214686231|NCT06605144|DRUG|2- Vasopressor - Mean arterial pressure 61-65|Vasopressor(s) will be titrated according to 61-65 range.
214686232|NCT06605144|DRUG|3- Vasopressor - Mean arterial pressure 66-70|Vasopressor(s) will be titrated according to 66-70 range.
214686233|NCT06605144|DRUG|4- Vasopressor - Mean arterial pressure 71-75|Vasopressor(s) will be titrated according to 71-75 range.
214375478|NCT04845724|OTHER|Standard Diet|
214686234|NCT06605144|OTHER|1- Platelet less than 10 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 10 x 109/L at the time of the planned procedure.
214686235|NCT06605144|OTHER|2- Platelet less than 20 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 20 x 109/L at the time of the planned procedure.
214686236|NCT06605144|OTHER|3- Platelet less than 30 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 30 x 109/L at the time of the planned procedure.
214375479|NCT04845724|OTHER|Modified Diet|
214375480|NCT00003305|DRUG|aminopterin|
214375481|NCT00003305|DRUG|leucovorin calcium|
214375482|NCT03802864|DRUG|Liposomal Bupivacaine|After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.
214375483|NCT03802864|DRUG|Standard Bupivacaine|After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
214686237|NCT06605144|OTHER|4- Platelet less than 40 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 40 x 109/L at the time of the planned procedure.
214686238|NCT06605144|OTHER|5- Platelet less than 50 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 50 x 109/L at the time of the planned procedure.
214686239|NCT06819657|DEVICE|Remote Ischemic Conditioning Treatment Instrument|Remote ischemic conditioning (RIC) was administered twice daily to the unilateral lower limb using a blood pressure cuff inflated to 200 mmHg for 7 consecutive days post-clipping
214686240|NCT06819657|OTHER|Guideline-based therapy|Guideline-based therapy
214686241|NCT06660654|DRUG|Raludotatug deruxtecan|IV administration Q3W
214686242|NCT06659627|BEHAVIORAL|Aerobic exercise therapy|Participants will follow an aerobic exercise therapy program for 16 weeks.
214686243|NCT06659627|BEHAVIORAL|Cognitive behavioural therapy|Participants will follow an cognitive behavioural therapy program for 12-16 weeks.
214686244|NCT06659627|OTHER|Usual care|Participants do not follow a program, but continue with care as usual
214686245|NCT04293874|BEHAVIORAL|Personalized Meal Plan|Personalized dietary plans will be developed incorporating the NPAGCS, while personalizing the plan based upon anthropometric characteristics, gender, age and self-reported activity level upon entry into the investigation, goals, typical dietary consumption patterns, and food preferences. A trained research assistant will use the USDA MyPlate88 site (www.choosemyplate.gov) to enter participant characteristics and determine the appropriate calorie level. A daily checklist will be then generated outlining the number of daily servings that should be consumed for each food group. Information will also be provided regarding serving sizes for different foods in the respective food groups and education will be provided regarding tailoring personal dietary preferences to meet the guidelines. Participants will be provided with a printed copy of their meal plan and instructed to initiate it for a 8-week period.
214987875|NCT01478646|OTHER|reflectory breathing therapy|duration: 60 minutes.
214987876|NCT00880217|DRUG|Atomoxetine 80 mg/d|40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
214686246|NCT04293874|BEHAVIORAL|Dietary Omega-3LC intervention|Following randomization, participants will be provided with fish to be consumed for 6 weeks. As a component of the dietary intervention, participants in high and low omega-3LC group will be provided with frozen, wild caught salmon (or if they dislike salmon, prepackaged, individual use foil packs of chunk light tuna). Salmon and chunk light tuna were chosen due to high omega-3LC content, low methylmercury content, low cost and ease of use. Vacuum packed, frozen salmon will be delivered to participants in large freezer bags and instructed to arrange visit times to ensure they can go directly home following the visit. Instructions for safe storage, fish handling and recipes to avoid fatigue of fish will be also be provided to participants when they receive the fish.
214375484|NCT02569437|DRUG|Doxycycline|Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
214686247|NCT06989086|BEHAVIORAL|Fearless in Neuro-Oncology|FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions.
214686248|NCT02738827|PROCEDURE|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
214686249|NCT06600659|OTHER|Non-Interventional Study|Non-interventional study
214686250|NCT03746574|BEHAVIORAL|Compassion Curriculum|12 session curriculum offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
214686251|NCT05797350|DEVICE|Glaucoma Drainage Device|Both the Paul glaucoma implant (PGI) and Ahmed glaucoma valve (AGV) are types of glaucoma drainage devices (GDDs) used to lower intraocular pressure in patients with refractory glaucoma. Devices will be implanted during a surgical procedure and work by diverting excess fluid from the eye to an external drainage tube, allowing the fluid to drain away from the eye and be absorbed into the surrounding tissue. This will help to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.
214686252|NCT05669378|BEHAVIORAL|Appetite to Play +|In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
214686253|NCT00004640|DRUG|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
214686254|NCT05592470|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).|Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
214686255|NCT02495649|OTHER|[18F]-DOPA|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
214686256|NCT02495649|DEVICE|PET-CT|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
214686257|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
214686258|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
214686259|NCT02350894|BEHAVIORAL|Graded and behavevial theraphy|Graded and behavevial theraphy
214686260|NCT02384499|BIOLOGICAL|ALLO-ASC injection|Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
214686261|NCT02384499|DRUG|Placebo|0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
214686262|NCT04532463|DRUG|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week|To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
214375485|NCT02569437|DRUG|methylprednisolone|oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
214375486|NCT02569437|DRUG|nasal saline spray|nasal saline sprays: 2 sprays each nostril three times a day
214375487|NCT02569437|DRUG|Flonase|daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
214375488|NCT02569437|DRUG|sugar pill|placebo pill to match doxycycline
214375489|NCT04315532|OTHER|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed for pregnant and non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken from all patients baseline and after 8 weeks.
214375490|NCT04315532|OTHER|Saliva samples|Saliva samples were taken from patients for the evaluation of sex steroid and stress markers baseline and after 8 weeks.
214375491|NCT04315532|OTHER|GCF samples|GCF samples were taken from patients for the evaluation of stress markers baseline and after 8 weeks.
214375492|NCT00325221|DEVICE|HM on|Home Monitoring activated after implantation
214375493|NCT00325221|DEVICE|HM Off|Home Monitoring activated 9 months after implantation
214375494|NCT02698540|OTHER|Nutritional Supplement|High calorie, high protein peptide based
214686263|NCT02345642|DEVICE|ActiveCare+SFT Supine|
214686264|NCT02345642|DEVICE|VenaFlow Elite Supine|
214686265|NCT02345642|DEVICE|ActiveCare+SFT Standing|
214686266|NCT02345642|DEVICE|VenaFlow Elite Standing|
214987877|NCT00880217|DRUG|Placebo|Placebo capsule once daily for 42 days
214987878|NCT00880217|DRUG|OROS methylphenidate HCl 54 mg/d|36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
214987879|NCT00880217|DRUG|JNJ-31001074 3 mg/d|3-mg capsule once daily for 42 days
214686267|NCT05528042|OTHER|Heart rate and respiratory rate measurement|"Validation of the performance of the heart rate (HR) measurement using COBOX medical device compared to a measurement carried out by applying the reference processes for taking measurements via a CE marked device.~Evaluation of the performance of the respiratory rate (RR) measurement using COBOX medical device compared to a measurement carried out by a reference method of manual counting"
214686268|NCT00982306|BEHAVIORAL|Brief intervention|20 minute one to one counseling session
214686269|NCT02797106|OTHER|Practice survey of health professionals|Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
214686270|NCT04509492|DIAGNOSTIC_TEST|Endoscopic ultrasound ( EUS )|"\- EUS will be done to all patients. During EUS examination the liver will be examined thoroughly to detect hepatic focal lesions with possible EUS-FNA of any detected lesions.~All EUS examination will being done by EUS linear array Echoendoscope, Pentax EG-3870UTK attached to Hitachi Avius US machine under Propofol deep sedation"
214686271|NCT03742960|BEHAVIORAL|Behavioral Sleep Restriction|Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.
214686272|NCT00262262|DRUG|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
214686273|NCT04072146|DRUG|Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|Cross over bioavailability study
214686274|NCT04072146|DRUG|OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg|Cross over bioavailability study
214686275|NCT04000672|PROCEDURE|3D printed patient specific metal jigs (PSI jig)|PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.
214686276|NCT04000672|PROCEDURE|HTO with navigation|In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
214686277|NCT06555367|DEVICE|scleral lenses|Wear scleral lenses
214686278|NCT02930655|DRUG|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
214686279|NCT02930655|DRUG|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
214686280|NCT05646303|DRUG|Psilocybin|Psilocybin and psychotherapy
214686281|NCT05646303|DRUG|Placebo|Placebo and psychotherapy
214686282|NCT01568905|OTHER|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
214686283|NCT01568905|OTHER|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
214686284|NCT01568905|OTHER|High level nicotine cigarette|smoke the study cigarette exclusively for one week
214686285|NCT04484519|OTHER|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging
214686286|NCT01066078|OTHER|Echocardiography and SonR recording|
214686287|NCT03796156|DRUG|Aspirin|75mg low dose non enteric coated or dispersible
214686288|NCT06671951|OTHER|Focal Vibration|Focal vibration is a 3x3 electrode placed on the athlete's muscle belly, and emits a high frequency vibration (150Hz) to stimulate the muscle spindle and generate greater muscle activation.
214375495|NCT02539043|DEVICE|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
214686289|NCT06671951|OTHER|Sham focal vibration|Is a focal vibration intervention but without conctact in the athelte's skin. Doing this we got a sham therapy
214686290|NCT01273688|BEHAVIORAL|Eccentric training (Flex-Bar)|6x15 repetitions of supination and pronation daily over 12 weeks
214686291|NCT01273688|DEVICE|EpiHit elbow brace|daily wearing of the EpiHit elbow brace
214686292|NCT02711761|DEVICE|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
214686293|NCT01193348|DRUG|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
214686294|NCT04475185|DEVICE|MakAir|MakAir artificial ventilator
214686295|NCT04070378|DRUG|Daratumumab Injection|Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion
214686296|NCT00501033|DEVICE|Mechanical induction of labor|
214686297|NCT00501033|DEVICE|Double Balloon|
214686298|NCT00501033|DEVICE|Foley Catheter|
214686299|NCT01370278|OTHER|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
214686300|NCT01370278|OTHER|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
214686301|NCT05256277|DRUG|CT101a|cytokine-induced memory-like NK cells
214686302|NCT00942045|BIOLOGICAL|Biologic - Osteocel Plus|Osteocel Plus
214686303|NCT05618457|DRUG|Aminoglycoside dose adjustment|Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC\~10 (8-12)
214686304|NCT06512441|DRUG|Vitamin B6 Tablets|The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.
214686305|NCT06512441|DRUG|Placebo|The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
214686306|NCT03008746|OTHER|water used for oral wash|
214686307|NCT03008746|OTHER|sputum|
214686308|NCT03008746|OTHER|oral wash|
214686309|NCT03259334|DRUG|Ontamalimab|Participants will receive 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
214686310|NCT03259334|OTHER|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
214686311|NCT03414840|DRUG|Atorvastatin|Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
214375496|NCT02539043|DEVICE|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
214686312|NCT03141086|DRUG|LML134|LML134
214686313|NCT03141086|DRUG|Placebo|placebo
214686314|NCT02756390|BEHAVIORAL|CBTI-CS|CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.
214686315|NCT02756390|BEHAVIORAL|Sleep Hygiene|Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.
214686316|NCT02756390|BEHAVIORAL|CBTI-CS via Telehealth|The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.
214686317|NCT02929563|DRUG|Pantoprazole|
214375497|NCT02626832|OTHER|Procedural|All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
214375498|NCT00441701|DRUG|Navarixin 1 mg|Navarixin 1 mg capsules
214375499|NCT00441701|DRUG|Navarixin 10 mg|Navarixin 10 mg capsules
214375500|NCT00441701|DRUG|Placebo to match navarixin|Placebo to navarixin capsules
214375501|NCT00441701|DRUG|Rescue medication|Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
214375502|NCT00077064|DRUG|captopril|Captopril 12.5 mg t.i.d. for first two weeks, increased to 25 mg t.i.d. for the second two weeks of therapy. Thereafter, the dose will be increased to 50 mg t.i.d. for the remainder of the one-year of therapy (52 total weeks of drug administration).
214375503|NCT01291979|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
214375504|NCT01291979|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
214375505|NCT05279625|DEVICE|exercise training|using either elastic band, dumbbells, treadmill, cycling, machines for 6 months
214375506|NCT05028426|PROCEDURE|Enhanced recovery program|Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.
214686318|NCT02929563|DRUG|Placebo (for pantoprazole)|
214686319|NCT05264090|OTHER|Ambulatory blood pressure monitoring|The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
214686320|NCT05264090|OTHER|Combined aerobic-resistance exercise|Combined aerobic-resistance exercise (group 2) was scheduled twice weekly in the form of 60-minute workouts with a load intensity at the level of sub-maximum heart frequency (75-85% SFmax). The minimum time span between the workouts was 24 hours. The workout consisted of a 10-minute warm-up, 25 minutes of aerobic exercise (spinning bicycle or bicycle ergometer), 15 minutes of resistance exercise on gym machines (bench press, leg extension and pull down) with 40-50% 1-RM (one repetition maximum) intensity (3 series of 10 exercises), and a 10-minute cool-down (stretching of the main muscle groups).
214987880|NCT00880217|DRUG|JNJ-31001074 1 mg/d|1-mg capsule once daily for 42 days
214987881|NCT00880217|DRUG|JNJ-31001074 10 mg/d|10-mg capsule once daily for 42 days
214375507|NCT04392778|BIOLOGICAL|MSC Treatment|"Protocol length: 1 week~Doses:~1. Application: 3 million cells/kg IV-------------------------------------------------0 day~2. Application: 3 million cells/kg IV ------------------------------------------------3rd day~3. Application: 3 million cells/kg IV -------------------------------------------------6th day~will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation."
214686321|NCT05264090|OTHER|The cardiovascular exercise|The cardiovascular exercise (group 4) took the form of sixty-minute workouts scheduled two to three times weekly. The nature of the workouts was similar, combined aerobic-resistance exercise (a 10-minute warm-up, aerobic endurance on bicycle ergo meter for 25 minutes, resistance exercise on multifunctional gym machines for 15 minutes, and a 10-minute cool-down). The workout intensity was set at the level of the first ventilation threshold (VAT-1), corresponding to the following workout parameters: load (W) and heart rate (HR).19,20 The resistance exercise intensity was specified by the 1-RM (one repetition maximum) method. The maximum load lifted across the full range of motion for every exercise was used as the benchmark for the workload intensity specification, corresponding to 30 - 60% 1-RM.
214686322|NCT00042081|DRUG|CGT003 (E2F Duplex Decoy)|
214686323|NCT03321240|PROCEDURE|visual and quantitative SEEG signal analysis|signal SEEG analysis
214686324|NCT03321240|PROCEDURE|Resective epilepsy surgery procedure|Surgical removal of the epileptogenic brain area
214686325|NCT03328130|BIOLOGICAL|AAV2/5-hPDE6B|Subretinal administration in one eye
214686326|NCT03421847|DIAGNOSTIC_TEST|Rotatory vestibular test|We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests
214686327|NCT05152446|OTHER|Infusion management scheme|"* To set up a pediatric intravenous infusion team;~* To form standardized procedures by carrying out a quality improvement program in collecting and sending samples for inspection once suspected CLABSI occurs (1 month for training and 3 months for continuous improvement ); providing infusion training curriculums to nurses in forms of lectures, group discussions, operation demonstrations, and scenario simulations, holding practice review meeting with them; providing elements to caregivers of educational leaflet, nurse-provided education during patients' infusion therapy( 6-month implementation);~* To observe the continued daily infusion practice in 6 months."
214686328|NCT06863649|OTHER|Gamified NON-IMMERSIVE VIRTUAL REALITY EXERCISES|The game phase lasts for 2 minutes. These targets are challenging for the participant.
214686329|NCT06863649|OTHER|video-based exercises|The participant will exercise by replicating the exercises demonstrated in a 2-minute video, recorded with the same movement patterns that they will find in the gamified intervention.
214686330|NCT06671652|BEHAVIORAL|Duyugoda igalenisodi (Starting again the right way)|Participants in the intervention arm will receive training and resources to build community resources and programming
214375508|NCT04392778|BIOLOGICAL|Saline Control|Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.
214375509|NCT02070068|DEVICE|PINPOINT System|
214375510|NCT00509834|DRUG|hLF1-11|"The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10"
214375511|NCT00509834|DRUG|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
214375512|NCT00509834|DRUG|Placebo|Placebo
214375513|NCT03112941|PROCEDURE|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
214375514|NCT03112941|OTHER|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
214375515|NCT01555190|DRUG|myo-inositol 1500 gr|
214375516|NCT01555190|DRUG|myo-inositol 2000 gr + folic acid 200 mcg|
214375517|NCT03987425|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
214375518|NCT04710927|DEVICE|Silver Diamine Fluoride|A single application of SDF 38% (Riva Star) on dry affected molar for 1 minute and immediately restored using HVGIC
214686331|NCT06671249|PROCEDURE|Laparoscopic breast-conserving surgery|Use laparoscopic surgery to treat breast cancer patients who want and have the opportunity to preserve their breast
214686332|NCT06671249|PROCEDURE|Traditional open breast-conserving surgery|Treat breast cancer patients who want and have the opportunity to preserve their breast with traditional open breast-conserving surgery.
214686333|NCT04951648|DRUG|Almonertinib|Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
214686334|NCT04951648|DRUG|chemotherapy|Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
214686335|NCT06244537|RADIATION|MR-linac|Patients enrolled will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX chemotherapy.
214686336|NCT06353945|DEVICE|vaginal moisturizer|vaginal moisturizer
214686337|NCT04080154|DRUG|Anlotinib|12mg orally (p.o.) every day (qd) for 2 weeks of every 3 week cycle (i.e. 2 weeks on, 1 week off)
214686338|NCT06686797|DRUG|PF-08049820|Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Part B (Cohorts 4 to 7).
214686339|NCT06686797|DRUG|Placebo|Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Part B (Cohorts 4 to 7).
214686340|NCT04122001|DEVICE|Active, in-person HD-tDCS or active remote tDCS|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (angular gyrus). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes. In the active, in-person HD-tDCS the current is delivered in a ring configuration. In the active remote tDCS current is delivered in one electrode patch.
214375519|NCT04710927|DEVICE|Papain-Based Gel|Papain based Gel (Papacare Duo) will be applied to the MIH affected molar for 60 seconds and repeated if required. The molar will be treated with SDF and restored using HVGIC
214686341|NCT04122001|DEVICE|Sham|Current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.
214686342|NCT04122001|OTHER|Word List Learning Intervention (WordLLI)|Participants will receive a word list learning intervention (WordLLI) of semantically related and unrelated word lists. Word lists are presented across 10 trials, with an additional trial after a 10-minute delay to assess delayed recall. Immediately following verbal presentation of word lists during each trial, participants will be instructed to recall as many of the words from the list as possible. Participants may use the written modality as a strategy during recall. Word lists include 12 words matched based on psycholinguistics attributes (e.g., imageability, frequency). This task is designed to help participants improve memory via enhancing list learning capabilities.
214375520|NCT04710927|DEVICE|High Viscosity Glass Ionomer Cement (HVGIC)|The molar will be restored with HVGIC
214375521|NCT00258999|DEVICE|Skin Cholesterol Testing|
214375522|NCT05867719|OTHER|Hypoxic breathing conditions|Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.
214686343|NCT07018336|OTHER|Mirror Therapy|Mirror Therapy will be applied to the affected upper extremity of hemiplegic patients by placing a mirror in the midsagittal plane, reflecting movements of the non-paretic limb to create the illusion that both limbs are moving symmetrically. Each session will include task-specific, functional hand and arm movements (e.g., grasping, wrist flexion/extension) performed for 30 minutes. Patients will be instructed to focus on the mirror image while actively engaging in the exercises.
214686344|NCT07018336|OTHER|Virtual Reality (VR) Therapy|Virtual Reality (VR) therapy will consist of a single 30-minute immersive session designed to engage the upper extremity of hemiplegic patients. Participants will wear a VR headset and interact with a virtual environment using motion-tracking controllers. Activities are task-oriented and aim to stimulate functional movement through simulated real-life scenarios (e.g., reaching, grabbing, stacking). This intervention offers multisensory feedback and high user engagement.
214686345|NCT01380405|BEHAVIORAL|education intervention|"Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
214496528|NCT06017700|BEHAVIORAL|Enhanced Usual Care|Participants attending schools in the control arm will receive enhanced usual care. In intervention and control arms, we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package (mhGAP). Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Adolescents in the control cluster reporting a current suicide plan (i.e. in the past 2 weeks) or suicide attempt in the past three months will be assessed by a psychosocial counsellor employed through the project and offered counselling or referral to other services as per need.
214496529|NCT03213028|OTHER|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
214496530|NCT05267769|DRUG|AP707|Preparation of Cannabis flowers (Cannabis flos)
214686346|NCT03988829|BEHAVIORAL|Low-C|This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.
214496531|NCT01788371|DRUG|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
214496532|NCT01788371|DRUG|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
214375523|NCT03328000|RADIATION|CTU and MR urethrography|computed tomographic and Magnetic Resonance Urethrography.
214375524|NCT01702441|DRUG|Subcutaneous AKB-9778|
214375525|NCT03359070|DRUG|Dapaconazole|Application of 1 gram on the lesion.
214375526|NCT03359070|DRUG|Miconazole Nitrate|Application of 1 gram on the lesion.
214496533|NCT00010088|DRUG|fluorouracil|
214496534|NCT00010088|DRUG|gemcitabine hydrochloride|
214496535|NCT00010088|DRUG|leucovorin calcium|
214496536|NCT00010088|PROCEDURE|conventional surgery|
214496537|NCT00010088|RADIATION|radiation therapy|
214496538|NCT00635700|DRUG|ziprasidone|20-160 mg/d
214496539|NCT00635700|DRUG|placebo|placebo
214496540|NCT00653172|DRUG|NXL103|600mg orally twice daily
214496541|NCT00653172|DRUG|comparator|comparator twice daily
214496542|NCT00653172|DRUG|NXL103|500mg orally twice daily
214496543|NCT03601715|OTHER|Coplanar|The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
214686347|NCT03988829|BEHAVIORAL|High-C|In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.
214375527|NCT01578148|PROCEDURE|Noxipoint Therapy|"Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:~1. Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named Noxipoints).~2. Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.~3. Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.~4. Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age."
214375528|NCT01578148|PROCEDURE|Physical Therapy|"The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:~1. TENS stimulation (45 minutes):~   • Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.~2. Other modalities of PT per the therapist's choice:~   * Infrared treatment on the pain areas (about 15 minutes)~  * Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).~  * Exercise and training:~     * Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or~    * Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes~  * Hot/cold pack to the pain area for about 15 minutes"
214375529|NCT03155932|DRUG|APD334|APD334 active treatment for 24 weeks.
214375530|NCT05012475|BEHAVIORAL|Modified Virtual Reality Gaming|Investigators customize each gaming session based on the motivators and interests of each participant. The intervention facilitates independent hand separations (minimizing stereotypies) and encourages independent arm/hand movement that serves to activate or control the computer-generated activities.
214375531|NCT05137379|BEHAVIORAL|A joint functional score based on the affected joint|A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )
214686348|NCT03988829|BEHAVIORAL|High-C+|A commercial video game will be used that requires a lot of demand on attentional control.
214686349|NCT02415296|OTHER|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
214686350|NCT02415296|OTHER|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
214686351|NCT02415296|OTHER|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
214686352|NCT06693128|DRUG|Camrelizumab|Camrelizumab 200mg
214686353|NCT06693128|DRUG|Apatinib|Apatinib 250mg
214375532|NCT00737425|DEVICE|PainShield|
214375533|NCT00737425|DEVICE|Sham PainShield|
214686354|NCT06693128|DRUG|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
214686355|NCT06693349|DRUG|the effect of platelet-rich fibrin in treatment of contaminated and uncontaminated immature permanent teeth|this procedure was anticipated to give superior effects than other procedure used in this study
214686356|NCT06693349|DRUG|the effect of apexification in treatment of contaminated and uncontaminated immature permanent teeth|this procedure was anticipated to be replaced by other procedure be used in this study
214686357|NCT06692218|DEVICE|Leadless pacemaker|Patients who will implant leadless pacemakers or already implanted leadless pacemakers since 1 Jan 2015 will be recruited. After the implantation, patients will be invited back for a noncontrast, ECG-gated CT heart. It will be timed at the end diastole and a 3D reconstruction will be performed.
214686358|NCT06693271|DIETARY_SUPPLEMENT|intervention of protein, blueberries|intervention of 30g/day (1 scoop) of a colorless, tasteless whey protein isolate powder supplement and 1 cup (150 grams) of blueberries per day.
214686359|NCT06693271|BEHAVIORAL|Exercise training|Three 60-minute multimodal exercise sessions per week. Exercise interventions will be individualized to each participant based on their fitness level as per recommended guidelines for older adults. Each session will include a warm-up and cool-down (\~5 minutes each), 30 minutes of moderate intensity aerobic exercise and 20 minutes of moderate intensity resistance training.
214686360|NCT06693505|COMBINATION_PRODUCT|caffeinated chewing gum|two pieces of caffeinated chewing gum at an absolute dose of 200 mg (Military Energy Gum®, Ford Gum and Machine Go, Akron, NY, USA)
214686361|NCT06693505|COMBINATION_PRODUCT|placebo|two pieces of similar looking and tasting placebo gum that did not contain caffeine (xylitol, lime mint, green; Lotte, Saitama, Japan) (PLA trial)
214686362|NCT06502977|DRUG|Tarlatamab|IV infusion
214686363|NCT06695325|DIAGNOSTIC_TEST|HbA1c test|Patients will be asked to have a HbA1c test in the clinic with a venous draw and then either fingerprick or upper arm draw. They will do the latter again at home.
214686364|NCT06688136|DRUG|ropivacaine|Ropivacaine 200 mg diluted to 50 mL
214686365|NCT06631833|BEHAVIORAL|Intervention measures based on the YPAP model.|The intervention group received an 8-week intervention program aimed at gradually increasing their physical activity levels. The intervention program included the following components: 1) 1-2 sessions of moderate-intensity physical activity per week, each lasting 45 minutes, with activities provided by physical activity experts; 2) one health education lecture every two weeks, each lasting 60 minutes; and 3) one family physical activity session per week, each lasting 30 minutes at a lower intensity. At the end of the intervention period, relevant questionnaires were used for measurement.
214686366|NCT03654248|BEHAVIORAL|Let's Get Organized group intervention|Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
214496544|NCT03601715|OTHER|Contraplanar|The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
214496545|NCT03601715|OTHER|Longitudinal|The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
214496546|NCT00123409|BEHAVIORAL|Telephone disease management|Telephone based care management
214496547|NCT00123409|BEHAVIORAL|Usual Care|Usual care
214496548|NCT05153681|OTHER|Peloid Therapy|Peloid therapy; A total of 10 sessions were applied for 30 minutes by heating the proximal part of the sole of the foot, including the heel part, at a temperature of 45 degrees. Kinesioband application: One strip is prepared as a rake with a length of about 25 cm, and the other strip is prepared as an I tape with a length of about 20 cm. The ankle is in a neutral position of 90 degrees. Lymphatic and mechanical correction technique is applied. Afterwards, the band is activated.
214496549|NCT00918333|DRUG|panobinostat|Given PO
214496550|NCT00918333|DRUG|everolimus|Given PO
214496551|NCT00918333|OTHER|laboratory biomarker analysis|Correlative studies
214496552|NCT00918333|OTHER|pharmacological study|Correlative studies
214496553|NCT00278135|DIETARY_SUPPLEMENT|DHA (nutritional supplement) or placebo|oral 900mg/day
214496554|NCT03135782|OTHER|Communication Skills Training|Undergo motivational interviewing training
214496555|NCT03135782|OTHER|Medical Chart Review|Undergo medical chart review
214496556|NCT03135782|OTHER|Questionnaire Administration|Ancillary studies
214496557|NCT03135782|OTHER|Tobacco Cessation Counseling|Attend phone or in-person motivational interviewing coaching sessions
214496558|NCT06837259|DRUG|PF-07328948|single oral dose day 1 and day 12 (Part A) and day 4 (part B)
214496559|NCT06837259|DRUG|cyclosporine|600 mg capsule day 12 (Part A)
214496560|NCT06837259|DRUG|clarithromycin|500 mg tablets twice daily day 1 to day 6 (Part B)
214496561|NCT03268135|DIAGNOSTIC_TEST|measurement of RNAs|
214496562|NCT01313884|DRUG|Irinotecan|50 mg/m2/day x 5 days
214496563|NCT01313884|DRUG|Vincristine|2 mg/m2 to a maximum of 2 mg
214496564|NCT01313884|DRUG|Temozolomide|100 mg/m2/day x 5 days followed by 2 weeks treatment-free
214496565|NCT01313884|DRUG|Doxorubicin|Starting dose 75 mg/m2 to a maximum of 450mg/m2
214496566|NCT01313884|DRUG|Cytoxan|1200 mg/m2
214496567|NCT01313884|DRUG|Pegfilgrastim|6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
214496568|NCT04056754|DRUG|Abiraterone Acetate|Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
214496569|NCT04056754|DRUG|Placebo|Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
214496570|NCT04056754|DRUG|Prednisone|Subjects administered 5mg prednisone twice daily in 28-day cycle.
214496571|NCT00263757|DEVICE|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
214496572|NCT00263757|OTHER|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
214496573|NCT02142309|DRUG|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
214496574|NCT02142309|DRUG|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) \<45 mL/min
214496575|NCT02142309|DRUG|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
214496576|NCT02142309|DRUG|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
214496577|NCT04092322|DEVICE|Actical accelerometers (Philips Respironics)|patients with stroke will be evaluated by using PASE scale and accelerometer results (accelerometer will be held from Monday to Friday
214496578|NCT04092322|OTHER|PASE|Physical Activity Scale for Elderly
214496579|NCT06822933|DEVICE|Urika|Self-management application for patients with gout receiving urate lowering therapy. The 'Urika'-app includes films and written information about gout and gout management, reminders for blood-tests and medication, a visualisation of serum urate level over time, and an algorithm to calculate the medication drug-dose escalation. The app also includes a chat function and a secure web-platform for remote monitoring and communication between the participant and nurse. The study nurse will log into the web-platform on weekdays to check patient-reported side effects, adherence to medication, the current dose, and the need for a renewal of urate lowering therapy prescription.
214496580|NCT06822933|OTHER|Nurse-led follow-up with telephone consultations.|Nurse-led follow-up in specialist healthcare with monthly blood tests and telephone consultations until the treatment target is reached.
214496581|NCT04269694|DRUG|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
214496582|NCT04269694|DEVICE|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
214496583|NCT06236984|OTHER|multiFiltratePRO with all CKRT treatment modes|Retrospective Data Analysis of CKRT treatments in adult mode with multiFiltratePRO
214496584|NCT03461666|BEHAVIORAL|Cognitive Behavior Therapy-Insomnia|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
214496585|NCT03461666|BEHAVIORAL|Focus of Attention|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
214496586|NCT03461666|BEHAVIORAL|Combined-CBT-I and FOA Group|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
214496587|NCT03461666|BEHAVIORAL|Sleep Hygiene|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
214375534|NCT05670483|DEVICE|Use Of APRV mode of Ventilation|"Post operatively, Patients will be ventilated with APRV mode using GE Carescape R860 ventilator Initial Settings15~1. P high at the P plateau (or desired P mean + 3cm H2O). keep P high below 30-35 cm H2O~2. T high at 4-6 seconds~3. P low at 0~4. T low at 0.5 to 0.8 seconds.~5. ATC (automatic tube compensation) on.~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of APRV will start as following, P-High will be lowered 2 or 3 cm of H2O pressure at a time, and T Low will be lengthened in 0.5-2.0 s increments, depending on patient tolerance. When the P-high reaches 10 cmH2O and the Thigh reaches 12-15 seconds, change the mode to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
214375535|NCT05670483|DEVICE|Use of conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode|"Post-operatively, Patients will be ventilated with conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode using GE Carescape R860 ventilator Initial Settings: 16~1. Tidal Volume 6-8 ml/kg predicted body weight~2. Respiratory rate (RR) 14 /min~3. Positive end expiratory pressure (PEEP)= 5 cmH2o~4. Pressure Support (PS) = 10 cmH2o~5. Inspiratory time 1.4 Sec~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of mechanical ventilation will be done by switching the ventilation to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
214375536|NCT00519701|DRUG|hydroxyurea|
214375537|NCT04285632|OTHER|Plyometrics exercises|"Counter Movement Jump exercise. The subject will be placed in an upright standing position, with his hands on his hip. It will perform a rapid downward movement in which it will flex the hips and knees and, immediately, a rapid extension of the legs that will result in the maximum vertical jump. During the flight phase the subject will keep the legs straight. The landing will be done with both feet at the same time. The intervention will be carried out for 300 seconds, in 2 series of 30 jumps each and with 3 minutes of rest between series.~Drop Jump exercise. The players will be placed on a step, standing and with their feet shoulder-width apart. They will drop forward, landing with both feet at the same time. Upon touching the ground they will perform a maximum vertical jump. The intervention will be carried out for 600 seconds, in 2 series of 25 jumps each, and with 3 minutes of rest between series."
214686367|NCT03654248|DEVICE|Individual Occupational Therapy|Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
214686368|NCT06693544|DIETARY_SUPPLEMENT|Peanut protein|Commercially available plant-based protein powders
214686369|NCT06692101|OTHER|oral care|We prepared the necessary tools and suction devices, then helped patients sit upright before starting oral care. Using a flashlight and toothbrush, we assessed the mouth and removed any food debris, aspirating saliva if needed. We cleaned the teeth using a toothbrush, dental floss, and an interdental brush with a small amount of fluoridated toothpaste. The Bass method was used for brushing. Finally, we cleaned the front two-thirds of the tongue with a damp toothbrush.
214686370|NCT06692101|DEVICE|Neuromuscular Electrical Stimulation (NMES)|We used the VitalStim® device to deliver neuromuscular electrical stimulation (NMES). Before placing the electrodes, participants were asked to shave any facial hair and clean their neck skin with alcohol wipes. We positioned four electrode pads horizontally, above and below the hyoid bone. The device provided stimulation at a pulse rate of 80 Hz with a biphasic pulse duration of 300 microseconds. Each session lasted 30 minutes, with the intensity gradually increased in 0.5 mA intervals, based on the patient's comfort level, and adjusted to their maximum tolerance.
214686371|NCT06693388|OTHER|Exercise|2 minutes each exercise with 30 sec break - 4 exercises prior to serial casting
214686372|NCT06693388|OTHER|Whole-Body Vibration|WBV prior to serial casting
214686373|NCT06693388|OTHER|Serial Casting|Serial Casting as provided by standard of care
214686374|NCT04349254|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision.
214686375|NCT06218238|OTHER|Powered prosthetic knee joint|Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
214496588|NCT03225625|PROCEDURE|Paraspinal|BMSC provided by paraspinal injection, intravenous and intranasal
214496589|NCT03225625|PROCEDURE|Paraspinal EX|BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
214496590|NCT03225625|PROCEDURE|Paraspinal VR|BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
214496591|NCT03918096|OTHER|Questionnaire|Questionnaire to the parents after the hospital discharge
214496592|NCT02191670|DRUG|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
214496593|NCT00347061|DRUG|afuzosin|
214496594|NCT01806207|DEVICE|Durolane injection|
214496595|NCT01806207|OTHER|Saline injection|
214496596|NCT00893698|PROCEDURE|bilateral allotransplantation|bilateral allotransplantation of upper limbs
214496597|NCT05197127|DEVICE|exoskeleton-based gait training|Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
214496598|NCT02576691|DEVICE|percutaneous coronary intervention|
214496599|NCT06517914|DRUG|YH35995|Oral administration of YH35995
214496600|NCT06517914|DRUG|Placebo|Oral administration of Placebo
214375538|NCT03607825|DEVICE|Neurapheresis System|CSF filtration system and lumbar catheter
214686376|NCT06218238|OTHER|Conventional prosthetic knee joint|Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
214686377|NCT07030283|DRUG|Paclitaxel|Paclitaxel is a chemotherapy medication that is FDA-approved to treat a number of cancer types. In this study, paclitaxel will be administered via the intraperitoneal port. Intraperitoneal paclitaxel is not FDA approved for pancreatic cancer.
214686378|NCT07030283|DRUG|NALIRIFOX|NALIRIFOX is a systemic chemotherapy treatment for metastatic pancreatic cancer that was approved by the FDA in February 2024. It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.
214686379|NCT07031297|DIAGNOSTIC_TEST|Meal Study|"Participants will consume a mixed meal drink (Ensure) equivalent to 40% of basil metabolic rate as calculated via Harris Benedict equation.~Following consumption of the drink they will undergo a series of blood draws over the following 4 hours:~* Plasma glucose will be measured according to a mixed meal test protocol every 10 minutes for the first hour and then every 15, then 30 minutes for the last 3 hours.~* 1 ml plasma aliquots for exosome analysis and insulin concentrations will be drawn every 30 minutes following consumption of ensure for 4 hours.~* Blood gasses will be drawn every 30 minutes for the 4 hours following the meal.~Participants will undergo a second abdominal adipose tissue biopsy 3 hours following mixed meal drink."
214686380|NCT06722846|BEHAVIORAL|Randomized Case Vignette Study|Particpants will complete about 16 questionnaires that will have questions about particpants quality of life, anxiety, health, andcase scenarios that are not real or based on particpants actual health situation.
214686381|NCT07054710|DEVICE|LED Light Treatment|The device will guide participants through a treatment that cycles through Red (4 minutes), Red + Infrared (4 minutes), and Blue (4 minutes) LED therapy in combination with vibration therapy, for a 12-minute treatment. Participants will be asked to use the device Monday through Saturday, on a clean face, as part of their evening routine.
214375539|NCT04135157|PROCEDURE|Pectoralis nerve block II|PECS II block will be performed 30 min. before general anesthesia.
214686382|NCT07054710|DEVICE|Vibration Only|On each Sunday of the 12-week program, participants will be asked to complete a 15-minute vibration-only treatment session as part of their evening routine.
214686383|NCT04322448|DEVICE|Mechanomyography (MMG)|MMG, as described in the cohort descriptions, to be used during surgery to see if they are predictive of patient outcomes.
214686384|NCT06815354|DEVICE|TRAQinform Theranostics|This prospective, multi-center, non-interventional clinical study will evaluate actionable outputs from TRAQinform Theranostics, a software only medical device that identifies, quantifies, tracks, and compares lesions between different imaging modalities and multiple imaging timepoints.
214686385|NCT07075926|DIAGNOSTIC_TEST|Echocardiographic Assessment|"All participants will receive a standardized transthoracic echocardiographic (TTE) examination within 2 hours after meeting weaning criteria. The following cardiac function parameters will be recorded:~LVOT Velocity Time Integral (VTI)~Mitral Annular Plane Systolic Excursion (MAPSE)~E/e' ratio~E/A ratio~Mitral Deceleration Time (MDT)~Myocardial Performance Index (Tei index)~The echocardiographic data will be used to investigate the association between left ventricular function and weaning success."
214375540|NCT04135157|PROCEDURE|Erector spine plane block|ESP block will be performed 30 minutes before general anesthesia.
214375541|NCT04135157|OTHER|Control|Only general anesthesia will be performed.
214686386|NCT05851443|DRUG|povorcitinib|povorcitinib
214686387|NCT05851443|OTHER|placebo|placebo
214686388|NCT05851443|DRUG|ICS-LABA|Background Therapy
214375542|NCT05943769|PROCEDURE|Apical microsurgery|inoculation of the periapical or the periradicular lesion with the sectioning of the apical 3mm of the root followed by root-end cavity preparation and retro-filling with the MTA or TotalFill with or without composite bone grafting according to patient allocation.
214375543|NCT02007434|DRUG|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
214375544|NCT02007434|DRUG|Placebo|Phosphate buffered saline placebo for injection
214375545|NCT02007434|OTHER|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
214375546|NCT02007434|DRUG|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
214375547|NCT02007434|DRUG|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
214375548|NCT02007434|DRUG|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
214375549|NCT02007434|OTHER|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
214686389|NCT07076407|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
214375550|NCT06274684|DEVICE|Use of Virtual Reality Assistance during prostate biopsies|Patient will be equipped with VR headset providing a immersive experience during prostate biopsies
214375551|NCT01287611|PROCEDURE|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture
214375552|NCT01287611|PROCEDURE|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked suturing
214375553|NCT03076476|DEVICE|Bioresorbable Vascular Scaffolds (BVS)|Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.
214375554|NCT03076476|DEVICE|Drug-Eluting Stent (DES) - slow|"Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
214375555|NCT03076476|DEVICE|Drug-Eluting Stent (DES) - standard(std)|Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
214375556|NCT01856712|DRUG|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
214375557|NCT02192970|DRUG|Bevacizumab|
214375558|NCT01321541|DRUG|Pixantrone + Rituximab|Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
214375559|NCT01321541|DRUG|Gemcitabine + Rituximab|Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
214375560|NCT01417052|DRUG|50 mg LX3305 QD|50 mg LX3305 once daily in capsule form
214375561|NCT01417052|DRUG|100 mg LX3305 QD|100 mg LX3305 once daily in capsule form
214375562|NCT01417052|DRUG|150 mg LX3305 QD|150 mg LX3305 once daily in capsule form
214375563|NCT01417052|DRUG|200 mg LX3305 QD|200 mg LX3305 once daily in capsule form
214375564|NCT01417052|DRUG|250 mg LX3305 QD|250 mg LX3305 once daily in capsule form
214375565|NCT01417052|DRUG|300 mg LX3305 QD|300 mg LX3305 once daily in capsule form
214375566|NCT01417052|DRUG|400 mg LX3305 QD|400 mg LX3305 once daily in capsule form
214686390|NCT07076407|DRUG|Placebo|Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
214686391|NCT07124013|DRUG|Olomorasib|Administered orally
214686392|NCT06081621|BIOLOGICAL|REGEND001|REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.
214686393|NCT06081621|BIOLOGICAL|Placebo|Placebo: Sodium chloride injection administrated by bronchoscopy.
214375567|NCT01417052|DRUG|250 mg LX3305 BID|250 mg LX3305 twice daily in capsule form
214375568|NCT01417052|DRUG|500 mg LX3305 QD|500 mg LX3305 once daily in capsule form
214375569|NCT01417052|DRUG|Placebo|Matching placebo dosing in capsule form
214375570|NCT03975699|OTHER|Assessment of psychological repercussions of SCD|Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.
214375571|NCT05578950|DRUG|itraconazole|100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
214375572|NCT05578950|DRUG|terbinafine|one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
214496601|NCT04700410|DEVICE|Pure-Vu System|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.
214686394|NCT07084961|DRUG|TS-172|Oral administration of TS-172 20 mg immediately before meal
214686395|NCT07084961|DRUG|TS-172|Oral administration of TS-172 20 mg immediately after meal
214375573|NCT02541032|PROCEDURE|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
214375574|NCT02541032|PROCEDURE|Standard dental treatment|Supragingival mechanical scaling and polishing.
214375575|NCT02541032|DRUG|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
214375576|NCT00213655|BIOLOGICAL|bladder tumor recurrence|bladder tumor recurrence assessed by clinical and biological exams
214375577|NCT04923555|BEHAVIORAL|Vegetable proteins (VP) rich in leucine, cystein, arginine|33 volunteers will consume 400 ml of yogurt with vegetable proteins (VP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of vegetable proteins.
214375578|NCT04923555|BEHAVIORAL|Animal proteins (AP)|33 volunteers will consume 400 ml of yogurt with animal proteins (AP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
214375579|NCT04923555|BEHAVIORAL|No protein (T)|33 volunteers will consume 400 ml of yogurt without any protein (T) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
214496602|NCT06226441|PROCEDURE|Continuous Renal Replacement Therapy|CRRT
214496603|NCT06506175|DRUG|HRS9531 tablets|HRS9531 tablets
214496604|NCT03578978|OTHER|No intervention|No intervention will be given to study subjects. Only blood will be obtained from study subjects.
214496605|NCT05626374|BEHAVIORAL|Basic Case Management|Usual case management support during 12-week training program
214496606|NCT05626374|BEHAVIORAL|Basic Case Management plus Distress Tool|Usual case management support during 12-week training program plus daily self-reports of distress using Distress Thermometer tool
214496607|NCT05626374|BEHAVIORAL|Basic Case Management plus rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus rapid access referral process for healthcare crisis services
214686396|NCT06929494|OTHER|Identification of risk factors for candidemia|Identification of risk factors for candidemia
214686397|NCT06930573|DRUG|AK112|After enrollment, patients receive AK112 at 20 mg/kg, administered via intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W). After four cycles, surgery is performed four weeks after the last dose. AK112 at 20 mg/kg is administered again four to eight weeks after surgery, via intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W), until disease progression, death, intolerable toxicity, withdrawal of consent, initiation of new anti-tumor therapy, or other reasons specified in the protocol for discontinuation of treatment. The maximum postoperative treatment duration with AK112 is 12 months.
214686398|NCT06929091|OTHER|Prenatal Intervention|Antenatal Breast Milk Expression (ABME). Collection of colostrum before delivery.
214686399|NCT06929091|OTHER|Postnatal Intervention|Follow a personalized Mediterranean-style meal plan for 6 months.
214686400|NCT06930339|DEVICE|Portable Neuromodulation Stimulator (PoNS)|No intervention
214375580|NCT04939545|DRUG|Ropivacain|"Intercostal continuous loco-regional ropivacaine (2 mg/ml) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h.~As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
214375581|NCT04939545|DRUG|NaCl 0.9%|"Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
214375582|NCT03389360|DIAGNOSTIC_TEST|procalcitonin|assessing the frequency of rising procalcitonin associated with infectious complications in immunosuppressed LDLTRx.
214375583|NCT02723058|BEHAVIORAL|ICMHM|ICMHM participants receive a collaborative care model adapted to include an engagement interview, attention to co-morbid conditions, and attention to basic needs.
214686401|NCT06930599|PROCEDURE|Pulmonary vein isolation plus transition zone modification|For those who are randomized to PVI+TZM arm, additional TZM should be performed after finishing PVI ablation. PVI could be performed using open-irrigated contact-force catheter.
214686402|NCT06930599|PROCEDURE|Pulmonary vein isolation alone|In periprocedural period, all antiarrhythmic drugs were discontinued for at least 5 half-lives and amiodarone for 2 months before the procedure. An electrophysiological study was performed after overnight fasting and mild sedated state with administration of intravenous midazolam and fentanyl. PVI should be performed under the CARTO or Ensite electroanatomic mapping system using an open-irrigated contact-force ablation catheter.
214686403|NCT05887167|BIOLOGICAL|autologous hematopoietic stem cells added to planned CAR T|Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.
214686404|NCT06930365|OTHER|Anti-itching and repairing treatment. Emollient.|Anti-itching and repairing treatment. Emollient.
214686405|NCT06930365|OTHER|Emollient cream|Emollient cream
214686406|NCT06930456|DRUG|hydrocortisone|A deidentified syringe (10 mL) containing 100 mg hydrocortisone will be given 15 minutes prior subarachnoid blockade. Spinal anesthesia will be performed with a 25-gauge Quincke spinal needle to administer 3.5 ml of a 0.5% hyperbaric bupivacaine plus 25 micrograms of fentanyl at the L3-L4 or L4-L5 level. Then, Patient will lie supine with slight head elevation. Intravenous Infusion of 500 ml normal saline over the initial post spinal 30 minutes. Sensory level and motor block will be verified. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) will be measured every 5 min for 6 readings during which the patient remains in the supine position with no application of torniquet.
214686407|NCT06930456|DRUG|ondansetron|A deidentified syringe (10 mL) containing 8 mg ondansetron will be given 15 minutes prior subarachnoid blockade. Spinal anesthesia will be performed with a 25-gauge Quincke spinal needle to administer 3.5 ml of a 0.5% hyperbaric bupivacaine plus 25 micrograms of fentanyl at the L3-L4 or L4-L5 level. Then, Patient will lie supine with slight head elevation. Intravenous Infusion of 500 ml normal saline over the initial post spinal 30 minutes. Sensory level and motor block will be verified. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) will be measured every 5 min for 6 readings during which the patient remains in the supine position with no application of torniquet.
214686408|NCT06930456|DRUG|Placebo|A deidentified syringe (10 mL) containing sterile distilled water for intravenous injection will be given 15 minutes prior subarachnoid blockade. Spinal anesthesia will be performed with a 25-gauge Quincke spinal needle to administer 3.5 ml of a 0.5% hyperbaric bupivacaine plus 25 micrograms of fentanyl at the L3-L4 or L4-L5 level. Then, Patient will lie supine with slight head elevation. Intravenous Infusion of 500 ml normal saline over the initial post spinal 30 minutes. Sensory level and motor block will be verified. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) will be measured every 5 min for 6 readings during which the patient remains in the supine position with no application of torniquet.
214375584|NCT00681616|DEVICE|Compartment Monitoring System (CMS)|The CMS consists of an Introducer, Pressure Measurement \& Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
214375585|NCT00681616|DEVICE|Compartment Monitoring System with Active Fluid Removal|Compartment Monitoring System with Active Fluid Removal
214375586|NCT00681616|DEVICE|Compartment Monitoring System without fluid removal|Compartment Monitoring System without fluid removal
214375587|NCT04449848|OTHER|Sitting after intra tympanic injection|Sitting after intra tympanic injection
214375588|NCT00035035|DRUG|GEMZAR|
214375589|NCT00035035|DRUG|ALIMTA|
214375590|NCT03357263|BIOLOGICAL|GC3114|High-dose Quadrivalent influenza vaccine
214375591|NCT03357263|BIOLOGICAL|GCFLU Quadrivalent|Quadrivalent influenza vaccine
214375592|NCT02656576|PROCEDURE|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
214375593|NCT02656576|PROCEDURE|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
214375594|NCT06097676|DRUG|Placebo|Placebo
214375595|NCT06097676|DRUG|Alprazolam 2 mg|Oral dose of alprazolam 2 mg
214375596|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg|Oral dose of GE-IR 200 mg
214375597|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg|Oral dose of GE-IR 450 mg
214375598|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg|Oral dose of GE-IR 700 mg
214375599|NCT02525003|DIETARY_SUPPLEMENT|Vitamin D2|Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
214375600|NCT02525003|DIETARY_SUPPLEMENT|Vitamin D3|Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
214375601|NCT02525003|OTHER|Vitamin D2 fortified bread|Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
214686409|NCT06930248|BIOLOGICAL|Platelet rich plasma injection|Our first step is the local anesthesia using a solution of decongestion nasal drops with 5% Emla and 10% Xylocaine spray in cotton, which is placed in the nose for 30 minutes. The 2nd step of the administration is the PRP injection in the olfactory area of the noseVia1 ml syringe with 30 G needle, PRP is injected in the olfactory area(located at superior turbinate and superior portion of lateral an medial portion of nasal cavity) approximately every 1 cm2 with the help of a nasal endoscope. The procedure is repeated 3 times with a 4 week interval with follow up patients for 6 months. A 4th time is injected after 3 months.
214686410|NCT07087002|BIOLOGICAL|GPC2-CAR T cells|Autologous T cells transduced with retroviral vector encoding a second-generation GPC2-targeted chimeric antigen receptor (GPC2-CAR), administered intracerebroventricularly. Up to 8 doses are given every 28 days, following an intrapatient dose escalation schema.
214686411|NCT07087002|DRUG|Fludarabine|Administered as part of a lymphodepleting chemotherapy regimen prior to GPC2-CAR T cell infusion. Dose: 30 mg/m²/day for 3 days.
214686412|NCT07087002|DRUG|Cyclophosphamide|Administered with fludarabine for lymphodepletion. Dose: 500 mg/m²/day for 3 days.
214686413|NCT05581004|DRUG|RO7502175|RO7502175 will be administered as per the schedules specified in the respective arms.
214686414|NCT05581004|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
214686415|NCT05581004|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedules specified in the respective arms.
214375602|NCT06350929|OTHER|Cardiac output monitoring by the Starling™ SV Sebac®|"During the surgery, the channels and monitoring equipment will be set up according to the usual procedure in the vascular surgery department. As part of the research, the Starling™ SV Sebac® electrodes will be installed (to measure cardiac flow, cardiac index (CI), stroke volume (VES), variations in stroke volume (VVES), and peripheral resistors (TPRI)).~Once the equipment is in place, anesthetic induction will be carried out according to the usual protocol with curarization and mechanical ventilation.~If the appearance of arterial hypotension is noted after anesthetic induction and mechanical ventilation, the patient will be definitively included in the study. As recommended, he will receive norepinephrine to treat hypotension.~The measurements from the monitoring will be collected at 3, 5, and 10 min after the administration of norepinephrine.~10 days after admission to the operating room, hospitalization data will be collected."
214375603|NCT06151990|OTHER|lipid profile|Measurements for CHOL,TG,LDL-C and HDL-C obtained following an overnight fasting
214375604|NCT04013100|DIAGNOSTIC_TEST|3D-VNE (virtual neck exploration)|The 3D-VNE model is obtained with VP Planning software (Visible Patient, Strasbourg, France), using DICOM (Digital Imaging and Communications in Medicine) images of contrasted Computed Tomography scan of the neck in operative positioning.
214375605|NCT06259643|OTHER|Power wheelchair soccer|Participants will practice power wheelchair soccer during the course of the power wheelchair soccer season (starting in November 2023 and ending in June 2024). Sessions are given once a week, by a coach with experience in this adaptive sport.
214375606|NCT02480595|DEVICE|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
214375607|NCT03299686|DRUG|CJM112|300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.
214686416|NCT01941368|DIETARY_SUPPLEMENT|Placebo|
214686417|NCT01941368|DIETARY_SUPPLEMENT|HMB-FA|
214375608|NCT03299686|OTHER|Placebo to CJM112|Placebo to match CJM112 + standard of care treatment
214375609|NCT03745222|DRUG|Tislelizumab|PD-1 inhibitor (monoclonal antibody against PD-1)
214375610|NCT03745222|DRUG|Concurrent chemoradiotherapy (cCRT)|Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
214375611|NCT03745222|OTHER|Placebo|Placebo
214375612|NCT02573025|DRUG|PEG-IFN alfa-2a BA-free formulation (Test)|Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
214375613|NCT02573025|DRUG|PEG-IFN alfa-2a market formulation (Reference)|Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
214375614|NCT04797091|OTHER|Retrospective data collection|Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.
214375615|NCT03291886|DRUG|Entinostat|Given PO
214686418|NCT01941368|PROCEDURE|High Intensity Interval Training|
214686419|NCT06783569|DRUG|JR8603|IV infusion on Days 1, 8, and 15 of continuous 28-day cycles
214686420|NCT00001529|DRUG|G-CSF|After medical clearance, volunteers will undergo outpatient mobilization with daily subcutaneous injections of filgrastim (G-CSF). The first dose will be administered at the NIH Clinical Center, with one-hour monitoring for immediate reactions. Volunteers may either return to NIH for daily injections or self-administer at home after training.
214686421|NCT05950464|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
214686422|NCT05950464|PROCEDURE|Biopsy Procedure|Undergo biopsy
214686423|NCT05950464|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214686424|NCT05950464|PROCEDURE|Computed Tomography|Undergo CT
214686425|NCT05950464|PROCEDURE|Electrocardiography|Undergo ECG
214686426|NCT05950464|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214686427|NCT05950464|DRUG|Tuvusertib|Given PO
214686428|NCT05950464|PROCEDURE|X-Ray Imaging|Undergo x-ray
214686429|NCT05891249|BIOLOGICAL|Luspatercept|Specified dose on specified days
214686430|NCT03531645|DRUG|Fulvestrant|"Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days."
214686431|NCT03531645|DRUG|Abemaciclib|"Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days."
214375616|NCT03291886|DRUG|Entinostat(Placebo)|Given PO
214686432|NCT06417177|DRUG|Placebo|Participants will receive a placebo in pill form.
214686433|NCT06417177|DRUG|Propranolol|Participants will receive oral propranolol (1 mg/kg).
214686434|NCT06417177|DRUG|Gemtesa|Participants will receive oral gemtesa (75 mg).
214686435|NCT03398408|BEHAVIORAL|Training|The intervention group will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
214686436|NCT00155285|PROCEDURE|computed tomography|
214375617|NCT03291886|DRUG|Exemestane|Given PO
214375618|NCT05240430|DRUG|Mesenchymal Stem Cell Antigen-1, Human|Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies
214686437|NCT06904794|BEHAVIORAL|GAMBL-OUT program|The GAMBL-OUT program consists of two sessions: the first one involves a digital escape room to be delivered in the classroom and a series of physical props to be used during the experience. In small groups (4-5 students), participants need to work together to solve different puzzles and riddles, all of them related to the story of young adults who are dealing with problem gambling. By the end of the game, which will have a limited time (50 minutes), each group will have gained access to a different password. The second session will start from here: each group will share their password so the final puzzle can be solved, and the game will conclude with in a group discussion about what was learned (40 minutes).
214686438|NCT07091448|DEVICE|Amnion chorion membrane|Alveolar ridge preservation of a single extraction socket site with a barrier membrane Biotivity™ A/C Plus.
214686439|NCT07091448|DEVICE|Collagen membrane|Alveolar ridge preservation of a single extraction socket site with a barrier membrane CopiOs..
214686440|NCT06233032|DRUG|Ephedrine|Patient Will receive 6mg IV
214686441|NCT06233032|DRUG|Dexmedetomidine|Patient Will receive 30mcg IV
214375619|NCT01291147|DRUG|Levobupivicaine|levobupivicaine 0.5% continous infusion for 48 hours
214375620|NCT01291147|DRUG|0.9% Saline|0.9% saline continous infusion for 48 hours
214375621|NCT05549765|PROCEDURE|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
214375622|NCT05549765|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
214375623|NCT00259922|DRUG|Placebo|Placebo
214375624|NCT00259922|DRUG|Alvimopan|0.5 mg QD
214686442|NCT00719732|DEVICE|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
214686443|NCT06910137|DRUG|retifanlimab|Administered intravenous as defined in the protocol.
214686444|NCT04143724|DRUG|ACE-536|Specified dose on specified days
214686447|NCT00687115|BEHAVIORAL|Weight Loss|liquid diet at 50% of weight maintaining intake
214375625|NCT00259922|DRUG|Alviompan|0.5 mg BID
214375626|NCT02986607|DRUG|parathyroid hormon 1-84|Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
214375627|NCT00785317|DRUG|Angemin vs Activelle|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
214686448|NCT00687115|BEHAVIORAL|Overfeeding|Overfeeding at 150% of weight maintaining intake
214686449|NCT00687115|BEHAVIORAL|Overfeeding Low Pro|Overfeeding 150% of normal intake at \<5% protein
214686450|NCT07109856|DIAGNOSTIC_TEST|POP-Score Assessment|A non-invasive score calculated within the first 6 hours after birth using peripheral muscle oxygenation (pTOI, measured via near-infrared spectroscopy), heart rate, arterial oxygen saturation (SpO2), systolic blood pressure (SABP), and subcutaneous fat layer thickness. The score is evaluated for its ability to predict C-reactive protein (CRP) levels ≥ 20 mg/L within 48 hours.
214686451|NCT07109856|DEVICE|Near-Infrared Spectroscopy (NIRS)|NIRS measurements are performed within 6 hours after birth using the NIRO 200NX device at four anatomical sites (forearm, forehead, infraumbilical region, and left flank). Measurements assess peripheral muscle, cerebral, intestinal, and flank oxygenation to identify possible differences in tissue perfusion associated with early inflammation or infection.
214686452|NCT07102381|DRUG|Zanidatamab|Administered intravenously (IV)
214686453|NCT07102381|DRUG|Paclitaxel|Administered intravenously (IV)
214686454|NCT07102381|DRUG|Docetaxel|Administered intravenously (IV)
214686455|NCT07102381|DRUG|Carboplatin|Administered intravenously (IV)
214686456|NCT07102381|DRUG|Trastuzumab|Administered intravenously (IV)
215090203|NCT01536483|DRUG|Butyrate enemas|"Seven enemas~* Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~* The study remains blinded for the investigation team through the intervention of a clinical research nurse~* According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~* Installation time and retention is setted at 15 minutes~* Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~* Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist"
214375628|NCT02209012|DRUG|Aminolevulinic Acid (ALA)|Levulan PDT given in CP0108
214686457|NCT07102381|DRUG|Pertuzumab|Administered intravenously (IV)
214375629|NCT02209012|DRUG|Topical Solution Vehicle|Vehicle PDT given in CP0108
214375630|NCT02209012|DEVICE|BLU-U Blue Light Photodynamic Therapy Illuminator|PDT given in CP0108
214375631|NCT02150200|OTHER|shorter hospitalization stay|
214375632|NCT02150200|OTHER|questionnaires|
214375633|NCT05255432|OTHER|nil intervention|Users observation using medical device on manakin, different scenarios per group
214686458|NCT05602597|DRUG|Itraconazole 200 mg|Study participants will be administered 200 mg itraconazole by mouth twice daily after the pharmacokinetic blood draw on Day 3 and once daily on Days 4 to 10, inclusive.
214686459|NCT05602597|DRUG|Fluconazole 400 mg|Study participants will be administered 400 mg fluconazole by mouth daily on Day 3 after the pharmacokinetic blood draw, and 200 mg fluconazole by mouth daily on Days 4 to 10, inclusive.
214686460|NCT05602597|DRUG|Rifampin 600 mg|Study participants will be administered 600 mg rifampin by mouth daily starting on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 11, inclusive.
214496608|NCT05626374|BEHAVIORAL|Basic Case Management plus Distress Tool and rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus daily distress self-reports plus rapid access referral process for healthcare crisis services
214686461|NCT05602597|DRUG|Rabeprazole 40 mg|Study participants will be administered 40 mg rabeprazole by mouth daily on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 9, inclusive.
214686462|NCT04977505|DEVICE|pushlock|The surgery procedure was performed with pushlock for fixation
214375634|NCT02028559|DEVICE|Propulse 1|Move kidney stones with Propulse 1 device.
214686463|NCT04977505|DEVICE|gryphon|The surgery procedure was performed with Gryphon for fixation
214375635|NCT01974037|DIETARY_SUPPLEMENT|Capsaicin|Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin\_effect subgroups
214496609|NCT00315185|DRUG|Cetuximab|
214496610|NCT05840185|DEVICE|Test myopia control lenses (DAL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
214496611|NCT04887337|PROCEDURE|Arthroscopic stabilization|Early arthroscopic stabilization with Bankart repair
214496612|NCT04887337|OTHER|Rehabilitation including a period of immobilization followed by physical therapy|Rehabilitation including a period of immobilization followed by physical therapy
214496613|NCT01567787|RADIATION|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
214496614|NCT01567787|RADIATION|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
214496615|NCT02798653|DRUG|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
214496616|NCT02798653|DRUG|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
214496617|NCT02798653|DRUG|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
214496618|NCT05625230|BEHAVIORAL|Behavioral Activation plus Dynamic Mental Imagery|This intervention consists of an 8-session behavioural activation treatment with an added dynamic imagery exercise after each session. The dynamic imagery exercise is structured as follows: (1) the therapist explains the intervention; (2) the therapist models dynamic simulation skill (dynamic imagery) and repeats with the participant while giving appropriate feedback; (3) the participant completes a 10-minute Kinect training; (4) the participant completes a short Actfulness exercise that involves focusing on the feelings of movements of breathing and hands and dynamic imagery of one planned activity. From the second session, participants memorize daily activities forming a short dynamic memory of the activity focusing on feelings of movements.
214686464|NCT05636618|DRUG|[203Pb]VMT-α-NET|\[203Pb\]VMT-α-NET is administered by intravenous bolus injection for single-photon emission computed tomography imaging.
214686465|NCT05636618|DRUG|[212Pb]VMT-α-NET|\[212Pb\]VMT-α-NET is administered by intravenous infusion for treatment of SSTR2 expressing neuroendocrine tumors.
214686466|NCT06915467|PROCEDURE|Umbilical vein catheterization through Wharton's jelly procedure|All patients included will receive the Umbilical vein catheterization through Wharton's jelly procedure as first-line treatment: placement of the umbilical line through Wharton's jelly, with simultaneous and systematic preparation of umbilical venous catheter (UVC)
214686467|NCT07110090|BIOLOGICAL|Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002)|dosage form: Injection dosage: 10 mL/bag, 1×10⁷ cells/mL frequency: Each subject will be administered a single infusion of XJ-MK-001 at their respective enrolled dose level.
214686468|NCT06920901|DRUG|APG777|APG777 subcutaneous injection
214686469|NCT06920901|DRUG|Placebo|Matching placebo subcutaneous injection
214375636|NCT01974037|DIETARY_SUPPLEMENT|NaCl|NaCl in various concentrations was desorved in the test solutions in Salt\_effect subgroups
214375637|NCT01064908|DEVICE|OxyMask|Novel vortex oxygen delivery mask
214375638|NCT01959347|PROCEDURE|Miduretheral Sling|MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health \& Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).
214686470|NCT06922110|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.
214686471|NCT06920056|DRUG|Paracetamol|oral, postprandial
214686472|NCT06920056|DRUG|Metformin Hydrochloride|Oral , Fasting
214987882|NCT00651846|DRUG|Yasmin (DRSP 3mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
214987883|NCT00651846|DRUG|Microgynon (LNG 0.15 mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
214987884|NCT01548235|DRUG|biphasic insulin aspart 30|Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
214375639|NCT01959347|OTHER|Miduretheral Sling with behavioral/pelvic floor therapy|MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
214375640|NCT01121302|DRUG|AZD5213|0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
214496619|NCT05625230|BEHAVIORAL|Behavioral activation|"The BA intervention is a short 8 session behavioural intervention. Participants learn to monitor the activities, plan anti-depressant activities for the next week and find support for the implementation of the activity."
214987885|NCT00527995|DRUG|Sildenafil|Orally administered, Sildenafil 100mg, unique administration
214987886|NCT03416101|PROCEDURE|Total Gastrectomy|The esophagus was resected at the arch level of the azygos vein, a frozen section of the resection margin was routinely performed to achieve a proximal clean resection margin. The surgical specimen was comprehensive of distal esophagus, stomach and omentum. Digestive tract continuity was established with Roux-en-Y esophagojejunostomy. Lymphadenectomy was extended to the thoracic stations R 2-4, 7-8-9, and L 4, numbered according to the Mountain's classification \[39\] (Suppl. File 2 Figure A) and to the abdominal stations 1-12, numbered according to the Japanese Research Society for Gastric Cancer (JRSGC) 1998 classification.
214375641|NCT01121302|DRUG|Placebo|
214375642|NCT02813356|DRUG|naloxegol|non-interventional study where naloxegol is prescribed during normal clinical practice
214375643|NCT02813356|DRUG|non-PAMORA|non-interventional study where patients are exposed to non-peripherally acting mu-opioid antagonists during the normal course of clinical practice
214375644|NCT03321825|DEVICE|Belotero® Volume Lidocaine|Mode of application: subdermal injection
214496620|NCT04237857|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
214496621|NCT06850792|BEHAVIORAL|Telemedicine-Based Adherence Support|The intervention consists of biweekly teleconsultations for six months, conducted by healthcare professionals, focusing on medication adherence, patient education, side effect management, and remote support for individuals with pulmonary arterial hypertension (PAH). Patients will receive structured guidance on treatment adherence, tailored counseling, and real-time problem-solving strategies. The goal is to improve adherence to oral PAH therapy and enhance clinical outcomes compared to standard care.
214496622|NCT06125197|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
214496623|NCT06125197|BIOLOGICAL|KEYTRUDA®|pembrolizumab, a monoclonal antibody binding PD-1
214686473|NCT06920056|DRUG|Warfarin|Oral , Fasting
214686474|NCT06920056|DRUG|BGM0504|Administered SC
214686475|NCT07122661|BIOLOGICAL|ABRYSVO|This is a non-interventional retrospective study; therefore, ABRYSVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.
214686476|NCT06931860|DIAGNOSTIC_TEST|Cologuard|Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.
214686477|NCT06931860|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.
214987887|NCT00025337|BIOLOGICAL|bevacizumab|Given IV
214987888|NCT00025337|DRUG|oxaliplatin|Given IV
214987889|NCT00025337|DRUG|leucovorin calcium|Given IV
214987890|NCT00025337|DRUG|fluorouracil|Given IV
214987891|NCT01214122|DRUG|AZD9668|60 mg orally twice daily for 11 days
214987892|NCT01214122|DRUG|Warfarin|10 x 2.5 (25) mg orally once daily on day 1 and on day 14
214987893|NCT02419950|DEVICE|Fixation of mesh in TEP|An endoscopic operative technique were mesh for preperitonelal placement in patients with inguinal hernias can be fixated in Place or left without fixation
214987894|NCT00225030|DRUG|antihypertensive drugs according to current guidelines|
214987895|NCT00634504|DRUG|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
214987896|NCT00634504|DRUG|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
214375645|NCT05428514|OTHER|Maternity Housing|Receives a bed in the maternity home, wrap-around services, etc.
214375646|NCT03954743|BIOLOGICAL|PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
214496624|NCT06073184|DRUG|Mounjaro|Weekly subcutaneous injection of 2.5mg tirzepatide at baseline with dose escalation by 2.5mg every 4 weeks to reach 15mg or the maximum tolerated dose, by Week 20
214987897|NCT00204737|DRUG|prednisone|20mg x 2 weeks
214375647|NCT03954743|BIOLOGICAL|Lyophilized formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
214375648|NCT00886067|DRUG|AZD1446|Solution, oral, single dose
214375649|NCT00886067|RADIATION|2-[18F]-F-A85380|iv, single dose
214987898|NCT00204737|DRUG|placebo|placebo
214987899|NCT05001620|OTHER|Palliative Care Consultation|The PC provider conducts the structured PCC-PAC via videoconference or telephone with the PLWD and/or their care partner and the social work (SW) champion in the NH. The SW and PC provider will set up a mutually agreed upon consultation day/time with the PLWD and/or care partner, within 5 business days of NH admission and follow up visits will occur no more than 30 days later (if needed).
214987900|NCT02593240|BEHAVIORAL|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food|The intensive iDiet® group behavioral weight loss program will be delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the iDiet® intervention will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.
214987901|NCT02593240|BEHAVIORAL|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher|The intensive iDiet® group behavioral weight loss program delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the Diet® intervention will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
214987902|NCT02593240|BEHAVIORAL|Human Performance Institute©|The Human Performance Institute© (HPI) training workshop is a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
214987903|NCT06249230|DIAGNOSTIC_TEST|Hematologic features|Hematologic features include coagulation indicators, autoimmune indicators, and endocrine indicators.
214987904|NCT06249230|DIAGNOSTIC_TEST|Ultrasound indices of uterine artery blood flow|Ultrasound indices of uterine artery blood flow include endometrial thickness, endometrial artery blood flow parameters , and bilateral uterine artery blood flow parameters.
214987905|NCT06249230|OTHER|Demographic characteristics|Demographic characteristics include age, the number of previous spontaneous abortions (including biochemical pregnancies), BMI, fertility history, past disease history, chromosomal status, family and genetic history, etc.
214987906|NCT03200223|BEHAVIORAL|Personalized healthcare service|Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring
214987907|NCT04383132|DEVICE|Abdominal Binder|abdominal binder is a kind of elastic abdominal compression device
214987908|NCT03806816|DIETARY_SUPPLEMENT|Melatonin|5 daily enteral doses of melatonin 10 mg/kg. (=2 ml/kg)
214375650|NCT01923805|DEVICE|Vitagel|Vitagel
214375651|NCT05982301|DRUG|Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU|The study has only one arm. Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.
214375652|NCT00860067|BIOLOGICAL|Q/LAIV (MEDI3250)|0.2 mL dose at Day 0
214375653|NCT00860067|BIOLOGICAL|FluMist/B/Yamagata|0.2 mL dose at Day 0
214375654|NCT00860067|BIOLOGICAL|FluMist/B/Victoria|0.2 mL dose at Day 0
214375655|NCT01373632|DEVICE|Firebird 2 sirolimus-eluting stent|the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform
214375656|NCT01373632|DEVICE|Excel sirolimus-eluting stent|the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform
214375657|NCT01282801|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
214375658|NCT01282801|DRUG|Effexor® XR|150 mg Extended-Release Capsule
214375659|NCT01455025|DRUG|Plerixafor granulocyte-colony stimulating factor|"Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.~Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5"
214375660|NCT00329121|DRUG|PEP005|
214375661|NCT04714801|DRUG|adipose derived mesenchymal stromal cells|Intravenous infusion of cells
214375662|NCT04714801|DRUG|Saline|Intravenous infusion of saline
214375663|NCT01988948|OTHER|Various biological sampling|
214987909|NCT03806816|OTHER|PLACEBO group|5 daily enteral doses of placebo 2 ml/kg
214987910|NCT00481676|DRUG|Omalizumab 75-375 mg|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
214987911|NCT00481676|DRUG|Placebo to omalizumab|Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
214686478|NCT04405271|DRUG|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks
214686479|NCT04405271|DRUG|Placebo|A dose of 1 tablet per day will be administered for a total of 12 weeks.
214686480|NCT07072832|DEVICE|3D-Shelf|Treatment of hip dysplasia using novel 3D printed 3D-Shelf device.
214987912|NCT00481676|DRUG|Loratadine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
214987913|NCT00481676|DRUG|Clemastine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
214686481|NCT07146997|DIETARY_SUPPLEMENT|Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB|"Group I - Placebo Group (Control) Intervention: Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB.~Purpose: This group serves as the control to establish a baseline anesthetic success rate without active premedication.~Expected Outcome: Lower IANB success rate due to lack of anti-inflammatory intervention."
214987914|NCT00413803|PROCEDURE|4-hour thrice weekly in center hemodialysis|conventional hemodialysis
214987915|NCT00413803|PROCEDURE|8-hour thrice weekly in center hemodialysis|long dialysis
214987916|NCT01555814|DRUG|Amisulpride|4-week open label amisulpride treatment
214987917|NCT01703156|PROCEDURE|Stress Test|
214375664|NCT00560612|DRUG|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
214987918|NCT01703156|PROCEDURE|No Stress Test|
214496625|NCT06073184|DRUG|Mirena|Levonorgestrel-releasing Intrauterine System (52mg) to deliver up to 20 mcg levonorgestrel per day
214987919|NCT05529433|PROCEDURE|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is highly accepted by the patients as there is no need for local anesthesia. It is a minimal invasive technique which preserves sound tooth structure as caries removal will be done by a sharp spoon excavator. It requires less time during caries removal. There is a chemical bond between the tooth and the glass ionomer adhesive material. So, there is no need for cutting sound tooth structure for retention of the restoration.
214987920|NCT05529433|PROCEDURE|Smart Burs|Smart Bur is a polymer bur which removes only soft infected dentin as the cutting edges become dull in contact with the hard affected dentin.Caries removal will be done by Smart Bur mounted on a low speed hand-piece leaving the affected dentin intact. It requires less time for caries removal.
214375665|NCT00560612|DRUG|Placebo|Placebo: same as paroxetine (active comparator)
214987921|NCT05529433|PROCEDURE|Chemo-Mechanical Caries Removal (CMCR)|Selecti-Solve gel is a dental gel which main active ingredient is Papain enzyme which selectively removes the caries without pain and has bacteriostatic, bactericidal and anti-inflammatory properties. The use of CMCR is recommended as an alternative treatment technique in anxious patients. The gel will be applied with a blunt spoon instrument and distributed well into the cavity according to manufacturer's instructions.
214987922|NCT01513590|DRUG|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
214987923|NCT00005996|DRUG|cisplatin|
214987924|NCT00005996|DRUG|gemcitabine hydrochloride|
214987925|NCT00005996|DRUG|semaxanib|
214987926|NCT00305526|DEVICE|Contak Renewal (CRT-D)|
214987927|NCT04452175|OTHER|JUUL E-CIGARETTE|JUUL E-CIGARETTE USAGE FOR 24 WEEKS
214987928|NCT01056276|DRUG|Bendamustine|Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
214987929|NCT01056276|DRUG|Bortezomib|"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
214987930|NCT01056276|DRUG|Dexamethasone|20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
214375666|NCT03346811|DRUG|Icotinib|Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
214375667|NCT00939601|BEHAVIORAL|Motivational Enhancement Therapy|
214375668|NCT00939601|BEHAVIORAL|Educational Counseling|
214375669|NCT00927056|PROCEDURE|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
214496626|NCT04551651|DEVICE|ApplTree|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
214496627|NCT04551651|DEVICE|Google Calendar|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
214686482|NCT07146997|DRUG|Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB|"Group II - Ibuprofen Group Intervention: Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB.~Purpose: Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and inflammation, which can enhance anesthetic efficacy.~Expected Outcome: Improved IANB success rate compared to placebo, but possibly lower than combination therapy."
214375670|NCT05636462|OTHER|Global postural re-education program|"Different postures of global re-education programs are used and stretch is applied in these postures.~3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks."
214375671|NCT05636462|OTHER|Conventional Physical Therapy|Isometrics and stretching is used as conventional treatment. 3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks.
214375672|NCT01379027|BEHAVIORAL|Pure self-help Internet CBT for depression|Internet, CBT, Depression
214375673|NCT01379027|BEHAVIORAL|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
214375674|NCT01379027|BEHAVIORAL|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
214375675|NCT05590208|PROCEDURE|sleeve gastrectomy+ cruroplasty+ omental rap|sleeve gastrectomy+ cruroplasty+ omental rap
214375676|NCT02387996|DRUG|Nivolumab|
214375677|NCT01060553|OTHER|Acupuncture treatment|This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
214375678|NCT02307591|DRUG|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is \>7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
214375679|NCT02307591|DRUG|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~* Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~* Children \< 29 kg: 5 mg/kg 3 times a day"
214375680|NCT01494428|DEVICE|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
214686483|NCT07146997|DRUG|Group III - Serratiopeptidase Group|"Group III - Serratiopeptidase Group Intervention: Patients will receive serratiopeptidase (10 mg or standard dose) orally, 1 hour before the IANB.~Purpose: Serratiopeptidase is a proteolytic enzyme with anti-inflammatory, mucolytic, and fibrinolytic properties. It helps reduce tissue inflammation by breaking down inflammatory mediators and possibly inhibiting prostaglandin production.~Expected Outcome: Improved IANB success rate compared to placebo; effectiveness may vary compared to ibuprofen alone"
214686484|NCT07146997|COMBINATION_PRODUCT|Group IV - Combination Group (Ibuprofen and Serratiopeptidase)|"Group IV - Combination Group (Ibuprofen and Serratiopeptidase) Intervention: Patients will receive a combination of ibuprofen and serratiopeptidase orally, 1 hour before IANB. The doses will be the same as those used in Groups II and III, respectively.~Purpose: This group is designed to test the synergistic effect of combining an NSAID (ibuprofen) and a proteolytic enzyme (serratiopeptidase) to maximize inflammation control and increase the success of IANB in inflamed pulp tissue.~Expected Outcome: Highest success rate of IANB due to dual action on prostaglandin inhibition and tissue inflammation reduction"
214686485|NCT07147062|PROCEDURE|Rectus Sheath Block|A total volume of 0.5 mL/kg of 0.25% bupivacaine-distributed equally between both sides-will be injected bilaterally under direct ultrasound guidance.
214987931|NCT01710423|BEHAVIORAL|Peer mentoring intervention ('Cooking with Friends')|"'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children."
214987932|NCT03493971|PROCEDURE|Carotid revascularization performed using CAS|Carotid artery stenting (CAS) is an endovascular stent procedure used to treat narrowing of the carotid artery and decrease the risk of stroke
214375681|NCT01494428|DEVICE|Autogenous bone/allograft bone dowel|An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
214375682|NCT05927025|PROCEDURE|Hand K-files|It is used for cleaning and shaping root canals.
214987933|NCT03493971|PROCEDURE|Carotid revascularization performed using CEA|Carotid endarterectomy (CEA) is a surgical procedure used to correct stenosis in the common carotid artery or internal carotid artery and reduce the risk of stroke
214375683|NCT03263221|PROCEDURE|reduction and fixation|Surgical procedures, as plating, Proximal Femoral Nail , Dynemic Hip screw and others procedures according to needed for each types
214987934|NCT00537836|DRUG|BAY 86-5310 (ZK 283197)|3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
214987935|NCT00537836|DRUG|Placebo|Placebo, once daily p.o. over 8 weeks
214987936|NCT00537836|DRUG|17ß-estradiol|1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
215090204|NCT05618093|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds. If two finger probes are available, measurements will alternate between fingers.
214686486|NCT07147062|PROCEDURE|Caudal Epidural Block|"A 22G caudal epidural needle will be inserted at approximately a 45° angle toward the sacral hiatus, and the characteristic click sensation will be felt upon passing the sacrococcygeal ligament. The needle will then be advanced carefully in the cephalad direction, parallel to the longitudinal axis of the spinal canal. After confirming correct placement by negative aspiration, 1 mL/kg of 0.25% bupivacaine will be administered."
214686487|NCT07150520|DEVICE|Virtual Reality-Based Optokinetic Stimulation (OKS)|A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.
214987937|NCT04057092|DIETARY_SUPPLEMENT|Dietary Supplement INergy-FLD|INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
214987938|NCT02832713|DRUG|Botulinum toxin A ( BoNT-A)|Intra-articular injection of BoNT-A
214987939|NCT02832713|DEVICE|Hyaluronic acid (HA)|Intra-articular injection of Hyaluronic acid
214987940|NCT00745602|PROCEDURE|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
214987941|NCT04892160|OTHER|Guided Imagery|Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will play an audio recording of an underwater guided imagery during one of these procedures: port access, dressing changes, and IV sticks. Guided imagery is an intervention that relies on a patient's imagination to create a sensory experience that utilizes mental images, sounds, smells, tastes, and touch. The guided imagery script used in this study describes an underwater scene and is meant to closely mimic the VR condition with the exception that it will be non-immersive. It will last approximately 15 minutes but can be played again if the procedure lasts longer than 15 minutes. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
214987942|NCT04892160|OTHER|Virtual Reality|Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will assist the patient in beginning the VR intervention during one of these procedures: port access, dressing changes, and IV sticks. The VR intervention consists of interactive audio and visual underwater experience. The VR software offers both passive and active gameplay over the course of 15 minutes, which can be repeated. In the passive experience, the software moves patients through an ocean filled with sea creatures and allows them to look around and observe the underwater scene. In the active experience, patients launch balls at the fish. Patients will be encouraged but not required to actively participate; staff will record whether the patient participates in the active portion of the VR program. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
214987943|NCT02054156|DRUG|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
214987944|NCT02054156|DRUG|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
214987945|NCT02054156|DRUG|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
214987946|NCT05106478|DEVICE|AuraGain|Ambu® AuraGain, a relatively novel supraglottic airway device, has been introduced recently. AuraGain has an inflatable cuff and a curved body.
214375684|NCT03640546|BEHAVIORAL|Within My Reach/ Within Our Reach|Relationship education workshops
214375685|NCT01546259|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
214375686|NCT02385019|BIOLOGICAL|Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease|"Regulatory T cells selected by a sequential 2 step procedure:~1. \- Negative selection of CD8 and CD19 cells~2. \- Positive selection of CD25 cells"
214375687|NCT04665011|DEVICE|Indicor|A simple, non-invasive tool to report pulse response to a Valsalva maneuver
214375688|NCT04665011|DEVICE|Caretaker|non-invasive blood pressure monitor
214686488|NCT07149584|PROCEDURE|ESPB|10 mL of 0.375% bupivacaine is injected on each side between the deep fascia of the erector spinae muscle and the transverse process. Additionally, tramadol is administered via intravenous patient-controlled analgesia.
214686489|NCT07149584|PROCEDURE|TPVB|10 mL of 0.375% bupivacaine is injected on each side between the superior costotransverse ligament and the pleura.
214686490|NCT07149584|PROCEDURE|IV|Tramadol is administered via intravenous patient-controlled analgesia.
214987947|NCT01649219|BEHAVIORAL|Exercise|
215090205|NCT05025696|OTHER|Blacksoap(R)|Blacksoap(R)
215090206|NCT05126628|DRUG|Proxalutamide|Proxalutamide 300mg q.d.(3 tablets of 100mg each) for 14 days.
215090207|NCT05126628|DRUG|Placebo|Placebo 3 tablets q.d. for 14 days
214987948|NCT05098561|OTHER|Music Treatment|The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
214375689|NCT00294099|BIOLOGICAL|Aluminum hydroxide|Aluminum hydroxide adjuvant.
214375690|NCT00294099|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
214375691|NCT01368445|DRUG|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM \& PM)
214375692|NCT01368445|DRUG|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
214375693|NCT01368445|DRUG|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
214987949|NCT02641821|DRUG|Nifedipine GITS|
214987950|NCT01404481|DEVICE|clean intermittent self catheterisation single use vs re use|Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
214987951|NCT01502553|DEVICE|Comparison Test to Yuyue Medical BP Meter, YYBP-212|DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
214987952|NCT00005988|DRUG|cyclophosphamide|
214987953|NCT00005988|DRUG|cyclosporine|
214375694|NCT03160287|BEHAVIORAL|Motivaltional interviews and infrequent motivational text messages|A self-management intervention will integrate use of mobile technology to prompt older adults to be physically active, provides ongoing monitoring of the amount of their physical activity and includes self-efficacy enhancements is a novel non-pharmacological intervention both for prevention and treatment of sleep deficiency in persons with OA
214375695|NCT00632281|RADIATION|Stereotactic Body Radiation Therapy|Prescription dose: 48 Gy or 60 Gy RT
214375696|NCT01949103|DRUG|TD-1607|
214375697|NCT01949103|DRUG|Placebo|
214375698|NCT06089122|BIOLOGICAL|IVIG|Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. At Visit 4, at least 20 patients will perform the PK assessment, collecting additional blood samples.
214375699|NCT01378910|DRUG|Unique|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
214375700|NCT04262765|DRUG|Ramipril, Amlodipine and Atorvastatin|compare the pharmacokinetic of ramipril (and ramiprilat), atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
214375701|NCT04763811|OTHER|Focus groups|discussion between participants about representations of health, dependance, fragility, and new technologies
214375702|NCT04763811|OTHER|Individual interviews|Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors
214375703|NCT02098018|BEHAVIORAL|Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
214375704|NCT02098018|BEHAVIORAL|Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
214375705|NCT06230614|OTHER|Colistin 1 MU in normal saline 1 ml|Colistin 1 MU diluted in normal saline 1 ml, total volume of 12 ml
214375706|NCT06230614|OTHER|Colistin 1 MU in normal saline 2 ml|Colistin 1 MU diluted in normal saline 2 ml, total volume of 12 ml
214375707|NCT04707196|DRUG|Abemaciclib|Administered orally
214987954|NCT00005988|DRUG|leucovorin calcium|
214987955|NCT00005988|DRUG|methotrexate|
214987956|NCT00005988|DRUG|methylprednisolone|
214987957|NCT00005988|PROCEDURE|in vitro-treated bone marrow transplantation|
214987958|NCT00005988|RADIATION|radiation therapy|
214987959|NCT02993276|DEVICE|Neurocap®|NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
214987960|NCT03697590|DRUG|No curettage|Standard PDT without curettage
214987961|NCT03697590|DRUG|Curettage|Standard PDT
214987962|NCT00128427|DRUG|Colchicine (for 1 month)|
214987963|NCT04424901|DRUG|Placebo|Daily dose while hospitalized up to 9 days
214987964|NCT04424901|DRUG|Dipyridamole Tablets|Daily dose while hospitalized up to 9 days
214987965|NCT00147238|DRUG|Ferumoxtran-10 (USPIO)|Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
214987966|NCT00147238|PROCEDURE|MR lymphangiography|First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
214987967|NCT00102973|DRUG|TLK286 in Combination with Carboplatin|Experimental Arm
214987968|NCT00102973|DRUG|Doxorubicin HCl Liposome Injection|Active Comparator
214987969|NCT04735302|OTHER|Radiographic Feature|Radiographic rewiev
214987970|NCT03874962|OTHER|Routine oral cleaning and professional oral care group|Besides routine oral cleaning was conducted by caregivers, professional oral care intervention was conducted by dental hygienists, and it included muscle massage, oral cleaning, and oral health education once a week.
214987971|NCT02857153|DRUG|Urapidil|If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
214375708|NCT04707196|DRUG|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole or anastrozole administered orally (physician choice)
214686491|NCT07152860|OTHER|5 Hz electroacupuncture combined tipronone capsules|Intervention Description: The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation. Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia. Frequency: 5 Hz Patients will also be administered SviShu (tipronone capsules) (Wei Cai Pharmaceutical Co., Ltd., National Drug Approval Number H20093656, dosage: 50 mg) orally, one capsule at a time, three times daily, after meals.
214686492|NCT07152860|DRUG|Simple tipronone capsules group(The basic treatment group)|Patients in the Simple tipronone capsules group(basic treatment group) will receive only conventional basic drug therapy. They will be given Svi-Shu (tipronone capsules) (Eisai Pharmaceutical Co., Ltd., national drug approval number H20093656, specification: 50 mg) orally, one capsule at a time, three times a day, after meals.
214375709|NCT04707196|DRUG|Fulvestrant|Administered intramuscularly
214375710|NCT02848716|PROCEDURE|Surgery followed with chemoradiation|"Patients with negative paraaortic lymph nodes will be managed with external beam radiotherapy to the pelvis (as defined by the surgical clips applied at the lower limit of the paraaortic node dissection) at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy (High Dose Rate (DR), Low DR or Pulse DR) with intent to cure.~Patients with metastatic disease to paraaortic lymph nodes will receive extended-field external beam radiotherapy followed by intracavitary brachytherapy with intent to cure. Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy (in the 2 sub groups above) will be given with definitive radiation therapy."
214375711|NCT02848716|RADIATION|Standard chemoradiation|"patients with negative paraaortic lymph nodes on PET imaging will be managed with external beam radiotherapy to the pelvis at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy with intent to cure (HDR, LDR or PDR). Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy will be given with definitive radiation therapy."
214496628|NCT06432790|BEHAVIORAL|CHAMPION|The CHAMPION program is an intensive health behavior and lifestyle treatment (IHBLT), formed through the integration of the Healthy Weight Clinic IHBLT and with MGB's pediatric Asthma Population Health Management Program. It consists of 30 hours of contact time with the CHAMPION team (physician, dietician, community health worker), consistent with the USPSTF and AAP recommendations, monthly individual clinic visits with the team (in person or virtual, per randomization), health coaching calls with a community health worker and/or registered dietician, monthly group sessions (in the first six months), and educational materials for families that reinforce healthy lifestyle behaviors and provide self-management education. In this study, all participants will participate in CHAMPION, but one arm will receive the experimental form (delivery via telehealth) and the other arm will receive the active comparator (delivery via telehealth).
214686493|NCT05860881|DRUG|Sirolimus Topical Cream|The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
214375712|NCT02848716|RADIATION|chemoradiation|
214496629|NCT06633926|BEHAVIORAL|Nutrition Education|Given nutrition education
214686494|NCT05860881|OTHER|Placebo|Cream containing only the base, or vehicle.
214987972|NCT02857153|DRUG|Phenylephrine|If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
214987973|NCT02857153|PROCEDURE|Low-level MAP|MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
214686495|NCT07150156|BEHAVIORAL|brief intervention|Provision of personal feedback on drinking risk level and guidance that encourages the patient to develop a realistic plan to reduce his or her alcohol consumption to a less risky level
214987974|NCT02857153|PROCEDURE|High-level MAP|MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
214987975|NCT03491488|OTHER|Brain Games|The Brain Games intervention package is used as a tool to improve children's self-regulation and executive function skills. Brain Games were developed as part of larger behavioral intervention package in the US, and are designed to build the fundamental self-regulation skills that children need to be successful in school as well as later in life. The games are designed to be played in the classroom between regular activities.
214987976|NCT02955693|DRUG|LAS41008 120 mg / Fumaderm® 120 mg|Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
214987977|NCT02041572|BEHAVIORAL|Attentional bias retraining|Participants complete a computer-based intervention, which is designed to correct cognitive biases associated with PTSD by training to attend to neutral information rather than the trauma-related cue words.
214375713|NCT01862796|BEHAVIORAL|Underfeeding diet|Heart healthy diet with 35% reduced calories
214375714|NCT01862796|BEHAVIORAL|Weight maintaining diet|Heart healthy weight-maintaining diet
214496630|NCT06633926|BEHAVIORAL|Lifestyle Counseling|Given lifestyle recommendations
214496631|NCT06633926|OTHER|Yoga|Participate in yoga
214496632|NCT06633926|PROCEDURE|Marma therapy|Participate in marma therapeutic touch
215090208|NCT00865839|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
215090209|NCT00865839|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
215090210|NCT02404649|DEVICE|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
214987978|NCT04034472|OTHER|Interdisciplinary intervention in obesity|Interdisciplinary weight loss intervention associate to the use of digital technology to treat obesity and related disorders
214987979|NCT03287765|DRUG|18F-AV-1451|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
214375715|NCT00146601|DRUG|Fulvestrant|
214496633|NCT06633926|OTHER|Educational Intervention|Attend online HEI sessions
214496634|NCT06633926|OTHER|Quality of Life Questionnaire Administration|Self-reported questionnaires are given to participants to complete
214496635|NCT06950814|PROCEDURE|postoperative adjuvant therapy|Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.
214375716|NCT05527067|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
214375717|NCT05527067|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
214375718|NCT04572178|BEHAVIORAL|Cash payment and brief behavioral counseling|"The intervention consists of: (i) in person brief behavioral counseling, (ii) the evaluation of the smoking status using breath carbon monoxide, and (iii) cash payment of 25 Euro if the reading does not exceed a carbon monoxide value 3 ppm ( ppm = parts per million) on two consecutive measurements per week. The intervention starts at the earliest in pregnancy week 15 and lasts until the delivery. If they relapse, the reward is not paid. However, in the following week they have the opportunity to quit smoking and being rewarded again."
214375719|NCT00228696|OTHER|none, screening only|Screening protocol with no intervention
214496636|NCT05775757|RADIATION|Hypofractionated radiation therapy|Both 3-week and 1-week hypofractioanted radiation therapy are allowed. (simultaneous or sequential tumor bed boost is allowed.) A 3-week regimen includes 42.4 Gy in 16 fractions. A 1-week regimen includes 26 Gy in 5 fractions or 28.5 Gy in 3 fractions, 30 Gy in 5 fractions.
214496637|NCT06202378|DRUG|3 ampoules of SHPL-49 Injection|3 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
214496638|NCT06202378|DRUG|6 ampoules of SHPL-49 Injection|6 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
214496639|NCT06202378|DRUG|0.9% Sodium Chloride Injection|100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
214496640|NCT04825379|DEVICE|bioactive composite|Cention N
214496641|NCT04825379|DEVICE|posterior composite|G-ænial Posterior
214496642|NCT03703440|OTHER|Active arm|≥3 group education sessions in addition to usual diabetes care, every 3 months for 12 months
214496643|NCT03703440|OTHER|Control arm|Usual diabetes care, every 3-month for 12 months
214496644|NCT06117085|DEVICE|CellFX® Percutaneous Electrode (PE) System|Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology
214496645|NCT05402384|DRUG|AVTX-801|"Medical grade D-galactose~dosage:2.0 g/kg/day"
214496646|NCT05402384|DRUG|Placebo|Matching placebo
214496647|NCT06797999|BIOLOGICAL|Antibody-drug conjugate (ADC)|ADCE-D01 is an antibody-drug conjugate (ADC) composed of an anti-urokinase plasminogen activator receptor-associated protein (uPARAP) antibody, AB-004, conjugated to a topoisomerase I inhibitor, P1021, via a protease cleavage tetra-peptide linker.
214496648|NCT04265794|BEHAVIORAL|H2GO!|Child participants will participate in a 6-week behavioral intervention consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. Each week consisted of a 1-hour health session and a 1-hour narrative session (delivered on separate days). Child participants will also receive reusable water bottles and a pictorial intervention booklet, which includes worksheets and parent-child take-home activities targeting attitudes, knowledge, and skills related to sugar-sweetened beverage and water consumption. Parent participants will be exposed to intervention messages (e.g., reduce SSB intake) through weekly parent-child take-home activities, child sharing of narratives produced, and a culminating open house event.
214496649|NCT05695196|BIOLOGICAL|nasal microbiota transplant (NMT)|nasal microbiota transplant
214496650|NCT05695196|BIOLOGICAL|Placebo|Placebo sterile saline
214496651|NCT06397118|BEHAVIORAL|Maternal Nutrition Education|Community Health Worker delivered Maternal Nutrition Education
214496652|NCT06397118|BEHAVIORAL|Standard Care|Standard care in the sickle cell disease (SCD) clinic
214496653|NCT04801823|OTHER|Home introduction|Cautious, graded introduction of individual tree nuts
214496654|NCT04801823|OTHER|Multi Nut oral food challenge|In hospital multi nut oral food challenge (almond, cashew, hazelnut, walnut)
214496655|NCT03241940|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
214496656|NCT03241940|DRUG|Cyclophosphamide|Given IV
214496657|NCT03241940|DRUG|Fludarabine Phosphate|Given IV
214496658|NCT03241940|OTHER|Laboratory Biomarker Analysis|Correlative studies
214496659|NCT03241940|OTHER|Questionnaire Administration|Ancillary studies
214496660|NCT06639035|OTHER|External oblique intercostal plane block|The external oblique intercostal plane block is applied to the patients at the end of the surgery.
214496661|NCT06639035|OTHER|intavenous tramadol|Intravenous tramadol will be administered with patient-controlled analgesia
214496662|NCT05065957|DRUG|D07001-softgel capsules + Xeloda (or TS-1)|"D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)"
214496663|NCT05065957|DRUG|mFOLFOX|intravenous infusion on Day 1 for 14-day cycle
214987980|NCT00297167|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
214686496|NCT07156708|OTHER|Aquatic aerobic exercise program|The aquatic exercise sessions include the following exercises: butt kick, frontal kick, cross-country skiing, and stationary running. These exercises are commonly used in water aerobics classes and provide controlled osteoarticular impact, being safe for older women (Alberton et al., 2019). Training intensity is prescribed using Borg's 6-20 rating of perceived exertion (RPE) scale. The adopted strategy is based on interval training, which alternates between high-intensity effort and low-intensity active recovery phases. Each block consists of 4 minutes of effort (RPE 13 - 15), with one minute for each exercise (butt kick, frontal kick, cross-country skiing, and stationary running) followed by 1 minute of active recovery (RPE 11), performed with stationary running. To facilitate monitoring, an RPE scale (measuring 0.90 × 1.20 m) is fixed to the outside of the pool, in front of the participants.
214686497|NCT07156708|OTHER|Cognitive tasks|This group performs the same aerobic training protocol used by the conventional aquatic program group. Additionally, cognitive tasks are performed during the active recovery phases. Cognitive training encompasses different domains of cognition in all sessions, including semantic fluency, processing speed, cognitive flexibility, inhibitory control, memory, attention, and reasoning. The exercises vary in each class, with progression in complexity in each mesocycle.
214686498|NCT07152470|BEHAVIORAL|Diet and Exercise Tracking|To determine if diet and/or exercise had any impact on weight loss while taking motus.
214686499|NCT07152613|DRUG|Saline (0.9%, sterile, for infusion)|Saline for control
214686500|NCT07152613|DRUG|Low Dose Corticosteroids|Methylprednisolone 0.5mg/kg ivgtt qd
214686501|NCT07152613|DRUG|Moderate dose corticosteroids|Methylprednisolone 1.0mg/kg ivgtt qd
214686502|NCT07160439|BEHAVIORAL|Digital Micro-Interventions|Digital Micro-Interventions are brief interventions that target specific behavioral and cognitive mechanisms of mental health, designed for brief periods of engagement.
214686503|NCT07162194|PROCEDURE|Digital Rectal Examination|Undergo DRE
214686504|NCT07162194|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/TRUS
214686505|NCT07162194|PROCEDURE|Pathologic Examination|Undergo prostate tissue mapping and evaluation using a special mold
214686506|NCT07162194|PROCEDURE|Targeted Prostate Biopsy|Undergo targeted prostate biopsy based on PIRADS
214686507|NCT07162194|PROCEDURE|Targeted Prostate Biopsy|Undergo targeted prostate biopsy using GL AI predictions
214686508|NCT07162194|PROCEDURE|Targeted Prostate Biopsy|Undergo targeted prostate biopsy using DL AI predictions
214686509|NCT07162194|PROCEDURE|Transrectal Ultrasound|Undergo MRI/TRUS
214987981|NCT00297167|DRUG|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
214987982|NCT00297167|DRUG|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
214987983|NCT00297167|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
214987984|NCT06485505|DRUG|ISOtretinoin 10 MG|Low dose isotretinoin as an adjuvant for itraconazole in treating onychomycosis
214987985|NCT06485505|DEVICE|excimer light|excimer light as an adjuvant for itraconazole in treating onychomycosis
214375720|NCT05835557|OTHER|BFR-ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Blood flow restriction will be applied for 2 mins during the passive rest at 80% of limb occlusion pressure.
214375721|NCT05835557|OTHER|ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Cycling will be conducted in an environmental chamber and participants informed that the altitude is set to 2500m - actual altitude will be sea level.
214375722|NCT02232841|DEVICE|Mechanical Ventilation|Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria
214686510|NCT07163884|OTHER|electrotherapy treatment|Patients in the electrotherapy group will receive 15 sessions of TENS, hotpack, and ultrasound, 45 minutes each, 5 days a week, for 3 weeks. The treatment program is planned for 20 minutes of TENS, 15 minutes of hotpack, and 10 minutes of ultrasound.
214686511|NCT07163884|OTHER|Facsial therapy|In addition to electrotherapy, the patients in the study group will receive a total of five sessions (one day per week for five weeks) of fascial therapy. The protocol will be developed by us. Fascial mobilization will be performed by a trained physiotherapist on the pectoral fascia, deltoid fascia, axillary fascia, and supscapularis fascia, once a week, for 180 seconds each repetition. These sessions will be performed at the pain threshold, and care will be taken to ensure that the pain does not exceed a VAS score of 2.
214987986|NCT06485505|DRUG|Itraconazole 200 mg|Itraconazole alone
214987987|NCT00178373|DRUG|Modafinil|
214375723|NCT02232841|DEVICE|CT Scan|Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
214375724|NCT03604757|DRUG|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
214375725|NCT03604757|DRUG|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
214686512|NCT07162233|PROCEDURE|derotation osteotomy utilizing Kirschner wires for the correction of congenital proximal radioulnar synostosis|"The level of distal radial and proximal ulnar osteotomies is determined under C- arm. A k-wire is inserted in the outer border of the metaphysis of the radius distal to the level of the osteotomy, engaging and transfixing the radioulnar joint, small skin incision is made over the dorsal aspect of the forearm at the level of distal radial osteotomy, dissection of subcutaneous tissue with good exposure of the extensor tendons, transverse osteotomy is done using 2.5 mm drill bit and small sharp osteotme, allowing derotation movement of the distal part of the radius using the k-wire.~Another small skin incision is made over the level of proximal ulnar osteotomy, dissection of subcutaneous tissue, another ulnar transverse osteotomy is done distal to the level of the proximal radioulnar synostosis. Derotaion of the forearm is adjusted in the functional position of the forearm in around (10˚:20˚supination), wound closure using absorbable Vicryl sutures. Above elbow cast is used f"
214987988|NCT00178373|DRUG|sugar pill|
214987989|NCT04232137|BEHAVIORAL|Postpartum coffee ceremony|The promise of a postpartum coffee ceremony
215090211|NCT02404649|DEVICE|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
215090212|NCT04075409|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
214686513|NCT07161908|DEVICE|Pulse oximeter|"To ensure proper treatment, the infant will be continuously monitored with a pulse oximeter. Based on oxygen saturation levels, the treatment may be adjusted according to pre-established protocols. It is required that the saturation stays above a certain value for more than 95 % of the 12-hour measurement period. If the defined saturation values are reached, the parents will reduce the oxygen flow by one degree for 20 minutes in the hospital/home setting (20 minute test) and if the saturation values remain at 93 % or more during this period, overnight 12 hour monitoring will also be performed to confirm stable saturation values of 93 % or more for 95 % or more of the monitoring time.~Thanks to modern specialized pulse oximeters, it is possible to ensure accurate, long-term, remotely managed monitoring of the infant and to interactively optimize oxygen therapy based on current oxygen saturation levels."
214686514|NCT07162545|OTHER|stroboskopic visual training|Players in the study group will wear stroboscopic glasses for 10 minutes a day, two days a week, for eight weeks during their routine training. Evaluations will be repeated at the end of the eight weeks.
214686515|NCT07162090|DRUG|Roxadustat|Patients were administered roxadustat orally to observe its impacts on renal anemia and sarcopenia.
214686516|NCT07162090|DRUG|Recombinant human erythropoietin (EPO)|Recombinant human erythropoietin was administered to patients as a control group to investigate its impacts on renal anemia and sarcopenia.
214686517|NCT06395441|DIETARY_SUPPLEMENT|American Ginseng|Given PO
214686518|NCT06395441|DRUG|Placebo Administration|Given PO
214686519|NCT06395441|OTHER|Questionnaire Administration|Ancillary studies
214686520|NCT06318897|DRUG|Carboplatin|Given by IV
214686521|NCT06318897|DRUG|Paclitaxel|Given by IV
214686522|NCT06318897|DRUG|Pembrolizumab|Given by IV
214686523|NCT06318897|DRUG|Doxorubicin|Given by IV
214686524|NCT06318897|DRUG|Cyclophosphamide|Given by IV
214686525|NCT06548386|DEVICE|Pleural gas analysis|"Patients enrolled in this study will undergo both VI and pleural gas analysis to assess for air leak following surgical chest tube placement.~For pleural gas analysis, an outlet gas analyzer will be kept on the outlet port of the chest drain for the entire duration of time that a chest tube is in place. We plan to collect both continuous data, looking for intermittent spikes and gas changes, along with episodic data collected during specific air leak assessments. The gas analyzer may better be able to measure an air leak during these specific procedures conducted twice per day, but it will also be used at the outlet port of the chest drain the rest of the time to continuously check for an air leak throughout the hospital stay."
214686526|NCT05137262|OTHER|Abiraterone acetate|Given by IV
214686527|NCT05137262|DRUG|Durvalumab|Given by IV
214686528|NCT05137262|DRUG|Methotrexate|Given by IV
214686529|NCT05137262|DRUG|Vinblastine|Given by IV
214686530|NCT05137262|DRUG|Doxorubicin Hydrochloride|Given by IV
214686531|NCT05137262|DRUG|Cisplatin|Given by IV
214686532|NCT02816697|OTHER|CEASE|"* Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)~* CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits"
214686533|NCT02816697|OTHER|Usual Care Tobacco Treatment Services|
214686534|NCT05096481|BIOLOGICAL|PEP-CMV|The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
214686535|NCT05096481|DRUG|Temozolomide|Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
214686536|NCT05096481|BIOLOGICAL|Tetanus Diphtheria Vaccine|Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
214686537|NCT04582383|DRUG|Spironolactone|Dispensation of spironolactone according to the arm description.
214686538|NCT04582383|DRUG|Doxycycline Hyclate|Dispensation of doxycycline hyclate according to the arm description.
214987990|NCT01537588|OTHER|Autograft STG harvest from ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
214987991|NCT01537588|OTHER|Autograft harvest contralateral to ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
214987992|NCT00145561|DRUG|Saquinavir and Ritonavir|
214987993|NCT04831554|PROCEDURE|single chest tube drainage|place single chest tube after surgery of PSP
215090213|NCT01754792|DIETARY_SUPPLEMENT|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
214686539|NCT06386315|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
214686540|NCT06386315|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
214686541|NCT06386315|RADIATION|Involved-site Radiation Therapy (3 Fractions)|Undergo ISRT in 3 fractions
214686542|NCT06386315|RADIATION|Involved-site Radiation Therapy (12 Fractions)|Undergo ISRT in 12 fractions
214686543|NCT06386315|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214686544|NCT06386315|OTHER|Questionnaire Administration|Ancillary studies
214686545|NCT05973487|BIOLOGICAL|TSC-204-A0201|Escalating doses of TSC-204-A0201 as a monotherapy
214686546|NCT05973487|BIOLOGICAL|TSC-204-C0702|Escalating doses of TSC-204-C0702 as a monotherapy
214686547|NCT05973487|BIOLOGICAL|TSC-200-A0201|Escalating doses of TSC-200-A0201 as a monotherapy
214686548|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-C0702|Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702
214375726|NCT04230655|DIETARY_SUPPLEMENT|Low energy diet using meal replacements|The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.
214375727|NCT04230655|BEHAVIORAL|CBT-based group treatment|All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
214375728|NCT04230655|DEVICE|Intragastric balloon|An IGB (Orbera IGB, Apollo Endosurgery Inc., Austin, Texas, (CE certified)) is set in place endoscopically by a gastroenterologist at Örebro University Hospital, Region Örebro county, and is left in the stomach for 6 months. A proton-pump inhibitor is prescribed to counteract an increased risk to develop a gastric ulcer. During the first 2 weeks, dietary adjustments are necessary to adapt to the IGB. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended identical to the control group. The IGB is removed endoscopically after 6 months IGB treatment.
214375729|NCT02459223|DIETARY_SUPPLEMENT|Nutritional biscuits and khichadi|Nutritional biscuits and Khichadi.
214375730|NCT02459223|DIETARY_SUPPLEMENT|Khichadi|Khichadi.
214375731|NCT02481375|DIETARY_SUPPLEMENT|Multiple micronutrients|12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine
214375732|NCT02481375|DIETARY_SUPPLEMENT|Iron|12-wk supplementation of iron
214375733|NCT02481375|DIETARY_SUPPLEMENT|Placebo|12-wk supplementation of placebo
214375734|NCT04037436|OTHER|Strength and Balance Training & Nutrition Education|Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
214375735|NCT04037436|OTHER|Usual Care|During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
214375736|NCT02382718|BIOLOGICAL|FAST fish mCyp c 1|Subcutaneous immunotherapy
214375737|NCT02382718|BIOLOGICAL|Placebo|Subcutaneous immunotherapy
214375738|NCT06112730|OTHER|Standard pulmonnary rehabilitation|Undergo routine pulmonary rehabilitation without dietary intervention
214375739|NCT06112730|OTHER|Nutritional supplementation intervention|Receive personalized dietary guidelines based on indirect calorimetry assessment
214686549|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-200-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
214686550|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-200-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-200-A0201
214686551|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-203-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-203-A0201
214686552|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-203-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-203-A0201
214686553|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-203-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-203-A0201
214686554|NCT05973487|BIOLOGICAL|TSC-203-A0201|Escalating doses of TSC-203-A0201 as a monotherapy
214686555|NCT05973487|BIOLOGICAL|TSC-204-A0101|Escalating doses of TSC-204-A0101 as a monotherapy
214686556|NCT05973487|BIOLOGICAL|TSC-201-B0702|Escalating doses of TSC-201-B0702 as a monotherapy
214686557|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-A0101|Escalating doses of TSC-204-A0201 in combination with TSC-204-A0101
214686558|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-201-B0702|Escalating doses of TSC-204-A0201 in combination with TSC-201-B0702
214686559|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-204-A0101|Escalating doses of TSC-204-C0702 in combination with TSC-204-A0101
214686560|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-201-B0702|Escalating doses of TSC-204-C0702 in combination with TSC-201-B0702
214686561|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-204-A0101|Escalating doses of TSC-200-A0201 in combination with TSC-204-A0101
214686562|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-201-B0702|Escalating doses of TSC-200-A0201 in combination with TSC-201-B0702
214686563|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-204-A0101|Escalating doses of TSC-203-A0201 in combination with TSC-204-A0101
214686564|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-201-B0702|Escalating doses of TSC-203-A0201 in combination with TSC-201-B0702
214686565|NCT05973487|BIOLOGICAL|TSC-202-A0201|Escalating doses of TSC-202-A0201 as a monotherapy
214686566|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-202-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-202-A0201
214686567|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-202-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-202-A0201
214686568|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-202-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-202-A0201
215090214|NCT05579769|DRUG|Ruxolitinib|Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
214686569|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-202-A0201|Escalating doses of TSC-203-A0201 in combination with TSC-202-A0201
214686570|NCT05973487|BIOLOGICAL|TSC-204-A0101 + TSC-202-A0201|Escalating doses of TSC-204-A0101 in combination with TSC-202-A0201
214686571|NCT05973487|BIOLOGICAL|TSC-201-B0702 + TSC-202-A0201|Escalating doses of TSC-201-B0702 in combination with TSC-202-A0201
214686572|NCT06644755|DRUG|DS-2243a|"Escalation Part: DS-2243a will be administered at escalating doses to determine the RDE~Expansion Part: DS-2243a will be administered at RDE"
214686573|NCT05215769|BEHAVIORAL|Health Education|Participate in a video intervention
214686574|NCT05215769|OTHER|Questionnaire Administration|Complete questionnaires
214686575|NCT05082597|DEVICE|Low energy ESWT|Therapeutic sessions: 4(once a week, for 4 weeks) Total dosage: 2500 shoots over axillary cord lesion (1000 over most fibrotic area, 500 over upper arm, 500 over forearm, 500 over other area) Energy: 0.056-0.065mJ/mm2
214686576|NCT05521568|DIAGNOSTIC_TEST|Index test: Abbott ID NOW STREP A 2|The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.
214686577|NCT05521568|DIAGNOSTIC_TEST|Reference standard test: Composite of culture and PCR-based tests based on a throat swab|"Throat samples will be obtained by use of a double-swab collection-transportation system :~* Swab #1 will be used to perform the rapid antigen detection test (see below)~* Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test."
214686578|NCT05521568|DIAGNOSTIC_TEST|Comparator test: Rapid antigen detection test (usual care)|As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
214686579|NCT06506253|OTHER|Swedish Massage Therapy|Touch therapy
214686580|NCT06506253|OTHER|Light Touch Therapy|Touch therapy
214496664|NCT05945849|BIOLOGICAL|CD33KO-HSPC; CART33|"CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells."
214496665|NCT06457971|DEVICE|Robotic Ventral Hernia Repair|The AnovoTM Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS with graspers and electrosurgery devices for endoscopic manipulation of tissue including grasping, blunt dissection, approximation, and electrosurgery, during single site, laparoscopic surgical procedures. The AnovoTM System's articulated robotic arms allow the surgeon to access and reach different structures in the pelvic and abdominal cavity. Closing the fascial defect robotically is easier from a technical standpoint than attempting it with classical laparoscopic instruments
214496666|NCT01342367|DRUG|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
214496667|NCT01342367|DRUG|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
214496668|NCT01342367|DRUG|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
214496669|NCT01342367|RADIATION|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
214496670|NCT03822988|OTHER|no intervention, only complete a survey|we will ask patients to answer to a survey
214496671|NCT03484988|DIETARY_SUPPLEMENT|Placebo oil|The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
214496672|NCT03484988|DIETARY_SUPPLEMENT|Echium oil|The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
214686581|NCT06481904|DRUG|TZIELD (teplizumab-mzwv)|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
214686582|NCT03471260|DRUG|Azacitidine|Given IV or SC
214686583|NCT03471260|DRUG|Ivosidenib|Given PO
214686584|NCT03471260|DRUG|Venetoclax|Given PO
214686585|NCT04491877|BIOLOGICAL|RSV vaccine formulation 1|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
214686586|NCT04491877|BIOLOGICAL|RSV vaccine formulation 2|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
214686587|NCT04491877|BIOLOGICAL|Placebo|Pharmaceutical form: Suspension Route of administration: Intranasal
214686588|NCT05306873|DRUG|Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
214686589|NCT05306873|DRUG|Placebo for Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
215090215|NCT05579769|DRUG|Mesna|Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
214375740|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (intervention group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
214375741|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (control group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
214375742|NCT03998683|DRUG|Guselkumab 100 mg|Guselkumab 100 mg will be administered as SC injection.
214375743|NCT03998683|DRUG|Placebo|Placebo will be administered as SC injection.
214375744|NCT03338621|DRUG|Pretomanid|200 mg tablets
214375745|NCT03338621|DRUG|Bedaquiline|100 mg tablets
214375746|NCT03338621|DRUG|Moxifloxacin|400 mg tablets
214375747|NCT03338621|DRUG|Pyrazinamide|500 mg tablets
214686590|NCT05306873|DRUG|Voclosporin|Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
214686591|NCT05306873|DRUG|Placebo for Voclosporin|Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
214375748|NCT03338621|DRUG|HRZE|isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
214686592|NCT05306873|DRUG|Mycophenolate Mofetil|"Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~* Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~* Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~* Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily"
214686593|NCT04590144|DEVICE|INVICTA lead|The implant or the attempt to implant an INVICTA lead
214686594|NCT05170438|DRUG|Lenvatinib Pill,Paclitaxel|Regimen Every 28 days as one cycle.Lenvatinib 16 or 12 mg/day orally (depends on the result of safety run-in phase), on day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15.
214686595|NCT06771739|OTHER|Electronic Health Record Review|Ancillary studies
215090216|NCT05579769|DRUG|Anti-thymocyte globulin (ATG)|Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
215090217|NCT05579769|DRUG|Cyclosporine|Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
214375749|NCT03338621|DRUG|HR|isoniazid 75 mg plus rifampicin 150 mg combination tablets
214375750|NCT00302432|BEHAVIORAL|Behavior therapy, cigarette holders, Flowers Menthol|
214375751|NCT00002537|DRUG|topotecan hydrochloride|
214375752|NCT00002537|RADIATION|radiation therapy|
214375753|NCT05030259|PROCEDURE|fasciotomy|To perform fasciotomy
214375754|NCT00989586|BIOLOGICAL|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
214375755|NCT00989586|BIOLOGICAL|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
214686596|NCT06771739|OTHER|Interview|Ancillary studies
214686597|NCT06771739|OTHER|Support|Receive $1000 preloaded cash card
214686598|NCT06771739|OTHER|Support|Receive $100 preloaded cash card
214686599|NCT06771739|OTHER|Survey Administration|Ancillary studies
214686600|NCT01988480|PROCEDURE|Image-guided surgery|Placement on residual bone around the implant
214686601|NCT01988480|PROCEDURE|Sinus lift surgery|Allograft bone
214686602|NCT05470491|DRUG|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Prednisone tapering doses given orally daily: -days -14 through -12: 1mg/kg/day -days -11 and -10: 0.75 mg/kg/day -days -9 and -9: 050 mg/kg/day -day -7: 0.25 mg/kg/day Pentostatin 4 mg/m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4. Busulfan IV AUC targeted dose of 14.8-23.0 mg\*h/L, on days -3 and -2.
214686603|NCT05470491|DRUG|GVHD prophylaxis|Cyclophosphamide 50 mg/kg IV daily Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion Mesna 50 mg/kg IV concomitant with cyclophosphamide
214686604|NCT05470491|PROCEDURE|allo HCT|bone marrow transplant
214686605|NCT05470491|DRUG|Plerixafor|In phase 1 dose level 3 and phase 2 only: Plerixafor 240 (Micro)g/kg subcutaneously every other day, starting day +1 through day +21
214686606|NCT05470491|DRUG|Maraviroc|Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
214686607|NCT01608074|PROCEDURE|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
214375756|NCT00989586|PROCEDURE|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
214686608|NCT01608074|OTHER|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
214686609|NCT01286272|DRUG|Bendamustine Hydrochloride|Given IV
214686610|NCT01286272|DRUG|Bortezomib|Given IV or SC
214686611|NCT01286272|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET
214686612|NCT01286272|OTHER|Laboratory Biomarker Analysis|Correlative studies
214686613|NCT01286272|BIOLOGICAL|Ofatumumab|Given IV
214375757|NCT00989586|PROCEDURE|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
214686614|NCT01286272|PROCEDURE|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
214686615|NCT06126380|DRUG|AT-1501|AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent
214686616|NCT06126380|DRUG|Tacrolimus|Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
214686617|NCT06259708|DEVICE|Low intensity focused ultrasound|Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).
214686618|NCT06789107|DRUG|Blinatumomab 9ug|Blinatumomab for Refractory/Active Systemic Lupus Erythematosus. Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
214686619|NCT01379495|BEHAVIORAL|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
214686620|NCT02420158|DEVICE|Trans-cutaneous vagal nerve electrical stimulation|
214686621|NCT04370093|DRUG|Pioglitazone 45 mg|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
214686622|NCT04370093|BEHAVIORAL|Weight Loss|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
214686623|NCT04370093|OTHER|Pioglitazone + Weight Loss|Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
214686624|NCT06246916|DRUG|fianlimab|Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab
214686625|NCT06246916|DRUG|cemiplimab|IV administration Q3W in combination with fianlimab
214686626|NCT06246916|DRUG|relatlimab+nivolumab|IV administration every 4 weeks (Q4W)
214686627|NCT06303986|OTHER|NeoMonki|Collection of Data for assessing the reliability of Neomonki and Realtime monitoring
214686628|NCT03022032|DEVICE|Fitbit Zip|Fitbit Zip
214686629|NCT03022032|OTHER|HOPE App|HOPE App
214686630|NCT03022032|OTHER|Standard of Care|Standard of Care
214686631|NCT03022032|DEVICE|Fitbit Charge 2|Fitbit Charge 2
214686632|NCT03022032|OTHER|SMART Study Intervention|SMART study app + Beiwe study app + Fitbit
214686633|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet (PROMED) Intervention|Researchers will provide individually tailored dietary advice and written materials to encourage 'a little and often' meal plan to support adoption of the PROMED intervention. The daily energy and protein requirements of each participant will be calculated based on National Institute of Health \& Care Excellence guidance for Nutrition Support in Adults at Risk of Malnutrition. Several resources have been developed to facilitate behaviour change: a) A PROMED Diet Information Booklet to include an overview of the PROMED Diet, tips for incorporating more PROMED foods into the diet and information on the health benefits of a PROMED diet, b) A PROMED Recipe Book offering ideas for breakfast, lunch and dinner as well as suitable snack ideas and c) key PROMED foods ordered through a local supermarket's online delivery service and delivered to participants' homes on a weekly or fortnightly basis for the 3-month active intervention phase.
214987994|NCT04186273|DRUG|Fibrosis-Inhibiting-Compound-FS2|There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
214987995|NCT04186273|OTHER|Vehicle moisture balancing base|Vehicle base without FS2.
214987996|NCT01927588|DRUG|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
214987997|NCT01927588|DRUG|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
214375758|NCT00989586|PROCEDURE|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
214375759|NCT00989586|PROCEDURE|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
214686634|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention|Participants will receive a dietary intervention identical to PROMED participants, plus an exercise intervention. The home-based exercises are based on a modified version of the 'ExWell@home' programme developed by health professionals with significant expertise in community-based exercise rehabilitation for chronic disease. Cardiorespiratory fitness will be determined using a 3-minute step test and pulse rate. Participants will receive access to pre-recorded exercise classes and a written resource designed for older adults (ExWell@home) and adapted for the current study. Participants will be encouraged to complete two sessions per week (30-60 minutes per session). To cater for differing abilities, four levels of classes will be available for participants: Chair based, basic, standard and advanced.
214686635|NCT06018350|BEHAVIORAL|Clinician-led adherence intervention|The clinician will review real time pharmacy refill data during clinic and use effective communication techniques to discuss adherence with the patient
214686636|NCT03894553|DEVICE|ExAblate Neuro|Unilateral stereotactic focused ultrasound lesioning of the contralateral mesencephalon
214686637|NCT01372696|OTHER|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
214686638|NCT06135753|OTHER|psychosomatic intervention based on cognitive restructuring.|Participants will receive information on psychosomatic phenomena and over-listening of somatic manifestations (Session 1), interpretation and possible catastrophization of somatic manifestations even when they might be well-known health problems or potential physiological or para-physiological manifestations (Session 2), pain-proneness (Session 3) and mental pain and psychological distress in somatizers (Session 4). The second part of each session will be devoted to group cognitive restructuring, thus participants will be stimulated in verifying how the phenomena illustrated are in their lives and how they can be differently conceptualized in order to be less intrusive and less able to reduce their own functioning.
214686639|NCT06135753|BEHAVIORAL|Control condition|The control condition will include 4 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health.
214375760|NCT00989586|PROCEDURE|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
214496673|NCT03484988|DIETARY_SUPPLEMENT|Mixed oil|The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
214686640|NCT06135753|OTHER|Experimental and control condition: Museum therapy|"Session 5-6-7: preselected painting works from the Uffizi Galleries (Florence) will be presented to the participants in order to trigger reflections and emotional responses on specific pain related topics. Session 8: visit the Galleria di Arte Moderna at Palazzo Pitti, in person. Each session will be aimed at facilitating emotional expressions and partecipants' behavioral activation and identifying thoughts associated with those emotions and, if appropriate, remodulating them in a functional way (cognitive restructuring).~Session 9: share the experience of the previous meetings and to recap strategies and skills which could be implemented in FM participants' daily life to cope with their illness."
214686641|NCT03625986|OTHER|Nicotine-Containing Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The experimental group in this project will receive a SREC device with liquid containing 58 mg/mL of nicotine."
214686642|NCT03625986|OTHER|Non-Nicotine Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The placebo group in this project will receive a SREC device with liquid containing 0 mg/mL of nicotine."
214686643|NCT05102864|DEVICE|Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex|iTBS will be administered to the left DLPFC for 10 consecutive days
214686644|NCT06787781|DRUG|Alpha Lipoic Acid|ALA was administrated in capsules at a xed oral daily dose of 600 mg for the entire duration of the study in addition to the atypical antipsychotic therapy.
215090218|NCT05579769|DRUG|Cyclophosphamide|Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
215090219|NCT05579769|DRUG|Fludarabine|Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
214496674|NCT06261710|OTHER|Sonography in labour|Using intrapartum sonography parameters in labour
214496675|NCT03971851|OTHER|Frailty risk groups|Patients older than 65 will be separated into groups of varying frailty risk
214496676|NCT05374889|OTHER|Open Kinetic Chain Proprioception Exercises|basketball-specific target shooting in open kinetic chain
214496677|NCT02352675|OTHER|Intraoperative Blood Sample|Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
214496678|NCT04449835|PROCEDURE|Intracept Procedure|radio frequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
214686645|NCT01803451|DRUG|exendin-(9-39)|hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
214686646|NCT01803451|DRUG|exendin -(9-39)|2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
214686647|NCT02198729|PROCEDURE|Endoscopic Submucosal Dissection|
214686648|NCT02198729|PROCEDURE|Endoscopic Mucosal Resection|
214686649|NCT06426121|DIAGNOSTIC_TEST|test Aerobic/F Culture Vials|an additional blood sample will be collected compared to clinical routine of blood culture, inoculated into the test culture vial, and compared with the blood culture results of the control vial collected from the same site and the same puncture point
214686650|NCT06426121|DIAGNOSTIC_TEST|control Aerobic/F Culture Vials|according to the clinical routine of blood culture, this blood sample should be collected and inoculated into the control vial, and its culture result will be collected
214686651|NCT05406700|DRUG|Niraparib|Oral, daily, dosage per protocol,4 Weeks
214686652|NCT05406700|DRUG|Resection/Treatment with Niraparib|"The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery.~Treatment can be held for an additional 28 days to allow for recovery from surgery, at the investigator's discretion. Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent."
214686653|NCT05495906|BIOLOGICAL|Nonavalent HPV vaccine|Routine dosing form and dosage
214686654|NCT04920084|OTHER|Plant based meals|For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
214686655|NCT03958617|DEVICE|Bilateral Deep brain stimulation of the thalamus, Medtronic Device|
214686656|NCT01847833|OTHER|MRI scan|
214686657|NCT00620321|DRUG|LY2181308 sodium|750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
214686658|NCT00620321|DRUG|cytarabine|1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
214686659|NCT00620321|DRUG|idarubicin|12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
215090220|NCT05579769|DRUG|Methotrexate|Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
215090221|NCT05579769|RADIATION|Total Body Irradiation (radiation treatment)|"Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons.~Dose rate should be \< 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor.~Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose.~An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia."
214686660|NCT06280261|OTHER|parenting stress index, Zarit burden scale, Rosenberg self esteem scale, stait trait anxiety inventory, struggles and difficulties questionnaire|Scales and questionnaires
215090222|NCT05579769|DRUG|Bone marrow infusion|Day 0
214375761|NCT00989586|BIOLOGICAL|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
214375762|NCT02920203|GENETIC|Heart and spleen tissue|genetic sequencing
214686661|NCT05892133|BEHAVIORAL|Maximal strength training|3 sessions/ week. leg press at \~85% of one repetition maximum for 8 weeks
214375763|NCT03582891|DEVICE|Summit RC+S for Motor|Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
214375764|NCT03582891|DIAGNOSTIC_TEST|8-week pilot trial of Closed-loop vs. Open-loop Stimulation|These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
214686662|NCT00547599|DRUG|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
214686663|NCT02299765|DRUG|Gefitinib|patients in arm A will be given gefitinib as target therapy
214686664|NCT02299765|DRUG|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
214686665|NCT02299765|DRUG|carboplatin|patients in arm A will be given carboplatin chemotherapy
214686666|NCT03148431|DRUG|LY3002815|Administered IV
214686667|NCT03148431|DRUG|Placebo|Administered IV
214686668|NCT02156960|DRUG|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
214686669|NCT02156960|DRUG|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
214686670|NCT02156960|DRUG|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
214686671|NCT04191967|DEVICE|Thermocoagulation|Treatment of positive screening results will be performed using the Liger Thermocoagulator device
214686672|NCT01431144|PROCEDURE|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
214686673|NCT01431144|PROCEDURE|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
214686674|NCT01734187|DIETARY_SUPPLEMENT|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
214686675|NCT01734187|DIETARY_SUPPLEMENT|Placebo|Placebo (30g/day)
214686676|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
214686677|NCT01109004|DRUG|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
214686678|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
214686679|NCT03444818|DRUG|[14C]-E6007|Oral administration
214686680|NCT04169594|DIAGNOSTIC_TEST|3D Gait Analysis with Statistical Parametric Mapping|A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.
214686681|NCT06845514|OTHER|Condition LL-RE|"LL-RE condition will consist of a 5-minute warm-up (slow-paced walking) and the following exercises: leg press, chest press, leg curl, and seated row. Three sets will be performed for each exercise with a 3-minute rest period between sets/exercises. Each exercise will be executed through a full range of motion, with participants encouraged to follow a 2-sec eccentric phase (guided by a mobile app metronome and supervised by an exercise physiologist) and to perform the concentric phase as fast as possible. Participants will be informed to: stop the set when they perceive to have reached the RIR target.~• LL-RE: The low load intensity protocol consists of 3 sets of each exercise at 50% 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2)."
214686682|NCT06845514|OTHER|Control|Control condition: During the control condition, participants will sit quietly in a room maintained at a temperature of 22-24°C to prevent any influence on blood pressure values, for 60 minutes. During this period, they will perform a standardized non-fatiguing cognitive task: watching Earth, a documentary following the migration paths of four animal families.
214686683|NCT06845514|OTHER|Condition HL-RE|"HL-RE condition will consist of a 5-minute warm-up (slow-paced walking) and the following exercises: leg press, chest press, leg curl, and seated row. Three sets will be performed for each exercise with a 3-minute rest period between sets/exercises. Each exercise will be executed through a full range of motion, with participants encouraged to follow a 2-sec eccentric phase (guided by a mobile app metronome and supervised by an exercise physiologist) and to perform the concentric phase as fast as possible. Participants will be informed to: stop the set when they perceive to have reached the RIR target.~• HL-RE: The high load intensity protocol consists of 3 sets of each exercise at 80% of 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2)."
214686684|NCT03805932|DRUG|Moxetumomab Pasudotox-tdfk|Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.
214686685|NCT03805932|BIOLOGICAL|Rituximab|Rituximab will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.
214686686|NCT03805932|BIOLOGICAL|Ruxience|Ruxience will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Ruxience is given on day -2, on subsequent cycles, Ruxience is given on day 1 (Delta)
214987998|NCT00754923|DRUG|sorafenib|administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
215090223|NCT05579769|DRUG|Busulfan|Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
214375765|NCT03582891|DEVICE|Summit RC+S for Sleep|Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
214375766|NCT00145301|DRUG|Lumiracoxib|
214375767|NCT02037438|OTHER|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
214375768|NCT02037438|OTHER|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
214375769|NCT02255032|DRUG|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
214375770|NCT02255032|DRUG|0.8 mg CLS-TA|8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
214375771|NCT05168813|BIOLOGICAL|Moderna mRNA-1273|COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).
215090224|NCT05579769|DRUG|Thiotepa|Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
214375772|NCT05168813|BIOLOGICAL|Vaccine 3 Dose|COVID-19 mRNA vaccine in 100 mcg dose given as IM injection into the deltoid muscle on Day 1, Day 29, and Day 169.
214496679|NCT01446497|DRUG|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
215090225|NCT02450968|DRUG|Dexamethasone|
215090226|NCT02450968|DRUG|Placebo|
215090227|NCT01908088|BIOLOGICAL|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
214375773|NCT05168813|BIOLOGICAL|Vaccine 2 Dose|COVID-19 mRNA vaccine is to be administered as IM injection into the deltoid muscle on Day 1 and Day 169.
214496680|NCT01446497|DRUG|Timolol|Twice per day, 1 drop at each time
214496681|NCT01693211|DEVICE|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
214496682|NCT01693211|DEVICE|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
214496683|NCT06435650|COMBINATION_PRODUCT|Cannabis suppositories and mindful-compassion for anal pain|This is a combined intervention that includes mindful-compassion and cannabis suppositories for anal pain
214496684|NCT06435650|BEHAVIORAL|Mindful-compassion|Mindful-compassion
214496685|NCT05484648|DRUG|Dexamethasone|"Dexamethasone has been used to generally favorable results in peripheral nerve blocks as adjunct. Several studies have reported prolongation in the duration of ropivacaine, mepivacaine and bupivacaine when used in combination with dexamethasone.~Various mechanisms for the beneficial adjunctive effect of dexamethasone with Local Anesthetics (LA) have been proposed. One theory suggests that the improved analgesia and increased blockade duration is due to its anti-inflammatory properties. It also acts as a local vasoconstrictor and thus may act by reducing LA absorption. Furthermore, it also increases the activity of inhibitory potassium channels on nociceptive C-Fibers."
214496686|NCT05484648|DRUG|Dexmedetomidine|Dexmedetomidine is another promising drug being used as a local anaesthetic adjuvant in peripheral nerve blocks. It is an alpha-2 agonist, which has shown to have prolonged duration of postoperative analgesia when given with LA for peripheral nerve blocks with other beneficial effects such as reducing the opioid consumption. Alpha-2-agonists such as dexmedetomidine cause hyperpolarization-activated cation currents which inhibit the transmission of nociceptive fibers.
214496687|NCT04248998|DIETARY_SUPPLEMENT|Fasting-mimicking diet|Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks
214496688|NCT04248998|DRUG|Metformin|Metformin 850 mg twice a day
214496689|NCT04248998|DRUG|Preoperative chemotherapy|"Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq"
214496690|NCT01236846|DIETARY_SUPPLEMENT|Fortified Yogurt Drink|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
214496691|NCT01236846|DIETARY_SUPPLEMENT|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
214496692|NCT00002156|DRUG|Fomivirsen sodium|
214496693|NCT00002156|DRUG|Ganciclovir|
214496694|NCT04621435|DRUG|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
214496695|NCT04621435|PROCEDURE|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes
214496696|NCT04621435|DRUG|Copper-64 labeled (64Cu-) FAP-2286|The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
214496697|NCT06379516|OTHER|Moisturising Cream (5%)|This intervention is a moisturiging cream of concentration 5% for topical application to the respective test sites.
214496698|NCT06379516|OTHER|Moisturising Cream (10%)|This intervention is a moisturiging cream of concentration 10% for topical application to the respective test sites.
214496699|NCT06379516|OTHER|Coconut Oil|This intervention is a 100% pure coconut oil product (Parachute Pure Coconut Oil) for topical application to the respective test sites.
214496700|NCT02097069|DIETARY_SUPPLEMENT|Folic acid|Folic acid 400 mcg/day
214496701|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol|myo-inositol 2000 mg twice a day
214496702|NCT02097069|DIETARY_SUPPLEMENT|D-Chiro-inositol|D-chiro inositol 250 mg twice a day
214496703|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol plus D-chiro inositol|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
214496704|NCT02796729|PROCEDURE|Magnetic resonance imaging|MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.
214496705|NCT02796729|DRUG|Gadovist (Gadobutrol)|Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
214496706|NCT02796729|DRUG|50% dextrose solution|50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
214496707|NCT02325349|DRUG|radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
214496708|NCT03035851|BEHAVIORAL|Aerobic exercise|
214496709|NCT03035851|BEHAVIORAL|Stretch and Strength|
214496710|NCT05766319|DEVICE|Withings ScanWatch|"Withings ScanWatch, from which the following features will be used:~* Measurement of peripheral oxygen saturation (%)~* Automatic recording of heart rate (beats/min)~* Automatic recording of activity (step count) (numbers/day)"
214496711|NCT05766319|DEVICE|Withings BPM Connect|"Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)"
214496712|NCT05766319|DEVICE|Withings Body|"Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)"
214686687|NCT03805932|DRUG|Dexamethasone|12 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Administer 0.5-2 hours before rituximab/Ruxience. If participant has previous reaction to rituximab/Ruxience, give 12mg. If participants tolerate rituximab/Ruxience without problems, may hold at discretion of provider. Pre-medications are given prior to rituximab/Ruxience on day 1.
214686688|NCT03805932|DRUG|Acetaminophen|650 mg Cycle 1, Day -2, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
214686689|NCT03805932|DRUG|Diphenhydramine|25-50 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Pre-medications are given prior to rituximab/Ruxience on day 1. May be given prior to moxetumomab pasudotox-tdfk at discretion of principal investigator.
214686690|NCT03805932|DRUG|Famotidine|20-40 mg Cycle 1, Day -2; Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
214686691|NCT03805932|DRUG|Aspirin|81 mg Cycle 1, Days 1-8; Cycles 2-8, Days 1-8. Only if platelet counts ≥ 100 x 109/L.
214686692|NCT05141435|PROCEDURE|infants receive primary non-invasive respiratory support by mean of nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-10 cmH2O) , with FiO2 (0.21-0.40)adjusted to target SpO2 from 89% to 94%. CPAP will be provided by either variable flow or continuous flow devices, as there is no clear evidence that one type of CPAP generator would be better than any other by pure CPAP system.
214686693|NCT05141435|PROCEDURE|infants receive primary non-invasive respiratory support by mean of NHFOV|neonates assigned to NHFOV will be started with the following boundaries: a) Paw of 6 cmH2O (the range 6-10 cmH2O); b) frequency of 10 Hz (the range 8-12 Hz). c) Inspiratory time 50% (1:1). d) amplitude 15 cmH2O(the range 15-25 cmH2O) NHFOV will only be provided with piston/ membrane oscillators able to provide an active expiratory phase (that is, Acutronic FABIAN-III, SLE 5000, Loweinstein Med LEONI+, Sensormedics 3100A).
214686694|NCT05742087|OTHER|Clinical examination|The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
214686695|NCT05742087|OTHER|electroneuromyography (ENMG)|Data from the ENMGs will be extracted from the cohort and analyzed.
214686696|NCT02410902|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
214686697|NCT02410902|DRUG|PLACEBO|Single unit dose powder of non-active substance administered 3 times per day for 90 days
214686698|NCT00219843|DRUG|PV-10 (rose bengal disodium, 10%)|
214686699|NCT00953043|DRUG|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
214686700|NCT00953043|DRUG|Placebo|Placebo medication given for three days
215090228|NCT06344260|PROCEDURE|human Neural Stem Cells (hNSC)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
214375774|NCT04805749|OTHER|Manual Therapy: osteopathy|"Osteopathic protocol applied at week 0, 1, 2 and 3:~1. Spinal mobilisation of L1, L2 and L3 vertebrae to stimulate the arterial supply of mesenteric attachments of the colon and small intestine.~2. Visceral osteopathic therapy to address adhesions/ fixations in the presacral fascia, Toldt fascia, posterior peritoneum and caudal peritoneum.~3. Circulatory techniques to stimulate the celiac plexus, the superior and inferior ganglia.~4. Cranial osteopathy techniques to address the vagus parasympathetic nerves."
214375775|NCT03332641|DIETARY_SUPPLEMENT|Citron peel extract|Citron peel extract for 12 weeks
214686701|NCT00953043|OTHER|Bowel preparation|Polyethylene glycol-based bowel preparation
214375776|NCT03332641|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
214375777|NCT05746481|DRUG|Tiragolumab|Tiragolumab (an investigational novel immune checkpoint inhibitor): 600 mg IV for induction treatment administered on Day 1 of each 21-day cycle for 4 cycles. Maintenance therapy will continue with tiragolumab on Day 1 of each 21-day cycle.
214375778|NCT05746481|DRUG|Atezolizumab|Atezolizumab (monoclonal antibody): 1200 mg IV administered on Day 1 of each 21-day cycle.
214686702|NCT03059810|DEVICE|etafilcon A|Investigational Contact Lens
214686703|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 30 mg, once daily, 28 days
214686704|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 100 mg, once daily, 28 days
214686705|NCT00909766|DRUG|BMS-830216|Capsules, oral, 300 mg, once daily, 28 days
214686706|NCT00909766|DRUG|BMS-830216|Capsules, oral, 600 mg, once daily 28 days
214686707|NCT00909766|DRUG|BMS-830216|Capsules, oral, 1200 mg, once daily, 28 days
214686708|NCT00909766|DRUG|BMS-830216|Capsules, Oral, to be determined, once daily, 28 days
214686709|NCT00909766|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
214686710|NCT03412474|DRUG|Bupivacaine|"The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%)."
214375779|NCT05746481|DRUG|Pemetrexed|Pemetrexed (antifolate antineoplastic agent chemotherapy): 500 mg/m2 administered IV on Day 1 of each 21-day cycle.
214375780|NCT05746481|DRUG|Carboplatin|Carboplatin AUC 5 (alkylating agent chemotherapy): injection administered on Day 1 of each 21-day cycle.
214686711|NCT03412474|DRUG|Dexmedetomidine|Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
214375781|NCT04943211|DRUG|fluorodeoxyglucose (18F-FDG)|max 6 MGBq/kg, no more than 100
214686712|NCT03412474|DRUG|paracetamol|paracetamol
214686713|NCT03134950|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions will be in person with a trained psychologist and the following 2-4 sessions will be web-based. Each web-based session will be followed by phone support.
214375782|NCT04941664|DRUG|0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELVA90) of cases of the aforementioned local anesthetic (LA), in order to produce the surgical anesthesia of the patients scheduled for shoulder surgeries. Based on the principal investigator's clinical experience, the initial volume of 8ml will be used. Depending on the success or failure of the superior trunk block, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 2ml. The upper dose limit of the study to minimize the potential for local anesthetic systemic toxicity will be 16ml and the lower dose limit will be 4ml, which will be of no clinical importance."
214686714|NCT05890417|OTHER|questionnaire|Female Sexual Function Index (FSFI) and WHO Quality of Life-BREF (WHOQOL-BREF) questionnaires at baseline and 6 months after starting hormone replacement therapy
214686715|NCT06049771|OTHER|Collect blood sample|Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose
214987999|NCT02448082|OTHER|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
214375783|NCT05375955|DRUG|PF-07038124 ointment 0.01%|Atopic Dermatitis and Plaque Psoriasis
214375784|NCT05375955|DRUG|Vehicle ointment|Atopic Dermatitis and Plaque Psoriasis
214375785|NCT05375955|DRUG|PF-07038124 ointment 0.03%|Atopic Dermatitis and Plaque Psoriasis
214375786|NCT05375955|DRUG|PF-07038124 ointment 0.06%|PF-07038124 ointment 0.06% (Plaque Psoriasis only)
214375787|NCT05911451|PROCEDURE|Arteriovenous fistula creation|It is recommended to create the arteriovenous fistula 3 to 6 months before the expected start of hemodialysis treatment using locoregional anesthesia. It is recommended to use minimal venous and arterial diameters of 2mm for radiocephalic fistulas and 3mm for brachiocephalic and brachiobasilic fistulas. It is recommended to avoid creating an arteriovenous fistula at the same side as a pacemaker, central venous catheter, or arterial stenosis. It is recommended to use the following order of preference for arteriovenous fistula creation: radiocephalic fistula as first choice, brachiocephalic fistula as second choice, and brachiobasilic fistula as third choice.
214375788|NCT05911451|PROCEDURE|Arteriovenous graft placement|It is recommended to implant the arteriovenous graft 2 weeks before the expected start of hemodialysis treatment under antibiotic prophylaxis. Implantation of an early-cannulation graft is recommended for patients who require more urgent start of hemodialysis to avoid the use of a temporary central venous catheter. It is recommended to use minimal arterial and venous diameters of 3mm and 4mm, respectively. It is recommended to avoid placing an arteriovenous graft at the same side as a pacemaker, central venous catheter, or arterial stenosis.
214375789|NCT05911451|PROCEDURE|Central venous catheter placement|It is recommended to place a tunneled central venous catheter just before the start of hemodialysis treatment under local anesthesia, with conscious sedation if preferred by the patient. The catheter should preferably be placed in the right internal jugular vein with ultrasound-guided puncture and fluoroscopy control under sterile conditions. According to usual practice at the trial center, catheters may be implanted by surgeons, interventional radiologists, or nephrologists.
214375790|NCT05013983|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
214375791|NCT05013983|OTHER|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium
214375792|NCT02933801|DRUG|ODM-201|ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
214375793|NCT02933801|OTHER|Placebo|Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
214375794|NCT01320943|DRUG|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
214375795|NCT01320943|OTHER|Stop TDF|Participants will stop TDF therapy
214988000|NCT02448082|OTHER|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
214988001|NCT00815074|OTHER|No intervention|no intervention
214375796|NCT00948779|OTHER|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
214375797|NCT00948779|OTHER|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
214375798|NCT04468269|OTHER|Task oriented balance training with sensory integration group|"Sitting position:~1. Sit in a chair without backrest while keeping the feet on floor.~2. Sit on a ball while keeping the feet on the floor.~Sit to stand:~1. Sit in a chair without a backrest~2. Sit in a chair without a backrest with and perform the sit-to-stand motion repeatedly.~3. Sit on a ball and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing Control Of Weight Shifting. Perform a semi-tandem stance. One Foot Standing.~Walking:~1. Walk forward~2. Walk forward cross an obstacle, and then continue to walk.~3. Walk Lateral~4. Walk Backward~5. Tandem walk"
214375799|NCT04468269|OTHER|Task oriented balance training without sensory integration group|"Sitting position:~1. Sit in a chair without a backrest while keeping the feet on a firm surface.~2. Sit on a ball while keeping the feet on the firm surface~Sit to stand:~1. Sit in a chair without a backrest with the feet on a firm surface and perform the sit-to-stand motion repeatedly.~2. Sit on a ball with the feet on the firm surface and perform the sit-to-stand motion repeatedly.~Standing position:~1. Perform bipedal standing on a firm surface.~2. Perform a semi-tandem stance on the firm surface~Walking:~1. Walk forward on a firm surface.~2. Walk forward on the firm surface, cross an obstacle, and then continue to walk.~3. Walk sideways~4. Walk Backward~5. Tandem walk"
214686716|NCT01734941|DRUG|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
214375800|NCT02727686|OTHER|Water Load (WL) Post-Operative Day 1|Patient will have normonatremic 0600 hr sodium level (Serum Sodium = 135 - 145 mmol/L), ability to safely take water by mouth, and cleared to continue by treating surgeon. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Vasopressin level will be determined. Patient will have 30 minutes to consume WL, or will be excluded. Included patients will have data collected as follows: 1 hour - serum sodium, urine output; 2 hour - serum sodium, urine output, vasopressin level; 6 hours - serum sodium, urine output.
214375801|NCT05319249|BIOLOGICAL|NK cells|NK cells will be given as a single intravenous infusion.
214375802|NCT05319249|DRUG|Talazoparib 1 MG [Talzenna]|Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.
214375803|NCT06191809|PROCEDURE|Controlled Ovarian Stimulation Protocol|"Ovarian Stimulation Process:~* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.~* Monitor response with ultrasound \& hormones (E2, LH, P4).~* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.~* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.~* Trigger ovulation when ≥2 follicles \>17mm (Triptorelin, hCG, or rhCG).~* Oocyte retrieval 36-38 hours later (\>10mm follicles aspirated).~Embryo Culture \& Monitoring:~* Fertilize with ICSI.~* Culture \& evaluate embryos (43-45 hours, day 3/5).~* Freeze all embryos."
214375804|NCT04096612|PROCEDURE|Orbital decompression combined with MPT|Orbital decompression combined with MPT
214375805|NCT00733980|DRUG|GSK561679|GSK561679
214375806|NCT00733980|OTHER|Placebo|Placebo
214375807|NCT01258634|DRUG|Dexrazoxane|"Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1"
214375808|NCT01258634|DRUG|Doxorubicin|"Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0"
214375809|NCT01258634|DRUG|Cisplatin|"Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Poor Responders:~Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol"
214686717|NCT01734941|DRUG|Placebo|
214375810|NCT01258634|DRUG|G-CSF|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000"
214375811|NCT01258634|DRUG|PEG-filgrastim|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy"
214375812|NCT01258634|DRUG|Etoposide|"Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1~Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4"
214375813|NCT01258634|DRUG|Ifosfamide|"Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4"
214686718|NCT03021798|OTHER|No Drug and no aspecific intervention|No intervention
214686719|NCT00002288|DRUG|Zidovudine|
214686720|NCT02159326|DRUG|Microgynon|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
214686721|NCT02159326|DRUG|Riociguat (Adempas,BAY63-2521)|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
214686722|NCT05041959|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours
214686723|NCT05041959|OTHER|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) in the day leading up to the scan and smoke one cigarette of their own brand immediately prior to scanning.
214988002|NCT04687397|BEHAVIORAL|Rehabilitation|Multidisciplinary rehabilitation
214988003|NCT05404841|DIETARY_SUPPLEMENT|CoffeeBerry Supplement|A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,
214988004|NCT05404841|DIETARY_SUPPLEMENT|Placebo|Placebo
214988005|NCT04736433|DRUG|ACE inhibitor|ACE inhibitor dispensing claim is used as the reference
214988006|NCT04736433|DRUG|Sacubitril/Valsartan|Sacubitril/Valsartan dispensing claim is used as the reference
214988007|NCT04292886|DRUG|Tamoxifen and femoston|oral
214988008|NCT04292886|DRUG|Vitamin C and femoston|Vitamin C and femoston
214988009|NCT01855269|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
214988010|NCT01855269|DIETARY_SUPPLEMENT|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
214988011|NCT01855269|DIETARY_SUPPLEMENT|placebo sterile water|
214988012|NCT06134388|DRUG|Sulfasalazine|Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.
214988013|NCT04968236|OTHER|Deep Dry Needling|In-and-out into different directions technique to encounter sensitive spots in an MTrP region.
214988014|NCT04968236|OTHER|Superficial Dry Needling|This technique involves inserting a needle at a depth that is into the subcutaneous tissue and may be combined with manipulation of the needle while in situ.
214375814|NCT01258634|DRUG|Mesna|"Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)"
214375815|NCT01258634|DRUG|Leucovorin|Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is \<0.1 uM
214375816|NCT01382329|BIOLOGICAL|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
214375817|NCT04508608|DIAGNOSTIC_TEST|Stress Gated blood pool SPECT|"After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
214375818|NCT04508608|DIAGNOSTIC_TEST|Dynamic SPECT|"The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.~At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.~The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
214375819|NCT02592538|DEVICE|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
214375820|NCT02592538|DRUG|S-1|In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if \<1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
214375821|NCT02592538|DEVICE|Stent|Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
214375822|NCT02708225|BEHAVIORAL|medical clown|a medical clown will assist the child during the performance of pulmonary function test
214375823|NCT02891057|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-036)
214375824|NCT02144922|DRUG|Pitavastatin|statin
214375825|NCT02144922|OTHER|Control|Life style modification alone
214375826|NCT03515382|DRUG|GLPG1690|A single oral dose of GLPG1690.
214375827|NCT03515382|DRUG|Itraconazole|A single oral dose of itraconazole.
214375828|NCT03515382|DRUG|Voriconazole|A single oral dose of voriconazole.
214375829|NCT05565729|DRUG|LY3471851|Administered SC.
214375830|NCT05565729|DRUG|Placebo|Administered SC.
214375831|NCT05565729|DRUG|Levocetirizine|Administered orally.
214375832|NCT00779779|BIOLOGICAL|Rotarix™|Two oral doses, with at least 4 weeks interval in-between
214375833|NCT00404495|DRUG|Irinotecan|Irinotecan 10 mg/m\^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
214375834|NCT00404495|DRUG|Temozolomide|Temozolomide 100-125 mg/m\^2 daily on days 1-5 in repeated 3 week cycles
214375835|NCT01287884|OTHER|Venous Blood Gas|patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
214375836|NCT04274959|OTHER|ceramic onlay with shoulder preparation design.|ceramic onlay with shoulder preparation design which allowing the largest possible enamel for adhesion ,
214686724|NCT02194101|PROCEDURE|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
214375837|NCT04274959|OTHER|,ceramic onlay with butt joint preparation design|ceramic onlay with butt joint preparation design with cusp reduction to protect teeth from occlusal loads and cuspal fracture
214375838|NCT05239910|DRUG|Tenalisib|Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.
214686725|NCT03706534|DEVICE|Ultrasound Image review with CADe|This software is a computer-aided detection (CADe) software application, designed to assist radiologist to analyze breast ultrasound images. S-Detect automatically segments and classifies shape, orientation, margin, lesion boundary, echo pattern, and posterior feature characteristics of user-selected region of interest. The device uses deep learning methods to perform tissue segmentation and classification of images.
214686726|NCT03706534|DEVICE|Ultrasound Image review with CADx|This software is also a computer-assisted diagnostic(CADx) software application, designed to assist a medical doctor in determining diagnosis by presenting whether a lesion is malignant in a breast ultrasound image obtained from an ultrasound imaging device.
214375839|NCT06336980|BEHAVIORAL|Increasing Inclusionary Practices in Faith Communities|Congregational inclusion committees will participate in monthly training meetings for approximately 1 year. Each month a new inclusion practice will be introduced and then the committee will be asked to implement it in their congregation. The 11 practice areas are:1) assessing inclusion needs of members, 2) providing opportunities for members with serious mental illness (SMI) to take on roles and responsibilities, 3) creating an inclusion committee, 4) ensuring that members with SMI are welcomed to all events, 5) creating sensory friendly spaces, 6) offer participation opportunities in multiple formats, 7) adopt policies and practices to support inclusion, 8) using inclusive language, 9) ensure that external communications indicate the congregation is welcoming to all, 10) providing support to family members of individuals with SMI, and 11) conducing outreach to mental health support systems. Goals may vary per congregation based on their current practices, needs, and preferences.
214375840|NCT00278538|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
214375841|NCT02661802|OTHER|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
214496713|NCT05869617|OTHER|Aquatic exercise|"Participants in the aquatic therapy group will receive aquatic therapy in a HydroWorx aquatic therapy pool at Hydrathletics.~In the aquatic therapy group the 20 minutes of aerobic exercise at each visit will involve walking on an underwater treadmill. The intensity of the walking will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on movement patterns that simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or increasing resistance."
214686727|NCT03706534|DEVICE|Ultrasound Image manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored.
214686728|NCT03706534|PROCEDURE|Biopsy|Suspicious lesions found on breast ultrasound are then followed either by ultrasound guided biopsy or ultrasound imaging every 6 months for two years. For those who undergo biopsy, ultrasound provides images which are used to localize the lesion and guide the placement of the biopsy needle. The sample is sent to pathology for diagnosis, while the ultrasound guidance images are stored. For those who have imaging follow-up, ultrasound images of the breast mass are obtained, digitally stored and interpreted by the radiologist typically using BIRADS scheme.
214686729|NCT04105205|DRUG|Apramycin injection|30-min infusion
214686730|NCT04105205|DRUG|Placebo injection|30-min infusion
215090229|NCT06344260|PROCEDURE|Saline (Placebo)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
214686731|NCT06055881|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214686732|NCT06055881|OTHER|Surveys|"Patients complete the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) survey and Was it Worth It questionnaire."
214686733|NCT06055881|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients receive stereotactic body radiation therapy (SBRT), metastasis-directed radiation therapy .
214686734|NCT06055881|PROCEDURE|Computed Tomography|Undergo CT, MRI and/or PET/CT
214686735|NCT06055881|PROCEDURE|Magnetic Resonance Imaging|Undergo CT, MRI and/or PET/CT
214686736|NCT06055881|PROCEDURE|Positron Emission Tomography|Undergo CT, MRI and/or PET/CT
214686737|NCT02709993|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
214686738|NCT01419704|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
214686739|NCT03542045|DEVICE|Cemented ATTUNE® Knee System|This product is for total knee arthroplasty. Four implant configurations are permitted: Cruciate Retaining Fixed Bearing (CR FB), Cruciate Retaining Rotating Platform (CR RP), Posterior Stabilizing Fixed Bearing (PS FB) and Posterior Stabilizing Rotating Platform (PS RP)
214686740|NCT06043050|DRUG|Platelets|Observational data: all platelet transfusions recorded in routine care medical file data.
214686741|NCT04389749|DEVICE|CPM|CPM-continuous passive motion device.
214686742|NCT04821973|DEVICE|Radius PPG Tetherless Pulse Oximetry (Masimo)|continuous monitoring by a portable, wireless and stand-alone device
214686743|NCT04821973|DEVICE|usual monitoring|usual nurse respiratory monitoring
214686744|NCT00121030|DRUG|darbepoetin alfa|
214686745|NCT00121030|DRUG|recombinant human erythropoietin (rHuEPO)|
214686746|NCT00701727|DRUG|ezetimibe|1 tablet,10mg, once a day, for 7 weeks
214686747|NCT00701727|DRUG|Placebo|1 tablet, once a day, for 7 weeks
214686748|NCT05291598|DRUG|IV meloxicam|Participants will be administered meloxicam 30 mg IV push pre-operatively.
214988015|NCT04968236|OTHER|passive stretching|Type of stretching in which you stay in one position for a set time. In this case, hip extension and knee flexion.
214375842|NCT03772899|DRUG|Fecal Microbial Transplantation|"All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017."
214375843|NCT06318442|DRUG|Semaglutide Oral Product|Oral semaglutide 3mg once uptitrated to twice daily
214375844|NCT06318442|DRUG|Metformin Oral Tablet|Metformin modified release tablets 500mg once daily uptitrated to twice daily).
214375845|NCT06318442|DRUG|Placebo|Placebo tablets
214375846|NCT02571465|OTHER|Passive leg raising test and fluid challenge|
214375847|NCT04187391|DEVICE|Active tDCS|Active tDCS anode is applied over the left DLPFC with the cathode over the right supraorbital region.
214375848|NCT04187391|DEVICE|Placebo tDCS|Placebo tDCS is applied but the current is turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period.
214375849|NCT04187391|BEHAVIORAL|Language training|patients receive language training
214375850|NCT04187391|BEHAVIORAL|Unstructured cognitive training|patients receive unstructured cognitive training.
214496714|NCT05869617|OTHER|Land-based Exercise|"Traditional land-based training will take place the Hydrathletics gym with similar exercises provided to the aquatic therapy group.~The aerobic exercise for the land-based therapy group will be 20 minutes of treadmill walking. The intensity will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on similar movement patterns to the aquatic therapy group to simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or the resistance used for the exercise."
214496715|NCT01638975|BEHAVIORAL|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
214496716|NCT04218383|DEVICE|Transcranial Direct Current Stimulation|Anode placed over the OFC and cathode placed over the right primary motor cortex.
214496717|NCT00402428|DRUG|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
214496718|NCT00402428|DRUG|peginterferon alfa-2a|180 mcg once a week for 48 weeks
214496719|NCT00402428|DRUG|Ribavirin|"1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,\> 75kg)"
214496720|NCT04699058|DIAGNOSTIC_TEST|COVID-antibody test|Questionnaire and COVID-antibody test for all participants
214496721|NCT01560494|OTHER|STAC curriculum|The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
214496722|NCT00515814|DEVICE|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation \& mobility.
214496723|NCT05403476|DRUG|FE 999049|FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
214496724|NCT05403476|DRUG|Placebo|Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
214496725|NCT02964741|DEVICE|Active Comparator|non-invasive brain stimulation (active protocol)
214496726|NCT02964741|DEVICE|Sham Comparator|non-invasive brain stimulation (sham protocol)
214496727|NCT06108024|DRUG|SM-020 gel 1.0%|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
214496728|NCT06108024|DRUG|Vehicle gel|Vehicle gel will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
214496729|NCT02840929|PROCEDURE|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
214496730|NCT02840929|DRUG|Esomeprazole|
214496731|NCT01300975|DRUG|pentavalent antimony|3 intralesional injections of antimony at D1, D3 and D7
214496732|NCT01300975|PROCEDURE|cryotherapy|Frozing of lesions with liquid nitrogen ad D1 and D14
214496733|NCT01300975|DRUG|placebo cream|topical emollient crean 3 times a day during 21 days
214496734|NCT04670887|PROCEDURE|Delayed surgery|Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
214496735|NCT04670887|PROCEDURE|Immediate surgery|Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
214496736|NCT01332175|DEVICE|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
214496737|NCT01332175|DEVICE|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
214496738|NCT01332175|PROCEDURE|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
214686749|NCT05291598|DRUG|Ketorolac|Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.
214686750|NCT02855684|DRUG|Insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214988016|NCT02701634|DRUG|ENTO|Tablets administered orally
214988017|NCT02701634|DRUG|Placebo|Tablets administered orally
214988018|NCT02458495|BEHAVIORAL|Diabetes MAP Intervention|
214988019|NCT03523286|OTHER|RAPID-VT Software guided ablation|Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software
214988020|NCT00006032|DRUG|etoposide|
214988021|NCT00006032|DRUG|ifosfamide|
214988022|NCT00006032|DRUG|topotecan hydrochloride|
214988023|NCT00006032|PROCEDURE|peripheral blood stem cell transplantation|
214988024|NCT06551753|OTHER|virtual reality app|virtual reality app
214686751|NCT02855684|DRUG|Insulin glargine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214686752|NCT02855684|DRUG|Non-insulin antihyperglycemic drugs|"Pharmaceutical form: capsule/tablet~Route of administration: oral"
214686753|NCT02757066|DRUG|NPC-15 Granules Lower Dose|NPC-15 granule which contains 1mg melatonin
214686754|NCT02757066|DRUG|NPC-15 Granules Higher Dose|Melatonin granule which contains 4 mg melatonin
214686755|NCT02757066|DRUG|NPC-15 Placebo Granule|Melatonin placebo granule which does not contains melatonin.
214686756|NCT00726817|DRUG|Butyrate|
214686757|NCT05113953|DRUG|Centanafadine|Sustained-release oral tablets
214686758|NCT05113953|DRUG|Placebo|Oral tablets
214686759|NCT00523341|BIOLOGICAL|Denosumab|Administered by subcutaneous injection once every 6 months.
214686760|NCT04864392|DRUG|LNA043 Dosing Regimen A|Injection to the knee
214686761|NCT04864392|DRUG|LNA043 Dosing Regimen B|Injection to the knee
214686762|NCT04864392|DRUG|LNA043 Dosing Regimen C|Injection to the knee
214988025|NCT02689960|DRUG|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
214988026|NCT02511717|OTHER|Transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
214988027|NCT02511717|OTHER|Sham transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
214988028|NCT02964624|OTHER|Rehabilitation|Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
214686763|NCT04864392|DRUG|LNA043 Dosing Regimen D|Injection to the knee
214496739|NCT04674995|PROCEDURE|Stent placement|All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
214496740|NCT00076648|DRUG|Poly SFH-P Injection|
214496741|NCT00640159|DRUG|Zelapar|Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
214496742|NCT00212251|BEHAVIORAL|moderate exercise and healthy, low-fat diet|
214686764|NCT04864392|DRUG|Placebo|Injection to the knee
214686765|NCT06187103|DEVICE|HyperSight Imaging|Patients receive standard of care radiation treatment on a Varian TrueBeam system equipped with HyperSight CBCT imaging. Images acquired for daily patient positioning from two different treatment fractions - typically one near the beginning of the treatment course and one at about the halfway point - will be analyzed for the study.
214686766|NCT02626819|BEHAVIORAL|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
214686767|NCT02626819|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
214686768|NCT01526018|BEHAVIORAL|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
214686769|NCT00313807|DRUG|Amino Acid|7% amino acid infusion
214686770|NCT00313807|DRUG|Placebo|0.9% Saline Infusion
214686771|NCT02773069|BEHAVIORAL|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
214686772|NCT00649649|DRUG|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
214496743|NCT01500200|DRUG|ALKS 5461|Two active tablets, given daily
214496744|NCT01500200|DRUG|Placebo|Two placebo tablets, given daily
214496745|NCT00455650|DRUG|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
214496746|NCT00455650|DRUG|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
214686773|NCT00649649|DRUG|Accupril® Tablets 40 mg|40mg, single dose fed
214686774|NCT01094002|OTHER|Occupational therapy intervention|"Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities."
214375851|NCT03993236|DRUG|Experimental: Rosuvastatin/Ezetimibe 10|"* Rosuvastatin/Ezetimibe 10/10mg~* orally administered once daily for 90 days"
214375852|NCT03993236|DRUG|Active Comparator: Rosuvastatin 20mg|"* Rosuvastatin 20mg~* orally administered once daily for 90 days"
214375853|NCT05736601|DEVICE|focus motion knee brace|knee brace that captures knee motion
214496747|NCT00455650|DRUG|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
214496748|NCT03053505|BIOLOGICAL|faecal human microbiota transplant (FMT)|"Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT."
214686775|NCT03422406|OTHER|Dietary iodine intake restriction|All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
214686776|NCT03334162|BEHAVIORAL|Sensorimotor training|"Supervised training sessions will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises, chosen from a standardized pool of exercises according to the child's age, with increasing difficulty (5 degrees of difficulty - e.g. by reducing the base of support, or dual task exercises - per exercise depending on the age group) in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue. Children will be given a training manual and diary to train at home after the study. Guardians will be instructed in order to be able to assist their children"
214686777|NCT02491437|DRUG|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
214686778|NCT02491437|DRUG|intravaginal progesterone gel 90 mg|
214686779|NCT02477085|OTHER|all women with an induced labor|all women who have an induced labor
214686780|NCT03013322|DRUG|Physostigmine|
214686781|NCT03013322|DRUG|Isotonic Saline|
214686782|NCT00551720|BEHAVIORAL|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
214686783|NCT00551720|BEHAVIORAL|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
214686784|NCT01839292|DEVICE|uncovered D-type stent insertion|
214375854|NCT00190905|DRUG|duloxetine HCl|
214375855|NCT01493960|DRUG|Cobitolimod|30 mg rectal dose at week 0 and 4
214496749|NCT03053505|DRUG|Vancomycin or Fidaxomicin|"Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13)."
214375856|NCT01493960|DRUG|Placebo|Rectal dose at week 0 and 4
214375857|NCT00765297|DEVICE|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
214496750|NCT03205072|DEVICE|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
214496751|NCT01718600|BEHAVIORAL|Neuropsychological testing|
214496752|NCT00621673|DRUG|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
214686785|NCT01839292|DEVICE|double-layered ComVi stent insertion|
214686786|NCT00502307|DRUG|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
214686787|NCT00502307|DRUG|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
214686788|NCT05297422|PROCEDURE|Forearm surgey|Microsurgery Clinic , KAT Hospital Athens
214988029|NCT02686411|OTHER|Survey Administration|Complete survey
214988030|NCT01337934|DRUG|Lactated Ringer|Lactated Ringer
214988031|NCT01337934|DRUG|Albumin|Albumin 4%
214988032|NCT04519190|DIAGNOSTIC_TEST|Prolonged continuous single-lead ECG monitor|We use Smartpatch, a listed ambulatory electrocardiographic system that can continuously record and save patients' cardiac rhythm for up to 45 days.
214988033|NCT04519190|DIAGNOSTIC_TEST|Intermittent ECG monitor|When using Smartpatch, we can set time markers by pressing the button on the device. We ask our subjects to press that button twice a day and also when they feel any discomfort. Analyzing the ECG 1 minute after those time markers can serve as a surrogate for intermittent ECG monitor.
214988034|NCT04519190|DIAGNOSTIC_TEST|Routine practice|Perform pulse palpation and also ECG if irregular rhythm is found.
214988035|NCT00772837|DRUG|Omeprazole + Clarithromycin + Amoxycillin|Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
214988036|NCT00772837|DRUG|Omeprazole + placebo antibiotics|omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
214988037|NCT05335616|OTHER|Guideline|Hypothetical guideline regarding the indications and treatment steps involved in dental restoration repair.
214988038|NCT05335616|OTHER|Treatment fee item|Arrangement of a hypothetical treatment fee item which can be charged in addition to the actual repair restoration.
214988039|NCT01842204|DEVICE|Magnetic field therapy device|Therapy device for 1 week.
214988040|NCT01842204|DEVICE|Non magnetic field therapy device.|Non-active device for 1 week.
214988041|NCT00025402|BIOLOGICAL|filgrastim|
214686789|NCT05297422|DRUG|Ropivacaine|Ropivacaine
214686790|NCT05297422|DRUG|Ketamine|Ketamine
214988042|NCT00025402|BIOLOGICAL|recombinant interferon alfa|
214988043|NCT00025402|DRUG|busulfan|
214988044|NCT00025402|DRUG|cyclophosphamide|
214375858|NCT00765297|DEVICE|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
214686791|NCT03593967|BEHAVIORAL|ARTISAN|"In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~* Week 1: Food and Play as our National Heritage~* Week 2: Our Voices, Our Singapore: Strengthening Bonds~* Week 3: Overcoming Adversities: Stories of Resilience~* Week 4: Beholding the Future: Dreams and Aspirations~* Week 5: Passing It On: The Stories We Share"
214496753|NCT04037813|PROCEDURE|Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx|"For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut."
214375859|NCT00249249|DRUG|Pitavastatin|
214375860|NCT00249249|DRUG|Atorvastatin|
214375861|NCT05358587|OTHER|Ultrasound guided PENG block with 20 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
214375862|NCT05358587|OTHER|Ultrasound guided PENG block with 30 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
214375863|NCT01899066|DRUG|Lucentis, chemotherapy|"Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2."
214496754|NCT04441775|OTHER|AI-assisted RT modelling|Artificial Intelligence assisted Radiation Treatment
214496755|NCT02412033|DRUG|Misoprostol|400 µg misoprostol vaginally 3 hours before IUD insertion.
214496756|NCT02412033|DRUG|Placebo|This group will receive placebo
214496757|NCT04860505|DRUG|Doxycycline|Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.
214988045|NCT00025402|DRUG|cytarabine|
214375864|NCT01899066|DRUG|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
214496758|NCT04860505|DRUG|Biktarvy|Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.
214496759|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
214496760|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
214496761|NCT02741505|DEVICE|Actigraph|Participants will be asked to wear an actigraph
214496762|NCT00606333|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
214988046|NCT00025402|DRUG|etoposide|
214988047|NCT00025402|DRUG|hydroxyurea|
214988048|NCT00025402|DRUG|idarubicin|
214988049|NCT00025402|PROCEDURE|allogeneic bone marrow transplantation|
214988050|NCT00025402|PROCEDURE|peripheral blood stem cell transplantation|
214988051|NCT00025402|RADIATION|radiation therapy|
214988052|NCT03781271|DEVICE|Electromagnetic Navigation|Electromagnetic navigation is a form of surgical navigation that can be incorporated into the cervical interstitial brachytherapy workflow to improve the current standards of guidance.
214988053|NCT04342169|DRUG|Hydroxychloroquine|HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days
214375865|NCT04318756|BEHAVIORAL|Translation and cultural adaptation go the cancer worry scale|To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.
214375866|NCT00975221|DRUG|Cinacalcet|Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
214375867|NCT00975221|DRUG|Placebo|Administered orally following the same tiitration regimen as the experimental arm.
214686792|NCT02297334|DEVICE|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
214686793|NCT03114306|PROCEDURE|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
214496763|NCT00606333|DEVICE|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
214496764|NCT03781349|DEVICE|MENS|
214686794|NCT03114306|PROCEDURE|regional-anaesthesiological catheter analgesia|Patients receive a single shot nerve block of the proximal Nervus ischiadicus and a catheter placed closed to the Nervus saphenus for perioperative pain control using ultrasound guided techniques.
214686795|NCT04037670|PROCEDURE|SASI bypass|Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
214686796|NCT04200677|OTHER|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following NMES parameters: (Monophasic Current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
214375868|NCT06317519|PROCEDURE|Physical Rehabilitation|5 sessions of physical rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.
214375869|NCT06317519|DEVICE|Gait Real-time Analysis Interactive Lab|5 sessions of GRAIL assisted rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.
214686797|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
214375870|NCT05418777|DRUG|Trimethoprim Sulfamethoxazole|Receipt of suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
214375871|NCT05418777|DRUG|Placebo|Receipt of suspension with placebo by mouth every 12 hours for 10 days
214496765|NCT03781349|DEVICE|TENS|
214496766|NCT04812249|OTHER|Clinical assessment|Clinical assessment and follow up of oral feeding ability
214686798|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
214686799|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
214686800|NCT04200677|OTHER|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Monophasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
214686801|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
214686802|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
214686803|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
214686804|NCT04200677|OTHER|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 25 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
214988054|NCT04342169|DRUG|Placebo oral tablet|Placebo to be taken on the same schedule as HCQ.
214375872|NCT04662502|DIETARY_SUPPLEMENT|Bifidobacterium longum 35624|Bifidobacterium longum 35624, 1 x 10\^9 CFU/capsule, 1 capsule/day over 1 month
214375873|NCT03935217|DRUG|Secnidazole|Oral Granules containing secnidazole
214375874|NCT03935217|DRUG|Placebo|Oral Granules of placebo manufactured to mimic secnidazole
214375875|NCT05192772|DEVICE|NPi200|Digital pupillometry performed during cardiopulmonary resuscutation (CPR) every CPR cycle end in case of not intubated patient, or every 2 minutes in case of intubated patient
214375876|NCT00874653|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
214496767|NCT05419466|DIETARY_SUPPLEMENT|dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm|dietary supplement is dosed at 1.9 mg of melatonin, 10 mg of zinc and 200 mg of lemon balm for one tablet
214496768|NCT01905800|DEVICE|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
214496769|NCT01209195|DRUG|MM-121|increasing doses of MM-121 IV QW
214686805|NCT04616443|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
214686806|NCT04616443|BIOLOGICAL|HX008 injection|Recombinant humanized anti-PD-1 monoclonal antibody of injection
214686807|NCT02141646|BEHAVIORAL|Motivational Interviewing|The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.
214375877|NCT01516203|DRUG|AZD5847|Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
214496770|NCT01209195|DRUG|Paclitaxel|Paclitaxel - 80 mg/m2 IV QW
214496771|NCT06303674|BEHAVIORAL|Physical activity with engaging cognitively|"This experimental condition will follow the following structure: involving 10 consecutive, 30 second-blocks of physical activity. This experimental condition will focus on aerobic metabolism. The total exercise time commitment is 10 minutes (30 seconds of working - 30 seconds of executing an engaging cognitive task, 1:1 work-to-rest ratio), plus 5 minutes of warm-ups and 5 minutes of cool-down activities. The cognitive task consists of solving various tangrams."
214496772|NCT06303674|BEHAVIORAL|Physical activity without engaging cognitively|This experimental condition will replicate the structure of the preceding one. Participants will engage in physical activity, guided by video observation and imitation. However, during the rest periods, they will refrain from engaging in cognitive tasks
214496773|NCT03001206|DEVICE|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
214496774|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 40 mg every other week, subcutaneous
214496775|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 80 mg every other week, subcutaneous
214496776|NCT03471585|DRUG|THC|A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.
214496777|NCT03471585|DRUG|Placebo oral capsule|A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
214375878|NCT01516203|DRUG|Ethambutol, isoniazid, pyrazinamide, rifampin|Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
214375879|NCT00663377|DRUG|losartan|losartan 50-100mg for 16 weeks
214375880|NCT02391935|DRUG|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
214375881|NCT02391935|DRUG|Placebo|Cryomedium
214496778|NCT01212744|DRUG|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
214496779|NCT06274203|DRUG|Vitamin D3|Subjects within SCD as well as healthy controls, received monthly oral vitamin D3 dose, for 6 months, according to the baseline status of vitamin D as follows: sufficient (\>30 ng/mL): 100,000 IU, insufficient (20-29.9 ng/mL): 150,000 IU, and deficient (\<20 ng/mL): 200,000 IU.
214496780|NCT01749319|DRUG|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
214496781|NCT01749319|DRUG|Intervenous baclofen|
214496782|NCT02340013|DRUG|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
214496783|NCT03547102|DIETARY_SUPPLEMENT|Cherry concentrate|
214496784|NCT03547102|DIETARY_SUPPLEMENT|Placebo concentrate|
214496785|NCT02588313|DIETARY_SUPPLEMENT|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
214496786|NCT02167451|DRUG|Maraviroc|
214496787|NCT05237999|BEHAVIORAL|KopOpOuders-PTSD|See arm description
214496788|NCT03510416|DRUG|Apatinib|apatinib is a kind of Inhibitor of VEGFR-2
214496789|NCT03510416|RADIATION|TACE|Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
214686808|NCT02141646|BEHAVIORAL|Behavioral Skills Training|Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
214686809|NCT01914887|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
214686810|NCT01673503|DEVICE|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
214686811|NCT06009224|OTHER|ERAS perioperative management|"* Epidural analgesia~* Fluid balance~* Other items are the same as conventional"
214686812|NCT00051558|DRUG|Teriparatide|20 micrograms/day, injection, 36 months
214375882|NCT02391935|DEVICE|Sham injection|skin penetration of the needle without injection of liquid
214375883|NCT01882595|OTHER|Nebulization through the tracheostomy|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
214375884|NCT01882595|OTHER|Nebulization through the mouth|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
214375885|NCT04188236|DEVICE|Hernia Blocking System|Hernia Blocking System device implanted during a lumbar discectomy procedure
214686813|NCT00051558|DRUG|Alendronate Sodium|10 mg/day, oral, 36 months
214686814|NCT00051558|DRUG|Placebo|Oral placebo, daily, 36 months
214686815|NCT00051558|DRUG|Placebo|Injection placebo, daily, 36 months
214686816|NCT03078036|GENETIC|Germline BRCA Test (blood)|If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice. (Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)
214375886|NCT01127217|DRUG|amlodipine/losartan|amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)
214375887|NCT01127217|DRUG|amlodipine|amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
214375888|NCT03559218|DEVICE|KeraStat(R) Cream|KeraStat Cream is a cream wound dressing that contains 5% keratin.
214988055|NCT02456896|DRUG|Oxcarbazepine|After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
214988056|NCT04096131|PROCEDURE|cataract surgery|phacoemulsification
214988057|NCT06516770|DEVICE|Transcranial direct current stimulation|The subject will receive the tDCS using 5X7 cm electrodes. The anodal electrode will be placed on M1 representing the back muscles (1 cm anterior and 4 cm lateral to the vertex), while cathodal electrode will be placed on contralateral supraorbital area. The intensity will be set at 2 mA with 10-second fade in/out. The subject will be stimulated by tDCS for 20 minutes
214988058|NCT06516770|DEVICE|Neuromuscular electrical stimulation|The participants will receive the NMES using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral LM. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total NMES time is 20 minutes.
214375889|NCT03559218|OTHER|Standard of care|Patients will be instructed to follow institutional standard of care for radiation dermatitis
214375890|NCT02882711|DRUG|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
214375891|NCT01595243|BEHAVIORAL|telephone consultations about psychoeducation program|experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
214375892|NCT04302623|BEHAVIORAL|Yoga|Upa Yoga program consisting of physical postures, breathing techniques, chanting, and meditation.
214375893|NCT02339896|BIOLOGICAL|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
214375894|NCT03400501|DRUG|Insulin Degludec|Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose
214375895|NCT03400501|DRUG|Insulin Glargine|Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose
214375896|NCT02887469|DRUG|3% hypertonic saline|The same as above
214375897|NCT02090335|BEHAVIORAL|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
214375898|NCT02090335|BEHAVIORAL|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
214375899|NCT00344812|DRUG|LAAM. buprenorphine and methadone|
214375900|NCT01012570|DRUG|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
214375901|NCT01333878|BIOLOGICAL|Subcutaneous Abatacept|Subcutaneous Abatacept 125 mg once weekly for 6 months
214496790|NCT01935063|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
214988059|NCT06516770|OTHER|Motor control exercise|The participant will be instructed to perform co-contraction of transverse abdominis and lumbar multifidus muscle, while performing self-selected pace forward bend. Emphasis will be given to move in control manner (smooth and symmetrical movement). The participant will perform 4 minutes of continuous movement for 4 sets with 1 minute rest between sets.
214375902|NCT04435171|PROCEDURE|Renal transplantation|Open or robot assisted renal transplantation
214375903|NCT05971901|DIAGNOSTIC_TEST|BV|The use of the BV test, ordered at the discretion of the treating physician
214375904|NCT05502614|DEVICE|Neuromodulation|Transcutaneous stimulation of the dorsal genital nerve using the Innocon Medical UCon device to provide on demand relief of bladder spasms
214375905|NCT02126683|DRUG|Hydroxychloroquine|
214375906|NCT06029595|DRUG|Experimental: CHF6001 3200 μg|800 μg/actuation - 2 inhalations of CHF6001 800 μg twice daily (BID) total daily dose 3200 μg
214375907|NCT06029595|DRUG|Placebo Comparator: CHF6001 Placebo|2 inhalations of CHF6001 matching placebo BID
214375908|NCT05164874|DEVICE|Mobile Mammography Unit|The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS
214375909|NCT00238381|PROCEDURE|5 cm colon-J-pouch|5 cm colon-J-pouch with/without temporary protective ileostomy
214375910|NCT00238381|PROCEDURE|side-to-end anastomosis|side-to-end anastomosis with/without temporary protective ileostomy
214496791|NCT01935063|OTHER|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
214375911|NCT00238381|PROCEDURE|straight coloanal anastomosis|straight coloanal anastomosis with/without temporary protective ileostomy
214496792|NCT00198419|DRUG|Vitrase|
214496793|NCT01218659|DRUG|migalastat hydrochloride|150-mg capsule administered orally QOD
214496794|NCT01218659|BIOLOGICAL|agalsidase|Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
214496795|NCT02631655|OTHER|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
214375912|NCT03720418|DRUG|OXB-102|Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
214375913|NCT03720418|OTHER|Imitation Surgical Procedure (ISP)|Participants randomized to the control group in Part B will receive an ISP
214375914|NCT04757467|OTHER|Standard physiotherapy neuro-rehabilitation|Treatment interventions which will be used for this group Passive range of movement exercises. Therapeutic positioning of the lower limb. Strengthening exercise for the lower limb. Over-ground gait training 5 times a week for 4 weeks. First week= 30 min exercise Second week= 1hour exercise Third week= 1hour and 30 min exercise Fourth week= 2 hours exercise All the treatment protocols will be applied to the patient for 5 times a week for consecutive 4 weeks. Interventions will be performed in the clinic and through home-based exercises using patient education
214375915|NCT04757467|OTHER|Repetition-CIMT|"In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr.~* Sit-to-Stand~* Forward and Backward stepping~* Stair Climbing and Descending (only the first stair will be used)~* Side-to-Side stepping with the affected limb~Each task will be performed 10 times per session in the first week and 2 sessions a day. In the second week, each task will be performed 20 times per session for 2 sessions a day. In the third week, each task will be performed 30 times per session for 2 sessions a day.In the fourth week, each task will be performed 40 times per session for 2 sessions a day. The session will be held 5 days in a week for the period of consecutive 4 weeks. Total of 1000 repetitions of the above mentions tasks will be performed in 4 weeks' study time by every participant"
214496796|NCT03297138|PROCEDURE|FiLAC laser|The technique consists in applying in a radial way to 360 ° an energy laser in the fistulous route. This energy allows a thermal destruction by coagulation of the wall of the fistula and the fabrics of granulations in a circular and regular way as well as a shrinkage of neighbouring fabrics. The repair is made by a call of macrophages and fibroblasts of neighbouring healthy fabrics so ending in a closure of the fistulous route
214496797|NCT02491489|OTHER|Glenohumeral mobilization|Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (\~50 degrees abduction, slight horizontal adduction, external rotation).
214686817|NCT03078036|GENETIC|FoundationOne Dx Genomic Profile (archival Tumour Specimen)|"Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:~* Tumour Specimen: Acceptable samples include formalin-fixed, paraffin embedded (FFPE) tissue (preferred) or FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.~* Tumour Testing (optional): archival tumour specimens, where available, will be tested for mutations in HRR genes including BRCA1 and BRCA2 and other genomic alterations using the FoundationOne Dx genomic profile."
214686818|NCT03078036|OTHER|Follow-up|"Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months.~\- Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study."
214686819|NCT05797454|PROCEDURE|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the lesion
215090230|NCT01013779|DRUG|Carboplatin|"During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1."
214375916|NCT04757467|OTHER|Hour-CIMT|A task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours. (15) Sessions will be held 5 days in the week for a period of consecutive 4 weeks.
214686820|NCT05797454|PROCEDURE|Wire-guided localization|Positioning guide wire in the center of the lesion
214686821|NCT02375958|DRUG|PCA062|
214686822|NCT05343806|DRUG|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
214686823|NCT05343806|DRUG|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
214686824|NCT01604057|DRUG|ZT-034 Low Dose Nasal Spray|Nasal Spray
214686825|NCT01604057|DRUG|ZT-034 Mid Dose Nasal Spray|Nasal Spray
215090231|NCT01013779|DRUG|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
214375917|NCT04395859|PROCEDURE|Questionnaire|At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
214686826|NCT01604057|DRUG|ZT-034 High Dose Nasal Spray|Nasal Spray
214686827|NCT01604057|DRUG|Teriparatide|20 mcg subcutaneous daily
214686828|NCT01604057|DRUG|Placebo|Nasal Spray
214686829|NCT04936724|OTHER|Pictorial Warning Labels|Participants will be randomized to one of two conditions and will view 4 pictorial warning labels from the assigned group for an eye-tracking task.
215090232|NCT01013779|RADIATION|Radiotherapy|"Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions"
215090233|NCT04243395|OTHER|Pork|1 oz lean pork
215090234|NCT04243395|OTHER|Egg|1 large whole egg
215090235|NCT04243395|OTHER|Black beans|0.5 cups cooked black beans
214686830|NCT05078606|DEVICE|IJV Ultrasonography|"Patient will be in supine position, The linear probe with frequency of 7- 12 M hz; depth of 3 cm. maximum IJV diameter (IJV-D) and area (IJV-A) will be recorded. M-mode will be used to obtain the distance between the 2 walls of the vein during inspiration and expiration.~Then, the patient will be positioned 10° Trendelenburg and similar ultrasonographic measurements will be again performed"
214686831|NCT05078606|DEVICE|Carotid Intima Media Thickness|"US Probe is slided superiorly (toward the head) or inferiorly (toward the feet) until the bifurcation of the common carotid artery (CCA) appears on the left side of the screen. This is the ideal location for imaging and CIMT measurements.~IMT is assessed in longitudinal view from the arterial far wall, along a 10mm length. CIMT will appear as two parallel lines (leading edges of two anatomical boundaries) from it: lumen- intima and media- adventitia interfaces perpendicular to ultrasound beams."
214686832|NCT05078606|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting position at level of L3-4 or L4- 5 interspaces with a 25-gauge spinal needle. Local infiltration of skin and subcutaneous tissue with 2% lignocaine will be applied. After confirming cerebrospinal fluid flow, 10 mg of 0.5% hyperbaric bupivacaine plus 25 mcg fentanyl will be injected. The degree of sensory block (cold test by alcohol gauze) will be assessed in the study with a goal of T8 dermatomal level block.
214686833|NCT00295698|DRUG|Diethylcarbamazine|
214686834|NCT05978362|PROCEDURE|Latarjet technique|Realization of a stop according to Latarjet
214686835|NCT04647227|DRUG|coagulation factor VIIa [recombinant]-jncw|a transgenically produced, activated, recombinant, human factor VII (rhFVIIa) protein with the brand name of SEVENFACT®. This protein is a clotting factor in the coagulation cascade that is produced in and purified from the milk of transgenic rabbits. SEVENFACT is approved for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.
214686836|NCT02397993|PROCEDURE|blood collection|blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
214686837|NCT02397993|PROCEDURE|fine needle aspiration|During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
214686838|NCT02397993|PROCEDURE|blood collection|blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
214686839|NCT01768598|OTHER|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
214686840|NCT01768598|OTHER|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
214686841|NCT01768598|OTHER|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
214988060|NCT06516770|OTHER|Isometric exercise|The participant will be instructed to perform isometric back extension exercise in modified Sorensen position. The participant will hold 60 seconds in neutral position for 5 repetitions with 3 minutes rest between repetitions.
214988061|NCT04409613|OTHER|Education and counseling|All patients or their caregivers will receive twenty minutes educational sessions for the first three visits according to patient ability to understand. At subsequent visits along the study duration, we will briefly review our educational material to refresh the patient's information. This will include: The objectives of treatment, disease progression process, risk factors, common symptoms of bleeding/thrombotic events and how to deal with this. Lifestyle modifications, including smoking cessation, blood pressure and diabetes control. Drug information: drug action, dose, indication, possible side effects, how to deal with the side effects, actions to take when missing the dose, storage conditions and when and how to administer. Possible interactions including drug-drug and drug-food interactions. Target INR and INR monitoring
215090236|NCT04243395|OTHER|Almonds|0.5 oz almonds
214375918|NCT04395859|OTHER|Data collection up to 1 year|Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
214375919|NCT02790073|DRUG|SNF472|SNF472 for calciphylaxis
214375920|NCT05235620|OTHER|PatientToc use in pharmacies|PatientToc has been adapted for use in pharmacies. Patients using specific medications will be prompted to complete questionnaires about their self-reported adherence.
214375921|NCT03393338|BEHAVIORAL|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
214375922|NCT00007280|DEVICE|Bioengineered skin|
214375923|NCT02401373|BIOLOGICAL|Ad5-EBOV|intramuscular injection
214375924|NCT05279222|OTHER|Gait adaptability training|All patients will receive two gait training interventions, each consisting of twelve one hour training sessions. The training sessions will be focussed on improving gait capacity.
214375925|NCT05465512|OTHER|response to neoadjuvant chemotherapy|Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
214375926|NCT05537480|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device will be worn by participants during several periods.
214375927|NCT05553847|OTHER|Automated oxygen titration based on the oxygen saturation during activity|A device will be used, which automatically adjusts the oxygen flow to the dosage necessary for keeping the saturation at the recommended level (90-94%). If the saturation falls below 90%, oxygen flow will increase, and if the saturation increases above 94%, oxygen flow decreases in order to stay on target.
214686842|NCT01768598|OTHER|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
214686843|NCT06188832|DIETARY_SUPPLEMENT|glucomannan, inulin, and psyllium|the subjects recieved fiber supplement containing glucomannan, inulin, and psyllium
214686844|NCT06188832|OTHER|placebo|the subjects recieved placebo
214686845|NCT06471634|BEHAVIORAL|CBTi|A 12 week intervention using CBTi to improve sleep measured using objective and subjective measures. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
214686846|NCT06471634|OTHER|Control - usual care|Participants will be given a leaflet summarising good sleep practice and the advantages of reducing sedentary behaviour. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
214686847|NCT06471634|BEHAVIORAL|Sedentary behaviour reduction|Participants will be encouraged to increase activity and thus reduce sedentary time. Investigators will use behaviour change techniques to aid in this goal. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
214686848|NCT01801046|DRUG|mitoxantrone hydrochloride|Given IV
214988062|NCT01776957|DEVICE|Device: Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
214375928|NCT05968040|PROCEDURE|Inferior vena cava diameter measurement by ultrasonography|The diameter of the inferior vena cava will be measured at 2 cm close to the entrance of the right atrium. Ultrasound images will be taken at the end of inspiration (Dmax) and at the end expiration (Dmin) to calculate the inferior vena cava dispensability index (dIVC), and will be recorded before and after fluid challenge test of 5 ml/kg crystalloid within 15 min. The IVC distensibility index (IVC-DI) will be calculated using the formula: IVC-DI = IVCmax - IVCmin/ IVCmin. The indices will be expressed as a percentage.
214496798|NCT04796792|DEVICE|Break Wave Lithotripsy and Ultrasonic Propulsion|Novel ultrasound technologies to facilitate passage of stones.This includes Burst Wave Lithotripsy (BWL), a technology to noninvasively fragment urinary calculi within the kidney and ureter, and ultrasonic propulsion, a technology to non-invasively reposition stones within the kidney and ureter. BWL uses short multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. Ultrasonic propulsion uses long multi-cycle bursts of low amplitude ultrasound to move stones within the collecting system.
214988063|NCT01849614|OTHER|Cardiac SPECT perfusion scan|A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
214686849|NCT01801046|DRUG|cytarabine|Given IV
214686850|NCT01801046|PROCEDURE|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
214686851|NCT01801046|OTHER|laboratory biomarker analysis|Correlative studies
214496799|NCT05770492|DIAGNOSTIC_TEST|anterior segment optical coherence tomography|Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.
214496800|NCT02555306|DRUG|0.5 mg of DE-122|DE-122 Injectable Solution
214496801|NCT02555306|DRUG|1.0 mg of DE-122|DE-122 Injectable Solution
214496802|NCT02555306|DRUG|2.0 mg of DE-122|DE-122 Injectable Solution
214496803|NCT02555306|DRUG|4.0 mg of DE-122|DE-122 Injectable Solution
214496804|NCT04497337|PROCEDURE|Complete excision to superficial lesions around the ear|Complete excision of these lesions and histopathology
214496805|NCT04650191|OTHER|Identification of genetic variants|DNA will be extracted from whole blood from study subjects
214686852|NCT03902366|DIAGNOSTIC_TEST|Neuropsychological assessment|Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
214686853|NCT03902366|BEHAVIORAL|Neuroimaging|Subjects, well characterized with respect to their substance use, will be evaluated with functional magnetic resonance imaging (fMRI) tasks, resting state MRI (rsMRI), high resolution anatomical MRI, standard diffusion weighted imaging (DWI) and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
214686854|NCT06527274|DEVICE|Experimental: Myopic defocus soft lens design (MDSL)|An optical device designed to provide a myopic defocus to control myopia progression
214686855|NCT06527274|DEVICE|Active Comparator: Single vision soft lens design (SVSL|An optical device designed to correct refractive error like myopia
214686856|NCT03393845|DRUG|Pembrolizumab|Pembrolizumab 200mg IV, 21 day cycles
214686857|NCT03393845|DRUG|Fulvestrant|Fulvestrant, 500mg IM, Loading dose: C1 D1 \& 15. Thereafter, Q4 wks
214686858|NCT05636579|BIOLOGICAL|EO2002|Intracameral injection of magnetic human corneal endothelial cells (EO2002)
214686859|NCT05636579|DRUG|Ripasudil|Daily use of Ripasudil drops
214686860|NCT01294735|DRUG|MK-4827|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
214988064|NCT00627692|DRUG|Prucalopride|0.5 mg o.d.
214988065|NCT00627692|OTHER|Placebo|o.d.
214988066|NCT00627692|DRUG|Prucalopride|1 mg o.d.
214686861|NCT01294735|DRUG|Temozolomide|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
214686862|NCT06071793|OTHER|Family involvement|Family delivery of mobility activities
214686863|NCT05645029|OTHER|glass ionomer-chlorhexidine|chlorhexidine will be added to glass ionomer
214686864|NCT05645029|OTHER|glass ionomer-titanium dioxide powder|titanium dioxide will be added to glass ionomer
214686865|NCT05645029|OTHER|glass ionomer|glass ionomer will be used without any additives
214988067|NCT00627692|DRUG|Prucalopride|2 mg o.d.
214686866|NCT00074100|DRUG|amonafide dihydrochloride|
214988068|NCT00627692|DRUG|Prucalopride|4 mg o.d.
214988069|NCT00300599|DEVICE|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
214988070|NCT00300599|OTHER|Placebo|Placebo
214988071|NCT03807024|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
214988072|NCT01640977|PROCEDURE|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
214375929|NCT05968040|PROCEDURE|difference between peak velocities of carotid artery by ultrasound|"Carotid ultrasound images will be obtained from the left CCA in both short-axis and long-axis views by experienced sonographers. The patient will be in supine position, with the head rotated slightly to the right. A broadband linear array transducer 12-4 MHz and the short-axis view will be used for orientation and identification of the CCA. Next, in the long-axis view, Peak Waveform Doppler signals will be acquired by placing a 0.5 mm calliper at the center of the vessel and parallel to the vessel walls, approximately 2 cm proximal from the carotid bifurcation. Insonation-angles between the ultrasound beam and blood flow will be maintained.~ΔVpeakCCA = (MaxCDPV-MinCDPV)+(MaxCDPV+MinCDPV)x100"
214375930|NCT05968040|PROCEDURE|cardiac output be transthoracic echocardiography|"CO will be recorded as baseline measure and after fluid administration. If CO increased more than 15%, it will be considered fluid responder. Increase in cardiac output = (cardiac output after first fluid challenge - cardiac output before)/cardiac output before) X 100.~TTE will be used to measure LTOT and VTI x HR."
214375931|NCT00685321|DEVICE|H1 deep TMS coil|20 daily deep rTMS treatment
214375932|NCT00685321|DEVICE|Sham|inactive treatment
214375933|NCT02020980|BIOLOGICAL|Botulinum toxin type A|"This is an observational study designed to reflect the clinical practice in real life as closely as possible.~Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines."
214375934|NCT05942755|OTHER|Concurrent evaluation of blood and CSF ionograms to determine if there is a correlation between CSF change and the development of hyoponatremia between day 0 and day 14.|"Blood samples are taken as part of routine care on arrival of patients and then every 24 hours if an arterial catheter is in place; otherwise, every Monday, Wednesday and Friday. Samples from the EVD will be taken on Day 0 and then every 24 hours. A urine ionogram is also performed every 24 hours as part of the usual management to regulate water, sodium and potassium intake by enteral or parenteral routine.~The ionic composition of CSF from patients with SAH will be compared with a control population of patients hospitalized with normal pressure hydrocephalus. A lumbar puncture is performed in the operating room to evacuate the chronic CSF effusion in the ventricles (hydrocephalus), before performing an intrathecal perfusion test. 1ml of the CSF thus collected will be analyzed to determine its ionic composition"
214496806|NCT02298166|DRUG|chemotherapy (Mitoxantrone, Cytarabine)|"Induction therapy:~* Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT) d 1-3~* Cytarabine 1000 mg/m² IV (500 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6~Consolidation therapy:~Younger adult patients (18 to 60 yrs):~Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).~Older patients (\> 60 yrs) and or previous allogeneic HCT:~Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²)."
214686867|NCT03299517|DRUG|Antiarrythmic Drugs|Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
214686868|NCT03299517|DRUG|Antiarrhythmic drugs|Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
214686869|NCT04430049|PROCEDURE|Covid ICU containment measures|The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU
214686870|NCT06166914|DRUG|Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml)|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml).
214686871|NCT06166914|DRUG|Placebo|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
214686872|NCT03445052|BEHAVIORAL|XPAND|The intervention is personalised to the psychosocial factors influencing poor photoprotection for each person. These factors could include beliefs that reduce motivation to protect as well as factors that prevent intentions being translated into action. The facilitator will use behaviour change techniques to target the factor most important for each person. Standardised content related to habit formation will be received. The intervention will be delivered via 7 1:1 sessions with a facilitator (psychologists or clinical nurse specialist). Sessions 1 (1.5 hours maximum) and 6 (45 minutes) will be delivered face to face in the home of the participant and the remaining sessions will be conducted via telephone calls or skype sessions.
214686873|NCT00751530|DRUG|raltegravir|New combination ART incorporating raltegravir with other ARVs.
214686874|NCT03927937|PROCEDURE|AUTOTRANSPLANTATION TOOTH|Tooth with imposible prognosis is replace with a healthy tooth from the same patient.
214686875|NCT04060173|DRUG|ABP-671|ABP-671 is an investigational drug
214686876|NCT04060173|OTHER|Placebo|Matching placebo
214686877|NCT06312267|DEVICE|Bioelectric dressing|Participants randomized into the experimental arm will have a bioelectric dressing applied 3 days before surgery, and 3 days post-surgery.
214686878|NCT05813171|DIETARY_SUPPLEMENT|Allicor|Participants will take Allicor capsules in addition to standard treatment for a year.
214686879|NCT05813171|DRUG|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
214686880|NCT03514758|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
214686881|NCT05205434|OTHER|Synchronous telerehabilitation programme|Exercise program and educational program
214686882|NCT05205434|OTHER|Asynchronous telerehabilitation programme|Exercise program educational program
214686883|NCT05105438|DIETARY_SUPPLEMENT|Consecutive Day Dosing|100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.
214686884|NCT05105438|DIETARY_SUPPLEMENT|Alternate Day Dosing|100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.
214988073|NCT01640977|PROCEDURE|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
215090237|NCT00330668|DRUG|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
214375935|NCT01789996|PROCEDURE|alternative six minute walk test|"Alternate instructions will be given Subjects will~1. walk as fast as they can in 6 minutes~2. walk as normally as they can in 6 minutes~3. walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
214375936|NCT01789996|PROCEDURE|Standard six minute walk test|Subjects will walk as far as they can in 6 minutes
214375937|NCT00199498|DEVICE|Apical RV lead placement|RV lead implanted ( according to randomization )at the apex
214375938|NCT00199498|DEVICE|Septal RV lead placement|RV lead is implanted (according to randomization), on septum
214375939|NCT03736343|DRUG|Alcohol|Participants will complete two drinking sessions.
214375940|NCT02357290|DRUG|Open-label Treatment with N-Acetylcysteine|
214375941|NCT04033172|DRUG|Pyrotinib Plus Fulvestrant|Pyrotinib: 400 mg/d, q.d., p.o. A course of treatment need 28 days. Fulvestrant: 500 mg/m2 q.d. i.m. A course of treatment need 28 day. First course needs extra dose of fulvestrant 500 mg/m2 q.d. i.m. on day 15.
214375942|NCT00006008|DRUG|arsenic trioxide|
214375943|NCT05936229|BIOLOGICAL|Interferon Beta-1A|Given IV
214375944|NCT05936229|PROCEDURE|X-Ray Imaging|Undergo x-ray
214375945|NCT05936229|PROCEDURE|Echocardiography|Undergo ECHO
214375946|NCT05936229|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214375947|NCT05936229|PROCEDURE|Computed Tomography|Undergo CT
214375948|NCT05936229|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215090238|NCT01669213|DRUG|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
215090239|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
214375949|NCT05936229|PROCEDURE|Lumbar Puncture|Undergo LP
214375950|NCT05936229|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214375951|NCT05936229|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214375952|NCT05936229|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214375953|NCT05936229|PROCEDURE|Biopsy|Undergo tissue biopsy
214375954|NCT00469469|DRUG|Bevacizumab|
214375955|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
214375956|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
214375957|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 3rd drug|To prepare 4 mL/kg dextrose 10%
214375958|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
214375959|NCT03921346|DEVICE|Conventional method 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
214375960|NCT03921346|DEVICE|Conventional method 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
214375961|NCT03921346|DEVICE|Conventional method 3rd drug|To prepare 4 mL/kg dextrose 10%
214375962|NCT03921346|DEVICE|Conventional method 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
214686885|NCT05120622|DRUG|Tremelimumab|"Tremelimumab 25 mg / 50 mg / 75 mg local cystoscopic injection into bladder wall at or adjacent to site of prior tumour resection (dose divided into 4 injection sites), administered 6 and 3 weeks before radical cystectomy.~Durvalumab 1500mg via IV infusion administered 6 and 3 weeks before radical cystectomy."
214686886|NCT02876770|DIETARY_SUPPLEMENT|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
214686887|NCT02876770|DIETARY_SUPPLEMENT|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
214686888|NCT01325831|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
214686889|NCT01325831|DEVICE|Sham repetitive transcranial magnetic stimulation(rTMS)|Sham repetitive transcranial magnetic stimulation(rTMS)
214686890|NCT02665234|DRUG|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
214686891|NCT02665234|DRUG|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
214686892|NCT01938963|BEHAVIORAL|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
214686893|NCT02987764|OTHER|cord milking|For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
214686894|NCT02849990|DRUG|Abiraterone Acetate|Given PO
214686895|NCT02849990|DRUG|Apalutamide|Given PO
215090240|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
215090241|NCT01669213|DRUG|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
214375963|NCT00710112|GENETIC|gene variations|comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
214375964|NCT00811447|DRUG|5-fluorouracil|600 mg/m²/day intravenous
214375965|NCT00811447|DRUG|Cisplatin|60 mg/m² or 75 mg/m² intravenous
214375966|NCT00811447|DRUG|Docetaxel|60 mg/m² intravenous
214375967|NCT01240954|DRUG|OSIRIS|OSIRIS current practice
214375968|NCT01240954|DRUG|OSIRIS other concentration 1|OSIRIS new concentration 1
214375969|NCT01240954|DRUG|OSIRIS other concentration 2|OSIRIS new concentration 2
214375970|NCT01388348|DEVICE|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
214375971|NCT04372225|OTHER|analysis of hypocalcemia|analysis of postoperative calcium and PTH levels
214686896|NCT02849990|DRUG|Degarelix|Given SC
214686897|NCT02849990|DRUG|Indomethacin|Given PO
214686898|NCT02849990|OTHER|Laboratory Biomarker Analysis|Correlative study
214686899|NCT02849990|DRUG|Prednisone|Given PO
214686900|NCT04573452|DIAGNOSTIC_TEST|Galectin-3|Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
215090242|NCT02221154|DIETARY_SUPPLEMENT|Inofolic®|
215090243|NCT02221154|OTHER|Gonadotropins; Folic Acid|standard ovarian stimulation
215090244|NCT03734068|DEVICE|Chemoembolization Using LifePearl|Chemoembolization Using LifePearl
215090245|NCT03734068|DRUG|Doxorubicin|Doxorubicin is loaded to LIfePearl
215090246|NCT02514668|DRUG|Isatuximab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214375972|NCT05011825|BEHAVIORAL|Pregnant Moms' Empowerment Program|The first session introduces women to the group, seeks to build an alliance and sense of group cohesion, and provides safety planning. The second session addresses intergenerational patterns of violence and how such violence contributes to psychopathology in both the prenatal and postnatal period, focusing on violence prevention. Information regarding cognitive restructuring, behavioral activation, and coping styles is provided in session three, as well as the role of healthy relationships and social supports in promoting resilience. This session begins with discussion on health in pregnancy, labor/delivery, and coordinating care across providers. This session also provides psychoeducation related to post-delivery parenting, including infant safety, care and breastfeeding. In the final session, group leaders assist mothers with identification, sensitivity, and responsiveness to infant cues.
214988074|NCT03094156|DRUG|Placebo|1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]
214686901|NCT04573452|DIAGNOSTIC_TEST|Placental Galactin-3|Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
214686902|NCT00133237|DEVICE|Sirolimus-eluting stent|cypher stent is implanted due to randomization.
214686903|NCT00133237|DEVICE|Paclitaxel-eluting stent|taxus stent is implanted due to randomization.
214686904|NCT01051986|PROCEDURE|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
214375973|NCT04524078|OTHER|intensive integrated intervention care program|intensive integrated intervention care program \[ICP\] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
214496807|NCT02298166|DRUG|Placebo|"Induction therapy:~Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with placebo will be given at the same dose tolerated during induction therapy."
214375974|NCT02935348|RADIATION|Whole Body MRI|Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
214375975|NCT02722343|DRUG|Tenofovir intravaginal ring|The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
214686905|NCT01051986|PROCEDURE|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
214686906|NCT02728258|DRUG|Copanlisib|Given IV
214686907|NCT02728258|OTHER|Laboratory Biomarker Analysis|Correlative studies
214686908|NCT05728086|OTHER|Group art therapy|The intervention is a manualised programme of group art therapy based on a bio-psychosocial therapeutic model. The programme is made up of six 60 - 90-minute art therapy group sessions facilitated by an experienced HCPC (Health and Care Professions Council) registered Art Therapists trained in the intervention.
214686909|NCT01725152|DRUG|Ganaxolone|oral suspension, given in 3 divided doses
214988075|NCT03094156|DRUG|BIA 6-512|1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]
214988076|NCT03094156|DRUG|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]
214686910|NCT01725152|DRUG|Placebo|oral suspension, given in 3 divided doses
214686911|NCT05201274|BEHAVIORAL|Baduanjin sequential therapy|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
214686912|NCT05201274|BEHAVIORAL|Aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.
214686913|NCT03614169|PROCEDURE|Implantation of a HIS-pacing lead|This intervention is attempted first
214686914|NCT03614169|PROCEDURE|Implantation of a LV-pacing lead|This intervention is attempted first
214988077|NCT03094156|DRUG|Comtan®|Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]
214988078|NCT01493713|OTHER|Evaluate the correlation of overall different objective response.|Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
214988079|NCT02645890|DRUG|CKD-397|Arm A:Tamsulosin/ Tadalafil Fixed dose combination
214988080|NCT02645890|DRUG|TD+TM|Arm B: Tamsulosin/ Tadalafil Coadministration
214988081|NCT06094465|OTHER|Different phase of the learning curve of RPD|Different phases of the learning curve of RPD (learning phase or proficiency phase)
214988082|NCT05273359|DRUG|Benralizumab|15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
214988083|NCT05273359|OTHER|Benralizumab placebo|15 subjects (\>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.
214988084|NCT05273359|OTHER|Comparison (control) group; no intervention|15 subjects (\<150 eosinophils/microliter) will not receive any intervention.
214988085|NCT04009837|BEHAVIORAL|Hip-focused rehabilitation intervention|The hip-focused intervention includes a blend of hip-focused rehabilitative techniques and some basic lumbar spine-directed techniques. The hip-focused arm includes tailored manual therapy, progressive strengthening exercises, and flexibility exercises for the hip, as well as spinal flexibility and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
215090247|NCT03979599|PROCEDURE|ultra-sound guided transversus abdominis plan block|comparing ultrasound guided transversus abdominis plan block using combination of magnisum sulphate and levobupivacaine versus levobupivacaine
214496808|NCT02298166|DRUG|Crenolanib|"Induction therapy:~Crenolanib to be given as p.o. TID starting d 7+, given continuously until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with Crenolanib is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy."
214686915|NCT01095575|DRUG|normal saline 3 ml, morphine 3mg|On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
214686916|NCT00750555|DRUG|Erlotinib|150 mg per day orally until disease progression occurs, up to a maximum of 12 months
214686917|NCT01111539|DRUG|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
214686918|NCT01111539|DRUG|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
214686919|NCT01111539|DRUG|Blinded capsule|Blinded capsule administered orally, once daily.
214686920|NCT05078463|DEVICE|Microneedle|Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.
214686921|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)|1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
214686922|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA (15-minute application time)|1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand
214988086|NCT04009837|BEHAVIORAL|Spine-focused rehabilitation intervention|The spine-focused rehabilitation intervention is a direct and comprehensive lumbar spine rehabilitative program, but it does not include hip treatment. The spine-focused arm includes spinal manual therapy, spinal flexibility exercises, and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
214686923|NCT05078463|DRUG|0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)|0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
214686924|NCT05078463|DEVICE|Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
214686925|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Conventional free gingival graft was applied to the area of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
214686926|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Partially de-epithelialized free gingival graft was applied to the other region of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
214686927|NCT04695106|DRUG|Ticagrelor|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.
214686928|NCT04695106|DRUG|Dabigatran Etexilate|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
214686929|NCT04695106|DRUG|Aspirin|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
214988087|NCT04270188|OTHER|evolution of patient symptoms|evolution of symptoms on the PGI-I scale (score 1, 2, or 3) 2 months after surgery
214988088|NCT01005381|DIETARY_SUPPLEMENT|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
214988089|NCT01005381|DIETARY_SUPPLEMENT|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
214988090|NCT01005381|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
214988091|NCT01005381|DIETARY_SUPPLEMENT|Calcium Placebo|"Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily."
214375976|NCT02722343|DRUG|Truvada|The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
214496809|NCT02298166|OTHER|Allogeneic stem cell transplantation|"In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.~Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC."
214496810|NCT03066609|DRUG|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
214496811|NCT03066609|DRUG|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
214496812|NCT03066609|DRUG|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
214496813|NCT01940107|OTHER|evaluations|Only evaluations
214496814|NCT01940107|PROCEDURE|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
214496815|NCT02551237|RADIATION|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
214496816|NCT02551237|DRUG|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
214496817|NCT02551237|RADIATION|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
214686930|NCT04695106|DRUG|Clopidogrel|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
214375977|NCT01213108|BEHAVIORAL|Örebro prevention program|6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth
214375978|NCT01213108|BEHAVIORAL|Business as usual|Regular alcohol prevention activities and curricula in Swedish schools
214496818|NCT02568306|DRUG|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.
214496819|NCT02568306|DRUG|placebo|Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.
214686931|NCT03628417|PROCEDURE|Calcium Electroporation|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
214988092|NCT05107037|DRUG|TQ-B3234 capsule|TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor
214988093|NCT02674659|BEHAVIORAL|resistance training|resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session was held for around 30 minutes.
214988094|NCT02674659|BEHAVIORAL|aerobic training|aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
214988095|NCT01572792|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
214988096|NCT01572792|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
215090248|NCT03979599|DRUG|magnesium sulphate& levobupivacaine|magnesium sulphate\& levobupivacaine
215090249|NCT03979599|DRUG|Levobupivacaine|levobupivacaine
214375979|NCT06156566|DRUG|Tecovirimat Oral Capsule|600 mg, twice daily, 14 days.
214375980|NCT06156566|DRUG|Placebo|3 capsules, twice daily, 14 days.
214375981|NCT05957484|DEVICE|Investigational brainstem neuromodulation device|This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.
214375982|NCT01239667|OTHER|Individual oriented planning of the rehabilitation program for patients with heart failure|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
215090250|NCT01052961|DRUG|Oseltamivir|oseltamivir 150 mg bd for 5 days
214375984|NCT03354364|DIETARY_SUPPLEMENT|Pea hull fiber|Snacks containing 15 g/day of ground pea hulls.
214375985|NCT03354364|DIETARY_SUPPLEMENT|Control|Snacks without added fiber.
214375986|NCT05257330|DIAGNOSTIC_TEST|CSF Examination|Lumbar puncture for CSF Examination
214375987|NCT02487498|DRUG|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
214496820|NCT01465152|DRUG|metformin|Adminstered orally during the three main meals for 24 weeks
214496821|NCT01465152|DRUG|repaglinide|Administered orally before the three main meals for 24 weeks
214496822|NCT04004494|OTHER|3D reconstruction|3-dimensional computed tomography reconstruction guided VATS segmentectomy
214496823|NCT06085729|DRUG|ADI-PEG 20|Given by Injection
214496824|NCT06085729|DRUG|Cabazitaxel|Given by IV (vein)
214496825|NCT06085729|DRUG|Carboplatin|Given by IV (vein)
215090251|NCT00636012|PROCEDURE|verum acupuncture|acupuncture at St36 and Pe6
214375988|NCT02487498|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
214375989|NCT02487498|DRUG|Placebo (umeclidinium/vilanterol )|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
214375990|NCT02487498|DRUG|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
214375991|NCT06371599|BEHAVIORAL|Playing game|Active Distraction Methods
214375992|NCT06371599|BEHAVIORAL|Watching cartoon|Passive Distraction Methods
214375993|NCT03171480|DRUG|Monoket Pill|Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
214375994|NCT03171480|DRUG|Placebo|The pharmacy has compounded an identical appearing placebo
214375995|NCT04744857|COMBINATION_PRODUCT|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.|Using the grip-loading system, the artificial aortic valve was squeezed and loaded into the sheath of the transporter through the vascular approach.The artificial aortic valve is delivered and positioned at the correct anatomical position for release. For example, the artificial main valve is displayed after partial release If the aortic valve is not in the correct anatomical position, the artificial aortic valve can be recovered and placed into the sheath tube of the transporter for re-positioning and release.
214375996|NCT00676130|DRUG|trimethoprim-sulfamethoxazole|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~\> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"
214496826|NCT05558358|DEVICE|Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation|6 months of active stimulation -- \> 6 months of sham stimulation
214496827|NCT05558358|DEVICE|Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation|6 months of sham stimulation -- \> 6 months of active stimulation
214496828|NCT03855293|PROCEDURE|Rhexis protection shield|In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
214496829|NCT04968886|DIAGNOSTIC_TEST|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
214988097|NCT01572792|DRUG|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day
214988098|NCT01572792|DRUG|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day
214988099|NCT01572792|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
214988100|NCT03607318|BEHAVIORAL|iASIST|Integrated Alcohol and Suicide Intervention for Suicidal Teens
214375997|NCT00676130|DRUG|Cephalexin|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~\> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"
214375998|NCT00079508|DRUG|Angiomax (bivalirudin)|250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. A starting bolus of 0.1 mg/kg and/or an infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
214496830|NCT06000202|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 21 days. She receives 3 sessions, in total. Each session consists of application of PS03 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 6 passes followed by R11 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 3 passes.
214496831|NCT06000202|DEVICE|Sham|Er:YAG laser is applied with sham handpiece.
214988101|NCT03932357|RADIATION|CBCT|measuring soft tissue thickness using a CBCT
215090252|NCT00636012|PROCEDURE|sham acupuncture|superficial needling at sham points
215090253|NCT01839656|DRUG|nusinersen|Administered by intrathecal (IT) injection
215090254|NCT05077358|PROCEDURE|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
215090255|NCT05077358|PROCEDURE|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
215090256|NCT00865085|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
215090257|NCT00865085|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
215090258|NCT01295684|OTHER|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
214496832|NCT04512456|BEHAVIORAL|Exercise training|Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.
214988102|NCT03530696|DRUG|Palbociclib|Palbociclib is to be taken orally on days 5-18 (14 days) of each cycle (each cycle length is 21 days). The starting dose will be 125mg.
214988103|NCT03530696|DRUG|T-DM1|The recommended dose of T-DM1 is 3.6 mg/kg and is given as an intravenous infusion on Day 1 of every cycle (every 21 days).
214988104|NCT02472353|DRUG|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
214988105|NCT02472353|DRUG|Doxorubicin|Standard of care treatment with doxorubicin
214988106|NCT05326516|DRUG|Revumenib|Participants will receive revumenib until meeting criteria for discontinuation.
214988107|NCT05326516|DRUG|Chemotherapy Regimen 1|Participants will receive 2 treatment cycles of chemotherapy. During Cycle 1, participants will receive prednisone, vincristine, pegaspargase/calaspargase pegol-mknL, and daunorubicin. During Cycle 2, participants will receive etoposide and cyclophosphamide.
215090259|NCT01295684|OTHER|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
215090260|NCT04970160|PROCEDURE|TSARP|We make four different surgical operations for female patients with rectovestibular fistula
215090261|NCT04970160|PROCEDURE|PSARP|Posterior sagittal anorectoplasty
215090262|NCT04970160|PROCEDURE|Classic ASARP|Anterior Sagittal anorectoplasty
215090263|NCT04970160|PROCEDURE|Modified ASARP|External anal sphincter preservation
215090264|NCT02899923|OTHER|Data collection|
215090265|NCT00284713|PROCEDURE|intracoronary infusion of BMC|catheter delivery of stem cells
215090266|NCT00161525|PROCEDURE|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
214375999|NCT05893264|OTHER|Data collection|"Several data will be collected such as:~Age, weight, height, gender, previous spine surgery, skoliosis (Y/N), palpable spinous process (Y/N), experience in years of anesthesiologist, spine level of epidural placement~and the following sonographic parameters at the level of epidural placement: skin-spinous process distance (cm), skin-transversous process distance (cm), erector spinae plane distance (cm), superior to inferior spinous process distance (cm)"
214686932|NCT03628417|PROCEDURE|Bleomycin based electrochemotherapy|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
214376000|NCT04391465|OTHER|Electrophysiological Pacing|Assess the MCA CBF velocity response at different paced heart rates.
214376001|NCT05185778|BIOLOGICAL|stool examination, blood sample collected|"Stool examination macroscopically for consistency, color, and presence of blood and/or mucus and microscopically using the following methods:~* Saline and iodine wet mount.~* Formalin-ethyl acetate sedimentation method.~* Modified Ziehl-Nielsen staining : It was done to all cases with manifestations suggestive of protozoa.~  * Collection of peripheral blood samples for Automated CBC and blood indices evaluation.~ * Molecular detection of inflammatory cytokines level (IFNγ, TNFα) and antiinflammatory cytokines (IL4, IL10) by Real-time PCR(polymerase chain reaction)."
214376002|NCT05994391|DIETARY_SUPPLEMENT|LasoperinTM|"Active ingredients:~Scutellaria baicalensis extract, 240 mg per capsule. Acacia catechu extract, 51 mg per capsule. With no less than 180 mg of baicalin, and no less than 30 mg of catechins from the above-mentioned extracts per capsule.~Inactive ingredients:~Maltodextrin"
214686933|NCT03263936|DRUG|Decitabine|Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over \_\_ hour on days 1 through 5
214686934|NCT03263936|DRUG|Vorinostat|Age \<18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
214686935|NCT03263936|DRUG|Filgrastim (G-CSF)|Given on days 5 until evidence of ANC recovery (\>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
214376003|NCT05994391|DIETARY_SUPPLEMENT|Placeo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose"
214376004|NCT01089322|DRUG|inhaled corticosteroid plus LABA plus oral corticosteroid|formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
214376005|NCT06524063|DRUG|Survivin-loaded dendritic cell injection|The injections will be given on days 0, 14, and 28. The administration will involve both intradermal (ID) and intravenous (IV) routes.
214686936|NCT03263936|DRUG|Fludarabine|30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
214686937|NCT03263936|DRUG|Cytarabine|2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
214686938|NCT01968720|DRUG|CAT-2003|
214686939|NCT01968720|DRUG|Placebo|
214686940|NCT04376333|BEHAVIORAL|Cognitive-Behavioral Treatment|Cognitive-behavioral coping skills training
214686941|NCT04376333|BEHAVIORAL|Individualized Assessment and Treatment Program|Experience-sampling based cognitive behavioral coping skills assessment and training
214686942|NCT04376333|OTHER|Standard Conservative Care|Standard conservative dental care for orofacial pain
214686943|NCT06163794|OTHER|Nutritional postprandial test|Metabolic responses to several test meals
214686944|NCT03539458|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
214686945|NCT06540859|DEVICE|Transcutaneous Spinal Cord Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver 1ms pulses with 10kHz carrier frequency at 30 Hz, which has demonstrated autonomic recovery in our previous studies. The location of tSCS is predetermined (at T10 and T11 vertebral levels). The stimulation intensity will range from 10 to 200 mA and specific criteria will be followed to determine the optimal therapeutic stimulation.
214686946|NCT06540859|DEVICE|Sham Stimulation|Non-invasive electrical stimulation of a lower extremity muscle group over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver sham stimulation. The intensity of electrical stimulation will be briefly ramped up to a level at which the participants report perceiving the stimulation (i.e., sensory threshold), then ramped down and turned off for the remainder of the intervention.
214686947|NCT05948722|BEHAVIORAL|Motivational Interview Group (MIG)|Brief MI intervention with the conventional treatment
214686948|NCT05948722|PROCEDURE|Conventional treatment group (CTG)|Conventional treatment
214686949|NCT02214836|DEVICE|Verasonics Data Acquisition System (VDAS)|Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
214686950|NCT01816646|DRUG|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
214686951|NCT01816646|DRUG|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
214988108|NCT05326516|DRUG|Chemotherapy Regimen 2|Participants will receive 2 treatment cycles of chemotherapy. During Cycles 1 and 2, participants will receive fludarabine and cytarabine.
214988109|NCT02297126|OTHER|Pharmacogenetic Intervention Arm (pharmacogenetic testing)|In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
214376006|NCT02450721|OTHER|Biomarkers serum level measurement|"Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO."
214376007|NCT00755222|BIOLOGICAL|AA4500|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
214376008|NCT00755222|BIOLOGICAL|Placebo|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
214376009|NCT04755270|DEVICE|VR Glasses|techniques of hypnofertility and VR glasses
214376010|NCT03712735|DRUG|Bupivacaine 0.08% - fentanyl 2mcg|In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
214376011|NCT00303160|DRUG|vitamin C & E supplements|
214376012|NCT05445544|OTHER|Observational studies, The diagnosis was preeclampsia|Observational studies, The diagnosis was preeclampsia
214376013|NCT01861574|DEVICE|Real TMS 45 min|Real TMS 45 minutes after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
214376014|NCT01861574|DEVICE|Sham TMS 45 min|Sham TMS 45 minutes after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
214376015|NCT01861574|DEVICE|Real TMS 4 Hours|Real TMS 4 hours after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
214376016|NCT01861574|DEVICE|Sham TMS 4 Hours|Sham TMS 4 hours after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
214376017|NCT00019032|BIOLOGICAL|monoclonal antibody Mik-beta-1|
214376018|NCT02492555|OTHER|SI|A routine scheduled (SI) screening of FC and DA every 3rd month
214376019|NCT02492555|OTHER|OD|A screening of FC and DA on demand (OD)
214376020|NCT01696331|BEHAVIORAL|Text Message Reminder|Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
214376021|NCT01074606|DEVICE|AcrySof Toric Intraocular Lens|Implantation of the AcrySof Toric Intraocular Lens (IOL)
214376022|NCT02435368|DRUG|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
214376023|NCT05599269|DEVICE|Examination of dentures with SR Phonares II teeth|The intraoral situation will be examined similar to a standard dental examination. The dentures are then removed, cleaned and examined extraoral. Pictures and an impression of the dentures are taken.
214376024|NCT00251095|DRUG|Taxol|
214376025|NCT00251095|DRUG|TOCOSOL Paclitaxel|100 mg/m2/week
214376026|NCT03830190|OTHER|Parkinson's disease nurse specialist care|Specialized nursing care provided by a Parkinson's disease nurse specialist
214376027|NCT05375708|RADIATION|Stereotactic body radiation therapy (SBRT)|Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.
214988110|NCT06080126|OTHER|Control: per usual practice|160 patients were included as per usual practice.
214988111|NCT06080126|OTHER|Intervention MAF|160 patients were included with MAF intervention.
214988112|NCT04769297|DRUG|Sublingual Micro-Dose Ketamine|daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic
215090267|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram \[mcg\]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
214686952|NCT01770418|RADIATION|Radiation with Concurrent Chemotherapy|"RADIATION: Proton Radiotherapy~Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions~Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions~Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions~Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions~CONCURRENT CHEMOTHERAPY:~Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.~Adjuvant chemotherapy is optional."
214686953|NCT05009472|DEVICE|expander with deferential opening and petit face mask|bonded expander with two screws and vertical hooks for attachment face mask. adjustment face mask with forehead and chin anchorage
214376028|NCT05375708|DRUG|Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)|"CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks."
214686954|NCT05490628|OTHER|Cognitive Rehabilitation|Language, memory, attention and executive function exercises are performed for the participants' deficient cognitive functions.
214686955|NCT05490628|OTHER|Conventional Therapy|Strengthening, walking, balance and coordination exercises are performed according to the needs of the participants.
214686956|NCT03406338|PROCEDURE|Fasciectomy|Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.
214686957|NCT03406338|DRUG|Collagenase Clostridium Histolyticum|Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
214686958|NCT06837480|DEVICE|LTU-904 Portable Laser Therapy Unit (active laser device)|The RianCorp LTU-904 laser therapy unit (active laser device) will be used for photobiomodulation therapy (PBMT).
214686959|NCT06837480|DEVICE|LTU-904 Portable Laser Therapy Unit (sham/inactive laser device)|The RianCorp LTU-904 laser therapy (sham/inactive laser device) unit will be used for sham therapy.
214686960|NCT05327023|PROCEDURE|donor lymphocyte infusion|The DLI will be given on Day +7 (Day +21 for dose level -1). If a recipient participant is deemed too critically ill/unstable to receive DLI on the protocol specified day, the DLI will be delayed up to 4 days at the discretion of the PI and given within this time frame once the recipient participant s clinical status has stabilized or improved. If the DLI cannot be given during this time frame, the recipient participant will be taken off study and not considered evaluable for DLT, outcomes, or adverse events since the experimental intervention will not have been given.
214376029|NCT03221088|DRUG|Jintrolong® low dose group|PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
214376030|NCT03221088|DRUG|Jintrolong® high dose group|PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.
214686961|NCT05327023|DRUG|Cyclophosphamide|HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
214686962|NCT05327023|DRUG|Busulfan|AUC targeted dose based on busulfan test dose, with a default dose of 130 mg/m2/day, given as IV infusion over 3 hours each day for 4 days Transplant days -6 through day -3
214686963|NCT05327023|DRUG|Mycophenolate mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
214686964|NCT05327023|DRUG|Fludarabine|40 mg/m2 IV infusion over 30-60 minutes once daily for 4 days Transplant days -6 through -3
214686965|NCT05327023|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, maximum initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +70 with no taper. Doses should be modified as appropriate for drug interactions.
214686966|NCT05635734|DRUG|Azeliragon 5 mg|"Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
215090268|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
214376031|NCT00936832|DRUG|FOLFIRI regimen|
214376032|NCT00936832|DRUG|fluorouracil|
214376033|NCT00936832|DRUG|irinotecan hydrochloride|
214376034|NCT00936832|DRUG|leucovorin calcium|
214376035|NCT00936832|DRUG|sunitinib malate|
214376036|NCT00936832|OTHER|laboratory biomarker analysis|
214376037|NCT00936832|OTHER|pharmacogenomic studies|
214376038|NCT00936832|OTHER|pharmacological study|
214376039|NCT02574000|OTHER|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
214376040|NCT02574000|OTHER|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
214376041|NCT05494827|OTHER|Regular consumption of natural mineral water Borjomi® with high bicarbonate content|"Natural mineral water Borjomi® is a transparent mineral water with specific alkaline taste and smell. The chemical composition includes sodium hydrocarbonate (HCO2-) 3995 mg/l (3500-5000 mg/l), chlorides (Cl-) 360 mg/l (250-500 mg/l), and nitrites (NO2-) \<0.005 mg/l (up to 1 mg/l). The Borjomi water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities."
214376042|NCT05494827|OTHER|Regular consumption of processed drinking water Smart Spring®|Processed drinking water Smart Spring® has no colour and smell with delicate specific taste. The chemical composition includes sodium (Na+) 33.6 mg/l, magnesium (Mg2+) 10.03 mg/l, calcium (Ca2+) 34.57 mg/l, chlorides (Cl-) 69.79 mg/l, sulfates (SO42-) 22.00 mg/l, and hydrocarbonates (HCO2-) 96.48 mg/l. The Smart Spring® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.
214376043|NCT05494827|OTHER|Regular consumption of still drinking water|Still drinking water Святой Источник®is a standard steal drinking water, that has no colour, taste, and smell. The Святой Источник® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. Participants were asked to abstain from mineral water consumption for the entire observation period.
214376044|NCT02384525|PROCEDURE|Fluid management by the value of over hydration in Bioelectrical impedance|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
214686967|NCT05635734|DRUG|Azeliragon 10 mg|"Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
215090269|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
214376045|NCT02384525|PROCEDURE|Fluid management by clinical-based ultrafiltration|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
215090270|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
215090271|NCT02546960|BIOLOGICAL|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
214376046|NCT04139980|OTHER|Virtual Reality (VR)|Each VR session is 30 minutes long. Participants are able to pause or discontinue at any time. Each participant will receive one VR sessions five times per week over the course of a two-week period.
215090272|NCT02546960|DRUG|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
215090273|NCT01595581|DRUG|Testosterone|8 weeks of testosterone administration beginning 2 weeks before ACL surgery
215090274|NCT01595581|DRUG|Placebo|8 weeks of saline administration beginning 2 weeks before ACL surgery
214686968|NCT05635734|DRUG|Azeliragon 20 mg|"Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
214686969|NCT02574780|OTHER|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
215090275|NCT02544256|PROCEDURE|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
214686970|NCT02574780|OTHER|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
214686971|NCT01230671|OTHER|Yoga|A 12 week yoga session will be offered to women with breast cancer.
214686972|NCT01619384|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
214376047|NCT05403164|PROCEDURE|Modified Widman flap|"1. Administration of anaesthesia~2. First incision (reversed bevel incision), scalpel is placed at 45 degree, 2mm apical to gingival margin in coronal-apical direction until touching the bone and moved continuously around the teeth without any vertical releasing incisions~3. Partial mobilization of the mucoperiosteal flap (full thickness flaps both facially and orally) within the attached gingiva to the alveolar crest~4. Second incision (sulcular incision)~5. Third incision (horizontal incision), also interdentally to remove the delineated tissue and all granulation tissue which is used later for analysis.~6. Root surface debridement~7. Flap adaptation, complete coverage interdentally and suturing."
214376048|NCT05403164|PROCEDURE|Gingivectomy|"1. Administration of anaesthesia~2. Marking the base of the sulcus with pocket marker tweezer.~3. First incision (gingivectomy incision), scalpel blade placed 1mm apical to the bleeding points and the incision should be beveled 45 degrees coronally.~4. Second incision (interdental) to free the tissue which is used for analysis later.~5. Debriding the area and applying periodontal pack."
214376049|NCT00962143|DEVICE|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
214376050|NCT00962143|PROCEDURE|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
214376051|NCT00145457|PROCEDURE|Blood sample|
214376052|NCT00145457|PROCEDURE|Radiography|
214376053|NCT05159323|DIAGNOSTIC_TEST|Diffusion Spectrum Imaging|A novel diffusion-based magnetic resonance imaging method
214376054|NCT03540355|DRUG|Cipros 20 association|oral, once a day
214376055|NCT03540355|DRUG|Crestor 20 mg|Oral, once a day
214376056|NCT05548439|BIOLOGICAL|VBI-2901a|Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.
214376057|NCT00784433|DIETARY_SUPPLEMENT|alcohol|150 cc
214496833|NCT00135200|DRUG|Iodine I 131 Tositumomab|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose."
214496834|NCT02389855|PROCEDURE|NeuroBlate® System Therapy|
214496835|NCT01404585|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
214496836|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
214496837|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
214496838|NCT05715502|RADIATION|brachytherapy|Radiation: focal low dose rate or high dose rate brachytherapy for the lesion with appropriate margin, defined in magnetic resonance or positron emission tomography All recruited participants will be treated with interstitial brachytherapy for local recurrence of prostate cancer. The low dose rate of brachytherapy is used with a total dose of 145 Gy in the clinical target volume for participants after hypofractionated radiotherapy, a high dose rate brachytherapy as monotherapy or boost with external beam radiotherapy The high dose rate brachytherapy with two fractions of 13 Gy in the clinical target volume with a 3 to 14 days break is used after primary low dose rate brachytherapy or external beam radiotherapy alone.
214496839|NCT05357911|DRUG|AB-106, digoxin|Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
214686973|NCT01405846|DRUG|Gefitinib|250mg od for 6 months
214686974|NCT02794051|BEHAVIORAL|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
214686975|NCT00372190|DEVICE|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
214686976|NCT00372190|PROCEDURE|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
214686977|NCT01188915|PROCEDURE|intensive screening|Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed.
214686978|NCT00718419|DRUG|Enzastaurin|"Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression."
215090276|NCT02621073|DRUG|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
215090277|NCT02621073|DEVICE|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
214686979|NCT00771407|DEVICE|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
214686980|NCT00771407|OTHER|Standard ostomy creation|Ostomy will be created as routinely performed
214988113|NCT05956743|OTHER|progressive relaxation exercise sessions|"Intervention Group: A total of 6 weeks of planning will be made with the working group.~1. week: Patients included in the study group and meeting the research criteria will be informed about the research. Pre-test data forms for each patient who accepted to participate in the study, Patient Identification Form, Pittsburgh Sleep Quality Index (PUKI) within 30 minutes will be collected.~2. ,3.,4.,5. week: Patients will practice a total of 12 progressive relaxation exercise sessions for 30 minutes, 3 times a week (Monday, Wednesday, Friday) for 4 weeks, accompanied by the training booklet and music player.~6\. week: In the last week of the application, individuals will be called to the hospital and in the Diabetes Polyclinic training room. A final test will be made by the researcher. The Pittsburgh Sleep Quality Index (PUKI) will be reapplied."
214376058|NCT01751230|BEHAVIORAL|WIC E-Moms|Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
214496840|NCT06518772|OTHER|hot application|The application procedure started with the application of hot gel packets at a temperature of 40-42°C to the soles of the feet of the women in the intervention group for 20 minutes when cervical dilation reaches 5 cm.
214376059|NCT05986123|OTHER|Topical cream Z for PIH|The topical cream Z contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract. Participants will used the topical cream twice daily for 20 weeks
214376060|NCT02659787|DRUG|0.2mg Buprenorphine|Sublingual buprenorphine tablets (0.2mg)
214376061|NCT02659787|DRUG|Placebo|Placebo
214376062|NCT04860817|BIOLOGICAL|Target CD7 CAR-T cells|"Enrolled participants are allocated to one of three different dose levels of target CD7 CAR-T cells. The infusion dose of CAR-T cells will start at low dose and then rise to higher dose after completion of low dose group.~1. Dose level one: 0.6×10\^7 cells/kg;~2. Dose level two: 1×10\^7 cells/kg;~3. Dose level three: 1.5×10\^7 cells/kg. Before CAR-T infusion, all participants will receive a preconditioning therapy suggested as: Fludarabine 30 mg/m\^2×6d, Cyclophosphamide 300 mg/m\^2×6d or Cyclophosphamide 600 mg/m\^2×6d. After completion of preconditioning therapy, infusion of CAR-T cells needs to start within 1 week. Participants will receive one infusion of CAR-T cells which will take between 15 and 30 mins."
214376063|NCT00582946|DEVICE|Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
214496841|NCT01595789|DRUG|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
214686981|NCT02745223|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
214686982|NCT02745223|DRUG|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
214686983|NCT03545724|DEVICE|Neofitoroid®|NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
214686984|NCT00000567|PROCEDURE|high-frequency ventilation|
214686985|NCT03095924|OTHER|News items with spin|Interpretation of news items with spin
214686986|NCT03095924|OTHER|News items without spin|Interpretation of news items without spin
214686987|NCT03432910|OTHER|CPAP Titration using a Bilevel S/T mode with minimal pressure support and background rate|The study performs within clinical routine with this exception that instead of the usually applied CPAP mode a modified BiLevel S/T mode is used. The modified BiLevel S/T mode meets the same requirements as the CPAP mode while providing the Forced Breath Technique to classify apneas as central or obstructive.
214686988|NCT04628728|OTHER|Survey based on questionnaire (self-designed)|Participants are handed a questionnaire to asses comprehension of medical content provided in the referral letters.
214686989|NCT04869579|DRUG|Selenium (as Selenious Acid)|Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.
214686990|NCT04869579|OTHER|Placebo|Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.
214686991|NCT00726323|DRUG|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
214686992|NCT02288728|PROCEDURE|Gastric tube anastomosis|"In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.~(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)"
214988114|NCT05956743|OTHER|Sham|"1\. week: After informing Sham group patients about the research at the first interview, Patient Information Form, Pittsburgh Sleep Quality Index (PUKI) will be applied.~6\. week: In the 6th week of the study, individuals will be called to the hospital and the post-test Pittsburgh Sleep Quality Index (PUKI) will be re-administered by the researcher in the diabetes outpatient training room. Since the study was terminated after the 6th week, a booklet and music player will be given to the patients. In addition, progressive relaxation exercise training will be given to the patients and the importance of using it in their lives will be explained."
214686993|NCT02288728|PROCEDURE|Double-track anastomosis|"Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).~(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)"
214988115|NCT06519630|DEVICE|Rehabotics Physiotherapy|The intervention will be consisted of sessions for participants in the intervention group which includes a repetition of each of the four Sollerman AR Games named, Wallet, Key, Jar, Screwdriver and one repetition of Balloon Pop. Participants will interact with the AR Box and Block Test (BBT) and the serious games under controlled conditions. A clinician will be present throughout the whole session providing help if participants encounter any difficulties. Following the games, the clinician will initiate a stretching program using the Active Exoskeletal Aid, performing 3 sets of 10 repetitions on the finger flexors of the patient's hand. Each rehabilitation session will last 30 minutes and will be conducted three times a week. Similarly, the traditional physiotherapy training program will be prescribed for the control group and will be consisted of sessions lasting 30 minutes per day, three days per week. Both programs duration will be five weeks.
214686994|NCT02793908|DRUG|Pleyris|Luteal phase will be supplemented starting by the ovulation day for 14 days
214686995|NCT02793908|DRUG|Crinone8|Luteal phase will be supplemented starting by the ovulation day for 14 days
214988116|NCT06519630|OTHER|Traditional Physiotherapy|Similarly, the hand functional training program prescribed for the control group consisted of sessions lasting 30 minutes per day, three days per week. Both programs lasted for five weeks and were designed by two clinical experts.
214686996|NCT03764215|DRUG|Nilotinib 150 MG|10 participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
214686997|NCT05314166|OTHER|meditation practice|Description: meditation practice
214686998|NCT04200170|DEVICE|Rose|Rose is a patient-centric, mobile mental health platform designed for in-between clinical mental health monitoring in form of mood tracking, clinical surveys and daily journaling. Rose is used as a participant-facing mobile app and clinician-facing dashboard. Each day, they complete mood and anxiety scales and update their journals. Biweekly, they are also asked to complete the PHQ-9 and GAD-7 assessments as well. The Rose mobile app sends timely self-help articles and notifications for users. The curated insights are selected based on participant responses to the daily mood and anxiety surveys, as well as a built-in sentiment analysis of the journaling. The clinical dashboard is a secure, web-based portal that has a unique login for each provider. Providers have access to only their patients through the system and are able to see all the health metrics collected with the Rose mobile app and the summarized metrics produced by our models.
214686999|NCT00676273|DEVICE|TVT-Obturator (TVT-O)|sub urethral sling
214687000|NCT00676273|DEVICE|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
214687001|NCT01620385|DEVICE|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
214376064|NCT04228640|OTHER|NMN|Investigational Product
214376065|NCT04228640|OTHER|Placebo|Starch Powder
214376066|NCT02615236|DEVICE|perineal ultrasound|transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
214376067|NCT02615236|PROCEDURE|Clinical diagnosis|diagnosis of OASIS clinically
214376068|NCT02098187|DRUG|Below target dose MP-3180|MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
214376069|NCT02098187|DRUG|At target dose MP-3180|MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
214376070|NCT02098187|DRUG|2 times above target dose MP-3180|MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
214376071|NCT02098187|DRUG|4 times above target dose MP-3180|MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
214687002|NCT01984541|BIOLOGICAL|Artemisia vulgaris|Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
214687003|NCT04808154|DRUG|SNP-630|Subjects will receive one single dose of SNP-630 at Day 1. Blood and urine samples will be obtained to determine the PK of orally administered SNP-630.
214687004|NCT01477697|DIETARY_SUPPLEMENT|Omega-3|50 mg/kg per day of omega-3 fatty acids
214687005|NCT01477697|DIETARY_SUPPLEMENT|Placebo|50 mg/kg per day of placebo equivalent
214376072|NCT02098187|DEVICE|ORFM prototype|The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time. Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk. The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
214376073|NCT02098187|OTHER|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
214687006|NCT05878808|DIAGNOSTIC_TEST|Psychometric assessment|Eighty subjects diagnosed with bipolar I disorder were enrolled in this study, subjects were divided according to the presence or absence of OCD to Group A: Bipolar disorder patients with OCD (n = 26), Group B: Bipolar disorder patients without OCD (n = 54). The following scales were applied: Dimensional Yale-Brown obsessive compulsive scale (DYBOCS)- Beck scale for Suicidal ideations (BSSI) - Hamilton depression rating scale (HDRS) and Young mania rating scale (YMRS).
214687007|NCT05894278|OTHER|Prescription data collection|Prescription data collection
214687008|NCT02742870|OTHER|Correlation of MRI results with clinical characteristics of the adnexal mass|"Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.~The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up."
214687009|NCT04547738|DRUG|TB treatment according to national guidelines|National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis
214687010|NCT02216253|DRUG|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
214687011|NCT02216253|OTHER|Placebo|Placebo tablet twice a day 7 days before and after surgery
214687012|NCT01487668|BEHAVIORAL|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
214988117|NCT01334359|BEHAVIORAL|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
214988118|NCT00710658|BEHAVIORAL|WebChoice|"Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.~Patients in the control group received usual care"
214988119|NCT01129128|BIOLOGICAL|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
214988120|NCT01129128|BIOLOGICAL|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
214988121|NCT01129128|BIOLOGICAL|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
214988122|NCT04587908|DRUG|TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]|・Treatment period：oral administration for 52 weeks, BID after meal
214988123|NCT04587908|DRUG|Placebo [Ambulatory Cohort] only|"* Observation period：oral administration for 2 weeks, BID after meal~* Treatment period：oral administration for 52 weeks, BID after meal"
214988124|NCT06429709|DEVICE|Advanced Ultrasound Otoscope|The Advanced Ultrasound Otoscope is a tool for visualization of the human tympanic membrane and detection of middle ear effusion type
214988125|NCT05523596|DRUG|ICM20|small molecules
214988126|NCT05523596|DRUG|Benznidazole|small molecule
214988127|NCT06275087|DRUG|Propofol|The experimental group will not receive volatile anesthetic, instead, they will receive propofol infusion
214988128|NCT06275087|DRUG|Sevoflurane|The control group will not receive TIVA, instead, they will receive sevoflurane via inhalation
214988129|NCT05043324|DRUG|AntiCov-220|The daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time.
214376074|NCT02401464|DRUG|TAK-536 Tablet|TAK-536 10 mg tablet
214376075|NCT02401464|DRUG|TAK-536 Dry Syrup Formulation|TAK-536 dry syrup formulation
214376076|NCT02401464|DRUG|TAK-536 Ganule Formulation|TAK-536 granule formulation
214376077|NCT01646190|DIETARY_SUPPLEMENT|Preoperative Carbohydrate load|oral intake in the evening before surgery and 2-3h before intubation
214376078|NCT01646190|PROCEDURE|individualized i.v fluids therapy|by Transoesophageal aortic US-Doppler done intraoperatively
214687013|NCT04632095|PROCEDURE|Aortic valve replacement due to sternotomy|conventional surgery of aortic stenosis
214687014|NCT04632095|PROCEDURE|Aortic valve replacement due to parasternal right anterior mini-thoracotomy|surgery of aortic stenosis in minimally invasive technique
214687015|NCT01986569|DRUG|[18F]fluoroestradiol (FES)|\[18F\]FES PET/CT will be performed 90 min (± 10 min) after administration of \[18F\]FES. Patients will undergo core needle biopsy or surgery within 15 days after \[18F\]FES PET; or patients will undergo core needle biopsy within 30 days before \[18F\]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
214988130|NCT05043324|DRUG|AntiCov-220 (placebo)|The daily maintenance, AntiCov-220 (placebo) dose is to take 3 times a day, 1 tablet each time.
214988131|NCT05171686|DRUG|Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
214988132|NCT06830109|DRUG|Oxymetazoline Nasal Spray|Intra-nasal alpha-adrenergic agonist and vasoconstrictor that is available over-the-counter (OTC)
214988133|NCT06830109|DRUG|Budesonide nasal spray|Intranasal corticosteroid that is available over-the-counter (OTC)
214988134|NCT06829485|BEHAVIORAL|Community health workers (CHW)|Participants will meet with a Community Health Worker (CHW) who will help facilitate and provide personalized navigation to existing resources for addressing health challenges such as food insecurity and access to care. CHW will meet with participants in person or virtually at least three times for approximately 15-60 minutes for over the six month period
214988135|NCT06829485|BEHAVIORAL|Educational Materials|Participants will receive one time educational materials including information of existing health resources. Participants will be able to review materials at participant discretion.
214988136|NCT01911949|DRUG|Single shot femoral nerve block|Nerve block in lingual crease using ultrasound guidance
214988137|NCT06846281|DRUG|Remibrutinib oral treatment|Remibrutinib tablet taken daily
214988138|NCT06846281|DRUG|Ocrelizumab|Ocrelizumab 600mg infusion or 920mg injection
214988139|NCT06850402|DEVICE|DeepDOF Images|Women referred for consultation for cervical biopsy(ies) and/or LEEP will be recruited into the experimental group of the study.
214988140|NCT06041789|DRUG|Donepezil|10 mg tablet
214988141|NCT06041789|DRUG|Memantine|10 mg tablet
214988142|NCT06368427|DRUG|budesonide / glycopyrronium / formoterol|"Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension.~The COnCORD study is an observational study that will be conducted in a real-life setting in Romania and is not designed to evaluate medicinal products given according to a specific randomised schedule. Treatment with BGF MDI treatment prescribed as per current practice, according to the SmPC and local market reimbursement criteria"
214988143|NCT04497883|DRUG|Maribavir (400 mg)|Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
214988144|NCT04497883|DRUG|Maribavir (200 mg)|Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
214988145|NCT04497883|DRUG|Maribavir (800 mg)|Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
214988146|NCT01840111|BEHAVIORAL|Quit Smoking 6 hours|participants will quit smoking 6 hours prior to the cue-exposure sessions
214988147|NCT01840111|BEHAVIORAL|Quit Smoking 24 hours|participants will quit smoking 24 hours prior to the fMRI scan
214988148|NCT06645158|DEVICE|Transcutaneous bilirubin level monitoring|self-monitoring by parents long-term: from birth to 30 days of age
214376079|NCT01646190|BEHAVIORAL|Fasting state after midnight|No preoperative glucose load
214376080|NCT01646190|BEHAVIORAL|No Nasogastric tube postoperatively|Withdrawal after complete awakening in operating room
214376081|NCT01646190|BEHAVIORAL|urinary catheter removal|at POD 1
214376082|NCT01646190|BEHAVIORAL|Oral liquids|0.3-0.5L oral liquids at 6h postoperatively on POD 0
214376083|NCT01646190|BEHAVIORAL|Stimulation of inspirex utilization|using 6-8 times/day to prevent pulmonary atelectasis
214376084|NCT01646190|BEHAVIORAL|Mobilization|First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), \>4h out of bed on POD1, \>6h on POD2, complete at POD3
214376085|NCT01646190|OTHER|Preanesthetic medication|Preanesthetic oral medication before surgery
214376086|NCT03611504|DEVICE|Hemospray®|Hemospray® application
214376087|NCT00864708|DEVICE|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
214376088|NCT04713267|DEVICE|ISABel Bed 1|During the intervention nights (2 out of 3 experiment nights), positional therapy by means of the automated bed will be applied in order to induce a change in the sleeping position.
214376089|NCT00489710|DRUG|talabostat mesylate|
214376090|NCT00489710|BIOLOGICAL|enzyme inhibitor therapy|
214376091|NCT00489710|DIAGNOSTIC_TEST|flow cytometry|
214376092|NCT00489710|DIAGNOSTIC_TEST|laboratory biomarker analysis|
214376093|NCT00489710|BIOLOGICAL|non-specific immune-modulator therapy|
214687016|NCT03000309|DRUG|Apremilast|
214988149|NCT05530694|BEHAVIORAL|Clinician communication training|The clinician training is a generic, skills- and attitude-based approach for clinicians to acknowledge their decision making conversations with patients that 1) there is more than one option, and 2) patient's views matter in deciding what to do next. This tools-free approach can be used on the spot when needed and is termed fostering choice awareness (FCA). The one-hour training consists of 4 parts: 1) a knowledge session on evidence and guidelines on effective conversations and SDM, 2) video-review of behaviors which foster or hinder choice awareness, 3) clinical simulations in which clinicians practice fostering choice awareness behaviors, and 4) a reminder card for use in future clinic visits. Video clips will be of patient-clinician conversations around treatment decision making to prompt and probe clinicians' experiences, improve understanding, and improve practice.
214988150|NCT05530694|BEHAVIORAL|Patient activation|"The patient activation component consists of three questions patients can ask their clinician to help them become more involved: 1. What are my options?; 2. What are the possible benefits and harms of those options?; 3. How likely are each of those benefits and harms to happen to me? These questions have been used in studies to promote improved communication in a number of conditions including cardiovascular disease, cancer, and women's health."
214376094|NCT02877030|OTHER|Video game|The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
214687017|NCT05081648|PROCEDURE|CT MuST|Multiple Single Cannulation Technique (MuST): Experimental technique
214988151|NCT05530694|BEHAVIORAL|RA Medication summary guide and RA Choice|RA Choice presents information on FDA-approved RA treatments in a set of cards, which can be used alone or in combination based on a patient's preference, values, and the clinician's experience. The RA medication summary guide describes options for medication, physical therapy, occupational therapy, and ways to stay healthy with diet and exercise. Tool development followed key principles of creating low literacy materials that featured icons, short phrases written in plain language, and included topics of interest to RA patients faced with a medication decision. For the proposed study, we will include a paper-based version of the tool, or a web-based version available for telephone or VA Video Connect (VVC) visits. The tools will be updated to include new FDA-approved therapies (e.g., JAK inhibitors).
214988152|NCT03609177|OTHER|Clinician Communication Skills Training|Communication skills training
214988153|NCT03609177|OTHER|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
214988154|NCT03609177|OTHER|Video Declarations (ViDec)|Recording of patient advance care planning videos
214376095|NCT02799186|PROCEDURE|blood sample for genetic analysis|
214376096|NCT05576532|DRUG|BCL2 Inhibitor plus IM2 regimen|oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy
214376097|NCT00695630|DRUG|Flumazenil|2 mL, 0.2 mg SM
214376098|NCT00695630|DRUG|Placebo|2 mL sterile saline SM
214376099|NCT01330316|DRUG|BI 201335|BI 201335 for 24 weeks
214988155|NCT02262832|DRUG|Metreleptin|administered subcutaneously 1-2 times/day
214988156|NCT03678025|DRUG|Abiraterone|Given PO
214988157|NCT03678025|DRUG|Bicalutamide|Given PO
214988158|NCT03678025|DRUG|Degarelix|Given via injection
214988159|NCT03678025|DRUG|Docetaxel|intravenous
214988160|NCT03678025|DRUG|Flutamide|Given PO
214988161|NCT03678025|DRUG|Goserelin Acetate|Given SC
214988162|NCT03678025|DRUG|Histrelin Acetate|Receive SC
214988163|NCT03678025|DRUG|Leuprolide Acetate|Receive SC or IM
214988164|NCT03678025|DRUG|Nilutamide|Given PO
214988165|NCT03678025|PROCEDURE|Orchiectomy|Undergo bilateral orchiectomy
214988166|NCT03678025|DRUG|Prednisone|Given PO
214988167|NCT03678025|OTHER|Quality-of-Life Assessment|Ancillary studies
214988168|NCT03678025|RADIATION|Radiation Therapy|Standard radiation
214988169|NCT03678025|PROCEDURE|Radical Prostatectomy|Standard surgery
214988170|NCT03678025|DRUG|Triptorelin|injection
214988171|NCT05084495|DIAGNOSTIC_TEST|Global peak atrial longitudinal strain and ECG|During the follow-up period the patient will have four clinical visits, during which clinical data, advanced echocardiographic data (strain and speckle tracking) and ECGs (Glasgow criteria) will be collected
214988172|NCT06423716|DRUG|Duloxetine|60mg duloxetine given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
214376100|NCT01330316|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
214687018|NCT05081648|PROCEDURE|Rope-ladder cannulation technique|Standard cannulation technique( Rope-ladder)
214687019|NCT03221322|BEHAVIORAL|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
214687020|NCT06523452|OTHER|Laser Speckle Imaging|At least three scans (four for skin sparing mastectomy) will be performed on participants randomised to the LSI Assisted Group. Further scans may be taken at the discretion of the surgeon.
214988173|NCT06423716|DRUG|Placebo|Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
214988174|NCT02974582|BEHAVIORAL|Exposure to smoking advertising with coupon|Direct mail marketing of smoking advertising with discount coupon
214988175|NCT02974582|BEHAVIORAL|Exposure to smoking advertising without coupons|Direct mail marketing of smoking advertising without discount coupon
214988176|NCT02974582|BEHAVIORAL|Exposure to non health related images|Control group
214988177|NCT00455871|DRUG|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
214988178|NCT00455871|DRUG|Lucentis|Lucentis intravitreal injection
214988179|NCT04157179|OTHER|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
214988180|NCT05722015|BIOLOGICAL|Pembrolizumab Formulated with Berahyaluronidase Alfa|Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
214988181|NCT05722015|DRUG|Pemetrexed|Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
214988182|NCT05722015|DRUG|Cisplatin|Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
214988183|NCT05722015|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
214988184|NCT05722015|DRUG|Paclitaxel|Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
214988185|NCT05722015|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
214988186|NCT05722015|BIOLOGICAL|Pembrolizumab|Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
214988187|NCT05722015|DRUG|Filgrastim|Filgrastim will be administered as per the schedule specified for the arm.
214988188|NCT05722015|DRUG|Pegylated filgrastim|Pegylated filgrastim will be administered as per the schedule specified for the arm.
214988189|NCT05740618|DRUG|Mannitol Inhalant Product|A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.
214988190|NCT06237296|BIOLOGICAL|RSV/hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
214988191|NCT06237296|BIOLOGICAL|RSV/hMPV mRNA LNP 2|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
214988192|NCT06237296|BIOLOGICAL|RSV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
215090278|NCT05809804|DRUG|Esketamine|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
215090279|NCT02352636|OTHER|magnetotherapy|The magnetic pellets will contain an average of \~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
215090280|NCT02352636|DEVICE|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
215090281|NCT02352636|OTHER|Placebo|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
215090282|NCT03322813|DEVICE|ExAblate 4000 - Type 2|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection
214376101|NCT00915135|DRUG|Ramelteon and Placebo (25 possible combinations total)|"Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
215090283|NCT00408590|BIOLOGICAL|carcinoembryonic antigen-expressing measles virus|
215090284|NCT00408590|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|
215090285|NCT00408590|GENETIC|reverse transcriptase-polymerase chain reaction|
215090286|NCT00408590|OTHER|laboratory biomarker analysis|
215090287|NCT02671565|DRUG|Hyaluronic Acid injections|
215090288|NCT03300297|OTHER|Cervical Spine Thrust Joint Manipulation|High velocity, short amplitude thrust to the cervical spine
215090289|NCT03300297|OTHER|Cervical Spine Sham Manipulation|Manipulative hold position shy of end range without a thrust
215090290|NCT03300297|OTHER|Home Program|therapeutic exercise program and education
215090291|NCT03300297|OTHER|Suboccipital Release|suboccipital soft tissue mobilization
215090292|NCT01180608|OTHER|MR Spectroscopy|"During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)"
214376102|NCT03516643|OTHER|Extracorporeal Shockwave Myocardial Revascularization|extracorporeal shockwave in ischemic area evaluated by SPECT
214376103|NCT01494155|DRUG|Capecitabine|825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
214376104|NCT01494155|DRUG|Hydroxychloroquine|400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
214376105|NCT01494155|RADIATION|Proton or Photon Radiation Therapy|Daily, beginning Week 2 for 5 consecutive days
214988193|NCT06237296|BIOLOGICAL|hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
214988194|NCT04058717|OTHER|Normal Nicotine Content research cigarettes|Research cigarettes with 11.6 mg nicotine/cigarette.
214988195|NCT04058717|OTHER|High Nicotine e-cigarette|E-cigarette containing high nicotine e-liquid
214988196|NCT04058717|OTHER|Very Low Nicotine Content research cigarettes|Research cigarettes with 0.2 mg nicotine/cigarette.
214988197|NCT04058717|OTHER|Zero Nicotine e-cigarette|E-cigarette containing zero nicotine e-liquid
215090293|NCT00473603|DRUG|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
215090294|NCT03633669|DIAGNOSTIC_TEST|Fecal calprotectin|Testing every 3 months
215090295|NCT03633669|OTHER|Routine care|As per treating gastroenterologist
215090296|NCT01534949|BIOLOGICAL|rituximab|375 mg/m2 by intravenous \[IV\] infusion
215090297|NCT05477199|OTHER|Cognitive behavioral principles-based treatment program|The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.
215090298|NCT05477199|OTHER|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
214376106|NCT01848379|PROCEDURE|ADT+FD|
214988198|NCT04105270|DRUG|Oral Restorative Microbiota Therapy (RMT) Capsules|Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
214376107|NCT01848379|PROCEDURE|FD|
214376108|NCT02800967|DIETARY_SUPPLEMENT|Pure Aronia juice|Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml
214376109|NCT02800967|DIETARY_SUPPLEMENT|Aronia juice-based beverage|Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
214496842|NCT01595789|DRUG|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
214496843|NCT00115089|DRUG|R926112|
214988199|NCT04105270|DRUG|Durvalumab 1500 mg IV|Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab
214988200|NCT04105270|DRUG|Cisplatin/pemetrexed or Carboplatin/pemetrexed|Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W
214988201|NCT04105270|OTHER|Placebo|Sixteen doses of oral placebo capsules given weekly
214988202|NCT05638295|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214988203|NCT05638295|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214988204|NCT05638295|PROCEDURE|Computed Tomography|Undergo CT scan
214988205|NCT05638295|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214988206|NCT05638295|BIOLOGICAL|Panitumumab|Given IV
214988207|NCT05638295|DRUG|Sotorasib|Given PO
214988208|NCT05999747|DRUG|pudexacianinium chloride|Intravenous
214988209|NCT06968611|OTHER|Education/information of risk|Participant will receive a message underscoring risk of vision loss from poorly controlled DM, and how this risk can be largely eliminated with excellent compliance with mediations and clinical visits.
214988210|NCT06968611|OTHER|Free eye glasses|Participants will receive a free pair of reading glass at their first appointment
214988211|NCT04513717|DRUG|Apalutamide|Given PO
214988212|NCT04513717|DRUG|Bicalutamide|Given bicalutamide
214988213|NCT04513717|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214988214|NCT04513717|PROCEDURE|Bone Scan|Undergo bone scan
214988215|NCT04513717|DRUG|Buserelin|Given buserelin
214988216|NCT04513717|PROCEDURE|Computed Tomography|Undergo CT scan
214376110|NCT02800967|DIETARY_SUPPLEMENT|Placebo beverage|A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
214496844|NCT00115089|DRUG|Beclomethasone dipropionate|
214988217|NCT04513717|DRUG|Degarelix|Given degarelix
214988218|NCT04513717|DRUG|Flutamide|Given flutamide
214988219|NCT04513717|DRUG|Goserelin|Given goserelin
214988220|NCT04513717|DRUG|Histrelin|Given histrelin
214376111|NCT03010462|DEVICE|Nexstim NBS guided active rTMS|Nexstim NBS guided active rTMS + standardized task-oriented therapy
214376112|NCT03010462|DEVICE|Nexstim NBS guided sham rTMS|Nexstim NBS guided sham rTMS + standardized task-oriented therapy
214496845|NCT02099123|DRUG|Atorvastatin|Atorvastatin 20 mg tablet
214496846|NCT02099123|DRUG|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
214496847|NCT03477305|BEHAVIORAL|Blackberry Consumption|Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
214687021|NCT02145299|DEVICE|TruePath CTO Device|"The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions."
214687022|NCT02145299|DEVICE|CROSSER CTO Device|
214988221|NCT04513717|DRUG|Leuprolide|Given leuprolide
214988222|NCT04513717|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
214988223|NCT04513717|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214988224|NCT04513717|OTHER|Quality-of-Life Assessment|Ancillary studies
214988225|NCT04513717|OTHER|Questionnaire Administration|Ancillary studies
214988226|NCT04513717|RADIATION|Radiation Therapy|Undergo radiation therapy
214988227|NCT04513717|DRUG|Relugolix|Given relugolix
214988228|NCT04513717|DRUG|Triptorelin|Given triptorelin
214988229|NCT03068741|DRUG|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
214988230|NCT03068741|DRUG|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
214988231|NCT03068741|DRUG|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
214988232|NCT03068741|DRUG|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is \<90mmHg and continued until systolic blood pressure is \>=100mmHg.
214988233|NCT05445141|BEHAVIORAL|Little ACF [in Swedish: Lilla ABC]|Little ACF is a modified version of the program called All Children in Focus \[in Swedish: Alla Barn i Centrum (ABC)\] that originally is developed for parents with children 3-12 years of age. The content is based on positive developmental psychology and involves role plays, discussions and exercises to try at home with the child. Printed material will be provided to the parents at each meeting/session. Little ACF is offered once a week during four weeks. Each session is 60 minutes, thereafter the parents can stay in the facility for 30 minutes to continue discussing with each other.
214376113|NCT03356730|DRUG|Vitamin D|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months."
214988234|NCT05445141|BEHAVIORAL|Lectures|The lectures are pre-recorded and available during four weeks. Each lecture is 10 minutes and the content is similar to, but more superficial than, the content in Little ACF.
214988235|NCT04604522|PROCEDURE|Biospecimen Collection|Undergo collection of blood, airway brushings.
214376114|NCT03356730|OTHER|Placebo|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo.~Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows:~• 10 drops per day for two months."
214988236|NCT04604522|OTHER|Medical Chart Review|Patients' medical records are reviewed
214988237|NCT05445843|DRUG|JDQ443|JDQ443 per os (PO) 200 mg twice a day continuously
214988238|NCT06334198|DRUG|Naldemedine|Naldemedine is administered orally once daily in the morning in a dosage of 0.2 mg.
215090299|NCT05607329|PROCEDURE|Secondary cytoreduction|Open surgery is conducted by senior clinicians in gynecological oncology. Operation time，location and number of relapsed lesions, location and number of excised lesions, Whether achieved R0 or not, and other information are recorded.
215090300|NCT05607329|DRUG|Chemotherapy|chemotherapy
215090301|NCT03648216|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
215090302|NCT00142623|BEHAVIORAL|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
215090303|NCT02038660|DEVICE|Balloon angioplasty|
215090304|NCT02430324|OTHER|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
215090305|NCT01440881|DRUG|Nesiritide|infuses at 0.01MCG/KG/min for 48 hours
215090306|NCT01440881|DRUG|Placebo|infuses at 0.01MCG/KG/min for 48 hours
215090307|NCT02035722|BEHAVIORAL|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
215090308|NCT02035722|BEHAVIORAL|Video|AMD-related information is presented as in the form of a video
214988239|NCT06334198|DRUG|Placebo|Placebo is administered orally once daily in the morning.
214988240|NCT06334198|DRUG|Tramadol|In both arms, tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200mg).
214988241|NCT05388656|DRUG|Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release|0.1 mg/day transdermal patch administered for 3 weeks
214988242|NCT05388656|DRUG|Placebo|Estradiol-matched placebo patch administered for 3 weeks
215090309|NCT05059964|OTHER|Circuit Training program|"The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs"
215090310|NCT05059964|OTHER|Continuous aerobic exercise Group|Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
215090311|NCT02426151|DRUG|BEPO-A|BEPO-A (Bioreactor manufacturing process)
214376115|NCT02207725|BIOLOGICAL|Andexanet|
214376116|NCT02207725|OTHER|Placebo|
215090312|NCT02426151|DRUG|REPO-A|REPO-A (Roller bottle manufacturing process)
215090313|NCT03474081|DRUG|FF/UMEC/VI|A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
214376117|NCT04911309|OTHER|functional exercise training|12 weeks functional exercise training twice per week, each session lasting 60 min
214376118|NCT04911309|OTHER|standard therapy / treatment|12 weeks standard therapy / treatment
214376119|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free
214376120|NCT03145766|BIOLOGICAL|VRVg 1|Initial formulation of Purified Vero Rabies Vaccine Serum Free
214376121|NCT03145766|BIOLOGICAL|Imovax Rabies|Purified inactivated rabies vaccine prepared on human diploid cell cultures
214376122|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free
214988243|NCT05388656|DRUG|Progesterone 200 mg|200 mg tablet administered by mouth once per day for 10 days after completion of the experimental phase of the study
214988244|NCT06933069|DRUG|CMAB017|CMAB017 was administered at a preset dose, and body weight was measured before each study dose; if body weight changed ≥10% from baseline, the dose should be recalculated. Administration was by intravenous infusion: for doses ≤1000 mg, intravenous infusion lasted 60±5 min; for doses \>1000 mg, intravenous infusion lasted 90±5 min.
215090314|NCT03474081|DRUG|Tiotropium|Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
215090315|NCT03474081|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
215090316|NCT03474081|DRUG|Placebo to match FF/UMEC/VI|Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
215090317|NCT03474081|DRUG|Placebo to match tiotropium|Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
215090318|NCT03474081|DEVICE|ELLIPTA inhaler|ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.
215090319|NCT03474081|DEVICE|HANDIHALER|Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.
215090320|NCT03474081|DEVICE|MDI|Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
215090321|NCT03315169|OTHER|External dressing|Application of external dressing whilst perianal abscess cavity heals.
214988245|NCT04140409|DRUG|Sandostatin|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
214376123|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free
214988246|NCT00713804|BEHAVIORAL|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
214988247|NCT00713804|BEHAVIORAL|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
214376124|NCT03145766|BIOLOGICAL|Human Rabies Immunoglobulins (HRIG)|Commercialized formulation of HRIG
214376125|NCT00431184|DRUG|Pentazocine|see arms description
214376126|NCT00431184|DRUG|Lorazepam|see arms description
214376127|NCT05083143|BEHAVIORAL|COVID-19 pandemic|Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
214376128|NCT01391325|DRUG|Allopurinol|Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
214496848|NCT05783791|DIAGNOSTIC_TEST|Newborn Screening Assay|"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."
215090322|NCT03315169|OTHER|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity - standard treatment.
215090323|NCT02955680|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
215090324|NCT02955680|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
215090325|NCT00693654|DRUG|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (\&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
215090326|NCT00693654|DRUG|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
215090327|NCT01805388|DRUG|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
215090328|NCT01805388|PROCEDURE|Control Non-Study Drug Group|Endodontic RTC with no study drug
215090329|NCT06108843|OTHER|Myofascial Arm Pull and Active Release Technique|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
215090330|NCT06108843|OTHER|Myofacial Arm Pull|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
215090331|NCT00320138|PROCEDURE|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
215090332|NCT03364972|DEVICE|Cataract surgery|Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
215090333|NCT03705975|OTHER|Manual treatment|Scapula mobilization, glenohumeral joint mobilization
215090334|NCT05053412|DIAGNOSTIC_TEST|Helio Liver Test|A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
214376129|NCT00171639|DRUG|zoledronic acid|
214376130|NCT03831984|DRUG|0,09% Bromfenac|topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
214376131|NCT03831984|DRUG|0,1% sodium hyaluronate|topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
214376132|NCT02731625|OTHER|Kettlebell training|Kettlebell training will be performed in 30 second work:rest intervals. Total training time will progress from 10 minutes at the beginning of the study to 20 minutes at the end.
214376133|NCT02731625|OTHER|Army Physical Readiness Training|Army Physical Readiness Training per Army Field Manual 7-22
214376134|NCT04382703|BEHAVIORAL|Self-Affirmation Exercise|"The self affirming exercise is as follow:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines provided, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will …………………………………..~Options are as follows:~think about the things I value about myself, remember things that I have succeeded in, think about what I stand for or think about things that are important to me"
214988248|NCT00671788|DRUG|Dasatinib|Given orally
214988249|NCT00671788|OTHER|Laboratory Biomarker Analysis|Correlative studies
214988250|NCT03290625|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
214376135|NCT04382703|BEHAVIORAL|Control|Given a questionnaire minus the self affirming exercise
214376136|NCT01253863|OTHER|exploration|exploration of wound for determining damaged tissue
214496849|NCT00909324|DRUG|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
214988251|NCT03290625|DRUG|Ketamine Hydrochloride|Dextrocetamine hydrochloride (KetaminTM), presented in a 10 mL vial containing 50 mg / mL solution for injection
214988252|NCT04331106|DIAGNOSTIC_TEST|Online Questionnaire|Online Questionnaire via SoSci Survey
214988253|NCT01832766|DRUG|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
214988254|NCT01832766|OTHER|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
214988255|NCT06283355|BIOLOGICAL|Nasal Microbiota Transplant (NMT)|nasal microbiota transplant
214988256|NCT06283355|BIOLOGICAL|Placebo|Placebo sterile swab
214988257|NCT06032806|OTHER|moderate intensity|"* Arm circles~* Leg swings~* Lunges"
214988258|NCT06032806|OTHER|High intensity|"* Arm circles~* Leg swings~* Lunges~* Butt kicks"
214988259|NCT06522113|DRUG|Cilostazol|patients were given cilostazol 100mg twice a day with aspirin
214988260|NCT06522113|DRUG|Clopidogrel|patients were given clopidogrel 75mg with aspirin
214988261|NCT00492011|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
214988262|NCT00492011|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
214988263|NCT00492011|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
214988264|NCT00492011|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
214988265|NCT02525523|DRUG|Alicaforsen|
214988266|NCT02525523|DRUG|Placebo|
214988267|NCT05446103|OTHER|Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An 40% occlusion pressure is set and subjects perform 4 sets of elbow flexion (30-15-15-15 reps) using 30% of 1 RM"
214988268|NCT05446103|OTHER|Sham Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An \<20% of occlusion pressure is set and subjects perform 4 sets of 10 reps of elbow flexion using 65% of 1 RM"
214988269|NCT06235554|PROCEDURE|Renal Stimulation|Renal Denervation procedure as per hospital routine practice
214988270|NCT03169439|PROCEDURE|Irreversible electroporation|minimal invasive ablative technique for tumors
214988271|NCT06532305|BEHAVIORAL|HOPE empowerment classes|A three-month empowerment course.
214988272|NCT01154660|OTHER|Tidal Volume|observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
214988273|NCT00960427|DRUG|systemic chemotherapy|
214988274|NCT00960427|GENETIC|RNA analysis|
214988275|NCT00960427|GENETIC|gene expression analysis|
214988276|NCT00960427|GENETIC|reverse transcriptase-polymerase chain reaction|
214988277|NCT00960427|OTHER|immunohistochemistry staining method|
214988278|NCT00960427|OTHER|laboratory biomarker analysis|
214988279|NCT00960427|PROCEDURE|endoscopic biopsy|
214988280|NCT00960427|PROCEDURE|neoadjuvant therapy|
214988281|NCT00960427|PROCEDURE|sigmoidoscopy|
214988282|NCT00960427|RADIATION|radiation therapy|
215090335|NCT02774655|DEVICE|Pai APP|prescribed 100 PAI weekly
214496850|NCT00909324|DRUG|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
214988283|NCT03702699|DEVICE|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
214988284|NCT01978756|OTHER|Outpatient clinic|The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
214988285|NCT03640819|PROCEDURE|Tattooing of biopsied node|Tattooing (marking) of biopsied node with carbon dye (SPOT dye) at the time of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
214988286|NCT01925417|BIOLOGICAL|RBX2660 (microbiota suspension)|
214988287|NCT03479905|OTHER|Salter nasal cannula|Oxygen will be delivered via standard nasal cannula during colonoscopy
214988288|NCT03479905|OTHER|Face mask|Oxygen will be delivered via face mask during colonoscopy
215090336|NCT02774655|DEVICE|FitBit APP|prescribed 10000 steps daily
215090337|NCT00862472|DRUG|DuoTrav APS|DuoTrav APS QD AM
215090338|NCT00862472|DRUG|DuoTrav|DuoTrav QD AM
214988289|NCT03479905|DEVICE|High Flow Nasal Cannula|A high flow nasal cannula will be placed on the patient at a setting of FiO2 100% and titrated up to 60L/min depending on patient tolerance. 60 L/min is the max flow rate and will be used as tolerated for maximum benefit.
214988290|NCT02057341|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
214496851|NCT02477514|DRUG|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
214988291|NCT06014645|OTHER|Rehabilitation|The study group will be given a core stabilization program in addition to education.
214988292|NCT06014645|OTHER|Control|The control group will receive post-operative cognitive training and will be encouraged to move.
214988293|NCT00720759|DRUG|D-cycloserine + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
214988294|NCT00720759|BEHAVIORAL|D-cycloserine + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
214988295|NCT00720759|DRUG|Placebo + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
214988296|NCT00720759|BEHAVIORAL|Placebo + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
214988297|NCT00439998|PROCEDURE|Ultrasound|ultrasound scan of the lumbar spine with 2-5 MHz curved array probe
214988298|NCT06308783|OTHER|Diaphragmatic Breathing|10 minutes each day during 6 weeks, before sleeping.
214988299|NCT06308783|OTHER|Global Postural Reeducation|10 minutes each day during 6 weeks, before sleeping.
214988300|NCT02880618|DEVICE|Barostim Neo™ System|
214988301|NCT00910585|BEHAVIORAL|Coaching, providing social support|Active telephone and in person coaching
214988302|NCT01047319|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
214988303|NCT02697045|DRUG|Aripiprazole 400mg LAI|Aripiprazole 400mg, IM, Once a month
214988304|NCT02837159|OTHER|mHealth application|Dietary and physical activity recommendations trough a mobile application
214988305|NCT04376567|PROCEDURE|One stage approach|Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
214988306|NCT02598661|DRUG|Imetelstat Sodium|Imetelstat sodium IV infusion.
214988307|NCT02598661|DRUG|Placebo|Imetelstat sodium-matching placebo IV infusion.
215090339|NCT01176955|BEHAVIORAL|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
215090340|NCT01176955|DRUG|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
214496852|NCT02477514|DRUG|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
214496853|NCT02477514|DRUG|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
214496854|NCT05216796|BEHAVIORAL|Diet Intervention|Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.
214988308|NCT01665742|DIETARY_SUPPLEMENT|Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene|"1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks~AND~4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks~in conjunction with a weight management programme"
214988309|NCT01665742|DIETARY_SUPPLEMENT|Placebo supplement|"1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks~AND~4 x film-coated placebo tablets daily for 8 weeks~in conjunction with a weight management programme"
214988310|NCT05923632|BEHAVIORAL|Dijital Game and Health Education|After the children in the experimental group are informed about the digital game designed according to The The Information-Motivation-Behavioral Skills Model (IMB) in diabetes management, active participation of the children in the digital game will be ensured for 9 weeks; and participation status will be followed in the background of the game. At the end of 9 weeks, children will be asked to complete all stages of the game. Children who do not complete the game will be contacted once a week in line with their background follow-up and reminders will be made.
214988311|NCT06562153|OTHER|Neuroimaging with Magnetic Resonance Imaging (MRI)|MRI will be used to observe brain states over time.
214988312|NCT03879694|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
214988313|NCT03879694|DRUG|Octreotide Acetate|Given IM
214988314|NCT03879694|BIOLOGICAL|Sargramostim|Given SC
214988315|NCT03879694|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
214988316|NCT03803137|OTHER|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry
214988317|NCT00988780|DRUG|maraviroc|"Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
214988318|NCT00988780|DRUG|Placebo|"Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
214988319|NCT05157373|DIAGNOSTIC_TEST|Endometrial sampling and Peripheral blood collection|The endometrial biopsy will be performed with a pipette. The pipelle will be inserted gently through the cervix and into the uterus. The pipelle procedure takes approximately one minute and involves gently moving the pipelle back and forth to obtain a sample. Then 10cc of peripheral blood will be collected.
215090341|NCT00402493|DRUG|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
214988320|NCT05157373|BEHAVIORAL|FSFI Scale|"The participants will fill up the Female Sexual Function Index (FSFI) questionnaire.~The FSFI is a 19-item self-report questionnaire designed to measure sexual functioning in women. It assesses six domains of sexual function: sexual desire, sexual arousal, lubrication, orgasm, satisfaction, and pain (i.e., pain associated with vaginal penetration)."
214988321|NCT05183646|DRUG|DMX-200|DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
214988322|NCT05183646|DRUG|Placebo|Patients will receive 120 mg capsules of Placebo twice daily
214988323|NCT07015541|OTHER|NMES and BFR|NMES is applied when patients perform quadriceps strengthening exercises. BFR is applied during compound exercises.
214988324|NCT07015541|OTHER|Standard physical therapy|Standard physical therapy (week 1-16) includes interventions for typical impairments following ACLR. The initial phase will focus on pain and effusion control, restoration of knee range of motion, followed by gait normalization, lower extremity strength training, then running and plyometrics.
214988325|NCT06626828|DEVICE|Electroacupuncture|Disposable sterilized needles are inserted into selected acupoints at a depth of approximately 17-25 mm and an angle of 15-30° along the scalp. Acupoints are then stimulated by the SDZ-II electroacupuncture device, with a dilatational wave pattern at 4/20 Hz. The intensity of the stimulation was adjusted to the patient\&#39;s tolerance.
214988326|NCT02416037|DEVICE|level of positive end expiratory pressure (Prone Proseva)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
214988327|NCT02416037|DEVICE|level of positive end expiratory pressure (Prone Talmor)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
214988328|NCT07022093|DEVICE|Custom made insoles|For the production of insoles using the CAD-CAM method; In the production of insoles, medial longitudinal arch support will be added so that the subtalar joints are in a neutral position, and additionally, transverse arch support between 3.5-5 mm, lateral longitudinal arch support between 4-6 mm, and finger-under supports to assist with palmar grip will be designed in three dimensions using the EasyCad modelling interface. Using a Vulcan Computer Numerical Control (CNC) milling machine, the insoles will be machined from Ethylene Vinyl Acetate (EVA) material placed in blocks. After this process, the insoles will be adjusted on the milling machine to fit the patient's shoes.For the production of insoles using the 3D printing method, the Elegoo Neptune 4 Max 3D printer will be used. Using TPU material, medial longitudinal arch support will be added, along with transverse arch support between 3.5-5 mm, lateral longitudinal arch support between 4-6 mm, and finger support to aid palmar grip.
214988329|NCT05297383|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid.|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA).
214988330|NCT05297383|DIETARY_SUPPLEMENT|Safflower Oil|4 grams safflower oil (AlaskOmega®) per day.
214988331|NCT05297383|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
214988332|NCT05297383|BEHAVIORAL|Flexibility Training|30 min of stretching 3 days/week for 6 weeks
214988333|NCT06871553|OTHER|Self management education program|"After returning home, patients will be encouraged to practice their self-management behaviors and record the behavior and data to the self-monitoring notebook.~At their next hemodialysis session, patients will bring their self-monitoring notebook, and the nurse will review the behavior and data, and offering feedback. The nurses will provide additional videos and education, and request the patients to share their experiences with other patients in the hemodialysis room. This cycle of education, self-monitoring, and feedback will continue with each hemodialysis session."
214988334|NCT07025369|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214988335|NCT07025369|PROCEDURE|Computed Tomography|Undergo PET/CT
214988336|NCT07025369|OTHER|Flotufolastat F-18 Gallium|Given flotufolastat F 18
214988337|NCT07025369|PROCEDURE|Laparoscopic Radical Prostatectomy with Robotics|Undergo robotic assisted radical prostatectomy
214988338|NCT07025369|PROCEDURE|Pelvic Lymphadenectomy|Undergo pelvic lymph node dissection
214988339|NCT07025369|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214988340|NCT07025369|DRUG|Relugolix|Given PO
214988341|NCT06701825|DRUG|Tacrolimus|"Tacrolimus at the dosage reccomended by the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing based on the subjects pharmacogenetic phenotype."
214988342|NCT06701825|DRUG|Tacrolimus|Subject allocated to this arm will receive tacrolimus according to clinical practice and the drug's product labelling. These subject will not receive a personalised dose based on their pharmacogenetic phenotype.
214988343|NCT03673644|OTHER|Questionnaires|Two questionnaires will be administered, one focusing on life space and the other focusing on low luminance.
214988344|NCT07027813|OTHER|Telemedicine|Provision of Telemedicine support to pediatric patients during ambulance transport.
214988345|NCT07027813|OTHER|Control|Provision of ambulance transport without any telemedicine support.
214988346|NCT07027345|DRUG|5% TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily to designated treatment areas for up to 4 months (Part 2 End of Study).
214988347|NCT07027345|DRUG|Topical Placebo Gel|Topical Placebo Gel is applied once-daily to designated treatment areas for up to 2 months (Part 1 End of Study).
214988348|NCT06810193|OTHER|Aerobic exercise|After the end-of-season assessments, participants in the Intervention (Exercise or Stretching) arm will be randomized to 2 weeks of daily aerobic exercise for 30 minutes or to 30-minutes of prescribed stretching.
214988349|NCT04902573|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
215090342|NCT00402493|DRUG|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
215090343|NCT00402493|DRUG|Ibuprofen|ibuprofen 200mg
215090344|NCT06105359|BEHAVIORAL|Dignity therapy|"Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session."
215090345|NCT06105359|OTHER|standardize care|Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
214376137|NCT05140291|OTHER|Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
214687023|NCT00458406|DEVICE|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months"
214687024|NCT00458406|DEVICE|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months."
214988350|NCT06705660|OTHER|WEB-based progressive relaxation training|"WEB-based progressive relaxation training will be given for 8 weeks, 2 days a week for 30-45 minutes (16 sessions), following the menstrual cycles of women. Measurements will be taken before and after (at the end of) the intervention. Measurements will be taken 4 weeks after the next menstrual cycle to ensure follow-up.~Progressive relaxation training is an easy-to-learn, non-invasive and side-effect free method. PGE beginners will be trained for at least 30 minutes and practitioners who have learned the basics of the method will be trained to introduce PGE for 15 minutes. Prior to the PGE, individuals will be informed that they should not come overly hungry or overly full (eating should be finished 2 hours before), wear loose and comfortable clothes, avoid clothes that tightly wrap the abdomen (pants, dresses, belts), remove contact lenses, glasses, jewelry and tight shoes. PGE will be administered in a quiet, comfortable and dimly lit place. Women will perform PCI in the supine posit"
214988351|NCT06705660|OTHER|The WEB-based lifestyle interventions|The WEB-based lifestyle interventions will be administered to women by monitoring their menstrual cycles for 8 weeks, with sessions held twice a week for 30-45 minutes each (totaling 16 sessions). Measurements will be taken both before the intervention and after its completion. An additional measurement will be conducted during the following menstrual cycle, 4 weeks later, to ensure follow-up.In this study, telehealth and counseling services will be provided. Through telehealth and counseling, women will have the opportunity to communicate online with healthcare professionals and receive guidance on health goals, nutrition, exercise, and stress management
214988352|NCT01366092|DRUG|Interleukin-2|Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus
214988353|NCT06715891|DRUG|Raphamin|Tablet for oral use.
214988354|NCT06715891|DRUG|Placebo|Tablet for oral use.
214988355|NCT05199285|BIOLOGICAL|Ipilimumab|Given IV
214988356|NCT05199285|BIOLOGICAL|Nivolumab|Given IV
214988357|NCT07039617|DEVICE|AIDANET + FCL|All participants will use AIDANET in fully closed loop (FCL) mode with instructions to avoid announcing meal boluses whenever possible during the four weeks.
214988358|NCT07039617|DEVICE|AIDANET + HCL|All participants will use AIDANET in hybrid closed loop (HCL) mode with instructions to announce all meal boluses using carbohydrate counting or easy bolus during the four weeks. All components of AIDANET will remain active during this phase but BPS in particular is expected to be triggered less often due to meal announcements.
214988359|NCT07039617|DEVICE|AIDANET in FCL-HCL-mixed mode|All participants will use AIDANET with instructions to choose whether to use fully closed loop (FCL) or hybrid closed loop (HCL) mode with meal announcements (carb counting or easy bolus) per their discretion each day.
214988360|NCT07039617|OTHER|Automated Insulin Delivery (AID) (usual care)|Participants will manage their diabetes as they normally do at home.
214988361|NCT06883279|OTHER|Intraplexus|The block needle will be advanced from the middle scalene muscle in a posterior-anterior direction and advanced between the C5-C6 nerve roots and the injection will be performed
214988362|NCT06883279|OTHER|Extraplexus|The block needle will first be advanced above the C5 nerve root and towards the anterior part of the brachial plexus and 10 ml of local anesthetic will be injected. Then, the needle will be withdrawn to the posterior surface of the brachial plexus and 10 ml of local anesthetic will be administered.
214988363|NCT07037875|DRUG|Linaprazan glurate 50 mg Twice Daily (BID)|"Participants in this group will receive a total daily dose of 100 mg of linaprazan glurate, administered as 50 mg in the morning and 50 mg in the evening.~In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that matches the appearance of the lansoprazole capsule. In the evening, they take another 50 mg linaprazan glurate tablet, without any additional placebo."
214988364|NCT07037875|DRUG|Linaprazan Glurate 50 mg Once Daily (QD)|"Participants in this group will receive a total daily dose of 50 mg of linaprazan glurate, taken once daily in the morning.~In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that mimics the lansoprazole capsule. In the evening, they take a placebo tablet that mimics the appearance of the linaprazan glurate tablet."
214988365|NCT07037875|DRUG|Lansoprazole 30 mg Once Daily (QD)|"Participants in this group will receive a total daily dose of 30 mg of lansoprazole, taken once daily in the morning.~In the morning, they take one 30 mg lansoprazole capsule along with a placebo tablet that mimics the linaprazan glurate tablet. In the evening, they take another placebo tablet resembling linaprazan glurate."
215090346|NCT02471768|PROCEDURE|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
214376138|NCT05140291|OTHER|Sham Dry Needling|Needle handles inside of guide tubes will be tapped in a way similar to an actual needle being set but the sham needles will be blunted.
214376139|NCT05983159|DRUG|Alpelisib|Oral alpha-specific PI3-kinase inhibitor
214376140|NCT05983159|DRUG|Mirdametinib|An investigational oral MEK inhibitor
214376141|NCT03852849|BEHAVIORAL|Personal involved intervention strategies|Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.
214687025|NCT03191656|DEVICE|IASD Implant|Implantation of the IASD device using trans-septal puncture and the IASD system
214687026|NCT01380106|DRUG|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
214687027|NCT01380106|DRUG|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
214687028|NCT00147732|RADIATION|Accelerated radiotherapy|68 Gy over 5.5 weeks
214687029|NCT00147732|RADIATION|ARCON|68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
214376142|NCT03852849|DRUG|The dosage of 400mg EFV|The dosage of 400mg EFV will be used in the antiviral therapy.
214376143|NCT03978910|OTHER|measurements of the accuracy of the reaching movements|Euclidian distance between final position and target
214376144|NCT03408275|OTHER|None - observational|None - observational
214376145|NCT03381404|DRUG|[14C] MT-8554|14-C MT-8554
214376146|NCT00529321|BIOLOGICAL|MVA-HCV (Immunotherapy)|MVA-HCV
214376147|NCT03767270|BIOLOGICAL|MRT5201|Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid with lipid-based nanoparticles
214376148|NCT03767270|OTHER|Placebo|5% dextrose in water
214376149|NCT02189902|DIETARY_SUPPLEMENT|4000 IU/d D3 over 12 weeks|
214376150|NCT02189902|DIETARY_SUPPLEMENT|7000 IU/d D3 over 12 weeks|
214376151|NCT01489644|DRUG|repaglinide|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
214376152|NCT01489644|DRUG|metformin|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
214687030|NCT05960188|BEHAVIORAL|AI Opinion|For each case, we give the radiologist a numeric score reflecting the AI's rating of the abnormality of the case.
214687031|NCT04527562|DRUG|Colchicine|Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
214687032|NCT04527562|DRUG|Placebo|Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
214988366|NCT07037082|OTHER|Self-saliva sampling|Self-saliva samples are taken every day from D1 inclusive over 1 consecutive cycle, to measure progesterone (P4) and estradiol (E2) concentrations.
214988367|NCT07037082|OTHER|Self-collection of dried blood spots|Self-blood sampling is done 5 times during the cycle to measure protéine C-Réactive (CRP) concentrations.
214988368|NCT07037082|OTHER|Wearing the connected ring|A connected ring is worn every day of the observed cycle, while maintaining lifestyle habits, to measure daily body temperature, assess heart rate variability and resting heart rate, evaluate physical activity and energy expenditure, assess stress level, and evaluate sleep quality.
214988369|NCT07037082|OTHER|Ovulation test|An ovulation test (Ovulatest®) is carried out from day 7 until a test is positive, or until day 39 if ovulation is not detected
214988370|NCT07045948|DIAGNOSTIC_TEST|Blood eosinophil Count|Blood sample for blood eosinophil count
214988371|NCT07045727|PROCEDURE|Accelerometry|Ancillary studies
214988372|NCT07045727|OTHER|Aerobic Exercise|Participate in aerobic training program
214988373|NCT07045727|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
214988374|NCT07045727|OTHER|Electronic Health Record Review|Ancillary studies
214376153|NCT01489644|DRUG|repaglinide and metformin combination tablet|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
214376154|NCT05087914|DRUG|Carbidopa-Levodopa (100mg/25mg):|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
214376155|NCT05087914|DRUG|Naproxen|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
214376156|NCT01492686|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
214376157|NCT01492686|DRUG|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
214376158|NCT01492686|DRUG|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
214376159|NCT01423214|PROCEDURE|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
214376160|NCT01423214|PROCEDURE|Laparoscopic surgery|Conventional laparoscopic procedures
214687033|NCT05566678|OTHER|Cigarette|Subjects who self-selected to continue smoking their own preferred brand of commercially available cigarettes.
214988375|NCT07045727|OTHER|Exercise Counseling|Receive health coaching check-in calls
214988376|NCT07045727|OTHER|Internet-Based Intervention|Use Connected mHealth app
214988377|NCT07045727|OTHER|Interview|Ancillary studies
214988378|NCT07045727|OTHER|Physical Performance Testing|Ancillary studies
214988379|NCT07045727|OTHER|Resistance Training|Participate in resistance training program
214988380|NCT07045727|OTHER|Survey Administration|Ancillary studies
214988381|NCT07045727|PROCEDURE|Tailored Intervention|Receive personalized exercise plan
214988382|NCT06883292|DIETARY_SUPPLEMENT|Tyrosol|phenolic compound found in olive oil
214988383|NCT06883292|DIETARY_SUPPLEMENT|Creatine|chemical produced naturally by the body used to rapidly regenerate ATP
214376161|NCT03569696|BIOLOGICAL|nivolumab|The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
214988384|NCT06883292|DIETARY_SUPPLEMENT|Resistant Dextrin|A type of soluble dietary fiber that is resistant to digestion in the small intestine. It is a byproduct of the starch hydrolysis process, where starch is broken down into smaller chains of glucose molecules
214988385|NCT07047716|DRUG|Lenacapavir Injection|Administered intramuscularly
214988386|NCT07047716|DRUG|Lenacapavir Tablet|Administered orally
214988387|NCT05554341|PROCEDURE|Biopsy Procedure|Undergo biopsy
214988388|NCT05554341|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214988389|NCT05554341|PROCEDURE|Computed Tomography|Undergo CT
214988390|NCT05554341|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214988391|NCT05554341|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO
214988392|NCT05554341|DRUG|Paclitaxel|Given IV
214988393|NCT06341205|DRUG|RiTUXimab Injection|Dose administered will depend on randomisation and for experimental Arm on the risk of having undetectable rituximab level after 3 months
214988394|NCT06745024|OTHER|Best Practice|Given SOC systemic anti-cancer therapy
214988395|NCT06745024|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214988396|NCT06745024|OTHER|Bone Metastases Treatment|Given bone modifying agent
214988397|NCT06745024|PROCEDURE|Computed Tomography|Undergo CT
214988398|NCT06745024|PROCEDURE|Conventional Radiotherapy|Undergo conventional RT
214988399|NCT06745024|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214988400|NCT06745024|OTHER|Patient Observation|Undergo SOC observation
214988401|NCT06745024|OTHER|Questionnaire Administration|Ancillary studies
214496855|NCT03575936|DEVICE|Home INR Monitoring|The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface. Pharmacists can follow up in real time if the patient forgets to self-test. An alert will also be sent to the pharmacists via email to follow up on any out of range results. This will help streamline pharmacists' workload to dedicate face-to-face time for patients that require such intervention. All home monitoring patients will be seen in clinic by the pharmacist at the end of the 3-month randomization period in order to assess compliance with meter-use and re-evaluate meter-use competency.
214496856|NCT03575936|PROCEDURE|Standard of Care|The patients in the standard of care group will have a clinic visit with the pharmacist at least once every 4 weeks or earlier, as deemed necessary by the pharmacist. The duration of the randomization period will be three months. At the end of the 3-month randomization period, patients will be provided the opportunity to cross over from the home INR monitoring group to the pharmacist-managed clinic group, or vice versa. The remainder of the study duration (post-3 month analysis) will purely be for observational purposes, in order to account for the loss of randomization and potential bias. The total duration of the study will be one year.
214988402|NCT06745024|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214988403|NCT06797635|BIOLOGICAL|Patritumab deruxtecan|Administered via IV infusion as neoadjuvant treatment
214988404|NCT06797635|BIOLOGICAL|Pembrolizumab|Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
214988405|NCT06797635|DRUG|Paclitaxel|Administered via IV infusion as neoadjuvant treatment
214988406|NCT06797635|DRUG|Carboplatin|Administered via IV infusion as neoadjuvant treatment
214988407|NCT06797635|DRUG|Doxorubicin hydrochloride|Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
214988408|NCT06797635|DRUG|Epirubicin hydrochloride|Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
214988409|NCT06797635|DRUG|Cyclophosphamide|Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
214988410|NCT06797635|DRUG|Capecitabine|Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
214988411|NCT06797635|DRUG|Olaparib|Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
214988412|NCT04983888|DRUG|Obinutuzumab|1g IV on day one and 1 g IV on day 15, followed by identical course at month 6
214988413|NCT07057388|DEVICE|continous wave compaction|post operative pain measurement using continous wave compaction
214988414|NCT06747507|DRUG|Dolutegravir Pill|Dose will be based on weight; brand names will be as supplied through the respective national programs
214988415|NCT06747507|DRUG|Darunavir+Ritonavir|Dose will be based on weight
214988416|NCT06343402|DRUG|BBO-8520|Participants will receive assigned dose of BBO-8520 orally (PO), QD
214988417|NCT06343402|DRUG|Pembrolizumab|Patients will receive IV pembrolizumab
214988418|NCT07059091|DRUG|Omalizumab (Xolair®)|The study drug (omalizumab or placebo) will be given as a subcutaneous injection, which means an injection into the fat layer just under the skin in your arm or leg. This is similar to an insulin injection and not as deep as a typical vaccine injection. After the injection, participants will be monitored for any side effects. The study team will determine the dose and how often the injection is given based on the participant's weight and blood test results. Injections will be either be given monthly, 12 doses, or twice per month, 24 doses. All injections will be given at the clinic.
214376162|NCT05561777|OTHER|Physician-targeted CDS tool for PCN allergy delabeling|This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
214687034|NCT05566678|OTHER|THS|Subjects who self-selected to quit smoking during the study duration will switch from cigarettes to using THS.
214988419|NCT07059091|DRUG|Sodium Chloride (NaCl) 0.9 %|The study drug (omalizumab or placebo) will be given as a subcutaneous injection, which means an injection into the fat layer just under the skin in your arm or leg. This is similar to an insulin injection and not as deep as a typical vaccine injection. After the injection, participants will be monitored for any side effects. The study team will determine the dose and how often the injection is given based on the participant's weight and blood test results. Injections will be either be given monthly, 12 doses, or twice per month, 24 doses. All injections will be given at the clinic.
214988420|NCT06580470|BEHAVIORAL|Tailored Cognitive Behavioral Therapy for Menopause|Cognitive Behavioral Therapy for Menopause (CBT-Meno) is an evidenced-based intervention that includes psychoeducation, cognitive, and behavioral strategies for coping with common menopause symptoms and experiences. In Aims 1 and 2, CBT-Meno materials and procedures will be tailored for women Veterans through an iterative process involving: a) data from preliminary studies and a pre-pilot trial; b) input from content area experts; and c) stakeholder advisory panels. This tailored version of CBT-Meno will then be test in this clinical trial.
214988421|NCT04386447|DRUG|Oxytocin|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
214988422|NCT04386447|DRUG|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~* Oxygen supply or non-invasive ventilation to target peripheral blood saturation \> 94%~* Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~* Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~* Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~* Prophylaxis for deep vein thrombosis~* Steroids are not routinely recommended but may be considered in selected patients."
214988423|NCT04724135|OTHER|Survey|The first part will assess the sociodemographic variables and reproductive characteristics, and the second part contain the Menopause-Specific Quality of Life (MENQOL) questionnaire The 29 questions of the MENQOL are divided into four domains: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29).
214988424|NCT02804217|OTHER|Genetic: mutation profile|
214988425|NCT03074500|DEVICE|Kinesiotaping|Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
214988426|NCT03074500|OTHER|Sham taping|Sham taping will be performed without using any technique
214988427|NCT03074500|OTHER|Exercise|Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
214376163|NCT03375476|DIAGNOSTIC_TEST|collection of cardiovascular risk scores and intraoperative cardiovascular parameters|collection of preoperative cardiovascular risk scores and intraoperative cardiovascular parameters
214376164|NCT03375476|DIAGNOSTIC_TEST|cardiac troponin assay|plasmatic concentration of high sensitive cardiac troponin will be measured at baseline and on postoperative day 1, 2 and 3
214376165|NCT03375476|DIAGNOSTIC_TEST|Electrocardiogram|12 derivations ECG will be made at baseline and on postoperative day 1, 2, and 3
214376166|NCT03244462|DRUG|BAY1834845|Single oral dose (IR \[immediate release\] tablets)
214376167|NCT03244462|DRUG|BAY1834845|I.v. infusion of \[13C6\]-labeled BAY1834845
214376168|NCT03244462|DRUG|Methotrexate|Single dose of commercially available MTX
214376169|NCT00108238|DRUG|Estradiol followed by progesterone|
214376170|NCT00108238|DRUG|Raloxifene|
214376171|NCT02612480|DRUG|ticagrelor|7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
214376172|NCT02612480|DRUG|Clopidogrel|7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
214376173|NCT02612480|DRUG|Acetylsalicylic acid lysinate|7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
214376174|NCT02612480|DRUG|Placebo|7 day treatment with placebo
214376175|NCT03215901|BEHAVIORAL|A Beautiful Future Video|Video delivering information on the longevity gains due to HIV treatment in the area.
214376176|NCT03215901|BEHAVIORAL|Active Control Video|Video on another topic.
214376177|NCT00005816|BIOLOGICAL|therapeutic autologous dendritic cells|
214376178|NCT00005816|PROCEDURE|conventional surgery|
214376179|NCT04775238|OTHER|Silver nanoparticles|AgNPs (19±5 nm)
214687035|NCT05566678|OTHER|Smoking Abstinence|Subjects who self-selected to quit smoking may be prescribed Nicotine Replacement Therapy (NRT) to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
214687036|NCT00520195|BEHAVIORAL|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
214687037|NCT06279897|OTHER|Skin Surface Rewarming|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~90°F and held here for the duration of the LBNP test.
214988428|NCT06783907|BEHAVIORAL|Non-invasive blood glucose monitoring|"Non-invasive wearable glucose monitoring device for capturing participants' blood glucose.~The intervention will include:~1. Training for self-management of diabetes and phone consultation.~2. Follow-up through phone calls or WhatsApp for hypoglycaemic or hyperglycaemic events.~3. Personalized care guided by sensor data.~The Investigator will monitor the health data from the device regularly. A mobile app will track and record compliance with blood glucose monitoring."
214988429|NCT06783907|BEHAVIORAL|Traditional blood glucose monitoring|"Traditional blood glucose monitoring~Participants will engage in traditional self-monitoring of blood glucose at home over the course of 8 weeks. They are recommended to check their blood glucose levels one to two times per week and record all results. This will allow for the collection of data using traditional monitoring methods."
214988430|NCT05881629|BEHAVIORAL|Maternal position change to side-lying lateral with peanut ball|Participants will be assisted into a position lying on their side, specifically the same side as the fetal spine diagnosed by ultrasound. An inflated peanut ball will be positioned between the legs to open the pelvis. They will be asked to maintain the position for 60 minutes.
214988431|NCT05881629|BEHAVIORAL|Free maternal position|Participants will be asked to adopt any position of their choosing and to maintain it for 60 minutes. They will be asked to not use a peanut ball during the 60 minute study period.
214988432|NCT06159582|BEHAVIORAL|eSTEP|eSTEP (Electronic Support to Engage with PrEP) is an mHealth intervention to promote engagement on the full PrEP care continuum and is tailored to the unique needs of GBMSM and TW. eSTEP is a mobile app (eSTEP) intervention with interactive components delivered before in-person HIV testing and PrEP initiation visit and interactive components delivered after PrEP is initiated.
214988433|NCT06159582|BEHAVIORAL|Usual Care|Usual HIV testing and PrEP clinical care
214988434|NCT05835999|DRUG|Everolimus 0.5 MG once per day|Everolimus is considered an mTOR kinase inhibitor
214988435|NCT05835999|DRUG|Everolimus 5 MG once per week|Everolimus is considered an mTOR kinase inhibitor
214988436|NCT05835999|DRUG|Placebo once per day|No therapeutic effect
214988437|NCT05835999|DRUG|Placebo once per week|No therapeutic effect
214988438|NCT05668273|OTHER|education with simulated patient|Students in the education with the simulated patient group will practice auscultation skills on the simulated patient with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
214988439|NCT05668273|OTHER|education with simulator|Students in the simulator group will practice auscultation skills on high fidelity simulator with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
214988440|NCT05668273|OTHER|control group|Students in the control group will practice auscultation skills on their peers with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination.
214376180|NCT04775238|OTHER|Copper nanoparticles|CuNPs (150-350 nm)
214376181|NCT01290211|DRUG|Maraviroc|maraviroc 300 mg BID x 5 days
214376182|NCT01290211|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
214376183|NCT01290211|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
214376184|NCT01290211|DRUG|Maraviroc|maraviroc 300 mg QD x 5 days
214376185|NCT01290211|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
214376186|NCT01290211|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
214376187|NCT03863522|PROCEDURE|Fine needle aspiration|Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.
214376188|NCT03863522|DEVICE|Cancer Detection cartridge|The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
214376189|NCT05857111|DEVICE|Celbrea|The test with the CELBREA® device will be added to the routine screening according to the protocols of the health facility.
214376190|NCT00032045|BIOLOGICAL|gp100 antigen|
214988441|NCT03608163|DRUG|Naloxone|Naloxone Nasal Spray
214988442|NCT03608163|DRUG|Diazoxide|Diazoxide (oral)
214988443|NCT03608163|DRUG|Placebo (for Naloxone)|Sterile water nasal spray
214988444|NCT03608163|DRUG|Placebo (for Diazoxide)|Taste matched oral placebo for diazoxide
214988445|NCT06774235|DRUG|Interferon Gamma 1-b|injection of interferon gamma 1-b
214988446|NCT06774235|DRUG|Placebo|Injection of placebo in the same condition of experimental traitment
214988447|NCT06843447|BIOLOGICAL|Raludotatug Deruxtecan|IV infusion on Day 1 of every 3-week cycle.
214988448|NCT06843447|DRUG|Carboplatin|IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
214988449|NCT06843447|DRUG|Paclitaxel|IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
214988450|NCT06843447|BIOLOGICAL|Bevacizumab|IV infusion on Day 1 of every 3-week cycle.
214376191|NCT00032045|BIOLOGICAL|incomplete Freund's adjuvant|
214376192|NCT00032045|BIOLOGICAL|ipilimumab|
214376193|NCT00304512|DRUG|migalastat HCl|
214376194|NCT00344604|BEHAVIORAL|Role of psychosocial and quality of life parameters prior to and following LASIK.|
214376195|NCT05684562|OTHER|Cardiopulmonary exercise test|CPET, the gold standard, will be used in the assessment of cardiorespiratory fitness. The cardiopulmonary exercise test system (Cosmed Quark CPET, Rome, Italy) is a safe method in which the patient can be monitored via ECG during the execution of the individual on a treadmill, and simultaneously lactate measurement, maximal O2 consumption, and CO2 production are evaluated. The Bruce protocol is the most commonly used method for KPET applied with a treadmill. However, since the Bruce protocol prefers high workload preferences, the Modified Bruce/half Bruce protocol with intermediate increments will be used. In addition, dyspnea, leg fatigue, and general fatigue at rest, during the test, and during the recovery phases after the test will be recorded with a sphygmomanometer using the Modified Borg Scale.
214376196|NCT05684562|OTHER|Pulmonary function test|Pulmonary function testing will be performed with a spirometer (Cosmed Quark CPET, Rome, Italy) connected to the CPET system using standard procedures. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be saved.
215090347|NCT05135611|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with sleep apnea,. 4-channel NMES is the protocol that provides sequential electrical stimulation to Rt. suprahyoid m (channel 1), Lt.suprahyoid m (channel 2), bilateral thyrohyoid m (channel 3), and biltateral sternothyroid m (channel 4). At this time, channels 1 and 2 start to contract first and stimulate for 1200ms, and channel 3 starts stimulation 150ms after channels 1 and 2, and applies stimulation for 1050ms. Channel 4 starts stimulation 250ms after stimulation of channels 1 and 2 and stimulates it for 950 ms.
214376197|NCT05684562|OTHER|Respiratory muscle strength test|Intraoral maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) will be used as indicators of respiratory muscle strength. A portable intraoral pressure gauge (MicroRPM, Micromedical, Kent, UK) and nose clip will be used during MIP and MEP assessments. MIP and MEP measurements will be obtained using standard procedures. 3 measurements will be made where the difference between each measurement is not more than 10% and the maximum value of MIP and MEP will be recorded.
214376198|NCT02607657|DRUG|Eplerenone 25 mg|
214496857|NCT01854151|OTHER|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
214687038|NCT06279897|OTHER|Skin Surface Warming|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~93°F and held here for the duration of the LBNP test.
214988451|NCT06771219|DRUG|SLV-154|SLV-154
214988452|NCT07070895|BEHAVIORAL|Cough Management|"CoughPro is a smartphone wellness application that uses algorithms to detect and count coughs continuously and passively (similar to a step counter, but for cough). CoughPro also includes a Cough Management (CM) component, which delivers short, structured behavioral lessons (based on BCST) designed to help users recognize their urge to cough and apply cough suppression strategies in real-world settings. The Cough Management wellness feature is the key area of investigation in this study.~The novel CM program is delivered entirely through participants' devices. The application aims to help users better understand and manage their cough by coupling real-time cough detection with self-management BCST resources:~* Reduce cough frequency (coughs per hour).~* Reduce cough intensity (as measured by cough bouts).~* Improve cough-related quality of life (as reported by patients and its correlation with cough-free time as measured objectively)."
214988453|NCT07070895|DEVICE|CoughMonitor Suite|CoughMonitor Suite's smartwatch is used in this study to continuously, automatically, and passively monitor cough frequency in a fully privacy-preserving way - no audio is recorded, stored, or synced to the cloud, and no human is in the loop.
214988454|NCT05789485|BEHAVIORAL|structured treadmill walking|Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment.
214988455|NCT06503146|DRUG|[18F]FAPI-74|Participants will receive a single intravenous (IV) dose of \[18F\]FAPI-74 prior to PET/CT imaging.
214988456|NCT06503146|DRUG|[18F]FDG|18F-FDG PET/CT or PET/MRI imaging will be done per standard of care.
214988457|NCT06469151|DRUG|AZD5148|Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus
214988458|NCT06469151|DRUG|Placebo|Participants will receive matching doses of placebo as an IM injection or IV bolus
214988459|NCT03335046|BEHAVIORAL|Home Visit|The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.
214988460|NCT03335046|BEHAVIORAL|Standard Care|Standard care will refer to the procedures carried out by the school district to address students with chronic absenteeism. This includes parent-teacher and parent-school administrator meetings and communications and may also include home visits carried out by classroom teachers or student support center staff.
214988461|NCT03857256|DRUG|CP105F|Natural Health Product
214988462|NCT03857256|DRUG|Placebo|tablet manufactured to mimic the CP105F beta-glucan
214988463|NCT07147790|DRUG|After successful revacularization, We will categorize patients into two groups : groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the woun|"After successful revacularization, We will categorize patients into two groups :~groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the wound with silver nanoparticle spray for 15 minutes (time needed for its absorption) before applying NPWT with foam soaked in silver nanoparticle spray) and group B (The patient's wounds will be cleaned and irrigated with a normal saline solution for 15 minutes before applying NPWT.). Standard NPWT setting will be used in both groups, with a continuous negative pressure range from 70 to 125 mmHg. Selection criteria for the application of VAC therapy will be presented by calcaneal, dorsal, or plantar foot ulcers with an area of 4.0 and 10.2 cm2. The NPWT dressing will be changed every 3 days. The endpoint of NPWT will be the appearance of healthy granulation tissue."
215090348|NCT01058941|DRUG|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
215090349|NCT01058941|DRUG|Placebo|Placebo LA and placebo oil capsules for 18 months
215090350|NCT02920957|DEVICE|comfilcon A|contact lens
215090351|NCT02920957|DEVICE|senofilcon C|contact lens
215090352|NCT04588155|DEVICE|Functional assessment|Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
214376199|NCT02607657|DRUG|Eplerenone 50 mg|
214376200|NCT02607657|DRUG|Eplerenone 100 mg|
214376201|NCT02607657|DRUG|Eplerenone 50 mg twice a day|
214376202|NCT02607657|DRUG|Eplerenone 25 mg twice a day|
214376203|NCT05357937|BEHAVIORAL|standard physiotherapy program|A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups
214988464|NCT07147790|DRUG|Silver Nanoparticles Irrigant|"After successful revacularization, We will categorize patients into two groups :~groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the wound with silver nanoparticle spray for 15 minutes (time needed for its absorption) before applying NPWT with foam soaked in silver nanoparticle spray) and group B (The patient's wounds will be cleaned and irrigated with a normal saline solution for 15 minutes before applying NPWT.). Standard NPWT setting will be used in both groups, with a continuous negative pressure range from 70 to 125 mmHg. Selection criteria for the application of VAC therapy will be presented by calcaneal, dorsal, or plantar foot ulcers with an area of 4.0 and 10.2 cm2. The NPWT dressing will be changed every 3 days. The endpoint of NPWT will be the appearance of healthy granulation tissue."
214988465|NCT00523211|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
214376204|NCT00706225|DRUG|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
214988466|NCT00523211|DRUG|Placebo|One tablet of placebo once daily.
214687039|NCT06279897|OTHER|Skin Surface Heating|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~95°F and held here for the duration of the LBNP test.
214988467|NCT07150078|DIAGNOSTIC_TEST|test|Descriptive tests will be applied
214988468|NCT07168512|OTHER|Exercises (Endurance and strengthening)|"Neck Strengthening and Endurance Exercises with Hot Packs~Preparation: A moist hot pack will be applied for 10-15 minutes to the cervical region before exercise to reduce stiffness and enhance tissue extensibility.~Exercise program:~Deep cervical flexor training: Chin tucks in supine and sitting, progressing to sustained isometric holds.~Extensor and scapular stabilizer training: Prone head lifts and shoulder retraction exercises with light resistance.~Endurance training: Low-load, high-repetition exercises focusing on maintaining cervical posture against gravity.~Progression: Intensity and duration will gradually increase, emphasizing endurance over maximal strength to correct postural deficits.~Frequency: 40 minutes per session, 3 times per week for 6 weeks~Rationale: The combined use of heat and targeted exercises improves neuromuscular control, enhances cervical stability, and supports better cervical curvature correction. Myofascial Release Technique"
214988469|NCT07168512|OTHER|Myofascial release technique|"Myofascial Release Technique~Target areas: Suboccipital muscles, upper trapezius, levator scapulae, and deep cervical fascia.~Method: A physiotherapist will perform gentle, sustained manual pressure and low-load, long-duration stretching on restricted cervical and upper thoracic fascia to reduce tension and improve soft tissue mobility.~Duration and frequency: Each session will include 30'to 50 minutes of myofascial release, delivered 3 times per week for the study period for 6 weeks.~Rationale: This technique aims to decrease myofascial restrictions contributing to abnormal cervical alignment and pain, thereby facilitating improved posture and muscle activation."
214988470|NCT07167914|DRUG|SFG-02|Transdermal Formulation (SFG-02)
214988471|NCT07167914|DRUG|Placebo|Transdermal Formulation (Placebo)
214988472|NCT07168941|BEHAVIORAL|KF-STRIDE|KF Stride works to improve identification (awareness) of personal character strengths and 2) express them in a socially appropriate way during a job interview
214988473|NCT07167979|BEHAVIORAL|Combining neck muscle strengthening with oculomotor saccade tasks.|"he exercise program begins at 30% of 1RM, progressing by first increasing repetitions (8-10 up to 8-12) and then intensity (+5% of 1RM). Training sessions include a 5-minute warm-up, 20 minutes of exercise, and a 5-minute cool-down, performed twice per week for 30 minutes per session.~Neck strengthening is performed using the Iron Neck, which provides constant resistance. Exercises include maintaining a neutral neck position, protraction-retraction, left-right rotation, dynamic figure-8 movements, and synchronized 360° head-body rotations. Each exercise consists of two sets of 8-12 repetitions, with 30 seconds rest between repetitions and 1 minute between sets.~After neck training, participants in the intervention group perform oculomotor saccade tasks while maintaining a neutral head position. Five visual targets appear randomly in front of the participant for 1 second each. The task lasts 40 seconds, followed by 1-2 minutes of rest, and is repeated three times."
214988474|NCT07167979|BEHAVIORAL|Neck Strengthening Only|he exercise program begins at 30% of 1RM, progressing by first increasing repetitions (8-10 up to 8-12) and then intensity (+5% of 1RM). Training sessions include a 5-minute warm-up, 20 minutes of exercise, and a 5-minute cool-down, performed twice per week for 30 minutes per session. Neck strengthening is performed using the Iron Neck, which provides constant resistance. Exercises include maintaining a neutral neck position, protraction-retraction, left-right rotation, dynamic figure-8 movements, and synchronized 360° head-body rotations. Each exercise consists of two sets of 8-12 repetitions, with 30 seconds rest between repetitions and 1 minute between sets.
214988475|NCT07168135|DRUG|propofol (drug)|Withholding the continuous propofol intravenous drip upon intubating the cecum during the colonoscopy.
214988476|NCT07167615|BEHAVIORAL|Caring Connections|Participants receive the Caring Connections intervention.
214988477|NCT07167615|BEHAVIORAL|Treatment as Usual (TAU)|Participants receive treatment as usual.
214988478|NCT07169071|OTHER|Home-based chest physiotherapy program|he program will include breathing exercises, teaching of relaxation positions, cough training, breathing control strategies, and physical activity recommendations.
214988479|NCT07169071|OTHER|Expiratory Muscle Training|Participants perform expiratory muscle training (EMT) using a threshold device at 30% of their maximum expiratory pressure (MEP). The program consists of twice daily sessions, each lasting 20 minutes, at least 5 days per week, for 8 weeks. Resistance will be increased by 10% each week, adjusted according to tolerance and the presence of any complaints for experimental group.
214376205|NCT04026165|DRUG|SEL|Tablet administered orally once daily
214376206|NCT04026165|DRUG|Placebo|Tablet administered orally once daily
214376207|NCT04384822|BEHAVIORAL|Tai Chi Group|Mind-body exercise intervention
214376208|NCT04384822|BEHAVIORAL|CBT-I Group|First-line clinically recommended non-pharmacological treatment of insomnia
214376209|NCT00817557|DRUG|Loteprednol|Anti-inflammatory
214376210|NCT00817557|OTHER|Rewetter|
214376211|NCT00675155|RADIATION|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
214376212|NCT05596513|OTHER|motor learning and occupational therapy|"1. Constraint-induced movement therapy (CIMT)~2. Hand-arm bimanual intensive training (HABIT)"
214376213|NCT05596513|OTHER|Motor Learning Approaches From Working on a Vertical Surface|"1. Ball on wall, kneel to stand~2. Kneel walk cross over~3. Vertical playground puzzles and games~4. Color on big boxes~5. Fridge magnets~6. Erasing a whiteboard or chalkboard~7. Tactile feedback from textured walls"
214376214|NCT02024035|RADIATION|Radiotherapy|
214376215|NCT04065100|DIAGNOSTIC_TEST|Sebum test|Measuring sebum in newborn
214376216|NCT05925374|BEHAVIORAL|Substance use stigma training|The intervention is an interactive professional educational training that is designed to manipulate behavioral and normative beliefs in order to address bias and alter professional practices towards patients who use drugs.
214988480|NCT07166952|DEVICE|SPRINT PNS System|This study will evaluate patient-reported outcomes, including pain and function, following standard clinical use of the SPRINT PNS System for posterior sacroiliac joint complex (PSIJC) pain.
214988481|NCT07168681|OTHER|Control group|"Active Comparator: Control group The exercise program to be implemented within the scope of the study is the SHRed (Sports Injury Prevention for the Lower Extremity, focusing on musculoskeletal and head-related injuries) neuromuscular training program. The program will be administered over six weeks, with two sessions per week.~The control group will perform the exercises under normal visual conditions. The exercise program to be implemented within the scope of the study is the SHRed (Sports Injury Prevention for the Lower Extremity, focusing on musculoskeletal and head-related injuries) neuromuscular training program. The program will be administered over six weeks, with two sessions per week. Previous research has shown that the SHRed injury prevention neuromuscular training program reduces ankle and knee injuries in youth basketball players by 36% \[35\]. The program consists of balance, agility, strength, and aerobic exercises."
214988482|NCT07169279|DRUG|Infigratinib is provided as a single dose of minitablets for oral administration|"* The initial cohort dose of infigratinib will begin at the protocol-specified starting dose, with subsequent cohort escalation based on protocol specific criteria.~* The target dose is the dose that will provide similar exposure to the dose of 0.25 mg/kg/day in participants 3 years old and older.~* The dose and number of minitablets will be calculated based on individual participant age and weight."
214988483|NCT07169279|DRUG|Infigratinib is provided as sprinkle capsules for daily oral administration|"* The cohort dose of infigratinib will be the dose identified in the Single Ascending Dose portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months."
214988484|NCT07169279|DRUG|Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration|"* The cohort dose of infigratinib or placebo will be the dose confirmed in the Phase 2 portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months."
214988485|NCT07169279|DRUG|Infigratinib is provided as sprinkle capsules for daily oral administration|"* The dose of infigratinib will be the dose confirmed in the Phase 2 portion and used in the Phase 2b portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months for the first year and every 6 months thereafter."
214988486|NCT07168278|DRUG|TNK|a dose of 0.25 mg/kg (max 25 mg) administered as a bolus
214988487|NCT07168278|DRUG|Standard medical treatment|antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.
214988488|NCT07167043|DIAGNOSTIC_TEST|AI-assisted diagnostic systems|Diagnosing neurological diseases on CT/MRI with and without AI-assisted tools
214988489|NCT07169344|RADIATION|preoperative|The radiotherapy will be delivered 2.85 Gy x 15 for both x-ray or proton radiotherapy. A comparative doseplan will decide if the patient will receive proton og x-ray radiotherapy.
214988490|NCT07169344|OTHER|Quality of life|Questionnaire
214988491|NCT07169344|OTHER|Functional outcome|Questionnaire
214988492|NCT07167381|DIAGNOSTIC_TEST|xDRIVE Tumor Profiling|Patients and physicians will receive tumor profiling data via xDRIVE Functional Precision Medicine and Artificial Intelligence analysis. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment.
214988493|NCT07168044|BEHAVIORAL|CAN-DO|usual programing offered as part of the congregate meal program plus 18 weekly group education sessions related to CVD risk reduction and nutrition.
214988494|NCT07168356|DRUG|Bepirovirsen|Bepirovirsen will be administered.
214988495|NCT07166900|PROCEDURE|Modified Thoracolumbar Interfascial Plane Block|The TLIP block, introduced as a modification of the lumbar interfascial plane block, targets the dorsal rami of the thoracolumbar nerves by injecting local anesthetic into the fascial plane between the multifidus and longissimus muscles. This technique is designed to provide analgesia to the posterior elements of the spine, which are often the primary sources of pain after laminectomy
214988496|NCT07169162|DRUG|ADZENYS XR-ODT|ADZENYS XR-ODT™ (amphetamine) is an extended-release orally disintegrating tablet approved for once-daily oral administration for the treatment of ADHD in patients 6 years and older.
214988497|NCT07169162|DRUG|Placebo Oral Tablet|Participants in this arm will be given placebo as matching ODT once daily during the double-blind treatment period.
214376217|NCT01078480|PROCEDURE|Operation using a precontoured titanium plate and screws|Operation using a precontoured titanium plate and screws
214376218|NCT01078480|PROCEDURE|Displaced midshaft fracture of the collar bone|Displaced midshaft fracture of the collar bone treated with an arm sling
214376219|NCT01448564|OTHER|Laser therapy|The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
214376220|NCT01448564|OTHER|Placebo laser therapy|The application of laser therapy will be a low intensity laser.
214376221|NCT01013610|DRUG|LNK-754|Escalating dose
214376222|NCT01013610|DRUG|Placebo|Escalating dose
214496858|NCT01089335|PROCEDURE|Histological investigation of the SN|99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
214376223|NCT03607357|DEVICE|High Flow Nasal Oxygen|The initial flow speed is set at 30L/min and increases at 5L/min in titrated type until the patient feels uncomfortable. The temperature is set at 37℃. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
214376224|NCT03607357|DEVICE|Non-invasive Ventilation|The values of initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
214988498|NCT07169539|DEVICE|SerenApp Digital Psychological Intervention|SerenApp is a co-created, personalized digital intervention designed to support the mental health of women in breast cancer follow-up or survivorship. The app includes modules targeting stress coping, anxiety, and depression, delivered via smartphone or computer. Content and functionalities were developed collaboratively with patients and healthcare professionals, ensuring usability, clinical relevance, and adherence to regulatory and ethical standards. The intervention is intended for self-guided use over eight weeks, with monitoring of engagement, completion, and user satisfaction.
214376225|NCT02255357|DRUG|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
214376226|NCT02255357|DRUG|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
214376227|NCT00804401|DRUG|Naproxen Tablets, 500 mg|
214988499|NCT07169396|OTHER|RNA extraction and gene expression|RNA extraction and gene expression
214988500|NCT07168187|OTHER|Reflexology|Reflexology, a complementary therapy rooted in ancient practices, involves applying pressure to specific points on the feet, hands, or ears thought to stimulate nerve pathways, potentially promoting relaxation and reducing stress. Evidence supporting reflexology's role in obstetrics is growing, with studies highlighting its ability to reduce anxiety, alleviate pain, and influence the duration of labor. Moreover, when reflexology was applied during the active phase of labor it was related to a significant reduction in labor pain intensity and improvements in maternal satisfaction.
214988501|NCT07169006|DRUG|Group 1|Will receive a single dose of gabapentin 300 mg preoperatively before standard general anesthesia
214988502|NCT07169006|DRUG|Group 2|will receive a placebo before standard general anesthesia
214376228|NCT05782049|OTHER|Ultrasound of the salivary glands|"Salivary gland ultrasound is, a non-invasive, non-irradiating and easily accessible examination, offers promising results for the diagnosis of primary SS. It allows the identification of changes in the homogeneity of the echostructure of the main salivary glands in the parotid and submandibular region.The patient lies on the examination table with the head slightly turned to the side opposite the gland being examined. The examination will be done on the parotid and submandibular glands on both sides.The parotid glands will be measured in length and width.The surface of the gland will be calculated: (length x width)/2.The sub-maxillary glands will be measured in length and surface.~The exam will be performed in 10 minutes."
214376229|NCT05782049|OTHER|Measurement of salivary flow|Saliva flow measurement, which consists of measuring the quantity of saliva that the patient can emit in 15 minutes
214988503|NCT07168564|DEVICE|AVA lenses|Participants are prescribed to receive AVA lenses through the AVA protocol and wear these lenses during 2 weeks.
214988504|NCT07168564|DEVICE|Standard lenses|Participants are prescribed to receive Standard lenses through the Gold standard protocol and wear these lenses during 2 weeks.
214988505|NCT07168213|DEVICE|Manual FiO2 titration with Philips oximeter (SpO2 target 90%)|FiO2 titration to reach the SpO2 target (set at 90%) with Philips oximeter
214988506|NCT07168213|DEVICE|Manual FiO2 titration with Nonin oximeter (SpO2 target 90%)|FiO2 titration to reach the SpO2 target (set at 90%) with Nonin oximeter
214988507|NCT07168213|DEVICE|Manual FiO2 titration with Philips oximeter (SpO2 target 94%)|FiO2 titration to reach the SpO2 target (set at 94%) with Philips oximeter
214988508|NCT07168213|DEVICE|Manual FiO2 titration with Nonin oximeter (SpO2 target 94%)|FiO2 titration to reach the SpO2 target (set at 94%) with Nonin oximeter
214988509|NCT07167134|RADIATION|D1-3-5 radiotherapy|23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D3, and D5
214988510|NCT07167134|RADIATION|D1-2-3 radiotherapy|23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D2, and D3
214988511|NCT07167524|BIOLOGICAL|Dosage concentration of piperacillin and tazobactam|The concentration of piperacillin and tazobactam will be quantified by liquid chromatography coupled with tandem mass spectrometry (HPLC-MS² - CIC-CRB 1404) at each of these times by transposition of the method already used in current practice.
214988512|NCT07167901|PROCEDURE|Free Gingival Graft|All patients will undergo free gingival graft surgery by the same surgeon using the same surgical protocol.
214988513|NCT07169097|BIOLOGICAL|free ceftriaxone concentration dosage|The proportion of patients with UTI for whom the time spent with a free ceftriaxone concentration above 1x MIC is 100% will be determined by calculating the ratio of the total number of patients meeting this criterion to the total number of patients included. Plasma ceftriaxone dosages will be integrated into a structural model from the scientific literature using the MonolixSuite 2023R1® package (Lixoft - Saclay) including a modeling module (Monolix) and a simulation module (Simulx). T. Individual pharmacokinetic parameters will be determined by Bayesian estimation by integrating the dosage performed in the protocol.
214988514|NCT07169292|PROCEDURE|Wet-cupping|"The intervention consists of three sessions of wet cupping therapy (Hijama), administered once every month over three consecutive months. This study's protocol is distinguished by its standardized, medically supervised approach, designed to align traditional Hijama practices with modern clinical trial standards.~Key features that distinguish this intervention include:~Standardized Procedure: The Hijama protocol follows a detailed, consistent method including suction, superficial skin incisions, and reapplication of suction, followed by honey dressing. All sessions use disposable, single-use instruments and follow strict infection control measures.~Timing Based on Prophetic Recommendation: Cupping is performed on the 17th, 19th, or 21st day of the Islamic lunar month, which is rooted in Islamic tradition and rarely standardized in scientific studies.~Certified Practitioner and Setting: Procedures are conducted by a licensed Hijama practitioner with"
214988515|NCT07167329|DRUG|Belzutifan|Patients with Von Hippel-Lindau Syndrome presenting with lesions or neoplasms requiring treatment with oral Belzutifan.
214376230|NCT05782049|OTHER|A Schirmer test|A strip of blotting paper graduated from five to five millimeters is placed in the eye for 5 minutes, avoiding any corneal contact.
214988516|NCT07167563|OTHER|Lithium (LI) based on clinical indication|Participants have for 4 weeks a pill box registering the time for lithium intake. Weekly phone calls will assess whether patients can remember the time for lithium intake.
214988517|NCT07168005|BEHAVIORAL|Informative Video on LMWH|A short (up to 5 minutes) informative video presented to postpartum women prior to their first LMWH (Clexane) injection. The video explains the rationale, process, and safety of LMWH use for thrombopr
214376231|NCT01546792|BEHAVIORAL|Combined lifestyle intervention|Exercise training, dietary advice, behaviour change counselling
214988518|NCT07168005|BEHAVIORAL|Standard Verbal Explanation|Participants receive the routine verbal explanation regarding postpartum LMWH (Clexane) administration, covering its purpose and method of injection
214988519|NCT07167238|BEHAVIORAL|Exercise|"Program Duration: 8 weeks Implementation: The conventional program plus supervised video game-based training sessions.~Additional Protocol: Video Game-Based Exercises~1. Breathing Labs - Breathing Games (Slovenia) Frequency: 3 days per week, on non-walking days, supervised at the hospital. Structure: 5 mini-games per session, performed sequentially.~   Exercises:~   Balloon: Weeks 1-4: Level 1; Weeks 5-8: Level 2. Focus on sustained controlled exhalation.~   Plane: Weeks 1-4: \~6 sec breath cycle; Weeks 5-8: \~8 sec breath cycle. Wolf: Weeks 1-4: Easy; Weeks 5-8: Medium. Flowers: Weeks 1-4: Sunflower module; Weeks 5-8: Rose module. Pluto: Weeks 1-4: Easy; Weeks 5-8: Medium. Intensity: Target MBS 4-6/10 for dyspnea and fatigue.~2. Nintendo Wii / Wii Fit - Functional Training Duration: \~5 minutes per game, 30-40 minutes total per session.~Games and targets:~Lower limb/aerobic: Basic Run, Basic Step, Obstacle Course, Island Cycling. Upper limb: Boxing, Canoe. Balance: Rhythm Parade."
214988520|NCT07167238|BEHAVIORAL|Exercise|"Program Duration: 8 weeks Implementation: Home-based, instructed face-to-face at baseline by a physiotherapist, supported with video materials, and monitored with regular feedback.~A) Posture + Breathing Exercises Frequency: 3 sessions per day (morning, noon, evening)~Content:~Shoulder girdle mobilization: Scapular elevation-depression, abduction-adduction (3 sets × 3 repetitions).~Stretching exercises: Shoulder, cervical, and trunk muscles; 5-second hold at end range.~Combined with breathing: Inspiration during concentric phase, expiration during eccentric phase.~B) Breathing Exercises Frequency: 3 sessions per day; 10 repetitions of each exercise per session~Content:~Pursed-Lip Breathing, Thoracic Expansion Exercises, Diaphragmatic Breathing, Breathing Control C) Walking Program Frequency: 2 days per week Duration: 30 minutes (5 min warm-up, 20 min walking, 5 min cool-down) Intensity: Self-selected pace targeting Modified Borg Scale (MBS) 4-6/10 for dyspnea."
214988521|NCT07169058|BEHAVIORAL|Vagus Nerve Fascial Mobilization|"Reference Points of the Body Regions for Mobilization~1. Occipito-Mastoid Suture (OM) The occipitomastoid suture is the cranial suture located between the occipital bone and the mastoid part of the temporal bone. The condylus squamosa mastoidea serves as the pivot point. The patient lies in the supine position while the physiotherapist sits at the head of the patient. One hand is placed under the occiput at the suture, while the other hand is placed on the mastoid portion of the temporal bone. The patient's head is turned toward the direction of mobilization, and mobilization is performed using the weight of the head (25). Each application is planned as a single repetition lasting 120 seconds.~2. Anterior Cervical Region (Triangle) Topographically, this region is located at the anterior part of the neck, extending along the seven cervical vertebrae (C1-C7). The anterior triangle is bordered superiorly by the lower margin of the mandible, laterally by the anterior median line of the s"
214988522|NCT07168993|OTHER|Standard medical treatment|Standard of care follow up per institution
214376232|NCT00099099|BEHAVIORAL|Caloric Restriction (CR)|
214988523|NCT07168993|OTHER|Standard medical treatment|SOC per institution
214376233|NCT00897130|DRUG|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
214376234|NCT02785874|DRUG|Statin|Divide HCC patients into two groups under randomization, one is with Statin and the other is without Statin to verify whether Statin could prolong disease-free survival
214376235|NCT05900856|OTHER|low caloric diet regimen|lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
214988524|NCT07168850|DEVICE|Exablate MR-guided Focused Ultrasound Pallidotomy|Active Pallidotomy
214376236|NCT05900856|DEVICE|ultrasound cavitation|patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks
214376237|NCT04496999|DRUG|HDM201|Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)
214376238|NCT04496999|DRUG|Midostaurin|Midostaurin 50mg bid d1-28 (morning, evening)
214376239|NCT04012060|PROCEDURE|Limited access aortic valve replacement.|Limited access aortic valve replacement through partial upper hemisternotomy
214376240|NCT04012060|PROCEDURE|Conventional aortic valve replacement|Aortic valve replacement through full median sternotomy
214376241|NCT04240184|OTHER|Physical workload|Cohort study - The specific study aims are to investigate 1) exposure-response associations between quantity of occupational lifting and short-term (day-to-day) changes in LBP, 2) the influence of accumulated workdays and rest days during a working week on LBP, 3) long-term association between occupational lifting exposure and LBP when assessed over 1 year, and 4) the role of psychological and social factors on the above associations.
214376242|NCT05817266|DEVICE|Field-cycling imaging (FCI)|FCI scan
214376243|NCT04338854|PROCEDURE|Restorative Treatment|9 groups were formed as 6 restorative and 3 protective applications. The restorative treatment groups included procedures with- and without-local anesthesia (LA). Procedures with LA included the groups as root canal treatment, pulpotomy, two-surface restoration and one-surface restoration. Procedures without LA included the groups as two-surface restoration and one-surface restoration. The protective application groups included the groups as fluoride application (by disposable arch tray or by cotton roll) and fissure sealant.
214376244|NCT05996666|DEVICE|Liver-cancer early detection test|Blood collection and liver-cancer early detection test
214988525|NCT07168850|DEVICE|Sham Sham Exablate MRgFUS Pallidotomy|Sham procedure. Identical setup without thermal lesioning. Participants cross over to Active Pallidotomy after 3 months.
214988526|NCT07168538|PROCEDURE|TAP Block Group|Bilateral ultrasound-guided transversus abdominis plane block performed at the end of surgery using 20 mL of 0.25% bupivacaine per side.
214376245|NCT03298282|OTHER|OCT (Optical Coherence Tomography)|Coronary images by OCT and selective CTA and FFR values will be registered.
214376246|NCT03298282|OTHER|Coronary CTA|Coronary images by OCT and Coronary CTA and FFR values will be registered.
214376247|NCT03298282|OTHER|FFR|Coronary images by OCT and selective CTA and FFR values will be registered.
214376248|NCT04105530|DEVICE|Anodal tDCS treatment|The Anodal intervention excites neuronal activity. For condition one, the anode will be attached to the left frontal region (Fp1) and the cathode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
214376249|NCT04105530|DEVICE|Cathodal tDCS treatment|The Cathodal intervention inhibits or reduces neuronal activity. We propose that the use of the cathodal tDCS to the superior temporal gyrus in survivors of childhood ALL may facilitate the inhibition of over connected motor-sensory and auditory neural networks. For condition two, the cathode will be attached to the left temporal region (T3) and the anode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
214376250|NCT04105530|DEVICE|Sham treatment|The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes. Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial.
214376251|NCT04105530|OTHER|NIH Toolbox List Sorting Working Memory Test|List Sorting is using information processing and storage. Performance tends to peak in early adulthood and then decline across the life span. This task assesses working memory and requires the participant to sequence different visually- and orally-presented stimuli. The list scoring task takes approximately 7 minutes to administer. List Sorting is scored by summing the total number of items correctly recalled and sequenced on Lists-1 and -2, which can range from 0-26.
214376252|NCT04105530|OTHER|NIH Toolbox Flanker Inhibitory Control and Attention Test|The Flanker tests inhibitory control and attention and the capacity for new learning and information processing novel situations. This performance also reaches a peak in early adulthood and tends to decline across the life span. A total of 40 trials require 4 minutes. Scoring is based on both accuracy and reaction time, which will we evaluate individually as well as in combination. The raw scores are converted to a scale score with a mean of 100 and SD of 15. Higher scores indicate higher executive function.
214376253|NCT04105530|OTHER|Grooved Peg Board Test|The Grooved Peg Board test measures visual-motor coordination and motor speed. Additionally, it is cognitively challenging and has been associated with attention, perceptual speed and non-verbal reasoning. Performance is better in the dominant/preferred hand and tends to improve in childhood and decline with advancing age. The test consists of placing metal pegs with ridges along onside in matching slots as quickly as possible. The score is the time in seconds required to compete the array with each hand. Longer times reflect worse performance. Times are compared to normative data that is organized by ethnicity, age, gender and education. The test takes approximately 5 minutes to complete.
214376254|NCT04105530|OTHER|Buschke Selective Reminding Test|This selective reminding task purports to distinguish verbal memory into short-term and long-term components. Scores are organized by short- and long-term storage and retrieval with normative scores organized by age and gender. The task requires participants to remember a list of orally-presented words and recall them with selective reminders of the words that they didn't recall. The test will last 5-10 minutes and is available in four different versions, thus reducing rehearsal effects.
214376255|NCT05526586|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
214376256|NCT05526586|OTHER|Zero Alcohol Gum Prototype|Participants will use 20 mL of Zero Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
214376257|NCT05526586|OTHER|Alcohol Gum Prototype|Participants will use 20 mL of Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
214376258|NCT05526586|OTHER|Listerine Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
214376259|NCT05526586|OTHER|5% Hydroalcohol|Participants will use 20 mL of 5% Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
214376260|NCT00518934|OTHER|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
214376261|NCT05061537|BIOLOGICAL|PF-07263689|Genetically engineered oncolytic vaccinia virus
214376262|NCT05061537|BIOLOGICAL|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2
214376263|NCT02579798|DEVICE|PEEP (positive end-expiratory pressure)|
214376264|NCT03315936|DRUG|BI 894416|powder for oral solution
214376265|NCT03315936|DRUG|Placebo|Oral solution
214376266|NCT03315936|DRUG|BI 894416|Tablet
214376267|NCT00525772|DRUG|ciclesonide|low dose- 50ug and 200ug
214376268|NCT00525772|DRUG|ciclesonide|high dose- 100ug and 400ug
214376269|NCT01457781|COMBINATION_PRODUCT|Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 1: 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L \[2440 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
214687040|NCT06279897|OTHER|Skin Surface Cooling|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will remain lowered to \~82°F for the duration of the LBNP test.
214988527|NCT07168538|PROCEDURE|Control Group|Standard ERAS-based multimodal analgesia protocol without regional block.
214988528|NCT07168980|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
215090353|NCT04588155|OTHER|Clinical assessment|"Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution"
214988529|NCT07168980|DRUG|Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
214988530|NCT07168980|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
214988531|NCT07168980|DRUG|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1
214988532|NCT07168980|DRUG|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4; Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,4(CNS2-3),8
214988533|NCT07168980|DRUG|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8
214988534|NCT07168980|DRUG|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1
214988535|NCT07167082|OTHER|Hand Grip Strength Measurement|Hand grip strength will be measured within the first 24 hours of hospitalization using a calibrated hand dynamometer. Measurements will be performed on the dominant hand, with patients seated, following standardized international procedures. Three consecutive measurements will be obtained, and the average value will be recorded. The test is non-invasive, quick, and performed by oncology clinicians trained in the protocol.
214988536|NCT07168837|DRUG|Letrozole tablets|to compare between Letrozole withncabergoline and letrozole alone in ovulation induction among PCOS female patients.
214988537|NCT07167550|DRUG|Dimephosphon®|1 g/ml, concentrate for solution for intravenous infusion
215090354|NCT00955604|DRUG|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
215090355|NCT00955604|DRUG|Group R Rasagiline|At least 2 months of rasagiline
215090356|NCT00955604|DRUG|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
215090357|NCT03712111|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
215090358|NCT03712111|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
215090359|NCT03712111|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
215090360|NCT03712111|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
215090361|NCT01274611|DRUG|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
215090362|NCT01274611|DEVICE|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
215090363|NCT03770104|PROCEDURE|ETT insertion depth using Spanish recommendations|Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
215090364|NCT03770104|PROCEDURE|ETT insertion depth using international recommendations|Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
215090365|NCT03713541|OTHER|No intervention|Survey during normal supply.
215090366|NCT04816604|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
215090367|NCT04816604|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) delivery
215090368|NCT02139904|DRUG|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
215090369|NCT02139904|OTHER|Active Symptom Control|
214687041|NCT02076256|BEHAVIORAL|The helping relationships intervention program|
214988538|NCT07167550|DRUG|Placebo|Placebo IV solution
214988539|NCT07168031|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|High definition tDCS will be applied, using a Soterix Medical device and 4x1 ring electrodes. A centre ring electrode overlying the target cortical region (left dlPFC at position F3 according to the 10-20 system) will be surrounded by four return electrodes (position F1, FC3, F5, and AF3).
214988540|NCT07168031|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|The same setup and device as in the active tDCS group will be used, but in this case stimulation will be turned off after a ramp-up phase of 30 seconds. This mimics the same sensory feeling as active tDCS.
215090370|NCT02644356|BEHAVIORAL|Online CE/CME course|Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
215090371|NCT01071616|DRUG|Cannabis Cigarette|
215090372|NCT01621867|DRUG|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
215090373|NCT01621867|DRUG|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
214376270|NCT01457781|COMBINATION_PRODUCT|Placebo delivered via INOpulse DS Device|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (Nitrogen N2, 99.999%) delivered via INOpulse DS Device and INOpulse DS nasal cannula
214376271|NCT01457781|COMBINATION_PRODUCT|Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 2: 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L \[4880 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
214376272|NCT01337557|DRUG|Bepotastine|1.5% bid
214376273|NCT04073264|PROCEDURE|monofilament|In the intervention group,monofilament absorbable suture,will be used.
214376274|NCT03912623|OTHER|SPA Treatment with therapeutic education and physical activity|3 weeks SPA Treatment plus therapeutic education plus physical activity
214376275|NCT03912623|OTHER|Week end|access to the station for a week end after maintenance of usual treatment during 6 months
214376276|NCT00896428|DRUG|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
214376277|NCT00896428|DRUG|Placebo.|1 tablet morning and evening for 12 months
214376278|NCT01674621|DRUG|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Active Patch
214376279|NCT01674621|DRUG|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Active Patch
214376280|NCT01674621|DRUG|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Active Patch
214376281|NCT01674621|DRUG|Abaloparatide Injection (80 mcg)|Abaloparatide Subcutaneous Injection
214376282|NCT01674621|DRUG|Abaloparatide Placebo|Abaloparatide Transdermal Microneedle Placebo Patch
214376283|NCT03355430|PROCEDURE|combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
214376284|NCT03355430|PROCEDURE|accelerated corneal collagen cross-linking (CXL)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
214988541|NCT07167693|DRUG|Arginine hydrochloride|Single intravenous infusion of arginine hydrochloride 30 g in 300 mL 10% solution (R-Gene® 10), administered over 30 minutes via infusion pump. Given as early as feasible after recognition of DKA and in addition to standard DKA care (fluids, insulin, electrolytes) at the treating clinician's discretion. Investigational pharmacy prepares and dispenses blinded study drug; containers are covered to mask appearance and infusion parameters match placebo. Continuous safety monitoring with prespecified stop criteria. Study blood draws at 0 (pre-infusion), 10, 30, and 90 minutes for C-peptide/glucose and amino acids; clinical labs track β-hydroxybutyrate clearance and total insulin over 24 hours.
214376285|NCT03312608|DIAGNOSTIC_TEST|Navigated transcranial magnetic stimulation|
214376286|NCT04575363|OTHER|Blood sample|Blood sample
215090374|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
214376287|NCT02566798|DRUG|Extract of grape and olive|"Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
214376288|NCT02566798|DRUG|Lactose|"Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
214376289|NCT01583439|DRUG|highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine|Atripla: one tablet administered orally once daily at bedtime, each tablet comprised of co-formulated: Efavirenz (EFV) 600mg, Emtricitabine (FTC) 200mg, Tenofovir disoproxil fumarate (TDF) 300mg(EFV/FTC/TDF). Note: the study will generally provide the fixed-dose combination Atripla, but it will also be permissible for the same drugs to be used at the same doses as individual components (or as Truvada, coformulated TDF/FTC). Other drug substitutions may be made per the protocol.
214376290|NCT00438620|BEHAVIORAL|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
214376291|NCT01859793|DRUG|sitagliptin|100 mg pill, administered once/day orally
215090375|NCT01763294|DEVICE|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
214376292|NCT01859793|DRUG|Placebo|Matching placebo in appearance given once/day orally
214376293|NCT04286126|DEVICE|Active bilateral DMPFC|Participants in this arm will receive rTMS to bilateral DMPFC. The DMPFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 100% of resting motor threshold (RMT).
214376294|NCT04286126|DEVICE|Active right-sided OFC|Participants in this arm will receive rTMS to the right OFC. The right OFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 110% of resting motor threshold (RMT).
214376295|NCT04586413|OTHER|No intervention - quality of life measure|Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months
214496859|NCT05529420|OTHER|measurement of the depth of neuromuscular blockade|time of TOF 1 measurement (= clinical effect, stimulation of the ulnar nerve - adductor pollicis muscle tension) will be documented in the CRF and if there is no need to add further doses of the muscle relaxant, TOF 2, TOF 3, TOF 4, and TOF-R ≥ 0,9 (= time to full recovery from the effect of the non-depolarizing muscle relaxant) will also be registered.
215090376|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
215090377|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
215090378|NCT01763294|DEVICE|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
215090379|NCT04721522|DIAGNOSTIC_TEST|blood sampling & ultrasound|"Blood sampling:~Serum P4 \& estradiol will be performed on the day of triggering and on the day of embryo transfer. Progesterone/ Estradiol (P4/E2) ratio will be calculated Ultrasound: On triggering day, at time of ovum pick up and on ET day, we will measure~1. Endometrial thickness~2. Endometrial pattern~3. Endometrial compaction: the difference in measurement of endometrial thickness between the day of embryo transfer and the day of triggering.~4. Junctional zone thickness~5. Uterine contraction (peristalsis).~6. Blood flow of uterine vessels: PI of the uterine arteries will be calculated also Endometrial - sub endometrial blood flow"
215090380|NCT02364440|DEVICE|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
215090381|NCT03423524|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted"
214376296|NCT02166957|PROCEDURE|Recanalization|"All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.~The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.~The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance."
214988542|NCT07167693|DRUG|Sodium Chloride 0.9%|Placebo comparator: 0.9% sodium chloride administered as a single 30-minute intravenous infusion using identical tubing, pump settings, and covered container as the active arm to preserve blinding. Initiated as early as feasible after recognition of DKA and provided in addition to standard DKA care at the treating clinician's discretion. Study assessments occur on the same schedule as the active arm (0, 10, 30, and 90 minutes) with continuous safety monitoring during and after infusion and follow-up through 90 days.
214988543|NCT07168460|BEHAVIORAL|Dog-assisted support|Children in the intervention group received dog-assisted support for 30 minutes per session, twice per week for 10-12 weeks. The process began with children meeting school dog with dog handlers either at their home or at school. During the intervention, children had physical contact with dogs as much as they wished and on consideration of dogs' welfare. The dog handler carried out some pedagogical tasks, such as children reading to the dog while the dog was next to the child or when its head was on the child's lap. The dog handler documented the process of each session in a protocol filled in after each session and observed the children on their educational tasks.
215090382|NCT04001972|BEHAVIORAL|Brief advice (AWARD model)|"Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention."
215090383|NCT04001972|DRUG|NRT-S|One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette \<30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette \>30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
214988544|NCT07168460|BEHAVIORAL|Special education teacher support|Children in the control group met special education teachers and received pedagogical tasks involving Swedish, mathematics, etc. Similar to the dog team, special education teachers documented the process and observed the performance of children's educational tasks.
215090384|NCT04001972|BEHAVIORAL|IM Apps and Chatbot|Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
215090385|NCT04001972|BEHAVIORAL|Regular SMS message|Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
215090386|NCT03449433|DRUG|LY900014|Administered SC
214376297|NCT06215651|DRUG|Cadonilimab lenvatinib|±TACE/HAIC
214988545|NCT07169370|BEHAVIORAL|SPIRIT Club CBI Pathway|A tailored, on-demand exercise and education program delivered via the SPIRIT Club virtual streaming platform. Content includes progressive adaptive workouts, safety videos, screening checkpoints, and prompts for a support person. Participants choose classes designed specifically for adults ≥9 months post-brain injury and after being placed in the appropriate archetype, complete activity surveys, and earn incentives for adherence. They are instructed on current physical activity guidelines (≥150 min moderate or ≥75 min vigorous activity per week) and to follow the CBI Pathway at their comfort level. Content was co-developed with clinical experts and survivors to ensure both usability and safety.
214988546|NCT05767359|DRUG|Ciltacabtagene Autoleucel|Genetically modified autologous T-cell immunotherapy, via intravenous infusion per protocol.
214687042|NCT03521154|DRUG|Osimertinib 80mg/40mg|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
214988547|NCT05767359|DRUG|Cyclophosphamide|Lymphodepleting conditioning regimen, nitrogen mustard-derivative, via intravenous infusion per standard care.
214988548|NCT05767359|DRUG|Fludarabine Phosphate|Lymphodepleting conditioning regimen, synthetic purine nucleoside, via intravenous infusion per standard care.
214988549|NCT01682525|OTHER|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
214988550|NCT03978767|DRUG|Ibuprofen 600 mg|NSAID pain medication to be used in the experimental bundle for postpartum analgesia
214988551|NCT03978767|DRUG|Ketorolac|NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section
214988552|NCT03978767|DRUG|Acetaminophen|Analgesic medication to be used in both treatment arms
214988553|NCT03978767|DRUG|Oxycodone|Analgesic medication to be used in both treatment arms
214988554|NCT05084456|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
214988555|NCT04898556|DRUG|Prasterone 6.5 MG|The dose to be applied will be one Intrarosa ovule (Prasterone 6.5mg) a day before going to bed for 12 weeks.
214988556|NCT04898556|OTHER|Placebo|Patients with a diagnosis of VVA who will not undergo treatment for 12 weeks.
214988557|NCT02953691|DRUG|Galacto-Oligosaccharide|Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
214988558|NCT02953691|DRUG|Maltodextrin (Placebo)|Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
214988559|NCT01754649|DRUG|Misoprostol|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
214988560|NCT03070652|BEHAVIORAL|NBO, Newborn behavioral observation|
214988561|NCT03070652|BEHAVIORAL|Practice as usual|
214988562|NCT01331434|DRUG|exemestane|25 mg tablet
214988563|NCT06116851|OTHER|MRI scan and laboratory visit|Prostate MRI scan is performed according to the protocol used in earlier studies (PMID 31158230). In addition to the PCa diagnostics, the scan will include abdominal imaging to body composition analysis (visceral and subcutaneous fat and psoas muscle). Baseline blood and urine samples are collected in Turku University Hospital laboratory.
214988564|NCT06116851|PROCEDURE|Prostate biopsies|The visit follows routine outpatient clinic protocol. The results from MRI and laboratory findings are discussed and the potential benefits and harms from prostate biopsies are evaluated. After a mutual decision, prostate biopsies are performed.
214988565|NCT06116851|PROCEDURE|Radical prostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Robotic assisted laparoscopic prostatectomy (RALP) is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
214988566|NCT06116851|PROCEDURE|TURP and blood, urine and tissue sampling|Baseline blood and urine samples are collected the time of surgery. TURP is performed according to normal protocol. Routine diagnostic histopathological procedures will be followed in the department of pathology. Additionally, tissue samples (a total of 10 resection chips) will be collected for study analyses. Due to the study, no additional tissue samples are removed, i.e. study samples are from the tissues removed as clinically indicated.
214988567|NCT06116851|PROCEDURE|Radical cystoprostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Radical cystoprostatectomy is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
214988568|NCT02050204|BEHAVIORAL|Intervention|The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
215090387|NCT03449433|DRUG|Insulin Lispro|Administered SC
215090388|NCT03449433|DRUG|Insulin Aspart|Administered SC
215090389|NCT03449433|DRUG|Insulin Aspart|Administered SC
215090390|NCT00099281|DRUG|YMB 1002|
214376298|NCT01735396|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
214687043|NCT03521154|DRUG|Placebo Osimertinib 80mg/40mg|"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
214687044|NCT02143362|DRUG|Anesthesia induction,propofol, remifentanil ,cisatracurium|"1. Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~2. Intermittent injection cisatracurium (0.15mg/kg).~3. A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60."
214376299|NCT04241692|DEVICE|CarnationTM Ambulatory Monitoring Sternal ECG Patch System|A newly developed cardiac rhythm monitoring system
214376300|NCT04241692|DEVICE|Conventional 24-Hour 7 Lead Holter Monitor Recorder|Traditional recordings made using a standard 24-hour Holter monitor.
214376301|NCT02006875|DEVICE|rTMS|Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
214376302|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus action observation training|Participants make an observation of actions related to the training they are going to perform before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
214376303|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus sham action observation training|Participants make a sham observation before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
214376304|NCT05565794|DRUG|Pemigatinib|Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
214376305|NCT05824390|DRUG|rituximab group|Rituximab is a human-mouse chimeric monoclonal antibody specifically targeting B cell surface antigen CD20. CD20 may act as a calcium channel to play a certain signal role and participate in the regulation of B cell maturation and differentiation. Once combined with CD20, RTX consumed CD20 + B fines through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis. Recent studies have shown that B cell depletion therapy has a certain effect on many autoantibodies-mediated kidney diseases ( such as membranous nephropathy, lupus nephritis, etc. ). Therefore, rituximab combined with CD20 antigen on the surface of B cells can exhaust B cells that produce antibodies and play a therapeutic role by reducing antibody production, so this therapy also has potential therapeutic value for IgAN patients.
214988569|NCT02930447|DEVICE|Autologous glue|Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
214988570|NCT01111669|DRUG|Tranexamic Acid|The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
214988571|NCT01111669|DRUG|Normal Saline (placebo)|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
214988572|NCT02634463|DRUG|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
214988573|NCT02634463|OTHER|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
214988574|NCT02634463|DRUG|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent \[eq.\] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
214988575|NCT02634463|DRUG|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
214988576|NCT00359684|DRUG|Cysteamine|Cystine-depleting agent
214988577|NCT04955691|OTHER|low carbohydrate diet|Participants will engage in a diet that limits carbohydrate intake to 15% of total daily calories for 2 weeks.
214988578|NCT04955691|OTHER|standard carbohydrate diet|Participants will engage in a diet that recommends standard carbohydrate intake with respect to total daily calories for 2 weeks.
214988579|NCT05084404|DRUG|Experimental: 4 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
214988580|NCT05084404|DRUG|Experimental: 8 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
215090391|NCT02320344|BEHAVIORAL|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
215090392|NCT05433740|DEVICE|Proseal Laryngeal mask fixation|fixation with Proseal Laryngeal mask adjustable ligament
215090393|NCT04445376|OTHER|Physical Exercises|Aerobic Training and Breathing Exercises.
215090394|NCT02534662|DEVICE|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
215090395|NCT01557881|DEVICE|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center \[SCC\] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
214376306|NCT03988582|BIOLOGICAL|EBV-specific T-cells|During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
214376307|NCT01148862|DEVICE|The MiniMed Paradigm® X54 System|"The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends."
214376308|NCT01478074|DRUG|G-CSF|5 mcg/kg daily from day -7 until post-nadir ANC \> 1000
214376309|NCT01478074|DRUG|Cytarabine|2 g/m2 daily from day -6 through -2
214496860|NCT04845386|DEVICE|TOF Cuff on arm|The TOF Cuff will be installed on one arm in opposite of TOF Scan. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
214496861|NCT04845386|DEVICE|TOF Cuff on lower leg|The TOF Cuff will be installed on one lower leg. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
214687045|NCT02143362|DRUG|Anesthesia maintenance , propofol,remifentanil,cisatracurium|"1. Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~2. Target Controlled Infusion remifentanil , targeted plasma concentrations are 3\~6ng/ml ,maintain heart rate to 60\~100 beats per minute and mean blood pressure to 70\~105 mmHg.~3. Intermittent injection cisatracurium (0.05mg/kg)."
214988581|NCT05335161|DEVICE|Home-based leg heat therapy|The Aquilo system consists of a garment that contains an inner water-circulating pad that is compressed by air bladders. The volume of air inflating the air bladders is pressure-controlled so the garment automatically adjusts to the shape and size of all legs. The touch screen console contains pre-programmed settings for ease of use. After baseline characteristics are established, patients will be provided with the Aquilo device and will be instructed on how to operate the equipment and how to rapidly remove the system if the alarm sounds or if they have any unusual feeling. Patients in both groups will also receive a logbook to record their sessions. Patients will undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. Water at 42ºC will be perfused through the water-circulating garment for 90 min, with the goal of increasing skin temperature in the calf to \~37ºC.
214988582|NCT02709902|DRUG|Adapalene/BP gel, 0.3%/2.5%|Gel
214988583|NCT02709902|DRUG|EPIDUO® FORTE|Gel
214988584|NCT02709902|DRUG|Placebo|Gel
214988585|NCT03344393|DRUG|Ketamine Hydrochloride|intravenous ketamine infusion intraoperatively
214496862|NCT04845386|DEVICE|TOF Scan on toe|The TOF Scan will be installed on hallux . After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
214988586|NCT03344393|DRUG|Normal saline|intravenous normal saline infusion intraoperatively
215090396|NCT05113667|OTHER|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program|Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
215090397|NCT01958892|PROCEDURE|TURP, TUERP|
215090398|NCT02739321|DEVICE|Sound to Sleep System|Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
215090399|NCT02994693|DEVICE|OFDI capsule imaging|Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
214376310|NCT01478074|DRUG|Fludarabine|30 mg/m2 daily from day -6 through -2
214376311|NCT01478074|BIOLOGICAL|Donor Natural Killer (NK) cells|Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10\^6 cells/Kg
214376312|NCT01478074|BIOLOGICAL|ALT-801|0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
214496863|NCT04845386|DEVICE|TOF Scan on adductor pollicis|The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
214496864|NCT04845386|DEVICE|TOF Scan on corrugator supercilii|The TOF Scan will be installed on corrugator supercilii. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
214496865|NCT04244058|DRUG|Amantadine + L-DOPA|Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg
214496866|NCT04244058|DRUG|NMDA blocker|NMDA blocker
214496867|NCT05769244|OTHER|near-infrared spectroscopy (NIRS)|NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
214496868|NCT03717467|DRUG|isotonic saline|100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
214496869|NCT03717467|DRUG|Magnesium Sulfate|40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
214988587|NCT03997305|DEVICE|AltaValve|Transcatheter Mitral Valve Replacement
214988588|NCT06832878|DRUG|Oral Tranexamic Acid|Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3
214376313|NCT06051487|OTHER|titanium dioxide nanoparticles in test group|Titanium dioxide nanoparticles added to acrylic baseplate in test group
214376314|NCT02474290|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
214376315|NCT00869882|PROCEDURE|Circumferential arthrodesis|"Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI."
214496870|NCT01237067|DRUG|Carboplatin|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
214496871|NCT01237067|DRUG|Olaparib|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
214496872|NCT04124432|DRUG|Cannabis|Cannabis will be smoked
214496873|NCT04124432|DRUG|Nicotine|Nicotine will be smoked or vaporized
214496874|NCT02311452|DEVICE|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
214496875|NCT00523419|DRUG|Pemetrexed|500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
214496876|NCT05719519|PROCEDURE|Initial periodontal therapy and 3D intraoral scanning|Initial periodontal therapy using GBT ( guided biofilm therapy) principle and 3D intraoral scanning
214496877|NCT02876016|DEVICE|functional MRI|locate the cerebral bases in functional imaging
214687046|NCT02143362|PROCEDURE|Awaken test|"1. Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~2. In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~3. Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~4. Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~5. Patients will receive initial anesthesia after finish awaken test."
214687047|NCT03747224|DRUG|ARO-ANG3|single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections
214988589|NCT06833788|DRUG|Ferric carboxymaltose IV|Single dose of Ferric carboxymaltose 1000 mg (20mL) IV infusion (20ml vial of 1000mg iron or two 10ml vials of 500mg)
214496878|NCT02379260|OTHER|Interview with a sociologist|
214988590|NCT06833788|DRUG|TIMOFÉROL®|100 mg once a day (2 pills of TIMOFÉROL® 50mg)
214988591|NCT04097561|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
214988592|NCT03990428|BEHAVIORAL|online surveys|Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
214988593|NCT03244995|PROCEDURE|Mind-Body Intervention Procedure|Undergo CBMB program
214988594|NCT03244995|OTHER|Quality-of-Life Assessment|Ancillary studies
214988595|NCT03244995|OTHER|Questionnaire Administration|Ancillary studies
214988596|NCT03166709|BEHAVIORAL|Preventing Addiction Related Suicide (PARS)|PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal
214988597|NCT03166709|BEHAVIORAL|Intensive Outpatient Program standard session|Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
215090400|NCT01711866|DRUG|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
215090401|NCT01359462|DRUG|tolvaptan|"Drug: tolvaptan~tablet, 15mg, Qd, for 7 days."
214496879|NCT06054841|BEHAVIORAL|Postpartum follow up card|The intervention will consist of a card given to patients at time of discharge. One side of the card will list the patient's name and a list of recommended postpartum follow-up appointments based on their diagnoses at the time of discharge. The back of the card will list relevant phone numbers to assist patients with scheduling.
214496880|NCT06054841|OTHER|Control|No deviation from standard discharge education
214687048|NCT03747224|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
214687049|NCT00376597|OTHER|quality of life assessment|Ancillary studies
214687050|NCT00376597|OTHER|educational intervention|Receive lymphedema educational materials
214687051|NCT00376597|PROCEDURE|Physical therapy|Complete physical therapy-focused intervention
214687052|NCT02857855|PROCEDURE|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
214988598|NCT04254263|DRUG|pyrotinib|pyrotinib 400 mg, orally once daily for one year
215090402|NCT01256762|DRUG|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
214988599|NCT04235764|DEVICE|modified resectoscope|The modified resectoscope will be used post cystectomy (En-bloc TURBT) to resect areas of the tumor from the cystectomy specimen. These resected tumors will be sent for histopathology to assess the size of resection, depth of resection, and ability to ascertain tumor orientation and compared to the remainder of the cystectomy specimens to see if the modified resectoscope can provide improved pathologic standards for the TURBT procedure.
214376316|NCT00869882|PROCEDURE|Posterolateral fusion with instrumentation|"Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~* Central stenosis: decompression is performed including medial facectomy, laminectomy;~* Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~* Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed."
214376317|NCT02939300|DRUG|Nivolumab|"* Melanoma:~  \- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.~* Non-small Cell Lung Cancer / Head and Neck Cancer:~  \- Combination therapy with Nivolumab 3 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  \- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 240 mg per cycle.~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Nivolumab 3 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle."
214376318|NCT02939300|DRUG|Ipilimumab|"* Non-small Cell Lung Cancer / Head and Neck Cancer:~  \- Combination therapy with Ipilimumab 1 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  \- Combination therapy with Ipilimumab 3 mg/kg for 4 doses~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Ipilimumab 3 mg/kg for 4 doses"
214376319|NCT05300802|DRUG|Placebo|50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
214376320|NCT05300802|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
214376321|NCT05300802|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
214376322|NCT05101135|DRUG|JT-001|Subjects take the investigational products once a day for 24 weeks.
214376323|NCT05101135|DRUG|JT-001 Placebo|Subjects take the investigational products once a day for 24 weeks.
214496881|NCT04929106|DEVICE|mHealth support tool|The final app is named Active Leisure and consists of an advanced activity planner based on the platform developed by the ideal company Smart Cognition AS. The app offers different interface options (symbols only, easy to read text, plain text, and read aloud). The activity planner will mostly be used by the individual with IDs and a support person (caregiver or health care provider). After completing an activity, a simple reward is available (e.g., a smiling face or to share a picture with other users of the app). The use of tailored communication through personalization: the use of individuals first name in the activity planner, adaptation: individually chosen activities, adjusted communication (symbols, easy-to-read text or plain text), preparation and planning, and feedback: rewarding and positive feedback (after activities have been performed) is expected to increase motivation, and thereby lead to higher levels of PA.
214496882|NCT01630824|OTHER|Structured education program|structured education program after kidney transplantation
214496883|NCT05850975|OTHER|intervention with this name in MindEase app|MindEase is an app which provides interventions against anxiety. The interventions are based on mindfulness, acceptance and commitment therapy, and cognitive behavioural therapy.
214496884|NCT05850975|OTHER|reading about anxiety|Participants are given an educational text to read about anxiety.
214496885|NCT02040363|PROCEDURE|Muscular biopsy|
214496886|NCT02040363|OTHER|5-10 weeks sport training|
214496887|NCT02492412|DRUG|HE 10|
214496888|NCT02492412|DRUG|Restasis|
214687053|NCT02857855|PROCEDURE|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
214687054|NCT04886622|DRUG|DT2216|DT2216 will be administered by intravenous infusion
214988600|NCT04235764|PROCEDURE|TURBT|All patients will receive routine surgical transurethral resection of bladder tumors (TURBT).
214988601|NCT06108674|OTHER|Pharmaceutical care via telepharmacy and usual care|Pharmacotherapeutic monitoring via telephone consultation
214988602|NCT06108674|OTHER|Pharmaceutical care in-person and usual care|Face-to-face pharmacotherapeutic monitoring
214988603|NCT03892200|BEHAVIORAL|Aim2 - Daily Mouth Care|"Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.~For Aim2 the intervention training is delivered by a research dental hygienist."
214988604|NCT03892200|BEHAVIORAL|Aim3 - Daily Mouth Care|"Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.~For Aim3 the intervention training is delivered by state public health dental hygienists."
214988605|NCT05751655|OTHER|Prehospital care following drowning accident|Prehospital care provided by the emergency medical service 83 (SAMU 83)
214988606|NCT02320435|DRUG|Pertuzumab|In general, patients will continue to receive 420 milligrams (mg) of pertuzumab administered as an intravenous infusion every 3 weeks following the guidance of the Parent protocol.
214988607|NCT02320435|DRUG|Trastuzumab|If trastuzumab intravenous infusions were given in combination with pertuzumab as part of the Parent study, patients will continue to receive treatment at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
214988608|NCT02320435|DRUG|Other Combination Anti-Cancer Therapies|If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
214988609|NCT03836053|DRUG|AMG 420|28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks
214988610|NCT05357651|DRUG|LB1410|anti-PD-1 and anti-TIM-3 bispecific antibody
214376324|NCT02826369|OTHER|3.0 Tesla in Magnetic Resonance Imaging|"Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.~The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition."
214988611|NCT04006457|DRUG|PF-06651600|50 mg oral tablets/capsules
214988612|NCT04006457|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
214988613|NCT04006457|BIOLOGICAL|Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
215090403|NCT01256762|DRUG|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
215090404|NCT01256762|DRUG|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
214376325|NCT06308094|DIAGNOSTIC_TEST|CT|Pre-ablation CT is clinically acquired in patients undergoing catheter ablation. This study entails additional acquisition of the left ventricle to assess extracellular volume (ECV)
214376326|NCT00735111|OTHER|Karnofsky Performance Status Score|Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
214376327|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
214376328|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
214988614|NCT06049212|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan injection powder for intravenous (IV) infusion.
214988615|NCT06049212|BIOLOGICAL|Pembrolizumab|Pembrolizumab solution for IV infusion.
214988616|NCT06049212|DRUG|Supportive care measures|Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
214988617|NCT05165368|OTHER|Intraneural Facilitation® Therapy (INF® Therapy)|INF® Therapy plus dietary education with weekly follow-up by a physical therapist. Includes meal preparation ideas and sample menus promoting a gluten-free diet.
214988618|NCT05165368|OTHER|INF® Therapy|"INF® Therapy only (INF® Therapy is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to pressurize the entire system The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside holding chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or holds are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle.)"
214988619|NCT05139173|DEVICE|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) and the exercise is started on the tablet, while patients are performing physiotherapy exercises.
214988620|NCT05685303|DEVICE|Alleviant ALV1 System|Creation of interatrial shunt
214988621|NCT05685303|OTHER|Sham-Control|Cardiac imaging
214376329|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
214376330|NCT02873819|DRUG|GL-0817|GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
214376331|NCT02873819|DRUG|Hiltonol|Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
214376332|NCT02873819|DRUG|Sargramostim|Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
215090405|NCT04973462|DRUG|standard treatment COVID-19 + Triazavirin|to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019
215090406|NCT06458231|DEVICE|Blood Catheters|Central line as a predisposing factor for Blood stream infection
215090407|NCT04254120|BEHAVIORAL|Cognitive-behavioral therapy|Psychological treatment focusing on changing cognitions and behaviors using information processing theory and learning theory approaches.
215090408|NCT04254120|BEHAVIORAL|Integrated motivational interviewing and cognitive-behavioral therapy|Motivational interviewing is a psychological treatment approach focusing on increasing motivation by eliciting patient talk favoring behavior change and resolving patient ambivalence about change.
215090409|NCT01631916|DRUG|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
215090410|NCT04353882|OTHER|Assess the difference in MOR-1 expression between healthy and tumor tissue|Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
215090411|NCT01345682|DRUG|Afatinib|Once daily
215090412|NCT01345682|DRUG|Methotrexate|Weekly
215090413|NCT00604617|PROCEDURE|Interferon-Gamma Release Assay|IGRAs
215090414|NCT00604617|DRUG|RT-23|TST - tuberculin skin test
215090415|NCT05042609|DRUG|TRS01|TRS01 eye drops Dosed four times a day (QID)
215090416|NCT05042609|DRUG|FDA approved steroid eye drop (masked)|FDA approved steroid eye drop Dosed four times a day (QID)
215090417|NCT00795288|DRUG|Simvastatin, 80 mg/day for 21 days|Active treatment group
215090418|NCT00795288|DRUG|placebo|Control group
215090419|NCT02643823|BIOLOGICAL|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
215090420|NCT02643823|DRUG|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
214376333|NCT02873819|DRUG|cyclophosphamide|cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
214988622|NCT06814236|BEHAVIORAL|Three-Stage Informed Consent Conversation Model for Anaesthesia Risk profiling|"Stage 1 Pre-information queries~Do you know about the risks involved in Anaesthesia?~If yes, where did you get information about the risks involved with Anaesthesia??~Which of these do you already know of and what concerns you most?~Why are you concerned more about that particular risk factor?~Stage 2 Informing Risks~The probability or chances of supposed anaesthesia risks could be:~Probable risk Possible risk Remote risk~We have the following risk management strategy in place for your reassurance and safety:~Employing ERAS protocol~The surgery you are going to undergo, also may have its own set of risks~Stage 3 Post-information Informing Risks~In view of the above conversation we had, do you have other point of concern or query on what we have talked about."
214988623|NCT06775379|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
214988624|NCT06775379|DRUG|Placebo|Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
214988625|NCT04484441|OTHER|Blood and placenta specimen collection.|Collection of maternal and paternal blood. Collection of infant cord blood and placenta.
214988626|NCT06788262|OTHER|Cerebral MRI|Cerebral MRI
214988627|NCT05444062|BEHAVIORAL|Educational material and treatment recommendations for patients, general practitioners and pharmacists|Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.
214988628|NCT00488878|PROCEDURE|Biospecimen Collection|Patients' residual tissue samples are collected
214988629|NCT00488878|OTHER|Electronic Health Record Review|Medical records are reviewed
214988630|NCT00463814|DRUG|AZD6244|Participants will receive single oral dose of AZD6244 as described in arm description.
215090421|NCT02747212|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
215090422|NCT04451473|PROCEDURE|Enhanced Recovery After Surgery (ERAS )|the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
214376334|NCT02873819|DRUG|Placebo|Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
215090423|NCT04451473|PROCEDURE|Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )|the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
214376335|NCT06245057|OTHER|Maternity care home model (MCHM)|The maternity care home model is defined as office based prenatal care integrated with comprehensive social services.
214376336|NCT05533528|PROCEDURE|periodontal surgery|A sulcular incision will be made in the affected teeth, followed by an incision from the buccal aspect in the mid-portion of the interproximal tissues The buccal and lingual flaps will be elevated. For periodontal granulation tissue preservation group, the soft tissues covering the alveolar crest will be prepared. A third incision will separate the pocket epithelium from the soft tissue (granulation tissue) attached to the bone. The pocket epithelium will be removed. The root surfaces will be carefully scaled and planed in both groups. Ethylenediaminetetraacetic acid (24%) will be applied to the root surfaces and removed after 2 minutes with abundant saline solution. In the experimental group, the preserved attached soft tissue and the space between it and the root surface will be irrigated with 10% polyvinylpyrrolidone-iodine. Finally, the flaps will be positioned and sutured.
215090424|NCT06340490|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
214376337|NCT06145048|DRUG|VGT-309|Intravenous drug to be given over 15-20 minutes by syringe pump.
214988631|NCT05292313|PROCEDURE|Single distal femur implant|Single implant fixation
214988632|NCT05292313|PROCEDURE|Dual distal femur implants|Dual implant fixation
214988633|NCT04864171|DEVICE|near-infrared spectroscopy|Near-infrared spectroscopy is an intravascular imaging device to visualize lipid-rich plaque of coronary artery.
214988634|NCT06835530|DRUG|Rituximab + Golcadomide (CC-99282)|A combination of Rituximab and CC-99282 as front-line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma evaluated with a simplified Geriatric Assessment (sGA).
215090425|NCT00897390|DRUG|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
214988635|NCT04184050|DRUG|MK-4002|IV infusion
215090426|NCT00897390|DRUG|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
215090427|NCT00897390|DRUG|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
215090428|NCT01294163|DRUG|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
215090429|NCT01294163|DRUG|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
214376338|NCT04474522|GENETIC|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
214988636|NCT06063538|COMBINATION_PRODUCT|CardiaMend in Combination with Amiodarone|"The first three patient will receive 600 mg amiodarone into the intact pericardial space. Amiodarone serum levels will be tested at post operative days 2 and 6. The study will only proceed if there is a serum amiodarone level less than 25% of the normal therapeutic level. This should insure lack of systemic toxicity. After the first 3 patients have demonstrated low amiodarone blood levels, a total of up to 60 patients will be enrolled in the study.~The CardiaMend patch will saturated per the instructions and be sutured into place. Amiodarone will be dripped directly over the heart."
214988637|NCT00714818|BEHAVIORAL|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
214988638|NCT00714818|BEHAVIORAL|Genetic Counseling|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
214988639|NCT05848063|OTHER|Global hip muscles strengthening exercises|Strengthening exercises will be given to all hip muscles
214988640|NCT05848063|OTHER|Hip abductors strengthening exercises|Strengthening exercises will be given to hip abductor muscles
214988641|NCT05695287|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
214988642|NCT05695287|DRUG|Isoflurane|Isoflurane
214988643|NCT05695287|DRUG|Sevoflurane|Sevoflurane
214988644|NCT03643848|BEHAVIORAL|Sleep with Sound Cues|Experimental manipulation to observe effects on memory for learned material.
214988645|NCT03643848|BEHAVIORAL|Sleep with Sham Cues|Sham manipulation
214988646|NCT06244160|OTHER|High flow oxygen therapy|High flow oxygen therapy delivered via nasal cannulae, at 50 litres flow with variable oxygen levels
214988647|NCT05231668|DRUG|SAR439459|Powder for solution for infusion; IV infusion
214988648|NCT05231668|DRUG|Placebo|Solution for infusion; IV infusion
214988649|NCT04935632|BEHAVIORAL|prevention training|Evaluate the impact of hypothermia prevention training on the proportion of patients hypothermic patients in the operating room
214988650|NCT02700841|DRUG|Melphalan|Given IV
214988651|NCT02700841|PROCEDURE|Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Undergo autologous CD34 HSCT
214988652|NCT02700841|PROCEDURE|Peripheral Blood Stem Cell Transplantation--AHSCT|Undergo AHSCT
214376339|NCT00581373|OTHER|water 16 fl oz|water 16 fl oz in AM and repeat in late afternoon
214376340|NCT04074200|PROCEDURE|Open Inguinal Hernia Repair|With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
214496889|NCT03003286|BEHAVIORAL|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
214687055|NCT06305104|BIOLOGICAL|2.5μg/ml EEC|0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
214988653|NCT02700841|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo autologous CD34 HSCT
214988654|NCT02700841|BIOLOGICAL|Tetanus Toxoid Vaccine|Given IM
214988655|NCT05423743|OTHER|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
214988656|NCT05423743|OTHER|Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having an abdominal infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
214988657|NCT04598113|DEVICE|Cervical Traction Device|"While The patient is lie on the back his or her head is housed within the specific head portion of the device. The investigator inflate progressively the device using a valve and ensuring the patient's relaxation. The process of inflation is continued until the level of 12 Kg of pressure is reached. This maximum level of traction is maintained for 10 minutes then the process of deflation is started until the pressure decreased to 0 Kg. This maneuver is reproduced once again after 5 minutes of rest.~The balance assessment using the force plate-from is done just before the intervention and 5 minutes after its end."
214988658|NCT04864054|BIOLOGICAL|ECT204 T cells|ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.
215090430|NCT01294163|DRUG|Propofol|Hourly dose of 2-4 mg/kg
215090431|NCT03442660|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional diagnostic or treatment procedures will be required. Subjects will be asked to complete electronic (or on paper when it's not possible to use electronic version) questionnaires.
215090432|NCT05011799|BEHAVIORAL|Cancer Educational Materials|Receive prostate cancer educational materials
215090433|NCT05011799|OTHER|Questionnaire Administration|Ancillary studies
215090434|NCT05011799|OTHER|Educational Intervention|Attend peer-led education sessions
215090435|NCT04166539|BEHAVIORAL|Questionnaires|You will be asked to complete a questionnaire about your family history of neurological diseases and current and past physical thinking activities.
214988659|NCT04864054|DRUG|Regorafenib (STIVARGA®, BAY73-4506)|Regorafenib pretreatment before an ECT204 infusion.
214988660|NCT01583361|DRUG|Oxaliplatin+S-1|S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
214988661|NCT01583361|DRUG|Adjuvant Oxaliplatin/S-1（SOX）|S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
214988662|NCT01800253|BEHAVIORAL|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
215090436|NCT04166539|BEHAVIORAL|Interviews|Behavioral and Memory interviews will take place with the patient.
214376341|NCT04074200|PROCEDURE|Laparoscopic Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
214376342|NCT04074200|DEVICE|Robotic-Assisted Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
214496890|NCT03003286|BEHAVIORAL|Parents and Teachers Supporting Students (PATSS)|The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
214496891|NCT04661306|BEHAVIORAL|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
214496892|NCT06494566|DIETARY_SUPPLEMENT|Omega-3|Omega-3 capsule
214496893|NCT06494566|DIETARY_SUPPLEMENT|Mineral Oil|Mineral Oil Capsule
214687056|NCT06305104|BIOLOGICAL|5μg/ml EEC|0.1ml, one time, containing high dose 5μg/ml of active ingredients
214988663|NCT01800253|PROCEDURE|Blood samples|Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
214988664|NCT01800253|PROCEDURE|Tissue samples|Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
214988665|NCT01800253|PROCEDURE|Oral glucose tolerance test|75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
214988666|NCT01800253|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
214988667|NCT00090103|DRUG|dutasteride 0.5mg once daily for 4 years|combination or single agent
214988668|NCT00090103|DRUG|tamsulosin 0.4mg once daily for 4 years|combination agent or single agent
215090437|NCT04166539|OTHER|Blood draw|Have a sample of blood drawn (4.2-5 tablespoons) for clinical and research tests.
214496894|NCT03496545|DRUG|Bromocriptine 5 MG|Bromocriptine 5 mg every 4 hours PO/NG/FT
214496895|NCT03496545|DRUG|Acetaminophen 650 MG|Acetaminophen 650 mg every 4 hours PO/NG/FT for 48 hours
214988669|NCT00675480|PROCEDURE|Thrombectomy|Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction
214988670|NCT00675480|PROCEDURE|Primary angioplasty|Standard primary angioplasty with stent implantation
214988671|NCT05658237|PROCEDURE|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
214988672|NCT04521452|DRUG|Evogliptin|Subjects will receive evogliptin 5 mg daily
215090438|NCT04166539|RADIATION|Magnetic Resonance Imaging|Each MR examination takes about 45 minutes and does not require the use of needles, medication or contrast enhancement. You will lie on your back and enter the MR scanner for the study, during which time you will hear knocking noises. People with pacemakers, aneurysm clips, cochlear implants, or metal/foreign objects in their eyes are not permitted to undergo MR studies. We will review your implants and determine your eligibility.
215090439|NCT04166539|DIAGNOSTIC_TEST|Echocardiogram|Each echocardiogram takes about 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
215090440|NCT00958217|BEHAVIORAL|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
214496896|NCT03247842|PROCEDURE|suprascapular nerve block|Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
214496897|NCT01437319|DEVICE|lotrafilcon A|To be used during run-in phase only.
214687057|NCT06305104|BIOLOGICAL|5 unit（U） EC|0.1 ml , one time, containing 5U of active ingredients
214988673|NCT05149105|PROCEDURE|Argon plasma coagulation|On D0, in the operating room, argon plasma coagulation will be performed around the perimeter of the anastomosis for a period of 5 to 10 min under general anesthesia. The removal of the catheter and the endoscope will be carried out under control. Patients will be kept under surveillance the night following the procedure. A liquid diet will be prescribed for 10 days. The follow-up will be carried out on an outpatient basis with a control endoscopy at 2 months, followed by a new procedure in the event of an anastomosis larger than 1.5 cm. A new endoscopic check will be carried out at 4 months if an argon plasma coagulation was performed during the previous check, with a third and last argon plasma coagulation if an anastomosis of more than 1.5 cm persists. The number of procedures will therefore be a maximum of 3. A control endoscopy will be performed at one year for the final control of the anastomosis.
214376343|NCT06578715|BEHAVIORAL|Emotional Freedom Technique|EFT basically involves serial tapping on acupuncture points, no needles are used, there is no invasive procedure, there are affirmation suggestions, it is an easy, painless, simple but effective method that can be done in minutes. It is realized by applying kinetic energy to certain meridians on the head and chest with the fingertips. The points where the tapping is done are the end points of the meridians in the body. They are located symmetrically on both sides of the body. Since these points are close to the skin surface, they are points that are more easily reached than the deeper buried parts of the meridians. While applying pressure with the fingertips, the individual needs to focus on the problem that bothers him/her. Another thing that needs to be done at the same time is for the person to make positive suggestions to himself/herself vocally.
214988674|NCT04476043|DRUG|INCB054707|Oral; Tablet
214376344|NCT06576921|DRUG|Serplulimab Combined With Chemotherapy|Serplulimab (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
214496898|NCT01437319|DEVICE|comfilcon A|To be assigned at randomization at phase 2 only.
214496899|NCT01437319|DEVICE|balafilcon A|To be assigned at randomization during phase 2 only.
214496900|NCT01437319|OTHER|etafilcon A|Assigned to Neophytes during Phase I for a 2-week period
214988675|NCT04476043|DRUG|Placebo|Oral; Tablet
214988676|NCT05718674|PROCEDURE|Extracorporeal Photopheresis|ECP is performed by collecting leucocytes from the patient through leukopheresis and incubating them with 8-MOP and UVA in extracorporeal circulation. The treatment steps are the collection of leucocytes, photoactivation and subsequent reinfusion of the treated cells.
214988677|NCT05205811|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
214988678|NCT05205811|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 7 weeks.
214988679|NCT05205811|DRUG|Placebo bupropion|Placebo bupropion for 7 weeks.
214988680|NCT05205811|DRUG|Placebo zonisamide|Placebo zonisamide for 7 weeks.
214988681|NCT05205811|OTHER|E-cigarette|e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
214988682|NCT02912312|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RNI
214988683|NCT02912312|OTHER|Laboratory Biomarker Analysis|Correlative studies
214988684|NCT02912312|OTHER|Quality-of-Life Assessment|Ancillary studies
214988685|NCT02912312|OTHER|Questionnaire Administration|Ancillary studies
214988686|NCT02912312|RADIATION|Radiation Therapy|Undergo standard RNI
214988687|NCT02977351|PROCEDURE|Non-surgical periodontal treatment|
214988688|NCT03143452|DRUG|lidocaine gel|2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
214988689|NCT03143452|DRUG|tetracaine eye drop|0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
214988690|NCT05666024|OTHER||Prospective observational study
214988691|NCT05220423|OTHER|sms and emails reminders|6 reminders encouraging influenza vaccination on top of the National annual communication campaign organized by the French Health System authorities
214988692|NCT05220423|OTHER|No reminders|no reminders on top of the National annual communication campaign organized by the French Health System authorities
214988693|NCT05267704|DEVICE|Samsung Gear Virtual Reality Headset|VR headset displaying preselected game during renal biopsy
214988694|NCT02517749|DEVICE|Chest Drain Insertion and Talc Pleurodesis|
215090441|NCT00958217|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
214988695|NCT02517749|DEVICE|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
214988696|NCT01467752|PROCEDURE|MCP joint|reconstruction of metacarpophalangeal (MCP) joint using a bone graft
214988697|NCT01923558|DRUG|Donepezil|Donepezil Hydrochloride tablets,23 mg
214988698|NCT04763967|DEVICE|PedSCath Pediatric Urinary Catheter|PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.
214988699|NCT04763967|DEVICE|Standard of Care|Current Standard of Care for pediatric patients
214988700|NCT05151185|OTHER|Case Management Service Program|The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program: Needs Assessment, Intervention, evaluation and follow up, etc. The case management program is provided by a trained case manager in a dementia clinic, as well as telephone consultations and follow-up are provided.
214988701|NCT02194465|DRUG|LY2623091|Administered orally
214988702|NCT02194465|DRUG|Tadalafil|Administered orally
214988703|NCT02194465|DRUG|Spironolactone|Administered orally
214988704|NCT02194465|DRUG|Placebo|Administered orally
215090442|NCT06523062|DEVICE|blood pressure measurement|automated blood pressure measurement on 3 occasions at each consultation, twice with one month apart
214988705|NCT01408641|DRUG|Topiramate|Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
214988706|NCT01408641|DRUG|Placebo|Placebo capsules without topiramate
214988707|NCT03979313|DRUG|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
214988708|NCT03979313|DRUG|Placebo|Commercially available 0.9% (w/v) saline
214988709|NCT00089648|DRUG|Sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
214988710|NCT01454752|DRUG|Intermittent parasite clearance|Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
214988711|NCT01454752|OTHER|Placebo|Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
214988712|NCT02224417|BEHAVIORAL|Diabetes Educational Program (DEP)|"Participants in this Arm will receive the Diabetes Educational Program (DEP), as required, which is part of usual care at the Polyclinic. It is delivered by a Health Counsellor at the point of diagnosis and focused education is provided during doctor visits for medication. The program at the Polyclinic comprises information on a series of diabetes-related issues.~The participant will receive the 2 or 3 study devices (patients will receive a glucometer if they do not already have one). The Site Study Coordinator will provide education on the use of the Fitbit Zip™ and the eCAP™. As part of usual care, patients who have difficulties with their glucometer will be referred to a Health Counsellor at the Polyclinic."
214988713|NCT02224417|BEHAVIORAL|DEP + Process Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for meeting specified goals:~* SGD3.50 weekly for meeting Glucose testing goals: measuring blood glucose on three non-consecutive days each week.~* SGD0.50 daily for Medication adherence: taking medications daily as prescribed, monitored by eCAP device. Assessed based on medication-taking times within specified time windows. Participants should be adherent at all specified mealtimes to be fully adherent for the day.~* SGD1.00 daily for Regular Physical activity: taking 8,000 steps during the day as recorded by Fitbit."
214988714|NCT02224417|BEHAVIORAL|DEP + Outcome Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for recording glucose readings within the normal range (i.e. between 4 to 7mmols/L two before a meal) on 3 non-consecutive days within the week using the glucometer.~* SGD 2 weekly if one glucose readings falls within the normal range,~* SGD 7 weekly if two glucose readings fall within the normal range,~* SGD 14 weekly if all three glucose readings fall within the normal range."
214988715|NCT00771108|BEHAVIORAL|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
214988716|NCT01445340|DRUG|Romidepsin (FR901228)|
215090443|NCT03239938|BEHAVIORAL|Modern pain neuroscience approach|The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
215090444|NCT03239938|BEHAVIORAL|Usual care evidence-based physiotherapy|The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
214988717|NCT03347591|GENETIC|WES|136 bleeding related OMIM (Online Mendelian Inheritance in Man)-proved genes involved in haemostasis will be selected from Whole Exome Sequencing (WES)
214988718|NCT03347591|DIAGNOSTIC_TEST|Several assays|Patients will be approached by their own treating physician. Data will be collected through questionnaires, a clinical interview, a blood and saliva sample obtained from each participant, and thorough review of electronic patient records. All procedures are study related. In case a physician visit with the treating physician is already planned, or in case a venepuncture for regular diagnostics or treatment is already planned, this can be combined with the study procedures to prevent an extra visit.
215090445|NCT02737384|BIOLOGICAL|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
215090446|NCT02666794|DRUG|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
215090447|NCT02666794|DRUG|Epidural sufentanil|20 mcg
215090448|NCT02666794|PROCEDURE|Placement of the epidural catheter|Placement of the epidural catheter
215090449|NCT02666794|DRUG|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
215090450|NCT02666794|DRUG|Intrathecal morphine|60 mcg
215090451|NCT02666794|PROCEDURE|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
214988719|NCT00423605|DRUG|Xyrem®|flexible dosing
214988720|NCT00396292|DRUG|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
214988721|NCT00396292|DRUG|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
214496901|NCT03930940|DEVICE|remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
215090452|NCT02666794|DRUG|Intrathecal sufentanil|5 mcg
215090453|NCT04350307|DEVICE|22-gauge needle|22-gauge Quincke needle used for epidural injection
214496902|NCT03930940|OTHER|Regular treatment|Regular treatment is based on associated guidelines for ICH.
214988722|NCT05203315|DRUG|Duobrii 0.01 % / 0.045 % Topical Lotion|Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
214988723|NCT05203315|DRUG|CeraVe, Topical Cream|CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
214988724|NCT05031767|OTHER|Usual care|"Conventional follow-up strategy with blood tests, patient-reported outcomes, and pre-scheduled visits at the hospital every 6th month.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
214988725|NCT05031767|OTHER|Remote monitoring|"Hospital health professionals perform remote monitoring of frequent patient-reported outcomes, blood test results, and physical activity data available on a digital platform.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital ."
214988726|NCT05031767|OTHER|Patient-initiated care|"No pre-scheduled visits or remote monitoring.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
215090454|NCT04350307|DEVICE|25-gauge needle|25-gauge Quincke needle used for epidural injection
215090455|NCT01075984|DRUG|Posaconazole|
215090456|NCT01075984|DRUG|Dextrose 5% in water|
215090457|NCT01133015|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
215090458|NCT01133015|DEVICE|IVUS|intravascular ultrasound
215090459|NCT00342706|PROCEDURE|Community based intervention|
215090460|NCT05293678|DRUG|REGN15160 (IV)|Administered in single intravenous (IV) dose
215090461|NCT05293678|DRUG|Matching Placebo (IV)|Administered in single IV dose
215090462|NCT05293678|DRUG|REGN15160 (SC)|Administered in single subcutaneous (SC) dose
215090463|NCT05293678|DRUG|Matching Placebo (SC)|Administered in single SC dose
215090464|NCT00156169|DRUG|Dunaliella|
215090465|NCT00418054|DRUG|Nitazoxanide plus peginterferon alfa-2b|
214496903|NCT01499849|DRUG|Rolapitant|(4 X 50 mg capsules) 200 mg PO
214496904|NCT01499849|DRUG|Granisetron|10 mcg/kg IV
214496905|NCT01499849|DRUG|dexamethasone|20 mg PO and 8 mg PO
214496906|NCT01499849|DRUG|Placebo|(4 X 0 mg capsules) 0 mg PO
214496907|NCT03282045|DRUG|Lysobact Complete Sprey|Inhaling spray
214496908|NCT03282045|DRUG|Tantum Verde® Spray|Inhaling spray
214496909|NCT03282045|DRUG|Pharyngal® Oromucosal Spray|Inhaling spray
214496910|NCT03282045|DRUG|Placebo|Inhaling spray
214496911|NCT02715518|DEVICE|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~1. FFR-guided strategy arm~2. Angiography-guided strategy arm"
214988727|NCT03183908|BIOLOGICAL|FLUAD®|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
214988728|NCT03183908|BIOLOGICAL|Fluzone® High-Dose|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
214988729|NCT06078982|DRUG|Disitamab Vedotin|2.0mg/kg, intravenously D1, once every 14 days (Q2W)
214988730|NCT06078982|DRUG|Toripalimab|3.0 mg/kg, once every 14 days (Q2W)
214988731|NCT02156258|DEVICE|FFDM Mammography|Standard mammography image collection
214988732|NCT02156258|DEVICE|DBT Mammography|Collection of breast images using DBT mammography
214988733|NCT00132626|DRUG|[123I]ß-CIT and SPECT imaging|
214988734|NCT04413045|OTHER|Prevalence of COVID-19|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
214988735|NCT03290651|DIETARY_SUPPLEMENT|Probiotic Natural Health Product - RepHresh Pro-B|Participants will take the probiotic or placebo daily for 90 days.
214988736|NCT03290651|DIETARY_SUPPLEMENT|Placebo|Participants will take the probiotic or placebo daily for 90 days.
214988737|NCT03977480|DRUG|Hemay007|Hemay007 will be orally administered.
214988738|NCT03977480|DRUG|Placebo|Placebo
215090466|NCT00418054|DRUG|Peginterferon alfa-2b|
215090467|NCT03346577|DEVICE|stent or balloon|Endovascular treatment with stent or balloon according to current practice
215090468|NCT02552862|DRUG|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
215090469|NCT02552862|DRUG|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
215090470|NCT01524081|DRUG|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. \- Cefuroxime in 100ml saline~2. \- Metronidazole in 500ml saline"
214496912|NCT00811941|DRUG|Placebo|as-needed use, tablets, orally, 52 weeks
214496913|NCT00811941|DRUG|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
215090471|NCT01524081|DRUG|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~1. \- 2x amoxicillin in 100ml saline~2. \- Fluconazole in 500ml saline"
214988739|NCT01060501|DRUG|Folinic Acid, interferon-alpha|5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
214988740|NCT01749371|DRUG|Vitamin E|1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
214988741|NCT01562990|DRUG|Rituximab, CMC544, Gemcitabine and Oxaliplatine|"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."
214988742|NCT04159376|DIAGNOSTIC_TEST|PET/MR|"All patients will have a PET/CT and PET/MR study performed at the same clinical setting using a single dose of tracer administration.~The study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed.~The tracers will be FDG, labelled PSMA labelled Somatostatin and F-DOPA in order to assess skeletal lesions detection of all tumor types.~Skeletal lesions will be divided into marrow-based lesions, lytic, blastic and scleroric lesions. Tracer uptake will be measured at baseline and after treatment. Metabolic PET parameters, CT appearance and MR parameters will be assessed.~The best MR-based attenuation algorithm for detection of lesions and monitoring response will be derived."
214988743|NCT03920800|OTHER|Data extraction from medical files|Data extraction from medical files
214988744|NCT03920800|BIOLOGICAL|Immunohistochemistry|Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
214988745|NCT01278368|PROCEDURE|Pancreatic resection after preoperative chemotherapy|Pancreatic resection after preoperative chemotherapy
214988746|NCT01278368|PROCEDURE|Pancreatic resection|Pancreatic resection
214988747|NCT01688713|DRUG|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
214988748|NCT01240746|BIOLOGICAL|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
214988749|NCT01240746|BIOLOGICAL|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
214988750|NCT01240746|BIOLOGICAL|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to \<9 years), Intramuscular
215090472|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. \- 100ml saline solution~2. \- 500ml saline solution"
215090473|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. \- 2x 100ml saline solution~2. \- 500ml saline solution"
215090474|NCT05152810|OTHER|Transcranial Magnetic Stimulation sessions|"* 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase"
214988751|NCT05393219|OTHER|Cardiac biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on emWave Pro software on a computer just before entering the examination circuit
214988752|NCT05393219|OTHER|Mindfulness|6 minutes of a guided video tape made for the study that inspires mindfulness like meditation associated just before entering the examination circuit.
214988753|NCT05393219|OTHER|Resources mobilization|6 minutes of a guided video tape that purpose to mobilize inner resources and strength of the student just before entering the examination circuit.
214988754|NCT05393219|OTHER|Control|6 minutes of standardized neutral video on general topics that generates no modification of affects just before entering the examination circuit.
214988755|NCT03738696|DRUG|Exparel|A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
214988756|NCT03738696|DRUG|Ropivacaine|A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
214988757|NCT02049203|DRUG|Ataciguat|
214988758|NCT02049203|DRUG|Placebo|
214988759|NCT01595828|DRUG|Pitavastatin|
214496914|NCT04056702|DRUG|Elexacaftor-tezacaftor-ivacaftor exposure|Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
214988760|NCT02566005|DEVICE|misoprostol|25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
214988761|NCT02566005|DEVICE|Foley bulb|a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
214988762|NCT05491577|OTHER|Filling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire|The SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire will all be filled in by the patients.
214988763|NCT02905708|DEVICE|Air-Activated heating packs|The subject disrobe and will dress in a jacket, pants, gloves and socks (ensemble) which will be removed from a vacuum pack. He will be assisted by the nurse in pre-operative area. The ensemble will remain in place until the subject is fully recovered from anesthesia.
214988764|NCT02905708|DEVICE|Forced Air Warming Device|forced air-warming inflatable device applied according to standard hospital protocol.
214988765|NCT06307379|OTHER|no intervention|only observational
214988766|NCT03617588|DRUG|Gallium-68 THP-PSMA|Subjects will undergo a Gallium-68 THP-PSMA scan in addition to standard of care monitoring. The results of this scan may influence the patient management plan.
214988767|NCT05424120|PROCEDURE|Manual aspiration|One option from standard of care
214988768|NCT05424120|PROCEDURE|Wall suction|One option from standard of care
214376345|NCT06576921|DRUG|Placebo combined with Chemotherapy|Placebo (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
214988769|NCT05424120|PROCEDURE|Vacuum bottle drainage|One option from standard of care
214988770|NCT01795612|OTHER|physical activity|
214376346|NCT03485677|DRUG|Eliglustat GZ385660|"Pharmaceutical form: Capsule, Liquid~Route of administration: Oral"
214376347|NCT03485677|DRUG|Imiglucerase GZ437843|"Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous"
214376348|NCT05306093|DIETARY_SUPPLEMENT|Nutraceutical|Food supplements are consumed during 8 weeks by healthy volunteers
214376349|NCT05306093|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 8 weeks by healthy volunteers
214376350|NCT04842162|DRUG|indocyanine green|indocyanine green (INFRACYANINE© 25mg/10mL).
214376351|NCT05028153|DRUG|Azithromycin Oral Liquid Product|10 mg/kg for 3 consecutive days
214376352|NCT05028153|OTHER|Placebo mixture|Placebo mixture containing no active substance
214376353|NCT03331133|OTHER|No intervention|
214687058|NCT05610748|PROCEDURE|Sub-Periosteal Peri-implant Augmented Layer technique|In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
214988771|NCT00152048|DRUG|Eflornithine hydrochloride|
214376354|NCT02206022|DRUG|Remifentanil|Pain's evaluation for Remifentanil Group
214376355|NCT02206022|DRUG|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
214376356|NCT04084977|DIAGNOSTIC_TEST|Antibody detection|detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside
214376357|NCT04892784|DEVICE|Press tack needle acupuncture|Pyonex press tack needle sized 0.20x1.2mm
214376358|NCT00076960|DRUG|Stanate (TM) [stannsoporfin, tin-mesoporphyrin]|Treatment with 4.5 mg/kg
214988772|NCT01184911|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine tablets, once
214988773|NCT03734341|DEVICE|EZ START Titration|"The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached.~Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours."
214988774|NCT03734341|DEVICE|APAP Titration|"The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours."
214988775|NCT00806065|DRUG|ENMD-2076|
214988776|NCT05262179|DRUG|CTO0101|1 drop/ once or three times a day/ for 17 days divided into stage2
214376359|NCT03297931|DIETARY_SUPPLEMENT|Corn Chips + Onion Dip|Non-pulse chip + non-pulse dip
214376360|NCT03297931|DIETARY_SUPPLEMENT|Yellow pea chip + hummus|Novel pulse chip + pulse spread
214988777|NCT05262179|OTHER|Placebo (vehicle)|1 drop/ once or three times a day/ for 17 days divided into stage2
215090475|NCT05152810|OTHER|Evaluations|"Before the first stimulation session, just after the 10th session, at 6 weeks, at 12 weeks and at 24 weeks.~The assessment included the collection of AEs/EIGs, the TAC, the VAS on desire to smoke, the TCQ, the QSU, BDI-II (except at S1), the CO tester, GoNoGo, the PQI and the ISI."
214376361|NCT03297931|DIETARY_SUPPLEMENT|Pinto bean chip + hummus|Commercial pulse chip + pulse spread
214376362|NCT03297931|DIETARY_SUPPLEMENT|Pinto bean chip + onion dip|Commercial pulse chip + non-pulse spread
214376363|NCT03297931|DIETARY_SUPPLEMENT|Yellow pea chip + onion dip|Novel pulse chip + non-pulse spread
214376364|NCT03297931|DIETARY_SUPPLEMENT|Corn chips + hummus|Non-pulse chip + pulse spread
214376365|NCT03156634|OTHER|PALS|PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
214376366|NCT03156634|OTHER|WebMD|WebMD is an internet based health information source.
214988778|NCT06078670|DRUG|CVL218|Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.
214988779|NCT00668239|DRUG|intravitreous triamcinolone|Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent
214988780|NCT00668239|PROCEDURE|laser therapy|pan fotocoaglulation by laser therapy
214988781|NCT00439439|RADIATION|Beamer Ablation (Argon Plasma Coagulation)|APC-Beamerablation of heterotopic gastric mucosa
214988782|NCT01926210|OTHER|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
214988783|NCT01926210|OTHER|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
214988784|NCT06158945|DIAGNOSTIC_TEST|urinary endothelin 1|assesment of endothelin 1 in urinary sample
214988785|NCT04719559|DEVICE|Laser-assisted drug delivery|All patients received treatment using the same protocol with the same fractional ablative carbon dioxide laser (eCO2 PlusTM, manufactured by Lutronic, South Korea). Each patient was applied with Lidopin 5% cream (Panion \& BF Biotech Inc.), which remained on the scar for 30 min for pain relief before each laser course. Later, the Lidopin 5% cream was gently removed using a normal saline-rinsed gauze, and the scar was treated with a fractional ablative carbon dioxide laser with two passes under a 10,600 nm wavelength, 120 mm spot size, pulse energy of 50 mJ, 30 W of power, and a density of 200. A topical steroid cream (clobetasol propionate, 0.05%) was evenly applied on the scar gently back and forth using a cotton swab immediately after the laser treatment. The patients underwent five full courses by the same doctor according to the same protocol, with each course given 4 weeks apart.
215090476|NCT06530134|OTHER|Driving situation and video feedback|At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation using video feedback.
215090477|NCT06530134|OTHER|Driving situation and usual recommendations (without video feedback)|"At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation without video feedback, according to the usual recommendations.~Comparison of responses to all questionnaires and interview grids sent before and after driving, to patients and professionals will determine whether video feedback promotes awareness of the difficulties of driving post-stroke patients."
215090478|NCT05549154|DRUG|High-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
215090479|NCT05549154|DRUG|low-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
215090480|NCT05549154|DRUG|placebo|placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
215090481|NCT01326832|DEVICE|Primoris|Total hip arthroplasty with the new Primoris femoral component
215090482|NCT03890328|PROCEDURE|radiofrequency ablation|apply RF therapy to the treatment of splenic trauma
215090483|NCT02757612|RADIATION|laser diode|laser diode
214376367|NCT03724396|BEHAVIORAL|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
215090484|NCT06081192|PROCEDURE|Implant placement surgery|Placement of six mini implants in the edentulous maxilla using a partially-guided protocol
215090485|NCT03566121|OTHER|Pelvic ultrasound / Urodynamic ultrasound|Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
215090486|NCT01024192|DRUG|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
215090487|NCT01685021|DRUG|MOR00208 (formerly Xmab5574)|
214496915|NCT05911867|OTHER|combination of mobilization with movement and muscle energy techniques|"The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range."
214496916|NCT05911867|OTHER|muscle energy techniques Interventions:|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applied manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
214988786|NCT05110612|BEHAVIORAL|Episodic Future Thinking|Episodic Future Thinking involves generating positive, autobiographical events that could realistically occur following each of five delays in the subsequent DD task: 1 day, 1 week, 1 month, 3 months, and 1 year. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
214988787|NCT05110612|BEHAVIORAL|Control Episodic Thinking|Control Episodic Thinking will report three real, positive events that occurred earlier in the session while playing mobile video games. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
214376368|NCT03724396|BEHAVIORAL|Novel Executive Function Training - NEXT|Modifies programs like CogSMART and cognitive remediation training to help participants improve executive functioning to adhere to recommendations from BWL.
214988788|NCT00293891|DRUG|Tacrolimus Cream|
214988789|NCT00102635|DRUG|Fenretinide (4-HPR)|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
214988790|NCT00102635|DRUG|SCH66336|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
214376369|NCT05525936|DIAGNOSTIC_TEST|Echocardiography and central venous pressure|To perform an echocardiography, transthoracic or transesophageal and to measure central venous pressure through a central venous line.
214376370|NCT03609346|DEVICE|PCI|The placement of 1 or more stents in the diseased coronary artery lesion(s).
214988791|NCT00187551|OTHER|Interruption of enfuvirtide|treatment interruption
214988792|NCT00187551|OTHER|enfuvirtide interrupton|enfuvitide will be interrupted in patients harboring resistant virus
214988793|NCT03871413|DEVICE|TRV-chair|Repositioning maneuvers in TRV-chair
214988794|NCT03871413|PROCEDURE|Manual repositioning maneuver|Treatment with manual repositioning maneuver
214988795|NCT00838851|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
214988796|NCT03636633|OTHER|Standard respiratory physiotherapy|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques.
214988797|NCT03636633|OTHER|Standard respiratory physiotherapy and inspiratory muscle training|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques. Addition to that, threshold IMT device will be used for the training. Training intensity will set at 40% of the maximum inspiratory pressure.
214376371|NCT06437197|PROCEDURE|Pulpotomy|Removal of the coronal pulp chamber in an adult teeth
214376372|NCT05706545|DIAGNOSTIC_TEST|Acquisition of cardiovascular signals and microcirculation sidestream darkfield images|ECG, arterial pressure and peripheral flow velocity via a percutaneous laser doppler will be acquired together with images of the sublingual microcirculation detected with sidestream darkfield images microscope
214988798|NCT00128843|DRUG|Exemestane|25mg/day until progression disease
214988799|NCT00128843|DRUG|Anastrozole|1mg/day until progression disease
214988800|NCT04087447|PROCEDURE|Thyroidectomy|Thyroidectomy
214988801|NCT01173250|PROCEDURE|adding diverting ileostomy|
214988802|NCT01173250|PROCEDURE|omitting diverting ileostomy|
214988803|NCT02234271|OTHER|Mobile Health Application|Mobile Health application for contraception information
214988804|NCT02234271|OTHER|Health Educator Counseling|Counseling via health educator
214988805|NCT01632319|BEHAVIORAL|Combined Motivational Interviewing and Cognitive Behavioral Therapy|"8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.~In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms"
214988806|NCT01632319|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
214988807|NCT05124548|DIAGNOSTIC_TEST|Sleep diagnostics|On study day 4, all participants perform a single night sleep assessment in a sleep lab via Polysomnography (PSG) and WHOOP strap, a digital Fitness and health Coach.
214988808|NCT02598310|DRUG|nab-paclitaxel|nab-paclitaxel 260mg/m2 q3w
214988809|NCT02598310|DRUG|Trastuzumab|trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
214988810|NCT04571203|BIOLOGICAL|Combined Deceased Donor Kidney and Hematopoietic Cell Transplants|This combined kidney and hematopoietic cell transplants with a conditioning regimen with irradiation and ATG creates an environment of immune-tolerance. This promotes hematopoietic cell engraftment.
214988811|NCT05727644|DRUG|NNC0194-0499|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
214988812|NCT05997745|DIETARY_SUPPLEMENT|study group|Patients will receive early enteral locally nutrition postoperatively following surgery for peritonitis
215090488|NCT05106010|OTHER|Balance Flow Yoga|The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
214988813|NCT04129541|OTHER|Same Day Discharge|Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
215090489|NCT06398925|DRUG|OCT461201 50 mg|Oral capsule
215090490|NCT06398925|DRUG|OCT461201 100 mg|Oral capsule
215090491|NCT06398925|DRUG|OCT461201 150 mg|Oral capsule
215090492|NCT06398925|DRUG|OCT461201 450 mg|Oral capsule
215090493|NCT06398925|DRUG|Placebo|Placebo capsule
214376373|NCT00823654|OTHER|Blood draw and questionnaires|"At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment~↓~Tests in the middle of chemotherapy (if applicable):~Blood draw and collection of monthly menstrual calendars ↓~Tests when chemotherapy is over (if applicable):~Blood draw and collection of monthly menstrual calendars~↓~Tests every 4 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire ↓~Tests every 6 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire~↓~Yearly follow-up for about 2 years:~Blood draw collection of monthly menstrual calendars, and questionnaire"
214376374|NCT00823654|OTHER|Blood draw and questionnaires|"Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent~↓ Register patients at Memorial Sloan-Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)~↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires~↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires"
214376375|NCT00387582|DRUG|Ranibizumab (Lucentis)|Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
214376376|NCT00387582|PROCEDURE|Argon Laser|Argon laser at entry to trial and then per protocol for the duration of the study.
214376377|NCT02770781|OTHER|Exercise regimen|Subjects will receive a personal exercise regimen based on their health history and individual capability.
214376378|NCT02386657|OTHER|Satisfaction|Satisfaction questionnaire to be filled in
214376379|NCT02386657|OTHER|Biological parameters|Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
214496917|NCT05911867|OTHER|mobilization with movement|Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.
215090494|NCT02198235|DRUG|Dexamethasone|
214376380|NCT02386657|OTHER|Pain management|Validated pain scale questionnaire to be filled in
214376381|NCT03045848|DEVICE|Biofreedom drug-coated stent|BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
214376382|NCT02721576|DRUG|Sodium Glycididazole|Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.
214376383|NCT01320930|BEHAVIORAL|Pulmonary rehabilitation|
214376384|NCT01320930|BEHAVIORAL|conventional care|
214496918|NCT02061124|DRUG|Sevelamer 1600 mg TID for 7 days|
214496919|NCT02061124|DRUG|Placebo 1600 mg TID for 7 days|
214496920|NCT05562102|BIOLOGICAL|Typbar-TCV, Bharat Biotech|Typhoid conjugate vaccine
214988814|NCT04129541|OTHER|Overnight Hospitalization|Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
214988815|NCT04017377|DRUG|Drug: Cisplatin; nab-paclitaxel|Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)
214988816|NCT03284554|DIETARY_SUPPLEMENT|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
214988817|NCT03284554|DIETARY_SUPPLEMENT|Non-encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
214988818|NCT03284554|DIETARY_SUPPLEMENT|Placebo|Nutrient not expected to stimulate release of GLP-1 and PYY
214988819|NCT02820415|OTHER|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
215090495|NCT02198235|DRUG|Buprenorphine|
214376385|NCT06363825|DRUG|camrelizumab|"TAE: 3-15ml iodized oil;~HAIC: Indurating arterial catheter, oxaliplatin 85mg/m\^2 D1, arterial infusion, lasting 1-2 hours (d1), LV 400mg/m\^2, arterial infusion, lasting 2-3 hours (d1), 5-Fu 400mg/m\^2, arterial infusion, lasting 3 hours (d1), and fluorouracil 2400 mg/m\^2 for 24-48h;~camrelizumab: 200mg, ivgtt, 30 min (not less than 20 min, not more than 60 min) every 3 weeks (21 days);~apatinib mesylate: 250mg, once a day, taken orally (the time of daily administration should be as much as possible), with warm water.Stop for 3 days before next cycle intervention.~Camrelizumab was given intravenously 1 day before TAE+HAIC treatment for each cycle, TAE+HAIC treatment was given on the second day, and oral apatinib was started after discharge."
214376386|NCT05272332|DIAGNOSTIC_TEST|Gastric ultrasound|Gastric ultrasound upon fasting, after 4 hours, and after nasogastric aspiration, to estimate gastric volume
214376387|NCT01886001|DRUG|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
214376388|NCT01886001|DRUG|Chlorhexidine|Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
214376389|NCT01886001|DRUG|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
214376390|NCT01886001|OTHER|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
214376391|NCT04949958|OTHER|Exercise Based Manual (Supervised)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise, Exercise and Education. The exercise will be supervised while other component will be home based.
214376392|NCT04949958|OTHER|Exercise Based Manual (Home Based)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise and Education. All two components will be home based.
214376393|NCT04949958|OTHER|Control|General advice to be active
214376394|NCT05158296|DRUG|Ultevursen|RNA antisense oligonucleotide for intravitreal injection
214988820|NCT04826562|DRUG|Dolutegravir/Lamivudine|single tablet antiretroviral
214988821|NCT02690727|DRUG|RP6530|Single oral dose
214988822|NCT00097435|DRUG|Albuferon|
214988823|NCT00097435|DRUG|Ribavirin|
214988824|NCT04032938|PROCEDURE|extracorporeal circulation during cardiac surgery|We will observe the cardiopulmonary bypass status and time of patients undergoing cardiac surgery and extracorporeal circulation due to their medical needs.
214988825|NCT01526980|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
214988826|NCT01526980|DRUG|biphasic insulin aspart 70|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
214988827|NCT01526980|DRUG|biphasic human insulin 30|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
214988828|NCT00657566|OTHER|duration of antibiotics|4 +/- 1 days of antibiotics
214988829|NCT00657566|OTHER|duration of antibiotics|active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
214376395|NCT05158296|OTHER|Sham-procedure|Sham-procedure (no experimental drug administered)
214376396|NCT01677143|DRUG|Bupivacaine 5mg/ml|5 ml in trocar area
214496921|NCT01341132|PROCEDURE|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
214496922|NCT03938337|DRUG|Cohort 1 Not Previously Treated|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
214496923|NCT03938337|DRUG|Cohort 2 Treated Previously|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
214496924|NCT04777383|DRUG|Acetylcholine|Iontophoretic administration of 5 different concentrations of acetylcholine
214988830|NCT04416789|OTHER|Exercise programme|1 session of trampolining/dry sports (1.5 hours) and 1 session of supervised swimming (1.5 hours) per week for 10 weeks.
214988831|NCT01295411|DEVICE|Magnetic Resonance Imaging|
214988832|NCT01295411|OTHER|EVALUATION NEUROPSYCHOLOGICAL|
214988833|NCT03784495|DRUG|Melatonin 1mg|1 mg/day 30 minutes before sleep
214988834|NCT03784495|DIETARY_SUPPLEMENT|Essential Aminoacids (eAA)|4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
214988835|NCT03784495|COMBINATION_PRODUCT|Essential Aminoacids + melatonin|4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
214988836|NCT03784495|OTHER|Placebo|an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
214988837|NCT04649723|DRUG|Rifampin|single oral dose, 600 mg, fasted.
214988838|NCT04649723|DRUG|SHR1459|single oral dose, 200 mg, fasted.
214988839|NCT03345797|DRUG|Testosterone Nasal Gel [Natesto]|nasal gel containing 4.5% w/w testosterone
214988840|NCT01603147|BIOLOGICAL|normal saline|saline 225 ml
214988841|NCT01603147|BIOLOGICAL|ch-mAb7f9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
214988842|NCT06094647|DEVICE|Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self-care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
214988843|NCT01782092|OTHER|Chiropractic Adjustment|Chiropractic adjustments will be administered using Activator Methods Basic protocol
214988844|NCT06535568|DEVICE|Drug-coated balloon|Essential pro (iVascular, Barceona, Spain) paclitaxel eluting coronary balloon dilatation catheter is a rapid exchange catheter, also known as RX because it has a proximal simple lumen configuration and a distal coaxial dual lumen, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this Arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.
214988845|NCT06535568|DRUG|Single antiplatelet therapy (SAPT)|The antithrombotic regimen is single antiplatelet therapy (SAPT). The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has been shown by these drugs in head-to-head trials versus clopidogrel in elderly PCI populations. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.
214988846|NCT06535568|DRUG|Dual antiplatelet therapy (DAPT)|The antithrombotic regimen will follow the standard of care with a dual antiplatelet regimen (DAPT) per local preferences and international guidelines/ARC consensus paper. The type of agent and treatment duration will be selected according to the patient's clinical characteristics.
214988847|NCT02219542|DRUG|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
214988848|NCT02219542|DRUG|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
214988849|NCT00158613|BIOLOGICAL|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap
214988850|NCT01814085|DRUG|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
214988851|NCT01859819|DRUG|Rituximab|
214988852|NCT01859819|DRUG|IT Cytarabine|
214988853|NCT03229603|OTHER|Cluster of 3000 women|An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.
214988854|NCT01062191|DEVICE|Aquacel AG, typical carboxymethylcellulose dressing|"4 X 4, Aquacel silver sheet"
214988855|NCT01062191|DEVICE|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Wound dressing
214988856|NCT06055582|DIETARY_SUPPLEMENT|Bread|81g (3 slices) harvest gold white bread as standard food.
214988857|NCT06055582|DIETARY_SUPPLEMENT|Mango|250g of mango pulp of each mango variety was given to the subjects.
214988858|NCT02320409|DRUG|Sulfatinib|250mg Sulfatinib ,single dose,oral
214988859|NCT00775034|DRUG|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
214988860|NCT00775034|PROCEDURE|Drainage|Mesh repair for open incisional hernia repair with drainage
214988861|NCT05302050|DEVICE|BT-001|"BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
214988862|NCT05302050|DEVICE|Control Mobile Application|The app asks patients brief questions about their health but does not include any behavioral therapy.
214988863|NCT03850626|BIOLOGICAL|Immunotherapy|subcutaneous injection
214988864|NCT02233257|DRUG|Lorenzo's Oil|Oral use of Lorenzo's oil to lower very long chain fatty acids
214988865|NCT03134807|OTHER|Observation prospective|No intervention
214988866|NCT00818844|DRUG|Nepafenac 0.1%|NSAID
214988867|NCT00818844|OTHER|BSS|BSS
214988868|NCT03710811|DRUG|Insulin|Continuous Subcutaneous Insulin Infusion
214988869|NCT03491592|BEHAVIORAL|Enhanced Physical Activity Intervention|Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.
214988870|NCT03491592|BEHAVIORAL|Original Physical Activity Intervention|Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
214988871|NCT02730130|DRUG|Pembrolizumab|
214988872|NCT02730130|RADIATION|Radiotherapy|
214988873|NCT05231967|OTHER|Cardioversion|In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
214988874|NCT00141921|DRUG|Etanercept|Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
215090500|NCT01742065|OTHER|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
215090501|NCT05644093|DRUG|SPL026 IV|IV dosing
215090502|NCT05644093|DRUG|SPL026 IM|IM dosing
215090503|NCT05620953|DIAGNOSTIC_TEST|respiratory specimen|nasopharyngeal swab or nasal aspiration or broncho-alveolar lavage
215090504|NCT00052156|BIOLOGICAL|CancerVax vaccine (CANVAXIN)|
215090505|NCT03693911|BEHAVIORAL|Acceptance and Commitment Therapy|6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
215090506|NCT02264548|RADIATION|Radio-Ablation|Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
214988875|NCT02497014|DEVICE|1 Stent|Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
214988876|NCT02497014|DEVICE|2 Stents|"Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion."
214496925|NCT04777383|DRUG|Norepinephrine|Iontophoretic administration of 5 different concentrations of norepinephrine
214496926|NCT04777383|DRUG|Phenylephrine|Iontophoretic administration of 5 different concentrations of phenylephrine
214988877|NCT05791110|DIAGNOSTIC_TEST|Fecal pancreatic elastase 1 test|Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
214988878|NCT01255020|DRUG|α-Keto Acid with restricted protein diet|"α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d"
215090507|NCT00498888|PROCEDURE|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
215090508|NCT00498888|PROCEDURE|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
215090509|NCT00498888|PROCEDURE|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
215090510|NCT00498888|PROCEDURE|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
215090511|NCT04619277|DEVICE|drug-coated balloon|drug-coated balloon
215090512|NCT05297526|BEHAVIORAL|Culturally adapted children's book|Tribe-specific children's book celebrating tribal culture with an embedded oral health message
215090513|NCT05297526|BEHAVIORAL|Standard informational brochure on children's oral health|Informational brochure about children's oral health designed by the NIH for American Indian/Alaska Native parents.
215090514|NCT03052530|DEVICE|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
215090515|NCT00354666|DRUG|GSK159797|
215090516|NCT00596115|DRUG|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
215090517|NCT02440789|DRUG|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
215090518|NCT01420419|OTHER|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
215090519|NCT01420419|OTHER|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
215090520|NCT03561935|DRUG|Propafenone|prescribing propafenone for the management of premature ventricular complex
215090521|NCT03561935|DRUG|Indenol|prescribing indenol for the management of premature ventricular complex
214496927|NCT04777383|DRUG|Atropine|Iontophoretic administration of 5 different concentrations of atropine
214496928|NCT04777383|DRUG|Neostigmine|Iontophoretic administration of 5 different concentrations of neostigmine
214496929|NCT04777383|DRUG|Sterile water|Iontophoretic administration of sterile water
214496930|NCT01961076|OTHER|overnight nutrition regime|Patients receive the specified overnight nutrition regimen
214496931|NCT00622700|DRUG|Teriflunomide|Film-coated tablet Oral administration
214496932|NCT00622700|DRUG|Placebo|Film-coated tablet Oral administration
214496933|NCT01602185|DRUG|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
214376397|NCT03285048|BEHAVIORAL|Cognitive Remediation Therapy|Brain HQ is a computer based cognitive training that uses hierarchical adaptive technology to provide challenging and demanding training that is not too frustrating or discouraging. Training includes auditory and visual sensory training, memory and executive function exercises. The Bridging group is based on similar training programs that focus on self-regulation training, problem focused cognitive behavior therapy and compensatory cognitive strategies.
214988879|NCT01255020|DRUG|Placebo plus restricted protein diet|"placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d."
214988880|NCT05665647|DRUG|Cohort 1: SIM0417/ritonavir and itraconazole|SIM0417/Ritonavir: Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1-Day2, Day9-Day10, BID; Day3,Day11(once only in the morning); Itraconazole：Dose: 200mg once；Day6-Day13, QD
214988881|NCT05665647|DRUG|Cohort 2: SIM0417/ritonavir and rifampicin|SIM0417/Ritonavir:Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1,Day11(once only in the morning); Rifampicin：Dose: 0.6g once; Day4-Day12, QD
214988882|NCT05665647|DRUG|Cohort 3: SIM0417/ritonavir and midazolam|SIM0417/Ritonavir: 750 mg SIM0417 coadministered with 100 mg ritonavir, Day3-Day6, BID; Day7(once only in the morning) Midazolam：Dose: 2mg once; Day1, Day6, QD
214988883|NCT00358488|DRUG|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
214988884|NCT00358488|DRUG|salbutamol|salbutamol
214988885|NCT00358488|DRUG|salmeterol 50mcg|salmeterol 50mcg
214988886|NCT00358488|DRUG|placebo|placebo
214988887|NCT02130609|DEVICE|Skintel|
214988888|NCT02490163|DEVICE|Spectra Optia|"The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.~Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.~The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow."
214988889|NCT04103840|OTHER|Testing stool mycobiota|Both cohorts of SAH and their family controls will be tested for fecal mycobiota
214988890|NCT03448848|DRUG|BCAA preparation Intravenous infusion|BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug
214988891|NCT03448848|DRUG|sterile normal saline|sterile normal saline in a volume equal to the study drug
214988892|NCT02122419|OTHER|lateral|spinal anesthesia performed during lateral position
214988893|NCT02122419|OTHER|sitting|spinal anesthesia performed during sitting position
214496934|NCT01602185|DRUG|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
214988894|NCT02742207|OTHER|Electrical atrial fibrillation Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
214988895|NCT02742207|OTHER|Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
214988896|NCT06394258|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy to the vaginal cuff with the aim to reproduce adjuvant high dose rate (HDR) brachytherapy dose distribution by means of external beam radiotherapy in patients operated for intermediate risk endometrial carcinoma
214988897|NCT02471339|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
214988898|NCT04286880|PROCEDURE|PRP injection|"Clinically proven cases of Trigger points in masseter muscle will be randomly and equally divided into test group and control group. The selected subjects will be divided into two groups.~Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle according to symptoms of patient at baseline (0 week). PRP will be prepared as per methodology mentioned by Okuda et al 2003."
214988899|NCT04286880|PROCEDURE|Dry needling|In control group all the armamentarium and procedure will remain same except that no PRP solution will be delivered. Only dry needling will be performed on the baseline.
214988900|NCT05356663|OTHER|Mulligan Mobilization|Medial glide MWM for knee flexion (supine) Lateral glide MWM for knee flexion (supine) Medial glide MWM for knee flexion.( prone ) Lateral glide MWM for knee flexion (prone)
214988901|NCT05356663|OTHER|Hold Relax|Hold-relax technique of PNF included, the affected knee will be flexed passively to the end of range with the therapist's hand on the patient's lower leg. Patients then performed 5 s of quadriceps contraction against the resistance of the therapist. Patients will be asked not to let move. At the end of 5 s, the patients will be asked to totally relax for 10 s and the therapist pushed the knee into more flexion and hold at that newly acquired range
214988902|NCT05662813|DRUG|Almonertinib|Almonertinib 110mg p.o qd. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
214988903|NCT00318396|PROCEDURE|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
215090522|NCT02410577|DRUG|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
215090523|NCT02410577|DEVICE|PET/CT Scan|
215090524|NCT02410577|DEVICE|MRI|
214376398|NCT01870362|DRUG|Probiotic (Inersan)|
214496935|NCT01602185|DRUG|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
214496936|NCT00861003|DEVICE|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
214376399|NCT01870362|DRUG|Placebo|
214496937|NCT00284752|DRUG|Abraxane|This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
214496938|NCT06246890|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
214988904|NCT00318396|PROCEDURE|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
214988905|NCT00564356|PROCEDURE|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
214988906|NCT01675778|DRUG|Hydromorphone|a fixed dose (1 mg) of hydromorphone will be given to the study subjects
214988907|NCT04067999|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
214988908|NCT01110941|DRUG|S-1, leucovorin, oxaliplatin|S-1(20mg、25mg), capsule, 40\~60mg, Bid,p.o., day1\~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1\~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
214988909|NCT06437756|OTHER|Theraband resistance training|Three sessions of 30 minutes each was used to complete the intervention over the course of six weeks (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session Participants were advised to take 5 mins rest before moving to next movement if they would feel fatigued after one movement. Thera-Band was utilized in only three different colors for the workouts.
214988910|NCT06437756|OTHER|Conventional Resistance Training|The intervention was carried out over the course of six weeks in three sessions of 30 minutes each (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session. The resistance-training program was performed with Universal weights.
214988911|NCT00626639|DRUG|Placebo|Administered by intravenous (IV) bolus injection
214988912|NCT00626639|DRUG|palifermin|Administered by intravenous (IV) bolus injection
214988913|NCT00626639|RADIATION|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation \[one fraction per day\])
214988914|NCT00626639|DRUG|Cisplatin|100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.
214988915|NCT00635505|DRUG|albuterol HFA (Armstrong's)|180 mcg QID 12 weeks
214988916|NCT00635505|DRUG|albuterol HFA (Proventil HFA)|180 mcg QID 12 weeks
214988917|NCT00635505|DRUG|HFA placebo|2 actuations QID 12 weeks or until use of rescue drug
214988918|NCT05042492|DEVICE|gekoTM|The gekoTM device is a small, transcutaneous nerve stimulator that is placed non-invasively on the skin, whereby the surface electrodes will be attached close to the peroneal nerve. Activation of the peroneal nerve causes contraction of the calf muscle pump, which will increase blood circulation that corresponds to 60% of walking. The increased blood circulation reduces the pressure difference between capillaries and the surrounding tissue and transfers the tissue fluid back into the veins and lymph fibers
214988919|NCT05018780|OTHER|Muscle Energy Technique|"Post isometric relaxation: Patient will be asked to perform isometrics on piriformis, iliopsoas and erector spinae muscles one by one. Each isometric contraction will be held for 10 seconds. After 10 seconds, contraction will be released with an exhalation. These contractions will be repeated for 5 times in one session.~Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Muscle Energy Technique."
215090525|NCT02410577|OTHER|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
215090526|NCT04573881|DEVICE|HistoSonics System|The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
215090527|NCT02313883|DRUG|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
214376400|NCT02542644|DEVICE|Ultrahigh resolution Spectral Domain OCT|"The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed."
214496939|NCT02506452|OTHER|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
214496940|NCT02506452|OTHER|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
215090528|NCT02434965|DRUG|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
215090529|NCT02434965|DRUG|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
215090530|NCT06365138|BEHAVIORAL|Bahaviour at the time of an aortic aneurysm rupture|Questionnaire and patient interview, diary for day of rupture and the three previous days
215090531|NCT02411786|BIOLOGICAL|pTVG-AR|Given ID
215090532|NCT02411786|BIOLOGICAL|gm-csf|Given ID
214988920|NCT05018780|OTHER|Sacral Manipulation|"* To manipulate an iliac anterior rotation displacement sacroiliac joint dysfunction and to restore posterior rotation of the ilium, participant will be positioned in side lying. Therapist will place one hand at Anterior superior iliac supine (ASIS) and the other at Ischial tuberosity. A quick thrust will be applied and ASIS will be pushed posteriorly while Ischial tberosity anteriorly. This will be maintained for 10 to 30 seconds.~* To manipulate an iliac posterior rotation displacement sacroiliac joint dysfunction and to restore anterior rotation of the ilium, participant will be in prone position. One hand of therapist will be at Posterior superior iliac supine (PSIS) and the other one at pubic rami. A quick thrust will be delivered and PSIS will be moved anteriorly while pubic rami posteriorly. This will be maintained for 10 to 30 seconds.~* Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Sacral Manipulation."
215090533|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
215090534|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
214376401|NCT05771701|DEVICE|Pain pressure threshold measurement|"Pain pressure threshold (PPT) is used to measure deep muscular tissue sensitivity. The test determines the amount of pressure over a given area in which a steadily increasing nonpainful pressure stimulus turns into a painful pressure sensation. A varying pressure is applied from 0.5 to 1 kg/sec in a perpendicular direction relative to the muscle. PPT has no standard protocol on administration and placement. Equipment used varies with many handheld electric algometers.~PPT has been used on a wide variety of patients and conditions, including musculoskeletal and neuromuscular disorders (eg, Parkinson disease, tension headaches, pelvic pain, low back pain, myofascial trigger points, sacroiliac joint pain, knee osteoarthritis, skin humidity, shoulder pain, lateral epicondylitis)."
214376402|NCT01190046|BEHAVIORAL|Resistance exercise training|Lower extremity resistance exercise training 3x/wk
214376403|NCT01581723|DEVICE|Monopolar diathermy|monopolar diathermy
214376404|NCT01581723|DEVICE|Bipolar diathermy|bipolar diathermy
214376405|NCT00378443|DRUG|prednisone + Inhibace/Cozaar|
214496941|NCT05508854|GENETIC|prenatal genetic counselling|Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb in terms of genetic diseases, the tests and risks that can be done for the diagnosis of the disease, the test results and information about the disease in case of illness and the presentation of options.
214496942|NCT04567459|DIETARY_SUPPLEMENT|Premium Amino Acids|after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening
214496943|NCT01199315|DRUG|AZD1446|oral capsule, Moderate Release
214988921|NCT01461551|DRUG|Sevoflurane|anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)
215090535|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
215090536|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
214376406|NCT00378443|DRUG|Inhibace/Cozaar|
214496944|NCT01199315|DRUG|Placebo|oral capsule
214496945|NCT03611556|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
214496946|NCT03611556|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
214496947|NCT03611556|DRUG|Gemcitabine|Participants will receive IV infusion of gemcitabine as stated in arm description.
214988922|NCT01461551|DRUG|Propofol|anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)
214988923|NCT01461551|DRUG|combine of sevoflurane and propofol|anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
214988924|NCT01155141|DRUG|H.P. Acthar Gel|Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
214376407|NCT02817035|DEVICE|noninvasive mechanical ventilation|To examined the physiological signals of patients and healthy subjects during spontaneous breathing and noninvasive mechanical ventilation.
214376408|NCT05541302|DEVICE|TMS|Transcranial Magnetic Stimulation
214496948|NCT03611556|DRUG|Nab-paclitaxel|Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
214496949|NCT03611556|DRUG|Oxaliplatin|Participants will receive IV infusion of oxaliplatin as stated in arm description.
214496950|NCT03611556|DRUG|Folinic acid|Participants will receive IV infusion of folinic acid as stated in arm description.
214376409|NCT00779974|OTHER|Evaluation|For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
214376410|NCT02571790|BEHAVIORAL|Relaxation optimized virtual reality|
214376411|NCT02571790|BEHAVIORAL|Classical relaxation (without Virtual Reality)|
214496951|NCT03611556|DRUG|5-FU|Participants will receive IV infusion of 5-FU as stated in arm description.
214496952|NCT03068988|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
214496953|NCT03068988|PROCEDURE|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
214376412|NCT03842839|DRUG|Tiotropium Inhalation Powder [Spiriva] 0.018mg|Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.
214376413|NCT03842839|DRUG|Salbutamol sulphate aerosol (Ventolin) 0.01mg|As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
214988925|NCT05052905|DEVICE|LibraVR|"LibraVR is a standalone VR-based rehabilitation software for use in physiotherapy. It is designed to work with standard off-the-shelf hardware that is tested and approved for use in conjunction with the software.~LibraVR system consists of the software (LibraVR Clinic) running on a PC (database of patients, creation of protocols, uploading protocols to mobile), and the LibraVR Mobile APP that runs on commercial mobile smartphones embedded in a lightweight cardboard or plastic VR viewer that the child wears as they would eyeglasses. The software displays a range of immersive VR exercises."
214988926|NCT00847028|OTHER|glucose 10%|2 minutes prior to the venipuncture, a 10% glucose concentration was administered orally
214988927|NCT00847028|OTHER|20% glucose|2 minutes prior to the venipuncture, a 20% glucose concentration was administered orally
214988928|NCT00847028|OTHER|glucose 30%|2 minutes prior to the venipuncture, a 30% glucose concentration was administered orally
214988929|NCT00847028|OTHER|sterile water|2 minutes prior to the venipuncture, sterile water was administered orally
214988930|NCT04055883|DRUG|DA-1229|All participants are administered one tablet per day for 96 weeks
214988931|NCT01720966|PROCEDURE|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
214988932|NCT01694134|DRUG|Hydrocortancyl.|Patients will receive an intradiscal injection of hydrocortancyl.
214988933|NCT01694134|DRUG|Lidocaine|
214988934|NCT02016118|DEVICE|Ialuril|The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
214988935|NCT00733434|DRUG|Prostaglandin E1|PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
214376414|NCT02595216|DEVICE|Profound System|The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
215090537|NCT03400813|BEHAVIORAL|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.
214376415|NCT00252434|BEHAVIORAL|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
214988936|NCT00733434|OTHER|Saline|500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
214988937|NCT03473197|DRUG|Diacerein 1% ointment|During the 3-week Induction Phase, diacerein 1% ointment and vehicle ointment were applied under fully occlusive patch conditions to two randomly assigned skin sites on the infrascapular region of the back twice each week for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. Following a rest period, during the Challenge Phase, the study products were applied to two naive sites once for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. A Re-Challenge was to be performed if a response observed during the Challenge Phase indicated photosensitization.
214988938|NCT00440843|DRUG|Olanzapine (Zyprexa)|OLZ
214988939|NCT00440843|DRUG|Typicals|Stay on typicals regimen
215090538|NCT00317408|BIOLOGICAL|anti-thymocyte globulin|
215090539|NCT00317408|DRUG|busulfan|
215090540|NCT00317408|DRUG|carboplatin|
215090541|NCT00317408|DRUG|carmustine|
215090542|NCT00317408|DRUG|cyclosporine|
215090543|NCT00317408|DRUG|cytarabine|
215090544|NCT00317408|DRUG|dexamethasone|
215090545|NCT00317408|DRUG|etoposide phosphate|
215090546|NCT00317408|DRUG|idarubicin|
214376416|NCT02583438|DRUG|Saxagliptin (Bristol-Myers Squibb Company)|6-month treatment of Saxagliptin 5mg Qd
214496954|NCT03766191|BEHAVIORAL|Food Ads|Exposure to foods ads embedded in an age-appropriate TV program
214496955|NCT03766191|OTHER|Non-food Ads|Exposure to non-food ads embedded in an age-appropriate TV program
214496956|NCT00482911|DRUG|cyclophosphamide|25-50 mg by mouth once daily on days 1-28.
214496957|NCT00482911|DRUG|lenalidomide|10 mg by mouth once daily on days 1-28.
214496958|NCT00482911|DRUG|sunitinib malate|12.5 - 25 mg by mouth once daily on days 1-28.
214988940|NCT01946945|GENETIC|Next Generation Sequencing after Blastocyst biopsy|PGD using blastocyst biopsy and testing of the biopsy by NGS
215090547|NCT00317408|DRUG|ifosfamide|
214496959|NCT00584675|DEVICE|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
214496960|NCT05503368|PROCEDURE|surgical treatment of vitiligo using NCES|NCES is the standard technique for surgical treatment of vitiligo, herein we compare the standard technique, to added autologous cellular micro-grafts and to follicle cell suspension
214496961|NCT02313675|DRUG|Acetaminophen|
214496962|NCT02313675|DRUG|Ketorolac Tromethamine|
214496963|NCT02313675|DRUG|Saline|
215090548|NCT00317408|DRUG|leucovorin calcium|
215090549|NCT00317408|DRUG|lomustine|
215090550|NCT00317408|DRUG|melphalan|
215090551|NCT00317408|DRUG|methotrexate|
215090552|NCT00317408|DRUG|mitoxantrone hydrochloride|
215090553|NCT00317408|DRUG|prednisolone|
215090554|NCT00317408|DRUG|thiotepa|
215090555|NCT00317408|DRUG|vinblastine sulfate|
215090556|NCT00317408|DRUG|vindesine|
215090557|NCT00317408|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
215090558|NCT00317408|PROCEDURE|autologous hematopoietic stem cell transplantation|
215090559|NCT00317408|PROCEDURE|peripheral blood stem cell transplantation|
215090560|NCT00317408|RADIATION|total-body irradiation|
215090561|NCT04151849|DRUG|GLP-1 receptor agonist|Treatment with GLP-1 agonist for up to 1 year.
215090562|NCT04151849|DRUG|SGLT2 inhibitor|Treatment with SGLT2 inhibitor for up to 1 year
214988941|NCT00267670|DRUG|Pentoxifylline|400mg PO TID
214988942|NCT00267670|DRUG|Placebo|1 pill PO TID
214988943|NCT01828658|OTHER|Strict bioimpedance guided dry weight prescription|Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
214988944|NCT00785629|DRUG|Calcium acetate|
214988945|NCT00785629|DRUG|Lanthanum Carbonate|
214988946|NCT00785629|DRUG|Sevelamer Carbonate|
214988947|NCT00785629|DRUG|Placebo|
214988948|NCT00014014|DRUG|Lamivudine/Zidovudine|
214988949|NCT00482833|DRUG|arsenic trioxide|"Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.~Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28)."
214988950|NCT00482833|DRUG|idarubicin|"Induction~Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .~If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.~Consolidation~1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.~3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1."
214988951|NCT00482833|DRUG|mercaptopurine|Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
214988952|NCT00482833|DRUG|methotrexate|Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
214988953|NCT00482833|DRUG|all-trans retinoic acid|"Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.~Consolidation~1. st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~2. nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~3. rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~Maintenance therapy~ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed."
214988954|NCT00482833|DRUG|all-trans retinoic acid (ATRA)|"Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.~Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26)."
214988955|NCT06397482|DIETARY_SUPPLEMENT|Encapsulated Calcium Butyrate|Contains at minimum 35% butyric acid
214988956|NCT01384656|DRUG|GIK solution|Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
214988957|NCT05241951|OTHER|Structured hand-off|Use of standardized checklist to provide synchronous or asynchronous handoff that conveys medication recommendations to the SNF clinical teams
214988958|NCT05241951|OTHER|Medication reconciliation during transitional period|Comprehensive medication reconciliation conducted during transitional period between hospital and SNF, focused on SNF-specific requirements for medication delivery (e.g., stop dates, titration instructions)
214988959|NCT05241951|OTHER|Transitional medication monitoring|Review of medication orders during first 7 days of SNF admittance to address barriers to translation of medication orders and appropriate medication delivery
214988960|NCT05241951|OTHER|Teleconsultation|Ad hoc consultation to provide additional clarification to SNF clinical teams
214988961|NCT05318326|DRUG|placebo group|placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
214988962|NCT05318326|DRUG|Yogliptin 400mg group|Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
214988963|NCT05318326|DRUG|Yogliptin 200mg group|Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
214988964|NCT05062473|BEHAVIORAL|Lifestyle Modification Webinars Focused on Hypertension Control|Participation in a 12-week health education telemedicine curriculum
214988965|NCT02671968|DEVICE|Continuous Glucose Monitoring System|
214988966|NCT00006039|BIOLOGICAL|pegylated interferon alfa|
214988967|NCT05413772|OTHER|Temocillin|To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections
215090563|NCT02631265|OTHER|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
214376417|NCT02104492|OTHER|a 12-week Respiratory Muscles Training Program (RMTP)|Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.
214376418|NCT02104492|OTHER|Active Comparator|Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
214376419|NCT03221725|PROCEDURE|sacrospinous ligament fixation|sacrospinous ligament fixation will be applied to prevent vaginal vault prolapse
214376420|NCT01455935|DRUG|Anti-platelets and statin|
214376421|NCT01455935|DRUG|alteplase|"Full dose Intravenous thrombolysis~* 0.9 mg/kg~* Maximum dose is 90 mg~* 10% of the dose will be given over one minute~* 90% of the dose will be infused over 1 hour~* Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~* Neuro checks every 5 minutes during the infusion~* Neuro checks every hour after the infusion for 24 hours"
214376422|NCT01455935|PROCEDURE|intra arterial intervention|"1. Intra arterial Activase (Maximum dose of 22 mg)~2. MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~3. PENUMBRA device (no standard time frame for how long the procedure takes)"
214988968|NCT01114555|DRUG|Bevacizumab, Irinotecan and Temozolomide|Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
214988969|NCT00851591|DRUG|fenugreek|3 capsules 3 times per day with a full glass of water each dose for 7 days
214988970|NCT00851591|DRUG|Placebo (Psyllium)|3 capsules 3 times a day with a full glass of water each dose for 7 days
214988971|NCT03320915|DRUG|Cholecalciferol|Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
214988972|NCT02458417|DEVICE|ReCell|A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.
214988973|NCT02458417|DEVICE|Full surface CO2 laser 200 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 144 µm) and density 3
214988974|NCT02458417|DEVICE|Full surface CO2 laser 150 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3
214988975|NCT02458417|DEVICE|Fractional CO2 laser 7.5 mJ, 20%|Pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density.
214988976|NCT00722696|OTHER|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
214988977|NCT05627687|BEHAVIORAL|Heart Rate Variability Biofeedback|Practice using the Inner Balance app and device, 10 minutes/day, 4-5 days per week
214988978|NCT05627687|BEHAVIORAL|Music Listening Control|Listening to music using the Coffeehouse playlist on either Pandora or Spotify app, 10 minutes/day, 4-5 days per week
214988979|NCT01543854|DRUG|RLX030|Intravenous infusion of RLX030 over 20 hrs
214988980|NCT01543854|DRUG|Placebo|Intravenous infusion of placebo over 20 hours
214988981|NCT01789268|DEVICE|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
214988982|NCT04794998|DRUG|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy
214988983|NCT04794998|DRUG|Control treatment schedule|Treatment regimens different from the recommended one according to family phisicians personal practice.
214988984|NCT03111433|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 soft gelatin capsule 100mg
214988985|NCT03111433|DRUG|Insulin|multiple dose insulin injection therapy
214988986|NCT00930462|DEVICE|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
214988987|NCT05156008|OTHER|Ultrasound-guided vascular access|Patients in this arm will have peripheral venous cannula inserted under realtime ultrasound guidance. Out of plane technique (in plane technique if too deep when tip of the needle is on vessel wall) used by experienced physicians in UGVA. Out of plane technique strictly used in step by step manner. That means moving probe with the tip of the needle to always locate its exact position, all the way into the vein. All performed insertions are carried out by skilled operators in UGVA with out of plane technique. Just before surgery in block room.
214988988|NCT04727619|BEHAVIORAL|SLEEP program|SLEEP is a 6-week educational program designed to improve sleep hygiene and habits.
214988989|NCT06329596|DIETARY_SUPPLEMENT|Xylitol gum|Two pieces of xylitol gum after meals, thrice a day.
214376423|NCT02404389|DRUG|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
214376424|NCT02404389|DRUG|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
214376425|NCT03265106|BIOLOGICAL|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
214988990|NCT06329596|DIETARY_SUPPLEMENT|Sorbitol gum|Two pieces of sorbitol gum after meals, thrice a day.
214988991|NCT01850992|DEVICE|Active CPAP|Effective CPAP will be administered
214988992|NCT01850992|DEVICE|Sham CPAP|This is placebo CPAP
214988993|NCT05989152|RADIATION|FDG-PET at the end of treatment for IE|FDG-PET at the end of treatment for IE in patients with a prosthetic valve
214988994|NCT06309394|DRUG|INCB099280|INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
214988995|NCT01066377|DIETARY_SUPPLEMENT|Prebiotic and probiotic mix|The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10\^8 - 10\^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested).
214376426|NCT04990869|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
214376427|NCT04990869|DIETARY_SUPPLEMENT|Placebo|Placebo
214376428|NCT03020225|DIETARY_SUPPLEMENT|White cheese|animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
214376429|NCT03020225|DIETARY_SUPPLEMENT|Green peas|Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
214496964|NCT05973279|OTHER|Tecno Body Prokin Isokinetic Balance System|It provides objectively measurable data in static and dynamic balance measurements. The moving balance platform of the system, which is driven by air piston servo motors, can measure at a working angle of 15 degrees in all directions. The results can be monitored and recorded live on the screen on the device. From these data, each individual's static and dynamic balance score is obtained by summing the forward-backward standard deviation and right-left standard deviation.
214988996|NCT06568679|OTHER|No intervention; observational|No intervention; observational
214988997|NCT04556747|OTHER|VR - Distraction|Participants will be instructed to use any application.
214988998|NCT04556747|OTHER|VR - Biofeedback|Participants will be instructed to use the Mindful Aurora application.
214988999|NCT00117234|DRUG|darbepoetin alfa|
214989000|NCT02266524|DRUG|Tamsulosin hydrochloride, very low dose|
214989001|NCT02266524|DRUG|Tamsulosin hydrochloride, low dose|
214989002|NCT02266524|DRUG|Tamsulosin hydrochloride, medium dose|
214989003|NCT02266524|DRUG|Tamsulosin hydrochloride, high dose|
214989004|NCT03173274|BEHAVIORAL|Brief Motivational Intervention|Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.
214989005|NCT03173274|BEHAVIORAL|Contingency Management|Contingent Reinforcement for negative breath CO samples
214989006|NCT03173274|BEHAVIORAL|Non-Contingent Reinforcement|Participants will receive reinforcement for submitting samples ona yoked schedule unrelated to CO sample value \[CM control\]
214989007|NCT00888745|DRUG|placebo|Intravenous and subcutaneous ascending dose
214989008|NCT00888745|DRUG|PRO283698|Intravenous and subcutaneous ascending dose
214989009|NCT00970580|DRUG|BIIB022 With Paclitaxel and Carboplatin|Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
214989010|NCT06356493|PROCEDURE|caesarean hysterectomy with prior placement of prophylactic occlusion balloons of both internal iliac arteries|Preoperative placement of prophylactic occlusion balloons of both internal iliac arteries (OBIIA) was performed at radiology department. Access to the internal iliac arteries was achieved by retrograde transcutaneous introduction of hydrophilic sheath kits of 8.5 mm under fluoroscopic guidance from both femoral arteries. Once in the lumens of the two internal iliac arteries, the radiologist inflated the balloons until blood flow ceased. The pressure at which occlusion of both internal iliac arteries was achieved was recorded for subsequent replication in the operating room. The radiologist secured the two kits to the skin and applied a compressive dressing. The patient was then directly transferred to the operating room.
214989011|NCT06356493|PROCEDURE|caesarean hysterectomy without prior placement of prophylactic occlusion balloons of both internal iliac arteries|"Caesarean hysterectomy was performed through a midline infraumbilical incision. The bladder-uterine peritoneum was dissected, followed by a vertical fundal hysterotomy away from the placenta, and the baby was delivered This was followed by clamping the umbilical cord and closure of the hysterotomy while leaving the placenta in situ without any attempt at traction or delivery and without oxytocin administration.~We proceeded with the remaining steps of hysterectomy."
214376430|NCT03020225|DIETARY_SUPPLEMENT|Mankai|Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
214376431|NCT00652938|BIOLOGICAL|HPV Vaccine (GSK580299) Cervarix TM|IM administration
214989012|NCT03097263|OTHER|Physical Rehabilitation program|
214376432|NCT00652938|BIOLOGICAL|Engerix B|IM administration
214989013|NCT05745168|DIAGNOSTIC_TEST|OraQuick|The intervention is based on respondent-driven sampling approach. Each selected seed from hotspots and on social networks is provided with two types of coupons for HIVST kit at partner pharmacy: electronic coupons (e-coupons) consisting of a pictured unique anonymous QR code and identifier and the address of pharmacies; paper coupons consisting of similar information to e-coupon. The seeds will then distribute coupons to their networks physically, via social media, and smart phone applications. Each recruited participant will bring the coupon to be scanned at the pharmacies to receive a free access HIVST kit. There, trained community worker will do the study visit including information/consent, e-CRF filling and providing link to send the test results. These recruited individuals will be considered as wave 1 and will each receive 10 additional coupons to recruit new members in the networks. The next round of individuals recruited and enrolled will be considered as wave 2, and so on.
214989014|NCT05001048|DRUG|Phenylephrine Hydrochloride|Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.
214376433|NCT05239325|BEHAVIORAL|World Cancer Day Walk|Health literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening
214376434|NCT03299790|OTHER|high-intensity interval exercise training (HIIT)|This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).
214989015|NCT05001048|OTHER|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
214376435|NCT03299790|OTHER|moderate-intensity exercise training (MIT)|This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.
214376436|NCT01412801|BIOLOGICAL|Group B streptococcus vaccine|Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.
214989016|NCT05001048|OTHER|Isocapnic Acute Hypoxia|During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.
214496965|NCT05973279|OTHER|Restorative Therapies RT300 leg/arm/cor:|RT300 is a motorised treatment system. In general there are 3 systems; Passive therapy, Active therapy and a combination of active therapy with some assistance from the motor. The device can be used from a chair, wheelchair or bed and there are two variants that can be used separately; Leg system, Arm system. Electrodes placed on the skin over specific muscle groups are connected via a cable or wirelessly to the RT300. These are used to stimulate peripheral motor nerves, causing the muscles to work. The software of the SAGE controller unit of the RT300 monitors the treatment process, including the stimulation patterns sent to the arms or legs, and the operation of the ergometer motor to produce smooth cycling motion. Contraindicated in the presence of lower limb fractures or pregnancy.
214687059|NCT05610748|PROCEDURE|Soft tissue augmentation|In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.
214687060|NCT05257408|DRUG|Nab-paclitaxel 80 mg/m^2|Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.
214989017|NCT05001048|OTHER|Hyperoxia|During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.
214989018|NCT03136198|OTHER|LUS-guided strategy-of-care|"For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.~2. Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)~3. Reassessment every 2 hours"
214989019|NCT03136198|OTHER|Usual Care|Patients will receive usual AHF care
214989020|NCT03136198|DRUG|Intravenous Loop Diuretic|IV loop diuretic
214989021|NCT03136198|DRUG|Vasodilator|IV, topical, or SL Vasodilator
215090564|NCT02631265|OTHER|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
214376437|NCT05540314|PROCEDURE|robotic bariatric surgery|robotic bariatric surgery
214376438|NCT02013492|DRUG|propranolol hydrochloride|Given PO
214687061|NCT05257408|DRUG|Relacorilant 150 mg once daily (QD)|Relacorilant is administered as capsules for oral dosing.
214989022|NCT03136198|DEVICE|Non invasive Ventilation (NIV)|Face, mouth, or nasal mask applied to provide positive pressure ventilation
214989023|NCT03727867|DRUG|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor|Oral EGFR TKI begins on day 1 and continues until disease progresses.
214989024|NCT03727867|DEVICE|Stereotactic Body Radiation Therapy|Participants were given Stereotactic Body Radiation Therapy in a dose of 60 Gy/8 fraction for the central tumor or 50 Gy/5 fraction for the peripheral lung cancer, respectively.
214989025|NCT03639415|DRUG|Increasing the Controlled-Release Oxycodone dose frequency|Keep the daily dose while increase the dose frequency of Controlled-Release Oxycodone so that reduce the single dose
214989026|NCT00668928|OTHER|Polyphenols (flavon-3-ol monomers and oligomers)|Flavanols
214989027|NCT04156529|BEHAVIORAL|ESU position|Semi-elevated supine (ESU) position was given during tube feeding
214989028|NCT04156529|BEHAVIORAL|ESRL position|Semi-elevated right lateral (ESRL) position was given during tube feeding
214989029|NCT01503788|DRUG|Midazolam|participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
214989030|NCT02030873|OTHER|Virtual simulation training|Virtual simulation training in the Visible Ear Simulator.
214989031|NCT05871801|DRUG|Bowel preparation for colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylenglycol (PEG) solution, 2 Liters of PEG-Asccorbic acid or 2L sodium picosulphate.
214989032|NCT05871801|DEVICE|Colonoscopic examination|Colonoscopy will be performed to every patient included in the study
214989033|NCT04995159|DRUG|Single anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.
214989034|NCT04995159|DRUG|Dual anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
214989035|NCT05840445|DRUG|Onabotulinum toxin A|Intramuscular application of onabotulinum toxin-A in the upper facial third.
214989036|NCT05840445|DRUG|Prabotulinumtoxin A|Intramuscular application of prabotulinum toxin-A in the upper facial third.
214687062|NCT05257408|DRUG|Nab-paclitaxel 100 mg/m^2|Nab-paclitaxel is administered as IV infusion on Day 1, 8, and 15 of each 28-day cycle.
214687063|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
214989037|NCT00435617|DEVICE|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
214989038|NCT04674956|DRUG|Camrelizumab|PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.
214989039|NCT04674956|DRUG|Paclitaxel(Albumin Bound) and Gemcitabine|Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.
214989040|NCT04674956|DRUG|Placebo|Placebo, 200mg, D1; every 21 days as a cycle.
214989041|NCT05110664|DRUG|PYY (3-36) Peptide|oral PYY3-36 solution
214989042|NCT05110664|DRUG|Placibo|oral placebo solution
214989043|NCT03492203|BEHAVIORAL|Active Cognitive Remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life. The novel components of CR in this study will be the delivery of treatment remotely.
214989044|NCT03492203|BEHAVIORAL|Cognitive Remediation Control|The investigators have developed a 'comparison' cognitive remediation treatment in collaboration with the same company that produced the cognitive exercises. These procedures include the same stimuli but are adjusted without increasing cognitive load.
214989045|NCT03492203|BEHAVIORAL|Online computer exercises|There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.
214989046|NCT03492203|BEHAVIORAL|Strategy monitoring|Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.
214989047|NCT03492203|BEHAVIORAL|Bridging strategies|The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).
214989048|NCT03713918|OTHER|Reinforced lithium silicate endocrowns|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with reinforced lithium silicate and cemented with self adhesive cement
214989049|NCT03713918|OTHER|Post retained reinforced lith silicate crn|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and reinforced lithium silicate crown will be cemented with self adhesive cement.
214989050|NCT01052948|OTHER|Retrospective study-|
214989051|NCT01052948|OTHER|Retrospective study-|
215090565|NCT02631265|OTHER|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
215090566|NCT05380323|DRUG|LY3541105|Administered SC.
215090567|NCT05380323|DRUG|Placebo|Administered SC.
214376439|NCT02013492|OTHER|Correlative Studies|"Correlative studies will be conducted using the following materials:~* Plasma derived from peripheral blood.~* Peripheral blood mononuclear cells (PBMC) derived from patient blood~* Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.~* Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease."
214376440|NCT00593125|DRUG|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
214376441|NCT05845775|PROCEDURE|Percutaneous dilatational tracheostomy|The percutaneous dilatational tracheostomy procedure will be performed via fiberoptic bronchoscopy
214376442|NCT05845775|DEVICE|Bronchoscopy|Fiberoptic bronchoscopy
214376443|NCT05845775|DEVICE|ultrasonography|ultrasonography
214376444|NCT05845775|DIAGNOSTIC_TEST|Bronchoscopy application|Fiberoptic bronchoscopy application
214376445|NCT05845775|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound examination
214376446|NCT04318158|DRUG|Bupivacaine|single shot US guided TAP block using 20 ml bupivacaine 0.25%.
214989052|NCT01052948|OTHER|Retrospective study-|
214989053|NCT01052948|OTHER|Retrospective study-|
214989054|NCT01935115|DRUG|Propofol|Propofol anesthesia for ECT
214989055|NCT01935115|DRUG|Ketamine|Ketamine anesthesia for ECT
214989056|NCT04795349|PROCEDURE|Vacuum-assisted breast biopsy|In those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen.
214989057|NCT01865019|DEVICE|mechanical ventilation|
215090568|NCT05008198|OTHER|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
214989058|NCT03510000|DRUG|Empagliflozin 25mg|Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.
214376447|NCT04318158|DRUG|Dexmedetomidine|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
214376448|NCT04318158|DRUG|Fentanyl|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
214376449|NCT03527355|BIOLOGICAL|Vi-DT|Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
214376450|NCT03527355|BIOLOGICAL|FluQuadri™|"Manufacturer: Sanofi Pasteur Dose: 0.25 ml~\*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding."
214376451|NCT03527355|OTHER|0.9% sodium chloride isotonic solution|Manufacture: Euro-Med Inc. Dose: 0.5 mL
214376452|NCT03154502|DIAGNOSTIC_TEST|Urinary sodium excretion|Urinary sodium and potassium were measured using the Ion-Selective Electrode (ISE) indirect Na-K-Cl for Gen.2 (Roche Diagnostic, Switzerland).
214376453|NCT02573922|DRUG|oxycodone-naloxone|
214376454|NCT02573922|DRUG|Oxycodone|
214376455|NCT04045444|OTHER|walking|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be walking at 3 km/h, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.
214376456|NCT04045444|OTHER|cognitive task|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be a cognitive task, a control cognitive task.
214376457|NCT00538928|OTHER|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
214376458|NCT04376554|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) PO q8h \[±1 hour\] for 10 days
214376459|NCT04376554|DRUG|amoxicillin-clavulanate|amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h \[±1 hour\] for 10 days
214376460|NCT06225102|BEHAVIORAL|Kegel Exercise|"* Before teaching Kegel exercises, it was recommended that the person empty his bladder and wear comfortable clothing.~* It was said that the person should extend his legs straight while exercising and not to contract his leg, hip and abdominal muscles and not to hold his breath while the pelvic floor muscles contract.~* The relevant muscles were told to contract for 10 seconds and then relax for 10 seconds. The person was also asked to do the exercises during daily activities.~* Exercise was implemented regularly 3 times a day (minimum 30-45 exercises) in the morning, noon and evening."
214687064|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
214989059|NCT03510000|DEVICE|Single hormone artificial pancreas|Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.
214376461|NCT04795310|DEVICE|Pulsed dye laser|"PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).~IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment."
214376462|NCT03591367|DIAGNOSTIC_TEST|MicroRNAs-155|Quantitative analysis of cell-free miR-155 using RT-qPCR.
214376463|NCT03591367|DIAGNOSTIC_TEST|Human telomerase reverse transcriptase|Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.
214376464|NCT04860947|DIAGNOSTIC_TEST|Brain MRI|"* Axial DWI with ADC card~* Axial 2D TSE T2/DP or 3DT2~* Gadolinium injection (0.1 mmol/kg)~* 3D Fluid-attenuated inversion recovery~* 3D T1 with Gadolinium injection."
214376465|NCT04860947|DIAGNOSTIC_TEST|Spinal Cord MRI|Sagittal T2 Sagittal T1 with Gadolinium injection
214376466|NCT04860947|DIAGNOSTIC_TEST|Retinal imaging|spectral-domain high definition optical coherence tomography
214376467|NCT00824980|DRUG|IP10.C8|IP10.C8 Gel 1%
214376468|NCT03711630|BEHAVIORAL|Meditation|Meditation practice will be through the InsightTimer smart device application. Participants will choose what types of meditation practices they will engage in and report their time spent meditating via REDCap.
214687065|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
214687066|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
214687067|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
214687068|NCT01168713|DRUG|Levofloxacin|"Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5"
214687069|NCT01168713|DRUG|CEM-101|"CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5"
214989060|NCT03510000|BEHAVIORAL|Meal strategies|Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.
214376469|NCT02978443|DRUG|Nivolumab|nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
214376470|NCT02978443|DRUG|Ipilimumab|ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
214376471|NCT01547299|DRUG|Enzalutamide|
214376472|NCT01547299|DRUG|Leuprolide|
214376473|NCT01547299|DRUG|Dutasteride|
214376474|NCT00829335|PROCEDURE|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
214376475|NCT00081302|BIOLOGICAL|cetuximab|
214376476|NCT00081302|DRUG|carboplatin|
214376477|NCT00081302|DRUG|paclitaxel|
214376478|NCT00081302|RADIATION|radiation therapy|
214376479|NCT06260735|DEVICE|Trans-spinal electrical stimulation|Trans-spinal electrical stimulation (ts-ES) at T11-L1 vertebral levels with short pulses at a set frequency (30Hz).
214989061|NCT00764114|DRUG|antibiotic|6 or 12 weeks
214989062|NCT02517788|DRUG|Interferon beta-1a HSA-free biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
214989063|NCT02517788|DRUG|Interferon beta-1a HSA+ biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
214989064|NCT02517788|DRUG|Interferon beta-1a original|6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
214989065|NCT02656030|OTHER|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
214989066|NCT02656030|OTHER|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
214989067|NCT02656030|OTHER|usual care|usual care, 2 time per week, 6 weeks duration
214989068|NCT00519350|PROCEDURE|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
214989069|NCT04124133|DEVICE|dressing with hyaluronic acid|Application of ialuset cream or gauzepad (hyaluronic acid)
215090569|NCT02564978|DRUG|Minocycline|Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
215090570|NCT03684694|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion.
214376480|NCT06260735|DEVICE|Electrical muscle activation|Peripheral nerve (PN) or muscle (NMES) stimulation strategy was developed for each participant to optimize stance/walk capacity based on personal needs/preferences.
214376481|NCT06260735|OTHER|Treadmill walking|Stepping on a treadmill with individually preferred speed.
214376482|NCT02931201|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
214376483|NCT02936050|PROCEDURE|Diagnostic ultrasound|All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
214376484|NCT05490264|BIOLOGICAL|[68Ga]Ga-NOTA-SNA002|\[68Ga\]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
214376485|NCT00853502|DRUG|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
214376486|NCT04706533|DIAGNOSTIC_TEST|Biomarkers of inflammation|Biomarkers were measured on blood samples collected within 48 hours of admission
214376487|NCT03831321|DRUG|Diclofenac Sodium|50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
214376488|NCT03831321|DEVICE|Cystoscopy|Diagnostic cystoscopy
215090571|NCT03684694|DRUG|Ibrutinib|Oral capsule.
215090572|NCT02881528|DRUG|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
214989070|NCT04222049|DEVICE|Vibro Tactile Gadget|The concept is to apply vibro tactile gadget to different nerve points which when applied transmit waves to the focused parts of brain which will result in blood flow and activation of dead cells. As a result some disabled part of the body because of those dead cells can show improvement.
214376489|NCT03831321|DRUG|Lubricant Gel|To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
214376490|NCT04409067|DIAGNOSTIC_TEST|electromyography|Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).
214376491|NCT01038115|PROCEDURE|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
214376492|NCT03642860|DRUG|Triheptanoin|Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
214496966|NCT05973279|OTHER|CSMI (CYBEX) Humac Norm Isokinetic Test and Exercise System|22 isolated joint movement models, 4 resistance modes (isokinetic, isotonic, isometric and passive) and a large number of reports to meet the measurement and exercise needs of today's clinicians and researchers. The exercise modes of the device include; Continuous passive movement, multi-angle isometry, proprioception training, standard and eccentric focused isokinetic strengthening, deceleration training, dynamic isotonic training, strength training. Test modes of the device include; Proprioceptive, co-measured, standard isokinetic, concentric/eccentric isokinetic, intermittent stroke isokinetic test.
214496967|NCT06425250|OTHER|Management, progression and risk factors for failure of BJI caused by Campylobacter spp.|Description of demographic data (sex, age), comorbidities (ASA and Charlson scores), orthopedic and septic history, and surgical and medical management (antibiotic therapy)
214496968|NCT06425250|OTHER|Description of the evolution and risk factors for failure of osteoarticular infections caused by Campylobacter spp.|"Failure of treatment: defined according to a composite criterion bringing together~* persistence of the infection under treatment, and/or~* recurrence of the infection after stopping antibiotic therapy, and/or~* need for surgical revision for septic reasons more than 5 days after initial treatment, and/or~* superinfection, and/or~* definitive explantation of the material, and/or~* decision for suppressive antibiotic therapy, and/or~* amputation, and/or~* death linked to infection"
214989071|NCT01933594|DRUG|Romidepsin|RMD administered over 4 hours via an intravenous (IV) catheter.
214989072|NCT01933594|DRUG|Placebo for Romidepsin|Placebo for RMD administered over 4 hours via an IV catheter.
214989073|NCT04796701|OTHER|Follow-Home-intervention|x
214989074|NCT03012646|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
214989075|NCT03678077|OTHER|Mild traumatic brain injury|This is a register based observational study and does not include interventions. Exposure is mild traumatic brain injury.
214989076|NCT00004261|DRUG|EF5|
214989077|NCT00004261|OTHER|flow cytometry|
214989078|NCT00004261|OTHER|fluorescent antibody technique|
214989079|NCT00004261|OTHER|immunohistochemistry staining method|
214989080|NCT00004261|PROCEDURE|biopsy|
214989081|NCT04289038|OTHER|Autogenic Relaxation|Autogenic relaxation
214376493|NCT03642860|DRUG|Placebo Oil|Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
214496969|NCT01222442|DRUG|AZD3199|Single dose, oral inhalation
214496970|NCT01222442|DRUG|Moxifloxacin|Single dose, oral encapsulated tablet
214496971|NCT01222442|OTHER|Placebo comparator|Single dose, oral inhalation
214496972|NCT00694889|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
214496973|NCT00694889|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
214687070|NCT05218850|DRUG|Butyrate|Butyrate enemas will be administered once a day for 12 weeks
214989082|NCT04289038|OTHER|virtual reality game application|virtual reality game application,
214989083|NCT04289038|OTHER|kidney function narration|kidney function narration
214989084|NCT02105090|DRUG|Anesthetics, Local|
214989085|NCT02105090|DRUG|Sodium Chloride 0.9%|
214989086|NCT03419468|OTHER|Self Geriatric Assessment Measure (SGAM)|Self Geriatric Assessment Measure
214989087|NCT04208230|DEVICE|XtremeCT|HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
214989088|NCT00370617|DRUG|metformin|
214989089|NCT04698811|BEHAVIORAL|VIRTUAL ENEAGRAM|"Presentation of the Virtual Enneagram and its content and realization of the first battery of tests (World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: IDATE E and T.) .~Guidance and training on personality and the Enneagram, its classification system, personality subtypes and dynamics of stress and growth allowing self-recognition.~Second test battery ((World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: (IDATE E and T.) and Enneagram Questionnaire."
214989090|NCT02410330|PROCEDURE|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.7 MHz S5-1 transducer
214989091|NCT02410330|PROCEDURE|Repeated diagnostic high mechanical index|Repeated diagnostic high mechanical index impulses (all \<2 usec pulse duration; MI=1.0) whenever very low mechanical index perfusion imaging detected microbubbles within the microvasculature
214989092|NCT01010178|DRUG|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
214989093|NCT01314729|DEVICE|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
214376494|NCT02768454|DRUG|medical review of controlled broad-spectrum antibiotics|medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
214376495|NCT00462137|PROCEDURE|Sleep Studies|
214376496|NCT01987817|BIOLOGICAL|AR101 powder provided in capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
214376497|NCT01987817|BIOLOGICAL|Placebo powder provided in capsules|Study product formulated to contain only inactive ingredients for use as defined in the protocol
214989094|NCT01314729|DEVICE|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
214989095|NCT04679207|PROCEDURE|Vacuum-assisted excision|Vacuum-assisted biopsy (VAB) is a minimally invasive technique performed under local anaesthetic as an outpatient procedure by radiologists using x-ray or ultrasound guidance. It was developed in the USA in the mid 1990s and has become well established as a diagnostic test for suspected breast disease. It uses the combination of a large gauge biopsy needle and suction to allow larger pieces of tissue to be removed than can be obtained with a standard needle biopsy device. The technique is used widely for diagnostic purposes and, in some centres, for the therapeutic removal of benign breast lumps such as fibroadenomas and papillomas.
214989096|NCT00034866|DRUG|Protease inhibitor tipranavir|
214989097|NCT03563573|DRUG|Potassium Gluconate Oral Capsule|Each subject will receive a dose of \~8 mg/kg of potassium. We will be giving a maximum of 14 mEq in a single dose.
214989098|NCT03563573|DRUG|Placebo oral capsule|Each subject will receive a dose of \~8 mg/kg of a placebo capsule
214989099|NCT04062695|DRUG|Tofacitinib 5 MG Oral Tablet [Xeljanz]|verum tablets
214989100|NCT04062695|DRUG|Placebo oral tablet|tablets containing placebo
214989101|NCT05350020|DRUG|Solu-Cortef 100 MG Injection|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.
214989102|NCT05350020|DRUG|Hydrocortisone 100mg/ml|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
214989103|NCT03837717|BEHAVIORAL|Holding|Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.
214989104|NCT03837717|OTHER|Saliva collection|Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin
214989105|NCT03837717|BEHAVIORAL|No Holding|Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.
214989106|NCT03736655|DEVICE|Interposition supraciliary implant|Surgical placement of an interposition supraciliary implant in the supraciliary space
214989107|NCT06230263|DIAGNOSTIC_TEST|Visual acuity test|"Assess near high-contrast visual acuity (40cm) using EyeChart PRO on an iPad.~Use the MNREAD app to measure:~Reading Acuity: Smallest font size read without errors. Critical Print Size: Smallest font size for peak reading speed. Maximum Reading Speed: Time to read comfortable font size, in words per minute. Reading Accessibility Index: Single metric summarizing visual access to print. Assess near visual function with the Near Activity Visual Questionnaire.~Evaluate distance visual acuity, both high and low contrast, using logMAR and the E-ETDRS (NIDEK SC-2000)."
214989108|NCT02573714|DRUG|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
214376498|NCT00188955|DRUG|sirolimus|
214376499|NCT01335516|OTHER|Glypressin (terlipressin)|Study drug (without placebo)
214376500|NCT04438863|DIAGNOSTIC_TEST|home spirometry|portable hand-held spirometer to collect and store daily spirometric data (including FVC, FEV1, forced expiratory flow after 25 to 75% of vital capacity has been expelled, and peak flow).
214376501|NCT06291662|DEVICE|3D printer applications|Patients will undergo TC/MRI as per routinary care. Custom 3D-devices will be printed on the basis of these images. The device will be used to establish pre-operative surgical options in terms of tissue/bones demolition/reconstruction.
214376502|NCT04244851|OTHER|Malnourished patients|"Data of included patients will be recorded during hospitalization using medical charts.~Every patient will be contacted by phone 3 months after hospital discharge. A sample of patients and their caregivers will be interviewed to better understand their perception of malnutrition and what they need to better take care of malnutrition."
214376503|NCT05408143|OTHER|CC|To promote prompt effective care for medically complex children at all hours, we developed an outpatient comprehensive care (CC) program at the University of Texas Health Science Center at Houston (UTH) that now includes a hospital consultation service by the outpatient CC providers (the hospital component) and a conventional telemedicine (CTM) audio-visual program (the home component).
214496974|NCT03024034|DRUG|TP-271|single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
214989109|NCT02573714|DRUG|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
214989110|NCT02573714|OTHER|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
214989111|NCT02573714|OTHER|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
214989112|NCT02573714|OTHER|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
214376504|NCT05408143|DEVICE|enhanced telemedicine (ETM)|"An enhanced telemedicine program (using HIPAA-compliant, mobile TytoCareTM devices) will be added to CC to allow providers to remotely visualize the skin, throat, \& ears, auscultate the heart \& lungs, and measure illnesses during clinic hours and chronic illnesses during the detailed patient evaluation to be conducted at least every 6 months by virtual patient rounds in the home. These visits will involve the parent(s), the PCP, and if needed any of 10 specialists, particularly pulmonology, gastroenterology, neurology, and physical medicine and rehabilitation. A social worker, nutritionist, or psychologist will be involved as needed. Each PCP will perform 2-3 virtual patient rounds per week to proactively identify medical problems, suboptimal adherence to treatment, dosing errors, or other problems and intervene before CMC develop a serious illness or require avoidable clinic visits, Emergency Department visits, or hospitalizations."
214496975|NCT00645359|PROCEDURE|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
214496976|NCT00575549|OTHER|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
214496977|NCT04124887|DRUG|Sodium Fluoride|Sodium Fluoride varnish was applied to the targeted teeth at baseline, one and three months.
214496978|NCT04124887|DRUG|Tricalcium Phosphate|Varnish with Tricalcium Phosphate was applied to the targeted teeth at baseline, one and three months.
214989113|NCT04091165|OTHER|My Plate Calorie Tracker|"My Plate Calorie Tracker is a user-friendly weight management, calorie record application, available for smart phone devices. Users have the option to input items manually (i.e., calories, carbohydrates, fats, and proteins), select from a list of popular food items, or scan barcodes on the food packaging. In addition to food entries, users can also enter daily water intake and physical activities. Once an account is created, data entered into the mobile application can be sync'd to the My Plate Calorie Tracker website."
214989114|NCT06083129|DRUG|Grafalon|10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)
214989115|NCT06083129|DRUG|Thymoglobulin|2.5 mg/Kg/day IV for 2 consecutive days (day-3 and -2 before transplantation)
214989116|NCT00315445|DRUG|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
214989117|NCT00315445|DRUG|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
214989118|NCT00315445|DRUG|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
214989119|NCT00315445|DRUG|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
214989120|NCT03851575|OTHER|Accelerated treatment of endocarditis|For the three main bacteria species we shorten the duration of antibiotic treatment
214989121|NCT03851575|OTHER|Usual guideline therapy|Usual guideline therapy
214989122|NCT03113734|OTHER|Construction and validation of a functional score|"All patients will be treated at the same way:~Completion of questionnaire by the physician with him. Once the consultation has been completed, the physician will issue prescriptions for the usual medical treatment, laximetry prescription (GNRB) to be performed when the knee is indolent and the prescription of the MRI to be performed .The physician will inform the patient that they should consult with the investigator's orthopedic surgeon once the results of GNRB and MRI are available.The study will end there for the patient. The surgeon will then follow his usual diagnostic procedure to decide on the future care of the patient."
214989123|NCT01833676|DRUG|Sevoflurane|
214989124|NCT01833676|DRUG|Desflurane|
214989125|NCT00636727|PROCEDURE|arthrocentesis|Irrigate the TMJ with lactated ringers
214989126|NCT00636727|PROCEDURE|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
214989127|NCT00636727|PROCEDURE|arthroplasty|The disc will be surgically repositioned with open surgery
214989128|NCT01811238|DRUG|Oxycodone/naloxone|Targin 5mg, 10mg, 20mg up to 40mg b.i.d
214989129|NCT01035138|DRUG|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
214989130|NCT03468621|PROCEDURE|Wound closure|Method of wound closure
214989131|NCT03297632|BEHAVIORAL|Functional resistance exercise|Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
214989132|NCT01470716|DRUG|Erlotinib|Neo-adjuvant Erlotinib treatment during maximum 8 weeks.
214989133|NCT03765606|DIETARY_SUPPLEMENT|Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
214989134|NCT03765606|DIETARY_SUPPLEMENT|De-xanthinated Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
214989135|NCT01579214|OTHER|Cellular Phone Text Messages|Cellular phone text message formats to be sent to participants after abnormal laboratory results to communicate information and request early return to clinic.
214989136|NCT02164916|BIOLOGICAL|cetuximab|Given IV
214989137|NCT02164916|DRUG|irinotecan hydrochloride|Given IV
214989138|NCT02164916|DRUG|vemurafenib|Given PO
214989139|NCT04366674|PROCEDURE|cleft palate repair|restoration of tensor veli palatini for the purpose of the muscle function recovery.
214989140|NCT01518101|DRUG|Vildagliptin/ Metformin|Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
214989141|NCT01518101|DRUG|Liraglutide|1.2 mg once daily by commercially available injection pens
214989142|NCT01518101|DRUG|Metformin|1000 mg tablets twice daily
215090573|NCT02881528|DRUG|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
215090574|NCT06339970|OTHER|Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
215090575|NCT06339970|OTHER|Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
214376505|NCT05674591|BEHAVIORAL|Cognitive Processing Therapy (CPT)|The CPT therapist will teach the patient about PTSD, depression, and anxiety, and outline the treatment regimen and rationale for its effectiveness. In the initial sessions, women will be asked to express their impact statements on the intimate partner violence to which they had been subjected. Women will be taught how to differentiate between events, thoughts, and emotions, as well as their interrelationships. Thoughts of self-blame and other misconceptions of the situation will be addressed using Socratic questioning. Women will be instructed on how to detect and counteract negative thoughts, as well as how to communicate more effectively. Women will be encouraged to evaluate negative thinking relating to five themes: safety, trust, power/control, self-esteem, and intimacy. During the final sessions, their impact statements on the violence to which they had been subjected will be altered to include emotional and cognitive insights obtained during the CPT.
214376506|NCT01576718|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening."
214989143|NCT04501900|DRUG|Clopidogrel|Study subjects diagnosed as stable, unstable ischemic coronary disease or myocardial infarction planning to undergo percutaneous coronary intervention (PCI) and no contradiction to prolonged DAPT are eligible for this trial. All subjects will provide written informed consent to participate. Subjects will be enrolled into the study before or within 24 hours after the index procedure. Subjects will be randomized to either discontinue P2Y12 inhibitor (clopidogrel or ticagrelor) (12 months total) or receive P2Y12 inhibitor for an additional 24 months (36 months total). Aspirin will be maintained in the entire study and can be replaced by cilostazol or indobufen if subjects are intolerant. Dosage of antiplatelet drugs will be according to local standard of practice. Subjects will be treated with XINSORB BRS only.
214989144|NCT03229499|DRUG|Anastrozole|"Anastrozole is an aromatase inhibitor indicated for:~* adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~* first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~* treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
214989145|NCT03229499|DRUG|Placebo Oral Tablet|matching placebo tablet
214989146|NCT00164359|DRUG|Amodiaquine plus artesunate|
214989147|NCT00164359|DRUG|chlorproguanil-dapsone plus artesunate|
214989148|NCT02916927|DRUG|Ketamine IV Infusion|Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
214989149|NCT02916927|DRUG|Ketamine IV push|Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
215090576|NCT00474617|DRUG|Sugammadex|
215090577|NCT00474617|DRUG|Rocurium|intravenous (IV) single bolus dose of 0.6 mg.kg-1
214989150|NCT00236717|DRUG|Topiramate; Carbamazepine; Valproate|
215090578|NCT04162522|DRUG|Escitalopram|Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.
215090579|NCT04162522|DRUG|Brexpiprazole|Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
215090580|NCT05231798|DRUG|[18F]-FEOBV Radiotracer|Participants will be administered an \[18F\]-fluoroethoxybenzovesamicol (FEOBV) radiotracer for diagnostic imaging purposes (PET scan).
215090581|NCT02870530|PROCEDURE|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
215090582|NCT03102060|OTHER|Dietary Intervention|Undergo gluten free diet
214496979|NCT04124887|DRUG|Xylitol-coated calcium and phosphate|Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.
214989151|NCT04938336|BEHAVIORAL|Delphi Procedure and interviews|Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers
215090583|NCT03102060|OTHER|Laboratory Biomarker Analysis|Correlative studies
215090584|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA high ligation, TME, routine splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized. Side-to-end sigmoido-rectal anastomosis is created.
215090585|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA low ligation, TME, selective splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. Then inferior mesenteric artery is skeletonized down to the origin of left colic artery and divided below it. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized only if sigmoid colon is unsuitable for anastomosis or doesn't reach the rectal stump. Then descending-rectal side-to-end anastomosis is created.
215090586|NCT05054543|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
215090587|NCT05054543|DRUG|Placebo|0.9% Sodium Chloride
215090588|NCT00187070|DRUG|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
215090589|NCT00187070|PROCEDURE|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
214376507|NCT01576718|OTHER|Placebo MDPI|Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
214989152|NCT01551667|BIOLOGICAL|Antibody assays for S. aureus|Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
214376508|NCT01576718|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
214989153|NCT01551667|BIOLOGICAL|Basic blood work|Hemogramme + CRP on Days 0, 2, 4 and 7
214989154|NCT01357772|DRUG|Tamoxifen|
214989155|NCT01357772|DRUG|placebo|
214989156|NCT02251847|DRUG|Rosuvastatin/Ezetimibe|Rosuvastatin 5mg
214989157|NCT00944554|DRUG|Varenicline|Varenicline given twice a day or five weeks.
214989158|NCT00944554|DRUG|Placebo|Placebo given twice a day or five weeks.
214989159|NCT00894192|DEVICE|Izon Wavefront-guided lenses|Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
214989160|NCT00894192|DEVICE|Conventional lenses|We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
214989161|NCT04788134|DIAGNOSTIC_TEST|Post-rotatory nystagmus test|The test is administrated with the person sit down with cross legs at a rotatory board, with the head positioned by the examiner in 30° of forward flexion. The position was maintained by the administration of the test. The administration consist in two administrations separate by one minute. Each administration consist in rotate the person 10 times in 20 seconds (the first 10 rotations in a counterclockwise direction in 20 s and the second 10 rotations in a clockwise direction in 20 s). After each administration the examiner counts the duration of the reflex in seconds.
214989162|NCT05836623|DRUG|Radiolabelled CB307|CB307 radiolabelled with 89-Zirconium (89Zr CB307): drug product is formulated at a concentration of 1 mg/mL (37 MBq)
214989163|NCT05836623|DRUG|CB307|Trispecific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
214989164|NCT01731548|RADIATION|hyperfractionated radiation therapy for both arms|1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
214989165|NCT00217451|DRUG|Fosmidomycin-clindamycin|
214989166|NCT00392106|DRUG|propafenone|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
215090590|NCT00187070|RADIATION|Radiation Therapy|See Detailed Description section for details of treatment interventions.
215090591|NCT01825941|DRUG|metoclopramide|10 milligrams, administered intravenously over 15 minutes
215090592|NCT01825941|DRUG|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
215090593|NCT01825941|DRUG|placebo|
215090594|NCT03716661|PROCEDURE|ORIF|Open Reduction Internal Fixation
215090595|NCT03076723|OTHER|Change in shunt opening pressure|An individually determined change in shunt opening pressure is compared to no change in opening pressure.
215090596|NCT03076723|OTHER|Simulated change in shunt opening pressure|The shunt opening pressure is reset to the same setting.
214376509|NCT01576718|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
214376510|NCT01336621|DRUG|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
214376511|NCT00210327|DRUG|Bortezomib (drug)|
214376512|NCT00056225|DRUG|Folate|
214376513|NCT00056225|DRUG|Vitamin B6|
214376514|NCT00056225|DRUG|Vitamin B12|
214376515|NCT03285841|DEVICE|OCT-AFI|Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.
214376516|NCT02459158|DRUG|ME1100 inhalation solution|Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
214376517|NCT02459158|DRUG|ME1100 inhalation solution|High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
214376518|NCT01237795|OTHER|Dentifrice|Dentifrices (4 formulations) used as auxiliary agents for brushing complete dentures.
214376519|NCT02521402|BIOLOGICAL|Biovance|decellularized, dehydrated human amniotic membrane
214376520|NCT03590756|OTHER|16 weeks mango intake|Participants will be provided fresh frozen Ataulfo mangoes.
214496980|NCT04124887|DRUG|Casein phosphopeptide amorphous calcium phosphate|Varnish with Casein phosphopeptide amorphous calcium phosphate was applied to the targeted teeth at baseline, one and three months.
214496981|NCT00402259|DRUG|Esomeprazole IV|
214989167|NCT00392106|DRUG|flecainide|Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
214989168|NCT00392106|DRUG|dofetilide|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
214989169|NCT00392106|DRUG|sotolol|Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
214989170|NCT00392106|DEVICE|Pulmonary vein ablation|Electrical isolation of pulmonary vein with high-intensity focused ultrasound
214989171|NCT00392106|DRUG|Amiodarone|Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
215090597|NCT06256991|DRUG|Patiromer 8400 MG [Veltassa]|Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
215090598|NCT06256991|DRUG|Placebo|Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
214376521|NCT01100554|DEVICE|Sleep endoscopy|Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
214376522|NCT01742364|DEVICE|Bioject ID Pen|Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
214989172|NCT06222307|OTHER|Game-Based Exercises|Week 1: Dough Kneading, Sorting Legumes, Cutting Lines with Scissors, Coloring with Dry Crayons Week 2: Dough Rolling, Scissor Use, Crumpling Paper, Finger Exercises, Tying Knots with Rubber Bands Week 3: Dough Cutting, Dough Rolling, Dough Stretching, Sewing with Needles, Wrapping Thread like a Spool, Sorting Legumes, Untying Knots in String Week 4: Rhythm Exercises, Dough Kneading and Rolling, Scissor Use, Sorting Legumes, Untying Knots in String Week 5: Stringing Beads on Thread, Unlocking, Tearing Paper, Sorting Legumes, Untying Knots in String Week 6: Tying Shoe Laces, Opening-Closing Jar Lids, Sorting Legumes
214989173|NCT02109757|OTHER|Software intervention and education|Personal attenuation rating measurements will be taken before and after educating the patient using software program
214989174|NCT02109757|OTHER|Education only|
214989175|NCT06160271|DRUG|PET scan of 68Ga-FAPI|Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
214989176|NCT00091858|DRUG|Darbepoetin Alfa|6.75 mcg/kg Q4W
214989177|NCT00091858|DRUG|Placebo|Placebo Q4W
214989178|NCT01535885|BIOLOGICAL|Cytotoxic T Lymphocytes|Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
214989179|NCT06427499|DRUG|Stannous fluoride toothpaste|brush 2 min morning \& night daily
215090599|NCT05375864|OTHER|Absorption test|Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
215090600|NCT02406729|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
215090601|NCT02406729|OTHER|Placebo|Route:subcutaneous
215090602|NCT05607706|BEHAVIORAL|Exposure to maternal odor|Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
214376523|NCT01742364|DEVICE|Needle and syringe|Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
214496982|NCT00402259|DRUG|Omeprazole IV|
214496983|NCT04453332|DRUG|Oral hormone therapy (estradiol and micronized natural progesterone)|Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month
214496984|NCT04453332|DRUG|Non-oral hormone therapy (estradiol and micronized natural progesterone)|Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
214989180|NCT06427499|DRUG|Colgate Cavity Protection Toothpaste|brush 2 min morning \& night daily
214989181|NCT02587936|OTHER|Collaborative Model of Primary care and Subspecialty care|Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.
214989182|NCT04909060|DEVICE|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children between 1 and 3 years old, scheduled for elective adeno-tonsillectomy, tonsillectomy or adenoidectomy and with no neurological or cardiac congenital deficits, no cardiac arrythmias (non-sinus rhythm), no implanted pacemakers, nor with a history of prolonged resuscitation at birth, and chronic therapy with drugs that have known effects on sympathetic and parasympathetic activity, ASA physical status III or higher and parent/guardian refusal will have a NIPE placed on their electrocardiogram, at least 20 minutes before the expected end of the surgery, the NIPE monitor will be connected to the anesthesia monitor at the end of the surgery, when the patient is considered ready to be transferred to the PACU, the NIPE will be disconnected and reconnected to the patient monitor once in PACU. Values will be recorded until the patient meets the discharge criteria from PACU not before 2hours
215090603|NCT00528996|DRUG|BEA 2180 BR|Solution
215090604|NCT00528996|DRUG|Tiotropium Bromide|Solution
215090605|NCT00528996|DRUG|Placebo|Solution
215090606|NCT01307462|DRUG|fluticasone propionate|Given inhaled PO
215090607|NCT01307462|DRUG|montelukast sodium|Given PO
215090608|NCT01307462|DRUG|azithromycin|Given PO
214376524|NCT02836223|DEVICE|Interdental cleaning device|Water Flosser
214376525|NCT02836223|DEVICE|Manual Tooth brush|Control
214376526|NCT00992667|DRUG|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
214376527|NCT04059757|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
215090609|NCT04291768|OTHER|Shortened antibiotic treatment|Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
214376528|NCT00682643|DRUG|fluticasone furoate nasal spray|fluticasone furoate nasal spray
214376529|NCT00682643|DRUG|vehicle placebo nasal spray|placebo
214496985|NCT06714552|DIETARY_SUPPLEMENT|Galacto-Oligosaccharide|24.0 g Oligomate® in 100 mL water
214496986|NCT06714552|OTHER|Glucose|17.8 g glucose in 100 mL water
214376530|NCT05767775|OTHER|Assessment of synovial- and adipose tissue-derived inflammatory biomarkers|"Parafﬁn-embedded synovial tissue (ST) specimens will be stained for H\&E and other sections will be stained for CD68, CD21, CD20, CD3, CD31 and Masson Trichrome Goldner with light green to assess the microanatomical organization of resident synovial inflammatory cells. Some synovial samples will be used for tissue resident macrophages subpopulations analysis using FACS gated on their expression of the CD64+/CD11b+/MHC-ClassII+/CD206+/-/Lineage-.~Each RA patient reaching a stable clinical (DAS\<1.6 for at least two different evaluations 6 months apart) and imaging (PDUS negative signal) remission under Tofacitinib treatment will undergo synovial biopsy and each synovial tissue sample will be processed as above.~Plasma levels of adipokines will be tested through ELISA method at baseline, 3, 6 and 12 months of follow-up in all patients."
214376531|NCT03482505|DEVICE|INVSENSOR00004|The INVSENSOR00004 will be placed on the subject's neck or chest to provide acoustic respiration rate.
214376532|NCT02243241|DRUG|HYD|Hydrocodone bitartrate 80 mg (day 9), 120 mg (day 12), 160 mg \[(1) 40 mg tablet + (1) 120 mg tablet\] (day 15) extended-release tablets administered orally every 24 hours.
214989183|NCT00177125|DEVICE|ErectAid|
214376533|NCT02243241|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally on the morning of day 9, day 12, and day 15 only.
214376534|NCT02243241|DRUG|Placebo for HYD|Placebo to match HYD tablets administered orally every 24 hours.
214376535|NCT02243241|DRUG|Placebo for moxifloxacin|Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
214376536|NCT00190502|DRUG|Polyclonal anti-T-cell antibodies|
214376537|NCT02529150|BEHAVIORAL|Exercise|This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
214376538|NCT02654210|OTHER|No Intervention|No Intervention
214989184|NCT04440488|BIOLOGICAL|ARALAST NP|Partcipants will be randomized to receive ARALAST NP 60 or 120 mg/kg BW/week IV infusion for a total of 104 weeks.
214989185|NCT05504525|PROCEDURE|Fascia Iliaca block|Ultrasound guided fascia iliaca block done by palpation of anterior superior iliac spine to identify the inguinal crease, then place the ultrasound probe on it to identify the sartorius muscle. Sonographic anatomy will be identified, from superficial to deep, consisting of subcutaneous fat, the internal oblique muscle, the transverse abdominis muscle, the fascia iliaca covering the iliacus muscle and the iliacus muscle itself. The block needle will be advanced in out-of plane to puncture the fascia iliaca. With the needle tip just below the fascia iliaca, 2 ml of a local anesthetic will be injected to confirm the tip location. Once the proper position is confirmed, 40 ml of bupivacaine 0.25% will be injected superficial to the iliacus muscle and deep to the fascia iliaca.
214496987|NCT06444451|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
214496988|NCT06444451|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: SC injection
214687071|NCT01735747|RADIATION|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
214687072|NCT01735747|DRUG|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
214989186|NCT05504525|PROCEDURE|Quadratus lumborum block|The patients will receive anterior ultrasound guided quadratus lumborum block QLB in the lateral position. The transducer will be first placed in a parasagittal orientation 3-4 cm lateral to the midline and over the sacrum to identify the L5 transverse process. The probe will then rotated into a transverse orientation with slight medial and caudal angulation to obtain a transverse oblique view at L5 transverse process .The ultrasound probe will be tilted , so the lateral end of the probe will be more cranial than the medial side of the probe to avoid the acoustic shadow of the iliac crest. Identify the quadratus lumborum and psoas major and inject the local anesthetic above the QL
214989187|NCT04131972|DEVICE|REGENERA|REGENERA breast implant
214376539|NCT04016948|DEVICE|Probe-based confocal laser endomicroscopy optical biopsy|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
214376540|NCT04016948|DEVICE|Intra-operative frozen section|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
214376541|NCT05848479|OTHER|Abdominal bracing|they will perform 3 times/week of static abdominal contraction for six weeks.
214376542|NCT05848479|OTHER|clamshell exercise|Each women will be positioned in side lying on the floor, with the pelvis and the spine in neutral position, the hips will bent at 45° and the knees flexed to 90°. She will abduct the top knee as far as possible, while keeping the heels together, then return to the starting position , the position will be maintained for 5 seconds in an abduction state, and repeated 10 times, with rest for 1 minute to minimize muscle fatigue,they will perform 3 times/week fo 6 weeks
214376543|NCT04681118|BIOLOGICAL|NurOwn (MSC-NTF cells)|Intrathecal administration
214376544|NCT04844580|DRUG|Inhaled Aviptadil|Aviptadil is the synthetic analogue of the Vasoactive Intestinal Peptide (VIP), a biologically active 28 amino acid natural peptide that is endogenously synthesized in humans. It is one of the signaling molecules of the neuroendocrine immune network and has vasodilator, anti-proliferative, anti-inflammatory and immunomodulatory properties.
214989188|NCT02332759|DEVICE|Materna Medical|
214989189|NCT03153657|DRUG|Piroxicam-Beta-Cyclodextrin|The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
214989190|NCT03153657|DRUG|Placebo|The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
214989191|NCT03320811|OTHER|Data record|
214989192|NCT00655889|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of biopsy from palate~2. Papillary priming procedure~3. Seven injection treatments to target sites~4. Performance of study assessments (investigator and subject)"
214496989|NCT06925620|OTHER|Multimodal Information Technology-based Hand Hygiene Strategies|The intervention, adapted from the WHO's multimodal strategy, incorporated IT-based components to enhance hand hygiene compliance. A one-time, 1-hour online education session via Google Meet covered the WHO's Five Moments and seven-step handwashing technique, with real-time feedback using fluorescent dye and UV light. Post-session videos were available on tablets for review. Visual reminders, such as screensavers and digital posters, reinforced learning. Smart sanitizer dispensers with seven-step lights and a 20-second countdown were installed at five key sites, RFID-linked to staff badges for automatic tracking. Monthly performance data were shared via bulletin boards and LINE, with SMS feedback to top and bottom performers. Daily audio reminders played at 9 a.m. and 5 p.m., and high performers were recognized in monthly meetings.
214496990|NCT06922526|DEVICE|Pacemaker implantation|Pacemaker implantation methods include right ventricular pacing, biventricular pacing, conduction system pacing
214496991|NCT06763848|DEVICE|Protein A immunoadsorption|The experimental group was treated with a combination of protein A immunoadsorption and intravenous methylprednisolone. The methylprednisolone was administered following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day. Protein A immunoadsorption was conducted every other day, unless a physician determined that the patient's condition was unsuitable for treatment, in which case treatment was administered according to medical advice. A total of 5 treatments were given, with each session involving the regeneration of plasma at 1 to 3 times the plasma volume.
214496992|NCT06763848|DRUG|intravenous methylprednisolone|The control group was treated with intravenous methylprednisolone, following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day.
214687073|NCT01735747|DRUG|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
214989193|NCT01089179|DRUG|Metformin|
214989194|NCT02255747|DRUG|Lactulose|
214989195|NCT02721784|DEVICE|mpMRI/VERDICT|Combined MRI sequences of T2, DCE, Diffusion and VERDICT
214989196|NCT02721784|RADIATION|External Beam Radiotherapy|78Gy (Gray) to Prostate +/- Pelvic
214989197|NCT01548365|OTHER|Infusion therapy nursing expert service|"The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.~If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.~If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device."
214989198|NCT03241693|OTHER|blended-learning in ethics|"Experimental group followed clinical practices in hospital centers during 8 months.~In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used."
214989199|NCT03241693|OTHER|control group|"Control group followed clinical practices in hospital centers during 8 months as usual.~In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out."
214989200|NCT04002986|GENETIC|Genetic Testing|A blood draw or saliva kit will be provided to collect subject cells
214989201|NCT01281696|DRUG|Bevacizumab, etoposide, cisplatin|Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles
214989202|NCT01281696|DRUG|Intrathecal methotrexate|Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
214989203|NCT04945811|DIAGNOSTIC_TEST|Interlukein 6 and procalcitonin serum levels|Blood tests
214989204|NCT02318940|DEVICE|central venous catheter|installation of Central venous catheter ultrasound guided
214989205|NCT02318940|DEVICE|central venous catheter|installation of Central venous catheter landmark guided
215090610|NCT04291768|OTHER|Standard antibiotic treatment|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
215090611|NCT01232855|GENETIC|protein expression analysis|
215090612|NCT01232855|GENETIC|western blotting|
214989206|NCT03475238|PROCEDURE|Nursing care|The nursing care will be defined as a lateral mobibization and a length of care superior or equal to 10 min
214989207|NCT05503498|OTHER|DATA RECORDING|RECORD PLASMA FIBRI LEVELS AFTER FIBRINOGEN ADMINISTRATION
214687074|NCT01735747|DRUG|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
214989208|NCT07024589|DRUG|AN2-502998|Oral Capsule
214989209|NCT07024589|DRUG|Placebo|Oral Capsule
214989210|NCT06711926|OTHER|Distilled water|Participants will receive 600ml distilled water with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
214989211|NCT06711926|OTHER|Semi-skimmed milk|Participants will receive \~600ml semi-skimmed milk with a strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).
215090613|NCT01232855|OTHER|flow cytometry|
215090614|NCT01232855|OTHER|laboratory biomarker analysis|
215090615|NCT06502808|OTHER|Hyperbaric oxygen therapy|Series of 30 HBOT sessions of 60 minutes at 2 ATA in the hyperbaric chamber for five consecutive days per week.
215090616|NCT02174653|DRUG|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
215090617|NCT02174653|DRUG|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
214989212|NCT06711926|OTHER|Whey permeate|Participants will receive \~600ml whey permeate (30g sachet, rehydrated with distilled water)with strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).
214989213|NCT06887842|DEVICE|Posterior Nasal Nerve neurectomy|Posterior Nasal Nerve neurectomy which is done by surgical resection.
214989214|NCT06887842|DEVICE|Posterior Nasal Nerve neurectomy|Posterior Nasal Nerve neurectomy which is done by using radiofrequency ablaion.
214989215|NCT06887842|DEVICE|Posterior Nasal Nerve neurectomy|Posterior Nasal Nerve neurectomy by coblation of the surface of the course of the nerve
214989216|NCT07042451|BEHAVIORAL|Pink Cloud|Participants randomized to the Pink Cloud condition will receive a subscription code to access the Pink Cloud mobile application for approximately 365 days. The app includes features such as a searchable database of over 245,000 12-Step meetings (in-person and virtual), a sobriety counter, customizable daily planners, personal inventory tools, and a resentment journal. Participants are encouraged to use the app as they see fit throughout the study period. No prompts or required usage schedules will be imposed; instead, engagement will be self-directed to reflect real-world usage patterns.
214989217|NCT07042451|BEHAVIORAL|Active Control|Participants randomized to the control condition will receive a code to access recovery-related resources hosted on a private study website. These materials include links to mutual-help groups, crisis support services, and educational content and treatment options. Participants may access the website at their discretion and engage with the resources as often and in whatever ways they choose. No prompts or required usage schedules will be imposed.
214989218|NCT06712563|DRUG|Budesonide/glycopyrrolate/formoterol fumarate|Budesonide/glycopyrrolate/formoterol fumarate (BGF) is a triple fixed-dose combination therapy for adults with moderate to severe COPD who are not adequately treated by a combination of inhaled corticosteroids and long-acting beta-agonist (LABA), or LABA and long-acting muscarinic-antagonist
214989219|NCT07045974|OTHER|Group A-Mulligan Mobilization|"Group A will receive Mulligan mobilizations (SNAGs). Mulligan SNAGs mobilization technique was applied at level C4/5. Subjects were placed in sitting position and therapist stood behind the patient with therapist's thumbs on spinous process of particular vertebra. Mobilization was given by active movement followed by passive overpressure based on the movement restricted. The duration of treatment was three sets of ten repetitions each.~Conventional treatment include the following:~Subjects in both the groups were treated with hot pack (20 min), TENS (2 to 10 Hz), and manual traction along with deep neck flexor, and isometric neck strengthening."
215090618|NCT02349685|PROCEDURE|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute \[amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC \> 1.0 μ g / ml; metronidazole (MET), MIC \> 8 μ g / ml; tetracycline (TC), MIC \> 4 μ g / ml; and moxifloxacin (MOX), MIC \> 1 μ g / ml).
215090619|NCT02349685|DRUG|14 day PBMT group|Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]
215090620|NCT02349685|DRUG|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
214376545|NCT04844580|DRUG|Placebo|Aviptadil Placebo will be used for this arm.
214376546|NCT05558865|BEHAVIORAL|somnovia|Participants receive access to the digital health application somnovia
214376547|NCT02020239|OTHER|Exercise|
214376548|NCT03017326|DRUG|Cisplatin|Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
214376549|NCT03017326|DRUG|Doxorubicin|Arms C, D and E used in combination
214376550|NCT03017326|DRUG|Carboplatin|Arms C and D used in combination
214376551|NCT03017326|DRUG|5Fluorouracil|Arm C used alone
214376552|NCT03017326|DRUG|Vincristine|Arms C and D used in combination
214376553|NCT03017326|DRUG|Etoposide|Arm D used in combination
214376554|NCT03017326|DRUG|Irinotecan|Arm D used in combination
214376555|NCT03017326|DRUG|Gemcitabine|Arm F used in combination
214376556|NCT03017326|DRUG|Oxaliplatin|Arm F used in combination
214376557|NCT03017326|DRUG|Sorafenib|Arm used in combination
214376558|NCT06349148|DIETARY_SUPPLEMENT|enteral immunonutrition|Patients in this group receives 2 bottles of immunonutrients per day (Impact, Nestlé, approximately 700 kcal).
214687075|NCT04153006|DEVICE|POC troponin analysis.|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Minicare® device.
214687076|NCT06141213|DIAGNOSTIC_TEST|Ultrasound screening|Ultrasound screening for fetal membrane thickness at 18-24 weeks of pregnancy.
214376559|NCT06349148|DIETARY_SUPPLEMENT|standard oral enteral nutrition|Patients in the control group receives isoenergetic standard oral enteral nutrition ( emulsion or Nutrison).
214376560|NCT02030730|BEHAVIORAL|Triple P Seminar Series|The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
214376561|NCT04211922|DRUG|Alkotinib Capsules|Alkotinib 400mg QD
214376562|NCT05180292|DRUG|Carvedilol 12.5 MG|Carvedilol 12.5 mg
214376563|NCT00566176|DEVICE|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
214376564|NCT03187990|DRUG|[68Ga]PSMA-11|PET/MRI with \[68Ga\]PSMA will be compared to mpMRI for biopsy guidance.
214376565|NCT03187990|DRUG|[18F]PSMA-1007|18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.
214687077|NCT03165136|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200 mg twice a day
214687078|NCT03165136|DRUG|Placebo|placebo of hydroxychloroquine
214687079|NCT05485272|OTHER|Silver Diamine Fluoride combined with Potassium Iodide.|Riva Star, Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia.
215090621|NCT03875664|DRUG|Liposomal bupivacaine|Extended-release local anesthetic
214376566|NCT05529160|DEVICE|FERTI LILY Conception Cup|The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.
214376567|NCT03390868|BEHAVIORAL|Web-based training for staff|This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.
214989220|NCT07045974|OTHER|Group B-Stretching Exercises|"Group B will receive stretching exercises. Subject was asked to lie supine on the plinth and the head was held at the edge of the plinth by the therapist. Then with one hand the therapist held the neck in cervical lateral flexion to the opposite side so as to achieve the stretching of the trapezius muscle. Myofascial release by applying sustained finger pressure for 5-10 s on the involved trapezius was given. A gentle myofascial stretching force was applied to take up slack and sustained until a release occurred. This protocol comprised four sets of 15 stretches with 3 min rest.~Conventional treatment include the following:~Subjects in both the groups were treated with hot pack (20 min), TENS (2 to 10 Hz), manual traction along with deep neck flexor, and isometric neck strengthening."
214376568|NCT01177423|PROCEDURE|Dental anesthesia|Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
215090622|NCT03875664|DRUG|Placebo - injection|Injectable normal saline solution
214376569|NCT04065503|BIOLOGICAL|Probiotic Strains|A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
214376570|NCT01870388|DRUG|Baricitinib|Administered orally
214376571|NCT02930473|BEHAVIORAL|NIC Psychotherapeutic Intervention(s) for Anxiety|Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.
214376572|NCT02930473|DRUG|Psychopharmaceuticals (any drugs prescribed by the psychiatrist)|Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
214376573|NCT00957606|PROCEDURE|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
214989221|NCT06709534|OTHER|Exercise Intervention|Participate in an individualized online home-based exercise intervention
214989222|NCT06709534|OTHER|Functional Assessment|Complete functional capacity assessment
214989223|NCT06709534|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
214989224|NCT06709534|OTHER|Questionnaire Administration|Ancillary studies
214989225|NCT06709534|OTHER|Supportive Care|Receive social support
215090623|NCT03394352|OTHER|Activity on Board|During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.
214376574|NCT00893399|DRUG|Gemtuzumab Ozogamicin (Mylotarg)|"Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.~Consolidation 2, 3: no GO"
214376575|NCT00893399|DRUG|standard chemotherapy|Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
214496993|NCT06775080|DRUG|propranolol (beta-blocker used treat high blood pressure)|Enrolled patients began receiving propranolol alone orally twice daily (10 mg bid) 10-14 days prior to surgery, and after 3 days of treatment, the dose of propranolol was increased to 20 mg bid daily until the day of surgery if the following three predefined criteria were met: systolic blood pressure greater than 90 mmHg, heart rate greater than 60 bpm, and no significant symptoms (e.g., syncope, insomnia, fatigue). The patient continues to be treated from 1 week after surgery.From 1 week after surgery, patients continue propranolol for 3 weeks. Patients will be monitored daily for symptoms, blood pressure, and heart rate and will be followed for observation at 6, 12, and 24 months after surgery until disease progression or clinical death, unless intolerable toxicity occurs and the patient refuses to continue treatment. The efficacy and safety of the preoperative propranolol β-blockade regimen in patients with gastrointestinal tract tumors was evaluated using the study objectives in S
214496994|NCT00972621|DEVICE|Vitrax II|Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.
214989226|NCT06732193|PROCEDURE|On-site respiratory physiotherapy|The patient attends face-to-face physiotherapy sessions prescribed by the doctor.
214989227|NCT06732193|DEVICE|Fissios App|The patient uses the Fissios App to perform respiratory physiotherapy exercises.
215090624|NCT03394352|OTHER|Usual Diabetes Care|Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.
214376576|NCT04770363|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an emerging non-invasive brain stimulation technique which has been utilized in examining cortical function in healthy subjects and also showed significant outcome in neurological rehabilitation. A safe, portable, noninvasive painless, reversible, selective and focal brain stimulation technique, applied by sponge electrodes over the scalp. tDCS is capable of modulating the excitability of targeted brain zones through delivering a sustained direct current (DC), showed altering neuronal membrane potentials based on the polarity of the current. Researchers demonstrated modulating effects of anodal (increases cortical excitability) and cathodal (decreases cortical excitability) tDCS on brain tissue. The expected effects of tDCS brain stimulation exceeds the duration. Animal studies showed neuronal depolarization and increasing neuronal excitability of the anodal stimulation, and opposite results with cathodal stimulation.
214376577|NCT00263328|DRUG|Tacrolimus|Standard of care
214376578|NCT00263328|DRUG|CP-690,550|CP-690,550 5 mg BID
214496995|NCT00972621|DEVICE|Viscoat|Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..
214376579|NCT00263328|DRUG|CP-690,550|CP-690,550 10 mg BID
214989228|NCT06737380|DIAGNOSTIC_TEST|Physical examination|The physical examination will be performed at the Screening visit and at each subsequent study and safety in clinic follow-up visit. The exam will include: measurement of vital signs (heart rate, peripheral arterial blood pressure, respiratory rate, and temperature), weight, height (at Screening visit only), cardiovascular and respiratory systems, abdominal examination, skin evaluation, mouth and eye evaluation, and neurological assessment. Abnormal findings will be recorded in the CRF.
214989229|NCT06737380|DIAGNOSTIC_TEST|Electrocardiogram|A twelve-lead electrocardiogram (ECG), including corrected QT interval (QTc interval), will be performed in all participants at the Screening visit.
214989230|NCT06737380|OTHER|SF-36 questionnaire|Patients will fill out the SF 36 survey, assessing physical and mental health outcomes prior to dosing and/or any other clinical assessments, on visits 1 (baseline), visit 5 (day 14), visit 6 (day 28), visit 11 (day 168) and early termination visit.
215090625|NCT02927821|BEHAVIORAL|ADS Plus|Contact occurs at a minimum for about 1 hour per month over 12 months (face-to-face/ telephone). Targeted education materials concerning clients' conditions and related matters are shared via email or traditional mail. The goal of each contact is to provide ongoing emotional support, situational counseling, education about importance of taking care of self, referrals/linkages and skills (e.g., stress reduction, behavioral management, how to talk with doctors). The care planning process is collaborative and flexible, reflecting CG fluctuating needs
215090626|NCT05645393|DRUG|topical estrogen product|estrogen topical gel or cream
215090627|NCT01797523|DRUG|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
214376580|NCT06194409|DIAGNOSTIC_TEST|Echocardiography, Urine analysis , blood culture|All patients will be investigated by ECG, Urine analysis, blood culture , Echocardiography
215090628|NCT01797523|DRUG|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
214376581|NCT02092558|DRUG|Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution|
214376582|NCT02092558|DRUG|cephalosporin with chemotherapeutics|Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
214376583|NCT00622180|DEVICE|NBUVB|NBUVB hand foot box
214376584|NCT00622180|DEVICE|Monochromacitc Excimer light|Treatment with Monochromacitc Excimer light
214376585|NCT06300255|BEHAVIORAL|H.O.O.V.E.S. Healing Intensives|"H.O.O.V.E.S. is a private, donor-supported charity dedicated to providing fully-funded, \[4\]-day, non-clinical healing intensives for veterans, their families and caregivers, and first responders across the nation who are seeking recovery from service-connected stress. 1~References~1\. Home. HOOVES for Vets. Accessed January 24, 2024. https://www.hooves.us/."
214376586|NCT00717821|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
214376587|NCT00717821|DRUG|Epoetin Beta|Participants who are receiving SC or IV epoetin beta will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
215090629|NCT01797523|DRUG|Everolimus|10 mg by mouth once daily in a 28 day cycle.
215090630|NCT06304506|OTHER|Cross sectional study|Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise
214376588|NCT00717821|DRUG|Darbepoetin Alfa|Participants who are receiving SC or IV darbepoetin alfa will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
214376589|NCT02280239|DRUG|Acetaminophen|one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
214376590|NCT02280239|DRUG|Placebo|one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
214376591|NCT05765279|DRUG|HH-120 nasal spray 1|HH-120 nasal spray 5 times daily for 3 consecutive days
214376592|NCT05765279|DRUG|HH-120 nasal spray 2|HH-120 nasal spray 8 times daily for 3 consecutive days
214376593|NCT05765279|DRUG|Placebo Comparator 1|Placebo nasal spray 5 times daily for 3 consecutive days
214376594|NCT05765279|DRUG|Placebo Comparator 2|Placebo nasal spray 8 times daily for 3 consecutive days
214376595|NCT04512066|DRUG|RO6889450|Participants will receive oral RO6889450 QD.
214376596|NCT04512066|DRUG|Placebo|Participants will receive oral placebo QD.
214496996|NCT06838364|OTHER|Infrared peripheral venous technique|use a infrared device for venous peripheral visualisation and catheter insertion
214376597|NCT04512066|DRUG|Risperidone|Participants will receive oral risperidone QD.
214376598|NCT05597657|OTHER|Fluid administration (Fresenius Kabi Sodium Chloride 0.9%)|All participants in substudy 2 will be administered 2 liters of isotonic saline infusion (Fresenius Kabi Sodium Chloride 0.9%) intravenously. CMR and echocardiography will be performed before and after infusion.
214376599|NCT01833143|DRUG|Bortezomib|
214376600|NCT01833143|DRUG|Acyclovir|
214989231|NCT06737380|DIAGNOSTIC_TEST|Clinical laboratory evaluations - Serology|Serologic testing for HIV, HBV, HCV, TB, and CMV will be performed; HBV and HCV PCR will be done only if serology is positive. Autoimmune tests (ANA, anti-ENA, total IgG, anti-nucleosome) will be done at Day 0 and end of study; ANA only at Screening if no positive ANA or anti-dsDNA in prior 6 months. Inflammatory markers (hs-CRP, ESR) will be tested at Day 0 and end of study. CBC with differential, biochemistry, anti-dsDNA, and complement C3/C4 will be assessed at each scheduled visit.
214989232|NCT06737380|DIAGNOSTIC_TEST|Clinical laboratory evaluations - Biochemistry|The panel will include analysis of albumin, blood urea nitrogen (BUN), creatinine, glucose, uric acid, calcium, phosphorus, potassium, sodium, lactate dehydrogenase (LDH), total protein, magnesium, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and hs-CRP. For biochemistry, 3 mL blood will be collected at each study visit. Results relating to inclusion criteria must be confirmed within 7 days prior to Day 1.
214989233|NCT06737380|DIAGNOSTIC_TEST|Clinical laboratory evaluations - Hematology|The complete blood count (CBC) will include: hemoglobin, hematocrit, white blood cells (WBCs) with complete manual or automated differential (total neutrophils, lymphocytes, monocytes, eosinophils, basophils; absolute or percentage will be acceptable), red blood cells (RBCs), platelet count. For CBC, 1mL blood will be collected at each study visit.
215090631|NCT05736419|DRUG|Fludarabine|PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.
215090632|NCT05736419|DRUG|Cyclophosphamide|Cyclophosphamide will be administered Post-Transplant
214376601|NCT01217008|BIOLOGICAL|GRNOPC1|One injection of 2 million GRNOPC1 cells.
214376602|NCT03995784|BIOLOGICAL|Coagulation Factor IX variant|Single intravenous injection of CB2679d/Dalcinonacog alfa
214376603|NCT03995784|BIOLOGICAL|Coagulation Factor IX variant|Daily subcutaneous injections of CB2679d/Dalcinonacog alfa for 28 days
214376604|NCT06185010|OTHER|One Resistance Training Set (Single Session)|The participants will perform a resistance training session with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions at 55% 1RM in the chest press, iv) 1 set of 10 repetitions in the sit-to-stand exercise, v) 1 set of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
214376605|NCT06185010|OTHER|Three Resistance Training Sets (Single Session)|The participants will perform a resistance training session with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions at 55% 1RM in the chest press, iv) 3 sets of 10 repetitions in the sit-to-stand exercise, v) 3 sets of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
214496997|NCT06838364|OTHER|Ultrasound-guided peripheral venous technique|Use the ultrasound-guided technique for venous peripheral visualisation and catheter insertion
215090633|NCT05736419|DRUG|Tacrolimus|Tacrolimus will be administered beginning on day +5
215090634|NCT05736419|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.
215090635|NCT05736419|BIOLOGICAL|Rabbit ATG|The dose and schedule of ATG will be determined according to the nomogram in Appendix A
215090636|NCT05736419|DRUG|Dexamethasone|Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.
215090637|NCT05736419|DRUG|Bortezomib|Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33
215090638|NCT05736419|DRUG|Rituximab|Rituximab on days -71, -58, -43, and -30.
215090639|NCT05767827|DRUG|ropivacaine, lidocaine with adrenaline|Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
215090640|NCT05767827|DRUG|Dexmedetomidine, ropivacaine, lidocaine with adrenaline|Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
215090641|NCT06434233|DRUG|Acetaminophen|"All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter."
214376606|NCT06185010|OTHER|One Resistance Training Set (8 Weeks)|The participants will perform eight weeks of resistance training with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions between 40-60% 1RM in the chest press, iv) 1 set of 6-12 repetitions in the sit-to-stand exercise, v) 1 set of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
214496998|NCT06838364|OTHER|Landmark technique|the gold standard technique with observationnal and palpation
214496999|NCT06855485|DEVICE|HANAROSTEN® HOT Plumber™ with Z-EUSIT™|An electrocautery-enhanced lumen-apposing metal stent designed for the drainage of pancreatic pseudocysts. The stent is delivered using a system that allows for single-step deployment without the need for guidewire exchanges or tract dilation.
214497000|NCT06875921|OTHER|McKenzie Exercise Group|"The intervention will last 7 minutes and will consist of the following exercises:~* Four Extension Exercises: Lying Face Down, Lying Face Down in Extension, Repeated Lumbar Extension in Lying, Repeated Lumbar Extension in Standing.~* Two Flexion Exercises: Repeated Lumbar Flexion in Lying, Repeated Lumbar Flexion in Sitting."
214497001|NCT06875921|OTHER|Pilates Exercise Group|The intervention will last 20 minutes and will include Pilates exercises focused on mobility and strengthening.
215090642|NCT06434233|DRUG|Ibuprofen|"All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter."
214989234|NCT06737380|DIAGNOSTIC_TEST|Pregnancy Test|"A serum b-hCG pregnancy test will be performed for women of child-bearing potential at the Screening visit;urine pregnancy tests will be performed for women of child-bearing potential at each study visit noted above, including on Day 0 prior to study treatment.~Pregnancy tests are not required for women unable to become pregnant for one of the following reasons: Menopause confirmed by healthcare provider, verbally reported by a participant that she has had her uterus or both ovaries or both fallopian tubes removed."
214376607|NCT06185010|OTHER|Three Resistance Training Sets (8 Weeks)|The participants will perform eight weeks of resistance training with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions between 40-60% 1RM in the chest press, iv) 3 sets of 6-12 repetitions in the sit-to-stand exercise, v) 3 sets of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
214376608|NCT06185010|OTHER|Control (8 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
214376609|NCT01665703|PROCEDURE|FDG PET/MR|Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
214376610|NCT01737099|DIETARY_SUPPLEMENT|DHA-O|
214376611|NCT01737099|DIETARY_SUPPLEMENT|Fish oil|
214376612|NCT01737099|DIETARY_SUPPLEMENT|Placebo|
214376613|NCT05378243|DEVICE|Robotic Gait Training|Use of a walker adapted with robotic components to promote proper walking gait
214376614|NCT05378243|BEHAVIORAL|Functional Clinical Therapy|Personalized program of physical therapy targeted to improving walking gait
214989235|NCT06737380|DIAGNOSTIC_TEST|Urinalysis|General urinalysis will include analysis of pH, specific gravity, protein, glucose, ketones, bilirubin, urobilinogen, leukocytes, erythrocytes. In addition samples will be assessed for presence of urinary casts. Spot urine protein/creatinine measure will be done at each visit. If no casts are observed at Screening, then machine assessment of further urinary samples is allowed. For urinalysis, 10mL urine will be collected at each study visit.
214989236|NCT06737380|DIAGNOSTIC_TEST|SLE activity evaluation|SLE status will be assessed using the Safety of Estrogens in Lupus Erythematosus National Assessment- SLE Disease Activity Index (SLEDAI 2K scale).SLE activity will also be assessed using British Isles Lupus Assessment Group (BILAG), physician global and participant global assessment allowing use of the Systemic Lupus Responder Index (SRI 4) and the BILAG-based Composite Lupus Assessment (BICLA) instruments to assess clinical response.
214989237|NCT06737380|DIAGNOSTIC_TEST|SLE biomarker profiling|"SLE biomarkers will be profiled at the study visit (Day 1) and at every subsequent follow up visit. For this purpose, urine and 10 ml blood will be collected.~Anti-ENA, Anti-dsDNA antibodies, total serum IgG levels, CBC, C3, C4, anti-nucleosome antibodies, erythrocyte sedimentation rate, CRP, protein/creatinine ratio in spot urine, 24-hour urine protein - Day 1 - Baseline and at end of study visit only; Mononuclear cell changes. This analysis includes lymphocyte subsets and innate immune cell subsets"
214989238|NCT06737380|DIAGNOSTIC_TEST|Cytokines and chemokine profiling|Samples will be analyzed for the following cytokines/chemokines: IFNγ, IL-6, IL-10, IL-18, TNFα, TGFβ1, CXCL10, CCL2, N-GAL, urine endothelin, KIM1. Serum and urine samples will be collected on Days 0, 28, 56, 140, 168, and early termination visit.
214989239|NCT06737380|BIOLOGICAL|single dose of UC-MSCs|participants will be treated on Baseline Day 1 with a UC-MSCs product administered subcutaneously. Participants will be observed for 2 to 3 hours after end of study treatment and then followed up for safety assessments over the subsequent 6-month period.
214989240|NCT06737380|OTHER|PROMIS instruments|PROMIS Fatigue, PROMIS, Depression, PROMIS Pain prior to dosing and/or any other clinical assessments, on visits 1 (baseline, day 0), visit 5 (day 14), visit 6 (day 28), visit 11 (day 168) and early termination visit.
215090643|NCT06434233|DRUG|Oxycodone|"Patients randomized to Arm 1 will receive Oxycodone 5 mg orally every 4 hours as needed x 12 tablets at post-operative discharge~Patients randomized to Arm 2 will not receive an Oxycodone prescription at post-operative discharge.~However, participants will be informed that if they need additional pain medications, these will not be withheld. Participants in the second arm who require additional pain medications will receive the same amount of Oxycodone as in arm 1"
215090644|NCT05691010|RADIATION|Intensity-modulated radiation therapy|After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
214376615|NCT01593202|BEHAVIORAL|Dialectical behavior therapy|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
214376616|NCT01593202|BEHAVIORAL|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
214497002|NCT06879301|DRUG|Intravitreal injection of aflibercept 8 mg|"Preoperative preparation: Patients were prepared by applying topical fluoroquinolone eye drops (moxifloxacin hydrochloride 0.5% Vigamox, Alcon, USA) 4 times daily for three days before injection.~Procedure: The intravitreal injection was carried out in the operating room under complete aseptic techniques with an operating microscope. After the topical application of anaesthetic drops (benoxinate hydrochloride 0.4%, Benox, Epico, Egypt) to the ocular surface followed by the topical application of 10% povidone-iodine (Betadine) to the periocular area, lids and eye lashes, 5% povidone iodine was administered inside the conjunctival sac for three minutes before the intravitreal injection. 0.07 ml of aflibercept (8 mg) was injected into the vitreous cavity in the inferotemporal quadrant of the globe using a 30-gauge needle 4 mm from the limbus.~Postoperative care: After injection, topical antibiotic drops (moxifloxacin hydrochloride 0.5% Vigamox, Alcon, USA) were applied, and the eye was"
214497003|NCT06762314|DRUG|Insulin|Insulin is a naturally occurring hormone your pancreas makes that's essential for allowing your body to use sugar (glucose) for energy.
214989241|NCT03546127|GENETIC|Next Generation Sequencing (NGS): exome, RNA seq|"Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms.~For both sequencing configurations:~* Data from each cancer and normal genome will be analysed for the presence of somatic variants.~* DNA and RNA sequencing results will be integrated.~* Technical replication for the mutations / chromosome alterations / transcript fusions that most likely drive the tumour process will be performed via Target Resequencing of the genomic / coding regions of interest."
215090645|NCT05691010|DRUG|Carboplatin|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
215090646|NCT05691010|DRUG|Paclitaxel|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
214376617|NCT05063214|DIAGNOSTIC_TEST|Muscle ultrasound evaluation|Muscle ultrasound evaluation will be performed in patients admitted with COVID-19 requiring invasive mechanical ventilation. The measurements of thickness and thickening fraction will occur for diaphragm, abdominal - rectus abdominis, internal oblique, external oblique and transverse abdomen - and parasternal intercostal muscles. Serial measurements of the thickness and echogenicity of the quadriceps femoris muscle will also be performed.
214376618|NCT02907814|DEVICE|Optical Coherence Tomography (OCT)|The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.
214376619|NCT02907814|OTHER|Eye Exam|This is a brief, non-contact ocular exam.
214376620|NCT05788835|PROCEDURE|DEB-TACE and HAIC|Drug-eluting bead transarterial chemoembolization sequential Hepatic Artery Chemotherapy Infusion
214376621|NCT05788835|PROCEDURE|DEB-TACE|Drug-eluting bead transarterial chemoembolization
214376622|NCT00834808|DRUG|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
214376623|NCT05956704|DEVICE|Orthokeratology with aspheric wide inversion zone design in the optical zone|An orthokeratology lens with an altered optical zone design is designed for an aspherical wide inversion arc in the optical zone
214376624|NCT05956704|DEVICE|Orthokeratology with traditional spherical design in the optical zone|Subjects wore the orthokeratology with traditional spherical design in the optical zone
214376625|NCT02716389|OTHER|Zebris CMS 70|
214497004|NCT06762314|DRUG|Semaglutide|Semaglutide is long acting glucagon like peptide which is parenterally administered as subcutaneous injection once weekly with a half-life of about 7 days
214687080|NCT05485272|OTHER|Silver Diamine Fluoride.|A clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride.
214687081|NCT05485272|OTHER|High-Viscosity Glass Ionomer.|A Glass Hybrid material.
214989242|NCT07055399|DRUG|neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cycles|"Neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab, cisplatin, and nab-paclitaxel for 1 cycle, then Iparomlimab and tuvonralimab continued for 2 cycles at 3-week intervals. Details:~Iparomlimab and tuvonralimab 5 mg/kg, IV infusion, Q3W for 3 cycles Cisplatin：75-80 mg/m2, IV infusion, (cycle 1) Nab-paclitaxel 260 mg/m2，30min，IV infusion,(cycle 1)"
214989243|NCT06868797|OTHER|Biological sample for the measurement of suPAR levels.|Biological sample for the measurement of plasminogen activator receptor (suPAR) level at baseline and at 6 months follow up to assess the evolution of cardio-renal interaction in HF patients listed for heart transplant treated by GDMT including dapagliflozin.
214989244|NCT06751433|DEVICE|Scar gel|Health care product (scar gel)
214989245|NCT06751433|DEVICE|Scar gel comparator|Health care product (Scar gel comparator)
214687082|NCT02537301|OTHER|joining in the platform|The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
215090647|NCT00988949|DRUG|PF-04455242|Single oral 18 mg dose of PF-04455242.
215090648|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
215090649|NCT00988949|OTHER|Placebo|Oral placebo.
215090650|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
215090651|NCT00988949|DRUG|PF-04455242|Single 30 mg oral dose of PF-04455242.
215090652|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
215090653|NCT01088854|DEVICE|CPAP|unique session of 30-minute of continuous airway positive pressure
214376626|NCT02716389|OTHER|3-D Bulls Eye Spirit Meter|
214376627|NCT03716284|PROCEDURE|Electromagnetic navigation bronchoscopy (ENB)|ENB is carried out by a ENB system（LungCare, China) with/without other guided bronchoscopy techniques and/or ROSE, which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
214376628|NCT00583622|DRUG|Bevacizumab|5 mg/kg by vein daily over 90 minutes for 2 Days
214376629|NCT00583622|DRUG|Carboplatin|333 mg/m\^2 by vein over 2 hours for 3 Days
214376630|NCT00583622|DRUG|Docetaxel|300 mg/m\^2 by vein over 2 hours for 1 Day
214497005|NCT06762314|DRUG|Empagliflozin|Empagliflozin lowers blood glucose levels by preventing glucose reabsorption in the kidneys, thereby increasing the amount of glucose excreted in the urine
214497006|NCT06765967|OTHER|displaying virtual reality images|Patients were shown content filmed in 4K resolution through the glasses.
214497007|NCT06765967|OTHER|music playback|With the permission of the Turkish Music Research and Promotion Group (TÜMATA), 'Acemaşiran Makamı' was played.
214497008|NCT06812429|DRUG|Dapagliflozin (DAPA)|Participants will receive 10mg of Dapagliflozin per day for three days.
214497009|NCT05771844|DEVICE|Transcranial Electrical Stimulation|Oscillating electrical current
214376631|NCT00583622|DRUG|Gemcitabine|1,800 mg/m2 by vein over 3 hours for 4 Days
214376632|NCT00583622|DRUG|Melphalan|50 mg/m\^2 by vein over 15 minutes for 3 Days
214376633|NCT00583622|PROCEDURE|Stem Cell Transplant|"* Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest~* Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen"
214376634|NCT04023071|DRUG|FT516|Experimental Interventional Therapy
214376635|NCT04023071|DRUG|Rituximab|Monoclonal Antibody
214376636|NCT04023071|DRUG|Obinutuzumab|Monoclonal Antibody
214376637|NCT04023071|DRUG|Cyclophosphamide|Conditioning agent
214376638|NCT04023071|DRUG|Fludarabine|Conditioning agent
214376639|NCT04023071|DRUG|IL-2|Biologic response modifier
214497010|NCT06765369|OTHER|Mediterranean diet|The MD is characterized by increased consumption of legumes, whole grains, vegetables, fruits, nuts, seeds and olive oil, moderate consumption of fish, poultry and dairy foods, with low consumption of processed foods and red meat. The nutritional profile of the MD intervention will consist of 46% carbohydrates, 17% protein, and 35% fat. A significant focus on dietary fat consumption with maintaining an omega 6:3 ratio of approximately 3:1 or lower. The MD will provide fibre-rich foods to meet the fibre recommendations for Canadians (males: 30 grams/day, females: 21 grams/day)
214497011|NCT06765369|OTHER|Westernized Diet|The WD is characterized by increased consumption of highly processed foods, refined grains, red meats, processed meats, added sugars, added salt, high intake of omega-6 PUFA, accompanied by a reduction in fibre, fruits and vegetables, whole grains, fish, as well as nuts and seeds.The nutrition composition of the WD intervention will consist of 46% of calories derived from refined carbohydrates and added sugars, 17% protein (sourced from red and processed meats) and 35% fat. The fatty acid profile will be characterized by higher amounts of n-6 PUFAs while lacking in n-3 PUFAs and MUFAs, with a omega 6:3 ratio of 15-20:1.
214497012|NCT06243471|PROCEDURE|Minimally invasive procedures for the Hallux Abductus Valgus.|Minimally invasive procedures for the Hallux Abductus Valgus
214989246|NCT06796114|OTHER|blood sample|"A total of 48 ml of blood will be collected at baseline (before STRIDE initiation):~* 6 EDTA 6 ml tubes for PBMC collection~* 2 EDTA 6 ml tube for plasma collection"
214497013|NCT06243471|PROCEDURE|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.
214497014|NCT06751420|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging Time Of Flight Angiography
214497015|NCT06750159|OTHER|No intervention (observational study)|no intervention(observational study)
214989247|NCT03966625|DIAGNOSTIC_TEST|tissue transglutaminase autoantibodies|celiac disease-specific autoantibodies
214376640|NCT04023071|DRUG|Bendamustine|Conditioning agent
214376641|NCT05403190|DEVICE|da Vinci SP system|using da Vinci SP system to perform extraperitoneal approach radical prostatectomy
214376642|NCT03266614|BEHAVIORAL|Recovery 4 Us|R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
214376643|NCT06104280|OTHER|Post-Illumination Pupillary Response (PIPR)|The PIPR is measured in six, 80-s test periods in which the stimulus, either Blue (470 nm) or Red (623 nm), is presented to the dilated eye while the pupil response of the un-dilated eye is measured (consensual pupil response
214376644|NCT06104280|OTHER|Polysomnography|Measure electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), electrocardiography (ECG), respiratory channels (effort and nasal pressure), and oxygen saturation.
214376645|NCT06104280|OTHER|Multiple Sleep Latency Test|Assist in the diagnosis of disorders of hypersomnolence,63 it is also used in research to quantify daytime sleepiness and serves as a more objective measure of daytime sleepiness than self-report questionnaires
214376646|NCT06104280|BEHAVIORAL|Ecological Momentary Assessments|Morning after overnight Visit 2, participants will complete ecological momentary assessments (EMAs) over a 10-day assessment period. Using EMA through the InsightTM mHealth platform to capture momentary craving, withdrawal and mood states across 10 days among persons who smoke and nonsmokers prior to an overnight procedures. Participants will complete morning and evening sleep diaries via the EMA InsightTM mHealth platform self-reported sleep and wake information, fatigue, naps, opioid craving and withdrawal.
214376647|NCT06104280|DEVICE|Actigraphy|7-day actigraphy period will be used to determine the habitual sleep start and wake times. The CamNTech MotionWatch8 (Cambridge, UK) is a solid-state piezo-electric accelerometer that collects data on activity (i.e., arm motion) and ambient light.Actigraphy data are downloaded from the MotionWatch8 into the software (MotionWare) for analysis, management, and exportation. Bed and wake times will be entered by the subjects via a REDCap link and this information coupled with the sleep diary reports will be entered to determine sleep intervals. Algorithms in the Motion Watch 8 software will determine sleep start, sleep end, total sleep time (duration), sleep quality, sleep efficiency, wake after sleep onset, and sleep fragmentation
214376648|NCT06104280|OTHER|DLMO|Participants will be given an evening meal and then be accompanied to the UAB Highlands Hospital Sleep Unit by 5:30pm. The sleep unit allows for strict control of light exposure (\< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels.Participants will be allowed to sleep in darkness until 8:00am, at which time they will be provided transportation.We will also bank frozen samples taken prior to the light exposure for later calculation of the Dim Light Melatonin Onset (DLMO), a circadian phase estimate.
214989248|NCT05777421|PROCEDURE|Conventional Physical Therapy for Knee Osteoarthriths|Participants of Group A will receive the conventional physical therapy for Knee Osteoarthistis for a duration of 6 weeks atleast 2 times a week
214989249|NCT05777421|PROCEDURE|Virtual Reality-Based Therapeutic Exercise regimes|"* Participants of Group B will receive Virtual Reality Based therapeutic exercises on the Xbox. The difficulty level of the games will progess each week. The duration of training will also also progress at treatment week progresses.~* Frequency: 2-3 times a week for 6 weeks. Minimum 12 sessions in total."
214989250|NCT00805259|BEHAVIORAL|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
214989251|NCT03186755|DRUG|Hyaluronic acid 0.05% & Ectoine 2.0%|Treatment of 1 drop three times a day in both eyes for 8 weeks
215090654|NCT01331967|DRUG|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
214989252|NCT03186755|DRUG|Olopatadine hydrochloride ophthalmic solution 0.1%|Treatment of 1 drop two times a day in both eyes for 8 weeks
214376649|NCT06104280|OTHER|Melatonin Suppression Test|The sleep unit allows for strict control of light exposure (\< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels. Participants will be asked to refrain from caffeine consumption 12 hours before reporting to the sleep unit and will provide 2-3 ml of saliva every 30 minutes starting at 6:00pm and ending after the light exposure. For melatonin suppression, 2-hours light exposure will begin 2 hours before the calculated mid-sleep time. Collection saliva samples 1-h, 30-min, and immediately before the light exposure and every 30 min throughout exposure. Samples will be centrifuged and frozen/stored at -20ºC until assay and remaining samples stored at -80ºC. Melatonin levels will be assayed via the Buhlmann Direct Saliva Melatonin. Melatonin suppression will be calculated as the percent decrease from the sample taken immediately prior to the light exposure
214376650|NCT03333850|DEVICE|Visual feedback of physical activity|A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).
214376651|NCT03333850|DEVICE|No feedback of physical activity|There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
214376652|NCT03333850|DEVICE|Measurement of physical activity|A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
214376653|NCT01511822|DRUG|Drospirenone Ethinyl estradiol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
214376654|NCT01511822|DRUG|Drospirenone Ethinyl estradiol Myo-inositol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
214376655|NCT01511822|DRUG|placebo|
214376656|NCT02717169|DEVICE|Biometrical tracker|35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
214376657|NCT05919693|DRUG|EYE103|EYE103 is a humanized antibody formulated for IVT administration
214376658|NCT06918379|DEVICE|Cogmed Working Memory Training (CWMT)|"This is an intensive, eye-tracking working memory (WM) training in school-aged children and young adults with severe cerebral palsy. The Cogmed Working Memory Training (CWMT) software was used as intervention software. The CWMT is adaptive, meaning, it becomes either progressively more difficult or less difficult depending on participants' performance. When a participant completes a trial correctly, the level will increase for the next trial. When a participant makes an error, the next trial will either remain on the same level or decrease in level depending on the type of error made. The CWMT program thus adapts on an individualized basis to participant's performance, allowing for training to occur at or close to an individual's highest capacity.~Participants with severe cerebral palsy, users of eye-tracking technology, trained for \~30 minutes, 5 days a week for 5 weeks, i.e. 25 training sessions in total."
214376659|NCT04221282|DRUG|Zebinix|ESL will be initiated by the investigator in patients as a first line monotherapy or adjunctive therapy. ESL will be prescribed according to the usual care. Posology and method of administration of ESL are defined by the summary of product characteristics. Then, data on the efficacy of ESL will be collected.
214376660|NCT00284141|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
214376661|NCT04932005|DRUG|DZD2269|Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
214376662|NCT04932005|DRUG|placebo|Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
214376663|NCT01255553|RADIATION|Partial Breast Irradiation|Partial breast irradiation will be administered using a 3D conformal external beam RT technique. Two fractions of 38.5 Gy separated by at least 6 hours will be given on 5 treatment days over a period of 5 to 10 days.
214376664|NCT04933201|OTHER|Music|Perioperative musical intervention
214376665|NCT04933201|OTHER|Routine perioperative treatment|Routine perioperative treatment
214989253|NCT04324229|DRUG|Liraglutide 6 MG/ML [Victoza]|Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.
214989254|NCT04324229|DRUG|Placebos|Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
214989255|NCT05407883|BEHAVIORAL|School traffic warden programme|Trained school traffic wardens placed at school crossing points to help children cross
214989256|NCT04309331|DIETARY_SUPPLEMENT|Motion|Amino acid based protein substitute
214989257|NCT01044524|RADIATION|SLV 334|2000 mg via i.v. solution
214989258|NCT07152704|DEVICE|Active therapy with non-ablative Er:YAG laser|three intravaginal and vulvar/clitoral treatments within 60 days
214989259|NCT07155538|OTHER|Assesment test for Validity and Reliability|Assesment test
214989260|NCT07156630|DEVICE|iCare ST500|Measurement of IOP
214989261|NCT07156630|DEVICE|iCare IC200|Measurement of IOP
214989262|NCT07156630|DEVICE|GAT|Measurement of IOP
214989263|NCT07156630|DEVICE|Tonovera|Measurement of IOP
214989264|NCT07168707|OTHER|Group-based Emotional Awareness & Expression Therapy - Hebrew|"This pilot study will use the eight-session group EAET manual developed by Mark A. Lumley and Howard Schubiner. Several adaptations to this manual were made: a) Manual's translation to the Hebrew language; b) Adaptations to the Israeli context and setting; c) Manual's language was changed from fibromyalgia to chronic pain and adaptations were made accordingly. Group participants will receive a class syllabus and an educational booklet of the EAET approach. Each group meeting will be led by two instructors, a psychologist and a physiotherapist."
214989265|NCT07168226|DRUG|Active Comparator|Megace F suspension 20mL, intake daily for 12weeks
214376666|NCT03361891|BEHAVIORAL|WalkMORE Group|Hospitalized Internal Medicine patients will walk with trained volunteer coaches twice daily until hospital discharge
214376667|NCT00332332|BIOLOGICAL|etanercept|etanercept subcutaneous injection
214376668|NCT01108458|DRUG|Pertuzumab|iv, 840 mg, 420 mg
214376669|NCT01108458|DRUG|Erlotinib|PO, 150 mg
214497016|NCT06748456|BEHAVIORAL|Podcast|A pre-recorded podcast with a urologist and a GP discussing the theme to promote preparatory reflections among the GPs before the cluster meeting
214497017|NCT06748456|BEHAVIORAL|Cluster meeting|A two-hour meeting facilitated by either the GPs cluster coordinator, another GP from the cluster or a facilitator outside the cluster chosen by the cluster itself with specific slides about PSA in general, guidelines, expert videos, data from the clinics, cases, and group discussions
214989266|NCT07168226|DRUG|ASCA101 24.32mg/kg|ASCA101 Inj. 24.32mg/kg, twice a week for 12 weeks
214376670|NCT02328703|OTHER|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
214376671|NCT01382602|BIOLOGICAL|AMDC-USR|AMDC-USR Treatment
214376672|NCT01382602|BIOLOGICAL|Placebo|Placebo treatment
214376673|NCT00792558|DRUG|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
214376674|NCT00744315|PROCEDURE|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
214497018|NCT06748456|BEHAVIORAL|Hand-out material 1|Hand-outs of the main take-home messages to facilitate further discussion in their respective GP offices
214497019|NCT06748456|BEHAVIORAL|Hand-out material 2|Hand-outs to be used by GP and patients to facilitate communication about the relevance of taking a PSA-test
214989267|NCT07168226|DRUG|ASCA101 32.43mg/kg|ASCA101 Inj. 32.43mg/kg, twice a week for 12 weeks
214989268|NCT07168226|DRUG|Placebo|0.9% normal saline injection
214989269|NCT07167667|OTHER|Paraffin Bath|Patients' hands will be dipped into the paraffin bath 8-10 times.
214989270|NCT07167667|OTHER|Extracorporeal Shock Wave Therapy|The patients will be treated with a sound wave pulse frequency of 15 Hz, an intensity of 1.5 bar, and a total number of pulses of 2000 for one session.
214989271|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.03 mg/kg.
214989272|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.07 mg/kg.
214989273|NCT07169240|DRUG|BT-114143|3 subjects will receive a single dose of BT-114143 injection at 0.15 mg/kg.
214989274|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.3 mg/kg.
214989275|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.6 mg/kg.
214989276|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 1.2 mg/kg.
214989277|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 2.4 mg/kg.
214989278|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 4.8 mg/kg.
214989279|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 8.4 mg/kg.
214989280|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 12.6 mg/kg.
214989281|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 15 mg/kg.
214989282|NCT07169240|DRUG|0.9% Sodium Chloride Injection as Placebo|Except that the S1 dose group was a pilot study group with 1 subject matched to receive a placebo, all other dose groups were each matched with 2 subjects who received placebo treatment as controls.
214989283|NCT07166978|BEHAVIORAL|Social story|Social story is a training method constituting of short stories to convey information in a step-by-step manner, so that ASD children can understand what to expect and how to behave in different situations in daily lives. Social stories have been implemented to introduce dentistry and improve oral hygiene to individuals diagnosed with ASD with promising results. However, the certainty of evidence for its effectiveness in reducing dental fear during dental visit was low as the results were derived from small-scaled non-randomized controlled studies.
214989284|NCT07169331|DRUG|Zanubrutinib|Administered orally
214989285|NCT07169513|DRUG|Aspirin 75 mg daily|For group 1 patients
215090655|NCT03372005|BEHAVIORAL|Floorball|This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
215090656|NCT05827315|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
215090657|NCT05827315|DIAGNOSTIC_TEST|T1 Cardiovascular Magnetic Resonance|T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
214989286|NCT07169513|DRUG|Clopidogrel 75 mg daily|For group 2 patients
214989287|NCT07169513|DRUG|Clopidgrel 75 mg daily|For group 1 patients
214989288|NCT07169513|DRUG|Aspirin 75 mg daily + Clopidgrel 75 mg daily|For group 2 patients
214989289|NCT07168473|DRUG|Experimental|"1. DW1807 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks~2. DW1807-R2 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks"
214989290|NCT07168473|DRUG|Comparator|"1. DW1807 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks~2. DW1807-R2 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks"
214376675|NCT03813342|BEHAVIORAL|Gait training with visual feedback of joint kinematics|Gait training will be accomplished using a Woodway treadmill. The visual feedback will contain information about the real-time lower-limb joint angles. We will instruct participants to use the feedback to reach a target walking pattern.
214376676|NCT06136715|BEHAVIORAL|blood products as a part of Massive Transfusion Protocol|This data repository will serve as a means to aggregate and analyze best practices as relative to MTP in the trauma patient, with specific interest in component best practices, whole blood protocols, and electrolyte/metabolite replacement
214376677|NCT00001064|DRUG|Allogenic Dendritic Cells|
214376678|NCT06015555|BEHAVIORAL|TAMO|TAMO therapy
214376679|NCT06015555|BEHAVIORAL|Postural Control exercises|Postural Control exercises
214376680|NCT02842944|DEVICE|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
214376681|NCT02842944|OTHER|Routine care|Standardized routine care
214376682|NCT02366897|DEVICE|Manus Sensor Pen|Manus Sensor Pen as made by Manus Neurodynamica Ltd
214376683|NCT03601455|BIOLOGICAL|Durvalumab|Given IV
214376684|NCT03601455|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214376685|NCT03601455|BIOLOGICAL|Tremelimumab|Given IV
214376686|NCT01811979|DIETARY_SUPPLEMENT|Oral sucrose solution|Oral sucrose solution plus topical anesthetics
214376687|NCT01811979|DIETARY_SUPPLEMENT|Steril water|steril water plus topical anesthetics
214376688|NCT06445387|OTHER|Virtual Reality Glasses|"Preparation Stage of Virtual Glasses: A 20-minute video consisting of nature scenes shot with a 360-degree camera was selected by the researchers from YouTube. Permission was obtained from the person who created the video.~For the selection of music, both the music that is good for diseases were examined in the literature and an expert opinion was taken from a faculty member (Phd, assistant professor) working at the Faculty of Music and Fine Arts of a university. The music used in the video was created with works selected from the Hüseyni maqam."
214376689|NCT06445387|OTHER|Ice Application Group|Features of the ice and ice bag used for patients in ice application; Ice cubes with dimensions of 9.5 x 26 x 3.5 cm were used. The ice bag is made of cotton and polyester coated fabric and is easily bendable. In this way, the ice bag was ensured to fit properly to the patient's femoral region. It is reusable and heat insulated. The procedure was carried out by following the cold application step protocol created by the researchers using the literature.
214376690|NCT06445387|OTHER|Control Group|They continued to receive their routine treatment and care. No changes were made in their routine treatment and care.
214376691|NCT04170686|BEHAVIORAL|Zemedy App for Irritable Bowel Syndrome|The Zemedy App for irritable bowel syndrome is designed to be an engaging, self-help app for people with irritable bowel syndrome. It is based on empirically supported cognitive-behavioral, and GI focused hypnotherapy interventions for IBS.
214376692|NCT03328143|DRUG|Lavender (Lavandula angustifolia)|Lavender (Lavandula angustifolia) is an essential oil.
214376693|NCT02542540|OTHER|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
214376694|NCT04963374|OTHER|risk evolution scale|Padua score、Caprini score、Prime score
214376695|NCT05152134|BEHAVIORAL|Empowered Relief On-Demand|Tailored interactive digital health treatment for chronic pain
214376696|NCT05152134|BEHAVIORAL|Health Education|The HE digital intervention is roughly 65 minutes with content discussing pain and health topics generally; it is devoid of pain education, psychological skills, and has no active strategies, worksheets, or supportive tools.
214376697|NCT02634840|PROCEDURE|bilateral sagittal split osteotomy|surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve
214989291|NCT07167264|OTHER|PGHD's AI intelligent model(APP)|To collect patient PRO (physical strength, pain, defecation, appetite, weight, etc.) data through the PGHD's AI intelligent model(APP), and use corpus collection cards, facial photography and other technologies to collect PGHD characteristic phenotypes.
214989292|NCT07167095|OTHER|Retrospective Data Collection and Analysis|This intervention refers to retrospective evaluation of clinical and laboratory data of advanced cancer patients who presented to the emergency department between December 2022 and March 2025. Data will be extracted from the hospital information system (HBYS) and national death registry (e-Nabız). Parameters include demographics, ECOG performance status, primary tumor type, metastatic sites, laboratory markers (e.g., NLR, CRP, albumin, LDH), and outcomes such as 90-day mortality, re-admissions, and re-hospitalizations. No experimental treatment, drug, or device is administered as part of the study.
214376698|NCT03620422|OTHER|Mannitol|Mannitol-Induced Cough Challenge
214376699|NCT03620422|DRUG|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
214376700|NCT03620422|OTHER|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
214376701|NCT02801669|DRUG|Du-176b|DU-176b orally administered at a dose of 15 mg once daily.
214376702|NCT02801669|DRUG|placebo|Placebo orally administered once daily.
214376703|NCT02696564|DRUG|Losartan|50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
214376704|NCT02696564|DRUG|Placebo|one capsule per day for two weeks, followed by two capsules per day for 46 weeks
214376705|NCT03161366|BIOLOGICAL|rVSVΔG-ZEBOV-GP|Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
214376706|NCT03131635|BEHAVIORAL|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
214376707|NCT02609321|PROCEDURE|Thoracic Paravertebral Block|Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
214376708|NCT02609321|PROCEDURE|Surgical Wound Infiltration|Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
214989293|NCT07167576|OTHER|Catinfo tool and discussion with physician|Patients in the study group watch a computer presentation with information about the cataract surgery
214376709|NCT05719948|PROCEDURE|Flouroscopic guidance cervical medial branch radiofrequency ablation|Electromagnetic wave deposition near nerve tissue for pain management
214989294|NCT07167576|OTHER|discussion with physician|Patients in the control group have a discussion with the physician
214376710|NCT06262061|DRUG|Propranolol|20mg oral propranolol BID x 14 days
214376711|NCT06262061|DRUG|Placebo|Placebo pill orally BID x 14 days
214376712|NCT06052917|OTHER|DECIdE|DECIdE is a decision aid. Its a communication tool to help health providers as general practitioners or community pharmacists, to practice shared medical decision about optional prescription drug. DECIdE provide robust scientific data about benefit and risks associated to the drug under consideration. DECIdE was built based on the consensus of potentials users ( care providers and patients ), tested on users testing and finally validated by a expert consensus ( DELPHI method).
214376713|NCT01105702|DRUG|Temozolomide|
214376714|NCT01105702|DRUG|Bevacizumab|
214376715|NCT01105702|DRUG|Lithium Carbonate|
214376716|NCT01105702|RADIATION|Radiation|
214376717|NCT01180543|DEVICE|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
214497020|NCT06549049|BEHAVIORAL|TranS-C for PTSD|The Transdiagnostic sleep and circadian intervention (TranS-C), developed by Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the goal of improving sleep and related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for veterans with PTSD. The modified approach, TranS-C for PTSD (TSC-PTSD), elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for veterans in the VA healthcare system.
214497021|NCT06549049|BEHAVIORAL|Sleep Psychoeducation Control|Participants will receive psychoeducation about sleep.
214497022|NCT06756217|DIAGNOSTIC_TEST|68Ga-grazytracer PET/CT|68Ga-grazytracer is designed to target granzyme B, and showed excellent in vivo metabolic stability and favorable targeting efficiency during immune responses. 68Ga-grazytracer PET/CT could directly display the killing effect of CD8+T cells on tumor. All enrolled patients underwent the same 68Ga-grazytracer PET/CT imaging.
214497023|NCT06754267|DRUG|Venetoclax|BCL-2 inhibotor
214376718|NCT01180543|DEVICE|Placebo Patch|same as active patch
214376719|NCT03166475|PROCEDURE|Surgical procedures|All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
214376720|NCT00615264|DRUG|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
214497024|NCT06754267|DRUG|Olverembatinib|Tyrosine kinase inhibitor
214497025|NCT06754267|DRUG|Predinisone|Glucocorticoids
214989295|NCT07168798|DEVICE|Pulse oximeter|OLV-4201 pulse oximeter with sensors: TL-272T3, TL-274T3 and TL-273T3
214376721|NCT00615264|DRUG|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
214376722|NCT05703984|DRUG|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
214376723|NCT05703984|DRUG|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
214376724|NCT05703984|DRUG|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
214376725|NCT05703984|DRUG|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
214376726|NCT00082732|BEHAVIORAL|behavioral dietary intervention|
214376727|NCT00082732|DIETARY_SUPPLEMENT|dietary intervention|
214376728|NCT00082732|PROCEDURE|therapeutic dietary intervention|
214497026|NCT06754085|DRUG|Florastamin[18F] Injection|The subjects will be intravenously injected with a single dose of 7±1 mCi (259±37 MBq) of Florastamin\[18F\] Injection and undergo PET/CT scan at 60-110 min after the injection.
214497027|NCT06751641|OTHER|patient participating in a clinical trial incorporating decentralized elements.|participating in a clinical trial incorporating decentralized elements.
214497028|NCT06753617|PROCEDURE|Cryoablation of brain neoplasm|The procedure begins with standard surgical exposure of the tumor, followed by a biopsy. Next, one or more cryoprobes will be positioned directly into the tumor for ablation. Once positioned, the cryoablation process will commence. A maximum of 2x10 minutes cryoablation cycles will be established followed by active thawing. Following ablation, resection of the tumor will be performed, after which patients will receive standard treatment and follow-up care. Ice formation around the cryoprobes will be monitored using intraoperative ultrasound to optimize the ablation process.
214687083|NCT05364905|DRUG|Chemotherapy|Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
214989296|NCT07168096|OTHER|Psychosocial and clinical assessment|Participants complete standardized self-report questionnaires and undergo medical record review at three time points (baseline, 3 months, and 6 months) to assess psychological symptoms (anxiety, depression, somatization), coping strategies, quality of life, cognitive difficulties, physical activity, nutrition, supportive care needs, and informed decision-making in the context of cancer treatment. No experimental treatment or therapy is administered.
214989297|NCT07167654|OTHER|Smartphone Application|"The Intervention: Serene Motherhood Application The Serene Motherhood application was a newly developed Android-based application created specifically for this study by the research team in collaboration with professional software developers. The content was adapted from authoritative guidelines provided by the American College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and Care Excellence (NICE), the World Health Organization, and the American Psychological Association (APA, 2023; Mota \& Bø, 2021; NICE, 2016; WHO, 2022). The application was developed using the research project budget and was provided free of charge to all participants.~The app aimed to integrate emotional and behavioral strategies, social support, and education for women with symptoms of PPD. The application combines evidence-based therapeutic techniques with user-friendly features supporting daily engagement with the app and self-management. Content and activities were grounded"
214989298|NCT07169422|OTHER|Usual care for diabetic kidney disease management without primary care provider.|Participants in the control group will receive usual care for diabetic kidney disease which includes virtual care, walk-in clinics, or mobile health clinics for people without a primary care provider.
214376729|NCT04256356|DIETARY_SUPPLEMENT|Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
214376730|NCT04256356|DIETARY_SUPPLEMENT|Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
214376731|NCT04256356|OTHER|Feeding infants with standard formula milk|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
214376732|NCT04256356|OTHER|Breastfeeding infants|reference group
214989299|NCT07169422|OTHER|Pharmacist-led validated diabetic kidney disease decision support algorithm.|Pharmacist working in community pharmacy primary care clinic in Nova Scotia will utilize previously validated diabetic kidney disease decision support algorithms for renin-angiotensin system inhibitors (RASi), sodium-glucose co-transporter 2 inhibitors (SGLT2i), or nonsteroidal mineralocorticoid receptor antagonists (nsMRA).
214989300|NCT07168382|BEHAVIORAL|DAPHNE Chatbot Intervention|The DAPHNE intervention consists of a conversational, AI-powered chatbot designed to identify and address health-related social needs (HRSNs) among caregivers of pediatric patients. Delivered via a secure mobile and web-based application, the chatbot facilitates natural language interactions to assess needs, generate personalized resource recommendations, and support real-time navigation to community-based services. Participants assigned to the intervention arm will have continuous access to the chatbot over a six-month period, including automated nudges, tailored prompts, and context-aware suggestions. The intervention is non-invasive and participant-driven.
214989301|NCT07168382|OTHER|Standard HRSN Screening and Referral (Usual Care)|Participants randomized to the control group will receive the standard-of-care HRSN screening and referral services as currently implemented in Nationwide Children's Hospital Primary Care Clinics. These services include in-clinic social needs assessments conducted during routine visits and referrals to internal or external resources, such as social work or care coordination teams. Participants in this group will not receive access to the DAPHNE chatbot.
214989302|NCT07167875|BEHAVIORAL|Personalized Digital Oral Health Coaching|All participants will use an electronic toothbrush and mobile app to record brushing behavior throughout the study. However, only the intervention arm will receive personalized digital coaching through the Oralytics app, including tailored feedback, educational messages, and motivational prompts.
214989303|NCT07167446|DRUG|Cannabidiol (CBD)|Oral hemp-derived CBD capsules, 150 mg twice daily (with titration in Cycle 1; dose reductions permitted for tolerability). Administered starting the day before oxaliplatin infusion and continued for 7 days after each chemotherapy cycle.
214989304|NCT07167446|DRUG|oxaliplatin-based chemotherapy|Standard of care oxaliplatin-based regimens per NCCN guidelines (e.g., FOLFOX or CAPEOX), administered in 2-3 week cycles for a maximum of 6 months.
215090658|NCT05827315|DIAGNOSTIC_TEST|Right heart catheterisation and coronary sinus blood sampling|10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
214376733|NCT02986490|BIOLOGICAL|Blood sample|Blood sample
214376734|NCT02105805|BEHAVIORAL|Dietetic group sessions|Group sessions to improve dietary adherence
214376735|NCT01705535|BEHAVIORAL|Individual supervised pelvic floor muscle exercises|Six individual treatments of 45 minutes by a physiotherapist specialized in pelvic floor disorders. Preparation of an individual adapted training program for the pelvic floor muscles. Encouragement to perform the pelvic floor muscle training program on a daily basis
214376736|NCT01705535|OTHER|Massage of the neck and back|six individual treatments of 30 minutes by a physiotherapist. The participants will get no instructions of pelvic floor muscle exercises.
214376737|NCT01705535|BEHAVIORAL|Standard information and guidance|Advice about diet and fiber supplements. Information about optimizing bowel emptying including use of medicine. Advice about use of antidiarrheal medication if appropriate.
214497029|NCT06769061|PROCEDURE|Acupuncture|Patients will receive 6 weeks of electroacupuncture, 2 sessions per week, 30 min per session Stainless steel, single-use, sterile, and disposable needles will be used. We will use the bilateral acupoints LI4 (He-Gu), TE5 (Wai-Guan), LI11 (Qu-Chi), and LU5 (Chi-Ze) for upper limbs. For lower limb numbness, we will use the bilateral acupoints of LV3 (Tai-Chong), ST41 (Jie-Xi), SP6 (San-Yin-Jiao), and GB34 (Yang-Ling-Quan) for the numbness of back of feet, or the bilateral acupoints of KI1 (Yong-Quan), KI3 (Tai-Xi), SP6 (San-Yin-Jiao), and GB34 (Yang-Ling-Quan). After skin disinfection, sterile adhesive pads will be placed on bilateral LI4 (Hegu), TE5 (Waiguan), LI11 (Quchi), and LU5 (Chize). Following each needle insertion, acupuncturists will perform equal manipulations of twirling, lifting, and thrusting on the needle by acupuncturists to achieve the de qi sensation. These 4 acupoints (He-Gu, Qu-Chi, San-Yin-Jiao, Yang-Ling-Quan) will be electrically stimulated for 30 min.
214687084|NCT06150573|DRUG|Test Dentifrice|Dentifrice containing 5% weight by weight (w/w) KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride.
214687085|NCT06150573|DRUG|Reference Dentifrice (Aquafresh Cavity Protection)|Dentifrice containing 1150 ppm fluoride as sodium fluoride.
215090659|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula With Fructose|Low-carbohydrate Enteral Formula With Fructose
215090660|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula Without Fructose|Low-carbohydrate Enteral Formula Without Fructose
215090661|NCT05565937|DEVICE|BL-3100-NBR03 multi-purpose solution|BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses
214376738|NCT01487876|BIOLOGICAL|HBV DNA vaccine|HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
214376739|NCT01487876|OTHER|Placebo|Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
214376740|NCT03035305|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement (LNS)|"For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks~* For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks"
214989305|NCT07167888|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will not receive the intervention of an exercise program. The interventional group (Group B) will be asked to keep the standardised exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain, without having received any intervention.
214376741|NCT03035305|DRUG|Seasonal malaria chemoprevention|"For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine"
214376742|NCT01454674|OTHER|2, 5 & 10 Vegetable doses|2,5 \& 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers \& tomatoes consumed for 3 week intervals
214376743|NCT03430063|DRUG|SDREGN2810|Standard dose intravenous (IV) infusion
214376744|NCT03430063|DRUG|SDREGN2810/ipi|Combination therapy dose IV
214376745|NCT03430063|DRUG|HDREGN2810|High dose IV
214376746|NCT00596596|DRUG|prucalopride|0,5 mg once daily
214376747|NCT00596596|DRUG|prucalopride|1 mg once daily
214376748|NCT00596596|DRUG|2 mg prucalopride|2 mg once daily
214376749|NCT00596596|DRUG|4 mg prucalopride|4 mg once daily
214376750|NCT00596596|OTHER|Placebo|placebo once daily
214376751|NCT05817578|DEVICE|Quantitative Sensory Testing / Dynamometry / Goniometry|Testing procedures that follow previously used protocols of the literature for all the Quantitative Sensory Testing, Dynamometry \& Goniometry
214376752|NCT03301727|OTHER|Cognitive-Behavioural Therapy for Insomnia (CBT-I)|Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
214376753|NCT04570995|DIETARY_SUPPLEMENT|Fish Oil|Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week
214376754|NCT04570995|DIETARY_SUPPLEMENT|Safflower Oil|Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week
214989306|NCT07167888|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine exercise program will be provided in a handout and given only to the intervention group (Group B), and will include simple basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study.
214989307|NCT07168655|DRUG|Mavacamten|According to the product label
214989308|NCT07167940|DEVICE|Transcranial magnetic stimulation|iTBS; 50 Hz triplets given at 5 Hz frequency with a cycle time of 2 seconds on and 8 seconds off). There will be 60 cycles for a total of 1800 pulses
214989309|NCT07167940|DEVICE|Sham transcranial magnetic stimulation|Sham iTBS; 50 Hz triplets given at 5 Hz frequency with a cycle time of 2 seconds on and 8 seconds off). There will be 60 cycles for a total of 1800 pulses
214376755|NCT01488708|DRUG|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
214376756|NCT01488708|DRUG|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
214376757|NCT03146832|BEHAVIORAL|Exposure therapy (according to habituation approach)|Exposure instruction focuses on fear reduction during exposure sessions
214376758|NCT03146832|BEHAVIORAL|Exposure therapy (according to inhibitory learning approach)|Exposure instruction focuses on expectation violation during exposure sessions
214376759|NCT00727818|DEVICE|guided bone regeneration|
214376760|NCT00389181|PROCEDURE|Interventional therapy|All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
214376761|NCT00389181|OTHER|Medical management|Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
214376762|NCT04219618|DEVICE|Off-Pump|After a standard median sternotomy, pericardium will be divided to expose the heart and major vessels, and the aortic cannulation sutures will be placed. Pyramid positioner will be applied to the apex of the heart, and the heart will be manually elevated upward. The inflow cannula placement location and placement of the sewing ring will be done with pledged sutures. The LV diaphragmatic site coring will be completed, and immediate LV digital exploration will be accomplished. The LVAD inflow cannula will be inserted through the sewing ring into the LV cavity. Upon completing proper LVAD inflow cannula placement into the LV and securing it in position, the heart will be dropped into the pericardial cavity with the outflow graft elevated for LVAD and outflow graft de-airing and to prevent potential later air embolization. A partial occlusion clamp will be placed on the ascending aorta and appropriately trimmed outflow graft will be sewn to the aorta.
214687086|NCT03034304|BIOLOGICAL|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
215090662|NCT05565937|DEVICE|renu® Advanced Formula multi-purpose solution|renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses
215090663|NCT06276998|DRUG|LNK01001|Capsule; Oral
214989310|NCT07169110|OTHER|SPIN-NA Developmental Observation Grid Assessment via Home-Based Standardized Video Recording|The SPIN-NA intervention consists of an analytical developmental assessment using a standardized clinical observation grid. Infants are filmed once between 1 and 6 months corrected age in their home environment by the grid's creators. Each video includes structured observation scenarios designed to evaluate eight developmental domains (e.g., stress signals, tonic regulation, sensory perception, emotional expressiveness, and parent-infant interaction). The videos are independently assessed by five experienced psychomotor therapists trained in the use of the SPIN-NA grid. No treatment or physical intervention is administered; the intervention is observational and non-invasive, aiming to validate the grid's reproducibility in a real-life setting.
214376763|NCT04219618|DEVICE|On-Pump|A standard median sternotomy incision will be performed and pericardium divided to expose the heart and major vessels. Cannulation will be done through the aorta and the right atrium and the patient will be put on cardiopulmonary bypass (CPB). The patient's heart will be freed from the surrounding tissues. With a cylindrical blade, the surgeon will excise a core of myocardium from the apex. The LVAD sewing ring will then be sutured to the margins of the apical hole. The LVAD will be inserted into the LV cavity through the sewing ring. The outflow graft will be measured for the anastomosis into the aortic root. Partial occlusion clamp will be placed on the aortic root and the anastomosis will be performed. De-airing will be performed and the LVAD will be started. The patient will then be weaned from CPB and decannulated.
214376764|NCT04671043|DIETARY_SUPPLEMENT|Caffeine and glucose|Caffeine and glucose powder dissolved in water
214376765|NCT04671043|DIETARY_SUPPLEMENT|Glucose alone|Glucose powder dissolved in water
214376766|NCT04671043|DIETARY_SUPPLEMENT|Placebo|Artificial sweetener dissolved in water
214376767|NCT00873665|OTHER|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
214376768|NCT00873665|OTHER|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
214376769|NCT04609124|DIAGNOSTIC_TEST|Abdominal ultrasound evaluation of antral area|ultrasound assessment of antral cross sectional area
215090664|NCT06276998|DRUG|Placebo|Capsule; Oral
215090665|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
215090666|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
215090667|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
215090668|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
215090669|NCT01099436|DRUG|cyclophosphamide|
215090670|NCT01099436|DRUG|docetaxel|
214376770|NCT02228395|DRUG|PF-04958242|Administered as specified in treatment arm
214376771|NCT02228395|DRUG|Placebo|Administered as specified in treatment arm
214376772|NCT01313611|DRUG|Rituximab + bendamustine|Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
214376773|NCT06025630|DRUG|TUDCA|Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
214376774|NCT06025630|DRUG|Placebo|Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
214687087|NCT03034304|DRUG|Ifosfamide|2g/m2/d, intravenous drip for 30min. Administration is conducted for continuous 5 days. After 4 weeks, the above cycle is repeated for 6 continuous cycles
214687088|NCT03034304|DRUG|PD1 antibody|200 mg/every two weeks ,four weeks is a cycle. Subjects were treated with MASCT-I combined with PD1 antibody until disease progression, MASCT-I intolerance or study completion. If PD1 antibody intolerance occurs, MASCT-I therapy alone will continue. MASCT-I and PD1 antibody are adminnistered according to their respective drug cycle without interfering with each other.
215090671|NCT01099436|DRUG|doxorubicin hydrochloride|
215090672|NCT01099436|DRUG|zoledronic acid|
214687089|NCT03034304|DRUG|Adriamycin|60mg/m2, from the first day of each cycle, it is used for 1-2 days, intravenous drip. Repeat the above cycle after 4 weeks, no more than 8 cycles
215090673|NCT01099436|PROCEDURE|neoadjuvant therapy|
215090674|NCT01022424|DRUG|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
215090675|NCT02706197|DEVICE|OxyChip|The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
215090676|NCT06479694|BEHAVIORAL|Real-life Dual-Task Training|The intervention is Real-life Dual-Task Training (Real-DTT) which uses instrumental activities of daily living training with explicit focus on the cognitive and motor elements and when to focus attention to one vs. the other to reduce fall risk. The Real-DTT sessions will be delivered once a week for 10 weeks during their occupational therapy sessions, delivered by a licensed occupational therapist. Real-DTT is a modified version of occupational therapy, with a protocol tailored to the participants.
215090677|NCT05415137|DRUG|Efzofitimod 3 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
215090678|NCT05415137|DRUG|Efzofitimod 5 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
215090679|NCT05415137|DRUG|Placebo|Placebo IV infusion every 4 weeks for a total of 12 doses
215090680|NCT02870738|PROCEDURE|Pelvic Floor Physical Therapy|Internal and/or external myofascial release of the pelvic floor muscles
215090681|NCT02870738|DRUG|Bladder Instillations|A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
215090682|NCT06794372|DRUG|[68Ga]Ga-FAPI-46 PET/CT|\[68Ga\]Ga-FAPI-46 PET/CT
215090683|NCT04253587|DEVICE|LabyrinthVR|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.
214989311|NCT07167784|OTHER|Ecological Momentary Assessment|Participants will be complete four daily EMA surveys via the Avicenna Research app (morning, 11 a.m., 3 p.m., and evening). Participants will be instructed to complete and submit each survey as soon as they see the app notification. If no response is provided within 15 minutes, a reminder notification will be sent. At the end of the 14-day period, devices will be returned using a prepaid envelope provided by the study team and participants will complete an end-of-study questionnaire to assess the acceptability of the study and will be invited to participate in a debriefing interview with a member of the research team.
214989312|NCT07166965|DIETARY_SUPPLEMENT|Hawthorn supplement|Hawthorn oral supplement
214989313|NCT07166965|DIETARY_SUPPLEMENT|Ketones|ketone oral supplement
214989314|NCT07166965|OTHER|Placebo Control|Placebo Control, oral supplement
214989315|NCT07168317|DRUG|tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone|tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.
214989316|NCT07167108|OTHER|Conventional program, with addition to Mulligan technique|The Mulligan Concept is a manual therapy approach developed by New Zealand physiotherapist Brian Mulligan in the 1980s. It includes techniques such as Mobilization with Movement (MWM) and the Sustained Natural Apophyseal Glide (SNAG), which have attracted significant attention for their effectiveness in treating neck pain. Recent research has supported the benefits of physiotherapy interventions like SNAGs in improving cervical range of motion (ROM) and reducing pain.
215090684|NCT04253587|DEVICE|Placebo Games|Commercially-available, narrative computer games marketed as cognitively enriching.
215090685|NCT04253587|DEVICE|Coherence|Head-mounted display virtual reality game designed to present an adaptive rhythm training routine.
214989317|NCT07167108|OTHER|Conventional Physical Therapy Program|Included exercises, electrical stimulation, and massage.
214989318|NCT07168954|DEVICE|Lumos Glasses|The Lumos Glasses provided tailored blue light therapy and blue light filtering based on the time of day and the user's ambient light conditions. It combines the effect of bright blue light therapy and blue light blocking.
214989319|NCT07168603|DRUG|aNPC|Eligible subjects must be diagnosed with disc herniation and scheduled for discectomy, nucleus pulposus tissue will be collected for cell culture. Cultured cells will be then reintroduced into the degenerated disc via injection. Subjects will undergo multiple follow-up visits after surgery to evaluate safety and efficacy, supplemented with imaging studies to assess disc height, tissue regeneration, and water-retention capacity.
214989320|NCT07167394|PROCEDURE|Interactive Virtual Reality Guidance with Restorative Dental Treatment|"Participants in this group will undergo a standardized restorative dental procedure on mandibular primary molars involving local anesthesia, caries excavation, and compomer restoration. Prior to the treatment, children will wear a virtual reality (VR) headset through which they will experience an interactive, animated educational game.~The VR content simulates the treatment steps-including sitting in the chair, receiving local anesthesia, caries removal, filling, and polishing-using engaging characters and storytelling. The aim is to reduce anxiety and perceived pain through immersive visual and cognitive distraction while standard dental procedures are being performed."
215090686|NCT04253587|DEVICE|Tablet|Tablet computer playing Labyrinth VR game but in 2.5D
214376775|NCT05298176|DRUG|Afatinib, Osimertinib, Carboplatin and Pemetrexed|This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
214376776|NCT02426723|DRUG|Phase 1a: CWP232291|CWP232291 administered alone twice weekly every 4 weeks.
214376777|NCT02426723|DRUG|Phase 1b: CWP232291, Lenalidomide, Dexamethasone|CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
214376778|NCT01300325|OTHER|3% hypertonic saline solution|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
214376779|NCT01337414|BEHAVIORAL|VMS diary booklet|
214376780|NCT01337414|BEHAVIORAL|Standard of Care|
214376781|NCT01872637|BEHAVIORAL|Progressive Multi-Component Intervention|
214376782|NCT01872637|BEHAVIORAL|Usual Care|
214376783|NCT01971164|DRUG|JTZ-951|Subjects will receive JTZ-951 or Placebo
214376784|NCT01971164|DRUG|Placebo|
215090687|NCT04835168|DRUG|BT-11 low|Oral
215090688|NCT04835168|DRUG|BT-11 high|Oral
215090689|NCT04835168|DRUG|Placebo|Oral
215090690|NCT01806064|DRUG|TRC105 and Axitinib|
214687090|NCT03034304|DRUG|Gemcitabine|1000 mg/m2, Intravenous drip for about 30 min, used on the first and eighth days of each cycle, and every 3-4 weeks as a cycle
215090691|NCT01806064|DRUG|Axitinib|
215090692|NCT01330966|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
215090693|NCT05004948|OTHER|Exercise training|The first group conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) combined with metformin, the second group conducted an aerobic exercise program (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group received only metformin without exercise intervention (Met group). The study program was conducted thrice weekly for consecutive twelve weeks.
215090694|NCT01417364|DRUG|Testosterone enanthate|100 mg. IM weekly throughout study
215090695|NCT01417364|DRUG|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
215090696|NCT01417364|DRUG|Placebo|Injected IM weekly throughout study
215090697|NCT01885910|DRUG|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
215090698|NCT01885910|DRUG|Aczone 5% gel|Aczone 5% gel twice daily
215090699|NCT03412253|PROCEDURE|Single-Anastomosis Gastric Bypass surgery (SAGB).|We checked the effect of SAGB on patients suffered from T2DM with BMI 25-30
215090700|NCT02557022|OTHER|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
215090701|NCT04631653|DEVICE|VeriSee®|Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
214376785|NCT05359783|DRUG|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.
214989321|NCT07167394|PROCEDURE|Tell-Show-Do Guidance with Restorative Dental Treatment|Participants in this group will also receive a standardized restorative dental procedure identical to the VR group, including local anesthesia, caries removal, and compomer filling of mandibular primary molars. Behavioral preparation will be conducted using the conventional Tell-Show-Do technique. The clinician will verbally explain each step, demonstrate the procedure using visual and tactile tools in a child-friendly manner, and then proceed with the actual intervention. This method aims to reduce dental fear and increase compliance by familiarizing the child with the clinical environment before the surgical procedure.
214989322|NCT07168395|DRUG|Non-selective beta blockers|Non-selective beta blockers are used in patients who have not had a previous variceal bleed to prevent bleeding by reducing blood pressure in the liver. These drugs also work by blocking beta receptors that reduce cardiac output and by causing vessel constriction in the abdominal organs, which lowers blood flow to the liver and the existing varices.
215090702|NCT02163213|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
215090703|NCT02215343|DIETARY_SUPPLEMENT|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R\&D Centre Europe).
215090704|NCT02215343|DIETARY_SUPPLEMENT|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
215090705|NCT04437992|GENETIC|NIPT|The test, which requires two 10 ml tubes of blood, will be performed simultaneously with the chemical biomarkers of the combined test at 10-12 weeks of gestation
215090706|NCT03046225|DEVICE|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
215090707|NCT03046225|DEVICE|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
214376786|NCT06460558|OTHER|Type 1 diabetes with insulin infusion system|No intervention
214376787|NCT04227574|OTHER|Zero Time Exercise training + WhatsApp anti-inertia reminders|"Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.~In addition, WhatsApp anti-inertia reminders will be sent daily by the research assistant to remind and encourage the participants to practice the Zero Time Exercise."
214376788|NCT04227574|OTHER|Zero Time Exercise training alone|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
214376789|NCT00985985|DRUG|Nicotine|2 mg or 4 mg nicotine lozenge
215090708|NCT03046225|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
215090709|NCT05287217|OTHER|Comparison of medication administration for pain control|Measuring pain control following FESS surgery
215090710|NCT05855655|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"This work aims to develop an internet-delivered MBI to address minority stress and its negative HIV-related health consequences experienced by young men who have sex with men (YMSM). This aim will examine the feasibility and acceptability of the internet-delivered mindfulness-based intervention (iMBI), called Mindfulness-based Queer Resilience (MBQR), for HIV prevention. The study will enroll and randomize a sample of 60 distressed, high-risk YMSM into one of two groups: MBQR intervention (n=30) or active control condition (n=30)."
215090711|NCT04441008|DEVICE|Accelerated Intermittent Theta Burst (aiTBS)|High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.
215090712|NCT04441008|DEVICE|Electroconvulsive therapy (ECT)|ECT as per standard clinical care and management.
215090713|NCT03261206|OTHER|5-ASA Withdrawal|Withdrawal of 5-ASA therapy
214376790|NCT00985985|DRUG|Placebo|placebo lozenge
214376791|NCT01993459|DRUG|Midazolam|We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
214376792|NCT01993459|DRUG|NaCl (sodium chloride) 0,9%|We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
214376793|NCT03266848|DIAGNOSTIC_TEST|Quantitative Magnetic Resonance Imaging|Radiological diagnosis
214376794|NCT04492319|DRUG|Control Test|spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml 0.9 normal saline in each side
214376795|NCT04492319|DRUG|Neostigmine|spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml neostigmine 500 μg in each side .
214376796|NCT03262857|DRUG|use of magnesium sulfate with lidocaine in inferior alveolar nerve block|
214376797|NCT00509236|DRUG|Sitagliptin|25 mg (one 25-mg tablet) once daily
214376798|NCT00509236|DRUG|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
214376799|NCT03788538|DRUG|dexmedetomidine|10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.
214376800|NCT03719794|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement once daily (xyz) for 12 weeks
214989323|NCT07168395|PROCEDURE|Retrograde transvenous obliteration|Pre-emptive retrograde transvenous obliteration will be performed in patients randomized to this arm to evaluate the effectiveness in decreasing gastric variceal bleeding. Either CARTO or PARTO (coil or plug-assisted retrograde transvenous obliteration) will be performed using EMBOLIZATION COILS or VASCULAR PLUGS of different sizes based on the size of the shunt. Additionally, Gelfoam (collagen sponges) slurry will be injected into the shunt and varices to completely obliterate them.
214376801|NCT03719794|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement once daily for 12 weeks
214376802|NCT04437095|OTHER|Psychological Support Based on Positive Suggestion delivered via pre-recorded MP3 message|Daily administration of audiorecording
215090714|NCT04720846|OTHER|Matrix-based physical therapy|Matrix-based physical therapy will be physical therapy that is based on the matrix categorization of the patient (stiff vs. mobile hips, weak vs. strong hips) and involves instructions on the amount of time that should be spent doing stretching and strengthening therapy.
215090715|NCT04720846|OTHER|Standard-of-care physical therapy|Physical therapy that is being conducted as standard-of-care
214376803|NCT05619874|BEHAVIORAL|HIFCT-S|"A functional circuit training of 30 sessions will be carried out as follows:~* Sessions 1 to 6: General circuit (two series) composed of four blocks of three exercises.~* Sessions 7 to 14: Concentrated circuit (two sets) composed of four blocks of three exercises of greater complexity than the exercises of the general circuit.~* Sessions 15 to 22: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~* Sessions 23 to 30: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
214376804|NCT05619874|BEHAVIORAL|HIFCT-P|"A functional circuit training of 30 sessions will be carried out as follows:~* Sessions 1 to 6: General circuit (two series) composed of two blocks of 6 exercises.~* Sessions 7 to 14: Concentrated circuit (two sets) composed of two blocks of 6 exercises of greater complexity than the exercises of the general circuit.~* Sessions 15 to 22: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~* Sessions 23 to 30: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
214989324|NCT07168525|DEVICE|Ultrasound spa|Each participant will sit in a bathtub which has been fitted with an ultrasound device which produces low frequency sound waves within the water.
214989325|NCT07168525|OTHER|Sham ultrasound spa|The control group will sit in the same tub for 45 minutes, 3 times per week for 8 weeks but without the ultrasound being turned on.
214989326|NCT05094336|DRUG|AMG 193|AMG 193: Orally via tablet
214989327|NCT05094336|DRUG|Docetaxel|Docetaxel: Intravenous infusion
214989328|NCT05094336|DRUG|Comparator AMG 193 Test Tablet|Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
214989329|NCT05528848|DRUG|Carfentanil, C-11|Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.
214989330|NCT05528848|DRUG|Naloxone|Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.
214989331|NCT05528848|DRUG|Loperamide Hydrochloride|Loperamide is an FDA- approved, over-the-counter drug for the control and symptomatic relief of acute or chronic diarrhea given orally prior to the optional HC third PET/CT scan only.
214989332|NCT03365648|DIETARY_SUPPLEMENT|Lertal® + standard therapy|"Lertal® is a novel food supplement. Each tablet contains the following active ingredients:~* Quercetin 150 mg: a natural flavonoid that inhibits the release of histamine, leukotrienes, PGD2, IL (IL-6, IL-8, TNF-alpha).~* Perilla frutescens 80 mg: A dry extract of the seeds containing rosmarinic acid, luteolin, apigenin and crysoeriol that inhibits the release of histamine and expression of interleukins (IL-6, TNF-alpha).~* Vitamin D3 5 mcg (200 IU), which contributes to the normal function of the immune system.~Standard therapy: antihistamine."
214989333|NCT03365648|OTHER|Placebo + standard therapy|"Placebo tablet identical in appearance, size and taste to Lertal® tablets. Standard therapy: antihistamine.~Standard therapy: antihistamine"
214989334|NCT03395964|PROCEDURE|Hybrid Dyna-CT guided localization|We will perform intraoperative lung tumor localization in CGMH hybrid operation room(Room 51) equipped with the Siemens Artis Zeego system with DynaCT imaging capabilities. The system provides images equivalent to a 16-slice spiral CT scanner in a single 6-s sweep.
214989335|NCT03395964|PROCEDURE|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
214989336|NCT04403633|OTHER|mobile health educational tool|Interactive educational tool delivered on iPad
215090716|NCT05160766|BIOLOGICAL|Comirnaty (BTN162b2)|Single booster shot (3rd dose in Part A and 4th dose in Part B)
215090717|NCT05160766|BIOLOGICAL|Spikevax (mRNA-1273)|Single booster shot (3rd dose in Part A and 4th dose in Part B)
215090718|NCT02292004|DEVICE|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
215090719|NCT02292004|PROCEDURE|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
214376805|NCT04131530|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
214376806|NCT06192147|DIETARY_SUPPLEMENT|protein restricted diet combined with vitamin D intervention|On the basis of conventional treatment, a protein restricted diet combined with vitamin D intervention plan is given
214376807|NCT02932059|BEHAVIORAL|Metamemory|Metamemory evaluation using a sentence construction strategy
214687091|NCT03034304|DRUG|Cisplatin|70mg/m2, Use on the first day of each chemotherapy cycle, intravenous drip for 30-120 min, and every 3-4 weeks as a cycle;
214376808|NCT05254548|DRUG|ACT-539313|100 mg ACT-539313 (hard capsules) will be administered twice per day in period 2 (morning and evening of Day 8), period 3 (morning and evening of Day 9 to 14) and period 4 (morning and evening of Day 15).
214376809|NCT05254548|DRUG|Flurbiprofen|One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
214376810|NCT05254548|DRUG|Omeprazole|A single dose of omeprazole 20 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
214376811|NCT05254548|DRUG|Midazolam|A single dose of midazolam 2 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
214376812|NCT05276232|DRUG|Cannabis(THC) inhaled|Cannabis vapor is produced from 500mg, approximately 5-10% High dose bulk cannabis plant material, 30-37.5 mg THC
214376813|NCT00792103|DRUG|NP101|NP101 study patch 4 hour application
214376814|NCT02769234|PROCEDURE|ERP/EEG test|The testing protocol consists of an auditory oddball ERP paradigm, followed by the collection of 3min of resting EEG. During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 3 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 45-60 minutes.
214376815|NCT02769234|PROCEDURE|Psychometric testing|Subjects that complete ERP/qEEG testing successfully will move on to clinical and neuropsychological evaluation. Demographic information with also be collected.
214376816|NCT03837808|DRUG|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
214376817|NCT03837808|DRUG|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
214376818|NCT03738839|DEVICE|Quantitative Light-Induced Fluorescence|White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
214376819|NCT03738839|PROCEDURE|Direct bonding|The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
214376820|NCT03738839|PROCEDURE|Indirect bonding|For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
214376821|NCT02498353|RADIATION|preoperative short-course radiotherapy with local boost|Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F
214376822|NCT02498353|RADIATION|preoperative short-course radiotherapy without local boost|Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F
214376823|NCT02498353|PROCEDURE|TME surgery|both study group and control group received surgery under TME principle after radiotherapy
214376824|NCT03074214|PROCEDURE|percutaneous coronary intervention|"All STEMI patients enrolled will at first receive Device(such as: stent or balloon) treatment for their coronary artery."
214989337|NCT01191749|DRUG|Alemtuzumab|10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
214376825|NCT00156858|DRUG|intravenous busulfan|
214497030|NCT06769061|DEVICE|sham acupuncture|Patients will receive 6 weeks of sham acupuncture, 2 sessions per week, 30 min per session. The Streitberger sham acupuncture needle designed specifically for sham acupuncture trials will be used. Patients will feel the needle on the skin, but the needle actually will not puncture the skin. These 4 acupoints (He-Gu, Qu-Chi, San-Yin-Jiao, Yang-Ling-Quan) will be connected to the electrical stimulation device KWD-808I MULTI-PURPOSE Health device (Great Wall Company), but not stimulated. The needle will remain for 30 minutes. without stimulating the acupoints. The sham acupuncture will be used within the trocar. The trocar will be fixed by a base on the skin with sticker. The trocar-base-sticker will be used for both acupuncture group and sham acupuncture control group, so they are exactly the same in appearance. Patients cannot see if there is acupuncture or sham acupuncture within the trocar.
214497031|NCT06768528|DIAGNOSTIC_TEST|Galectin-3 dosage|Peripheral blood sample will be collected in the 24h before CABG
214497032|NCT06763510|DRUG|Chirocaine|Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Isobaric levobupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.
214687092|NCT03034304|DRUG|Carboplatin|5mg/ml/min, Use it on the first day of each chemotherapy cycle, intravenous drip for 30 minutes, and every 3-4 weeks as a cycle
214989338|NCT03454555|BEHAVIORAL|Shared Decision Making|The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. Participants in the SDM arm received their regular pain care visits with a designated SDM-trained clinician over a 12-month period. SDM intervention participants scheduled pain visits as often as needed for pain management (typically quarterly). SDM participants also received an electronic and physical packet of educational materials after randomization.
214989339|NCT03454555|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention, including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. MI + CBT-CP participants received one MI session plus up to eight weekly CBT-CP group sessions.
214989340|NCT05399680|DEVICE|S.M.A.R.T. RADIANZ™ Vascular Stent System|The S.M.A.R.T. RADIANZ™ Vascular Stent System is designed to deliver the S.M.A.R.T.™ self-expanding stent (S.M.A.R.T.™ stent) to the iliac arteries, superficial femoral arteries and/or proximal popliteal arteries using a 6F (2.0 mm) sheathed delivery system introduced through the radial artery.
214989341|NCT05399680|DEVICE|BRITE TIP RADIANZ™ Guiding Sheath|BRITE TIP RADIANZ™ is a catheter guiding sheath that facilitates percutaneous entry of an intravascular device into the peripheral vasculature through the radial artery.
214989342|NCT05399680|DEVICE|SABERX RADIANZ™ PTA Balloon Catheter|SABERX RADIANZ™ is a catheter with a distal inflatable balloon.
214989343|NCT06280313|COMBINATION_PRODUCT|Splenectomy+Targeted therapy+ Immunotherapy|Eligible patients with unresectable hepatocellular carcinoma accompanied by cirrhotic portal hypertension were enrolled in the trial, and all participants underwent either open or laparoscopic splenectomy, with or without devascularization around the cardia. Starting two weeks post-surgery, patients began intravenous infusion of PD-1 monoclonal antibody, Tislelizumab, at a dosage of 200mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8mg (≤60kg) or 12mg (\>60kg), once daily.
214989344|NCT04770805|PROCEDURE|Fetoscopy|After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
214989345|NCT04530630|DRUG|BIC/F/TAF 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.
214989346|NCT00850642|DRUG|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
214989347|NCT00850642|DRUG|Placebo|"Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"
214989348|NCT03675308|BIOLOGICAL|Placebo|Placebo for risankizumab administered by subcutaneous injection
214989349|NCT03675308|BIOLOGICAL|Risankizumab|Risankizumab administered by subcutaneous injection
214989350|NCT06128954|DRUG|900mg TETA 4HCl Once Daily Formulation|3x300mg trientine base tablets as a single AM dose
214989351|NCT06128954|DRUG|900mg TETA 4HCl Cuprior®|6 x150mg trientine base tablets in two equally divided doses
214989352|NCT06548750|OTHER|Intrinsic and Ectrinsic Exercise|Intrinsic and extrinsic muscle strengthening exercises
214989353|NCT06548750|OTHER|Intrinsic Exercise|Intrinsic muscle strengthening exercises
214376826|NCT02459821|OTHER|GE-O SYSTEM|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
214497033|NCT06763510|DRUG|Bupivacaine|Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Hyperbaric bupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.
214989354|NCT03360721|DRUG|Abiraterone Acetate|Given PO
214989355|NCT03360721|DRUG|Apalutamide|Given PO
214989356|NCT03360721|DRUG|Prednisone|Given PO
214989357|NCT02002663|DRUG|ropivacaine 0.2%|PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
214989358|NCT02002663|DRUG|Methylprednisolone 1mg/kg|
214989359|NCT02002663|DRUG|saline 0.9%|
214989360|NCT06568276|PROCEDURE|Additional deep deltoid ligament suture|The deep deltoid ligament will be sutured through a curved incision lifting the tibialis posterior tendon out to be sutured back after tying the ligament to an anchor in the talus.
214989361|NCT04206072|DRUG|D-0316 Capsule|"The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316."
214989362|NCT04206072|DRUG|Icotinib Hydrochloride Tablets|"Icotinib (125 mg three times daily, orally), treatment should continue until disease progression or meet the withdrawal criteria. A cycle of treatment is defined as 21 days of three times daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Icotinib arm and confirmed T790M mutation positive have the option to receive D-0316 (crossover to active D-0316)."
214989363|NCT05868265|DRUG|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.
214989364|NCT05868265|PROCEDURE|Radical surgery|Radical surgery, such as radical nephroureterectomy, nephrectomy or ureterectomy is to take place within 60 days from the last dose of treatment end of cycle 3 (i.e., cycle 3 day 22).
214989365|NCT01288430|DRUG|DS-2248|Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
214989366|NCT01775098|DRUG|allopurinol|No arms will not be change as the study as been closed.
214989367|NCT04131803|DRUG|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
214989368|NCT04131803|DRUG|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
214989369|NCT00962767|DRUG|gemtuzumab ozogamicin|2 IV infusions 6 mg/m2 administered monthly
214989370|NCT00962767|DRUG|ATRA plus 6-MP and MTX|6-MP 50 mg/m2/day PO; MTX 15 mg/m2/q week IM; ATRA 45 mg/m2/day PO
214989371|NCT04742179|OTHER|Manteinance and care intervention on the green areas.|Manteinance and care intervention on the green areas.
214989372|NCT04607096|BEHAVIORAL|Intermittent fasting|The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.
214376827|NCT02459821|OTHER|Conventional training|The conventional walking group will be subjected to a conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
214376828|NCT02500329|DRUG|Gemigliptin|Gemigliptin for 4 weeks
214376829|NCT02500329|DRUG|Acarbose|Acarbose for 4 weeks
214376830|NCT02294188|DEVICE|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product
214376831|NCT02294188|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
214376832|NCT02294188|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
214989373|NCT04607096|BEHAVIORAL|Control diet|Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
214989374|NCT02970864|DEVICE|Polynerve|Polymer biomaterial nerve conduit
214989375|NCT00672009|DRUG|Ixabepilone|Ixabepilone 35 mg/m\^2 intravenously over 3 hours every 21 days for 4 cycles.
214989376|NCT05538845|DEVICE|Screw fixation|Screw fixation to patients
214989377|NCT05538845|DEVICE|Suture button|Suture button for patients
214989378|NCT03077867|PROCEDURE|sinus floor augmentation with bone graft|sinus floor augmentation with lateral approach with bone graft
214989379|NCT02702856|OTHER|ExoIntelliScore Prostate|
214989380|NCT01386385|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-conformal RT
214989381|NCT01386385|DRUG|Carboplatin|Given IV
214989382|NCT01386385|OTHER|Laboratory Biomarker Analysis|Correlative studies
214989383|NCT01386385|DRUG|Paclitaxel|Given IV
215090720|NCT05859074|BIOLOGICAL|MQ719|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
214376833|NCT01145807|DRUG|TDT067|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
214497034|NCT06769477|OTHER|Experimental Group|individuals will receive diabetes education with motivational interviewing technique based on health belief model
214989384|NCT01386385|OTHER|Placebo Administration|Given PO
214989385|NCT01386385|DRUG|Veliparib|Given PO
214989386|NCT02617251|OTHER|No intervention|
214497035|NCT06768697|BIOLOGICAL|KFD1(0µg )|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(0µg + 80µg)
214989387|NCT05347355|OTHER|Spencer technique along with conventional treatment|"Subjects in this group will receive conventional exercises and 7 stages of Spencer technique: (A) extension, (B) flexion, (C) circumduction with compression, (D) circumduction with traction, (E) abduction, (F) internal rotation, (G) lymphatic pump.~Spencer technique will be used to increase range of motion of the glenohumeral joint. The patient will be positioned lying on the side with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand will provide force into the restrictive barrier of shoulder in 7 different movements. These will be shoulder extension, circumduction with distraction, abduction, adduction with internal rotation and glenohumeral pump. During all the movements, patient will be asked to use muscle energy against the slight resistance offered by the therapist for 3-5 seconds. The exercise will be repeated 3-5 times with rest intervals over 3 sessions per week on alternate days for 4 weeks."
214989388|NCT05347355|OTHER|Gongs Mobilization along with conventional treatment|The Gong's mobilization can be done either in high sitting or in side-lying position with the affected shoulder upward. The subject's shoulder will be abducted at 90° so that the humerus will be maintained at vertical position. The elbow joint will be flexed and maintained at 90°; the therapist will maintain this position by placing his/her hand below the subject's elbow. The humeral head will be pressed from anterior to posterior direction with the other hand. The therapist will hold the vertical axis of the humerus by maintaining the shoulder in abduction and the elbow in 90°. The therapist will raise his own body by slightly pulling on the anterior capsule and this pull will be maintained for 10-15 seconds and then relax for five seconds and will be performed for about two to three minutes. At this moment the subject will be asked to perform shoulder abduction with no external rotation, while elbow flexion will be maintained throughout.
215090721|NCT05859074|DRUG|Pembrolizumab|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
215090722|NCT04617522|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
214497036|NCT06768697|BIOLOGICAL|KFD1(20µg)|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(20µg + 80µg)
214497037|NCT06768697|BIOLOGICAL|KFD1(40µg)|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(40µg + 80µg)
214497038|NCT06768697|BIOLOGICAL|KFD1(80µg)|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(80µg + 80µg)
214989389|NCT02927626|DRUG|Yang Yin Fu Zheng therapy|Yang Yin Fu Zheng is a Chinese herbal compound.
214989390|NCT02927626|DRUG|Routine medical care|Routine medical care
214989391|NCT05795335|DRUG|CDK4/6 inhibitor|CDK4/6 inhibitors
214989392|NCT05386888|DRUG|GFH018|Administered as oral
214989393|NCT05386888|DRUG|Toripalimab|Administered as an IV infusion
214989394|NCT05386888|DRUG|Paclitaxel|Administered as an IV infusion
214989395|NCT05386888|DRUG|Carboplatin|Administered as an IV infusion
214989396|NCT05386888|DRUG|Cisplatin|Administered as an IV infusion
214989397|NCT05386888|DRUG|Pemetrexed|Administered as an IV infusion
214989398|NCT05386888|RADIATION|Thoracic Radiation Therapy (TRT)|Thoracic Radiation Therapy (TRT)
214989399|NCT05386888|DRUG|GFH018|Administered as an IV infusion
214989400|NCT04639063|OTHER|Microscopic examination using H&E stained slides|Reexamination of the stained slides of the patients from the hospital archive and adding a CD10 stain when required
214989401|NCT04853290|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
214989402|NCT04853290|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by the registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture protocol instituted in the hospital where the study will be conducted
214989403|NCT05032183|DRUG|Cyclophosphamide|Given IV
214989404|NCT05032183|DRUG|Cytarabine|Given IT
215090723|NCT04438291|OTHER|MDL-SHPVP|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
215090724|NCT04438291|OTHER|30-minute educational video|A 30-minute education video (DVD) on HPV, cervical cancer and the HPV vaccine that is designed to enhance HPV vaccine acceptance
215090725|NCT02991469|DRUG|Sarilumab SAR153191 (REGN88)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
215090726|NCT01051401|DRUG|rosuvastatin|Given PO
215090727|NCT01051401|OTHER|placebo|Given PO
214376834|NCT01145807|DRUG|Placebo|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
215090728|NCT01051401|OTHER|survey administration|Correlative study
215090729|NCT01051401|PROCEDURE|management of therapy complications|
215090730|NCT01282294|DEVICE|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
215090731|NCT04753021|OTHER|Exercise|Progressively increasing training load
215090732|NCT04167865|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
215090733|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
215090734|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
214376835|NCT01145807|DRUG|Transfersome|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
214989405|NCT05032183|DRUG|Dexamethasone|Given IV or PO
214989406|NCT05032183|BIOLOGICAL|Filgrastim-sndz|Given SC
214989407|NCT05032183|DRUG|Leucovorin|Given IV
215090735|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
215090736|NCT01278589|DIETARY_SUPPLEMENT|Placebo|Liquid (80g) without Plantago asiatica L. extract
215090737|NCT01076413|BEHAVIORAL|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
214989408|NCT05032183|DRUG|Mercaptopurine|Given PO
214376836|NCT04617184|OTHER|NO INTERVENTION|THERE IS NO INTERVENTION TO THIS TRIAL. THIS IS A REGISTRY
214376837|NCT02648984|OTHER|The intervention is performing an exercise test|Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
214497039|NCT05468320|DRUG|Caplacizumab|Lyophilized powder for solution for injection.
214497040|NCT05468320|DRUG|Corticosteroids|Solution for injection or Tablet
214989409|NCT05032183|DRUG|Mesna|Give IV
214989410|NCT05032183|DRUG|Methotrexate|Given IT
214989411|NCT05032183|BIOLOGICAL|Pegfilgrastim|Given SC
214989412|NCT05032183|DRUG|Prednisone|Given PO
214989413|NCT05032183|BIOLOGICAL|Rituximab|Given IV
215090738|NCT01076413|BEHAVIORAL|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
215090739|NCT02796508|BEHAVIORAL|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
215090740|NCT02796508|BEHAVIORAL|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
215090741|NCT03013049|PROCEDURE|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
214376838|NCT02796430|OTHER|Time needed to start indirect calorimetry measurement|Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
214376839|NCT02796430|OTHER|Indirect calorimetry measurement|Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
214989414|NCT05032183|BIOLOGICAL|Tagraxofusp-erzs|Given IV
214989415|NCT05032183|DRUG|Vincristine|Given IV
214989416|NCT05045482|DRUG|Saroglitazar Magnesium 1 mg|Group-8: Total of 18 subjects will be enrolled in the Group-8. Group 8A (n=6, consist of mild hepatic impairment subjects); Group 8B (n=6, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
214376840|NCT03319784|DRUG|Ketorolac|Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
214376841|NCT03319784|DRUG|Triamcinolone Acetonide|Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
214376842|NCT03587142|DRUG|Buspirone|Buspirone tablet
214376843|NCT03587142|DRUG|Placebo|"Sugar pill manufactured to mimic buspirone 10 mg tablet"
214376844|NCT02768662|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
214376845|NCT03874065|OTHER|Medical Chart Review|Collection of data from participant's medical chart
214376846|NCT02470858|DRUG|LDV/SOF+ASV|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
214376847|NCT02470858|DRUG|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
214376848|NCT02470858|DRUG|SOF+DCV+ASV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
214376849|NCT03673462|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution. Route of administration: Intramuscular
214376850|NCT03673462|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)|Pharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular
214376851|NCT03673462|BIOLOGICAL|Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine|Pharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
214376852|NCT03673462|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214376853|NCT03673462|BIOLOGICAL|Rotavirus Vaccine|Pharmaceutical form: Oral solution Route of administration: Oral
214376854|NCT03673462|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
214376855|NCT03673462|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous
214989417|NCT05045482|DRUG|Saroglitazar Magnesium 2 mg|Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
214989418|NCT03550885|OTHER|High taurine and saturated fat diet|This is a 3-week (21 day) isocaloric Western-type diet with all meals, snacks, beverages and condiments provided.
214989419|NCT03550885|OTHER|Low in taurine and saturated fat diet|This is a 3-week (21 day) isocaloric largely plant-based diet with all meals, snacks, beverages and condiments provided.
214989420|NCT06480565|DRUG|ADI-270|Anti-CD70 CAR-T
214989421|NCT06480565|DRUG|Fludarabine|Chemotherapy for Lymphodepeletion
214989422|NCT06480565|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
214989423|NCT06122272|OTHER|Test Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Test Formula will be provided during this 12 month.
214376856|NCT03673462|BIOLOGICAL|Varicella Virus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Subcutaneous
214376857|NCT01677702|DIETARY_SUPPLEMENT|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
214376858|NCT01677702|DIETARY_SUPPLEMENT|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
214376859|NCT01677702|DIETARY_SUPPLEMENT|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
214376860|NCT05149092|DIETARY_SUPPLEMENT|Chicken protein hydrolysate supplement|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
214376861|NCT05149092|DIETARY_SUPPLEMENT|Placebo|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
214376862|NCT00677443|DRUG|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
214376863|NCT00677443|DRUG|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
214376864|NCT01432496|DRUG|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity
214376865|NCT01432496|DRUG|saline 15 ml|Nebulization of saline 15 ml in the peritoneal cavity
214497041|NCT05468320|BIOLOGICAL|anti-CD20 antibody|Solution for injection
214989424|NCT06122272|OTHER|Control Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Control Formula will be provided during this 12 month.
214989425|NCT06368778|OTHER|Verbal Advice|The participant will receive verbal instructions following the standard physical therapy.
214989426|NCT06368778|OTHER|Bathroom Scale|The participant is given a sense of what a 20 kg load feels like using a scale.
215090742|NCT03013049|PROCEDURE|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
215090743|NCT05776212|RADIATION|18F-fluoride PET|Positron emission tomography using 18F-fluoride as a tracer
215090744|NCT06777303|DRUG|curcurmin loaded on chitosan nano-particles|the formulation of curcumin and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
215090745|NCT06777303|DRUG|hyaluronic acid loaded on chitosan nano-particles|the formulation of hyaluronic acid and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
215090746|NCT06777303|PROCEDURE|scaling and root planning|the -ve control group in the study
214989427|NCT06368778|DEVICE|Loadsol Biofeedback|Average peak force (N) with be measured during partial weightbearing physical therapy routine for 2-minutes using the Loadsol device.
214376866|NCT03324659|BEHAVIORAL|Exercise and Meditation|The Exercise and Meditation group will listen to recorded meditations (15 minutes) that are based on mindfulness. They will then walk on a treadmill for 30 minutes at a moderate intensity. The intervention is completed five days per week for four weeks.
214989428|NCT05183347|DRUG|BI 1291583|BI 1291583
214989429|NCT05183347|DRUG|Placebo|Placebo
215090747|NCT06777303|DRUG|chitosan nano-particles|the +ve control group in the study
215090748|NCT01762813|PROCEDURE|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
214989430|NCT03768999|DIAGNOSTIC_TEST|Non-contrast magnetic resonance coronary angiography (MRCA)|Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
215090749|NCT02587546|PROCEDURE|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
215090750|NCT02587546|PROCEDURE|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
215090751|NCT02587546|PROCEDURE|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
215090752|NCT06316973|DRUG|CS-1103|CS-1103 for infusion
215090753|NCT06316973|DRUG|Sterile Saline|Sterile Saline for Injection
215090754|NCT01665534|BEHAVIORAL|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
215090755|NCT06120101|BEHAVIORAL|Reflexology Massage|The researcher washed his hands with an antibacterial soap before cleaning the patient's feet. The feet were cleaned according to the patient's preference; To wash feet with water or use disposable wet cloth. The patients were placed in a supine position on the bed in the room and their joint points were supported. The researcher stood at the end of the patient's bed during treatment. Unscented sesame oil at room temperature was used to provide lubrication during reflexology. The application started with the patient's right foot. The foot was first relaxed by applying effleurage, shaking, rotation and stretching methods. During the application, the researcher used the fingers of the other hand while supporting the patient's foot with one hand, and the thumb and caterpillar technique was mostly used. In other applications, the index finger and other fingers were used. The training ended by applying solar plexus pressure to both feet.
214376867|NCT03324659|BEHAVIORAL|Control|The Control group will listen to a recorded audio book for 15 minutes, They will then sit quietly for 30 minutes. The intervention is completed five days per week for four weeks.
214376868|NCT04389502|DEVICE|CaPtyVa app|The apps stores all the current local Clinical practice guidelines information related to CRC screening and surveillance and through its decision algorithms assist physicians in the screening process. In the screening function, CaPtyVa helps the physicians to classify patient´s according to their individual CRC risk and to determine how and when to start with screening tests. In the surveillance, function the app assist the physician in determining when to repeat the next colonoscopy according to guideline recommendation
214989431|NCT05802940|BEHAVIORAL|Electronic health record best practice alert|The electronic health record will identify patients at high-risk for preeclampsia and candidate for low dose aspirin (LDA) prophylaxis. For those in the intervention group, a best practice alert will notify the healthcare provider within the patient's chart during a prenatal visit that LDA should be recommended.
214989432|NCT05652101|OTHER|collection of medical data|"The data collected concerns:~* Sex~* Age~* Socio-professional category of patients or parents / level of education of the parents~* Family history~* Neonatal patient data (pregnancy, childbirth)~* Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation)~* Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years)~* Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG))~* Genetic data if available"
214989433|NCT05652101|OTHER|Vineland Adaptive Behaviour Scales (VABS2) questionnaire|"This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.~Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose."
214989434|NCT06125743|BEHAVIORAL|Usual Care|Participants will conduct self-care activities prescribed by their treating lymphedema therapists.
214989435|NCT06125743|BEHAVIORAL|In-Person LEF-SMP|Participants will receive the in-person LEF-SMP intervention.
215090756|NCT05207163|BEHAVIORAL|Continuing medical education|Education section about knowledge of transmissions, severity of viral hepatitis B-C and update treatment strategy of the HBV-HCV
215090757|NCT05970120|DEVICE|NUVISION NAV Ultrasound Catheter|Participants will be scheduled to have a clinically-indicated ablation procedure using NUVISION NAV ultrasound catheter for management of atrial procedure.
215090758|NCT00004445|PROCEDURE|Surgery|
215090759|NCT00004445|DEVICE|IRS-8|
214989436|NCT06125743|BEHAVIORAL|Telehealth LEF-SMP|Participants will receive the telehealth LEF-SMP intervention.
214989437|NCT06056102|DRUG|Cyclophosphamide|"* Safety Run-in: 375mg/m\^2 daily x 3~* Cohort 1: 375mg/m\^2 daily x 3~* Cohort 2: 375mg/m\^2 daily x 3~* Cohort 3: 375mg/m\^2 daily x 3"
214989438|NCT06056102|BIOLOGICAL|CART-BCMA|"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
214376869|NCT04389502|OTHER|Control group|current physician knowledge on local current CRC screening and surveillance guidelines
214376870|NCT06103084|DIETARY_SUPPLEMENT|Bahgina|Bahgina, a locally produced cereal based food, will be provided at 200g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
214376871|NCT06103084|DIETARY_SUPPLEMENT|SQLNS|Small quantity lipid based nutrient supplement (SQ-LNS) will be provided at 20g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
214376872|NCT04885270|DRUG|cisplatin i.p.|paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1
214376873|NCT04060602|BEHAVIORAL|Personalized Feedback|A report comparing the participant's cannabis use to peer usage, and summarizing problems experienced and risk associated with future use.
214376874|NCT04060602|BEHAVIORAL|Education|Canada's Lower-Risk Cannabis Use Guidelines prepared by the Centre for Addiction and Mental Health which outlines methods to help reduce health risks associated with cannabis use.
214376875|NCT03749122|PROCEDURE|Waiting time for hip fracture surgery|Time from hospital admission to start of hip fracture surgery
214376876|NCT03503825|DRUG|[Tc-99m]-RPI-T-087 Injection|A single intravenous injection of \[Tc-99m\]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
214989439|NCT06056102|BIOLOGICAL|huCART19|"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
214989440|NCT06056102|DRUG|Fludarabine|• Cohort 3: 24mg/m\^2 daily x 3
214989441|NCT05874271|COMBINATION_PRODUCT|Revised case management package|"1. Point-of-care quantitative G6PD testing using G6PD STANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total) (Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PD activity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DP activity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
214989442|NCT00003720|DRUG|semaxanib|
214989443|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 100 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 100 Hz, performed at a sub-motor threshold for 30 minutes.
214989444|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 50 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.
214989445|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a single dose of baclofen, a centrally-acting muscle relaxant belonging to the class of gamma-aminobutyric acid (GABA) analogs. Its primary mechanism involves acting on the GABA receptors in the brain and spinal cord to decrease spasticity. Participants will receive baclofen orally at a single dose of 10 mg."
214376877|NCT01770301|DRUG|Paclitaxel|
214376878|NCT01770301|DRUG|Bevacizumab|
214376879|NCT04028310|OTHER|Phonological|"* Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks"
214376880|NCT04028310|OTHER|Visual-attention|"* Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks"
215090760|NCT04692077|DRUG|Cabotegravir (CAB) tablet|30 mg tablets
215090761|NCT04692077|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter.
215090762|NCT04692077|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet|300 mg/200 mg fixed-dose combination tablets
215090763|NCT06343532|DRUG|SXC-2023|200 mg capsules
215090764|NCT06343532|DRUG|SXC-2023 Placebo|200 mg capsules
215090765|NCT05533372|DRUG|IA-14069|IA-14069 for oral administration.
215090766|NCT05533372|DRUG|Placebo|Placebo for oral administration.
214376881|NCT00871884|BEHAVIORAL|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
214376882|NCT00871884|BEHAVIORAL|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
215090767|NCT05533372|DRUG|Methotrexate|Methotrexate for oral or SC administration.
215090768|NCT05533372|DRUG|Methotrexate|Methotrexate for oral administration.
215090769|NCT06339515|BEHAVIORAL|Universal Design Model|Universal design-based learning is based on the application of universal design approach principles to education. Universal design-based learning considers three broad networks of the brain to enable learning. These are recognition networks, strategic networks and affective networks. Universal design-based learning is a student-centered approach and curricula are designed to appeal to all students. Curricula consist of objectives, teaching methods, teaching materials and assessment and evaluation elements. Students' interests, needs and abilities are taken into consideration when designing curricula. Students' learning disabilities are identified and alternative practices are planned to eliminate these disabilities. All students are given equal opportunity to learn
214376883|NCT00871884|BEHAVIORAL|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
214376884|NCT05102123|DRUG|Cytisine|Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
214376885|NCT05102123|BEHAVIORAL|Video Messaging|Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.
214989446|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a medication called tizanidine, which is an alpha-2 adrenergic agonist. This medication works by inhibiting presynaptic motor neurons, resulting in a reduction of muscle spasticity. It is commonly used to manage spasticity caused by neurological disorders. Each participant will be given a single oral dose of 4 mg of tizanidine as part of this trial."
214989447|NCT06274021|DEVICE|Sham transcutaneous spinal stimulation|Sham Transcutaneous spinal stimulation (TSS) involves placing two surface electrodes midline on the lower back (T11-12 spinal processes). The stimulation frequency during the intervention is 50 Hz, performed for 30 minutes.
214989448|NCT05942313|DRUG|Buprenorphine/ Methadone exposure|Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
214989449|NCT04486716|DRUG|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)
214989450|NCT06565559|DEVICE|Wearable Wireless Sensor|Stage III is a shadow mode evaluation of the device with participants wearing sensors pre-, intra-, and post-operatively. Sensor and clinical data will be collected contemporaneously in the clinical environment. No sensor data is made available to clinical teams for decision making, with no change in patient care.
214989451|NCT03737994|DRUG|Alectinib|Given PO
214989452|NCT03737994|DRUG|Brigatinib|Given PO
214989453|NCT03737994|DRUG|Carboplatin|Given IV
214989454|NCT03737994|DRUG|Ceritinib|Given PO
214989455|NCT03737994|DRUG|Cisplatin|Given IV
214989456|NCT03737994|DRUG|Crizotinib|Given PO
214989457|NCT03737994|DRUG|Ensartinib|Given PO
214989458|NCT03737994|DRUG|Lorlatinib|Given PO
215090770|NCT04667416|BIOLOGICAL|PalinGen Flow Amniotic Tissue Allograft|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
215090771|NCT03157765|PROCEDURE|endometrial biopsy|endometrial biopsy
214376886|NCT03542097|OTHER|MGMT methylation evaluation|The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples
214497042|NCT06649149|OTHER|Genially|In the study, an educational intervention will be prepared with the https://genially.com/ program, which is one of the interactive learning methods.
214687093|NCT00069095|DRUG|Oxaliplatin 130 mg/m^2|Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
214989459|NCT03737994|DRUG|Pemetrexed|Given IV
214989460|NCT00879177|DRUG|Varenicline|Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
214989461|NCT00879177|BEHAVIORAL|behavioral therapy|confirmed negative smoking status at different time points
215090772|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a corridor|6-minutes walking test on a corridor : patient will be asked to achieve the longest possible distance without running. He/she will be allowed to take breaks if he/she feels the need to do so.
214989462|NCT02340325|DRUG|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
214989463|NCT02340325|DRUG|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
215090773|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a treadmill|6-minutes walking test on a treadmill : patient will be asked to achieve the longest possible distance without running on the treadmill. He/she will be allowed to take breaks if he/she feels the need to do so.
214376887|NCT04703296|BEHAVIORAL|MBAT course|"The MBAT will involve:~(i) 4 weekly 1.5-hour course sessions. The sessions will provide guided exercises, didactic information, and discussions to promote greater mindfulness.~(ii) Daily mindfulness practice that will be facilitated by the Measuring Mindfulness App (MMA) and/or instructor-delivered mindfulness practices. The daily mindfulness practice will require about 15 minutes to complete."
214376888|NCT00978965|GENETIC|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
214376889|NCT03782090|DEVICE|Endobronchial intubation|"1. In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1\*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~2. In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated."
214497043|NCT06649149|OTHER|Education|In the study, a case study prepared for the management of an aggressive individual will be discussed in a classroom environment.
214497044|NCT06769451|RADIATION|Stereotactic Arrhythmia Radioablation (STAR) with Proton Therapy|STAR with a single dose of 25Gy(RBE) Proton Therapy
214989464|NCT04661228|DIAGNOSTIC_TEST|Composite International Diagnostic Interview 5th version (CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders in the general population
214989465|NCT05058976|DRUG|Romosozumab|Monthly dose: 210 mg subcutaneous injection
214989466|NCT05058976|DRUG|Placebo|Monthly saline injection
214989467|NCT05058976|DRUG|Zoledronic acid|5 mg IV infusion at Month 12 Visit
214497045|NCT06767865|OTHER|online support programe|Individuals in the experimental group received online training and were subsequently provided with continuous follow-up, counseling, motivation and informative message support for three months. In addition, patients were given a target board containing a daily diabetes management program and were asked to use it for three months.
214989468|NCT05058976|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
214989469|NCT02332707|DRUG|Grazoprevir|One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
215090774|NCT04243330|BEHAVIORAL|Audit and Feedback|The following components will be incorporated into the audit and feedback intervention: i) individualized facility performance data (site level), ii) frequent delivery intervals (monthly), iii) comparisons with other sites, iv) graphical and text form displays of information, v) constructive, non-punitive tone, vi) target performance or benchmark provided, and vii) specific actions or recommendations for meeting the target.
215090775|NCT04243330|BEHAVIORAL|External Facilitation|Facilitation will be conducted by a team of facilitators who will employ the facilitation process to improve uptake of VA Risk ID. Trained external facilitators will flexibly deliver the facilitation process utilizing an integrated set of implementation strategies (e.g., stakeholder engagement, identification of barriers and facilitators, education, problem solving, the use of formative data, communication, and ongoing support).
215090776|NCT06664502|DRUG|EYE201|EYE201 solution for intravitreal administration
214497046|NCT06761495|PROCEDURE|Baseball Suturing Technique|(Baseball Suturing Technique): A corner suture was placed at the right corner of the incision. Next, the second stitch was placed at the apex of the left corner and tied with a knot. Then, the free end of the suture was cut and running baseball stitch pattern was started. The suturing pattern was performed by taking bites from the inside out through the upper and lower lips of the wound at approximately 1 cm intervals with a 1 cm margin from the wound edges
214687094|NCT00069095|DRUG|Capecitabine 1000 mg/m^2|Capecitabine was taken within 30 min after the end of breakfast and dinner.
214687095|NCT00069095|DRUG|Bevacizumab 7.5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
214687096|NCT00069095|DRUG|Placebo for bevacizumab 7.5 mg/kg|Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
214687097|NCT00069095|DRUG|Oxaliplatin 85 mg/m^2|Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.
214989470|NCT02332707|DRUG|Uprifosbuvir|Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
214989471|NCT02332707|DRUG|Elbasvir|One EBR 50 mg tablet (Part A), taken q.d. by mouth.
215090777|NCT06083584|OTHER|RNA sequencing|RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample
215090778|NCT02753127|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
215090779|NCT02753127|DRUG|Fluorouracil|
215090780|NCT02753127|DRUG|Leucovorin|
214989472|NCT02332707|DRUG|Ruzasvir|Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
215090781|NCT02753127|DRUG|Irinotecan|
214989473|NCT02332707|DRUG|Uprifosbuvir (+) Grazoprevir (+) Ruzasvir|Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
214989474|NCT02332707|DRUG|Ribavirin|RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
214989475|NCT02887001|OTHER|Pharmacist consultation|
214989476|NCT05536908|BEHAVIORAL|Residential Written Exposure Therapy|Residential Written Exposure Therapy (resWET): TAU plus 5-individual WET sessions (40-60 min each; Marx \& Sloan, 2019) twice a week for two weeks and once a week for the final session, administered by WET trained psychologists, social workers, or postdoctoral residents. Treatment instructions are read, patients write for 30 minutes, and the writing is briefly processed. No formal written homework is required.
214989477|NCT05536908|BEHAVIORAL|Treatment as Usual|Treatment as Usual (DOM SUD): The DOM SUD (TAU) is a 24-bed intensive SUD residential program with a typical 28-day length of stay. The program focuses on evidence-based treatments for SUD such as Cognitive-Behavioral Therapy, Motivational Enhancement Therapy, Medication Assisted Treatment, and Contingency Management therapy. Patients diagnosed with PTSD are typically referred to outpatient PTSD treatment following DOM SUD and often attend Seeking Safety during the program. Most of the programming is group-based though Veterans also have weekly individual case management appointments.
214376890|NCT01433523|DRUG|ALK HDM AIT Placebo|Oral lyophilisate, Placebo, to be administered sublingually once daily
214376891|NCT01433523|DRUG|ALK HDM AIT 6 DU|Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
214989478|NCT04367246|OTHER|No Intervention|No intervention is assigned.
214989479|NCT01473134|DEVICE|Oxford Cementless Partial Knee|Oxford Partial Knee applied without bone cement.
214989480|NCT01473134|DEVICE|Oxford Cemented Partial Knee|Oxford Partial Knee applied with bone cement.
215090782|NCT02753127|DRUG|Bevacizumab|
215090783|NCT04043598|DRUG|0.9% Sodium-chloride|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
215090784|NCT04043598|DRUG|Ringer's Lactate|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
215090785|NCT05040906|DRUG|H02+CHOP|"Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
215090786|NCT05040906|DRUG|Rituxan +CHOP|"Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
215090787|NCT02785419|BEHAVIORAL|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
215090788|NCT03826342|BEHAVIORAL|Health Check-up for Expectant Moms|A brief intervention (one session plus two booster sessions)
215090789|NCT03826342|BEHAVIORAL|Time, attention, and information-matched control|We will include facts about alcohol/drug use and risky sex during pregnancy, along with informational brochures that provide face validity.
214376892|NCT01433523|DRUG|ALK HDM AIT 12 DU|Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
214376893|NCT05713201|PROCEDURE|Percutaneous Coronary Intervention|Treatment of coronary stenoses with a drug-eluting stent or balloon
214376894|NCT05550363|DRUG|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
214497047|NCT06761495|PROCEDURE|Single-Layer Locked Continuous Suturing Technique|(Single-Layer Locked Continuous Suturing Technique): A corner suture was placed at the right corner of the incision. Next, the second stitch was placed at the apex of the left corner and tied with a knot. Then, the free end of the suture was cut and single-layer-locked continuous suturing was started. The suturing pattern was performed by taking bites from outside to inside through the lower lip and inside to outside through the upper lip of the wound. Each time, a lock was formed by passing through the loop formed by the previous suture. The suturing was performed at approximately 1 cm intervals with a 1 cm margin from the wound edges
214376895|NCT05550363|OTHER|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
214376896|NCT03502616|DRUG|Tofacitinib|Oral administration twice per day
214376897|NCT02008591|PROCEDURE|Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique|Three different techniques, using the same medications (bupivacaine and fentanyl)
214376898|NCT02924324|DEVICE|propofol|
214376899|NCT02924324|DRUG|ropivacaine|
215090790|NCT05913102|DRUG|PDLLA|Administer PDLLA/saline every 2 weeks for 2.5 months
215090791|NCT05705752|OTHER|Balance training|12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.
214376900|NCT02924324|BEHAVIORAL|Wong-Baker FACES® Pain Rating Scale|Nurses will record patient-reported pain scores.
214376901|NCT02924324|BEHAVIORAL|Post-procedural quality of life (QOL)|
214376902|NCT00727324|DRUG|bovine intestinal alkaline phosphatase (BIAP)|30,000U/24h for 7 consecutive days via a duodenal catheter
214497048|NCT06761495|PROCEDURE|Single-Layer Unlocked Continuous Suturing Technique|(Single-Layer Unlocked Continuous Suturing Technique): The uterotomy line was closed in a single-layer continuous suturing pattern that is explained above as group 2 but without passing the needle through the loop formed by the previous sutu
214989481|NCT06217809|BEHAVIORAL|The intervention curriculum addresses sexual activity, abstinence, and adulthood preparation topics.|The intervention is youth-co-led, and targets youth in Detroit, Out-Wayne County or geographically similar areas through a 16-unit curriculum totaling 20 hours. Each participant and their parent/guardian will also receive one individual session with a case planner. Parents will receive 3 hours of parental support group. EmpowHer contains lessons and activities focusing on topics relating to abstinence, and teen pregnancy prevention, focusing on adulthood preparation subjects (APS), such as parent-child communication, adolescent development, healthy life skills, and healthy relationships.
214989482|NCT06957275|PROCEDURE|Nasal packing|group c will not receive pharyngeal packing
214989483|NCT06957275|PROCEDURE|Nasal packing|Group (P): will include the patients who will receive pharyngeal packing
214989484|NCT06214741|DRUG|survodutide|once weekly subcutaneous injection
215090792|NCT05705752|OTHER|Pilates training|12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
215090793|NCT00434798|BIOLOGICAL|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10\^6-10\^9 CFU
215090794|NCT01694108|BIOLOGICAL|BCG-vaccine (SSI)|
215090795|NCT01657760|DRUG|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
215090796|NCT01989611|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
214687098|NCT00069095|DRUG|Leucovorin 200 mg/m^2|Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.
214687099|NCT00069095|DRUG|Fluorouracil 400 mg/m^2|
214989485|NCT06214741|DRUG|Placebo matching BI 456906|Once weekly subcutaneous injection
214989486|NCT04716829|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot allows the adaptation of movements during rehabilitation sessions according to the individually generated strength.
214989487|NCT04594187|OTHER|Immunotherapy|All patients must be planned for treatment with any immunotherapy agent after sentinel lymph node biopsy (e.g. pembrolizumab or nivolumab). For patients receiving radiation therapy initiation may be before, during or after radiation.
214989488|NCT04594187|OTHER|Quality-of-Life Assessment|Ancillary studies
214989489|NCT04594187|RADIATION|Radiation Therapy|Undergo nodal radiation therapy
214989490|NCT06953323|DRUG|Paclitaxel/Paclitaxel-albumin|"WJB001 Capsules:120mg(or 80mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Paclitaxel:80 mg/m2(or 60 mg/m2 ,50 mg/m2), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;~Paclitaxel-albumin:260mg/m2(220mg/m2,180mg/m2),On day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles；"
214989491|NCT06953323|DRUG|Carboplatin/Nedaplatin|"WJB001 Capsules: 80mg(or 60mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18), Every 21 days;~Carboplatin: AUC 5 mg/ml\*min(or 4mg/ml\*min,3mg/ml\*min), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;~Nedaplatin: 100mg(80mg/m2 ,60mg/m2), Day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles;"
214989492|NCT06953323|DRUG|Paclitaxel+Carboplatin|"WJB001 Capsules: 40mg,Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Paclitaxel: 60 mg/m2, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;~Carboplatin: AUC 2mg/ml\*min, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;"
214989493|NCT06953323|DRUG|Niraparib|"WJB001 Capsules: 120mg(or 80mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Niraparib:Niraparib:300mg(or 200mg,100mg),Oral QD Every 21 days;"
215090797|NCT00044187|DRUG|Sibutramine|
215090798|NCT03409510|RADIATION|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
215090799|NCT02506660|DRUG|Bupivacaine|
215090800|NCT02506660|DRUG|Perineural dexamethasone|Dexamethasone in nerve block
215090801|NCT02506660|DRUG|Intravenous dexamethasone|
215090802|NCT02506660|DRUG|Intravenous saline|
214376903|NCT01802814|DRUG|SR-A + Epratuzumab|
214376904|NCT01802814|DRUG|SR-B + Epratuzumab|
214376905|NCT06400966|OTHER|Training method|Jigsaw Technique
214376906|NCT02062866|PROCEDURE|Purse-String|"The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound."
214376907|NCT02062866|PROCEDURE|Second Intent|The wound will not be sutured, and allowed to heal on its own.
214376908|NCT01729884|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
214376909|NCT00628901|PROCEDURE|Uterine Fibroid Embolization (UFE)|Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
215090803|NCT02506660|DRUG|Perineural saline|Saline in nerve block
215090804|NCT00832494|DRUG|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
214989494|NCT06953323|DRUG|Bevacizumab|"WJB001 Capsules: 120mg(or 80mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Bevacizumab: 15mg/kg(or 7.5mg/kg),intravenous infusion, 21 days 1 cycle, up to 22 cycles or unacceptable side effects；"
215090805|NCT04326660|OTHER|SCOPE-Chinese Women|SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
214376910|NCT00628901|DEVICE|Contour SE™ Microspheres|Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
214376911|NCT00628901|DEVICE|Embosphere® Microspheres|Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
214989495|NCT05435508|OTHER|Pain Neuroscience Education|A total of 1 PNE sessions (Neuroscience pain education) will be carried out, in addition medical treatment similar to control group (Usual care). The PNE sessions will be conducted by an experienced PNE certified proffesional in 35 minute face-to-face sessions. In PNE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
214989496|NCT05435508|OTHER|Usual care|The control group (Usual care) is treated with pre-anesthetic assessment + usual treatment, management for analgesic medication pre, during and post hysterectomy. Depending on the medical needs and criteria of patients´s care physician.
214989497|NCT04761822|BIOLOGICAL|Moderna COVID-19 Vaccine|Intramuscular injection
214989498|NCT04761822|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine|Intramuscular injection
214989499|NCT04761822|BIOLOGICAL|Placebo|Intramuscular injection
214989500|NCT04570410|PROCEDURE|primary focal resection plus lymph node dissection|Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma
214989501|NCT04570410|DRUG|Tislelizumab|Tislelizumab IV infusion of 200 mg Q3W
214989502|NCT04570410|DRUG|Gemcitabine plus cisplatin|GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks
214989503|NCT06136585|DRUG|2 mg/kg sugammadex|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.
215090806|NCT02125565|OTHER|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
215090807|NCT02187315|DEVICE|Chrono-chemotherapy pump:Melodie|
215090808|NCT02187315|DEVICE|Routine intravenous drip|
214376912|NCT02847299|DEVICE|"increase of cough peak flow (Astral ventilator)"|instrumental increase of cough peak flow with a ventilator by hyper-insufflation and with air stacking method
214376913|NCT04193839|OTHER|Computerized Provider Order Entry (CPOE) plus Bar Code Medication Administration (BCMA)|Computerized provider order entry (CPOE) refers to the process of providers entering and sending treatment instructions - including medication, laboratory, and radiology orders - via a computer application rather than paper, fax, or telephone. The bar Code Medication Administration (BCMA) is a system that consists of a bar code reader, a portable or desktop computer with wireless connection, a computer server, and some software. Before the administration of medications to the patients the patient unique barcode identification is scanned in order to verify the patient's identity.
214687100|NCT00069095|DRUG|Bevacizumab 5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
214989504|NCT06136585|DRUG|0.07 mg/kg neostigmine|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).
215090809|NCT02187315|DRUG|induction chemotherapy|
215090810|NCT02187315|DRUG|cisplatin chrono-chemotherapy|
215090811|NCT02187315|RADIATION|intensity-modulated radiation therapy|
215090812|NCT02187315|DRUG|cisplatin routine-chemotherapy|
215090813|NCT04836988|OTHER|Three months of digitally delivered osteoarthritis treatment|Digitally delivered osteoarthritis management including education and exercise and weight control if needed
215090814|NCT04836988|OTHER|Three months of face-to-face delivered osteoarthritis treatment|Face-toface delivered osteoarthritis management including education and exercise and weight control if needed
215090815|NCT04771325|BEHAVIORAL|Support from a trained companion|Birth companions trained on how to effectively support women during labor
214989505|NCT05913804|BIOLOGICAL|YTS104 Cells injection|YTS104 Cell injection(LILRB4 dual STAR-T Cell Injection/BCMA LILRB4 Dual STAR-T Cell Injection)) is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
214989506|NCT05644834|OTHER|I'm Fully Empowered for Her (IFE4Her)|IFE4Her consists of 2 key components: 1) An awareness-raising messaging campaign with messages about PrEP that includes posters and Peer Networkers; and 2) access via a mobile medical unit outreach delivery model linking women in public housing to care from the PrEP providers of a university healthcare system and other complementary screening services (i.e., blood pressure, blood glucose monitoring, and HIV testing).
214989507|NCT06290102|DRUG|TEV-56248|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
214989508|NCT06290102|DRUG|Fp MDPI|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
215090816|NCT06492473|DEVICE|ECHO|type and size of ventricular septal defect
215090817|NCT04788056|PROCEDURE|Parasternal Subpectoral Plane Block|Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.
215090818|NCT06546176|OTHER|End to end with Omega suture|After the rectum was divided with a linear stapler, the circular stapler was placed allowing the anvil rod to penetrate the rectal stump near the linear stapler line. An omega suture including both ends of the linear stapler line was placed. The linear stapler line was approximated around the anvil rod of the circular stapler in an omega shape fashion as the omega suture was tied. This technique resulted in a complete resection of linear stapler line by the circular stapler.
215090819|NCT06546176|OTHER|End to anterior rectal wall|"A burse string suture was applied over the anvil of the circular stapler at the transection point of the descending colon using prolene 2/0.~The circular stapler introduced though the anus and its rod directed toward the anterior rectal wall and colorectal anastomosis was performed."
215090820|NCT04387266|RADIATION|modified reduce-volume target IMRT|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
215090821|NCT05093803|BEHAVIORAL|CONTROL GROUP|Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.
214376914|NCT00770432|DRUG|Polyethylene glycol 3350|Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
215090822|NCT05093803|BEHAVIORAL|HEALTH APP GROUP|"Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators."
215090823|NCT02667756|OTHER|Non-interventional|
214376915|NCT00770432|OTHER|Placebo, maltodextrin 500 powder for solution|Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
214376916|NCT05967780|OTHER|Group A: Patients with FHP receiving standard cardiac rehabilitation|Consenting participants in this group will receive a standard cardiac rehabilitation protocol that includes preoperative education and post-operative exercises, chest physiotherapy, functional mobility and care. Phase 1 begins after the patient has been considered clinically compensated due to the optimization of the clinical treatment and/or the use of an interventional procedure. In this phase, a combination of low-intensity physical exercise (that includes range of motion exercises for upper \& lower extremities + progressive mobilization from sitting on bedside to walking short distance and up to stair climbing), incentive spirometry exercise, percussions, breathing exercises and effective coughing exercises.
214497049|NCT06791161|DRUG|Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor|BRCA1/2 mutated hormone receptor-positive HER2-negative early high-risk breast cancer is treated with 3 3 treatment options after surgery：Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor
214989509|NCT04734652|COMBINATION_PRODUCT|Biktarvy®|"Biktarvy® is a fixed dose combination, single tablet containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) for oral administration.~BIC is an integrase strand transfer inhibitor (INSTI). FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Each tablet contains 50 mg of BIC (equivalent to 52.5 mg of bictegravir sodium), 200 mg of FTC, and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose."
214989510|NCT04734652|COMBINATION_PRODUCT|TLD- fixed-drug combination single tablet|Standard of care Dolutegravir-based regimen
214989511|NCT04646434|PROCEDURE|Electroencephalography|Undergo EEG
214989512|NCT04646434|PROCEDURE|Electromyography|Undergo EMG
214989513|NCT04646434|OTHER|Questionnaire Administration|Complete questionnaire
214989514|NCT04646434|PROCEDURE|Urodynamics (UDS)|Undergo UDS
215090824|NCT01331928|DRUG|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
215090825|NCT04803955|DRUG|16mg，KB|16mg,Q8h±3min,Day1-Day7
215090826|NCT04803955|DRUG|Placebos|16mg,Q8h±3min,Day1-Day7
214497050|NCT04043494|DRUG|Cyclophosphamide|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
214687101|NCT00069095|DRUG|Placebo for bevacizumab 5 mg/kg|Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
214687102|NCT05369962|DEVICE|Ultrasound|Ultrasound measurements of the Qcsa
214989515|NCT01246167|DEVICE|Philos|"Conservative treatment versus Philos locking plate in 2 part fracture group.~Conservative treatment versus Philos locking plating versus Epoca prosthesis in MFF group."
215090827|NCT04648514|PROCEDURE|Using of hydraulic lifter device for closed sinus lifting|Using of recent closed minimally invasive technique (hydraulic left technique) by hydraulic lifter device for closed sinus lifting then evaluation of the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement for patients with posterior edentulous maxilla .
214989516|NCT01246167|DEVICE|Epoca|Conservative treatment versus Philos locking plate versus Epoca fracture prosthesis in MFF group
214989517|NCT01246167|OTHER|Control group|Conservative control group
214989518|NCT06531109|DRUG|Ritlecitinib|As provided in the real world practice.
214989519|NCT02233413|DEVICE|Active LLLT helmet application|LED helmet applied with light activated
214989520|NCT02233413|DEVICE|Non-active LLLT helmet application|LED helmet applied without light activated
214989521|NCT06153459|PROCEDURE|Umbilical Cord Clamping at ~30 seconds|Care team will wait to clamp the umbilical between 1-\<60 seconds after birth. 30 seconds is the ideal time of clamping.
214989522|NCT06153459|PROCEDURE|Umbilical Cord Clamping at ~120 seconds|Care team will wait to clamp the umbilical cord between 60-180 seconds after birth.120 seconds is the ideal time of clamping
214497051|NCT04043494|DRUG|Cytarabine|"No involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2).~Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)"
214989523|NCT06153459|PROCEDURE|Umbilical Cord Milking|"For infants who need their cord clamped before the target in the DCC-120 group. Care team may milk the umbilical cord towards the infant four times. Cord milking should NOT be performed if the delay meets or exceeds 60 seconds.~Umbilical cord milking will not be provided among participant-infant dyads in the DCC-30 group."
215090828|NCT04648514|BEHAVIORAL|patient satisfaction evaluation after using hydraulic lifter device|Evaluation of patient satisfaction numerically will be done after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
214989524|NCT04865705|DRUG|tislelizumab|Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
214989525|NCT06021522|DRUG|Ecopipam|Selective dopamine D1 and D5 receptor antagonist
214989526|NCT03991143|DRUG|ATH3G10|intravenous
214989527|NCT03991143|DRUG|Placebo|intravenous
215090829|NCT06504069|BEHAVIORAL|Prosocial VR intervention|A five-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include five weekly sessions, each lasting between 10 to 15 minutes. Each session will depict a different daily life scenario-home, school, street, park, and shopping mall, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
214497052|NCT04043494|DRUG|Dexamethasone|Part of the experimental therapy in Randomization R1 (Protocol Ia-Dexamethasone) and in Randomization R2 (Intensified Protocol M)
214497053|NCT04043494|DRUG|Daunorubicin|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
214497054|NCT04043494|DRUG|Doxorubicin|Part of standard chemotherapy
214497055|NCT04043494|DRUG|Ifosfamide|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
214989528|NCT01908244|OTHER|Music|Pentatonic music
214989529|NCT04451538|DIETARY_SUPPLEMENT|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g (12 spoons, 500 kcal)/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g \[12 spoons, 440 kcal\]/day, twice a day).
214989530|NCT04451538|DIETARY_SUPPLEMENT|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
215090830|NCT01984450|PROCEDURE|ACIC|"Autologous Collagen Induced Chondrogenesis (ACIC):~ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation."
215090831|NCT01984450|PROCEDURE|MCIC|"Mesenchymal Cell Induced Chondrogenesis (MCIC):~MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation."
214989531|NCT05611801|DRUG|marstacimab|marstacimab
214989532|NCT03265964|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
215090832|NCT01984450|DEVICE|implant with a collagen + fibrin gel mixture|
214989533|NCT03265964|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
214989534|NCT00890162|DRUG|Epinephrine|
214989535|NCT00890162|DRUG|Omalizumab (Xolair)|
214989536|NCT00890162|DRUG|Placebos|
214989537|NCT03238534|DEVICE|Neobianacid®|Oral administrations of Neobianacid® (30' after meals and on demand)
214989538|NCT03238534|DRUG|Omeprazole 20mg|Daily administration Omeprazole 20mg (per os, 30' before breakfast).
215090833|NCT06441474|BEHAVIORAL|Presentation of personal breast cancer risk estimate|All participants will be presented with their personal breast cancer risk estimate, calculated using the Gail Model
214989539|NCT03238534|OTHER|Neobianacid® placebo|Oral administrations of Neobianacid® placebo (30' after meals and on demand)
214989540|NCT03238534|OTHER|Omeprazole placebo|Daily administration Omeprazole placebo (per os, 30' before breakfast).
214989541|NCT05978323|BEHAVIORAL|Brief intervention|Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
214989542|NCT05251428|PROCEDURE|Excision of the A1 pulley|Participants will undergo excision of the A1 pulley. Wounds will then be irrigated and closed in the standard fashion.
214989543|NCT05251428|PROCEDURE|Incision of the A1 pulley in the standard fashion|Participants will undergo incision of the A1 pulley in the standard fashion. Wounds will then be irrigated and closed in the standard fashion.
214989544|NCT02196103|DEVICE|Double balloon cervical catheter|
214989545|NCT06172660|DRUG|Nirsevimab|Immunoprophylaxis against RSV
214989546|NCT00223574|DRUG|Control - high carbohydrate, high glycemic index foods|
214989547|NCT00223574|DRUG|high carbohydrate, low glycemic index foods|
214989548|NCT00223574|DRUG|low carbohydrate, high monounsaturate fat foods|
214989549|NCT00211367|DRUG|Anecortave Acetate|
214989550|NCT05296278|DRUG|IBI-323 combined with bevacizumab plus Platinum|IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression
214989551|NCT06215911|DRUG|Tovinontrine (CRD-750)|Tablets administered orally
214989552|NCT06215911|DRUG|Placebo|Tablets administered orally
214989553|NCT06645041|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|The hypertensive patients with vitamin D deficiency will receive a Vitamin D capsule with a dose of 25,000 IU. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
214989554|NCT06645041|DIETARY_SUPPLEMENT|Placebo Capsule(s)|The hypertensive patients with vitamin D deficiency will receive a Placebo capsule. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
214989555|NCT06517381|OTHER|Digital Online Warning Signs of Mental Illness Literacy Program|Digital Online Warning Signs of Mental Illness Literacy Program is comprised of 30-minute pre-recorded video and question-and-answer sessions. The videos were followed by case studies, success stories, and interactive question-and-answer sessions
214989556|NCT01408472|DRUG|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
214989557|NCT04658355|OTHER|Chlorhexidine Gluconate|4% Chlorhexidine Gluconate vaginal cleansing solution as a surgical preparation.
214989558|NCT04658355|OTHER|Povidone-iodine|10% povidone-iodine vaginal cleansing solution as a surgical preparation.
214989559|NCT01898416|DRUG|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|"60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given."
214989560|NCT05812404|DRUG|DWP14012|Potassium-competitive acid blocker
214989561|NCT05812404|DRUG|DWC202201|Atorvastatin Calcium Trihydrate
214989562|NCT01563939|DRUG|Remifentanil|"Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg."
214989563|NCT02385318|DRUG|Ingenol Mebutate (Perrigo)|
214989564|NCT02385318|DRUG|Ingenol Mebutate (Reference)|
214989565|NCT02385318|DRUG|Placebo gel|
214989566|NCT01409473|RADIATION|Prostate SBRT with concurrent boost to intraprostatic lesion(s)|40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
214989567|NCT03773588|DEVICE|Closed-Loop propofol Target controlled infusion by Entropy and SPI|Closed loop target infusion of propofol using BD TCI pumps guided by entropy and Surgical pleth index
214989568|NCT03773588|DEVICE|Open-loop propofol target controlled infusion|Propofol target controlled infusion using Schnider algorithm to determine effect site concentration
214989569|NCT03642314|DIAGNOSTIC_TEST|HIV self test kit|HIVST receptor will be invited to priority access to PrEP sites
214989570|NCT04132713|DRUG|Capecitabine 150Mg Oral Tablet|Advanced breast cancer patients with first-line medication
214989571|NCT03526705|DEVICE|NB-UVB|Phototherapy
214989572|NCT05627596|BEHAVIORAL|Ask-Advise-Refer|All patients will be asked if they smoke, advised to quit, and referred to the state quitline
214989573|NCT05627596|DRUG|Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release|14 mg transdermal nicotine patch
214989574|NCT05627596|DRUG|Nicotine lozenge|4mg nicotine lozenge
214989575|NCT02425553|OTHER|Diet|High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)
214989576|NCT02425553|OTHER|Diet|High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)
214989577|NCT02425553|OTHER|Diet|Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)
214989578|NCT02425553|OTHER|Diet|High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
214989579|NCT02429466|DRUG|Guadecitabine (SGI-110)|SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
214989580|NCT00248560|DRUG|docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
214989581|NCT00248560|DRUG|Gemcitabine|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
214989582|NCT01462604|OTHER|non-drug intervention educational programme|educational programme
214989583|NCT03782597|BEHAVIORAL|Semi-structured interviews or focus groups to explore families representations and strategies about their teenagers involved in radicalisation process|A sample of representative French families (parents, siblings, and persons identified as attachment figures) of adolescents or young adults (12-25 years old) involved in the radicalisation process will be asked to participate in semi-structured interviews or focus groups to explore their representations and strategies about radicalisation. It will be supplemented by genogram draw sociodemographic data.
214989584|NCT03336970|OTHER|EDTA|
214989585|NCT03336970|OTHER|NaOCl|
214989586|NCT03336970|OTHER|CHX|
214989587|NCT03336970|OTHER|Calcium hydroxide|
214989588|NCT06302036|OTHER|EFT|EFT
214989589|NCT00200382|DRUG|PS-341 (Velcade-drug)|
215090834|NCT03584243|PROCEDURE|A crosslinking with oxygen treatment|"A supplemental oxygen system during the cross linking will be used to apply filtered, humidified oxygen across the surface of the eye through a mask. The oxygen flow will be turned on immediately prior to initiation of irradiation, and will continue through the irradiation period. The supplemental oxygen flow will be shut off following completion of the programmed irradiation time.~All subjects will be evaluated at screening, day 3, and 1, 3, 6, 12 and 24 months after treatment. At the same time all the potential adverse effects will be relieved."
215090835|NCT01660620|DRUG|Betaxolol|
215090836|NCT01660620|DRUG|topical betaxolol|given topically
214989590|NCT04356651|PROCEDURE|Fu's subcutaneous needling(FSN)|In this study, physician will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin from anterior superior iliac spine(ASIS) to 1/3 superior border of patella. Then the physician will push forward the needle parallel to the skin surface. The physician will sway the needle 45 times in 30 seconds. After swaying the needle, the physician will instruct the subject to do sole dorsiflexion for 10 seconds resisting the physician's opposite force, then the subject take a rest for 10 seconds. The above actions are 3 repetitions. Then the subject do knee flexion and extension for 10 seconds, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the physician will take out the needle to finish the treatment.
214989591|NCT04356651|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes. TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction.
214989592|NCT00527059|DRUG|Levosimendan in addition to standard therapy|intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy
214989593|NCT00527059|DRUG|spironolactone, beta-blockers,ecc|
214989594|NCT03778632|BEHAVIORAL|individualized desensitization exercises|implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
214989595|NCT02471183|DRUG|Selexipag|Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
214989596|NCT00532467|DRUG|SRX251|
214989597|NCT04085016|DEVICE|Keratograph 5M, Oculus, Wetzlar, Germany|
215090837|NCT04180566|OTHER|Ultrasound Examination|Includes a regular growth ultrasound examination.
214376917|NCT05967780|OTHER|Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises|"The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.~Therapeutic exercises will be delivered to the participant by treating physiotherapist in physical, verbal and written formats as individualized sessions on the ward 4 weeks before the surgery and keep him doing exercises under supervision while staying in the ward before surgery. A log will be provided to measure performance to ensure program compliance. After discharge from the hospital, the patient will continue exercises at home as performed and guided physically by the therapist and also in the exercises manual and flyer given to the patient. Patients will be instructed to follow therapeutic exercise for 4 weeks pre-operatively and 4 weeks postoperatively after discharge from the hospital."
214376918|NCT05967780|OTHER|Group C: Patients without FHP receiving standard cardiac rehabilitation|The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
214376919|NCT01552122|DRUG|Odanacatib|Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
214376920|NCT01552122|DRUG|Alendronate|Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
214376921|NCT01552122|OTHER|Placebo (odanacatib)|One compressed tablet administered orally, once-a-week, for 24 months.
214497056|NCT04043494|DRUG|6-Mercaptopurine|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
214497057|NCT04043494|DRUG|Methotrexate|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
214687103|NCT02869854|BEHAVIORAL|Mindfulness|Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
214989598|NCT03399344|OTHER|MRI|In addition to the standard diagnostic work-up patients will receive an additional MRI scan 0-21 days prior to their scheduled surgery.
214989599|NCT02082951|BEHAVIORAL|Empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
214989600|NCT02082951|BEHAVIORAL|Empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
215090838|NCT04180566|OTHER|Antenatal Testing (biophysical profile)|Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
214376922|NCT01552122|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
214376923|NCT01552122|DIETARY_SUPPLEMENT|Calcium carbonate|Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
214376924|NCT01552122|OTHER|Placebo (alendronate)|One compressed tablet administered orally, once-a-week, for 24 months.
214376925|NCT02836158|DRUG|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
214497058|NCT04043494|DRUG|PEG asparaginase|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Protocol Ib\* (Randomization R2)
214989601|NCT02585206|BEHAVIORAL|Personalization|"Phase I Factor~Personalized text messages using the participant's username and gender (Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!). Both data points will be pulled from BecomeAnEX registration data."
214989602|NCT02585206|BEHAVIORAL|Integration|"Phase I Factor~Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:~Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community~Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online."
214989603|NCT02585206|BEHAVIORAL|Dynamic Tailoring|Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
214989604|NCT02585206|BEHAVIORAL|Message Intensity|"Phase I Factor~Varying levels of text message intensity over a 12-week period."
214989605|NCT02585206|BEHAVIORAL|Optimal-Adherence Text|Optimal-adherence text message intervention developed in Phase I
214989606|NCT02181595|OTHER|Group reading and discussion|
214989607|NCT03085303|DEVICE|Full Body Blue Light Device|Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
214989608|NCT02721069|DRUG|NRL-1|
214989609|NCT04440384|OTHER|Functional evaluation|"Patients will complete these forms and tests :~Box and block test, Purdue peg board, Percival, Nine hole peg, T-GAP, EGF, MAHVIE, DASH, RAND36, CHQ-PF28, CHQ-CF45, CGI-S"
214989610|NCT03786393|DIAGNOSTIC_TEST|ACR 1990 fibromyalgia critters|ACR 1990 fibromyalgia critters
214989611|NCT03934775|DEVICE|Finapres Nova|Non-invasive mesurement of hemodynamic parameters and heart rate variability
214989612|NCT03453736|OTHER|No intervention|This is a qualitative study involving staff interviews and observations. No intervention is being applied.
214989613|NCT00827567|DRUG|RAD 001|RAD 001-10 mg by mouth once everyday
214989614|NCT01946867|DEVICE|NBTXR3 activated by IMRT|
214989615|NCT00989300|DRUG|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
214989616|NCT00989300|DRUG|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
214989617|NCT00989300|OTHER|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
214989618|NCT04507113|OTHER|DTI sequence acquisition|DTI sequence acquisition
214989619|NCT02007772|DEVICE|nHF|nasal high-flow is used over a period of 6 weeks (outpatient)
214989620|NCT02007772|DEVICE|BiPAP|BiPAP is used over a period of 6 weeks (outpatient)
214989621|NCT03797729|DRUG|Tirofiban|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
214989622|NCT03797729|DRUG|Normal saline|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
214989623|NCT02326883|BEHAVIORAL|Care Management|The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
214989624|NCT02326883|BEHAVIORAL|Skills Training|The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
215090839|NCT03527524|OTHER|exercise with ball|exercise with ball
215090840|NCT03527524|OTHER|exercise without ball|exercise without ball
215090841|NCT02738424|OTHER|Calculate the ADC scores|The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
215090842|NCT06960629|DRUG|Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution|Patients with pseudophakic bullous keratopthy and glaucoma will receive topical netarsudil/latanoprost 1x daily for 3 months.
215090843|NCT06960629|DRUG|Placebo|Patients with pseudophakic bullous keratopathy and glaucoma will receive topical placebo 8artificial tear substitute) 1x daily for 3 months.
215090844|NCT02101489|OTHER|Foley Catheter|20 with intraoperative Foley catheter measurement of the urethral length and 20 without
215090845|NCT02961946|DRUG|Nitroglycerin|Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
214989625|NCT02326883|BEHAVIORAL|Usual Care|Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
214376926|NCT03615781|PROCEDURE|Two week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
214376927|NCT03615781|PROCEDURE|Four week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
214376928|NCT03615781|DRUG|Two week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
214376929|NCT03615781|DRUG|Four week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
214376930|NCT01364597|DRUG|Brivaracetam (BRV)|The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight \>40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights \>50kg) is reached.
214376931|NCT01498822|DRUG|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
214989626|NCT03921983|OTHER|Oxygen supplementation|short term O2 supplementation during 1 hour
214376932|NCT01498822|DRUG|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
214376933|NCT03262558|OTHER|No intervention|Patients will undergo standard clinical routine practice in this indication
214376934|NCT02889601|OTHER|Psycho-behavioural assessment|DAPHNE Scale
214376935|NCT04203537|DRUG|CA-008|Local administration during surgery
214376936|NCT04203537|DRUG|Placebo|Local administration during surgery
214376937|NCT05497427|DEVICE|BrainCheck Assessment|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
214989627|NCT02460003|BEHAVIORAL|Physiotherapy|A program of physiotherapy including manual therapy, exercise, pain education.
214376938|NCT04078360|BEHAVIORAL|AMBIT (Alcohol use disorders- mobile based Brief Intervention treatment) intervention|"The intervention will consist of participants receiving messages and/IVR calls not more than twice or thrice a week on their mobile phone for a duration of 8 weeks. Messages/IVR calls will be sent through VIAMO's technology platform. Each week messages will be focussed on specific content areas derived from the formative research of the study. Some of the components of the intervention include:~1. Self awareness messages~2. Self reflection messages~3. Motivational messages~4. Messages on safe drinking, alcohol reduction, drinking management, risk management, craving management and drinking alternatives.~5. Health education messages~6. Personalized feedback and information~7. Help-seeking resources~8. Goal setting messages"
214376939|NCT04078360|BEHAVIORAL|Face to face Brief Intervention|The intervention will consist of the participants receiving the BI based on the WHO Mental Health Gap Action Programme (mhGAP) intervention from a trained researcher. The BI will be conducted over a single session (5-10 mins).
214497059|NCT04043494|DRUG|Prednisone|Part of standard chemotherapy
214497060|NCT04043494|DRUG|Prednisolone|No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
214497061|NCT04043494|DRUG|Thioguanine|Part of standard chemotherapy
214497062|NCT04043494|DRUG|Vincristine|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
214497063|NCT04043494|DRUG|Vindesine|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
214497064|NCT06770504|BIOLOGICAL|YTS109|In this study, subjects will receive YTS109 Cell Injection(0.5-1E6 STAR+T cell/kg) once.
214687104|NCT02869854|BEHAVIORAL|PAP|Physical Activity on Prescription, after 3 months a new prescription
214687105|NCT02823665|DRUG|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
214687106|NCT02823665|DRUG|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
214989628|NCT02460003|OTHER|Home exercise program|Home exercise program
214989629|NCT02339207|DRUG|AL-335 matching placebo|
214989630|NCT02339207|DRUG|AL-335|
214989631|NCT05173311|BEHAVIORAL|Intervention arm|The intervention arm groups were instructed to use the Mole's Veggie Adventures mobile application for 3-4 weeks.
214989632|NCT04024137|DRUG|ZSP1273 200 mg|1 X 200-mg tablet taken orally
214989633|NCT04024137|DRUG|Placebo|2 tablets taken orally
214989634|NCT04024137|DRUG|ZSP1273-400 mg|2 X 200-mg tablet taken orally
214989635|NCT04024137|DRUG|Placebo|1 tablet taken orally
214989636|NCT04024137|DRUG|ZSP1273-600 mg|3 X 200-mg tablet taken orally
214989637|NCT04024137|DRUG|Placebo|3 tablets taken orally
214989638|NCT04024137|DRUG|Placebo|Subjects will receive matching placebo of ZSP1273
214989639|NCT05689437|OTHER|Application of ILD prediction machine learning model to planning imaging|The ILD prediction machine learning model will be applied to the treatment planning imaging of lung cancer patients receiving radiation therapy (RT). The model will score the risk as high risk or low risk for having underlying ILD.
215090846|NCT01659099|DRUG|GA101|in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
215090847|NCT01659099|DRUG|Rituximab|in R-ACBVP or in R-CHOP 375 mg/m² on D1
214376940|NCT04078360|BEHAVIORAL|BI leaflet intervention|The intervention will consist of an educational BI leaflet consisting of health information on alcohol consumption, and tips to manage and reduce drinking.
214989640|NCT05689437|OTHER|Routine, automatic presentation of ILD risk level for evaluation by the clinician.|Participating clinicians will be provided with an ILD risk estimate for all lung cancer patients receiving RT who are deemed potentially high-risk based on the model. In these cases, the clinician will receive an email identifying the patient medical record number (MRN) and 'potential high-risk for ILD' flag. Clinicians will then be able to decide whether, based on the information, they want to reassess the patient for ILD prior to starting treatment. Clinicians will also be presented with a short survey each time they are sent an email for a potential high-risk for ILD case so the study team can better understand how that information was used, if at all.
214989641|NCT05689437|OTHER|Application of SGR machine learning model to diagnostic and planning imaging|The SGR machine learning model will be applied to the imaging of lung cancer patients with node negative lung cancer receiving stereotactic RT. The automatic calculation will compare target lesions on the patient's diagnostic images with those same lesions on treatment planning images.
214989642|NCT05689437|OTHER|Routine estimation of tumor specific growth rate (SGR) for lesions being considered for radiation therapy presented to clinician.|Participating clinicians will be provided with an SGR calculation for each lung cancer patient with node negative lung cancer receiving stereotactic RT. This SGR calculation will be presented to clinicians, who will then be able to decide, based on the information, how they want to address and track a patient's overall survival and failure free survival. Clinicians will also be presented with a short survey each time they are provided with a patient's SGR calculation so the study team can better understand how that information was used, if at all.
214989643|NCT05689437|OTHER|Application of CBCT machine learning model to on-treatment imaging|The CBCT machine learning model will be applied to on-treatment imaging as part of routine care for patients with node positive lung cancer receiving standard RT. An indicator of lung density changes will be calculated automatically by comparing cone beam CTs (CBCTs) completed prior to each treatment.
214989644|NCT05689437|OTHER|Routine monitoring of lung density changes during the course of treatment presented to clinician.|Participating clinicians will be provided with a daily indicator of lung density changes for each patient with node positive lung cancer receiving standard RT. This measurement will be presented to the clinical team, who will then be able to decide, based on the information, how they want to address and track relevant outcomes such as pneumonitis. Additionally, this information may provide the clinical team with feedback about the lung reaction occurring as a result of treatment. Density changes will be documented and monitored for future validation studies, which are outside of the scope of this application.
215090848|NCT01659099|DRUG|Doxorubicin|in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
215090849|NCT01659099|DRUG|Cyclophosphamide|in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
215090850|NCT01659099|DRUG|Prednisone|in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
215090851|NCT01659099|DRUG|Bleomycin|in ACBVP 10 mg from D1 to D5
215090852|NCT01659099|DRUG|Vindesin|in ACBVP 2 mg/m² from D1 to D5
215090853|NCT01659099|DRUG|Vincristine|in CHOP 1,4 mg/m² on D1
215090854|NCT05218525|OTHER|Algorithm|"Participants in the intervention group will receive the general offer of the telehealth intervention including the telehealth system with the implemented COPD prediction algorithm. The participants are asked to measure their vital signs and respond to COPD related questions as usual. As usual refers to fixed days in the week, either Monday or Thursday, where the participants must measure their vital signs. In addition, the participants must weekly measure two oxygen saturation measurements drawn from the fingertip pulse oximeter."
215090855|NCT00086099|DRUG|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
214497065|NCT06770868|DEVICE|Patient specific reconstruction plate for patients suffering from mandibular segmental defects|Patients with mandibular segmental defect including coronoidectomy managed with patient specific reconstruction plate with custom made temporalis tendon enthesis
215090856|NCT00086099|DRUG|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
215090857|NCT00114088|PROCEDURE|hysterectomy|
215090858|NCT00114088|PROCEDURE|endometrial ablation|
215090859|NCT04555837|DRUG|Alisertib|Given PO
214376941|NCT05507658|DRUG|Tislelizumab combined with Oxaliplatin and Capecitabine|"Drugs:~1. Tistelizumab 200mg, iv.gtt, D1, Q3W;~2. Chemotherapy (XELOX) : oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W.~Neoadjuvant therapy:~1. Tislelizumab combined with XELOX, Q3W, for 2\~3 cycles;~2. D2 radical gastrectomy after neoadjuvant therapy.~Adjuvant therapy:~1. From 4 to 8 weeks after surgery, the treatment dose was the same as above;~2. Patients who achieved MPR and non-MPR on pathological evaluation were treated with tirelizumab +XELOX 3\~8 cycles;~3. Tumor evaluation performed every 3 cycles;~4. The maximum duration of adjuvant therapy was not more than 8 cycles."
214497066|NCT06774716|BEHAVIORAL|Internet-based cognitive behavioural treatment and relapse prevention|A self help program consisting of 12 modules and access to therapist guidance through messages. Including three video session.
215090860|NCT04555837|BIOLOGICAL|Pembrolizumab|Given IV
215090861|NCT06477796|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.
215090862|NCT06477796|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
215090863|NCT05632783|DRUG|Chondroitin Sulfate Sodium|Chondroitin sulfate 800 mg tablets
215090864|NCT05632783|OTHER|Placebo|Placebo tablets
215090865|NCT05773976|DEVICE|Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil|"At baseline visit (V0), as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~* Afomill Refreshing Soothing~* Afomill Anti-redness Eye Drops~* Iridil"
214497067|NCT06774716|BEHAVIORAL|Face-to-face cognitive behavioural treatment or short-term psycodynamic therapy with relapse prevention|Face-to-face therapy with a licenced psychologist or licenced psychotherapist, including 10-15 sessions.
214497068|NCT06775275|DRUG|Adebellizumab|adebrelimab
214497069|NCT06775275|DRUG|Bevacizumab|bevacizumab
214376942|NCT04164654|BEHAVIORAL|Loneliness Intervention|28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)
214376943|NCT05351619|PROCEDURE|oral care bundle implementation|oral care bundle encompasses oral assessment, tooth brushing, oral / lip moisturization, and suctioning oropharyngeal secretions above the cuff.
214376944|NCT02178410|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
214497070|NCT06775275|DRUG|Platinum-based chemotherapy|paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.
214497071|NCT06777381|PROCEDURE|single visit root canal treatment using ProTaper Universal rotary system|single visit endodontic treatment will be performed using ProTaper Universal rotary system for root canal preparation.
214989645|NCT06557681|DEVICE|Virtual Reality-Treadmill Training Group (VTT)|The Virtual Reality-Treadmill Training Group (VTT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy followed by an additional 30 minutes of virtual reality-treadmill training. The sequence of these therapies can vary with each session. The virtual reality-treadmill training, conducted under the supervision of a therapist, will focus on five key components: precision stepping, obstacle negotiation, direction of progression, precision acceleration, and walking velocity. Evaluations of walking and balance abilities will be conducted before and after the intervention.
214989646|NCT06557681|OTHER|Conventional Therapy Group (CT)|The Conventional Therapy Group (CT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy, aimed at improving walking and balance functions. The therapy will be administered by a therapist and may include exercises focused on muscle strength increase, gait training for step length and walking speed improvement, and balance training. Evaluations of walking and balance abilities will be conducted before and after the intervention.
214989647|NCT00471965|DRUG|Oxaliplatin + 5-Fluorouracil/Leucovorin|"Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
214989648|NCT00471965|DRUG|Doxorubicin|Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
214989649|NCT06216496|OTHER|dynamic test for amino acid metabolism|"Subjects are fasting, and the dynamic test is performed as follows:~Placement of 1 peripheral venous line (for infusions).~* H0-H1.5: infusion of a 10% glucose solution at increasing flow rate (3 steps of 30 min each: 0.06g/kg/h then 0.12g/kg/h then 0.25g/kg/h of glucose)~* H1,5: initial blood sampling (amino acid assay)~* H1.5-H4.5: infusion of amino acid solution (Aminoven 5%, Fresenius Kabi, Sèvres, France) at constant speed (flow rate 10.5 mg/kg/h of nitrogen or 1.30 ml/kg/H) in Y with glucose infusion (0.25g/kg/h of glucose)~* H4.5: Final blood sampling (amino acid assay) Each amino acid is plotted as a function of its perfusion rate on the abscissa and its variation in plasma concentration on the ordinate."
214989650|NCT03698461|DRUG|Atezolizumab|"* 1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~* 840mg IV D1 of C1-12 (Cycle: every 2 weeks)"
214989651|NCT03698461|DRUG|Bevacizumab|5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab
214989652|NCT03698461|DRUG|Oxaliplatin|85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
214989653|NCT03698461|DRUG|Levoleucovorin|200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
214989654|NCT03698461|DRUG|5-FU|"* 5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~* 5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)"
214376945|NCT02178410|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
214376946|NCT02178410|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
214376947|NCT02178410|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
214376948|NCT02569359|DIETARY_SUPPLEMENT|shea nut oil extract|
214497072|NCT06777381|PROCEDURE|single visit root canal treatment using M-Pro rotary system|single visit endodontic treatment will be performed using MPro rotary systems for root canal preparation.
214989655|NCT04335864|PROCEDURE|Laparoscopic salpingectomy|39 patients with hydrosalpinx will have laparoscopic salpingectomy
214989656|NCT04335864|PROCEDURE|Hystroscopic proximal tubal occlusion|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
214989657|NCT03337126|DRUG|Metronidazole Tablet|Comparator Drug
214989658|NCT02552602|DIETARY_SUPPLEMENT|Multivitamin A|Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)
214989659|NCT02552602|DIETARY_SUPPLEMENT|Multivitamin B|Multivitamin containing 22 micronutrients at RDA
214989660|NCT02552602|DIETARY_SUPPLEMENT|Multivitamin C|Multivitamin containing 22 micronutrients at three times the RDA
214989661|NCT06412003|BEHAVIORAL|Home-based balance training|This is a family member supported home-based balance training program designed for community-dwelling people with MS to improve balance and walking abilities as well as cognitive functions. The intervention program aims to have participants with MS reach high-intensity balance tasks during the program. A bi-weekly two-on-one, semi-structured, video-chat session with participants and their exercise supporter and research team will be conducted using videoconferencing techniques (e.g., Zoom, Skype, or Facetime).
214989662|NCT03012776|DEVICE|Total Posterior Spine System (TOPS)|Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis
214376949|NCT02569359|OTHER|Placebo|
214376950|NCT03579290|BEHAVIORAL|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~* Understanding and changing patterns of drug use,~* Coping with craving,~* Substance refusal skills,~* Seemingly irrelevant decisions,~* Planning for emergencies, and~* Problem-solving skills.~* Staying Safe"
214376951|NCT06304662|OTHER|Yoga intervention|Over 12 weeks, students will attend 50-minute yoga sessions twice a week. Sessions start with 10 minutes of mindful breathing and gentle warm-up movements, followed by 30 minutes of tailored yoga postures for relaxation and stretching. Students progress from basic to advanced postures, with adaptations for individual needs. Each session ends with a guided meditation for inner calm. A 10-minute cool-down encourages deep relaxation. Emphasis is on stress reduction, flexibility, and mindfulness, tailored to university life challenges. Continuous assessment ensures sessions meet students' evolving needs and optimize yoga's benefits in the university setting.
214376952|NCT01566630|DRUG|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
214989663|NCT03012776|PROCEDURE|Transforaminal Lumbar Interbody Fusion (TLIF)|Fusion with placement of interbody cage and posterolateral instrumentation
214376953|NCT01566630|DRUG|RLX030|RLX030 1 mg/mL vials
214376954|NCT06133114|DRUG|Clonazepam|0.5 mg twice a day (1 mg a day)
214376955|NCT06133114|DRUG|Olanzapine|2.5 mg once a day of Olanzapine
214989664|NCT06425016|PROCEDURE|Laparoscopic Sleeve Gastrectomy (LSG)|Bariatric Surgery
214989665|NCT06425016|PROCEDURE|Robotic Sleeve Gastrectomy (RSG)|Bariatric Surgery
214989666|NCT00315367|DRUG|Donepezil HCI (drug)|
214989667|NCT00005663|DRUG|Valacyclovir hydrochloride|
214376956|NCT06133114|DRUG|Buprenorphine|2 mg once a day of Buprenorphine
214376957|NCT04173767|DEVICE|high flow nasal cannula ventilation|High-flow nasal cannula (HFNC) ventilation therapy: supply heated \& humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.
214989668|NCT04877002|DIAGNOSTIC_TEST|Sona Saliva C-19 Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
215090866|NCT03542279|PROCEDURE|Plasma exchange (PE)|PE is performed every other day using a multi-filtrate apheresis device (Fresenius, Bad Homburg, Germany), and 5 times in total for each course. The plasma removed during PE is replaced with an equal volume of substitution (half 5% albumin with normal saline and half plasma). The plasma volume to be replaced was estimated according to the following formula: plasma volume (L) = 7.5%×weight (kg)×(1-hematocrit)×1000ml. Heparin was added to the exchange circuit to prevent blood clotting. The exchange rate was monitored, recorded, and balanced to prevent cardiovascular instability. Blood pressure and other vital signs were closely monitored every 15 minutes throughout the exchange.
214376958|NCT01351532|BEHAVIORAL|smoking cessation program|cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,
214376959|NCT01351532|BEHAVIORAL|Lifestyle counseling|ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion
214376960|NCT01908322|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
214989669|NCT02736617|DRUG|Ibrutinib|Given PO
214989670|NCT02736617|BIOLOGICAL|Obinutuzumab|Given IV
214376961|NCT03131960|DEVICE|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation movements.
214376962|NCT03131960|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
214376963|NCT05486442|BEHAVIORAL|ACT for weight-related experiential avoidance|Participants in the experimental group received weight concern-related ACT training in a group setting. Each session focused on different dimensions of ACT and included relevant exercises and homeworks. Dimensions studied included creative hopelessness, control strategies, mindfulness exercises, values and barries to values and commitment to action.
214989671|NCT01319968|DRUG|Estriol 0.1% vaginal cream|Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
214376964|NCT02768415|DRUG|Apatinib|
214376965|NCT02768415|DRUG|Oral Vinorelbine|
214376966|NCT01361373|DRUG|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
214376967|NCT01361373|DRUG|placebo|placebo for 2 weeks
214989672|NCT04657913|OTHER|cold water spray application|It will be sprayed into the mouth of patients every hour.
214989673|NCT04657913|OTHER|cold saline spray application|It will be sprayed into the mouth of patients every hour.
214989674|NCT01718691|DRUG|SyB L-0501|A dose of 90 mg/m\^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
214989675|NCT01718691|DRUG|rituximab|A dose of 375 mg/m\^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
214376968|NCT03579914|DRUG|intravenous Placebo|Patients receive intravenous Placebo (saline) injection
214376969|NCT03579914|DRUG|Metoprolol Injectable Product|Patients receive intravenous Metoprolol injection
214376970|NCT03579914|DEVICE|Romote Ischemic Conditioning (RIC)|Patients receive RIC treatment
214376971|NCT03579914|COMBINATION_PRODUCT|Metoprolol & RIC|Patients receive Metoprolol \& RIC treatment
214376972|NCT05649345|DRUG|TR64|TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
214376973|NCT04806646|DRUG|Sonidegib|TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.
214989676|NCT02502500|DRUG|Celecoxib|
214989677|NCT02502500|DRUG|AKB-6548|
214989678|NCT05348434|PROCEDURE|3D printed polyether ether ketone facial implants in repairing maxillofacial deformities|All patients underwent Computed Tomography (CT) scans under the condition of providing a large number of slices (more than 200 slices) per axis, and the thickness of each slice is less than 1 mm with 64-bit resolution, Then the design of the required facial implant was carried out in coordination between the designer and the surgical team. The final form of the facial implant was printed from PolyEther Ether Ketone (PEEK), and then surgical work was performed for patients under general anaesthetic according to the appropriate surgical entrance. The implants were fixed in place using titanium screws
214376974|NCT06291311|OTHER|Cold physical Plasma|The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.
214376975|NCT06291311|OTHER|Control group|A potential natural healing of the HPV infection will be anticipated
214376976|NCT06459895|DIAGNOSTIC_TEST|Long non-coding MALAT1 gene expression assay:|RNA extraction (isolation from whole blood) II-Synthesis of CDNA from RNA by reverse transcription III-Gene expression assay by RT-PCR reaction
214376977|NCT04754672|BEHAVIORAL|Continuous aerobic and resistance exercise intervention|Continuous aerobic and resistance exercises intervention
214376978|NCT04754672|BEHAVIORAL|Continuous aerobic and aerobic interval exercise intervention|Continuous aerobic and aerobic interval exercise intervention
214989679|NCT02494011|OTHER|traditional exercise|mobilization stretching exercise
214989680|NCT02494011|OTHER|Russian current stimulation|stimulation to wrist flexors for 15 minutes
214376979|NCT01609816|DRUG|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
214376980|NCT03139396|PROCEDURE|tub shaped inlay bridge design|inlay retained bridge with tub shaped retainer on both abutments
214376981|NCT02653573|BEHAVIORAL|Coaching|Self-management education
214376982|NCT01625923|DRUG|Olanzapine|Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD \< 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
214376983|NCT00347997|DEVICE|217z Laser|LASIK correction of myopia and myopic astigmatism
215090867|NCT03542279|DRUG|intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)|IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
215090868|NCT06250738|BEHAVIORAL|Mindfulness-based Stress reduction program: Virtual|Through mindfulness meditation and a series of carefully crafted exercises, MBSR equips individuals with powerful tools to manage stress, reduce anxiety, and enhance their overall well-being. Participants will complete 4 weekly virtual sessions covering topics like introduction to stress and its consequences, awareness of sensations, and thoughts, mindful eating, and mindful walking.
215090869|NCT06250738|BEHAVIORAL|Home exercises|Following each virtual session, participants will be given home exercises like practicing awareness of breathing, awareness of thoughts, and awareness of eating.
214376984|NCT02929550|OTHER|Well-controlled|Both groups got treatment but well-controlled reached target of LDL-C\<1.8 mmol/l
214989681|NCT02494011|OTHER|closed kinetic chain exercise|wall press exercise plyometric exercise
214989682|NCT03318562|DRUG|eFT508|200 mg eFT508 dosed BID for 3 week cycles
215090870|NCT05838573|DRUG|Metformin treatment|Participants assigned to the metformin group will receive 500mg metformin three times daily (tid) for 24 weeks. The initial dose will be 500 mg orally in the evening for the first two days, followed by an increase to 500mg twice a day for the subsequent two days. By day 5, the dosage will be further increased to 500mg tid. The highest tolerated dosage will be maintained for participants who could not tolerate the maximum dosage.
215090871|NCT05838573|DRUG|Placebo treatment|Parallel-dose adjustments will be made for the placebo group to maintain consistency in dosing between the two groups.
215090872|NCT05838573|OTHER|Baseline assessments|Schizophrenic participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations.
214376985|NCT02390427|DRUG|Taselisib|
214376986|NCT02390427|DRUG|Trastuzumab emtansine|
214376987|NCT02390427|DRUG|Pertuzumab|
214497073|NCT06771089|OTHER|Manual therapy and bandaging|The MTG group received an intervention based on anterior-posterior mobilizations of the talus and fibula and taping, both based on Mulligan® techniques Individually, participants received Grade IV passive mobilizations lasting approximately 30 seconds, totalling 12 active mobilizations performed by the participant. Furthermore, a tape was applied, placed on the anterior part of the talus with a posterior and caudal direction, with its ends anchored near the heel. Due to its placement, this taping maintained a sustained posterior force on the talus throughout the training session. This intervention was conducted on the affected limb(s) with DF deficits.
214989683|NCT03883373|PROCEDURE|alveolar bone graft with cancellous bone and a cortical block|alveolar bone graft with cancellous bone only
214989684|NCT03883373|PROCEDURE|alveolar bone graft with cancellous bone only|alveolar bone graft with cancellous bone only
214989685|NCT02952417|OTHER|Excess mortality|Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
214989686|NCT02911116|DRUG|Ustekinumab|Subcutaneous Injection
215090873|NCT05838573|OTHER|Volunteer assessments|Apart from psychiatry scales(Hamilton Depression Scale, Young Mania Rating Scale and Self-reporting Inventory-90), other assessments for the healthy subjects are the same as the baseline for sczhiophrenic participants.
215090874|NCT03493607|DRUG|AMO-01|Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
214376988|NCT02390427|DRUG|Trastuzumab|
214376989|NCT02390427|DRUG|Paclitaxel|
214376990|NCT00594191|DRUG|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
214376991|NCT00594191|DRUG|Placebo|Placebo with the same characteristics of the drug and at the same dose
214376992|NCT00159705|DRUG|pregabalin|
214376993|NCT02575898|OTHER|First Session|Creative Practice and Positive Re-enforcement
214376994|NCT02575898|OTHER|Second Session|Disease Related
214376995|NCT02575898|BEHAVIORAL|Third through Sixth Sessions|Life Review and Legacy
214376996|NCT01457105|DEVICE|Endoscopic retrograde cholangiography (ERC) (ComVi biliary stent)|Metal stents placement in the main biliary duct during ERC
214376997|NCT00021034|DRUG|chemotherapy|
214376998|NCT00021034|DRUG|taurolidine|
214989687|NCT02911116|DRUG|Ustekinumab|Intravenous Infusion
214989688|NCT03974958|GENETIC|Tissue-library|circulating biomarkers (miRNA panel) analysis of blood samples
214376999|NCT03243643|DRUG|HS-10241|HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
214377000|NCT03243643|DRUG|Apatinib|Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
214497074|NCT06771089|OTHER|Therapeutic exercise|"Therapeutic exercise protocol lasting approximately 5-10 minutes, performed before regular training sessions. It included 2 exercises, each performed in 3 sets of 10 repetitions with 1-minute rest intervals.~Exercise 1: Weighted DF in a kneeling position. From this position, ankle DF is performed with the front leg, on which the weight of the arms and the torso is placed to force the movement.~Exercise 2: Ankle lunge with band resistance at the ankle. The player performs ankle DF with a medium-resistance green Theraband® providing a posterior force vector on the talus.~This intervention was applied to the affected limb(s) with ankle DF limitations and was supervised by a physiotherapist. It was performed before training session at each club's facilities."
214497075|NCT06771089|OTHER|No specific treatment|The Control group received no specific treatment; they only participated in the current training sessions.
214497076|NCT06775457|OTHER|sample collection|Blood samples and fecal samples will be taken from patients during evaluation visits. Blood samples will be analyzed for the study of HERVs. While fecal samples will be analyzed for the characterization of gut microbiota.
214497077|NCT02078648|DRUG|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated)."
214497078|NCT02078648|DRUG|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
214989689|NCT04796415|BEHAVIORAL|the DEMA-Pro intervention|Trained DEMA-Pro coaches will deliver six weekly, 1-hour telephone sessions. The first session is an orientation to the DEMA-Pro intervention and development of the initial Weekly Activity Plan based on the patient's self-identified meaningful activity. Over the next five weekly sessions, the coach uses problem-solving strategies to facilitate dyad collaboration to mutually identify meaningful activities and make a realist plan to achieve the patient-identified meaning activity goals. In each session, the patient and caregiver also select, review, and discuss one of six topics in the Self-Management Toolkit (e.g., planning meaningful activities; learning strategies for living with subjective cognitive impairment; finding resources, planning for the future).
214989690|NCT03045172|BIOLOGICAL|Platelet Rich Plasma|PRP
214989691|NCT03045172|DRUG|Placebo|Saline
214989692|NCT02469857|DRUG|AB103 0.5 mg/kg|
214989693|NCT02469857|OTHER|NaCl 0.9%|
214989694|NCT02368392|OTHER|Exposure for cardiac arrests|There is no particular intervention. This study merely observes the occurrence of cardiac arrests
214989695|NCT03555552|DEVICE|Anticoagulation and Thrombosis Point of Care Test(AT-POCT)|Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.
214377001|NCT06344234|DIAGNOSTIC_TEST|End-inspiratory Maneuvers|Airway pressure, flow, and esophageal pressure will be continuously recorded in all patients using a dedicated pneumotachograph and pressure transducer: all signals will be acquired and stored. Once a stable ventilation pattern is observed NIV will be administered by setting ventilator in invasive-pressure support ventilation. PEEP and PS-level will by kept constant while expiratory trigger will be adjusted to optimize patient-ventilatory synchrony. Immediately after, sudden end-inspiratory and end-expiratory occlusion maneuvers will be performed to measure plateau pressure and end-expiratory airway occlusion pressure (ΔPocc), respectively. Invasive PSV will be used only to perform the occlusion maneuvers, subsequently, PSV will be delivered in non-invasive PSV mode. Patient's blood-gas parameters and vital signs will be collected, including discomfort assessment. During the occlusion maneuvers, diaphragm ultrasound will be performed, and images will be recorded.
214497079|NCT02078648|DRUG|SL-701 + GM-CSF|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~150 μg GM-CSF should be administered as a SC injection immediately after SL-701 emulsion administration and within 1 cm from the center of the SL-701 emulsion injection site."
214989696|NCT03555552|DEVICE|Duke Central Automated Laboratory (DCAL)|DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.
214989697|NCT02590783|PROCEDURE|experimental intervention surgery|Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).
215090875|NCT04163367|BEHAVIORAL|Safer Kids|A behaviorally based parent training program with the purpose to reduce or prevent child abuse.
215090876|NCT04163367|OTHER|Intervention as usual (IAU)|Everything that's included in the social service units' regular handling of cases; such as the formal investigation and family treatment. The units cannot offer Safer Kids as a part of IAU.
214497080|NCT02078648|DRUG|Imiquimod|Within 5 minutes following the administration of the SL-701 emulsion, approximately 125 mg of imiquimod cream will be applied topically on the injection site. The imiquimod cream should be rubbed in until the cream is no longer visible.
214497081|NCT06799546|DRUG|HSK39297 tablets|200mg QD for 24 weeks
214497082|NCT06799546|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
214377002|NCT01105013|DRUG|Clotrimazole|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
214377003|NCT00974701|DEVICE|PillCam ESO2|The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
214377004|NCT04404478|BEHAVIORAL|B-SWELL: Midlife Black Women's Stress Reduction Wellness Program|Stress reduction and culturally tailored information on healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on per support, goal setting, stress reduction, and culturally relevant information.
214377005|NCT04404478|BEHAVIORAL|WE: Wellness program for Midlife Black Women|Culturally tailored information will be provided about healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on peer support and culturally relevant content.
214377006|NCT04114747|OTHER|Starting at high or low blood pressure|Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
214377007|NCT00640237|DIETARY_SUPPLEMENT|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
214377008|NCT00839345|DRUG|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
214377009|NCT02568943|DRUG|Panobinostat|Panobinostat (PAN \[LBH589\]) is an orally administered pan-deacetylase inhibitor (DACi) belonging to a structurally novel class of compounds deregulating cell proliferation and survival mechanisms of cancer cells.
214497083|NCT06780579|DRUG|Bulevirtide|10 mg BLV will be administered via subcutaneous injection
214497084|NCT06775821|DEVICE|Ultrasound or CT of the abdominal aorta|Patient underwent ultrasound or CT of the abdominal aorta
214497085|NCT06752460|DEVICE|EF192B|EF192B will be applied after the tape strriping procedure and will be reapplied after 12 hours.
214497086|NCT04088227|DRUG|Experimental Group|Patients will receive platelet rich plasma injection two times prior to surgery.
214497087|NCT04088227|OTHER|Control Group|Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
214989698|NCT02590783|PROCEDURE|control intervention|Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
214989699|NCT06340659|BEHAVIORAL|HbAEx|Participants will have a 1-week (3 session) on-boarding period where study interventionists will deliver all necessary equipment (bike, pulse oximeters, etc.) to the participants' home, review the AEx program and prescription, and supervise the first 3 sessions to ensure participant understanding and fidelity of the AEx program. Thereafter, the remaining 33 sessions will be conducted by the participant without the direct supervision (asynchronous telerehabilitation) of the study interventionists. Subjects will cycle on recumbent stationary cycles at moderate-vigorous intensity individualized as 50-70% of heart rate reserve (HRR) and/or 11-14 on Borg Category Ratio-15 Rating of Perceived Exertion (RPE) Scale, for 30-50 minutes per session. Following the completion of each session, during the check-in meeting with the participant, the study interventionist will gather information from the participant (including HR and RPE) for dose quantification.
214377010|NCT05591248|DEVICE|VRR|Eligible patients meeting the inclusion criteria and signed a consent, will have 3x/week the guided rehabilitation session with the VR-tool (with a maximum of 9 VRR-sessions).
214377011|NCT00000157|DRUG|Aspirin|
214377012|NCT02561169|DRUG|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
214377013|NCT02561169|OTHER|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
214377014|NCT05506865|DRUG|Indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
214377015|NCT05506865|DRUG|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
214377016|NCT02904902|DRUG|adalimumab|Subcutaneous Injection
214497088|NCT06264362|BEHAVIORAL|Tailored Physical Activity Program|Adaptation of physical activity as an intervention for pain management using the 3-Step Tailored Approach: assessing in Step 1 the Person Living with Dementia (PLWD), in Step 2 the Environment, and in Step 3 the Caregiver. With this approach, traditional exercises can be adapted to 1) functional activities (e.g., stair climbing) that are tailored to the interests (e.g., dancing, boxing) and preserved abilities of PLWD; 2) preferred and well-tolerated environments (e.g., home); and 3) account for extent and type of interventionist and caregiver involvement.
214497089|NCT06709404|OTHER|Telemedicine|Receive telehealth navigation intervention
214377017|NCT05864300|BEHAVIORAL|Neurocheck frequency|Randomized to hourly or every-other-hour examinations
214377018|NCT03911427|OTHER|Active oat beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
214377019|NCT03911427|OTHER|Control rice beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
214377020|NCT01720823|DEVICE|home polysomnography (GETEMED)|
214989700|NCT06340659|BEHAVIORAL|HbExergame|Participants will cycle as described in the HbAEx protocol while engaging in cognitive training for the duration of cycling. Cognitive training will include 20 levels of difficulty with 8-10 task scenarios in the context of three virtual worlds (environments. In each of the environments, the participant must follow directions and navigate to a destination where the scenario (cognitive task) will be performed. The game will inform the participant of the assigned task and, automatically, determine and inform the participant of the fastest route from the starting point to the scenario destination where the task will be performed. The participant will be required to remember the assigned task, follow the directions and navigate to the destination, and then remember what action is required to complete the task. A scenario-specific cognitive task will be triggered once the destination has been reached. The cycling and cognitive tasks will be completed throughout the sessions.
214989701|NCT02110693|OTHER|Interviewer and tablet administration of the TAPS Tool|All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
214989702|NCT05190133|DRUG|UIC201602 and co-administration of UIC201601 and UIC201602|"* UIC201602 4 Cap/day for 14 days~* Wash out 21 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
214989703|NCT05190133|DRUG|UIC201601 and co-administration of UIC201601 and UIC201602|"* UIC201601 4 Tab/day for 7 days~* Wash out 14 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
214989704|NCT01489423|GENETIC|RNA analysis|
214989705|NCT01489423|GENETIC|in situ hybridization|
214989706|NCT01489423|GENETIC|polymerase chain reaction|
214989707|NCT01489423|OTHER|enzyme-linked immunosorbent assay|
214989708|NCT01489423|OTHER|flow cytometry|
215090877|NCT05727722|BIOLOGICAL|a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy|"A single course will be divided into an accelerated titration design phase and a 3+3 design phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The accelerated titration design phase starts at a starting dose of 0.15x10\^9, moving to the 3+3 design phase at the dose of 0.5x10\^9. According to the semi-logarithmic incremental (10\^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10\^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored."
215090878|NCT05327127|DRUG|K-877-ER|K-877-ER tablet
215090879|NCT05327127|DRUG|CSG452|CSG452 tablet
215090880|NCT05327127|DRUG|Placebo|Placebo tablet
215090881|NCT05369832|DRUG|Ozanimod|Specified dose on specified days
214377021|NCT01720823|DEVICE|standard polysomnography (BRAINNET II)|
214377022|NCT02413463|PROCEDURE|augmented recession|medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)
214377023|NCT02413463|PROCEDURE|Faden|medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
214377024|NCT06495541|DRUG|Pyrotinib|Administration method: Pyrrolitinib standard dose: 400 mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 21 days per cycle. The dosage can be determined by the doctor according to the actual situation Make adjustments. Other medications: The doctor selects the medication plan based on the actual situation.
215090882|NCT03691350|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
214377025|NCT02002182|BIOLOGICAL|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
214377026|NCT03788460|OTHER|no intervention|no intervention
214377027|NCT02635074|DRUG|Cytarabine|Given IV
214377028|NCT02635074|DRUG|Ibrutinib|Given PO
214377029|NCT02635074|DRUG|Idarubicin|Given IV
214377030|NCT04190147|OTHER|Structural, functional and metabolic eye examinations|Structural, functional and metabolic eye examinations
214377031|NCT03472703|OTHER|Break-Lunch time|The time for the break and lunch will be contrary, depending on their visit/session
214377032|NCT01535742|DEVICE|Ambu Aura-i size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
214377033|NCT01535742|DEVICE|air-Q ILA size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
214377034|NCT01535742|DEVICE|Ambu Aura-i size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
214497090|NCT06709404|OTHER|Survey administration|Ancillary studies
214497091|NCT06709404|OTHER|Electronic health record review|Ancillary studies
214989709|NCT01489423|OTHER|immunohistochemistry staining method|
214989710|NCT01489423|OTHER|laboratory biomarker analysis|
214377035|NCT01535742|DEVICE|air-Q ILA size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
214377036|NCT04042116|DRUG|Lucitanib|Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.
214377037|NCT04042116|DRUG|Lucitanib|Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.
214989711|NCT05801692|PROCEDURE|Weaning of mechanical ventilation|Weaning of mechanical ventilation is the time when the patient is ready for separation from ventilatory support until breathing without invasive support
214989712|NCT00004059|DRUG|7-hydroxystaurosporine|
214989713|NCT00004059|DRUG|fluorouracil|
214377038|NCT04042116|DRUG|Lucitanib|"Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria."
214497092|NCT06709404|OTHER|Best Practice|Receive standard caregiving experience
214989714|NCT02205138|DRUG|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
214989715|NCT03183206|PROCEDURE|Cryosurgery , IRE surgery ,surgery|surgery will be used in local tumor
214377039|NCT04042116|DRUG|Nivolumab|IV nivolumab 480 mg will be administered once every 4 weeks.
214377040|NCT00125593|DRUG|Simvastatin 20 mg|Once daily
214377041|NCT00125593|DRUG|Ezetimibe 10mg|Once daily
214377042|NCT00125593|DRUG|Placebo|Once daily
214377043|NCT06065813|DRUG|Toripalimab|200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation
214989716|NCT03183206|BIOLOGICAL|γδ T cells|γδ T cells will be used against
214989717|NCT03183206|OTHER|γδ T cells/ Surgery|Combination γδ T cell and Cryosurgery, IRE surgery or surgery will be used in Breast Cancer
214989718|NCT06326047|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
214989719|NCT06326047|DRUG|Placebo|Placebo will be administered subcutaneously.
214377044|NCT06065813|RADIATION|Conventional segmental radiotherapy|the does of radiation will be 40-45Gy. The day of the first dose of Toripalimab and the first day of radiation must be the same day.
214377045|NCT06065813|OTHER|opreation|The operable patients will accept radical operated in 28-42 days after the third dose of Toripalimab
214377046|NCT01597505|DRUG|Surotomycin|250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days
214377047|NCT01597505|DRUG|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
214377048|NCT01597505|DRUG|Placebo|Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
214377049|NCT03735563|DRUG|Ketamine|Individuals will receive randomly either ketamine or fentanyl as a premedication
214989720|NCT06326047|DRUG|Trizepatide|Trizepatide will be administered subcutaneously.
214989721|NCT00956189|DRUG|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
214989722|NCT00956189|DRUG|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
214989723|NCT00002302|DRUG|Epoetin alfa|
214989724|NCT03409380|DIETARY_SUPPLEMENT|Arginine Drink|10 g of arginine in a formulated drink
214989725|NCT03409380|DIETARY_SUPPLEMENT|Plain Drink|formulated drink
214989726|NCT00937950|OTHER|Gynaecological follow-up|Subjects received a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years in this gynaecological follow-up study (HPV-052 EXT 008). No vaccine was administered in this extension study. Subjects received 3 doses of Cervarix/Havrix vaccine, administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the HPV-008 (NCT00122681) primary study.
214989727|NCT00448799|RADIATION|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of \[123I\] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
214989728|NCT00777842|DEVICE|GTX™ Drug Eluting Coronary Stent System|Drug eluting stent
214989729|NCT03036943|RADIATION|Fluciclovine|Fluciclovine (18F) PET/CT scan completed \>= 48 hours prior to surgical resection for breast cancer
214989730|NCT03763981|PROCEDURE|prolene seton treatment|patients with perianal fistulas will treated with seton placement by prolene thread
214989731|NCT03763981|PROCEDURE|silk seton treatment|patients with perianal fistulas will treated with seton placement by silk thread
214989732|NCT02768155|OTHER|Amniotic Fluid 4.0ml dose|Injection of Amniotic Fluid
214989733|NCT02768155|OTHER|Amniotic Fluid 2.0ml dose|Injection of Amniotic Fluid
214989734|NCT02768155|OTHER|Placebo Control|Normal Saline
214989735|NCT03873532|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 21-day treatment cycle).
214989736|NCT03873532|DRUG|Capecitabine|Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
214989737|NCT06135038|OTHER|Suprascapular nerve block with physical therapy|"Suprascapular nerve block was applied to the relevant shoulder area of all patients before treatment. Afterwards, a physical therapy program (5 days a week for 3 weeks, a total of 15 sessions) was applied, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
214989738|NCT06135038|OTHER|Group 2 Physical therapy|"A physical therapy program (5 days a week for 3 weeks, a total of 15 sessions), including a hot pack at 60 ° C for 20 minutes, conventional TENS at 80 Hz for 20 minutes and US at 3 MHz frequency and an intensity of 1.5 watts / cm2, was applied to the relevant shoulder area of all patients.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
214989739|NCT04810962|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
214989740|NCT04810962|DRUG|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
214989741|NCT01586325|DRUG|JNJ-47910382 30 mg|JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
214989742|NCT01586325|DRUG|JNJ-47910382 90 mg|JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
214989743|NCT01586325|DRUG|JNJ-47910382 200 mg|JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
214989744|NCT01586325|DRUG|Placebo|Matching Placebo administered once daily as monotherapy for 5 days.
214989745|NCT00070525|DRUG|tipifarnib|Given orally
214989746|NCT05136638|BEHAVIORAL|dCBTi|The dCBTi adopts a multi-module approach, consisted of 6 weekly modules including psychoeducational on sleep, insomnia, sleep hygiene, sleep restriction and prescription, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep.
214989747|NCT05136638|BEHAVIORAL|Virtual coaching|A virtual coach will be added to the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
214989748|NCT05136638|BEHAVIORAL|Non-therapist coaching|A research intern will answer questions and address concerns raised by the participant at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
214989749|NCT05136638|BEHAVIORAL|Therapist coaching|A clinical psychology trainee will provide therapeutic support to enhance the use and adherence to CBTi treatment strategies at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
214989750|NCT05136638|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
214989751|NCT02475668|DEVICE|Pulse oximeter|Hypoxia
214989752|NCT02315183|OTHER|This is an observational Study|THis study has no intervention
214989753|NCT05169905|COMBINATION_PRODUCT|RSV MAT vaccine|"Single dose of the RSV MAT vaccine reconstituted with NaCl solution was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~RSV MAT vaccine was no longer administered to participants at Day 31. No vaccine was administered in the dTpa\_RSV-P Group, since there were no participants assigned to it."
214377050|NCT03735563|DRUG|Fentanyl|Individuals will receive randomly either ketamine or fentanyl as a premedication
214377051|NCT04225624|BEHAVIORAL|Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based AR-ERT. This intervention aims to build attention regulation skills (i.e., the ability to flexibly shift and sustain attention) by teaching participants exercises for Orienting their attention and Allowing the presence of negative emotions. Participants are taught to apply these skills to counteract reactive perseverative thinking when negative emotions arise as well as proactively engage with emotion-laden situations that trigger repetitive negative thinking.
214377052|NCT04225624|BEHAVIORAL|Supportive Psychotherapy (SPT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based SPT. This intervention addresses factors that may affect participants' repetitive negative thinking symptoms (for example, relationships, work, stress), and teaches skills for managing challenges by improving self-esteem and positive coping skills.
214377053|NCT03215940|DRUG|Delta-9-Tetrahydrocannabinol|An oral dose of Delta-9-Tetrahydrocannabinol (THC) will be given once a day for five day with pain ratings taken before and after each dose every day.
214377054|NCT03215940|DRUG|Cannabidiol|An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.
214377055|NCT03215940|DRUG|Placebos|An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
214377056|NCT06018909|BEHAVIORAL|Cognitive-Behavioral Interventions Package|CBIP was developed by researchers in line with the relevant literature according to the developmental characteristics of children. Opinions were obtained from experts in the field of pediatrics or psychiatric nursing regarding CBIP. CBIP consisted of cognitive and behavioral practices to prevent/reduce procedural pain and anxiety.
214377057|NCT01650493|DEVICE|Clinpro 5000|Dentrifice containing 950ppm fluoride
214377058|NCT01650493|DEVICE|MI Paste Plus|Dentrifice containing 950ppm fluoride
214377059|NCT01650493|DEVICE|Tom's of Maine|Dentrifice that is fluoride free
214377060|NCT05261191|BIOLOGICAL|MGD020|MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
214377061|NCT05261191|BIOLOGICAL|MGD014|MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
215090883|NCT03691350|DRUG|Cigarette|Smoke usual brand
215090884|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC with nicotine
215090885|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC without nictoine
215090886|NCT03691350|OTHER|Laboratory Biomarker Analysis|Correlative studies
215090887|NCT03691350|DRUG|Nicotine Replacement|Receive NRT comprising patch, gum, or lozenge
215090888|NCT03691350|OTHER|Questionnaire Administration|Ancillary studies
214989754|NCT05169905|COMBINATION_PRODUCT|dTpa vaccine|"Single dose of the dTpa vaccine was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~Two formulations of dTpa vaccine are licensed in the US and outside of the US (ex-US), respectively. dTpa-US formulation was administered to participants in centers located in the US, while dTpa-ex-US formulation was planned to be administered to participants in centers ex-US. The dTpa-ex-US formulation was not applicable in this study anymore as no non-US sites were initiated before the decision to stop the study.~The participants in RSV\_dTpa-P and RSV\_dTpa-A study groups were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.~No vaccine was administered in the dTpa\_RSV-P Group, since there were no participants assigned to it."
215090889|NCT00149019|DRUG|Cell therapy with bispecific antibodies|
215090890|NCT05021549|DEVICE|nasal prong|apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong during preintubation apnia
215090891|NCT04356794|OTHER|Acupuncture needle with electrical stimulation|EA is treated for 4 weeks, 3 times per week.
214377062|NCT00895622|RADIATION|54 Gy radiotherapy|External beam radiation therapy (EBRT) to a total dose of 54 Gy (RBE) in 30 fractions. 1.8 Gy (RBE) daily, 5 fractions per week, excluding weekends. 3D-CRT or IMRT or Proton allowed.
214377063|NCT00895622|RADIATION|60 Gy radiotherapy|External beam radiation therapy using intensity-modulated radiation therapy (IMRT) to a total dose of 60 Gy in 30 fractions. 2.0 Gy daily, 5 fractions per week, excluding weekends.
215090892|NCT04356794|OTHER|Sham electroacupuncture|Sham EA is treated for 4 weeks, 3 times per week.
214377064|NCT01433484|BEHAVIORAL|Maintenance of Weight Loss--Control|As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
214497093|NCT06162338|BIOLOGICAL|LY-M001 Injection|With 5.0 × 10\^12 vg/kg as the initial effective dose (first dose group), 1 to 2 subjects are expected to be included. The first dose group was enrolled by sentinel method, and the first subject in this group was observed for at least 28 days after receiving LY-M001 (dose-limited toxicity \[DLT\] observation period) to enroll the next subject. After the first participant completes the safety evaluation of dosing for at least 28 days, the investigator (PI) and the partner discuss the safety and efficacy data and decide to maintain the first dose or increase/reduce it to another dose group
214989755|NCT02412657|DRUG|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
214989756|NCT02412657|DRUG|Normal Saline|
215090893|NCT04487171|OTHER|Questionnaire|The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.
215090894|NCT00547950|DRUG|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid\*1year.
215090895|NCT04732104|DRUG|Lidocaine topical|intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
215090896|NCT04732104|DRUG|Lidocaine Hydrochloride|injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
215090897|NCT05501743|DRUG|Intra-articular injection of microfat and PRP|The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
215090898|NCT05501743|PROCEDURE|Total denervation of the wrist|The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
215090899|NCT02846649|BEHAVIORAL|PIER|Daily text message queries with tailored support
215090900|NCT06065657|DIETARY_SUPPLEMENT|Ketone Supplement|Ketone supplement 3x day with control diet for 3 days.
214377065|NCT01433484|BEHAVIORAL|Maintenance of Weight Loss--Experimental|
214377066|NCT01490125|DRUG|QVA149|QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI
214377067|NCT01490125|DRUG|Tiotropium|Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
214377068|NCT01490125|DRUG|Placebo to QVA149|Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
214377069|NCT01490125|DRUG|Placebo to tiotropium|Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
214377070|NCT01490125|DRUG|Salbutamol/albuterol|salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
214377071|NCT01160874|OTHER|Polysomnography|Sleep study monitoring
214377072|NCT01160874|OTHER|Maintenance Wakefulness Test|Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
215090901|NCT06065657|OTHER|Control Diet|Control Diet breakfast, lunch, and dinner for 3 days.
215090902|NCT06065657|OTHER|Ketogenic diet|Ketogenic Diet breakfast, lunch, and dinner for 3 days.
214377073|NCT01160874|BEHAVIORAL|Neuropsychological evaluation|Neuropsychological evaluation for cognitive functions study
214377074|NCT01160874|OTHER|Driving test on a simulator|Driving simulator test during wich a camera register different parameters as the position of the vehicle.
214377075|NCT06064864|DRUG|Infliximab-Dyyb|Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
214989757|NCT04899037|OTHER|No intervention|This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
214989758|NCT02027493|DRUG|Reiferon R|subcutaneous injection of 100 μg/m2
214989759|NCT02027493|DRUG|Ribavirin|15 mg/kg daily on two divided doses
214989760|NCT01913184|DEVICE|AKITA|
214989761|NCT00550004|DRUG|RP101|190 mg oral tablet
214989762|NCT00550004|DRUG|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
214989763|NCT05265754|BEHAVIORAL|sujok therapy|sujok therapy
214989764|NCT03101345|OTHER|Peptamen® 1.5 vanilla|Administration orally
214989765|NCT00460798|OTHER|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
214377076|NCT04616014|DRUG|ORMD-0801 QD|16 mg, QD, two capsules, 8 mg each.
214377077|NCT03060798|DRUG|Desflurane|general anesthesia using desflurane.
214377078|NCT03060798|DEVICE|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vessel occlusion test
214989766|NCT03349047|BEHAVIORAL|Behavioral intervention group|Patients will hold the peanut or tree nut in a cup and will be asked to touch the nut with their finger.
214989767|NCT03349047|BEHAVIORAL|Education|The group will be educated about what can occur with contact with or being in proximity of peanuts or tree nuts.
215090903|NCT06065657|DRUG|Ethanol|After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
215090904|NCT04645745|DIETARY_SUPPLEMENT|myo-inositol, alpha-lactalbumin, folic acid|Evaluating the improvement vs the baseline after three and six months of treatment
214377079|NCT03517423|DRUG|Brivaracetam|An antiepileptic drug whose putative mechanism of action is as a result of direct inhibition of SV2A receptors, responsible for the successful release of excitatory neurotransmitters from the the neuronal presynaptic membrane.
214377080|NCT02889666|DRUG|Cisplatin|Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
214377081|NCT02889666|DRUG|Carboplatin|Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
214377082|NCT02889666|DRUG|Docetaxel|Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
214497094|NCT05451290|DRUG|Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur|Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
214989768|NCT03419650|DRUG|ACTHar|Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
214989769|NCT00088855|DRUG|Bortezomib|Given IV
214989770|NCT00088855|OTHER|Laboratory Biomarker Analysis|Correlative studies
214989771|NCT00088855|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214989772|NCT01898130|BIOLOGICAL|bevacizumab|Given IV
214989773|NCT01898130|PROCEDURE|quality-of-life assessment|Ancillary studies
214989774|NCT02866383|DRUG|Nivolumab|3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
214989775|NCT02866383|DRUG|Ipilimumab|1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
214989776|NCT02866383|RADIATION|Radiotherapy|15 Gy x 1 fraction given on day 1
214989777|NCT03183440|DIETARY_SUPPLEMENT|PREBIOTICS|women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery
214989778|NCT03183440|OTHER|PLACEBO|women will daily take placebo (maltodextrin) from inclusion to delivery
214989779|NCT01458626|DRUG|mirtazapine|mirtazapine 30mg QD
214377083|NCT02889666|DRUG|Gemcitabine/Carboplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
214989780|NCT01458626|DRUG|paroxetine 20mg QD|paroxetine 20mg QD
214989781|NCT04892407|DEVICE|Algeness® DF 3.5%|dermal filler CE Mark approved for treatment of cheek and midface volume loss
214989782|NCT04892407|DEVICE|Juvéderm Voluma|dermal filler CE Mark approved for treatment of cheek and midface volume loss
214989783|NCT02636621|DEVICE|Brazilian Dental Appliance|Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
214989784|NCT02636621|OTHER|Placebo|The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
214989785|NCT00322036|DRUG|MPC-7869|Oral 800 mg BID
214989786|NCT00322036|DRUG|MPC-7869|Oral BID dosing
214989787|NCT02478333|DRUG|ALS-008176 (250 mg)|Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
215090905|NCT00913393|DRUG|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
215090906|NCT00913393|DRUG|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
215090907|NCT00913393|DRUG|Placebo|Placebo IV every 2 weeks for 22 weeks
215090908|NCT04531514|OTHER|Sensitivity to phonological rules & referents OR: Toddlers|Assess whether the inclusion of a semantic reference decreases OR phonological rule learning
214377084|NCT02889666|DRUG|Gemcitabine/Cisplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
214377085|NCT02889666|DRUG|Docetaxel/Oxaliplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
214377086|NCT02889666|DRUG|Docetaxel/Carboplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
214377087|NCT02889666|DRUG|Placebo|Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
214377088|NCT02507778|DEVICE|CellCollectorTM (Gilupi, Germany) needle|needle will be inserted before and after biopsy and will measure circulating tumor cells.
214377089|NCT06038435|BEHAVIORAL|Cognitive Orientation Approach|Cognitive training will be given for the selected occupation
214989788|NCT02478333|DRUG|ALS-008176 (500 mg)|Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
214989789|NCT02478333|DRUG|ALS-008176 (750 mg)|Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
214989790|NCT02478333|OTHER|Placebo|Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
214989791|NCT05655871|OTHER|Transtheoretic Model Based Video Exercise Training|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. Participants 10-12. No application will be made between weeks and the last test will be done in the 12th week.
214989792|NCT05655871|OTHER|Standard Maintenance Practice|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. The final test will be done at week 12.
214989793|NCT00630292|OTHER|Magnetic Resonance Angiography (MRA) of the Breast|Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
214377090|NCT06038435|BEHAVIORAL|Ayres Sensory Integration Therapy|Sensory integration therapy will be applied.
214377091|NCT02237508|DRUG|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
214377092|NCT02237508|DRUG|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).
214377093|NCT02237508|DRUG|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
214989794|NCT03602001|BEHAVIORAL|Attentive eating smartphone application.|A smartphone application that encourages a more attentive eating style.
214989795|NCT03602001|BEHAVIORAL|Standard dietary advice and text tips.|Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.
214989796|NCT00141609|DRUG|Slow Sodium|
214989797|NCT03099525|OTHER|ILD|This is an observational study without any intervention.
214377094|NCT02237508|DRUG|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
214377095|NCT03151681|DRUG|Propranolol Pill|1mg/kg of propranolol 60 minutes prior to memory reactivation
214497095|NCT06186973|OTHER|Monitoring with Neobeat heart rate meter|"At the designated time for cord clamping as per clinical indication, a 10 cm segment of the umbilical cord will be double-clamped and 5 ml of preferably arterial blood will be obtained.~In infants brought to the resuscitation table, six ECG electrodes will be placed on the skin and cardiac output will be measured with a hemodynamic monitor (PhysioFlow®) for at least 10 min, or until the end of resuscitation/stabilization."
214497096|NCT06186973|OTHER|Maternal arterial blood gases|Arterial blood gases will be drawn from a radial artery line and analyzed at the end of a contraction at pre-specified time points during labor.
214497097|NCT06186973|OTHER|Amniotic fluid lactate|Amniotic fluid will be collected (2mL) and analyzed at pre-specified time points after rupture of the membranes.
214989798|NCT00142415|DRUG|111-In-DOTA-cG250|On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
214989799|NCT00142415|DRUG|177-Lu-DOTA-cG250|On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.
214989800|NCT03742596|DIETARY_SUPPLEMENT|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
214989801|NCT03742596|DRUG|Control|The Placebos will be coded in a specific label by a researcher.
214989802|NCT00139529|BEHAVIORAL|Motivational Interviewing Telephone Counseling|Participants will receive up to 5 phone calls.
214989803|NCT00139529|BEHAVIORAL|Educational Intervention|Educational intervention will be completed during pregnancy.
214989804|NCT01189266|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
214989805|NCT01189266|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
214989806|NCT01189266|OTHER|Laboratory Biomarker Analysis|Correlative studies
214989807|NCT01189266|DRUG|Vorinostat|Given PO
214989808|NCT04970940|DRUG|Treatment A|AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days
214989809|NCT04970940|DRUG|Treatment B|AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days
214989810|NCT04970940|DRUG|Treatment C|AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days
214377096|NCT04130139|OTHER|oocyte pick up simulator|oocyte pick up simulation
214989811|NCT00537277|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
214989812|NCT02294266|DRUG|Mephedrone and alcohol|"Single oral dose mephedrone~Single oral dose alcohol"
214989813|NCT02294266|DRUG|Mephedrone|Single oral dose mephedrone
214989814|NCT02294266|DRUG|Alcohol|Single oral dose alcohol
214989815|NCT02294266|DRUG|Placebo|Single oral dose placebo
214989816|NCT02146183|DIETARY_SUPPLEMENT|Carbohydrate steviol glycosides|To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.
214989817|NCT02146183|DIETARY_SUPPLEMENT|Placebo Corn Starch|500 mg/day
214989818|NCT04779177|DRUG|Lumateperone 42 mg|Lumateperone 42 mg, oral administration
214989819|NCT04779177|DRUG|Lumateperone 28 mg|Lumateperone 28 mg, oral administration
214989820|NCT04729517|DRUG|AI201901|Twice daily inhaled AI201901 for 4 weeks
215090909|NCT04531514|OTHER|Sensitivity to phonological rules & referents FR: Toddlers|Assess whether the inclusion of a semantic reference increases FR phonological rule learning
215090910|NCT06292104|DIAGNOSTIC_TEST|multimodal diagnostic testing|Serological testing, cardiac MRI, skin biopsy, cardiovascular testing, blood volume measurements
214687107|NCT06235684|OTHER|Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion|During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at month 3, at month 12 and in case of unscheduled visit. Questionnaires and standardised voice collection will be collected (optionally) at different time points using the Colive web app. Physical activity and sleep quality will be optionally monitored via a smartwatch that will be provided to interested participants. Biological sample(s) and imaging data will be collected at different time points (baseline; 3 months; 12 months; unscheduled visit). A long-term follow-up (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term follow-up medical data are collected on a yearly basis, and questionnaires are collected every 6 months.
215090911|NCT05661903|OTHER|Spinal Cord Stimulator Set to Minimal/No Stimulation Setting|Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.
215090912|NCT05661903|OTHER|Usual Care|Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.
215090913|NCT05661903|DRUG|Positron Emission Tomography / Magnetic Resonance Imaging|Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study. This imaging involves administration of the \[11C\]PBR28 radioligand, which is an investigational drug. Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.
214377097|NCT01446484|BIOLOGICAL|CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10\^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
214377098|NCT01446484|DRUG|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
214377099|NCT01446484|DRUG|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
214989821|NCT04729517|DRUG|Azelastine Hydrochloride|Twice daily inhaled Azelastine Hydrochloride for 4 weeks
214989822|NCT05145764|DRUG|Suvorexant|Encapsulated suvorexant (matched for color, weight, and size)
214989823|NCT05145764|DRUG|Placebo|Encapsulated placebo (matched for color, weight, and size)
214989824|NCT00003297|DRUG|mitoxantrone hydrochloride|
214989825|NCT00003297|DRUG|thiotepa|
214989826|NCT00003297|DRUG|topotecan hydrochloride|
214989827|NCT00003297|PROCEDURE|peripheral blood stem cell transplantation|
214989828|NCT05624853|DRUG|pregabalin sustained release tablet|pregabalin sustained release tablet 150mg qd for 8weeks
214989829|NCT05624853|DRUG|pregabalin immediate release capsule|pregabalin immediate release capsule 75mg bid for 8weeks
214989830|NCT06401291|DEVICE|Transcutaneous Electrical Nerve Stimulation|Device consists of two electrodes that are applied to the chest region and are connected to a battery operated TENS (Frequency 80Hz, pulse width 150us and amplitude variable (patient dependent)). The device will be used a minimum of three times daily for 30 minutes and additionally during symptoms.
214989831|NCT03620162|BIOLOGICAL|Prevnar 13™|Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.
214989832|NCT03620162|BIOLOGICAL|V114|V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.
214989833|NCT03620162|BIOLOGICAL|RotaTeq™|RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.
214989834|NCT03620162|BIOLOGICAL|Pentacel™|Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
214989835|NCT03620162|BIOLOGICAL|RECOMBIVAX HB™|RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
214989836|NCT03620162|BIOLOGICAL|HIBERIX™|HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
215090914|NCT06316752|OTHER|Observational study|It is an observational study involving non-invasive routine examinations without treatment, thus posing no additional risk to patients. This project does not involve the use of medications, medical techniques, or the market status of medical equipment.
214377100|NCT01446484|DRUG|Sirolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
214989837|NCT03620162|BIOLOGICAL|M-M-R™ II|M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.
214989838|NCT03620162|BIOLOGICAL|VARIVAX™|VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.
214989839|NCT06447974|BEHAVIORAL|Exposure mitigations|Behavioural interventions with an aim to reduce exposure by targeting occurrences of high exposure
214989840|NCT00952198|DRUG|ARRY-403, glucokinase activator; oral|multiple dose, escalating
214687108|NCT01071044|DRUG|Lisdexamfetamine Dimesylate|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
214989841|NCT00952198|DRUG|Placebo; oral|matching placebo
214989842|NCT02515474|PROCEDURE|Laparoscopy|After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.
214989843|NCT02515474|PROCEDURE|Endoscopy|Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
214989844|NCT00437463|DRUG|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
214989845|NCT03777241|BEHAVIORAL|Behavioral Intervention Team|Multidisciplinary team to assist with actively identifying and managing mental illness and substance abuse disorders at their earliest possible time during hospitalization.
214989846|NCT03777241|BEHAVIORAL|Standard of care|Participants in this group will receive standard of care.
214989847|NCT06462677|DIAGNOSTIC_TEST|Babesia NAT|Blood donors will be tested with Babesia NAT
214989848|NCT03336346|DRUG|dolutegravir|HIV integrase strand transfer inhibitor used in combination ART
214989849|NCT03336346|DEVICE|ENG implant|Reversible contraception implant
214989850|NCT03336346|DRUG|Efavirenz|non-nucleoside reverse transcriptase inhibitor used in combination ART
214989851|NCT01019993|PROCEDURE|conventional OLV followed with IL-HFPPV|The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory \[I: E\] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio \<0.3 and R.R 60 breaths/min.
215090915|NCT05011877|DEVICE|High-flow nasal cannula therapy|High-flow nasal cannula therapy (HFNC) (from 25 - 60 L/min based on patient's tolerance) will be used in 21 participants during one additional sleep study to investigate its acute impact on reducing sleep abnormalities. Inspired fraction of oxygen will be titrated to maintain patient SpO2 similar to the levels during standard oxygen therapy.
215090916|NCT06012110|DEVICE|Transcutaneous electrical stimulation|While participants are supine with a pillow placed below the knees for comfort, one 30-minute transcutaneous electrical stimulation session will be performed at a frequency of 50 Hz, pulse width of 400 microseconds and individualized amplitude will be completed.
215090917|NCT06328452|DEVICE|FibroScan|All the study population will be submitted to Fibroscan examination with CAP (Echosens FibroScan® Compact 530). To evaluate steatosis and fibrosis, participants will be asked to fast for at least 3 hours before the test. To capture a controlled attenuation parameter (CAP) score and liver stiffness measurement (LSM), 10 valid scans per subject will be needed.
215090918|NCT01556321|DIETARY_SUPPLEMENT|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
214377101|NCT01446484|DRUG|Tacrolimus|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
214377102|NCT01446484|DRUG|Cyclosporine|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
214377103|NCT01446484|DRUG|Everolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
214377104|NCT01446484|PROCEDURE|Kidney transplantation|Living related kidney transplantation
214377105|NCT02816086|OTHER|Interdisciplinary collaboration structure|A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
215090919|NCT01556321|DIETARY_SUPPLEMENT|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule \[84.5 mg EGCG + 2.1 mg caffeine \], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
215090920|NCT00214474|BEHAVIORAL|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
215090921|NCT00214474|BEHAVIORAL|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
215090922|NCT00419315|BEHAVIORAL|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
215090923|NCT00419315|BEHAVIORAL|Usual Care|Usual care included a referral to a specialty addiction treatment program.
215090924|NCT02036762|OTHER|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
214687109|NCT01071044|DRUG|"Placebo 30, 50 or 70 mg"|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
214989852|NCT04367896|OTHER|Survey Group|"The survey sought to elucidate equity principles that are influencing transplant decision making. The group of respondents included solid organ transplant doctors (surgeons, referring doctors, transplant physicians, transplant coordinators, ICU transplant doctors), COVID-doctors (ICU doctors, Infectious Disease Doctors, Pulmonologists, Internists), and Ethicists with experience of transplant related issues.~Respondent identification:~A. The e-mail addresses of corresponding authors from Scopus January 1, 2017 and march 20, 2020:~All (surgery) AND subj (medi) and key (transplantation), All (critical care) AND subj (medi) and key (transplantation), All (ethics) AND subj (medi) and key (transplantation). B. Emailing through the mailing list of scientific societies. C. The link to the survey published online. D. The link to the survey circulated through personal contacts and via social media sites."
214989853|NCT04429958|OTHER|GDM|different degrees of hyperglycaemia during pregnancy
215090925|NCT01818284|DRUG|Filgrastim|5 µg/kg in the morning daily for 4 days.
214687110|NCT06823271|OTHER|Resting and exercise right heart catheterization|At rest and after different modes of exercise, exercise right heart catheterization will be performed.
214687111|NCT06823271|OTHER|Right ventricular mapping|At the beginning and at the end of the exercise modes right ventricular mapping will be performed.
214989854|NCT02767531|DRUG|Orlistat|Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
215090926|NCT01818284|DRUG|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
214377106|NCT02377037|OTHER|Metabolic cost and HR associated with distinct postural behaviors|The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
214377107|NCT02138669|DEVICE|Intacs|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
214377108|NCT00232960|PROCEDURE|Radiotherapy 50 Gy|
214377109|NCT03150498|DRUG|BTD-001|BTD-001 in fed vs fasted state
214377110|NCT01218529|DRUG|Lapatinib|Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
214377111|NCT06434792|DRUG|Bronpass Tab.|Twice daily for 12 weeks
214377112|NCT06434792|OTHER|Placebo|Twice daily for 12 weeks
214377113|NCT03911453|DRUG|Rucaparib|Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
214377114|NCT03919370|OTHER|No intervention|there will be NO intervention
214377115|NCT04829383|DRUG|Atezolizumab|1,200 mg
214377116|NCT04829383|DRUG|Bevacizumab|15 mg/kg
214377117|NCT04260477|DRUG|6EH³R³Z|"A triple dose is defined as the triple of the routine dose used for a specific WHO weight band. Hence, the mg/kg within a weigh-band varies, as is the case in routine practice.~Dosing takings into consideration the fixed dose combination (FDC) tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E). Dosage relies on tables with dosage by weight-bands used by WHO for the Cat. 1 regimen. The dosage used for the intensive phase of the Cat. 1 regimen applies for the whole treatment duration. A double dose of H and R is added to the recommended normal dose for adults (WHO,2003)"
214377118|NCT04260477|DRUG|6EHRZ|"Recommended normal dose adults (WHO, 2003)~* H: 5 (4-6) mg/kg/day~* R: 10 (8-12) mg/kg/day~* Z: 25 (20-30)mg/kg/day~* E: 15 (15-18)mg/kg/day"
214377119|NCT04630496|BEHAVIORAL|Fitbit|Electronic activity tracker
214377120|NCT06066086|PROCEDURE|A hinge flap will be performed to reinforce the buccal advancement flap to close the oroantral fistula at the most posterior area of the maxilla|The hinge flap is raised via circular incision around the oral side of the oroantral fistula then sutured with purse suture to close the sinus membrane perforation and it is used as an additional layer that reinforce the buccal advancement flap
214377121|NCT06066086|PROCEDURE|An anteriorly based palatal flap will be performed to close the oroantral fistula at the most posterior area of the maxilla|Two paralleling incisions will be performed on the palatal side of the fistula. The distance between the two incisions will be 2 to 3 mm greater than the width of the fistula. Then the two incisions will be connected together via a circular incision at the bony end of the hard palate. The flap reflection will be performed, and the greater palatine vessels will be legated and cauterized to allow lateral repositioning of the flap over the fistula. The flap will be sutured to the buccal tissues.
214989855|NCT01478659|DIETARY_SUPPLEMENT|Control study food with no added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
214989856|NCT01478659|DIETARY_SUPPLEMENT|Study food with added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
214989857|NCT04865809|OTHER|Peribioma Toothpaste and Mousse|Use of Peribioma Toothpaste and Mousse for home oral care.
214989858|NCT04865809|OTHER|Standard toothpaste|Use of Biorepair Plus Parodontgel for home oral care
214377122|NCT04422093|DEVICE|OrthoKontrol|Fixing OrthoKontrol Sensor on multibracket appliance to measure cooperation
214687112|NCT06963554|BEHAVIORAL|Project Support|The Project Support intervention involves up to four 60-minute individual counseling sessions focused on teaching caregivers how to listen to and comfort their child. Participants will receive didactic instruction and feedback on their use of the skills in role-plays with a treatment provider and with their child. In the role-plays the provider first demonstrates how to use the skill in a brief example of typical situations in which the skill could be used. In these examples the caregiver takes on the role of their child and the provider takes on the role of the caregiver. Subsequently the caregiver and provider switch roles so the caregiver has an opportunity to practice executing the skill. The provider helps the caregiver process their experience of each role-play and provides real-time, targeted feedback to help the caregiver develop their ability to use the skills.
214989859|NCT04264741|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
214989860|NCT04264741|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped sham Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
214377123|NCT06071026|DEVICE|Net Ultra Filtration Rate|The net ultra filtration rate is modified every 6 hours accordingly to randomisation
214377124|NCT06385457|BEHAVIORAL|Mindhelper- A national youth mental health promotion website|Mindhelper is an open-access, digital self-directed mental health service that provides information, self-help tools and guidance to young people in Denmark.
214989861|NCT00382616|DRUG|Phosphatidylserine-Omega3|
214989862|NCT00769418|DRUG|odanacatib|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days."
215090927|NCT01818284|PROCEDURE|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
215090928|NCT06779669|OTHER|Questionnaire CAM|Selected patients will answer a questionnaire about their practice and habits with regard to alternative and complementary medicines. Of these patients, 12 will also complete an additional qualitative questionnaire.
215090929|NCT06970184|PROCEDURE|tooth extraction with alveolar ridge preservation|alveolar ridge preservation performed after tooth extraction
215090930|NCT06970184|PROCEDURE|Implant placement|Implant placement
214377125|NCT05852223|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab 200mg Q3W will be administered via IV infusion for 2 courses from the date of randomization until to the date of thyroidectomy.
214377126|NCT06250946|DRUG|HRS-7535;Placebo|HRS-7535;Placebo
214377127|NCT06250946|DRUG|Placebo|Placebo
214377128|NCT05908357|OTHER|Exergaming|Use of the exergame XboX 360 series with kinect sensor
214377129|NCT05908357|OTHER|Booklet|Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
214377130|NCT04285307|BEHAVIORAL|Sleep Hygiene tips|Students receive a packet of information on how to improve their sleep habits and hygiene.
214377131|NCT04967963|PROCEDURE|HAM|Transplantation of HAM
214377132|NCT06679309|OTHER|Integrated care plan|Complex care plan facilitated by the integrated care lead with 90 day follow-up, 24/7 phone support and connection with resources and services
214377133|NCT06584175|BEHAVIORAL|Internet Delivered Cognitive Behavioural Therapy|The tinnitus ICBT program consists of 1) an overview of tinnitus, depression, and anxiety; 2) managing unhelpful thoughts and learning problem solving strategies association with pain, anxiety, depression, and disability; 3) management of common symptoms associated with tinnitus, anxiety, and depression; 4) developing strategies to maintain activities while minimizing fatigue; and 5) strategies to improve quality of life through effective goal setting. Supplementary lessons can be accessed at any time (e.g., sleep, communication, problem solving, assertiveness training). Materials are presented in a didactic (i.e., text-based and audio with visual images) and case-enhanced learning format (i.e., stories demonstrate the application of skills). Case vignettes that specifically reflect the experiences of those with tinnitus are included.
214687113|NCT06963554|BEHAVIORAL|Case Management Services|"Case management services, or treatment as usual, may involve referrals for financial resources or donated goods, as well as assistance with court, law enforcement, or information about orders of protection. The nature of these services depends on the needs identified by the family and case manager. There is currently no standard treatment offered to families on the waitlist. This condition will receive individually tailored services, as needed."
214989863|NCT00769418|DRUG|Comparator: Placebo|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days."
214989864|NCT04877964|DEVICE|Ultrasound|Using ultrasound with transverse median and paramedian sagittal oblique approach, the screens that show the target epidural space in the center are obtained and stored for evaluation.
214989865|NCT03579667|BEHAVIORAL|Diet intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
214989866|NCT04632121|DRUG|Nicorandil 20 MG|Nicorandil is a nicotinamide ester that dilates peripheral and coronary resistance vessels via action on ATP-sensitive potassium channels and possesses a nitrate moiety that promotes systemic venous and coronary vasodilation. As a result of these dual actions, nicorandil reduces preload and afterload and results in an increase in coronary blood flow. In addition to these effects, nicorandil may have cardioprotective actions mediated through the activation of potassium channel
214989867|NCT04561791|DEVICE|Tethered Capsule Endomicroscopy|Participants will be asked to swallow the TCE device. Participants may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE device is past the pharynx. The TCE device will be advanced until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
214989868|NCT02935387|OTHER|Taper|Taper
214989869|NCT02232347|DRUG|Ketamine|
214989870|NCT02232347|DRUG|Sufentanil|
214989871|NCT01838876|DRUG|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
214989872|NCT01838876|DRUG|Antidepressant Therapy (ADT)|ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
214989873|NCT02101294|DEVICE|Interossei Lumbricals Neuro Interface|Finger Relief's keyboard home row layout \[actual home row placement order: asdeihotlrn\], plus substitutions on the upper row \[qwfgjyuk;p\] and bottom row \[zxcvb'm,.\] moves or shifts finger and thumb movement from the elbow muscles to the finger muscles. The movement of finger bending toward the palm is shifted to the interosseous and lumbrical muscles of the hand and fingers from the full flexion and extension muscle control to reduce contraction and expansion of tendons and the movement in the carpal canal adjacent to the median nerve and reduces pressure on the median nerve. Pressure on the median nerve compromises the nerve leading to symptoms of the carpal tunnel syndrome of pain, tingling, and numbness.
214989874|NCT02101294|DEVICE|Standard QWERTY keyboard|Report of onset and severity symptoms of carpal tunnel syndrome when typing with QWERTY keyboard and the Finger Relief device.
214989875|NCT03315260|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
214989876|NCT03416179|DRUG|glasdegib|"Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
214377134|NCT04201106|BEHAVIORAL|Open Label Placebo with Rationale|In the OLP + rationale group, the participants will be prescribed to take placebos for 2 weeks with the standard 4-point accompanying rationale: (1) the placebo effect is powerful, e.g. in clinical trials placebos are roughly 80% as effective as antidepressants; (2) classical conditioning is a possible mechanism for automatic self-healing - meaning that the body can automatically respond to taking placebo pills like Pavlov's dogs who salivated when they heard a bell; (3) placebo-treated patients who are more compliant have better outcomes, therefore the placebos should be taken faithfully; and (4) positive expectations increase placebo effects, but it is OK to have doubts.
214377135|NCT04201106|BEHAVIORAL|Open Label Placebo without Rationale|In the OLP without rationale group, the adolescents will be asked to take placebos for 2 weeks but they will be told that the pills contain inert substance and do not have any pharmacological effect.
214377136|NCT03761589|BEHAVIORAL|AFL Intervention|The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.
214687114|NCT02047513|DRUG|perioperative nab-paclitaxel/gemcitabine|2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
215090931|NCT03440190|DRUG|Methylphenidate|Patients are tested for their normal prescription methylphenidate medication
215090932|NCT03681678|DEVICE|fCO2 Laser Therapy Group|Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
215090933|NCT04175769|DIETARY_SUPPLEMENT|Nutritional supplement|Subjects will orally consume two gelatin capsules of nutritional supplement (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
214989877|NCT03416179|DRUG|daunorubicin + cytarabine|"'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');"
214989878|NCT03416179|DRUG|azacitidine|Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
214989879|NCT03416179|DRUG|Placebo|"Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
214989880|NCT03416179|DRUG|Placebo|Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
214989881|NCT03416179|DRUG|glasdegib|"Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.~Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first."
214989882|NCT03416179|DRUG|cytarabine|Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
214989883|NCT03416179|PROCEDURE|HSCT|If required, and done per standard of care post Induction(s).
214989884|NCT05445089|DRUG|Carvacrol|Carvativir 6 mg/ml diluted for oral solution.
214989885|NCT05445089|OTHER|Control group|Placebo
214989886|NCT00042211|BEHAVIORAL|Problem Solving Treatment|Brief Cognitive Behavioral Therapy
214989887|NCT00042211|BEHAVIORAL|Control|No treatment control
214989888|NCT02646163|DRUG|REP 2055|"(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks."
214989889|NCT04179214|OTHER|Thoracic manipulation|Session will be performed twice a week for a three week period if a pop sound occurred then the therapist moved on next procedure ,if not subject will be repositioned and technique will performed again. This procedure will be performed for maximum of two attempts. Approximately 3 minutes of time is required to complete thrust manipulation subjects assigned to thrust manipulation also received general exercise program and manual pressure release technique as the control group. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
215090934|NCT04175769|OTHER|Placebo|Subjects will orally consume two gelatin capsules of placebo (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
215090935|NCT05717062|DRUG|Varespladib intravenous form|This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
215090936|NCT05717062|DRUG|varespladib-methyl- oral form|Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
215090937|NCT05717062|DRUG|Placebo intravenous form|The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
214377137|NCT03761589|BEHAVIORAL|Wait-List Control|Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
214377138|NCT05550415|DRUG|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
214377139|NCT05550415|DRUG|Placebo|The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
214377140|NCT04954586|OTHER|Pain Informed Movement|Participants will attend a twice weekly exercise program.
214377141|NCT05590884|DRUG|Gadopiclenol|Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).
214687115|NCT02047513|DRUG|adjuvant nab-paclitaxel/gemcitabine|Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
214687116|NCT00210340|DRUG|intrathecal rituximab|
214687117|NCT05127616|BEHAVIORAL|Minimal Contact-Cognitive Behavior Therapy|This 4 session largely home-based version of CBT with minimal therapist contact treatment is aimed at improving UCPPS symptoms by teaching symptom self-management skills that modify illness beliefs, information processing strategies, and reactions that aggravate pelvic pain and urinary symptoms.
214989890|NCT04179214|OTHER|conventional pt protocol|This group will receive manual pressure release technique along with general exercises program. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
214989891|NCT05502731|DRUG|Filgotinib|Filgotinib is a small molecule that reversibly inhibits Janus kinases (JAK, selectively JAK 1), thereby inhibiting downstream signalling events induced by various pro-inflammatory and regulatory cytokines.
214989892|NCT05502731|DRUG|Adalimumab|Adalimumab is a monoclonal antibody selectively inhibiting the pro-inflammatory cytokine TNF-alpha.
214989893|NCT02481700|PROCEDURE|Third molar removal|The surgical removal of third molars
214989894|NCT02295319|OTHER|Individual discharge|"See previous description in Arms"
214989895|NCT06330415|OTHER|The SME tool|The intervention comprises of an open-access website targeting the employer of the sick-listed employee. The website provides practical resources, including templates, communication videos and information on legislation, workplace accommodations and most common reasons of sickness absence.
214989896|NCT04640116|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents (GORE® VIATORR) were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the patients received a diuretic treatment and a salt-limited diet until the ascites disappeared.
214989897|NCT04640116|PROCEDURE|microwave ablation (MWA)|MWA: After the patient's ascites disappears, MWA therapy will be performed. A MWA antenna was gradually inserted into the tumor along the predetermined angle under the guidance of Computed Tomography (CT). The whole thermal procedure was conducted under intravenous anesthesia. Vital signs were monitored during the procedure. The settings of the ablation parameters depended upon the manufacturer's recommendation and our experience. Ablation volume was determined by physicians according to liver function, tumor invasion site, and tumor stage. An upper abdominal CT scan was carried out immediately after the procedure to evaluate the ablation area and complications.
214989898|NCT01348243|DRUG|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
214989899|NCT01348243|DRUG|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
214989900|NCT00475332|DRUG|Iodine I -01 Tositumomab (Bexxar)|"Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed dosimetric dose, involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm\^3) total body radiation dose can be calculated."
214989901|NCT00475332|PROCEDURE|External Beam Radiation Therapy|All patients are to receive 20 Gy in 10 fractions of 200 cGy to the PTV
214989902|NCT03134768|OTHER|This is not an interventional study|This is an observational study
214377142|NCT05840081|OTHER|Milk or yogurt beverage|Commercially available milk or yogurt (depending on experimental arm) will be incorporated into flavored drinks/smoothies to minimize perceived differences among these items, preserving the double-blind nature of the study design.
214377143|NCT04997317|DRUG|177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)|177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
214377144|NCT04997317|DRUG|177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4|177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
214377145|NCT04997317|DRUG|177Lu-DOTA-JR11 (Phase I/II)|In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
214377146|NCT04000594|DRUG|RO7234292 (RG6042)|RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.
214377147|NCT06133842|DIAGNOSTIC_TEST|Intra-op EEG and CO data collection|Intra-op EEG and CO data will be collected non-invasively. This will not guide or affect patient care of procedure in any way.
214989903|NCT00058032|OTHER|screening questionnaire administration|
214989904|NCT00058032|PROCEDURE|annual screening|
214989905|NCT01286350|BEHAVIORAL|FL3X: Flexible Lifestyle Empowering Change|The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
214989906|NCT01682031|DIETARY_SUPPLEMENT|selenomethionine|Given PO
214989907|NCT01682031|OTHER|placebo|Given PO
214989908|NCT01682031|DRUG|cisplatin|Given IV
214989909|NCT01682031|RADIATION|radiation therapy|Undergo radiotherapy
214989910|NCT01682031|PROCEDURE|quality-of-life assessment|Ancillary studies
215090938|NCT05717062|DRUG|Placebo - oral form|Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
215090939|NCT06522243|BEHAVIORAL|8-week mindful parenting program|The current study adopts the Mindful Parenting program developed by Prof Susan Bögels (Bögels \& Restifo, 2013), which is an application of mindfulness-based intervention which aims to improve parenting by reducing parents' own stress levels, decreasing parental automatic reactivity, increasing open and unbiased attitudes towards children, and decreasing inter-generational dysfunctional parenting (Bögels et al., 2014). The program consists of eight consecutive weeks of parent groups and one follow-up session two months after the last session. Each parent group will include 15-20 participants. The original Mindful Parenting Program will last for around 3 hours for each session, with the longest practice of 40 minutes. Considering parents recruited in the study may have a higher risk of psychiatric conditions than the general population, each session of mindful parenting group will be reduced to 2 to 2.5 hours with the longest mindfulness practice of 30 minutes (Baer et al., 2019).
214989911|NCT00325637|DRUG|cilnidipine|Cilnidipine 10\~20mg, qd, po for 4 weeks.
214989912|NCT04000113|DEVICE|laser acupuncture|low level laser emission on specific acupuncture points
214989913|NCT04000113|DEVICE|Sham laser|Sham laser
214989914|NCT03199690|DRUG|Dolutegravir|Antiviral (integrase inhibitor)
214989915|NCT03199690|DRUG|Rifampicin|Antibiotic
215090940|NCT05696782|DRUG|Durvalumab|Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes. Each treatment is called a cycle and lasts for four weeks (or 28 days).
214687118|NCT05127616|BEHAVIORAL|Patient Education/Support|This 4 session largely home-based treatment is aimed at improving UCPPS symptoms through the provision of support and science-based information about UCPPS symptoms, how it is diagnosed, its causes, impacts, and triggers, treatment options and a collaborative relationship between the patient and clinician.
214687119|NCT05061550|DRUG|Durvalumab|Participants will receive Durvalumab via intravenous route.
214989916|NCT04841291|BEHAVIORAL|Diabetes Foot Care Education (DFCE)|Virtual simulation-based DFCE sessions on seven topics (the reasons for inspecting one's feet, risk factors and prevention strategies of diabetic foot ulcer, how to wash and moisturize feet, comfortable sock and shoe choices, what to look for, and what to do during feet inspection, how to trim fingernails, and how to maintain foot health) at University of Gondar computer lab for 30 minutes.
214989917|NCT04051580|DRUG|Lactated Ringer|Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
214377148|NCT03513003|DEVICE|Functional Pacifier|Children swap from their habitual pacifier to the functional pacifier and stop baby bottle
214377149|NCT03513003|BEHAVIORAL|Stop habit|Children stop the use of their pacifier and/or baby bottle
214687120|NCT05061550|DRUG|Oleclumab|Participants will receive Oleclumab via intravenous route.
214687121|NCT05061550|DRUG|Monalizumab|Participants will receive Monalizumab via intravenous route.
214687122|NCT05061550|DRUG|Dato-DXd|Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
214687123|NCT05061550|DRUG|AZD0171|Participants will receive AZD0171 via intravenous route.
214687124|NCT05061550|DRUG|Carboplatin|Carboplatin as chemotherapy
214989918|NCT01809067|OTHER|Lavender aromatherapy inhalers|Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
214989919|NCT00025467|DRUG|thalidomide|Given orally
214989920|NCT00025467|OTHER|laboratory biomarker analysis|Correlative studies
214989921|NCT00658853|BEHAVIORAL|4 times 4 minutes high aerobic intensity one leg cycling|3 times per week for 10 weeks
214989922|NCT00435058|DRUG|timolol maleate 0,5%|
214989923|NCT00435058|DRUG|brimonidine tartrate 0,2%|
214989924|NCT00435058|DRUG|travoprost 0,004%|
214989925|NCT02950571|BEHAVIORAL|Digital Picture Frame|The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.
214989926|NCT02950571|BEHAVIORAL|Standard Care|High level of support from an interdisciplinary team.
214989927|NCT02684175|DEVICE|Remote CI Counseling|The remote setup includes a 500 series teleconference audio and video live set-up. The teleconference set-up will be situated on a telemedicine cart and placed within the sound-proof booth at the testing site (UK ENT practice in Morehead, KY). The audiologist will deliver the session remotely.
215090941|NCT05696782|OTHER|the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)|Participants will be asked to answer all 30 items on the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30). This patient-reported outcome measure is designed to measure cancer patients' physical, psychological and social functions. The measure can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is approximately 11 minutes (
215090942|NCT05696782|DIAGNOSTIC_TEST|COPD Assessment Test (CAT)|Participants will be asked to answer all items on the COPD assessment test (8 items) and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
215090943|NCT05696782|DIAGNOSTIC_TEST|Modified Medical Research Council (mMRC) dyspnea scale|Participants will be asked to answer the modified medical research council dyspnea scale (1 item), and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
214377150|NCT05899179|BIOLOGICAL|Recombinant Mycobacterium Tuberculosis Fusion Protein|"Dosage form:injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1\. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm."
214377151|NCT05899179|BIOLOGICAL|Purified Protein Derivative of Tuberculin|"Dosage form:injection. Main ingredients and contents:Pure protein derivatives of tuberculin,0.1ml per bottle.~Usage:0.1ml (5IU) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method."
214377152|NCT06120803|DRUG|Esomeprazole 40 mg|Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.
214989928|NCT02684175|OTHER|In-Person CI Counseling|The standard face-to-face counseling that will occur between the participant and audiologist is the standard of care. No technology will be used. The audiologist will deliver the session face-to-face with the participant in the same room (standard practice).
214989929|NCT02819817|DRUG|Aloe Vera Gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
214989930|NCT02819817|OTHER|Ultrasound gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
214989931|NCT01545336|DRUG|Anastrozole|1 mg tablet to be taken 1 time daily
214989932|NCT01545336|DRUG|Placebo|1 mg tablet to be taken 1 time daily
214989933|NCT02266485|DRUG|BIBB 515 BS|
214989934|NCT02266485|DRUG|Pravastatin|
214989935|NCT02266485|DRUG|Placebo|
214989936|NCT02826213|DEVICE|LifePort® perfusion device|Renal Perfusion with LifePort® perfusion device
214989937|NCT02826213|DEVICE|Waves perfusion device|Renal Perfusion with Waves perfusion device
214989938|NCT01369550|OTHER|SDA soybean oil-containing foods|3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.
214989939|NCT01369550|OTHER|High-oleic sunflower oil containing foods|3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day
214989940|NCT01369550|OTHER|Eicosapentaenoic acid|3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
214989941|NCT01101100|DRUG|AMG 827|210 mg SC or 140 mg SC
214989942|NCT01481467|BEHAVIORAL|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
215090944|NCT01068249|DRUG|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
215090945|NCT01068249|DRUG|RAD001 (Everolimus)|10 mg by mouth daily
214377153|NCT03855787|PROCEDURE|Ureteroscopy|Ureteroscopy for 1.5cm or less renal stones.
214377154|NCT04754139|OTHER|WeChat mobile mini-application|Sexual health education and the role of PrEP
214377155|NCT03301012|OTHER|Recovery support as usual|same as arm
214687125|NCT05061550|DRUG|Cisplatin|Cisplatin as chemotherapy
214687126|NCT05061550|DRUG|Pemetrexed/Cisplatin|Pemetrexed/Cisplatin as chemotherapy
214687127|NCT05061550|DRUG|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin as chemotherapy
214687128|NCT05061550|DRUG|Carboplatin/Paclitaxel|Carboplatin/Paclitaxel, as chemotherapy
214687129|NCT05061550|DRUG|Volrustomig|Participants will receive Volrustomig via intravenous route.
214687130|NCT05061550|DRUG|Rilvegostomig|Participants will receive Rilvegostomig via intravenous route.
214989943|NCT03080285|DEVICE|over-glasses patch|Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
214989944|NCT03080285|DEVICE|Conventional patch|Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
214989945|NCT06108921|DRUG|Xylitol Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of xylitol solution once a day for 2 months.
214989946|NCT06108921|DRUG|Salt Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of normal saline once a day for 2 months.
214989947|NCT04076683|DEVICE|Algodrep|Algorithm computing the volume of blood to be transfused and the interval between apheresis which are necessary to maintain an individual objective of HbS percentage.
214989948|NCT01911247|DRUG|Metformin|Metformin 850 mg once daily
214989949|NCT00970554|OTHER|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
215090946|NCT05139797|OTHER|EchoNet-LVH screening for cardiac amyloidosis|An AI algorithm identifies LVH, low voltage, and high suspicion for cardiac amyloidosis. The intervention is the suspicion score. Patients with high suspicion score will be referred to specialty clinic for standard of care evaluation, screening, and treatment as determined by physicians.
214377156|NCT03301012|OTHER|Smartphone assisted relapse prevention|same as arm
214989950|NCT00970554|OTHER|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
214377157|NCT06064877|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
214377158|NCT06064877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
214377159|NCT06064877|OTHER|Placebo|Placebo for this study will be normal saline
214377160|NCT04522180|DRUG|GHR-LRX|GHR-LRX was administered by SC injection.
214377161|NCT02890953|DRUG|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
214377162|NCT02890953|DRUG|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
214687131|NCT05456035|BEHAVIORAL|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The study has two intervention arms to which depressed adolescents will be randomized: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT only is cognitive behavioral therapy without the additional social cognitive training component.
214989951|NCT01138735|DRUG|adapalene/benzoyl peroxide|daily topical application for 12 weeks
214989952|NCT01138735|DRUG|Topical Gel Vehicle|daily topical application for 12 weeks
214989953|NCT05043935|PROCEDURE|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
214989954|NCT05043935|PROCEDURE|antimicrobial photodynamic therapy without L-PRF|application of antimicrobial photodynamic therapy without L-PRF in the defect
214989955|NCT02744586|BEHAVIORAL|Strengthening Our Vows (SOV)|"Participants, led by a counselor, will discuss options to keep HIV from entering their relationship including both sex partners remaining monogamous, using condoms every time they have sex with outside partners, and being tested together with outside partners to ensure they are HIV negative (Together HIV Free Plan). Participants will discuss options in the event of an outside exposure to HIV including abstaining from having sex with their spouse or by using condoms every time they have sex with their spouse until they can be retested for HIV after 30 days (Protecting my Spouse Plan).~Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners."
214989956|NCT02744586|BEHAVIORAL|Good Health Package Plus (GHPP)|Participants, led by a counselor, will discuss how to prevent, screen, and treat neglected tropical diseases (helminths and schistosomiasis), non-communicable diseases (hypertension and diabetes) and diarrheal diseases through basic hygiene and sanitation. The facilitator will demonstrate proper handwashing techniques and chlorination of water and discuss diet and lifestyle changes. Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will also be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners.
214989957|NCT02585440|DRUG|CMX157|Oral tablet
214989958|NCT02585440|DRUG|placebo|Oral tablet
214989959|NCT01056536|BEHAVIORAL|Structured intervention for the prevention of sexually transmitted infections (STI).|The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
214989960|NCT01056536|DEVICE|Free condoms|Subjects will be proposed free condoms at the end of the pre-travel consultation.
214989961|NCT06072664|BEHAVIORAL|Caloric Compensation Index (COMPX)|Researcher gives child opportunity to consume high- and low-calorie preloads and then free access to a palatable snack
214989962|NCT04335799|BEHAVIORAL|Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training|12-month evidence based weight loss intervention with additional training on stress management strategies
214377163|NCT04705467|DEVICE|Gynecological brachytherapy|Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
214377164|NCT01905046|DRUG|metformin hydrochloride|given PO
214377165|NCT01905046|OTHER|placebo|given PO
214377166|NCT03689075|DRUG|Envarsus Oral Product|Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
214377167|NCT05218993|DIAGNOSTIC_TEST|A new dual-task measurement method with images|Football players will perform Illinois t test with and without cognitive demand with images. These images will represent scenarios from football with some of the players in the scene are from his team and others from opposing team. The player will be asked to look at the image and say the number on the player in following scenarios; The player to whom he can pass the ball, The player who is most likely to intervene the ball, The player who can score the goal. In order to reduce the other possibilities, opposing team players will be positioned in a specific way to block all team-mates but one.
215094618|NCT04326764|DRUG|Panobinostat|"Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules."
214497098|NCT04099992|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction (MBSR) is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session. MBSR teaches to become more aware of thoughts, feelings, and sensations, and to skillfully respond to stressors. Each of the sessions includes education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. Participants learn formal mindfulness practices (e.g., meditation, yoga, body scan, body scan) as well as informal such as awareness of breath, thoughts, or emotions, and mindfulness of daily activities. Participants will receive digital audio (MP3) downloads with guided MM practices, a home practice manual, and handouts with each week's assignments. Daily home practice will consist of 40-45 minutes of recorded practice. Participants will log their daily practice. If a participant misses a class, it is possible to make up the class on a different day.
214497099|NCT04099992|BEHAVIORAL|Health enhancement program (HEP)|"8-week health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP matches MBSR in structure and content, and in parallel to MBSR, consists of music therapy, nutritional education, posture and balance movements, walking and stretching. Work with all practices with group discussion and exercises during an all-day spa day will match the all-day retreat in MBSR. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions. Participants will receive MP3 downloads on an MP3 player with recordings of health education topics, a home listening manual, and weekly handouts with each week's listening assignments. Participants will listen to these MP3 recordings daily for 40-45 minutes and log their daily adherence."
214497100|NCT04099992|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|Participants self-administer tVNS twice per day for 8 weeks. tVNS is delivered using a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and a button for operator control of the stimulation intensity. Conductive gel is applied to the stainless steel round discs on the device and placed vertically on the skin overlying the vagus nerve under the angle of the mandible, between the trachea and sternocleidomastoid muscle. A low-voltage electrical signal is delivered consisting of 5-kilohertz (kHz) sine wave series for 1 ms and repeated every 40 ms, with a maximum delivery of 24 V and 60 milliampere (mA) output. Stimulation amplitude is adjusted by the user and is increased until there is a vibration and slight muscle contraction in the lower face or neck. Stimulation is delivered for 2 minutes on the left side of the neck, and 2 minutes on the right side of the neck, for a total 4 minutes per one dose.
214497101|NCT04099992|DEVICE|Sham-transcutaneous Vagus Nerve Stimulation (tVNS)|Participants self-administer sham-tVNS twice per day for 8 weeks. Sham stimulation will be delivered using a sham device that is identical in appearance and function, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve.
214497102|NCT03747133|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.
214497103|NCT01675492|DEVICE|LASIK|Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
214497104|NCT06893770|BEHAVIORAL|Quran recital|standard treatment and care
214377168|NCT05218993|DIAGNOSTIC_TEST|A new dual-task measurement method with cards|Football players will perform Illinois t test with and without cognitive demand with cards and balls. On the path of Illinois t test, there will be 3 football balls, 3-meters apart from each other, and there will be cards behind each, which can only be seen when the player about to hit the ball. This cards will vary in color (blue or red), which mean right or left. If the player sees red card, he will shoot the ball to the left side goal and if the player sees blue card, he will shoot the ball to the right side.
214497105|NCT06893770|OTHER|standard treatment and care|standard treatment and care
214377169|NCT06547892|DRUG|Vasopressin|"To dilute vasopressin, an ampoule containing 20 IU/ml (1 ml) of vasopressin will be used, which will be mixed with 100 ml of 0.9% physiological solution, resulting in a solution with a concentration of 0.2 IU/ ml. In this study, both central and peripheral vein infusion will be permitted.~The vasopressin administration protocol will consist of an initial dose of 0.02 IU/min (equivalent to 6 ml/h), which can be increased to 0.03 IU/min (9 ml/h) if the mean arterial pressure (MAP) is less than or equal to 65 mmHg. On the other hand, if MAP exceeds 90 mmHg, the dose can be reduced to 0.01 IU/min (3 ml/h). The minimum period for adjusting the drug dosage should be one hour."
214377170|NCT06547892|OTHER|0,9% saline solution|Similar to the intervention protocol, but using a placebo composed of 0.9% saline solution.
214377171|NCT06334042|DIAGNOSTIC_TEST|Serum Chromium Level|Measuring serum chromium levels from patients who admitted in intensive care unit.
214687132|NCT05854615|BIOLOGICAL|Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
214377172|NCT05885282|DEVICE|paraspinal vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the cervical and lumbar paraspinal muscles. Spinal stabilization exercises will be as in the control group. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV will be applied before the exercises. LV will be applied to the cervical paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are in a sitting position. LV will be applied to the lumbar paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
214497106|NCT06847386|PROCEDURE|Hysterocopic metroplasty|If the uterine cavity is normal during intraoperative hysteroscopy, the operation will be finished and embryo transfer will be scheduled in 1 month after the operation; if the uterine cavity is narrowed or the uterine wall is coalesced, hysteroscopic metroplasty and IUD placement will be performed, and a second hysteroscopy with IUD retrieval will be performed after 2-month postoperative estrogen-progesterone treatment, then embryo transfer will be scheduled after 1-month estrogen-progesterone treatment.
214497107|NCT06752889|OTHER|Group( 1): Control Group (pulpectomy using zic oxide eugenol based sealer Zical):|Zinc oxide eugenol based sealer (Zical) will be mixed into a thick paste and packed into the pulp chamber to fill the canal.
214497108|NCT06752889|OTHER|Group ( 2) Experimental group modified 3-MIX-TATIN):|Modified 3Mix-tatin will be prepared by mixing three commercially available antibiotics with simvastatin. This powder will be mixed with zinc oxide eugenol based sealer called Zical which will act as a carrier or vehicle to form a creamy paste of 3Mixtatin at the time of application
214497109|NCT06828627|PROCEDURE|TLSA|"TLSA surgery procedure. (A) On the greater curvature of the stomach, the gastrocolic ligament is incised along the avascular area between the left and right gastric omentum vessels, and the gastric fundus is separated upward to the cardia to protect the vagus nerve.~(B) The cardia, lower esophagus, and diaphragm is exposed, and the confluence of the left and right crus of the diaphragm is revealed.~The retroperitoneum at the left and right crus of the diaphragm is incised, and the lower esophagus is dissociated for about 3-5 cm. The gastric fundus and the posterior wall of the esophagus are fully dissociated from the upper spleen. (C) Non-absorbable thread is used to intermittently suture the left and right crus of diaphragm in order to reconstruct the esophagus hiatus with a diameter of about 1.5 cm. (D) Then, the surgeon inserts the patch and fixes it on the crus of diaphragm if the hiatal hernia is larger than 5 cm or the diaphragm on both sides is weak. (E) A small incisio"
214497110|NCT06828627|PROCEDURE|TBSA|Traditional bilateral surgical approach (TBSA) surgery procedure. (A) Separation is initiated from the avascular area of the lesser omentum, and the hepatic branch of vagus nerve is preserved as far as possible. Careful separation is performed upward to expose the right crus of diaphragm. (B) At the greater curvature of the stomach, two to three short gastric vessels are cut off to expose the left crus of diaphragm, and the space between the anterior and posterior of esophagus is dissociated. (C) The diaphragmatic esophageal membrane is incised and the lower part of the esophagus is dissociated about 4-5 cm, then the gastroesophageal valve flap is reformed and the His angle is restored. During the operation, it mainly protects the anterior and posterior trunk of the vagus nerve. The anterior and posterior trunk of the vagus nerve are mainly protected during the operation. (D) Both sides of the crus of the diaphragm are intermittently sutured with non-absorbable thread to reconst
214497111|NCT04699786|OTHER|Arm A , Arm B, Arm C, & Arm D|All arms will receive the same intervention, but at different time points. All arms will be offered the option to learn their research results in personalized five-year risk estimate of getting Alzheimer disease dementia. Arms A \& C participants will receive their risk estimate about two weeks after consent is signed and Arms B\& D will receive their risk estimate about one year after consent is signed. The risk estimate returned to participants is based on research results from individual genotyping results, imaging or plasma amyloid testing \& demographic characteristics. All arms will complete psychosocial and cognitive testing. Also, surveys used in this study will ask about participants' experiences and feelings after learning their risk estimate. All arms will receive follow up calls at one week post disclosure of the risk estimate and surveys two, six, and twelve months post disclosure. Arms A \& C will have extra surveys at twenty-four months post disclosure.
214497112|NCT06765486|OTHER|Lower limb resistance training|Exercise intervention with leg extensions on the dominant quadriceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.
215090947|NCT05332275|BEHAVIORAL|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
215094619|NCT01073878|DEVICE|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
215094620|NCT05117203|DEVICE|WB-EMS (Whole body electrostimulation)|Application of physical exercise and electrical stimulation on the abdominal muscles through the WB-EMS during 20 minutes training session with specific exercise (CORE)
215094621|NCT05117203|DEVICE|EMS|Application of physical exercise and electrical stimulation on the abdominal muscles through the EMS during 20 minutes training session with specific exercise (CORE)
215094622|NCT05117203|DEVICE|WB-EMS off|Application of physical exercise without electrical stimulation on the abdominal muscles through the WB-EMS off during a 20 minutes training session with specific exercise (CORE).
215094623|NCT03970616|DRUG|Tivozanib|Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day
214377173|NCT05885282|DEVICE|gastrosoleus muscle complex vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the gastrosoleus muscle complex. LV application will be applied sequentially, bilaterally, to the gastrosoleus complex. LV will be applied before the exercises. LV will be applied for a total of 10 minutes (5 minutes each on the right and left) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
215094624|NCT03970616|DRUG|Durvalumab|1500mg every 28 days
214377174|NCT05885282|OTHER|Control Exercise|Lumbar spinal stabilization exerciseswill be given. Lumbar spinal stabilization exercises; Diaphragmatic breathing, and contraction of the transversus abdominis and multifidus muscles will be taught in the supine position. Activation of these muscles will be studied in different positions (prone, crawling, sitting, and sitting on different surfaces). The focus will be on increasing kinesthetic awareness. It will be desirable to ensure and maintain the activation of these muscles during subsequent exercises. Exercises will be continued according to the patient's functional status and individual needs. Advancement of exercises; extremity movements on dynamic surfaces, narrowing of support surfaces, reciprocal movements, increasing the number of resistance and repetitions. The duration of a session will be 40 minutes.
214377175|NCT03489057|BEHAVIORAL|Prostate Cancer Education and Resources for Couples (PERC)|PERC uses mHealth technologies to dramatically increase couples' accessibility to posttreatment supportive care whenever and wherever they feel comfortable accessing it. PERC aims to improve QOL for both patients and partners by enhancing positive appraisals of illness and boosting self-efficacy, social support from multiple sources, and healthy behaviors for symptom self-management at home.
214377176|NCT03489057|BEHAVIORAL|usual care plus NCI website|The usual care plus NCI website provides generic information about prostate cancer treatment options, research, causes, and statistics; coping resources that are not prostate cancer-specific; support from non-providers via a toll free phone and LiveHelp Online Chat about cancer-related questions, clinical trials, and quitting smoking.
214377177|NCT05869682|PROCEDURE|Bright White Light Therapy|Wear AYOpro BWL therapy
214377178|NCT05869682|DRUG|Combination Drug Therapy|Receive SOC ADT combination therapy
214377179|NCT05869682|OTHER|Electronic Health Record Review|Ancillary studies
214377180|NCT05869682|OTHER|Quality-of-Life Assessment|Ancillary studies
214377181|NCT05869682|OTHER|Questionnaire Administration|Ancillary studies
214377182|NCT03267680|DRUG|Cyclophosphamide|Given IV
214377183|NCT03267680|DRUG|Indomethacin|Given PO
214377184|NCT03267680|BIOLOGICAL|IRX-2|Given via submucosal injection or SC
214377185|NCT03267680|OTHER|Laboratory Biomarker Analysis|Correlative studies
214497113|NCT06765486|OTHER|Upper limb resistance training|Exercise intervention with brachial biceps curl on the dominant brachial biceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.
214497114|NCT06206252|OTHER|Medical Cannabis|Participants will be restricted to specific medical cannabis products from Ethos Dispensary. They will be randomized to one medical cannabis formulation (tincture or vaporization) for the duration of the study. Each month for three months, they will purchase a different composition (predominantly THC, predominantly CBD, or balanced products) of their designated formulation. The order of compositions will be randomized and double-blinded, so participants and the research team will not know which compositions of medical cannabis they are using each month.
214497115|NCT03718364|PROCEDURE|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
214377186|NCT03267680|DIETARY_SUPPLEMENT|Multivitamin|Given zinc-containing multivitamin PO
214377187|NCT03267680|DRUG|Omeprazole|Given PO
214377188|NCT03267680|OTHER|Placebo|Given via submucosal injections or SC
214377189|NCT03267680|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
214989963|NCT04335799|BEHAVIORAL|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics|12-month evidence based weight loss intervention with an attention control of general women's health topics
214989964|NCT05653843|DEVICE|Endoscopic clip placement in the gastrointestinal tract.|The placement of a mechanical endoscopic clip in the gastrointestinal tract.
214989965|NCT01582204|DRUG|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd \& pelvis), 124I-cG250-PET/CT \& Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan \& 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, \& pelvis with contrast after cycles 2, 3, 4 \& 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline \& week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, \& serial blood sampling, following the lst inj of 124I-cG250.
214377190|NCT06632704|DEVICE|Colgate Toothbrush assist|toothbrush handle assignment to all subjects; subjects will have a choice between two brush heads
214989966|NCT05881811|DRUG|HSK16149，probenecid, cimetidine|40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4
214377191|NCT04734548|DRUG|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
214377192|NCT04734548|OTHER|Placebo|White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
214377193|NCT03394521|OTHER|Routine clinical practice|This is an observational study
214377194|NCT05649644|PROCEDURE|Selective Trunk Block (SeTB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. After local anesthetic (LA) infiltration (1-2 ml lidocaine 1%), the nerve block needle will be inserted and placed within the interscalene groove. Then, a 7 ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. After that, the tip will be redirected lateral to the middle trunk. A further 8 ml of the LA mixture will be injected after which the nerve block needle will be completely withdrawn. The transducer will then be manipulated to a sub-omohyoid position. After LA infiltration, the nerve block needle is inserted in-plane until the needle tip is positioned close to and lateral to (9-12 o'clock position) the inferior trunk. A 10 ml of the LA mixture is injected in small aliquots and the needle will be removed after the injection.
214377195|NCT05649644|PROCEDURE|Supraclavicular Brachial Plexus Block (SC BPB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. Patient will receive a subcutaneous infiltration with 1-2 ml of 0.9% normal saline (NS) at the superior and middle trunk level after which the needle will be completely withdrawn. Then, a local anesthetic (LA) infiltration (1-2 ml lidocaine 1%) will then be performed at the supraclavicular fossa and the nerve block will be inserted in-plane to place the needle tip at the corner pocket. After that, 15-ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. Once completed, the needle tip is gently withdrawn and redirected into the cluster formed by the divisions of brachial plexus. Then, the remaining 10-ml of the same LA mixture will be injected in small aliquots and the needle will be removed after the injection.
214377196|NCT02030782|OTHER|Quality Improvement (QI) for depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
214377197|NCT02030782|OTHER|Usual Care|Usual care enhanced by provider education regarding depression evaluation and management
214989967|NCT02729233|OTHER|patients receiving biopsies|Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
214377198|NCT03551275|BIOLOGICAL|BCD-132|Dose Escalation Study
214377199|NCT00559299|DRUG|GSK163090|
214377200|NCT00324584|DEVICE|Telemonitoring of glucose values using GlucoNet device|
214377201|NCT01368900|DEVICE|Ulthera® System treatment|Focused ultrasound energy delivered below the surface of the skin.
214377202|NCT05171751|DRUG|Octreotide Injection|Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine
214377203|NCT01786902|DRUG|DA-3002|
214497116|NCT06547827|OTHER|robotic rehabilitation|"Treatment will occur in a gym equipped with devices for all the domains, with two physiotherapists supervising groups of 4 to 6 patients, depending on their clinical severity.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients."
214497117|NCT06547827|OTHER|traditional rehabilitation|"A physiotherapist-to-patient ratio of 1:1 is provided for the treatment in all participating centres.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients."
214989968|NCT05456672|OTHER|Test meals and food baskets|"Interventional dietary study using standardized test meals and personalized food baskets to investigate the impact of food combination on the glycemic response. The study period is organized as follows:~(Day 1: Continuous blood glucose monitoring system (CGM) activation) Days 2 and 3: Two standardized daily menus (breakfast, lunch, afternoon snack and dinner) provided on a randomized crossover basis.~Days 4 to 7: four standardized test meals, participants will be asked to substitute one meal each day (lunch or dinner) for a test meal according to a pre-defined randomization plan.~Days 8 to 10: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items.~Days 11 to 13: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items and following dietary recommendations developed by the study staff.~(Day 14: CGM sensor removed)"
214989969|NCT06307548|DRUG|Aminolevulinic Acid|Given PO
214989970|NCT06307548|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214989971|NCT06307548|PROCEDURE|Computed Tomography|Undergo CT
214989972|NCT06307548|PROCEDURE|Fluorescence-Guided Surgery|Undergo fluorescence-guided surgery
214989973|NCT06307548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214989974|NCT06307548|DRUG|Photodynamic Therapy|Undergo PDT
214989975|NCT06307548|PROCEDURE|Surgical Procedure|Undergo surgery
214989976|NCT05115929|PROCEDURE|Decompressive Laparotomy|As described in the study protocol a long midline laparotomy is performed and open abdomen therapy using negative pressure dressings initiated to lower abdominal pressure and thereby improve venous return from the brain to lower intracranial pressure.
214989977|NCT05115929|PROCEDURE|Decompressive Craniectomy|As described in the study protocol a sufficiently sized hemi-craniectomy is performed and the skin closed over the bony defect to allow cerebral swelling and thereby lower intracranial pressure.
214989978|NCT00302900|BEHAVIORAL|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
214989979|NCT00302900|BEHAVIORAL|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
214377204|NCT05478980|DIETARY_SUPPLEMENT|Night Time Tea|Night-time Tea
214377205|NCT05478980|DIETARY_SUPPLEMENT|Control Tea|Feel New Tea
214377206|NCT02201914|DRUG|Clomiphene citrate|patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection
214377207|NCT02201914|DRUG|Daily FSH and LH plus Cetrorelix|Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.
214989980|NCT00302900|BEHAVIORAL|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
214989981|NCT00911911|PROCEDURE|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
214989982|NCT00911911|PROCEDURE|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
214989983|NCT00911911|PROCEDURE|SURGERY|Surgery after neoadjuvant chemotherapy
214989984|NCT00924898|DRUG|efavirenz, emtricitabine, and tenofovir|Once daily ART with emtricitabine, tenofovir DF and efavirenz
214989985|NCT05253014|PROCEDURE|sphenopalatine ganglion block|block of the sphenopalatine ganglion using either lidocaine or bupivacaine to relief postdural puncture headache
214989986|NCT05253014|DRUG|paracetamol|intravenous paracetamol every 8 hours
214377208|NCT02201914|DRUG|Triptorelin plus daily FSH anh LH|women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.
214497118|NCT06533436|PROCEDURE|Corded tube care|The caregiver cut a 6 cm strip of Tensoplast® and wrapped it around the intubation probe at the level of the prescribed fixation mark at the corner of the mouth. The cord strands are placed around the patient's head, tightened, and a double knot is tied at the patient's cheek. Compresses are placed over the ears to protect them from possible lesions caused by the cords.
214497119|NCT06533436|DEVICE|Tube care attached by AnchorFast|"Shaving is recommended for patients with beards, and prior family consent is required for patients with beards.~AnchorFast is Suitable for intubation probes from 5 to 10 mm in diameter, it adapts to different morphologies thanks to hydrocolloid dressings bonded to the face and an adjustable cord around the neck. Due to its rigidity, this device is not recommended for patients whose condition requires them to be positioned in the ventral decubitus (VD) or lateral decubitus position."
214989987|NCT01285518|DRUG|PF-05231023|0.5 mg QD IV x 1 day
214377209|NCT05753787|OTHER|preservative-free solution of standard post-cataract eye drops|Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
214377210|NCT04027348|DRUG|Dexamethasone|Given IV
214497120|NCT06533436|OTHER|Caregiver's evaluation on each tube fixation|The caregivers who performs the interventions according to the study will fill question form to assess the worload and the confort of the tube care for each intervention type The caregivers are both a research actor and a study population. One of the secondary aims of this study is to evaluate the two types of tube-fixing with regard to caregiver workload and comfort in performing care. Caregivers will complete identical questionnaires assessing their satisfaction with the two types of tube fixation studied in arms 1 and 2.
214497121|NCT05189496|BEHAVIORAL|hyperbaric oxygen therapy|hyperbaric oxygen therapy
214497122|NCT06812195|DEVICE|Plate and nail|spinal anesthesia in supine position, lateral approach to the femur is used to do corrective osteotomies and introduction of nail according to preoperative plan. After that, plate is applied to lateral border to the femoral shaft
214497123|NCT04972097|DEVICE|Irreversible Electroporation|IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.
214497124|NCT05423145|BEHAVIORAL|self-administered acupressure|The acupressure intervention is self-administered. The intervention group receives an app that instructs them on how to perform a stimulating acupressure protocol, consisting of six acupoints with four of the acupoints performed on both the left and the right sides of the body for a total of ten points. Each of the ten acupoints is to be stimulated for 3 minutes per point for a total treatment time of 30 minutes daily for 6 weeks.
214497125|NCT06466798|DRUG|Nivolumab|Nivolumab infusions will be given intraventricularly once every other week for 12 weeks. Dosing will be based upon patient body weight.
214989988|NCT01285518|DRUG|PF-05231023|1.5 mg QD IV x 1 day
214989989|NCT01285518|DRUG|PF-05231023|5 mg QD IV x 1 day
214989990|NCT01285518|DRUG|PF-05231023|15 mg QD IV x 1 day
214989991|NCT01285518|DRUG|PF-05231023|50 mg QD IV x 1 day
214989992|NCT01285518|DRUG|PF-05231023|100 mg QD IV x 1 day
214989993|NCT01285518|DRUG|PF-05231023|200 mg QD IV x 1 day
214989994|NCT01285518|OTHER|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
214989995|NCT02991079|OTHER|Intervention group|"Smartphone with APP (EVIDENT) for 3 months, cardio-health rides and feeding workshop.~Counseling on physical activity and Mediterranean diet."
214989996|NCT02991079|OTHER|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
214989997|NCT01417169|DRUG|micafungin|Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting \<50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
214989998|NCT01830517|DRUG|Amlodipine, Losartan|
214377211|NCT04027348|DRUG|Metoclopramide|Given IV
214377212|NCT04027348|DRUG|Octreotide|Given IV
214377213|NCT03943966|DIAGNOSTIC_TEST|18F-GP1 PET CT|PET CT scan using platelet radiotracer 18F-GP1
214989999|NCT03747471|BEHAVIORAL|Diabetic Conversation Map|"Diabetic Conversation Map education tools are a series of tools for facilitated group education 5-8that were developed by Healthy Interactions in collaboration with the International Diabetes Federation (IDF) and are sponsored by Lilly Diabetes.~CM-based education guides people with diabetes through a process with the aim of helping them understand and internalize information about their disease and generate insightful conclusions, which may then result in improved self-management decisions and actions."
214990000|NCT00199173|DEVICE|SIR Spheres intra-arterial hepatic|
215094625|NCT06213285|DEVICE|Watchman FLX left atrial appendage occlusion|Early (30-120 days) CT follow-up after Watchman FLX LAAO
214377214|NCT02701127|DRUG|Oral niacinamide, 1 gram daily|
214377215|NCT02701127|DRUG|Oral niacinamide, 3 gram daily|
214377216|NCT02701127|DRUG|Placebo|
214990001|NCT02474641|RADIATION|Standard Radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
214377217|NCT04737902|PROCEDURE|Erector spinae plane block|Unilateral ESP block was performed between T3 and T7 levels depending on the thoracic surgical incision. The patient is placed in lateral decubitus position, under sterile conditions, a high frequency (6-15 MHz) linear-array transducer (Sonosite® Edge II, Bothell, USA) was placed in a longitudinal parasagittal orientation 2 cm from the posterior midline to visualise the tips of the transverse processes deep to the erector spinae muscle (ESM). A 21 G, 50 mm or 100 mm needle (Pajunk UniPlex NanoLine; Germany) was advanced in-plane with the ultrasound beam. The needle tip was directed to the plane between the transverse process and the posterior fascia of the ESM. Correct needle tip location was confirmed by ultrasound visualisation of linear fluid spread in the fascial plane. The injection of 0.5 to 1 ml of bupivacaine was 0.5% with epinephrine 5 µg/ml; then, a total of 20-30 ml of the same local anaesthetic was administered.
214377218|NCT04859634|DEVICE|Taking an ultra-widefield fundus image|The participant only needs to take an ultra-widefield fundus image as usual.
214377219|NCT00283920|DRUG|[(11)C] PBR28|
214377220|NCT03209141|DIAGNOSTIC_TEST|Diastolic function evaluation|Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
214377221|NCT01686880|DEVICE|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
214377222|NCT02076984|PROCEDURE|Laparoscopic incisional or ventral hernia repair|
214377223|NCT03075059|BEHAVIORAL|Child Life|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
214377224|NCT04747730|OTHER|Transcendental Meditation training|The programme targets inmates in HMP Warren Hill who are eligible to learn the meditation technique, who are staying in prison for at least six months since the beginning of the programme and who provide the signed informed consent. The sample of eligible inmates is approximately 190 inmates out of 250 currently in the prison. Inmates will be contacted by the research team in prison during introductory sessions of the research intervention.
214377225|NCT02487472|OTHER|Data collection|Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
214377226|NCT05962710|DEVICE|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
214377227|NCT01093144|DEVICE|pelvic measurements using the LaborPro Device|pelvic measurements using the LaborPro Device,ultrasound non invasive measurements
214377228|NCT02277743|DRUG|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
214990002|NCT02474641|RADIATION|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
214377229|NCT02277743|DRUG|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
214377230|NCT04505501|DRUG|N-803|N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.
214377231|NCT04654988|DRUG|Prednisone|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months
214377232|NCT04654988|DRUG|Azathioprine|Azathioprine: 2 mg/kg daily for 12 months
214377233|NCT04654988|DRUG|Placebo Prednisone|Placebo Prednisone
214377234|NCT04654988|DRUG|Placebo Azathioprine|Placebo Azathioprine
214377235|NCT01224158|DEVICE|Experimental Power Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day with the experimental toothbrush and toothpaste provided) moving to the next quadrant of the mouth at 30-second intervals.
214377236|NCT01224158|DEVICE|Flat trimmed Manual Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day using the toothbrush and toothpaste provided) in their usual manner.
214377237|NCT03785067|DRUG|telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg|1 capsule taken orally once daily for 36 months
214990003|NCT04194632|PROCEDURE|Temporary right ventricular pacing|As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
215090948|NCT05332275|BEHAVIORAL|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and followup to address potential contamination effects across study arms.
215090949|NCT06108830|DRUG|Esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
214377238|NCT03785067|DRUG|Placebo oral capsule|1 capsule taken orally once daily for 36 months
214377239|NCT05598242|BIOLOGICAL|Amniotic membrane extract eye drops (AMEED)|Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.
215090950|NCT06108830|DRUG|Remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
214377240|NCT01622010|BEHAVIORAL|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
214377241|NCT01622010|OTHER|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
214377242|NCT01622010|DEVICE|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
214377243|NCT01674374|OTHER|placebo|Given PO
214377244|NCT01674374|PROCEDURE|quality-of-life assessment|Ancillary studies
214377245|NCT01674374|OTHER|questionnaire administration|Ancillary studies
214377246|NCT01674374|DRUG|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules|Given PO
214377247|NCT02055157|DRUG|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
214497126|NCT06466798|DRUG|Methotrexate|2 mg methotrexate infusions will be given intraventricularly daily for 4 consecutive days per week every other week for 12 weeks.
214497127|NCT06466798|DRUG|5-Azacytidine|10 mg 5-Azacytidine infusions will be given intraventricularly once weekly for twelve consecutive weeks.
214377248|NCT03976466|DEVICE|Antibiotic local prophylaxis with medicated calcium sulfate beads|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
214377249|NCT03976466|PROCEDURE|Classical parenteral antibiotic prophylaxis|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
214377250|NCT03817138|OTHER|Exposures: Markers of disease progression|From early phases of the study, it is expected that six main domains will be assessed which will include over N=100 potential markers reflecting different markers of dementia disease progression identifiable from patients' primary care EHR.
214377251|NCT00733499|DEVICE|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
214377252|NCT00733499|DEVICE|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
214377253|NCT06405399|OTHER|Educational intervention. observation guide|An observation checklist based on the Lasater Clinical Judgment Rubric (LCJR) was created and adapted to the simulated clinical experience in order to address the learning outcomes to be achieved by nursing students. This resulted in a list of forty items divided into four main groups: patient safety (8 items), communication and relationship with the patient (7 items), teamwork (7 items) and technical skills (18 items).
214377254|NCT03809364|BEHAVIORAL|START Together|Behavioral intervention using a cognitive behavioral couple therapy (CBCT) framework designed to improve the couple's communication and problem-solving behavior.
214377255|NCT03177122|DRUG|Myo-inositol|Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
214497128|NCT02659293|DRUG|Lenalidomide|"* Cycle 1: 15 mg days 1-21~* Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~* Cycles 5 and beyond: best tolerated dose days 1-21"
214990004|NCT01242982|PROCEDURE|Closed reduction and fixation with 2 pins|Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months
214990005|NCT01242982|PROCEDURE|Reduction and Plaster of Paris|Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
214990006|NCT01471990|DRUG|Pituitary Adenylate Cyclase-Activating Polypeptide-38|10 pmol/kg/min over 20 mins
214990007|NCT01471990|DRUG|Vasoactive Intestinal Peptide|8 pmol/kg/min over 20 mins
214990008|NCT05406089|OTHER|Medication history|The study was retrospective and did not involve the application of interventions
214990009|NCT00294658|PROCEDURE|thymectomy plus prednisone|The thymectomy will be performed as soon as possible after randomization.
214990010|NCT00294658|DRUG|prednisone alone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
214990011|NCT00836108|BEHAVIORAL|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
214990012|NCT02726347|BIOLOGICAL|PPV-23|one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
214990013|NCT01500980|BIOLOGICAL|P. falciparum infection|P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
214990014|NCT01500980|DRUG|Chloroquine|Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
214990015|NCT01500980|DRUG|Primaquine|Primaquine (45 mg) on day 2 or 3 post ITV infection
214377256|NCT02897908|PROCEDURE|vibration controlled transient elastography (VCTE)|Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.
214377257|NCT05995626|DRUG|Hyaluronidase|Hyaluronidase injection is used during fluid administration under the skin to help achieve hydration, to increase the dispersion and absorption of other injected drugs, or during some types of urography (imaging of the urinary tract) to help improve resorption of drugs used during the procedure.
214990016|NCT01500980|DRUG|Primaquine|Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
214990017|NCT00570947|OTHER|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
214990018|NCT00581191|DRUG|SLV-351|SLV-351 capsules taken once
214990019|NCT03805841|DRUG|tarloxotinib bromide|weekly intravenous infusion
214990020|NCT02815761|OTHER|NO intervention, just observation|No intervention.
214990021|NCT01584934|DRUG|Sodium oxybate|Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
214990022|NCT01584934|DRUG|Placebo|Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
214497129|NCT02659293|DRUG|Carfilzomib|"* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~* Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~* Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16"
214497130|NCT02659293|DRUG|Dexamethasone|"* Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~* Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22"
214990023|NCT01643213|DEVICE|Non Boston Scientific SCS Trial Therapy|No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain
214990024|NCT01643213|DEVICE|BSC approved SCS Trial Therapy w/ OMG|No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain
214990025|NCT06208501|DIAGNOSTIC_TEST|Urine sample for proteomic analysis|Urine sample for proteomic analysis in screen visit (before renal denervation procedure).
214990026|NCT06208501|DIAGNOSTIC_TEST|ABPM|ABPM in screen visit and 3 months after renal denervation procedure.
214990027|NCT06208501|DIAGNOSTIC_TEST|OBPM|OBPM in screen visit and 3 months after renal denervation procedure.
214990028|NCT04224116|DRUG|Tranexamic acid injection|to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
214990029|NCT04224116|DRUG|SSI|Serum Salin isotonic injected
214990030|NCT00063453|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (400 IU/day all rac-α-tocopheryl acetate)
214990031|NCT00063453|DIETARY_SUPPLEMENT|Selenium|selenium (200 μg/d L-selenomethionine)
214990032|NCT00063453|DIETARY_SUPPLEMENT|Vitamin E placebo|placebo
214990033|NCT00063453|DIETARY_SUPPLEMENT|Selenium placebo|placebo
214990034|NCT03077217|DRUG|Rifaximin|The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy
214990035|NCT00262379|DRUG|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
214990036|NCT00846365|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
214990037|NCT00846365|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
214990038|NCT00846365|DRUG|Olmesartan medoxomil-hydrochlorothiazide|"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
214990039|NCT05623527|DEVICE|cardiac electronic implants|Cardiac electronic implants(CIED) includes permanent pacemaker (PPM), implantable cardioverter defibrillator (ICD), three-chamber pacemaker for cardiac resynchronization therapy defibrillator, lead free pacemaker, etc.
215090951|NCT06108830|DRUG|Esketamine and remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
214377258|NCT05995626|DEVICE|CO2 laser|CO2 lasers use an aiming beam to see where the treatment beam will impact the focus tissue, which will then be cleanly incised. The CO2 lasers have greater precision for laser surgery and have more flexibility in tip sizes and protocols.
214377259|NCT06501898|DIETARY_SUPPLEMENT|CoreBiome|300 mg, once daily of tributyrin for 4 weeks
214377260|NCT06501898|DIETARY_SUPPLEMENT|Placebo|300 mg, once daily of placebo for 4 weeks
214990040|NCT03795948|OTHER|PROMs|"Introduction and assessment of the ICHOM standard set consisting of demographic and medical data as well as questionnaires filled in by patients, shortly after admission to the stroke unit, at discharge, and at 90 and 360 days after stroke.~Specifically the intervention includes an assembly of clinical records, in particular records of complications, recurrence of disease and mortality. Further patients will be required to complete a questionnaire assessing their situation in terms of housing and symptom burden as well as their self-perceived autonomy and quality of life.~Telephone assessments will be administered to support patients if necessary and validate their responses."
214377261|NCT00967382|DRUG|dalteparin sodium|"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
214377262|NCT00177203|BEHAVIORAL|Brief Behavioral Treatment of Insomnia or Information|"The behavioral treatment involves education about sleep and its disorders; habits that help and hurt sleep; and recommendations about sleep hours and time in bed. It involves two meetings with a nurse who is part of the research team.~In the information condition, participants are given similar information in printed brochures that are published by the American Academy of Sleep Medicine. They are instructed to read the information."
214377263|NCT02218879|DRUG|Tecfidera|Oral Tecfidera 240 mg bid
214377264|NCT05782257|DIETARY_SUPPLEMENT|Zinc Supplementation|Take one 25mg Zn gluconate tablet daily
214377265|NCT05782257|OTHER|Zn-Optimized Diet|Consume 11 mg/day of zinc-rich foods for females and 14 mg/day in males.
214377266|NCT03455322|DRUG|norepinephrine versus midodrine & octreotide|either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6h.
214990041|NCT04583501|BIOLOGICAL|Omalizumab|Omalizumab will used as dose comparable to to 0.016 mg/kg/IU in serum.
214990042|NCT05079971|DIAGNOSTIC_TEST|Group B: aEEG with concurrent multichannel (full) continuous cEEG review by clinical neurophysiology|In group B, the standart-care equivalent aEEG review is undertaken by NICU staff via a 2-channel display. In addition to the standard care, concurrent full EEG is reviewed remotely with regular feedback by a specialist trained clinical neurophysiologist. The clinical neurophysiology reports only on seizure burden, no information or direction is provided regarding clinical management.
215090952|NCT06108830|DRUG|normal saline|Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
214377267|NCT01552954|BEHAVIORAL|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
214377268|NCT03929562|BEHAVIORAL|Brief advice|One 10-minute brief advice session
214377269|NCT03929562|BEHAVIORAL|Health coaching|Two 45-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
214377270|NCT00516464|DRUG|Lucentis (ranibizumab)|
214377271|NCT01265901|DRUG|Sunitinib|As per label.
214377272|NCT01265901|BIOLOGICAL|GM-CSF|Intradermal injection of GM-CSF as adjuvant.
214377273|NCT01265901|DRUG|Cyclophosphamide|One single low-dose i.v. infusion prior to the first vaccination
214377274|NCT01265901|DRUG|IMA901|Intradermal vaccinations with IMA901 vaccine.
215090953|NCT06973811|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
215090954|NCT06973811|DRUG|Rituximab (R)|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
215090955|NCT06973811|DRUG|Zanubrutinib|160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
214377275|NCT03119727|DEVICE|FreeO2|All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
214377276|NCT04843930|DEVICE|AKL-T01|AKL-T01 will be administered as a 6-week intervention. It is an algorithmically delivered iPad-based video game designed to improve cognitive health by targeting attention and attentional control processes.
214497131|NCT02659293|DRUG|Lenalidomide (Control)|"* Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~* Cycles 5 and beyond: best tolerated dose days 1-28"
214990043|NCT02629770|DRUG|usual antibiotic treatment|pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
214990044|NCT04337788|OTHER|telehealth applications|telehealth applications during 30 days/patient
214990045|NCT03654417|DRUG|EMLA|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
214990046|NCT03654417|DRUG|Lidocaine|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
214990047|NCT04270461|BIOLOGICAL|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
214990048|NCT01047449|PROCEDURE|No-touch SVG harvest vs conventional SVG harvest technique|Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)
214990049|NCT01047449|DIETARY_SUPPLEMENT|Fish oil supplementation vs placebo|Fish oil supplementation \[1g tablets (55% fish oils - EPA:DHA 33%:22%)\] taken twice daily for 1 year post-op
214990050|NCT02937441|OTHER|Ultrasonic Measurement|"How we measure;~1. First measurement shall be taken in 4 hours.~2. Second measurement shall be taken at 12 hours in mild and 12-18 hours measurement shall be taken for severe diabetic ketoacidosis,~3. Third measurement shall be taken after fluid treatment.~4. Fourth measurement shall be taken at patients polyclinic control."
214990051|NCT00404313|DRUG|MK0633|Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
214990052|NCT00404313|DRUG|Comparator: placebo|Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
214990053|NCT01134666|DRUG|Cetuximab|FOLFOX Oxaliplatin 100 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 FOLFIRI Irinotecan 180 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 CETUXIMAB Cetuximab administered at loading dose of 400 mg/m2/week over 120 min followed by maintenance dose of 250 mg/m2/ week over 60 min, till disease progression or dose limiting toxicity
214990054|NCT00146471|DRUG|Levetiracetam|1500-2000 mg daily add-on or Placebo Diazepam as needed
214497132|NCT06749509|OTHER|Face-to-face musculoskeletal rehabilitation|Kela's rehabilitation course for those with MSD includes two 5-day periods and one 3-day period of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation center over a 9-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation course is group-based and provided free of charge. The 9-month rehabilitation period also includes calls to the participants before and after rehabilitation. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A medical statement is required when applying for the rehabilitation course.
214990055|NCT00146471|DRUG|Placebo|1500-2000 mg daily add-on or Placebo Diazepam as needed
214497133|NCT06749509|OTHER|Musculoskeletal telerehabilitation|Kela´s MSD telerehabilitation course is arranged entirely as telerehabilitation, and it includes videoconferencing, online rehabilitation, and group-based rehabilitation days implemented by a multidisciplinary team of rehabilitation experts. Participation does not require particular IT skills, but appropriate equipment (e.g., mobile phone, laptop, tablet computer) is needed. The rehabilitation course is free of charge, and the total duration, including the calls before and after rehabilitation, is approximately 7 months. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A physiotherapist's recommendation is required when applying for the telerehabilitation course
214990056|NCT00862992|DRUG|Cariprazine 3 mg|
214990057|NCT00862992|DRUG|Cariprazine 6 mg|
214990058|NCT00862992|DRUG|Cariprazine 12.5 mg|
214990059|NCT02912936|DIETARY_SUPPLEMENT|Ketogenic medium chain triglyceride drink (MCT drink)|10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
214990060|NCT02912936|DIETARY_SUPPLEMENT|Placebo|10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
214990061|NCT02094040|BEHAVIORAL|Receive municipality-based follow-up visit|Systematic electronic referral from hospital to municipality of high risk people at discharge from a medical ward. Contact from municipality service to primary physician and citizen, to arrange first home visit within 7 days with focus on: medication, rehabilitation plan and health care appointments, functional level and need for further health care initiatives. The visit is concluded by planning of further visits (up till tree) and division of responsibilities between primary physician and the municipality service.
214990062|NCT02872441|BIOLOGICAL|blood sample|One blood sample of 50 milliliter 24 hours after the inclusion
214990063|NCT03704740|BIOLOGICAL|NBP607-QIV|Purified inactivated influenza virus surface antigens of four strains (quadrivalent)
214990064|NCT03704740|BIOLOGICAL|Agrippal|Influenza virus surface antigens of three strains (trivalent)
214990065|NCT06381232|OTHER|No Intervention|This is an observational study, there are no interventions.
214990066|NCT02688790|DRUG|Dalbavancin|
215090956|NCT06973811|DRUG|Methotrexate (MTX)|Methotrexate 3.5g/m2 intravenous infusion d1, every 21 days for cycle 5 and 6 only.
215090957|NCT06966791|OTHER|No intervention will be performed as part of this study. However, regardless of the study, all participants will have breast cancer surgery|No intervention will be performed as part of this study. However, regardless of the study, all participants will have breast cancer surgery and other breast cancer treatments.
215090958|NCT03714503|DEVICE|Retina re-attachment repair using C3F8 gas tamponade|Assigning a one day post-operative head positioning
215090959|NCT05644041|DRUG|gemcitabine + docetaxel|The study drugs, Gemcitabine and Docetaxel, will be administered intravesically at 1000 mg and 40 mg, respectively.
215090960|NCT04979910|DRUG|Ixekizumab|a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
214990067|NCT03164824|OTHER|questionnaire|"Cross-cultural adaptation stage:~The FRI was cross-culturally adapted to Thai (called the Thai FRI) and the pre-final version of the Thai FRI was administered to patients.~Psychometric properties testing stage:~The questionnaires were administered 3 times: the first visit, the second visit and at 2 weeks.~At the first visit: the patients with back pain completed the Thai FRI , Thai Roland-Morris Disability (Thai RM), Thai modified Oswestry Low Back Pain Disability (Thai modified ODQ), Thai multi-level Roland-Morris Disability (Thai multi-level RM). The patients with neck pain completed the Thai FRI and Thai Neck Disability Index.~At the second visit: all patients completed the Thai FRI and Global Perceived Effect Scale (GPES).~At 2 weeks: the patients completed the same questionnaires as the first visit. All patients and their treating physical therapists completed the GPES."
214377277|NCT01970605|PROCEDURE|Surgical reconstruction|"In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.~Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.~Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible."
214377278|NCT03042598|DEVICE|Biphasic Cuirass Ventilation|The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.
214377279|NCT04391946|BEHAVIORAL|Data registry|Collection of clinical data, treatment regimens and survival data
214377280|NCT01599923|BIOLOGICAL|Antivenin Centruroides (scorpion) equine immune F(ab')2|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
214377281|NCT01355601|OTHER|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
214497134|NCT06749509|OTHER|Controls|The control participants have an MSD diagnosis and musculoskeletal symptoms. Based on an occupational physiotherapist's brief evaluation they are eligible to apply for Kela's musculoskeletal rehabilitation (the interventions below). By them own choice, however, they will not participate in these rehabilitation programs in the near future. The controls are recruited via two occupational health care producers in the private sector.
214497135|NCT06777277|OTHER|Cognitive-behavioral therapy|The intervention will be delivered in 16, 60-minute sessions (1st session 90 mins). The treatment manual was informed by a 12-session (75 min each) CBCT developed by our team for genito-pelvic pain. The SIAD manual focuses on empirically supported interpersonal factors relevant to SIAD, informed by the Interpersonal Emotion Regulation Model of women's sexual dysfunction. The goals of the CBCT are to: (1) re-conceptualize low sexual desire/arousal as multidimensional in which both partners affect and are affected by the SIAD symptoms (2) modify and/or accept those factors that are associated with low sexual desire/arousal to increase adaptive coping, facilitate sexual desire/arousal, and reduce sexual distress, (3) as per our theoretical model, improve couple interactions related to sexuality (e.g., communication, intimacy) via enhanced emotion regulation, and (4) consolidate skills.
214497136|NCT04282356|DRUG|Intraperitoneal chemotherapy during surgery|During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
214497137|NCT05637177|BEHAVIORAL|Anging Wisely|The program includes 11 meetings of two hours in a group of up to eight people. The sessions are held weekly. Each lesson is given a homework assignment. A total of 10 groups will take place.
214497138|NCT05637177|BEHAVIORAL|Music therapy|Music therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 12. A total of 10 groups will be implemented.
214990068|NCT03922373|DRUG|Group A: Benzonatate 100mg|Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
214990069|NCT03922373|DRUG|Group B: Benzonatate 200mg|Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
214377282|NCT01355601|OTHER|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
214990070|NCT03922373|DRUG|Group C: Benzonatate 400mg|Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
214990071|NCT01009567|DRUG|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
214990072|NCT01009567|DRUG|Control|Receive human albumin 20% infusion
214990073|NCT02692079|PROCEDURE|T-PRF|Flap Surgery
214990074|NCT02692079|PROCEDURE|Allograft|Flap Surgery
214990075|NCT01093508|DRUG|APD916|
214990076|NCT04626076|OTHER|Comparative Observational Cohort Study|This is a comparative observational cohort study; therefore, no preventive interventions, visits or laboratory tests are mandated. Dosing and duration of potential prophylactic treatment is at the discretion of the institution and/or healthcare provider, in accordance with regular local practice. However, serology testing for SARS-CoV-2 antibodies will be offered to the first 50% of participating HCWs per country, at enrollment and at the last follow-up (i.e. at Week 12)
214990077|NCT05046704|DEVICE|peripartum transperineal Ultrasound|The anovaginal distance (AVD) will be measured by transperineal ultrasound ,The distance between the anal edge of the internal sphincter and the probe will then be measured in millimeters The ultrasound assessment of the anal sphincters at rest and during contraction will be performed postnatally using a dynamic 2-dimensional transperineal ultrasound with the patient in a supine position, an empty bladder.
215090961|NCT06366230|DRUG|Urea in the dialysate|Adding urea to the dialysis fluid. Ure-Na 15 grams would be used. It would be added to the acid component of the dialysis fluid. The amount added would depend on the serum BUN concentration and is determined by a simple calculation. It would be available in powder form. Urea would be added just to the first 1-3 dialysis treatments as needed.
214377283|NCT03655925|DIAGNOSTIC_TEST|plasmatic HLA-G|plasmatic HLA-G by blood sample
214377284|NCT00223626|DRUG|Topiramate|the maximum topiramate test dose is 200 mg/d.
214377285|NCT00545961|DRUG|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
214990078|NCT01811719|BEHAVIORAL|Enhanced NFP (NFP+)|Women in the experimental group received three possible interventions. First they received regular and periodic structured intimate partner violence (IPV) assessments from their nurse. Those who indicted any IPV - whether physical violence or emotional abuse or controlling behavior - were then given the Parker-McFarlane Brochure Intervention. Finally, all women were provided the Markman and Stanley Within My Reach curriculum according to their needs and interests.
214990079|NCT01811719|BEHAVIORAL|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
214377286|NCT00545961|DRUG|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
214497139|NCT05637177|BEHAVIORAL|Reminiscence therapy|Reminiscence therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 10. A total of 5 groups will be implemented.
214990080|NCT02538991|DEVICE|Bulkamid|"Urethral injections will be performed policlinically under local anesthesia (10 ml lidocain, two injections on both sides of the urethra). The Bulkamid-injections will be transurethral four injections (0.2 - 1ml) in locations ten, two and five and seven o'clock within 0.5 to 1 cm from the bladder - urethra junction.~Additional injections will be avoided and can be injected only if the first injections fail. After the operation the patient urinates to empty the bladder. The PVR is checked after the treatment with ultrasound simultaneously with evaluation of stability of the Bulkamid-injections. The treatment will be photographed as before and after still pictures for later evaluation."
214990081|NCT02538991|DEVICE|Tension-free Vaginal Tape|TVT will be performed under local anesthesia (70 - 100 ml 0.25% prilocain cum epinephrine) with i.v. pain medication phentanyl two doses and more on request. Operation will be performed with TVT-Exact® kit. Operation can be performed policlinically or in an operation theatre depending on the patient's medical condition. Cystoscopy will be performed after the set of tapes. A cough stress test with 250 to 300 ml bladder fulfillment will show the right tension of the tape. Before the operation a prophylactic antibiotic of Cefuroxime 1.5 g i.v will be given (Dalacin 900 mg i.v in cases of allergy to penicillin). The patient can go home after 2 to 4 hours follow-up, when PVR is under 150 ml. A sick leave of 5 days is recommended.
215090962|NCT04030962|DRUG|AGN-242428|Ophthalmic solution administered as a topical eye drop
215090963|NCT04030962|DRUG|AGN-231868|Ophthalmic solution administered as a topical eye drop
214990082|NCT05987384|DIETARY_SUPPLEMENT|Arachidonic acid|D3 ARA group will receive ARA capsules from the third day of the study. D6 ARA group will receive ARA capsules from the sixth day of the study
214497140|NCT05637177|BEHAVIORAL|Cognitive training|"Intervention cognitive training will take place once a week for 45 minutes for 20 weeks. Seniors can choose from two options: 1. group training full-time or home training (online) using the comprehensive training program MENTEM."
214497141|NCT05637177|BEHAVIORAL|Educational activities|Interventions in educational activities will run for one academic year. In total, seniors will attend 16 lectures in each educational module. The lectures will run 1 x 14 days for 90 minutes.
214497142|NCT04440735|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
214990083|NCT05987384|DIETARY_SUPPLEMENT|Sunflower oil|The placebo group and D6 ARA group will receive sunflower oil capsules from the third day of the study. D6 ARA group will stop receiving sunflower oil capsules from the fifth day of the study.
214377287|NCT01931735|PROCEDURE|Randomized Meniscectomy|Arthroscopic meniscectomy
214377288|NCT01931735|PROCEDURE|Randomized Lavage|Arthroscopic Lavage
214497143|NCT04440735|BIOLOGICAL|Atezolizumab|Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
214497144|NCT06778408|RADIATION|Hybrid Palliative Radiation Therapy|Hybrid Palliative Radiation Therapy will be administered to all patients.
214990084|NCT05987384|BIOLOGICAL|Rabies Vaccine (Vero Cell) for Human Use|Every participant will receive three doses of rabies vaccination.
214990085|NCT00430326|DRUG|Avotermin|
214990086|NCT04270877|DRUG|Naltrexone Pill|Treatment with LDN for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
215090964|NCT04030962|OTHER|AGN-242428 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
215090965|NCT04030962|OTHER|AGN-231868 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
215090966|NCT04030962|DRUG|Lifitegrast 5% Ophthalmic Solution|Ophthalmic solution administered as a topical eye drop
215090967|NCT06976255|BEHAVIORAL|Cinnamon sugar|In the 2nd and 3rd month of the study, the participants were asked to eat 1 g of cinnamon candies 3 times a day for a total of 4 days, three days before the menstrual cycle and the first day of menstruation.
215090968|NCT06976255|BEHAVIORAL|Dark chocolate|In the 2nd and 3rd month of the study, they were asked to eat 40 mg of 60% cocoa dark chocolate daily for a total of 4 days, three days before the menstrual cycle and the first day of menstruation.
215090969|NCT06975137|BEHAVIORAL|Zithandani Stepping Stones and Creating Futures|Delivered to heterosexual couples. 14 group based sessions, with each session lasting approximately 3 hours. Sessions are delivered by two trained facilitators. Intervention focused on transforming gender norms, strengthening communication, reducing symptoms of poor mental health and improving relationship dynamics. Mixture of couples focused, same-gender discussions, and whole group discussions.
215090970|NCT04023227|DRUG|Sacubitril/valsartan|50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.
214377289|NCT01931735|PROCEDURE|Standard of Care Meniscectomy Pre-Amend|Arthroscopic meniscectomy
214377290|NCT01931735|PROCEDURE|Standard of Care Meniscectomy Post-Amend|Arthroscopic meniscectomy
214377291|NCT04786379|PROCEDURE|Arthroscopic Irrigation and Debridement|Patients with confirmed septic arthritis treated with multiple small incisions to perform irrigation and debridement with partial synovectomy.
214377292|NCT04786379|PROCEDURE|Open Arthrotomy with irrigation and debridement|Patients with confirmed septic arthritis treated with a single large incision, open arthrotomy to perform irrigation and debridement with partial synovectomy.
214990087|NCT04270877|DRUG|Placebo oral tablet|Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
214990088|NCT03004040|BIOLOGICAL|Flu Vaccine|
214990089|NCT02428400|BIOLOGICAL|TG1050|TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
214990090|NCT02428400|BIOLOGICAL|Placebo|Placebo: adenovirus reference material (ARM) buffer
214990091|NCT03100747|PROCEDURE|Bilamellar 3 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3 mm from the eyelid margin
214990092|NCT03100747|PROCEDURE|Bilamellar 5 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5 mm from the eyelid margin
214990093|NCT03100747|PROCEDURE|Trabut 3 mm|Trichiasis surgery using Trabut procedure with incision 3 mm from the eyelid margin
214990094|NCT05475145|PROCEDURE|Resin based sealing [RBS]|
214990095|NCT00374478|DRUG|Scopolamine|
214990096|NCT02072200|DRUG|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
214990097|NCT03332615|BEHAVIORAL|Motivational Interviewing|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
214990098|NCT03332615|BEHAVIORAL|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
214990099|NCT03513419|BEHAVIORAL|The AMOR Method|The parent resilience training involves a series of eight weekly 90-minute group sessions with up to 8 parents of young children with ASD (4- 10:11 years old) per group, as well as three individual sessions.
214990100|NCT05545917|OTHER|Experimental: APP care|The experimental arm will receive advanced physiotherapy care (APP) care. Patients will be independently managed (assessment and intervention) by a PT. The PT will make a diagnosis and initiate an intervention plan (e.g. education and exercise). If relevant, the PT will make recommendations for medical imaging tests or medication. PTs will also recommend the proper discharge from the emergency department (ED), such as hospitalization, discharge without medical consultation/follow-up or discharge with a medical follow-up or rehabilitation in an outpatient setting.
215090971|NCT04023227|DRUG|Enalapril|5 mg and 10 mg will be available for dose adjustments.
215090972|NCT06017258|BIOLOGICAL|CD371-specific/YSNVz/I-18 CAR T cells|Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.
214990101|NCT05545917|OTHER|Control - Usual physician care|The control arm will receive usual ED physician care delivered only by an ED physician. This will include independent assessment, treatment and discharge by an ED physician with no physiotherapy within the ED but physician's referral to outpatient physiotherapy or other professionals/medical specialists will be possible; overall care offered by the ED physician will not be standardized but will be systematically documented.
214990102|NCT03199105|OTHER|Preoperative education with image illustrations and/or local tetracaine mucilage|The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
214990103|NCT03112551|DRUG|Adminstration of magnesium Sulphate for treatment of eclampsia|A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).
214990104|NCT00658619|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
214990105|NCT00658619|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
214990106|NCT00658619|OTHER|Sham (no implant)|Sham in one or both eyes on Day 1 and Month 6.
214990107|NCT06403371|OTHER|Fluoride varnsh|Fluoride varnish was applied to the teeth surfaces before aligner therapy
214990108|NCT06403371|OTHER|Normal saline|Normal saline was applied to the teeth surfaces before aligner therapy
214990109|NCT01977833|OTHER|High Calorie Breakfast (BTdiet)|High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
214990110|NCT01977833|OTHER|High Caloric Dinner (DTdiet)|High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
214990111|NCT03443297|OTHER|breast milk|Feeding with breast milk will be started in early feeding group from 24 to 48 hours of age or in late feeding group, from 48 to 72 hours of age. Initially 4 hourly feeding will be started with 0.5ml and 1 ml expressed breast milk in babies with birth weight \<1200 grams and \>1200 grams respectively. gradually volume of milk should be increased
214990112|NCT06055374|DRUG|BxC-I17e|Pharmaceutical form : solution for injection
214990113|NCT06055374|DRUG|Placebo|Pharmaceutical form : solution for injection
214990114|NCT03261193|DRUG|ITM + Sham QLB|Sham subcutaneous non-anesthetic infiltration with saline
214990115|NCT03261193|DRUG|ITM + Bupivacaine QLB|QL plane block with local anesthesia
215090973|NCT05394064|GENETIC|SBT101|SBT101 Treatment
215090974|NCT05394064|PROCEDURE|Imitation Procedure|Procedure that mimics SBT101 infusion, but contains no drug administered
215090975|NCT05487885|DEVICE|Continuous theta burst stimulation (cTBS)|a form of transcranial magnetic stimulation, to dorsomedial prefrontal cortex (dmPFC)
214377293|NCT05732792|OTHER|CIPS Survey|"The survey is endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) and will be distributed from February 2023 onwards to its members for a period of 3 months.~Each anesthesiologist's participation to the survey will be voluntary and anonymous individual consent will be implied by the person's willingness to complete the survey.~The survey will also mention this.~All surveys will be administered via SurveyMonkey. Surveymonkey allows to build Health Insurance Portability and Accountability Act (HIPAA) compliant surveys that follow strict rules around the protection of health information.~Of note, Surveymonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored on the surveymonkey database. The access to the result database is held by a password that only the authors can use to analyze the data yielded at the end of the survey period."
214377294|NCT05957926|PROCEDURE|hyaluronic acid added to hydroxyapetite|"1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite with hyaluronic acid will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
214377295|NCT05957926|PROCEDURE|Hydroxyapatite alone|"1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
214377296|NCT00947661|DRUG|SPARC0912|Eye drops, once daily, 12 weeks
214497145|NCT06767163|DEVICE|iBalance|"Participants will engage in the device test, clinical assessment tests. The whole test will last twelve months, and the outcome will be assessed pre- and post-implementation for comparison and validation.~The intervention results are used to compared with traditional tests and clinical diagnosis, to identify whether the sensor provides a higher accuracy in predicting fall risk, and to explore the feasibility of the sensor in clinical scenarios."
214990116|NCT00000552|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
214990117|NCT00000552|PROCEDURE|coronary artery bypass|
214990118|NCT00000552|DRUG|thrombolytic therapy|
214990119|NCT04913922|DRUG|Azacitidine Injection|s.c. 75 mg/m2 BSA for 7 days
214990120|NCT04913922|DRUG|Nivolumab|480 mg i.v.
215090976|NCT05487885|BEHAVIORAL|Positive Affect Training|Psychosocial add-on intervention that could enhance the effects of TBS. PA Therapy (Craske et al., 2016) is an innovative cognitive and experiential technique developed to address anhedonia specifically and, ideally, change altered patterns of frontostriatal function. Standing in contrast to Cognitive Behavioral Therapy, PA training has efficacy for enhancing positive affect and reducing negative affect (Craske et al., 2018). This treatment can be easily applied, and we propose that it will enhance neural circuit-level changes elicited by TBS.
214377297|NCT00947661|DRUG|Reference0912|Eye drops, once daily, 12 weeks
214497146|NCT06560138|DRUG|SHR-4602|SHR-4602 will be administered through IV infusion.
214497147|NCT06841588|OTHER|Mulligan's Mobilization with Movement and Dry Needling|"the intervention group 1 was treated using Mulligan Mobilization with Movements and Dry Needling (DN\&MWM) for soft tissue trigger points, (N=15).~The treatment duration was 6 sessions, 3 sessions per week ( day after day)."
214990121|NCT04913922|DRUG|Relatlimab|80-160mg i.v.
214990122|NCT04084015|DEVICE|Axillary Impella®|All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy
214990123|NCT02750293|DRUG|Cholecalciferol|Vitamin D preparation
214990124|NCT02750293|DRUG|Placebo|placebo
214990125|NCT02696798|DRUG|Ixekizumab|Administered SC
214990126|NCT02696798|DRUG|Placebo|Administered SC
215094626|NCT06354374|DIAGNOSTIC_TEST|volume survey|All subjects will receive oral hygiene instructions and, if needed. A dental cleaning of plaque and calculus. After calibration using digital photographs and digital intraoral scans, CBCT scans will be taken as a prerequisite for dental implant treatment protocol. one dentist who will not be involved in the screening phase will obtain all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width) to avoid any bias. After finishing data collection, a customized treatment plan for each patient will be performed and dental implant treatment will be completed for each patient.
214990127|NCT03311906|DRUG|0.8% Hyaluronic Acid|Application of 0.8% hyaluronic acid after scaling and root planing
214990128|NCT03311906|PROCEDURE|Scaling and Root Planing|Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
214990129|NCT01277861|DRUG|Fentanyl|FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
214990130|NCT04399447|RADIATION|Echocardiography|left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS
214990131|NCT03537833|OTHER|pemetrexed-related hematological toxicity|hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria
214990132|NCT02735564|PROCEDURE|Bariatric Surgery|
214990133|NCT00857389|DRUG|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
214990134|NCT00857389|DRUG|Clofarabine|40 mg/m\^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
214377298|NCT04309825|PROCEDURE|transgastrostomal endoscopy|Placement the endoscope through the g-tube port and not through the mouth of a patient undergoing an upper gi endoscopy
214377299|NCT00865943|DRUG|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
214377300|NCT00865943|DRUG|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
214990135|NCT00857389|DRUG|Busulfan|"Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3."
214377301|NCT00586170|DEVICE|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
214990136|NCT00857389|PROCEDURE|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
214990137|NCT00857389|DRUG|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
214377302|NCT00586170|DEVICE|Placebo Device|10 hours of treatment per day for up to 24 weeks
214377303|NCT00586170|PROCEDURE|Surgery|Open Reduction and Internal Fixation of the nonunion site
214377304|NCT02725125|BIOLOGICAL|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
214377305|NCT00774384|BIOLOGICAL|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
214377306|NCT03034018|DRUG|suvorexant|10-20 mg taken at bedtime for four weeks
214990138|NCT00857389|DRUG|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
214990139|NCT00857389|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
214990140|NCT00857389|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
214990141|NCT00857389|DRUG|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
214990142|NCT00857389|DRUG|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
214990143|NCT00847314|DRUG|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients \> 35yrs in medical practices fulfilling all criteria for documentation.
214990144|NCT03451370|DRUG|Capecitabine|"750 mg/sqm/bid, day 2 to 15; if toxicities grade ≥2 do not occur, pts may subsequently receive capecitabine 1000 mg/sqm/bid, day 2 to 15 starting the second cycle based on investigator's choice.~To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal."
214990145|NCT03451370|DRUG|Oxaliplatin|100 mg/sqm iv over 2 hours, day 1 To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.
214990146|NCT03451370|DRUG|Bevacizumab|"7.5 mg/kg iv over 90 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered in 30 minutes.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal. To be repeated every 3 weeks (21 days), for a maximum of 8 cycles."
214990147|NCT01499589|PROCEDURE|regional anesthesia|regional anesthesia procedure
214990148|NCT00757653|DEVICE|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
214990149|NCT00757653|DEVICE|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
214377307|NCT03034018|DRUG|placebo|placebo taken at bedtime for four weeks
214377308|NCT03538483|DRUG|Bupivacaine Hcl 0.25% Inj|30 ml %0,25 bupivacaine
214377309|NCT03538483|DRUG|Bupivacaine HCl Inj 0.25%|20 ml %0,25 bupivacaine
214377310|NCT01194284|DRUG|Mifamurtide|Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
214377311|NCT02552238|DRUG|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
214377312|NCT04285658|PROCEDURE|Ureteroscopy|An outpatient endoscopic surgery that accesses the ureters and kidneys per the urethra to fragment and remove the stones. Many patients who undergo ureteroscopy (URS), Shockwave lithotripsy (SWL), or percutaneous nephrolithotomy (PCNL) also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
214377313|NCT04285658|PROCEDURE|Percutaneous Nephrolithotomy|A minimally invasive surgery in which a \~1cm flank incision is made, and a scope is passed through a tubular sheath into the kidney to fragment and remove the stone. There is typically a 1- to 2-day hospital stay. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
214497148|NCT06841588|OTHER|Dry Needling (DN)|The intervention group 2 was treated using Dry Needling (DN) for soft tissue trigger points, (N=15). The treatment duration was 6 sessions, 3 sessions per week ( day after day).
214990150|NCT00757653|DEVICE|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
214990151|NCT00055562|DRUG|CC 5013|
214990152|NCT02251639|BEHAVIORAL|Questionnaire|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
214990153|NCT02251639|DEVICE|POS + PS2 + VELscope|Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
214990154|NCT02251639|PROCEDURE|Oral Brush Biopsy|If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
214990155|NCT04853485|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|All subjects with early psychosis will be divided into three subgroups determined by their psychotic symptoms and cognition. There are three rTMS strategies: (1) For subgroup 1, characterized by negative symptoms, iTBS over cerebellum and 1 Hz over right DLPFC; (2) For subgroup 2, characterized by cognition deficits, 20 Hz over the left inferior parietal cortex; (3) For subgroup 3, characterized by positive symptoms: 10 Hz over ACC. Ten to twenty sessions of rTMS will be delivered to each patients during the intervention period.
214990156|NCT05047744|DEVICE|Touch Dual Mobility CMC I Prosthesis|Surgery
214377314|NCT04285658|PROCEDURE|Shock Wave Lithotripsy|A non-invasive outpatient procedure that targets stones in the kidney or ureter with x-ray or ultrasound and uses shockwaves generated outside the body to fragment them; the fragments pass down the ureter and the patient expels them in the urine. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
214377315|NCT00898040|GENETIC|polymorphism analysis|
214377316|NCT00465933|DRUG|AIDA|
214377317|NCT02036645|BIOLOGICAL|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
214377318|NCT02036645|BIOLOGICAL|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
214377319|NCT02036645|BIOLOGICAL|IV Placebo|Placebo for IV injection
214377320|NCT02036645|BIOLOGICAL|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
214497149|NCT06838455|OTHER|Spinopelvic mobility exercise|Participants will complete a 15-20 min session of therapeutic exercises performed by patients with assistance of a pre-recorded video. The exercise regimen has been developed by the investigators of this study to incorporate exercises to increase a patient's spinopelvic mobility. Study staff that has been properly trained will be present to guide the patient through the exercise regimen and ensure the exercises are being performed accurately.
214497150|NCT06392958|OTHER|Traditional Chinese Medicine exercises - Baduanjin|According to the four steps of the cross-theoretical model, the behavior stage (pre-intention stage, intention stage, preparation stage, action stage and maintenance stage) and the family empowerment (clarify the problem, express the emotion, formulate the plan, implement the plan, and evaluate the effect). Combined with the characteristics of elderly patients after PCI, the cardiac rehabilitation management plan was designed focusing on the timing of cardiac rehabilitation, the way of health guidance, safety and compliance management.
214990157|NCT03226587|PROCEDURE|Blue light|Subjects will be exposed to blue light (453 nm wavelength) for 30 minutes
214990158|NCT03226587|PROCEDURE|control exposure|Subjects will get control exposure to 30 minutes of whole body, which causes only comparable warming of skin as with blue light exposure.
214990159|NCT02056678|DRUG|acetaminophen, IV preparation|
214990160|NCT05532878|DRUG|Apixaban|Apixaban 2.5 mg daily
214990161|NCT02970084|OTHER|Nutraceutical product based on vitamin K2 (PLAK2)|
214990162|NCT06107114|DRUG|Cetuximab|Cetuximab 400mg/m2 (The first week), 250mg/m2(Follow-up weekly) The drug was administered every week (QW). The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
214990163|NCT06107114|DRUG|Zimberelimab|Zimberelimab 240 mg, The drug was administered every week (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
214497151|NCT06618755|OTHER|Experimental group : PSH (usual care) with motivational interviewing|The experimental group will begin follow-up after the 1st inclusion visit, during hospitalisation for withdrawal. The first motivational interview will take place 1 to 4 days before discharge from full hospitalisation. The following 10 motivational interviews will be held 2 weeks apart and will follow a framework based on the following objectives: to create a relationship of trust and an effective and lasting therapeutic alliance from the first interview; to create personalised objectives for the user, in line with their addictive pathology; to support the user as they modify, 'fail' and 'succeed' in achieving these objectives; to encourage the emergence and maintenance of the user's desire to change.
214497152|NCT06761079|PROCEDURE|Thoracolumbar interfascial plane block|Ultrasound-guild bilateral Thoracolumbar interfascial plane block with a total 40 ml, 0.25% bupivacaine by anesthesiologist
214497153|NCT06761079|PROCEDURE|Local anesthetic infiltration|0.25%bupivacaine infiltration at surgical wound site by orthopedic surgeon
214990164|NCT06107114|DRUG|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
214990165|NCT06107114|DRUG|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
214990166|NCT01157845|DEVICE|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
215094627|NCT04515953|DRUG|ND-340|ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
215094628|NCT04515953|DRUG|IV-PCA|IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
215094629|NCT02079935|BEHAVIORAL|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
214377321|NCT02461810|DEVICE|Vertebral fracture surgery SpineJack®|Vertebral augmentation for one osteoporotic vertebral compression fracture
214377322|NCT02461810|PROCEDURE|Balloon Kyphoplasty|
214377323|NCT03781921|OTHER|No intervention|There is no intervention. Each group will conduct the same tasks and questionnaires and we will compare performances between groups.
214377324|NCT02136433|DEVICE|Tablet - self exercise|
214377325|NCT02136433|OTHER|GRASP self exercise|
214990167|NCT05146752|DEVICE|extremely low frequency electromagnetic fields|extremely low frequency electromagnetic fields
214990168|NCT05146752|OTHER|routine care|routine care
214990169|NCT05041400|OTHER|Evaluation of the strength of knee flexors and extensors|Each participant will benefit from a clinical evaluation and an evaluation of the strength of knee flexors and extensors using an isokinetic dynamometer after a 10-minute warm up.
214990170|NCT03311555|DRUG|Apalutamide|240mg tablet daily for 36 weeks
214990171|NCT03311555|DRUG|Androgen deprivation|ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
214990172|NCT03311555|RADIATION|Salvage radiation therapy|On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks
214990173|NCT03311555|DRUG|Docetaxel|About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
214990174|NCT05685121|DEVICE|Apollo Neuro|The device is a wearable nerve stimulator.
214990175|NCT05159934|DRUG|0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine|Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
214990176|NCT05159934|DRUG|Saline|Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline
214990177|NCT02164617|OTHER|Wheelchair-bound Senior Elastic Band exercise program (WSEB)|Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
214990178|NCT03025321|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
214990179|NCT01831843|DEVICE|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
214377326|NCT05225688|BEHAVIORAL|Bike exertion test|maximal exercise test
214377327|NCT05648162|DEVICE|Electrical acupuncture|Electrical acupuncture (2Hz, 150 μs) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
214377328|NCT05648162|DEVICE|Acupuncture|Electrical acupuncture (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
214990180|NCT01831843|DEVICE|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer \& Paykel)was used in group E patient
214990181|NCT01831843|DEVICE|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
214990182|NCT00267436|BEHAVIORAL|Community PROMISE|The Community PROMISE begins with a community assessment to identify HIV risk factors. Once risk factors have been identified, individuals from the targeted at-risk community are recruited and trained to be peer advocates. Trained peer advocates interview members of the community about their behavior. Role model stories are written based on the interviews. Role model stories are personal accounts from individuals in the target population which explain how and why they took steps to practice HIV risk-reduction behaviors and the positive effects the choice has had on their lives. Each week, peer advocates distribute role model stories and supplies, such as condoms, to 10 to 20 members of their social networks.
214990183|NCT01273259|DRUG|DHEA Treatment|DHEA : 200 mg/day hard gelatine capsule
214990184|NCT01273259|DRUG|DHEA Treatment|DHEA : 25 mg/day hard gelatine capsule
214990185|NCT05349305|DRUG|continuous renal replacement therapy|continuous renal replacement therapy
214990186|NCT06054711|OTHER|joint puncture|Patients reporting complications such as pain hindering mobility or affecting quality of life, or any other symptoms suspecting prosthesis failure or infection will undergo joint fluid aspiration.
214990187|NCT02830711|OTHER|Positive and Negative Affect Scale for Children|A 36-item instrument, including the Mood and Anxiety Symptom Questionnaire (MASQ)16 developed by Chang and Yeh and the Positive and Negative Affect Scale for Children developed by Watson and Clark
215094630|NCT02079935|BEHAVIORAL|Physical Activity and Dietary Therapy|Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
214377329|NCT05648162|DEVICE|tDCS|tDCS (1mA) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
214990188|NCT04481139|DRUG|SHR0302|SHR0302, oral, once daily
214990189|NCT04481139|DRUG|SHR0302 placebo|SHR0302 placebo, oral, once daily
215094631|NCT02477553|BEHAVIORAL|DA - Quantitative|
215094632|NCT02477553|BEHAVIORAL|DA - Verbal|
215094633|NCT03757754|DRUG|HPPH 2.5 mg/m2|HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
214990190|NCT05883514|BEHAVIORAL|Motivational interviewing|According to the Miller and Rollnick principles, the framework of the motivational interviewing group's sessions was taken from the workbook of the intervention's six sessions of motivational interviewing. A researcher recruited participants in groups of 7 patients for six sessions of 60-90 minutes each (two sessions per week). The training sessions covered topics like stress alleviation, appropriate drug usage, quitting smoking, regular physical activity, healthy eating habits, and regular physical activity. Patients in the control group got standard treatment for PPM, including education on proper medication usage, nutrition, and exercise, as well as regular checking.
214377330|NCT05648162|DEVICE|sham tDCS|tDCS (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
214377331|NCT05648162|OTHER|NDT-Bobath Rehabilitation|NDT-Bobath Rehabilitation once daily (five times a week), for 30 minutes each session, totaling 20 sessions.
214377332|NCT00953537|DRUG|capecitabine|
214377333|NCT00953537|OTHER|laboratory biomarker analysis|
214377334|NCT00953537|OTHER|pharmacological study|
214377335|NCT00103961|BEHAVIORAL|Questionnaire|A behavioral questionnaire will occur at Week 8
214377336|NCT00285493|DRUG|Antibiotics|
214990191|NCT01580956|OTHER|VARIABLE-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
214377337|NCT06253949|PROCEDURE|ligation of inferior mesenteric artery in colorectal cancer|This study will include two groups of patients: group (A) and (B). In group (A), the inferior mesenteric artery will be ligated at its origin (high-tie), While in group (B), it will be ligated after the origin of the left colic artery (low-tie).
214377338|NCT01727063|PROCEDURE|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
214377339|NCT00742638|DRUG|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
214377340|NCT00742638|DRUG|Sodium valproate|Sodium valproate tablet 200 mg
214377341|NCT01741116|DRUG|TKI258|Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
214377342|NCT05114525|BEHAVIORAL|Survey questionnaire|The survey questionnaire will include semi-structured questions about patient demographics and patient understanding of the risks and benefits of radiation, different treatment options, the treatment process, utility of visual aid presentation and information gathering preference using a semi-structured questionnaire
214497154|NCT06752798|DRUG|Trilaciclib + Cisplatin|Trilaciclib: 240 mg/m², intravenous infusion over 30 minutes, administered within 4 hours prior to each chemotherapy session. Cisplatin: 40 mg/m², intravenous infusion over 2-3 hours, once a week, for a total of 6-7 times.
214497155|NCT06776445|DRUG|minocycline combined with hydroxychloroquine|Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
214497156|NCT06776445|DRUG|gabapentin 300mg bid|Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
214497157|NCT06776445|DRUG|gabapentin 300mg tid|Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
214497158|NCT04435756|OTHER|Biomarker Analysis|Correlative study
214497159|NCT04435756|PROCEDURE|Blood Product Collection|Undergo collection of blood
214497160|NCT04965155|DRUG|Isatuximab-dexamethasone|Isatuximab 10 mg/kg IV: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3 Dexamethasone 40 mg OS: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3
214497161|NCT05999526|OTHER|Reconnection to mechanical ventilation for 1 hour|As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
214377343|NCT05290844|OTHER|cricoid pressure|cricoid force in pediatric patients
214377344|NCT01778556|BIOLOGICAL|Metreleptin|Recombinant analog of the human hormone, leptin
214497162|NCT05999526|OTHER|Direct extubation|The participant will be extubated immediately after the spontaneous breathing trial.
214497163|NCT01638533|OTHER|Pharmacological Study|Correlative studies
214497164|NCT01638533|DRUG|Romidepsin|Given IV
214990192|NCT01580956|OTHER|STANDARD-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
214990193|NCT03020368|BIOLOGICAL|Leeches|
214990194|NCT03020368|DRUG|Diclofenac|
214377345|NCT04520802|DIAGNOSTIC_TEST|18F-DPA-714 PET/CT neuroimaging|"* Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI.~* Longitudinal neuropsychological examinations (up to 6 months postoperatively)~* Blood samples are drawn to assess the severity of the systemic inflammatory response"
214377346|NCT00061763|DRUG|Deferasirox|
214377347|NCT06023875|DRUG|Cadonilimab|Cadonilimab 10mg/kg. The drug was administered every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
214377348|NCT06023875|DRUG|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
214377349|NCT06023875|DRUG|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
214377350|NCT06520943|OTHER|blood gas analysis|"1. Airway pressure (P plateau, Ppeak) values are taken from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (routinely from pharyngeal temperature probe),~4. Oxygen saturation (routinely from the patient monitor)~5. End-tidal CO₂,~6. inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. inspiratory and expiratory desflurane concentrations,~9. tidal volume,~10. MAC is routinely obtained from anesthesia device data.~11. Blood Gas Analysis (COHgb, Ph, PO2, PCO2, SaO2, HCO3, Base deficit, glucose, lactate)"
214377351|NCT04837859|DRUG|Tislelizumab|age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients
214377352|NCT03188120|DRUG|Spiriva Respimat|Drug
214990195|NCT05165433|BIOLOGICAL|NG-350A plus Pembrolizumab|Patients receive three doses of NG-350A by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion
214990196|NCT04058405|BEHAVIORAL|Observational|Cross-sectional observations
214990197|NCT00788671|OTHER|Laboratory Biomarker Analysis|Correlative studies
214990198|NCT00788671|DEVICE|Levonorgestrel-Releasing Intrauterine System|Undergo placement of a levonorgestrel-releasing intrauterine system
214990199|NCT00788671|OTHER|Quality-of-Life Assessment|Ancillary studies
214990200|NCT05542147|DRUG|Fenofibrate 145 mg|1 tablet per day
214377353|NCT02807428|DRUG|AYX1 Injection 660 mg/6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
214377354|NCT02807428|DRUG|Placebo Injection 6 mL|6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
214377355|NCT05647525|DIAGNOSTIC_TEST|Perform autoimmune encephalitis titer tests|We only follow up without intervention.
214377356|NCT06184243|BEHAVIORAL|Parent Training|Parent training will cover the topic of creating social skills, goal setting, creating a video model, how to implement the video model intervention, and the parent-child interaction procedures during play. Parents will learn the steps in the fidelity checklist and demonstrate the steps at 90% proficiency by the end of the training. Parent coaching will continue before and after child intervention sessions.
214377357|NCT06184243|BEHAVIORAL|Video Modeling|The child will be recorded for a video model engaging in play at their home. The videos will be created with the parent and researcher in the home. A video using the same materials in the same location will be created depicting the child in a play scenario. The video will be two-to-three minutes in length. Each child will receive at least three sessions of intervention and no more than five sessions of intervention per week.
214377358|NCT00871650|OTHER|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
214377359|NCT00871650|OTHER|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
214377360|NCT00871650|OTHER|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
214377361|NCT03278535|DIAGNOSTIC_TEST|CAREN-based gait analysis|subjects only walk at CAREN at different speed
214377362|NCT04305002|DRUG|Exenatide|Injections, 2 mg once weekly for 18 months
214377363|NCT04305002|DRUG|Placebo|Injections, once weekly for 18 months
214377364|NCT02012062|DRUG|TPF neoadjuvant chemotherapy|
214377365|NCT02012062|DRUG|Concurrent chemotherapy with cisplatin during radiotherapy|
214377366|NCT02012062|DRUG|Concurrent nimotuzumab during radiotherapy|
214377367|NCT02012062|RADIATION|Radical radiotherapy|
214377368|NCT01092481|DRUG|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
214377369|NCT01023243|OTHER|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
214377370|NCT01023243|OTHER|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
214377371|NCT00070811|PROCEDURE|Lip revision surgery|Full or partial muscle thickness lip revision surgery.
214377372|NCT00782496|DEVICE|Education + new meter|Diabetes education and a new meter with basic features
214377373|NCT00782496|DEVICE|Education + new meter + feature activation|Diabetes education and a new meter with advanced features
214377374|NCT01481545|RADIATION|Radiation therapy|Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
214377375|NCT01481545|DRUG|Oxaliplatin|100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
214377376|NCT01481545|DRUG|Raltitrexed|2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
214377377|NCT01481545|DRUG|levofolinic acid|250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
214497165|NCT06775483|DRUG|JSKN016|Administered intravenously according to protocol.
214990201|NCT05542147|DRUG|Placebo|1 tablet per day
214990202|NCT04069897|DRUG|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
214377378|NCT01481545|DRUG|5-fluorouracil|800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
214377379|NCT01481545|DRUG|Bevacizumab|will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
214377380|NCT02503683|DRUG|ALN-AAT|Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
214377381|NCT02503683|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
214377382|NCT00584402|DRUG|perflutren lipid microspheres|perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
214377383|NCT00477477|OTHER|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
214377384|NCT00477477|OTHER|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
214377385|NCT03281824|BIOLOGICAL|ALT-P7 (HM2-MMAE)|Antibody-Drug Conjugate
214377386|NCT03715712|OTHER|standardized blood pressure management|Standardized blood pressure management of a mean blood pressure \> 65mmHg and a systolic blood pressure of \< 160mmHg using norepinephrine continuous infusion
214497166|NCT06775483|DRUG|Docetaxel|Administered intravenously according to protocol.
214497167|NCT05549661|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214497168|NCT05549661|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214497169|NCT05549661|DRUG|Onvansertib|Given PO
214377387|NCT03715712|OTHER|Individualized blood pressure management|Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
214377388|NCT05453747|OTHER|Exercise|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
214377389|NCT05453747|OTHER|Exercise 2|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
214377390|NCT03571737|DRUG|Ibuprofen|Ibuprofen tablet
214377391|NCT03571737|DRUG|Lidocaine Patch 4%|Lidocaine patch
214377392|NCT00002928|DRUG|paclitaxel|
214377393|NCT01874145|DRUG|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
214377394|NCT01874145|DRUG|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
214377395|NCT05772429|DRUG|Epidiolex|Administered as an oral solution
214377396|NCT06419244|DIAGNOSTIC_TEST|Myosteatosis|Determination of myosteatosis by imaging
214377397|NCT02178566|DRUG|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
214377398|NCT03731754|PROCEDURE|Traditional Closure|Primary closure discontinuously the perineal wound of APR
214377399|NCT03731754|PROCEDURE|"Cross closure"|Two triangles of skin in the horizontal direction are excised to enlarge the skin incision, and the tumor resected. Then circumferential subcuticular suture of wound, and with tightening of the circumferential suture, the wound resembles a cross.
214377400|NCT02934620|DEVICE|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
214377401|NCT02934620|DEVICE|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
214377402|NCT02934620|BEHAVIORAL|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
214377403|NCT02992587|OTHER|CAF, Comprehensive assessment of frailty|CAF, Comprehensive assessment of frailty. A scoring system of the patients physical status. By smaller physical test of balance, strength and walking speed.
214377404|NCT02070484|BIOLOGICAL|NuCel|
214497170|NCT05549661|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
214990203|NCT04069897|DRUG|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
214377405|NCT02070484|BIOLOGICAL|Demineralized Bone Matrix|
214377406|NCT01474213|DRUG|dexmedetomidine group|1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
214377407|NCT01474213|DRUG|remifentanil group|target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
214377408|NCT02658630|DEVICE|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
214377409|NCT02124343|OTHER|Interval Exercise|
214377410|NCT02915094|DRUG|Anakinra|
214377411|NCT02206490|DRUG|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
214377412|NCT02206490|DRUG|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
214377413|NCT01737346|DRUG|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
214377414|NCT01054261|DRUG|avanafil|200 mg avanafil tablet QD
214377415|NCT05635292|BEHAVIORAL|Tele-CBT|8 weekly 1-hr telemedicine visits with a licensed Ph.D. psychologist from the University of Pennsylvania (permissible to practice across state lines under PSYPACT), plus usual care and referral to an IBD Help Center (email, phone, online chat with IBD information specialist)
214377416|NCT02803268|DRUG|MT-8554 low dose|
214497171|NCT01162096|DEVICE|Haploidentical Allogeneic Transplantation|Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
214990204|NCT06114849|BEHAVIORAL|Treatment as usual|Treatment-as-usual will follow the existing RallyPoint procedures for concerning posts on the site. In the current procedures, a RallyPoint staff member sends a supportive message to the member containing resource information on the Veteran's Crisis line, 911, and connecting with a therapist. This information is typically sent within 24 hrs of seeing a concerning post. Participants in both the control and intervention conditions will receive treatment-as-usual.
214377417|NCT02803268|DRUG|MT-8554 middle dose|
214377418|NCT02803268|DRUG|MT-8554 high dose|
214377419|NCT02803268|DRUG|Placebo|
215094634|NCT03757754|DRUG|HPPH 3 mg/m2|HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
214377420|NCT03238300|DRUG|N-Acetylcysteine|N-Acetylcysteine; 600mg capsules by mouth, two pills twice daily (total 2400 mg/day). Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
214377421|NCT03238300|DRUG|Placebo Oral Capsule|N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
214497172|NCT05691595|OTHER|Online survey data collection|The data will be collected via a web-survey created with the SurveyMonkey® software. The web-survey will be distributed among nurses at IRCCS Policlinico San Donato (San Donato Milanese, Italy) and ASST Grande Ospedale Metropolitano Niguarda (Milan, Italy).
214497173|NCT03485287|DRUG|Midomafetamine HCl|Three sessions of MDMA-assisted therapy with flexible dose of midomafetamine HCl from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
214497174|NCT03485287|BEHAVIORAL|Manualized therapy|Non-directive therapy
214497175|NCT03158818|OTHER|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
214497176|NCT05413798|OTHER|Urine HPV testing|Human papillomavirus (HPV) testing in urine sample.
214990205|NCT06114849|BEHAVIORAL|Barrier Reduction Intervention|"After a post is identified in real-time by the risk algorithm, participants will be shown a pop-up message offering information on mental health resources (e.g., crisis line). Participants will be asked about their likelihood of using these resources. For participants who indicate they are not likely to use these resources, they will then be presented with a list of common barriers to help-seeking, drawing from research in this area (e.g., Treatment is too expensive or I'm concerned about the police or paramedics getting involved.). Participants will be asked to click on any reason that resonates with them. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns and encourage professional help-seeking."
214990206|NCT05387980|DRUG|CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
214990207|NCT05388474|OTHER|No ibalizumab or Pre-ibalizumab treatment|Patient registry
214990208|NCT05388474|BIOLOGICAL|On ibalizumab treatment|Patient registry
214990209|NCT03970720|DRUG|Metoclopramide|10 mg metoclopramide four times a day
214497177|NCT05413798|OTHER|Self-collected cervicovaginal specimen|Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.
214497178|NCT05413798|OTHER|Provider-collected cervical samples|Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.
214497179|NCT06334601|DIAGNOSTIC_TEST|Tests of upper airway collapsibility and muscle responsiveness.|"Upper airway collapsibility, upper airway muscle responsiveness and loop gain will be assessed during single study visit.~Polysomnography"
214990210|NCT03970720|DRUG|Placebo|10 mg matching placebo capsules four times a day
214990211|NCT05037812|DRUG|Saline injection|Saline
214990212|NCT05037812|DRUG|Multimodal injections|"5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection)."
214990213|NCT03405870|DRUG|Smoflipid|Administration of lipid injectable emulsion
214990214|NCT06621251|DRUG|TRL1068 (calpurbatug), a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
214990215|NCT06621251|PROCEDURE|DAIR|DAIR procedure will be performed between days 15-22
214990216|NCT06431763|DRUG|Inclisiran sodium|300 mg s.c. administered at day 1 and day 90
214990217|NCT06431763|DRUG|BPA|180 mg daily per oral
214990218|NCT04310930|DRUG|Amikacin|Adults: Intravenous amikacin 5mg/kg once daily or 7.5mg/kg twice daily or 20-25 mg/kg thrice weekly. Children:Intravenous amikacin 15-30 mg/kg once daily, maximum dose 1500mg
214990219|NCT04310930|DRUG|Tigecycline|Adults: Intravenous Tigecycline 25 mg increasing by 5 mg every two doses until either maximum dose reached (50mg) or until patient is unable to tolerate twice daily. Children (≥8 years of age) intravenous tigecycline: Day 1- 0.6mg/kg twice daily to a maximum of 25mg. Day 2- 0.6mg/kg (maximum 25mg) in the morning, 1.2 mg/kg (maximum 50mg) at night. Day 3- 1.2mg/kg (maximum 50 mg) twice daily
214990220|NCT04310930|DRUG|Imipenem|Adults: Intravenous Imipenem (≥50kg) 500mg twice daily (\<50kg) 15 mg/kg twice daily. Children: intravenous imipenem Day 1- 2- 25mg/kg (maximum 1g) twice daily. DAY 3- 25mg/kg (maximum 1g) four times daily (drop to 3 if not tolerated).
215094635|NCT03757754|DRUG|HPPH 3.5 mg/m2|HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
214377422|NCT01741519|DRUG|LDLL600|Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
214377423|NCT01741519|DRUG|Brevibloc|Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
214377424|NCT03011723|BEHAVIORAL|Resource oriented music therapy|"10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.~The music therapy consists of one or more of the following activities:~1. Singing~2. Listening to live music~3. Listening to recorded music~4. Dancing~5. Conversations about memories/reminiscence~6. Exercising to music~7. Breathing exercises and relaxing exercises~The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)"
214377425|NCT03620630|DEVICE|myCOPD|myCOPD is a multi faceted web based application designed to support people with COPD in the Long term management of their COPD.
214377426|NCT01774864|DRUG|DA-8159 (Udenafil)|
214377427|NCT01774864|DRUG|Placebo|
214377428|NCT02009202|DRUG|polyethylene glycol|
214377429|NCT02009202|DRUG|picosulphate|
214497180|NCT04477200|DRUG|Mycophenolate Mofetil|500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
214497181|NCT04477200|RADIATION|Radiation Therapy|40.5 Gy in 15 fractions
214497182|NCT04477200|PROCEDURE|Re-resection (as part of standard of care)|Re-resection or biopsy of tumor as part of standard of care
214377430|NCT04365517|DRUG|Sitagliptin|We propose a randomized controlled open label intervention study. Patients with type 2 diabetes admitted to COVID-19 and randomized to the study group will be treated with sitagliptin at an adjusted dosage for estimated glomerular filtrate: 100 mg once daily (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2 ) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
214377431|NCT00656318|OTHER|oral contraceptive pill (OCP; OCPs)|Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
214377432|NCT04064242|DRUG|CMK389|single i.v. dose every 4 weeks
214377433|NCT04064242|DRUG|Placebo|single i.v. dose every 4 weeks
214377434|NCT03520400|BEHAVIORAL|Exercise Therapy|Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
214377435|NCT01654601|DRUG|DWCZP|Multiple dose
214377436|NCT01654601|DRUG|Clozaril|multiple-dose
214377437|NCT05716984|DRUG|recombinant human brain natriuretic peptide|rhBNP 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
214377438|NCT05716984|DRUG|Placebo|placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
214377439|NCT00163995|DRUG|urotensin II|
214377440|NCT04398537|DEVICE|5mm retraction of clip deployment apparatus.|Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.
214377441|NCT04398537|DEVICE|No retraction of clip deployment apparatus.|This is one method of standard of care and the clip will be deployed at the biopsy site.
214377442|NCT03994783|DRUG|Rituximab|2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
214377443|NCT03994783|DRUG|Methylprednisolone|Intravenous infusion of methylprednisolone
214377444|NCT03994783|DRUG|Intravenous Immunoglobulin|High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
214377445|NCT03994783|PROCEDURE|Plasma Exchange|Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
214377446|NCT00615394|PROCEDURE|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
214377447|NCT00201864|DRUG|Exemestane|25 mg orally per day
214377448|NCT00201864|DRUG|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
214377449|NCT02932839|DEVICE|NeuroPort micro-electrode array|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
214497183|NCT04477200|DRUG|Temozolomide|Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
214497184|NCT04477200|DRUG|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT.
214497185|NCT04477200|DRUG|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
214377450|NCT02783222|DRUG|Nab-paclitaxel|comparison of different dosages of drug
214377451|NCT04610216|DEVICE|Naida CI M hearing device|speech intelligibility measurement with Naida CI M hearing device
214377452|NCT02867514|DEVICE|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
214377453|NCT00299000|DRUG|Naglazyme|Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
214377454|NCT02412501|DEVICE|Resolute Onyx Stent - 2.0 mm|Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
214377455|NCT02760056|DRUG|Liothyronine sodium|Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
214377456|NCT02760056|DRUG|Placebo|Patient will receive a matching placebo to take twice daily for one week.
214377457|NCT05720585|OTHER|Intervention of mobile health application|According to the contents of the Subjective Memory Complaint (SMC) application intervention program for the older adults previously formulated, the intervention time and the frequency (30min / time, once a week) of each training module and other contents were determined. The application will be implemented and lasted for a total of 1 month.
214377458|NCT02429687|DRUG|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
214377459|NCT02429687|DRUG|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
214497186|NCT04477200|RADIATION|Radiation Therapy|60 Gy in 30 fractions
214497187|NCT04479696|OTHER|Educational Intervention|Receive standard of care verbal and written education materials
214377460|NCT02429687|DRUG|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
214377461|NCT02429687|DRUG|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
214377462|NCT02429687|DRUG|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
214377463|NCT00001866|PROCEDURE|horizontal muscles of the eye will be cut and then reattached in the same position|
214377464|NCT02635165|DEVICE|Thoracic osteosyntheses with Stracos|
214377465|NCT03784235|OTHER|18F NaF-PET/CT and cone beam CT scans|Cross sectional measures of 18F NaF-PET/CT and cone beam CT scans
214377466|NCT01933971|DRUG|Filgrastim test|0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
214377467|NCT01933971|DRUG|Filgrastim reference|"0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous"
214377468|NCT04703634|PROCEDURE|erector spinae block (ESP)|Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra
214377469|NCT04482829|DRUG|Jing-yan-kang Granule|Jing-yuan-kang granule will be administered 6 days on and 1 days off for 12weeks.
214497188|NCT04479696|OTHER|Questionnaire Administration|Ancillary studies
214497189|NCT04479696|OTHER|Survey Administration|Complete optional survey
214497190|NCT04479696|OTHER|Video|Watch NIRS video
214990221|NCT04310930|DRUG|Cefoxitin|Adults: If imipenem is poorly tolerated intravenous cefoxitin 200 mg/kg thrice daily. Children: if imipenem is poorly tolerated intravenous cefoxitin 50mg/kg (maximum 4g) four times daily.
214990222|NCT04310930|DRUG|Azithromycin|"Adults: Oral azithromycin 500mg (≥40kg) once daily, (\<40kg) 250mg once daily.During consolidaiton: 500mg (≥40kg) thrice weekly, (\<40kg) 250mg thrice weekly.~Children: Oral azithromycin:10mg/kg (maximum 500mg) once daily. During consolidation 10mg/kg once daily maximum 500mg."
214990223|NCT04310930|DRUG|Clarithromycin|Adult: If azithromycin is poorly tolerated use oral clarithromycin 500mg twice daily.Children: If azithromycin is poorly tolerated use oral clarithromycin. In children 1 month old- 11years of age the following dosing applies: \<8kg: 7.5mg/kg twice daily, maximum dose 62.5mg, 8-11kg: 62.5mg twice daily, maximum dose 62.5mg, 12-19 kg: 125mg twice daily, maximum dose 125mg, 20-29 kg: 187.5mg twice daily, maximum dose 187.5mg, 30-40 kg: 250mg twice daily, maximum dose 250mg, Children 12-18 years of age: 500 mg twice daily
214990224|NCT04310930|DRUG|Clofazimine|Adult: Oral clofazimine 100mg once daily. Children: Oral clofazimine: 3-5mg/kg once daily. Maximum dose of 50mg once daily if \<40kg or 100mg if ≥40kg once daily.
214990225|NCT04310930|DRUG|Ethambutol|Adults: with confirmed mixed NTM infections (slow growers + MABS) oral ethambutol can be added at either 15 mg/kg once daily or 25mg/kg thrice weekly. Children with confirmed mixed NTM infections (slow growers + MABS) oral ethambutol can be added at 20 mg/kg once daily.
214990226|NCT04310930|DRUG|Amikacin|adult: Inhaled amikacin 500mg twice daily. Children: Inhaled amikacin 500mg twice daily
215090977|NCT05487885|DRUG|Ketamine Injectable Solution|Ketamine is FDA-approved as an anesthetic agent that will be used off-label in this study. It is used routinely in both pediatric and adult patients and is considered extremely safe in substantially higher, anesthetic doses. The dose to be administered here (0.5 mg/kg) is a much lower, subanesthetic dose, and the administration route (intravenous) is the standard when used in anesthesia. Published studies and metaanalyses of this dose of intravenous ketamine as an off label use in depression show clearly that there are no increased risks in this population, including a recent study in adolescents (Dwyer et al, 2021, American Journal of Psychiatry). A single dose of ketamine will be used to determine if it alters the functioning of the anhedonia-related reward functioning and frontostriatal biomarkers assessed in this study.
215090978|NCT06433180|DRUG|Administration of fecal microbiota transplantation ( FMT capsules)|Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.
215090979|NCT06433180|DRUG|Administration of the sham (PLACEBO)|Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
214377470|NCT04482829|DRUG|PC chemotherapy and symptomatic treatment|"Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used."
214497191|NCT05030493|DRUG|mFOLFOX6 + panitumumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
214497192|NCT05030493|DRUG|mFOLFOX6 + bevacizumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
214497193|NCT06699771|DRUG|GCC2005|CAR-NK Cell Therapy
214497194|NCT06699771|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214497195|NCT06699771|DRUG|Fludarabine|Lymphodepleting chemotherapy
214497196|NCT05721573|DRUG|ABC008|Given by subcutaneous injection
214497197|NCT05301101|RADIATION|Re-irradiation|Patients will undergo re-irradiation following treatment planning based on current standard practice as determined by treating physicians and multidisciplinary teams.
214497198|NCT05377060|BEHAVIORAL|Plasma p-tau risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, MMSE score, and plasma p-tau results.
214497199|NCT05377060|BEHAVIORAL|Standard risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, and MMSE score.
214497200|NCT03762850|DRUG|sparsentan|Target dose of 400 mg daily
214377471|NCT00956696|DRUG|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
214990227|NCT04310930|DRUG|Linezolid|"Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral linezolid 600mg once daily.~Children: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Age 1 week - 9 years 10mg/kg twice daily maximum dose of 300mg. Age 10-12 years 10mg/kg twice daily maximum dose of 600mg. \>12 years 600mg once daily."
214377472|NCT05583214|DRUG|Ondansetron 8mg|8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia
214377473|NCT05583214|DRUG|Dexamethasone 8mg|8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia
214377474|NCT05583214|DRUG|Normal saline|Normal saline will be given IV stat to the group after induction of spinal anesthesia
214377475|NCT01909570|PROCEDURE|Elective single embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.
214377476|NCT01909570|PROCEDURE|Double embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
214377477|NCT01862991|OTHER|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
214377478|NCT01862991|DRUG|Misoprostol|400 mcg buccal misoprostol 90 pre-op
214497201|NCT03762850|DRUG|irbesartan|Target dose of 300 mg daily
214497202|NCT03762850|DRUG|Dapagliflozin|Target dose of 10 mg daily
214990228|NCT04310930|DRUG|co-trimoxazole|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral Co-trimoxazole (TMP-SMX) 160/800mg twice daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral co-trimoxazole 5mg TMP/kg maximum dose of 160mg TMP/ 800mg SMX twice daily.
214990229|NCT04310930|DRUG|Doxycycline|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral doxycycline 100mg once daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral doxycycline (ages ≥ 8 years) 2mg/kg once daily maximum dose 100mg.
215090980|NCT06372652|DRUG|TE-8214 - SAD|Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg
215090981|NCT06372652|DRUG|Placebo|Single subcutaneous dose of matching placebo across the cohorts
214497203|NCT02398786|OTHER|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
215090982|NCT06450106|DRUG|STM-416p|STM-416p monotherapy
215090983|NCT06082830|BEHAVIORAL|Intervention|"The intervention arm includes five components:~1. Personalized goal: Participants will complete an interview with a registered dietitian to review their baseline diet quality data and establish their personalized dietary goals.~2. Meal timing: Participants will receive information on why eating later at night is detrimental and specific strategies on how to limit eating past 8pm in the evening.~3. Nutrition skills: Participants will receive nutrition education and cooking skills text messages, using adolescent specific guidance from the Dietary Guidelines for Americans.~4. Home food environment: Participants will receive text messages on how to better select and prepare foods in the home environment (e.g., fruit and vegetable availability).~5. Engagement strategies: Researchers will design and implement text messages that recognize participant time and effort (e.g., text badges in recognition of completing the first study week)."
214377479|NCT01862991|DRUG|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation
215090984|NCT05765175|DEVICE|Varian Cardiac Radioablation (CRA)|Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.
215090985|NCT05765175|PROCEDURE|Catheter Ablation (CA)|Subjects randomized to the CA arm will be treated according to a uniform CA protocol.
215090986|NCT05965401|OTHER|Pharmacogenetic-guided dosing|SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
215090987|NCT05965401|OTHER|GLAD-PC guided dosing|SSRI dosing based on GLAD-PC clinical practice guidelines
215090988|NCT06321055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Retrospective analysis.
215090989|NCT06277245|DRUG|LNK01001|Capsule; Oral
215090990|NCT06277245|DRUG|Placebo|Capsule; Oral
214377480|NCT01862991|DRUG|Mifepristone|200 mcg Mifepristone orally
214377481|NCT03419416|OTHER|Kangaroo mother care (KMC)|Skin to skin contact of newborns with mothers and exclusive breast feeding
214497204|NCT05606614|GENETIC|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
214497205|NCT03083366|DEVICE|PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)|Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
214497206|NCT05570617|BEHAVIORAL|Transition Coach Intervention|The Transition Coach Intervention will include 8, 1-hour sessions over 6-months. The transition coach will independently meet one-on-one with each youth using an individualized, patient-centred approach beginning with an introductory session, followed by 5 sessions covering each topic in the Youth Transition Roadmap. These topics include: Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. The clinical psychologist will lead 2 sessions beginning with the Patient Health Questionnaire for Anxiety and Depression as a screening tool. The clinical psychologist will discuss psychological and social well-being in the context of their disease covering personally relevant issues/concerns.
214377482|NCT03122054|PROCEDURE|laparoscopic cholecystectomy|First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.
214377483|NCT00286208|DRUG|Mifepristone, misoprostol|
214377484|NCT03857568|DRUG|SHR0410|drug will be dosed repeatedly
214377485|NCT03857568|DRUG|Placebo|Placebo will be dosed repeatedly
214497207|NCT05570617|BEHAVIORAL|Standard of Care- Youth Transition Roadmap|All participants will receive the Youth Transition Roadmap (standard of care) which discusses 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. This is an informational pamphlet and will not require any additional meetings with the patient beyond their normal healthcare interactions
214990230|NCT04310930|DRUG|Moxifloxacin|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral moxifloxacin 400mg once daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral moxifloxacin 10-15mg/kg once daily, maximum dose 400mg
214990231|NCT04310930|DRUG|Bedaquiline|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral bedaquiline (18-64 years of age) 400mg once daily for the first two weeks followed by 400mg thrice weekly for 22 weeks (maximum duration of 6 months).
214990232|NCT04310930|DRUG|Rifabutin|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral rifabutin: 5mg/kg once daily, maximum 300-450mg. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral rifabutin 5mg/kg once daily
214990233|NCT06367439|BEHAVIORAL|Virtual reality exercise condition|Participants will complete a virtual reality exercise (i.e., Supernatural) tutorial (YouTube instruction and in-headset gameplay instruction/practice) and will complete a 18-20 minute affect measurement medium intensity virtual reality exercise (i.e., Supernatural) session in the Behavioural Medicine Lab (UVic).
214990234|NCT06367439|BEHAVIORAL|Virtual reality exercise condition|Participants will be provided a virtual reality headset (Meta Quest 3 Headset) and subscription to a virtual reality exercise game (i.e., Supernatural) for 10 weeks. Participants will be instructed to participate in 75 minutes of medium intensity Supernatural physical activity (equivalent to 75 minutes of vigorous physical activity) per week in their own home.
214990235|NCT05713071|PROCEDURE|Bariatric Endoscopic Antral Myotomy|BEAM will be performed using a standard gastric peroral endoscopic myotomy (G-POEM) technique, however with the myotomy targeting only the antrum and leaving the pyloric ring intact. G-POEM is commonly and widely employed for gastric emptying and nutritional issues and is covered by most insurance plans. This involves injecting fluid into the submucosal space, making a mucosal incision to enter the submucosal space, and tunneling along the antrum to the pylorus. A myotomy is then performed, however, in BEAM the pyloric ring is spared and the myotomy is only performed in the antrum. The incision is then closed with clips. No endoscopic suturing will be performed.
214990236|NCT06955403|DEVICE|Precision 7 contact lenses|Acuvue Oaysis contact lens wearers have will be refit into precision 7 contact lenses.
215090991|NCT05288166|DRUG|Abemaciclib|Administered orally.
215090992|NCT05288166|DRUG|Abiraterone|Administered orally.
215090993|NCT05288166|DRUG|Prednisone or Prednisolone|Administered orally.
215090994|NCT05288166|DRUG|Placebo for Abemaciclib|Administered orally.
215090995|NCT06980727|DRUG|Salbutamol 2,5 mg|In this study group, patients will receive 1000mg intravenous injection of paracetamol in combination with 4ml IV normal saline as placebo, and 5mg salbutamol in 5ml nebulisation during 10min.
215090996|NCT06980727|DRUG|Dexamethasone|Patients will receive 1000mg intravenous injection of paracetamol in combination with 4ml intravenous dexamethasone (8mg), and 5ml nebulisation of of normal saline during 10min as placebo.
215090997|NCT06980727|DRUG|Placebo|Patients will receive 1000mg intravenous injection of paracetamol in combination with 4ml intravenous dexamethasone (8mg), and 5ml nebulisation of of normal saline during 10min as placebo.
215090998|NCT06980831|PROCEDURE|ECT group|VR-ECT group, nursing students will practice via virtual reality for taking care of patients with ECT.
215090999|NCT06979739|BEHAVIORAL|reiki|6 week reiki
215091000|NCT06979739|BEHAVIORAL|refleksologia|6 week refleksologia
215091001|NCT06979739|BEHAVIORAL|reiki and refleksologia|6 week reiki and refleksologia
215094636|NCT03757754|DRUG|HPPH 4 mg/m2|HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
214990237|NCT06025539|BEHAVIORAL|Animal-assisted resilience training|Participants take part in 12 sessions (120 minutes each), each session focuses on a topic that is related to resilience. The intervention takes part outdoors on a farm, and includes interactions with several different animals. The training takes place in small groups, and includes exercises, observations, and discussions.
214990238|NCT05172609|BEHAVIORAL|Exposure Based Implementation Strategy (EBIS)|EBIS will include psychoeducation, assessment/hierarchy building. guided practice, and guidance for application to clinical practice.
214990239|NCT05172609|BEHAVIORAL|Implementation as Usual (IAU)|IAU will consist of standard didactic training and ongoing consultation activities for enrolled clinicians
214990240|NCT05119907|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
214990241|NCT05975216|OTHER|Contact the patient|Phone call, email or letter to contact the patient to relink them.
214377486|NCT02815787|DRUG|SP2086|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
214377487|NCT02815787|DRUG|Glyburide|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
214377488|NCT00570024|PROCEDURE|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
214990242|NCT03910959|OTHER|Animal-assisted therapy|Therapy in the presence and with interaction with an animal. Involved animals can be all species that live at REHAB Basel and are part of the AAT program. All animals are trained for the specific service with vulnerable patients.
214377489|NCT00570024|PROCEDURE|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
214377490|NCT06001502|DEVICE|Virtual Reality distraction therapy|The VR device simulates a 3-dimensional virtual enviroment, seeking to immerse the user in virtual surroundings
214990243|NCT03910959|OTHER|Conventional therapy|Parallelled conventional therapy sessions (treatment as usual)
214990244|NCT06791291|DRUG|Teplizumab|Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion
214990245|NCT04482062|DEVICE|Edwards EVOQUE System|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT
214990246|NCT04482062|DRUG|Optimal Medical Therapy|Optimal Medical Therapy
214990247|NCT06955598|DRUG|SHR-2173|SHR-2173
214990248|NCT06782542|DRUG|Olutasidenib|Olutasidenib will be supplied as 150 mg capsules to be administered orally, twice per day (BID) on an empty stomach (fasting at least 1 hour before or 2 hours after a meal), starting on Cycle 1 Day 1, and will be given continuously.
214377491|NCT03767725|BIOLOGICAL|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART cells.
214990249|NCT06782542|DRUG|Venetoclax|"Participants will receive Venetoclax as a 100mg tablet to be self-administered orally with a meal and water once daily, two hours after starting Olutasidenib administration, starting on Cycle 1 Day 1. The dosing regimen of Venetoclax is as follows:~* Cycle 1: Days 1 - 21 over a 28-day cycle~* Cycle 1 Week 1: Ramp-up dosing schedule up to 400mg (4 x 100mg/tablet)~* For participants with blast clearance: Cycle 2 and beyond: Days 1 - 14 over a 28-day cycle~* For participants with persistent clearance: Cycle 2 through 4: Days 1 - 21"
214990250|NCT06782542|DRUG|Azacitidine|Participants will receive Azacitidine 75 mg/m2 per day via subcutaneous (SC) injection or intravenous (IV) infusion on Days 1-7 of each cycle.
215091002|NCT06979934|BEHAVIORAL|3D printing splint group|Wear 3D printing design splint for position for 60 minutes each time, plus 20 minutes of exercise which including:(1) Raise hands for 5 minutes, and bend and straighten the elbow for 5 minutes for proximal movement exercise;(2) Wear 3D printed design hand splint and change objects according to the ability of grasp, such as hold a cup, handle, eraser, pen, etc.
215091003|NCT06979934|BEHAVIORAL|functional splint group|Wear functional splint for position for 60 minutes each time, plus 20 minutes of exercise which including:(1) Raise hands for 5 minutes, and bend and straighten the elbow for 5 minutes for proximal movement exercise;(2) Grasp the holder according the grasp ability, such as hold a cup, handle, eraser, pen, etc.
214377492|NCT06019689|BEHAVIORAL|CAMI|Culturally Adapted manual-assisted problem solving training based Mobile Intervention (CAMI) for Suicidal Ideation. CMAP is a manual-assisted intervention which has been adapted from a self-help guide called Life After Self-Harm based on the principles of Cognitive behavioral therapy (CBT). This intervention is an evaluation of suicidal ideation, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships and relapse prevention strategies.
214990251|NCT06274489|DRUG|Setanaxib|Setanaxib (formerly GKT137831) is a first-in-class inhibitor of the human protein NADPH NOX1/4. It is a low molecular weight organic molecule and a member of the pyrazolopyridine dione chemical class.
214990252|NCT06274489|DRUG|Placebo|Matching film-coated placebo tablets, containing only excipients
214990253|NCT05654012|DEVICE|MRI|Grey Matter Volume (T1) Resting state BOLD
214990254|NCT05654012|DEVICE|Thermal Stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
215091004|NCT06979479|BEHAVIORAL|school-based intervention|AFL is a four-day program aimed at combating the stigma associated with mental health conditions and reducing suicidal ideation among youth. The program focuses on improving knowledge about depression and mental illness, enhancing self-efficacy skills for coping and seeking help, and increasing receptiveness to receiving assistance. Facilitated by mental health experts, the educational curriculum equips youth with the necessary tools to address feelings of hopelessness.
215091005|NCT06980545|DRUG|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin) will be given in complete six cycles
215091006|NCT06980493|DRUG|Amphotericine in liposome (Ambisome®)|The aim of the study will be to evaluate the efficacy and safety of topical amphotericin B solution in treatment of non-inflammatory type of tinea capitis after resistant response to oral systemic treatment
214990255|NCT05654012|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
214377493|NCT01945567|DEVICE|Up to 3 mA, 60 us, 130 Hz deep brain stimulation|
214990256|NCT05654012|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 10 or 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
214990257|NCT05654012|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.
214990258|NCT05654012|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.
214990259|NCT05654012|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples will be collected for analyses of sex hormone levels
214990260|NCT05654012|BEHAVIORAL|Migraine-related measures|Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.
214990261|NCT05654012|BEHAVIORAL|Neural assessments|MRI and fMRI scans
214990262|NCT05654012|DIAGNOSTIC_TEST|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-
214990263|NCT00549055|DRUG|Macugen|Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
214990264|NCT02903108|DRUG|SRP plus boric acid gel|SRP followed by 0.75% boric acid placement into intrabony defect
214990265|NCT02903108|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
214990266|NCT03846479|DRUG|Itacitinib|for up to 56 days
214990267|NCT04599140|DRUG|CXCR1/2 Inhibitor SX-682|Given PO
214377494|NCT01945567|DEVICE|Empirical unblinded deep brain stimulation programming|
214377495|NCT02348684|RADIATION|Radiation therapy groups|Radiation Therapy treatment between 2000 and 2007.
214377496|NCT03435575|DEVICE|Boosth|Boosth activity tracker which measures steps
214497208|NCT05810363|DRUG|Etomidate - propofol mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
214377497|NCT02307201|DRUG|Magnesium Sulfate|The patient will receive magnesium sulfate for 24 hours postpartum
214377498|NCT01572389|BEHAVIORAL|Healthy Outcomes through Patient Empowerment (HOPE)|HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
214990268|NCT04599140|BIOLOGICAL|Nivolumab|Given IV
214990269|NCT04301284|DRUG|CAD-1883|150 mg filled capsules
214990270|NCT04301284|DRUG|Placebos|capsules
214990271|NCT06267391|DEVICE|ReCET Treatment|Treatment arm will receive the ReCET therapy. The ReCET procedure utilizes the ReCET catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum. Participants will be followed for 12 months post procedure.
214990272|NCT06267391|DEVICE|Sham Procedure|The Control arm will receive a sham procedure. The sham procedure consists of placing the ReCET catheter as described above without therapy applied. Participants will be followed for 12 months post procedure and will be offered cross-over to receive the ReCET therapy after 12 months.
215091007|NCT06980571|DEVICE|radiofrequency ablation|FDA approved intervention being compared with gold standard (most common intervention)
215091008|NCT06980818|OTHER|No intervention|No intervention will take place.
215091009|NCT06657378|OTHER|No Intervention|This is a non-interventional study.
215091010|NCT01495468|BIOLOGICAL|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
215091011|NCT05570071|DEVICE|physical therapy|medical treatment of pelvic floor
215091012|NCT01114360|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
215091013|NCT01114360|DRUG|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
215091014|NCT06979999|PROCEDURE|Positive End-Expiratory Pressure (PEEP)|Application of 10 cmH₂O PEEP during mechanical ventilation after pneumoperitoneum creation in patients undergoing laparoscopic cholecystectomy.
215091015|NCT06980714|BEHAVIORAL|Powered|The intervention involves the use of the Oral-B iO6 powered toothbrush, which provides oscillating-rotating brushing action with personalized feedback via its smart pressure sensor and app integration. Participants in this group are instructed to brush for at least two minutes twice daily. The toothbrush is designed to ensure consistent brushing performance, with real-time feedback on brushing technique and duration, allowing for improved oral hygiene habits. The intervention aims to standardize brushing duration and technique, eliminating potential variations found with manual brushing.
215091016|NCT06980714|BEHAVIORAL|Manual|The intervention involves the use of the TePe Select Soft manual toothbrush, which features soft bristles for gentle yet effective plaque removal. Participants in this group are instructed to brush for at least two minutes twice daily, with guidance on proper brushing technique. To ensure compliance with the brushing duration, participants are required to use a smartphone app that tracks and records their brushing sessions. The manual toothbrush allows for participant control over brushing pressure and technique, with no additional oral hygiene aids allowed during the study period.
215094637|NCT03757754|DRUG|HPPH 5 mg/m2|HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
215094638|NCT03757754|DRUG|HPPH 6 mg/m2|HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
214377499|NCT01572389|BEHAVIORAL|Enhanced Usual Care|All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
214377500|NCT05610891|DRUG|CLR 131|CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
214377501|NCT04802343|DRUG|BAY1817080|Oral, tablet.
214377502|NCT04802343|DRUG|Placebo|Oral, tablet.
214377503|NCT00977756|DRUG|Raltegravir (RAL)|400 mg twice daily (BID)
214377504|NCT00977756|DRUG|Atazanavir (ATV)|300 mg daily
214377505|NCT00977756|DRUG|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
214377506|NCT00977756|DRUG|Tenofovir (TDF)|300 mg daily
214377507|NCT00977756|DRUG|Etravirine (ETV)|200 mg BID
214377508|NCT00977756|DRUG|Darunavir (DRV)|Dosing by weight
214377509|NCT00977756|DRUG|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
214377510|NCT00977756|DRUG|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
214377511|NCT02673710|OTHER|No intervention|Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
214377512|NCT03535064|OTHER|Hand Hygiene Workshop|Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
214377513|NCT04185714|OTHER|Kinesiotaping|Kinesiotaping (KT) is an approach that supports injured muscles and joints and helps relieve pain.
214377514|NCT04185714|OTHER|Placebo taping|sham taping
215091017|NCT06981117|OTHER|12 hr Respite Service|12 hours of respite service within 3 months will be provided by volunteers. Volunteers will provide elderly-sitting service (accompany the care recipient) during the service session, and provide cognitive training or physical training to the care recipient if situation allows.
214377515|NCT01287520|DRUG|LY2090314|Administered intravenously
214377516|NCT01287520|DRUG|pemetrexed|Administered intravenously
215091018|NCT06981117|OTHER|36 hr Respite Service|36 hours of respite service within 3 months will be provided by substitute caregivers. Substitute caregivers will provide elderly-sitting service (accompany the care recipient) during the service session, and provide cognitive training or physical training to the care recipient if situation allows.
214377517|NCT01287520|DRUG|Carboplatin|Administered intravenously
214377518|NCT01287520|OTHER|ranitidine|Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.
214377519|NCT02524301|DRUG|Positron Emission Tomography using [11C]diprenorphine|PET using \[11C\]diprenorphine
214377520|NCT04144803|DIAGNOSTIC_TEST|Cerebral near-infrared spectroscopy|Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
214377521|NCT00708435|BIOLOGICAL|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
214377522|NCT00708435|BIOLOGICAL|Fresh frozen plasma|Intravenous Infusion, dosage depending on baseline INR and body weight
214377523|NCT02352363|DRUG|CVT-301|
214377524|NCT02352363|OTHER|Observational cohort|
214377525|NCT00118261|BIOLOGICAL|bevacizumab|Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
214377526|NCT00118261|DRUG|erlotinib hydrochloride|Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
214377527|NCT00118261|DRUG|fluorouracil|Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
214377528|NCT00118261|DRUG|leucovorin calcium|Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
214377529|NCT00118261|DRUG|oxaliplatin|Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
214377530|NCT01683162|DRUG|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
214377531|NCT01683162|DRUG|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
214377532|NCT01683162|DRUG|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
214377533|NCT03193671|DIAGNOSTIC_TEST|Diagnosis|Improving diagnosis
214377534|NCT05301062|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Treatment with Radium-223 should follow the approved local product information according to National Medical Products Administration (NMPA) approved label
214377535|NCT00030420|DRUG|Celecoxib|400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
214377536|NCT00030420|DRUG|Docetaxel|On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
214377537|NCT05916976|DIAGNOSTIC_TEST|cardiac MRI|Multiparametric MRI of the heart
214377538|NCT01896284|DRUG|0.5mg aflibercept|0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
214377539|NCT05553639|BIOLOGICAL|HB-302/HB-301 Alternating 2-Vector Therapy|Alternating Therapy of HB-302 and HB-301. The first 5 doses will be administered every 3 weeks. The 6th dose will be administered 6 weeks after the 5th dose. Subsequent doses will be administered every 6 weeks.
214377540|NCT04995237|BEHAVIORAL|PPP|Participants will be provided with a weekly bag of produce, information about how to cook the produce, assistance in setting quality of life goals, and individualized teaching to support meeting participant's set goals.
214377541|NCT05025501|BEHAVIORAL|Family based Executive Function Training|Training the executive funtions of shcoolage ADHD children through tasks and games repeatly but with fun. Giving the parental training and support for the parenting role parents strategies to help the shcoolage ADHD childred coping the symptoms and develop EF in the reallife and improve parent-child relationship.
214377542|NCT05801458|PROCEDURE|Modeling Resin Insertion Technique|One drop of modeling resin will be dispensed into a clean mixing well. Following the placement of the resin composite into the prepared site, a composite instrument (round-ended plugger with a diameter of 2 mm) will be dipped into the modeling resin. With modeling resin on the instrument, the resin composite is sculpted and manipulated to the desired shape. This will be repeated with each increment. Each increment will be polymerized for 20 sec with a LED light-curing unit.
214377543|NCT05801458|PROCEDURE|Conventional resin composite Incremental Placement Technique|A three-step etch-and-rinse adhesive system will be used according to the manufacturer's instructions. 37.5% phosphoric acid (Kerr Co, Orange, CA, USA) will be applied to the enamel and dentin for a period of 30 s and 15 s, respectively. Subsequently the cavities will then be rinsed with an air/water spray for 15 s. A layer of primer will be applied to the dentin for 30 sec, afterward gentle air-drying for 5 sec. Then, the bond (AdheSE adhesive) will be applied on the enamel and dentin and light cured with a LED curing unit for about 30 sec. Tetric N-Ceram will then be applied using an incremental filling technique, each increment will not exceed 2mm in thickness. Each increment will be polymerized for 20 sec with a LED light-curing unit.
214377544|NCT05716620|DIAGNOSTIC_TEST|MRI|USG and MRI will be performed on the same day. US will be performed prior to MRI. There will be two rounds of screening 6 months apart using paired US and non-enhanced AMRI.
215091019|NCT06980363|DRUG|traditional inferior alveolar nerve block by articaine|use articaine for inferior alveolar nerve block with buccal infiltration to anesthetized lower molar teeth
215091020|NCT06980363|DRUG|hyaluronidase plus articain buccal infilteration|use of articain plus hyaluronidase enzyme buccal infiltration to anesthetized lower molar teeth
214377545|NCT06120673|DRUG|Obinutuzumab|"Participants will receive an intravenous infusion of 1,000mg Obinutuzumab at Weeks 0, 2, 24 and 26.~Prior to the administration of obinutuzumab, the participant will receive pre-medications consisting of all three:~* IV methylprednisolone 80 mg,~* Paracetamol 1,000 mg orally,~* Either cetirizine 10 mg orally or diphenhydramine 50 mg orally. These pre-medications must be completed between 30 to 60 minutes prior to the obinutuzumab infusion."
214377546|NCT06120673|DRUG|Oral prednisolone and cyclophosphamide|"Participants will receive a combination of oral prednisolone and cyclophosphamide with 2 options (Option A and B).~Option A: Cyclical prednisolone and cyclophosphamide with IV methylprednisolone~* IV methylprednisolone 500-1000 mg will be given on days 1, 2 and 3 at the start of months 1, 3, and 5.~* Oral prednisolone will be given at 0.5 mg/kg/day (max 50 mg/day) in months 1, 3, and 5.~* Oral cyclophosphamide will be given in months 2, 4 and 6, adjusted by age and weight~Option B: Concurrent prednisolone and cyclophosphamide without IV methylprednisolone~* Oral prednisolone will be given to meet a cumulative dose equivalent to 0.5 mg/kg/day for 90 days (max 50 mg/day).~* Oral cyclophosphamide will be given for 90 days, adjusted by age and weight"
214377547|NCT01737684|DRUG|Vibegron|50 mg tablet, oral
214377548|NCT03990584|PROCEDURE|three irrigation activation methods|passive ultrasonic irrigation, sonic irrigation, manual dynamic irrigation
214377549|NCT03990584|PROCEDURE|conventional needle irrigation|conventional needle irrigation
214497209|NCT05810363|DRUG|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
214497210|NCT05841706|BIOLOGICAL|Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)|Receive conservative transfusion strategy (Hgb \< 7 g/dL)
214497211|NCT05841706|BIOLOGICAL|Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)|Receive liberal transfusion strategy (Hgb \< 9 g/dL)
214497212|NCT05841706|PROCEDURE|Computed Tomography|Undergo CT scan
214497213|NCT05841706|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214497214|NCT05841706|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214497215|NCT05841706|OTHER|Survey Administration|Ancillary studies
214377550|NCT05747339|BIOLOGICAL|tumor treatment vaccine injection|Patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml / week, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml / week.The interval between injections can be shortened or extended depending on the patient's condition and response.The duration of treatment should be extended as long as possible, at least 6-12 months.
214377551|NCT05741099|BIOLOGICAL|Umbilical cord mesenchymal stem cells implantation|Patient in Mscs group will receive MSCs implantation by intravenous injection.
214377552|NCT05741099|OTHER|Comparator|Patients in comparator group will receive placebo treatment
214377553|NCT04167995|DRUG|Probiotic Formula lacteal forte|Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
214497216|NCT05841706|PROCEDURE|Pancreatectomy|surgical removal of all or part of pancreas
214497217|NCT03668899|PROCEDURE|irrigation|irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
214497218|NCT05490732|BIOLOGICAL|Blood sampling|"Patient will be subjected to 3 blood sampling over 24hours. At H0, H4 and H12-24.~For each one, one microsampling and one venipuncture"
214497219|NCT06416072|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
214377554|NCT00472771|DRUG|INNO-206|
214990273|NCT05651256|DRUG|Botulinum toxin type A injection|The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.
214990274|NCT05461209|DRUG|Talquetamab|Talquetamab will be administered as subcutaneous injection.
214990275|NCT05461209|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered as intravenous infusion.
214990276|NCT06956586|OTHER|Therapeutic communication techniques|"Therapeutic communication techniques will be applied to children in the intensive care unit for two days."
214990277|NCT05020015|BIOLOGICAL|TAK-007|TAK-007 intravenous injection.
214990278|NCT05020015|DRUG|Chemotherapy Agents|Fludarabine and cyclophosphamide as per standard of care.
214990279|NCT05612490|DRUG|Furosemide stress test|The FST corresponds to the intravenous single-dose administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. In the 12 hours following the first RRT liberation, a FST will be performed. The test will be considered positive if urinary output is ≥200 mL in the two hours following furosemide administration.
214377555|NCT01386996|DRUG|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
214377556|NCT01386996|DRUG|Symbicort Turbuhaler forte|2 inhalations as a single dose
214377557|NCT00877981|PROCEDURE|Minimal invasive Parathyroid surgery|
214377558|NCT01822938|OTHER|incentive program for physical activity|
214377559|NCT02462850|DRUG|CL-108|
214377560|NCT02990416|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
214377561|NCT02990416|BIOLOGICAL|Pembrolizumab|A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
214377562|NCT02990416|RADIATION|Ionizing Radiation|Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
214377563|NCT02266602|RADIATION|Intraoperative Radiation Therapy|Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
214377564|NCT05389111|OTHER|Internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, will be led by a professional of the training field, specialist of the trail activity and trained in the use of mental strategies
214377565|NCT05389111|OTHER|Non internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, and will be conducted by a professional of the training field, specialist of the trail activity and coach of mountain guide
214377566|NCT02224963|BEHAVIORAL|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
214377567|NCT02224963|BEHAVIORAL|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
214377568|NCT01276561|PROCEDURE|Single Incision Splenectomy|Patients will undergo laparoscopic splenectomy through a single incision
214377569|NCT01276561|PROCEDURE|Laparoscopic Splenectomy|Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
214377570|NCT01106053|DRUG|Pramipexole|Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
214377571|NCT01117701|PROCEDURE|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.
214990280|NCT03994159|DEVICE|"Use of the PARO emotional robot"|PARO is an advanced interactive therapeutic robot designed to stimulate patients with Dementia, Alzheimer's, and other cognition disorders.
214990281|NCT02921100|PROCEDURE|cytology|The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.
214990282|NCT02921100|PROCEDURE|DNA ploidy|DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy
214990283|NCT02921100|PROCEDURE|EUS-FNA|All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.
214990284|NCT02921100|DEVICE|EUS-guided fine needle|
214990285|NCT02795143|DRUG|Isotretinoin|
214990286|NCT02795143|OTHER|Placebo|
214377572|NCT02572947|DRUG|Dolutegravir|
214377573|NCT03645135|OTHER|Goal elicitation|Patients will be asked to list 2 goals for their visit
214377574|NCT01598402|DRUG|amoxicillin/clavulanic acid suspension|625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
214377575|NCT00591201|DRUG|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
214377576|NCT00591201|DRUG|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
214990287|NCT02358629|DEVICE|NovaCross™ microcatheter|successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
214990288|NCT00345306|DRUG|Comparison between two different progesterone administration|
214990289|NCT00908700|PROCEDURE|Surgical occlusion of the left atrial appendage|Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.
215091026|NCT00755547|OTHER|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
215091027|NCT06983769|DEVICE|MAD|"Mandibular Advancement Device. It is a custom-fitted oral appliance used primarily to treat obstructive sleep apnea (OSA) and snoring. The device works by gently advancing the lower jaw (mandible) forward, which helps keep the airway open during sleep by preventing the tongue and soft tissues from collapsing and blocking the airway.~MADs are a non-invasive alternative to CPAP therapy and are especially suitable for patients with mild to moderate OSA or those who are intolerant to CPAP"
215091028|NCT06983769|DEVICE|CPAP|"CPAP stands for Continuous Positive Airway Pressure. It is the standard treatment for obstructive sleep apnea (OSA). A CPAP machine delivers a constant stream of air through a mask worn over the nose or nose and mouth during sleep. This air pressure keeps the airway open, preventing pauses in breathing caused by airway collapse.~CPAP is highly effective, especially for moderate to severe OSA, but some patients may find it uncomfortable or difficult to tolerate."
215091029|NCT06855641|PROCEDURE|Opioid based Anesthesia|in this group, patient will receive standard of care at UCLA including fentanyl administration during surgery
215091030|NCT06855641|PROCEDURE|opioid free anesthesia|In this group, patients will not receive any opioids intraoperatively
215091031|NCT06981221|DEVICE|Masimo Radical-7 Pulse Oximeter|"PVI is continuously monitored using the Masimo Radical-7 pulse oximetry device to evaluate respiratory variation in the plethysmographic waveform amplitude during laparoscopic-assisted vaginal hysterectomy (LAVH). No fluid intervention is applied; device use is for observational measurement of fluid responsiveness."
214377577|NCT06056921|BIOLOGICAL|CD19 targeted CAR-T cells|A single infusion of CD19 CAR-T cells will be administered intravenously
214377578|NCT01691521|DRUG|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
214990290|NCT00908700|PROCEDURE|Best medical practice|Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
214990291|NCT02515253|OTHER|Bra prescription|
214377579|NCT01691521|DRUG|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
214377580|NCT01691521|DRUG|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
214497220|NCT03220074|DRUG|Oral Tablet|study drug given and monitored for efficacy and tolerability
214497221|NCT05276297|DRUG|GSK3228836|2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.
214990292|NCT02515253|OTHER|Standard Care|
214990293|NCT04521296|OTHER|Part 1|\- DWJ1248 600mg PO (100mg 2 tab, TID)
214990294|NCT04521296|OTHER|Part 2|\- DWJ1248 600mg PO (200mg 1 tab, TID)
214990295|NCT06400810|DEVICE|Analog Devices Inc.|Wearable wrist device that collects Photoplethysmography, accelerometer data among other parameters.
214990296|NCT01954615|DRUG|5 mg ACT-281959 prodrug formulation I (Group A)|
214377581|NCT01691521|DRUG|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
214990297|NCT01954615|DRUG|20 mg ACT-281959 prodrug formulation I (Group B)|
214990298|NCT01954615|DRUG|ACT-281959 prodrug formulation I (Groups C to G doses to be defined)|
214990299|NCT01954615|DRUG|ACT-281959 prodrug formulation II (Group G dose to be defined)|
214990300|NCT01954615|DRUG|ACT-246475 (Group G dose to be defined)|
214990301|NCT01954615|DRUG|Placebo (Groups A to F)|
214377582|NCT04503096|DEVICE|High-dose accelerated rTMS|A MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System will be utilized. All participants will receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within an eight-day span. A single session = 600 pulses at 120% resting motor threshold (rMT), intermittent Theta Burst Stimulation (iTBS) triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 s to left dorsolateral prefrontal cortex. Total pulses = 14,400. To enable adherence and retention, the days do not need to be contiguous. Same day sessions will be separated by 10-15 minutes, but more accounting for participant comfort.
214377583|NCT01480596|BIOLOGICAL|Belimumab|10mg/kg IV infusion
214377584|NCT01480596|OTHER|Placebo|placebo IV infusion
214377585|NCT01581840|DRUG|radiochemotherapy|Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
214377586|NCT01581840|DRUG|Panitumumab|3 or 6 mg/kg (according to dose level)
214377587|NCT02343003|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
214377588|NCT02343003|DRUG|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
214377589|NCT01299090|DEVICE|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
214497222|NCT05276297|BIOLOGICAL|GSK3528869A|"The GSK3528869A chronic Hepatitis B targeted immunotherapy (CHB-TI) consisting of 4 doses administered intramuscularly as follows:~* 1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period.~* 1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period.~* 2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period."
214497223|NCT05276297|DRUG|Control|4 doses of non-active control administered intramuscularly in the deltoid region of the non-dominant arm at Days 1, 57, 113 and 169 to participants in ASO24 and ASO12 control groups during Treatment 2 period.
214497224|NCT05464368|DRUG|[18F]RO-948|"Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
214990302|NCT05917379|BIOLOGICAL|fecal microbiota|FMT utilizes stool from a healthy donor and puts them into capsules after processing
214990303|NCT05917379|OTHER|Placebo|Starch into the same outlook capsule with fecal microbiota
214990304|NCT05917379|DIETARY_SUPPLEMENT|synbiotics|Lactobacillus Helveticas+ Bifidobacterial longum + inulin(3g/day)
214990305|NCT06087211|DRUG|Magnesium sulphate and Duloxetine|Patients received Duloxetine 30mg orally and an intravenous infusion of magnesium sulphate 50mg/kg mixed with 200 ml of normal saline.
214990306|NCT06087211|DRUG|Duloxetine|Patients received Duloxetine 30mg orally and 200 ml of normal saline.
214990307|NCT06087211|DRUG|Placebo and normal saline|Patients received a placebo capsule and an intravenous infusion of 200 mL of normal saline.
214990308|NCT02534480|DRUG|NGP 555|Gamma-secretase modulator for the treatment of Alzheimer's disease
214990309|NCT02625740|DEVICE|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
214990310|NCT02625740|DEVICE|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
214990311|NCT02625740|DEVICE|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
214990312|NCT02625740|DRUG|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
214990313|NCT02625740|PROCEDURE|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
214990314|NCT05413941|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy in which individuals are taught to identify and modify maladaptive thinking and behavior to improve their psychological status and coping skills. CBT in this trial will be delivered digitally (internet-based).
214990315|NCT05592366|BEHAVIORAL|Care Partner Hospital Assessment Tool|Complete the adjusted CHAT as well as demographic and caregiving questionnaires during and after loved one's hospitalization.
214990316|NCT03170297|OTHER|Research interventions of blood sampling and data collection|Patient-Specific Functional Scale (PSFS) survey will be administered to patients to record symptoms at both the time of evaluation in the emergency department and in follow up by phone at 3, 7, 14, 21 and 28 days after discharge from the emergency department or hospital. The rest of the patients' care will be as usual care, and patients will have had research interventions of blood sampling and data collection as noted in the previously approved SC2i Tissue Data Acquisition Protocol (TDAP) Pro00054947 (ClinicalTrial.gov ID: NCT02182180).
214990317|NCT03967834|OTHER|Patient with Soft Tissue Sarcoma|"* Tumor specimens will be collected for the study at diagnosis.~* A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.~* Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years."
214990318|NCT06217380|DEVICE|Masimo SafetyNet Alert (MSNA)|This study will explore the feasibility of implementing the Masimo SafetyNet Alert (MSNA) oxygen saturation monitoring system and the acceptance of MSNA by individuals living in a supportive housing program, who inject opioids.
214990319|NCT04539236|DRUG|Lenalidomide|Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
214990320|NCT04539236|DRUG|Luspatercept|Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
214990321|NCT04109963|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
214990322|NCT05539170|BEHAVIORAL|Immediate positive parenting feedback|Individual positive feedback concerning their parenting and their child's behavior.
214990323|NCT06582524|DRUG|Pegzilarginase|SC administration of pegzilarginase over 12 weeks in subjects with ARG1-D who are \< 24 months of age
214990324|NCT03054896|DRUG|Venetoclax|Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor
214990325|NCT03054896|OTHER|DA-EPOCH-R|Intensive chemotherapy regiment
214990326|NCT03054896|OTHER|R-CHOP|Intensive chemotherapy regiment
214990327|NCT04848961|BEHAVIORAL|LungTalk|MSK developed LungTalk, a novel computer-tailored health communication and decision support tool to (1) increase awareness and knowledge about lung screening; (2) decrease perceived barriers to screening based upon misinformation; and (3) increase screening rates.
214990328|NCT00005584|BIOLOGICAL|bleomycin sulfate|
214990329|NCT00005584|DRUG|ABVD regimen|
214990330|NCT00005584|DRUG|BEACOPP regimen|
214990331|NCT00005584|DRUG|epirubicin hydrochloride|
214990332|NCT00005584|DRUG|prednisone|
214377590|NCT01033214|DEVICE|Endovascular repair of TAA in the descending Thoracic Aorta|Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
214990333|NCT00005584|DRUG|vinblastine sulfate|
214990334|NCT00005584|RADIATION|radiation therapy|
214990335|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
214990336|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
214990337|NCT04661904|DEVICE|Continuous theta burst stimulation (cTBS)|Our active treatment consisted of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group received 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation was given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation were given at 8 am, 8:30 am and 9:00 am on postoperative day 1and 2, respectively.
215091032|NCT06980311|OTHER|Aerobic Exercise|"Traditional Aerobic Exercise group will undergo treadmill-based aerobic exercise training under the supervision of a physiotherapist twice a week for a total of 8 weeks. For participant safety, they will be instructed to hold onto the handrails while walking, and proper use of the safety key will be ensured during each session.~Using the ULTIMA DC-5000 treadmill, participants will follow an exercise protocol based on the guidelines of the American College of Sports Medicine (ACSM), consisting of: a 10-minute warm-up, a 20-30-minute loading phase at 40-60% of heart rate reserve (moderate-to-vigorous intensity), and a 10-minute cool-down, all performed at 0% incline.~Throughout the sessions, participants' heart rate and oxygen saturation levels will be monitored via a fingertip pulse oximeter. Fatigue and dyspnea levels will also be assessed and recorded using the Modified Borg Scale."
215094639|NCT00421642|DRUG|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
215094640|NCT01997190|BIOLOGICAL|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
215094641|NCT04402541|DRUG|CB-5339|25mg and 75mg capsules
215094642|NCT05529004|DRUG|Oral Capsule pregapalin|oral cap of pregapalin has been administration to patient before surgery to prvent PONV
214377591|NCT01153269|DRUG|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
214377592|NCT05733962|DEVICE|Use of the device DBL-4pen|"During the treatment period, the patient will use~* the DBL-4pen device (consisting of a software hosting the Diabeloop algorithm installed on a smartphone)~* the associated device #1: Dexcom G6, Continuous Glucose Monitoring (CGM)~* the associated device #2: Two Mallya caps for their rapid- and long-acting insulin pens.~The regulation algorithm hosted by DBL-4pen software recommends insulin doses to be administrated by the patient."
215094643|NCT05529004|DEVICE|laparoscope device|general anesthesia with complete relaxation under laparoscopic cholecystectomy
214377593|NCT05517200|DIAGNOSTIC_TEST|Machine Learning Test for Migraine|Resting EEG, and Visual and Auditory Stimulation
214377594|NCT02558270|DRUG|Dapagliflozin|
214377595|NCT02558270|DRUG|Placebo|
214377596|NCT01566175|DEVICE|Neovac coronary sinus reducer|reducer
214377597|NCT02252614|DRUG|naproxen sodium codein|Pain intensity, contramal consumption
214377598|NCT02252614|DRUG|paracetamol codein|Pain intensity, contramal consumption
214377599|NCT02252614|DRUG|Placebo|Pain intensity, contramal consumption
214377600|NCT03852966|BEHAVIORAL|CBT-i/ADHD|Cognitive Behavioral Therapy for insomnia adjusted for patients with ADHD
215091033|NCT06980311|OTHER|Aerobic exercise with music therapy|Music Therapy-Based Aerobic Exercise Training group will follow the same treadmill exercise program as the Traditional Aerobic Exercise group. However, during the exercise sessions, music therapy will be applied according to the beats per minute (BPM) ranges specified below: Warm-up (10 minutes, BPM: 80-100): Low-intensity walking accompanied by slow-tempo music Loading Phase (20-30 minutes, BPM: 120-140): Moderate-to-high intensity walking accompanied by rhythmic, motivational music Cool-down (10 minutes, BPM: 80-100): Low-intensity walking accompanied by slow-tempo sedative music Music will be used throughout the exercise sessions to regulate participants' heart rate and blood pressure, reduce perceived fatigue, enhance motivation, and support rhythmic movement patterns. During training, participants' heart rate and oxygen saturation will be monitored using a fingertip pulse oximeter.
214377601|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
214377602|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
214377603|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
214377604|NCT00818363|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
214377605|NCT00818363|DRUG|SABER-Placebo|Injectable Solution; 5.0 mL SABER-Placebo/Once
214377606|NCT00988221|DRUG|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
214377607|NCT00988221|DRUG|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
214377608|NCT00977496|PROCEDURE|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
214377609|NCT00483834|DRUG|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
214377610|NCT00483834|DRUG|Irinotecan|200mg/m\^2, IV, day 1 each cycle
214377611|NCT00483834|DRUG|Capecitabine|1000mg/m\^2 or 750mg/m\^2 for patients over 65yrs old PO BID, day 1-14 each cycle
214377612|NCT00633919|BIOLOGICAL|SLITone(TM) Dermatophagoides mix|Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
214377613|NCT00633919|BIOLOGICAL|Placebo|Sublingual immunotherapy once daily for 2 years
214377614|NCT00633919|DRUG|Salbutamol inhaler|200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
214377615|NCT00633919|DRUG|Budesonide/formoterol inhaler|80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
214377616|NCT00633919|DRUG|Prednisone tablet|5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
214377617|NCT00633919|DRUG|Desloratadine tablet|5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
214377618|NCT00633919|DRUG|Budesonide nasal spray|64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
214377619|NCT04154215|DIAGNOSTIC_TEST|PET-CT FDG brain scan|"Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated."
214497225|NCT05464368|DRUG|18F-MK6240|"18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
214497226|NCT05464368|DRUG|18F-GTP1|"18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location."
215091034|NCT06592222|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
215091035|NCT06592222|DRUG|Standard of care|Standard of care
214377620|NCT05135546|DRUG|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
214377621|NCT05135546|DRUG|Placebo|6 ml of 0.9% solution of NaCl for inhalation
214377622|NCT02672501|DRUG|anti-CD19-CAR-T cells|a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences
214377623|NCT03509532|DEVICE|PCI|PCI
214377624|NCT02756832|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets
214990338|NCT04661904|DEVICE|Sham stimulation|The sham stimulation group received a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 3 days) with the coil set at 90 against the skull. The first set of stimulation was given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation were given at 8 am, 8:30 am and 9:00 am on postoperative day 1 and 2, respectively.
214377625|NCT01040390|DRUG|Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
214377626|NCT01461330|OTHER|DASH diet plus exercise|"DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat~Exercises: the recommended physical activity will consist of using a pedometer during the experimental period."
214377627|NCT01461330|OTHER|ADA diet|Adoption of ADA diet.
214377628|NCT00906048|DRUG|Levofloxacin (HR355) and Rifampicin Therapy|"Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight \< 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight \> 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin"
214377629|NCT05384925|OTHER|comparison|abdominal surgery as a risk factor for diverticulosis
214377630|NCT05157074|BEHAVIORAL|Group Drumming Music Therapy|"All 24 Armstrong Rhythm Cycle™ sessions is conducted in a circle to ensure maximum line of sight for each participant. A variety of diverse percussion instruments ranging from hand drums, stick drums, shakers, and rhythm sticks are available as well as adaptive measures to address limited physical functioning. Instrument choice is dependent on ease of use for the level of the physical ability, skill development needs, and personal choice. Participants are informed that they are free to use the same instrument for the duration of each session or to switch instruments at any time.~Utilizing the five components of The Armstrong Rhythm Method, this protocol guides participants through three phases to achieve rhythmic skill development and group cohesion for their therapeutic benefit."
214377631|NCT03221101|DEVICE|Home ventilator|
214377632|NCT00002396|DRUG|Tenofovir disoproxil fumarate|
214377633|NCT02013596|OTHER|TEAS pretreatment|Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction
214377634|NCT02013596|OTHER|TEAS treatment|Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
214377635|NCT03028090|DEVICE|SHERLOCK 3CG™ Tip Confirmation System with MODUS Software|The SHERLOCK 3CG™ Tip Confirmation System (TCS) is a fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology. It was cleared by the FDA on March 19, 2012 and is indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients. In order to further develop the SHERLOCK 3CG™ platform and simplify the PICC placement for the clinician, Bard Access Systems, Inc. is developing MODUS, a software package.
214990339|NCT06529159|PROCEDURE|HEAPE|The stomach is filled with sodium chloride solution which is then treated with APC to activate it into an antibacterial solution.
214377636|NCT04597502|DIETARY_SUPPLEMENT|Terminalia Chebula fruit extract|Oral TC fruit extract supplement taken by mouth twice per day
214377637|NCT04597502|DIETARY_SUPPLEMENT|Placebo|Oral placebo taken by mouth twice per day
214377638|NCT04597502|OTHER|Topical Terminalia Chebula|Applied to both forearms and dorsal hands
214377639|NCT04597502|OTHER|Topical Placebo|Applied to both forearms and dorsal hands
214377640|NCT03884504|DEVICE|Ventricular Assist Device System|Ventricular Assist Device System
214377641|NCT01781390|OTHER|Placebo|Matching placebo solution for infusion.
214377642|NCT01781390|BIOLOGICAL|Mesenchymal Precursor Cells (MPC) 12.5 M|MPC 12.5 M solution for infusion.
214377643|NCT01781390|BIOLOGICAL|Mesenchymal Precursor Cells (MPC) 25 M|MPC 25 M solution for infusion.
214377644|NCT04912674|DEVICE|Symphony OCT System|Surgical intervention will be patient specified by treating surgeon.
214377645|NCT04097405|DRUG|D-0120|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
214377646|NCT04097405|DRUG|Placebo oral tablet|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
214377647|NCT04313569|PROCEDURE|Arthroscopic menisctomy|Arthroscopic medial menisctomy
214377648|NCT00634816|RADIATION|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
214377649|NCT04750655|DRUG|Moxifloxacin (Topical)|We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
214377650|NCT01216163|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
214990340|NCT06529159|PROCEDURE|Pre-HEAPE|Plasma activated sodium chloride solution (prepared outside of the body) is administered into the patients stomach through an endoscope channel using a syringe.
215094644|NCT00969072|DRUG|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
215094645|NCT00969072|DRUG|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
215094646|NCT00969072|DRUG|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
215094647|NCT01063088|BIOLOGICAL|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
215094648|NCT03166072|OTHER|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
215094649|NCT03166072|OTHER|No Intervention|Participants will continue to receive treatment as usual
215094650|NCT05527886|OTHER|AAROM|AAROM with knee to wall exercise, 3x30 reps
214377651|NCT01216163|DRUG|Acetaminophen|Single-dose of acetaminophen (1000mg)
214377652|NCT01216163|DRUG|Placebo|Single-dose of placebo
214497227|NCT06307938|DIAGNOSTIC_TEST|liquid biopsy|based on a panel of circulating tumor DNA markers
214497228|NCT02475343|DEVICE|Schiotz tonometer|The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
214377653|NCT01438463|BIOLOGICAL|Placebo|Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
214990341|NCT05581030|DRUG|Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)|"Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term hyper refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.~Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.~Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient."
214990342|NCT05581030|DRUG|Calaspargase Pegol|Calaspargase pegol 2000 IU/m\^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.
214990343|NCT05581030|DRUG|Rituximab|Rituximab 375mg/m\^2 will be administered once per cycle for patients with CD20+ ALL.
214990344|NCT06257550|BEHAVIORAL|THRIVE Intervention|"THRIVE Intervention includes:~1. Weekly Pulse Surveys~2. Adaptive culturally tailored messages~3. Personalized Dietitian Coaching~4. Produce Prescription FARMacy Mobile Market~5. Linkages to Social Services"
214990345|NCT06257550|BEHAVIORAL|Active Comparator|The Active Comparator arm will receive standard produce bags through our food is medicine partner, and will receive the linkages to needed social and health resources intervention components.
214990346|NCT06506344|BEHAVIORAL|5S Trial|Participants will receive caring contacts/recruitment outreach, suicide risk screening, suicide safety planning, and, if indicated, connection to healthcare services, resources and the CLASP virtual outreach intervention.
214990347|NCT04917575|OTHER|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing.
214377654|NCT01438463|BIOLOGICAL|PURETHAL Mites 6,667 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
214497229|NCT02475343|DEVICE|UVA/riboflavin|The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
214377655|NCT01438463|BIOLOGICAL|PURETHAL Mites 20,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
214377656|NCT01438463|BIOLOGICAL|PURETHAL Mites 50,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
214377657|NCT01438463|BIOLOGICAL|PURETHAL Mites 100,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
214377658|NCT00210262|BEHAVIORAL|Feedback and Education|
214377659|NCT02080104|DRUG|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
214497230|NCT02475343|DEVICE|femto-LASIK|The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
214497231|NCT02475343|DEVICE|Tomey SP-100 Pchymeter , Topolyzer Vario|Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
214990348|NCT04917575|OTHER|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information, and information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
214990349|NCT06438211|PROCEDURE|superficial or deep serratus anterior plane block for mastectomy|group I: superficial SAP Block for postoperative analgesia for mastectomy group II: deep SAP Block for postoperative analgesia for mastectomy
214990350|NCT06295250|BEHAVIORAL|Manualized Group Based Psychotherapy|Manualized Group Based Psychotherapy. Adapted from the World Health Organization (WHO) Problem Management Plus (PM+) intervention, this intervention includes behavioral activation, enhancing social support, and problem management.
214990351|NCT06295250|OTHER|Poverty Alleviation|Modeled on the well-known Graduation Program, a poverty alleviation strategy widely used in low income countries, this intervention includes an asset transfer (agricultural animals), financial literacy education, a 6 month stipend, savings accounts, veterinary support, feed, and agricultural training
214990352|NCT06323954|PROCEDURE|tVNS stimulation|Electrical stimulation to the vagus nerve area.
214990353|NCT06323954|PROCEDURE|Sham stimulation|Electrical stimulation to the non-vagus nerve area.
215094651|NCT05527886|OTHER|Slow Load|Single leg heel raise, 3x10 reps
215094652|NCT05527886|OTHER|Plyometric|Double leg 5 inch wall hops, 3x10 sec
214377660|NCT03973866|DEVICE|Alfapump|Implantation of alfapump
214990354|NCT03991169|DRUG|Ferrous Sulfate|Oral iron will be given in the form of immediate-release iron sulfate, 3-6 mg/kg/day of elemental iron to children with body weight ≤43 kg, and 65 mg of elemental iron (325 mg of iron sulfate) to children with body weight \>43 kg.
214990355|NCT04232631|DEVICE|SnapshotNIR, Kent Imaging|Vascular imaging device
214377661|NCT00557609|DRUG|ARQ 197|360 mg administered twice daily until disease progression or other discontinuation criterion is met
214377662|NCT02555462|DEVICE|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
214497232|NCT02475343|DEVICE|Topcon CT-80, Topcon, Japan|Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
214990356|NCT06958380|BEHAVIORAL|Corrective exercise and rehabilitation|This is a longitudinal single-subject case study in which one adult patient diagnosed with Fanconi anemia will undergo a structured, supervised corrective exercise and rehabilitation program. The subject will serve as their own control, with baseline measurements compared to post-intervention outcomes.
214990357|NCT00634517|DRUG|Armstrong Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
214990358|NCT00634517|DRUG|Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
214990359|NCT05106907|BIOLOGICAL|ThisCART19 cells|0.2-60 x 10\^6 CAR T cells per kg body weight
214990360|NCT05129696|BEHAVIORAL|Treatment (T)|Children area offered to participate in bimonthly group sessions. Each session will have materials and activities appropriate for children spanning a 6-month range (6-12 m, 12-18 m, 12-24 m, 24-30 m) and can accommodate a maximum of 10 children per age group. If more households are interested than can be accommodated by the program, interested families will be randomly selected for participation. A total of 40 children per site will be able to participate in the ECD activities at any one time. With bi-monthly meetings, each child will be exposed to 12 sessions for each age group, and is eligible to transition to the next.
215091036|NCT06610552|BEHAVIORAL|Powerly|Powerly is a mental well-being mobile app, in which pregnant women can track their mood and level of stress, and receive personalized psychological modules to increase their mental health and well-being. By integrating evidence-based content and cognitive behavioral techniques with insights from pregnant and postpartum individuals and health professionals, Powerly offers a comprehensive psychological support including reappraisal, mental imagery, gratitude, mindfulness, self-efficacy and behavioral activation exercises.
214497233|NCT02475343|DEVICE|Corvis-ST|Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
214990361|NCT05129696|BEHAVIORAL|Treatment + (T+)|Caregivers/children participating to the group ECD sessions will be invited to play within a play space equipped with books, and homemade/purchased age-appropriate toys. This will be phased in after 6 months of implementation.
214990362|NCT02549118|DRUG|Tenoxicam|
215091037|NCT05698745|PROCEDURE|bioespecimen samples|Blood, serum, plasma, urine, stools, small/large bowel tissue.
215091038|NCT06993480|DRUG|AHB-137|AHB-137 300 mg will be injected subcutaneously once a week (total 24 weeks).
214377663|NCT05958563|DEVICE|continuous positive airway pressure treatment|CPAP treatment for one year
214377664|NCT06070350|BIOLOGICAL|Low Titer Group O Whole Blood (LTOWB)|LTOWB is whole blood from group O donors with low titer (\<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.
215091039|NCT06600308|OTHER|Walk tests|"Performance of the following walking tests using inertial measurement units: TUG; 10 m test at a comfortable and fast speed and TM6 (according to the recommendations of the American Thoracic Society).~At the end of each walking test, measurement of the difficulty of exertion using the Borg scale."
214377665|NCT06070350|DRUG|Placebo|Placebo will be provided to the research pharmacy at each of the clinical sites
214377666|NCT06070350|DRUG|Tranexamic Acid (TXA)|TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure. Dose is 25mg/kg IV or IO (maximum 2 grams).
214377667|NCT06070350|BIOLOGICAL|Component Therapy (CT)|Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo
214377668|NCT05256771|DEVICE|EMS|Abdominal muscle stimulation using EMS
214377669|NCT05256771|DEVICE|1064 nm diode laser|Adipose tissue heating using 1064 nm diode laser
214377670|NCT05256771|DEVICE|RF/PEMF|Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF
214990363|NCT02549118|DRUG|Pethidine|
214990364|NCT04213261|BIOLOGICAL|FCX-007 (dabocemagene autoficel; see below for FCX-007 description)|FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
214990365|NCT03112538|DEVICE|Insulin Pump|Medtronic Minimed Paradigm Veo Insulin Pump
214990366|NCT03112538|DRUG|Multiple daily injections of insulin|Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart) before each meal
214990367|NCT05453721|PROCEDURE|Indocyanine green fluorescence imaging method|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
214990368|NCT05453721|PROCEDURE|Modified inflation-deflation method|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
215091040|NCT06600308|OTHER|ecological (real-life) assessment of walking ability|Delivery of an actimeter, inertial units and logbook for ecological assessment (in real life) of walking ability for 7 days
215091041|NCT06993584|OTHER|Adult patients in cardiogenic shock|evaluate the elimination clearance of levosimendan (LVSMD) in the group without extracorporeal membrane oxygenation (ECMO) and in the group with ECMO.
215091042|NCT06155682|DEVICE|repetitive transcranial magnetic stimulation (active)|non-invasive active repetitive stimulation applied to the scalp surface
215091043|NCT06155682|DEVICE|repetitive transcranial magnetic stimulation (sham)|non-invasive active repetitive stimulation applied to the scalp surface
215091044|NCT06856668|BEHAVIORAL|Behavioral Activation (Action Brings Change Project 10-Minute Version)|"A behavioral activation SSI where users learn about negative thought spirals, give advice to an imagined peer, then create an action plan of helpful activities to do in the near future. This is a shorter version of the original 15-minute Action Brings Change SSI."
215091045|NCT06856668|BEHAVIORAL|Mindful Acceptance|A clinical psychologist explains a few ways to use mindful acceptance to deal with difficult thoughts and feelings.
214377671|NCT05465902|BIOLOGICAL|Recombinant COVID-19 variant Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
214377672|NCT05465902|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
214377673|NCT05465902|BIOLOGICAL|mRNA COVID-19 vaccine (Moderna)|1dose, Intramuscular Injection
214990369|NCT03283917|BIOLOGICAL|Daratumumab|Given IV
214377674|NCT05465902|BIOLOGICAL|Viral Vector COVID-19 vaccine (AstraZeneca)|1dose, Intramuscular Injection
214377675|NCT03879408|DRUG|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
214377676|NCT03879408|DRUG|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
214377677|NCT03879408|DRUG|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
214377678|NCT03879408|DRUG|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
214377679|NCT03879408|DRUG|Placebo tablet|Single dose of four placebo tablets
214377680|NCT03918070|DEVICE|Yukon Choice PC and Yukon Chrome PC|The Yukon Choice PC \& the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
214377681|NCT02601534|BEHAVIORAL|Zero-time Exercise|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve physical activity habit.
214377682|NCT02601534|BEHAVIORAL|Healthy Eating|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve dietary habit.
214990370|NCT03283917|DRUG|Dexamethasone|Given IV or PO
215091046|NCT06856668|BEHAVIORAL|Moral Elevation|Users learn about moral elevation, then watch a touching video where a man does good deeds for people in his community (originally a Thai life insurance advertisement). Finally, they plan a positive action they can take to help others in their own life.
215091047|NCT06856668|BEHAVIORAL|Mindful Attention Skills|A series of videos teach mindfulness skills: how to release thoughts and re-evaluate negative interpretations.
214377683|NCT05807919|OTHER|Diet low in all FODMAP groups|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
214990371|NCT03283917|DRUG|Ixazomib|Given PO
215091048|NCT06856668|BEHAVIORAL|5 Habits to Beat Depression|A clinical psychologist and science communicator describes his top 5 one-minute habits to beat depression.
215091049|NCT06856668|BEHAVIORAL|Interactive Cognitive Reappraisal|An interactive SSI where participants learn how to reframe negative thoughts
215091050|NCT06856668|BEHAVIORAL|Expressive Writing (AI-supported)|Participants describe a negative thought they struggle with and an LLM helps them to consider a story in which a peer overcomes that thought.
215091051|NCT06856668|BEHAVIORAL|Inner Child Healing Walk|An interactive journey to reconnect and heal one's inner child through breathing exercises, positive affirmations, and supportive animal companions.
215091052|NCT06856668|BEHAVIORAL|Savoring Strategies|An SSI introducing savoring strategies to improve mood.
214990372|NCT03349463|DRUG|Fluciclovine F18|All study participants will receive 10 mCi of 18F-Fluciclovine (Axumin) one time administered through injection through the catheter into participant's arm immediately before PET/CT scan.
215091053|NCT06856668|BEHAVIORAL|Personalized Intervention Recommender|Identifies the kinds of depression one struggles most with and offers a personalized recommendation for future depression support options
214990373|NCT00947544|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
214377684|NCT05807919|OTHER|Diet - Mediterranean|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
214377685|NCT00000881|DRUG|Cidofovir|
214377686|NCT00000881|DRUG|Probenecid|
214377687|NCT02622204|PROCEDURE|Corrective osteotomy|corrective osteotomy for varus alignment
214377688|NCT01557322|BIOLOGICAL|etanercept|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
214377689|NCT01557322|DRUG|methotrexate (MTX)|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
214377690|NCT00220974|BEHAVIORAL|Internet-based tailored advice on cardiovascular risk|
214377691|NCT02247336|BEHAVIORAL|Family health history platform (MeTree)|Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
214377692|NCT04983563|DEVICE|Actigraphy, eTact|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy.
214377693|NCT00973661|BEHAVIORAL|Electronic tool set for counseling overweight patients|"Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients."
214377694|NCT02739347|DEVICE|Active Trans-cranial direct-current stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
214377695|NCT02739347|DEVICE|Sham Trans-cranial direct current stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
214377696|NCT00153959|BEHAVIORAL|acute psychiatric day care|
214377697|NCT00524199|DRUG|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
214990374|NCT00947544|DRUG|NaPBA|NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
214377698|NCT00524199|OTHER|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
214377699|NCT01986101|DRUG|Placebo|Placebo comparator
214377700|NCT01986101|DRUG|SM-13496|SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
214377701|NCT01986101|DRUG|SM-13496|SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
214990375|NCT04542941|BIOLOGICAL|COVID Convalescent Plasma|Plasma collected from recovered COVID 19 individuals
214990376|NCT05322486|PROCEDURE|surgery of the primary tumour|Surgical resection of the colon tumour, R0. No surgical intervention on metastasis.
214377702|NCT03295513|OTHER|Veneered zirconia|he use of veneered zirconia is well documented in the literatures as successful restoration modality. A two Clinical performance of two different CAD/CAM-fabricated ceramic crowns revealed no chipping for veneered zirconia
214377703|NCT03295513|OTHER|Monolithic zirconia|Monolithic zirconia product presented a new generation of polycrystalline material by which full anatomical crowns and bridges can be produced
214377704|NCT05373797|BEHAVIORAL|Procedures performed on the experimental and control groups|Intervention Group:26 Control Group (n=26):
214990377|NCT05322486|DRUG|chemotherapy|Chemotherapy with or without biological drugs.
214990378|NCT01080261|DEVICE|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System
214990379|NCT05683067|OTHER|Hand Held Capillary Microscopy|The investigator will visualize the blood vessel appearance, number, and size they have in their hands, feet, and under the tongue. This procedure is non-invasive and will not cause any pain.
214990380|NCT05683067|OTHER|Mobile 'O' Graph|The aortic stiffness will be measured non-invasively using a special blood pressure monitor called Mobile 'O' Graph, which is about size of a pocket diary. 24 hour blood pressure monitoring is optional.
214990381|NCT05683067|OTHER|quality of life using questionnaires|The investigator will evaluate the quality of life using questionnaires such as EQ-5D-5L questionnaire and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
215091054|NCT06856668|BEHAVIORAL|Dialectical Behavioral Therapy Skills|Presents videos from dialectical behavioral therapy on various ways to control negative emotions.
214377705|NCT04251871|DRUG|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days."
215091055|NCT06856668|BEHAVIORAL|All about Trout|An 8-10 minute educational program with information and interactive exercises about trout fish. Intended to capture one's attention and require some effort, while minimizing influence on depressive symptoms.
214377706|NCT04251871|DRUG|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
214377707|NCT00166725|DRUG|Octreotide LAR|
214497234|NCT05517265|DRUG|Calquence|acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
214497235|NCT05517265|DRUG|Calquence|acalabrutinib according to Calquence® SmPC.
214497236|NCT06950736|DIETARY_SUPPLEMENT|NR|600 mg/d of oral NR for two months
214497237|NCT06950736|DIETARY_SUPPLEMENT|Vit E|200 mg/d of oral Vitamin E for two months
215091056|NCT06856668|BEHAVIORAL|Reframing Negative Thoughts|An audio-only program in which users are guided to reflect on how they might challenge negative automatic thoughts and beliefs they struggle with.
215091057|NCT01603316|BEHAVIORAL|surveys|Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
215091058|NCT01603316|BEHAVIORAL|Focus groups|Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
215091059|NCT06675331|OTHER|Medically Tailored Meal Program with Traditional Navajo Foods|Patients will receive medically-tailored meals incorporating local traditional Navajo foods
215091060|NCT06534424|OTHER|Best Practice|Receive standard care
215091061|NCT06534424|PROCEDURE|Biospecimen Collection|Undergo collection of blood or mouthwash sample
215091062|NCT06534424|OTHER|Counseling|Receive tailored counseling
215091063|NCT06534424|PROCEDURE|Discussion|Participate in phone discussion
215091064|NCT06534424|PROCEDURE|Genotyping|Undergo genotyping
215091065|NCT06534424|PROCEDURE|Molecular Risk Assessment|Undergo enhanced risk assessment
215091066|NCT06534424|OTHER|Questionnaire Administration|Ancillary studies
215091067|NCT03007745|DEVICE|autoadjusting continuous positive airway pressure|Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
215091068|NCT05649514|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
215091069|NCT05649514|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
215091070|NCT05649514|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
214990382|NCT03095235|DIETARY_SUPPLEMENT|Dietary riboflavin|Dietary riboflavin is vitamin B2. It has been shown to be safe in children in the treatment of migraines at doses of 400 mg per day. There are no known documented side effects
215091071|NCT05649514|PROCEDURE|Actimetrics|Measurement of actimetrics for 14 days at inclusion and at 24 months
214990383|NCT01922999|DRUG|Melatonin|patients will receive placebo, 1mg melatonin or 3mg melatonin
214990384|NCT04920669|PROCEDURE|erector spinae block with bupivacaine|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
215091072|NCT05649514|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
215091073|NCT06616831|DEVICE|Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific Training|Each participant will complete 2 weeks, 3 times per week, task-specific training paired with transcutaneous auricular vagal nerve stimulation.
215091074|NCT03500588|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction was used to diagnose gene polymorphism.
214497238|NCT04919811|DRUG|Taletrectinib|400mg or 600mg QD
214990385|NCT04920669|PROCEDURE|erector spinae block with bupivacaine + dexmedetomidine|Patients will receive a sonar-guided erector spinae plane block with 19 ml of bupivacaine 0.5%+ 1 ml dexmedetomidine
214990386|NCT00004497|DRUG|UT-15|
215091075|NCT03500588|DEVICE|Doppler ultrasound|Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
215091076|NCT06860880|OTHER|Exercise|Each patient will receive an individualized exercise prescription that will encompass both aerobic and resistance training, with modifications as necessary to accommodate each patient's needs, abilities, and medical condition. For those not participating in any formal exercise at baseline, the exercise prescription will consist of a basic conditioning program targeting 150 minutes of moderate physical activity weekly with the assistance of a physical therapist if deemed appropriate.
215091077|NCT06860880|OTHER|Diet|Participants will undergo nutritional consultations with a registered dietitian who specializes in oncology. The dietitian will provide tailored dietary recommendations using evidence-based nutrition guidelines. Participants will also be screened ffor ormal nutrition based on American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines as indicated.
215091078|NCT06794255|DIETARY_SUPPLEMENT|Vitamin C|Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
215091079|NCT06794255|OTHER|Placebo|Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
214497239|NCT06148740|OTHER|Manuka Health Pro Vitality Daily Restorative Face Serum with Propolis & Vitamin C|Skin serum containing propolis, vitamin C, and manuka honey.
214497240|NCT06290570|DIAGNOSTIC_TEST|12-Lead ECG|A clinically performed 12-lead ECG tracing within 30 days of the appointment will be obtained from the subject medical record and will be used for AI-ECG analyses.
214990387|NCT05668455|DRUG|Hydrocortisone|1 drops 4 times a day
214990388|NCT05668455|DRUG|Dexamethasone|1 drops 4 times a day
214990389|NCT05668455|OTHER|Povidone|1 drops 4 times a day
214990390|NCT01204242|DRUG|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
214990391|NCT01204242|DRUG|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
214990392|NCT06550908|OTHER|Lutetia Training Plattform - real images|Training platform Lutetia offers training the Paris classification using real images of colon polyps.
214990393|NCT06550908|OTHER|Lutetia Training Plattform - artifical images|Training platform Lutetia offers training the Paris classification using artificial images of colon polyps.
214990394|NCT05080491|DIAGNOSTIC_TEST|immuno analysis and neuropsychological tests|"A venous blood sample will be taken for assay in immuno-analysis including and for assay in chromatography with mass spectrometry. Patients will participate in computer neuropsychological tests: .~Venous blood collection and the administration : the tubes are transported to the biochemistry laboratory of the University Hospital Center of Nice (CHU Nice) which prepares five aliquots (4 for assays in immuno-analysis including 2 on site, and one for assay in chromatography with mass spectrometry.~Administration of two neuropsychological tests on computer(Attention Network Task and Tower of London)."
214990395|NCT04146701|OTHER|Blood draw|venous blood withdraw (ca. 40ml)
215091080|NCT05211401|DRUG|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 1000 mg of rituximab\* in 500 ml of NaCl 0.9% \* Mabthera® and all registered biosimilars are likely to be used in this trial
214377708|NCT01257711|PROCEDURE|Roux-en-Y or Billroth II|Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.
214377709|NCT03324880|BIOLOGICAL|rhPTH (1-84)|rhPTH (1-84) SC injection.
214377710|NCT03324880|BIOLOGICAL|Placebo|Placebo QD SC injection.
214990396|NCT03023501|DRUG|Gabapentin|
214990397|NCT03023501|DRUG|Placebo Oral Capsule|
214990398|NCT02398344|DEVICE|tDCS active|Transcranial direct current stimulation (tDCS) the active tDCS and placebo will be applied to the temporal cortex (T3) associated Cardiac Frequency Variability (HRV).
214990399|NCT02398344|DEVICE|tDCS Sham|Active stimulation application time or placebo 20 minutes. In all sham stimulation, electrode placement procedures will also be performed like the procedures with anodic tDCS, the left and right temporal cortex, however, the stimulator is turned on for 30 seconds only, and the patient will be told that he will feel a slight initial tingling, but it will reduce, disappear or remain during the 20 minutes of application. Thus, individuals will feel it initially, but receive no stimulation in the remaining time. This procedure is a valid form of control in challenge studies transcranial direct current ³³. The equipment itself has a sham configuration.
214990400|NCT00409825|DRUG|17-OHPC|Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
214990401|NCT00409825|PROCEDURE|Blood Draws|10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
214990402|NCT03245606|PROCEDURE|Liver biopsy|Measurement of liver fibrosis
214990403|NCT03245606|DEVICE|Abdominal MRI|Measurement of liver fibrosis
214990404|NCT03245606|DEVICE|Transient elastography|Measurement of liver fibrosis
214990405|NCT02594111|DRUG|Colchicine vs Placebo|Colchicine vs Placebo 1.8 mg PO over 1 hour
214990406|NCT06153550|OTHER|preparation in Respiratory Physiotherapy|"preparation in Respiratory Physiotherapy consist to:~* 3 sessions per week with the physiotherapist~* spirometry and pulse oximetry test 3 weeks before surgery, the day before surgery and the day after surgery."
214990407|NCT05926921|OTHER|music|Brahms' Lullaby will be played from a speaker at 50 decibels
214990408|NCT01241929|BEHAVIORAL|video decision aid|video of CPR
214377711|NCT05509725|DRUG|Probiotic formulation|Participants will be asked to take 2 doses daily
214377712|NCT05509725|DRUG|Placebo|Participants will be asked to take 2 doses daily
214377713|NCT03300570|DRUG|Dolcanatide|Given PO
214377714|NCT03300570|OTHER|Laboratory Biomarker Analysis|Correlative studies
214377715|NCT03300570|OTHER|Placebo Administration|Given PO
214377716|NCT03300570|OTHER|Questionnaire Administration|Ancillary studies
214377717|NCT00116272|DRUG|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
214497241|NCT06290570|DIAGNOSTIC_TEST|Apple Smart Watch Single Lead ECG|A single lead ECG tracing will be collected using an Apple Smart Watch and tracing will be used for AI-ECG analyses.
214990409|NCT04521868|DRUG|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
214990410|NCT04521868|DIETARY_SUPPLEMENT|placebo|Placebo is made of starch
215091081|NCT05211401|DRUG|Placebo arm|Placebo arm: 1 bag of 500 ml of NaCl 0.9%
215091082|NCT00841750|PROCEDURE|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
215091083|NCT00841750|PROCEDURE|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
214990411|NCT01963611|DRUG|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
214990412|NCT01963611|DRUG|Copaxone 20 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
214990413|NCT01963611|DRUG|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
214990414|NCT01963611|DRUG|Plovamer acetate 10 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
214990415|NCT01963611|DRUG|Plovamer acetate 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
214990416|NCT01318434|DRUG|EB-1010 25mg BID|capsule once daily
214990417|NCT01318434|DRUG|SSRI Active|Active Comparator
215091084|NCT06902662|DIETARY_SUPPLEMENT|SS-MN4|Participants in the SS-MN4 group will take 2 capsules daily containing a total of 1000 mg/day of Sanghuangporus sanghuang mycelia extract for 42 consecutive days. The capsules are identical in appearance to the placebo.
215091085|NCT06902662|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take 2 capsules daily of an inert substance designed to match the SS-MN4 capsules in color, taste, and appearance. The placebo contains no active ingredients and will be taken for 42 consecutive days.
214377718|NCT01417611|PROCEDURE|i-scan CE, SE, TE mode|I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
214377719|NCT00920023|DRUG|Superparamagnetic Iron Oxide Magnetic Resonance Imaging|Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
214377720|NCT01235403|DRUG|Lacosamide|"Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks"
214377721|NCT04859660|DRUG|Tamsulosin|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
214990418|NCT01318434|DRUG|EB-1010 50mg BID|Experimental Active
215091086|NCT02811913|OTHER|repetitive transcranial magnetic stimulation (rTMS)|"3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS"
214497242|NCT06290570|DIAGNOSTIC_TEST|AliveCor KardiaMobile 6-Lead ECG|A 6-lead ECG tracing will be collected using an AliveCor KardiaMobile device and tracing will be used for AI-ECG analyses.
214497243|NCT04966858|OTHER|Individualized Caloric Refeeding (ICR)|Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved
214497244|NCT04966858|OTHER|Higher Calorie Refeeding (HCR)|Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved
214497245|NCT06782165|PROCEDURE|Arthroscopy & saline irrigation alone|Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly
214497246|NCT06782165|PROCEDURE|Discectomy|Discectomy refers to open temporomandibular joint surgery where the joint disc is completely removed without being replaced.
214990419|NCT01318434|DRUG|Placebo|Placebo comparator
214990420|NCT00750334|DRUG|clofarabine|Drug given Daily x 14 days and 7 days of rest for 21 day cycle
214990421|NCT00750334|DRUG|clofarabine|Drug given Daily X 14 days and 7 days of rest for 21 day cycle
214990422|NCT04791176|RADIATION|concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance|Radiotherapy with IMRT or VMAT with 40-60Gy/20-30f; Concurrent Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po. (Note: Levatinib can be given to patients in four weeks before Radiotherapy is applied, so that it can control disease during waiting for Radiotherapy). Maintenance Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
214990423|NCT01759927|BEHAVIORAL|physical activity coaching|After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
215091087|NCT02811913|OTHER|peripheral sensory stimulation|peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS
215091088|NCT03917069|DRUG|Chemotherapeutic Combinations|nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
215091089|NCT03917069|DRUG|chemotherapy|paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
215091090|NCT00114920|DRUG|Resiquimod|
215091091|NCT03605069|DRUG|QR-313|QR-313 will be applied topically once daily for 8 weeks of treatment.
215091092|NCT03605069|DRUG|Placebo|Placebo will be applied topically once daily for 8 weeks of treatment.
215091093|NCT05187754|OTHER|Mindfulness-based breathing therapy program|Participant caregivers of palliative patients were randomized into the intervention and the control groups. Prior to randomization, participants and nurses were informed online abut the aim of the research and their written consent was obtained. Once the study ended, mindfulness-based breathing therapy were recommended to the patients in the control group. Data were collected online via Google forms survey and the interviews were conducted online via Zoom.
214377722|NCT04859660|DRUG|Placebo|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
214377723|NCT02296190|DRUG|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
214377724|NCT02296190|DRUG|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
214377725|NCT03253484|RADIATION|NAFL-treatment|non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
214377726|NCT03217435|PROCEDURE|Corneal epithelial allograft|A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
214377727|NCT03217435|PROCEDURE|Limbal conjunctival allograft|A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
214377728|NCT03217435|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
214377729|NCT03217435|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
214990424|NCT04700943|PROCEDURE|Regional awake anesthesia|We want to assess the impact of regional anesthesia on diaphragmatic function in patients undergoing Video-assisted thoracoscopic surgery pulmonary biopsy in interstitial lung disease
214990425|NCT02580656|BEHAVIORAL|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
214990426|NCT01126424|DRUG|Solifenacin|tablet
214990427|NCT01126424|DRUG|Oxybutynin|capsule
214990428|NCT01126424|DRUG|Placebo|tablet
214990429|NCT05090254|OTHER|Treatment algorithms targeting cardiac output|Treatment algorithms targeting maximization or personalization of cardiac output
214990430|NCT01323556|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
214990431|NCT01323556|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
214990432|NCT05970458|OTHER|Quality of life assessment|EQ5D-5L and Stoma QoL
214990433|NCT04292951|PROCEDURE|Fluid and inotropic/vasoactive management protocol|GDT protocol: keep SVV 10-13% and give fluid when SVV \> 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate
214990434|NCT03478280|DRUG|Brodalumab|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
214990435|NCT03478280|DRUG|Placebos|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
214990436|NCT04013464|DRUG|Escitalopram|Escitalopram 10-20mg/d
214990437|NCT02127853|DRUG|gabapentin|100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
214990438|NCT02127853|DRUG|placebo|the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
215091094|NCT01146288|DRUG|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
214377730|NCT04588935|DRUG|Bisoprolol; Perindopril;|based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
214377731|NCT04490564|DIAGNOSTIC_TEST|PD-L1 Kit|Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples
214377732|NCT00421434|DRUG|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
214377733|NCT00421434|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
214377734|NCT00421434|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
214377735|NCT00421434|DRUG|Ribavirin|Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
214377736|NCT00421434|DRUG|Ribavirin|Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
214377737|NCT01339286|DRUG|atomoxetine|Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.
214377738|NCT00800280|DRUG|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
214377739|NCT00800280|DRUG|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
214377740|NCT00800280|DRUG|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
214377741|NCT03551314|OTHER|Nasal Intermittent Positive Pressure|"\- NIPPV The following parameters: inspiratory pressure = 15 cmH2O / final expiratory positive pressure = 6 cmH2O / inspiratory time = 0.40 / flow = 6-8 L.min-1 / respiratory rate = 24.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
214377742|NCT03551314|OTHER|Continuous Positive Airway Pressure|"\- CPAP The following parameters: pressure of 6 cmH2O, with flow of 6-8L/min.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
214377743|NCT00844909|DRUG|CNTO 136|
214377744|NCT01208740|DRUG|Metformin|500 mg three times daily
214377745|NCT01208740|DRUG|Placebo|1 pill three times daily
214377746|NCT04002804|BIOLOGICAL|Dendritic Cells Vaccine|"Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient."
214377747|NCT03562065|BIOLOGICAL|mesenchymal stem cells|"Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~* 1.10\^6 CSM / kg~* 2.10\^6 CSM / kg~* 4.10\^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
214990439|NCT04148456|PROCEDURE|Covered Endovacular Reconstruction of Aortic Bifurcation|"* The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters.~* After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage.~* A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath.~* The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation."
214990440|NCT01798290|BEHAVIORAL|narrative medicine: reading workshop|
214990441|NCT01798290|BEHAVIORAL|critical reading|
214377748|NCT04021186|OTHER|Prevention of hyperglycemia|Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
214377749|NCT03392207|BIOLOGICAL|Seasonal Influenza Vaccine|Trivalent, Fragmented, Inactivated Seasonal Influenza Vaccine (2018 Southern Hemisphere Season) produced at Butantan Institute
214497247|NCT06379932|OTHER|Surveys completion|"A questionnaire (including the NRS) will be given to the patient on the day of the procedure, immediately after the biopsy, in the treatment room and without staff intervention (responses will be analyzed by two study investigators at a later date).~The patient health questionnaire (PHQ-9) will also be provided at the same time as the self-report questionnaire, for the assessment of depressive symptoms.~Assessment of the participant's frailty using the Clinical Frailty Scale (CFS) will be carried out prior to the procedure.~Further data will be collected by telephone by a study investigator 15 +/- 2 days after the biopsy and 30 +/- 2 days after the biopsy."
214497248|NCT06057974|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational model for healthcare staff working in NICUs. It aims to improve the ability of the members of the NICU healthcare team to I) observe the infants' individual behaviors and needs, II) support parents to take the initiative and share their observations and understanding of their infant's behaviors and to collaboratively plan the infant's care with the healthcare staff, III) understand the individual story of the family regarding parenthood through a dialogue with parents, and IV) involve parents in the decision-making about the care of their baby from an early stage of care through to the preparation for discharge. The final goal is to improve the care culture in the NICUs by changing the attitudes of the healthcare staff and the care practices of the unit to be more in line with family-centered care principles.~It usually takes 1.5 years for each NICU to complete the intervention."
214497249|NCT04406272|DRUG|VB11|Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
214497250|NCT04406272|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
214497251|NCT04406272|OTHER|Placebo|Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.
214990442|NCT00954876|DRUG|capecitabine and cetuximab|"Cetuximab 500 mg/m2 IV infusion over 1-2 hours Once every 2 weeks~Capecitabine 1500 mg/m2 PO BID Days 1-7 followed by 7 days of no treatment and repeated every 2 weeks"
214990443|NCT02758470|DRUG|Acetazolamide|250 mg, taken orally three times per day
214990444|NCT02758470|DRUG|Methazolamide|100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.
214990445|NCT02758470|OTHER|Placebo|A placebo will be taken three times per day
214990446|NCT02630654|OTHER|This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.|
214990447|NCT05546762|DRUG|Povidone-iodine solution|Pleural irrigation with 2% povidone iodine
214990448|NCT05546762|DRUG|Normal saline|Pleural irrigation with normal saline
214377750|NCT02468102|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|"Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban \[od\], tablets).~Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
214990449|NCT05076929|DIAGNOSTIC_TEST|ultrasound|Ultrasonographic measurement of Inferior Vena Cava Collapsibility Index
214377751|NCT02468102|DRUG|Standard of care drugs|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
214377752|NCT02162303|DRUG|Colchicine|0.6 mg a day of active treatment or placebo for 24 weeks
214377753|NCT02162303|DRUG|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment
214377754|NCT02283489|DRUG|recombinant human endostatin adenovirus|"Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study."
214990450|NCT04089319|OTHER|Music recording|Participants will listen to music for 45 minutes while they rest with acupuncture needles in place.
215091095|NCT01146288|DRUG|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
214377755|NCT02283489|DRUG|Cisplatin injection|Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
214377756|NCT02283489|DRUG|Paclitaxel injection|Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
214377757|NCT01667367|DRUG|RG1662|Single oral dose
214377758|NCT01667367|DRUG|placebo|Single oral dose
214377759|NCT03371641|BEHAVIORAL|ASQ parental questionnaire|ASQ parental questionnaire
214990451|NCT04089319|OTHER|Mindfulness recording|Participants will listen to a recording of mindfulness for 15 minutes and then listen to music for 30 minutes while they rest with acupuncture needles in place.
214377760|NCT03371641|BEHAVIORAL|Development scales|WPPSI - IV and NEPSY development scales
215091096|NCT02811783|DRUG|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
215091097|NCT02811783|DRUG|Placebo Lotion|Topical TID for 2 weeks
215091098|NCT00385723|DIETARY_SUPPLEMENT|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
215091099|NCT00385723|DIETARY_SUPPLEMENT|Placebo|matching placebo capsule daily for 4 months
215091100|NCT05070910|BEHAVIORAL|Therapy|The intervention performed in the practicum will not be able to be influenced by the study investigators and the intervention may be different for each child based on their needs
214377761|NCT03371641|BEHAVIORAL|Scale of Conners|Scale of Conners
214377762|NCT03371641|BEHAVIORAL|SCQ Questionnaire|SCQ questionnaire
214377763|NCT03371641|PROCEDURE|Blood sample (mother)|Blood sample (mother) before delivery
214377764|NCT03371641|PROCEDURE|Cord blood sample|Cord blood sample after delivery
214377765|NCT03371641|PROCEDURE|Placenta sample|Placenta sample
214377766|NCT00990340|DEVICE|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
214377767|NCT00990340|PROCEDURE|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
214377768|NCT02541825|DEVICE|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
214377769|NCT02541825|DEVICE|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
214377770|NCT03575338|PROCEDURE|Open Scarf Osteotomy|Open Scarf Osteotomy
214377771|NCT03575338|PROCEDURE|Minimally invasive scarf Osteotomy|Minimally invasive scarf Osteotomy
214377772|NCT05248321|DRUG|Tranexamic Acid Powder|2g tranexamic acid powder will be given via the endoscopy directly to the peptic ulcer
214990452|NCT05939167|DRUG|mesenchymal stem cell|Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).
214990453|NCT05939167|OTHER|saline|saline is used as placebo in the placebo comparator group
214990454|NCT00689741|BIOLOGICAL|Cervarix|3 doses of IM injection
214990455|NCT00689741|BIOLOGICAL|placebo|3 doses of IM injection of Al(OH)3 placebo
214377773|NCT04615182|DEVICE|Transplant|To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
214377774|NCT02821624|DRUG|G1T38 (CDK 4/6 Inhibitor)|CDK 4/6 Inhibitor
214990456|NCT05203016|OTHER|Hipotermia/Normotermia|The temperature will be measured at the beginning and at the end of the surgery, as well as during admission to the Post-Anesthesia Care Unit, where the temperature normalization time will be noted in the event of hypothermia. In retrospect, those variables corresponding to the late postoperative period will be evaluated and the telephone interview will be conducted to assess the quality of care received. All the data will be reflected in the collection booklet that we present in the annex.
214990457|NCT01659905|DRUG|Montelukast|Chewable Tablet
214990458|NCT01659905|DRUG|Singulair|5 mg Chewable Tablet
215091101|NCT05559125|DRUG|STSA-1002 Injection|Intravenous injection
215091102|NCT05559125|DRUG|STSA-1005 Injection|Intravenous injection
215091103|NCT03455829|DRUG|G1T38|CDK 4/6 inhibitor
214377775|NCT02821624|DRUG|Placebo|Placebo
214377776|NCT02629211|DEVICE|NaviAid™ AB|NaviAid™ AB Procedure
215091104|NCT03455829|DRUG|Osimertinib|EGFR TKI; 80 mg
214377777|NCT02094521|DRUG|NNC0113-0987|For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
214377778|NCT00206193|DRUG|mifepristone|
214377779|NCT00206193|DRUG|misoprostol|
214377780|NCT00206193|DRUG|sulprostone|
214377781|NCT05338918|OTHER|Mental Imagery with Virtual Reality Training|Mental Imagery TASK Practice with Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks, Part 1: 2-3 minutes of relaxation Part 2: Visual Imagery (external motor imagery training) for 5-8 minutes Part 3: Actual Task Practice for 10 minutes Part 4: Virtual Reality based training (including games for lower limb functions) for 10 minutes Part 5:Task Oriented training for 10 minutes Tasks for both (mental imagery + actual task practice) will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
214990459|NCT05884619|DEVICE|Dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
214377782|NCT05338918|OTHER|Virtual Reality Training|Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks. Games will include River rush, 20000 water leaks, reflex ridge along with task oriented training. Tasks will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
214377783|NCT04247997|PROCEDURE|disconnect pulmonary vague nerve branches|When the operation is in the right side, the Azygous vein bow is used as the marker, and in the left side, the aortic arch is used as the marker to identify the vagus nerve trunk.Then the surgeons dissect the vagus nerve trunk. This is used as a clue to find the vagus nerve pulmonary branch leading to the hilum. The position of the detachment is after the anterior and posterior pulmonary branches of the vagus nerve separating from the trunk and before the formation of the lung plexus.
214497252|NCT04406272|DRUG|Bevacizumab|A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.
214990460|NCT01324752|DRUG|PA21 and Losartan with Food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
214990461|NCT01324752|DRUG|No PA21; Losartan with food|The maximum dose of Losartan will be 100 mg/day.
214990462|NCT01324752|DRUG|PA21 with food and Losartan 2 hours later|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
214990463|NCT03801252|DRUG|Cefazolin|intravenous drugs used as prophylactic antibiotics
214990464|NCT03801252|DRUG|Placebo|Intravenous saline
214990465|NCT03801252|DRUG|Azithromycin|prophylactic antibiotic
214990466|NCT02451878|BEHAVIORAL|E-Couch|e-couch is an online CBT based intervention
214497253|NCT06782191|PROCEDURE|Arthroscopic lysis and lavage|Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly.
214990467|NCT01627717|DRUG|Maraviroc (5 days)|Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
214990468|NCT01627717|DRUG|Maraviroc and boceprevir (14 days)|From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
215091105|NCT02086201|BEHAVIORAL|Problem Solving Therapy|PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.
215091106|NCT02086201|BEHAVIORAL|Engage|Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
215091107|NCT03166579|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
215091108|NCT01305655|DRUG|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is \>250 µM, 36 hour levels \>30 µM or 42 hours levels \>10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
214377784|NCT02995850|DRUG|CRS+HIPEC|"1. Ib~   * Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~2. II~   ① CRS If PCI \<12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~   If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI \<12, CRS will be done.~   ② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~   ③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~   ④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks."
214377785|NCT03054038|DRUG|Afatinib|Given by mouth
214377786|NCT03054038|BIOLOGICAL|Necitumumab|Given IV
214377787|NCT03054038|OTHER|Laboratory Biomarker Analysis|Correlative studies
214377788|NCT05214313|BEHAVIORAL|Music Therapy|"The standardised music therapy protocol of 45 minutes will include at each session :~* 10 min of musical listening in a soothing environment (relaxation chair and reduced and coloured lighting) in sensory isolation (with headphones) and aimed at relaxation as a preamble to the active phase of the protocol~* Active phase: (25 min)~* 5 min of receptive music therapy linked to a given emotion, different at each session (joy, sadness, anger and fear) aimed at emotional management (feeling and distancing),~* 20 minutes of active music therapy with instrumental and vocal improvisation that solicits the body physiologically,~* 10 minutes of musical listening in sensory isolation for a state of rest.~The entire protocol is carried out with the permanent perception of heartbeats set to a physiological frequency of 50 to 100 BPM."
214990469|NCT01134042|DRUG|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
214990470|NCT01134042|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
214990471|NCT01134042|DRUG|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
214990472|NCT01134042|OTHER|Placebo Inhalation Powder 1|Placebo in novel dry powder inhaler once daily
214990473|NCT01134042|OTHER|Placebo Inhalation Powder 2|Placebo in Diskus inhaler twice daily
214990474|NCT04189523|OTHER|SOC Pain Management|Study subjects will be compared to historical controls selected for same age +/- 5yrs, gender, fracture type who meet the inclusion criteria and do not have historical documentation of one of the exclusion criteria. Controls will be identified by the ICD-10 injury codes selected for use in this study. Clinical course and pain management data will be collected through the EMR only.
214990475|NCT04189523|PROCEDURE|Early US Guided Nerve Block Administration|US-Guided regional anesthesia (fascia illiaca compartment block or brachial plexus block)
214990476|NCT02478671|DEVICE|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
214990477|NCT00804271|DRUG|memantine|memantine tablets, OD, 12 weeks
214990478|NCT06541015|DEVICE|InTENSity 10 TENS Stimulator|InTENSity 10 TENS stimulator is a portable electrotherapy device featuring Transcutaneous Electrical Nerve Stimulation (TENS) therapeutic device. The stimulator sends a gentle electrical current to underlying nerves and muscle group via electrodes applied on the skin. The parameters of device are controlled by the buttons.
214990479|NCT02534961|DRUG|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
214990480|NCT05525468|DRUG|TDM-180935|TDM-180935 topical ointment
214990481|NCT05525468|DRUG|Placebo|Placebo for TDM-180935 topical ointment
214990482|NCT00000629|DRUG|Valproic acid|
214990483|NCT00000629|DRUG|Zidovudine|
214990484|NCT00539474|PROCEDURE|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
214990485|NCT04208932|DRUG|SSRIs|Selective Serotonin Reuptake Inhibitors
214990486|NCT01060488|OTHER|GHRH+Arg, GHRH+Arg, ITT|GHRH+Arg repeatability test (2 tests) + comparison with one IT test
215091109|NCT02846246|OTHER|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
214990487|NCT01060488|OTHER|ITT, ITT, GHRH+Arg.|IT repeatability test (2 tests) + comparison with one GHRH+Arg test
214990488|NCT00393367|DRUG|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
214990489|NCT00393367|DRUG|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
214990490|NCT00393367|DRUG|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
215091110|NCT02846246|OTHER|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
215091111|NCT02876874|DRUG|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
215091112|NCT01270152|DRUG|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
215091113|NCT03189966|PROCEDURE|transversalis fascia plane block|With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
214377789|NCT00637819|DRUG|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
215091114|NCT03189966|PROCEDURE|quadratus lumborum block|The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
214377790|NCT02140710|PROCEDURE|Osteopathic treatment|visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
214377791|NCT03204058|DRUG|Placebos|Oral prophylaxis followed by placement of placebo gel
214377792|NCT03204058|DRUG|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
214377793|NCT03204058|DRUG|Metformin|Oral prophylaxis followed by placement of metformin gel
214377794|NCT05128643|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).
214990491|NCT00393367|DRUG|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
214990492|NCT05841550|BIOLOGICAL|TG01|All participants will receive the same treatment as described under arm
214990493|NCT02456558|DRUG|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
214990494|NCT02456558|DRUG|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
214990495|NCT05330949|DIAGNOSTIC_TEST|Optical coherence Tomography Angiography, Uterine artry doppler|vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters
214990496|NCT04452838|DRUG|Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)|4 mg administered under fasted condition.
214990497|NCT04452838|DRUG|Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)|4 mg administered under fasted conditions.
214377795|NCT00628836|DEVICE|BION stimulation|"The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated."
214377796|NCT01659398|DEVICE|External Counterpulsation (EECP)|A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
214377797|NCT01273428|DRUG|HP011-101|
214377798|NCT01273428|DEVICE|HP-828-101|
214377799|NCT01273428|OTHER|Standard Care|
214377800|NCT05715359|PROCEDURE|Reconstruction|Standardized template for reconstruction of continious defects of the jaws.
214377801|NCT01861834|DRUG|Omegaven 10%|"Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.~Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN"
214990498|NCT04452838|DRUG|Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)|4 mg administered under fed conditions.
214990499|NCT04452838|DRUG|Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)|4 mg sprinkled on apple sauce administered under fasting conditions
214990500|NCT04452838|DRUG|Fesoterodine BIC SR4 fed (Treatment E in Part B)|4 mg administered under fed conditions
215091115|NCT04326855|OTHER|Incremental shuttle walking protocol (ISWT)|Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
214990501|NCT02560467|DRUG|Echo and myocardial contrast echocardiography perfusion imaging|"Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses."
214990502|NCT04596423|DIAGNOSTIC_TEST|Fetal echocardiography|fetal heart examination by medical ultrasound
214990503|NCT06109740|DIETARY_SUPPLEMENT|lactobacillus GG|probiotic
214990504|NCT03286504|BEHAVIORAL|FANMI - Cohort Care|FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
214990505|NCT05708664|PROCEDURE|precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction|Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
214990506|NCT01459926|DRUG|TD-1211|once daily
214990507|NCT01459926|DRUG|TD-1211|Once daily
214990508|NCT01459926|DRUG|TD-1211|Once daily
214990509|NCT01459926|DRUG|Placebo|Once daily
214990510|NCT02090257|BEHAVIORAL|TRANSIT|Educational Modules, staff follow up.
214990511|NCT05350423|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
214990512|NCT05350423|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
214990513|NCT01965795|DIETARY_SUPPLEMENT|Whole Coffee Fruit Concentrate (WCFC)|Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain-Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
214990514|NCT01965795|DIETARY_SUPPLEMENT|Nutrim|Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
214990515|NCT06060366|PROCEDURE|Pulmonary endarterectomy|removal of chronic thrombus from pulmonary arterial system
215091116|NCT04326855|OTHER|Endurance shuttle walking (ESW) protocol|Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
215091117|NCT04326855|OTHER|First Intermittent shuttle walking protocol|All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
215091118|NCT04326855|OTHER|Second Intermittent shuttle walking protocol|To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
214990516|NCT01432327|DEVICE|SenseWear display|"Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.~The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals."
214990517|NCT01432327|DEVICE|Pedometer|Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.
214990518|NCT01432327|DEVICE|SenseWear Armband|Participants wear the SenseWear Armband for 4 weeks
214990519|NCT01432327|BEHAVIORAL|Personal Coaching|A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
214377802|NCT00595972|DRUG|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
214990520|NCT04729712|PROCEDURE|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Erector Spinae block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the erector spinae plane prior to surgical incision. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
214990521|NCT04729712|PROCEDURE|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Paravertebral block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the paravertebral space after the thoracoscopic ports have been sited. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
214990522|NCT00512668|DRUG|leuprolide acetate|Given intramuscularly
215091119|NCT04326855|OTHER|Focus group study|Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
214377803|NCT01635075|BEHAVIORAL|Exercise|1-mile treadmill walk
214377804|NCT01635075|BEHAVIORAL|passive control|20 min inactivity
214377805|NCT04898712|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets
214377806|NCT04898712|DRUG|Placebo|The placebo will consist of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed.
214377807|NCT04485130|DRUG|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
214377808|NCT04485130|DRUG|Placebo|This study will provide placebo. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days
214377809|NCT00402337|DRUG|linaclotide acetate|oral, once daily.
214377810|NCT00402337|DRUG|Matching placebo|oral, once daily
214377811|NCT05909839|OTHER|7T MRI network analysis for deep brain stimulation in essential tremor|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in ET patients.
214377812|NCT04341961|OTHER|Pomegranate Juice|Drinking 8 oz of pomegranate juice daily for 2 weeks.
214377813|NCT03249506|DRUG|Canagliflozin|Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
214497254|NCT06782191|PROCEDURE|Operative arthroscopy|Operative arthroscopy refers to an arthroscopic procedure where the temporomandibular joint is accessed via two ports of entry. The joint is rinsed with saline solution and the anterior disc attachment is released with cold ablation where after the posterior attachment is sclerosed with the coagulation mode on the coblator.
214497255|NCT02036970|DRUG|Bardoxolone methyl|
214497256|NCT02036970|DRUG|Placebo|
214377814|NCT03249506|DRUG|Empagliflozin|Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
214497257|NCT00979459|DRUG|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
214497258|NCT00979459|DRUG|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
214497259|NCT02266654|OTHER|IV fluids|Normal Saline 0.9%
214497260|NCT02266654|OTHER|Hospital Notification|Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
214497261|NCT06699628|DRUG|IRL757|IRL757 capsules
214497262|NCT02298842|DEVICE|Platelets stored in InterSol|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
214990523|NCT00512668|DRUG|goserelin acetate|Given subcutaneously
214990524|NCT00512668|DRUG|bicalutamide|Given PO
215094653|NCT02597088|OTHER|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
215094654|NCT00086645|DRUG|citalopram hydrobromide|10mg/5ml solution
215094655|NCT00086645|OTHER|placebo|up to equivalent of 20 mg of active comparator daily
215094656|NCT03380767|PROCEDURE|Trauma-induced coagulopathy treatment|Transfusion as needed according to the assay methodology
215094657|NCT05823272|OTHER|ONS|oral nutritional supplement
215094658|NCT05288140|OTHER|use of diary|a diary is made for the experimental group where the events and events during the period of sedation and intubation are explained
214377815|NCT03249506|DRUG|Dapagliflozin|Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
214497263|NCT02298842|DEVICE|Platelets stored in Plasma|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
214497264|NCT02386098|DRUG|BMS-955176|HIV Maturation Inhibitor
214990525|NCT00512668|DRUG|nilutamide|Given PO
214990526|NCT00512668|DRUG|flutamide|Given PO
214990527|NCT00512668|DRUG|temsirolimus|Given IV
214497265|NCT02386098|DRUG|Atazanavir (ATV)|Atazanavir
214497266|NCT02386098|DRUG|Ritonavir (RTV)|Ritonavir
214990528|NCT00512668|OTHER|laboratory biomarker analysis|Optional correlative studies
214990529|NCT04706221|DEVICE|CM-1500|Blood volume monitor CM-1500
214990530|NCT03320369|OTHER|Elemental Diet Therapy|Elemental diet is a formula composed of amino-acids, carbohydrates, and lipids that is 100% nutritionally complete
214990531|NCT00092729|DRUG|etoricoxib (MK0663)|Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
214497267|NCT02386098|DRUG|Dolutegravir (DTG)|Dolutegravir
214497268|NCT02386098|DRUG|Tenofovir (TDF)|Tenofovir
214497269|NCT03287232|DRUG|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
214497270|NCT03287232|DRUG|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
214990532|NCT00092729|DRUG|Comparator: placebo (unspecified)|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
214990533|NCT00092729|DRUG|Comparator: naproxen sodium|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
214990534|NCT04753112|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor
214990535|NCT05608863|OTHER|Lifestyle - group sessions|The Combined Lifestyle Intervention Program consists of a total of 7 individual coaching sessions and 16 group sessions in a 2 year program. The individual coaching sessions will be done in a virtual setting.
214990536|NCT05608863|OTHER|Lifestyle - individual coaching|The Individual Intervention consists of a total of 7 individual coaching sessions in a 2 year program and additional written information. These will be done in a virtual setting.
214990537|NCT06843551|RADIATION|Stereotactic Body Radiation Therapy|"The radiation therapy (RT) prescription biologically effective dose (BED10) goal for tumor (α/β=10) aims to achieve at least BED10= 60 Gy for a single fraction plan and at least BED10=100 Gy for a multi-fraction plan. This equates to a prescription dose of at least 20 Gy in a single fraction, 42 Gy over 3 fractions, 50 Gy over 5 fractions, and 62 Gy over 10 fractions.~Radiation therapy must be completed for up to 10 daily treatments within a 15-day course."
214990538|NCT06843551|DRUG|Botensilimab|Participants will be receive 75mg of Botensilimab immunotherapy administered via intravenous infusion, every six weeks for up to 4 doses, about 24 weeks. Botensilimab therapy will begin no later than seven (7) days after completion of radiation therapy.
214990539|NCT06843551|DRUG|Balstilimab|Participants will receive 240mg of Balstilimab immunotherapy, administered via intravenous infusion, every 2 weeks for up to one (1) year. Balstilimab therapy will begin no later than seven (7) days after completion of radiation therapy.
214990540|NCT05849077|OTHER|Sat75|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
214990541|NCT05849077|OTHER|Sat50|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
214990542|NCT01732692|DRUG|MOVIPREP|MOVIPREP solution
214990543|NCT00888082|DRUG|Goserelin acetate|3.6 mg depot injectable preparation
214990544|NCT05594160|BEHAVIORAL|Psychotherapy|Patients treated at the inpatient psychotherapy unit of a University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers and physiotherapists.
214377816|NCT03249506|DRUG|Dipeptidyl Peptidase-4 Inhibitor (DPP-4)|Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
214377817|NCT03249506|DRUG|Glucagon-Like Peptide-1 Agonist (GLP-1)|Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
214377818|NCT03249506|DRUG|Thiazolidinedione (TZD)|Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
214377819|NCT03249506|DRUG|Sulfonylureas|Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
214990545|NCT01951066|DRUG|Dexamethasone Implant|Patients will receive a single injection of a dexmethasone implant
214990546|NCT01951066|DRUG|Anti-VEGF injection|Patients will receive PRN injections of an anti-VEGF agent
214990547|NCT04608864|PROCEDURE|varicocelectomy|microsurgical subinguinal varicocelectomy
214990548|NCT03427281|BEHAVIORAL|questionnaire|questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
214990549|NCT04195412|DEVICE|tDCS + upper limb rehabilitation|Stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. Stimulation intensity will be 2 mA with current ramping up and down of 10 seconds each. The stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
214990550|NCT04195412|DEVICE|Sham tDCS + upper limb rehabilitation|Sham stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each sham stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. The anode will be placed to the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off automatically after 30 seconds. The sham stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
214990551|NCT00177489|BEHAVIORAL|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
214990552|NCT00177489|OTHER|Control arm|"Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention."
214990553|NCT03881774|BIOLOGICAL|CAR-T cells|collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg
214990554|NCT03818568|DIETARY_SUPPLEMENT|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
214990555|NCT04649424|DEVICE|CanSwab|New nasopharyngeal swab design.
214990556|NCT03316781|DRUG|HLX03|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
214990557|NCT03316781|DRUG|adalimumab|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
214990558|NCT05627804|OTHER|Low-moderate intensity exercise|The participants will perform low-intensity cycling exercise at 90% lactate threshold under moderate hypoxia
214990559|NCT05627804|OTHER|Sprint interval training|The participants will perform sprint interval cycling exercise at a load of 7.5% bodyweight under moderate hypoxia.
214990560|NCT05627804|OTHER|Functional exercise|The participants will perform bodyweight exercises under moderate hypoxia.
214990561|NCT05627804|OTHER|Control|No exercise will be performed.
214990562|NCT02030600|DRUG|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
214990563|NCT02030600|DRUG|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
214990564|NCT03272152|GENETIC|Genome-wide DNA methylation|Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
214990565|NCT01155323|DEVICE|etafilcon A|1-day soft contact lens
214990566|NCT01155323|DEVICE|omafilcon A|1-day soft contact lens
214990567|NCT02250638|OTHER|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
214990568|NCT03953716|DEVICE|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes \* 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
214990569|NCT03953716|DRUG|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
215091120|NCT05824936|BEHAVIORAL|Pilot study arm for technology-enhanced asthma intervention|Participants will be enrolled in a remote monitoring program using monthly remote study visits which will include the use of a mobile spirometer (device for testing lung function). Participants will complete monthly remote study visits visits using telehealth platform and will complete lung function testing during the visit using a mobile spirometer as well as remote study measures.
214497271|NCT04555668|OTHER|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks
214990570|NCT03953716|DRUG|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
214990571|NCT03953716|DRUG|Marvelon|Marvelon 1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle
214990572|NCT03805139|DIETARY_SUPPLEMENT|Ajwa Date (phoenix dactylifera)|Effect of Ajwa on Dyslipidemia
215091121|NCT06125691|BIOLOGICAL|ARCT-2138|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
215091122|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for younger adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
214990573|NCT04530071|BIOLOGICAL|CordSTEM-DD (0.7 x 10^7 cells)|CordSTEM-DD (0.7 x 10\^7 cells)
214990574|NCT04530071|BIOLOGICAL|CordSTEM-DD (2.1 x 10^7 cells)|CordSTEM-DD (2.1 x 10\^7 cells)
214990575|NCT04530071|BIOLOGICAL|Placebo|HA + saline + placebo comparator
214990576|NCT02052635|DRUG|ticagrelor|Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
214990577|NCT02052635|DRUG|clopidogrel|Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
214990578|NCT00406237|DRUG|tigecycline|Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
214990579|NCT06283017|DEVICE|Hypoglossal nerve stimulation|Device stimulation of the hypoglossal nerve
214990580|NCT04732585|PROCEDURE|Physiotherapy or Surgery|"Physiotherapy: Guidelines suggest a tailored and progressive exercise program to improve muscle strength and control, joint mobility, and patient understanding of the problem and how to manage it. Additional interventions like tape or manual treatment can also be implemented but should not be exclusive~Surgery: ACL surgical reconstruction"
214990581|NCT05466058|DIAGNOSTIC_TEST|palpation - ultrasonography|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
214990582|NCT05144243|DRUG|Venetoclax|Tablet: Oral
214990583|NCT05144243|DRUG|Azacitidine|Subcutaneous Injection (SC)
214990584|NCT05513911|OTHER|Acute Intermittent Hypoxia|Acute Intermittent Hypoxia is administered in 30-60 second bouts of 9% O2 concentration, followed by 60-90 seconds of normoxic air concentrations (21% O2, room air). This procedure is repeated 15 times for a 30 minute session
214990585|NCT05675670|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
214990586|NCT03340883|BIOLOGICAL|BION-1301|a solution for intravenous (IV) administration, diluted and administered Q2W
214990587|NCT03552406|BIOLOGICAL|ISU104|Intravenous Infusion for 1 hour.
214990588|NCT03552406|DRUG|Cetuximab|Intravenous Infusion for 1 hour (2 hours at initial dose)
214990589|NCT05225662|DIAGNOSTIC_TEST|radiofrequency ablation|Mesuring change in Speckle tracking analysis before and after the radiofreqency ablation
214990590|NCT01622322|DRUG|Nitrous Oxide|Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
214990591|NCT01622322|OTHER|oxygen|Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
214990592|NCT05142735|DIETARY_SUPPLEMENT|N-Acetylcysteine|2000 mg (4 x 500-mg tablets) every morning
214990593|NCT05142735|DIETARY_SUPPLEMENT|Placebo|4 placebo tablets every morning
214990594|NCT02240329|BEHAVIORAL|Neuropsychological Testing and Measures of TBI severity|A brief cognitive assessment will be given to each participant when he or she presents for this project.
214990595|NCT02240329|BEHAVIORAL|Respiratory measures|We will collect measures of cough airflow and breathing strength.
214990596|NCT02240329|DRUG|Capsaicin cough sensitivity testing|Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
214990597|NCT03200821|BIOLOGICAL|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
214990598|NCT03200821|DRUG|Gemcitabine|1000 µg/m\^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
214990599|NCT03736304|DEVICE|AKI alert|An AKI alert will send to the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
214990600|NCT03736304|OTHER|Usual care|Patients will receive standard clinical care by the doctor in charge.
214990601|NCT02619188|OTHER|PUQE-form inclusion|PUQE-form encompassing last 24 hours completion
214990602|NCT02619188|OTHER|Nutritional form inclusion|Food-list form encompassing last 24 hours completion
214990603|NCT02619188|OTHER|Blood sampling inclusion|Measurement of biochemical nutrition marker(s); Prealbumin
214990604|NCT02619188|OTHER|Intervention at discharge|PUQE-form, nutritional form and Blood sampling
214990605|NCT04029844|DEVICE|Colibri TAVI System|Implantation of Colibri heart valve
214990606|NCT01285544|DRUG|Atorvastatin (Lipinon)|treatment of dyslipidemia administration : PO, qod
214990607|NCT01285544|DRUG|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
214990608|NCT04807413|DRUG|Nitric Oxide|The balloon will be opened to deliver nitric oxide at 40 ppm through the cardiopulmonary bypass machine
214990609|NCT04807413|OTHER|standard of care treatment|standard of care treatment
214990610|NCT04820504|DEVICE|Augmented Infant Resuscitator (AIR)|Device provides visual feedback related to air leak, obstruction, hyperventilation, hypoventilation, and harsh breaths
214990611|NCT04820504|DEVICE|AIR device without feedback|Device provides no visual feedback to clinician but records data on ventilation effectiveness
214990612|NCT03555799|DIAGNOSTIC_TEST|Inferior vena cava ultrasound|Abdominal ultrasound to identify IVC between hepatic veins and right atrium. Measurement of dimensions throughout respiratory cycle (before and after labor epidural)
214990613|NCT01799694|DRUG|Inject of Autologous Adipose-derived stem cells|Inject in muscle of autologous adipose derived stem cells
214990614|NCT04154956|DRUG|SAR408701|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion
214990615|NCT04154956|DRUG|Docetaxel|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: IV infusion
214990616|NCT00257530|DRUG|Imiquimod|
214990617|NCT01344564|DRUG|Degarelix acetate, Leuprolide acetate|Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
215091123|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for older adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
214990618|NCT05079087|PROCEDURE|Pericapsular nerve group blockade|The PENG-block will be administered under ultrasound (US) guidance with a low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease at the level of the anterior superior iliac spine. Scanning will be done with gradual caudal movement of the probe. After the anterior inferior iliac spine (AIIS) is visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of the superior pubic ramus is visible. The Psoas muscle with its prominent tendon will be identified just above the pubic ramus. The target is the plane between the 2 structures. While aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a 22 Go 10 cm needle will be introduced and 20 ml of anesthetic solution administered.
214990619|NCT05079087|DRUG|Midazolam Ketamine arm|Patients in the second group will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
214990620|NCT03791931|DIAGNOSTIC_TEST|oxidative stress measurement|oxidative stress measurement
214990621|NCT00310518|DRUG|ARQ 501|
214990622|NCT05959291|OTHER|Discontinuation of Anti-HER-2 Maintenance Treatment|Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
214990623|NCT00805532|BEHAVIORAL|Behavioral Activation treatment|Behavioral Activation (BA) is a present-focused psychotherapy based on behavioral theory and principles of change, that aims to re-engage individuals with meaningful and pleasurable life activities by targeting and problem-solving patterns of avoidance. It is well-established as a treatment for depression and has been modified for the current study to address PTSD-related problems.
214990624|NCT00805532|OTHER|Treatment as Usual|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
214990625|NCT01761188|PROCEDURE|Ablation|electrophysiology substrate mapping is the critical difference between both groups
214990626|NCT01859741|DRUG|OMP-59R5|OMP-59R5 administered intravenously
214990627|NCT01859741|DRUG|Etoposide|administered intravenously
214990628|NCT01859741|DRUG|Placebo|administered IV
214990629|NCT01859741|DRUG|Cisplatin or Carboplatin|administered intravenously
214990630|NCT00452569|DRUG|Thalidomide|Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
214377820|NCT03249506|DRUG|Insulin|Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
214377821|NCT00187330|DRUG|Intravenous N-acetylcysteine|
214377822|NCT04462315|DRUG|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
214377823|NCT04462315|DEVICE|Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)|Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation
214377824|NCT00793156|DRUG|Nalfurafine HCl 2.5 µg|Daily dose of 2.5 µg
214377825|NCT00793156|DRUG|Nalfurafine HCl 5.0 µg|Daily dose of 5.0 µg
214497272|NCT04555668|OTHER|Hamstring Stretch Program|Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
214497273|NCT05955040|DRUG|Nifedipine|Standard of care for treatment of elevated blood pressure during pregnancy
214990631|NCT00452569|DRUG|Dexamethasone|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
214497274|NCT05955040|DRUG|Labetalol|Standard of care for treatment of elevated blood pressure during pregnancy
214497275|NCT04826159|DRUG|IMB-1018972|Modified release tablet for oral administration
214497276|NCT06000956|DRUG|Jitongning tablets|The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.
214497277|NCT06000956|DRUG|a simulated agent of Jitongning tablets|The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.
214497278|NCT06129838|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a brain \[11C\]-CS1P1 PET scan
214377826|NCT00793156|OTHER|Placebo|Placebo daily dose
214377827|NCT02821819|OTHER|Random start ovarian stimulation|Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.
214377828|NCT02821819|DRUG|Gonadotrophins|Urinary FSH 150-225 IU/d
214377829|NCT02821819|DRUG|GnRH antagonist|Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
214377830|NCT02821819|DRUG|GnRH agonist|GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
214377831|NCT01203839|RADIATION|multiple beams utilizing either intensity-modulated or 3D-conformal techniques|A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
214377832|NCT02911350|DRUG|Hormone Suppressors|
214377833|NCT02911350|DRUG|Paclitaxel|
214377834|NCT02911350|RADIATION|Radiation Therapy|
214377835|NCT02293772|OTHER|Hypoxic ambulatory|21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
215091124|NCT02896036|PROCEDURE|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
214377836|NCT02293772|OTHER|Hypoxic Bedrest|21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
214377837|NCT02293772|OTHER|Normoxic Bedrest|21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
214377838|NCT01199159|DRUG|Misoprostol|400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
214377839|NCT01199159|DRUG|Vitamin B 6|20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
214377840|NCT01985828|RADIATION|CyberKnife|
214377841|NCT01985828|OTHER|Androgen Deprivation Therapy (ADT)|
214377842|NCT01985828|RADIATION|Intensity Modulated radiation therapy (IMRT)|Per current standard of care
214377843|NCT04013217|COMBINATION_PRODUCT|Eribulin ORA|Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
214377844|NCT06682078|OTHER|Not applicable . Non-interventional retrospective study, only on datas.|Not applicable . Non-interventional retrospective study, only on datas.
214377845|NCT05851937|BEHAVIORAL|Written language intervention|Young adults with Intellectual and Developmental Disabilities (IDD) are taught reading comprehension strategies in three phases (before, during, after) using a graphic organizer as visual support. At the beginning of each phase, the interventionist: (a) defines the strategies, (b) describes and models how to use the strategies, and (c) answers questions about the strategies. Then the participant practices the strategies during 45-min sessions, two times per week, over 3 months. Each session follows the teach-model-coach-review format, the interventionist: (a) reviews the strategies (5 min), (b) models the strategies using a think-aloud (10 min), (c) prompts the participant to practice the strategies with support (15 min), (d) prompts the participant to use a think-aloud to practice the strategies independently using a functional literacy text (10 min), and (e) reviews and summarizes the session (review; 5 min).
214377846|NCT06077773|DRUG|Oral EP262|Once daily
214497279|NCT05013216|DRUG|Cohort A: Patients at high risk of developing pancreatic cancer.|"1. KRAS peptide vaccine with poly-ICLC adjuvant will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13. All subjects will return to the study site approximately 28 days (+ 7 days) after the last vaccination for an End of Treatment (EOT) and safety evaluation.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
214497280|NCT05013216|DRUG|Cohort B: Patients must have evidence of a pancreatic cystic neoplasm|Patients will receive KRAS peptide vaccine with poly-ICLC adjuvant as two prime vaccinations on weeks 1 and 2. Surgery is considered standard of care. Surgery will occur at the discretion of the treating hepatobiliary surgeon and is not dictated by this protocol. Subjects will return to the study site approximately at week 4 (+ 7 days) for a safety evaluation prior to surgery. Subjects will have an End of Treatment (EOT) visit at study Week 8 (+ 7 days).
214497281|NCT04280718|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous administration of efgartigimod
214497282|NCT06792994|OTHER|Observational|The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively
214497283|NCT06518551|DRUG|Elotuzumab|Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.
214497284|NCT06518551|DRUG|Iberdomide|A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.
214377847|NCT06077773|DRUG|Placebo|Once daily
214497285|NCT06518551|DRUG|Dexamethasone|Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.
214497286|NCT02388828|BIOLOGICAL|lentiviral-based CART meso therapy|
215091125|NCT02896036|PROCEDURE|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
215091126|NCT02519569|OTHER|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
215091127|NCT00491920|DRUG|cholecalciferol (Vitamin D3)|"20 000 Iu x2/week~\+ calcium 500 mg/cholecalciferol 400 IU x2/d"
215091128|NCT00491920|DRUG|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
215091129|NCT03689712|DRUG|GC4419 90mg|60 minute IV infusion
215091130|NCT03689712|DRUG|Placebo|60 minute IV infusion
214377848|NCT06134856|PROCEDURE|Ankle mobilization|Ankle joint mobilization as described in treatment arm description
214377849|NCT06134856|PROCEDURE|Sham treatment|Light passive movement of the foot and ankle, avoiding the end-ranges which may actually elicit a mechanical change
214377850|NCT06327464|DIETARY_SUPPLEMENT|Exogenous ketones|Consumption of a single exogenous ketone supplement with breakfast
214377851|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus Placebo|15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule.
214377852|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus iron Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
214377853|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus zinc Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
214377854|NCT02081950|BIOLOGICAL|Enoxaparin sodium|comparison of 2 different administration of drug
214377855|NCT04073810|DIAGNOSTIC_TEST|PET imaging|Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months
214377856|NCT04073810|DIAGNOSTIC_TEST|Coronary CT angiography|CTCA at baseline and 2 years
214377857|NCT04073810|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI at 1 year
214377858|NCT01203670|DIETARY_SUPPLEMENT|Phytalgic|Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
214990632|NCT06449157|OTHER|Inhalation induction with parosmia|"The experimental group will then be told that the patient's favorite smell will be put into the face mask via the magical machine. The patient will be asked to take a deep breath thinking about that smell and then introduce sevoflurane. The patient will be asked if the chosen flavor is smelled and their response will be noted."
214990633|NCT03974906|OTHER|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO）|Applying continuous hemodynamic monitoring system ( LiDCO) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
214990634|NCT03988647|DRUG|Pembrolizumab|Pembrolizumab administered at 200 mg IV every 3 weeks
214377859|NCT03852043|BEHAVIORAL|High-intensity interval training|The intervals of high intensity are conducted between 90 and 95 % of heart rate maximum (HRmax) and resting between 50 and 60 % of the HRmax 15 loads of 30 seconds at high intensity, with 60 seconds of recovery at loads of moderate intensity.
214497287|NCT06296992|BEHAVIORAL|12-week TEAM peer mentor program|A 12-week peer-led behavioural intervention that supports increased physical activity. It will consist of 3 weekly contacts between participants and peer mentors that will be a mix of in-person, virtual, and texting. The intervention components and communication between adolescents and peer mentors with T1D will be guided by SDT, and designed to overcome the key psychosocial barriers to PA. The peer mentors that complete the training will deliver a 12-week intervention to increase behavioural skills that foster autonomy for goal setting and overcoming barriers to PA.
214497288|NCT05897294|DRUG|Voriconazole Inhalation Powder|dry powder inhalation of voriconazole
214990635|NCT03988647|RADIATION|Radiation Therapy|9 Gy X 3 (27 Gy in 3 fractions), or 4-6 Gy X 5 (20-30 Gy in 5 fractions).
214990636|NCT05202405|DRUG|AD-221|AD-221 Oral Tablet
214497289|NCT04000750|OTHER|Time Restricted Eating|Diet will be tracked and reported every day to a qualified dietitian.
214990637|NCT05202405|DRUG|AD-221A and AD-221B|AD-221A Oral Tablet + AD-221B Oral Tablet
214990638|NCT04681300|OTHER|Skin biopsy|a skin sample will be taken using a 4 mm punch biopsy in lesional skin
214990639|NCT04681300|OTHER|Plastic surgery remnants|healthy skin from plastic surgery interventions
214990640|NCT04447365|DIAGNOSTIC_TEST|device interrogation|All patients will have a pre-existing ICD and a diagnosis of cardiomyopathy with left ventricular systolic function of 35% or less by echocardiogram done within 3 years of the time of enrollment.
214990641|NCT03448003|OTHER|Cancer Prevention|Attend IO prevention program
214990642|NCT03448003|OTHER|Questionnaire Administration|Ancillary studies
214990643|NCT00154466|BEHAVIORAL|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
214990644|NCT02724436|PROCEDURE|TACE|
214990645|NCT02724436|PROCEDURE|radioembolization with Y-90|radioembolization with Y-90
214990646|NCT05508802|OTHER|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
214990647|NCT05508802|OTHER|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
214990648|NCT02871427|DRUG|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
214990649|NCT03927391|DRUG|Enzalutamide|enzalutamide treatment
214990650|NCT04922762|BEHAVIORAL|Moderate Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 3 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
214497290|NCT04000750|OTHER|Normal Feeding|Diet will be tracked and reported every day to a qualified dietitian.
215091131|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
214377860|NCT03852043|BEHAVIORAL|Moderate-intensity continuous training|The continuous training will be carried out at an intensity between 65 and 75% of the HRmax.
214497291|NCT04000750|OTHER|Resistance Training|8 weeks of supervised and programmed whole body resistance training, performed 4x per week
214990651|NCT04922762|BEHAVIORAL|High Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 31 minutes/day 10 minute warm up at 50% of heart rate maximum 2 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 7 minute cool down at 50% of heart rate maximum~Week 2 3 days/week for 38 minutes/day 10 minute warm up at 50% of heart rate maximum 3 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 2 TIMES 7minute cool down at 50% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day 10 minute warm up at 50% of heart rate maximum 4 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 3 TIMES 7 minute cool down at 50% of heart rate maximum"
215091132|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
214377861|NCT05968014|PROCEDURE|PENG vs FICB|pericapsular nerve group block versus fascia iliaca compartment block
214377862|NCT04987632|DRUG|Letrozole|Letrozole, an aromatase inhibitor, is considered to be the first-line drug for ovulation induction in PCOS.
214990652|NCT04922762|BEHAVIORAL|Moderate Intensity, High Volume Exercise Training|"Week 1 5 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 5 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 5 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
214990653|NCT04747002|DRUG|DSP-7888|Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides
214990654|NCT01476072|OTHER|MRI scan|MRI scan only, methodology study with no other intervention
214990655|NCT05316493|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|dietary guidance, exercise guidance, lifestyle intervention
214990656|NCT05316493|DRUG|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
214990657|NCT05316493|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg|enrolled patients will be treated with LNG-IUS.
214990658|NCT03823131|DEVICE|ImmunoPulse|Intratumoral
214990659|NCT03823131|DRUG|Epacadostat|Given PO
214990660|NCT03823131|DRUG|Pembrolizumab|Given IV
214990661|NCT03823131|BIOLOGICAL|CORVax|Intratumoral
214990662|NCT03823131|DRUG|Tavokinogene telseplasmid|Intratumoral
214990663|NCT02251392|OTHER|Chamomila recutita Gel|Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve
214990664|NCT02251392|OTHER|Chamomila recutita Infuse|chamomila infuse in a concentration of 2,5% already determined in a dose response curve
215091133|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
215091134|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
215091135|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
214497292|NCT04000750|DIETARY_SUPPLEMENT|Whey Protein|Consumed on all exercise days.
214497293|NCT04539704|DEVICE|magnet and sham|In same subject some areas will have magnet and others will have sham
214497294|NCT04682288|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
214497295|NCT05861570|DRUG|normal saline|Ultrasound guided injection using 3ml normal saline
214990665|NCT02251392|DRUG|Urea cream based|Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
214990666|NCT02846402|OTHER|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
214990667|NCT06328699|PROCEDURE|Spiritual Therapy|Undergo chaplain led compassionate centered spiritual health sessions
214990668|NCT06328699|OTHER|Best Practice|Receive a traditional chaplain consultation and will receive care upon request
214990669|NCT02909647|PROCEDURE|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
214990670|NCT02909647|PROCEDURE|Osteosynthesis|osteosynthesis using volar locking plate
214990671|NCT01967875|DRUG|Capecitabine+Cisplatin|Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
214990672|NCT01967875|DRUG|Docetaxel+Capecitabine|Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
214990673|NCT01281306|DRUG|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
214990674|NCT01281306|DRUG|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
214990675|NCT01281306|DRUG|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
214990676|NCT01281306|DRUG|Placebo|Placebo was supplied as tablets in blister cards.
214990677|NCT04491994|DRUG|HCQ|Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days
214990678|NCT02054195|BEHAVIORAL|Training|Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
214990679|NCT02054195|BEHAVIORAL|No Training|Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
214990680|NCT06418815|OTHER|Concept map group|The intervention group will create a concept map regarding neonatal toxic stress.
214990681|NCT03719664|DRUG|Albuvirtide|Intravenous infusion of Albuvirtide
214990682|NCT03719664|DRUG|3BNC117|Intravenous infusion of 3BNC117
214990683|NCT03719664|DRUG|Baseline ART|Subjects continuing on baseline ART
214990684|NCT03589703|OTHER|Target ear points related to chronic low back pain (T-APA)|Light touch using vaccaria seeds on specific points of the ear.
214990685|NCT03589703|OTHER|Non-Target ear Points not related to chronic low back pain (NT-APA)|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
214990686|NCT03589703|OTHER|Enhanced Educational Control Group (CG-2)|No contact with the subject. Participants in the enhanced educational control group will be given the cLBP educational booklet.
214990687|NCT03174522|DRUG|REX-001|REX-001 is administered through an intra-arterial catheter.
214990688|NCT03174522|DRUG|Placebo|Placebo is administered through an intra-arterial catheter.
214990689|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) IV|Intravenous Injection
214990690|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) SC|Subcutaneous Injection
214990691|NCT03209960|DIAGNOSTIC_TEST|Bedside Referral Tool|Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents. Each primary care provider will perform elements of a physical exam guided by the bedside referral tool to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
214377863|NCT04987632|DEVICE|acupuncture|Domestic and foreign studies suggest that acupuncture and electroacupuncture can improve the menstrual cycle of PCOS and reduce the level of total testosterone; Acupuncture can regulate glucose homeostasis by stimulating the autonomic nervous system of PCOS patients. Our previous studies and a large number of literatures have proved that acupuncture can improve insulin resistance in PCOS, and acupuncture can improve the pregnancy rate in PCOS.
214377864|NCT04987632|OTHER|Governor vessel moxibustion|It can warm the kidney, promote digestion and absorption, remove dampness and promote blood circulation
214377865|NCT06022835|OTHER|Chlorhexidine Gluconate-gel (CHG) Dressing|Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
214377866|NCT00110890|DRUG|cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
214377867|NCT00110890|OTHER|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
214990692|NCT03209960|OTHER|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
214377868|NCT05446610|OTHER|Fermented product of Pleurotus eryngii mushroom|I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
214990693|NCT06573528|DRUG|CS060380|Tablets administered orally
214990694|NCT04033536|RADIATION|Involved Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Involved Target using IMRT/VMAT/RapidArc
214990695|NCT04033536|RADIATION|Elective Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Elective Target using IMRT/VMAT/RapidArc
214990696|NCT04547439|DRUG|Melatonin|Melatonin 3 mg will be taken nightly for 8 weeks
214990697|NCT04547439|OTHER|Placebo|Placebo will be given nightly for 8 weeks
214990698|NCT04494815|DRUG|SR419|Each participant will receive 1 dose of 20 mg SR419 oral suspension.
214990699|NCT04494815|DRUG|active control|Each participant will receive 1 dose of 300 mg active control capsule.
214990700|NCT04494815|DRUG|SR419 placebo|Each participant will receive 2 doses of SR419 placebo oral suspension.
214990701|NCT04494815|DRUG|active control placebo|Each participant will receive 2 doses of active control placebo capsule.
214990702|NCT04740970|DRUG|JNJ-64304500|JNJ-64304500 injection will be administered subcutaneously.
215091136|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
215091137|NCT04465565|PROCEDURE|9% Sodium Chloride (NaCl) IV|9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
215091138|NCT03545997|DRUG|Montelukast 10mg|The capsules will be presented in box of 95 capsules packaged in unit blister
214377869|NCT06040996|BEHAVIORAL|Improving Parenting Skills adult ADHD (IPSA)|Parent training program for parents with ADHD. The program combines structured group-based skills training with individualized support, including occupational therapist support to help parents improve their own prerequisites for bringing about change and facilitate use of the introduced parenting skills.
214377870|NCT06040996|OTHER|Continued Routine Services|Continued Routine Services while waiting for IPSA (offered approximately 6 months later)
214497296|NCT05861570|DRUG|(Sodium Hyaluronate (Hyruan One , LG)|Ultrasound guided injection using 3ml of Sodium Hyaluronate
214377871|NCT05780294|DRUG|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
214377872|NCT05780294|DRUG|Lobaplatin|30mg/m2, used on the 1st and 28th day of each cycle.
214377873|NCT05780294|DRUG|Placebo|2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.
214497297|NCT05861570|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
214497298|NCT05861570|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 4ml of 40mg triamcinolone acetonide
214990703|NCT04740970|DRUG|Placebo|Matching placebo injection will be administered subcutaneously.
214990704|NCT05803343|BEHAVIORAL|Regulating Together-Canine|RT-C is an animal assisted, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. RT-C meets for 1.5 hours, twice weekly for five weeks with concurrent youth and caregiver groups. The children progress through skills including relaxation training, arousal ratings, problem size, mindfulness, problem solving, and cognitive flexibility. The caregivers learn crisis management, reward systems, and coaching strategies for topics taught to the children. Homework is utilized to reinforce use of skills outside the group. The canines are present throughout as both a calming presence and teaching assistant. Children will be able to interact with the dog when practicing relaxation at the beginning of each session and throughout the session. Additionally, the dog will help to emphasize certain curriculum concepts.
214990705|NCT05803343|BEHAVIORAL|Regulating Together-Standard|RT-S an established, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
215091139|NCT03545997|DRUG|Placebo|Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
214377874|NCT05780294|DRUG|leucogen|40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy.
214497299|NCT02961075|OTHER|local surface anesthesia|Airway anesthesia for Bronchoscopy
214497300|NCT02961075|DEVICE|Laryngeal tube|
214497301|NCT04503681|OTHER|Enhanced compassion video|"Added five additional sentences to the standard introduction video. Those five sentences were compassion-focused statements. The compassionate statements added to the enhanced compassion video were based on the results of a recent systematic review of clinician compassionate behaviors, which found incorporating statements of support, acknowledgement, patient's perspective, emotion naming, and validation increased patient perception of compassion."
214497302|NCT04503681|OTHER|Standard introduction video|Standard introduction video sent to a new patient via email introducing the new patient to the cancer center prior to the initial consultation.
214990709|NCT05474820|OTHER|Samples collection and ELISA analyses|"The serum and unstimulated saliva samples were taken from all patients between 8:00 and 10:00 in the morning. Saliva samples were centrifuged at 10,000 rpm (10 min) whereas venous blood samples were centrifuged at 4000 rpm for 10 min.~For the analysis of irisin and IL-6 specific ELISA Kits (Elabscience, Houston, Texas, USA) were used to determine the molecules in both serum and saliva samples in accordance with the manufacturer's instructions. All samples were run in duplicate, and values have been averaged."
214990710|NCT05474820|DIAGNOSTIC_TEST|Evaluating periodontal paramètres|The clinical periodontal parameters (plaque index (PI), probing pocket depth (PD), gingival recession (GR), clinical attachment loss (CAL), and bleeding on probing (BOP)) were recorded on periodontal charts in each patient
214990711|NCT03188471|DRUG|GnRH antagonist|GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
214990712|NCT03188471|DRUG|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
214990713|NCT01609192|DRUG|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
214990714|NCT03419871|OTHER|Monitoring Sleep|An accelerometer will be placed on the wrist or ankle of the child while the child sleeps in their home. Caregivers will be instructed to keep the accelerometer on their toddler's ankle to measure sleep duration, latency and sleep efficiency. Seven nights of data will be obtained because actigraphy is most reliably measured in young children over this time frame.
214990715|NCT03419871|OTHER|stress biomarkers|"Salivary and hair cortisol measurements were used to obtain a change in baseline from 12 to 24 months. Data on the timing of the saliva collection will be collected using a Medical Electronic Monitoring System (MEMScapTM) - a digital memory cap that records the timing and frequency of opening.~Cortisol will be measure in the morning and bedtime samples. A small amount of hair (30mg) will be cut from the posterior vertex of the child's head. Due to the expected variability in hair length of toddlers, documentation of hair length will be completed. Each centimeter represents 1 month history of stress and ideally 3 cm of hair length will be collected to provide a three month history of stress."
214990716|NCT03150186|OTHER|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
215094659|NCT00651963|DRUG|ezetimibe|"Ezetimibe 10 mg daily was added during 4 weeks.~The patients continued taking their usual Statin without titrating the dose."
214377875|NCT05020262|OTHER|CT Image reconstruction|Retrospectively collects CT Images and reconstruct using PI/PC and Idose4/Cardiac Images to assessment the performance of the two new software functions of Incisive CT. No direct intervention to patients. And ICF is exempted by EC.
214687133|NCT06973551|BEHAVIORAL|Brain Health Nostalgic VR Program|"The Brain Health Nostalgic VR Program is a culturally tailored virtual reality intervention integrating nostalgic content from Taiwanese culture (e.g., vintage photographs, familiar objects, historical TV clips, traditional settings) with interactive cognitive training tasks. The program targets seven cognitive domains: attention, imagination and creativity, observation, memory, reasoning, reading comprehension, and thinking. Each weekly session spans 60-90 minutes, with 10-30 minutes of actual VR use based on participant tolerance, each participant will use VR for no more than 30 minutes per session before taking a break. The intervention is delivered once per week over a 12-week period in long-term care settings, with researcher support provided throughout."
214377876|NCT03926793|DRUG|GB002|GB002 low dose or high dose for inhalation
214377877|NCT03926793|DRUG|Placebo|Placebo for inhalation
214377878|NCT03926793|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 or Placebo delivery
214377879|NCT03549884|PROCEDURE|Delayed cord clamping|Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section
214377880|NCT03549884|PROCEDURE|Early cord clamping|Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
214497303|NCT01782846|DRUG|Ixprim®|
214377881|NCT01975220|DRUG|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
214377882|NCT01975220|DRUG|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
214377883|NCT01975220|DRUG|25 mg Empagliflozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
214377884|NCT01975220|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
214497304|NCT01782846|DRUG|Dafalgan-Codeine®|
214377885|NCT01975220|DRUG|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
214990717|NCT03150186|OTHER|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
214990718|NCT03150186|OTHER|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
214990719|NCT04504760|DRUG|ONO-2910|Single ascending dose of ONO-2910 will be administered orally.
214990720|NCT04504760|DRUG|Placebo|Single dose of placebo will be administered orally.
214990721|NCT04504760|DRUG|ONO-2910|Multiple ascending dose of ONO-2910 will be administered orally.
214990722|NCT04504760|DRUG|Placebo|Multiple dose of placebo will be administered orally.
214990723|NCT05492435|DEVICE|transcranial direct current stimulation|tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.
214377886|NCT01975220|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
214377887|NCT00003884|DRUG|zoledronic acid|
214377888|NCT00003884|PROCEDURE|quality-of-life assessment|
214497305|NCT04359069|OTHER|Urinary catheter removal on postoperative day 1|Urinary catheter will be removed on day 1 (experimental) instead of day 3 (standard of care).
214990724|NCT01953237|BEHAVIORAL|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
214990725|NCT01953237|DEVICE|Smartphone|
214990726|NCT05551988|OTHER|Retrospective observational study of diabetic foot ulcer|This is a retrospective observational study of antibiotic resistance and risk factors of amputation in diabetic foot ulcer patients
214990727|NCT03936127|PROCEDURE|Ultrasound (US) Targeted Fusion Biopsy|Ultrasound (US) Targeted Fusion Biopsy
214990728|NCT02428153|OTHER|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
214377889|NCT02839343|RADIATION|radiation therapy|
214377890|NCT02839343|PROCEDURE|surgery|
214377891|NCT02839343|DRUG|mFOLFIRINOX|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
214377892|NCT02839343|DRUG|FOLFOX|oxaliplatin IV, leucovorin IV and 5-FU IV
214377893|NCT02980926|DRUG|Mepivacaine|This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
214377894|NCT02980926|DRUG|Bupivacaine|This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
214377895|NCT00710632|OTHER|laboratory biomarker analysis|
214497306|NCT04359069|OTHER|Urinary catheter removal on postoperative day 3|Urinary catheter will be removed on day 3 (standard of care)
214377896|NCT00710632|OTHER|physiologic testing|
214377897|NCT00710632|OTHER|questionnaire administration|
214377898|NCT00710632|PROCEDURE|management of therapy complications|
214377899|NCT05878392|OTHER|bone filling materials|the buccal jumping gap was packed using PRF in group 1 the buccal jumping gap was packed using xenograft in group 2 the buccal jumping gap was packed using Alloplastic β-tricalcium phosphate in group 3
214377900|NCT01915576|DRUG|BAY1125976|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
214377901|NCT01915576|DRUG|BAY1125976|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
214377902|NCT01915576|DRUG|BAY1125976|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
214377903|NCT05813067|DIETARY_SUPPLEMENT|JDS-HF 3.0|Take 2 capsules once daily in the mornings with food
214377904|NCT05813067|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules once daily in the mornings with food
214377905|NCT04182711|DEVICE|Device|Phase 1: Time taken for each patient is 25 mins Phase 2: Time taken for each patient is 30 mins
214377906|NCT04885933|DIAGNOSTIC_TEST|sarcopenia measurement|BIA for fat free muscle mass hand grasp strength
214377907|NCT00114361|DRUG|Ribavirin|1200 mg a day, 48 weeks
214377908|NCT00114361|DRUG|Peginterferon alpha 2a|180 µg per week, 48 weeks
214497307|NCT03065049|BEHAVIORAL|Peer-Facilitated Counseling|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
214497308|NCT03065049|BEHAVIORAL|Fitbit activity tracker|Participants will be given a Fitbit activity tracker to monitor physical activity.
214990729|NCT00051506|DRUG|ALIMTA|
214377909|NCT01852058|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.
214377910|NCT02434289|DIETARY_SUPPLEMENT|Dietary protein products|Increased protein intake via dairy products, guided by a dietician.
214990730|NCT00051506|DRUG|carboplatin|
214497309|NCT01492049|BEHAVIORAL|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
214497310|NCT01492049|BEHAVIORAL|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
214990731|NCT00051506|DRUG|cisplatin|
214990732|NCT05651737|BEHAVIORAL|Sui App (SRK)|"The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification"
214990733|NCT01597362|PROCEDURE|laparoscopy|Trocar access in laparoscopy
214990734|NCT01597362|PROCEDURE|Laparoscopy|"The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume."
214990735|NCT01597362|PROCEDURE|Laparoscopy|"Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field."
214990736|NCT01597362|PROCEDURE|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
214990737|NCT02320396|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
214990738|NCT02320396|DRUG|Placebo|Placebo tablets
214990739|NCT00977977|DRUG|Rituximab Infusion|Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
214990740|NCT00977977|DRUG|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
214990741|NCT01125553|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
214990742|NCT03171870|DIAGNOSTIC_TEST|high resolution computed tomography|high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
214990743|NCT04803500|DRUG|Simvastatin|single injection of simvastatin gel in the gap around immediately placed implant
214990744|NCT04803500|DRUG|Placebo|single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
214990745|NCT05700838|BEHAVIORAL|Cough Skill Training - with Variable Practice|"Variable practice will involve three targets that reflect a range of cough airflows, including strong, moderate, and weak coughs."
214990746|NCT04657900|OTHER|Observational|Observational - no intervention given
214990747|NCT03331562|DRUG|Pembrolizumab|pembrolizumab solution for infusion
214990748|NCT03331562|DRUG|paricalcitol|Paricalcitol solution for injection
214990749|NCT03331562|DRUG|placebo|normal saline solution for injection
214990750|NCT03718000|DEVICE|Daily self-weighing (DSW)|DSW was conducted using digital WiFi scales during the holiday season. Participants received electronic graphic feedback of their weight fluctuations immediately after weight measurement.
214990751|NCT04951960|OTHER|Higher PEEP setting|PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
214990752|NCT04951960|OTHER|Lower PEEP setting|PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
215091140|NCT01221194|BEHAVIORAL|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
215091141|NCT01221194|DEVICE|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
215094660|NCT02780973|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
214377911|NCT02434289|OTHER|Resistance exercise training|Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.
214377912|NCT05234359|DIAGNOSTIC_TEST|Serology Testing|A simple home sampling kit containing volumetric absorption microsampling devices (Mitra(R) cartidge device, Neoteryx LLC) will be used by the participants to collect a finger stick blood sample (10 ul; a few drops). Kits will be delivered to participants' homes and returned by mail. An instructional video will be provided.
214377913|NCT05234359|DIAGNOSTIC_TEST|Stool sample|Stool samples collected for genetic, microbial and viral analysis.
214497311|NCT01492049|BEHAVIORAL|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
214497312|NCT06219434|BEHAVIORAL|Mindfulness Relaxation|Participate in mindfulness program
214497313|NCT06219434|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
214990753|NCT02374983|OTHER|Gamma knife radiosurgery re-planning with convolution algorithm|"The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment.~Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms."
214990754|NCT02441283|DRUG|ABT-493|ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
214377914|NCT01576822|OTHER|This protocol will utilize a sauna as the primary method of detoxification.|"This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna)."
214377915|NCT04729894|OTHER|Medication Lockbox|Participants will receive a medication lockbox to store medications in their home.
214377916|NCT04729894|BEHAVIORAL|Education|Participants will receive information on safe medication storage practices.
214377917|NCT04104750|OTHER|assessment scales (BFI, QLQ, TESS)|the patient's Fatigue will be measured during the treatment period with antiblastic drugs and part of the followup period. To this end the BFI scale validated in Italian will be used (Mendoza et al 1999; Catania et al, 2013) which includes 9 items with a score for each of 0 to 10 and a consequent total score from 0 to 90. The measurement will take place in 4 times: the day of enrollment, 6 months, 12 months and 24 months after enrollment.the quality of life of patients measured by the EORTC QLQ C-30 scale (Aaronson et al, 1993) and the level of autonomy measured by the TESS scale (Davis et al, 1996) in 4 steps: the enrollment day , at 6 months, at 12 months and at 24 months from enrollment.
214497314|NCT06219434|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214497315|NCT06219434|OTHER|Questionnaire Administration|Ancillary studies
214990755|NCT02441283|DRUG|ABT-530|ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
214990756|NCT05002803|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
214990757|NCT05775653|OTHER|ADAPT program|The ADAPT program is a structured and individualized group-based program, in which two occupational therapists teach groups of people the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT program 3.0 includes 10 two-hour sessions and is followed by two booster sessions to support sustainable gains.
214990758|NCT05775653|OTHER|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focus on improving ADL ability e.g. by practicing the performance of ADL task. UOT typiccally includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement.
214687134|NCT05228002|OTHER|sFlt-1/PlGF ratio - Active Comparator: Standard|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation"
214687135|NCT05228002|OTHER|sFlt-1/PlGF ratio - Experimental: Biomarkers|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation."
214687136|NCT05216393|OTHER|RecTech Match Website|Participants will have access to the Rectech Match website. These participants will receive 9 health coaching calls. Fitbit physical activity data will be collected on an ongoing basis during the intervention.
215091142|NCT06905444|COMBINATION_PRODUCT|Myofascial Release Technique|"GROUP A (Multimodal Therapy) Group A was treated with multimodal therapy for 30-45 minutes for 2 sessions per week for 6 weeks. Postural education like correct posture and forward head posture exercises like chin tuck in. Patient was sitting on chair. Therapist was standing on side of patient treated part. Strengthening exercises for the deep cervical flexors, shoulder blade stabilizers, and core muscles with 3 Sets of 3 repetitions with hold for 5 seconds of each exercise. Then breathing exercises for 1 minute. Then grade A (pain free range) cervical spine mobilization 1 Set of 3 repetition. During entire treatment session, the therapist kept close eye on patient's discomfort."
215094661|NCT04784468|OTHER|No intervention|Case-control design, one single investigation
215094662|NCT05257343|DIETARY_SUPPLEMENT|Liquid Placebo Supplementation|8-weeks of supplementing with a visually identical liquid placebo supplement.
214377918|NCT00180128|DRUG|all-trans retinoid acid|
214377919|NCT00180128|DRUG|idarubicin|
214377920|NCT00180128|DRUG|mitoxantrone|
214377921|NCT00180128|DRUG|daunorubicin|
214497316|NCT03986359|DEVICE|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
214497317|NCT00506844|DRUG|Cetuximab, Irinotecan, Capecitabine|
214497318|NCT02394054|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
214687137|NCT04857112|DRUG|Low Dose MT-1303|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
214377922|NCT00180128|DRUG|cytarabine|
214377923|NCT01602081|DEVICE|reinforce soft tissue|reinforce soft tissue
214377924|NCT02249455|DEVICE|Acapella|Treatment time for 20 min twice daily
214377925|NCT02249455|OTHER|ELTGOL|ELTGOL technique 20 min twice daily
214377926|NCT02249455|OTHER|conventional physiotherapy|Conventional physiotherapy was given twice daily for 20 min
214377927|NCT02000414|DRUG|intraperitoneal daptomycin|intraperitoneal daptomycin administartion and study of daptomycin kinetics
214990759|NCT05509504|OTHER|Low-intensity online intervention|The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills. Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for \~45 minutes. Participants will attend these sessions once a week.
214990760|NCT00226655|DRUG|hCRF [XERECEPT (corticorelin acetate injection)]|2mg/day
214990761|NCT02262871|DEVICE|High flow nasal oxygen cannula|HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
214990762|NCT02262871|DEVICE|Noninvasive ventilation|The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
214990763|NCT05893641|BEHAVIORAL|A regular training volume|Participate will maintain their training volume of 35 h/week
214990764|NCT05893641|BEHAVIORAL|A lower exercise volume group|Participate will conduct 85% of the control group weekly training volume (i.e., 30h/week)
214990765|NCT05893641|BEHAVIORAL|A longer rest group|Participate will maintain the 35 h/week of exercise training
214990766|NCT04934358|BEHAVIORAL|Physical and motivational follow-up treatment|Physical and motivational follow-up treatment
214377928|NCT01814059|DRUG|sirolimus|
214377929|NCT03490214|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
214377930|NCT00755014|OTHER|red wine|One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
214377931|NCT02296632|BEHAVIORAL|Motion sensors and daily online assessments|Patients will be asked to wear motion sensors during their waking hours and complete daily Patient Reported Outcomes online assessments.
214377932|NCT04465825|BEHAVIORAL|HITT: intermittent high intensity exercise|Intermittent bouts of 30-60 seconds of exercise at 90% of peak intensity (HITT).
214377933|NCT01099514|DRUG|Nilotinib|D1\~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
214377934|NCT03241602|DRUG|Intraperitoneal lidocaine|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure.
214377935|NCT03241602|PROCEDURE|Pulmonary Recruitment|pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
214377936|NCT03241602|COMBINATION_PRODUCT|Combined intraperitoneal lidocaine and pulmonary recruitment maneuver|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure before the recovery of the patient pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
214377937|NCT02261584|DEVICE|Microwave Thermal Coagulation|Microwave thermal coagulation of splenic parenchyma.
214377938|NCT02261584|DEVICE|Partial Splenic Embolization|Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
214377939|NCT03056625|OTHER|Vitamin A fortified rice|Lactating women will receive fortified rice one meal per day on weekdays for a period of 14 weeks.
214377940|NCT03056625|OTHER|Normal rice|Lactating women will receive normal rice one meal per day on weekdays for a period of 14 weeks.
214377941|NCT01003925|BEHAVIORAL|Standard of care for osteoarthritis treatment|Standard of care educational materials to inform patients about choices for knee pain.
214377942|NCT01003925|BEHAVIORAL|Conjoint Analysis for Osteoarthritis|Conjoint Analysis computer software to inform patients about choices for knee pain.
214377943|NCT01909414|BIOLOGICAL|GEO-D03 DNA Vaccine|DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
214377944|NCT01909414|BIOLOGICAL|MVA/HIV62B Vaccine|MVA/HIV62B vaccine will be administered as a 1 x 10\^8 TCID50 dose IM.
214377945|NCT01909414|BIOLOGICAL|Placebo for DNA GEO-D03|Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
214377946|NCT01909414|BIOLOGICAL|Placebo for MVA/HIV62B Vaccine|Placebo for MVA/HIV62B 1 x 10\^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
214377947|NCT01199926|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
214377948|NCT01199926|DRUG|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
214377949|NCT01960530|DRUG|Hydrocortisone granules|Multi-particulate granules
214377950|NCT01960530|DRUG|Hydrocortisone Tablet|Standard hydrocortisone tablets
214377951|NCT01960530|DRUG|i.v. Hydrocortisone Injection|Standard hydrocortisone solution for intravenous injection
214377952|NCT01960530|OTHER|Dexamethasone|Challenge agent
214377953|NCT03899168|OTHER|Social Tag Popularity|The relative size of treatment tags in a tag cloud was either larger for antidepressant treatments or psychotherapy treatments.
214377954|NCT03899168|OTHER|Confidence in Prior Attitudes|Participants thought back of situations in which they were either confident or doubtful about their own knowledge. This should elicit a mindset where participants are more or less confident about their own prior attitudes.
214377955|NCT03899168|OTHER|Source Credibility|The source credibility of the community that allegedly collected and labelled the blog posts was either high or low in terms of expertise. Either experts (high credibility) or first semester students (low credibility) did allegedly collect blog posts. This was indicated by banners on top of the navigation platform in the internet browser.
214497319|NCT02394054|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
214497320|NCT06523478|PROCEDURE|Intratonsillar immunotherapy (ITIT)|During injection, the operator needs to gently shake the injection bottle about 20 times, the drug must be mixed to ensure the consistency of allergen concentration, and carefully check the patient's name and concentration on the bottle. Allergy extracts should not be injected intravenously, so the syringe will be aspirated to avoid inadvertent intravascular injection. Before each injection, after inserting the needle into the selected tonsil, before injecting the dose, the investigator will slightly pull the plunger of the syringe. If blood returns from the syringe, the syringe, and its contents will be discarded. The other tonsil will be selected and a new syringe will be prepared.
214497321|NCT06523478|PROCEDURE|Subcutaneous immunotherapy (SCIT)|Injection requires shaking bottle 20x to mix drug for consistency. Verify patient name \& concentration. Use 1 ml skin test syringe for deep subcutaneous injection at 45° angle, 1 cm into outer upper arm. Lift skin folds for deeper injection, avoid subcutaneous, muscular or intravascular. Inject slowly, 1 min for 1 ml. Avoid shallow injections which may cause local side effects. Alternate between left \& right arm for 5 min after injection for compression.
214990767|NCT04934358|BEHAVIORAL|Usual care|Usual rehabilitation program
214990768|NCT06463678|DRUG|IVIEW-1201|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
214990769|NCT06463678|DRUG|NATACYN®|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
214990770|NCT02540304|BEHAVIORAL|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
214990771|NCT01113242|OTHER|Neuropsychological Assessment|Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,…) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) \<16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.
214990772|NCT06284161|DIAGNOSTIC_TEST|Quadriceps Combined Test|The recording of the motor response on the quadriceps is done using self-adhesive surface electrodes on the motor point of the vastus medialis muscles (active electrodes) and on the patella (reference electrode), using a classic electromyography device that allows calculations and measurements of amplitude, duration and speed.
214990773|NCT02808988|PROCEDURE|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
214990774|NCT02808988|PROCEDURE|gingival crevicular fluid collection|gingival crevicular fluid collection by periopapers
214990775|NCT02808988|OTHER|zoledronic acid|5 mg/year zoledronic acid (i.v.)
214990776|NCT02525068|DRUG|AZD5363|Until confirmed disease progression.
214990777|NCT02525068|DRUG|Enzalutamide|Until confirmed disease progression.
214990778|NCT03048786|BEHAVIORAL|Control|Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
214990779|NCT03048786|BEHAVIORAL|Peer Mentoring|"Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date."
214990780|NCT04501250|DRUG|Rinsulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
214990781|NCT04501250|DRUG|Humulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
214990782|NCT04642222|BEHAVIORAL|APOLO-Teens web-based intervention|The APOLO-Teens web-based intervention is a 6-month cognitive-behavioral lifestyle program developed to optimize treatment as usual for pediatric obesity in public portuguese hospitals.
215091143|NCT06905444|COMBINATION_PRODUCT|Multimodal Therapy|Group B (Myofascial Release Technique) Group B was treated with multimodal therapy for 30-45 minutes for 2 sessions per week for 6 weeks. Palpate the muscles and fascia to identify areas of restriction. Apply gentle, sustained pressure to the restricted area using the fingertips or knuckles for Fascial Unwinding. Hold the pressure for 3-5 minutes to allow the fascia to release. Encourage the patient to breathe deeply and slowly to promote relaxation. The stretching of tight muscles 1 set of 3 repetitions. Apply gentle, sustained pressure to release tension of these tight muscles, Suboccipital, Scalene, Pectoralis Major, Trapezius, Levator Scapulae
214990783|NCT04642222|OTHER|Treatment as Usual for Pediatric Obesity|Treatment as Usual for pediatric obesity in portuguese public hospitals.
214990784|NCT01719653|DRUG|MiraLAX|MiraLAX consumed as described in each arm.
214990785|NCT01719653|OTHER|Gatorade|Gatorade consumed as described in each arm.
214990786|NCT01719653|DRUG|MoviPrep|MoviPrep consumed as described in each arm.
214377956|NCT05461261|DRUG|Docetaxel|Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.
214377957|NCT05461261|DRUG|Prednisolone Acetate|5mg Prednisolone Acetate will be given orally twice a day during treatment.
214377958|NCT05461261|DRUG|Platinum-based drugs|Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.
214990787|NCT01719653|DRUG|SUPREP|SUPREP consumed as described in each arm.
214990788|NCT01757548|PROCEDURE|open operation|high ligation of spermatic vein by open operation
214990789|NCT01757548|PROCEDURE|microsurgery|high ligation of spermatic vein by microsurgery
214990790|NCT01910441|DRUG|Vildagliptin|Vildagliptin 50 mg twice daily
214990791|NCT01910441|DRUG|Glimepiride|Glimepiride 1-6 mg once daily
214377959|NCT06451822|DEVICE|mIntense L+AS|The investigated dermal filler mIntense L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
214377960|NCT01121198|DRUG|ASP1941|oral
214377961|NCT01121198|DRUG|placebo|oral
214377962|NCT02676596|DRUG|K-312 10 mg QD|
214377963|NCT02676596|DRUG|K-312 25 mg QD|
214377964|NCT02676596|DRUG|K-312 50 mg QD|
214377965|NCT02676596|DRUG|K-312 100 mg QD|
214377966|NCT02676596|DRUG|K-312 200 mg QD|
214377967|NCT02676596|DRUG|K-312 400 mg QD|
214377968|NCT02676596|OTHER|Placebo|
214377969|NCT01301274|DRUG|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
214990792|NCT01910441|DRUG|Metformin|Metformin (1000-1500 mg daily)
214990793|NCT03727282|PROCEDURE|adjust dobutamine according to the ejection volume index|adjust dobutamine dose
214990794|NCT03727282|PROCEDURE|adjust dobutamine according to the attending physician|adjust dobutamine dose
214990795|NCT00152022|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
214990796|NCT04711577|BEHAVIORAL|Track clinician-determined symptoms|Participants will track clinician-determined symptoms
214990797|NCT04711577|BEHAVIORAL|Track clinician-determined and self-determined symptoms|Participants will track clinician-determined symptoms and a self-determined symptom
214990798|NCT00478959|DRUG|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
214990799|NCT01807533|BEHAVIORAL|Family-centered intervention program|This program was in-hospital intervention, after-discharge intervention, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
214990800|NCT01807533|BEHAVIORAL|Usual care intervention program|This program was in-hospital intervention, after-discharge consultation, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The after-discharge service was provided 7-phone calls for the general health consultation.
214990801|NCT05975489|DIETARY_SUPPLEMENT|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women
214990802|NCT03744832|DIAGNOSTIC_TEST|Alere i™ Strep A assay|Point of care (POC) molecular-based, nucleic acid amplification test (NAAT). This isothermal molecular assay is CLIA waived (Clinical Laboratory Improvement Amendments) and Health Canada licensed for POC use, and is anticipated to have approval for use without need for back up culture testing.
214990803|NCT03744832|DIAGNOSTIC_TEST|Throat culture|Standard bacterial throat culture.
214990804|NCT05474001|DRUG|Fentanyl|10mg bubivacain intrathecal ( 2ml ) with 20microgram intrathecal fentanyl
214990805|NCT05474001|DRUG|Bupivacain|10mg bubivacain intrathecal (2ml) with 0.5 ml saline with no intrathecal fentanyl
214990806|NCT05474001|DRUG|intravenous graniseton|10mg bubivacain intrathecal ( 2ml ) with 0.5 ml saline with no intrathecal fentanyl with 1mg iv granisetron
214990807|NCT00067080|DRUG|ICL670, deferoxamine|
214990808|NCT02217956|DRUG|Cisplatin|
214990809|NCT02217956|DRUG|Bevacizumab|
214377970|NCT01301274|DRUG|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
214377971|NCT02890537|DRUG|Core decompression/PREOB® implantation|All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
214377972|NCT02890537|DRUG|Core decompression/BMC implantation|All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
214377973|NCT00661661|DRUG|CP-690,550|5 mg BID up to 10 mg BID until launch
214990810|NCT01104961|DEVICE|Contact lens packaging solution|These test solutions are the intervention being tested.
214990811|NCT01104961|DEVICE|Balanced salt solution (BSS)|BSS is isotonic to the tissues of the eyes.
214990812|NCT02340949|DRUG|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
214990813|NCT02340949|DRUG|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
214990814|NCT02340949|DRUG|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
214990815|NCT02340949|DRUG|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
215091144|NCT01117935|RADIATION|intensity modulated external beam radiation therapy|"Low risk - 69.6 Gy in 2.4 Gy fractions to prostate~Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes~High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes"
214990816|NCT02644018|DRUG|Imidazolyl ethanamide pentandioic acid|
214990817|NCT02644018|DRUG|placebo|
215091145|NCT05718037|BIOLOGICAL|Recombinant Zoster Vaccine|0.5mL, Intramuscular
215091146|NCT05718037|BIOLOGICAL|Placebo|0.5mL, Intramuscular
215091147|NCT05718037|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted|0.5mL, Intramuscular
215091148|NCT00005976|DRUG|carboplatin|
215091149|NCT00005976|DRUG|pyrazoloacridine|
215091150|NCT05015790|DEVICE|virtual reality Bliss Solution|use virtual reality Bliss Solution
214377974|NCT04836117|OTHER|SomaSignal Test Results|SomaLogic, Inc. translates patterns from 5000 protein measurements made in thousands of participants in clinical trials into validated models (SomaSignal Tests) that predict important health outcomes or correlate with established health measures. SomaLogic, Inc. has developed these protein-based tests for the detection, subtyping and prognosis of heart disease and related medical, physiological and behavioral conditions. These tests are demonstrated in large retrospective studies to provide information superior to best available alternatives.
214377975|NCT03916601|DRUG|SAR341402|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
214377976|NCT03916601|DRUG|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
214377977|NCT03916601|DRUG|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
214377978|NCT03916601|DRUG|SAR341402|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
214377979|NCT03489096|DEVICE|Cryoballoon Ablation: PVI + substrate modification|Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
214687138|NCT04857112|DRUG|High Dose MT-1303|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
214687139|NCT04857112|DRUG|Placebo|Matching placebo, QD (Day 1-85)
214990818|NCT03995563|DRUG|Dexamethasone|"Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.~."
214990819|NCT03995563|DRUG|Ropivacaine|Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
214377980|NCT01893827|DRUG|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
214377981|NCT01893827|DRUG|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
214990820|NCT02879058|PROCEDURE|Intraoperative contact ultrasonography|In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
215091151|NCT01504581|BIOLOGICAL|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
215091152|NCT01504581|BIOLOGICAL|HM10660A placebo|Single dose of HM10660A Placebo
214377982|NCT01897701|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
214377983|NCT01897701|BIOLOGICAL|Adjuvant 1|
215091153|NCT01504581|BIOLOGICAL|Pegasys|Single dose of Pegasys 180ug
214687140|NCT04857112|DRUG|MT-1303|0.4 mg MT-1303 QD for 36 weeks for those participants who continue on to the OLE period from the double-blind portion of the clinical study
214687141|NCT00992901|DRUG|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
214377984|NCT01897701|BIOLOGICAL|Placebo|
214377985|NCT02740855|DEVICE|Alcomed 3011®|Endtidal ethanol measurement
214377986|NCT03288090|OTHER|FSS: Fatigue Severity Scale|Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).
214687142|NCT00992901|DRUG|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism
214687143|NCT00992901|DRUG|GLP-1 and GIP|A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
214687144|NCT04908449|DRUG|Rectus sheath block with bupivacaine|Rectus sheath block with local anesthetic versus sham block with saline
214687145|NCT05301283|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Participants will be treated with intensity modulated radiation therapy (IMRT) with photons, which is FDA (U.S. Food and Drug Administration) approved radiation delivery system.
214687146|NCT05301283|DIAGNOSTIC_TEST|MRI|Participants will receive pretreatment diagnostic MRIs to generate MRI habitats. These images will identify radioresistant cells within tumor.
215091154|NCT06302894|BEHAVIORAL|Self-sufficiency|Rewarding positive behavior and developing alternative behaviors towards obstacles such as feeling restless, depressed or angry if internet use is reduced or controlled.
215091155|NCT01724424|DRUG|Melatonin|20 mg oral single dose
215091156|NCT01724424|DRUG|Melatonin|30 mg oral single dose
215091157|NCT01724424|DRUG|Melatonin|50mg oral single dose
215091158|NCT01724424|DRUG|Melatonin|100mg oral single dose
215091159|NCT04070495|DRUG|KW-6356|A single oral dose will be administered at Day 1 and 15
215091160|NCT04070495|DRUG|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
215091161|NCT04070495|DRUG|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
215091162|NCT06280534|DRUG|Test drug XT1061 capsules and placebo,Single dose group|Eight people took capsules of the test drug XT1061 and two people took a placebo.
214990821|NCT04003909|PROCEDURE|ultrasound-guided Erector spinae plane block|The patients will be in lateral position. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. Local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle will be inserted inplane to the ultrasound beam in a cranial-to-caudal direction until contact made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total volume of 20ml bupivicaine 0.25% and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
214990822|NCT04003909|PROCEDURE|subarachonoid block|Local anesthesia 2ml of lidocaine 2% will be applied intradermally to the needle entrance point. A 22-G block needle will be inserted, free cerebrospinal fluid flow will be observed and 20mg of hyperbaric bupivacaine 0.5% and 10μg of fentanyl will be injected for 30 seconds.
214990823|NCT00122603|DRUG|Fosamprenavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
214990824|NCT00122603|DRUG|Saquinavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
214990825|NCT05730426|PROCEDURE|Deep dry needling|Method to decrease pain and improve function in musculoskeletal disorders.
214990826|NCT05730426|PROCEDURE|Muscle energy technique|Method to decrease pain and improve function in musculoskeletal disorders.
214990827|NCT05730426|PROCEDURE|Neck stability exercise|Method to decrease pain and improve function in musculoskeletal disorders.
214990828|NCT06294470|DIAGNOSTIC_TEST|Ballon expulsion test|Rectal latex balloon probe filled with saline solution. Patients expelled balloon and time recorded (\<1 or \>1 min).
214990829|NCT06294470|DIAGNOSTIC_TEST|Colonic transit time|Patients ingested capsules with 24 radiopaque markers and underwent standing abdominal radiographs on Day 3 and Day 5. Over 80% expulsion within five days was considered normal, while retention indicated defecatory obstruction.
214990830|NCT06294470|PROCEDURE|Stapled hemorrhodopexy|Circumferential stapled hemorrhoidopexy with a 34mm circular stapler is a surgical procedure used to treat mucohemorrhoidal prolapse.
214990831|NCT01774526|OTHER|Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes|
214990832|NCT01737801|PROCEDURE|Lung function test|Lung function test.
214990833|NCT01192178|DRUG|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
214990834|NCT01192178|DRUG|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
214990835|NCT04546841|BIOLOGICAL|multipeptide cocktail|"Three groups of participant will be administered the multipeptide cocktail~1. Part I: Age 18-55 at the time of screening~2. Part II: Age 56-74 years at the time of screening~3. Part III: Age ≥ 75 years at the time of screening"
214990836|NCT01943617|DRUG|Entecavir|anti-viral therapy
214990837|NCT01943617|DRUG|Thymosin-α|anti-viral and antitherapy
214990838|NCT02351921|DEVICE|Transcranial magnetic stimulation|Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (\~1 hour) in neural activity in the brain. The delivery of cTBS requires \~ 40 seconds in total.
214990839|NCT02868515|OTHER|Hot cereal contain 3 g dietary fiber|Intervention involves consumption of a hot cereal over 14 day period
214990840|NCT06213116|DEVICE|MADgic Atomizer|Device to deliver directly lignocaine
214990841|NCT06213116|DEVICE|Lignocaine pump spray|Lignocaine 30 mg (3 puffs) given via 10mg Lignocaine Pump Spray prior to endotracheal intubation
215091163|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Multiple dosing group|D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.
215091164|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Food Impact Group|Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.
215091165|NCT04485572|DIAGNOSTIC_TEST|Straight Leg Raise test (SLR) and Bragard test (B)|The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)
214377987|NCT03288090|OTHER|Neuropsychological evaluation battery|A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.
214497322|NCT04277156|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063|7 drops contain Lactobacillus rhamnosus GG 5x10\^9 CFU; and Lactobacillus reuteri 1x10\^8 CFU.
214497323|NCT04277156|DIETARY_SUPPLEMENT|L rhamnosus ATCC 53103|5 drops contain Lactobacillus rhamnosus 5x10\^9 CFU.
214497324|NCT02305511|DEVICE|Peripheral venous catheterization|Cannulation using standard method
214497325|NCT02305511|DEVICE|Jamshidi|intraosseous access using the Jamshidi device
214497326|NCT02305511|DEVICE|BIG|intraosseous access using the BIG device
214990842|NCT02812784|DEVICE|Nephrocheck TM|
214990843|NCT02460289|DRUG|Treatment: Minoxidil 5% / Botanical Hair Solution for Men|
214990844|NCT00244179|DRUG|interferon-gamma|
214990845|NCT00244179|DRUG|infliximab|
214990846|NCT00244179|DRUG|dmard|
214990847|NCT03783637|OTHER|Whole grain oats|A meal containing whole grain oats
214990848|NCT03783637|OTHER|Whole grain wheat|A meal containing whole grain wheat
214990849|NCT04722406|OTHER|This item is not applicable to our observational study.|This item is not applicable to our observational study.
214990850|NCT02683629|BIOLOGICAL|NTCELL Implantation|NTCELL Implantation
214990851|NCT02683629|OTHER|Sham Surgery|Sham Surgery
214990852|NCT00611052|BEHAVIORAL|the Adolescent Coping with Stress|A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
215091166|NCT04485572|DIAGNOSTIC_TEST|Fajersztajn test (F) and Sicard test (S)|The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)
215091167|NCT04485572|DIAGNOSTIC_TEST|Passive Neck Flexion test (PNF)and Kernig test (K)|The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)
214990853|NCT00611052|BEHAVIORAL|Treatment as usual|The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
214990854|NCT00611052|OTHER|usual health education|usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
214990855|NCT03303222|DIAGNOSTIC_TEST|breath|measurement of volatile compounds, such as TMAO in exhaled breath and blood
215091168|NCT04485572|DIAGNOSTIC_TEST|Slump test (ST) and Dejerine triad (DT)|The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)
215091169|NCT04485572|DIAGNOSTIC_TEST|MRI scan|All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
215091170|NCT01549795|PROCEDURE|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
215091171|NCT01549795|RADIATION|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
214377988|NCT03288090|OTHER|Other functional scores|Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale
214377990|NCT04211415|DRUG|DS-2741a|Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks
214377991|NCT04211415|DRUG|Placebo|Single, subcutaneous injection administered weekly for 4 weeks
214377992|NCT02005315|DRUG|Vantictumab|Administered intravenous (IV) infusion.
214687147|NCT05114590|DRUG|Insulin glargine/Lixisenatide|Solution for injection in a pre-filled pen by subcutaneous injection. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
215091172|NCT01549795|RADIATION|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
215091173|NCT01549795|DRUG|Capecitabine|Capecitabine - administered till liver transplantation
215091174|NCT01549795|PROCEDURE|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
214377993|NCT02005315|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
214377994|NCT02005315|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
214990856|NCT02825823|DIETARY_SUPPLEMENT|Ketone Salt|
214377995|NCT02970253|PROCEDURE|Capsular resection|Capsular resection
214377996|NCT02970253|PROCEDURE|Capsular retention|Capsular retention
214377997|NCT04182880|DRUG|CPL-01|CPL-01 will be administered
214377998|NCT04182880|DRUG|Placebo|Placebo will be administered
214377999|NCT03324399|DIETARY_SUPPLEMENT|probiotic|a proprietary probiotic formulation
214378000|NCT04154865|OTHER|Hypercapnia|Eligible subjects will undergo transcranial Doppler assessment before and after hypercapnia exposure.
214378001|NCT04154865|DEVICE|Transcranial Doppler|A transcranial Doppler ultrasound probe will be used to assess middle cerebral artery velocity to quantify cerebral blood flow at various time points throughout the study visit.
214378002|NCT04154865|DEVICE|Cycle ergometer|A cycle ergometer will be used to acutely increase cerebral blood flow.
214378003|NCT04154865|OTHER|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
214378004|NCT03389477|DRUG|Palbociclib|Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
214687148|NCT05673018|DEVICE|Multi-Cancer Early Detection Test (Galleri®)|Blood collection and multi-cancer early detection testing with return of results.
214687149|NCT05643482|DEVICE|Hyperbaric Oxygen Treatment|Pressurization at 2.0 ATA with 100% oxygen
214990857|NCT02825823|DIETARY_SUPPLEMENT|Placebo|
214990858|NCT00395577|DRUG|VX-702|
214990859|NCT01931384|DRUG|Human chorionic gonadotrophin|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
215091175|NCT03519061|DRUG|Budesonide|Nasal saline irrigations with budesonide
215091176|NCT04976933|BEHAVIORAL|mHealth adherence app|The mHealth app is designed to remind caregivers to give medication in the outpatient setting, track adherence, and capture real time barriers to adherence if medication is missed.
215091177|NCT03842683|OTHER|CGM|This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.
215091178|NCT03328858|OTHER|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
215091179|NCT01533922|DRUG|Placebo|placebo matching tiotropium + olodaterol FDC
215091180|NCT01533922|DRUG|Tiotropium|Tiotropium 5 mcg once daily
215091181|NCT01533922|DRUG|Olodaterol|Olodaterol 5 mcg once daily
215091182|NCT01533922|DRUG|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
215091183|NCT01533922|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
214990860|NCT01931384|DRUG|Placebo|Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
214990861|NCT01207193|BIOLOGICAL|cell injection|injection of mesenchymal cells to bone cyst defect
214990862|NCT04315402|OTHER|prospective, descriptive study via survey|"* Survey administered at check out.~* Patient's rate of follow-up data gathered via chart review."
214990863|NCT00296517|DRUG|323U66 (Bupropion Hydrochloride Sustained Release)|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
214378005|NCT03389477|DRUG|Cetuximab|-Cetuximab must not be administered as an IV push or bolus
214378006|NCT03389477|DRUG|Cisplatin|-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
214378007|NCT03389477|RADIATION|Intensity-Modulated Radiation Therapy|-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
214990864|NCT00296517|DRUG|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
214990865|NCT02517658|OTHER|Video|Watching a YouTube video containing post tonsillectomy discharge instructions.
214990866|NCT02517658|OTHER|Standard discharge teaching|Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
214990867|NCT03905083|OTHER|Exercise Rehab|Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
214990868|NCT04830280|PROCEDURE|posterior quadratus lumborum block|administration local anesthetic solution between the middle layer of the thoracolumbar fascia and QL muscle at the posterior edge of the quadratus lumborum muscle
214990869|NCT03505346|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
214990870|NCT06251804|OTHER|Water exercise program|The exercise program includes a short foot exercise and will be given in water.
214990871|NCT06251804|OTHER|Land-based-program|The exercise program includes a short foot exercise and will be given on land.
214990872|NCT02359240|PROCEDURE|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
214990873|NCT02359240|PROCEDURE|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
214378008|NCT03389477|PROCEDURE|Tumor biopsy|"* Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~* If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline."
214378009|NCT03389477|PROCEDURE|Peripheral blood draw|Baseline and post-treatment
214378010|NCT03020875|DRUG|Ofirmev|Intravenously administered acetaminophen.
214378011|NCT03020875|DRUG|Per Os Acetaminophen|Orally administered acetaminophen.
214378012|NCT06203886|DEVICE|LumbaCure|LumbaCure® is a device developed to induce specific mobilization of the lower back in patients requiring physical rehabilitation for orthopaedic disorders, particularly chronic low back pain.
214378013|NCT06410495|BEHAVIORAL|NiteCAPP SINCC|Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
214378014|NCT06581809|OTHER|Algosteril|hemostatic dressing
214378015|NCT06581809|OTHER|Other Dressings: interface, hydrocellular, hydrofiber|Non-haemostatic dressing
214378016|NCT05726058|DEVICE|XyCAM with oxygen|After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.
214378017|NCT06100510|DRUG|Aspirin 325mg|Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.
214378018|NCT03536546|BEHAVIORAL|Alcohol Peer Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
214497327|NCT02305511|DEVICE|Cook|intraosseous access using the Cook device
214497328|NCT02305511|DEVICE|EZIO|intraosseous access using the EZIO device
215091184|NCT01533922|DEVICE|Respimat|Respimat inhaler
215091185|NCT00799539|DRUG|bortezomib|From cycles 1-4, 1.3mg/m\^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
215091186|NCT00799539|DRUG|bortezomib|From cycles 5-9, 1.3mg/m\^2 on days 1, 8, 22, and 29 of each 6-week cycle
215091187|NCT00799539|DRUG|melphalan|9 mg/m\^2 once daily on days 1-4 of each 6-week cycle
215091188|NCT00799539|DRUG|prednisone|60 mg/m\^2 once daily on days 1-4 of each 6-week cycle
215091189|NCT02338375|BIOLOGICAL|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
215091190|NCT02634606|DRUG|Gamma Delta Tocotrienols - Low Dose|250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
214378019|NCT03536546|BEHAVIORAL|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
214378020|NCT04044729|DRUG|Cannabidiol|500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding
214378021|NCT04044729|DRUG|Placebo|Placebo
214990874|NCT06472648|OTHER|Proprioception training exercise plan with BOSU|"A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BOSU with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BOSU where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BOSU where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BOSU and the ball held in both hands in front of them.~2' rest between exercises."
214990875|NCT06472648|OTHER|Proprioception training exercise plan with Blackboard (BB)|"A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BB with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BB where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BB where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BB and the ball held in both hands in front of them.~2' rest between exercises."
214378022|NCT06292351|DRUG|DMB-I (Dimebon)|20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
214378023|NCT06292351|OTHER|Placebo|20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
214378024|NCT00142727|DRUG|Methadone|
214497329|NCT05047458|DRUG|ALXN2050|Powder-in-capsule (PIC).
215091191|NCT02634606|DRUG|Gamma Delta Tocotrienols - High Dose|250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
215091192|NCT02634606|DRUG|Sugar Pill|250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
215091193|NCT05740917|DRUG|XZB-0004|XZB-0004 orally Twice daily of every 28-day cycle
215091194|NCT04286672|DIAGNOSTIC_TEST|Metadherin|study alterations of MTDH gene expression in the serum of bladder cancer patients
215091195|NCT05335902|DIAGNOSTIC_TEST|ultrasound measurement of the optic nerve sheath diameter|ultrasound measurement of the optic nerve sheath diameter
214497330|NCT05047458|DRUG|Placebo|PIC.
214497331|NCT01262963|DRUG|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
215091196|NCT05335902|DIAGNOSTIC_TEST|MoCA test|MoCA test is a short bedside test for measuring cognitive disfunction
215091197|NCT05226091|BEHAVIORAL|Letter|Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
215094663|NCT05257343|DIETARY_SUPPLEMENT|Liquid Iron Supplement (Blood Builder ®)|8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
215094664|NCT01107782|DRUG|sildenafil|50 mg TDS orally until birth
214378025|NCT00142727|DRUG|Full opioid agonist|
214378026|NCT00142727|DRUG|Partial opioid agonist|
214497332|NCT04382313|PROCEDURE|the adequate hydration group guided by Vigileo|If the patient is mechanically ventilated, the following scheme is adopted: if SVV≤10%, then adjust the rehydration speed to 1 ml/kg/h; if 10%\<SVV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if SVV≥15%, then adjust the rehydration speed to 3 ml/kg/h. The hydration lasts 24 hours after operation, and the rehydration speed is changed according to the SVV. If the patient does not use mechanical ventilation, the following scheme is adopted: 250ml normal saline is administered within 10 minutes after direct PCI, and the rehydration volume changes to 125ml in patients with mild-to-moderate congestive heart failure. If the increment of SV≥15%, then adjust the rehydration speed to 3 ml/kg/h; if 10%≤the increment of SV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if the increment of SV\<10%, then adjust the rehydration speed to 1 ml/kg/h. Reassessed every 1 hour until SV is stable，and the hydration also lasts 24 hours after operation.
214497333|NCT00357916|DRUG|PEP005 Topical Gel (0.01% concentration)|
214497334|NCT01961466|OTHER|psychological and social self-administered questionnaires|
214687150|NCT05643482|OTHER|Placebo gas|Pressurization at 2.0 ATA with 10.5% oxygen to mimic normal air
214687151|NCT05438563|PROCEDURE|MRI-Guided Transurethral Ultrasound Ablation|Undergo MRI-Guided TULSA
214687152|NCT05438563|OTHER|Questionnaire Administration|Ancillary studies
214687153|NCT05438563|PROCEDURE|Digital Rectal Examination|Undergo DRE
214687154|NCT05438563|PROCEDURE|Cystoscopy|Undergo cystoscopy
215094665|NCT01107782|DRUG|placebo|50mg tid
214378027|NCT00142727|DRUG|Opioid antagonist|
214378028|NCT02439749|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
214378029|NCT02439749|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
214378030|NCT04332042|DRUG|Tofacitinib|Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
214378031|NCT00609427|BEHAVIORAL|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
214378032|NCT00609427|BEHAVIORAL|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
214687155|NCT05438563|PROCEDURE|Biopsy|Undergo biopsy
214990876|NCT03342066|DIAGNOSTIC_TEST|reproducability of caries risk assessment|reproducability of caries risk assessment CAMBRA verses cariogram
214990877|NCT01824667|DIETARY_SUPPLEMENT|B-GOS|
214990878|NCT01824667|DIETARY_SUPPLEMENT|Maltodextrin|
214990879|NCT00964782|DRUG|Sildenafil|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will be randomized to receive Sildenafil first and then crossed over to receive the opposite intervention, placebo.
214990880|NCT00964782|DRUG|Placebo|Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
214990881|NCT00964782|DRUG|Sildenafil 2|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will receive Sildenafil, the crossed over intervention from their initial intervention (Placebo).
214378033|NCT02635269|OTHER|Sugar|10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
214378034|NCT05505877|DRUG|BR790+Tislelizumab|"BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose."
214378035|NCT04143841|DEVICE|Viveye OMNS treatment|The Viveye OMNS treatment ( \~30 min) will be applied once, during the treatment visit only
214378036|NCT04143841|DEVICE|Viveye OMNS sham treatment|The Viveye OMNS sham treatment ( \~30 min) will be applied once, during the treatment visit only
214378037|NCT03202381|DRUG|Degarelix|"Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~* Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~* Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression."
214378038|NCT00871052|DRUG|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
214687156|NCT05438563|PROCEDURE|Bone Scan|Undergo bone scan
214687157|NCT05438563|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
214687158|NCT05438563|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
214687159|NCT03504800|DEVICE|Optical Coherence Tomography|This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B \& C.
214990882|NCT00964782|DRUG|Placebo 2|Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
214990883|NCT03869099|OTHER|Pneumonia Case Management Practices|Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.
214990884|NCT03434288|OTHER|Bone sampling|Bone biopsy in Diabetic patients with foot osteomyelitis
214990885|NCT03513952|DRUG|Atezolizumab|Given IV
214990886|NCT03513952|PROCEDURE|Biopsy|Undergo biopsy of tumor
214990887|NCT03513952|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
214990888|NCT03513952|PROCEDURE|Computed Tomography|Undergo CT
214687160|NCT06474377|BIOLOGICAL|Sinovac PCV24 formulation 1|One dose of Sinovac PCV24 formulation 1（0.5mL）
214687161|NCT06474377|BIOLOGICAL|Sinovac PCV24 formulation 2|One dose of Sinovac PCV24 formulation 2（0.5mL）
214687162|NCT06474377|BIOLOGICAL|Pneumovax®|One dose of Pneumovax® (0.5 mL) contains 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F saccharides.
214687163|NCT06474377|BIOLOGICAL|Placebo|0.5 mL of 0.9%NaCl solution (normal saline)
214990889|NCT03513952|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given IM
214990890|NCT03513952|OTHER|Laboratory Biomarker Analysis|Correlative studies
214990891|NCT03513952|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214990892|NCT03513952|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT
215094666|NCT02963701|DRUG|Ibuprofen|Fixed dose combination
215094667|NCT02963701|DRUG|Pseudoephedrine-HCl|Fixed dose combination
215094668|NCT05546073|OTHER|Advanced point-of-care technology|"The intervention consists of:~* focused lung ultrasound scan(FLUS)~* venous blood samples for leucocytes with 5-part differential count, creatinin, sodium, potassium, urea"
215094669|NCT01548742|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
215094670|NCT01548742|BEHAVIORAL|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
215094671|NCT01761812|OTHER|MRI with gadofosveset and MR elastography|
215094672|NCT05257369|DEVICE|Blue-Green LED photoherapy|Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
215094673|NCT00786539|DEVICE|Diffuse Optical Spectroscopy|mitochondria
215094674|NCT00896649|OTHER|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
215094675|NCT00896649|PROCEDURE|digital mammography|standard screening mammogram
215094676|NCT00896649|PROCEDURE|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
215094677|NCT00383396|DRUG|Topical Cyclosporine|
215094678|NCT00449449|DRUG|Pertubation with Lidocain Solution|
215094679|NCT02495493|DRUG|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
215094680|NCT04726059|DEVICE|Transcutaneous Spinal Cord Stimulation|Therapeutic TSCS will be delivered during ABT using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). Stimulation will involve charge balanced monophasic rectangular waveforms with 1.0-ms pulses, administered at 30 Hz, with a carrier frequency of 10 kHz and a current ranging from 10 to 130 mA.
214378039|NCT03403426|DEVICE|Wingman Crossing Catheter|Endovascular CTO crossing
214378040|NCT02616887|RADIATION|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
214497335|NCT03496558|OTHER|Variability of the lipid profile in pregnant women|"The women participants will be divided into two groups. Group 1 comprised of healthy women and group 2 by pregnant women with a history of risk. A personal, family history and a detailed medical history will be taken in each group. We will proceed to see all possible variables that influence the level of biomarkers (lipids and prolactin).~At least 60 healthy pregnant women and 60 pregnant women with a history of risk (20 for each risk) x 2 series (three years) will be tried, a total of 240-300 women to whom 5 analytical tests would have to be performed."
214990893|NCT02033512|DRUG|Transdermal Hormone Replacement Therapy|"The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal progesterone was prescribed. The patients were evaluated 3 months after THRT treatment protocol.~All the patients were instructed about how to use the progesterone pump for transdermal application, performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
214990894|NCT02033512|DRUG|Transdermal Nanoformulation|The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.
214990895|NCT02033512|DRUG|Transdermal formulation|66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.
214378041|NCT04834310|DRUG|Cefazolin|All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.
214378042|NCT04834310|DRUG|Cephalexin|The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
214378043|NCT04834310|OTHER|Placebo|The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
214378044|NCT05217238|DRUG|Remifentanil|Advanced intravenous injection of remifentanil before the rocuronium injection
214378045|NCT00859651|DRUG|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
214378046|NCT00859651|DRUG|Placebo capsule|Matching placebo capsules
214497336|NCT02053298|DRUG|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
214990896|NCT05442658|OTHER|Microbiota|
214990897|NCT05553717|DRUG|Carvedilol|Carvedilol 12.5mg\\12hr
214990898|NCT01715051|DRUG|D-serine|The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
214990899|NCT01715051|BEHAVIORAL|Cognitive Behavioral Therapy|CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
214990900|NCT01715051|DRUG|Placebo|The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
214990901|NCT02938663|BEHAVIORAL|Questionnaires and Measurements|Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
214990902|NCT05232890|OTHER|Datterino tomato purée from hydroponic technology|Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
214990903|NCT05232890|OTHER|Datterino tomato puree from conventional cultivation|Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
214497337|NCT06387810|DRUG|irinotecan liposome II combined with 5-FU/LV and oxaliplatin|"irinotecan liposome II: 60mg/m2, intravenously for at least 90min, D1, administered every 2 weeks; oxaliplatin: 85 mg/m2, intravenous infusion, D1, every 2 weeks; calcium leucovorin: 400 mg/m2, 30±10min intravenously, D1, every 2 weeks; 5-fluorouracil: 2400 mg/m2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks.~Irinotecan liposome II, oxaliplatin, LV and 5-FU were given successively, and corresponding prophylactic administration could be selected according to clinical needs."
214497338|NCT00235937|DRUG|Anastrozole and goserelin|
214497339|NCT00028548|DRUG|R(+)XK469|
214497340|NCT03223688|BEHAVIORAL|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
214990904|NCT04398472|BEHAVIORAL|KIND Challenge|The KIND challenge consists of nominating an activity to complete over a 4 week period. The activities involve doing an activity with others in your neighbourhood. These activities are positive, engaging and feasible to the average individual. Activities adhere to relevant country or state department health and safety guidelines. For example; having a chat with a neighbour online, or bringing in rubbish bins for an elderly neighbour.
214990905|NCT01867775|DRUG|Mirtazapine|Mirtazapine 15 mg, at night, once a day for 14 days
214378047|NCT00445679|DRUG|DVS SR|Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
214378048|NCT00445679|DRUG|Paroxetine|20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
214497341|NCT03223688|BEHAVIORAL|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
214497342|NCT03223688|BEHAVIORAL|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
214378049|NCT06509451|DRUG|Giomer pit and fissure sealant without etching|S-PRG filler containig pit and fissure sealant without etching step
214378050|NCT06509451|DRUG|Giomer pit and fissure sealant with etching|S-PRG filler containig pit and fissure sealant with etching step
214687164|NCT05854641|BIOLOGICAL|Stempeucel®|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
214990906|NCT00774475|DRUG|comparison of different dosage of clopidogrel|clopidogrel 75 mg/day versus clopidogrel 150 mg/day
214990907|NCT00774475|DRUG|doubled therapy|clopidogrel 150 mg/day
214497343|NCT03352713|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
214687165|NCT03161067|DEVICE|BiCNS|Surgical implantation
214687166|NCT06550180|DRUG|Spinal anaesthesia group (S)|Spinal anaesthesia is given to all patients in S group. They will receive 20 mg of 0.5% hyperbaric bupivacaine plus 25 microgram fentanyl
214990908|NCT02703766|BEHAVIORAL|overfeeding induced weight gain|
214990909|NCT00483665|PROCEDURE|Computed tomography angiography|Computed tomography angiography
214990910|NCT00483665|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging after injection of Vasovist
214990911|NCT03385538|DRUG|Clopidogrel|increasing doses of clopidogrel depending on PRU values (75-300 mg)
214990912|NCT00596635|DIETARY_SUPPLEMENT|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
214990913|NCT00596635|DIETARY_SUPPLEMENT|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
214990914|NCT04903301|PROCEDURE|Contoura Vision LASIK|Topography-Guided LASIK using Phorcides Analytic Software
214990915|NCT01484340|DRUG|Nicotine|"The nicotine patch be given in three phases:~* 2 weeks of patches at enrollment~* 6 weeks of patches at two-week follow-up visit~* 2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg."
214990916|NCT01484340|BEHAVIORAL|Intensive Counseling|"The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~* Baseline~* 2-week follow-up (Quit Day)~* 1-month follow-up~* 2-month follow-up~* 3-month follow-up~* 6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again."
214990917|NCT01143324|DEVICE|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
214990918|NCT02630030|DRUG|Ixazomib|Given PO
214990919|NCT05218694|DIAGNOSTIC_TEST|CCTA guided focused coronary angiography examination.|Focused examination based on Images from CCTA, by choice of optimal catheter used and projection.
214990920|NCT01010763|DEVICE|Total Hip Arthroplasty|Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
214990921|NCT02258672|OTHER|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
214990922|NCT03059368|DEVICE|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
214990923|NCT02771756|DIETARY_SUPPLEMENT|zhen qishen capsule and Oral Supplement of Yuyikang|
214990924|NCT02771756|DIETARY_SUPPLEMENT|zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo|
214990925|NCT02771756|RADIATION|chemotherapy|
215094681|NCT04726059|DEVICE|SHAM (low-intensity) Transcutaneous Spinal Cord Stimulation|Ineffective stimulation will be administered at the same anatomical location as therapeutic TSCS.
214378051|NCT06332079|PROCEDURE|166Holmium TARE|166Ho-TARE treatment comprises of two hospital visits: one for a work-up procedure and another for the therapy procedure, with usually a 1-2 weeks interval.
214990926|NCT02771756|OTHER|nutrition education|
214990927|NCT04184141|DRUG|Hydroxyzine Hydrochloride|Hyroxyzine hydrochloride is given to the patient one hour before surgery.
214990928|NCT04184141|DRUG|Alprazolam tablet|Alprozolam is given to the patient one hour before surgery.
214687167|NCT06550180|DRUG|Subcostal TAP block and spinal anesthesia group (STAP)|patient receive Subcostal TAP block before spinal anesthesia. Patients in STAP group will receive 20 ml of 0.25% isobaric bupivacaine for each side before spinal anesthesia
214990929|NCT04184141|DRUG|Placebo|Placebo candy
214990930|NCT03852511|BIOLOGICAL|NG-350A|NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
215091198|NCT05969132|PROCEDURE|Fully digital guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement.~3. Oral hygiene instructions (OHI)~4. Presurgical intraoral scanning using an intraoral scanner (IOS)~5. Fabrication of the Gingivectomy guide:~   * Convert (DICOM) file to STL file then merged to STL file corresponding oral soft tissues 3D data obtained by IOS using software of surgical planning.~  * Digital waxing up with new desired positions of gingival margins and zenith points performed.~  * Designing Gingivectomy guide then exported to a 3D printer and mill a transparent resin gingivectomy guide.~6. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~7. Postoperative care"
215094682|NCT04726059|DEVICE|Activity-Based Therapy|"Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.~For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics."
215094683|NCT06387641|BEHAVIORAL|Life review|Life review is a process that involves a thorough examination and reflection on one's past experiences, memories, and life events. This process often involves the identification and examination of significant themes, patterns, and lessons learned throughout one's lifespan. Through life review, individuals can gain a deeper understanding of their own identity, values, and beliefs, and how these have shaped their present circumstances and future outlooks. It can serve as a tool for personal growth, self-discovery, and the promotion of a sense of meaning and purpose in life.
214990931|NCT06125665|DRUG|Aminophylline-Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h and IV bolus of aminophylline of 5 mg/kg based on the ideal body weight (IBW) over 30 min, followed immediately by intravenous infusion at 0.6 mg/kg IBW/h. The study solutions will be diluted in 50 ml normal saline.
214990932|NCT06125665|DRUG|Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h. The study solutions will be diluted in 50 ml normal saline.
214990933|NCT00221780|DEVICE|left ventricular pacing|
214990934|NCT01101178|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
214378052|NCT06332079|DRUG|Cetuximab|Target agent
214378053|NCT06332079|DRUG|Panitumumab|Target agent
214378054|NCT06332079|DRUG|5-Fluorouracil|Chemotherapy
214378055|NCT06332079|DRUG|Bevacizumab|Target agent
214378056|NCT06332079|DRUG|Capecitabine|Chemotherapy
214378057|NCT05199623|DRUG|tailored Guizhi decoction|Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
214378058|NCT05199623|BEHAVIORAL|Olfactory training (OT)|Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
214378059|NCT00217646|DRUG|Sorafenib Tosylate|Given orally
214378060|NCT01818674|BEHAVIORAL|Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)|A 6-month intervention program (sessions and educational materials) aims to increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement.
214378061|NCT01818674|BEHAVIORAL|Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)|This basic program (6 month) aims to increase participants knowledge about diabetes self-management, but without structured social interaction programming. While group classroom setting is still used for delivery of the educational curriculum, the education program in group B have no group-based or team-building activities, group goal setting, and classroom program is lecture style with more limited class participation and interaction.
214378062|NCT06447350|BEHAVIORAL|Induced hypocrisy|Induced hypocrisy task
214378063|NCT06447350|BEHAVIORAL|social identity mapping|Social identity mapping task
214378064|NCT06447350|BEHAVIORAL|Motivational modeling|Motivational modeling task
214990935|NCT01101178|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
214990936|NCT01091610|OTHER|no intervention|purely observational retrospective study. no interventions are planned.
214990937|NCT04700865|DIAGNOSTIC_TEST|AF screening|Continous ECG monitoring for minimum 3 days
214990938|NCT04237363|BEHAVIORAL|Exercise|Underwater treadmill training and supplemental overground walk training
214990939|NCT01850641|DRUG|PA21|
214378065|NCT06447350|BEHAVIORAL|motivational interviewing|motivational interviewing
214990940|NCT04745117|BEHAVIORAL|READHY - questionnaire|The READHY tool consists of 70 questions divided into three sections, one with a focus on eHealth literacy, one on self-management and one on the social context. The READHY consists of the eHealth Literacy Questionnaire (eHLQ) that includes seven scales, supplemented with four scales from the Health Education Impact Questionnaire (heiQ) and two scales from the Health Literacy Questionnaire (HLQ). The READHY tool has been validated. Each question presented to the participant as a statement and scored on a 4-point rating, from 1=strongly disagree to 4=strongly agree. The overall score of each scale was calculated as the mean score of the 4-6 items (i.e., statements) that constitute the scale (2).
214990941|NCT00447408|BEHAVIORAL|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
214990942|NCT00447408|BEHAVIORAL|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
214990943|NCT05968235|OTHER|Collecting blood samples|Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.
214990944|NCT04131296|DIAGNOSTIC_TEST|influenza screening|positive influenza screening
214990945|NCT05672719|DIAGNOSTIC_TEST|Right Heart Catheterization|Procedure
214990946|NCT01694680|DIETARY_SUPPLEMENT|Lutein-enriched-egg beverage (NWT-02)|Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
214990947|NCT01694680|DIETARY_SUPPLEMENT|Placebo|color-, taste- and energy-matched powder without enriched egg-yolk
214990948|NCT00141817|DRUG|pantoprazole for approximately 9 weeks.|
214990949|NCT00522834|DRUG|Elesclomol (STA-4783)|213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
214990950|NCT00522834|DRUG|Paclitaxel|80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
214990951|NCT06026397|DRUG|SK10|Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
214990952|NCT06026397|DRUG|Placebo|Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
214990953|NCT00127803|BIOLOGICAL|Placebo (vaccine diluent)|0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
214378066|NCT02385994|DEVICE|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
214378067|NCT05203120|RADIATION|Proton therapy|All patients will receive proton therapy 67.5Gy/15fx
214990954|NCT00127803|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
214990955|NCT00127803|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
214990956|NCT00127803|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
214990957|NCT02530541|DRUG|CHG|Varied application times
214990958|NCT01348841|OTHER|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
214990959|NCT02258581|DRUG|GS-4774|Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.
214990960|NCT02258581|DRUG|GS-9620|Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
214990961|NCT02258581|DRUG|Tenofovir disoproxil fumarate (TDF)|Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
214378068|NCT02837354|OTHER|No intervention|
214378069|NCT04366726|COMBINATION_PRODUCT|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto an sMTS array for transdermal administration of abaloparatide.
214497344|NCT04300244|BIOLOGICAL|UV1 vaccine + leukine|The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT). UV1 vaccination amplifies the pool of hTERT specific tumor-reactive T cells from the naive repertoire and has the potential to increase the breadth and diversity of the tumor-reactive T cell response (epitope spreading). Vaccination with UV1 can thus provide the basis for increased efficacy of checkpoint inhibition therapy, by augmenting the pool of tumor specific T cells in patients with limited or insufficient numbers of T cell clones spontaneously primed by tumor antigens. Reciprocally, the efficacy of UV1 vaccination may be enhanced in combination with checkpoint inhibitors, since the clonal expansion and effector activity of UV1 induced T cells will otherwise be restricted by intrinsic immune regulatory and tumor induced suppressor mechanisms.
214497345|NCT04300244|BIOLOGICAL|ipilimumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
214497346|NCT04300244|BIOLOGICAL|nivolumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
214497347|NCT01812759|DRUG|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
214990962|NCT01950962|OTHER|Sampling of blood|
214990963|NCT04872283|PROCEDURE|great toe (1st metatarsophalangeal joint) fusion|Great Toe joint fusion surgery
214990964|NCT04872283|DRUG|IV Ketorolac|Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
215094684|NCT06387641|BEHAVIORAL|Routine community health services|"Routine community health services refer to a comprehensive health care service system that is government-led, community-participated, and guided by superior health institutions. It focuses on grass-roots health institutions and is staffed with general practitioners as the backbone. By rationally utilizing community resources, it provides a series of comprehensive health care services to community residents. These services center on human health, target families as the unit, cover the entire community, and aim to meet the basic health service needs of community residents.~Specifically, routine community health services include the following aspects: Health Education, Prevention and Control, Health Care Services and so on."
214378070|NCT06320301|DRUG|Adebrelimab + GEMOX + TKI|"Adebrelimab 20 mg/kg, once every 3 weeks (Q3W), maintained for 1 year. The interval between two doses should not be less than 12 days.~Tyrosine kinase inhibitor (TKI) Lenvatinib: 12 mg (3 capsules 4 mg) or 8 mg (2 capsules 4 mg) once daily (QD) at fixed times daily, on an empty stomach or with food; Apatinib: 250mg orally, QD, 5 days of medication, 2 days off (5 on 2 off) or once every other day (QOD), half an hour after meals; Sorafenib: 0.4g (2 × 0.2g) twice or once daily on an empty stomach or with a low-fat or medium-fat diet Anlotinib: 12 mg orally before breakfast, QD. The drug was taken continuously for 2 weeks and stopped for 1 week.~GEMOX: gemcitabine 800mg/m2 and oxaliplatin 85mg/m2, intravenous infusion, D2, D15, D29, until 6 cycles of treatment were completed, or the patients who did not reach 6 cycles had intolerable adverse reactions, then the combination chemotherapy was terminated."
214378071|NCT02636270|DRUG|Increlex|Treat PAPP-A2 deficient patients with Increlex
214378072|NCT01119898|DRUG|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
214378073|NCT01119898|DRUG|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
214378074|NCT02572557|DEVICE|TruFreeze Spray CryoTherapy|TruFreeze Spray CryoTherapy using liquid nitrogen
214378075|NCT02572557|DRUG|Liquid nitrogen|TruFreeze Spray CryoTherapy using liquid nitrogen
214378076|NCT02432469|BEHAVIORAL|APP intervention|The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
214497348|NCT01812759|DRUG|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
214497349|NCT01812759|OTHER|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
214497350|NCT03260452|PROCEDURE|Abdominal subcutaneous biopsies and Blood test|Abdominal subcutaneous biopsies and blood test for each volunteer.
214497351|NCT02819999|DRUG|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
214497352|NCT02819999|DRUG|Cisplatin|
214497353|NCT02819999|DRUG|Etoposide|
214990965|NCT04872283|DRUG|Ketorolac Pill|Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
214378077|NCT01806584|BIOLOGICAL|SRM003|One time implant (3 SRM003 pieces) on surgery day.
214378078|NCT01806584|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
214378079|NCT03207139|DRUG|Ga-68 PSMA ligand|"For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq."
214497354|NCT00716170|BIOLOGICAL|Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|"Day A: Oral glucose tolerance test (50g glucose)~Day B: Isoglycemic intravenous (iv) glucose infusion~Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)~Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)~Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)~Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E."
214497355|NCT06179446|BIOLOGICAL|pdmFlu vaccine|Intramuscular injection
214497356|NCT06179446|BIOLOGICAL|Placebo|Intramuscular injection
214497357|NCT06179446|BIOLOGICAL|Licensed influenza vaccine|Intramuscular injection
214990966|NCT04872283|DRUG|5/325mg Oxycodone-Acetaminophen|Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
214990967|NCT04872283|DRUG|Aspirin 81Mg Ec Tab|Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
214990968|NCT02353780|DRUG|TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)|TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
214378080|NCT03945864|DEVICE|antimicrobial synthetic bone graft|It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
214378081|NCT03945864|DEVICE|parentaral antimicrobials and pure bone grafts|Historical data of the department will be used for comparison of the results
214378082|NCT01455207|BEHAVIORAL|Neuropsychological testing|assessment of memory, executive functions and ataxia
214497358|NCT01413659|BIOLOGICAL|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
214497359|NCT03179046|DIAGNOSTIC_TEST|Laboratory tests and cardiac imaging|Laboratory tests (blood count, liver and kidney functions, antibodies, acute phase reactants), Echocardiography and gadolinium enhanced cardiac MRI
214497360|NCT01015872|DEVICE|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
214497361|NCT00360269|DRUG|Atomoxetine|25 to 100 mg daily
214497362|NCT00360269|PROCEDURE|Motivational enhancement therapy|Three sessions
214497363|NCT00360269|DRUG|Placebo|25 to 100 mg daily
214497364|NCT02704052|DRUG|Real time enoxaparin dose adjustment|Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
214497365|NCT02704052|DRUG|Standard enoxaparin dose|Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
214497366|NCT02351791|OTHER|Patch 1|Patch 1:standard adhesive with own feces in sleeve
214497367|NCT02351791|OTHER|Patch 2|Patch 2:standard adhesive with own feces mixture in sleeve
214497368|NCT02351791|OTHER|Patch 3|Patch 3: standard adhesive with simulated feces in sleeve
214990969|NCT02353780|DRUG|Abatacept|Abatacept; SQ; specifics to be determined by the treating rheumatologist.
214990970|NCT02353780|DRUG|Tocilizumab|Tocilizumab; SQ; specifics determined by the treating rheumatologist.
214990971|NCT03133013|DEVICE|SLEEPSCOPE|Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
214990972|NCT00056680|BEHAVIORAL|Psychoeducational video|
214990973|NCT00056680|BEHAVIORAL|Infant massage|
214990974|NCT00056680|BEHAVIORAL|Brazelton Neonatal Behavioral Assessment Scale|
214990975|NCT02774889|BEHAVIORAL|Stepping Online|"Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~1. Fall prevention tips~2. Fall prevention exercise videos with narrations for proper technique and safety precautions~3. Guest expert videos with online access to the guest expert to ask questions~4. Tools to set exercise goals, get reminders and track progress~5. Access to a fall prevention specialist for personal feedback and suggested group homework~6. Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~7. Fall prevention resources"
214990976|NCT02608619|RADIATION|F-choline PET Scan|
214990977|NCT02608619|DEVICE|FDG-PET|
214990978|NCT02608619|PROCEDURE|biopsy|
214378083|NCT01455207|BIOLOGICAL|blood draw|hepatic markers, red blood markers and vitamin markers
214378084|NCT01455207|GENETIC|genetic testing|genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
214378085|NCT01455207|OTHER|Brain imaging examination|MRI, DTI and PET examinations
214378086|NCT03021668|DEVICE|Prevena Peel & Place Dressing|Prevena Peel \& Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
214378087|NCT03021668|OTHER|Standard Closure of the Surgical Incision|This would involve standard closure of the incision site
214378088|NCT00909428|DRUG|Solifenacin Succinate|Participants take 10mg daily solifenacin succinate for 30 days
214497369|NCT02351791|OTHER|Patch 4|Patch 4:standard adhesive with simulated feces mixture in sleeve
214497370|NCT02351791|OTHER|Patch 5|Patch 5:standard adhesive with buffer in sleeve
214497371|NCT02351791|OTHER|Patch 6|Patch 6:standard adhesive with buffer mixture in sleeve
214990979|NCT04025424|GENETIC|Genetic tests of the available tumor and plasma samples|Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
214990980|NCT00858988|DRUG|Rifaximin|100mg of rifaxin for 7 consecutive days, twice daily
214990981|NCT00858988|DRUG|Placebo|twice daily for 7 consecutive days
214990982|NCT04155801|DIETARY_SUPPLEMENT|Salix Probiotic Blend|Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus \[NCFM\]® and Lactobacillus paracasei \[Lpc-37\]®).
214990983|NCT00416273|DRUG|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
214990984|NCT00416273|DRUG|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
214990985|NCT01885065|OTHER|Gel-based artificial saliva|"Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.~Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks."
214990986|NCT00337883|DRUG|Erlotinib HCl (OSI-774)|
214990987|NCT00492869|DRUG|AEB071|
215094685|NCT06184958|DRUG|Lidocaine group|Group A: Lidocaine group( 25 patients) will receive 5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
215094686|NCT06184958|DRUG|Ketamine group|Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
215094687|NCT06184958|DRUG|Placebo group|Group C:placebo group (25 patients) will receive placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
215091199|NCT05969132|PROCEDURE|Convectional guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement with OHI~3. Gingivectomy guide fabrication:~   * Impressions and casts obtained.~  * Waxing-up included new positions of gingival margins and zenith points.~  * Silicone index with condensation silicone impression materials made with pressure on the cast to reproduce the details of the wax, then filled after setting with resin material and placed in the patient's mouth.~  * Resin mock-up trimmed with blade to define the correct new gingival level.~  * After the patient accept the mock-up design will used as Gingivectomy guide.~4. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~5. Postoperative care"
215091200|NCT00286221|DRUG|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
215091201|NCT00286221|DRUG|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
215091202|NCT02447094|DRUG|Alteplase|Intravenous (i.v.) tPA per the standard of care
215091203|NCT00889200|DRUG|eszopiclone|6 weeks standard oral therapy
214990988|NCT05257616|OTHER|Traction Mobilization technique|Traction Mobilization was given by Researcher at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again. Participant sits comfortably or leans against a chair backrest. Palms of the hands are placed on the mastoid processes of the patient's skull while pressing the elbows in a caudal direction. It was held for 5 seconds then relaxed.
214990989|NCT05257616|OTHER|Traction Mobilization technique with SNAGS|Traction Mobilization with SNAGS were given at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again The position of the therapist is behind him or her, medial border of therapist's right thumb is used to contact the spinous process of C6 vertebrae i.e. level above the suspected painful or hypo mobile region. Therapist's left thumb reinforces his/her (right) contact thumb. Therapist fingers are gently placed along the patient's mandible or thorax. Following the treatment plane towards the eye, lift comes from the mobilizing thumb not the contact thumb. While the glide is maintained, the patient is asked to rotate his/her head towards the side of pain or hypo mobility.
214990990|NCT02857868|DRUG|ABL001|
214990991|NCT00355927|PROCEDURE|Sedation with IV propofol|Propofol(50 microgram/kg/min.), I.V. for 5-10 minutes, Until a level of light sedation is achieved
214990992|NCT03955315|BIOLOGICAL|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
214990993|NCT03955315|PROCEDURE|Sham|Needle puncture under the muscular layer in front of the intervertebral disc
214990994|NCT05578339|DEVICE|Biometry|Lens thickness, lens shape, anterior chamber depth, axial eye length and angle-to-angle will be used as explanatory variables (independent variables) and the size of the capsular bag will be used as main outcome parameter (dependent variable).
214378089|NCT03904030|OTHER|Rehabilitation with or without Anti-Gravity Treadmill|The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
214378090|NCT06318325|DIAGNOSTIC_TEST|examination|examination of tendon, muscle joints and injuries
214990995|NCT01692574|BEHAVIORAL|Behavior Modification for Weight Loss|
214990996|NCT01692574|BEHAVIORAL|Alternative Approach to Weight Loss|
214990997|NCT01692574|BEHAVIORAL|Cognitive-Behavior Therapy for Depression|
214990998|NCT01692574|BEHAVIORAL|Depression Support and Education|
214990999|NCT00559078|OTHER|Interview|Hour-long, qualitative, phone interview
214991000|NCT02515929|DIETARY_SUPPLEMENT|Oligomeric Proanthocyanidins|
215091204|NCT00154362|DRUG|Oxcarbazepine|
215091205|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low carbohydrate diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
214378091|NCT01122381|DRUG|ethosuximide|ethosuximide (ESX)
214378092|NCT01122381|OTHER|placebo comparator|placebo
214378093|NCT02461095|OTHER|Impairment based approach|This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.
214497372|NCT03450642|OTHER|Observational|Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
214687168|NCT05374447|PROCEDURE|Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy|Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.
214687169|NCT05186714|BEHAVIORAL|Tai Chi versus wellness education|12 weeks of Tai Chi (2x/week) or a wellness education (2x/week)
214991001|NCT02515929|DIETARY_SUPPLEMENT|Placebo|
214378094|NCT02461095|OTHER|PFPS Algorithm approach|Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
214378095|NCT01507636|OTHER|Occupational Therapy|Occupational therapy using a special arm function training.
214378096|NCT01507636|OTHER|Physical therapy|Physical therapy for arm force training.
214378097|NCT03078088|DRUG|Tham|alkalinizer
214378098|NCT03078088|DRUG|Saline|Placebo
214991002|NCT05346029|BEHAVIORAL|Lifestyle intervention|Resistance training and nutritional counseling
214378099|NCT00554008|PROCEDURE|laparoscopic appendectomy|appendix removal via scope
214378100|NCT00554008|PROCEDURE|open appendectomy|open operation for removal of appendix
214991003|NCT05071924|BEHAVIORAL|PLH Teens Original: In-person PLH programme for parents and teens by community-based workers|This in-person intervention is delivered over 14 sessions (10 joint parent and teen sessions and 4 separate parent and teen sessions).
214991004|NCT05071924|BEHAVIORAL|PLH Teens Hybrid: Hybrid delivery for parents and teens by facilitators|The hybrid intervention delivered over 12 sessions (8 sessions delivered via WhatsApp groups to parents only and 4 sessions delivered in-person to parents and teens together).
214991005|NCT03133676|DRUG|KA34|50 µg - 400 µg intra-articular injection (single or multiple doses)
214991006|NCT03133676|DRUG|Placebo|50 µg - 400 µg intra-articular injection (single or multiple doses)
214991007|NCT05968378|BEHAVIORAL|Standard healthy eating advice|Subjects in this group will be provided with standard healthy eating advice according to the Irish National Healthy Eating Guidelines and Food Pyramid and will be asked to follow this advice for 8-weeks.
214378101|NCT00667472|DRUG|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
214378102|NCT00667472|DEVICE|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
214991008|NCT05968378|BEHAVIORAL|eTRE plus Mediterranean diet|Subjects in this group will be asked to consume all meals between 8am - 4pm and to adhere to a Mediterranean style diet daily for 8-weeks.
214991009|NCT02715453|OTHER|Intervention on frailty|"Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):~* Nutritional evaluation and intervention after randomization and regularly during follow-up~* Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year~* Psychiatrist or psychologist assistance for 1 year after discharge"
214991010|NCT04696198|OTHER|Manual Therapy Intervention|Manual Therapy Interventions to improve range of motion and decrease pain
214991011|NCT04696198|OTHER|Standard care|standard care
214991012|NCT03000153|OTHER|Completing the Goals Form|The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
214378103|NCT05435755|BIOLOGICAL|hAESCs treatment|Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
214378104|NCT05435755|BIOLOGICAL|placebo (saline)|2 times placebo (normal saline) injections as control group
214378105|NCT02174887|DRUG|Nab-paclitaxel + Gemcitabine|"Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days:"
214378106|NCT04798443|PROCEDURE|subureteral endoscopic Injection of Dextranomer/Hyaluronic acid (Dexell)|The subureteral endoscopic injection was done under general anesthesia. the investigators used the subureteral injection technique (STING), as described by O'Donnell and Puri. The volume of Dexell was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
214378107|NCT04798443|PROCEDURE|open ureteral reimplantation (Lich-Gregoir)|The juxtavesical ureter is dissected by open surgery and a submucosal groove is created extending laterally from the ureteral hiatus along the course of the ureter. The ureter is placed in the groove and the detrusor is closed over the ureter with ureteric stent fixation for 21 days. the surgical wound is closed in layers. Urethral catheter for bladder drainage for 3-5 days.
214378108|NCT04567511|DRUG|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
214991013|NCT04161196|PROCEDURE|tonsil pillars suturing|The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
214991014|NCT04161196|PROCEDURE|tonsillectomy without tonsil pillars suturing|tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
214991015|NCT00002846|BIOLOGICAL|aldesleukin|
214991016|NCT00002846|PROCEDURE|conventional surgery|
214378109|NCT02824302|OTHER|Survey|Patients coming for induction of labor will be handed a survey regarding their expectation of their coming labor pain. And then will be followed up after 24 hours of their delivery.
214991017|NCT04901624|BEHAVIORAL|Family Risk Messaging|"Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19."
214991018|NCT04901624|BEHAVIORAL|Personal Risk Messaging|"Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19."
214991019|NCT04901624|BEHAVIORAL|Loss Protection|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.
214991020|NCT04901624|BEHAVIORAL|Lottery Incentive|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
214991021|NCT00602485|OTHER|Action Control Education|30 minute educational intervnetion
214991022|NCT00012909|BEHAVIORAL|Hormone Replacement Therapy Decision-Aid|
214991023|NCT04488952|DEVICE|nerve block combined with general anesthesia|Patients in this group receive nerve block combined with general anesthesia.
214991024|NCT04488952|DEVICE|spinal anesthesia|Patients in this group receive spinal anesthesia.
214991025|NCT02655003|OTHER|TIME|
214991026|NCT02655003|OTHER|Education-only intervention|The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
214378110|NCT01768208|DRUG|Saxagliptin|
214378111|NCT01705743|DRUG|Sevoflurane+Nitrous oxide|60% nitrous oxide +40% oxygen+ Sevoflurane
214378112|NCT01705743|DRUG|Sevoflurane|100% oxygen+ Sevoflurane
214378113|NCT02833688|DRUG|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
214378114|NCT02833688|DRUG|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
214378115|NCT00740558|PROCEDURE|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
214497373|NCT02822703|DEVICE|rTMS Active 20Hz|Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
214991027|NCT05673122|DEVICE|Implant(Flotecno)|"The implants It has a tapered body design and Sandblasting with Large grit that facilitates the osseointergration process.~made in Italy Flotecno srl via.Turati,38 20121 MILANO (Italia)"
214991028|NCT03667287|PROCEDURE|Repair of parastomal hernia|Surgical repair of symptomatic parastomal hernia.
214991029|NCT01866670|BEHAVIORAL|spiritual support|-Spiritual Support: deep breathing + guided image + meditation
214991030|NCT01866670|BEHAVIORAL|relaxation therapy|Relaxation Therapy: deep breathing
214991031|NCT00001305|DRUG|Humatrope|Patients receive a subcutaneous injection.
214991032|NCT06676033|DRUG|epcoritamab|Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
214378116|NCT00740558|PROCEDURE|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
214378117|NCT03661502|DEVICE|VVV|ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
214991033|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy lifestyles
214991034|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy homes
214991035|NCT03199209|BEHAVIORAL|Patient Visit|Attend study visit with research staff
214991036|NCT03199209|OTHER|Questionnaire Administration|Ancillary studies
214991037|NCT03199209|OTHER|Text Message|Receive information about healthy lifestyles
214991038|NCT03199209|OTHER|Text Message|Receive texts about healthy homes
214991039|NCT06357182|DRUG|Azacitidine|Given SC
214991040|NCT06357182|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214991041|NCT06357182|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214991042|NCT06357182|PROCEDURE|Echocardiography Test|Undergo ECHO
214991043|NCT06357182|DRUG|Iadademstat|Given PO
214991044|NCT06357182|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214991045|NCT06357182|OTHER|Questionnaire Administration|Ancillary study
214991046|NCT06357182|DRUG|Venetoclax|Given PO
214991047|NCT06552234|DRUG|Repotrectinib|Repotrectinib 160 mg BID, until progression or unacceptable toxicity
215091206|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low low fat diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
215094688|NCT02998034|DEVICE|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
215094689|NCT02998034|DEVICE|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
215094690|NCT04736134|BIOLOGICAL|BMS-986326|Specified dose on specified days
215094691|NCT04736134|OTHER|Placebo matching BMS-986326|Specified dose on specified days
214991048|NCT05960175|DEVICE|New telemonitoring approach using 2 connected devices : Scanwatch connected watch + Asten&masanté application|"The home healthcare provider will monitor the treatment remotely and make home visits, as in the control group. However, in the case of technical alerts concerning CPAP treatment (problems with observance, leaks, residual apneas), the provider will send the patient a notification via the mobile application in order to provide advice/instructions so that the patient can resolve the alert independently. The provider will monitor the resolution of alerts remotely and may contact the patient by telephone or come to your home if necessary.~If the connected watch detects an abnormal heart rhythm at night, the patient receives a notification and can undergo an electrocardiogram."
214378118|NCT03661502|DEVICE|PCV|ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
214378119|NCT01161368|DRUG|Lapatinib, Vinorelbine|"Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly \[Days 1 and 8\] for 2 weeks, followed by a rest week in a 3-week cycle."
214378120|NCT01771393|DEVICE|CBCT prior to MDCT|Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.
214378121|NCT01771393|DEVICE|MDCT prior to CBCT|Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
214378122|NCT04612946|BEHAVIORAL|Referral to Telemedicine LCS Counseling Visit|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit, and asked for permission to be referred directly to the LCS navigator to help schedule an appointment. They will also be given the option to directly contact the LCS navigator. Telemedicine counseling visits will be conducted using established clinical procedures for virtual or telephone visits at Penn Medicine. In accordance with reimbursement policies for lung cancer screening, these visits will be conducted by a physician or nurse practitioner within the Lung Cancer Screening Program at Penn Medicine. Counseling visits are covered without co-pay as standalone visits according to USPSTF guidelines and costs will not be covered by the study. LCS is an evidence-based practice and considered standard of care for those who are eligible and desire to be screened. Clinicians retain full control on how to conduct LCS counseling or LDCT in this trial.
214497374|NCT02822703|DEVICE|rTMS Sham|The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
214497375|NCT00753337|DEVICE|Assurant® Cobalt Iliac Stent System|Iliac Stenting
214497376|NCT03733574|DRUG|LY03005|Drug: LY03005 80 mg, oral tablets, single dose
214497377|NCT03733574|DRUG|Pristiq|Drug: Pristiq 50 mg, oral tablets, single dose
214497378|NCT03849937|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
214497379|NCT05160779|OTHER|Analysis of genetic polymorphisms of vasoactive peptides in COVID-19|Evaluate the frequency of the insertion/deletion (I/D) polymorphism in the ACE gene; to assess the frequency of polymorphism in the bradykinin B2 receptor gene; to assess the frequency of the polymorphism in the CK-M gene and compare the frequencies of these polymorphisms between patients with severe and mild conditions.
214497380|NCT04779645|DRUG|REMD-477|12-Week, once weekly subcutaneous injection with 70mg REMD-477
214497381|NCT04779645|DRUG|Placebo|12-Week, once weekly subcutaneous injection with placebo
214497382|NCT04284878|GENETIC|PCR-RFLP|PCR-Restriction fragment length polymorphism
214497383|NCT04999007|OTHER|Artificial intelligence algorithm|Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
214497384|NCT03437733|DEVICE|Radiofrequency Ablation|RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter
214497385|NCT03407144|BIOLOGICAL|pembrolizumab|2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
214687170|NCT06194136|DEVICE|PBM light therapy|The PBM machine consists of a dual light emitting diode (LED) cluster array with 105 light diodes within the 660 nanometer (nm) red light wavelength and the 850 nm near-infrared light wavelength. These wavelengths are both within the ranges noted in previous literature for neuropathic pain (1) and are within the World Association for Photobiomodulation (Laser) Therapy (WALT) guidelines for PBM therapy (2). Dosage will be determined according to the following equation: Laser output Power (Watts) x Time (seconds) divided by Beam Area (cm2)= J/cm2 (1). The PBM unit generates energy equal to 115 mW/cm2 with a surface area of 54.6 cm x 17 cm. Thus, for a target power output of 3.45 J, the participant will have a continuous irradiation duration of 30 seconds for each application (1). The participant will be asked to utilize the PBM device on breast tissue post-mastectomy for 30 seconds 3 times per week with at least 24 hours between each session. The duration of treatment will be 6 weeks.
214991049|NCT05063916|DRUG|AK104|Given By IV
214991050|NCT03768063|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
214991051|NCT03768063|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
214991052|NCT03768063|DRUG|Alectinib|Alectinib will be administered as directed per the parent study.
215094692|NCT04736134|BIOLOGICAL|Multiple Ascending Dose SC|Specified dose on specified days
215094693|NCT04736134|OTHER|Multiple Ascending Dose Placebo|Specified dose on specified days
214497386|NCT03407144|DRUG|doxorubicin|"25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
215094694|NCT04672421|DEVICE|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)
215091207|NCT02115360|DRUG|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
215091208|NCT02115360|DRUG|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
215091209|NCT04284566|BEHAVIORAL|TAU + multicomponent treatment FIBROWALK|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30min.)~* Mindfulness techniques (30 min.)~* Physical exercise(30 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
215094695|NCT04672421|DEVICE|Placebo|No device after laparoscopic surgery
215094696|NCT06540989|BEHAVIORAL|Immediate treatment|Participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
214378123|NCT04612946|BEHAVIORAL|Usual Care|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their providers.
214378124|NCT01580839|DRUG|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
214378125|NCT01580839|DRUG|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
214378126|NCT01373762|BEHAVIORAL|Exercise Videogame Bikes|The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
214378127|NCT03474549|DEVICE|Tigertriever revascularization device|Mechanical Thrombectomy
214378128|NCT03988075|OTHER|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
214378129|NCT03988075|OTHER|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
214378130|NCT02223039|BIOLOGICAL|AbGn-168H|AbGn-168H monoclonal antibody
214378131|NCT02223039|BIOLOGICAL|Placebo|Placebo of AbGn-168H
214378132|NCT04741516|DRUG|Foquest|The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®). Foquest® is a novel formulation of MPH developed by Purdue Pharma (Canada) and is approved in Canada for the treatment of ADHD in patients six years of age and older. Foquest® is the first methylphenidate product approved in Canada with an onset of action within one hour and a duration of action up to and including 16 hours (Wigal et al.2016). Foquest® is an ADHD treatment option for patients who require a rapid onset of action and extended duration of action
214378133|NCT00921063|DRUG|PD 0332334|250 mg capsule, BID for 4 weeks
214378134|NCT00921063|DRUG|PD 0332334|100 mg capsule, BID for 4 weeks
214378135|NCT00921063|DRUG|placebo|0 mg capsule, BID for 4 weeks
214378136|NCT00921063|DRUG|Alprazolam extended release|1 mg capsule, BID for 4 weeks
214378137|NCT04997707|DRUG|Propofol Abbott|in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group
214378138|NCT04997707|DRUG|Sevoflurane Inhalation Solution|in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.
214497387|NCT03407144|DRUG|vinblastine|"6 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
214497388|NCT03407144|DRUG|dacarbazine|"375 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m\^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
214378139|NCT04997707|DIAGNOSTIC_TEST|transcranial motor evoked potential(Tcm|using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.
214378140|NCT04369001|BEHAVIORAL|Community-Based Exercise|Participants will complete 150 minutes of exercise per week for 12 weeks. Exercise per week will be documented using exercise logs. The exercise protocol will be a culturally-tailored community-based exercise intervention based on the aerobic exercise goals used in the Program ACTIVE study and psychoeducational materials adapted from Program ACTIVE based on feedback from Black men with T2D. Exercise in Program ACTIVE will be obtained through individualized community-based activities that participants in the focus groups indicate as feasible rather than the highly controlled laboratory environment. Exercise goals will be adapted to accommodate the physical and medical restrictions of an older-adult diabetes population.
214991053|NCT03768063|DRUG|Cobimetinib|Cobimetinib will be administered as directed per the parent study.
214991054|NCT03768063|DRUG|Vemurafenib|Vemurafenib will be administered as directed per the parent study.
214991055|NCT03768063|DRUG|FAP IL2V|FAP IL2V will be administered as directed per the parent study.
214991056|NCT03768063|DRUG|Venetoclax|Venetoclax will be administered as directed per the parent study.
214991057|NCT03768063|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
214378141|NCT04369001|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive 10 sessions of CBT using a manualized approach based on Beck's model of cognitive therapy. Sessions are to be completed once weekly in conjunction with weekly exercise. The Program ACTIVE CBT intervention includes: presentation of CBT model; thought records, cognitive distortions, counterarguments, cognitive reframing, automatic thoughts, core beliefs, and relapse prevention. Session goals will be tailored to the needs of men so that the order of topics may vary. Each session will begin with the designation of session goals, review of previously assigned homework, and introduction of new concepts and skills. Individually-tailored homework assignments designed to provide practice with the concepts/skills of the session will be assigned.
214378142|NCT01406522|DRUG|Oral tacrine|Tacrine, 160 mg per day, four times daily
214378143|NCT01406522|DRUG|Oral placebo|Microcrystalline cellulose
214378144|NCT04236258|DRUG|NIFEdipine ER|Postpartum women with high blood pressure will be randomized to receive nifedipine extended release 30mg daily as their starting antihypertensive.
214378145|NCT04236258|DRUG|Enalapril|Postpartum women with high blood pressure will be randomized to receive enalapril 10 mg daily as their starting antihypertensive.
214378146|NCT00270361|DRUG|nesiritide|
214378147|NCT00270361|DRUG|usual long term cardiac medications|
214378148|NCT00270361|DRUG|nesiritide|
214378149|NCT00020553|PROCEDURE|psychosocial assessment and care|
214378150|NCT01933022|DRUG|Eligard|Subcutaneous Injection
214991058|NCT03768063|DRUG|Pembrolizumab|Pembrolizumab will be administered as directed per the parent study.
214378151|NCT06113848|DRUG|Intra-Arterial TNK and Albumin|The study population was divided into four groups, one of which had intra-arterial TNK and albumin.
214378152|NCT06113848|DRUG|Intra-Arterial TNK|The study population was divided into four groups, one of which had intra-arterial TNK .
214378153|NCT06113848|DRUG|Intra-Arterial Albumin|The study population was divided into four groups, one of which had intra-arterial albumin.
214378154|NCT06113848|OTHER|sham|The study population was divided into four groups, one of which had no intra-arterial TNK and albumin.
214378155|NCT00356954|DRUG|N-acetylcystein|
214497389|NCT03407144|DRUG|cyclophosphamide|500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
214497390|NCT03407144|DRUG|vincristine|"1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
214497391|NCT03407144|DRUG|prednisone/prednisolone|"60 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
214991059|NCT03768063|DRUG|Sunitinib|Sunitinib will be administered as directed per the parent study.
214991060|NCT03768063|DRUG|Niraparib|Niraparib will be administered as directed per the parent study.
214991061|NCT03768063|DRUG|Cabozantinib|Cabozantinib will be administered as directed per the parent study.
214991062|NCT03768063|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
214991063|NCT03768063|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
214991064|NCT03768063|DRUG|Emactuzumab|Emactuzumab will be administered as directed per the parent study.
214991065|NCT03768063|DRUG|Rucaparib|Rucaparib will be administered as directed per the parent study.
214991066|NCT05895643|DRUG|Semaglutide Injectable Product|Once weekly injections s.c with semaglutide (Wegovy)
214991067|NCT05895643|DRUG|Placebo|Once weekly injections s.c with placebo (BD Posiflush)
214991068|NCT06830590|PROCEDURE|Molecular characterisation|All patients treated by surgery were included without any neoadjuvant therapy
214991069|NCT02310594|OTHER|cytology specimen collection procedure|Undergo blood sample collection
214991070|NCT02310594|OTHER|laboratory biomarker analysis|Correlative studies
214991071|NCT02818257|OTHER|Strip A|Adhesive strip A
215091210|NCT04284566|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
215091211|NCT03600454|DRUG|General anesthesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol
215091212|NCT03600454|DRUG|Spinal anesthesia|The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid
214991072|NCT02818257|OTHER|Strip B|Adhesive strip B
214991073|NCT02818257|OTHER|Strip C|Adhesive strip C
214991074|NCT01184807|DRUG|OPB-51602|OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
214991075|NCT00135655|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
214991076|NCT05750082|DEVICE|CCTA CT-FR CAG OCT|Per the protocol, patients will have a CCTA (coronary computed tomography angiography), CT-FFR (fractional flow reserve derived from CTA), ICA (invasive coronary angiography), OCT (optical coherence tomography).
214991077|NCT03105401|OTHER|Assessment of hallucinations in Parkinson's disease|Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
214991078|NCT06111625|DRUG|blinatumomab|Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion.
214991079|NCT05887973|BEHAVIORAL|The T.R.I.G.G.E.R Project|"The T.R.I.G.G.E.R Project includes the following core components to address root causes of gun violence:~* Summer Employment~* Social and Emotional Learning~* Future Orientation~* Adult and Peer Support~* Critical Consciousness~* Civic Efficacy and Engagement"
214991080|NCT06047119|PROCEDURE|Blood pressure|Blood pressure targets during general anesthesia and 2 hours after
214991081|NCT06047119|PROCEDURE|Positive end expiratory pressure|Positive end expiratory pressure during general anesthesia
214991082|NCT06047119|PROCEDURE|Tidal volume|Tidal volume during general anesthesia
214991083|NCT06047119|PROCEDURE|Fraction of inspired oxygen|Fraction of inspired oxygen during general anesthesia and 2 hours after
214991084|NCT03068910|DRUG|Micronized progesterone|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
214991085|NCT03068910|DRUG|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
214991086|NCT03068910|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
214991087|NCT06468033|BIOLOGICAL|Ropeginterferon alfa-2b|"Pre-filled Syringe.~Dosage: up to 500mcg"
214991088|NCT06468033|OTHER|Placebo|Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.
214991089|NCT06387979|OTHER|Non-Interventional Study|Non-Interventional Study
215091213|NCT03600454|DRUG|General anesthesia and epidural analgesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2 µg/kg and propofol. A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).
215091214|NCT00016965|DRUG|ixabepilone|
215091215|NCT03169257|BEHAVIORAL|diet plus physical activity|OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
215091216|NCT02276547|DEVICE|Mitral valve replacement|Transcatheter mitral valve replacement
214991090|NCT01120197|OTHER|Exercise group|Weekly exercises
214991091|NCT01120197|OTHER|Control Group|No Intervention, control group only
214991092|NCT05900245|OTHER|Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）|EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.
214991093|NCT03632447|DEVICE|Leva|Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.
214991094|NCT03632447|DEVICE|PFDx|All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
215091217|NCT01038726|OTHER|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
215091218|NCT01038726|OTHER|Cognitive Training|Based on cognitive training program Brain Fitness®
215091219|NCT01038726|OTHER|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
215091220|NCT01038726|OTHER|Educational Sessions|DVD-based educational programs on history, art, and literature
215091221|NCT03721809|BIOLOGICAL|Blood samples|"There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient."
214378156|NCT00356954|DRUG|ascorbic acid|
214378157|NCT01620567|OTHER|avocado|1 avocado/day for 6 months
214378158|NCT01620567|OTHER|potato or chickpea|1 cup potatoes or chickpeas/day for 6 months
214378159|NCT00256503|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
214378160|NCT00241527|DRUG|Esomeprazole|
214378161|NCT03977558|BEHAVIORAL|Intervention group|Isocaloric diet including \~50g canola oil
214378162|NCT03977558|BEHAVIORAL|Control group|ESC/EAS Guidelines for the management of dyslipidemias
214378163|NCT03445065|DEVICE|Eversense XL CGM System|The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).
214378164|NCT03445065|DEVICE|Usual SMBG or FGM device used by participants|Commercially available products in France for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM) were considered as comparators for this study.
214378165|NCT03315130|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
214378166|NCT03315130|DRUG|Placebo|Daily subcutaneous (SC) injection
214378167|NCT02707692|BIOLOGICAL|Fluarix|Intramuscular injection with Fluarix® .
214378168|NCT02707692|BIOLOGICAL|Pneumovax|Intramuscular injection with Pneumovax.
214378169|NCT02707692|OTHER|Placebo|Intramuscular injection with sterile saline (placebo).
214991095|NCT06463275|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument).
214991096|NCT04178018|DEVICE|Photoacoustic imaging|-Emerging technique in which a short-pulsed laser beam penetrates diffusively into a tissue sample
214991097|NCT04178018|DEVICE|Ultrasound|-The ultrasound is being used in conjunction with the photoacoustic imaging
214991098|NCT03115710|DIAGNOSTIC_TEST|Rotating Scheimpflug camera (Pentacam HR)|One visit to Ophthalmology Department is required from participant. Parents or legal guardians must attend with their child. The interview and test during visit take approximately 15 minutes. Interview includes filling out a questionnaire about risk factors of the disease and double check on understanding the consent form. The child will sit in front of the instrument (Pentacam HR Scheimpflug imaging system). The rotational measuring procedure generates Scheimpflug images in three dimensions. The images taken during the examination are digitalized, and all image data are transferred to the computer. It calculates a 3D virtual model of the anterior eye segment, from which all additional information is derived.
214991099|NCT05489588|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.
214991100|NCT06096870|DRUG|Enzalutamide|Enzalutamide at 160 mg once daily on every day of the cycle (every 28 days)
214991101|NCT06096870|DRUG|PDS01ADC|PDS01ADC at 12.0 microgram/kg by subcutaneous injection (every 28 days)
214991102|NCT06469801|DEVICE|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO. Patients will undergo imaging within 36 hours of ECMO initiation/cannulation. Patients that remain on ECMO will have repeat imaging at 72-120 hours of ECMO therapy and again weekly for the duration of their ECMO course. Patients will also undergo a portable MRI within 24 hours of clinical head imaging, if applicable.
214991103|NCT04799470|DEVICE|Novel DBS stimulation patterns|Stimulation patterns
214991104|NCT06398158|DRUG|Ravulizumab|All study participants will receive commercially covered ravulizumab consistent with the indication, dose and frequency contained within the approved label.
214991105|NCT05611307|DIAGNOSTIC_TEST|Lipid profile|Advanced lipid profile
214991106|NCT05611307|DIAGNOSTIC_TEST|Coronary artery assessment|Coronary artery assessment via CT scans
214991107|NCT05611307|DIAGNOSTIC_TEST|Hormone levels for hypogonadism|Hormone levels for hypogonadism
214991108|NCT02521480|DEVICE|Active Transcranial Magnetic Stimulation|TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.
214991109|NCT02521480|DEVICE|Sham Transcranial Magnetic Stimulation|Inactive treatment (simulation of active TMS)
214991110|NCT04448808|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
214991111|NCT04448808|DRUG|Placebo|Placebo of BX-1, oral solution
214991112|NCT03113097|OTHER|Embryo transfer|Transfer of different qualities of embryos at blastocyst stage
214991113|NCT04943783|DRUG|Atorvastatin 20mg|One with the intervention (Atorvastatin, 20mg OD), 20 patients for this arm.
214378170|NCT00036998|PROCEDURE|conventional surgery|
214991114|NCT04118972|BEHAVIORAL|Mirror exposure and text prompt responses|Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)
214991115|NCT05282784|OTHER|Hyperthermia|"Patients will be treated with hyperthermia 2 or 3 times a week. Treatment will be performed for 1 hours per each visit.~Patients will be treated with radiotherapy 5 times a week."
214991116|NCT05282784|RADIATION|Radiotherapy|Patients will be treated with radiotherapy 5 times a week.
214991117|NCT04799990|DRUG|Risankizumab|Subcutaneous Injection
214991118|NCT04799990|BIOLOGICAL|Comparator 1|Subcutaneous or Intravenous Injection
214991119|NCT04799990|DRUG|Comparator 2|Oral, Opthalmic, Subcutaneous or Intravenous Injection
214378171|NCT00036998|PROCEDURE|neoadjuvant therapy|
214378172|NCT00036998|PROCEDURE|thermal ablation therapy|
214991120|NCT02840565|DRUG|BIA 5-453|Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
214991121|NCT02840565|DRUG|Placebo|The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
214991122|NCT03726476|BEHAVIORAL|Patient centered pre-op education|To implement a patient centered education intervention to evaluate post-op narcotic use.
214991123|NCT03726476|BEHAVIORAL|routine preop education|To implement routine patient education intervention to evaluate post-op narcotic use.
214991124|NCT00766220|DRUG|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
215091222|NCT01754194|PROCEDURE|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
215091223|NCT01754194|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
214378173|NCT04451408|DRUG|LY3372993|Administered IV or SC.
214378174|NCT04451408|DRUG|Placebo|Administered IV or SC.
214497392|NCT03407144|DRUG|bleomycin|10 units/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
214497393|NCT03407144|DRUG|etoposide|125 mg/m\^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
214497394|NCT03407144|RADIATION|Radiotherapy (RT)|RT administered daily, dose dependent on randomization group and disease response.
214497395|NCT06074679|PROCEDURE|Open cholecystectomy|The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.
215091224|NCT01099657|BEHAVIORAL|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
214991125|NCT00766220|DRUG|Cetuximab|"400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."
214991126|NCT00766220|DRUG|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
214991127|NCT02019069|DRUG|liposomal cytarabine-daunorubicin CPX-351|Given IV
214991128|NCT00614393|BIOLOGICAL|dalotuzumab|IV infusion
214991129|NCT00614393|DRUG|irinotecan hydrochloride|IV infusion
214991130|NCT00614393|BIOLOGICAL|cetuximab|IV infusion
214991131|NCT00614393|DRUG|placebo|IV infusion
214991132|NCT02328105|DRUG|Carboplatin|Dosing: AUC = 6; on Day 1
214991133|NCT02328105|DRUG|Abraxane|100 mg/m\^2; Days 1, 8, 15
214991134|NCT03132389|OTHER|No intervention|All patients included in the study will be offered the same examination and treatment procedure as the patients who are not included. Identical procedures and examinations will be performed in participants and non-participants.
214991135|NCT02544789|DRUG|Clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
214991136|NCT05796453|DEVICE|Clareon Vivity IOL - Non Toric|Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
214991137|NCT05796453|DEVICE|Clareon Vivity IOL - Toric|Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
214991138|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Non Toric|Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
214991139|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Toric|Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
214378175|NCT04248647|BEHAVIORAL|Multimodal prehabilitation|"This arm will receive a 4-week prehabilitation program consisting of:~Exercise: Participants will receive a 3x/week aerobic and strength training exercise program. They will perform 2 workouts per week at home and attend an in-hospital supervised exercise session once per week.~Nutritional counselling: Participants will meet with a registered dietician who will provide personalized nutritional recommendations and a whey protein supplement, tailored according to participants' self-reported dietary intake and anthropometric measurements.~Psychological support: Participants will receive a 90-minute session at baseline, and weekly in-hospital follow-ups throughout the preoperative period. The sessions will aim to reduce preoperative distress and improve adherence to the exercise program and nutritional recommendations. Psychological support will be delivered by a trained master's student, under the direct supervision of a registered Clinical Psychologist."
214991140|NCT05442112|BEHAVIORAL|Wellness Patient Message|The intervention is a detailed patient message containing information on strategies for exercise in MS, how to maintain proper sleep, and dietary improvements to maximize health. These strategies are derived from information provided by the National MS Society in their website and covers these topics in greater detail than would normally be addressed in a normal clinic visit. The message also directs patients to the National MS Society website if they would like more information.
214991141|NCT00739232|DRUG|HSD-016|
214991142|NCT00739232|OTHER|placebo|
214991143|NCT03870386|PROCEDURE|EUS-BD with LAMS|Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy
214991144|NCT03870386|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
214991145|NCT00855582|DRUG|Tadalafil|tablet once daily by mouth for 12 weeks.
215091225|NCT01099657|BEHAVIORAL|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
214991146|NCT00855582|DRUG|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
214991147|NCT02612857|DRUG|IMO-8400 Dose Group 1|IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
214991148|NCT02612857|DRUG|IMO-8400 Dose Group 2|IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
214991149|NCT02612857|DRUG|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
214991150|NCT01588509|DRUG|Romosozumab|Administered by subcutaneous injection
214991151|NCT03276143|DRUG|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
214991152|NCT03276143|DRUG|Apixaban|2.5 mg apixaban administered as tablet orally twice daily
214991153|NCT03276143|DRUG|BAY1213790|Single dose of BAY1213790 administered as intravenous infusion
214991154|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with Preventicus®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
214991155|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
214991156|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with Apple Watch®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
214991157|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with 6L Kardia Mobile®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
214991158|NCT03345004|BIOLOGICAL|Diamyd|Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)
215091226|NCT00450736|DRUG|celecoxib|
214378176|NCT06979414|BEHAVIORAL|Nurse-led Transfer Programme with Family Involvement|This behavioral intervention was structured in three phases: (1) Pre-transfer preparation, where the patient's primary caregiver visited the ICU for emotional support following verbal instruction and infection control measures; (2) Accompanied transfer to the general ward, led by an ICU nurse, with the caregiver present to provide emotional reassurance; (3) Post-transfer monitoring, where the patient's vital signs and anxiety levels were reassessed within 30-60 minutes of arrival. The goal of the intervention was to reduce ICU transfer-related anxiety through nurse-led, family-involved emotional support.
214378177|NCT05448300|DEVICE|Colonoscopy with water exchange or air insufflation methods|Using computer-aided polyp detection algorithm on colonoscopy with water exchange or air insufflation methods. This computer-aided algorithm does not intervene directly the colonoscopy procedure.
214378178|NCT05323461|BIOLOGICAL|SCTV01C|intramuscular injection
214497396|NCT03865199|BEHAVIORAL|Narrative Intervention|"Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported."
214991159|NCT03345004|DIETARY_SUPPLEMENT|Vitamin D|Oil suspension of Vitamin D
214991160|NCT03345004|BIOLOGICAL|Placebo for Diamyd|Alhydrogel® only
214991161|NCT03345004|DIETARY_SUPPLEMENT|Placebo for Vitamin D|Placebo oil suspension for Vitamin D
214991162|NCT03238469|DEVICE|Microwave ablation|A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
214991163|NCT03070145|OTHER|Exercise Intervention|12-week moderate-intensity aerobic and strength training exercise intervention
214991164|NCT00165074|DRUG|Infasurf (drug)|Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
214991165|NCT01531179|DRUG|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
214991166|NCT01531179|DRUG|Placebo|Placebo for 3 months
215091227|NCT00450736|PROCEDURE|adjuvant therapy|
215091228|NCT00450736|RADIATION|radiation therapy|
214378179|NCT05323461|BIOLOGICAL|SCTV01E|intramuscular injection
214378180|NCT05323461|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
214378181|NCT05323461|BIOLOGICAL|Comirnaty|intramuscular injection
214378182|NCT00649558|DRUG|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
214378183|NCT00649558|DRUG|Actos® Tablets 45 mg|45mg, single dose fasting
214378184|NCT01888211|DIETARY_SUPPLEMENT|Omega 3 fatty acid supplementation|2 grams Omacor daily
214378185|NCT01888211|DIETARY_SUPPLEMENT|Olive Oil|2 grams olive oil daily
214497397|NCT00210106|DEVICE|Ablathermy|
214687171|NCT06469736|PROCEDURE|Standard of Care Ureterorenoscopy|The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
214991167|NCT01013753|DRUG|Placebo|Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
214991168|NCT01013753|DRUG|Olodaterol (BI 1744) high|Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
214991169|NCT01013753|DRUG|Olodaterol (BI 1744) medium|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
214991170|NCT01013753|DRUG|Olodaterol (BI 1744) very low|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
214991171|NCT01013753|DRUG|Formoterol 12 mcg|Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
214991172|NCT01013753|DRUG|Olodaterol (BI 1744) low|Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
214991173|NCT05886881|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
214991174|NCT05886881|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
215091229|NCT06476158|DEVICE|Kaiku Health|Digital follow-up with Kaiku Health as medical device
215091230|NCT02042313|OTHER|continuous epidural infusion|
215091231|NCT02042313|OTHER|combined paravertebral infusion and single shot of TAP block|
215091232|NCT02502513|BEHAVIORAL|Brief computerized intervention|"Computer game Tetris"
215091233|NCT03208530|BEHAVIORAL|Brief motivational interview intervention|A brief (\<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
215091234|NCT02594800|DRUG|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
215091235|NCT05713084|OTHER|mandibular setback using BSSRO|mandibular setback using BSSRO
215091236|NCT02163785|PROCEDURE|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
215091237|NCT03255759|DIAGNOSTIC_TEST|Multiplex molecular diagnostic assay|To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
215091238|NCT00803972|DRUG|rHuPH20|recombinant human hyaluronidase PH20
215091239|NCT00803972|DRUG|Insulin Human Injection|injection
215091240|NCT00803972|DRUG|Insulin Lispro Injection|injection
215091241|NCT06262256|BEHAVIORAL|High-intensity interval training|supervised exercise conducted on stationary bikes after individualized intensity prescription.
215091242|NCT01479582|DRUG|Access to unlicensed cord blood units|
214378186|NCT04180644|OTHER|Skin tape strips|Skin tape strips will be collected from lesional and non-lesional skin. Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. These discs will then be used to evaluate proteins and lipids in the upper layers of skin.
214378187|NCT05129267|OTHER|Group B|Scaling and Root debridement + iPRF
214378188|NCT05129267|OTHER|Group C|Scaling and Root debridement + iPRF together with vitamin C
214378189|NCT00212498|PROCEDURE|Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies|Blood sample
214378190|NCT03540914|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
214378191|NCT03540914|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
214378192|NCT03790670|DRUG|sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
214378193|NCT06859879|DIETARY_SUPPLEMENT|Dietary Supplement: low-dose Rosemary and Daylily extract|Supplement containing Rosemary and Daylily extract
214378194|NCT06859879|DIETARY_SUPPLEMENT|Dietary Supplement: medium-dose Rosemary and Daylily extract|Supplement containing Rosemary and Daylily extract
214378195|NCT06859879|DIETARY_SUPPLEMENT|Dietary Supplement: control|Supplement containing placebo
214378196|NCT04131569|DIAGNOSTIC_TEST|ESBL-E fecal carriage screening according to routine care|ESBL-E fecal carriage screening according to routine care
214378197|NCT03664505|DEVICE|Compression garment (manual)|Garment based on manual measurement
214687172|NCT06469736|PROCEDURE|Standard of Care Ureterorenoscopy with MediNiK|The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Application of MediNiK to embbed the residual stones in the hydrogel and extract it with a basket. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
214378198|NCT03664505|DEVICE|Compression garment (scan)|Garment based on scan measurement
214378199|NCT06711744|DIAGNOSTIC_TEST|Implant stability quotient|Screw a smart peg into the implant and record the values from a dedicated device
214378200|NCT06384339|DIAGNOSTIC_TEST|CSIV, Social motive|The CSIV is a self-report measure and assesses interpersonal values using eight octant scales, which are aggregated into overall communion and agency scores, ranging from -4 to +4 .
215091243|NCT05969717|DRUG|GD-iExo-001|One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
215091244|NCT05969717|OTHER|normal saline|One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
215091245|NCT03344640|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
215091246|NCT03344640|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
215091247|NCT04095689|DRUG|Docetaxel|Microtubule-targeting drug (inhibits microtubule depolymerization)
215091248|NCT04095689|DRUG|Pembrolizumab|Programmed cell death-1 (PD-1) inhibitor
214378201|NCT06384339|DIAGNOSTIC_TEST|Interpersonal messages and behavior|"The Impact Message Inventory - Circumplex (IMI-C) Brief Version is a self-report transactional inventory designed to measure a target person's interpersonal behavior on four octant scales dominance, hostility, submissiveness, and friendliness by assessing the covert responses or impact messages of another person. Each subscale consists of 7 items, with each item scored on a 4-point Likert scale from 1 (not at all) to 4 (very much so). The minimum score per scale is 7 and the maximum score is 28."
215091249|NCT04095689|DRUG|IL-12 gene therapy|Adenoviral-mediated IL-12
215091250|NCT01403376|DRUG|teriflunomide|"Film-coated tablet~Oral administration"
215091251|NCT01403376|DRUG|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
214991175|NCT05886881|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
215091252|NCT01403376|BIOLOGICAL|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
215091253|NCT05458661|DEVICE|Clinical Prototype BioBase (SN 07 and SN 08)|Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps \>6mm diameter and corneal pachymetry maps \>6mm.
214378202|NCT06384339|DIAGNOSTIC_TEST|CCS, Social motive|The CCS is a elf-report inventory, that measures tendencies towards competitiveness versus caring in social interactions. The minimum score for the two subscales competitiveness and caring are 9 and the maximum score is 90.
214497398|NCT04515992|BEHAVIORAL|High Intensity Body-weight Circuit Training (HIBC)|HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
214497399|NCT00825344|DRUG|Etanercept|50 mg subcutaenous preoperatively
214991176|NCT05886881|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
215091254|NCT05123521|DIAGNOSTIC_TEST|urine analysis|Urine was then tested for evidence of substance abuse using the multi-drug screen panel dip steak ABONtm (Abon Biopharm (Hangzhou) CO., Ltd) which is a lateral flow chromatographic immunoassay . It allowed for qualitative detection of multiple drugs in a single run. This kit was chosen for its ability to detect the most commonly abused substances in Egypt, namely: opioids, benzodiazepines, hashish, and tramadol. A single coloured line at region C for of a specific drug indicated a positive result, whilst two coloured lines at both regions C and T indicated a negative result. The absence of coloured lines was an indication of the invalidity of the particular kit, and the kit was discarded.
215091255|NCT02982499|DEVICE|magnetic resonance image (MRI)|Radiographic imaging that takes about 30-45 minutes
215091256|NCT02982499|DEVICE|Optical Coherence Tomography (OCT)|Images taken from the back of the eye (retina)
215091257|NCT03254277|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS
215091258|NCT03254277|DRUG|Placebo|Placebo
214497400|NCT00825344|DRUG|Saline|Given subcutaneously preoperatively
214497401|NCT04357158|DEVICE|AeonoseTM|All participants will be asked to breathe into an electronic nose (eNose, the AeonoseTM, The eNose Company, Zutphen, the Netherlands) for 5 minutes during the pre-colonoscopy intake and just prior to the procedure to assess reproducibility (with \>2 weeks in between).
214497402|NCT06952309|DRUG|Intracheal dexmedetomidine|Group D received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
214991177|NCT05886881|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
214991178|NCT06583460|OTHER|Early and systematic oncosexological supporting care|"Each patient included in the study will be cared by an anthropologist and a sexologist.~This therapeutic support care will be based on :~* 2 qualitative semi-directive interviews (Baseline and M18),~* 2 individual consultations with questionnaires (Baseline and M18).~The qualitative semi-structured interviews will be conducted with the anthropologist, and the individual consultations with the sexologist.~At the end of the first oncosexology consultation, patients will be given the opportunity to decide whether or not to accept further systematic oncosexology support care, which will be based on :~* 3 individual and/or couple consultations,~* 3 group workshops.~Patients are under no obligation to accept this additional oncosexology support care."
215091259|NCT01928823|BEHAVIORAL|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
214378203|NCT06130176|PROCEDURE|Single-step Functional Sinus Endoscopy and Transoral Surgery|In each patient, the operation will be carried out by an otorhinolaryngologist and a maxillofacial surgeon. The procedures of the functional sinus endoscopy (FSE) will performed as follow: Under general anesthesia, the origin of the turbinate, and the lateral nasal wall will be conducted. The following stage will be infundibulotomy, which ensures that the uncinate process will be completely removed. The ostium will be dilated with a Stammberger dilatator starting with a 0-degree endoscope then shift to a 30- or 45-degree endoscope to clean the sinus. The cavity will be irrigated after removal of the odontogenic diseases and the purulent discharge will suctioned.In addition to FSE, the maxillofacial surgeon will conduct the necessary oral surgery procedures.The needed transoral procedures will be tooth extraction, oro-antral fistula closure or cystectomy.
214497403|NCT06952309|DRUG|Intravenous lidocaine|Group L received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
214497404|NCT06952309|DRUG|Intravenous lidocaine combined with intracheal dexmedetomidine|Group LD received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
214497405|NCT06952309|DRUG|Saline (NaCl 0,9 %) (placebo)|Group C received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
214991179|NCT05201001|DRUG|APX005M|adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
214991180|NCT05742295|DRUG|Vitamin K|Coadministration of vitamin K with the first dose of cefoperazone/sulbactam
215091260|NCT01928823|DRUG|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
215091261|NCT05768243|DRUG|Hyaluronic acid|hyaluronic acid is used as an adjunctive treatment to scaling and root planing
215091262|NCT05768243|PROCEDURE|red injectable platelet rich fibrin (i-prf)|injecting red i-prf into the pocket after scaling and root planing
215091263|NCT03770247|PROCEDURE|Intraoperative celiac plexus neurolysis|neurolysis of celiac plexus by intraoperative techniques
215091264|NCT03770247|PROCEDURE|CT guided celiac plexus neurolysis|Neurolysis of celiac plexus percutaneously by CT guidance
215091265|NCT00553007|PROCEDURE|Periodontal therapy|Normal periodontal therapy is performed.
215091266|NCT00182897|BEHAVIORAL|Skills Building for Caregiver Health and Care-recipient|
215091267|NCT00815191|DEVICE|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
214991181|NCT06240182|PROCEDURE|conventional surgery|Surgery performed using conventional rotary burs
214991182|NCT06240182|PROCEDURE|piezoelectric device|surgery performed using piezoelectric device.
214991183|NCT01656499|DIETARY_SUPPLEMENT|Arabinoxylanoligosaccharides|
214991184|NCT01656499|DIETARY_SUPPLEMENT|Maltodextrine|
214991185|NCT00580099|OTHER|assisted exercise|4 weeks of passive range of motion exercise
214991186|NCT00580099|OTHER|cuddle|cuddle infant for 20 minutes
214378204|NCT06130176|PROCEDURE|Functional sinus endoscopy|All patients in this group will only be treated with FSE, which will be conducted by an otolaryngologist. The FSE procedures will be carried out in the same way as the group of Single-step Functional Sinus Endoscopy and Transoral Surgery.
214378205|NCT06130176|PROCEDURE|Trans oral Surgery|Every patient in this group will only be treated with transoral surgical procedures to remove dental pathology. Oral and maxillofacial surgeons will undertake these treatments. The procedure will be either tooth extraction, oro-antral fistula closure, or cystectomy. If extraction is not needed, endodontic treatment will be performed to remove necrotic pulp. The oro-antral fistula will be closed in two layers using a buccal advanced flap and a palatal rotational flap. In the case of odontogenic cysts, the lesion will be removed by raising a trapezoidal flap.
214378206|NCT03535337|BEHAVIORAL|CPS|Assessment of participant's medication adherence and barrier problem solving via phone conversation
214991187|NCT04757636|BIOLOGICAL|2.0 mg OPT-302|intravitreal injection
214991188|NCT04757636|BIOLOGICAL|2.0 aflibercept|intravitreal injection
214991189|NCT04757636|PROCEDURE|Sham|intravitreal injection
214991190|NCT01733953|DRUG|Atorvastatin|6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
214991191|NCT01733953|DRUG|Sugar Pill (Placebo)|6-Months of placebo (sugar) pill; oral, once daily
214991192|NCT00494312|DRUG|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
215091268|NCT00815191|DEVICE|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
215091269|NCT02117635|BIOLOGICAL|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
215091270|NCT02996799|OTHER|Umbilical cord milking|Milking of the umbilical cord at delivery
215091271|NCT05153707|BEHAVIORAL|Discharge Education Program|medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally \[by using Teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model).
215091272|NCT00877721|DEVICE|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
215091273|NCT03715296|DRUG|Lenalidomide 25mg|Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2-6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5\*\[GFR(ml/min)+25\]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,
215091274|NCT02320851|BEHAVIORAL|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
215091275|NCT02320851|BEHAVIORAL|Self-help group (SHG)|(see description of corresponding study arm)
215091276|NCT04638842|BEHAVIORAL|Online Intervention Grief COVID-19|The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
215091277|NCT03825692|DRUG|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
214378207|NCT03535337|BEHAVIORAL|SMS|Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
214991193|NCT00494312|DRUG|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
214991194|NCT00142753|BIOLOGICAL|Engerix B|Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
214991195|NCT00142753|BIOLOGICAL|Twinrix for ATN 024|Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
214991196|NCT00142753|BIOLOGICAL|Recombivax|Dosage at entry and week 24; non-responders ((\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
214991197|NCT00142753|BIOLOGICAL|Twinrix for ATN 025|Doses at Entry and Week 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
214991198|NCT02825810|BEHAVIORAL|Cervical motor control|Intervention will consist in a tailored exercise training following a previous published motor control protocol
215091278|NCT03825692|DRUG|Zhizhu Kuanzhong Placebo Capsule|Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
215091279|NCT03514498|PROCEDURE|Dental surgery|All types of dental surgery
215091280|NCT02576860|DRUG|CLS001 (Omiganan)|Topical gel
214378208|NCT02427711|DEVICE|Bipolar sealer|Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
214991199|NCT04261166|DRUG|A1|Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)
214991200|NCT04261166|DRUG|A2|Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)
214991201|NCT04261166|DRUG|A3|Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)
214991202|NCT04261166|DRUG|A4|Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)
214991203|NCT04261166|DRUG|A5|Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)
214991204|NCT04261166|DRUG|B1|Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)
214991205|NCT04261166|DRUG|B2|Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)
214378209|NCT05153395|OTHER|Carbon dioxide breathing|Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
214378210|NCT05153395|OTHER|Neurovascular Coupling|Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
214378211|NCT05153395|DRUG|Human insulin|Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
214378212|NCT04754607|OTHER|Low Level Laser Therapy|Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.
214378213|NCT04754607|OTHER|Sham|Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.
214378214|NCT06858566|OTHER|Kaligo + score|The Kaligo + Score will be taken twice a week during baseline and intervention and once a week during follow-up.
214497406|NCT01675063|DEVICE|Retia Non-Invasive Sensors|Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
214497407|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) food introduction-1st|1 serving size of food proven to induce histologic and clinical symptoms in EoE
214497408|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (E0E) food introduction-2nd|Either 1 serving size of different food (not food in arm 1) to induce histologic and clinical symptoms in EoE or Increase the food in arm 1 to 2 serving size a day
214991206|NCT04261166|DRUG|B3|Sublingual tablets. CBD 40 mg (1 tablet)
214991207|NCT04261166|DRUG|B4|Sublingual tablets. CBD 40 mg (1 tablet)
214991208|NCT02018107|DIAGNOSTIC_TEST|N-13 ammonia or F-18 fluorodeoxyglucose|PET tracer
214991209|NCT02018107|DIAGNOSTIC_TEST|PET scan|PET scan
215091281|NCT02576860|DRUG|Vehicle|Vehicle gel
215091282|NCT06164288|DRUG|Human Amniotic Epithelial Stem Cell Injection|"The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~1. Dose Level 1: 1×106 cells/kg;~2. Dose Level 2: 2×106 cells/kg;~3. Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients."
214497409|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) Food introduction-3rd dose|Either 1 serving size of different food (not food in arm 1 or 2) to induce histologic and clinical symptoms in EoE or Increase the food in arm 2 to 2 serving size a day or unlimited amounts of food arm 1
214497410|NCT05247866|DRUG|Dupilumab|"All patients will receive open label dupilumab at the following doses \>12 years of age \> 40 kg 300 subcutaneous (SQ) weekly~6-11 years of age 5-15 kg 100 mg SQ every 2 weeks (Q2W) 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W"
215091283|NCT04147936|DIETARY_SUPPLEMENT|AXA1665|Dietary supplement: AXA1665
214991210|NCT06080815|DEVICE|CAD/CAM Complete denture|four implant-supported CAD/CAM complete overdenture
214991211|NCT01784263|BEHAVIORAL|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
214991212|NCT01784263|BEHAVIORAL|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
214991213|NCT01308710|DIETARY_SUPPLEMENT|Omega-3 fatty acid (Eicosapentaenoic acid)|1.0 grams daily for 6 weeks
214991214|NCT00191919|DRUG|Duloxetine Hydrochloride|
214991215|NCT00191919|DRUG|Placebo|
214991216|NCT00674297|DRUG|Fluvastatin|Fluvastatin 40 mg daily for 3 months
214991217|NCT05499936|DRUG|68Ga-FAPI|68Ga-FAPI were injected into the patients before the PET/CT scans
214991218|NCT01433913|DRUG|metformin hydrochloride|Given PO
214991219|NCT01433913|OTHER|placebo|Given PO
215091284|NCT04147936|DIETARY_SUPPLEMENT|Placebo|Placebo
215091285|NCT00259688|DEVICE|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
215091286|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 1
215091287|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 2
214991220|NCT01433913|OTHER|laboratory biomarker analysis|Correlative studies
214991221|NCT02487121|BEHAVIORAL|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
214991222|NCT02487121|BEHAVIORAL|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
215091288|NCT06506994|DRUG|Tolvaptan|Tolvaptan tablets
215091289|NCT05453994|DRUG|H. pylori eradication|PPIs-based Antimicrobial agents for H. pylori eradication
215091290|NCT05281770|DRUG|Erenumab|treatment with erenumab as chosen by treating physician
215091291|NCT05281770|DRUG|Fremanezumab|treatment with fremanezumab as chosen by treating physician
215091292|NCT05281770|DRUG|Galcanezumab|treatment with galcanezumab as chosen by treating physician
214991223|NCT03115970|PROCEDURE|capillary and venous lactate level measurement|capillary and venous lactate level measurement
214991224|NCT03243799|BEHAVIORAL|Group psychoeducation|Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
214991225|NCT00820300|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
215091293|NCT01611220|BEHAVIORAL|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
215091294|NCT04644913|BEHAVIORAL|Quality of life questionnaire|Sending of 2 questionnaires (SF 36 and TESS)
214378215|NCT05335382|BEHAVIORAL|Brief Interventions (BI)|'Brief Interventions' (BI) is a multitude of interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI), however interventions from other schools of therapy can also be used. The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
214378216|NCT05335382|BEHAVIORAL|Care As Usual (CAU)|Care As Usual includes the PCC's current routine care for patients with mental and behavioral problems. This can include a multitude of procedures and treatment, such as pharmacological treatment, supportive care, cognitive behavioural therapy (CBT) and psychodynamic therapy of varying lengths. Interviews with patients as well as medical journals will be used to categorise what type of care each individual patient has received.
214687173|NCT06287489|OTHER|Mediterranean diet|Mediterranean diet for three month
214687174|NCT06287489|OTHER|Regular diet|regular diet
215091295|NCT02131519|PROCEDURE|internal jugular vein catheter placement|
215091296|NCT01825278|DEVICE|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
215091297|NCT05661305|OTHER|Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
214687175|NCT06381466|DRUG|AZD0233|Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)
214687176|NCT06381466|DRUG|AZD0233 Placebo|Randomized participants will receive matching placebo orally as a SAD or MAD.
214687177|NCT05896384|DRUG|BI 456906|BI 456906
214991226|NCT01271972|DRUG|nesvacumab (REGN910/ SAR307746)|
214991227|NCT05743855|DIETARY_SUPPLEMENT|Nutritional Supplement|Nutritional Supplement + Chiropract sessions
214991228|NCT05743855|OTHER|Placebo|Placebo + Chiropractic sessions
214991229|NCT02097277|BIOLOGICAL|BMS-986036|
214991230|NCT02097277|BIOLOGICAL|Placebo (Matching with BMS-986036)|
214991231|NCT00742456|DIETARY_SUPPLEMENT|Glucose solution|single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
215091298|NCT03335254|DRUG|TSX-011|TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
215091299|NCT04623515|OTHER|REDCap Questionnaires|Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
214991232|NCT00742456|DIETARY_SUPPLEMENT|Placebo|single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
214991233|NCT03398135|DRUG|risankizumab|subcutaneous (SC) injection
214991234|NCT03398135|DRUG|placebo for risankizumab|subcutaneous (SC) injection
214991235|NCT00195325|DRUG|TTI-237|
214378217|NCT00278070|DRUG|vinorelbine oral formulation|Patients will take three times a week \[Monday, Wednesday and Friday\] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
215091300|NCT06204861|OTHER|Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode.
214991236|NCT06847360|DEVICE|Home-based taVNS intervention|Home-based taVNS intervention will be administered using the non-invasive taVNS device, Parasym system (Parasym Health, Inc, London, UK).
214991237|NCT06847230|DEVICE|Dailies total 1 contact lenses|successful refit into dt1 will be determined
214991238|NCT01091259|DRUG|Irinotecan|
214991239|NCT01091259|DRUG|Bevacizumab|
214991240|NCT00002265|DRUG|Zalcitabine|
214991241|NCT04890990|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature two underage professionals (ages 16) acting as a simulated patient. All videos will focus on an empowered presenter with depression sharing her personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted her in overcoming symptoms of the illness. The actors will include a Black girl and a white girl.
215091301|NCT06204861|OTHER|Balance Training|The training program consists of five exercises: single-limb stance, single-limb stance with ball toss, single-limb stance with kicking, step-down with a single-limb stance, and wobble board. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
215091302|NCT06204861|OTHER|Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode. However, the B+CRET group received balance training along with CRET treatment.
215091303|NCT01355796|DRUG|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
215091304|NCT01355796|DRUG|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
215091305|NCT04469231|DEVICE|Anterior Cervical Discectomy & Fusion|ACDF
215091306|NCT01340508|RADIATION|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
214378218|NCT05968976|PROCEDURE|Awake DBS|55 patients receive awake DBS (current standard procedure)
214378219|NCT05968976|PROCEDURE|Asleep DBS|55 patients receive asleep DBS
214497411|NCT06197217|DRUG|WPV01|Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
214497412|NCT06197217|DRUG|Placebo|Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
214991242|NCT00811408|DRUG|carboplatin|
214991243|NCT00811408|DRUG|cidofovir|
214991244|NCT00811408|GENETIC|protein expression analysis|
214991245|NCT00811408|OTHER|laboratory biomarker analysis|
214991246|NCT00811408|RADIATION|brachytherapy|
214991247|NCT00811408|RADIATION|radiation therapy|
214991248|NCT03813654|BEHAVIORAL|8-h Afternoon-Evening Sleep|8 consecutive hours time in bed during the afternoon/evening.
214991249|NCT03813654|BEHAVIORAL|8-h Free Sleep|8 consecutive hours time in bed at any time.
214991250|NCT06554236|OTHER|physical therapy and sensory training|Physical therapy standard of care and 5 minutes of sensory training.
214991251|NCT04948125|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
214991252|NCT04948125|DRUG|Apatinib Mesylate|250 mg qd
214991253|NCT01485835|DRUG|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
214991254|NCT01485835|DRUG|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
214991255|NCT01485835|DRUG|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
214378220|NCT02089230|DRUG|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
214378221|NCT01921816|DEVICE|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
214378222|NCT00686140|DRUG|celecoxib|400mg/day, twice a day, 12 weeks
214378223|NCT00686140|DRUG|Placebo|twice a day, 12 weeks
214378224|NCT06619691|OTHER|Fine motor skills|Only intervention
214497413|NCT03363529|DEVICE|Dynamic light|Dynamic lighting is light that changes in intensity and spectral distribution during the day
214497414|NCT03363529|DEVICE|Standard|Standard lighting is non-dynamical light corresponding to standard hospital lighting.
214497415|NCT02795754|DRUG|GSK2838232 PIB|GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
214497416|NCT02795754|DRUG|GSK2838232 IR1|GSK2838232 will be available as film-coated tablet for oral use
214497417|NCT02795754|DRUG|GSK2838232 IR2|GSK2838232 will be available as film-coated tablet for oral use
214497418|NCT02795754|DRUG|Placebo PIB|Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
214991256|NCT01044667|BEHAVIORAL|GI and Quality of Life Assessment|
214991257|NCT01719302|DRUG|Gemcitabine|1500 mg/m\^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
214378225|NCT05465161|DEVICE|Sting Mark Fiducial Marker|Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
214991258|NCT01719302|DRUG|Docetaxel|50 mg/m\^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
214991259|NCT01719302|DRUG|Pazopanib|Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
214991260|NCT01617213|DRUG|Melphalan|200 mg/m2/IV
214991261|NCT01617213|DRUG|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
214991262|NCT04841174|OTHER|Abdominal massage|The effect on gastric problems by applying abdominal massage to eligible participants in the study will be examined.
214991263|NCT04892667|OTHER|Intervention|"Evaluation of the sensitivity of the cardiac uptake of 18F-FDG measured on D28 +/- 7 days, D42 +/- 7 days ou D56 + 4 days of the administration of ATCs to identify at 1 year the patients at risk of occurrence of a LVSD defined by a drop of more than 10 units of the LVEF and LVEF \&lt; 53%.~The patient participating in the study needs to respect a minimum of 12-hour fasting period, a high protein and a low-carbohydrate diet prior to performing PET/CT in order to limit physiological 18F-FDG myocardial fixation."
214991264|NCT05609227|OTHER|mobile application|The application, compatible with IOS and android systems for patients candidate for stem cell transplantation, could be applied whenever needed information relating to transplantation process.
214991265|NCT03609840|DRUG|Thiotepa|Given IV
214497419|NCT02795754|DRUG|Ritonavir|It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
214991266|NCT00026338|DRUG|erlotinib hydrochloride|150 mg po daily
214991267|NCT00026338|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
214991268|NCT01051804|OTHER|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
214991269|NCT01051804|OTHER|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
214991270|NCT00507572|OTHER|Medical Chart Review|Medical records are reviewed
214991271|NCT04330872|DRUG|Enteric Coated Aspirin Tablet|Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).
214991272|NCT04330872|DRUG|Plain Aspirin|Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
214991273|NCT04991961|DIAGNOSTIC_TEST|withdraw antihypertensive drugs|patients need to withdraw of all antihypertensive drugs or change therapy to Doxazosin/Diltiazem for 2-4 weeks prior
215091307|NCT02570880|OTHER|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
214378226|NCT02561286|BEHAVIORAL|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
214497420|NCT01532310|DRUG|belimumab|Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
214991274|NCT06091943|DRUG|Tislelizumab IV|Planned doses will be administered intravenously.
214991275|NCT06091943|DRUG|Tislelizumab SC|Planned doses will be administered via subcutaneous injection.
214378227|NCT02561286|BEHAVIORAL|Health Promotion Intervention|"Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals."
214991276|NCT06091943|DRUG|Histology-Based Chemotherapy Doublet|"Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
214991277|NCT05632523|OTHER|Blood sample|Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion
214991278|NCT05632523|OTHER|urinary sample|Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion
214991279|NCT04690426|BIOLOGICAL|PRV-101|Coxsackie Virus B vaccine
214378228|NCT06626373|OTHER|Elderberry Juice|Participants will consume elderberry juice 1-week.
214497421|NCT04886505|DEVICE|Electrolytic eCLIPs Bifurcation System|The electrolytic eCLIPs bifurcation system will be implanted into patients with bifurcated saccular intra-cranial aneurysms.
214497422|NCT02186509|RADIATION|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
214497423|NCT02186509|RADIATION|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
214497424|NCT02186509|DRUG|Alisertib|Given PO
214991280|NCT04690426|OTHER|Placebo|Placebo
215091308|NCT00860015|DRUG|Alimta|"500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer."
214991281|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 1|1 dose of Flu mRNA Formulation 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
214991282|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 2|1 dose of Flu mRNA Formulation 2 is administered intramuscularly in the non-dominant upper deltoid to YA at Day 1.
214991283|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 3|1 dose of Flu mRNA Formulation 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
214991284|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 4|1 dose of Flu mRNA Formulation 4 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
214991285|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 5|1 dose of Flu mRNA Formulation 5 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
214991286|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 6|1 dose of Flu mRNA Formulation 6 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
214991287|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 7|1 dose of Flu mRNA Formulation 7 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
214991288|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 8|1 dose of Flu mRNA Formulation 8 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
214991289|NCT06431607|COMBINATION_PRODUCT|Active Comparator 1|1 dose of active comparator 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
214991290|NCT06431607|COMBINATION_PRODUCT|Active Comparator 2|1 dose of active comparator 2 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
215091309|NCT00860015|DRUG|Gemcitabine|"1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy."
215091310|NCT03371953|DRUG|Vecuronium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
215091311|NCT03371953|DRUG|Atracurium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
215091312|NCT03371953|DRUG|Vecuronium + Atracurium|A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
215091313|NCT02288013|PROCEDURE|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
215091314|NCT04403594|OTHER|dry needling|dry needling followed by functional electrical stimulation and treadmill training
214378229|NCT06626373|OTHER|Placebo Beverage|Participants will consume placebo beverage twice/day for 1-week.
214378230|NCT06624774|OTHER|Prehabilitation|The structured exercise sessions will be conducted in a homebased setting, consisting of 8 resistance exercises (RE). The 8 RE's will include 4 upper body and 4 lower body exercises (Sit to stand, chest press, heel raises, bicep curls, leg abduction, tricep kickbacks, lunges, mid row). This is adapted from an existing home-based trial in cardiac patients. In addition, the structured exercise programme will include a walking programme. Participants will receive a Fitbit charge 5 activity monitor. Additionally, participants will conduct daily IMT via a Powerbreathe medic plus device. Participants will conduct 6 sets of 6 breaths at 50% of peak inspiratory pressure that has been measured at baseline. Education will be delivered via pre-recorded videos or in person
214378231|NCT06625424|OTHER|Short Sprint Interval Training with passive recovery|"Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which Subject will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc. Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
214378232|NCT06625424|OTHER|Short Sprint Interval Training with Active Recovery|"Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which the Subjects will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc.~Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
214378233|NCT06624891|OTHER|perioperative fluid responsiveness with the Pleth variability index|Perioperative fluid challenge and responsiveness will be based on monitoring the pleth variability index. In fact, volemia will be estimated with the PVI.
214378234|NCT06624891|OTHER|perioperative fluid responsiveness with delta PP|fluid challenge and responsiveness during intervention will be based on monitoring delta PP.
214497425|NCT02186509|PROCEDURE|Quality-of-life assessment|Ancillary studies
214497426|NCT01163981|OTHER|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
214497427|NCT06407804|OTHER|Thrower's Ten Exercise Program|No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 2 sets for 10 repetitions with 1 minute rest between sets.
214991291|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 9|1 dose of Flu mRNA Formulation 9 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
214991292|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 10|1 dose of Flu mRNA Formulation 10 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
214991293|NCT06431607|COMBINATION_PRODUCT|Active Comparator 3|1 dose of active comparator 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
215091315|NCT03340194|RADIATION|Radiography|Radiography of the hand and feet (face incident) the day of the inclusion
215091316|NCT03340194|PROCEDURE|Veinous punction|Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
214991294|NCT06431607|COMBINATION_PRODUCT|Active Comparator 4|1 dose of active comparator 4 is administered intramuscularly in the non-dominant upper deltoid to OA at Day1.
214991295|NCT03353051|OTHER|Observational study|Observational study
214378235|NCT06624761|DEVICE|ShotBlocker|A randomized study investigating ShotBlocker in painkillers containing different active ingredients could not be found.
214378236|NCT05871710|OTHER|Turkish version of the Tele-Pulmonary Rehabilitation Acceptance Scale|The Tele-Pulmonary Rehabilitation Acceptance Scale is a measuring tool that assesses the level of acceptance towards telerehabilitation programs among healthcare providers and patients in the field of pulmonary rehabilitation. It is used to evaluate the attitudes, beliefs, and perceptions of potential users towards telerehabilitation, which is a form of healthcare delivery that utilizes telecommunication technology to provide remote rehabilitation services to patients. The scale is intended to provide a standardized data collection tool that can be used to measure the level of acceptance of telerehabilitation programs among different groups of potential users. This scale will be translated into Turkish by a researcher who has an advanced level of knowledge in English and whose native language is Turkish.
214378237|NCT05871710|OTHER|Scale Evaluation Form|The healthcare providers and the patients will be asked about their opinions on the scale's construction, usefulness, and scope using a 100 mm visual analog scale.
214378238|NCT02272725|DRUG|Ibuprofen|Ibuprofen
214378239|NCT02272725|DRUG|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
214378240|NCT04959890|GENETIC|Strimvelis|This non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with gRV-GT. The study does not require subjects to undergo any further treatment, intervention or blood withdrawal. Eligible samples will be shipped to a central laboratory and will undergo DNA extraction prior to S-EPTS/LM-PCR analysis. Each analysis run will include a control DNA sample and up to four subject samples. Each sample will be analysed in triplicate.
214378241|NCT05047874|BEHAVIORAL|systemic methylprednisolone|short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone
214378242|NCT01949233|DRUG|Irbesartan 150-300mg capsules daily for 6 months|
214378243|NCT01949233|DRUG|Doxycycline 100-200mg capsules daily for 6 months|
214497428|NCT06407804|OTHER|Routine physical therapy.|"In this, the exercises will be performed in 2 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min Per Session)"
214497429|NCT04235998|DIAGNOSTIC_TEST|Systematic lung ultrasound|"Patients will undergo a systematic lung ultrasound including review of:~* Sonographic characteristic of effusion~* Parietal, diaphragmatic and visceral pleura~* Pleural nodules~* Lung parenchyma~* Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment."
214991296|NCT01208051|DRUG|Cediranib|Given PO
214991297|NCT01208051|DRUG|Cediranib Maleate|Given PO
214378244|NCT01949233|DRUG|Doxycycline placebo capsules daily for 6 months|
214378245|NCT01949233|DRUG|Irbesartan placebo capsules daily for 6 months|
214378246|NCT05159401|PROCEDURE|prevention of respiratory failure|Positive dynamics during CT or X-ray examinations in the form of reduction of hypoventilation zones, straightening of lung tissue
214378247|NCT02790021|PROCEDURE|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
214497430|NCT02261805|DRUG|Ganetespib|
214497431|NCT02261805|DRUG|Doxorubicin|
214378248|NCT01009879|DRUG|Etanercept|Etanercept 50 mg SQ qweek
214497432|NCT00895609|DRUG|Sugammadex, Neostigmine, Saline|"Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)"
214687178|NCT05896384|DRUG|Microgynon®|Ethinylestradiol (EE) and Levonorgestrel (LNG)
214991298|NCT01208051|OTHER|Laboratory Biomarker Analysis|Correlative studies
214991299|NCT01208051|DRUG|Lenalidomide|Given PO
214991300|NCT02646059|OTHER|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
214991301|NCT02646059|OTHER|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
214991302|NCT00255177|DRUG|VGX-410 (Mifepristone)|VGX-410 tablets taken daily or twice daily for 28 days
214991303|NCT00255177|DRUG|Placebo|Placebo for VGX-410 tablets taken daily or twice daily for 28 days
214378249|NCT06916689|DRUG|1L PEG-Asc|PEG 3350 plus sodium sulfate plus sodium chloride plus potassium chloride plus ascorbic acid plus sodium ascorbate
214497433|NCT00325767|DRUG|nebulized albuterol (2.5 mg/3ml/dose)|
214497434|NCT00325767|DRUG|nebulized levalbuterol (1.25 mg/3ml/dose)|
214497435|NCT00325767|DRUG|nebulized placebo (3ml/dose)|
214497436|NCT01389921|OTHER|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
214687179|NCT04833933|OTHER|Phone survey about smoking cessation process since intervention in DISCO trial|We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.
214991304|NCT03268187|DEVICE|Biofeedback|The skin conductance of the patient is measured and fed back to the patient via screen.
214991305|NCT03268187|BEHAVIORAL|Self-Alert Training|Self-Alert Training
214378250|NCT06925594|OTHER|Human TH-SC01 cell injection|Human TH-SC01 cell injection is a cell suspension in aseptic buffered solution containing human expanded umbilical cord-derived stem cells of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
214378251|NCT06925594|OTHER|Saline solution|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
214991306|NCT03268187|BEHAVIORAL|Relaxation Training|Relaxation Training
214378252|NCT06925035|DEVICE|1927nm fractional thulium fiber laser(TFL)|Prior to each session, Compound Lidocaine Cream (Beijing Ziguang Medication Manufacture Corporation Ltd.) was administered topically to the participants' faces for a duration of 30-40 minutes. Following sterilization with alcohol, the entire facial area was treated with a 1927 nm fractional thulium fiber laser (TFL) (WONTECH, Lavieen, South Korea). TFL parameters included a pulse energy of 8-10 mJ, an output power of 10 W, and a pulse spacing of 0.8 mm, ensuring comprehensive coverage of photodamaged regions.
214991307|NCT00973973|DRUG|Placebo|Matching placebo tablets taken orally once a day
214378253|NCT06925035|DRUG|supramolecular salicylic acid(SSA)|30% SSA (SSA and placebo are provided by Broda ,Shanghai Rui Zhi Medicine Technology, Shanghai, China.) or placebo(the base material of 30% SSA) were randomly assigned to be applied on one side of the face immediately after completion of the 1927nm TFL treatment. The 30% SSA was maintained on facial skin until reaching the clinical endpoint, manifested as mild erythema and/or a characteristic frost-like epidermal whitening. Additionally, the combination therapy side of the subjects was treated with one session of 30% SSA biweekly and 2% SSA daily over a period of 16 weeks.
214378254|NCT06926270|DEVICE|TMS|Magstim ,Rapid 2
214378255|NCT06925971|DEVICE|Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)|Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)
214497437|NCT04553549|DEVICE|Transradial approach|"Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
214497438|NCT01296100|BEHAVIORAL|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
214497439|NCT01296100|BEHAVIORAL|Lifestyle intervention (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
214497440|NCT01354782|DRUG|Roflumilast|"Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days."
214687180|NCT02439281|DRUG|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
214991308|NCT00973973|DRUG|Elagolix|Immediate release (IR) tablets taken orally once a day
214991309|NCT05775705|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.
214991310|NCT04197960|PROCEDURE|Microwave ablation|Use thermal energy to destroy tumor
215091317|NCT02578433|BEHAVIORAL|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
214378256|NCT06925971|DEVICE|Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)|Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)
214378257|NCT06925971|DEVICE|Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China),|Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China)
214378258|NCT03469284|OTHER|Best Practice|Given standard of care therapy
214991311|NCT04197960|PROCEDURE|Surgical resection|Resect tumors
214991312|NCT03641365|DEVICE|Test group|Guided Implant placement Positioning/placement of dental implants thought the fully acrylic surgical template without metallic sleeves.
214378259|NCT03469284|DRUG|Methylene Blue|Given lower dose PO
214378260|NCT03469284|DRUG|Methylene Blue|Given medium dose PO
214378261|NCT03469284|DRUG|Methylene Blue|Given higher dose PO
214378262|NCT03569839|DRUG|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
214687181|NCT02439281|DRUG|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
214991313|NCT03641365|DEVICE|Control group|Guided Implant placement Positioning/placement of dental implants thought the acrylic surgical template with metallic sleeves.
215091318|NCT02578433|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
215091319|NCT01314560|OTHER|Blood sample|Blood sample
214378263|NCT06351111|DEVICE|Active VNS|Subjects will receive active VNS paired with either of the three rehabilitation trainings
214991314|NCT01571791|DRUG|Placebo|to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
214991315|NCT01571791|DRUG|Ketorolac-Lidocaine|receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
214991316|NCT03277040|OTHER|CSA membership|Bi-weekly fresh food delivery
214991317|NCT00120939|DRUG|Motexafin Gadolinium|
214991318|NCT03695081|PROCEDURE|Patient Pathway Pharmacist intervention|"1. Medication reconciliation at admission to hospital~2. Medication review post surgery~3. Optimised list of drugs in the discharge summary, in accordance with hospital procedures~4. Medication reconciliation, six weeks after discharge~5. Medication review, six weeks after discharge"
214991319|NCT01541748|OTHER|Axis|Coloplast's Axis™ Allograft Dermis is used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.
214991320|NCT06057064|BIOLOGICAL|Biological: AZD3152|300 mg single dose of AZD3152 IM
214991321|NCT06057064|BIOLOGICAL|Biological: Placebo|Single dose of Placebo IM (0.9% sodium chloride)
214991322|NCT01691664|RADIATION|Only radiation therapy|Patients only radiation therapy after surgery
214991323|NCT01691664|OTHER|Radiation therapy plus DC-CIK cellular therapy|Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
214991324|NCT00227916|BEHAVIORAL|Behavior Therapy|
214991325|NCT05361759|DEVICE|Cardiac Implantable Electronic Devices|Description of Cardiac Implantable Electronic Devices
214991326|NCT02433717|DRUG|Paliperidone ER|Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
214378264|NCT04203927|DRUG|Empagliflozin 25 MG|SGLT-2 inhibitor
214378265|NCT04702880|BIOLOGICAL|BMS-986012|Specified dose on specified days
214991327|NCT01016002|DRUG|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
214378266|NCT04702880|DRUG|Carboplatin|Specified dose on specified days
214378267|NCT04702880|DRUG|Etoposide|Specified dose on specified days
214378268|NCT04702880|BIOLOGICAL|Nivolumab|Specified dose on specified days
214991328|NCT03483090|DIETARY_SUPPLEMENT|Swisse High Strength Deep Sea Krill Oil|Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.
214991329|NCT03483090|OTHER|Placebo|No therapeutic effect
214991330|NCT04422132|RADIATION|5 days Radiation Therapy (32.5 Gy in 5 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
215091320|NCT03140982|DIAGNOSTIC_TEST|FOUR coma scale and frontal espectrograpy evaluation|systematic evaluation using the validated FOUR coma scale during propofol administration
215091321|NCT01497613|BEHAVIORAL|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
215091322|NCT01497613|BEHAVIORAL|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
214378269|NCT01486615|DRUG|meloset (melatonin)|3 mg melatonin tablet 1-2 hour prior surgery
214378270|NCT01486615|DRUG|stresnil ( melatonin and alprazolam)|3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
214378271|NCT01486615|DRUG|(alprax) alprazolam|0.5 mg alprazolam
214378272|NCT01486615|DRUG|placebo|similar looking placebo tablet
214378273|NCT04182230|OTHER|No intervention. This study was an evalution with no intervention.|Not an interventional study
214378274|NCT04186676|OTHER|MINOCA registry|Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes
214378275|NCT04186676|DIAGNOSTIC_TEST|CCTA Phenotypes|"1. Complete normal coronary arteries~2. Diffuse non-obstructive coronary artery disease~3. Non-obstructive high-risk plaques~4. Myocardial bridges"
214991331|NCT04422132|RADIATION|20 days Radiation therapy (55 Gy in 20 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
214991332|NCT00436761|BIOLOGICAL|anti-thymocyte globulin|
214991333|NCT00436761|BIOLOGICAL|graft-versus-tumor induction therapy|
214991334|NCT00436761|BIOLOGICAL|sargramostim|
214378276|NCT03298620|OTHER|Electric toothbrush|
214378277|NCT03298620|OTHER|Control|Manual toothbrush
214497441|NCT03056313|BEHAVIORAL|Proactive support of labor|In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.
214991335|NCT00436761|DRUG|busulfan|
214991336|NCT00436761|DRUG|cyclosporine|
214991337|NCT00436761|DRUG|melphalan|
214991338|NCT00436761|DRUG|methylprednisolone|
214991339|NCT00436761|OTHER|flow cytometry|
214991340|NCT00436761|OTHER|immunologic technique|
214991341|NCT00436761|OTHER|laboratory biomarker analysis|
214991342|NCT00436761|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214991343|NCT00436761|PROCEDURE|umbilical cord blood transplantation|
214991344|NCT02832037|DRUG|BI 425809 dose 1|
214991345|NCT02832037|DRUG|BI 425809 dose 2|
214991346|NCT02832037|DRUG|BI 425809 dose 3|
214991347|NCT02832037|DRUG|BI 425809 dose 4|
215091323|NCT05473013|BEHAVIORAL|Behavioral Therapy for Eating Disorders|Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
214378278|NCT03610737|DEVICE|MILD Procedure|"The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.~Other Name: MILD lumbar decompression"
214378279|NCT03610737|OTHER|Conventional Medical Management (CMM)|CMM can include physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
214378280|NCT05220007|DIAGNOSTIC_TEST|Humphrey visual field testing|Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.
214497442|NCT03056313|BEHAVIORAL|support of labor as usual|In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
214497443|NCT05405244|DRUG|Placebo|2 capsules, orally administered once
214687182|NCT03016442|DEVICE|Cook Double Balloon Catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours
214687183|NCT03016442|DRUG|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
214687184|NCT04986449|BEHAVIORAL|nutritional and culinary intervention|"Each family will attend a total of 4 culinary-nutritional workshops between April and June 2021. Workshops 1 and 2 will be held in the kitchen located at the Science Building of the University of Navarra and will be given individually to each family.~Workshops 3 and 4 will be online (Zoom) and will be held in groups of 5 families. These workshops will be held from 5.30 pm to 7.30 pm on Fridays or from 11.30 am to 1.30 pm on Saturdays.~Finally, a meeting will be organized with all the families (parents and children) where the recipes prepared by the children for the n-CHEF challenge will be shared and prizes will be awarded."
214687185|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
214687186|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
215091324|NCT05473013|BEHAVIORAL|Skills Monitoring On|Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
215091325|NCT05473013|BEHAVIORAL|Automated Reminder Messages|Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
215091326|NCT05473013|BEHAVIORAL|JITAIs|Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
215091327|NCT01616979|PROCEDURE|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
215091328|NCT00724113|PROCEDURE|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
215091329|NCT00724113|PROCEDURE|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
215091330|NCT00128713|PROCEDURE|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10\^11 platelets per m\^2 BSA
214378281|NCT03303677|DRUG|Saline Nasal|topical nasal saline rinses
214378282|NCT03303677|DRUG|Budesonide Nasal|saline + budesonide nasal saline irrigation
214497444|NCT05405244|DRUG|Bromocriptine-QR|1.6mg (2 0.8mg capsules), orally administered once
214497445|NCT05206981|DEVICE|IlluminOss Device|Patients may enroll in the registry if they have been implanted (retrospective) or will be implanted (prospective) with the IlluminOss device.
214687187|NCT05937269|COMBINATION_PRODUCT|Near-infrared fluorescence lymphatic imaging|All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.
214687188|NCT05937269|DEVICE|advanced pneumatic compression therapy|The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy.
214687189|NCT06079268|OTHER|the initial gastric ultrasound|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
215091331|NCT00128713|PROCEDURE|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10\^11 platelets per m\^2 BSA
215091332|NCT00128713|PROCEDURE|Higher Dose Prophylactic Platelet Transfusions|4.4 \* 10\^11 platelets per m\^2 BSA
215091333|NCT03817294|OTHER|Comparison of exercise training modalities|As above
215091334|NCT00196768|DRUG|Arsenic trioxide|
215091335|NCT00196768|DRUG|Trisenox|
215091336|NCT02090790|DRUG|iv dexamethasone|2 ml 8 mg iv dexamethasone
215091337|NCT02090790|DRUG|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
215091338|NCT02090790|DRUG|serum physiologic|2 ml iv serum physiologic
215091339|NCT02018874|DRUG|LY2780301|"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D."
215091340|NCT02018874|DRUG|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
215091341|NCT01537146|DRUG|Ropivacaine|Bolus infusion via catheter/6H for 24H
214378283|NCT03303677|DRUG|Topical Antibacterial (Product)|The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
214378284|NCT00575497|PROCEDURE|More frequent hemodialysis|Six Day per week short daily hemodialysis
214378285|NCT00575497|PROCEDURE|More frequent hemodialysis|Six nights per week nocturnal hemodialysis
215091342|NCT01537146|DRUG|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
214378286|NCT00575497|PROCEDURE|More frequent hemodialysis|Every other day short daily hemodialysis
214378287|NCT00575497|PROCEDURE|More frequent hemodialysis|Every other night hemodialysis
214378288|NCT00575497|PROCEDURE|More frequent hemodialysis|5 days per week short daily hemodialysis
214378289|NCT00575497|PROCEDURE|More frequent hemodialysis|5 nights per week hemodialysis
214497446|NCT00739934|DRUG|voriconazole (Vfend)|"Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
215091343|NCT04340440|PROCEDURE|D1 lymphadenectomy|Radical gastrectomy with D1 lymphadenectomy
215091344|NCT04340440|PROCEDURE|D2 lymphadenectomy|Radical gastrectomy with D2 lymphadenectomy
215091345|NCT02037490|BEHAVIORAL|Grow2Gether|"Participants in this intervention will:~Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~1. View educational videos addressing topics related to healthy infant growth~2. Create photos/videos modeling healthy behaviors and post them to the group~3. Provide and receive feedback on posts~4. Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person."
215091346|NCT04400929|DRUG|Sargramostim|Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
214378290|NCT00575497|PROCEDURE|Conventional Hemodialysis|3 days per week short daily hemodialysis
214378291|NCT01788345|OTHER|non- invasive ventilation|non-invasive bi-level ventilation with IPAP and EPAP.
214497447|NCT03418922|DRUG|Lenvatinib|Specified doses will be administered orally on specified days.
214497448|NCT03418922|DRUG|Nivolumab|Specified doses will be administered intravenously on specified days.
214497449|NCT03451422|DRUG|Efavaleukin Alfa|Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
214497450|NCT03451422|DRUG|Placebo|The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
214497451|NCT03158506|DRUG|HMS5552|\[14C\]-labelled HMS5552
214497452|NCT02315118|DRUG|T-cell therapy + Rituximab + IL-2|"* T cells collection~* T cells expansion and modification in the laboratory~* T cells infusion back to the patients"
214497453|NCT04495140|DRUG|[14C]PF-06882961, 50 mg|A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.
214497454|NCT04495140|DRUG|PF-06882961, 50 mg and [14C]PF-06882961, 100 ug|A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.
214378292|NCT03221010|BEHAVIORAL|Motivational Interviewing|Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.
214497455|NCT03044652|DEVICE|WO2085 Moisturising Cream|2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. After improvement of the symptoms the frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
214378293|NCT03221010|BEHAVIORAL|Traditional cognitive-behavioral approach|This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
214378294|NCT00095914|DRUG|paclitaxel|
214378295|NCT00095914|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
214378296|NCT01616875|DRUG|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
214378297|NCT04319601|DRUG|Rituximab|a new chemotherapy regimen
214497456|NCT03044652|DRUG|Estriol Cream 0.1%|0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
214687190|NCT06079268|OTHER|the gastric ultrasound last 3 minutes|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
214687191|NCT05856773|RADIATION|Proton Therapy|Pencil Beam Scanning (PBS)
215091347|NCT04400929|OTHER|Normal Saline 0.9%|IV normal saline 0.9% for 5 days
215091348|NCT03802539|DEVICE|Glass Liner|restoration of root caries according to two different protocols
215091349|NCT03612323|DRUG|Intra-ligamentary Piroxicam|Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
215091350|NCT03612323|DRUG|Intra-ligamentary Articaine|Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
215091351|NCT04887389|DRUG|Nano Silver Fluoride varnish|Nano Silver Fluoride(5%) is a new experimental formulation containing silver nanoparticles, chitosan and fluoride combines preventive and antimicrobial properties. It is a yellow solution and safe to be used in humans
215091352|NCT04887389|DRUG|nano-hydroxyapatite varnish|nano-hydroxyapatite (10%) has antibacterial effect, higher solubility, surface energy and bioactivity and its structure is similar to dental apatite.
215091353|NCT04887389|DRUG|sodium Fluoride Varnish|Fluoride varnish (5%) applied every six months is effective in preventing caries in the primary and permanent dentition of children and adolescents
214991348|NCT02832037|DRUG|Placebo|
214991349|NCT01820832|DRUG|Calcitriol|Calcitriol 0.5 ug/BIW for 24 weeks.
214991350|NCT05604300|DIETARY_SUPPLEMENT|Vitamin E incorporated oat supplement|A twice daily supplementation of Vitamin E incorporated oat for 12 weeks
215091354|NCT00663299|DEVICE|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
215091355|NCT02927275|BEHAVIORAL|Experimental: Standing Modality|Cognitive performance when standing
215091356|NCT02927275|BEHAVIORAL|Experimental: Biking Modality|Cognitive performance when biking slowly
215091357|NCT02927275|BEHAVIORAL|Experimental: Walking Modality|Cognitive performance when walking at 1mph
215091358|NCT02927275|BEHAVIORAL|No Intervention: Seated Modality|Cognitive performance when sitting.
215091359|NCT01965223|RADIATION|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
214378298|NCT03841123|OTHER|Dietary Counseling|"The intervention will consist of an individualized, face-to-face, 20 to 30 minute counseling session to mothers by trained health workers who will address healthy eating practices during the first two years of life. A printed, colorful and illustrated material will be used to assist mothers in appropriate food choices, mainly to avoid the introduction of sugar and ultra-processed foods. In addition, they will receive a booklet which addresses the Ten Steps of Healthy Feeding for children from Birth to Two years of life. The research team will focus on Step2: Do not give added sugar or foods with added sugar, and Step8:Do not offer ultra-processed foods as candies and soft drinks. To reinforce the intervention, mothers will receive telephone calls up to the infant reach six months."
215091360|NCT01965223|RADIATION|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
215091361|NCT00135252|PROCEDURE|nasal cannula oxygen delivery|
215091362|NCT00135252|PROCEDURE|supplemental oxygen delivery by hood|
215091363|NCT01708447|DRUG|L.M.X.4.® cream|A lidocaine topical anesthetic cream
215091364|NCT01708447|OTHER|A placebo cream|Placebo cream containing no anesthetic properties.
214378299|NCT02674932|BEHAVIORAL|Identifying and Using Signature Strengths|The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.
215091365|NCT01708447|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
215091366|NCT04051554|OTHER|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
215091367|NCT04051554|OTHER|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
214687192|NCT05669001|BIOLOGICAL|TCD601|Investigational Product
214687193|NCT05669001|BIOLOGICAL|belatacept|Study Product
214687194|NCT05669001|DRUG|ATG|Comparator
214687195|NCT05669001|DRUG|TAC|Comparator
214687196|NCT05669001|DRUG|MPA|Immunosuppression Therapy
215091368|NCT00424268|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
215091369|NCT00424268|DRUG|Placebo|once daily
215091370|NCT05274360|BEHAVIORAL|Mobile evidence-based aphasia therapy|Use of mobile application to practice language for 2 weeks with a recommendation of 2 sessions per day of 20 minutes. The Android application, which is a Unity-based 2D game, will be installed on the patient's own phone, and they will play individually with the support of a family member if needed. The patients are free to start and stop using the application at any time. The application is safe to use, and it consists of therapeutic training methods such as object-matching, word search, writing, and manual voice recordings.
215091371|NCT05274360|BEHAVIORAL|Conventional aphasia rehabilitation|Control Group (conventional aphasia rehabilitation). No therapy as patients are in the chronic stage, where they do not receive healthcare rehabilitation training.
215091372|NCT02335060|DRUG|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
214687197|NCT05669001|DRUG|Corticosteroids|Immunosuppression Therapy
214687198|NCT06689085|COMBINATION_PRODUCT|Testosterone enanthate|XYOSTED 50mg, XYOSTED 75 mg, XYOSTED 100 mg
214687199|NCT03347617|DRUG|Ferumoxytol|Given IV
214991351|NCT05604300|DIETARY_SUPPLEMENT|Oat supplement|A twice daily supplementation of oat for 12 weeks
215091373|NCT02335060|DRUG|N-acetylcysteine|A pill given orally.
215091374|NCT02335060|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
215091375|NCT02335060|DRUG|Placebo|"Placebo sugar pill given orally with no N-acetylcysteine."
214378300|NCT02674932|BEHAVIORAL|Identifying and Writing Down Coping Skills|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.
215091377|NCT05577546|OTHER|Moor S brace treatment|The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.
215094697|NCT06540989|BEHAVIORAL|Deferred treatment|This group of participants will receive the same treatment as those in the immediate treatment group. The only difference is the timeline of treatment onset. Therefore, participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
214378301|NCT02674932|BEHAVIORAL|Treatment as Usual|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
214378302|NCT05538182|DEVICE|Spectacles|Based on the refraction results, study participants diagnosed with refractive error will be dispensed two free pairs of distance spectacles.
214378303|NCT02931890|DRUG|Docetaxel|3 weekly course of docetaxel i.v in arm 1 and 2
214378304|NCT02931890|DRUG|Oxaliplatin|3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
214378305|NCT02931890|DRUG|Capecitabine|oral capecitabine in arm 1 and 2
214378306|NCT02931890|PROCEDURE|gastrectomy|resection of gastric cancer after pre-operative chemotherapy for all arms
214378307|NCT02931890|RADIATION|radiotherapy of gastric cancer|5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
214378308|NCT02931890|DRUG|Paclitaxel|5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
214378309|NCT02931890|DRUG|Carboplatin|5 weeks of carboplatin i.v once a week (in arm 2 and 3)
214378310|NCT04438902|DRUG|osimertinib mesylate tablets and anlotinib hydrochloride capsules|osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle
214378311|NCT01047644|OTHER|Reduced port-flush schedule|3-month port-flushing
214687200|NCT03347617|OTHER|Laboratory Biomarker Analysis|Correlative studies
214687201|NCT03347617|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol MRI
214687202|NCT03347617|BIOLOGICAL|Pembrolizumab|Given IV
214687203|NCT05473520|DRUG|Doxycycline|A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
214991352|NCT04773795|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
214991353|NCT05897554|DRUG|intra-arterial alteplase|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
214991354|NCT00552838|BEHAVIORAL|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
214991355|NCT00472238|BEHAVIORAL|endurance training|control group.
214991356|NCT00472238|BEHAVIORAL|exercise training|Treadmill exercise training to optimize physical endurance
214991357|NCT01555775|DIETARY_SUPPLEMENT|P-CHO supplement|In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
215094698|NCT00946673|DRUG|Vorinostat|Orally up to 400 mg
215094699|NCT00946673|PROCEDURE|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
215094700|NCT02032654|DRUG|Flucloxacillin|
215094701|NCT02032654|DRUG|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
215094702|NCT00930007|OTHER|Blood sampling|Blood sampling for later hormone measurements
215094703|NCT03990506|PROCEDURE|Epi-on PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
214991358|NCT01555775|DIETARY_SUPPLEMENT|Fruit Milk Shake|The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
214991359|NCT06548490|DRUG|Semaglutide Pen Injector|Semaglutide will be provided using an injection pen
215094704|NCT03990506|PROCEDURE|Epi-Off PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
214991360|NCT06548490|DRUG|Placebo|Placebo will be a dry needle stick; no substances will be injected
214991361|NCT00193986|DEVICE|Arbitrary Waveform Defibrillator|
214991362|NCT03344211|DRUG|Enzalutamide|Given PO
214378312|NCT06286553|BEHAVIORAL|Trunk exercise|Trunk stabilization exercises including the following components: (a) progressive deep abdominal muscle retraining (transversus abdominis), (b) progressive pelvic floor muscle retraining, (c) abdominal muscle strengthening exercises (rectus abdominis and obliques), (d) combination of abdominal muscle control and distal extremity movements, and (e) progressive functional exercises.
214378313|NCT06286553|BEHAVIORAL|Inspiratory Muscle Training (IMT)|Inspiratory muscle strengthening exercises using inspiratory resistance (IMT devices)
214991363|NCT03344211|OTHER|Laboratory Biomarker Analysis|Correlative studies
214991364|NCT03344211|RADIATION|Radium Ra 223 Dichloride|Given IV
214991365|NCT01534793|PROCEDURE|Holmium Laser Enucleation of the Prostate (HoLEP)|Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
214991366|NCT03573856|BEHAVIORAL|Active Living|Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.
214991367|NCT03573856|OTHER|Health and Safety|Participants will be provided with education related to general health and safety topics.
214991368|NCT04358523|DRUG|ASC18|ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg
214991369|NCT04358523|DRUG|ravidasvir and sofosbuvir|RDV 200 mg and SOF 400 mg
214991370|NCT04358523|DRUG|ASC18|ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg
214991371|NCT05135533|DEVICE|Portable Neuromodulation Stimulation|The PoNS group will receive electrical stimulation. Net direct current to the tongue electrode less than 1 µA (micro ampere) will be administered three times a week for four weeks in-lab setting, followed by three times a week for eight weeks at-home setting. Participants will continue to be enrolled in the study for additional 12 weeks without any intervention to evaluate long term effects.
214991372|NCT05135533|DEVICE|Sham|The Sham group will not receive electrical stimulation.
214991373|NCT05135533|OTHER|Gait and balance training|During each session participants will receive gait training exercises for 20 minutes, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for four weeks in-lab setting. This will be followed by 20 minutes of gait training exercises, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for eight weeks at-home setting. Participants will continue to be enrolled in the study for additional 12 weeks without any intervention to evaluate long term effects.
214378314|NCT06286553|BEHAVIORAL|Control Group|Participants in the Control Group will receive general management information for DRA, written instructions and a single educational exercise session for contracting the deeper abdominals and pelvic floor muscles.
214378315|NCT01802684|BIOLOGICAL|aflibercept|Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
214991374|NCT03662568|DRUG|GLS4|Administered GLS4 120 mg orally three times daily in fed state
214991375|NCT03662568|DRUG|RTV|Administered RTV 100 mg orally three times daily in fed state
214991376|NCT03662568|DRUG|ETV|Administered orally ETV 0.5 mg once daily in fasted state
214991377|NCT03662568|DRUG|TDF|Administered TDF 300 mg orally once daily in fasted state
214991378|NCT06063928|PROCEDURE|Archive Sample Retrieval|Undergo collection of archival tumor tissue
214991379|NCT06063928|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
215094705|NCT03652675|BEHAVIORAL|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (\~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
215094706|NCT04060966|BEHAVIORAL|Cold-Pressor Task (CPT)|The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.
214991380|NCT06063928|OTHER|Electronic Health Record Review|Medical records reviewed
214378316|NCT02710305|DRUG|oral hyoscine butyl bromide tablets plus lidocaine cream|patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
214378317|NCT02710305|DRUG|oral placebo tablets plus placebo cream|patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
214687204|NCT05473520|DRUG|Placebo|Placebo + standard anti-tuberculous treatment
214991381|NCT06063928|OTHER|Genetic Testing|Undergo genetic testing
214991382|NCT06063928|OTHER|Questionnaire Administration|Complete questionnaires
214991383|NCT04035083|DEVICE|Laser activated irrigation|Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
214991384|NCT04035083|DEVICE|Passive ultrasonic irrigation|ultrasonic activation inside the canal for 1 min
214991386|NCT04502277|DRUG|Fluconazole Powder|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
214991387|NCT04159064|DIAGNOSTIC_TEST|Thromboelastometry, Impedance Aggregometry|Study of coagulation changes after cardiac surgery on CPB using Minimal Extracorporeal Circulation
214991388|NCT02078167|OTHER|nutraceutical combination (red yeast rice, policosanols and berberine)|
214991389|NCT03243019|DRUG|rapamycin|oral administration
214991390|NCT03243019|DEVICE|MRI|cervicofacial MRI
214991391|NCT03243019|BIOLOGICAL|Rapamycin dosage|Biological dosage of Rapamycin level
215091378|NCT05577546|OTHER|Schroth Three-Dimensional Scoliosis Exercise Treatment|Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
214378318|NCT02991482|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
214378319|NCT02991482|DRUG|Gemcitabine|"Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide)."
214991392|NCT05283837|BIOLOGICAL|Pertuzumab (ZRC-3277)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
214991393|NCT05283837|BIOLOGICAL|Pertuzumab (Perjeta®)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
214991394|NCT05994807|DRUG|DC-806|Oral tablets
214991395|NCT05994807|DRUG|Itraconazole|Oral capsules
214378320|NCT02991482|DRUG|Vinorelbine|Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
214378321|NCT01724645|DIETARY_SUPPLEMENT|Korean traditional diets|"The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.~The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods."
214378322|NCT01724645|DIETARY_SUPPLEMENT|Control group|"Told to  eat as usal diets."
214378323|NCT05426564|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
214378324|NCT04293588|DIAGNOSTIC_TEST|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
214378325|NCT05721508|OTHER|Combined physical and cognitive program|All participants will complete 12-week training sessions combining physical and cognitive activities, with two 1-hour sessions per week.
214497457|NCT04584658|DIAGNOSTIC_TEST|Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.
214991396|NCT05994807|DRUG|Carbamazepine|Oral tablets
215091379|NCT01020162|DRUG|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
215091380|NCT01020162|PROCEDURE|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
214497458|NCT04584658|DIAGNOSTIC_TEST|Videofluoroscopy|A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.
214991397|NCT01137786|DRUG|Non ionic contrast media comparator|One time administration for PCI
214991398|NCT01137786|DRUG|Non ionic contrast media comparator|one time administration for PCI
214991399|NCT01285089|DRUG|activated recombinant human factor VII|Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
214991400|NCT02711787|DEVICE|Experimental group|Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
214991401|NCT02711787|DEVICE|Control group|Physiotherapy and occupational therapy.
214378326|NCT00532324|OTHER|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
214991402|NCT02711787|DEVICE|traditional rehabilitation|Assisted stretching, shoulder and arm exercises, and functional reaching tasks
214991403|NCT06372236|BIOLOGICAL|UTAA06 injection for treatment of advanced malignant solid tumors|The subjects who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1×10\^8CAR+gdT、3×10\^8CAR+gdT、5×10\^8CAR+gdT、8×10\^8CAR+gdT、1×10\^9CAR+gdT groups inder of sequence.And the subjects will be administered once.
214991404|NCT01186081|RADIATION|Preoperative chemoradiotherapy|Preoperative chemoradiation with conventional radiotherapy (46 Gy in 23 fractions to the whole pelvis followed by a boost dose of 4 Gy in 2 fractions) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
214991405|NCT01186081|RADIATION|Postoperative chemoradiotherapy|Postoperative radiotherapy with conventional radiation schedule (50 Gy in 25 fractions to the whole pelvis) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
214991406|NCT01531153|DRUG|Galantamine|8mg or 16mg
214991407|NCT01531153|DRUG|Placebo|Placebo dose.
214991408|NCT03406468|RADIATION|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
214991409|NCT06205589|BIOLOGICAL|ID93 + GLA-SE vaccine|At Step 2 entry, participants will receive one 0.5 mL injection of ID93 + GLA-SE administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
214991410|NCT06205589|BIOLOGICAL|Placebo vaccine|At Step 2 entry, participants will receive one placebo injection (sodium Chloride, 0.9%) administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
214991411|NCT05075369|DIAGNOSTIC_TEST|water drinking test|Water drinking test-glaucoma diagnostic test - marker for outflow facility reserve to detect IOP instability when the body ingests 800 ml of water within a 5 minute period of time
214991412|NCT02385890|OTHER|Control|Non pulse ingredient bagel
214991413|NCT02385890|OTHER|Pea flour|Pulse ingredient bagel
214991414|NCT02385890|OTHER|Pea fibre|Pulse ingredient bagel
214991415|NCT02385890|OTHER|Pea protein|Pulse ingredient bagel
214991416|NCT02385890|OTHER|Pea flour + pea protein|Pulse ingredient bagel
214991417|NCT02385890|OTHER|Pea fibre + pea protein|Pulse ingredient bagel
214378327|NCT04121481|DIETARY_SUPPLEMENT|Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement|Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample
214378328|NCT04121481|DIETARY_SUPPLEMENT|Broad Spectrum Safety|Benefits in Sports Nutrition
214378329|NCT00400543|DEVICE|Continuous positive airway pressure (CPAP)|
214991418|NCT00770367|DRUG|Pioglitazone then Placebo|Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.
214991419|NCT00770367|DRUG|Placebo then Pioglitazone|Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
215091381|NCT05790980|DEVICE|Abdominal ultrasound|Abdominal US to exclude splenomegaly and hepatomegaly or liver cirrhosis Echocardiology to show cardiac dysfunction
214378330|NCT02396537|DRUG|Lidocaine|Administered intranasally prior to Midazolam administration.
214378331|NCT02396537|DRUG|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
214378332|NCT02396537|DRUG|0.9% Saline|Administered intranasally prior to Midazolam administration.
214687205|NCT00498875|BEHAVIORAL|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
214687206|NCT00498875|BEHAVIORAL|Depression Intervention|"Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques."
214687207|NCT04026438|DRUG|Potassium Phosphate Injection|One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline
214991420|NCT03323762|DEVICE|Remote Ischaemic Conditioning (RIC)|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
214991421|NCT00435942|DEVICE|Relay Thoracic Stent-Graft|implant
214991422|NCT00435942|PROCEDURE|Open Repair|Open surgery
214991423|NCT02786966|OTHER|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
214991424|NCT06304363|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
215091382|NCT00261703|DRUG|Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
214991425|NCT05614076|PROCEDURE|conserved chalky white enamel margins of class V cavities|during cavity preparation, we conserved chalky white enamel margins of class V cavities and then restored them with resin composite restorations,we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
214991426|NCT05614076|PROCEDURE|Total removal of demineralized enamel margins of class V cavities|during cavity preparation, we removed the total chalky white enamel margins of class V cavities and then restored them with resin composite restorations, we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
214991427|NCT05134844|OTHER|Hydrotherapy- Snoezelen|Multi sensory approach in water
214991428|NCT05134844|OTHER|Snoezelen|Multu Sensory approach on land
214378333|NCT03774602|BEHAVIORAL|Health promotion and provision of RMNCH services|Implementation of quality, high-impact interventions at institutional and community levels to increase access to and utilization of RMNCH services
214991429|NCT00463424|DEVICE|NeuFlex metacarpophalangeal implant|
215091383|NCT00261703|DRUG|Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
215091384|NCT00261703|OTHER|Cisplatin + radiotherapy|Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
215091385|NCT00143533|DRUG|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
215091386|NCT02356887|DIAGNOSTIC_TEST|Jugular venous ultrasound|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions at rest, jugular occlusion and valsalva maneuver. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
215091387|NCT00002342|DRUG|Tecogalan sodium|
215091388|NCT01697943|PROCEDURE|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
215091389|NCT00199888|DRUG|124-Iodine-cG250 (124I-cG250)|
215091390|NCT04419441|DRUG|Immune checkpoint inhibitor|concomitant administration of radiotherapy and immune checkpoint inhibitor
215091391|NCT02030288|BEHAVIORAL|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
215091392|NCT06197087|OTHER|cross-sectional observational survey study|Patients' pain intensity (with VAS), quality of life (with SF-12), sleep quality (with Pittsburgh sleep quality scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspect of pain (with Pain Catastrophizing Scale), presence of central sensitization (with the central sensitization scale), functional status (with the Fibromyalgia impact questionnaire), and chronotype preferences will be evaluated with the Morningness and Eveningness Questionnaire.
215091393|NCT05186441|OTHER|DMPFC iTBS|The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
215091394|NCT05186441|OTHER|DLPFC iTBS|The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
215094707|NCT04060966|BEHAVIORAL|Control CPT|The control CPT involves participants submerging their dominant forearm in warm water (\~30°C) for 3 minutes.
214378334|NCT05447624|PROCEDURE|Radiofrequency ablation of genicular nerves|The RF cannula will be placed near the nerve with an in-plane technique from proximal to distal. Sensory stimulation will be performed at 50 Hz to ensure localization. The sensory threshold should be less than 0.6 V. To prevent ablation of the motor nerves, when the nerve is stimulated with 2.0 V at 2 Hz, it will be seen that there is no fasciculation in the relevant region of the lower extremity. Before starting the ablation procedure, 2 mL of 1% lidocaine solution will be injected around the nerve, after vascularity control, in order to reduce the pain and the risk of neuritis during the procedure. Then the temperature will be adjusted to 80° degrees and applied for 90 seconds and the process will be terminated.
214378335|NCT00871403|DRUG|pazopanib and pemetrexed|oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily
214378336|NCT00871403|DRUG|pemetrexed and cisplatin|pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks
214378337|NCT01057615|DIETARY_SUPPLEMENT|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
214378338|NCT01057615|DIETARY_SUPPLEMENT|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
214378339|NCT01057615|DIETARY_SUPPLEMENT|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
214378340|NCT01057615|DIETARY_SUPPLEMENT|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
214991430|NCT00463424|DEVICE|Swanson metacarpophalangeal implant|
214991431|NCT01199770|OTHER|Control, small|control pasta, small portion
214991432|NCT01199770|OTHER|Experimental B, small|experimental pasta, small portion
214991433|NCT01199770|OTHER|Experimental pasta C, small|experimental pasta C, small portion
214991434|NCT01199770|OTHER|control, medium|control pasta, medium portion
214991435|NCT01199770|OTHER|experimental pasta B, medium|experimental pasta B, medium portion
214991436|NCT01199770|OTHER|experimental pasta C, medium|experimental pasta C, medium portion
214991437|NCT01199770|OTHER|NL|no pasta, water only
214991438|NCT01161888|DRUG|Imiquimod|250mg sachets to be applied at a start dose of 5 days a week. Dose will be adjusted using an algorithm according to tolerability.
214991439|NCT04547699|COMBINATION_PRODUCT|A single step culture medium|A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK
214991440|NCT01756755|DEVICE|PMX-20R Hemoperfusion|Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
214991441|NCT00820092|DRUG|Xerecept 1.0|24 hour infusion
214991442|NCT00820092|DRUG|Xerecept 2.0|24 hour infusion
214378341|NCT01562912|DEVICE|Radiofrequency Ablation Procedure|Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.
214378342|NCT01562912|DEVICE|PVAC Ablation Procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
214378343|NCT05420441|DEVICE|Phonophoresis with chitosan|Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
214378344|NCT05420441|DEVICE|Phonophoresis with glucoasmine|Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
214378345|NCT05420441|PROCEDURE|Conventional Physical Therapy|Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
214378346|NCT03405272|BIOLOGICAL|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）|Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
214378347|NCT00787319|OTHER|no intervention|Outpatients with age-related macular degeneration (AMD)
214991443|NCT00820092|DRUG|Xerecept 3.0|24 hour infusion
214991444|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) 1 hour pre-exercise
214991445|NCT04862208|DIETARY_SUPPLEMENT|Whey supplement|whey (25g in 12 oz water) 1 hour pre-exercise
214991446|NCT04862208|DIETARY_SUPPLEMENT|Water|non-caloric control (12 oz flavored water) 1 hour pre-exercise
214991447|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) with no exercise
215091395|NCT01401712|PROCEDURE|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
215091396|NCT01401712|PROCEDURE|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
215091397|NCT03100214|OTHER|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
214378348|NCT01729117|OTHER|Meal Replacement|5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
214378349|NCT01729117|OTHER|Standard Care|Standard Care only
214378350|NCT00371527|DRUG|ipratropium|
214378351|NCT02312856|DEVICE|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
214378352|NCT02342665|DRUG|Copanlisib (BAY80-6946)|Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
214497459|NCT04584658|OTHER|Dysphagia Handicap Index (DHI)|This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
214991448|NCT05285969|BEHAVIORAL|Motivational interview|The new CR program with MI will be structured in 4 sessions and an optional fifth during the six months after discharge. The methodology of the MI sessions will follow the four phases logical sequence of MI proposed by Rollnick and Millner. 1) engage in a collaborative relationship, 2) focus on a particular change, 3) evoke intrinsic motivations for change, and 4) plan an immediate step for change
214991449|NCT05285969|BEHAVIORAL|Active Comparator: Standard care group|All patients in the control group will receive a kit with informative material with the actions and procedures to follow (diet, physical activity, smoking cessation, and other recommendations about secondary prevention).
214991450|NCT00042146|BEHAVIORAL|Cognitive-behavior therapy|
214991451|NCT00042146|DRUG|zolpidem|
214991452|NCT01618591|DRUG|Single dose rifaximin 1650 mg|Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
214991453|NCT01618591|DRUG|Single dose azithromycin 500 mg|Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
214378353|NCT05461014|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation. The coaches are trained to provide assistance with adult care transition readiness."
214378354|NCT00063102|DRUG|ABT-751|
214378355|NCT01170195|DIETARY_SUPPLEMENT|Calmera-Licorice Root Extract (Licogen)|100 mg per day
214378356|NCT03861520|DEVICE|Midtrimester anomaly scan|A detailed anomaly scan to detect soft markers at 16 to 24 weeks pregnancy
214378357|NCT03861520|GENETIC|Fetal Karyotyping|Fetal karyotyping after birth to confirm chromosomal anomaly diagnosed clinically
214378358|NCT04415151|DRUG|Tofacitinib 10 mg|Tofacitinib will be administered in a dose of 10 mg twice daily by mouth (PO BID) until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
214378359|NCT04415151|DRUG|Placebo|Matching placebo tablets will be administered.
214991454|NCT01618591|DRUG|Single dose levofloxacin 500 mg|Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
214991455|NCT01618591|DRUG|Single dose azithromycin 1000 mg plus loperamide|Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
214991456|NCT01618591|DRUG|Single dose azithromycin 1000 mg plus placebo|Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
214991457|NCT05428865|OTHER|correlation study|investigate the correlations between body mass index, spasticity, functional ability and isolated motor control in children with spastic diplegia.
214991458|NCT00635284|DRUG|ABI-009|nab-rapamycin
214991459|NCT01859000|OTHER|Multidimensional Family Therapy|MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.
214991460|NCT01859000|OTHER|Group CBT|Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
214991461|NCT03837834|OTHER|Functional Electrical Stimulation Leg Cycling Exercise|FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.
214991462|NCT00243321|PROCEDURE|high dose-rate brachytherapy|High dose-rate brachytherapy
214991463|NCT00243321|PROCEDURE|intensity-modulated radiation therapy|intensity-modulated radiation therapy
214991464|NCT05113303|DEVICE|Navigated Revision Total Knee Arthroplasty|Patients in the case group receive a Columbus® Revision knee prosthesis, implanted with computer assisted surgery
214991465|NCT05113303|DEVICE|Manual Revision Total Knee Arthroplasty|Patients in the control group will correspond to a historical cohort of patients in which manual jig-assisted knee revision was done.
214991466|NCT00994539|DRUG|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
214991467|NCT00920816|DRUG|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
214991468|NCT00920816|DRUG|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
214991469|NCT05516069|OTHER|Our Healthbox (smart vending machine or interactive dispensing system)|Our Healthboxes or interactive dispensing systems (IDS) will be placed in various locations across Canada and will house HIV self-test kits (provided by REACH), harm reduction supplies (provided by the provincial governments / local community based organizations; e.g. sterile drug use kits for safer injection, naloxone kits, syringes), other community determined needs (including but not limited to hats, mittens and/or socks, rapid Covid-19 antigen kits, KN95 masks). Individuals will be able to access the HIV self-test kits and harm reduction and other materials directly from the machine. Our Healthbox will also provide health information, and a support services directory for people to find the health care they need - in their community.
214991470|NCT00255333|DRUG|INNO-105|
214991471|NCT06125990|OTHER|Experimental: Study Group (SGr)|For 6 weeks, in addition to institutional conventional exercise 2 days a week, one day a week of home exercise, breathing exercises to increase lung volumes and 7 sets of video-based breathing exercises were applied, each set consisting of 2 minutes of performance and 1 minute of rest.
214991472|NCT06125990|OTHER|Sham Comparator: Control Group (CGr)|Only institutional conventional rehabilitation was implemented.
214991473|NCT01180777|DEVICE|etafilcon A (A)|Daily wear contact lens
214991474|NCT01180777|DEVICE|etafilcon A (B)|Daily wear contact lens
214991475|NCT01180777|DEVICE|etafilcon A (C)|Daily wear contact lens
214991476|NCT05758792|OTHER|Muscle Quality Index|Evaluations are applied to older adults to compare the results of muscle quality.
214991477|NCT05029947|PROCEDURE|Microsurgical Clipping of Unruptured Intracranial Aneurysm|Microsurgical Clipping of Unruptured Intracranial Aneurysm
214378360|NCT02732626|PROCEDURE|radiofrequency ablation|
214378361|NCT01778946|DRUG|Low Dose Nicotine (7mg)|
214378362|NCT01778946|DRUG|Moderate Dose Nicotine (14mg)|
214378363|NCT05414097|OTHER|Semi-structured focus group discussions - Women|Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.
214991478|NCT03976128|BEHAVIORAL|Nordic Walking Training|The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
214378364|NCT05414097|OTHER|semi-structured focus groups discussions - Men|Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening.
214378365|NCT05414097|OTHER|In-depth key stakeholders interviews|In-depth interviews to contextualise findings from women and men focus group discussions.
214378366|NCT05414097|OTHER|Discrete Choice Experiment - Women|Discrete Choice Experiment to determine preferences to different cancer screening models.
214378367|NCT05414097|OTHER|Development and User Pre-testing Workshops|Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 \&2.
214378368|NCT03237520|OTHER|Virtual Reality Therapy|VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained
214378369|NCT03237520|OTHER|mCIMT|Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
214378370|NCT01310309|DEVICE|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
214378371|NCT03046511|DRUG|Cefazolin|A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
214378372|NCT02150837|OTHER|5 & 2 & 2 Plan|Medifast has developed the 5 \& 2 \& 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 \& 2 \& 2 Plan consists of 5 Medifast meal replacements, 2 Lean \& Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, \>72g protein, \>100g of carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
214378373|NCT02150837|OTHER|4 & 2 & 1 Plan|Medifast has developed the 4 \& 2 \& 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 \& 2 \& 1 Plan consists of 4 Medifast meal replacements, 2 Lean \& Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, \>72g protein, \>100g carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
214687208|NCT06978231|PROCEDURE|EUS+ERCP|EUS were performed during the same session with ERCP under continuous sedation/anesthesia
214378374|NCT02922790|BEHAVIORAL|standard health information|Subjects will review standard health information
214378375|NCT02922790|BEHAVIORAL|standard health information plus info. on DNA damage|Subjects will review standard health information and information on DNA damage
214378376|NCT02922790|BEHAVIORAL|Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage|Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
214378377|NCT03365986|DIAGNOSTIC_TEST|genetic screening|Patients receive genetic test to see whether they have germline cancer susceptibility gene mutations
214378378|NCT02560935|DRUG|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
214378379|NCT02560935|DRUG|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
214378380|NCT02608905|DRUG|Dapagliflozin|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
214378381|NCT02608905|DRUG|Placebo|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
214687209|NCT06978231|PROCEDURE|ERCP|Only ERCP was performed in the control group
214687210|NCT01925001|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
214687211|NCT01925001|DRUG|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
214687212|NCT06019780|OTHER|blood flow restriction trainin|"Following exercise will be performed~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption İndividual in the group will be having two session per week, 16 session of exercise training for 8 weeks.50% of arterial occlusion pressure (60 to 80 mmHg) will be applied for total duration of 15mins. Occlusion pressure will be calculated according to formula for each patient \[Pressure=0.4x(systolic BP)+2.7x(shoulder circumference)+62\].4 sets with one set of 30 repetition and three sets of 15 repetition. After each set subject will have 30 seconds of rest with cuff inflated."
214378382|NCT05019274|OTHER|Culinary Medicine Intervention|Participants randomized to the Culinary Medicine intervention will complete a series of 6 virtual culinary medicine cooking classes (1 class per month for 6 months). Virtual sessions will be delivered via Zoom using a combination of large group instruction and small group break-out sessions in which participants prepare a recipe in their home kitchen with the virtual assistance from trained group facilitators. After preparing the dish, participants will enjoy the dish they prepared and report-back to the large group about their dish and experience. Classes will be conducted in English and Spanish with language-concordant instructors and facilitators.
214378383|NCT05019274|OTHER|Standard of Care Nutrition Visits|Participants randomized to standard of care nutrition visits will complete a series of 6 nutrition visits (1 session per month for 6 months) led by bilingual (English/Spanish) dieticians. Sessions will consist of a mix of individual and small group sessions per standard of care in the clinic.
214991479|NCT03976128|BEHAVIORAL|Conventional endurance training|15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
214991480|NCT05956093|RADIATION|FAPI PET CT|the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT to accurately stage high-grade epithelial ovarian cancers.
214991481|NCT03988660|DIAGNOSTIC_TEST|Circulating fibrocytes|Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
214991482|NCT00350220|OTHER|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb \>13.0 g/dl
214991483|NCT00350220|OTHER|Low Hb transfusion group|RBCs will not be transfused unless the Hb \< 9.0 g/dl
214991484|NCT02369926|PROCEDURE|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
214991485|NCT02369926|PROCEDURE|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
214991486|NCT00360204|BEHAVIORAL|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
214991487|NCT02022930|DEVICE|Hydros|
214991488|NCT02022930|DEVICE|Hydros-TA|
214991489|NCT02022930|DRUG|Triamcinolone Acetonide|
214991490|NCT02595710|OTHER|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
214991491|NCT02595710|OTHER|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
214991492|NCT02595710|OTHER|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
214378384|NCT03533634|PROCEDURE|Open Reduction Internal Fixation superior plate|3.5mm superior reconstruction plate
214378385|NCT03533634|PROCEDURE|Open Reduction Internal Fixation anteroinferior plate|3.5mm anteroinferior reconstruction plate
214378386|NCT02329301|DRUG|MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
214378387|NCT02329301|DRUG|Focal MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
214378388|NCT03075904|DRUG|ALXN1830|Administered via IV infusion.
214378389|NCT04261660|OTHER|NO intervention|NO INTERVENTION
214991493|NCT04329455|PROCEDURE|Endoscopic thyroidectomy|Endoscopic thyroidectomy in Thyroid Nodules
214991494|NCT03479151|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|MRgHIFU treatment will be delivered using a Philips Sonalleve system, which integrates a high intensity phased array focused ultrasound transducer with our Philips 3T Achieva imaging system. An electromechanical transducer positioning system is used to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively. The MR system is used to provide images to plan the therapy, and to guide and monitor the thermal ablation with thermal imaging during the treatment.
214991495|NCT00624260|OTHER|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
214991496|NCT00624260|OTHER|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
214991497|NCT05009420|OTHER|Avocado|avocado served with crackers as breakfast
214991498|NCT02941003|DEVICE|microscope|Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
214991499|NCT02941003|OTHER|immunostaining|Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
214991500|NCT02941003|DEVICE|NGS|The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
214991501|NCT04622956|DRUG|Methotrexate Injectable Solution|"Phase 1:~* Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9\*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~* Level 0 \[Starting Dose\]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~* Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~* Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial"
215091398|NCT03100214|OTHER|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
215091399|NCT02265315|OTHER|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
215091400|NCT02265315|BEHAVIORAL|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
215091401|NCT05714943|BEHAVIORAL|DigiKnowIt News: Teen|Participants will interact with a multimedia educational website that will teach them about pediatric clinical trials, including topics such as participant rights and safety and different types of procedures used in trials, and will provide strategies for parent-teen shared decision-making about clinical trials.
214991502|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
214991503|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
215091402|NCT05052060|OTHER|Group A|19 patients will be treated with pelvic tilt exercises
215091403|NCT05052060|OTHER|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
214378390|NCT04446715|DRUG|sufentanil|Patients will receive sufentanil in spinal anesthesia
214991504|NCT02619513|DRUG|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
214991505|NCT02619513|DRUG|Ropivacaine|Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
214378391|NCT04446715|DRUG|meperidine|Patients will receive meperidine in spinal anesthesia
214991506|NCT02619513|DEVICE|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
214991507|NCT03755076|BEHAVIORAL|Perceptual cuing|Participants were provided four perceptual cues (or feedback) in a pseudorandom order: (a) indiscriminate, (b) Altered gain, (c) Coordination, (d) Dual: altered gain and coordination
214991508|NCT04167462|DRUG|BMS-986165|Specified dose on Specified Days
214991509|NCT04167462|OTHER|Placebo|Specified dose on Specified days
214991510|NCT05408221|DRUG|Rulonilimab+Lenvatinib|Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
214991511|NCT05408221|DRUG|Rulonilimab placebo +Lenvatinib|Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
215091404|NCT00636259|DRUG|Bicalutamide (Casodex)|150mg
215091405|NCT04229355|DRUG|DEB-TACE plus Sorafenib|Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
215091406|NCT04229355|DRUG|DEB-TACE plus Lenvatinib|Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
215091407|NCT04229355|DRUG|DEB-TACE plus PD-1 inhibitor|Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
215091408|NCT01188057|DRUG|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
214378392|NCT04446715|DRUG|Bupivacaine|Patients will receive 0.5% heavy bupivacaine in spinal anesthesia
214378393|NCT00099593|BIOLOGICAL|Autologous Dendritic Cell Vaccine|
214378394|NCT03155230|OTHER|no intervention|no intervention
214378395|NCT03717662|DRUG|nicotine gum or nicotine patch|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
214378396|NCT03784092|OTHER|feedback|feedback by electronic pedometers regarding patient mobility while undergoing labor induction
214378397|NCT03353259|COMBINATION_PRODUCT|Tranexamic acid and Tocilizumab|The first intervention is Tranexamic acid, The second intervention is Tocilizumab
214991512|NCT05993169|OTHER|Body Composition optimization visits|Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.
214991513|NCT02638441|OTHER|hospital anxiety and depression scale|Detection of infertility effect on emotional status
215091409|NCT01188057|DRUG|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
215091410|NCT02505568|DRUG|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
215094708|NCT04060966|DEVICE|fMRI|Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
215094709|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
214378398|NCT04501289|DRUG|Low dose magnesium sulphate|Participants in this arm will receive 4g of 20% intravenous (I.V.) MgSO4 (Magphate®) given over 10 minutes, followed by 3g of 50% intramuscular (I.M.) MgSO4 in each buttock statim. Then, maintenance doses will be given as 2.5g of 50% MgSO4 administered intramuscularly 4 hourly for 24 hours, for participants with severe preeclampsia and for 24 hours post delivery or post last seizure episode, whichever occurs last, for cohorts with eclampsia.
214378399|NCT04501289|DRUG|Pritchard regimen|Participants in this arm will receive loading dose as 4g of 20% MgSO4 I.V. over 10 minutes, followed by 5g of 50% MgSO4 I.M. in each buttock. Maintenance doses will be given as 5g of 50% MgSO4 I.M. 4 hourly in alternate buttock until 24 hours for patients with eclampsia and for 24 hours after delivery or after last fit, whichever occurs later, for cohorts with eclampsia.
214991514|NCT04976257|PROCEDURE|Angiogram|Undergo angiogram
214991515|NCT04976257|PROCEDURE|Catheterization|Undergo prostatic arterial catheterization
214991516|NCT04976257|DRUG|Gallium Ga-labeled PSMA-11|Given IV and IA
214991517|NCT04976257|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214991518|NCT02820636|BEHAVIORAL|S-CBT|The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual \& 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication \& trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
214991519|NCT02820636|BEHAVIORAL|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
214991520|NCT03955445|DRUG|LNP023|LNP023 capsules
214991521|NCT00169325|PROCEDURE|Magnetic resonance imaging|
214991522|NCT02606253|DRUG|tolvaptan|Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
214991523|NCT02606253|DRUG|Chlorothiazide|Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
214991524|NCT02606253|DRUG|Metolazone|Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
214991525|NCT06344949|DRUG|Ciprofol|The sedation before tracheal intubation with Ciprofol
214991526|NCT06344949|DRUG|Propofol|The sedation before tracheal intubation with Propofol
214991527|NCT03411538|OTHER|Collect data on clinical history|Collect data on clinical history, clinical manifestation, comorbidity, admission data, use of invasive medical intervention, history of antibiotic treatment and antibiotic susceptibility test results
214991528|NCT02508064|DRUG|BMS-663068|BMS-663068
214991529|NCT00383825|PROCEDURE|Anterior segment indocyanine green angiography|
214378400|NCT00175968|PROCEDURE|bed rest, hypocaloric nutrition|
214378401|NCT00625235|DIETARY_SUPPLEMENT|VLED followed by a high protein or high carbohydrate diet|
214378402|NCT04215185|DEVICE|Arterial LIne|Continuous non-invasive recording of CS6BP will be taken parallel to the recording of an invasive arterial line. ECG data recorded in the ICU will also be collected.
214378403|NCT03427554|DRUG|Tretinoin cream 0.1%|Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
214378404|NCT03427554|DRUG|RETIN-A® Cream|RETIN-A® (Tretinoin) Cream (Valeant)
214378405|NCT03427554|DRUG|Vehicle of the test product|Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
214991530|NCT03650075|DRUG|MG-S-2525|The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
214991531|NCT05987280|OTHER|eDelphi method|eDelphi method
214991532|NCT00890721|DRUG|SKY0402|During the operation, 30cc of SKY0402 are injected into the wound.
214991533|NCT00890721|DRUG|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
214991534|NCT06494163|BEHAVIORAL|Exercise|The MICT and HIIT intervention groups will complete supervised virtual exercise sessions for 12 weeks using Zoom care or Microsoft Teams as a backup resource. The appointments will be scheduled and conducted 2 days per week. Initially, exercise intensity will be determined from participants' peak HR achieved during a baseline CPET.
214991535|NCT06569368|DRUG|Metronidazole|Given by PO
214991536|NCT00003969|DRUG|tanespimycin|
214991537|NCT06306391|DRUG|Intravenous naloxone|Nyoxid 1.8 mg nasal spray, solution in single-dose container. Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
214378406|NCT00659984|DRUG|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg \[3.7 MBq/kg\] (minimum dose 1mCi \[37MBq\] but not to exceed 5 mCi \[185 MBq\]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
214378407|NCT00659984|DRUG|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed \> 23 Gy to the kidneys, \> 30 Gy to the liver, or \> 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
214991538|NCT06306391|DRUG|Intranasal naloxone|Naloxone Kern Pharma 1 mg in total (from 0.4 mg/mL injectable solution). Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
214378408|NCT06510530|DIETARY_SUPPLEMENT|Astragalus|Patients in the intervention group will receive capsules of the Astragalus plant (scientific name: Astragalus membranaceus, common name: Huang Qi) at an initial dose of 2 grams (4 capsules) per day with the option of increasing the dose to 4 grams (8 capsules) per day according to researchers' assessment and patient tolerance. The dose was determined by a focus group of 5 herbalists and according to data from the literature on oncology patients. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
214378409|NCT06510530|DIETARY_SUPPLEMENT|Placebo|Placebo capsules that look similar to Astragalus capsules will be given to patients from the control group, between 4 and 8 capsules per day according to the researcher's assessment and tolerability. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
214378410|NCT02648971|PROCEDURE|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
214378411|NCT02648971|PROCEDURE|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
214687213|NCT06019780|OTHER|exercise|"Following exercises will be performed without application of pneumatic cuff~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption Conventional treatment will include: Hot pack 5 mins Maitland grade 3 and 4 mobilization: inferior glide (10reps x3sets), posterior glide (10reps x 3sets), anterior glide (10 reps x 3sets) Home plan: wand exercise, pendulum exercise, wall walking exercise (10reps x 2sets each)"
214991539|NCT06367179|OTHER|Virtual reality and AI use|The experimental group will receive interventions of virtual reality and artificial intelligence wound detecting system.
214991540|NCT06367179|OTHER|Health education leaflet|The control group maintained the traditional pressure injury health education with oral introduction and health education leaflet.
214991541|NCT01772771|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva/buccal swab samples
214991542|NCT01772771|OTHER|Genetic Testing|Correlative studies
214991543|NCT01772771|OTHER|Medical Chart Review|Review of medical records
214991544|NCT06569238|DIAGNOSTIC_TEST|Conventional bacterial culture|Participants will have DFU ulcer tissue collected and sent to the laboratory (per usual care practices) that includes the use of conventional bacterial culture analysis (i.e., plates).
214991545|NCT06569238|DEVICE|Rapid diagnostic group using mNGS technology|Participants will have DFU ulcer tissue collected and have metagenomics sequencing performed. The name of the devices listed for this study are the Illumina MiSeq System with MiSeq Reagent Kit V2 from Illumina and the MinION sequencer (Oxford Nanopore Technologies).
214991546|NCT06306742|OTHER|Open-label placebo|Light pressure manual therapy
214991547|NCT06306742|OTHER|Osteopathic manipulative treatment|Manual therapy
214991548|NCT05970757|DIAGNOSTIC_TEST|Extended MRI|Extension of the brain tumor MRI-protocol
214991549|NCT02171455|DRUG|Dabigatran etexilate low dose|
214378412|NCT03620838|DRUG|oral contraceptive pill, oral progesterone|ovarian endometrioma cyst excision
214378413|NCT02530814|OTHER|Blood Collection|Onetime blood collection.
214378414|NCT03894150|DRUG|F0002-ADC|Every 21 days for 1 cycle, continue treatment until a maximum 16 cycles. Dose Escalating: 0.3 - 4.8 mg/kg
214378415|NCT03862287|DRUG|Lidocaine|See arm description.
214378416|NCT03862287|DRUG|Bupivacaine Hcl 0.5% Inj_#2|See arm description.
214991550|NCT02171455|DRUG|Dabigatran etexilate medium dose|
214991551|NCT02171455|DRUG|Dabigatran etexilate high dose|
214991552|NCT02171455|DRUG|Placebo|
214991553|NCT03885388|DRUG|MTX|multicourse methotrexate chemotherapy
214991554|NCT03885388|DRUG|MTX+ACTD|combination use of methotrexate and actinomycin
214991555|NCT02234180|OTHER|Placebo|Given PO
214991556|NCT02234180|DRUG|Regorafenib|Given PO
214991557|NCT03641729|OTHER|individualized exercise training program|The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
214991558|NCT03401047|DRUG|Estradiol|Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
214991559|NCT00815737|DRUG|rhubarb|14 days of rhubarb
214991560|NCT00815737|DRUG|Placebo|14 days of Placebo
214991561|NCT05561062|DRUG|Atorvastatin 80mg|Atorvastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of its basic lipid-lowering properties
214991562|NCT03862781|PROCEDURE|Right Hemicolectomy|Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
215091411|NCT05216627|DIAGNOSTIC_TEST|Self-administered saliva-based viral testing|Participants will be instructed on how to inactivate the virus and bring their sample to their laboratory's central PCR machine, where they will take an assay test. They will be instructed to collect saliva into a 1.5 milliliter (mL) collection tube containing inactivation buffer (TCEP and EDTA) using a small funnel and inactivate at 95°C for 10 minutes. Participants will then transfer 6ul of saliva into 2 PCR tubes containing amplification master mix and primers, put tubes in a heat block or PCR machine at 65°C for 45 minutes and assess fluorescence using a simple battery-powered fluorescence viewer. Once they assess their sample, they will be instructed to dispose of the saliva sample safely and in accordance with best laboratory practices. No saliva samples will be collected by the research team at any time as part of this study.
215091412|NCT06137872|OTHER|Music Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. In the music group, the pregnant woman, who was assigned to the next group according to randomization during the non-stress test, was allowed to listen to music with disposable headphones for at least 20 minutes until the procedure was completed. At the same time, the mother will be asked to close her eyes and be relaxed. Headphones used to prevent infection were given to the pregnant woman as a gift at the end of the procedure.
214991563|NCT02022917|DRUG|Bevacizumab|Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
215091413|NCT06137872|OTHER|Control Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. During the non-stress test, routine non-stress test was performed on the pregnant control group, which was assigned to the next group according to randomization.
215091414|NCT02544373|DEVICE|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
214378417|NCT01208298|DEVICE|Cold Sore Patch|All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
214687214|NCT02026622|BEHAVIORAL|psychometric tests|NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
214687215|NCT02026622|DEVICE|MRI|ASL, rest f-MRI, FLAIR, white matter hyper intensities load
214991564|NCT06018012|DEVICE|MRS and ABR|Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry
214991565|NCT05522751|DEVICE|DBS|Bilateral DBS electrodes will be implanted into the limbic pallidum of participants with severe alcohol use disorder and advanced but compensated liver disease.
214991566|NCT02251353|PROCEDURE|intervention|hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery
215091415|NCT01927042|BEHAVIORAL|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
215091416|NCT01927042|BEHAVIORAL|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
215091417|NCT04098978|OTHER|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
214378418|NCT05485610|DIETARY_SUPPLEMENT|NMN intervention|NMN capsules (total of 600mg/day) for 3 months
215091418|NCT05734274|OTHER|Probiotics|Probiotics lozenge containing at least 200 million active Limosilactobacillus reuteri.
215091419|NCT05734274|OTHER|Negative control|Sugar-free negative control lozenges.
215091420|NCT02059954|PROCEDURE|Hysterectomy|
214378419|NCT05485610|OTHER|Placebo|NMN-free placebo capsules for 3 months
214687216|NCT02026622|DEVICE|transcranial doppler and TPI|transcranial doppler TPI
214687217|NCT02026622|BEHAVIORAL|explicitative interview|
214687218|NCT05309369|BEHAVIORAL|Preferred Music|Participants will listen to selected music using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
214687219|NCT05309369|BEHAVIORAL|Nature Sounds|Participants will listen to nature sounds using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
214991567|NCT02251353|DRUG|systemic treatment|Systemic therapy
214497460|NCT04584658|OTHER|Voice Symptom Scale (VoiSS)|This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.
214991568|NCT06632301|DEVICE|Primary hip replacement with cementless stem|Total Hip Arthroplasty is today one of the most established surgical orthopaedic procedures worldwide.
214378420|NCT01694602|BIOLOGICAL|(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)|Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
214378421|NCT05379257|COMBINATION_PRODUCT|Random dosage and time of furosemide|Random dosage and time of furosemide, using a designated app
214378422|NCT05067569|BEHAVIORAL|SleepFix mobile application|The SleepFix app is a novel, innovative way to deliver digital brief behavioural therapy for insomnia for adults.
214378423|NCT05067569|BEHAVIORAL|Sleep Health Education|These internet-based modules provide an active control intervention consisting of 3 modules provided bi-weekly. The participant will receive a link to this information as each module is made available. Control participants will have full access to these modules for the duration of the study. They reflect basic educational information regarding sleep health for poor sleepers that is otherwise easily accessible on the internet.
214378424|NCT00955786|DRUG|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
214378425|NCT01347385|PROCEDURE|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
214378426|NCT01347385|PROCEDURE|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
214378427|NCT05936606|DRUG|Clopidogrel monotherapy|Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.
214378428|NCT05936606|DRUG|Tailored anti-platelet therapy|In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
214378429|NCT05675852|OTHER|68-electrode electroencephalography with steady state visual evoked potentials|"Electroencephalography is registered through a 68-electrode electroencephalography while stimuli will be presented at the centre of the screen at a distance of 150cm.~The pattern of visual stimulation is based on the technique of steady state visual evoked potentials. These potentials consist of the presentation of a visual stimulus at a (relatively fast) periodic rate to produce an EEG signal over the occipital cortex exactly at the frequency of stimulation. By varying the value of a parameter of the stimulation (e.g. the contrast of the stimulus) varies. This variation makes it possible to determine the threshold value where an EEG response is perceived, and thus to evaluate visual parameters such as visual acuity, contrast sensitivity or recognition of more complex shapes."
214378430|NCT05631184|BEHAVIORAL|Self-administered acupressure group|Self-administered acupressure treatment group was developed on the basis of previous systematic reviews and clinical studies of acupuncture and acupressure for depression. It has robust theoretical basis of TCM. The acupoints selected are commonly used for depression according to a recent systematic review and recommended by other clinical practice guidelines.
214378431|NCT05631184|BEHAVIORAL|Mental health education group|Mental health education training group was developed based on the materials regarding depression and mental health from the Centre of Health Protection, Department of Health, the Government of Hong Kong SAR and reviewed by a clinical psychologist.
214378432|NCT00429689|PROCEDURE|Saliva sample|
214497461|NCT05533658|DIETARY_SUPPLEMENT|VisionPure Dietary Supplement|Subjects will consume two softgels capsules of the Treatment (VisionPure) once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
214687220|NCT02564848|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
214991569|NCT02653105|BIOLOGICAL|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
214991570|NCT06110793|DRUG|Lenvatinib|20mg orally PO daily
214991571|NCT06110793|DRUG|Pembrolizuma|400mg IV Q6W
214991572|NCT06110793|DRUG|Fulvestrant|500mg IM Q4W
214991573|NCT03441061|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
214991574|NCT02475213|BIOLOGICAL|Enoblituzumab Schedule 1|enoblituzumab is administered by IV infusion once per week for up to 51 doses.
214991575|NCT02475213|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
215091421|NCT03016923|DEVICE|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
215091422|NCT04216407|PROCEDURE|Remote ischemic preconditioning|An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.
214991576|NCT02475213|BIOLOGICAL|Enoblituzumab Schedule 2|Enoblituzumab is administered by IV infusion every 3 weeks for up to 17 doses
214378433|NCT00927355|DRUG|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
214378434|NCT00927355|DRUG|Placebo|"The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
214378435|NCT03842410|DEVICE|Single-Incision Sling|Solyx Single-Incision Sling for correction of stress urinary incontinence done in the office.
214378436|NCT05313750|DRUG|anti-infective therapy sitafloxacin|anti-infective therapy
214378437|NCT05313750|DRUG|anti-infective therapy levofloxacin|anti-infective therapy
214378438|NCT03975764|DIAGNOSTIC_TEST|Collection of fecal sample|Analysis of fecal microbiome
214378439|NCT01800201|BEHAVIORAL|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
214378440|NCT03704532|PROCEDURE|Operative treatment|Open surgical repair of tendon rupture
214378441|NCT03704532|PROCEDURE|Nonoperative treatment|Nonoperative treatment with lower leg orthosis and functional rehabilitation
214378442|NCT03654339|PROCEDURE|root coverage|"Group A: After administration of local anaesthesia using ophthalmic microsurgical knives a V-shaped incision was made in the gingival recession area. the gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then secured with 6-0 absorbable sling suture without tension. the surgical procedure was done with seilar microscope 40X magnification.~Group B: After administration of local anaesthesia using 15 no blade a V-shaped incision was made in the gingival recession area . gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then carefully secured with 4-0 absorbable sling suture"
214378443|NCT02895022|DRUG|Lidocaine 2% adrénalinée|
214991577|NCT02475213|BIOLOGICAL|retifanlimab|Retifanlimab is administered by IV infusion every 3 weeks for up to 17 doses
214991578|NCT04432623|DRUG|Benserazide Only Product|Investigational drug
214378444|NCT02895022|DEVICE|Epidural catheter|
214378445|NCT02895022|PROCEDURE|Caesarean section|
214378446|NCT03819725|DEVICE|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla®) . Interstitial glucose measurements will be recorded during 2-5 days and during meals.
214378447|NCT03733561|DRUG|LY03003|LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
214378448|NCT03733561|DRUG|Neupro 4Mg/24Hr Transdermal Patch|neupro patch
214991579|NCT05453539|DRUG|DSPE-DOTA-Gd Liposomal Injection|Single dose, intravenous infusion
214991580|NCT05236010|DEVICE|rTMS|Transcranial magnetic stimulation is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. During an rTMS session, an electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain being targeted.
214991581|NCT05236010|DEVICE|HD-tDCS|Transcranial direct current stimulation (tDCS), is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain. A constant, low intensity current is passed through two electrodes placed over the head which modulates neuronal activity.
215091423|NCT03381027|PROCEDURE|Baby Massage|Structured massage of the baby
214378449|NCT05811039|DEVICE|Remo-Wax® Oil|Remo-Wax® Oil (abbreviated RWO; GMDN (Global Medical Device Nomenclature) code 46259, Earwax softening oil), is a CE-marked, non-sterile fluid mixture, used for prevention of impacted earwax. Remo-Wax® Oil also moisturizes the skin in the ear canal and reduces itching and irritation caused by the ear canal dryness
214378450|NCT03541044|DRUG|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 2mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
214378451|NCT03541044|DRUG|Nicorette Mini Lozenge|A single dose of a 2 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
214378452|NCT01864863|DRUG|HGP1206|One Bosentan 125 mg tablet
214378453|NCT01864863|DRUG|Traclear|Two Bosentan 62.5 mg tablets
214378454|NCT02190825|DEVICE|NeuGuide device|The NeuGuideTM device is indicated for anchoring sutures to ligaments of the pelvic floor
214378455|NCT04665622|OTHER|Eye-Tracking / Neuropsychological evaluations|Use of Eye-Tracking / Neuropsychological évaluations in 4 groups
214378456|NCT02635724|DRUG|Peramivir|
214378457|NCT02111837|OTHER|Standard infant formula|
214378458|NCT02111837|OTHER|Standard infant formula with PL1|
214378459|NCT02111837|OTHER|Standard infant formula with PL2|
214991582|NCT05236010|OTHER|Attention Process Training|Attention Process Training (APT) is a multi-session exercise designed to help improve the ability to focus on relevant material while ignoring irrelevant distractions. Further, it helps improve the speed of processing information.
215091424|NCT01761500|OTHER|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
215091425|NCT05587166|OTHER|ultrasound guided adductor canal block|ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
214378460|NCT05794516|DRUG|ZB004|ZB004 single doses administered subcutaneously as solution
214378461|NCT05794516|DRUG|Placebo|Placebo single doses administered subcutaneously as solution
214378462|NCT04334421|DEVICE|Composite mesh|Pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) to improve healing and prevent perineal herniation.
214378463|NCT04048863|DEVICE|B. Braun Peripheral Advantage (PA) Program|B. Braun PA includes: Christie VeinViewer® Vision2 , Introcan Safety® IV Catheters, STEADYCare™ Smallbore Extension Set, and the PA Education
214378464|NCT04048863|DEVICE|Hospital Standard of Care|Standard of Care for PIVC access per hospital protocol
214991583|NCT04836936|DEVICE|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. Application of this placebo device will be performed in the same manner as the treatment, but without the expulsion of nitrogen gas.
214991584|NCT04836936|DEVICE|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. The tip of the cryopuncture will be sanitized and placed on each treatment point of the ear, releasing a spurt of nitrogen gas for 2 seconds on each point (6 points total).
214991585|NCT04571138|BIOLOGICAL|SCRI-CAR22v2|Single infusion of SCRI-CAR22v2
214378465|NCT04596137|BEHAVIORAL|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
214378466|NCT00212901|DRUG|High dose ACE-I vs ARB|
214378467|NCT05966935|COMBINATION_PRODUCT|Fenugreek Cumin Powder|Fenugreek and Cumin seeds will be procured from the market. They will be cleaned of debris, winnowed, and grinded to fine powder passed through a mesh size of 30 for metal cleaning. 5g of fenugreek powder and 5g of cumin powder will be packed in packets. Participants in the intervention group will be instructed to consume the powder before breakfast and dinner with a glass of water.
214378468|NCT01930630|DEVICE|Extraesophageal saline injection (ESI)|The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
214378469|NCT01262326|OTHER|Calorie and Carbohydrate Restriction|Carbohydrate Restriction = \<20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
214378470|NCT01446796|DEVICE|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
214378471|NCT01446796|DEVICE|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
214378472|NCT02424591|DRUG|Ketamine|Infusion at a rate of 10 mcg/kg/min
214378473|NCT02424591|OTHER|Placebo|Placebo IV
214378474|NCT01426243|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
214378475|NCT01426243|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
214378476|NCT03354650|DIAGNOSTIC_TEST|blood culture|blood culture to determine causative organisms of neonatal sepsis
214378477|NCT00312702|BIOLOGICAL|Falciparum Malaria Protein 11 with AS02A adjuvant|vaccine
214378478|NCT00003315|BIOLOGICAL|sargramostim|
214378479|NCT00003315|DRUG|liposomal amphotericin B|
214378480|NCT02038686|DEVICE|PFN-A|
214497462|NCT05533658|DIETARY_SUPPLEMENT|Placebo|Subjects will orally consume two softgel capsules of Placebo once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
214497463|NCT05437666|OTHER|Education and booklet|The education program was given both an educational presentation accompanied by a physiotherapist once a week for six weeks and a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
214497464|NCT05437666|OTHER|Booklet|The control group will be given a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
214378481|NCT02948881|DRUG|ibandronate|
214378482|NCT03059875|BEHAVIORAL|Medical consultation for a Standardized Geriatric Evaluation|
214378483|NCT01453348|BIOLOGICAL|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.
214378484|NCT01453348|BIOLOGICAL|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 \& 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
214378485|NCT01453348|BIOLOGICAL|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
214378486|NCT01453348|BIOLOGICAL|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
214378487|NCT04146246|DIAGNOSTIC_TEST|G6PD assay|A test for G6PD deficiency.
214378488|NCT06163352|DRUG|Norepinephrine|The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
214497465|NCT04804566|OTHER|This is a non-interventional study|This is a non-interventional study
214497466|NCT01440166|DRUG|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
214497467|NCT01440166|OTHER|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
214497468|NCT03072888|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation will be apply
215091426|NCT00963768|DRUG|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
215091427|NCT00963768|DRUG|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
214991586|NCT05433467|PROCEDURE|CT-guided localization for micro hepatocellular carcinoma before surgical resection|After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
214378489|NCT02085681|OTHER|Tele-medicine|Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.
214378490|NCT02085681|OTHER|Conventional referral|All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
214497469|NCT01617707|DRUG|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
214497470|NCT01617707|DRUG|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
214497471|NCT03355573|DRUG|Bimekizumab|Bimekizumab at a prespecified dose.
214497472|NCT05335044|DRUG|CKD-331|QD, PO
214497473|NCT05335044|DRUG|EX5619|QD, PO
214497474|NCT04730206|DRUG|Camostat|100 milligram tablets
214497475|NCT04730206|DRUG|Placebo|oral tablets, identical in size and shape
214497476|NCT04730206|DRUG|Molnupiravir|200 milligram tablets
214497477|NCT01025167|DIETARY_SUPPLEMENT|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
214497478|NCT01025167|DIETARY_SUPPLEMENT|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
214497479|NCT01567605|DRUG|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
214497480|NCT01567605|OTHER|Placebo lubricant|Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
214497481|NCT02534285|DEVICE|hearing protection|Attenuation of hearing during surgery
214991587|NCT02537548|OTHER|Laboratory Biomarker Analysis|Correlative studies
214991588|NCT02537548|PROCEDURE|Retroperitoneal Lymph Node Dissection|Undergo RPLND
214378491|NCT00602914|DEVICE|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
214378492|NCT00602914|DEVICE|MicronJet|MicronJet, Intradermal Injection
214378493|NCT01673893|DEVICE|ClearWay™ Rx catheter|
214378494|NCT04919902|PROCEDURE|Electric cardioversion|Electric cardioversion in short sedation according to established clinical practice and indications
214497486|NCT00059826|BIOLOGICAL|interferon-alfa-2b|IV
214497487|NCT00059826|DRUG|cisplatin|IV
214497488|NCT00059826|DRUG|5-fluorouracil|IV
214991589|NCT02623712|OTHER|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
214378495|NCT02999425|OTHER|Education|Educational intervention
214497489|NCT00059826|RADIATION|radiation therapy|
214497490|NCT06463145|DIETARY_SUPPLEMENT|Vanizem|Aframomum melegueta seed extract standardized to 10% of total Vanilloid and at least 1.5% of 6-paradol
214497491|NCT06463145|DIETARY_SUPPLEMENT|Placebo|Food grade Maltodextrin 12
214497492|NCT04191824|OTHER|Timing of return of results|Participants will be randomized to immediate versus delayed APOL1 return of results
214497493|NCT00821301|DRUG|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
214497494|NCT03631407|DRUG|Vicriviroc|Vicriviroc tablets administered orally, QD at dose level 1 or 2.
214497495|NCT03631407|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1.
215091428|NCT03172130|DEVICE|Straight CPAP|
215091429|NCT03172130|DEVICE|Sham CPAP|
214991590|NCT02623712|OTHER|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
214378496|NCT04821128|OTHER|Radiologic and pathological review.|"We will analyse the pre operative scannographic and MRI (if available) images, and the post operative pathological analyses.~The scanners will be reviewed by 2 well trained clinicians (one head and neck radiologist and one head and neck surgeon).~Then we will analyse the correlation between the radiological and the pathological analysis."
214378497|NCT03432884|DRUG|BGB-3111|Subjects will receive BGB-3111
214378498|NCT03432884|DRUG|Placebo|Subjects will receive Placebo
214378499|NCT03432884|DRUG|Moxifloxacin|Subjects will receive Moxifloxicin
214378500|NCT03763916|PROCEDURE|Ureteric dissection|clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
214378501|NCT03763916|PROCEDURE|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy \[Karl storz\] is done to identify the ureteric orifices. ureteric catheters \[Roche\] are inserted followed by the insertion of Foley's urethral catheter
214378502|NCT03763916|PROCEDURE|Cesarean hysterectomy|lateral dissection of the uterus is completed from the pelvic side wall, followed by very CAREFUL BLADDER DISSECTION. Finally clamping of the uterine vessels is done below the level of the placenta with or without complete removal of the cervix. Closure of the uterine stump is performed followed by CAREFUL HEMOSTASIS then closure of the abdomen is performed after leaving two wide bore drains
214378503|NCT01412190|DEVICE|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
214378504|NCT01412190|OTHER|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
214378505|NCT04359771|DEVICE|Yellow micro-pulse laser|applying 577-nm yellow laser in a micro-pulse mode over the macular area including the fovea
214378506|NCT04359771|DEVICE|Diode micro-pulse laser|applying 810-nm infra-red diode laser in a micro-pulse mode over the macular area including the fovea
214378507|NCT03629860|PROCEDURE|Atrophic maxillary alveolar ridge augmentation|Autogenous bone blocks from chin and ascending ramus are obtained and used for reconstruction of atrophic maxillary ridges
214378508|NCT04122391|OTHER|sound level volume|Noise level during cardiac arrest
214378509|NCT00257959|DRUG|amiodarone beta blocker sotalol|
214378510|NCT05296291|DEVICE|High-translucent monolithic zirconia Bridge|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
214687221|NCT04759248|DRUG|Atezolizumab + Trastuzumab + Vinorelbine|"* Atezolizumab IV 1200 mg in combination with~* Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and~* Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV."
214991591|NCT06031272|DRUG|3BNC117-LS-J|Administered by intravenous (IV) infusion
214991592|NCT06031272|DRUG|10-1074-LS-J|Administered by intravenous (IV) infusion
214991593|NCT06031272|DRUG|Placebo for 3BNC117-LS-J|Administered by intravenous (IV) infusion
214991594|NCT06031272|DRUG|Placebo for 10-1074-LS-J|Administered by intravenous (IV) infusion
214991595|NCT05555017|PROCEDURE|PSMA-radioguided surgery|Approximately 15-24 hours prior to surgery, 400-600 Megabecquerel (MBq) of 99mTc-PSMA-I\&S will be intravenously administered to the patient at the Nuclear Medicine department. Following this injection patients will be allowed to return home, and then present for their 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery the next day.
214991596|NCT05555017|DRUG|ADT|Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.
214991597|NCT00505921|DRUG|Campath-1H|3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
214991598|NCT00505921|DRUG|G-CSF|10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
214991599|NCT00505921|DRUG|GM-CSF|250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
214991600|NCT00505921|DRUG|BCNU|300 mg/m2 IV over 1 hour on day -6
214378511|NCT05296291|DEVICE|Zirconium oxide ceramics Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
214991601|NCT00505921|DRUG|Stem Cell Transplant|Stem cell infusion on Day 0.
214991602|NCT00505921|DRUG|Preparative Regimen for Allogenic Stem Cell Transplantation|Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
214991603|NCT00505921|DRUG|Cytarabine|200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
214991604|NCT00505921|DRUG|Etoposide|200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
214991605|NCT00505921|DRUG|Melphalan|140 mg/m2 IV on day -1.
214991606|NCT00505921|DRUG|Campath|15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
214991607|NCT00505921|DRUG|Fludarabine|30 mg/m2 IV/day (days -6 to -4)
214991608|NCT00505921|DRUG|Cyclophosphamide|750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
214991609|NCT00505921|RADIATION|Low dose total body irradiation|Low dose total body irradiation of 2 Gy day 0.
214991610|NCT04011852|DEVICE|Electrical Impedance tomography|Monitoring with Electrical impedance tomography during spontaneous breathing trials on T-piece in children
214378512|NCT05296291|DEVICE|Metal-ceramic Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
214378513|NCT05330416|DEVICE|Group Reference Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration and drainage with a seton.
214378514|NCT05330416|OTHER|Group Test Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration without drainage via a seton.
214378515|NCT03427190|OTHER|APSOM vs Control|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
214378516|NCT04005027|OTHER|Intermittent graded exercise test|Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
214378517|NCT03495804|DRUG|polyethylene glycol|Experimental group was given polyethylene glycol as oral contrast agent.
214378518|NCT03495804|DRUG|mannitol|Active comparator group was given mannitol as oral contrast agent.
214991611|NCT05732714|BEHAVIORAL|Healthy lifestyle behaviors around the time of surgery|Healthy lifestyle choices, such as improving diet and beginning to exercise around the time of surgery and it's influence on an individual's long term risk of developing cardiovascular disease.
214991612|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).
214378519|NCT01405755|BEHAVIORAL|Appropriate complementary feeding messages|Messages delivered through National Vaccine Program and radio
214497496|NCT04428710|OTHER|assessment with psychometric questionnaire|"At the initial genetic consultation patients are informed about hereditary cancer risk and the genetic testing process. At the second genetic counseling appointment, after patients done tests, all participants were informed about the study purpose, and they signed the informed consent before the psychometric assessment. Those patients who agreed to participate, they were given the questionnaires to fill in. Also, background characteristics were reported including age, marital relationship, level of education, psychiatric antecedents.~The time for completion the self-report measures was about 10 minutes. The psychometric assessment was occurred prior to delivering the results of genetic testing."
214497497|NCT01378416|DRUG|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine.
214497498|NCT04592185|DEVICE|Fenestrated Anaconda™ Device|Treatment of complex abdominal aortic aneurysms
214497499|NCT04305821|OTHER|Dosage of S100β protein|Dosage of S100β protein
214497500|NCT04769596|DEVICE|NEUROMARK™ System|The NEUROMARK™ System is designed to deliver energy to the nasal cavity intended to interrupt nasal nerves aimed to reduce symptoms related to Chronic Rhinitis.
214497501|NCT04769596|DEVICE|Sham Device|A Sham device will be used in the nasal cavity
214991613|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, high bioavailability|Participants will consume a protein meal consisting of heated oat protein concentrate (amount based on body weight, 0.3g of protein/kg bodyweight).
214991614|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole yellow peas (amount based on body weight, 0.3g of protein/kg bodyweight).
214991615|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, high bioavailability|Participants will consume a protein meal consisting of heated pea protein isolate (amount based on body weight, 0.3g of protein/kg bodyweight).
214991616|NCT06142084|DIETARY_SUPPLEMENT|Protein-free meal|Participants will consume a protein-free meal to correct analyses for endogenous protein losses.
214991617|NCT06564974|DRUG|Vamorolone|"Patients on treatment with Vamorolone (AGAMREE®) Dosage: Oral Suspension: 40 mg/mL . Per package insert, the recommended dosage is 6 mg/kg taken orally once daily, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.~Decrease dosage gradually when administered for more than one week."
214991618|NCT01644214|OTHER|6 month follow up for pessary check in the clinic setting|The standard of care is considered to be pessary checks every 3 months, therefore those that are checked every 6 months will be considered to be in the intervention group.
214991619|NCT06547554|DRUG|Xeruborbactam|Experimental
214991620|NCT06547554|DRUG|Cefiderocol|Experimental
214991621|NCT06547554|DRUG|Xeruborbactam/Cefiderocol|A combination of Xeruborbactam and Cefiderocol.
214991622|NCT06547554|DRUG|Dextrose 5% in water|Placebo
214991623|NCT05169983|DIAGNOSTIC_TEST|iPad-Based Visual Field Test|In this study, the investigators aim to teach the participants to use the the visualFields easy App . The investigators will be using the app in the clinic with the patients watching, demonstrating its use and discussing and explaining its functions. Having observed how to use the application, the participant will then complete the visual field assessment.
214991624|NCT01325441|DRUG|BBI608|
214991625|NCT01325441|DRUG|Paclitaxel|
214991626|NCT05906862|DRUG|AMT-253|Administered intravenously
214991627|NCT06415721|DEVICE|Active Transcranial Magnetic Simulation|1 session of active continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. TMS will be delivered using the Magventure MagPro X100.
214991628|NCT06415721|DEVICE|Sham|1 session of sham continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. The MagVenture MagPro x100 is capable of administering a sham stimulation. The reverse side of the TMS coil is plated with a magnetic shield such that electromagnetic energy cannot stimulate the brain. The device offers compatibility with Transcutaneous Electrical Nerve Stimulation devices such that titrated electrical pulses can be delivered to the scalp location to mimic the sensation of a TMS pulse without stimulating the brain.
214991629|NCT00642486|OTHER|Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)|portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
214991630|NCT00642486|OTHER|Standard polysomnography (PSG)|laboratory-based testing
214991631|NCT02040220|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|2 mg of Eylea will be treated per one injection at more than one months interval usually.
214497502|NCT01141803|DIETARY_SUPPLEMENT|Apples|550g of apples/day
214497503|NCT01141803|DIETARY_SUPPLEMENT|Apple pomace|22g apple pomace/day
214497504|NCT06270524|PROCEDURE|Blood sampling|Blood sampling will be taken for further analysis
214991632|NCT05653271|DRUG|Cyclophosphamide|Lymphodepleting agent
214991633|NCT05653271|DRUG|Fludarabine|Lymphodepleting agent
214991634|NCT05653271|DRUG|ACE1831|Allogeneic gamma delta T (gdT) cell therapy
214991635|NCT05653271|DRUG|Obinutuzumab|Anti-CD20 monoclonal antibody
214991636|NCT04641351|DRUG|Zilretta Injectable Product or Placebo|The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
214991637|NCT05681819|DRUG|SHR-1707|Multiple-ascending Dose
214991638|NCT05681819|DRUG|SHR-1707 placebo|Multiple-ascending Dose
214991639|NCT05779748|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
214991640|NCT02382939|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
214991641|NCT02382939|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
214991642|NCT06399718|DRUG|BOTOX|Intramuscular Injections
214991643|NCT06399718|DRUG|Placebo|Intramuscular Injections
214991644|NCT02438579|OTHER|Nasal Irrigation & Gargling|Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
214991645|NCT06133257|PROCEDURE|Goal-Directed Fluid Therapy guided by Inferior Vena Cava Collapsibility Index|Measuring Inferior vena cava(IVC) diameter using ultrasound then calculation Inferior vena cava(IVC) collapsibility index and administer fluid accordingly.
214991646|NCT06133257|PROCEDURE|standard fluid management|standard fluid management
214991647|NCT05822752|DRUG|Budigalimab|Intravenous (IV) Infusion
214991648|NCT05822752|DRUG|Livmoniplimab|Intravenous (IV) Infusion
214991649|NCT05822752|DRUG|Lenvatinib|Oral: Capsule
214991650|NCT05822752|DRUG|Sorafenib|Oral: Tablet
214991651|NCT02026297|DRUG|Tranexamic Acid|1 gram IV over 10 minutes
214991652|NCT02026297|DRUG|Placebo; Normal Saline|0.9% Normal Saline
214991653|NCT05383209|DRUG|EYP-1901|EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle. Each EYP-1901 IVT insert has been designed to deliver vorolanib into the vitreous humor for approximately 6 to 9 months.
214991654|NCT05383209|OTHER|Sham IVT|Sham injections will be used to maintain masking of investigational EYP-1901 therapy for study subjects.
214991655|NCT06411067|DRUG|Erenumab|Monthly injection of erenumab for fibromyalgia
214991656|NCT06411067|DRUG|Saline|Monthly injection of 0.9% saline for control
214497505|NCT01760382|DEVICE|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
214991657|NCT01582451|DRUG|LY2605541|
214378520|NCT05068739|PROCEDURE|PA-EMR|Standard oval-shaped, braided wire polypectomy snare with 10 mm or 20 mm loop diameter will be used. With the duodenoscope in a semi-long position, the tip of the snare will be anchored just below the transverse fold of the ampulla and opened above-downwards fashion until the orifice will be seen. The orifice will be strictly preserved to avoid the risk of PEP and approximately the upper two-thirds of the ampullary mound will be grabbed by the snare. The direction and the depth will be controlled by combined movements of the elevator and wheels of the duodenoscope. After removal of the mucosa, the wall of choledochus will be seen clearly and standard wire-guided cannulation (WGC) will be performed. If cannulation can not be achieved with WGC, an additional incision will be performed to the wall of the choledochus with a needle knife.
214378521|NCT05068739|PROCEDURE|NKF|The needle knife will be placed at the junction of the upper one-third and lower two-thirds of the papillary roof (bulging portion). Minimal, superficial incisions will be made in the 11-12 o'clock direction. The length of the fistulotomy will be at the endoscopist's discretion, depending on the shape of the papilla. The cut will be extended until bile juice, the pinkish bile duct mucosa, and/or the bulging of the white sphincter of the Oddi's muscle is visible.
214497506|NCT00415649|BIOLOGICAL|VRC-HIVDNA016-00-VP|
214497507|NCT00415649|BIOLOGICAL|VRC-HIVADV014-00-VP|
214991658|NCT01582451|DRUG|Insulin glargine|
214991659|NCT05114174|OTHER|mami-educ|The intervention corresponds to sending 3 messages a week through Telegram, with nutritional information, for 12 consecutive weeks (a different nutritional topic each week). The messages address the three domains of learning, cognitive, affective, and psychomotor for each topic.
214991660|NCT06270719|GENETIC|Delandistrogene Moxeparvovec|No study medication will be provided by the sponsor during this study.
214991661|NCT06270719|DRUG|Standard of Care|No study medication will be provided by the sponsor during this study.
214991662|NCT01298258|DRUG|Aliskiren|Aliskiren 150mg
214991663|NCT02229838|DRUG|BIBB 1464 MS tablet|
214991664|NCT02229838|DRUG|BIBB 1464 MS solution|
214991665|NCT02229838|DRUG|BIBB 1464 MS placebo|
214991666|NCT02229838|OTHER|Standard dinner|
214991667|NCT03954171|OTHER|Patients treated with platinum based-chemotherapy|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~* before treatment initiation (blood sample),~* during hospitalisation for surgery (blood sample),~* during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study."
214991668|NCT05472974|DEVICE|Use of a powered alternating pressure air mattress|Patients with a medium to high risk of pressure injury, without pressure injury, up during the day, will ly a on a specific P-APAM (DOMUS 4 /AUTO)
214991669|NCT02035124|DRUG|BKM 120|
214991670|NCT02035124|DRUG|Cabazitaxel|
214991671|NCT04210518|OTHER|Neuromuscular training|This intervention consisted of a supervised multimodal exercise protocol addressing different aspects of balance including static and dynamic tasks on the injured ankle. The training program comprised 6 exercises that were progressively adapted depending on the patient's execution controlled by an expert physiotherapist
214991672|NCT04210518|OTHER|Stroboscopic glasses|Patients included in this group performed the same protocol described in the balance training group with the addition of the stroboscopic glasses during the intervention.
214991673|NCT01200641|DRUG|Melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
214991674|NCT01200641|DRUG|Gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
214991675|NCT01200641|DRUG|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
214991676|NCT00717886|RADIATION|isosulfan blue dye|"At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies day of mapping for patient convenience."
214991677|NCT00540917|PROCEDURE|cooling spray during laser treatment|skin temperature measurement
214991678|NCT00716417|DRUG|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
214497508|NCT00415649|BIOLOGICAL|Vaccine placebo|Placebo comparator
214497509|NCT02008669|PROCEDURE|Blood sampling|A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
214497510|NCT02008669|OTHER|Gustatory sensitivity test using Taste strips|"16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.~Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)"
214991679|NCT00716417|DRUG|BIBW 2992|low to high dose, daily
214991680|NCT01520753|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
214991681|NCT01520753|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast and lunch
214991682|NCT01520753|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at dinner
214991683|NCT01553851|DRUG|GSK1120212|Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
214991684|NCT01369433|DRUG|Tivozanib + paclitaxel|Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
214991685|NCT01369433|DRUG|Tivozanib + temsirolimus|Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
214991686|NCT01369433|DRUG|Tivozanib|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
214991687|NCT01369433|DRUG|Tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
214991688|NCT01369433|DRUG|Tivozanib + capecitabine|Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
214991689|NCT01369433|DRUG|Tivo|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
214991690|NCT04068532|DRUG|Placebo|Administered as specified in the treatment arm.
214991691|NCT04068532|DRUG|BIIB104|Administered as specified in the treatment arm.
214991692|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie without probiotic|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
214991693|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie with probiotic added post fermentation|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
214991694|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie with probiotic added pre-fermentation|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
214991695|NCT01399996|DIETARY_SUPPLEMENT|A capsule containing the probiotic|A capsule taken daily will provide between 10x\^y9 and 10x\^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
214991696|NCT04144816|OTHER|Not applicable (no intervention)|Not applicable (no intervention)
214991697|NCT05557214|BEHAVIORAL|Audit and Feedback Letter|Physicians in the Audit and Feedback Letter Arm will receive an initial letter indicating their high prescriber status with guidance on reducing unnecessary antimicrobial use. They will also receive a follow-up letter at the 6 month mark indicating any change in prescribing habits. There will be a study closure letter mailed at the 12 month mark.
214991698|NCT01200914|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
214991699|NCT01200914|PROCEDURE|PTA alone without use of the GORE VIABAHN|Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
214991700|NCT05093868|DEVICE|Electrographic Flow Mapping|Electrographic Flow Mapping will be collected
214991701|NCT05319678|OTHER|evaluation with Meludia music software|"Measurement instruments:~1. \- MuMu Questionnaire~2. MuRQoL Questionnaire~3. Questionnaire for subjects aged 6-17 years~4. Music tool Meludia (www.meludia.com)~5. Acoustic analysis of the voice: the Praat programme~6. Audiological tests"
214378522|NCT00545350|OTHER|Fall prevention exercise program|"Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.~The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
214991702|NCT06342882|DIAGNOSTIC_TEST|dysphagia assessment|Twenty-one patients underwent the Modified Barium Swallowing Study and Swallowing Ability and Function Evaluation (SAFE) assessments. The Penetration Aspiration Scale (PAS) and SAFE physical examination, oral phase and pharyngeal phase domains was used to determine the dysphagia severity.
214991703|NCT06342882|DIAGNOSTIC_TEST|functional independence level|Functional independence was evaluated by the Functional Independence Measurement (FIM) motor and cognitive domains.
214378523|NCT01991821|DRUG|APD421|
214378524|NCT01991821|DRUG|Placebo|
214378525|NCT00480896|DRUG|tacrolimus ointment|Topical application
214378526|NCT00480896|DRUG|Placebo ointment|Topical application
214378527|NCT00390195|DRUG|RAD001 (everolimus)|Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily
214378528|NCT00390195|DRUG|RAD001 (everolimus)|Arm 2: 20, 30, 50 or 70 mg of RAD001 daily
214378529|NCT00363610|DRUG|Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma|
214378530|NCT00326638|RADIATION|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"IMRT using Helical Tomotherapy\* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks~* Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23~* Boost IMRT to Prostate 3,200 cGy/16"
214378531|NCT00326638|OTHER|Arm A: 3D-Conformal Radiation|"3DCRT 7800 cGY/39 Fractions/ STD Technique\* once daily Monday to Friday for 8 weeks~* Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~* Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
214378532|NCT05172895|OTHER|Presence, prevalence, severity, and morphological characteristics of anemia|Evaluation of the presence, prevalence, severity, and morphological characteristics of anemia, trying to define, when possible, the underlying pathogenetic mechanisms, paying particular attention to the characteristics of menstrual cycles, the iron, folate and vitamin B12 metabolism, any chronic inflammatory state, and thyroid hormones.
214378533|NCT05172895|OTHER|Effect of gluten-free diet on anemia|Evaluation of the therapeutic responses (i.e., improvement/regression) of anemia after at least one year of GFD.
214378534|NCT00187915|DRUG|Mycophenolate mofetil + Tacrolimus|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
214497511|NCT02008669|OTHER|Questionnaires|"Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):~* Fatigue (EMIF-SEP)~* Dysphagia (DYMUS)~* Food intake (semi-structured questionnaire)~* Depression (BDI-II)~* Daily energy expenditure (NAP)~* Visual analog scale to study quality of sleep"
214991704|NCT05312203|OTHER|the App|The App provides content for mobile-based stress relief that can be used on most Android and iOS-based mobile devices. Content for stress relief consists of three modules; meditation, cognitive approach, and relaxation sounds. Additionally, the App includes the module for objective stress monitoring. The APP was originally designed and developed in Korean, but English, Chinese, and Japanese versions are also available. For use in the treatment environment, the manufacturer also provides a service that allows therapists to check their patients' application usage and their stress level measured by the stress monitoring module.
214991705|NCT01807455|DEVICE|Restylane Vital Lidocaine|
214378535|NCT00187915|DRUG|Mycophenolate mofetil + Cyclosporin|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
214378536|NCT00890175|DRUG|Inhaled loxapine @ 0 & 10 h|10 mg, 2 doses, 10 hours apart
214378537|NCT00890175|DRUG|Inhaled placebo @ 2 & 10 hours|placebo, 2 doses, 10 hours apart
214378538|NCT01537679|BEHAVIORAL|Kirtan Kriya meditation|Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.
214378539|NCT01537679|BEHAVIORAL|Relaxation|Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
214991706|NCT04402242|DEVICE|Bispectral index|Anesthesia monitoring
214991707|NCT04402242|DEVICE|Bispectral index + NOL index|Anesthesia monitoring
214991708|NCT00487188|DRUG|Enfuvirtide|90 mg subcutaneous injection twice a day
214991709|NCT00487188|DRUG|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
214991710|NCT02321527|DRUG|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
214991711|NCT02321527|DEVICE|Contrast-Enhanced Ultrasound (CEUS)|Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
214378540|NCT04678921|DRUG|TJ210001|human anti-C5aR monoclonal antibody
214378541|NCT01543412|DRUG|FOLFIRI|Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
214497512|NCT04729855|DIAGNOSTIC_TEST|PBMCs and Tissue expression of HOTTIP ,EIF4EBP1 and serum SNP HOTTIP rs1859168|5 ml fresh blood sample, normal and CRC tissue
214497513|NCT01411566|BEHAVIORAL|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
214497514|NCT01411566|BEHAVIORAL|regular treatment|regular treatment
214497515|NCT03746938|DEVICE|VB-C01|Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
214497516|NCT03042741|BIOLOGICAL|atherosclerosis vaccine|Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue
214378542|NCT01852331|DRUG|PGD granules|The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
214378543|NCT01852331|DRUG|Placebo|The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
214378544|NCT04581200|BEHAVIORAL|Lift|The intervention is a mobile app-based mindfulness training program designed to be used over a 1-month period.
214378545|NCT03511417|DEVICE|over-the-counter hearing device|Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
214378546|NCT01423786|DIETARY_SUPPLEMENT|Early Oral Nutrition|Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
214991712|NCT02321527|PROCEDURE|Biopsy + Radioactive Seed Placement|Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
214991713|NCT02321527|BEHAVIORAL|Phone Call|Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
214378547|NCT03584503|OTHER|Suction Above Cuff Endotracheal Tube|Suction Above Cuff Endotracheal Tube (SACETT) has a dorsal port above the cuff designed to allow continuous or intermittent suctioning of secretions from the subglottic space
214497517|NCT03042741|BIOLOGICAL|Placebo pills|Half of the patients will be randomly assigned to receive placebo pill
214497518|NCT01201772|DRUG|Prasugrel|Prasugrel 10mg, 30mg, or 60mg
214497519|NCT05314049|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
214991714|NCT03315637|PROCEDURE|Fetoscopic repair of spina bifida|Fetoscopic intrauterine repair of open spina bifida
214991715|NCT04718701|DRUG|Anlotinib+Toripalimab+Nab-paclitaxel|Using combination treatment of anlotinib (12 mg, po. qd.) plus toripalimab (240 mg, ivgtt. q3w.) and nab-paclitaxel (260 mg/m2, ivgtt, q3w) with every 3 weeks as a cycle.
214378548|NCT05829291|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|"Alpha DaRT Applicators (the Alpha Needle Applicator, the Alpha Flex Applicator, and the Alpha Plant Applicator) and radioactive sources named Alpha DaRT Seeds - Ra-224 coated onto stainless steel tubes inserted into the tumor. Collectively, the Alpha DaRT Applicators and Seeds are referred to as the Alpha DaRT Device."
214378549|NCT04559282|DEVICE|New Sound Processor|The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.
214991716|NCT04818801|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|The spike (S) protein is the main surface antigen of SARS-CoV-2, mediates entry of SARS CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The RBD interacts with ACE2 and can generate potent neutralizing anti-RBD antibodies.
214991717|NCT04818801|OTHER|Placebo|Normal saline (0.9% sodium chloride solution),
214991718|NCT00484510|DRUG|Ascorbic acid (Vitamin C)|Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
214991719|NCT00484510|DRUG|placebo|Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
214991720|NCT01882452|BEHAVIORAL|Memory Specificity Training|This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
214991721|NCT01882452|BEHAVIORAL|Education and Support|The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
214991722|NCT01241149|PROCEDURE|anti-reflux surgery|Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
214991723|NCT02196831|DRUG|tesamorelin|
214991724|NCT02196831|DRUG|Placebo|inactive substance that looks like tesamorelin
214991725|NCT03606161|OTHER|Questionnaire Administration|Ancillary studies
214991726|NCT03606161|PROCEDURE|Transcranial Magnetic Stimulation|Undergo nrTMS
214991727|NCT00149643|DRUG|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
214991728|NCT00149643|OTHER|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
214991729|NCT03335527|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
214991730|NCT03335527|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
214991731|NCT05340699|DEVICE|Defocus Distributed Multi-point lens|Wear DDM lens
214991732|NCT05340699|DEVICE|Single vision lens|Wear single vision lens
214378550|NCT04325087|DEVICE|iTBS|Administration of an iTBS protocol over the dlPFC
214378551|NCT04325087|DEVICE|Placebo iTBS|Administration of a placebo TMS protocol over the dlPFC
214378552|NCT02112760|OTHER|specific stabilization exercise|The specific stabilization exercise refers to an exercise that targets the deep trunk muscle, including the multifidus and transversus abdominis with ultrasound feedback.
214378553|NCT00622713|DRUG|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm\^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\^2.
214378554|NCT04866121|PROCEDURE|Acupuncture|A standardized acupuncture protocol will be administered
214378555|NCT03051022|DRUG|Dexamethasone 8 mg|Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
214378556|NCT03051022|DRUG|Morphine 2 mg|Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
214378557|NCT01462162|DRUG|Tocilizumab|
215091430|NCT05445895|DRUG|Renexin CR 200/160mg|Renexin CR 200/160mg will be added to Aspirin 100mg
214378558|NCT03853460|PROCEDURE|epidural catheter|ultrasound low frequency probe will be used to determine the depth of the posterior complex to assists placement of midline thoracic epidural
214378559|NCT03853460|PROCEDURE|nerve block catheter|ultrasound guided placement of bilateral quadratus lumborum catheters
214378560|NCT03485911|DRUG|BCX7353 capsules|BCX7353 oral capsules administered once daily
214378561|NCT03485911|DRUG|Placebo oral capsule|Matching oral capsules administered once daily
214378562|NCT04757818|OTHER|0.07% cetylpyridinium chloride (CPC) in mouthwash|A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.
214378563|NCT04757818|OTHER|Distilled water with the same colorant as the experimental product|A mouthwash and gargles with 15 ml of distilled water for 1 minute
214378564|NCT00282724|DRUG|Liarozole|
214497520|NCT05314049|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
215091431|NCT05445895|DRUG|Plavix 75mg|Plavix 75mg will be added to Aspirin 100mg
214378565|NCT05383664|OTHER|Ultra Violet Light Exposure|Subjects will stand at the determined distance from the UV lamps facing towards them to achieve full body UV exposure. They will stand for the time indicated to achieve the appropriate dose. Each exposure will range from about 1 minute to 4.5 minutes to deliver a dose ranging from 0.22J/cm2 to 0.88J/cm2. Subjects will then rotate to irradiate their back side for the same time to achieve the same dose. On the second visit clinical examination will be conducted for erythema. If no erythema is apparent, the dosage on subsequent visits may increase to the max of 0.88 J/cm2.
214991733|NCT01654887|OTHER|Lung Ultrasound|Six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
215091432|NCT02218593|DEVICE|WREX orthosis|Upper extremity exoskleton used to assist movement
214378566|NCT03775226|DEVICE|ChampioNIR® SFA Stent|The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.
214378567|NCT00909480|DRUG|insulin detemir|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
214378568|NCT00909480|DRUG|insulin glargine|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
214378569|NCT01215357|DRUG|Ecopipam|50mg tablets
214378570|NCT00861601|DRUG|eltrombopag 12.5 milligrams (mg) tablet|eltrombopag 12.5 mg tablet once a day
214378571|NCT00861601|DRUG|eltrombopag 25 mg tablet|eltrombopag 25 mg tablet once a day
214378572|NCT00355017|PROCEDURE|BNP-guided care in addition to multidisciplinary management|
214378573|NCT04978259|DRUG|Remdesivir|Intravenous remdesivir during hospital stay up to 10 days in addition to standard care.
214378574|NCT05782205|PROCEDURE|Severe complications following radical gastrectomy|The respondents are limited to surgeons who had previously experienced severe complications following radical gastrectomy as chief surgeons.
214378575|NCT00977405|DEVICE|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
214378576|NCT00098163|BIOLOGICAL|ALVAC-HIV vCP1521|One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
214378577|NCT00098163|BIOLOGICAL|ALVAC HIV-1 vCP1521|One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.
214378578|NCT00002159|DRUG|Itraconazole|
214378579|NCT00002159|DRUG|Amphotericin B|
214378580|NCT04599738|OTHER|Wheat muffin|Participants consumed a control muffin made of wheat flour.
214378581|NCT04599738|OTHER|Finger millet grain muffin|Participants consumed a test muffin made of finger millet grain and wheat flour.
214378582|NCT04783064|PROCEDURE|Interscalene brachial plexus block|Interscalene brachial plexus block is performed at ipsilateral side of the affected shoulder.
214378583|NCT04191109|OTHER|Observational study|This is an observational study in which the amount of therapy performed during the rehabilitation program will be registered.Data regarding feasibility and safety of the program will be also recorded. Indeed, functional, cognitive and quality of life outcomes will be assessed.
214378584|NCT04990206|BEHAVIORAL|TranS-C|"TranS-C will be provided in eight weekly, one-on-one 50-minute sessions delivered remotely by two-way video conferencing. Each week will include goal setting and homework assignments which will be reviewed in the following session.~The sessions will include information on sleep and circadian rhythms, behavioral change and motivation, and goal setting. The topics covered in the sessions include establishing regular sleep-wake times, learning a wind-down route, learning a wake-up routine, improving daytime functioning, correcting unhelpful sleep-related beliefs, and maintenance of behavior change."
214378585|NCT04180241|PROCEDURE|POEM|Peroral endoscopic myotomy
214378586|NCT05647863|OTHER|Functional Cognitive and Sensory Treatment (F-CaST)|F-CaST, a client-centered care, is a functional cognitive sensory intervention focusing on improving Executive Function (EF) and sensory modulation impairments using a modification of the Functional and Cognitive Occupational Therapy Treatment.
214378587|NCT02410993|PROCEDURE|CABG surgery|
215091433|NCT03878901|COMBINATION_PRODUCT|high risk warm|Bair HuggerTM Forced-air Warming System to 30min pre- and entire operation warming, combined fluid warming
215091434|NCT03878901|COMBINATION_PRODUCT|moderate risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System cotton blanket warming and fluid warming through operation
215091435|NCT03878901|COMBINATION_PRODUCT|low risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System and cotton blanket warming through operation
215091436|NCT03878901|OTHER|passive warming|cotton blanket warming through operation
215091437|NCT01384032|DIETARY_SUPPLEMENT|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
214378588|NCT05458167|DEVICE|Hedia Diabetes Assistant bolus calculator with a physical activity module|Hedia Diabetes Assistant bolus calculator with a physical activity module is a software device that calculates an insulin bolus based on blood glucose, carbohydrates and physical activity.
214497521|NCT05314049|DEVICE|inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
214991734|NCT01654887|RADIATION|Chest X-Ray|Posterior-Anterior and lateral views of the chest via chest radiography followed by a lung ultrasound which is comprised of six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
214378589|NCT06363058|OTHER|ES Cycling Training|Implementing Electrical Stimulation (ES) Cycling combined with priming strategies to enhance motor learning tasks
214378590|NCT01544959|DRUG|fentanyl|Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
214497522|NCT05314049|DEVICE|Heat Therapy|superficial heating for 20 minutes
214497523|NCT02550951|PROCEDURE|lymphangiography|
214497524|NCT04867824|DIETARY_SUPPLEMENT|Case (use of inhaled vanilla essential oil)|Use of inhaled vanilla essential oil during frenotomy for a tongue-tie
214991735|NCT01730313|DRUG|Pyridoxine|
214991736|NCT01730313|DRUG|Sodium Valproate|
214991737|NCT01730313|DRUG|Phenytoin|
214991738|NCT01730313|DRUG|Placebo|
214991739|NCT02632318|DEVICE|Light|30 minutes of dawn simulation
214991740|NCT02722109|OTHER|No intervention|No intervention will be done
214991741|NCT04562558|DRUG|Methotrexate|50mg intramuscularly on Days 1, 3, 5, 7 . Repeat every 14 days
214991742|NCT04562558|DRUG|Leucovorin|15mg intramuscularly on Days 2, 4, 6, 8. Repeat every 14 days
214991743|NCT04562558|DRUG|Dactinomycin|1.25mg/m2 (2mg max dose)intravenous every 14 days.
214991744|NCT01375101|DRUG|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
214991745|NCT01375101|DRUG|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
214991746|NCT03001102|DEVICE|4% Chlorhexidine gluconate|Cationic biguanide - antimicrobial action rubbing in the skin.
214991747|NCT03001102|DEVICE|10% PVPI degermante|Polymer soluble in water of iodine with polyvinylpyrrolidone (PVP) - antimicrobial action rubbing in the skin.
214991748|NCT03001102|DEVICE|Soap without antiseptic|Liquid soap with glycerin, neutral pH. Skin cleansing
214991749|NCT04587713|DRUG|TD-1473 [Tablet A]|TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation
214991750|NCT04587713|DRUG|TD-1473 [Tablet B]|TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
214991751|NCT02875457|DRUG|apatinib;etoposide and cisplatin|
214991752|NCT02875457|DRUG|placebo;etoposide and cisplatin|
214991753|NCT05867875|OTHER|Unblinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and both values will be provided to investigator
214991754|NCT05867875|OTHER|Blinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and only SpO2 values will be provided to investigator
214991755|NCT01658410|DRUG|BQ-123|BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
214991756|NCT01658410|DRUG|NaCl|NaCl, Route: intracoronary
214378591|NCT01544959|DRUG|beta-blocker (esmolol, metropolol)|esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
214378592|NCT00380016|PROCEDURE|Percutaneous Transluminal Angioplasty|
214378593|NCT02375282|PROCEDURE|Ambulation orderly|The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
214378594|NCT04080310|DRUG|Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin|"This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily."
214378595|NCT01959191|DRUG|Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery|aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
214378596|NCT00006002|DRUG|dexamethasone|
214378597|NCT00006002|DRUG|semaxanib|
214378598|NCT01616576|DEVICE|Control first, then Experimental|Control condition is currently marketed sound processing strategy.
214378599|NCT01616576|DEVICE|Experimental first, then Control|Experimental condition is newly modified sound processing strategy.
214378600|NCT00997737|DEVICE|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
214378601|NCT04172805|DRUG|anlotinib and toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
214991757|NCT05342844|DRUG|Dexmedetomidine 0.5 mcg|0.5 mcg/kg
214991758|NCT05342844|DRUG|Dexmedetomidine 1 mcg|1 mcg/kg
214991759|NCT06525727|OTHER|Falls Decision Rule|The Falls Decision Rule is a rule used to assess the risk of intracranial haemorrhage in geriatric patients and to prevent brain tomography (CT) in low-risk patients. This rule recommends that brain CT is not necessary in patients who do not have significant head trauma, memory loss, newly developing neurological examination disorder, or frailty score lower than 5 after a fall.
214991760|NCT01567410|OTHER|e-learning|Braden scale and pressure ulcer classification
214991761|NCT01567410|OTHER|traditional classroom training|Braden scale and pressure ulcer classification
214991762|NCT04480879|DRUG|AZD8154 nebuliser|Nebuliser suspension
214991763|NCT04480879|DRUG|AZD8154 Monodose DPI presented in capsules|AZD8154 Monodose DPI formulation delivered dose
214991764|NCT04480879|DRUG|AZD8154 Placebo Monodose DPI presented in capsules|The dose correspond to AZD8154 Monodose DPI formulation
215091438|NCT01384032|DIETARY_SUPPLEMENT|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
214497525|NCT04867824|DIETARY_SUPPLEMENT|Control (use of inhaled lavender essential oil)|Use of inhaled lavender essential oil during frenotomy for a tongue-tie
214497526|NCT02646618|BEHAVIORAL|Get Social|Online-delivered weight loss intervention
214497527|NCT02646618|BEHAVIORAL|Traditional|Group-delivered weight loss intervention
214991765|NCT04882800|DEVICE|Lyric extended wear hearing aid device A|Current commercially available extended wear hearing aid
215091439|NCT01384032|DIETARY_SUPPLEMENT|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
214497528|NCT02646618|DEVICE|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
214497529|NCT00898352|PROCEDURE|regional lymph node dissection|
214497530|NCT00898352|RADIATION|radiation therapy|
214497531|NCT03896659|DRUG|Hydrocortisone Oral|Hydrocortisone 160 mg tablet
214991766|NCT04882800|DEVICE|Lyric extended wear hearing aid with fitting modification device B|Extended wear hearing aid with fitting modifications
214991767|NCT03139513|DRUG|Cobimetinib|Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
214991768|NCT03139513|DRUG|Vemurafenib|Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
214991769|NCT02305979|DRUG|Loratadine|
214991770|NCT02682121|DRUG|Metformin|Metformin 850 mg twice daily
214991771|NCT02682121|DRUG|Placebo|Placebo twice daily
214991772|NCT04809753|DEVICE|Eustachian tube dilation|Dilation of the eustachian tube with an endovascular balloon
214991773|NCT06465056|DRUG|Botulinum toxin type A|Botulinum toxin application between 3-14 days after direct eyebrow lift surgery.
214378602|NCT00353613|BEHAVIORAL|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
214378603|NCT01605760|DRUG|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
214378604|NCT01379976|DRUG|Acetylcarnitine|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
214378605|NCT01379976|DRUG|Placebo|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
214378606|NCT04278378|DIETARY_SUPPLEMENT|Riboflavin|1.6 mg riboflavin / day for 24 weeks
214378607|NCT04278378|DIETARY_SUPPLEMENT|Folic acid|0.4 mg folic acid / day for 24 weeks
214378608|NCT04278378|DIETARY_SUPPLEMENT|Placebo|
214378609|NCT04396080|PROCEDURE|Partial restoration in posterior teeth|Teeth in need of onlays that will be treated with this type of treatment, choosing the most suitable material for each patient and following the manufacturer's instructions for their cementing and adhesion.
214378610|NCT05299021|PROCEDURE|Double-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration. And use the same method targeting the plane between the serratus anterior muscle and the third rib.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5 μ g/kg dexmedetomidine mixture will be injected into the two points with 15 ml separately.
214378611|NCT05299021|PROCEDURE|Single-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture will be injected.
214378612|NCT03040921|PROCEDURE|Uterine transposition.|Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
214378613|NCT05531032|OTHER|Phone Interview|Phone interview questionnaire
214378614|NCT05266963|DRUG|CREON|The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
214378615|NCT05266963|DRUG|Placebo|Placebo
214378616|NCT04921384|DRUG|Placebo|0.9% normal saline, intravenously
214378617|NCT04921384|DRUG|Eptinezumab|Solution for infusion, intravenously
214497532|NCT03896659|DRUG|Placebo Oral Tablet|Hydrocortisone-matched Placebo tablet
214991774|NCT05704712|BEHAVIORAL|Monetary Incentives|Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.
214991775|NCT02341079|DRUG|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
214991776|NCT02341079|DRUG|Indwelling femoral nerve block|Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
214991777|NCT05707169|PROCEDURE|Saphenous Ablation|Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture.
214991778|NCT05707169|DEVICE|Endogenous Laser Ablation (EVLA)|Endogenous Laser Ablation (EVLA)
214991779|NCT05707169|DRUG|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
215091440|NCT05082727|DIETARY_SUPPLEMENT|KOVIR (TD0068) oral softgel|KOVIR (TD0068) is a softgel containing Allium sativum extract 270mg, Colostrum156.4 mg, fine powder mixed herbs 43.6mg
215091441|NCT05082727|DIETARY_SUPPLEMENT|Placebo oral softgel|Placebo
215091442|NCT05499624|DEVICE|MicroTrend System|The hands-free device measures oral mucosal carbon dioxide pressure (POMCO2) and functions outside of the body and does not require a surgical procedure or any significant deviation from standard practice to operate.
214378618|NCT04754256|BEHAVIORAL|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients and for correlation of scores with lung function, CAT-score and other
214497533|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
214497534|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
214497535|NCT01299194|DRUG|ATORVASTATIN|80mg once daily for 3 months
214497536|NCT06343493|DRUG|Normal saline heated up to 50 °C|Saline heated up to 50 °C used for irrigation
215091443|NCT06231433|DEVICE|CO2 Vaginal Laser|CO2 Vaginal laser
214378619|NCT05174884|DRUG|22.2 mg Etonogestrel (ENG)|Subdermal insertion of a single Casea S pellet (22.2 mg ENG) in healthy female participants
214378620|NCT05174884|DRUG|44.4 mg Etonogestrel (ENG)|Subdermal insertion of a two Casea S pellet (44.4 mg ENG) in healthy female participants
214378621|NCT03266822|OTHER|No intervention|Observational study
214378622|NCT02523521|BEHAVIORAL|Physical activity program|physical activity program for a bronchopulmonary dysplasia children.
214378623|NCT04309929|DRUG|Analgesics|All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
214378624|NCT02576158|PROCEDURE|TCT，HPV，colposcopic inspection|
214378625|NCT02283359|DRUG|Selinexor|Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.
214378626|NCT02283359|DRUG|Irinotecan|Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
214378627|NCT05423327|PROCEDURE|No Intervention|Single blood draw
214378628|NCT02335151|DRUG|Desflurane|Apply desflurane as anesthetic
214378629|NCT06324019|OTHER|putting on an examination gown|During the gynecological examination, the patient in the experimental group will be made to wear an examination gown, while the patient in the control group will use the routine practice of the hospital. In this way, with the gynecological examination clothing to be developed, the body privacy of the patients will be protected during the examination. In addition, women will feel less anxiety during gynecological examination and important steps will be taken in maintaining women\&#39;s health by ensuring regular gynecological examination.
214378630|NCT04535323|OTHER|Quality-of-Life Assessment|Ancillary studies
214378631|NCT04535323|OTHER|Questionnaire Administration|Ancillary studies
214378632|NCT04535323|BIOLOGICAL|Therapeutic Autologous Platelet-rich Plasma|Given via injection
214378633|NCT02420145|BEHAVIORAL|Yoga|12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
214378634|NCT03154372|OTHER|Expert supervised practice with validated metrics|
214378635|NCT03154372|OTHER|self guided practice with validated metrics|
214378636|NCT04479280|DEVICE|Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA|studying coagulation disorders in COVID19 critically ill patients
214378637|NCT05341323|DRUG|Ketamine.|Peritonsillar infiltration of ketamine
214378638|NCT05341323|DRUG|Bupivacaine|peritonsillar infiltration of Bupivacaine
214378639|NCT02786264|DRUG|Dexmedetomidine with propofol|A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start. This group was subsequently modified in light of retrospective data collection to specify a group receiving dexmedetomidine in combination with propofol.
215091444|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
214378640|NCT02786264|DRUG|Propofol|A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start. This definition was subsequently modified to include patients who received propofol infusion but not dexmedetomidine.
214378641|NCT01047722|DRUG|Aspirin ingestion followed by doing a Bleeding Volume Test|Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
214378642|NCT01047722|PROCEDURE|Gatorade Placebo followed by Bleeding Volume Test.|Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
214378643|NCT04699227|PROCEDURE|Cuff application with inflation|The blood pressure cuff will be placed on the arm and inflated.
214378644|NCT04699227|OTHER|Sham inflation|The blood pressure cuff will be placed on the arm and not inflated.
215091445|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
215091446|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Escalating dose 2 X 10\^9, 4 X 10\^9, 8 X 10\^9/mL
215091447|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Escalating dose 8 X 10\^9, 4 X 10\^9, 8 X 10\^9 mL
214378645|NCT00351897|DEVICE|pulsed dye (585nm) laser therapy|
214378646|NCT05414318|DEVICE|Conformable GORE® TAG® Thoracic Endoprosthesis|Thoracic Endoprosthesis
214378647|NCT01526590|DRUG|Definity Contrast|While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
214378648|NCT03798600|DRUG|Caspofungin|In accordance with routine clinical practice, Caspofungin will be given at the loading dose of 70 mg followed by 50 mg daily (for people \< 80 kg body weight). No dose reduction will be performed in Child-Pugh score A or B. Duration of therapy will be performed in accordance with ESCMID guidelines and clinical conditions.
214378649|NCT05250401|DIAGNOSTIC_TEST|liver functions and thyroid functions|laboratory tests
214378650|NCT04372160|OTHER|Dietary assessment|24-hr dietary recall
214497537|NCT05609929|DRUG|Multiple administration of omeprazole Single administration of AB-106|Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour
214497538|NCT05628064|DEVICE|1C70|Investigational energy storage and return prosthetic foot with using novel elastic elements.
214497539|NCT05628064|DEVICE|Pro-Flex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects.
215091448|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day (8:8:8)|Dosed 8 X 10\^9, 8 X 10\^9, 8 X 10\^9 mL
215091449|NCT04580095|OTHER|AI algorithm for apical foreshortening in echocardiography|The algorithm is based on artificial intelligence, giving the sonographer performing the echocardiographic exam real-time feedback on left ventricular apical foreshortening.The algorithm is developed using deep learning techniques by technologists at the Department of Circulation and Medical Imaging, NTNU.
215091450|NCT03087292|OTHER|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
214497540|NCT03304587|DIAGNOSTIC_TEST|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
214497541|NCT03304587|DIAGNOSTIC_TEST|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
214497542|NCT03304587|OTHER|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
214991782|NCT06219239|GENETIC|KL003 cell injection Drug Product|No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
214991783|NCT02597114|DRUG|AGT-181|intravenous infusion over 3-4 hours
214991784|NCT03822416|DRUG|Nicotine patch|Nicotine patch (dose based on number of cigarettes per day) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
215091451|NCT06203587|RADIATION|[68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347|The dose of \[68Ga\]Ga-NOTA-WWH347 or \[18F\]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq \[0.05-0.1 mCi\]/kg, and was administered as an intravenous push, with a single dose given once.
215091452|NCT04784624|BEHAVIORAL|Lifestyle program|The cardiometabolic and weight loss program is based on The Wellness Institute clinically validated lifestyle medicine program and will be delivered virtually using a digital platform and artificial intelligence that is supported by a health coach. The program focuses on building individual's self-efficacy, motivation and importance to make and sustain healthy choices. The 16-week program begins with a health risk assessment and a personalized wellness plan. The plan includes a personalized exercise plan and nutrition strategy. Each user will regularly check-in with their personal health coach whose role is to provide expert advice and also empower, support and help make the user accountable as they build a healthy lifestyle. Coaching includes identifying obstacles to changing behaviors and how to develop new behaviors that will become the norm.
215091453|NCT05455931|DRUG|Poteligeo|Poteligeo treatment will be used as prescribed by the Investigator in accordance with the terms of the reimbursed indication within the relevant country. The assignment of the patient to a particular therapeutic strategy falls within current practice and the prescription of Poteligeo is clearly separated from the decision to include the patient in the study.
215091454|NCT05531526|DRUG|AR1001|AR1001 Active Oral Tablet
215091455|NCT05531526|DRUG|Placebo|Placebo Oral Tablet
214991785|NCT03822416|DRUG|Nicotine lozenge|Nicotine lozenge (2 or 4 mg if less or greater than 30 minutes to first cigarette in the morning respectively) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
215091456|NCT00694850|DRUG|Riociguat (Adempas, BAY63-2521).|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
215091457|NCT05869500|DEVICE|Left Bundle Branch Area Pacemaker|Implantation of Medtronic 3830 lead for left bundle branch area pacing
215091458|NCT05869500|DEVICE|Right Ventricular Pacemaker|Implantation of a conventional right ventricular pacemaker lead
215091459|NCT00555737|DEVICE|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
215091460|NCT04934644|PROCEDURE|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment 90 min from start to start of decompression. The chamber is pressurized to 2,4 ATA and the patients will be breathing 100% oxygen. Treatments will be given once daily, five days a week (no treatments on weekends and holidays).
215091461|NCT02783170|BIOLOGICAL|Tetanus, Diphtheria, and Pertussis Vaccine|
215091462|NCT02783170|BIOLOGICAL|2016-2017 Quadrivalent Inactivated Influenza Vaccine|
214378651|NCT03394443|BEHAVIORAL|Semi-structured interviews|"Semi-structured interviews of the parents of preterm infants. 3 weeks after their child has left hospital. They will be made either at the University Hospital of Besançon. They will take place in a dedicated hospital ward to ensure the confidentiality of the statements made between the investigator and the parent.~They will follow a predefined questionnaire. They will be fully recorded on a dictaphone with note taking during the interview by the investigator and will be transcribed in writing anonymously and confidentially on Word.~The content of the interviews will be analyzed:~* As a first step, it will be a vertical analysis of the thematization of each interview~* Then, in a second step, a transversal analysis between the contents of the different interviews."
214378652|NCT01302561|DIETARY_SUPPLEMENT|Sucrose|5 g of sucrose twice daily for 24 weeks
214378653|NCT01302561|DIETARY_SUPPLEMENT|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks
214991786|NCT03822416|BEHAVIORAL|Therapy|In-person meeting at baseline, 6 phone counseling sessions with participants over 8 weeks after initial in-person meeting, possible additional phone counseling (3 phone calls) from 8 weeks to 6 months after initial in-person meeting, and possible text messages when agreed to by participants during the 8 week to 6 month phase
214991787|NCT03822416|OTHER|Information|Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
214991788|NCT01869374|DEVICE|MagVenture MagPro MST|Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.
214378654|NCT00217880|PROCEDURE|Bronchoscopy|A bronchoscopy test will occur to view the participant's airways.
214378655|NCT05707611|OTHER|Running|The participant perform running on treadmill at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
214378656|NCT05707611|OTHER|Cycling|The participant perform cycling on cycle ergometer at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
214497543|NCT03304587|OTHER|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
214497544|NCT03304587|DIAGNOSTIC_TEST|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
214991789|NCT01869374|BIOLOGICAL|RUL ECT|RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.
214991790|NCT01680796|DRUG|Dovitinib|"Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily"
215091463|NCT02783170|BIOLOGICAL|2017-2018 Quadrivalent Inactivated Influenza Vaccine|
215091464|NCT06081894|DRUG|Aficamten|Oral Tablet
214497545|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|"8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
214991791|NCT01680796|DRUG|Bortezomib|"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"
214991792|NCT01680796|DRUG|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
214991793|NCT04666298|DRUG|Inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270.
214991794|NCT04666298|DRUG|Placebo|Subcutaneously injected on Day 1, 90, and 270.
214991795|NCT03033888|BEHAVIORAL|Health-Literacy Focused Education Session|
214991796|NCT00785889|PROCEDURE|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
214991797|NCT03942588|BEHAVIORAL|High-intensity interval training|
214991798|NCT02924961|DEVICE|Triathlon PS total knee system with mobile-bearing|
214991799|NCT02924961|DEVICE|Triathlon PS total knee system with fixed-bearing|
214991800|NCT00844519|DRUG|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
214991801|NCT00844519|DRUG|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
214991802|NCT01757132|DEVICE|Implantable Miniature Telescope|Device - Implantable Miniature Telescope
214991803|NCT06281249|DEVICE|Ultrasound placement device|Device to assist in placement of epidural procedure
214991804|NCT05490082|DRUG|Mirabegron, Propevirine, Solifenacin|Efficacy comparison
215091465|NCT06081894|DRUG|Placebo|Oral Tablet
215091466|NCT06797037|OTHER|Decentralised Pathway Coordinated by the Advanced Practice Nurse|"For each patient enrolled in the study: a decentralised treatment delivery route will be organised. To achieve this, two visits will be planned by the investigating centre's Advanced Practice Nurse (APN) and carried out at the patient's home by a service-providing nurse. During these visits, the APN will take the patient's vital signs before handing over the treatment.~In addition, for the purposes of the study, during the 2nd visit the patient will be asked to complete a satisfaction questionnaire."
214991805|NCT06438601|DEVICE|Lens A (omafilcon A)|15 minutes of daily wear.
214991806|NCT06438601|DEVICE|Lens B (comfilcon A)|15 minutes of daily wear.
214991807|NCT06034184|OTHER|Virtual Reality|The nursing students use glasses and handcontrollers (High Fidelity Simulation) in the VR scenario for training and learning mass casualty incidents.
214991808|NCT05548907|BEHAVIORAL|sleep restriction treatment|"Treatment consists of sleep restriction treatment for insomnia. In this treatment, participants limit their bedtimes to the time they actually sleep. If they sleep most of the time in bed again then bedtimes are slowly built up again. This treatment technique has already been studied in several trials and found to be effective.~Mode of delivery is an online booklet, online exercises and weekly telephone support"
214991809|NCT05548907|BEHAVIORAL|sleep diary monitoring|As an active control condition people monitor their sleep with a sleep diary (also included in the sleep restriction intervention)
214991810|NCT03803826|DEVICE|CRT-D re-programming|"The previously implanted, ineffective CRT-D is reprogrammed under supervision of Trans-Thoracic Echocardiography (TTE) to:~1. adjust the atrioventricular interval so that E and A waves do not overlap~2. the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains."
214991811|NCT03803826|DIAGNOSTIC_TEST|Trans-Thoracic Echocardiography|"This intervention relates to the determination of strains and atrioventricular interval and supplies data for reprogramming the ineffective CRT-D~Transthoracic echocardiography performed to determine the left ventricular ejection fraction as an outcome measure is not considered intervention here (as it is also performed in the control group and that would cause an error cross-referencing."
214991812|NCT00397124|DEVICE|PET/CT imaging|
214991813|NCT05579834|PROCEDURE|posterior correction surgery|Cases of hemothorax developing after posterior correction surgery for spinal deformities
214991814|NCT06448780|DRUG|Caffeine citrate 20 mg/kg|Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
214378657|NCT05707611|OTHER|Swimming|The participant perform swimming at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
214378658|NCT05155995|DRUG|HCP2001|Take it once per period.
214378659|NCT05155995|DRUG|RLD2007|Take it once per period.
214378660|NCT05155995|DRUG|RLD2008|Take it once per period.
214378661|NCT05155995|DRUG|RLD2102|Take it once per period.
214378662|NCT03108729|DRUG|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, taken once daily for 1 year. The daily maintenance dose will be within the range of 300 mg to 1600 mg ESL, and is determined by body weight, clinical response and tolerability.
214378663|NCT00720174|BIOLOGICAL|Cixutumumab|Given IV
214378664|NCT00720174|DRUG|Doxorubicin Hydrochloride|Given IV
214378665|NCT00720174|OTHER|Laboratory Biomarker Analysis|Correlative studies
214378666|NCT00009581|DRUG|L-NMMA|
214378667|NCT00009581|DRUG|Acetylcholine|
214378668|NCT05437276|DEVICE|PoNS®|The PoNS device used in conjunction with rehabilitative physical therapy
214378669|NCT05960370|OTHER|Observational non intervention study|An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.
214378670|NCT04296890|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
214378671|NCT04392037|DRUG|Iberdomide plus low-dose cyclophosphamide and dexamethasone|Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity
214378672|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation|"In addition to standard touch-up of pulmonary vein isolation, subjects receive targeted source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF-identified sources with activity above the threshold (≥ 25%) are considered significant and targeted with radiofrequency ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold."
214991815|NCT06448780|DRUG|Caffeine citrate 30 mg/kg|Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
214991816|NCT03149770|DRUG|Naloxone then placebo|naloxone intranasal 4mg, then placebo
214991817|NCT03149770|DRUG|Placebo then Naloxone|placebo then naloxone intranasal 4mg
214991818|NCT00090688|BIOLOGICAL|meCS6 + LT(R192G)|
214991819|NCT02993809|BIOLOGICAL|BM-ECs and PRPE|
214991820|NCT02993809|BIOLOGICAL|BM-ECs|
214991821|NCT01311661|DRUG|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
214991822|NCT01311661|DRUG|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
214991823|NCT01311661|DRUG|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
214991824|NCT01311661|DRUG|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
214991825|NCT01311661|DRUG|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
214991826|NCT01311661|DRUG|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
214991827|NCT03390153|OTHER|semi flexible socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
214378673|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping (no ablation)|"In addition to standard pulmonary vein isolation (PVI), subjects receive Electrographic Flow™ (EGF) mapping. PVI may be performed using any commercially available platform/catheter.~EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF-identified sources with activity above the threshold (≥ 25%) are marked as relevant; however, no EGF-guided ablations are performed during this index procedure. If subjects have AF recurrence after the 90-day blanking period, they may undergo a recurrence procedure and EGF-guided ablation."
214497546|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|"8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
214497547|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|"8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
214497548|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|"8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
214497549|NCT03304587|OTHER|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
214991828|NCT03390153|OTHER|rigid fiber socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
214378674|NCT00798226|DIETARY_SUPPLEMENT|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
214378675|NCT00798226|DIETARY_SUPPLEMENT|olive oil|Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
214378676|NCT02962570|DEVICE|On Demand Oxygen Delivery|Supplemental oxygen flow is controlled such that it is on only during inhalation.
215091467|NCT00258466|RADIATION|radiation therapy|
215091468|NCT02943915|DEVICE|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
215091469|NCT02943915|DEVICE|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
215091470|NCT05845463|DEVICE|Cerebro endoscopy quality control tool|The AI provides feedback via a separate screen to the endoscopists to inform them which part of the upper GI tract have been adequately visualised.
214378677|NCT02962570|DEVICE|Traditional, Always-On, Oxygen Delivery|Supplemental oxygen flow is constantly on, irrespective of whether the patient is inhaling or exhaling.
214378678|NCT02962570|DEVICE|Oxygen Flow Stopped|Supplemental oxygen flow is stopped completely for a brief period to allow undisturbed end-tidal oxygen and CO2 measurements
214378679|NCT00617695|DRUG|Zolmitriptan|5mg nasal spray
215091471|NCT05455801|DEVICE|negative preassure wound therapy|wound treated with negative pressure therapy dressing
214378680|NCT00617695|DRUG|Placebo|
214378681|NCT05400746|BIOLOGICAL|Pfs48/45 in Matrix-M|Three doses of Pfs48/45 in Matrix-M at different doses
214378682|NCT05514951|DIAGNOSTIC_TEST|Blood sampling|Blood sampling
214991829|NCT01952860|OTHER|Hatha Yoga|18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.
214378683|NCT05454410|DRUG|MIJ821 Subcutaneous Injection 1 mg|MIJ821 supplied in vials as a powder for solution for injection, reconstituted and administered as a single SC injection on Day 1.
214378684|NCT05454410|DRUG|MIJ821 Subcutaneous Injection 4 mg|MIJ821 supplied in vials as a powder for solution for injection, reconstituted and administered as a single SC injection on Day 1.
214378685|NCT05454410|DRUG|MIJ821 Subcutaneous Injection 10 mg|MIJ821 supplied in vials as a powder for solution for injection, reconstituted and administered as a single SC injection on Day 1.
214378686|NCT05454410|DRUG|Placebo Subcutaneous Injection|0.9% sodium chloride solution administered as a single SC injection on Day 1.
214991830|NCT01952860|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
214991831|NCT01637168|DRUG|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin|A tablet, 2 times daily (12/12 hours).
214991832|NCT01637168|DRUG|Ginkgo Biloba (Tebonin®)|A tablet, 2 times daily (12/12 hours).
214991833|NCT01465269|BEHAVIORAL|Group Interactive Structured Treatment|GIST groups consist of 8 group participants and two group therapists. Group members receive the workbook and are asked to bring it to each session. During each of the 13, 1.5 hour sessions, key concepts from the previous session are reviewed, a new topic is discussed, strategies and skills are practiced interactively, and real-life social problems are addressed. Previously covered topics are integrated into each session through discussion and problem solving to provide repetition and reinforcement of information.
214991834|NCT01465269|BEHAVIORAL|Alternative Intervention|Participants in the alternative treatment will attend 13 weekly classroom sessions, where they will view video presentations of the same curriculum topics covered in the GIST workbook. The group therapists will serve as moderators and will meet with participants individually. Group interaction will not be encouraged. Homework exercises will be offered but participants will not be asked to return their homework and will not receive any feedback.
214991835|NCT01041911|DRUG|Euphorbia tablets|50 mg, tablet, once daily, 14 days
214991836|NCT01041911|DRUG|Euphorbia tablets|100 mg, tablet, once daily, 14 days
214991837|NCT01041911|DRUG|Euphorbia tablets|200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
214991838|NCT01041911|DRUG|Placebo tablets|placebo, tablet, once daily, 14 days
214991839|NCT02459626|OTHER|Diagnostic P-V-loops and MRI|Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function
214378687|NCT02294617|OTHER|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
214378688|NCT02294617|OTHER|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
214378689|NCT06593431|RADIATION|Consolidative Radiation|Participants will receive treatment through radiation therapy
214378690|NCT01220869|DRUG|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
214378691|NCT03804606|OTHER|Referral to MTM Pharmacist|Patients will be referred for an encounter with a medication therapy management pharmacist.
214991840|NCT01346098|PROCEDURE|Pancreaticoduodenectomy with pancreatic anastomosis|Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia
214378692|NCT05004688|BIOLOGICAL|Biological/Vaccine: Bacillus Calmette-Guerin (BCG)|Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10\^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
214378693|NCT05551702|BEHAVIORAL|CBT-txt|Cognitive Behavioral Therapy delivered via automated text messaging.
214378694|NCT06770556|DEVICE|Sham iTBS|Participants will receive sham iTBS
214378695|NCT06770556|DEVICE|Active iTBS|Participants will receive active iTBS
214378696|NCT06770556|DEVICE|10 Hz TMS|Participant will receive 10 Hz TMS
214378697|NCT06770556|DEVICE|1 Hz TMS|Participant will receive 1 Hz TMS
214991841|NCT01346098|PROCEDURE|Total pancreatectomy with islet autotransplantation|If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
214991842|NCT04490460|DIETARY_SUPPLEMENT|WBF-0031|Medical food formulation WBF-0031
214991843|NCT00207740|DRUG|CNTO148|Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
214991844|NCT00207740|DRUG|Placebo|Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
214991845|NCT00624208|DRUG|droperidol and saline|droperidol 20 mcg.kg-1 and saline
214991846|NCT00624208|DRUG|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
214991847|NCT00624208|DRUG|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
214991848|NCT00624208|DRUG|saline and saline|saline and saline
214991849|NCT05372367|DRUG|BI 907828|BI 907828
215091472|NCT06264856|PROCEDURE|bronchoscopic sputum suction|"Bronchoscopy is a medical procedure in which a flexible tube called a bronchoscope is passed through the mouth or nose and into the lungs. Bronchoscopic suction is a technique used during bronchoscopy to remove secretions, mucus, or foreign objects from the airways.~The bronchoscope is equipped with a suction port and a suction channel that allows the doctor to remove fluids or other material from the airways. The suction port is connected to a vacuum source, and the suction channel runs through the bronchoscope and terminates at the tip of the instrument."
215091473|NCT06264856|PROCEDURE|negative pressure aspiration suction|The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient could receive sputum suction as medical routine (every 2-4 hrs) if needed.
215091474|NCT04349956|DRUG|UBX0101 or placebo|This is an observational study. No intervention is administered.
215091475|NCT01308229|DEVICE|Nile PAX® paclitaxel-eluting coronary stent|Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
214991850|NCT05372367|DRUG|Rifampicin|Rifampicin
215091476|NCT04677127|BEHAVIORAL|Health Belief Model and Health Literacy Level based Education and Counseling|Patients given education and counseling constructed with health belief model (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cue to action, self-efficacy). The constructed education given through groups dichotomised by health literacy levels (low/high). Groups of 11-13, had weekly educations for 6 weeks, 6 weeks of counselling and 12 week of follow-up.
214378698|NCT05800704|DIETARY_SUPPLEMENT|Nagasin|Lactobacillus, Lactococcus and Bifidobacteria strains with antimicrobial effect against C. difficile
215091477|NCT05595733|DEVICE|Ventilator mode|Neurally Adjusted Ventilatory Assist (NAVA) mode is a new mode of ventilator, using electronic potential of diaphragm to adjust tidal volume. At the same time, this mode can trigger and cycle-off inspiratory time by high sensitivity of electronic potential of diaphragm, increase patient-ventilator synchrony, reduce sedative drug, improve oxygenation, shorten mechanical ventilation day and reduce the rate of diaphragm atrophy. It can improve survival rate and hospital day of patients. Both the animal and human experiment have the effect of lung and diaphragm protection.
215091478|NCT00633828|BEHAVIORAL|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
215091479|NCT04969341|OTHER|Survey Administration|Complete survey
214378699|NCT05800704|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin (placebo comparator)
214378700|NCT02628392|DRUG|DS-8500a|DS-8500a tablets 25mg, 50mg, 75mg
214378701|NCT02628392|DRUG|Sitagliptin|capsules
214378702|NCT02628392|DRUG|placebo|matching DS-8500a tablets and sitagliptin capsules
214378703|NCT03184896|PROCEDURE|Hip Fracture Surgery|Hip Fracture Surgery
214378704|NCT06792968|DRUG|Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets|1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated table
214991851|NCT05372367|DRUG|Itraconazole|Itraconazole
214991852|NCT05426473|OTHER|QuickDASH form|Patients have to complete these two forms, Quick DASH and SF-36, before surgery then 6 weeks after
214991853|NCT02591810|PROCEDURE|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
214991854|NCT02591810|PROCEDURE|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
214991855|NCT02591810|PROCEDURE|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
214991856|NCT04815356|BIOLOGICAL|CD22CART cell infusion|The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD22CART infusion (starting at dose level 1 \[DL1\]: 1 x 105 transduced CAR-T cells/kg) on Day 0 participants will be evaluated for response at Day 28 post-CD22CART infusion.
214991857|NCT05790135|DEVICE|shear wave elastography|Shear wave elastography and CEUS will be used to evaluate the reliability in diagnosing graft versus host disease of the gut after hematopoietic stem cell transplantation
215091480|NCT04969341|OTHER|Electronic Health Record Review|Review of medical records
214991858|NCT05542563|BEHAVIORAL|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
214378705|NCT06792968|DRUG|Synjardy 5 mg/1000 mg film-coated tablets|1 tablet of Empagliflozin+Metformin 5 mg/1000 mg filmcoated tablets
214378706|NCT02227316|DRUG|IV Ibuprofen|Uterine fibroid embolization
214378707|NCT02227316|DRUG|IV Acetaminophen|Uterine fibroid embolization
214378708|NCT02227316|DRUG|Intravenous placebo/Intravenous placebo|Uterine fibroid embolization
214378709|NCT05971914|PROCEDURE|Autogenous tooth derived particulate graft and a novel split thickness papilla curtain flap|Extracted deciduous teeth were prepared immediately after removal according to the manufacturer's instructions with the Bonmaker® device. Ready to use autogenous tooth bone graft (ATB) was mixed with fibrin glue in 3D planned and printed plastic cuvettes to obtain a sticky graft closely matching the shape and extent of the bony defect. The preshaped sticky ATB graft was inserted and compacted in the cleft defect. Subsequently, the tension-free split thickness flap was repositioned by shifting all buccal surgical papillae mesially to the adjacent or the second adjacent interproximal space, depending on the horizontal extent of the cleft.
214378710|NCT04491812|OTHER|Kinesio Tape|Elastic Kinesiology Tape
214378711|NCT04491812|OTHER|Physical therapy program|designed physical therapy program
214378712|NCT01081041|DRUG|Cetuximab|Administered intravenously
214378713|NCT01081041|DRUG|Cisplatin|Administered intravenously
214497550|NCT03304587|OTHER|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
214497551|NCT03304587|OTHER|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
214991859|NCT05203172|DRUG|Binimetinib only treatment|Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Parent Studies C4211001 and C4211003 with water irrespective of food, continuously, starting on Day 1.
214991860|NCT05203172|DRUG|Encorafenib only Treatment|Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.
214991861|NCT05203172|DRUG|Encorafenib & Binimetinib Treatment|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
214991862|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Ribociclib|Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binimetinib tablets BID. The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area.
214378714|NCT01081041|DRUG|Carboplatin|Administered intravenously
214378715|NCT01081041|DRUG|5-Fluorouracil|Administered intravenously
214378716|NCT06082414|OTHER|no interventions|no interventions because of an observational study
214378717|NCT04804098|PROCEDURE|Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute non-linear compression schedule on a rotating daily basis. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
214378718|NCT04804098|PROCEDURE|Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute linear compression schedule on a rotating daily basis with compression. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
214378719|NCT02555839|DRUG|Pomalidomide|4mg capsule on d1 through 21 of a 28 day cycle
214378720|NCT02555839|DRUG|Dexamethasone|40 mg (≤75 years) or 20mg (\>75 years) oral on d1, 8, 15, 22 of a 28 day cycle
214378721|NCT02555839|DRUG|Pomalidomide|4mg capsule on d1 through 14 of a 21 day cycle
214378722|NCT02555839|DRUG|Dexamethasone|cycle 1-8: 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle; from cycle 9 onwards: Dexamethasone 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 8, 9 of a 21 day cycle
214378723|NCT02555839|DRUG|Bortezomib|cycle 1-8: Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle; from cycle 9 onwards: Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle,
214378724|NCT01345084|RADIATION|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
214378725|NCT01345084|DRUG|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
214991863|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Cetuximab|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
214991864|NCT05343013|DRUG|TAS-102|GIven by PO
214378726|NCT01345084|DRUG|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
214378727|NCT05997290|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)|BNT162b2 monovalent (Omicron XBB.1.5)
214378728|NCT05997290|BIOLOGICAL|BNT162b2 (Omi JN.1)|BNT162b2 monovalent (Omicron JN.1)
214378729|NCT05997290|BIOLOGICAL|BNT162b2 (Omi KP.2)|BNT162b2 monovalent (Omicron KP.2)
214378730|NCT04974398|DRUG|Penpulimab|Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) +cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per cycle; followed by penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment.
214378731|NCT04974398|DRUG|placebo|Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per cycle; followed by placebo(200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment. Subjects in Arm B will have the opportunity to crossover to openlabel treatment with penpulimab monotherapy after radiographic disease progression.
214378732|NCT06562842|OTHER|Regular exercise|Participants will perform regular exercise training for 12 weeks, followed by 4 weeks of detraining.
214378733|NCT06562842|OTHER|Control comparator|Participants will remain sedentary throughout the 16-weeks intervention period.
214378734|NCT04910984|BEHAVIORAL|Chatbot messages|Automated personalized messages containing HIV testing-related information, motivation and skills
214497552|NCT03304587|OTHER|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
214991865|NCT00390013|DRUG|Gabapentin|"300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time."
214991866|NCT00390013|DRUG|Placebo oral capsule|"Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time."
214991867|NCT02287077|PROCEDURE|Umbilical Cord Milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
214991868|NCT06350318|DRUG|Zanubrutinib|Zanubrutinib is an anti-cancer medication administered orally.
214991869|NCT06350318|DRUG|Rituximab|Rituximab is a biologic medication administered intravenously or subcutaneously.
214991870|NCT00722020|DEVICE|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
215091481|NCT06960655|BEHAVIORAL|Referral to Pharmacist-Driven Medication Management Program|Medication initiations and titrations are based on an established drug-treatment algorithm that utilizes a statutory-defined Collaborative Drug Therapy Management Agreement (CDTM) approved by the BWH Pharmacy and Therapeutic Committee to initiate and titrate lipid-lowering medications. Scenarios outside the prescribed medication algorithm are routed to the supervising physician, and changes are signed off by a pharmacist and communicated to the patient and care team by a patient navigator under the supervision of physicians. After each change in medication, re-assessment and lab monitoring are collected in an iterative process until targets are achieved. Details of the programs can be found in the references.
214378735|NCT04910984|BEHAVIORAL|Attention-matched educational materials|Attention-matched educational materials manually sent by our research assistant. These educational materials will be retrieved from CDC and WHO websites and curated into short articles (\<200 words) and pictures. All educational materials will be screened by HIV experts from University of Malaya to ensure accuracy before being sent to participants.
214378736|NCT04787510|DRUG|low molecular weight Heparin as standard of care treatment|STANDARD OF CARE
214378737|NCT02475603|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
214378738|NCT00674466|DRUG|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
214378739|NCT00674466|DRUG|Placebo|twice-a-week
214378740|NCT05847179|DRUG|Progerinin|"This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.~. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase."
214378741|NCT05460923|OTHER|Proprioceptive Neuromuscular Facilitation|including trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
214991871|NCT00998192|BIOLOGICAL|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
214991872|NCT00998192|DRUG|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
214991873|NCT00998192|DRUG|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
214991874|NCT03188822|DEVICE|Bioabsorbable steroid releasing sinus implant|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable steroid releasing implant placed in the frontal sinus opening, which will remain in place for 14 days.
214991875|NCT03188822|DEVICE|Bioabsorbable nasal dressing impregnated with steroid|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable nasal dressing impregnated with steroid placed in the frontal sinus opening, which will remain in place for 14 days.
214991876|NCT04903522|BEHAVIORAL|Baroque music listening|"Patients will listen to a 30-minute musical path of baroque pieces. Before and after this, anxiety, depression and consciousness fluidity will be evaluated thanks to different questionnaires"
214991877|NCT01883167|DRUG|RDEA3170 10 mg|RDEA3170 10 mg once daily (qd)
214991878|NCT01883167|DRUG|Febuxostat 40 mg|Febuxostat 40 mg qd
214991879|NCT01883167|DRUG|placebo|placebo qd
214991880|NCT01260129|DRUG|Silodosin|Silodosin 8 mg orally, once daily after morning meal
214991881|NCT01260129|DRUG|Silodosin|Silodosin 4 mg orally, twice daily after morning and evening meal
214991882|NCT04909762|OTHER|Early Rehabilitation and Mobilisation (ERM)|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package. It is provided by health professionals from multiple disciplines and care-givers within intensive care settings.
214991883|NCT06641570|OTHER|Aquatic Exercise Program|This intervention will include 16 sessions of an aquatic-exercise program, twice a week, over 8 weeks at a water temperature between 32-34°C. Each session will be conducted in groups of 8 to 12 patients and will last about 45 minutes.
214991884|NCT06641570|OTHER|Land-based Exercise Program|This intervention will include 8 sessions in 8 weeks, once a week. Each session will last between 25 to 35 minutes and will be divided into two components: core stability exercises and stretching of the trunk and lower limbs.
214991885|NCT05359861|DRUG|SRF388|SRF388 will be administered by intravenous injection (IV)
214991886|NCT05359861|DRUG|Atezolizumab|Azezolizumab will be administered by IV
214378742|NCT05460923|OTHER|Swiss Ball Exercises|trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
214991887|NCT05359861|DRUG|Bevacizumab|Bevacizumab will be administered by IV
214991888|NCT05359861|DRUG|Placebo|Placebo will be administered by IV
214991889|NCT05318664|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
214991890|NCT03509558|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
214991891|NCT03509558|OTHER|Physical Therapy|physical therapy to improve walking and standing functions
214991892|NCT05760599|DRUG|Candonilimab|10mg/kg, iv.drip, every 3 week
214991893|NCT05760599|DRUG|Bevacizumab|15mg/kg, iv.drip, every 3 week
214991894|NCT02232867|BEHAVIORAL|Arm and Leg Cycling Exercise Program|Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
214991895|NCT05558371|OTHER|No intervention.|No intervention administered as part of this study; observational only.
215094710|NCT02950376|OTHER|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
214991896|NCT01211249|DRUG|GLPG0259 oral capsule|Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
214991897|NCT01211249|DRUG|Placebo|Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
214991898|NCT01211249|DRUG|GLPG0259 (Part B)|Capsule, dosage to be established based on results of Part A
214991899|NCT01211249|DRUG|Placebo (Part B)|Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
214991900|NCT03129646|DRUG|Miltefosine|Miltefosine 10mg and 50mg capsules
214378743|NCT01847170|BIOLOGICAL|Fecal Microbial Transplantation|
214378744|NCT01970787|DEVICE|Radiofrequency Ablation (RFA) using the HALO Ablation System|
214378745|NCT01395823|DIETARY_SUPPLEMENT|ergocalciferol supplementation|50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
214378746|NCT01395823|OTHER|placebo|placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
214991901|NCT03129646|DRUG|Paromomycin|Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
214991902|NCT03129646|DRUG|Sodium stibogluconate|Sodium stibogluconate 33% 30 ml inj.
214991903|NCT01998360|PROCEDURE|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
214991904|NCT01998360|PROCEDURE|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
214991905|NCT01307072|PROCEDURE|Vitrectomy|Vitrectomy. Diabetic retinopathy
214991906|NCT02138383|DRUG|Enzalutamide|The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.
214991907|NCT02138383|DRUG|Gemcitabine|The starting dose of gemcitabine will be 1000 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
214991908|NCT02138383|DRUG|Nab-paclitaxel|The starting dose of nab-paclitaxel will be 125 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
214991909|NCT04975425|DIAGNOSTIC_TEST|Fractional Flow Reserve|Comparison between FFR and NHPR before and after guiding catheter disengagement
214378747|NCT01633125|OTHER|Group music therapy|The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
214378748|NCT00795457|BIOLOGICAL|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
214378749|NCT00795457|BIOLOGICAL|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
214378750|NCT00524914|DRUG|apomorphine|Acute apomorphine subcutaneous 3 mg
214378751|NCT00524914|DRUG|placebo|placebo subcutaneous
214378752|NCT02607371|OTHER|VKAs|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214378753|NCT02607371|OTHER|NOACs including Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214378754|NCT02607371|OTHER|Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214378755|NCT02607371|OTHER|Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214378756|NCT02607371|OTHER|Dabigatran-etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
214378757|NCT02564783|OTHER|No intervention|No intervention
214378758|NCT03381222|DIAGNOSTIC_TEST|epiaoryic scan|Epiaortic scan will be performed by use L15-7i Phillips®. Ultrasound probe cover with sterile cover. Five standard epiaortic views will be collected
214378759|NCT03146039|RADIATION|Radiation Therapy|"Whole pelvis radiation therapy will be delivered according to institutional standard of care.~SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning."
214378760|NCT01996358|DRUG|Succinylcholine|Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.
214497553|NCT03304587|OTHER|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue \& sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
214497554|NCT04187573|DEVICE|Neqstent|Adjunctive device providing stable aneurysm neck coverage for the placement of embolization coils within the aneurysm sac and long term stable occlusion of the aneurysm.
214991910|NCT00504400|DRUG|Intravitreal injection ranibizumab|Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
214991911|NCT02035540|OTHER|Decellularized human valves|
214991912|NCT05389267|DRUG|Kinezodianone R hydrochloride|Eyedrops
214991913|NCT05389267|DRUG|Placebo|Placebo
214991914|NCT04132219|BEHAVIORAL|eHealth Intervention|Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
214378761|NCT01996358|DRUG|Rocuronium 0,3|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
214378762|NCT01996358|DRUG|Rocuronium 0,6|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
214378763|NCT05076149|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
214378764|NCT05076149|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
214378765|NCT05076149|DRUG|IVA|Tablet for oral administration.
214378766|NCT05076149|DRUG|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
214378767|NCT05076149|DRUG|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
214378768|NCT05076149|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
214378769|NCT00717314|DRUG|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
214378770|NCT00717314|DRUG|CNI (50%)|50% reduction from BL
214378771|NCT00717314|DRUG|CNI (≥75%)|≥75% reduction from BL
214378772|NCT05219266|DRUG|midostaurin|Patients receive midostaurin
214378773|NCT00844116|DEVICE|spirometry|Conventional and telematic spirometry
214378774|NCT02087501|DEVICE|Horizon™ Abdominal Aortic Aneurysm Stent Graft System|All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
214378775|NCT03907163|DRUG|Dronabinol|Capsules containing 5 mg Dronabinol
214378776|NCT03907163|OTHER|Placebo|capsules identical in appearance to dronabinol
214378777|NCT00584935|DRUG|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
214378778|NCT00094328|DRUG|Bicalutamide|oral
214378779|NCT00094328|DRUG|Anastrozole|oral
214378780|NCT03682705|DRUG|Elsubrutinib|Elsubrutinib capsule will be administered orally.
214378781|NCT03682705|DRUG|Upadacitinib|Upadacitinib tablet will be administered orally.
214378782|NCT03682705|DRUG|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
214378783|NCT03682705|DRUG|Placebo for upadacitinib|Placebo tablet for upadacitinib will be administered orally.
214378784|NCT04410289|PROCEDURE|Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
214378785|NCT04410289|PROCEDURE|Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
214378786|NCT04158180|DIAGNOSTIC_TEST|Questionnaire|A battery of questionnaires will be propose to the participants
214378787|NCT00117156|DRUG|Fludarabine|
214378788|NCT00117156|DRUG|Rituximab|
214378789|NCT01919970|OTHER|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
214378790|NCT01919970|OTHER|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
214378791|NCT04043962|BEHAVIORAL|Web-based CBT (Web-MAP)|see arm description
214378792|NCT05233943|DEVICE|Spinal Mouse and Digital Inclinometer|"The spinal mouse device is non-invasive and does not have any danger. The posture is evaluated by moving from top to bottom on the spine of the person. Data on the device is transferred to the computer via Bluetooth. The person's posture is evaluated in the sagittal plane by making maximum flexion, neutral stance and maximum extension positions, and in the frontal plane by lateral flexion to the right and left.~Digital Inclinometer; It is a non-invasive measurement tool that investigators measure the position sense of the body, which has two parts, one fixed and one movable. The immobile part of the digital inclinometer is placed at the sacrum and the movable part is placed at the T4 spine level. The person is made 30 degrees of trunk flexion. Then, he is expected to perform 5 repetitions of 30 degrees of trunk flexion with his eyes closed. Deviation angles are recorded."
214378793|NCT02084537|PROCEDURE|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7fr double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
214991915|NCT04111835|DIAGNOSTIC_TEST|Offering an alternative cervical cancer screening method - hrHPV molecular testing.|"Women randomized to this screening strategy group will take a hrHPV molecular test.~hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -\> colposcopy~Normal reflex LBC -\> repeat LBC in 6 months~Positive - colposcopy~Negative - rescreen in 3 years~HPV-negative - rescreen in 5 years"
214991916|NCT00742950|PROCEDURE|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
214991917|NCT00742950|PROCEDURE|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
214991918|NCT00742950|PROCEDURE|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
214991919|NCT00587093|OTHER|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
214991920|NCT02554396|DRUG|PRX-100|ophthalmic solution
214991921|NCT02554396|DRUG|Placebo|saline ophthalmic solution
214991922|NCT01583881|PROCEDURE|renal denervation|Renal denervation
214991923|NCT01093417|DRUG|Vitamin D|Vitamin D 4000 IU will be administered to enrollees on the active comparator arm
214991924|NCT01093417|OTHER|Placebo|Placebo pills will be administered to enrollees in this arm
214991925|NCT04793568|DRUG|Recombinant Interferon gamma 1b (IMUKIN®)|100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)
214991926|NCT04793568|DRUG|Recombinant Interferon gamma 1b placebo|5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).
214991927|NCT03265795|DEVICE|Poly Ether Ether Ketone PSI (patient specific implant).|reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
214991928|NCT01349595|DRUG|Bortezomib|"Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month hiatus. At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area)."
214991929|NCT03750721|OTHER|Role of rifampin in staphylococcal PJI|the aim is to determine if the dose and the duration of rifampin influenced the prognosis
214991930|NCT00497107|DRUG|UFT, Calcium Folinate, PSK|
214991931|NCT00497107|DRUG|UFT, Calcium Folinate|
214991932|NCT02965651|BEHAVIORAL|ECA System|"The ECA system, named Gabby, included content pertaining to stress management, nutrition and physical activity as well as dialogue scripts and media such as meditations. The scripts included motivational interviewing dialogue: dialogue to simulate shared decision making interactions and additional longitudinal interaction using techniques such as goal setting, problem solving, tips, and homework. Gabby was available on a web browser through a username and secure password login."
214991933|NCT02811770|OTHER|kidney biopsy|
214991934|NCT03510065|DEVICE|Prevision®|One time Evaluation with documentation of one follow-up visit
214991935|NCT01235221|DRUG|BIIB041 (Fampridine-SR)|10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
214991936|NCT04584788|DEVICE|Masimo O3 Regional Oximeter|Study sensors will be placed on somatic tissues. Readings will be taken from the tissues underneath the O3 sensors.
214991937|NCT04877600|OTHER|dual task performance|dual task performance measurement
214497555|NCT06799962|OTHER|Enhanced Body-Swap for Anorexia Nervosa|The protocol begins with a baseline session, where participants familiarize themselves with their virtual body and provide anamnesis and therapeutic efficacy baseline data. The treatment phase includes 12 bi-weekly sessions where participants embody a virtual avatar in a VR environment. During each session, the Body Mass Index (BMI) of the virtual body is incrementally increased toward a target BMI approximating normal weight (18.5). Follow-ups are conducted at 4, 8, and 12 weeks to assess long-term effects.
215091482|NCT06960655|BEHAVIORAL|Best-Practice Alert|This strategy will employ automated, asynchronous, best-practice alerts (BPAs). Provider notifications via electronic health records (EHRs) are clinical tools designed to improve adherence to evidence-based guidelines by providing real-time alerts that have been widely implemented across healthcare systems to enhance patient safety, reduce clinical inertia, and standardize care delivery. However, their effectiveness depends on factors such as alert fatigue, provider engagement, and integration into existing workflows. BPAs are one of the most common types of automated EHR-based provider notifications.
214378794|NCT02084537|PROCEDURE|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic cystogastrostomy with internal debridement.
214378795|NCT04603976|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
214378796|NCT04952584|BIOLOGICAL|CD30.CAR-EBVST cells|"The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach a MTD.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Day 0 of study, patients will receive their planned single dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL."
214378797|NCT06181032|DRUG|Adebrelimab|Adebrelimab: 1200mg or 20mg/kg, iv, D1, Q3W;
214378798|NCT06181032|DRUG|Apatinib|Apatinib: 250 mg, po, QD, Q3W;
214378799|NCT06181032|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2, iv, 30min, D1, D8, Q3W;
214378800|NCT06181032|DRUG|Cisplatin|Cisplatin: 25 mg/m2, iv, 30min, D1, D8, Q3W; Injection sequence: adebelizumab → gemcitabine → cisplatin (sequential interval of at least 30 min), 3 cycles of neoadjuvant therapy.
214378801|NCT02384655|DRUG|Fenugreek seed meal|3x3 capsules of fenugreek seeds per day for 14 days
214378802|NCT03803891|PROCEDURE|Endoscopic full-thickness resection|Endoscopic full-thickness resection (EFTR) with Over-The-Scope-Clip in colorectal lesions
214378803|NCT06333210|BIOLOGICAL|anti-TRBV9 monoclonal antibody infusions|infusions
214378804|NCT06333210|OTHER|Placebo infusions|infusions
214378805|NCT06333210|DRUG|Adalimumab subcutaneous injection|subcutaneous injection
214378806|NCT06333210|OTHER|Placebo subcutaneous injection|subcutaneous injection
214497556|NCT06799962|OTHER|Emotional Rescripting for Bulimia Nervosa|The protocol starts with an assessment phase (1 session), gathering anamnesis and baseline therapeutic efficacy data. This is followed by an evaluation phase (2 sessions), where participants rate craving responses for virtual foods and environments in immersive VR, with physiological data collected via biosensors. Using this data, a personalized exposure hierarchy is created, combining the most craving-inducing foods and environments into 40 interactive 3D scenarios. The treatment phase involves 9 VR sessions focusing on emotional regulation and craving management. Follow-ups at 4, 8, and 12 weeks evaluate progress.
214497557|NCT06799962|OTHER|Standard Therapy for Anorexia Nervosa (Control)|Participants follow a similar structure with a baseline session to collect anamnesis and baseline data, but without VR immersion. The treatment phase consists of 12 bi-weekly sessions of standard cognitive-behavioral therapy (CBT), focusing on addressing maladaptive thought patterns, promoting healthy eating behaviors, and reducing body image disturbances. Follow-ups are conducted at 4, 8, and 12 weeks to monitor progress. No VR or AI technologies are integrated.
214378807|NCT05726682|DRUG|SAR445419|Pharmaceutical form: cell suspension Route of administration: Intravenous (IV) injection
214497558|NCT06799962|OTHER|Standard Therapy for Bulimia Nervosa (Control)|Participants undergo an assessment phase (1 session) to collect baseline data and an evaluation phase (2 sessions) using standard craving questionnaires without VR immersion or biosensors. The treatment phase includes 9 sessions of traditional CBT targeting binge-purge cycles and emotional triggers. Follow-ups at 4, 8, and 12 weeks monitor progress without the integration of VR or AI technologies.
215091483|NCT03790631|OTHER|The study is observational.|The study is observational.
214378808|NCT03516864|DEVICE|MIMOSA Imager|The MultIspectral MObile tiSsue Assessment (MIMOSA) Imager acquires digital images to calculate anatomical details of chronic wounds (e.g. diameter, surface area, and perimeter). The device can be worn from a lanyard, and clips onto a smartphone, using natural ambient lighting to capture images of a wound. The MIMOSA also uses up to 6 near-infrared LEDs to illuminate tissue with different wavelengths of light to assess tissue oxygenation.
214378809|NCT03516864|DEVICE|Kent Camera|The Food and Drug Administration (FDA) has previously approved a near-infrared device called the Kent camera for the assessment of tissue oxygenation.
214378810|NCT03129048|BEHAVIORAL|MedDiet|"Research subjects will be randomly assigned to one of three intervention groups.~The MedDiet-A group will learn about and how to adhere to the Mediterranean Diet. Over the course of 8 months, they will receive twenty-two classes 60-minute in length.~The MedDiet-WL group will learn about the Mediterranean Diet, how to adhere to is and engage in lifestyle choices like exercising and eating fewer calories so that they will loose weight. Over the course of 8 months they will receive 22 classes, each 90 minutes in length.~The Typical Diet Control group will be asked to maintain current eating and activity patterns over the course of the 14 month study."
214378811|NCT05529745|OTHER|Neurorehabilitation cerebellar cognitive disorder|Influence of neurorehabilitation treatment lines of physiotherapy and exercise therapy including scheduled occupational therapy to adapt and improve cognitive-affective disorders in cerebellar lesions.
214378812|NCT01771822|DRUG|Ibuprofen 5% topical gel|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
214378813|NCT01771822|DRUG|Topical gel vehicle|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
214378814|NCT01771822|DRUG|Sodium lauryl sulfate 0.2%|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
214378815|NCT01771822|DRUG|Sodium chloride solution 0.9% (saline)|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
214378816|NCT00001565|DRUG|phenylbutyrate|
214378817|NCT00280826|DRUG|Efalizumab|Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
214378818|NCT04902820|OTHER|PrEPTECH website|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine \[200 mg\]/tenofovir disoproxil fumarate \[300 mg\]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
214378819|NCT04902820|OTHER|Online PrEP resource list|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
214378820|NCT03299764|DEVICE|Pursed lip breathing ventilation|A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.
214378821|NCT03299764|DEVICE|Standard non-invasive ventilation|Standard non-invasive ventilation
214378822|NCT05013866|PROCEDURE|Repair resin composite proximal|Repair proximal composite resin restoration, removing the defective material and then restoring it with another composite resin
214497559|NCT06803134|OTHER|Selected physical therapy program|Both groups will receive a selected physical therapy program in the form of trans-cutaneous electrical nerve stimulation (TENS), moist hot pack, posture education, and strengthening exercises for deep neck flexors, for 30 minutes, 3 sessions per week, for 8 weeks.
214497560|NCT06803134|OTHER|Kinetic control retraining|"Each patient in the experimental group will receive kinetic control retraining for 30 minutes, 3 sessions per week, for 8 weeks. Each session is based on the progression on the motor control rating scale (MCRS) related to kinetic control management frame. For each movement direction, specific control tests will be conducted. The direction and site of the uncontrolled movement will be evaluated using special tests in accordance with the pain history of the patient. The tests will be chosen according to the patients symptoms; screening of all patients will be done through at least three tests in each direction according to the patients symptoms."
214497561|NCT06494189|BIOLOGICAL|Tislelizumab|200mg IV Q3W
214497562|NCT06494189|DRUG|Afatinib|30mg PO QD
214497563|NCT06494189|RADIATION|Low dose radiotherapy|The phase Ia clinical trial took low dose radiotherapy doses of 2Gy/1f (on day 1) for group 1, 4Gy/2f (from days 1 to 2) for group 2, and 10Gy/5f (from days 1 to 5) for group 3. The radiotherapy doses in phase Ib were judged according to the efficacy and toxicity of phase Ia.
214991938|NCT05619133|DEVICE|PBM|"In this study, the health benefits of the addition of NIR to the light spectrum of a desk lamp already available in the market will be investigate; Ikea Ypeperlig, to which a module with high power Lumileds NIR-Leds will be attached with beam angle of 90 degrees. They will be attached in such a way that, when the lamp is installed in the right place, a 1sr beam that covers the users face, neck and hands and lower arms on the desk with the required intensity of 5mW/cm2 of NIR at the skin surface.~The device will be equipped with 3 sensors:~1. A distance sensor connected to the driver of the NIR-leds, such that when the user leans forward or backward, the intensity of the NIR is automatically adjusted such that the intensity on the skin remains 5mW/cm2 (see figure below).~2. a presence sensor~3. ambient vertical lux sensor by which amount of light that enters the users' eye will be measured since it is known that these have an effect sleep, mood and performance."
214991939|NCT04480528|OTHER|Blood Flow Restriction Training (BFRT)|A pressurized cuff is applied to the proximal thigh in order to partially occlude blood flow as the patient exercises.
214991940|NCT04480528|OTHER|Sham Blood Flow Restriction Training (Sham BFRT)|A minimally pressurized cuff is applied to the proximal thigh in order to mimic the active blood flow restriction unit as the patient exercises.
214991941|NCT02655341|DEVICE|Body Composition Monitoring|using Fresenius device; two measurements before and after coronary intervention;
214378823|NCT04929808|OTHER|Hydrating emollient for acute radiodermatitis|"The emollient has a calming effect, and hydrating and anti-oxidative properties.~An absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist."
214378824|NCT04929808|OTHER|Standard institutional skin care|The control patients will receive the institutional standard skin care, which includes the application of Flamigel® (Flen Pharma, Kontich, BELGIUM). In addition, Mepilex® (Mölnlycke Health Care, Berchem, Belgium), an absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist.
214378825|NCT05072184|PROCEDURE|ESP block|ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
214378826|NCT04626973|DRUG|Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)|"For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 10 or 20 mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
214991942|NCT02655341|PROCEDURE|Coronarography|Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.
214991943|NCT02655341|PROCEDURE|Primary Percutaneous Coronary Intervention|An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
214991944|NCT02655341|PROCEDURE|Renal Angiography|After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
214991945|NCT03481049|BEHAVIORAL|Usual CM|Behavioral reinforcement for alcohol abstinence
214991946|NCT03481049|BEHAVIORAL|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
214991947|NCT03481049|BEHAVIORAL|Shaping CM|Behavioral reinforcement for alcohol abstinence
214991948|NCT00770809|OTHER|Laboratory Biomarker Analysis|Correlative studies
214991949|NCT00770809|DRUG|Lapatinib Ditosylate|Given PO
214991950|NCT00770809|DRUG|Paclitaxel|Given IV
214991951|NCT00770809|BIOLOGICAL|Trastuzumab|Given IV
214991952|NCT03748329|DEVICE|Ultrasound|Will deposit local anaesthetic intra-orally with the aid of ultrasound to guide the location of the final deposition.
214991953|NCT06225739|OTHER|Electronic pregnancy register|Electronic pregnancy register will be created based on local ANC register to monitor pregnancy outcomes across all sites. Pregnant women of all ages attending antenatal care (ANC) facility will be registered
214991954|NCT06225739|OTHER|In-depth interviews and focus group discussions|In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes
214991955|NCT03187470|DEVICE|Different programming of a CRT defibrillator|Different programming of a CRT defibrillator using pacing modalities of a quadripolar left ventricular lead
214991956|NCT04957394|BEHAVIORAL|Family Partner|"The Family Partner intervention is based on well-known elements for preventing child abuse and neglect, such as 1) high intensity intervention with home visitations, 2) coordination of services, 3) an ecological perspective, 4) parental guidance, and 5) an emphasis on a therapeutic relationship with parents to create trust, change and agency.~Family Partners must have relevant professional background and education, such as social work, child welfare services and other health/welfare occupations. They must have a personal attitude for relation-based service delivery in a home-setting, a long work experience and in-depth knowledge of municipal welfare services.~Each practitioner will follow five families. The estimated duration of the intervention is 12 months, but might go over longer stretches of time if it is considered beneficial for the families. The minimum duration of the intervention is 3 months."
214991957|NCT00001956|PROCEDURE|Blood draw|
214991958|NCT00001956|PROCEDURE|Oral surgery|
214991959|NCT00001956|PROCEDURE|Tissue biopsy|
214991960|NCT02806076|PROCEDURE|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
214991961|NCT02806076|PROCEDURE|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
214991962|NCT03618277|PROCEDURE|Biopsy|Micro-biopsies will be performed using a punch of 1 mm in diameter, by pulling the skin at the time of sampling, after disinfection and anesthesia.
214991963|NCT05194930|BEHAVIORAL|The ABC of Insomnia (Acceptance and the Behavioral Changes to treat Insomnia)|5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) provided by a trained instructor.
214991964|NCT05194930|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
214497564|NCT05840887|PROCEDURE|Knee osteotomy associated with meniscal allograft transplantation|Patients will undergo knee osteotomy associated with meniscal allograft transplantation, which will be implanted by arthroscopic technique with body fixation by all-inside and transosseous sutures to the posterior horn and if necessary to the anterior horn.
214497565|NCT05840887|PROCEDURE|Knee osteotomy|Knee osteotomy
214497566|NCT01458366|DRUG|Bendamustine|"Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."
214497567|NCT01458366|DRUG|Ofatumumab|"Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1"
214497568|NCT01458366|DRUG|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
214497569|NCT01458366|DRUG|Etoposide|Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
214497570|NCT01458366|PROCEDURE|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
214497571|NCT01458366|PROCEDURE|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
214497572|NCT01458366|GENETIC|Stem Cell Transplant (STC)|"For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"
214497573|NCT02397096|DRUG|Doravirine, Tenofovir, Lamivudine|Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
214497574|NCT02397096|DRUG|Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor|Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
214497575|NCT02397096|DRUG|Baseline regimen of cobicistat-boosted elvitegravir|Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
214497576|NCT02397096|DRUG|Baseline regimen of a non-nucleoside reverse transcriptase inhibitor|Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
214991965|NCT05944718|DEVICE|Continuous glucose monitor|"Continuous Glucose Monitoring (CGM) is a technology used to measure glucose levels in people with diabetes. Unlike traditional finger prick self-monitoring of blood glucose (SMBG), CGM devices provide continuous and real-time glucose readings throughout the day and night.~CGM systems consist of a small sensor that is inserted under the skin to measure glucose levels in the interstitial fluid, a transmitter that sends the glucose data to a receiver or smartphone, which shows the glucose readings. The sensor measures glucose levels automatically at regular intervals, eliminating the need for frequent finger pricks.~CGM devices can track glucose trends, identify high or low glucose levels, and provide alerts for hypo- or hyperglycemia. This can help individuals make more informed decisions regarding their diabetes management, such as adjusting insulin doses, dietary choices, or physical activity levels."
214497577|NCT02397096|DRUG|Baseline regimen of two nucleoside reverse transcriptase inhibitors|Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
214991966|NCT06963606|DIAGNOSTIC_TEST|Artificial intelligence-assisted chest X-ray in TB screening|After the completion of the chest DR Examination, the chest X-ray was analyzed by the artificial intelligence-assisted system (JF CXR-1) to identify the potential signs of tuberculosis. Meanwhile, the doctor analyzed the results of the chest X-ray. After the analysis results were confirmed, the initial judgment results of the doctor and the analysis results of the artificial intelligence-assisted system were recorded, and the reading results of the artificial intelligence-assisted system were fed back to the doctor. Review the doctor's comprehensive analysis results of the artificial intelligence-assisted system, make a final judgment on the chest X-ray results, and determine whether further relevant examinations (such as etiological examination, CT examination, etc.) are needed. Record the doctor's judgment results. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system.
215091484|NCT04158154|OTHER|Evidence-based fixed-dose combination protocol based treatment|The intervention has been adapted based on a local needs' assessment including exploration of health care workers and patient's knowledge, attitudes, and behaviors related to HTN, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable barriers to HTN treatment and control across capability, intentional, and system domains using CFIR. Sites will randomly be assigned to receive either: Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 2 separate pills); Step 3 amlodipine 10 mg + losartan 100 mg (as 4 separate pills); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo) or Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 1 single pill combo); Step 3 amlodipine 10 mg + losartan 100 mg (as 2 single pill combo); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo).
215091485|NCT06436937|DIETARY_SUPPLEMENT|Single meal containing 20 g of 15N intrinsically labelled protein from honey chlorella|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
214497578|NCT01705886|PROCEDURE|Total Knee Arthroplasty|Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
214497579|NCT01705886|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
214497580|NCT01705886|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
214497581|NCT01705886|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
214497582|NCT01705886|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
214378827|NCT04626973|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|"For statin naive patients, patients would initially receive Rosuvastatin 20mg or Atorvastatin 40 or 80 mg.~For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
214497583|NCT05321992|BEHAVIORAL|eCHEC program|The eCHEC program is the enhanced Community-based Health Education and Communication (CHEC) model to prevent O. viverrini in an effort to decrease cholangiocarcinoma (CCA) in Khon Kaen, Thailand
214497584|NCT06228573|PROCEDURE|Yoga|Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
214991967|NCT06963606|OTHER|Routine doctors analyze the process of chest X-rays|After the chest DR Examination is completed, a regular doctor reviews the films without using an artificial intelligence-assisted system. Once the results of the regular doctor's review are confirmed, a final judgment is made on whether further related examinations (such as etiological tests, CT scans, etc.) are needed, and the doctor's judgment is recorded. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system
214991968|NCT01566370|DRUG|Zonisamide|titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
214991969|NCT01566370|DRUG|Placebo|placebo
215091486|NCT06436937|DIETARY_SUPPLEMENT|Single meal containing 20 g of 15N intrinsically labelled protein from faba bean meat analogue|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
215091487|NCT05729009|DIAGNOSTIC_TEST|skin microvascular reactivity|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
214497585|NCT06418334|DIAGNOSTIC_TEST|Thoracal hyperkyphosis study form|Thoracal hyperkyphosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
214497586|NCT06418334|DIAGNOSTIC_TEST|Scoliosis graphy|Patients whose forward bending test and clinical evaluation results are compatible with hyperkyphosis and scoliosis radiographs are requested. Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
214497587|NCT06418334|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help participant healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken."
214497588|NCT06418334|DIAGNOSTIC_TEST|Ultrasonographic Measurement|Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter-cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
214497589|NCT05580003|DRUG|PF-07817883|Oral suspension or solid oral formulation(s)
214497590|NCT05580003|DRUG|Placebo|Placebo suspension
214497591|NCT05580003|DRUG|Midazolam|midazolam oral solution
214497592|NCT05580003|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet
214991970|NCT02323009|DEVICE|Esophageal Balloon|Esophageal balloon was used to measure esophageal pressure (Paux) which was used as an estimate of pleural pressure. Transpulmonary pressure (Ptp) was calculated as the difference between airway pressure (Pao) and Paux. Applied PEEP was then adjusted to overcome negative Ptp which we maintained between 0 to 10 cm H20. All measurements were made at end-expiration.
214991971|NCT02323009|OTHER|Cstat|PEEP was adjusted to achieve the best CStat in this group of patients
214991972|NCT06098846|DIETARY_SUPPLEMENT|Vitamin D phosphate|Application of a Vitamin D phosphate active patch
214991973|NCT06098846|DIETARY_SUPPLEMENT|Placebo transdermal patch|Application of a placebo transdermal patch
214991974|NCT03147612|BIOLOGICAL|Blinatumomab|Given via central catheter
214991975|NCT03147612|DRUG|Cyclophosphamide|Given IV
214991976|NCT03147612|DRUG|Cytarabine|Given intrathecally or IV
214991977|NCT03147612|BIOLOGICAL|Filgrastim|Given SC
214991978|NCT03147612|DRUG|Methotrexate|Given intrathecally or IV
214991979|NCT03147612|BIOLOGICAL|Pegfilgrastim|Given SC
214991980|NCT03147612|DRUG|Ponatinib|Given PO
214991981|NCT03147612|BIOLOGICAL|Rituximab|Given IV
214991982|NCT03147612|DRUG|Vincristine|Given IV
214991983|NCT06023563|DEVICE|Virtual reality active video gaming using Nintendo switch sports|Playing 2 pre-selected VR active video games from beach tennis, soccer, volleyball, badminton, bowling, and chambara for 10 minutes each with a 5 minute break in-between. Total duration 30-40 minutes.
215091488|NCT03469011|DRUG|Imatinib Oral Tablet|3+3 trial design. Cohorts of 3-6 patients with escalating imatinib doses. No intra-patient dose escalation allowed.
214378828|NCT04626973|DRUG|Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)|"For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 5 or 10mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
214378829|NCT04626973|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|For statin naive patients, patients would initially receive Rosuvastatin 10 or 20mg or Atorvastatin 20 or 40mg. For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
214991984|NCT06023563|BEHAVIORAL|Standard physical therapy balance exercises|Balance exercises: Standing with feet together for 10 seconds 5 times, standing with 1 foot in front of other for 10 seconds 5 times on both sides, standing on one leg for 10 seconds 5 times on both sides, walking with one foot in front of other on a 1-meter-long line for 5 repetitions and standing on a balance board for 30 seconds for 3 repetitions. 5 minutes each of warm-up and cool down exercises. Total duration 20-30 minutes.
214991985|NCT06320652|OTHER|Cardiac telerehabilitation (video consultation and home monitoring)|Patients with cardiac disease and earlier experiences with cardiac rehabilitation, family members, and nurses in the Departments of Cardiology at Amager and Hvidovre Hospital will be invited to work in a partnership and through a course of innovative co-creative workshops. It is recommended that usability studies have 5-15 participants, which is why we plan to enroll 3 cardiac patients, 3 relatives and 3 nurses from the outpatient clinic. Through the workshops, a rehabilitation program offering cardiac telerehabilitation will be co-created to comply with the preferences and perspectives of patients and family members and nurses from the outpatient clinic. Through these workshops we will learn which important components and elements should be prioritized when offering cardiac telerehabilitation (how, when, and why?).
214991986|NCT00328536|DRUG|Omacor|
214991987|NCT02505061|BEHAVIORAL|Hospital-based Program|"The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team."
214991988|NCT02505061|BEHAVIORAL|Regular Therapy Program|"The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase"
214991989|NCT05824585|DRUG|DZD8586|DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
214991990|NCT00145067|BEHAVIORAL|Disease Management Assessment|
214991991|NCT06378476|BEHAVIORAL|IMPaCT Community Health Worker Program|The IMPaCT intervention consists of three stages: goal-setting, tailored support, and connection with long-term support. CHWs first seek to understand the patient's individual circumstances, life histories, and priorities by using a semi-structured interview guide inquiring about social and behavioral determinants of health. CHWs will then partner with patients to create customized action plans based on patient needs.
214991992|NCT06378476|OTHER|Trauma-Informed Care Training|Primary care providers and staff at two General Internal Medicine clinics will receive training in providing supportive care to patients who have experienced trauma. The trainings are all action focused and include a review of racism in medicine, understanding intergenerational trauma and its impact on care, naming and mitigating barriers to health equity, and the basics of motivational interviewing
214991993|NCT06782386|DEVICE|OneStep Foot Scanner|Daily scans with the OneStep Foot scanner will provide thermal and visual data of the soles of the feet to assist in early identification of risk factors associated with Diabetic Foot Ulcers
214991994|NCT05631899|BIOLOGICAL|KRAS-EphA-2-CAR-DC|5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.
214991995|NCT05631899|DRUG|Abraxane|Intravenous abraxane 125 mg/m\^2/day on day-5.
214991996|NCT05631899|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
214991997|NCT05631899|DRUG|Anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
214497593|NCT04524247|DEVICE|Physician Modified Endografts|"Modification procedure Description of modified device is detailed in Section 3.5 of IDE. In summary, the steps involved in modification of the Zenith Alpha thoracic stent grafts are;~1. Unsheathing of the stent graft~2. Retrieval of a trigger wire from the inner cannula of the delivery system~3. Rerouting of the trigger wire along the stent graft~4. Removal of proximal barbs.~5. Creation of fenestrations and/or branch cuffs~6. Placement of radiopaque markers around the fenestrations/ branch cuffs~7. Placement of temporary and/or permanent diameter constraining ties~8. (Optional) Placement of preloaded wires through the fenestrations/branch cuffs"
214378830|NCT00730314|PROCEDURE|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
214378831|NCT00416260|OTHER|High Frequency Oscillation and Tracheal Gas Insufflation|Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
214378832|NCT05238064|DRUG|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib.~Maintain treatment: 2.5mg orally every day continuously, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
214378833|NCT05238064|DRUG|CHOP|Cyclophosphamide: 750mg/m2, IV, d1 Doxorubicin: 50mg/m2, IV, d1 Vincristine: 1.4mg/m2, IV, d1 (maximum 2mg) Prednison: 100mg, po, d1-5 21 days per cycle
214991998|NCT05631899|DRUG|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
214991999|NCT03154606|OTHER|Micellar Casein (#1)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
214992000|NCT03154606|OTHER|Micellar Casein (#2)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
214992001|NCT03154606|OTHER|Calcium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
214992002|NCT03154606|OTHER|Sodium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
214992003|NCT03154606|OTHER|Milk Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
214992004|NCT03154606|OTHER|Pure Protein Blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
214992005|NCT03154606|OTHER|Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
214992006|NCT03154606|OTHER|Native Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
214992007|NCT03154606|OTHER|Soy Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
214992008|NCT03154606|OTHER|Pea Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
214992009|NCT03154606|OTHER|Native Whey: Micellar Casein (50:50) blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
214992010|NCT03154606|OTHER|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
214378834|NCT04634461|DEVICE|Cardiac Monitor|RHYTHMSTAR Mobile Cardiac Monitoring System
214378835|NCT06111144|BEHAVIORAL|Polarized training intensity distribution (TID) and mental training using mindfulness|Polarized TID model group with mindfulness program (POL+)
214378836|NCT06111144|BEHAVIORAL|Pyramidal training intensity distribution (TID) and mental training using mindfulness|Pyramidal TID model group with mindfulness program (PYR+)
214378837|NCT06111144|BEHAVIORAL|Polarized training intensity distribution (TID) without mindfulness|Polarized TID model group without mindfulness program (POL-)
214378838|NCT06111144|BEHAVIORAL|Pyramidal training intensity distribution (TID) without mindfulness|Pyramidal TID model group without mindfulness program (PYR-).
214378839|NCT04557826|DEVICE|RD19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens
214378840|NCT03402516|DEVICE|18.5 resector|hysteroscopic myomectomy with a 18.5 Fr resector after cervical dilatation until Hegar bougie number 7
214378841|NCT03402516|DEVICE|26Fr resector|hysteroscopic myomectomy with a 26Fr resector after cervical dilatation until Hegar bougie number 10
214497594|NCT00495976|OTHER|A commercially produced cordial drink|
214378842|NCT03705819|DRUG|[11C]-NOP46|Subjects will receive a microdose (≤10 µg) of \[11C\]-NOP46.
214378843|NCT03705819|RADIATION|PET/CT scan|After subjects receive a microdose of \[11C\]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.
214378844|NCT04631705|BIOLOGICAL|DZIF-10c|Inhaled administration of the human monoclonal antibody DZIF-10c
214992011|NCT03987048|OTHER|Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.|"Data were collected regarding medical background, medical condition and management, both at admission and during the ICU stay. These included demographics, clinical, biological and therapeutic data.~Outcome at ICU discharge and at one year were also recorded."
214992012|NCT02235740|DRUG|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
214378845|NCT04631705|BIOLOGICAL|DZIF-10c|Intravenous administration of the human monoclonal antibody DZIF-10c
214378846|NCT04631705|DRUG|Placebo|Inhalation of DZIF-10c diluent as placebo
214992013|NCT02235740|DRUG|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
214992014|NCT05843565|DEVICE|Cobalt video laryngoscope blade|Non-standard hyperangulated Cobalt video laryngoscope blade
214992015|NCT05843565|DEVICE|Miller video laryngoscope blade|Standard Miller video laryngoscope blade
214992016|NCT04781673|DRUG|Ketamine|Will receive titratable infusion.
214992017|NCT04781673|DRUG|Lidocaine|Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
215091489|NCT05235061|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PTE is an adaptation of the HOBSCOTCH program for people with a traumatic brain injury and post-traumatic epilepsy that incorporates education about TBI, PTE, and cognition into the education module.
215091490|NCT05235061|BEHAVIORAL|HOBSCOTCH-PTE for Caregivers|Select components of the HOBSCOTCH-PTE program delivered to caregivers consist of session 1 of the HOBSCOTCH-PTE (virtual) program (education module), guidance and instructions on utilizing quick relaxation, and session 8 of the HOBSCOTCH-PTE program (program wrap-up and maintenance planning).
215091491|NCT06638710|DRUG|oral administration of midazolam or placebo|If the patient is opposed to a treatment (resistance to care ≥3 on the Pittsburgh scale), the nurse administers an oral dose of midazolam or placebo to the patient according to the random allocation.
214378847|NCT04631705|DRUG|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
214378848|NCT04551092|DEVICE|NEVR|a non-invasive, non-pharmacological alternative to treat pain by combining an innovative electroencephalography (EEG)-based Neurofeedback solution in an immersive virtual reality (VR) environment.
214378849|NCT01450202|OTHER|bowel insufflation gas|air insufflation, during colonoscopy and esophagogastroduodenoscopy
214378850|NCT01450202|OTHER|bowel insufflation gas|CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
214378851|NCT03013088|DEVICE|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
214378852|NCT05809661|BEHAVIORAL|implementation of the nurse navigation program|Adult patients with intestinal stoma were contacted continuously for 6 months.
214378853|NCT02130284|DEVICE|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
214378854|NCT00066430|PROCEDURE|infrared photocoagulation therapy|
214378855|NCT00066430|DEVICE|Infrared Coagulator|IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
214378856|NCT02041689|BEHAVIORAL|Interview|Each participant will complete two interview sessions with the primary investigator. Each interview will be conducted in a private, quiet room. Parents may choose to remain with the child during the interview if they would like, but only the responses of the child will be analyzed. Each interview session will last no more than one hour; if the child is not able to respond to each of the primary interview questions during this time, a second follow-up session will be scheduled so that the remainder of the questions can be answered. All interviews will be audio-recorded and transcribed.
214992018|NCT04968106|DRUG|Doxorubicin|Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
214992019|NCT04968106|DRUG|Ifosfamide|Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
214992020|NCT04968106|DRUG|INCMGA00012|Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
214992021|NCT03712943|DRUG|Regorafenib|Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
214992022|NCT03712943|DRUG|Nivolumab|Nivolumab 240 mg administered intravenously every 2 weeks.
214378857|NCT02041689|BEHAVIORAL|Observations|Observations help to give insights about interpersonal interactions, actions, non-verbal cues, and the activities and function of areas within the hospital. Three kinds of observation will be used: participant observation, non-participant observation, and guided activities. These observations will be conducted to learn more about the hospital environment as it intersects with the learning experiences of the participants.
215091492|NCT05601102|BEHAVIORAL|danceSing Care|\- Physical activity interventions, including multi-component (chair-based) exercises or dancing, and music therapies have been shown to improve multidimensional health markers in older adults.
214992023|NCT05955651|DIAGNOSTIC_TEST|Peritoneal washings|"Peritoneal washing will be done at designated point in the surgical procedure. one hundred cc of normal saline, will be used to irrigate the peritoneal cavity. Samples of the fluid will be collected, with the goal to collect as much fluid as possible for the study, with minimum of 60 cc should be collected. Samples will be sent to the pathology lab.~1. First washing will be collected after obtaining entry into the peritoneal cavity with placement of the first laparoscopic trocar, before any manipulation of the uterus.~2. Second washing will be done after the hysterectomy and containment of the uterus in the bag.~3. Third washing will be collected after scalpel morcellation of the uterus in the containment bag, extraction and closure of the vaginal cuff."
214992024|NCT06133140|DEVICE|Unblinded postoperative vital sign monitoring|Unblinded postoperative GE Portrait monitoring
214992025|NCT06133140|DEVICE|Blinded postoperative vital sign monitoring|Blinded postoperative GE Portrait monitoring
214992026|NCT06045611|DIETARY_SUPPLEMENT|Isolated Pea Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
214992027|NCT06045611|DIETARY_SUPPLEMENT|Isolated Whey Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
214992028|NCT06045611|DIETARY_SUPPLEMENT|Isolated Faba Bean Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
214992029|NCT06045611|DIETARY_SUPPLEMENT|Placebo|Participants will consume the placebo in an opaque mug wearing a nose clip.
214992030|NCT05962957|DRUG|carbidopa-levodopa|Levodopa is typically prescribed to a patient with Parkinson disease once symptoms become more difficult to control with other anti-parkinsonism drugs. The drug can also be used for postencephalitic parkinsonism and symptomatic parkinsonism due to carbon monoxide intoxication
214992031|NCT05962957|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy via suppression of the TLR4/NF-κB network signaling pathway. Moreover, Pentoxifylline has a potential antioxidant capacity mostly via nuclear erythroid 2-related factor 2 (Nrf2) activation with subsequent up-regulation and expression of several antioxidant enzymes
214992032|NCT05962957|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
214992033|NCT05367505|DEVICE|iFuse-3D implant|The iFuse Implant System consists of cannulated triangular titanium implants (Ti 6AI4V ELI, ASTM F136) with a porous coating of commercially pure titanium plasma spray (C.P. Ti, ASTM F1580) and a setting instrument. The coating and special shape of the implants prevent rotation or displacement of the sacroiliac (SI) joint. The placement instrument uses guide pins to achieve precise placement.
214992034|NCT06478589|BEHAVIORAL|Adapted Patient Priorities Care (PPC) approach|Step 1 is a PPC facilitation encounter, at which the facilitator will help the participant identify patient priorities, such as clarifying values (what matters most); setting meaningful, specific, and realistic outcome goals; describing healthcare preferences (care that is helpful and/or burdensome) and tradeoffs; and discussing priorities with clinicians. The participant's healthcare priorities are then documented and transmitted to clinicians, in order to facilitate changes in the patient's care plan to align it with his/her priorities. In step 2, the clinician considers patient's priorities and potential healthcare options (options might include starting or stopping treatments; adding or removing medications; ordering more or fewer tests; recommending or removing self-management tasks). In step 3, the clinician discusses care options with the participant, using strategies for aligning care with patient priorities.
214992035|NCT06478589|OTHER|Usual Care|Usual care for breast cancer survivorship includes regular visits with the oncology provider and yearly mammograms for surveillance.
214992036|NCT04923542|RADIATION|Stereotactic Radiosurgery (SRS)|Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
214992037|NCT04923542|DRUG|Abemaciclib|Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
214378858|NCT02041689|BEHAVIORAL|Guided Activities|"This study will use three different types of arts and play-based activities to give participants a variety of ways to express their thoughts and perceptions of what it is like to learn about their cancer diagnosis and treatment.~The first activity will be a guided medical play opportunity that prompts the child to use actual medical equipment while taking care of a doll.~For the second activity, the child will be given a digital camera to use and a prompt that asks them to photograph things and individuals in the hospital that have helped them to learn about their diagnosis and treatment.~The third activity will be an open-ended art prompt in which the child will create an artistic representation of what it means to have cancer and get treatment."
214378859|NCT02125448|DEVICE|MRI and PET-CT|
214378860|NCT00377780|DRUG|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
214378861|NCT01875185|DRUG|Aspirin 81 mg|Aspirin 81 mg orally daily for 7 days
214378862|NCT00511979|DRUG|Technosphere Insulin|
214378863|NCT00511979|DRUG|Technosphere insulin|
214378864|NCT00511979|DRUG|Technosphere insulin|
214378865|NCT00511979|DRUG|Regular human insulin|
214378866|NCT05124093|PROCEDURE|Apnoeic oxygenation|"After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%."
214378867|NCT02048748|DEVICE|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
214378868|NCT02048748|DEVICE|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
214378869|NCT01521884|OTHER|SC anti-TNF|SC anti-TNF
214497595|NCT04326140|DEVICE|mirror therapy|The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
214497596|NCT04326140|DEVICE|robotic-assisted training|The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
214992038|NCT04923542|DRUG|Endocrine therapy|Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
214992039|NCT05897788|BEHAVIORAL|Text Message Check-ins|Patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything AND patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.
214497597|NCT04326140|DEVICE|sham mirror therapy|The mirror was masked. The intervention was the same as the mirror therapy.
214497598|NCT02052440|DRUG|Baclofen|Treatment arm: baclofen 10mg tid
214497599|NCT02052440|DRUG|Placebo|Sugar pill by mouth three times daily
214497600|NCT01830049|OTHER|Take blood|
214497601|NCT01534091|BEHAVIORAL|Pedometer with supervision|
214497602|NCT01534091|BEHAVIORAL|Pedometer without supervision|
214497603|NCT04203394|OTHER|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
214497604|NCT04203394|OTHER|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
214497605|NCT05051982|DEVICE|Sedline EEG in View|EEG monitor (Sedline) will be in full view of the Anesthesiologist during surgery.
214497606|NCT06482632|PROCEDURE|Discectomy of Omohyoid|Will be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
214497607|NCT06482632|PROCEDURE|Control group no discectomy of Omohyoid|Will not be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
214992040|NCT05897788|BEHAVIORAL|Contingency Management|Patients will receive incentives for engagement with treatment. Participant will receive compensation for filling their buprenorphine scripts at discharge and attending their follow-up care appointments.
214992041|NCT04625647|DRUG|Sotorasib|Given PO
214992042|NCT01606475|BIOLOGICAL|Allogeneic islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
214992043|NCT03862950|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
214992044|NCT03862950|DRUG|Metformin|Active medication
214378870|NCT06203184|OTHER|video based exercises|Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.
214378871|NCT04601441|DRUG|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
214378872|NCT05041816|DEVICE|Focal vibration therapy|Myovolt delivers vibration with a frequency between 60-300 Hz, and acceleration force between 1.8g to 19.1g peak to peak. Myovolt intensity will be set to \~up to 2X the participant's initial Myovolt perception threshold (however, the maximum intensity will be limited to 19.1g which is the maximum intensity the device can deliver). If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
214378873|NCT00910455|DRUG|SRX246|single oral dose of SRX246 capsule
214378874|NCT00910455|DRUG|Placebo|Single oral dose of placebo capsule
214497608|NCT03190603|DRUG|Celecoxib|Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
214497609|NCT00328692|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
214497610|NCT00328692|DRUG|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
214497611|NCT01297894|DRUG|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
214497612|NCT01297894|DRUG|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
214497613|NCT04411888|OTHER|observation|observation
214497614|NCT03333109|BIOLOGICAL|Erenumab|70 mg/mL pre-filled syringe administered subcutaneously
214497615|NCT03333109|OTHER|Placebo|Matching placebo in pre-filled syringe administered subcutaneously
214497616|NCT03959384|DRUG|Curosurf 80Mg/Ml Intratracheal Suspension|CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
214497617|NCT03959384|OTHER|Ambient Air|Ambient air aspirated in sterile syringes
214497618|NCT04474496|OTHER|Assessing the impact of COVID-19|Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
214497619|NCT01447706|DRUG|MM-121|MM-121 (SAR256212) (IV)
214497620|NCT01447706|DRUG|Paclitaxel|Standard dosing Paclitaxel (IV)
214497621|NCT00918203|BIOLOGICAL|Olaratumab|15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.
214497622|NCT00918203|DRUG|Paclitaxel|200 mg/m2 is then administered IV over 3 hours
215091493|NCT04648202|DRUG|FS120|Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
214378875|NCT06459830|OTHER|Mime Therapy with Neural Mobilization|"Experimental group will receive mime therapy and neural mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Facial Neural Mobilization:~Facial mobilization technique will apply when the patient in supine position with head on the table in neural rotation.~The circular movement and horizontal traction will be applied 25 times in three sets with a 5-second rest period in between a single manipulation and a 30- second rest period in between the sets.~All the participates in the experimental group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
214992045|NCT06838962|DRUG|Daratumumab Injection|"intravenous Daratumumab administration~This study adopts a prospective, single arm, open design method. Thirty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (Daratumumab 16mg/kg/w) for 4 weeks.~The first stage is the main research stage (d1-w4), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Daratumumab once a week for 4 weeks to observe the safety and efficacy during treatment.~The second stage (w5-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Daratumumab after treatment."
214992046|NCT03819322|DRUG|sofosbuvir/velpatasvir|12 week, oral, fixed dose
214992047|NCT01212250|DRUG|carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
214992048|NCT01212250|DRUG|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
214992049|NCT02703363|DRUG|Minocycline|
214992050|NCT02703363|DRUG|Celecoxib|
214992051|NCT02703363|DRUG|Placebo|
214992052|NCT00119639|DRUG|Sorafenib (BAY43-9006, Nexavar)|All subjects were given a open-label, single dose of 400mg sorafenib
214992053|NCT02355223|OTHER|FAST|See information in arm description
214992054|NCT05255107|COMBINATION_PRODUCT|Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the experimental arm, riboflavin will be administered (1 drop every 2 min for 40 min with PESCHKE-L solution \[0.23%\], or longer as needed to assure adequate corneal penetration). Then the eye will be aligned under the PXL Platinum 330 light (the treatment plane will be at the correct working distance from the PXL Platinum 330 beam aperture when the border of the projected beam is in sharp focus). The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).
214992055|NCT05255107|OTHER|Standard of Care Therapy + Sham CXL + Artificial Tears|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the Sham comparator group, artificial tears (1 drop every 2 min for 40 min) will be administered. After instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min, during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
214992056|NCT06281392|DEVICE|CADe system|Colonoscopy assisted by an artificial intelligence system (CADe).
214992057|NCT06281392|DEVICE|NBI|Virtual colonoscopy assisted by NBI
214992058|NCT05983952|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
214992059|NCT06033469|DRUG|Infliximab|Pediatric patients with IBD suitable for treatment with infliximab
214992060|NCT06033469|DRUG|Adalimumab|Pediatric patients with IBD suitable for treatment with adalimumab
215091494|NCT05759793|DRUG|CAR-GPRC5D|CAR-GPRC5D (RD118) is an individualized, gene-modified autologous T-cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. The CAR structure comprises a fully human single-domain antibody fragment (VHH) targeting GPRC5D, fused with intracellular co-stimulatory (4-1BB) and activation (CD3ζ) signaling domains.
215091495|NCT03460210|DRUG|Atomoxetine|Patients are tested for their normal prescription atomoxetine medication
215091496|NCT02106611|OTHER|Clinical Assessment|HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
214378876|NCT06459830|OTHER|Mime Therapy with Placebo Mobilization|"Control group will receive mime therapy and placebo nerve mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Placebo Nerve Mobilization Technique:~The placebo nerve mobilization followed all the procedures of real nerve mobilization without applying horizontal and circular auricular traction. The purpose of this placebo nerve mobilization is not to deprived the control group from therapy and equalize the time duration of treatment protocol.~All the participates in the control group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
214378877|NCT04183907|BEHAVIORAL|Transform|"The Partner, Blue Mesa Health, has developed a lifestyle intervention program for pre-diabetics that aims to prevent or delay the onset of type 2 diabetes through incremental changes to health behaviours. Transform is based on the CDC's National Diabetes Prevention Program (DPP). Blue Mesa Health adapted the National DPP into a digital experience by combining the use of technology- an app, wearable activity trackers (Fitbit) and digital scales- with the professional guidance of remote health coaches.~It is a 6-month intervention that helps individuals establish healthier lifestyle habits. Each participant strives to achieve 2 primary goals:~Attaining 5 to 7 percent weight loss from their starting bodyweight Engaging in at least 150 minutes of weekly physical activity"
214378878|NCT03565068|DRUG|MK-8189|MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.
214378879|NCT03565068|DRUG|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
214497623|NCT00918203|DRUG|Carboplatin|AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
214497624|NCT00369109|OTHER|biologic sample preservation procedure|
214992061|NCT04512690|DEVICE|Epidural electrical stimulation (EES) of the cervical spinal cord|All participants enrolled in this group will undergo a surgical procedure to implant a system which provides epidural electrical stimulation (EES) of the cervical spinal cord. Researchers will quantify the ability of EES to recruit arm and hand muscles and produce distinct kinematic movements. The implant will be removed after less than 30 days.
214992062|NCT05302999|DRUG|Gabapentin|Generic gabapentin
214992063|NCT05302999|DRUG|Placebo|Inert cellulose
214992064|NCT03658525|DEVICE|MR LINAC|MR GUIDED PROSATE RADIOTHERAPY
214992065|NCT03318341|DEVICE|Real Stimulation|The device applies wrist vibration at a subthreshold (imperceptible) level.
214992066|NCT03318341|DEVICE|Sham Stimulation|The device applies no vibration.
214992067|NCT04194112|DIAGNOSTIC_TEST|immediate urine cytology|Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
214992068|NCT04885608|OTHER|PReGe|There will be two weekly sessions of 45 minutes, outdoors in outdoor fitness parks. The components of balance, gait, resistance, strength and elasticity will be worked on and breathing exercises will be performed. The sessions will be guided and dosed by physiotherapists, considering the level of perception of effort. Indications will be given to carry out other sessions of 60 to 120 minutes of therapeutic walking (minimum speed of 4 km/hour) during the week, to complete the 150-300 minutes per week of physical activity recommended by the WHO.
214992069|NCT00474019|DRUG|esomeprazole|IV qd for 4 days
214992070|NCT01805999|DIETARY_SUPPLEMENT|7 g Ispaghula|
214992071|NCT01805999|DIETARY_SUPPLEMENT|7 g placebo|
214992072|NCT01805999|DIETARY_SUPPLEMENT|3.5g Ispaghula + 3.5 g placebo|
214992073|NCT00002703|RADIATION|high-LET heavy ion therapy|
214992074|NCT00002703|RADIATION|low-LET photon therapy|
214992075|NCT05849922|DRUG|SAR442970|1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
214992076|NCT05849922|DRUG|Placebo|1 mL extractable volume of placebo filled in 2 mL glass vial
214378880|NCT03565068|DRUG|Background AAP Therapy|Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone \[not to exceed daily dose of 6 mg\], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.
214378881|NCT05368181|DRUG|Methylprednisolone|Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
214497625|NCT00369109|OTHER|immunohistochemistry staining method|
214497626|NCT00369109|OTHER|laboratory biomarker analysis|
214497627|NCT00369109|PROCEDURE|biopsy|
214497628|NCT01870830|OTHER|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
214497629|NCT02788019|DRUG|Ropivacaine|Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
214992077|NCT04224467|OTHER|Intravenous ICG and Real-Time Near-infrared Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then real-time near-infrared imaging will be conducted during surgery.
214992078|NCT04429880|DRUG|Oxytocin|Oxytocin given by intravenous route
214992079|NCT03479827|DEVICE|Monofocal Contact Lens|A monofocal contact lens will be used for this measurement.
214992080|NCT03479827|DEVICE|Bifocal Contact Lens|A bifocal contact lens will be used for this measurement.
214992081|NCT04285086|BIOLOGICAL|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg
214992082|NCT04285086|DRUG|Anagrelide|Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement
215091497|NCT02106611|PROCEDURE|Stress cardiac MRI|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
215091498|NCT02106611|PROCEDURE|Stress echocardiogram|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
215091499|NCT06980974|BEHAVIORAL|ACT-for-chemsex|16 weeks of acceptance and commitment therapy, delivered online weekly, 45-55 minute sessions
215091500|NCT06980974|OTHER|Treatment as Usual (TAU)|Participants in TAU will receive health/mental health interventions as needed
215091501|NCT06979765|BIOLOGICAL|blood sampling|3 blood tubes will be taken during a standard check-up
215091502|NCT06979765|OTHER|self-administrated questionaires|4 self administrated questionaires and scales at the inclusion
215091503|NCT06981039|DEVICE|Patella Anatomical Locking Plate|Patients in the patella anatomical locking plate group will undergo internal fixation with an anterior locking plate and screw construct using the 2.7mm variable angle (VA) locking patella plating system (DePuy Synthes, Zuchwil, Switzerland)
214992083|NCT04098835|BEHAVIORAL|ASCEND|ASCEND is a behavioral intervention that combines computer-based cognitive exercise, strategy coaching with a neuropsychologist, and homework exercises in order to improve attention, working memory, and cognitive control after stroke.
214992084|NCT02759640|DRUG|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
214378882|NCT06205797|DRUG|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder~Other Names:~IncobotulinumtoxinA"
214992085|NCT00000935|BIOLOGICAL|Intravenous immune globulin (IVIG)|given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
214378883|NCT06205797|DRUG|Xeomin®|"Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~Other Names:~IncobotulinumtoxinA"
214378884|NCT03280771|COMBINATION_PRODUCT|Hope Soap|HOPE SOAP© is a colourful, translucent bar of soap with a toy embedded in its centre.
214378885|NCT03280771|COMBINATION_PRODUCT|Control group soap|A colourful, translucent bar or soap with the toy alongside it
214378886|NCT01978080|DEVICE|Kinesia HomeView|
214497630|NCT06132594|PROCEDURE|Conventional arthrocentesis followed by I-PRF injection|An auriculotemporal nerve block using Mebacaine 0.5% was administered near the mandible's neck. The patient sat at a 45° angle with their head turned. The posterior entry point was 10 mm from the midtragus and 2 mm below the line, while the anterior entry point was marked 20 mm from the midtragus and 10 mm below the line. A biting block kept the mouth open. 2-3 ml of Ringer lactate was injected with an 18-gauge needle to enlarge the joint space. A second needle allowed the solution to flow freely. After lavaging the joint, 1 ml of I-PRF was injected into the upper joint space. Jaw manipulation was done to address adhesions and improve disc mobility.
214992086|NCT01932606|DRUG|Nitrite|Study drug (NaNO\_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
214992087|NCT01932606|DRUG|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
214992088|NCT06053944|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|UFR is a novel IVUS-derived modality for fast computation of FFR without pressure wires and adenosine.
214378887|NCT00085202|BIOLOGICAL|filgrastim|Given subcutaneously
214378888|NCT00085202|DRUG|cisplatin|Given IV
214378889|NCT00085202|DRUG|cyclophosphamide|Given IV
214992089|NCT02598115|OTHER|Collaborative Pharmaceutical Care|The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
214992090|NCT06115122|OTHER|Pre-eclampsia screening program|Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.
214992091|NCT05565807|BIOLOGICAL|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.
214992092|NCT02508389|DRUG|Low Dose GC4419: 30mg/day|Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
214992093|NCT02508389|DRUG|High Dose GC4419: 90mg/day|High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
214992094|NCT02508389|DRUG|Placebo|Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
214992095|NCT02508389|RADIATION|Intensity-Modulated Radiation Therapy|Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks
214992096|NCT02508389|DRUG|Cisplatin|"Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.~Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor"
214378890|NCT00085202|DRUG|vincristine|Given IV
214378891|NCT00085202|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
214378892|NCT00085202|RADIATION|radiation therapy|Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
214378893|NCT05978505|DRUG|Reboxetine 4 MG Oral Tablet|7 nightly doses (4mg) to commence after surgery.
214378894|NCT05978505|DRUG|Placebo|7 nightly doses to commence after surgery.
214378895|NCT05558514|OTHER|Place-based cochlear implant mapping|Pre-operative, 3D CT scans of the temporal bone will be uploaded into a deep learning-based tool which automatically resamples, crops, segments, analyzes, and measures the patient's specific cochlear anatomy. These measurements will be input into an individualized pitch mapping function to determine a patient-specific tonotopic distribution of frequencies (place-based map). At device activation (approximately 1 month post-surgery) CIs will be programmed according to the place-based map.
214378896|NCT05558514|OTHER|Default cochlear implant mapping|At device activation (approximately 1 month post-surgery) CIs will be programmed according to the clinical default program.
214992097|NCT01809652|OTHER|Remote Implant Support Capability|Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
214992098|NCT03329001|DRUG|Niraparib Tablet|Niraparib tablet formulation
214992099|NCT03329001|DRUG|Niraparib Capsule|Niraparib capsule formulation
214992100|NCT01568541|DRUG|Regular toothpastes|One tooth brushing
214378897|NCT05423691|DRUG|CK0804|CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
214992101|NCT01568541|DRUG|Children's toothpastes|One tooth brushing
214992102|NCT02011178|PROCEDURE|Optimal medical treatment and surgery|
214992103|NCT02011178|PROCEDURE|Optimal medical treatment|
214992104|NCT00022373|DRUG|iseganan HCl oral solution|
214992105|NCT00022373|PROCEDURE|management of therapy complications|
214992106|NCT00809198|OTHER|Sodium Hyaluronate|
215091504|NCT06981039|DEVICE|Tension Band Wiring|Patients in the tension band wiring group will undergo open anatomical reduction and internal fixation with a tension band wire construct.
215091505|NCT06980558|OTHER|Progressive relaxation exercises|"Sit or lie down comfortably and close your eyes.~* Feel the rhythm of your breathing.~* Breathe in through your nose and out through your mouth throughout the process.~* Relax as much as you can.~* Get rid of negative thoughts in your mind.~* Stretch your hands by hanging your arms down to your sides, tighten your fists as much as you can and then open them and let them relax."
215091506|NCT06980779|OTHER|ultrasonographic examination|ultrasonographic examination
215091507|NCT06980155|BIOLOGICAL|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine
214378898|NCT00658138|DEVICE|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
214378899|NCT00658138|DEVICE|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
214378900|NCT04668300|BIOLOGICAL|Durvalumab|Given IV
214378901|NCT04668300|BIOLOGICAL|Oleclumab|Given IV
214378902|NCT06444360|BEHAVIORAL|IMPACT|The IMPACT intervention consists of 10 sessions: 2 sessions focused on HIV acquisition/transmission risk reduction (RR), 1 session focused on orienting and rationale to behavioral activation (BA), 6 sessions integrating BA and HIV RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.
214992107|NCT00809198|OTHER|Carboxymethylcellulose sodium|
214992108|NCT02178956|DRUG|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
214992109|NCT02178956|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
214992110|NCT02178956|OTHER|Placebo|Orally two times daily
214992111|NCT02513875|DIETARY_SUPPLEMENT|vitamin D|60,000 IU per week for 8 weeks
214992112|NCT02513875|DIETARY_SUPPLEMENT|Placebo|placebo +diet and lifestyle
214378903|NCT06444360|BEHAVIORAL|eSOC|The eSOC group consists of 2 sessions focused on HIV acquisition/transmission risk reduction (RR).
214992113|NCT01138046|DRUG|Lapatinib in combination with weekly paclitaxel|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
214378904|NCT00006018|DRUG|BMS-214662|This is a dose-escalation study of BMS-214662. BMS-214662 IV over 1 hour on day 3 of course 1. For all subsequent courses, patients receive BMS-214662 IV over 1 hour on day 1 (30 minutes after paclitaxel). Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
214992114|NCT01034423|DIETARY_SUPPLEMENT|Omega-3|Capsules with omega-3 fatty acids.
214992115|NCT01034423|DIETARY_SUPPLEMENT|sun flower oil|Capsules with sun flower oil.
214992116|NCT01510639|BIOLOGICAL|Platelet Rich Plasma|The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
214992117|NCT04557774|OTHER|Cognitive function test|"Laboratory and imaging test~* Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.~* Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers~Neuropsychological test~-Attention, Language, Visuospatial, Memory, Frontal/executive"
215091508|NCT06980155|BIOLOGICAL|PD-1 inhibitor|Toripalimab
215091509|NCT06981091|OTHER|XH-S004 20 mg|Administered once per day for 24 weeks.
215091510|NCT06981091|OTHER|XH-S004 40 mg|Administered once per day for 24 weeks.
215091511|NCT06981091|OTHER|Placebo|Administered once per day for 24 weeks.
215091512|NCT06981260|PROCEDURE|Group A Deactivated TENS with beeping sound (15-second interval)|Deactivated TENS with beeping sound (15-second interval)
215091513|NCT06981260|PROCEDURE|Group B|Deactivated TENS without sound
215091514|NCT06981468|DIETARY_SUPPLEMENT|Low Sodium Beverage 1|The first interventional product for this study is a low-sodium beverage containing Dose 1 of glycerol, whey protein, and water. It will come in a ready to drink format for the participants.
214378905|NCT00006018|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of course 1. For all subsequent courses, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
214992118|NCT03769493|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
214992119|NCT04952896|DIAGNOSTIC_TEST|Synovitis diagnosis|
214992120|NCT06467734|DEVICE|Joint aspiration|Joint puncture to extract joint fluid.
214992121|NCT05855720|OTHER|FIT model project|Several statutory health insurance (SHI) funds have established contracts with hospitals for an alternative remuneration / financing of patients treated in the hospital (FIT hospital). Some of those contracts already started in 2013 and were prolonged. Some FIT contracts will start freshly (until June 2026). These contracts encourage FIT hospitals to test alternative treatment options for their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment.
214992122|NCT00084630|DRUG|imatinib mesylate|Given orally
214992123|NCT00084630|OTHER|laboratory biomarker analysis|Correlative studies
214992124|NCT04010305|DRUG|Sublingual film containing BXCL501 (Dexmedetomidine)|Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia
214992125|NCT04010305|DRUG|Placebo film|Placebo film for BXCL501
214992126|NCT05441904|DRUG|PXL770|A single dose of 500 and 750 mg was administered to each subject.
214992127|NCT00884988|DRUG|Lymphomyosot|20 drops X3/day, until discharge
214992128|NCT00884988|DRUG|Placebo remedy|20 drops X3/day, until discharge
214992129|NCT03846791|OTHER|Observational Study Post MAKO Robotic Surgery|To assess clinical outcomes and surgery related resource use in the year post surgery for patients undergoing hip replacement surgery using the MAKO robot
214992130|NCT03510936|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
215091515|NCT06981468|DIETARY_SUPPLEMENT|Low Sodium Beverage 2|The second interventional product for this study is a low-sodium beverage containing dose 2 of glycerol, whey protein, and water. It will come in a ready to drink format for the participants.
214378906|NCT01394874|BEHAVIORAL|TLC|Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
214378907|NCT05256095|BEHAVIORAL|Thinking in Speech|Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.
214378908|NCT06578936|OTHER|abdominal massage andwarm application|Abdominal massage and hot application will be applied to the patients at least 30 minutes after the morning and evening meals (08:30 am, 20:30 pm) for 15 minutes each, similar to the literature. The hot application will be applied to the abdominal area with a hot water thermophore for 15 minutes before the abdominal massage. After the hot application, abdominal massage will be started. In the abdominal massage, which will be applied clockwise to stimulate bowel movements, four basic movements will be used: superficial exertion, deep exertion, petrisage and vibration.
214378909|NCT01286441|DRUG|10% EISO|During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
214992131|NCT01986998|DRUG|Methylprednisolone 1250 mg/24h x3 days|Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
215091516|NCT06981468|OTHER|Control (placebo) group|Water
215091517|NCT06187987|DEVICE|Mechanical thrombectomy|Aspirational mechanical thrombectomy
215091518|NCT06187987|DRUG|Intravenous thrombolysis|Intravenous thrombolysis with tissue-type plasminogen activator (tPA)
215091519|NCT06980753|DEVICE|Participants will use the biossensor for 48 h|Participants will use the biossensor for 48 h
215091520|NCT04908280|DRUG|Ruxolitinib|1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.
215091521|NCT06980532|DRUG|Glumetinib Combined with Fruquintinib|"Fruquintinib: 3mg, po.qd, d1-14，q3w;~Guemitinib:~Grade 1:200mg, po, qd, q3w; Grade 2:250mg, po, qd, q3w; Phase I: The dose of Glumetinib (200 mg → 250 mg) is dynamically adjusted using the 3+3 dose-escalation rule to determine the optimal dose of Fruquintinib.~Phase II: The RP2D (Recommended Phase II Dose) of Glumetinib identified in Phase I is continued in combination with Fruquintinib."
215091522|NCT06675630|BEHAVIORAL|Education|Consumers will receive monthly targeted educational materials on fibre
215091523|NCT06675630|BEHAVIORAL|Control|Consumers will receive educational materials on healthy eating at two timepoints
214378910|NCT01286441|DRUG|Placebo|During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
214378911|NCT01286441|DRUG|20% EISO|During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
214378912|NCT01286441|DRUG|30% EISO|During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
214378913|NCT02101086|OTHER|Blood transfusion|Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
214378914|NCT01435655|DRUG|tafamidis|tafamidis meglumine 20 mg QD
214378915|NCT01436201|DRUG|Digoxin|Administered orally
214687222|NCT06853483|BEHAVIORAL|Family-School based smoking cessation intervention package|The Family-School based smoking cessation intervention programme will be developed using the multiple strategies provided by the BCW framework, with face-to-face + online as the primary mode of implementation. Specifically, educational training based on the school curriculum will be conducted to create a supportive environment for smokers to quit, guide smokers to discover motivation to quit, encourage smokers to cope with key barriers to quitting, as well as incorporate relapse prevention strategies, using formats such as online videos and supplemental materials, with interventions designed to help students and parents of smokers to understand the health hazards of smoking, to enhance cessation action and supportive skills, and inspire healthy action.
214992132|NCT01986998|DRUG|Oral Methylprednisolone 625 mg/24h x3 days|Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
214992133|NCT01431742|DRUG|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
214992134|NCT04228939|BEHAVIORAL|Recovery Record aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16."
214992135|NCT04228939|BEHAVIORAL|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.
214992136|NCT01294540|DRUG|Drug: E2609|E2609 orally at varying ascending doses
214992137|NCT01294540|DRUG|Placebo|Matching Placebo
214992138|NCT04837170|DRUG|Conventional therapy + S (+)-Ketamine|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction,maintenance or postoperative analgesia.
214992139|NCT04837170|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
214992140|NCT02709369|DEVICE|HIRREM|HIRREM is a noninvasive, closed-loop, allostatic, acoustic stimulation neuro-technology to facilitate recipient-unique relaxation, auto-calibration, and self-optimization of cortical neural oscillations by reflecting auditory tones in near real time. After an initial HIRREM assessment, evaluating patterns of brain electrical rhythms, subjects get a series of 90-120 minute HIRREM sessions, including 5 to 9 individualized protocols. A protocol is a combination of sensor montage and specific software design, during which dominant brain frequencies, recorded at high spectral resolutions, are translated to audible tones, and reflected back via earphones with as little as 8 milliseconds delay. Protocols are received sitting or reclining in a chair, some with eyes open, others eyes closed.
214992141|NCT02957448|DRUG|BMS 986141|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
214992142|NCT02957448|DRUG|Rifampin|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
214992143|NCT05891444|DEVICE|High frequency transcranial random noise|High frequency tRNS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
214992144|NCT05891444|DEVICE|Sham high frequency transcranial random noise|In the sham condition, tRNS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
214992145|NCT06201325|OTHER|virtual reality based exercises|play VR games
214992146|NCT06201325|OTHER|conventional physical therapy|streching and strengthening exercises
214992147|NCT06201325|OTHER|home exercises program|home exercises
214378916|NCT01436201|BIOLOGICAL|Dulaglutide|Administered as subcutaneous injection
214687223|NCT05366855|BIOLOGICAL|Imsidolimab|Solution for infusion; Solution for injection
214687224|NCT05366855|OTHER|Placebo|Solution for injection
214992148|NCT02749890|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214992149|NCT02749890|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214992150|NCT02749890|DRUG|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: Oral"
214992151|NCT01900314|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
214497631|NCT06132594|PROCEDURE|3d surgical guided Arthrocentesis followed by I-PRF injection|Patients underwent arthrocentesis with Ringer lactate, followed by I-PRF injection in the TMJ's superior space using a CT-planned 3D-printed guide. Positioned at a 45° angle, patients were comfortably seated, and disinfection was performed. The patient-specific guide, fitting over maxillary teeth and the face, was employed unilaterally or bilaterally with a biting block for mouth opening maintenance. An 18-gauge needle administered 2-3 ml of Ringer lactate, widening the joint space, followed by a second needle allowing free solution flow (80-90 ml) to flush the superior joint space. Post-arthrocentesis, 1 ml of I-PRF was injected. To enhance joint mobility and free the disc, gentle manipulation of the lower jaw was performed after removing the needles and guide.
214497632|NCT02928250|DIETARY_SUPPLEMENT|Carnosine|Patients in intervention group received carnosine capsules orally daily
214497633|NCT02928250|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
214992152|NCT05182437|RADIATION|LINAC-based Stereotactic Radiotherapy|Target definition: the target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations (e.g. 3, 7 Tesla MRI or Stereo-EEG) of the presurgical path. Planning target volume (PTV) = GTV. A single fraction SRT with a prescribed isotoxic dose of 24 Gy to the 100% surrounding isodose. Dose is depending on the proximity and maximum tolerable dose to the radiosensitive organs at risk and EZ volume resulting in a V12\<= 10 cc reducing the risk on radionecrosis.
214992153|NCT05926713|DIETARY_SUPPLEMENT|Sarcojoint®|All participants are administered Sarcojoint® containing leucinine 1 g, arginine 1.5 g, Vitamin D 7.5μg, chondroitin 400 mg, calcium 300 mg, and glucosamine 700 mg per package, and take 1 package twice a day.
214992154|NCT05926713|BEHAVIORAL|supervised exercise|All participants are required to walk 6500 steps every day for 12 weeks, and the data are recorded by Xiaomi-smart-band.
214992155|NCT03104803|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
214992156|NCT05378152|DEVICE|Pipelle biopsy catheter|A speculum will be inserted into the vagina. A Pipelle biopsy catheter will be inserted through the cervix up to the fundus of the uterus. The internal piston will be withdrawn to create negative pressure. The catheter will be moved back and forth and rotated to collect the biopsy. The catheter will then be removed, followed by the speculum. The sample will be sent to the laboratory for assessment.
214992157|NCT05378152|DEVICE|Sham procedure|A speculum is inserted into the vagina and then removed
214992158|NCT05958303|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Total dosing of 1000 mg vitamin C, 600 IU vitamin E, and 600 mg of alpha lipoic acid.
214992159|NCT05958303|OTHER|Placebo|Placebo
214992160|NCT03797612|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
214992161|NCT03797612|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
214992162|NCT04277585|OTHER|Telehealth|Early Psychosis Coordinated Specialty Care Services via telehealth.
214992163|NCT03318068|OTHER|Yoga Intervention|The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
214992164|NCT06009874|DRUG|Dapagliflozin 10mg Tab|patients will be treated with DAPA 10 mg once daily for three months
214992165|NCT06009874|DRUG|Placebo|patients will be treated with a placebo tab once daily for three months
214992166|NCT04582071|BEHAVIORAL|Psychotherapy|Psychotherapy is a term that we use to describe the use of the psychological method to understand and improve an individual's well-being and mental health. The Principal Investigator of this study, a clinical psychologist will be leading each of the sessions.
214992167|NCT05257187|DEVICE|Transcervical foley catheter|The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
214992168|NCT00585182|DRUG|Enoxaparin 0.5 mg/kg once daily|Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
214992169|NCT01642316|OTHER|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
214992170|NCT01642316|OTHER|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
214992171|NCT03005756|DEVICE|Needle guiding robot|This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
215091524|NCT02759536|RADIATION|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
214497634|NCT04694014|BEHAVIORAL|EI Open ended Pre-Survey and Semi Structured Interview|Provide Interview questions via online survey with informed consent to the participants then contact a 60 minute member checking interview in person or virtually via recorded Zoom sessions for each participant
214497635|NCT04694014|BEHAVIORAL|Behavioral and Cognitive Assessment|Use Predictive index for both cognitive and behavioral assessment of the paticipants
214497636|NCT04694014|BEHAVIORAL|Geneva Emotional Competence Test (GECO)|Administer the Geneva Emotional Competence Test to each participant
214497637|NCT06137898|BIOLOGICAL|biological check-up|Blood sampling
214687225|NCT06609668|BIOLOGICAL|Additional blood samples|"* 1 dry tube (5 mL)~* 1 EDTA tube (6 mL)~Performed at inclusion (before any glucocorticoid and/or immunosuppressive treatment) and at follow-up visit (3 months after inclusion)"
214687226|NCT06858813|DRUG|Lenvatinib|Oral Capsule
214687227|NCT06858813|DRUG|ABBV-324|Intravenous (IV) Infusion
214687228|NCT00515372|OTHER|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
215091525|NCT06675513|BIOLOGICAL|An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name:|"Autologous WD-01 CAR-T therapy with Wondercel's Warrior armor strategy will be explored for its advantage over other armor platforms."
214687229|NCT00515372|OTHER|Usual Care|Lists of professional resources and referral recommendations will be provided.
214992172|NCT00366769|DEVICE|Wavefront-guided LASIK using CustomVue platform|
214992173|NCT01104766|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
214992174|NCT01104766|DRUG|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
214992175|NCT01104766|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
214992176|NCT02222324|DRUG|Placebo|8 placebo tablets matching E2609
214687230|NCT06992427|DRUG|Gabapentin|Given PO
214992177|NCT02222324|DRUG|E2609|E2609 will be administered as 8 tablets
214992178|NCT02222324|DRUG|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
214992179|NCT02753673|BEHAVIORAL|qualitative interviews with patients|
214992180|NCT02753673|BEHAVIORAL|questionnaires|
214992181|NCT01341470|DRUG|LY2495655|administered intravenously or subcutaneously
214992182|NCT01341470|DRUG|Placebo|administered intravenously or subcutaneously
214992183|NCT02095288|PROCEDURE|Blood draw|This is a single blood donation, no drugs or devices administered
214992184|NCT04905277|DRUG|Atenolol 50 MG|50 mg Atenolol daily
214992185|NCT04905277|DRUG|Placebo|one placebo daily
214992186|NCT03716427|DRUG|CT1812|
214992187|NCT03716427|DRUG|tolbutamide|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide
214992188|NCT03716427|DRUG|dextromethorphan|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan
214992189|NCT03716427|DRUG|Omeprazole|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole
214992190|NCT03716427|DRUG|midazolam|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam
214992191|NCT06257446|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
215091526|NCT06621407|PROCEDURE|24 hours active subperiostal drainage|24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
215091527|NCT06621407|PROCEDURE|24 hours passive subdural drainage|24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
215091528|NCT06600867|DIAGNOSTIC_TEST|Tooth mobility assessment|The examiner, holding the instruments (two clinical mirror handles), will apply labial/lingual or labial/palatal displacement movements using the subjective technique, just as routinely done. Using the endodontic spacer and the stop, the deflection will be measured in millimeters. Subsequently, the examiner, with the instruments in hand (tensiometer and dynamometer), will apply labial/lingual and labial/palatal displacement movements, determining the force required to achieve the same displacement previously established by the subjective method (reference/limit of displacement).
215091529|NCT03957941|BEHAVIORAL|FamilyLink Pumping|Viewing baby via FamilyLink while pumping
215091530|NCT03957941|BEHAVIORAL|Standard Pumping|Not viewing baby via FamilyLink while pumping
214992192|NCT05969561|PROCEDURE|ultrasound-guided femoral nerve block|The local analgesia is injected and infiltrated around the femoral nerve under ultrasound guidance.
214687231|NCT06992427|DRUG|Placebo|Given PO
214687232|NCT06992427|DRUG|Chemotheraphy|Receive standard of care chemotherapy
214687233|NCT06992427|RADIATION|Radiation Therapy|Undergo standard of care radiation
214687234|NCT06992427|DRUG|Analgesic Agent|Receive standard of care pain medication
214687235|NCT06992427|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214687236|NCT06992427|OTHER|Survey Administration|Ancillary studies
214687237|NCT05372575|BIOLOGICAL|PCV13 PAC study|To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.
214687238|NCT01901133|DRUG|MDV3100|Oral
214687239|NCT02703805|OTHER|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
214687240|NCT02703805|OTHER|Standard YMCA membership|A 12 week standard YMCA membership.
214687241|NCT05262595|DRUG|NNC0471-0119 A|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
214992193|NCT05969561|DRUG|Intravenous or intramuscular pain medication|Intravenous or intramuscular pain medication is given for patients with hip fracture.
214992194|NCT04744181|DRUG|Ferric carboxymaltose|administration of a single dose of ferric carboxymaltose in those patietns who fulfill the inclusion criteria
214992195|NCT04744181|DRUG|B vitamin|administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria
214992196|NCT04744181|DRUG|Folic acid|administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
214992197|NCT03907436|OTHER|USDA Diet|Participants will receive counseling and education on USDA Guidelines for Americans, 2010
214992198|NCT03907436|OTHER|Mediterranean Diet|Participants will receive counseling and education on a Mediterranean diet.
214992199|NCT04057235|DEVICE|FlareHawk Interbody Fusion System|Expandable lumbar intervertebral body fusion device
214992200|NCT00389870|BIOLOGICAL|panitumumab|
214992201|NCT00389870|DRUG|cyclosporine|
214378917|NCT00524225|DRUG|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
214378918|NCT04045730|DRUG|Gemcitabine|All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
214378919|NCT03118284|OTHER|urine collection|
214378920|NCT03118284|OTHER|Blood collection|
214378921|NCT03118284|BEHAVIORAL|NRS|
214378922|NCT01949688|BIOLOGICAL|HLA-A*2402 or A*0201 restricted peptides|"Open Label, Non-Randomized, Safety/Efficacy study:~1. HLA-A\*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A\*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.~2. HLA-A\*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A\*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant."
214378923|NCT00887276|DRUG|Moxifloxacin|"intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~1. 20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~2. 20 ml physiologic saline solution (placebo) (over 30 min)~3. 20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2. 2 capsules Placebo~3. 2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days"
214378924|NCT00887276|DRUG|Ampicillin;Amoxicillin|"intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~1. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~3. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 2 capsules Amoxicillin (0,5 g)~2. 2 capsules Amoxicillin (0,5 g)~3. 2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days"
215091531|NCT07033247|DEVICE|EDDY Sonic Activation System|EDDY is a sonic irrigation activation system operating at 6,000 Hz frequency with a flexible polyamide tip (25/04). In endodontic procedures, the EDDY tip is inserted 2 mm short of the working length into the root canal and activated for 20 seconds in three consecutive cycles. The sonic activation enhances irrigant agitation through cavitation and acoustic streaming, improving cleaning efficacy within the root canal system, especially in curved canals. The device does not contact dentin walls, reducing the risk of iatrogenic damage. In this study, EDDY was used to activate sodium hypochlorite solutions of either 2.5% or 5.25% concentration depending on the assigned group.
215091532|NCT07033247|DEVICE|Passive Ultrasonic Irrigation (PUI)|Passive Ultrasonic Irrigation (PUI) involves the use of an ultrasonically activated file or tip inserted into the root canal 2 mm short of the working length, without contacting the dentinal walls. The ultrasonic tip is operated in a non-cutting, passive manner to generate acoustic streaming and cavitation within the irrigant. In this study, after initial irrigation with 2 mL of sodium hypochlorite (either 2.5% or 5.25%, depending on the group), ultrasonic activation was performed for 20 seconds in three consecutive cycles. Each activation was followed by 1 mL NaOCl irrigation. This method is designed to enhance the penetration and effectiveness of irrigants, especially in anatomically complex areas of the root canal system.
214378925|NCT05316584|BEHAVIORAL|Remote monitoring|See prior description of the intervention.
214378926|NCT04989127|DIAGNOSTIC_TEST|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
214378927|NCT04989127|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
214378928|NCT04989127|BIOLOGICAL|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
214378929|NCT04989127|DRUG|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
214378930|NCT04989127|DRUG|Analgesic|Analgesics are prescribed for the patients.
214687242|NCT05262595|DRUG|NNC0471-0119 B|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
214992202|NCT00389870|DRUG|irinotecan hydrochloride|
214992203|NCT02205645|DEVICE|FibroFix™ Meniscus scaffold|"The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.~The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear."
214992204|NCT03047252|DEVICE|Home-based rehabilitation with a digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-2) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and extensors Ice pack application after each session and throughout the day as needed STAGE 2 (weeks 3-6) Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors and extensors and knee stabilization Progression to standing exercises without support lying, sitting and standing (with support) Exercises with steps Ice pack application after each session and throughout the day as needed STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Multi-directional exercises"
215091533|NCT07036822|DEVICE|Skeletal Anchored Maxillary Expander (MARPE)|Mini implant assisted rapid maxillary expander (MARPE) used for skeletal maxillary expansion in adolescent and adult patients
214378931|NCT04989127|DRUG|Antibiotic|Patients with penicillin allergy
214687243|NCT05262595|DRUG|NNC0471-0119 D|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
214992205|NCT03047252|OTHER|Conventional Home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-2) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Gait training with bilateral support Open kinetic chain exercises without added resistance Strengthening of hip flexors and extensors Ice pack application STAGE 2 (weeks 3-6) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors/ extensors and knee stabilisation Gait training with progressive withdrawal of external support Ice pack application STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Weight-bearing exercises on uneven surfaces Ice pack application"
214378932|NCT04978155|DIAGNOSTIC_TEST|Duplex ultrasound performed by the surgeon after locoregional anesthesia|Just after locoregional anesthesia, the surgeon perform a duplex ultrasound to determinate if the target vessel chosen to create the arterio-venous fistulae match with the pre-operative duplex performed during the consultation. So the plan can be changed such as more distal, more proximal creation, changing vein or artery target.
214378933|NCT06341621|DRUG|3-year abemaciclib without chemo|aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
215091534|NCT06847867|DRUG|Momelotinib|Momelotinib will be administered.
215091535|NCT06545656|DRUG|Doxycycline|Doxycycline (DOX) will be given orally at 100mg doses. Participants will take the study medication for 7 consecutive days.
215091536|NCT02981524|DRUG|CY|CY is administered intravenously at 200 mg/m2
214378934|NCT06341621|DRUG|treatment of physician's choice|treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.
214378935|NCT01353222|BIOLOGICAL|DN24-02|DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
214378936|NCT01353222|OTHER|Standard of Care|Observation only until documentation of disease recurrence.
214378937|NCT04762693|DEVICE|Hyfe cough tracker|A mobile app that runs in the background of smartphones and detects putative cough sounds.
214992206|NCT04276220|DIAGNOSTIC_TEST|Tenosynovial biopsy|Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.
214992207|NCT02959762|DIETARY_SUPPLEMENT|Placebo-Control|two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
215091537|NCT02981524|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
214992208|NCT02959762|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
214992209|NCT02959762|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
215091538|NCT02981524|DRUG|Pembrolizumab|Pembrolizumab is administered intravenously at 200 mg
215091539|NCT06213142|OTHER|CBToolkit|CB Toolkit Mindful Awareness module to increase awareness and tolerance of physical sensations and emotional experiences using mindfulness practices. The module involves videos with motion graphics, video demos, voiceover, music, and sound effects intermixed throughout with a variety of interactive exercises tailored to specific core components. The module aims to establish understanding of the intervention concept (psychoeducation), increase self-efficacy in mindfulness skills via active practice and personalized feedback, and facilitate self-reflection and understanding of strengths and improvement areas related to mindfulness. CBToolkit Flexible Problem Solving module to promote cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies. Videos and activities will be tailored to provide examples of effective problem-solving techniques and provide personalized reinforcing and/or scaffolded feedback.
215091540|NCT03116542|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
215091541|NCT00612859|DRUG|levetiracetam|
215091542|NCT00266344|DRUG|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
215091543|NCT00266344|DRUG|Placebo / Duration of Treatment 3 Weeks|
215091544|NCT00247442|BEHAVIORAL|Decision aid|
215091545|NCT05046691|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
214378938|NCT03407690|OTHER|nasal swab|collection of nasal swab to allow carriage of pneumococci to be assessed
214378939|NCT01574768|PROCEDURE|Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle
214378940|NCT01473498|OTHER|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients."
214687244|NCT05262595|DRUG|Faster aspart|"Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
214378941|NCT01473498|OTHER|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
214992210|NCT03841981|DIAGNOSTIC_TEST|Anthropometric and physical examination|"* Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\]."
214992211|NCT03841981|DIAGNOSTIC_TEST|Indirect calorimetry, accelerometer and seven-day dietary recall|Energy availability assessment.
214992212|NCT03841981|DIAGNOSTIC_TEST|Biochemical, hormonal and metabolic phenotyping|"* Lipid profile.~* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~* Sex steroid profile.~* Hypothalamic-pituitary-adrenal axis study.~* Ferrokinetic study.~* Subclinical chronic inflammatory markers."
214992213|NCT03841981|DIAGNOSTIC_TEST|Sonographic studies|"* Polycystic ovarian morphology.~* Carotid intima-media thickness.~* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness."
214992214|NCT03841981|DIAGNOSTIC_TEST|24-hour Ambulatory blood pressure monitoring|A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).
214378942|NCT04482543|DRUG|Methotrexate|Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.
214378943|NCT03791580|BEHAVIORAL|Commitment nudge|"The commitment nudge will ask clinicians to commit to discussing high-risk polypharmacy at the next office visit with patients who have high-risk polypharmacy. Clinicians who commit will receive a reminder just before the next office visit begins. The patient will also receive notification of the commitment via EHR patient portal.~This nudge will be operationalized via two sequential clinician-facing EHR best practice alerts (BPAs): the first at time of opening any encounter (including encounters other than a face-to-face office visit, e.g., medication refills), and the second (contingent on making a commitment to discuss high-risk polypharmacy) at time of opening the subsequent encounter for a face-to-face office visit. Each of these BPAs will describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies."
214378944|NCT03791580|BEHAVIORAL|Justification nudge|The justification nudge will ask clinicians who prescribe or renew a drug that meets high-risk polypharmacy criteria (in the context of the patient's other medications) to write a brief justification for prescribing this high-risk medication. This written justification will be recorded in the patient's medical record. The best practice alert requesting the justification will also describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies.
214378945|NCT01920048|PROCEDURE|Percutaneous Coronary Intervention|
214378946|NCT01920048|DRUG|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
214378947|NCT01920048|DEVICE|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
214992215|NCT03841981|PROCEDURE|Percutaneous biopsy|Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
214992216|NCT03841981|DIAGNOSTIC_TEST|Cardiovascular autonomic function studies|Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.
214992217|NCT03841981|DIAGNOSTIC_TEST|Oral smear and feces specimen|Microbiome studies.
214992218|NCT05056220|DRUG|Human albumin|20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
215091546|NCT01194622|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
215091547|NCT01194622|DRUG|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
215091548|NCT01194622|DRUG|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
215091549|NCT01521299|DRUG|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
215091550|NCT00483041|OTHER|PLACEBO|Placebo administered as a single intravenous infusion
215091551|NCT00483041|BIOLOGICAL|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
214378948|NCT01086865|DRUG|Apetiviton BC|"Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily."
215091552|NCT05109260|DIAGNOSTIC_TEST|Point-of-Care Immunoassay device|2 POC Immunoassay devices will be used. One will measure D-dimer levels in capillary blood, the other will measure venous.
215091553|NCT05650671|DEVICE|instrumented wheelchair|Measurements of pressure, temperature and humidity at the subject/cushion interface
215091554|NCT05124379|DEVICE|Hemoclin Gel|Non sterile gel for intra-rectal use
215091555|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
215091556|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
215091557|NCT02189707|OTHER|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
214992219|NCT05056220|DRUG|sodium chloride|0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
214992220|NCT03811561|DRUG|Semaglutide|Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
214992221|NCT03811561|DRUG|Placebo (semaglutide)|Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
214992222|NCT04225832|BEHAVIORAL|CBT Coping Intervention|A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
214992223|NCT02723474|DEVICE|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
214992224|NCT05526417|PROCEDURE|Computed Tomography|Undergo CT
214992225|NCT05526417|OTHER|Educational Intervention|Receive educational materials
214992226|NCT05526417|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214992227|NCT05526417|PROCEDURE|Physical Therapy|Receive prehabilitation physical therapy
214992228|NCT05526417|OTHER|Questionnaire Administration|Ancillary studies
214992229|NCT05526417|OTHER|Telemedicine|Attend telemedicine visits
214378949|NCT02621957|DRUG|GDC-0810|During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
214378950|NCT02621957|DRUG|Pravastatin|Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
214378951|NCT02447289|DRUG|Intranasal ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL administered into the nose with an atomizer; dose of 4.0 mg/kg, maximum 100.0 mg
214378952|NCT02447289|DRUG|Oral ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
214992230|NCT05736848|DEVICE|OviTex® PRS|OviTex® PRS is a reinforced tissue matrix intended to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
214992231|NCT02997293|OTHER|Enhanced Recovery protocol|The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.
214992232|NCT00311168|DEVICE|Intervention/treatment|"Device: VIP On~Device: VIP Off"
214378953|NCT02447289|DRUG|Intranasal midazolam|Midazolam injectable solution in a concentration of 5.0 mg/mL administered into the nose with an atomizer; dose of 0.2 mg/kg, maximum 5.0 mg
214378954|NCT02447289|DRUG|Oral midazolam|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent
214378955|NCT01563848|PROCEDURE|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
214378956|NCT01563848|PROCEDURE|Implantation of loop recorder|"The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events"
214378957|NCT01563848|PROCEDURE|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
214378958|NCT00651053|DEVICE|EUS|Sensitivity and specificity of EUS will be compared with PFT as reference standard.
214378959|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
214378960|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
214992233|NCT05712772|OTHER|Blue Light|Blue light exposure
214992234|NCT05712772|OTHER|Red Light|Red light exposure
214992235|NCT04302025|DRUG|Alectinib|Participants will receive oral alectinib twice per day (BID)
214992236|NCT04302025|DRUG|Entrectinib|Participants will receive oral entrectinib daily
214992237|NCT04302025|DRUG|Vemurafenib (Enrollment closed)|Participants will receive oral vemurafenib BID
214378961|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
214378962|NCT02131870|DIETARY_SUPPLEMENT|L plantarum DSM 9843 or placebo|
214687245|NCT01544595|DRUG|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
214992238|NCT04302025|DRUG|Cobimetinib (Enrollment closed)|Participants will receive oral cobimetinib daily
215091558|NCT02855723|OTHER|Surgery: GS strategy|sentinel node biopsy
215091559|NCT02855723|OTHER|Surgery: Classic strategy|systematic lymphadenectomy
215091560|NCT04832945|DRUG|Ivermectin 6 Mg Oral Tablet|Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
215091561|NCT03609476|PROCEDURE|Room temperature saline instillation|Saline is used as room temperature
215091562|NCT03609476|PROCEDURE|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
215091563|NCT03609476|PROCEDURE|No saline instillation|No saline is used prior to catheter removal
215091564|NCT03119389|BEHAVIORAL|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
215091565|NCT03688243|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
215091566|NCT01354704|DRUG|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
215091567|NCT04489121|DRUG|Omalizumab|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
215091568|NCT05413122|DRUG|Varenicline|At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.
215091569|NCT05413122|DRUG|Nicotine patch|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
215091570|NCT05413122|DRUG|Nicotine gum|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
215091571|NCT05413122|BEHAVIORAL|Intensive Behavioral Counselling|Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (\~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice.
215091572|NCT05413122|BEHAVIORAL|Peer Counselling|Participants randomized to the Peer Support condition will be engaged by a peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
215091573|NCT02203955|DRUG|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
215091574|NCT02203955|DRUG|Maltodextrin|4 chews (maltodextrin) daily for 12 months
214378963|NCT02640248|DEVICE|Cuff ETT|
214378964|NCT00116844|DRUG|Valaciclovir|Valtrex 1g once daily
214378965|NCT00116844|DRUG|Placebo|placebo
214378966|NCT04760522|GENETIC|WGS Diagnostic: Blood take for genetic diagnostic|Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).
214378967|NCT01899313|BEHAVIORAL|CBT- based SMS text messaging intervention|
214378968|NCT01899313|BEHAVIORAL|CBT group therapy|
214378969|NCT04810117|DIAGNOSTIC_TEST|Serodiagnosis of IgG and IgM|IgG and IgM antibodies will be detected in COVID-19 patients
214378970|NCT02380222|OTHER|Interview|Single interview lasting approximately one hour
214687246|NCT01544595|DRUG|Placebo|Placebo
214687247|NCT02508727|OTHER|MRI|
214687248|NCT02508727|OTHER|3D cardiac ultrasound|
214992239|NCT04302025|DRUG|Pralsetinib (Enrollment closed)|Participants will receive oral pralsetinib daily
214992240|NCT04302025|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion
214992241|NCT04302025|DRUG|SBRT|Patients will receive SBRT given concurrently starting with the first dose of atezolizumab
214992242|NCT04302025|PROCEDURE|Resection|Participants will receive surgical resection of the primary tumor along with selected lymph nodes
214992243|NCT04302025|DRUG|Chemotherapy|Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician
214992244|NCT04302025|DRUG|Divarasib|Participants in the KRAS G12C cohort will receive divarasib for approximately 8 weeks until the day before surgery.
215091575|NCT01123473|DRUG|capecitabine|
215091576|NCT01123473|DRUG|cisplatin|
215091577|NCT01123473|DRUG|epirubicin hydrochloride|
215091578|NCT01123473|DRUG|fluorouracil|
215091579|NCT01123473|DRUG|lapatinib ditosylate|
215091580|NCT06046469|DIAGNOSTIC_TEST|CT with contrast|CT abdomen and pelvis with IV contrast
215091581|NCT06046469|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis with contrast
215091582|NCT06046469|PROCEDURE|TURBT|transurethral resection of bladder tumor
215091583|NCT05275790|DEVICE|Vestal device|Battery powered non-invasive neurostimulation device
214992245|NCT02981693|PROCEDURE|Root canal sealer|Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
214992246|NCT05994690|DRUG|Standard Intervention Rc|3 consolidation courses (HAM + HA3E + FLA)
214992247|NCT05994690|DRUG|Investigational Intervention Rc|2 consolidation courses (HAM + FLA)
214992248|NCT05994690|DRUG|Standard Intervention Ri|No addition of GO to first induction course
214992249|NCT05994690|DRUG|Investigational Intervention Ri|Addition of GO to first induction course
214992250|NCT02483403|OTHER|Hyperpolarized Helium-3|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
214992251|NCT02483403|DEVICE|MRI|
214992252|NCT06314568|RADIATION|Radiochemotherapy plus interventional radiotherapy|All patients with vaginal cancer will undergo radiochemotherapy (45 Gy on pelvis and tumor in association with cisplatinum) plus interventional radiotherapy (28 Gy on residual disease) with exclusive intent
214992253|NCT04041648|DRUG|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
214992254|NCT04041648|DEVICE|L606 Inhalation System|Single ascending dose
214378971|NCT02582138|OTHER|Multicomponent intervention (MCI)|"The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .~The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:~* a daily total energy intake of 25-30 kcal/kg body weight;~* an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.~The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme."
214992255|NCT04041648|OTHER|Placebo Solution|Single ascending dose
214992256|NCT04559230|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
214992257|NCT05551741|BIOLOGICAL|IBC-Ab002|An anti-PD-L1 monoclonal antibody
214992258|NCT05551741|OTHER|Placebo|Normal Saline
214992259|NCT06060873|OTHER|Non-Interventional Study|Non-interventional study
214992260|NCT03076463|DIETARY_SUPPLEMENT|GRAPOM|The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
214992261|NCT05730205|DRUG|Nexplanon 68 MG Drug Implant|Progestin contraceptive device
214992262|NCT04485013|DRUG|TTX-080|Variable dose (Q3W)
214992263|NCT04485013|DRUG|TTX-080|Specified dose (Q3W)
214992264|NCT04485013|DRUG|pembrolizumab|Specified dose (Q3W)
214992265|NCT04485013|DRUG|cetuximab|Specified dose on specified days
214992266|NCT04485013|DRUG|FOLFIRI|Specified dose (Q2W)
214992267|NCT04485013|DRUG|cetuximab|Specified dose (Q2W)
214378972|NCT02582138|OTHER|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
214992268|NCT04485013|DRUG|TTX-080|Specified dose (Q2W)
214992269|NCT05698823|DEVICE|Lumoral Treatment|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
214992270|NCT02578797|DRUG|Apalutamide|Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
214992271|NCT04443413|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
214992272|NCT04443413|OTHER|Questionnaire Administration|Ancillary studies
214992273|NCT04443413|RADIATION|X-ray Therapy|Undergo x-ray therapy
214992274|NCT05658887|DRUG|Gabapentin|One dose of preoperative gabapentin 300 mg prior to vaginal apical support procedure
214992275|NCT05658887|DRUG|Gabapentin Placebo|Gabapentin Placebo
214992276|NCT04731480|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
214992277|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
214992278|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to Schneider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
214992279|NCT04731480|DRUG|Propofol|Manual propofol administration will be done using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
214992280|NCT06641089|DRUG|Sonelokimab|Sonelokimab
214992281|NCT06641089|DRUG|Placebo|Placebo
214992282|NCT06641089|DRUG|Risankizumab|Active comparator
214992283|NCT06640426|BEHAVIORAL|Two Messaging Nudges|This intervention involves receiving one personalized email and one personalized text message, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
214992284|NCT06640426|BEHAVIORAL|Five messaging nudges|This intervention involves patients receiving up to five personalized email and text messages, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
214992285|NCT06492993|OTHER|Education|The CHN meets with DDBHH participant over sessions to provide navigation support through the cancer screening process.
214992286|NCT06637332|DRUG|Daptomycin for Injection|Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
214687249|NCT01401829|BEHAVIORAL|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
214992287|NCT06637332|DRUG|Vancomycin (IV)|Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
214992288|NCT06950398|OTHER|NMP viability testing|NMP viability testing before transplantation of discarded livers
214992289|NCT05401201|DEVICE|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
214992290|NCT05401201|OTHER|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self care.
214992291|NCT04928391|DRUG|Dexmedetomidine|A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
214992292|NCT04928391|DRUG|Nalbuphine|A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery
214992293|NCT04928391|OTHER|0.9% saline|Same volume of saline placebo IV at the end of surgery
214992294|NCT05865314|OTHER|Optimisation of nutrition therapy coupled with early mobilisation|"Optimisation of nutrition therapy coupled with early mobilisation with:~* Optimisation of nutrition therapy during ICU stay~* Optimisation of physiotherapy during ICU stay~* Better communication and closer collaboration between physiotherapy and nutrition teams.~* Optimisation of continuity of the care."
214992295|NCT05865314|OTHER|Standard care|Patients will receive nutritional therapy and mobilisation according to local standard procedures.
214992296|NCT05905536|DEVICE|Vitalstream|The device will be placed on the subject and monitoring started in the holding room on the morning of surgery. Monitoring will continue postoperatively until the pulmonary artery catheter (PAC) is removed (Standard of Care) or discharged, or at study team discretion. At Intensive Care Unit (ICU) admittance and again 3 hours later a straight leg raise will be done to monitor for changes in hemodynamics.
214992297|NCT05836077|OTHER|Education with pecha kucha method|Education with pecha kucha method
214992298|NCT05635006|OTHER||No special intervention, randomly classify the subjects
214992299|NCT06328712|DRUG|EN001|"* Cohort 1: EN001 1.25×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.~* Cohort 2: EN001 2.5×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals."
214992300|NCT04472299|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the intervention group will have ultrasound guided bilateral T3 paravertebral catheters placed prior to surgery. Prior to surgery, these patients will have 5ml of 1.5% lidocaine with 1:200,000 epinephrine injected in each catheter. Ropivacaine 0.2% will be administered via programmed intermittent bolus of 7ml every 60 minutes through each catheter during and after surgery.
214992301|NCT06619444|BEHAVIORAL|Aerobic exercise only|Aerobic exercise training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous (50-80% of heart rate reserve). Intensity of the exercise sessions will be built of gradually. Sessions will occur 2 times per week for the duration of the year trial
214992302|NCT06619444|BEHAVIORAL|30 min of resistance exercise|30 min of resistance exercise (RE) will consist of 30 total minutes of resistance exercise each week (15 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 15 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 4 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 45 min per session. Sessions will occur 2 times per week for the duration of 1 year.
215091584|NCT05275790|BEHAVIORAL|Lifestyle intervention|All subjects will be prescribed a diet plan and instructed to follow it for the duration of the 12-week study. The diet plan will be designed by the P.I. who is a qualified, obesity management coach.
215091585|NCT04825431|DRUG|TAS-205, [14C]TAS-205|single oral administration under fasted conditions on day 1
214687250|NCT01401829|BEHAVIORAL|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
214378973|NCT05535543|PROCEDURE|Prone Positioning|Patients will be turned to prone position and they will be left in prone position for a duration of at least 16 hours to a maximum of 24 hours. This duration is recommended by the ARDS guidelines.
214378974|NCT04453423|DRUG|Anlotinib + Pemetrexed+Carboplatin|"Anlotinib: 12mg, QD, PO, d1-14, 21 days per cycle~Carboplatin: AUC 5 on day 1 of 21 days per cycle~Pemetrexed: 500mg/m2 iv on day 1 of 21 days per cycle"
215091586|NCT05183269|DEVICE|Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)|Use of the Oncomfort virtual reality monitor
214378975|NCT04453423|DRUG|Pemetrexed|500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)
214378976|NCT04453423|DRUG|Anlotinib + Pemetrexed|"Anlotinib:12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)~Pemetrexed:500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)"
214378977|NCT04453423|DRUG|Anlotinib|12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)
214378978|NCT02789475|DRUG|Amlodipine|Amlodipine administration
214378979|NCT02789475|DRUG|Rosuvastatin|Rosuvastatin administration
214378980|NCT05084417|OTHER|N/A This is an observational study|As this is an observational study, there are no interventions assigned to either cohort.
214378981|NCT03829163|DEVICE|Hydraulic Adjustable Walker|The HAW is a based on a conventional walker but has innovative telescoping legs with a leg adjustment assembly that includes at least one valve and at least one tube that delivers hydraulic fluid into the legs and allows a user to control the length of each leg. The legs of the walker are hydraulically adjustable, so that the front legs may be shortened and the back legs extended, or two side legs shortened and the two opposing side legs extended, so as to allow the walker to be securely placed on two different steps. This allows the user to be able to stand on a stair without worrying about sharing the same stair with the device. It also ensures that the height of the walker continues to be the right height for the user to minimize loss of balance.
214378982|NCT03829163|DEVICE|Conventional Walker|A walker consists primarily of a metal frame with four legs which are stabilized by crossbars. These walker frames come in a variety of shapes and sizes; many consist primarily of two inverted U-shaped leg modules connected by crossbars. Regardless of the shape or form of the leg modules, each walker frame forms a 3-sided box with an opening in which the user may stand.
214992303|NCT06619444|BEHAVIORAL|60 min of resistance exercise|60 min of resistance exercise (RE) will consist of 60 total minutes of resistance exercise each week (30 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 30 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 8 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 60 min per session. Sessions will occur 2 times per week for the duration of 1 year.
214992304|NCT06619444|BEHAVIORAL|120 min of resistance exercise|120 min of resistance exercise (RE) will consist of 120 total minutes of resistance exercise each week (60 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 60 min session of resistance exercise will consist of 3 sets of 8-15 repetitions at 50-80% of 1-rep max of 10 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 90 min per session. Sessions will occur 2 times per week for the duration of 1 year.
214992305|NCT00431418|DRUG|Sildenafil|Sildenafil oral solution
214992306|NCT00431418|DRUG|Placebo|Placebo solution
214992307|NCT02754453|BEHAVIORAL|Behavioral lifestyle intervention|20 session lifestyle behavioral intervention with the goal of altering diet and physical activity and decreasing problematic behaviors associated with weight regain and session behavioral intervention addressing increasing physical activity, improving adherence to dietary recommendations and altering problematic eating behaviors.
214992308|NCT03679793|PROCEDURE|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger
214992309|NCT03679793|PROCEDURE|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
214992310|NCT03965923|DRUG|Dapivirine (DPV) Vaginal Ring (VR)|Vaginal ring containing 25 mg of DPV
215091587|NCT06515314|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|"AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously.~Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days"
215091588|NCT02334488|DRUG|Everolimus|Active Comparator
214378983|NCT02491190|BEHAVIORAL|EMPOWER Educational Module|Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
214378984|NCT03737084|BEHAVIORAL|CBCT Intervention|The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
214378985|NCT06341725|OTHER|malignant lymph nodes|observational study
214378986|NCT05514080|OTHER|Insulin closed-loop|41-hour intervention period in which the participants are treated with rapid insulin in the closed-loop system.
214378987|NCT01905644|PROCEDURE|Perineal ultrasound|Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
214378988|NCT01988272|DEVICE|SPECT/CT imaging|Patients will undergo scanning on the above system.
214378989|NCT00674622|DRUG|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
214378990|NCT00674622|PROCEDURE|Placebo|Saline/lidocaine
214378991|NCT02442843|DEVICE|Active tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
214378992|NCT02442843|DEVICE|Sham tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
214992311|NCT03965923|DRUG|Truvada Tablet|Tablet taken orally
215091589|NCT02334488|DRUG|Tacrolimus|Active Comparator
215091590|NCT02334488|DRUG|Mycophenolate sodium|Experimental Arm
214378993|NCT00738101|DRUG|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
214378994|NCT03621202|DEVICE|Saranas Early Bird Bleed Monitoring System (EBBMS)|Participants will undergo their planned endovascular procedure with monitoring for internal bleeding using the Saranas EBBMS.
214378995|NCT03680625|DEVICE|Passive Distraction|Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal and/or removal of sutures. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.
214992312|NCT04491799|DIAGNOSTIC_TEST|Fecal calprotectin|Fecal calprotectin is a protein found in human neutrophils, and it is released during active periods of inflammation of intestine. The sensitivity and specificity has been reported at 93% and 96%, respectively in differentiating inflammatory bowel disease from irritable bowel syndrome in outpatient setting.
214992313|NCT00516607|DRUG|enzastaurin hydrochloride|
214992314|NCT00516607|DRUG|temozolomide|
214992315|NCT00516607|OTHER|pharmacological study|
214378996|NCT03680625|DEVICE|Virtual Reality Distraction|Patients in this group will be offered virtual reality distraction through the use of Oculus Quest® while they undergo their pins' removal and/or removal of sutures. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus head-mounted device and computer will be available in the procedure room and ready for immediate use. The head-mounted device will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin and/or suture removal in order for the child to get acquainted with the game and immersed in the virtual environment.
214378997|NCT00671203|PROCEDURE|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
214378998|NCT02007005|DRUG|abnobaVISCUM Fraxini|intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
214378999|NCT04834817|DEVICE|Celluma POD|A blue and near infrared handheld LED device
214379000|NCT06361472|OTHER|Standard Care|Standard Care includes exercises, mobilization, manual therapy, education, and Neck Wellness Home Care Guide (NWHCG). The rehabilitation program is based on current clinical practice guidelines aimed at reducing neck pain, improving range of motion, enhancing functionality, and promoting physical activity motivation. Each patient will receive active exercises and manual therapy techniques. Educational components will cover pain science, physical activity benefits, and return to normal activities , supplemented by a NWHCG. Treatment sessions will be conducted, featuring a one-to-one interaction between the participant and the physiotherapist. It will last 4 weeks, with two sessions per week, 45 minutes/session (8 treatment sessions).
214379001|NCT06361472|BEHAVIORAL|Contextual Factors|Bundle of contextual factors divided into three categories: professional, treatment, and healthcare setting features. Regarding the professional contextual factors, they include reputation, appearance, and positive attitudes. The treatment contextual factors encompass positive attitudes, verbal communication, non-verbal communication, empathetic therapeutic alliance, therapeutic touch, and the use of a mirror to show the patient what is being performed. Finally, the healthcare setting contextual factors feature a comfortable setting, adequate environmental conditions, and appropriate design.
214687251|NCT01401829|BEHAVIORAL|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
214992316|NCT03963388|OTHER|Speech therapy|Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
214992317|NCT02712853|OTHER|Saliva collection|Collection of saliva via swab for miRNA processing
214992318|NCT02712853|OTHER|Vineland Adaptive Behavior Scale-II Assessment|
214992319|NCT06095193|BEHAVIORAL|menopause education|Women will be taught the physiology of female reproductive organs, physiology of menopause, vaginal symptoms in menopause, sexual myths in menopause and practices that will support sexuality in menopause, in 50 minutes for 4 weeks.
214992320|NCT03368430|DIETARY_SUPPLEMENT|Melatonin|After performing scaling and root planing (SRP) in the test group, melatonin 10 mg oral capsule was taken once daily at night prior to bedtime for only 2 months during the 6-month study period
214992321|NCT03368430|DRUG|Placebo|After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
214992322|NCT05322343|OTHER|Questionnaires|"Participants will complete a series of three questionnaires at the V1 (at home, by a trained interviewer) repeated at V7 for the follow up phase:~1. A general questionnaire, with collection of general health history and exposure data~2. A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5, V6 visits. and V7, V9, V10 et V11 for the follow-up phase~3. An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety."
214992323|NCT05322343|OTHER|Fasting blood sampling.|"In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.~The blood collection is repeated at V8 during the follow-up phase (21 mL)."
214379002|NCT06614049|BEHAVIORAL|Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications|Receive personalised feedback and educational content curated by local clinicians and pharmacists through the CADENCE D-PHA app coupled with six sessions of human coaching on top of usual clinical care for lipid management over 6 months
214379003|NCT00091247|DRUG|tetracycline hydrochloride|
214379004|NCT00091247|OTHER|placebo|
214379005|NCT05273255|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
214379006|NCT06634069|DRUG|Sodium Lactate|0.5M HSL (containing 504mM of sodium and lactate)
214379007|NCT06634069|DRUG|3% NaCl|active compartor 3% NaCl
214379008|NCT00459238|OTHER|counseling intervention|subjects will receive telephone based counseling
214379009|NCT00459238|OTHER|educational intervention|subjects will received telephone based education
214379010|NCT05352802|BEHAVIORAL|Multimodal prehabilitation program|Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.
214379011|NCT05352802|BEHAVIORAL|ERAS protocol|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
214379012|NCT01817192|DRUG|Adjuvant Chemotherapy|Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
214379013|NCT01817192|OTHER|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.
214379014|NCT01817192|OTHER|14-Gene Prognostic Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
214379015|NCT06913127|OTHER|High intensity exercise post stroke|The patients are all admitted with an acute/ subacute stroke in an inpatient rehabilitation ward. They are randomized into a high intensity exercise or a low intensity exercise group that will last for 20 consecutive sessions. At the end of the experimental period, outcomes including functional outcomes, questionnaires, physical activity and fNIRS (functional near infrared spectroscopy) measurements will be compared between the two groups.
214379016|NCT05208554|BEHAVIORAL|Integrated health counseling and step prescription|8 weekly dyad-based sessions with a health counselor to train couples in the use of communal coping strategies to support one another in achieving physical activity goals plus individualized step prescription based on remotely-monitored Fitbit-derived step counts the week prior
214379017|NCT02640378|OTHER|NO intervention|This study was a cross-sectional study. It had no intervention.
214379018|NCT03895437|BIOLOGICAL|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
214379019|NCT03895437|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
214992324|NCT05322343|OTHER|Saliva collection and nasal or nasopharyngeal swab|On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
214379020|NCT05627401|PROCEDURE|Modified multiple orbital wall decompression|Thyroid dysfunction of all patients is stabilized by ATDs until treatment of TAO is completed. All patients with sight-threatening GO were admitted for emergency steroid pulse therapy. And additional drugs for protecting gastrointestinal mucous membrane, potassium and calcium supplements, and sedatives were used. All emergency cases, whose signs of visual impairment clinically attributable to GO existed despite first-line steroid treatment, were referred and discussed at the surgical board of our interdisciplinary center for prompt surgical orbital decompression. Urgent orbital decompression was performed when response is absent or poor within 1-2 weeks.
214379021|NCT05474729|DRUG|minocycline|minocycline capsule 100mg per day orally
214379022|NCT02843802|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
214379023|NCT02843802|BIOLOGICAL|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
214379024|NCT03950180|OTHER|Prostate Cancer Comorbidity Index (PCCI) score|Life expectancy information
214379025|NCT02202434|DEVICE|Lotus Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
214992325|NCT05322343|OTHER|Urine and stool samples|During the V2 visit, the nurse will collect urine and stool samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator. Stool sampling os repeated at V8 during the follow-up phase.
214379026|NCT02202434|DEVICE|CoreValve/Evolut R Transcatheter Aortic Valve Replacement System|Procedure: Transcatheter aortic valve replacement (TAVR)
214379027|NCT02202434|DEVICE|LOTUS Edge Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
214379028|NCT06244121|DRUG|Pyridoxine|pyridoxine (Vitamin B6) will be given as an anti oxidant.
214379029|NCT06244121|DRUG|Placebo|Placebo will be given in control group
214992326|NCT05322343|OTHER|Hair and a tonenail (or hand nail) sampling|During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope. The hair collection is repeated at V8 during the follow-up phase.
214992327|NCT05322343|OTHER|Nasal microbiota|Nasal or nasopharyngeal swab
215091591|NCT01188616|BEHAVIORAL|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
215091592|NCT06520631|OTHER|Ice packs (cryotherapy)|"One group of patients receives ice pack applied on the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.~The second group of patients receives ice pack applied on contralateral to the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis."
214379030|NCT03128437|BEHAVIORAL|Aerobic Exercise|At each of the six exposure sessions, participants will be invited to engage in 2-minute warm-up on the treadmill. Following this warm-up period, participants will be asked to briskly walk or jog on the treadmill at a speed that maintains their heart rate at 60-80% of maximum age-predicted heart rate for 20 minutes using the formula: (220-age) x (0.60 \[lower bound\] or 0.80 \[upper bound\]). Participants will be fitted with a heart rate monitor, which will be checked by a research assistant at 5-minute intervals in order to ensure adherence to this prescription; participants will be asked to adjust treadmill speed in order to remain in this range. Following each 20-minute exposure, participants will complete 5 minutes of cool down walking on the treadmill. Assessments will take place at baseline, week 2 (post-intervention), week 4, and week 8.
214379031|NCT04013958|DRUG|IV Ketamine|IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
214379032|NCT04013958|DRUG|IM Ketamine|IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
214379033|NCT02365974|DEVICE|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.
214379034|NCT02365974|DEVICE|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
214379035|NCT02323347|OTHER|Progesterone|Progesterone level
214379036|NCT02129816|DRUG|Bryophyllum|
214379037|NCT01114750|DRUG|Insulin in dextran matrix capsule (and placebo)|Single dose capsule (and placebo)
214379038|NCT03075501|BEHAVIORAL|Paired|Drug conditioning is assessed by pairing drug administration with a given context.
214379039|NCT03075501|DRUG|Stimulant or sedative|CS+ for paired, CS0 for unpaired
214379040|NCT03075501|DRUG|Placebo|CS- for paired, CS0 for unpaired
214379041|NCT06217887|DRUG|loxenatide Group|Loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
214497638|NCT02957799|BEHAVIORAL|Accountable Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive ongoing monitoring and supervision. CHW will monitor mother's health and linkage to care; CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. CHW will also have a mobile phone to record information at each visit. CHW will log their home visits each day, rate the content and skills addressed on the mobile phone, weigh children, and report outcome achievements (e.g., receiving the child grant, immunizations, breastfeeding, and retention/ adherence to HIV care). The CHW in this arm will receive data-informed supervision. CHW will be monitored weekly with review of contact logs, recorded outcomes, and random site visits by supervising in-service training on a monthly basis. The Accountable Condition will last for two years (until the child is 24 months old).
214497639|NCT02957799|BEHAVIORAL|Control Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive supervision and monitoring consistent with local government practices. CHW will monitor mother's health and linkage to care. CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. The Control Condition will last for two years (until the child is 24 months old).
214497640|NCT01645046|DRUG|Coenzyme A|Coenzyme A 200mg per day.
214497641|NCT01645046|DRUG|Coenzyme A|Coenzyme A 400mg per day.
214497642|NCT01645046|DRUG|Placebo|Capsule without coenzyme A.
214992328|NCT05322343|OTHER|Measurements|"In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit. Some of these measures (blood pressure, grip strength, screening of sarcopenia and Parkinson's syndromes) are repeated at V8 during the follow-up visit.~Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes."
214992329|NCT05322343|OTHER|Neuroimaging|"A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes.~The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed"
215091593|NCT00413010|DRUG|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
215091594|NCT00413010|DRUG|placebo|placebo + concurrent GAD treatment from the open-label study period
215091595|NCT04494724|DRUG|Clazakizumab|Infusion
215091596|NCT04494724|DRUG|Placebo|Infusion
214379042|NCT06217887|DRUG|Gliclazide Group|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
214379043|NCT02261090|DRUG|Formulation B: Pramipexole Slow release (SR) tablet|
214379044|NCT02261090|DRUG|Formulation C: Pramipexole Slow release tablet|
214379045|NCT02261090|DRUG|Formulation D: Pramipexole Slow release tablet|
214379046|NCT02261090|DRUG|Formulation E: Pramipexole Slow release tablet|
214379047|NCT02261090|DRUG|Formulation F: Pramipexole Slow release tablet|
214379048|NCT02261090|DRUG|Formulation G: Pramipexole Slow release tablet|
214379049|NCT02261090|DRUG|Formulation H: Pramipexole Slow release tablet|
214379050|NCT02261090|DRUG|Pramipexole immediate release (IR) tablets|
214379051|NCT05142670|PROCEDURE|experimental group: task-oriented training individualized by the gravity perception|All participants received 50 minutes of physical therapy per session for 5 days per week for 8 weeks. Subjects in the experimental group underwent 20 minutes of task-oriented training individualized by the gravity perception following 30 minutes of regular physical therapy. All outcome measurements were evaluated on the day before intervention (pretraining), 4 weeks and 8 weeks after training by the same physical therapist (who was blinded to the group of the subjects). These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
214379052|NCT05142670|PROCEDURE|control group: visual feedback treatment|Subjects in the control group underwent 20 minutes of visual feedback (VF) treatment. The regular physical therapy protocols for the control group were the same as those used for the experimental group. These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
214379053|NCT00818103|DRUG|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
214379054|NCT00818103|DRUG|β-interferon|β-interferon 50ug i.m. qod for 2 years
214497643|NCT00993174|PROCEDURE|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
214497644|NCT00993174|PROCEDURE|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
214687252|NCT03699839|BIOLOGICAL|High-dose influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
214687253|NCT03699839|BIOLOGICAL|MF59-adjuvanted influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
214992330|NCT05322343|OTHER|Medical visit|For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.
214992331|NCT03282097|BEHAVIORAL|DECAD decision aid|A mammography decision aid directed toward family caregivers of older women with Alzheimer's disease and other dementias to assist with decisions about breast cancer screening.
214992332|NCT03282097|OTHER|Home safety guide|The home safety guide to provide tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
214992333|NCT02226159|DRUG|Lidocaine|
214379055|NCT00818103|DRUG|EPO|EPO 10000U i.h. bid for 5 days
214497645|NCT05853861|BEHAVIORAL|JASPER|JASPER is an evidence based early intervention that focuses on the core social communication and engagement skills of young children that are important to improvements in communication and language.
214497646|NCT05853861|BEHAVIORAL|Babble Bootcamp|Babble Bootcamp is a new intervention focusing on the speech-motor system and aims to improve babbling and early word use in infants known to be at risk for language delay.
214992334|NCT02226159|DRUG|Lidocaine with Dexamethasone|
214992335|NCT02120326|DEVICE|Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* 2 mA intensity~* Continuous stimulation for 20 min with rise times and fall times of 10 seconds each"
214992336|NCT02120326|DEVICE|simulation of Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* The intensity of the stimulation current is 2 mA~* The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation."
215094711|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
215094712|NCT01345383|PROCEDURE|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
214497647|NCT03989388|BEHAVIORAL|Occupational self-analysis|"The Occupational Self-Analysis program provides participants with a space where they can learn to analyse the barriers and supports for occupational participation."
214497648|NCT03989388|BEHAVIORAL|Vocational guidance|To explore participant´s job interests and learned how to find a job and define a professional profile.
214497649|NCT03989388|BEHAVIORAL|Usual Rehabilitation|Usual rehabilitation: occupational therapy and/or physiotherapy.
214497650|NCT02859844|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS)|
214497651|NCT06403540|DIAGNOSTIC_TEST|ultrasonography|Using ultrasonography to measure diaphragm thickness
214497652|NCT06129500|BEHAVIORAL|Cognitive Behavioural Therapy for Problematic Impulsive Behaviours|Up to 12 sessions of Cognitive Behavioural Therapy adapted to focus on mood-driven impulsivity in adults with bipolar disorder.
214497653|NCT06453577|DRUG|Recompensation (guideline directed medical therapy)|Recompensation mainly achieved by intravenous diuretics and/or vasodilators but no requirement for positive inotropic drugs such as catecholamines or levosimendan.
214497654|NCT00225407|DRUG|Smoking of cannabis cigarettes (different strength)|
214497655|NCT00138541|DRUG|vildagliptin|
214687254|NCT03699839|BIOLOGICAL|Standard intramuscular influenza vaccine|The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
214687255|NCT04461847|PROCEDURE|subcutaneous mastectomy|Operating subcutaneous mastectomy
214687256|NCT04461847|PROCEDURE|endoscopic subcutaneous mastectomy|Operating endoscopic subcutaneous mastectomy
214379056|NCT03357120|OTHER|Follow-up after neoadjuvant chemotherapy|"Sequential plasma samples for ctDNA mutations analysis will be taken during the post-surgery visit (within 2-5 weeks after surgery) and every 6 months (+/- 1 month) thereafter for 5 years. In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated). Next Generation Sequencing (NGS) analysis will be performed on post-neoadjuvant chemotherapy residual tumor tissue samples. The mutations identified by NGS in residual tumor will be tracked in ctDNA using personalized digital PCR (dPCR) or by an NGS technique whose bioinformatics pipeline is adapted to the analysis of ctDNA.~In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated)."
214379057|NCT01105806|BEHAVIORAL|(CPR) video and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
214992337|NCT01410825|BIOLOGICAL|Retrovirus-mediated gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
214992338|NCT05753800|DEVICE|INTORUS|Motor intervention protocol with Intorus consisting of a series of exercises of progressive difficulty
214992339|NCT01732211|BIOLOGICAL|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
215091597|NCT04981028|OTHER|Questionnaires (including PHQ-9, TYM and SF-36)|For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1). There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis. For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2). Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months. The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
214379058|NCT01105806|BEHAVIORAL|cardiopulmonary resuscitation (CPR) narrative script and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
214379059|NCT03279055|BEHAVIORAL|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a publicly available insomnia intervention program. It focuses on 5 treatment components that form the core of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention.
215091598|NCT02179255|DRUG|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
215091599|NCT02179255|DRUG|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
215094713|NCT01975610|DRUG|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
214379060|NCT01886963|DEVICE|SPY - Unblinded use of SPY Elite|Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging
214379061|NCT01886963|DEVICE|Control - Blinded use of SPY Elite|Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
214379062|NCT02813967|RADIATION|Radiotherapy 54 Gy|Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.
214379063|NCT02813967|RADIATION|Radiotherapy 60 Gy|Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.
214379064|NCT02813967|DRUG|S-1|S-1 70mg/m2 was administered on days 1-14 and 29-42.
214379065|NCT05520385|DIAGNOSTIC_TEST|blood group and Rh|check of blood group , Rh for patient and control
214379066|NCT02994602|DRUG|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
214992340|NCT01732211|OTHER|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
214992341|NCT06050993|OTHER|Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.|During the preoperative procedure scheduled at the Paul Brousse hospital, 3 additional blood tubes (total volume 12 ml) will be withdrawn in addition of samplings already done for the patient's standard of care.
214992342|NCT05404100|PROCEDURE|Aortic valve replacement|SAVR or TAVR
214992343|NCT00363740|DRUG|GW685698X Aqueous Nasal Spray|
214992344|NCT06001021|DRUG|Psychopharmacological Intervention|Escitalopram 5-10 mg in antenatal period; Sertraline 12.5-25 mg in postnatal period) and/or Benzodiazepine (Alprazolam, 0.25-0.50 mg).
214992345|NCT06001021|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT intervention from a trained psychologist in CBT.
214992346|NCT06001021|OTHER|Combination of Psychopharmacological Intervention and CBCT|Medication will be prescribed by a consultant gynecologist and CBCT (conditions: with or without Zikr) will be provided by a trained psychologist.
214992347|NCT06001021|OTHER|Placebo and No Intervention|Control waitlist group will be provided with either a placebo by a consultant gynaecologist or no intervention by a trained psychologist
214992348|NCT03575169|DEVICE|BIS Monitor|Unilateral BIS electrode
214497656|NCT01155206|DRUG|glucagon|glucagon 3ng/kg/min
214497657|NCT00589875|BIOLOGICAL|CAN-2409|Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.
214379067|NCT03659253|DIAGNOSTIC_TEST|Oral Fluid Based Self Testing|The intervention will introduce provider supervised and unsupervised self-testing as an option for early HIV diagnosis among MSM community in Denpasar Bali Indonesia.
214379068|NCT03659253|PROCEDURE|Simplified ART Initiation|In this intervention, there will be a change in the clinical practice of ART initiation. In the current practice, clients are asked to perform full pre-ART laboratory examination (complete blood count, liver and renal function tests) before decision of ART initiation. In this intervention, the study participants who are already confirmed as HIV positive and meet specific clinical criteria (see below) will initiate ART (antiretroviral therapy) immediately (after clients' approval) without having to perform full pre-ART laboratory examination. Here, laboratory criteria for initiating ART will be simplified and specific laboratory examination, I.e. creatinine test will be delayed in two weeks after ART initiation.
214379069|NCT03659253|PROCEDURE|CBO AND BROTHEL-BASED ART SERVICE|The CBOs involved in this intervention are Kebaya and Vesta. Kebaya is an CBO working for Transgender (TG) community. It serves as community gathering place for TG and others, as HIV testing site on regular bases, and also as shelter for homeless HIV patients. The proposed intervention Is that HATI Project will provide HIV testing and treatment in the community, CBO and brothel in collaboration with nearby Puskesmas.
214379070|NCT03659253|BEHAVIORAL|SMS REMINDER|HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.
214379071|NCT03659253|PROCEDURE|MOTIVATIONAL INTERVIEWING|"The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence"
214379072|NCT02177539|DRUG|Cyclopentolate|Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
214379073|NCT02177539|DRUG|Cyclopentolate+tropicamide+phenylephrine|New scheme. All drugs together and wait 30 minutes for retinoscopy
214379074|NCT01686165|DRUG|belinostat|Given IV
214379075|NCT01686165|BIOLOGICAL|rituximab|Given IV
214379076|NCT01686165|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
214379077|NCT05918562|DIETARY_SUPPLEMENT|Low fiber diet|Low fiber diet including cereal, white bread, eggs, meat, dairy
214379078|NCT05918562|DIETARY_SUPPLEMENT|Standard clear liquid diet|Standard clear liquid diet including broth, jello, water, juice
214379079|NCT02753205|DRUG|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
214992349|NCT02755090|DRUG|Nitrous Oxide|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
214992350|NCT02755090|DRUG|IV Saline|
214992351|NCT06019078|DEVICE|SedLine|Continuous 4 channel processed neurological monitor
214379080|NCT02753205|DRUG|normal saline|infusion of normal saline
214379081|NCT01062763|DRUG|spironolactone|25 to 50 mg once daily
214379082|NCT01062763|DRUG|placebo|addition of placebo 1 to 2 tablets daily
214379083|NCT06190262|BEHAVIORAL|The intervention is community based group psychoeducation|The intervention is community based group psychoeducation
214379084|NCT05510726|DEVICE|shearwave elastography|shearwave elastography on upper or lower limb
214379085|NCT02494921|DRUG|Docetaxel-PNP|Given IV
214379086|NCT02494921|DRUG|Ribociclib|Given Orally
214379087|NCT02494921|DRUG|Prednisone|Given Orally
214379088|NCT02494921|DRUG|Filgrastim|Given IV
214992352|NCT00758888|PROCEDURE|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
215091600|NCT01189292|DRUG|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
215091601|NCT01189292|OTHER|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
215091602|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)"
214379089|NCT01913158|DRUG|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone acetate suppositories
214379090|NCT01913158|DRUG|Placebo suppository|Hydrogenated palm kernel oil suppositories
214379091|NCT03534765|DIAGNOSTIC_TEST|CT abdomen +/- pelvis|Diagnostic CT scan (only if requested by responsible clinicians)
214992353|NCT00758888|PROCEDURE|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
215091603|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))"
214992354|NCT00758888|OTHER|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
214992355|NCT04940221|BEHAVIORAL|Shared Decision Making|Telephone delivered non-persuasive shared decision-making for lung cancer screening.
214992356|NCT00512434|PROCEDURE|Osteosynthesis|Nail or external fixator Intervention 'Osteosynthesis'
214992357|NCT02926014|DEVICE|Videolaryngoscopy|A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
215091604|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)"
214379092|NCT03534765|DIAGNOSTIC_TEST|Edmunton Frailty Score|Patient completed previously valided questionnaire quantifying frailty.
214379093|NCT03534765|PROCEDURE|Emergency laparotomy for general surgical pathology|Emergency general surgical laparotomy (defined by the UK NELA body)
214379094|NCT00345319|BIOLOGICAL|rabies vaccine|Administration of PCECV according to ESSEN regimen
215091605|NCT00605891|DRUG|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
214379095|NCT02152228|DRUG|EnteraBio's Oral Parathyroid Hormone (1-34)|Oral administration
214379096|NCT01247714|DIETARY_SUPPLEMENT|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
214379097|NCT01247714|DIETARY_SUPPLEMENT|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
214992358|NCT02926014|OTHER|Reflux Symptom Index Questionnaire|A validated clinical tool for suspecting laryngopharyngeal reflux (LPR). The questionnaire was proposed by Belafsky et al. (2002) and consists of 9 most common gastroesophageal reflux disease (GERD) and LPR symptoms: hoarseness or a problem with your voice; clearing your throat; excess throat mucus or postnasal drip; difficulty swallowing food, liquids, or pills; coughing after you ate or after lying down; breathing difficulties or choking episodes; troublesome or annoying cough; sensation of something sticking in your throat or a lump in your throat; heartburn, chest pain, indigestion, or stomach acid coming up. Each symptom is evaluated on a scale from 0 to 5 (0 - no complaint, 5 - severe symptom). The sum of all symptom evaluations ranges from 0 to 45.
214992359|NCT02926014|OTHER|Dysphagia Screening Questionnaire|"A validated questionnaire, proposed by Ohkuma et al. (2002). Lithuanian version of the questionnaire consists of 16 questions: choking during swallowing meals / liquids; difficulty eating solid foods; difficult swallowing; feeling of food getting stuck in the throat; longer than before eating time; feeling of food remaining in the mouth; feeling that food or liquid is going up into the throat from the stomach; feeling of food being stuck in the esophagus; weight loss; food getting stuck in the throat; food falling from the mouth; difficulty coughing during or after meals; occurrence of pneumonia; hoarseness; coughing during the night. Interpretation of dysphagia screening questionnaire:~Advanced symptom - 2 points; Moderate intensity symptom - 1 point; No symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points."
214992360|NCT04696471|DEVICE|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
214992361|NCT04696471|DEVICE|Sham Continuous Theta Burst Stimulation (Sham cTBS)|Sham cTBS goes through the motions of applying cTBS to the brain but administers very low current so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
214992362|NCT05577000|BIOLOGICAL|Manufactured Anti-BCMA CAR-T cells|Given IV
214992363|NCT05577000|DRUG|Fludarabine|Given IV
214992364|NCT05577000|DRUG|Cyclophosphamide|Given IV
214992365|NCT04928599|OTHER|Electronic Health Record Review|Review of medical records
214992366|NCT04928599|OTHER|Interview|Complete interview
214992367|NCT04928599|OTHER|Survey Administration|Complete survey
214379098|NCT01247714|DIETARY_SUPPLEMENT|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
214379099|NCT01247714|DIETARY_SUPPLEMENT|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
214379100|NCT04618822|BEHAVIORAL|Teaching involving whole-body movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve whole-body movements and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
214992368|NCT05735834|DRUG|Rituximab|Truxima concentrate for solution for infusion 500 mg/50 ml
214992369|NCT05735834|DRUG|Zanubrutinib|Zanubrutinib 80 mg hard capsules
214992370|NCT06083896|PROCEDURE|Photodynamic nails|stab incision is made at the entry site
214379101|NCT04618822|BEHAVIORAL|Teaching involving hand movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve movements using hands and arms and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
214992371|NCT03515746|DEVICE|Exergaming in virtual environment|"The 10 cubes task will be performed in virtual environment - either in 2D on a laptop computer or in 3D using 3D goggles"
214992372|NCT01938326|PROCEDURE|Approach Method|SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
214992373|NCT01943604|OTHER|Nutella Breakfast|Breakfast composed of bread and Nutella, milk and apple slices
214992374|NCT01943604|OTHER|Waffle Breakfast|Breakfast composed of waffles and syrup, milk, and apple slices
214992375|NCT05389904|OTHER|Arm 1: Routine care|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive standard of care.
214992376|NCT05389904|OTHER|Arm 2: Preemptive C. difficile infection prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive a preemptive prevention bundle for C. difficile. The prevention bundle will include enhanced room cleaning, C. difficile precautions (staff entering room must wear gown and gloves and wash hands with soap and water upon exiting the room), pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
215091606|NCT00605891|DRUG|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
215091607|NCT00120055|DRUG|Atorvastatin (Lipitor)|
214497658|NCT00589875|DRUG|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
215094714|NCT01975610|DRUG|Placebo|Twice daily for 28 days
215094715|NCT01853956|DRUG|Alprazolam 0.25 mg|Reference product
215094716|NCT01853956|DRUG|Alprazolam 0.25 mg|Test product
215094717|NCT01649024|DRUG|Tremelimumab|Given IV
214379102|NCT04618822|BEHAVIORAL|Teaching involving minimal motor movements (control)|The control condition consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in groups of app. twelve children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities are completed seated on a chair using paper and pencil.
214379103|NCT00660335|DRUG|RG1068 (synthetic human secretin)|Single-dose, IV infusion
214379104|NCT02795208|PROCEDURE|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
214992377|NCT03913039|PROCEDURE|Transperineal biopsy Protocol|"1. Transperineal biopsy approach with avoidance of rectal flora~2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~4. Multi-antibiotic prophylaxis~5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
214992378|NCT01853865|OTHER|Instruction in self-referral|
214992379|NCT04797169|BEHAVIORAL|Noom Health|In Noom Health, participants will be encouraged to use the Noom app multiple times a day to log eating episodes, physical activity and weight. They will also have the ability to interact with coaches to receive advice and feedback specific to weight loss.
214992380|NCT04797169|BEHAVIORAL|Noom Digital Health|In Noom Digital Health, participants will use a simplified version to log eating episodes and weight. Both conditions will receive the same weight loss advice content.
214379105|NCT03942679|OTHER|PRP|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 2015). After the injection, patients will be instructed to limit the use of shoulder for at least 24 hours and to use cold therapy for pain. After the third injection, ROM, and stretching exercises will be allowed and one month after the end of injections, patients will be recommended to begin the strengthening program as tolerated. Exercise is performed with 10 repeats five sessions per week.
214992381|NCT05429320|PROCEDURE|Local ablative therapy|In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT. In Part II of the study, patients will be randomized to standard of care (continuation of systemic therapy) vs. LAT to all sites of disease
214992382|NCT05429320|OTHER|Blood collection to assess for ctDNA|Participants will undergo ctDNA collection in conjunction with their standard of care therapy.
214992383|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 25mg|25mg CTx-1301 (Dexmethylphenidate tablet)
214992384|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 37.5mg|37.5mg CTx-1301 (Dexmethylphenidate tablet)
214992385|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 50mg|50mg CTx-1301 (Dexmethylphenidate tablet)
214992386|NCT05631626|DRUG|Placebo|Placebo
214379106|NCT03942679|OTHER|physiotherapy|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks). After the physical therapy, the exercise program will be continued as homework during the follow-up period.
214379107|NCT02825134|DEVICE|Transcatheter aortic valve replacement|Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
214379108|NCT02825134|DEVICE|Surgical aortic valve replacement|Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
214379109|NCT01468779|DIETARY_SUPPLEMENT|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
214379110|NCT01468779|DIETARY_SUPPLEMENT|Sugar pill|
214992387|NCT04109924|DRUG|Irinotecan|Given IV
214992388|NCT04109924|BIOLOGICAL|Bevacizumab|Given IV
214992389|NCT04109924|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214992390|NCT03498261|DRUG|Gabapentin|Gabapentin has been commonly used as an adjuvant in the treatment of neuropathic pain.
214379111|NCT02254083|DRUG|BIBT 986 BS - low|
214379112|NCT02254083|DRUG|BIBT 986 BS - high|
214687257|NCT06993597|DRUG|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Subjects with glaucoma may be prescribed prostaglandin analogs as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
214379113|NCT02254083|DRUG|Placebo|
214992391|NCT03498261|DRUG|Placebos|Placebo
214992392|NCT05473039|DIETARY_SUPPLEMENT|Seidivid Ferty4|The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
214992393|NCT05473039|OTHER|Placebo|The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
214379114|NCT04845464|OTHER|Cognitive Assessment (not diagnostic)|Sleep quality and cognition will be assessed in young adults
214379115|NCT05168917|DIAGNOSTIC_TEST|LIAISON Calprotectin|Immunoassay for fecal calprotectin measurement
214379116|NCT00764374|DRUG|YM443|oral
214379117|NCT05434143|BEHAVIORAL|Chorus Sleep|"During the 6-week intervention, participants will receive daily reminders to complete their daily sleep log and a link to a chorus sleep class for them to listen to that night.~The daily sleep class involve listening to 15 minute audio sessions, which include guided mediation and breathing exercises."
214379118|NCT05398380|OTHER|Liver transplantation|Liver transplantation
214379119|NCT00649363|DRUG|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
214379120|NCT00649363|DRUG|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
214379121|NCT01313546|OTHER|Stimulation of quariceps muscle|stimulation of quadriceps muscle through the stimulating catheter
214379122|NCT03615521|OTHER|Hotpack|Hotpack applied 20 minutes for knee 3 session for 6 weeks
214379123|NCT03615521|OTHER|Ultrasound|Ultrasound applied 10 minutes for knee 3 session for 6 weeks
214379124|NCT03615521|OTHER|Combine Exercise|Proprioceptive Neuromusculer Facilitation Technique İnclude eccentric and concentric contractions 3 session for 6 week
214379125|NCT03615521|OTHER|Repeated Contraction Exercise|Proprioceptive Neuromusculer Facilitation Technique include concentric contractions 3 session for 6 week
214379126|NCT03615521|OTHER|Standart Exercise Therapy|"Quadriceps, hamstring and hip muscle strength exercise. Hamstring stretch exercise.~3 session for 6 week"
214497659|NCT00589875|DRUG|Temozolomide|Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.
214497660|NCT00589875|RADIATION|Radiation therapy|Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.
214497661|NCT05786352|PROCEDURE|ERAS protocol|The combination of interventions explained in arm descriptions.
214497662|NCT06813027|BIOLOGICAL|EV|"Extracellular secretomes ( extracellular vesicles EV) derived from mesenchymal stroma cells (MSCs)"
214497663|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
214497664|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
214497665|NCT03488719|DRUG|Metoprolol Succinate 25 MG|A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
214497666|NCT03488719|DRUG|Metoprolol Succinate 50 MG|A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
214497667|NCT03488719|DRUG|Metoprolol Succinate 100 MG|A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
214497668|NCT06842537|DRUG|SYH2062 injection|SYH2062 for sc injection
214497669|NCT06842537|DRUG|SYH2062-Matching placebo|Normal saline matching volume of SYH2062 doses will be administered
214497670|NCT06598553|BEHAVIORAL|Projet Jeune Leader Comprehensive Sexual Education|PJL provides trained educators to deliver a 22 week comprehensive sexual education (CSE) curriculum in participating middle schools. All adolescents enrolled in the school receive the CSE program.
214687258|NCT06993597|DRUG|Beta Blocker|Subjects with glaucoma may be prescribed topical beta blockers as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
214687259|NCT06993597|DEVICE|Brillouin Microscopy|Brillouin microscopy is a non-contact optical imaging method used to assess the biomechanical properties of the cornea in vivo with three-dimensional resolution. It will be used to evaluate corneal stiffness in all study subjects.
214687260|NCT06236074|OTHER|Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours|Observation Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours
214687261|NCT06236074|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
214687262|NCT02200458|DEVICE|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
214687263|NCT02493309|OTHER|Prolonged sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.
214687264|NCT02493309|OTHER|Light activity breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
214687265|NCT01596075|DRUG|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade\>2). Cannabidiol will be given up to 90 days.
214992394|NCT06450925|DRUG|Vitamin A|Enrolled subjects will receive one observed oral vitamin A dose, prior to their HSCT, in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.
214992395|NCT06450925|OTHER|Placebo|Placebo pills containing microcrystalline cellulose will be dispensed in patients who are randomized to the placebo arm.
214992396|NCT04921943|DRUG|Hypertonic saline|Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
214992397|NCT04921943|DRUG|Azithromycin|Standard of care
214992398|NCT04921943|DRUG|Ethambutol|Standard of care
214992399|NCT04921943|DRUG|Rifampin|Standard of care
214992400|NCT06033846|DRUG|Minocycline|treatment with minocycline combined with first-line drugs for autoimmune encephalitis
214992401|NCT05963113|BEHAVIORAL|Pharyngeal Swallowing Exercises|12-weeks of proactive pharyngeal swallowing exercises conducted 5 times per week. The exercise program will include the following four exercises: effortful saliva swallows, tongue-hold swallows, effortful pitch glides and posterior lingual resistance. Each exercise set will include 10 repetitions of each exercise (40 reps per set). The number of sets will be gradually increased as tolerance builds.
214992402|NCT05963113|DIETARY_SUPPLEMENT|Protein Supplementation|12-week supply of the commercially-available Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink). Participants will be asked to consume one drink per day for the 12-week intervention period.
214992403|NCT05963113|DEVICE|MRI|Participants will be scanned using a 3T MRI scanner and a 16-channel phased array neck coil.
214992404|NCT05092451|DRUG|Cyclophosphamide|Given by IV
214992405|NCT05092451|DRUG|CAR.70/IL15-transduced CB-NK cells|Given by IV
214992406|NCT05092451|DRUG|Fludarabine phosphate|Given by IV
214992407|NCT04919408|OTHER|telephone survey|telephone survey with a questionnaire to assess pain at 3 months and then 6 months after their cesarean section
215091608|NCT03825237|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
215091609|NCT04845139|DRUG|Nivolumab|Nivolumab given intraventricularly
215091610|NCT06266104|PROCEDURE|Image Enhanced Endoscopy Filters|Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).
215091611|NCT05605171|PROCEDURE|Posterior reconstruction urethrovesical anastomosis.|Rocco stitch.
215091612|NCT05605171|PROCEDURE|Conventional vesicourethral anastomosis.|Standard of care.
215091613|NCT00958737|DRUG|FOLFOX regimen|6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))
215091614|NCT00958737|DRUG|CAPOX|4 or 8 cycles
215091615|NCT02475616|DRUG|PCO371|
215091616|NCT02475616|DRUG|Placebo|
214992408|NCT06850051|BIOLOGICAL|TIV-HA Vaccine formulation 1 at low dose|Suspension for injection in a vial. Route of administration: IM injection
214992409|NCT06850051|BIOLOGICAL|TIV-HA formulation 1 at high dose|Suspension for injection in a vial. Route of administration: IM injection
214992410|NCT06850051|BIOLOGICAL|TIV-HA formulation 2 at low dose|Suspension for injection in a vial. Route of administration: IM injection
214992411|NCT06850051|BIOLOGICAL|TIV-HA formulation 2 at high dose|Suspension for injection in a vial. Route of administration: IM injection
214992412|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 2 at low dose|Suspension for injection in a vial. Route of administration: IM injection
214992413|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 1 at high dose|Suspension for injection in a vial. Route of administration: IM injection
214992414|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 2 at high dose|Suspension for injection in a vial. Route of administration: IM injection
214992415|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 1 at low dose|Suspension for injection in a vial. Route of administration: IM injection
214992416|NCT06850051|BIOLOGICAL|RIV4 (Supemtek®)|Solution for injection in a prefilled syringe. Route of administration: IM injection
214992417|NCT05037370|DEVICE|Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation|Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye
214992418|NCT05718219|DRUG|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1, Day 8, Day 15, Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
214992419|NCT05718219|DRUG|SIM0348 + Sintilimab|Selected doses from Part 1A will be evaluated for SIM0348 when they were combined with Sintilimab (200mg once every 3 weeks).
215091617|NCT05105113|PROCEDURE|Zirconia dental implant installation surgery|Dental implant installation surgery using zirconia one-piece implant (Tav-dental)
215091618|NCT05039658|DRUG|IBI110 plus sintilimab|Sintilimab is a NMPA approved high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
215091619|NCT05039658|DRUG|IBI110|BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.
215091620|NCT03917550|BEHAVIORAL|Recovery (Transdiagnostic & self)|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.
214379127|NCT04297787|DEVICE|Thrombolysis in combination with endhole aspiration|The treatment protocol the study team will be following is as follows. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
214379128|NCT00823420|PROCEDURE|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
214497671|NCT06978296|RADIATION|Stereotactic body radiotherapy (SBRT)|"The acceptable regimens are:~* 27 Gy / 3 fractions / 3 fractions per week~* 35 Gy / 5 fractions / 3 fractions per week An interval of at least 24 hours should be kept between two consecutive fractions.~Prescription must be defined on 80% isodose or higher, maximum dose up to 130% of the isodose prescription. At least 90% of the Planning Target Volume should receive the prescribed dose. A coverage of \<90% of the Planning Target Volume will be considered as acceptable deviation, and coverage of \<80% of the target volume as an Unacceptable Deviation. At least 90% of the Gross Tumoral Volume should receive the prescribed dose.~Only a part of the Gross Tumoral Volume\_Total could be considered for radiation, depending on the ratio with Bone Marrow Reserve. High-risk and/or symptomatic metastases will be prioritized over other metastases.~Anatomic bone marrow reserve (BMR) will be first determined for each patient:~BMR = Total trabecular bone - (Total trabecular bone ∩ GTV\_Total)"
214497672|NCT04321603|BEHAVIORAL|Walking|Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
214497673|NCT05567497|PROCEDURE|trigeminal nerve block|ultrasound guided trigeminal nerve block
214497674|NCT06824155|DRUG|177Lu-RAD202|177Lu-RAD202 administered at Imaging (im) and Treatment (tr) doses
214497675|NCT06952218|PROCEDURE|Injection of cross linked hyaluronic acid filler|Injection of cross linked hyaluronic acid filler
214497676|NCT00585156|DRUG|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
214992420|NCT05090800|DRUG|Definity contrast during ultrasound|Participants will undergo an ultrasound contrast evaluation of both kidneys. This will include placement of an intravenous (IV) catheter in a vein and the delivery of Definity ultrasound contrast agent through the IV. Imaging will be completed for each kidney. The proposed total dose for adult patients will not exceed 20 microliters/kilograms (kg). Each individual dose not to exceed 10 microliters/kg. At initiation of patient studies, the dose will start at 10 microliters/kg for the first injection and a second 10 microliters/kg dose to evaluate the contralateral kidney. However, if ultrasound findings in patient studies demonstrate a dose that is too high (unable to make accurate ultrasound assessment), the dose will be reduced.
214992421|NCT02236364|DEVICE|Photographic Image Capture System|Collection of images of the iris along with corresponding fingerstick blood glucose
215091621|NCT03917550|BEHAVIORAL|Transdiagnostic|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
215091622|NCT04023617|DRUG|Nivolumab|Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
214497677|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspention; QID
214497678|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspension; QID
214497679|NCT01118754|DRUG|DE-101 ophthalmic suspension vehicle|ophthalmic suspension vehicle; QID
214497680|NCT06590064|DEVICE|Non-invasive Blood Pressure Measurement|Non-invasive Blood Pressure Measurement in Both Upper and Lower Limbs
214687266|NCT00601523|DRUG|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
214687267|NCT00601523|DRUG|Pramipexole|ER 0.375-4,5 mg
214687268|NCT03643432|BEHAVIORAL|Exercise adherence intervention|Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
214687269|NCT03643432|BEHAVIORAL|Usual Care|Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
214687270|NCT04415489|DEVICE|Office hysteroscopy|Use of hysteroscopy in the clinical setting to directly visualize the cavity. If pathology amenable to immediate treatment is visualize, removal will be attempted by hysteroscopic graspers.
214992422|NCT02535312|DRUG|Cisplatin|Given IV
214992423|NCT02535312|DRUG|Methoxyamine|Given PO
214992424|NCT02535312|DRUG|Pemetrexed Disodium|Given IV
215091623|NCT00708734|BEHAVIORAL|functional exercise training|twice weekly group sessions for 5 weeks
215091624|NCT00265018|DRUG|Adriamycin|
215091625|NCT00265018|DRUG|Bleomycin|
215091626|NCT00265018|DRUG|Vinblastine|
215091627|NCT00265018|DRUG|DTIC|
215091628|NCT00265018|RADIATION|30 Gy IF-RT|
215091629|NCT00265018|RADIATION|20 Gy IF-RT|
215091630|NCT01252524|DRUG|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
214379129|NCT05885113|BEHAVIORAL|NIDCAP Developmental Care|The intervention of Individualized Developmental Care (IDC) is designed to minimize the mismatch between the fragile infant brain's expectations and the experiences of stress and pain inherent in the hospital environment. An ICU that provides individualized, developmentally-supportive care includes a soothing environment, supports parents as their child's primary caregiver, providing continual adjustment of caregiving in support of the child's wellbeing by reading the infant's cues and providing interventions to calmness throughout caregiving, capitalizing on the infant's strengths, and providing supports toward healing, growth and learning. NIDCAP is the experimental intervention to be tested in the current study. NIDCAP is the only evidence-based, comprehensive, internationally recognized program of IDC.
214379130|NCT05404230|DIETARY_SUPPLEMENT|Fish oil|Fish oil containing poly unsaturated fatty acids.
214379131|NCT05404230|DIETARY_SUPPLEMENT|Corn oil|Corn oil
214379132|NCT03045029|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
214379133|NCT02679521|DEVICE|ESWT|"Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).~The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.~Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz)."
214992425|NCT06385132|OTHER|Psychological Tests' administration|to assess global psychological and psychiatric profile of patients affected by GBM and H\&N-C by means of standardized questionnaires
214992426|NCT04688736|DRUG|Placebo|The tablet resembles chlorpheniramine but has no therapeutic value.
214992427|NCT04688736|DRUG|Chlorpheniramine|An antihistamine that reduces the natural chemical histamine in the body.
214992428|NCT06441214|DRUG|Zanubrutinib|Patients will be treated with Zanubrutinib as per routine clinical practice.
214992429|NCT06260904|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) orally
214992430|NCT06260904|DRUG|Apremilast|Apremilast 30 mg twice daily orally
214992431|NCT06260904|DRUG|Methotrexate|Methotrexate 15 mg weekly orally
214992432|NCT06283628|PROCEDURE|Radiofrequency ablation of lumbar medial branch nerves.|"Traditional approach:~The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve.~Parasagittal (new) approach:~The RF cannula is placed parasagittally and more dorsally. The remainder of the procedure does not differ from the traditional method."
214992433|NCT03839641|OTHER|High fat meal|60% fat meal
214992434|NCT03839641|OTHER|Low fat meal|20% fat meal
214992435|NCT00029237|BEHAVIORAL|Cognitive-behavioral relaxation (Positively Living)|
214992436|NCT00029237|BEHAVIORAL|Spiritual growth group|
214992437|NCT00029237|BEHAVIORAL|Focused Tai Chi|
214992438|NCT04221490|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
214992439|NCT02942290|DRUG|Azacitidine|Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 \& Days 1-2 of Week 2 of 28 day cycle.
214992440|NCT02942290|DRUG|Venetoclax|Oral; Tablet
214992441|NCT05123625|PROCEDURE|Reduce surgical procedures|In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
214992442|NCT05940012|OTHER|Manual Therapy|Hands on treatments including manipulation, mobilization and soft-tissue mobilization with therapeutic intent.
214379134|NCT02679521|DEVICE|Placebo|Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
214379135|NCT00128011|BIOLOGICAL|killed oral cholera vaccine|
214992443|NCT05776888|OTHER|Ofatumumab|There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
214379136|NCT02714868|BEHAVIORAL|Project TEAM|Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.
214992444|NCT00837889|DRUG|diuretics, inotropica|
214992452|NCT05898204|OTHER|Ketogenic diet|Prescription of a ketogenic diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
214992453|NCT05898204|OTHER|Balanced diet|Prescription of a balanced diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
214992454|NCT05761171|PROCEDURE|Biospecimen Collection|Undergo collection of blood and CSF samples
214992455|NCT05761171|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214379137|NCT02714868|BEHAVIORAL|Matched Comparison|Participants set goal to try a new activity in the community
214379138|NCT05449886|PROCEDURE|TVC|Tidal volume challenge from 6ml/kg to 10ml/kg for 1 min.
214379139|NCT01547520|DRUG|Meperidine|intramuscular, 25 mg, 5 to 10 minutes before EGD
214379140|NCT01547520|DRUG|normal saline|25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
214379141|NCT04717973|DIAGNOSTIC_TEST|laboratory testing of CBC, serum ferritin, and vitamin B 12|"laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass."
214497681|NCT06861335|OTHER|Exercise|For each participant included in the exercise group, an individualized pelvic floor muscle exercise program will be created based on the results of digital palpation and the PERFECT assessment system. The first exercise session will be conducted with the physiotherapist, and the participant will be provided with a home-based program. During pregnancy check-ups, the pelvic floor muscles will be re-evaluated, and the exercise program will be updated according to the new evaluation results. To monitor the home-based program, participants will be given an exercise tracking chart that they will be asked to fill out daily
215091631|NCT01252524|DRUG|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
214497682|NCT06861335|BEHAVIORAL|Control|Participants in the control group of our study will receive standard pregnancy care and check-ups. Within this scope, the general health status of the pregnant women will be evaluated during routine antenatal follow-up visits, check-ups appropriate to their gestational weeks will be performed, and necessary medical interventions will be carried out. Additionally, participants will receive detailed education about pelvic floor anatomy, the functions of the pelvic floor muscles, and the changes that occur in these muscles during pregnancy. Within the scope of general health education, information will be provided about nutrition, hygiene, exercise, and other lifestyle recommendations during pregnancy. The participants in the control group will not be given the specific pelvic floor muscle training program applied in the experimental arm of the study; they will only receive standard pregnancy care and general information
214497683|NCT06416839|BEHAVIORAL|VR exercise|Participation in high intensity interval training delivered on a virtual reality headset over six-week period. Participants may exercise with others in the multiplayer mode and use any feature of the application.
214992456|NCT05761171|DRUG|Calaspargase Pegol|Given IV
214992457|NCT05761171|DRUG|Cytarabine|Given IV and IT
214992458|NCT05761171|PROCEDURE|Echocardiography Test|Undergo ECHO
214992459|NCT05761171|DRUG|Fludarabine Phosphate|Given IV
214992460|NCT05761171|DRUG|Hydrocortisone Sodium Succinate|Given IT
214992461|NCT05761171|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214992462|NCT05761171|DRUG|Methotrexate|Given IT
214992463|NCT05761171|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214992464|NCT05761171|DRUG|Prednisolone|Given PO or via NG, NJ, ND or G-tube
214992465|NCT05761171|DRUG|Prednisone|Given PO or via NG, NJ, ND or G-tube
214992466|NCT05761171|DRUG|Revumenib|Given PO or via NG, NJ, ND or G-tube
214992467|NCT05761171|DRUG|Vincristine Sulfate|Given IV
214992468|NCT06341114|DRUG|BAT8008 injection|BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.
215091632|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
215091633|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
214379142|NCT00997724|PROCEDURE|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
214379143|NCT00487734|RADIATION|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level \<500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
214379144|NCT00487734|DRUG|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
214379145|NCT03436134|OTHER|Sessions of conventional apheresis|"Patient receiving sessions of Plasma exchange as treatment of chronic antibody mediated rejection.~The plasma exchange uses a single filter to remove whole plasma and the volume is replaced with a matched volume of blood products +/- saline.) 8 sessions plasma exchange.Patients will have one session per day, 4 consecutive days and then three days without, then one session per day for 4 consecutive days. That's 11 days of treatment at all. The fourth and eighth sessions will be followed by an infusion of Rituximab 375 mg / m2.~At the beginning and at the end of each session, the patients will have a blood test to measure the parameters of the routine care and the analyzes, collection of biological samples planned for the study."
214379146|NCT03436134|OTHER|Sessions of news apheresis with double filtration|"Patient receiving DFPP as treatment of chronic antibody mediated rejection. 8 sessions~A Double filtration plasmapheresis (DFPP) is a variation of plasma exchange. The circuit contains two plasma filters : the first is a standard plasma filter and the second is a high molecular weight filter that primarily removes immunoglobulins. The depleted plasma is returned to the blood circuit and then to the patient."
214379147|NCT00002443|DRUG|Indinavir sulfate|
214379148|NCT00002443|DRUG|Zidovudine|
214992469|NCT06341114|DRUG|BAT1308 injection|One vial of 4 mL of concentrate contains 100 mg of BAT1308
214992470|NCT03034967|DRUG|Danirixin|Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
214379149|NCT04380129|OTHER|Music therapy-conversation sessions|"The intervention will be performed four times per patient at a frequency once weekly. An effort shall be made to ensure that each treatment is exactly seven days from the previous one within ± one day. The musical hearing will include Helen Bonny's program Caring, which is proposed by the author of this Music therapy model as the most suitable for patients with chronic and severe pain. The program is as follows:~* Haydn - Cello Konzert in C, Adagio~* Dvorak - Serenade in E-Dur, Larghetto~* Warlock - Capriol Suite, Pieds en I'air"
214379150|NCT04380129|OTHER|Music Listening|Music Listening to Helen Bonny's programme.
214379151|NCT00409695|DRUG|Low Dose Thymoglobulin (ATG)|2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
214379152|NCT00409695|DRUG|High Dose Thymoglobulin (ATG)|1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
214379153|NCT02596763|DRUG|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
214379154|NCT02710786|PROCEDURE|Gastric bypass|Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
214379155|NCT02057601|DRUG|Levobupivacaine infiltration group|The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
214379156|NCT00998907|DEVICE|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
214379157|NCT00998907|DEVICE|PDS II|polyglactin 910 suture material for abdominal wall closure
214379158|NCT00084214|DRUG|STA-4783|
214379159|NCT00084214|DRUG|Paclitaxel|
214379160|NCT01833312|DEVICE|Hypothermia|In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.
214379161|NCT01833312|DRUG|Buspirone|anti-shivering treatment
214379162|NCT01833312|DRUG|Pethidine|anti-shivering treatment
214379163|NCT03634501|BIOLOGICAL|Activated NK|Cell suspension
214379164|NCT02183935|DEVICE|Duodena-jejunal liner|
214379165|NCT02347514|BEHAVIORAL|Diabetes group visit|
214379166|NCT01861821|DEVICE|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication
214379167|NCT01861821|DEVICE|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication
214379168|NCT00357045|DRUG|Paroxetine|
214379169|NCT05514262|OTHER|The stress ball|Covid-19 vaccination procedure with individuals in the stress ball group: With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.
214379170|NCT05514262|DEVICE|The Buzzy® device|Covid-19 vaccination procedure with individuals in the Buzzy® group: Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
214379171|NCT05514119|DRUG|Fenofibrate|160mg once daily orally for 12 weeks
214379172|NCT06066710|DRUG|Propranolol|Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.
214379173|NCT06066710|DEVICE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.
214379174|NCT06066710|DRUG|Placebo|Placebo will be given on the same schedule as the propranolol regime.
214497684|NCT03534726|DEVICE|7 T CMR|7 tesla MRI device
214497685|NCT06677710|DRUG|IDP-023|NK cell therapy
214992471|NCT03034967|DRUG|Danirixin matching placebo|Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
214992472|NCT03034967|DRUG|Standard of care|Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
214497686|NCT06677710|DRUG|Ocrelizumab|Anti-CD20 antibody therapy
214497687|NCT06677710|DRUG|Interleukin-2|Immune cytokine
214497688|NCT06677710|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214497689|NCT06677710|DRUG|Fludarabine|Lymphodepleting chemotherapy
214497690|NCT06677710|DRUG|Mesna|Chemoprotectant
214992473|NCT03034967|DRUG|Rescue medication|Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
214992474|NCT00334308|PROCEDURE|Barley protein bread or control (casein) bread|
214992475|NCT06533449|DEVICE|Couplet Care Bassinet|Couplet Care Bassinet
214992476|NCT06533449|DEVICE|Standard Bassinet|Standard Bassinet
214992477|NCT00007748|BEHAVIORAL|Aerobic exercise|
214992478|NCT00007748|BEHAVIORAL|Cognitive behavioral therapy|
215091634|NCT02688868|DEVICE|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
214497691|NCT05677451|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
214497692|NCT05677451|DRUG|placebo|matching active drug
214497693|NCT06699459|DRUG|Irinotecan Liposome|②LV: 400mg/m2, intravenous infusion, Q2W, d1; ③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2;
214379175|NCT05867641|BEHAVIORAL|Immersive VR Therapy in Head-Mounted Display (HMD) (Solo)|"Caregivers will be trained to administer VR\&R therapy to their loved ones with dementia, in their private home/residence. Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, approximately every other day (or as desired), for two weeks. The caregiver will use the custom application on a tablet to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
214379176|NCT05867641|BEHAVIORAL|Immersive VR Therapy in a Head-Mounted Display (HMD) (Social)|"Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, 2 to 3 times per week, for 2 weeks. A research assistant who is trained in dementia care will use the custom application on a tablet to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
214379177|NCT06000319|BIOLOGICAL|Natural Matrix Protein (NMP) Fibers|human bone allograft
214992479|NCT00643175|BEHAVIORAL|Automated follow up|Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
214992480|NCT04279483|BEHAVIORAL|Tobacco retailer|Assigned to make a small (\~$3.00) purchase from a tobacco retail store(s) using a study-provided debit card during each retail environment visit
214992481|NCT04279483|BEHAVIORAL|Non-tobacco retailer|Assigned to make a small (\~$3.00) purchase from a store that does not sell tobacco (non-tobacco retailer) using a study-provided debit card during each retail environment visit.
214992482|NCT02077699|DIETARY_SUPPLEMENT|Lactobacillus casei DG|Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks
214992483|NCT01496742|DRUG|Placebo|Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
214992484|NCT01496742|DRUG|RO5490258|15 mg/kg iv, Day 1 of each 21-day cycle
214992485|NCT01496742|DRUG|bevacizumab [Avastin]|15 mg/kg iv, Day 1 of each 21-day cycle
215091635|NCT06516744|DIETARY_SUPPLEMENT|Bye Bye Bloat Capsules|Bye Bye Bloat Capsules contain the following ingredients: Organic Fenugreek Seed Powder, Organic Dandelion Root Powder, Organic Fennel Seed Powder, Organic Ginger Root Powder, Organic Parsley Leaf Powder, Amylase Complex, Protease Complex, Pepsin Complex, Lipase Complex, Bromelain Complex, Papain Complex. Other ingredients include Hypromellose Capsule, Maltodextrin, Microcrystalline Cellulose, and Magnesium Stearate. Participants will take 2 capsules immediately after eating at least 3 times a week and during times of hormonal bloating for 4 weeks.
214992486|NCT01496742|DRUG|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
214992487|NCT01496742|DRUG|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
214992488|NCT01496742|DRUG|pemetrexed|500 mg/m2, Day 1 of each 21-day cycle
214992489|NCT00434486|DRUG|SKI-606|
214992490|NCT05453383|DRUG|Anlotinib;Toripalimab|Anlotinib Hydrochloride;Toripalimab injiection
214992491|NCT06343324|BEHAVIORAL|Web-based education|Patients using noninvasive ventilation at home will receive detailed information about accessing, logging in and using web-based training. Pretest data will be collected, then week 4 and week 8 data will be collected.
214992492|NCT02620280|DRUG|Carboplatin|Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
214992493|NCT02620280|DRUG|Abraxane|Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
214992494|NCT02620280|DRUG|MPDL3280A|MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
214992495|NCT02620280|PROCEDURE|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
214992496|NCT02620280|DRUG|Anthra|AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
215091636|NCT00895661|DRUG|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
215091637|NCT02395211|BEHAVIORAL|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks"
215091638|NCT02395211|DEVICE|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
215091639|NCT06427694|DRUG|Aldesleukin|IL2 antagonist
215091640|NCT06427694|DRUG|Dextrose 5% in water|matched placebo to active
215091641|NCT04773873|DEVICE|PFM Crowns on gold coping cast-on|Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
215091642|NCT04773873|DEVICE|hybrid abutment lithium disilicate crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
215091643|NCT04773873|DEVICE|hybrid abutment ceramic polymer infiltrated crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
214992497|NCT05743894|DEVICE|Symplicity Spyral RENAL DENERVATION (RDN) SYSTEMTM Livewire™ Reflexion™ Catheter|Renal sympathetic denervation (RDN) was considered an effective alternative for patients whose blood pressure (BP) is not optimally controlled. The RDN works mainly by selectively ablating the sympathetic fibres around the renal arteries and damping the sympathetic overdrive. Blood pressure response by renal nerve stimulation (RNS) during the RDN procedure using the previous generation of the Symplicity Flex catheter have been reported to be potential parameter to assess the intra-procedure efficacy and predict the BP response 6 months after RDN
214992498|NCT03160950|DEVICE|LuxaCrown|"Teeth that would be requiring RCT, would be initially treated by a endodontist using the standardized principles of rotary endodontics.~Restoration using the LuxaCrown as a direct composite crown: In short, the impression material will be loaded with the LuxaCrown material (DMG, Germany). Approx. 0:40 minutes after the start of mixing, the filled impression will be placed in the patient's mouth and will stay there for approx. 1:45 - 2:20 minutes, that is, till the material is partially set. The impression will then be taken out and the material will be allowed to set outside patient's mouth up to approximately 5 minutes after the start of mixing. The Crown will then be finished using a fine buff and pumice, followed by application of Glaze and Bond (DMG, Germany). The preparation will then be cleaned and slightly roughened with a bur or sand blaster at the adhesion sites. The crown fabricated will then be cemented using PermaCem 2.0 luting cement (DMG, Germany)."
214992499|NCT06406972|OTHER|Brief Admission by self-referral (BA)|Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.
214992500|NCT02869035|DRUG|Escitalopram|Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
214992501|NCT02869035|DRUG|Duloxetine|Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
214992502|NCT03658772|DRUG|grapiprant|Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
214992503|NCT03658772|DRUG|grapiprant and pembrolizumab|Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
214992504|NCT02255864|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
214992505|NCT02020642|PROCEDURE|Renal transplantation|Renal transplantation from cadaveric or live donor
214992506|NCT00125944|BIOLOGICAL|FluMist|
215091644|NCT00689754|PROCEDURE|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
215091645|NCT04888143|OTHER|questionnaires|evaluation of hearing performance and quality of life questionnaires
215091646|NCT04888143|OTHER|Evolutionary algorithm|application of the evolutionary algorithm and customized frequency allocation on a separate program.
215091647|NCT03412149|PROCEDURE|Mini Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
215091648|NCT03412149|PROCEDURE|Roux en Y Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
215091649|NCT00922805|DIETARY_SUPPLEMENT|guar gum|guar gum (20 g/l of formula) for one week
215091650|NCT05701436|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
215091651|NCT05701436|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
215091652|NCT05701436|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
215091653|NCT05701436|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
215091654|NCT05701436|DRUG|Oxaliplatin, Leucovorin, fluorouracil|Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
215091655|NCT05701436|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
215091656|NCT04139681|DRUG|A. Vogels Sore Throat lozenges|5 times 1 A. Vogels sore throat lozenges daily for 4 days
215091657|NCT02789891|PROCEDURE|D2 lymphadenectomy including No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
215091658|NCT02789891|PROCEDURE|lymphadenectomy excluding No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
215091659|NCT05269030|DRUG|Ivermectin Topical|Ivermectin 1% in a dose of two drops per nostril twice daily.
215091660|NCT05269030|DRUG|Budesonide Nasal|64 µg per puff in a dose of 1 puff for each nostril twice daily.
215091661|NCT06172400|DRUG|Mepivacaine, Combinations|Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
215091662|NCT03785951|DIETARY_SUPPLEMENT|Whey Protein Isolate|"Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
214992507|NCT03474575|OTHER|Prevention|The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
214992508|NCT06086249|PROCEDURE|Regeneration using Injectable platelet-rich fibrin|root canals of affected molars will be cleaned and shaped chemo-mechanically, after two weeks I-PRF will be applied.
214992509|NCT06086249|PROCEDURE|Root canal treatment|Conventional root canal treatment using gutta-percha obturation
214992510|NCT04289948|DRUG|Phage|The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
215091663|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein|"Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
215091664|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein with Leucine|"Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks."
215091665|NCT06486272|OTHER|Financial Navigator|"Intervention: Access to a Financial Navigator We anticipate the Financial Navigator will meet at least 2 times and up to 2 additional visits, at a time convenient for the family. Examples of financial services that will likely be offered by the Financial Navigator are tax filing, applying for benefits and financial counseling. The program will be flexible and family centered. Families can choose if they would like to meet the Financial Navigator in person at the NNFU appointment, during another medical appointment, or at another time during a virtual visit. The Financial Navigator will be integrated into the existing SickKids Resource Navigation Service. At the 18-month NNFU visit the study will be completed."
214379178|NCT06000319|PROCEDURE|Lumbar interbody fusion|Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between L1 and S1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
214379179|NCT06000319|PROCEDURE|Cervical interbody fusion|Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between C2 and T1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
214379180|NCT03450655|OTHER|10-week aerobic exercise program|An aerobic exercise program consisting of 45-60 minute sessions 3 times a week for 10 weeks.
214379181|NCT02692690|DEVICE|Stimulette r4x|
214379182|NCT00327184|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
214379183|NCT00327184|BIOLOGICAL|Infanrix Penta|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
214379184|NCT00327184|BIOLOGICAL|Infanrix hexa|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
214379185|NCT00327184|BIOLOGICAL|Neis-Vac-C|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
214379186|NCT05391932|BEHAVIORAL|MINDGAPS|Utilize wearable sensor technology to provide simple, precise measures of gaze and postural stability, as well as remote monitoring of patient adherence to vestibular exercises during a 6-week training period. Additionally, NIH Toolbox data will be used to display patient status compared to normative values and to indicate progress over time relative to measurement error.
214379187|NCT00401635|DRUG|liposomal doxorubicin|
214379188|NCT00401635|DRUG|carboplatin|
214379189|NCT05873725|DRUG|Follitropin delta|Evaluation of the IVF cycle using the prescribed medication
214379190|NCT06191263|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
214379191|NCT06191263|DRUG|Venetoclax|Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis
214379192|NCT06847126|DRUG|Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks|Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks and standard care
214379193|NCT06847126|DRUG|Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks|Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks
214379194|NCT06847126|OTHER|Standard medical care|Percutaneous drainage or aspiration of the abscess along resuscitative and symptomatic medications
214379195|NCT03396484|DRUG|Methyldopa|Tablet for oral dosing
214379196|NCT03396484|DRUG|Placebo|Tablet for oral dosing
214379197|NCT02320422|BEHAVIORAL|Behavioral Telehealth|The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
214379198|NCT01421095|DRUG|recombinant FSH|Each participant will recieve recombinant FSH (150 IU) intravenously
214379199|NCT04398446|DRUG|Hemp-based CBD|3x Daily dosing for 12 weeks
214379200|NCT04398446|OTHER|Placebo oral tablet|3x Daily dosing for 12 weeks
214379201|NCT02105441|DEVICE|Cochlear implant|Implantable hearing device
214379202|NCT05624840|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir-ritonavir (Paxlovid)
214992511|NCT05004025|DEVICE|Novocure Optune|Novacure Optune with Opdivo and Yervoy
214992512|NCT05004025|DRUG|Opdivo|Novacure Optune with Opdivo and Yervoy
214992513|NCT05004025|DRUG|Yervoy|Novacure Optune with Opdivo and Yervoy
214992514|NCT05991375|DRUG|DEXmedetomidine|28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL
214992515|NCT05991375|OTHER|saline|28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL
214992516|NCT06245499|BEHAVIORAL|Aging Brain Care Virtual Program|The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.
214992517|NCT04733534|DRUG|Dasatinib plus Quercetin|Dasatinib (100 mg/day) plus Quercetin (500 mg twice daily) on days 1, 2, 3, 30, 31, 32 taken orally under observation of the study nurse.
214992518|NCT04733534|DRUG|Fisetin|Fisetin (20mg/kg/day) on days 1, 2, 30 and 31 taken orally under observation of the study nurse. Fisetin will be dispensed based on weight of 20 mg/kg/day on the four separate days.
214992519|NCT02838355|DEVICE|Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.
214992520|NCT02838355|OTHER|Standard Non-invasive Respiratory Depression Monitoring|Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
214992521|NCT05693220|DEVICE|Zymot Multi sperm separation device|Sperm preparation with Zymot Multi sperm preparation device
214992522|NCT05693220|OTHER|Density gradient centrifugation|Sperm preparation with density gradient centrifugation
214497694|NCT06699459|DRUG|Capecitabine|① Capecitabine, 1250mg/m2 orally, bid, Q3W, d1-14;
214992523|NCT06538246|BEHAVIORAL|Blueprint|This is a mobile app-based adaptive coping skills intervention that lasts 1 month
214992524|NCT06538246|BEHAVIORAL|Education program|This is a mobile app-based education program that lasts 1 month
214992525|NCT04546646|OTHER|Elastic Band Exercises|Resistance exercise will be performed using theraband. The color of the band denotes the degree of elasticity and resistance level(yellow , red ,green ,blue, black or silver).Exercise load in terms of individual yielding elasticity (band color) in resistance training will set at a level that a patient perceived as somewhat hard, which is equivalent to a 13-grade rating (moderate intensity exercise) on the RPE, According to American College of Sports Medicine. For each exercise movement 3 sets of 10 repetitions of gentle concentric and eccentric contractions through the full range of motion will be slowly performed using a yellow Thera band initially. The exercise intensity will be increased when the patient is able to achieve a perceived yield strength corresponding to a 13- grade rating on the RPE scale.
214992526|NCT01670006|DEVICE|Cochlear Nucleus Cochlear Implant System|
214992527|NCT00843973|PROCEDURE|iliac crest bone graft|iliac crest bone graft procedure
214992528|NCT00843973|PROCEDURE|Reamer Irrigator Aspirator|Reamer Irrigator Aspirator (RIA) Procedure
214992529|NCT04800627|BIOLOGICAL|Pembrolizumab|Given IV
215091666|NCT00905086|OTHER|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
215091667|NCT00905086|PROCEDURE|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
214497695|NCT06705582|OTHER|Fortified Bread|Intervention group will be supplied with fortified bread delivering 10 -15 μg (400-600 IU) vitamin D3 in a daily portion and will receive dietary advice to incorporate fortified foods that are commonly available on the market in their diet.
214687271|NCT03063775|DEVICE|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
214687272|NCT03063775|OTHER|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
214992530|NCT04800627|DRUG|Pevonedistat|Given IV
214992531|NCT04926233|DRUG|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
214992532|NCT04926233|DEVICE|Sp(t)iolto® Respimat®|Sp(t)iolto® Respimat®
214992533|NCT02845804|DEVICE|Alpine|
214992534|NCT05395442|DIAGNOSTIC_TEST|Training on web-based diabetic foot care based on the Health Belief Model|Training on web-based diabetic foot care based on the Health Belief Model will be implemented.Four materials will be used in the research, namely the Introductory Information Form, the Foot Care Behavior Scale, the Diabetic Foot Care Self-Efficacy Scale.
214992535|NCT02084797|DRUG|V2R (Vasopressin 2 receptor)|All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).
214992536|NCT01887808|OTHER|Cetaphil DermaControl Oil Control Moisturizer SPF 30|
214992537|NCT02550795|DRUG|Dexmedetomidine|administration of dexmedetomidine only
214992538|NCT02550795|DRUG|Dexmedetomidine and dexamethasone|administration of dexmedetomidine and dexamethasone
214992539|NCT02550795|DRUG|Control|administration of normal saline
214992540|NCT00177697|BEHAVIORAL|behavioral weight loss program|
214497696|NCT06705582|OTHER|Unfortified bread|Placebo control group will be supplied with unfortified bread and will receive dietary advice to incorporate fortified foods that are commonly available on the market in their diet.
214497697|NCT06714461|DRUG|Leflunomide|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
214687273|NCT03063775|OTHER|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
214992541|NCT04544917|BEHAVIORAL|SmartManage for HIV+ cancer survivors|Ten weekly therapist delivered group sessions delivered via web conference. Sessions focus on cognitive behavioral stress management, psychoeducation, and management strategies for dual diagnosis of HIV and cancer. Participants will have access to the SmartManage web platform which has all intervention material, resources, and exercises.
214992542|NCT04544917|BEHAVIORAL|Educational Control|Participants in the control condition will view ten videos over ten weeks, consisting of informational and educational material relevant to cancer and HIV.
214992543|NCT06564389|DRUG|PF-07832837|escalated doses of PF-07832837
214992544|NCT06564389|OTHER|Placebo|placebo
214992545|NCT01971177|DEVICE|Femtosecond laser cataract surgery|"The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.~The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.~Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.~All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform."
214992546|NCT01971177|PROCEDURE|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
214992547|NCT01113099|OTHER|Academic detailing|Education of physicians by pharmacists regarding indications for statins in diabetic patients
214992548|NCT03983031|DRUG|Rituximab|Infusion
214379203|NCT05900622|OTHER|Reduced postoperative braking and bed rest time.Lower extremity on the puncture side with a 2-hour brake+Get out of bed after 4 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
214379204|NCT05900622|OTHER|Significantly reduce postoperative braking and bed rest time.No braking of the lower limb on the side of the puncture+Get out of bed after 2 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
214379205|NCT00756522|OTHER|There is no intervention. Study is observational.|There is no intervention. Study is observational.
214379206|NCT00518128|PROCEDURE|Surgical OSA treatment|uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
214379207|NCT00518128|PROCEDURE|Positive Airway Pressure Therapy|Continuous positive airway pressure for treatment of obstructive sleep apnea
214379208|NCT05899660|DIETARY_SUPPLEMENT|Active Comparator: Omega-3|It is a dietary supplement made of fish oil rich in n-3 PUFA.
214992549|NCT04620200|DRUG|Nivolumab|3mg/kg
214992550|NCT04620200|DRUG|Ipilimumab|1mg/kg
214992551|NCT00889434|DIETARY_SUPPLEMENT|ECGC|1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
214992552|NCT00889434|DIETARY_SUPPLEMENT|Tocotrienol|One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
214992553|NCT00889434|DIETARY_SUPPLEMENT|EGCG + Tocotrienol|combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
214992554|NCT01868672|BEHAVIORAL|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
214379209|NCT05899660|DIETARY_SUPPLEMENT|Placebo Comparator: olive oil|Refined olive oil is the usual placebo used in studies with n-3 PUFA.
214992555|NCT04226677|OTHER|aerobic exercise|Treadmill training is include warming, cooling and training phase according to rating of perceived exertion for participants.
214992556|NCT04226677|OTHER|Video based exercise|Exergame training include virtual reality games by xbox kinect.
214992557|NCT04226677|OTHER|Control group|first and last evaluations will be made
214992558|NCT04627688|BEHAVIORAL|Time restricted feeding|Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.
214992559|NCT04627688|BEHAVIORAL|Standard dietary advices|Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.
214992560|NCT03318198|OTHER|Enhanged Attending Supervision|Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.
215091668|NCT00905086|PROCEDURE|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
214379210|NCT02599103|OTHER|Fat-free milkshake|participants drinks a fat-free milk shakes
214379211|NCT02599103|OTHER|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
214379212|NCT02599103|OTHER|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
214379213|NCT02599103|OTHER|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
214379214|NCT02599103|OTHER|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
214379215|NCT02599103|OTHER|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
214379216|NCT02599103|OTHER|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
214379217|NCT02599103|OTHER|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
214379218|NCT02599103|OTHER|Tallow|participants drinks the milk shakes prepared from 60g of tallow
214379219|NCT02599103|OTHER|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
214379220|NCT05989373|DIAGNOSTIC_TEST|Scratch collapse test|Scratch test performed by the surgeon but with a dynamometer
214379221|NCT00748124|DEVICE|PleuraSeal Sealant System|Lung Sealant Device + standard tissue closing techniques (sutures/staples)
214379222|NCT00748124|PROCEDURE|Standard Tissue Closure Techniques|Standard tissue closure techniques (sutures/ staples) alone
214379223|NCT00602680|DRUG|SSR180711C|duration of treatment: 4 weeks
214379224|NCT00602680|DRUG|donepezil|duration of treatment: 4 weeks
214379225|NCT00602680|DRUG|placebo|duration of treatment: 4 weeks
214379226|NCT00460720|OTHER|Observational treatment compliance survey|Observational treatment compliance survey
214379227|NCT01581697|DIETARY_SUPPLEMENT|Oat bran|
214379228|NCT03360877|OTHER|Health-care associated infection (HCAI)|Cleaning of the child with soap and water administered by the child's accompanying person in a structure or - a cleaning of the child with chlorhexidine gluconate administered by the child's accompanying person in the other structure
214497698|NCT07043543|RADIATION|Adaptive radiotherapy|"Patient will be treated by concomitant:~* adaptive radiotherapy 5 days a week for 4 weeks with hypofractionated irradiation 55 Gy / 20 fractions +/- pelvic inclusion 44 Gy/20 fractions (SIB).~* chemotherapy if not contraindicated :~  * Cisplatin : 20 mg/m2/day on day 1 to day 4 and day 22 to day 25 (or 80 mg/m2 during week 1 and 4 of radiotherapy) Or~ * Gemcitabine: 80 to 100 mg/m2/week Or~ * Mitomycin C: 12 mg/m2 on day 1 only + 5FU infusion 500 mg/m2/day during 5 days on week 1 and 4 of radiotherapy (alternatively : capecitabine taken twice daily at a dose of 825 per square meter per day on the days of radiotherapy)"
214497699|NCT07043543|RADIATION|standard radiotherapy|"Patient will be treated by concomitant:~* standard 5 days a week for 4 weeks with hypofractionated irradiation 55 Gy / 20 fractions +/- pelvic inclusion 44 Gy/20 fractions (SIB).~* chemotherapy if not contraindicated :~  * Cisplatin : 20 mg/m2/day on day 1 to day 4 and day 22 to day 25 (or 80 mg/m2 during week 1 and 4 of radiotherapy) Or~ * Gemcitabine: 80 to 100 mg/m2/week Or~ * Mitomycin C: 12 mg/m2 on day 1 only + 5FU infusion 500 mg/m2/day during 5 days on week 1 and 4 of radiotherapy (alternatively : capecitabine taken twice daily at a dose of 825 per square meter per day on the days of radiotherapy)"
214497700|NCT07043764|OTHER|Caring Contacts Text Messages|Caring Contacts are brief, hopeful, supportive text messages.
214379229|NCT02478021|OTHER|Hydrocortisone|Effects of hydrocortisone compared to placebo on cognition
214379230|NCT02459249|OTHER|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
214992561|NCT03318198|OTHER|Standard of Care|Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
214992562|NCT04844320|DIAGNOSTIC_TEST|Cobb angle measurements|PA Chest x-rays will be taken in all patients in the preoperative, postoperative 1st year and 2nd year
214379231|NCT02459249|OTHER|Placebo Comparator (Treatment of Mexican Health Minister)|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
214379232|NCT00335686|DRUG|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
214379233|NCT00335686|DRUG|Nevirapine (Viramune): 1 comp (200mg)/12h|Nevirapine (Viramune): 1 comp (200mg)/12h
214992563|NCT05932888|DRUG|QLM3003|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）
214992564|NCT05932888|DRUG|QLM3003 Placebo|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）(matching corresponding study medication)
214992565|NCT05455775|DEVICE|Camera-based monitoring technology|Unobtrusive, vital sign measurement with remote photoplethysmography and laser speckle vibrometry
214992566|NCT00879658|DRUG|BAF312|
214992567|NCT00879658|DRUG|Placebo|
214992568|NCT02373865|DRUG|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
214379234|NCT02080195|DRUG|Cyclophosphamide|14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
214379235|NCT02080195|DRUG|Fludarabine|30 mg/m\^2/day on Days -6 through -2.
214379236|NCT02080195|DRUG|Tacrolimus|Starting on Day 5. Dose will be adjusted according to blood levels.
214379237|NCT02080195|DRUG|Mycophenolate Mofetil|15 mg/kg three times per day from Day 5 to Day 35.
214379238|NCT02080195|DRUG|Rabbit antithymocyte globulin|0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.
214379239|NCT02080195|RADIATION|Total body irradiation|200 centigray on Day -1.
214379240|NCT02080195|BIOLOGICAL|Allogeneic bone marrow transplant|Infusion on Day 0.
214379241|NCT02211534|DEVICE|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
214497701|NCT06892691|PROCEDURE|Pleuroscopy first|Pleuroscopies are performed under moderate sedation with local anesthesia. Through a 1-cm incision a camera is introduced into the pleural space and the space is inspected after draining all fluid. Targeted biopsies under direct visualization are obtained using forceps. The aspirated fluid and biopsies obtained are sent to the cytology and pathology laboratories for analysis.
214497702|NCT06892691|PROCEDURE|Thoracentesis first|Thoracenteses are performed under local anesthesia with the insertion of a 5-8Fr catheter into the pleural space. The aspirated fluid obtained is sent to the cytology laboratory for analysis.
214992569|NCT02373865|DRUG|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
214992570|NCT02373865|DRUG|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
214992571|NCT02373865|DRUG|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
214992572|NCT01926158|DRUG|Denosumb|Prefilled syringe of 1 mL denosumab solution
214992573|NCT01926158|DRUG|Placebo (for denosumab)|
214379242|NCT02211534|DEVICE|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
214379243|NCT03505476|DEVICE|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
214379244|NCT03505476|OTHER|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
214379245|NCT03505476|OTHER|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
214379246|NCT00328640|DRUG|Optimal treatment|
214379247|NCT01427192|DRUG|acetazolamide|250 mg bid
214379248|NCT01427192|OTHER|Supplemental oxygen|Oxygen deliverded by nasal cannula
214379249|NCT01427192|PROCEDURE|Non-invasive ventilation|Bi-level non-invasive ventilation via nasal mask
214379250|NCT01427192|OTHER|Room air|Room air applied via sham oxygen concentrator
214379251|NCT01427192|DRUG|Placebo tablet|Placebo tablet (Mannitol) similar to acetazolamide
214379252|NCT01295567|DRUG|Dipyridamole|prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
214379253|NCT01295567|DRUG|placebo|prior to CABG surgery 3 day treatment with placebo capsules twice daily
214379254|NCT05107479|BEHAVIORAL|COVID-19 Vaccine IVR Training|The intervention consists of 5 interactive voice response (IVR) modules conveying information about COVID-19 vaccines and vaccine administration best practices. Module topics include the following: 1) the importance of COVID-19 vaccines and recipient eligibility, 2) overview of and differences between approved COVID-19 vaccines , 3) surveillance of adverse vaccine events, 4) organizing a vaccination site, and safe storage and handling COVID-19 vaccines, and 5) micro planning and communication strategies for COVID-19 vaccination efforts. The training will be offered in five local languages: French, Lingala, Swahili, Kikongo, and Tshiluba.
214379255|NCT05107479|BEHAVIORAL|Control Condition|The control arm will receive the COVID-19 Vaccine IVR Training after an estimated month-long delay. The control arm will be told upon completion of the baseline survey that the training will commence at a later estimated date and will not receive any additional information until the treatment group completes training.
214379256|NCT03837392|DIAGNOSTIC_TEST|Baseline Assessment (18-26 weeks pregnant)|At baseline, participants will complete several interviews and questionnaires online and via phone to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables.
214992574|NCT00314145|BIOLOGICAL|ChimeriVax™-JE|0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
214992575|NCT00314145|BIOLOGICAL|JE-VAX®|0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
214992576|NCT04732234|PROCEDURE|Superior Hypogastric Plexus Block|Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra
214992577|NCT02727712|PROCEDURE|bilateral thoracic paravertebral block|group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml\*4)program
214992578|NCT02727712|DEVICE|Transesophageal Echocardiography（TEE）|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~2. Goal-directed fluid management"
214992579|NCT02727712|DEVICE|Lung protection measure during the surgery（Dräger Primus）|Protective ventilation strategy(Low tidal volume about 6\~7ml/kg, joint use of PEEP)
214992580|NCT02727712|DRUG|Anesthesia drugs during the surgery|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia • Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01\~0.04ug/kg•min, Sevoflurane 0.5\~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06\~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
214992581|NCT02727712|PROCEDURE|thoracic paravertebral block|group B under(TPVB T3/4)by ropivacaine(0.3%,20ml\*2)program
214992582|NCT02339636|OTHER|PDUS examination|
214992583|NCT00128063|DRUG|succinylated human serum albumin|
214992584|NCT01794468|OTHER|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
214992585|NCT04529694|OTHER|Psychotherapy|
214992586|NCT03907215|DRUG|ACT541468|50 mg; film-coated tablet for oral use
214992587|NCT03907215|DRUG|ACT541468 placebo|film-coated tablet for oral use
214992588|NCT03907215|DRUG|Citalopram|20 mg; tablet tor oral use; for single- or repeated dosing
214992589|NCT00909467|OTHER|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
214992590|NCT00580840|DRUG|Certolizumab pegol|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
214992591|NCT00580840|DRUG|Certolizumab pegol|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
214992592|NCT00580840|OTHER|Placebo|placebo (saline) administered as two injections every 2 weeks
214379257|NCT03837392|BEHAVIORAL|Online Intervention and Phone Coaching Interventions|ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The active comparator is the Supportive Control. Two phone coaching sessions will occur 2- and 4-weeks post-intervention in both conditions.
214379258|NCT03837392|DIAGNOSTIC_TEST|Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum|The follow-up assessments at 34-36 weeks pregnancy and 4-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.
214379259|NCT03837392|DIAGNOSTIC_TEST|Follow Up Assessments: 8 weeks postpartum|The follow-up assessment at 8-weeks postpartum will be completed via phone.
214379260|NCT00539643|DEVICE|Bead Block microspheres|Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
214379261|NCT00539643|OTHER|Bead + Dox Arm|Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
214379262|NCT03697525|DEVICE|Vibration|Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).
214379263|NCT04935814|DRUG|Vasopressin, Arginine|Once vasopressin infusion started, patients positions will be randomized: Trendelenburg (-30°), anti Trendelenburg (+30°) and supine position (0°).
214379264|NCT02220296|DRUG|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
214379265|NCT02220296|DRUG|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
215091669|NCT00905086|PROCEDURE|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
215091670|NCT00907296|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection
214497703|NCT06741293|OTHER|No intervention: observational study|No intervention: observational study
214497704|NCT06895200|DEVICE|CVS-Notifier SaMD|The CVS-Notifier SaMD reminds surgeons to time-out to check the CVS before the division of the cystic duct.
214497705|NCT06778772|BEHAVIORAL|transition pathway to adult care services for epilepsy patients.|This proposal aims to create a coordinated and shared transition pathway between pediatric and adult epilepsy services, addressing the needs of patients with chronic conditions. The primary objective is to assess the readiness of both patients and their caregivers for the transition, by comparing the Transition Readiness Assessment (TRAQ) questionnaire results between the last pediatric neuropsychiatric visit and the first adult neurology visit. Secondary objectives include evaluating changes in emotional-behavioral issues and quality of life, using the CBCL, YSR, and PedsQoL questionnaires. Assessments will be conducted at both pediatric and adult epilepsy services. The ultimate goal of the transition protocol is to improve care and outcomes for adolescents and young adults during the transition, focusing on emotional-behavioral and psychosocial aspects, and to develop a best-practice model that could influence future guidelines.
214379266|NCT02220296|DRUG|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
214379267|NCT02220296|DRUG|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
214379268|NCT05438186|DRUG|Liraglutide|Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily)) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.
215091671|NCT00907296|DRUG|Placebo|Administered by subcutaneous injection
214379269|NCT00500240|DRUG|Insulin Glargine|Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
214497706|NCT06811857|DEVICE|hyperbaric oxygen therapy and povidone-iodine wet compresses|The hyperbaric oxygen group receives 30-40 sessions of hyperbaric oxygen therapy (100% oxygen at a pressure of 2.0 ATA) and povidone-iodine wet compresses.
214497707|NCT06811857|OTHER|wet compresses of povidone-iodine|wet compresses of povidone-iodine
214379270|NCT00500240|DRUG|Insulin Aspart|Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
214379271|NCT02508532|DRUG|Avapritinib|avapritinib tablets
214379272|NCT06371131|PROCEDURE|Right -stellate ganglion block|The experimental group was given right stellate ganglion block 30 minutes before anesthesia induction
214497708|NCT06752018|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass or sleeve gastrectomy
214497709|NCT06755944|DRUG|XY03-EA|"The sample size was 360 patients, and 72patients were treated with XY03-EA 150 mg, 300mgA group ,300mgBgroup,450mg and placebo respectively. The 150mg group took two tablets of placebo and one tablet of XY03-EA once, three times a day. For 90 days The 300mg A-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. For 90 days The 300mg B-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. Use continuously for 14 days.Placebo is used for 15-90 days.~The 450mg group took three tablets of XY03-EA once,three times a day. For 90 days.~The placebo group took three tablets of placebo once ,three times a day.For 90 days."
214497710|NCT06764355|DRUG|Tislelizumab|200 mg, 1h-IVF, Q3W on day 1 for 2 cycles
214497711|NCT06764355|DRUG|Paclitaxel|Paclitaxel 175 mg/m2, 3h-IVF, Q3W on day 1 for 2 cycles
214379273|NCT04725656|PROCEDURE|Smoking cessation counseling|Smoking cessation counseling at baseline, week 1, and week 4.
214379274|NCT04725656|OTHER|Open system vape device and nicotine salt e-liquids|Ad libitum use of nicotine salt e-liquids during three months.
215091672|NCT04292457|DRUG|Propofol|Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
215091673|NCT04292457|DRUG|Sevoflurane|Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
215091674|NCT05271825|DEVICE|Broadband amplification from hearing aids|Amplification from 125 Hz to 10 kHz
215091675|NCT05271825|DEVICE|Band-limited amplification from hearing aids|Amplification from 25 Hz to 3-4 kHz
215091676|NCT01657708|OTHER|Shared Decision Making|
214379275|NCT05072925|OTHER|Tobacco products|Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions
214379276|NCT02334566|BEHAVIORAL|NET TX|Intervention procedures are a behavioral intervention (NET \& KIDNET) with 8-12 sessions administered on a weekly basis.
214379277|NCT05639790|COMBINATION_PRODUCT|Electronic cigarettes + Health Counselling|Ad libitum use of electronic cigarettes for 1 month
214379278|NCT05639790|OTHER|Health Counselling|Health Counselling from a licensed mental health counselor
214379279|NCT01933451|OTHER|Intraoperative fluid therapy|Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
214379280|NCT02640443|DRUG|Sulfamethoxazole|60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
214379281|NCT01664520|DRUG|Dexmedetomidine infusion|"Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.~Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments"
214379282|NCT02452086|DEVICE|Low Level Laser(Ga-As)|Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
214497712|NCT06764355|DRUG|Cisplatin|Cisplatin 75 mg/m2, 2h-IVF, Q3W on day 1 for 2 cycles
214497713|NCT06764355|RADIATION|Chemoradiotherapy|"Chemoradiotherapy~* Paclitaxel 50 mg/m2, 1h-IVF, on days 1, 8,15, 22, and 29;~* Cisplatin 30 mg/m2,1h-IVF, on days 1, 8,15, 22, and 29;~* RT: 1.8 Gy/fraction, 5 days a week, for 25 fractions (total dose= 45 Gy)."
214497714|NCT06761430|DEVICE|ClearPlasma|ClearPlasmais an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasmaTM is a non-pyrogenic, sterile, single-use medical device.
214497715|NCT06761456|OTHER|Providing training models|The experimental group was trained using the Clinical Education Module on 3 Parenteral Interventions in the Nursing Fundamentals laboratory.
214497716|NCT06761456|OTHER|Control|The control group was trained using standard training models.
214497717|NCT06762132|BIOLOGICAL|CD33 CAR T-cells|Each subject receive CD33 CAR T-cells by intravenous infusion
214497718|NCT06760650|DIAGNOSTIC_TEST|Fluorescein angiography|Fluorescein angiography
214497719|NCT04616209|BIOLOGICAL|donor-derived NK cell infusion|PB103 administrations will be separated by 4-week interval
214497720|NCT06720961|PROCEDURE|Collection of surgical specimen|Specimens of CD patients and non-IBD related patients will be collected during the surgery performed for clinical practice, without other risks for the patients, since we will use only leftover material after pathologist analysis. All of the collected surgical samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
215091677|NCT01278784|DEVICE|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
215091678|NCT01278784|DEVICE|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
215091679|NCT02137187|PROCEDURE|AV junction ablation|AV junction ablation
214379283|NCT02452086|PROCEDURE|Placebo|LLLT with zero intensity
214379284|NCT00174603|DRUG|quetiapine|
214379285|NCT03097861|DRUG|Lubiprostone|24 mcg administered orally BID
214379286|NCT03097861|DRUG|Placebo|24 mcg administered orally BID
214379287|NCT02281760|DRUG|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
214379288|NCT02281760|DRUG|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
214379289|NCT03183583|PROCEDURE|Tissue adhesive in primary Total Hip and Total Knee arthroplasty|Use of tissue adhesive in primary Total Hip and Total Knee arthroplasty
214379290|NCT03582605|DRUG|Amoxicillin|see previous descriptions
214379291|NCT03582605|DRUG|Placebo oral capsule|see previous descriptions
214379292|NCT02446795|DRUG|Sunitinib|Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
214379293|NCT02446795|DRUG|Isoquercetin|Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
214379294|NCT02446795|DRUG|Placebo|Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
214379295|NCT01576367|BIOLOGICAL|ACZ885|
214379296|NCT02428244|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
214379297|NCT02428244|BEHAVIORAL|Motivational Interviewing + Follow-up|"Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.~In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months."
214379298|NCT04564950|OTHER|Observation of serum and salivary Galectin-3 levels|Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
215091680|NCT02137187|DEVICE|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
215091681|NCT02137187|DRUG|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
214687274|NCT03063775|DEVICE|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
214992593|NCT05255419|DEVICE|OnCall mobile health peer support app|"Mobile health platform that provides anonymous access to peer support services that has been co-design by and for Canadian public safety personnel. OnCall is for frontline public safety providers; features include links to mental health self-assessment tools, a wellness toolbox, tips to cope articles and peer wisdom videos, and options to reach out to a peer support provider of their choice via telephone or text. The OnCallSupport app is for the peer support providers which includes a list of resources and an opportunity to create post-action reports following the peer support encounter. Connections are made to peer support via a telephone service that disguises the contact information of both parties. The app platform includes options to complete feedback surveys related to the app and to the peer support encounter."
214992594|NCT02804893|PROCEDURE|VATS|Thorax thoracoscopic surgery (lobectomy)
214992595|NCT02804893|PROCEDURE|RATS|Thorax robotic surgery (lobectomy)
214992596|NCT02659904|OTHER|Less than 2 mm remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
214992597|NCT02659904|OTHER|2 mm or more remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
214992598|NCT01955304|DRUG|fruquintinib|Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
214992599|NCT01258868|DRUG|Celebrex|400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.
214992600|NCT01258868|BIOLOGICAL|Tumor cell vaccine|A minimum of 1x10e7 and a maximum of 1x10e8 patient tumor cells that have been exposed to 1 mcM decitabine for 6 days, exposed to 100 Gy radiation and emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections; if subject shows immune response, vaccine will be given every three months from months 9 - 24
214992601|NCT01046942|DRUG|Clopidogrel+acetylsalicylic acid|loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
214992602|NCT01046942|DRUG|acetylsalicylic acid|aspirin 75 mg daily, started 6-24 hours after surgery
214992603|NCT03335176|BEHAVIORAL|Endurance ad Resistance Training Exercise|Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
214992604|NCT00998283|DRUG|HM10460A 5μg/kg|Subcutaneously administrate at 0 hour on Day 1
214992605|NCT00998283|DRUG|HM10460A 15μg/kg|Subcutaneously administrate at 0 hour on Day 1
214992606|NCT00998283|DRUG|HM10460A 45μg/kg|Subcutaneously administrate at 0 hour on Day 1
214992607|NCT00998283|DRUG|HM10460A 135μg/kg|Subcutaneously administrate at 0 hour on Day 1
214992608|NCT00998283|DRUG|HM10460A 350μg/kg|Subcutaneously administrate at 0 hour on Day 1
215091682|NCT02137187|DEVICE|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
215091683|NCT02238340|DRUG|Extended-release oxycodone|10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
215091684|NCT02238340|DRUG|Extended- release Oxycodone|
215091685|NCT02238340|DRUG|ketoprofen|
214687275|NCT04247022|OTHER|Health care product (intimate gel)|heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days
214992609|NCT00998283|DRUG|Placebo|Subcutaneously administrate at 0 hour on Day 1
214992610|NCT01551173|DRUG|Fluvastatin sodium|Fluvastatin sodium Extended Release Tablets 80mg
214992611|NCT04817982|DRUG|Perineural dexamethasone|Dexamethasone 4mg will be added perineurally to an ulnar nerve block with bupivacaine.
214992612|NCT04817982|DRUG|Lidocaine|Lidocaine 40 mg will be added perineurally to an ulnar nerve block with bupivacaine.
214992613|NCT04817982|DRUG|Placebo|Saline will be added perineurally to an ulnar nerve block with bupivacaine.
215091686|NCT02238340|DRUG|dipirone|
214992614|NCT04817982|DRUG|Systemic dexamethasone|Dexamethasone will be added perineurally to an ulnar nerve block with bupivacaine, some will be reabsorbed and distributed systemically. Thereby, the investigators control for the systemic effects of adding perineural dexamethasone to an ulnar nerve block.
214992615|NCT02511756|DEVICE|Computed tomography X-ray system|Contrast-enhanced computed tomography of liver metastases
215091687|NCT02238340|DRUG|dexametasone|
215091688|NCT02238340|DRUG|Morphine IV (rescue)|
215091689|NCT02283307|OTHER|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
215091690|NCT02283307|OTHER|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
215091691|NCT02554214|DEVICE|Glafkos drainage device|
215091692|NCT00842101|DEVICE|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
215091693|NCT01824706|PROCEDURE|craniectomy|craniectomy
215091694|NCT05041348|DIAGNOSTIC_TEST|CT at the level of the third lumbar vertebra (L3)|Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
215091695|NCT06007625|OTHER|Machine learning-based prediction model|This model will utilize patient characteristics and disease features to determine the disease's prognosis. The scoring system will also include management information to facilitate prediction of clinical outcomes of different management strategies and potential management that would yield the best prognosis.
215091696|NCT02126007|BEHAVIORAL|Sleep and Rhythm Intervention|
215091697|NCT02126007|BEHAVIORAL|Dietary Modifications|
215091698|NCT02066129|DRUG|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
215091699|NCT02066129|DRUG|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
215091700|NCT06505486|DRUG|Gemcitabine-Oxaliplatin Regimen|Hepatic arterial infusion chemotherapy (HAIC) of gemcitabine and oxaliplatin (GEMOX) plus systemic gemcitabine chemotherapy (GEM-SYS) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor.
214379299|NCT04944355|OTHER|ultrasound|diagnosis of morbid adherent placenta and incidence of urinary tract injuries during surgery
214379300|NCT03577158|DEVICE|Closed-loop controller with exercise mitigation module|"Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
214379301|NCT03577158|DEVICE|Closed-loop controller without exercise mitigation module|"On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
214379302|NCT03577158|DEVICE|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.
214379303|NCT01898702|BEHAVIORAL|Diabetes expert patients programme|Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
214379304|NCT06450717|DEVICE|Khymeia VRRS|VRRS is an electronic device for remote rehabilitation of cognitive (e.g., memory, attention, spatial perception, logical-mathematical skills, language, executive functions...) and motor (gross and fine motor skills) functions. It can be used in on-line and off-line mode at home, and the exercises are chosen by the therapist according to the patient's specific difficulties and needs from a cognitive and motor library.
214379305|NCT04340128|DRUG|Meglumine antimoniate|Intra-lesional injection once a week, 0.1/cm2
214379306|NCT04340128|DRUG|Meglumine antimoniate|Intra-lesional injection twice a week, 0.1/cm2
214379307|NCT03138174|DEVICE|OneTouch Verio Flex Blood Glucose Monitoring System|Blood Glucose Monitoring System
214379308|NCT00595270|BIOLOGICAL|IC51|
214379309|NCT01059032|OTHER|Using a 3 dimentional post processing filter|Using a 3 dimentional post processing filter
214379310|NCT00003137|DRUG|irinotecan hydrochloride|
214992616|NCT06525818|OTHER|Tube weaning therapy intervention|Participants in the intervention group will be invited to weekly virtual group therapy mealtime sessions with the Speech-Language Pathologist and other participants in the intervention group. Additionally, families will engage in individual virtual therapy sessions at least biweekly focused on individualized goals informed by the expertise of the study team and published expert programs. Therapies intervention group participants are already receiving or who begin to receive during the study period will not be stopped during this intervention. The Speech Therapist and Occupational Therapist will be utilized as needed for the child's individualized care plan. They will consult with the registered dietitian and Developmental and Behavioral Pediatrician as needed.
214992617|NCT06525818|OTHER|Feeding Group|All participants in the control group will be invited to a weekly virtual group therapy mealtime session with other enrolled control group participants and a speech therapist who is not involved with the intervention. During this informal session, families will have the opportunity to meet other children with feeding tubes and their parents. The investigators will assess level of engagement (frequency of participation) and parental experience at interval assessments. Therapies research participants are already receiving or who begin to receive during the study period (early intervention community therapies, center-based therapies) will not be stopped during this intervention. Data will be collected on the frequency of these standard of care therapies. The assessments used for the control group will be the same assessments as the intervention group and will include the Speech Therapy Assessment; Occupational Therapy Assessment; and Pediatric Eating Assessment Toll.
214992618|NCT01402726|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
214992619|NCT00974454|DRUG|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
214379311|NCT00002763|BIOLOGICAL|recombinant interferon alfa|
214379312|NCT00954733|OTHER|Arterial blood draw|One arterial blood draw
214379313|NCT03592277|DRUG|Vitamin C|Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).
214379314|NCT03592277|DRUG|Vitamin B1|Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
214992620|NCT00974454|DRUG|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
215091701|NCT04861428|OTHER|IQOS|IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).
215091702|NCT04861428|OTHER|Smoking as Usual|Cigarette smoking
215091703|NCT03930992|DRUG|Colaren in HIV positive|1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
215091704|NCT03930992|DRUG|standard treatment in HIV positive|2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
214379315|NCT03571984|BEHAVIORAL|Moving on ABC Plus|The intervention has two components. CBT Moving on After Breast Cancer
214379316|NCT01492491|DEVICE|SUPRA-HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
214379317|NCT02131038|OTHER|Medica device, drug-like|Ectoin (R) Allergy Nasal Spray
214379318|NCT03528174|DEVICE|Artificial Pancreas Control system (APC)|This intervention is a single hormone closed loop system including a Nexus 5 smart phone, two tslim insulin pumps, a Dexcom G5 CGM and two PDT glucose sensing cannulas that together make up a new experimental, investigational device system. The algorithm included in the APC is an automated version of the Fading Memory Proportional Derivative (FMPD) insulin and glucagon control algorithm.
215091705|NCT03930992|DRUG|Colaren in HIV negative|3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
215091706|NCT03930992|DRUG|standard treatment in HIV negative|4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
215091707|NCT05418595|OTHER||
214379319|NCT03528174|DEVICE|Pacific Diabetes Technologies CGM Insulin Infusion system|An integrated combination CGM/insulin infusion system
214379320|NCT02374632|OTHER|Meal tests after saline injection|Fixed breakfast meal and ad libitum lunch meal
214379321|NCT02374632|OTHER|Meal tests after octreotide injection|Fixed breakfast meal and ad libitum lunch meal
214379322|NCT02374632|OTHER|Sham feeding|
214379323|NCT05878119|DRUG|Investigational Product - MIB 626|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
214379324|NCT05878119|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC
214379325|NCT05878119|OTHER|Standardized, progressive, high intensity, multidimensional exercise|Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.
214992621|NCT05672056|PROCEDURE|Computer guided placement of a stock plate pre-bent on a 3D printed model|We aim to design a novel guide that can secure the construct of the fibular segments and pre bent plate onto the native mandible and effectively and efficiently translate the VSP into the surgical field.
214992622|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml."
214992623|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml."
214379326|NCT05878119|OTHER|Usual Physical Activity|Participants will be asked to perform usual physical activity per listed in the protocol
214992624|NCT00382512|DRUG|Raptiva (efalizumab)|
214992625|NCT01719276|OTHER|Graded Activity|The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
214992626|NCT01719276|OTHER|Supervised Exercises|The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
214992627|NCT02632942|PROCEDURE|HAQ criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~1. 60% or greater diameter of the main AVF~2. 50% diameter of AVF with at least one more av\>40% in diameter.~3. 50% in diameter and divides into branches of same size.~4. av likely to interfere with cannulation on physical examination.~5. \>30% in diameter and associated with stenosis at site of origin."
214992628|NCT02632942|PROCEDURE|Current Recommendation|Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
214992629|NCT05920239|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI imaging is a diagnostic technique that uses magnetic fields and radio waves to create detailed images of the body's internal structures. It provides high-resolution images of soft tissues, organs, and bones, allowing for the detection and evaluation of various medical conditions.Two experienced radiologists specializing in musculoskeletal imaging will evaluate the images obtained through conventional MRI. Cases demonstrating involvement, characterized by findings such as thickening exceeding 4 mm in the inferior glenohumeral capsuloligamentous complex, signal increase indicating edema on fluid-sensitive sequences, and a reduction in axillary recess volume (greater than 0.53 ml), will be included in the study.
214992630|NCT05920239|DIAGNOSTIC_TEST|Sonoelastography|Sonoelastography is a medical imaging technique that combines ultrasound imaging with elastography. It is used to assess the mechanical properties and stiffness of tissues in the body.The probe will be carefully positioned perpendicular to the anterior part of the glenohumeral capsuloligamentous complex (IGHCC), ensuring no pressure is applied and preventing anisotropy. It will be specifically oriented in the coronal plane towards the axillary recess. The grayscale examination will reveal irregularly thickened and heterogeneous structures at the axillary recess level in the patient group. On the other hand, in the control group, measurements will be taken from the anterior band of the normal, thin, smooth, and homogeneous structure of the IGHCC.
214379327|NCT04359030|DIAGNOSTIC_TEST|Multislice CT scanning for aortic wall calcification|Multislice CT scanning for aortic wall calcification
214379328|NCT04359030|DIAGNOSTIC_TEST|Transthoracic stress echocardiography|Transthoracic stress echocardiography
214379329|NCT03078153|BEHAVIORAL|Financial Incentive|Participants will receive a $50 gift card at 3- and 6- month follow-up visits.
214379330|NCT03078153|BEHAVIORAL|Social Media Group|Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP
214379331|NCT03002038|DRUG|Azathioprine|Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.
214379332|NCT03002038|DRUG|Rituximab|Patients will receive 1 g of Rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months.
214379333|NCT01356316|BIOLOGICAL|AdimFlu-S Vaccine 2010-2011|Per ml contains following strains 30μg, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
214379334|NCT04976114|PROCEDURE|Story book with information about surgery techniques|Presurgery use of Story book. The parents with the child read a book with information about surgery techniques the days before surgery.
214379335|NCT04976114|PROCEDURE|Video with information about surgery techniques|Presurgery use of video. The parents with the child watch a video with information about surgery techniques the days before surgery.
214379336|NCT04976114|PROCEDURE|Story book and Video with information about surgery techniques|Presurgery use of video and story book. The parents with the child watch a video and read a book (both) with information about surgery techniques the days before surgery.
214379337|NCT03690830|OTHER|metabolomics analysis|collect blood samples and endometrial cells
214379338|NCT05436912|DRUG|Selpercatinib|Administered orally.
214379339|NCT00003086|BIOLOGICAL|filgrastim|
214379340|NCT00003086|DRUG|CAF regimen|
214379341|NCT00003086|DRUG|carboplatin|
214379342|NCT00003086|DRUG|cisplatin|
214379343|NCT00003086|DRUG|cyclophosphamide|
214379344|NCT00003086|DRUG|doxorubicin hydrochloride|
214379345|NCT00003086|DRUG|fluorouracil|
214379346|NCT00003086|DRUG|ifosfamide|
214379347|NCT00003086|DRUG|melphalan|
214379348|NCT00003086|DRUG|paclitaxel|
214379349|NCT00003086|DRUG|thiotepa|
214379350|NCT00003086|PROCEDURE|peripheral blood stem cell transplantation|
214379351|NCT00003086|RADIATION|samarium Sm 153 lexidronam pentasodium|
214379352|NCT01295723|RADIATION|Hypofractionated Whole Breast Radiation Therapy|"Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~* Single reference dose per fraction: 2.7 Gy (ICRU)~* Number of fractions: 15~* Number of fractions per week: 5~* Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~* Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy"
214379353|NCT01295723|RADIATION|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
214379354|NCT02904616|DEVICE|mobile spectrofluorimeter|
214379355|NCT04453514|BEHAVIORAL|Trauma-informed yoga video recording|Pre-recorded video of a 45-minute trauma-informed yoga practice. The yoga practice can be done standing or sitting in a chair. The yoga practice is comprised of slow, gentle movements combined with paying attention to the body and the breath. The practice uses invitational language and encourages participants to make choices and customize the movements according to their individual needs.
214379356|NCT04441723|DEVICE|Osteosynthesis with Gamma 3 nail , using a dynamic lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with dynamic lag screw as proximal fixation
214379357|NCT04441723|DEVICE|Osteosynthesis with Gamma 3 nail , using a static lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with static lag screw as proximal fixation
214379358|NCT03885011|DRUG|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
214379359|NCT03885011|DRUG|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
214379360|NCT03885011|DRUG|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
214379361|NCT04658823|DRUG|HOV-12020 (Palm tocotrienols complex)|Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily
214379362|NCT04658823|DRUG|Placebo|Oral Softgel capsule containing soybean oil; 1 capsule twice daily
214379363|NCT06636838|BEHAVIORAL|Spanish-Speaking Provider|Spanish speaking patients will be seen by our Spanish-speaking provider
214379364|NCT04780698|DIAGNOSTIC_TEST|SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection|COVID-19 infection and antibody testing
214379365|NCT02826590|OTHER|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
214379366|NCT02826590|OTHER|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
214379367|NCT03813212|DEVICE|MRI|Magnetic resonance imaging. Trans-abdominal sonography (TAS) and transvaginal sonography (TVS) will be performed using a 3.5 or 5 MHz transabdominal convex transducer and a 7 MHz trans-vaginal transducer.
214379368|NCT06315803|DEVICE|Real-time 3D Xplane ultrasound|After the puncture needle is in the skin, the longitudinal section of the Xplane mode can be adjusted to keep the needle in the proposed plane.
214379369|NCT01719237|DRUG|Ropivacine and Chloroprocaine mixture|Chloroprocaine is added to Ropivacaine
214379370|NCT01719237|DRUG|Ropivacaine only|Ropivacaine diluted with normal saline instead of chloroprocaine
214379371|NCT02926235|DRUG|Amino Acid|Treatment arm
214379372|NCT02926235|OTHER|Placebo|
214379373|NCT02712398|DEVICE|Phasix™ ST|Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
214379374|NCT06431438|DRUG|TQA3810|TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
214379375|NCT01141023|DRUG|DaTscan|
214992631|NCT04317027|DEVICE|New Fighting Clothing|VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
214379376|NCT05863286|DRUG|Botulinum toxin type A|"Botulinum toxin is produced by the gram-positive, anaerobic, spore-forming bacterium Clostridium botulinum, and is one of the most lethal biological toxins known to man.~Botulinum toxin has seven antigenically different serotypes and exerts a paralytic action by rapidly and strongly binding to presynaptic cholinergic nerve terminals. It is then internalized and ultimately inhibits the exocytosis of acetylcholine by decreasing the frequency of acetylcholine release. Without its nerve supply, the muscle fiber will deteriorate; however, the muscle will regain its strength as the nerves regenerate."
214379377|NCT00699140|BIOLOGICAL|IGIV3I Grifols|Immune Globulin Intravenous (Human)
214497721|NCT06720961|PROCEDURE|Collection of stool sample|One week before the surgery to remove the stricture, fecal samples from CD patients belonging to B1, B2, B3 groups will be collected. They will be used for the exploratory objective. All of the collected fecal samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
214497722|NCT05709574|DRUG|Tadalafil 20 MG|Tadalafil 20 mg tablets will be taken daily for 2 weeks alone and then for 8 weeks in combination with neoadjuvant chemotherapy in the window between gastric/GEJ adenocarcinoma diagnosis and interventional surgery.
214992632|NCT02998112|DRUG|fecal microbiota transplantation|Fecal microbiota which was purified from fresh stool defecated by a healthy donor
214992633|NCT02998112|DRUG|Saline|
214992634|NCT05237050|OTHER|Sound therapy associated with relaxation|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~Sessions will start with relaxation. Then, sound therapy will be delivered using weighted medical tuning forks which resonate at a specific frequency. At the end of the session, the patient will be invited to take a short rest."
214992635|NCT05237050|OTHER|Relaxation alone|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~The procedure will be exactly the same than the other arm (relaxation, rest time), but the operator will not activate any tuning fork (so there will be no sound delivered during the session)."
215091708|NCT02068417|DEVICE|shock waves|extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
215091709|NCT01990456|DEVICE|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
215091710|NCT01990456|DEVICE|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
214497723|NCT06773247|OTHER|I. Myofascial Release Technique ,Cupping Technique and II. Conventional Physical Therapy|"The cupping procedure was performed as follows: Massage oil was applied over the area first to improve contact and makes it easier to move the cup's position. double-walled glass cups (6 glasses with diameters from 75 to 100 mm) were held inverted, after which each glass was placed on an afflicted area overlying the low back muscle (acupoint: BL23).~Myofascial Release Technique Vertical stroking technique was performed in lumbar region to quadratus lumborum. AIt was performed as follow; Quadratus lumborum is palpated in prone and side lying for trigger points. The technique is applied by the patient positioned in side lying with a pillow under waist to exaggerate stretch of the muscle. The therapist stands at level of patient's hip posterior and counter pre"
214497724|NCT04550377|DRUG|Cannabidiol|The drug product to be used in this study is an oral formulation of CBD
214497725|NCT04550377|DRUG|Placebo|non-active medication
214497726|NCT06775470|DIAGNOSTIC_TEST|Patients must have been diagnosed with ovarian cancer and be BRCA positive|Patients must have been diagnosed with ovarian carcinoma by 31/12/2021, have undergone BRCA testing at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S. Orsola by 31/12/2021 and have been taken on for follow-up and/or treatment at the Medical Oncology - Zamagni and/or Gynaecological Oncology - De Iaco of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months.
214497727|NCT06775470|DIAGNOSTIC_TEST|BRCA1 and BRCA2 positive, and be affected by Ovarian Cancer|Patients must have been diagnosed with ovarian carcinoma by 31/12/2021, have undergone BRCA testing at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S. Orsola by 31/12/2021 and have been taken on for follow-up and/or treatment at the Medical Oncology - Zamagni and/or Gynaecological Oncology - De Iaco of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months.
214497728|NCT06771713|BEHAVIORAL|Brief Pain Reprocessing Therapy (BPRT)|"Participants will have three 90-minute behavioral intervention sessions over a 3-week period, completing 35 days of brief daily assessments, and one additional set of questionnaires.~Participants will also complete study questionnaires at 1, 2, 3, and 6 months after attending the 3 behavioral intervention sessions."
214687276|NCT03638947|DEVICE|Swab and decolonization using povidone-iodine cleansing|Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
214992636|NCT04530344|DRUG|ruxolitinib|ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
214992637|NCT04530344|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
214992638|NCT04616521|PROCEDURE|Deep brain stimulation|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
215091711|NCT02787590|DRUG|Simvastatin|
215091712|NCT02787590|DRUG|Matched Placebo (for Simvastatin)|
215091713|NCT03867019|DIAGNOSTIC_TEST|Heart rate variability parameters monitoring|"No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~1. Dizziness Handicap Inventory (DHI) - hebrew version.~2. Stait-Trait Anxiety Inventory (STAI)"
215091714|NCT01821456|DRUG|Antiinfectives|To analyze to efficacy of (novel) drug therapies
214379378|NCT04047511|DEVICE|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
214379379|NCT04047511|BEHAVIORAL|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.
214497729|NCT06770192|OTHER|Calisthenics|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks.
214497730|NCT06770192|OTHER|Plyometric|: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
214992639|NCT05031221|BEHAVIORAL|Yoga + behavioral weight loss|A 12-week, one-arm proof-of-concept and feasibility study will be conducted at the University of Colorado Anschutz Medical Campus (CU-AMC) to assess the processes critical for the success of future randomized trials including: a) Evaluating the feasibility and acceptability of adding a multi-component yoga program to a standard BWL intervention and b) Examining pre-post changes in relevant clinical/cardiometabolic, psychological, and energy balance/behavioral outcomes to inform the design of future trials. Participants will receive a comprehensive, group-based BWL intervention consistent with current guidelines for obesity treatment and a carefully designed multi-component yoga intervention delivered through pre-recorded videos delivered through a cloud-based platform that will be completed in-person and at-home (BWL+yoga).
214497731|NCT06770192|OTHER|Control|compare with other groups
214497732|NCT06771141|BEHAVIORAL|Virtual Reality Video Session|This intervention involves a 10-minute virtual reality (VR) video session designed to reduce pre-procedural anxiety and promote relaxation in pediatric patients. The video immerses participants in a calming virtual environment with interactive and visually engaging content tailored for children. It is administered prior to the endoscopy procedure to help manage anxiety and stabilize vital signs, such as blood pressure, heart rate, and oxygen saturation. The VR session serves as a non-pharmacological approach to anxiety management during medical procedures.
214992640|NCT01402700|DEVICE|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
214497733|NCT06778993|OTHER|Breastfeeding Education Program Accompanied by a Wearable (Hybrid) Simulator|This training is conducted in both theoretical and practical formats. The theoretical training consists of two sessions, each lasting 25 minutes, with a 10-minute break in between, totaling 60 minutes. Following the theoretical training, simulation-based skill training is conducted. This phase also comprises two sessions of 25 minutes each, with a 10-minute break, making a total duration of 60 minutes.
214992641|NCT05814835|DRUG|2-4 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
215091715|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always \>= 0.4 mL/h."
215091716|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
214379380|NCT04047511|BEHAVIORAL|Group Psychoeducation|A single sesstion will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
214379381|NCT01304121|DEVICE|Bioactive glass (SP53P4)|Commercial resorbable bone graft substitute (Vioxid Ltd)
214379382|NCT00517985|DRUG|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
214992642|NCT05814835|DRUG|4-6 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
214992643|NCT05814835|DRUG|6-8 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
214992644|NCT00936819|BIOLOGICAL|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
214379383|NCT04402164|DEVICE|Herbst appliance|telescopic appliance for mandibular advancement
214379384|NCT02238717|DRUG|PF-06372865 (65mg)|single oral dose (65 mg)
214379385|NCT02238717|DRUG|PF-06372865 (15mg)|single oral dose (15mg)
214379386|NCT02238717|DRUG|Pregabalin|single oral dose (300mg)
214379387|NCT02238717|DRUG|Placebo|matching oral placebo
214379388|NCT04342624|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon supplement
214379389|NCT04342624|OTHER|Placebo|Placebo
214379390|NCT01441817|PROCEDURE|Internal fixation|Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
214379391|NCT05302505|OTHER|simulation-based training|Based-simulation training for nurses in a simulation center : puncture of arteriovenous fistula and utilization of echograph and conversational hypnosis
214379392|NCT01235572|PROCEDURE|standard follow-up care|Undergo early discharge and standard outpatient care
214379393|NCT01235572|OTHER|medical chart review|Undergo early discharge and standard outpatient care
214379394|NCT01235572|PROCEDURE|quality-of-life assessment|Ancillary studies
214379395|NCT01725386|DRUG|Capecitabine|Oral tablet(s) administered according to prescribing information
214992645|NCT00936819|BIOLOGICAL|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
214992646|NCT00936819|BIOLOGICAL|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
215091717|NCT01243489|OTHER|compliance supporting measures|"Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary"
215091718|NCT02573246|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
214379396|NCT01140334|BEHAVIORAL|Voucher Reinforcement|Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
214379397|NCT01140334|BEHAVIORAL|Standard Control|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
214379398|NCT02204137|OTHER|Falls Risk Questionnaire|
214379399|NCT02204137|OTHER|Cancer and Aging Research Group Geriatric Assessment|
214379400|NCT02204137|OTHER|Falls Efficacy Scale-International (FES-1)|
214379401|NCT02204137|OTHER|Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)|
214379402|NCT03018002|OTHER|iSTAR|"Each component of the iSTAR intervention targets a specific point along the HIV continuum: confidential, onsite integrated laboratory tests during baby showers targets HIV diagnosis (b) church-based Health Advisors (CHAs) trained in motivational interviewing and quality improvement skills as promotoras target linkage, engagement and adherence by providing counseling and other support to HIV-infected women and children (c) integrated network of community and clinic case management targets reduction in loss to follow-up.~CHAs will support participants during the study period by being available to accompany them to clinic visits, review laboratory results and medications after clinic visits. They will be available to speak with them at intervals to see how they are doing either by phone or through home visits as they prefer. At each follow-up study visit, the trained CHA will review and collect data on participants' clinic visits, treatment, and laboratory results."
214379403|NCT01596218|DRUG|Brentuximab Vedotin|Starting dose is 0.6 mg/kg weekly x 3
214379404|NCT03690219|OTHER|no intervention|no intervention
214379405|NCT03517618|DRUG|S-1+leucovorin|"Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
214497734|NCT06777836|DEVICE|Personalised Discharge training|Discharge education also contributes to the empowerment of diabetic surgery patients in diabetes management. During the training process, patients will be informed about blood glucose control, diet, exercise and medication management.
214992647|NCT03453216|BEHAVIORAL|neuropsychological tests|"Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone)."
214379406|NCT05434117|BEHAVIORAL|High-intensity interval Nordic walking|Participants will complete supervised exercise sessions twice weekly for 10 weeks. Exercise specialists will educate participants in proper use of walking poles and basic Nordic walking techniques and supervise the exercise training sessions. HIIT-NoW will be 45 min in duration using Nordic poles and consists of (i) a 10-min warm-up at 30-59% heart rate reserve (HRR, light-to-moderate intensity); (ii) 4 × 4 min of high-intensity work periods at 60-89% HRR (vigorous intensity) interspersed with 3 min of low-intensity work periods at 30-59% HRR (light-to-moderate intensity); and, (iii) a 10-min cooldown at 30-39% HRR (light intensity). To allow participants to acclimatize to the HIIT-NoW protocol, the training intensity will target 60-69% HRR for the first week, 70-79% HRR in the second week, and 80-89% HRR from the third week onward. If participants do not tolerate 89% HRR well, they will exercise as close to 89% HRR as possible.
214992648|NCT04442048|BIOLOGICAL|IMM-101|Three doses of IMM-101 on days 0, 14, and 45.
214992649|NCT04442048|OTHER|Observation|No active treatment. Observation only
214992650|NCT04638517|DRUG|Danazol|Danazol up to 800mg daily in two-divided doses.
214992651|NCT04638517|DRUG|Placebo|Matching placebo.
214992652|NCT05449002|BEHAVIORAL|Practicing the Opposite (PTO)|This 30-45-minute digital program is designed to help youths on the waitlist feel better prior to treatment and may also improve their treatment engagement and outcomes.
214992653|NCT05449002|OTHER|Usual Clinical Care|Usual care provided by participating youth mental health clinics in the United States.
215091719|NCT02573246|DEVICE|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
215091720|NCT02573246|DEVICE|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
215091721|NCT01827813|PROCEDURE|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
214379407|NCT05434117|BEHAVIORAL|Standard cardiovascular rehabilitation|Individuals assigned to standard CR will attend onsite exercise-based CR comprised of one onsite exercise session per week for 8-10 weeks. The onsite CR offers exercise sessions tailored to the fitness of patients and strengthening exercise.
214379408|NCT00006232|DRUG|dexamethasone|
214379409|NCT00006232|DRUG|doxorubicin hydrochloride|
214379410|NCT00006232|DRUG|idarubicin|
214379411|NCT00006232|DRUG|vincristine sulfate|
214379412|NCT03551808|DRUG|using of Ketorolac Tromethamine Eye Drop|using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
214379413|NCT00710372|BIOLOGICAL|CYT006-AngQb|s.c. injection
214379414|NCT05388058|DRUG|Cannabidiol|Applied topically
214379415|NCT05388058|DRUG|Placebo Administration|Applied topically
214379416|NCT05388058|OTHER|Quality-of-Life Assessment|Ancillary studies
214379417|NCT05388058|OTHER|Questionnaire Administration|Ancillary studies
214379418|NCT05289258|BEHAVIORAL|Neuropsychological treatment|combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying difficulty. These exercises automatically adjust your difficulty to maintain an 85% rate of return. Treatment is carried out in groups of 10 cancer survivors. It consists of 10 weekly sessions of 2 hours each (the first hour for memory training and the second for processing speed exercises). In order to improve the adherence to treatment of the participants, emails and telephone text messages will be sent with reminders of appointments and tasks to be performed.
214497735|NCT06770465|DRUG|Different categories of antibiotics|Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.
214992654|NCT05484804|OTHER|Data Accountability and Transparency|Collaboration with Practice Facilitators; Maternal Early Warning System; Disparities Dashboard; Racial Equity Training
214992655|NCT05484804|OTHER|Community-Based Doula (CBD) Support|Community-Based Doula support for high-risk patients; Racial Equity Training
214992656|NCT05783323|DRUG|Larotrectinib monotherapy|Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
214992657|NCT05783323|RADIATION|131I therapy|Patients will receive 131I therapy after 6 months of larotrectinib.
214379419|NCT05289258|BEHAVIORAL|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used (Barlow et al., 2015). All patients receive the workbook to help them read the contents of each session, do the recommended exercises between sessions, and to help them once the treatment is finished. The treatment lasts 10 weeks (one session a week). As in the previous intervention group, emails and telephone text messages will be used with reminders of appointments and tasks to be carried out.
214379420|NCT05289258|BEHAVIORAL|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
214379421|NCT03812536|OTHER|No Void|Currently the protocol at The Ohio State University Hospital requires voiding spontaneously prior to discharge from the PACU. Our intervention group will be discharged home without having to void spontaneously as a discharge criteria.
214379422|NCT05720013|DIETARY_SUPPLEMENT|Beetroot Juice supplement|The experimental arm includes orally ingesting 140 mL Beet-It Sport Nitrate 400.
214379423|NCT05720013|DIETARY_SUPPLEMENT|Placebo supplement|he placebo arm involves orally ingesting a 140 mL placebo solution with the dietary nitrate removed.
214379424|NCT02812472|OTHER|Treadmill training with functional electrical stimulation|
214379425|NCT02812472|OTHER|Treadmill training without functional electrical stimulation|
214379426|NCT02914314|DRUG|perampanel|oral suspension.
214379427|NCT03564782|BIOLOGICAL|PVSRIPO|The live, attenuated, oral (Sabin), serotype 1 poliovirus vaccine booster will be administered 1 week before PVSRIPO injection. The study drug, PVSRIPO, is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). It will be given at a dose of 1x10\^8 TCID50 (tissue culture infectious dose) directly into the breast tumor.
214379428|NCT03597035|DRUG|Spironolactone|The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose. If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
214379429|NCT05680974|OTHER|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).
214379430|NCT00102479|DRUG|Aripiprazole|
214379431|NCT04702568|DRUG|BCX9930|BCX9930 for oral administration
214379432|NCT04702568|DRUG|Eculizumab|Administered at stable dose at the time of study entry
214379433|NCT04702568|DRUG|Ravulizumab|Administered at stable dose at the time of study entry
214497736|NCT06822244|BEHAVIORAL|Pranayama exercise|"The people in the pranayama experimental group were first informed about the practice (At the deepest point of the breath, the left nostril is closed with the index finger of the right hand and exhaled through the right nostril. When it reaches the deepest point, close the nostril with the thumb and exhale through the left nostril. At least 3 more rounds are continued in this way.~one Pranayama session (approximately 30 minutes). The people in the experimental group were taught pranayama exercises during the application and were given a brochure with written instructions on home application and were info"
214497737|NCT06822244|BEHAVIORAL|normal breathing|normal breathing 20 breath per min
214497738|NCT06822582|BEHAVIORAL|Pelvic Health Module|Telerehabilitation program involving pelvic floor exercises, education and counselling.
214992658|NCT06008587|DEVICE|AIRVO3 TM|A device that provides high flows of heated and humidified respiratory gases to patient who breath spontaneously. Patients will be treated with the device up to 15 days or until the occurrence of respiratory acidosis defined by pH\<7.35, whichever come first.
214497739|NCT06881927|DRUG|Hydrocortisone Hemisuccinate: 200 mg per day.|The hydrocortisone hemisuccinate is a powder and solvent for injectable solution at 100 mg. The powder must be dissolved in the solvent to ensure final isotonicity. The solution must be used within 24 hours. The injection is performed as a slow direct IV injection, either via an electric syringe pump or as a bolus of 50 mg every 6 hours
214992659|NCT06008587|OTHER|Standard therapy|Standard therapy depends on the acute respiratory failure etiology. Treatments will be administered at the investigator's discretion in accordance with the standard of care.
214992660|NCT06304792|PROCEDURE|Immediate FET in a stimulated or programmed cycle|Patients will undergo FET in the cycle immediately following oocyte retrieval and a failed fresh embryo transfer or freeze all.
214992661|NCT03279952|DRUG|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
214992662|NCT06208878|OTHER|Non Interventional|Safety and Efficacy Assessment
214497740|NCT06881927|OTHER|reduction of the level of immunosuppression|"In this arm, the usual immunosuppressive treatment of the patients will be discontinued.~Patients will receive hydrocortisone hemisuccinate 200 mg per day (slow direct intraveinous injection of 50 mg four times a day, or through an electric syringe pump)."
214497741|NCT06810050|DRUG|CGB-500 with 0.5% tofacitinib|CGB-500 is a proprietary ointment formulation
214497742|NCT06810050|DRUG|CGB-500 Ointment with 1% tofacitinib|CGB-500 is a proprietary ointment formulation
214497743|NCT06810050|DRUG|Vehicle (placebo)|placebo ointment
214497744|NCT06750926|DIAGNOSTIC_TEST|video image through laryngeal mask specific channel|patients placed SaCoVLM will be checked the proper position of placement by native camera through specific video channel and fiberoptic endoscopy through ventilation channel perspectively
214992663|NCT06582849|OTHER|Standard assistance|Standard assistance includes all community and institutional resources currently available for which the participant qualifies.
214992664|NCT06582849|OTHER|Enhanced assistance|Enhanced assistance includes gift cards and checks to support food, housing, utilities, transportation, pharmacy, and other non-medical costs
214992665|NCT03868540|DRUG|BI 1291583|tablet
214379434|NCT04598906|BEHAVIORAL|Virtual environment rehabilitation|The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.
214992666|NCT03868540|DRUG|Placebo|tablet
214992667|NCT01883674|OTHER|Resistance training|All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
214379435|NCT04598906|BEHAVIORAL|Paper-pencil rehabilitation|The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.
214379436|NCT02484001|DRUG|ESL 800 mg|one (1) tablet of 800 mg (QD).
214379437|NCT02484001|DRUG|ESL 1200 mg|one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
214379438|NCT02484001|DRUG|ESL 1600 mg|two (2) tablets of 800 mg (QD).
214379439|NCT02484001|DRUG|ESL 400 mg|half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
214379440|NCT01583023|DRUG|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
214379441|NCT01583023|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
214379442|NCT01583023|OTHER|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
214379443|NCT01583023|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
214379444|NCT04111523|DRUG|SY-007|A single dose of SY-007 or placebo injection(1mg-45mg)
214379445|NCT02650232|DEVICE|SOMNOtouch device (Somnomedics)|In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)
214379446|NCT02650232|PROCEDURE|Orthostatic test|"For each arm we will proceed to an orthostatic test day one and day two with :~* 10 minutes in supine position~* 10 minutes in sitting position~* 5 minutes in standing position~* 5 minutes in supine position"
214379447|NCT02650232|DEVICE|Finapres Nova device (FMS system)|
214379448|NCT00363194|DRUG|Pazopanib (GW786034)|Pazopanib (GW786034)
214992668|NCT00808704|DRUG|recombinant human erythropoietin|r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
214992669|NCT02080416|DRUG|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
214379449|NCT00653549|DRUG|Torsemide|Tablets, 20 mg, single-dose
214992670|NCT05148728|PROCEDURE|Endoscopic fulguration|already included. WE will use Storz monopolar device for fulguration
214379450|NCT00653549|DRUG|Demadex|tablets, 20 mg, single-dose
214379451|NCT01973036|DEVICE|Foley Catheter|The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
214992671|NCT06354608|BEHAVIORAL|Audio Book Group|Audiobook will be applied during the entire IM injection procedure and until the end of the procedure. After the procedure is over, the children will be taken to the waiting area. After being allowed to rest for 1-2 minutes, the child will be asked to rate their level of pain and fear during the procedure. A parent who is with the child and observes the child's behavior, and the same nurse who is independent from the study, will independently rate the child's pain and fear level during the procedure.
214379452|NCT01973036|DRUG|Oxytocin|Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
214379453|NCT01455792|PROCEDURE|Biopsies using image fusion|MRI and soft image fusion guided biopsy
214379454|NCT01455792|PROCEDURE|Gold standard biopsy|Gold standard TRUS biopsy
214379455|NCT06547372|OTHER|Dietary Intervention on Atopy|The primary aim of this dietary intervention study is to assess the effectiveness of a dietary pattern characterized by lower saturated fats, higher wholegrains, fruit, and vegetables in reducing the severity of AD in young Singapore adults, as measured by changes in Scoring Atopic Dermatitis (SCORAD) scores, over a 2-month intervention period.
214379456|NCT00803621|OTHER|Toxoplasma PCR assay|Toxoplasma PCR assay
214379457|NCT04235634|DRUG|Prostavasin|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
214379458|NCT01821417|DEVICE|Microtextured dental implant treatment|Microtextured dental implant treatment will include a surgically inserted device implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
214379459|NCT01821417|DEVICE|Dental implant treatment|Treatment with dental implants; implants with a machined collar will be surgically implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
214379460|NCT05988164|OTHER|Eye Mask|Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier.
214379461|NCT03561337|DIETARY_SUPPLEMENT|PROTEIN-CARBOHYDRATE|PRO before and PRO-CHO after training
214992672|NCT06354608|DEVICE|Local Vibration Group|In the local vibration group, IM injection will be performed with a vibrating massage device. After the procedure is finished, the children will be taken to the waiting section. After being allowed to rest for 1-2 minutes, the child will be asked to rate their level of pain and fear during the procedure. A parent who is with the child and observes the child's behavior and the same nurse who is independent from the study will independently rate the pain and fear level of the child during the procedure.
214379462|NCT03561337|DIETARY_SUPPLEMENT|CARBOHDYRATE|CHO before and after training
214379463|NCT02702700|DRUG|Cisplatin, liposomal|Lipoplatin IV 200 mg/m2
214992673|NCT06550648|PROCEDURE|Right Heart Catheterization (Swan Ganz Catheter)|Swan Ganz Catheter only for PAH patients, Using the swan ganz and pressure transducer
214379464|NCT02702700|DRUG|Verteporfin|Visudyne® IV 3 mg/m2
214379465|NCT02702700|DEVICE|Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry|Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of \<10mWcm2.
214379466|NCT04599101|DEVICE|Nose Frida nasal suction device|Caregivers will be given a Nose Frida device to remove the child's nasal secretions.
214379467|NCT04599101|DEVICE|Bulb syringe nasal suction device|Caregivers will be given a bulb syringe device to remove the child's nasal secretions.
214379468|NCT00000230|DRUG|Buprenorphine|
214497745|NCT05025384|OTHER|Acupressure|"Acupressure stickers will be applied to one ear in accordance with the NADA protocol acupuncture technique. Application will occur at designated points including Shen Men, Liver, and Lung: in the room with the mother; and potentially during breast feeding, holding, skin to skin contact or bottle feeds. Stickers will remain in place for 24 hours.~At 24 hours, skin will be assessed, and stickers will then be rotated to the opposite ear every 48 - 72 hours if there are no adverse effects such as skin irritation."
214497746|NCT06235411|DRUG|Psilocybin therapy|"Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 25 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual)."
214992674|NCT00040638|DRUG|TLK286|
214992675|NCT00002470|BIOLOGICAL|recombinant interferon alfa|
214992676|NCT00002470|DRUG|fluorouracil|
214992677|NCT06434350|DRUG|Enfortumab Vedotin|Given by IV
214992678|NCT06434350|RADIATION|Radiation Therapy|Given by Radiation Therapy
214992679|NCT06378047|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that will be administered via IV infusion.
214992680|NCT06378047|DEVICE|Irreversible Electroporation|Participants will undergo IRE as standard of care treatment.
214379469|NCT05125393|PROCEDURE|Laparoscopic linear stapler|The ileocecal or ascending colon tumors were resected using a combined cephalic caudal approach. When the accessory right colonic vein is separated from the head and then turned to the caudal side for upward dissociation. After no metastasis of 203 groups of lymph nodes is confirmed according to ICG development during the operation, the Henle stem and its root tissue were resected with a linear stapler.
214379470|NCT04804774|BEHAVIORAL|WW program modified for people with Type 2 diabetes|This 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and private online community. The program involves: self-monitoring of weight, dietary intake, and physical activity; dietary changes; increasing physical activity; shift in mindset; and behavioral strategies to manage goals. Participants will set goals and weigh-in with a coach via virtual workshop weekly and be encouraged to use the app and private online community daily. The virtual workshop features a behavior change technique and enables the participant to practice it to support their goals. Participants are given a personalized food plan based on expert healthy eating guidelines, an activity plan to promote regular physical activity and techniques to help shift mindset for lasting change. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals weekly. Participants will be encouraged to participate in a private Facebook group for motivational support.
214379471|NCT02909036|DEVICE|Melphalan|
214379472|NCT02909036|DRUG|Pegfilgrastim|
214379473|NCT02909036|PROCEDURE|Autologous Hematopoietic Progenitor Cell Transplant|
214379474|NCT05288023|DRUG|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g).~Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
214992681|NCT06468137|BEHAVIORAL|Swedish I-ACE|Rehabilitative programme with focus on communication strategies and problem solving for people with hearing loss.
214992682|NCT06468137|BEHAVIORAL|Clinical visit|Visit in the clinic with focus on audiologic rehabilitation.
214992683|NCT06468137|OTHER|No follow-up|Participants choosing no follow-up.
214992684|NCT05827835|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
215091722|NCT01827813|PROCEDURE|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
215091723|NCT01827813|PROCEDURE|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
214379475|NCT04459559|DEVICE|Tactile Cueing Device|Each participant receives an individual training on how to use the Tactile Cueing Device and the set-up of the TCD will be done according to the results of a 10MWT and the participant's preferences. Gait assessments with an activated or deactivated TCD are executed using the Timed Up and Go test, the 2-Minute Waling test and a treadmill (C-Mill). Also a long-term test run of the TCD during one day is planned.
214379476|NCT00098254|DRUG|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
214379477|NCT04146896|DRUG|NYX-2925 50 mg|NYX-2925 administered orally
214379478|NCT04146896|DRUG|Placebo|Placebo administered orally
214379479|NCT03017131|BIOLOGICAL|Aldesleukin|Given SC
214379480|NCT03017131|DRUG|Cyclophosphamide|Given IV
214379481|NCT03017131|DRUG|Decitabine|Given IV
214379482|NCT03017131|BIOLOGICAL|Genetically Engineered NY-ESO-1-specific T Lymphocytes|Given IV and IP
214379483|NCT03017131|OTHER|Laboratory Biomarker Analysis|Correlative studies
214379484|NCT00006115|DRUG|FOLFIRI regimen|
214379485|NCT00006115|DRUG|FOLFOX regimen|
214379486|NCT00006115|DRUG|fluorouracil|
214992685|NCT05827835|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
214992686|NCT05325034|BEHAVIORAL|Early Intervention|"Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies."
214992687|NCT05019638|DRUG|Regional anesthesia group|bupivacaine 0.25% with epinephrine 1:400,000.
214992688|NCT05019638|DRUG|Local multimodal analgesia group|5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
214992689|NCT04862286|DRUG|Risankizumab|Subcutaneous (SC) injection.
214992690|NCT05507424|PROCEDURE|Prone Positioning|Newborn will be prone position for 30-60 seconds during delayed umbilical cord clamping
214992691|NCT05507424|PROCEDURE|Supine Positioning|Newborn will be supine position for 30-60 seconds during delayed umbilical cord clamping
214992692|NCT06366269|OTHER|Acupuncture|traditional and electroacupuncture
214992693|NCT06366269|BEHAVIORAL|Behavioral management|based on American urologic association guidelines
214992694|NCT06366269|OTHER|Physical therapy|pelvic floor with biofeedback
214992695|NCT02489539|DEVICE|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
214992696|NCT05402761|BEHAVIORAL|Nurse-guided BBTi group|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi. In the end of week 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
214992697|NCT05402761|BEHAVIORAL|Mobile-delivered BBTi group|They will use the app in conjunction with the standard BBTi procedures provided by the app, such as stimulus control, sleep restriction and audio-guided relaxation techniques (suggest to use before bedtime).
214992698|NCT05371158|BEHAVIORAL|Online intervention|The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
215091724|NCT00003358|DRUG|chemotherapy|
215091725|NCT00003358|DRUG|cisplatin|
215091726|NCT00003358|DRUG|gemcitabine hydrochloride|
215091727|NCT01961960|BIOLOGICAL|ASP7374|intramuscular
214379487|NCT00006115|DRUG|irinotecan hydrochloride|
214379488|NCT00006115|DRUG|leucovorin calcium|
214379489|NCT00006115|DRUG|oxaliplatin|
214379490|NCT00004924|DRUG|irinotecan hydrochloride|
214379491|NCT00004924|DRUG|paclitaxel|
214379492|NCT02118337|BIOLOGICAL|MEDI0680|Participants will receive IV infusion of MEDI0680 0.1 or 0.5 or 2.5 or 10 or 20 mg/kg Q2W in dose-escalation phase and 20 mg/kg Q2W in dose-expansion phase.
214379493|NCT02118337|BIOLOGICAL|Durvalumab|Participants will receive IV infusion of durvalumab 3 and 10 mg Q2W in dose-escalation phase and 750 mg Q2W in dose-expansion phase.
214379494|NCT02118337|BIOLOGICAL|Nivolumab|Participants will receive IV infusion of nivolumab 240 mg Q2W in dose-expansion phase.
214379495|NCT03628963|DEVICE|Concerto+|a user-centered, multifunctional and personalized eHealth platform
214379496|NCT06382285|DRUG|Continues peripheral block|ropivacaine (Naropin) 0.2% according to a protocol 8-10 cc per hour up to 24 hours after surgery
214497747|NCT06235411|DRUG|Inactive Psilocybin therapy|"Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 1 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual)."
214992699|NCT06466187|DRUG|PF-08052666|Given into the vein (IV; intravenously)
214992700|NCT06242795|DRUG|7% Hypertonic Saline via nebulization|Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
214992701|NCT06275477|DIAGNOSTIC_TEST|68Ga-FAPI46|Depending on the situation, it is planned that this evaluation will be transversal (performing \[68Ga\] Ga-FAPI PET/CT at baseline) or longitudinal (performing \[68Ga\] Ga-FAPI PET/CT at baseline and at 3/6 months for patients benefiting from an intensification of therapeutic management at inclusion).
215091728|NCT01219933|DRUG|methylprednisolone|starting dose \>/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule
215091729|NCT01219933|DRUG|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
215091730|NCT03694743|DEVICE|2Shape rotary system|root canal preparation
215091731|NCT03661736|OTHER|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
214379497|NCT06464471|OTHER|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
214992702|NCT06505811|BEHAVIORAL|Guaranteed Income ($500/monthly)|Participants receive $500 monthly for up to 18 months.
214992703|NCT06505811|BEHAVIORAL|Active Comparison ($20/monthly)|Participants receive $20 monthly for up to 18 months.
214992704|NCT04467593|DEVICE|Whole body hyperthermia|Whole body hyperthermia to treat stage IV cancer patients
214992705|NCT04467593|DRUG|Standard of Care (SOC) chemotherapy according to the NCCN guidelines.|Whole body hyperthermia to treat stage IV pancreatic cancer patients combined with standard of care chemotherapy
214992706|NCT04727944|OTHER|Reach and grasp tasks in healthy participants using MEG technique (Experiment 1)|"Human participants will perform reach and grasp movements to various objects (e.g. a cube, sphere, or rod) driven either by perceived action affordances, or instruction cues. A rotating carousel will be used to present subjects with various objects affording different types of grasps (e.g. a precision pinch, a whole hand 'power' grasp, or a tripod grasp).~Prior to the experiment, subjects will be tested outside the scanner by asking them to grasp each object as they would naturally to ensure that each object elicits the expected grasp type. Subject-specific, 3D-printed head-casts will be created based on high resolution MRI scans from each subject, and worn by subjects during the MEG experiment (Experiment 1) to reduce within-session head movement associated with reaching and grasping.~At the end of this session an experimental task is added: detection of tons in presence of multitonal masks, in order to verify how beta peaks might be generated by a stimulus auditory."
214992707|NCT04727944|OTHER|Reach and grasp tasks in healthy participants using EEG technique (Experiment 2)|Experiment 2 consists of a task of reaching for and grasping several objects (e.g. a cube, sphere, or rod) ; the task used for experiment 2 is the same as that used for experiment 1. EEG signals will be measured.
215091732|NCT01902888|DEVICE|GORE® VIABAHN® Endoprosthesis|
215091733|NCT03930550|PROCEDURE|Tracheal intubation by endoscopy with flexible bronchoscope|A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
214379498|NCT04636606|PROCEDURE|Home Exercise|Educational training program about oral dysphagia in patients with temporomandibular disorders.
214497748|NCT06235411|OTHER|Electroencephalogram|"* Rest EEG prior to first treatment administration~* EEG during first treatment administration~* Rest EEG during integration session after second treatment administration"
214497749|NCT06235411|OTHER|Blood samples for the analysis of immune and inflammatory profiles|Three 7ml EDTA tubes will be taken in the morning on an empty stomach at day 0 and at 3 weeks.
215091734|NCT00316888|BIOLOGICAL|cetuximab|Given IV
215091735|NCT00316888|DRUG|cisplatin|Given IV
215091736|NCT00316888|DRUG|fluorouracil|Given IV
215091737|NCT00316888|RADIATION|radiotherapy|Given once daily 5 days a week for 5 weeks
215091738|NCT01944579|OTHER|Blackberries|Participants will receive blackberries as part of a controlled diet.
215091739|NCT01944579|OTHER|Control|Participants will receive a control food (jello) as part of a controlled diet.
215091740|NCT06244836|OTHER|Implementation of a bundle of care|
215091741|NCT06461728|DEVICE|a new prototye device that heat and activate sodium hyochlorite (Aseptico)|endoactivator : it is a sonic activator device
215091742|NCT03329716|OTHER|Brace weaning|For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
215091743|NCT03084042|DEVICE|fMRI|
215091744|NCT05919641|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
215091745|NCT05838014|OTHER|Sleep deprivation|Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise
215091746|NCT05838014|OTHER|Normal sleep|Participants will undertake \~8 hours of normal sleep prior to completing exercise
215091747|NCT00914550|OTHER|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
214379499|NCT04636606|PROCEDURE|Manual Therapy Combined with Home Exercise|Manual therapy program combined with educational training program about oral dysphagia in patients with temporomandibular disorders.
215091748|NCT02680470|DEVICE|Virtual observed therapy|Virtual Observation of participants taking their medication
214379500|NCT04636606|PROCEDURE|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|Orofacial Myofunctional Therapy program with combination of Manual therapy and educational training program about oral dysphagia in patients with temporomandibular disorders.
214379501|NCT02707419|DEVICE|Experimental group|Video of the exercises
215091749|NCT01837667|DRUG|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
214379502|NCT02707419|DEVICE|Control group|video of nature scenes
214497750|NCT06235411|OTHER|stool samples|Stool sampling at day 0 and 3 weeks Analysis of intestinal microbiota is carried out on a stool sample, which is stored at -20°C for a maximum of 24 hours. The sample is then transferred cold to the CRB of the Nîmes University Hospital, where it is stored at -80°C until the microbiology laboratory can perform a group analysis.
214497751|NCT06235411|OTHER|MRI functional and cerebral|MRI functional and cerebral at day 0 and 3 weeks
214497752|NCT06810817|COMBINATION_PRODUCT|tDCS & cognitive behavioral programme with home-based physical training|Participants will receive 16 sessions of tDCS and 7 sessions of cognitive behavioral programme over 8 weeks and have physical training at home for 8 weeks.
214497753|NCT06810817|BEHAVIORAL|sham tDCS & cognitive behavioral programme with home-based physical training|Participants will receive 16 sessions of sham-tDCS and 7 sessions of cognitive behavioral programme over 8 weeks and have physical training at home for 8 weeks.
214497754|NCT06810817|BEHAVIORAL|physical training|Participants will have physical training at home for 8 weeks.
214497755|NCT02404870|DRUG|Placebo|Placebo
214497756|NCT02404870|DRUG|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
214497757|NCT06888544|BEHAVIORAL|HIIT program for 24 weeks with a frequency of 2 times per week.|Participants will receive a 24-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 37 to 40 minutes with progression of training. Each HIIT section will include six high-impact weight-bearing exercise. For Weeks 1-4, the HIIT section will include 12 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 11 intervals of 60 seconds of active recovery. To ensure the subjects' safety, a chair will be used for assistance during training in the first month. Additionally, a 3 kg weight will be incorporated for the training in the final two months.
214497758|NCT06888544|BEHAVIORAL|Non-exercise control|Workshop participants in the non-exercise control group will receive a series of workshops related to daily recreation.
214497759|NCT06785298|DRUG|Levodopa/carbidopa|A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD
214497760|NCT06785298|DRUG|Fexofenadine|Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines
214497761|NCT05605496|DRUG|NP137|IV infusion, 14mg/kg, Q3W
214497762|NCT05605496|DRUG|anti-PD-1/PD-L1|IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.
215091750|NCT01837667|DRUG|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
215091751|NCT01369186|DRUG|Morphine|i.v. bolus injection
215091752|NCT01369186|DRUG|Placebo|i.v. bolus injection
215091753|NCT04463849|DIAGNOSTIC_TEST|Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection|"All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.~The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols."
215091754|NCT04656106|DRUG|Ryzodeg®|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
215091755|NCT00680758|DRUG|cisplatin|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients"
214497763|NCT00521846|DEVICE|Biomet Explor Modular Radial Head Replacement|As part of the patient's routine care, they will undergo a radial head replacement using the Biomet Explor Modular Radial Head system.
214379503|NCT02707419|DEVICE|Conventional physiotherapy|Mobilization, exercises and transfer practice.
214379504|NCT00073437|DRUG|Infliximab|
214379505|NCT02115997|DRUG|Methylprednisolone|Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
214379506|NCT02115997|DRUG|Prednisone|Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day \[mg/kg/day\]) at the discretion of investigator given daily until participants are off the drug.
214497764|NCT03381300|PROCEDURE|Ovarian tissue cryopreservation|Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue
214497765|NCT06619613|BIOLOGICAL|Alzheimer Disease (AD)|CM383 injection
214497766|NCT06619613|OTHER|Placebo|Matched placebo
214379507|NCT02115997|DRUG|Rituximab|Rituximab will be administered at 375 milligrams per meter square (mg/m\^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
214379508|NCT02053025|DIETARY_SUPPLEMENT|mycoprotein|
214379509|NCT02053025|DIETARY_SUPPLEMENT|control protein|
214379510|NCT05091866|OTHER|Quality-of-Life Assessment|Ancillary studies
214379511|NCT05091866|OTHER|Questionnaire Administration|Ancillary studies
214379512|NCT05091866|BIOLOGICAL|Therapeutic Progesterone|Given SC
214379513|NCT02914379|DRUG|[¹⁴C]-LY3337641|Administered orally
214379514|NCT01515189|BIOLOGICAL|Ipilimumab|
214379515|NCT02746042|DRUG|Sinupret extract coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
214497767|NCT05575752|OTHER|high temperature (32℃) group|The exposure group will be exposed to high temperature (32℃) in a chamber for about 2 hours, resting during the whole periods.
214497768|NCT05575752|OTHER|moderate temperature (22℃) group|The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole periods.
214497769|NCT06511700|PROCEDURE|It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique|Internationally, some experiences demonstrate that the administration of intravitreal injections, especially by nurses trained in aseptic techniques, is feasible without compromising patient safety. Although there is already some experience in Spain, it is a new procedure within the nursing field of the Ophthalmology service for which no results have been reported.
214497770|NCT06512051|DRUG|SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin|"Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin"
214497771|NCT05637489|BEHAVIORAL|PING|Brief survey of goals and preferences
214497772|NCT04247191|BEHAVIORAL|P-Chat|The P-Chat is a brief individually delivered intervention based on the principles of Motivational Interviewing (MI) and focuses on increasing parents' motivation to reduce permissiveness toward underage alcohol use while reducing defensiveness and barriers to implementing these rules with their teen.
214992708|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention|"Focus of the SEMC-protocol is on increasing PA gradually towards the national recommendations. Emphasis of counseling is on incidental exercise, endurance, and strength training. Techniques of motivational interviewing are utilized.~Baseline; MD+PT counseling, medical clearance, mapping lifestyle \& life situation, goal setting, measurements, questionnaires, feedback. weeks 1-6: guided group resistance training 1hr, 1x/week. 5-10-minute warm-up, 9 exercises with weight stack equipment on large muscle groups. 2-3 sets, 12-15 repetitions. Modified individually, e.g. according to musculoskeletal problems. Emphasis on learning the basics and safety aspects. After 6 weeks unsupervised training. 3-month: MD counseling and questionnaires. 6-month: MD+PT counseling, assessing safety of PA, measurements, questionnaires, feedback. 12-month: MD+PT counseling (feedback, ensuring continuity of lifestyle changes; redirecting to municipality/NGO activities), measurements, questionnaires, feedback"
214992709|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention combined with enhanced behavioral support -intervention (EBS)|"In addition to the SEMC-protocol, the participants will be contacted 3 times during the first 3 months (live / online as preferred). Themes:~Session 1: Motivation and illness perceptions. Exploring CPAP use, PA, and SB. Session 2: Self-regulation (feedback, goal setting, self-monitoring, action planning, problem solving), activating social support, prompts/cues, and preparatory behaviors. (Included BCTs from Michie et al 2013 taxonomy: 3.2, 12.2, 8.3,) Session 3: Assessing progress and agenda setting, self-regulation, maintenance of PA.~Measurements and questionnaires as with SEMC-protocol."
214992710|NCT06173791|DEVICE|DFDBA fibers|Bone Allograft fibers used in dental sinus reconstruction surgery
214379516|NCT02746042|DRUG|Placebo coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
214992711|NCT06173791|DEVICE|DFDBA particles|Bone Allograft particles used in dental sinus reconstruction surgery
214379517|NCT01261143|DRUG|BK-C-0701|tablet, 8 weeks
214379518|NCT04506190|PROCEDURE|Revisional bariatric surgery|Subjects who undergo revisional bariatric surgery
214379519|NCT04855305|DRUG|Hyperpolarized 129Xe|Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
214379520|NCT02974881|DEVICE|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
214379521|NCT06249763|DIETARY_SUPPLEMENT|High gluten diet|Trial period A: gluten free diet added daily granola bars with 10 g gluten/day (intervention).
214379522|NCT06249763|DIETARY_SUPPLEMENT|Gluten free diet|Trial period B: gluten free diet added daily granola bars with \<1 g gluten/day (placebo).
214379523|NCT00722579|DEVICE|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
214379524|NCT04886427|OTHER|No intervention|Measure the experiences of the current care
214379525|NCT00960674|PROCEDURE|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
214379526|NCT00960674|BEHAVIORAL|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
214379527|NCT02826525|DRUG|AZD4076|Investigational product
214379528|NCT02826525|DRUG|Placebo|Control
214379529|NCT01186614|DEVICE|Automated CPR|Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
214379530|NCT01186614|DEVICE|ECMO|Insertion of peripheral VA ECMO
214379531|NCT01186614|PROCEDURE|Coronary angiography|Coronary angiography and intervention where necessary will be performed following ECMO insertion
214379532|NCT01186614|PROCEDURE|Therapeutic Hypothermia|Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
214379533|NCT01126060|DRUG|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
214379534|NCT01126060|PROCEDURE|Thyroidectomy|surgical removal of bilateral thyroid glands
214379535|NCT04430413|BIOLOGICAL|Platelet Rich Plasma|Autologous PRP obtained via double centrifugation process of the participant's blood sample. PRP was prepared by the double Spain strategy.
214379536|NCT03889613|OTHER|prospective follow-up with videocapsule|prospective follow-up with videocapsule
214379537|NCT04453215|DEVICE|GaAlAs semiconductor diode laser device|low-level laser therapy
214379538|NCT02139358|DRUG|Gemcitabine|The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m\^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m\^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
214379539|NCT02139358|DRUG|Trastuzumab|Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
214992712|NCT06173791|DEVICE|DBBM|DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.
214992713|NCT06665217|DRUG|Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy.
214992714|NCT06350526|DIAGNOSTIC_TEST|Complete Blood Count|blood sample
214379540|NCT02139358|DRUG|Pertuzumab|Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
214379541|NCT04575727|DRUG|[11C]MPC6827|Subjects will receive a microdose ( 10 µg) of \[11C\]MPC6827 (dose of 20 mCi)
214379542|NCT05784805|DEVICE|PLIFU|Participants will be treated with up to 2 sessions of PLIFU (on the same day), while monitored with surface EEG and will be observed for the remainder of the hospital stay as deemed by the primary care team. The system non-invasively delivers ultrasound sonications intracranially that selectively target specific areas of the brain.
214379543|NCT04846023|DEVICE|aEEG via vEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes. There is a new aEEG technology available: VEEGix, developed by NeuroServo Inc. It is a miniaturized aEEG, non-intrusive, portable and resistant to patient's movements. Its main advantage is its simplicity of use as a single adhesive strip including all electrodes is fixed to the patient's forehead and is connected to the VEEGix device
214379544|NCT02540395|DRUG|Tacrolimus (for Group B)|Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
214379545|NCT02540395|DRUG|MMF (mycophenolate mofetil) (for Group B)|"MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax.~From day 8 on, patients will not receive MMF."
214379546|NCT02540395|DRUG|6-methyl prednisolone (Steroids) (for Group B)|"At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).~Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed."
214379547|NCT02540395|DRUG|Tacrolimus (for Group A)|"The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study.~Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption."
214992715|NCT06350526|DIAGNOSTIC_TEST|C-reactive protein|serum sample
214497773|NCT04247191|BEHAVIORAL|PBI|"The PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of the two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third, is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
214497774|NCT04247191|BEHAVIORAL|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above. Parents in this arm of the study will receive both interventions.
214992716|NCT06350526|DIAGNOSTIC_TEST|O2 saturation|blood sample
214992717|NCT06350526|DIAGNOSTIC_TEST|Serum ferritin and D-dimer|Blood sample
214992718|NCT06350526|DIAGNOSTIC_TEST|Liver and renal function tests|Blood sample
214992719|NCT06350526|DIAGNOSTIC_TEST|Lactate dehydrogenase|Blood sample
214992720|NCT06350526|DIAGNOSTIC_TEST|coronavirus (SARS-CoV-2) swab|Throat swab
214992721|NCT06350526|RADIATION|CT chest|Radiation
214992722|NCT05277207|BEHAVIORAL|Personalized Smoking Cessation Facilitation Meetings|Participants will participate in 5-7 meetings in which they will receive cognitive-behavioral therapy for tobacco cessation.
214992723|NCT05277207|DRUG|Personalized Smoking Cessation Pharmacotherapy|Participants may receive pharmacotherapy for smoking cessation based on VA Pharmacy Benefits Management Services guidelines. Medications may include nicotine-replacement therapy, varenicline, and/or bupropion.
214992724|NCT05277207|BEHAVIORAL|Personalized Text Messaging Support|If the participant has a working cell phone and is willing to receive text messages, supportive, personalized text messages will be sent to the participant starting after Session 1 and extending through 6 months post-quit using VA's Annie texting capability.
214379548|NCT02540395|DRUG|Mycofenolate mofetil (MMF) (for Group A)|"Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™).~The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation."
214379549|NCT02540395|DRUG|6-methyl prednisolone (Steroids) (for Group A)|"At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).~Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day."
214379550|NCT06547034|DEVICE|Ultrasound|Breast Ultrasound
214379551|NCT04838613|DRUG|[18F]CTT1057|Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
214379552|NCT04838613|DRUG|[68Ga]Ga-PSMA-11|Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
214379553|NCT03651050|BEHAVIORAL|Faith Based Outreach (FBO)|Faith base outreach groups will be trained in P-MHDT
214379554|NCT03651050|BEHAVIORAL|community-health-workers (CHW)|COmmon health workers will be trained in P-MHDT
214379555|NCT03319082|COMBINATION_PRODUCT|Corneal Collagen Cross-linking|Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
214379556|NCT01686581|DRUG|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
214497775|NCT06471504|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
214497776|NCT05431946|BEHAVIORAL|Advance Care Planning and the consequent actions|"The palliative care intervention is based on the advance care planning process and the actions taken as a consequence of these conversations. The goal is the identification, assessment, and treatment of physical, psychosocial, or spiritual symptoms and problems.~Advance care actions~These are the actions taken to fulfill the advance care plan and can include, but are not limited to:~treatments: pharmacological, psychosocial (priest, psychologist, etc.) referrals: rehabilitation, specialized palliative care team, hospice, etc. communication initiatives with relatives, primary care, public authorities"
214992725|NCT05277207|BEHAVIORAL|SmokefreeVET|Participants will receive a referral to SmokefreeVET, a text-messaging intervention designed to help veterans prepare for and attempt quitting smoking.
214992726|NCT05277207|BEHAVIORAL|VA Quitline|Participants will receive a referral to VA Quitline, which is a nationally available telehealth intervention that provides assistance to veterans who wish to quit tobacco use. Quitline includes five sessions of cognitive-behavioral treatment.
214992727|NCT05277207|OTHER|Education about pharmacotherapy|Participants will receive a handout that provides them with information about pharmacotherapies for tobacco cessation.
214992728|NCT02770703|DEVICE|DynaMesh visible mesh|Implantation of a MRI visible mesh
214992729|NCT06377514|DEVICE|Test IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the Test IOL Model DEN00V in both eyes for the duration of the study
214992730|NCT06377514|DEVICE|Control IOL Model DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model DCB00 in both eyes for the duration of the study
215091756|NCT00680758|DRUG|everolimus|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients"
214379557|NCT00008021|BIOLOGICAL|filgrastim|
214379558|NCT00008021|BIOLOGICAL|monoclonal antibody Lym-1|
214379559|NCT00008021|DRUG|cyclosporine|
214992731|NCT06645093|OTHER|Fasting|Fasting implies 0 kilojoule. Water ad libitum is permitted.
214992732|NCT05523297|DRUG|Octaplex|Prothrombin complex concentrate
214992733|NCT05523297|DRUG|Frozen Plasma Product, Human|If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma
214992734|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 1
214992735|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 2
214379560|NCT00008021|DRUG|paclitaxel|
214379561|NCT00008021|PROCEDURE|peripheral blood stem cell transplantation|
214992736|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 3
214992737|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 4
214992738|NCT04847024|DRUG|Parecoxib|40 mg IV
214992739|NCT04847024|DRUG|Dexketoprofen|50 mg IV
214992740|NCT03347643|DEVICE|tDCS with real stimulation|tDCS is a non-invasive brain stimulation. Real stimulation includes 2mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
215091757|NCT00680758|DRUG|paclitaxel|"* Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients"
215091758|NCT01972685|PROCEDURE|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchial vs. VATS biopsy
215091759|NCT01972685|PROCEDURE|Transbronchial Biopsy|
215091760|NCT01972685|PROCEDURE|VATS biopsy|
215091761|NCT06299722|OTHER|STEEL|Relatively heavy strength training
215091762|NCT06299722|OTHER|Circuit training|Circuit training
214379562|NCT00008021|RADIATION|indium In 111 monoclonal antibody Lym-1|
214379563|NCT00008021|RADIATION|yttrium Y 90 monoclonal antibody Lym-1|
214992741|NCT03347643|DEVICE|tDCS with sham stimulation|Sham stimulation includes 0mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
214992742|NCT03462680|DIETARY_SUPPLEMENT|niacin|Niacin or nicotinic acid 250 mg tablets
214992743|NCT03462680|OTHER|placebo|placebo tablet
214992744|NCT03203785|DIETARY_SUPPLEMENT|Carbohydrate (maltodextrin)|maltodextrin flavored
214379564|NCT00600379|DEVICE|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
214379565|NCT05325255|OTHER|Myofascial release of subscapularis|It is the application of manual pressure over myofascial trigger point that induces ischemia and causes release of trigger points
214379566|NCT05325255|OTHER|Maitland mobilization|It is the type of mobilization technique that uses passive accessory mobilization to reduce pain and stiffness and increasing range of motion
214379567|NCT05325255|OTHER|Stretching exercises|It is the technique use to increase flexibility and range of motion of short and hypomobile structures
214379568|NCT05325255|OTHER|Cold pack|It is the application of cold to provide analgesic effects
214379569|NCT02287116|DEVICE|Easy Flow system and INCA® nasal cannulae set|
214379570|NCT04802096|OTHER|inspiratory muscle training|Intensity of inspiratory muscle training will be set at 30% of maximal inspiratory pressure. Subjects in intervention experimental group will perform 15 breaths per set, 6 sets per day on daily basis. The intervention will be last for 8 weeks.
214379571|NCT04802096|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation consists of aerobic exercise training, strength training, and education related to airway clearance and drug utilization. All of subjects will receive 8-week pulmonary rehabilitation.
214379572|NCT02378740|DRUG|Saline|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
214379573|NCT02378740|DRUG|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
214379574|NCT01618084|DEVICE|Tritanium acetabular component|Total hip arthroplasty using a tritanium uncemented acetabular component
214379575|NCT02597465|DRUG|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
214497777|NCT06351709|OTHER|Stretching|Static stretching technique was applied to the quadriceps and hamstring muscle groups in both the dominant and non-dominant extremities of the participants in the stretching group. All stretches were performed twice for 20 seconds with a 3-second rest.
214497778|NCT06351709|OTHER|Hot pack application|Hot pack application was applied to the participants in the hot group to warm the extremities locally after the pre-tests were completed. For the application of hotpack, which is a superficial and moist temperature agent, a Chattanooga ® brand hotpack pad (DJO Global, Chattanooga; CA, USA) with 10 slices and a size of 28 cm x 39 cm was used. The hotpack pad was taken with the help of tongs from the Chattanooga ® brand hot pack boiler (DJO Global, Chattanooga; CA, USA) at 80° temperature and wrapped in a total of 5 layers with the help of 2 towels. A hotpackpad was placed on each knee of the participant. Hotpack pads were applied for 15 minutes in total.
214992745|NCT03203785|OTHER|Placebo|non-caloric drink
214992746|NCT04225975|DIAGNOSTIC_TEST|electroencephalogram|Within the 5 min after birth the electroencephalogram of the neonates will be recorded with the aid of a patch on the scalp
214992747|NCT04225975|DIAGNOSTIC_TEST|oxymetry|Within the 5 min after birth the cerebral oxymetry of the neonates will be recorded with the aid of a patch on the scalp
214992748|NCT02270268|DIETARY_SUPPLEMENT|Pectin|Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
214992749|NCT02270268|DIETARY_SUPPLEMENT|maltodextrin|
214992750|NCT05345080|BEHAVIORAL|Exposure-Reduction Intervention|The customized exposure-reduction intervention includes a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), and a customized asthma self-management and exposure-reduction plan developed using motivational interviewing techniques, support, and exposure-reduction supplies.
214379576|NCT02597465|DRUG|Reference1507|Investigators choice including chemotherapy or supportive therapy
214992751|NCT02333643|DRUG|CLS003|
214992752|NCT02333643|DRUG|Furosemide|
214992753|NCT02333643|DRUG|Digoxin|
214992754|NCT02333643|DRUG|Vehicle topical|
214992755|NCT02576496|DRUG|Tinostamustine|
215091763|NCT03149003|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
215091764|NCT03149003|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
215091765|NCT02177409|DRUG|Telmisartan|
215091766|NCT02177409|DEVICE|Amlodipine|
215091767|NCT02177409|DRUG|Placebo|
215091768|NCT00967161|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
215091769|NCT00967161|PROCEDURE|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
214379577|NCT00913185|DRUG|Acne Free, Proactiv|
214379578|NCT03778034|OTHER|female with Forward head posture|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
214379579|NCT03778034|OTHER|healthy female without (FHP)|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
214992756|NCT05844046|BIOLOGICAL|durvalumab, tremelimumab, bevacizumab|durvalumab, tremelimumab and bevacizumab will be administered in the respective arms either as up-front triple treatment or as combined treatment with durvalumab and tremelimumab followed by the addition of bevacizumab
214992757|NCT02246777|DEVICE|Ex-PRESS® Glaucoma Filtration Device, Model P50PL|
214379580|NCT01925027|DEVICE|Nano+ DES|All patients will be treated with the NanoTM Polymer-free Sirolimus Coronary Stent System. All patients will undergo angiographic (QCA) investigation at baseline (pre- and post-procedure) and at 3 months follow-up. All patients will undergo OCT investigation at 3 months follow-up. All patients will be evaluated clinically at 3, 4, 5 months (for patients with 6 months OCT follow-up evaluation will be at 8 months) and at 1 and 2 years.
214379581|NCT05042089|OTHER|No intervention will be applied.|The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.
214379582|NCT03857230|DRUG|Follitropin alfa (Primapur)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
214379583|NCT03857230|DRUG|Follitropin alfa (Gonal-F)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
214992758|NCT00182819|DRUG|temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
214379584|NCT02976142|PROCEDURE|neoadjuvant chemoimmunotherapy|
214992759|NCT00182819|RADIATION|radiation therapy|50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
214992760|NCT00439621|BIOLOGICAL|RP 01|Active immunotherapy
214379585|NCT02522858|DRUG|Atropine|"To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01\~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.~During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group."
214379586|NCT02522858|DRUG|Dexmedetomidine|Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
214379587|NCT02522858|DRUG|Ephedrine|Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
214992761|NCT00498303|BIOLOGICAL|trivalent split influenza vaccine|
214992762|NCT00825006|DEVICE|Triple site pacing mode|"The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months."
214992763|NCT00870701|RADIATION|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
214379588|NCT05346848|DRUG|Association of darolutamide and EBRT|"Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~\- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD"
214497779|NCT06351709|OTHER|Cold pack application|For participants in the cold group, MSD ® brand cold pack gel (MVS Inmotion, MSD cold pack; Weftdijk 1502830, Belgium), 15 cm x 25 cm in size, was used to cool the extremities locally. The cold pack gel, kept in the freezer, was wrapped in a paper towel and placed on the knee area. Cold pack was applied to both knees for a total of 15 minutes.
214497780|NCT03610581|BIOLOGICAL|Ad26.HPV16|Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
214992764|NCT00870701|OTHER|absence of radiotherapy|absence of radiotherapy
214497781|NCT03610581|BIOLOGICAL|Ad26.HPV18|Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
214992765|NCT02401230|DRUG|Truvada|Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
214992766|NCT02401230|DEVICE|Gel lubricant|Five ml of an over the counter sexual lubricant will be dispensed using an applicator.
214992767|NCT03076879|BEHAVIORAL|Promoting participation in cervical cancer screening|"Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.~Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.~Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.~Brochure; The brochure for cervical cancer and screening will be given after group training."
214992768|NCT00683995|DRUG|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
214992769|NCT00916734|PROCEDURE|MDT (McKenzie Method)|Subjects who perform exercises in their direction of preference.
214992770|NCT00916734|PROCEDURE|Spinal thrust manipulation|Subjects who receive spinal thrust manipulation as an intervention.
214992771|NCT04133909|BIOLOGICAL|Mepolizumab|Mepolizumab was a sterile liquid formulation. It was administered as a subcutaneous injection (100 milligrams per milliliter \[mg/mL\]) delivered once every 4 weeks using a pre-filled safety syringe.
214992772|NCT04133909|DRUG|Placebo|Placebo was a 0.9% sodium chloride solution. It was administered as a subcutaneous injection delivered once every 4 weeks using a pre-filled safety syringe.
214992773|NCT03505775|DIAGNOSTIC_TEST|23Na magnetic resonance imaging|Imaging/diagnostic: Evaluation of the muscular and cutaneous sodium storage by 23Na magnetic resonance imaging. 23Na magnetic resonance imaging: 23NA-MRI protocol on a 3T scanner (Magnetom PRISMA, Siemens, Erlangen) implementing a 3D sequence.
214992774|NCT06376136|DRUG|BAT8010 for Injection|Intravenous
214992775|NCT06376136|DRUG|BAT1006 for Injection|Intravenous
214992776|NCT05402059|DRUG|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Any kind of treatment or observation (no treatment) initiated or planned in accordance with current clinical practice
214992777|NCT00830765|DRUG|Progesterone (OHP17)|100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
215091770|NCT03444454|BEHAVIORAL|VRRS Khymeia|"Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.~Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
214379589|NCT05346848|DRUG|Association of ADT and EBRT|"Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~* Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~* Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD"
214497782|NCT03610581|BIOLOGICAL|MVA.HPV16/18|Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
214992778|NCT00830765|DRUG|Placebo|2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
214992779|NCT06201312|OTHER|COP exercise|crossover point intensity exercise
215091771|NCT03444454|BEHAVIORAL|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
215091772|NCT03444454|BEHAVIORAL|VRRS Khymeia plus active tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
214497783|NCT03610581|BIOLOGICAL|Placebo|Participants will receive matched placebo as a solution for intramuscular injection.
214497784|NCT02045381|PROCEDURE|MRI Group|A single research MRI
214497785|NCT03312920|DEVICE|active anodal tDCS|active anodal tDCS with memory task
214497786|NCT03312920|DEVICE|sham tDCS|sham tDCS with memory task
214497787|NCT03312920|DEVICE|active cathodal tDCS|active cathodal tDCS with memory task
214379590|NCT02217280|DRUG|Injection with Gadolinium|Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
214379591|NCT01015976|PROCEDURE|bariatric surgery|Roux en Y bariatric surgery
214379592|NCT01015976|OTHER|control|No surgery
214379593|NCT02329184|DRUG|MYK-461|
214379594|NCT00736489|DRUG|AZD3199|Dry powder for inhalation, single dose
214992780|NCT03959657|OTHER|No intervention performed by authors|Observational and retrospective study, no intervention performed
214379595|NCT00736489|DRUG|Formoterol|Dry powder for inhalation, single dose
214379596|NCT00736489|DRUG|Placebo|Dry powder for inhalation, single dose
214379597|NCT00016692|DRUG|Z-100|
214379598|NCT02515565|DRUG|cephalosporin with or without erythromycin|Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
214379599|NCT02515565|OTHER|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
214379600|NCT00709462|BIOLOGICAL|CDX1307|
214379601|NCT01933880|DRUG|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
215091773|NCT03444454|BEHAVIORAL|VRRS Khymeia plus placebo tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
214379602|NCT01933880|OTHER|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
214379603|NCT02513108|PROCEDURE|same day discharge|same day discharge after PCI for stable CAD
214379604|NCT04418635|DIETARY_SUPPLEMENT|Prosta-OK® Neo or Prosta-OK® Neo-matched placebo|the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
214379605|NCT04781361|DRUG|Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose|Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
214379606|NCT04781361|DRUG|Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L|"Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride \< 130 mmol/L"
214379607|NCT03135665|DEVICE|Ultrasound|"Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.~Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.~SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral."
214379608|NCT04751422|OTHER|Electronic Health Record Review|Medical data is collected
214497788|NCT06214819|DEVICE|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion
214497789|NCT06214819|DEVICE|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion
214497790|NCT02868970|BIOLOGICAL|Meningococcal B|Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
214497791|NCT02868970|BIOLOGICAL|High-Dose TIV|Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.
214497792|NCT02868970|BIOLOGICAL|Tdap (tetanus-diphtheria-acellular pertussis)|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
214497793|NCT02868970|BIOLOGICAL|Meningococcal ACWY|Meningococcal ACWY vaccine is indicated for active immunization of individuals up to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitides serogroups A, C, W-135 and Y.
214992781|NCT01087060|PROCEDURE|partial or radical nephrectomy|
214992782|NCT01299909|BEHAVIORAL|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
214992783|NCT01299909|BEHAVIORAL|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
214992784|NCT01299909|BEHAVIORAL|Quitline|Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
215091774|NCT02584361|PROCEDURE|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
214992785|NCT03023995|PROCEDURE|CAF with Platelet rich fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it and secured with 4-0 non resorbable sutures.
214379609|NCT05278689|OTHER|No intervention|No intervention
214992786|NCT03023995|PROCEDURE|CAF with connective tissue graft|In control group, connective tissue graft was harvested, after which the flap was coronally positioned over the graft to completely cover it and secured with 4-0 non resorbable.
214992787|NCT02435134|OTHER|no intervention|
214497794|NCT02868970|BIOLOGICAL|Herpes Zoster|Herpes zoster vaccine is indicated for the immunization of individuals 50 years of age or older for the prevention of herpes zoster (shingles).
214497795|NCT02868970|BIOLOGICAL|Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever)|Hepatitis A vaccine is indicated for immunization against infections caused by hepatitis A virus; Hepatitis B vaccine is indicated for immunization against infection caused by hepatitis B virus; and typhoid fever vaccine is indicated for active immunization against Salmonella typhi, the organism which causes typhoid fever.
214497796|NCT06816784|DRUG|Autologous serum therapy|5 ml of blood will be collected and centrifuged at 3000 r.p.m for 10 min to obtain serum,2 ml of the serum will be injected into the gluteus muscle. We will give the patients 9 injections of Autologous Serum intramuscularly once a week
214992788|NCT06405919|DIAGNOSTIC_TEST|Histopathology|Thyroidectomy for patients and histological examination of specimen to determine incidence of malignancy.
214992789|NCT01256515|BEHAVIORAL|Health Education|CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
214992790|NCT01256515|BEHAVIORAL|Health Education Training|8 weeks of group training regarding health education techniques.
214992791|NCT00493675|PROCEDURE|endoscopic bile duct stenting|
214992792|NCT00460967|DEVICE|Rheopheresis|8 rheopheresis treatments over 10 wks.
214992793|NCT00460967|DEVICE|Rheopheresis|Sham treatment
214992794|NCT03305718|OTHER|Meal sequence: 3C1A2B4D|Participants receive test meals in the sequence 3C1A2B4D
214992795|NCT03305718|OTHER|Meal sequence: 2A3D4C1B|Participants receive test meals in the sequence 2A3D4C1B
214992796|NCT03305718|OTHER|Meal sequence: 2D4B3A1C|Participants receive test meals in the sequence 2D4B3A1C
214992797|NCT03305718|OTHER|Meal sequence: 3B2C1D4A|Participants receive test meals in the sequence 3B2C1D4A
214992798|NCT03305718|OTHER|Meal sequence: 4C2B1A3D|Participants receive test meals in the sequence 4C2B1A3D
214379610|NCT05396989|OTHER|No intervention|No intervention
214379611|NCT03784040|DRUG|OTSGC-A24|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
214497797|NCT06816784|DRUG|Oral levocetirizine|Group B will receive oral levocetirizine 5mg 1 tablet HS.
214992799|NCT03305718|OTHER|Meal sequence:1B4D3C2A|Participants receive test meals in the sequence 1B4D3C2A
214992800|NCT03305718|OTHER|Meal sequence:4A1C2D3B|Participants receive test meals in the sequence 4A1C2D3B
214992801|NCT03305718|OTHER|Meal sequence:1D3A4B2C|Participants receive test meals in the sequence 1D3A4B2C
214992802|NCT03305718|OTHER|Meal sequence: 4D3B2C1A|Participants receive test meals in the sequence 4D3B2C1A
214992803|NCT03305718|OTHER|Meal sequence: 3A4C1B2D|Participants receive test meals in the sequence 3A4C1B2D
214992804|NCT03305718|OTHER|Meal sequence: 1C2A3D4B|Participants receive test meals in the sequence 1C2A3D4B
214992805|NCT03305718|OTHER|Meal sequence: 2B1D4A3C|Participants receive test meals in the sequence 2B1D4A3C
214992806|NCT04130841|PROCEDURE|Internal Limiting Membrane Peeling|After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.
214992807|NCT00873652|BIOLOGICAL|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
214992808|NCT03087240|PROCEDURE|Dental Prophylaxis|Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
214992809|NCT02860052|DRUG|SB208 2%|Apply once daily to one or both feet for 14 days
214992810|NCT02860052|DRUG|SB208 4%|Apply once daily to one or both feet for 14 days
214992811|NCT02860052|DRUG|SB208 16%|Apply once daily to one or both feet for 14 days
214992812|NCT02860052|DRUG|Vehicle Gel|Apply once daily to one or both feet for 14 days
214992813|NCT04019639|DEVICE|application of CG Paste+EasyFoam|Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
214992814|NCT04019639|DEVICE|application of EasyFoam|Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
214992815|NCT04262219|BEHAVIORAL|iShare|The iShare intervention consists of a two-episode educational podcast series containing information about breast cancer patients' sexual problems, approaches for addressing sexual concerns, and information about discussing sexual concerns with patients, such as initiating a conversation about sexual health and asking questions to assess sexual concern. Both episodes feature expert guests and relevant discussions or case studies.
214992816|NCT02546570|DRUG|Oxytocin|See arm/group descriptions for dosage amount and procedure.
214992817|NCT02546570|DRUG|Placebo|See arm/group descriptions for dosage amount and procedure.
214992818|NCT06403800|OTHER|No intervention|No intervention
214992819|NCT01772082|BEHAVIORAL|Internet mediated walking program|
214992820|NCT00112229|BIOLOGICAL|group 1|Melan-A analog peptide + CpG + Montanide
214992821|NCT00112229|BIOLOGICAL|group 2|Melan-A natural peptide + CpG + Montanide
214992822|NCT00112229|BIOLOGICAL|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
214992823|NCT00112229|BIOLOGICAL|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
215091775|NCT02584361|PROCEDURE|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
215091776|NCT03458858|OTHER|Mixed Berry Diet|Mixed Berry Treatment
215091777|NCT03458858|OTHER|Carbohydrate Control Jello|Carbohydrate Control
215091778|NCT03458858|OTHER|Fiber Enriched Jello|Fiber Control
215091779|NCT03458858|OTHER|Low Fiber Mixed Berry Juice|Anthocyanin Control
214379612|NCT03784040|DRUG|Nivolumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
214497798|NCT03906292|DRUG|Imatinib|Imatinib 400 mg QD and asciminib 60 mg QD
214497799|NCT03906292|DRUG|Nilotinib 300 mg|Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
214497800|NCT03906292|DRUG|Dasatinib|Dasatinib 100 mg QD and asciminib 80 mg QD
214497801|NCT03906292|DRUG|Asciminib|Asciminib 80 mg QD Monotherapy
214497802|NCT06659055|RADIATION|DXA Imaging|DXA imaging: lumbar spine, bi-lateral femoral necks
214497803|NCT06659055|RADIATION|EOSedge imaging|Full body or full spine image
214992824|NCT00467766|BEHAVIORAL|Psychosocial information, counseling, and support|
214497804|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype AA|Hemodialysis
214497805|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype BB|Hemodialysis
214497806|NCT02377570|DEVICE|THERNOVA 400 dialyzer prototype CC|Hemodialysis
214497807|NCT02377570|DEVICE|FX CorDiax 80 dialyzer|Hemodialysis
214992825|NCT00467766|DRUG|Donepezil (Aricept)|
214992826|NCT03882632|DEVICE|Fat Grafting for Fecal Incontinence|Autologous adiopse tissue harvesting/grafting using Lipogems
214992827|NCT03088397|BEHAVIORAL|Patient Decision Aid|One sheet of postpartum contraceptive information arranged in a grid.
214992828|NCT03088397|BEHAVIORAL|Website|Patient directed to website with information on various contraceptive methods.
214992829|NCT03088397|BEHAVIORAL|Shared- Decision Making Counseling|Counseling using principles of shared-decision making
214992830|NCT03069989|DRUG|GSK3008348|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
214992831|NCT03069989|DRUG|Placebo|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
214992832|NCT03069989|DRUG|[18F]-FBA-A20FMDV2|Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
214992833|NCT01303484|DIETARY_SUPPLEMENT|Bi2muno® GOS|5.5g/day for 10 weeks
214992834|NCT01303484|DIETARY_SUPPLEMENT|Maltodextrin|5.5g daily for 10 weeks
215091780|NCT04668235|DRUG|AZVUDINE|5 tablets QD + standard treatment for up to 14 days
215091781|NCT04668235|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment for up to 14 days
215091782|NCT02097342|DRUG|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
215091783|NCT02097342|DRUG|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
215091784|NCT02097342|DRUG|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
215091785|NCT05525949|DEVICE|VIVID Brain|Participants receive visual perceptual training using the VIVID Brain software.
215091786|NCT05525949|OTHER|No-treatment Control|No-treatment is administered during control period.
215091787|NCT04363047|OTHER|40ml blood sample|We'll be collecting cells, DNA and serum.
215091788|NCT01330654|DRUG|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
214992835|NCT03579511|PROCEDURE|External Pop-out|The original techniques of fetal head extraction entail the introduction of the obstetricians' hands or other instruments into the LUS. This puts the LUS at risk of damage and incision extensions with its consequences of increased blood loss, increased operative time,infection adhesions and blood transfusion.To the available, the generated good quality evidence bases practice in CS is anticipated to decrease such morbidities
214379613|NCT03784040|DRUG|Ipilimumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
214379614|NCT04916964|OTHER|Test and exercise home-based program|"Eight home-based physiotherapy sessions will occur in two months, once a week, to activate the preserved implicit memory (PIM). The recommendations are to train three weeks with the same exercise program, three times a week (one time coached by the attributed physiotherapist and two times coached by a natural or family caregiver). After three weeks, the participants can choose if they want to keep the same exercises or change all or some of these, in testing other tasks. Every training session will be planned to last 45 minutes. During each training session, the participant will note on his/her own Training booklet each task performed. The Training booklet will be used to plane, organize, and remember details for the next training session."
214379615|NCT02395133|DRUG|Dupilumab|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
214379616|NCT02395133|DRUG|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
214379617|NCT02609646|DRUG|Linezolid|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
214379618|NCT02609646|DRUG|Meropenem|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
214379619|NCT02609646|DRUG|Piperacillin-tazobactam combination product|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
214379620|NCT02609646|DRUG|Vancomycin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
214992836|NCT06514859|PROCEDURE|Laparoscopic repair of inguinal hernia|Laparoscopic repair of inguinal hernia
214992837|NCT06514859|PROCEDURE|Open repair of inguinal hernia|Repair of inguinal hernia by open technique-mesh hernioplasty -
214992838|NCT01740206|DRUG|Amphetamine and/or methylphenidate|Patients who took their stimulant medication the day of surgery.
214992839|NCT01740206|OTHER|Hold stimulant medication|Patients who held their stimulant medication the day of surgery.
214992840|NCT06018103|BEHAVIORAL|MBCT-vision|8-week mindfulness group learning course, using Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision). Participants meet once weekly only, with daily home practice between sessions.
214992841|NCT00569491|DEVICE|TAXUS Express 2™|TAXUS Express™ Paclitaxel-Eluting Coronary Stent System
214992842|NCT00155987|PROCEDURE|Early decompressive craniectomy|Large bifrontotemporal decompressive craniectomy
214992843|NCT04801095|DRUG|WM-S1-030|WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.
214992844|NCT04705090|DRUG|YY-20394 treatment|Each treatment cycle is comprised of 28-day consecutive dosing of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if they are benefit from the treatment and the toxicity is tolerable.
214992845|NCT01277029|OTHER|No drug|Psychopathology, personality traits of patients with lower urinary tract symptoms
214992846|NCT03194477|BEHAVIORAL|Mobile-enhanced Engagement Intervention|Mobile phone based enhanced case management intervention for HIV positive \& HIV negative young Black men who have sex with men.
214992847|NCT02478827|BEHAVIORAL|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
214992848|NCT06207799|DRUG|Elranatamab|Given by SC
214992849|NCT06207799|DRUG|Lenalidomide|Given by PO
214992850|NCT06207799|DRUG|Plerixafor|Given by SC
214992851|NCT06207799|DRUG|Melphalan|Given by IV
214992852|NCT06207799|DRUG|Busulfan|Given by PO
214992853|NCT06207799|DRUG|G-CSF|Given by IV
214992854|NCT06207799|PROCEDURE|Stem cell transplant|Given by IV
214992855|NCT01985984|RADIATION|Radiation alone|Radiation alone
214992856|NCT01985984|RADIATION|Radiation in combination with systemic therapy|Radiation in combination with systemic therapy
214992857|NCT06387303|DRUG|Methadone|Intravenous Methadone
214992858|NCT06387303|DRUG|Morphine|Intrathecal Morphine
214992859|NCT05504070|DEVICE|Venclose System (digiRF generator w EVSRF catheter)|The Venclose System is intended for use in endovascular coagulation of blood vessels in patients with superficial vein reflux.
214992860|NCT05504070|DEVICE|Venclose MAVEN System (digiRF generator w MAVEN catheter)|The Venclose MAVEN System is intended for use in endovascular coagulation of blood vessels in patients with perforator or tributary vein reflux.
215091789|NCT03828474|DRUG|Acetazolamide Pill|Acetazolamide pill
215091790|NCT03930875|OTHER|Aspirin Resistance testing|Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
214379621|NCT01057784|PROCEDURE|Bariatric surgery.|Bariatric Surgery
214379622|NCT03968757|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
214992861|NCT05019430|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.
214992862|NCT05019430|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
214992863|NCT05019430|DRUG|Zolmitriptan|The pharmacodynamic effects of zolmitriptan maintenance will be determined.
215091791|NCT01528761|BEHAVIORAL|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
214379623|NCT03245385|DRUG|Treatment with Halobetasol propionate 0.05% topical spray|Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
214379624|NCT03444233|OTHER|Diet|7 days fruit-rich diet, 7 days HFCS-rich diet
214379625|NCT00722501|DRUG|ERB-257|
214379626|NCT00722501|OTHER|placebo|
214379627|NCT04896632|DRUG|INE 963|Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days
214379628|NCT04896632|OTHER|Placebo|Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.
214379629|NCT05360030|DRUG|Naloxone|The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
214379630|NCT05360030|DRUG|Saline|The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
214379631|NCT05360030|DRUG|Ketamine Hydrochloride|The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
214379632|NCT05360030|DEVICE|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
214379633|NCT05360030|DEVICE|pcTBS of DLPFC|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left DLPFC at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
214379634|NCT05360030|DEVICE|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
214497808|NCT05637970|DEVICE|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
214497809|NCT05637970|DEVICE|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manualpressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
214992864|NCT04874311|DRUG|Bintrafusp alfa|Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.
214992865|NCT04874311|DRUG|Doxorubicin|Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
214992866|NCT05399485|DRUG|Rimegepant|Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12
214992867|NCT05399485|DRUG|Placebo|Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
214992868|NCT05886842|OTHER|Test-retest|Test-retest
214992869|NCT06125964|BEHAVIORAL|Intensity-Based Goals|On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Intensity-based goals ask participants to maintain a target heart rate range during physical activity based on age-adjusted heart rate (HR) max. Goals progressively increase from 55% to 60% HR max across two weeks. Research staff will show participants how to monitor their heart rate using their Fitbit Versa. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on heart rate (intensity-based goals only) and exercise duration.
215091792|NCT01528761|OTHER|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
214379635|NCT03062202|BEHAVIORAL|SilverCloud|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
214379636|NCT03156322|DRUG|5 mL epidural initiation volume (bupivacaine + fentanyl)|5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
214379637|NCT03156322|DRUG|10 mL epidural initiation volume (bupivacaine + fentanyl)|10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
214992870|NCT06125964|BEHAVIORAL|Affect-Based Goals|"On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Affect-based goals ask participants to engage in either a type or context of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity in a place, in a social situation, or while listening to something that makes them feel good. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on exercise duration while featuring a smiley face emoticon."
214992871|NCT06125964|BEHAVIORAL|TYPE/CONTEXT Enhancement|The TYPE/CONTEXT enhancement will augment affect-based treatment effects by additionally providing tailored recommendations for activity types and contexts that satisfy personally important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk were used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm recommends the corresponding activity type or context while accounting for reported constraints. Different psychological needs will be selected each day. Tailored recommendations are incorporated immediately following the morning goal module.
214992872|NCT06125964|BEHAVIORAL|SAVOR Enhancement|The SAVOR enhancement will augment affect-based treatment effects by additionally implementing a brief savoring exercise on the smartphone during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty.
214992873|NCT02462096|DEVICE|ReLeaf|The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
214992874|NCT06394882|BEHAVIORAL|Family-Centered Healthy Lifestyle Program (FamCe-HLP)|A multidisciplinary-led healthy lifestyle program will provide a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (IBT) and a four-month maintenance behavioral therapy (MBT). The program will run on scheduled days using one of the center's offices for the IBT and the center's seminar room for the MBT.
214992875|NCT05306340|DRUG|Giredestrant|Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
214992876|NCT05306340|DRUG|Exemestane|If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
214992877|NCT05306340|DRUG|Fulvestrant|If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
214379638|NCT03156322|DRUG|20 mL epidural initiation volume (bupivacaine + fentanyl)|20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
214379639|NCT00962247|DEVICE|Television reduction device|A TV allowance helps turn off the television when the time limits have been met.
214992878|NCT05306340|DRUG|Tamoxifen|If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
214379640|NCT01487044|DRUG|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only."
214497810|NCT05668819|DEVICE|TH-001|TH001 is a software program intended to treat adults with prediabetes.
214497811|NCT06766708|OTHER|self-management lymphedema (SML) education program|The content of the booklet was prepared based on literature review.. In addition to the above intervention methods, the phone number of each patient was taken and the patients were followed up by phone for 12 months. For this purpose, the patient was asked to fill in the compliance chart prepared in order to monitor the patient's compliance and was checked by the researcher every two weeks by phone call. By phone call; compliance with skin care, SLD, compression garments and exercise practices included in the SMLEP were evaluated and recorded. Within the scope of the SMLEP, the patients were asked to do exercises and SLD at least 3 days a week and 2 times a day (morning and evening) for 12 months. It was recommended to wear compression garments, especially during exercises and throughout the day.
214497812|NCT06763835|DIAGNOSTIC_TEST|Blood is drawn to test for specific biomarkers|After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.
214992879|NCT05306340|DRUG|Everolimus|Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
214992880|NCT05306340|DRUG|LHRH Agonist|Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
214992881|NCT05306340|DRUG|Dexamethasone Mouth Rinse|A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
214992882|NCT04573920|DRUG|Atrasentan|Film-coated tablet
215091793|NCT05629507|DEVICE|Virtual Reality|"The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios)."
215091794|NCT03554135|OTHER|Personalization of palliative radiotherapy|Observe the rates of pain control and the need to retreat patient, when applied to personalization of indications and maximum technological support for palliative radiotherapy to patients with \< 6 months prognostic score attendance
214379641|NCT02653638|OTHER|Control|"1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
214992883|NCT06376526|BIOLOGICAL|Linvoseltamab|"Participants will be administered Linvoseltamab intravenously (IV), using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 5mg~* Cycle 1, Day 8: 25mg~* Cycle 1, Days 15 and 22: 200mg~* Cycles 2 and 3, Days 1, 8, 15 and 22: 200mg~* Cycle 4, Days 1 and 15: 200mg.~For participants who are MRD-positive after four (4) cycles of study treatment:~* Cycles 5 and 6, Days 1 and 15: 200 mg"
214379642|NCT02653638|DRUG|Indomethacin|"1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
214379643|NCT02233933|OTHER|Hemospray|hemospray is used after argon coagulation to stop bleeding
214379644|NCT00346801|DRUG|Celecoxib|100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
214379645|NCT00346801|DRUG|Cisplatin|25 mg/m\^2 IV over 60 minutes on Day 1, Weeks 2-8
214992884|NCT06111586|DRUG|Frexalimab|Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102
214992885|NCT06111586|DRUG|Placebo|IV Infusion at Day 1 and SC Injection from W2 to W102
214992886|NCT06111586|DRUG|Insulin|SC injection, dose and frequency will be established and/or adjusted by investigator
214992887|NCT06406309|BEHAVIORAL|Power Down manipulation|The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for children with ADHD). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep during the 2-week intervention phase. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.
215091795|NCT00769028|DRUG|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
215091796|NCT00769028|DRUG|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
215091797|NCT00281190|PROCEDURE|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
215091798|NCT00281190|PROCEDURE|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
215091799|NCT03432416|DRUG|NES-E2 CVR|NES-E2 CVR
214379646|NCT00346801|DRUG|CPT-11|30 mg/m\^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
214379647|NCT00346801|RADIATION|Concurrent Thoracic Radiation Therapy|63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
214379648|NCT00509548|DRUG|TG100801|Eye drop, twice a day, 30 days.
214497813|NCT06812741|DRUG|Transversus abdominis plane (TAP) block with 0.25 % bupivacaine|The probe was placed in a plane transverse to the lateral abdominal wall in the mid-axillary line immediately cephalad to the iliac crest. The needle was advanced immediately anterior to the probe using the in-plane needle-probe orientation and advanced posteriorly until the needle was observed to penetrate the interface between the internal oblique and transversus abdominis muscles. Thereafter, a local anesthetic (0.2 mL/kg of 0.25 % bupivacaine) was injected incrementally, and the spread was observed within the plane.
214992888|NCT06551805|DRUG|Safety assessment of Ferumoxytol.|"Observe the injection site for skin invagination, rash, or urticaria during injection. Patients and their relatives were asked about any subjective adverse events before, during, and after drug injection, and all adverse events were recorded on the case report forms, and adverse events were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) from Grade 1 mild to Grade 5 death, Observe the vital signs of patients. Patients undergoing MRI underwent electrocardiogram (ECG) monitoring before and within 60 minutes after ferumoxytol administration, specifically including: biochemical panel, iron metabolism, liver and kidney function, cytokines, blood routine, urine routine, 24-hour urine volume, glycosylated hemoglobin and so on. All patients received a total of 3 blood and urine collections at 7 days before injection, 48 hours after injection, 1month to 3months after injection."
214992889|NCT06551805|DRUG|Assessment of the diagnostic value of Ferumoxytol for MR angiography.|steady-state, high-spatial-resolution, three-dimensional fast low-angle shot acquisition technique, T2W-MDIR imaging, polysaccharide superparamagnetic iron oxide injection enhanced T1W and T2W, T2\* mapping, and Steady state free precession sequence, T2 weighted black blood sequence, T2 preparation single shot steady state free precession sequence, T2\* weighted multi-echo/gradient echo sequence, polysaccharide superparamagnetic iron oxide injection enhanced imaging, Breath-triggered Transverse 3D Balance-Vortex Field Echo (b-TFE) Magnetic Resonance Angiography, iMSDE-SPGR Sequence, 4D Flow MRI. the MRI anxiety questionnaire.
214992890|NCT02308878|BEHAVIORAL|Mobile health cognitive stimulation|
214992891|NCT06775782|DEVICE|Remote Ischemic Conditioning (RIC) treatment|RIC will be given twice a day for 10-14 days. RIC will be applied using an automated RIC device. The cuff of the RIC medical device will be placed around the bilateral upper limbs. Five cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes) for a total procedure time of 50 minutes.
214992892|NCT06775782|DRUG|Medical Management|Patients will receive standard guideline-directed medical therapy, which will include monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic therapy if appropriate.
214992893|NCT00369083|PROCEDURE|Hospital at home treatment|
214992894|NCT04278690|OTHER|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent. Instruction sheets include optimized instructions (mL-only, doses appropriately rounded, visuals of recommended tool (e.g. 1-mL syringe best for doses of \<1 mL), explicit frequency information (e.g. 'morning and night' instead of '2x/day') reinforced by pictograms (e.g. sun/moon icons)). For each medication, staff will: 1) review the dose (refer to the pictographic dose diagram, which illustrates optimal dosing tool filled to correct amount), 2) demonstrate the dose using optimal dosing tool, 3) ask parent to 'teachback'/'showback' dose (e.g. parent shows provider how much they would give by pulling back plunger on syringe to right level), 4) provide optimal dosing tool for the parent to take home. We anticipate this process will take \~5-10 minutes.
214992895|NCT04278690|OTHER|HELPix+Tech|After parent receives usual care and HELPix , trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app. For each medicine: A. Dosing module with optimized instructions (c/w HELPix); parent teachback/showback of dose B. Frequency module supports simplified, explicit intervals (e.g. 'morning and night'), parent chooses convenient times (text reminders sent based on preferences). Time for TECH depends on # medicines and parent baseline knowledge; structured protocol used to see # teachback rounds needed .
215091800|NCT00205543|PROCEDURE|uvulopalatopharyngoplasty with or without sutures|standard UPPP
214379649|NCT04151784|OTHER|Pulmonary Group|Data collection will be obtained on the day an individual has an appointment at the pulmonary clinic. After patients meet with their pulmonary physicians, the physicians will inform them about the study and explain that participation is voluntary. If a patient agrees, the researcher will provide copies of the questionnaires and again clarify that participation is voluntary. The workflow of the clinic will not be interrupted while the researcher conducts the study, and he will only ask participants to fill out the questionnaires if they have enough time to participate.
214497814|NCT06812741|DRUG|Ilioinguinal/iliohypogastric Nerve Block with 0.25 % bupivacaine|The ultrasound probe was placed immediately medial and slightly cephalad to the upper aspect of the anterior superior iliac spine to obtain a short-axis view of the nerves situated between the two abdominal muscles (internal oblique and transversus abdominis), A 22 G needle tip \~1 cm caudal to the probe surface was introduced and was advanced until a characteristic 'tenting' of the interface between the two muscles was seen and was then further advanced deep to this interface until a pop was felt and then the injectate (0.2 mL/kg of 0.25 % bupivacaine) was observed spreading between these two layers.
214497815|NCT06837584|OTHER|Questionnaire and Physical Exam|Questionnaire and Physical Exam
214379650|NCT04151784|OTHER|Healthy Control|The second group will be recruited as a control group consisting of healthy adult participants through purposive convenience sampling at other collaborating UAB sites. The principal investigator will collect self-report responses through a questionnaire packet given to anyone willing to participate in the study
214379651|NCT04059692|OTHER|Cervical manipulation intervention|Cervical manipulative technique
214379652|NCT04059692|OTHER|Placebo intervention|Sham intervention
214497816|NCT06786559|BEHAVIORAL|Assistive Device and health Education|After discharge they will be assessed and followed by RA nurses through home visit and tele services for 2 months. The nurses will contact the patients periodically over telephone, and follow up their regular self-care activities, adjustment to devices, exercise and adaptive behavior.
214379653|NCT04242433|DRUG|Direct Acting Antivirals|"All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent."
214379654|NCT03945318|DRUG|BION-1301 Single Dose|A solution for IV infusion administered as a single dose.
214379655|NCT03945318|DRUG|Placebo Single Dose|A solution by IV infusion administered as a single dose.
214379656|NCT03945318|DRUG|BION-1301 Multiple Doses|A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
214379657|NCT03945318|DRUG|Placebo Multiple Doses|A solution by IV infusion administered as multiple doses.
214379658|NCT03945318|DRUG|BION-1301 Single Dose|SC injection administration as a single dose using vials or pre-filled syringes (PFS) (Part 4 only).
214379659|NCT04040257|BEHAVIORAL|Team-based approach|Team-based participation in the The Perinatal Quality Foundation Fetal Monitoring Credentialing (PQF/FMC) exam.
214379660|NCT05282290|DRUG|Antihypertensive drugs (no restriction on the type of drugs)|"The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out.~The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening."
214379661|NCT04235790|DEVICE|Eye Tracking Device|Eye tracking glasses
214379662|NCT02093325|DRUG|Eltrombopag|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
214992896|NCT04997733|DRUG|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of saline (NaCl 0.9%), (FMT vehicle in the terminal ileum or the colon.~At W12 and W24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain 0.8g of stools by visit)."
214992897|NCT04997733|DRUG|Sham-transplantation (placebo)|"The colonoscopy for sham-transplantation will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration, 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either sham transplantation (frozen preparation of NaCl 0.9% with 10% glycerol) in the terminal ileum or the colon.~At S12 and S24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain placebo)."
214992898|NCT04132999|BEHAVIORAL|Family-informed intervention|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team
214992899|NCT04132999|BEHAVIORAL|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
214992900|NCT04534153|DRUG|Fexofenadine Hydrochloride without sodium lauryl sulfate|without sodium lauryl sulfate
214992901|NCT04534153|DRUG|Fexofenadine Hydrochloride with sodium lauryl sulfate|with sodium lauryl sulfate
214992902|NCT05358938|OTHER|Exercise|30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
214992903|NCT05358938|DRUG|Checkpoint Blockade, Immune|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
214992904|NCT03624543|DRUG|CFI-400945|32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily
214992905|NCT00392353|DRUG|Azacitidine|Given SC
214992906|NCT00392353|OTHER|Laboratory Biomarker Analysis|Correlative studies
214992907|NCT00392353|OTHER|Pharmacological Study|Correlative studies
214992908|NCT00392353|DRUG|Vorinostat|Given PO
214992909|NCT00002462|BIOLOGICAL|bleomycin sulfate|
214992910|NCT00002462|DRUG|doxorubicin hydrochloride|
214992911|NCT00002462|DRUG|mechlorethamine hydrochloride|
214992912|NCT00002462|DRUG|prednisone|
214992913|NCT00002462|DRUG|procarbazine hydrochloride|
214992914|NCT00002462|DRUG|vinblastine sulfate|
214992915|NCT00002462|DRUG|vincristine sulfate|
214992916|NCT00002462|RADIATION|low-LET cobalt-60 gamma ray therapy|
214992917|NCT00002462|RADIATION|low-LET photon therapy|
214992918|NCT00002462|RADIATION|radiation therapy|
214992919|NCT06034470|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214992920|NCT06034470|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
214992921|NCT06034470|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215091801|NCT00573807|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
215091802|NCT02916147|DRUG|Sevoflurane|
215091803|NCT02916147|DRUG|Propofol|
215091804|NCT03464916|BIOLOGICAL|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
215091805|NCT03276949|DEVICE|Blood glucose measurement|Device used to measure blood glucose levels
215091806|NCT01317511|DIETARY_SUPPLEMENT|Protein|Protein drink
215091807|NCT00997399|DRUG|panobinostat (LBH589)|
214992922|NCT06034470|DRUG|Cytarabine|Given IV
214992923|NCT06034470|PROCEDURE|Echocardiography|Undergo ECHO
214992924|NCT06034470|DRUG|Fludarabine|Given IV
214992925|NCT06034470|DRUG|Granulocyte Colony-Stimulating Factor|Given SC
214992926|NCT06034470|DRUG|Idarubicin|Given IV
214992927|NCT06034470|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214992928|NCT06034470|DRUG|Pivekimab Sunirine|Given IV
214992929|NCT05478304|DEVICE|AtriClip LAA Exclusion System|LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery
214992930|NCT05329623|DRUG|JDQ443|All the participants will receive a single oral dose of JDQ443.
214992931|NCT06839794|BEHAVIORAL|Cognitively challenging physical activity for paediatric cancer patients|"The intervention is a structured cognitively challenging physical activity (PA) program specifically designed for pediatric cancer patients undergoing acute therapy. It stands out from other interventions by combining motor and cognitive tasks simultaneously. Therefore, the target executive functions are inhibition, shifting, and updating. Additionally, the whole body is addressed by enhancing PA.~The PA program spans 12 weeks, with each participant engaging in guided, supervised 45-minute sessions three times weekly. Each session includes a warm-up, the cognitive challenging PA task and a subsequent multimodal sports programme with a cool-down. Exercises are adaptive and tailored to each participant's physical and health condition by offering three levels of intensity in both cognitive and physical difficulty. In addition, exercise counselling in maintenance therapy or aftercare supports young patients to reintegrate into the life after the disease."
214992932|NCT06839794|OTHER|Physical activity recommendations|The children and adolescents receive general physical activity recommendations at the baseline measurement (t0). At the end of the intervention (after 12 weeks), i.e. after the final measurement (t3), they receive individualised and tailored exercise recommendations based on the test results from t0-t3.
214992933|NCT05389293|DRUG|Mosunetuzumab|During Cycle 1, mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.
214992934|NCT05389293|DRUG|Zanubrutinib|In Cohort 2, zanubrutinib is concurrently administered continuously starting on Cycle 1, Day -7 and is given for 12 months in both patients with CR and those with PR
214992935|NCT03420963|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
214992936|NCT03420963|DRUG|Cyclophosphamide|Given IV
214992937|NCT03420963|DRUG|Etoposide|Given IV
214992938|NCT05895604|BEHAVIORAL|Nurse-Family Partnership|Nurse-Family Partnership is a prenatal and infancy home visiting program providing regular visits to first-time mothers until the child is two years old
214992939|NCT04693403|PROCEDURE|HFNC|40-60l/min humidified oxygen by nasal cannula
214992940|NCT04693403|PROCEDURE|CPAP|Oxygen therapy by boussignac Continuous positive airway pressure face mask
214992941|NCT04693403|PROCEDURE|Standard Oxygen|Oxygen therapy by low flow (upto 15l/min) by Non-rebreather face mask
214992942|NCT03764124|DIAGNOSTIC_TEST|PET/CT imaging|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events were applied.
214992943|NCT06831188|OTHER|daily life exercise group|random games which includes physical activity
214992944|NCT06831188|OTHER|specific type exercise group|10 minutesTreadmill Walk, Playdough or ball squeeze, Towel wring,Throwing to target, catching the tennis ball, bouncing a ball inside borders without losing control, dribbling a ball inside borders without losing control, tandem walk, Single leg stance balance on balance pad or pillow, rolling forward, Jumping exercises, Side stepping, etc
214992945|NCT06793475|BIOLOGICAL|anti-BCMA/GPRC5D bispecific CAR-T|Autologous BCMA/GPRC5D bispecific CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA/GPRC5D bispecific CAR-T cells/kg.
214992946|NCT06793475|DRUG|Apornemin|Apornemin 10mg/kg will be administered by i.v. infusion. Apornemin will be administered on Days 1-5, 15-19 during bridging therapy, and on Days 1-5 every 28-day cycle during maintanance treatment.
214992947|NCT06793475|DRUG|Carfilzomib|Carfilzomib 27mg/m\^2 will be administered by i.v. on Days 1,2,8,9 during bridging therapy.
214379663|NCT02093325|DRUG|Placebo|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
214379664|NCT03080116|DRUG|ARN-509|240mg/day (4x60mg tablets, Oral administration: OS)
214379665|NCT03080116|DRUG|Degarelix|1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
214992948|NCT06793475|DRUG|Thalidomide|Thalidomide (150mg/d) will be administered by p.o. on Days 1-14 during bridging therapy, and Days 1-28 every 28-day cycle during maintanance treatment.
214992949|NCT06793475|DRUG|Dexamethasone|Dexamethasone (20mg/d) will be administered by i.v. or p.o. on Days 1-4,8,9 during bridging therapy.
214379666|NCT03080116|OTHER|Placebo|4 tablets, per OS
214379667|NCT01443221|DRUG|mitiglinide and metformin|Free combination of Mitiglinide 10mg and Metformin 500mg
214992950|NCT03595397|DRUG|Bupivacaine|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
214992951|NCT03595397|DRUG|Magnesium Sulfate|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg Magnesium Sulfate, followed by continuous infusion of 8 ml/hour mixture of 0.125% bupivacaine and 20% Magnesium sulfate
215091808|NCT00970983|PROCEDURE|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
214992952|NCT03595397|DRUG|Fentanyl|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour.
214992953|NCT03595397|PROCEDURE|Thoracic epidural|All patients will receive mid-thoracic epidural analgesia
214992954|NCT04092075|DEVICE|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
214992955|NCT04092075|DEVICE|Control placebo with no RF|Placebo control, toothbrush with no RF
214992956|NCT05030441|DRUG|Ivosidenib|. Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
214992957|NCT03233256|PROCEDURE|Feasibility of measuring 2H:1H and 18O:16O in saliva and breath.|The investigators propose to demonstrate the feasibility of measuring 2H:1H and 18O:16O in saliva and breath. The natural abundances of 2H:1H and 18O:16O of urine, saliva, and breath samples will be determined from samples obtained simultaneously from 50 relatively healthy human subjects. We will also measure 2H:1H and 18O:16O enrichments in urine, saliva, and breath of 10 relatively healthy human subjects obtained after consuming a standard DLW dose and compare the estimates of TDEE using these different matrices.
215091809|NCT00970983|PROCEDURE|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
215091810|NCT05818761|DEVICE|virtual reality|wearing virtual reality glasses
215091811|NCT05818761|BEHAVIORAL|stress ball|squeezing the stress ball during the attempt
214992958|NCT06422871|DEVICE|HeRO® Graft System or Super HeRO® System|Treatment attempted with the HeRO® or Super HeRO® device.
214992959|NCT06830642|DRUG|MTR-601|Capsule
214992960|NCT06830642|DRUG|Placebo|Capsule
215091812|NCT02385916|OTHER|EstroSense®/MD|A natural product already approved by Health Canada
215091813|NCT02385916|OTHER|Placebo|Placebo
215091814|NCT00034879|DRUG|ZD1839 (Gefitinib)|
215091815|NCT03622177|PROCEDURE|biopsie|Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
215091816|NCT03622177|BIOLOGICAL|blood drawn|Additional blood drawn by venepuncture
214992961|NCT06832891|OTHER|Survey|Patients complete survey
215091817|NCT06491290|OTHER|No intervention administered|NA (not applicable)
215091818|NCT00779961|PROCEDURE|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
215091819|NCT00779961|PROCEDURE|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
215091820|NCT01023386|DRUG|YM155|I.V.
215091821|NCT02834923|BEHAVIORAL|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
215091822|NCT02834923|BEHAVIORAL|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
214992962|NCT01224704|OTHER|Hypertonic saline infusion|Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.
214992963|NCT01224704|OTHER|Water deprivation|24 hour water deprivation
214992964|NCT02469233|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
214992965|NCT04131829|DRUG|Fluoxetine - immediate treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
214992966|NCT04131829|DRUG|Fluoxetine - delayed treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
214992967|NCT03617432|DRUG|Chidamide|Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
215091823|NCT04135859|BEHAVIORAL|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
215091824|NCT04135859|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
215091825|NCT04346030|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
214379668|NCT01443221|DRUG|mitiglinide and metformin|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
214992968|NCT03617432|DRUG|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
214992969|NCT03617432|DRUG|Doxorubicin|Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
215091826|NCT04346030|DRUG|lidocaine hydrochloride|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
214379669|NCT02165332|DRUG|Part 1: SAD RO7033877|Single dose
214379670|NCT02165332|DRUG|Part 1: SAD placebo|Single dose
214379671|NCT02165332|DRUG|Part 2: Treatment A, RO7033877|Single dose RO7033877 and moxifloxacin placebo
214379672|NCT02165332|DRUG|Part 2: Treatment B, RO7033877|Single dose RO7033877 and moxifloxacin placebo
214379673|NCT02165332|DRUG|Part 2: Treatment C, moxifloxacin|Single dose moxifloxacin and RO7033877 placebo
214379674|NCT02165332|DRUG|Part 2: Treatment D, RO7033877 and moxifloxacin placebo|Single dose moxifloxacin placebo and RO7033877 placebo
214379675|NCT05882201|PROCEDURE|Fascia Iliaca compartment block group|"Group FICB Fascia: with the patient supine, the skin was prepped and draped with alcohol solution 70%,~. A 22-G needle will be visualized entering the fascia Lata and the FI. bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40 ml will be injected after aspiration beneath the fascia Lata."
214992970|NCT03617432|DRUG|Vincristine|Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
214992971|NCT03617432|DRUG|Etoposide|Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
214992972|NCT03617432|DRUG|Prednisone|Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
214992973|NCT06792019|BIOLOGICAL|CM313(SC) injection-low dose|Phase IB:CM313(SC) administered at low dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.
214992974|NCT06792019|BIOLOGICAL|CM313(SC) injection-high dose|Phase IB:CM313(SC) administered at high dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.
214992975|NCT04932109|OTHER|No intervention|No intervention in this group
215091827|NCT04346030|DRUG|normal saline|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
215091828|NCT05656833|DEVICE|Fractional 1927nm Low-Powered Diode Laser|Clear \& Brilliant Permea® Laser used on the side of the face randomized to receive laser
215091829|NCT05656833|OTHER|Topical Cysteamine|Topical Cysteamine cream will be used on the entire face.
215091830|NCT02073357|PROCEDURE|Light general anaesthesia (BIS = 50)|
214379676|NCT05882201|PROCEDURE|Femoral nerve block group|✓ Group FNB; With the patient supine, the skin will be prepped and draped with alcohol solution 70% The nerve in the crosssection is a triangular white structure lateral to the femoral artery. Ultrasoundallows direct visualization of the needle and nerve as well as real-time monitoring of the injection of local anesthetic. An in-plane approach will be used to direct needle placement to the femoral nerve and inject after aspiration with bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40ml.
214379677|NCT05882201|PROCEDURE|General care|using ordinary technique
214379678|NCT02073825|BEHAVIORAL|Web Brief Intervention (WBI)|4-session WBI
214379679|NCT04595721|BEHAVIORAL|Hidden object|Participant will be instructed to look at the hidden object image on the overhead light to look for a number of objects and observe the image.
214379680|NCT04595721|BEHAVIORAL|Stress ball|Participants will be handed a single-use, squeezable stress ball and instructed to squeeze the stress ball.
214379681|NCT01437163|DEVICE|TopHat 655 rejuvenation system|TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
214379682|NCT01437163|DEVICE|Laser and/or Light Hair Rejuvenation System|A red incandescent light source replaces all lasers and light emitting diodes.
214497817|NCT05630651|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose level is 5.0×10\^12vg/kg.
215091831|NCT02073357|PROCEDURE|deep general anaesthesia (BIS = 35)|
215091832|NCT06436586|OTHER|No intervention|No intervention
215091833|NCT04283565|OTHER|Systematic screening of AOMI by BPI measurement.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
215091834|NCT04283565|OTHER|Management of CVRF by a motivationnal interviewing.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
215091835|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Medtronic 4th gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Medtronic 4th gen balloon
215091836|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Boston 2nd gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Boston 2nd gen balloon
215091837|NCT00983736|DRUG|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
215091838|NCT00983736|DRUG|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
215091839|NCT04433559|DRUG|Tadalafil 1,5 mg oral tablets|Use of tadalafil in the treatment of FSIAD
215091840|NCT04433559|DRUG|Placebo oral tablets|Use of placebo in control group
215091841|NCT00777699|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
215091842|NCT00777699|DRUG|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
215091843|NCT00185874|BIOLOGICAL|Intratumoral Dendritic Cell Immunotherapy|
215091844|NCT00185874|BIOLOGICAL|autologous dendritic cells|
214992976|NCT04574518|BEHAVIORAL|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
214992977|NCT04574518|BEHAVIORAL|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
214992978|NCT03474107|DRUG|Enfortumab Vedotin|Intravenous infusion
214992979|NCT03474107|DRUG|Docetaxel|Intravenous infusion
214992980|NCT03474107|DRUG|Vinflunine|Intravenous infusion
214992981|NCT03474107|DRUG|Paclitaxel|Intravenous infusion
214992982|NCT05070845|BIOLOGICAL|PF-06835375|CXCR5 inhibitor
214992983|NCT05359237|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214992984|NCT05359237|DRUG|Vincristine|Given IV per standard of care
214992985|NCT01787838|OTHER|Focused Health Education|"A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.~The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it."
214992986|NCT05395039|OTHER|VCHIPS|Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
214992987|NCT06284109|DEVICE|Cryoanalgesia|Participants will receive cryoanalgesia with the The iovera° system. . The specific nerves targeted will be both the sciatic, targeted first (as distal as possible, but not more distal than the bifurcation), and femoral, targeted second (as distal as possible, but not more distal than the adductor canal). Cryoanalgesia will result from an 8-minute-long percutaneous cryoneuroablation procedure consisting of several freeze/defrost cycles. Per routine, all patients will have a nerve block with single shot ropivacaine.
214992988|NCT06284109|DEVICE|Sham Cryoanalgesia|Participants will receive Sham cryoanalgesia with the The iovera° system. The specific nerves targeted will be both the sciatic, targeted first (as distal as possible, but not more distal than the bifurcation), and femoral, targeted second (as distal as possible, but not more distal than the adductor canal). Per routine, all patients will have a nerve block with single shot ropivacaine.
214992989|NCT05666973|PROCEDURE|Open Mesh Hernioplasty|"* Steps of surgery:~  * Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~ * Incision:~* Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~  * bleeding controlled by forcep coagulation.~ * Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~ * Nerve Iliohypogastric \& ilioinguinal will be preserved (by taking aside from the field)~ * Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~ * Sac ligated with Polygalactin 2-0 suture.~ * Lichtenstein method of repair~* Mesh type: large pore polypropylene mesh~* Mesh size: 3 x 6 inches(7.5 x 15 cms)~* Mesh Fixation: polypropylene 2-0~  * External oblique closure~ * Skin closure: Ethilon 2 - 0 suture"
214992990|NCT04336683|DEVICE|Interstitial and intracavitary brachytherapy|Standard of care in interstitial or intracavitary brachytherapy is to insert the brachytherapy needle and applicator with no standard real-time image guidance. Interstitial brachytherapy is done under general anesthesia. Trans-abdominal and trans-rectal standard 2D ultrasound is used in some cases, but is typically not consistent and therefore its value is limited. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning
215091845|NCT01814670|BIOLOGICAL|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
215091846|NCT04043832|DIAGNOSTIC_TEST|quantitative ultrasonic technique|Collection of all quantitative ultrasonic data was performed by one ultrasound physician
215091847|NCT06917690|DRUG|Oleogel-S10|Topical gel
215091848|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
215091849|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
215091850|NCT02710942|BEHAVIORAL|SPHERE|
215091851|NCT02710942|BEHAVIORAL|PRISM|
215091852|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
214992991|NCT03095287|BIOLOGICAL|Alphanate|Bolus IV injection.
214992992|NCT00058981|DRUG|DiaPep277|
214992993|NCT02367560|PROCEDURE|Needle decompression|Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
215091853|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
215091854|NCT04047420|DRUG|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
215091855|NCT04175574|OTHER|Music|The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
215091856|NCT02410265|BEHAVIORAL|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
215091857|NCT02410265|BEHAVIORAL|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
215091858|NCT05610046|DEVICE|Infrared sauna heating|Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
214992994|NCT02367560|PROCEDURE|Shockwave therapy|A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
214992995|NCT02367560|DRUG|Depo medrol|Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
214992996|NCT02367560|DEVICE|Ultrasound device|Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
214992997|NCT00526175|DRUG|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
214992998|NCT00526175|DRUG|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
214992999|NCT00526175|DRUG|Daunorubicin|30 mg/m2, i.v., days 8 and 15
214993000|NCT00526175|DRUG|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
214993001|NCT00526175|DRUG|Cyclophosphamide|1000 mg/m2, i.v., day 22.
214993002|NCT00526175|DRUG|Methotrexate|Age \<1 year 1-2 years 2-3 years \> 3 years MTX 5 mg 8 mg 10 mg 12 mg
215091859|NCT05610046|DEVICE|Sham sauna|Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.
215091860|NCT04395287|BEHAVIORAL|Leisure screen time|Questionnaire-based assessment of typical amount of time per week spent using screen-based media devices during leisure, assessed at two time points. Continuously scaled in main analyses; a difference is computed (18-month follow-up value minus baseline value). Additionally, screen time amount at the two time points will be scaled categorically, according to being classified as low or high according to WHO criteria for preschool children (Low (recommended): \<=1 hour/day, high: \>1 hour/day): High-high, high-low, low-high, and low-low.
214993003|NCT00526175|DRUG|Cytosine Arabinoside|Edad \<1 year 1-2 years 2-3 years \> 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
214993004|NCT00526175|DRUG|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
214993005|NCT00526175|DRUG|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
214993006|NCT01431976|DRUG|Lamictal|No comparison
214993007|NCT00608920|OTHER|Single Photon Emission Computed Tomography (SPECT)|
214993008|NCT04118400|PROCEDURE|NIV-NAVA|NAVA mode during Non-invasive ventilation
214993009|NCT04118400|PROCEDURE|Nasal CPAP or NIMV mode|Nasal CPAP or NIMV mode during Non-invasive ventilation
214993010|NCT00055237|BIOLOGICAL|Bevacizumab|15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.
215091861|NCT01873690|DRUG|Ciprofloxacin|Once, 400 mg IV
215091862|NCT01873690|DRUG|Placebo|5% Dextrose in water
215091863|NCT00538993|BEHAVIORAL|Stage based counseling|
215091864|NCT05367141|OTHER|"CDSS (MedicBK)"|"Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care."
214993011|NCT06775626|DEVICE|Implanon NXT® subdermal implant|"Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year"
215091865|NCT00450034|PROCEDURE|drug - oriented multifaceted intervention|oriented multifaceted intervention
215091866|NCT03470363|DRUG|Sevoflurane Volatile Liquid|
215091867|NCT03470363|DRUG|Bupivacaine / SUFentanil|
215091868|NCT01903889|OTHER|clinic based intervention|counseling C\&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
215091869|NCT01903889|OTHER|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
215091870|NCT03242018|DRUG|Placebo|Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
215091871|NCT03242018|DRUG|Sotagliflozin|Sotagliflozin 200 mg, tablet, orally, once daily.
215091872|NCT03070197|OTHER|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
214993012|NCT06775626|DRUG|Etonogestrel 68mg implant|"Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year"
214993013|NCT03276299|OTHER|six minute walking test|six minute walking test
214993014|NCT03276299|OTHER|six minute walking test|six minute walking test with encouragement
214993015|NCT04601506|BEHAVIORAL|Choice Architecture Nudge|"Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options.~PCPs will also be sent alerts when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order."
214993016|NCT04601506|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
214993017|NCT00867932|DRUG|Eculizumab|5 mg/mL solution in 5% Dextrose
214993018|NCT02625584|BEHAVIORAL|Reading Together - Pausing for Reading|
214993019|NCT02625584|BEHAVIORAL|Reading Together - Dialogic Reading|
214993020|NCT02625584|BEHAVIORAL|Reading Together - Shared Reading Control|
214993021|NCT03829176|GENETIC|Whole Genome Sequencing|Participants in this arm will have their sample analyzed by whole genome sequencing (WGS), and a report will be included in their medical record. Analysis will be phenotype-driven (gene list will be curated based on primary indication for testing and other available medical history information), and may include genes on ACMG 59 list if participant elects for these results. This report will include pathogenic, likely pathogenic, and suspicious VUS results identified in the genes analyzed.
214993022|NCT05688228|OTHER|questionnaire|Female Sexual Function Index (FSFI) and self-administrative questionnaires on sexuality just after abortion and repeated at 1, 3 and 6 months
215091873|NCT03070197|OTHER|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
215091874|NCT03262116|DRUG|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
215091875|NCT03262116|DRUG|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
215091876|NCT03262116|DRUG|BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
215091877|NCT03262116|DEVICE|Bionic Pancreas|The insulin-only bionic pancreas will be used in all three arms of the study
214379683|NCT03944044|OTHER|Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol|Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
214379684|NCT01665339|OTHER|preload diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
214379685|NCT01665339|OTHER|control diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
214379686|NCT01217424|OTHER|questionnaire administration|
214379687|NCT01217424|PROCEDURE|aromatherapy and essential oils|
214379688|NCT01217424|PROCEDURE|management of therapy complications|
214379689|NCT01217424|PROCEDURE|massage therapy|
214379690|NCT01217424|PROCEDURE|psychosocial assessment and care|
214379691|NCT01217424|PROCEDURE|reflexology procedure|
214379692|NCT04076410|DEVICE|Z1 lens|CE marked device
214379693|NCT04076410|DEVICE|Experimental Lens 1|CE marked device
214379694|NCT04076410|DEVICE|Experimental Lens 2|CE marked device
214379695|NCT04076410|DEVICE|Experimental Lens 3|CE marked device
214379696|NCT04076410|DEVICE|Experimental Lens 4|CE marked device
214379697|NCT04099043|DEVICE|Cascade Continuous Glucose Monitoring System|Continuous Glucose Monitoring for 15 days
214379698|NCT02234063|OTHER|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
214379699|NCT03009682|DRUG|Olaparib|"Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack."
214379700|NCT04106232|OTHER|No change in procedure except for specimen collection throughout procedure|Stool specimens will be taken before and during the HyGIeaCare procedure. Microbiome comparisons will be made across all specimens
215091878|NCT03047018|BEHAVIORAL|The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program|The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
215091879|NCT04867941|DRUG|ACP-196|All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
214379701|NCT04142502|DRUG|Propofol|Propofol as a sedation drug
214379702|NCT04142502|DRUG|Dexmedetomidin|Dexmedetomidine as a sedation drug
214379703|NCT02228954|PROCEDURE|Molecular imaging|
214379704|NCT01793025|BIOLOGICAL|ATAC Therapy|Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
214379705|NCT02946918|DRUG|Levothyroxine|Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily
215091880|NCT01276366|OTHER|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
215091881|NCT01276366|OTHER|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
215091882|NCT01276366|OTHER|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
215091883|NCT02365285|DRUG|Galantamine|16 mg po prior to the infusion of intralipid
214379706|NCT02467517|DRUG|Ketamine|
214379707|NCT02467517|DRUG|Magnesium Sulfate|
214379708|NCT02467517|DRUG|placebo : sodium chloride|
214379709|NCT00496405|DRUG|bevacizumab|
214379710|NCT01125722|DEVICE|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
214993023|NCT03197727|DIAGNOSTIC_TEST|GC Saliva-Check BUFFER|Evaluating the saliva flow rate, saliva pH and saliva buffering capacity
214993024|NCT05897151|DRUG|Continuous spinal anesthesia|"Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics.~Norepinephrine starting. dose 0.01 micg/kg/min will be ready for both groups if needed (Mean arterial pressure \< 70 or Mean arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics."
214993025|NCT05897151|DRUG|General anesthesia|After establishing of ASA monitoring, a wide bore cannula (18 G) will be inserted. Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
214993026|NCT04888416|BEHAVIORAL|I-STROM|I-STROM is a combination of the following implementation strategies: (a) initial and ongoing training, (b) learning collaboratives/knowledge sharing meetings, and (c) outcome measure champions
214993027|NCT04736875|DIAGNOSTIC_TEST|Doppler ultrasound study|Transcutaneous Doppler ultrasound (DUS) study was performed at the mid brachial artery to assess diameter, VF and RI, and at the mid segment of the efferent vein to assess the diameter and wall thickness.
214993028|NCT02705170|PROCEDURE|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
214993029|NCT04980729|DEVICE|Acetabular reconstruction after tumor resection.|In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction. In the traditional operation group (n = 14), the patients underwent the same surgery but without the navigation template. To compare the displacement of the hip rotation center before and after surgery between the two groups, an innovative method based on pelvic CT was developed and a validation group of cases was used to assess the effectiveness of this measurement approach. In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without hip joint reconstruction were included. The displacements for the validation group were calculated and compared with 0 cm, the theoretical value. Subsequently, the displacements between the template-guided group and the traditional operation group were compared.
214993030|NCT02545192|DEVICE|Low Field Magnetic Stimulation|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
214993031|NCT00440687|DRUG|Fluticasone 500mcg BD via accuhaler or identical placebo|
214993032|NCT04825522|DRUG|Vancomycin|During spinal surgery, participants will receive intrawound vancomycin powder in their wound before closure.
214993033|NCT02127671|OTHER|IDEAL intervention|
214993034|NCT02127671|OTHER|Control|
214993035|NCT03426150|DRUG|CPP-ACP|The surfaces of specimens were pretreated with CPP-ACP for 3 min
214993036|NCT03426150|DRUG|Placebos|The surfaces of specimens were pretreated with deionized water for 3 min
215091884|NCT02365285|DRUG|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
215091885|NCT02365285|DRUG|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
215091886|NCT02365285|DRUG|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
215091887|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
215091888|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
214379711|NCT01125722|DEVICE|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
214379712|NCT03732625|DRUG|Raltegravir|DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
214379713|NCT05613114|DRUG|Dalfampridine 10 MG|The participants in the experimental group received dalfampridine administered as 10 mg extended-release tablets every twelve hours for 8 weeks.
214993037|NCT02215759|DRUG|BI 44370 TA|
214993038|NCT02215759|DRUG|Placebo|
214993039|NCT04539964|PROCEDURE|Implant Procedure|The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
214993040|NCT04539964|DRUG|Conventional Synthetic DMARD|All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
214993041|NCT04539964|DEVICE|Active stimulation|Active stimulation for 1 min once per day
214993042|NCT04539964|DEVICE|Non-active stimulation|Non-active stimulation for 1 min once per day
214993043|NCT04250480|DIETARY_SUPPLEMENT|beta-alanine|beta-alanine tablet
214993044|NCT04250480|DIETARY_SUPPLEMENT|placebo|rice powder tablet
214993045|NCT05422508|BIOLOGICAL|MG1111 (BARICELA)|0.5ml, single dose, subcutaneous injection
214993046|NCT05422508|BIOLOGICAL|VARIVAX|0.5ml, single dose, subcutaneous injection
214993047|NCT05422508|BIOLOGICAL|Suduvax|0.5ml, single dose, subcutaneous injection
214993048|NCT01136954|DRUG|Zonisamide|Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
214993049|NCT05284253|OTHER|Gold microparticles|Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum
214993050|NCT05284253|OTHER|Gold thiosulphate|Gold Sodium Thio Sulphate, 1 % w/v in petrolatum
214379714|NCT05613114|DRUG|Placebo|Control group received a placebo drug with the same administration method (2 times per week for the total duration of 8 weeks).
214379715|NCT05613114|BEHAVIORAL|Physiotherapy|Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.
214379716|NCT04606537|DRUG|Itraconazole|200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.
214379717|NCT04606537|DRUG|Rifampin|600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.
214379718|NCT04606537|DRUG|KBP-5074|0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21
214993051|NCT05395585|PROCEDURE|Manual placental separation|Manual separation of the placenta from uterus
214993052|NCT02394275|BIOLOGICAL|Fecal Microbiota Transplant|All eligible patients will receive fecal microbiota transplant
214993053|NCT05751967|DRUG|Placebo Combined With Ursodeoxycholic Acid|1 tablet/ day
214993054|NCT05751967|DRUG|Fenofibrate Combined With Ursodeoxycholic Acid|200 mg/day
214993055|NCT03834168|OTHER|standardized Study Diet|Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
214993056|NCT00782067|DRUG|Midostaurin (PKC412)|Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
214993057|NCT04678674|PROCEDURE|tooth root augmentation|Autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement.
214993058|NCT00408226|DRUG|MKC-1|capsules, twice daily for 14 days in 21 day cycle
214993059|NCT00408226|DRUG|pemetrexed|standard dosing of 500 mg/m2 infused every 21 days
214993060|NCT06343701|OTHER|Implicit motor imagery|Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).
214993061|NCT06343701|OTHER|Explicit motor imagery|In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
214379719|NCT05884463|DRUG|18F-FAPI|Intravenous injection of one dosage of 18F-FAPI.
214379720|NCT05884463|DRUG|18F-FDG|Intravenous injection of one dosage of 18F-FDG.
214379721|NCT02473458|DRUG|Licorice whole extract|"Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~1. Starch-filled capsules (as placebo)~2. 450 mg whole licorice extract capsules~3. 900 mg whole licorice extract capsules"
214379722|NCT02473458|DRUG|Placebo|
214379723|NCT05802186|PROCEDURE|Computed Tomography|Undergo CT
214379724|NCT05802186|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214379725|NCT05802186|PROCEDURE|Positron Emission Tomography|Undergo PET
214379726|NCT05802186|OTHER|Quality-of-Life Assessment|Ancillary studies
214379727|NCT05802186|OTHER|Radiology, Treatment Planning|Undergo radiation planning with AI-directed analysis for dose recommendation
214379728|NCT05802186|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214379729|NCT05802186|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214379730|NCT04182854|DRUG|Furosemid hydrochlorothiazide|furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;
214993062|NCT03725007|DRUG|Upadacitinib|Upadacitinib is administered as an oral solution or tablet as described in protocol.
214993063|NCT06139653|DEVICE|Moment 1: IMT. Moment 2 CardioBreath.|"Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
215091889|NCT00276627|BEHAVIORAL|communication lecture|lecture on communication skills with oncology patients
215091890|NCT00276627|BEHAVIORAL|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
215091891|NCT01956045|OTHER|Patient's capacity|
215091892|NCT03738059|DRUG|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
215091893|NCT03738059|OTHER|normal saline 0.9%|will receive intravenous normal saline 0.9%
214379731|NCT04192084|PROCEDURE|microvascular partial toe transfer|we will perform microvascular partial toe transfer for patients with traumatic amputation of one or more digits
214379732|NCT04871984|DEVICE|Ureteroscopy for upper tract stone treatment with Holmium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Holmium laser
214379733|NCT04871984|DEVICE|Ureteroscopy for upper tract stone treatment with Thulium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Thulium laser
214379734|NCT00069784|DRUG|insulin glargine (HOE901)|Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
214379735|NCT00069784|DRUG|omega-3 polyunsaturated fatty acids (PUFA)|Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
214379736|NCT00069784|DRUG|placebo|Matching placebo gelatin capsules (containing olive oil) for oral administration
214379737|NCT00069784|DEVICE|reusable pen device for insulin injection|
214379738|NCT00106132|DRUG|Triamcinolone Acetonide|
214497818|NCT06800859|DRUG|Supplement fluids|To ensure optimal recovery and manage potential complications, patients are advised to supplement fluids by increasing their oral intake or receiving intravenous fluids as necessary. Bed rest is recommended to reduce physical strain and promote healing. Additionally, a blood patch procedure may be performed to alleviate symptoms such as headaches that can occur after certain medical procedures, particularly spinal taps. This involves injecting a small amount of the patient's own blood into the epidural space to seal any leaks of cerebrospinal fluid, thereby providing relief and aiding in recovery. Proper monitoring and follow-up care are essential to ensure the effectiveness of these interventions
214993064|NCT06139653|DEVICE|Moment 1: CardioBreath and moment 2: IMT.|"CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act.~Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks."
215091894|NCT04660227|PROCEDURE|Exercise Trainning|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour. Before starting the exercise, the risk of possible injury will be minimized by doing warm-up exercises and preparations will be made to start the exercise. Then, the exercise program will be started with aerobic exercise. Strengthening exercises will be planned for large muscle groups, targeting body parts such as hips, knees, shoulders, abdomen and trunk. In exercises, it is planned to do 2 sets of 10-15 repetitions using elastic band, free weights or body weight. The exercise program will be created according to the condition of the people and progression will be provided every 2 weeks. After the exercises are completed, cool down will be done with relaxation and stretching exercises.
215091895|NCT04660227|OTHER|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks. After the final evaluations, they will be directed to the exercise group.
214497819|NCT05021562|DRUG|Niraparib|Niraparib capsules
215091896|NCT01813838|DRUG|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
215091897|NCT01813838|DRUG|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
215091898|NCT01813838|DRUG|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
214379739|NCT06139068|OTHER|Narrative Group Counseling|Two of the principles that explain how narrative therapy works are: to always maintain a stance of curiosity on the part of the practitioner and to ask questions to which the practitioner does not actually know the answers and to which the answer is known to the participants. To guide therapeutic conversations that include these questions, Michael White and David Epston have designed a series of conversation maps in the application of narrative therapy. Taking these maps into consideration, the sessions were planned with the guidance of relevant literature and structured with expert opinions. Group counseling was applied to the intervention group once a week in 8 sessions. The intervention was completed face to face, in a calm, quiet and bright environment, with a round seating plan. One session lasted 90 minutes. Each session was completed in two parts with a 10-minute break.
214379740|NCT06139068|OTHER|stress coping interviews|In addition to the students' routine practices, four sessions of stress coping interviews will be held for the control group, with an interval of two weeks, after the information meeting.
214379741|NCT01106443|PROCEDURE|Total Thyroidectomy + CLND|Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.
214379742|NCT01106443|PROCEDURE|Total thyroidectomy - CLND|Removal of all possible thyroid tissue without dissection of neck level 6.
214497820|NCT06814782|OTHER|Action Observation Training|Action Observation Training (AOT) consists of patients observing videos of specific movements, followed by practice of those movements
214993065|NCT05900284|DRUG|Metformin low dose|If randomized to the 500 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
214993066|NCT05900284|DRUG|Metformin high dose|If randomized to the 1000 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
214993067|NCT05900284|DRUG|Placebo|If randomized to the Placebo arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
214993068|NCT05038254|OTHER|Best Practice|Receive standard of care telemedicine
214993069|NCT05038254|PROCEDURE|Patient Monitoring|Undergo remote monitoring
214993070|NCT05038254|OTHER|Questionnaire Administration|Ancillary studies
214993071|NCT05130827|DRUG|Plinabulin|40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.
214993072|NCT03556683|DEVICE|3% Hypertonic Saline|4 mL of 3% hypertonic saline
214993073|NCT03556683|DEVICE|7% Hypertonic Saline|4 mL of 7% hypertonic saline
214993074|NCT03556683|DRUG|Salbutamol|4 puffs (90 mcg/actuation)
214993075|NCT04163263|DRUG|BOS-356|topical gel
214993076|NCT04163263|DRUG|Vehicle|topical gel
214993077|NCT01599962|DRUG|Cinacalcet|single administration, 90mg
214993078|NCT01599962|DRUG|Placebo|single administration
214993079|NCT01949272|DEVICE|esophageal pressure mesurement|"EXPRESS study ventilatory setting the optimization of PEEP with esophageal pressure mesurement"
214993080|NCT03127059|OTHER|Breathing Exercises|"Key points in the intervention are~* Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.~* Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.~* Inclusion of the breathing modification into walking and other physical activities.~* Daily home exercise of BrEX."
214993081|NCT03127059|OTHER|Usual care|Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
214993082|NCT05883488|OTHER|Robot-assisted upper extremity rehabilitation|The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes in addition to the conventional rehabilitation program. Participants will receive a total of 4 weeks of treatment.
214993083|NCT05883488|OTHER|Conventional rehabilitation|Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
214993084|NCT03175458|PROCEDURE|sinus lift,implant placement,tenting|elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation
214993085|NCT03175458|PROCEDURE|sinus lift,implant placement,bovine bone|sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
214379743|NCT01106443|PROCEDURE|Hemi-thyroidectomy + CLND|Removal of one thyroid lobe and ipsilateral central lymph nodes
214379744|NCT01106443|PROCEDURE|Hemi-thyroidectomy - CLND|Removal of one thyroid lobe only. No lymphatic dissection.
214379745|NCT04209413|PROCEDURE|Patients referred for a knee ligamentoplasty|knee ligamentoplasty
214379746|NCT03339284|DRUG|Dexamethasone sodium phosphate|Dexamethasone injection
214993086|NCT03555786|OTHER|minimum effective volume|"The determination of MEV90 and its 95% confidence interval (CI) will be based on a biased coin up-and-down sequential design"
214993087|NCT04381715|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
214993088|NCT03173963|DRUG|Empagliflozin|10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
214993089|NCT03173963|OTHER|Placebo|1placebo tablet per day
214993090|NCT03600792|GENETIC|whole exome sequencing (WES)|"WES analysis will be performed in the UF de Génomique du Développement (APHP, Pitié-Salpêtrière hospital), using DNA extracted from amniotic fluid for the foetus (also used for chromosomal studies) and DNA extracted from peripheral blood for both parents. There will be no supplemental invasive sampling for this study. The result of WES will be returned during a consultation with the geneticist and the associated prognosis will be explained in case of molecular diagnosis"
214993091|NCT03972917|DIAGNOSTIC_TEST|Transvaginal ultrasonographic examination|Evaluation of endometrial thickness; myoma size and volume
214993092|NCT05173636|OTHER|cervical lateral glide|A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
214993093|NCT05173636|OTHER|thoracic mobilization technique|Participants in group B will be given cervical lateral glide along with thoracic mobilization technique in prone position.
214993094|NCT00764517|DRUG|Cladribine|Given IV
214993095|NCT00764517|OTHER|Laboratory Biomarker Analysis|Correlative studies
214993096|NCT00764517|BIOLOGICAL|Rituximab|Given IV
214379747|NCT03339284|DRUG|Ropivacaine Hydrocloride|Ropivacaine injection
214497821|NCT06814782|OTHER|Action Observation and Motor Imagery|Action Observation and Motor Imagery (AOMI) consists of patients observing videos of specific movements, followed by mental rehearsal of those movements
214497822|NCT06814782|OTHER|Exercise|After watching a landscape video, patients will have to perform specific postural and balance exercises
214497823|NCT05080504|DEVICE|Eko DUO|"Each subject will take an Eko DUO device home and take DUO recordings immediately before or after their prescribed CardioMEMS measurements.~The DUO recordings will be taken at 3 predefined chest locations: the right upper sternal border, left upper sternal border, and right anterolateral. Each DUO recording lasts about 15 seconds. The total time per recording session is expected to be 2-4 minutes, which allows for time between recordings and any potential repeat recordings. Study participation will last for 90 days."
214993097|NCT00764517|DRUG|Vorinostat|Given PO
214993098|NCT04681378|PROCEDURE|double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
214993099|NCT00520468|DRUG|Erythropoietin|40,000 units injected under the skin (SQ) weekly
214993100|NCT00520468|DRUG|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
214993101|NCT00520468|DRUG|G-CSF|300 mcg injected under the skin (SQ) two times per week
214993102|NCT00520468|DRUG|Prednisone|60 mg per day for 7 days, taper over 1 month
214379748|NCT03339284|DRUG|Sodium Chloride 9mg/mL|Sodium Chloride injection
214379749|NCT02654990|DRUG|Panobinostat Capsules|20 mg, 10 mg or 15 mg (for dose reductions only)
214497824|NCT06811831|DRUG|Macitentan 10 mg tablet, once daily.|After the patient signed an informed consent form, Macitentan was given as an oral medication (10 mg once daily) for a period of 4 weeks
214497825|NCT04477629|DRUG|Belatacept|Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.
214497826|NCT04477629|DRUG|Tacrolimus|Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.
214497827|NCT04477629|DRUG|Mycophenolate Mofetil|Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).
215091899|NCT03864393|OTHER|Multimodal overground locomotor training|Locomotor training sessions use various movement drills emphasizing power, stability, and stepping in a specific direction: forward, backward, lateral, rotational. Sessions also have an additional focus on gait initiation or steady-state walking. After circuit-style warm up exercises, participants perform overground movement drills that are specific to the emphasis of the individual training session, culminating in practicing everyday overground walking. Participants wear a heart rate monitor to ensure that the majority of the training session is performed at an aerobic intensity greater than 60% age predicted heart rate maximum (220-age +/- 5 bpm).
214379750|NCT02654990|DRUG|Bortezomib Injection|1.3 mg/square meter subcutaneous administration. Cycle 1-4: 2 weeks on/1 week off, BIW for participants ≤ 75 years at time of screening; once a week for participants \> 75 years. Cycle 5+: once a week for all participants.
214379751|NCT02654990|DRUG|Dexamethasone tablets|Pre and 24 hours after bortezomib administration. Participants ≤ 75 years at time of screening: 20 mg/dose participants; \> 75 years: 10 mg/dose.
214379752|NCT00910403|PROCEDURE|LASIK|Excimer Laser Ablation using LASIK
214379753|NCT02262546|DRUG|Pramipexole extended-release (ER) tablets|
214379754|NCT02262546|DRUG|Pramipexole immediate-release (IR) tablets|
214993103|NCT02584296|BEHAVIORAL|BSMA|Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, \~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
214379755|NCT02262546|DRUG|Moxifloxacin|
214379756|NCT02262546|DRUG|Pramipexole Placebo|
214379757|NCT02262546|DRUG|Moxifloxacin Placebo|
214379758|NCT00045435|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
214687277|NCT03691402|BEHAVIORAL|MCT-Silver|Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
214687278|NCT03691402|BEHAVIORAL|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
214379759|NCT00045435|DRUG|fludarabine phosphate|Given IV
214379760|NCT00045435|RADIATION|total-body irradiation|Undergo TBI
214993104|NCT02556450|DRUG|Spironolacton|Administration of Spironolacton 25 mg per day
214379761|NCT00045435|DRUG|cyclosporine|Given PO
214379762|NCT00045435|DRUG|mycophenolate mofetil|Given PO
214379763|NCT00045435|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
214379764|NCT00493077|DRUG|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
214993105|NCT01890577|DRUG|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
214993106|NCT04159155|RADIATION|External Beam Radiation|Radiation therapy given outside the patient to a particular part of the body.
214993107|NCT04159155|DRUG|Niraparib|Oral drug
214379765|NCT02484170|DRUG|Mannitol cream|Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
214379766|NCT02484170|DRUG|Placebo|Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
214379767|NCT00402194|DRUG|Losartan|Tablet, 100mg, once per day for 3 months
214379768|NCT01948635|DEVICE|tapered PVC-cuffed tracheal tubes|Patients will be intubated with tapered-shape tracheal tubes
214379769|NCT01948635|DEVICE|Standard PVC-cuffed tracheal tube|Patients will be intubated with standard PVC cuffed tracheal tubes
214379770|NCT04895514|PROCEDURE|Gamma-irradiated corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of gamma-irradiated preserved corneal tissue will then be placed into the pocket
214379771|NCT03288896|BEHAVIORAL|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
214379772|NCT05839223|OTHER|Education|"educational process (recommendations) about isotretinoin by a clinical pharmacist.~The information included: the degree of the importance of adherence to the drug and the recommendations, the correct method of taking it, the importance of doing periodic laboratory tests (lipid profile, liver enzyme test, and pregnancy test), common side effects, how to properly avoid and deal with side effects, precaution warnings they should pay attention to, and what are the cases in which the drug should be stopped."
214993108|NCT04159155|RADIATION|Vaginal high-dose rate brachytherapy|Internal radiation to the vagina
214993109|NCT04159155|OTHER|Observation - no drugs|Observation
214993110|NCT00835926|BIOLOGICAL|Influenza virus vaccine|0.5 mL, Intramuscular
214993111|NCT00835926|BIOLOGICAL|Influenza virus vaccine|0.5 mL, Intramuscular
214993112|NCT05229081|BEHAVIORAL|vaccine education|The educational content was developed based on research and expert perspectives and included general information about immunization, pneumonia, and pneumococcal vaccines, as well as vaccine myths. This information was first conveyed to the patients verbally, and then booklets with the same material were handed to them. The Pneumococcal Conjugate Vaccine 13 (PCV13) vaccination was recommended based on Infectious Disease Society of America (IDSA), Advisory Committee on Immunization Practices (ACIP), and national adult immunization guidelines.
214379773|NCT05722470|BEHAVIORAL|eating disorders|Assessment of eating disorders among adolescents
214379774|NCT01958840|BEHAVIORAL|Behavioral Activation for Depression Treatment|
214379775|NCT01958840|BEHAVIORAL|Supportive Counseling|
214993113|NCT00469547|OTHER|62% ethanol in emollient gel|62% ethanol in emollient gel used as a topical male microbicide
214379776|NCT04416698|BEHAVIORAL|Individual qualitative interview|Individual interviews will be conducted to understanding the needs and concerns of youth smokers of e-cigarette or other new tobacco products, including their risk perceptions, and the behaviour, attitudes, and experiences related to these tobacco products.
214993114|NCT00469547|DRUG|Placebo|15% ethanol in emollient gel used as a topical male microbicide
214993115|NCT00469547|OTHER|15% ethanol in emollient gel|15% ethanol in emollient gel used as a topical male microbicide
214993116|NCT04433598|BEHAVIORAL|Nutrition Education Intervention|Each participant were interviewed by face- to- face using Arabic language, after 1 hour when they finish their assessment by medical doctors. The researcher was collected the data from the participants in a special room for 10-15 minutes, after only one hour of completing the necessary tests with the treating physician to allow participants to go for a meal before the nutrition education starts.12 classes (1:30 hour each session):- 100 participants / 5 days = 20 participants each class was offered twice per day to cover the number of participants and to enhance attendance for them can not attend at first morning. the classes was designed according to health belief model (HBM). The topics were about the type 2 diabetes and its complications,the benefits of diabetes plate and eating vegetables before carbohydrates.
214379777|NCT04416698|BEHAVIORAL|cross-sectional survey study|structured questionnaire will be constructed for a cross-sectional survey to further explore the behaviour, attitudes, and experiences related to electronic cigarettes or other new tobacco products among youth.
214379778|NCT03520465|DEVICE|DynaMesh®-CICAT longitudinal measure 10x35 cm|
214379779|NCT03448159|DRUG|Fluoxetine Hydrochloride|Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).
214993117|NCT06844110|DRUG|68GA-DOTA-dPNE|Intravenous administration of 68GA-DOTA-dPNE tracer
214993118|NCT06161948|OTHER|Time-restricted enteral nutrition therapy group|Control the daily enteral nutrition time to 8-12 hours, enteral nutrition start time: 06:00 \~ 08:00, end time: 16:00 \~ 18:00. Enteral nutrition lasts until the patient discontinues enteral nutrition, the patient dies, the patient is transferred from the ICU, or enteral nutrition is used until 28 days, whichever event occurs first.
214993119|NCT06161948|OTHER|Continuous enteral nutrition control group|The control group was continuous enteral nutrition (24 hours), which lasted until the patient stopped taking enteral nutrition, the patient died, the patient was transferred from the ICU, or enteral nutrition was used until 28 days, whichever event occurred first.
214379780|NCT03448159|OTHER|Placebo|Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).
214497828|NCT04477629|DRUG|Corticosteroid|Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
214687279|NCT06556056|OTHER|SesZen-Bio Serum|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liduid Frequency: Daily Night application. Route of administration: Topical"
214993120|NCT05360953|DRUG|Clonidine|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 0.375 clonidine. Using capsules of 0,075 mg clonidine.
214993121|NCT05360953|DRUG|Doxazosin|"All patients enrolled establish their individually tolerable dose by dose. Dosage up to a maximum of 10 mg doxazosin. Using capsules of 2 mg doxazosin.~Titration."
214993122|NCT05360953|DRUG|Placebo|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.
214379781|NCT03448159|BEHAVIORAL|Exercise Program|All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.
214379782|NCT01397994|DRUG|Nicorandil|Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
214379783|NCT01397994|DRUG|Atenolol|Patients in the control arm would be advised atenolol 50 mg od
214379784|NCT04953364|BEHAVIORAL|SMART|SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. The tablet will also allow asynchronous contact with trainers through a secure website.
214379785|NCT04953364|BEHAVIORAL|Control|The control group will receive a care booklet and weekly contacts for 6 weeks.
214379786|NCT05119075|OTHER|Dopaminergic OFF-drug state|Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
214379787|NCT05119075|OTHER|Dopaminergic ON-drug state|Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
214379788|NCT00203060|DRUG|Rasagiline Mesylate|tablet, 1 or 2 mg, daily, 58 weeks
214379789|NCT00203060|DRUG|placebo|tablet, once daily, 58 weeks
214379790|NCT03311932|DRUG|Infacort®|Immediate release multiparticulate formulation (granules) of hydrocortisone
214379791|NCT03311932|DRUG|Cortef®|Immediate release hydrocortisone tablets
214379792|NCT01928134|DIETARY_SUPPLEMENT|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
214379793|NCT01928134|DIETARY_SUPPLEMENT|Vit K2+CaCO3|
214497829|NCT06752655|OTHER|Curcumin with photodynamic thearpy|root canals will irrigated with final irrigation procedure: curcumin+photodynamic therapy. The teeth will be isolated with a rubber dam, and an access cavity will be created. After root canal preparation, the final irrigation procedure will be performed. Root canal treatments will be completed, and the patients' postoperative pain levels will be recorded using follow-up forms.
214993123|NCT00621530|DRUG|ketorolac tromethamine opthalmic solution|ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
214993124|NCT00621530|DRUG|placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
214379794|NCT02168764|DEVICE|ATI Neurostimulation System|All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.
214379795|NCT00051168|DRUG|Travatan|Travoprost (0.004%) 1 drop each eye once daily
214379796|NCT00709059|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks
214379797|NCT00709059|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (\<65 kg: 800 mg; 65 - 85 kg: 1000 mg; \>85 kg: 1200 mg) orally for 48 weeks
214379798|NCT06053034|DEVICE|Solio alpha cure plus|The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
214379799|NCT05048849|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
214379800|NCT05823246|DRUG|QLF31907|Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
214379801|NCT04531566|DIETARY_SUPPLEMENT|Oral Feed|Infant will be seen by occupational therapist (OT) twice a week and assessed for oral cues. If infant shows oral cues then the occupational therapist will proceed with feeding strategies. Oral feeding strategies include pacifier dips, open nipple trials with syringe controlled bolus size (1-4mls) and po trials up to 10mls.
214379802|NCT04531566|DIETARY_SUPPLEMENT|Usual care|Infants will not start oral feeds until on HFNC 2 Litres or less. Oral feeds will be started on the discretion of the physician.
214497830|NCT06752655|OTHER|Control group|root canals will irrigated with routine root canal final irrigation with NaOCl and EDTA. The teeth will be isolated with a rubber dam, and an access cavity will be created. After root canal preparation, the final irrigation procedure will be performed. Root canal treatments will be completed, and the patients' postoperative pain levels will be recorded using follow-up forms.
214993125|NCT06182085|DRUG|PRI-002|Oral administration
214993126|NCT06182085|DRUG|Placebo|Oral administration
214993127|NCT05941936|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
214993128|NCT00693264|DIETARY_SUPPLEMENT|Hoodia Gordonii|750 mg capsule will be taken one time
214993129|NCT00693264|DIETARY_SUPPLEMENT|Placebo|Placebo capsule to be taken one time
214993130|NCT04302285|OTHER|PKU type meal and Exercise|"* Exercise was conducted prior to PKU type meal.~* PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat."
214379803|NCT02355613|RADIATION|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
214379804|NCT02355613|RADIATION|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
214379805|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
214379806|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
214497831|NCT06765187|BIOLOGICAL|RIV3|intramuscular injection
214993131|NCT04302285|OTHER|PKU type meal|PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
214993132|NCT00748800|BEHAVIORAL|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
214993133|NCT00748800|BEHAVIORAL|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
215091900|NCT04500340|BEHAVIORAL|Group CBT for test anxiety|The cognitive-behavioral therapy protocol developed by Flaxman, Bond \& Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
215091901|NCT02750384|DRUG|DSM265 50% SDD granules|Single oral dose 400 mg
215091902|NCT02750384|DRUG|DSM265 25% SDD powder for suspension|Single oral dose 400 mg
215091903|NCT02986100|DRUG|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib
215091904|NCT02986100|DRUG|Rucaparib|200 \& 300 mg tablet
215091905|NCT03778320|DRUG|CTP-692|Single oral dose
215091906|NCT03778320|DRUG|D-Serine|Single oral dose
215091907|NCT03414112|BIOLOGICAL|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
215091908|NCT02221518|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
215091909|NCT03590132|BEHAVIORAL|Strong African American Families Program|SAAF is a 7 session family skills training program
215091910|NCT03590132|BEHAVIORAL|Strong African American Families--Teen Program|SAAF-T is a 5 session family skills training program
215091911|NCT02106247|DRUG|BI 1181181 high dose|two tablet
214993134|NCT04607551|PROCEDURE|Prone positionning|4 to 5 persons required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube, the jugular ECMO cannula and the ventilator lines and another dedicated to the femoral ECMO cannula. The person at the head of the bed will coordinate the steps. The other persons will stand at each side of the bed. The direction of the rotation will be decided giving priority to the side of the central venous lines. The length of vascular and ventilator lines will be checked for appropriateness, the endotracheal tube and gastric tube will be secured, and the patient's knees, forehead, chest, and iliac crests will be protected using adhesive pads. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. Patients will be proned at least four times during the first days on ECMO. Each prone session will stand for at least 16 hours
215091912|NCT02106247|DRUG|BI 1181181 low dose|one tablet
215091913|NCT02106247|DRUG|Placebo|tablet
215091914|NCT02478450|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
215091915|NCT00625612|DRUG|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
215091916|NCT00625612|DRUG|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
214993135|NCT04607551|PROCEDURE|Supine position|Patients assigned to supine will remain in a semi-recumbent position.
214993136|NCT04398966|DEVICE|Prostatic Artery Embolization (HydroPearl® compressible microspheres)|Embolic material
215091917|NCT02636946|DRUG|Bimatoprost SR|Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
215091918|NCT02636946|DRUG|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
215091919|NCT02636946|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
215091920|NCT02636946|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
214993137|NCT02884648|DRUG|Bevacizumab|15 mg/kg by vein on Day 1 of every 21-day study cycle.
214993138|NCT04106037|OTHER|Data extraction from medical files|Data extraction from medical files
214993139|NCT01868568|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin).
215091921|NCT00647114|BIOLOGICAL|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
215091922|NCT00647114|BIOLOGICAL|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
215091923|NCT05855343|OTHER|BIDI Stick e-cigarette|The BIDI will be dispensed, and subjects will be instructed to use the BIDI as often as they like during the 12 week period, and to switch completely to the BIDI within 1 week. If, however, they do smoke any CC, they will also be instructed to use the BIDI immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The BIDI will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute BIDI for CCs by the end of the first week of use.
215091924|NCT00060580|PROCEDURE|Raman scattering spectroscopy|
215091925|NCT03690180|DIAGNOSTIC_TEST|serum magnesium|assessment of serum magnesium in all patients
214379807|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
214993140|NCT01868568|DRUG|insulin degludec/insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
214687280|NCT06556056|OTHER|Minoxidil hair serum (1%)|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
214993141|NCT01868568|DRUG|insulin degludec/insulin aspart 40|A single dose administered subcutaneously (s.c., under the skin).
214993142|NCT01868568|DRUG|insulin degludec/insulin aspart 45|A single dose administered subcutaneously (s.c., under the skin).
214993143|NCT01868568|DRUG|insulin degludec/insulin aspart 55|A single dose administered subcutaneously (s.c., under the skin).
214993144|NCT01868568|DRUG|insulin aspart|A single dose administered subcutaneously (s.c., under the skin).
214379808|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
214993145|NCT01868568|DRUG|biphasic insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
214993146|NCT01868568|DRUG|placebo|A single dose administered subcutaneously (s.c., under the skin).
214993147|NCT00177411|DRUG|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
214993148|NCT06519331|DEVICE|Research FibroScan (FS)|"Patients #1 to #25:~Exam 1: Examination with Research FibroScan. Exam 2: Examination with the Reference FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #26 to #75:~Exam 1: Examination with the Research or Reference FibroScan. Exam 2: Examination with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #76 to #114:~Exams 1 \& 2: 2 consecutive examinations with the Research or Reference FibroScan.~Exams 3 \& 4: 2 consecutive examinations with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exams 1 \& 2."
214993149|NCT02033798|DRUG|Tamsulosin|Once Daily 0.2mg per oral for 6 months
214993150|NCT02984137|OTHER|testing, evaluation, sampling|neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.
214993151|NCT06398938|RADIATION|Interventional Radiotherapy|The patients will undergo four IRT fractions in one week
214993152|NCT05985759|DRUG|N acetyle cystiene|N acetyle cystien is administerd due to its antibacterial action and anti inflamatory action
214993153|NCT00988338|BIOLOGICAL|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
214993154|NCT03079830|DRUG|Piritramid|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
214993155|NCT03079830|DRUG|Saline|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
214993156|NCT00671060|DRUG|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
214993157|NCT00671060|DRUG|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
214993158|NCT06290817|DRUG|Orelabrutinib combined with R-CDOP regimen|All participants were treated with the orelabrutinib combined with R-CHOP regimen (O-RCDOP). The treatment plan involved orelabrutinib tablets at 150mg QD (once daily) from day 1 to day 21, Rituximab at 375mg/m2 on day 1; Cyclophosphamide at 750mg/m2 on day 1; Liposomal Doxorubicin at 30mg/m2 on day 0; Vincristine at 25mg/m2 on day 1 (maximum dose 40mg); and Prednisone at 100mg from day 1 to day 5. The treatment cycles were set every 21 days for a total of 6-8 cycles. Dose adjustments were made for elderly patients for Cyclophosphamide and Liposomal Doxorubicin based on age: 70-80% of the dose for those aged 70-80 years old, and 50-60% of the dose for those older than 80 years.
214993159|NCT02515786|OTHER|oxygen humidification|humidification for oxygen delivered by nasal catheter
214993160|NCT01273961|DEVICE|AuraLevée treatment|A single treatment, on day 0, on each of no more than two treatment sites, using the AuraLevée device. Treatment sites are the face, abdomen, upper arm, thigh or neck.
215091926|NCT04214912|COMBINATION_PRODUCT|Personalized Survivor Care Plan (PSCP)|Based the above literature review and our previous 10 years' efforts in OC patients' distress and care needs survey, we categorize OC patients' distress and needs into 6 major dimensions (1) symptoms management and dysfunction prevention (different kind of symptom, such as swallowing difficulty, eating difficulty, speaking difficulty, difficulty in opening mouth/trismus, shoulder dysfunction, mucositis, pain, fatigue, etc), (2) enhancing physical function (exercise skills, types for major parts of muscle training), (3) Confronting and dealing with psychological distress (fear, anxiety, depression, uncertainty), (4) nutrition assessment and counseling, (5) Social connection and RTW counseling (attitudes and skills for returning to work), and (6) overall needs assessment and supports.
214687281|NCT06556056|OTHER|Placebo|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
214687282|NCT06556056|OTHER|Liposomal Form of SesZenBio|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Frequency: Daily Night Application Rout of administration: Topical"
214379809|NCT06053554|PROCEDURE|Phakoemulsification|Femtolaser is used to perform a standard 5.0mm CCC centred on the pupil or limbus and to fragment the lens nucleus toguarantee reproducible results in every eye.After the CCC and nucleus fragmentation the anterior segment is filled with viscoelastics, the rhexis lenticule is removed and hydrodisection of the nucleus is performed. Subsequently phacoemulsification for nucleus and irrigation/aspiration of the lens cortex is performed. The capsular bag and AC is then filled with a cohesive viscoelastic and the IOL is implanted with the haptics in the back or with the haptics in the sulcus. At the end of surgery, the viscoelastic is removed using the irrigation aspiration probe, intracameral antibiotic is instilled, the CCI and paracenteses are hydrated and sealed.
214379810|NCT06053554|DEVICE|Ziemer Z8 Femtolaser|The femto second laser used for certain steps (capsulorhexis, nucleus fragmentation) of the cataract surgery.
214993161|NCT00455624|DRUG|Androgen deprivation therapy|According to standard medical care
214993162|NCT01821313|OTHER|Moderate exercise|
214379811|NCT06053554|DEVICE|Kowa Avansee Preset|The used 3 piece intra ocular lens
214379812|NCT01786330|DEVICE|Procare abdominal binder|
214379813|NCT01786330|OTHER|Standard of Care|
214379814|NCT01154569|DRUG|Azithromycin|500 mg single dose
214379815|NCT06487598|DRUG|inj insulin to one group|One group- only inj insulin for 3 months.
214379816|NCT06487598|DRUG|Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day|second group- Inj Insulin with Tab Nisha-Dhatri 500 mg twice a day
214993163|NCT01821313|OTHER|High Intensity Interval Exercise|
215091927|NCT06358586|DRUG|Tachipirina® 120 mg/5 mL oral suspension, new flavour|A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
215091928|NCT02791412|PROCEDURE|percutaneous coronary intervention or coronary-artery bypass graft|
215091929|NCT04208048|DEVICE|FLXfit 15TM device|In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
215091930|NCT03396510|OTHER|IMPROVED intervention|Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the investigators will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the investigators will not provide guidance about what actions to take in response to patients' symptoms.
214379817|NCT03584620|OTHER|Inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
214379818|NCT03584620|OTHER|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
214379819|NCT00411593|DRUG|Bevacizumab|15 g/kg by vein every 3 weeks on day 1 of each cycle.
214379820|NCT00411593|DRUG|Bortezomib|"Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I."
214379821|NCT01568346|OTHER|MRI|Breast MRI
214379822|NCT05924399|BEHAVIORAL|Affect Labeling Training|(1) Participants will view combat-relevant images and then label the image or how they feel while viewing the image. (2) Participants will view facial expressions and then label the image. (3) Participants will view negative combat- irrelevant images (such as snakes or spiders) and then label the image or how they feel while viewing the image. (4) Participants will complete Go-NoGo trials similar to the fMRI Go-NoGo task described above. Participants will receive all four types of inhibitory training.
214379823|NCT02172625|DIETARY_SUPPLEMENT|Protandim Dietary Supplement|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
214993164|NCT02020941|DRUG|carfilzomib|Given IV
214993165|NCT02020941|DRUG|dexamethasone|Given IV or PO
214993166|NCT02020941|OTHER|laboratory biomarker analysis|Correlative studies
214993167|NCT06494956|PROCEDURE|Implant device|A subcutaneous tunnel was established under general anesthesia, the electrode was connected to the stimulator, and the pulse generator was implanted in the skull.
214993168|NCT03572296|DIETARY_SUPPLEMENT|Placebo|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
214993169|NCT03572296|DIETARY_SUPPLEMENT|Polyphenol and fibre|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
214993170|NCT03572296|DIETARY_SUPPLEMENT|Fibre|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
214993171|NCT00131300|DEVICE|Synvisc (hylan G-F 20)|
214379824|NCT02172625|OTHER|Placebo Group|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
214993172|NCT04127929|OTHER|Restoration of cavities using glass carbomer material (GCP Dental)|Detection of caries then restoration of cavities
214993173|NCT04127929|OTHER|Restoration of cavities using nanocomposite resin (Tokuyama Estelite Posterior)|Detection of caries then restoration of cavities
214993174|NCT05951686|DRUG|Desflurane|In inhalation group, desflurane will be used for general anesthesia maintenance under the screening with Patient State Index (PSI) between a score of 25-50. Remifentanil infusion is used with desflurane with a dose of 0.05-2 mcg/ kg/ min according to PSI . Fresh gas flow is used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
214993175|NCT05951686|DRUG|Remifentanil infusion|Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.
214993176|NCT05951686|OTHER|Fresh gas|Fresh gas flow will be used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
214993177|NCT05951686|DRUG|Propofol infusion|Propofol infusion will be used for general anesthesia maintenance with a dose of under the screening of Patient State Index (PSI) between a score of 25-50 in group tiva.
214993178|NCT00189514|DRUG|pramlintide acetate|Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
214993179|NCT00189514|DRUG|placebo|subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
214993180|NCT02476162|DEVICE|iHealth Wireless Blood Pressure Monitor|"Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening."
214993181|NCT04139135|DRUG|HLX10|neoadjuvant treatment phase：HLX10（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：HLX10（4.5mg/kg/3w IV）
214993182|NCT04139135|DRUG|Placebos|neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
215091931|NCT02162212|OTHER|Optimized Shoulder Movement Program|"A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity."
215091932|NCT02162212|OTHER|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c \< 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is \<130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
215091933|NCT04615325|DRUG|RO7303359|RO730359 will be administered as a single intravitreal injection.
215091934|NCT02332733|BIOLOGICAL|TV003|10\^3 plaque forming units (PFU) of rDEN1 delta 30, 10\^3 PFU of rDEN2/4 delta 30(ME), 10\^3 PFU of rDEN3 delta 30/31-7164, and 10\^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
215091935|NCT02332733|BIOLOGICAL|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
215091936|NCT03112304|BEHAVIORAL|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
214379825|NCT00414739|DRUG|Benzalkonium chloride|
214379826|NCT01218945|PROCEDURE|Cell Culture|Aim of this study is to isolate and cultivate fat-derived progenitor cells and differentiation into osteoblasts. Therefore, our research idea is to pre-engineer large synthetic bone grafts and study the vascularization process in vivo.
214993183|NCT05564923|DRUG|there is no intervention|there is no intervention
214993184|NCT03396562|OTHER|Assessments of Development and Growth|Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 5 years, 6 years, 7 years, 8 years, 9 years of age.
214993185|NCT06486701|BEHAVIORAL|have a sing|Singing
214993186|NCT02214472|BEHAVIORAL|Biofeedback|
214993187|NCT02214472|DRUG|Placebo|
214993188|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 7g|Xylitol 7g in 300mL tap water
214993189|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 10g|Erythritol 10g in 300mL tap water
214993190|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 17g|Xylitol 17g in 300mL tap water
214993191|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 35g|Xylitol 35g in 300mL tap water
214993192|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 25g|Erythritol 25g in 300mL tap water
214993193|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 50g|Erythritol 50g in 300mL tap water
214993194|NCT06150547|DIAGNOSTIC_TEST|FDG Positron Emission Tomography|Imaging using an FDG radioactive tracer to look at the head.
214379827|NCT06565104|BEHAVIORAL|Multidimensional Sleep Health Sessions|The two sleep health educational sessions will include didactic content on defining sleep health, reviewing sleep recommendations, outlining the role of sleep in preserving cardiometabolic health, and correcting unhelpful sleep-related beliefs and debunking myths. Participants will learn to maximize the benefits of self-monitoring using a Fitbit and will receive a sleep mask, ear plugs, a blue light blocker, and an indoor air purifier to improve their sleep environment.
214379828|NCT06565104|BEHAVIORAL|Healthy Diet Sessions|The two diet sessions include an overview of nutrition basics, examples of healthy dietary patterns and cooking methods to increase consumption of plant-based foods such as fruits, vegetables, and whole grains, promote choosing more lean proteins such as fish, and reduce intakes of red and processed meats, sugary foods, and sugar-sweetened beverages.
214497832|NCT06763679|OTHER|mobilization|"Acromioclavicular joint mobilization:~* The patient is placed in the supine position and the upper limb is placed in a physiological position with the patient's arm clinging to the body and the hand on the abdomen, which causes the capsule to stretch less and the technique to be less painful.~* The therapist placed the tips of his both thumbs on the anterior surface of the clavicle adjacent to the ACJ and spread his other fingers out for stability and his forearm was situated in line with the posterior movement at the ACJ.~* ACJ mobilization was performed in up to 30-minute individual sessions by a single trained therapist.~* The treatment techniques were anterior to posterior passive accessory glides of the distal end of the clavicle categorized from Grade III~* Grade III is used at a large amplitude from the middle of the joint ROM to the start of the constraint. Grade III will apply for stimulating a stretching to relieve joint stiffness in a shorter tissue"
214993195|NCT06150547|DIAGNOSTIC_TEST|Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.
214497833|NCT06763679|OTHER|traditional physical therapy|"Spencer technique:~* The patient was resting on their side, with the affected shoulder raised.~* In 7 separate movements, the therapist used the proximal hand to stabilize the shoulder girdle, while the distal hand applied force to the restrictive barrier of the shoulder.~* Shoulder extension, circumduction with compression, shoulder flexion, circumduction with distraction, abduction, adduction with internal rotation, and glenohumeral pump were the exercises performed.~* The patients were advised to employ their muscle energy technique against the small resistance provided by the therapist for 3-5 seconds throughout each movement.~* Over the course 5 days a week, the exercise was repeated 3-5 times per session, with rest breaks."
214497834|NCT06809374|DRUG|gemcitabine|neoadjuvant therapy for resectable pancreatic cancer using gemcitabine +S1 or gemcitabine + nab-Paxitaxel
214993196|NCT03864432|DRUG|Gemigliptin 25mg|Gemigliptin 50mg 1/2T
214993197|NCT03864432|DRUG|Gemigliptin 50mg|Gemigliptin 50mg 1T
214993198|NCT03864432|DRUG|Gemigliptin 100mg|Gemigliptin 50mg 2T
214993199|NCT03864432|DRUG|Gemiglptin 50mg multiple dose|Gemigliptin 50mg 1T \* 10days
214993200|NCT01038765|BEHAVIORAL|Mindfulness Based Cognitive Therapy|8-weeks group based intervention of mindfulness and cognitive behavioural techniques
214993201|NCT00107588|BEHAVIORAL|Reinforcement for homework completion|Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
215091937|NCT03112304|OTHER|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
215091938|NCT01365624|DRUG|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
215091939|NCT02345096|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae|
215091940|NCT02345096|DIETARY_SUPPLEMENT|Placebo|
215091941|NCT00897624|GENETIC|gene expression analysis|
215091942|NCT00897624|GENETIC|reverse transcriptase-polymerase chain reaction|
214687283|NCT06556056|OTHER|Minoxidil Hair Serum (5%)|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Frequency: Daily Night Application Rout of administration: Topical"
214993202|NCT00107588|BEHAVIORAL|Reinforcement for Abstinence|Provides contingent reinforcement for submitting marijuana-free urine specimen
215091943|NCT00897624|OTHER|laboratory biomarker analysis|
215091944|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term \[ST\], 42 months long term \[LT\])
214497835|NCT06254872|BEHAVIORAL|Peer Mentors|Peer mentors provide daily guidance and encouragement to mentees via smartphone app based on training.
214993203|NCT00107588|BEHAVIORAL|Case Management|Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
214993204|NCT03931122|DEVICE|Ear Size Based Method (Ambu® AuraOnce™ Laryngeal Mask Airway)|"The Laryngeal Mask Airway (LMA) is one of the devices used to maintain airway during general anesthesia. Its appropriate size is selected according to patients body weight as recommended by the manufacturer.~However its appropriate size can also be selected via several other methods and one of them is patients external ear size. In this study the investigators will compare external ear size based method for LMA selection with the standard weight based method for LMA size selection.~Vertical Ear length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal Ear length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W)~LMA Size LMA Cuff Length (cm) corresponding to vertical ear length.~LMA Cuff Width (cm) corresponding to horizontal ear width."
214993205|NCT02107898|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
214993206|NCT02107898|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
214379829|NCT06565104|BEHAVIORAL|Physical Activity Sessions|The two physical activity sessions provide an overview of the physical activity guidelines and include 30-60 minutes of exercise and a healthy living community resource mapping exercise. These sessions also address achieving and maintaining a healthy body weight.
214379830|NCT05128149|OTHER|no intervention|no intervention
214379831|NCT05055856|DIAGNOSTIC_TEST|urine sample|Each participant will give a urine sample for diagnose of asymptomatic bacteriuria
214379832|NCT05055856|DIAGNOSTIC_TEST|Blood and urine sample|Each participant will give a urine and blood sample for diagnose of SIADH
214379833|NCT03007654|DEVICE|Mediclore|apply medical device fully around intrauterine surgery area
214379834|NCT03007654|DEVICE|Adept|apply medical device fully around intrauterine surgery area
214993207|NCT02107898|DRUG|Lipid-Modifying Therapy (LMT)|Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
214993208|NCT03868800|OTHER|SDM-DC|The SDM-DC intervention is designed for patients with kidney failure who must make a decision regarding type of dialysis: haemodialysis or peritoneal dialysis. SDM-DC consists of patient and his or her relative(s) being given a patient decision aid called 'Dialysis choice' and booked for meetings with a dialysis coordinator. There were optional videos describing other patients' experiences making this decision. The dialysis coordinators were trained in the why, what and how in relation to SDM-DC and to deliver the intervention by tailoring to patients' needs and using three different communication skills: mirroring, active listening and value clarification.
214993209|NCT00855608|DRUG|adalimumab|intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
214993210|NCT06114862|BEHAVIORAL|Stigma-reduction intervention|"Participants will be presented with a list of common reasons why people report not wanting to tell other people about their mental health concerns, drawing from research in this area. Participants will be asked to click on any reason that resonates with them or about which they are interested in learning more. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns. For example, if a participant replies that they wouldn't reach out to peers because others don't understand what I'm going through, we might present context showing that many of their peers have had similar challenges with mental health and have found peer support helpful. Participants will be able to click on as many reasons on this list that they would like to."
214379835|NCT06626152|DRUG|Apo-levocarb|As above.
214497836|NCT05359133|DRUG|Tetrodotoxin|TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
214993211|NCT03329989|BIOLOGICAL|Collagenase Clostridium Histolyticum|During 3 treatment visits 12 injections will be given per treatment area
214993212|NCT02569983|OTHER|Observational cohort|No intervention - observational study
214993213|NCT06433726|DRUG|BY101921 tablets|An oral PARP7 Inhibitor
214993214|NCT02011399|PROCEDURE|Brain Computer Interface for Mu Rhythm|"Device: Brain Computer Interface Subjects will wear an EEG (electrode) cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate a computer. Subjects will be asked to participate in 4-20 sessions.~Arms: Brain Computer Interface Keyboard"
214993215|NCT02708056|DRUG|Sugammadex|
215091945|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
214497837|NCT05359133|DRUG|Placebo|"Placebo for injection is a sterile 0.9% sodium chloride injection or normal saline for injection. To ensure blinding, subjects receiving placebo will receive the same volume (1.0 mL) for injection to match the volume used for the cohorts assigned to receive active trial drug.~Route and frequency: 1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days in each treatment Cycle."
214497838|NCT01713660|DEVICE|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
214993216|NCT04272515|OTHER|blood sampling|collection of blood sample for preparation of DNA
215091946|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
214993217|NCT04272515|OTHER|skin biopsy sampling|preparation of primary cultures of dermal fibroblasts from skin biopsy sample
214993218|NCT04272515|OTHER|explanted liver of BA patients sampling|cryoconservation of liver tissue for molecular analyses
214993219|NCT00002818|DRUG|cytarabine|
215091947|NCT00121641|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
215091948|NCT00121641|DRUG|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
215091949|NCT00121641|DRUG|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
215091950|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
214379836|NCT00186498|DRUG|memantine|Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT
214379837|NCT00186498|DRUG|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
214379838|NCT06899893|DEVICE|iTBS|Sixty patients experiencing post-stroke negative emotions were recruited and categorized into groups based on their conditions. The group with post-stroke balance dysfunction underwent intermittent theta burst stimulation (iTBS) of the cerebellum, while the group with post-stroke cognitive dysfunction received iTBS stimulation of the left dorsolateral prefrontal cortex (DLPFC), and the group with post-stroke motor dysfunction underwent iTBS stimulation of the primary motor cortex (M1).The TMS stimulation protocol consisted of 20-minute sessions, five times a week, for a total of ten sessions, utilizing a figure-of-eight coil (model B9076, coil diameter 92 mm, manufactured by Yiruide Company in Wuhan, China, transcranial magnetic therapy device model NS5000). The stimulation intensity was set at 80% of the active motor threshold, with the coil positioned tangentially to the scalp and the handle oriented upwards.
214993220|NCT00002818|DRUG|deoxycytidine|
214993221|NCT00620542|DRUG|Rosuvastatin|capsule, oral, once daily
214993222|NCT00620542|DRUG|Atorvastatin|capsule, oral, one daily
215091951|NCT00121641|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
215091952|NCT01792518|DRUG|Placebo|
214379839|NCT06899477|DRUG|mFOLFOXIRI|Up to 6 cycles, every 2 weeks, mFOLFOXIRI: Oxaliplatin 85 mg/m2 2 h day 1, Irinotecan 150 mg/m2 60-90 min day 1, Folinic acid 400 mg/m2 \~1 h day 1, followed by 5-FU 2400 mg/m2 46 h
214993223|NCT01582347|DRUG|RBP-6300|"Participants randomized to the RBP-6300 treatment arm take either 10, 20 or 30 mg/day RBP-6300 tablets during the Transfer Period (study days 1-7).~Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate."
214379840|NCT06899477|DRUG|mFOLFOX-6|Up to 6 cycles, every 2 weeks, mFOLFOX-6: Oxaliplatin 85 mg/m2 2 h day 1, Folinic acid 400 mg/m2 \~1 h day 1, (optional: 5-FU 400 mg/m2 bolus), followed by 5-FU 2400 mg/m2 46 h.
214379841|NCT06899477|DRUG|CAPOX|Up to 4 cycles, every 3 weeks, CAPOX: Oxaliplatin 130 mg/m2 3 h day 1, Capecitabine 1000 mg/m2 ORALLY taken twice daily d1-d14
214379842|NCT06898983|DRUG|Romiplostim N01|Romiplostim N01 will be administered via subcutaneous injection once weekly when patients develop Grade 3 thrombocytopenia (platelet count \< 50×10⁹/L) following leukemia treatment. The recommended initial dose is 5 µg/kg, with a maximum single dose not exceeding 250 µg. Treatment may continue for up to 8 doses.
214379843|NCT06901128|BEHAVIORAL|cognitive therapy|The CT-SAD-A manual developed by Clark and Leigh
214379844|NCT01147289|DRUG|Dextralgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
214379845|NCT01147289|DRUG|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
214993224|NCT01582347|DRUG|Subutex®/Suboxone®|"Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone."
214993225|NCT01582347|DRUG|Placebo for RBP-6300|"Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period."
214993226|NCT01582347|DRUG|Placebo for Subutex®/Suboxone®|Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
214993227|NCT02208440|PROCEDURE|Best Repair of torn Rotator Cuff|
214993228|NCT02208440|DEVICE|InSpace™ system|
214993229|NCT01426126|DRUG|Genexol PM|Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
214379846|NCT06846554|DRUG|APL-9796|3 Cohorts are planned in Part A.
214379847|NCT06846554|DRUG|APL-9796|The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).
214379848|NCT05145413|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
214379849|NCT05145413|DRUG|Placebo|Placebo Capsules
214993230|NCT03520530|DEVICE|Mouth Guard|Patient will wear mouth guard while pushing in the second stage of labor
214993231|NCT00525304|BEHAVIORAL|Self-management program for chronic illness|Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
215091953|NCT01792518|DRUG|Linagliptin 5mg|
215091954|NCT05648682|OTHER|Salin|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use. SF solution was obtained from the medical company as 500 ml separately for each patient.
215091955|NCT05648682|OTHER|Sodium bicarbonate|Patients were told that they should gargle using approximately two tablespoons of the solution given for each use. The 500 ml distilled water bottle to be used for the SB solution was obtained from the medical company, separately for each patient.
215091956|NCT05648682|OTHER|Thyme honey|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use.
214379850|NCT06924983|PROCEDURE|Simple neuroendoscopic hematoma evacuation|For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, only simple neuroendoscopic evacuation of hematoma will be performed
214379851|NCT06924983|COMBINATION_PRODUCT|Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate|For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, they will be treated with the combination of neuroendoscopic hematoma evacuation and sodium methylprednisolone succinate. Administer sodium methylprednisolone succinate for injection by intravenous injection 6 hours after the onset of the disease. Specific administration: Intravenous injection at a dosage of 2 mg/kg, once daily, for three consecutive days.
214379852|NCT06921304|BEHAVIORAL|Intensive Lifestyle Intervention|ILI combines a low-calorie dietary approach with improved lifestyle and physical activity, in addition to usual medical care. Behavioral support for lifestyle intervention will also be provided.
214379853|NCT06925191|DIAGNOSTIC_TEST|Group A (Experimental): 29 affected ankles of both genders diagnosed with Chronic ankle instability (CAI) who met the inclusion criteria. Group B (Control): 29 matched non-affected with CAI|"1-90-90Active knee extension test 2.Core muscles endurance tests(a. The static endurance tests b. The dynamic endurance tests)~Time Frame: 1 session"
214379854|NCT06926556|DEVICE|Defocus microlenses|Different microlenses array (H.M.E.C，High Precision Micro Encircle and H.A.L.T, highly aspheric lenslet technology) for controlling myopia progression in children and adolescents.
214379855|NCT00211978|DRUG|calcium acetate|667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
215091957|NCT05648682|OTHER|Control|The patients continued to use the antifungal solution containing the active ingredient nystatin, which was prescribed routinely in the clinical procedure, 3 times a day.
215091958|NCT04229836|DRUG|Tildrakizumab 100 mg Solution for Injection|Participants will be treated with tildrakizumab 100 mg.
215091959|NCT00247455|DRUG|Low fibre breakfast cereal (puffed rice/cornflakes)|
214379856|NCT00211978|DRUG|placebo|gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
214379857|NCT05059912|BIOLOGICAL|Humanized CD7 CAR-T cells|Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma
214379858|NCT05312437|OTHER|Interruptive Alert, CDS|"Experimental: CDS Intervention Adult patients in the highest predicted risk tier (\>=2% predicted risk) at the time visit registration (aka check-in).~The Intervention would then be described as:~Physicians review a Best Practice Advisory describing the patient's risk and choose from the following options:~1. Document face-to-face suicide risk screening with the Columbia Suicide Severity Rating Scale (CDS complete once the CSSRS is complete)~2. Agree to screen using an alternative method chosen at the clinician's discretion (CDS complete)~3. Disagree with alert and provide a rationale for disagreement (CDS complete)~4. Indicate suicide risk face-to-face screening has already occurred (CDS complete)~5. Dismiss the alert. The alert will be available in Epic Storyboard persistently until acted on further. The Storyboard functionality after dismissal is identical to the Passive Prompt, CDS intervention (below)"
214379859|NCT05312437|OTHER|Passive Prompt, CDS|"Adult patients in the highest predicted risk tier (\>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm."
214993232|NCT01401166|DRUG|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
214993233|NCT01401166|DRUG|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
214993234|NCT01401166|DEVICE|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
214993235|NCT01401166|DEVICE|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 mL.
214993236|NCT02353663|OTHER|Echocardiography|Echocardiography examination
214993237|NCT04629833|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
214993238|NCT04629833|BIOLOGICAL|BAT|BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
214993239|NCT03901300|BEHAVIORAL|Fundamental Motor Skills App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.
214993240|NCT03901300|BEHAVIORAL|Unstructured Physical Activity App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
215091960|NCT00247455|DRUG|High fibre cereal (All Bran/Bran Flakes)|
214993241|NCT01283386|DRUG|Chlorambucil|10 mg/m\^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
215091961|NCT04469348|DIAGNOSTIC_TEST|nasal swab|nasal swab will be performed to analysis biological markers at every visit.
215091962|NCT04808193|OTHER|Survey|Participants will fill in the survey
215091963|NCT05612360|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
215091964|NCT03759470|DIAGNOSTIC_TEST|CSF examination|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperature. Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with \~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit."
214993242|NCT01283386|DRUG|Cyclophosphamide|150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
214993243|NCT01283386|DRUG|Fludarabine|20 mg/m\^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
214993244|NCT01283386|DRUG|Rituximab|375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
214993245|NCT06361108|DRUG|YJ001 for Spray Use|Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)
214993246|NCT06361108|DRUG|Placebo of YJ001 for Spray Use|Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water
214993247|NCT02689778|DRUG|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
214993248|NCT02689778|DRUG|Placebo|Identical tablets without active substance
214993249|NCT02115152|DRUG|fluorouracil|
214379860|NCT01457040|DRUG|TBI+CY+VP-16|CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
214379861|NCT01457040|DRUG|FA+TBI+CY+VP-16|NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10\~-6d; AraC: 1g/m2/d, -10d\~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
214379862|NCT03972774|DIAGNOSTIC_TEST|PET Stress Test|Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management
214379863|NCT03972774|OTHER|Non-PET Medical Management|Appropriate medical management without cardiac PET stress-imaging
214993250|NCT02115152|DRUG|capecitabine|
214993251|NCT02115152|DRUG|cyclophosphamide|
214993252|NCT02115152|DRUG|Epirubicin|
214993253|NCT05568290|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
214993254|NCT05568290|OTHER|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
214993255|NCT03436719|DRUG|Oral antibiotic|Metronidazole - 500 mg and Erythromycin - 500 mg per os \*3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
214993256|NCT03436719|DRUG|Intravenous antibiotic|Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
214993257|NCT03436719|DRUG|Mechanical Bowel Preparation|Beginning of MBP at 4 p.m. in a day before surgery
214993258|NCT02210195|DRUG|aprepitant|125 mg daily for 8 weeks.
214379864|NCT04768933|DIETARY_SUPPLEMENT|Toddler Milk|At least three 130 mL servings daily of study formula are recommended for a total daily intake of 390 mL. Study participants will continue this feeding regimen Days 4 to 28 (approximately 4 weeks).
214993259|NCT02210195|DRUG|Placebo|Placebo daily for 8 weeks.
215091965|NCT06933706|DRUG|losartan 25 mg|Losartan is an angiotensin-II inhibitor that modulates the renin-angiotensin system by blocking the activation of angiotensin type 1 receptors, thus preventing binding with angiotensin-II and decreasing blood pressure. Losartan has a broader therapeutic potential for muscle healing and treatment for diseases ranging from rheumatoid arthritis, osteoarthritis, chronic kidney disease, Marfan syndrome, and fatty liver. TGF-β plays an active role in fibrosis leading to the formation of adhesions and scar tissue. By limiting the formation of adhesions and scar tissue, losartan may reduce pain, myofibroblast activity, synovitis, fibrosis, and cartilage degeneration.
214687284|NCT06556056|OTHER|SesZen-Bio Serum + SesZen-Bio 350 mg extract|"Mode of Usage of serum: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Frequency: Daily Night Application Rout of administration: Topical Mode of Usage of Capsule: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Frequency: One time daily after meal Rout of administration: Oral"
214993260|NCT02210195|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
214993261|NCT01422109|DRUG|YH14659|YH14659 capsule by oral
214993262|NCT01422109|DRUG|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
214993263|NCT03853928|DIETARY_SUPPLEMENT|Probiotics|"Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII)."
214993264|NCT04320875|OTHER|Transcranial direct current stimulation|Anode electrode -C3/C4 (International 10-20 electroencephalogram system), contralateral side of the most affected knee) Cathode electrode- contralateral supraorbital area. 2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
214993265|NCT04320875|OTHER|Conventional Physiotherapy|"1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
214993266|NCT02388009|BIOLOGICAL|Flexyn2a|Intramuscular doses of 0.5 mL
214993267|NCT02388009|BIOLOGICAL|Placebo|Intramuscular doses of 0.5 mL
214993268|NCT02388009|BIOLOGICAL|Flexyn2a plus adjuvant|Intramuscular doses of 0.5 mL
214993269|NCT05770310|DRUG|JS015|Patient receives specific dose of JS015. The administration method of JS015 is intravenous infusion.
214993270|NCT06323382|PROCEDURE|Locoregional therapy|"TACE procedure The decision to utilize transarterial artery chemoembolization (TACE) was performed through the tumor-feeding artery. The embolization emulsion was a mixture of Epirubicin 30-60 mg, Lobaplatin 30-50 mg, and Lipiodol 10-30 ml, and it was infused into tumor-feeding arteries via a 2.7/2.8 Fr micro-catheter.~HAIC procedure Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2."
214993271|NCT06323382|DRUG|Bevacizumab|15mg/kg or 7.5mg/kg intravenously every 3 weeks
214993272|NCT06323382|DRUG|Atezolizumab|1200mg intravenously every 3 weeks
215091966|NCT06933706|OTHER|Placebo capsule|The placebo capsule will look identical to the active study drug, but will not have any active ingredient and will be filled with corn starch
215091967|NCT03010020|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
214379865|NCT04000659|DEVICE|Episealer Knee System|The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
214379866|NCT04000659|PROCEDURE|Microfracture|Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.
214379867|NCT04716413|DRUG|Dsuvia|Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
214379868|NCT01342185|DEVICE|medical ozone therapy with tianyi|Medical ozone therapy with instrument made in China Patients in this arm will receive autohemotherapy. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
214993273|NCT06323382|DRUG|Tislelizumab|200mg intravenously every 3 weeks
214379869|NCT01342185|DEVICE|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
214379870|NCT01342185|DRUG|Diammonium glycyrrhizinate Capsules|Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
214993274|NCT06323382|DRUG|Toripalimab|220mg intravenously every 3 weeks
214993275|NCT06323382|DRUG|Sintilimab|200mg intravenously every 3 weeks
215091968|NCT03010020|BEHAVIORAL|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
215091969|NCT04705948|DRUG|Magnesium sulfate versus ketamine|Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
215091970|NCT03801746|DRUG|vadadustat|Oral dose 300 mg
215091971|NCT03801746|DRUG|Rifampin|IV Rifampin
215091972|NCT03801746|DRUG|Probenecid|Oral Probenecid
215091973|NCT03801746|DRUG|Cyclosporins|Oral Cyclosporine
215091974|NCT02235103|OTHER|Sperm Chromatin Dispersion Test|
215091975|NCT05167903|OTHER|Normal Diet|All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).
214993276|NCT06323382|DRUG|Camrelizumab|200mg intravenously every 3 weeks
214993277|NCT00689832|DRUG|Tacrolimus 0.03%|ointment
214993278|NCT00689832|DRUG|Fluticasone 0.005%|ointment
214993279|NCT03339362|PROCEDURE|Active Procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Active: 4 X-ray guided intra-articular lumbar facet-joint injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml bupivacaine + 20mg methylprednisolone per joint"
214993280|NCT03339362|PROCEDURE|Sham procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Sham: 4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 0.9% sodium chloride per joint."
214379871|NCT00345813|DIETARY_SUPPLEMENT|soy isoflavones|Given orally
214379872|NCT00345813|DIETARY_SUPPLEMENT|soy protein isolate|Given orally
214379873|NCT00345813|OTHER|placebo|Given orally
214379874|NCT06106815|OTHER|Rehabilitation exercises|The Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve upper extremity function in individuals with stroke. The GRASP program includes exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
214993281|NCT05884450|OTHER|Acupressure|Acupressure is an integrated method of applying physical pressure to acupuncture points on the body surface with hands, elbows or various tools. With good counseling, patients can apply this method, which is non-invasive, easy to apply and safe, on their own.
215091976|NCT05167903|BEHAVIORAL|Time-restricted eating|All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).
215091977|NCT04809155|BEHAVIORAL|Girl2Girl|The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
215091978|NCT01030614|DRUG|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
215091979|NCT01030614|DRUG|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
214993282|NCT05900427|DRUG|Liposomal bupivacaine|Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
214993283|NCT05900427|DRUG|Bupivacaine|Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
214993284|NCT00082316|DRUG|Capsaicin Dermal Patch|
214993285|NCT01359423|DRUG|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
214379875|NCT06106815|OTHER|Usual Care|Usual Care
214379876|NCT01163903|DRUG|pantoprazole sodium for injection|Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
214379877|NCT01163903|DRUG|doxorubicin hydrochloride injection|60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
214993286|NCT01359423|DRUG|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
214993287|NCT00432120|DRUG|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
214993288|NCT00494117|DEVICE|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
214993289|NCT06003036|DEVICE|sham stimulation|sham delivery of transcranial magnetic stimulation
214993290|NCT06003036|DEVICE|transcranial magnetic stimulation|accelerated intermittent theta burst stimulation
214993291|NCT03483103|BIOLOGICAL|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
214993292|NCT02695459|DRUG|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
214993293|NCT00435643|PROCEDURE|nasal continuous positive airway pressure|After an average interval of three months, 10 patients with severe OSAS (AHI of more than 30 events per hour of sleep) treated with a mean nCPAP pressure of 11.2 ± 0.7 cm of H2O were reassessed and all mentioned measurements above were repeated
214379878|NCT00976703|OTHER|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
214379879|NCT00976703|OTHER|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
214993294|NCT05690243|BEHAVIORAL|Group psychotherapy delivered via video telehealth|Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.
214993295|NCT05766748|DRUG|Azeliragon|Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
214993296|NCT00004855|DRUG|Lopinavir/Ritonavir|
214379880|NCT02349568|PROCEDURE|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
214379881|NCT02349568|PROCEDURE|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
215091980|NCT01171209|DRUG|Interferon-beta and human leukocyte Interferon-α|One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
215091981|NCT04468074|DEVICE|Virtual Reality Therapy for Chronic Pain|"1. A 1 1/2 PowerPoint-based education session on the science behind chronic pain and a basic overview of the VR therapy~2. Virtual Reality Therapy: a virtual reality therapy consisting of different psychological training exercises"
214379882|NCT04290065|OTHER|Manual therapy|The patient will be lying supine, relaxed. The physiotherapist, located at the patient's head, will cover the occipital bone with one hand while the palm of the hand will rest on the lambdoid suture, and the fingers will be introduced into the suboccipital space. The other hand, with a glove, will be inserted into the patient's oral cavity, resting respectively the index and middle fingers, each in an upper dental hemiarchy, on the chewing face of the tooth. An axial traction will be carried out until the three tension barriers of equal size between them are overcome, in an estimated time between 1.50 and 3 minutes. All manual therapy sessions will be performed by the same physiotherapist, following the same protocol and under the same conditions.
214379883|NCT05762614|OTHER|Dyspnea assessment|Dyspnea assessment, respiratory variability, Spirometry, Electromyography
214379884|NCT00847795|DRUG|Avotermin|Intradermal administration
214379885|NCT00847795|DRUG|Placebo|Placebo
214379886|NCT01556698|DRUG|NVN1000|
214379887|NCT01556698|DRUG|Vehicle|Placebo
214379888|NCT03260127|BEHAVIORAL|Computerized executive function training plus CPT (CEFT-CPT)|Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
214379889|NCT03260127|BEHAVIORAL|Word game training plus CPT (WT-CPT)|Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
214379890|NCT01713699|PROCEDURE|lumbar puncture|
214379891|NCT00369681|DRUG|Bleomycin|
214379892|NCT00369681|BIOLOGICAL|Rituximab|
214993297|NCT00004855|DRUG|Abacavir sulfate|
214993298|NCT00004855|DRUG|Nevirapine|
214993299|NCT00004855|DRUG|Lamivudine|
214993300|NCT00004855|DRUG|Stavudine|
214993301|NCT02189824|BIOLOGICAL|Partially HLA-matched unrelated donor cells|
214993302|NCT03406676|DRUG|Methylene Blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
214993303|NCT03186365|DRUG|Zepatier Oral Product|Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
214993304|NCT02908230|BEHAVIORAL|Enhanced Care|8-week (nutrition, physical activity, and mental health) summer curriculum/program
214993305|NCT02908230|BEHAVIORAL|Standard Care|8-week (nutrition and physical activity) summer curriculum/program
214993306|NCT02908230|BEHAVIORAL|Active Control|8-week (non-nutrition, physical activity or mental health) summer curriculum/program
214379893|NCT00369681|DRUG|Dacarbazine|
214379894|NCT00369681|DRUG|Doxorubicin|
214379895|NCT00369681|DRUG|Vinblastine|
214379896|NCT02317224|PROCEDURE|"3-Hole subxiphorid and subcostal approach"|"3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection"
214379897|NCT02317224|PROCEDURE|Trans sternal approach|Trans sternal approach anterior mediastinum tumor resection
214379898|NCT02317224|PROCEDURE|VATS approach|Video-assisted thoracoscope anterior mediastinum tumor resection
214379899|NCT00204269|DRUG|Testosterone Gel Wolff|
214379900|NCT06020664|DRUG|NOX-1416+SOC|NOX1416+SOC as provided in Arm/group description
214993307|NCT05355207|DRUG|TRL1068|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
214993308|NCT02664883|PROCEDURE|Computed Tomography|Correlative studies
214993309|NCT02664883|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
214993310|NCT02664883|OTHER|Laboratory Biomarker Analysis|Correlative studies
214993311|NCT02664883|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
214993312|NCT06627803|DRUG|Alcohol (Oral)|Participants will drink a beverage that will have alcohol or no alcohol. The amount of alcohol consumed will be similar to consuming around 3-4 drinks, with breath alcohol concentration peaking at or around the legal limit for driving (0.08%).
215091982|NCT00915148|OTHER|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
215091983|NCT03854539|OTHER|Transdermal Vagus Nerve Stimulation|intermittent transdermal stimulation of the aurical vagus
214379901|NCT06020664|OTHER|Placebo+SOC|Placebo+SOC as provided in Arm/group description
214993313|NCT04115059|DRUG|Dasatinib|Oral, daily, dosing per protocol, once a day for cycle
214993314|NCT03934801|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
214993315|NCT03934801|OTHER|Ranking Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
214993316|NCT03934801|OTHER|Ranking Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
214993317|NCT03934801|OTHER|Ranking Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
214993318|NCT01635179|PROCEDURE|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
214379902|NCT01022086|PROCEDURE|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
214379903|NCT01022086|BIOLOGICAL|Biomarker Testing|"In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.~Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay."
214379904|NCT00888758|DEVICE|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
214379905|NCT00888758|DEVICE|everolimus|200 patients with STEMI will be treated with PROMUS DES.
214379906|NCT03815084|DRUG|pd-1 and DC-NK cells|total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
214379907|NCT04740203|DRUG|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
214993319|NCT06571045|DRUG|Ranibizumab|Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
214993320|NCT06571045|DRUG|EYE103|EYE103 is a humanized antibody formulated for intravitreal administration
214993321|NCT06420232|DEVICE|weighted blanket|Blanket weighted with 10% or less of body weight applied to child prior to meals for duration no more than 15 minutes
214993322|NCT06210685|DEVICE|Automatic Continuous Effusion Shunt implantation|The catheter pump chamber is placed with part of the chamber between adjacent ribs and part of the chamber under the skin and external to the ribs. The pump chamber is used to transfer pleural fluid into the peritoneal cavity.
214993323|NCT01979900|DRUG|Vaccae|One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
214993324|NCT01979900|DRUG|placebo|One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
214993325|NCT05971589|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
214993326|NCT03881371|DRUG|Safinamide|At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.
214993327|NCT03881371|OTHER|Placebo|At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication
214993328|NCT00933933|DEVICE|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
214993329|NCT00933933|DEVICE|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
214993330|NCT06003764|OTHER|Pulsed electromagnetic field|low-frequency PEMFT (15 Hz, 50% intensity output for 5 s/min for 20 minutes)
214993331|NCT06003764|OTHER|traditional skin care|traditional skin care( the patients received the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing was used. Additionally, the patient was advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing
214993332|NCT04758338|OTHER|VUMC telehealth services|Participants will access the CTS link (sent to them via email), which will connect them directly to a videoconference and enable them to see and hear the facilitators and other patients in the group.
215091984|NCT00882739|DRUG|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
215091985|NCT00882739|DRUG|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
215091986|NCT00882739|DRUG|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
214687285|NCT05319535|OTHER|Implementation Strategy: Foundational REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Caregivers FIRST for context and provides tools for ongoing Caregivers FIRST evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully incorporate Caregivers FIRST into routine practice.
214379908|NCT05772234|DRUG|Lactated ringers solution|Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
214379909|NCT05772234|DRUG|normal saline|Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
214379910|NCT00694382|DRUG|Semuloparin sodium|"0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
214379911|NCT00694382|DRUG|Placebo (for semuloparin)|"0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
214379912|NCT05158478|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
214993333|NCT04758338|OTHER|Interview|25-30 participants will be interviewed
214379913|NCT05158478|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
214379914|NCT01420432|BIOLOGICAL|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat repeated after three months
214379915|NCT06215001|PROCEDURE|Mechanical ventilation setting (Positive end-expiratory pressure) according to Expiratory Flow Limitation|Positive End expiratory pressure will be set according to the positive end-expiratory pressure able to revert the expiratory flow limitation.
214379916|NCT06215001|PROCEDURE|Mechanical ventilation setting (Positive end-expiratory pressure) not according to Expiratory Flow Limitation|Positive End expiratory pressure will be set not according to the positive end-expiratory pressure able to revert the expiratory flow limitation but to a standard level of 4 cmH2O.
214379917|NCT00351637|DRUG|Sublingual Methadone|
214379918|NCT04328402|DIAGNOSTIC_TEST|Polysomnography|Polysomnography, referred to as type I, allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables to document tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial and other muscular activity during sleep. The apnea and hypopnea index (AHI) is defined as the number of obstructive apneas and hypopneas per hour of sleep. Obstructive Sleep Apnea is defined in PSG when AHI≥1 and is divided into the following categories, according to severity: mild OSA (AHI 1-4.9), moderate OSA (AHI 5-9.9) and severe OSA (IAH≥10). Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or episodes are greater than or equal to 4 (high frequency SB, severe bruxism).
214379919|NCT01921881|OTHER|St John's wort|
214993334|NCT04758338|OTHER|Educational materials|Participants will be provided educational materials
214993335|NCT00141375|DRUG|Pregabalin|
214379920|NCT01396577|DRUG|perampanel|3 x 2 mg perampanel once per day
214379921|NCT01396577|DRUG|perampanel|6 mg perampanel once per day
214993336|NCT00782444|PROCEDURE|Computer navigated knee replacement|Total knee replacement performed with the use of navigation system from Brainlab with the Profix total knee implant.
214993337|NCT00782444|PROCEDURE|Conventional knee replacement|Conventional total knee replacement performed in a traditional way with the use of intramedullary rods, with the Profix implant.
214993338|NCT00134576|BEHAVIORAL|Computer Assisted Education for Behavioral Change|TLC-Detect will provide subjects in the intervention group with information about each diagnosed mental health disorder. TLC-Detect will then give the Treatment Module and will tell the intervention subjects that it will call back in one month for a follow-up or the next week if a subject is comorbid with other disorders.
214993339|NCT01592838|OTHER|Data collection|The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
214379922|NCT03134014|DIETARY_SUPPLEMENT|Breakfast|If randomized to a breakfast consuming group, participants will be given breakfasts to consume between 6:00-8:00 am.
214379923|NCT00276107|BIOLOGICAL|Prevenar|
214687286|NCT05319535|OTHER|Implementation Strategy: Enhanced REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators posit that higher intensity strategies (defined as Enhanced REP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
214993340|NCT04732676|OTHER|Smartphone application|"Ecological Momentary Assessment (EMA)~: ambulatory assessment of behaviors/symptoms in real-time on smartphones"
215091987|NCT03875807|PROCEDURE|ACLR done at 0 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
214993341|NCT05740202|DRUG|SHR-7367|The study was divided into three phases, the dose escalation phase and the dose extension phase and therapeutic effect extension of SHR-7367 in subjects with advanced malignant tumors.
215091988|NCT03875807|PROCEDURE|ACLR done at 30 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
214379924|NCT01619332|DRUG|Placebo|Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
214379925|NCT01619332|DRUG|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
214379926|NCT01619332|DRUG|LEZ763|LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
214993342|NCT00963235|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
214993343|NCT00963235|PROCEDURE|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
214993344|NCT01260506|DRUG|VB-111|
214993345|NCT01260506|DRUG|Bevacizumab|Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
214993346|NCT06475001|DRUG|VER-01|"Herbal medicinal product, containing as active substance a soft extract of Cannabis sativa L., cannabis flos (Cannabis flower), adjusted to a content of 50 mg/g delta-9-tetrahydrocannabinol (THC).~VER-01 is adjusted to a concentration of 19 mg/mL THC by adding the excipient sesame oil."
214993347|NCT06475001|DRUG|Placebo|Comparator without active ingredient
214993348|NCT00594555|DRUG|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
215091989|NCT02605317|OTHER|WhatsApp|Consultations used WhatsApp Messenger
214687287|NCT06998550|OTHER|Patient Satisfaction Questionnaire|An online survey designed to assess patient experiences and satisfaction levels with pulmonary rehabilitation (PR) programs. The questionnaire covers aspects such as accessibility, communication, program structure, perceived outcomes, and overall satisfaction. It is administered via Google Forms and completed voluntarily by patients who have completed a PR program.
215091990|NCT05303688|DRUG|iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)|The primary predictor variable was preventive analgesia group. Patients were randomly divided in two groups. 50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey) were administrated 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15
215091991|NCT05303688|DRUG|Steril Salin (control)|30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15) and iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15).
214993349|NCT00594555|DRUG|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
214993350|NCT01056679|DRUG|Doxorubicine|50mg/m2 day 1 + 15
214379927|NCT03083535|PROCEDURE|Tooth Brushing|Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
214379928|NCT03083535|PROCEDURE|aloe vera Massaging|Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel
214379929|NCT03083535|PROCEDURE|SRP with aloe vera massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with aloe vera ge; shall be carried out by the patients/subjects
214993351|NCT01056679|DRUG|DTIC|375mg/m2 day 1 + 15
214993352|NCT01056679|DRUG|Lenalidomide|day 1 - 21
214993353|NCT01056679|DRUG|Vinblastine|6mg/m2 day 1 + 15
214993354|NCT01579864|DRUG|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
214993355|NCT01579864|DRUG|rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
214993356|NCT01136915|DRUG|Iopamidol 370|one time administration for PCI
214993357|NCT01136915|DRUG|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
214993358|NCT01699828|DRUG|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
214993359|NCT01699828|DRUG|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
214379930|NCT01407588|PROCEDURE|Magnetic navigation|Ablation with use of the magnetic navigation system
215091992|NCT01995955|PROCEDURE|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
215091993|NCT00002460|DRUG|goserelin acetate|
214379931|NCT01407588|PROCEDURE|Ablation performed with manual navigation|Atrial fibrillation ablation performed with manual navigation
214379932|NCT03913208|PROCEDURE|Priority to freeze|Priority for cryopreservation and later on embryo transfer in artificial cycle with endometrium preparation by the exogenous administration of estrogen-progesterone.
214993360|NCT05486468|DRUG|Yutiq 0.18 MG Drug Implant|YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
214993361|NCT05486468|OTHER|Sham Injection|Sham injection
214379933|NCT03913208|PROCEDURE|Fresh embryo transfer|usual strategy of giving the priority for fresh embryo transfer
214379934|NCT04108481|DRUG|Durvalumab|Immunotherapy
214379935|NCT04108481|RADIATION|Yttrium-90 RadioEmbolization|Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
214379936|NCT02691689|OTHER|Genetic testing|Genetic testing by DNA sequencing on blood samples after DNA extraction
214687288|NCT06998550|OTHER|Institutional Survey on PR Program Structure and Team Composition|A structured online questionnaire completed by the designated PR program coordinator or team member. It includes questions on organizational features of the PR program, such as team composition, session frequency, assessment tools, referral and admission
214993362|NCT02792127|BEHAVIORAL|Online Program for Social Anxiety|This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
214993363|NCT06378970|OTHER|Audio Book Application|The Audio Book Application Preference Form asked about book preferences other than horror and thriller genres. The selected audiobook was played with headphones via tablet/smartphone. Separate headphones were used for each patient. Patient Follow-up Form and Facial Anxiety Scale evaluations; the initial measurement (M0) was evaluated before the intervention, the first measurement (M1) at the 15th minute of the intervention, the second measurement (M2) at the 30th minute of the intervention, and the third measurement (M3) 30 minutes after the end of the intervention. Care was taken to ensure that there was no deterioration in the comfort of individuals due to the intervention. In the selection of audio books, language fluency, spelling rules and accessibility were taken into consideration and audiobook platforms to which the researchers were members were used.
214993364|NCT05646992|PROCEDURE|Uterine Allotransplantation|Temporary allogenic uterus transplantation from a living donor with the goal of achieving pregnancy and delivering viable baby.
215091994|NCT00002460|DRUG|tamoxifen citrate|
214379937|NCT04923477|OTHER|Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome|Therapeutic exercise of resistance and mobility via a combination of HEP and in-person/virtual visits 5 days/ wk. Exercise program instruction in person, then 2-3 visits /wk x 8 wks (in-person or virtual) with a trained professional for the progression of exercises. Adherence to exercise will be measured daily via text and recorded in a mobile app. Patients will start with Phase 1 exercises of shoulder external \& internal rotation, scapular stabilization, and active shoulder elevation; resistance levels of elastic bands will be assigned and progressed based on patient-reported shoulder pain and perceived difficulty. Patients will be advanced to Phase 2 when they complete Phase 1. The exercise protocol will be delivered with the methods previously published by Tate, 2010 and Mintken 2016.
214379938|NCT05770830|DEVICE|Esophageal temperature|Temperature data measured by esophageal temperature probe (disposable probe, Ace-medical, Seoul, Korea)
214379939|NCT05770830|DEVICE|Skin core temperature|Temperature data measured by skin core temperature device measured by 3M™ Bair Hugger™
214379940|NCT06329193|OTHER|Mid-Season Camp Period Loading|The daily gym included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), crunches, sit-ups, reverse sit-ups, prone bridge, side bridge, bench press, mini squat (with body weight and/or ancillary equipment), lunge (with body weight and/or ancillary equipment), leg extension, leg curl, leg press, calf raises (with body weight and/or ancillary equipment), and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities). The field-based exercises included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), dynamic balance (with different balance trainer such as Both Sides Utilized \[BOSU\], trampoline), tactical training, passing, dribbling, and shooting practice, agility and speed practice, and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities)
214379941|NCT01494870|PROCEDURE|PCI|urgent PCI on admission
214379942|NCT00433615|DRUG|R744|100μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
214379943|NCT00433615|DRUG|R744|150μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
214379944|NCT02354716|DEVICE|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions \& function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- \& post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, \& what characteristics determine \& predict refractory \& recurrent strictures.
214379945|NCT00242801|DRUG|Gefitinib|
214497841|NCT06320262|PROCEDURE|Wet cupping therapy (WCT)|"Type of cupping: Triple-stage wet cupping therapy (Hijama) will be used; sucking, scarification, sucking.~Cupping points will include one cup on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra (Alkahil area); two points in the inter-scapular region 3cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra, two points at inferior angle of the scapula (3cm lateral to lower border of the spinous process of the 7th thoracic vertebra, 2 points at lumbar regions, in addition to the most painful areas.~After the procedure: Areas of cupping will be covered using sterile gauze. All used tools and materials will be collected in red bags to ensure proper waste disposal. Sharp objects will be disposed of in the sharps disposal box. Telephone follow-up with all patients 48 hours after cupping will be done."
214497842|NCT06205550|DRUG|Flecainide|Flecainide monotherapy
214497843|NCT06205550|DRUG|Flecainide + beta-blocker|Flecainide + beta-blocker
214497844|NCT06749171|PROCEDURE|coronary artery bypass grafting|ONCAB (on-pump coronary artery bypass grafting), OPCAB (off-pump coronary artery bypass grafting), NTA (no-touch aorta technique), MICSCAB (minimally invasive multiple coronary artery bypass grafting)
214497845|NCT06832124|PROCEDURE|Sham alpha-tACS|A sinusoidal ± 2mA current adjusted to the individual alpha peak frequency with in-phase stimulation at parieto-occipital brain areas and anti-phase stimulation in frontal brain areas. The stimulation will involve a 10s ramp-up, followed by an immediate 10s ramp-down (no stimulation afterwards).
214993365|NCT05646992|DRUG|Tacrolimus|Used as daily immunosuppression. Started at 3mg twice daily (PO) on post-operative Day 1, adjusted to achieve serum trough concentrations of 8-10ng/ml.
214993366|NCT05646992|DRUG|Imuran|Used as daily immunosuppresion. 100 mg for total body weight less than 75 kg and 150 mg for total body weight greater than or equal to 75 mgs
214993367|NCT04391907|PROCEDURE|IPL|Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.
214993368|NCT06449014|DEVICE|Mini-implants assisted maxillary expansion|The intervention involved the placement of orthodontic mini-screws in the patient's palate, varying in diameter from 2 to 2.3 mm and in length from 11 to 15 mm. After mini-screw insertion, another intraoral scan was taken for the fabrication of the appliance. Approximately three weeks later, the expander was placed in the patient's palate, and maxillary expansion was initiated immediately afterward according to the chosen protocol.
215091995|NCT00002460|PROCEDURE|ablative endocrine surgery|
215091996|NCT00002460|PROCEDURE|oophorectomy|
215091997|NCT01929538|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
215091998|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 12mm in diameter|
215091999|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 10mm in diameter|
215092000|NCT01519739|DEVICE|MediGuide™|MediGuide™ system will be used to guide CRT implants
215092001|NCT00249613|BEHAVIORAL|Women-Only|Gender-responsive treatment for women only
215092002|NCT01496911|DRUG|Levocetirizine|a single oral dose of 5 mg
215092003|NCT01496911|DRUG|Hydroxyzine|a single oral dose of 50 mg
215092004|NCT01496911|DRUG|Placebo|a single oral dose
215092005|NCT02378207|BIOLOGICAL|H4:IC31|H4 contains Mtb antigens Ag85B and TB10.4
215092006|NCT02378207|BIOLOGICAL|H56:IC31|H56 contains Mtb antigens ESAT-6, and Rv2660c
215092007|NCT02378207|BIOLOGICAL|BCG|
215092008|NCT02378207|BIOLOGICAL|Control Sodium Chloride 0.9%|
214379946|NCT04092179|DRUG|Enasidenib|Enasidenib is a drug that blocks a protein called isocitrate dehydrogenase (IDH) 2 from working. The family of IDH proteins have been indicated in the development of leukemia. By blocking IDH2, enasidenib may help stop cancer cells from growing. It is believed that the drug may be more useful in patients with a change (mutation) in their IDH 2 protein. The IDH2 gene (substances in the body that contain instructions for the proper development and function of cells) makes IDH2 proteins. As such, only patients with IDH 2 mutated gene are eligible for this study. Enasidenib is currently approved for the treatment of IDH2 mutated AML.
214379947|NCT04092179|DRUG|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells. Venetoclax is currently approved for the treatment of type of blood cancer called chronic lymphocytic leukemia (CLL) who have received prior treatment.
214993369|NCT04521140|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
214993370|NCT04521140|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection
214993371|NCT04574713|DRUG|Candesartan Oral Tablet 8 mg|1 over-encapsulated tablet once daily, containing candesartan 8 mg, for 12 weeks (84 days).
214993372|NCT04574713|DRUG|Candesartan Oral Tablet 16 mg|1 over-encapsulated tablet once daily, containing candesartan 16 mg, for 12 weeks (84 days).
214993373|NCT04574713|DRUG|Placebo oral tablet|1 over-encapsulated tablet once daily, containing placebo, for 12 weeks (84 days).
214993374|NCT03868956|DIAGNOSTIC_TEST|Colour doppler ultrasound with or without D-dimer test|"* Positive CDUS: anticoagulant treatment~* Negative CDUS: no anticoagulant treatment~* Non diagnostic CDUS : reference to routine D-dimer test~  * Negative test : no anticoagulant treatment~ * Positive test : second CDUS 7 days (±2) after first one~    * No change in CDUS : no anticoagulant treatment~   * Change in CDUS : anticoagulant treatment"
215092009|NCT04963907|DEVICE|Active Alpha-Stim CES|Active Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
215092010|NCT04963907|DEVICE|Sham Alpha-Stim CES|Sham Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
215092011|NCT00357383|DRUG|Azithromycin (T1225)|
215092012|NCT06025812|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
214497846|NCT06832124|PROCEDURE|alpha-tACS|Active tACS with a sinusoidal ± 2mA current adjusted to the individual alpha peak frequency with a 10s ramp-up and 10s ramp-down after stimulation. In-phase stimulation will be applied to parieto-occipital brain areas and anti-phase stimulation will be applied to frontal brain areas
214497847|NCT06776770|DRUG|Adebrelimab|"Phase I: Cohort 1: Adebrelimab 10 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle; Cohort 2: Adebrelimab 1200 mg or 20 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle.~Phase II: Adebrelimab (RP2D, Q3W) + (XELOX regimen), with a 3-week (21-day) treatment cycle.~XELOX regimen：Oxaliplatin 130 mg/m2 iv.gtt d1，Capecitabine 1,000 mg/m2 p.o.b.i.d.d1\~14."
214993375|NCT01319370|DRUG|Minoxidil|1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
214993376|NCT01319370|DRUG|vehicle of 5% Minoxidil topical foam|1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
214993377|NCT02724579|DRUG|Cisplatin|Given IV
214993378|NCT02724579|DRUG|Cyclophosphamide|Given IV
214993379|NCT02724579|OTHER|Laboratory Biomarker Analysis|Correlative studies
214993380|NCT02724579|DRUG|Lomustine|Given PO
214993381|NCT02724579|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214993382|NCT02724579|RADIATION|Radiation Therapy|Undergo craniospinal radiation therapy
214993383|NCT02724579|DRUG|Vincristine|Given IV or via minibag
215092013|NCT06025812|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).
214379948|NCT00406471|DRUG|Ranibizumab (Lucentis)|500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
214993384|NCT02724579|DRUG|Vincristine Sulfate|Given IV or via minibag
214993385|NCT04287062|DRUG|Suvorexant|Dual orexin receptor antagonist
214993386|NCT04287062|DRUG|Placebos|Weight and color matched placebo
214993387|NCT06640920|BIOLOGICAL|Cohort A|Administered IV High dose
215092014|NCT01985763|DRUG|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
215092015|NCT01444586|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
215092016|NCT01184417|DRUG|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
215092017|NCT01184417|DRUG|placebo|100 m l saline
214993388|NCT06640920|BIOLOGICAL|Cohort B|Administered SC Low Dose
214993389|NCT06640920|BIOLOGICAL|Cohort C|Administered SC Mid Dose
214379949|NCT00791115|PROCEDURE|whole-mount sectioning of the prostate|A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
214379950|NCT06696040|DEVICE|Passive mobilization using a device|"The protocol consists of three moments: initial assessment, use of the device, and final assessment.~In the initial assessment, participants will be positioned supine on a stretcher, where the muscle tone of the lower limb(s) will be tested using the Modified Ashworth Scale. After the physical test with the Modified Ashworth Scale, the TUG test will be carried out, and, finally, gait assessment with the BAIOBIT Inertial Meter with Accelerometer and Gyroscope.~At the end of the initial assessment, the Autofisio500 device will be used. To do this, the participant will be positioned again and comfortably supine on the stretcher, and the previously tested lower limb will be attached to the device for movement, between the knee and ankle joints, for 30 minutes, at maximum speed (11 RPM).~For the final assessment, the Modified Ashowrth Scale, TUG and gait assessment with the Inertial Meter with Accelerometer and BAIOBIT Gyroscope will be applied again."
214379951|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
214379952|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
214379953|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
214379954|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
214379955|NCT02536001|DEVICE|One mesh Endofast reliant system|One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse
214379956|NCT02536001|DEVICE|two meshes Endofast reliant system|Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
214379957|NCT02998814|OTHER|acid-etch|acid-etch
214379958|NCT02998814|OTHER|self-etch adhesive|Self etch (7th generation ) bonding agent
214379959|NCT02998814|OTHER|etch-and-rinse adhesive|Total etch bonding agent (5th generation)
214687289|NCT04695847|DRUG|M1231|M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
214993390|NCT06640920|BIOLOGICAL|Cohort D|Administered SC High Dose
214993391|NCT06476379|PROCEDURE|Testicular sperm extraction (TESE)|Surgical procedure used to retrieve sperm directly from the testicles of men who have low sperm production or no sperm in their ejaculate
214993392|NCT06476379|OTHER|Ejaculate|Ejaculate processing for ICSI
215092018|NCT03912701|DIAGNOSTIC_TEST|Vitalpac early warning score (VIEWS)|The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.
215092019|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
215092020|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
214379960|NCT02998814|OTHER|self-etch adhesive after acid-etch|acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
214379961|NCT05621083|DIETARY_SUPPLEMENT|Omega- 3|In the fish oil supplement period, the participants will receive concentrated fish oil which is equal to in total 2.3 g EPA+DHA per day during 6 weeks.
214379962|NCT05621083|DIETARY_SUPPLEMENT|HOSO|In the HOSO period, the participants will receive similar amount of HOSO per day during 6 weeks.
214379963|NCT04143334|DIAGNOSTIC_TEST|Conventional survey|
214379964|NCT01435434|DEVICE|the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.|
214379965|NCT02415777|DRUG|Ursodeoxycholic acid, thiamine, riboflavin|
214379966|NCT01610154|DRUG|Sitagliptin|Sitagliptin 100 mg QD for 12 weeks
214379967|NCT04953338|OTHER|Exposure of mental health condtion of interest|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.
214379968|NCT03322826|PROCEDURE|systematic sampling of the lymph-node|Systematic Sampling of lymph nodes
214379969|NCT03322826|PROCEDURE|lymphadenectomy|Routine lymph nodes dissection in lung cancer
214687290|NCT04695847|DRUG|M1231|M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
214687291|NCT01201538|DRUG|Nilotinib|
214687292|NCT07003100|OTHER|Non-Interventional Study|Non-interventional study
214687293|NCT03760432|PROCEDURE|Laser Custom Corneal Collagen Cross-Linking|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for smoothing the anterior corneal surface and removing any present opacities. The surgeon uses the OCT data to plan treatment parameters while preserving at least 360 microns of residual corneal stroma using a phototherapeutic keratectomy procedure. After the laser procedure, adjunctive MMC or saline solution will be applied to the cornea in accordance with the group to which the treated eye is randomized. The CXL procedure is then performed following the FDA-approved CXL regimen by Avedro, Inc.
214993393|NCT06639217|OTHER|a comprehensive nursing care protocol|a comprehensive nursing care protocol provided for nurses who provide direct care for women with pelvic organ prolapse and urinary incontinence on their knowledge and practices as well as its impact on the women quality of life
214993394|NCT06952751|OTHER|Differential ultracentrifugation|Differential ultracentrifugation
214993395|NCT06952751|OTHER|OptiPrep™ density gradient ultracentrifugation|OptiPrep™ density gradient ultracentrifugation
214993396|NCT06952751|OTHER|Size-exclusion chromatography|Size-exclusion chromatography
215092021|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
215092022|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
215092023|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
215092024|NCT03554980|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush.
214379970|NCT03413254|OTHER|Routine follow-up|Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
214379971|NCT03413254|PROCEDURE|Second look DLS|Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
214379972|NCT03413254|PROCEDURE|Third look DLS|Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
214379973|NCT03623932|DRUG|immunosuppressor/TNFalpha|Standard Treatment : immunosuppressor/TNFalpha as in standard practice
214379974|NCT03623932|BEHAVIORAL|Hypnosis|8 hypnosis group sessions during 2 months
214379975|NCT03780127|DRUG|Fenfluramine Hydrochloride|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.
214993397|NCT06952751|OTHER|Combined techniques|Combined techniques
214993398|NCT03909477|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
214993399|NCT03909477|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
214993400|NCT03909477|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFTs)|Participants will have their lung function evaluated using PFTs
215092025|NCT03554980|DRUG|Sodium Fluoride varnish|NaF will be applied with a brush
215092026|NCT06508359|DRUG|Norepinephrine|Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
214379976|NCT05043701|DRUG|Personalized drug combination|A personalized drug combination will be prescribed to each patient based on the functional drug screen
214379977|NCT02949921|DEVICE|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
214379978|NCT02715817|OTHER|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.
214497848|NCT06748378|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery on gait.|66 stroke patients were randomly assigned to three groups (22 people each) with different therapies (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, and the Riablo device to measure gate parameters. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
214497849|NCT06748378|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery on gait parameters.|66 stroke patients were randomly assigned to three groups (22 people each) with different therapies (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, and the Riablo device to measure the gate parameters. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
214497850|NCT06747923|DRUG|SB17170|Taking SB17170 orally once a day
214497851|NCT06747923|DRUG|Placebo|Taking Placebo orally once a day
215092027|NCT06508359|DRUG|Phenylephrine|Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
215092028|NCT01943019|DRUG|Linagliptin|
215092029|NCT05737719|BEHAVIORAL|Rehabilitation before knee surgery (prehab)|Physiotherapy strategies for preparing the patient awaiting the surgical procedure
215092030|NCT05737719|BEHAVIORAL|Post-surgery rehabilitation|Physiotherapy strategies to manage post-surgery recovery
215092031|NCT00906958|DEVICE|Nexus Flow Generator|The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
215092032|NCT00906958|DEVICE|VPAP Flow Generator 25|Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
214993401|NCT03909477|DIAGNOSTIC_TEST|Six Minute Walk Test (6MWT)|Participants \>35 years of age will perform the six minute walk test as a measure of exercise capacity
214993402|NCT03909477|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants \<35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
214993403|NCT03909477|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
214993404|NCT03909477|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
214993405|NCT05810948|BIOLOGICAL|efgartigimod IV|Intravenous (IV) infusion of efgartigimod
214993406|NCT05810948|OTHER|Placebo|Intravenous (IV) infusion of placebo
214993407|NCT05472142|OTHER|UP FOR IT - practice facilitation|"Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The practice facilitation collaborative trains and supports clinical teams to use the Model for Improvement to make breakthrough improvements in diabetes care and DSMES utilization by recognizing barriers and changing clinical systems and care practices."
214993408|NCT05472142|OTHER|UP FOR IT - health information technology|Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
214379979|NCT02715817|OTHER|Conventional therapeutic exercises|It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.
214379980|NCT02715817|OTHER|Virtual Rehabilitation and Conventional Therapeutic Exercise|It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
214379981|NCT03075241|DRUG|Zolpidem|Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights
214379982|NCT03075241|DRUG|Zoplicone|Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights
214379983|NCT03075241|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
214379984|NCT06267443|PROCEDURE|Comparison of erector spina plane block, parasternal block plus local infiltration to the tube sides for postoperative analgesia|"Group 1: erector spina plane block: With USG guidance at the thoracal level of 4-5, with 20ml 2.5% bupivacaine ESPB will be performed. after surgery in the ICU pain score and atelectasia will be evaluated.~Group 2: With USG guidance parasternal block will be performed after intubation bilaterally with 10 ml 0.25% bupivacaine each side. at the end of the surgery infiltration of chest tube sides will be performed with 10 ml 2.5% bupivacain."
214379985|NCT00720408|DRUG|Prograf-XL|oral
214379986|NCT00720408|DRUG|Prograf|oral
214379987|NCT00720408|DRUG|MMF|oral
214379988|NCT02304250|DRUG|Dexamethasone|dexamethasone 1ml (5mg)
214379989|NCT02304250|DRUG|saline|saline 1ml
214379990|NCT05236621|DRUG|Pomalidomide|4 mg pomalidomide capsules administered orally
214379991|NCT05236621|DRUG|Dexamethasone|40 mg dexamethasone tablets administered orally
214379992|NCT02757482|OTHER|training|
214379993|NCT04108546|DEVICE|Electroacupuncture device|The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% \& low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.
214379994|NCT04108546|DRUG|Epidural analgesia|Epidural analgesia with lidocaine 2%, 1.5 ml, and Dexamethasone 8 mg
214379995|NCT06158763|BEHAVIORAL|Web-based CBT guided self-help Interventions|An existing CBT-based transdiagnostic self-help manual (Naeem et al., 2014) that has been used successfully in RCTs (Amin et al., 2020; Naeem et al., 2014) and has been used as an online intervention (http://khushiorkhatoon.com/) will be further adapted. The intervention consists of seven modules, including cognitive restructuring, problem-solving and behavioural activation.
214379996|NCT03570983|DRUG|Allopurinol|Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
214497852|NCT05162261|DEVICE|Tixel C|Tixel C by Novoxel®, Israel is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
214993409|NCT06415630|PROCEDURE|Type A aortic dissection surgery|Patients with type A aortic dissection undergone surgery.
214993410|NCT04518085|BEHAVIORAL|Medical hypnosis|Single session 20 minutes hypnosis session originally developed and tested by Montgomery et al. (2007) in a similar setting. Delivered by an experienced clinical psychologist.
214379997|NCT03570983|DRUG|Carmustine|Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
214379998|NCT03570983|DRUG|Etoposide|Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
214379999|NCT03570983|DRUG|Cytarabine|Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.
214497853|NCT05162261|DEVICE|LipiFlow|Thermal pulsation (LipiFlow) consists of the localized application of heat and therapeutic pressure on the four eyelids (upper and lower) with the aim of improving drainage of the Meibomian glands.
214993411|NCT04518085|BEHAVIORAL|Internet-based Acceptance and Commitment Therapy (iACT)|Access to an online platform developed to this study containing video clips and audio files with ACT consistent material
214993412|NCT04518085|BEHAVIORAL|Mindfulness session|Single session mindfulness session delivered by audio file
214993413|NCT04518085|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual as part of post-surical care
214993414|NCT05778539|PROCEDURE|Lateral retinacular release|During the implantation of a total knee arthroplasty a lateral retinacular release is performed in the intervention group
214993415|NCT05690828|BEHAVIORAL|Cognitive remediation|The cognitive remediation programme shall be run either in video workshops or face to face workshops and in home sessions via a web app. The programme will run for 4 months during which there will be 3 different evaluations. A first evaluation after randomisation, a second evaluation 4 months after inclusion (corresponding to the end of the programme), and a third evaluation 8 months after inclusion for the experimental group (4 months after the end of the programme). The face to face workshops will take 8 to 10 participants and will be led by a neuropsychologist.
214993416|NCT00332397|DEVICE|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
214993417|NCT00332397|DEVICE|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
214993418|NCT00332397|DEVICE|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
214993419|NCT05497128|DEVICE|Ultrahigh-speed cut rate 27-gauge system|The ultrahigh-speed cut rate 27-gauge system (27+®GA HYPERVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
214993420|NCT05497128|DEVICE|Standard cut rate 27-gauge system|The current standard cut rate 27-gauge vitrectomy system (27+®GA Advanced ULTRAVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
215092033|NCT02580513|BEHAVIORAL|Circadian Misalignment|
214380000|NCT03570983|DRUG|Melphalan|Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
214380001|NCT05340257|DRUG|Augmentin ES|Amoxicillin and clavulanic acid in fixed dose combination will be administered
214380002|NCT05516225|DRUG|PBCLN-003|Human Milk Oligosaccharide Concentrate
214380003|NCT04508179|DRUG|7HP349 Single Ascending Dose|Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
214993421|NCT05398588|OTHER|Cyriax Deep Friction Massage|Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week Cyriax DFM on targeted muscles (Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis) 3 minutes each muscle (15 mins in total ) x 1 set , 3 days / week
214993422|NCT05398588|OTHER|Spencer Muscle energy technique|"Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week The Spencer technique will be applied in Abduction, External rotation and Internal rotation for targeting muscles Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis.~10 repetitions x 3set , 3 days/week."
214993423|NCT03586193|PROCEDURE|Pars plana vitrectomy|pars plana vitrectomy without ICG staining and ILM peeling
214380004|NCT04508179|DRUG|7HP349 Multiple Ascending Dose|Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)
214497854|NCT05885763|DRUG|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
214497855|NCT06446284|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
214497856|NCT06446284|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
214380005|NCT04508179|DRUG|Placebo Single Ascending Dose|Part A: Placebo Capsules, Single Ascending Dose (SAD)
214497857|NCT02215928|GENETIC|mutation analysis|Correlative studies
214497858|NCT02215928|OTHER|cytology specimen collection procedure|Correlative studies
214497859|NCT02215928|OTHER|laboratory biomarker analysis|Correlative studies
214497860|NCT05578976|DRUG|Epcoritamab|Subcutaneous Injection (SC)
214497861|NCT05578976|DRUG|Cyclophosphamide|Intravenous (IV) Injection
214380006|NCT04508179|DRUG|Placebo Multiple Ascending Dose|Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
214380007|NCT04508179|DRUG|7HP349 Food Effect|Part C: 7HP349 Capsules, Food Effect
214380008|NCT03542526|DEVICE|electrogradiogram|12 lead ecg ambulatory blood prussre
214380009|NCT03542526|DEVICE|ambulatory blood prussre|ambulatory blood pressure to measure blood pressure
214380010|NCT03585296|DRUG|ATI-502|Topical Solution
214380011|NCT03654781|DRUG|Triple therapy|triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)
214497862|NCT05578976|DRUG|Rituximab|IV Infusion
214497863|NCT05578976|DRUG|Vincristine|IV Infusion
214497864|NCT05578976|DRUG|Doxorubicin|IV Infusion
214497865|NCT05578976|DRUG|Prednisone|Oral; Tablet
214497866|NCT06778694|OTHER|Motor control exercises|Bridging Dead bug Plank Pelvic tilts Squatting and lunges
214497867|NCT06778694|OTHER|Isolated strengthening lumbar exercises|Child pose Mckenzie Lat pull down Russian twist
214497868|NCT06800781|PROCEDURE|Prolonged treatment with posterior pericardial chest tube plus standard care|Prolonged treatment with posterior pericardial chest tube plus standard care All patients will receive chest tubes based on each surgeon's preference. Usually, 1 or 2 tubes are inserted in the mediastinum, and 1 is inserted into each open pleural cavity. Patients in the intervention arm will receive an additional posterior 20Ch chest tube. In cases where the surgeon routinely inserts 2 mediastinal chest tubes, they will use 1-2 anterior mediastinal tubes in the intervention group, based on their preference. The posterior chest tube will be positioned between the inferior aspect of the heart and the pericardium and connected to an active suction system per routine. Once the remaining chest tubes are extracted, the posterior chest tube will remain positioned in the pericardium and be reconnected from active suction to a collection bag for passive drainage. The chest tube will be removed on postoperative Day 3 or when chest tube output is \<50 mL/24 h.
214993424|NCT01829607|OTHER|Functional electrical stimulation of peripheral muscles|
214993425|NCT05168423|DRUG|CART-EGFR-IL13Ra2 Cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
214993426|NCT06280638|OTHER|Virtual stent-guided incremental optimization strategy (VIOS)|"PCI is performed according to strategy recommended by Imaging-Heart Team based on VIOS protocol."
214993427|NCT06280638|OTHER|Standard angiographic strategy|PCI is performed based on international guidelines, local protocols and practice.
214993428|NCT05874141|DIAGNOSTIC_TEST|HBA1C|blood sample on EDTA
214993429|NCT05874141|DIAGNOSTIC_TEST|Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides|serum sample
214993430|NCT05874141|DIAGNOSTIC_TEST|Urine analysis and urinary albumin-to-creatinine ratio|Morning urine sample
214993431|NCT05874141|DIAGNOSTIC_TEST|Serum creatinine and estimated glomerular filtration rate|serum sample
214993432|NCT05874141|DIAGNOSTIC_TEST|Complete blood count|blood sample on EDTA
214993433|NCT05874141|DIAGNOSTIC_TEST|Thyroid-stimulating hormone|serum sample
214993434|NCT05874141|DIAGNOSTIC_TEST|Serum iron, TIBC, Transferrin saturation and serum ferritin if needed|serum sample
214993435|NCT05874141|PROCEDURE|Electrocardiography (ECG)|by electrocardiogram
214993436|NCT05874141|PROCEDURE|Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound|imaging
214993437|NCT05874141|PROCEDURE|Arterial duplex ultrasound of both lower limbs|imaging
214993438|NCT05874141|DIAGNOSTIC_TEST|Random blood glucose|serum sample
214993439|NCT05874141|DIAGNOSTIC_TEST|AST, ALT, albumin|serum sample
214993440|NCT04303078|OTHER|Varying levels of harness support during walking|Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).
214993441|NCT04651673|OTHER|This is a non interventional registry|All patients, at listed investigational sites, that get prescription for a knee orthosis indicated for Knee OA symptomatic treatment, get an invite to partake in the evaluation registry.
214993442|NCT05633355|DRUG|Rocatinlimab|Subcutaneous (SC) injection
214993443|NCT06441578|DRUG|Recombinant ADAMTS13|Recombinant ADAMTS13, Intravenous injection
214993444|NCT05143671|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting in coronary revascularization.
214993445|NCT05143671|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention in coronary revascularization.
214993446|NCT05143671|PROCEDURE|Surgical valve replacement|Surgical mitral and / or aortic valve replacement.
214993447|NCT05143671|PROCEDURE|Carotid artery stenting|Carotid artery stenting.
214993448|NCT01698788|DRUG|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone
214993449|NCT03410420|DRUG|Pimonidazole hydrochloride|administration of pimonidazole-HCl
214993450|NCT06087627|DRUG|Dupilumab SAR231893 (REGN668)|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
214993451|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Imatinib|
214993452|NCT01771458|PROCEDURE|Tumor biopsy|
215092034|NCT02914288|OTHER|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
214380012|NCT03654781|PROCEDURE|professional periodontal treatment|periodontal treatment consisting of mechanical periodontal treatment (scaling and root planing) Oral hygiene insruction Periodontal treatment started concurrently with triple therapy
214380013|NCT03270514|DRUG|Exparel Injectable Product|Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
214497869|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants A|Peer participants in group A will self select a peer coach and will be contacted weekly by peer coaches.
214497870|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants B|Peer participants in group B will self select a peer coach and will be contacted bi-weekly by peer coaches.
214497871|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants C|Peer participants in group C will be matched with a peer coach and will be contacted weekly by peer coaches.
214993453|NCT01771458|DRUG|Standard Chemotherapy|
214993454|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Everolimus|
214993455|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Vemurafenib|
214993456|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Sorafenib|
214993457|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Erlotinib|
214993458|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
215092035|NCT04276688|DRUG|Lopinavir/ritonavir|400mg/100mg twice daily for 14 days
215092036|NCT04276688|DRUG|Ribavirin|400mg twice daily for 14 days
215092037|NCT04276688|DRUG|Interferon Beta-1B|0.25mg subcutaneous injection alternate day for 3 days
215092038|NCT00806442|DRUG|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
215092039|NCT00806442|DIETARY_SUPPLEMENT|Corn Oil|9 g/day of corn oil
214380014|NCT03270514|DRUG|Bupivacaine Hydrochloride|Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
214497872|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants D|Peer participants in group D will be matched with a peer coach and will be contacted bi-weekly by peer coaches.
214497873|NCT05038709|DEVICE|The Pink Pad Hip Kit|The pad is placed between the patient and the traction table to reduce pressure to the pudendal nerve exerted by the perineal post.
214497874|NCT06814821|OTHER|Web-based rehabilitation|Participants perform their rehabilitation independently with the instructions from the web-based platform.
214993459|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Dasatinib|
214993460|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
214993461|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Abiraterone|
214993462|NCT04931095|DRUG|Cannabis|Cannabis will be orally ingested via a brownie
214993463|NCT04931095|DRUG|Alcohol|Alcohol will be orally ingested via a flavored drink
214993464|NCT05340673|DRUG|Agent Affecting Integumentary System|Apply Miaderm
214993465|NCT05340673|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Apply to skin
214993466|NCT05340673|OTHER|Quality-of-Life Assessment|Ancillary studies
214993467|NCT05340673|OTHER|Questionnaire Administration|Ancillary studies
214993468|NCT04412096|DRUG|Timolol 0.5% ophthalmic solution|1 drop BID
214993469|NCT04412096|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop QD
214993470|NCT06559267|BEHAVIORAL|Remaking Recess|Remaking Recess (RR) is a school-based social engagement intervention designed to enhance elementary school contextual factors to better support peer engagement during recess. Remaking Recess is delivered to educators through direct training and in vivo coaching by a certified Remaking Recess Coach.
214993471|NCT06559267|OTHER|TEAM|Schools that are randomized to the TEAM condition will receive an additional implementation support intervention. TEAM will leverage existing human resources in the school to specifically focus on developing an implementation blueprint to foster a supportive implementation context for paraeducators to use Remaking Recess.
215092040|NCT02621398|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
215092041|NCT02621398|DRUG|Carboplatin|Given IV
215092042|NCT02621398|RADIATION|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
215092043|NCT02621398|OTHER|Laboratory Biomarker Analysis|Correlative studies
215092044|NCT02621398|DRUG|Paclitaxel|Given IV
215092045|NCT02621398|BIOLOGICAL|Pembrolizumab|Given IV
215092046|NCT05551975|OTHER|Control Product|Fed from Study Day 1
215092047|NCT05551975|OTHER|Experimental Product 1|Fed from Study Day 1
214380015|NCT05613101|PROCEDURE|Erector Spinae Plane Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed parasagittally 2-3 cm lateral to the spinous process at the L3 or L4 level and the transverse process was visualized. The peripheral block needle (85 mm B Braun Stimuplex A) was advanced in plane up to the transverse process and 10 ml 0.5% bupivacaine hydrochloride 10 ml 0.9% isotonic NaCl mixture was applied on the erector spina muscle.
214497875|NCT06814821|OTHER|Standard rehabilitation|Participants attend physical visits at the clinic to get instructions and support in their rehabilitation. Written and verbal instructions will be given.
214993472|NCT02337829|DRUG|Acalabrutinib (Arm A)|"* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"
214993473|NCT02337829|DRUG|Acalabrutinib (Arm B)|"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."
214993474|NCT01696721|OTHER|No intervention|
214993475|NCT06263946|DEVICE|Essilor® Stellest® spectacle lenses|patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.
214993476|NCT05869552|OTHER|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management. The intervention will consist of an initial session with the youth focusing on accessing mental health care plus case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to three months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
214993477|NCT05869552|OTHER|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 3 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training and support on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 3 months.
214993478|NCT04957095|DRUG|Apomorphine Injectable Solution|Apomorphine injected for therapeutic relief
214993479|NCT04957095|OTHER|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
214993480|NCT04197440|DRUG|BAM8-22 2mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
214993481|NCT04197440|DRUG|BAM8-22 1mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
214993482|NCT04197440|DRUG|BAM8-22 0.5 mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
214993483|NCT04197440|DRUG|Placebo|20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop
214993484|NCT04197440|DRUG|BAM8-22 with 1 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop
214993485|NCT04197440|DRUG|BAM8-22 with 5 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop
214993486|NCT04197440|DRUG|BAM8-22 with 25 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop
215092048|NCT05551975|OTHER|Experimental Product 2|Fed from Study Day 1
215092049|NCT00180167|DRUG|randomization between two established Chemotherapies|
215092050|NCT04665115|DRUG|Ibrutinib|Given PO
215092051|NCT04665115|OTHER|Quality-of-Life Assessment|Ancillary studies
215092052|NCT04104074|RADIATION|Radiotherapy|"Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy."
215092053|NCT04104074|DRUG|Sintilimab|Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
215092054|NCT02871687|DRUG|Simvastatin|Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
215092055|NCT02871687|DRUG|Pravastatin|Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
215092056|NCT02871687|OTHER|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
215092057|NCT01808885|DRUG|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
215092058|NCT01808885|DRUG|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
215092059|NCT00351182|DRUG|Telithromycin|
215092060|NCT00351182|DRUG|Doxycycline|
215092061|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
215092062|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
215092063|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
215092064|NCT01264770|DRUG|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
215092065|NCT01264770|DRUG|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
215092066|NCT03328923|DIETARY_SUPPLEMENT|500mg brown seaweed powder|
215092067|NCT03328923|DIETARY_SUPPLEMENT|Placebo|
214380016|NCT05613101|PROCEDURE|Adductor Canal Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed in the middle between the medial condyle and the SIAS, and the superficial femoral artery (FSA) was visualized under the sartorius muscle. By following the FSA distally, the point where the sartorius muscle crosses the adductor magnus muscle, which is the beginning of the adductor canal, was found and the saphenous nerve was visualized hyperechoic in the anterolateral aspect of the FSA. 20 cc 0.5% bupivacaine hydrochloride was applied
214993487|NCT04197440|DRUG|BAM8-22 with inactivate cowhage spicules|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
214993488|NCT06553651|DEVICE|Cryotechnology Necrosectomy Procedure|Subjects undergo necrosectomy with 1.7 mm flexible cryoprobes, either concurrently with stent placement or post-placement, at the Investigator's discretion. The cryoprobe will freeze the necrotic tissue and extracted en-bloc. A maximum of 4 cryotechnology procedures will be performed, with each procedure aiming for significant debris removal and clinical improvement of walled-off pancreatic necrosis (WOPN) symptoms.
214993489|NCT02924870|OTHER|Health education program|"2 sessions, at 15 and 30 days after hospital discharge. The first session will consist of four stages:~* Basic formation: basic lung anatomy and physiology, COPD concept, importance of tobacco, diagnostic tests for COPD, and how COPD is treated.~* Care in COPD: diet, breathing exercises, physical exercise (walking, cycle, treadmill ...), lifestyle (clothing, hygiene, preening, exercise, rest, sexuality, social relations).~* Management of conventional treatment: inhalers, oxygen therapy and smoking cessation.~* Action Plan: the patient and the nurse will establish a target about the activities that the patient must perform as well as their frequency and duration, according to WHO guidelines.~Second session: changes from the previous session; compliance with the physical activity plan and the deviation causes; weaknesses of the patient; skills in the management of inhalers, oxygen, and breathing exercises; and a new physical activity plan."
214993490|NCT02924870|OTHER|Conventional management|Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
214993491|NCT05850494|DRUG|HFA MDI|"* Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
214993492|NCT05850494|DRUG|HFO MDI|"* Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
215092068|NCT04533074|BIOLOGICAL|Single-visit regeneration protocol|In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.
215092069|NCT04533074|BIOLOGICAL|Multiple-visits regeneration protocol|In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
215092070|NCT02839694|DRUG|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
215092071|NCT02839694|DRUG|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
215092072|NCT02839694|DRUG|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
215092073|NCT02699372|DRUG|Placebo|
215092074|NCT02699372|DRUG|RO6889450|
215092075|NCT02103374|DRUG|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
215092076|NCT02103374|DRUG|Placebo|1 capsule lactose during 48 weeks
215092077|NCT04039867|DRUG|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
215092078|NCT04548362|OTHER|Meat arm|Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
215092079|NCT04548362|OTHER|Starchy foods arm|Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
215092080|NCT05840107|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously
215092081|NCT02660892|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
215092082|NCT06036953|DEVICE|electrical muscle stimulation|The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
215092083|NCT02051023|DRUG|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
215092084|NCT02051023|DRUG|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
214380017|NCT03841656|PROCEDURE|PARORISKIMPLANT|Patients attending periodontal and implant treatment at the Department of Periodontology of the Dental Faculty at Strasbourg, France, between 2000-2015.
214380018|NCT03395808|DRUG|Tramadol|IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
214380019|NCT05124106|DIAGNOSTIC_TEST|Raman Spectrometry|Bladder tumor is examined with Raman spectrometry during endoscopy
214380020|NCT03781830|OTHER|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
214380021|NCT01633801|DEVICE|Use of high flows versus oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
214687294|NCT06672692|DIAGNOSTIC_TEST|LIAISON NES FLU A/B, RSV & COVID-19|The LIAISON® NES FLU A/B, RSV \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA RSV viral RNA, and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
214993493|NCT05993481|DIAGNOSTIC_TEST|Blood Pressure Measurement|"NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program."
214993494|NCT04416269|DRUG|Oral Anti-diabetes Drugs alone|OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
214993495|NCT04416269|DRUG|Basal bolus insulin|Basal insulin with glargine or detemir will be used as per the hospital formulary.
214380022|NCT01633801|DEVICE|oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
214380023|NCT05046522|DRUG|Palmitoylethanolamide sold as Levagen +|Investigational product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
214380024|NCT05046522|DRUG|Placebo comparator - maltodextrin and microcrystalline cellulose mix|Placebo product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
214380025|NCT04100122|PROCEDURE|Blood drawing|Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)
214380026|NCT05742243|DRUG|Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)|Abatacept injected subcutaneously once per week and nasal insulin inhaled for 10 consecutive days initially and twice per week thereafter
214380027|NCT05742243|DRUG|Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)|Abatacept injected subcutaneously once per week and nasal placebo inhaled for 10 consecutive days initially and twice per week thereafter
214993496|NCT04416269|DRUG|Supplemental insulin|Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG \>140 mg/dl.
214993497|NCT04416269|DEVICE|Continuous glucose monitoring (CGM)|"A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes."
214993498|NCT03751813|DIETARY_SUPPLEMENT|Supplement|Supplement will be given to this group to take daily for 8 weeks
214993499|NCT00957359|DRUG|Psilocybin|Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
215092085|NCT02012088|DRUG|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
214380028|NCT00462670|DRUG|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
214380029|NCT00026858|BEHAVIORAL|collaboration|
214380030|NCT02205216|DEVICE|Active tDCS|anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.
214380031|NCT02205216|DEVICE|Sham tDCS|"anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary tingling sensation without effects on the brain."
214993500|NCT00957359|DRUG|Niacin|Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg
214993501|NCT00392041|DRUG|Eszopiclone|3mg qpm for 12 weeks
214993502|NCT00392041|DRUG|placebo|1 pill qpm for 12 weeks
214993503|NCT04513912|DRUG|Seltorexant|Participants will receive seltorexant over-encapsulated tablet orally.
215092086|NCT02012088|DRUG|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
215092087|NCT00424190|DRUG|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
214993504|NCT04513912|DRUG|Matching placebo to Seltorexant|Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
214993505|NCT04513912|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
214993506|NCT04513912|DRUG|Matching placebo to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
215092088|NCT00424190|DRUG|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
214380032|NCT02205216|BEHAVIORAL|Rehabilitation Therapy|"All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:~1. cognitive training: attentional strategies (mental counting, mental obstacle)~2. transfer training: everyday activities~3. motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory)."
214380033|NCT02245763|DEVICE|Leaflet Clip|
214380034|NCT06546098|DRUG|Molgramostim nebulizer solution|Solution for inhalation
214380035|NCT02144948|DRUG|e.-coli-nissle|1 ml qd for 24 weeks
214380036|NCT02160171|DEVICE|Algorithm for Neonatal Seizure Recognition|Software system for neonatal seizure detection recognition
214380037|NCT03606122|DRUG|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
214380038|NCT04940013|DRUG|Misoprostol|Study participants are given misoprostol alone for menstrual regulation.
214380039|NCT00039325|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
214380040|NCT03082716|DRUG|Custodiol Solution|After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
214380041|NCT03082716|DRUG|Blood cardioplegia|After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
214380042|NCT01942902|DEVICE|Continuous Glucose Monitoring System|
214380043|NCT04981691|BIOLOGICAL|anti-MESO CAR T cells|Autologous genetically modified anti-MESO CAR T cells
214380044|NCT00799695|BEHAVIORAL|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
214380045|NCT03798002|OTHER|Neuro-muscular exercise training Group|"Training takes place 3 days a week for 8 weeks follow up, under the supervision of physical therapist A training session lasts for 40 minutes, and consists of three parts.~PART 1:Warming up:~warm-up period consists of ergometer cycling for 10 minutes~PART 2: Circuit program:~comprises four exercises, core stability/postural function; postural orientation; lower extremity muscle strength; and functional exercises. Each exercise is performed 2-3 sets 10-15 repetitions.~PART 3:Cooling down:~The cooling down part consists of walking exercises forward and backwards, about 10 meters in each direction, in front of mirror (mobility exercises for the lower extremity muscles for a total of about 10 minutes. Changes in patient's symptom assessed by structural questionnaire"
214380046|NCT03798002|OTHER|quadriceps training program|"Apply Tens (10min+ hot pack 7-10min) Before excercise ROM,Quadriceps and hamstring stretching exercise's and strengthening exercises.~4th-6th week (in addition): Straight leg raise, Quads over a roll, Hamstring curls. 7th and 8th week (in addition): Elastic band exercise, Hamstring curls, Quads chair, isometric strengthening All exercises are performed in set of 10 repetitions. 1 set of all exercises was twice a day for first 3 week, and 2 sets twice a day until 6th week and then 3 sets twice a day until 8th week"
214380047|NCT03497507|DEVICE|Sham bracelet|Patients will wear bracelets on both hands
214380048|NCT03497507|DEVICE|Acupressure bracelet|Patients will wear bracelets on both hands.
214380049|NCT00840008|OTHER|Educational intervention|As per detailed protocol.
214380050|NCT03313102|BIOLOGICAL|blood samples|sample of 16 blood tubes
214380051|NCT01469455|DRUG|DT01|"DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions."
214380052|NCT00633932|DRUG|Esomeprazole|20mg once daily
214993507|NCT06465667|BEHAVIORAL|Dashboard|The Dashboard intervention, representing current standard of care, will consist of a standard e-mail message with a link to the dashboard and text explanation. No performance data will be included in the e-mail, and links will not be monitored for clickthrough with repeat e-mail.
214993508|NCT06465667|BEHAVIORAL|Precision Feedback Push|"The experimental intervention, precision feedback e-mail messaging, will consist of an e-mail with a link to the dashboard along with tailored information about a participant's performance in the quality process measure of interest. For example, e-mail subject lines may read You have room for improvement in stent omission, accompanied by a visual display in the body of the e-mail showing a participant's performance relative to a top performing peer. The behavior change intervention delivery component will also involve modifications to existing procedures. Namely, performance feedback will be reported directly in the e-mail as either plain text, or an embedded or attached image with graphed data."
215092089|NCT00563823|DRUG|vatalanib|
214380053|NCT00633932|DRUG|Esomeprazole|40 mg once daily
215092090|NCT00048750|DRUG|Micafungin|IV
215092091|NCT00048750|DRUG|Placebo|IV
215092092|NCT05623111|DRUG|Incobotulinumtoxin-A 100 UNIT Injection|Perineural injection
215092093|NCT05623111|DRUG|Saline|Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
215092094|NCT00351273|DRUG|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
215092095|NCT00351273|DRUG|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
215092096|NCT00351273|DRUG|Placebo|Methylcellulose
215092097|NCT02604758|BEHAVIORAL|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
215092098|NCT06172920|DRUG|Tramadol hydrochloride|Patients are receiving tramadol hydrochloride under thoracic surgery
215092099|NCT06172920|DRUG|Aldolan|Patients are receiving meperidine under thoracic surgery
215092100|NCT06172920|DRUG|Morphine hydrochloride|Patients are receiving Morphine hydrochloride under thoracic surgery
215092101|NCT03217799|DEVICE|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
215092102|NCT03094559|DEVICE|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
215092103|NCT01926769|DRUG|Metformin|
215092104|NCT04878536|DIETARY_SUPPLEMENT|Collagen drink|Testing product
214380054|NCT00633932|DRUG|Omeprazole|20mg once daily
214993509|NCT05470010|BEHAVIORAL|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state through meditation and gentle mindful movements.
214993510|NCT00600496|DRUG|AZD6244|twice daily oral dose
215092105|NCT04878536|DIETARY_SUPPLEMENT|Blank|Placebo drink
214993511|NCT00600496|DRUG|Dacarbazine|intravenous infusion
214993512|NCT00600496|DRUG|Erlotinib|daily oral dose
214380055|NCT01662531|BIOLOGICAL|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
214380056|NCT01207323|DRUG|MEHD7945A|MEHD7945A will be administered as specified in the individual arms.
214380057|NCT04719663|BEHAVIORAL|Biological illness and treatment rationale|Depression is described as a brain disorder and the role of monoamine, brain structures, and brain functions are reported as central mechanisms of relevance for its etiology and treatment. Biological processes are illustrated using typical charts and visualizations. Psychological influences are mentioned, but only as a byproduct of the disorder.
214993513|NCT00600496|DRUG|Docetaxel|intravenous infusion
214993514|NCT00600496|DRUG|Temsirolimus|intravenous infusion
214380058|NCT04719663|BEHAVIORAL|Psychological illness and treatment rationale|Depression is described as a psychological disorder resulting from emotion regulation deficits. The suppression of emotions receives a special role in explaining depression. The psychological processes are illustrated using charts and visualizations. Biological aspects are mentioned, but only as a byproduct of the disorder.
214380059|NCT04719663|DRUG|Active pharmacological placebo|"The active placebo pill does not have direct effects on the brain. Buscopan (butylscopolamine, 10 mg daily, 1 pill in the morning) does not cross the blood-brain barrier, yet induces some smaller side effects that resemble those of antidepressants (e.g., mouth dryness, fatigue, nausea). Treatment duration is 4 weeks. The rationale is briefly explained to participants as stimulating the biological balance in humans with depression, using a well-tolerated drug similar to Buscopan, which is well-known from pain treatments."
214993515|NCT06556862|DRUG|Dalpiciclib|100 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
215092106|NCT01672866|BIOLOGICAL|Placebo|Placebo to match SIM via subcutaneous injection every week
215092107|NCT01672866|BIOLOGICAL|SIM|Subcutaneous injection every week
214993516|NCT06556862|DRUG|Chidamide|25 mg/BIW, po. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
214993517|NCT06556862|DRUG|Enitinostat|5mg/QW，po.
214993518|NCT05912244|DRUG|IO102/IO103|IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.
214993519|NCT05912244|DRUG|Nivolumab-Relatlimab|Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.
214993520|NCT01407263|PROCEDURE|Lymph node template|Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence. .No lymph nodes will be removed in patients randomized to the no PLND arm.
214993521|NCT01407263|PROCEDURE|Transverse versus vertical closure|Transverse versus vertical closure of the port site incision
214993522|NCT01407263|DRUG|antibiotic prophylaxis|One vs. three days of antibiotic prophylaxis at catheter removal
214993523|NCT01407263|DRUG|Hemostatic Agent|For the patients randomized to routine indwelling HA agent use, the operating surgeon may choose to use either Surgicel™, Surgicel SNoW™, Arista™, FloSeal or surgeon's choice HA directed at the prostatic fossa, ligated dorsal vein complex, or neurovascular bundles. Because there is no standard HA or method of application, the surgeon will apply the HA according to the surgeon's experience and document both the HA used, and the location applied in the operative report. For patients randomized to no routine indwelling HA use, surgeons will only apply a HA if they are unable to achieve hemostasis using traditional means or feel it would be unsafe to complete the operation without using a HA for additional hemostasis. Providers in either arm may use HA as needed provided the intention is not to leave the HA indwelling.
215092108|NCT02483390|OTHER|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
215092109|NCT00918554|DRUG|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
215092110|NCT00918554|DRUG|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
214380060|NCT04719663|BEHAVIORAL|Active psychological placebo|"Emotional writing consists of writing about emotional experiences (4 sessions, one per week, 30 minutes each). The study instructor will be present displaying standard psychotherapeutic attitudes but will not read the participant's notes. The rationale for this treatment is briefly explained as improving the dealing with emotions to achieve a psychological balance in humans with depression."
214380061|NCT00482274|DRUG|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
214380062|NCT03221062|DEVICE|Laser en Bloc Resection|Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
214380063|NCT03794258|DRUG|SOF+DCV+CDI-31244|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg administered orally once daily.
214993524|NCT05145010|DRUG|Infigratinib|Infigratinib minitablets or sprinkle capsules to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
214993525|NCT05145010|DRUG|Infigratinib|Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the subjects naïve to Infigratinib will be 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
214993526|NCT06370780|OTHER|EPI LOVE|Observational cohort only
214380064|NCT03794258|DRUG|SOF+DCV+CDI-31244+ASV|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
214380065|NCT01262443|PROCEDURE|Radiofrequency Ablation|Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
214380066|NCT04184323|DRUG|EX-527 (Selisistat)|EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1). It is being given to reverse the effects of endometriosis, namely progesterone resistance, that is thought to interfere with the establishment of pregnancy in women with endometriosis
214380067|NCT04184323|DRUG|Placebo|We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
214380068|NCT06468072|OTHER|Expressivity protocol for children with autism|The activities proposed by this protocol stimulate different expressive skills, which are often lacking in people with autism. For this reason, the protocol is based on the strengthening of the following skills: perception of the body in movement in the space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
215092111|NCT00810940|DRUG|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours
214380069|NCT06468072|OTHER|Expressivity protocol for non-autistic children|The activities proposed by this protocol stimulate different expressive skills. The protocol is based on the strengthening of the following skills: perception of the body in movement in space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
214380070|NCT02695602|PROCEDURE|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|
214380071|NCT02695602|PROCEDURE|Submucous Resection with non powered instrument|
214380072|NCT04394507|DIAGNOSTIC_TEST|Near-Infrared Fluorescence imaging|.Near-infrared imaging was used to evaluate the function of the superficial lymphatic vessels in the right lower leg and foot as previously described.doi: 10.1161/CIRCIMAGING.118.008074.
214380073|NCT04394507|DIAGNOSTIC_TEST|Strain Gauge Plethysmography|Strain Gauge Plethysmography to asses capillary filtration rate og the lower limb
214380074|NCT05147168|OTHER|Questionnaire|Psychometric Validation of Chinese Version of the EORTC QLQ-PAN26 and EORTC QLQ-C30 in Taiwan
214380075|NCT05923580|BEHAVIORAL|Group- based cardiac telerehabilitation|Group-based cardiac telerehabilitation promotes information, skills, and support for the management of coronary artery disease in coronary patients. The rehabilitation model includes independent familiarization with information content, assignments, and group meetings, as well as the opportunity for a chat and peer support. The intervention is a health professional- lead, and registered rehabilitation model with a start and end.
214993527|NCT06637072|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection of efgartigimod PH20 SC
214993528|NCT06637527|DRUG|OK-101 0.05%|0.05% Ophthalmic Solution
214993529|NCT06637527|DRUG|OK-101 0.1%|0.1% Ophthalmic Solution
214993530|NCT06637527|DRUG|Placebo|Placebo
214993531|NCT06641076|DRUG|Sonelokimab|Randomized treatment, parallel-group
214993532|NCT06641076|DRUG|Placebo|Randomized treatment, parallel-group
214993533|NCT06557460|DEVICE|Surgical implantation of the CPCB-RPE1 implant|Surgical implantation of the CPCB-RPE1 implant
214993534|NCT02734771|DRUG|Brentuximab vedotin|
214993535|NCT02734771|DRUG|Rituximab|
214380076|NCT00642798|DRUG|sitagliptin phosphate|Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.
214993536|NCT02734771|DRUG|Cyclophosphamide|
214993537|NCT02734771|DRUG|Doxorubicin|
214993538|NCT02734771|DRUG|Prednisone|
215092112|NCT00810940|DRUG|mannitol|mannitol plus standard treatment
214380077|NCT02941393|DEVICE|Intrauterine pressure catheter|
214380078|NCT02941393|DEVICE|External tocodynamometry|
214380079|NCT03060564|PROCEDURE|tendon graft|JRF Orthopedics Tendon Graft
214993539|NCT04118036|DRUG|Pembrolizumab|intravenously over 30 minutes every 21 days (+/- 3 days)
214993540|NCT04118036|DRUG|Abemaciclib|Oral 2 times a day
214993541|NCT05090891|DRUG|INCB000928|INCBG000928 will be administered QD orally.
214993542|NCT05090891|DRUG|Placebo|Placebo will be administered QD orally.
214993543|NCT05989048|DRUG|Zavegepant|The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
214993544|NCT05989048|DRUG|Placebo|Single dose of matching placebo taken within Treatment Phase.
214993545|NCT04297917|BIOLOGICAL|ChAdOx1-HBV|chimpanzee adenovirus-vectored hepatitis B virus vaccine
214993546|NCT05457556|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214993547|NCT05457556|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214993548|NCT05457556|DRUG|Busulfan|Given intravenously (IV)
214993549|NCT05457556|DRUG|Cyclophosphamide|Given IV
215092113|NCT04333342|DEVICE|heart rate monitoring using wearable devices|Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
214993550|NCT05457556|PROCEDURE|Echocardiography Test|Undergo ECHO
214993551|NCT05457556|DRUG|Fludarabine|Given IV
214993552|NCT05457556|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo haploHCT
214993553|NCT05457556|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
214993554|NCT05457556|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214993555|NCT05457556|PROCEDURE|Matched Unrelated Donor Hematopoietic Cell Transplantation|Undergo MUD-HCT
214993556|NCT05457556|DRUG|Melphalan|Given IV
214993557|NCT05457556|DRUG|Methotrexate|Given IV
214993558|NCT05457556|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214993559|NCT05457556|DRUG|Mycophenolate Mofetil|Given IV
214993560|NCT05457556|PROCEDURE|Myeloablative Conditioning|Receive myeloablative conditioning regimen
214993561|NCT05457556|OTHER|Quality-of-Life Assessment|Ancillary studies
214993562|NCT05457556|OTHER|Questionnaire Administration|Ancillary studies
214993563|NCT05457556|BIOLOGICAL|Rituximab|Given IV
214993564|NCT05457556|PROCEDURE|T-Cell Depletion Therapy|Undergo haploHCT with alpha beta T cell depletion
214993565|NCT05457556|DRUG|Tacrolimus|Given IV
214993566|NCT05457556|DRUG|Thiotepa|Given IV
214993567|NCT05457556|RADIATION|Total-Body Irradiation|Undergo TBI
214993568|NCT04913311|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
215092114|NCT05361642|DRUG|Bupivacaine HCl 0.5% Injectable Solution|using nasal block including sphenopalatine ganglion block with general anesthesia to optimize surgical field
215092115|NCT05361642|DRUG|Dexmedetomidine|using dexmedetomidine with induction of general anesthesia to optimize surgical field
215092116|NCT04319744|OTHER|other|Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
215092117|NCT06267638|DRUG|Ketamine group|Participants will receive intraoperative ketamine during total knee arthroplasty
214380080|NCT03060564|OTHER|No intervention|No intervention
214380081|NCT06001983|OTHER|imaginary resisted exercises|"1. Imagination of squeezing a Sponge ball 15 reps~2. Imagination of Finger Exerciser 15 reps~3. Imagination of Theraband 15 reps~4. Imagination of pressing Rubber ball 15 reps~5. Imagination of pressing Hard object 15 reps"
214380082|NCT06001983|OTHER|physical resisted exercises|"1. Resisted exercise of Squeezing a Sponge ball 15 reps~2. Resisted exercise of Finger Exerciser 15 reps~3. Resisted exercise of pulling theraband 15 reps~4. Resisted exercise of pressing Rubber ball 15 reps~5. Resisted exercise of pressing Hard object 15 reps"
214380083|NCT02948959|DRUG|Dupilumab|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
214380084|NCT02948959|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
214497876|NCT06830564|DRUG|we will give the patient 0.1 mg nalbuphine 15 min before the end of the procedure|The study medications will be prepared by the local pharmacy as 10 ml syringes of nalbuphine IV that will be handled to the anesthesiologist in charge in OR room who will be blinded to the nature of the medications used, and study medications will be given 15 minutes before the end of surgical procedure and it will be given slowly for five minutes. . After extubation, patients will be taken to postanesthetic care unit . on arrival vital data will be measured. The anesthesiologist following up the patient will be blinded to the groups. The time of extubation will be defined as zero and after 15 minutes will be defined as one . Assessment of agitation will be done at time zero and time 1 and every fifteen minutes for 30 minutes using paediatric anaesthesia Emergence delirium scale (PAEDS)
214497877|NCT06830564|DRUG|we will give the patient 0.5 mg dexmedetomidine 15 min before the end of the procedure|The study medications will be prepared by the local pharmacy as 10 ml syringes of dexmedetomidine IV that will be handled to the anesthesiologist in charge in OR room who will be blinded to the nature of the medications used, and study medications will be given 15 minutes before the end of surgical procedure and it will be given slowly for five minutes. . After extubation, patients will be taken to postanesthetic care unit . on arrival vital data will be measured. The anesthesiologist following up the patient will be blinded to the groups. The time of extubation will be defined as zero and after 15 minutes will be defined as one . Assessment of agitation will be done at time zero and time 1 and every fifteen minutes for 30 minutes using pediatric anesthesia Emergence delirium scale (PAEDS) .
214497878|NCT06667817|BEHAVIORAL|Exercise|16 weeks of exercise training (Exercise Group) will be prescribed via a smart phone application. Results from this group will be compared to results of the sedentary control group.
214497879|NCT06827600|BEHAVIORAL|Structured breastfeeding education and follow-up|"Breastfeeding education was provided face-to-face to mothers assigned to the experimental group. The authors developed a breastfeeding education program and prepared a booklet. This booklets were distributed to experimental group.Follow-up were carried out on the 3rd day and at the 1st, 3rd, and 6th months postpartum. each follow-up session, the educational program's core components were reinforced through a standardized summary, ensuring continuity and clarity in the information provided.~Training Content~* Significance of Breastfeeding~* Advantages of Breastfeeding~* Overview of Colostrum~* Duration for Breastfeeding~* Breastfeeding Positions~* Strategies for Enhancing Breast Milk Production~* Increasing Breast Milk Supply~* Techniques for Placing the Baby on the Breast~* Implications of Improper Baby Positioning~* Indicators of Sufficient Breast Milk for the Infant~* Expressing Breast Milk~* Recommendations for Storing Expressed Milk"
214497880|NCT06827015|BEHAVIORAL|Laughter-Based Anger Reduction Program|This intervention involves structured Laughter Yoga sessions lasting 40 minutes each, conducted twice a week. It specifically targets students with high anger levels. The program combines breathing exercises, playful laughter activities, and relaxation techniques to reduce stress and promote emotional regulation. Unlike other interventions, this program uniquely emphasizes laughter as a tool for managing anger and enhancing overall well-being.
214993569|NCT04913311|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with BAL
214993570|NCT04913311|OTHER|Chemoradiotherapy|Undergo concurrent chemoradiation per standard of care
214993571|NCT04913311|PROCEDURE|Computed Tomography|Undergo computed tomography scan
214993572|NCT04913311|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214993573|NCT04913311|DRUG|Immune Checkpoint Inhibitor|Receive CPI per standard of care
214993574|NCT04913311|PROCEDURE|Nasal Wash and Collection|Undergo nasal wash
214993575|NCT04913311|OTHER|Quality-of-Life Assessment|Ancillary studies
214993576|NCT04913311|OTHER|Questionnaire Administration|Ancillary studies
214993577|NCT04913311|PROCEDURE|Spirometry|Under lung spirometry tests
214993578|NCT06643442|DRUG|Empagliflozin Tablets|Empagliflozin 10mg p.o. once daily (commercially available tablet)
215092118|NCT06267638|DRUG|Placebo group|Participants will receive intraoperative normal saline during total knee arthroplasty
214993579|NCT04776525|DRUG|Ifosfamide|3 g/m2 each day for three days
214380085|NCT02948959|DRUG|Asthma Controller Therapies|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral"
214993580|NCT04776525|DRUG|Doxorubicin|80 mg/m2 over four hours day 1
214993581|NCT02226770|DEVICE|Implantable Cardioverter Defibrillator (ICD)|
215092119|NCT06013436|DRUG|Autologous serum tears combined with 0.05% cyclosporin eye drop|All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
215092120|NCT01908166|PROCEDURE|ultrasound elasticity imaging|Undergo ultrasound elastography
215092121|NCT04073160|DRUG|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
214380086|NCT02948959|DRUG|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
214380087|NCT02199821|DIETARY_SUPPLEMENT|Formula with soybean oil, medium-chain triglycerides|
214380088|NCT02199821|DIETARY_SUPPLEMENT|Soybean oil formula commonly used in the hospital|
214380089|NCT03062059|DRUG|Intravesical 2000mg/52.6ml gemcitabine instillation|Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
214380090|NCT03062059|OTHER|Normal saline|Intravesical 52.6ml normal saline instillation after radical nephroureterectomy in upper urinary tract urothelial carcinoma
215092122|NCT04073160|DRUG|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
214380091|NCT06091462|OTHER|Virtual Reality Based Interactive Therapeutic Dementia Patient Education Program|"Virtual reality is an interactive three-dimensional environment where computer simulation-based fictions and the real and virtual worlds are combined.~Within the scope of this training, in the content of the module on the subject of Dementia; dementia definition, risk factors, signs and symptoms, complications, treatment and nursing care and patient and/or caregiver education. exists. After applying the dementia module, students complete the program by switching to a virtual reality-based simulation program for dementia."
214380092|NCT05936632|OTHER|Discrete Choice Experiment (DCE)|DCE survey experiment
214380093|NCT00560664|PROCEDURE|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
214380094|NCT00560664|PROCEDURE|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
214380095|NCT02596022|DRUG|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
214380096|NCT02596022|DRUG|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
214380097|NCT00103337|DRUG|cilengitide|Given IV
214380098|NCT00103337|OTHER|laboratory biomarker analysis|Correlative studies
214380099|NCT00793221|DEVICE|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
214380100|NCT00793221|DEVICE|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
214380101|NCT05198193|BEHAVIORAL|No Message Given|Participants in this arm are not given any intervention.
214380102|NCT05198193|BEHAVIORAL|Positive Message Given - Older Adults|Participants in this arm are given a positively framed message from an older adult's point of view.
214380103|NCT05198193|BEHAVIORAL|Negative Message Given - Older Adults|Participants in this arm are given a negatively framed message from an older adult's point of view.
214380104|NCT05198193|BEHAVIORAL|Positive Message Given - Younger Adults|Participants in this arm are given a positively framed message from an adult child's point of view.
214380105|NCT05198193|BEHAVIORAL|Negative Message Given - Younger Adults|Participants in this arm are given a negatively framed message from an adult child's point of view.
214380106|NCT04736017|DEVICE|TSB Axo|The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
214380107|NCT02461875|DRUG|Cabergoline|Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
214380108|NCT02461875|DRUG|GnRH antagonist rescue & cabergoline|when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
214993582|NCT04764045|DRUG|Ropivacaine|Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
214993583|NCT06492460|DRUG|Drug：Cisplatin|Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
214380109|NCT05151497|OTHER|Experimental group:Halliwick + Método Watsu|Carrying out the Ten Points Program through the Halliwick Concept, together with the Watsu Method through a series of relaxation maneuvers and mobilization of the body in float, and an immersion time of 15 minutes without doing physical activity in a pool at a temperature of 30ºC , to decrease spasticity of various muscles.
214993584|NCT00384631|OTHER|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
214380110|NCT05151497|OTHER|Control group:Halliwick|Exclusive use of treatment through the Halliwick Concept Ten Point Program, along with immersion in hot water to reduce spasticity in various muscles.
214380111|NCT01759069|PROCEDURE|Surgical treatment with microscope|
214993585|NCT00384631|DRUG|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
214993586|NCT00000640|DRUG|Primaquine|
214993587|NCT00000640|DRUG|Sulfamethoxazole-Trimethoprim|
214993588|NCT00000640|DRUG|Dapsone|
214993589|NCT00000640|DRUG|Clindamycin|
214993590|NCT04675710|PROCEDURE|Conventional Surgery|Undergo surgery
214993591|NCT04675710|DRUG|Dabrafenib|Given PO
214993592|NCT04675710|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214993593|NCT04675710|BIOLOGICAL|Pembrolizumab|Given IV
214993594|NCT04675710|OTHER|Quality-of-Life Assessment|Ancillary studies
214993595|NCT04675710|DRUG|Trametinib|Given PO
214380112|NCT02675790|DRUG|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
214380113|NCT02675790|DRUG|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
214380114|NCT01167283|DEVICE|Electrostimulation|Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week
214380115|NCT01167283|DEVICE|Sham stimulation|Sham stimulation: 1 h; 5 times/week
214380116|NCT01756521|DRUG|Moxifloxacin|
214497881|NCT06738290|BEHAVIORAL|Targeted home-based touchscreen training|Participants will practice the Swipe-Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants perform different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 min. per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. Feedback will be provided during the rest periods.
214497882|NCT05485805|DRUG|Naproxen sodium and caffeine (BAY2880376)|Tablet, oral use, single dose
214497883|NCT05485805|DRUG|Naproxen sodium (Aleve)|Tablet, oral use, single dose
214497884|NCT05485805|DRUG|Caffeine|Tablet, oral use, single dose
214497885|NCT05485805|DRUG|Placebo|Tablet, oral use, single dose
214497886|NCT06723080|DRUG|VC005 low dose group|VC005 low dose group repeat administration
214497887|NCT06723080|DRUG|VC005 high dose group|VC005 high dose group repeat administration
214497888|NCT06723080|DRUG|VC005 Placebo group|VC005 Placebo group repeat administration
214497889|NCT01586104|RADIATION|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
214497890|NCT04218357|DRUG|Probenecid or placebo single administration|study drug administration with alcohol in the laboratory
214497891|NCT05142345|OTHER|CONTINUUM Intervention|The intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consists of a video visit conducted by an oncology nurse practitioner within three business days of hospital discharge, to: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
214497892|NCT05142345|OTHER|Usual Care|Patients assigned to the usual care group will have their post-discharge follow-up scheduled per hospital, outpatient oncology team, and patient preference.
214497893|NCT06446154|DRUG|Fruquintinib|Fruquintinib was given orally for 5mg/ days. After 3 weeks, the drug was stopped for 1 week.
214993596|NCT05050383|OTHER|Pharyngeal Manometry|Catheters will be passed into the nose and advanced to the pharynx to measure airway pressures during drug-induced sleep.
214993597|NCT05050383|OTHER|Submental Ultrasound|Ultrasound of airway soft tissues
214993598|NCT00166699|PROCEDURE|ultrasound|The use of ultrasound to guide the insertion of combined spinal epidural needle
214993599|NCT02802228|DRUG|Ifetroban|thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
214380117|NCT05529784|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab 300mg in pre-filled injector Q2W
214993600|NCT02802228|DRUG|Placebo|matched placebo delivered as infusion and oral capsule
214993601|NCT06627569|BEHAVIORAL|Exercise|12 weeks of aerobic exercise, with 4 sessions per week.
214993602|NCT00695019|DRUG|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
214993603|NCT00695019|DRUG|placebo lozenges|200 mg matching placebo lozenges
214993604|NCT03410316|OTHER|No intervention|
214993605|NCT00000964|DRUG|Ranitidine hydrochloride|
214993606|NCT00000964|DRUG|Foscarnet sodium|
214380118|NCT03921190|PROCEDURE|Local anesthesia|Patients scheduled for a dental procedure that requires local anesthesia will be given the injection using two 2 techniques; an open-mouth and closed-mouth techniques
214380119|NCT00825097|PROCEDURE|Selective tibial neurotomy|Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
214380120|NCT00825097|DRUG|Botulinum toxin injection|Botulinum toxin type A
214380121|NCT03072225|DRUG|Herbal Medicine C-117|Herbal Medicine C-117 formula including 2 herbals and 2 insects
214497894|NCT06019377|BEHAVIORAL|Stronger Youth Networks and Coping (SYNC)|SYNC is a 8-module online curriculum adapted from evidence-based cognitive change methods, including Coping Effectiveness Training (CET), co-facilitated by service providers in Independent Living Programs (ILPs; federally-funded transition skill-building services accessed by most foster youth in the US) and near-peers (have lived experience in foster care). SYNC aims to increase youth capacity to appraise stress and regulate emotional responses, to flexibly select adaptive coping strategies, and to specifically promote informal and formal help-seeking as an effective coping strategy.
214497895|NCT06363578|DRUG|Dexmedetomidine 0.5 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg diluted in saline.
214993607|NCT05580120|BEHAVIORAL|Online-supervised exercise group|Participants in the online-supervised exercise group were provided with an online-supervised exercise program by using the video conferencing method three times a week for 6 weeks on the Zoom application. The exercise program was carried out synchronously
214993608|NCT05580120|BEHAVIORAL|Unsupervised-exercise training group|The unsupervised-exercise training group was informed about how to do the same exercises by another researcher, a nurse academician, on the online platform by using the lecturing method. Each training intervention took approximately 30 minutes.
214993609|NCT00340483|BEHAVIORAL|Smoking cessation|
214993610|NCT01014091|BIOLOGICAL|GSK pandemic vaccine GSK2340272A|2 intramuscular injections
214380122|NCT03072225|DRUG|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 formula including 4 herbals
214380123|NCT00058201|DRUG|fluorouracil|Given IV
214380124|NCT00058201|DRUG|gemcitabine hydrochloride|Given IV
214380125|NCT00058201|DRUG|leucovorin calcium|Given IV
214497896|NCT06363578|DRUG|Dexmedetomidine 1 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 1 μg/kg diluted in saline.
214497897|NCT05349838|DRUG|Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy|Daily oral tablet
214497898|NCT05075395|DEVICE|PARO therapy seal|PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
214497899|NCT05411484|DRUG|NanoDOX® Hydrogel|NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
214497900|NCT05411484|DEVICE|CO2 Ablative Fractional Laser|CO2 Ablative Fractional Laser will be applied to healthy skin areas
214993611|NCT06217549|OTHER|ozone therapy|Medical ozone is a mixture of pure ozone gas (0.05-5%) and pure oxygen (99.95-95%). It is produced from pure medical oxygen by medical ozone generators. It is applied to the participants 10 sessions by the intravenous method.
214993612|NCT01796522|DRUG|progesterone 200 mg / day vaginally|
214993613|NCT01796522|DRUG|nifedipine (60 mg / day orally)|
214993614|NCT06375993|DRUG|ADI-001|Anti-CD20 CAR-T
214993615|NCT06375993|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
214993616|NCT06375993|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
214993617|NCT04463706|OTHER|Predictors adverse evolution|Predictors adverse evolution in all hospital participant admitted patients
214993618|NCT04463706|OTHER|Predictors of health care provide|Predictors of death, unequity, variability in process of care, cost in all COVID positive patients form the Basque Country
214380126|NCT00058201|OTHER|clinical observation|No intervention
214380127|NCT05797064|PROCEDURE|Natural Orifice Specimen Extraction Surgery|Natural Orifice Specimen Extraction Surgery (NOSES) is a minimally invasive surgical technique that aims to reduce the size and number of incisions required during certain surgeries. In NOSES, the surgical specimen (such as a diseased organ or tumor) is removed from the body through a natural orifice (such as the mouth, anus, or vagina), rather than through an incision in the abdominal wall. In this trial, we will extract surgical specimens from the rectum to reduce trauma to the abdominal wall.
214380128|NCT02544828|DRUG|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
214380129|NCT02544828|DRUG|placebo|placebo (normal saline) is administered after anesthesia induction
214993619|NCT05998447|DRUG|GEN-001|The capsules taken by mouth. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)
214993620|NCT05998447|DRUG|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
214993621|NCT05998447|DRUG|mFOLFOX|mFOLFOX given by intravenous (IV) once every 2 weeks for only cohort 3
214380130|NCT01021774|PROCEDURE|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
214380131|NCT02378532|DRUG|Chloroquine|Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level. Based on the results of the DSMB an additional leven of 300mg was added.
214380132|NCT02378532|RADIATION|Radiotherapy|Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.
214993622|NCT03197129|OTHER|sensory adapted waiting room|The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. A lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
214993623|NCT05145114|PROCEDURE|THERAPEUTIC POSITIONS|Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.
214993624|NCT04525820|DRUG|Single high dose vitamin D|Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU
214993625|NCT04525820|DRUG|Placebo|Patient receives a single dose of a placebo solution
214380133|NCT02378532|DRUG|Temozolomide|Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
214497901|NCT03254914|PROCEDURE|Home Blood Pressure|Measure Home Blood Pressure
214993626|NCT04525820|DRUG|Treatment as usual vitamin D|Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
214993627|NCT04373941|DRUG|Filgrastim|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
215092123|NCT04073160|RADIATION|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
214380134|NCT04785664|OTHER|Community-based pro-Active Monitoring Program|The Intervention provides phone monitoring addressed to all the clients and home visits tailored to the individual needs. Moreover, it activates other formal or informal care resources based on the needs of the patients reported in the Individualized Care Plan (ICP) which derives from the assessment of multidimensional frailty. The main peculiarity of the program is that the operators identify the main problem of the client and try to track down the best solution in agreement with the client. It can be a health or social intervention or a different kind. Interventions may include assistance to make clients' houses safer thereby reducing risk factors for falls or reviewing the therapeutic scheme to improve patient adherence to the treatment in collaboration with the GP.
214380135|NCT04458116|DIETARY_SUPPLEMENT|Curcumin|Participants will receive 1.5 grams of turmeric 95% curcumin for 1 month (3 capsules / day containing 500mg each for 4 weeks).
214380136|NCT01896635|BIOLOGICAL|FMT infusions|Active FMT derived from healthy anonymous pre-screened donors
214380137|NCT01896635|OTHER|Placebo infusion|Placebo infusion not containing any donor microbial material
214380138|NCT04125524|DIAGNOSTIC_TEST|Terahertz metamaterials|A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.
214497902|NCT06756399|OTHER|Questionnare, hand grip and respiratory muscle strength|Upper extremity strength will be assessed using the Jamar hand dynamometer to measure hand grip strength. For lower extremity muscle strength, participants will undergo the five-repetition sit-to-stand test. Respiratory muscle strength, both inspiratory and expiratory, will be measured through mouth pressure assessments. Additionally, participants will complete a questionnaire addressing components related to sarcopenia diagnosis, including questions on strength, assistance with walking, rising from a chair, climbing stairs, and incidence of falls.
214993628|NCT05634369|BIOLOGICAL|GEM/DOX + TGFBi expanded NK cells|"8 cycles consisting of gemcitabine, docetaxel, supportive dexamethasone and pegfilagrastim, and universal donor, TGFBi ex vivo expanded NK cells~* Each cycle will be repeated every 21 days based upon disease response and toxicity criteria~* Tumor response assessed after Cycles 2, 4, 6, and 8~  1. Gemcitabine 675mg/m2/dose IV on Days 1 and 8~ 2. Docetaxel 75mg/m2/dose IV on Day 8~ 3. Dexamethasone 3mg/m2/dose (max 8 mg/dose) PO BID on Days 7, 8, and 9~ 4. Pegfilgrastim (Peg-GCSF) 0.1mg/kg/dose (max 6 mg/dose) SQ on Day 9~ 5. NK cells 1 x 10e8 cells/kg/dose IV on Day 12 (+ 1-2 days)"
214993629|NCT06026813|DEVICE|test pressure alternating shoes|test pressure alternating shoes
214993630|NCT02368509|OTHER|Perform sensory tests|
214993631|NCT06496243|DRUG|obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks|10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks
214993632|NCT02879695|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214993633|NCT02879695|BIOLOGICAL|Blinatumomab|Given IV
214993634|NCT02879695|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214993635|NCT02879695|BIOLOGICAL|Ipilimumab|Given IV
214993636|NCT02879695|BIOLOGICAL|Nivolumab|Given IV
214993637|NCT06787599|BEHAVIORAL|Home-based Tele Exercise|The participants in the study group will be given an online personalized exercise program at home in non-peritoneal dialysis (PD) days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of teleexercises will be private and the professional will send the link for each training session and will control the access of the participants. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
214993638|NCT04248244|OTHER|Palliative Care|Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.
214993639|NCT04248244|OTHER|FACT-MM questionnaire|FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
214993640|NCT04248244|OTHER|HADS questionnaire|HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
214993641|NCT06425471|DEVICE|KARL STORZ fetoscope arm|The type of fetoscope used in utero(either straight or curved or both ) will depend on the location of the placenta. The fetoscope will be used to cauterize abnormal blood vessels that cause twin-to-twin transfusion syndrome (TTTS)
214993642|NCT04978636|OTHER|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
215092124|NCT04073160|DRUG|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
215092125|NCT02241187|DRUG|PEGPH20|
214380139|NCT05915962|PROCEDURE|collecting a Nanofat-type microfat autograft|"Collecting and preparing a Nanofat autograft.~The protocol provides for the fat sample to be taken in a doctor's office during a consultation. The preparation will then be carried out at the MEARY center for cell and gene therapy of the AP-HP, at the Saint Louis hospital in Paris."
214380140|NCT01115985|DRUG|ASP1585|oral
214380141|NCT01115985|DRUG|atorvastatin|oral
214380142|NCT04477421|PROCEDURE|FS-SMILE|Femtosecond small incision lenticule extraction
214380143|NCT04477421|PROCEDURE|S-LASIK|Femtosecond laser Insitu keratomileusis
215092126|NCT02241187|DRUG|Cetuximab|
215092127|NCT02241187|DEVICE|DW & DCE-MRI|
215092128|NCT02241187|OTHER|blood draws|Blood samples will be drawn at various time points.
215092129|NCT00539929|DRUG|E6201 0.005%|
215092130|NCT00539929|DRUG|E6201 0.01%|
215092131|NCT00539929|DRUG|E6201 0.03%|
215092132|NCT00539929|DRUG|Placebo|
215092133|NCT02186717|DIETARY_SUPPLEMENT|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
214380144|NCT00154310|DRUG|Everolimus|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
214380145|NCT00154310|DRUG|Cyclosporine|Tablets orally twice a day to maintain protocol specific target blood levels
214380146|NCT00154310|DRUG|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
214380147|NCT00154310|DRUG|Corticosteroids|Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
214380148|NCT05118230|OTHER|Inclisiran|Prospective observational study. There is no treatment allocation. Chinese Patients who receive inclisiran in authorized health institutions are eligible to enroll into this study.
214380149|NCT04458623|DIAGNOSTIC_TEST|Air Test|.The Air-Test may represent an accurate, simple, inexpensive and non-invasive method for diagnosing postoperative atelectasis.
214993643|NCT04978636|OTHER|Continuous low tidal volume ventilation with using FiO2 of 1.0|The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
214993644|NCT04978636|OTHER|Apnea During CPB|There will be no ventilation used. But, during the sub-study part of the Apnea CPB extra blood samples will be drawn before and after CPB.
214993645|NCT06283485|DEVICE|ultrasound examination|"Phase 1 1: Taking ultrasound images from healthy volunteers (150 volunteers) to produce artificial intelligence - How to take PENG and Suprainguinal Fascia Iliaca Block sonoanatomical images is as follows.~Phase 2: In the second phase of the study, Smart Alfa Teknoloji San. and Tic. Inc. Artificial intelligence technology called Nerveblox, which was developed with the data received in the first stage with the support of the company, will be used. It is the validation and accuracy study of the artificial intelligence technology developed in the first stage. The accuracy study will be conducted on 40 healthy volunteers. 20 men and 20 women will be included in the study."
214993646|NCT06807099|DEVICE|Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE)|Target Lesion treated with WRAPSODY CIE
214993647|NCT05595915|DIETARY_SUPPLEMENT|COMP-4|COMP-4 is a novel compound that consists of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.
215092134|NCT00076518|DRUG|Fenofibrate|
215092135|NCT00076518|DRUG|Fish Oil|
214380150|NCT00961025|DRUG|DA-1229|"single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg"
214380151|NCT00961025|DRUG|Placebo|placebo
214380152|NCT05680961|DEVICE|Monitoring Device|Monitoring Device
214380153|NCT01511796|OTHER|upper limb rehabiliation|3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
215092136|NCT04279145|DEVICE|swan ganze catheter /echocardiography|"Right heart catheterization and mixed venous blood samples will be obtained for ABG, biomarkers (troponin , uric acid and micro RNA).~Each subject will have echocardiography, 6 MWD, clinical functional class and blood sample at the day of right heart catheterization or at least less than week of right heart catheterization"
215092137|NCT01020903|PROCEDURE|Aprepitant|40 mg po pre-op
215092138|NCT01020903|DRUG|Placebo|Orally, pre-op
215092139|NCT02048215|DRUG|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
215092140|NCT02048215|DRUG|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
215092141|NCT02048215|DRUG|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
215092142|NCT02048215|OTHER|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
214993648|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in virtual reality|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells. The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in VR:~We will use 360° 3D videos for exposure using an HTC Vive Pro headset. Six different videos will be used for exposure: 1) Taking a seat on a bench in a public park, 2) Being introduced as a new employee, 3) Performing a presentation at a meeting, 4) Entering and shopping in a grocery store, 5) Visiting a café and 6) Using public transportation. The therapist can choose the length of the exposure as well as the difficulty of the exposure. While the participant is in the VR-scenario HR and EDA are measured. These data are collected to continuously estimate the anxiety levels."
214380154|NCT01398423|DRUG|Active Control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
214380155|NCT01398423|DRUG|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
214380156|NCT06160622|DRUG|Leritrelvir|Oral
214380157|NCT01445223|DRUG|Lopinavir ritonavir|400mg BD 100mg BD
214380158|NCT01445223|DRUG|Atazanavir ritonavir|300mg QD 100mg QD
214380159|NCT01445223|DRUG|Efavirenz|600mg QD
214380160|NCT03372837|DRUG|Rituximab|The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
214380161|NCT03247374|DEVICE|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The computer will produce visual feedback of the muscular activity on the screen. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: they are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The experimental group will perform this training for 45 minutes."
214497903|NCT06934798|DRUG|Vasopressin intravenous infusion|Vasopressin will be administered intravenously in a blinded 250 mL bag of 5% glucose solution, at a final concentration of 0.12 U/mL. The infusion will begin at 5 mL/h and be increased by 2.5 mL/h every 10 minutes during the first hour, up to a maximum rate of 30 mL/h (equivalent to doses from 0.01 to 0.06 U/min). The target is to reach and maintain mean arterial pressure (MAP) ≥65 mmHg. If this is not achieved, open-label norepinephrine may be added. Hemodynamic and echocardiographic parameters will be measured before and after the target MAP is reached.
214497904|NCT06934798|DRUG|Norepinephrine intravenous infusion|Norepinephrine will be administered intravenously in a blinded 250 mL bag of 5% glucose solution, at a final concentration of 120 µg/mL. The infusion will begin at 5 mL/h and be increased by 2.5 mL/h every 10 minutes during the first hour, up to a maximum rate of 30 mL/h (equivalent to doses from 10 to 60 µg/min). The goal is to reach and maintain MAP ≥65 mmHg. If the MAP target is not reached, open-label norepinephrine may be initiated. Clinical and hemodynamic parameters will be collected at baseline and after MAP stabilization.
214497905|NCT06766396|DEVICE|Postpartum Intrauterine Contraceptive Device (PPIUCD).|Participants in the intervention arm will receive a postpartum intrauterine contraceptive device (PPIUCD) immediately after delivery. For vaginal deliveries, the PPIUCD will be inserted manually using Kelly's forceps under aseptic conditions, while for cesarean deliveries, the device will be inserted before uterine incision closure. All insertions will be performed by trained healthcare professionals
214497906|NCT06748807|PROCEDURE|APRVplus|Early Pathophysiology-driven Airway Pressure Release Ventilation (APRVplus)
214497907|NCT06748807|PROCEDURE|TCAV|Time-Controlled Adaptive Ventilation (TCAV)
214497908|NCT06757309|BEHAVIORAL|Mediterranean Diet|Intervention consists in personalized counseling to adopt the Mediterranean diet, focusing on whole foods, healthy fats, and lean proteins. Participants receive tailored meal plans, educational materials, and practical tips. Follow-up sessions at weeks 4 and 12 offer support, progress reviews, and goal-setting to ensure adherence and improved health outcomes
214497909|NCT06714578|OTHER|Questionnaire and Physical Exam|The investigators use questionnaire to assess biological factors (sleep quality, externalizing problem behavior, prosocial tendencies, sensation seeking, and hedonic hunger), psychological factors (risk awareness of drug misusing, indulgence of drug misusing, self-efficacy of drug misusing, and ACEs), and social factors (whether work in a special place, whether have drug-addicts around, cognition of traditional drug types, and cognition of NPS types) and demographic data
214497910|NCT06755112|OTHER|Placebo cream|Placebo cream application
214497911|NCT06755112|OTHER|active cream|Active cream application
214497912|NCT06747546|PROCEDURE|"goal-directed treatment strategy based on oxygen supply and consumption balance"|"The oxygen extraction rate immediately after CPB is set as E1, the oxygen extraction rate at 4 hours after surgery is E2, and the oxygen extraction rate at 8 hours after surgery is E3. A goal-directed treatment strategy based on oxygen supply and consumption balance is defined as: Combined with the value of E2 at 4 hours after CPB, the increasing oxygen consumption (VO2) after CPB is compensated by increasing oxygen delivery (DO2) to different degrees. The goal of E3 not increasing significantly compared with E1 is achieved at 8 hours after CPB, and the severity of low cardiac output is finally reduced within the golden 8 hours after CPB."
214497913|NCT06747546|PROCEDURE|Conventional Treatment group|Ventilation support is adjusted to maintain arterial oxygen partial pressure and oxygen saturation. Appropriate fluid infusion to stabilize central venous pressure and ensure preload; Combined use of vasoactive drugs to maintain heart rate and blood pressure; Appropriate diuresis can improve urine output and reduce cardiac afterload. Blood transfusion is used to improve coagulation function and maintain appropriate hematocrit.
214497914|NCT02488408|DRUG|Bemcentinib|
214497915|NCT02488408|DRUG|Cytarabine|
214497916|NCT02488408|DRUG|Decitabine|
214497917|NCT06507150|OTHER|AI-assisted migraine education (AIME)|AIME Group will undergo the established migraine education plus AI-assisted education.
214497918|NCT03110575|DRUG|TNX-102 SL|2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
214380162|NCT03247374|OTHER|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy receiving verbal feedback from the speech and language therapist. They are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The control group will perform this training for 45 minutes."
214380163|NCT02689934|DIETARY_SUPPLEMENT|Lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
214380164|NCT02689934|DIETARY_SUPPLEMENT|Placebo lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
214380165|NCT04996290|PROCEDURE|PENG + LFCN block|Regional anesthesia technique
214380166|NCT04996290|DRUG|Ropivacaine injection|Local anesthetic used for peripheral nerve block.
214380167|NCT03735160|DEVICE|pressure sensor|Pressure sensor at the angle of intratracheal tube and nasal alar
214380168|NCT02235363|PROCEDURE|thread lift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
214380169|NCT01108757|DRUG|Bactrim|Bactrim DS BID for 3 days
214380170|NCT01108757|OTHER|Placebo|Corn starch capsules
214380171|NCT02853461|OTHER|Sonication|Ultrasound bath (40 kHz, 1 W/cm2, 1 min) of bearing components of the prosthesis in sterile conditions.
214993649|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in vivo|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells.The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in vivo:~Exposure is taking place at Centre for Telepsychiatry and the surrounding areas. The therapist is planning the exposure with the participant and is accompanying the participant during the exposure."
214993650|NCT05328908|DRUG|Nivolumab-relatlimab FDC|Specified dose on specified days
214993651|NCT05328908|DRUG|Regorafenib|Specified dose on specified days
214993652|NCT05328908|DRUG|TAS-102|Specified dose on specified days
214993653|NCT04298541|DRUG|Ga-68- DOTATATE|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
214993654|NCT04298541|DRUG|Ga-68-DOTATOC|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
214993655|NCT04129515|DEVICE|NovoTTF-200A|•NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle
214993656|NCT04129515|DRUG|Pembrolizumab|Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle
214993657|NCT04442724|PROCEDURE|Fiducial marker placement|placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection
214993658|NCT04442724|DIAGNOSTIC_TEST|Multiparametric MRI (mpMRI)|In this study, mp-MRI is defined as MRI that includes T1 \& T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.
214993659|NCT04272060|DIAGNOSTIC_TEST|CT angiography|Diagnostic CT angiography
214993660|NCT04272060|DIAGNOSTIC_TEST|Invasive coronary angiography|Diagnostic invasive coronary angiography
214993661|NCT06688864|BEHAVIORAL|EPIO App|Participants will receive access to the app-based cognitive-behavioral pain self-management intervention program (EPIO) for 3 months.
214993662|NCT06496607|BIOLOGICAL|NSI-8226|Solrikitug
214993663|NCT06496607|BIOLOGICAL|NSI-8226|Solrikitug
214993664|NCT06496607|BIOLOGICAL|NSI-8226|Solrikitug
215092143|NCT04512638|DRUG|Antibiotics|"Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed."
215092144|NCT04512638|DRUG|Chlorhexidine mouthwash|Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.
214380172|NCT02853461|OTHER|Microbiological analysis|Plating the sonicates on agar plates.
214380173|NCT02918500|DRUG|Nicoderm Patch|Nicotine replacement therapy patch
214380174|NCT06444022|BIOLOGICAL|Human amniotic epithelial stem cells（hAESCs）|Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (hAECs-GVHD)
214380175|NCT06444022|BIOLOGICAL|placebo (cell preservation solution)|Same dose placebo (cell preservation solution) injections as control group
214380176|NCT05815732|OTHER|Physical exercise|Personalized exercise program, with defined modalities, intensity, duration, frequency and progression of the exercise.
214380177|NCT01536041|DRUG|ONO-6950|200 mg QD, single dose
214380178|NCT01536041|DRUG|ONO-6950|20 mg QD, single dose
214380179|NCT01536041|DRUG|Montelukast|10 mg Montelukast, QD single dose
214380180|NCT01536041|DRUG|Placebo|Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
214380181|NCT00247819|PROCEDURE|Blood draw|
214380182|NCT02019134|BEHAVIORAL|relaxation exercise|relaxation exercise
214380183|NCT02019134|OTHER|ususal care|
214380184|NCT01373996|DEVICE|Wireless invasive blood pressure monitoring (Hybymed® Wireless IBPM System)|"The readings of invasive arterial pressure were obtained from 2 identical pressure transducers, connected to a common arterial line via a Y connector. Data was collected from one transducer via a direct cable connection and from the second transducer via wireless transmission of the signal to the patient's bedside monitor using the HMW 10 Wireless System.~A comparison of data received by patient's bedside monitor from the two transducers was done (standard connection vs. wireless connection), as well as a comparison of data collected by the transmitter and data received by the receiver of the HMW 10 Wireless System."
214380185|NCT01503840|DRUG|sugammadex|sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
214380186|NCT01503840|DRUG|Sodium chloride solution|Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
214380187|NCT01110343|BEHAVIORAL|mindfulness intervention|a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up
214380188|NCT01110343|BEHAVIORAL|Conventional parent Support Group|a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
214380189|NCT01255943|BEHAVIORAL|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
214380190|NCT00507741|DRUG|Vintafolide|Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
214380191|NCT00507741|DRUG|Ertafolide|
214380192|NCT04175353|DIETARY_SUPPLEMENT|Dairy snack|The effects of dairy snack are compared with orange juice.
214380193|NCT04175353|DIETARY_SUPPLEMENT|Berry snack|The effects of two berry snacks are compared with berry soup.
214380194|NCT00002757|BIOLOGICAL|filgrastim|
214380195|NCT00002757|DRUG|cyclophosphamide|
214380196|NCT00002757|DRUG|cytarabine|
214380197|NCT00002757|DRUG|doxorubicin hydrochloride|
214380198|NCT00002757|DRUG|etoposide|
214380199|NCT00002757|DRUG|methotrexate|
214380200|NCT00002757|DRUG|prednisolone|
214380201|NCT00002757|DRUG|prednisone|
214380202|NCT00002757|DRUG|therapeutic hydrocortisone|
214380203|NCT00002757|DRUG|vincristine sulfate|
214380204|NCT06342427|DIAGNOSTIC_TEST|DESTINEX|A panel of microRNA, whose expression level is tested in serum samples.
214380205|NCT02394041|DEVICE|Acupuncture|Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
214380206|NCT02394041|DEVICE|Sham acupuncture|Sham acupuncture with sham needles
214993665|NCT06496607|BIOLOGICAL|Placebo|Placebo
214993666|NCT05952648|PROCEDURE|Lower tract respiratory samples|Within 1 hour from HAP or VAP suspicion, quantitative tracheal aspirate or bronchoalveolar lavage will be performed to confirm the diagnosis. Clinicians will be encouraged to perform BAL whenever possible
214993667|NCT05952648|DIAGNOSTIC_TEST|Multiplex PCR assay (Film-array Pneumonia Panel Plus)|The lower tract respiratory samples will be analyzed with Multiplex PCR assay (Film-array Pneumonia Plus).
214993668|NCT05952648|DIAGNOSTIC_TEST|Lower respiratory tract standard culture|The lower tract respiratory samples will be analyzed using convention microbiological methods (including conventional Gram stain and semiquantitative culture on both selective/differential and screening agar media)
214993669|NCT05952648|DIAGNOSTIC_TEST|Blood sample standard culture|When HAP or VAP are suspected, blood samples from peripheral vein will be collected and analyzed with conventional microbiological methods
214993670|NCT02401295|DRUG|ATRA|
214993671|NCT02401295|DRUG|Celecoxib|
214993672|NCT02401295|DRUG|Itraconazole|
214993673|NCT04606446|DRUG|PF-07248144|KAT6 Inhibitor
214993674|NCT04606446|DRUG|Fulvestrant|Endocrine Therapy
214993675|NCT04606446|DRUG|Letrozole|Endocrine Therapy
214993676|NCT04606446|DRUG|Palbociclib|CDK4/6 Inhibitor
214993677|NCT04606446|DRUG|PF-07220060|CDK4 inhibitor
214993678|NCT04606446|DRUG|PF-07850327, ARV-471, vepdegestrant|PROTAC (PROteolysis Targeting Chimera) ER degrader
214993679|NCT05217810|OTHER|Atectura inhalation capsule (150/80ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
214993680|NCT05217810|OTHER|Atectura inhalation capsule (150/160ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
214993681|NCT05217810|OTHER|Atectura inhalation capsule (150/320ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
214993682|NCT04893798|COMBINATION_PRODUCT|Sayana Press|Sayana Press is a drug-device combination and is considered a medical product in the EU.
214993683|NCT05045963|OTHER|Electronic Health Record Review|Medical record reviewed
214993684|NCT02442349|DRUG|AZD9291|Once daily tablet 80 mg
215092145|NCT04512638|PROCEDURE|Minimally invasive surgery with LPRF|Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
215092146|NCT04512638|PROCEDURE|Surgical resection|Primary surgical management consisting of the removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
215092147|NCT00160654|DRUG|Levetiracetam|"* Pharmaceutical form: oral tablets~* Concentration: 500 mg~* Route of administration: Oral use"
215092148|NCT03258060|PROCEDURE|Temporary pacing study|
215092149|NCT03258060|RADIATION|Body Surface Mapping|
215092150|NCT06116695|DRUG|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
214993685|NCT06055036|BEHAVIORAL|Black Impact Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
214993686|NCT05536011|DRUG|Pitolisant|Exposure to at least one dose of pitolisant at any time during pregnancy
214380207|NCT01346514|BEHAVIORAL|Intensive Addiction/Housing Case Management|AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
214380208|NCT01346514|BEHAVIORAL|Housing Support Group|The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
214380209|NCT05275491|DIAGNOSTIC_TEST|Calcium|Free calcium serum levels
214993687|NCT05536011|DRUG|Comparator Products|Exposure to at least one dose of a comparator product at any time during pregnancy
214993688|NCT06001398|BEHAVIORAL|Parent Acceptance and Commitment Therapy (PACT)|PACT is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature
214993689|NCT06001398|BEHAVIORAL|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate
214380210|NCT05275491|DIAGNOSTIC_TEST|Fibroblast growth factor 23|Serum level
214993690|NCT01284543|DEVICE|Use of the Tan EndoGlide to insert donor graft|Using the Tan EndoGlide to insert donor graft into the eye
214993691|NCT01284543|DEVICE|Busin Glide for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye
215092151|NCT06116695|DRUG|Mineral Tri-Oxide Aggregate|mineral trioxide aggregate was used as control
215092152|NCT05002842|BEHAVIORAL|LovingKindess Meditation|Participants will have access to a recording of a script to guide them through meditation
215092153|NCT04430647|PROCEDURE|combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)|performing ultrasound ciliary plasty then performing standard phacoemulsification
215092154|NCT04430647|PROCEDURE|Phacoemulsification alone|standard phacoemulsification for catarct extraction
215092155|NCT04664582|PROCEDURE|Sentinel Lymph Node Biopsy|see intervention group description
215092156|NCT03204669|OTHER|Trace elements replacement|
215092157|NCT03740568|DRUG|Low Progesterone|"Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 \<10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.~Group 2b (Restored Progesterone Group, P on D5 \>10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
214380211|NCT05275491|DIAGNOSTIC_TEST|Sclerostin|Serum level
214380212|NCT05275491|DIAGNOSTIC_TEST|parathyroid hormone|serum level
214380213|NCT02299258|DEVICE|Standard stents MTN-CG-s-20/100|The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
214380214|NCT02299258|DEVICE|Tailored stents MTN-WE-20/100-A|cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
214380215|NCT04454086|OTHER|Aerobic Exercise|Undergo aerobic exercise
214380216|NCT04454086|OTHER|Exercise Counseling|Receive behavioral activity counseling
214380217|NCT04454086|OTHER|Nutritional Assessment|Receive nutritional counseling
214380218|NCT04454086|OTHER|Quality-of-Life Assessment|Ancillary studies
214380219|NCT04454086|OTHER|Questionnaire Administration|Ancillary studies
214380220|NCT04454086|OTHER|Resistance Training|Undergo resistance exercises
214380221|NCT02881008|DRUG|Entecavir|
214380222|NCT02881008|DRUG|Myrcludex B|
214497919|NCT06007053|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning.
214380223|NCT04002583|DIAGNOSTIC_TEST|Computer assisted ambulatory electroencephalogram|A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
214380224|NCT03982043|BEHAVIORAL|Text2Connect|Text2Connect is a personalized text messaging intervention for patients and parents that targets self-identified barriers to engaging in treatment to increase the likelihood that a depressed or suicidal patient will initiate recommended services.
214380225|NCT02263001|OTHER|Auricular acupuncture|Auricular therapy for treatment of musculoskeletal pain
214380226|NCT02263001|OTHER|Usual Care|Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
214380227|NCT06339554|DRUG|Alectinib 150 MG [Alecensa]|First line treatment for cohorts A and B
214380228|NCT01208155|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
214380229|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 1, single dose
214380230|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 2, single dose
214380231|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 3, single dose
214497920|NCT06007053|BEHAVIORAL|Supportive Therapy|The supportive therapy treatment consists of 12 sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
214497921|NCT06828081|OTHER|Range of Motion Exercises|Will get standard shoulder muscle exercises, including rigid and stretchy ones with bands that offer resistance.
214993692|NCT05179629|DRUG|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 30 ml (15 ml for each side) of %0,25 bupivacaine.
214993693|NCT02135198|DRUG|2 mg AZD7325|A single 2 mg oral dose of AZD7325
214993694|NCT02135198|DRUG|10 mg AZD7325|A single 10 mg oral dose of AZD7325
214993695|NCT02135198|DRUG|Placebo|A single oral dose
214993696|NCT05162092|OTHER|Conventional physiotherapy|Participants will be given Conventional Physiotherapy. It included Passive Soft tissue elongation of tight muscles, Lower limb resistance exercises, Movement transitions, balance board and foam board standing, walking and stair climbing.
214993697|NCT05162092|OTHER|Vestibular stimulation with conventional physiotherapy|Participants in group B will be given conventional physiotherapy and vestibular stimulation exercises. It included conventional is same as given to the conventional and Vestibular Stimulation
214993698|NCT01776229|BEHAVIORAL|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
214993699|NCT03669471|OTHER|Testing of performance|"The cross-sectional evaluation will involve assessment of:~1. Hip muscle function~2. Single leg jump performance~3. Self-reported hip and groin function~4. Evaluation of return to sport~5. Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk."
214380232|NCT01054573|DRUG|Telaprevir|750 mg orally every 8 hours (q8h) for 12 weeks
214380233|NCT01054573|DRUG|pegylated interferon (Peg-IFN) alfa-2a|180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.
214380234|NCT01054573|DRUG|ribavirin (RBV)|1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
215092158|NCT03740568|DRUG|Normal Progesterone|"Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
214380235|NCT00979602|BIOLOGICAL|GSK2340274A|One intramuscular injection
214380236|NCT00979602|BIOLOGICAL|GSK2340273A|One intramuscular injection
214380237|NCT01069575|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
215092159|NCT01595594|DRUG|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
214497922|NCT06828081|OTHER|Strengthening exercises with theraband|They will go through the GRASP method, which involves special workouts just for them, teaching them about their health and ways to deal with pain.
214993700|NCT05608655|DEVICE|DKutting LL balloon|After pre-dilation balloon is used (if any), DKutting LL balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
214993701|NCT05608655|DEVICE|Chocolate balloon|After pre-dilation balloon is used (if any), Chocolate balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
214993702|NCT01694238|PROCEDURE|Cruciate incision|
214993703|NCT01694238|PROCEDURE|Circular incision|
214993704|NCT01694238|OTHER|Mesh enforced cruciate incision|
214993705|NCT00914212|DRUG|Placebo|Single dose placebo to sibutramine in two of three treatment periods.
214380238|NCT04803617|OTHER|Assessment of pulmonary function and pectoralis muscle strength|In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
214497923|NCT06875453|OTHER|Exercise|The Schroth Best Practice program, which is widely used in the conservative treatment of scoliosis, consists of 6 modules including physiological exercises to correct the sagittal plane, activities of daily living, 3D correction techniques, powerful Schroth exercises, de-tethering exercises and gait rehabilitation. Detethering exercises in this program will be performed in this study.
214687295|NCT07007195|DEVICE|Ad Libitum Use followed by Instructed Use of the Inspire Device|Participants in this condition will use the novel olfactory stimulation delivery system (Inspire), to smell a specific order designed to assist with smoking cessation for 7 days. Participants will then be instructed to record every urge to smoke and report times when they think they might smoke in the smartphone-based smoking cessation app, Insight™. When urges above 0 are reported, the app will instruct participants to use the Inspire device. On day 8, participants will receive a notification on the smartphone-based smoking cessation app, Insight™, to switch to the Instructed Use condition. Participants will then be instructed to use the Inspire device only when participants report a cigarette craving about 0 at each of the surveys prompted from the smartphone-based smoking cessation app, Insight™.
214993706|NCT00914212|DRUG|Comparator: sibutramine|Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
214993707|NCT05166642|DEVICE|Bandgrip Micro-Anchor Wound Closure|This treatment group will utilize a suture closure technique for the deep dermal layers with Bandgrip being applied to the most superficial layer of the surgical incision
214993708|NCT05166642|DEVICE|Suture closure|This treatment gourd will utilize suture closure technique for all layers of the surgical incision.
214993709|NCT03724331|BEHAVIORAL|Light Physical Activity 1|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital."
214993710|NCT03724331|BEHAVIORAL|Light Physical Activity 2|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital."
214993711|NCT03724331|BEHAVIORAL|Support Education Activity|"Participate in a supportive cancer-related education activity including a direct 10 - 15 minute phone conversation with a Registered Nurse researcher each week for 6-weeks after returning home from the hospital. Wear a pedometer each day of the study.~Recording pedometer steps in the daily diary each day."
214993712|NCT06132477|DRUG|GLP-1 receptor agonist|Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
214993713|NCT02371811|DEVICE|uterine manipulator (v care)|
214993714|NCT00005849|DRUG|bryostatin 1|
214993715|NCT00005849|DRUG|paclitaxel|
215092160|NCT01595594|DRUG|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
215092161|NCT03158181|OTHER|Non interventional study|None intervention will be conduct on patient. Only the operating room will be randomized to have an intervention or not (Bundle of measure for optimizing the discipline of personnel in the operating room)
215092162|NCT05685056|BEHAVIORAL|Text messages|Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
215092163|NCT01387724|GENETIC|RNA analysis|
214380239|NCT05075187|DIAGNOSTIC_TEST|Genetic Screening|Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.
214380240|NCT02872298|DEVICE|Targeted Lung Denervation (TLD)|The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.
214497924|NCT06724926|DRUG|Azeliragon|"Azeliragon is orally administered. Patients start Azeliragon 7 days before CSI and take their last dose 7 days post-CSI.~The first 6 patients will start at Dose Level 1 \[DL1\] (Loading dose for 7 days: 30 mg twice daily; Concurrent/adjuvant dose: 20 mg once daily).~If 1 or fewer of 6 patients develop dose-limiting toxicity (DLT) then the recommended dose will be DL1. If at least 2 of 6 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -1 \[DL-1\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 10mg once daily).~If 1 or fewer out of 6 patients at DL-1 develop DLT, then the recommended dose will be DL-1. If at least 2 of 6 at DL-1 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -2 \[DL-2\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 5mg once daily).~At the recommended dose, an additional 14 patients will be enrolled for the Dose Expansion portion."
214993716|NCT04883853|PROCEDURE|Mild _moderate Ptosis tucking|A modified levator muscle tucking procedure.The level of sutures was determined according to the levator muscle function and the desired eyelid height. The middle (main) suture was taken first at the level of the medial part of the pupil and was tightened to keep the lid height at the superior limbus and the other two sutures (medial and lateral) were then adjusted. A spindle-shaped, horizontal part of the levator aponeurosis (2.5-3 mm wide and 0.5 mm deep) was excised at the site of insertion into the tarsus before tightening the central suture to induce strong fibrosis and adhesion between the tucked levator aponeurosis and the tarsus
214993717|NCT04947501|DRUG|Cyclophosphamide|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~\*\*\*\*\*\*\* Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
214993718|NCT04947501|DRUG|Topotecan|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
214993719|NCT04947501|DRUG|Vincristine|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
214993720|NCT04947501|DRUG|Doxorubicin|"Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
215092164|NCT01387724|GENETIC|polymerase chain reaction|
215092165|NCT01387724|GENETIC|protein expression analysis|
215092166|NCT01387724|GENETIC|proteomic profiling|
215092167|NCT01387724|GENETIC|western blotting|
215092168|NCT01387724|OTHER|enzyme-linked immunosorbent assay|
215092169|NCT01387724|OTHER|immunohistochemistry staining method|
215092170|NCT01387724|OTHER|laboratory biomarker analysis|
215092171|NCT01387724|OTHER|liquid chromatography|
215092172|NCT01387724|OTHER|mass spectrometry|
215092173|NCT03999086|PROCEDURE|Intervention|We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
215092174|NCT03999086|OTHER|Control Group|Laboratory analysis to guide transfusion
215092175|NCT03055390|DRUG|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
215092176|NCT03055390|DRUG|placebo|2ml of saline intravenous
215092177|NCT06129110|BEHAVIORAL|Diet Weight Loss|Low calorie diet of meal replacement shakes
215092178|NCT03861156|DRUG|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
215092179|NCT06194461|BIOLOGICAL|AZD5851|Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.
215092180|NCT06194461|BIOLOGICAL|AZD0754|Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729.
214380241|NCT02704897|OTHER|Wound Assessment Tool|A set of questions relating to the symptoms of wound infection
214380242|NCT01516411|BEHAVIORAL|Mobile Intervention for Lifestyle Eating/Exercise @ Stanford|Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
214380243|NCT04670237|DEVICE|Liberty677MTY Multifocal Toric IOL|multifocal, toric intraocular lens (IOL)
214380244|NCT05345379|OTHER|Single intervention|Single intervention at the day of fixed orthodontic appliance bonding
214380245|NCT02822560|DEVICE|pEVAR|percutaneous femoral access using a suture-mediated closure device
214497925|NCT06724926|PROCEDURE|CSI|Patients will receive CSI.
214497926|NCT06939725|OTHER|Transversus abdominis plane (TAP) block|We apply different nerve blocks to patients for pain relief after cesarean surgery. Transversus abdominis plane block was applied to this group
214993721|NCT04947501|DRUG|Ifosfamide|Administration of ICE - cycle 2 Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs.
214993722|NCT04947501|DRUG|Etoposide|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
214993723|NCT04947501|DRUG|Carboplatin|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
214993724|NCT04947501|DRUG|Mesna|"Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Administration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.~Administration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion."
214993725|NCT03296683|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
214993726|NCT04054167|DRUG|Low Dose Radiation Therapy|Undergo ultra low dose radiation
214993727|NCT02099058|DRUG|Osimertinib|It is administered orally everyday.
214993728|NCT02099058|DRUG|Nivolumab|It is an intravenous infusion administered every 14 days.
214993729|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 21-day dosing cycles.
214993730|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 28-day dosing cycles.
214993731|NCT02099058|DRUG|Erlotinib|It is administered orally everyday.
214497927|NCT06939725|OTHER|Transversalis Fascia Plane Block|We apply different nerve blocks to patients for pain relief after cesarean surgery. Transversalis Fascia Plane Block was applied to this group
214993732|NCT05041127|BIOLOGICAL|Cetuximab|Given IV
214993733|NCT05041127|OTHER|Questionnaire Administration|Ancillary studies
214993734|NCT04406792|BEHAVIORAL|DPP only|Participation in the online DPP only with a mixed group of participants at risk for type 2 diabetes and doula divas are not the team leaders.
214993735|NCT04406792|BEHAVIORAL|Diabetes Prevention Program (DPP) online + doula divas|Participation in the DPP online intervention with doula divas as team leaders.
214993736|NCT03884998|DRUG|Copanlisib|Given IV
214380246|NCT02822560|PROCEDURE|open femoral access|cutdown to femoral artery and surgical closure
214380247|NCT04627519|DIETARY_SUPPLEMENT|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after the meal (every 12 hours)
214380248|NCT00152009|DRUG|SPD503 (Guanfacine hydrochloride) (2 mg)|
214380249|NCT00152009|DRUG|SPD503 (3 mg)|
214380250|NCT00152009|DRUG|SPD503 (4 mg)|
214380251|NCT00152009|DRUG|Placebo|
214380252|NCT05773014|PROCEDURE|Speculum Exams|Same as arm
214380253|NCT05773014|PROCEDURE|Digital Exams|Same as arm
214380254|NCT00393523|BIOLOGICAL|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
214497928|NCT04701203|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
214993737|NCT03884998|BIOLOGICAL|Nivolumab|Given IV
214993738|NCT03507790|DRUG|CT1812|Active Study Drug
214993739|NCT03507790|DRUG|Placebo|Non-active study drug
214993740|NCT06181799|DIAGNOSTIC_TEST|Mass spectrometry using the PTR TOF-1000 (IONICON PTR-TOF-MS - Trace VOC Analyzer, Eduard-Bodem-Gasse 3, 6020 Innsbruck, Austria (Europe).|"Once enrolled in the study, all participants are scheduled to undergo the following tests:~Analysis of the exhaled breath volatile organic compounds using real-time analytical methods (PTR-TOF-MS-1000; real-time mass spectrometer with ionization by the proton transfer method) before and after the physical exertion test, during 1 minute. Machine learning models will be employed to analyze the patterns identified in the exhaled air volatilome data.~Before and immediately after the physical exertion test, all participants are scheduled to record a single-lead ECG and pulse wave for 3 minutes, using a portable single-lead recorder (Cardio-Qvark) (Russia, Moscow). Single-lead ECG and pulse wave parameters will be analyzed using machine learning models."
214993741|NCT05581303|DRUG|Placebo|Placebo given by subcutaneous injection once every 12 weeks (Q12W).
214993742|NCT05581303|DRUG|Olpasiran|Olpasiran given by subcutaneous injection Q12W.
214993743|NCT01426529|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
214993744|NCT01426529|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
214993745|NCT01426529|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
214993746|NCT01155765|DRUG|Prasugrel|Prasugrel 10 mg/day for 15 days
214993747|NCT01155765|DRUG|Clopidogrel|Clopidogrel 150 mg/day for 15 days
214993748|NCT00481546|GENETIC|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
214380255|NCT00393523|BIOLOGICAL|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
214687296|NCT07007195|DEVICE|Instructed Use followed by Ad Libitum Use of the Inspire Device|Participants in this condition will use the novel olfactory stimulation delivery system (Inspire), to smell a specific order designed to assist with smoking cessation for 7 days. Participants will be instructed to use the Inspire device only when participants report a cigarette craving about 0 at each of the surveys prompted from the smartphone-based smoking cessation app, Insight™. On day 8, participants will receive a notification on the smartphone-based smoking cessation app, Insight™, to switch to the Ad Libitum condition. Participants will then control how often they use Inspire and will be instructed to record every urge to smoke and report times when they think they might smoke in the smartphone-based smoking cessation app, Insight™.
214993749|NCT01160614|DRUG|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
214993750|NCT06262438|DRUG|Quizartinib|"Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective but reversible inhibition of FMS-like tyrosine kinase FLT3. The dose will be adjusted for the patient's body weight (BW) as measured at the start of each course. Quizartinib will be administered orally once daily and is taken for 14 consecutive days during induction and consolidation courses.~Induction course 1: Start on day 13; Induction course 2: Start on day 9; Consolidation course 1: Start on day 6; Consolidation courses 2 and 3 (only if no allo-SCT is done): Start on day 6.~Continuation courses 1-6: patients will receive quizartinib for six 28-day courses. For the first 15 days of course 1 a starting dose will be applicable. On course 1 Day 16, the dose will be increased if the average QTc of the triplicate Electrocardiograms is ≤450 msec on course 1 Day 15. Once the dose is increased, the patient may continue on this dose as long as dose reduction is not needed."
214993751|NCT06262438|DRUG|Etoposide|"Induction course 1: 150 mg/m2 once daily by Intravenous (IV) infusion over 2 hours (+/- 30 mins) on days 1-5 inclusive (total 5 doses).~Induction course 2: 150 mg/m2 once daily by IV infusion over 2 hours (+/- 30 mins) on days 6-8 inclusive (total 3 doses).~Consolidation course 2 (only if no allo-SCT is done): 100 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 1-5 inclusive (total 5 doses)."
214993752|NCT06262438|DRUG|Dexrazoxane|"Induction course 1: 250 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on day 6-10 inclusive (total 5 days), per investigator discretion and per institutional guidelines and availability.~Induction course 2: 600 mg/m2 once daily by 15 mins IV infusion shortly before daunorubicin on day 2,4,6 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability.~Consolidation course 1: 500 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on 3-5 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability."
214993753|NCT06262438|DRUG|Mitoxantrone|"Induction course 1: 5 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 6-10 inclusive (total 5 doses). Please note that mitoxantrone and cytarabine should not be given concomitantly. Mitoxantrone should be completed before cytarabine is given.~Consolidation course 1: 10 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 3-5 inclusive (total 3 doses)."
214993754|NCT06262438|DRUG|Cytarabine|"Induction course 1: 200 mg/m2 once daily by IV infusion over 12 hours (+/- 1 hour) on days 6-12 inclusive (total 7 doses), following mitoxantrone. Induction course 2: 100 mg/m2 once daily by continuous IV infusion on days 1-2 inclusive. And 100 mg/m2 twice daily as a 30min (+/- 10 mins) IV infusion every 12 hours on days 3-8 inclusive (total 12 doses). Consolidation course 1: 1000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 min) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 2 (only if no allo-SCT is done): 3000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 mins) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 3 (only if no allo-SCT is done): 2000 mg/m2 once daily by IV infusion over 3 hours (+/- 1 hour) starting 4 hours after fludarabine on days 1-5 inclusive (total 5 doses), following fludarabine."
215092181|NCT01815632|OTHER|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
215092182|NCT01815632|OTHER|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
215092183|NCT00704561|DEVICE|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
215092184|NCT00704561|DEVICE|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
215092185|NCT00704561|DEVICE|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
215092186|NCT00704561|DEVICE|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
215092187|NCT05275322|BEHAVIORAL|Unified Protocol|The Unified Protocol for transdiagnostic treatment of EDs (hereinafter UP) is a transdiagnostic treatment based on emotional regulation published in 2011 by David H. Barlow et al. (Barlow et al., 2011). It consists of eight treatment modules, with five of them being central (mindfulness, cognitive flexibility, countering emotional behaviors, tolerating physical sensations, and emotional exposure).
215092188|NCT01919736|BEHAVIORAL|Gait Retraining|
215092189|NCT03128190|OTHER|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
215092190|NCT03762967|BIOLOGICAL|Lipoaspiration and SVF introduction.|Lipoaspiration, isolation of SVF and introduction into testis Interstitium.
215092191|NCT03762967|DRUG|Standard therapy.|Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
214380256|NCT02139657|BIOLOGICAL|RIG-C|
214380257|NCT00227864|BEHAVIORAL|Behavior Therapy|
214380258|NCT00227864|OTHER|Treatment as Usual|
214380259|NCT04618263|DRUG|GATE-101|GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
214380260|NCT04257708|DIAGNOSTIC_TEST|ultrasound|Transvaginal us to assess the cavity
214380261|NCT01947660|DRUG|Systemic analgesia + Continuous regional anesthesia|Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
214380262|NCT01947660|DRUG|Systemic analgesia|Systemic analgesia as usual
214380263|NCT03614338|BEHAVIORAL|Small changes weight loss program|"This intervention uses a small-changes approach to calorie reduction (operationalized as 6 100-calories changes per day) along with increasing leisure-time physical activity and self-regulation strategies to produce weight loss. The intervention will be delivered via 12 face-to-face group sessions."
214380264|NCT00993824|DRUG|colesevelam HCl|3.75 grams of colesevelam HCl (6 tablets)
214380265|NCT00993824|DRUG|placebo|
214380266|NCT01949597|PROCEDURE|laparoscopic surgery for deep endometriosis|
214380267|NCT05834036|DRUG|Amoxicillin Oral Capsule|Amoxicillin 875mg every 12 hours for 7 days.
214993755|NCT06262438|DRUG|Methotrexate|"Induction course 1: Methotrexate (MTX) Intrathecal therapy (IT) prophylaxis is age-adjusted. If MTX is given at diagnosis omit IT therapy on day 6 unless in case of CNS involvement (CNS3). For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently. For children with CNS2, CSF must be investigated on day 22; if leukemic cells persist, treat as CNS3.~Induction course 2, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 1, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 2 and 3, Day 1 (only if no allo-SCT is done): MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently."
214993756|NCT06262438|DRUG|Daunorubicin|Induction course 2: 60 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 2,4,6 inclusive (total 3 doses).
214993757|NCT06262438|DRUG|Fludarabine|Consolidation course 3 (only if no allo-SCT is done): 30 mg/m2 once daily by IV infusion over 30 mins (+/- 10 mins) on days 1-5 inclusive (total 5 doses).
214993758|NCT06262438|OTHER|allo-SCT|The SCT procedure is left to the discretion of the investigator and not part of this protocol.
214993759|NCT05950711|OTHER|Combination use of MBCT and IV Ketamine|Group with Major Depression who will receive a single dose of IV Ketamine embedded within a course of MBCT.
214993760|NCT05107375|BIOLOGICAL|Tetravalent influenza virus lysis vaccine|Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
214993761|NCT05107375|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
214993762|NCT01738958|BIOLOGICAL|L. retueri|two tablets a day for 6 weeks
214993763|NCT01738958|BIOLOGICAL|Placebo|
214993764|NCT01680614|BEHAVIORAL|CASI|
214993765|NCT06034743|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths:~* 1 mg per tablet for 1 mg baxdrostat Arm;~* 2 mg per tablet for 2 mg baxdrostat Arm."
214993766|NCT06034743|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
214993767|NCT04098003|DRUG|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
214993768|NCT04098003|DRUG|Placebo|Matched placebo control
215092192|NCT04391452|DIETARY_SUPPLEMENT|Stress Resist® (oral dietary supplement)|Stress Resist® (dietary supplement) is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg). Oral supplementation. All subjects in the MAGRITTE study will receive either a dietary supplement or a placebo for 28 days (morning intake). The effects on stress will be studied both with questionnaires, biological samples (blood, urine and stool), with a Heart Rate Variability test. 40 subjects (20 subjects per group) will have an fMRI exam.
215092193|NCT01713556|DRUG|Propranolol|
215092194|NCT01713556|OTHER|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
215092195|NCT01713556|DRUG|placebo|
215092196|NCT02580383|PROCEDURE|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
214993769|NCT06344364|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph-FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite score that aggregates quantitative histological features of fibrosis severity measured by high resolution quantitative image analysis.
214993770|NCT00432822|DRUG|tetrahydrobiopterin (BH4)|
214993771|NCT04597450|DRUG|Lu AG06466|Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
214380268|NCT01749072|DRUG|Gefitinib group|Gefitinib 250mg once per day until the progression disease or intolerant side effects
214380269|NCT01749072|DRUG|Vinorelbine, Ifosfamide, Mesna|Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
214380270|NCT03148236|DRUG|Vitamin C|200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
214993772|NCT04597450|DRUG|Placebo|Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
215092197|NCT00037674|DRUG|Topiramate|
214380271|NCT03148236|OTHER|Placebo|50mL infused over 30 minutes
214380272|NCT06494969|DEVICE|Intraocular pressure measurement|Intraocular pressures were measured and recorded at 8 predefined time points using a tonometer; before anesthesia induction (T1), 10 min after induction (T2), immediately before the beginning of CPB (T3), 3 minute after the beginning of CPB (T4), 3 minute after cross-clamping (T5), 3min after cross-clamp removal (T6), immediately before the weaning of CPB (T7), and end of the surgery (immediately after skin closure) (T8).
214380273|NCT01617317|DRUG|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
214380274|NCT01617317|DRUG|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG
214380275|NCT06320665|OTHER|Radiographic measurement|Measurements taken on 3D radiographs, to assess third molar inclusion and skeletal typology (vertical and sagittal)
214380276|NCT06100055|DEVICE|Rectal Irrigation|"Rectal irrigation is the introduction of warm tap water through the anal canal into the rectum to initiate defaecation.~Two alternative irrigation systems based on volume delivered exist: low-volume irrigation system depending on the manufacturer delivers approximately between 110ml to 300ml per irrigation and high-volume irrigation system delivers between 300ml to 1500ml per irrigation."
214380277|NCT05021003|OTHER|pressure biofeedback|: Core stabilization training with pressure biofeedback unit
214380278|NCT05021003|OTHER|core stabilization exercises|: Core stabilization training without pressure biofeedback unit
214380279|NCT00423852|BIOLOGICAL|filgrastim|
214380280|NCT00423852|DRUG|carboplatin|
214380281|NCT00423852|DRUG|ifosfamide|
214380282|NCT00423852|DRUG|paclitaxel|
214380283|NCT00423852|PROCEDURE|autologous hematopoietic stem cell transplantation|
214380284|NCT00423852|PROCEDURE|peripheral blood stem cell transplantation|
214380285|NCT06189404|DRUG|Tigulixostat|300 mg oral dose
214380286|NCT06189404|DRUG|Theophylline|400 mg oral dose
214380287|NCT04772053|PROCEDURE|Tumor biopsy|Archived or fresh tumor biopsy samples will be collected.
214380288|NCT06323811|DIAGNOSTIC_TEST|CMR|Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
214380289|NCT01191060|DRUG|Lenalidomide, Bortezomib|"Lenalidomide/Bortézomib/Dexamethasone cycles:~Number of cycles: 8 cycles for arm A~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
214380290|NCT01191060|DRUG|Lenalidomide, Bortezomib|"Lenalidomide Bortezomib Dexamethasone cycles:~Number of cycles: 5 cycles for arm B~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
214380291|NCT01916941|DRUG|Prazosin|
214380292|NCT01916941|DRUG|Placebo|
214497929|NCT04701203|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
214380293|NCT03491423|OTHER|Short and fast step test without measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
214380294|NCT03491423|BIOLOGICAL|glucose meter|glucose meter to measure lactatemia
214380295|NCT03491423|OTHER|ECG / heart rate|ECG and heart rate (HR) collection by telemetry
214380296|NCT03491423|OTHER|questionnaires|VAS pain assessment and evaluation of effort perception according to Borg's scale
214380297|NCT03491423|OTHER|Short and fast step test with measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
214380298|NCT02835846|DRUG|Estrogen Cream|Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
214380299|NCT02415374|OTHER|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
214380300|NCT06134323|DEVICE|medication-combined transcutaneous vagus nerve stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for active stimulation
214497930|NCT05553418|DEVICE|In-clinic wear first|Participant will remain in clinic and wear devices adhered on abdomen or arm approximately 27hrs prior to injection
214497931|NCT05553418|DEVICE|Home wear first|Device will be applied to the abdomen or arm to deliver placebo subcutaneously. After device application, participant will go home and return to clinic before delivery.
214380301|NCT06134323|DEVICE|medication-combined sham stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for sham stimulation
214380302|NCT05389891|OTHER|Hemoglobinopathy Nursing Program|"Hemoglobinopathy Nursing Program is more informative for Groupe 1 than Group 2"
214993773|NCT03437954|OTHER|Diet modification|Patients will be randomized to follow the standard post-tonsillectomy diet at our institution, which consists of soft foods for ten days, or will be in the non-restricted diet group following surgery.
214993774|NCT04529408|DEVICE|EarSats Pulse Oximeter Probe|Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
214993775|NCT04808921|DIAGNOSTIC_TEST|Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
214993776|NCT05845619|BEHAVIORAL|Enhanced virologic monitoring|"The pilot intervention will include the following components:~1. More frequent viral load collection: Participants who enroll in the first 3 months of the pilot study period will be eligible for a 3-month follow-up visit and will have viral load assessed again at that time.~2. Rapid return of viral load results: Mentor mothers (peer counselors) will be trained to return viral load results to patients. Viral loads will will be processed with GeneXpert point of care technology.~3. Enhanced viral load counseling: Mentor mothers will reinforce adherence with all patients with undetectable levels via scripted messaging to reward and encourage healthy behavior. For those with any detectable levels, mentor mothers will be trained to provide targeted counseling with scripted messaging according to viral load level (undetectable, low-level viremia (50-1000), high viral load (\>1000))."
215092198|NCT06019806|OTHER|POSTURAL CORRECTION four exercises|"The program will involve four exercises, including two strengthening exercises and two stretching exercises.~1. Chin tuck (deep cervical flexor)~2. Strengthening shoulder retractors~3. Sternocleidomastoid muscle stretch~4. Pectoralis stretch Participants will be instructed to perform three sets of 12 repetitions for the strengthening exercises, with a 30-second rest period allotted between each set. For the stretching exercises, participants will be instructed to hold each stretch for 30 seconds, with a 30-second rest period allotted between each exercise The experimental group will also receive postural Correction education"
215092199|NCT06019806|OTHER|postural Correction education with a manuscript|The control group would receive postural Correction education and they would be provided with a manuscript. They would be then guided to follow these guidelines as a home plan for four weeks. At the end of the Fourth week, they would be assessed.
215092200|NCT03710304|DRUG|Oxytocin|20 IU oxytocin or placebo ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal plus 110 ml saline by slow infusion
215092201|NCT03710304|DRUG|Tranexamic acid plus misoprostol|1 gm TA or separate placebo will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision,
215092202|NCT03710304|DRUG|misoprostol|400 μg misoprostol (2 tablets of 200 μg) will be give buccally after spinal anesthesia and few minutes before skin incision;
214380303|NCT04191681|DRUG|Sacubitril-Valsartan|Sacubitril-valsartan at low or equivalent dose to be initiated or added to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
214380304|NCT04191681|DRUG|Usual care (standard-of-care) arm|Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
215092203|NCT04024423|OTHER|Epidemiologic investigation|Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
215092204|NCT03203733|DEVICE|Cooral™|An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
215092205|NCT03203733|OTHER|cryotherapy|Oral cooling by ice chips or crushed ice or ice pop
215092206|NCT02502981|DRUG|Spironolactone|25mg orally once a day for 40 weeks
215092207|NCT02502981|DRUG|Chlortalidone|25mg orally once a day for 40 weeks
215092208|NCT04252495|DRUG|Aprocitentan|A single oral dose of 25 mg.
215092209|NCT01345552|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
215092210|NCT01762995|DRUG|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
214380305|NCT01261715|PROCEDURE|Dermabond- liquid skin adhesive|Dermabond- liquid skin adhesive
214380306|NCT04404608|DIAGNOSTIC_TEST|Complete blood picture, bone marrow aspiration cytology|none except the regular routine investigations in such cases
214380307|NCT04249219|OTHER|Viewing e-cigarette ads|All participants will see the same e-cigarette ads presented in a random order.
214380309|NCT04669223|DEVICE|Seldinger chest drain insertion|Different sizes of chest drain will be inserted with seldinger technique
214380310|NCT05590546|OTHER|No intervention|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
214380311|NCT04394585|BEHAVIORAL|smart phone app based human coaching program|"1. experimental arm~   * 1:1 coaching using smart phone app~  * Patients are provided several articles about postoperative care (symptom management, diet, and exercise) in the app.~  * Patients are encouraged to report their diet diaries and exercise everyday by the coach.~  * Patients can ask to the coach using the app and the coach answer when they check them.~2. Comparator arm - Patient have consulting with clinical nutritionist at 1 month and 3 months postoperatively."
214380312|NCT03787680|DRUG|Olaparib|300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
214380313|NCT03787680|DRUG|AZD6738|160 mg by mouth daily for days 1-7 of a 28-day cycle.
214380314|NCT02541383|DRUG|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
215092211|NCT01762995|DRUG|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
215092212|NCT01762995|DRUG|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
215092213|NCT01918449|OTHER|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
215092214|NCT01516567|DRUG|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
215092215|NCT00220207|BEHAVIORAL|Internet co-management module|
214380315|NCT02541383|DRUG|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
214380316|NCT02541383|DRUG|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
214380317|NCT05647551|DRUG|BOTOX®/VISTABEL®|Facial Injection
214993777|NCT05979883|RADIATION|Machine Learning Assisted Radiation (MLAP) RapidPlan|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist. The preliminary plan will be run through the RapidPlan module, which will give a list of possible improvements to the plan. The dosimetrist will then make an amendment to the plan according to RapidPlan suggestions, followed by plan change requests and approval by the physician.
214993778|NCT05979883|RADIATION|Radiation Therapy Standard of Care (SOC)|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist, followed by plan change requests and approval by the physician.
214993779|NCT03636477|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12"
214993780|NCT03636477|DRUG|veledimex|"* 2 doses (10mg/day, 20mg/day)~* 15 oral daily doses of veledimex"
214993781|NCT03636477|DRUG|Nivolumab|"* 2 doses (1mg/kg, 3mg/kg)~* Every 2 weeks"
214993782|NCT05705557|DEVICE|ABSOLOK™ Clip System|Use of ABSOLOK™ Clip System during parenchymal transection for open liver resection
214993783|NCT06011239|BEHAVIORAL|Team-building processes|"All staff in one of the four role groups (medical assistants (MAs); clerical/administrative staff; nursing staff; and physicians/nurse practitioners/physician assistants) will be sent an anonymous survey. The survey will ask staff to consider what help participants wish to ask for and what help participants can offer to staff in the other three roles at times when people are busy or overwhelmed. These ideas will be combined into a typed idea list for each role and then staff in clinics will discuss. Once these are finalized the clinics will implement these.~At several points during the year, the study team will send out brief surveys. These surveys will collect the clinic and job role and ask participant to rate how much effort has been made in different ways, and if there are open-ended comments about what is or is not working. This information will be used to improve the intervention at each clinic."
214993784|NCT04086264|DRUG|Azacitidine|Commercially available formulation given subcutaneously (SC) or intravenous (IV)
214993785|NCT04086264|DRUG|IMGN632|Study formulation given intravenously (IV)
214993786|NCT04086264|DRUG|Venetoclax|Commercially available formulation administered orally
214993787|NCT04762992|DRUG|subcutaneous Enoxaparin|Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
214993788|NCT04762992|OTHER|standard of care|Obsteric standard of care.
214993789|NCT06461403|DEVICE|Inhaler Trainer System|The system consists of an instrumented training inhaler capable of accurately measuring the real-time inspiratory airflow achieved by the user when they perform their inhale maneuver. The inhaler trainer system consists of a detachable/disposable mouthpiece and a reusable electronics module. The electronics module measures flow/pressure achieved by the patient and wirelessly transmits this data to a PC. The PC software analyzes the real-time inhalation flow data to enable the monitoring of the following quantities: Flow Rate, Duration, and Maximum Pressure Slope. These quantities will be used in the computation of the assessment metric, providing the user with real-time feedback about their inhalation technique. In addition, the software includes features to support the human study and provides fully functional inhaler education features for the expert test evaluators.
214993790|NCT06461403|OTHER|Initial Inhaler Use Assessment|Patients will undergo an initial assessment of their respiratory inhaler technique for their respiratory inhaler devices using device-specific checklists
214993791|NCT06461403|OTHER|Inhaler Use Instruction|Participants will then be given step-by-step verbal instructions and a copy of written instructions by the trained educator describing appropriate inhaler technique for their respiratory inhalers.
214993792|NCT05503771|BEHAVIORAL|ISA-MI|Parents seen by clinicians randomized to the intervention group will complete the Infant Sleep Assessment (ISA), either prior to their visit using MyChart (Epic patient portal) or on a tablet computer in the exam room while they wait for their clinician; 2) a Clinical Decision Support (CDS) smart form is created in the EMR based on the assessment results, with risks and MI-informed strategies highlighted; this information will be derived from a pre-programmed algorithm and theory-based, tailored communication strategies and messages; 3) the clinician uses the CDS smart form to guide counseling with the parent during the visit, applying their training in MI-informed counseling skills; and 4) Clinician gives the parent an After Visit Summary (AVS) from the EMR (or informs them that they can access the AVS in MyChart if the parent or other caregivers use the patient portal, MyChart), which summarizes and reinforces the safe sleep counseling.
214380318|NCT05647551|DEVICE|Juvéderm® VOLBELLA® with Lidocaine|Facial Injection
214380319|NCT05647551|DEVICE|Juvéderm® VOLIFT® with Lidocaine|Facial Injection
215092216|NCT02918708|BIOLOGICAL|Synflorix|10-valent pneumococcal conjugate vaccine
215092217|NCT02918708|BIOLOGICAL|Prevenar13|13-valent pneumococcal conjugate vaccine
215092218|NCT04326816|PROCEDURE|Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)|
214380320|NCT05647551|DEVICE|Juvéderm® VOLUMA® with Lidocaine|Facial Injection
214380321|NCT05425303|DIAGNOSTIC_TEST|Exposure to risk for injury|Athletes will be examined in the preseason stage and will be monitored during the competitive season.
214380322|NCT06411769|BEHAVIORAL|50K4LIfe|This intervention will consist of the Walking Challenge only.
215092219|NCT03918707|DIAGNOSTIC_TEST|Rapid Whole Genome Sequencing (rWGS)|rWGS will be performed on blood samples from subjects in the prospective group in addition to standard of care laboratory testing and imaging studies. Blood samples will also be obtained from biological parents (if available), to determine if variants are inherited or de novo and for variant segregation.
214380323|NCT06411769|BEHAVIORAL|SMS Text Messaging|In this intervention, participants will received notifications onto the Pathverse app
214380324|NCT06411769|BEHAVIORAL|Individual|In this Phase 2 individual-level intervention, participants will receive remote education modules and one-to-one monthly phone-based coaching.
214380325|NCT06411769|BEHAVIORAL|School|In this Phase 2 school-level intervention, participants will receive group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and participate in work time/weekend group walks/hikes.
214380328|NCT00785525|DRUG|Filgrastim|PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
214380329|NCT06160752|DRUG|Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
214497932|NCT05738720|DEVICE|Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer)|Pulmonary Function Test (PFT): Pulmonary function test will be performed with a Teknikel Spirobank home pulmonary function test device. In the study group, the patient will make weekly measurements at home and send it to the physiotherapist. In the control group, evaluation will be made with the device only at the beginning and end of the treatment.
214687297|NCT07007195|DEVICE|Smart-T Smoking Cessation App with the Inspire Device Condition|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempts. Smart-T app contains multiple components, including an EMA delivery and data transfer system, automated messages based on EMA responses, and on-demand content. Participants will use Smart-T for 13 weeks. Participants will also use the Inspire device.
214380330|NCT06160752|DRUG|Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
214380331|NCT04250753|OTHER|Walking task|30 meters walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30 meters walking task twice. Inertial sensors are put on each participant foot.
214380332|NCT02753348|OTHER|Echocardiography|
214380333|NCT02753348|OTHER|Blood analysis from umbilical cord blood|
214687298|NCT07007195|DEVICE|Smart-T Smoking Cessation App Without the Inspire Device Condition|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempts. Smart-T app contains multiple components, including an EMA delivery and data transfer system, automated messages based on EMA responses, and on-demand content. Participants will use Smart-T for 13 weeks.
214687299|NCT07007195|DRUG|Nicotine replacement therapy (NRT)|NRT patches will be provided to assist with cravings and withdrawal symptoms following the quit attempts.
214687300|NCT07007195|DEVICE|Inspire Device|The Inspire Device is a novel olfactory stimulation delivery system. It is a self-contained system with seven sealed chambers, with six gel matrix's that contain a distinct odor and one odorless gel matrix. Participants will press a button on the device to release an odor for participants to smell.
214687301|NCT06622005|DRUG|Cxcr1/2 Inhibitor SX-682|Given PO
214687302|NCT06622005|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
214687303|NCT06622005|DRUG|Carfilzomib|Given IV
215092220|NCT05118490|DRUG|Daily rifapentine and isoniazid for 4 weeks|Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)
214380334|NCT02753348|OTHER|ECG|
214380335|NCT02753348|OTHER|Measurement of oxygen saturation|
214380336|NCT00702416|PROCEDURE|Ultrasound-guided continuous interscalene brachial plexus block|"With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.~A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.~At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots."
214380337|NCT00702416|PROCEDURE|Continuous interscalene brachial plexus block using electrical nerve stimulation|"With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.~A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.~An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought~Injection of the local anesthetic will start with a visible motor response at a current \<0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA."
214380338|NCT00702416|DRUG|Ropivacaine|"Block induction \[1% (wt/vol) solution\]:~20 ml (200 mg)~Postoperative analgesia \[0.2% (wt/vol) solution\]:~* Background infusion: 4 ml/h (8 mg/h)~* Incremental on-demand dose: 2 ml (4 mg)~* Lockout time: 15 min"
214380339|NCT00702416|DRUG|Paracetamol|1 g iv q8h
214380340|NCT00702416|DRUG|Morphine|5 mg im prn q1h (in the postoperative period)
214380341|NCT00702416|DRUG|Fentanyl|50 µg iv prn (in the intraoperative period)
214687304|NCT06622005|DRUG|Dexamethasone|Given PO
215092221|NCT05118490|DRUG|Weekly rifapentine and isoniazid for 12 weeks|Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
215092222|NCT00327990|DRUG|Ibandronate|
215092223|NCT00327990|DRUG|Alendronate|
215092224|NCT00307554|BIOLOGICAL|Pneumococcal (vaccine)|
214993793|NCT05503771|OTHER|Standard of Care (SOC)|Parents seen by clinicians randomized to the control group will receive the usual practice that pediatric residents are taught which follows the American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age and developmentally based anticipatory guidance. As part of their training, residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
215092225|NCT04052776|DRUG|Buspirone|40mg
215092226|NCT04052776|DRUG|Levodopa-Carbidopa|400mg/100mg
215092227|NCT04052776|DRUG|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
214380342|NCT00702416|PROCEDURE|General anesthesia|"Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.~The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well."
214380343|NCT02320747|OTHER|Tai Chi|
214380344|NCT02286167|OTHER|Diet modification|All patients will be participate in the intermittent, modified Atkins diet
214380345|NCT01737281|BEHAVIORAL|Proactive outreach|Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.
214380346|NCT01737281|BEHAVIORAL|Usual care|Usual smoking cessation care from VA clinical staff.
214380347|NCT02995902|DEVICE|FLT-PET|
214380348|NCT02995902|DEVICE|MRI|
214380349|NCT01988896|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose as specified via IV infusion.
214380350|NCT01988896|DRUG|Cobimetinib|Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
214380351|NCT05341778|OTHER|Shoulder bridge|The shoulder bridge is great for, strengthening your gluteal muscles, quadriceps, hamstrings, pelvic floor, abdominals and back muscles; most notably the tiny ones which control movement of each individual vertebrae and can weaken after episodes of back pain.
214687305|NCT06622005|PROCEDURE|Biospecimen Collection|Undergo Blood sample collection
214993794|NCT04155528|OTHER|Music therapy|The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
214993795|NCT06482346|BIOLOGICAL|MT-3534|Solution for infusion; Intravenous (IV)
214993796|NCT06482346|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
214993797|NCT04365374|DEVICE|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
214993798|NCT04365374|RADIATION|Stereotactic Radiation Therapy|External Beam Radiation Therapy
214380352|NCT05341778|OTHER|Clam shell|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
214687306|NCT06622005|PROCEDURE|Bone Marrow Aspiration|Undergo Bone Marrow Aspiration
214993799|NCT04261192|OTHER|Constitution of tumor and blood samples|Constitution of tumor and blood samples
214993800|NCT05373680|DRUG|Metformin|Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
214993801|NCT05373680|DRUG|Empagliflozin|Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
215092228|NCT04052776|DRUG|Placebo oral tablet|Non-active metabolite
215092229|NCT02033213|OTHER|Restrictive group|"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
215092230|NCT02033213|OTHER|Liberal group|"A group of patients who received \> 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
214380353|NCT05341778|OTHER|Scissors|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
214380354|NCT05341778|OTHER|Adductor squeeze|Adductor Squeeze exercise The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees.
214380355|NCT05341778|OTHER|Pelvic clock supine|The pelvic clock is a brilliant exercise to help achieve flexibility and strength in the lower back, pelvic floor, and core-in order to prevent pain and injury.
214380356|NCT05341778|OTHER|urine hold and tummy tuck in|During tummy tuck patients are able to strategically tighten and reinforce the muscles around the pelvic floor, urethra, and other structures. This increased strength and support greatly reduces stress urinary incontinence
214687307|NCT06622005|PROCEDURE|Echocardiography|Undergo ECHO
214687308|NCT06622005|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214687309|NCT06622005|PROCEDURE|Computed Tomography|Undergo PET/CT
214687310|NCT06622005|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214687311|NCT07008677|OTHER|online questionaire|The online questionnaire includes demographic data: age, gender, instrument, professional background, and oral health behavior
215092231|NCT05538390|OTHER||
215092232|NCT00005079|PROCEDURE|conventional surgery|
215092233|NCT02383433|DRUG|Regorafenib|Given PO
215092234|NCT02383433|DRUG|Gemcitabine Hydrochloride|Given IV
214380357|NCT05341778|OTHER|Bridging|A bridge exercise isolates and strengthens your gluteus (butt) muscles - the gluteus maximus, medius and minimus - and hamstrings, which are the main muscles that make up the posterior chain. It is done by lying on your back with your knees bent, feet flat on the ground and at a comfortable distance from your butt.
214993802|NCT05373680|OTHER|Control|Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
214993803|NCT05143255|BEHAVIORAL|KNOW|KNow the Optimal Way (KNOW) is a manualized ADRD patient-care partner intervention designed to increase engagement in advance care planning (ACP) and completion of advance directives among early stage ADRD patients and their care partners using theoretically grounded distress tolerance techniques (inhibitory learning theory) and communication skills (cognitive-social processing theory) consistent with recommended guidelines for discussions about ACP in ADRD care.
214993804|NCT04940065|OTHER|Kesimpta|Prospective observational cohort study. There is no treatment allocation.
214993805|NCT05568511|OTHER|App-based exercise program|Remotely-controlled, app-guided exercise program
214993806|NCT05568511|OTHER|Standard of Care|These participants will follow the usual post-sepsis care after returning to home. The participants will be asked to log their daily activities in the app's health diary. The app will be activated for the baseline and follow-up physical function assessments, which will be supervised be a blinded coordinator via a video call.
214993807|NCT05797506|DRUG|Sulforaphane (Avmacol Extra Strength)|4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.
214380358|NCT05341778|OTHER|Split table top|To strengthen your abs, shoulders, arms and legs. The most important part of this move is to contract your abs fully before you start to lower your hips
214380359|NCT05341778|DEVICE|Electrical muscle stimulation|Electric stimulation works by mimicking the natural way by which the body exercises its muscles. The electrodes attached to the skin deliver impulses that make the muscles contract. It is beneficial in increasing the patient's range of motion and improves the circulation of the body.
214380360|NCT06437665|BEHAVIORAL|The intervention name in this study is ADAS-integrated driver simulation training.|The intervention involves providing older drivers (≥65 years of age) with training sessions utilizing a high-fidelity driving simulator. This training focuses on the integration and use of Lane Departure Warning (LDW), Cruise Control (CC), and Forward Proximity Warning (FPW) technologies, collectively referred to as ADAS. The training is designed to familiarize participants with these advanced driver assistance systems, enabling them to effectively utilize these features while driving.
214993808|NCT05797506|DIETARY_SUPPLEMENT|Placebo|These tablets will be matched placebos and will be provided by Avmacol.
214993809|NCT04458194|OTHER|Standard Care|Standard Care is used as a control condition. Cancer survivors assigned to this arm continue to receive standard care from their medical providers.
214993810|NCT04458194|BEHAVIORAL|YOCAS©® yoga|Yoga for Cancer Survivors, YOCAS©®, intervention is a low to moderate intensity mode of exercise that draws from two basic types of yoga; gentle Hatha and Restorative yoga. The program includes specific physical postures and mindfulness exercises focused on breathing and meditation. Cancer survivors will participate in 8 virtual YOCAS sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
214993811|NCT03621592|DEVICE|Cutimed® Sorbact®|Dialkylcarbomoyl chloride based wound dressing
214993812|NCT03621592|DEVICE|Acticoat®|Silver impregnated contact layer dressing
214993813|NCT02382380|DRUG|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
214993814|NCT02382380|OTHER|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
214993815|NCT02984410|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection
214993816|NCT02984410|PROCEDURE|Trans Oral Surgery (TOS)|TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection
214993817|NCT01149083|PROCEDURE|Biopsy|Undergo biopsy
214993818|NCT01149083|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214993819|NCT01149083|DRUG|Carboplatin|Given IV
214993820|NCT01149083|PROCEDURE|Computed Tomography|Undergo CT
215092235|NCT02312778|OTHER|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
214993821|NCT01149083|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215092236|NCT01256021|DRUG|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
214993822|NCT01149083|DRUG|Veliparib|Given PO
214993823|NCT05555043|DEVICE|Irrisafe ip|This portion of endodontic treatment includes chemical disinfection of the root canal system with these different devices that activate the disinfection solution and distribute it throughout the root canal system with ultrasonic energy.
214993824|NCT05555043|DEVICE|GentleWave System|Prepare, clean and irrigate root canals including activation of the disinfection solution and distribution throughout the root canal system.
214993825|NCT05555043|DEVICE|Waterlase iPlus|Prepare tooth and root canal, including enlargement, to debride, clean and disinfect after endodontic treatment.
214993826|NCT04153864|BEHAVIORAL|Brief Behavioral Activation Treatment|A manualized 6-8 session BA treatment delivered individually to each participant.
214993827|NCT05129150|OTHER|Ultrasound examination|Ultrasound examination with Tissue Pulsatility Imaging (TPI) TPI is a relatively simple, rapid and non-invasive ultrasound examination which consists of applying a standard ultrasound probe to the acoustic window of the temporal bone to first measure the velocity of the middle cerebral artery in Doppler mode and secondly the cerebral pulsatility (CP) of a region of approximately 10cm2 centred on the middle cerebral artery in B-Echo mode. After collecting the information, the TPI examination will be performed by MRRC staff specially trained in TPI by engineers. The duration of the examination is between 20 and 30 minutes, including hardware installation. Four 30-second PC acquisitions will be collected per examination, with the patient lying supine on the bed in the day hospital room, then one measurement every minute for 3 minutes after standing.
214993828|NCT00724945|DEVICE|balafilcon A|multifocal contact lens
215092237|NCT02535416|DRUG|ARC-520|
215092238|NCT02535416|DRUG|cetirizine|
214993829|NCT00724945|DEVICE|senofilcon A|multifocal contact lens
214993830|NCT06252207|DRUG|Desflurane|General anesthesia with desflurlane
215092239|NCT02535416|DRUG|diphenhydramine|
215092240|NCT05164146|DRUG|propofol|during the induction, remimazolam dose was controlled according to sedline (Psi target 40)
214380361|NCT04848194|PROCEDURE|skin biopsy and blood sampling|"* 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.~* A blood sample"
214380362|NCT03881176|DEVICE|PoNS Treatment|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
214380363|NCT05458024|DRUG|Vitamin D 2|300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules.
214993831|NCT06252207|DRUG|Isoflurane|General anesthesia with isoflurane
214993832|NCT04356833|DRUG|Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1|"Patients in the rt-PA group received the first dose as soon as possible after registration.~Initial dosing regime: 10 mg of rt-PA dissolved in 5 ml of diluent given every 6 hrs (resulting in a total daily dose of 40mg) for a maximum of 66 hrs, in addition to standard of care for COVID-19 acute respiratory distress syndrome (ARDS). Following protocol amendment, dosing duration was increased from 3 days to up to 14 days of rt-PA treatment."
214993833|NCT04356833|DRUG|Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV|Patients on IMV received 60mg daily over three doses for up to 14 days
214993834|NCT04356833|DRUG|Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV|NIV patients received 60mg daily over 3 doses for two days, followed by 12 days receiving 40mg daily over two doses.
214993835|NCT04817410|DRUG|Emergency Department Initiated Oral Naltrexone|Emergency Department Initiated Oral Naltrexone
214993836|NCT06517576|DEVICE|Blood glucose monitor with Digital Platform and Health Coaching|Blood glucose monitors will be used daily to measure blood glucose measurements.
214993837|NCT06517576|DEVICE|Continuous glucose monitor|Continuous glucose monitors will be used daily to measure blood glucose measurements.
214993838|NCT06517576|OTHER|Usual Care|Usual care for type 2 diabetes
214993839|NCT06327100|DRUG|Ruxolitinib|Given by PO
214993840|NCT06327100|DRUG|Tasquinimod|Given by PO
215092241|NCT05164146|DRUG|remimazolam|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
215092242|NCT01107938|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
215092243|NCT01107938|DRUG|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
215092244|NCT01107938|DRUG|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
214380364|NCT05458024|DRUG|Vitamin D2 Placebo|Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU
214380365|NCT05120648|BEHAVIORAL|Biofeedback|We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
214497933|NCT05738720|OTHER|Exercise Programme|"Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test."
214497934|NCT04243226|DEVICE|telehealth-based aerobic walking exercise|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
214497935|NCT06760793|OTHER|manual static stretching exercises on plantar flexors|A manual static stretching exercises was performed on the plantar flexors in both knee extension and flexion. The stretch was applied while the participant was in a prone position
214993841|NCT06776510|DRUG|nicotinamide adenine dinucleotid/nicotinamide mononucleotide|"Drug: intravenous nicotinamide adenine dinucleotide (Coenzyme I for Injection) administration This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with nicotinamide adenine dinucleotide (100mg/d) for 1 week.~Drug: oral nicotinamide mononucleotide administration This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with nicotinamide mononucleotide 450mg BID for 2 weeks.~The first stage is the main research stage (d0-w2), which is the core treatment period. The aim is to observe the safety and efficacy during treatment.~The second stage (w2-w8) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after treatment."
214993842|NCT01509105|BIOLOGICAL|13-valent pneumococcal vaccine|0.5mL IM (Intramuscular administration) as per recommended schedule
214993843|NCT03363035|DRUG|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
214993844|NCT03363035|DRUG|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
214993845|NCT03363035|DRUG|Enoxaparin|Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
214993846|NCT03595748|BEHAVIORAL|Peer mentorship|Participants randomized to this arm of the study will speak with their dialysis peer mentor once a week about fluid intake and adherence to dialysis.
214993847|NCT05595460|DRUG|RYZ101 Dose Level 1|Dose Level 1
214993848|NCT05595460|DRUG|RYZ101 Dose Level 2|Dose Level 2
214993849|NCT05595460|DRUG|RYZ101 Dose Level 3|Dose Level 3
214993850|NCT05595460|DRUG|RYZ101 Dose Level -1|Dose Level -1
214993851|NCT05595460|DRUG|Atezolizumab|Atezolizumab
214993852|NCT05595460|DRUG|Carboplatin|Carboplatin
214993853|NCT05595460|DRUG|Etoposide|Etoposide
214993854|NCT05934084|BEHAVIORAL|Lifestyles Implemented-Survivorship Care Plan (LS-SCP)|Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.
214993855|NCT05700526|DEVICE|Planning of multiplanar and/or multifocal osteotomies in children by using VSP, PSIs and customized structural bone allograft|Preoperative VSP is performed starting from 3D digital models obtained from DICOM data of CT-scan with a segmentation process. If applicable, a model of the contralateral limb is obtained and used as reference for the correction. The surgeon and the engineer together define the surgical strategy, establishing the correction, the design of Patient-Specific Instruments (PSIs) and the hardware to implant. Then, through VSP, an ideal model of the bone graft is designed.
214993856|NCT05700526|DEVICE|Routine preparation of bone graft according to standard protocols|The size dimensions obtained through VSP are used by the tissue bank to manually cut a structural bone graft according to the standard protocols.
214993857|NCT05700526|DEVICE|Preparation of bone graft with virtual bone-matching and GSIs|The best donor bone is identified by matching the 3D models provided by bone bank with the planned graft, considering not only the size but also the most suitable configuration of cortical and medullary bone. Then GSIs are designed and 3D printed to perform the exact cut on the donor bone according to the experimental protocol.
214993858|NCT05700526|PROCEDURE|Corrective osteotomy|The acute surgical correction is performed according to VSP using PSI and the customized bone graft. Preoperative variables (age, sex, disease, deformity), intraoperative variables (operation time, intraoperative complications, use of fluoroscopy, intraoperative bleeding) are registered.
214993859|NCT06327048|OTHER|Individual cognitive rehabilitation training based on Remind strategy was given|This training educates and learns patients from the aspects of assessment of cognitive function and strategic compensation for the impact of cognitive impairment on patients, and then conducts attention, memory and executive function training and attention retraining based on patients' cognitive function to improve patients' cognitive function
214993860|NCT05352763|DRUG|simufilam|simufilam 100 mg oral tablet, twice daily
214993861|NCT04809974|DRUG|Niagen|The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
214993862|NCT03687359|OTHER|Standard of care|Treatment as per standard practice
214993863|NCT00805688|BEHAVIORAL|Questionnaires|Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)
215092245|NCT02752464|BEHAVIORAL|Counseling|Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
214380366|NCT05851248|PROCEDURE|Buccal muco-gingival tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation. The incisions will be made in the same way as in the recipient area, including both papillae. The vertical incision will measure the distance from the cementoenamel junction (CEJ) to the bony dehiscence in the GR tooth, plus at least 2 mm. The tissue between the incisions will be elevated fjull or partial thickness close to the bone in the keratinized portion and superficially in the mucosal portion. A soft tissue substitute will be adapted and sutured to protect the donor site."
214380367|NCT05851248|PROCEDURE|Palatal connective tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation A connective tissue graft will be taken from the palatal area, at the level of the premolars, which will include the two papillae. The size of the graft will be the same as that of the recipient area. A soft tissue substitute will be adapted and sutured to protect the donor site, especially if there is exposed bone."
214993864|NCT00805688|PROCEDURE|Blood Draws|Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.
214993865|NCT00805688|DEVICE|Pedometer|Worn daily to measure physical activity.
215092246|NCT02752464|BEHAVIORAL|feedback report|All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
215092247|NCT05285306|BEHAVIORAL|PEACE Program|This pilot will consist of 3 individual telemedicine sessions to teach cognitive behavioral coping skills and provide education related to gynecologic cancer surveillance and psychological distress.
215092248|NCT03631212|BEHAVIORAL|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
215092249|NCT04912752|GENETIC|Migraine CNV|Copy number variation effect on migraine disease
215092250|NCT03038893|DIAGNOSTIC_TEST|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
214380368|NCT05701176|DIAGNOSTIC_TEST|[18F]F-AraG PET scan|\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
214380369|NCT03589742|DEVICE|AblaView® Ablation Catheter|The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
214380370|NCT04706130|DRUG|Primaquine|After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites
214380371|NCT04706130|DRUG|Artesunate|All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
214380372|NCT03653832|DRUG|Dexmedetomidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
214497936|NCT06760793|OTHER|deep friction massage on plantar flexors|Deep Friction Massage was applied to both the gastrocnemius muscle and the Achilles tendon. Participants were positioned in a prone posture for both applications
214497937|NCT06828575|OTHER|predictions|predictions of learning language models
214497938|NCT06140290|DRUG|Etrasimod Immediate Release (IR)|An immediate release tablet
214497939|NCT04042402|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
214497940|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Preperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
214993866|NCT05486169|PROCEDURE|Sleeve Gastrectomy|surgery of laparoscopic sleeve gastrectomy
215092251|NCT03038893|DIAGNOSTIC_TEST|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
214993867|NCT00003871|BIOLOGICAL|fowlpox virus vaccine vector|
214993868|NCT00003871|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
214993869|NCT05814510|BEHAVIORAL|Asthma CHAMPS full program|Full program includes (1) education for staff, students, and caregivers (2) environmental education and intervention (3) asthma care coordination (4) resources
214993870|NCT05814510|BEHAVIORAL|Asthma CHAMPS Wait List Control|Stepped wedge design
214993871|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention employing Neurofeedback|Virtual Reality-based intervention augmented with real-time EEG-based neurofeedback targeting auditory hallucinations in schizophrenia
215092252|NCT05981183|DEVICE|Transcutaneous electrical nerve stimulation unit (TENS)|The TENS unit will be applied to participants' right ear at the cymba conchae. The dose is dependent on which arm (Intervention A or Intervention B) the participant is assigned to. Participants will undergo 15 minutes of vagal nerve stimulation.
215092253|NCT05549557|DRUG|IMM40H|IMM40H is a monoclonal antibody with a molecular generated from ImmuneOnco's antibody platform. IMM40H targets CD70 (a tumor cell marker).
215092254|NCT05365126|BEHAVIORAL|Complete Vocal Technique Voice Therapy|A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
214380373|NCT03653832|DRUG|Clonidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
214380374|NCT03653832|DRUG|Propofol|Patients will continue to receive intravenous propofol according to current usual care.
214993872|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention|Virtual Reality-based intervention targeting auditory hallucinations in schizophrenia
214993873|NCT05708521|DRUG|Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery|POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
214993874|NCT05708521|DRUG|Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery|SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
214993875|NCT06433310|DRUG|L-Phenylalanine 500 mg Veg Capsule product|500 mg Veg Capsule product
214993876|NCT05415215|DRUG|Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
214993877|NCT05415215|DRUG|Pertuzumab IV|Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
214993878|NCT05415215|DRUG|Trastuzumab IV|Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.
214993879|NCT05415215|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
214993880|NCT05415215|DRUG|Investigator's Choice of Chemotherapy|Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
214993881|NCT05415215|PROCEDURE|Surgery|After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
214993882|NCT05415215|RADIATION|Radiotherapy|After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
214993883|NCT05493111|DRUG|0.003% AR-15512 ophthalmic solution|Active ingredients administered via topical ocular instillation
214993884|NCT05493111|DRUG|AR-15512 vehicle ophthalmic solution|Inactive ingredients administered via topical ocular instillation
214993885|NCT04262843|DRUG|Cyclophosphamide|Given IV
214993886|NCT04262843|DRUG|Fludarabine|Given IV
214993887|NCT04262843|DRUG|Fludarabine Phosphate|Given IV
215092255|NCT06347146|BEHAVIORAL|Financial Literacy Training (FLT) workshops|Adolescents and youths and their caregivers will receive six 1-2 hour workshop sessions that cover components on saving, and financial management. The sessions will: introduce participants to saving, saving strategies, career planning, and the utilization of financial institutions, including saving in banks.
214380375|NCT02760329|PROCEDURE|Blood draw|Biomarkers analyses
214380376|NCT02760329|PROCEDURE|Urine|Biomarker analyses
214497941|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Intraperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
214380377|NCT02760329|PROCEDURE|Lung function measurements|FEV1, FVC, PEF, FEF25-75%, IC, calculated FEV1/FVC ratio and calculated FEV1 % predicted
214380378|NCT02760329|PROCEDURE|Fractional Exhaled Nitric Oxide (FENO)|Measures level of exhaled nitric oxide.
214380379|NCT05257057|DIAGNOSTIC_TEST|Immunohistochemical staining|Immunohistochemistry will be performed on the endometrial tissue specimens
214993888|NCT04262843|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Growth factor therapy
214993889|NCT04262843|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
214993890|NCT04262843|PROCEDURE|Intensity-Modulated Radiation Therapy|Undergo TMLI
214993891|NCT04262843|DRUG|Mycophenolate Mofetil|Immunosuppressive therapy
214993892|NCT04262843|DRUG|Tacrolimus|Immunosuppressive therapy
214993893|NCT01525771|OTHER|Docetaxel|"The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.~* Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)~* Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days~* Cisplatin 60mg/m2 IV (D1) every 21 days"
214993894|NCT01970371|DRUG|plazomicin|
214993895|NCT01970371|DRUG|colistin|
214993896|NCT01970371|DRUG|meropenem|
214993897|NCT01970371|DRUG|tigecycline|
214380380|NCT04046003|BEHAVIORAL|Tai chi exercise|24-form Yang style Tai Chi (60 min/session, 3 sessions/week) for 8 weeks
214380381|NCT05654168|DIAGNOSTIC_TEST|Imaging|The thickness of the musculature to be studied will be measured with ultrasonography
214380382|NCT05229653|DRUG|Ketamine|Participants in this arm will receive intravenously (IV) ketamine (0.6 mg/kg) while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver 0.6 mg/kg ketamine over at least 30 minutes.
214380383|NCT05229653|DRUG|Placebo|Participants in this arm will receive intravenously (IV) matching equal dose of placebo while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver equal volume saline over at least 30 minutes.
214380384|NCT01845974|DEVICE|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
214380385|NCT01845974|DEVICE|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
214380386|NCT06023901|DIAGNOSTIC_TEST|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
214380387|NCT05310279|OTHER|GAIMplank|The GAIMplank video game controller will be used to play active video games.
214380388|NCT02667886|DRUG|X4P-001|Continuous, oral dosing
214380389|NCT02667886|DRUG|axitinib|Continuous, oral dosing
214380390|NCT06028958|OTHER|Neck Isometrics Exercises|Isometric exercises are tightening (contractions) of a specific muscle or group of muscles. During isometric exercises, the muscle doesn't noticeably change length. The affected joint also doesn't move. Isometric exercises help maintain strength.
214380391|NCT06028958|OTHER|Global Posture Re-Education|Global postural rehabilitation (GPR) is an approach that considers the body in its overall aspect. This technique aims to relax the envelope of the muscles (fascia) while relaxing the muscle chains to reduce the strain on the joints. The end result is a more suitable posture and less pain.
214380392|NCT05487794|DRUG|Testosterone Cypionate 100 MG/ML|Testosterone is also responsible for increasing hematocrit by stimulating erythropoiesis (Velho et al., 2017). In cisgender men, who are hypogonadal and do not adequately produce testosterone, treatment with the use of testosterone is associated with stimulation of erythropoiesis, which can potentially increase blood viscosity, resulting in secondary erythrocytosis (Hajjar et al., 1997).
214380393|NCT04893590|BEHAVIORAL|Fatigue self-management SMS intervention|Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
214380394|NCT00594217|DRUG|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
214380395|NCT00594217|OTHER|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
214380396|NCT00856947|DIETARY_SUPPLEMENT|Cholecalciferol D3|2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
214380397|NCT00856947|OTHER|Placebo tablet|2 tablets containing no active substance
214497942|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
214497943|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
214497944|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide|High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
214993898|NCT01970371|DRUG|antibiotic of Investigator's choice|
214993899|NCT01348269|DRUG|Aclasta|1 x intravenous non-current drip (infusion)
214993900|NCT01348269|DRUG|Placebo|NaCl Solution
214380398|NCT04949711|BEHAVIORAL|ridesharing voucher|Ridesharing vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
214380399|NCT04949711|BEHAVIORAL|online shopping voucher|Online shopping vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
214380400|NCT04959929|DEVICE|Focal vibration therapy|Myovolt is a wearable rehabilitative device that delivers vibration to the region of the body where the motors are worn. Participants are asked to apply the vibration to specific leg locations twice a day, for about 30 minutes at a time, and to record their response using a provided log. They may be asked to try applying the device at different location or using different vibration parameters (pulse frequency or intensity).
214380401|NCT06844539|DEVICE|Fully automated insulin delivery with CamAPS HX|Fully automated insulin delivery with CamAPS HX app, Libre 3 glucose sensor and Ypsopump insulin pump.
214380402|NCT06844539|DEVICE|Standard diabetes therapy with a glucose sensor|Standard diabetes therapy with a Freestyle Libre 3 glucose sensor
214380403|NCT03635489|DRUG|Paclitaxel|175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.
214380404|NCT03635489|DRUG|Bevacizumab|15 mg/kg IV infusion on Day 1 of each 21-day cycle.
214380405|NCT03635489|DRUG|Carboplatin|Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
214380406|NCT03635489|DRUG|Placebo|Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
214380407|NCT01454453|DRUG|Patients- dose titration|dose titration (patients) - 4-10 weeks
214380408|NCT02401074|BIOLOGICAL|Segmental Bronchoprovocation with Allergen (SBP-Ag)|Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
214380409|NCT00973570|BEHAVIORAL|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
214380410|NCT05094167|OTHER|V9|one times a day during the whole treatment
214380411|NCT05094167|OTHER|placebo|placebo
214380412|NCT02702310|OTHER|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
214380413|NCT02702310|OTHER|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
214380414|NCT05078060|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
214380415|NCT05078060|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
214993901|NCT04727749|BEHAVIORAL|Therapy Dog Team Visit|For the intervention group, patient interacts with the therapy dog, handler shares information about the therapy dog, asks about patient's pets, and offers a trading card of the therapy dog at the conclusion of the visit.
214993902|NCT04622995|DRUG|Benzodiazepine|Benzodiazepine prescribing
214993903|NCT01481779|DRUG|Glargine|Administered by SC injection via a pen device.
214993904|NCT01481779|DRUG|LY2605541|Administered by SC injection with a pen device.
214993905|NCT01481779|DRUG|Insulin Lispro|Administered by SC injection with a pen device.
214993906|NCT02827968|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
214993907|NCT02378181|BEHAVIORAL|Health Education Toolkit|An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.
214993908|NCT02378181|BEHAVIORAL|Treatment-as-usual|Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
214380416|NCT03167684|DEVICE|Oral appliance therapy|Fitted oral appliance
214380417|NCT04822844|OTHER|Lavender Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
214380418|NCT04822844|OTHER|Ginger Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
214380419|NCT04957862|PROCEDURE|Robotic Assisted Evacuation|On the day of surgery, the patient is placed in the prone position. After the Mayfield skull clamp is positioned to reduce interference, the videometric tracker of robot will automatically scan the preliminary markers to complete patient-to-image registration. Following the registration, the robotic arm will move on command according to the planned puncture trajectory and stop at a defined distance to the marked target point. The entry point is marked on the scalp along the puncture trajectory, then a scalp incision and burr-hole drilling will be performed. After penetrating the dura with unipolar electrocautery, a drainage tube will be gently inserted to the defined depth under the indication of the disinfected robotic arm. The liquefied hematoma will be withdrawn slowly by a 10 mL syringe.
214380420|NCT06374940|PROCEDURE|Manipulator-assisted Abdominal Hysterectomy|Manipulator-assisted Abdominal Hysterectomy
214380421|NCT04531163|DRUG|N Acetylcysteine|(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
214993909|NCT04890613|DRUG|CX-5461|150 mg sterile lyophilized powder containing 1% sucrose
214993910|NCT02145676|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
214993911|NCT02145676|DRUG|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
214993912|NCT04626674|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
214993913|NCT05524129|OTHER|rehabilitation exercise|Conventional rehabilitation exercise.
214993914|NCT05524129|OTHER|electrotherapy|A middle frequency electro-therapy
214993915|NCT05229588|DRUG|Lurbinectedin 4 MG Injection [Zepzelca]|"Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate."
214993916|NCT05593640|OTHER|biological samples|blood and synovial liquid will be sampled
214993917|NCT04599985|OTHER|star excursion balance training (SEBT)|The SEBT is aimed to be maintained the single limb stance on one leg while reaching farthest possible with the swing leg. An individual can reach farthest with the swing leg while maintaining the balance on the stance leg
214993918|NCT04599985|OTHER|Simplified star excursion balance training (SSEBT)|It is one of the training protocols, in a simplified way, with respect to star excursion balance test. It consists a series of reaching tasks for the lower limbs in three-directions i.e., anteromedial, medial and posteromedial.
214993919|NCT01088789|DRUG|Cyclophosphamide|Cohort 1 (J0810 Arm B), Cohort 3, Cohort 4, and Cohort 5 patients will receive 200mg/m\^2 CY administered IV on day 0 of each Cycle (every 6 months). Cohort 2 patients will receive 200mg/m\^2 CY administered IV on Day 0 of the first 3 cycles (every 28 days) and Day 0 of subsequent Cycles (every 6 months).
215092256|NCT06347146|BEHAVIORAL|Mentorship|Each adolescent and youth will have a mentor who will visit with them monthly for the duration of the intervention. The one-to-one mentorship program is intended to help AYaAIDS overcome a variety of challenges they face in daily life by fostering meaningful and lasting relationships with near peer or adult role models. Resilience theory posits that having a supportive adult outside the family reduces the impact of stress on AY's mental health. Mentors will be high school students who will be trained by the schools or NGO staff depending on study condition. All mentors will be reimbursed for their transport expenses to the field, plus an equivalent of a $5 gift card for airtime per visit.
215092257|NCT06347146|BEHAVIORAL|Income Generation Activity (IGA)|Participants will be trained on investing in income-generating activities (IGA) during the FLT workshops and will be allowed to use up to 30% of their matched savings to invest in an IGA intended to benefit the adolescent and youth (AY) and their caregiving families. The IGA portion is intended to promote economic stability.
215092258|NCT06347146|BEHAVIORAL|Youth Development Accounts (YDA)|Each adolescent and youth (AY) will receive a youth development account, which is a matched savings account held in the AY's name in a financial institution under the Central Bank (Bank of Uganda). Any of the AY's family members, relatives, or friends is encouraged to contribute towards the YDA. The account is then matched with money from the program. The match cap (maximum family contribution to be matched by the program) will be an equivalent of US$10 a month per family or US$200 for the 20-months intervention period. AY who save the maximum amount will have $600 ($200 plus $400 in match-a 2:1 match rate).
215092259|NCT03175224|DRUG|APL-101 Oral Capsules|Subjects will receive APL-101 capsules BID for oral administration.
215092260|NCT03709394|PROCEDURE|Full utrasound guidance|The target vein is directly identified by portable ultrasound device and the complete procedure of peripheral venous cathether insertion is controlled by ultrasound guidance in real time
214993920|NCT01088789|DRUG|Cyclophosphamide Pill|Cohort 1 patients (J0810 Arm C) will receive 50mg oral CY once a day starting 28 days prior to GVAX and for 28 days post-GVAX (every 6 months).
214993921|NCT01088789|BIOLOGICAL|GVAX Pancreas Vaccine|Cohort 1, 3, 4, and 5 patients will receive GVAX on day 1 of each Cycle (every 6 months). Cohort 2 patients will receive GVAX on Day 1 of the first 3 cycles (every 28 days) and Day 1 of subsequent Cycles (every 6 months).
214380422|NCT01359267|DRUG|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
214380423|NCT00943306|DRUG|lomitapide|5-60 mg po every day
214380424|NCT05765864|DIAGNOSTIC_TEST|Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3|The questionnaires will cover general and demographic data, information on previous treatments, medication received, mental disorder at discharge (ICD), psychosocial situations (ICD), physical illnesses (ICD), COVID status (vaccinated, recovered, tested), use of psychoactive substances, history of self-harm, suicide attempts, school performance, experience with peers, sexual orientation and identity, residence, family composition, family history of mental disorders, self-harm and suicide attempts.
214380425|NCT05765864|DIAGNOSTIC_TEST|Columbia Suicide Severity Rating Scale (CSSRS)|"The questionnaire is scientifically supported, has the most evidence of utility and efficacy, and is internationally accepted. It has been translated into more than 100 different languages, including Slovene. It is easy to use, suitable for all age groups and adapted for successful use outside the hospital setting, for example in schools, colleges, police, military and elsewhere. It contains 2 screening questions on suicidality and 4 more specific questions, 6 items in total.~Posner K, Brown GK, Stanley B, et al. Am J Psychiatry 2011;168:1266-77."
215092261|NCT03709394|PROCEDURE|Partial ultrasound guidance|The target vein is directly identified by ultrasound but the procedure of peripheral venous cathether insertion is performed conventionally, without ultrasound guidance
215092262|NCT03709394|PROCEDURE|No ultrasound guidance|The target vein is identified and peripheral venous catheter is inserted by conventional approach without use of any guiding devices
214380426|NCT05765864|DIAGNOSTIC_TEST|The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT)|"used for research purposes to assess the core characteristics of NSSI (form, frequency, function) as well as the secondary characteristics of NSSI (habituation, context of NSSI, perceived impact on life and treatment).~Whitlock J, Exner-Cortens D, Purington A. Psychol Assess 2014;26:935-46."
214380427|NCT05765864|DIAGNOSTIC_TEST|Experiences in Close Relationships-Relationship Structures (ECR-RS)|"Assesses the pattern of attachment to attachment figures (friend, romantic partner, mother, father) in adults and adolescents. The questionnaire has been officially translated into Slovene and used with several samples of Slovene adults and adolescents.~Fraley RC, Waller NG, Brennan KA. J Pers Soc Psychol 2000;78:350-65."
214380428|NCT05765864|DIAGNOSTIC_TEST|Trauma Symptom Checklist for Children (TSCC)|"The questionnaire helps to assess children's/adolescents' experiences of various traumatic experiences, such as physical or sexual violence, peer violence, loss, witnessing violent acts, natural disasters, etc. The questionnaire consists of 6 clinical scales (Anxiety, Depression, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), Sexual Concerns) and 2 validity scales. 6 clinical scales (Anxiety, Depressiveness, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), and 2 validity scales) are included.~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikotravmatiziranostiotrokinmladostnik. aspx"
214380429|NCT05765864|DIAGNOSTIC_TEST|Personality Assessment Inventory-Adolescent (PAI-A)|"An objective-type self-assessment questionnaire for assessing personality in adolescents. It has 264 items to be answered on a 4-point scale. 22 independent scales are obtained (Inconsistency, Rarity, Negative impression, Positive impression, Physical complaints, Anxiety, Anxiety-related disorders, Depressiveness, Mania, Paranoid, Schizophrenia, Borderline traits, Antisocial traits, Alcohol problems, Drug problems, Aggressiveness, Suicidal ideation, Stress, Lack of support, Refusal to deal, Dominance, Warmth).~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikzaocenoosebnosti-oblikazamladostnike-PAI-A.aspx"
214380430|NCT05765864|DIAGNOSTIC_TEST|Inventory Of Statements About Self-Injury; ISAS|"A self-assessment questionnaire used for research purposes to assess the basic characteristics of NSSI (form, frequency, function, time to event). It also assesses the desire to stop. The questionnaire has been previously translated into Slovene and used in a population of adolescents with self-injurious behaviour.~Glenn CR, Klonsky ED. One-year test-retest reliability of the Inventory of Statements about Self-Injury (ISAS). Assessment. 2011 Sep;18(3):375-8. doi: 10.1177/1073191111411669."
214993922|NCT06571006|OTHER|music|"The musical intervention will start 10 minutes before the lumbar puncture procedure begins and continue for another 20 minutes after the intervention. Babies will be kept away from noise during this study. W.A. It was decided to use the piece Adagio from the Violin Concerto No. 3 in G major, KV 216, composed by Mozart. The track will be played through two speakers on opposite sides, 30 cm away from the baby's ears, to optimize sound perception. High quality digital audio will be used to make babies listen. Music will be played at a level that can be heard in high noise pollution (i.e. the noise of incubator operation and the white noise of the recorder), but taking into account the permissible sound level recommended by the American Academy of Pediatrics, i.e. 65-70 dB"
214993923|NCT00075231|DRUG|Kaletra® (lopinavir/ritonavir)|
214993924|NCT00075231|DRUG|Combivir® (lamivudine, zidovudine)|
214993925|NCT00075231|DRUG|Sustiva® (efavirenz)|
214993926|NCT04152590|DEVICE|Uincare|Interactive digital healthcare system
214993927|NCT05787223|OTHER|Baseline Treatment|Control Group that will be provided with be given baseline treatment of static balance training (static exercise like standing on balance board, bounce on one foot, heel rises/toe rises, standing on one foot, jumping on trampoline)
214993928|NCT05787223|OTHER|Dynamic Training|Experimental Group that will be provided with base line treatment along with dynamic balance training (cross, side \&tandem walking, step up and down, jumping \&hopping on floor). Exercises Will be given the 40 minutes with 2 sessions per week over the period of 08 weeks
214993929|NCT03517137|DRUG|Brentuximab Vedotin|For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)
214993930|NCT03517137|DRUG|Adriamycin|For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
214993931|NCT03517137|DRUG|Vinblastine|For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)
215092263|NCT03295396|DRUG|Dordaviprone (ONC201)|Dordaviprone (ONC201) is a central nervous system (CNS)-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
215092264|NCT03317119|OTHER|Laboratory Biomarker Analysis|Correlative studies
215092265|NCT03317119|DRUG|Trametinib|Given PO
215092266|NCT03317119|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
215092267|NCT05196555|PROCEDURE|Repair of cleft palate with intravelar veloplasty (IVVP)|A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
215092268|NCT02831933|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
215092269|NCT02831933|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
215092270|NCT02831933|RADIATION|SBRT|Low-dose SBRT
215092271|NCT02831933|DRUG|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
215092272|NCT01089790|DRUG|Dutogliptin|400 mg tablet, once daily
215092273|NCT01089790|DRUG|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
215092274|NCT02687100|DRUG|Beclomethasone|beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
215092275|NCT02687100|DRUG|Placebo|patients will receive 8 mL of saline without any drug
215092276|NCT05943210|RADIATION|Short Course Radiation Therapy (scRT)|Eligible patients will receive short course radiation therapy (scRT) of 25Gy over 5 days (fractions) for their localized rectal cancer. Research bloods stool and tissue will be collected at three time points: Baseline, end of radiation therapy and at surgery.
214993932|NCT03517137|DRUG|Dacarbazine|For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
215092277|NCT05943210|PROCEDURE|Total Mesenteric Excision (TME)|Subjects are expected to undergo total mesenteric Excision(TME) even if subjects have achieved complete response by imaging.TME is a specific surgical technique used in the treatment of rectal cancer in which the bowel with the tumor is entirely removed along with surrounding fat and lymph nodes.
215092278|NCT00463554|DEVICE|GYNECARE TVT-SECUR* System|A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
215092279|NCT03568669|OTHER|NIH Toolbox Cognition Battery|An app-based cognitive assessment of executive function, attention, memory, and language that takes approximately 45 minutes to complete on an iPad
215092280|NCT05698524|DRUG|PCI 24781|Participants will take PCI-24781/Abexinostat on days 1 - 4, 8 - 11, and 15 - 18 of each 28-day cycle.
215092281|NCT05698524|DRUG|Temozolomide|Participants will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.
215092282|NCT05042284|DRUG|Non-enteric coated pancreatic enzyme preparation|The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
215092283|NCT05597332|OTHER|Care bundle for AKI|To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
215092284|NCT04584242|DRUG|gluconon tab 15mg|frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST
215092285|NCT04584242|DRUG|suganon tab 5mg|frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
215092286|NCT06957444|PROCEDURE|Sylke Adhesive Dressing|Topical wound closure device, made from silk fibroin woven mesh coated with a pressure-sensitive acrylic adhesive.
215092287|NCT06957444|PROCEDURE|Exofin Skin Glue|2-octil cyanoacrylate formulation, applied using a soft and flexible applicator.
215092288|NCT06957444|PROCEDURE|Suture Strip Plus|Flexible wound closure strip designed for primary wound closure made up of macroporous non-woven polyamide with a pressure sensitive adhesive.
214993933|NCT03517137|DRUG|Etoposide|For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)
214993934|NCT03517137|DRUG|Cyclophosphamide|For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)
214993935|NCT03517137|RADIATION|Radiation Therapy|Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.
215092289|NCT06450886|DRUG|Ulviprubart (ABC008)|All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
215092290|NCT04601896|OTHER|SF36 questionnaire via telephone interview|SF36 questionnaire via telephone interview
215092291|NCT03623009|BEHAVIORAL|An article meant to trigger certain psychosocial behaviors|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
215092292|NCT03623009|BEHAVIORAL|a neutral article|The control arm will receive a neutral article prior to completing the assessment.
215092293|NCT02636686|DRUG|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
215092294|NCT02204488|PROCEDURE|Total Joint Arthroplasty|Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
215092295|NCT02204488|PROCEDURE|Trapeziectomy|Trapeziectomy
215092296|NCT03665584|DEVICE|FxCO2 Laser|The FxCO2 laser allows a microablative effect in soft tissue.
215092297|NCT03665584|DEVICE|Sham Laser|The Sham laser will be used on the participants who receive the sham treatment.
214380431|NCT05765864|DIAGNOSTIC_TEST|The Level of Personality Functioning Scale-Brief Form 2.0; LPFSBF 2.0|"A short, user-friendly instrument that gives a quick impression of the expression of personality pathology. It consists of 12 items grouped into two higher-order domains: self-functioning and interpersonal functioning. Participants are asked to rate the 12 items on a four-point Likert scale ranging from 1 (completely false) to 4 (completely true). A total score (sum of all items), a self-functioning score (sum of items 1-6) and an interpersonal functioning score (sum of items 7-12) can be calculated. Satisfactory internal consistency and promising construct validity have been demonstrated. Sensitivity to change after three months of treatment was high.~Weekers LC, Hutsebaut J, Kamphuis JH. The Level of Personality Functioning Scale-Brief Form 2.0: Update of a brief instrument for assessing level of personality functioning. Personal Ment Health 2019;13:3-14."
214380432|NCT05765864|DIAGNOSTIC_TEST|Borderline Personality Features Scale, BPFSC-11|"The BPFS-C-11 includes BPD indicators such as affective instability, identity problems and negative attitudes. Responses to the items are on a 5-point Likert scale ranging from 'not at all true' to 'always true'. Studies have shown construct validity of interpretations of BPFS-C-11 scores through positive associations with other measures of BPD and positive associations with measures of BPD correlates, including emotional dysregulation. In a recent sample, the Cronbach's α over 4 years of follow-up was 0.86, 0.85, 0.86 and 0.90, respectively. The scale has been officially translated into Slovenian and will be used with the permission of the authors. It is intended for use by children and adolescents aged 9-11 years and consists of 11 items.~Sharp, C., Steinberg, L., Temple, J., Newlin, E. An 11-Item Measure to Assess Borderline Traits in Adolescents: Refinement of the BPFSC Using IRT . Personality Disorders: Theory, Research, and Treatment 2014;5(1):70-78."
214380433|NCT05765864|OTHER|Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV)|"It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. The evaluation is efficient and takes less than five minutes. The nurse in charge of each patient completes the DASA-YV once a day.~Dutch SG, Patil N. Validating a Measurement Tool to Predict Aggressive Behavior in Hospitalized Youth. J Am Psychiatr Nurses Assoc 2019;25:396-404."
214380434|NCT05765864|OTHER|Adolescent Self-Harm Risk Scale; ASHRS|It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. This is the scale we developed for the present study. It will be used to assess and predict the short-term risk of self-harm behaviour during hospitalisation (assessment at admission) and the long-term risk after discharge (assessment at discharge).
214380435|NCT05765864|DIAGNOSTIC_TEST|Lifetime Incidence of Traumatic Events questionnaire (LITE)|"Is a short checklist for screening and assessing the exposure to trauma in children and adolescents. It covers a broad range of potentially upsetting situations that can cause trauma to children and adolescents, such as a car accident, fire, death of a family member, exposure to threats, sexual assault, or witnessing violence. The questionnaire had been validated on a Slovene population of children and adolesscents.~Greenwald R, Rubin A. Assessment of posttraumatic symptoms in children:~development and preliminary validation of parent and child scales. Res Soc Work Pract. (1999) 9:61-75. doi: 10.1177/104973159900900105 Uršicˇ K, Bucik V, Klemencˇ icˇ S, Bratina N, Battelino T, Dovcˇ K and Drobnicˇ Radobuljac M (2021) Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia. Front. Psychiatry 12:665315. doi: 10.3389/fpsyt.2021.665315"
214380436|NCT05765864|GENETIC|Genetic methods|DNA isolation, Sequencing, Libraries preparation, Analisys; Bioinformatics (Base Calling, Variant Calling, Quantification and evaluation of short tandem repetitions, Methylation sites detection).
214380437|NCT01615354|DRUG|Aleglitazar|Multiple oral doses
214380438|NCT01615354|DRUG|Microgynon®|Multiple oral doses
214380439|NCT01615354|DRUG|Placebo|Multiple oral doses
214380440|NCT04987190|PROCEDURE|alveolar bone graft|alveolar bone graft with Scarpa fascia done when patients were at 9 year of age
214380441|NCT00372801|DRUG|Ibuprofen|
214380442|NCT00898014|GENETIC|fluorescence in situ hybridization|
214380443|NCT00898014|OTHER|immunologic technique|
214380444|NCT00898014|OTHER|laboratory biomarker analysis|
214380445|NCT02323087|DEVICE|FLEXICULT™ SSI-Urinary Kit|Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.
214497945|NCT04294446|DEVICE|Biodesign Hernia Graft|The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
214497946|NCT06789679|DRUG|Gemcitabine, albumin-bound paclitaxel, S-1|Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，q2w Gem：1000mg/m2，ivgtt，D1，q2w S-1：40-60mg Bid，PO，d1-7，q2w
214993936|NCT01866592|DRUG|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
214497947|NCT06789679|DRUG|Gemcitabine, albumin-bound paclitaxel|Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，D8，q3w Gem：1000mg/m2，ivgtt，D1，D8，q3w
214993937|NCT06465810|DRUG|Treatment of transthyretin (ATTR) amyloidosis in observational study setting|Data will be collected on patients with ATTR amyloidosis in a real-world setting
215092298|NCT01882868|DRUG|Aflibercept|Pharmaceutical form: Concentrated solution (100 mg/4 mL \[25 mg/mL\], 200 mg/8 mL \[25 mg/mL\]) for infusion; Route of administration: Intravenous
215092299|NCT01882868|DRUG|Levofolinate|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
215092300|NCT01882868|DRUG|Irinotecan|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
214380446|NCT02323087|DEVICE|ID FlexicultTM|Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
214380447|NCT04617132|BEHAVIORAL|MBCT/MBSR|This intervention teaches the practice of mindfulness - being aware of the present moment without judgement - to help reduce the emotional reactivity to thoughts and bodily sensations, which prevents downward spirals into depression, anxiety, or fear.
214497948|NCT05911230|DIAGNOSTIC_TEST|Advanced diffusion-weighted MRI (ADW-MRI)|An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.
214993938|NCT06193382|BEHAVIORAL|PCIT|Participants will receive the adapted Pocket PCIT Online via a web-based learning platform for up to 5 weeks. Participants will engage in this intervention weekly for about 1 hour per week. During engaging with the adapted Pocket PCIT Online version of PCIT, caregivers will learn positive parenting skills to increase the warmth of the parent-child relationship as well as strategies to effectively set limits. Participants will also participate in 15-minute check-in phone calls with a therapist each week throughout the course of treatment.
214993939|NCT06451120|DRUG|Platelet-Rich Plasma (PRP) Injections|Bloods will be drawn prior to the PRP injection, and repeated at 2 weeks, 12 weeks, possibly 14 weeks for crossover patients follow up visits. Under aseptic technique with a surgical drape/curtain in place to block the study subject's view of the knee. Syringes will be covered with aluminum foil and subjects will have a cover over their eyes, so that neither subjects nor the clinical investigator will know if the injection delivered is PRP injection or a normal saline injection
214993940|NCT06451120|DEVICE|Centrifuge|The Eppendorf Centrifuge is used to make the PRP. In our opinion, the centrifuge is a nonsignificant risk device. The centrifuge, sterile vials for blood collection and PRP injection syringes do not present a potential risk for serious health, safety or welfare of a subject. It is not needed to support or sustain human life. It is not of substantial importance in diagnosis, curing, mitigating or treating disease for the health, safety and welfare of the patients. There are no potential for serious risk to the health, safety or welfare of a subject.
214993941|NCT06451120|DRUG|Control saline injection|A placebo injection of 6 mL of 0.9% saline will be prepared by the unblinded research assistant in an adjacent room. The syringed will be prepared in a 10 mL syringe and covered with Aluminum foil, such that the investigator performing the injection cannot tell if there is PRP or saline to be injected.
214993942|NCT03979417|OTHER|Blood draw and liver resection|The samples are transferred to the research unit for immunological studies.
214993943|NCT02412943|OTHER|Fresh Frozen Plasma|Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
215092301|NCT01882868|DRUG|5-FU|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
215092302|NCT06206655|DIAGNOSTIC_TEST|rapid ACTH stimulation test|Take 2ml blood/saliva sample at baseline. Then, we will inject synacthen 250mcg IV to patients and collect 2ml blood/saliva after 30minutes and 60 minutes.
215092303|NCT00102284|DRUG|levodopa|
214380448|NCT02168543|DRUG|Alendronate|
214380449|NCT02168543|DRUG|Placebo|
214380450|NCT01648621|BEHAVIORAL|40 minute standardized education session|40 minute standardized education session based on the Living Well with COPD Patient's Education Tool on study enrolment to assess and improve understanding of disease and ability to monitor symptoms and recognize exacerbation
214497949|NCT06949371|OTHER|Morning chronotype|All assessment measurements determined for individuals with morning chronotype will be performed first at 09:00 in the morning and then again at 19:00 in the evening. Muscle strength balance assessments performed in the morning and evening will be compared.
215092304|NCT00102284|DRUG|rivastigmine|
215092305|NCT00102284|DRUG|pergolid|
215092306|NCT00102284|DRUG|modafinil|
215092307|NCT04544683|DRUG|Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate|Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
214993944|NCT02190201|DEVICE|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
214993945|NCT02190201|DEVICE|Direct laryngoscope|A kind of traditional laryngoscopes
214993946|NCT05866224|OTHER|Telerehabilitation program|The supervised telerehabilitation program will be performed in the home of each patient and supervised by an experienced physiotherapist with more than 4 years of clinical experience in therapeutic exercise for chronic diseases.
215092308|NCT04135014|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
215092309|NCT04135014|DRUG|Dexmedetomidine|intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
215092310|NCT04135014|DRUG|Midazolam and Dexmedetomidine|oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
215092311|NCT01992211|DRUG|Rosuvastatin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
215092312|NCT01992211|DRUG|Metformin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
215092313|NCT01992211|DRUG|BCWP_C003|Participant will be administered a single oral dose of BCWP\_C003 under Fasting condition or Fed condition according to sequence.
215092314|NCT06208566|BEHAVIORAL|Conversational Agent Zenny|The intervention group involves a newly developed conversational agent self-care program. This program consists of 40 separate modules based on empirically supported techniques. Modules include the following core sections: cognitive behavioral skills, interpersonal relationships, positive psychological growth, relaxation, goal setting, and emotional regulation skills. The modules focus on cognitive-behavioral skills for reducing emotional distress, improving behavioral activation and healthy behaviors, and problem-solving skills. The intervention was delivered via a decision-tree based conversational agent in WhatsApp messenger.
215092315|NCT06208566|BEHAVIORAL|Web-based Wellness Resources|"The control group involved referral to a menu of freely-available evidence-based wellness resources linked from the study website, Your Healthiest Self: Wellness Toolkits, Doing What Matters in Times of Stress, and How Right Now. These website choices involved self-selection of relevant modules for improving mood, reducing stress and anxiety, addressing relationship problems, and other wellness topics. These programs required only access to the websites and could be completed in a self-help format by participants at their own pace."
215092316|NCT01073930|DRUG|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
215092317|NCT01073930|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
214993947|NCT02313155|DRUG|Subcutaneous injection of TAK-850|TAK-850 0.5 mL, Subcutaneous injection
215092318|NCT01073930|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
214380451|NCT01648621|BEHAVIORAL|Individualized action plan|Individualized action plan using the Living Well with COPD template with patient individualized modification to address management strategies for exacerbation of comorbidity developed during the initial 40 minute session with case manager.
214380452|NCT01648621|BEHAVIORAL|Individualized care plan|Individualized care plan for management of COPD and comorbidities developed by the case manager in consultation with family physician and specialists.
214380453|NCT01648621|BEHAVIORAL|Standardized reinforcement/motivational interviewing and action plan teach-back sessions|Standardized reinforcement/motivational interviewing and action plan teach-back sessions based on Living Well with COPD modules as well as assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions) (telephone script; NOTE: case managers will make up to 3 attempts to contact participants during each week of the 12 weeks of weekly phone calls before determining inability to contact the participant for that week.
214497950|NCT06949371|OTHER|Evening chronotype|All assessment measurements determined for individuals with evening chronotype will be performed first at 09:00 in the morning and then again at 19:00 in the evening. Muscle strength balance assessments performed in the morning and evening will be compared.
214993948|NCT02313155|DRUG|Intramuscular injection of TAK-850|TAK-850 0.5 mL, Intramuscular injection
214993949|NCT04684316|OTHER|Electronic survey with selective consultations|Participants complete an online questionnaire, after which the 20% employees that mostly need contact with the occupational physician (based on their survey score) are invited to a consultation with the occupational physician.
214993950|NCT04426032|DIAGNOSTIC_TEST|Renal Doppler Ultrasound|Measurement of Renal resistive index
214993951|NCT00689936|DRUG|Lenalidomide and low-dose dexamethasone|"Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression"
214380454|NCT01648621|BEHAVIORAL|Tele-home monitoring|"Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.~Inclusion criteria for tele-home monitoring:~a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness \[MRC\] Class 4 \& 5 or modified MRC \[mMRC\] 3 \& 4) f. frequent ED visits (\> 2) in last 12 months~5\. 12 weeks of clinical stability with no ED visits."
214380455|NCT01648621|BEHAVIORAL|Coordinated and improved communication|Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
214380456|NCT01648621|BEHAVIORAL|Priority access|Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
214380457|NCT01648621|BEHAVIORAL|Dictated patient summary|Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
214380458|NCT01648621|BEHAVIORAL|in-hospital rehabilitation/self-management program|"Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:~1. have had a recent exacerbation, but are now clinically stable;~2. symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;~3. have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and~4. have sufficient motivation to participate."
214380459|NCT01648621|BEHAVIORAL|Smoking cessation|Referral to a smoking cessation program (as applicable)
214380460|NCT01648621|BEHAVIORAL|Action plan Respirologist|Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
214380461|NCT01648621|BEHAVIORAL|Web based self management materials|Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
214380462|NCT02081222|PROCEDURE|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
214380463|NCT01759654|BIOLOGICAL|AdimFlu-V|
214380464|NCT06245122|DRUG|CS23546|Tablets administered orally.
214380465|NCT00925821|PROCEDURE|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
214380466|NCT00925821|DRUG|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
214380467|NCT03114917|OTHER|Cognitive AppRoaches to coMbatting Suicidality (CARMS)|The investigators' psychological therapy is a recovery-focused, structured, time-limited, socio-cognitive intervention. It is based upon the investigators' recently developed treatment manual (Tarrier et al., 2013) and pilot RCTs in the community (Tarrier et al., 2014) and in prison (Tarrier et al., accepted). The intervention modifies negative appraisals of emotional regulation, social support, and interpersonal problem-solving. As a consequence, perceptions of defeat, entrapment, and hopelessness will be improved indirectly. In addition, perceptions of defeat, entrapment, and hopelessness will be worked on directly during the therapy.
214380468|NCT06391684|BEHAVIORAL|Social/non social; predictable vs unpredictable|Task 1: social predictable vs social unpredictable ; Task2 a. social \& b. non social, predictable/unpredictable (for both)
214497951|NCT06952127|OTHER|Rehabilitation program|"* 5-minute warm-up including easy global exercises~* 5 resistance training exercises targeting upper and lower muscle groups~* 30 secondes break between sets~* Cooldown with breathing and stretching exercises"
214993952|NCT00689936|DRUG|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|"lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles"
214993953|NCT00689936|DRUG|Melphalan, Prednisone and Thalidomide|Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
214380469|NCT00432081|DRUG|indomethacin|
214380470|NCT01036022|DRUG|GSK1399686|Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
214380471|NCT04904822|PROCEDURE|Vaginal bisection|Uterine bisection vaginally by scalpel 24
214380472|NCT04904822|PROCEDURE|Abdominal bisection|Uterine bisection by endokinfe
214993954|NCT04315324|DRUG|AKR1C3-activated Prodrug AST-3424|Given IV
214993955|NCT04315324|PROCEDURE|Biopsy Procedure|Undergo biopsy
214993956|NCT04315324|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214993957|NCT04315324|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
214993958|NCT04315324|PROCEDURE|Computed Tomography|Undergo CT scan
214993959|NCT00386828|DRUG|Bevacizumab:|
214993960|NCT00636571|BEHAVIORAL|Exercise|Upright bike intervention for post-surgical lung cancer survivors.
214993961|NCT04876937|DRUG|Dexmedetomidine|Dexmedetomidine is infused at a rate of 0.1-0.2 μg/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
214993962|NCT04876937|DRUG|Placebo (normal saline)|Placebo (normal saline) is infused at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
214993963|NCT00080418|DRUG|Liposome Entrapped Paclitaxel Easy to Use|
214993964|NCT00080340|DRUG|TLK286 (Telcyta) HCl for Injection|
214993965|NCT00080340|DRUG|gefitinib (Iressa)|
214993966|NCT03057418|DRUG|Aurixim|Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
214993967|NCT00166816|DRUG|sirolimus, cyclosporine, tacrolimus|
214993968|NCT04700436|DRUG|Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)|Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
214993969|NCT04700436|DRUG|Suvast tablet 10 mg (Rosuvastatin 10 mg)|\- Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)
214497952|NCT06953115|OTHER|Vagal stimulation physiotherapy with trigger point release|"The patient will be instructed to remain in a seated position, with the knee slightly ahead of the feet and the feet firmly planted on the floor, with the hips higher than the knees. The therapist will stand behind the patient. Myofascial release will be performed on the upper trapezius (UT) while the patient slowly turns their head from side to side and lets it drop forward. The therapist will then apply pressure on the opposite side of the rotation.~* Therapist's position: Behind the patient.~* Patient's position: Seated with the spine in a neutral position."
214993970|NCT01823900|DRUG|Test formulation|Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
214993971|NCT01823900|DRUG|Reference formulation|Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
214993972|NCT04293536|OTHER|Cases study|Patients with a retained device or almost
214993973|NCT02392910|DRUG|Iron Sucrose|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
214993974|NCT02392910|DRUG|Placebo|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
214993975|NCT02032485|DRUG|Indocyanine Green|An iv injection will be performed for the colorectal cancer patient before the operation.
214993976|NCT01396564|DRUG|Metformin|850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
214993977|NCT01396564|DRUG|Pioglitazone|15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
214993978|NCT01532089|BIOLOGICAL|Bevacizumab|Given IV
214993979|NCT01532089|DRUG|Erlotinib|Given PO
214993980|NCT01532089|DRUG|Erlotinib Hydrochloride|Given PO
214993981|NCT01532089|OTHER|Laboratory Biomarker Analysis|Correlative studies
214687312|NCT07007819|BEHAVIORAL|Modified Sleep and Circadian Intervention|The modified sleep and circadian intervention has 5 individual sessions that will be delivered via Zoom to parents over 12 weeks and consists of 4 cross-cutting modules (functional analysis, goal setting, motivational interviewing, sleep education), 5 core sessions, and 7 optional modules that are delivered based on personalized treatment goals. The intervention format is as follows: (1) 60-minute session with consultation on setting goals and developing an action plan to improve sleep timing, quantity, and regularity; (2) 5-minute weekly follow-ups and a 3-night sleep diary; and (3) four 30-45-minute booster sessions every 3 weeks. Child attendance is optional.
214687313|NCT07007819|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) is an active comparison treatment balanced for time and attention. Participants will be asked to maintain their typical sleep schedules. EUC sessions will review the interrelationships between stress, diet, health, exercise, and behavior, with a sleep education portion \< 10 minutes and no encouragement to change behavior. EUC sessions will be used to establish rapport and promote study retention. EUC participants will not complete weekly sleep diaries. At the end of Week 12, EUC participants will receive a 1-hour optional Zoom session with the PI on sleep education.
214687314|NCT05605327|DEVICE|EUS-guided gastroenterostomy|EUS-guided gastroenterostomy using the Hot-Axios and the WEST approach.
214687315|NCT05605327|OTHER|Laparoscopic gastroenterostomy|Laparoscopic gastroenterostomy
214687316|NCT06866262|PROCEDURE|Biopsy|Undergo biopsy
214687317|NCT06866262|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214380473|NCT02447835|DRUG|Olanzapine|Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)\[1,5\]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
214687318|NCT06866262|PROCEDURE|Computed Tomography|Undergo CT
214687319|NCT06866262|DIETARY_SUPPLEMENT|Inulin|Given PO
214993982|NCT04916678|OTHER|R-TEP EMDR intervention|"During the intervention period, trained psychologists are available in the ER and will provide preferentially a short early 1-hour R-TEP EMDR intervention for patients selected with high risk of PCLS. Patient's selection will be conducted using a score developed in previous studies. If therapist considers R-TEP EMDR unsuitable, he could provide another type of intervention (such as reassurance) that will be recorded.~When no high-risk patient is identified, the therapist could assess other patients and treat them if judged necessary. In this context, they could provide either a R-TEP EMDR or short intervention such as reassurance according to therapist assessment."
214993983|NCT04144829|PROCEDURE|HIFU|Intravaginal HIFU procedure, lengths 1.5, 3 and 4.5 mm - 200, 200 and 100 impulses respectively
214687320|NCT06866262|BIOLOGICAL|Ipilimumab|Given IV
214687321|NCT06866262|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214687322|NCT06866262|BIOLOGICAL|Nivolumab|Given IV
214687323|NCT06866262|OTHER|Questionnaire Administration|Ancillary studies
214687324|NCT07003763|DEVICE|Electroacupuncture treatment|"Participants in this group will receive electroacupuncture (EA) based on a semi-standardized protocol. Each treatment session will involve needling at six main acupoints and two supplementary points, selected based on individual symptoms.~* Main acupoints: Baihui (GV20), Yintang (EX-HN3), Guanyuan (CV4), Qihai (CV6), bilateral Zusanli (ST36), bilateral Sanyinjiao (SP6).~* Supplementary acupoints: Selected from Shenting (GV24), Sishencong (EX-HN1), Fengchi (GB20), Neiguan (PC6), Hegu (LI4), Shenmen (HT7), Yanglingquan (GB34), Taixi (KI3), and Taichong (LR3).~All patients will be placed in the supine position. After routine disinfection of all acupoints using 75% alcohol, needles will be inserted using a gentle tapping technique. Once Deqi sensation is achieved, three pairs of electrodes from an EA device will be connected to the handles of the needles at Baihui and Yintang, and bilaterally at Zusanli and Sanyinjiao. Each treatment session will last for 30 minutes."
214687325|NCT07003763|OTHER|Superficial acupuncture at Non-Acupoints|"Participants in this group will receive superficial acupuncture at six pseudo-acupoints that do not correspond to any recognized meridian or traditional acupoint. These points are anatomically matched in location (head, upper limbs, lower limbs, and trunk) to the main acupoints used in the electroacupuncture group but are located at non-meridian, non-acupoint sites in a horizontal position. Acupuncture needles will be connected to an electroacupuncture device with broken wires and thus no electrical stimulation is actually delivered.~All patients will be placed in a supine position. After routine disinfection of the selected sites using 75% alcohol, adhesive pads will be gently affixed to the designated locations. A blunt-tipped, retractable needle will then be used to lightly tap the pad, without penetrating the skin, until the patient perceives a tactile sensation, at which point the stimulation will be stopped. The needle will be retained for 30 minutes."
214993984|NCT04144829|PROCEDURE|Fibrin|Injection of 2ml platelet-rich fibrin from centrifuged for 5 min patient's blood under the urethra
214993985|NCT02806999|DRUG|Berberine; Insulin|Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
214993986|NCT02806999|DRUG|Insulin|Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
214993987|NCT00691964|BIOLOGICAL|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
214993988|NCT00691964|BIOLOGICAL|etanercept|SQ injection 50 mg BIW
214993989|NCT00691964|DRUG|placebo|SQ placebo injections for ABT-874 and etanercept
214993990|NCT05375305|DRUG|SHR8554 Injection|SHR8554 Injection; high dose
214993991|NCT05375305|DRUG|SHR8554 Injection|SHR8554 Injection; low dose
214993992|NCT05375305|DRUG|Saline Solution|Saline Solution
214993993|NCT05375305|DRUG|Morphine|Morphine
214993994|NCT01303419|DEVICE|CE-BMRI|Contrast-enhanced breast imaging using Magnetic Resonance
214993995|NCT01303419|DEVICE|DE-CEDM|Breast imaging using Dual-energy, contrast-enhanced digital mammography
214993996|NCT01995201|DRUG|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
214993997|NCT01995201|DRUG|methotrexate|stable dose
214380474|NCT00160420|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 months
214380475|NCT04686162|OTHER|bae application|"Patients will be assisted by a research team member to install and configure the application bae on their smartphone; then, they will be trained to use it.~Bae proposes 4 types of assessments :~1. 5 times a day during 3 days, every month (5 minutes) : patients can assess their emotions, their thoughts, their behavior and their occurrence context.~2. Weekly (7 minutes) : consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends), and their quality of life.~3. Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.~4. Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help.~They can contact a relative or call the psychiatric emergency service directly by clicking on a button.~Patients can try to identify their own warning signs, to prevent suicidal behavior."
214380476|NCT04238312|DEVICE|RESPeRATE™|Fifty-five anxious pediatric dental patients received a breathing session of 10 minutes, using the RESPeRATE™ device.
214993998|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
214993999|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
214994000|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
214994001|NCT04994964|DIAGNOSTIC_TEST|Electromyography|Needle vocal cord electromyography using Medtronic NIM monitor
214994002|NCT04619537|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
214994003|NCT03697746|DRUG|paracetamol|paracetamol 1000 mg vial
214380477|NCT04238312|BEHAVIORAL|Tell, Show and Do technique|Fifty-five anxious pediatric dental patients received a traditional behavior management technique (Tell-Show-Do).
214380478|NCT04362163|DEVICE|Snorkel-based improvised personal protective equipment|An improvised PPE design based on a full face snorkel mask mated to a heat-and-moisture exchange filter via a 3D printed adaptor.
214380479|NCT03070717|PROCEDURE|Observation & Diagnosis|SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
214994004|NCT03697746|DRUG|Dexketoprofen Trometamol|dexketoprofen trometamol 50 mg bulb
214994005|NCT03697746|DRUG|Ibuprofen|ıbuprofen 400 mg vial
215092319|NCT04660396|DEVICE|BVA-100|"The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin (a commonly used tag is 131I, resulting in 131I -HSA). Data inputs to the software come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and transudation rate are reported, with statistics showing the quality of the results. The subject blood samples and calibration standards are measured in a gamma counter, whose output is automatically, or manually, input to this calculation program."
215092320|NCT00959127|DRUG|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
215092321|NCT04708860|BEHAVIORAL|Prolonged Nightly Fasting|Restriction of consumption of calorie-containing food/drinks after 8pm
215092322|NCT04708860|BEHAVIORAL|Exercise|Personalized moderate-intensity, aerobic exercise and strength training
215092323|NCT02555176|DIETARY_SUPPLEMENT|Dietary intervention|Follow a low-carbohydrate diet
214380480|NCT01491074|DRUG|Tocilizumab 280 mg|Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
214994006|NCT00137319|DEVICE|Impedance threshold device|
214994007|NCT01001156|OTHER|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
214380481|NCT01491074|DRUG|NaCl 0.9% 100 ml|Placebo
214380482|NCT00576732|DRUG|Placebo|Oral solution qd or bid for 6 weeks
214994008|NCT00622518|DRUG|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
214994009|NCT02456064|BEHAVIORAL|Lifestyle counseling|"* Group medical visits~* Telephone medical consultations~* Expert patient~* Training workshops"
214994010|NCT06168214|DRUG|Rabeprazloe+bismuth+amoxicillin+clarithromycin|PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
215092324|NCT02081599|DRUG|Teneli (Teneligliptin)|
215092325|NCT02081599|DRUG|Placebo|
214380483|NCT00576732|DRUG|Risperidone high dose|Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks
214380484|NCT00576732|DRUG|Risperidone low dose|Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
214380485|NCT01769170|DRUG|Brincidofovir|
214994011|NCT06168214|DRUG|Vonoprazan+amoxicillin+clarithromycin 14 days|VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
214994012|NCT06168214|DRUG|Vonoprazan+amoxicillin+clarithromycin 7 days|VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
214994013|NCT06168214|DRUG|Vonoprazan+tetracycline+furazolidone 14 days|VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
214994014|NCT06168214|DRUG|Vonoprazan+tetracycline+furazolidone 7 days|VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
214994015|NCT06168214|DRUG|Vonoprazan+amoxicillin+furazolidone 7 days|hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.
214994016|NCT06168214|DRUG|Vonoprazan+amoxicillin+tetracycline 14 days|hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.
215092326|NCT02081599|DRUG|Insulin|
215092327|NCT01266590|DRUG|LY2216684|Administered orally
215092328|NCT01266590|DRUG|Digoxin|Administered orally
215092329|NCT04500886|DRUG|PEG-rhG-CSF|PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
214994017|NCT06168214|DRUG|Vonoprazan+amoxicillin 7 days|hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
214994018|NCT06168214|DRUG|Vonoprazan+amoxicillin 14 days|hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
214994019|NCT05316467|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|"* dietary guidance~* exercise guidance~* lifestyle intervention"
214994020|NCT05316467|DRUG|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
214994021|NCT03692806|DIETARY_SUPPLEMENT|Stablor|Stablor sachet
214994022|NCT03692806|DIETARY_SUPPLEMENT|placebo|placebo sachet
214994023|NCT05676437|DIAGNOSTIC_TEST|Stress radiography|Radiographic examination during clinical stress test of knee laxity
214994024|NCT04229576|DEVICE|TENs|Assessing the efficacy of TENs in pain relieve during office hysteroscopy .
214994025|NCT05842291|DEVICE|Active rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
214994026|NCT05842291|DEVICE|Sham rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days, using sham stimulation coils that comprehensively mimic the active condition. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
214994027|NCT05842291|DEVICE|Active rTMS with long inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 50 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
214994028|NCT01644838|DRUG|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
214994029|NCT01644838|DRUG|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
214994030|NCT00977145|BIOLOGICAL|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|"Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.~Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions."
215092330|NCT04500886|DRUG|rhG-CSF|rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
215092331|NCT04274335|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|1 gram of tranexamic acid to be administered intravenously
214380486|NCT01769170|OTHER|Placebo|
214380487|NCT04961008|OTHER|Bottle-PEP|A device that gives positive pressure from a bottle with the help of a non deflating tube
214994031|NCT04652648|DRUG|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID or 41 observation for 10 days
214994032|NCT01577121|DRUG|indomethacin|50 mg / 6 hours during 5 days
214994033|NCT01577121|DRUG|placebo|50 mg / 6 hours during 5 days
214994034|NCT06197282|PROCEDURE|Major surgery involving general anesthesia|EHR documented SAR-CoV-2 PCR nasopharyngeal swab results confirming Covid-19 status within one year of undergoing surgical procedure at Kern Medical Center.
214994035|NCT00158730|DRUG|AmBisome|
214994036|NCT00448045|BEHAVIORAL|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough. These subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
214994037|NCT00448045|BEHAVIORAL|Incentive spirometry|These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
215092332|NCT04274335|DRUG|Tranexamic Acid Oral Solution|4 grams of tranexamic acid given as an oral solution
215092333|NCT04274335|DRUG|Tranexamic Acid Injectable Product|1 gram of tranexamic acid given as 2 separate intramuscular injection
214380488|NCT04961008|OTHER|Routine physiotherapy|Routine pulmonary physiotherapy
214994038|NCT05707325|DRUG|engineered red blood cell|engineered red blood cell
214994039|NCT03788330|DEVICE|Fresh air system with filtration|Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms
214994040|NCT02013414|DEVICE|3D ultrasound-guided biopsy|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
215092334|NCT03795727|DEVICE|MD ring and precontoured sectional matrix by TOR VM|MD ring (separation ring) and precontoured sectional matrix (thickness 0.035mm hard) and a wedge was used to secure matrix in place
215092335|NCT03795727|DEVICE|Circumferential matrix and tofflemire retainer by Kerr|Circumferential matrix (thickness 0.038mm) applied by tofflemire retainer and secured in place with wedge
214380489|NCT02536638|OTHER|Exposure to pyelonephritis|Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
214380490|NCT04902222|DRUG|Morphine|Administration of 0.1 mg/kg (IBW) intravenous morphine
214380491|NCT04797182|DRUG|avatrombopag|avatrombopag,60 mg/d,po
214380492|NCT00693576|DRUG|simvastatin|20 mg simvastatin daily
215092336|NCT02595294|PROCEDURE|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
214380493|NCT01592162|DRUG|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
214994041|NCT04115722|OTHER|IBD ACTIVIT|Effect of IBD disease and activity of disease on coagulation parameters
214994042|NCT06278168|OTHER|Awareness training with using Oculus.|"The protocol consists of 2 phases:one conducted in groups,one individually. In the first session, through interactive activities such as passing a wool ball while sharing passions and interests, and filling out personal cards, participants get to know each other and develop an atmosphere of mutual acceptance.~In the second session,participants explore neurodiversity through viewing videos, guided discussions and creating symbols representative of the group concept. Optical illusions are explored to understand differences in individual perception.In addition, issues of hypersensitivity and hyposensitivity are addressed,encouraging participants to reflect on their special interests and ways of presenting themselves. The second phase consists of 12 individual meetings to promote emotional well-being and self-awareness. During the meetings, the Oculus device will be used in which relaxation videos will be shown. In addition, heart rate will be detected with sensors placed in the chest."
214994043|NCT06278168|OTHER|Awareness training without using Oculus|The control group will carry out the same steps as the experimental group, heart rate will be taken through the use of sensors but in this case the Oculus device will not be used to watch relaxation videos.
214994044|NCT02543411|DRUG|Lidocaine 1%|"Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol"
214994045|NCT02543411|DRUG|Normal saline|"Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol"
214994046|NCT05944952|DRUG|buprenorphine/naloxone|Participants will be dosed with buprenorphine/ naloxone strips
214994047|NCT05123924|OTHER|Evaluation of respiratory capacity, respiratory muscle strength and fatigue|"The demographic information of the participants will be taken with the form prepared for the people in this group. Then, respiratory function with Minispir Light Spirometer, respiratory muscle strength with MD Diagnostics RP Check and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale will be evaluated. All assessments will be completed on the same day and will not be repeated after a certain period of time."
214994048|NCT01580644|DRUG|GLPG0187 prodrug|
214994049|NCT03232944|DEVICE|Cardiac Resynchronization Therapy - MPP|The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
214994050|NCT05972135|DRUG|Teclistamab|Teclistamab will be administered subcutaneously at step-up doses on Day 1, Day 4 and Day 8, one week after first treatment dose and weekly thereafter. In participants who have a partial response (PR) or better after 6 months of therapy, dosing frequency may be reduced to every 2 weeks.
214994051|NCT05972135|DRUG|Talquetamab|Talquetamab will be administered subcutaneously at step-up doses on Day 1, Day 4, Day 8 and Day 15, one week after first treatment dose and every 2 weeks thereafter. In participants who have a very good partial response (VGPR) or better after Cycle 4, dosing frequency may be reduced to every 4 weeks
214994052|NCT05972135|DRUG|Tocilizumab|Tocilizumab will be administered as a pretreatment medication in advance of administration of the first step-up dose of teclistamab or talquetamab on Cycle 1 Day 1.
214994053|NCT02342730|BEHAVIORAL|Weight Loss Specialist|Referred to a weight loss specialist
215092337|NCT04483336|OTHER|Virtual Reality Distraction|Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.
214380494|NCT01592162|DRUG|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
214380495|NCT01592162|DRUG|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
215092338|NCT04483336|OTHER|TV Screen Distraction|A cartoon video was played on a regular TV screen.
215092339|NCT01372176|OTHER|Early Goal-Directed Nutrition|"1. Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).~2. Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.~3. Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
214380496|NCT01592162|DRUG|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
214380497|NCT01592162|DRUG|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
214994054|NCT02342730|OTHER|Quality-of-Life Assessment|Complete EORTC-QLQ questionnaires
214994055|NCT02342730|OTHER|Medical Chart Review|Chart reviews are performed
214994056|NCT05989139|PROCEDURE|NPPV/HFNC|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each. NPPV will be delivered through a full-face mask with a FiO2 starting at 100% and then titrated to achieve an SpO2 of 92-98%. Expiratory positive airway pressure (PEEP) will be firstly set to 5 cmH2O and then increased to a maximum of 15 cmH2O based on SpO2. Pressure support (PS) will be set to an initial value of 10 cmH2O and then increased if signs of respiratory distress persisted or worsened to a maximum value of 20 cmH2O. After 40 minutes, patient is shifted to HFNC ventilation support for 40 minutes.~At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
214994057|NCT05989139|PROCEDURE|HFNC/NPPV|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each.~HFNC oxygen therapy will start at a flow rate of 60 L/min and will be gradually decreased by 5 cmH2O at time if the patient experienced discomfort. FiO2 will be started at 100% and then titrated to maintain a peripheral oxygen saturation of 92%-98%. Active heating and humidification were provided using MR850, Fisher and Paykel, with a temperature chamber of 37°C. After 40 minutes, patient is shifted to NPPV ventilation support for 40 minutes At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
214994058|NCT04153136|DRUG|Sacubitril-Valsartan 49-51Mg Oral Tablet|By mouth twice daily
214994059|NCT04153136|DRUG|Placebo oral tablet|Placebo oral tablet By mouth twice daily
214994060|NCT05376358|DEVICE|MoodRing App|"Adolescents and parents in the MR arm will receive instructions to download the MR app and AWARE app, customize the app, utilize an app-based self-guided onboarding, and review questions with the research team. The MR app provides the adolescent and their parent a notification to view a weekly report predicting their mood score (i.e. depression severity level similar to the Patient health questionnaire-9). The MR app will provide a library of coping strategies for adolescents and opportunities to self-track their mood.~Clinicians in the MR Arm will get access to a MR portal online. They will be able to view patients they are a provider for. The clinician will receive in-person and/or video-based training to use the portal."
214994061|NCT05376358|OTHER|Usual Care|Adolescents and parents in the usual care arm will receive instructions to download the AWARE app. This app will only track data and will not be interactive. Otherwise they will receive care as per routine by their healthcare provider team.
214994062|NCT03225482|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
214994063|NCT03225482|BEHAVIORAL|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
214994064|NCT05508906|DRUG|Palazestrant|Complete estrogen receptor antagonist (CERAN)
214994065|NCT05508906|DRUG|Ribociclib|All subjects in Treatment Group 1 will receive palazestrant in combination with ribociclib.
214994066|NCT05508906|DRUG|Alpelisib|All subjects in Treatment Group 2 will receive palazestrant in combination with alpelisib.
214994067|NCT05508906|DRUG|Everolimus|All subjects in Treatment Group 3 will receive palazestrant in combination with everolimus.
214994068|NCT04584671|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
214994069|NCT04584671|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
214994070|NCT04584671|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
214994071|NCT04584671|DIAGNOSTIC_TEST|Six Minute Walk Test (6MWT)|Participants will perform the six minute walk test as a measure of exercise capacity
214994072|NCT04584671|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
214994073|NCT04584671|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
214994074|NCT04584671|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
214994075|NCT06403839|PROCEDURE|No preoperative dental screening|Discontinuance of mandatory preoperative dental screening prior surgical valve replacement which also can include oral surgery.
214994076|NCT05290649|DIAGNOSTIC_TEST|clinical assessment|mini mental test, pulmonary function test, respiratory muscle strength test, trunk impairment scale, timed up and go test, barthel index
214994077|NCT04392206|DRUG|Adipose Derived Mesenchymal Stem Cells|The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution
214994078|NCT05835882|BIOLOGICAL|Red Blood Cell concentrates from organ donor|"Intervention is a 3-step procedure consisting of 1) recovering blood from the donor during organ procurement; 2) processing donor blood to RBC units; 3) transfusing donor blood to recipients, if necessary during surgery.~1. Donor blood recovery. A: Donor evaluation. During the donor workup, the donor coordinator team gathers additional information from the donor relatives. If no contraindication to blood collection exists, the donor-recipient ABO-crossmatch is performed, and if negative the donor is considered eligible. B: Donor blood collection. It is carried out by a trained investigator, through the continuous autotransfusion system CATSmart (Fresenius Kabi) in the surgery room.~2. Donor blood processing, carried out using the continuous flow CATSmart device. About 4 RBC units are collected.~3. Donor RBC unit transfusion to recipients according to procedures usually adopted at our hospital (final hb level 8-9 g/dL)."
214380498|NCT01592162|DRUG|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
214380499|NCT01592162|DRUG|Propofol (B-Braun) and NaCl 0.9%|propofol administered by a closed-loop system and saline
214380500|NCT01592162|DRUG|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
214994079|NCT05733689|COMBINATION_PRODUCT|FLOT|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Docetaxel 50 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1 Every 14 Days"
214994080|NCT05733689|COMBINATION_PRODUCT|FOLFOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
214994081|NCT05733689|COMBINATION_PRODUCT|FOLFIRI|"* Irinotecan 180 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
214994082|NCT05733689|COMBINATION_PRODUCT|FOLFIRINOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Irinotecan 150 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 days"
214994083|NCT05733689|COMBINATION_PRODUCT|PACLITAXEL with or without CARBOPLATIN|"* Paclitaxel 200 mg/m2 IV on Day 1~* Carboplatin AUC 5 IV on day 1 Every 21 Days~OR~\- Paclitaxel 80mg/m2 IV on Days 1,8,15 Every 28 Days"
214380501|NCT01592162|DRUG|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
214994084|NCT05733689|COMBINATION_PRODUCT|DOCETAXEL and IRINOTECAN (alone or combined)|"* Docetaxel 35 mg/m2 IV on Days 1 and 8~* Irinotecan 50 mg/m2 IV on Days 1 and 8 Every 21 Days~* Docetaxel 75 mg/m2 IV on Day 1 Every 21 Days~* Docetaxel 150 mg/m2 IV on Day 1 Every 14 Days"
214994085|NCT05733689|DRUG|NIVOLUMAB (alone or when added to a regimen above)|"* 240 mg IV on Day 1 every 14 days, or~* 360 mg IV on Day 1 every 21 days, or~* 480 mg IV on Day 1 every 28 days"
214994086|NCT05733689|DRUG|PEMBROLIZUMAB (alone or when added to a regimen above)|"* 200 mg IV on Day 1 every 21 days, or~* 400 mg IV on Day 1 every 42 days"
214994087|NCT05733689|DRUG|Durvalumab|\- 1500 mg IV on Day 1 every 28 days
214994088|NCT05733689|DRUG|Trastuzumab|"* 8 mg/kg on Day 1, then 6 mg/kg IV every 21 days, or~* 6 mg/kg on Day 1, then 4 mg/kg IV every 14 days"
214994089|NCT06641869|DIETARY_SUPPLEMENT|procyanidin C1|Proprietarily extracted procyanidin C1
214994090|NCT06641869|DIETARY_SUPPLEMENT|Placebo|Placebo
214380502|NCT03145571|PROCEDURE|Continuity of midwifery care|Pre-natal care in rural villages performed by the midwives from the local hospital
214380503|NCT01765595|OTHER|DDI+|
214380504|NCT03771196|OTHER|Bioactive Restorative Material|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth
214380505|NCT03771196|OTHER|Resin-modified glass ionomer|Enhanced glass ionomer with acceptable mechanical properties and esthtic properties
214380506|NCT02465996|DEVICE|pCLE examination|All FD patients received pCLE examination.
214380507|NCT02465996|DRUG|Puyuanhewei|FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
214380508|NCT02914925|DEVICE|ArmeoSpring/CIT|Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
214380509|NCT05096208|BIOLOGICAL|RSVpreF (Group 1)|RSV vaccine (RSVpreF)
214380510|NCT05096208|BIOLOGICAL|RSVpreF (Group 2)|RSV vaccine (RSVpreF)
214994091|NCT06641869|DIETARY_SUPPLEMENT|PCC1 complex|5 mg of procyanidin C1. Frequency: Administered once daily. Duration: 12 weeks.
214994092|NCT06582433|OTHER|Intervention|"1. Process: implementation of pre-tests~2. Process: Solution-focused counseling, 60 minutes once a week for a total of 6 sessions~3. Final test after 2 months"
214994093|NCT02213926|DRUG|ACP-196 (acalabrutinib)|
214994094|NCT01234116|DRUG|emtricitabine/tenofovir disoproxil fumarate|Each health care worker will receive one of the Treatment Arms for 28 days.
214994095|NCT00107289|DRUG|iobenguane I 131|"Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) IV over 30 minutes to 4 hours or for 15 minutes for smaller patients on day 0. Patients undergo radiation dosimetry following the first dose of \^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.~After completion of study treatment, patients are followed at 4-6 weeks after \^131I-MIBG administration and then every 3 months for up to 1 year. Once patients are off treatment on this protocol, they will begin long term follow up through 5 years from enrollment."
214994096|NCT05096715|DRUG|Atezolizumab|Intravenous Infusion
214994097|NCT05096715|DRUG|Bevacizumab|Intravenous Infusion
214994098|NCT05096715|RADIATION|Stereotactic body radiation therapy (SBRT)|External Beam Radiation
214994099|NCT01697579|DRUG|Fosaprepitant|Administered intravenously (IV) as a single dose
214380511|NCT05096208|BIOLOGICAL|RSVpreF (Group 3)|RSV vaccine (RSVpreF)
214994100|NCT01697579|DRUG|Fosaprepitant Placebo|Administered IV as a single dose
215092340|NCT01372176|OTHER|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
215092341|NCT06202040|PROCEDURE|Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.|The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.
215092342|NCT06202040|PROCEDURE|Bilateral Rectus Sheath Block (RSB) will be performed.|When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.
215092343|NCT04558359|OTHER|Standard of Care|These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
215092344|NCT04558359|DRUG|Angiotensin II|These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
215092345|NCT06244680|DEVICE|MRI of the prostate|Patients with suspicion for prostate cancer underwent mpMRI on a new 3-Tesla-MRI scanner with a maximum gradient strength of 200 mT/m, a slew rate of 200 T/m/s and DL reconstruction for image postprocessing.
215092346|NCT02364934|DRUG|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
214497953|NCT06953115|OTHER|Positional Release Therapy|"A 30-minute session of positional release therapy will be provided every two weeks, in addition to personalized antihypertensive treatment, from the start of treatment (T0) until the final measurement (days 28 to 35 after obstetric resolution).~Keeping the cervical spine in a neutral position, the participant will be asked to lie down in a relaxed supine position. The therapist will progressively apply more pressure to the trigger points identified with their thumb. In the next step, the therapist will move to a more comfortable position that exerts less stress. The therapist will passively hold the patient's upper limbs in an abducted position, with a rest period between each repetition.~* Therapist's position: On the side of the patient.~* Patient's position: Supine."
214497954|NCT06954415|OTHER|No intervention (observational study)|Questionnaire without intervention
214497955|NCT06952959|OTHER|Acupuncture|Cosmetic acupuncture
214994101|NCT01697579|DRUG|Ondansetron|Administered IV according to local labeling and/or local standard of care
214994102|NCT01697579|DRUG|5-hydroxytryptamine 3 antagonist|Administered IV according to local labeling and/or local standard of care
214994103|NCT03159637|PROCEDURE|Laparoscopic Surgery|Insufflation of a gas (carbon dioxide) into the peritoneal cavity producing a pneumoperitoneum will be done. The positioning of the patients in Trendelenburg position will be done. intraoperative and postoperative outcomes will be assesed
214994104|NCT02587416|DRUG|Gemcabene 300 mg|1x300 mg gemcabene tablets orally once daily (QD) for 11 days
214994105|NCT02587416|DRUG|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
214994106|NCT02587416|DRUG|Atorvastatin|2x40 mg Atorvastatin tablets orally once daily (QD)
215092347|NCT02364934|DRUG|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
215092348|NCT05984485|PROCEDURE|neoadjuvant chemotherapy plus total mesorectal excision|Neoadjuvant chemotherapy regimen recommended FOLFOX6, XELON, FOLFOX, mFOLFOX for 4-6 courses, and TME surgical treatment after preoperative tumor restaging 1-2 weeks after neoadjuvant chemotherapy.
215092349|NCT05984485|PROCEDURE|total mesorectal excision|Standard total mesorectal excision
214994107|NCT01863108|BIOLOGICAL|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
214994108|NCT04635345|OTHER|External Vibrator - patient-administered.|Patient provided with external vibrator for self-use, as well as vaginal dilators.
214994109|NCT04635345|OTHER|Standard care|Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.
214994110|NCT01044498|DRUG|Tocilizumab|Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
214994111|NCT01044498|DRUG|Ortho-Novum® 1/35|Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
214994112|NCT00954083|BEHAVIORAL|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
214994113|NCT00954083|BEHAVIORAL|Routine care|Routine care
214994114|NCT00767871|DRUG|Lexapro|12 week treatment with lexapro
214994115|NCT00743093|DRUG|acetaminophen|500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
214994116|NCT00743093|DRUG|placebo|placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
214994117|NCT00820534|DRUG|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
214994118|NCT00820534|DRUG|Placebo|Placebo every 2 hous during waking hours for 96 hours
214380512|NCT05096208|BIOLOGICAL|Placebo|Placebo
214380513|NCT05842785|DRUG|Phase I dose escalation|The eligible subjects will receive TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
214380514|NCT05842785|DRUG|Phase II-HNSCC|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
214380515|NCT05842785|DRUG|Phase II-Advanced melanoma|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
214380516|NCT05842785|DRUG|Phase II-solid tumors or lymphomas|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
214380517|NCT02978001|OTHER|Stabile Isotope tracers|Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
214380518|NCT03458767|BEHAVIORAL|Eight weekly 90-minute group educational sessions|Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
214380519|NCT04338425|BEHAVIORAL|Voice call|Attending surgeons will contact with their patients on the day of surgery after discharge via voice call.
214380520|NCT04338425|BEHAVIORAL|Video call|Attending surgeons will contact with their patients on the day of surgery after discharge via video call (video conferencing application such as FaceTime or Skype)
214380521|NCT04330365|BEHAVIORAL|Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm|Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.
214380522|NCT06010901|DRUG|TQB2618 injection|TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.
214380523|NCT06010901|DRUG|Penpulimab injection|Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.
214380524|NCT06010901|DRUG|Anlotinib hydrochloride capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
214380525|NCT02920775|OTHER|Non-interventional study - retrospective database review|
214380526|NCT01905254|DEVICE|Transient elastography (TE)|TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.
214380527|NCT01905254|OTHER|Liver biopsy|Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
214380528|NCT01876641|DRUG|Vemurafenib + Cobimetinib, Decitabine|
214380529|NCT06287996|OTHER|footbath and actigraphy|Receive warm water foot bath for 4 weeks, 1 hour before going to bed every night (7-9PM), temperature 42℃ for 20 minutes, water depth 10cm above the ankle joint and wearing an actigraphy for 4 weeks
214380530|NCT06287996|DEVICE|actigraphy|Wearing an actigraphy for 4 weeks
214380531|NCT02213328|DRUG|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
214687326|NCT07003763|OTHER|Standard care|"All participants, regardless of group assignment, will receive standard care as part of routine oncological and psychological management. Standard care includes:~* Basic psychological support: General psychological counseling or emotional support provided by nursing staff or clinical psychologists as needed, without structured psychotherapy or pharmacological antidepressant interventions unless clinically indicated.~* Health education: Guidance on sleep hygiene, nutrition, and stress management, along with education about cancer-related emotional symptoms and coping strategies.~* Medication management: Participants will continue their current medications for chronic comorbidities (e.g., antihypertensives, antidiabetics) as previously prescribed. However, cancer-related medications associated with active treatment-such as chemotherapy, targeted therapies, immunotherapy, or hormonal therapy-will be excluded during the trial period to avoid confounding effects."
214687327|NCT07007676|DEVICE|real-time CGM|real-time CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.
214380532|NCT03207906|DRUG|VBP-926|Topical VBP-926 solution
214687328|NCT06866613|DRUG|Esflurbiprofen Topical System (EFTS)|One EFTS is applied to the injured area over consecutive 7 days
214380533|NCT05617001|DEVICE|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V1 and V2 in a sequential fashion along with the V4 and Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 5 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
214380534|NCT02457416|OTHER|Peanut|Treatment with peanut in increasing doses until a maintenance dose
214380535|NCT04459286|DRUG|Nitazoxanide and atazanavir/ritonavir|1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal
214687329|NCT06866613|DRUG|Placebo Patch|One placebo patch is applied to the injured area over consecutive 7 days
214380536|NCT04459286|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
214380537|NCT03861806|BEHAVIORAL|PAS true|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
214380538|NCT03861806|BEHAVIORAL|PAS sham|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
214380539|NCT00226512|DRUG|Campath-1H /ATG|
214380540|NCT02402296|DRUG|β-1,3/1,6-D-glucan|15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
214380541|NCT02402296|OTHER|Placebo|15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
214380542|NCT00737880|OTHER|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
214994119|NCT03831997|DRUG|Dextrose 5% W/ Sodium Chloride 0.225%|D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.
214994120|NCT05679505|DEVICE|Auricular transcutaneous vagus nerve stimulation|Transcutaneous vagus nerve stimulation (taVNS) was performed with an FDA-approved Vagustim stimulation device and an electrode-shaped earpiece. In the participants included in the study and randomized to two groups, i) left ear taVNS was applied to the first group and ii) double-ear taVNS was applied to the second group.
214994121|NCT02327078|DRUG|Nivolumab|specified dose and dosing schedule
214994122|NCT02327078|DRUG|Epacadostat|oral twice daily continuous at the protocol-defined dose
214994123|NCT02327078|DRUG|Chemotherapy|Specified dose on specified days
214994124|NCT06579612|OTHER|Personalized follow-up and support|After a pulmonary rehabilitation program, an interview with a professional will enable the professional to identify the barriersand enablers of physical activity engagement, and to identify (with the patient) a plan for maintaining a physical activities adapted in daily life. Adapted solutions will then be proposed.
214994125|NCT05496998|DEVICE|Medtronic Intrepid™ TMVR TF System|Patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC will have a Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR Transfemoral System
214994126|NCT02115698|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
214994127|NCT02115698|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
215092350|NCT05270798|DRUG|triiodothyronine|Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.
214380543|NCT02541214|DEVICE|Trial Nasal Mask|
214380544|NCT01025934|DRUG|Bevacizumab|
214380545|NCT01025934|OTHER|sham|
214380546|NCT02729935|DRUG|Parecoxib|40 mg of intravenous parecoxib 30 min before surgery
214380547|NCT02729935|DRUG|Placebo|An equal volume of saline
214380548|NCT01508013|BEHAVIORAL|Appearance-Focused Website Intervention|The intervention is a teen-friendly website with information concerning the health and appearance effects of indoor tanning.
214380549|NCT01508013|BEHAVIORAL|Control Website|The control website contains information about alcohol and drug abuse which is oriented for a teen audience.
214994128|NCT02115698|DIETARY_SUPPLEMENT|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
214994129|NCT02115698|DIETARY_SUPPLEMENT|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
214994130|NCT02115698|DIETARY_SUPPLEMENT|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
214994131|NCT06366841|OTHER|Psychological tests administration|Psychological tests administration to evaluate stigma, personality characteristics and quality of life of rectal and anal cancer patients.
214380550|NCT03718962|DEVICE|Surrounding needling+ phototherapy|Surrounding needling+ phototherapy
214380551|NCT03718962|DEVICE|phototherapy|phototherapy
214380552|NCT00781066|PROCEDURE|Controlled cord traction|"1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.~2. Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.~3. Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).~4. With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.~5. If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:~   * Gently hold the cord and wait until the uterus is well contracted again;~  * With the next contraction, repeat CCT with counter-pressure."
214497956|NCT06953557|DIAGNOSTIC_TEST|To compare the effect of salivary glycine , proline , lysine and alanine concentration between participants with high caries activity and participants with negative caries activity|The investigators will measure Salivary-free amino acids by using reverse phase high performance liquid chromatography
214497957|NCT06953765|OTHER|PSQI|Prospective observational cohort study: Cohort o: Stratified according to baseline sleep disorder severity (PSQI score ≥7 vs. \<7).
214497958|NCT06953765|OTHER|PQSI|PQSI-Sleep quality assessment scale
214497959|NCT06954701|DEVICE|Novel Personalizable Pessary|Novel personalizable pessary.
214687331|NCT03421990|PROCEDURE|General anesthesia|general anesthesia and regional anesthesia techniques are used
215092351|NCT02905669|DEVICE|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
215092352|NCT06034249|BEHAVIORAL|Mindfulness-Based VR|Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
215092353|NCT06034249|BEHAVIORAL|Audio|The mindfulness-based audio files for six weeks.
214380553|NCT00781066|PROCEDURE|No controlled cord traction|"1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).~2. No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).~3. After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity."
214380554|NCT00001060|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
214380555|NCT04727073|DRUG|Experimental: Spironolactone|Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was \> 30 mL/min/m2 and potassium \< 4.5 mmol/L.
214380556|NCT04727073|DRUG|Placebo Comparator|Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
214380557|NCT02294539|DRUG|Losartan 50mg/amlodipine 5mg|once daily, 1T, PO medication
214380558|NCT02294539|DRUG|Losartan 100mg/amlodipine 5mg|once daily, 1T, PO medication
214380559|NCT02294539|DRUG|Losartan 50mg/Hydrochlorothiazide 12.5mg|once daily, 1T, PO medication
214380560|NCT02294539|DRUG|Losartan 100mg/Hydrochlorothiazide 25mg|once daily, 1T, PO medication
214380561|NCT03612427|DIETARY_SUPPLEMENT|S. Cholesterol S. Triglyceride|S. Cholesterol S. Triglycerides
214380562|NCT04931394|OTHER|Adjuvant chemotherapy guided by organoid drug sensitivity test|Adjuvant chemotherapy guided by organoid will be given to pancreatic cancer patients.
214380563|NCT00347581|PROCEDURE|Base-in prism glasses for reading|
214380564|NCT00347581|PROCEDURE|Placebo reading glasses|
214380565|NCT02487095|DRUG|Topotecan|Topotecan (in combination with VX-970 (M6620) administered by intravenous (IV) Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.
214380566|NCT02487095|DRUG|VX-970 (M6620)|VX-970 (M6620 (in combination with Topotecan) administered by intravenous (IV) Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
214497960|NCT06953401|OTHER|Muscle contraction protocol for electromyographic assessment|Participants will perform a set of standardized lower limb muscle contractions (isometric, concentric, and eccentric) involving the gastrocnemius and soleus muscles while lying on an examination table and in standing position both static and dynamic as well as walking. Surface electromyography (mDurance® sEMG system) will be used to record muscle activation during each phase. The task is designed for physiological measurement only and does not constitute a therapeutic intervention. Protocol includes 3 trials per muscle and side, using standardized test conditions.
214497961|NCT06953596|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Eight rTMS sessions will be administer per day at 60-minute intervals for 5 consecutive days.~Each rTMS session will consist of 600 pulses of theta-burst stimulation (iTBS), a pattern of 3 TMS pulses every 200 milliseconds for 2 seconds (i.e., 3 x 50 Hz bursts repeated at 5 Hz) for 3 minutes at 100% of resting motor threshold. The left dorsomedial prefrontal cortex (DMPFC) will be targeted via the Fz EEG site (30% of the nasion-inion distance posteriorly along the nasion-inion line)."
214497962|NCT06952842|DRUG|ZVS203e|ZVS203e injection is a clear, transparent liquid containing a recombinant adeno-associated virus serotype 8 (rAAV8) vector that expresses humanized SauriCas9 protein and single guide RNA (sgRNA) targeting specific mutations in the RHO gene.
214994132|NCT04987879|BEHAVIORAL|Exercise|Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).
214994133|NCT04949776|DIAGNOSTIC_TEST|Mammograms|"In the women participating in the study, two strategies for reading mammograms will be carried out:~Strategy 1: Standard reading of the program. Double independent and non-consensual reading of all cases, without any artificial intelligence system (standard strategy).~Strategy 2: Reading strategy based on the global Score granted by Transpara® (strategy based on artificial intelligence):~* In studies with a Score \<8 (studies with a low probability of cancer): They will not be evaluated by any radiologist.~* In studies with a Score\> 7 (studies with a high probability of cancer): double reading will be carried out, assisted by Transpara®."
214994134|NCT05428917|BEHAVIORAL|Simple task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform flexion / extension movements of the fingers of the left hand at 0.5 Hz."
214994135|NCT05428917|BEHAVIORAL|complex task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform an exercise based on the nine hole peg test"
214994136|NCT03540940|OTHER|PEEP|7cmH2O positive end expiratory pressure
214994137|NCT03540940|OTHER|ZEEP|0 cmH2O positive end expiratory pressure
214994138|NCT05052008|DRUG|Erenumab|Erenumab is monoclonal antibody used for management of migraine
214380567|NCT00347243|PROCEDURE|phacoemulsification (cataract surgery)|
214380568|NCT03555357|OTHER|Platelet Rich Fibrin|Platelet Rich Fibrin (PRF) is the next generation of PRP and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. Due to a lack of anticoagulant in the tube, PRF becomes a gel after 15-20 minutes of being isolated. These properties make PRF useful in reconstructive and aesthetic medicine but may also be beneficial for scar therapy in the same way PRP is currently used.
214380569|NCT03555357|OTHER|Platelet Rich Plasma|Platelet Rich Plasma (PRP) has been used in surgical settings to stimulate healing and promote tissue regeneration. In the field of cosmetic medicine, PRP has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss therapies, laser treatments, and microneedling. Harvested PRP has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis
214380570|NCT05998200|OTHER|Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA|Participants will used the serum twice daily for 8 weeks
214380571|NCT01802255|DRUG|Sevoflurane|Sedation with inhaled anesthetic via AnaConDa.
214380572|NCT01802255|DRUG|Midazolam|Intravenous sedation.
215092354|NCT02404428|DIETARY_SUPPLEMENT|Standard broccoli soup|300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
215092355|NCT02404428|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
215092356|NCT03970369|BEHAVIORAL|Usual care|Personalized goals and an activity prescription.
215092357|NCT03970369|BEHAVIORAL|Monitor|Participants wear a step counter to track activity goals.
215092358|NCT02446080|DIETARY_SUPPLEMENT|Milk drink with probiotic culture|The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
215092359|NCT02446080|DIETARY_SUPPLEMENT|Milk drink|The control group was asked to drink 150 ml per day of dairy drinks.
215092360|NCT00720343|DRUG|Choline|Oral Choline 20 grams before surgery
215092361|NCT00720343|DRUG|Placebo|Gelatin Capsule
215092362|NCT03305978|DEVICE|Ultra low dose chest CT|An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
214994139|NCT04975867|OTHER|Targeted therapeutic hypothermia|Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
214994140|NCT04975867|OTHER|Targeted therapeutic normothermia|Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
214994141|NCT05331144|DRUG|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.
214994142|NCT05331144|OTHER|PCP|Participants will follow their PCP's recommendations for BP control.
214994143|NCT04963920|DEVICE|Cytosorb® 300 ml|patients will receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines
214994144|NCT05756153|DRUG|GFH925|GFH925 tablets administered orally daily.
214994145|NCT05756153|DRUG|Cetuximab|Cetuximab administered intravenously Q2W.
214994146|NCT06138275|DRUG|Elranatamab|subcutaneous (under the skin) injection
214994147|NCT04147494|PROCEDURE|Computed Tomography|Undergo PET/CT scan
215092363|NCT03305978|DEVICE|Low dose chest CT|standard diagnostic low dose chest CT
215092364|NCT06964620|DRUG|Sanggua tablets|Patients will continue their background medications and receive Sang Gua tablets, twice daily (bid).
215092365|NCT06964620|DRUG|Placebo|Patients will continue their background medications and receive placebo, twice daily (bid).
215092366|NCT05862649|OTHER|NeuraLight|NeuraLight software-based platform
215092367|NCT06494085|OTHER|Measuring Respiratory Mechanics|"First, for each patient enrolled we will perform inspiratory and expiratory occlusions - routinely performed diagnostic maneuvers to measure patient's breathing effort - at the clinically set level of breathing assistance by the mechanical ventilator. Importantly, we will measure pressure-muscle-index (PMI).~Second, we will set the level of assistance (i.e. pressure support, PS) in order to make PMI=0. The PS level at which PMI=0 (PS PMI=0) will be used as reference for the study protocol. After 5 minutes at PS PMI=0 we will perform inspiratory and expiratory occlusions."
215092368|NCT06494085|OTHER|Randomized Pressure Support|3 steps of PS above (+2, +4, +6 cmH2O) and 3 below (-2, -4, -6 cmH2O) PSPMI=0 done in a randomized order (sequence in envelopes opened blindly by the investigators). Each step will last ≤5 minutes if poorly tolerated (see tolerance rule in description). At the end of each step we will perform 1 inspiratory occlusion and 3 expiratory occlusions. Each of the expiratory occlusion will be separated by 30 seconds in order to restore the patient's breathing pattern. We will resume a 3-minutes clinical PS in between each step to minimize changes in PaCO2. If not yet comprised by the study steps each patient will undergo an adjunctive 5 minutes step at PS 0 (zero) cmH2O.
215092369|NCT05315726|OTHER|Dynamometer|Measurement of elbow/wrist spasticity
215092370|NCT05315726|OTHER|Muscle vibrations|1 session of 10 minutes
215092371|NCT05315726|OTHER|Muscle vibrations|3 times/week for 6 weeks
214380573|NCT01965379|OTHER|Restriction on food containing phosphorus additives|The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.
214380574|NCT01965379|OTHER|Standard care|The control group mantained the usual renal diet oriented prior to the study with a booklet.
214380575|NCT00775814|DRUG|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
214380576|NCT00775814|DRUG|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
214380577|NCT01680393|DEVICE|Sequential compression device|a sequential compression device will be applied to the legs
214380578|NCT01680393|OTHER|TED stockings|TED stockings will be applied to the patients legs during surgery
214380579|NCT01807650|DRUG|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
214380580|NCT01807650|DEVICE|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
215092372|NCT05315726|OTHER|Placebo muscle vibration|3 times/week for 6 weeks
214380581|NCT02260401|OTHER|Individualized report|Each patient will receive an individualized report that contains their own outcome data for the first years of the LESS trial (including pain and function following treatment with epidural injections)
214994148|NCT04147494|RADIATION|Gallium Ga 68 FAPi-46|Given IV
214994149|NCT04147494|RADIATION|Gallium Ga 68-labeled PSMA-11|Given IV
214994150|NCT04147494|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214380582|NCT03076944|DRUG|UltraEZ|Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.
214380583|NCT03076944|DRUG|Enamelast|Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.
214994151|NCT04147494|RADIATION|18F-FDG|Given IV
214994152|NCT01966367|BIOLOGICAL|CD34 Stem Cell Selection Therapy|The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
214994153|NCT06062108|OTHER|Pain evaluation|All included patients will have an evaluation of their pain, if they have no pain, the assessment stop with one date (pain or no pain), if they have pain, an assessment is done (localization of the pain, pain intensity), if they have a pain duration over 3 months, a DN4 questionnaire, HAD scale, ISI scale and SF-1 questionnaire is evaluated.
214994154|NCT05884983|PROCEDURE|participants will undergo dual-energy CT and endoscopy|Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy
214994155|NCT05513950|BIOLOGICAL|CHF10067 starting dose -- 1000mg (Cohort A)|Intravenous administration of a starting dose of the monoclonal antibody
214994156|NCT05513950|BIOLOGICAL|CHF10067 intermediate dose -- 2000mg (Cohort B)|Intravenous administration of an intermediate dose of the monoclonal antibody
214994157|NCT05513950|BIOLOGICAL|CHF10067 high dose -- 3000mg (Cohort C)|Intravenous administration of a high dose of the monoclonal antibody
214994158|NCT05513950|DRUG|Placebo|Intravenous administration of a physiological solution as placebo
214994159|NCT04871477|OTHER|Communication Intervention|Audio record part of clinic visit
214994160|NCT04871477|OTHER|Questionnaire Administration|Ancillary studies
214994161|NCT06504446|DRUG|NOC-110|Inhalation powder
214994162|NCT06504446|OTHER|Placebo|Inhalation powder
214994163|NCT06001866|BEHAVIORAL|Retrieval-based verb learning: Repeated Spaced Retrieval condition|"A set of novel verbs are practiced on 2 consecutive days (the same verbs are used each day). Half of the novel verbs are learned in the repeated spaced retrieval condition and half are learned in the repeated study condition, with the two conditions interleaved on each day.~The repeated spaced retrieval condition consists of study and retrieval trials. At the start of the sessions, retrieval trials immediately follow study trials. Thereafter, retrieval trials are spaced for each verb, occurring after 3 other words have intervened between the retrieval trial and the last study trial for that verb."
214994164|NCT06001866|BEHAVIORAL|Retrieval-based verb learning: Repeated Study condition|"A set of novel verbs are practiced on 2 consecutive days (the same verbs are used each day). Half of the novel verbs are learned in the repeated spaced retrieval condition and half are learned in the repeated study condition, with the two conditions interleaved on each day.~The repeated study condition consists of study trials only (with no retrieval practice)."
214994165|NCT02903914|DRUG|INCB001158|Arginase Inhibitor
214380584|NCT02486679|DRUG|Prostin (PGE2) tablets|
214994166|NCT02903914|DRUG|Pembrolizumab|PD-1 Inhibitor
214994167|NCT04002180|DRUG|Vedolizumab (Genetical Recombination)|Vedolizumab IV infusion
214994168|NCT03817970|DRUG|Granisetron|An antiemetic regimen containing granisetron 2 mg oral or IV.
214994169|NCT03817970|DRUG|Ondansetron|An antiemetic regimen containing ondansetron 8 mg oral or IV.
214994170|NCT03817970|DRUG|Palonosetron|An antiemetic regimen containing palonosetron 0.25 mg IV.
214994171|NCT03968406|OTHER|Quality-of-Life Assessment|Ancillary studies
215092373|NCT05293626|DRUG|NR082 Injection|"The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC."
214497963|NCT06954506|BEHAVIORAL|Reiki Group|Patients were informed about the application, and a Reiki application video prepared/selected by the researchers was shared with the patients. Patients were asked to perform Reiki every day for a week following each chemotherapy session for 4 cycles. A reminder message was sent to the patients the day before each cycle for the Reiki application. The level of hopelessness was reassessed at the end of each week.
214497964|NCT06954090|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide will be introduced at a dose of 0.25 mg/week subcutaneous injection, escalated to 0.5 and 1.0 mg/week after 4 and 8 weeks if tolerated.
214994172|NCT03968406|RADIATION|Radiation Therapy|Undergo radiation therapy
214994173|NCT03968406|DRUG|Talazoparib|Given PO
214994174|NCT05777408|PROCEDURE|Conventional Physical Therapy|"* 15 mins of TENS (frequency 100 Hz, phase duration 50 μs) with moist heat over the area of pain~* Isomeric Stretching of neck muscles followed by neck isometrics"
215092374|NCT05293626|DEVICE|Injection needle|"19G 1 1/2IN TW filter needle with filter element (BD 305200)，used to NR082 Intraocular injection solution dose preparation; 30G 1/2IN injection needle (BD 305106)，used to NR082 Intraocular injection solution administration;~1 ml screw top syringe (BD 309628),used to NR082 Intraocular injection solution dose preparation and administration."
214380585|NCT02486679|DEVICE|Foley catheter|
214380586|NCT06243185|DRUG|Dalpiciclib plus letrozole|Dalpiciclib 150mg qd, d1-21, repeated once every 4 weeks. Letrozole 2.5mg qd, repeated once every 4 weeks.
214380587|NCT01674348|DRUG|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
214380588|NCT01674348|DRUG|Placebo|Placebo
214380589|NCT00762632|DRUG|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
214380590|NCT00762632|DRUG|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
214380591|NCT02244164|DRUG|Incretinomimetics|
214994175|NCT05777408|PROCEDURE|Natural Apophyseal glides|-Will be applied in sitting position Therapist right hand would cradle the head such that the little finger would rest on the spinous process of the vertebra that is to be mobilized. The other hands thumb would be used to apply over pressure. Direction of force will be parallel to highly irritable-grossly restricted cervical facet joints. Intervention would involve 3 sets of 20 repetitions in 15minutes, 3 days a week for 2 weeks comprising of total 6 session.
214380592|NCT02244164|DRUG|DPP-4 inhibitors|
214380593|NCT02645084|OTHER|Offering an online risk assessment questionnaire|Offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
214497965|NCT06954090|DRUG|Finerenone Oral Tablet|Finerenone will be introduced at a dose of 10 mg/day in patients with a serum potassium level \< 4.8 mmol/l and eGFR \< 60 ml/min/1.73 m2 and escalated to 20 mg/day after 4 weeks if the serum potassium level is still \< 4.8 mmol/l. Starting dose is 20 mg/day if eGFR ≥ 60 ml/min/1.73 m2. The dosage will be reduced or discontinued in patients who develop hyperkalemia (serum potassium \> 5.5 mmol/l).
214497966|NCT06954090|DRUG|Dapagliflozin (DAPA)|Dapagliflozin will be introduced at a dose of 10 mg/day. The dose can be reduced at any time during the trial if required by the subject's tolerance to the product.
214497967|NCT06737263|DEVICE|BioHPP abutment|Patients in the test group receive abutments made of BioHPP
214497968|NCT06737263|DEVICE|Titanium abutment|Patients in the control group receive abutments made of titanium
214497969|NCT06737263|DEVICE|Zirconia abutment|Patients in the control group receive abutments made of zirconia
214497970|NCT06765616|DRUG|Adebrelimab Injection combined with radiotherapy and chemotherapy|"Radiotherapy regimen: SCRT short-term radiotherapy of 5 × 5Gy Immunotherapy regimen: Adebrelimab Injection 1200 mg or 20 mg/kg, iv., followed by administration on the 1st day of each subsequent chemotherapy cycle.~Chemotherapy regimen: CAPOX regimen (chemotherapy cycle d1, to chemotherapy cycle d14):~Oxaliplatin 130 mg/m2 iv d1~Capecitabine 1000 mg/m2 po bid d1\~14~Repeat every 3 weeks for 6 cycles~After completing 6 cycles of chemotherapy, the patient underwent TME surgery 2-3 weeks later."
214994176|NCT05777408|PROCEDURE|Cranial Base Release|Will be performed in lying position. therapist fingers will contact the sub occipital muscles and upward pressure would be given until the tissues and muscles relax. it will be given once daily for 3 days a week and will continue for 2 weeks
214994177|NCT00181025|DRUG|Tasonermine (TNFa)|
215092375|NCT06060028|DEVICE|Interoceptive stimulation treatment with mechanical stimulation of C-LTMRs afferences|The intervention is a non-invasive interoceptive stimulation (affective touch) delivered to the left volar forearm. The stimulation is delivered using a device with a small tactile probe that touches the skin in a circular motion. The device is designed to induce maximum firing frequency in the peripheral C-Ts nervous afferents, which respond to low-force, low-velocity stimuli, specifically 3 cm/sec, 2.5mN. The stimulation will be delivered in 18 blocks, each consisting of 6 short periods of stimulation of varying durations presented in random order, with pauses of 6 seconds after every single stimulation, the entire stimulation protocol will have a total duration of 30 minutes.
215092376|NCT06060028|DEVICE|Sham treatment|In the sham condition, patients will receive a similar stimulation with the interoceptive tactile device, however, the device will be turned on for only 3 seconds every minute, and consequently turned off for 57 seconds. The entire duration of the stimulation will be approximately 30 minutes, similar to the experimental condition.
214380594|NCT03252080|BEHAVIORAL|short-term intensive education|The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.
214380595|NCT03252080|BEHAVIORAL|Holistic management|The specialist nurses talk individually with the patients for 10-15 min per week. The nurses ask the patients about their results of self-blood glucose monitoring, help them find the reasons of poor blood glucose control as well as answer the patient's questions.
214380596|NCT00114608|DEVICE|The Focus™ Neuromuscular Stimulation System|"Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds on and 48 seconds off per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles."
214497971|NCT01318486|OTHER|Heparin free dialysis technique|Saline flushes or predilution
214497972|NCT01318486|DEVICE|Evodial|Evodial dialyer
214497973|NCT06767241|DEVICE|Non-invasive auricular vagus nerve stimulation|Non-invasive transcranial direct current auricular vagus nerve stimulation (tDC-aVNS)
214497974|NCT06767241|OTHER|Standard Medical Therapy|Standard of care treatment for moderate to severe COVID-19
215092377|NCT06371417|DRUG|RAY121|Injection
215092378|NCT05722743|BEHAVIORAL|Harmony at HOME|The Harmony at HOME (Help Online Modifying the Environment) intervention builds on prior successful foundations of dementia care interventions with a novel approach combining remote implementation, antecedent education, and home environment intervention. The intervention will teach caregivers how to 1) assess the home environment as an antecedent to behavior for the person with ADRD, and 2) design and implement individualized environmental modification through an environmental cueing approach to address the needs of the person with ADRD in a supportive environment.
214994178|NCT00181025|DRUG|Melphalan|
214994179|NCT04038424|OTHER|Art therapy|Art therapy including coloring, painting and listening to music
214994180|NCT02402244|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection
214994181|NCT02402244|OTHER|Medical Chart Review|Undergo medical data review
214994182|NCT06039878|BEHAVIORAL|Bonding-Evoked Oxytocin|Mother participates in bonding activity with infant at ages 1, 3, and 6 months
214994183|NCT06039878|BEHAVIORAL|Distress Relieving Effects of Sucrose|Researcher elicits distress in the infant (sequence of unswaddling, pacifier removal, and arm restraint), followed by delivery of oral sucrose in one condition and water in other condition
214994184|NCT06039878|BEHAVIORAL|Hedonic Response to Sucrose|Researcher gives infant opportunity to suck from two bottles, one containing sucrose and one plain water at infant ages 1, 3, and 6 months
214994185|NCT06039878|BEHAVIORAL|Typical versus Challenging Feeding-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) regular size nipple versus smaller aperture nipple ('challenging') and (2) providing social interaction while feeding versus not.
214994186|NCT06039878|BEHAVIORAL|Caloric Compensation-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) offering a bottle feeding ad lib for 3 hours versus offering a bottle feeding every hour for 3 hours; (2) providing social interaction while feeding versus not.
214994187|NCT06039878|BEHAVIORAL|Ability to Delay Gratification for Food in Infants-Social Task (ATDG-FIT-Social)|When mother indicates infant is hungry, she presents the infant the bottle but withholds feeding for 5 minutes, feeds for one minute, withholds feeding for 30 seconds, and then resumes feeding. She does so under two conditions (providing social interaction during feeding versus not) on two counterbalanced days at infant ages 1, 3, and 6 months.
214994188|NCT04955249|DRUG|Dexmedetomidine|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
214994189|NCT04955249|DRUG|Placebo|Patients in this group receive routine patient-controlled intravenous analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
214994190|NCT03948802|DIAGNOSTIC_TEST|Interleukine 33 test in blood plasma|ELISA test for Interleukin 33
214994191|NCT05238675|DRUG|BI 1291583|BI 1291583
214994192|NCT05238675|DRUG|Placebo|Placebo
214994193|NCT06176235|DRUG|Teriflunomide|Teriflunomide 7 mg orally once daily for 24 weeks. Dose adjustments were made throughout the study based on individual platelet counts.
214994194|NCT06176235|DRUG|Dexamethasone|Dexamethasone 40 mg orally once daily for four consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 14).
214497975|NCT06766877|OTHER|core stability exercise|"1. Isometric quadriceps exercises involving knee extension~2. Maximum isometric exercise for the quadriceps"
214380597|NCT04618601|DRUG|Spironolactone|Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is \>5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
214380598|NCT01677364|DRUG|Oxytocin|Arm - Induction of labour
214380599|NCT01385358|PROCEDURE|Thoracoscopically Assisted Surgical Ablation|Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
214380600|NCT01385358|PROCEDURE|Catheter Ablation|In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
214497976|NCT06766877|OTHER|foot-ankle strengthening exercise|"1. Isometric quadriceps exercises involving knee extension~2. Maximum isometric exercise for the quadriceps"
214380601|NCT02730182|OTHER|altitude exposure|altitude exposure
214497977|NCT06765824|DEVICE|Repetitive Transcranial Magnetic Stimulation|The protocol will be applied with the MagVenture R30 stimulation device and the cool-B70 coil for active treatment. The protocol will consist of two sessions per day, with a 50-minute break between sessions, every day of the week (Monday to Friday) for three and a half weeks (a total of 36 sessions). Each session will consist of the application of a 1Hz protocol (2000 pulses at 120% of the motor threshold) in the right dorsolateral prefrontal cortex (F4) followed by an intermittent theta-burst protocol (1800 pulses at 90% of the motor threshold) in the left dorsolateral prefrontal cortex (F3). The cortical target localization will be performed using the beam-F3/F4 technique that combines different electroencephalographic positioning parameters and measurements to accurately locate said cortical targets. The motor threshold of each patient will be calculated at the beginning of each week of treatment using an electromyography system.
214497978|NCT06765824|DEVICE|Transcranial Magnetic Stimulation Sham|The same protocol described in the intervention group will be carried out in the control group. The device used is the same, the difference is the coil that maintains the same appearance and generates the same sound as the active treatment coil, but unlike the latter, it does not produce an effective magnetization to depolarize the cerebral cortex on which we act.
214380602|NCT03537079|OTHER|hypoxia air|Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.
214380603|NCT02079064|DRUG|Desflurane|Inhalational anesthetic
214497979|NCT06765655|DRUG|Insulin Lispro Injection|point-of-care glucose monitoring via fingerstick perioperatively
214497980|NCT06765655|DIAGNOSTIC_TEST|glucose testing|POCT glucose testing via fingerstick
214497981|NCT06766318|DEVICE|group A will receive cryo-ultrasound therapy combined with conventional physical therapy for two months|Cryo-ultrasound therapy combines two therapeutic methods: cryotherapy (using cold) and ultrasound (using sound waves). The ultrasound component provides a therapeutic heating effect, improving blood circulation and tissue flexibility, while the cold component reduces pain and inflammation
214994195|NCT04341636|RADIATION|Bitewing X ray|"Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol ."
214994196|NCT04491643|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
214994197|NCT04491643|DRUG|Rosuvastatin|At a dosage of 10 mg/day
214380604|NCT02079064|DRUG|Propofol|Intravenous anesthetic that can be given by continuous infusion
214380605|NCT05841238|DRUG|LY3502970|Administered orally.
214994198|NCT06243510|OTHER|apixaban|Participants will be randomized to receive a prescription for prophylactic apixaban
214994199|NCT06243510|OTHER|enoxaparin|Participants will be randomized to receive a prescription for prophylactic enoxaparin
214994200|NCT06431074|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214994201|NCT06431074|DIETARY_SUPPLEMENT|Calm Active Study Product 1.1 Usage|Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
214497982|NCT06766318|DEVICE|LASER therapy|group B will receive LASER therapy combined with conventional physical therapy.
214687332|NCT06622434|BIOLOGICAL|immunization|One month after completion of concurrent radiochemotherapy, patients will be immunized during the adjuvant phase of monthly temozolomide with subcutaneous injections of the vaccine formulation (D0, W2, W4, W6, and then every 2 months until progression) consisting of 2 tumor antigens (TERT and PTPRZ1) adjuvanted with synthetic melanin and a TLR9 agonist (CpG-ODN).
214380606|NCT02462954|DEVICE|ContraGel|
214380607|NCT02462954|DEVICE|HEC Universal Placebo gel|
214380608|NCT06383780|DRUG|GP combined with Tislelizumab|Gemcitabine combined with cisplatin regimen combined with Tislelizumab
214380609|NCT06383780|DRUG|TPC combined with Tislelizumab|cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab
214380610|NCT05420922|DRUG|Lenvatinib Oral Product|Lenvatinib or Sorafenib
214380611|NCT05420922|DRUG|PD-1 inhibitor|Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
214380612|NCT05420922|PROCEDURE|Local treatment|Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
214380613|NCT00002947|RADIATION|indium In 111 pentetreotide|
214380614|NCT02310022|DRUG|Drug Omega 3|4 g (4 capsules) once a day, administered with food
214380615|NCT02310022|DRUG|Drug Omega-3 Comparator|4 g (4 capsules) once a day, administered with food
214380616|NCT05421338|DRUG|BI 456906 (C-14)|BI 456906 (C-14)
215092379|NCT05722743|BEHAVIORAL|National Institute on Aging Program|"Standard of care will address behaviors and psychiatric symptoms of dementia (BPSD) for persons with ADRD, as recommended by their medical provider. Caregivers will receive training regarding home safety via a home safety handout based on National Institutes on Aging Home Safety and Alzheimer's Disease webpage."
215092380|NCT05266339|OTHER|Cross-education training|The strengthening exercises for rotator cuff muscles will be performed in the contralateral side of the affected side.
214380617|NCT02981901|OTHER|Patient with ovarian epithelial cancer|
214380618|NCT00830622|OTHER|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
214380619|NCT04061226|DEVICE|Overnight polysomnography|Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
214380620|NCT02843256|DEVICE|Isomark Canary|The Isomark Canary will analyze the exhaled air and generate a breath delta value.
214380621|NCT03800732|OTHER|With Meal during night work|Two nights of work with a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
214380622|NCT03800732|OTHER|Without Meal during night work|Two nights of work without a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
214380623|NCT03800732|OTHER|Sleep night|Two sleep nights and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
214380624|NCT03757143|DRUG|Povidone-Iodine-Alcohol|Povidone-Iodine-Alcohol will be used to disinfect the skin
214380625|NCT03757143|DRUG|Chlorhexidine-Alcohol|Chlorhexidine-Alcohol will be used to disinfect the skin
214380626|NCT03757143|DEVICE|Insyte Autoguard BC Winged|Pose of Insyte Autoguard BC Winged
214380627|NCT03757143|DEVICE|Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes|Pose of Nexiva single port catheter
214380628|NCT05683717|DRUG|TT-01488 Tablets|TT-01488 tablet will be administered orally once daily per protocol defined schedule.
214994202|NCT06431074|DIETARY_SUPPLEMENT|Placebo Control 6.1|Participants will use their Placebo Control 6.1 as directed for a period of 6 weeks.
214994203|NCT06431074|DIETARY_SUPPLEMENT|Calm Active Study Product 6.1 Usage|Participants will use their Radicle Calm Active Study Product 6.1 as directed for a period of 6 weeks.
214994204|NCT06651177|DRUG|Tirzepatide|The tirzepatide pen is a pre-filled, disposable, injection device designed for subcutaneous administration. Each pen is pre-filled with a single dose of tirzepatide and is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg/0.5 mL. A UMC will administer the once-weekly SQ dose of tirzepatide. Consistent with tirzepatide's prescribing guidelines, participants will be initiated at a once-weekly SQ dose of 2.5 mg/week with a dose increase to 5mg/week at week 5. Consistent with tirzepatide's prescribing information, once the participant has received 5 mg/week for 4 weeks they are eligible for a dose increase if needed
214994205|NCT06651177|OTHER|Placebo|"Saline administered subcutaneously with a syringe will be used as the placebo for the trial. The placebo which will be administered by a study UMC. The process for deciding on dose increases will be the same for placebo and tirzepatide."
214994206|NCT06036615|OTHER|Exercise Intervention|Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 3-month de-training period, continuing their normal physical activity.
215092381|NCT05266339|OTHER|Standard exercise program|The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.
215092382|NCT05646862|DRUG|Inavolisib|Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.
214380629|NCT01147484|DRUG|Foretinib|foretinib, at a continuous oral daily dose of 60 mg
214380630|NCT00855010|DRUG|pioglitazone|pioglitazone 45 mg daily
215092383|NCT05646862|DRUG|Fulvestrant|Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
215092384|NCT05646862|DRUG|Alpelisib|Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
214380631|NCT00855010|DRUG|placebo|one daily
214380632|NCT05382754|DIAGNOSTIC_TEST|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
214380633|NCT05382754|DIAGNOSTIC_TEST|In-lab polysomnography|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
214380634|NCT03340948|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|An 8-week course in mindfulness meditation, yoga training and weekly group support in the form of weekly 2,5 hour meetings at the hospital.
214380635|NCT02969525|OTHER|Placebo|
214380636|NCT02969525|DRUG|Bimekizumab|Bimekizumab in different dosage regimens.
214687333|NCT07018869|OTHER|Intervention website access|Receive access to CTAC intervention website with educational content and interactive modules
214687334|NCT07018869|OTHER|Control website access|Receive access to CTAC control website with general health education
214687335|NCT07018869|OTHER|Interview|Ancillary studies
214687336|NCT07018869|OTHER|Questionnaire Administration|Ancillary studies
215092385|NCT05710432|OTHER|Quasi-Isometric Neck Flexion|Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).
215092386|NCT05710432|OTHER|Inspiratory Muscle Training|"Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique \[IO\], external oblique \[EO\], transversus abdominis \[TrA\] and rectus abdominis \[RA\] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued."
215092387|NCT06441617|DEVICE|Online Program for Fatigue|An MS-specific fatigue management program, delivered as a stand-alone, fully automated intervention via an internet-browser.
214994207|NCT06294106|DEVICE|Electroencephalogram personalized Transcranial Magnetic Stimulation (eTMS)|EEG is utilized to determine a personalized frequency to then apply TMS to the frontal lobe.
214994208|NCT06374537|OTHER|Muscle Therapy|Participants will attend 2 muscle therapy sessions a week for 12 months, for one hour each.
215092388|NCT06231966|DRUG|Combination therapy of high-intensity dose rosuvastatin and ezetimibe|Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg
214380637|NCT05962983|BEHAVIORAL|Small Steps for Big Changes Program|Participants will be asked to attend six one on one sessions providing diet and exercise counselling each lasting 20-30 minutes over the course of six weeks. The nutrition counselling will introduce participants to a healthy dietary changes for reducing added sugar intake and refined/processed carbohydrate intake as well as increasing vegetable consumption. After counselling sessions, participants will complete their chosen form of aerobic exercise: 1) traditional continuous exercise that involves exercising at a constant pace for 20-30 minutes (moderate-intensity continuous training, MICT); or 2) interval exercise that involves alternating between 30 seconds and 1-minute of brisk exercise and 1-minute of easy exercise for \~15 min (high-intensity interval training, HIIT). Both exercise forms could be completed on treadmill, elliptical or stationary bike. In total, each session will last approximately one hour.
214380638|NCT05035368|DRUG|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).
214380639|NCT05035368|OTHER|Placebo|Placebo is administered with the same schedule of Ladarixin.
214994209|NCT06018428|DRUG|bempikibart (ADX-914)|Subcutaneous administration of bempikibart (ADX-914)
214994210|NCT05497401|BIOLOGICAL|MesenCure|Enhanced mesenchymal cell-based product
214994211|NCT05497401|OTHER|Placebo|Saline
215092389|NCT06231966|DRUG|Rosuvastatin monotherapy for treat-to-target|Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)
215092390|NCT04214678|PROCEDURE|Underwater clip closure|Closure of post-resection defect with endoscopic clips by underwater technique
215092391|NCT04214678|PROCEDURE|Conventional clip closure|Closure of post-resection defect with endoscopic clip by conventional technique
215092392|NCT06523985|BEHAVIORAL|Push messages (standard)|Push messages will be developed based on best practice recruitment principles in cooperation with an external marketing team and then reviewed and finalized by the study team. Messages will be different each month and sent across 12 months. The monthly time frame was selected based on our need to balance contact with responders and research or expert opinions on push messaging saturation.
215092393|NCT06523985|BEHAVIORAL|Push messages (customized)|These messages are similar to content in the standard push messages but are customized to address common misperceptions about opioid overdose and naloxone.
214380640|NCT00524030|DRUG|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
214380641|NCT00524030|DRUG|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
214380642|NCT05302557|OTHER|Ileostomy stimulation|Daily stimulation of the efferent loop will be performed during the two weeks prior to the surgery.
214994212|NCT03410121|DEVICE|IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108.|Implantation of intravenous medical device in thoracic location
214994213|NCT03410121|DEVICE|Vital Port®Minititanium|Implantation of intravenous medical device in humeral location
214994214|NCT04624230|DRUG|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
214380643|NCT00849004|OTHER|silicone gel|silicone gel
214380644|NCT00849004|OTHER|silicone sheet|silicone sheet
214380645|NCT00849004|OTHER|paper tape|paper tape
214497983|NCT06952543|DIAGNOSTIC_TEST|Ultrasound Imaging|"Non-invasive ultrasound will be performed using Angio Flow Reactivity Analysis (AFRA)~The ultrasound probe will be attached to the subject's calf muscle and a pressure cuff will be secured around thigh. Ultrasound data will be collected for 1 minute.~The cuff will then be induced to a tolerable pressure of no more than 160 mm Hg, and ultrasound data will be collected for 3 minutes while cuff is inflated.~The cuff pressure will be released, and ultrasound data will be collected for 2 minutes after the release.~Subject will be asked to perform 1 minute plantar flexion exercise, and ultrasound data will be collected for two minutes after the completion of exercise"
214687337|NCT06873802|OTHER|Non-Interventional Study|Non-interventional study
214994215|NCT06278259|OTHER|Telerehabilitation program bases aerobic and Baduanjin exercises|It is an interventional study in which 68 stroke patients are estimated to enroll according to random allocation and divided into two groups. The study group participants involve in Telerehabilitation sessions is based on aerobic exercises, guided by video. The telerehabilitation program is aerobic exercise 3 times per week for 3 months. With the Baduanjin exercise program is delivered individually, at each patient's home, through telerehabilitation, with direct remote supervision by a physiotherapist
214994216|NCT06278259|OTHER|Telerehabilitation program bases aerobic exercises|The telerehabilitation program is aerobic exercise 3 times per week for 3 months.
214994217|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 6.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
214994218|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 12.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
214994219|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 18.75mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
214994220|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 25.0mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
214994221|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 31.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
214994222|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 37.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
214994223|NCT05924594|DRUG|Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
214994224|NCT02329717|DRUG|PBI 05204|PBI 05204 daily dosing
214994225|NCT05041140|DEVICE|29-XeMRI imaging|129-XeMRI scan
214994226|NCT02097706|DRUG|NMDA receptor antagonist (active drug)|
214994227|NCT02097706|OTHER|Lactose packed capsule (inert/inactive arm)|
214994228|NCT05752539|DEVICE|CEREC System by Dentsply Sirona|CEREC Tessera blocks achieve exceptional three-way performance through a unique chemistry that incorporates two complementary crystal structures within a glassy zirconia matrix. These two crystals work together to create an unprecedented fusion of strength and beauty in one block while significantly improving overall processing time.
214994229|NCT06200961|DEVICE|Transnasal Endoscopy|Unsedated endoscopic evaluation through the nose.
214994230|NCT06200961|PROCEDURE|Esophagogastroduodenoscopy|Sedated endoscopic evaluation through the mouth.
214994231|NCT04418960|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI pre- and postoperatively for detailed analysis of the ventricle and the mitral annulus. The first MRI will be performed on the admission day before surgery. The second MRI will be performed during the hospital stay, between 3 and 7 days after the operation. The MRI images are interpreted through a specialized cardiologist and radiologist.
214380646|NCT01060202|DRUG|No intervention|This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
215092394|NCT02933554|DEVICE|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
214380647|NCT05806749|COMBINATION_PRODUCT|Donor CD34+, CD3+. and belumosudil|"Immediately after living donor kidney transplantation, subjects will begin a conditioning regimen of rATG and total lymphoid irradiation. An infusion of at least 8 X106 donor CD34 cells/kg recipient weight and of at least 10 X106 donor CD3 cells/kg recipient weight will then be given. A triple immunosuppressive regimen of tacrolimus, corticosteroids, and mycophenolate will be utilized.~Corticosteroids will be given on a tapering schedule from day 0 through the first four months. Tacrolimus will be given on a tapering schedule from day 1 through month 18. Mycophenolate will be given at a fixed dose from day 11 through month 12.~Subjects will receive belumosudil 200 mg by mouth daily from day 28 following the kidney transplant through month 24."
214380648|NCT05944055|BIOLOGICAL|Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?|Vitamin D overdose is frequent among preterm infants receiving the current supplementation (Mauras 2022, Kołodziejczyk-Nowotarska 2021). In our NICU, the protocol was to daily administrate 55 UI vitamin D during parenteral nutrition then 1000 UI during enteral nutrition for babies weighing more than 1000 g and 1200UI during enteral nutrition for babies weighing less than 1000 g. The dosage was adapted each month after a plasmatic measure of 25OH-D in order to maintain 25OH-D between 50 nmol/L and 120 nmol/L.
214380649|NCT06624748|BEHAVIORAL|emotional and physical support to the pregnant woman provided by attendant|The companion will provide emotional and physical support to the pregnant woman (such as massage, supporting the pregnant woman while moving, taking a warm shower, etc.), and all interventions made by the companion and their duration will be recorded by the researcher in the 'Birth Process Support Form'. When the cervical dilatation is 8 cm, the Birth Comfort Scale will be applied to the pregnant woman, and two hours after the birth, the Birth Satisfaction Scale and the Postpartum Comfort Scale will be applied. Information about the birth process will be recorded in the Birth Information Form. In addition, semi-structured questions in the 'Companion Interview Form' will be asked to the companions selected for qualitative interviews and voice recording will be recorded.
214380650|NCT06462716|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
214380651|NCT00421213|DRUG|Darinaparsin|300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.
214380652|NCT06925009|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
214380653|NCT00193713|DRUG|bifeprunox|
214380654|NCT01165073|DIETARY_SUPPLEMENT|Osmolite and B.C.A.A.|Feeding inserted into enteral tubes
214380655|NCT01165073|DIETARY_SUPPLEMENT|Normal oral intake & supplementation if necessary|Enteral nutrition
214380656|NCT05880589|DIETARY_SUPPLEMENT|Milk secretory supplement group|Take 2 tablet 2 times per day for 14 days
214380657|NCT05880589|DIETARY_SUPPLEMENT|Placebo group|Take 2 tablet 2 times per day for 14 days
214380658|NCT03909802|BEHAVIORAL|Self-and family management of diabetic foot ulcers programs|The intervention combines self-management and family management focusing on behavioral changes in patients with diabetic foot ulcers. Self-management focuses on intensive health education of physical activities, diet, medication, foot care, and blood glucose control. Family management focuses on problem-solving, establishing roles, and effective involvement in providing care amid individuals suffering DFU.
214380659|NCT03909802|OTHER|Usual care|Usual care
214380660|NCT04410679|BIOLOGICAL|injectable PRF|blood sample and centrifuged to obtain i-PRF
214380661|NCT01816763|BEHAVIORAL|NRS pain one week|Eligible patients will be randomly assigned to complete a patient-reported 'NRS one week' on a tablet prior to making contact with a nursing staff vital signs screener.
214380662|NCT01816763|BEHAVIORAL|PEG|Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.
214380663|NCT01816763|BEHAVIORAL|DVPRS|Eligible patients will be randomly assigned to complete a patient-reported 'DVPRS' on a tablet prior to making contact with a nursing staff vital signs screener.
214380664|NCT03651063|OTHER|social robot|Reach To Grasp games with a social robot
214380665|NCT03651063|OTHER|computer group|reach to grasp games with a computer screen
214497984|NCT06834750|OTHER|Experimental Group|"The application methods of kinesiology tape for the experimental group are as follows:~1. Promoting supraspinatus muscle: Use an I-shaped tape (with natural tension).~2. Promoting the anterior fibers of the deltoid muscle: Use an I-shaped tape (with natural tension).~3. Promoting the posterior fibers of the deltoid muscle: Use an I-shaped tape (with natural tension).3. Promoting the posterior fibers of the deltoid muscle: Use an I-shaped tape (with natural tension).~4. Fixing the shoulder joint: Use an I-shaped tape (with moderate tension).~5. Inhibiting biceps brachii muscle / promoting triceps brachii muscle (depending on the patient's recovery stage and different functional impairments, different taping methods are used).~6. Promoting wrist extensor muscles / inhibiting wrist flexor muscles (depending on the patient's recovery stage and different functional impairments, different taping methods are used)"
214497985|NCT06834750|OTHER|Control group (placebo)|The control group was pasted with sports white tape (the pasting method was the same as above, replaced with sports white tape).
214497986|NCT06745622|DRUG|HSK39297 tablets|HSK39297 tablets until the end of treatment
214497987|NCT06771440|OTHER|EPR search|A stored query in the EPR, that checks for re-exposure to the culprit antibiotic or class-member, from the date of AAL registration to the date of patient inclusion
214380666|NCT02271750|PROCEDURE|lumbar puncture|for spinal fluid
214380667|NCT01170975|DRUG|Tesetaxel 10 mg with and then without food|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
214380668|NCT01170975|DRUG|Tesetaxel 10 mg without and then with food|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
214380669|NCT04934137|BEHAVIORAL|Sensoria|The Sensoria system uses a force-sensing mat installed under the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays information about weight shifts, goal-setting functions, and feedback on performance/outcomes.
214380670|NCT04934137|BEHAVIORAL|AW-Shift|The AW-Shift system uses a pressure-sensing mat installed on top of the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays visual representation of the seating surface and can set reminders for weight shifts.
214380671|NCT00311155|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
214380672|NCT02241720|DRUG|regorafenib|
214380673|NCT01633086|DRUG|nitric oxide gel|"1. st gel: sodium nitrites,BID local use X 28 days~2. nd gel: maleic/ascorbic acids ,BID local use X 28 days"
214380674|NCT01633086|DRUG|placebo gel|placebo gel,BID local use X 28 days
214380675|NCT02327624|DRUG|Clopidogrel|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
214380676|NCT02327624|DRUG|Ticagrelor 60|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
214380677|NCT02327624|DRUG|Ticagrelor 90|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
214380678|NCT02215330|DRUG|Eplerenone|
214380679|NCT02215330|DRUG|Maltodextrin|
214994232|NCT04376671|DEVICE|Electroencephalography|The patients underwent EEG recordings according to previously published methods (Bonanni et al., 2008). . EEG recordings were analyzed with methods described in our previous work (Bonanni et al., 2008) by 2 experimenters unaware of the clinical conditions of the subjects. Briefly, quantitative EEGs (QEEGs) were recorded from 21 scalp derivations. Ag/AgCl disk scalp electrodes (19) were placed according to the international 10-20 system, EEG was recorded from Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T 4, T5, T6, O1, and O2. Two additional electrodes were placed on A1 and A2. EEG activity was analyzed from single or multiple leads grouped to define the following scalp regions: anterior (Fz, Fp2, F7, Fp1, F3, F4, and F8), central (Cz, C3, and C4), posterior (Pz, P3, P4, O1, and O2), and temporal (T3, T4, T5, and T6).
214380680|NCT03125590|OTHER|Testing the PEQ (Personalized Exercise Questionnaire)|Administer the questionnaire to 114 participants to classify their facilitators, barriers and preferences to exercise
214380681|NCT03423875|DIAGNOSTIC_TEST|PrEDICT game score|PrEDICT game score will be shared with the emergency physicians and health care professionals
214994233|NCT06419270|OTHER|Observation|Observational
214994234|NCT04914338|OTHER|Health Promotion|Participate in MDT-intervention
214994235|NCT04914338|OTHER|Quality-of-Life Assessment|Ancillary studies
214994236|NCT04914338|OTHER|Questionnaire Administration|Ancillary studies
214994237|NCT06078683|DIETARY_SUPPLEMENT|C8 Ketone Supplement|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the supplement twice a day for 6 weeks. The supplement is a C8 Ketone Diester supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein. For the proposed studies all participants will drink 5.4 oz of supplement, delivering 50g of C8 Ketone Supplement daily in a split serving fashion where half will be consumed in the morning with breakfast, and the other half with lunch."
214994238|NCT06078683|DIETARY_SUPPLEMENT|Placebo|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the placebo twice a day, once at breakfast, and once around lunch time for 6 weeks. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any ketones (BHB), which will be replaced with a similar caloric content of fat in the form of canola oil."
214994239|NCT06078683|DIETARY_SUPPLEMENT|Ketone Ester Acute|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink two servings of the supplement at once (50g total C8 Ketone Supplement), and images obtained before and after consumption. The supplement is a C8 Ketone Supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein."
214380682|NCT00429494|DRUG|Leuprolide Acetate|22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
214380683|NCT00429494|BEHAVIORAL|Questionnaire|Questionnaires taking about 15 minutes to complete.
214380684|NCT00429494|PROCEDURE|Hematopoietic Stem Cell Transplantation|Stem cell infusion on Day 0.
214380685|NCT00675324|DRUG|Laxabon|Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
214380686|NCT00675324|DIETARY_SUPPLEMENT|Fresubin Energy drink|30 kcal/kg\*day five days before colonoscopy
214380687|NCT04684641|DRUG|Standard Dose YPT-01|Participants will be randomized to receive the standard dose of phage therapy YPT-01.
214380688|NCT04684641|OTHER|Placebo|Participants will be randomized to receive the placebo.
214380689|NCT05595421|DEVICE|Transcranial direct current stimulation (tDCS)|See detail in arm/group descriptions regarding the intervention.
214380690|NCT05267314|DEVICE|pharyngeal exerciser + standard therapy|Use of Pharyngeal exerciser
214380691|NCT02041247|BIOLOGICAL|VAC-3S|VAC-3S is administered via intra-muscular route in the arm.
214380692|NCT00347100|DRUG|Insulin Glargine|Throughout study period
214380693|NCT00347100|DRUG|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
214380694|NCT00347100|DRUG|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
214380695|NCT00347100|DRUG|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
214380696|NCT00347100|DRUG|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
214380697|NCT00347100|DRUG|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
214380698|NCT03289481|DIETARY_SUPPLEMENT|Active lozenge|nitric oxide generating lozenge
214380699|NCT03289481|DRUG|Placebo|placebo tablet
214380700|NCT02184663|OTHER|without APA program|Control Arm : chemotherapy alone
214380701|NCT02184663|OTHER|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
214380702|NCT02392611|DRUG|Alobresib|Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
214380703|NCT02392611|DRUG|Exemestane|Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
214380704|NCT02392611|DRUG|Fulvestrant|Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
214380705|NCT05182073|DRUG|FT576 (Allogenic CAR NK cells with BCMA expression)|Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).
214380706|NCT05182073|DRUG|Cyclophosphamide|Conditioning Agent
214380707|NCT05182073|DRUG|Fludarabine|Conditioning Agent
214380708|NCT05182073|DRUG|Daratumumab|Anti-CD38 Monoclonal Antibody
214380709|NCT05182073|DRUG|Bendamustine|Conditioning Agent
214380710|NCT03325205|OTHER|Anodal tDCS|Anodal Transcranial direct current stimulation (tDCS) is a non- invasive brain stimulation technique. Low intensity current (1-2 mA) is induced to increase excitability, stimulate plasticity and enhance cognitive functions.
214380711|NCT03325205|OTHER|Sham tDCS|The electrodes are placed over the same areas as in the anodal tDCS condition. Participants will receive sham tDCS instead of anodal tDCS
214994240|NCT06078683|DIETARY_SUPPLEMENT|Placebo Acute|Participants will undertake a controlled feeding intervention where they will drink two servings of the placebo at once (50g total placebo), and images obtained before and after consumption. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any BHB, which will be replaced with a similar caloric content of fat in the form of canola oil.
214994241|NCT04301154|BIOLOGICAL|HIVIS DNA/MVA-CMDR|HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.
214994242|NCT04301154|BIOLOGICAL|HIVIS DNA + Cervarix and MVA-CMDR|Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
214994243|NCT04301154|BIOLOGICAL|Cervarix|Cervarix by IM needle injection at weeks 0, 4 and 24.
214994244|NCT04912687|DIAGNOSTIC_TEST|EGFR gene mutation analysis on liquid biopsy|Blood samples will be collected at inclusion for plasma DNA collection and analysis.
214994245|NCT05412394|DRUG|Prednisolone|Liquid, 5mg/kg per week, for one year
214994246|NCT06333769|RADIATION|Short-course Radiotherapy|Rectal lesion + metastatic lymph nodes, GTV 30Gy/5Fx. Pelvic lymphatic drainage area, CTV 22.5Gy/5Fx.
214994247|NCT06333769|DRUG|Tislelizumab|Tislelizumab：200mg，d1，q3w，2 cycles.
214994248|NCT06333769|DRUG|Capecitabine|Capecitabine：1000mg/m2，d1-14，bid, q3w, 2 cycles.
214994249|NCT06333769|DRUG|Oxaliplatin|Oxaliplatin：130mg/m2, d1, q3w, 2 cycles
214994250|NCT06650553|PROCEDURE|Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.|Conditioning regimen consisted of the following1)Severe aplastic anemia(SAA):FC-ATG:Flu 30 mg/m\^2/d ×4d (- 7d- -4d), CTX 22.5 -25mg/kg/d × 4d (-7d- -4d), ATG 7.5mg in total（- 5d- -2d).2)Transfusion-dependent non-severe aplastic anemia（TD-NSAA) and Paroxysmal nocturnal hemoglobinuria (PNH) acquired clonal-aplastic anemia(AA):BU/FC-ATG:Bu 0.8mg/kg(q6h -8d）+FC-ATG. The GVHD prophylaxis program was Application of Anti-CD25 Humanized Monoclonal Antibody 50mg (+1d,+4d);cyclosporine A + mycophenolate mofetil (MMF)+short course methotrexate (MTX).The infusion time of umbilical cord blood (UCB) stem cells in the UCB-assisted haploidentical hematopoietic stem cell transplantation (UCB-Haplo-HSCT) group: 4 hours before the infusion of peripheral blood stem cells.In the follow-up phase, outcome evaluation indicators must be collected according to the follow-up plan, ensuring data quality.
214994251|NCT06118411|DRUG|Upadacitinib|Oral Tablets
214994252|NCT06118411|DRUG|Placebo|Oral Tablets
214380712|NCT05624866|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
214994253|NCT06118411|OTHER|NB-UVB (narrow-band ultraviolet B) Phototherapy|NB-UVB phototherapy is a commonly used treatment modality in participants with vitiligo and can be administered in an office setting or at home 2 times per week
214994254|NCT04680988|DRUG|SHR-1210|SHR-1210 intravenously every 3 weeks
214994255|NCT04680988|DRUG|SHR-1020|SHR-1020 Orally once daily
214994256|NCT04680988|DRUG|Physician's choice chemotherapy|Investigators will declare one of the following regimens:Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection
214994257|NCT03884413|OTHER|questionnaires|Longitudinal observational study. Collection of health data using self-administered questionnaires online.
215092395|NCT04624763|PROCEDURE|Left bundle branch pacing|"LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met:~   1. Selective LBBP with an iso-electrical window between the pacing spike and QRS onset;~  2. If using dual-lead method with one at His-bundle and the other at LBB region, a retrograde His-bundle potential is recorded from His-bundle lead during LBBP;~  3. LVATs at lead tip pacing of 1.5V/0.5ms and 10V/0.5ms are ≤ 80ms and the difference is \< 10ms;~  4. A discrete LBB potential is recorded from lead tip and LVAT at tip pacing of 3V/0.5ms is ≤ 80ms19.~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
215092396|NCT04624763|PROCEDURE|Right ventricular pacing|Implantation of a RV pacing lead is attempted using the standard-of-care technique first.
214994258|NCT04725188|BIOLOGICAL|Pembrolizumab/Vibostolimab coformulation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
214994259|NCT04725188|DRUG|Docetaxel|Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
214994260|NCT04725188|DRUG|Placebo|Normal saline IV infusion Q3W up to approximately 2 years
214994261|NCT06850610|DIAGNOSTIC_TEST|Pulse oximeter accuracy under hypoxic conditions|This study will specifically evaluate the accuracy of the Owlet pulse oximeter sensor, currently FDA cleared for infants 1-18 months of age in an expanded hypoxia lab trial.
214994262|NCT06558487|OTHER|Cancer Admission Score Prediction Model|A prediction model that calculates the chance for a patient to be admitted after triage and after first blood results
214994263|NCT05658549|DRUG|N-acetyl cysteine|N-acetyl cysteine dosage 600 mg and 1200 mg
214380713|NCT05624866|DRUG|Triamcinolone|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
214380714|NCT04822740|DEVICE|Control Glucose Monitoring System|"With a sensor, transmitter and display device (receiver and/or compatible smart device).~The CGMS sends glucose readings to a compatible smart device every 5 minutes. In this study the CGMS for all patients with use of the results of the device in real time by the health care team for the Experimental arm and without the use of the results by the health care team for Active Comparator (Conventional strategy ."
215092397|NCT04667910|DRUG|601 1.25mg|Solution for injection (intravitreal use)
215092398|NCT04667910|DRUG|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
215092399|NCT01773304|OTHER|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
215092400|NCT02008773|DRUG|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
215092401|NCT02008773|DRUG|placebo|placebo capsules 6/day oral for 16 weeks
215092402|NCT06232785|DRUG|Ibuprofen|0.8g intravenous injection 30min before the end of the operation
215092403|NCT06232785|DRUG|sufentanil|0.2ug/kg intravenous injection 30min before the end of the operation
215092404|NCT04179253|DIAGNOSTIC_TEST|office micro hysteroscopy|One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
215092405|NCT02198794|DRUG|SD-809|SD-809 will be administered per dose and schedule specified in the arm.
214380715|NCT06331429|BEHAVIORAL|EmoTiCare|"The EMOTICARE technological platform intervenes in users through a serious game, i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself.~The game works in 6 areas, each of which refers to one of the variables that are analysed or considered important in the adaptation to the disease: Area 1. Psychoeducation of DM1; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication"
214380716|NCT04243460|PROCEDURE|Xenogeneic collagen matrix (XCM) graft augmentation|"12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate TKT at two points using ultrasound equipment (Pirop®, Echoson).~Intraoral radiographs were taken using a paralleling technique with a Rinn-type film holder in high resolution mode (Visualixe HD®, Gendex®, USA). Two images of each region were selected to calculate the marginal bone changes:"
214380717|NCT04243460|PROCEDURE|Connective tissue graft augmentation (CTG)|12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate STT (soft tissue thickness) at two points using ultrasound equipment (Pirop®, Echoson).
214380718|NCT05430048|DRUG|nasal Desmopressin|compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
214380719|NCT01129531|DRUG|AGN-214868|AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
214380720|NCT01129531|DRUG|Placebo to AGN-214868|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
214380721|NCT02176044|DRUG|Sodium Nitroprusside infusion|
214380722|NCT02176044|OTHER|Placebo|
214380723|NCT02030912|DRUG|3 doses of amoxicillin daily for 7 days|
214380724|NCT02030912|DRUG|2 doses of minocycline daily for five days|
214380725|NCT02030912|OTHER|2 doses of placebo daily for five days|
214380726|NCT00981474|DRUG|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised
214380727|NCT00981474|DEVICE|Control group|Institutional standard of care.
214380728|NCT04639778|OTHER|Control Group|Clinical visits conducted by a multidisciplinary team every year
214994264|NCT05565560|DRUG|Apremilast|Oral tablets
214994265|NCT05935722|BEHAVIORAL|Parenting Young Children|PYC is a home-based intervention programme involving weekly, one-hour sessions over a period of at least six months. The programme has two core modules (1) Parent-Child Interaction and (2) Child Care Skills and Safety. The Parent-Child Interaction module focuses on the parent-child relationship and interaction skills such as parents' responsiveness to the child's signals, giving the child attention and encouragement, and supporting prosocial behaviour. The Child Care Skills and Safety module targets safety at home and the parent's caring skills (e.g. food, health, and hygiene). Checklists are adapted to each parent in order to support the PYC practitioner and the parent. The programme is compiled in a manual that includes work tasks, instructions for how to perform the tasks, and teaching materials.
214994266|NCT05935722|BEHAVIORAL|Treatment as Usual|TAU consists of a variety of interventions from the social services. The support will be logged and classified in accordance with the Swedish National Board of Health and Welfare's guidelines for classifications of its activities. TAU will be divided into the following five categories: 1) conversation counselling or emotional support, 2) practical support, 3) skills training, 4) compensatory strategies, and 5) other support. Support will also be classified based on whether it is home-based or given outside the home and whether it is individualised or in a group setting.
214994267|NCT05019677|DRUG|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
214994268|NCT05086315|DRUG|SAR443579|Powder for solution for infusion; by IV infusion
214994269|NCT05438511|BEHAVIORAL|Focus group|A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
214994270|NCT05438511|BEHAVIORAL|Organizational Readiness for Implementing Change|measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
214994271|NCT03765073|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Various formulations at three dose levels
214994272|NCT03765073|BIOLOGICAL|Placebo|Saline control
214994273|NCT05308407|OTHER|Focus Groups|No intervention involved in this phase of the study
214994274|NCT05308407|OTHER|Pilot randomized controlled trial|The intervention is a virtually delivered, 12 weekly group-based active video game-centered lifestyle physical activity intervention (POWER UP) targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors.
215092406|NCT02198794|DRUG|Placebo|Placebo matching to SD-809 will be administered per schedule specified in the arm.
215092407|NCT00081133|DRUG|arsenic trioxide|
215092408|NCT00081133|DRUG|imatinib mesylate|
215092409|NCT02995798|OTHER|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
214380729|NCT04639778|OTHER|Intervention Group|Clinical visits are triggered by weight evolution measured by connected balance
214994275|NCT06301035|DEVICE|Asymmetric High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
214994276|NCT06301035|DEVICE|Standard(symmetric) High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
214994277|NCT01426451|OTHER|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
214994278|NCT01426451|OTHER|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
215092410|NCT04159792|OTHER|no intervention|No intervention
214380730|NCT00172120|DRUG|ALX1-11|
214380731|NCT05439239|OTHER|Repeated sprint training|"Participants will perform 7 weeks of cycling repeated sprint training (2x/week). Inspired oxygen fraction (FiO2) will be set to 14.6% and 20.9% for the hypoxic and normoxic group to simulate an altitude of 3000 m and 300 m, respectively.~The training sessions will consist of a 10-min warm up followed by 3 sets of 5 x 10-s all-out repeated sprints on the cycle ergometer. The number of sets will decrease to two during week 7. Participants will be instructed to try to reach and maintain maximal power output during each sprint. An active recovery at 30% of VO2max will be allowed for 20 s between sprints and for 5 min between sets. The training will end with a 10-min cool down at 30% VO2max. An individual fixed torque of 0.7 will be used during the sprints and it will be reduced to 0.5 Nm/kg at week 7."
214380732|NCT00965003|PROCEDURE|MRI scan|Standard of Care
214380733|NCT00939731|DRUG|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
215092411|NCT03137498|DRUG|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
215092412|NCT03137498|DRUG|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection x 1dose
214380734|NCT00939731|DRUG|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
214687338|NCT06701851|BEHAVIORAL|Voluntary and involuntary conditions|"An task fMRI/EEG acquisition during the prodromal phase preceding the episode of abnormal movements.~A task fMRI/EEG acquisition the episode of abnormal movements A task fMRI/EEG acquisition when the subject voluntary mimics the sequence of events (prdrosomal phase + episode of dyskinesia)"
215092413|NCT03404622|DRUG|IUCD|IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
215092414|NCT00710463|DEVICE|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
215092415|NCT05360069|DEVICE|Linear stapler|Linear stapler is adopted in esophagojejunostomy
215092416|NCT05360069|DEVICE|Circular stapler|Circular stapler is adopted in esophagojejunostomy
215092417|NCT05330793|DIETARY_SUPPLEMENT|Oral probiotic|an oral probiotic intervention with or without a novel ADP1 toothpaste
215092418|NCT05330793|DIETARY_SUPPLEMENT|Placebo|placebo without Oral probiotic or toothpaste
215092419|NCT00771797|DIETARY_SUPPLEMENT|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
215092420|NCT00771797|DIETARY_SUPPLEMENT|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
215092421|NCT04670393|DIETARY_SUPPLEMENT|FertyBiotic Woman Plus|4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum
215092422|NCT04670393|OTHER|Placebo|400 mcg folic acid
215092423|NCT03025178|PROCEDURE|4Fr central venous catheter insertion|The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
215092424|NCT05002387|DEVICE|NanoScope™ Operative Arthroscopy (Arthrex, Inc)|Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
215092425|NCT01232153|DEVICE|Non invasive ventilation|Non invasive ventilation
215092426|NCT04872517|DEVICE|Meridian Electroacupuncture Analysis Device (MEAD)|use MEAD to detect energy change in patient with head and neck cancer
215092427|NCT06437912|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
215092428|NCT01936493|GENETIC|DNA analysis|At a future time DNA analysis will be performed
215092429|NCT01936493|OTHER|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
214380735|NCT03800979|DRUG|Tofacitinib|Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
215092430|NCT00701805|DRUG|Paricalcitol|Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
214380736|NCT05289284|OTHER|No intervention|No intervention
214380737|NCT02185885|PROCEDURE|Increased bloodpressure during CPB.|
214497988|NCT06951087|DRUG|Dexamethasone sodium phosphate|In patients with stable DR and no significant macular edema, intravitreal anti-VEGF injections after phacoemulsification surgery can prevent the worsening of postoperative macular edema and potentially improve final visual outcomes while maintaining safety. Laser coagulation and intravitreal anti-VEGF injections are currently considered the standard treatments for PDR. However, the cost of anti-VEGF drugs often prevents many patients from receiving regular and timely injections. Intravitreal corticosteroids may be used as an alternative to anti-VEGF agents.
214994279|NCT04325386|OTHER|ECHO Intervention|Project ECHO (Extension for Community Healthcare Outcomes) based intervention 26 CME educational sessions. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes. 1.25 hour long. Also consultation line and ATHELAS device.
214994280|NCT04325386|OTHER|eTAU|Consultation Line and ATHELAS device only
214994281|NCT06015581|BEHAVIORAL|Workforce Development: Tailored Motivational Interviewing and Technical Assistance|TMI training includes an initial 12 hour virtual workshop, standard patient interaction with feedback, group coaching, and a final standard patient interaction and feedback. TMI relies on experiential activities developed by the network while minimizing didactic presentations. Stigma-reducing communication is emphasized by practicing autonomy supportive and empathic statements and improving cultural humility practices. Role plays map on to the Mystery Shopper domains focusing on risk reduction counseling and PrEP referral. TA addresses factors in the EPIS framework.
214994282|NCT06015581|BEHAVIORAL|Quality Management, Mystery Shopper Feedback|Mystery shoppers visit each agency two times per quarter to systematically examine testing clinics' environmental characteristics and their experiences with clinic staff (e.g., quality of testing session, safer sex discussions, perceived provider competency, PrEP discussions and referral). The investigator team meets with each agency once per quarter to review the data and provide technical assistance.
214994283|NCT00452595|DRUG|DVS-233 SR (desvenlafaxine sustained release )|
214994284|NCT06086275|DRUG|Buprenorphine|At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.
214994285|NCT05622149|BEHAVIORAL|Diet Only|Food tracking based on macronutrient goals.
215092431|NCT03865485|BEHAVIORAL|Parenting for Lifelong Health (PLH)|The Parenting for Lifelong Health (PLH) initiative is focused on the development, evaluation, and dissemination of parenting programs to reduce violence against children and improve child wellbeing in LMIC. It was established to address the need to develop low-cost, evidence-based parenting programs that can be integrated within existing service delivery systems in LMIC. The PLH for Young Children from 2-9 y. (PLH 2-9) program includes general content like one-on-one time/child-led play; praising and rewarding children; instructions, household rules, and routines; managing difficult behaviours: ignore and consequences; reflection and moving on. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
215092432|NCT03035682|OTHER|Augmented Media Group|The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.
214497989|NCT06950424|DIETARY_SUPPLEMENT|black cumin seed oil|500mg of black cumin seed oil standardized for 3% thymoquinone)
214380738|NCT05957302|DRUG|Ketamine|100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg
214380739|NCT05957302|DRUG|Fentanyl|100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
214380740|NCT05174923|BEHAVIORAL|Short Performance Physical Battery (SPPB Test)|The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.
214497990|NCT06950359|DEVICE|Gelatin Sponge Dressing (Cutanplast®)|Absorbable gelatin-based hemostatic sponge used for all study groups as a wound contact dressing.
214497991|NCT06950359|DEVICE|Cyanoacrylate Tissue Adhesive (PeriAcryl®)|High-viscosity N-Butyl Cyanoacrylate/2-Octyl Cyanoacrylate adhesive applied as a topical barrier to the palatal wound site in the Cyanoacrylate Group.
214687339|NCT06292494|DEVICE|Exablate 4000 Transcranial MRgfUS System|Focused ultrasound interrupt structure of epilepsy network to improve seizure.
214994286|NCT05622149|BEHAVIORAL|Training Only|Subjects completed 16 weeks of supervised resistance training
214994287|NCT05622149|BEHAVIORAL|Diet plus Training|Food tracking plus resistance training.
214380741|NCT05174923|BEHAVIORAL|30 Second Chair Stand Test (30CST)|The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.
214380742|NCT05174923|BEHAVIORAL|Hand grip dynamometry|Grip strength is used as a marker of overall muscle strength.
214380743|NCT04463121|DEVICE|Moderato IPG's CNT pacing signals|Assesment of cardiac function and sympatheric activity will be obtained simultaneously
214380744|NCT04463121|DEVICE|CD Leycom Pressure/Volume Combination Catheters|Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.
214380745|NCT04409548|OTHER|All of the spatial and Temporal Gait parameters|
214994288|NCT05039710|DRUG|JNJ-75220795|JNJ-75220795 will be administered as SC injection.
214994289|NCT05039710|OTHER|Placebo|Matching placebo will be administered as SC injection.
214994290|NCT05998642|DRUG|Methotrexate|3.5mg/m2 IV
214994291|NCT05998642|DRUG|Rituximab (where available)|375mg/m2 / 1400mg IV or SC
214994292|NCT05998642|DRUG|Ibrutinib|Dose and schedule assigned at enrollment
214994293|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet before Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 6 days. 2 x 24 hour urines will be collected on days 3 and 4.
214994294|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose before Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 1 gram of sucralose on day 5 of the 6-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
214994295|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Program|Subjects will go on a 10-week Intestive level Optifast VLCD weight loss program
214994296|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Transition Phase|After completion of the 10-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 4 weeks.
214994297|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet after Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 11 days and collect 2 x 24 hour urines on days 8 and 9
214994298|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose after Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 1 gram of sucralose on day 10 of the 11-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
214994299|NCT05300282|DRUG|Atezolizumab|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice)."
214994300|NCT05300282|COMBINATION_PRODUCT|BEGEV|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I."
214380746|NCT02760758|DRUG|CDI-31244|NNI
214380747|NCT02760758|DRUG|Placebo|no active ingredients
214380748|NCT05813626|DRUG|Toripalimab|Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
214497992|NCT06950359|DEVICE|Polyglycolic Acid Sheet (Neoveil®)|Bioresorbable PGA sheet placed over the gelatin sponge in the Polyglycolic Acid Group to enhance wound protection and healing.
214497993|NCT06951256|DRUG|Scalp block with bupivacaine alone|In Group SB: (LA) was done by 20ml of Bupivacaine 0.25%. maximal dose of Bupivacaine did not exceed (2.5 mg/kg) Scalp nerve block will be done by anesthesiologist who is blind to the drug being injected and under complete septic condition where local infiltration of local anesthetic (LA) will be done guided by bony superficial landmarks to block the supraorbital, supratrochlear, auriculotemporal, occipital, and post auricular branches of the greater auricular nerves
214380749|NCT02670252|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
214380750|NCT02670252|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
214380751|NCT02670252|RADIATION|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
214380752|NCT05995080|OTHER|clorhexidine gluconate bathing|daily skin cleansing with chlorhexidine gluconate
214380753|NCT02336919|BEHAVIORAL|Txt2Prevent|A 60-day text messaging program called Txt2Prevent (see description in the arm description).
214380754|NCT04094337|BEHAVIORAL|Internet-assisted treatment|Internet-assisted treatment
214380755|NCT02489266|BIOLOGICAL|AKTi-treated TIL|On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).
214994301|NCT02272270|DRUG|Minocycline with chemoradiation (temozolomide and radiation therapy)|Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
214994302|NCT05879432|DRUG|LSALT Peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
214994303|NCT05879432|DRUG|Placebo|0.9% saline solution
214994304|NCT05967689|DRUG|TAS6417|Oral tablets
214994305|NCT05967689|DRUG|CYP Cocktail|Single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.
214994306|NCT05967689|DRUG|Transporter Cocktail|Single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.
214994307|NCT06645236|DEVICE|therascreen® KRAS RGQ PCR Kit|The investigational device, therascreen® KRAS RGQ PCR Kit, will be used to determine the KRAS G12C mutation status of patients during the screening period of Amgen's clinical trial (20210081)
214994308|NCT04225039|DRUG|INCMGA00012|500mg IV neoadjuvant treatment; 500 mg adjuvant treatment
214994309|NCT04225039|DRUG|INCAGN01876|300mg IV neoadjuvant treatment; 300 mg adjuvant treatment
214994310|NCT04225039|DRUG|SRS|administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).
214994311|NCT04225039|PROCEDURE|Brain surgery|maximal safe surgical resection of the tumor.
214994312|NCT03258242|DRUG|Keluo Xin capsule|four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
214994313|NCT03258242|DRUG|Placebo oral capsule|four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
214994314|NCT03747003|OTHER|No intervention is provided|No intervention is provided
214380756|NCT02489266|DRUG|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
214380757|NCT02489266|DRUG|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
214380758|NCT02489266|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
214380759|NCT04988425|DRUG|TNFα Monoclonal Antibody|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
214994315|NCT02320175|BEHAVIORAL|Patient and Family Centered I-PASS|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
214994316|NCT05498727|DIAGNOSTIC_TEST|Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics|This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.
214994317|NCT02704858|DRUG|Perillyl alcohol|Intranasal administration
214994318|NCT05884593|DEVICE|Pedicle screw instrumentation using Mazor X robotic system|Pedicle screw instrumentation using Mazor X robotic system
214994319|NCT00734565|BIOLOGICAL|Haemophilus influenzae type b|1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
214994320|NCT01246284|DRUG|Triamcinolone acetonide|Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
214994321|NCT01246284|OTHER|Normal saline|
214380760|NCT04988425|DRUG|Methylprednisolone|Injection of 500mg of methylprednisolone immediately after admission before surgery.
214380761|NCT04988425|DRUG|Saline|Injection of the same volume of saline immediately after admission before surgery
214687340|NCT06713083|OTHER|Exercise|Specifically designed and structured exercise program (based on resistance/strength, designed to be executed in bed or minimal mobility). It is an adaptation from the exercise program described by Brun CR et al (Brun CR, Shoemaker JK, Bocking A, Hammond JA, Poole M, Mottola MF. Bed-rest exercise, activity restriction, and high-risk pregnancies: a feasibility study. Applied Physiology, Nutrition, and Metabolism. 2011;36(4):577-582).
214380762|NCT02540785|PROCEDURE|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully
214380763|NCT02540785|PROCEDURE|small-incision lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
214380764|NCT03880084|OTHER|Observation|To systematically assess the onset of delirium, quantify the level of agitation/sedation, estimate the grade of pain and survey the level of dyspnea in patients undergoing non invasive mechanical ventilation
214380765|NCT03690934|PROCEDURE|Fistula-tract laser closure (FiLAC™)|The procedure was performed with a diode laser platform emitting laser energy of 15 W at a wavelength of 1470 nm by means of a radial ﬁber. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the laser ﬁbre withdrawn at a rate of approximately 1 cm per 2-3s.
214380766|NCT03690934|PROCEDURE|Monopolar coagulation of fistulous tract|The procedure was performed with a monopolar coagulator platform emitting monopolar coagulation. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the monopolar energy with suturing the internal fistulas opening.
214380767|NCT04372823|BEHAVIORAL|Policy/program|Policy/program to improve nutrition and increase physical activity
214994322|NCT02242630|DRUG|Methylprednisolone, 20 mg|Compared with intrabursal triamcinolone
214994323|NCT02242630|DRUG|Methylprednisolone, 40 mg|Compared with intrabursal triamcinolone
214994324|NCT02242630|DRUG|Triamcinolone, 20 mg|Compared with methylprednisolone
214994325|NCT02242630|DRUG|Triamcinolone, 40 mg|Compared with methylprednisolone
214994326|NCT05310136|BEHAVIORAL|BBTi|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi, sleep diaries, and adherence record. In the end of weeks 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
215092433|NCT03035682|OTHER|Traditional Group|The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
215092434|NCT00002112|DRUG|Nystatin|
215092435|NCT00002112|DRUG|Fluconazole|
215092436|NCT04105868|OTHER|Neurofeedback|Participants will receive feedback during a computerized task that is based on their own visuocortical activity evoked by attention to negative distractors and task-relevant stimuli on the computer screen.
215092437|NCT02795325|DRUG|DCR-PH1|IV infusion of DCR-PH1
215092438|NCT02795325|OTHER|Placebo|
215092439|NCT00468988|DRUG|Travatan® Z|
215092440|NCT00468988|DRUG|Xalatan®|
215092441|NCT00418977|BEHAVIORAL|"Family-Based Therapy (Maudsley Method)"|The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
214380768|NCT05094193|PROCEDURE|Trocar-site infiltration|20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 6 mm trocar site)
214380769|NCT05094193|PROCEDURE|TAP block|bilateral ultrasound-guided TAP block with 20 mL of ropivacaine 0.375% in each side
214380770|NCT05094193|PROCEDURE|Trocar site infiltration placebo|20 mL of normal saline
214380771|NCT05094193|PROCEDURE|TAP block placebo|bilateral ultrasound-guided TAP block with 20 mL of normal saline in each side
214380772|NCT05642026|DRUG|Ropivacaine|Patients in this group will receive CINB (continuous local intercostal infusion of 0.2% Ropivacaine). A single catheter will be placed for short segment involvement and two catheters will be placed in series for longer segments of involvement. If necessary and as part of standard of care, CINB treatment will continue after patient discharge. The administration of CINB therapy will continue in the same manner as inpatient therapy.
214380773|NCT05642026|DRUG|Non steroidal anti-inflammatory drug and opioids|Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
214380774|NCT04636801|DRUG|Experimental: CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg).
214380775|NCT04636801|DRUG|Experimental: CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg).
214380776|NCT04636801|DRUG|Placebo|CHF6001 matching placebo, 2 inhalations bid.
214380777|NCT01285193|BEHAVIORAL|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
214380778|NCT04404621|BEHAVIORAL|Physical exercise (PE) training and computer-based brain (CBB)|18 weeks of PE and CBB.
214380779|NCT06047236|OTHER|Sampling|Evaluation of immune characteristics by using patient's stool, saliva and blood samples.
214380780|NCT04588818|DRUG|Adalimumab plus Methotrexate|"Adalimumab 40 mg (≥30kg weight) or 20mg (\<30kg weight) subcutaneously every other week without loading dose.~Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) ."
214380781|NCT00056940|BEHAVIORAL|Stages of Change|
214380782|NCT00056940|BEHAVIORAL|Safety Check approach|
214380783|NCT00294216|DRUG|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
214380784|NCT04034459|DRUG|Bevacizumab|Bevacizumab 5 mg/kg BW iv over 30 to 90\* min day 1
214994327|NCT06001645|DIAGNOSTIC_TEST|Blood and bronchoalveolar fluid collection and analysis|Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.
214994328|NCT06001645|DIAGNOSTIC_TEST|Chest CT scan|Computed Tomography Scan per normal clinical practice
214380785|NCT04034459|DRUG|Irinotecan|Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
214380786|NCT04034459|DRUG|Folinic acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
214380787|NCT04034459|DRUG|Oxaliplatin|Oxaliplatin 85mg/m² day 1
214380788|NCT04034459|DRUG|5-FU|5-FU 3000 mg/m² iv over 48 h days 1-2
214380789|NCT04034459|DRUG|Cetuximab|Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
214380790|NCT00380120|DRUG|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
214380791|NCT00380120|DRUG|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
214380792|NCT00482638|DRUG|MK0493|
214380793|NCT02831179|DRUG|Capecitabine|Given PO
214380794|NCT02831179|DRUG|Temozolomide|Given PI
214380795|NCT02831179|DRUG|Veliparib|given PO
214380796|NCT02831179|OTHER|Pharmacological Study|Correlative studies
214380797|NCT02831179|OTHER|Laboratory Biomarker Analysis|Correlative studies
214380798|NCT01213043|BIOLOGICAL|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks
214380799|NCT01213043|BIOLOGICAL|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks
214380800|NCT04930107|DRUG|Fluconazole 150 mg|Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Females presenting with a suspected first-time yeast infection will be treated with fluconazole 150 mg orally.
214380801|NCT04930107|DRUG|Boric Acid Supp,Vag|Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Women that have had a prior documented VVC infection that has recurred on fluconazole will be treated with boric acid, 600 mg intravaginally at bedtime for 7 days.
214994329|NCT01477983|PROCEDURE|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
214994330|NCT01477983|DRUG|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
214994331|NCT01477983|PROCEDURE|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
214994332|NCT01477983|DRUG|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
214994333|NCT01477983|PROCEDURE|Control|Following successful PV isolation, intravenous ATP is not administered.
214994334|NCT01477983|DRUG|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
214994335|NCT01477983|PROCEDURE|Control|Following successful PV isolation, intravenous ATP is not administered.
215092442|NCT00418977|BEHAVIORAL|Individual Supportive Psychotherapy|The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
215092443|NCT00877370|DRUG|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
215092444|NCT03926988|DEVICE|NeVa Stent Retriever|mechanical neurothrombectomy
214994336|NCT01477983|DRUG|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
214994337|NCT04070534|OTHER|PALS|patient activated learning system
214994338|NCT01311791|DEVICE|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
214994339|NCT01311791|DRUG|Standard medical therapy|as defined per protocol
214994340|NCT00036400|DRUG|epoetin alfa|
215092445|NCT03106285|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10\^8 CFU L retueri DSM17938
215092446|NCT03106285|DIETARY_SUPPLEMENT|Placebo|5 drops of placebo drops
215092447|NCT03610009|DEVICE|2D ultrasound|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
215092448|NCT03610009|DEVICE|SonoAVC|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
215092449|NCT00837603|BEHAVIORAL|Training|Controlled home ergometer training
215092450|NCT03350555|DEVICE|Additioned Endoscopy|To evaluate the use of additioned endoscopy in ERCP treatment.
215092451|NCT01705093|DIETARY_SUPPLEMENT|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
214994341|NCT04125459|PROCEDURE|Joint Biopsy|a synovial biopsy of a joint that has been affected by a gout attack
214994342|NCT05483647|PROCEDURE|Local infiltrative anaesthesia|In prone position, before the skin incision, patients in G1 underwent local infiltrative anaesthesia et the level of incision. The skin, subcutaneous tissue and muscles up to the foramen intervertebral were anesthetized by the surgeon employing forty millilitre solution of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018%.
214380802|NCT05484583|DRUG|Durvalumab + carboplatin/cisplatin + etoposide|Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip
214380803|NCT05484583|RADIATION|Consolidation radiotherapy|Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.
214380804|NCT05484583|DRUG|Durvalumab|Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion
214380805|NCT03514862|BEHAVIORAL|Mindfulness Booster Training|Four additional mindfulness booster sessions after the 4-week MBI program.
214380806|NCT03514862|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|MBI program is delivered once a week for 4 weeks, 90 minutes each preceded by a 90-minute orientation session. The training sessions will include discussion, and introduction and practice of mindfulness practices.
214380807|NCT03514862|BEHAVIORAL|Self-Practice|4 weeks of self-practice after the MBI training.
214380808|NCT03839485|DRUG|Endodontic treatment using Guedes-Pinto Paste|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
214380809|NCT03839485|DRUG|Endodontic using Guedes-Pinto Paste without antibiotic|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
214380810|NCT05332977|DEVICE|CAD-CAM fabricated provisional prosthesis|Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla
214380811|NCT05332977|DEVICE|DC (denture conversion) provisional prosthesis|Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
214380812|NCT00426322|DEVICE|bovine bone mineral particles (Bio-Oss®)|bovine bone mineral particles used for sinus augmentation prior to dental implant placement
214380813|NCT03609125|OTHER|CBS eyedrop|The product is dispensed as sterile frozen vials containing 0.8 ml of product for the daily administration. The product is thawed and administered at a dose of 1 drop / 8 times each eye during the waking period.
214380814|NCT01678443|BIOLOGICAL|indium In 111 anti-CD45 monoclonal antibody BC8|Given IV
214380815|NCT01678443|RADIATION|yttrium Y 90 anti-CD45 monoclonal antibody BC8|Given IV
214994343|NCT05483647|PROCEDURE|Erector spine plane block|The transverse vertebral process of the required level of spine was identified using the mobile C-arm X-ray System. When the tip of the 22G needle reached to the transverse vertebral process 3 cm lateral to the spinous process, a solution of 40 millilitres of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018% was injected under the erector spinae muscle bilaterally.
214994344|NCT06265636|PROCEDURE|Percutaneous nerve stimulation|Percutaneous nerve stimulation (PENS) involves inserting a dry needling needle through muscle tissue until it reaches a nerve branch. At this point, a bipolar TENS current with different parameters is applied to the needle with the goal of improving the patient's pain perception.
214994345|NCT06265636|OTHER|Manual therapy|Digital pressure techniques in muscle areas with the aim of reducing the perception of stiffness and pain
214994346|NCT06265636|OTHER|exercise|Exercises for improving mandibular mobility, occlusion coordination and regulation of temporomandibular muscle tone
214994347|NCT06280716|DRUG|Placebo|Subcutaneous injection
214994348|NCT06280716|DRUG|Lebrikizumab|Subcutaneous injection
214994349|NCT06280716|DRUG|Topical Corticosteroid|Topical Corticosteroid
214380816|NCT01678443|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
214380817|NCT01860443|OTHER|Telepsychiatry collaborative program|"The intervention includes:~* Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression~* Online supervision in a web platform by specialists~* Telephone monitoring"
214380818|NCT01860443|OTHER|Usual care|"* Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression"
214380819|NCT01380886|OTHER|experimental infant formula with alternate protein source|experimental infant formula to be fed ad libitum
214380820|NCT01380886|OTHER|Infant formula powder|powdered infant formula to be fed ad libitum
214380821|NCT05138159|DRUG|Donafenib|Donafenib: 200mg po bid.
214380822|NCT05138159|DRUG|S1|S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, \> 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
214380823|NCT02221856|PROCEDURE|Motion View|Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
214380824|NCT02221856|PROCEDURE|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
214380825|NCT01007890|OTHER|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
214380826|NCT01024790|BEHAVIORAL|Exercise group|24 week group exercise class supplemented with behavioral activation strategies
214497994|NCT06951256|DRUG|Scalp block by adding dexmedetomidine as an adjuvant to bupivacaine|local infiltration of total volume 20ml which include (Bupivacaine 0.25%. + Dexmedetomidine 1mcg/kg) was done Dexmedetomidine preparation was done by 2ml (200 mcg) diluted by 18 ml normal saline in 20 ml syringe as 1ml was contain 10 mcg and injected at same points as above
214380827|NCT00750100|DRUG|human chorionic gonadotropin|hCG 200IU in the late follicular phase
214380828|NCT00750100|DRUG|recombinant gonadotropins|200 IU per day during controlled ovarian stimulation
214497995|NCT06954012|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|ice every 2 waking hours during the first 24 to 48 hours,a brace early in rehabilitation , strain counters strain technique
214497996|NCT06954012|OTHER|Exercise|RICE, anterior-to-posterior talar mobilization, orthoses
214380829|NCT02435771|DRUG|Ergocalciferols|Treatment 1- 400,000 IU
214380830|NCT02435771|DRUG|Ergocalciferols|Treatment 2- 800,000 IU
214380831|NCT01175148|DRUG|Atorvastatin calcium (Lipitor)|40 mg PO daily
214380832|NCT00714532|BEHAVIORAL|Expert System Only|Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
214497997|NCT06953544|BEHAVIORAL|Father-Sensitive Education|he father-sensitive education program preserves the basic structure of the Childbirth Preparation Education program, but has been enriched with original content that supports the active emotional and functional participation of fathers-to-be in the birth process.
214380833|NCT00714532|BEHAVIORAL|Enhanced Expert System|"The intervention consists of 3 components:~* Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~* scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~* telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~* a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
214380834|NCT00073879|BIOLOGICAL|alemtuzumab|
214380835|NCT00073879|BIOLOGICAL|graft-versus-tumor induction therapy|
215092452|NCT01705093|DIETARY_SUPPLEMENT|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
215092453|NCT02252965|DRUG|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
215092454|NCT02252965|DRUG|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
215092455|NCT00867555|DIETARY_SUPPLEMENT|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
215092456|NCT06249906|DEVICE|Commercial bone implant product Group|Commercial bone implant product Group with a smooth surface （without particular microstructures）.
214380836|NCT00073879|DRUG|cyclophosphamide|
214380837|NCT00073879|DRUG|fludarabine phosphate|
214380838|NCT00073879|PROCEDURE|allogeneic bone marrow transplantation|
214380839|NCT00073879|PROCEDURE|peripheral blood stem cell transplantation|
214497998|NCT06953544|BEHAVIORAL|Standardized birth education|The control group received a total of 12 hours of standard childbirth preparation training, consisting of four three-hour sessions.
214994350|NCT06131021|DRUG|Amoxicillin|Amoxicillin belongs to the penicillin category, and it is a commonly prescribed broad-spectrum antibiotic as a periodontal treatment adjunct.
214994351|NCT06131021|DRUG|Metronidazole|Metronidazole is effective against anaerobic bacteria, and it is often combined with Amoxicillin for an enhanced antimicrobial effect as a periodontal treatment adjunct.
214994352|NCT06131021|OTHER|Placebo|Placebo in identical drug-safe vials with capsules identical in appearance to the active drugs
214994353|NCT06124846|BEHAVIORAL|CB-Abst|incentivized, biochemically verified abstinence via contingency management
215092457|NCT06249906|DEVICE|Mirco-structured Bioceramic Group|β-tri-Calcium phosphate with microstructures such as grooves, patterns and so on.
214380840|NCT02117232|DEVICE|Visualization balloon|"The Visualization Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the Visualization Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The Visualization Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The Visualization Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon."
214380841|NCT02117232|DEVICE|Traditional CO2 insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
214380842|NCT00367913|DRUG|Addition of clarithromycin to rifampicin and ethambutol|
214380843|NCT00367913|DRUG|Addition of Ciprofloxacin to rifampicin and ethambutol|
214497999|NCT06951776|BEHAVIORAL|Morning administration group of teriparatide|Eligible participants will be randomly assigned (1:1) to either subcutaneous injection of 20 μg teriparatide at 08:00 a.m. in the morning (Group A) and subcutaneous injection of 20 μg teriparatide at 20:00 p.m. in the evening (Group B).
214498000|NCT06951776|BEHAVIORAL|Evening administration group of teriparatide|Eligible participants will be randomly assigned (1:1) to either subcutaneous injection of 20 μg teriparatide at 08:00 a.m. in the morning (Group A) and subcutaneous injection of 20 μg teriparatide at 20:00 p.m. in the evening (Group B).
214994354|NCT06124846|BEHAVIORAL|CB-Mon|monitoring with no required abstinence
214994355|NCT05220046|DRUG|Psilocybin|Psilocybin, 25mg administered orally drug during an 8-hour monitored session with supportive pre- and post- session counseling
215092458|NCT05294081|BEHAVIORAL|Exposure therapy|10 sessions based on an individualized pain hierarchy
215092459|NCT05294081|BEHAVIORAL|Cognitive behavioral therapy|10 sessions with graded activity, relaxations techniques and cognitive interventions
215092460|NCT03599245|DRUG|Ocrelizumab|Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.
214498001|NCT06954558|DRUG|GK01 Injection|Autologous tumor-reactive T cells injection
214498002|NCT06952322|OTHER|Questionnaire and Physical Exam|Questionnaire results of groups will be compared.
215092461|NCT04795050|BEHAVIORAL|Project POWER|Diabetes health promotion/cardiovascular disease risk reduction educational curriculum
215092462|NCT05822011|PROCEDURE|Rhomboid intercostal subserratus plane block|Fascial plane block
215092463|NCT05822011|PROCEDURE|Erector spinae plane block|Fascial plane block
215092464|NCT06038383|DEVICE|Group A - Intervention with Virtual Reality (VR)|Group of people with kidney disease that performed VR intervention during hemodialysis.
214380844|NCT00367913|BIOLOGICAL|Vaccination with M.vaccae|
214393847|NCT02780986|BEHAVIORAL|Female entertainment worker intervention group|"The following summarises the content of each session:~Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.~Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.~Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.~Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms."
215092465|NCT06038383|DEVICE|Group B - Intervention with Stationary Bike (SB)|Group of people with kidney disease that performed SB intervention during hemodialysis.
215092466|NCT06038383|DEVICE|Group A - Intervention with Stationary Bike (SB) - Crossover|Group of people with kidney disease that performed SB intervention during hemodialysis after the washout period.
215092467|NCT06038383|DEVICE|Group B - Intervention with Virtual Reality (VR) - Crossover|Group of people with kidney disease that performed VR intervention during hemodialysis after the washout period.
215092468|NCT05816395|DRUG|RHH646|RHH646 capsule for oral use
215092469|NCT05816395|DRUG|Placebo|RHH646 placebo capsule for oral use
215092470|NCT06578234|DRUG|Adenosine|Standard dose 140 μg/kg/min and high dose 210 μg/kg/min adenosine
215092471|NCT02740361|BEHAVIORAL|Deprexis, DeprexisPlus|Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.
215092472|NCT03913689|DEVICE|StimRouter Neuromodulation System|An implantable neuromodulation device that treats chronic peripheral nerve pain.
215092473|NCT01733771|OTHER|Reflexology|Reflexology intervention involved a 15-minute treatment in the induction room, provided by three reflexologists from the hospital staff. The reflexology protocol was developed through a Delphi method.
215092474|NCT01733771|OTHER|Sham reflexology|Sham reflexology intervention were given by two complementary medicine practitioners with knowledge in touch therapy (shiatsu) and included 15 minutes of gentle, nonspecific foot massage. Similarly to the true reflexology protocol, the protocol for this treatment was also determined in a consensus-reaching process among a group of four experienced reflexologists.
215092475|NCT04570683|DRUG|Nivolumab 10 MG/ML|Se previously
215092476|NCT04570683|DEVICE|Ablative fractionated laser|Se previously
215092477|NCT01522261|OTHER|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
215092478|NCT01522261|OTHER|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
215092479|NCT04691856|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
215092480|NCT04691856|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
215092481|NCT04691856|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
214498003|NCT05017532|BEHAVIORAL|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+)|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+) is a personalized CR treatment targeting social cognition (e.g. theory of mind, emotion recognition) using virtual reality to emulate daily social interactions
214994356|NCT06538337|RADIATION|External beam Radiotherapy|Five fractions of radiation therapy using adaptive planning and CT or MRI guidance (6 Gy per fraction) delivered once every other day excluding weekends and holidays
214994357|NCT06700447|BEHAVIORAL|Enhanced inoculation message|"Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: Inoculation message with a BE boost for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime."
214994358|NCT06700447|BEHAVIORAL|Nutrition information|Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.
214994359|NCT00001647|PROCEDURE|White blood cell infusion|
214994360|NCT06792825|DRUG|Tafasitamab|Tafasitamab 12 mg/kg IV on Day 1, Day 8, Day 15 and day 22.
215092482|NCT04691856|DRUG|Morphine|All patients were instructed to use intravenous patient-controlled analgesia (IV PCA). All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
215092483|NCT03331822|OTHER|Bright Light|high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day\*Light Classic Light will be positioned at each nursing station in the ICU hallway.
215092484|NCT04773990|DEVICE|Biodex Balance System|Subjects will receive several unique training modules using biodex
214498004|NCT04297605|DRUG|Pembrolizumab|Pembrolizumab 200 mg
214498005|NCT04297605|OTHER|Pemetrexed (Chemotherapy)|500 mg/m2 day 1 of 21 day cycle (for non-squamous only)
214994361|NCT06792825|DRUG|Rituximab|Rituximab 375 mg/m2 IV on day 1
214994362|NCT06792825|DRUG|Lenalidomide|Lenalidomide 20 mg PO Day 1 through Day 21
215092485|NCT04773990|OTHER|specific physical therapy exercise program|Subjects will receive recommended PT program
215092486|NCT01785823|OTHER|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
215092487|NCT01785823|OTHER|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
214994363|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Fiber Sachet|"A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
214994364|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Placebo sachet|"A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
214994365|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Fiber Sachet|"A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
214994366|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Placebo sachet|"A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
214994367|NCT06019754|PROCEDURE|one point combined Lumbar and sacral plexus block|performing an ultrasound-guided one-point combined Lumbar and sacral plexus block using a one-point puncture. Block success will be assessed using the perfusion index (PI) before and after performing the block
214994368|NCT05988138|BEHAVIORAL|Family Promoting Positive Emotions|An 8-week dyadic intervention using cognitive and behavioral skills to up-regulate positive emotions in children and mothers
214994369|NCT05988138|BEHAVIORAL|Psychoeducation|An 8-week comparison condition that offers education in mental health, depression prevention, and accessing mental health resources
214994370|NCT05707806|DEVICE|MRI|Enables the use of custom pulse sequence
214498006|NCT04297605|OTHER|Nab-paclitaxel (Chemotherapy)|100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
214994371|NCT06189352|OTHER|Positive feeding of the preterm infant|Feeding strategy for the preterm infant with description of nutritional needs and based on the infants development and cues.
214994372|NCT06695247|OTHER|Exercise Training|Patients will be recommended to exercise 3 days/week, 20 minutes per session, for 12 weeks using personalized intervention determined by a consultation with a clinical exercise physiologist (CEP)
214994373|NCT05357495|BEHAVIORAL|Affective Posner fMRI frustration induction task|During the frustration induction paradigm, children play a game with monetary reward. The game is rigged, thus inducing frustration. The control task does not have any reward component. All participants complete both the control task scanning session and the frustration induction scanning session.
214994374|NCT05802355|OTHER|Manual Diaphragm Release|The participant was supine, with his or her limbs relaxed. With the therapist's forearms aligned toward the participant's shoulders, the therapist gradually increased the depth of contact inside the costal margin during the subsequent respiratory cycles.
214994375|NCT05802355|OTHER|control group|Respiratory re-training was given to participants in control group in form of slow and deep diaphragmatic breathing, exhalation through the nose with pursed lips (the participants were trained to emphasis on expiratory pressure against pursed lips), Breathing control and breathing-hold exercises, and Relaxation techniques:
214994376|NCT05355337|DRUG|Pramipexole|9 weeks of treatment with Pramipexole
214994377|NCT05355337|DRUG|Placebo|9 weeks of treatment with Placebo
214994378|NCT05686694|OTHER|Video Education|"Sharing of Planned Education Videos on Instagram In this research, the platform where planned video education will be shared was determined as Instagram, which is the most used social media platform by pregnant women. In the Instagram user name @ogttegitim account, 6 education videos that will be created and shared."
214994379|NCT02477449|DRUG|istaroxime|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
214994380|NCT02477449|DRUG|9% Saline (NS)|infusion for 24 hours
214994381|NCT05316220|DRUG|Mesalamine|Oral Capsules
214994382|NCT05316220|DRUG|Placebo|Oral Capsule
214994383|NCT06358469|PROCEDURE|Surgery|Re-excision of vulvar cancer margin
214994384|NCT06358469|OTHER|Active Surveillance|The investigator will follow the patient to watch for side effects and keep track of patient's health
214994385|NCT05217446|DRUG|Encorafenib|capsule
214498007|NCT04091295|DRUG|DNG64|Intravenous infusions of DNG64 for treatment of advanced pancreatic cancer, sarcoma and carcinoma of breast
214498008|NCT06441149|OTHER|AI-based informed consent|Patients receiving personalized data-based informed consent procedure before bronchoscopy
214498009|NCT06441149|OTHER|Standard informed consent|Standard informed consent
214498010|NCT06084416|DRUG|Sovilnesib|Sovilnesib tablets will be given orally.
214498011|NCT05536076|OTHER|Hypercapnia treatment|Intermittent hypercapnia treatment five days per week for two weeks.
214994386|NCT05217446|BIOLOGICAL|Cetuximab|IV
214994387|NCT05217446|BIOLOGICAL|Pembrolizumab|IV
214994388|NCT04126070|DRUG|Androgen Deprivation Therapy|Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
214994389|NCT04126070|DRUG|Nivolumab|Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
214994390|NCT04126070|DRUG|Docetaxel|Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
214994391|NCT00359476|DRUG|Vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
214994392|NCT00988026|DRUG|Minocycline vs Lymecycline|Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
215092488|NCT01785823|OTHER|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
215092489|NCT06010173|DRUG|Gadopiclenol|Dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.05 mmol/kg BW
215092490|NCT06010173|DRUG|Comparator|Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW
214380845|NCT03446105|BEHAVIORAL|App-based behavioral intervention|Achieving Wellness After Kancer in Early life (AWAKE) is a behavioral intervention that includes a smartphone app and coaching. AWAKE contains eight modules, and participants will complete the one module every week. App functioning will facilitate weekly homework assignments and include health education messaging, the ability to track progress toward goals over time via self-monitoring and graphical depictions of progress, audio-recordings of guided imagery exercises and relaxation exercises (e.g., progressive muscle relaxation), videos of topic-related inspirational material, and a portal for interacting with the coach. The coach will call each intervention participant weekly. Each coaching session will last roughly 30 minutes and involve four segments that will correspond to the module for the week. The coach will send daily text messages to participants encouraging their goal pursuits and providing other sources of support related to that week's homework.
214380846|NCT03446105|BEHAVIORAL|Attention control group|The attention control group will receive the same components as the intervention group, but the educational modules will contain different content than those receiving the AWAKE intervention.
214380847|NCT01091623|OTHER|training|
214380848|NCT01091623|OTHER|training|
214380849|NCT01091623|OTHER|training|
214994393|NCT05211700|OTHER|This is an observational study, there is no intervention in this study.|There is no intervention in this study
214380850|NCT01010477|DRUG|Nicotine Nasal Spray|minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day
214380851|NCT01010477|BEHAVIORAL|Behavioral counseling|Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
214380852|NCT01917305|DEVICE|platform-shifted implant|
214380853|NCT01520389|DRUG|MM-151|MM-151
214380854|NCT01520389|DRUG|MM-151 + irinotecan|MM-151 + irinotecan
214380855|NCT05639907|DEVICE|K21 Cavity cleanser|K21 Cavity cleanser is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
214380856|NCT05639907|DEVICE|Ethanol control|Ethanol is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
214994394|NCT04194840|OTHER|physical therapy consult|Physical therapy consult to assess physical functioning on a separate office visit prior to attending the Transplant Wellness Clinic. Full evaluation that incorporates several tools to measure the risk of falling and to assess mobility and strength
214994395|NCT04194840|OTHER|Cognitive Assessment|Montreal cognitive assessment (MoCA) and the Blessed Orientation-Memory-Concentration Test (BOMC)
214994396|NCT04194840|OTHER|Cancer Aging Research Group (CARG) assessment|CARG assessment - utilized to capture information about a participant's medical history as well as functional, cognitive, and psychosocial status
215092491|NCT01883752|PROCEDURE|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
215092492|NCT00702494|BIOLOGICAL|TB-403|Multiple IV
215092493|NCT00167388|OTHER|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
215092494|NCT04538313|DRUG|Tumor infiltrating lymphocyte|Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
215092495|NCT04435600|DRUG|Risankizumab|Subcutaneous Injection
215092496|NCT04435600|DRUG|Ustekinumab|Subcutaneous Injection
215092497|NCT03893877|DEVICE|nasal cannula|experimental group will be applied nasal cannula
215092498|NCT03893877|DEVICE|nasal mask|active comparator group will be applied nasal mask
215092499|NCT01943006|DRUG|Hirudoid cream 0.3 % Mucopolysaccharide polysulfate|Hirudoid cream
215092500|NCT01943006|DRUG|Placebo cream without active substance|
214380857|NCT05130255|DRUG|GD2-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA, both will be administered as an IV infusion
214380858|NCT02636972|DRUG|OCPs|"Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra"
214380859|NCT04436458|DRUG|Niclosamide Oral Tablet|Continued SOC therapy together with niclosamide TID for 14 days
214380860|NCT04436458|DRUG|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
214380861|NCT04421742|DRUG|Beclomethasone Dipropionate/Formoterol Fumarate|BDP/FF NEXThaler® 100/6 μg b.i.d.
214994397|NCT04194840|OTHER|Medication Review|Medication Review via Beers Assessment
214994398|NCT04194840|OTHER|Nutrition assessment|Nutrition assessment Via Mini Nutrition Assessment (MNA)
214994399|NCT04194840|OTHER|Laboratory studies|Laboratory studies including urine toxicology screen, C-reactive protein, albumin, pre-albumin, vitamin D
215092501|NCT06341010|PROCEDURE|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis
215092502|NCT05501795|DEVICE|WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
214994400|NCT04194840|OTHER|Patient satisfaction questionnaire|Patient satisfaction questionnaire
214994401|NCT04194840|OTHER|Physician Questionnaire|"Physician Questionnaire:~Questionnaire to learn about physician satisfaction with information received from reports and participant questionnaires."
214994402|NCT04194840|OTHER|Patient follow-up questionnaire|"Patient follow-up questionnaire:~Questionnaire to learn more about participant opinions concerning the clinic and the quality of care received during visits with specialists"
214994403|NCT03542760|DRUG|Methylene Blue|Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
214994404|NCT01642368|OTHER|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
214994405|NCT01081990|DRUG|cyclobenzaprine|Cyclobenzaprine 5 mg TID for 7 days
214994406|NCT02064062|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
214994407|NCT00646516|DRUG|budesonide/formoterol (Symbicort)|
214994408|NCT01879267|BEHAVIORAL|Exercise training|6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
214994409|NCT05567458|DRUG|Luspatercept|Specified dose on specified days
214994410|NCT05567458|DRUG|Placebo|Specified dose on specified days
214994411|NCT05984030|OTHER|PrEP Navigation Services|Trained professional PrEP navigators will connect with intervention arm participants following study onboarding. Primary navigator responsibilities include helping participants engage in PrEP care, assisting with completing necessary paperwork for insurance, referral to PrEP care, and application for drug assistance programs, as needed. Navigation services will be available to participants for the first 6 months of participation (active intervention period). Navigation services are tailored to the individual needs of each intervention arm participant
214994412|NCT05984030|OTHER|Telehealth PrEP Services Referral|PrEP Navigators can link interested intervention arm participants to telehealth PrEP services via self-referral. The study facilitates referral for intervention arm participants to pre-existing telehealth PrEP services. The telehealth PrEP services participants receive are not provided, financed, or staffed by the study. Participants will receive telehealth PrEP services via the technology platform or service that the provider typically employs. PrEP clinical eligibility, visit frequency, monitoring labs, and all other PrEP management will be at the discretion of the established PrEP provider. PrEP navigators can assist with appointment scheduling, reminders, and other provider-access issues, as requested, for the first 6 months of study participation.
214994413|NCT05984030|BEHAVIORAL|HealthMpowerment Digital Health Intervention - Enhanced|The Enhanced version of the HealthMpowerment Digital Health Intervention includes all features from the Basic version, plus the following additional features: Interactive skill-building health activities; social support newsfeed/group chat; Ask the Expert anonymous health question and answer; Medication Tracker; Health Behavior Tracker; Gamification features for participant engagement.
214994414|NCT05984030|BEHAVIORAL|HealthMpowerment Digital Health Intervention - Basic|The Control Arm version of the HealthMpowerment Digital Health Intervention includes: Study Timeline and Calendar, publicly-available PrEP locator feature, Dried Blood Spot self-collection kit ordering, Educational Health Resource Center.
214994415|NCT01508000|DRUG|FOLFOX6|5-FU, folinic acid, oxaliplatin
214994416|NCT01508000|BIOLOGICAL|Bevacizumab|Targeted therapy
214994417|NCT01508000|BIOLOGICAL|Panitumumab|Targeted therapy
214994418|NCT01508000|PROCEDURE|Surgery|
214994419|NCT05524532|DRUG|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.
214994420|NCT05524532|DIETARY_SUPPLEMENT|Placebo|Placebo is an inert form of cellulose acetate.
214994421|NCT06032546|DRUG|Budigalimab|Intravenous (IV) Infusion
214994422|NCT06032546|DRUG|Placebo for Budigalimab|IV Infusion
214994423|NCT06032546|DRUG|ABBV-382|IV Infusion
214994424|NCT06032546|DRUG|Placebo for ABBV-382|IV Infusion
214994425|NCT06032546|DRUG|Budigalimab|Subcutaneous (SC) Injection
214994426|NCT02225587|BIOLOGICAL|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
214994427|NCT02225587|BIOLOGICAL|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
214994428|NCT02225587|BIOLOGICAL|Placebo|Injections are to be administered into the deltoid muscle of the upper arm.
214994429|NCT05250232|OTHER|onlays conservative|Partial coverage of cusps with shoulder finish line
214994430|NCT05250232|OTHER|onlays conventional|all coverage of cusps as overlay with shoulder finish line
214994431|NCT03776045|OTHER|Standard care plus exercise|The exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted \~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training).
214994432|NCT04447729|DRUG|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
214994433|NCT01983631|OTHER|Whole body vibration training|
214994434|NCT05155358|DIAGNOSTIC_TEST|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
214498012|NCT03965949|DRUG|Hormone Replacement cycle 1|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
214994435|NCT06294561|DRUG|Itraconazole+TGRX-326|healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Itraconazole 200 mg with TGRX-326 60 mg orally on day 11
214994436|NCT06294561|DRUG|Efavirenz+TGRX-326|healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Efavirenz 600 mg with TGRX-326 60 mg orally on day 20
214380862|NCT02799303|DEVICE|Multi-parametric MRI|Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
214380863|NCT02799303|OTHER|PSA testing|Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
214994437|NCT03116230|DEVICE|Cutaneous Stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
214994438|NCT03116230|DEVICE|Knee Sleeve|Commercially-available knee sleeve.
214994439|NCT02323256|OTHER|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
214994440|NCT02323256|OTHER|Speech-ABR|
214994441|NCT02323256|OTHER|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
214994442|NCT02323256|OTHER|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
214994443|NCT06197204|OTHER|Blood sampling|"* at first visit in the reference center~* at each follow-up visit ( once a year)~* before and after specific treatment~* in case of flare"
214994444|NCT06197204|OTHER|Biopsy|In case of flare
214994445|NCT06197204|OTHER|Blood sampling|Once at inclusion visit
214994446|NCT00207428|DRUG|Carbamazepine|
214994447|NCT03220893|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
214994448|NCT03220893|RADIATION|Scintimammography|Undergo MBI
214994449|NCT06487962|DEVICE|CGM Intervention|The intervention has 4 components with CGM uptake and maintenance as a primary focus. (1) Participants will visit their primary care provider (PCP) at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of CGM data and insulin therapy adjustments as indicated. Intervention providers received rigorous training in T1D management and CGM via Project ECHO (Extension for Community Healthcare Outcomes). (2) After each PCP visit, the CDCES will follow-up with participants to ensure participant understanding of the education/instructions provided at the PCP visit. (3) Next, participants will receive 4-weekly sessions of culturally sensitive, intensive CGM education and training led by a CDCES with accompaniment of a supportive family member or friend. (4) Virtual group support sessions, led by a peer educator, will follow over 5 months. During this period, the peer-led sessions will take place every two weeks and then move to every three weeks.
214994450|NCT06487962|OTHER|SMBG Control Condition|The SMBG control condition consists of 3 components delivered over 6 months. (1) Participants will visit their PCP at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of SMBG data and insulin therapy adjustments as indicated. Control providers received rigorous training in T1D management via Project ECHO. (2) Commencing after the first PCP visit, participants will have 4-weekly telehealth visits for knowledge and skills reinforcement for SMBG. (3) CDCES support phone calls will follow over 5 months. During this period, the support phone calls will take place every two weeks and then move to every three weeks.
214994451|NCT01933932|DRUG|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
214994452|NCT01933932|DRUG|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
214994453|NCT01933932|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
214994454|NCT01933932|DRUG|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
214994455|NCT06636214|BEHAVIORAL|CHATO-I|Online communication education program
214994456|NCT04315558|DRUG|Revefenacin Inhalation Solution [Yupelri]|nebulized drug comparison
214994457|NCT04315558|DRUG|Ipratropium Bromide|nebulized drug comparison
214994458|NCT06634706|DEVICE|RefleXion X1 Radiotherapy System [Imaging Only]|kVCT and FDG-PET imaging using the RefleXion X1 Radiotherapy System in different anatomical regions
214994459|NCT00858546|DEVICE|Repetitive transcranial stimulation|Repetitive transcranial stimulation
214994460|NCT06520163|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
214994461|NCT06520163|DRUG|Cytarabine|Day 1\~Day 2: 200g/m\^2, q12h
214994462|NCT06520163|DRUG|PEG-rhG-CSF|Day 6: 6mg
214994463|NCT06520163|DRUG|G-CSF|Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
214994464|NCT06520163|COMBINATION_PRODUCT|CHOP|\[Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) \]± Rituximab (R)
214994465|NCT06520163|COMBINATION_PRODUCT|Hyper-CVAD|\[Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone (DXM)\] ± Rituximab
214380864|NCT02110732|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|
214380865|NCT05304715|DRUG|Bezlotoxumab|Single intravenous infusion of bezlotoxumab
214380866|NCT05304715|DRUG|Normal saline 0.9% or 5% dextrose water|Single intravenous infusion - Placebo arm
214380867|NCT02425748|BIOLOGICAL|DC-CIK|DC-CIK cells will be used against tumor cells.
214498013|NCT03965949|DRUG|Hormone Replacement cycle 2|Hormone Replacement cycle with GnRHa suppression
214498014|NCT05333367|OTHER|Samples collection|Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)
214994466|NCT06520163|COMBINATION_PRODUCT|ID-MTX + Ara-C|\[High-Dose Methotrexate (MTX) + Cytarabine\] ± Rituximab
214994467|NCT06520163|COMBINATION_PRODUCT|DA-EPOCH|\[Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone\] ± Rituximab
214994468|NCT06520163|COMBINATION_PRODUCT|GDP|\[Gemcitabine (G) + Cisplatin (P) + Dexamethasone (DXM)\] ± Rituximab
214380868|NCT02425748|BIOLOGICAL|γδ T Cell|γδ T cells will be used against non small lung tumor.
214994469|NCT06520163|COMBINATION_PRODUCT|GDPE|\[Gemcitabine + Cisplatin + Dexamethasone + Etoposide\] ± Rituximab
214380869|NCT02425748|BIOLOGICAL|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against lung tumor.
214380870|NCT02529475|DRUG|Gadoteric acid|Comparison with patients with Meniere's disease
214380871|NCT06463821|OTHER|observational questionnaires|Patient data were collected from questionnaires.
214380872|NCT04836858|BIOLOGICAL|CMK389|Active
214380873|NCT04836858|BIOLOGICAL|Placebo|Placebo Comparator
214380874|NCT05781139|DIAGNOSTIC_TEST|levels of Neurofilaments (NfL) in serum|the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
214380875|NCT00813696|DRUG|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
214380876|NCT00813696|DRUG|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
214994470|NCT06520163|COMBINATION_PRODUCT|ICE|\[Etoposide + Ifosfamide (IFO) + Carboplatin\] ± Rituximab
214994471|NCT06520163|COMBINATION_PRODUCT|DICE|\[Dexamethasone + Ifosfamide + Ifosfamide + Etoposide\] ± Rituximab
214994472|NCT06520163|DRUG|G-CSF|From Day 6, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
214994473|NCT06634979|PROCEDURE|Selective lymph node dissection|For 0.5 \< CTR \< 1 and ≤ 2 cm diameter cT1N0M0 invasive non-small cell lung cancer patient sex for selective lymph node (lower mediastinal lymph nodes are not required to be cleared for upper lobe tumors and upper mediastinal lymph nodes are not required to be cleared for lower lobe tumors)
214994474|NCT03823027|DEVICE|SiPore15™|SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.
215092503|NCT04856254|PROCEDURE|Trial of labor after cesarean section|The pregnant females with history of previous cesarean section will be classified according to clinical and ultrasound score as patient suitable to undergo trial of labor after CS \[TOLAC\]or not suitable for \[TOLAC\] so undergo from the beginning to elective repeated cesarean section.
215092504|NCT00820404|DRUG|BLI-489|
215092505|NCT00820404|DRUG|Placebo|
215092506|NCT03133221|DRUG|Zydelig|Zydelig given at 150mg continuously in 28-day cycles
215092507|NCT02797184|DRUG|KNO3, potassium nitrate|Potassium nitrate (KNO3) will be given orally in 2 gelatin capsules, which will be compounded by the Barnes-Jewish Hospital Pharmacy. The doses are 10 mmol and 20 mmol KNO3.
214498015|NCT03752684|DIETARY_SUPPLEMENT|Moderately high oxalate/low calcium diet non-colonized|Subjects will be instructed to ingest a controlled diet moderately high in oxalate before colonization
214498016|NCT03752684|DIETARY_SUPPLEMENT|Oxalobacter formigenes|Subjects will ingest live preparation of O. formigenes
214380877|NCT00004011|DRUG|carboplatin|
214380878|NCT00004011|DRUG|paclitaxel|
214380879|NCT00004011|PROCEDURE|conventional surgery|
214380880|NCT00001015|DRUG|Ribavirin|
214380881|NCT00621907|DRUG|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
214380882|NCT00621907|DRUG|sodium chloride|sodium chloride : 0,9% 30 ml
214380883|NCT01654991|BEHAVIORAL|Home Screening|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
214380884|NCT01654991|BEHAVIORAL|Clinic Screening|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
214380885|NCT03361787|BEHAVIORAL|"Parentship- a multi dimensional intervention program to improve parental resilience"|"Parentship is a multi dimensional intervention program to improve parental resilience and adolescent participation using the OPC model."
214380886|NCT03434002|OTHER|Training by Virtual Reality Simulation|Those Randomized 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
214380887|NCT03434002|OTHER|Training by Mannequin Based Simulation|Randomized other 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
214498017|NCT03752684|DIETARY_SUPPLEMENT|Moderately high oxalate/low calcium diet colonized|Subjects will be instructed to ingest a controlled diet moderately high in oxalate after colonization
214994475|NCT01031082|PROCEDURE|Middle ear fluid, nasopharyngeal aspirate and urine sample.|Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
214994476|NCT02721888|DRUG|Liraglutide|
214994477|NCT02721888|DRUG|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|
214994478|NCT02721888|BIOLOGICAL|Blood sample|
214994479|NCT02721888|OTHER|Kinetic substudy (10 patients)|
214994480|NCT00754780|DRUG|Pirfenidone|Capsule 800 mg TID, oral
214994481|NCT02066454|DRUG|Apixaban|2.5mg x 2 per day during 6 months
214994482|NCT05930288|BEHAVIORAL|Walking exercise|The target physical activity level for participants is to walk 10,000 steps per day and to meet or exceed that level (but not exceed 15,000 steps) seven days a week for three to four weeks. Participants will be advised to gradually increase their daily step count in proportion to their physical condition. Exercise will be performed by brisk walking or jogging using the indoor treadmill equipped by the Neurosurgery Department of Xiangya Hospital or outdoors. Each workout will begin with a 5-minute warm-up and end with a 5-minute cool-down.
215092508|NCT04526691|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)
215092509|NCT04526691|DRUG|KEYTRUDA®|Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
215092510|NCT04526691|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)
215092511|NCT04526691|DRUG|Cisplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/m\^2)
215092512|NCT04121286|DRUG|JAB-3312|JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.
214994483|NCT02598908|DIAGNOSTIC_TEST|Quality control - enzyme activity|A blood sample will be collected from patients and staff donors, no more than twice per year.
214498018|NCT01596231|DIETARY_SUPPLEMENT|Kudzu|Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
214994484|NCT03073759|DEVICE|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
214994485|NCT03073759|DEVICE|Sham device|The device will administer a sham.
214994486|NCT05926960|DRUG|encorafenib|encorafenib
214994487|NCT05926960|DRUG|binimetinib|binimetinib
215092513|NCT04642053|BEHAVIORAL|Dynamic Temporal and Tactile Cuing|Dynamic Temporal and Tactile Cuing is based on principles of integral stimulation where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment will begin by training the child to imitate and simultaneously produce syllables/words with the clinician. Sessions will focus on establishing accurate movement transitions in treated words. The child will be asked to imitate the clinician's production of the target. If the child's imitation is inaccurate, they will be instructed to simultaneously produce the target with the clinician. Simultaneous productions will continue to provide practice opportunity with maximal cuing. As the child gains greater accuracy, simultaneous productions will be faded and direct imitation will be attempted again. Over the course of treatment, the movement gesture will be shaped with the goal being accurate production with normal rate and naturalness.
215092514|NCT01878344|DRUG|NAC|
215092515|NCT01878344|DRUG|Saline|
215092516|NCT04304014|DIETARY_SUPPLEMENT|L. reuteri|(10\^8 CFU) once a day
215092517|NCT04304014|DIETARY_SUPPLEMENT|B. longum and P. Pentosaceus|(10\^9 CFU) once a day
215092518|NCT05149313|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
215092519|NCT05149313|DRUG|Lebrikizumab-matching Placebo|Matching Placebo solution for injection administered subcutaneously.
215092520|NCT04831424|BEHAVIORAL|Trier social stress test|The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
215092521|NCT03095820|BEHAVIORAL|Supportive therapy|
215092522|NCT03095820|BEHAVIORAL|Multidomain intervention|
215092523|NCT00069992|RADIATION|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
215092524|NCT00069992|DRUG|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
215092525|NCT00069992|DRUG|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
215092526|NCT01731067|DRUG|Cocktail probe drugs|
214994488|NCT05926960|DRUG|pembrolizumab|pembrolizumab
214994489|NCT05926960|DRUG|ipilimumab|ipilimumab
214994490|NCT05926960|DRUG|nivolumab|nivolumab
214994491|NCT03181997|DEVICE|Native aortic valve|Native valve, with any transcatheter heart valve type
214994492|NCT03181997|PROCEDURE|Transcatheter aortic valve implantation (TAVI)|Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.
214994493|NCT06616818|OTHER|DASH-FV|12weeks of fruit and vegetable delivery to the home
214994494|NCT06616818|OTHER|nutrition counselling only|nutrition counselling as part of standard of care
214994495|NCT05869955|DRUG|CC-97540|Specified dose on specified days
214994496|NCT05869955|DRUG|Fludarabine|Specified dose on specified days
214994497|NCT05869955|DRUG|Cyclophosphamide|Specified dose on specified days
215092527|NCT06267066|DRUG|Betamethasone Valerate 0.1% Cream|Moderate potency
215092528|NCT06267066|DEVICE|SmartXide® fractional carbon dioxide laser|Ablative
215092529|NCT06267066|DRUG|Vaseline Topical Product|Emollient
214994498|NCT05869955|DRUG|Tocilizumab|Specified dose on specified days
214994499|NCT04510415|DRUG|Olmutinib|"600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
214994500|NCT05789797|DRUG|Remaxol|Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
215092530|NCT04476927|DEVICE|DiaNose|"DiaNose system is an electronic nose device that can smell diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.~The DiaNose prototype system consists the following elements:~* A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.~* Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).~* Laptop - Laptop is used to activate and save the test measurements."
215092531|NCT00422994|DRUG|ropinirole dosing for up to 28 days|
215092532|NCT02248402|BIOLOGICAL|Vax-DC/MM|
214498019|NCT01596231|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
214498020|NCT03790215|DRUG|Dydrogesterone|The investigators give participants oral dydrogesterone(as described in arm description).After 3 cycles of treatment, the investigators evaluate the treatment effects.
214994501|NCT03033615|DEVICE|PixelShine|Machine learning algorithm
214994502|NCT03033615|DEVICE|Conventional processing|Iterative reconstruction software
214994503|NCT01542281|DIETARY_SUPPLEMENT|Whey protein and dietary supplements|Whey protein and dietary supplements in addition to pre-hab exercise
214994504|NCT01542281|OTHER|prehab exercise|minimum 4 weeks and maximum 8 weeks; 3 times a week
214994505|NCT03390660|OTHER|WIC program participation|WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
214380888|NCT04599686|DRUG|ADT|On the day of enrollment, luteinizing hormone-releasing hormone agonist (LHRHa) was given for ADT.
214498021|NCT04720794|DEVICE|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
214498022|NCT01214031|DEVICE|Confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
214498023|NCT06380478|DEVICE|aspicio Monofocal IOL|A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
214498024|NCT03301870|DRUG|ATx201 Gel 2%|2% active gel
214498025|NCT03301870|DRUG|ATx201 Gel 4%|4% active gel
214498026|NCT03301870|DRUG|Positive Control|Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
214498027|NCT03301870|DRUG|Negative Control|Water for Injection, USP
214498028|NCT03301870|DRUG|ATx201 Placebo|matching placebo gel
214498029|NCT03835559|PROCEDURE|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
214498030|NCT03835559|PROCEDURE|Surgical stripping|All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
214498031|NCT02722434|OTHER|Laboratory Biomarker Analysis|Correlative studies
214498032|NCT02722434|OTHER|MC5-A Scrambler Therapy|Undergo Scrambler therapy
214994506|NCT01564407|DRUG|ICX-RHY-013|"Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~1. Empty control no injection~2. Vehicle only (0.5 ml of HypoThermosol solution)~3. 5 million cells / cm² , single administration at Day 0~4. 5 million cells/ cm² , single administration at week 4~5. 5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks"
214994507|NCT02976389|OTHER|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
214380889|NCT04599686|RADIATION|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT) (3-5 fractions).
214498033|NCT02722434|OTHER|Questionnaire Administration|Ancillary studies
214498034|NCT02722434|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
214498035|NCT01038934|PROCEDURE|samples collected by buccal cytobrush|
214498036|NCT06070961|DIAGNOSTIC_TEST|Cellular immunity vs SARS-CoV-2|Evaluation of cellular immunity vs SARS-CoV-2 by ELISpot assay
214380890|NCT03056664|PROCEDURE|Routine drainage surgery|
214380891|NCT03056664|BIOLOGICAL|MSC injection 01|Local MSC injection in peri-anal with a dose of 3×10E6/kg
214380892|NCT03056664|BIOLOGICAL|MSC injection 02|Local MSC injection in peri-anal with a dose of 6×10E6/kg
214380893|NCT03056664|OTHER|placebo|NS injection instead of MSC
214498037|NCT06070961|DIAGNOSTIC_TEST|Humoral immunity vs SARS-CoV-2|Evaluation of Humoral immunity vs SARS-CoV-2 by ELISA assay (IgG anti-RBD and anti-N)
214498038|NCT06070961|DIAGNOSTIC_TEST|Cellular immunity vs Varicella Zoster Virus|Evaluation of cellular immunity vs VZV by Enzyme-Linked immunoSPOT (ELISPOT) assay
214498039|NCT06070961|DIAGNOSTIC_TEST|Humoral immunity vs Varicella Zoster Virus|Evaluation of humoral immunity vs VZV by ELISA (VZV gE-binding IgG)
214498040|NCT06070961|DIAGNOSTIC_TEST|Diphtheria toxin-binding IgG|Evaluation of diphtheria toxin-binding IgG by ELISA assay
214498041|NCT06070961|DIAGNOSTIC_TEST|Tetanus toxoid-binding IgG|Evaluation of tetanus toxoid-binding IgG by ELISA assay
214498042|NCT06070961|DIAGNOSTIC_TEST|T-cell populations and markers characterization|Characterization of T-cell populations and markers by flow cytometry
214498043|NCT02378922|BIOLOGICAL|Gene-Modified HIV-Protected Hematopoietic Stem Cells|Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
214498044|NCT02378922|OTHER|Laboratory Biomarker Analysis|Correlative studies
214498045|NCT02378922|OTHER|Transplant Conditioning|Undergo high-dose chemotherapy or chemoradiotherapy
214380894|NCT05735457|OTHER|A short, animated storytelling video on dietary sodium|Participants in the Intervention Arm will view a short, animated storytelling video on dietary sodium and the risks of cardiovascular disease due to increased intake of sodium.
214380895|NCT05735457|OTHER|A short, animated storytelling attention placebo video|The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial.
214380896|NCT05258123|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract with 360mg was administered
214994508|NCT02976389|OTHER|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
214994509|NCT02976389|OTHER|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
214994510|NCT03729479|BEHAVIORAL|DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
214994511|NCT03729479|BEHAVIORAL|Very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
214994512|NCT03729479|BEHAVIORAL|Extras|Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
214994513|NCT05682378|DRUG|Inclisiran|Inclisiran sodium 300mg (equivalent to 284mg inclisiran\*) in 1.5mL solution administered subcutaneously in pre-filled syringe
214994514|NCT06087718|DEVICE|Maastro applicator|The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size \< 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.
214994515|NCT06219226|PROCEDURE|Chlorine dioxide mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
214380897|NCT05258123|DRUG|Placebo oral tablet|Placebo with nine tables was administered
214380898|NCT06159374|OTHER|exercise and environmental conditions|Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.
214380899|NCT01835600|OTHER|PEEP|PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
214994516|NCT06219226|PROCEDURE|Chlorhexidine mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
214380900|NCT03038984|BEHAVIORAL|At Home Screening procedure On demand|Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
214380901|NCT03038984|BEHAVIORAL|At Home Screening procedure every 3 months|Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
214380902|NCT05910086|OTHER|collection of data from the medical record|"collection of data from the medical record:~1. During epidural space puncture = cerebrospinal fluid (CSF) reflux, presence of glucose / strip, saline injection, intrathecal catheter insertion, intrathecal levobupivacaine and sufentanil injection, catheter insertion time, number of punctures, function of the person performing the procedure.~2. Analgesia and hemodynamics during labor, blood pressure, pulse rate, amount of local anesthetic used, whether emergency cesarean section was performed~3. Demographic data (age, weight, height, body mass index (BMI))~4. Post-partum monitoring of decubitus or orthostatic headaches, intensity, any other associated clinical signs~5. Analgesics used and their efficacy~6. The use of one or more blood patches, with the volume injected and their efficacy~7. Identification of the breach during epidural analgesia or after delivery~8. Call the patient at 1 week to reassess the episode and its consequences."
214380903|NCT03644355|BEHAVIORAL|Lifestyle counseling|Inter-disciplinary, interactive, family based behavioral intervention for overweight children
214380904|NCT02309177|DRUG|nab-Paclitaxel|
214380905|NCT02309177|DRUG|Nivolumab|
214380906|NCT02309177|DRUG|Gemcitabine|
214498046|NCT02720432|OTHER|CIMT|Constraint-induced movement therapy
214380907|NCT02309177|DRUG|Carboplatin|
214380908|NCT03459703|BEHAVIORAL|Early Time-Restricted Feeding|Eat all meals between 7 am - 3 pm for an average of ≥6 days per week.
214498047|NCT02720432|OTHER|HABIT|hand-arm bimanual intensive training
214498048|NCT02720432|OTHER|baby-massage|instructions for baby-massage
214498049|NCT01444690|DRUG|Dimiracetam|Capsules for oral administration twice daily
214498050|NCT01444690|DRUG|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
214380909|NCT03459703|BEHAVIORAL|Control Schedule|Eat all meals over a 12-hour or longer period for an average of ≥6 days per week.
214380910|NCT03459703|BEHAVIORAL|Structured Weight Loss Program|A structured weight loss program with physical activity recommendations and dietary counseling.
214380911|NCT01098149|OTHER|BD and BVC, AFB|Some patients are randomized into the AFB, the others into the BD and BVC
214380912|NCT01749501|DRUG|Rocuronium|0.6 mg/Kg once
214994517|NCT05342519|DRUG|Rapamycin|While rapamycin is not approved for the treatment of vitiligo, it has been found to be efficacious in stopping disease progression in animal models. Another recent study in humans showed that doses of 0.5cc daily of 0.001% of the topical formulation are able to achieve improvement in hypopigmented lesions of the skin at both the clinical and histological level. At this dose, improvement in cell function was observed regarding maintenance of proliferative potential and prevention of senescence, with avoidance of total inhibition of cell growth as has been seen at higher potencies used for immunosuppression.
214994518|NCT05342519|DRUG|Rapamycin|Rapamycin is an immunosuppressant that works by inhibiting the mammalian target of rapamycin (mTOR) leading to inhibition of the cell cycle and antibody production. It has also been shown to promote expansion of Treg populations. Although studies evaluating alternative dosing for vitiligo are limited, topical rapamycin has previously been used to treat angiofibromas related to Tuberous Sclerosis, vascular malformations such as port-wine stains, and inflammatory lesions such as plaque psoriasis. In a 2019 meta-analysis, 38 out of 40 reports included used topical formulations of 1% or lower potency rapamycin; the majority of publications were focused on the treatment of Tuberous Sclerosis, where the median concentration of mTOR inhibition was 0.1% dosed twice daily.
214994519|NCT05342519|DRUG|Placebo|All patients will be assigned to received topical placebo cream to the lesion not being treated with the active study drug.
214994520|NCT06439225|DRUG|Docetaxel|75mg/m2 q21 days
214994521|NCT06439225|DRUG|Carboplatin|AUC5 q21 days
214994522|NCT06444113|DRUG|Ofatunumab|No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
214994523|NCT05609331|OTHER|Simulated Online Adaptive Planning|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
214994524|NCT05609331|RADIATION|Stereotactic MRI-guided adaptive radiotherapy-SMART|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
214994525|NCT04041154|BEHAVIORAL|Cognitive Fatigue|Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.
214994526|NCT04041154|BEHAVIORAL|Physical Fatigue|Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
214994527|NCT04041154|BEHAVIORAL|Rewarding Stimuli|Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
214994528|NCT04545242|DRUG|Dexamethasone|Intravenous dexamethasone (low vs. moderate doses) during 10 days
214994529|NCT05982730|BEHAVIORAL|Sensory-Augmented Postural Training|To examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control and to assess the effectiveness of postural training using Segway
214994530|NCT04003285|DRUG|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
214994531|NCT04003285|DRUG|Allopregnanolone|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
214994532|NCT04003285|DRUG|Allopregnanolone|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
214994533|NCT06330675|OTHER|Early mobilization|Short-term bed-rest and immobilization
214994534|NCT06330675|OTHER|Standard of care|Bed-rest and immobility until the day-after procedure
214994535|NCT05841056|DRUG|Amiodarone Hydrochloride 200 MG|200 mg daily for 4 weeks
214994536|NCT05703373|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,
214380913|NCT01749501|OTHER|Placebo|Normal saline same amt as 0.6mg/kg of study drug
214994537|NCT05401487|OTHER|Pre-hospital and hospital care|Pre-hospital care not exceeding 60 min and a whole body CT scan within 45 min for patients categorized as unstable or critical by the pre-hospital doctor and 90 minutes for patients deemed potentially serious.
215092533|NCT03199391|DEVICE|BioWick SureLock Implant|The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
214380914|NCT01698086|OTHER|Vestibular rehabilitation: balance and eye movement exercises|The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
214380915|NCT00157274|DRUG|alemtuzumab|
214380916|NCT00976469|BIOLOGICAL|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
214380917|NCT00976469|BIOLOGICAL|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
215092534|NCT05018026|BEHAVIORAL|Nutri-Grade labels|All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
215092535|NCT02297555|DEVICE|ENDOBARRIER®|This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
215092536|NCT05755568|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
214380918|NCT04180839|BEHAVIORAL|gaming-related retrieval-extinction|"During one training session,participants will first view a 5-min retrieval video containing gaming content and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole training includes 2 training sessions. Participants will receive one training session once a day for two consectutive days."
214380919|NCT04180839|BEHAVIORAL|nongaming-related retrieval-extinction|"During one session,participants will first view a 5-min neutral video and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole procedure includes 2 sessions. Participants will receive one session once a day for two consectutive days."
214994538|NCT06433960|DIAGNOSTIC_TEST|Modified Allen Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~Instruct the patient to clench their wrist while the examiner occlude with three fingers the patients ulnar and radial arteries; instruct the patient to unclench their wrist; release the ulnar artery. The MAT result is negative or positive considering in how long the palm flushes:~≤5 seconds: negative MAT; good collateral hand circulation (suggesting harvestable radial artery).~greater than 5 seconds: positive MAT; poor collateral hand circulation (suggesting not-harvestable radial artery)."
214994539|NCT06433960|DIAGNOSTIC_TEST|Pulse-oximetry guided Modified Allen Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~A pulse-oximetry probe is positioned on the patients index finger; both radial and ulnar arteries are occluded by the examiner (with three fingers) until flattening of pulse waveform is obtained. Pressure on the ulnar artery is released and the result of the assessment is calculated considering in how long the pulse waveform returns to baseline:~≤5 seconds: negative result (suggesting harvestable radial artery). greater than 5 seconds: positive result (suggesting not harvestable radial artery).~(Busti and Kellogg, 2015)"
214994540|NCT06433960|DIAGNOSTIC_TEST|Barbeau Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 2 minutes.~A pulse-oximetry probe is positioned on the patients thumb; the radial artery is then compressed by the examiner, and the pulse waveform is analysed for up to 120 seconds, providing four result patterns of ulno-palmar patency:~1. No damping of the pulse tracing immediately after compression (suggesting harvestable radial artery)~2. Damping of the pulse tracing (suggesting harvestable radial artery)~3. Loss of the pulse tracing, followed by recovery within 120 sec (suggesting harvestable radial artery)~4. Loss of the pulse tracing, without recovery within 120 sec (suggesting not harvestable radial artery).~(Zalocar et al., 2020)"
214994541|NCT06433960|DIAGNOSTIC_TEST|Ultrasound examination of the forearm arteries|"Pre-operative intervention aimed at evaluating morphological characteristics (diameter, presence of calcifications) of the radial and ulnar arteries. Duration: 5 minutes.~The radial artery is surgically exposed (negative result) when the following apply:~1. ulnar artery inner diameter ≥2 mm~2. radial artery inner diameter ≥2 mm~3. absence of radial artery intraluminal calcifications and plaques.~(Vukovic et al., 2017)"
214994542|NCT06433960|DIAGNOSTIC_TEST|Measurement of oxygen saturation|"Intra-operative intervention aimed at evaluating the blood oxygen level in the hand if the radial artery was harvested. Duration: 1 minute.~The radial artery is surgically harvested when the oxygen saturation reading (SpO2) from the thumb through pulse-oximetry remains at 95% or above when an occlusive atraumatic clamp is applied on the mobilised radial artery."
214994543|NCT06433960|OTHER|Radial Artery Quality Evaluation Survey|"Intra-operative intervention (validated structured questionnaire) aimed at evaluating anatomical and physiological characteristics of the radial artery and suitability for coronary graft implantation.~The radial artery is surgically harvested when its morphology and pathology (diameter, calcifications, presence of pulsatile flow), quality of harvesting technique and surgical accessibility are considered satisfactory, good or optimal.~The Radial Artery Quality Evaluation Survey is completed by surgical care practitioners."
215092537|NCT03024190|OTHER|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
214380920|NCT00597714|DRUG|Non-myeloablative Stem Cell Transplantation|The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
214380921|NCT01350141|OTHER|Placebo|An infusion lasting approximately 60 minutes
214380922|NCT01350141|DRUG|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
214380923|NCT01350141|DRUG|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
214498051|NCT05291403|OTHER|Medical thoracoscopic cryotherapy combined with standard first-line therapy for advanced non-cell lung cancer|"Medical thoracoscopic cryotherapy: medical thoracoscopy biopsy hole insert bendable freezing probes, place the frozen probe placed in the center of the tumor at the top will be frozen carbon dioxide gas source pressure adjustment to the bar of 50-60 bar, tread down switch, foot pedal to start the probe, after about 30 s at the top of the probe to form a ice hockey, local tissue after frozen white, sometimes a small amount of bleeding; Fix the probe, loosen the pedal, and wait 30 seconds for automatic melting and rewarming (bleeding probability is low after full rewarming). Freeze 5 to 10 at a time.~In addition, all patients were treated with standard first-line regimens according to guidelines of non small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) scores."
214380924|NCT00802555|DRUG|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
214380925|NCT06121960|DIAGNOSTIC_TEST|spirometry|"Inclusion visit:~Performing spirometry.~Visit 2 (in the month following the inclusion visit):~Induction of a self-induced cognitive trance by the participant; performance of spirometry before, during the trance then 8 minutes after the end of the trance Actimetry during trance"
214994544|NCT06433960|OTHER|Follow-up Radial Artery Harvesting Scale|"Postoperative intervention (ordinal symptoms scale) aimed at evaluating patients finger movements, cold tolerance sensitivity and tactile/touch perception at post-operative day 2 to 5 and at follow-up appointment (3-6 weeks after surgery). Bilateral comparison between hands and forearms is undertaken. Tactile perception is assessed through monofilaments (single touch). Cold sensitivity is assessed through the use of ice-pack.~The Follow-up Radial Artery Harvesting Scale was developed from a verbal rating scale (VRS) questionnaire documented in the literature. The VRS questionnaire was re-adapted to appreciate people postoperative experience with their finger movements, cold sensitivity and tactile/touch perception of their forearm."
214994545|NCT04386005|DEVICE|Continuous Glucose Monitoring Device|The Dexcom G7 Glucose Monitoring System (San Diego, CA) reports continuous interstitial blood glucose concentrations every 5 minutes, does not require calibration, and involves only 1 needle stick to place the sensor. The manufacturer recommends that a single sensor may be used for up to 10 days. The Dexcom G7 system is the only FDA approved CGM system for children (age \>2 years).
214994546|NCT03126110|DRUG|INCAGN01876|In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().
214994547|NCT03126110|DRUG|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
214994548|NCT03126110|DRUG|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
214687341|NCT06713694|OTHER|cognitive-behavioral therapy|The treatment will consist of eight weekly sessions, each lasting one hour. The first session will focus on the rationale of cognitive behavioral therapy, i.e. the influence of (irrational or dysfunctional) cognitions and attitudes on (restrictive) feelings and behaviors. Additionally, goal setting will be initiated. Since patients may have a wide diversity of psychiatric problems (i.e. PTSD, anxiety disorders and depression), the treatment manual will encompass five optional modules for the therapist that focus on each of these disorders (i.e. exposure based for anxiety and PTSD, behavioral activation for depression). The subsequent sessions (2-6) will target teaching the patient to identify and challenge dysfunctional cognitions and attitudes related to IBD. Each session will address specific illness-related cognitions. If possible, dysfunctional cognitions and attitudes will be replaced by helpful cognitions and attitudes.
214994549|NCT06489483|BEHAVIORAL|Action Regulation Movement Task|A joystick is utilized to trace the movement of a visual stimulus on a computer screen. In stop signal task, the subjects are required to move a reference dot to reach to a target dot by controlling a joystick and stop their movements when the target turns red. During the switch task, subjects will be required to switch their joystick movement trajectory when the target location is switched to one of the other target locations.
214994550|NCT04543383|DRUG|Milvexian|Milvexian will be administered orally.
214994551|NCT04543383|BIOLOGICAL|4-Factor Prothrombin Complex Concentrate (4F-PCC)|4F-PCC will be administered intravenously.
215092538|NCT03024190|OTHER|stretching exercise|15- min stretching exercise for upper extremity twice daily
214994552|NCT04543383|BIOLOGICAL|Recombinant Human Factor VIIa (rFVIIa)|rFVIIa will be administered intravenously.
214994553|NCT04543383|BIOLOGICAL|Placebo matching to 4F-PCC|Placebo matching to 4F-PCC will be administered intravenously.
214994554|NCT04543383|BIOLOGICAL|Placebo matching to rFVIIa|Placebo matching to rFVIIa will be administered intravenously.
214994555|NCT06305676|DIAGNOSTIC_TEST|combined HPV 16 DNA and host gene methylation oral biomarker panel|DNA Methylation Profiling
215092539|NCT03024190|OTHER|OT rehabilitation program|regular rehabilitation program for 3 weeks
215092540|NCT04736628|DRUG|Avenciguat|Avenciguat
215092541|NCT04736628|DRUG|Placebo|Placebo
215092542|NCT04927663|PROCEDURE|Computed Tomography|Undergo CT imaging
215092543|NCT04927663|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215092544|NCT04927663|PROCEDURE|Positron Emission Tomography|Undergo PET imaging
215092545|NCT04927663|DRUG|11C-YJH08|Given IV
214380926|NCT06476626|OTHER|Maternal Reflective Function Workshop|4 session group online intervention focused on psycho-educational knowledge regarding emotional regulation and specifically MRF. group size- up to 15 participants. 2 sessions will be during pregnancy and 2 sessions will taken place 1 and 3 months after birth.
214380927|NCT02398058|DRUG|trabectedin|trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
214380928|NCT02398058|DRUG|olaparib|olaparib will be administered in a continuous daily dose every 12 hours
214380929|NCT00519896|DRUG|sunitinib malate|Given PO
214994556|NCT04892901|PROCEDURE|c-ESPB|In the c-ESPB group an ultrasound-guided ESPB will be performed by the attending anaesthesiologist at the end of surgery, immediately after the last surgical stitch and before extubation. After an initial bolus of 20 ml 0,2% ropivacaine, a catheter will be left in place into the fascial plane deep to the erector spinae muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
214380930|NCT03192540|OTHER|Exercise|Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
214380931|NCT00810082|DEVICE|ActiveStep|ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
214380932|NCT00810082|OTHER|Standard Physical Therapy for Fall Prevention|Standard physical therapy for fall prevention
214994557|NCT04892901|PROCEDURE|c-SAPB|In the c-SAPB group SAPB will be performed by surgeons intraoperatively, immediately before the closure of chest wall muscle planes, by injection of 20 ml 0,2% ropivacaine into the fascial plane above the Serratus Anterior muscle. After the initial bolus, a catheter will be left in place into the superficial fascial plane of the Serratus Anterior muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
214994558|NCT04892901|PROCEDURE|ICNB|"In the ICNB-group ICNB will be performed by surgeons intraoperatively, immediately before chest drain placement, by injection of 20 ml of 0,2% ropivacaine into the intercostal spaces (III-VII), below the parietal pleura, under direct visualization of the neurovascular bundle. The one-shot ICNB will be associated in this group with intravenous administration of tramadol (300 mg/48 h) by elastomeric pump."
214380933|NCT06297681|DRUG|Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin|The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone: subcutaneous injection of 1800mg of Daratumumab, d1, 8,15,22 (28 day cycle); (After 2 cycles of improvement in cardiac indicators, it can be adjusted to intravenous injection of daratumumab); Bortezomib 1.3 mg/m2 d1, 8, 15, 22; D1, 8, 15, 22; Dexamethasone 20 mg d1, 2, 8, 9, 15, 16, 22, 23. When NTProBNP is greater than 5400ng/ml, bortezomib 1.0mg/m2; When NTProBNP is greater than 8500ng/ml, bortezomib is 0.7mg/m2. When NTProBNP is greater than 10000ng/ml, bortezomib is temporarily not allowed; NTProBNP greater than 4500ng/ml dexamethasone starts at 10 mg/dose. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
214380934|NCT01588990|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m\^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
214994559|NCT04235374|BEHAVIORAL|FFC-AC-EIT|The two intervention arms will receive the same educational information. The education group will not be exposed to any other activities. The FFC-AC-EIT will focus strongly on motivation of staff and patients to get the patients engaged in functional and physical activities.
214994560|NCT05029869|DIAGNOSTIC_TEST|ctDNA|The blood samples for ctDNA and other tumor markers will be first collected within 14 days before surgery, and then be tested after gastrectomy in scheduled interval
214994561|NCT05835726|DRUG|Daratumumab|NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
214994562|NCT05858164|DRUG|BAY2862789|Oral administration, solution or tablets
214994563|NCT05785845|RADIATION|Computed tomography-guided stereotactic adaptive radiotherapy|Fractions will be delivered on consecutive business days.
214994564|NCT05785845|DEVICE|ETHOS|ETHOS is a unique ring-gantry CT-guided linear accelerator notable for having an on-board cone beam CT (CBCT) imaging unit with improved definition and resolution to enable target and organ-at-risk contouring. It also has a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
214994565|NCT05050799|DEVICE|Central Venous Access|The Surfacer® Inside-Out® Access Catheter System is intended to obtain central venous access to facilitate catheter insertion into the central venous system for patients with upper body venous occlusions or other conditions that preclude central venous access by conventional methods.
215092546|NCT04927663|PROCEDURE|Optional Tumor Biopsy|Optional procedure to obtain tumor tissue
214380935|NCT01588990|DRUG|Capecitabine|Participants will receive capecitabine 1000 mg/m\^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
214380936|NCT01588990|DRUG|Bevacizumab|Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
214380937|NCT01588990|DRUG|Leucovorin|Participants will receive leucovorin 400 mg/m\^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m\^2 or 50 mg total dose).
214380938|NCT01588990|DRUG|5-Fluouracil|Participants will receive 5-fluouracil loading dose of 400 mg/m\^2 IV on Day 1 followed by 2400 mg/m\^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
214380939|NCT01588990|DRUG|Irinotecan|Participants will receive irinotecan 180 mg/m\^2 IV on Day 1 every 2 weeks during Phase B treatment.
214380940|NCT01286220|OTHER|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
214380941|NCT01286220|OTHER|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
214994566|NCT04825132|OTHER|Geriatric assessment tools|Multidimensional Prognostic Index (Living status, medications, ADL, IADL, MMSE mental evaluation, ESS pressure sores, chronic disease, nutritional assessment)
214994567|NCT00922584|DRUG|sorafenib (Nexavar)|oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
215092547|NCT05414240|DRUG|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
215092548|NCT05414240|BEHAVIORAL|Medical management|All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.
214380942|NCT05635318|DEVICE|FDA approved medications for ADHD plus Quantitative EEG Neurofeedback|A mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG.NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training.
214380943|NCT05635318|DRUG|FDA approved medications for ADHD|Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)
214380944|NCT02892487|OTHER|Swallowing therapy|Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
214380945|NCT02784470|DEVICE|gastroduodenal stent placement|
214380946|NCT02784470|PROCEDURE|gastrojejunostomy|
214380947|NCT05642546|DRUG|NM8074|Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
214380948|NCT05642546|DRUG|Placebo|Saline Placebo
214380949|NCT03388112|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
214380950|NCT02367716|DEVICE|CRT|The study will include the Quartet™ family of left heart leads or any newer St. Jude Medical quadripolar CRT systems, including CRT-P systems, that China Food and Drug Administration (CFDA) might approve in the future
214380951|NCT02900612|OTHER|Water aerobics training.|The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
214380952|NCT02900612|OTHER|Water resistance training.|The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
214498052|NCT05291403|OTHER|Sequential intrathoracic injection of cisplatin/erythromycin combined with standard first-line therapy for advanced non-cell lung cancer|"The pleural effusion was fully drained and cisplatin 40mg/m2 was given, dissolved in 100mL 0.9% sodium chloride (NaCl) solution 100 mL, then injected into the pleural cavity and retained for 24 hours. Erythromycin was sequentially injected into the thorax to seal the pleural cavity.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
214498053|NCT05291403|OTHER|Standard first-line therapy for advanced non-cell lung cancer without intrathoracic treatment|"Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
214994568|NCT05495997|BEHAVIORAL|Mental Imagery Training|Participants will practice mental imagery of everyday tasks daily for 6 weeks.
214994569|NCT05495997|BEHAVIORAL|Psychoeducation|Participants will receive psychoeducation on cognition and brain health.
214994570|NCT06572033|BEHAVIORAL|Simulation|Observational study with simulations.
214994571|NCT05324189|DIAGNOSTIC_TEST|Referable versus Non Referable Diabetic Retinopathy diagnostic test|Artificial intelligence read reports Referable versus Non Referable Diabetic Retinopathy
214994572|NCT00104689|DRUG|capecitabine|
214994573|NCT00104689|DRUG|oxaliplatin|
214994574|NCT00976027|BIOLOGICAL|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
214380953|NCT02900612|OTHER|Control Group|The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
214380954|NCT00750282|DRUG|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
214380955|NCT00494260|BEHAVIORAL|Social Learning and Cognitive Behavioral Therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques
214498054|NCT00300404|DRUG|daraprim|
214498055|NCT00300404|DRUG|pyrimethamine|
214498056|NCT00300404|DRUG|folinic acid|
214498057|NCT06352905|OTHER|Whole body vibration (WBV)|WBV is a platform that vibrates while a person stands or sits and performs exercises. The WBV session will consist of 5 sets of 60 seconds set at 6 Hertz (frequency), 3 mm (amplitude) while performing mid-squats. There will be a 1 minute rest in between each set. These parameters were chosen as commonly used parameters in previous studies of WBV in people with PD.
214498058|NCT06352905|OTHER|Control|Mid-squats performed on level ground 5 repetitions of 60 seconds with 1 minute rest in between each set.
214498059|NCT02200705|DEVICE|Ice-Sense3TM/ ProSenseTM|
214994575|NCT00976027|BIOLOGICAL|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
214994576|NCT00073931|BIOLOGICAL|filgrastim|5 µg/kg/day subcutaneously
214994577|NCT00073931|BIOLOGICAL|sargramostim|250µg/m2/d subcutaneously
214994578|NCT00073931|PROCEDURE|autologous bone marrow transplantation|autologous stem cells given via central catheter
214994579|NCT00073931|PROCEDURE|peripheral blood stem cell transplantation|autologous stem cells given via central catheter
214994580|NCT00073931|RADIATION|tositumomab and iodine I 131 tositumomab|given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with \~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)
214994581|NCT00261040|PROCEDURE|Minimally Invasive Surgery|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
214994582|NCT00261040|PROCEDURE|Standard Surgery|The standard way that an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision.
214380956|NCT00494260|BEHAVIORAL|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
214994583|NCT05791331|OTHER|Surfactant administration following lung mechanics assessment in addition to clinical assessment|Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O\*s /L
214380957|NCT02999711|DRUG|REGN3500|REGN3500 dose
214380958|NCT02999711|DRUG|Placebo|Matching placebo
214380959|NCT05165953|OTHER|no intervention|there was no intervention in the study
214380960|NCT03229616|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
214380961|NCT03229616|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
214380962|NCT03229616|DRUG|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
214380963|NCT04048759|BEHAVIORAL|Remote Low|Participants will attend 40 min remotely delivered group MVPA sessions once a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
214380964|NCT04048759|BEHAVIORAL|Remote High|Participants will attend 40 min remotely delivered group MVPA sessions 3x a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
214380965|NCT04048759|BEHAVIORAL|Personal Coach|Participants will receive a step counter, access to resources for increasing MVPA, and monthly remote individual support/education.
214380966|NCT02100150|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
214380967|NCT02100150|DRUG|Placebo|Strawberry flavored solution 0.5% v/v in Water for Injection
214994584|NCT05791331|OTHER|Surfactant administration following clinical assessment|Surfactant is administered following oxygenation-based criteria
214994585|NCT05967091|DEVICE|Targeted Lung Denervation|Targeted Lung Denervation (TLD) is a bronchoscopically guided, minimally invasive procedure using the Ryme Medical Lung Denervation System
214994586|NCT01767220|PROCEDURE|Strategy 1 - endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
214994587|NCT01767220|PROCEDURE|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
214994588|NCT05991453|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
214380968|NCT05344261|PROCEDURE|Targeted Muscle Re-innervation|Targeted Muscle Re-innervation involves re-routing transected nerve ends to functional motor nerves proximal to the site of amputation.
214380969|NCT05344261|PROCEDURE|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface involves placing transected nerve ends in harvested muscle grafts.
214380970|NCT05344261|PROCEDURE|Standard Post-Amputation Surgical Care|Standard post-amputation surgical care involves placing transected nerve ends into muscle/soft tissue proximal to the site of amputation.
214380971|NCT01971606|DRUG|Rosuvastatin|"Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period."
214380972|NCT02691104|DEVICE|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
214380973|NCT02691104|DEVICE|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
214994589|NCT05991453|OTHER|Anesthetic technique inhaled agent|Must administer inhaled agent.
214994590|NCT05033054|DRUG|SGLT2 inhibitor|Participants will ingest a standard dose of SGLT2i prescribed by the standard of care physician.
214994591|NCT05275426|DRUG|LY2880070|Patients will receive treatment in 21-day cycles with LY2880070 50 mg twice daily orally on days 2-6, 9-13, and 16-20
214994592|NCT05275426|DRUG|Gemcitabine|Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15
214380974|NCT03584893|PROCEDURE|Blood sampling for Cholestanol Analysis|Cholestanol analysis will be performed to see the Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases
214380975|NCT05772975|BIOLOGICAL|H-PRF (Horizontal-platelet rich fibrin)|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. it serves as a biological healing matrix by supporting cell migration and cytokine release. H-PRF is obtained by horizontal centrifugation using (Bio-PRF) centrifuge on 700 g force for 8 minutes. This way the cells separate much more efficiently throughout the entire membrane/clot.
214994593|NCT06549985|BEHAVIORAL|PEEPS|Participants will participate in the PEEPS program in addition to usual care.
214994594|NCT06549985|BEHAVIORAL|Education|Participants will receive an educational handout on endometriosis in addition to usual care.
215092549|NCT05414240|DRUG|Placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
215092550|NCT06234215|DEVICE|functional electrical stimulation|electrical stimulation during function
215092551|NCT06234215|OTHER|functional task training|functional exercise
215092552|NCT03722654|BEHAVIORAL|MTFS-I Installation|MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
215092553|NCT03462953|PROCEDURE|Gingival tissue samples will be harvested|"Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~1. Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~2. Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin ."
215092554|NCT04924153|OTHER|No Intervention|Administered as specified in the treatment arm.
215092555|NCT05605340|BEHAVIORAL|Meal Delivery|10 healthy, home-delivered meals per week + brief weekly remote behavioral support
215092556|NCT05207046|OTHER|Mechanical Ventilation|Patients will be assessed and measurements will be taken during controlled ventilation (most likely \<72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.
215092557|NCT04878952|OTHER|Garmin Vivofit Activity Tracker|Activity tracker that is worn on the wrist.
215092558|NCT01124877|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
215092559|NCT04247126|DRUG|SY-5609|An oral CDK7 Inhibitor
215092560|NCT04247126|DRUG|Fulvestrant|Estrogen receptor antagonist
215092561|NCT04247126|DRUG|Gemcitabine|Nucleoside metabolic inhibitor
215092562|NCT04247126|DRUG|Nab-paclitaxel|Taxane-type chemotherapy
215092563|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of low dose casein (5 gram)
215092564|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of high dose casein (15 gram)
215092565|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
215092566|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
215092567|NCT01509469|OTHER|Saline|Ileal infusion with saline (180mL in total)
214380976|NCT05772975|BIOLOGICAL|E-PRF|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. In order to extend its resorption period heating method is used. After centrifugation of blood using (Bio-PRF) centrifuge on 700 g force for 8 minutes top layer is heated for 10 minutes at 75°C in BIO-Heat device. When cooled it is mixed with cell rich buffy coat. This way PRF with extended life is obtained.
214380977|NCT02585596|DRUG|YH23537 1000mg/day|YH23537 500mg 2 tab
214380978|NCT02585596|DRUG|YH23537 2000mg/day|YH23537 500mg 4 tab
214380979|NCT02585596|DRUG|YH23537 3000mg/day|YH23537 500mg 6 tab
214994595|NCT02767973|OTHER|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
214994596|NCT05550350|DRUG|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
214994597|NCT05550350|OTHER|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
215092568|NCT01509469|DIETARY_SUPPLEMENT|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
215092569|NCT02880527|OTHER|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~1. medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~2. general practitioners~3. the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5\) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
215092570|NCT00238914|DRUG|Naltrexone|50mg of oral naltrexone daily
215092571|NCT00238914|BEHAVIORAL|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
215092572|NCT00238914|BEHAVIORAL|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
215092573|NCT02060032|DRUG|1.2% Atorvastatin local drug delivery|
215092574|NCT02060032|DRUG|1.2% simvastatin local drug delivery|
215092575|NCT02060032|DRUG|Placebo local drug delivery|
215092576|NCT01566578|DRUG|Human recombinant epidermal growth factor|topical
215092577|NCT01566578|OTHER|Placebo cream|Dermal cream without EGF
215092578|NCT04142151|DRUG|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
215092579|NCT04142151|DRUG|Aspirin|Aspirin produced by Bayer Co., Ltd.
215092580|NCT04142151|DRUG|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
215092581|NCT04142151|DRUG|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
215092582|NCT06507475|DRUG|Semaglutide|Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
214994598|NCT04528134|DEVICE|Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish|This is a light-cured, durable coating that forms an immediate layer of protection that releases fluoride, calcium and phosphate and can be recharged with fluoride by using fluoride-containing products over the 6-month life of the product.
214380980|NCT02585596|DRUG|placebo|YH23537 500mg tab placebo
214994599|NCT04528134|DEVICE|5% Sodium Fluoride Varnish|This is a 5% Sodium Fluoride varnish that hardens on the teeth upon contact with saliva.
214994600|NCT05561543|DIETARY_SUPPLEMENT|Peppermint oil|Peppermint oil
214380981|NCT06340165|DRUG|Anlotinib|Anrotinib is available in 12 mg, 10 mg, and 8 mg doses. The recommended dose of Anrotinib is 12 mg taken by mouth once daily, continuously, for 2 weeks on and 1 week off, in a 21-day cycle.
214380982|NCT00358137|BEHAVIORAL|Aerobic Conditioning Program|
214994601|NCT05561543|OTHER|Placebo|Placebo
214994602|NCT06294548|DRUG|Valemetostat|Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2).
215092583|NCT01310478|DRUG|recombinant human endostatin (Endostat)|mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
215092584|NCT01727011|RADIATION|IPAS|
215092585|NCT02733653|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
215092586|NCT02504307|DEVICE|Sirolimus Eluting Stent Inspiron|Angioplasty with Sirolimus Eluting Stent Inspiron implantation
215092587|NCT02504307|DEVICE|Bare Metal Stent|Angioplasty with Bare Metal Stent Cronus implantation
214380983|NCT00358137|BEHAVIORAL|Strength Training Program|
214380984|NCT06164925|DIAGNOSTIC_TEST|Nutrition screening and assessment|"The patient is interviewed for changes in body weight in the last six months and food intake in the last two weeks.~The investigator evaluates the patient's diet, symptoms related to their nutritional status, and functional capacity according to the Subjective Global Assessment (SGA). The SGA tool itself is completed by the researcher.~Height and weight of the patient are measured, if not yet recorded, and BMI is calculated.~The patient's muscle mass is measured using mid-upper arm circumference (MUAC), calf circumference (CC) and bioelectrical impedance (BIA), and their muscle function assessed using hand grip strength."
214994603|NCT06294548|DRUG|Atezolizumab|Atezolizumab is commercially available. Atezolizumab combined with bevacizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.
214994604|NCT06294548|DRUG|Bevacizumab|Bevacizumab is commercially available. Bevacizumab combined with atezolizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.
214994605|NCT06569667|BEHAVIORAL|PRC supported text + AI driven SDH-enhanced text|This interventional study evaluates an AI-driven texting tool combined with peer recovery coach support to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
215092588|NCT03418558|DRUG|Trastuzumab emtansine|
215092589|NCT06200883|DRUG|Placebo oral vial|In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
214994606|NCT06569667|BEHAVIORAL|AI driven SDH-enhanced text only|This interventional study evaluates an AI-driven SDH-enhanced texting tool to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
214994607|NCT06569667|BEHAVIORAL|Treatment as Usual (TAU)|Control Arm-3 will receive treatment as usual (i.e., verbal instructions, NYC Dept of Health pamphlets detailing access to OUD and social services, health system smartphone application EMR patient portal).
214380985|NCT06139874|BEHAVIORAL|THRIVE|Early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
214380986|NCT06139874|BEHAVIORAL|Parenting Wisely|Online asynchronous parenting program.
214380987|NCT04508556|DEVICE|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
214380988|NCT04508556|DIAGNOSTIC_TEST|Nasopharyngeal swab|Is a method for collecting a clinical test sample of nasal secretions from the back of the nose and throat.
214994608|NCT04650581|DRUG|Ipatasertib|400 mg PO QD days 1-21 every 28 days
214994609|NCT04650581|DRUG|Fulvestrant|500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles
214994610|NCT04650581|OTHER|Placebo|PO QD days 1-21 every 28 days
214994611|NCT05406167|DEVICE|Registry - Observational|Observation Registry for Medical Device
214994612|NCT01771107|DRUG|Brentuximab Vedotin|Given IV
214994613|NCT01771107|DRUG|Dacarbazine|Given IV
215092590|NCT06200883|DRUG|Choline Bitartrate|In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
215092591|NCT02390180|OTHER|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
215092592|NCT03922165|PROCEDURE|Adenotonsillectomy|Routine AT per clinical care.
215092593|NCT00828152|BEHAVIORAL|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
215092594|NCT00828152|BEHAVIORAL|On line discussion group|Placebo. On line discussion group.
215092595|NCT03543943|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively.
214994614|NCT01771107|DRUG|Doxorubicin Hydrochloride|Given IV
214994615|NCT01771107|OTHER|Pharmacological Study|Correlative studies
214994616|NCT01771107|DRUG|Vinblastine|Given IV
215092596|NCT03543943|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
215092597|NCT03543943|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
215092598|NCT02764684|DRUG|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
215092599|NCT01075503|PROCEDURE|brachial plexus block|0.5% Ropivacaine 40ml
215092600|NCT05769049|BIOLOGICAL|REC610|administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older
215092601|NCT05769049|BIOLOGICAL|Shingrix|Shingrix
215092602|NCT05251753|DEVICE|K-Lock|Patients will be randomized to either A) left side K-Lock with right side suture-based technique or B) right side K-Lock with left side suture-based technique.
215092603|NCT00890682|DRUG|SKY0402|Local infiltration of 8cc SKY0402
215092604|NCT00890682|DRUG|Placebo|Local infiltration of 8cc Placebo
214380989|NCT04508556|DIAGNOSTIC_TEST|oropharyngeal swabs|Is a method for collecting a clinical test sample from the back of the throat.
214380990|NCT00219440|OTHER|Actos plus standard diet|Actos plus standard diet
214380991|NCT00219440|OTHER|Actos plus structured diet|Actos plus structured diet
214380992|NCT00219440|OTHER|Metformin plus standard diet|Metformin plus standard diet
214380993|NCT02761655|BEHAVIORAL|Memory Strategies|Memory strategies on encoding retention, retrieval, execution and monitoring
214994617|NCT05621772|OTHER|Meridian Activation Remedy System for Parkinson's Disease (MARS-PD)|MARS-PD is a complex therapy developed by researchers to enhance the synergistic effects of acupuncture and exercise.
214994618|NCT00619528|BIOLOGICAL|Infusion of Donor Hematopoietic Stem Cells and Campath-1H|Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (\>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
215092605|NCT02915185|PROCEDURE|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
214994619|NCT04526054|DIAGNOSTIC_TEST|ENT exam|ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy.
214380994|NCT03207217|OTHER|Web-based training Product|A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.
214380995|NCT03719053|DRUG|Tenofovir|pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
214380996|NCT01641926|BIOLOGICAL|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
214380997|NCT01641926|BIOLOGICAL|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
214380998|NCT01111838|DRUG|STA-9090|Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
214380999|NCT03347175|PROCEDURE|Volume controlled ventilation|Volume controlled ventilation mode
214381000|NCT03347175|PROCEDURE|Pressure controlled ventilation|Pressure controlled ventilation
214381001|NCT03347175|PROCEDURE|CPAP mode|CPAP mode only
214381002|NCT02707458|DRUG|Probucol|"Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US."
214498060|NCT04655833|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
214498061|NCT05788965|DRUG|Semaglutide|glucagon-like peptide 1 (GLP-1) receptor agonist
214994620|NCT04526054|DIAGNOSTIC_TEST|Olfactometry|Olfactometry test using odorous pens (Sniffin's stick test).
214994621|NCT04526054|DIAGNOSTIC_TEST|Brain MRI|Brain MRI focused on the olfactory bulbs (3 teslas).
214994622|NCT03870490|DRUG|VNRX-5133 + cefepime|IV infusion (3 doses)
214498062|NCT05485532|DEVICE|Telemonitoring System using Cosinuss° Two and/or Garmin Vivoactive 4|Development and validation of a telemonitoring system using smart devices
214498063|NCT00277914|DRUG|Flibanserin|flibanserin flexible dosing
214498064|NCT03786211|PROCEDURE|IANB by the guide of Panoramic|IANB will be injected by the guide of panoramic radiograph
214498065|NCT03786211|PROCEDURE|IANB without the guide of Panoramic|IANB will be injected without the guide of panoramic radiograph, in the routine way.
214498066|NCT05662436|OTHER|Open Sky School program|Teachers lead students in 2 hours of outdoor activities per week for 12 weeks, as detailed in the arm description
214498067|NCT02490956|BIOLOGICAL|Verorab® (PVRV; Purified Vero Cell Vaccine)|"* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
214498068|NCT00786864|OTHER|exercise programme|Specific low back pain exercise programme for children
214498069|NCT00368394|DRUG|Insulin glulisine|
214498070|NCT05249153|DRUG|low dose of dexmedetomidine with sufentanil|low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)
214498071|NCT05249153|DRUG|high dose of dexmedetomidine with sufentanil|high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
214498072|NCT03595969|DIAGNOSTIC_TEST|Relative copy number of mitochondrial DNA|Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).
214994623|NCT01147445|BIOLOGICAL|Double Mutant Heat- Labile Toxin (dmLT)|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.
214994624|NCT06403943|DRUG|BaiDiZiYin Pill, ShenQiYiFei Pill|"Indications of BaidiZiyin Pill: Nourishing the lungs and kidneys, cooling blood and removing steam. Used as an adjunctive treatment for tuberculosis caused by lung and kidney deficiency and qi yin injury, including coughing, shortness of breath, dry cough with less phlegm, hot flashes and night sweats, cold and spontaneous sweating, hoarseness, palpitations, cold limbs, and emaciation.~Indications of ShenqiYifei Pill: expectorant and cough relieving. It is suitable for patients with pulmonary tuberculosis and spleen diseases, as well as phlegm dampness retention. Symptoms include short breath, low sound, clear and thin phlegm, limited appetite, bloating and loose stools, pale complexion, fatigue and chest tightness, emaciation, and fear of cold and spontaneous sweating."
214994625|NCT06403943|DRUG|Anti tuberculosis chemotherapy|2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
214994626|NCT05117996|OTHER|capsule endoscopy|capsule endoscopy
214994627|NCT05117996|OTHER|standard small bowel preparation|2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
214994628|NCT05117996|OTHER|Simplified small bowel preparation|Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
214994629|NCT05076838|DRUG|Diazepam Nasal Spray [Valtoco]|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
214381003|NCT06158425|RADIATION|long-leg radiograph|A flat-panel digital radiography(DR) equipment (Siemens DR AXIOM Aristos AX/VX) was used to capture full-length bipedal lower extremities in a standing position. The technician moved the detector from top to bottom, capturing four parts: the bilateral hip joints, femur, tibia and fibula and ankle joint. The exposure parameters for each part were as follows: 1st exposure - 85kV, 75mAs; 2nd exposure - 80kV, 50mAs; 3rd exposure - 75kV, 40mAs; 4th exposure - 68kV, 20mAs. The distance from the source (kv-kg) was 300cm, and the field of view was 43.18cm x 43.18cm. All 4 X-rays were stitched using the Siemens DR Station.
214498073|NCT02387658|PROCEDURE|translesional gradient measurement|Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
214498074|NCT02359448|DRUG|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
214498075|NCT06332677|DIAGNOSTIC_TEST|the main genes and expression by comparing the transcriptomic lipidomic profile|To identify the main genes and pathways differentially expressed and the main factors associ- ated in order to evaluate the role of SUV420H1/H2
214994630|NCT03662373|RADIATION|carbon ions radiation therapy|Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
214994631|NCT03662373|RADIATION|protons radiation therapy|Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
214381004|NCT01960647|DEVICE|Percutaneous transluminal angioplasty with uncoated balloon|
214498076|NCT02310152|BEHAVIORAL|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
214498077|NCT02310152|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
214498078|NCT03322995|DRUG|First-line Chemotherapy|The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.
214498079|NCT03322995|DRUG|Second-line Chemotherapy|Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.
214498080|NCT03322995|RADIATION|Chemoradiation|50.4 Gy in 28 fractions.
214498081|NCT03594305|BEHAVIORAL|Educational seminar|Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
214381005|NCT01960647|DEVICE|Percutaneous transluminal angioplasty with Paclitaxel balloon|
214381006|NCT03062774|BIOLOGICAL|PB-119 injection|
214381007|NCT02916797|OTHER|Stepping training with feedback|Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
214381008|NCT00084643|BIOLOGICAL|GTI-2040|Given IV
214498082|NCT04762914|OTHER|Prehabilitation|Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
214498083|NCT06148441|DIAGNOSTIC_TEST|bone morphogenetic protein-2 (BMP-2)|novel biomarkers associated with in-stent restenosis after percutaneous coronary intervention
214994632|NCT02296125|DRUG|AZD9291 80 mg/40 mg + placebo|"The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
214994633|NCT02296125|DRUG|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214994634|NCT02296125|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214994635|NCT02296125|DRUG|Erlotinib 150/100 mg|"The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
214994636|NCT02296125|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
215092606|NCT02915185|DEVICE|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
215092607|NCT01761695|OTHER|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
215092608|NCT05588245|BEHAVIORAL|Standard of Care|Participants will undergo the same SDoH screener (AHC-Health Related Social Needs Tool) as full intervention participants, which will serve as the basis for a one-time brief session with the clinical research coordinator that will involve review of a 'Resource Guide' that provides a listing of available community resources to meet common social needs. Participants in this arm will also complete other prenatal and postpartum data collection items over the course of the study (with the exception of qualitative interviews).
215092609|NCT05588245|BEHAVIORAL|Community-based prenatal/perinatal/postpartum patient navigator|Uses Freeman's principles of navigation to enhance patient access to care (e.g., help patients manage appointments), promote patient self-efficacy (e.g., connect patients to community housing, food, transportation resources), and sustain engagement with the healthcare system (e.g., bridge perinatal and primary care).
214381009|NCT00084643|DRUG|oxaliplatin|Given IV
214381010|NCT00084643|DRUG|capecitabine|Given orally
214381011|NCT00084643|OTHER|pharmacological study|Correlative studies
214381012|NCT00084643|OTHER|laboratory biomarker analysis|Correlative studies
214381013|NCT00288301|BEHAVIORAL|Weight loss intervention|weight loss intervention
214381014|NCT00415792|DRUG|Arvekap, Pregnyl|
214381015|NCT03303469|DRUG|FMISO|FMISO PET/CT imaging at baseline
214381016|NCT03303469|DRUG|FMISO|FMISO PET/CT post TACE
214381017|NCT03303469|DRUG|FMISO|FMISO PET/CT post SBRT
214381018|NCT02294630|DRUG|Surfactant|Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
214498084|NCT03026920|PROCEDURE|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
214498085|NCT01083732|DRUG|dabigatran etexilate|Experimental dose chosen based on age and weight
214498086|NCT02893800|DEVICE|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
214498087|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
214498088|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
214381019|NCT04040881|BEHAVIORAL|Remote monitoring using smartphone accelerometer|"Patients will be instructed to carry the smartphone around their hips during waking hours, regardless of whether they are at home or outside (a nylon hip holster will be provided) and to keep it turned on at all times.~Daily steps will be recorded for at least seven days before the start of chemotherapy, and the median baseline number of daily steps will be calculated for each patient.~On the first day of chemotherapy, patients will receive side effect education as per standard of care. Patients will be instructed to continue carrying the smartphone daily as indicated for the entire duration of the first three chemotherapy cycles.~At the end of the follow-up period (or sooner in cases of early interruption of chemotherapy due to toxicity or disease progression; a change in chemotherapy regimen; or hospitalizations lasting ≥3 days), patients will rate their satisfaction with the intervention using a Likert-scale questionnaire and open-ended questions."
214381020|NCT01920425|DEVICE|Kinesia HomeView|Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.
214381021|NCT01920425|OTHER|Hand-written diary|Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.
214994637|NCT02296125|DRUG|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
214994638|NCT05456503|DRUG|FPI-2620|Radiotracer
214994639|NCT03611738|DRUG|Ceritinib|Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
214994640|NCT03611738|DRUG|Docetaxel|Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
214381022|NCT00749125|DRUG|Lexapro|10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
214381023|NCT02567825|DEVICE|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used.
214498089|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
214994641|NCT05935787|DRUG|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 15 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 25 days
214994642|NCT05935787|DRUG|Placebo|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 15 days + Placebo, 2 tablets 2 times a day, for 25 days
214994643|NCT00457353|DRUG|Bacillus Clausii|For 5 days
214994644|NCT00457353|OTHER|Oral rehydration therapy|For 5 days
214994645|NCT03543163|PROCEDURE|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap|A horizontal incision of 1.5cm in long will be made at the bottom of the vestibule with the #15 blade in the region of maxillary first and second molars, depending on side of the recipient site. A curved hemostat will be used in the blunt dissection through the buccinators muscle to temporarily reposition and loose the surrounding fascia which will allow the buccal fat pad to be exposed in the oral cavity. A portion of adipose tissue equals to the required graft size will be excised with the microsurgical scissors. The grafting material will be placed on a saline-soaked gauze until its transfer to the recipient site. Finally, the patient's check will be compressed, in order to promote the closure of the wound edges then immediately close the donor site with simple 5.0 silk thread interrupted sutures
214994646|NCT03543163|PROCEDURE|sub-epithelial connective tissue graft|a sub- epithelial connective tissue graft is harvested from the hard palate is used to treat area with gingival recession
214994647|NCT02098772|DRUG|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
214994648|NCT02098772|DRUG|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
214994649|NCT06433648|DEVICE|Ottobock CLeg4 + Ottobock foot|Commercially available Ottobock CLeg 4 microprocessor knee unit and Ottobock foot.
215092610|NCT06229977|DRUG|Palmitoylethanolamide (PEA)|Participants will receive PEA at a dose of 600mg twice daily for 6 weeks.
215092611|NCT06229977|DRUG|Placebo|Participants will receive placebo (a tablet that contains no active ingredient) to be taken twice daily for 6 weeks
215092612|NCT06229977|DRUG|Treatment as Usual (TAU)|subjects will receive a mood stabilizer per usual care
214994650|NCT06433648|DEVICE|SRALAB Hybrid Knee + Polycentric Ankle|Experimental powered prosthesis: SRALAB Hybrid Knee and powered polycentric ankle.
214994651|NCT06433648|DEVICE|SRALAB Hybrid Knee + Passive Ankle|Experimental powered prosthesis: SRALAB Hybrid Knee and passive ankle.
214994652|NCT06433648|DEVICE|Ottobock CLeg 4 + Polycentric Ankle|Commercially available Ottobock CLeg 4 prosthetic knee and SRALAB powered polycentric ankle.
214994653|NCT00157755|DEVICE|Enterra Therapy|Gastric electrical stimulation using Enterra Therapy.
214994654|NCT02141555|DRUG|Vaginal Misoprostol|Misoprostol inserted into vagina
214994655|NCT02141555|DRUG|Buccal Misoprostol|Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
214994656|NCT01217346|OTHER|no intervention is involved in this study|no intervention is involved in this study
214994657|NCT02149134|DIETARY_SUPPLEMENT|TeHF2013-01|
214994658|NCT06525168|DRUG|DA414 Granules|DA414 Granules single ascending doses. DA414 will be orally administrated at single ascending doses of 12.5 mg, 25mg, 50 mg, 100mg and 200 mg.
214994659|NCT06525168|DRUG|DA414 placebo|DA414 placebo single ascending doses. DA414 placebowill be orally administrated at single ascending doses of 25mg, 50 mg, 100mg and 200 mg.
215092613|NCT05730348|BEHAVIORAL|Post mealtime activity|Therapist lead movement post meals
215092614|NCT02046070|DRUG|Cyclophosphamide|Cyclophosphamide tablets
215092615|NCT02046070|DRUG|Ixazomib|Ixazomib capsules
215092616|NCT02046070|DRUG|Dexamethasone|Dexamethasone tablets
214994660|NCT02998853|OTHER|QFR measurement by dedicated workstation on xrays angio selected runs|The patient undergoes coronary angiography; if at least one stenosis from 40 to 90% in non culprit is present and FFR is indicated by guidelines the patient is enrolled to 3d Angio QFR evaluation; no adjunctive invasive procedures are needed for QFR measurements
214994661|NCT05754710|DRUG|Xeljanz|Juvenile Idiopathic Arthritis (JIA) patients with Xeljanz
214994662|NCT03314935|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
215092617|NCT02593656|BEHAVIORAL|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
214381024|NCT02567825|DRUG|Amoxicillin-Clavulanate and/or Ceftriaxone|Children randomized to nonsurgical management will receive stepwise therapy with amoxicillin-clavulanate (90/6.4 mg/kg in two divided doses for 10 days), and in the event of inadequate response, ceftriaxone (75 mg/kg intramuscularly, repeated in 48 hours), as recommended in the American Academy of Pediatrics guidelines.
214381025|NCT02567825|DRUG|Ofloxacin Otic|Participants randomized to receive tympanostomy tubes will also be followed overtime for recurrences of AOM and treated with topical ofloxacin (Floxin® 0.3%, 5 mL) 5 drops into the affected ear twice daily for 10 days. Persistence of otorrhea after 7 days of treatment will be considered inadequate response, and children so affected will be prescribed empiric amoxicillin-clavulanate (90/6.4 mg/kg/day in two divided doses) followed by culture-directed therapy 48 hours later.
214994663|NCT03314935|DRUG|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
214994664|NCT03314935|DRUG|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
214381026|NCT05962320|OTHER|Education and counselling|Education and counselling of patients and their parents
214381027|NCT05962320|OTHER|Avoiding the use of nasogastric catheters, drains and urinary catheters|Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible
214381028|NCT05962320|OTHER|Stimulation of intestinal motility in the postoperative period|Stimulation of intestinal motility in the postoperative period
214381029|NCT05962320|OTHER|Initiation of oral intake in the early postoperative period|Initiation of oral intake in the early postoperative period
214381030|NCT05962320|OTHER|Early removal of the patient by reducing postoperative IV fluid infusion|Early removal of the patient by reducing postoperative IV fluid infusion
214994665|NCT03314935|DRUG|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
214994666|NCT03314935|DRUG|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
214994667|NCT03314935|DRUG|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
214994668|NCT03314935|DRUG|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
214994669|NCT06202820|BEHAVIORAL|CV Care Program|Comprised of two, in-clinic, counseling sessions with oncology nurse practitioner or physician assistant for education on cardiovascular disease (CVD) and cardiovascular risk factors as well as recommendations for management.
215092618|NCT02593656|BEHAVIORAL|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
215092619|NCT00835133|OTHER|biologic sample preservation procedure|one blood sample
215092620|NCT00835133|OTHER|medical chart review|confirmation of cancer diagnosis
215092621|NCT00835133|OTHER|survey administration|at baseline enrollment and 12 months post-enrollment
215092622|NCT06256926|DRUG|Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)|Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
215092623|NCT06256926|DRUG|Placebo product|Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
215092624|NCT04213378|DEVICE|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon
215092625|NCT04213378|DEVICE|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon
214994670|NCT05884580|DEVICE|Neuflo BPH Treatment System|The Neuflo BPH Treatment System is designed to treat patients with lower urinary tract symptoms (LUTS) associated with BPH. It is an outpatient-based, minimally invasive treatment option and uses hydrolysis to reduce prostatic tissue in the lateral lobes of the prostate. Reduced pressure and constriction of the urethra alleviates urinary and other symptoms of BPH.
214994671|NCT05667506|BIOLOGICAL|single dose of CNCT19|"Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously.~Lymphodepletion treatment:~Drugs:Fludarabine Drugs: Cyclophosphamide"
214994672|NCT04217980|DIAGNOSTIC_TEST|Lung ultrasonography (LUS) or Chest X ray (CXR)|pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.
214994673|NCT00168298|DRUG|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
214994674|NCT00168298|DRUG|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
214994675|NCT00168298|OTHER|Sham Injection|Sham injection on Day 0.
214994676|NCT03283878|DRUG|Cefazolin|"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."
214994677|NCT06292663|DEVICE|Virtual Reality|The subjects get a supplement of information via. a Vitual Reality (VR) headset. The information they get through the VR headset is about their course on the day of their surgery.
214994678|NCT04253730|OTHER|Cold Stress|60-90 mins of cooling via a liquid perfused suit circulating \~4-10°C liquid.
214994679|NCT02617277|DRUG|AZD1775|AZD1775 (adavosertib) is available in capsules for oral administration.
214994680|NCT02617277|DRUG|MEDI4736|MEDI4736 (durvalumab) will be administered by IV infusion.
214994681|NCT06270394|DRUG|68Ga-Fibroblast activation protein inhibitor|Fibroblast activation protein (FAP), a type II transmembrane serine protease with dipeptidyl peptidase and endopeptidase activities. FAP is a specific surface marker for activated fibroblasts in the mesenchyme of tumors, which account for 90% of the stroma of epithelial neoplasms. FAP inhibitors (FAPIs) can specifically target and bind to FAP. These inhibitors that are radiolabeled with gallium 68 (68Ga-FAPIs) can be probes for visualization of the FAP tumor stroma. Previous studies have demonstrated that 68Ga-FAPI-04 is not dependent on blood glucose levels, has an equal or better tumor-to-background ratio, and clearly visualizes primary tumors and their metastatic foci. In addition, previous studies on 68Ga-FAPI-04 have focused on PET/CT and the efficacy of PET/MR with FAPI for postoperative evaluation of GI tumors remains to be clarified.
214994682|NCT06471933|DEVICE|Juläine|Dermal filler (PLLA)
214994683|NCT05807477|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
214994684|NCT05746325|OTHER|Digital Photography|Digital photographs taken of array placement
214994685|NCT05746325|PROCEDURE|Lumbar Puncture|Undergo LP
214994686|NCT05746325|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214994687|NCT05746325|DEVICE|Medical Device Usage and Evaluation|Transducer arrays applied and wear NovoTTF-200T
214994688|NCT05746325|PROCEDURE|Biospecimen Collection|Undergo collection of cerebrospinal fluid (CSF) during screening if no CSF testing for malignancy has been done previously
214381031|NCT05962320|OTHER|Initiation of early mobilization of the patient in the postoperative period|Initiation of early mobilization of the patient in the postoperative period
214381032|NCT05962320|OTHER|Reducing opioid use and ensuring pain management|Reducing opioid use and ensuring pain management
214994689|NCT06166992|DRUG|BI 1291583|BI 1291583
214994690|NCT06166992|DRUG|[14C]-BI 1291583|\[14C\]-BI 1291583
214994691|NCT04401748|DRUG|Venetoclax|Tablet: Oral
214994692|NCT04401748|DRUG|Azacitidine|Subcutaneous (SC) or Intravenous (IV) injection
214994693|NCT04401748|DRUG|Placebo|Tablet; Oral
214994694|NCT03785366|DRUG|VeraCept|VeraCept Intrauterine Device (IUD)
214994695|NCT03785366|DRUG|ParaGard|ParaGard intrauterine copper contraceptive
214994696|NCT06340633|DRUG|Ebselen|Glutathione peroxidase mimetic
214994697|NCT06340633|DRUG|Placebo|Matching placebo containing excipients
214994698|NCT05763797|BEHAVIORAL|Individual Interview|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
214994699|NCT05763797|BEHAVIORAL|Meditation Exercise|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
214994700|NCT04008602|DEVICE|Quick icing|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
214994701|NCT04008602|DEVICE|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the decreased nerve conduction velocity.
214994702|NCT06391918|BIOLOGICAL|GEN2 + Valganciclovir|Gene therapy vector product
214381033|NCT05962320|OTHER|Implement nausea and vomiting prophylaxis|Implement nausea and vomiting prophylaxis
214381034|NCT05962320|OTHER|Management of thirsty|Management of thirsty
214381035|NCT05962320|OTHER|Management of fear and stress|Use of recommended non-pharmacological interventions in the management of fear and stress
214381036|NCT05512429|OTHER|measured of body composition with computed tomography|Multislice and single-slice computed tomography images were used for assessment of body composition including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle mass volume (SMMV)
214381037|NCT03170245|DIAGNOSTIC_TEST|Interleukin-6|serum samples used for doing the test by ELISA
214381038|NCT03170245|DIAGNOSTIC_TEST|HsC-RP|serum samples used for doing the test by ELISA
214381039|NCT03170245|DIAGNOSTIC_TEST|Adiponectin level|serum samples used for doing the test by ELISA
214381040|NCT03170245|DIAGNOSTIC_TEST|Carotid intima media thickness|Done by carotid doppler
214994703|NCT04751890|BEHAVIORAL|Structured home-based exercise|Low-intensity interval walking program prescribed at hospital and performed at daily at home
214994704|NCT04751890|BEHAVIORAL|Walking advice|Walking advice according to the guidelines for peripheral artery disease patients
214381041|NCT02444663|RADIATION|Clinician Valgus|Clinician performed valgus stress X-ray under fluoroscopy
214381042|NCT02444663|RADIATION|Clinician Varus|Clinician performed varus stress X-ray under fluoroscopy
214381043|NCT02444663|RADIATION|Device Valgus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
214994705|NCT04235686|DRUG|Mydayis Extended-Release Capsule|Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®
214994706|NCT04235686|DRUG|Placebo|Matching placebo
214994707|NCT01744587|OTHER|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
215092626|NCT01174394|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
215092627|NCT01174394|PROCEDURE|Body electro-acupuncture (Hwato®/ Dongbang®)|Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
215092628|NCT01174394|PROCEDURE|n-CEA (Strietberger®)|Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
215092629|NCT01174394|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
215092630|NCT06822439|DEVICE|Fetal ECG monitoring|Patients will wear a fetal ECG monitor which they will place on their abdomen
214381044|NCT02444663|RADIATION|Device Valgus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed varus stress X-ray under fluoroscopy.
214381045|NCT02444663|RADIATION|Device Valgus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
214381046|NCT02444663|RADIATION|Device Valgus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
214381047|NCT02444663|RADIATION|Device Varus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
214381048|NCT02444663|RADIATION|Device Varus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
214381049|NCT02444663|RADIATION|Device Varus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
214381050|NCT02444663|RADIATION|Device Varus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
214381051|NCT03202095|DRUG|Creatine Monohydrate|5 grams daily of oral creatine monohydrate powder.
214381052|NCT00766454|GENETIC|DNA analysis|
214381053|NCT00766454|GENETIC|mutation analysis|
214381054|NCT00766454|GENETIC|polymorphism analysis|
214381055|NCT00766454|OTHER|laboratory biomarker analysis|
214381056|NCT00766454|OTHER|medical chart review|
214381057|NCT00766454|OTHER|questionnaire administration|
214498090|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
214994708|NCT01744587|DIETARY_SUPPLEMENT|Placebo|Placebo qd (2# bid) for 3 years
214994709|NCT06460116|BEHAVIORAL|School-Based Community Health Worker (SB-CHW) intervention|The school-based community health worker will support students with chronic poor attendance and their parent/guardian for a minimum of two 30-minute encounters focused on addressing social determinants needs, understanding the range/student encounter varies greatly due to the intensity of the social need(s) (e.g., crisis/noncrisis) and the number of needs being jointly addressed. The SB-CHW will build relationships across encounters and apply trauma-informed best practices.
214994710|NCT06460116|BEHAVIORAL|Enhanced Usual Care (EUC) Methods|The network of school-based health centers without school-based community health workers will receive reminders of the the existing online social services directory.
214994711|NCT06472271|DRUG|Polymyxin e|Increased starting colistin dose
214994712|NCT05514535|DRUG|Semaglutide|Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.
214994713|NCT05514535|DRUG|Insuline glargine U100 (reduced)|Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
214381058|NCT00766454|PROCEDURE|evaluation of cancer risk factors|
214381059|NCT03749577|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline 9g per day (capsule, per os) during 14 days;
214381060|NCT03749577|DIETARY_SUPPLEMENT|Beetroot juice|Concentrated 70 ml beetroot juice bottles containing 6.45 mmol of nitrates
214994714|NCT05514535|DRUG|Insuline glargine U100 (titrated)|Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
215092631|NCT06524479|PROCEDURE|SEEG recordings and SPES|This study will utilize stereoelectroencephalography (SEEG) recordings combined with single-pulse electrical stimulation (SPES) to investigate functional brain connectivity and cortical excitability patterns in patients with epilepsy during both wakefulness and sleep states. The SEEG recordings will provide high-resolution intracranial electrophysiological data, while SPES will be employed to actively probe and quantify cortico-cortical connections. This combined approach will enable characterization of state-dependent neural network dynamics.
214381061|NCT03749577|DIETARY_SUPPLEMENT|L-citrulline placebo|L-citrulline placebo (maltodextrin) 9g per day (capsule, per os) during 14 days
214381062|NCT03749577|DIETARY_SUPPLEMENT|Denitrated beetroot juice|Concentrated 70 ml nitrate-depleted beetroot juice
215092632|NCT06667713|BEHAVIORAL|ENTRUST - substance use and HIV counseling and goal setting with economic empowerment and photovoice training|The ENTRUST intervention consists of an adapted counseling intervention based on motivational interviewing techniques and goal setting (SBIRT-T); Economic skill building using a tailored app (WorthIt for ENTRUST); and, Photovoice Activities with an optional photo exhibit
215092633|NCT06667713|BEHAVIORAL|SBIRT-T only|An adapted screening brief intervention and referral to treatment intervention to link transgender women to substance use and HIV services
215092634|NCT04436068|DEVICE|Hyperfine MRI scan|Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.
215092635|NCT05100836|DEVICE|Impella 5.5|Impella 5.5 mechanical circulatory support
215092636|NCT04619004|DRUG|Patritumab Deruxtecan (Fixed dose)|Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
215092637|NCT04619004|DRUG|Patritumab Deruxtecan (Up-Titration)|Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.
214381063|NCT02923102|DIETARY_SUPPLEMENT|Aloysia citriodora extract|2 capsules with 200mg - daily dosage 400mg
214381064|NCT02923102|DIETARY_SUPPLEMENT|Maltodextrin|2 capsules with 200mg - daily dosage 400mg
214381065|NCT01548937|DRUG|I-123 ADAM|"This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
214381066|NCT05626764|OTHER|QoL & irAEs determinants|Assesment of the QoL \& irAEs determinants in patients diagnosed with solid tumor and treated in France, Netherlands, Portugal, Spain, with immunotherapy by immune checkpoint inhibitors.
214381067|NCT05626764|OTHER|QoL & irAEs determinants|Assesment of the QoL \& irAEs determinants in patients diagnosed with hematologic cancer and treated in France, Netherlands, Portugal, Spain, by CAR-T cells.
214381068|NCT01626222|DRUG|Exemestane|Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
214994715|NCT05507866|OTHER|CSNEI|CSNEI is a policy intervention designed to address childhood obesity by modifying lunch and breakfast meal/menu items, changing the school cafeteria environments, and making changes to purchasing and procurement practices.
214994716|NCT05239728|DRUG|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
214994717|NCT05239728|BIOLOGICAL|Pembrolizumab|400 mg via IV infusion
214498091|NCT00788541|OTHER|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
214498092|NCT02430766|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
214498093|NCT02430766|DEVICE|NanoKnife|
214498094|NCT01199185|BEHAVIORAL|Smoking Cessation|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
214994718|NCT05239728|DRUG|Placebo|Oral tablet
214994719|NCT03653338|BIOLOGICAL|CD3/CD19 depleted leukocytes|Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.
214994720|NCT03653338|BIOLOGICAL|CD45RA depleted leukocytes|Negative selection for CD45RA will be performed on the CliniMACS® depletion device.
214994721|NCT03653338|DRUG|Hydroxyurea|Sickle Cell Disease Conditioning
214994722|NCT03653338|DRUG|Rituximab|Sickle Cell Disease Conditioning
214994723|NCT03653338|DRUG|Alemtuzumab|Sickle Cell Disease Conditioning
214994724|NCT03653338|DRUG|Fludarabine|Sickle Cell Disease Conditioning
214994725|NCT03653338|DRUG|Thiotepa|Sickle Cell Disease Conditioning
214994726|NCT00569127|BIOLOGICAL|Bevacizumab|Given IV
214994727|NCT00569127|OTHER|Laboratory Biomarker Analysis|Correlative studies
214994728|NCT00569127|DRUG|Octreotide Acetate|Given IM
214994729|NCT00569127|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given SC
214994730|NCT06442800|BEHAVIORAL|Liver Cancer|Participants will view messages about the risk of liver cancer from alcohol consumption.
214994731|NCT06442800|BEHAVIORAL|Throat and Mouth Cancer|Participants will view messages about the risk of throat and mouth cancer from alcohol consumption.
214994732|NCT06442800|BEHAVIORAL|Colorectal Cancer|Participants will view messages about the risk of colorectal cancer from alcohol consumption.
214994733|NCT06442800|BEHAVIORAL|Multiple Cancers|Participants will view messages about the risk of multiple cancers from alcohol consumption.
214381069|NCT01626222|DRUG|Everolimus (RAD001)|Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
214994734|NCT06442800|BEHAVIORAL|Liver Disease|Participants will view messages about the risk of liver disease from alcohol consumption.
214994735|NCT06442800|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
214994736|NCT06442800|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
214381070|NCT04741802|BEHAVIORAL|TOPS|weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors in the local chapter of a national African American breast cancer support group (Sisters Network Triangle North Carolina, SNTNC).
215092638|NCT05803252|BEHAVIORAL|Focused Acceptance and Commitment Therapy|"FACT aims to increase one's psychological flexibility so that one will not generate feelings of distress and suffering when confronted with painful life situations. The intervention of this study will follow the FACT principles laid out by Strosahl, Robinson and Gustavsson to increase parents' psychological flexibility. Three core processes influence one's psychological flexibility: awareness, openness, and engagement.~The key objectives of each core process are:~1. Awareness: Able to experience the present moment, able to take perspective on self~2. Openness: Able to detach distressing private experiences and associated rules, able to take a non-judgemental, accepting stance towards painful material~3. Engagement: Exhibits strong connection with values, able to sustain values-consistent action"
214994737|NCT06442800|BEHAVIORAL|Drinking Guidelines|Participants will view messages about guidelines for alcohol consumption.
214994738|NCT06442800|BEHAVIORAL|Current Warning|Participants will view the current warning that is required on most alcoholic beverage containers sold in the US.
215092639|NCT05803252|OTHER|Waitlist Control|The waitlist control group participants will commence their FACT intervention immediately after they complete their follow-up assessment.
215092640|NCT06026163|DRUG|Caffeine citrate|Caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base)
214994739|NCT06442800|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
214994740|NCT04222751|DEVICE|Ankle Splint|Ankle splint will be slightly modified from the commercial form to include a pneumatic air cell secured under the forefoot below the splint's padded lining. This replaces the foam wedge provided by the manufacturer, allowing a gradual adjustment of the forefoot/toe region.
214994741|NCT04279522|DEVICE|Relivion®DP- Active|Relivion®DP- Active stimulation device
215092641|NCT06026163|OTHER|Placebo|Equivalent volume of saline
215092642|NCT06574139|BEHAVIORAL|Unstained|Unstained is an individual-level, virtual intervention that involves three \~60-minute sessions delivered over a 3-6 week period. Each session includes watching two videos (six videos total), followed by a discussion facilitated by study coordinators.
215092643|NCT06574139|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Participants will receive a link to the film and will be asked to watch it independently. The film does not include information related to the outcomes of interest for the study.
215092644|NCT00306475|DRUG|Divalproex Sodium Extended-Release Tablets|divalproex sodium extended-release (ER) 1000 mg
215092645|NCT00306475|DRUG|placebo|placebo identical in appearance to active comparator
214994742|NCT04279522|DEVICE|Relivion®DP- Sham|Relivion®DP- Sham stimulation device
214994743|NCT04938830|BIOLOGICAL|Clesrovimab|IM injection
214994744|NCT04938830|BIOLOGICAL|Palivizumab|IM injection
214994745|NCT04938830|BIOLOGICAL|Placebo|IM injection
214994746|NCT02282969|BEHAVIORAL|Interviews|Interviews performed by study staff encompassing lung cancer screening and patient decision aids.
214994747|NCT02282969|BEHAVIORAL|Questionnaires|Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
214994748|NCT04698967|BEHAVIORAL|Purposeful Pathways|Purposeful Pathways is a manualized intervention to assist veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.
214994749|NCT04698967|BEHAVIORAL|Transitional Work Experience|Provides Veterans with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TWE is time-limited. TWE is staffed by vocational rehabilitation specialists (VRS).
214381071|NCT04863989|PROCEDURE|tube thoracostomy|insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
214687342|NCT06713694|OTHER|Wait first, then cognitive-behavioral therapy|participants assigned to the waiting-list control condition will wait 3.5 months before they are treated with CBT. This period corresponds to the duration of the CBT intervention and follow-up assessment of the experimental group. After this 3.5 month waiting period the participants in the waiting-list control condition will be asked to complete a follow-up after waiting/baseline before CBT assessment before starting treatment.
214687343|NCT02991053|DRUG|ketamine|
214687344|NCT06704724|DRUG|PF-07985045|KRAS inhibitor
214687345|NCT06704724|COMBINATION_PRODUCT|Gemcitabine|Chemotherapy (antimetabolite)
214994750|NCT05776719|BEHAVIORAL|Health & Wellness|PowerPoint slide decks will be shown via shared screen. The wellness group will be largely educational in nature and will encourage discussion, setting goals, and making healthy choices. Similar topics covered in this group have been used previously in health promotion classes.
214994751|NCT05776719|BEHAVIORAL|Warrior Renew|The group format includes warm-up community building exercises, psychoeducational presentation of material standardized by the use of PowerPoint slides, followed by discussion of the information and interactive exercises, and closes with exercises to improve affect management skills, such as mindfulness or guided imagery.
214994752|NCT06265220|DRUG|AB-101|NK Cell Therapy
214994753|NCT06265220|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214994754|NCT06265220|DRUG|Fludarabine|Lymphodepleting chemotherapy
214994755|NCT06265220|DRUG|Rituximab|Anti-CD20 antibody therapy
214994756|NCT06265220|DRUG|Obinutuzumab|Anti-CD20 antibody therapy
214994757|NCT06549413|OTHER|Non-Interventional Study|Non-interventional study
214994758|NCT04258319|DIAGNOSTIC_TEST|Ultrasound Procedure|Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
214994759|NCT01292408|DRUG|Hydrochloroquine|800 mg per os once, and then 400 mg per day
215092646|NCT05991934|BEHAVIORAL|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
215092647|NCT02159755|DRUG|Ibrutinib|Given PO
215092648|NCT02159755|OTHER|Laboratory Biomarker Analysis|Correlative studies
215092649|NCT02159755|DRUG|Palbociclib|Given PO
215092650|NCT02159755|OTHER|Pharmacological Study|Correlative studies
215092651|NCT05879276|DRUG|Empagliflozin 10 MG|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.
215092652|NCT06644222|BEHAVIORAL|AIRROSTI exercises|Group A will receive AIRROSTI exercises for 45 minutes / one session daily for five days per week
215092653|NCT06644222|BEHAVIORAL|Thera band exercises|Group B will receive Thera band exercises for 45 minutes/one session per day for five days per week.
215092654|NCT06653010|BIOLOGICAL|Universal CAR-T cells injection for treating mCRC|A novel universal CAR-T platform to treat cancer patients
214381072|NCT01212536|DEVICE|Airtraq laryngoscopy|laryngoscopy and intubation
214381073|NCT03195465|DIETARY_SUPPLEMENT|Dark Chocolate|Dark Chocolate bars with 70% cacao and 30% organic cane sugar where 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m. daily for four weeks.
215092655|NCT02144545|PROCEDURE|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
214381074|NCT02943889|BIOLOGICAL|Mesenchymal stem cell transplantation|Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.
214381075|NCT00553098|BIOLOGICAL|Alemtuzumab|Given IV
214381076|NCT00553098|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo HCT
214381077|NCT00553098|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
214381078|NCT00553098|DRUG|Cyclosporine|Given PO or IV
214381079|NCT00553098|DRUG|Fludarabine Phosphate|Given IV
214381080|NCT00553098|OTHER|Laboratory Biomarker Analysis|Correlative study
214381081|NCT00553098|DRUG|Mycophenolate Mofetil|Given PO or IV
214381082|NCT00553098|RADIATION|Total-Body Irradiation|Undergo low dose TBI
214381083|NCT05250622|OTHER|Japanese-translated evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to Japanese-translated version of evidence summaries.
214381084|NCT05250622|OTHER|English evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to English version of evidence summaries.
214381085|NCT01785563|DEVICE|Nasal NIV-NAVA|Infants will be placed on nasal NIV-NAVA. Patients initial NAVA level will be set to generate a peak inspiratory pressure that is 8 cm of water greater than their current peak end expiratory pressure. If the infants are on nasal NIV-NAVA at the time of study entry their NAVA level will be increased by 50% rounded up to the nearest 0.1 cm of water per microvolt.
214381086|NCT02913976|DEVICE|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
214381087|NCT02913976|DEVICE|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
214381088|NCT00167895|PROCEDURE|Adding platelet concentrate to the wound|
214381089|NCT04865211|DRUG|Liposomal bupivacaine|Use of liposomal bupivicaine as intraoperative local anesthesia
214381090|NCT04865211|DRUG|Bupivacaine Injection|Use of bupivicaine as intraoperative local anesthesia
214687346|NCT06704724|COMBINATION_PRODUCT|Nab-paclitaxel|Taxane-type Chemotherapy
214994760|NCT04925635|BEHAVIORAL|experimental group|"The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group. Arteriovenous fistula care mobile health application will be installed in daytime groups during working hours during or at the end of dialysis according to the patient's request. In addition, the information contained in the arteriovenous care mobile health application will be verbally explained to the patients and their relatives, as well as shown in practice. The training results were evaluated by the researcher in the 1st and 3rd months in the Scale for Evaluation of Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients, Final Level of Renal Failure Compliance Scale, Arteriovenous Fistula Care Education Knowledge Level Evaluation Form (Post-Training Section) and  Visual Benchmarking Scale ."
214994761|NCT04925635|BEHAVIORAL|control group|"Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given. The information contained in the booklet will be explained orally to the patients and their relatives by the researcher, and will also be shown in practice. The results of the training were determined by the researcher at the 1st and 3rd months of the Self-Care Behaviors Scale for Arteriovenous Fistula in Hemodialysis Patients, End Stage Renal Failure Compliance Scale, Arteriovenous Fistula Care Training Information Level Assessment Form (Post-training section) and Visual It will be evaluated with the Comparison Scale."
215092656|NCT02144545|PROCEDURE|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
215092657|NCT02144545|PROCEDURE|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
215092658|NCT02144545|PROCEDURE|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
215092659|NCT06851130|DIETARY_SUPPLEMENT|ferrous sulfate 80 mg|1 tablet per day
215092660|NCT06851130|DIETARY_SUPPLEMENT|ferrous sulfate 160 mg|2 tablets per day
214381091|NCT04865211|DRUG|Placebo|Use of saline as placebo for local anesthesia
214994762|NCT00055146|DRUG|ONTAK|
214994763|NCT01373619|DRUG|Ivabradine|ivabradine titrated to 7.5 mg BID
214994764|NCT05067387|DRUG|Placebo|Oral placebo
214994765|NCT05067387|DRUG|THC|Oral THC (20 mg)
214994766|NCT05067387|DRUG|CBD|Oral CBD (20 mg)
214994767|NCT05067387|DRUG|THC + CBD|Oral THC (20 mg) + CBD (20 mg)
214994768|NCT04743830|OTHER|Neurodevelopmental Treatment (Bobath) + Scapular Training|The Bobath concept for 40 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed with 20 minutes scapular training including scapular exercise such as Proprioceptive Neuromuscular Facilitation (PNF), dynamic hug, towel-wall slide, scapular punch exercises etc. 3 days a week for 8 weeks.
215092661|NCT06979830|BEHAVIORAL|yoga exercises|"The yoga program, based on Hatha yoga content, will be conducted in groups of 10 participants, for 12 weeks, 3 days a week, at the same time each day (12:00-13:00), and will be administered by an experienced physiotherapist (Appendix 4).~Before starting the training program, the exercise group will be given a one-week adaptation period, during which the exercises to be performed in three sessions per week will be taught.~Participants in the exercise group who miss sessions for various reasons will be given an additional one-week period to make up for missed sessions. Participants who miss more than four sessions will be excluded from the study.~Participants were informed in advance about any personal items they might need before each yoga session (such as towels, tissues, etc.) and were advised to bring their own. The yoga sessions were held in the sports hall of the Artvin Çoruh Dormitory, where the required equipment for yoga (e.g., mats, blocks) was provided. The yoga program was"
215092662|NCT06979960|BEHAVIORAL|cancer screening education|It will be carried out to examine the effect of the educational intervention given using the cancer screening training booklet on women's knowledge, attitude and shyness levels.
215092663|NCT06979648|DIETARY_SUPPLEMENT|Qualia Magnesium+®|Qualia Magnesium+® manufactured by Qualia Life Sciences
214381092|NCT02430701|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
214381093|NCT02430701|DEVICE|NanoKnife|
214381094|NCT00498563|PROCEDURE|altitude exposure in hypobaric chamber|
214381095|NCT05489939|DRUG|The compound methyl salicylate liniment|The compound methyl salicylate liniment (Ammeltz) has been developed by Japan Sendai Kobayashi Pharmaceutical Co. and has been listed in Japan for many years. It is composed of various components, such as methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol.
214687347|NCT06704724|COMBINATION_PRODUCT|Cetuximab|Monoclonal Antibody (EGFR Inhibitor)
214687348|NCT06704724|COMBINATION_PRODUCT|Fluorouracil|"Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)"
214687349|NCT06704724|COMBINATION_PRODUCT|Oxaliplatin|"Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)"
214687350|NCT06704724|COMBINATION_PRODUCT|Leucovorin|"Part of FOLFOX chemotherapy regimen~Folic Acid Analog"
214994769|NCT04743830|OTHER|Neurodevelopmental Treatment (Bobath)|The Bobath concept for 60 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed 3 days a week for 8 weeks.
214994770|NCT02169232|DEVICE|Videolaryngoscope|
214994771|NCT02169232|DEVICE|Fiberoptic|
214994772|NCT02452190|DRUG|Reslizumab|Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
214994773|NCT02452190|DRUG|Placebo|Matching Placebo
214994774|NCT04361175|DRUG|Letrozole|Each group will be followed up for ovulation by day 12 ovulation monitoring by Transvaginal ultrasound for mature griffian follicle and measure endometrial thickness and volume then day 21 test serum progesterone level to confirm ovulation and if pregnancy occurred confirm by serum pregnancy test at day 35 of the cycle and follow pregnancy till confirmed by fetal pulsation by ultrasound.
214994775|NCT04361175|DRUG|Clomiphine Citrate|Clomiphine Citrate
215092664|NCT06979648|DIETARY_SUPPLEMENT|Placebo|Rice Flour
215092665|NCT06981494|DRUG|Dexmedetomidine|"Loading Dose:~Dexmedetomidine is usually administered as a loading dose of 0.25 mcg/kg slowly.~Maintenance Dose:~After the loading dose, the maintenance infusion rate is typically 0.2 to 0.7 mcg/kg/hour in syringe pump . The exact rate can be adjusted based on the hemodynamics of the patient (blood pressure and heart rate) and the patient's response."
214381096|NCT02991443|BEHAVIORAL|Mindfulness based stress reduction|Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
214381097|NCT02319070|OTHER|Survey|Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine
214381098|NCT02319070|OTHER|Survey|Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine
214381099|NCT04266639|DEVICE|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion
214381100|NCT04266639|DEVICE|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
214381101|NCT03017157|OTHER|Echo-cardiogram|Patients will undergo echo-cardiogram to determine improvement in their heart function and this will be compared to thyroid function
214381102|NCT03017157|OTHER|Blood test|Blood test to determine thyroid function
214381103|NCT01540565|OTHER|Laboratory Biomarker Analysis|Correlative studies
214381104|NCT01540565|DRUG|Veliparib|Given PO
214381105|NCT04399356|DRUG|Niclosamide|Participants in the treatment arm will receive Niclosamide 2 grams orally once daily for 7 days in addition to current standard of care treatment. Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14. Fecal samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14, 21. A baseline fecal and oropharyngeal sample will be obtained on Day 1 prior to starting dosing of Niclosamide/ placebo.
214994776|NCT04593602|BEHAVIORAL|Early Mobilization|Nurse-driven early mobilization activities twice daily
214994777|NCT04593602|BEHAVIORAL|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
214498095|NCT01199185|BEHAVIORAL|Smoking Cessation plus Weight Loss|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
214994778|NCT06052124|DEVICE|Augmented Reality Device|AR device will be used to determine where to place SEPS drain
214381106|NCT04399356|DRUG|Placebo|The collection of oropharyngeal samples will be observed by a Study Team member via the telehealth platform.
214994779|NCT04467489|OTHER|observational|There is no intervention for any group in this observational study.
215092666|NCT06981494|DRUG|Dexmedetomidine and ketamine ( Ketodex )|"Ketodex Group (Combination of Ketamine and Dexmedetomidine) (K):~Ketamine Component:~Loading Dose:~Ketamine is typically given at a dose of 0.5 mg/kg as a bolus injection.~Maintenance Dose:~A maintenance infusion of 0.2 to 0.5 mg/kg/hour is common to maintain anesthesia in syringe pump.~Dexmedetomidine Component:~Loading Dose:~As with the dexmedetomidine group, a loading dose of 0.25 mcg/kg slowly is administered.~Maintenance Dose:~The maintenance infusion rate for dexmedetomidine remains 0.2 to 0.7 µg/kg/hour in syringe pump."
215092667|NCT06979791|DRUG|Dexmedetomidine + Midazolam 0.4 mg/kg|Participants in this arm will receive intranasal dexmedetomidine at a dose of 2 mcg/kg combined with intranasal midazolam at a dose of 0.4 mg/kg, administered 30 minutes before the induction of general anesthesia.
215092668|NCT06979791|DRUG|Dexmedetomidine + Midazolam 0.2 mg/kg|Participants in this arm will receive intranasal dexmedetomidine at a dose of 2 mcg/kg combined with intranasal midazolam at a dose of 0.2 mg/kg, administered 30 minutes before the induction of general anesthesia.
214994780|NCT04716998|BIOLOGICAL|MesenCure|Three administrations of MesenCure in addition to standard care
214994781|NCT06277063|DEVICE|Transcutaneous auricular vagus nerve stimulation|The vagus nerve's auricular branch is primarily distributed in the tragus, tragus sulcus, and concha cavity. It can activate the nucleus tractus solitarius through the vagus afferent fibers, thereby activating various areas of the vagus nerve in the central nervous system. This stimulation technique involves applying a constant current of around 2-3mA to the epidermal terminals of the ear using an electrode. It aims to regulate the vagus nerve, modulate the autonomic nervous system, release neurotransmitters, improve cerebral blood flow, and alleviate headache symptoms. In the implementation, non-invasive transcutaneous vagus nerve stimulation was performed by having the subject wear a vagus stimulator and adjusting the appropriate stimulation intensity.
214994782|NCT06121011|BIOLOGICAL|Cipaglucosidase alfa|Enzyme Replacement Therapy (ERT) via intravenous infusion
214994783|NCT06121011|DRUG|Miglustat|Participants received ATB200 co-administered with AT2221 (Miglustat)
214994784|NCT06121011|BIOLOGICAL|Alglucosidase alfa or Avalglucosidase alfa|Patients prescribed other commercially available ERT after local regulatory approval
214994785|NCT06121011|OTHER|Untreated|Patients who are not currently receiving any medical therapy for Pompe disease.
214994786|NCT03504956|DEVICE|Cardiac MRI|MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
214994787|NCT03504956|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
215092669|NCT05087719|COMBINATION_PRODUCT|experimental group|patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks
215092670|NCT05087719|COMBINATION_PRODUCT|conventional treatment|patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
215092671|NCT00003842|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
215092672|NCT00003842|DRUG|isolated perfusion|
215092673|NCT00003842|PROCEDURE|surgical procedure|
214381107|NCT04399356|OTHER|Telehealth monitoring|In addition to Niclosamide or placebo treatments, all enrolled patients will be provided a home thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. The collection of oropharyngeal samples will be directly observed by a Study Team member via the telehealth platform.
214994788|NCT03504956|DRUG|Beta blocker|Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
214994789|NCT03401398|DRUG|Hydrocortisone, sodium succinate|Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
215092674|NCT03522727|BEHAVIORAL|Single self-incentivising implementation intention|Participants are asked to form a single self-incentivising implementation intention (if-then plans)
215092675|NCT03522727|BEHAVIORAL|Multiple self-incentivising implementation intentions|Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
215092676|NCT03522727|BEHAVIORAL|Self-generated self-incentivising implementation intentions|Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
215092677|NCT02258529|DRUG|Idelalisib|150 tablets administered orally twice daily
215092678|NCT02258529|BIOLOGICAL|Rituximab|375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
215092679|NCT02938273|DRUG|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
215092680|NCT02938273|RADIATION|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
215092681|NCT02938273|DRUG|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
215092682|NCT01778920|DRUG|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
214381108|NCT01101360|DEVICE|Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
214381109|NCT01101360|DEVICE|Matrix RF followed by Pulse Dye Laser|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
214381110|NCT01101360|DEVICE|Pulse Dye Laser followed by Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
214381111|NCT00904891|BEHAVIORAL|Cognitive-behavioral group|Six sessions of cognitive-behavioral depression prevention group intervention
214381112|NCT00904891|BEHAVIORAL|Cognitive-behavioral bibliotherapy|"Cognitive-behavioral bibliotherapy, delivered from the book Feeling Good"
214381113|NCT00790153|DRUG|Insulin|Insulin infusion given during 3 hours at one occasion.
214381114|NCT00790153|DRUG|AZD1656|Single dose oral suspension given at one occasion.
214381115|NCT02875275|OTHER|Glucose with grass jelly solution|50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
214381116|NCT02875275|OTHER|Glucose with grass jelly (solid)|50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
214381117|NCT02875275|OTHER|Porridge and juice with coconut oil|Add instant porridge with hot water with oil. Consume with commercially available orange juice
214381118|NCT02875275|OTHER|Porridge and juice with coconut oil gel|Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
214498096|NCT00978016|DRUG|arbaclofen placarbil-Cohort 1|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
214498097|NCT00978016|DRUG|Placebo-Cohort 5|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
214498098|NCT00978016|DRUG|arbaclofen placarbil-Cohort 2|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
214498099|NCT00978016|DRUG|arbaclofen placarbil-Cohort 3|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
214498100|NCT00978016|DRUG|arbaclofen placarbil-Cohort 4|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
214498101|NCT00978016|DRUG|PPI|Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
214498102|NCT00545519|DRUG|thymoglobulin|
214498103|NCT03442777|DEVICE|Allevyn® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith\&Nephew (Allevyn® brand).
214498104|NCT03442777|DEVICE|Mepilex® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
214498105|NCT04580459|BEHAVIORAL|CARE Parenting Group Treatment|The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.
214498106|NCT04580459|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
214498107|NCT03551600|PROCEDURE|Near-infrared spectroscopy (NIRS)|NIRS analyzes regional oxygen saturations (rSO2)
214994790|NCT03401398|DRUG|Normal saline|Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
214994791|NCT04980794|BEHAVIORAL|Parent-child intervention|Families (two adult caregivers, child between 4 and 17) receive four interactive, asynchronous psychoeducation modules to review on their own paired with weekly contact with a communication coach and two live sessions with a communication coach to discuss psychoeducation, receive feedback on their interactions, and practice a communication technique.
214994792|NCT04980794|BEHAVIORAL|Self-study Intervention|Families (two adult caregivers) receive information in a newsletter format to review on their own, paired with weekly contact from a communication coach to answer questions and direct their attention toward specific topics in the newsletter.
214381119|NCT05730790|OTHER|Cognitive-motor dual task training (DTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min dual tasking, 2 min rest, 2 min dual tasking, 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min dual tasking, 1.5 min rest, 2.5 min dual tasking, 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min dual tasking, 1 min rest, 3 min dual tasking, 1 min rest. The treadmill speed is maintained at 40%, 50% and 60% of participant's original gait speed at session 1 to 3, 4 to 6, and 7 to 14 respectively.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%."
214381120|NCT05730790|OTHER|Cognitive single task training (CSTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min VR gaming, 2 min rest, 2 min VR gaming and 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min VR gaming, 1.5 min rest, 2.5 min VR gaming and 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min VR gaming, 1 min rest, 3 min VR gaming and 1 min rest.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%."
214381121|NCT05730790|OTHER|Motor single task training (MSTT)|For session 1 to 3, the training comprises of 4 cycles of the following: 8 min treadmill walking at 40% of participant's original gait speed followed by 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 8 min treadmill walking at 50% of participant's original gait speed followed by 2 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 8 min treadmill walking at 60% of the participant's original gait speed followed by 2 min rest.
214994793|NCT06199726|BEHAVIORAL|REFLECT web-based tool|Partnering with Nest Genomics, Investigators have developed a customizable web-based tool to support AYA patients through their cancer diagnosis journey for topics related to future family building and genetics. This interactive tool will include educational content to organize knowledge, make connections between concepts, and will include web links to more in-depth content and embedded videos. The interface will allow users to document questions that would be helpful in provider discussions and include decision support to assist with determining values and needs for proceeding with consultations related to genetic counseling and testing, and fertility.
214381122|NCT03548116|DEVICE|Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
214381123|NCT03548116|DEVICE|Sham Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
214381124|NCT00302783|BEHAVIORAL|Multi-Source Feedback: including self-assessment & coaching|
214381125|NCT02833441|BEHAVIORAL|Peer Support|
214498108|NCT06389890|PROCEDURE|Pancreatic resection procedure|Pancreatic resection procedure
214498109|NCT02458924|BIOLOGICAL|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
214498110|NCT03167944|DEVICE|Low thermal electrosurgery system|PEAK Plasmablade
214498111|NCT03167944|DEVICE|Conventional Electrocautery|Conventional Electrocautery
214498112|NCT01611545|GENETIC|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
214498113|NCT06274099|OTHER|nursing care|It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.
214498114|NCT05485818|DRUG|Low Dose|12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
214498115|NCT05485818|DRUG|Middle Dose|12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
214994794|NCT05287113|DRUG|Retifanlimab|Retifanlimab 500mg will be administered intravenously every 4 weeks.
214994795|NCT05287113|DRUG|INCAGN02385|INCAGN02385 350mg will be administered intravenously every 2 weeks.
214994796|NCT05287113|DRUG|INCAGN02390|INCAGN02390 400 mg will be administered intravenously every 2 weeks.
214994797|NCT05287113|DRUG|Placebo|Placebo will be administered intravenously.
214994798|NCT04705831|DRUG|Ruconest|C1 Esterase Inhibitor
214498116|NCT05485818|DRUG|High Dose|12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
214994799|NCT06566118|DEVICE|Auricular Vagus Nerve Stimülation|After exercise loading, active ear VSS was applied to Group 1. Application was made simultaneously in both ears, with a 300 microsecond pulse duration, a biphasic asymmetric waveform, and a frequency of 25 Hz, for a total of 20 minutes. All assessments were recorded 3 times: at the beginning of the test, after exercise loading, and after active VSS application.
214498117|NCT05485818|OTHER|Placebo|15 subjects will be randomly assigned to the placebo for 7 days
214498118|NCT04593238|DRUG|Double Antibiotic paste|Metronidazole and Ciprofloxacin
214498119|NCT04593238|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
214498120|NCT05224024|PROCEDURE|Retzius-repairing robot-assisted radical prostatectomy|Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.
214498121|NCT04325711|DRUG|CSPCHA131|CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
215092683|NCT02767739|BEHAVIORAL|Physical, social and cultural activities|This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
215092684|NCT02784600|DEVICE|Bioinductive implant|
215092685|NCT01458834|BEHAVIORAL|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
214994800|NCT06566118|DEVICE|Sham Auricular Vagus Nerve Stimülation|After the exercise challenge, Group 2 underwent sham VSS. Device parameters were set to the same as Group 1 (300 microsecond pulse duration, biphasic asymmetric waveform, and 25 Hz frequency). Both headphones were worn for a total of 20 minutes. However, the participant heard only the device's power-on tone and received no current. All assessments were recorded three times: at the beginning of the test, after the exercise challenge, and after sham VSS.
214994801|NCT06220435|RADIATION|Ultra-hypofractionated radiotherapy regimen.|"* Prostate tumor(s): 49 Gray (Gy)/7 fractions~* Prostate gland: 42.7 Gy/7 fractions~* Elective lymph nodes: 29.4 Gy/7 fractions~* Seminal vesicles: 31.15 Gy/7 fractions"
214994802|NCT06374550|BEHAVIORAL|Jump Start on the Go|Centers will receive the Jump Start On The Go mental health program via a mobile app. This will entail receiving 12-24 mental health consultation sessions in which a licensed mental health consultant will use a mobile app that will provide directors and teachers with access to information such as videos, infographics, and an Artificial Intelligence Chatbot on how to work with children with challenging behaviors. Participants will receive the intervention once per week for up to 1 hour.
215092686|NCT01458834|BEHAVIORAL|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
214994803|NCT06374550|BEHAVIORAL|Jump Start Plus Coronavirus Support|The Jump Start Plus Coronavirus Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
214994804|NCT05142774|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.
214381126|NCT01222468|DRUG|nabilone 0.5 mg|nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
214381127|NCT01222468|DRUG|placebo|placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
214381128|NCT02478346|DRUG|Fluorescein Sodium|Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
214381129|NCT01250964|PROCEDURE|Lens insertion during cataract surgery|After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
214381130|NCT02321280|DRUG|Denosumab|Single dose subcutaneous administration
214994805|NCT00967785|DRUG|Mozobil (TM)|twice daily subcutaneous injection or via continuous subcutaneous infusion
214498122|NCT01005849|DIETARY_SUPPLEMENT|Protecflor|1 Capsule to be taken once a day during the entire study period
215092687|NCT02942654|DRUG|LY900014|Administered subcutaneously (SC)
214381131|NCT05363657|PROCEDURE|Partial Nephrectomy (PN)|Conservative removal of kidney tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
214381132|NCT05363657|PROCEDURE|Radical Nephrectomy (RN)|Surgical removal of the affected kidney. Adrenal removal can be performed according to surgeon choice and clinical characteristics of the renal tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
214381133|NCT05363657|PROCEDURE|Ablation therapy (AT)|The procedure of tumor ablation performed with radiofrequency or cryoablation. The procedure can be performed either with a laparoscopic approach or percutaneous access.
214381134|NCT05363657|DIAGNOSTIC_TEST|Active Surveillance (AS)|Active surveillance is defined as the initial management including the monitoring of renal tumor size by serial imaging with delayed treatment in case of progression.
214381135|NCT00612157|DRUG|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
214498123|NCT01005849|DIETARY_SUPPLEMENT|Placebo|1 Capsule to be taken once a day during the entire study period
214994806|NCT01903226|OTHER|High intensity training|
214994807|NCT01903226|OTHER|Moderate intensity training|
215092688|NCT02942654|DRUG|Insulin Lispro|Administered SC
214498124|NCT03378791|DRUG|Iron bisglycinate Oral Tablet|
214498125|NCT03378791|DRUG|Ferrous Fumarate Oral Tablet|
214498126|NCT00232375|DRUG|Insulin|
215092689|NCT01557959|DRUG|cisplatin|Given IV
214381136|NCT00612157|DRUG|Placebo control|Matching placebo
214381137|NCT00305500|DRUG|escitalopram|
214994808|NCT03112603|DRUG|Ruxolitinib|Ruxolitinib twice daily at the protocol-defined starting dose.
215092690|NCT01557959|BIOLOGICAL|pegfilgrastim|Given SC
215092691|NCT01557959|DRUG|erlotinib hydrochloride|Given PO
214381138|NCT04508296|DIAGNOSTIC_TEST|Goal directed de-escalation therapy|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI \> 650 mL/m2 or EVLWI \> 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI \< 650 mL/m2 or EVLWI \< 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL
214381139|NCT04566302|DEVICE|SECM Skin Imaging|Consented Participants will be asked to allow their forearm to be imaged by the dermatoscope on the same skin/lesions as a control comparison. We will be trying to image pigmented skin/lesions present on the forearm. This will be followed by imaging using the SECM Skin imaging device
214381140|NCT00965796|DRUG|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
214381141|NCT02111226|OTHER|SMS text messaging|short message service
214381142|NCT05822336|OTHER|Duration of Intramuscular Injections|This study was a single-group crossover clinical trial, where each participant acted as their own control. Two intramuscular injections into the right and left Dorsal Gluteal Region (DRG) were recorded for each participant. One was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. A day after, the same nurse gave the other injection in the opposite DGR, taking 40 seconds to administer. The five-second injections were considered the control group, while the 40 seconds injections were the intervention group. The order of interventions was randomized. The pain level was determined and recorded immediately after each injection.
214381143|NCT05885919|DRUG|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
214381144|NCT05885919|DRUG|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
214381145|NCT05437354|OTHER|survey|Oncology medical staff should respond to a survey
214498127|NCT05969899|DRUG|FOLFIRI+Bevacizumab|irinotecan liposome 60 mg/m2, iv, for at least 90 minutes LV 400 mg/m2, iv, for at least 2 hours FU 400 mg/m2, iv, followed by FU 2400 mg/m2, iv for at least 46 hours bevacizumab 5mg/kg IV. The above scenario is repeated every two weeks. Patients were treated until disease progression, toxic intolerance, initiation of a new antitumor therapy, withdrawal of knowledge, or investigator judgment that subjects should withdraw from study therapy.
214994809|NCT03112603|DRUG|Extracorporeal photopheresis (ECP)|Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
214381146|NCT06249490|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
214381147|NCT06249490|DEVICE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214687351|NCT06704724|COMBINATION_PRODUCT|Bevacizumab|VEG-F inhibitor
214687352|NCT06704724|COMBINATION_PRODUCT|Pembrolizumab|immune checkpoint inhibitor (PD-1 inhibitor
214687353|NCT06704724|COMBINATION_PRODUCT|Sasanlimab|immune checkpoint inhibitor (PD-1 inhibitor)
214687354|NCT06704724|COMBINATION_PRODUCT|pemetrexed|"Can be used in Platinum-based Chemotherapy regimen~Antimetabolite"
214994810|NCT03112603|DRUG|Low-dose methotrexate (MTX)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
214994811|NCT03112603|DRUG|Mycophenolate mofetil (MMF)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
214994812|NCT03112603|DRUG|mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
214687355|NCT06704724|COMBINATION_PRODUCT|Cisplatin|"Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)"
214687356|NCT06704724|COMBINATION_PRODUCT|Paclitaxel|"Can be used in Platinum-based chemotherapy regimen~Taxane"
214687357|NCT06704724|COMBINATION_PRODUCT|Carboplatin|"Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)"
214687358|NCT06704724|COMBINATION_PRODUCT|PF-07284892|SHP2 Inhibitor
214687359|NCT07036458|DRUG|14C Epaminurad Oral Solution|Subjects will receive a single administration of 14C Epaminurad Oral Solution
214994813|NCT03112603|DRUG|Infliximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
214994814|NCT03112603|DRUG|Rituximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
215092692|NCT01557959|OTHER|laboratory biomarker analysis|Optional correlative study
215092693|NCT01557959|GENETIC|polymorphism analysis|Correlative study
215092694|NCT01557959|OTHER|pharmacogenomic studies|Correlative study
214381148|NCT06249490|DRUG|Lidocaine Hydrochloride Injection|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
214498128|NCT01026805|DEVICE|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
214498129|NCT05901532|DRUG|Szechwan Lovage Rhizome, Biod Magnolia Bud, Taiwan Angelica Root, Wild Mint Herb, Baikal Skullcap Root, and Borneol|The bilateral nasal cavity was irrigated with a plastic bottle containing 1 gram of Szechwan Lovage Rhizome, 1 gram of Biod Magnolia Bud, 0.5 gram of Taiwan Angelica Root, 0.5 gram of Wild Mint Herb, 1.5 gram of Baikal Skullcap Root, and 0.5 gram of Borneol dissolved in 240 ml of warm normal saline once a day for 2 months.
214498130|NCT05901532|DRUG|edible caramel|The bilateral nasal cavity was irrigated with a plastic bottle containing edible caramel dissolved in 240 ml of warm normal saline once a day for 2 months.
214994815|NCT03112603|DRUG|Pentostatin|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
214994816|NCT03112603|DRUG|Imatinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
214994817|NCT03112603|DRUG|Ibrutinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
214994818|NCT05733286|DRUG|Suvorexant 20 mg|Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
214994819|NCT05733286|DRUG|Placebo|Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
214994820|NCT02817880|DEVICE|rTMS|
214994821|NCT02817880|DEVICE|tDCS|
214381149|NCT02749851|DEVICE|MRI|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
214498131|NCT05168397|OTHER|RV4857A|RV4857A formula CD2110 is a sunscreen product
214498132|NCT00442104|DRUG|Ganaxolone|
214498133|NCT00830856|DRUG|Fluconazole|Fluconazole 800mg po qday
214498134|NCT00830856|DRUG|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
214498135|NCT00830856|DRUG|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
214498136|NCT04881305|DIAGNOSTIC_TEST|questionnaires and neuropsychological assessment|Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
214994822|NCT02817880|DEVICE|tsDCS|
214994823|NCT05247047|DEVICE|TENA SmartCare Change Indicator|The intervention is a medical device system that consists of a reusable electronic sensor and an application installed on one or more smart phones. The device estimates the saturation level of an absorbing incontinence product used by a study subject. The device is non-invasive and does not have any effect on the function of the absorbing incontinence product.
214994824|NCT05618067|BEHAVIORAL|breathing exercise training|Participants will engage in weekly breathing exercises. They will be trained once a week for 4 weeks, and will use an app called Inner Balance and an device called Firstbeat Bodyguard 3 to track data about their hearts while practicing the exercises at home for 10 minutes a day, twice a day, once before bedtime.
214994825|NCT04433572|DRUG|Temsirolimus|0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
215092695|NCT01557959|GENETIC|genetic linkage analysis|Correlative study
215092696|NCT01557959|DRUG|docetaxel|Given IV
215092697|NCT01019837|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
215092698|NCT05690750|OTHER|No intervention|No intervention as this is an observational study.
215092699|NCT00151788|DRUG|Pactimibe sulfate|
215092700|NCT04730427|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
215092701|NCT04730427|DRUG|GX-I7 vehicle|Formulation buffer of recombinant human interleukin-7 hybrid Fc
215092702|NCT00888641|PROCEDURE|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
215092703|NCT05276895|DIETARY_SUPPLEMENT|Quercetin and Fisetin tab.|1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks over 15 weeks .
214381150|NCT02749851|DEVICE|MRI - IUGR|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
214381151|NCT01335503|DIETARY_SUPPLEMENT|AN-PEP|Endoprotease enzyme (AN-PEP)
214994826|NCT04433572|DRUG|Saline placebo|Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
214994827|NCT04696692|OTHER|Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.|"Blood samples will be collected :~* at baseline (before the 1st R-CHOP cycle)~* before the 3d administration of chemotherapy (CT) (i.e. after 2 cycles of CT and same timepoint as interim FDG-PET/CT)~* after the 4th administration of the CT~* at the end of induction (i.e. end of R-CHOP treatment)~* at 24 months after initiation of R-CHOP treatment~* at the time of progression (if progression occurs before 24 months of treatment).~Tumor samples will be collected at baseline (from an archived initial diagnostic tumor specimen) and at the time of progression (if applicable from lymph node biopsy performed as part of a standard of care surgical procedure).~Bone marrow samples will be collected at baseline and at the time of progression (if applicable) only in patients for whom a bone marrow aspiration (BMA) is necessary as part of their standard of care, upon physician's decision."
214994828|NCT05604417|DRUG|TAZEMETOSTAT|Dosage and treatment timings per protocol
214994829|NCT05604417|DRUG|Zandelisib|Dosage and treatment timings per protocol
214994830|NCT06285643|DRUG|AAV2-GDNF Gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
214994831|NCT06285643|PROCEDURE|Control Surgery|Bilateral partial burr/twist holes without dural penetration
214994832|NCT05791201|DRUG|VX-264|Allogeneic human stem cell-derived islets.
214994833|NCT03093844|DEVICE|Miltenyi CliniMACS® CD34 Reagent System|Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
214381152|NCT05016544|DRUG|inetetamab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
214381153|NCT05016544|DRUG|Pytotinib|"Starting pytotinib Dose of 240mg:~Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w."
214381154|NCT03278301|DEVICE|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
214381155|NCT00133939|PROCEDURE|Mechanical ventilation|
214381156|NCT04530539|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C, at bedtime
214687360|NCT03227848|DEVICE|Automated Heart Murmur Detection AI|Automated AI algorithm-based analysis of digital heart sound recordings to detect and classify heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. AI algorithm results for each recording include: AHA classification (Class I (pathologic heart murmur) versus class III (innocent heart murmur or no heart murmur), murmur timing, murmur grade, heart rate and S1/S2 identification.
214994834|NCT06791187|DRUG|dabigatran etexilate|dabigatran etexilate
214994835|NCT06791187|DRUG|BI 1291583|BI 1291583
214994836|NCT04123197|OTHER|Stress Challenge|The stress challenge will assess how different parts of the body react to stress. Participants will be given no specific details about the contents of the test before administration.
214994837|NCT03595150|DRUG|Diclofenac|Diclofenac rectally given before the ERCP to prevent pancreatitis
214994838|NCT06273618|OTHER|Micro-Learning|Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.
214994839|NCT06207305|DRUG|Dexamethasone|Given by PO
214994840|NCT06207305|DRUG|Diphenhydramine|Given by PO
214381157|NCT04530539|DIETARY_SUPPLEMENT|melatonin|10mg melatonin, at bedtime
214381158|NCT04530539|DIETARY_SUPPLEMENT|Placebo|Placebo at bedtime
214994841|NCT06207305|DRUG|Famotidine|Given by PO
214994842|NCT06207305|DRUG|Paclitaxel|Given by PO
214994843|NCT01336270|OTHER|biological collection|to collect some human cell samples in melanoma
214994844|NCT06551272|DRUG|EXL01|EXL01 contains an unmodified single strain of F. prausnitzii
214994845|NCT06833294|DEVICE|GentleFit Mask, Gentlefit Prong, Standard of Care Interface|The subject will be randomized to sequence of interfaces. The subject will wear each of three NIV interfaces for 8 cumulative hours, for a total of 24 hours. Pressure achieved using each GentleFit interface will be compared to pressure achieved by standard of care interface.
214994846|NCT06837857|DRUG|Opioid|Subjects will receive oral oxycodone as needed for pain which will be titrated weekly based on pain response, adverse effects, and patient preference. Subjects with intolerance to oxycodone will receive the equivalent dosing of morphine as an alternative.
214994847|NCT06837857|DRUG|Opioid Placebo|Subjects will receive a placebo capsule identical to oxycodone, which will similarly be titrated weekly. Subjects with intolerance to the first placebo will receive another placebo capsule identical to morphine.
214994848|NCT06836414|PROCEDURE|Low-dose Computerized tomography (CT) of Chest|Undergo CT for lung cancer screening
214994849|NCT06836414|OTHER|Questionnaires|Participants will complete questionnaires on or before the day of the scan.
214381159|NCT04530539|OTHER|Symptom Survey|Daily symptom survey to be completed by patient electronically
214687361|NCT06881459|OTHER|Placebo|Saline
214687362|NCT06881459|DRUG|Oxytocin|Oxytocin
214994850|NCT06836414|OTHER|Medical History|Medical history will be obtained in person and via medical record review
214994851|NCT06229912|DRUG|Revumenib|Given by PO
214994852|NCT03579888|BIOLOGICAL|Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|Given IV
214994853|NCT03579888|DRUG|Cyclophosphamide|Given IV
214994854|NCT03579888|DRUG|Fludarabine|Given IV
214381160|NCT03900377|DRUG|SyB L-0501RI|The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
214381161|NCT00175461|PROCEDURE|hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty
214381162|NCT01247519|OTHER|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
214381163|NCT06062940|BEHAVIORAL|SHARE Approach|The SHARE Approach training was given at each of these centers, teaching skills to clinicians about shared decision making.
214994855|NCT06836258|OTHER|AI assisted documentation|This study will use Gosta Aide AI-assisted documentation platform
214994856|NCT06485245|DRUG|CS060304|Tablets administered orally
214381164|NCT00668499|DRUG|VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin|VEGF-AS either 100 or 200mg/m2 IV days 1-5, Pemetrexed 500mg/m2 and Cisplatin 75mg/m2 IV on day 1. Cycle repeated every 3 weeks until 6 cycles completed, unless PD or toxicities
214994857|NCT04590326|DRUG|REGN5668|Administer per the protocol
214381165|NCT04232046|OTHER|Massage|Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.
214381166|NCT03115749|OTHER|Intestinal biopsies during colonoscopy|Intestinal biopsies during colonoscopy
214381167|NCT03115749|OTHER|Biopsies taken on surgical specimen|biopsies taken on surgical specimen after intestinal resection
214381168|NCT00885573|DEVICE|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
214381169|NCT01287637|PROCEDURE|Early reversal of temporary ileostomy|Temporary ileostomy is reversed 8-13 days after the primary surgery
214381170|NCT01287637|PROCEDURE|Standard reversal of temporary ileostomy|Patients in the control group will have the ileostomy reversed according to standard treatment, which is 12-26 weeks after primary operation
214381171|NCT00034840|DRUG|telmisartan, valsartan|
214381172|NCT04481828|PROCEDURE|gastrectomy|gastric resection with lymph node dissection(D1+,D2) for stomach cancer.
214381173|NCT03187015|DRUG|Entinostat|HDAC (histone deacetylase inhibitor)
214381174|NCT03187015|DRUG|Midazolam|benzodiazepine central nervous system (CNS) depressant
214381175|NCT02841293|PROCEDURE|Biological mesh|The intervention consists of suturing a biological mesh in the pelvic floor defect. The mesh will be sutured at each side of the coccyx or distal sacrum and directly to the residual pelvic floor muscle and fascia by using interrupted or continuous hand-sewn sutures with an appropriate amount of tension. The mesh that will be used is the Cellis prosthesis from Meccellis Biotech, reference C1015E which size is 10x15cm.
214381176|NCT02841293|PROCEDURE|Primary perineal wound closure|The intervention consists of stitching the ischioanal and subcutaneous fat using interrupted Vicryl sutures in one or two layers similar to primary perineal closure
214994858|NCT04590326|DRUG|Cemiplimab|Administer per the protocol
214994859|NCT04590326|DRUG|Ubamatamab|Administer per the protocol
214381177|NCT05737433|DRUG|[14C]-rencofilstat 225mg|radio-labelled 225mg oral dose of rencofilstat
214381178|NCT00274001|DRUG|Nevirapine|
214381179|NCT04303312|OTHER|Benzydamine Hydrochloride|Patients will rinse by mouth three times daily for 20 days
214498137|NCT05458466|OTHER|Pilates training|Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
214994860|NCT04590326|DRUG|Sarilumab|Administer per the protocol
214994861|NCT04590326|DRUG|Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]|Administer per the protocol
214994862|NCT05219552|BEHAVIORAL|personalized lactation support|Our intervention design aims to address food insecurity and mental health by providing an unconditional cash transfer and lactation support across the perinatal period, when women are out of the workforce caring for their infant child. The study will include pregnant women living with HIV in Kisumu Kenya. The lactation support component will focus on milk insufficiency primarily as that has been a main concern of women we've worked with in this population, in addition to general breastfeeding support which will all be delivered in one-on-one sessions with a professional lactation consultant. The cash transfer will be delivered to women from their third trimester to 6 months postpartum. The amount of the cash transfer is based on preliminary data and consultation with key stakeholders to determine a reasonable and sufficient amount to basic living expenses during this period.
214381180|NCT04303312|COMBINATION_PRODUCT|Solcoseryl and pumpkin seed oil|Patients will receive by mouth three times daily for 20 days
214381181|NCT00868699|DRUG|lurasidone|lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
214994863|NCT03916926|DEVICE|"A simple medical strategy consisting of silver diamine fluoride (SDF)"|Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)
214381182|NCT00868699|DRUG|lurasidone|lurasidone 20 mg/day for Days 1-7
214381183|NCT00868699|DRUG|Placebo|Placebo Comparator
214381184|NCT01834222|BIOLOGICAL|Non-intervention|Non-intervention
215092704|NCT05276895|DIETARY_SUPPLEMENT|Quercetin Cap/Tab,Fisetin Cap/tab and Glycyrrhizin capsules|quercetin + Fisetin for 3 consecutive days followed by 100mg/day glycyrrhizin for one week every 3 weeks over 15 weeks
214994864|NCT03916926|DEVICE|"B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)"|GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
214994865|NCT05359484|DIAGNOSTIC_TEST|Uroflowmetry|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.
214381185|NCT02398968|DIETARY_SUPPLEMENT|iron fumerate|iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
214381186|NCT04251065|DRUG|Daratumumab|"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP).~Induction phase:~4-6 courses (according to response after cycle 4 and to patient compliance) of D-GDP every 21 days pursuant to the following schedule: Daratumumab cycle 1: 8 mg/kg i.v. on day 2 and on day 9; cycle 2-6: 16 mg/kg i.v. on day 2 and day 9) Gemcitabine 1000 mg/sm i.v. day 1 and day 8 (gemcitabine on day 8 to be skipped in case of grade 3-4 toxicity) Cisplatin 75 mg/sm i.v. day 1 Dexamethasone 40 mg i.v. or po days 1-2-3-4-9 G-CSF from day 3 to 6, and from day 10 to 13 (to be prolonged if necessary)~Maintenance:~starting 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade \> 1, after toxicity is resolved) and up to 24 cycles from start of D-GDP according to the following schedule: Daratumumab 16 mg/kg single administration every 28 days."
214381187|NCT03892629|BEHAVIORAL|Baduanjin exercise|Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
214498138|NCT01267643|DRUG|Alefacept|"Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly"
214498139|NCT01857076|PROCEDURE|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
214498140|NCT01857076|PROCEDURE|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
214994866|NCT00950001|RADIATION|Stereotactic Radiosurgery|Undergo SRS
214994867|NCT05639556|DIAGNOSTIC_TEST|BMI and lean mass index from DXA|Estimate and compare correlation between lean mass index from DXA and BMI
215092705|NCT05276895|OTHER|Placebo|Placebo capsule for one week every 3 weeks over 15 weeks
215092706|NCT03623061|DIAGNOSTIC_TEST|F-Point|F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
214498141|NCT01857076|OTHER|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
214994868|NCT05639556|DIAGNOSTIC_TEST|Anthropometric Measurements|Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.
214994869|NCT05639556|DIAGNOSTIC_TEST|Hand-grip strength|A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.
214994870|NCT05639556|DIAGNOSTIC_TEST|Six-minute walk Test|This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.
215092707|NCT01012921|DEVICE|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
214381188|NCT03892629|DEVICE|Instrument rehabilitation|Participants received pulmanory rehabilitation by using tri-ball respiratory trainer. Each instrument exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
214381189|NCT04813601|DEVICE|ATLAS 2030|The participant will attend the laboratory every week, two days a week. The therapy will consist of the use of the exoskeleton for rehabilitative purposes. At the end of each three-month period, each patient's data will be monitored.
214381190|NCT03213990|OTHER|Continuous infusion|Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
214994871|NCT05639556|DIAGNOSTIC_TEST|Sit-to-Stand Test|This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.
215092708|NCT01012921|DEVICE|MembraGel|Device application at surgery
215092709|NCT01012921|OTHER|Bio-Gide® membrane|Device application at surgery
214381191|NCT03213990|OTHER|Intermittent infusion|Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
215092710|NCT04266470|DEVICE|Lara Scan|"Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan."
214994872|NCT05639556|DIAGNOSTIC_TEST|Short physical performance battery (SPPB)|This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).
214994873|NCT05639556|DIAGNOSTIC_TEST|BIA Sub-study|A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).
214994874|NCT05639556|DIAGNOSTIC_TEST|Accelerometry to assess physical activity|Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.
214994875|NCT05639556|OTHER|Gastrointestinal (GI) and nutrition questionnaires:|Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).
214994876|NCT05639556|OTHER|Psychosocial questionnaire: PHQ-8|This is an 8-item scale that measures depressive symptoms over the past two weeks.
214994877|NCT05639556|OTHER|Psychosocial questionnaire: GAD-7|This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.
214381192|NCT02694003|BEHAVIORAL|BNBD-NDD Intervention|The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
214994878|NCT05639556|OTHER|Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)|This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.
214381193|NCT04244435|PROCEDURE|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
214381194|NCT04244435|DRUG|thoracic epidural analgesia|thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)
214381195|NCT04244435|DRUG|analgesia of opioids|Opioids will be used for perioperative analgesia
214381196|NCT00235924|DRUG|soy isoflavone|
214381197|NCT06107764|DEVICE|intermittant theta burst stimulation (iTBS)|iTBS consists of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.
214498142|NCT02530892|PROCEDURE|EmbryoHug|"An oocyte or embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the oocyte or embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the oocyte or embryo."
214498143|NCT05518214|DIETARY_SUPPLEMENT|Beetroot|Participants receive a 12-week supply of beetroot juice.
215092711|NCT04266470|DIAGNOSTIC_TEST|PET/CT Scan - Pre-treatment and Post-treatment|The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
215092712|NCT02679820|DEVICE|Copper T intrauterine device|
215092713|NCT02334397|BEHAVIORAL|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
215092714|NCT01072825|OTHER|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
214381198|NCT06107764|DEVICE|continuous theta burst stimulation (cTBS)|cTBS consists of 3 pulses at 50 Hz repeated at 5 Hz (every 200ms) continuously for a total of 600 pulses
214381199|NCT06107764|DEVICE|sham rTMS|sham rTMS does not deliver a significant change in magnetic field strength
214381200|NCT01031875|DRUG|pazopanib hydrochloride|
214381201|NCT01031875|RADIATION|fludeoxyglucose F 18|
214381202|NCT01696318|BEHAVIORAL|Support for the Family Health Team|Participation in physical educator, dietitian and pharmacist in primary health care
214381203|NCT03282279|PROCEDURE|TVOR|Ultrasound guided transvaginal oocyte retrieval (TVOR) in deep sedation for IVF.
214498144|NCT05518214|DIETARY_SUPPLEMENT|Placebo|Participants receive a 12-week supply of placebo beetroot juice.
214381204|NCT01222429|OTHER|vegan diet|Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study
214498145|NCT01584167|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
214498146|NCT01584167|DEVICE|EMCOOLS Flex.Pads|Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
214994879|NCT05639556|OTHER|Psychosocial questionnaire: CF Fatalism Scale|The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.
214994880|NCT05639556|OTHER|Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)|The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.
214994881|NCT05639556|OTHER|12-month Questionnaire|A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.
214994882|NCT05639556|OTHER|Oral glucose tolerance testing (OGTT)|For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.
214994883|NCT05639556|DEVICE|Continuous glucose monitoring (CGM)|Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.
214994884|NCT05639556|DIAGNOSTIC_TEST|Chest CT scans (When available within the past 6 months in medical records)|Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.
214994885|NCT05639556|DIAGNOSTIC_TEST|Hologic Dual X-Ray Absorptiometry (DXA)|DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.
214381205|NCT01222429|OTHER|diet following ADA guidelines|participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
214381206|NCT02013336|DRUG|MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide|chemotherapy
214994886|NCT05639556|DIAGNOSTIC_TEST|Ultrasound Sub-study of assessment of appendage muscles using ultrasound|A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.
214381207|NCT04521517|BEHAVIORAL|pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning|a pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning
214381208|NCT02207517|PROCEDURE|Office-based vergence/accommodative therapy|The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
214994887|NCT05639556|DIAGNOSTIC_TEST|Psychosocial questionnaire: Hunger Vital Sign questionnaire|Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.
214498147|NCT05483985|DEVICE|Hera Score|The device uses patient metadata (patient age, day of image capture) and a software algorithm to analyze features of the blastocyst morphology to provide adjunctive information that may predict further development of the embryo to clinical pregnancy after embryo transfer.
214994888|NCT05639556|OTHER|Respiratory symptom questionnaire: CRISS|Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.
214498148|NCT06476769|OTHER|blow bottle technique|There were 20 patients in group A received blow bottle device and postural drainage for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
214994889|NCT05639556|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.
214994890|NCT05639556|OTHER|Psychosocial questionnaire: Additional Health Questionnaire|Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.
214994891|NCT05639556|OTHER|CF Management Questionnaire|Assessment of prior 12-month management of cystic fibrosis, including treatments, medication intake and hospitalizations. This questionnaire will only be completed at 24- and 36- month visits.
214994892|NCT05639556|OTHER|Food Frequency Questionnaire|Assessment of prior 12-month nutritional intake being completed at Baseline (no later than 6-month visit) and 12-month visit.
215092715|NCT01072825|BIOLOGICAL|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if\> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
215092716|NCT01072825|OTHER|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
214498149|NCT06476769|OTHER|percussion|Group B: There were 20 patients in group B received postural drainage with percussion for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
214498150|NCT04680845|BEHAVIORAL|Self-affirmation|According to self-affirmation theory (Steele, 1988), defensiveness arises because people are motivated to defend their global sense of self-worth, which in the present case is threatened by perceptions of hearing aids/loss. However, if a person's self-image can be bolstered (affirmed) in a domain that is important to them, thereby preserving self-integrity, the individual should be less likely to process the threatening (i.e., stigmatizing in the present context) information defensively (Steele, 1988).
214498151|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
214498152|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
214687363|NCT07043335|DEVICE|Extracorporeal Shock Wave Therapy|For patients in Group 2, Extracorporeal Shock Wave Therapy will be applied to the lateral epicondyle area at 10-15 Hz frequency, 1.5-2.5 bar energy density, and 2000 pulses. Patients will receive a total of 5 sessions of Extracorporeal Shock Wave Therapy (ESWT), with one session every 7 days.
214994893|NCT06442033|OTHER|High intensity stationary cycling|All community based exercise sessions are: 3x/week for 40 min, which includes a 5-min warm up \& cool down and a 30-minute main exercise set. Exercise parameters will be set by a neurologically trained physical therapist and will be progressed over time with the ultimate goal of the individual reaching moderate-vigorous exercise. Moderate-vigorous exercise for this project is defined as a cadence of 75+ rpms and a target HR of 60-80% of their age-predicted max
214994894|NCT03422302|DEVICE|Biphasic Positive Airway Pressure|Receive BiPAP
214994895|NCT03422302|PROCEDURE|Computed Tomography|Undergo CT simulation scans
214994896|NCT03422302|PROCEDURE|Continuous Positive Airway Pressure|Receive CPAP
214994897|NCT03422302|PROCEDURE|Deep Inspiration Breath Hold|Complete DIBH
214994898|NCT03422302|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo CT simulation scans
214994899|NCT03422302|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214994900|NCT06358885|OTHER|Facilitation (FAC)|The facilitation approach will use a flexible clinic level implementation strategy that helps clinics to address common barriers, such as counselor skills, competing priorities, and resource deficits.
214994901|NCT06358885|BEHAVIORAL|Experiential Brief Alcohol Intervention (EBAI)|Clinic staff will be offered the experiential BAI prior to implementation. The BAI comprises 2 in-person sessions and 2 booster phone sessions. Clinic staff responsible for delivering the BAI to PWH participants will be offered 3 additional consolidation sessions to integrate their experiences receiving the BAI with their delivery of the BAI.
214994902|NCT04763980|OTHER|Educational Intervention|Participate in educational session with health coach
214994903|NCT04763980|OTHER|Genetic Testing|Undergo genetic testing
214994904|NCT04763980|OTHER|Survey Administration|Complete surveys throughout course of study.
214994905|NCT04763980|OTHER|ProGene Artificial Intelligence (AI) Platform|AI Platform to be used by health coach during sessions
214994906|NCT04763980|OTHER|Interviews|Participant and provider interviews will be conducted by study staff.
214994907|NCT06798974|OTHER|Three-dimensional video|Patients who meet the criteria for inclusion in the study will be randomly assigned to intervention and control groups. The intervention group will be shown a 3D lemon video with virtual reality glasses. The video will be created by a company that shoots 3D videos. Opinions of three experts will be obtained for the suitability of the video. The video will be shown to patients for 5 minutes. In order to control the effects that may arise from the practitioner during the study, the virtual reality glasses application will be applied to all patients by the same clinic nurse. The control group will not receive any intervention and will receive standard care. Data collection forms will be given to the patient by the researcher and will be collected after the patient fills them out.
214994908|NCT03330197|BIOLOGICAL|Ad-RTS-hIL-12|2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
214994909|NCT03330197|DRUG|Oral Veledimex - Arm 1 (Pediatric Brain Tumor)|1 dose level (10mg/day) 15 oral daily doses of veledimex
214994910|NCT03330197|DRUG|Oral Veledimex - Arm 2 (DIPG)|2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
214994911|NCT02654574|OTHER|IADL administration by phone|The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
215092717|NCT01072825|OTHER|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
215092718|NCT01072825|OTHER|Bone evaluation|PQCT scanner, BMD assessment
215092719|NCT02861911|OTHER|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
215092720|NCT02861911|DEVICE|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
215092721|NCT03738319|GENETIC|Sequencing of miRNA/lncRNA|Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
214687364|NCT07043335|PROCEDURE|Mesotherapy|Intradermal mesotherapy involving lidocaine, pentoxifylline, meloxicam, and thiocolchicoside will be applied to painful elbow points using a 4 mm, 30G needle in a point-by-point technique at a 90° angle (0.1 cc per point). A nappage technique at a 45° angle will then be applied around the common extensor tendon. A total of five sessions will be administered, one every 7 days.
215092722|NCT04723225|OTHER|Cat-Cow Yoga|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided
215092723|NCT04794764|DEVICE|McGrath Mac|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
215092724|NCT04794764|DEVICE|Macintosh Laryngoscope|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
215092725|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
215092726|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
215092727|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
215092728|NCT02633553|RADIATION|adjuvant radiotherapy|50Gy/25Fx
215092729|NCT01360177|PROCEDURE|124 PET/CT imaging|Standard of Care
215092730|NCT01360177|DRUG|Na134I|25 to 150 mCi
215092731|NCT01360177|DRUG|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
215092732|NCT01360177|DRUG|Tri-iodothyronine|20 mg/day x 2
215092733|NCT01496105|DRUG|Lidocaine|
215092734|NCT01496105|DRUG|saline|
214381209|NCT02243774|BEHAVIORAL|Core letter signed by Surgeon General|The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
214994912|NCT06042140|DEVICE|NEOX Cord 1K applied fetoscopically|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (human umbilical cord) will be used for skin closure at the discretion of the Pediatric Neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
214994913|NCT04030559|DRUG|Niraparib|Given PO
214994914|NCT04030559|DRUG|Niraparib Tosylate Monohydrate|Given PO
214994915|NCT04030559|PROCEDURE|Radical Prostatectomy|Undergo standard of care surgery
214994916|NCT04667234|DRUG|AMG 510|Administered as an oral tablet.
214994917|NCT02436707|DRUG|Ibrutinib|
214994918|NCT02436707|DRUG|Rituximab|
214994919|NCT02436707|DRUG|Gemcitabine|
214994920|NCT02436707|DRUG|Dexamethasone|
214994921|NCT02436707|DRUG|Cisplatin|
214994922|NCT02436707|DRUG|Mesna|
214994923|NCT02436707|DRUG|Cyclophosphamide|
214994924|NCT02436707|DRUG|Etoposide|
214994925|NCT02436707|DRUG|G-CSF|
214994926|NCT02436707|DRUG|Selinexor|
214994927|NCT04315142|DEVICE|Experimental TTNS|30-minute TTNS intervention is performed 2 days a week during a treatment period of 6 weeks
214994928|NCT04315142|DEVICE|Sham TTNS|30-minute sham intervention is performed 2 days a week during a treatment period of 6 weeks
214381210|NCT02243774|BEHAVIORAL|Core letter signed by the Director of the National Vaccine Program|The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
214381211|NCT02243774|BEHAVIORAL|Core letter signed by Surgeon General + implementation prompt|The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.
214381212|NCT02243774|BEHAVIORAL|Core letter signed by SG + enhanced implementation prompt|"The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to decide now - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated."
214381213|NCT05453175|OTHER|Interrupting sitting with Physical activity|Participants will engage in three minutes of walking, five sit to stands and five calf raises every thirty minutes
214994929|NCT04981613|DRUG|Kunxian capsule|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
214994930|NCT06485258|BIOLOGICAL|3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection
214994931|NCT06485258|BIOLOGICAL|7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection
214994932|NCT06485258|OTHER|Placebo|0.5 mL sterile saline administered via IM injection
214994933|NCT05261425|DEVICE|Monocryl buried|Participants randomized to this group will receive the Monocryl (suture) buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
214994934|NCT05261425|DEVICE|Nylon (FDA Approved) not buried|Participants randomized to this group will receive the Nylon (FDA Approved) (suture) not buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
214994935|NCT06236516|RADIATION|One fraction stereotactic body radiotherapy|Radiotherapy will consist of one-fraction SBRT using the Ethos linear accelerator and online adaptive treatment planning system.
214994936|NCT06236516|DEVICE|HyperSight|HyperSight is a novel on-board imaging platform equipped with rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for both simulation and treatment.
214994937|NCT06236516|DEVICE|Ethos|Ethos is a unique ring-gantry CT-guided linear accelerator notable for having a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
214994938|NCT04801329|DRUG|Vyndamax (tafamidis 61mg)|As prescribed in real world practice
214994939|NCT03456778|DEVICE|Shear Wave Elastography|An ultrasound (US) technique, known as shear wave elastography (SWE), is used to examine structure and biomechanical function. The examination takes place in the ultrasound room at the study site and lasts for approximately 20 minutes.
215092735|NCT01020708|DRUG|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
215092736|NCT01020708|DRUG|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
215092737|NCT01020708|DRUG|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
214381214|NCT04091360|DRUG|Part A: RPL554|Single dose RPL554 via metered dose inhaler.
214381215|NCT04091360|DRUG|Placebos|Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
214381216|NCT04091360|DRUG|Part B: RPL554|Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
214381217|NCT03813628|OTHER|polished celtra press full coverage crown|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
214381218|NCT03813628|OTHER|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
214381219|NCT03813628|OTHER|contralateral natural teeth|the polished and glazed all ceramic crowns will be compared by the contralateral natural teeth
214381220|NCT00440089|BEHAVIORAL|Hands-on-Healing|
214381221|NCT01998490|OTHER|Animal-assisted activity|
214381222|NCT01998490|OTHER|Robot-assisted activity|
214498153|NCT00987272|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
214498154|NCT00987272|DRUG|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
214381223|NCT02230436|OTHER|Early drain removal|Removing drain(s) on postoperative day 3
214381224|NCT02230436|OTHER|Late drain removal|Removing drain(s) on postoperative day 4 or later
214381225|NCT05799664|DEVICE|TLD|Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.
214381226|NCT05799664|OTHER|Sham TLD procedure|Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.
214381227|NCT05799664|OTHER|Standard of care|Patients will also receive standard of care that meet the recommendations of GOLD guideline.
214381228|NCT04266288|DRUG|Ketamine|Active drug
214381229|NCT04266288|DRUG|Sodium Chloride 0.9%|Placebo
214381230|NCT05108064|DIAGNOSTIC_TEST|Artificial intelligence model|Results of artificial intelligence model will be compared with the gold standard
214381231|NCT01426282|OTHER|no intervention|no intervention
214381232|NCT01426282|OTHER|health education|"15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults "
214381233|NCT00572338|OTHER|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
214381234|NCT04339517|PROCEDURE|Aspiration of seroma fluid|Fluid will be collected from the lumpectomy site of patients between one to six weeks post-surgery and tested for the presence of persistent tumor cells (PTCs).
214381235|NCT02544802|DRUG|Adipose-Derived Mesenchymal Stem Cells|
214381236|NCT00779558|DRUG|Heparin sulfate infusion at 10 units/kg/hour|Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
214381237|NCT00779558|DRUG|Placebo infusion|Infusion of normal saline
214381238|NCT00980005|BIOLOGICAL|GSK investigational vaccine GSK1557482A|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
214381239|NCT00980005|BIOLOGICAL|Fluzone®|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
214381240|NCT01774318|OTHER|aEEG and conventional EEG measurement|aEEG and conventional EEG measurement including video-polysomnography
214381241|NCT03934632|OTHER|Postabsorptive|Saline will be infused to mimic postabsorptive circulating amino acid concentrations
214381242|NCT03934632|OTHER|Postprandial|An amino acid infusate will be administered to mimic postprandial circulating amino acid concentrations
214381243|NCT03934632|PROCEDURE|Immobilisation|One leg will undergo 2 days immobilisation prior to the test day
214498155|NCT03328364|DRUG|enzalutamide|oral
214498156|NCT03328364|DRUG|docetaxel|intravenous infusion
214498157|NCT05995262|OTHER|Chart Review|Data collection via retrospective chart review of patients from the Cedar Hill Clinic who had at least two visits with the clinical pharmacist between January 5, 2022 through December 31, 2022
214498158|NCT06950749|PROCEDURE|Robotic Gloves assisted Task-oriented mirror therapy|"Robotic gloves assissted task-oriented Mirror therapy along with conventional therapy.~Conventional therapy consists of stretching exercises,active assisted and active ROMS of shoulder along with weight bearing and reaching activities.~Robotic gloves assisted task-oriented Mirror therapy will be delivered by syrebo robotic hand rehabilitation device.~it has different training modes including Mirror mode and task-oriented training.~5 sessions per week will be provided for 8 weeks exercises: 30 minutes (3 sets of 10 reps)~* In mirror training mode: Synchronized flexion and extension training with both hands."
214687365|NCT07039045|DRUG|LY4065967|Oral dose
214687366|NCT07039045|RADIATION|[14C]-LY4065967 Oral|Oral dose
214687367|NCT07039045|RADIATION|[14C]-LY4065967 IV|IV dose
214687368|NCT01064648|DRUG|Cediranib Maleate|Given orally
214687369|NCT01064648|DRUG|Cisplatin|Given IV
214994940|NCT05776966|BEHAVIORAL|Gender-specific digital intervention (GSDI)|The GSDI is a digital intervention that incorporates factors that are more prevalent in women with opioid use disorder that may affect their treatment outcomes. The content for the intervention was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes.
214994941|NCT05776966|OTHER|Treatment as usual|Participants will receive treatment as usual for opioid use disorder which is a mix of medication treatment and individual and group therapy services across various levels of care.
214994942|NCT04553718|OTHER|experimental group|provide mHealth program, which has pregnant women using wearable device and app
214994943|NCT06229717|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
214994944|NCT06229717|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
214994945|NCT06229717|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
214994946|NCT06229717|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
214994947|NCT06229717|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
214994948|NCT06409156|PROCEDURE|Oblique Subcostal Transversus Abdominis Plane Block|With the OSTAP block, local anesthetic is injected into the fascial plane between the posterior rectus sheath and the transversus abdominis muscle beneath the subcostal margin.
214381244|NCT00572624|BEHAVIORAL|Diet|Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
214381245|NCT00572624|PROCEDURE|Gastric bypass surgery|The same surgeon performed all bypass procedures using standard techniques. A small (\~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
214381246|NCT01026714|DRUG|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
214381247|NCT01026714|DRUG|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
214498159|NCT06950749|PROCEDURE|Task-Oriented Mirror Therapy|"Interventional group (B) will receive Task-Oriented Mirror Therapy along with conventional therapy.~To perform Task-Oriented Mirror Therapy both the extremities of the subject will be placed on the table and the mirror (40×60 cm) will be placed in the patients' mid-sagittal plane. Mirror will be placed in such a way that the reflection of the non-affected arm can be seen. The subjects will be instructed to perform the movement bilaterally. The movement on the impaired limb will be performed. Affected arm is involved in exercise therapy either through patients trying to move themselves or with a therapist in assisting movement.~5 sessions per week will be provided for 8 weeks.~* Task-Oriented Mirror therapy exercises: 30 minutes. (3 sets of 10 reps)~* Hand flexion and extension through the tennis ball.~* Grasping and releasing (cylindrical grasp, spherical grasp, hook grasp, pincer grasp)~* Task oriented activities: positioning the cup upright, carrying a woode"
214498160|NCT04732000|DRUG|N-acetyl cysteine|Intravenous infusion started during the clinically indicated surgery at a rate of 50mg/kg over 1 hour followed by 50mg/kg over 3 hours. This will be an accumulated total of 100 mg/kg over 4 hours.
214994949|NCT06409156|PROCEDURE|External Oblique Intercostal Fascial Plane block|With the EOIF block, local anesthetic targets the terminal part of the thoracoabdominal nerves pass behind the costal cartilage and continue anteriorly in the plane between the internal oblique and transversus abdominis muscle, before piercing the rectus abdominis sheath as anterior cutaneous branches supplying the skin of the midabdomen.
214994950|NCT02693067|DRUG|Rose bengal disodium|Percutaneous intralesional injection to NET tumor
214498161|NCT04732000|OTHER|Normal Saline|Intravenous infusion at a time and rate to mimic the active treatment. The infusion will be given over 4 hours beginning during the clinically indicated surgery
214687370|NCT01064648|OTHER|Laboratory Biomarker Analysis|Correlative studies
214687371|NCT01064648|DRUG|Pemetrexed Disodium|Given IV
214687372|NCT01064648|OTHER|Placebo Administration|Given orally
214381248|NCT01026714|DRUG|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
214381249|NCT00419653|DRUG|Amisulpride|
214381250|NCT00419653|DRUG|Olanzapine|
214994951|NCT06067711|DEVICE|resistance band|The program will consist of six exercises: triceps press, biceps curl, lat pull down, leg press, leg extension and sit-ups using resistance band.
214687373|NCT06731933|DRUG|BVEC|The study drug will be administered by home nurse at Subjects home for the participants residing in US. No drug will be applied when at study site. The subjects enrolled in Bari, Italy will not be administered BVEC.
214687374|NCT06733519|DRUG|Nalmefene|Th-104 Nalmefene Mucoadhesive Buccal strip
214687375|NCT06733519|DRUG|Placebo|Matching placebo to TH-104
214994952|NCT05047302|DEVICE|BlueLeaf Procedure|The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
214994953|NCT02290418|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
214994954|NCT02290418|PROCEDURE|Omega-Loop Gastric Bypass|Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
214994955|NCT01124253|DRUG|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
214687376|NCT00977574|BIOLOGICAL|Bevacizumab|Given IV
214994956|NCT02222467|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers.
214994957|NCT02404142|DRUG|Curare (Atracurium)|Curare (Atracurium) versus saline isotonic solution for tracheal intubation
214994958|NCT02404142|DRUG|saline isotonic solution|
214994959|NCT01650428|BIOLOGICAL|Bevacizumab|5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).
214994960|NCT01650428|DRUG|Irinotecan|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
214994961|NCT01650428|DRUG|Oxaliplatin|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
214994962|NCT01650428|DRUG|5-Fluorouracil|3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
214994963|NCT01416662|DRUG|gemcitabine hydrochloride|
214994964|NCT06962345|DEVICE|Hormone-free vulvovaginal gel with tested composition XCM® INTIM and PROMs questionnaire.|"Management of GSM in post-menopausal women will be measured with the combination of the application of the hormone-free vulvovaginal gel along the 8 weeks of the study and the use of a PROMs questionnaire. PROMS questionnaire will be delivered to the women at baseline and at the end of the study. Daily living quality of life domains of activities of daily living, emotional well-being, sexual functioning, self-perception and body image will be evaluated."
214994965|NCT06961851|OTHER|aTMS utilizing the MagVenture TMS device|Participants will complete 6 MagVenture TMS sessions per day for 5 days at the SLP Clinic. Sessions will take place with at least 30 minutes between each session. The first session will determine the baseline motor threshold for delivering aTMS. We will be stimulating the dorsolateral prefrontal cortex (DLPFC) which is within the FDA approved uses. Participants will complete a PHQ9 on all 5 treatment days and 1, 2, 4, and 6 weeks post treatment via REDCap Participants will complete daily adverse event logs via REDCap
214994966|NCT06963177|DRUG|GenSci048|Administered SC.
214994967|NCT06963177|DRUG|Placebo|Administered SC.
214994968|NCT02854462|BEHAVIORAL|Language comprehension intervention|
214994969|NCT02854462|BEHAVIORAL|Counting intervention|
214994970|NCT06962904|BIOLOGICAL|3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection
214381251|NCT00419653|DRUG|Haloperidol|
214381252|NCT02951559|DEVICE|Nasal Brushing|"Nasal brushing will be performed in non-sedated patients as follows. After administration of a local vasoconstrictor (1% epinephrine) with the use of a nasal tampon, inserted into the nasal cavity of the patient to locate the olfactory mucosa lining the nasal vault. A sterile, disposable brush (Copanflock, Copan, Brescia, Italy) will be inserted gently rolled on the mucosal surface, withdrawn,and immersed in 0.9% saline solution, UTM (Universal Transporter Medium) or 4% formaldehyde. Two swabs will be collected for each nostril."
214381253|NCT05433155|DEVICE|Nasotracheal intubation|Nontracheal intubation using clinical standard videolaryngoscopy or direct laryngoscopy
214381254|NCT03102658|DRUG|Micafungin|Administration of study drug
214381255|NCT00640796|PROCEDURE|Haploidentical donor derived natural killer cell infusion|Therapeutic cell infusion
214381256|NCT00640796|DRUG|Chemotherapy|Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
214381257|NCT00640796|DEVICE|CliniMACS|Cell selection system based on magnetic-activated cell sorting
214381258|NCT04588233|DIETARY_SUPPLEMENT|Melatonin|Each subject will receive 3mg of melatonin 1 hour prior to bedtime for 12 consecutive nights
214381259|NCT04588233|OTHER|Placebo|Each subject will receive a placebo 1 hour prior to bedtime for 12 consecutive nights
214381260|NCT03179943|DRUG|Atezolizumab|Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
214381261|NCT03179943|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
214381262|NCT04060225|OTHER|Coffee|Starbuck's brand blonde roast coffee, 20 ounces
214381263|NCT00548067|DRUG|Valsartan/hydrochlorothiazide (HCTZ)|
214381264|NCT00548067|DRUG|Valsartan/amlodipine|
214381265|NCT00548067|DRUG|Amlodipine/hydrochlorothiazide(HCTZ)|
214381266|NCT00548067|DRUG|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
214381267|NCT00181090|BEHAVIORAL|Modified Atkins diet|
214381268|NCT00709748|DEVICE|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
214381269|NCT00709748|DEVICE|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
214994971|NCT06962904|BIOLOGICAL|7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection
214381270|NCT05059054|OTHER|Strengthening exercise|"Strengthening exercise program Participants performed this protocol at home for 3 times per day. The participants progress their exercise based on the achievement of the previous level of each exercise protocol. The physical therapist recorded the level of each exercise for each participant during eight times of treatment. Total time for this section is approximately 30 minutes. Detail of the strengthening exercise is in the following.~1. Toe curl exercise (toe flexors strengthening)~2. Ankle evertor exercise (peroneal strengthening)~3. Ankle invertor exercise (tibialis posterior strengthening)~4. Heel raise exercise (high-load strength training)"
214381271|NCT05059054|OTHER|Insole (CFO) group|"The CFO insole group The participants will receive the foot assessment before making the CFO for each participant. The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC) and one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort.~The participants will be asked to use the CFO in daily life during weight-bearing activities."
214381272|NCT02104635|BEHAVIORAL|Delivery of a Post-Partum Package|
214381273|NCT00744263|BIOLOGICAL|VACCINE: placebo|0.5 mL, single intra-muscular injection
214381274|NCT00744263|BIOLOGICAL|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
214381275|NCT04261179|DRUG|Lymphoseek|50 μg microgram(s), timepoint: 30-60 minutes
214994972|NCT06962904|OTHER|Placebo|Placebo MNP (containing sucrose, sorbitol, maltodextrin, methylcellulose, HEPES, sodium chloride, and calcium chloride) administered intradermally
214994973|NCT04466293|BEHAVIORAL|Choice Architecture|"1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach. This will be adapted to the country context and may include a pre-printed prescription pad (Mozambique), adaptations in clinical stationary (Zimbabwe), or adaptations to an electronic prescribing system (Malawi).~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
215092738|NCT06269237|DEVICE|M22|"Participants in the group with 3 sessions of IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.~Other Names:~• IPL"
214381276|NCT04261179|DRUG|Nanocoll|500 μg microgram(s), timepoint: 30-60 minutes
214381277|NCT03648203|BEHAVIORAL|Technology Enabled Asthma Management System|See description of arm
214381278|NCT03577574|PROCEDURE|retrobulbar anesthesia|2% lidocaine 4ml injected into retrobulbar space
214381279|NCT03577574|PROCEDURE|peribulbar anesthesia|2% lidocaine 4 to 8ml injected into peribulbar space
214381280|NCT03577574|PROCEDURE|two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
214381281|NCT01351428|DRUG|Nifedipine|30-60 mg, twice daily
214687377|NCT00977574|DRUG|Carboplatin|Given IV
214994974|NCT02843308|BEHAVIORAL|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
214381282|NCT03748017|DIETARY_SUPPLEMENT|Placebo-Control Supplement|A once-daily oral dose of the placebo-control supplement will be consumed by adults for 14 consecutive days.
214381283|NCT03748017|DIETARY_SUPPLEMENT|Streptococcus-Containing Probiotic Supplement|A once-daily oral dose of the streptococcus-containing probiotic supplement will be consumed by adults for 14 consecutive days.
214381284|NCT03596437|DEVICE|Ultra High Frequency ultrasound system|Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.
214381285|NCT01448954|DRUG|ADC3680B oral|Once daily for 28 days
214381286|NCT01448954|DRUG|Placebo oral|Once daily for 28 days
214381287|NCT02771730|BIOLOGICAL|Ad4-mgag|A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.
214994975|NCT06379321|DEVICE|Triathlon Hinge Knee (THK) System|Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use
214994976|NCT03765177|BIOLOGICAL|CLIC-1901|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.
214994977|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
215092739|NCT06269237|DEVICE|sham M22|Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
215092740|NCT04476875|OTHER|Open Outpatient Clinic Programme|
215092741|NCT05432167|DRUG|CIN-107|Patients will take CIN-107 tablets by mouth once daily.
215092742|NCT05432167|DRUG|Placebo|Patients will take placebo tablets by mouth once daily.
214381288|NCT02771730|BIOLOGICAL|Ad4-EnvC150|A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.
214381289|NCT02771730|OTHER|Placebo Comparator|Oral sucrose capsules
214381290|NCT02771730|BIOLOGICAL|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
214381291|NCT05232513|OTHER|Hand massage|Hand massage is an initiative that improves the communication between the massager and the individual, reduces anxiety, and provides comfort and relaxation.
214687378|NCT00977574|DRUG|Ixabepilone|Given IV
214687379|NCT00977574|OTHER|Laboratory Biomarker Analysis|Correlative studies
214687380|NCT00977574|DRUG|Paclitaxel|Given IV
215092743|NCT01267175|DEVICE|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
214381292|NCT00910520|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
214381293|NCT00910520|DRUG|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
214381294|NCT02482636|BIOLOGICAL|DTaP/IPV/Hib vaccine|Given at 2, 3 and 4 months to Group 1 and 2
214381295|NCT02482636|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
214381296|NCT02482636|BIOLOGICAL|Rotavirus vaccine|Given at 2 and 3 months to Group 1 and 2
214994978|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
214994979|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.
214994980|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.
214994981|NCT05985785|OTHER|Autologous bone marrow aspirate concentrate (BMAC)|Bone marrow aspirate concentrate BMAC is a biologically substance harvested from a patient for autologous use. Bone marrow aspirate concentrate (BMAC) has been determined by the FDA to be a minimally manipulated biologic prepared for autologous use and does not require premarket FDA approval for clinical use.
214994982|NCT05985785|DRUG|Corticosteroid injections|Current standard of treatment for OA of the knee is corticosteroid injection.
214994983|NCT05985785|OTHER|Crossover Autologous bone marrow aspirate concentrate (BMAC)|Subjects who participate in this study and who are randomized to receive the BMAC may experience decreased pain and increased functionality after the injection compared to those that receive a corticosteroid injection. As such, participants who continue to have pain after a corticosteroid injection will be allowed to crossover to a BMAC injection at 24 weeks or 6 months post-surgery.(ARM 3)
214994984|NCT06516211|DEVICE|Clara Pregnancy Test|Multi-Level Pregnancy Test
214994985|NCT06516211|DEVICE|Professional Marketed Pregnancy Test|Early Pregnancy Test
214994986|NCT03054519|DRUG|Metformin|Participants will be prescribed up to 2,000 mgs daily of metformin
214994987|NCT03054519|DRUG|Placebo|Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
214994988|NCT06553872|DRUG|Pirtobrutinib|Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.
214994989|NCT06553872|DRUG|Brexucabtagene Autoleucel|Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).
214994990|NCT04537299|DRUG|Fisetin|\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 \& 1 and Days 8 \& 9)
214994991|NCT04537299|DRUG|Placebo|Placebo looks exactly like the treatment drug, but it contains no active ingredient
214994992|NCT04993846|DIAGNOSTIC_TEST|Dental plaque sampling|Dental plaque sampling
214994993|NCT04993846|DIAGNOSTIC_TEST|qPCR|qPCR
214994994|NCT03806296|OTHER|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning
214994995|NCT03806296|OTHER|Decrease evening blue light|Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed
214994996|NCT03806296|BEHAVIORAL|Sleep scheduling|Participants will advance their weekday bedtime and maintain their weekday risetime on weekends
214994997|NCT03806296|BEHAVIORAL|Monitor sleep, mood, and substance use|Participants will monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraphy
214381297|NCT02482636|BIOLOGICAL|4-component Meningococcal B vaccine|Given at 2, 4 and 12 months to Group 1 and 2
214381298|NCT02482636|BIOLOGICAL|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Given at 12 months to Group1 and 2
214381299|NCT02482636|BIOLOGICAL|Measles/Mumps/Rubella Vaccine (MMR vaccine)|Given at 13 months to Groups 1 and 2
214381300|NCT05240274|DRUG|Metformin|metformin 500mg OD for 3 months to start within 10 days post-renal transplant
214381301|NCT05240274|DRUG|Placebo|placebo 500mg OD for 3 months to start within 10 days post-renal transplant
214381302|NCT03214289|BIOLOGICAL|Fecal Microbiota Transplantation|Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
214381303|NCT04169711|DRUG|ARO-HIF2|Multiple doses of ARO-HIF2 by intravenous infusion
214381304|NCT03467438|DRUG|Zinc-l-carnosine|Patients will be asked to take the investigational product as already mentioned (blindly).
214381305|NCT03467438|OTHER|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
214381306|NCT00279656|BEHAVIORAL|Pharmaceutical care|
214687381|NCT00977574|DRUG|Temsirolimus|Given IV
214994998|NCT03304236|DEVICE|Myelopathy Hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists)
214994999|NCT04897243|DRUG|Biktarvy|B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.
214995000|NCT04897243|BEHAVIORAL|Patient Experience|To capture and integrate the patient experience, this study will collect patient-reported experience measures, conduct qualitative interviews, and engage patients as well as providers.
214381307|NCT00130793|BIOLOGICAL|Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
214381308|NCT00130793|BIOLOGICAL|Comparator: zoster vaccine live (Oka/Merck) frozen formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
214381309|NCT06012864|PROCEDURE|PNL|percutaneous extraction of the stones in the kidney
214381310|NCT00624715|DRUG|THC|"* High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~* Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~* Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint"
214381311|NCT00624715|DRUG|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
214381312|NCT04175418|OTHER|Supervised Exercise Program|The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.
214381313|NCT04175418|OTHER|Online Education Program|The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
214995001|NCT03220789|PROCEDURE|Drilling at low speed|
214995002|NCT03220789|PROCEDURE|Drilling at conventional or high speed|
214995003|NCT00876343|DRUG|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
214995004|NCT00876343|DRUG|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
214995005|NCT00876343|DRUG|Placebo|administered orally once daily, 6 weeks
214995006|NCT04582526|BEHAVIORAL|BMS program|A BMS program with three components: relaxation exercises, healthy eating, expressive arts therapy
214995007|NCT06158828|DRUG|Rabbit Anti thymocyte globulin|rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.
214995008|NCT06158828|DRUG|Busulfan|Busulfan is administered intravenously either Q6H or Q24H, with a recommended target Busulfan AUC of 70-90 mg\*h/L.
214995009|NCT06158828|DRUG|Fludarabine|Fludarabine is administered intravenously at a dose of 40 mg/m\^2/dose once daily for 4 days.
214995010|NCT06158828|DRUG|Thiotepa|Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.
214995011|NCT06158828|DRUG|Melphalan|Melphalan is administered intravenously at a dose of 70 mg/m\^2/dose once daily for 2 days.
214995012|NCT06158828|BIOLOGICAL|TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft|The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10\^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.
214995013|NCT06158828|BIOLOGICAL|memory-like natural killer cells|The ML NK cells (dose: max capped at 20 x 10\^6/kg recipient weight, minimum dose allowed is 0.5 x 10\^6/kg recipient weight) will be infused on Day +7.
214995014|NCT06158828|BIOLOGICAL|IL-2|IL-2 is administered subcutaneously at a dose of 1 million units/m\^2 on Days +7, +9, +11, +13, +15, +17, and +19 (7 doses total).
214995015|NCT06158828|DRUG|Plerixafor|If suboptimal collection of stem cells is predicted, plerixafor may be administered at a dose of 0.24 mg/kg subcutaneous injection once (maximum 40mg/dose). For patients with renal impairment, plerixafor will be administered at a dose of 0.16 mg/kg subcutaneous injection (maximum 27 mg/day).
214995016|NCT06158828|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|G-CSF will be administered at a dose of 10 mcg/kg/day for 5 days, or 6 days if two days of collection are needed.
214995017|NCT06158828|DEVICE|CliniMACS|After stem cells are collected by leukapheresis, in order to create the HPC product, the stem cells will be washed to remove platelets and the cell concentration will be adjusted per laboratory and CliniMACS technology recommendations. The cells are then labeled using the CliniMACS TCRαβ Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product.
214995018|NCT06176066|PROCEDURE|CEST PH MRI based resection of glioblastoma|Using pre-operative amine chemical exchange saturation transfer pH weighted MRI, regions of interest that correspond to infiltrating glioblastoma will be identified and via intraoperative neuronavigation, guide resection of glioblastoma
214995019|NCT03539510|BEHAVIORAL|HF-ACP Website|Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
214995020|NCT04620499|DEVICE|EEG|PEER EEG
214995021|NCT00002791|BIOLOGICAL|filgrastim|
214995022|NCT00002791|DRUG|dacarbazine|
214381314|NCT00211237|DEVICE|Balloon Kyphoplasty|Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.
214381315|NCT00211237|OTHER|Non Surgical Management|Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
214381316|NCT05016011|BIOLOGICAL|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Human umbilical cord-derived mesenchymal stem cells
214381317|NCT05016011|PROCEDURE|Marrow cellution|Patients will undergo marrow cellution surgical procedure.
214381318|NCT06053060|OTHER|Randomisation Standard Dynacup or Dynacup One C|Randomisation
214381319|NCT00227500|DRUG|Pravastatin|
214995023|NCT00002791|DRUG|doxorubicin hydrochloride|
214995024|NCT00002791|DRUG|ifosfamide|
214995025|NCT00002791|DRUG|mesna|
214995026|NCT00002791|PROCEDURE|conventional surgery|
214995027|NCT00002791|RADIATION|brachytherapy|
214995028|NCT00002791|RADIATION|intraoperative radiation therapy|
214995029|NCT00002791|RADIATION|radioisotope therapy|
214995030|NCT06636448|PROCEDURE|the effect of body mass index during low-flow anesthesia|The investigator planned to evaluate the effect of body mass index on patient outcomes during low-flow anesthesia in patients undergoing gynecologic cancer surgery.
214995031|NCT06635213|OTHER|Desensitisation|This technique is utilized to decrease, or normalize, the body's response to particular sensations.
214995032|NCT06635213|OTHER|Pain neuroscience education|PNE is an educational intervention aiming to alter a patient's beliefs and cognitions regarding their pain experience.
214995033|NCT06785636|DRUG|Pocenbrodib|Pocenbrodib is a selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on histones.
214995034|NCT06785636|DRUG|Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617|Pocenbrodib alone or in combination
214995035|NCT06548035|BEHAVIORAL|Adapted Relaxation Response Resiliency Program (3RP)|The 3RP intervention is an integrated program of relaxation response (RR) eliciting meditation and mindfulness exercises, social support, cognitive skills training, and positive psychology focused on developing skills to reduce the stress response, elicit the relaxation response and enhance resiliency.
214995036|NCT02455622|DRUG|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
214995037|NCT06216158|DRUG|Iberdomide|Iberdomide p.o. (1.0 mg, day 1-21 of each 29-days cycle)
214995038|NCT06216158|DRUG|Isatuximab|Isatuximab s.c. (1400 mg, cycle 1: day 1, 8, 15, 22; cycles 2-3: day 1 and 15; from C4: day 1)
214995039|NCT06216158|DRUG|Dexamethasone|Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
214995040|NCT04161898|DRUG|Upadacitinib|Upadacitinib will be administered as oral tablet
214995041|NCT04161898|DRUG|Placebo for Upadacitinib|Placebo for upadacitinib will be administered as oral tablet
214995042|NCT04161898|DRUG|Prednisolone|Prednisolone will be administered as oral tablet
214995043|NCT04941430|DIAGNOSTIC_TEST|Magnetic Resonance Imaging using 7 Tesla MRI|Undergo 7T MRI
214995044|NCT06496620|DRUG|Biological: Solrikitug low dose|Solrikitug subcutaneous injection
214381320|NCT03733743|OTHER|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
214995045|NCT06496620|DRUG|Biological: Solrikitug high dose|Solrikitug subcutaneous injection
214995046|NCT06496620|OTHER|Placebo|Placebo subcutaneous injection
214995047|NCT03938389|DRUG|Sacubitril-Valsartan Tab 97-103 MG|Participants will take Sacubitril-Valsartan for 26 weeks
214995048|NCT03938389|DRUG|Valsartan 160mg|Participant will take Valsartan for 26 weeks
214995049|NCT03938389|DRUG|Placebo Oral Tablet|Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
214995050|NCT05482022|DEVICE|Shiley™ phonate speaking valve|The device connects to the tracheostomy tube. Usually used to aid vocalization.
214995051|NCT05482022|OTHER|control|no intervention
214995052|NCT05109650|DRUG|BAT6026|IV infusions
214381321|NCT00875732|DEVICE|Bi Ventricular Pacing|
214995053|NCT05109650|DRUG|BAT1308|Ⅳ infusions
214995054|NCT04896385|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
214381322|NCT00875732|DEVICE|Right Ventricular Pacing|
214381323|NCT03758118|DIETARY_SUPPLEMENT|Citicoline|Citicoline administered in oral solution
214381324|NCT05491369|OTHER|Epilepsy application|Nanacara is an epilepsy application which helps people with epilepsy to self-manage their conditions.
214381325|NCT01013792|DEVICE|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs)
214381326|NCT01013792|DEVICE|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
214381327|NCT00001495|DRUG|irinotecan (CPT-11)|
214995055|NCT04896385|DRUG|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
214995056|NCT03386227|OTHER|Withholding antibiotic prophylaxis|Our intervention will be a deviation from our current standard of care which is universal antibiotic prophylaxis, even in low risk populations. Our intervention will be withholding antibiotic prophylaxis in low risk populations.
214995057|NCT01940588|BEHAVIORAL|Neuropsychoanalytic therapy|Psychotherapy, medication management
214995058|NCT01635088|DRUG|Mometasone furoate 220|dry powder inhaler QD for 28-43 days
214995059|NCT01635088|DEVICE|KoKo Spirometry|
214995060|NCT01635088|DRUG|Mometasone furoate 440|dry powder inhaler QD for 28-43 days
214995061|NCT01635088|DEVICE|Oscillometry|
214995062|NCT05614609|DRUG|Lidocaine topical|Comparing lidocaine spray and muscle relaxing medication
214995063|NCT05086757|BEHAVIORAL|TRRP|Receive TRRP services
214995064|NCT05086757|BEHAVIORAL|Enhanced Usual Care|Participants will receive an educational flyer with service referrals
214995065|NCT06492252|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
214995066|NCT06492252|BEHAVIORAL|Adaptation|Auditory adaptation in speech
214995067|NCT06492252|BEHAVIORAL|Adaptation|Auditory baseline in speech
214995068|NCT06466551|OTHER|intravenous catheterization|This randomized experimental study was planned to examine the effect of virtual reality goggles and squeezing a stress ball as a distraction method during intravenous catheter application on pain and fear in children aged 6-12 years.
214381328|NCT03154944|DEVICE|Ostomy device 1|This device consists of a known adhesive and a new top film
214381329|NCT03154944|DEVICE|Ostomy device 2|This device consists of a new adhesive and a known top film
214381330|NCT03154944|DEVICE|Ostomy device 3|This device consists of a known adhesive and a new top film
214381331|NCT02100722|PROCEDURE|FFR guided PCI|
214381332|NCT02100722|PROCEDURE|CABG|Coronary Artery Bypass Graft Surgery (CABG)
214381333|NCT02100722|DEVICE|Resolute Integrity Stent|Durable polymer zotarolimus-eluting stent
214381334|NCT02100722|DEVICE|Resolute Onyx Stent|Durable polymer zotarolimus-eluting stent
214381335|NCT01782963|DRUG|Lenalidomide|
214995069|NCT05034289|BEHAVIORAL|PINPOINT Digital Educational Tool|"The intervention prototype called the PINPOINT Digital Educational Tool will be comprised of four main sections that include information about: 1) precision oncology; 2) clinical trials; 3) Learn More screens; and 4) discussion points and questions for the treating clinician. The intervention prototype will also include a search function, short videos of patient testimonials, patient-provider interaction about immunotherapy and clinical trials, as well as a list of questions/concerns that the patient could print (or save electronically) and take with them to their provider visit. An optional chatbot will be available in the corner of the screen. Users can ask the chatbot questions about any of the material on the website or request additional information. The chatbot will also be able to help patients search for molecularly targeted and immunotherapy clinical trials and offer additional resources (such as websites and online support groups)."
214995070|NCT05783622|DRUG|JANX008|JANX008 is dosed via IV weekly in a 21-day cycle
214995071|NCT04468061|DRUG|Sacituzumab Govitecan|Intravenous Infusion
214381336|NCT01782963|DRUG|Bortezomib|
214381337|NCT01782963|DRUG|Dexamethasone|
214995072|NCT04468061|DRUG|Pembrolizumab|Intravenous Infusion
214995073|NCT04960618|DRUG|Gemcitabine|Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles
214995074|NCT04960618|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles
214995075|NCT03255694|DRUG|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
214995076|NCT05843994|OTHER|online survey|Participants will complete an online survey and submit photographs.
214995077|NCT06071442|DRUG|Vemircopan|Participants will receive oral tablets of Vemircopan.
214995078|NCT06071442|DRUG|Rosuvastatin|Participants will receive oral coated tablets of Rosuvastatin.
214995079|NCT06071442|DRUG|Metformin|Participants will receive oral film-coated tablets of Metformin.
214995080|NCT06071442|DRUG|Levonorgestrel / Ethinyl Estradiol|Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.
214995081|NCT06071442|DRUG|Carbamazepine|Participants will receive oral chewable tablets of Carbamazepine.
214995082|NCT05543941|DEVICE|XPERIENCE Advanced Surgical Irrigation|The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.
214995083|NCT05543941|DEVICE|Dilute Betadine|The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.
214995084|NCT05258721|DRUG|ClōSYS® Sensitive Fluoride Toothpaste|ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.
214995085|NCT05258721|OTHER|ClōSYS® Sensitive Rinse|ClōSYS® Sensitive Rinse is a cosmetic product containing 0.1% stabilized chlorine dioxide.
214995086|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care and education|Group 1 will download an enhanced mobile app that will include education and support resources related to food allergy and its management.
214995087|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care, education and support resources|Group 2 will download an enhanced mobile app that will include education and support resources related to food allergy and its management, a symptom monitoring and tracking system that allows mobile app users to log symptoms they may experience as caregivers of children newly diagnosed with food allergy, e.g. fatigue and anxiety, and symptom based interventions (recommendations) that may improve a caregiver's ability to self-manage experienced symptoms.
214995088|NCT01931098|DRUG|topotecan|Taken .25 mg orally, daily continuous until progression up to one year.
214995089|NCT01931098|DRUG|pazopanib|600 mg orally, daily until progression, up to one year.
214995090|NCT05973214|BEHAVIORAL|Cognitive Behavioral Therapy|CBT for IEI
214995091|NCT02818673|RADIATION|labelled human serumalbumin (125-I, Séralb®CisBio)|Intra-veinous injection of 0,015 MBq/Kg ; 0,5 to 2 mL injected over less than a minute
214381338|NCT06215690|DIAGNOSTIC_TEST|Ultrasound measurements|"Evaluation will be performed by ultrasonography. The following measurements will be taken with the ultrasonographic examination.~* BPD (Biparietal Diameter)~* HC (Head Circumference)~* AC (Abdominal Circumference)~* FL (Femur Length)~* EFW (Estimated Fetal Weight)~* Umbilical Artery Doppler Sistole/Diastole (S/D) ,Pulsatility İndex (PI), Resistance İndex (RI)~* Middle Cerebral Artery S/D,PI,RI~* Uterine Artery Doppler PI~* Anterior Cerebral Artery S/D,PI,RI~* CPUR (Cerebral - Placental - Uterin PI Ratio)~* CPR (Cerebral - Placental PI Ratio)~* The deepest free single vertical pocket in the amnion mai~* Cavum Septum Pellucidum: Width - Length Diameters~* OFD (Occipitofrontal length)~* FAPD (Frontal Anterior Posterior Diameter)~* FAPD/OFD ratio~* Cerebellar diameter~* Lateral ventricle depth~* Insular depth~* Sylvian fissure depth"
214381339|NCT04973111|DRUG|CT-868 as SC Injection|CT-868
214381340|NCT04973111|DRUG|Placebo as SC Injection|Placebo
214995092|NCT02818673|RADIATION|labelled albumin (99m-Tc, Vasculocis®, Cisbio)|intra-peritoneal injection of 200 MBq of labelled albumin (99m-Tc, Vasculocis®, Cisbio) ; 5 ml injected over less than a minute
215092744|NCT05687006|PROCEDURE|Colour Doppler Ultrasound|The main perforators were examined using a LOGIQ S8/V1 CDU device (GE Healthcare, Chalfont St Giles, Great Britain) with a linear transducer of frequency 4-11 MHz. Measured parameters were: 1) calibre of artery and vein; 2) Peak systolic velocity (PSV) of blood in the artery \[cm/s\]; 3) blood velocity in the perforator vein \[cm/s\]; 2) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
215092745|NCT01013363|OTHER|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
214381341|NCT04973111|DRUG|Active Comparator as SC Injection|Active Comparator
214381342|NCT00185510|DRUG|Methylprednisolone Aceponate (Advantan, BAY86-4862)|In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.
215092746|NCT02295241|OTHER|No intervention|This is an observational trial, no interventions are being used.
214381343|NCT00185510|DRUG|Placebo|2 days a week Vehicle (Advabase)
214381344|NCT03705455|BEHAVIORAL|ISAP SMS|ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
214995093|NCT00559000|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children
215092747|NCT01702168|OTHER|Provider training: Cognitive Processing Therapy (CPT)|
215092748|NCT04750980|OTHER|food allergy|food allergy
215092749|NCT04750980|OTHER|respiratory allergy|respiratory allergy
215092750|NCT04750980|OTHER|healthy controls|healthy controls
214687382|NCT06741189|OTHER|Home monitoring|"The key parameters (heart rate, arterial oxygen saturation, weight) will be measured at home using the measurement tools used by the parents, and tele-transmitted at a discontinuous rate, i.e. once a day for 4 weeks, then once a week for 20 weeks. The measurement tools will be given to the family before discharge from the hospital ward. These parameters will be entered into the Exolis platform, in addition to a very brief questionnaire designed to provide information about the child's diet, muscle tone and any medication he or she is taking. taken by the child.~An alert will be automatically generated for the pediatric cardiology team if the data transmitted by the measurement sensors deviates from an individualized standard, defined for each child and/or each care pathway at the multidisciplinary consultation meeting before the child returns home.~The response will be standardized on the basis of a protocol shared by the 4 investigating centers."
215092751|NCT03546218|DEVICE|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
215092752|NCT03546218|DEVICE|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
215092753|NCT00875173|DRUG|Selenium|selenium as a drug according to Brazilian regulation laws
215092754|NCT00875173|DRUG|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
215092755|NCT03576313|DRUG|dihydroartemisinin-piperaquine (DP)|DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food
215092756|NCT03576313|DRUG|ivermectin (IVM)|IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water
215092757|NCT03576313|OTHER|standard malaria control interventions only|this is the standard malaria control interventions in the Gambia
215092758|NCT00046150|DRUG|Insulin glulisine (HMR1964)|
215092759|NCT03125694|DRUG|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
215092760|NCT03125694|DRUG|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
215092761|NCT00261508|DRUG|risperidone|
215092762|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
214381345|NCT05509543|DRUG|IY-NT-T|Ilaprazole 20mg
214381346|NCT05509543|DRUG|IY-NT-R|Ilaprazole 10mg
214687383|NCT06741189|OTHER|usual medical monitoring|"During the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram.~During the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures."
214995094|NCT00230737|DRUG|Melatonin 0.4 mg|
214995095|NCT00230737|DRUG|Melatonin 4.0 mg|
214995096|NCT00230737|DRUG|Placebo|
214995097|NCT04508816|DRUG|cetuximab (CTX) or nimotuzumab (NTZ)|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.
215092763|NCT04404270|BEHAVIORAL|Questionnaire|"Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3).~The questionnaire includes:~* medical data (height, weight, smoking, history of intense stress);~* socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.);~* clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19;~* use of care, hospitalization, work stoppage in the last 3 months;~* contact with people who are symptomatic or proven COVID-19."
215092764|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 serological controls and serum neutralization|Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
215092765|NCT03062241|PROCEDURE|Cryoablation|After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
214381347|NCT05236413|BEHAVIORAL|High Intensity Interval Exercise|"Patients will be required to report for three sessions of supervised stationary cycling exercise per week over a period of 4-weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). All sessions will be supervised by trained personnel.~Patients will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~Each training session will begin with a 10-min warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will be weighed prior to every exercise session and weight tracked to ensure that their volume status hasn't changed significantly. Subjects will be instructed to maintain usual levels of physical activity and usual diet during the study and not to make any modifications to the same."
214995098|NCT04194970|DEVICE|With WBM smart insole system to monitor compliance of specified weight bearing limits data in live feedback on and off situations|"Weight Bearing Protocol (Duration: Post-Op. 6 week)~* Post-op 3 week non-weight bearing (%0 body weight of patient)~* Post- op 3 week touch down weight bearing (%10-%20 body weight of patient) Group I - monitoring with device while the live feedback mechanism turned on Group II- monitoring with device while the live feedback mechanism turned off"
214381348|NCT05236413|BEHAVIORAL|Dietary Approaches to Stop Hypertension (DASH) Diet|Patients will be interviewed with regard to their food/religious preferences and food allergies and a 7-day rotating meal plan will be designed per their preferences along with a registered dietitian. This will ensure that patients receive food that is acceptable to them. Participants will then be provided pre-packaged meals for 4-weeks with macronutrient compositions as follows - (Carbohydrates -55-60%, Protein -15-20%, Fat -15-25%, Fiber -35-45g/day). All foods will be labeled, sealed, and packed for weekly delivery and will be designed such that they can be refrigerated or frozen and stored without significant alterations to nutritional content. All food will be prepared by the UVA Hospital Nutrition Services department in conjunction with a registered dietician. Deviations (if any) from the study meal plan will be recorded by the participants in a food record provided at the start of each diet intervention period.
214995099|NCT04529174|DIETARY_SUPPLEMENT|CardioLux™HDL|"Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
215092766|NCT02451891|BIOLOGICAL|MVA-EBO Z|
215092767|NCT02451891|BIOLOGICAL|ChAd3-EBO Z|
214687384|NCT06773949|DEVICE|Theta burst stimulation|Cool B70 cooled-coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
214687385|NCT06512207|DRUG|Leuprorelin acetate + Sintilimab|Leuprolide, an FDA-approved GnRH agonist, reduces sex hormone production and is widely used in clinical practice.
214687386|NCT06512207|DRUG|Sintilimab|PD-1 inhibitor
215092768|NCT05442177|PROCEDURE|Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment|
215092769|NCT04325230|DEVICE|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
215092770|NCT01836081|OTHER|Volume expansion|
215092771|NCT02072525|BIOLOGICAL|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
215092772|NCT02072525|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
215092773|NCT02072525|BIOLOGICAL|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
215092774|NCT02072525|BIOLOGICAL|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
215092775|NCT00242333|DRUG|AD 237|
215092776|NCT05208775|PROCEDURE|PDT|"Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.~Laser irradiation:~48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts."
215092777|NCT05208775|PROCEDURE|ESD|The patients received standard endoscopic submucosal dissection after enrollment.
215092778|NCT00311116|DRUG|Vitamin E|
215092779|NCT00875342|DRUG|DCS|1\. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
215092780|NCT00875342|OTHER|Placebo|2\. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
215092781|NCT01839136|PROCEDURE|Intrauterine transfer of gametes|
215092782|NCT01839136|PROCEDURE|Intrauterine transfer of embryos|
215092783|NCT02553538|BEHAVIORAL|Patient Navigation|Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
215092784|NCT01420822|DRUG|Fluticasone|Collection of safety data
215092785|NCT04094584|DRUG|Vivitrol (Extended Release Naltrexone)|Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
215092786|NCT02690649|OTHER|Health Messaging (Non-Procedural)|Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
215092787|NCT02686476|DRUG|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
215092788|NCT00399399|DRUG|azathioprine|
215092789|NCT00399399|DRUG|cyclophosphamide|
215092790|NCT03677297|DRUG|Rosuvastatin|Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
215092791|NCT04264143|DRUG|Infusate with MTX110 and gadolinium|Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
215092792|NCT04264143|DEVICE|Convection-Enhanced Delivery (CED)|CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
214995100|NCT04529174|DIETARY_SUPPLEMENT|Placebo|"Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
214995101|NCT03146390|DRUG|Essential oils|all subjects will perform all interventions of all arms
214995102|NCT03146390|DRUG|Alcohol free essential oils|all subjects will perform all interventions of all arms
214995103|NCT03146390|OTHER|Water|all subjects will perform all interventions of all arms
215092793|NCT05640609|COMBINATION_PRODUCT|Capeox regimen combined with Sintilimab and Bevacizumab|Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before
214995104|NCT05810662|OTHER|Lactated ringer and dextrose 5%|Fluid use perioperative
215092794|NCT05928611|PROCEDURE|Inferior alveolar nerve block with dexamethasone|Using articaine for inferior alveolar block with intraligmentary dexamethasone
215092795|NCT05928611|PROCEDURE|Buccal infiltratation with dexamethasone|Using articaine for buccal infiltratation with intraligmentary dexamethasone
215092796|NCT05928611|PROCEDURE|Inferior alveolar nerve block|Using articaine for injection
215092797|NCT00791557|DRUG|Infliximab|IV drug given at weeks 1,2,14,22
214381349|NCT05236413|BEHAVIORAL|Exercise + DASH Diet|Patients will undergo both the exercise training intervention and DASH diet as explained above.
214995105|NCT03923920|PROCEDURE|Biopsy|During clinically-scheduled spinal stenosis surgery, ligamentum flavum tissue (which may contain surrounding tissue and subcutaneous fat) that is removed during the procedure will be sent to pathology to be analyzed with amyloid-specific staining.
214995106|NCT05496764|DRUG|Dexamethasone|we planned to inject steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in group A
214995107|NCT05496764|DRUG|Glucose Injection|inject10 ml glucose 5% into the carpal tunnel in group B
214995108|NCT01925794|DEVICE|COBRA PzF|
214995109|NCT00790036|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
215092798|NCT00003963|BIOLOGICAL|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
215092799|NCT00003963|DRUG|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
215092800|NCT04357509|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
215092801|NCT05545202|OTHER|Pentaisomaltose|Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
215092802|NCT02892721|OTHER|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
215092803|NCT03313336|DRUG|EMLA test patch|EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
214381350|NCT02479997|DRUG|Indocyanine green|"ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.~In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty."
214381351|NCT02479997|DRUG|Radioisotope|Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
214995110|NCT00790036|DRUG|Everolimus Placebo|Everolimus placebo was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
214995111|NCT02511353|DRUG|ivermectin|
214995112|NCT02511353|DRUG|placebo|Placebo for ivermectin.
214995113|NCT02511353|DRUG|dihydroartemisinin-piperaquine|
214995114|NCT00859118|DRUG|AG-013736|Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
214995115|NCT00859118|DRUG|AG-013736|Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
215092804|NCT03313336|DRUG|EMLA current reference patch|EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
214995116|NCT02973620|DRUG|Levosimendan|levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
215092805|NCT03313336|DRUG|Placebo Patch|Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
214498162|NCT06145984|BEHAVIORAL|Mindfulness|Participants receive a two-hour professional training to get familiar with the basic techniques of mindfulness. The training is given by a mindfulness professional and consists of psycho-education, instructions for mindfulness and guided practice. It focuses mainly on attending to stimuli such as breathing, external sounds or bodily sensations and becoming aware of where one's attention is. After the professional training, participants receive instructions about the audio application with which participants continue performing short exercises using the learned technique every day guided by an application on their smartphone customized for this research. Specifically, participants perform one short exercise (10 min) per day for in total six days. The exercises that are being performed are: attention to breathing part 1, attention to breathing part 2, attention to sounds, attention to bodily sensations, attention to thoughts, attention to emotions and feelings.
214393848|NCT02780986|BEHAVIORAL|Heterosexual men intervention group|"This will be delivered via 3 main activities:~1. Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.~2. Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.~3. Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants"
214498163|NCT06145984|BEHAVIORAL|Positive Fantasizing|"In a two-hour training session by a professional trainer, participants get familiar with the positive fantasizing technique. Participants receive psycho-education about the role of dysfunctional beliefs. The positive fantasizing technique starts with identifying dysfunctional beliefs and schema and subsequently fantasize about a positive fantasy belief. Participants are guided by the professional using imagery and experiencing thoughts and feelings that would be elicited when using their fantasy belief as if in an ideal world. After using imagery techniques, participants are asked, with help of the professional, to reflect on their experience during the fantasizing exercise and to think of how they could implement this fantasy belief more in their daily life, by adapting their fantasy belief into a more practical belief. After the training, participants are asked to perform one exercise per day using the fantasizing technique using a mobile application for six days in total."
214498164|NCT03230643|DEVICE|Barostim neo implantation|"The Barostim neo Implantation is a new promising treatment option for patients with advanced heart failure (HEFrEF) as it might improve cardiac and vascular function by restoring sympathovagal-balance through its effects on the autonomic nervous system.~In this observational study, data from patients who have received the Barostim neo System as part of clinical routine will be collected and analyzed. The implantation of this new device is not part of the study."
214995117|NCT00169832|DRUG|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
214995118|NCT04512287|DRUG|Autologous Platelet Rich Plasma|2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.
214995119|NCT04512287|OTHER|Saline Solution|2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.
214995120|NCT06237881|DRUG|KSQ-001EX|Given by IV
214995121|NCT06237881|DRUG|Interleukin-2|Given by IV
214995122|NCT06237881|DRUG|Cyclophosphamide|Given by IV
214995123|NCT06237881|DRUG|Fludarabine|Given by IV
214995124|NCT04724668|DIETARY_SUPPLEMENT|Melatonin (3hrs before DLMO)|Melatonin 3mg (3hrs before DLMO)
215092806|NCT03695822|DRUG|Mirabegron 25mg|The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
215092807|NCT00660985|DRUG|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
215092808|NCT00660985|DRUG|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
215092809|NCT00518297|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
215092810|NCT00518297|DRUG|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
215092811|NCT00518297|DRUG|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
214995125|NCT04724668|DIETARY_SUPPLEMENT|Placebo (3hrs before DLMO)|Placebo capsule (3hrs before DLMO)
214995126|NCT04724668|DEVICE|Morning light version 1|Morning light version
214995127|NCT04724668|DEVICE|Morning light version 2|Morning light version
214995128|NCT02943759|DRUG|Neem leaf extract|A natural irrigant solution act as anti-inflammatory and anti bacterial
215092812|NCT03445221|DIETARY_SUPPLEMENT|IV Immunonutrition|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
215092813|NCT03445221|DIETARY_SUPPLEMENT|Conventional Diet|patients will continue preoperative oral conventional diet.
215092814|NCT05329870|OTHER|SNP array|SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
215092815|NCT01804309|PROCEDURE|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
214995129|NCT02943759|DRUG|Chlorhexidine gluconate|2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
214995130|NCT03426865|DRUG|Axumin PET scan|PET scan prior to RPLND
214995131|NCT06179069|DRUG|ZL-1310|Drug: ZL-1310
214995132|NCT06179069|DRUG|Atezolizumab|Drug Atezolizumab
214381352|NCT05758545|DEVICE|COMS One device|The COMS One device incorporates technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of light emitting diodes (LEDs) in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectra. The magnetic stimulation component is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectra. The COMS One is a lightweight, portable device. The device is locally applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific feature that has been modified for the purpose of blinding is sensor detecting whether the device is lying on the skin.
214381353|NCT05758545|DEVICE|Sham device|The Sham device is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific features that have been modified for the purposes of blinding include the following: 1) therapeutic output, and 2) sensor detecting whether the device is lying on the skin.
214381354|NCT06335108|PROCEDURE|General Anaesthesia|Breast surgery is carried out under general anesthesia.
214381355|NCT06335108|PROCEDURE|Local tumescent anaesthesia|Breast surgery is carried out under local tumescent anesthesia.
214381356|NCT06250439|OTHER|ECMO-Flow variations|"The protocol unfolds in 5 steps as follows, each step lasting between 10 and 15 minutes to allow for the patient's hemodynamic adaptation. At each step, invasive and non-invasive hemodynamic evaluation is performed.~1. The 1st step is called 100% flow: it involves recording the patient's hemodynamic measurements at the baseline, i.e., at 100% of their ECMO-VA flow, previously set by the clinician entirely independently of the study.~2. The 2nd step is called 125% flow: the patient's ECMO-VA flow is increased to 125% of the initial flow.~3. The 3rd step is called 150% flow: the patient's ECMO-VA flow is increased to 150% of the initial flow.~4. The 4th step is called 175% flow: the patient's ECMO-VA flow is increased to 175% of the initial flow.~5. The 5th and final step is called 200% flow: the patient's ECMO-VA flow is increased to 200% of the initial flow."
214381357|NCT03961009|BIOLOGICAL|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
214381358|NCT06285565|COMBINATION_PRODUCT|Nurse-led telephone coaching intervention with home telemonitoring of vital signs|In addition to standard care, the intervention group will receive a nurse-led supportive programme that involves a pre-discharge educational meeting and 6-month telephone coaching sessions. Patient's caregivers will also be invited to participate. After discharge, patients will be asked to measure their vital signs, daily. In case of alteration, the nurse will ascertain the presence of congestion symptoms and decide to reinforce the recommendations for self-management, request a specialist medical consultant, or refer to the emergency services
214381359|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy + app|In the group ACT+app, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer and interleaved non-contact activities, which will serve as support for each of the modules. The non-contact activities will consist of assigning tasks, practices (mindfulness, breathing), reminder systems, recording, reinforcement and monitoring. Resources such as short texts, videos, audio files and recording systems will be used
214381360|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy|In the group ACT, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer
214381361|NCT03351218|BEHAVIORAL|Behavioral testing - computerized tasks|Cognitive behavioral testing and cerebral MRI
214393849|NCT01930643|DEVICE|EMS|HELEX 573 : strength aggravation mode with middle frequency carrier(1500Hz), minimal voltage for visible muscle contraction(maximum output is 75mA) , 32 minutes per day.
214393850|NCT03680040|DIAGNOSTIC_TEST|Subjects previously implanted with a RESILIA aortic tissue valve.|Subjects to undergo multi-slice computed tomography and echocardiogram to assess predictors of valve durability in previously implanted Edwards aortic valves with RESILIA tissue.
214995133|NCT06179069|DRUG|Carboplatin|Drug Carboplatin
214995134|NCT06141135|OTHER|Preimplantation genetic testing for aneuploidy (PGTA)|24 chromosome screening for aneuploidy in the preimplantation embryo(blastocyst stage)
214995135|NCT02368496|DEVICE|HR-pQCT|
214995136|NCT04744623|DRUG|large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP|10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
214995137|NCT04171622|DRUG|Lenvatinib|Given PO
214995138|NCT04171622|BIOLOGICAL|Pembrolizumab|Given IV
214995139|NCT06337552|OTHER|FEED-FF|3-6 servings of any combination of the following fermented foods/day (from 1 week prior to treatment to approximately 12 weeks after the start of treatment): Yogurt, cottage cheese, kefir, kombucha, sauerkraut, and kimchi.
215092816|NCT05194527|OTHER|Biomarker validation and VOC profile identification|Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
215092817|NCT01878994|BEHAVIORAL|Counselling group|
215092818|NCT01878994|BEHAVIORAL|Nereu group|
214381362|NCT03875079|DRUG|RO6874281|"Part I Safety Run in:~Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study.~Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome).~Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule."
214381363|NCT03875079|DRUG|Pembrolizumab|"Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks).~Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome)~Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)"
214381364|NCT06058923|PROCEDURE|M-MIST|This is characterized by a vestibular mucoperiosteal envelope flap without relaxing incisions. Sulcular incisions will be made on the vestibular surface of the teeth included in the surgical area, adjacent to the infraosseous defect. The mesiodistal extension of the flap will be kept to a minimum necessary to access the defect. In the papillary area over the infraosseous defect, an oblique or horizontal incision will be made at the level of the interdental papilla, following the contour of the bone crest. The vestibular flap will be elevated, leaving the lingual/palatal portion adhered, only to allow access to the bone defect. The defect will be instrumented with mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after this procedure. Primary closure will be achieved with internal vertical and/or horizontal mattress sutures, which may be complemented with simple sutures, all using specific suture threads.
214393851|NCT04063111|DEVICE|vacuum assistant closure|Expose the open wound bed to negative pressure. This pressure removes edema or hemorrhage, mechanically pulls on the wound edges, decreases in wound surface area, improves circulation, and enhances proliferation of granulation tissue that filled the soft tissue defect.
214393852|NCT04063111|DEVICE|CONVENTIONAL DRESSING|CONVENTIONAL DRESSING for wound of open fracture of tibia grade III B
214393853|NCT03860064|OTHER|Non intervention|Non
214995140|NCT06337552|OTHER|Standard of Care (SUC)|Standard of Care (SUC) is the treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by health care professionals. Standard of Care will comprise general healthy eating handouts that describe typical healthy foods and the suggested level of servings per day.
214393854|NCT01414218|BEHAVIORAL|Humor as a Way of Life Seminar|One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
214995141|NCT00261521|DRUG|epoetin alfa|
214995142|NCT00361985|DRUG|Esomeprazole|Esomeprazole 40mg once daily orally.
214995143|NCT00361985|DRUG|Esomeprazole|Esomeprazole 40mg once daily orally
214995144|NCT03733535|DRUG|Benralizumab|Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
214995145|NCT03733535|DRUG|129 Xenon|1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
214995146|NCT04907266|OTHER|Structured Questionnaire|A structured proforma to assess outcome
214995147|NCT05917340|DRUG|High dose rifampicin (25mg/kg)|Given for 2 months
214995148|NCT05917340|DRUG|Moxifloxacin 400mg|Given for 2 months
214995149|NCT05917340|DRUG|Aspirin 150 mg|Given for 2 months
214995150|NCT05917340|DRUG|Isoniazid|Given for 6 months
214995151|NCT05917340|DRUG|Pyrazinamide|Given for 6 months
214995152|NCT05917340|DRUG|Steroid|Tapering dose of dexamethasone or prednisolone upto 8 weeks
214393855|NCT02951650|DEVICE|Cyberonics VNS|Vagus nerve stimulation
214995153|NCT05917340|DRUG|Rifampicin|Standard dose for 4 months after the initial treatment with high dose
214995154|NCT05917340|DRUG|HRZE|2 months
214995155|NCT05917340|DRUG|HRE|7-10 months as per TB program guidelines
214995156|NCT03274817|DRUG|Escitalopram Pill|Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
214995157|NCT03274817|DRUG|Venlafaxine Pill|Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
214995158|NCT03274817|DRUG|Placebo Oral Tablet|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
214995159|NCT05107115|DRUG|rilzabrutinib|Tablet, oral use
214995160|NCT05107115|DRUG|placebo|Tablet, oral use
214995161|NCT04834596|OTHER|retrospectives analysis on hepatic scanner|hepatic scanner will be analysed by two radiologist and by the software
214995162|NCT02497066|OTHER|Neuropathic pain cream|Subjects will apply the cream to the painful area.
214995163|NCT02497066|OTHER|Nociceptive pain cream|Subjects will apply the cream to the painful area.
214995164|NCT02497066|OTHER|Mixed pain cream|Subjects will apply the cream to the painful area.
214995165|NCT05778565|PROCEDURE|Extraocular muscle stretching|Extraocular muscle stretching to test its efficacy as a weakening procedure
214995166|NCT02072616|OTHER|Pancreatic adenocarcinoma diagnosis|
214995167|NCT03179384|DRUG|Ceftriaxone|ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
214995168|NCT00747604|BIOLOGICAL|mecasermin [rDNA origin] injection|As prescribed by the physician.
214995169|NCT04767451|DIAGNOSTIC_TEST|ultrasound assessment|Lead (Pb), Cadmium (Cd), Gadolinium (Gd), Arsenic (As), Mercury (Hg), Cobalt (Co), Vanadium (V), Titanium (Ti), Sulfur (S), Chromium (Cr), Silver (Ag), Molybdenum (Mo), Boron (B), Lithium (Li), and Nickel (Ni) measurements
214393856|NCT03385057|DRUG|Ibuprofen|Grape-flavored ibuprofen 100mg/5mL (Leader®) will be dispensed. Ibuprofen will be dosed at 10mg/kg (max dose 600mg) QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
214995170|NCT01641536|GENETIC|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
214995171|NCT05145972|OTHER|Ultrasound Guided Superior Hypogastric Plexus|The division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography , and the body of the fifth (5th) Lumbar vertebra will be identified by placing the transducer transversely. A skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. A 15-cm Long 22-G Chiba needle will be used with out of plane technique, and the needle will be advanced under USG-guidance to reach the anterior- most point of the fifth Lumber vertebral body avoiding the vascular structures. The needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. After confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. The uniform spread of the drug will be confirmed under real-time sonography.
214995172|NCT00712504|DRUG|sunitinib|25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
214995173|NCT00712504|DRUG|docetaxel|60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
214995174|NCT03588338|DRUG|Perfalgan|For postoperative pain
214995175|NCT03588338|DRUG|Control|For postoperative nausea and vomiting
214995176|NCT01799083|DRUG|Decitabine|A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
214995177|NCT01799083|BIOLOGICAL|cytokine-induced killer cell|Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
214995178|NCT02440867|DEVICE|Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
214995179|NCT02440867|DEVICE|Sham TBS|Sham stimulation
214995180|NCT04049461|DIAGNOSTIC_TEST|Bone alkaline phosphatase|Hematologic indicators reflecting ossification.
214995181|NCT04049461|RADIATION|Abdominal CT scan|Observe whether HOAI occurs.
214995182|NCT05223127|OTHER|Aloe vera|The leaves of Aloe vera (Aloe barbadensis) will be identified and verified by Selçuk University Faculty of Agriculture. Aloe vera leaves will be washed with antiseptic solution and cut crosswise using gloves and sterile knife. The thick epidermis will be removed from the middle of the leaf. The gel will be obtained from the parenchyma of the thick juicy leaves of aloe vera.
214995183|NCT05434702|BEHAVIORAL|Digital Diet Diary|Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.
214995184|NCT05434702|BEHAVIORAL|NHANES Food Frequency Questionnaire (FFQ)|Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.
214995185|NCT05434702|BEHAVIORAL|Fitbit data collection|Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.
214995186|NCT05434702|BEHAVIORAL|Quality of Life questionnaire|The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.
214995187|NCT05434702|BEHAVIORAL|Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire|The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
214995188|NCT05434702|BEHAVIORAL|Godin Exercise Leisure-Time questionnaire|The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).
214995189|NCT05434702|BEHAVIORAL|Zoom interviews|A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
214995190|NCT06048224|DRUG|HS628+MTX|Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week
214995191|NCT06048224|DRUG|Actemra +MTX|Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week
214498165|NCT03106922|DRUG|PMF104|"Powder for oral solution:~* Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~* Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water"
214995192|NCT00992875|BEHAVIORAL|Mindfulness-Based Stress Reduction|Behavioral intervention, mindfulness meditation in form of yoga, sitting meditation, body scan and mindfulness to routine activities
214995193|NCT02572167|DRUG|brentuximab vedotin|1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
214381365|NCT06058923|PROCEDURE|MIST|A vestibular envelope flap, without vertical relaxing incisions, will be raised on the vestibular and lingual/palatal sides. Primary intrasulcular incisions will be made to the alveolar crest, encompassing the teeth included in the surgical area. In the interproximal area, incisions will follow the principle of preserving the papilla (Modified Papilla Preservation Technique = MPPT or Simplified Papilla Preservation Flap = SPPF), depending on the available interproximal space (Cortellini et al., 1995, 1999). The mesiodistal extension of the flap will be minimized to provide adequate access to the defect. The defect will be instrumented using mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after these procedures. Flap closure will be achieved with internal horizontal and/or vertical mattress sutures, which may be modified or complemented with simple sutures, all using specific suture threads.
214381366|NCT05503966|BEHAVIORAL|Attentional Bias Modification|The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
214381367|NCT03946800|BIOLOGICAL|MEDI1191|Subjects will receive MEDI1191 (at least twice)
214381368|NCT03946800|BIOLOGICAL|Durvalumab|Subject will receive durvalumab every 4 weeks
214381369|NCT04658186|DRUG|UCB0599|Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
214381370|NCT04658186|DRUG|Placebo|Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
214995194|NCT02572167|DRUG|nivolumab|3 mg/kg by intravenous (IV) infusion for up to 4 cycles
214995195|NCT05262101|DRUG|TQB2858 injection|TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
214995196|NCT04761250|DIETARY_SUPPLEMENT|Lifestyle|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
214995197|NCT06571305|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|"BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time spent in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week."
215092819|NCT01711593|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
214381371|NCT05652036|BIOLOGICAL|Intradetrusor Botox Injections|100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
214381372|NCT05675332|BEHAVIORAL|Task-based behavioral intervention|Brief behavioral intervention is absent of stressors.
214995198|NCT06571305|BEHAVIORAL|My Sleep Our Sleep (MSOS)|"MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week."
215092820|NCT01711593|PROCEDURE|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
215092821|NCT06915376|DEVICE|CPES Monitoring|Noninvasive blood pressure data will be collected using a combined pulse oximeter and ECG signal system (CPES) during elective non-cardiac surgery under general anesthesia. This system is used for observational purposes and does not alter the standard of care. The goal is to compare CPES-derived blood pressure values with invasive arterial blood pressure measurements.
214381373|NCT05675332|BEHAVIORAL|Task-based behavioral intervention|Brief behavioral intervention involves interacting with common everyday types of stress.
214381374|NCT05335109|DRUG|Xenon|"Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days."
214381375|NCT05335109|DRUG|Oxygen 30 %|"Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days"
214381376|NCT05786274|DIAGNOSTIC_TEST|Cerebral autoregulation monitoring|Perioperative characterization of cerebral autoregulation and autonomic function; characterization of adverse events after surgery
214381377|NCT04978545|OTHER|calciumhydroxide, intracanal medicament|In the CH group, calcium hydroxide powder (Calxyl; OCO Products, Dirnstein, Germany) was mixed with saline in a ratio 1:1 and the paste was inserted into the canal by using lentulo spirals (Malleifer-Dentsply).
214381378|NCT04978545|OTHER|chlorhexidine, intracanal medicament|, chlorhexidine gel 2% (Gluco-Chex 2% gel, Cerkamed, Stalowa Wola, Polland) was placed into the root canals of this group with an Ultradent Capillary Tip (Ultradent products).
214995199|NCT00888836|PROCEDURE|Bariatric surgery: Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
214381379|NCT05500703|DRUG|Dexmedetomidine Injectable Solution|continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
214381380|NCT05500703|DRUG|Sodium Chloride 0.9% Inj|the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
214381381|NCT06077110|OTHER|Precision Care Clinic services|The Service Intervention is the Precision Care Clinic being delivered at the Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.
214381382|NCT03705845|DRUG|placebo softgel|Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
214381383|NCT03705845|DRUG|DeltaGold® Tocotrienol 70%|DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
214381384|NCT04804371|DRUG|F18-FDG|Evaluate FDG uptake
214381385|NCT06599619|DRUG|Single agent, adjuvant anti-PD1 therapy|"One of the following Single-agent, adjuvant anti-PD1 therapies:~Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.~Dose = 240 mg IV every 2 weeks/480 mg every 4 weeks or, Pembrolizumab is a monoclonal antibody and a type of immune checkpoint inhibitor that's used in cancer immunotherapy. It works by attaching to the PD-1 protein on the surface of T cells, which are immune cells. This prevents cancer cells from suppressing the immune system, allowing the immune system to attack and kill the cancer cells.~Dose = 200 mg IV every 3 weeks/ 400 mg every 6 weeks"
214381386|NCT06647524|DRUG|THC|Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)
214381387|NCT06647524|DRUG|Placebo|Participants will be administered identical plant material from which all THC has been removed by solvent extraction.
214381388|NCT05815316|DRUG|18F-PSMA-1007|(3S, 10S, 14S)-1-\[4-\[\[(2S)-4-carboxy-3-\[(2S)-4-carboxy-2-(6-\[18F\]fluoropyridin-3- amido)butanamido\]butanamido\]methyl\]phenyl\]-3- \[(naphtalen-2-yl)methyl\]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
214381389|NCT03390777|PROCEDURE|surgery|surgery without the use of prgf
214498166|NCT03106922|DRUG|Klean-prep|"Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water"
214498167|NCT01238146|DRUG|bendamustine hydrochloride|Given IV
214498168|NCT01238146|DRUG|obatoclax mesylate|Given IV
214498169|NCT01238146|BIOLOGICAL|rituximab|Given IV
214498170|NCT00790413|DRUG|iodine I 131 metaiodobenzylguanidine|
214995200|NCT00888836|PROCEDURE|Bariatric surgery: Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
214995201|NCT00888836|BEHAVIORAL|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (\<30% total fat and \<10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
214995202|NCT03833310|DIAGNOSTIC_TEST|Osteoprotegerin marker in serum in inflammatory bowel disease|I will measure Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand markers in serum of patient with inflammatory bowel disease
214498171|NCT00790413|DRUG|Fludarabine|
214498172|NCT00790413|DRUG|Thiotepa|
214498173|NCT00790413|PROCEDURE|T-cell depletion|
214498174|NCT00790413|PROCEDURE|Haploidentical stem cell transplantation|
214498175|NCT00790413|PROCEDURE|Donor Lymphocyte Infusion|
214498176|NCT00790413|DRUG|Rituximab|
214498177|NCT00790413|PROCEDURE|Co-transplantation of mesenchymal stem cells|
214498178|NCT03551379|DEVICE|Double Balloon Endoluminal Platform|A DBA platform will be use din this registry study to facilitate ESD
214498179|NCT05493644|OTHER|Remedial treatment within 3 months|Remedial therapy was performed within 3 months
214498180|NCT05493644|OTHER|Remedial treatment within 3 to 6 months|Remedial therapy was performed within 3 to 6 months
214498181|NCT05493644|OTHER|Remedial treatment within 6 to 12 months|Remedial therapy was performed within 6 to 12 months
214498182|NCT05493644|OTHER|Remedial treatment after 12 months|Remedial therapy was performed after 12 months
214498183|NCT01307085|PROCEDURE|remote ischemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
214381390|NCT03390777|DEVICE|PRGF after surgery|surgery and application of PRGF
214381391|NCT05706532|DIAGNOSTIC_TEST|active standing|Data are acquired with patients resting in supine position for 10 minutes and for 10 minutes during active standing
214381392|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 1|Compensation of a hearing loss with Sound Processing Principle 1.
214995203|NCT00005047|DRUG|cisplatin|
214995204|NCT00005047|DRUG|doxorubicin hydrochloride|
214995205|NCT00005047|DRUG|methotrexate|
214995206|NCT00005047|DRUG|vinblastine|
214995207|NCT06502483|BEHAVIORAL|Promoting Resilience in Stress Management Program|Promoting Resilience in Stress Management (PRISM; Rosenberg et al., 2018; Rosenberg et al., 2021) is is an evidence-based skills-based resilience intervention. In the current study, PRISM sessions with be facilitated by a trained mental health provider to equip participants with skills for coping with anxiety, low mood, and adjustment to cancer diagnosis and to target four resilience resources (i.e., stress management, goal setting, cognitive reframing, and meaning-making). Sessions will be conducted by phone or Zoom, a HIPAA-compliant telemedicine platform. The optional mPRISM phone application includes 6 modules to practice PRISM skills and is available for iOS/Android.
214995208|NCT06357767|BEHAVIORAL|Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence|A culturally-tailored, trauma-informed group intervention to support smoking cessation by leveraging Lakota values, mindfulness, and a storytelling approach.
214995209|NCT04609696|DRUG|Danicopan: Powder-In-Capsule 1|Danicopan (200 milligrams) will be administered orally on Day 1.
214995210|NCT04609696|DRUG|Danicopan: Powder-In-Capsule 2|Danicopan (200 milligrams) will be administered orally on Day 1.
214995211|NCT04609696|DRUG|Danicopan: Tablet|Danicopan (200 milligrams) will be administered orally on Day 1.
214995212|NCT05722301|DRUG|Testosterone Therapy|The testosterone pellet implantation will be performed 2 weeks before surgery. The dose is determined by baseline levels of sex hormone binding globulin (SHBG) in the following manner: If SHBG \> 60nmol/L implant 5 Testosterone Compounded 200mg (total 1000mgs testosterone). If SHBG 41-59 nmol/L implant 4 Testosterone Compounded 200mg (total 800mgs testosterone). If SHBG \<40 nmol/L implant 3 Testosterone Compounded 200mg (total 600mgs testosterone).
214995213|NCT05722301|OTHER|No Testosterone Therapy|For the sham procedure no pellets will be implanted.
214995214|NCT00232882|DRUG|Candesartan Thiazide|Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
214995215|NCT00232882|DRUG|Atenolol Thiazide|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
214995216|NCT00232882|DRUG|Thiazide Candesartan|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
214995217|NCT03301259|OTHER|One-shape rotationary system|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
214381393|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 2|Compensation of a hearing loss with Sound Processing Principle 2.
214498184|NCT01650896|OTHER|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
214498185|NCT05166590|BEHAVIORAL|Sleep Restriction|Sleep Deprivation
214995218|NCT06437171|BIOLOGICAL|Omalizumab|Omalizumab dose and frequency based on baseline subject weight and total IgE
214995219|NCT03120273|DRUG|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
214995220|NCT03120273|DRUG|Lansoprazole Injection|30 mg q12h for 5 days.
214995221|NCT05167539|PROCEDURE|Aortic valve surgery|mechanical aortic valve replacement versus ross procedure and stentless bioprothesis
214381394|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 3|Compensation of a hearing loss with Sound Processing Principle 3.
214381395|NCT03500640|BEHAVIORAL|DPP Intensive: 30-minute calls|Ongoing DPP intervention and behavioral progress review to prevent relapse and improve cardiometabolic and functional health targets as keys to healthy aging.
214381396|NCT03500640|BEHAVIORAL|DPP Support: 15-minute calls|No further behavioral intervention materials provided; phone-contacts for mutual social support and accountability
214381397|NCT06139718|BEHAVIORAL|ACT Guide Lite|ACT Guide Lite is a single session online mental health program that is designed to take 30-45 minutes to complete. The single session self-guided intervention includes a series of sections that teach key ACT skills.
214381398|NCT03754205|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
214498186|NCT01911767|DRUG|Dimethyl fumarate|Administered as specified in treatment arm.
214498187|NCT01911767|DRUG|Peginterferon beta-1a|Administered as specified in treatment arm.
214995222|NCT00088153|DRUG|Physiologic Estrogen/progesterone|Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
214995223|NCT00088153|OTHER|Placebo|Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
214995224|NCT04589767|BEHAVIORAL|CAPD scale|Two nurses will apply CAPD scale. One nurse will repeat the CAPD evaluation two minutes later
214995225|NCT00107497|RADIATION|Radiation therapy|
214995226|NCT00208975|DRUG|Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF|"Initial patients (n=9) received fludarabine (25 mg/m\^2 intravenously) and mitoxantrone (10 mg/m\^2 intravenously)with sequential administration of GM-CSF(Granulocyte-macrophage colony stimulating factor) (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m\^2 intravenously) and cyclophosphamide (250 mg/m\^2 intravenously)with sequential administration of GM-CSF (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8. All patients received additional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
214995227|NCT01349387|DRUG|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
214381399|NCT03546348|OTHER|no intervention|only measurement of the carrying angle
214381400|NCT01108393|DRUG|Agomelatine A|"Agomelatine 25 mg film-coated tablet~Agomelatine 2x25mg film-coated tablet"
214381401|NCT01108393|DRUG|Placebo|Placebo
214381402|NCT03264963|OTHER|Smart phone game play|Voice controlled smart phone game play 15 minutes daily and recording sounds of sleep environment 2 night per week for 12 weeks
214381403|NCT03264963|OTHER|Control|Recording of sleep environment 2 nights per week for 12 weeks
214381404|NCT01650519|DRUG|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
214498188|NCT03562325|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The main target in ACT for ME/CFS (as for Fibromyalgia and Chronic pain in previous studies by our group) is to promote a shift of perspective in life from symptom reduction (when it does not work) to a valued life. As such it entails acceptance and exposure to discomfort, in order to lessen the effects of negative experiences (symptoms, emotions, thoughts) on behaviours in everyday life.
214498189|NCT02479672|DEVICE|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
214498190|NCT02479672|PROCEDURE|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
214995228|NCT04065620|DIAGNOSTIC_TEST|ambulatory blood pressure measurement|24-hour ABPM will be made using validated devices, following ABPM device should be programmed to take measurements every 30 minutes . Patients will be instructed in their use. Periods of activity and rest will be pre-determined in short windows: for Asian and European Countries daytime period will be defined between 10:00 and 8:00 pm; and night-time period between 00:00 am and 6:00 am. For Latin American Countries daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 00:00 am and 6:00 am. For Africa daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 11 PM and 5 AM In addition, the duration of ABPM (hours), the percentage of valid readings, and the mean SBP/DBP values during periods of activity, rest and in 24 hours will be recorded. Records with a duration \<24 hours, those without one good reading per hour and those with \<70% of satisfactory readings will be excluded
214995229|NCT05289882|BEHAVIORAL|PASS Program Condition:|Participants randomized to this condition will be invited to take part in weekly ball hockey games (once per week), that will last approximately 60 minutes, and will be followed by opportunities to socially connect afterwards. The results of our feasibility study indicated that the PASS program acted as an important conduit to direct participants to other support services and resources (e.g., counseling, career transition centre, employment, education). Military veteran men are often reluctant to access such supports, especially if they attach stigma to such services (e.g., mental health services). At each site, a military veteran will be trained as a facilitator to operate as a conduit to refer participants to the relevant support services and agencies.
214995230|NCT05251870|DRUG|autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70|Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.
214498191|NCT02479672|DEVICE|VividTrac®|
214498192|NCT00610558|DEVICE|Arm 1: Juvenile Myoclonic Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
214498193|NCT00610558|DEVICE|Arm 2: Frontal Lobe Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
214995231|NCT04612400|OTHER|Oral amino acid tracer|Whole body protein metabolism response to a dose of the supplement will be measured using a continuous oral sip-feeding (every 10 minutes) method of stable isotope tracer.
214995232|NCT05486728|DRUG|SHJ002/Vehicle|Topical ophthalmic
215092822|NCT01339117|OTHER|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
214381405|NCT01650519|DRUG|IV ketorolac|30 mg ketorolac for patients \< 65 years of age (15 mg ketorolac for patients \> 65 years of age) administered intravenously over no less than 15 seconds
214381406|NCT04808375|OTHER||
214381407|NCT00259415|BEHAVIORAL|Caregiver support via telephone|
214381408|NCT04031521|DIAGNOSTIC_TEST|Near infrared spectroscopy|NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
214381409|NCT05581615|OTHER|Inulin|Each intervention provided 10 g/d inulin split into two dosages of 5 g.
214381410|NCT02993939|PROCEDURE|Interscalene block|Ultrasound guided single shot block above the clavicle
214381411|NCT02993939|PROCEDURE|Infraclavicular-suprascapular block|Combined block of nerves far away from phrenic nerve
214381412|NCT01202487|DRUG|LET - Lidocaine Epinephrine Tetracaine|One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
214498194|NCT00610558|DEVICE|Arm 3: Normal Controls|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
214498195|NCT05645068|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography
214498196|NCT05645068|OTHER|multidisciplinary care program|multidisciplinary care program including sports activity
214498197|NCT01557036|DEVICE|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
214498198|NCT01291628|DEVICE|socks containing copper-oxide fibers|The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
214498199|NCT04639869|DRUG|Phenyramydol HCl 400 mg Film Tablet|Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
214498200|NCT04639869|DRUG|Cabral 400 mg Film Tablet|Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
214498201|NCT04718610|OTHER|Osteopathic intervention|Nerve vagus stimulation
214381413|NCT04092465|PROCEDURE|Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy|Resection of the downstaged locally advanced NSCLC through formal thoracotomy
214381414|NCT00015821|DRUG|thalidomide|Given PO
214381415|NCT00015821|OTHER|laboratory biomarker analysis|Correlative studies
214381416|NCT02705781|DEVICE|smARTrack Feeding Tube System|
214381417|NCT01639105|PROCEDURE|Laser treatment|10 600 NM ABLATIEVE FRACTIONATED LASER
214381418|NCT05398146|BEHAVIORAL|mathematical operations|Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.
214381419|NCT05398146|BEHAVIORAL|ball squeezing|For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.
214381420|NCT05398146|BEHAVIORAL|listening to music|Children were allowed to listen to music with headphones during dressing changes.
214381421|NCT05398146|OTHER|kontrol grubu|No application was made during dressing change in children. Routine dressing change of the clinic was applied.
214381422|NCT04888247|DEVICE|CLARITY|Trans-septal mitral valve replacement
214381423|NCT03860168|OTHER|PICU Up!|The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
214381424|NCT05889923|DEVICE|With EDU|using the EDU to perform the procedure
214381425|NCT05965843|OTHER|underling disease|"Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.~For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.~More efforts shoud be make to explore the association between underlying diseases and severe COVID-19."
214381426|NCT00732602|OTHER|GIP-infusion|
214381427|NCT00732602|OTHER|Sodium-chloride|
214381428|NCT00732602|OTHER|GLP-2 infusion|
214498202|NCT04718610|BIOLOGICAL|CRP assessment|Blood CRP will be assessed during trial
214995233|NCT00643253|BEHAVIORAL|LC and Electronic Prompt|Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
214995234|NCT06310135|DEVICE|Filtered Eyewear|Filtered binocular viewing condition will be produced by eyeglasses frames with orange-tinted blue-blocking filter, eliminating all optical radiation for wavelengths shorter than 540 nm. For the filtered monocular condition, only the lens on the eyeglasses frame on the non-dominant eye will be tinted with the blue-blocking filter.
214995235|NCT06310135|DEVICE|Unfiltered Eyewear|For the unfiltered binocular, the subjects will wear transparent eyeglasses frames with no optical power. Unfiltered monocular vision will be produced by an opaque eyepatch occluding the non-dominant eye.
214995236|NCT06310135|OTHER|No Filters|Dim lights with no filters.
214995237|NCT04426656|BEHAVIORAL|Phone application|"The mini-app (used in Part 2) has four main functions:~1. a knowledge center that contains a series of HIV-, sexual health-, and PrEP-related educational articles in Chinese;~2. an HIV self-test toolkit ordering system that allows users to order a finger-prick HIV rapid test toolkit and shipped to home for free (one piece at a time);~3. an asynchronous message function that allows users to chat with a study staff (C.Li); and~4. a user profile page where users can manage all HIV test orders."
214381429|NCT05433324|OTHER|MRI and PET Scans|All groups will undergo cognitive tests and brain imaging scans (MRI \& PET)
214381430|NCT05336409|BIOLOGICAL|CNTY-101|CNTY-101 cells for intravenous (IV) infusion
214381431|NCT05336409|BIOLOGICAL|IL-2|IL-2 subcutaneous (SQ) injection
214381432|NCT05336409|DRUG|Lymphodepleting Chemotherapy|LDC as prespecified in the protocol.
214381433|NCT04856501|BEHAVIORAL|PALS intervention condition|The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.
214381434|NCT04856501|BEHAVIORAL|Control condition|Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
214498203|NCT04718610|BEHAVIORAL|QLQ-C30 questionnaire|Completion of QLQ-C30
214498204|NCT06457516|COMBINATION_PRODUCT|Mirror Therapy|A mirror is used to create a reflective illusion of an affected limb in order to trick the brain into thinking movement has occurred without pain, or to create positive visual feedback of a limb movement. It involves placing the affected limb behind a mirror.
214498205|NCT06457516|OTHER|Music Therapy|Music therapy, an allied health profession, the clinical and evidence-based use of music interventions to accomplish individualized goals
214381435|NCT06411327|DEVICE|Augmented reality|Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.
214995238|NCT05664789|DRUG|N acetyl cysteine|N-acetylcysteine (NAC) is an over-the-counter dietary supplement that is relatively well tolerated and exhibits minimal side effects, even at high dosages. N
214995239|NCT05664789|DRUG|Placebo|matched placebo
214995240|NCT04754074|BEHAVIORAL|Education|Weekly education related to behavior change
214995241|NCT04754074|BEHAVIORAL|Personalized coaching|Weekly calls with personalized coaches in behavior modification, nutrition, and physical activity/exercise.
214995242|NCT04754074|BEHAVIORAL|Weekly behavior modification challenges|Weekly challenges to address behavior change
214995243|NCT03952741|BEHAVIORAL|Physical Therapy|
214995244|NCT06504862|DRUG|Zongertinib|Zongertinib
214995245|NCT06504862|DRUG|Dabigatran-etexilate|Dabigatran-etexilate
214995246|NCT06504862|DRUG|Rosuvastatin|Rosuvastatin
214995247|NCT06504862|DRUG|Metformin hydrochloride|Metformin hydrochloride
214995248|NCT06504862|DRUG|Furosemide|Furosemide
214381436|NCT06411327|DEVICE|LCD Screen|LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.
214687387|NCT07042516|DRUG|Asimadoline|Asimadoline TP0052 2.5 mg two (2) tablets bid (two on awakening and two before bed), total of four (4) tablets daily (10 mg) for 8 weeks.
214995249|NCT06526429|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
214995250|NCT04451785|BIOLOGICAL|blood sample|6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).
214995251|NCT04451785|DIAGNOSTIC_TEST|Pulse wave velocity|Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.
214995252|NCT01500551|DRUG|Tofacitinib|"Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet \[mg BID\] or solution \[ml BID\]) 5 - \< 7 kg (2 mg or 2 ml) 7 - \< 10 kg (2.5 mg or 2.5 ml) 10 - \<15 kg (3 mg or 3 ml) 15 - \<25 kg (3.5 mg or 3.5 ml) 25 - \<40 kg (4 mg or 4 ml) \>=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing \<40 kg. Oral tablets (5 mg) will be used for subjects weighing \>=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing."
214995253|NCT01500551|DRUG|Tofacitinib|For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
214381437|NCT06818201|DEVICE|NIBS|A total of 16 sessions will be scheduled, distributed over 8 weeks (2 sessions/week). The continuous current intensity will be set at 2 mA, for 20 minutes. Two electrodes, anode (red) and cathode (black), will be used along with two sponge pads with conductive gel, all combined into a helmet for each patient. The electrodes will be placed according to the international 10-20 system in tDCS. The stimulated area will be the primary motor cortex (M1), so the anode will be placed at the C3 or C4 points and the cathode will be placed at the contralateral supraorbital area Fp1 or Fp2.
214381438|NCT06818201|PROCEDURE|Rehabilitation|This protocol will consist of 72 sessions, distributed as 3 sessions per week over a period of 24 weeks. Strength will be the prioritized method of work and will be present in all phases. Additionally, periodic measurements will be included to ensure that the patient is making adequate progress and meets the necessary progression criteria to advance to the next phase
214381439|NCT06818201|BEHAVIORAL|Sham Comparator|The device will be configured to produce an ascending ramp lasting 30 seconds, identical to the one used in the experimental group, followed by a descending ramp of another 30 seconds. Thus, the control group will experience a sensation of tingling on the scalp, similar to that felt by the experimental group. This stimulation will have a total duration of 1 minute, which will not be sufficient to induce changes in cortical excitability
214381440|NCT03557086|BEHAVIORAL|Advance Care Planning Video Decision Support Tool|Advance care planning video intervention as previously described
214381441|NCT03557086|OTHER|Verbal Narrative|Verbal description of end of life care options
214687388|NCT06739226|BIOLOGICAL|Antigen-specific CAR T, CTL and DCvac to treat melanoma.|Antigen-specific CAR T, CTL and DCvac to treat melanoma.
214687389|NCT02798497|OTHER|Serum and Blood samples|
214995254|NCT04208529|BIOLOGICAL|CTX001|CTX001 infusion.
214995255|NCT04132778|DEVICE|AsthmaTuner|Conventional treatment was defined as non-digital self-management using paper individual treatment plans, which contained treatment adjustments of prescribed medications according to symptoms of controlled, partly controlled or uncontrolled asthma, along with instructions according to national guidelines.
214995256|NCT05128383|DRUG|Dupilumab|Dupilumab a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits interleukin (IL)-4 and IL-13 signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes.
214995257|NCT03838354|DRUG|Chidamide|In the 2.5 mg group, chidamide will be administered orally at an initial dose of 2.5 mg twice per week for 12 weeks. If an initial response was achieved by week 12, the allocated treatment could continue. Patients in 2.5 mg group were allowed to increase dose to 5 mg if platelet counts were less than 30×10\^9 cells per L or less than two-times increase from baseline platelet count at week 12 according to investigators' advice and the patients' decision.
214687390|NCT06784336|DRUG|Iron chelation|Patients will receive Iron chelation with deferasirox (Jadenu 7 mg/kg/day preferred versus Exjade 10 mg/kg/day) beginning on day -14 and continuing through day +100
214381442|NCT06362902|PROCEDURE|Laparoscopic right hemicolectomy with transrectal specimen extraction|Laparoscopic right hemicolectomy with transrectal specimen extraction
214381443|NCT00555022|DRUG|GSK1160724|GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
214381444|NCT00555022|DRUG|Tiotropium bromide|Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.
214381445|NCT00555022|DRUG|Placebo|Subjects will receive placebo.
214381446|NCT05740410|DEVICE|ClotTriever Catheter|Treatment of iliofemoral deep vein thrombosis with the ClotTriever catheter
214995258|NCT03838354|DRUG|Chidamide|In the 5 mg group, chidamide will be administered orally at an initial dose of 5 mg twice per week for 12 weeks. If an initial response was achieved by week 12, the allocated treatment could continue. Patients who did not respond to chidamide at 5 mg for 12 weeks would stop the allocated treatment and were continuously followed up.
214381447|NCT00156806|PROCEDURE|Aloe barbadensis topical application in a moisturizing cream vehicle.|
214381448|NCT04504643|OTHER|Technology-assisted circuit training|Circuit training assisted by Fitlight™ 3 times a week for one hour during 8 weeks
214381449|NCT04504643|OTHER|Conventional circuit training|Conventional circuit training including single and dual task 3 times a week for one hour during 8 weeks
214381450|NCT04504643|OTHER|Nordic walking|Classic nordic walking 3 times a week for one hour during 8 weeks
214381451|NCT01454635|DRUG|Sertraline|dosage,frequency and duration
214687391|NCT06784336|DRUG|Potato Resistant Starch|Patients will receive PRS beginning on day -6 and continuing through day +100. Patients will take 20g packet twice daily
214995259|NCT04379050|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
214995260|NCT02275533|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214995261|NCT02275533|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214995262|NCT02275533|OTHER|Clinical Observation|Undergo standard of care clinical observation
214995263|NCT02275533|PROCEDURE|Echocardiography Test|Undergo ECHO
214995264|NCT02275533|BIOLOGICAL|Nivolumab|Given IV
214995265|NCT00700765|DRUG|insulin detemir|For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
214995266|NCT06543173|PROCEDURE|Prophylactic Catheter-based VT Ablation|Prophylactic Catheter-based VT Ablation refers to a treatment strategy where participants undergo a procedure known as catheter-based ventricular tachycardia (VT) ablation shortly after receiving their primary implantable cardioverter defibrillator (ICD).
214995267|NCT04780321|BIOLOGICAL|Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1
214995268|NCT04780321|DRUG|Placebo|30 patients receipt placebo intravenous infusion on day 1
214995269|NCT04357795|DRUG|CequaTM (Cyclosporine 0.09%) ophthalmic solution|One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
214995270|NCT03843528|DRUG|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
214995271|NCT03843528|DRUG|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
214995272|NCT02523209|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.
214381452|NCT02390934|RADIATION|Radium 223|
214381453|NCT01129635|PROCEDURE|Cardiac Resynchronization Therapy (CRT) implantation|"The impedance measurement is performed during device implantation following CMR. After the RV and LV leads are inserted, secured and tested, they will be connected to the impedance monitor. Impedance recording of at least ten beats will be acquired and stored for future analysis. Each recording will be tagged with the anatomical location of the LV lead. Subsequently, the LV lead will be moved to a different location and the same procedure will be repeated until accessible coronary sinus sites are exhausted. The ultimate LV lead location is determined by the implanting electrophysiologist and is not constrained by the study protocol. Finally, the LV lead will be tested again and the rest of the implantation procedure will proceed as routine.~Arm: CRT Candidate"
214381454|NCT00925535|DRUG|Lersivirine|1000 mg once daily for 10 days
214687392|NCT07058077|DRUG|Enlicitide Decanoate|Enlicitide decanoate taken by mouth
214381455|NCT00925535|DRUG|Rifabutin|300 mg once daily for 10 days
214381456|NCT00925535|DRUG|Lersivirine|1000 mg once daily for 10 days
214381457|NCT00925535|DRUG|Rifabutin|300 mg once daily for 10 days
214381458|NCT00978484|BEHAVIORAL|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
214381459|NCT00978484|BEHAVIORAL|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
214687393|NCT07058077|DRUG|Placebo|Placebo tablet matched to enlicitide decanoate taken by mouth
214995273|NCT02523209|DEVICE|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( \<15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
214995274|NCT05784675|DEVICE|MOBI-CPR game|Participants use MOBI-CPR game at home environment.
214995275|NCT05644925|DEVICE|PiCSO Impulse System|The PiCSO Impulse System is intended to reduce infarct size by intermittently occluding the coronary sinus outflow in patients undergoing a percutaneous coronary interventional procedure for myocardial infarction and presenting with Thrombolysis in myocardial infarction (TIMI) flow of 0 or 1.
214995276|NCT05644925|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Minimally invasive procedures used to open clogged coronary arteries
214995277|NCT06627764|BEHAVIORAL|SER Familia|SER Familia is a six-session intervention co-developed and delivered by community health workers (CHWs) that uses strategies to reduce acculturative stress, promote resilience, improve parent-child and family level health, while simultaneously helping families maintain strong social networks and better navigate community resources to address social determinants of health (SDOH).
214995278|NCT06387069|DRUG|HMPL-306 Regimen|Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.
214995279|NCT06387069|DRUG|Salvage Chemotherapy Regimen|"Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:~* EA±Mitox regimen: etoposide injection 100 mg/m2, cytarabine injection 100-150 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).~* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 1000-2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).~* LoDAC: -Cytarabine Injection 20 mg every 12 hours, subcutaneous or IV for 10 consecutive days (Days 1-10).~* Azacitidine: Azacitidine Injection 75 mg/m2, QD, subcutaneous or IV for 7 consecutive days (Days 1-7)."
214995280|NCT05248386|DRUG|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
214995281|NCT05248386|DRUG|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
214995282|NCT02571985|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation System|Zenith® Branch Endovascular Graft-Iliac Bifurcation (Branch Graft) with the ConnectSX™
214995283|NCT03534323|DRUG|Duvelisib|This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
214995284|NCT03534323|DRUG|Venetoclax|Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
214995285|NCT02312843|BEHAVIORAL|Exercise/Aerobic|
214995286|NCT02312843|BEHAVIORAL|Exercise/Stretching|
214995287|NCT06174207|OTHER|Oxygen|Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula.
214995288|NCT03303248|BEHAVIORAL|Web-based Educational Intervention|A web-based educational tool, created for patients with congenital heart disease, will be given to patients using an ipad. This additional educational tool will be used with the standard of care visit with provider.
214995289|NCT05242211|OTHER|exercise test|Each participants will conducted an exercise test on treadmill (using Modified Bruce Protocol) and cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange. 10 minute after the graded exercise test Supra maximal exercise test (SMT) will be done for 2 minutes one stage (treadmill protocol) or 10% at cycle protocol higher than highest load achieved in the incremental test.
214995290|NCT05348317|BEHAVIORAL|VetReach|Telehealth-delivered MI-CBT substance use disorder care model
214995291|NCT00077818|DRUG|Enoxaparin sodium|
214995292|NCT00287820|DRUG|Olanzapine|olanzapine 5-40 mg/day
214995293|NCT00287820|DRUG|olanzapine|olanzapine 5-40 ,mg/day
214995294|NCT00287820|DRUG|risperidone|risperidone 1-12 mg/day
214995295|NCT05100667|OTHER|Hypoxia|altitude (3800m)
214995296|NCT05100667|OTHER|Normoxia|sea level
214995297|NCT04909138|DEVICE|DRG stimulation 20 Hz 30/90|Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF
214995298|NCT04909138|DEVICE|DRG stimulation 5 Hz 30/90|Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
214995299|NCT03435419|DIAGNOSTIC_TEST|LoopampTM Leishmania Detection Kit|LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection
214995300|NCT03435419|DIAGNOSTIC_TEST|CL DetectTM Rapid Test|CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection
214995301|NCT06000670|PROCEDURE|stromal vascular fraction injection in the osteoarthritic knee|stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.
214995302|NCT04928300|DRUG|Dexmedetomidine|low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.
214995303|NCT04928300|DRUG|Ketamine|low dose ketamine infusion 2.5 µ/kg/min for 5 days.
214995304|NCT04928300|OTHER|0.9% saline|the same dose and duration of normal saline will be given for 5 days.
215092823|NCT01339117|OTHER|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
215092824|NCT00110461|DRUG|Aripiprazole|Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
214995305|NCT06172361|DRUG|Prednisone+Tofacitinib|"Withdrawal of prednisone (or equivalent dose of methylprednisolone) within 4 weeks: 5mg tid for 2 weeks, 5mg bid for 1 week, 5mg qd for 1 week, then discontinue.~Take Tofacitinib 10mg/d for 3 months, then 7.5mg/d for 2 months, followed by 5mg qd for 2 months, then 5mg qod for 2 months, and finally 5mg every 3 days for 2 months, discontinue the Tofacitinib for 1 month. If there is a relapse during the dose reduction process, resume Tofacitinib at the original dosage."
214995306|NCT06172361|DRUG|Prednisone|Prednisone 15mg (or equivalent dose of methylprednisolone) was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-10 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 6-8 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. If reducing pred dosage is difficult, Methotrexate (MTX) 10mg qw can be added after 24 weeks.
214381460|NCT03204084|DEVICE|Low-temperature Plasma Surgery System|In pterygium surgery with fibrin glue(FG) and conjunctival autograft we use Low-temperature Plasma Surgery System(LTP)do the ablation of tissue and hemostasis.
214381461|NCT01279343|DEVICE|Foley bulb|This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
214995307|NCT04324112|DRUG|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
214995308|NCT04324112|DRUG|Encorafenib|Encorafenib will be given orally at a dose of 450mg QD continuously for 28-day cycles with no resting period between cycles.
214995309|NCT04657991|DRUG|Encorafenib|Encorafenib
214381462|NCT05288725|BIOLOGICAL|Bone Marrow Derived MSCs|Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.
214381463|NCT05288725|DRUG|Corticosteroid|The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.
214381464|NCT05288725|DEVICE|Bone Marrow Aspirate|The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.
214381465|NCT03340584|OTHER|the Nine Castle Net Format Taping|The intervention group received traditional rehabilitation and Taping throughout all rehabilitation period.The taping including a Nine Castle Net Format of taping in both side of surgery knee.We will exchange the new taping for every two days， for a week.Traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
214381466|NCT03340584|OTHER|traditional rehabilitation|traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
214381467|NCT01529281|DIETARY_SUPPLEMENT|Branch Chain Amino Acid (BCAA)|Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with \~300 ml of water.
214381468|NCT01529281|DIETARY_SUPPLEMENT|Placebo - asparmate|Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with \~300 ml of water.
214381469|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
214381470|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
214381471|NCT04444284|OTHER|Placebo|Single dose administered intranasally on Day 1
214381472|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3)|Single dose administered intranasally on Day 1
214381473|NCT06540001|DEVICE|Automated visual acuity|The automated visual acuity device is developed in collaboration with Tan Tock Seng Hospital, Singapore Institute of Technology and Nanyang Technological University. It uses artificial intelligence for pose estimation and speech recognition to infer if the participant is reading the correct letters displayed on the screen.
214687394|NCT06754943|DRUG|Treatment A_Period 1|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
214381474|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
214381475|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
214381476|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, \<= 4 mg, Once daily, 7 days
214381477|NCT00836602|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
214381478|NCT00161070|DRUG|anticoagulation|
214381479|NCT00161070|DRUG|aspirin and dipyridamole|
214381480|NCT00161070|DRUG|aspirin alone|
214381481|NCT03245255|DRUG|Sonazoid|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Sonazoid infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure, SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
214381482|NCT03163576|DRUG|Niacin|tablets
214381483|NCT03163576|DRUG|Phosphate Binder|tablets
214381484|NCT03454464|PROCEDURE|Conventional|Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure
214381485|NCT03454464|PROCEDURE|central neck dissection first|central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
214381486|NCT00968435|OTHER|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
214381487|NCT01919359|DIETARY_SUPPLEMENT|Multizyme Cellular Vitality Cyruta Plus SHEP|
214995310|NCT04657991|DRUG|Binimetinib|Binimetinib
214995311|NCT04657991|DRUG|Pembrolizumab|Pembrolizumab
214381488|NCT01196208|DRUG|brentuximab vedotin|Every 21 days by intravenous infusion (1.8 mg/kg)
214381489|NCT04765735|DEVICE|Open-loop testing, Closed-loop testing - External Spinal Cord Stimulator (SCS)|SCS therapy with an external neurostimulator using either open-loop or closed loop algorithm
214381490|NCT02623114|DRUG|methylphenidate|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
214381491|NCT02623114|DRUG|atomoxetine|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
214381492|NCT05640622|OTHER|Gait Outcomes Assessment List (GOAL)|Gait Outcomes Assessment List (GOAL) is a scale developed to contribute to the determination of treatment goals. This questionnaire includes the priorities, expectations, and goals of children with CP who can walk and reveals their walking characteristics.
214687395|NCT06754943|DRUG|Treatment B_Period 2|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
214995312|NCT06129734|DRUG|Venetoclax|Venetoclax is a BCL2 inhibitor. It is administered at low doses and used in combination with other hypomethylating agents such as decitabine to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants will initiate therapy with decitabine that will be followed by venetoclax 400 mg oral 6-8 hours later. Participants will continue this dose each week. The venetoclax dose will be reduced to 100 mg once per week if the participant is being treated with posaconazole or voriconazole (strong CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). The venetoclax dose will be reduced 200 mg once per week if the participant is being treated with fluconazole or isavuconazole (moderate CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). This clinical trial is administering venetoclax well below the current FDA approved dosing.
214995313|NCT06129734|DRUG|Decitabine|Decitabine is a hypomethylating agent. It is administered at low doses and used in combination with venetoclax to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants initiate therapy with 5 mg/m2 decitabine subcutaneous every week followed by venetoclax.
214995314|NCT03776630|OTHER|Blood sample|"Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample."
214995315|NCT02588365|BEHAVIORAL|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving
214995316|NCT02588365|BEHAVIORAL|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving
214995317|NCT02588365|BEHAVIORAL|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem solving
214995318|NCT02627807|RADIATION|IMRT using individualized CTV|Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
214995319|NCT02627807|RADIATION|IMRT using traditional CTV|Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
214995320|NCT02627807|DRUG|Gemcitabine and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
214995321|NCT02627807|DRUG|Docetaxel and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
214381493|NCT01800695|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
214381494|NCT01800695|DRUG|Temozolomide|Temozolomide will be administered per label and local prescribing regulations.
214381495|NCT01800695|RADIATION|Whole Brain Radiation|Whole Brain radiation will be administered in 30 fractions.
214381496|NCT02458001|BEHAVIORAL|SAFFRON stepped care|"Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.~Assessment Algorithm FSFI Interventions~Level 1:~Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.~Level 2:~A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.~Level 3:~16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)"
214381497|NCT06386081|DIETARY_SUPPLEMENT|Citrus pectin with low DE|Dietary intervention with citrus pectin with low DE. Participants will orally take the supplement twice a day, after dissolving it in 100ml of water, for 2 months.
214381498|NCT06386081|DIETARY_SUPPLEMENT|Apple pectin with high DE|Dietary intervention with apple pectin with high DE. Participants will orally take the supplement twice a day, after dissolving it in 100ml of water, for 2 months.
214381499|NCT06386081|DIETARY_SUPPLEMENT|Placebo|Participants will orally take the placebo (maltodextrin) twice a day, after dissolving it in 100ml of water, for 2 months. Maltodextrin is highly digestible and in small amounts will have limited impact on gut microbiome.
214687396|NCT06754943|DRUG|Treatment A_Period 3|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
214687397|NCT06754943|DRUG|Treatment B_Period 4|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
214381500|NCT04670926|DIAGNOSTIC_TEST|TruGraf|"TruGraf results will be available in real-time and used by the physician in conjunction with other standard of care labs to guide management of immunosuppression as follows:~Patients with a stable serum creatinine and eGFR of \> 45 mL/min who also have a TruGraf TX result at month 3 will have their Mycophenolate Mofetil or Mycophenolate Sodium decreased from a standard dose of 1000 mg twice daily to 500 mg twice daily or 720 mg twice daily to 360 mg twice daily respectively.~Patients with a stable serum creatinine and estimated eGFR of \> 45 mL/min who also have a TruGraf TX result at months 4, 5, and 6 will have their Tacrolimus target trough level decreased to a target between 3 and 6.~Patients with TruGraf not-TX will have no further immunosuppression reduction and continued to be monitored."
214381501|NCT04670926|OTHER|Standard of Care|Patient's immunosuppression will be managed per the current CPMC standard of care that includes continuation of Mycophenolate Mofetil or Mycopheonolate Sodium at 1000 mg bid or 720 mg bid respectively. The dose may be decreased at the discretion of the physician for drug adverse effects such as diarrhea or other gastrointestinal side-effects or neutropenia as is the standard of care. Patients will be maintained on Tacrolimus at target levels that are considered standard of care by the managing physician.
214381502|NCT01495221|DRUG|Alfilbercept|All patients will receive 2.0 mg intravitreal aflibercept injection.
214381503|NCT01556074|BEHAVIORAL|Yoga treatment|Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
214381504|NCT05655104|OTHER|Couplet Care|In the Couplet Care model, the parents are provided access to the infant stabilisation room and encouragement for early skin-to-skin contact, mothers receive their postpartum care in the same NICU room with the infant, and fathers/partners also have a bed in the same NICU room.
214381505|NCT06529549|OTHER|Organoid-Based Drug Sensitivity Screening|Residual tissue of bone metastatic sites from biopsies for genetic testing will be collected to culture organoid and perform drug sensitivity screening
214381506|NCT05340218|OTHER|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
214381507|NCT01250119|DRUG|erlotinib [Tarceva]|150 mg daily, orally
214381508|NCT00002163|DRUG|Abacavir sulfate|
214381509|NCT01383057|PROCEDURE|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
214381510|NCT03508999|DRUG|Metronidazole gel|The application of metronidazole gel is effective in the management of gingivitis in patients undergoing orthodontic therapy. Additionally, the constant reminder therapy at weekly interval would also lead to improvement in the oral hygiene.16 According to pertinent literature survey, none of the study has been conducted to compare the effectiveness of SMS reminders and use of anaerobic gel to reduce gingival inflammation.
214381511|NCT03508999|OTHER|SMS text reminder|Subjects will be provided biweekly reminder via 'SMS text reminder' in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
214381512|NCT03508999|OTHER|Placebo gel|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
214995322|NCT02627807|DRUG|Cisplatin 100mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
214995323|NCT02627807|DRUG|Cisplatin 80mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
214995324|NCT04869280|OTHER|No Intervention|This is a non-interventional study.
214995325|NCT01139879|DEVICE|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
214995326|NCT03859297|BEHAVIORAL|Rumination-Focused CBT|"RF-CBT targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effectively coping with rumination. RF-CBT specifically targets rumination through psychoeducation, adopting a functional analytic approach to the learned habitual behavior of rumination, and a focus on shifting process style. The adolescent is taught to notice triggers to ruminate as well as the consequences of rumination and to shift into practicing a more adaptive strategy such as an attention training exercise, behavioral activation, thinking in a concrete way, or active problem-solving. RF-CBT directly teaches adolescents to recognize rumination or when the participant gets stuck in their head and to notice the influence this has on their mood."
214995327|NCT03859297|BEHAVIORAL|Relaxation-based Therapy|Sessions will include progressive muscle relaxation, simple breathing techniques, and guided imagery that focus on bodily and somatic relaxation. Adolescents randomized to Relaxation Therapy (RelaxT) will also receive exercises to do as homework in between sessions, parallel to the RF-CBT group.
214995328|NCT04321512|OTHER|There is no intervention given to the subjects|Not appicable
214995329|NCT03867084|BIOLOGICAL|Pembrolizumab|IV infusion of Pembrolizumab 200 mg.
214995330|NCT03867084|DRUG|Placebo|IV infusion of 0.9% normal saline.
214381513|NCT02887989|DEVICE|Virtual Reality|A menu of VR experiences, lasting from 3-30 minutes each. For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.
214995331|NCT06297668|DRUG|Treatment A: BGF MDI HFA|Participants will receive 4 inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer.
214995332|NCT06297668|DRUG|Treatment B: BGF MDI HFO|Participants will receive 4 inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer.
214995333|NCT06297668|DRUG|Treatment C: BGF MDI HFO|Participants will receive 4 inhalations of BGF MDI HFO as a single dose without spacer.
214995334|NCT06297668|DEVICE|AeroChamber Plus Flow-Vu spacer|Participants will receive 4 inhalations of BGF MDI HFA (Treatment A) and BGF MDI HFO (Treatment B) as a single dose with spacer.
214381514|NCT02887989|DEVICE|Health and Wellness Channel|Relaxing content broadcast passively on the patient in-room television channel.
214381515|NCT00076791|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|900 mg of TDF combined with 600 mg emtricitabine
214381516|NCT00076791|DRUG|Tenofovir disoproxil fumarate|600 mg oral dose of TDF
214381517|NCT04762225|BIOLOGICAL|RPTR-168|Escalating doses of RPTR-168 as a monotherapy
214381518|NCT01342822|DEVICE|Angioplasty (PROMUS Element™, and Xience™ Prime stent)|Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
214381519|NCT05648357|BIOLOGICAL|Fluarix Tetra Vaccine|A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.
214381520|NCT00255346|DRUG|Dasatinib (BMS-354825)|70 mg orally twice daily
214381521|NCT03813550|DIAGNOSTIC_TEST|Fecal and blood samples|Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
214381522|NCT05855902|BEHAVIORAL|group art therapy|Art therapy will be offered in a weekly 1.5 hour group. Clients are provided a prompt and then asked to express their feelings using art, such as drawing/painting/etc.
214381523|NCT00894634|DRUG|Brompheniramine maleate|
214498206|NCT02809599|BEHAVIORAL|DIZZTINCT|The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
214995335|NCT03191058|DEVICE|Magnetic Seizure Therapy|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
214995336|NCT03191058|DEVICE|Electroconvulsive Therapy|In the ECT arm treatment, the MECTA spectrum 5000Q or the MECTA Sigma devices will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
214995337|NCT04967222|BEHAVIORAL|Cognitive Reappraisal by Distancing|Reappraisal-by-distancing treatment. Participants meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique. .
214995338|NCT04967222|BEHAVIORAL|Control Downregulate Condition|Participants either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
214995339|NCT01295944|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
214995340|NCT01295944|DRUG|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
214381524|NCT06428461|PROCEDURE|Supraclavicular brachial plexus block|A supraclavicular brachial plexus block will be performed under ultrasound guidance. The patient will be taken to the preoperative block room, positioned supine with the bed elevated at a 30° angle, and the head turned away from the arm being blocked. To avoid intraneural injection, the block will use both ultrasound and a nerve stimulator (Plexygon, Vygon-Italy) with a 22G 50 mm 20° stimulating needle (Echoplex, Braun-France). A low-frequency ultrasound probe will be placed above the clavicle to visualize the subclavian artery and vein. Using an in-plane approach, the needle will be inserted laterally to medially from the mid-clavicular point through the skin and subcutaneous tissue. Under ultrasound guidance, the needle will be advanced towards the anatomical corner where the brachial plexus and subclavian artery are adjacent (corner pocket), and a local anesthetic agent will be injected to perform the block.
214995341|NCT05139602|BIOLOGICAL|Lutikizumab|Subcutaneous Injection
214995342|NCT05139602|DRUG|Placebo|Subcutaneous Injection
214995343|NCT05018221|DRUG|Vitamin K1|Vitamin K1 capsule (10mg) to be administered 3 times per week following the subject's hemodialysis session.
214498207|NCT00982436|DRUG|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
214498208|NCT00982436|RADIATION|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
214498209|NCT00982436|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
214381525|NCT06428461|DEVICE|Measurement of Optic Nerve Sheath Diameter (ONSD) Using B-Mode Ultrasound|Before the block, both eyes will be measured for optic nerve sheath diameter (ONSD) using B-mode ultrasound (USG) with a GE LOGIQ E device. The patient will be supine with the bed elevated at a 30° angle, eyes closed, and a protective barrier applied. Both globes will be filled with water-soluble ultrasound gel, and imaging will be done with a 7.5 MHz linear probe at a 7 cm depth. For transverse ONSD measurement, the probe will be placed transversely in the coronal plane, with the marker notch pointing right. When the optic nerve entry into the globe is clear, transverse ONSD will be measured 3 mm below. For sagittal measurement, the probe will be placed sagittally in the coronal plane, with the marker notch pointing towards the body. Sagittal ONSD will be measured 3 mm below the entry point. Both internal and external diameters of the optic nerve sheath will be measured in transverse and sagittal planes, and the transverse diameter of the globe will also be measured.
214381526|NCT06428461|DEVICE|Assessment of Peripheral Nerve Block Success Using Perfusion Index Measurement|Investigator plan to measure the Perfusion Index (PI) as an objective method for determining the success of peripheral nerve blocks, different from traditional tests. PI is an indicator of peripheral perfusion that can be continuously measured non-invasively with a pulse oximeter. PI represents the ratio of pulsatile blood flow to non-pulsatile blood flow in peripheral tissue. The Mindray uMEC 12 device will be used for this measurement.
214381527|NCT06428461|DEVICE|End-Tidal Carbon Dioxide (EtCO2) Measurement|End-tidal carbon dioxide (EtCO2) measurement: The Medtronic Capnostream 35 device will be used for EtCO2 measurements. All patients will receive oxygen support at a rate of 1-2 L/min. If peripheral oxygen saturation falls below 95%, oxygen support will be increased to 3-6 L/min via nasal cannula.
214498210|NCT00463229|OTHER|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
214498211|NCT04478487|DIETARY_SUPPLEMENT|Medolac human milk based human milk fortifier (MHMHMF)|MHMHMF is admixed with expressed or donor human milk in graded doses according to tolerated feed volume according to established guidelines and maintain adequate micronutrient levels.
214498212|NCT01932970|DRUG|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
214995344|NCT05018221|DRUG|Magnesium citrate|Magnesium Citrate tablet (150mg) to be administered 3 times per per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
214995345|NCT05018221|DRUG|Sodium Thiosulfate|Sodium Thiosulfate injection (25g/100ml) to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
214995346|NCT05018221|DEVICE|High Flux Dialyser|Hemodialysis using a high flux dialyser.
214995347|NCT05018221|DEVICE|Medium Cut-off Dialyser|Hemodialysis using a medium cut-off dialyser.
214995348|NCT05018221|DRUG|Placebo injection (normal saline)|Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
214995349|NCT05018221|DRUG|Placebo capsule (Vitamin K1)|Placebo to be administered 3 times per week following the subject's hemodialysis session.
214995350|NCT05018221|DRUG|Placebo tablet (Magnesium citrate)|Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
214498213|NCT04228913|OTHER|Root Canal Obturation Technique|This study aims to compare the effects of three different obturation techniques(cold lateral condensation,thermoplasticized solid-core carrier method, cold free flow compaction technique) on postoperative pain following the endodontic therapy
214995351|NCT01962415|DRUG|Hydroxyurea|Oral administration
214995352|NCT01962415|DRUG|Alemtuzumab|Intravenous (IV) administration.
214995353|NCT01962415|DRUG|Fludarabine|IV administration
214687398|NCT06754943|DRUG|Treatment B_Period 1|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
214995354|NCT01962415|DRUG|Melphalan|IV administration
214995355|NCT01962415|DRUG|Thiotepa|IV administration
214995356|NCT05382091|DRUG|naltrexone implant|3.6 g per implant set each containing 60% naltrexone
214995357|NCT04140656|OTHER|Plantar sensitive exercises|"Plantar sensitive exercises:~40 minutes / 3 days per week / 8 weeks Warm up exercise (5 minute) Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min) Cooling exercise (5 min)"
214995358|NCT04140656|OTHER|Textured insole|"Textured insole group.~Plantar sensitive exercises with insole 40 minutes / 3 days per week / 8 weeks (all exercises will be done with insoles) Warm up exercise (5 minute) Walking on flat ground (15 minute) Exercise with roller under the sole of the foot (5 minute) Seated work with barbed balance pad (5 min) Dorsi flexion and plantar flexion and hip flexion exercises (5min). Cooling exercise (5 min)"
214995359|NCT05884203|DEVICE|Caregiver socket|A prosthetic socket whose shape was captured by a study helper using digital methods (i.e., 3D scanner). The digital file describing the socket dimensions will be sent to a central fabrication facility where the prosthetic socket will be manufactured.
214995360|NCT05884203|DEVICE|Prosthetist socket|A prosthetic socket whose shape was captured by a prosthetist using traditional, hand casting methods. The hand cast will be plaster filled to create a positive model. A prosthetist socket will be fabricated over the positive model using thermoplastic materials.
214995361|NCT06315257|DRUG|PVX7|PVX7 Immunotherapy
214381528|NCT00708526|OTHER|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
214381529|NCT00708526|DEVICE|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
214381530|NCT01828190|OTHER|Hyperbaric oxygen|HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
214381531|NCT05683106|DEVICE|Custom silicone digital orthosis (CSDO)|Custom silicone digital orthosis (CSDO) will be made under mold to provide realignment of toes, protection or replacement of a segment that was amputated.They will be indicated for corrections of rigid/fixed or flexible toes deformities.CSDO will be constructed using different types of silicone and different hardness considering whether the deformities are rigid or flexible and,when necessary,these components of the orthoses will be merged.Intervention participants will be asked to clean the CSDO and interdigital spaces with soap and water;adequate drying of the fingers and interdigital region;always wear the CSDO with appropriate footwear and socks;keep monitoring the integrity of the CSDO and always communicate any identification of changes in the feet or CSDO.Adverse effects will be evaluated, such as:possible skin irritation; discomfort or pain;contractures;trauma due to friction.Adherence will be verified every 3 months and via telephone contact,monthly.
214381532|NCT05099913|DRUG|Deanxit|Central neuromodulators was applied in refractory FD patients for different time
214381533|NCT03697382|BEHAVIORAL|Very Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
214381534|NCT03697382|BEHAVIORAL|Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
214381535|NCT03697382|BEHAVIORAL|Moderate Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
214381536|NCT00409786|BEHAVIORAL|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
214381537|NCT01884714|OTHER|High fat/high calorie meal|All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
214381538|NCT03389841|OTHER|Education|Education of the caregiver about early symptoms and signs of heart failure
214381539|NCT02275247|DRUG|Stellate Ganglion Block|stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
214381540|NCT02492113|PROCEDURE|Positive end-expiratory pressure (PEEP)|"Titrated-PEEP. After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
214498214|NCT03452254|DEVICE|Active Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Active tDCS: The anodic electrode will be put on affected M1. The cathodic electrode will be put on contralateral M1. We will apply a constant current of 2mA of intensity during 20 minutes while the patient performs the occupational therapy session."
214687399|NCT06754943|DRUG|Treatment A_Period 2|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
214995362|NCT05568719|DIAGNOSTIC_TEST|Testing of hepatic AAV Vector integration|Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated
214995363|NCT05476497|BIOLOGICAL|VLP Peanut|solution for subcutaneous administration
214381541|NCT02492113|PROCEDURE|ZEEP|"After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0-5 cmH2O, with the PSV=0 and FiO2 unchanged."
214381542|NCT01496534|DRUG|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
214381543|NCT01496534|DRUG|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
214381544|NCT04676126|DIETARY_SUPPLEMENT|Lumega-Z|Medical food which contains lutein, zeaxanthin, and meso-zeaxanthin
214381545|NCT04676126|DRUG|Dorzolamide Hcl 2% Oph Soln|Topical carbonic anhydrase inhibitor
214381546|NCT04676126|OTHER|Placebo|Specially formulated non macular pigment-containing formulation which tastes similar to the commercial medical food being evaluated in this study
214995364|NCT05476497|BIOLOGICAL|Placebo|solution for subcutaneous administration
214995365|NCT05476497|BIOLOGICAL|VLP Peanut|solution for Skin-prick testing
214995366|NCT05621733|OTHER|ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.
214995367|NCT05168800|BEHAVIORAL|Dialogue-Based Webinar|One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.
215092825|NCT00110461|DRUG|Aripiprazole|Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
215092826|NCT00110461|DRUG|placebo|Placebo tablet
214381547|NCT05268575|OTHER|performing endoscopy|Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
214498215|NCT03452254|DEVICE|Sham Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Sham tDCS: We will use the same place and parameters of stimulation applied for the active group, but the stimulator will deactivate after 30 seconds of stimulation. This will ensure that the patient will feel the initial tingling sensation at the beginning of the tDCS which is a requisite for blinding. The occupational therapy session will last one hour."
214498216|NCT03452254|OTHER|Modified Constraint Induced Movement Therapy|"Both groups will perform the mCIMT during a period of seven consecutive days. This protocol consists of two elements:~1. Restriction of the movements of the non-affected hand by wearing a mitt during six hours a day: we will use a mitt that limits the movement of the fingers but allows the free movements of the wrist, elbow, and shoulder.~2. Intensive and individualized training of the affected arm during 2 hours a day guided by an occupational therapist: the two hours training will be divided into two sessions of one hour each. Sessions will be organized in three blocks: preparation, activation, and function. In the third block, devoted to function, the patient has to choose one activity of daily living that he wants to improve."
214498217|NCT01150656|GENETIC|gene expression analysis|
214498218|NCT01150656|GENETIC|microarray analysis|
214498219|NCT01150656|GENETIC|protein expression analysis|
215092827|NCT05772078|OTHER|Assess compliance rate and demographics|Records to evaluate attendance rate
215092828|NCT05342337|OTHER|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management.~Telerehabilitation group participate in the sessions that last for one and a half hours, 3 days a week for 12 weeks, video conference over the Zoom program. The investigator, who provides supervision during the sessions, also participates in the exercises simultaneously."
215092829|NCT05342337|OTHER|Control group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
215092830|NCT06218706|DEVICE|Low Intensity Focussed Ultrasound|The major objective of this study is to further test safety, tolerability, and feasibility of LIFU in this population as well as investigate the impact of LIFU on opioid and other substance use. The primary endpoint is 90 days (Post-LIFU Week 12) following Active/Sham LIFU. After the primary endpoint is reached, the blind will be broken and the group who received Sham LIFU will cross-over and receive Active LIFU
214381548|NCT04734535|DEVICE|HEMOBLAST™ Bellows|Intraoperative bleeding during epidural spine surgery will be treated with HEMOBLAST™ Bellows
214381549|NCT04734535|DEVICE|absorbable gelatin sponge with thrombin|Intraoperative bleeding during epidural spine surgery will be treated with absorbable gelatin sponge with thrombin
214381550|NCT04885114|GENETIC|Intraparenchymal rAAV1 - (mi)RNA HTT|Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
214381551|NCT00642629|DRUG|STA 5326 mesylate|STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
214381552|NCT00642629|DRUG|Placebo|Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
214381553|NCT04937426|DIAGNOSTIC_TEST|Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori|Diagnostic laboratory test for detection of helicobacter pylori
214381554|NCT06139991|DRUG|Treatment A (BDA MDI HFO)|Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.
214381555|NCT06139991|DRUG|Treatment B (BDA MDI HFA)|Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.
214498220|NCT01150656|GENETIC|reverse transcriptase-polymerase chain reaction|
214498221|NCT01150656|GENETIC|western blotting|
214498222|NCT01150656|OTHER|laboratory biomarker analysis|
214498223|NCT01150656|OTHER|pharmacological study|
214498224|NCT00609297|OTHER|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
214498225|NCT00609297|OTHER|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
214498226|NCT00609297|OTHER|survey administration|Given to patient and caregivers throughout the study
214498227|NCT03380494|OTHER|Overhead perturbation training|A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
214687400|NCT06754943|DRUG|Treatment B_Period 3|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
214995368|NCT05168800|BEHAVIORAL|Social Media Website|A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.
214381556|NCT00237484|DRUG|Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin|"1. Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:~2. powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~3. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
214381557|NCT00237484|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) ribavirin|"1. Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
214498228|NCT03380494|OTHER|Non-perturbed training|A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
214498229|NCT01362075|PROCEDURE|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
214498230|NCT01362075|PROCEDURE|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
214498231|NCT00978588|DRUG|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
214498232|NCT01384890|RADIATION|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
214498233|NCT01384890|RADIATION|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
214498234|NCT03177590|OTHER|Recordings of facial and vocal emotional productions|"Children are asked to perform three tasks:~1. an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)~2. an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation~3. Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context."
214995369|NCT05168800|OTHER|Enhanced Usual Practice|COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.
214498235|NCT03739658|OTHER|Education|Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.
214995370|NCT06801145|OTHER|Education Video|48 hours before the surgery, patients were watched the training video.
214995371|NCT06801145|OTHER|Training video will not be watched group|No training was given about the intensive care process
214995372|NCT05477069|DEVICE|Innovative medical device for sampling small intestine content|Ingestion of the medical device by the volunteer
214995373|NCT03240874|BEHAVIORAL|SweetMama Focus Groups|Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.
215092831|NCT03311984|DIAGNOSTIC_TEST|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
215092832|NCT02616393|DRUG|Tesevatinib|
215092833|NCT05481099|BEHAVIORAL|Intervention|Cognitive-behavioural-based intervention combined with mindfulness (attention focus), psychoeducation, and relaxation techniques (short version of Jacobson's progressive relaxation, breathing exercises)
214381558|NCT03298503|OTHER|task-priority strategies|"posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray)."
214498236|NCT01767467|BIOLOGICAL|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
214498237|NCT01767467|DRUG|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
214498238|NCT01358669|DRUG|Denosumab|60mg denosumab by injection as a single dose
214498239|NCT01358669|OTHER|Placebo|Placebo by injection as a single dose
214498240|NCT03958773|DEVICE|Cardiovalve transfemoral Mitral valve system|Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.
215092834|NCT05513313|BIOLOGICAL|JYNNEOS|smallpox vaccine
215092835|NCT01041443|DRUG|5-fluoro-2-deoxycytidine|Given IV
215092836|NCT01041443|DRUG|tetrahydrouridine|Given IV
215092837|NCT01041443|OTHER|laboratory biomarker analysis|Correlative studies
215092838|NCT01041443|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
215092839|NCT01041443|GENETIC|DNA methylation analysis|Correlative studies
215092840|NCT02188498|PROCEDURE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
214381559|NCT06475469|BIOLOGICAL|Blood sampling & Chest CT without injection|Anlaysis of the repartition of non-tumorous lymphocytic subpopulation in patients with untreated Chronic Lymphocytic Leukemia (CLL)
214381560|NCT00170404|DRUG|Folic Acid|
214381561|NCT00170404|DRUG|Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.|
214498241|NCT04160936|DRUG|Marcaine Injectable Product|Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration
214498242|NCT05808205|DEVICE|• ALIAXIN EV: Essential Volume • ALIAXIN FL: Lips • ALIAXIN SR: Shape & Restore • ALIAXIN GP: Global Performance • ALIAXIN LV: Lips Volume|"According the investigator judgment and IP' Instruction For Use (IFU), each subject can be treated in one or more of following face area:~* Temporal / frontal area~* Orbital / Malar area~* Perioral area~* Lips."
214498243|NCT06511089|PROCEDURE|carotid artery stenting during EVT|"Patients with an ipsilateral high grade carotid artery stenosis or occlusion of presumed atherosclerotic origin and an proximal intracranial large vessel occlusion in the anterior circulation will be randomized using a web-based randomization tool to immediate carotid artery stenting or deferred treatment strategy of carotid artery stenosis.~In the intervention group, the cervical carotid artery lesion will be treated with a stent during the EVT (just before or directly after intracranial thrombus removal), the control group will be treated according to the national guidelines with carotid endarterectomy of carotid artery stenting (for patients with non-disabling stroke) or medical management alone (for patients with severe disabling stroke)."
214498244|NCT06511089|OTHER|no carotid artery stenting during EVT|A deferred treatment approach: carotid revascularization within two weeks after stroke onset or best medical management only, depending on the functional recovery of the patient.
214498245|NCT02455765|OTHER|Rice and Amino Acid mixtures|Rice and amino acid mixture
214498246|NCT00131274|DRUG|Imatinib Mesylate (Gleevec)|
214995374|NCT03240874|BEHAVIORAL|SweetMama Individual Testing|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 2 weeks, engage in periodic check-ins with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage."
214995375|NCT03240874|BEHAVIORAL|SweetMama Feasibility Testing - Pilot Randomized Trial|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will determine acceptability, feasibility, and pilot procedures in anticipation of a fully powered randomized controlled trial. Women will use SweetMama from enrollment (early pregnancy) to up to 8 weeks postpartum, engage in periodic check-ins with the research assistant, and participate in surveys and a semi-structured interview upon completion of SweetMama usage."
214995376|NCT05322005|PROCEDURE|partial meniscectomy|Arthroscopic procedure
214995377|NCT05322005|DEVICE|Condrotide® (polynucleotides gel: class III medical device)|Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection
214995378|NCT05988528|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis.
215092841|NCT03278431|DRUG|Albendazole|Albendazole (400 mg) from Janssen, donated by the World Health Organization
215092842|NCT03278431|DRUG|Pyrantel Pamoate|Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
215092843|NCT03278431|DRUG|Oxantel Pamoate|Oxantel pamoate (20mg/kg) will be produced by the University of Basel
215092844|NCT03278431|DRUG|Mebendazole|Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
215092845|NCT02314364|RADIATION|SBRT with protons or photons|
214381562|NCT00170404|DRUG|Selenium|
215092846|NCT04202198|BIOLOGICAL|A-PRF|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
214381563|NCT00170404|DRUG|Vitamin A|
214381564|NCT01758861|DRUG|EPO group|
214381565|NCT01758861|DRUG|Placebo|
214687401|NCT06754943|DRUG|Treatment A_Period 4|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
214687402|NCT06898047|DRUG|Rimegepant for acute migraine treatment|Rimegepant for acute migraine treatment
214381566|NCT01357590|DEVICE|Thoracic Endovascular Stent Graft System (ThoraflexTM)|Thoracic Endovascular Stent Graft System
214381567|NCT05362682|OTHER|Sinopharm Vaccine|Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign
214381568|NCT01974505|DEVICE|intubation using optiscope|Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
214381569|NCT05269784|PROCEDURE|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol
214381570|NCT05269784|PROCEDURE|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol
214381571|NCT01231841|DRUG|cyclosporine|Given orally
214381572|NCT01231841|BIOLOGICAL|anti-thymocyte globulin|Given IV
214381573|NCT02674490|DEVICE|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
214381574|NCT02674490|BEHAVIORAL|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
214381575|NCT02674490|DEVICE|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
214381576|NCT02440594|BEHAVIORAL|Enhanced BHL Program Services|Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.
214381577|NCT02440594|BEHAVIORAL|Standard BHL Program Services|Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.
214381578|NCT06205732|OTHER|Immunotherapy, targeted therapy.|Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
214381579|NCT05125523|DRUG|Sirolimus for Injection (Albumin Bound)|Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)
214381580|NCT00144872|DRUG|Lamotrigine|Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
214995379|NCT05988528|DRUG|Nifuroxazide|Nifuroxazide is an oral antibiotic that has been approved as an effective antidiarrheal agent with no side effects in several gastrointestinal infections
214995380|NCT05706051|OTHER|posturography|posturography will be performed when diagnosis of ARHL, in need of hearing aid fitting, is done and after information and written approval from patient. Posturography is performed later when hearing aid fitting and 3months after hearing aid use
214995381|NCT05504967|DRUG|Oradexon|With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
214995382|NCT05504967|DRUG|Ropivacaine|With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
214995383|NCT05504967|DRUG|Saline solution|With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
214995384|NCT05052957|BIOLOGICAL|P140K-MGMT|Ex Vivo Cultured P140K MGMT CD34+ Cells. The transduced cells are a biological product and production is detailed in the Cellular Therapy Lab standard operating procedures and IND 14099
214995385|NCT05052957|DRUG|O6-benzylguanine|O6BG is a low molecular-weight purine analog which selectively and irreversibly inactivates the DNA-repair enzyme, O6- alkylguanine DNA-alkyltransferase.
214995386|NCT05052957|RADIATION|Photon Based Radiotherapy|Standard of care, photon-based radiotherapy (60Gy in 30 fractions) will be performed in both arms without concomitant TMZ between to 6 weeks post-operatively. Radiotherapy will be performed at UH-SCC.
214995387|NCT05052957|DRUG|temozolomide|Temozolomide is not directly active but undergoes rapid non-enzymatic conversion at physiologic pHto the reactive compoundMTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylationof DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine
215092847|NCT04202198|PROCEDURE|pinhole surgical technique only|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
215092848|NCT02804308|BEHAVIORAL|Combined Training|
215092849|NCT04454645|BEHAVIORAL|mABC|Intervention targets parenting sensitivity and nurturance.
215092850|NCT04454645|BEHAVIORAL|mDEF|Intervention targets parenting enhancing infant cognitive development
215092851|NCT00975065|DRUG|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
214381581|NCT00512551|PROCEDURE|Tumor Biopsies|Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
214381582|NCT01657630|DEVICE|Accu-Chek Combo System|12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
214381583|NCT05902130|OTHER|symptoms of a myocardial infarction|Analysis of the differences in symptoms of a myocardial infarction between a man and a woman
214381584|NCT03988010|DRUG|Amantadine Sulfate|200mg/500ml i.v. solution for infusion
214381585|NCT03988010|DRUG|Placebo (for amantadine sulphate)|500 cc 0.9% sodium chloride
214687403|NCT02924506|DEVICE|Mobi-C prothesis|Mobi-C Prothesis, LDR Medical (company)
214687404|NCT02924506|DEVICE|ProDisc-C prothesis|ProDisc-C prothesis, Vivo Depuy Synthes (company)
215092852|NCT00975065|DRUG|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
215092853|NCT02471781|DEVICE|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
214381586|NCT01625195|DIETARY_SUPPLEMENT|omega-3 fatty acid supplementation|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
214381587|NCT01625195|DIETARY_SUPPLEMENT|corn/soybean oil placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4x 1285 mg capsules/d, two capsulesat breackfast and two capsules at dinner. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials.
214381588|NCT01738022|OTHER|Administration of gas mixtures|
214381589|NCT00584805|BIOLOGICAL|Inactivated, Dried, TSI-GSD 104, EEE|Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is \< 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
214381590|NCT00613288|DRUG|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~1. Placebo (hypogonadism after leuprorelide injection)~2. Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~3. Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~4. No treatment."
214498247|NCT02170259|OTHER|The suboccipital technique|"The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it hangs from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements"
214498248|NCT02170259|OTHER|The articulatory technique|The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
214498249|NCT02170259|OTHER|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
214498250|NCT02785159|DRUG|IDP-118 Lotion|Lotion
214498251|NCT02785159|DRUG|Tazorac Cream|Cream
214498252|NCT02785159|DRUG|IDP-118 Vehicle Lotion|Lotion
214498253|NCT02785159|DRUG|IDP-118 Vehicle Cream|Cream
214498254|NCT03578965|DRUG|Cefazolin|-If patient has a penicillin allergy then clindamycin will be used. Prophylactic antibiotics should be administered prior to skin incision
214498255|NCT01787032|DRUG|BI 113608|tablet
214995388|NCT05052957|DRUG|Filgrastim|Filgrastim is a 175 amino acid protein manufactured by recombinant DNA technology. Endogenous filgrastim is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells, which regulates the production of neutrophils within the bone marrow.
214995389|NCT05052957|DRUG|carmustine|BCNU is a lipid soluble agent which has alkylating properties, plus an isocyanate metabolite which interferes with DNA and RNA synthesis.
214995390|NCT06287385|DIETARY_SUPPLEMENT|Goat-milk Based Formula|Provided Goat-milk Based Formula for babies 1-2 years old
214498256|NCT01787032|DRUG|BI 113608|tablet
214995391|NCT05111015|DEVICE|Concomitant Open Heart Surgical Ablation Procedures|AtriCure's Concomitant Open Heart Surgical Ablation Devices used for the treatment of Atrial Fibrillation.
214995392|NCT05111015|DEVICE|Hybrid (Convergent) Ablation Procedures|AtriCure's Hybrid (Convergent) Ablation Devices used for the treatment of Atrial Fibrillation.
214498257|NCT01787032|DRUG|BI 113608|tablet
214498258|NCT01787032|DRUG|Ketoconazole|tablet
214498259|NCT01787032|DRUG|Voriconazole|tablet
214995393|NCT05111015|DEVICE|AtriCure Hybrid Totally Thoracoscopic Ablation Procedures|AtriCure's Hybrid Totally Thoracoscopic Surgical Ablation Devices used for the treatment of Atrial Fibrillation.
214995394|NCT05111015|DEVICE|AtriCure LAA Exclusion Procedures|AtriCure's LAA Exclusion Devices used to exclude the Left Atrial Appendage for the treatment of Atrial Fibrillation.
214995395|NCT04891640|OTHER|Standard TNFi Therapy|Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.
214995396|NCT04891640|OTHER|TNFi fixed longer dosing intervals|"Participants randomly assigned to this arm will increase the time between TNFi medication doses.~* Adalimumab- from every 2 to 3 weeks~* Certolizumab- from every 2 to 4 weeks~* Etanercept- from every 1 to 2 weeks~* Golimumab- from every 4 to 6 weeks~* Infliximab- from baseline to baseline + 2 weeks"
214995397|NCT04891640|OTHER|Stop TNFi treatment|Participants randomly assigned to this arm will stop TNFi medication.
214498260|NCT00776009|DRUG|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
214381591|NCT01760746|OTHER|Injection of Avastin / Lucentis, sampling aqueous humour|"Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.~On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .~Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays."
214381592|NCT01993823|DRUG|G238|Five drops into the ear canal twice daily for 14 days
214381593|NCT01993823|DRUG|Clotrimazole|Five drops into the ear canal twice daily for 14 days
214381594|NCT00213564|DRUG|response to infliximab associated with methotrexate|
214381595|NCT03915080|DRUG|Oktokog alpha|adjusting dose and dose interval according to MyPKFIT
214381596|NCT04017429|PROCEDURE|Open flap debridement with osteoplasty|Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the tooth.
214381597|NCT04017429|PROCEDURE|Open flap debridement without osteoplasty|Treatment of furcation grade III defect with open flap debridement only.
214381598|NCT00739895|PROCEDURE|Cardiac magnetic Resonance study|follow-up studies
214498261|NCT00776009|DRUG|Placebo|Placebo Comparator
214498262|NCT01640951|DRUG|AIN457 150 mg|(1 injection per dose) and placebo to Secukinumab 150 mg
214498263|NCT01640951|DRUG|AIN457 300 mg|Secukinumab 150 mg (2 injections per dose)
214498264|NCT01640951|DRUG|Placebo|
214498265|NCT06021275|OTHER|Microneedling with topical application of regular insulin|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
214498266|NCT06021275|OTHER|Microneedling with topical application of saline|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
214995398|NCT06123052|OTHER|Interview|"This is a descriptive qualitative study using semi-structured individual interviews. The interview will aim to collect more information about the patients' underlying motives that influence their ability or willingness to use IBD-CE. An interview guide has been developed for this purpose, based on topics derived from the Unified Theory of Acceptance and Use of Technology (UTAUT) model, the COM-B model for behavioural change and the model of positive health. This interview guide is divided into four sections, each introduced by an initial question. Subsequent follow-up questions will be formulated based on the patients' responses.~Furthermore, patient characteristics, disease characteristics, and socio-demographic data will be collected from the Electronic Medical Record (EMR). These data will provide insights into various aspects of the patients' profiles and are based on characteristics that seem to be determinants of technology acceptance and/or digital health literacy."
215092854|NCT03181295|BEHAVIORAL|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
215092855|NCT02538133|BIOLOGICAL|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
215092856|NCT03412097|OTHER|active surveillance|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
214381599|NCT00739895|PROCEDURE|Blood testing|Blood sample tested for myocardial biomarkers
214381600|NCT03232320|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
214381601|NCT03232320|DRUG|Placebo|Placebo (Normal saline)
214381602|NCT03133663|OTHER|Electrocardiogram group|Experimental
214381603|NCT03133663|OTHER|Pulse oximeter and auscultation group|Control
214381604|NCT02341456|DRUG|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
215092857|NCT03530085|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -9 to -7.
215092858|NCT03530085|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
214381605|NCT02341456|DRUG|Paclitaxel|Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
214381606|NCT02341456|DRUG|carboplatin|Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
214381607|NCT05819905|DIAGNOSTIC_TEST|PET/CT|Pre treatment staging 18F-FDG PET/CT
214381608|NCT03043222|DEVICE|UroLift as artifical device for prostatic urethral lift.|UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
214498267|NCT06327282|BEHAVIORAL|education on pain and related knowledge|Before surgery, pain related knowledge was educated.
214498268|NCT01611337|OTHER|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
214498269|NCT04378413|OTHER|exercise|exercise for low back pain
214498270|NCT02776982|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy will be performed during clinically indicated endoscopy.
214498271|NCT02776982|PROCEDURE|Mucosal impedance|Mucosal impedance will be performed at the time of clinically indicated endoscopy.
214381609|NCT03043222|DEVICE|Embospheres Microspheres as embolic agents for prostate artery embolization|Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
214381610|NCT03668730|RADIATION|Intensity-modulated radiation therapy|Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy
214381611|NCT03668730|DRUG|Paclitaxel liposome|Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.
214498272|NCT02776982|PROCEDURE|Research biopsies|Research biopsies will be obtained during clinically indicated endoscopy.
214498273|NCT02776982|PROCEDURE|Bravo ambulatory pH monitor|Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
214498274|NCT00630357|DRUG|Levetiracetam (Keppra)|
214498275|NCT04036955|OTHER|INFOSA-DEM|Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
214498276|NCT06015308|DRUG|Amlitelimab|Subcutaneous injection in abdomen, outer thigh, or upper arm
214498277|NCT06015308|DRUG|Placebo|Subcutaneous injection in abdomen, outer thigh, or upper arm
214498278|NCT06015308|BIOLOGICAL|Tdap vaccine|Intramuscular (IM) injection into the deltoid muscle of the upper arm
214498279|NCT06015308|BIOLOGICAL|PPS vaccine|Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm
214995399|NCT05717348|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
214995400|NCT05847504|BEHAVIORAL|mSTARS|mSTARS combines inpatient cognitive-behavioral skills training and outpatient use of a mobile app encouraging application of acquired skills to real life situations.
214995401|NCT05347225|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD.
214995402|NCT05922202|OTHER|Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months|At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.
214995403|NCT04958707|OTHER|Information including knowledge and skills related to dementia patient care|The intervention will be administered to the participants via a smartphone app (Zalo app). Weekly, the investigator will post one of the eight topics identified in Phase 1 in the chat room. After posting the topic, one investigator will call the participants to ensure they read and understand the contents.
214381612|NCT03668730|DRUG|Cisplatin|Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.
214381613|NCT03668730|DRUG|5-Fluorouracil|Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
214381614|NCT00888901|DRUG|eltrombopag|eltrombopag tablets daily, in increasing dosage, for three months
214381615|NCT00888901|DRUG|corticosteroids (Aprednislon)|corticosteroids in decreasing dosage
214498280|NCT03666468|OTHER|PlayMed|A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
214498281|NCT03666468|OTHER|Online Package|Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
214498282|NCT03666468|OTHER|Paper Guidelines|Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
214498283|NCT02406092|DRUG|Rituximab|Rituximab SC 1400 mg
214498284|NCT02406092|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice.
214498285|NCT02406092|DRUG|Doxorubicin|Doxorubicin will be administered as per standard local practice.
214498286|NCT02406092|DRUG|Vincristine|Vincristine will be administered as per standard local practice.
214498287|NCT02406092|DRUG|Prednisone|Prednisone will be administered as per standard local practice.
214498288|NCT02406092|DRUG|Fludarabine|Fludarabine will be administered as per standard local practice.
214498289|NCT06143501|DIAGNOSTIC_TEST|Blood Sample|6 ml blood (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
214498290|NCT06143501|DIAGNOSTIC_TEST|Stool Sample|pea-sized amount (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
214498291|NCT06143501|DIAGNOSTIC_TEST|Urine Sample|8 ml (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
214498292|NCT04074096|RADIATION|Stereotaxic radiosurgery (SRS)|For patients randomised to arm B only: Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases \>5 mm).
214498293|NCT04074096|DRUG|Binimetinib Oral Tablet|All patients: binimetinib 45 mg PO BID.
214498294|NCT04074096|DRUG|Encorafenib Oral Capsule|All patients: encorafenib 450 mg PO QD
214498295|NCT04074096|DRUG|Pembrolizumab|All patients: pembrolizumab 200 mg IV Q3W
214498296|NCT00587275|DRUG|AST-120|Oral, sachet, 2 grams daily for 4 weeks
214498297|NCT00587275|DRUG|Celphere CP-305|Oral, sachet, 2 grams daily for 4 weeks
214498298|NCT01065649|DRUG|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
214995404|NCT04958707|OTHER|Usual care|Caregivers will be introduce to the website www.alzheimer.org to search for eligible information
214995405|NCT04587830|DRUG|ADI-PEG 20|Investigational Medicine
214995406|NCT04587830|DRUG|Temozolomide|Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.
214995407|NCT04587830|DRUG|Placebo|Investigational Medicine
214995408|NCT05470920|BEHAVIORAL|Electronic Decision Aid|Decision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires
214995409|NCT05470920|BEHAVIORAL|Pre-Test Genetic Counseling|Receive pretest counseling with a genetic counselor. Will complete surveys/questionnaires
214381616|NCT06179264|BEHAVIORAL|ACT Guide for Chronic Health Conditions|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. The current project is an online, self-guided, 6-session intervention based on ACT. The program is intended to help individuals with chronic health conditions improve their quality of life and mental health. Each session is expected to take about 30 minutes each, and the entire program will take 6 weeks to complete, as users will be encouraged to work on one session per week. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and chronic health condition specific vignettes, and apply ACT concepts to their own lives and situations related to their chronic health condition. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
214995410|NCT04447222|OTHER|Quality-of-Life Assessment|Ancillary studies
214995411|NCT04447222|OTHER|Questionnaire Administration|Ancillary studies
214995412|NCT04447222|OTHER|Survey Administration|Complete survey
214995413|NCT05893511|PROCEDURE|Endoscopic ultrasound-guided gallbladder drainage|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .
214381617|NCT05603988|DEVICE|Intracanal Diode laser irradiation|After endodontic retreatment, root canals will be irradiated with a 980 nm diode laser coupled with optical fibre 200 μm (Litemedics, Italy) with setting 1.2-watt power, in pulsed mode. The irradiation protocol will be of 5-sec irradiation followed by a 10-sec pause, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth. The tip will be positioned 1 mm short of the apex. Followed by activation during which it will be slowly dragged at a speed of approximately 2 mm/ sec in a way that the root canals will be irradiated from the apical to the coronal portion, in a helicoidal movement touching the canal walls.
214995414|NCT05893511|DRUG|Antibiotics first|Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
214995415|NCT05457855|DRUG|Montelukast|Montelukast claim is used as the exposure group.
215092859|NCT03530085|DRUG|Fludarabine(Flu)|Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.
215092860|NCT02062983|DRUG|Herceptin|"Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression."
215092861|NCT00148447|DRUG|escitalopram|
214381618|NCT05603988|OTHER|Placebo|"After endodontic retreatment, mock laser application (Placebo group) will be applied:~The fiberoptic tip will be inserted inside the root canal, mimicking the laser irradiation group, but not activated"
214381619|NCT01349413|DRUG|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
214381620|NCT01349413|OTHER|Placebo|Identical looking placebo
214381621|NCT01812382|DRUG|Retapamulin Microdialysis|After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
214381622|NCT00509002|DRUG|Gefitinib|250 mg by mouth once a day, every day, at about same time in morning.
214381623|NCT00460317|DRUG|AMG 706|125 mg QD orally every day
214995416|NCT05457855|DRUG|Fluticasone|Fluticasone claim is used as the reference group.
215092862|NCT01028170|DRUG|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
215092863|NCT01028170|DRUG|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
215092864|NCT02657564|DRUG|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
215092865|NCT01889134|DRUG|Sedron (alendronate)|
214381624|NCT00460317|DRUG|placebo|125 mg QD orally every day
214381625|NCT00460317|DRUG|paclitaxel|200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
214381626|NCT00460317|DRUG|carboplatin|AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
214381627|NCT03619941|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
215092866|NCT01889134|PROCEDURE|Parathyroidectomy|
215092867|NCT04246814|DEVICE|LG1|Application of LASER AsGa 904nm 10 J/cm².
215092868|NCT04246814|DEVICE|LG2|Application of LASER AsGa 904nm 8 J/cm².
215092869|NCT04246814|DEVICE|LG3|Application of LASER AsGa 904nm 4 J/cm².
215092870|NCT04246814|DEVICE|CC|Application of placebo LASER.
215092871|NCT04246814|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
215092872|NCT02412709|DEVICE|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
214381628|NCT03619941|DIETARY_SUPPLEMENT|Placebo|Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
214381629|NCT03068013|BEHAVIORAL|CALM|CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality
214381630|NCT03068013|BEHAVIORAL|SPI|Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
214498299|NCT01065649|DRUG|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
214498300|NCT02195232|DRUG|Isoquercetin|
214498301|NCT02937493|BEHAVIORAL|Lunar phases|Observation if lunar phases had an influence on occurrence of IPV
214498302|NCT03865875|BEHAVIORAL|Exercise Program|Participants will start the exercise program within 2 weeks of enrollment and will continue until surgery. This program will consist of twice weekly individualized sessions with a trainer.
214995417|NCT06023498|OTHER|Manual Therapy and Exercise|"The 20-minute manual therapy procedures will include:~* Distraction-manipulation: manually assisted segmental lumbar traction manipulation using a specialized treatment table~* Neural mobilization: rhythmic stretches of the sciatic and femoral nerves75~* Hip, sacroiliac and lumbar facet mobilizations to improve joint mobility~* Soft tissue mobilization of lumbopelvic and lower extremity muscles using manual pressure over taut bands/myofascial trigger points and post-isometric (contract-relax) stretching techniques."
214995418|NCT06023498|OTHER|Intramuscular Electroacupuncture|As described previously
214995419|NCT05039164|BEHAVIORAL|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
214995420|NCT05039164|BEHAVIORAL|CBT for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
214995421|NCT05039164|BEHAVIORAL|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
214995422|NCT05039164|BEHAVIORAL|Initial Training (CC)|School personnel will participate in an initial live remote training.
214995423|NCT05039164|BEHAVIORAL|Initial Training plus Video (RV)|School personnel will participate in an initial live remote training and receive access to asynchronous video training modules.
214381631|NCT03149016|PROCEDURE|Corticotomy-assisted Retraction|Using a tunneling technique, the researcher will perform the intervention in the alveolar bone surrounding the upper incisors before retraction.
214381632|NCT04903457|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
214381633|NCT04903457|BEHAVIORAL|Motor learning|Sequential finger tapping task training is applied to stroke patients.
214381634|NCT00301080|DRUG|D-cycloserine|
214381635|NCT00301080|OTHER|Placebo|
214381636|NCT01595412|PROCEDURE|Laparoscopic Resection Rectopexy|laparoscopic sigmoidectomy with suture rectopexy
214381637|NCT01595412|PROCEDURE|Laparoscopic Ventral Rectopexy|laparoscopic ventral rectopexy with mesh
214381638|NCT01532817|DEVICE|AlphaCore|A single 90 second stimulation to the vagus nerve on the right side of the neck
214381639|NCT05914402|PROCEDURE|axillary surgery de-escalation after NAT|the process of axillary surgical evaluation will be spared after NAT using the prediction model if the probability is more than 90%.
214498303|NCT03865875|BEHAVIORAL|Nutrition Program|Each patient enrolled will undergo nutritional assessment at their initial post-enrollment visit to develop an individualized nutrition plan to be implemented up until when the patient undergoes surgery.
214687405|NCT06758401|DRUG|Sigvotatug Vedotin|MMAE-Antibody Drug Conjugate targeting Integrin Beta-6
214687406|NCT06758401|DRUG|Pembrolizumab|Anti-PD-(L)1
214381640|NCT00618696|BIOLOGICAL|anti-CD45 monoclonal antibody AHN-12|150 mg/m\^2 cold antibody at Day 0
214498304|NCT01023542|DRUG|delayed, low-dose CNI|immunosuppression
214498305|NCT01023542|DRUG|BU-CNI|Immunosuppression
214498306|NCT01023542|DRUG|BU-Everolimus|Immunosuppression
214498307|NCT00213395|DEVICE|Interface for noninvasive ventilation|
214687407|NCT06780423|PROCEDURE|Minimal invasive fine needle muscle biopsies|Fine needle muscle biopsies will be taken from the m. erector spinae and the m. vastus lateralis. Participants are placed in a standardized prone position on the examination table for measurements of the m. erector spinae and in a supine position for measurements of the m. vastus lateralis.
214687408|NCT04212793|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery
214995424|NCT05039164|BEHAVIORAL|Initial Training plus Video plus Coaching (RV+)|School personnel will participate in an initial live remote training, receive access to asynchronous video training modules, and receive coaching support from study staff.
214381641|NCT00618696|RADIATION|yttrium Y 90 anti-CD45 monoclonal antibody AHN-12|Dose per scheduled level; 2.5-12.5 mCi/m\^2
214381642|NCT03066622|DRUG|Standard of Care as per attending physician|Patients are randomized to standard of care medication (as determined by attending physician)
214381643|NCT03066622|DRUG|5mg rapidly dissolving olanzapine|5mg rapidly dissolving olanzapine
214381644|NCT03311425|DRUG|Methylprednisolone|Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure
214381645|NCT03311425|DRUG|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
214381646|NCT03380793|DRUG|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
214381647|NCT03485014|DRUG|Exparel|EXPAREL 4 mg/kg
214381648|NCT02899364|DRUG|Sodium thiosulfate|see description under experimental arm
214381649|NCT02899364|DRUG|Sodium chloride 0.9%|see description under placebo comparator arm
214381650|NCT02899364|PROCEDURE|primary percutaneous coronary intervention|Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
214995425|NCT02629159|DRUG|Placebo for Adalimumab|Administered by subcutaneous injection once every other week
214995426|NCT02629159|DRUG|Adalimumab|Administered by subcutaneous injection once every other week
214995427|NCT02629159|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
214995428|NCT02629159|DRUG|Upadacitinib|Tablets taken orally once a day
214995429|NCT04383223|BEHAVIORAL|iTransition|Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
214381651|NCT02899364|OTHER|cardiac magnetic resonance imaging|CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
214381652|NCT00641719|DRUG|Duloxetine hydrochloride|Duloxetine 40 mg QD, PO, 1 year
214381653|NCT00641719|DRUG|Duloxetine hydrochloride|Duloxetine 60 mg QD, PO, 1 year
214381654|NCT00885963|DRUG|sapacitabine|twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
214381655|NCT02487550|BIOLOGICAL|DC-CIK|Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.
214381656|NCT02487550|BIOLOGICAL|IL-2/IFN-α|Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
214381657|NCT03469349|DRUG|Actovegin|Actovegin intravenous infusion and tablets.
214381658|NCT03469349|DRUG|Placebo|Actovegin placebo-matching intravenous infusion and tablets.
214381659|NCT02590692|BIOLOGICAL|CPCB-RPE1|Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
214381660|NCT04194996|PROCEDURE|Surgical intervention|Surgical interventions will be patient specified by treating surgeon.
214381661|NCT01850368|RADIATION|Stereotactic ablative radiotherapy|"The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by \>48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy."
214381662|NCT01028261|DRUG|ZGN-433|Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
214381663|NCT05244811|DRUG|Combined Oral Contraceptive|effect of cocs in treatment of ovarian cysts
214687409|NCT04212793|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
214381664|NCT05244811|DRUG|Progestin|effect of progestin in treatment of ovarian cystn
214995430|NCT04990726|BEHAVIORAL|Assessment|Undergo medical assessments
214995431|NCT04990726|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214995432|NCT04990726|OTHER|Quality-of-Life Assessment|Ancillary studies
214995433|NCT04990726|OTHER|Questionnaire Administration|Complete questionnaires
214995434|NCT04654312|DRUG|Hydrochlorothiazide|Please see arm descriptions
214995435|NCT04654312|DRUG|Placebo|Please see arm descriptions
214995436|NCT04289142|DRUG|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20-60 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
214995437|NCT05355272|DRUG|Recombinant human growth hormone|recombinant human growth hormone (rhGH)
214995438|NCT03036254|DEVICE|HBOT intervention|"HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2"
214995439|NCT03036254|DEVICE|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
214381665|NCT03395249|DRUG|SPR994|"SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1."
214381666|NCT03395249|DRUG|Placebo Oral Tablet|Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
214381667|NCT03395249|DRUG|Orapenem®|Tebipenem pivoxil granules
214498308|NCT05063864|OTHER|Nursing Support Program|"Within the scope of the nursing support program, counselling services were provided to women by making regular phone calls that lasted 15-20 minutes once a week. Within the scope of the support program, two training booklets titled Life After Hysterectomy Surgery and Women's Health During Menopause were prepared by reviewing the literature."
214498309|NCT02172560|DRUG|Tiotropium|
214498310|NCT05459350|DIAGNOSTIC_TEST|Safe Discharge Classification|Safe Discharge Classification
214498311|NCT03041233|OTHER|Observation / Data Collection|"The following data will be reviewed / collected:~Baseline Visit: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.~Ablation Procedure: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).~6- and 12-month follow-up (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
214498312|NCT01937494|DRUG|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
214498313|NCT02513043|DRUG|medical abortion|medical abortion
214687410|NCT06842693|BEHAVIORAL|Control|"Products carry neutral control label when containing non-nutritive sweeteners. Additionally, to match the current Chilean legislation, products carry an octagonal label that states high in sugar when high in added sugars, and/or an octagonal label that states high in calories when high in calorie density."
214995440|NCT05701800|BIOLOGICAL|mRNA-1468|Sterile liquid dispersion for injection
214995441|NCT05701800|BIOLOGICAL|Placebo|Sterile liquid for injection
214995442|NCT05701800|BIOLOGICAL|Shingrix|Sterile suspension for injection
214381668|NCT04476420|DIETARY_SUPPLEMENT|Nigella sativa oil|Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.
214995443|NCT04245514|DRUG|Durvalumab|Immunotherapy
214995444|NCT04245514|RADIATION|Radiotherapy|Immune-modulatory radiotherapy to the primary tumor, with either Cohort A: 20 x 2 Gy weekdaily Cohort B: 5 x 5 Gy weekdaily Cohort C: 3 x 8 Gy q2d
214995445|NCT04889924|RADIATION|Axillary Radiotherapy|Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
214995446|NCT04889924|PROCEDURE|Lymphadenectomy|Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain
214995447|NCT05826418|DIETARY_SUPPLEMENT|MEND diet|Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
214381669|NCT04476420|DRUG|Betamethasone Valerate|it is a conventionally used drug for treating OSMF
214498314|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 50 mg
214498315|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 300 mg
214498316|NCT00002945|BIOLOGICAL|aldesleukin|IV
214498317|NCT00002945|BIOLOGICAL|filgrastim|IV
214498318|NCT00002945|DRUG|cyclophosphamide|IV
214498319|NCT00002945|DRUG|cytarabine|IV
214498320|NCT00002945|DRUG|etoposide|IV
214498321|NCT00002945|DRUG|idarubicin|IV
214498322|NCT00002945|DRUG|melphalan|IV
214498323|NCT00002945|PROCEDURE|peripheral blood stem cell transplantation|IV
214498324|NCT00002945|RADIATION|radiation therapy|delivered to the cancer cells
214498325|NCT00156208|DRUG|Asoprisnil|10mg Tablet, oral Daily for 18 months
214498326|NCT00156208|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 18 months
214498327|NCT03710252|DRUG|paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin|OMB/PTV/r + DSV +/- RBV
214498328|NCT01182649|DEVICE|coronary stent|coronary angioplasty with stent implantation
214498329|NCT01182649|DEVICE|stent|coronary angioplasty with stent implantation
214498330|NCT03794219|OTHER|Kinesio Tape|To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.
214498331|NCT03794219|DRUG|oral naproxen|750 mg/day oral naproxen is administered for 10 days.
214498332|NCT00942266|DRUG|fluorouracil|Given IV
214498333|NCT00942266|DRUG|leucovorin calcium|Given IV
214498334|NCT00942266|DRUG|vorinostat|Given orally
214381670|NCT02306265|DEVICE|FFDM|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
214381671|NCT02306265|DEVICE|DBT|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
214381672|NCT04524728|DRUG|Palbociclib|tablets
214381673|NCT04524728|DRUG|Letrozole 2.5mg|tablets
214381674|NCT04524728|DRUG|Fulvestrant|intramuscolar injections
214381675|NCT01113619|DRUG|RP-G28 or placebo|Qualified subjects randomized to daily dosing with RP-G28 or placebo
214381676|NCT01113619|DRUG|RP-G28 or placebo|Daily dosing
214381677|NCT00022217|DRUG|carboplatin|
214381678|NCT00022217|DRUG|cisplatin-e therapeutic implant|
214381679|NCT00022217|DRUG|paclitaxel|
214381680|NCT00829205|BIOLOGICAL|filgrastim|
214381681|NCT00829205|BIOLOGICAL|rituximab|
214381682|NCT00829205|DIETARY_SUPPLEMENT|Se-methyl-seleno-L-cysteine|
214381683|NCT00829205|DRUG|carboplatin|
214381684|NCT00829205|DRUG|etoposide|
214381685|NCT00829205|DRUG|ifosfamide|
214381686|NCT00829205|OTHER|laboratory biomarker analysis|
214381687|NCT00829205|OTHER|pharmacological study|
214381688|NCT02970513|OTHER|Psychiatric evaluation|The purpose of this study is to determine whether the presence of pathogenic Escherichia coli in colon is associated with psychiatric disorders.
214498335|NCT00942266|OTHER|pharmacological study|Correlative study
214498336|NCT06274060|BEHAVIORAL|Case management|Participants will receive case management delivered by a peer with PrEP experience/success for seven months, with the goal of improving self-efficacy to take PrEP. The intention of this intervention is to help participants to develop individualized strategies to address and overcome barriers to PrEP use, as well as develop disclosure strategies. This strategy includes weekly face-to-face support with the case manager for the first month of the trial, followed by monthly face-to-face support for the remainder of the trial follow up period. The strategy will also include client-initiated on-demand phone consultation with the case manager and mental health/substance use screening and referrals. Participants randomized to this strategy may also opt into daily timed PrEP pill-taking reminders via short message service (SMS).
214498337|NCT06274060|BEHAVIORAL|Food vouchers|Participants will be given food vouchers with a value of 200 South African Rand at the time of PrEP initiation and at 1- and 4-month standard of care visits at which clinical checkups and PrEP refills are provided. The goal of these vouchers is to improve participants' capacity to persist on PrEP. While PrEP can be taken without food, some experience increased side effects or prefer to take pills with food, making adherence difficult if they cannot afford food at times.
214381689|NCT04488003|DRUG|Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
214498338|NCT06274060|BEHAVIORAL|PrEP support buddy|Participants will identify a person in their network (such as a friend, partner, parent) that they wish to support them in their PrEP usage, with the goal of improving participants' motivation and self-efficacy to persist on PrEP and providing social support to facilitate ongoing PrEP use. Support buddies selected by FSW and AGYW randomized to this intervention will receive a one-time training session on PrEP and support strategies as well as informational materials and text reminders to assist them in providing ongoing PrEP support.
214498339|NCT06274060|BEHAVIORAL|Community-based PrEP pickup points|Participants will be able to pick up PrEP from alternative pick-up points within the community that are convenient for them, with the goal of making PrEP more accessible to participants. Ten pickup points will be established at existing Hubs of Hope throughout the subdistricts served by the TB HIV Care programme. Hubs of Hope are based in the War Rooms within subdistricts, where the TB HIV Care programme operates, and serve as meeting places for service users to receive support searching for jobs, completing online courses, and other personal development activities to support a multi-sectoral approach to health. A TB HIV Care ambassador is based at each Hub of Hope to coordinate activities and provide support to service users. Participants who choose to use pick-up points will have the option of either completing an HIV self-test or testing with the on-site TB HIV Care staff to confirm HIV-negative status prior to receipt of PrEP refills.
214498340|NCT00833313|PROCEDURE|Atrial biopsy|Biopsy of left atrial free wall and possibly left atrial appendage
214498341|NCT02979184|OTHER|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
214381690|NCT04488003|DRUG|Physician's Choice|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
214381691|NCT04219722|DEVICE|Injection of DESIRIAL®|"DESIRIAL® is a hyaluronic acid injectable gel intended to treat symptoms associated with vulvovaginal atrophy in postmenopausal women by vaginal mucosa rehydration in this study.~1 mL of DESIRIAL® will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
214498342|NCT02955719|DRUG|Sertraline|
214381692|NCT04219722|OTHER|Injection of placebo|"Placebo is an isotonic saline solution (0.9% NaCl).~1 mL of placebo will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
214381693|NCT03447730|DRUG|SYNB1020|SYNB1020 was supplied at a concentration of approximately 1 × 10\^11 CFU/mL in a buffered solution in 5 mL cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
214381694|NCT03447730|OTHER|Placebo|Subjects received placebo orally in a chilled buffered solution (100 mL).
214381695|NCT05712161|DEVICE|DurAVRTM THV System|The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve
214381696|NCT03349268|DEVICE|Pulsed xenon ultraviolet (PX-UV) Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
214498343|NCT02955719|DRUG|Venlafaxine|
214498344|NCT02955719|OTHER|CBT/Psychological Therapy|
214498345|NCT02955719|OTHER|Psychiatric Consultation|
214498346|NCT02955719|OTHER|Lifestyle Intervention Resources|
214498347|NCT02139436|OTHER|FES-row-training|
214995448|NCT05826418|DIETARY_SUPPLEMENT|mNICE diet|Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
214995449|NCT02250352|OTHER|cytology specimen collection procedure|Correlative studies
214995450|NCT02127398|BIOLOGICAL|fecal microbiota|fecal microbiota in capsule form
214995451|NCT04544462|OTHER|M2 Test|DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
214995452|NCT05091710|OTHER|HF follow up care|The intervention will consist of follow up phone calls and visits during which the CHWs will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.
214995453|NCT05091710|OTHER|HF Standard of Care (SOC)|SOC after discharge for HF is to notify patients of a follow-up visit at the hospital/clinic - about 7 days after discharge and provide patients about 30 days of medications at discharge. If a patient does not return for a follow-up appointment, there are no systems to track this missed visit, or to trigger active attempts to contact patients. For patients who come back to their scheduled 7-day visit, there is generally a 14-day visit followed by a 28-day visit.
214995454|NCT05233228|DRUG|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
214995455|NCT05233228|BEHAVIORAL|Self-help materials (to support smoking cessation)|"The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit."
214995456|NCT05233228|BEHAVIORAL|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 26-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
214995457|NCT06436651|OTHER|Digital Storytelling|4 stages of digital storytelling will be implemented.
214995458|NCT03331341|DRUG|Dacarbazine|Given IV
214995459|NCT03331341|DRUG|Doxorubicin Hydrochloride|Given IV
214381697|NCT03349268|DEVICE|Sham Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
214381698|NCT01927692|OTHER|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
214381699|NCT01927692|OTHER|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
214381700|NCT04678622|DEVICE|Bioferula3D|Custom splint with 3D technology classified as a custom medical device
214381701|NCT01706419|DIETARY_SUPPLEMENT|Fortified rice cold extruded kernel|
214381702|NCT01706419|DIETARY_SUPPLEMENT|fortified rice warm extruded kernel|
214381703|NCT01706419|DIETARY_SUPPLEMENT|fortiified rice hot extruded kernel|
214995460|NCT03331341|OTHER|Laboratory Biomarker Analysis|Correlative studies
214995461|NCT03331341|BIOLOGICAL|Pembrolizumab|Given IV
214995462|NCT03331341|DRUG|Vinblastine|Given IV
214995463|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI
214995464|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|OPTIMAL MEDICAL TREATMENT (OMT)
215092873|NCT06228690|OTHER|Gold Fish exercises|Specific exercise for the flexibility of TMJ that will target the Jaw muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Gold Fish exercises for jaw flexibility, pain and maximum mouth opening.
214381704|NCT01187329|OTHER|hyperinsulinemic normoglycemic clamp (HNC)|Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is \<110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose \> 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
214498348|NCT02139436|OTHER|Arms-only-row training|
214498349|NCT02139436|OTHER|Time Control|
215092874|NCT06228690|OTHER|Cervico-thoracic postural correction training|"Cervico-thoracic postural correction training for upper thoracic and neck muscles.~Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Muscle energy technique to improve range of motion, pain and maximum mouth opening."
214381705|NCT01187329|OTHER|control group|Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose \>150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose \< 180 mg/dL.
214381706|NCT04001179|OTHER|Pulmonary embolism diagnosis by nuclear medicine imaging|nuclear medicine imaging
214381707|NCT04586777|DEVICE|transvertebral direct current stimulation (tvDCS)|tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
214381708|NCT02487940|DRUG|Intralipid 20%|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
214381709|NCT02487940|DRUG|Normal saline|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
214381710|NCT02501213|DRUG|Spironolactone (+/- Furosemide)|Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
214498350|NCT05910203|OTHER|The effectiveness of education|Training will be provided on smoking cessation.
214498351|NCT05162560|OTHER|patients with acute diverticulitis|registry and hospital charts of patients with acute diverticulitis
214995465|NCT06106360|DEVICE|Locus Health iPhone App|In this pilot study patients are enrolled into three (3) different groups which will vary by the frequency of the queries being sent to the patients during their chemotherapy cycle. The patients will be separated into three groups of 33-34 patients each. Each group will have a different frequency of symptom questions sent to them via the Locus Health iPhone App to determine patient fatigue and the compliance impact of different query cadences. Patients will be assigned to these 3 groups sequentially since the platform could not assign patients to these three cohorts in a random manner.
214995466|NCT06452719|DRUG|Letrozole|Letrozole 10 mg orally daily for three consecutive days
214995467|NCT06452719|DRUG|Misoprostol|Misoprostol 800 mcg vaginally within 24 hours of final letrozole dose
214995468|NCT03463408|DRUG|nivolumab|240 mg every 2 weeks
214381711|NCT01994356|BEHAVIORAL|Physician self-disclosure of personal IUC use|Physicians self-disclosed personal intrauterine contraceptive use to subjects in intervention arm of study during contraceptive counseling
214381712|NCT01994356|BEHAVIORAL|Usual contraceptive counseling|all subjects recieved usual contraceptive counseling
214381713|NCT03436966|DEVICE|MULTI SLICE CT|Positive enteric contrast, can, however, obscure IV contrast enhancement of the bowel wall. In addition, positive oral contrast agents opacify but do not always well distend the bowel. IV contrast is administered and images are acquired in the portal venous phase, which is optimized for visceral organ evaluation.
214381714|NCT02952664|BEHAVIORAL|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
214381715|NCT02168790|DEVICE|Amniotic membrane ring|The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
214381716|NCT04213313|DRUG|Treatment of bacterial keratitis|0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID
214381717|NCT04213313|DRUG|Treatment of fungal keratitis|1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID
214381718|NCT04213313|DRUG|Treatment of viral keratitis|0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID
214995469|NCT03463408|DRUG|ipilimumab|1 mg/kg every 6 weeks
214995470|NCT05738213|DEVICE|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
214995471|NCT05738213|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
214381719|NCT04213313|DIAGNOSTIC_TEST|corneal scraping|culture and sensitivity of corneal ulcerated infiltrating edge tissue
214498352|NCT00257881|DRUG|CMD-193|
214498353|NCT00211549|DRUG|IDEA-033|
214498354|NCT00317395|DRUG|Otamixaban (XRP0673)|intravenous administration
214498355|NCT00317395|DRUG|unfractionated heparin|intravenous administration
214498356|NCT00317395|DRUG|eptifibatide|intravenous administration
214498357|NCT03317652|OTHER|Hyperventilation|The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
214687411|NCT06842693|BEHAVIORAL|Chilean non-nutritive sweetener label|"Products carry rectangular label that states contains non-nutritive sweeteners, not recommended for children when containing non-nutritive sweeteners. Additionally, to match the current Chilean legislation, products carry an octagonal label that states high in sugar when high in added sugars, and/or an octagonal label that states high in calories when high in calorie density."
214381720|NCT04213313|OTHER|Sequencing|polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing
214381721|NCT06111690|PROCEDURE|Blood Flow Restriction Training (BFRT)|Participants will be performing low-resistance exercise with (BFRT). Intervention will start at least seven days after initial evaluation, so it does not influence measures of real-time physical activity. We will use a log to register exercise completion and to record bilateral knee pain before, during and after each intervention session
214381722|NCT02611544|BEHAVIORAL|Acceptance and Commitment Therapy|6-week ACT intervention group (n=33)
214381723|NCT02611544|BEHAVIORAL|Survivorship Education|6-week survivorship education group (SE; n=32)
214381724|NCT02611544|BEHAVIORAL|Enhanced Usual Care|enhanced usual care (EUC; n=26)
214381725|NCT05177575|PROCEDURE|Thoracotomy application|The chronic pain findings of the patients who underwent thoracotomy will be questioned at the postoperative 3rd and 6th months.
214381726|NCT00642135|DRUG|Mydriasert®|Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
214381727|NCT00642135|DRUG|phenylephrine and tropicamide eyedrops|Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
214381728|NCT03621293|DRUG|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
214381729|NCT02734680|RADIATION|Concurrent chemoradiotherapy(CCRT)|Radiation and take gemcitabine(GEM)
214381730|NCT02734680|RADIATION|Stereotactic Radiotherapy(SBRT)|Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)
214381731|NCT02734680|DRUG|S-1|Taking S-1 orally after radiation
214381732|NCT00363337|DRUG|aripiprazole|open label treatment with aripiprazole
214381733|NCT00714623|DEVICE|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
214381734|NCT05859633|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte Ratio in acute pancreatitis|role of Neutrophil/Lymphocyte Ratio in acute pancreatitis
214381735|NCT01992705|OTHER|Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable|Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
214381736|NCT01992705|DRUG|-Oxaliplatin 85 mg/m2 IV on Day 1|Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
214498358|NCT03317652|OTHER|6% CO2 breathing|The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
214995472|NCT05738213|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
214995473|NCT05738213|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
214381737|NCT01992705|DRUG|-Irinotecan 180 mg/m2 IV on Day 1|Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
214381738|NCT01992705|DRUG|-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours|5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
214381739|NCT04106843|DRUG|Lutetium Lu 177 Dotatate|Given IV
214381740|NCT00273559|DRUG|prednisone|group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
214381741|NCT02273297|OTHER|Maternal factors|
214381742|NCT01589952|DRUG|Pegalyted interferon, Entecavir|Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
214381743|NCT01474460|DIETARY_SUPPLEMENT|phytonadione|Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
214381744|NCT00692406|BEHAVIORAL|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
214381745|NCT02082626|DRUG|Eribulin mesylate|
214498359|NCT03317652|DRUG|Infusion of sodium nitroprusside|Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
214498360|NCT01697891|DEVICE|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
214498361|NCT02503722|OTHER|Laboratory Biomarker Analysis|Correlative studies
214498362|NCT02503722|DRUG|Osimertinib|Given PO
214498363|NCT02503722|OTHER|Pharmacological Study|Correlative studies
214498364|NCT02503722|DRUG|Sapanisertib|Given PO
214498365|NCT04706754|OTHER|Questionnaires|Participants will complete the survey(s) at the initial visit and every 3 months and/or whenever there is an update in their treatment protocol. Patients may also choose to opt out of the surveys and only consent to primary data collection at the site.
214995474|NCT05738213|BEHAVIORAL|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
214381746|NCT03350243|OTHER|CCENT Intervention|"1. Acceptance and Commitment Therapy approach: engaging families through structured individual or group sessions within the NICU and continue this support once discharged.~2. Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~3. Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support."
214381747|NCT05345288|DEVICE|BrainHQ cognitive training|"Posit Science's BrainHQ exercises are based on the science of neuroplasticity, also called brain plasticity. Brain plasticity is your brain's natural ability to remodel itself throughout life. The brain is always changing, sometimes for better, and sometimes for worse. What BrainHQ's exercises do is harness that change and direct it in ways that can enhance your overall performance and improve the quality of your life. BrainHQ exercises are grouped into six categories: Attention, Memory, Brain Speed, Intelligence, People Skills, and Navigation."
214381748|NCT05345288|DEVICE|BrainHQ control games|BrainHQ also offers control games for research studies. The control activities will be games similar to candy crush, connect four, gem swap and battleship.
214381749|NCT06288711|BEHAVIORAL|Prolonged exposure therapy|Twelve weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by therapists trained in prolonged exposure therapy.
214995475|NCT05738213|BEHAVIORAL|PedMIDAS (Pediatric Migraine Disability Assessment)|Adolescents with migraine will complete questions regarding their headache frequency. Migraine disability will be assessed using PedMIDAS (Pediatric Migraine Disability Assessment). This self-reported questionnaire assesses the number of days that headaches affect participant's daily activities. This is a widely used, reliable and validated tool to assess migraine disability.
214995476|NCT05738213|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples (approximetly 2 tablespoons) will be collected for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone).
214995477|NCT05738213|OTHER|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-Wave 3 survey, which allows for differentiation between pre-, early-, late-, and post-pubertal status. Early puberty is defined as a score of 3 and no menarche, mid-puberty is defined as 4 and no menarche, late pubertal is defined as a score of 7 points or less and with menarche, and post pubertal is defined as a score of 8 and menarche. For boys, pubertal maturation status will be determined by the Physical Development Scale using the body hair growth voice change and facial hair questions. Early puberty is defined as a score of 4-5, mid-puberty is defined as a score of 6-8, late pubertal is defined as a score of 9-11 points, and post pubertal is defined as a score of 12.
214995478|NCT06327555|OTHER|telerehabilitation|The telerehabilitation group uses smart wearables and mobile apps worn around the knee joint to perform telerehabilitation at home. Both sets of training sessions are identical.
215092875|NCT06228690|OTHER|Conventional PT treatment|"Conventional PT including Hot Pack for 10mins, Active-Passive neck Stretching Exercise + jaw Isometric Exercises.~* Frequency: hold followed by 5secs rest. 2-3times for 3 times/week for 4 weeks, Intensity: moderate-high intensity (depending on pain tolerance) Time: 30-45 mins for Active-Passive neck Stretching.~* Frequency: 3secs hold, 6 times repetitions for Isometric Exercises. Type: conventional treatment for pain, ROM, MMO."
215092876|NCT05848765|DRUG|Epcoritamab|Bispecific antibody
215092877|NCT05848765|DRUG|Lenalidomide|Immunomodulatory agent
215092878|NCT05848765|DRUG|Rituximab|Monoclonal antibody
215092879|NCT05848765|DRUG|Obinutuzumab|Monoclonal antibody
214381750|NCT06288711|BEHAVIORAL|Financial incentives|Financial incentives contingent upon completion of prolonged exposure therapy sessions
214381751|NCT06288711|BEHAVIORAL|Treatment as usual|Continued standard buprenorphine or methadone maintenance treatment from current treatment provider.
214381752|NCT05971134|BEHAVIORAL|Acupreesure applied|Acupressure was applied to the LI4 acupuncture point for 3 minutes by the researcher for the intervention group
214995479|NCT06327555|OTHER|in-person rehabilitation|The in-person rehabilitation group uses a face-to-face approach, with therapists providing outpatient rehabilitation guidance to patients three times a week for six weeks. After that, patients exercise at home according to the rehabilitation manual.
214995480|NCT00278408|BIOLOGICAL|filgrastim|
215092880|NCT05848765|DRUG|Bendamustine|Alkylating agent (chemotherapy drug)
215092881|NCT05848765|DRUG|Vincristine|Antineoplastic, Vinca Alkaloid
214498366|NCT02230046|DRUG|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
214995481|NCT00278408|BIOLOGICAL|rituximab|
214995482|NCT00278408|DRUG|cyclophosphamide|
214995483|NCT00278408|DRUG|doxorubicin hydrochloride|
214995484|NCT00278408|DRUG|prednisone|
214995485|NCT00278408|DRUG|vincristine sulfate|
214995486|NCT00278408|RADIATION|radiation therapy|
214995487|NCT05280730|OTHER|No intervention|There is no intervention
214995488|NCT05285891|DRUG|Ocrelizumab|Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
214995489|NCT05285891|DRUG|Placebo for Ocrelizumab|Placebo infusions every 6 months from Month 30 through Month 48.
215092882|NCT05848765|DRUG|Doxorubicin|Anthracycline
215092883|NCT05848765|DRUG|Cyclophosphamide|Alkylating agent (chemotherapy drug)
215092884|NCT05848765|DRUG|Prednisone|Corticosteroid
215092885|NCT05848765|DRUG|Investigation agent 2|The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
215092886|NCT05848765|DRUG|Investigation agent 3|The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
215092887|NCT03756831|DIAGNOSTIC_TEST|Core Stability Assessment|Core Stability Assessment will be consisted of bilateral static balance with open and close eye, right foot balance test, and dynamic balance test.
214995490|NCT05599490|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
214381753|NCT05461690|DRUG|Niraparib|200mg once a day for patients with body weight \<77kg or baseline platelet count \<150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.
214381754|NCT04151875|DEVICE|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
214381755|NCT04151875|DEVICE|Non-extraction orthodontic treatment|Non-extraction orthodontic treatment
214381756|NCT02869919|OTHER|AKI|Vitamin D levels
214381757|NCT00003379|DRUG|cisplatin|
214381758|NCT00003379|DRUG|paclitaxel|
214381759|NCT00003379|RADIATION|brachytherapy|
214381760|NCT00003379|RADIATION|radiation therapy|
214381761|NCT05230979|OTHER|Common bean baked snack|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
214381762|NCT05230979|OTHER|Cooked beans|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
214381763|NCT05230979|OTHER|White bread|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
214381764|NCT05230979|OTHER|Anhydrous glucose (first session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume a reference glucose solution containing 25 g of anhydrous glucose per 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to drink the reference glucose solution. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
214995491|NCT03741127|DRUG|Rimiducid may be administered as indicated|Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
214995492|NCT03033355|DRUG|Intra-detrusor injection of Onabotulinumtoxin-A|Using cystoscopy, Onabotulinumtoxin-A is injected into the bladder.
214995493|NCT06387394|DRUG|BOTOX|Intramuscular Injections
214995494|NCT06387394|DRUG|Placebo|Intramuscular Injections
214995495|NCT05115474|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo MRI imaging with and without contrast.
214995496|NCT04717557|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen (HBO2) 1-2 times daily for up to 10 times after amputation
215092888|NCT03562468|DIETARY_SUPPLEMENT|300 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment with 300 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
215092889|NCT03562468|DIETARY_SUPPLEMENT|1000 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment 1000 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
214381765|NCT05230979|OTHER|Anhydrous glucose (second session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
214995497|NCT03745287|BIOLOGICAL|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan.
214995498|NCT04184895|BIOLOGICAL|ASP2390|Intradermal
214995499|NCT04184895|BIOLOGICAL|Placebo|Intradermal; normal saline solution
214995500|NCT03964116|OTHER|Questionnaires set all 3 months|"This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview."
214381766|NCT05230979|OTHER|Common bean baked snack (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
214995501|NCT04592172|BEHAVIORAL|Bedtime Routine Education|The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
214381767|NCT04323982|PROCEDURE|new surgical procedure|（ACCC + I / A + PCCC + TA+ A-vit) or （ACCC + I / A + PCCC + IOL + TA + A-vit）
214687412|NCT06842693|BEHAVIORAL|Colombian non-nutritive sweetener label|"Products carry octagonal label that states contains non-nutritive sweeteners  when containing non-nutritive sweeteners. Additionally, to match the current Chilean legislation, products carry an octagonal label that states high in sugar when high in added sugars, and/or an octagonal label that states high in calories when high in calorie density."
214995503|NCT06401980|DRUG|Darolutamide|Darolutamide will be supplied in bottles as 300 mg film-coated tablets for oral intake
214995504|NCT06401980|OTHER|Standard of care|"* Docetaxel~* Cabazitaxel~* LuPSMA~* Radium 223~* Olaparib, in case of BRCA1 or 2 mutated or HRR deficient tumors~The standard of care is chosen by the local investigator and respecting the country specific approvals."
215092890|NCT03562468|DIETARY_SUPPLEMENT|Placebo|Treatment with placebo capsules will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
215092891|NCT02850900|BEHAVIORAL|Internet Survey|Weekly survey will be emailed, subjects should complete them
215092892|NCT01600053|DRUG|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
215092893|NCT00516035|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
215092894|NCT05047575|OTHER|REASSURE|REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
215092895|NCT01389999|OTHER|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
215092896|NCT01404455|OTHER|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
215092897|NCT04477057|DRUG|HS-10241|HS-10241 is a tablet in the form of 100 mg, oral, once daily.
215092898|NCT00127335|DRUG|cellulose placebo vs. atorvastatin|drug
215092899|NCT05830877|OTHER|the acupuncture group|"The primary choice is to puncture GB20 with a quick puncture, which means regulate the mind and open the way. ①Scalp acupuncture: Du 20(Baihui), EX-HN 3(Yintang), EX-HNl(Sishencong); ②Select acupoints from six acupoints for mind-regulating, ear points (both sides): heart, lung, and Shenmen; body points (both sides): LI20(Yingxiang), EXTRA 12(Anmian), ST36(Zusanli) as the main hole. ③Sleeping three needles(both sides): HT7(Shenmen), PC6(Neiguan), SP6(Sanyinjiao); ④Opening four gates: LI4(Hegu) , LR3(Taichong) ⑤Abdominal four needles:ST25(Tianshu), CV12(Zhongwan), CV4(Guanyuan). For body acupuncture, a 0.3 mm×40 mm needle was used to insert directly for 0.5-1.0 cun, and twisting to gain the qi; for auricular points, a 0.25 mm×40 mm needle was used for 2-3 minutes without manipulating the needle. The acupuncture points were retained for 30 min, and the treatment was performed once every other day, three times a week, and the curative effect was evaluated after 4 weeks of treatment."
215094718|NCT03511456|PROCEDURE|PELD operation|"Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed."
215094719|NCT04464096|OTHER|non|non
214381768|NCT04323982|PROCEDURE|traditional surgical procedure|（ACCC + I / A + PCCC + A-vit) or （ACCC + I / A + PCCC + IOL + A-vit）
214498367|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
214498368|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
214498369|NCT03910738|DRUG|Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
215092900|NCT05830877|OTHER|the placebo acupuncture group|Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device. This needle has a retractable shaft and a blunt tip, they could not penetrate the skin. We gently placed the sham needle and Park device on the skin. The sham needle is then no longer manipulated to minimize any physiological effects. The selected acupoints and needle retention time were the same as for the acupuncture group. Since oblique insertion is required for acupuncture points on the head, the fixed acupuncture body of the Park device could not be used. Therefore, blunt needles are used to stimulate the head points to reduce the amount of stimulation produced by acupuncture. At the end of the treatment, the acupuncturist also used a dry cotton swab to press the acupoints so that patients could feel the withdrawal of 'real' needles.
215092901|NCT00139217|DRUG|iNO|
214995505|NCT03731000|DEVICE|PHIL® device|Using PHIL® device for treatment of intracranial dural arteriovenous fistulas
214995506|NCT03727880|DRUG|Pembrolizumab|Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.
214995507|NCT03727880|DRUG|Defactinib|Following 2 cycles of standard of care neoadjuvant chemotherapy, subjects will receive 400 mg defactinib twice a day up until 2 days preceding their surgery (approximately 6 weeks) during the immunotherapy cycles with pembrolizumab. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 400mg defactinib twice a day for 24 weeks.
214995508|NCT02213003|BIOLOGICAL|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
214995509|NCT06242470|BIOLOGICAL|MGC026 Dose Escalation|Escalating doses of MGC026
214995510|NCT06242470|BIOLOGICAL|MGC026 Dose for Expansion|MGC026 recommended dose for expansion
214995511|NCT04837716|BIOLOGICAL|Bevacizumab|Given IV
214995512|NCT04837716|DRUG|Carboplatin|Given IV
214995513|NCT04837716|DRUG|Ensartinib|Given PO
214995514|NCT04837716|DRUG|Pemetrexed|Given IV
214995515|NCT05808920|GENETIC|Molecular Analyses|Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected.
215092902|NCT00139217|PROCEDURE|Non-invasive nitric oxide|
214381769|NCT00544960|DRUG|AT-101 and docetaxel|AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
214381770|NCT00544960|DRUG|placebo and docetaxel|placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
214995516|NCT05352399|OTHER|NeuViCare application|Intervention arm participants will engage with NeuViCare AI, including all variations of its 5 components: 1) NeuViCare Planner - enables review of ordered tests and external resources recommended by the care provider; 2) NeuViCare Task-Support Service - provides context-sensitive, personalized text-based assistance to help patients' complete care plan captured in the NeuViCare Planner; 3) NeuViCare Resource Advisor - presents trusted, unbiased advice to locate nearby resources listed within their care plan; 4) NeuViCare Advisor - educates and trains Persons Living With Dementia (PLWD) and their care partners at the moment of need; and 5) NeuViCare Community Hub - a safe virtual space which enables care partners to interact with other peer care partners to gain their experiential knowledge and emotional support.
214995517|NCT06618885|BIOLOGICAL|SUM-101|Three immunizations every 4 weeks for 3 months (total 3 immunizations)
214995518|NCT06374485|DRUG|AU409|Oral administration
215092903|NCT04250597|DRUG|GNX102|Dose Escalation
215092904|NCT04250597|DRUG|GNX102|Expansion Phase
215092905|NCT01518504|OTHER|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
214381771|NCT04602897|OTHER|forced coughing|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
214381772|NCT04145037|DRUG|AVR-RD-02|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase).
214381773|NCT06354335|OTHER|Employees exposed to a major hospital reorganisation|Occupational exposure
214381774|NCT01762423|DEVICE|Active Device (IVIVI SofPulse)|
214381775|NCT01762423|DEVICE|Sham Device|
214381776|NCT03324711|DIAGNOSTIC_TEST|"Antillanisée Mini Mental State Examination (MMSEa)"|"Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture."
214381777|NCT05713682|PROCEDURE|alveolar ridge preservation|bone grafting at extracted sites
214381778|NCT00812513|DRUG|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
214381779|NCT04294394|OTHER|rhomboid block|Rhombid block, on the other hand, is a method which make up analgesia by providing lokal anestethetic enjection between intercostal muscles and rhomboid muscles and blocks between t3- t9 levels
214995519|NCT05484778|PROCEDURE|Dual tasking paradigm|The dual task methodology is a testing model that requires one person to perform two tasks at the same time. The dual task is divided into two as motor-motor or motor-cognitive. Dual tasks provide an opportunity to examine the attention demands of both tasks and allow possible interference to be observed. The idea behind this design is that central processing capacity has a limit and must be distributed among concurrent tasks.
214381780|NCT04294394|OTHER|erector spinae block|The Erector spinae plan block is a recently developed regional block method .Adminestering of lokal anesthetic between the transver proces and erector spinae muscles provides the dorsal and ventral branch blokades of regional spinal nerve and make up the analgesia.İt have a wide range usage such as surgery of thoracal and abdominal area
214381781|NCT04294394|OTHER|control|For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
214498370|NCT03910738|DRUG|Placebo 4 mL Solution for Injection|Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
214498371|NCT03910738|PROCEDURE|MRI|Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
214995520|NCT05609435|OTHER|REASSURE|REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
214995521|NCT06432517|OTHER|Power Bike（Ergoselect 100P）|Changes in the participants' energy balance will be measured through moderate to high intensity exercise. Observation of food intake, body composition, metabolic rate, food assimilation rate.
214995522|NCT03370224|BEHAVIORAL|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
214995523|NCT03370224|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
214995524|NCT06220656|PROCEDURE|Biopsy|Local anesthetic is usually given and a small needle is used to take cells from the thyroid under ultrasound guidance through several 'passes' and placed into specialized media for pathology evaluation.
214995525|NCT06220656|PROCEDURE|Active Monitoring|Ultrasound and a check-up at 6 months. Depending on ultrasound results, either biopsy and further care (as for the treatment arm called 'biopsy'), or continue with active monitoring.
214381782|NCT02418975|OTHER|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (\~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
214381783|NCT02418975|OTHER|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (\~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
214498372|NCT03910738|BEHAVIORAL|Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
214498373|NCT03910738|BEHAVIORAL|Assessment of disability|EDSS (Baseline, week 30 and 66)
214498374|NCT00756574|DEVICE|Surgical mask|Surgical mask worn for patients with febrile respiratory illness
214498375|NCT00756574|DEVICE|N95 mask|N95 mask worn for patients with febrile respiratory illness
214498376|NCT00236535|DRUG|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
214995526|NCT05041998|DEVICE|Trans-femoral prosthetic socket|"Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~1. Soft socket (Socket made from softer material than unmodified original)~2. Stiff socket (Socket made from stiffer material than unmodified original)~3. moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~4. slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~5. Oversized socket (The socket volume is 6% larger than the unmodified original)~6. Undersized socket (The socket volume is 6% smaller than the unmodified original)~7. CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~8. MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)"
215092906|NCT01518504|OTHER|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
215094720|NCT00093821|DRUG|tanespimycin|Given IV
215094721|NCT00093821|OTHER|pharmacological study|Correlative studies
214381784|NCT05320016|DRUG|Remimazolam|Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery
214381785|NCT01756560|DRUG|dexamethsone|
214381786|NCT01756560|DRUG|Bupivacaine|
214381787|NCT05122572|BIOLOGICAL|Oncolytic Virus Injection (RT-01）|Intravenous injection of RT-01 with or without Nivolumab
214381788|NCT00433953|DRUG|Mycophenolate Mofetil (CellCept)|
214498377|NCT05697705|OTHER|ChAdOx1 nCOV-19 vaccine (Vaxzeria)|Used as 2nd booster, 1st booster, or primary series
214498378|NCT05697705|OTHER|BNT162b2 (Pfizer)|Used as 2nd booster, 1st booster, or primary series.
214498379|NCT05697705|OTHER|Ad26.COV2.S (Janssen)|Used as 2nd booster, 1st booster, or primary series.
214498380|NCT05697705|OTHER|CoronaVac (Sinovac)|Used as 2nd booster, 1st booster, or primary series.
214498381|NCT04845321|DRUG|VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
214498382|NCT04845321|DRUG|Placebo for VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
214381789|NCT00433953|BEHAVIORAL|Dietary Monitoring|
214381790|NCT00433953|BEHAVIORAL|Drug Diary|
214381791|NCT00433953|PROCEDURE|Blood Sampling|
214381792|NCT04363385|BIOLOGICAL|Biological test|Blood sample
214381793|NCT01907139|BEHAVIORAL|Robot-assisted therapy|Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
214381794|NCT01907139|BEHAVIORAL|Distributed constraint-induced therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
214381795|NCT01907139|BEHAVIORAL|Dose-matched control therapy|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
214381796|NCT00754975|DEVICE|JACTAX LD DES|Drug Eluting Stent
214381797|NCT00754975|DEVICE|TAXUS™ Libertè™ DES|Drug Eluting Stent
214381798|NCT02307513|DRUG|Apremilast|Tablets for oral administration
214498383|NCT04035447|BEHAVIORAL|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
214498384|NCT05907603|DRUG|RD13-02 cell infusion|CAR-T cells
214498385|NCT04564443|OTHER|Medaxis Debritom+|Advanced micro fluid jet therapy to clean and stimulate wound
214498386|NCT04564443|OTHER|Sharp Surgical Debridement|Scalpel or Curette to clean and debride wound
214498387|NCT04564443|OTHER|Additional Outer Dressing Application|Application of moisture retentive dressing, and a multi layer compression dressing
214498388|NCT04564443|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
215092907|NCT02855944|DRUG|Chemotherapy|Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
214381799|NCT02307513|DRUG|Placebo|Tablets for oral administration
214381800|NCT00179699|DRUG|CC-5013|
214381801|NCT00179699|DRUG|pemetrexed|
214498389|NCT04564443|OTHER|Fibracol Wound Dressing|Application of a collagen alginate dressing
214498390|NCT06402422|DEVICE|Theta-burst stimulation|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). Concurrent iTBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
214498391|NCT06110468|OTHER|CoreDISTParticipation|CoreDISTparticipation is a multi-disciplinary individualized intervention that concurrently combine 1) providing PwMS and their employers with information on MS, possibilities for work-adaptations within the welfare system and the importance of physical activity 2) Structured goal-setting regarding reducing barriers for work and regarding physical function and activity for PwMS 3) A physiotherapy intervention focusing on improving the underlying prerequisites for balance and walking along with high intensive training and promotion of physical activity 4) structured evaluation and adjustment of goals.
214498392|NCT05880108|BEHAVIORAL|12-weeks of Weight Loss|Participants will be asked to participate in a 1x/week center-based or tele-health nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for \~12 weeks.
215092908|NCT02855944|DRUG|Rucaparib|Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day
215092909|NCT05942118|PROCEDURE|Breast conservative surgery|Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
215092910|NCT01874938|BIOLOGICAL|LY2875358|Administered IV
215094722|NCT00093821|OTHER|laboratory biomarker analysis|Correlative studies
214381802|NCT02055937|PROCEDURE|immediate implant breast reconstruction|Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™
214498393|NCT05880108|BEHAVIORAL|12-weeks of Weight Stability|Participants will be asked to participate in a 1x/week center-based or tele-health education class, 2x/week center-based stretching/balance classes, and 1x/week stretching/balance session conducted on their own for \~12 weeks.
214995527|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Stand Training|Participants may use a standing apparatus or a less assistive device such as walker or cane. In case of upper limbs and trunk control insufficient for safely using the standing apparatus, participants will be placed on the treadmill, and a body weight support system. In this case, the level of body weight support will be continuously reduced as the individuals increase their ability to bear weight. A trainer positioned behind the participant will aid in pelvis and trunk stabilization. Trainer(s) positioned at the lower limb will provide manual facilitation for knee extension during standing. Manual facilitation at the trunk-pelvis and at the legs will be used only when needed.Participants will be encouraged to stand for as long as possible throughout the training session, with the goal to stand for 60 minutes with the least amount of assistance.
214381803|NCT01560260|OTHER|Laboratory Biomarker Analysis|Correlative studies
214381804|NCT01560260|DRUG|Linsitinib|Given PO
214381805|NCT01560260|OTHER|Pharmacological Study|Correlative studies
214381806|NCT05242016|OTHER|structured individual reminiscence|reminiscence therapy
214381807|NCT05242016|OTHER|unstructured social interview|placebo
214381808|NCT02534532|OTHER|AF screening|Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
214381809|NCT00057187|BEHAVIORAL|Contracting, Prompting and Reinforcing|
214381810|NCT01837290|DRUG|dexmedetomidine infusion for premedication|Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
214381811|NCT01837290|DRUG|Midazolam|intravenous Midazolam 0.02 mg/kg for premedication
214498394|NCT04515238|DRUG|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
214687413|NCT06850870|OTHER|Door-through-door companion rideshare|Door-through-Door Companion Drivers, unlike traditional rideshare services, are certified in CPR and first aid, and undergo onboard training to support older adults, individuals with mobility impairments, and those with AD/ADRD. They are trained to observe behaviors of AD/ADRD patients, monitor and detect risk of falls, elopement, and other events that may require extra assistance or emergency care during transport. Drivers accompany riders continuously until they can hand off riders to clinicians or other caregivers, or return them to their home. Technology features in the rideshare platform enable continuity of care, for consistent rider-driver matching and matching of riders to drivers based on support needs.
214995528|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Step Training|Participants may be placed on the treadmill in an upright position and suspended in a harness. All trainers are careful to provide manual assistance only when needed. A trainer positioned behind the research participant will aid in pelvis and trunk stabilization, as well as appropriate weight shifting and hip rotation during the step cycle. Trainers positioned at each limb will provide manual assistance to promote knee extension and knee flexion and toe clearance. Research participants will step at various body weight load and speed. Research participants will take a break and rest at any time they feel the need to during the session. If independence is achieved during stepping, some training might be performed overground with appropriate assistive device and manual assistance to maintain participant safety. Participants will be encouraged to step for 60 minutes with the least amount of assistance. Seated or standing resting periods will occur when requested by the individuals
215092911|NCT04844086|BIOLOGICAL|RPM CD19-mbIL15-CAR-T cells|"Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
215092912|NCT03403309|DRUG|1) Inosine 5'-monophosphate|1\) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
214381812|NCT01837290|DRUG|saline infusion|Saline infusion to facilitate blinding
214381813|NCT01837290|DRUG|Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg|Hyperbaric bupivacaine injection for spinal block
214498395|NCT04515238|BIOLOGICAL|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
214498396|NCT04515238|BIOLOGICAL|Zanubrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 160mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 160mg p.o"
214687414|NCT06850870|OTHER|Curb-to-curb rideshare services|Curb to curb rideshare services provided by a transportation network company (TNC) with drivers who don't have specialized training in supporting healthcare riders and who don't undergo fingerprint background checks or drug and alcohol testing.
215094723|NCT03442296|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner (if applicable)
214381814|NCT04654247|BEHAVIORAL|Quality audit and feedback|Endoscopists received quality report generated by Endo.Adm.
214381815|NCT04654247|BEHAVIORAL|Control|None feedback.
214381816|NCT05952297|DEVICE|Sleep Wellness Device (BeCurie)|This device emits micro electromagnetic stimulation
214381817|NCT02777996|DEVICE|Low Dose Computed Tomography|Assessment protocol were adopted from the ELCAP study (modified) for Non Calcific Nodule with a diameter of less- equal than 5 mm at baseline and 3mm at repeated.
214381818|NCT03622203|DEVICE|Biofreedom|Use of Biofreedom in real life patients
214381819|NCT03375632|DRUG|FYU-981|Oral daily dosing for 14 weeks
214381820|NCT00282997|DRUG|pregabalin|
214381821|NCT02936713|OTHER|Fermented milk product with probiotics (FMPP)|2 pots of 125g FMPP / day
214381822|NCT06044363|OTHER|Satir group|Participants in the intervention group will receive a 10-session, 3-hour/session intervention that spans over a period of five days (2 sessions/day). The intervention program will be conducted on specific weekends, with a gap of 1 to 2 weeks. The total duration of the intervention will be 30 hours.
214381823|NCT03868241|DEVICE|Coated devices|Gold-silver-palladium coated devices (endotracheal tube, central venous catheter and urinary catheter) will be used whenever necessary. All three devices are required to be inserted as soon as possible after randomization and need for all three devices are the main inclusion criteria
214498397|NCT04515238|BIOLOGICAL|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
214498398|NCT04289324|PROCEDURE|regular lung recruitment|stepwise oxygenation-guided lung recruitment at regular (twelve hours) intervals during high frequency oscillation ventilation
214498399|NCT06044441|BEHAVIORAL|ENABLE-SG model|Patients and caregivers will receive individual structured psycho-educational sessions with a health coach. These sessions will be primarily delivered over the phone. Patient and caregiver dyads will have different health coaches. Patients will have six sessions on the topics of maintaining positivity, self-care, coping with stress, managing symptoms, exploring what matters most, and life review. Caregivers will have four sessions on the topics of maintaining positivity, self-care, coping with stress, and managing symptoms. All sessions will begin with screening for distress using the Distress Thermometer and Problem List culturally adapted from the National Comprehensive Cancer Network. From screening results, the health coach can flexibly change the order of the topics to address specific problems. It will take approximately three months to complete all sessions.
214498400|NCT06044441|OTHER|Wait-list control|"* 6-month wait-list control. Participants will receive the ENABLE-SG model six months after baseline (six sessions for patients and four sessions for caregivers) at an approximately weekly interval.~* Interventions: ENABLE-SG model"
214498401|NCT04589598|DEVICE|Femoral Neck System|femoral neck system using bolt and antirotation screw with one/two hole plate
214498402|NCT04589598|DEVICE|Multiple Cannulated Screw|multiple cannulated screw using 3 or 4 cannulated screw
214995529|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Bladder Capacity Training|We will initially conduct daily training for capacity in a supervised on-site lab setting. Optimal configurations will be used. The storage phase configuration will be used until the time for voiding/catheterization. The training procedure will be repeated for up to 8 hours daily on-site until three consecutive stable days of maintaining a consistent capacity values are achieved and deemed safe. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation (urodynamics and questionnaires). On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home-based training for bladder capacity.
215092913|NCT03403309|DRUG|Placebo|2\) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
215094724|NCT03442296|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
215094725|NCT03299712|DEVICE|ArteFill|soft tissue filler
214381824|NCT03868241|DEVICE|Control|Devices without coating available at each participating intensive care unit
214381825|NCT02235701|DRUG|170 mg/m2 aldoxorubicin|administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
214381826|NCT02235701|DRUG|250 mg/m2 aldoxorubicin|administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
214381827|NCT01053754|BIOLOGICAL|"long synacthen stimulation test"|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
214381828|NCT05285254|OTHER|Certified Child Life Specialist Support|Provides psychosocial care to children and families confronting stressful and painful situations
214381829|NCT00525265|DRUG|OPC-41061(Tolvaptan)|Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
214381830|NCT00525265|DRUG|Placebo|Subjects will be orally administered placebo once daily after breakfast for seven days.
214381831|NCT00073827|DRUG|levalbuterol tartrate MDI|levalbuterol 90 mcg QID
214381832|NCT00073827|DRUG|racemic albuterol MDI|racemic albuterol 180 mcg QID
214381833|NCT00073827|DRUG|Placebo|Placebo MDI QID
214381834|NCT05006677|DRUG|non-vitamin K antagonist oral anticoagulants (NOACs)|Collecting information of patients with VT who received NOACs
214381835|NCT05006677|DRUG|vitamin K antagonists (VKAs)|Collecting information of patients with VT who received VKAs
214381836|NCT05006677|DRUG|antiplatelet agents|Collecting information of patients with VT who received antiplatelet agents
214381837|NCT05006677|OTHER|non-antithrombotic therapy|Collecting information of patients with VT without any antithrombotic therapy
214381838|NCT01083940|OTHER|Computerized reminders on hypertension intensification|Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
214381839|NCT06383702|DRUG|pregabalin sustained-release tablets|Subjects will take pregabalin sustained-release tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
214498403|NCT06088758|DEVICE|Normothermic machine perfusion (NMP) of steatotic liver|Steatotic liver grafts that are selected will be run on NMP to assess quality of graft and determine whether it meets criteria for transplantation
214498404|NCT05615051|DEVICE|Surface decontamination procedure aiming at reconstructive therapy|Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
214498405|NCT03605901|DRUG|Standard dosing of methadone|Subject will receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
214498406|NCT03605901|DRUG|Aliquots of methadone titrated to apnea|Subjects will receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals.
214687415|NCT06158841|DRUG|Etentamig|Intravenous (IV) Infusion
214687416|NCT06158841|DRUG|Carfilzomib|IV Infusion
214995530|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Bladder Voiding Efficiency Training|We will conduct training for voiding efficiency in a supervised on-site lab setting while the participant continues his/her training for capacity. Voiding without catheterization will be attempted. The training procedure will be repeated for up to 8 hours on-site until three stable days of maintaining a consistent voiding efficiency are achieved and deemed safe. The participant will be sent home for one day to perform the stimulation at home. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation and questionnaires. On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home program integrating bladder training for capacity and voiding
214381840|NCT06383702|DRUG|Placebo|Subjects will take placebo tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
214381841|NCT06061432|PROCEDURE|Endoscopic restoration of gastrointestinal continuity after Hartmann procedure|EndoHARP is a new technique proposed to restore gastrointestinal continuity after the Hartmann's procedure. For EndoHARP, a fixed loop of the large intestine will be identified on endosonography after an echoendoscope is inserted into the rectal stump under endoscopic guidance. Then, using the set for inserting self-expandable metal transmural endoprosthesis (20 mm in diameter and 10 mm in length) with electrocautery (as in endoscopic gastroenterostomy), EUS-guided anastomosis of the rectal stump to the large intestine loop will be performed, allowing the natural passage of intestinal contents through the endoscopic anastomosis, restoring gastrointestinal continuity. The aim of leaving the self-expandable transmural endoprosthesis in the anastomosis is not only to maintain the patency of the intestinal anastomosis of at least 20 mm in diameter, but also to diminish the risk of endoscopic intestinal anastomotic leak by completely covering the prosthesis with a polymer layer.
214381842|NCT03107377|DRUG|EVO100|5 g dose applied up to 1 hour prior to coitus
214381843|NCT03107377|DRUG|Placebo|5 g dose applied up to 1 hour prior to coitus
214381844|NCT03826511|OTHER|Tiszasüly hot mud-pack therapy|Patients received Tiszasüly hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
214381845|NCT03826511|OTHER|Kolop mud-pack|Patients received Kolop hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
214381846|NCT04361032|DRUG|Tocilizumab Injection|Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
214498407|NCT04540588|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214498408|NCT06107842|BEHAVIORAL|Gerofit exercise|Individualized exercise prescription as well as a group exercise class based on physical function assessments offered 3x/week
214995531|NCT05477277|DIAGNOSTIC_TEST|MAsS|Add MAsS to standard of care MRI scan
214995532|NCT02846623|DRUG|Atezolizumab|Given IV
214381847|NCT04361032|DRUG|Deferoxamine|Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
214498409|NCT06107842|BEHAVIORAL|Health education|Scheduled monthly in-person health education discussion sessions covering 12 different health topics not including a physical activity/exercise promotion session
214498410|NCT05777200|BEHAVIORAL|Supportive psychotherapy|Counselling patients, providing supportive psychotherapy to help them detox their illicit drug usage, and help them rehabilitate again into society.
214498411|NCT03842085|DRUG|Recombinant Humanized Bispecific Monoclonal Antibody MBS301|The patients confirming to the eligibility criteria will be assigned to the 8 dose groups based on the sequence of inclusion. MBS301 will be administered intravenousely on day 1 of each 21-day cycle for each patient.The first intravenous infusion for each patient will be last for 90 minutes.It could be changed to 60 minutes for the subsequent infusions if the drug is well tolerated.
214498412|NCT05517655|DRUG|129Xe|Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
214498413|NCT05263830|OTHER|Quantitative assay of GlypicanPC-3|Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein
214498414|NCT05384223|BEHAVIORAL|RRFT (Risk Reduction through Family Therapy)|RRFT is an adaptation and integration of existing empirically-supported interventions with similar theoretical rationales targeting similar populations, particularly Multisystemic Therapy principles (MST)for adolescent SUP and Trauma Focused-Cognitive Behavioral Therapy (TF-CBT) components for PTSD in youth. RRFT consists of seven primary components: Psychoeducation and Engagement, Coping, Family Communication, Substance Use, PTSD, Healthy Dating and Sexual Decision-Making, and Revictimization Risk Reduction.
215092914|NCT05318820|DRUG|HMPL-523|This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
215092915|NCT04408911|DRUG|Midazolam vs. Lormetazepam|In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
215092916|NCT06425432|DEVICE|OVITZ xwave aberrometer|wavefront aberrometer
214381848|NCT06539975|DRUG|Evening Primrose Oil 1000 MG|Evening primrose oil 1000mg vaginally plus misoprostal for induction of labor
214687417|NCT06158841|DRUG|Pomalidomide|Oral Capsule
215094726|NCT01487993|DRUG|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
214995533|NCT02846623|OTHER|Laboratory Biomarker Analysis|Correlative studies
214995534|NCT02846623|BIOLOGICAL|Obinutuzumab|Given IV
214995535|NCT02846623|DRUG|Venetoclax|Given PO
215094727|NCT01487993|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
214381849|NCT03084497|PROCEDURE|Infant Massage|"The first day, investigators will make the initial assessment of the baby through Psychomotor Development Scale of Early Childhood Brunet- Lézine. Participants will keep the sessions early attention and will participate in the course of Infant Massage, which develop for 5 weeks.~Infant Massage course will take place with families and is based on the methodology and program of the International Association of Infant Massage ( IAIM ), created by Vimala McClure. The course will consist of 5 sessions (one per week) approximately 90 minutes. Parents will practice everyday the movements learned during the time of the study.~When the course of Infant Massage finished, Investigators will conduct the final evaluation of the baby, the same way as in the initial evaluation."
214995536|NCT06195228|DRUG|dabrafenib plus trametinib with or without PD-1 antibody|advanced thyroid cancer patients who harbor BRAF V600E mutation
214381850|NCT02872727|OTHER|Respiratoy health, biological investigations|Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data (and their evolution since the first study) will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
214498415|NCT05384223|BEHAVIORAL|ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)|Encompass is currently a research to practice treatment for adolescents with co-occurring substance use disorders and mental health problems and is used as the standard treatment in the target study settings.
214498416|NCT05760248|DRUG|10XB-101 Solution for Injection, 6.0%|The active drug (adipolytic) given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
214498417|NCT05760248|DRUG|Placebo Solution for Injection (no active ingredient)|Placebo given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
214498418|NCT05805826|BIOLOGICAL|C. difficile vaccine (previously studied formulation).|Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection
214498419|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 1.|C. difficile vaccine formulation 1 given as an intramuscular injection
214995537|NCT06195228|DRUG|entrectinib or larotrectinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor NTRK mutation
214995538|NCT06195228|DRUG|pralsetinib or selpercatinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
214995539|NCT06195228|DRUG|anlotinib or anlotinib plus anti-PD-1 antibody|For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
214995540|NCT06195228|DRUG|lenvatinib plus anti-PD-1 antibody|Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
214995541|NCT06195228|DRUG|Other Targets: precise treatment based on the target|Advanced thyroid cancer patients who had other treatment targets not included above
214995542|NCT01802281|PROCEDURE|Uterosacral ligament suspension|The USLS procedure used in this protocol is a modification of the technique described by Shull.
214995543|NCT01802281|PROCEDURE|Uphold® LITE|The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
214995544|NCT05574127|BEHAVIORAL|Behavioral Activation|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
214995545|NCT05574127|BEHAVIORAL|Supportive Psychotherapy|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
214995546|NCT05861739|BEHAVIORAL|Endometriosis Self-care Support Program|ESSP will be applied to the women in the intervention group in four sessions, one week apart. In the first and second sessions, a self-care training program will be applied. In the third and fourth sessions, motivational interview will be made by contacting the women by phone.
214995547|NCT05484115|DEVICE|endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|treatment of AAA's with wide proximal neck diameters with Endurant II/IIs endograft system
214995548|NCT05484115|DEVICE|endosuture aneurysm repair (ESAR) using Heli-FX EndoAnchor system|treatment of AAA's with wide proximal neck diameters with the Endurant II/IIs in conjunction with the Heli-FX EndoAnchor system
214995549|NCT03314181|DRUG|Dexamethasone|Infusion; Intravenous (IV), or Tablet; Oral
214995550|NCT03314181|DRUG|Daratumumab|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
214995551|NCT03314181|DRUG|Venetoclax|Tablet; Oral
214995552|NCT03314181|DRUG|Bortezomib|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
214995553|NCT06003166|DRUG|4-Aminopyridine|Study drug will be a one time, 10mg dose of 4-aminopyridine
214995554|NCT06003166|OTHER|Placebo|Matched placebo
214995555|NCT05639231|BEHAVIORAL|INTOMOB intervention|"The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment:~PATIENTS:~* Information booklet on the importance/benefits of mobility, consequences of low mobility, how to be more active (with concrete information).~* Customizable diary to document mobility goals, results, difficulties and needs.~* Exercise booklet with explanations \& pictures of mobility exercises (supine, sitting, standing).~* iPad 10.2'' with videos of the exercises.~HCPs (physicians \& nursing staff):~* E-learning on the consequences of low mobility, barriers/facilitators to hospital mobility; recommendations, documentation, communication \& interdisciplinary collaboration regarding mobility; implementation.~* Oral presentation on the intervention.~* Checklist to remind HCPs to address mobility.~ENVIRONMENT:~* Posters in the wards about mobility and other topics of interest to older adults.~* Walking itineraries in the wards."
214498420|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 2.|C. difficile vaccine formulation 2 given as an intramuscular injection
214381851|NCT02977884|BEHAVIORAL|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
214381852|NCT00453102|DRUG|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
214381853|NCT00453102|DRUG|Ibritumomab Tiuxetan|"IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³"
214381854|NCT00159978|PROCEDURE|18F-FLT and 18F-MISO-PET|18F-FLT-PET-images will be acquired one hour after injection of 250 MBq FLT. 18F-MISO-PET: 400 MBq FMISO will be injected intravenously. Marker administration: The day before surgery (≤ 24h) pimonidazole (500 mg/m2) will be administered intravenously in 100 ml saline over 20 min. IdUrd (200 mg) will be administered as bolus injection 20 min before surgery.
214995556|NCT05884411|DEVICE|Left bundle branch area pacing|A cardiac pacing electrode is inserted into the left bundle branch area of the myocardium via a transvenous approach.
214995557|NCT05884411|DIAGNOSTIC_TEST|Cardiac MRI|A diagnostic imaging test using magnetic resonance imaging to evaluate cardiac function.
214381855|NCT05921071|DRUG|Tranexamic acid|One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery
214381856|NCT05921071|DRUG|Placebo|patients will receive 10 ml of normal saline 0.9% intravenously.
214995558|NCT05049837|OTHER|Group Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
214995559|NCT05049837|OTHER|Group Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
214995560|NCT05049837|OTHER|Group Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples
214995561|NCT05049837|OTHER|Group Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
214995562|NCT05049837|OTHER|Group Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
214995563|NCT05049837|OTHER|Group Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
214995564|NCT06220396|PROCEDURE|Right Heart Catheterization with Hemodynamics and Limited Echocardiogram|"Right Heart Catheterization (RHC) with Hemodynamics and Limited Echocardiogram is an invasive procedure that involves insertion of a catheter through a blood vessel in the neck, groin, or arm to the right side of the heart. Hemodynamic measurements such as the blood pressure inside the veins, heart, and arteries as well as measurements of blood flow and how much oxygen is in the blood will be completed during the catheterization procedure. It is a way to see how well the heart is working during your procedure. During the RHC procedure a limited echocardiogram, using ultrasound waves, will be collected to evaluate the structure and function of the heart.~All measurements will be conducted at rest and during exercise using a supine cycle ergometer"
214995565|NCT06220396|PROCEDURE|Magnetic Resonance Imaging (MRI)|"MRI is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. CMR Imaging will assess myocardial structure, function, and fat content.~An additional limited MRI sequence of the the abdomen and one sequence in the thigh will be used to evaluate for visceral adipose tissue (VAT) as a measurement of body composition."
214995566|NCT06220396|PROCEDURE|Dual X-ray absorptiometry (DEXA) scan|A DEXA scan measures the amount of fat in the body using an x-ray that measures bone, calcium and fat.
214995567|NCT05674929|DRUG|BPL-003|A single dose administered intranasally
214995568|NCT02685735|DRUG|Gabapentin|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
214995569|NCT02685735|DRUG|Placebo|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
214995570|NCT06590792|OTHER|exhaustive exercise training session|Cardiovascular exercise test will be performed by the participants. This test is sustained until the participants feel exhausted.
214995571|NCT06827782|BIOLOGICAL|anti-CD19 CAR-NK cells|lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
214381857|NCT02980003|DRUG|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.
214381858|NCT02980003|DRUG|i.v. sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.
214498421|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 3.|C. difficile vaccine formulation 3 given as an intramuscular injection
214381859|NCT02980003|DRUG|oral sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
214995572|NCT06268808|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
214995573|NCT04282616|OTHER|Home-based unstructured physical activity program|Counselling on physical activity according to American College of Sports Medicine guidelines
214381860|NCT00827593|BEHAVIORAL|Standard behavioral weight loss treatment|Participants will receive 12 months of university-based behavioral weight loss treatment
214498422|NCT05805826|OTHER|Saline Placebo.|0.9% sodium chloride solution given as an intramuscular injection
214498423|NCT04572906|COMBINATION_PRODUCT|NTX-001|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
214498424|NCT05933733|OTHER|Salvage treatment (surgery and/or radiation therapy)|Appropriate salvage treatment (surgery and/or radiation therapy) will be selected by the treating clinicians considering the disease status.
214498425|NCT01379482|DRUG|Multimodal treatment|"3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)"
214498426|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received one drain.|patients who underwent two level lumbar decompression with BESS procedure received one drain.
214381861|NCT00827593|BEHAVIORAL|Weight Watchers|Participants will receive 12 months of Weight Watchers
214498427|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received two drain.|patients who underwent two level lumbar decompression with BESS procedure received two drains
214498428|NCT03660618|DEVICE|laser speckle flowgraphy|blood flow state of the skin as real time two dimensional image
214687418|NCT06158841|DRUG|Elotuzumab|IV Infusion
214995574|NCT04282616|OTHER|Home-based structured low-intensity physical activity program|Structured home-based low-intensity intermittent walking program
214995575|NCT04282616|OTHER|In-hospital structured supervised physical activity program|Supervised exercise training program
214995576|NCT06843720|BEHAVIORAL|HR-HPV Testing|Given by Interview and focus groups
214995577|NCT06849726|PROCEDURE|Standard Epidural Analgesia|Administration of conventional epidural analgesia using an 18G Tuohy needle for catheter placement and subsequent administration of a standardized dose of bupivacaine with fentanyl.
215092917|NCT01581008|OTHER|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
215092918|NCT01581008|BEHAVIORAL|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
214381862|NCT00827593|BEHAVIORAL|Combined Treatment|Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
214381863|NCT05790239|DRUG|3,4-methylenedioxymethamphetamine|Initial doses per Experimental Session include 68 mg or 100 mg MDMA (equivalent to 80 mg or 120 mg MDMA HCl), followed 1.5 to 2 hours later by a supplemental dose of 34 mg or 50 mg MDMA (equivalent to 40 mg or 60 mg MDMA HCl).
214381864|NCT05790239|DRUG|d-amphetamine|Initial dose per experimental session will be 5 mg or 10 mg d-amphetamine, followed 1.5 to 2 hours later by supplemental dose of 2.5 mg or 5 mg d-amphetamine.
214381865|NCT05790239|BEHAVIORAL|Therapy|Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
214381866|NCT06473701|DRUG|Dronabinol 2.5mg Capsule|Dronabinol 2.5 mg pr capsule. Titration up till 20 mg daily dose.
214995578|NCT06849726|PROCEDURE|Dural Puncture Epidural Analgesia|Administration of epidural analgesia that incorporates a dural puncture with a 27G spinal needle prior to epidural catheter placement, followed by the same standardized dose of bupivacaine with fentanyl.
215092919|NCT03931915|DRUG|TAK-385|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
215092920|NCT03931915|DRUG|Leuprorelin acetate|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
215092921|NCT03032445|OTHER|Alcoholic Beer|Subject will be asked to consume alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
215092922|NCT03032445|OTHER|Non alcoholic beer|Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
214995579|NCT05157386|OTHER|Braining|Core components of Braining: Personnel-led training sessions, motivating contact with psychiatric staff, measurement and evaluation before and after the training period; usually 12 weeks. PE is added on to treatment as usual (TAU). The training sessions are moderate to intense aerobic group training, 30-45 minutes. Each training session is preceded by a short (5-10 minutes) individual meeting with staff including assessment of daily form, motivational work, and the opportunity to ask questions. The target frequency for participation is preferably at least three training sessions/week during a 12 week period. The training period for each patient begins with an informative and motivating group or individual lecture or and an individual introductory meeting with staff including psychiatric and somatic examination, self-assessment scales for symptoms and quality of life, and blood samples. The training period ends with a meeting with staff with follow-up on the parameters.
214995580|NCT05560685|OTHER|Outcomes4Me|Patient participants will use the outcomes4Me app to answer PROs over the first 12 weeks of endocrine therapy.
214995581|NCT05560685|OTHER|Semi-structured interview|Team member participants will complete a semi-structured interview.
214995582|NCT05965427|OTHER|No intervention|Study is retrospective data collection only
214995583|NCT05620212|BEHAVIORAL|Recovery College participation|Recovery College participation in any way (visitors, course/retreat participants, volunteers, employees).
214381867|NCT06473701|DRUG|Placebo|Dronabinol-matched placebo capsule containing no active substance.
214381868|NCT02583763|OTHER|Echocardiography|During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
214498429|NCT00281892|BIOLOGICAL|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
214498430|NCT00281892|DRUG|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
214498431|NCT02816398|DEVICE|Percutaneous creation of an arteriovenous fistula|Use of catheter system for percutaneous creation of an arteriovenous fistula
214995584|NCT02101788|DRUG|Letrozole|Given PO
215092923|NCT03619135|DEVICE|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
214381869|NCT02583763|PROCEDURE|Blood sample|The investigators will take a blood sample from the umbilical cord at birth and again at 9 years of age.
214381870|NCT05796518|OTHER|PREVENT Cardiovascular Health Assessment Tool|Participants will access a heart health information visualization tool online using a personal device or a study tablet computer using their e-mail address to log-in. Investigators will review participant lab results specifically related to their cardiovascular health (e.g. blood pressure, cholesterol) in order to personalize the heart health tool for participants. A brief survey before and after use of the tool will also be completed by participants.
214381871|NCT05796518|OTHER|Survey|A brief survey before and after use of the tool will also be completed by participants.
214498432|NCT05859659|DIAGNOSTIC_TEST|This study does not intervene in this process.|This study does not intervene in this process.
214498433|NCT04895696|DRUG|Afimetoran|Specified dose on specified days
214498434|NCT04895696|OTHER|Placebo|Specified dose on specified days
214498435|NCT05616754|BIOLOGICAL|Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|The antigen protein of this product is designed to be expressed in tandem with Delta variant R319-N356 and Omicron variant R319-N356. The antigen is called DO-RBD for short.
214995585|NCT02101788|DRUG|Paclitaxel|Given IV
214995586|NCT02101788|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214995587|NCT02101788|OTHER|Quality-of-Life Assessment|Ancillary studies
214995588|NCT02101788|OTHER|Questionnaire Administration|Ancillary studies
214995589|NCT02101788|DRUG|Tamoxifen Citrate|Given PO
214995590|NCT02101788|DRUG|Topotecan|Given IV
214995591|NCT02101788|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
214995592|NCT05466929|BEHAVIORAL|TeACH System Resources|Patients who screen positive for anxiety will receive psychoeducation and mental health recommendations (e.g., evidence-based apps) selected for use with the TeACH System through a collaborative, stakeholder-engaged approach completed in phases 1 and 2 of this project.
215092924|NCT03619135|OTHER|Placebo|No use of the Buzzy (standard IV access techniques)
215092925|NCT01105455|OTHER|Nutrition education|Group nutrition classes supplemented by handouts and provision of key study foods.
215092926|NCT00575874|DRUG|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
215092927|NCT00575874|DRUG|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
215092928|NCT00575874|DRUG|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
215092929|NCT00575874|DRUG|pioglitazone HCl|30 mg capsules once daily for 12 weeks
215092930|NCT00575874|DRUG|placebo|matching tablets or capsule once daily for 12 weeks
215092931|NCT04391166|OTHER|Non invasive visual acuity testing|This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.
214687419|NCT06158841|DRUG|Selinexor|Oral Tablet
214687420|NCT06158841|DRUG|Bortezomib|Subcutaneous or IV Injection
214687421|NCT06158841|DRUG|Dexamethasone|Oral Tablet or IV Infusion
215092932|NCT01722435|DRUG|Opiate Substitution Treatment|
214381872|NCT05796518|OTHER|Interview Regarding Heart Health|Participants will be asked questions related to their heart health.
214381873|NCT00885989|DRUG|SLV338|5 - 1000 mg IV
214995593|NCT05770479|BEHAVIORAL|Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules|ME-CCT is a traditionally a manualized group-based behavioral intervention (8 weeks, 2 hours per week) designed to improve cognitive and everyday functioning in patients with MCI. Our booster modules will be shortened and distilled from ME-CCT using the IM Adapt protocol (and thus will not be new information but rather 'reminder' content) for a personalized four-session sequence of booster training targeted toward specific everyday functional needs of individual participants.
214381874|NCT00885989|DRUG|Placebo|Placebo
214498436|NCT05616754|BIOLOGICAL|Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|This strain was made from the NCP-RBD receptor binding region of the spike glycoprotein of novel coronavirus expressed in recombinant CHO cells, which was purified and added with aluminum hydroxide adjuvant
214498437|NCT01368744|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Groups: OSNA Breast Cancer System"
214498438|NCT00697060|DRUG|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
214498439|NCT00423020|DRUG|Erythropoietin|
214498440|NCT06221215|PROCEDURE|trauma|The main purpose of this study is to observe whether the early hormone changes and trends in the two groups of patients with or without trauma.
214498441|NCT05843240|PROCEDURE|Repetitive transcranial magnetic stimulation|After enrollment, patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
214498442|NCT05843240|PROCEDURE|Sham repetitive transcranial magnetic stimulation|After enrollment, patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
214381875|NCT01533571|PROCEDURE|Immediate implant placement with simultaneous bone grafting|"* Flapless surgery is used for surgical implant installation.~* Implant is placed in the cingulum position of adjacent teeth incisal edge.~* After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.~* Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .~Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material."
214381876|NCT05437822|DRUG|Tranexamic acid|2 g of tranexamic acid in 50 mL of saline
214498443|NCT00837954|DEVICE|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
214995594|NCT05770479|OTHER|Treatment As Usual|Treatment for MCI is generally managed by Primary Care or Neurology. Participants will continue to receive their usual care with their current providers. With no effective pharmacological treatment known for persons with MCI, providers tend to focus on encouraging a healthy lifestyle, prevention and management of modifiable risk factors for cognitive impairment, and treatment of behavioral and psychiatric symptoms.
214995595|NCT05768685|BEHAVIORAL|Affective touch paradigm|Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm. After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness. As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch inclose relationships.
214995596|NCT03943173|DRUG|Chemotherapy|Given standard chemotherapy
214995597|NCT03943173|DRUG|Olaparib|Given PO
215092933|NCT00397007|BEHAVIORAL|Biofeedback-based cognitive-behavioural intervention|
215092934|NCT00273156|BEHAVIORAL|Telephone quitline|
215092935|NCT01329913|DRUG|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
215092936|NCT01329913|DRUG|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
215092937|NCT01329913|DRUG|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
214381877|NCT06412328|OTHER|Psychoeducation|The psychoeducation program based on psychosocial support is a total of 8 sessions. Families participating in the study received the psychoeducation program over 4 weeks, with two sessions per week, each session lasting 60 minutes. Parents were included in group work during the psychoeducation program.
214498444|NCT00837954|DEVICE|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
214498445|NCT00837954|PROCEDURE|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
214995598|NCT03943173|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214995599|NCT01092377|DIETARY_SUPPLEMENT|DHA and EPA Fish Oil capsule|2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day
214995600|NCT01092377|DIETARY_SUPPLEMENT|Iron tablet|1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
214995601|NCT01092377|OTHER|Placebo tablet|Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
214381878|NCT06465277|DIAGNOSTIC_TEST|Dobutamine stress CMR|"Dobutamine stress testing will be undertaken in keeping with local departmental clinical guidelines with a graded increase in dobutamine infusion up to a maximum of 10microgram/kg/min. The patients' medications will be managed in keeping with the usual clinical practice and departmental guidelines.~At rest and on each graded level of dobutamine infusion we will collect cine loops of the cardiac cycle including a short-axis stack of the ventricles, a four-chamber view and flow imaging perpendicular to the main, left and right pulmonary arteries.~Post-processing will be dual reported by blinded observers using the Argus analysis software (Siemens) according to a standardised protocol. A safety report of each CMR scan will be generated by a consultant cardiologist, any abnormalities identified will be referred to the appropriate medical speciality and highlighted to the patient's clinical team."
214381879|NCT06465277|DIAGNOSTIC_TEST|Cardiac biomarker sample|blood samples will be collected pre-operatively, in recovery, on post-operative days 1 and 2, and at 4-8 weeks post-operatively
215092938|NCT01329913|DRUG|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
214381880|NCT04378660|DIAGNOSTIC_TEST|Artificial intelligence for polyp detection|Colonoscopy enriched with artificial intelligence tool developed for polyp detection, implemented as a second observer
214381881|NCT04859894|DIAGNOSTIC_TEST|Physiological testing|Cardiopulmonary exercise testing, Lung Function Testing and in some cases echocardiography. 20 subjects will perform DNA-methylation testing.
214381882|NCT06453096|OTHER|prevalence of personality disorders|the prevalence of personality disorders will be investigated with a retrospective study
214381883|NCT05777174|DRUG|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
214381884|NCT05777174|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants had the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System was initiated to collect background fluorescence. When this was completed, participants received a single dose of MB-102. Fluorescent measurements were collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements were continued until the sensor no longer detected MB-102 in the body.
214381885|NCT06084533|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
214381886|NCT02690077|PROCEDURE|Family-Centered Cesarean|Procedure involves lowering part of the surgical drape exposing a transparent window through which the mother can watch the birth of her baby; the baby will be placed on her chest immediately after the delivery. Cleaning and evaluation of the baby will be done by a nurse who is standing at the head of the bed.
214381887|NCT02690077|PROCEDURE|Traditional Cesarean|Procedure involves keeping the surgical drape up throughout the entire surgery so that the birthing process will not be visible to the mother, and the baby will be taken to the warmer to be evaluated and cleaned after birth but is available to be laid on the mother's chest at any point upon request.
214381888|NCT05472584|OTHER|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
214381889|NCT05472584|OTHER|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
214381890|NCT05472584|OTHER|Electrophysiology assessment - spinal motoneuron|Kinematics and spinal motoneuron excitability
214381891|NCT05472584|OTHER|Activity-based training|Motor task
214381892|NCT05472584|OTHER|Transcutaneous spinal cord stimulation|Non-invasive spinal cord stimulation
214381893|NCT05819073|OTHER|Plain water|Subjects will use plain water as an oral rinse twice a day for 3 days.
214381894|NCT05819073|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
214381895|NCT03694132|DEVICE|functional MRI|conditioning brain activity with peripheral stimulations
214381896|NCT03694132|DEVICE|structural MRI|diffusion MRI and tractography for evaluating the brain structures
214687422|NCT06331377|OTHER|Non-Interventional Study|Non-interventional study
214381897|NCT03694132|DEVICE|EEG/MEG|conditioning brain activity with peripheral stimulations
214498446|NCT01588951|DRUG|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
214995602|NCT01092377|OTHER|Placebo capsule|Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
214995603|NCT03653481|DIETARY_SUPPLEMENT|Oligofructose-enriched Inulin OI|Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
214498447|NCT01588951|DRUG|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
214995604|NCT03653481|DIETARY_SUPPLEMENT|Maltodextrin|Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
215092939|NCT01329913|DRUG|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
215092940|NCT01329913|DRUG|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
215092941|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive a second cycle of vaccination
215092942|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive vaccination according to the guidelines.
215092943|NCT04903145|DIAGNOSTIC_TEST|REOM|To compare data generated by the REOM device with data from the tremoflo C-100 device
215092944|NCT04280874|DRUG|Dinoprostone 0.5 MG|0.5mg dinoprostone applied intracervically
214498448|NCT00736463|DRUG|Simvastatin|One arm of randomized crossover
214498449|NCT00736463|DRUG|Atorvastatin 80 mg|Second arm of randomized crossover
215092945|NCT04280874|DRUG|Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly|2mg dinoprostone applied intravaginally
214381898|NCT03997578|PROCEDURE|NIPSA (Non-incised papilla surgical approach)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the regenerative biomaterials will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
214381899|NCT03997578|PROCEDURE|NIPSA plus connective tissue graft|In these patients, the following methodology will be added to the technique described for the NIPSA group: once the biomaterials are applied, a connective tissue graft, taken at the level of the first upper molar, will be sutured to the base of the soft supra-alveolar tissue and to the palatal tissue, which has not been disinserted, using simple sutures.
214381900|NCT03442673|DRUG|Vinorelbine|Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells
214381901|NCT03442673|DRUG|Gemcitabine|Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells
214381902|NCT03442673|DRUG|G-CSF|Cytokine stimulation with G-CSF for mobilization of autologous stem cells
214498450|NCT03919721|BEHAVIORAL|Applied Behavioral Analysis|Children are receiving Applied Behavioral Analysis therapy to treat their autism. Therapy is comprised of 15-20 discrete programs that are intended to shape specific behaviors. Tutors collect data on child's performance towards goals. For each child, some of the programs will be tracked with paper data collection methods, others will use electronic data collection. This study is to test the usefulness of the electronic data collection system to replace paper in existing interventions.
214498451|NCT04006834|OTHER|No intervention involved|No intervention involved
214498452|NCT02727634|OTHER|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
214498453|NCT02707666|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab every 21 days for three cycles
214498454|NCT02707666|DRUG|Cisplatin and Pemetrexed|Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
214995605|NCT03866694|BEHAVIORAL|BRIGHT|Dyadic therapeutic parenting intervention (BRIGHT) beginning in third trimester of pregnancy through six months postpartum focusing on child-parent relationship, mental health, infant social-emotional development, and recovery. Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic.
214995606|NCT03866694|OTHER|STAR/TAU+|Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic
214995607|NCT04646629|DEVICE|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days.After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
214995608|NCT04646629|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
214498455|NCT01917994|BEHAVIORAL|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
214498456|NCT01917994|BEHAVIORAL|Appointment Reminders|
214995609|NCT05839977|OTHER|Individual telerehabilitation|The exercise will consist of strength and balance exercises using the Homebalance ® system
214381903|NCT05809531|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214381904|NCT04399460|OTHER|Dairy-based commercially available food products|Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses
214498457|NCT06650202|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
214498458|NCT01595282|DRUG|Ketorolac|For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
214498459|NCT01595282|DRUG|Ibuprofen|For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
214498460|NCT06458010|DRUG|YOLT-101|The IP is administered intravenously at the predetermined dose.
214498461|NCT00348751|DEVICE|CholGate|
214995610|NCT05839977|OTHER|Home exercises based on videos|intervention include 12 video recordings of exercises created by a physiotherapist for home exercises, according to which they will also exercise
214995611|NCT05853263|DRUG|paracetamol|paracetamol IV to substitute morphine IV.
214995612|NCT05853263|DRUG|Morphine|standard care
214995613|NCT01470170|DRUG|Alfentanil|Give Alfentanil before TCI Propofol sedative bronchoscope
214995614|NCT01470170|DRUG|Normal saline|Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
214995615|NCT01470170|DEVICE|Targeted controlled infusion|The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
214995616|NCT01470170|DRUG|Propofol|The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
214995617|NCT02641041|BIOLOGICAL|BIIB033|single or multiple dose
214381905|NCT04399460|OTHER|Restrictive Eating|Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein
214381906|NCT00617721|OTHER|Blood withdrawal|Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
214381907|NCT03486587|DRUG|Bacillus Cereus tablets|Bacillus Cereus tablets was taken two tablets three times a day.
214381908|NCT03764098|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
214381909|NCT03764098|OTHER|Placebo|Placebo
214381910|NCT06413784|OTHER|Morning chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of morning chronotype individuals were examined.
214381911|NCT06413784|OTHER|Intermediate chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of intermediate chronotype individuals were examined.
214381912|NCT06413784|OTHER|Evening chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of evening chronotype individuals were examined.
214498462|NCT04190108|DIAGNOSTIC_TEST|Fecal calprotectin assay|FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.
214995618|NCT02641041|OTHER|Placebo|single or multiple dose
214995619|NCT00927472|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
214995620|NCT00927472|DRUG|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
214995621|NCT01991951|DRUG|warfarin|
214995622|NCT06530329|OTHER|Classical massage|Classical massage was started by general stroking 3 times. Then, it was continued by kneading 3 times. After the kneading movement, fibrocytic nodules on the muscle were searched and friction was applied to the found nodules one by one. The massage of the muscle was completed by applying stroking 3 times. The application was carried out 3 times a week for 2 weeks to evaluate the short-term effect.
214995623|NCT06530329|OTHER|Ischemic compression|Ischemic compression was applied to the trigger points in the upper trapezius muscle using an average pressure of 1 kg at a right angle, and after compression, passive stretching was applied to the upper trapezius muscle 3 times in 20-second periods. The application was performed 3 times a week for 2 weeks to evaluate the short-term effect.
214995624|NCT05973448|OTHER|Novel Lighting Condition|Horizontal and vertical lights over a doorway visible from the bed
214995625|NCT05973448|OTHER|Control Lighting Condition|Standard night light plugged into wall socket
214498463|NCT06102616|DIAGNOSTIC_TEST|measure Osteocalcin level|in gingival crevicular fluid before and during orthodontic tooth movement
214498464|NCT04570358|OTHER|Static stretching|During the static stretching training for the calf muscles, the ankle joint is moved into maximal dorsiflexion until the point of discomfort is reached. The ankle joint is then held in this maximal position for 30 s followed by a rest period of 30 s. Afterwards, the procedure is repeated with the knee in flexed position to stretch the soleus muscle.
214687423|NCT07073976|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|Non-invasive ultrasound imaging of the heart to evaluate right ventricular and right atrial function using parameters such as TAPSE, tricuspid S', RV-FAC, right atrial area, and pulmonary valve acceleration time. TTE will be performed once within 2 hours prior to extubation decision as part of routine care.
214995626|NCT03897621|DRUG|Tranexamic Acid|tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
214995627|NCT03897621|DRUG|Placebo|Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
214995628|NCT00647816|DRUG|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fasting
214995629|NCT00647816|DRUG|Inderal® LA Capsules 160 mg|160mg, single dose fasting
214995630|NCT01091207|DRUG|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
214995631|NCT03997136|PROCEDURE|Supratentorial high grade gliomas resection.|Total, near total or subtotal/debulking resection of the brain supratentorial high grade gliomas
214995632|NCT05552339|DRUG|Finerenone (Kerendia, BAY94-8862)|Following the physicians' decision.
214995633|NCT05552339|DRUG|Type 2 DM drugs|Following the physicians' decision
214995634|NCT03882099|DIAGNOSTIC_TEST|Determination of Vitamin D by ELISA|Blood samples
214995635|NCT03399773|BIOLOGICAL|Dilanubicel|Given IV
214995636|NCT03399773|DRUG|Cyclophosphamide|Given IV
214995637|NCT03399773|DRUG|Fludarabine|Given IV
214995638|NCT03399773|DRUG|Thiotepa|Given IV
214995639|NCT03399773|RADIATION|Total-Body Irradiation|Undergo TBI
214381913|NCT02650843|OTHER|DAT SPECT imaging|
214381914|NCT05250011|DRUG|Dapagliflozin|Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.
214381915|NCT06278246|RADIATION|PET Scan|PET scan using the novel \[11C\]MK-6884 tracer to measure M4R during the antipsychotic-free state
214381916|NCT06823843|DRUG|Glycerin trinitrate (GTN)|2 sublingual puffs for a total dose of 800 µg
214381917|NCT06823843|DRUG|Saline (NaCl 0,9 %) (placebo)|2 puffs of sublingual saline
214381918|NCT05672680|DRUG|0.25% Bupivacaine|received during TAP block
214381919|NCT05672680|DRUG|Placebo|placebo equivalent
214995640|NCT03399773|PROCEDURE|Umbilical Cord Blood Transplantation|Given IV
214995641|NCT03399773|OTHER|Laboratory Biomarker Analysis|Correlative studies
214995642|NCT03399773|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215092946|NCT05883722|PROCEDURE|Catheter ablation|The ablation approach includes: pulmonary vein isolation, left side linear ablation, left side driver ablation and right atrial driver ablation
214381920|NCT05672680|PROCEDURE|TAP block|The intervention is a transabdominal plane (TAP) block given in the abdomen to block pain receptors on nerves -during surgery can presumably decrease postoperative pain. Currently, TAP blocks are approved for use and performed based on surgeon preference (e.g. some surgeons perform them on every case, others variably, etc.).
214381921|NCT03614962|DEVICE|Warmth + TENS|"A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.~A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius."
214381922|NCT03614962|DEVICE|Warmth + placebo-TENS|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. The TENS electrodes are presented in the cap but no output will be delivered via these electrodes.
214381923|NCT03614962|DEVICE|TENS|A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.
214381924|NCT03614962|DEVICE|Warmth only|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. No built-in TENS electrodes in the cap.
214381925|NCT03614962|DEVICE|control|No warmth pad and TENS electrodes presented in the cap.
214381926|NCT05408468|BEHAVIORAL|FAMCOPE-ICU|(1) FAMCOPE-ICU is a digital eHealth emotion regulation and coping intervention. FAMCOPE-ICU contains three digital modules representing the three interventional doses. Corresponding with Gross's Extended Process Model of Emotion Regulation, the three respective doses entail assessments, adaptive feedback, and interactive activities pertaining to understanding their affective experiences, learning strategies to regulate emotions and stress, and practicing these skills in a virtual decision-making task. Each dose of the intervention is expected to last 10-15 minutes
214381927|NCT04913129|OTHER|Exercise Training|8 week home-based exercise therapy 4-5 times/week
214381928|NCT00747123|BIOLOGICAL|ACE-011|ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
214381929|NCT00747123|BIOLOGICAL|Placebo|Placebo given by the subcutaneous route of administration monthly for 4 doses.
214381930|NCT06452511|DRUG|Metformin|In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) and infertility will receive a combination treatment of Letrozole and Metformin. Letrozole, aimed at inducing ovulation, will be administered according to a specified dosage regimen, alongside Metformin, an insulin-sensitizing agent used to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and final evaluation of ovulation rates and pregnancy outcomes at the study's end. This arm seeks to determine the efficacy of Metformin as an adjunct to Letrozole in improving ovulation induction and pregnancy rates among overweight women with PCOS.
214498465|NCT04570358|OTHER|Proprioceptive neuromuscular facilitation stretching|During the proprioceptive neuromuscular facilitation stretching, the ankle joint is moved into maximal dorsiflexion. While the foot is kept in this position, the child will perform a (sub-) maximal isometric contraction of the plantar flexors against the resistance of their parents. Afterwards, the ankle joint will be moved further into greater dorsiflexion and is held there for the remaining seconds followed by 30 s of rest. Subsequently, the stretch will be applied with the knee flexed.
214498466|NCT02660294|BIOLOGICAL|platlet rich plasma|Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
215092947|NCT00348894|DRUG|[S,S]-Reboxetine|\[S,S\]-reboxetine
214498467|NCT00429338|PROCEDURE|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
214498468|NCT00429338|PROCEDURE|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
214995643|NCT03399773|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate and biopsy
214995644|NCT03399773|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspirate and biopsy
215092948|NCT00348894|DRUG|Any|Any standard of care treatment for DPN
215092949|NCT01171586|BEHAVIORAL|mDiet|"The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics."
214995645|NCT03399773|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215092950|NCT02282904|DRUG|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
214498469|NCT01333800|DRUG|Beclomethasone|200 to 400 mcg per day for 6 months
214498470|NCT01333800|DRUG|Ciclesonide|80 to 160 mcg per day for 6 months
214995646|NCT03399773|PROCEDURE|Electrocardiography|Undergo ECHO
214995647|NCT03399773|PROCEDURE|Computed Tomography|Undergo CT
215092951|NCT02282904|BIOLOGICAL|Donor peripheral blood stem cells.|Infuse donor graft.
214381931|NCT06452511|DRUG|pep2dia|In the Pep2dia arm of this study, 50 overweight women diagnosed with polycystic ovary syndrome (PCOS) and experiencing infertility will receive a combination treatment of Letrozole and Pep2dia. Letrozole, utilized to induce ovulation, will be administered according to a specified dosage regimen, along with Pep2dia, a peptide-based therapy tailored to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and a final evaluation of ovulation rates and pregnancy outcomes at the conclusion of the study period. This arm seeks to ascertain the effectiveness of Pep2dia as an adjunct to Letrozole in enhancing ovulation induction and pregnancy rates among overweight women with PCOS.
214381932|NCT04186403|DRUG|Brexpiprazole|Administered as tablets.
214381933|NCT06188065|DIAGNOSTIC_TEST|Blood eosinophil count|To determine the time it takes for blood eosinophil count to recover to baseline stable state following severe exacerbation of COPD associated with admission eosinopenia and to explore independent factors associated with admission eosinopenia.
214381934|NCT06851104|DRUG|Cadonilimab (AK104)|Patients with hepatocellular carcinoma after curative hepatectomy would receive cadonilimab 10 mg/kg intravenous infusion (dissolved in 0.9% NaCl 250 mL, within 60 minutes) Q3W, until disease progression, death, intolerance to toxicity, withdrawal of informed consent, initiation of new anti-tumor treatment, or termination of treatment for other reasons specified in the protocol. The maximum treatment duration for cadonilimab is 6 months.
214381935|NCT03461848|OTHER|CYPHP Evelina London Model of care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Targeted services offered dependent on need. Children with any of the tracer conditions will be offered pathway based care including early intervention for physical and related mental health needs, paediatric nursing support, care plans shared with schools, medication reviews, and peer-led parenting support. Self-management support, social support signposting, and safety-netting are offered to all.
214381936|NCT03461848|OTHER|Enhanced Usual Care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Self-management support, social support signposting, and safety-netting are offered to all.
214381937|NCT06143696|DRUG|Qingxin Zishen decoction|Oral administration, 1 dose daily, twice a day
214381938|NCT06143696|DRUG|Femoston|Oral administration, 1 pill each time, once a day
214381939|NCT06342180|DIAGNOSTIC_TEST|Serum uric acid level|An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.
214381940|NCT04918225|RADIATION|Magnetic Resonance Imaging|"Encephalic (about 30 minutes\*)~* lesion location assessment: 3D FLAIR, 3DT1, 3DT2 (standard OFSEP protocol)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1)~* tract location assessment: 30 directions diffusion imaging (standard OFSEP protocol)~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities~  ● Spinal cord (about 50 minutes\*)~* lesion location assessment: cervical and thoracic sagittal T2 TSE (0.7x0.7x2.5mm3), axial cervical MEDIC T2\* (0.7x0.7x3mm3), axial thoracic T2 (0.5x0.5x3mm3)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1, 0.7x0.7x3mm3) on the cervical cord and on the thoracic cord~* tract location assessment: performed from registration on atlas~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities"
214381941|NCT04918225|DIAGNOSTIC_TEST|Neurological examination|Global disability will be scored using the Expanded Disability Status Scale score
214381942|NCT04918225|DIAGNOSTIC_TEST|Multiple Sclerosis Functional Composite|"* Walking disability will be scored using the 25-foot timed-walked test~* Arm disability will be scored using the nine-hole peg test"
214381943|NCT04918225|DIAGNOSTIC_TEST|Physiotherapist examination|"* American Society Injury. Association motor subscore for each limb~* The muscle strength using a dynamometer. Two muscle groups will be tested for the upper (elbow flexors and extensors) and lower limbs (hip flexors and ankle dorsiflexion).~* The Ashworth Scale and the Tardieu Scale to assess spasticity.~* 6 minutes walking test~* Fatigue Severity Scale~* MFIS : Modified Fatigue Impact Scale"
214381944|NCT04967391|PROCEDURE|Tumescence During STSG Harvest|Tumescence injections performed prior to STSG harvest
214381945|NCT06560957|BEHAVIORAL|Time restricted eating|Time restricted eating involves restricting the window in which calories are consumed to 8-10 hours, without altering diet quality or caloric intake. In this study, time restricted eating will be a consistent 10-h eating window between 06:00 and 19:00, considered an early TRE pattern, for all days of the week, as chosen by the participant. They will need to consume all food and beverages (except water) during this window for the duration of the 8-week intervention.
214381946|NCT06560957|BEHAVIORAL|Eating ad libitum with nutritional counselling|Nutritional counselling will include customized advice delivered by a registered dietician about dietary choices while allowing individuals to eat at any time of day.
214381947|NCT01447849|DRUG|lubiprostone|24mcg twice a day (BID) 1 week
214381948|NCT01447849|DRUG|placebo|Placebo pills twice a day for one week.
214381949|NCT02774603|OTHER|Aquatic Locomotor Training|
214381950|NCT02774603|OTHER|Land Locomotor Training|
214498471|NCT05113810|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
214498472|NCT05113810|OTHER|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
215092952|NCT02282904|DRUG|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
215092953|NCT02282904|RADIATION|Total body 200cGy|Day -1
215092954|NCT02282904|DRUG|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
215092955|NCT02282904|DRUG|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
215092956|NCT02282904|DRUG|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
215092957|NCT04139278|OTHER|Observational|Observational retrospective study
215092958|NCT01555515|PROCEDURE|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
215092959|NCT01555515|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
215092960|NCT00226863|BEHAVIORAL|meditation plus education|
214995648|NCT04556097|BEHAVIORAL|Care Ecosystem|"The Care Ecosystem model uses a telephone-based intervention to support persons with dementia and their care partners, screening for common dementia-related problems and providing modular standardized support protocols and caregiver education. Specially trained health care navigators systematically identify needs and address health status, advance care planning, medication management and management of challenging behaviors. Health care navigators receive backup support from a nurse, social worker, dementia specialist, and pharmacist, and maintain close communication with the primary care provider of the persons with dementia.~This Care Ecosystem model will be adapted to augment the dementia care provided by experienced Integrated Care Management Program nurse care managers engaged in the care of high-risk, high-cost patients in a large health system."
214995649|NCT06468046|BEHAVIORAL|Mama Empoderada [Mom Power]|'Mamá Empoderada' \[Mom Power\] is a theory-based, trauma-informed group intervention to promote mental health and positive parenting among mothers with young children (0-5 years). It has been adapted for migrant mothers, and will conduct a pilot randomized controlled trial (RCT) of the intervention with migrant mothers with young children (MMC). The intervention group (IG) will receive 10 group and 3 individual sessions addressing attachment theory, hands-on parenting skills, linkage to resources (e.g., food, shelter), social support, and self-care and resilience.
214381951|NCT03123289|DRUG|68-Gallium citrate PET/CT scan|After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously. Whole body PET/CT scan will be performed after 60 minutes of uptake phase.
214381952|NCT03123289|DRUG|18F FDG PET/CT scan|Subjects will undergo FDG PET/CT scan using the same imaging parameters either on the same day or within the next 24-48 hours. The subjects will be requested to fast for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG (Zevacor Molecular, Somerset, NJ, USA) intravenously. The subject will be placed in uptake room for 60 minutes to allow for optimal localization of the compound. The subjects will be requested to void prior to administration of 18FDG and again prior to image acquisition.
214381953|NCT05448898|DRUG|Traditional Chinese Medicine CU Xiu Tang|Oral Traditional Chinese Medicine CU Xiu Tang once a day and repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
214381954|NCT05448898|OTHER|Olfactory Training|repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
214381955|NCT04879199|DIAGNOSTIC_TEST|Static stability measurement|"The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s."
214687424|NCT06927375|DRUG|Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)|Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8. Flupentixol/Melitracen is given orally at a dose of 0.5 mg/10 mg twice daily for 8 consecutive weeks starting from Week 0.
214687425|NCT06927375|DRUG|Tocilizumab(400mg)|Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8.
214687426|NCT03471676|OTHER|Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording
214995650|NCT06510296|BEHAVIORAL|Digital Mind Body Intervention mobile application|A DMBI mobile application with psychoeducation and skill-building in illness perception, coping, mindfulness, and disease acceptance informed by needs/barriers of Black and Hispanic patients with IBD who have elevated psychological distress and GI professionals caring for IBD patients.
214995651|NCT04812015|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS) 15 minutes|Sham 60 minutes and taVNS active stimulation for 15 minutes
214995652|NCT04812015|DEVICE|taVNS 30 minutes|Sham 45 minutes and taVNS active stimulation for 30 minutes
215092961|NCT00226863|BEHAVIORAL|group psychotherapy with hypnosis plus education|
215092962|NCT00226863|BEHAVIORAL|education|
215092963|NCT01475162|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
215092964|NCT00901797|PROCEDURE|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
215094728|NCT01873248|DRUG|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
215094729|NCT00251251|DEVICE|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
215094730|NCT00251251|DEVICE|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
215094731|NCT01739543|DEVICE|Hem-Avert|Application of Hem-Avert
214381956|NCT04879199|DIAGNOSTIC_TEST|Dynamic stability measurement|"The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized."
214381957|NCT02201056|DRUG|TAK-935|TAK-935 oral solution
214381958|NCT02201056|DRUG|Placebo|TAK-935 placebo-matching oral solution
214381959|NCT04732208|DIAGNOSTIC_TEST|Colour fundus photography|Fundus images will be captured before and after administration of mydriatic agent
214381960|NCT01789697|OTHER|cellular device/computers|A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
214687427|NCT02718833|DRUG|Elotuzumab|
214687428|NCT02718833|DRUG|Pomalidomide|
214381961|NCT05305014|DIAGNOSTIC_TEST|blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP)|Bioassays of blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP) from sera babcocked in the HYCORE mother study.
214381962|NCT05189054|RADIATION|stereotacitic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
214381963|NCT00426426|BEHAVIORAL|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
214381964|NCT00426426|BEHAVIORAL|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
214381965|NCT00426426|BEHAVIORAL|Waiting list|
214381966|NCT00405639|DRUG|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is \>90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
214381967|NCT00405639|DRUG|Placebo|Normal saline will be used for placebo.
214381968|NCT05916092|DEVICE|TransLoc 3D|TransLoc 3D SI Joint Fusion System
214381969|NCT04498195|BEHAVIORAL|increased exercise and physical activity|Participants were encouraged to increase physical activity for 12-week study duration and wear an activity tracker for a minimum of 12 hours a day.
214381970|NCT01483937|DEVICE|Usual care physical therapy plus SEMD|Patients will receive usual care physical therapy while wearing SEMD. SEMD protocols will also be provided to device subjects.
214498473|NCT02130557|DRUG|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
214498474|NCT02130557|DRUG|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
214498475|NCT05738369|DIETARY_SUPPLEMENT|Biogaia L. reuteri Prodentis® lozenges|Participants were instructed to use the lozenges twice daily after brushing their teeth; once in the morning and once in the evening
214498476|NCT05738369|DIETARY_SUPPLEMENT|Hersheyland Ice Breakers Mints sugar free lozenges|Hersheyland Ice Breakers Mints sugar free lozenges
214995653|NCT04812015|DEVICE|taVNS 45 minutes|Sham 30 minutes and taVNS active stimulation for 45 minutes
214995654|NCT04812015|DEVICE|taVNS 60 minutes|Sham 15 minutes and taVNS active stimulation for 60 minutes
214995655|NCT04812015|DEVICE|taVNS 75 minutes|Sham 0 minutes and taVNS active stimulation for 75 minutes
214995656|NCT04812015|DEVICE|taVNS 0 minutes|Sham taVNS 75 minutes
214995657|NCT05566171|DIETARY_SUPPLEMENT|Activia Probiotic Yogurt|Activia probiotic Yogurt will be consumed by participants in this group
214995658|NCT05330897|PROCEDURE|Implantation of an eCLIPs™ device|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
214995659|NCT05330897|DEVICE|eCLIPs™ Electrolytic Bifurcation Systems|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
214995660|NCT02516241|DRUG|MEDI4736 (Durvalumab)|IV infusion
214995661|NCT02516241|DRUG|Tremelimumab|IV infusion
214381971|NCT01483937|OTHER|Usual care physical therapy only|Subjects will receive usual care physical therapy from vestibular and balance specialists.
214381972|NCT00265330|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
214381973|NCT01268202|DRUG|Pravastatin|Pravastatin 40mg/day during 12 months
214381974|NCT02138266|DEVICE|Topcon Specular Microscope SP-1P|
214498477|NCT02408887|PROCEDURE|Total Thyroidectomy (TT)|Total removal of thyroid
214498478|NCT02408887|PROCEDURE|Prophylactic central neck lymph node dissection (pCND)|Lymph node dissection
214498479|NCT03366506|OTHER|Observation|
214498480|NCT01541059|DRUG|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
214498481|NCT01541059|DRUG|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
214498482|NCT02134262|DRUG|Cyclophosphamide or Bendamustine|Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.
214498483|NCT02134262|GENETIC|Dose Level -1|CD19-CAR-T \[1 x 10\^5 cells/kg x 1 day and 2 x 10\^5 cells/kg x 1 day Intravenous (IV)\] are administered.
214498484|NCT02134262|GENETIC|Dose Level 1|CD19-CAR-T \[1/3 x 10\^6 cells/kg x 1 day and 2/3 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
214995662|NCT02516241|DRUG|Cisplatin|IV infusion
214995663|NCT02516241|DRUG|Carboplatin|IV infusion
214995664|NCT02516241|DRUG|Gemcitabine|IV infusion
214995665|NCT03425526|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given IV
214995666|NCT06551155|DIAGNOSTIC_TEST|Vitality and biological activity of peripheral blood mononuclear cells (PBMCs)|Diagnostic test based on the vitality and biological activity of peripheral blood mononuclear cells (PBMCs) tested analyzing approximately 2-5 mL of blood from healthy patients and from osteopenic and osteoporotic (both fractured and non-fractured) patients of both genders
215094732|NCT00188903|PROCEDURE|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
214995667|NCT05725239|DEVICE|Vagus Nerve Stimulation|All taVNS sessions will use the following parameters: 25Hz, 500us pulse width, on for 7 seconds, off for 12 seconds.The length of VNS treatment sessions will be identical to TMS treatment sessions and will have the same 30 minute break between each treatment session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active.
214995668|NCT05725239|DEVICE|Transcranial Magnetic Stimulation|Participants will receive 20 trains of 30 pulses each for a total of 600 pulses per session. We will repeat this for 6 sessions each day, with at least 30 minutes between each session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active, so participants will get 24 TMS sessions over the course.
214995669|NCT05634746|DRUG|APT-1011|"APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate"
214995670|NCT05634746|DRUG|Placebo oral tablet|"Placebo orally disintegrating tablet.~Other Names:~PBO"
214995671|NCT05634746|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
214381975|NCT02138266|DEVICE|Konan Specular Microscope CELLCHEK XL|
214381976|NCT02117934|BIOLOGICAL|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
214381977|NCT02117934|BIOLOGICAL|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
214381978|NCT06163664|BEHAVIORAL|Use of chatGPT for 1 week|Use of chatGPT for 1 week
214381979|NCT03108157|PROCEDURE|Endometrial scratch|Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
214381980|NCT05520840|DIAGNOSTIC_TEST|blood sampling for screening of biomarkers|Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
214381981|NCT06259383|DRUG|Ivermectin|3-day 1 daily dose of 400 μg/kg oral ivermectin
214381982|NCT05706090|DRUG|fentanyl will be added|If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added
214381983|NCT05706090|PROCEDURE|general anesthesia|If adequate anagesia is not provided with the block, general anesthesia will be administered.
214381984|NCT01758484|OTHER|palliative care|Undergo supportive care intervention
214381985|NCT01758484|OTHER|questionnaire administration|Ancillary studies
214381986|NCT01758484|PROCEDURE|quality-of-life assessment|Ancillary studies
214381987|NCT04534114|DRUG|Fesomersen sodium (BAY2976217)|Study intervention will be injected subcutaneously.
214381988|NCT04534114|DRUG|Placebo|Matching placebo to BAY2976217 will be injected subcutaneously.
214381989|NCT03040284|DEVICE|Echodia® hand-held equipment (ELIOS)|
214381990|NCT03287414|DRUG|VAY736|300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks
214381991|NCT03287414|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks for 48 weeks
214381992|NCT03287414|DRUG|Standard of Care (SoC)|Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy
214381993|NCT00367965|DRUG|Eszopiclone|eszopiclone 3 mg
214381994|NCT00367965|DRUG|placebo|placebo tablet
214381995|NCT02759185|DRUG|High THC cannabis|Three weeks of smoking cannabis containing more THC than CBD with amount smoked limited to no more than 1.8 g per day.
214381996|NCT02759185|DRUG|High CBD cannabis|Three weeks of smoking cannabis containing more CBD than THC with amount smoked limited to no more than 1.8 g per day.
214381997|NCT02759185|DRUG|THC/CBD cannabis|Three weeks of smoking cannabis containing equal amounts of THC and CBD with smoking limited to no more than 1.8 g per day.
214381998|NCT02759185|DRUG|Placebo cannabis|Three weeks of smoking cannabis with low levels of THC and CBD with smoking limited to no more than 1.8 per day.
214381999|NCT02110745|DRUG|Sevofluorane|Comparison of different induction drugs and techniques
214498485|NCT02134262|GENETIC|Dose Level 2|CD19-CAR-T \[1 x 10\^6 cells/kg x 1 day and 2 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
214498486|NCT02134262|GENETIC|Dose Level 3|CD19-CAR-T \[1/3 x 10\^7 cells/kg x 1 day and 2/3 x 10\^7 cells/kg x 1 day Intravenous (IV)\] are administered.
214498487|NCT05996393|DRUG|Ciclosporin|3-5 mg/kg/d orally, trough concentrations: 100-200 ng/ml
214382000|NCT02110745|DRUG|Propofol|Comparison of different induction drugs and techniques
214382001|NCT01226914|DRUG|EVICEL|EVICEL
214382002|NCT02613221|DRUG|Panitumumab + TAS-102|panitumumab + TAS-102 combination therapy
214382003|NCT01465607|BEHAVIORAL|Mujer Segura|Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).
214382004|NCT01465607|BEHAVIORAL|CENSIDA counseling program|Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
214382005|NCT01970852|OTHER|Standard tablet computer|No special enhancements or links to personal health information.
214382006|NCT01970852|OTHER|Enhanced tablet computer|Tablet computer with personalized access to data from the patient's electronic health record.
214382007|NCT01087996|BIOLOGICAL|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
214498488|NCT05996393|DRUG|Avatrombopag|60 mg/d orally, 24 weeks
214498489|NCT05996393|DRUG|Anti-Human Thymocyte Immunoglobulin, Rabbit|rabbit anti-human thymocyte immunoglobulin (r-ATG 3mg/kg/d), intravenously, 5 days;
214995672|NCT05776277|BIOLOGICAL|Iltamiocel|Single external anal sphincter (EAS) injection of 300 x 10\^6 cells.
214995673|NCT05776277|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
214995674|NCT05493046|BEHAVIORAL|Interactive Hand Exercise Game|Interactive Hand Exercise Game to Improve Vascular Maturity and Grip Strength in Patients undergoing Arteriovenous Fistula Surgery
214995675|NCT05493046|BEHAVIORAL|Soft ball exercise ( routine care)|Soft ball exercise ( routine care)
214995676|NCT04430218|DEVICE|iSens|The study involves a surgical implant of cuff electrodes on the nerves in the amputated limb, and muscle recording electrodes the remaining muscles. These will be connected to an implanted stimulator. The stimulator will connect wirelessly to an advanced prosthesis. This may allow a user to move the prosthetic hand intuitively and feel what your prosthesis is touching.
214995677|NCT03228537|DRUG|Atezolizumab|Given IV
214995678|NCT03228537|DRUG|Cisplatin|Given IV
214995679|NCT03228537|PROCEDURE|Extrapleural Pneumonectomy|Undergo EPP
214382008|NCT01087996|BIOLOGICAL|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
214382009|NCT02411838|OTHER|Calorie restriction|"Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.~Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI \<28 will follow a regimen of fasting for two days per week while patients with BMI\>28 will follow a regimen of fasting for three days per week."
214382010|NCT01984801|DRUG|0.3% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
214382011|NCT01984801|DRUG|1% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
214498490|NCT01800487|DRUG|silymarin|140 mg three times a day for 4 weeks
214995680|NCT03228537|DRUG|Pemetrexed Disodium|Given IV
214498491|NCT01800487|DRUG|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
214995681|NCT03228537|PROCEDURE|Pleurectomy|Undergo PD
214995682|NCT03228537|RADIATION|Radiation Therapy|Undergo RT
214995683|NCT06360289|OTHER|Standard of Care|This is an observational study. No study drug will be administered as a part of the study, participants will be treated according to the decision of the treating physician.
214498492|NCT05733559|DEVICE|QIAstat-Dx® Respiratory Panel Plus (RPP)|An observational prospective performance evaluation study of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target against a marketed comparator, using NPS collected per the manufacturer's instructions and eluted in Universal Transport Media (UTM) from subjects with signs and symptoms of respiratory infection
214498493|NCT02072499|PROCEDURE|KTP Green Light Prostatectomy|
214498494|NCT02072499|DEVICE|Green Light|
214498495|NCT02072499|PROCEDURE|Open prostatectomy|
214498496|NCT06828900|BEHAVIORAL|Written Decision Aid|Participants will receive a structured booklet developed based on IPDAS guidelines to support informed decision-making regarding medication vs. no medication for ADHD treatment. The booklet provides a clear explanation of ADHD, the role of medication, and the option of not using medication, including the potential benefits, risks, and uncertainties of each choice. It presents evidence-based information in a balanced manner, helping parents understand possible outcomes such as symptom management, side effects, and long-term considerations. The booklet also includes value clarification exercises to help parents align their decision with personal preferences and concerns.
214687429|NCT02718833|DRUG|Bortezomib|
214995684|NCT06239116|DRUG|Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)|Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
215092965|NCT00901797|PROCEDURE|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
215092966|NCT00490022|DRUG|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
215092967|NCT00490022|DRUG|Placebo gel|Placebo gel for one month
215092968|NCT04079543|OTHER|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
214995685|NCT06239116|DRUG|Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)|Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)
214995686|NCT06239116|DRUG|Part C: RM-718|Multiple ascending doses of RM-718 (specific to Part C single cohort)
214995687|NCT06354777|DEVICE|Atrial Ablation|Left atrial radiofrequency ablation for the treatment of atrial fibrillation; this may include Pulmonary Vein Isolation (PVI) with or without additional ablation lesions as warranted during the procedure
214995688|NCT05975983|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
214995689|NCT05975983|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
214995690|NCT06546813|OTHER|scales and questionnaire administration|evaluation of the quality of prosthetic intervention, verification of the adequacy of assistive devices, and outcomes measurement
214995691|NCT05864144|DRUG|SNS-101 (anti-VISTA)|SNS-101 IV every 21 days.
214995692|NCT05864144|DRUG|Cemiplimab|Cemiplimab IV every 21 days.
214995693|NCT05040568|DRUG|Cetuximab|Given IV
214995694|NCT05040568|DRUG|Expanded CB-NK cells|Given IV
214995695|NCT05040568|DRUG|Fludarabine phosphate|Given IV
214995696|NCT05040568|DRUG|Cyclophosphamide|Given IV
214382012|NCT01984801|DRUG|0.3%/1% vehicle gel only|200 mg of the gel will be applied to individual patches by using a spatula
214382013|NCT01984801|OTHER|Sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
214382014|NCT01984801|OTHER|0.5% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
214382015|NCT01984801|OTHER|0.1% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
214382016|NCT01984801|OTHER|Patch only|Only patch will be applied
214382017|NCT04307459|OTHER|standard operating procedures|standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.
214382018|NCT03626532|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc."
214995697|NCT06487195|BEHAVIORAL|Peer-facilitated, Recovery-based Self-illness-management programme|The Peer-RESIM program will consist of 10 1.5-hour sessions (7-12 day intervals; 4 months), based on the modified CORE program workbook/manual and psychoeducation programmes developed by the research team.
214995698|NCT06487195|BEHAVIORAL|Psycho-education group|The psychoeducation group (6 subgroups; 10-12 participants per subgroup) will be led by one experienced psychiatric nurse trained in psychiatric rehabilitation and psychoeducation group programmes.
214995699|NCT06487195|BEHAVIORAL|Treatment-as-usual only|Participants in the TAU group will receive routine community mental healthcare services.
214995700|NCT03182335|OTHER|sedation awakening trial|vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
214995701|NCT05093634|DRUG|Setmelanotide|Subcutaneous Injection
214995702|NCT05093634|DRUG|Placebo|Subcutaneous Injection
214382019|NCT03626532|BEHAVIORAL|Lifestyle Education (LifeEd)|This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
214995703|NCT06487273|DEVICE|SIMEOX|Use of the CE-marked SIMEOX medical device. No specific limitation of the number of use but recommendation to use it daily (and more if needed).
215092969|NCT04079543|OTHER|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
214382020|NCT03758014|DRUG|Chlorogenic acid for Injection|Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation.
214382021|NCT03758014|DRUG|Lomustine|Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use.
214382022|NCT01704911|PROCEDURE|Transradial Coronary Intervention|
214382023|NCT01704911|PROCEDURE|Transfemoral Coronary Intervention|
214687430|NCT02718833|DRUG|Dexamethasone|
214995704|NCT06487273|OTHER|Remote Physiotherapy|Remote Physiotherapy with physiotherapists, once a month for the first 3 months and once every 3 months after
214995705|NCT05818709|DEVICE|HAC 22L|Subcutaneous and/or Supraperiosteal injection
214995706|NCT05720130|DRUG|[²¹²Pb]Pb-ADVC001|"Ph1b Escalation~Drug: \[²¹²Pb\]Pb-ADVC001administered intravenously per dose escalation scheme~Dose Level 1~\- 60 MBq, 4 cycles every 6 weeks~Dose Level 2a~\- 120 MBq, 4 to 6 cycles every 4 weeks~Dose Level 2b~\- Optional cohort of 120 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3a~\- 160 MBq, 4 to 6 cycles every 4 weeks~Dose Level 3b~\- Optional cohort of 160 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3c~\- Optional cohort of 160 MBq, 4 to 6 cycles every week~Dose Level 4a~* 200 MBq, 4 to 6 cycles every 4 weeks~Dose Level 4b~\- Optional cohort of 200 MBq, 4 to 6 cycles every 2 weeks~Dose Level 4c~\- Optional cohort of 200MBq, 4 to 6 cycles every week~Ph2a Expansion~Drug: \[²¹²Pb\]Pb-ADVC001 at recommended phase 2 dose and schedule"
214995707|NCT05380947|DRUG|BI 1810631 - trial formulation 1 (TF1)|BI 1810631 - trial formulation 1 (TF1)
214995708|NCT05380947|DRUG|BI 1810631 - new formulation (NF)|BI 1810631 - new formulation (NF)
214995709|NCT05380947|DRUG|Rabeprazole sodium|Rabeprazole sodium
214382024|NCT01704911|DEVICE|Coronary Stent System|Any kind of coronary stent system
214995710|NCT05394116|DRUG|Garetosmab|Garetosmab is supplied as a liquid drug product and will be administered IV.
214382025|NCT04236921|DRUG|DopaSnap®|immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
214382026|NCT04236921|DRUG|RDL of CD-LD|(immediate release CD/LD 25/100mg; Merck Sharp \& Dohme Corp., USA),
214687431|NCT07075276|PROCEDURE|Liquid Phase Concentrated Growth Factor|16 patients with anterior disc displacement with or without reduction randomly allocated to be treated with injection of liquid phase concentrated growth factor
214687432|NCT07075276|PROCEDURE|Conventional arthrocentesis|16 patients with anterior disc displacement with or without reduction randomly allocated to be treated with conventional arthrocentesis
214995711|NCT05394116|DRUG|Placebo|Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
215092970|NCT04147598|OTHER|LFD|Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.
214995712|NCT05831579|RADIATION|Proton GRID Radiotherapy|The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
214995713|NCT05239403|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
215092971|NCT04147598|OTHER|SAD|Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
214382027|NCT01322789|BIOLOGICAL|Intravenous Mesenchymal stem cell infusion|Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
214382028|NCT05030896|OTHER|Invasive treatment and exercise therapy|The subjects of experimental group will perform therapeutic exercise program and they will be receive Percutaneous Electrolysis therapy and the subjects of experimental group will perform the same exercise program and they will be receive only needling puncture
214382029|NCT01913106|DRUG|HSV-tk +Valacyclovir in Combination with Brachytherapy|"The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein."
214382030|NCT01838408|OTHER|Ez2go Complete|EZ2Go Complete
215094733|NCT04369625|BEHAVIORAL|CHIMPS-T|CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
214382031|NCT01838408|OTHER|LoSo Prep|LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
214382032|NCT02668016|DRUG|Atorvastatin|Atorvastatin 20mg tablets taken orally once daily for one month.
214382033|NCT02668016|OTHER|Placebo|Placebo tablets taken orally once daily for one month
214382034|NCT06255015|DEVICE|Breastfeeding toolkit card|The card is delivered at 24 weeks and is also referred to in the 32 and 36 week antenatal meetings. It will also be referred to in the first 24 hours post-partum and in home visits.
214382035|NCT02848482|DEVICE|Photodynamic therapy|Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
214382036|NCT02848482|PROCEDURE|Mechanical debridement|Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
214382037|NCT02848482|DRUG|Irrigation|0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
215094734|NCT04369625|BEHAVIORAL|CHIMPS-P|CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention.
214382038|NCT00019539|DRUG|bevacizumab|
214382039|NCT00019539|DRUG|thalidomide|
214382040|NCT02978053|BEHAVIORAL|Bright light|Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
214382041|NCT02978053|BEHAVIORAL|Red light|Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
214382042|NCT00449098|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
214382043|NCT00449098|DRUG|Trabeculectomy with MMC|Trabeculectomy with MMC
214382044|NCT00248196|DEVICE|Reprieve Endovascular Temperature Therapy System|
214382045|NCT00594971|OTHER|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
214382046|NCT00594971|OTHER|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
214382047|NCT00812188|OTHER|Medium Dose UVA-1|UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
214382048|NCT00812188|OTHER|High Dose UVA-1|High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
214995714|NCT05239403|OTHER|Questionnaire Administration|Complete questionnaires
214995715|NCT05442047|DRUG|NNC6019-0001|Participants will receive i.v infusionof NNC6019-0001.
214995716|NCT05442047|DRUG|Placebo (NNC6019-0001)|Participants will receive i.v. infusion of placebo (NNC6019-0001).
214995717|NCT05404490|DRUG|Bupivacain|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
214995718|NCT05404490|DRUG|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
214995719|NCT06275282|DEVICE|Intramuscular electrodes|Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, small electrodes will be implanted into these RPNIs.
214995720|NCT02273375|DRUG|MEDI4736|
214995721|NCT02273375|DRUG|Placebo|
214995722|NCT03678740|OTHER|Odyssey 2 Survey|Odyssey2 will retain the strengths (simplicity, brevity, confidentiality, and data quality assurance measures) which made Odyssey1 successful. While Odyssey2 adds some refinements based on experience learned from Odyssey1, the basic questions are changed as little as possible to maximize comparability, and the additions are limited. Odyssey1 consisted of between 16 and 23 questions, depending on skip patterns, and took an estimated 15 minutes to complete. Odyssey2 consists of between 23 and 33 questions, depending on skip patterns and we estimate that it will take approximately 20 minutes to complete.
215092972|NCT05501314|OTHER|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. During home monitoring, heartrate, respiratory rate, posture and movement are monitored every 5 minutes for at least 4 days, using a wearable sensor. Core temperature is monitored using an ear thermometer. Patients are contacted once per day by a nurse from the Virtual Monitoring Centre (VMC) to assess pancreatitis related complaints, intake of fluids and food, pain and the use of analgesics. Patients are asked to provide information to the hospital using a smartphone app.
215092973|NCT02608450|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
214382049|NCT01298921|DRUG|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
214382050|NCT01298921|DRUG|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
214382051|NCT04846764|OTHER|Neuropsychological tests|"Scales and tests to evaluate:~* laterality~* anxiety~* depression~* professional level~* education level~* pre-morbid level~* memory disorders~Experimental procedure"
214382052|NCT05958160|OTHER|Modified Atkins diet|The modified Atkins diet is a less restrictive version of the ketogenic diet
214382053|NCT05958160|DRUG|Topiramate|Topiramate is an anti-seizure medication
214382054|NCT06201221|PROCEDURE|single-port laparoscopy surgery|The two groups underwent different surgical procedures.
214382055|NCT06201221|PROCEDURE|multiport laparoscopy surgery|The two groups underwent different surgical procedures.
214382056|NCT04636346|BEHAVIORAL|Acceptance and Commitment Therapy|Seven group sessions
214382057|NCT04636346|OTHER|Questionnaires|Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two follow-up time points.
214382058|NCT00632008|DRUG|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
214498497|NCT06828900|BEHAVIORAL|Decision Aid + Decision Coaching|Participants will receive the written decision aid booklet, developed based on IPDAS guidelines, along with a one-on-one decision coaching session. The decision coaching will follow a structured script based on the Ottawa Personal Decision Guide (OPDG), refined through training with the principal investigator (PI). The decision coach will not give medical advice but will help parents clarify their values, address uncertainties, and weigh the benefits and risks of medication vs. no medication. Through guided value clarification exercises, parents will explore their concerns and preferences to make a well-informed decision.
214498498|NCT06828900|BEHAVIORAL|AI-Driven Support|"Participants will interact with a large language model-based AI tool (Claude) to assist in their decision-making process regarding medication vs. no medication for ADHD treatment. This AI-driven intervention is designed to provide structured, personalized decision support while maintaining an unbiased, evidence-based approach.~Participants will receive 10 structured prompts to ask the AI, covering key aspects of ADHD treatment (e.g., benefits and risks of medication, long-term outcomes, alternatives).~Following this structured phase, participants will have 15 minutes of free interaction with the AI to explore any remaining questions or concerns.~At the end of the session, they will receive a summary output of their AI interactions to review.~The AI tool is designed to translate complex medical information into user-friendly language, provide comparative treatment insights, and help parents clarify their values and concerns. However, it will not offer direct medical recommendations."
214498499|NCT05961553|BEHAVIORAL|Physical Activity Counseling session|The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.
214498500|NCT05961553|OTHER|Pulmonary Reabilitation|The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.
214498501|NCT06186128|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
215092974|NCT02608450|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
215092975|NCT02744807|OTHER|Chronic endometritis|with or without Chronic endometritis
215092976|NCT05620784|DRUG|Furosemide|20mg of IV furosemide injection during the morcellation phase of HoLEP
215092977|NCT05597072|BEHAVIORAL|Intervention|Less people within the OR but longer waiting time.
215092978|NCT05597072|BEHAVIORAL|Control|More people in the OR but shorter waiting time
215092979|NCT02871089|DEVICE|Closed-loop system (Florence M or CamAPS FX)|"The automated closed-loop system (FlorenceM) will consist of:~* Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.~The automated closed-loop system (CamAPS FX) will consist of:~* Dana R or RS insulin pump~* Dexcom G6 real-time CGM~* CamAPS FX App on an unlocked android smartphone.~Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue)."
214382059|NCT00632008|DRUG|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
214382060|NCT04065217|PROCEDURE|Diode laser 980-nm|Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) \[ONLY MEDICAL; CAT No. R331/72394/P001\] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles \[CE; DIR 8001100L4\]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.
214382061|NCT00399763|DRUG|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
214382062|NCT00399763|DRUG|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
214382063|NCT02681705|DRUG|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
214382064|NCT02681705|RADIATION|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
214382065|NCT04075617|DEVICE|electronic habit reminder|Habit reminder in the form of wrist watch with music that display as reminder is one of recent innovations for cessation of the habit in short time and the child accepts it and it's comfortable
214382066|NCT04075617|OTHER|palatal crib|Fixed palatal crib is commonly used and recommended for treating thumb/finger sucking habit.
214382067|NCT06059534|DIETARY_SUPPLEMENT|Dietary supplementation with placebo.|Volunteers will be provided with the placebo capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
214382068|NCT06059534|DIETARY_SUPPLEMENT|Dietary supplementation with DracoBelleTM Nu.|Volunteers will be provided with the DracoBelleTM Nu capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
214382069|NCT04197011|DEVICE|prosthetic device|Individuals with TFA will use a combination of prosthetic devices.
214382070|NCT02172703|DEVICE|Non-invasive ICP measurement device|"The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.~The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA)."
214382071|NCT03879603|BIOLOGICAL|VRC-WEVVLP073-00-VP|VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
214382072|NCT03879603|OTHER|VRC-GENMIX083-AL-VP|VRC-GENMIX083-AL-VP is an adjuvant
214382073|NCT03475121|COMBINATION_PRODUCT|Combination Chemotherapy plus Intrathecal Topotecan|Adjuvant chemotherapy with a reduced dose (compared to GALOP I protocol) of carboplatin
214382074|NCT03475121|COMBINATION_PRODUCT|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan
214382075|NCT03475121|COMBINATION_PRODUCT|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan and Orbital Radiotherapy|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan and orbital radiotherapy (45 Gy) up to chiasm
214382076|NCT03475121|OTHER|No Adjuvant Therapy|Patients will not receive any adjuvant therapy after enucleation of the affected eye.
214382077|NCT03746184|OTHER|Treatment course|Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
214382078|NCT00513786|DRUG|Carboplatin|AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
214498502|NCT02781857|OTHER|No intervention|
214498503|NCT03480698|DRUG|Cerebrolysin|Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
214498504|NCT06489431|DRUG|Chlorhexidine|Irrisept is a self-contained jet lavage that contains chlorhexidine gluconate (CHG) as a preservative to offer broad-spectrum activity against various microorganisms in the bottled solution
214498505|NCT06489431|DRUG|Gentamicin|Aminoglycoside antibiotic irrigation
214687433|NCT06813651|DRUG|TBO-309: 60 mg|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation. By targeting PI3Kβ, TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal haemostasis.
214382079|NCT00513786|DRUG|Paclitaxel|175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
214382080|NCT00513786|DRUG|bevacizumab|15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
214498506|NCT06489431|DRUG|Rifampin|Antibacterial known to inhibit DNA-dependent RNA polymerase
214498507|NCT05347927|DEVICE|water resistante padding|"* Delta-Dry® Softliner~* Tensoban®~* Delta-Dry®"
215094735|NCT04369625|BEHAVIORAL|CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.
214382081|NCT03764540|DRUG|Cabazitaxel plus prednisone|"Cabazitaxel 25 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
214687434|NCT06813651|DRUG|TBO-309: 120 mg|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation. By targeting PI3Kβ, TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal haemostasis.
214382082|NCT03764540|DRUG|Docetaxel plus prednisone|"Docetaxel 75 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
214382083|NCT03794375|OTHER|Telehealth|After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
214382084|NCT03794375|OTHER|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
214382085|NCT06406062|DEVICE|ANDOANGEL|"Polyps were identified by endoscopists assisted by an AI system: rectangular box marks; Monitoring of ileocecal position: whether blindness was reached was displayed in the lower left corner of the interface.~Mirror entry and exit time monitoring: the operation time is displayed in the upper left corner of the interface.~Colonoscopy withdrawal speed monitoring: the relative withdrawal speed was displayed on the left side of the interface."
214382086|NCT06489223|DEVICE|Orofacial Myofunctional Rehabilitation Pacifier|The pacifier will be offered to the child
214382087|NCT05133882|DRUG|Clifutinib Besylate|The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
214498508|NCT05347927|DEVICE|non water resistante padding|"* Delta-Net® Stockinette~* Delta-Rol®"
214498509|NCT05577910|DEVICE|Vectored thermal pulsation (VTP) therapy|VTP purchased from TearScience®️ is an automated thermal pulsation system that is designed to heat and simultaneously evacuate the meibomian gland contents. It is performed by the unmasked treating investigators as described by the equipment manufacturer. In brief, one to two drops of topical anesthesia are applied prior to the bilateral application of the activators. The inner portion of the activator applies a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applies directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Participants will receive one session of VTP treatment only (month 0).
214498510|NCT05577910|DEVICE|Intense pulsed light with meibomian gland expression (IPL+MGX) therapy|"IPL is delivered using the proprietary dry eye mode setting of the Lumenis®️ M22TM system per the Toyos protocol. Pulse intensity (11-14 J/cm2) is inversely related to the Fitzpatrick skin phototype of each participant and will be used for the same patient throughout the study. IPL will be delivered to four overlapping zones inferior to each eye and a fifth pulse applied temporally adjacent to the lateral canthus four times. Both eyelids are closed and sealed with IPL-Aid disposable eye shields. MGX is immediately performed on both upper and lower eyelids of each eye and pain will be minimized by topical anesthetic. Participants will receive four-session IPL and MGX treatment (month 0, 1, 2 ,3)."
214382088|NCT05067933|DRUG|VXA-CoV2-1.1-S|COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine
214498511|NCT05577910|BEHAVIORAL|Eyelid Warm Compress Therapy (EW)|EW using warm wet towel to each eye is performed twice daily for 10 mins. A treatment diary will be given for patients randomized to EW for daily recording which will be reviewed and recorded by the unmasked study coordinator at each study visit.
214498512|NCT05577910|DRUG|Topical eye drops (Hypromellose, 3mg/ml)|All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
214382089|NCT05067933|OTHER|Placebo Tablets|Placebo tablets matching the active vaccine tablets
215092980|NCT02871089|OTHER|Multiple Daily Injections|"Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.~Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed."
215092981|NCT00560495|DRUG|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
215092982|NCT00560495|OTHER|immunoenzyme technique|
215092983|NCT00560495|OTHER|laboratory biomarker analysis|
215092984|NCT00560495|RADIATION|Tc 99m sestamibi|
214382090|NCT04553692|DRUG|Aplitabart (IGM-8444)|DR5 Agonist Investigational Drug
214498513|NCT06749340|OTHER|Assigned Interventions|"Psychometric Hepatic Encephalopathy Scoring (PHES) Test~* Digit Symbol Test~* Number Combination Test-A~* Number Combination Test-B~* Serial Punctuation Test~* Line Drawing Test~  6 Minute Walk Test~  5 Times Sit and Stand Test~Manual Muscle Test~Hand Grip Strength Test~Quadriceps muscle thickness measurement with ultrasonography~All evaluations will be repeated 5 times."
214498514|NCT06749340|OTHER|Face-to-face Exercise|Participants will undergo exercise sessions 3 days a week for 12 weeks. Sessions will include a warm-up, upper and lower extremity strengthening (1/3 set - 8/12 repetitions) and cool-down program. Theraband will be used in strengthening exercises. Theraband offers different resistance levels with its different colors. In order from lightest to heaviest; skin color, yellow, red, green, blue, black, grey, gold. Exercises (theraband color, intensity, number of sets and repetitions) will be made into a personalized program according to the tolerance level of the participants in the first session. Exercise intensity will be determined using the OMNI - Resistance Exercise Scale (OMNI - RES). The warm-up and cool-down periods in the exercise program will be carried out at levels 9 - 12 according to the Borg Scale.
215092985|NCT00560495|RADIATION|radiation therapy|once daily, 5 days a week, for 6-7 weeks
215092986|NCT05170789|DRUG|Elotuzumab, Selinexor, and Dexamethasone (ESd)|This is a single-arm, interventional, phase II clinical trial, in which the anticipated 18 enrolled patients will receive the trial drug, a combination of Elotuzumab, Selinexor, and Dexamethasone in monthly cycles. The study tests the theory of synergy between these drugs, as detailed in the study description above.
215092987|NCT02090361|PROCEDURE|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
214995723|NCT06597240|DEVICE|AMCOR|Participants will collect biometric and quality of life data for 9 or 10 weeks at home, depending on treatment schedule. Continuous step counting will be used to register physical activity. Participants will be asked to measure their blood pressure, heart rate, oxygen saturation level, pain level and temperature each morning, and weight 3 times a week. These measurements consume little time and are not harmful. Once a week they will perform a finger stick test themselves to determine creatinine concentration in the blood. In addition, patients fill in three questionnaires at four time points which will take approximately 20 minutes to complete per time point. We do not foresee reasonable risks of these diagnostic procedures for the participants.
214382091|NCT04553692|DRUG|FOLFIRI|Chemotherapy Regimen
214382092|NCT04553692|DRUG|Bevacizumab (and approved biosimilars)|Targeted Therapy
214382093|NCT04553692|DRUG|Birinapant|SMAC-mimetic Investigational Drug
214382094|NCT04553692|DRUG|Venetoclax|Targeted Therapy
214382095|NCT04553692|DRUG|Gemcitabine|Chemotherapy
214382096|NCT04553692|DRUG|Docetaxel|Chemotherapy
214382097|NCT04553692|DRUG|Azacitidine|Chemotherapy
214382098|NCT06806020|OTHER|SEAS approach|"The SEAS approach provides a thorough evaluation of the patient before the treatment starts. In addition to the usual measurements for the specific assessment of the scoliosis (Cobb degrees, Bunnel, trunk decompensation, sagittal postural structure and aesthetic parameters), the patient performs a series of tests. The objectives are: assessment of physical conditions (strength and elasticity of certain muscle areas that are more likely 6 influence the structure of the pelvis and the spine), assessment of neuromotor ability related to the alignment of the spine and the pelvis (balance, management of body movements with closed eyes, optical/manual skills) (Romano et al, 2015).~The main aim of SEAS is to reverse the Stokes vicious cycle, so, the abnormal loading created by the scoliosis with an asymmetric growth leading to worsening of curves that will lead to further asymmetric growth due to increased asymmetrical loading (ettany et al 2014).~The goal of SEAS exercises is to develop an a"
214382099|NCT06806020|OTHER|BSPTS school|"Barcelona scoliosis physical therapy school (BSPTS): Based on the theory that scoliosis posture promotes curve progression, according to the vicious cycle model, Barcelona Scoliosis Physical Therapy School (BSPTS) is a physiotherapeutic method that can be defined as a therapy plan of cognitive, sensory-motor, and kinesthetic training to teach the patient to improve their scoliosis 3D posture and shape. The BSTPS method aims to: 1) improve aesthetics and correct scoliotic posture; 2) stabilize the spine and stop the progression of the curve; 3) inform patients and their families about the condition and available treatments; 4) enhance breathing; 5) increase activity, including daily living activities and functional mobility; 6) enhance general self-image and self-esteem; and 7) reduce pain. The initial ideas serve as the foundation for BSPTS correctional Principles (Berdishevsky et al 2016)."
214995724|NCT02324751|BIOLOGICAL|Vi-TCV|Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge
214995725|NCT02324751|BIOLOGICAL|Vi-PS Vaccine|Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge
214995726|NCT02324751|BIOLOGICAL|Control (Men ACWY)|Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge
214995727|NCT03778671|DRUG|Levobupivacaine|Patients will receive Levobupivacaine 5%
215092988|NCT04518163|DRUG|Tranexamic Acid|Intravenous 1 gm tranexamic acid in 100 ml saline by slow infusion before skin incision
214382100|NCT04677400|OTHER|More than Body Appearance (MBA) Intervention|"The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them."
214382101|NCT03522077|DEVICE|RadAR EasyCLik plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the RadAR EasyCLik compression device
214687435|NCT06813651|DRUG|TBO-309: 30 mg|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation. By targeting PI3Kβ, TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal haemostasis.
214687436|NCT06894563|BEHAVIORAL|12-week exercise regimen|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week, and strength/balance exercise performed 2 days a week.
214687437|NCT06894563|BEHAVIORAL|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
214995728|NCT03778671|DRUG|Dexmedetomidine Injection [Precedex]|Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine
214995729|NCT03778671|DRUG|fentanyl|Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
214995730|NCT06857448|PROCEDURE|Split Thickness Skin Graft (STSG)|Partial thickness skin in STSGs are performed by harvesting via dermatome the donor site. Donor sites are typically taken from a flat surface on the thigh, lower back, or gluteal region to allow for a graft of even thickness and the selection of donor site is to be based on clinical standard practice. These grafts are placed on the prepared recipient site.
215092989|NCT04518163|DRUG|placebo to TA|Intravenous 110 ml saline by slow infusion before skin incision
215092990|NCT04518163|DEVICE|Bakri Balloon|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
214382102|NCT03522077|DEVICE|TR BAND® Compression device plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the TR BAND® compression device
214382103|NCT03522077|DEVICE|SoftSeal®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot
214382104|NCT03522077|DEVICE|VascBand™ Hemostat|The VascBand™ Hemostat is an FDA-approved compression device designed to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites.
214382105|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+CS + PO)|The enucleation procedures, which were meticulously carried out in order to remove the odontogenic keratocyst in one piece without breaking its lining or leaving any epithelial remnants.The peripheral ostectomy treatment will be carried out with a large spherical bur and plenty of irrigation.After filling the bone cavity with more sterile gauze, the Carnoy's solution was slowly injected into it with a plastic syringe. The gauze was continuously injected with CS until it was fully saturated without leaking too much into the surrounding tissues. The CS was held in place for 3 minutes.
214382106|NCT06133764|PROCEDURE|Decompression/ marsupialization (D/M)|A surgical window will be created in the cyst wall to drain the contents while retaining continuity between the cyst and the oral cavity
214382107|NCT06133764|PROCEDURE|Enucleation (E)|The enucleation will be accomplished in the same manner that it will be performed in the group of Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
214382108|NCT06133764|PROCEDURE|Enucleation+Carnoy's solution (E+CS)|Both enucleation and Carnoy's solution will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
214382109|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy (E+ PO)|Both enucleation and peripheral ostectomy will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+ Carnoy's solution chemical cauterization (E+ PO+ CS).
214382110|NCT06534073|DEVICE|Socks|Plantar orthotic elements will be designed, according to the participants' previous baropodometric pattern, to alleviate pathological plantar pressure. These elements will be integrated into commonly worn items by patients, such as stockings or socks.
214382111|NCT06534073|DEVICE|Standard device|Removable device of digital alignment to stabilize and unload the affected metatarsophalangeal joint. They do not require frequent replacement as they are washable and reusable elements.
214382112|NCT06534073|DEVICE|Foot orthoses|Custom-made foot orthoses.
214382113|NCT04570774|PROCEDURE|Repetitive transcranial magnetic stimulation|rTMS over cerebral motor cortex and cerebellar hemisphere
214498515|NCT06749340|OTHER|Home-based Exercise|Participants will follow the same program as in the face-to-face exercise group. The first meeting with the participants will be held face to face and the details of the study will be explained. Home-based exercises will be carried out with the Fiziu (Fiziu Sağlık Hizmetleri Teknoloji A.Ş., Istanbul, Türkiye) program and the exercise program will be delivered to the participants through this program. Therabands with which the participants will do their exercises will be provided by the researchers. The progression program will be determined in line with the difficulty and effort felt by the participants through weekly meetings.
214498516|NCT06749340|OTHER|Control|Participants assigned to the control group will have the same evaluation sessions as participants assigned to the experimental groups. The first evaluation will be made at the beginning of the study, the second evaluation after the 8-week period, the third evaluation after the 12-week period, the fourth evaluation after the 6-month follow-up, and the fifth evaluation after the 12-month follow-up. Participants who will not be included in any study sessions during this process will be included in the study program that appears to be effective as a result of the study. Participants in this group will be offered the program recommended by the US Office of Disease Prevention and Health Promotion and used in individuals who have previously had a liver transplant. This program consists of aerobic exercises (walking, cycling, etc.) starting from 60-65% of the maximum heart rate and progressing to 75-80%.
214995731|NCT06857448|PROCEDURE|Base of wound fat graft with STSG Reconstruction (Autologous Layered Composite Grafting).|Autologous Layered Composite Grafting consists of the layered strategy of simultaneous fat and skin grafting. Fat is harvested by minimally invasive liposuction and applied directly to the wound base without any chemical or biologic processing. Skin is harvested as a split thickness skin graft by dermatome and applied over the layer of adipose tissue.
214995732|NCT03997422|PROCEDURE|Vertical Sleeve Gastrectomy (VSG)|Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
214995733|NCT06991530|DRUG|Low Molecular Weight Heparine|the LMWH group received injections of 4100 IU/d LMWH from the day of transplant
214995734|NCT06538220|BEHAVIORAL|Questionnaires and focus group|"To evaluate the Chronic Disease Unit care pathway, patients will respond to questionnaires : quality of life (SF-12), personal efficacy scale (GSES), Specific self Efficacy related to Weight Management (SEWM), Rosenberg self-esteem, body image satisfaction (QIC), state of anxiety and depression (HAD), Chronic Disease Unit satisfaction. Some patients will also participate to focus group."
214995735|NCT06624046|BEHAVIORAL|Sleep stability intervention|The sleep stability intervention will consist of three theory-based intervention components our team has developed and used in prior interventions: 1) self-monitoring using a wearable sleep tracker (Fitbit). This is well-liked by participants and increases awareness of their sleep goals. 2) Accountability coaching via weekly check-ins and daily monitoring of participants' wearable sleep tracking data and a coaching protocol.
214995736|NCT07102459|DRUG|Experimental: LTG-001 High Dose|High Dose Active
214995737|NCT07102459|DRUG|Experimental: LTG-001 Low Dose|Lower Dose Active
214995738|NCT07102459|DRUG|Active Comparator: HB/APAP|Active Comparator
214995739|NCT07102459|DRUG|Placebo Comparator|Placebo
214995740|NCT07103239|BEHAVIORAL|Video Based Visits|Video based visit with Heart Failure team
214995741|NCT07103239|BEHAVIORAL|Remote Self-Care Education|Self Guided Training
214995742|NCT07103239|BEHAVIORAL|Remote Patient Monitoring|Participant will use home devices to monitor blood pressure and weight; Participant will then send results to RN educator
214382114|NCT03652753|DRUG|N-acetylcysteine|4 mL of a 20% solution of NAC will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
214995743|NCT06323291|BEHAVIORAL|Coaching Sessions|"Enrolled participants will set up an account through a secure and encrypted web portal managed by Osara Health.~Coaches will follow-up with their designated patients and/or caregivers to schedule individual coaching sessions via phone, text, or email depending on the participant's communication preference. Participants will have an initial coaching consultation by phone to go over the purpose and structure of coaching sessions.~Participants will then have an additional 3-4 coaching sessions (depending on time availability and need) to discuss symptom management, nutrition and exercise, sleep, and mindfulness.~Participants will receive content for each of the modules via email."
214498517|NCT06754007|PROCEDURE|ROPES Training Programme|ROPES is a training programme that involves resistance training, whole-body exercises and HIIT aerobic sessions with each session lasting no longer than 45 minutes.
214498518|NCT06465576|DRUG|Solifenacin|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
214498519|NCT06465576|DRUG|Mirabegron|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
214498520|NCT06465576|DRUG|Solifenacin + Mirabegron|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
214498521|NCT04148495|DRUG|placebo of acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%"
214498522|NCT04148495|DRUG|acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g"
214995744|NCT06831409|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Coronary Computed Tomography Angiography (CCTA) is a non-invasive medical imaging test that uses X-rays to create detailed 3D images of the heart and its blood vessels, specifically the coronary arteries.
214498523|NCT06777563|BEHAVIORAL|Brief psychological counselling and health education|This is a brief 1-on-1 psychological counselling, including potential mood fluctuation during pregnancy, possible prepartum depressive symptoms, and available psychiatric consultation and medication in Hong Kong with self-help psychoeducational materials.
214498524|NCT06777563|BEHAVIORAL|2 Weeks of Ecological Momentary Assessment (EMA)|The 2-week EMA period will start the next day. Participants will be prompted to answer questions about emotion (e.g. worry, enjoyment, anxiety, etc.) and other lifestyle and environmental triggers through the smartphone notification function. There will be a 2-hour window for each assessment before expiration and total 5 assessments a day.
214498525|NCT06777563|BEHAVIORAL|10 weeks of mobile health psychological support|A total of 20 regular instant messages (e.g., via WhatsApp) personalised by baseline demographic characteristics (current pregnancy details, history of postpartum mental illness) and results of EMA will be sent to the participants in multi-media formats.
214498526|NCT06777563|BEHAVIORAL|CBT-guided telephone counselling booster|A 45-minute telephone counselling based on CBT.
214498527|NCT06831370|DRUG|Brentuximab Vedotin|Brentuximab Vedotin IV infusion
214498528|NCT06831370|DRUG|Doxorubicin|Doxorubicin IV infusion
214498529|NCT06831370|DRUG|Vinblastine|Vinblastine IV infusion
214995745|NCT04322383|DRUG|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
214995746|NCT04307667|BIOLOGICAL|Whole lung antigen challenge (WLAC)|Whole lung antigen challenge with cat hair, house dust mite, or short ragweed allergen extracts.
214995747|NCT04307667|RADIATION|[18F]FEPPA|\[18F\]FEPPA is a radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia.
214995748|NCT03333343|DRUG|EGF816|Study Drug
214995749|NCT03333343|DRUG|trametinib|Study Drug
214995750|NCT03333343|DRUG|ribociclib|Study Drug
214995751|NCT03333343|DRUG|LXH254|Study Drug
214382115|NCT03652753|DRUG|Saline|4 mL of a 20% solution of saline will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
214382116|NCT04127552|PROCEDURE|Adrenalectomy|Adrenalectomy according to 2016 ESE guidelines
214382117|NCT06285968|BEHAVIORAL|Multidimensional Sleep Health Promotion Intervention|Multi-component multidimensional sleep health promotion intervention that includes sleep health and sleep hygiene education, behavioral coaching, personalized feedback, goal setting and establishment of a sleep health plan, self-monitoring, supportive accountability, and addressing light and noise in the sleep environment.
214382118|NCT03002064|DRUG|Docetaxel|60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
214498530|NCT06831370|DRUG|Dacarbazine|Dacarbazine IV infusion
214995752|NCT03333343|DRUG|INC280|Study Drug
214995753|NCT03333343|DRUG|gefitinib|Study Drug
214995754|NCT05677139|OTHER|None (Observational Study)|Not applicable since it's an observational study.
214995755|NCT05232916|BIOLOGICAL|Placebo|0.9% Normal Saline
214995756|NCT05232916|BIOLOGICAL|GLSI-100|500 mcg/mL GP2 and 125 mcg/mL GM-CSF
214995757|NCT03850574|DRUG|Tuspetinib|Daily (QD), continuous dosing
214995758|NCT03850574|DRUG|Venetoclax Oral Tablet|Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets
214995759|NCT03850574|DRUG|Azacitidine for Intravenous Infusion|Azacitidine will be given to study participants in Part D as intravenous infusion at a dose of 75 mg/m\^2
214995760|NCT04375332|DEVICE|HARPOON™ Beating Heart Mitral Valve Repair System|Repair of the chordae tendinae in the mitral valve.
214995761|NCT05337553|DRUG|taldefgrobep alfa|DB Phase: 35 mg/50 mg weekly subcutaneous injection
214382119|NCT03002064|DRUG|Fluorouracil|5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
214382120|NCT03002064|DRUG|Cisplatin|Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
214382121|NCT03706118|OTHER|Magnetic resonance imaging|At month 0, 12, 24 and 36 participants will be examined by quantitative magnetic resonance imaging of brain, cervical and part of thoracic spine.
214382122|NCT04444648|COMBINATION_PRODUCT|No intervention|No intervention
214382123|NCT04463368|PROCEDURE|Isolated hepatic perfusion|The procedure is performed under general anaesthesia. The caval vein is isolated infrahepatically above the renal veins and suprahepatically between the diaphragm and the pericardium. A catheter is placed in the retrohepatic portion of the caval vein for perfusion outflow. The portal vein is clamped and the proper hepatic artery is cannulated via the gastroduodenal artery. The liver perfusion is performed at a rate of 8- 9 ml/kg/min with a target liver temperature of 40 degrees Celsius. The leakage from the system was continuously recorded using Technetium labelled albumin (Vasculosis) injected into the perfusion circuit. Melphalan (1 mg/kg bodyweight divided into two doses, given 30 minutes apart) is added to the perfusion system. The perfusion is then continued for 60 minutes, after which the perfusion was discontinued.
214382124|NCT04463368|DRUG|Ipilimumab|4 courses of ipilimumab 3mg/kg every third week
214382125|NCT04463368|DRUG|Nivolumab|4 courses of nivolumab 1mg/kg every third week
214382126|NCT01065350|DRUG|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
214382127|NCT01065350|DRUG|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
214382128|NCT00626366|RADIATION|Sinus CT Scan|Subjects will undergo a Xoran miniCAT scan of their sinuses
214382129|NCT00626366|DRUG|Omnipaque 240 Contrast Solution|Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
214382130|NCT00626366|DRUG|Omnipaque 240 mg I/mL|Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
214382131|NCT02844699|DRUG|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
214382132|NCT02844699|DRUG|Placebo|5% infusion solution of dextrose (glucose)
214382133|NCT00001599|DRUG|Thalidomide|
214382134|NCT01657266|DRUG|PRO-155|Pre-medication (before surgery) and maintenance treatment.
214382135|NCT01657266|DRUG|Nevanac|Pre-medication (before surgery) and maintenance treatment.
214498531|NCT06649500|OTHER|Treadmill|The Walker View system is a treadmill equipped with a loaded cell sensor belt and a 3D camera that allows you to detect every single angular movement of the subject. Furthermore, thanks to the two optics, a classic one for 2D shooting in high resolution, and a revolutionary one for infrared rays, it is possible to reconstruct the position of the subject in space in three-dimensional mode and in real time. The reflected image reconstructed by the system helps to improve movement through the \&#34;continuous feedback system\&#34; method.
214498532|NCT06649500|OTHER|conventional therapy|Conventional therapy intervention will follow the usual treatment according to current clinical practice. This treatment will be delivered to patients in a group session in order the balance disorders.
214995762|NCT05337553|DRUG|Placebo|DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
214995763|NCT05337553|DRUG|taldefgrobep alfa|Extension Phase: 35 mg/50 mg weekly subcutaneous injection
214995764|NCT04070703|BEHAVIORAL|The Go for Exercise & Healthy Aging Project|Exercise and Cognition
214995765|NCT05904886|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
214995766|NCT05904886|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
214995767|NCT05904886|DRUG|Tiragolumab|Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
214995768|NCT05904886|OTHER|Placebo|Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
214995769|NCT05783817|DRUG|3,4-Methyl enedioxy methamphetamine|MDMA (3,4 methylenedioxymethamphetamine) is a synthetic, psychoactive drug that is chemically similar to the stimulant methamphetamine.
214995770|NCT05783817|DRUG|Methamphetamine|Methamphetamine is a stimulant that affects the central nervous system. This is used as a control in the study.
214995771|NCT05783817|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy with exposure and response prevention performed by therapist team.
214995772|NCT05962424|DRUG|Ketamine Hydrochloride|Ketamine is an FDA-approved dissociative anesthetic.
214995773|NCT04700124|BIOLOGICAL|Pembrolizumab|200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.
214382136|NCT05601934|OTHER|Neurophysiological Facilitation Techniques|Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.
214382137|NCT02636257|PROCEDURE|Recessive Spherical Headed Silicone Intubation|Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.
214498533|NCT06224660|GENETIC|SRD-001|SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.
214498534|NCT06646692|BEHAVIORAL|Mindful Self Compassion|(MSC) is a mind-body integrative health intervention that utilizes meditations, other contemplative practices, home practices, and experiential exercises (including group discussions) to increase SC. MSC can be done in groups of 10-25. To increase feasibility of MSC for use in residential drug treatment facilities, we will aim to adapt MSC to 7 sessions (6 weekly sessions in alignment with the MSC short course plus the half day retreat included in the full course to facilitate skill consolidation). Sessions will be conducted in a group-based format: prior research found group-based formats equivalent to individual-level interventions for PTSD/SUD.
214498535|NCT06646692|BEHAVIORAL|Treatment as Usual (TAU)|"Selecting appropriate attention control groups for behavioral intervention research, particularly for mindfulness-based interventions, can be problematic. Comparator groups often also improve as they tend to target related mechanisms (e.g., social support, health behaviors, improved attention). After weighing the pros and cons, a treatment as usual (TAU) approach was selected, whereby the MSC will be compared to TAU. However, to control for the confound of weekly compensation, TAU participants will meet with study staff seven times over the 6-week period and fill out short psychosocial surveys on non-distressing topics (e.g., personality tests, attitudes surveys) in exchange for compensation commensurate with the MSC group. We believe this will also help with retention of the TAU group over time and strike an appropriate balance between controlling for the effects of study participation while minimizing confounds that often occur with active control groups in behavioral trials."
214498536|NCT05908955|PROCEDURE|PVI|pulmonary vein isolation
214498537|NCT05908955|PROCEDURE|PVI+ quantitative SVCI|pulmonary vein isolation and superior vena cava isolation guided by quantitative ablation index
214382138|NCT02636257|PROCEDURE|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
214382139|NCT00000605|DRUG|hormone replacement therapy|
214382140|NCT00000605|DRUG|estrogens|
214382141|NCT00000605|DRUG|medroxyprogesterone|
214382142|NCT03566303|DRUG|Rivaroxaban 15 mg|Rivaroxaban 15 mg BID
214382143|NCT03566303|DRUG|Warfarin|Warfarin
214382144|NCT05093049|DEVICE|Renuvion APR System|The Renuvion APR Handpiece (K191542) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. The Renuvion APR Handpiece is compatible with the Electrosurgical Generators BVX-200H/P (K170188), and APYX-JS3/RS3 (K192867) owned by Apyx Medical that are indicated for delivery of radiofrequency energy and/or helium gas plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures.
214382145|NCT05093049|PROCEDURE|Gynecomastia Correction Surgery|Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.
214382146|NCT05850468|DRUG|fentanyl infusion after general anesthesia and erector spinea block|intraoperative opioid infusion in active comparative group
214382147|NCT05850468|DRUG|lidocaine 2% and dextometometidine infusion after general anesthesia and erector spinea block|intraoperative non opioid infusion in experimental group
214382148|NCT04768842|DRUG|LY3209590|Administered SC.
214382149|NCT01053377|DRUG|Tamiflu (verum)|
214382150|NCT01053377|DRUG|Tamiflu placebo|
214382151|NCT02805426|DRUG|Tranexamic Acid|
214382152|NCT02805426|DRUG|Placebo|
214382153|NCT02805426|DRUG|Misoprostol|
214382154|NCT02623010|DRUG|Imbruvica|Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
214382155|NCT01191203|DRUG|Copper IUD|Copper IUD (CuT360)
214382156|NCT01191203|DRUG|Depo Medroxyprogesterone acetate|DMPA 150 mg IM q 3 months
214382157|NCT02719379|BIOLOGICAL|Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)|
214382158|NCT01316770|DRUG|Dexamethasone Parotid Irrigation|Irrigation of the parotid gland from one side of the mouth with dexamethasone.
214382159|NCT01316770|DRUG|Placebo Parotid Irrigation|Irrigation of the parotid gland on the opposite side of the mouth with placebo saline.
214382160|NCT04138836|DRUG|BBT-877|BBT-877 oral capsule.
214382161|NCT04138836|DRUG|Midazolam|Midazolam oral syrup.
214382162|NCT04138836|DRUG|Itraconazole|Itraconazole oral capsule.
214382163|NCT04138836|DRUG|Esomeprazole|Esomeprazole oral capsule.
214382164|NCT03595930|DRUG|Arnuity|ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
214382165|NCT00246987|DRUG|Muraglitazar|
214382166|NCT06068231|DEVICE|Temporary Crown|Implants were loaded with temporary restorations 6 to 8 weeks after implantation and had occlusal contact with opposing dentition.
214382167|NCT06068231|DEVICE|Permanent Crown|Implants were loaded with permanent restorations at least 3 months after implantation and had occlusal contact with opposing dentition.
214382168|NCT04958330|PROCEDURE|lateral prostate capsule sparing|When resect the bladder and prostate, the lateral prostate capsule will be preserved.
214382169|NCT01618474|DRUG|DX|Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
214382170|NCT01618474|DRUG|XELOX|oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
214995774|NCT04700124|BIOLOGICAL|Enfortumab vedotin (EV)|1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.
214382171|NCT02102880|GENETIC|the polymerase chain reaction (PCR)|
214382172|NCT02571374|DIETARY_SUPPLEMENT|symbiotic group|this group received sachets of symbiotic
214382173|NCT02571374|DIETARY_SUPPLEMENT|placebo group|this group received placebo
214382174|NCT06148220|RADIATION|[18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging|Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
214382175|NCT03322098|DRUG|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia
214382176|NCT03322098|DRUG|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
214382177|NCT03294889|RADIATION|Stereotactic body radition (SBRT)|"Ultra-hypofractionated single-fraction SBRT with urethra-sparing with image-guidance and intra-fractional control motion with the Calypso® system.~* 19 Gy in a single fraction to the whole prostate gland ± proximal seminal vesicles~* 17 Gy in a single fraction to the urethra planning-risk volume (PRV)"
214382178|NCT05837208|OTHER|RV4369A cosmetic product|"The product is applied 1 or 2 times during the 2 study visits. The product is recovered by the technician after application of the product by the volunteer.~Application modalities:~Inclusion Assessment: The study product is given to the volunteer who applies it to his face (forehead) according to his usual habits.~After a waiting time and Multispectral camera measurements, the study product is again applied by the volunteer to his face according to his usual habits.~Final assessment: The study product is applied by the Clinical Research Technician on the subject's forearm on 4 delimited areas at specific quantities.~After a waiting period and Multispectral camera measurements on the forearm areas, the study product is given to the volunteer who applies it on his face according to the recommendations of use provided by the Technician."
214382179|NCT04227743|DEVICE|cryobiopsy|. The cryobiopsy samples will be obtained by advancement of the cryoprobe into the working channel of the bronchoscope to touch the tip of the endobronchial tumor. The freezing time will be approximately 4 seconds. Then, flexible bronchoscope together with tissue sample attached to the tip of the frozen probe will be extracted outside the bronchial tree. The tissue sample will be released from the probe's tip by plunging it into saline at room temperature. FB will be reintroduced after cryobiopsy to evaluate and control the bleeding.
214382180|NCT04882774|DRUG|Treprostinil Diolamine|Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID
214382181|NCT01468441|DRUG|Triptorelin|Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
214995775|NCT04700124|PROCEDURE|RC + PLND|Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
214995776|NCT04700124|DRUG|Gemcitabine|1000 mg/m\^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
214382182|NCT01468441|DRUG|Cetrorelix|When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
214382183|NCT03269240|BEHAVIORAL|Acquisition of Knowledge and clinical skills|LDHF is a novel training approach that is being compared to the traditional training approach
214382184|NCT03269240|OTHER|Onsite training|Participants are training at their health facilities
214382185|NCT03269240|OTHER|Off-site training|Participants from different health facilities are gathered together in a central location for training, away from their workplaces
214382186|NCT03684122|BIOLOGICAL|Injection of Umbilical cord derived MSCs|Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
214382187|NCT05145725|BEHAVIORAL|Quality of life questionnaires|Different questionnaires to fill : SRS-22r, SF-36 score, TAPS, KIDSCREEN10
214382188|NCT01622244|OTHER|Co-ordinated Access to Care from Hospital Emergency Departments|brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
214687438|NCT06816147|OTHER|Investigators will evaluate the acceptance and adherence to a healthy lifestyle recommender solution (HLRS), a digital app, among participants|The intervention will include collecting blood, stool, urinary samples as well as measuring anthropometrics and collecting data (socio-demographics, general health, well-being, PA, and eating patterns, among others) via questionnaires completed in part from a mobile application.
214687439|NCT06930027|OTHER|Resistance Training (High-Intensity)|Leg press exercise performed at 70-80% of 1RM, structured as 4 sets × 10 repetitions, with controlled tempo and standardized rest intervals (2 minutes).
214995777|NCT04700124|DRUG|Cisplatin|70 mg/m\^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
214382189|NCT01622244|OTHER|Coordinated Access to Care from Hospital Emergency Departments|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
214382190|NCT01622244|BEHAVIORAL|Counseling and Resource Education|Participants will receive usual care as well as an educational session and resource guide outlining community-based services
214382191|NCT04146649|PROCEDURE|Arthrocentesis|Patients will receive a joint arthrocentesis to remove fluid from the joint.
214382192|NCT04999644|DRUG|Full Nicotine Cigarettes|A full nicotine tobacco cigarette that will be smoked by participants
214382193|NCT04999644|DRUG|Reduced Nicotine Cigarettes|A reduced nicotine tobacco cigarette that will be smoked by participants
214382194|NCT04999644|BEHAVIORAL|Average Nicotine Expectancy|"Participant instructed the cigarette is the same level of nicotine as your usual brand."
214382195|NCT04999644|BEHAVIORAL|Very Low Nicotine Expectancy|"Participant instructed the cigarette is a very low level of nicotine compared to your usual brand."
214382196|NCT03547492|BEHAVIORAL|Teaching Talking|Written packet including 8 lessons: What's My Corrected Age, Watch Me Learn (language milestones in the 1st year of life), Reading Aloud, Sing-a-long: Sleepy Songs, Sing-a-long: Alert Songs, Copying First Sounds, Playing Games, Talk to Your Baby.
214382197|NCT03547492|BEHAVIORAL|LENA recordings-language|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, after reviewing Teaching Talking and linguistic feedback of first recording, 4 and 12 months of age. Participants are mailed feedback of their 2nd, 4 and 12 month recordings.
214382198|NCT03547492|BEHAVIORAL|LENA recordings-motor|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, 2nd, 4 and 12 months of age. Participants are mailed feedback on recordings after completing study.
214382199|NCT03547492|BEHAVIORAL|Mastering Movement|A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...
214382200|NCT03547492|BEHAVIORAL|Language text messages|12 weekly text messages. Each is 1-2 sentences to review concepts of Teaching Talking
214382201|NCT03547492|BEHAVIORAL|Motor text messages|4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement
214382202|NCT01691625|OTHER|concurrent chemoradiotherapy plus DC-CIK immunotherapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period."
214498538|NCT06759181|DRUG|anti-BCMA/FcRL5 CAR T|"anti-BCMA/FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.~Other Name:"
214498539|NCT06168851|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
214498540|NCT06275750|DEVICE|Spinal decompression with BTL-6000 spinal decompression system (BTL Industries Ltd.)|The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
214498541|NCT05360329|PROCEDURE|Transarterial geniculate artery embolization|The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
214498542|NCT02517268|PROCEDURE|Pancreaticoduodenectomy|
214995778|NCT06123377|DIAGNOSTIC_TEST|Angiogenic factor|sFLt-1/PGIF below or equal to 33
214995779|NCT03539536|DRUG|Telisotuzumab vedotin|Intravenous (IV) infusion
215092991|NCT04353700|BEHAVIORAL|Yoga group|During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
215092992|NCT01283542|DRUG|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
215092993|NCT01143987|DRUG|Cinacalcet|starting with 25 mg daily dose with titration, maximum dose 100 mg daily
214498543|NCT05143866|BEHAVIORAL|Cognitive behavioral therapy guided self help (CBTgsh)|Based on evidence based cognitive behavioral treatment for eating disorders. Self-help version described in self-help book. Participant follows self-help program with encouragement and support of a non specialist guide
214498544|NCT03246802|RADIATION|HDR partial prostate brachytherapy|temporary radioactive implant
214498545|NCT03011541|PROCEDURE|Arm 1|"Procedure/ Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)"
214498546|NCT06778980|OTHER|The chin tuck posture|A chin tuck is a posture correction technique where the individual gently tucks their chin towards their chest while keeping the rest of the body straight. This movement helps align the head and neck, reducing forward head posture and improving spinal alignment. After performing the unguided exercises, the patients will be taught the chin tuck position. From this point onward, they will be instructed to maintain the chin tuck position while performing the exercises using both external and internal focus strategies.
214995780|NCT02664753|DRUG|56 days of weight-adjusted L-Carnitine treatment|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~\< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization"
215092994|NCT03583827|OTHER|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
215092995|NCT03583827|OTHER|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
215092996|NCT04285489|DEVICE|Hakim Shunt Programmable System|patient accept Hakim Shunt Programmable System due to HCP
215092997|NCT03443427|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.
215092998|NCT03443427|BIOLOGICAL|Placebo|One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
215092999|NCT00068510|BIOLOGICAL|therapeutic autologous dendritic cells|
214382203|NCT01691625|OTHER|Concurrent chemoradiation only|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation."
214382204|NCT03468959|BEHAVIORAL|Maternal Supplemental PUFA Intake|Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
214382205|NCT01583101|OTHER|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
214382206|NCT01583101|OTHER|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
214382207|NCT05401643|OTHER|Xemio mobile application|"The study consists in a mHealth intervention provided through the Xemio mobile application for breast cancer survivors. This application is installed in the personal smartphones of the participants after they are randomized in the mHealth intervention group. The Xemio app components are symptom tracking, up-to-date calendar of events organized by patient's organizations, virtual talks with experts, articles regarding new information of the disease, physical activity tracking, and evidence-based information regarding symptoms, non-pharmacological treatments for side effects, and information about common drugs to treat breast cancer. The participants can freely use the Xemio mobile application for a total of 12 months.~The control group does not have access to the Xemio application for the duration of the study but they are offered access to it at the completion of the intervention. The participants of both arms continued to receive the usual care from their oncology teams."
214382208|NCT02633930|DRUG|Berberine|: given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID
214382209|NCT02633930|DRUG|clarithromycin|Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
214382210|NCT02633930|DRUG|Bismuth|Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
214382211|NCT02633930|DRUG|Lansoprazole|Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
214498547|NCT06777992|OTHER|Home topographic scans|Patients randomized to the Intervention arm of the trial will additionally use Momentum SpineTM assessment from home at 2-month intervals. If a progression is detected using Momentum SpineTM the participant will be promptly invited to acquire a second set of scans for confirmation. In case of confirmation of the progression using the images from the repeated scans, the scan results will be sent to their local orthopedic surgeon.
215093000|NCT04625868|OTHER|Educational video|Patients will watch a preoperative educational video on proper opioid use and disposal.
214382212|NCT02633930|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
214382213|NCT04444635|PROCEDURE|Serratus Anterior Plan Block+ Fentanyl infusion|"After induction of anesthesia, the patients will be put on the lateral position with the diseased side up. A linear ultrasound transducer will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage.~Then counting down ribs till the fifth rib will be identified in the mid-axillary line. The following muscles will be identified overlying the fifth rib: the latissimus dorsi (superficial and posterior),teres major (superior) and serratus muscles (deep and inferior). Under complete sterile conditions, the needle (25 G needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. Then, 2 mg/kg of 0.25% bupivacaine will be injected with continuous ultrasound guidance. In addition to continuous fentanyl infusion"
214382214|NCT04444635|DRUG|Fentanyl|Continuous fentanyl infusion throughout the surgical procedure.
214382215|NCT04450186|OTHER|EEG/fMRI neurofeedback|EEG/fMRI neurofeedback
215093001|NCT00322946|BIOLOGICAL|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
214687440|NCT06930027|OTHER|Resistance Training (Low-Intensity)|Leg press exercise performed at 20-30% of 1RM, structured as 4 sets (30/15/15/15 repetitions), with controlled tempo and shorter rest intervals (1 minute).
214687441|NCT06930027|OTHER|Normobaric Hypoxia|Environmental intervention simulating an altitude of approximately 3500 meters (\~13.5% FiO₂) using a normobaric hypoxic chamber.
214382216|NCT01021592|DRUG|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
214382217|NCT06197906|DEVICE|Device implant|subcutaneous device implanting
214382218|NCT01422525|PROCEDURE|spectral domain optical coherence tomography|RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
214382219|NCT02345525|BEHAVIORAL|mCIMT|"This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT."
214382220|NCT02345525|BEHAVIORAL|hCIMT|"This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.~In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week)."
214382221|NCT04511416|DRUG|Metformin XR, 500-2000mg nocte|Metformin XR, 500-2000mg nocte
214382222|NCT01974700|DRUG|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
214382223|NCT02519101|DEVICE|continuous noninvasive blood pressure monitoring ClearSight-Device|Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
214382224|NCT04604067|DRUG|Acalabrutinib|"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
214382225|NCT04553263|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
214382226|NCT04553263|DRUG|Bupropion|Bupropion is FDA-approved and marketed both as an antidepressant agent (Wellbutrin®) and treatment for smoking cessation (Zyban®) and has shown efficacy in reducing symptoms of depression and drug craving in stimulant users. it is also a promising candidate to improve cognition function.
214382227|NCT03443713|DEVICE|Dexcom G6 CGM|Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
214382228|NCT04686279|DRUG|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
214382229|NCT01756261|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
214382230|NCT04036461|DRUG|CC-99712|CC-99712
214382231|NCT04036461|DRUG|BMS-986405|BMS-986405
214382232|NCT04255342|DEVICE|Implant Placement and Temporary Crown using AstraTech Implant System EV, Final Crown Delivery|At least 3 months after tooth removal and bone grafting, a dental implant will be placed using Azento, a commercially-available product that uses computer technology to plan the dental implant placement using the AstraTech Implant System EV and an immediate implant temporary crown using Azento. After 3 months with the temporary crown, a definitive all-ceramic crown, made using a digital workflow will be placed.
214382233|NCT05277675|DRUG|Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab|Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
214687442|NCT06930027|OTHER|Normoxia|Training under normal atmospheric oxygen conditions (\~20.9% FiO₂).
215093002|NCT00322946|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-4995
214687443|NCT06929325|DRUG|Sirolimus for Injection (Albumin-bound)|IV infusion, every 2 weeks, 4 weeks per treatment cycle
214687444|NCT06929325|DRUG|Fulvestrant Injection|IM injection, 500 mg, on day 1 and day 15 of Cycle 1, and then on day 1 of each cycle thereafter, 4 weeks per treatment cycle
215093003|NCT00477269|DRUG|Imatinib mesylate|
215093004|NCT00477269|DRUG|Placebo|
215093005|NCT01989702|OTHER|Fermented blueberry drink|
215093006|NCT01989702|OTHER|Placebo drink|
215093007|NCT01989702|OTHER|Sachets with probiotic bacterial powder|
215093008|NCT01989702|OTHER|Sachets with placebo powder|
215093009|NCT05960084|OTHER|screening|screening for colistin resistant E. coli
215093010|NCT00213096|DRUG|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
215093011|NCT00993733|PROCEDURE|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
214995781|NCT02664753|DRUG|10 days of intravenous placebo (isotonic saline)|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening."
214995782|NCT06234462|DRUG|Amantadine|Participants that have been randomized to the study group will be instructed to begin taking amantadine on the day after this study visit. They will self-administer amantadine 100 mg twice daily (morning and noon) for four weeks
215093012|NCT04941404|DRUG|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
215093013|NCT05613582|DEVICE|Transcranial Direct Current Stimulation|The flow of DC electric current 1 mA for 20 minutes. The position of the electrode placement follows the international EEG 10/20 system.
214382234|NCT05277675|PROCEDURE|RFA|RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
215093014|NCT01822613|DRUG|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
215093015|NCT01822613|DRUG|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
215093016|NCT01822613|DRUG|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
215093017|NCT01822613|DRUG|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
215093018|NCT01822613|DRUG|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
215093019|NCT03263780|DRUG|18F-Fluciclovine|Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)
215093020|NCT05386212|DEVICE|web app healthcare instructions for relieving back pain|This study designed web-based dynamic pain relief instructions for women with spinal compression fractures.
214382235|NCT05098106|DIAGNOSTIC_TEST|Bronchoscopy, blood sampling; testing.|BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.
214382236|NCT01672853|BIOLOGICAL|Simtuzumab|Subcutaneous injections weekly for a total of 96 injections
214382237|NCT01672853|BIOLOGICAL|Placebo|Subcutaneous injections weekly for a total of 96 injections
214382238|NCT05878275|BEHAVIORAL|Parent Informational Session|Parents will receive a brochure on the importance of tummy time and limiting baby gear and watch a video on the importance of tummy time and limiting baby gear and receive support for implementing tummy time if requested.
214382239|NCT04765319|BEHAVIORAL|CPT for PTSD|Evidence based psychotherapy for PTSD
214382240|NCT04875364|DRUG|Eszopiclone|2mg of Eszopiclone just before going to sleep.
214382241|NCT04875364|OTHER|Supplemental Oxygen|Constant oxygen flow at 4 Liters per minutes for the duration of time in bed via nasal cannula.
214382242|NCT04875364|DEVICE|Continuous Positive Airway Pressure (CPAP)|A standard CPAP device will be provided using the settings as prescribed by the treating physician.
214382243|NCT01620905|PROCEDURE|Manipulation|Single level cervical spine joint manipulation
214382244|NCT01858467|DEVICE|Endotracheal intubation|Portex endotracheal tube 6.5mm or 7.0mm internal diameter
214382245|NCT01858467|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
214382246|NCT06016530|BEHAVIORAL|Sleep Deprivation|During a sleep deprivation period lasting over 36 hours, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant while adhering to a standardized diet. To achieve this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs).
214382247|NCT06016530|DRUG|Dexamethasone Supplementation|"Dexamethasone belongs to the drug class of corticosteroids. It is a synthetic glucocorticoid that activates glucocorticoid receptor (GR) and the hypothalamic-pituitary-adrenal (HPA) axis selectively.~Following the administration of 1 mg of dexamethasone as a pharmacological stressor, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant under a standardized diet. To facilitate this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs)."
214382248|NCT01897831|DRUG|xin te mie|durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
214687445|NCT06929325|DRUG|Placebo for Sirolimus for Injection (Albumin-bound)|IV infusion, every 2 weeks, 4 weeks per treatment cycle
214995783|NCT06234462|OTHER|Physical, Occupational, Speech Therapy|Physical Therapy (PT) and Occupational Therapy (OT) train patients on breathing exercises and gradual reconditioning. Patients are referred to speech therapy (SLP) for cognitive remediation and metacognitive strategies.
214995784|NCT06234462|OTHER|Provider Counseling|Clinic providers will provide counseling/education on Long-COVID.
214995785|NCT06234462|OTHER|Medications for symptoms management|Clinic providers may recommend targeted pharmacologic management for symptoms the patient is experience. As an example, if a patient reports a headache the provider may recommend over-the-counter or prescription medications to target this particular symptom.
214995786|NCT06963580|DRUG|MI078 capsule dose 1|MI078 capsule dose 1 for 3 days
214995787|NCT06963580|DRUG|MI078 capsule dose 2|MI078 capsule dose 2 for 3 days
214995788|NCT06963580|DRUG|placebo|placebo for 3 days
214995789|NCT06229145|BIOLOGICAL|Pegloticase|IV infusion
214382249|NCT01126138|DRUG|Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
214382250|NCT01126138|DRUG|Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine|"Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.~Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity"
214382251|NCT01690884|DRUG|Adenosine|Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
214382252|NCT02649062|BIOLOGICAL|NGM282|
214382253|NCT02649062|OTHER|Placebo|
214382254|NCT04131790|BEHAVIORAL|Tele-Behavioral Activation|Five 1-hour sessions of BA delivered by a trained interventionist via video-conferencing
214382255|NCT04131790|BEHAVIORAL|Tele-Friendly Visiting|Five 1-hour FV sessions delivered by a trained interventionist via video-conferencing
214382256|NCT03079310|DEVICE|Spinal cord stimulation|Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient
214382257|NCT03185559|DEVICE|Relievion Device- Treatment Stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
214382258|NCT03185559|DEVICE|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
214382259|NCT02914132|DEVICE|Seraph 100 Filter|Treatment of renal replacement therapy patients with bacteremia.
214382260|NCT00295438|DEVICE|Robot-Based Tele-Echography (TER)|Robot-Based Tele-Echography, ultrasound performed by the radiologist
214382261|NCT00295438|DEVICE|ultrasound method FAST|FAST,ultrasound performed by the emergency doctor
214382262|NCT02944656|DRUG|Gabapentin|Participants in this group will receive 600 mg of gabapentin given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion. Gabapentin is an FDA approved medication that is used to prevent seizures and to treat various forms of chronic and acute pain.
214382263|NCT02944656|DRUG|Placebo|Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
214995790|NCT06229145|DRUG|Methotrexate|Oral
214995791|NCT06027957|BIOLOGICAL|anti-CD19 CAR T-cells|"For Biological: CD19 CAR T-cells~* Dose: 1-2.10e6 cells/kg of weight~* Route: intravenous infusion~For Chemotherapy Drug:~* Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3.~* Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3.~* Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after."
214995792|NCT05977868|DRUG|Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid|COpAT (oral antimicrobial therapy) on hospital discharge
214995793|NCT05977868|DRUG|Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem|Standard of care (IV antimicrobial therapy) on hospital discharge
214995794|NCT05388006|DRUG|Acalabrutinib|Given PO
214995795|NCT05388006|BIOLOGICAL|Durvalumab|Given IV
214995796|NCT05388006|DRUG|Venetoclax|Given PO
214382264|NCT00017056|DRUG|ixabepilone|
214382265|NCT01583244|DRUG|No Intervention (subjects were previously treated with Orencia®)|No Intervention
214382266|NCT04868760|DRUG|Ipilimumab|Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
214382267|NCT04868760|DRUG|IBI310|Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
214382268|NCT05091853|DEVICE|Adhesix mesh|2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh
214382269|NCT04394364|DEVICE|Bispectral index|The BIS monitor will be attached to patients' forehead before anesthetized and kept until the end of the surgery
214995797|NCT05388006|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214995798|NCT05388006|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214995799|NCT05388006|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214995800|NCT05388006|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET/CT
214995801|NCT05388006|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
214995802|NCT06784024|DRUG|Lidocaine topical|Topical lidocaine (SPRAY SOLUTION 10 g) 10% will be applied to the cervix and cervical canal prior to the MVA procedure in a number of 20 sprays separated by 3 seconds between each spray (0.06 ml/spray).
214995803|NCT06784024|OTHER|Saline solution|Placebo (0.9% saline) will be applied topically to the cervix and cervical canal prior to the MVA procedure in a number of 20 sprays separated by 3 seconds between each spray (0.06 ml / spray).
214995804|NCT06161519|DRUG|PLX038|PLX038 is given intravenously (IV) at the assigned dose level over about 1 hour on day 1 of each 21-day cycle
214995805|NCT05048797|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan administered by intravenous infusion
214382270|NCT02232308|DRUG|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
214995806|NCT05048797|DRUG|Cisplatin|Investigator's choice of platinum chemotherapy (cisplatin) administered by intravenous infusion
214995807|NCT05048797|DRUG|Carboplatin|Investigator's choice of platinum chemotherapy (carboplatin) administered by intravenous infusion
214995808|NCT05048797|DRUG|Pembrolizumab|Pembrolizumab administered by intravenous infusion
214995809|NCT05048797|DRUG|Pemetrexed|Pemetrexed administered by intravenous infusion
214382271|NCT02232308|DRUG|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
214382272|NCT02232308|DRUG|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
215093021|NCT02706665|OTHER|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
215093022|NCT05578378|DRUG|Cladribine|Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.
214995810|NCT04385888|BEHAVIORAL|Low-calorie sweetener restriction|Participants will avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners for 12 weeks and will instead consume unsweetened alternatives, such as still or sparkling water
214382273|NCT01330602|BEHAVIORAL|IMPRESS intervention|"The key elements of the IMPRESS intervention include:~* Promoting a healthy lifestyle~* Supporting lifestyle and risk modification~* Encouraging active self-management of risk and chronic disease~* Improving coordination of care~* Pharmacological therapy"
214498548|NCT06772272|DRUG|Roxadustat|Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) used to treat anemia. Participants in the Roxadustat group will receive 100mg of Roxadustat orally three times per week for three weeks (two weeks prior to surgery and one week post-surgery). The dosage may be adjusted based on hemoglobin levels during the perioperative period: if hemoglobin rises above 150g/L, the drug will be stopped; if hemoglobin increases by more than 20g/L from baseline but is still below 130g/L, the dosage will be reduced to 70mg; if hemoglobin drops by more than 20g/L from baseline, the dosage will be increased to 120mg.
214498549|NCT06270251|BEHAVIORAL|CBIT|"8sessions of CBIT following a published treatment manual delivered over 10 weeks (the last two sessions are biweekly)~CBIT is a well-established behavioral treatment that is considered by the American Academy of Neurology to be the first-line intervention for tics."
214498550|NCT05854160|PROCEDURE|Electrical Pulse Train Stimulation|sEEG provides the ability to stimulate neural circuits via implanted electrodes by delivering mild intra-cranial electrical stimulations in different brain structures to estimate their impact on cognitive tasks.
214498551|NCT05881265|DRUG|Chidamide+venetoclax|Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
214995811|NCT06253520|DRUG|Aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
214995812|NCT06253520|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
214498552|NCT05908331|DEVICE|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
214498553|NCT05908331|DEVICE|Plan balloon Angioplasty (POBA)|Plan balloon used to open clogged or narrow coronary arteries due to underlying atherosclerosis
214382274|NCT04537468|OTHER|Skin squame collection|Subjects underwent skin squame collection by scraping. The investigator gently scraped the surface of a lesional skin area for patients with psoriasis, and of a non-lesional skin area for healthy volunteers to collect superficial cells. These samples were analyzed by gene expression analyses.
214995813|NCT06253520|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
214382275|NCT04537468|OTHER|Tape strip collection|The first subjects had up to 35 tape strips from a maximum of 4 areas (4 X 35 strippings) on the trunk or limbs (excluding the genital area). Patients with atopic dermatitis or psoriasis had tape stripping performed on lesional skin areas and the control subjects had tape stripping performed on nonlesional skin areas. The next subjects were used to determine the optimal number of tape strips required to obtain a good signal by gene expression analyses.
214498554|NCT03054831|DRUG|liquid oxycodone|"The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).~In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU)."
214498555|NCT05579730|DRUG|Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%|combination ophthalmic solution
214498556|NCT05579730|DRUG|Brimonidine Tartrate 0.025%|ophthalmic Solution
214498557|NCT05579730|DRUG|Ketotifen Fumarate 0.035%|ophthalmic Solution
214995814|NCT06253520|BIOLOGICAL|KRAS TCR-Transduced PBL|Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine).
214995815|NCT06253520|BIOLOGICAL|GRT-C903/GRT-R904|Day 0 (GRT-C903): Injection of 1.0 mL at each of 2 bilateral vaccine injections. Weeks 4, 8 and 12 (as applicable, GRT-R904): Injection of 0.25 mL of diluted GRT-R904 at each of 2 bilateral vaccine injections
214498558|NCT05579730|DRUG|Vehicle|ophthalmic Solution
214498559|NCT06239896|BEHAVIORAL|Facilitated Group ACP Session|Group Facilitators will adhere to the standardized scripts and protocols to engage participants in ACP through group sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
214995816|NCT05136677|BIOLOGICAL|Nivolumab|Specified dose on specified days
214995817|NCT05136677|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214995818|NCT05136677|DRUG|Pemetrexed|Specified dose on specified days
214995819|NCT05136677|DRUG|Cisplatin|Specified dose on specified days
214995820|NCT05136677|DRUG|Carboplatin|Specified dose on specified days
214995821|NCT02716441|DEVICE|Radio-opaque Tissue Markers|All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
214995822|NCT06229600|OTHER|Standard rehabilitation|Respiratory rehabilitation
214995823|NCT05162443|DRUG|adagrasib (MRTX849)|adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
214995824|NCT06299189|BEHAVIORAL|MinADHD|Guided self-help, 7 modules Interventions
214382276|NCT04537468|OTHER|Tape strip and skin biopsy collection|Subjects had tape stripping on up to 3 different skin areas (2 areas on lesional skin and one area of nonlesional skin for patients with atopic dermatitis or psoriasis, and 2 areas of healthy skin for control subjects) using the optimal number of tape strips, as determined in the previous part. One 4-mm skin biopsy on a tape stripped area plus one 4-mm biopsy on non-tape-stripped skin (2 biopsies per subject) were also collected.
214382277|NCT00385892|DEVICE|Abdominal binder|
214382278|NCT05721001|DEVICE|Surgical Repair|In Frozen Elephant Trunk procedure, the proximal aortic arch is replaced with a dacron graft, and a thoracic stent graft, sutured to the distal end of the dacron prosthesis, is deployed antegradely into the descending aorta. This mostly one-stage alternative approach eliminates the interval mortality rate related to the conventional elephant trunk procedure. Moreover, it constitutes a solution in fragile patients who cannot safely complete a second major operation after surviving the first.
214382279|NCT06606366|PROCEDURE|Blood sample taken for the liquid biopsy|36 mL will be taken for the study.
214382280|NCT03387202|PROCEDURE|Laparoscopic lateral suspension with mesh|V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level
214382281|NCT03387202|DIAGNOSTIC_TEST|Transperineal ultrasound|Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.
214382282|NCT05473000|BEHAVIORAL|Exercise|Submaximal and maximal exercise
214382283|NCT05473000|OTHER|Ozone|Delivery of ozone air pollution at 170ppb
214382284|NCT05473000|OTHER|Room air|Delivery of room air
214382285|NCT06667505|BEHAVIORAL|Choice-ICD|The eHealth intervention theoretically driven, interactive and provides personalised information to patients and family members when and where they wish to access it. Five short (2-3 minutes) videos, involving patients, caregivers and professionals, are uploaded onto the APP, alongside animation clips and useful links to online resources. A discussion forum will be accessible for participants using the APP, which will be closely moderated by the researcher, who will ensure any concerning posts or dialogue are promptly removed, and the necessary action is taken. The diary function will allow patients to record and be reminded of future appointments. Patients and family members will engage with the intervention for 3 months.
214382286|NCT06613529|OTHER|online mindfulness training|"Use publicly available online mindfulness training resources. The training content was to guide patients to practice mindfulness techniques, including where the body is, the mind is and relaxation learning."
214382287|NCT06625008|OTHER|3D-printed model|The Department of Radiology at Vanderbilt University Medical Center will create a 3D-printed human torso model that includes the colon, rectum, and a stoma on the abdominal wall. This model will be used to provide pre-operative counseling during the surgical consent for patients.
214382288|NCT06626113|DRUG|ascorbic acid|ascorbic acid
214498560|NCT06239896|BEHAVIORAL|Facilitated one-on-one ACP visits|Facilitator adheres to the scripts and protocols to engage participants in advance care planning through one-on-one ACP sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook that they can use to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
214498561|NCT05439850|PROCEDURE|arthroscopic rotator cuff repair|This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
214498562|NCT05439850|BIOLOGICAL|Bioinductive implant|A bioinductive implant that is designed to promote healing of the torn rotator cuff tendon after surgery.
214498563|NCT05439850|DIAGNOSTIC_TEST|Ultrasound Imaging|An ultrasound will be performed on each patient one year postoperatively.
214687446|NCT06929819|RADIATION|Intraoperative Radiation Therapy in Malignant Cerebral Tumor|This technique can fully expose the tumor bed during the operation, and pull the brain tissue around the tumor under the microscope to de-radiation, so as to exceed the total dose level of standard conformal conventional external radiation therapy (EBRT), maximize the radiobiological effect of a single high-dose irradiation, and deliver precise radiation to the tumor bed, while minimizing the radiation dose of peripheral nerve tissue. This technique is also a good choice for patients with orthotopic recurrent tumors who can no longer tolerate one more EBRT. Intraoperative radiotherapy technology can reduce the chance of postoperative tumor recurrence and improve the survival and prognosis of patients by providing a higher effective total dose to the tumor bed, while promoting dose escalation without significantly increasing the occurrence of complications in normal tissues, and improving the local control rate.
214995825|NCT06797245|DEVICE|RiSolve App|Participants randomized to intervention will be given access to the RiSolve PDTx app for 10 weeks after initial activation.
214995826|NCT06797245|BEHAVIORAL|AUGS Patient Handouts|"AUGS Overactive Bladder and Pelvic Floor Muscles and Bladder Training Patient Fact Sheets will be provided and reviewed."
214995827|NCT05431101|PROCEDURE|Carpal Tunnel Release|Transection of flexor retinaculum for patients who have carpal tunnel syndrome
214995828|NCT06332534|DRUG|Upadacitinib|Oral Solution/ Extended-Release Tablets
214995829|NCT05756543|BEHAVIORAL|Counterfactual Inference Test|All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
214995830|NCT06104917|DRUG|High Dose Maolactin|Once daily dose of 2 capsules (2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day)
214382289|NCT06624553|DEVICE|FreeStyle Libre 2, flash glucose monitoring|"Currently, at the Hospital de la Santa Creu i Sant Pau, when starting monitoring in people with DM2, capillary glycemia monitoring is used, following the therapeutic education protocols in basal insulinization in the debut of DM2 and in optimization of treatment, protocols that are also applied to similar cases.~The intervention group (FreeStyle Libre 2) will be provided with the necessary material to carry out the monitoring via a glucose sensor. Satisfaction with treatment will be assessed at the final study visit."
214382290|NCT05304598|DRUG|Dexmedetomidine|a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes
214382291|NCT05304598|OTHER|Usual Care|routine awake intubation as per current unit standard of care,
214382292|NCT06687265|DRUG|Metformin|one pill of 500 mg per os twice a day for 28 days.
214382293|NCT06687265|DRUG|Placebo|one pill per os twice a day for 28 days.
214687447|NCT06929234|OTHER|Peer-Supported Health Education|Peer-supported health education will be provided to paticipants in 1 session for an average of 60 minutes in a suitable classroom. In this session, health education will be provided by the researchers and the peer will support the health education. The peer will share her experiences about each part of the training content with the target group in line with the guidance of the researchers, answer questions and make a motivational speech for screening.
214995831|NCT06104917|DRUG|Low Dose Maolactin|Once daily dose of 2 capsules (1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day)
214995832|NCT06104917|DRUG|Maltodextrin|Once daily dose of 2 capsules
214995833|NCT03841513|PROCEDURE|Laparoscopic Burch Colposuspension|The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
214995834|NCT06847100|DIAGNOSTIC_TEST|Blood withdrawal|Optional collection of 5 mL of blood to assess the contribution of 16 gene polymorphisms AF-associated
214995835|NCT04912869|DRUG|Crovalimab|Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).
214995836|NCT04912869|DRUG|Placebo|Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
214382294|NCT04454398|BIOLOGICAL|COVI-GUARD|COVI-GUARD (STI-1499) is a monoclonal antibody which targets the COVID-19 spike protein
214382295|NCT04454398|OTHER|Standard of Care|Standard of Care as determined by the Investigator
214382296|NCT04454398|DRUG|Placebo|Diluent
214382297|NCT06926517|OTHER|life and death courses|Life and death issues in the post-epidemic era - Curriculum planning that integrates life and death care, reflective learning and teaching practice on the new coronavirus pneumonia issue, introducing 18-week theme courses, each course is 100 minutes
214382298|NCT06901076|DIETARY_SUPPLEMENT|Nisatol|Nisatol® (developed by PharmExtracta) containing Nigella sativa seeds oil and Vitamin E, 1 capsule soft gel after breakfast and 1 capsule soft gel after dinner for 6 months
214382299|NCT06901076|OTHER|Placebo|Placebo
214382300|NCT06917235|PROCEDURE|Wrist and carpal arthrodesis|All patients that fit the inclusion criteria and accept the arthrodesis surgery will be followed up over the course of 1 year. The wrist and carpal arthrodesis procedures will include radioscapholunate, scaphoid-trapezium-trapezoid (STT), and four-corner arthrodeses.
214382301|NCT02055703|DRUG|E2609|
214382302|NCT02055703|DRUG|itraconazole|
214382303|NCT02055703|DRUG|rifampin|
214382304|NCT02055703|DRUG|digoxin|
214382305|NCT02055703|DRUG|donepezil|
214382306|NCT01178437|DEVICE|T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)|daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months
214382307|NCT04472780|DEVICE|Hyperbaric oxygen Therapy HBOT|HBOT therapy protocol: in an eight-seat hyperbaric chamber 40 sessions of HBOT duration: 1 hour rhythm: 5 sessions / week pressure: 1.7 ATA (7 meters) O2 concentration: 100%
214382308|NCT02818660|DRUG|Synachten|To stimulate the adrenals to increase the cortisol Production as much as possible
214382309|NCT01265030|DRUG|Sirolimus|"* Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~* Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"
214382310|NCT02243631|DRUG|Probenecid|Treatment
214382311|NCT04878419|OTHER|Virtual Educational Program|Multiple virtual interactive sessions to provide education/knowledge about Type 1 Diabetes Mellitus care
214382312|NCT03117517|DRUG|Metformin|Metformin (1000 mg)
214382313|NCT03117517|DRUG|Metformin, Pioglitazone|Metformin (1000 mg) Pioglitazone (30 mg)
214382314|NCT02110446|DRUG|SS-1|"The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.~SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day."
214382315|NCT02110446|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
214382316|NCT02765555|DRUG|RBP-7000|Single dose
214382317|NCT01992549|BIOLOGICAL|Human-cl rhFVIII|
214382318|NCT03717675|DEVICE|NovaCross™ Chronic Total Occlusion micro-catheter|The NovaCross™ micro catheter is a guidewire positioning and support micro catheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment. Investigators will use the NovaCross Micro catheter during a standard of care catheterization of patients diagnosed with coronary total occlusion.
214995837|NCT04474002|DRUG|4L Klean Prep®|Patients allocated to the control group shall mix two sachets of PEG in 2L water. At 6pm the evening before examination, they shall consume 250ml solution every 15mins, and finish in 2hours. At 7am the day of examination, drink another 2L Klean-prep in 2 hours.
214382319|NCT05834582|DRUG|Fluzoparib+Paclitaxel|Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy
214382320|NCT05834582|DRUG|Epirubicin+Cyclophosphamide|Epirubicin+Cyclophosphamide
214382321|NCT04198740|DIAGNOSTIC_TEST|Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry|During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.
214498564|NCT06763094|DRUG|Calcium dobesilate (Doxium)|This intervention is unique because Calcium Dobesilate is not a hormonal agent and does not carry the risks associated with hormonal therapies, such as potential impact on fertility or long-term endocrine effects. Additionally, it may be more suitable for patients who cannot tolerate hormonal treatments due to contraindications such as previous thrombotic events or risk factors for thrombosis.
214498565|NCT06763094|DRUG|Tranexamic Acid|Tranexamic Acid stands out due to its non-hormonal action in managing menorrhagia, providing an alternative for women who are contraindicated for hormonal treatments or prefer non-hormonal solutions. Unlike other hormonal treatments, Tranexamic Acid does not impact fertility or have significant endocrine effects.
214498566|NCT06829134|PROCEDURE|laparoscopic renal artery perivascular nerve blockade|"1. When only the main renal artery is present: The complete dissection of the renal artery should be performed in the distal 2/3 portion, close to the renal hilum. The connective tissue and nerve tissue within a 1 cm radius from the center of the renal artery lumen must be completely separated (using instruments such as an ultrasonic scalpel or monopolar hook, etc.). The length of the dissected renal artery should be at least 0.5 cm, forming a dissection ring.~2. When accessory renal arteries are present: In addition to the main renal artery meeting the aforementioned standards, the accessory renal arteries must also be dissected. The radius of the dissection ring should be 0.7 cm, with a length ranging from 0.3 to 0.5 cm.~3. When renal polar arteries are present: Dissection may be performed appropriately based on the surgical conditions.~4. The prerequisite is to ensure the safety of the surgery, specifically the safe resection of the primary lesion."
214498567|NCT06829134|PROCEDURE|surgery related to the primary disease|The surgeries related to the primary disease include laparoscopic partial nephrectomy, laparoscopic adrenalectomy, and other similar procedures.
214498568|NCT06758700|DRUG|Teniposide administration|Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 5 consecutive days, with 21 days as one cycle of treatment.
214687448|NCT06929234|OTHER|Basic Health Education|What is cervical cancer, what is the importance of cervical cancer, what are the risk factors for cervical cancer, what are the symptoms of cervical cancer, how to screen for cervical cancer, where to get cervical cancer screenings. Participants will be given health education with a power point presentation in a suitable classroom for an average of 45-50 minutes in 1 session.
214995838|NCT04474002|DRUG|1L Klean prep® and 2 sachets Picoprep®|Patients allocated to the study group shall mix each sachet of Picoprep® in 150ml warm water. The patient shall take the 1st dose at 4pm the day before procedure followed by at least five 250ml drinks of clear fluid before the next dose. The 2nd dose shall be taken approximately 6hrs later and followed by at least three 250ml drinks of clear fluid before bed. On 7am the day of procedure, they shall take 1L PEG in 1 hour.
214382322|NCT04855110|DRUG|Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)|Warfarin started on day 2 after caesarean section in patients with mechanical heart valve prosthesis
214382323|NCT04855110|DRUG|Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)|Warfarin started on day 5 after caesarean section in patients with mechanical heart valve prosthesis
214382324|NCT02948348|DRUG|Nivolumab|Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
214382325|NCT02948348|DRUG|Ipilimumab|For only Cohort D,1 mg/kg at six-week intervals
214498569|NCT05829824|BEHAVIORAL|CareConnect|A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)
214498570|NCT05829824|OTHER|AutoReach|Phone call / SMS Text
214498571|NCT05829824|PROCEDURE|Biospecimen samples|Optional saliva sample
214498572|NCT06320041|DRUG|Low dose oxelidine group|Analgesic dose
214498573|NCT06320041|DRUG|High dose oxelidine group|Analgesic dose
215094736|NCT04369625|BEHAVIORAL|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
215094737|NCT00794066|PROCEDURE|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
215094738|NCT03299283|DIAGNOSTIC_TEST|BioFire test platform|Analysis of analyte stability under various conditions as measured by BioFire test platforms
215094739|NCT05088668|OTHER|Augmented reality|"The subjects will perform scapular repositioning exercise using glasses of augmented reality to see their scapular movement simultaneously. Furthermore, they will also see at the same time a video record of an ideal scapular movement, and will me encouraged to simulate that ideal scapular movement."
214498574|NCT06320041|DRUG|Hydromorphone group|Analgesic dose
214498575|NCT05124041|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
214995839|NCT06420908|DRUG|Adebrelimab+TP/FP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage:~TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
214382326|NCT01590771|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
214382327|NCT01590771|DRUG|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
214382328|NCT01590771|DRUG|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
214382329|NCT01590771|DRUG|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
214382330|NCT01590771|DRUG|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
214382331|NCT06421909|BEHAVIORAL|mindfulness-based educational intervention|Mindfulness-based educational intervention is a structured program that incorporates principles of mindfulness to help individuals develop greater awareness and acceptance of their thoughts, feelings, and bodily sensations. The intervention typically includes mindfulness meditation practices, cognitive-behavioral techniques, and educational components about stress management and emotional regulation. By fostering a non-judgmental and present-focused attitude, participants learn to manage their symptoms more effectively and improve their overall quality of life.
214382332|NCT01705275|DRUG|ONO-8539|ONO-8539
214382333|NCT01705275|OTHER|Placebo|Identical to ONO-8539 tablet but without active ingedient
214382334|NCT03765463|BEHAVIORAL|Habit Reversal Training|4 sessions of habit reversal training
214382335|NCT04358341|DRUG|Irinotecan|150 mg/m2 ivdrip every 14 days
214382336|NCT04358341|DRUG|DOXOrubicin Liposome Injection|25 mg/m2 ivdrip every 14 days
214382337|NCT04358341|DRUG|5fluorouracil|400mg/m2 iv bolus and 2400 mg/m2 civ 46h every 14 days
214382338|NCT04166929|BIOLOGICAL|Haplo SCT with NK cells|Patients in this arm receive haplo-SCT followed by one boost of NK cells one/two weeks after the transplant. Lymphocyte are collected by apheresis from the donor one-two weeks after BM harvest. CD3 negative/CD56 positive cells are selected by immunomagnetic columns (other lymphocytes are stored to be used as DLI)
214382339|NCT04166929|BIOLOGICAL|Haplo SCT|Patients in this arm receive a standard haplo-SCT. All administerd therapies are the same as in other arm, except for the NK cell boost..
214382340|NCT03220945|OTHER|Yoga|Receive yoga instruction
214382341|NCT01785628|DIETARY_SUPPLEMENT|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
214382342|NCT01785628|DIETARY_SUPPLEMENT|Placebo Capsule|Placebo is dextrin composition.
214382343|NCT03880318|PROCEDURE|Joint Preserving Surgery in spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies
214382344|NCT04255082|OTHER|assess the impact of mindfulness-based interventions on inpatients' and outpatients' stress, patient-provider communication, and other measures of SDM at MDMC.|"Effectiveness of the mindfulness-based intervention which will be assessed by:~Baseline and post-intervention perception of stress and anxiety Impact of stress on communication Emotional/Brain state Level of SDM during a pivotal visit with provider e.g. treatment planning visit (for outpatients only) The Emotional Distress-Anxiety (PROMIS, 2016), Communication Short Form (Cella, PROMIS, 2013), Emotional/Brain State Question (Mellin, 2017) and The Shared Decision Making dyadic OPTION scale (Melbourne, 2016) will be used to evaluate these outcomes.~Feasibility of such a study in the patient population and setting. This will be measured by the barriers encountered and the ability to successfully carry out the study."
214382345|NCT00840996|DRUG|Lidocaine|perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
214382346|NCT00840996|DRUG|placebo|perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
214382347|NCT00321334|PROCEDURE|Chemotherapy+Surgery|Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles
214382348|NCT01364402|DRUG|Epoetin beta|50,000U intravenously
214382349|NCT01364402|DRUG|Saline 0.9%|normal saline intravenously
214382350|NCT04674774|DRUG|Tegoprazan|oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days
214382351|NCT04674774|DRUG|Lansoprazole|oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day
215094740|NCT05088668|OTHER|Scapular repositioning exercise|Subjects will perform scapular repositioning exercises for improving scapular movement.
215094741|NCT01667874|DRUG|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
214382352|NCT01900054|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
214382353|NCT01934699|DEVICE|Cardiac ultrasound|Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.
214382354|NCT01934699|DEVICE|MRI scanner|Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
214382355|NCT05936203|OTHER|Insulin therapy adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
214382356|NCT05936203|OTHER|Nutritional adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
214382357|NCT05936203|OTHER|Combination of strategies|Strategies used to manage glucose control during a prolonged aerobic exercise
214995840|NCT06420908|DRUG|Adebrelimab+FP/TP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage: (switch to a different chemotherapy drug which not used during the earlier induction phase)~FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
214382358|NCT06039228|BEHAVIORAL|Acceptance and commitment therapy|Four sessions of group acceptance and commitment therapy, with each session lasting for 1.5 hours.
214382359|NCT05601921|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders. In recent years, TMS studies have been conducted in many painful conditions, which are thought to have complex pain mechanisms in the pathogenesis, and its effectiveness has been reported.
214382360|NCT05601921|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
214382361|NCT05027737|PROCEDURE|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
214382362|NCT03648125|DEVICE|with artificial occlusal disturbance|"A silicon artificial occlusal disturbance is made from a mould of the rowers mouth and placed in the mouth during the training session.~With artificial occlusal disturbance : Maximal Intercuspal Occlusion (MIO) with silicone splint increases the vertical dimension of occlusion of 1, 2 and 4 mm."
214498576|NCT04108351|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
214498577|NCT04108351|OTHER|Car-following test|Intervention Description: Driving with simulator program for DCV measurement
214498578|NCT04108351|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
214498579|NCT06531018|DRUG|Eltrombopag 25 MG|Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
214995841|NCT05374460|BEHAVIORAL|Explanatory diagram|Participant is told there will be a mismatch between their target finger and the visual indicator of target finger position. They will be shown a diagram explaining this.
214995842|NCT05374460|BEHAVIORAL|Direct vision|Foamboard under mirror removed, making the mirror see-through and the hand directly visible. Mismatch between target hand and visual indicator will be directly visible.
214382363|NCT03648125|DEVICE|without artificial occlusal disturbance|The training session is performed without occlusal disturbance
214382364|NCT01108835|OTHER|Comprehensive care programme|"Intervention group:~* Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions~* Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)~* Respiratory physician assessment and optimization of treatment~* Patients will also be taught about a personalized action plan by the physician and respiratory nurse.~* Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries."
214382365|NCT01858480|DRUG|D-ribose|D-ribose powder for oral solution and D-ribose for injection.
214382366|NCT01858480|OTHER|Placebo|Placebo dosage form designed to mock active.
214382367|NCT00638196|DRUG|Linoleic Acid/Oleic Acid|Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
214498580|NCT06531018|DRUG|Prednisolone|Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
214498581|NCT06382818|RADIATION|COHORT A|"IMRT radiotherapy on whole breast according to the investigator's decision among:~* Moderate whole breast hypofractionated RT according to the START B schema with Fixed Field IMRT Technique: 40.05 Gy in 15 daily fractions over 3 weeks and a Sequential boost (+ 16 Gy/8 fr) or (+13.5/5 fr) if applicable.~* Extreme whole breast hypofractionated RT according to :~  * The FAST schema: Once-a-week ultra-HypoRT with Fixed Field IMRT Technique, 28.5 Gy in 5 fractions in 5 weeks~ * The FAST-Forward schema: Very accelerated course of HypoRT with Fixed Field IMRT Technique, 26 Gy in 5 fractions in 5 consecutive days"
214995843|NCT05374460|BEHAVIORAL|Movement feedback, target hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will be displaced.
214498582|NCT06382818|RADIATION|COHORT B|"Breast radiotherapy according to the investigator's decision among:~* External partial VMAT: 40 Gy in 15 fractions to the partial breast only (tumorectomy bed).~* Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days.~* Whole Breast Normo fractionated IMRT with Fixed Field IMRT Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (60 Gy/25 fr) treatment for boost if applicable."
214498583|NCT06382818|RADIATION|COHORT C|"Whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol:~VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions)."
214382368|NCT03285295|DEVICE|Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay|For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
214382369|NCT03285295|DEVICE|Alinity s HTLV I/II Assay|For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
214382370|NCT03285295|DEVICE|Alinity s Anti-HCV Assay|For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
214382371|NCT03285295|DEVICE|Alinity s HIV Ag/Ab Combo Assay|For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
214382372|NCT03285295|DEVICE|Alinity s Anti-HBc Assay|For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
214382373|NCT03285295|DEVICE|Alinity s Chagas Assay|For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
214382374|NCT02424409|BEHAVIORAL|2: Intervention|"1. The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.~   A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter~2. A written action plan with formalized recommendations for the patient~3. A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.~   The ED doctor at discharge will explain all these documents orally~4. Recommendations for an early contact with the general practitioner;~5. Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner."
214382375|NCT02424409|BEHAVIORAL|1: Control|patients without discharge protocol
214995844|NCT05374460|BEHAVIORAL|Movement feedback, pointing hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will not change, but the cursor indicating pointing hand position will change.
215093023|NCT05578378|DRUG|Fludarabine|"Control arm~Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen"
214382376|NCT02479516|BEHAVIORAL|Community Health Assessment Program Philippines (CHAP-P)|
214382377|NCT00517465|DRUG|Placebo|po bid
214498584|NCT06382818|RADIATION|COHORT D|"Breast radiotherapy based on available clinical trials:~\- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered."
214498585|NCT06825312|BIOLOGICAL|Japanese Encephalitis Vaccine (Vero Cell), Inactivated|0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology Co., Ltd., administered in the deltoid area of lateral arm by intramuscular injection.
214498586|NCT06825312|BIOLOGICAL|Japanese Encephalitis Vaccine, Live|0.5ml for each dose, manufactured by Chengdu Institute of Biological Products Co., Ltd., administered subcutaneously in the lower part of the deltoid area of lateral arm.
214687449|NCT07077746|DRUG|HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells|Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells). Dose: 200 million cells (+/- 20%) suspended in 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: HB-adMSCs syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).
214995845|NCT05374460|BEHAVIORAL|No movement feedback|The visual indicator of the target hand will be displaced, but there will be no cursor to indicate the pointing hand's position.
214995846|NCT05374460|BEHAVIORAL|Attend to the targets|Participants will not be told anything about the visuo-proprioceptive mismatch. Instead, they will be asked simply to attend to the target positions.
215093024|NCT01055678|DRUG|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
215093025|NCT01055678|PROCEDURE|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
215093026|NCT06160830|DIETARY_SUPPLEMENT|synbiotic|Two capsules of synbiotic per day, each containing 500 mg of synbiotic
214498587|NCT03044158|DEVICE|GeneXpert I|Onsite molecular testing with GeneXpert I as a replacement for microscopy
215093027|NCT06160830|OTHER|placebo|Two capsules of placebo containing maltodextrin per day
214382378|NCT00517465|DRUG|RG1511|Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
214382379|NCT03804515|DRUG|14C-labeled poziotinib|a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally
214382380|NCT02047565|DRUG|60mg edoxaban|
214382381|NCT02047565|DRUG|180mg edoxaban|
214382382|NCT02047565|DRUG|50 IU/kg Beriplex P/N|
214382383|NCT02047565|DRUG|25 IU/kg Beriplex P/N|
214382384|NCT02047565|DRUG|10 IU/kg Beriplex P/N|
214382385|NCT02128165|DEVICE|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
214382386|NCT02128165|DEVICE|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI below 45
214382387|NCT02382237|DEVICE|PET/TDM|Evaluation of nutrition absorption by TEP/TDM
214382388|NCT02746575|DRUG|metoprolol|
214382389|NCT02839122|DRUG|Tadalafil|
214382390|NCT02839122|DRUG|Dutasteride|
214382391|NCT04691713|DRUG|Targeting CD276 autologous chimeric antigen receptor T cells|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
214382392|NCT04910815|DEVICE|Atmo Gas Capsule|The Atmo gas capsule is an ingestible electronic device. This capsule consists of gas and temperature sensors, electronic circuits, radio transmitter and silver oxide batteries. It can measure the concentrations and types of intestinal gases in individuals and give an indication of gut transit time. This data is used for research purposes to gain an understanding of the microbiota's localised functionality. The data from the sensors is transmitted out of the body over the radio frequency to a handheld receiver. The capsule passes out of the human body at the end of the measurement and is disposable.
214382393|NCT04910815|DIAGNOSTIC_TEST|Glucose Breath Test|Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
214382394|NCT04910815|DIAGNOSTIC_TEST|Fructoolifosaccharides (FOS) Breath Test|FOS is a long chain carbohydrate that can only be broken down by bacteria with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
214382395|NCT04910815|PROCEDURE|Jejunal Aspiration and culture|Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases
215093028|NCT03177096|BEHAVIORAL|Peds QL questionnaire and diabetes modulate|Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
215093029|NCT03177096|BEHAVIORAL|WHO-5 questionnaire|WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
215093030|NCT03177096|BEHAVIORAL|Felt questionnaire|Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
214382396|NCT04910815|DRUG|Rifaximin|Rifaximin (550g) 1 capsule twice a day for 14 days.
214382397|NCT04910815|DRUG|Placebo|randomised administration of either placebo or Rifaximin (550g) 1 capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch
214382398|NCT01938105|OTHER|Nimotuzumab+chemoradiotherapy|"Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.~\--------------------------------------------------------------------------------"
214382399|NCT00561444|BEHAVIORAL|Questionnaire|Questionnaires taking 20 minutes to complete.
214382400|NCT03966079|DRUG|recombinant tissue plasminogen activator|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
214382401|NCT05551481|PROCEDURE|To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 2 years.|resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)
214382402|NCT04655079|DEVICE|Anodal transcranial direct current stimulation (a-tDCS)|tDCS is delivered by a battery-driven constant current stimulator thought a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the left dlPFC (F3) according to the 10 to 20 international electroencephalogram coordinates) and the cathode is placed over the right deltoid muscle. During real stimulation a constant current of 2mA (milli Ampere) is applied for 20 minutes.
214382403|NCT04655079|DEVICE|Sham Condition|For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation.
214382404|NCT00004585|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
214382405|NCT00004585|DRUG|Lamivudine/Zidovudine|
214382406|NCT00004585|DRUG|Abacavir sulfate|
214382407|NCT00004585|DRUG|Efavirenz|
214382408|NCT00957931|PROCEDURE|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
214382409|NCT00957931|BIOLOGICAL|Mesenchymal Stromal Cells|
214498588|NCT03044158|BEHAVIORAL|Process re-design|Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
214382410|NCT02682212|OTHER|Physiotherapy intervention|Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
214382411|NCT04178538|PROCEDURE|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique
214382412|NCT04178538|PROCEDURE|Standard ACL reconstruction with all inside technique|Standard ACL reconstruction with all inside technique
214382413|NCT05488938|OTHER|Rehabilitative Intervention|Each program will require the daily performance of different postures and therapeutic activities at the girls' educational facilities and homes, based on the availability of families, for 10 months. Specific strategies that will be implemented will include maintaining asymmetrical postures that oppose the scoliosis curve during activities and exercises in sitting, standing, and walking positions (according to each participant's functional abilities). These strategies refer to a hypercorrective postural positioning of scoliosis. In addition, activities involving weight bearing on the lower limbs, such as walking and standing for at least two hours a day, will be encouraged, and passive stretching and spinal mobilization exercises will be conducted.
214382414|NCT02409550|OTHER|CARATKids Questionnaire|
214498589|NCT03044158|OTHER|Performance Feedback|Feedback of TB diagnostic evaluation quality indicators to health center staff
214498590|NCT06742905|DIAGNOSTIC_TEST|Robot-guided echo|This echo will be performed by a remote sonographer, though a robot
214382415|NCT00857805|PROCEDURE|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
214382416|NCT00857805|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
214382417|NCT02372123|OTHER|lifestyle advice|Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
214498591|NCT06742905|DIAGNOSTIC_TEST|Standard echocardiogram|Echocardiogram acquired by a sonographer at the patient's bedside
214498592|NCT05127161|BEHAVIORAL|Broad Implementation of Outpatient Stewardship (BIOS) intervention|The BIOS intervention consists of 3 components: (1) online educational modules covering topics related to appropriate antibiotic prescribing for ARTIs, (2) individualized audit and feedback reports displaying clinicians' rates of antibiotic prescription with peer comparison, (3) facilitation provided by the study team and by health system champions to support effective implementation of the intervention and to encourage clinicians to engage meaningfully in the intervention activities.
214498593|NCT06839898|DEVICE|EYECRYLTM Phakic Toric Intraocular Lens Treatment Arm|The patients will be implanted with Eyecryl Phakic IOL at this arm based on randomization.Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.
214498594|NCT06839898|DEVICE|Visian® Toric ICL Treatment Arm|The patients will be implanted with Visian® Toric Implantable Contact Lens at this arm based on randomization. Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.
214498595|NCT06761053|DIAGNOSTIC_TEST|Intervention/Exposure for the GDM Group (Experimental Arm)|"Gestational Diabetes Diagnosis: The intervention for this group involves the diagnostic procedure of the 100-gram oral glucose tolerance test (OGTT) after an initial glucose challenge test (GCT) with a result equal to or greater than 140 mg/dL. The test assesses fasting plasma glucose and post-glucose consumption plasma glucose levels at 1 hour and 2 hours, which is used to diagnose GDM.~Biomarker Analysis: The albumin to high-sensitivity C-reactive protein (hsCRP) ratio is measured as a biomarker to explore its potential role in GDM diagnosis and related pregnancy outcomes."
214498596|NCT06761053|DIAGNOSTIC_TEST|Intervention/Exposure for the Control Group|"Glucose Challenge Test (GCT): The control group participants are exposed to the glucose challenge test (GCT), where plasma glucose levels are measured one hour after the consumption of 50 grams of glucose. If their glucose levels are below 140 mg/dL, they are categorized as not having GDM.~Biomarker Analysis: Similar to the GDM group, the albumin to hsCRP ratio is measured for participants in the control group to compare the biomarker levels between those with and without GDM."
214498597|NCT05426785|DEVICE|1:1 ratio for Treatment Group and Control Group|Randomization also will be performed at latest 10 days after ICD implantation, and the specified device programming settings for the allocated group will be set after successful implantation of the investigational devices.
214498598|NCT06829121|DIAGNOSTIC_TEST|Ultrasound|The thickness of the psoas muscle and the musculus quadriceps femoris will be measured by ultrasound
214498599|NCT00667121|DRUG|citalopram hydrobromide|
214498600|NCT00667121|DRUG|escitalopram oxalate|
214498601|NCT00667121|DRUG|gabapentin|
214498602|NCT00667121|DRUG|sertraline hydrochloride|
214498603|NCT00667121|DRUG|tamoxifen citrate|
214498604|NCT00667121|DRUG|venlafaxine|
214687450|NCT07077746|DRUG|0.9% sodium chloride|0.9% sodium chloride Dose: N/A - 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: Placebo syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).
214687451|NCT05590637|DRUG|Pimavanserin|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
214687452|NCT05590637|DRUG|Quetiapine|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
214995847|NCT06165016|DEVICE|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
214995848|NCT06165016|DEVICE|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
215093031|NCT02297165|BEHAVIORAL|olfactory stimulation program|"8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one at the beginning of the trial, the second 5 weeks later and the third at 6 month).~For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor."
214382418|NCT02372123|OTHER|connective tissue manipulation|Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
214382419|NCT01712555|PROCEDURE|autologous fat grafting with PRP to anophthalmic orbits|
214382420|NCT00659594|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
214382421|NCT00659594|DRUG|Placebo|placebo
214382422|NCT06319768|DRUG|Pentoxifylline|Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection
214382423|NCT06319768|DRUG|platelet rich plasma|Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP
214382424|NCT06319768|DRUG|combined pentoxifylline and platelet rich plasma|Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes
214382425|NCT04867785|DRUG|LY3437943|Administered SC
214382426|NCT04867785|DRUG|Dulaglutide|Administered SC
214382427|NCT04867785|DRUG|Placebo|Administered SC
214382428|NCT01289041|DRUG|BKM120|
214382429|NCT00208585|DRUG|sertraline|
214382430|NCT04162990|BEHAVIORAL|Lifestyle remodeling Intervention|Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.
214382431|NCT04162990|BEHAVIORAL|Does Comparator: regular treatment|Participants in this group would be treated as usual, which contained the healthy education.
214382432|NCT01751815|PROCEDURE|Acu-TENS|Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
214382433|NCT01751815|PROCEDURE|Placebo-TENS|Patients randomized to the control group will receive placebo-TENS at the same acupoints.
214382434|NCT01110083|DRUG|EMD 1204831|Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
214382435|NCT01403441|DEVICE|Radiosurgical Neuromodulation using the Cyberknife|our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
214382436|NCT03926065|OTHER|Plain Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables
214382437|NCT03926065|OTHER|Plain Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables
214382438|NCT03926065|OTHER|Enhanced Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables
214382439|NCT03926065|OTHER|Enhanced Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
214498605|NCT00667121|GENETIC|molecular genetic technique|
214498606|NCT00667121|OTHER|high performance liquid chromatography|
214498607|NCT00667121|OTHER|laboratory biomarker analysis|
214498608|NCT00667121|OTHER|pharmacological study|
214687453|NCT03663530|BEHAVIORAL|Meal times|Meal times vary based on the arm: aligned or misaligned
214498609|NCT00667121|PROCEDURE|adjuvant therapy|
214498610|NCT03391921|BIOLOGICAL|Vaccine|All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.
214382440|NCT04661475|DRUG|Dexmedetomidine Injection [Precedex]|ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.
214382441|NCT04661475|DRUG|Normal saline|while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
214382442|NCT03833128|DRUG|Low Dose REN001|Oral
214382443|NCT03833128|DRUG|High Dose REN001|Oral
214382444|NCT01914809|OTHER|samples blood|
214382445|NCT01914809|OTHER|biopsy placentaire|
214382446|NCT03833180|DRUG|Zilovertamab vedotin|Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
214382447|NCT02300337|DEVICE|Reduce Cuff pressure|We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
214382448|NCT02393521|DEVICE|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
214382449|NCT03394456|OTHER|diabetes program|Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)
214382450|NCT03394456|OTHER|telehealth training and support for Community Health Workers|weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
214382451|NCT01293019|PROCEDURE|Osteopathic treatment|Real treatment of osteopathy
214382452|NCT01293019|PROCEDURE|Sham Placebo|Sham treatment of osteopathy
214498611|NCT06826521|PROCEDURE|Single construct versus dual constructs will give satisfactory radiological and functional outcomes|Single construct like cephalomedullary nail or long DHS in fixation of both neck and shaft fractures, dual constructs like DHS or cannulated screws and retrograde nail or DHS or cannulated screws and dymanic compression plate in fixation of both fractures.
214498612|NCT03268421|BEHAVIORAL|Fibromyalgia Integrative Training for Teens|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
214382453|NCT01293019|PROCEDURE|Usual care|Classical treatment of pain in cystic fibrosis patients
214382454|NCT03239873|BIOLOGICAL|VARIVAX® PE34 Process|Varicella virus vaccine live manufactured with a new passage extension process (PE34)
214382455|NCT03239873|BIOLOGICAL|VARIVAX® 2016 Commercial Process|Varicella virus vaccine live manufactured with the 2016 commercial process
214687454|NCT06241222|DRUG|Probiotic Blend Oral Tablet|In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
214687455|NCT06910943|DRUG|Choline Chloride for Injection|Intravenous use
215093032|NCT04093804|DEVICE|Glenosphere size for Reverse Shoulder Arthroplasty|Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
215093033|NCT02904655|OTHER|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
214382456|NCT03239873|BIOLOGICAL|M-M-R II®|Measles, Mumps, and Rubella virus vaccine live
214382457|NCT02446925|DEVICE|Surefire® Infusion System|Utilization of Surefire® Infusion System for Y-90 glass microsphere embolization
214382458|NCT02446925|DEVICE|Standard End-hole catheter|Utilization of Standard End-hole catheter for Y-90 glass microsphere embolization
214687456|NCT06910943|DRUG|Placebo|Water for injection
214687457|NCT07092228|DEVICE|virtual reality and plyometric workout|to evaluate exercise capacity in teenage females with abdominal obesity using virtual reality and plyometric workouts
214687458|NCT06943495|DRUG|177Lu-PSMA-617|6 cycles of personalized activity (1st cycle based on BSA and eGFR; cycles 2-6 based on renal dosimetry), maximum 22.2 GBq, every 6 weeks
214687459|NCT06943495|DRUG|177Lu-PSMA-617|6 cycles of 7.4 GBq every 6 weeks
214382459|NCT03996408|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
214382460|NCT03996408|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214382461|NCT02040987|DRUG|AZD3293|AZD3293 oral solution - one single dose (low dose).
214382462|NCT02040987|DRUG|AZD3293|AZD3293 oral solution - one single dose (high dose).
214382463|NCT02040987|DRUG|Placebo|Placebo oral solution - one single dose
214382464|NCT02040987|DRUG|Moxifloxacin|Moxifloxacin tablet - one single dose
214382465|NCT06297499|DRUG|Ondansetron 8mg|administration of an IV solution of 8mg ondansetron (4ml)
214382466|NCT02169895|DRUG|BIA 9-1067|
214382467|NCT02169895|DRUG|Placebo|
214382468|NCT02169895|DRUG|Prolopa®|levodopa/benserazide 100/25 mg
214995849|NCT06537401|BEHAVIORAL|Hypercaloric, High Fat Diet|Participants will select meals from a list of sample breakfast, lunch, and dinner options from grocery stores. Typical intake will be estimated as 160-170% of resting metabolic rate, which will then be multiplied by 1.65 as the target calorie intake for the HFD. Target fat intake will be 65% of the HFD calorie target. To ensure participants will achieve the desired calorie and fat intake, they will also be provided with pre-made nutrient shakes and half-and-half. Participants will supplement their food intake with one to three shakes per day for each of the three days, depending on the fat and calorie content of the foods they select. They will be asked to add half-and-half equally between across the shakes.
214995850|NCT03575364|DEVICE|ClotTriever|Thrombectomy
214382469|NCT02505139|OTHER|the number of circulating tumor cells|
214382470|NCT05491668|DIAGNOSTIC_TEST|Non-hyperemic pressure ratio assessment pre and post PCI|Pre and post PCI invasive physiologic assessment
214382471|NCT00239018|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214382472|NCT01239693|DIETARY_SUPPLEMENT|IFA|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
214382473|NCT01239693|DIETARY_SUPPLEMENT|MMN|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
214382474|NCT01239693|DIETARY_SUPPLEMENT|LNS|Women during pregnancy: 1 sachet of LNS-P\&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P\&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
214382475|NCT01926522|DEVICE|Technological Rehabilitation|"The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.~Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.~The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions."
214382476|NCT01926522|OTHER|Control Rehabilitation|When needed, more than on e therapist are employed in the intervention for safety reasons.
214382477|NCT02670538|DRUG|Cariprazine|Cariprazine capsule one per day orally.
214382478|NCT02670538|DRUG|Placebo|Matching placebo capsule one per day orally.
214382479|NCT01886638|DRUG|Abacavir|
214382480|NCT02819856|DRUG|Placebo|0 mg SPI-1005 bid po x 21d
214382481|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x1|200 mg SPI-1005 bid po x21d
214995851|NCT04849741|DRUG|zilganersen|zilganersen will be administered by ITB injection.
214995852|NCT04849741|DRUG|Placebo|zilganersen-matching placebo will be administered by ITB injection.
214995853|NCT05451862|DEVICE|Holmium-166 treatment|Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.
215093034|NCT04334564|DRUG|Ginkgo biloba capsule|Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
215093035|NCT04334564|DRUG|Placebos|Placebos were controls.
215093036|NCT03307031|OTHER|High Volume Group|Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
215093037|NCT03307031|OTHER|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
214382482|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x2|400 mg SPI-1005 bid po x 21d
215093038|NCT03307031|OTHER|Control Group|Did not exercise, during 10 weeks.
215093039|NCT01105585|DEVICE|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
214382483|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x3|600 mg SPI-1005 bid po x 21d
214382484|NCT01486602|DRUG|carboplatin|IV
214382485|NCT01486602|DRUG|paclitaxel|IV
214382486|NCT01486602|RADIATION|radiation therapy|Defined per the protocol
214382487|NCT03820531|DIAGNOSTIC_TEST|Next Generation Sequencing|DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes
214382488|NCT03820531|DIAGNOSTIC_TEST|CEA and lipase|"Measuring CEA and lipase level in pancreas cyst fluid:~CEA \> 192 ng/ml and lipase \> 200 U/l = mucinous cyst"
214382489|NCT03820531|DIAGNOSTIC_TEST|Cytology|"Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma"
214382490|NCT03820531|DIAGNOSTIC_TEST|Histology of resected pancreas cyst|Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
214382491|NCT00436579|DRUG|sorafenib tosylate|Given orally
215093040|NCT01105585|DEVICE|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
214382492|NCT00436579|OTHER|pharmacological study|
214382493|NCT00436579|PROCEDURE|assessment of therapy complications|Ancillary studies
214382494|NCT00436579|OTHER|laboratory biomarker analysis|Correlative studies
214382495|NCT01132638|DRUG|Magnesium Pantoprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
214382496|NCT01132638|DRUG|Magnesium Esomeprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
214382497|NCT06359600|DRUG|HS-10501 tablet|Administered orally
214382498|NCT06359600|DRUG|Placebo|Administered orally
214382499|NCT03620721|BEHAVIORAL|mindfulness|8-week mindfulness based group intervention
214382500|NCT05309538|OTHER|Modified eply & Semont maneuver|repositioning maneauvers
214382501|NCT05309538|OTHER|betahistine & Modified eply & Semont maneuver|antihistamine plus repositioning maneuvers
214382502|NCT03644069|BIOLOGICAL|Nexvax2|Nexvax2 subcutaenous (SQ) injections: 32 in total, at twice weekly intervals
214382503|NCT03644069|BIOLOGICAL|Placebo|Placebo SQ injections: 32 in total, at twice weekly intervals
214382504|NCT01083147|DEVICE|FORESEE HOME|Home Monitoring
214382505|NCT00674323|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.
214382506|NCT00674323|DRUG|Ranibizumab|Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
214382507|NCT03595501|DEVICE|Hematology Analyzer - OLO|Complete blood counts from OLO will be determined from analysis of whole blood samples
214382508|NCT03595501|DEVICE|Hematology Analyzer - Predicate|Complete blood counts from Predicate will be determined from analysis of whole blood samples
214382509|NCT05765084|BIOLOGICAL|Dendritic cell vaccination|WT1/DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered on day 14 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Additional WT1/DC vaccinations after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week).
214382510|NCT05765084|DRUG|Atezolizumab|Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.
214382511|NCT05765084|DRUG|Platinum/pemetrexed based chemotherapy|On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
214382512|NCT00675194|DRUG|Cisplatin, Irinotecan, Capecitabine|
214382513|NCT02437474|BEHAVIORAL|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
214382514|NCT02437474|BEHAVIORAL|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
214382515|NCT02437474|BEHAVIORAL|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
214382516|NCT01989286|OTHER|Assessment|The posture, motor development and balance are going to be assessed.
214382517|NCT01408758|OTHER|Virtual Clinician Research Tool (VCRT)|The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
214498613|NCT03268421|BEHAVIORAL|Cognitive Behavioral Therapy|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
214498614|NCT03268421|BEHAVIORAL|Graded Aerobic Exercise|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
214382518|NCT01408758|OTHER|No VCRT, only physician counseling at visits|No intervention
214382519|NCT01381627|DRUG|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
214382520|NCT01381627|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
214498615|NCT06831123|BEHAVIORAL|L2B|a 6-session, group-based intervention that helps youth develop mindfulness skills
214498616|NCT06831123|BEHAVIORAL|L2B + App|the Learning to Breathe plus App condition, the 6-session L2B intervention augmented by a mobile application designed to support the use of mindfulness skills in daily life
214382521|NCT01061437|DRUG|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
214382522|NCT01061437|DRUG|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
214382523|NCT01061437|DRUG|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
214382524|NCT04777929|OTHER|test Phthalates, estrogen and progesterone|test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
214498617|NCT06831123|BEHAVIORAL|skills for success|a 6-session life skills intervention designed to support decision making and healthy relationships
214687468|NCT02609685|OTHER|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
214687469|NCT06946550|DEVICE|1470nm non-ablative fractional laser|Patients with scarring alopecia will be treated with the non-ablative Sciton HALO laser (1470nm).
214687470|NCT06951828|BIOLOGICAL|CT-P43|CT-P43, 45 mg in 0.5 ml, a single subcutaneous (SC) injection via auto-injector (AI)
214687471|NCT06951828|BIOLOGICAL|CT-P43|CT-P43, 45 mg in 0.5 ml, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
214687472|NCT05094362|BEHAVIORAL|Spinal Reflex Operant Down Conditioning|This is a training intervention in which people with a spinal cord injury are trained to reduce the activity of a certain spinal reflex. By decreasing this reflex, individuals decrease hyperactivity in the reflex and can reduce spasticity.
214687473|NCT07142707|DRUG|MBX 4291|MBX 4291 will be administered subcutaneously (SC)
214995854|NCT05451862|DEVICE|Holmium-166 work-up|Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
214995855|NCT04803279|DEVICE|Collection of Pure tone thresholds from audiogram measured prior to fitting of Ponto 3 SuperPower|Unmasked and if available masked BC thresholds from audiogram obtained prior to Ponto 3 SuperPower were fitted.
214382525|NCT01042899|BEHAVIORAL|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
214382526|NCT01042899|BEHAVIORAL|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
214382527|NCT01042899|BEHAVIORAL|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
214382528|NCT00805493|DRUG|Riluzole|
214382529|NCT01676532|OTHER|Students attending SBHC|School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
214382530|NCT05017324|DEVICE|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation
214382531|NCT00248300|OTHER|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
214382532|NCT02208570|OTHER|PPV>14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
214382533|NCT02208570|DRUG|Volume loading|Hydroxyethyl starch solution 6ml/kg iv injection
214382534|NCT02208570|OTHER|PPV<14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
214382535|NCT05065385|DIAGNOSTIC_TEST|INTER-NDA|Neurodevelopmental Screening Test at age 2 years.
214382536|NCT02610218|OTHER|CTC and cfDNA analysis|The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
214382537|NCT04470219|OTHER|Cognitive support by RemindMe|
214382538|NCT06305689|PROCEDURE|Surgery|Surgical procedure to the gastrocnemius and/or plantar fascia
214382539|NCT06305689|PROCEDURE|Serial Casting|Repeated casts weekly until desired dorsiflexion range achieved
214382540|NCT05468515|DIAGNOSTIC_TEST|pulse oxygen saturation|preductal oxygen saturation
214498618|NCT06812949|DIAGNOSTIC_TEST|PEEP Titration with Echocardiographic, Hemodynamic, and Ventilatory Measurements|This intervention consists of clinical recruitment maneuvers performed in mechanically ventilated patients by adjusting positive end-expiratory pressure (PEEP) at two levels: low PEEP (5 cmH₂O) and high PEEP (15 cmH₂O). Throughout these maneuvers, echocardiographic imaging, hemodynamic assessments, and ventilatory measurements are performed to evaluate the cardiorespiratory effects of PEEP adjustments. Transthoracic echocardiography (TTE) is used to assess right ventricular function, pulmonary pressures, and venous congestion, while mechanical ventilator parameters are recorded to monitor lung mechanics and compliance.
214498619|NCT05184933|OTHER|At-home Polysomnography|Participants will complete one night of unattended polysomnography in their home environment (SOMNOtouch RESP, SOMNOmedics America Inc., FL, USA).
214687474|NCT07142707|DRUG|Placebo|Placebo: Placebo will be administered subcutaneously (SC)
214995856|NCT04803279|DEVICE|Collection of BC In-situ thresholds from BC In-situ audiogram measured during fitting of Ponto 3 SuperPower|BC In-situ thresholds will be collected from the BC In-situ audiogram obtained when Ponto 3 SuperPower were fitted
214995857|NCT04803279|DEVICE|Collection of Aided sound field thresholds measured with the Ponto 3 SuperPower|Sound field thresholds for frequencies 500Hz, 1kHz, 2 kHz, 3kHz and 4kHz will be collected from sound field audiogram obtained as follow-up after Ponto 3 SuperPower fitting, typically this is collected 3 months post fitting, alternatively from the fitting visit. Thresholds will be obtained aided, and when available unaided
214995858|NCT04803279|DEVICE|Collection of speech intelligibility scores|"Speech intelligibility is measured in a sound treated room using sentence tests. The sentence tests used at Norwich and Norfolk hospital is the BKB (Bamford-Kowal-Bench) and/or the The AB\[s\] Isophonemic Monosyllabic Word test (7).~The sentence tests are measured in quiet and/or with background speech-weighted noise."
214995859|NCT04803279|DEVICE|Skin reaction|Classification of skin reactions around skin penetrating implants will be made using the Holgers score. The Holgers classification is a scale from 0 to 4 that is used to grade skin reactions
215093041|NCT04234958|OTHER|Osteopathic manipulative treatment|Specific protocol including 4 osteopathic techniques targeting the pericardium
215093042|NCT04234958|OTHER|Sham therapy|Sham therapy mimicking the osteopathic techniques applied to experimental group
214382541|NCT02045433|RADIATION|SABR Boost Therapy|"1. Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~2. Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment."
214382542|NCT02880007|RADIATION|External Beam Radiation Therapy|45 Gy pelvis / 25 fr
214382543|NCT02880007|RADIATION|PDR Brachytherapy|1 puls/hour ; 12 Gy / day
214382544|NCT02880007|DRUG|Cisplatin|increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
214382545|NCT03971838|BEHAVIORAL|Positive Outcomes for Women|"Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2\. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight."
214382546|NCT05217043|OTHER|intracranial brain recording|Any patient benefiting from a long-term intracranial brain recording.
214382547|NCT01406704|DRUG|Rosiglitazone|Rosiglitazone (8 mg/day)
214382548|NCT01406704|DRUG|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
214382549|NCT01406704|DRUG|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
214382550|NCT03279848|OTHER||Stroke rehabilitation
214382551|NCT04369638|DEVICE|3D NAM|"After consent and birth of the child, a face MRI will be taken of the newborn before discharge from the hospital utilizing the feed and swaddle technique. The MRI will be sent to the dental team to convert into a format compatible with 3D software. With the image, a NAM appliance will be digitally fabricated and 3D printed. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment."
214382552|NCT04369638|DEVICE|Traditional NAM|The patient will be seen for visit at the clinic for traditional intraoral impression and a dental stone model will be poured. An acrylic NAM will be fabricated on the stone model. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment.
214382553|NCT02825901|DIETARY_SUPPLEMENT|Placebo|Ingest placebo drink 100ml/day for 8 weeks
214382554|NCT02825901|DIETARY_SUPPLEMENT|Djulis-Buckwheat|Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
214382555|NCT02825901|DIETARY_SUPPLEMENT|Buckwheat|Ingest Buckwheat drink 100ml/day for 8 weeks
214382556|NCT02986061|DEVICE|Urinary catheter|
214382557|NCT01656837|BEHAVIORAL|Comprehensive Community Treatment|
214382558|NCT01656837|BEHAVIORAL|MST-BSF|
214382559|NCT01112514|DRUG|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
214382560|NCT02768948|DRUG|telmisartan during 6 months|telmisartan during 6 months
214382561|NCT02768948|DRUG|Losartan during 6 months|Losartan during 6 months
214382562|NCT02768948|PROCEDURE|blood sample|blood sample
214382563|NCT04235101|DRUG|SYD985 + Niraparib|SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
214382564|NCT02852018|GENETIC|Identification of genetic polymorphisms|
214687475|NCT07154121|DRUG|5-fluorouracil group|Patients in the intervention group underwent standard En-DCR surgery, with all procedures performed by the same senior oculoplastic surgeon; After suturing to create a new nasolacrimal duct during surgery, Schirmer strips were placed at the ostium to measure its size and photographed for record-keeping. The ostium was then covered with a gelatin sponge soaked in 12.5 mg/mL 5-fluorouracil for 3 minutes, after which the gelatin sponge was removed and the area thoroughly rinsed with saline.
214687476|NCT07154121|OTHER|saline group|Patients in the intervention group underwent standard En-DCR surgery, with all procedures performed by the same senior oculoplastic surgeon; Similarly, after suturing to create a new nasolacrimal duct during surgery, Schirmer strips were placed at the ostium to measure its size and photographed for record-keeping. The ostium was then covered with a gelatin sponge soaked in saline solution for 3 minutes, after which the gelatin sponge was removed and the ostium was thoroughly rinsed with saline solution.
214995860|NCT04803279|DEVICE|Collection of Glasgow Benefit Inventory|The Glasgow Benefit Inventory (GBI) contains 18 health status questions, which ask specific questions about how the health problem, in this study hearing loss, has affected their quality of life at the time the GBI is completed. In this study GBI has been collected on patients before intervention and 3 months after fitting of Ponto 3 SuperPower on abutment.
214382565|NCT02176421|DEVICE|VOLBELLA® with lidocaine|VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
214382566|NCT02406885|DRUG|Apixaban|New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
214382567|NCT01614639|PROCEDURE|Acupuncture|A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
214382568|NCT01995019|DRUG|Methylprednisolone|1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
214382569|NCT01995019|DRUG|Physiologic saline|1 ml intra-articular placebo
214382570|NCT06010290|DRUG|18F-SMBT-1|Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.
214382571|NCT05672303|BEHAVIORAL|Palmar grasp reflex|The reflex can be stimulated by moving an object distally across the palm. In the study, at the beginning of the vaccine administration, the right hand of the infant will be moved distally along the palm with the researcher's index finger, thus providing reflex stimulation.
214382572|NCT06437730|OTHER|Integrated Neuromuscular Inhibition Technique:|MTrPs points will be released with ischemic compression, position of ease will be acquired, and in the last METs will be performed. Ischemic compression applied through thumb on trigger point present in any muscle around the knee joint. Compression will be increased gradually until first resistance will feel and maintained until it resolves, further increases then until no tissue resistance will be felt under thumb. This process is maintained for 30sec and repeated 3-5 times per session. Positional release technique: after applying pressure on trigger point, patient will acquire position of ease that is maintained for 20 sec whether its extension or flexion of knee. This process is repeated 3-5 times per session. Muscle Energy Technique will be applied on the muscle in which isometric contraction is maintained for 7-10sec against 20-25% strength. After completion of muscular contraction, the limb is moved away for muscular stretch and then position is maintained for 30 seconds
214382573|NCT06437730|OTHER|Dry needling:|"Dry needle will be targeting trigger points (TrPs) using in-and-out techniques such as 'pistoning' or 'sparrow pecking'. 0.25x25mm needle is inserted.~For vastus laterals patient is supine line with knee extended performing an isometric quadriceps contraction, maintaining a clean technique by using gloves and performing an alcohol wipe down bracket the tissue to be treated and inserting needle with direct approach towards the femur, performing pistoning. For vastus medialis patient is supine line with 30 degrees of knee flexion. A headless 0.25x25mm needle fixed between the fingers of non-dominant hand and inserted perpendicularly to the MTrPs with metacarpophalangeal flexion extension of 1st and 2nd fingers of dominant hand. For Gastrocnemius patient is prone lying and bolstered supported slight knee bend, for the upper part anterior medial approach is used and center of muscle belly slight medial anterior approach is used."
214995861|NCT04803279|DEVICE|Collection of power-on usage time with Ponto 3 SuperPower|Average power-on usage hours from Ponto 3 SuperPower will be collected.
214382574|NCT05913375|RADIATION|Stereotactic Body Radiotherapy|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate defined with electroanatomical mapping (EAM)
214382575|NCT05594849|DRUG|Budesonide Orodispersible Tablets (Jorveza)|Patients that swith to Budesonide Orodispersible Tablets (Jorveza)
214382576|NCT01486134|PROCEDURE|Multipolar Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
214382577|NCT02070120|DRUG|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
214382578|NCT02070120|PROCEDURE|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
214382579|NCT02145078|DRUG|docetaxel|Given IV
214382580|NCT02145078|DRUG|pemetrexed disodium|Given IV
214382581|NCT02145078|DRUG|gemcitabine hydrochloride|Given IV
214382582|NCT02145078|OTHER|laboratory biomarker analysis|Correlative studies
214382583|NCT03375580|DIETARY_SUPPLEMENT|TLC|transform life custom (TLC)
214382584|NCT03375580|DRUG|metformin|0.5g metformin group，PO tid
214382585|NCT03375580|DRUG|Compound Zhenzhu Tiaozhi capsule|Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.
214382586|NCT03375580|DRUG|Simvastatin|20mg simvastatin, PO qn
214382587|NCT00158210|DRUG|Rivastigmine|
214382588|NCT04170868|OTHER|ADHD Psycheducation|The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
214498620|NCT05184933|OTHER|Circadian Protocol|Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
214995862|NCT04035005|DRUG|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300 milligrams (mg), IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusion, should be maintained between each infusion.
214995863|NCT04035005|DRUG|Placebo|The first dose of placebo will be administered as two IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single infusion every 24 weeks, with a minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusions, maintained between each infusion.
214995864|NCT02378246|DIETARY_SUPPLEMENT|Iodine|
214995865|NCT02378246|DIETARY_SUPPLEMENT|Placebo|
214995866|NCT05826873|BEHAVIORAL|Discharge antibiotic stewardship intervention|Hospitalists will be provided with group-level, quarterly feedback reports illustrating the number of prescriptions that had the appropriate antibiotic duration and appropriate antibiotic choice for each of the three conditions.
214995867|NCT06635447|DRUG|Capivasertib|400 mg, oral, twice daily; 4 days on and 3 days off
214995868|NCT06635447|DRUG|Fulvestrant|Fulvestrant IV
214995869|NCT04167748|PROCEDURE|Preimplantation genetic testing for aneuploidy (PGT-A)|24-chromosome screening for aneuploidy in the preimplantation embryo (blastocyst stage)
214382589|NCT03775408|DEVICE|FAST|Orthopaedic surgeons will use the FAST device to facilitate entry point selection and alignment of a guidewire for intramedullary nailing of femoral shaft fractures.
214382590|NCT05164731|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third does was given 3, 4, 5 or 6 months after two doses
214382591|NCT00018005|BEHAVIORAL|Self-Management|18 in-person group sessions providing self-management training.
214382592|NCT00018005|OTHER|attention control|18 educational mailings follow by a a telephone call.
214382593|NCT02999620|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
214382594|NCT02999620|DIETARY_SUPPLEMENT|Placebo|Identical looking placebo tablet to active (Alpha-cyclodextrin)
214382595|NCT01839357|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
214382596|NCT01077362|DRUG|placebo|SC injections
214382597|NCT01077362|DRUG|ustekinumab 45 mg|SC injections
214382598|NCT01077362|DRUG|ustekinumab 90 mg|SC injections
214382599|NCT01503138|BEHAVIORAL|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
214382600|NCT00125099|BIOLOGICAL|VRC-HIVDNA009-00-VP|
214382601|NCT06310902|DIAGNOSTIC_TEST|Single-cell Sequencing Analysis|Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.
214382602|NCT02766179|DEVICE|CPAP|CPAP is used for 6 weeks
214382603|NCT02766179|DEVICE|Somnoguard|Somnoguard is used for 6 weeks
214382604|NCT01872910|DRUG|Placebo|Administered orally
214382605|NCT01872910|DRUG|LY3023703|Administered orally
214382606|NCT01872910|DRUG|Celecoxib|Administered orally
214382607|NCT05806502|DIAGNOSTIC_TEST|Nω-hydroxy-nor-arginine|Arginase inhibitor
214382608|NCT02093676|BEHAVIORAL|"experimental protocol treatment The New Authority"|
214382609|NCT00458614|DRUG|Lansoprazole|
214382610|NCT00815035|DRUG|Peanut OIT|Peanut flour that is orally ingested in a graded fashion.
214382611|NCT00815035|DRUG|Placebo|Oat flour used as a placebo that is orally ingested a graded fashion
214382612|NCT01767935|PROCEDURE|cryosurgery|Undergo cryosurgery
214498621|NCT05184933|OTHER|Rested Wakefulness Trial|Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner \~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (\<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted \~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
214687477|NCT07151118|OTHER|Blood Sampling for ctDNA Analysis|Approximately 20 mL of peripheral blood will be collected from patients with advanced biliary tract cancer. Samples will be obtained prior to systemic therapy initiation (in about two-thirds of patients) or prior to subsequent therapy (in about one-third of patients). Additional blood draws may be performed at progression in patients with FGFR2 fusion, IDH1 mutation, or HER2 amplification. Collected samples will be centrally analyzed for genomic alterations using ctDNA profiling.
214382613|NCT01767935|RADIATION|radiation therapy|Undergo radiation therapy
214382614|NCT01767935|PROCEDURE|quality-of-life assessment|Ancillary studies
214382615|NCT05224635|PROCEDURE|Vascular Injury|The Society of Vascular Surgery has established a robust vascular disease registry but this organization's focus is on vascular disease and lacks capture of the data points necessary to discern trauma-specific outcomes. Recent military experience from the United States and United Kingdom, including the Balad Vascular Registry and the Global War on Terror (GWOT) Vascular Registry have provided a contemporary assessment of wartime vascular injury, but again these studies have been retrospective case series and registry reviews. Furthermore, applications of lessons learned in wartime vascular injury do not completely translate to management in trauma centers in the United States.
214382616|NCT01238224|DRUG|Tadalafil|This is an acute study. Tadalafil 20 mg administered prior to a meal
214382617|NCT02861144|OTHER|Ma ka hana ka ̒ike|Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.
214382618|NCT02861144|OTHER|Hanapū Provider Toolbox|Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
214382619|NCT00310323|DRUG|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
214382620|NCT00310323|DRUG|Caffeine|Administered as 4 ounces of Coca-Cola
214382621|NCT06160739|DRUG|Sirolimus 1Mg Oral Tablet|patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam \& ultrasound \& MRI to compare lesion size before \& after use of the drug with observation of potential side effects \& after exclusion of it before use of the drug
214382622|NCT05872529|BEHAVIORAL|Education|The education which consists processed EEG monitoring and SBI approach
214382623|NCT03101241|DRUG|CX-8998|T-type calcium channel blocker
214382624|NCT03101241|DRUG|Placebo|Placebo comparator
214382625|NCT02746913|DEVICE|Urodynamics|Urodynamics is performed with the Aquarius XT Laborie system and a fluoroscopic images are obtained with a GE OCE 9800 c-arm fluoroscopy unit. Urodynamic testing will be performed in a seated position with a pessary from the ambulatory pessary trial in place. Post residual void will be measured at the start of the urodynamics.
214382626|NCT02746913|DEVICE|Pessary|A pessary is a silicone disc that is used in to support the uterus and vagina of women with vaginal prolapse. During this study, the pessary that will be used is a ring with support. This is a disc shape with a membrane stretched across the center. It is a device used in standard practice and is safe to keep in place for up to 3 months at a time. The subjects will be fit with a pessary asked to wear the pessary for 3 days.
214382627|NCT01998594|PROCEDURE|Arthroplasty|A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
214382628|NCT01904214|DRUG|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
214382629|NCT00975988|DRUG|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
214382630|NCT00191360|DRUG|Somatropin|
214382631|NCT02925260|OTHER|MRI with ileal pouch contrast and enema.|Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
214382632|NCT00975052|DRUG|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
214382633|NCT00975052|DRUG|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
214382634|NCT00975052|DRUG|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
214382635|NCT00975052|DRUG|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
214498622|NCT05184933|OTHER|Overnight Sleep Trial|Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (\<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
214498623|NCT05184933|BEHAVIORAL|Regularized Sleep Schedule|All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.
214995870|NCT05307666|OTHER|Medication minimization|During the medication minimization visit, and any necessary follow-up visits, patients and providers work together to gradually minimize medication dosages (e.g. reducing 1/4 or 1/2 dose at a time) using the following approach: 1) Medications Treating Symptoms: Find the minimum dose that controls the symptom, 2) Drugs that Lower Blood Pressure: Reduce dosages until systolic BP is in the upper 10mmHg of the target range (e.g. target 130 - 140 mmHg), 3) Drugs That Lower Blood Sugar: Reduce dosages until HbA1c is in the upper 5% of the target range (e.g. target 7.5 - 8.0%).
214995871|NCT05943678|DEVICE|Siemens Magnetom 7T Plus|Magnetic Resonance Spectroscopy
214995872|NCT04596046|PROCEDURE|steroid injecting|Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
214995873|NCT04528498|OTHER|Preimplantation Genetic Testing|Embryo biopsies will undergo preimplantation genetic testing for aneuploidies as per standard of care, and polygenic disease risk (PGT-P) will be computed for these samples.
214382636|NCT00242203|DRUG|Zometa|
214382637|NCT00242203|DRUG|Epirubicin|
214382638|NCT00242203|DRUG|Docetaxel|
214382639|NCT00242203|DRUG|Trastuzumab|ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
214382640|NCT00242203|RADIATION|External beam radiation|
214382641|NCT00242203|PROCEDURE|Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection|
214382642|NCT04049903|DRUG|MP0310|MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
214382643|NCT01090908|DRUG|Antibiotic|
214382644|NCT04299334|PROCEDURE|adjustable neochordae Technique|"Classic ring annuloplasty will be done using Carpentier or physio ring, then neochordal placement will be done using the looping technique. The length of the chordae is adjusted to achieve the optimal length.~In this study, Surgeons use relatively short loops because of the augmentation of the length with extra loops suspended with Gortex. Placement of at least 8-12 chordae of the corresponding heads of the papillary muscle tip to achieve proper management of the prolapse and longevity of the repair."
214382645|NCT01422369|DRUG|Pitavastatin (NK-104)|Pitavastatin (NK-104) 4mg once daily (QD)
214382646|NCT01422369|DRUG|Darunavir/Ritonavir (Prezista)|Darunavir/Ritonavir (Prezista) 800 mg/100 mg
214382647|NCT05082896|PROCEDURE|Type of anesthesia choice|Use of conscious sedation vs. general anesthesia
214382648|NCT06186557|OTHER|No intervention|No intervention
214382649|NCT01077726|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
214382650|NCT03984032|DEVICE|LMA Protector Cuff Pilot|Assessing the clinical performance of LMA Protector Cuff Pilot
214382651|NCT03984032|DEVICE|LMA Supreme|Assessing the clinical performance of LMA Supreme
214382652|NCT01393080|DRUG|Nimotuzumab and TP regimen|"1. TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~2. Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
214382653|NCT01393080|DRUG|TP regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
214382654|NCT05829980|PROCEDURE|Laser assisted in-situ keratomileusis|Laser-Assisted In Situ Keratomileusis is a procedure that permanently changes the shape of the cornea using an excimer laser and the mechanical microkeratome (a blade device) used to cut a flap in the cornea.
214382655|NCT05829980|PROCEDURE|Photorefractive keratectomy|Photorefractive keratectomy is a laser refractive procedure used to ablate the corneal stroma to correct refractive errors without cutting flap
214382656|NCT00079911|DRUG|valacyclovir hydrochloride|valacyclovir hydrochloride
214382657|NCT06383325|COMBINATION_PRODUCT|Chemotherapy|Detection of hepatotoxicity in acute leukemia patients during chemotherapy
214995874|NCT04492670|PROCEDURE|Tui-na|For administering of Tui-na manipulation practice, responsible Tui-na CMP must have at least 2 years of clinical experience. The pre-trial workshops led by a senior practitioner will be organized to ensure standardization of Tui-na treatment manipulation and procedures.
214382658|NCT06481254|OTHER|Hawthorn Vinegar Group|To routine oral mucositis treatment, patients with DM in the hawthorn vinegar group gargled with 1 tablespoon (10 cc) of diluted hawthorn vinegar (mixed with 40 cc water) for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
214995875|NCT04492670|DRUG|Du-Huo-Ji-Sheng-Tang (DHJST)|This study medication is derived from Du-Huo-Ji-Sheng-Tang (DHJST) and concentrated Chinese Medicine granules will be used.
214995876|NCT06514157|COMBINATION_PRODUCT|budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)|BDA MDI 160 μg/180 μg (single dose administered as 2 actuations of 80 μg/90 μg)
214995877|NCT05889910|PROCEDURE|Health education workshop|"The intervention will consist of 5 initial sessions, plus a reinforcement session at 6 months. The sessions will last 2 hours and will preferably be distributed one day a week.~The objective of the intervention is to reduce the fear of falling and falls in people over 65 years of age who live in the community. To this end, nursing interventions will be included to improve the knowledge, skills and attitudes of the participants regarding the improvement of their functional capacity, the prevention of falls and their preventive measures, as well as the improvement in the management of anxiety and coping with the fear of falling and falls.~The activities carried out during the intervention have been extracted from standardized nursing interventions through the Nursing Interventions Classification (NIC).~The following interventions and activities will be addressed: 1665, 5612, 6490, 6486, 4700, 5820 and 5230."
214995879|NCT06003803|BEHAVIORAL|digital learning in motivational interviewing|Receive digital learning in motivational interviewing for three months, once a week, 40 minutes each time
214995880|NCT04188535|DIAGNOSTIC_TEST|MRI IMAGING|Imaging with MRI will be performed as per disease site standards.
214995881|NCT06585891|BIOLOGICAL|VRC-HIVMAB0121-00-AB|The CAP256J3LS bispecific antibody (bsAbs) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of the light chain of CAP256V2LS, linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.
214382659|NCT06481254|OTHER|Black Mulberry Syrup Group|To routine oral mucositis treatment, patients with DM in the black mulberry syrup group pure black mulberry syrup for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
214382660|NCT06481254|OTHER|Green Tea Group|To routine oral mucositis treatment, patients with DM in the green tea group gargled with 50 cc green tea for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
214382661|NCT01961596|OTHER|Cooling Ice Spray|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test."
214382662|NCT01961596|OTHER|water|A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
214382663|NCT01572246|OTHER|Optimal placement of return pad|The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
214382664|NCT00166686|DRUG|Clonidine|
214382665|NCT04572529|PROCEDURE|Cardiac Valve replacement|Open heart surgery to replace the valvular infective endocarditis
214382666|NCT05256693|DRUG|Vancomycin|Oral vancomycin (powder) 125mg twice a day
214995882|NCT05918640|DRUG|Lurbinectedin|Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
215093043|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on M1 and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The participants will be positioned in ventral decubitus position. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on C3 to stimulate the left primary motor cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
214382667|NCT05256693|DRUG|Placebo|Vancomycine placebo (powder) twice a day
214382668|NCT01678820|DRUG|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
214995883|NCT04092777|BEHAVIORAL|Strong Minds|The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.
214382669|NCT01678820|DRUG|Sitagliptin|Sitagliptin 100 mg tablet
214382670|NCT01678820|DRUG|Simvastatin|Simvastatin 40 mg tablet
214382671|NCT01678820|DRUG|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet
214382672|NCT01678820|DRUG|Placebo to simvastatin|Matching placebo to simvastatin 40 mg tablet
214382673|NCT01678820|DRUG|Placebo to Sitagliptin/Simvastatin FDC|Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
214995884|NCT04092777|OTHER|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
215093044|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on DLPFC and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on F3 to stimulate the left dorsolateral cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
215093045|NCT04496661|DEVICE|Sham tDCS and PES|For sham tDCS and PES stimulation, patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes. The anodic electrode will be positioned on the left primary motor cortex, but the current will be turned off automatically after 30 seconds. The reference electrode will be positioned in the supra orbital contralateral region. For sham PES stimulations, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed), but the current will be turned off automatically after 30 seconds.
214498624|NCT04049890|OTHER|FAI-O|"Administration of Family Adjustment Inventory in the version Only-child"
214498625|NCT04049890|OTHER|FAI-S|"Administration of Family Adjustment Inventory in the version Sibling"
214382674|NCT01678820|DRUG|Metformin|Participants will continue on their stable, pre-screening metformin daily dose of \>= 1500 mg for at least 12 weeks prior to randomization and during the study
214382675|NCT01678820|DRUG|Glimepiride|Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
214382676|NCT04069260|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
214382677|NCT02893683|OTHER|Paris Visual Learning Test|
214382678|NCT00825032|PROCEDURE|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
214382679|NCT00825032|PROCEDURE|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
214498626|NCT04049890|OTHER|Personal Data Questionnaire|This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year
214498627|NCT06797284|DEVICE|Transcranial Magnetic Stimulation|repetitive transcranial magnetic stimulation, or transcranial direct current stimulation, or daytime timed bright light exposure
214382680|NCT02223117|BIOLOGICAL|Thrombosomes|Freeze-dried platelets
214382681|NCT02223117|BIOLOGICAL|Placebo|
214382682|NCT03769805|DRUG|Anlotinib|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week.
214382683|NCT02351323|DRUG|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
214382684|NCT02351323|BEHAVIORAL|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
214498628|NCT06823921|OTHER|Exercise|HIIT will include aerobic, strength, and balance exercises and boxing
214498629|NCT05310734|DRUG|Spinosad Topical|A topical suspension indicated for the treatment of scabies is used for this PK and Safety Study
214498630|NCT05913752|DRUG|CMND-100|The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class
214498631|NCT03474159|DEVICE|Magnetic Resonance Imaging|Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
214498632|NCT03474159|DEVICE|Transthoracic echocardiography|Aortic distensibility measured in TTE of the same segments in TM and in B mode
214498633|NCT03474159|DEVICE|Echography UltraFast|Carotid pulse rate measured on carotid arteries by UF
214382685|NCT02300285|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical team but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
214382686|NCT03919812|DIETARY_SUPPLEMENT|Cholecalciferol supplementation|supplementation received by subject according to their vitamin D status: insufficiency or deficiency.
214382687|NCT02780830|DRUG|AZD2014|AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
214995885|NCT05706116|BIOLOGICAL|Trichuris trichiura Egg Inoculum|Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV. Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use. Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.
214995886|NCT06352606|DIAGNOSTIC_TEST|Spinal anesthesia|Oxygen supply will be done via nasal prong (2 L/min) when necessary. The local anesthetic used will be bupivacaine 0.6 mg/kg.
214995887|NCT06352606|DIAGNOSTIC_TEST|General anesthesia|Patients will receive sevoflurane for induction and maintenance in an air/oxygen mixture along. Endotracheal tube will be inserted. No opioids or nitrous oxide was used intraoperatively.
215093046|NCT04409717|PROCEDURE|Type II endoleak treatment|Type II endoleak endovascular treatment
214382688|NCT02780830|DRUG|Ibrutinib|Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
214382689|NCT01618890|PROCEDURE|Hepatic venous pressure gradient measurement|"Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.~In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.~In hemodynamic responders (HVPG second measurement\< 12 mmHg or \>20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up."
214382690|NCT06439940|DIAGNOSTIC_TEST|Blood sample extraction|We do not alter the patient\&#39;s regular gynecological check-up in any way. The patient will undergo a mammogram and a blood draw. We will then separate a small aliquot of blood for the purposes of the research protocol.
214382691|NCT04485715|OTHER|AI system|The real-time assistance of AI system
214382692|NCT02628132|DRUG|Paclitaxel|Paclitaxel will be given weekly for 6 cycles
214382693|NCT02628132|DRUG|Durvalumab|Durvalumab will be given q2 wks concurrently with paclitaxel.
214382694|NCT00578721|DRUG|Aspirin|325 mg taken daily with an arginine-restricted diet
214382695|NCT02440347|DEVICE|Computer controlled anesthetic delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject).
214382696|NCT02440347|DEVICE|Conventional anesthetic delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
214382697|NCT01472874|DRUG|Once a day Trientine|Trientine at a dosage of \~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
214382698|NCT03219008|DRUG|Fluoxetine|Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
214382699|NCT03219008|COMBINATION_PRODUCT|fluoxetine + cognitive-behavioral treatment（CBT）|the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.
214382700|NCT03219008|DRUG|fluoxetine + Amfebutamone|Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.
214382701|NCT03219008|COMBINATION_PRODUCT|physical treatment+fluoxetine+amfebutamone|the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.
214382702|NCT03219008|DRUG|Fluvoxamine|Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.
214382703|NCT03219008|DRUG|Lithium+fluvoxamine|the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.
214382704|NCT03219008|COMBINATION_PRODUCT|fluvoxamine + lithium + physical therapy|the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.
214382705|NCT03219008|COMBINATION_PRODUCT|Cognitive behavior treatment +fluvoxamine|the investigators recommend behavioral therapy as well as drugs.
215093047|NCT03597607|BEHAVIORAL|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
215093048|NCT03597607|BEHAVIORAL|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
215093049|NCT05827601|DIAGNOSTIC_TEST|respiratory specimen|participants will perform self-sampling with a nasopharyngeal swab
215093050|NCT05827601|DIAGNOSTIC_TEST|serum|participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
214382706|NCT03219008|DRUG|Mirtazapine/SNRIs|Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.
214382707|NCT03219008|COMBINATION_PRODUCT|mirtazapine+ Cognitive behavior treatment|the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .
214382708|NCT03219008|DRUG|mirtazapine + SNRIs|the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.
214382709|NCT03219008|COMBINATION_PRODUCT|mirtazapine + SNRIs + physical therapy|the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.
214382710|NCT03219008|OTHER|TAU(treat as usual)|patients in this group would receive therapy strategies according to their symptoms and preference.
214382711|NCT00671008|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214382712|NCT00671008|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214382713|NCT05375435|DRUG|triple therapy|high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor
214382714|NCT05375435|DRUG|dual-therapy|high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
214382715|NCT02810093|OTHER|retrospective medical records analyze|Ten thousand medical records (between years 2000 and 2016) will be analyzed
214382716|NCT03877965|DRUG|Digoxin|Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
214382717|NCT04534634|COMBINATION_PRODUCT|IFN-α combined with CAR-T cell therapy|"Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.~Children: 14 daily intramuscular injections 200mg/m\^2 of Interferon-α for a 28-day cycle.~CAR T cell: (1-2)×10\^7/kg, intravenously infusion."
214382718|NCT03992534|COMBINATION_PRODUCT|LACTIN-V|Vaginal supplementation with L. crispatus CTV-05.
214382719|NCT00142922|BEHAVIORAL|Breaking Down Barriers|completed
214995888|NCT05600920|DRUG|Recombinant human interleukin (IL) 7-hyFc|Structural Formula: NT-I7 is a fusion protein comprising human IL-7 fused to the human IgD hinge region. This in turn is fused to the N-terminal region of CH2 from IgD and two key regions of the antibody IgG4: C-terminal region of CH2 and the entire CH3 region. NT-I7 will be administered by IM injection once every 12 weeks for a total of 3 doses, with the final dose at week 24. In the absence of treatment delays due to AEs, a treatment course of 24 weeks will be pursued in all enrolled participants. The dose levels to be used in this study are 240, 480, and 720 microgram/kg. NT-I7 dosing will be determined using the weight recorded at the screening visit. The dose will be based on the participant s actual body weight, unless the participant has a BMI \>=30 kg/m2, in which case adjusted body weight will be used.
214995889|NCT02306161|DRUG|Cyclophosphamide|Given IV
214995890|NCT02306161|DRUG|Doxorubicin|Given IV
214995891|NCT02306161|DRUG|Doxorubicin Hydrochloride|Given IV
214995892|NCT02306161|DRUG|Etoposide|Given IV
214995893|NCT02306161|DRUG|Etoposide Phosphate|Given IV
214995894|NCT02306161|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214995895|NCT02306161|BIOLOGICAL|Ganitumab|Given IV
214995896|NCT02306161|DRUG|Ifosfamide|Given IV
214995897|NCT02306161|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
214382720|NCT00501878|DRUG|2.5% or 10% phenylephrine|
214382721|NCT04566588|PROCEDURE|EAR HoLEP|early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
214995898|NCT02306161|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
214382722|NCT04566588|PROCEDURE|Classic HoLEP|classic holmium enucleation of the prostate as a surgical treatment for benign prostatic hyperplasia
214995899|NCT02306161|DRUG|Vincristine|Given IV
214995900|NCT02306161|DRUG|Vincristine Sulfate|Given IV
214995901|NCT06229704|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
215093051|NCT05207969|PROCEDURE|Instruction to urinate|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
215093052|NCT00002807|RADIATION|radiation therapy|45 Gy in 25 fractions over 5 weeks
215093053|NCT00620152|BEHAVIORAL|1|Low glycemic load diet by telephone counseling
215093054|NCT00620152|BEHAVIORAL|2|Low fat diet by telephone counseling
215093055|NCT02439567|DEVICE|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
215093056|NCT03781791|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
215093057|NCT03781791|DRUG|Placebo Treatment|Placebo will be administered in tablet form, once daily.
215093058|NCT01028066|OTHER|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
215093059|NCT01028066|BEHAVIORAL|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
215093060|NCT02406352|DEVICE|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
214382723|NCT05778526|BEHAVIORAL|Virtual reality|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session of the Social VR intervention lasts for a maximum of 20 minutes. The intervention contains three real-life virtual scenarios, including (1) a classroom and playground, (2) an MTR station and compartment, and (3) a supermarket and restaurant.
214382724|NCT05778526|BEHAVIORAL|Traditional social skills training|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session lasts for a maximum of 20 minutes. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise.
214382725|NCT05425251|DIAGNOSTIC_TEST|GFAP and UCH-L1|2x5mL blood samples will be used to determine the performance of the automated VIDAS TBI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
214382726|NCT03839732|DIAGNOSTIC_TEST|Score of abdominal aorta calcifications|Radiographs showing VC will be used to assess whether the computer assisted VC scoring (primary objective) and Quantitative Vertebral Morphometry (QVM, limited to lumbar spine, secondary objective n.1) through the Calcify2D software are less variable with respect to the traditional visual scoring of VC and QVM.
214382727|NCT05791890|DRUG|Gilteritinib|observational study to evaluate the incidence of infections during therapy with Gilteritinb
214382728|NCT05764291|BEHAVIORAL|FIT-TEENS|FIT-TEENS is a digital behaviour change intervention which provides information on physical activity and behaviour change support towards physical activity, presented in multimedia format through an online learning platform (EdApp). The contents is developed in Malay language and consist of 10 self-paced modules and activities. The objectives of FIT-TEENS are for the participants to be able to 1) review the definitions and health benefits of physical activity 2) provide an overview of physical activity guidelines 3) write a SMART goal about physical activity 4) be aware of barriers to physical activity and how to overcome them.
214382729|NCT00058227|DRUG|alvocidib|Given IV
214382730|NCT00058227|DRUG|fludarabine phosphate|Given IV
214382731|NCT00058227|BIOLOGICAL|rituximab|Given IV
214382732|NCT00058227|OTHER|pharmacological study|Correlative studies
214382733|NCT00615134|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
214382734|NCT00615134|DRUG|Optimized background ARV therapy|As prescribed
214382735|NCT04379037|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation involves stimulating the auricular branch of the vagus nerve with a imperceptible electrical current within the concha of the ear.
214382736|NCT03908073|DEVICE|Transcutaneous vagal nerve stimulation|The use of a transcutaneous vagal nerve stimulator by the participant
214382737|NCT02237339|DRUG|Allopurinol|Uric acid lowering medication.
214382738|NCT02237339|DRUG|Placebo|
214382739|NCT02066896|DEVICE|Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
214382740|NCT02066896|DEVICE|Sham Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
214382741|NCT06118996|DEVICE|3D Ultrasound Image Acquisition|A custom device will be used with a clinical ultrasound machine to acquire ultrasound images of the breast.
214382742|NCT00246233|DRUG|methylphenidate|
214382743|NCT02106585|DRUG|JTT-251 or Placebo|Subjects will receive JTT-251 or Placebo
214687478|NCT07151716|DRUG|Dexmedetomidine|"For patients with endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.2 μg/kg/h dexmedetomidine and increased/decreased by 0.1 μg/kg/h dexmedetomidine every 15 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches 0.7 μg/kg/h dexmedetomidine, or adverse reactions occur. Daytime (06:00-20:00) sedation is provided as above when considered necessary, with a target RASS score of -2 to +1.~For patients without endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.10 μg/kg/h dexmedetomidine and increased/decreased by 0.05 μg/kg/h dexmedetomidine every 15 min, until the RASS reaches -1, maximal infusion rate reaches 0.2 μg/kg/h dexmedetomidine, or adverse reactions occur. Daytime (06:00-20:00) sedation is typically not provided."
214382744|NCT03186482|DRUG|Descovy® (TAF/FTC)|25/200 mg once daily for 28 days (DAYS 1-28).
214382745|NCT03186482|DRUG|Viread® (TDF)|245 mg once daily for 28 days (DAYS 57-84).
214382746|NCT03186482|DRUG|Rifadin® (Rifampicin)|600 mg once daily for 28 days (DAYS 29-56).
214382747|NCT05272670|BEHAVIORAL|A digital foot self-management program|A 4-week digital foot self-management program based on Bandura's Self-Efficacy model. The proposed functions include checking conditions of foot, cleaning, cutting or removing corns and calluses, trimming, clipping nails, foot exercise, dietary related to foot care, foot care logs, etc. Which was developed for older adults with diabetic foot self-management by the study team. Week 1 one-hour face-to-face training session after participant recruitment and allocation. The outline session is 30 min to introduce key topics and function in the app platform, 15 min to install the app and to demonstrate the use of the app, 15min to discuss and practice. Week 2 to week 4 following phone call once per week at the end of week and LINE messages 3 times per week.by research nurse, who will encourage and monitor participant's compliance with the program at home by using the digital platform. Participants are informed that technical phone support is available during the trial.
214382748|NCT02210793|PROCEDURE|transepithelial PRK|
214382749|NCT02210793|PROCEDURE|LASIK|
214382750|NCT04942808|RADIATION|Periapical radiographs|Periapical radiographs on reevaluation
214382751|NCT04363099|OTHER|observational|observational management of outpatients COVID 19
215093061|NCT02317952|OTHER|Experimental Extensively Hydrolyzed Formula|
214382752|NCT03425448|DRUG|Heparin|Heparin hemodialysis catheter lock solution
214382753|NCT03425448|DEVICE|Neutrolin|Neutrolin hemodialysis catheter lock
214382754|NCT05684913|PROCEDURE|Zn granulate stent after FGG surgery|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes and the ZnG was prepared according to the manufacturer guidelines. Briefly, approximately 10 grams of granulate was poured into hot water and then manually shaped to cover the surgical area. The retention was achieved from the palatal, occlusal and buccal surfaces of the teeth. The patient was asked to wear the ZnG for 7 days except for eating.(
215093062|NCT02317952|OTHER|Active Comparator Formula|
214382755|NCT05684913|PROCEDURE|Hemostatic agent suturing|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes. Then hemostatic agent containing cellulose were sutured on the palatal wound area with 4.0 vicryl sutures in this group. Sutures were removed after 7 days.
214382756|NCT05222464|OTHER|Standard of care treatments|Interventions will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
214498634|NCT06696352|BEHAVIORAL|Partners4Pain|This is a group program that will teach participants about different things they can do to manage their pain. They will watch educational videos and do workbook activities. They will learn and practice different exercises and mind-body strategies for pain including back and neck exercises (like strengthening and stretching), mind-body exercises (like meditation, relaxed breathing, guided imagery, and muscle relaxation), problem solving, and how to communicate with others about your pain. They will also have an opportunity to take part in discussions with other group members. The program will be delivered via weekly 90 minute sessions over 9 weeks and will be offered in-person or via videoconference.
214498635|NCT06696352|BEHAVIORAL|Keys to Wellbeing|This is a group program that will teach participants about different things they can do to improve their health and wellbeing. Participants will watch educational videos and do workbook activities. They will learn different back and neck exercises (like strengthening and stretching) and be introduced to different health-related topics including information and tips about health, pain and wellbeing; keeping active and well; the importance of rest and relaxation; and working with meaning and purpose in your life. They will also have an opportunity to take part in discussions with other group members. The program will be delivered in weekly 90 minute sessions over 9 weeks and will be offered in-person or via videoconference.
214382757|NCT00771225|PROCEDURE|fascial repair|surgery to treat genital prolapse with fascia repair
214382758|NCT00771225|PROCEDURE|mesh repair|surgery to genital prolapse with mesh
214382759|NCT00816933|PROCEDURE|appendectomy|appendectomy according to the number of trocar
214382760|NCT02205801|PROCEDURE|Superficial Cervical Plexus Block|0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
214382761|NCT02205801|PROCEDURE|Local Wound Infiltration|0.50% Marcaine is injected at the site of incision (10mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
214498636|NCT06832215|DIAGNOSTIC_TEST|Blood and urine samples collection|Blood and urine were collected at a single time point for all participants, from the tree study groups. Fasting for blood collection and the first urine in the morning were required.
214498637|NCT06828315|OTHER|Reflexology|Reflexology is a practice based on the fact that the organs in the body are connected to the reflex areas in the hands and feet.
214498638|NCT06456515|DRUG|Regorafenib and Sintilimab in combination with electroacupuncture|Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.
215093063|NCT04808271|DIETARY_SUPPLEMENT|Bifidobacterium breve Bif195|1 capsule daily for 8 weeks
214382762|NCT02205801|DRUG|0.9% saline|
214498639|NCT06319170|DRUG|Olanzapine Extended Release|Powder and vehicle for injectable suspension
214498640|NCT06319170|DRUG|Olanzapine|IntraMuscular Injection
214498641|NCT06583070|RADIATION|Radiation therapy|Administer radiation therapy to achieve as complete coverage as possible of all identifiable primary and metastatic lesions in conjunction with targeted and immunotherapy
214498642|NCT06583070|DRUG|Targeted and immunotherapy|Targeted and immunotherapy
214498643|NCT06826937|BEHAVIORAL|Reconsolidation based short term therapy|This is a behavioral intervention that uses imaginal and in vivo exposure in daily meetings.
214498644|NCT04912856|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
215093064|NCT04808271|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 8 weeks
215093065|NCT05733728|OTHER|any therapy suitable|any therapy suitable
214382763|NCT02205801|DRUG|Marcaine|
214382764|NCT06445790|BEHAVIORAL|Cognitive Behavior Therapy for Chronic Pelvic Pain-CBT-cp|CBT-cp will be administered weekly sessions for 12 weeks.
214382765|NCT02733783|DEVICE|Cold dry air machine|Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
214382766|NCT06356194|DRUG|Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK|A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
214382767|NCT06356194|DRUG|Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered.|A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
214382768|NCT03915184|BIOLOGICAL|zevor-cel|A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
214382769|NCT00674089|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A 50,000 IU
214382770|NCT00674089|DIETARY_SUPPLEMENT|Placebo|Vitamin A Placebo
215093066|NCT06233994|BIOLOGICAL|ZG005 Powder for Injection|ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
215093067|NCT06233994|DRUG|Donafenib Tosilate Tablets|Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
215093068|NCT06233994|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
214382771|NCT06127576|DEVICE|paraboloid geometry double and triple dental abutment-implant|"The implants were inserted with the margin between machined and micro-rough surface at bone level. The abutment and crowns were assembled and screw retained onto the implant with a torque of 35 Ncm.~The implants were cylindrical with internal hexagon and without surface treatment, presenting 4.0 mm in diameter and length varying between 10 and 13 mm.~Acording to the manual work model measurements, DA or TA acrylic individualized design and paraboloid surfaces of the DA (elliptical) and TA (hyperbolic) had been made."
214498645|NCT05858437|DIETARY_SUPPLEMENT|Sodium propionate|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
214498646|NCT05858437|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
214498647|NCT05613907|OTHER|CLTI Clinic|This is a specialist clinic designed to assess and manage patients with CLTI. Patients are assessed and imaged, and undergo elective revascularization procedures if appropriate
214498648|NCT06827756|DRUG|Norfloxacin 400 MG|Patients receiving Norfloxacin 400 Mg to prevent SBP
214498649|NCT06827756|DRUG|Nitazoxanide 500 MG|Patients receiving Nitazoxaide 500 Mg to prevent SBP
214498650|NCT06827756|DRUG|Colistin|Patients receiving Colistin 15ml three times/ day to prevent SBP
214498651|NCT06827093|OTHER|Skill Building Dyadic Intervention|The focal point of skill-building interventions contains some strategies that facilitate problem-solving, goal setting, communicating with care experts, stress management, hands-on training in such skills (lifting and mobility techniques and assistance with activities of daily living), and modification of communication according to the needs of stroke survivors.
214498652|NCT06461052|PROCEDURE|music therapy|The patient will benefit from viewing the video and the music therapy session in the waiting room of the operating room. The patient will be asked again for their anxiety score using an anxiety scale. This will define the main outcome of the study. Following this collection and in order not to influence the response, investigators will collect from the patient his compliance with the two proposed techniques as well as his appreciation of the tool.
214498653|NCT05949593|DRUG|Tinlarebant|5 mg tablet taken orally once a day
214498654|NCT05949593|DRUG|Placebo|Placebo tablets for tinlarebant 5 mg prepared similarly.
214498655|NCT06075732|BEHAVIORAL|Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccine hesitancy and increase willingness and uptake in Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccination.
214995902|NCT06229704|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
214498656|NCT04238715|DRUG|E7090|E7090 tablets orally.
214995903|NCT06229704|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
214995904|NCT06229704|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
214995905|NCT06229704|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
214995906|NCT03935048|DIETARY_SUPPLEMENT|Higher protein, low glycemic load diet|"All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided."
214995907|NCT03326336|COMBINATION_PRODUCT|Gene therapy: GS030-DP AND Medical device: GS030-MD|GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)
214498657|NCT03626571|OTHER|18F-FDG|Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
214995908|NCT06005103|DEVICE|Treatment with MoodHeadBand (T-PEMF treatment)|The patients will receive treatment with T-PEMF using a headband containing 20 coils placed symmetrically around the head of the patient. The device delivers 55 Hz magnetic field. Duration of treatment is 30 minutes once a day for 8 weeks.
214382772|NCT00840255|BEHAVIORAL|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
214382773|NCT00840255|OTHER|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
214382774|NCT06210906|OTHER|Assessment of gastric volume|Gastric volume is assessed using ultrasound.
214382775|NCT00189592|DEVICE|ArthroCare TOPAZ™ MicroDebrider™ using Coblation|Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
214382776|NCT00189592|PROCEDURE|Surgical Fasciotomy|Standard surgical fasciotomy using an incision to treat the plantar fascia.
214382777|NCT05356390|OTHER|Stabilization exercises|"Stabilization training is an active form of physical therapy designed to strengthen muscles to support the spine and help prevent lower back pain.~Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
214382778|NCT05356390|OTHER|Muscle energy techniques|"Muscle Energy Technique (MET) is a is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.~Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
214498658|NCT04627883|OTHER|Inspiratory-to-expiratory (I : E) ratio of 1:2|After preoxygenation and induction of anesthesia, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2 for 5 min before endotracheal intubation.
214498659|NCT04627883|OTHER|Inspiratory-to-expiratory (I : E) ratio of 2:1|After preoxygenation and induction of anesthesian, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1 for 5 min before endotracheal intubation.
214498660|NCT06077461|BEHAVIORAL|mandala painting|Patients in this group will be subjected to mandala painting.
214498661|NCT06824428|OTHER|Pain perception threshold|The patients' pressure pain threshold will be evaluated with a manual pressure algometer (Baseline Dolorimtre®).The patients' pain perception thresholds will be measured bilaterally in the midfrontal region, the midpoint of the trapezius muscle, the lateral epicondyle, the midpoint of the web between the 1st and 2nd fingers, the greater trochanter, and the medial crease of the knee.
214498662|NCT05696561|DEVICE|Canaloplasty Device|Canaloplasty
214498663|NCT05812183|DEVICE|Bariatric surgery|Gastric sleeve resection will be performed by experienced surgeons. Postoperative care will follow UCLA's postoperative care pathways for gastric sleeve resection.
214498664|NCT05812183|DRUG|Medical weight loss|The medical weight loss intervention will follow UCLA's RFO standard protocol. Over a period of 12 months, patients in the medical weight loss group will follow a very low caloric diet (VLCD) at the UCLA RFO program. All study patients will be prescribed a VLCD, an exercise regimen and will participate in group classes on behavioral modification. The caloric intake consists of a commercially prepared meal replacement powder supplying 700-800 cal/day. Each formula packet provides 100kcal and 15g of high biological value protein, and the daily allowance of required minerals and vitamins. Some patients may recieve adjuvant drug therapy including Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), Naltrexone-bupropion (Contrave), Liraglutide (Saxenda), Semaglutide (Wegovy), Tirzepatide (Zepbound) or Setmelanotide (Imcivree).
214498665|NCT06586645|BEHAVIORAL|Safety Planning|Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction.
214498666|NCT06586645|BEHAVIORAL|Give to Others Module|"The Give to Others Module is a brief cognitive behavioral intervention targeting youth burden-related beliefs. It consists of one primary session and brief phone follow-up."
214498667|NCT06826651|PROCEDURE|laparoscopic appendectomy|By using laparoscopy, after achieving conclusive identification of the mesoappendix
214498668|NCT06826651|PROCEDURE|bipolar diathermy|the mesoappendix coagulated using bipolar diathermy, then cut with scissor.
214995909|NCT06005103|DEVICE|Inactive treatment with MoodHeadBand (Placebo)|Patients will use an identical device, which does not deliver T-PEMF treatment. The patients will use the headband as the active group for 30 minutes, once a day, for 8 weeks.
214995910|NCT06343792|DRUG|RLS-0071|RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
214995911|NCT06409260|OTHER|Acceleromyography (AMG)|Philips IntelliVue NMT Module
214995912|NCT06409260|OTHER|Electromyography (EMG)|Senzime TetraGraph
214382779|NCT03393702|DRUG|Gabapentin|"1. Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin.~2. Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day."
214498669|NCT06826651|PROCEDURE|clips closure|mesoappendix will be divided between 3 clips, two placed distally and one proximally. The mesoappendix will be cut in between the clips.
214498670|NCT06828354|DRUG|SHR-A1811|SHR-A1811.
214498671|NCT06828354|DRUG|Paclitaxel Injection|Paclitaxel Injection.
214498672|NCT06828354|DRUG|Doxorubicin Hydrochloride Liposome Injection|Doxorubicin Hydrochloride Liposome Injection.
214382780|NCT03393702|DRUG|Placebo|"1. Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.~2. Patients after surgery receive identical placebo capsules 2 times per day."
214498673|NCT06828354|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection.
214498674|NCT06828354|DRUG|Topotecan Hydrochloride for Injection|Topotecan Hydrochloride for Injection.
214498675|NCT04728711|DRUG|ADX-629|ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
214498676|NCT04728711|DRUG|Placebo|Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
214498677|NCT05760846|DEVICE|REAplan®|motor skill learning with the REAplan® rehabilitation robot, to be performed with both arms
214498678|NCT05760846|DEVICE|Dextrain Manipulandum®|motor skill learning with the Dextrain Manipulandum® dexterity tool to be performed with both hands
214498679|NCT00748709|DRUG|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
214498680|NCT04660721|COMBINATION_PRODUCT|sFilm-FS|sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.
214498681|NCT04660721|COMBINATION_PRODUCT|TACHOSIL®|TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.
214498682|NCT03546335|DRUG|89Zr-DFO-CZP|89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
214498683|NCT03809715|DEVICE|Coroflex® ISAR NEO coronary stent system|"treatment of coronary artery disease with Coroflex® ISAR NEO of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
214498684|NCT06253585|OTHER|Algorithm Alarm- Crystalloids|"The study uses an algorithm implemented within the Electronic Health Record (EHR). This algorithm identifies patients who belong to a sepsis subphenotype known as Group D, in whom published data has shown a mortality benefit from balanced crystalloids compared to normal saline.~The intervention is an EHR alert when clinicians order normal saline on Group D patients randomized to intervention. In the intervention arm, if a clinician orders normal saline in a patient classified as Group D, there will be an EHR alert to change the order to balanced crystalloids (i.e., Lactated Ringer or Plasma-Lyte solution)."
214498685|NCT06253585|OTHER|Standard of Care|Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care. In the usual care arm, the clinicians will not have any feedback from the algorithm and will not know the Group classification of their patient or the recommended fluid type.
214498686|NCT05483517|DEVICE|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A normal energy of high-PEMF with a rate of 2 pulse per second is applied to the patient.
214498687|NCT05483517|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(normal energy, a rate of 2 pulse per second) with the difference that the energy output doesn't export to the patient.
214498688|NCT05483517|BEHAVIORAL|physiotherapy|Physiotherapy includes shoulder range of motion (ROM), stretching and muscle strengthening exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
214382781|NCT06214858|DRUG|SHEN211 tablets|SHEN211 tablets, tablets, specification: 0.11g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
214382782|NCT06214858|DRUG|SHEN211 placebo tablets|placebo tablets, tablets, specification: 0g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
214498689|NCT06748768|DIAGNOSTIC_TEST|group 1|To determine the optimal treatment for dry eyes in term of cost effectiveness and time efficiency by comparing omega 3 supplements versus warm compression
214498690|NCT03031483|DRUG|clarithromycin and lenalidomide|"Each treatment course will consist of:~Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total."
214498691|NCT06359821|DRUG|ZA-001|Study drug ZA-001 administered via intravenous injection.
214995913|NCT04855851|PROCEDURE|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|The subjects of this group will receive an amount of six sessions that will be applied within 12 weeks. Every 15 days, the subjects will come for a consultation to receive a PNE session and review of the exercise program, which will be carried out 3 times a week for 12 weeks.
214995914|NCT04855851|PROCEDURE|USUAL CARE|"Aerobic exercises will consist of a standard table of low intensity stretching exercises, commonly prescribed to fibromyalgia patients. There will be three series of 30 seconds of each stretch, having a total duration of approximately 40 minutes. Each session will be held twice a week, following the recommendations of the American College of Sport Medicine. Monitoring will be performed every 15 days by a physiotherapist."
214995915|NCT05728775|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia.
214995916|NCT05728775|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia.
214995917|NCT01081951|DRUG|olaparib|Tablets Oral BID
214995918|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
214995919|NCT01081951|DRUG|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
214995920|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
214995921|NCT01081951|DRUG|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
214995922|NCT05551949|DRUG|Vaginal estradiol tablets|Vaginal estradiol tablets (10mcg).
214995923|NCT04443452|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
215093069|NCT04454541|PROCEDURE|Ultrasound-guided nerve block for headache management|The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
215093070|NCT02142036|DRUG|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
215093071|NCT04155606|DEVICE|microsurgery; endovascular interventions|microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
215093072|NCT04584593|BIOLOGICAL|Sample|Men will give semen, saliva, nasopharyngeal, urine and blood specimens
215093073|NCT00551603|DRUG|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
215093074|NCT00551603|DRUG|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
215093075|NCT01502163|DEVICE|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
215093076|NCT01502163|DEVICE|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
215093077|NCT06246812|BEHAVIORAL|Deans' Fit Family Challenge|An annual 8-week physical activity and weight loss competition between VCOM-Auburn, AU College of Nursing, and AU Harrison School of Pharmacy
214995924|NCT04443452|RADIATION|Radiographic Evaluation|Tibiofemoral and patellofemoral radiographs of the most painful knee will be taken using a standardised protocol (standing posterior-anterior (PA) and skyline views) and will be scored by a single experienced observer in order to generate data for correlation analyses with the primary and secondary outcomes. A Perspex Rosenberg template with lead beads is used for the standing PA view to standardising the degree of knee flexion, foot rotation and magnification. PA radiographs are taken with the participant facing the x-ray tube while standing on the Rosenberg jig and leaning forwards with their thighs touching the anterior aspect of the jig, the x-ray beams passing from the posterior aspect through to the anterior aspect of the knee. Variable jigs are used for the skyline view to obtaining 300 of knee flexion with the participant lying in a reclined supine position on a couch. Grading of radiographs for changes of OA will be based on the Kellgren and Lawrence (K/L) score.
215093078|NCT06246812|BEHAVIORAL|Text message|Three text messages per week to promote and motive physical activity
215093079|NCT04999527|DRUG|DISC-0974|DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
214382783|NCT06248840|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
214382784|NCT06248840|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
214995925|NCT04443452|PROCEDURE|Ultrasound-guided Aspiration|Ultrasound scanning will be conducted on the most painful knee to identify synovial effusion. During the ultrasound scan, the supra-patellar pouch, medial and lateral recess of the knees will be assessed for synovial thickening, synovial fluid/effusion and for positive power Doppler. An ultrasonic probe will be used to direct ultrasonic waves onto the knee joint during sonography, and a computer converts the signals received so that they can be presented on the screen. During skin application, a sterile probe cover and sterile acoustic gel will be used. Once the best aspiration location is identified and the location of the needle insertion marked, the skin will be prepared with a cleansing agent such as iodine or chlorhexidine. The needle may be introduced into the skin either parallel to the probe or perpendicular to the probe. Once the aspiration is completed, the needle will be removed, the skin cleansed, and a bandage will be applied.
214382785|NCT01547988|OTHER|Balance Training Intervention|The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
214382786|NCT01373450|DRUG|Oxyntomodulin|3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
214382787|NCT01373450|DRUG|Liraglutide 0.6 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
214382788|NCT01373450|DRUG|Liraglutide 1.2 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
214382789|NCT01373450|DRUG|Placebo for Oxyntomodulin|IV infusion in the morning of the day of GGI (Day 1)
214382790|NCT01373450|DRUG|Placebo for Liraglutide|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
214382791|NCT05541562|DIAGNOSTIC_TEST|clinical laboratory tests, and imaging characteristics|Data included the demographic status, etiology of the liver disease, clinical laboratory tests, and imaging characteristics. Clinical laboratory tests included D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin III, international normalized ratio (INR), thrombin time (TT), albumin (Alb), serum creatinine, hemoglobin, platelet count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, model for end-stage liver disease (MELD) score, and Child-Pugh score. Imaging characteristics included splenic vein diameter, splenic vein velocity, portal vein diameter, and portal vein velocity.
214382792|NCT03893201|OTHER|Questionnaires|Questionnaires to assess quality of life
214382793|NCT02985983|DRUG|Brodalumab|Administered Brodalumab by subcutaneous (SC) injection until week 66.
214382794|NCT02985983|DRUG|Placebo|Administered Placebo by subcutaneous (SC) injection until week 16. Administered Brodalumab by SC injection from week 17 until week 66.
214382795|NCT04761614|BIOLOGICAL|Bevacizumab|Given IVPB
214382796|NCT04761614|DRUG|Fluorouracil|Given IV
214382797|NCT04761614|DRUG|Leucovorin Calcium|Given IVPB
214382798|NCT04761614|DRUG|Oxaliplatin|Given IVPB
214382799|NCT04761614|DRUG|Riluzole|Given PO
214382800|NCT00627900|DEVICE|bare metal stent|implantation of a bare metal stent
214382801|NCT00627900|DEVICE|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
214382802|NCT06483425|GENETIC|Sequencing of DNA, RNA, and Proteins|Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.
214382803|NCT02865070|DEVICE|Skin Sensor|Wireless vitals monitor
214382804|NCT00158340|BEHAVIORAL|Guided self-help cognitive behavioral therapy (CBT)|Participants receive eight sessions of guided self-help CBT.
214382805|NCT00158340|BEHAVIORAL|Usual clinical care|Control group participants receive treatment as usual.
214382806|NCT01139463|DRUG|Haloperidol or olanzapine|Haloperidol tablet - 5 mg twice daily (morning and evening) by mouth Olanzapine tablet - 5 mg twice daily (morning and evening) by mouth
214382807|NCT02206308|BIOLOGICAL|Chimeric anti-CD20 monoclonal antibody|
214382808|NCT04659395|OTHER|Emergency nurses|Emergency nurses who are trained for one-day in ultrasound-guided femoral nerve block
214498692|NCT05682300|PROCEDURE|peripheral nerve block|After signing the informed consent by the patient, specific for this observational study, the peripheral regional anesthesia technique will be performed following the usual practice of the anesthesiologist responsible for the surgery. Under standard monitoring and taking into account the necessary aseptic measures, either peripheral nerve blocks (for surgeries involving extremities) or fascial blocks (for surgeries involving the chest wall, abdomen, or spine) will be performed.
214995926|NCT04443452|DIAGNOSTIC_TEST|Muscle Strength Assessment|Isometric testing will be done at 30 and 60 degrees of flexion as done in the previous study and the participant will be in sitting position with hips and knees strapped to keep the position standardised.
214382809|NCT01536184|BEHAVIORAL|Circle of Security (COS)|COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
214382810|NCT04623320|DIAGNOSTIC_TEST|euglycaemic clamp test|clamp test (golden standard) to determine insulin resistance
214995927|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (A)|"The participant will start in a seated position. The participant will stand up upon therapist's command, walk 3 meters, turn around, walk back to the chair and sit down. The time will stop when the participant is seated. The subject can use an assistive device. If the assistive device is used, it will be documented.~Important Note: A practice trial will be completed before the timed trial."
214995928|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (B)|The 30-Second Chair Test is administered using a chair. The participant is seated in the middle of the chair with arms crossed at the wrists and held against the chest. The participant will practice a repetition or 2 before completing the test. If a participant must use their arms to complete the test, they are scored 0. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand. While monitoring the participant's performance to ensure proper form, the tester silently counts the completion of each correct stand. The score is the total number of stands within 30 seconds (more than halfway up at the end of 30 seconds counts as a full stand). Incorrectly executed stands are not counted. The 30-second chair stand involves recording the number of stands a person can complete in 30 seconds rather than the amount of time it takes to complete a pre-determined number of repetitions.
214995929|NCT04443452|DIAGNOSTIC_TEST|Balance Assessment|Static balance and postural sway either in the medial-lateral or antero-posterior direction will be assessed using the RS Scan force plate. The participant will be asked to stand on the plate looking straight forward for 30 seconds in two conditions: first with their eyes open and then with eyes closed. Medial-lateral, antero-posterior and total sway will be recorded.
214382811|NCT04623320|DIAGNOSTIC_TEST|13C glucose breath test|13C glucose breath test to compare with the golden standard
214382812|NCT01928316|DRUG|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
214382813|NCT01928316|DRUG|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
214382814|NCT01906671|DRUG|Xaluprine|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
214498693|NCT05580978|BEHAVIORAL|GEM|The intervention group will be given Libre 2 supplies for 4 months, an activity monitor, and the 4-chapter GEM paper guide. The intervention group will complete a virtual or inperson study visit where they will receive instructions on how to apply their unblinded Freestyle Libre and connect it to the study account, as well as how to register their Fitbit to the study account. Participants will receive one telephone call to review use of the GEM Guide and call at two weeks and six weeks later when the probability of dropouts from lifestyle intervention peaks. Participants will follow the self-directed GEM guide for 4 months (a 1-month treatment period followed by a 3-month maintenance period) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM.
214498694|NCT05580978|OTHER|Routine Care|Participant's current prediabetes treatment.
214498695|NCT02751528|BIOLOGICAL|ETBX-021|ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
214995930|NCT05579600|BEHAVIORAL|Caring Contacts letters|Caring Contacts involves sending individuals at risk for suicide brief, non- demanding messages of care.
214995931|NCT05579600|BEHAVIORAL|Reports, re-engagement, and training|Behavioral health providers will receive training in reaching out to and re- engaging patients who pass through the justice system, as well as training in suicide risk assessment (the Columbia Suicide Severity Rating Scale; C-SSRS) and response (the Safety Planning Intervention; SPI).
214995932|NCT05320042|DEVICE|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
215093080|NCT04999527|DRUG|Placebo|Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
215093081|NCT02916251|DRUG|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
214382815|NCT01906671|DRUG|Puri-Nethol|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
214382816|NCT05794802|DIETARY_SUPPLEMENT|BHB supplement|Oral consumption of 0.5 g/kg of a BHB supplement (KE4; Ketoneaid®, Falls Church, Virginia, USA)
214382817|NCT05794802|OTHER|Placebo solution|80 to 120 ml of a placebo solution, depending on the participant's body weight, with the addition of stevia and bitter agent solution (Bitrex, Scotland, UK) as well as the same flavouring as the ketone supplement drink (provided by Ketoneaid)
214382818|NCT03192644|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
214382819|NCT03192644|PROCEDURE|TACE|transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
214382820|NCT03192644|DRUG|epidoxorubicin and cisplatin and lipiodol|epidoxorubicin and cisplatin and lipiodol
214382821|NCT03192644|DRUG|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
214498696|NCT03936101|DIAGNOSTIC_TEST|Prenatal Genomic Sequencing|Whole genome sequencing (which initially will be masked and reported as exome only)
215093082|NCT02916251|DRUG|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
215093083|NCT00169507|BIOLOGICAL|Pneumococcal (vaccine)|
214498697|NCT06809972|OTHER|Ultrasound imaging|Ultrasound, MRI and elastography to screen for and follow subclinical synovial changes in ankle, elbow and knee.
214498698|NCT06056570|DRUG|dontinurad|dotinurad alone
215093084|NCT02402413|PROCEDURE|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
214382822|NCT03260582|OTHER|LifePod®|The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
214382823|NCT02813746|DIETARY_SUPPLEMENT|Fitness program|
214382824|NCT02813746|BEHAVIORAL|Stop smoking|
214382825|NCT02813746|PROCEDURE|Endometrial fluid collection|
214382826|NCT06382714|OTHER|For the intervention group, a museum visit with virtual reality glasses will be applied.|Patients will visit a museum while undergoing hemodialysis with virtual reality glasses for a total of five sessions for intervention group
214382827|NCT04653441|BEHAVIORAL|Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention|"The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy)."
214498699|NCT06056570|DRUG|dotinurad + allopurinol|dotinurad + allopurinol 300mg
214498700|NCT06056570|DRUG|allopurinol|allopurinol 300 mg alone
214995933|NCT05320042|DEVICE|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
214995934|NCT05464095|DEVICE|mHealth Intervention|The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
214995935|NCT05464095|DEVICE|Usual Care|The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
214995936|NCT02993367|DRUG|Butylphthalide Soft Capsules|DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.
214995937|NCT02993367|DRUG|Placebo Butylphthalide Soft Capsules|
214995938|NCT01963234|BEHAVIORAL|Seva|Patients were given access to use Seva. This is a mobile application that uses social and behavioral theories to help support people after alcohol use disorder recovery.
214995939|NCT06189313|DEVICE|Cleaner Pro Thrombectomy System|"The Cleaner™ Pro Thrombectomy System (Cleaner Pro) is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister."
214995940|NCT04975763|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
214995941|NCT04975763|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
214995942|NCT00835718|DRUG|Comparator: MK0594 5 mg/day|MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
214382828|NCT00235599|PROCEDURE|IGFBP-3 Stimulation Test|
214382829|NCT00510458|DEVICE|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
214498701|NCT06887764|DEVICE|RKO-assisted walking in children with CP|The investigators will assess walking in each of the following conditions: shod (shoes or shoes + AFO) and RKO-assisted (shoes + RKO), to achieve the following: (1) Evaluate the effect of RKO, compared to shod upon endurance in children with CP at GMFCS level II, and (2) Evaluate the effect of RKO, compared to shod, upon temporal-spatial parameters, lower limb sagittal joint kinematics, and muscle EMG in children with CP at GMFCS level II.
214995943|NCT00835718|DRUG|Comparator: MK0594 1 mg/day|MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
214995944|NCT00835718|DRUG|Comparator: MK0594 1 mg/week|MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
214995945|NCT00835718|DRUG|Comparator: Placebo to MK0594|Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
214995946|NCT04578756|DRUG|Cariprazine Flexible Dose|1 capsule to be taken orally at approximately the same time of day (morning or evening)
214995947|NCT04578756|DRUG|Cariprazine Flexible Dose|Dose solution (in milliliters) to be taken orally at approximately the same time of day (morning or evening)
214995948|NCT05823805|OTHER|Community Health Worker|"Physicians will work with a Community Health Worker (CHW) to review the data presented in their Quality Improvement reports, and triage patients for proactive outreach (e.g. No action necessary, Call patient to check-in, Arrange BP, weight and labs, Book for phone appointment, Book for in-person appointment)."
214995949|NCT04750226|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
214995950|NCT02890017|OTHER|postoperative hotel|"Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.~Postoperative consultation at 1 and 3 months."
214995951|NCT02890017|OTHER|conventional hospitalization|Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
214382830|NCT05555992|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
214382831|NCT02516722|DEVICE|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
214498702|NCT06763471|DEVICE|Neuropixels recording intraoperatively during planned neurosurgery|"The SUNAN study is a basic science study involving a procedure to record single-unit neurophysiological activity with human participants who are already undergoing a transcranial neurosurgical procedure on the brain.~As part of the surgery, a region of cerebral cortex on the convexity of the brain will be:~* Resected e.g., as removal of part of a tumour or epilepsy focused. Or~* Transgressed as part of the surgical approach to reach a deeper target e.g., resection of a deep tumour or cavernoma.~Or~• Transgressed by the passage of a surgical implant e.g., a ventriculoperitoneal shunt catheter or deep brain stimulation electrode.~Within this region of the brain that is going to be resected or transgressed, the research team will undertake a single-unit resolution neurophysiological recording (NR) using a digital neural probe (Neuropixels) for a maximum of 15 minutes."
214498703|NCT04402151|DRUG|PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
214498704|NCT04402151|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive standard of care radiation therapy (SBRT)
214498705|NCT06773390|PROCEDURE|Percutaneous liver biposy|Percutaneous liver biopsy in pediatric patient diagnostic significance and pattern of liver diseases
214498706|NCT06575621|BEHAVIORAL|Support program|education, medical navigation, exercise
214995952|NCT01070680|DRUG|Precedex|mkg/ml,continuous infusion at rate 0.7 µg/kg/h
214995953|NCT01070680|DRUG|sodium chlorid 0,9%|continuous intravenous infusion
214995954|NCT02170714|OTHER|Clinical and laboratory assessment|Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI\>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
214995955|NCT02646085|DRUG|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
215093085|NCT02402413|PROCEDURE|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
215093086|NCT02402413|DEVICE|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
215093087|NCT01699568|DEVICE|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
214498707|NCT06828107|DEVICE|SENSE device|The SENSE Device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage and/or cerebral edema.
214498708|NCT05348577|DRUG|capivasertib|"320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.~Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment."
214498709|NCT05348577|DRUG|docetaxel|Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
214995956|NCT00497510|PROCEDURE|Chiropractic manipulation|
214995957|NCT05793723|DIAGNOSTIC_TEST|Pulmonary function testing device|Patients will undergo pulmonary function tests with the Exhalyzer D (Ecomedics, Switzerland) device. This device consists of 1) an ultrasonic flow measuring system for measuring flow, volume and molecular mass, 2) a nitrogen washout system to measure functional residual capacity (FRC) and other indices, 3) a carbon dioxide infrared measurement device for monitoring the level of carbon dioxide in exhaled breath.
214995958|NCT06188000|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|The patients was given extra virgin olive oil, an unrefined (not processed with chemicals or heat) for of olive oil
214995959|NCT06188000|DIETARY_SUPPLEMENT|Olive Oil|The patients was given olive oil.
214995960|NCT06188000|DIETARY_SUPPLEMENT|Placebo|The patients was given empty capsule
215093088|NCT00952887|BIOLOGICAL|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
215093089|NCT00952887|BIOLOGICAL|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
215093090|NCT03419065|BEHAVIORAL|Relaxation Intervention|Relaxing Music combined with Progressive Muscle relaxation and guided imagery
215093091|NCT02913768|DRUG|Ondansetron|
215093092|NCT02913768|DRUG|Normal saline|
215093093|NCT00320463|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
215093094|NCT04868149|PROCEDURE|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.
214995961|NCT00975923|BEHAVIORAL|Collaborative Group|"In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these virtual learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams."
214382832|NCT05573503|OTHER|Bring it up - Assessment and support of patients' sexuality in cancer nursing|"Participants will attend a five week online university course, Bring it up - Assessment and support of patients' sexuality in cancer nursing. The course addresses theories and models about sexuality in relation to cancer illness, conversation techniques, models for addressing sensitive topics, methods for assessing the impact of cancer on sexuality, methods for preventing and treating sexual problems in relation to cancer, relevant nursing interventions for person-centred counselling about sexuality, and ethical aspects.~The teaching consists of literature, online lectures, seminars, clinical practice, and written exams. A university certificate will be issued to participants who pass all exams."
214382833|NCT02034253|DRUG|Risperidone|Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
214382834|NCT01175889|DEVICE|E-Z Clean ACE Blade|The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
214382835|NCT03607188|DRUG|Alkotinib|Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
214382836|NCT05164302|PROCEDURE|Auricular acupuncture|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, we use press tack needles to perform auricular acupuncture.
214498710|NCT05348577|OTHER|placebo|matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
214498711|NCT05943197|DIAGNOSTIC_TEST|dental prosthetics, biofilm response and oral microbiota|microbiota, biofilm, oral mucosa
214498712|NCT06922240|DRUG|Riociguat|On the basis of the comprehensive treatment in line with the guidelines, including conventional diuresis, anticoagulation, oxygen inhalation, etc., continue oral administration of riociguat for treatment.
214498713|NCT06922240|DRUG|Routine Treatment|On the basis of the comprehensive treatment in line with the guidelines, including conventional diuresis, anticoagulation, oxygen inhalation, etc, and stop taking riociguat
214995962|NCT00975923|BEHAVIORAL|Tool Kit|Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
214995963|NCT01344928|BEHAVIORAL|HIT exercise intervention|
214995964|NCT01344928|BEHAVIORAL|Aerobic exercise intervention|
215093095|NCT03708666|OTHER|Telemonitoring of blood pressure|Blood pressure monitoring at least once a week.
214382837|NCT02043028|DEVICE|Chest compression with a step stool|Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes
214382838|NCT02043028|DEVICE|Chest compression with a kneeling stool|Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
214382839|NCT05102422|DRUG|Propofol 1 % Injectable Suspension|Induction and maintenance of general anesthesia using the intravenous anesthetic
214382840|NCT05102422|DRUG|Sevoflurane inhalant product|Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane
214382841|NCT02929225|DRUG|Bifid Triple Viable Capsules|BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals.
215093096|NCT01456312|DRUG|Peginterferon alfa-2a|Duration and combination
215093097|NCT01456312|DRUG|Entecavir|combination
215093098|NCT06549439|RADIATION|Electron FLASH radiotherapy|A nominal electron energy of 9 MeV will be used for both Flash-RT and Conv-RT, which guarantees ≥ 90% dose coverage up to a depth of 2.8 cm. Shallower lesions will be treated with the same electron energy and with a bolus. In order to treat these patients, field sizes between 2x2cm2 and 10x10cm2 will be used, which can be delivered with sufficient flatness (\<5%) and symmetry (\<2%) by the FlashTrueBeam v2.7.5.
215093099|NCT02317978|PROCEDURE|ICSI|records of women who had ICSI will be reviewed and analysed for determining FSI
215093100|NCT00218699|BEHAVIORAL|Cognitive-Behavioral Intervention|
214382842|NCT02929225|OTHER|placebo|placebo is also prescribed as a dose of 4 capsules twice daily
214382843|NCT04433962|OTHER|Exercise training|
214382844|NCT02503267|OTHER|none intervention|
214382845|NCT03120689|OTHER|Live Surgery using VITOM|The vaginal operative field will be filmed with a VITOM® camera and the image from the VITOM® camera will be projected live within the operating room, so that the operating team can reference the image during the surgery.
214382846|NCT03120689|OTHER|Live Surgery without VITOM|The vaginal operation will not be filmed and learner observation will take place in the traditional way, with them looking at the physical surgical field.
214382847|NCT03120689|OTHER|Video viewing with VITOM|They will view the 10-minute standardized video filmed with the VITOM® camera.
214382848|NCT03120689|OTHER|Video viewing with standard handheld high-definition camera|They will view the 10-minute standardized video filmed with the standard, handheld high-definition camera.
214382849|NCT03352843|DRUG|Primaquine|All patients will be administered with a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen, and then followed-up for 28 days for clinical and laboratory assessment to assess safety and efficacy.
214995965|NCT04935606|BEHAVIORAL|Usual Care|Usual Care participants will receive their standard medical care as usual and all study assessments. Providers will not receive information about their drug use. To reduce Hawthorne effect biases and to mask the study's purpose, RAs will provide the Usual Care arm patients with a cancer screening booklet and have them view a cancer screening Video Doctor. Participants will receive re-contact calls (5 min) to provide attentional control for the Usual Care arm, motivate continued trial participation by reminding next research assessment and study incentives, update contact information, and address participation barriers, but do not provide intervention. At study end, Usual Care will receive the QUIT video doctor and drug use reduction booklet materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
214995966|NCT04935606|BEHAVIORAL|QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)|"QUIT's core components include:~1. patient screening with the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST, score 4-26);~2. face-to-face brief clinician advice on reducing drug use (2-3 minutes);~3. video doctor reinforcing the clinician message;~4. drug use reduction brochure;~5. 2- and 6-week telephone health coaching sessions to enhance self-efficacy in reducing drug use, via motivational interviewing and cognitive behavior therapy (CBT) techniques (20-30 minutes)."
214995967|NCT04935606|BEHAVIORAL|QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)|"The QUIT-Mobile intervention includes QUIT's core components and adds:~1. SMS/IVR/mobile-app self-monitoring survey prompts twice-weekly during the QUIT coaching through 6 weeks, and then weekly self-monitoring and automated feedback via SMS/IVR/app through 12-months.~2. Web-based dashboards will be used by coaches for monitoring of patients' self-monitoring data to enhance 2- and 6-week coaching sessions and for monitoring during the post-coaching self-management and monitoring period from 7-weeks to 12-months and intervening accordingly. The mobile platform will provide the same intervention functions (self-monitoring surveys and feedback messages) and robust data transfer protocols across three mobile technology platforms."
214995968|NCT04428671|BIOLOGICAL|Cemiplimab|Given IV
214995969|NCT04428671|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
214995970|NCT04428671|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214995971|NCT06801704|BEHAVIORAL|Top Set Resistance Training|Participants will receive four warm-up sets at increasingly higher resistance, followed by three sets of eight repetitions per set on six resistance-training exercises. During training participants will be allowed 1-minute rests between sets. Participants will come in person for up to 12 weeks, twice per week, for approximately 45 minutes per day.
214995972|NCT06801704|BEHAVIORAL|Power Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set on six power resistance-training exercises. During training participants will be allowed 1-minute rests between sets. Participants will come in person for up to 12 weeks, twice per week, for approximately 45 minutes per day.
214382850|NCT00087542|DRUG|ACP-103|
214382851|NCT02269514|OTHER|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
214382852|NCT02269514|OTHER|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
214382853|NCT02269514|OTHER|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
214382854|NCT02269514|OTHER|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
214382855|NCT02269514|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
214382856|NCT04645784|OTHER|Supporting Student-Athletes Mental Wellness|The module addresses: 1) managing your own mental wellness; 2) signs and symptoms of mental health problems; 3) role of student-athletes in creating a positive team environment that is supportive of mental health care seeking; 4) the role of a student-athlete in helping teammates; 5) how to identify emergency and non-emergency mental health situations.
214382857|NCT01575743|BEHAVIORAL|aerobic exercising|All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
214382858|NCT01861522|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
214382859|NCT01861522|DRUG|Placebo|Two Placebo tablets will be taken orally twice a day
214382860|NCT01395654|DRUG|isoniazid, rifampin, pyrazinamide|rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
214382861|NCT00425425|BIOLOGICAL|cetuximab|
214382862|NCT00425425|DRUG|fluorouracil|
214382863|NCT00425425|DRUG|oxaliplatin|
214382864|NCT00425425|PROCEDURE|conventional surgery|
214382865|NCT00425425|PROCEDURE|neoadjuvant therapy|
214382866|NCT00425425|RADIATION|radiation therapy|
214498714|NCT05071430|DRUG|HB-01|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
214498715|NCT05071430|DRUG|Placebo|HB-1 matched placebo
214498716|NCT06745232|DEVICE|FAST MAP|Patients with complete arch restorations loaded immediately with a full digital workflow using stereophotogrammetry Intraoral impression
214995973|NCT00310544|DRUG|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
214995974|NCT00310544|DRUG|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
214382867|NCT02716038|DRUG|MPDL3280A|MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand programmed cell death-1 ligand 1 (PD-L1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
214498717|NCT05958823|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block
214498718|NCT05958823|PROCEDURE|PECS I-II|PECS I-II
215093101|NCT05280600|OTHER|Not applicable - non-interventional study|Not applicable - non-interventional study
215093102|NCT01816867|DEVICE|Intramesh T1 implantation|
215093103|NCT01688115|PROCEDURE|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
215093104|NCT01688115|OTHER|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
215093105|NCT04913662|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy|Aerosolization of chemotherapic agent for intraperitoneal chemotherapy
214382868|NCT02716038|DRUG|Carboplatin|Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin area under the curve (AUC)=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.
214498719|NCT05662098|DRUG|Hydroxyurea|All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
214498720|NCT04152551|DRUG|Risedronate Oral Tablet|Oral bisphosphonate
214498721|NCT05014503|OTHER|Adaptive Therapeutic gaming|All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
214995975|NCT03674138|DIAGNOSTIC_TEST|DNA-guided choice of therapy|Buccal swab for DNA genotyping to identify best antidepressant therapy
214995976|NCT03674138|OTHER|Clinical management|Clinical management to identify best antidepressant therapy
214995977|NCT06121674|PROCEDURE|Shaeer-II|"SHAEER-I targets ligation of the internal pudendal vein at the point where the vein exits Alcock's canal, and courses lateral to the ischial tuberosity.~Patient is oriented in the lithotomy position. The ischial tuberosity is marked. An incision is cut medial to the ischial tuberosity. Subcutaneous fat is dissected down to the neurovascular bundle harboring the internal pudendal vein. The vein is then ligated."
214995978|NCT06121674|PROCEDURE|PPI|Penile Prosthesis Implantation will be performed
214995979|NCT05168904|DRUG|fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
214995980|NCT06025110|BIOLOGICAL|TCD601|Investigational Product
214995981|NCT06025110|OTHER|Placebo|Comparator
214995982|NCT03941821|DRUG|Glecaprevir/Pibrentasvir|Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment
214995983|NCT05433688|DEVICE|Robotic assisted gastric bypass surgery|The product under investigation and the conventional suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
215093106|NCT04073485|PROCEDURE|Microwave ablation|Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
214382869|NCT02716038|DRUG|Nab-paclitaxel|Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
214382870|NCT03760263|DRUG|Tacrolimus|Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.
214382871|NCT04006925|DRUG|Sodium Oxybate|"Sodium Oxybate will be titrated up weekly by 1.5g nightly dose increments from an initial 4.5g total nightly dose (which could be given in two unequal doses if needed, or one single dose no greater than 4.5g) to an optimal individual dose based on clinical response on RBD symptoms and tolerance, to a maximum nightly dose of 9g (flexible dose period lasting up to 8 weeks). The optimal dose will then be continued for at least 4 weeks (stable dose)."
214382872|NCT04006925|OTHER|Placebo|Placebo will be similar in appearance, smell and flavor to the subjects, so that the investigators and participants will be unable to distinguish it from sodium oxybate.
214382873|NCT06480214|PROCEDURE|endoscopic spine surgery|we would administer the endoscopic spine surgery to patients with Lumbar spinal stenosis and Lumbar disc herniation.
214382874|NCT01874314|DRUG|SQ109|300mg or 450mg of SQ109 administered orally, once daily for 7 days.
214382875|NCT01874314|OTHER|SQ109 Placebo|Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
214382876|NCT01874314|DRUG|Moxifloxacin|400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
214382877|NCT04549311|DRUG|Antibiotic 1 arm (amoxicillin + clavulanic acid)|Prescription of antibiotics (amoxicillin + clavulanic acid) after incision and drainage of perianal abscess.
214382878|NCT04549311|DRUG|Antibiotic 2 arm (ciprofloxacin + metronidazole)|Prescription of antibiotics (ciprofloxacin + metronidazole) after incision and drainage of perianal abscess.
214382879|NCT01755143|OTHER|Magnetic Resonance Imaging scan sequences of the head, neck, and chest|
214382880|NCT01755143|DEVICE|Pacemaker System|
214382881|NCT04963361|OTHER|patients were exposed to fear of movement|Patients completed the questionnaires independently
214382882|NCT04963361|OTHER|patients were not exposed to fear of movement|Patients completed the questionnaires independently
214382883|NCT05796180|BEHAVIORAL|Behavioral: sexual health counseling based on the BETTER model|"The content of the research will be discussed by face-to-face interviews with women who gave birth vaginally and applied to the hospital for birth control 8-10 weeks after delivery. Pre-evaluation forms will be applied to women who have agreed to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method.~An appointment will be made for interviews with the women in the experimental group. It is planned that these meetings will be held in the form of online video calls and will last an average of 45 minutes. The final tests will be held 8 weeks after the online meetings are over."
214382884|NCT01706302|OTHER|Data collection|The previous study has used four primary data sources: the General Practice Research Data (GPRD \[recently re-named Clinical Practice Research Datalink (CPRD)\], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
214382885|NCT03626441|DIETARY_SUPPLEMENT|Ginger|Capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger
214382886|NCT03626441|DIETARY_SUPPLEMENT|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
214382887|NCT03757234|DRUG|Omadacycline|po tablets
214382888|NCT03757234|DRUG|Levofloxacin|iv solution/po tablets
214382889|NCT03757234|DRUG|Omadacycline|iv solution
214382890|NCT01623648|OTHER|Arm 1 Whey Breakfast|The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
214382891|NCT01623648|OTHER|Arm 2 No Whey Breakfast|The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
214382892|NCT01623648|OTHER|Arm 3 Low Protein Breakfast|The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
214382893|NCT01292070|BIOLOGICAL|Intradermal Human Fcγ1-Fel d1 fusion protein|"Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm."
214995984|NCT05234567|BIOLOGICAL|Asfotase Alfa|All participants will receive asfotase alfa subcutaneously per standard of care. Unless otherwise specified per the Physician's standard of care, participants aged \< 2 years are recommended for a clinic visit approximately every 3 months after Enrollment until 2 years of age, after which they should have a clinic visit approximately every 6 months. Participants should be followed for 5 years, as possible.
214995985|NCT05512390|DRUG|ABBV-319|Intravenous (IV); Infusion
214995986|NCT04613453|DRUG|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
214995987|NCT04613453|DRUG|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
214995988|NCT06229730|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
214382894|NCT01292070|BIOLOGICAL|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
214382895|NCT01292070|BIOLOGICAL|Positive Control - Histamine Prick|1.0 mg/mL
214382896|NCT01292070|BIOLOGICAL|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
214382897|NCT04212364|BEHAVIORAL|Peer Education|In this intervention, people who use opiates will be trained to be peer educators.
214382898|NCT04212364|DRUG|Narcan Nasal Product|All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
214382899|NCT04345458|DRUG|prefilled liquid etanercept(Yisaipu)|
214382900|NCT04345458|DRUG|lyophilized etanercept powder(Yisaipu)|
214382901|NCT03430141|OTHER|Nutritarian Diet-style|Nutritarian Diet-style: Daily consumption of greens, beans/legumes, a variety of other vegetables, fresh or frozen fruits, nuts, seeds and whole grains. Participants are encouraged to minimize consumption of refined grains, vegetable oils, processed foods, and to limit animal products.
214382902|NCT01555164|DRUG|Ranolazine|Ranolazine tablet(s) administered orally
214382903|NCT01555164|DRUG|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
214382904|NCT01555164|DRUG|Metformin|Metformin tablet(s) administered orally once daily
214382905|NCT01555164|DRUG|Placebo to match metformin|Placebo to match metformin for the duration of the study
214382906|NCT01555164|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
214382907|NCT01555164|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
214382908|NCT03253016|DIAGNOSTIC_TEST|vaginal swab -microbiome test and blood test for cytokines|vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
214382909|NCT00003640|BIOLOGICAL|filgrastim|
214382910|NCT00003640|DRUG|cisplatin|
214382911|NCT00003640|DRUG|doxorubicin hydrochloride|
214382912|NCT00003640|DRUG|methotrexate|
214382913|NCT00003640|DRUG|vinblastine sulfate|
214382914|NCT00003640|PROCEDURE|surgical procedure|
214382915|NCT00003640|RADIATION|radiation therapy|
214382916|NCT02477280|DRUG|Methylphenidate|Cross-over
214382917|NCT02477280|DRUG|Placebo|Medikinet
214382918|NCT06250647|OTHER|vitamin K diet|500mcg of Vitamin K intake provided by the selection of vitamin k rich foods in the menu.
214382919|NCT00097643|BEHAVIORAL|exercise|
214995989|NCT06229730|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
214382920|NCT00097643|BEHAVIORAL|health promotion|
214382921|NCT01396317|DRUG|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
214382922|NCT01709305|DRUG|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
214382923|NCT01709305|DRUG|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
214382924|NCT01709305|DRUG|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
214382925|NCT01709305|DRUG|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
214382926|NCT01709305|DRUG|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
214382927|NCT01709305|DRUG|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
214382928|NCT00813137|DRUG|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1\~7, D15\~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
214382929|NCT03909178|PROCEDURE|Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group)|Patients randomized to the SPT group provided consent for arthroscopic acetabular labral repair with femoroacetabular osteoplasty. As previously described in various technique publications from our group, the senior surgeon's (S.D.M.) hip arthroscopy technique includes intra-articular fluid distension for initial portal placement, puncture capsulotomy, autograft capsular augmentation if insufficient or degenerative labral tissue is encountered, intermittent traction, sparing use of electrocautery, and preservation of the chrondrolabral junction. All SPT patients underwent a standardized postoperative physical therapy protocol developed jointly by the senior author (a sports medicine fellowship-trained orthopaedic surgeon) and the physical therapists. Patients were kept weightbearing as tolerated on crutches for 6 weeks to maintain a level pelvis without lurching when walking and were instructed to avoid impact loading exercises for 6 months.
214995990|NCT06229730|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
214995991|NCT06229730|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
214995992|NCT06229730|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21-item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
214995993|NCT05580562|DRUG|Dordaviprone (ONC201)|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
214995994|NCT05580562|DRUG|Dordaviprone (ONC201) + Placebo|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments
214995995|NCT05580562|OTHER|Placebo|Participants will receive placebo (same number of capsules as the ONC201 dose) on dosing days
214995996|NCT02693535|DRUG|Palbociclib|drug
214995997|NCT02693535|DRUG|Sunitinib|drug
214995998|NCT02693535|DRUG|Temsirolimus|drug
214382930|NCT03909178|PROCEDURE|Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)|PTA patients were assigned a standardized, 24-week course of supervised, core-based PT. This course was designed in concert with physical therapists within our institution to help address symptoms of labral tear in patients older than 40 who had mild to moderate OA. Weeks 1 and 2 focused on normalizing gait, and weeks 3 through 24 focused on optimizing range of motion (ROM) while slowly integrating strength training. Unlike the prerandomization PT protocol, the PTA protocol was predominantly physical therapist-supervised (at least 1 in-person visit per week).
214382931|NCT03267823|DIAGNOSTIC_TEST|International Normal Ratio (INR)|Blood test for INR using laboratory and point of care methods
214382932|NCT03465020|OTHER|Observation|Safety and efficacy outcomes of patients on different treatments
214382933|NCT05904223|DIAGNOSTIC_TEST|Respiratory Panel PCR Sputum|Multiplex PCR Respiratory Panel from Biomerieux used on Patients Sputum
214382934|NCT02294136|BEHAVIORAL|Prep-C|PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
214382935|NCT02294136|BEHAVIORAL|Educational Control|Attention Control
214382936|NCT01710163|DRUG|Lithium|Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
214382937|NCT01710163|DRUG|Aripiprazole|Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
214382938|NCT05556317|BEHAVIORAL|Resistive exercise|advices and resistive exercise
214382939|NCT02294474|DRUG|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
214382940|NCT02294474|DRUG|Humalog|Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
214382941|NCT02294474|DRUG|insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
214382942|NCT01456234|DRUG|Oseltamivir|Oseltamivir 75 mg BID
214995999|NCT02693535|DRUG|Trastuzumab and Pertuzumab|drug
214996000|NCT02693535|DRUG|Vemurafenib and Cobimetinib|drug
214996001|NCT02693535|DRUG|Regorafenib|drug
214996002|NCT02693535|DRUG|Olaparib|drug
214996003|NCT02693535|DRUG|Pembrolizumab|drug
214996004|NCT02693535|DRUG|Nivolumab and Ipilimumab|drug
214996005|NCT02693535|DRUG|Abemaciclib|drug
214996006|NCT02693535|DRUG|Talazoparib|drug
214996007|NCT02693535|DRUG|Atezolizumab and PHESGO|drug
214996008|NCT02693535|DRUG|Atezolizumab and Talazoparib|drug
214382943|NCT03178955|DRUG|Etanercept|Circadian activity rhythm parameters will be evaluated for 7 days prior to Enbrel treatment through 7 days after initiation of Enbrel treatment and again 28-35 days after the second Enbrel treatment.
214382944|NCT06340074|BEHAVIORAL|HELM|HELM is a 9-month, data-driven organizational and leadership implementation strategy that entails eight core components: 1) Assessment and Feedback. 2) Initial Training. 3) Leadership Development Plan. 4) Individual Coaching. 5) Group Coaching. 6) Organizational Strategy Development. 7) Professional Learning Collaboratives. 8) Graduation.
214382945|NCT06340074|BEHAVIORAL|Implementation Attention Control (IAC)|Schools assigned to the IAC condition received an online, self-paced, independent studies program broadly focused on leadership and management. The program did not specifically discuss implementation leadership or climate. The program included four content modules hosted on a web-based learning portal: 1) Motivating and Engaging Employees, 2) Authentic Leadership, 3) Managing Diverse Teams, and 4) Fostering an Idea Culture. Each module consisted of one content-specific 60-minute webinar.
214382946|NCT01001949|DIETARY_SUPPLEMENT|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
214382947|NCT01001949|DIETARY_SUPPLEMENT|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
214382948|NCT02333760|GENETIC|Autologous CD34+ cells transduced with WASP lentiviral vector|Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene
214382949|NCT04296474|DRUG|ALK Alutard 5-grasses and birch|Intralymphatic injections
214382950|NCT04296474|DRUG|ALK Diluent|intralymphatic injections
214382951|NCT01362556|DRUG|Sodium bicarbonate|"Administration of a calculated amount of sodium bicarbonate 8% \[SB\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SB \[ml\] = -BE \* kg \* 0.1"
214382952|NCT01362556|DRUG|Sodium Chloride|"Administration of a calculated amount of sodium chloride 0.9% \[SC\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SC \[ml\] = -BE \* kg \* 0.1"
214382953|NCT04015115|BEHAVIORAL|Youth Opioid Recovery Support service model|see arm 1 description
214382954|NCT00203151|DRUG|edratide|0.5 mg, 1.0 mg, 2.5 mg injection once weekly
214382955|NCT04815317|OTHER|Auditive stimulation|"The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes."
214382956|NCT04815317|OTHER|Sensitive stimulation|Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes.
214382957|NCT04815317|OTHER|Auditory control|"The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise."
214382958|NCT04815317|OTHER|Sensitive control|The sensitive control condition will be achieved by administering fresh air on the calf.
214382959|NCT06014736|DRUG|XJ101 for Injection|XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.
214382960|NCT06014736|DRUG|Placebo|Placebo contains only excipients.
214382961|NCT00171873|DRUG|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
214382962|NCT00171873|DRUG|Placebo|Sodium chloride intramuscularly every 28 days
214382963|NCT02891343|OTHER|2-hour period of hypoxia|During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
214382964|NCT04496141|DIAGNOSTIC_TEST|SARS-CoV-2 antibody immunoassays|Different commercial SARS-CoV-2 antibody immunoassays
214382965|NCT05200936|DRUG|MM-120|MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.
214382966|NCT05200936|OTHER|Placebo|A treatment which is designed to have no therapeutic value.
214382967|NCT05664932|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
214382968|NCT05664932|BIOLOGICAL|ZF2001|Intramuscular injection of ZF2001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
214382969|NCT03115554|PROCEDURE|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
214382970|NCT03115554|PROCEDURE|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
214996009|NCT02693535|DRUG|Entrectinib|drug
214996010|NCT02693535|DRUG|Larotrectinib|drug
214996011|NCT02693535|DRUG|Tucatinib plus Trastuzumab Subcutaneous (SC)|drug
214996012|NCT02693535|DRUG|Futibatinib|drug
214996013|NCT04457258|PROCEDURE|Computed Tomography|Undergo PET/CT
214996014|NCT04457258|DRUG|Gallium Ga 68 FAPi-46|Given IV
214996015|NCT04457258|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214996016|NCT04457258|RADIATION|18F-FDG|Given IV
214996017|NCT06307665|COMBINATION_PRODUCT|BDA MDI|Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
214996018|NCT06307665|COMBINATION_PRODUCT|AS MDI|Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
214996019|NCT06770400|OTHER|Temperature Optimized for Sleep|Using the cloud-controlled thermostat, we will prescribed bedroom temperature based on the observed relationship between the individual's sleep quality and the temperature of their bedroom.
214996020|NCT06770400|OTHER|Participant's Preferred Temperature|Temperature is set by the individual based on their own habits and preference.
214996021|NCT05291689|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
214996022|NCT03246932|BEHAVIORAL|Peer-led psycho-education group|A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
214996023|NCT03246932|BEHAVIORAL|Profession-led psycho-education group|A psychoeducation group program (12 sessions, bi-weekly).
214996024|NCT03246932|OTHER|Routine psychiatric care|Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
214996025|NCT05091242|DRUG|Clonidine|Clonidine injection 3 mcg/kg once
214996026|NCT05091242|DRUG|Sodium chloride|Sodium chloride 0.9 % injection 0.2 mL/kg once
215093107|NCT05496556|OTHER|Test Leeds Food Preference Questionnaire (LFQP-France)|"The version of this questionnaire has been adapted to French eating habits. and based on the presentation of food photos, each representing one of the four categories below : salty-high in fat / salty-low fat / sugary-high fat / sweet-low fat The answers given to the LFQP predict a more or less caloric food intake. This tool makes it possible to objectify changes in eating behavior according to the nutritional status and protein status of patients.~The implied wanting score for salty-high-fat, salty-low-fat, sweet-high-fat, and sweet-low-fat foods is calculated based on the frequency and speed of choice for one food type out of 150 combinations.~For each of the food modalities, the software will return a score with its standard deviation. The modality preferred by the patient is the one with the highest score"
214382971|NCT06351644|DRUG|ON 123300|"dosed starting at 200 mg of ON 123300 (NARAZACICLIB) daily for four weeks. Dose levels will be 160 mg, 200 mg, 240 mg, 280 mg, 320 mg. Treatment cycles will be four weeks long.~ON 123300 (NARAZACICLIB) is available as an oral formulation ON 123300 (NARAZACICLIB) monolactate capsules (containing 40 mg free base) and is provided in 120 cc high-density polyethylene (HDPE) bottles with child-resistant closures containing 30 hard gelatin capsules. ON 123300 (NARAZACICLIB) is also available in tablet form. The tablets are 40 mm (oblong) and 120 mg (round). Either form, capsules or tablets, may be used in this study."
214382972|NCT06351644|DRUG|Dexamethasone|Weekly oral dexamethasone 20mg
214382973|NCT05104502|BEHAVIORAL|Dietary Fasting|"The study will consist of two days of eating a controlled habitual diet and one 36-hour period of water-only fasting with glucose monitoring as a measure of compliance. Water intake will be limited to 2 liters/day to prevent electrolyte abnormalities. Subjects will undergo 4 separate blood-draws consisting of an overnight fasted sample (Baseline), a 2-hour postprandial sample (Fed), a 36-hour fasted sample (Fasted), and final 2-hour postprandial sample after the fasting period (Refed)."
214382974|NCT00946335|DRUG|veliparib|Given PO
214382975|NCT00946335|DRUG|temozolomide|Given PO
214382976|NCT00946335|OTHER|pharmacological study|Correlative studies
214382977|NCT00946335|OTHER|laboratory biomarker analysis|Correlative studies
214382978|NCT04352478|DIAGNOSTIC_TEST|Histopathological result|Incidental gallbladder cancer and other pathology
214382979|NCT06480110|DRUG|Docetaxel + Ebastine|Ebastine is administered once daily.
214382980|NCT06480110|DRUG|Docetaxel|docetaxel every three weeks
214382981|NCT04893655|DRUG|Dobutamine Hydrochloride|dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
214382982|NCT06491199|OTHER|Home blood pressure telemonitoring program and clinician monitoring|"Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Clinician monitoring includes OBIM physicians reviewing transmitted BP data and contacting patients to adjust antihypertensive medication regimens."
214382983|NCT00234156|PROCEDURE|oral fructose and high fat diet|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (\~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (\~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
215093108|NCT04751188|DRUG|Bezafibrate 200 MG Oral Tablet|Bezafibrate one tablet every 12 hours for six months.
215093109|NCT04751188|DRUG|Placebo|Placebo one tablet every 12 hours for six months.
214996027|NCT00340093|BEHAVIORAL|Managing Diabetes|
214382984|NCT06810622|OTHER|Navigate-Kidney CHW|A CHW will provide support during visits every 2 weeks for 3 months (i.e., 6 visits during first 3 months) followed by monthly visits until end of study or until 3 months following KRT start. As well as receiving educational materials that describe prevention of CKD progression, KRT options, and conservative management in English or Spanish
214382985|NCT06810622|OTHER|Standard Care|Participants will receive standard medical care as well as educational materials developed that describe prevention of CKD progression, KRT options, and conservative management in English or Spanish
214382986|NCT04839198|BEHAVIORAL|Android Wear smartwatch|All participants will wear an Android Wear smartwatch, and will complete ecological momentary assessments (EMA).
214382987|NCT04839198|BEHAVIORAL|Adaptive Treatment|"Participants will have access to a Dashboard button in the InsightTM app that displays personalized statistics based on their progress and patterns in the study.The dashboard will update as more data is collected about the participant's smoking habits, starting in the pre-quit period and continuing through the post-quit period. Second, in the post-quit period, participants will receive treatment messages when the machine learning algorithm determines that they are at high risk for lapse.At the follow-up visit, participants will complete a survey to evaluate what they liked and disliked about the intervention, how accurate they thought the app was in predicting their risk, and how useful they found the dashboard."
214996028|NCT04649307|BEHAVIORAL|MI-CBT|Education, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
214996029|NCT03831724|DEVICE|EndoFLIP™ System with FLIP Topography Module|The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
215093110|NCT04751188|DRUG|Ursodeoxycholic Acid|At a dose of 13 to 15 mg per Kg per day.
215093111|NCT00168454|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
214382988|NCT04839198|DRUG|Nicotine Patch|At Visit 2, participants will be asked to begin their attempt to quit smoking and will receive a 12-week supply of nicotine replacement therapy (i.e., nicotine patches and gum)
214382989|NCT04839198|BEHAVIORAL|interviewing-based counseling|At Visit 2, participants will be asked to begin their attempt to quit smoking and meet with a Tobacco Treatment Specialist, who will provide motivational interviewing-based counseling, help the participants develop a quit plan, and discuss relapse prevention. During the 6-weeks of the study, participants will have the option of attending up to 6 counseling sessions with the Tobacco Treatment Specialist, either in-person or via phone or web.
214996030|NCT04248361|DIAGNOSTIC_TEST|TEM-PCR URI Panel|Target Enriched Multiplex Polymerase Chain Reaction (TEM-PCR™) is a breakthrough molecular multiplex technology that allows rapid DNA/RNA identification of multiple pathogens (i.e., bacteria and viruses) in a single sample, typically within one day of specimen receipt.
214996031|NCT04248361|OTHER|SOC/Empiric Diagnosis|The SOC for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
214996032|NCT05179512|DRUG|Tiotropium|Tiotropium dispensing claim is used as the reference group.
214382990|NCT04916418|DRUG|Placebo|TTP block with initial dose of placebo (NaCl0.9%) 20 ml per catheter (total volume 40ml), followed by 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
214382991|NCT04916418|DRUG|Ropivacaine|TTP block with initial dose of ropivacaine 0.5% (5 mg / ml) 20 ml per catheter (total volume 40ml), followed by doses of ropivacaine 0.2% (2 mg / ml) 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
214996033|NCT05179512|DRUG|salmeterol-fluticasone|Salmeterol/Fluticasone dispensing claim is used as the exposure group.
214996034|NCT06530550|DRUG|PI3K inhibitor|Linperlisib 80mg QD orally, or Duvelisib 25mg BID orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
214996035|NCT03012243|PROCEDURE|Gallbladder aspiration|Percutaneous ultrasound-guided aspiration of bile from the gallbladder. This is performed without leaving a drain in the gallbladder. The aspiration is performed with the intention to relief the pressure in the gallbladder, without drain.
214996036|NCT03012243|PROCEDURE|Cholecystostomy|Ultrasound-guided insertion of drain in the gallbladder. The drain is left in the gallbladder until clinical assessment and laboratory analyses show that the acute cholecystitis has been successfully treated.
214996037|NCT01901562|DEVICE|Ductoscopic papillectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
214996038|NCT02612155|BIOLOGICAL|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
215093112|NCT00168454|DRUG|Placebo|Placebo (normal saline) injected into detrusor on Day 1
215093113|NCT03938324|BEHAVIORAL|PiCASO Intervention Group|This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence.
214382992|NCT05694182|OTHER|Other: Oral superfruits supplement|The supplement contain superfruits that are beneficial for human health
214382993|NCT04699916|OTHER|EEG based protocol for deep sedation|Protocol established to guide sedation drug dosification to maintain the patient with a Suppression Rate (SR) less than 1% and a Spectral Edge Frequency 95 over 10 Hz
214996039|NCT02612155|BIOLOGICAL|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
214996040|NCT06493747|DEVICE|Combined Low- and High-Frequency rTMS Intervention|This intervention involves the application of rTMS using an 8-shaped coil with a frequency of 1Hz for low-frequency stimulation and 5Hz for high-frequency stimulation, in accordance with the study protocol.
214996041|NCT06493747|DEVICE|Combined High- and Low-Frequency rTMS Intervention|Similar to Arm A, but the sequence of low and high-frequency rTMS is reversed.
214996042|NCT06493747|DEVICE|rTMS|Participants receive an individualized rTMS therapy plan based on integrated analysis of assessment data, targeting specific brain areas to enhance language function recovery post-stroke.
214996043|NCT06493747|DEVICE|rTMS + Acupuncture|"Participants undergo a combined treatment of rTMS as described for the rTMS Experimental Group and traditional Chinese acupuncture based on the Kaiqiao Jieyan method, targeting specific acupoints to facilitate recovery."
214996044|NCT06493747|DEVICE|rTMS|Participants receive a conventional rTMS treatment as per established guidelines, serving as an active comparator to the experimental interventions.
214996045|NCT06493747|DEVICE|Acupuncture|"Participants receive Kaiqiao Jieyan acupuncture therapy alone, without rTMS, following traditional Chinese medicine protocols for post-stroke aphasia rehabilitation."
214996046|NCT05484947|DIAGNOSTIC_TEST|Elisa HIV testing|HIV testing on a voluntary basis
214996047|NCT03590327|DEVICE|Transcranial Magnetic Stimulation|rTMS
214996048|NCT03324113|DRUG|SAR408701|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214996049|NCT03324113|DRUG|dexamethasone|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
214996050|NCT03324113|DRUG|naphazoline|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
214996051|NCT03324113|DRUG|diphenhydramine|"Pharmaceutical form: tablet~Route of administration: oral"
214996052|NCT04055493|DRUG|Ribociclib 200Mg Oral Tablet|3 x 200 MG per os
214996053|NCT05558761|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics. PTX exerts anti-inflammatory effects by inhibiting phosphodiesterase and activating the adenosine 2 receptor
214996054|NCT03625128|DRUG|F-18|This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
214996055|NCT05383378|DRUG|si-544|Subcutaneous injection in the abdomen
214996056|NCT05383378|DRUG|Placebo|Subcutaneous injection in the abdomen
214996057|NCT05975645|DRUG|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death 1 (PD-1).
214996058|NCT05975645|DRUG|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3).
214996059|NCT05975645|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
214996060|NCT02249325|DIETARY_SUPPLEMENT|Probiotic dietary supplement|Florajen3 is a commercially available probiotic supplement containing three bacteria of human origin (\>7.5 x10\^9 L. acidophilus, \>6.0 x10\^9 .B. lactis, and \>1.5 x10\^9 B .longum). Once capsule was administered daily by mouth from 28 through 36 weeks gestation.
214996061|NCT02789748|DEVICE|Kinesthetic stimulation|Activation of mechanoreceptors by vibration bursts
215093114|NCT03938324|BEHAVIORAL|Sham Comparator: Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
215093115|NCT03401385|DRUG|Datopotamab Deruxtecan (Dato-DXd)|A total anti-TROP2 antibody and MAAA-1181a
215093116|NCT03401385|DRUG|Steroid Containing Mouthwash|A mouthwash containing a steroid ingredient administered in sub-study
214996062|NCT04878900|OTHER|Survey|Survey
214996063|NCT01124240|DRUG|Cilengitide|"Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption.~Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA \< 1.7; 100 mg p.o. if BSA ≥ 1.7) is given over a period of 6 weeks (RTX Monday to Friday, both TMZ and PCB seven days a week).~After a break of 4 weeks, adjuvant TMZ (50mg/m2 p.o in first cycle, 60 mg/m2 p.o. in subsequent cycles) and PCB (50 mg p.o. if BSA \< 1.7; 100 mg p.o. if BSA ≥ 1.7) are then given daily D1 to 20. This TMZ/PCB cycle is repeated every 28 days over a total period of 6 cycles."
214996064|NCT06254339|PROCEDURE|OAGB|using OAGB procedure as metabolic bariatric surgery
214996065|NCT06254339|PROCEDURE|DJB-SG|using DJB-SG procedure as metabolic bariatric surgery
214996066|NCT04680039|DEVICE|Continuous monitoring|Identifying intradialytic hypotension using a PPG-based wearable monitor
214996067|NCT06189950|DEVICE|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
214996068|NCT04435626|DRUG|Finerenone (BAY94-8862)|"For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD.~For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets."
214996069|NCT04435626|OTHER|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
214996070|NCT00427596|DRUG|Solabegron|
215093117|NCT03401385|OTHER|Non-Steroid Containing Mouthwash|A mouthwash containing a non-steroid ingredient administered in sub-study
214382994|NCT05034848|PROCEDURE|Assessment of BMD by DXA and HRpQCT|"* DXA : BMD assessment at the left hip, rachis and both legs~* HRpQCT : Volumic Bone mineral density, cortical and trabecular parameters, at the non dominant radius and legs~* Biological samples"
214382995|NCT03104647|OTHER|VRP-Clinic|Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
214382996|NCT00118898|DRUG|Abacavir/Lamivudine|600 mg abacavir/300 mg lamivudine tablet taken orally daily
214382997|NCT00118898|DRUG|Atazanavir|300 mg tablet taken orally daily
214996071|NCT05129085|DRUG|Dexamethasone 4mg|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the ESI group, 8mg of dexamethasone (4mg/ml) added to 1 ml of normal saline will be given (total 3ml volume).
214382998|NCT00118898|DRUG|Efavirenz|600 mg tablet taken orally daily
214382999|NCT00118898|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
214383000|NCT00118898|DRUG|Ritonavir|100 mg tablet taken orally daily
214383001|NCT00118898|DRUG|Abacavir/Lamivudine placebo|Placebo tablet taken orally daily
214383002|NCT00118898|DRUG|Emtricitabine/Tenofovir disoproxil fumarate placebo|Placebo tablet taken orally daily
214383003|NCT06243289|OTHER|Tolerance induction|Exposure of peripheral blood mononuclear cells extracted from donated patient blood to a combination of vitamin D3 and interleukin 10 to test whether tolerogenic dendritic cells can be generated and have the same functional capacity between donors with and without kidney disease (exposure of PBMC to the uremic environment)
214383004|NCT01338012|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
214383005|NCT06181721|DEVICE|Omnipod 5 Automated Glucose Control System|The Omnipod 5 Automated Glucose Control System will provide automated insulin delivery
214383006|NCT01905709|BIOLOGICAL|Human fecal matter|
214383007|NCT05879198|BEHAVIORAL|Computer-based Intervention|The current project proposes to pilot a computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
214383008|NCT06163560|DEVICE|"Smartphone app Happy Baby HK"|"Happy Baby HK will provide developmental stage, developmental aspects, parenting videos and cartoon images created for new mothers."
214383009|NCT06163560|DEVICE|Family Health Service parenting booklet|The parenting booklet is publicly available and provides brief caretaking tips for mothers with children under 3 years of age.
214383010|NCT04567394|BEHAVIORAL|Peer Network Counseling-txt|4-week text counseling program
214383011|NCT04396821|DRUG|TST001|TST001 is a humanized IgG1 monoclonal antibody.
214383012|NCT04396821|DRUG|Nivolumab Injection [Opdivo]|Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
214383013|NCT04396821|DRUG|mFOLFOX6|mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
214383014|NCT04396821|DRUG|Gemcitabine|Chemotherapy medication
214383015|NCT04396821|DRUG|Albumin-Bound Paclitaxel|Chemotherapy medication
214383016|NCT06624319|DRUG|Dexmedetomidine as adjuvent to bupvacaine in tap block|The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block
214383017|NCT06624579|PROCEDURE|confocal endomicroscopy|The study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in UC patients. Confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing.
214383018|NCT06926465|OTHER|Conventional treatment|conventional treatment including (hot pack, Stretching of the pectoralis minor, Resisted shoulder external rotation , Prone Extension ,Prone Horizontal Abduction with External Rotation ,Side-lying Forward Flexion ,Posterior capsule stretch (sleeper stretch)
214383019|NCT06926465|OTHER|Trunk integrated kinetic chain exercises|"This group will receive conventional treatment plus four trunk integrated kinetic chain exercises:~1. Quadruped shoulder flexion~2. Shoulder flexion with trunk rotation~3. Shoulder external rotation from shoulder at 45° internal rotation and the elbow at 90° flexion with trunk rotation~4. Shoulder external rotation from shoulder at 90° abduction and the elbow at 90° flexion while with trunk rotation"
214383020|NCT02332343|OTHER|No intervention - Natural history study|
215093118|NCT02769962|DRUG|EP0057|"EP0057 (formerly CRLX101) intravenous (IV) every (Q) 2weeks Day 1 and Day 15, administered in 28-day cycles, until disease progression or development of intolerable side effects.~Plus olaparib (by mouth (PO) days 3-13\* and days 17-26\*) administered in 28-day cycles, until disease progression or development of intolerable side effects. Phase (P)1: Dose Escalation P2: recommended phase 2 dose (RP2D).~(\* On days 13 and 26, only one dose of olaparib will be administered in the morning)"
214383021|NCT03681418|PROCEDURE|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.|Ultrasound-guided axillary lymph node fine needle aspiration and\\or core needle biopsy of the most suspicious lymph node. If all the lymph nodes appeared similar or normal, the lymph node that is lowest in the axilla will be selected because it is considered to most likely be the sentinel node.
214996072|NCT05129085|PROCEDURE|epidural platelet rich plasma injection|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the EPRP group, 3 ml of PRP will be injected. The total volume of injectate for both groups of patients is 3ml.
214996073|NCT01023321|DRUG|GLPG0555|single ascending doses, oral solution
214996074|NCT01023321|DRUG|placebo|single dose, oral solution
214996075|NCT01023321|DRUG|GLPG0555|multiple dose, oral solution, 7 or 14 days
214996076|NCT01023321|DRUG|placebo|multiple dose, oral solution, 7 or 14 days
214996077|NCT03739931|BIOLOGICAL|mRNA-2752|Solution for intratumoral injection
214996078|NCT03739931|BIOLOGICAL|Durvalumab|Solution for infusion after dilution
214996079|NCT05049694|DEVICE|zirconia crowns|esthetic crowns for capping permanent molars with caries
214383022|NCT02073097|DRUG|Carfilzomib|"Given IV, according to dose level. Cohorts begin with dose level (DL)1, escalated in standard 3+3 design to identify a recommended phase 2 dose DL (-2) 11 mg/m2 on day 1 and 2 every 21 days, cycles 1-6~DL (-1) 15 mg/m2 on days 1 and 2 every 21 days, cycles 1-6~DL (1) 20 mg/m2 days 1,2 every 21 days, cycles 1-6~DL (2) 20 mg/m2 days 1,2 of cycle 1 followed by 27 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL (3) 20 mg/m2 days 1,2 of cycle 1 followed by 36 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL(4) 20 mg/m2 days 1,2 of cycle 1 followed by 45 mg/m2 days 1,2 every 21 days for cycles 2-6~DL (5) 20 mg/m2 days 1,2 of cycle 1 followed by 56 mg/m2 days 1,2 every 21 days for cycles 2-6"
214383023|NCT02073097|BIOLOGICAL|Rituximab|Given IV (375mg/m\^2)
214383024|NCT02073097|DRUG|Cyclophosphamide|Given IV (750mg/m\^2)
214383025|NCT02073097|DRUG|Doxorubicin hydrochloride|Given IV (50mg/m\^2)
214383026|NCT02073097|DRUG|Vincristine sulfate|Given IV (1.4mg/m\^2)
214383027|NCT02073097|DRUG|Prednisone|Given PO (100mg)
214383028|NCT02073097|DRUG|Pegfilgrastim|6 mg SC day 4 (every 21 days). Filgrastim 300 or 480 mcg IV/SC daily days 1-10 may be substituted if pegfilgrastim is not available. ONPROTM is also an acceptable method of administration.
215093119|NCT02769962|DRUG|olaparib|"Olaparib (by mouth (PO) days 3-13\* and days 17-26\* administered in 28-day cycles, until disease progression or development of intolerable side effects Plus EP0057 (formerly CRLX101) (intravenous (IV) every (Q) 2 weeks, Day 1 and Day 15) administered in 28-day cycles, until disease progression or development of intolerable side effects. Phase (P)1: Dose Escalation P2: recommended phase 2 dose (RP2D).~(\* On days 13 and 26, only one dose of olaparib will be administered in the morning)."
215093120|NCT02769962|DIAGNOSTIC_TEST|CT scan|Screening and baseline.
215093121|NCT02769962|DIAGNOSTIC_TEST|CT chest, abdomen, and pelvis|Metastatic castration-resistant prostate cancer (mCRPC) participants only at screening, baseline, cycle 2 Day 1, and end of treatment/disease progression.
214383029|NCT02073097|DRUG|Acyclovir|PO (400mg)
214996080|NCT05049694|DEVICE|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
214996081|NCT01410942|OTHER|Placebo|Capsules by mouth twice daily.
214996082|NCT01410942|DRUG|Methylphenidate|Starting dose 5 mg by mouth twice daily.
214996083|NCT01410942|BEHAVIORAL|Counseling Sessions|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
214996084|NCT01410942|OTHER|Sham Exercise|Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
214996085|NCT01410942|OTHER|Standardized Exercise Intervention Program|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
214996086|NCT01410942|OTHER|Cognitive Behavioral Therapy (CBT)|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
214996087|NCT02605239|DRUG|Bleaching teeth|bleaching teeth with carbamide peroxide 10% for 3 weeks
214996088|NCT05120271|BIOLOGICAL|CAR-GPC3 T Cells|Five dose levels each with LD chemotherapy
215093122|NCT02769962|DIAGNOSTIC_TEST|Bone scan|Metastatic castration-resistant prostate cancer (mCRPC) participants only at screening, baseline, cycle 2 Day 1, and end of treatment/disease progression.
215093123|NCT02769962|DIAGNOSTIC_TEST|ECG|Screening, baseline, Day 1, Day 15 and cycle 2, Day 1.
215093124|NCT02769962|DIAGNOSTIC_TEST|Echocardiogram|At screening.
214383030|NCT03874845|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
214383031|NCT03874845|BEHAVIORAL|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
214383032|NCT06900868|OTHER|Assigned Interventions|SDR Smart dentine replacement material nonbioactive
214383033|NCT06899841|DRUG|Dexmedetomidine|different doses of dexmedetomidine added to bupivacaine in erector spinae plane block
214383034|NCT05984680|OTHER|Observational Phase 1|Noninterventional study
214383035|NCT05984680|OTHER|Observational Phase 2, Group I|Noninterventional study
214383036|NCT05984680|OTHER|Observational Phase 2, Group II|Noninterventional study
214383037|NCT05984680|OTHER|Observational Phase 3|Noninterventional study
214383038|NCT06900582|PROCEDURE|Sentinel Lymph Node Mapping|The SLN mapping protocol will follow the EU guidelines and the consensus in competency assessment tool. Prior to SLN mapping, a full inspection of the pelvic areas with white light is performed to exclude the presence of extrauterine disease. The next surgical steps will be 1- identification of external iliac vessels, 2- identification of internal iliac artery, 3- dissection of the ureter, 4- development of paravesical space and 5- identification of obliterated umbilical ligament. The dissection technique must avoid disrupting lymphatic channels and isolate nodal tissue from the local anatomy. Indocyanine green (1.25mg/mL) will be injected in the cervix at the 3 and 9 o'clock positions, with 1mL superficial and 1mL deep, for a total of 4mL. All mapped SLNs must be completely excised, and any visually suspicious nodes should also be removed, regardless of the mapping results. If the SLN mapping appears to be unfeasible, a side-specific pelvic lymphadenectomy will be performed.
214383039|NCT06900582|PROCEDURE|Comprehensive pelvic and para-aortic lymphadenectomy|"The resection of at least one lymph node in each of the 12 retroperitoneal regions is necessary:~A: upper para-aortic region B: lower para-aortic region C: interaorto-caval region D: paracaval region E: right and left iliaca communis region F: right and left iliaca externa region G: right and left fossa obturatoria region: defined by external and internal arteria iliaca, pelvic sidewall H: right and left iliaca interna region: lymph nodes adjacent to or medial of the internal iliacal artery"
214383040|NCT06900673|BEHAVIORAL|Collaborative Life Skills|Student, parents, and teachers in the intervention condition will receive the digitally adapted Collaborative Life Skills program.
214383041|NCT06899386|OTHER|Group CI and CII - BeautiBond Xtreme (total-etch technique) + Beautifil LS|the enamel was etched for 30 seconds and the dentin for 15 seconds using 35% phosphoric acid gel (Ultradent). The acid was then rinsed off, and excess moisture was removed with an air spray. To protect the dentin during air blasting, an absorbent paper was held over it using clinical tweezers, ensuring a whitish appearance for the enamel and slightly moist dentin. Excess water on the cotton roll was dried as well. The BeautiBond Xtreme adhesive system was applied without any waiting time, followed by a gentle air spray for 3 seconds and then a strong air blast to ensure solvent evaporation. Finally, the adhesive was light-cured for 5 seconds using a LED photopolymerizer (Gran Valo LED Curing Light, Ultradent).
214383042|NCT06899386|OTHER|Group TI and TII - BeautiBond Xtreme (self-etch technique) + Beautifil LS:|no acid etching was performed on either the enamel or dentin. The BeautiBond Xtreme adhesive system was applied immediately, without any waiting time, followed by a gentle air spray for 3 seconds and then a strong air blast to ensure solvent evaporation. The adhesive was then light-cured for 5 seconds using a LED photopolymerizer (Gran Valo LED Curing Light, Ultradent).
214383043|NCT06899386|OTHER|Group TIII and TIV - BeautiBond Xtreme (selective acid-etch technique) + Beautifil LS|the enamel was etched for 15 seconds using 35% phosphoric acid gel (Ultradent). The acid was then rinsed off, and excess moisture was removed with an air spray, leaving the enamel with a whitish appearance. Excess water on the cotton roll was also dried. Next, the BeautiBond Xtreme adhesive system was applied immediately, without any waiting time, followed by a gentle air spray for 3 seconds and then a strong air blast to ensure solvent evaporation. The adhesive was then light-cured for 5 seconds using a LED photopolymerizer (Gran Valo LED Curing Light, Ultradent).
214383044|NCT06900101|OTHER|Study the evolution and correlation between cerebral autoregulation index|"Objective n°1: Study the correlation between autoregulation index:~The investigators will look for a correlation between several auroregulation index such as the PRx, ORx and Cox.~Objective n°2: Evaluation and detection of EEG prognostic patterns: The investigators will look for quantitaive EEG changes during the early phase of acute brain injuries."
214383045|NCT06899581|DIETARY_SUPPLEMENT|Enteral nutrition Food Derived Ingredient|"For this case-control analysis, children with AML will be matched to cancer-free controls for age, sex and race. No antibiotics for 6 months. In collaboration with Professor Konstantinos Gerasimidis Professor of Clinical Nutrition School of Medicine. University of Glasgow. Healthy children have been recruited from the community via poster and social media advertisement. The whole bowel movement was collected in a disposable stool collection kit and stored in a benchtop freezer provided to study participants. Researcher defrosted the sample, homogenised it with mechanical kneading and aliquots were stored in -80.~Cases: children with AML: Stool specimens will be obtained at three predefined time points for microbiome analysis: baseline start of AML treatment (within 2 weeks of admission); after induction chemotherapy initiation (6-8weeks); recovery phase 6-8 months."
214383046|NCT06900790|PROCEDURE|ERCP|There are two intervention methods for pediatric pancreatic duct stones. One is to remove the pancreatic duct stones through Endoscopic Retrograde Cholangiopancreatography(ERCP), while simultaneously dilating the pancreatic duct and placing a stent to assist in the normal drainage of pancreatic juice. The other is local resection of the pancreatic head combined with longitudinal pancreaticojejunostomy (Frey surgery).
214383047|NCT06899685|OTHER|tradional physical therapy treatment|Instructions, hot backs, Deep transverse friction massage, passive \&self stretch, Neck isometric and Scapular retraction exercises
214383048|NCT06899685|OTHER|KT|Kinesiotaping
214383049|NCT06899685|DEVICE|IASTM|Instrument Assisted Soft Tissue Mobolization
214996089|NCT03757923|DRUG|TAB METFORMIN|INSULIN SENSITIZING AGENTS
214996090|NCT03757923|DRUG|TAB PIOGLITAZONE|INSULIN SENSITIZING AGENT
214996091|NCT06551675|DIETARY_SUPPLEMENT|Silkworm pupa tablets|Participants will begin taking the silkworm pupa tablets immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
214996092|NCT06551675|DIETARY_SUPPLEMENT|Control product|The sham comparator contains 0.5% of the active ingredient of the study product, indistinguishable in appearance. Participants will begin taking the control immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
214996093|NCT04765631|OTHER|Patients with Type 2 diabetes|No intervention
214996094|NCT04765631|OTHER|Placebo|Placebo comparator
214996095|NCT05285527|DEVICE|MiSight 1 Day|Subjects will wear MiSight 1 day lenses for three years.
214383050|NCT06899659|DEVICE|JuggerStitch™ Meniscal Repair Device|Participants assigned to investigational group undergoing arthroscopy meniscal repair with JuggerStitch™ Meniscal Repair Device.
214383051|NCT06899659|DEVICE|Fast-Fix 360 Meniscal Repair System|Participants assigned to control group undergoing arthroscopy meniscal repair with the Fast-Fix 360 Meniscal Repair System.
214996096|NCT04913298|DEVICE|Cytosorb therapy|Start of Cytosorb therapy is at the discretion of the attending physician
214996097|NCT02595892|DRUG|Berzosertib|Given IV
214996098|NCT02595892|DRUG|Gemcitabine|Given IV
214996099|NCT02595892|DRUG|Gemcitabine Hydrochloride|Given IV
214996100|NCT02864992|DRUG|Tepotinib|Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
214996101|NCT05467215|DRUG|Pure oxygen (99%) from Praxair, Edmonton, DIN# 02014408|Participants will receive oxygen (99%) or room air (placebo) delivered through a face mask at a flow rate of 10 litres/min for 2 minutes. The participants will be exposed twice to both conditions over 4 experiments at a minimum of 2 week intervals between each testing session.
214996102|NCT05252702|DEVICE|Aveir DR Leadless Pacemaker System|Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
214996103|NCT06095388|DRUG|JR-441|IV infusion
214996104|NCT06095388|DRUG|JR-441|IV infusion
214996105|NCT06095388|DRUG|JR-441|IV infusion
214996106|NCT06271681|DRUG|21-valent pneumococcal conjugate vaccine|FDA approved pneumococcal vaccines 21 valent conjugate vaccine administered at enrollment
214996107|NCT04614155|OTHER|Educational Intervention|Take part in health education session
214996108|NCT04614155|PROCEDURE|HPV Self-Collection|Receive HPV self-collection kit
214996109|NCT04614155|OTHER|Questionnaire Administration|Complete questionnaires
214996110|NCT05785611|DRUG|Filgotinib|Tablets administered orally once daily
214996111|NCT05785611|DRUG|Placebo|Tablets administered orally once daily
214996112|NCT05441917|DEVICE|Sanae method with LED|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and phototherapy.
214996113|NCT05441917|DEVICE|Sanae method with Radiofrecuency|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and radiofrequency.
214996114|NCT05385861|DRUG|nanoliposomal irinotecan plus carboplatin|"Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= \[(140-age) x weight x 0.85 (if female)\] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria."
215093125|NCT02769962|PROCEDURE|Biopsy|Baseline Day 4 and end of treatment/disease progression.
215093126|NCT00837759|DRUG|Insulin|
215093127|NCT00837759|DRUG|Lansoprazole|
215093128|NCT00837759|DRUG|Sitagliptin|
215093129|NCT00837759|BIOLOGICAL|Diamyd|
215093130|NCT00837759|DRUG|GAD65 (Diamyd)|
215093131|NCT05266560|DRUG|ciprofol|A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-\[(1R)-1-cyclopropylethyl\]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
215093132|NCT05266560|DRUG|Propofol|Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
215093133|NCT02759081|DEVICE|cap-assisted water exchange|a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.
215093134|NCT02759081|PROCEDURE|water exchange|water was infused and suctioned at the same time during insertion of colonoscope
215093135|NCT05035433|PROCEDURE|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
215093136|NCT05035433|PROCEDURE|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
215093137|NCT03719989|DRUG|azacitidine plus R-GDP|azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
215093138|NCT04816318|OTHER|Social and public health measures against COVID-19|"1. Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings~2. Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds~3. Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds"
215093139|NCT04816318|OTHER|Control|The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)
215093140|NCT03079219|DRUG|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
215093141|NCT03079219|DRUG|Experimental drug: Ondansetron|Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
215093142|NCT03079219|DRUG|Experimental drug: Dexamethasone|Day 1: 12mg QD
214996115|NCT05316935|DRUG|GnRHa|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.
215093143|NCT03079219|DRUG|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
215093144|NCT03079219|DRUG|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
215093145|NCT03079219|DRUG|Standard: Ondansetron|Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
215093146|NCT03079219|DRUG|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
215093147|NCT05688488|DRUG|Curcumin|Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
215093148|NCT05688488|DRUG|Mitomycin-C|Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
215093149|NCT04228601|DRUG|Fluzoparib|PARP
215093150|NCT04228601|DRUG|Fluzoparib placebo|Placebo
215093151|NCT04228601|DRUG|mFOLFIRINOX|mFOLFIRINOX
214383052|NCT06900179|OTHER|MFWs with AR|MFWs with AR This study utilized MyWeb AR as the primary development platform to create an AR-enhanced teaching curriculum for malignant fungating wound (MFW) care. Based on the 2022 Clinical Care Guidelines for Malignant Fungating Wounds and expert input from oncology specialists, the content covers key aspects of MFW care, including wound assessment, symptom identification, and care principles such as odor control, exudate management, and infection prevention. The program uses 3D object elements and animations to create interactive AR scenarios, allowing participants to engage in simulated clinical decision-making and care management, thereby enhancing their skills in a safe and controlled environment.
214996116|NCT05316935|DRUG|Letrozole 2.5mg|2.5mg po qd and no more than 24 weeks
214996117|NCT05316935|DRUG|Diane-35|Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.
214996118|NCT05316935|DRUG|MET|500mg po tid
214996119|NCT05666999|DEVICE|FibDex®|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
214996120|NCT05666999|DEVICE|Suprathel|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
214996121|NCT05666999|DEVICE|Aquacel Foam|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
214996122|NCT06493253|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph- FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite
214996123|NCT06193512|DEVICE|SwishKit + Oral care treatment as usual|SwishKit + Oral care Treatment as usual (TAU) group, instillation of chemical antimicrobial agents care and tooth brushing will be performed as in Oral Care TAU, but SwishKit care will be conducted after other oral care interventions, and prior to instillation of the chemical antimicrobial agent.
214996124|NCT06193512|PROCEDURE|Oral care treatment as usual|Oral care will be delivered per standard operating procedure of the ICU, which may include the instillation of chemical agents for the purpose of reducing bacterial load, will be administered at 4-hour intervals, and tooth brushing performed twice daily (morning and evening).
214996125|NCT04880824|BEHAVIORAL|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
214996126|NCT03834688|DRUG|Venetoclax|"Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)~Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days)."
214996127|NCT03834688|DRUG|Bendamustine|Cycle 1-6: Bendamustine 90 mg/m² intravenous (IV) on Days 1 and 2 of each cycle. Bendamustine may be started at 70 mg/m² in patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.
214996128|NCT03834688|DRUG|Rituximab|Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle. After 2 consecutive cycles of Rituximab IV are well tolerated, Rituximab may be given subcutaneously.
214996129|NCT05728450|DEVICE|Light amplification by stimulated emission of radiation (LASER)|"* The points for application of laser acupuncture will be cleaned before application. All patients in the study group will be submitted to infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~* The plug of the laser unit will inserted into the main current supply and on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~* Acupuncture detector (Pointer Excel II) will be used for definite location of acupuncture points"
214996130|NCT05135975|DRUG|Cabozantinib|Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
214383053|NCT06900179|OTHER|Classroom Teaching|Classroom Teaching and Case Sharing Introduction to Updated MFWs Care Guidelines and Clinical Applications MFWs Wound Care Management of Common MFWs-Related Complications Case Sharing on MFWs Complication Management: Researchers
214383054|NCT06901102|DRUG|Bee Venom Injection|This intervention involves the administration of purified bee venom from Apis mellifera species (Abevac) via subcutaneous injections. The dosage starts at 0.05 mL three times a week and gradually escalates to 0.5 mL three times a week by week 5. The total duration of the treatment is 6 months. Bee venom is being evaluated for its potential immunomodulatory effects, including enhancing regulatory T cell function and improving mineral bone disorder (MBD) in patients undergoing hemodialysis.
214996131|NCT03537690|OTHER|Laboratory Biomarker Analysis|Correlative studies
214996132|NCT03537690|DRUG|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
214996133|NCT03537690|OTHER|Pharmacokinetic Study|Correlative studies
214383055|NCT06901102|DRUG|Standard Care for CKD-MBD|This intervention represents the standard care for patients with chronic kidney disease-mineral bone disorder (CKD-MBD) undergoing hemodialysis. The treatment typically includes phosphate binders to control phosphorus levels, vitamin D receptor activators to regulate calcium and phosphorus metabolism, and calcimimetics to control parathyroid hormone (PTH) levels. The specific regimen may vary according to individual patient needs, but the control group will not receive bee venom injections as part of their therapy.
214996134|NCT06052956|DRUG|Methylene Blue|Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
214996135|NCT06052956|DRUG|Lipid Emulsion|The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
215093152|NCT02263443|PROCEDURE|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
214383056|NCT06899464|DRUG|14-day Cerebrolysin treatment|14-day cerebrolysin treatment initiated within 6 hours of onset of stroke
214383057|NCT06899464|OTHER|Standard of Care (SOC)|Standard of care treatment
214383058|NCT06899906|OTHER|Determine patient demographic and clinical characteristics at baseline|Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, and medical management (antibiotic therapy)
214996136|NCT06052956|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
214996137|NCT06052956|DEVICE|Laser Illumination (pre-defined dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.
214498722|NCT05014503|OTHER|Non-adaptive Therapeutic gaming|All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
214498723|NCT03980717|DEVICE|Goldbal Detachable Balloon and delivery microcatheter|Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
214996138|NCT06052956|DEVICE|Optical Spectroscopy Measurement|The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
214996139|NCT06052956|DEVICE|Laser Illumination (patient-specific dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.
214383059|NCT06899698|OTHER|Inspiratory muscle training|Only participants in the Study group 'Thirty chronic hemiplegic patients with mild cognitive impairment, and suffering from orthostatic hypotension' will receive inspiratory muscle training using Respiratory muscle strength: Threshold Inspiratory muscle trainer (TIMT): Philips Respironics model (Tayland- B00J417PHM), for 30 minutes per day for at least 3 days a week for 8 weeks.
214498724|NCT01958021|DRUG|Ribociclib|Ribociclib (600 mg, in three 200 mg hard gelatin capsules or tablets) was administered orally once daily on Days 1-21 of each 28-day cycle.
214498725|NCT01958021|DRUG|Letrozole|Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
214498726|NCT01958021|DRUG|Placebo|Placebo (hard gelatin capsules or tablets) was administered orally once daily on Days 1-21 of each 28-day cycle.
214498727|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
214498728|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
214498729|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
214498730|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
214498731|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
214498732|NCT04810611|DRUG|MBG453|Anti-TIM3 monoclonal antibody
214498733|NCT04810611|DRUG|NIS793|Anti-TGF-β monoclonal antibody
214996140|NCT06052956|PROCEDURE|Standard of care abscess drainage|Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
214498734|NCT04810611|DRUG|canakinumab|Anti-IL-1β monoclonal antibody
214498735|NCT02625441|DRUG|Pertuzumab|Pertuzumab 420 mg i.v. 3-weekly for 3 cycles
214498736|NCT02625441|DRUG|Trastuzumab|Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
214498737|NCT03481491|OTHER|transcranial magnetic stimulation of the cerebellum|The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.
214498738|NCT04828577|BEHAVIORAL|Real Time Neurofeedback|Participants receive feedback from own brain activity.
214498739|NCT04828577|BEHAVIORAL|"Idealized/Sham Neurofeedback"|Participants receive idealized feedback not related to their own brain activity.
214498740|NCT04677153|OTHER|Test and treat plus peer mentors|Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.
214498741|NCT04677153|OTHER|Usual care|Participants are referred to another location for HCV treatment.
214996141|NCT04529655|DEVICE|Capillary Refill Assessment|Device to quantify capillary refill time
214498742|NCT05178030|OTHER|vena punction|Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis. Blood for analysis of mutation in ctDNA will be collected at the same moment a CT-scan is performed
214498743|NCT03186391|OTHER|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
214498744|NCT04640974|DEVICE|Cingal|Single injection into the ankle joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
214383060|NCT06899698|OTHER|Traditional Training|Both the study and control group 'Sixty chronic hemiplegic patients with mild cognitive impairment, and suffering from orthostatic hypotension' will receive a. bobath technique 'passive mobilization associated with tactile and proprioceptive stimuli aims to inhibits spasticity'; b. Proprioceptive neuromuscular facilitation 'based on spiral and diagonal patterns of movements in line to achieve normal movements' c. Rood technique 'focuses on the developmental sequence of recovery (from basic to complex) and the use of sensory stimulation to facilitate movement and postural responses' d. Johnstone method 'includes positioning and splinting to inhibit abnormal patterns and controlling tone to restore central control' e. Functional electrical stimulation; f. Balance training, j. Pelvic, and gait training, h. Activities of daily living, and finally, g. Sensrimotor training 'Active and active-assistive range-of motion exercises, Graded activities Start with easy activities'.
214383061|NCT06900387|DIETARY_SUPPLEMENT|Tablet Calcinum-Calcium Carbonate (500mg) daily and Vitamin D3 (Cholecalciferol) tablet (60,000 IU) once a month.|Oral Calcium Carbonate supplement 500 mg from La Renon Healthcare Pvt Ltd to be administered daily for the period of 6 months. Oral Vitamin D3 (Cholecalciferol) supplement 60,000 IU from Eris Lifesciences Ltd to be administered once a month for the period of 6 months.
214383062|NCT06900387|DIETARY_SUPPLEMENT|Tablet Tayo- Vitamin D3 (Cholecalciferol) (60,000 IU) once a month.|Oral Vitamin D3 (Cholecalciferol) supplement 60,000 IU from Eris Lifesciences Ltd to be administered once a month for the period of 6 months.
214383063|NCT06900387|OTHER|Control Group|No additional intervention was given to control group.
214687479|NCT07151716|DRUG|Dexmedetomidine-esketamine combination|"For patients with endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.1 μg/kg/h dexmedetomidine and 0.05 mg/kg/h esketamine, increased/decreased by 0.05 μg/kg/h dexmedetomidine and 0.025 mg/kg/h esketamine every 15 min, until the RASS reaches -2 to -1, maximal infusion rate reaches 0.35 μg/kg/h dexmedetomidine and 0.175 mg/kg/h esketamine, or adverse reactions occur. Daytime (06:00-20:00) sedation is provided as above when considered necessary, with a target RASS score of -2 to +1.~For patients without endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.05 μg/kg/h dexmedetomidine and 0.025 mg/kg/h esketamine, and increased/decreased by 0.025 μg/kg/h dexmedetomidine and 0.0125 mg/kg/h esketamine every 15 min, until the RASS reaches -1, maximal infusion rate reaches 0.1 μg/kg/h dexmedetomidine and 0.05 mg/kg/h esketamine, or adverse reactions occur. Daytime (06:00-20:00) sedation is typically not provided."
214996142|NCT02315612|BIOLOGICAL|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
214996143|NCT05984654|PROCEDURE|Platelet rich plasma therapy|"Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma."
214996144|NCT02783274|DEVICE|Actis Total Hip System|Total Hip Replacement and Hemi-hip Replacement
214996145|NCT05386914|DRUG|Sirolimus|1 mg of Sirolimus taken orally once a day for 4 weeks.
214383064|NCT06899958|DEVICE|Fractional Laser|Three fractional laser treatments to the abdomen and thighs at 4 week intervals.
214383065|NCT06875947|DIETARY_SUPPLEMENT|Moringa Oleifera Leaf Micronized Powders in Capsule|"Moringa Oleifera Leaf Micronized Powders (MOLMP)~Source: Derived from finely ground Moringa Oleifera leaves using micronization technology to enhance bioavailability.~Dosage: 650 mg per capsule, taken three times daily (1,950 mg/day). Administration Duration: 60 days. Monitoring: Self-administration under weekly compliance checks."
214383066|NCT06875947|DIETARY_SUPPLEMENT|Standard Iron Tablets (Fe + Folic Acid)|Dosage: One tablet containing 60 mg iron and 400 mcg folic acid per day. Administration Duration: 60 days.
214996146|NCT06273865|DIAGNOSTIC_TEST|Several assays|Standard blood draw by venipuncture is performed in all study participants to collect blood samples in four 2.7 mL citrated blood tubes. Tube one is a dummy tube and is discarded. Tube two is used for the FVIII activity and thrombin generation assay on the EnzySystem. Tube three is used to perform conventional FVIII activity and thrombin generation assays. Tube four is used for duplicate measurements of the conventional assays and measurement of prothrombin F1+2 antigen levels, ADAMTS13 activity, FVIII antigen, VWF (von Willebrand Factor) antigen and von Willebrand ristocetin cofactor activity levels.
214996147|NCT04262856|DRUG|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
214498745|NCT06791915|PROCEDURE|Radiofrequency Ablation with FCV.|Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Flow Controlled Mechanical Ventilation (FCV).
214996148|NCT04262856|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
214498746|NCT06791915|PROCEDURE|Radiofrequency Ablation with VCV.|Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Volume Controlled Mechanical Ventilation (VCV).
214996149|NCT04262856|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
215093153|NCT02263443|PROCEDURE|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
214498747|NCT06795672|BEHAVIORAL|Telerehabilitation|Three hours of cognitive rehabilitation per week, performed remotely and independently, using a computerized device, which is pre-programmed based on the patient's needs.
214498748|NCT06795672|BEHAVIORAL|Traditional in-person rehabilitation.|Three hours of in-person cognitive rehabilitation per week using a computerized device.
214498749|NCT06753994|DRUG|SGLT-2 inhibitor|Empagliflozin is an SGLT2i that aids in blood glucose reduction through the urination of excess glucose in the context of hyperglycemia. In this study, participants will start with a dose of 2.5 mg of empagliflozin for four weeks, which will then be increased to 10 mg for the following nine weeks.
215093154|NCT02263443|PROCEDURE|No enema|Patients NPO groups will NPO and no bowel preparation.
214383067|NCT06829901|PROCEDURE|Fetoscopic Laser Photocoagulation|Patients who choose to undergo fetoscopic selective laser photocoagulation for complicated monochorionic-diamniotic twin pregnancies with twin-to-twin transfusion syndrome will be offered participation in the study. All participants will undergo selective laser photocoagulation and entry into the uterus will be achieved using one of two accepted methods, either direct entry or the Seldinger technique.
214996150|NCT03954535|BEHAVIORAL|Free2b|The intervention will consist of a website and 9 sessions. The intervention sessions will facilitate youths' acquisition of personal and social cognitive-behavioral skills. The intervention will focus on goal setting, decision making, enhancing self-worth, coping with stress, combating distorted thinking, communication skills, using alcohol and other drugs and a review session. Each session will require approximately 20 minutes and must be finished in a single sitting. Sessions will be delivered on a weekly basis. The website will include entertainment features and resources.
214383068|NCT06763107|PROCEDURE|Athletic Shoulder (ASH) and Inverse Athletic Shoulder (IASH) Tests|Participants perform the Athletic Shoulder (ASH) test and Inverse Athletic Shoulder (IASH) test to measure maximal isometric shoulder strength in three positions (180º, 135º, 90º) during two separate sessions. Data is used to assess test reliability and validity for high-performance swimmers.
214383069|NCT06735261|PROCEDURE|Sphenopalatine Ganglion Block using 2% lidocaine|A hollow-stem swab soaked in viscous Xylocaine is inserted into the patient's nasal cavity (one swab per nostril) until it stops. 1.5ml Lidocaine 20% (20mg/ml) is injected into each swab using a 5ml syringe and a pink trocar. Both swabs are left in place for 10 min.
214383070|NCT06370689|OTHER|Preoxygenation|Preoxygenation of volunteers over 3 minutes
214383071|NCT06900400|DIAGNOSTIC_TEST|"Sustained-Paced Finger Tapping (Petilli et al., 2018)"|"Sustained-Paced Finger Tapping (Petilli et al., 2018) a computerized test that lasts approximately 10 minutes. It involves maintaining and reproducing the rhythm of a sound (auditory version)."
214383072|NCT06925256|DIAGNOSTIC_TEST|nerve conduction study|median ulnar and radial motor- sensory nerve conduction studies will be performed.
214498750|NCT02577185|DRUG|Botulinum Toxin Type A|
214383073|NCT06925828|OTHER|No intervention|No intervention
214383074|NCT06926088|DRUG|Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety|Patients aged ≥18 years with advanced HR-positive breast cancer who received CDK4/6 inhibitors at six hospitals in China were included in this study.
214383075|NCT06900192|BIOLOGICAL|Orca-Q|Allogeneic (donor) stem cell graft
214383076|NCT06900192|DRUG|myeloablative regimen|Myeloablative regimen of busulfan, fludarabine, and thiotepa.
214383077|NCT01438788|OTHER|Low protein diet|Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
214383078|NCT06736977|BEHAVIORAL|The Onsite Nurse-Led Education Programme on IPC|"The programme was designed to enhance CCWs' IPC knowledge and attitudes through lectures, interactive discussions, information sharing, and Q\&A sessions. It also aims to improve their IPC practices and self-efficacy through demonstrations, role-playing exercises, and a work assignment focused on IPC self-monitoring.~The programme includes five educational sessions totalling 12 hours, along with one session for work assignment on daily self-monitoring of IPC practices over five days. The educational sessions cover the following topics:~1. General concepts of infectious diseases~2. Vaccination~3. Standard precautions: The use of personal protective equipment, environmental cleaning and disinfection, handling food and feeding, and waste management~4. Standard precautions: Hand hygiene~5. Common infectious diseases in DCCs and management."
214383079|NCT06736977|BEHAVIORAL|The Online Nurse-Led Education Programme on IPC|The online version of the nurse-led education programme was conducted using an online meeting platform. It includes the same content, learning activities, and materials as the onsite delivery programme, except for the practice stations, which cannot be provided to participants in the online delivery. Additionally, all documents will be available for download via the online platform.
214383080|NCT06887621|DRUG|Encapsulated amisulpride 50 mg (matched for color, weight, smell and size)|Amisulpride will be delivered orally 1 hour before anesthesia induction.
214383081|NCT06887621|DRUG|Encapsulated placebo (matched for color, weight, smell and size)|Placebo will be delivered orally 1 hour before anesthesia induction.
214383082|NCT06901375|DRUG|Vonoprazan|20 mg tablet twice daily
214383083|NCT06901375|DRUG|Amoxicillin|1 g tablet three times daily
214687480|NCT07160621|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Receive mobile CBT
214996151|NCT03954535|BEHAVIORAL|Attention-Placebo|Access to the website with entertainment features and resources - but no session content.
214996152|NCT04016389|DRUG|Cisplatin|Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
214687481|NCT07160621|BEHAVIORAL|Education|Receive educational materials
214687482|NCT07160621|OTHER|Questionnaires|Ancillary studies
214996153|NCT04016389|DRUG|Carboplatin|Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
214996154|NCT04016389|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.
214996155|NCT04016389|PROCEDURE|Trachelectomy|Surgery to remove the cervix but keep the uterus intact.
214996156|NCT06285747|OTHER|Non-Interventional Study|Non-Interventional Study
214996157|NCT00373672|DRUG|armodafinil (Nuvigil)|armodafinil (Nuvigil)150 mg qd
214996158|NCT00373672|DRUG|placebo|identical in appearance to active comparator
214996159|NCT06685133|DEVICE|Robotic assisted bronchoscopy|Subjects will undergo a robotic navigated bronchoscopy to biopsy peripheral pulmonary nodules.
215093155|NCT05433597|DRUG|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
215093156|NCT05433597|DRUG|Cisplatin|Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.
214498751|NCT02577185|DRUG|Sodium chloride 9 mg/ml|
214498752|NCT04484623|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
214498753|NCT04484623|DRUG|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
214498754|NCT04484623|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
214498755|NCT04484623|DRUG|Bortezomib|Proteasome Inhibitor will be administered.
214498756|NCT05562960|PROCEDURE|Plasmapheresis|Regular plasmapheresis to remove anti-NRIP autoantibody
214498757|NCT00149175|OTHER|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
214498758|NCT04920006|BEHAVIORAL|Enhancing Active Caregiver Training|The intervention has three components within each session. Step 1, View, involves group viewing of a caregiving scenario, developed during previous research, which portrays a situation in which a caregiver is dealing with a challenging behavioral symptom. Step 2, Practice, involves small-group rehearsal activities that facilitate understanding, making choices, and examining possible responses. Step 3, Reflect, involves self-reflection and group processing surrounding choices and observations.
214498759|NCT04419480|DEVICE|CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization|Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.
214383084|NCT06901375|DRUG|Zuojin Wan|3 g tablet twice daily
214383085|NCT06926400|DEVICE|Coronary artery sawtooth cutting balloon dilation catheter|Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a coronary artery sawtooth cutting balloon dilation catheter.
214383086|NCT06926400|DEVICE|Cutting balloon catheter|Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a cutting balloon catheter.
214383087|NCT06925087|OTHER|Myofascial Release Technique|During the application of Myofascial Release Technique (MRT), the fingers or hand will be first placed on the treatment area. Pressure will be applied to the soft tissue until the restricted layer was felt, and then the fascia was moved along the surface of the underlying layers while maintaining contact with the deeper layers. Tension will be applied for approximately 60-90 seconds, and if a release will not felt, the duration will extended until the release occurred. MRT will be performed with dry hands, without the use of any intermediary substances, and will be applied in both supine and prone positions. In the treatment program, anterolateral release techniques (targeting fascia superficialis, fascia transversalis, and fascia extraperitonealis) will be applied in the supine position, while posterior release techniques (targeting fascia thoracolumbalis and erector spinae) will be applied in the prone position.
214383088|NCT06925087|OTHER|Kinesio Taping Technique|"Two different techniques will be used in the Kinesio Taping application. First, four I-shaped Kinesio tapes (Kinesio Tex® Gold), each 5 cm wide and 0.5 mm thick, will be applied in a star-shaped pattern using the space correction technique with 25-50% tension at the S2-S4 level (sacral region) while the participant will in a seated position. Additionally, to direct the uterus into retroversion during menstruation, a 15 cm long I-shaped tape will be applied to the suprapubic region using the ligament correction technique with 100% tension."
214383089|NCT06907095|DIAGNOSTIC_TEST|biological samples|biological samples (blood, urine, saliva, stools in option)
214383090|NCT05963386|DRUG|177Lu-DOTA-EB-FAPI radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.3 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
214383091|NCT06384456|DRUG|Topical TRanexamic Acid|10mL of 100mg/mL TXA will be administered into the surgical wound prior closure.
214383092|NCT06384456|DRUG|Placebo|10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.
214383093|NCT06925867|OTHER|Frequency Filtered Music|The frequency filtered music intervention is 2.5 hours of classical music that has been filtered by applying an algorithm to alternate narrowing and expanding the range of acoustic frequencies over time, with the alternations intensifying in frequency range over the course of administration. The filtering is optimized for the frequency response of adult human hearing and intended to mimic the expression of the human voice around a central set of frequencies of 800-1200 Hz, the approximate resonant frequency of the human ear. The filtering method is similar to adjusting the treble and bass settings on a stereo system while music is playing; the melody and instruments can still be heard, but the highest and lowest pitches are modulated over time.
214383094|NCT06925867|OTHER|Unfiltered Music|The unfiltered music intervention is 2.5 hours of classical music with. The playlist of pieces is identical to the filtered music condition.
214383095|NCT06925867|BEHAVIORAL|Cognitive Processing Therapy for PTSD|Cognitive processing therapy (CPT) is a cognitive therapy that focuses on why patients believe the traumatic event occurred, how that event affected their beliefs about self and others, and how to evaluate their beliefs. Patients then learn to label events, thoughts, and subsequent emotions while the therapist helps them examine the facts and context of the trauma through Socratic questioning. Using progressive worksheets, patients are taught to examine their own thoughts and emotions and develop new, more balanced thinking about traumatic events.
214383096|NCT06924905|DIAGNOSTIC_TEST|the pelvic floor disability index|20 questions divided into three sections: Pelvic Organ prolapse Distress Inventory 6 (POPDI-6), Colorectal-Anal distress Inventory 8 (CRAD-8) and Urinary distress Inventory 6 (UDI-6).
214687483|NCT07158632|BEHAVIORAL|handwashing education|Arm A: This arm receive handwashing education using social and behavioral change communication
214996160|NCT06683378|PROCEDURE|Reparative Autologous peripheral nerve tissue|"At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed.~From the biopsied section, the epineurium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the nucleus basalis of Meynert (NBM) or substantia nigra (SN)."
214996161|NCT06348108|BIOLOGICAL|Talquetamab|Given subcutaneously (SQ)
214383097|NCT06925698|DRUG|Placebo plus immunosuppression|"Participants in this arm will receive placebo plus standard immunosuppressive therapy consisting of:~Azathioprine (2.5 mg/kg/day, maximum 200 mg/day, oral) Methylprednisolone (0.5 mg/kg/day, oral, tapered over 12 weeks according to protocol) This intervention represents the standard treatment for venous thrombosis associated with Behçet's Disease and serves as the control arm of the study."
214687484|NCT07158632|BEHAVIORAL|water chlorination|Arm B: This arm receives water chlorination intervention
214687485|NCT07158632|BEHAVIORAL|combined intervention|Arm C: This arm receives combined handwashing and water chlorination intervention
214383098|NCT06925698|DRUG|Rivaroxaban plus immunosupression|"Participants in this arm will receive standard immunosuppressive therapy as described above, plus Rivaroxaban (20 mg/day, oral, for 12 months).~This intervention aims to evaluate whether the addition of oral anticoagulation (Rivaroxaban) to immunosuppressive therapy reduces the risk of thrombotic relapse and post-thrombotic syndrome compared to immunosuppressive therapy alone."
214996162|NCT06348108|DRUG|Iberdomide|Given orally (PO)
214383099|NCT05474534|DEVICE|Neurofeedback (MUSE 2)|During each at-home treatment session, mothers will place the MUSE 2 on their heads and connect it to the app on their personal device. Their brain activity is monitored by the MUSE 2 and is represented on the app through audio-based feedback (e.g., birds chirping, sounds of waves lapping on the beach) that mothers will listen to with earbuds as they direct their focus on maintaining a calm state of mind during the session; when a calm state is maintained, they are rewarded with calming sounds. The goal is to gain increased conscious control over their own brain activity. The audio feedback, primarily composed of nature-based sounds, is meant to guide their brain activity into a calm state. The session will begin, and the MUSE 2 will provide audio feedback in real time to guide their brainwave activity into an optimal frequency bandwidth range (e.g., as their brain activity reaches the target state, sounds of wind would subside to peaceful waves or other rewarding audio feedback).
214383100|NCT01693692|DRUG|TD-9855 Group 1|
214383101|NCT01693692|DRUG|TD-9855 Group 2|
214383102|NCT01693692|DRUG|Placebo|
214383103|NCT06767293|BEHAVIORAL|I-InTERACT Parenting Intervention (I2P) and coaching sessions|Online learning sessions for parents of preterm children
214383104|NCT06767293|BEHAVIORAL|I-InTERACT Parenting Microlearning Intervention (I2P Micro) and coaching sessions|Online microlearning sessions for parents of preterm children
214383105|NCT06767293|OTHER|Internet Resources|control condition
214383106|NCT06907550|DIAGNOSTIC_TEST|The Mitomic Endometriosis Test (MET) blood test for early detection of endometriosis|Patients will complete a questionnaire about their endometriosis symptoms and a sample of blood will be taken prior to their laparoscopy and sent to the laboratory for testing.
214383107|NCT06916780|OTHER|Laser and ultrasound|Laser and ultrasound will be applied in group A as traditional method. On the other hand they will applied axillary in experimental groups
214383108|NCT05118815|OTHER|Slim abutment|Use a narrower abutment to see if they present a better biological seal.
214383109|NCT05118815|OTHER|Standard abutment|Use a standard abutment
214383110|NCT06922903|DRUG|INR101|INR101
214383111|NCT00663117|DRUG|Naltrexone-HCl|naltrexone 4.5 mg
214383112|NCT00663117|DRUG|Placebo|Placebo
214383113|NCT01628211|PROCEDURE|Laparoscopy|second look laparoscopy to evaluate for peritoneal carcinosis
214383114|NCT01628211|PROCEDURE|peritonectomy|for patients with PCI \< 20
214383115|NCT01628211|DRUG|Folinic Acid|20 mg/m2 IV given just before HIPEC for patients with PCI \< 20
214383116|NCT01628211|DRUG|5-Fluorouracil|400 mg/m2 IV given just before HIPEC in patients with PCI \< 20
214383117|NCT01628211|DRUG|Oxaliplatin|460 mg/m2 intraperitoneal hyperthermic perfusion for patients with PCI \< 20
214383118|NCT01628211|DRUG|systemic chemotherapy|according to national Italian (AIOM) guidelines and may include biotherapies for patients with PCI \> 20
214383119|NCT02947464|PROCEDURE|Standard clinical practice|Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.
214383120|NCT02947464|DEVICE|Standard clinical practice + Rapid Maxillary Expansion|Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
214383121|NCT00395915|DRUG|aripiprazole|
214383122|NCT04285437|BEHAVIORAL|infant massage|Mother will be trained how to massage their babies by International Association of Infant Massage (IAIM) Certified Infant Massage Instructor, and then their babies will be massaged by themselves during the first 2 months after birth.
214383123|NCT02831829|OTHER|water-based exercise training|Water-based training will be performed in upright position, in waist to xyphoid process deep thermo-neutral water at temperature of 32,8 C. The immersed exercise will include two session of aerobic and calisthenic exercise per day, six days of a week, both lasting 30 minutes
214383124|NCT02831829|OTHER|land-based exercise training|Land-based training will include two aerobic and calisthenic exercise session per day, six days of a week, both lasting 30 minutes
214687486|NCT07162051|DRUG|Fuzaparib|"Folfoxapril:~Take 2 times a day (once in the morning and once in the evening, 150mg in the morning and 100mg in the evening; vice versa is also acceptable). Each 3-week period constitutes one cycle. For the first to fourth cycles, a total of 4 cycles are required."
214996163|NCT06348108|DRUG|Dexamethasone|Given PO
214687487|NCT07162051|OTHER|standard chemotherapy|standard chemotherapy
214383125|NCT04722861|OTHER|GVFQ-40|GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons.
214383126|NCT01484795|DEVICE|BILEVEL (Respironics)|Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
214383127|NCT01484795|DEVICE|Continuos positive airway pressure (Respironics)|CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
214687488|NCT07162402|OTHER|Super Skills for Life (SSL) Program|Its Cognitive Behaviour Therapy (CBT) Based 8 sessions Super Skills for Life (SSL) Program for childhood Anxiety Management.
214687489|NCT07162402|OTHER|No Active Intervention|Routine Activities in Class
214996164|NCT06348108|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214996165|NCT04768972|DRUG|ION363|ION363 will be administered by IT bolus injection.
214996166|NCT04768972|DRUG|Placebo|Placebo will be administered by IT bolus injection.
214996167|NCT05612100|OTHER|Electronic Health Record Review|Ancillary studies
214996168|NCT05612100|OTHER|Questionnaire Administration|Complete alopecia questionnaires
214498760|NCT04840134|BEHAVIORAL|From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk|"The intervention will be delivered in three consecutive phases:~1. Intensive Intervention Phase (weeks 1 to 6), consisting of 6 weekly group sessions and 4 one-on-one coaching sessions to navigate financial resources.~2. Intermediate Phase (weeks 7 to 12), consisting of 3 biweekly group sessions, and either 3 biweekly or 2 monthly one-on-one coaching sessions, based on participant preference.~3. Follow up Phase (weeks 13 to 24), consisting of 3 monthly group sessions, and either 3 monthly or 6 biweekly one-on-one coaching sessions based on participant preference.~Key intervention components:~1. Peer-led group sessions~2. Individual peer coaching sessions to complement group sessions"
214383128|NCT04708301|DIAGNOSTIC_TEST|T1 mapping|T1 mapping is a specialised heart scan that measures the magnetic properties of heart tissue and displays them as an image or map
214996169|NCT05612100|OTHER|Survey Administration|Complete alopecia surveys
214383129|NCT05176704|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
214383130|NCT05611697|PROCEDURE|Single anastomosis sleeve ileal bypass|The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
214498761|NCT02655575|BEHAVIORAL|BI + VR + CBT|Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
214498762|NCT02655575|BEHAVIORAL|BI + phone calls|Brief intervention (information and advice). Patients are followed-up by phone calls
214498763|NCT02767999|DRUG|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
214498764|NCT02767999|DRUG|Placebo|cellulose placebo per day from D0 to D90
215093157|NCT05433597|RADIATION|Radiotherapy|Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.
215093158|NCT05433597|DRUG|TNF|TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.
215093159|NCT05433597|DRUG|Placebo|Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
214498765|NCT02767999|RADIATION|fMRI|functional resting state MRI
214687490|NCT07162064|DRUG|Heparin - Therapeutic dosage|Intra-arterial sheath injection of heparin 2500 units before operation
214687491|NCT07162064|DRUG|Saline (0.9% NaCl)|Intra-arterial sheath injection of 2mL saline (0.9% sodium chloride)
214996170|NCT06666075|OTHER|Digital and Interactive Reminiscence|The intervention for the experimental group aims to enhance the psychological well-being of institutionalized seniors with Alzheimer's through a digital and interactive reminiscence therapy program. It begins with selecting participants based on specific inclusion and exclusion criteria, followed by developing personalized digital profiles that include photographs, music, videos, and life anecdotes to evoke emotional memories. Care staff receive training in using the digital software and reminiscence techniques. The core intervention consists of digital reminiscence sessions held twice a week for eight weeks, lasting about 60 minutes each, featuring multimedia content to encourage discussion and memory sharing. Interactive activities foster active participation, with facilitators promoting emotional expression and connection among participants, creating a supportive environment that stimulates cognitive function and reduces isolation.
214996171|NCT06322342|DRUG|RVP-001|MRI contrast agent
214996172|NCT02108054|DEVICE|7T MRI|Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
214996173|NCT05255991|DRUG|Placebo|Placebo administered QID
214996174|NCT05255991|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
215093160|NCT06142617|DRUG|Pembrolizumab, pemetrexed, platinum|Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks.
214996175|NCT05255991|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
214996176|NCT03575832|OTHER|Counseling|Complete nutrition counseling sessions
214996177|NCT03575832|OTHER|Informational Intervention|Receive an exercise plan and printed materials
214996178|NCT03575832|OTHER|Quality-of-Life Assessment|Ancillary studies
214996179|NCT03575832|OTHER|Questionnaire Administration|Ancillary studies
215093161|NCT06142617|DRUG|Osimertinib|Osimertinib will be the sequential treatment strategy at progression until resistance develops.
215093162|NCT06254859|PROCEDURE|Traditional thyroid surgery.|The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.
215093163|NCT06848023|PROCEDURE|Reverse Total Shoulder Arthroplasty|standard of care treatment reverse total shoulder arthroplasty delivered
215093164|NCT06848023|PROCEDURE|Rotator Cuff Repair|standard of care treatment rotator cuff repair delivered
214383131|NCT05611697|PROCEDURE|Sleeve gastrectomy|In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.
214383132|NCT01959945|BIOLOGICAL|Flublok® Quadrivalent Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
214383133|NCT01959945|BIOLOGICAL|Fluarix Quadrivalent® Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
214383134|NCT02729636|DEVICE|multi-pad functional electrical stimulation (FES)|"Treatment includes two automated phases: optimization of stimulation parameters and application during the walk.~Optimization of stimulation parameters: The stimulator generates short bursts of electrical impulses and sends them to each of the 16 pads of the multi-pad electrode. Each pad is the same size. Pads are sorted in two rows by 8 pads. Common anode is placed under the knee. Based on FES-induced foot movements, automated algorithm suggests parameters which are evaluated by medical doctor/therapist.~Assisted walking: During assisted walking, pattern for plantar flexion is activated in push off phase and pattern for dorsiflexion in swing phase of the gait."
214996180|NCT03575832|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching calls
214996181|NCT03136146|DRUG|Bortezomib|Given SC
214996182|NCT03136146|DRUG|Clofarabine|Given IV
214996183|NCT03136146|DRUG|Cyclophosphamide|Given IV
214996184|NCT03136146|DRUG|Dexamethasone|Given IV or PO
214996185|NCT03136146|DRUG|Etoposide|Given IV
214996186|NCT03136146|BIOLOGICAL|Ofatumumab|Given IV
214996187|NCT03136146|BIOLOGICAL|Pegfilgrastim|Given SC
214383135|NCT02729636|OTHER|Conventional therapy|2\. All study subjects received the conventional stroke rehabilitation program of physiotherapy based on the neurodevelopmental facilitation approach and occupational therapy focused on activities of daily living during the treatment for 60 min a day, 5 days a week, for 4-weeks. Conventional therapy was given by trained therapists and consisted of the following strategies: strategies to joint mobilization and range of motion exercises; exercises to improve strength; strategies to manage spasticity; exercises for increase range of motion, compensatory strategy; strategies to improve balance, and mobility.
214383136|NCT04489589|DRUG|Midodrine|10mg PO/NG q8h
214383137|NCT04489589|DRUG|Placebo|10mg PO/NG q8h
214498766|NCT04649047|BEHAVIORAL|Goal-oriented episodic future thinking|All participants will receive a 3-week web-based intervention plus individual health coaching. The intervention topics include stress management, healthy eating, and physical activity
214498767|NCT04314219|DRUG|Cyclophosphamide 50mg|Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5
214498768|NCT04314219|DRUG|Methotrexate|Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6
214996188|NCT03136146|BIOLOGICAL|Rituximab|Given IV
214498769|NCT06934616|DRUG|GB268|GB268 will be administered via intravenous infusion once every 3 weeks on Days 1 of each 21-day cycle
214498770|NCT06043791|RADIATION|1.5 Tesla magnet MR arthrography|MR arthrogram is an invasive procedure where the patient's joint is injected with a mixture of dilute gadolinium, iodinated contrast medium, local anesthetic, and saline solution followed by imaging with 1.5 Tesla MRI.
214687492|NCT07162558|BEHAVIORAL|Child-Centered Empowerment Intervention|"Participants in this group receive the child-centered empowerment program, a structured behavioral intervention designed to enhance coping skills, promote self-efficacy, and improve lifestyle in children with leukemia. The program is based on four dimensions of empowerment:~Perceived Threat: Increasing awareness of illness, its complications, and the treatment process through group discussions.~Self-Efficacy: Practicing problem-solving and self-management techniques to strengthen self-belief, self-control, and confidence in handling illness-related challenges.~Educational Participation: Children receive educational cards at the end of each session and are encouraged to share the learned content with family members to reinforce responsibility and engagement.~Evaluation: Continuous follow-up and assessment of learning after each session to ensure understanding and active participation."
214996189|NCT03136146|DRUG|Vincristine Sulfate Liposome|Given IV
214996190|NCT05168540|OTHER|no intervention|Children will be included on the occasion of an admission to pediatric unit, the emergency room, the intensive care unit or a consultation in a specialized unit for children at risk of abuse. Their primary care pathway will be analyzed.
214996191|NCT06440707|DEVICE|High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)|The active study treatment involves delivering a weak form of electrical stimulation via 5 small electrodes to the brain tissue at risk of infarction.
214996192|NCT06440707|DEVICE|Sham tDCS|Sham patients will have cap and electrodes in place, but no stimulation will be delivered.
214996193|NCT03927885|OTHER|Placebo Administration|Given open labeled placebo PO
214996194|NCT03927885|OTHER|Quality-of-Life Assessment|Ancillary studies
214996195|NCT03927885|OTHER|Questionnaire Administration|Ancillary studies
214996196|NCT03927885|OTHER|Waiting List|Assigned to a waiting list
214996197|NCT04929002|OTHER|No intervention|No intervention
214996198|NCT04871074|DRUG|UCB-J|PET imaging with UCB-J
214996199|NCT04871074|DEVICE|MRI Scan|MRI exams will be performed using a 3T MRI scanner, scan duration is typically 60 minutes
214996200|NCT04871074|DEVICE|PET Scan|PET imaging may be collected using either a PET scanner or a PET/Computed Tomography (CT) scanner, a PET scan will be initiated with the injection of radiotracer
215093165|NCT06338202|DRUG|Mavacamten|As detailed in the product label
214383138|NCT00000990|DRUG|Zidovudine|
214383139|NCT02253524|DRUG|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
214383140|NCT02253524|DRUG|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
214383141|NCT01490203|DRUG|Gd-EOB-DTPA|"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
214383142|NCT01490203|DRUG|Gd-EOB-DTPA|"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
214383143|NCT01490203|PROCEDURE|MRI|"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
214383144|NCT01490203|PROCEDURE|MRI|"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
214383145|NCT02689856|DRUG|Hydrocortisone acetate and lidocaine hydrochloride|Hydrocortisone and lidocaine in combination
214383146|NCT02689856|DRUG|Placebo control|Vehicle cream alone
214383147|NCT02689856|DRUG|Hydrocortisone acetate|hydrocortisone alone
214383148|NCT02689856|DRUG|Lidocaine hydrochloride|lidocaine alone
214383149|NCT00896129|OTHER|HRQOL Survey Packet|Questionnaires
214383150|NCT02019563|PROCEDURE|RCT Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.
214383151|NCT02019563|PROCEDURE|MTA/FS pulpotomy Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
214383152|NCT01916499|OTHER|3 tesla magnetic resonance imaging findings; coronary artery status|
214383153|NCT01916499|OTHER|3 tesla magnetic resonance imaging findings; ventricular function and morphology|
214498771|NCT06043791|RADIATION|3 Tesla magnet non-contrast MRI|3T MRI uses very powerful magnets that produce a 3-tesla magnetic field. A 3-tesla magnetic field is twice as powerful as the fields used in conventional high-field MRI scanners, and as much as 15 times stronger than low-field or open MRI scanners. This results in a clearer and more complete image. Studies have shown that it is highly sensitive and specific in detecting labral and cartilage pathology
214498772|NCT06839521|OTHER|Walk Test-T|6MWT will be conducted according to traditional protocols. During the test, parameters such as heart rate, oxygen saturation, and walking distance will be measured and compared with traditional methods.
214996201|NCT06114875|BEHAVIORAL|Peer support intervention|"Flags will appear beside posts that the risk algorithm has identified as containing descriptions of distress or mental health concerns (these flags will not be visible to the original poster). Next to these flags, users will also see a brief blurb such as: This person might be going through something difficult. To learn more about what to say to peers who may be experiencing distress, click this banner. RallyPoint users will then have the option of clicking on these flags, where they will be directed to a psychoeducational information page on how to provide support to peers who may be experiencing distress."
214996202|NCT06011798|DRUG|Aflibercept|Anti-VEGF control
214996203|NCT06011798|DRUG|foselutoclax|Experimental drug
214687493|NCT07164131|DRUG|Doxycycline|Subjects will receive Doxycycline (orally or intravenously) in combination with beta-lactam therapy within 12 hours of hospital admission. Treatment duration will be 5-7 days.
214996204|NCT06605404|DIAGNOSTIC_TEST|blood and tissue samples|routine standard of care
214996205|NCT06605404|OTHER|blood and tissue samples|Routine standard of care
214996206|NCT06228092|DRUG|neostigmine/glycopyrrolate|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
214996207|NCT06228092|DRUG|Sugammadex|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
214383154|NCT02323035|DEVICE|Headgear|Investigative Headgear with CPAP Mask.
214383155|NCT04866511|OTHER|Narrative Exposure Therapy|"NET is a trauma-focused psychological treatment for people who experienced multiple traumas (Schaeur et al., 2011).~An adaptation named KIDNET was developed for use with children and young people (Neuner et al., 2008; Schauer et al., 2011, 2017).~Participants will be offered 6-10 weekly sessions of NET lasting approximately 90 minutes each. The sessions will be delivered by a Trainee Clinical Psychologist via videoconferencing, in line with the UK's Government guidelines around reducing face-to-face contacts during the Covid-19 pandemic."
214383156|NCT00726336|DRUG|GSK1349572 and tenofovir|
214383157|NCT05468775|BEHAVIORAL|Naked eye 3D vision training|20 minutes of naked eye 3D vision training every day
214383158|NCT02585037|OTHER|Kinesio Taping® bandage|"The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups."
214383159|NCT02585037|OTHER|Dynamometer Jamar® pressure|The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
214996208|NCT05963516|OTHER|LIVEBORN: A Mobile Health Application (app) for Newborn Resuscitation|LIVEBORN is a mobile health application designed to help providers learn from their clinical practice during newborn resuscitation through real-time guidance and debriefing. Using LIVEBORN, an observer can document events during a resuscitation such as the actions of the provider and when the baby cries. A battery-operated heart rate meter, NeoBeat, measures and sends the newborn's heart rate to the LIVEBORN app via Bluetooth. LIVEBORN integrates data from the observer and NeoBeat to provide audio-visual real-time guidance to the provider during a resuscitation. Following the resuscitation, providers can also debrief using LIVEBORN. The app operates on the Android system and is functional off-line, except for the need for an internet connection to upload data to the cloud for research.
214996209|NCT05963516|DEVICE|NeoBeat: Heart Rate Meter for Newborn Resuscitation|NeoBeat is a low-cost device for the measurement of newborn heart rate (HR) that was developed by Laerdal Global Health for use in low-resource settings. It is applied by placing the device around the torso of the newborn. It detects HR accurately, quickly (\<5 sec), is reusable and can be easily disinfected. NeoBeat's dry electrodes detect HR which is digitally displayed and recorded. It uses an impedance system to sense skin contact and motion detection to validate signal quality. It does not require the use of buttons, adhesive, gel or cables and has no disposable parts. A single birth attendant can apply NeoBeat in 2-3 seconds.
214996210|NCT04388475|DRUG|OKN-007|Drug: OKN-007 (400 mg OKN-007/mL in a phosphate buffer) Administered via IV infusion, at a dose level of 60 mg/kg, given three times a week for 12 weeks, two times a week for a further 12 weeks and once per week until disease progression or up to two years.
214996211|NCT04388475|DRUG|Temozolomide (TMZ)|Administered via oral, at a dose level of 150 mg/m2, once daily on Days 1-5 of each 28 day cycle in Cycle 1. If this dose level is tolerated, then in Cycle 2 (and subsequent cycles), at a dose level of 200 mg/m2, once daily on Days 1-5 of each 28 day cycle.
214383160|NCT02585037|OTHER|Placebo|For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
214383161|NCT00485576|DRUG|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
214383162|NCT00162643|DRUG|zidovudine+lamivudine+lopinavir/ritonavir|
214383163|NCT00162643|DRUG|zidovudine + lamivudine + efavirenz|
214383164|NCT06285760|DRUG|Standarized diuretic therapy|Patients hospitalized with decompensated heart failure and fluid overload who require diuretic treatment for relieve of congestion. Standarized diuretic protocol according to guidelines will be applied. It consists of intravenous furosemide, SGLT2 inhibitors and acetazolamide if congestion persist.
214383165|NCT01997320|OTHER|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.
214383166|NCT01997320|OTHER|Nutrition supplement|Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
214383167|NCT02209636|DRUG|Lanthanum carbonate|Non-calcium containing phosphorus binder
214383168|NCT02209636|DRUG|placebo|Table identical to lanthanum carbonate but with no active ingredient
214383169|NCT02209636|DRUG|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
214383170|NCT02209636|DRUG|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
214383171|NCT02209636|PROCEDURE|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
214383172|NCT02209636|PROCEDURE|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
214383173|NCT02209636|PROCEDURE|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
214996212|NCT03837964|DRUG|BI 1291583|Tablet
214383174|NCT02705040|OTHER|Normal|bone mineral density T\>=-1.0
214383175|NCT02705040|OTHER|Osteopenia|bone mineral density -1.0\>T\>=-2.5
214383176|NCT02705040|OTHER|Osteoporosis|bone mineral density T\<-2.5
214498773|NCT06839521|OTHER|Walk Test-A|In order to develop Android-based 6DYT, the system will be designed with a multidisciplinary team consisting of software engineer and physiotherapist. In this programme, separate algorithms will be developed for indoor and outdoor environments so that individuals can be evaluated in a hospital environment, at home or in daily life. In indoor environments, the GPS signal is lost or there is not enough signal strength. For this reason, the programme will be developed so that the gyroscope of the phone can be used for distance measurement. GPS signals will be used outdoors. In this way, the physical activity level of the individual both in the hospital and in daily life will be measured.
214498774|NCT00719888|DRUG|Cyclophosphamide|Given IV
214498775|NCT00719888|DRUG|Cyclosporine|Given IV and PO
214498776|NCT00719888|PROCEDURE|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
214383177|NCT04022889|DEVICE|INTERCEPT Treated Platelets|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.
214383178|NCT04048499|DEVICE|the Colour Assessment and Diagnosis (CAD) test|The CAD test (City Occupational Ltd, London, UK) measures the severity of red-green and yellow-blue colour vision loss according to red-green and yellow-blue thresholds which are expressed in CAD units and diagnoses accurately the subject's class of colour vision
214383179|NCT00003320|PROCEDURE|surgical procedure|
214383180|NCT00003320|RADIATION|radiation therapy|
214383181|NCT00003320|RADIATION|stereotactic radiosurgery|
214383182|NCT01568632|DRUG|Imetelstat|
214383183|NCT02942680|DRUG|acetylsalicylic acid started for 24 hours before surgery|
214383184|NCT02942680|DRUG|acetylsalicylic acid stayed for 5 days before surgery|
214383185|NCT05606315|DRUG|Remimazolam Besylate|NS 50ML + Remimazolam besylate(50mg , 2mg:2ml), IV-Pump,maintenance dose 0.5-3mg/kg/h.
214996213|NCT06500078|BEHAVIORAL|Intermittent dietary restriction|"Intermittent dietary restriction will include the ILCD and ICR, which will be self-administered interventions in daily lives. The ILCD intervention will ask participants to restrict carbohydrate intake to ≤ 50 g/d on two consecutive or discontinuous days per week. The ICR intervention will ask participants to restrict caloric intake to 600 kcal/d for boys and 500 kcal/d for girls on two consecutive or discontinuous days per week.~At baseline, participants will receive face-to-face oral dietary instructions (e.g., principle of dietary restriction, sample menus, food list with macronutrients). Participants will receive the intervention booklets containing dietary advice and sample menus for diet according to the requirements of the dietary intervention.~Participants will be required to record dietary and physical activity data on a regular basis. The total intervention duration will be 12 months, including a 3-month intervention phase and a 9-month self-maintenance phase."
214996214|NCT06500078|BEHAVIORAL|General health education|General health education based on dietary and physical activity guidelines for Chinese children and adolescents, will regularly send offline and online promotional materials to participants.
214996215|NCT00098475|DRUG|Dexamethasone|Given PO
214996216|NCT00098475|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214996217|NCT00098475|DRUG|Lenalidomide|Given PO
214996218|NCT00098475|DRUG|Thalidomide|Given PO
214996219|NCT05351580|DEVICE|DiSCERN|Smart watch Monitoring
214996220|NCT05667324|DRUG|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)
214996221|NCT05667324|DRUG|Dexamethasone|Plus 4 mg dexamethasone
214383186|NCT05606315|DRUG|Propofol|Propofol (50ml, 0.5g), IV-Pump, maintenance dose 0.3-4.0mg/kg/h.
214383187|NCT05606315|DRUG|Midazolam|Midazolam (10mg,2ml), IV-Pump, maintenance dose 0.02-0.1mg/kg/h.
214383188|NCT03221504|OTHER|Longer therapy duration|Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
214383189|NCT03221504|OTHER|Shorter therapy duration|Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
214383190|NCT00674635|DRUG|GSK3152314A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
214383191|NCT00674635|DRUG|Placebo|matching placebo
214383192|NCT00753883|DRUG|simvastatin|simvastatin 20 mg/QD for 6 Weeks.
215093166|NCT06293976|OTHER|Changes in the ventilator respiratory rate and tidal volume|"With the ventilator on volume control and Vt at 6 ml/kg of predicted body weight (PBW) (standard clinical practice), an end-expiratory occlusion of 30 seconds on the ventilator will be performed to search for intrinsic respiratory rate (RR). The set RR will be modified from 6 breaths per minute (bpm) below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (random order). The changes in RR described above will be repeated with Vt set at 5, 7 and 8 ml/kg PBW (random order). The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure \>35 cmH2O.~If an intrinsic respiratory rate ≥8 bpm is present and P/F ratio is ≥150, it will be propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well, it will be propose to the clinician to maintain the patient in pressure support ventilation,"
215093167|NCT05063539|DRUG|LY3372689|given orally
215093168|NCT05063539|DRUG|LY3372689|given orally
215093169|NCT05063539|DRUG|Placebo|given orally
215093170|NCT05791240|BEHAVIORAL|Family Initiated Interpretation|Interpreter tablet will be given to families so they can contact an interpreter themselves.
214383193|NCT00753883|DRUG|Ezetimibe|Ezetimibe 10 mg/QD for 8 weeks.
214383194|NCT01950442|DEVICE|Balloon dilation|
214383195|NCT03375125|DIETARY_SUPPLEMENT|Probiotic|L. reuteri DSM 17938 \& L. reuteri ATCC PTA 5289 ) will be given at a dose of 2x10\^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
214383196|NCT03375125|OTHER|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
214383197|NCT00937170|DEVICE|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
214383198|NCT00937170|DEVICE|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
214383199|NCT00937170|DEVICE|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
214498777|NCT00719888|DRUG|Fludarabine|Given IV
214498778|NCT00719888|OTHER|Laboratory Biomarker Analysis|Correlative studies
214498779|NCT00719888|DRUG|Mycophenolate Mofetil|Given IV and PO
214498780|NCT00719888|RADIATION|Total-Body Irradiation|Undergo high-dose or moderate-intensity TBI
214498781|NCT00719888|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
214498782|NCT00719888|DRUG|Thiotepa|Given IV
214996222|NCT05667324|DRUG|Placebo|A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)
215093171|NCT05819892|DRUG|Paclitaxel|Given by IV (vein)
215093172|NCT05819892|DRUG|Carboplatin|Given by IV (vein)
215093173|NCT05819892|DRUG|Dostarlimab|Given by IV (vein)
215093174|NCT05819892|DRUG|Cisplatin|Given by IV (vein)
215093175|NCT05503225|DRUG|Colchicine 0.5 MG|0.5mg Orally Taken Colchicine
215093176|NCT05766839|DRUG|Patiromer|Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split
214383200|NCT01296490|OTHER|Stress test|Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
214996223|NCT05393232|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
214996224|NCT05393232|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
214383201|NCT04242420|DIAGNOSTIC_TEST|Genotyping|Genotyping for single nucleotide polymorphisms for Connexin 37\&43, Mannose binding lectin (MBL) and transforming growth factor beta (TGF beta) genotypes
214383202|NCT04242420|DIAGNOSTIC_TEST|Lung function|Spirometry,
214383203|NCT04242420|DIAGNOSTIC_TEST|Microbiology|Bacterial culture from Sputum or swab
214383204|NCT04242420|DIAGNOSTIC_TEST|Blood sample|Interleukin-8 assay (via chemiluminescence) blood cell count
214383205|NCT04242420|DIAGNOSTIC_TEST|Induced Sputum|Interleukin-8 assay (via chemiluminescence) blood cell count
214383206|NCT01492179|DRUG|Normal saline|Normal saline would be administered intravenously and intra-abdominally.
214383207|NCT01492179|DRUG|Intravenous Lidocaine|Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
215094742|NCT04778800|DRUG|almonertinib|Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.
214383208|NCT01492179|DRUG|Intra-abdominal Lidocaine|Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
214383209|NCT00808301|OTHER|Gluten-free products|Gluten-free bakery products containing oatmeal.
214383210|NCT02970032|DRUG|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
214498783|NCT04161755|DRUG|Atezolizumab|Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
214498784|NCT04161755|BIOLOGICAL|RO7198457|RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
214498785|NCT04161755|DRUG|mFOLFIRINOX|mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
214498786|NCT05037513|BEHAVIORAL|SBCM-PrEP|Multi-session SBCM intervention adapted for PrEP initiation focus
214498787|NCT05037513|BEHAVIORAL|CDC-PrEP|1 session PrEP education following CDC guidelines
214498788|NCT05886777|BIOLOGICAL|Combination [RSVpreF+BNTb162b2]|Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
214498789|NCT05886777|BIOLOGICAL|Bivalent BNT162b2 (original/Omi BA.4/BA.5)|Bivalent BNT162b2 given as an intramuscular injection
214383211|NCT02970032|DRUG|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
214383212|NCT01230606|OTHER|discharge vs. overnight stay|At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
214383213|NCT02471885|PROCEDURE|Remote Ischaemic Conditioning|each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) upto 200mm Hg (systolic BP + 20 mm Hg for low platelets, e.g. 50-150 x 10\^9/L; skip RIC if platelets \< 50 x 10\^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
214383214|NCT02471885|OTHER|Placebo|Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
214383215|NCT00221949|DEVICE|Ultrasound|
214383216|NCT06155578|DRUG|Topical 25% sodium metabisulfite (SM) in pediatric cold cream|Topical 25% sodium metabisulfite (SM) in pediatric cold cream will be applied twice daily on hand calcinosis.
214383217|NCT06155578|DRUG|Placebo|Pediatric cold cream will be applied twice daily on hand calcinosis.
214383218|NCT02678767|DRUG|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
214383219|NCT00082537|DRUG|caspofungin acetate|Duration of Treatment: 28-90 days
214383220|NCT00082537|DRUG|Comparator: AmBisome|Duration of Treatment: 28-90 days
214383221|NCT01918696|BEHAVIORAL|Anger Reduction Treatment|Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.
214383222|NCT01918696|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.
214498790|NCT05886777|BIOLOGICAL|RSVpreF|RSVpreF given as an intramuscular injection
214498791|NCT05886777|BIOLOGICAL|QIV|Licensed QIV given as an intramuscular injection
214498792|NCT05886777|BIOLOGICAL|Normal Saline Placebo|Normal saline (0.9% sodium chloride solution for injection)
214996225|NCT05514548|DRUG|INV-202|INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
214996226|NCT05514548|DRUG|Placebo|Placebo Matching size and number of tablets
214383223|NCT01918696|BEHAVIORAL|Control Condition|Eight 15-minute sessions of informative videos on healthy living.
214383224|NCT01077479|DRUG|Metformin|Metformin 1500mg nocte for 6 months
214383225|NCT03873194|OTHER|Meditation|Participants will be instructed to find a comfortable position, with a straight back, feeling the general state of their bodies (tensions, pains, heat, cold, etc.), to relax and pay attention to their own breathing, being aware of the air that gets into and out of the lungs. The women will be told that whenever their attention disperses (to another focus such as a thought, a sound, a body sensation, a judgment, etc.) they should go back to the original focus (breathing) with no feeling/judgment about the loss of focus. The practice involves focus and attention exercises and the gradual insertion of other anchors (focus points) as participants improve their skills in this practice.
214498793|NCT03884543|PROCEDURE|Individualized high PEEP strategy|Patients are randomized and intra-operatively ventilated with an individualized high PEEP strategy (Highest PEEP with the lowest driving pressure with recruitment maneuvers)
214498794|NCT06310681|BEHAVIORAL|"Encompass group programme"|"* Groups will take place over ten modules~* They will take place in-person at a local community venue~* The groups will be two hours long, with a break for refreshments in the middle. They will take place every fortnight in term-time only over approximately 6 months.~* The groups predominantly follow a participatory learning approach and although the facilitators have manuals, the activities tend to include some imparting of information, key points for discussion, examples from other settings and activities for the group to practice.~* They are run by two facilitators - one parent with lived experience and one healthcare professional"
214498795|NCT01009177|DRUG|Bosentan|Bosentan 500 mg bid
214498796|NCT01009177|DRUG|Placebo|Placebo
214996227|NCT06136169|BEHAVIORAL|Reminder-cue scanning training|Auditory reminders to scan when scanning to the side of the field loss is inadequate
214996228|NCT04324619|OTHER|Online interactive learning activities|"1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)"
214996229|NCT02619201|DRUG|Ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
214996230|NCT02619201|DRUG|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
214996231|NCT06388213|DEVICE|Gastric Ultrasonography|Evaluation of cross sectional area of the antrum by gastric ultrasonography in healthy patients and in patient treated by GLP-1 receptor agonists after a fasting period (6 hours for solid and 2 hours for clear liquids). For the GLP-1 receptor agonists group the gastric ultrasonochography will be repeated each 2 days during 7 days. In the non GLP-1 receptors agonists group the evaluation will be executed one time.
214996232|NCT04520373|OTHER|Best Medical Management: Occupational and Physical Therapy|Observation while undergoing Occupational and Physical Therapy for 6 months
214996233|NCT04520373|BIOLOGICAL|Autologous, Adipose Derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.
214996234|NCT06069908|OTHER|Complex Decongestive Treatment|Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach. It will be applied 5 days a week for 3 weeks
214996235|NCT06069908|OTHER|Sham transcutaneous vagus nerve stimulation|In sham transcutaneous vagus nerve stimulation application, the device electrode will be placed in the superior scapha region of the outer ear, where the vagus nerve has no innervation, and no current will be given.Complex Decongestive Therapy and sham transcutaneous vagus nerve stimulation.It will be applied 5 days a week for 3 weeks.
214996236|NCT06069908|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation will be applied in addition to Complex Decongestive Therapy.It will be applied 5 days a week for 3 weeks.
214996237|NCT06069908|OTHER|Exercise|Patients will undergo lymphedema-specific exercises 5 days a week for 3 weeks.
214996238|NCT04838444|BIOLOGICAL|VLA1553|Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
215093177|NCT05268042|OTHER|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
214498797|NCT00548236|BEHAVIORAL|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
214498798|NCT05248503|BEHAVIORAL|Complex Care Training of Hereditary Epidermolysis Bullosa|Training in the care of epidermolysis bullosa by combining theoretical content on the disease and practical workshops.
214687494|NCT07164131|DRUG|Azithromycin|Subjects will receive Azithromycin (orally or intravenously) in combination with beta-lactam therapy within 12 hours of hospital admission. Treatment duration will be 5-7 days.
214383226|NCT03873194|OTHER|conventional treatment|"Early prenatal care, when possible, is recommended as the first measure. Prenatal appointments usually take place fortnightly or weekly for hypertensive pregnant women. Extensive lab testing including specific tests for the first trimester, as well as tests for the diagnosis of superimposed pre-eclampsia and for the evaluation of lesions in target organs.~Drug treatment is only used when non-drug measures against hypertension are inefficient to decrease blood pressure levels and diastolic pressure is 90 mmHg or higher (in the first half of pregnancy) and over 100 mmHg (after 20 weeks)."
214383227|NCT03841825|BEHAVIORAL|Oral hygiene instructions|Oral hygiene instructions and motivation
214383228|NCT00605319|DRUG|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
214383229|NCT03410290|OTHER|Online Questionnaire|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
214383230|NCT00580996|OTHER|water high dose|water 16 oz PO x 1
214383231|NCT00580996|OTHER|water tiny dose|water 1 oz PO x 1
214383232|NCT06241690|OTHER|the cold applications in post-suture pain reduces the child's pain|The experimental groups was applied cold applications immediately after 20 minutes the suture. Later, The experimental groups was applied cold applications again for 20 minutes 1 hour, 2 hours and 6 hours after the suture.
214383233|NCT02790216|PROCEDURE|Brachytherapy|Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
214383234|NCT04806230|DRUG|sertraline, mirtazapine, venlafaxine, citalopram, escitalopram|Naturalistic treatment
214498799|NCT06936020|OTHER|deep peripheral sensory stimulation|The proprioceptive stimulus will consist of intermittent mechanical pressure on the skin, localized at the neuromuscular motor points of the rectus femoris, vastus lateralis, and vastus medialis of the quadriceps. The tissue subjected to this precise pressure in areas of high neuromuscular innervation facilitates the stimulation of kinesthetic cortical sensitivity. The experimental group (EG) will be randomly and crosswise subdivided into two groups, so that both receive the intervention in two different modalities at two different times.
214996239|NCT05334836|DIAGNOSTIC_TEST|MRI for pancreatic fat and liver fat quantitation|MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2\* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.
214498800|NCT06936111|DIAGNOSTIC_TEST|Assessment of residual cholesterol and inflammatory risk factors|The prespecifed risk factors include CRP, SAA, TNF-α, IL-6, MCP-1, Lp-PLA2, PCSK-9, Lp(a)
214996240|NCT03370276|DRUG|Nivolumab|Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.
214996241|NCT03370276|DRUG|Cetuximab|Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.
215093178|NCT05268042|OTHER|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
215093179|NCT06078956|DEVICE|Measuring of analytes|Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.
214383235|NCT00171132|DRUG|valsartan|
214383236|NCT00171132|DRUG|atenolol|
214383237|NCT00171132|DRUG|hydrochlorothiazide|
214383238|NCT01478113|DRUG|Amphetamine/dextroamphetamine|The amphetamine/dextroamphetamine will be in a pill formulation. The dosage of the amphetamine/dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.
214383239|NCT01478113|DRUG|Placebo|The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
214383240|NCT01478113|BEHAVIORAL|Well-being therapy|Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
214383241|NCT02991235|DIETARY_SUPPLEMENT|PRJ212|6 capsules of study product will be taken daily and orally.
214996242|NCT05749822|DRUG|Fenofibrate 200mg|Fenofibrate 200mg/day
214383242|NCT02991235|DIETARY_SUPPLEMENT|Placebo|6 capsules of study product will be taken daily and orally.
214383243|NCT01703702|DRUG|florbetapir (18F)|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
214383244|NCT00721656|DRUG|Placebo|
214996243|NCT05749822|DRUG|Placebo|1 tablet/ day
215093180|NCT03505320|DRUG|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
215093181|NCT03505320|DRUG|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
215093182|NCT03505320|DRUG|leucovorin|Leucovorin will be administered as a 2-hour IV infusion.
215093183|NCT03505320|DRUG|fluorouracil|Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
214383245|NCT00721656|DRUG|KLS-0611|
214383246|NCT05099016|OTHER|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and 14) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
214383247|NCT05099016|OTHER|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use use. Participants will also be offered basic reliable non personalized information on lower-risk cannabis use in the form of official public websites.
214383248|NCT03837613|PROCEDURE|tumor resection and neck dissection|Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.
215093184|NCT03505320|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes.
215093185|NCT03505320|DRUG|folinic acid|Folnic acid will be administered as a 2-hour IV infusion.
214383249|NCT00891306|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
214383250|NCT00891306|DRUG|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
214383251|NCT00891306|DRUG|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
214383252|NCT00891306|DRUG|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
214383253|NCT03093428|DRUG|Radium-223|Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.
214498801|NCT00872729|DRUG|Cystagon®|"Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H."
214498802|NCT00872729|DRUG|RP103|"Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product."
214687495|NCT07162779|DRUG|Radioactive drugs are administered through intravenous injection.|\[68Ga\]DOTA-IR-780-C-4 is administered through a superficial vein on the back of the hand. A PET/CT scan was performed approximately 1 h,2 h and 3 h after injection
214996244|NCT05749822|DRUG|UDCA|UDCA 13-15mg/kg/day
214996245|NCT04796857|DRUG|PD-1 Antibody|Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
214996246|NCT04796857|DRUG|Lenalidomide|"Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase"
214996247|NCT05867121|DRUG|RO7496353|RO7496353 will be administered as per the schedules specified in the respective arms.
214996248|NCT05867121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
214996249|NCT05867121|DRUG|Capecitabine|Capecitabine will be administered as per the schedule specified in the respective arm.
214996250|NCT05867121|DRUG|S-1|S-1 will be administered as per the schedule specified in the respective arm.
214996251|NCT05867121|DRUG|Nivolumab|Nivolumab will be administered as per the schedule specified in the respective arm.
214996252|NCT05867121|DRUG|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
214996253|NCT05867121|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as per the schedule specified in the respective arm.
214996254|NCT05867121|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
214383254|NCT03093428|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor. Pembrolizumab binds to human PD-1 and blocks the interaction between PD1 and its ligands.
214383255|NCT06152016|OTHER|BE-FAST|This intervention includes those randomized to the education with the BE-FAST mnemonic.
214383256|NCT06152016|OTHER|FAST|This intervention includes those randomized to the education with the FAST mnemonic.
214383257|NCT00978354|DRUG|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
214383258|NCT00978354|DRUG|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
214383259|NCT04334239|OTHER|Oncological certification|Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.
214498803|NCT03664804|OTHER|No Study Drug was Administered in this Study|No study drug was administered in this study
214498804|NCT06508450|BEHAVIORAL|Just Do You|Just Do You Core Intervention utilizes creative arts and a provider team of a licensed clinician and professional peer to increase young adult engagement in adult outpatient mental health programs. Content addresses recovery, advantages of using mental health services, working with providers, stigma, and mental health literacy.
214498805|NCT06508450|BEHAVIORAL|Component A|Content addresses participant cultural identities and how they may be barriers and facilitators to on-going engagement with services.
214498806|NCT06508450|BEHAVIORAL|Component B|Content addresses identity-based motivations for on-going engagement with services and hope for the future.
214498807|NCT06508450|BEHAVIORAL|Component C|Content addresses community and environmental barriers and facilitators to on-going engagement with services and self-efficacy.
214498808|NCT06935513|BEHAVIORAL|Wearable Devices|Participants utilize wearable devices (smart wristbands) 24 hours a day for 6 months. Wearable devices can provide medication reminders for each use and heart rate monitoring.
214687496|NCT07164118|BEHAVIORAL|Pranayama Breathing Exercise|Pranayama breathing technique consisting of 6 cycles, demonstrated by the researcher before the operation, supported by the brochure, and lasting 8-10 minutes every 2 hours from the 4th post-operative hour.
214687497|NCT07164118|BEHAVIORAL|Deep Breathing Exercise|Deep breathing exercise, demonstrated one-on-one before surgery and supported by a guide, applied 6 times every 2 hours from the 4th post-operative hour onwards.
214687498|NCT07162285|DEVICE|Delivery Room Bubble CPAP|delivery room bubble CPAP initiated within 10 minutes of birth for preterm neonates \<34 weeks, using water-seal oscillation system via nasal prongs.
214996255|NCT02337127|DRUG|Lamivudine|Lamivudine, 100mg/day, per os
214383260|NCT04707404|PROCEDURE|Cranioplasty|The surgery implanted artificial material to repair the skull defect.
214996256|NCT00010998|PROCEDURE|Yoga|
214996257|NCT02607072|DRUG|Acetylsalicylic acid (ASA)/aspirin 200 mg daily|
214996258|NCT02607072|DRUG|Acetylsalicylic acid (ASA)/aspirin 100 mg daily|
214996259|NCT02607072|DRUG|Placebo|
214996260|NCT00297401|DRUG|ruboxistaurin|32 mg, QD, PO, up to 8 weeks
214996261|NCT00297401|DRUG|placebo|QD, PO, up to 8 weeks
214996262|NCT02512419|BEHAVIORAL|Text-Enhanced Physical Activity Intervention Arm|Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.
215093186|NCT03505320|DRUG|nivolumab|Nivolumab will be administered intravenously according to institutional standards.
214996263|NCT02512419|BEHAVIORAL|Health Education Control Arm|Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
214383261|NCT03295903|DIETARY_SUPPLEMENT|Cannabidiol supplement|Subjects will be administered in a double-blinded, randomized and cross-over design
214383262|NCT00954954|DEVICE|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
214383263|NCT00954954|DEVICE|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
214383264|NCT03980184|DRUG|Guanfacine|Guanfacine 3mg/day Versus Placebo
214383265|NCT03980184|OTHER|Behavioral Counseling|placebo
214498809|NCT06744010|PROCEDURE|Sub sartorial canal block and popliteal block in ankle surgeries|"All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4."
214687499|NCT07162285|OTHER|Delivery Room Supplemental Oxygen|Standard oxygen therapy initiated within 10 minutes of birth via mask/tubing, without positive pressure support.
214996264|NCT02512419|DEVICE|Actigraph GT3X|
214687500|NCT07164066|DEVICE|Digital Occlusal Analysis Device|Computerized occlusal analysis performed using T-Scan and ModJaw devices to record occlusal contacts, timing, and force distribution during prosthesis fitting and function.
214996265|NCT00831844|BIOLOGICAL|cixutumumab|Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
214996266|NCT00831844|OTHER|laboratory biomarker analysis|Correlative studies
214996267|NCT03568617|DEVICE|rTMS|The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.
214996268|NCT05202301|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
214996269|NCT05202301|DRUG|Enzalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
215093187|NCT03505320|DRUG|Docetaxel|Docetaxel will be administered as a 1-hour IV infusion.
215093188|NCT03995706|DRUG|Sacituzumab Govitecan|All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
214383266|NCT01653808|DEVICE|Elisio-210H|comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
214383267|NCT01653808|PROCEDURE|conventional hemodialysis|comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
214383268|NCT01653808|PROCEDURE|on line hemodiafiltration|comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
214383269|NCT02811016|DRUG|Budesonide 200|200 µg inhaled at 7:00 a.m. and 7 p.m.
214383270|NCT02811016|DRUG|Budesonide 800|800 µg inhaled at 7:00 a.m. and 7 p.m.
214383271|NCT02811016|DRUG|Placebo|Placebo Inhalation at 7:00 a.m. and 7 p.m.
214383272|NCT02504437|BIOLOGICAL|BMMSCs|
214383273|NCT03491345|DRUG|Avelumab|avelumab 10mg/kg, IV, q 2 weeks
214383274|NCT02304965|BEHAVIORAL|Daily physical activity|A combination of walking (\> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
214383275|NCT01392716|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
214996270|NCT05202301|DRUG|Apalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
214996271|NCT04208919|BIOLOGICAL|Donor-derived DCreg|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to the start of immunosuppression weaning.
215093189|NCT06004336|DRUG|Pembrolizumab|Given by vein (IV)
215093190|NCT06004336|RADIATION|Radiation therapy|Given by vein (IV)
215093191|NCT03748459|OTHER|Closure with Permanent Suture|Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
214383276|NCT05859802|DRUG|Dalfampridine Pill|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking dalfampridine 10 mg two times day
214383277|NCT05859802|DRUG|Placebo|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking a placebo pill two times day
214383278|NCT04239729|BEHAVIORAL|ACT Website and Coaching|The ACT website includes sixteen sessions and is designed to teach a series of skills from ACT applied to hoarding. The intervention also includes brief supportive coaching (an initial phone call and weekly support over email).
214383279|NCT02372760|DEVICE|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)
214996272|NCT03771716|BEHAVIORAL|African Dance|Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.
214383280|NCT02372760|OTHER|BA classic anesthesia|This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
214383281|NCT02372760|DRUG|Anesthesia|Both groups will receive lidocaine as the anesthesia for bronchoscopy
214383282|NCT00150995|DRUG|Tetrathiomolybdate|
214383283|NCT03136796|DRUG|Meropenem|Patients will receive intravenous antibiotics eighter empirically or based on a culture.
214383284|NCT01740102|PROCEDURE|RIPC|The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
214383285|NCT00102050|DRUG|NM-702 (phosphodiesterase inhibitor)|
214383286|NCT03266471|DIAGNOSTIC_TEST|Baseline blood sample|Blood sample for cytokine measurements and genetics.
214383287|NCT03266471|DIAGNOSTIC_TEST|Baseline intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
214383288|NCT03266471|OTHER|Crohn's disease activity index (CDAI)|To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.
214383289|NCT03266471|DIAGNOSTIC_TEST|Post treatment blood sample|Blood sample for cytokine measurements after patients have been on therapy for at least 6 weeks but no more than 52 weeks.
214383290|NCT03266471|DIAGNOSTIC_TEST|Post treatment intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 6 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
214996273|NCT03771716|BEHAVIORAL|African Cultural Immersion|The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
214687501|NCT07161674|BEHAVIORAL|Digital health literacy program|A 6-week digital health literacy program delivered through weekly face-to-face training sessions and WhatsApp activities. Additional support may be provided if needed.
214687502|NCT07163078|DIETARY_SUPPLEMENT|Common form supplementation|The intervention product would represent part of a typical supplement given to people including those with CF
214687503|NCT07163078|DIETARY_SUPPLEMENT|Uncommon nutrient supplementation|The intervention product would represent part of a possible new supplement given to people including those with CF
214996274|NCT04930991|DRUG|Omeprazole|Treatment will consist of Omeprazole 12-14 days prior to surgical therapy of pancreatectomy.
214996275|NCT05920759|DIAGNOSTIC_TEST|Cerebral blood flow|Transcranial Doppler (TCD) is a non-invasive diagnostic tool used to estimate cerebral blood flow velocity (CBFV), cerebral autoregulation, cerebrovascular reactivity (CVR), intracranial pressure, cerebral perfusion pressure as well as other indicators of cerebral hemodynamics and autoregulation.
214383291|NCT03266471|DIAGNOSTIC_TEST|Baseline stool sample|Stool sample for inflammatory markers or microbiome analysis.
214383292|NCT03266471|DIAGNOSTIC_TEST|Post treatment stool sample|Stool sample for inflammatory markers or microbiome analysis.
214383293|NCT03975426|PROCEDURE|open reduction and internal fixation with fixation by absorbable screws|Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws.
214383294|NCT01616771|DEVICE|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
214383295|NCT01616771|DEVICE|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
214383296|NCT01616771|DEVICE|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
214383297|NCT01784692|DIETARY_SUPPLEMENT|Immulina|
214383298|NCT06626100|BEHAVIORAL|Exercise-themed game|The intervention includes three parts: quiz questions on knowledge on and benefits of exercise; monitored step count using smartphone tracker; whatsapp reminders on the benefits of exercise.
214383299|NCT06626100|BEHAVIORAL|Diet-themed game|The intervention includes two parts: quiz questions on knowledge on and benefits of healthy diet; whatsapp reminders on the benefits of healthy diet.
214383300|NCT06321978|DEVICE|Mepilex Border Flex|Usage of Mepilex Border Flex according to intended use and standard of care.
214383301|NCT03492736|DIETARY_SUPPLEMENT|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
214383302|NCT03492736|OTHER|Placebo|30 days placebo taken nightly 1 hour before bed
214383303|NCT01624649|DRUG|Methylphenidate hydrochloride|Form = tablet, route = oral, administered as a flexible dosage
214383304|NCT01624649|DRUG|Atomoxetine|Form = tablet, route = oral;
214383305|NCT04041440|BEHAVIORAL|clEAR auditory training|Children play auditory brain training computer games
214383306|NCT02784223|DEVICE|Radiation : PET-CT with F18-choline examination|PET-CT with F18-choline examination will be performed before surgery
214383307|NCT02773680|DEVICE|"electrical impedance tomography"|One continous electrical impedance tomography (EIT) measurement per subject of approximately 5 minutes duration (2 min prior to MDCT scanning, during end-inspiratory MDCT acquisition and 2 min after MDCT scanning)
214383308|NCT05852028|DRUG|Selinexor|this is a real-world. Patients who use selinexor-based regimens in lymphoma will be followed up without interfering with the choice of treatment options for patients
214383309|NCT00008463|DRUG|Ribavirin|
214383310|NCT00008463|DRUG|Interferon alfa-2a|
214383311|NCT00008463|DRUG|Peginterferon alfa-2a|
214383312|NCT06265883|PROCEDURE|Len+DEB-TACE+HAIC|Patients received TACE with drug-eluting beads and FOLFOX-HAIC. DEB-TACE and/or HAIC was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
214996276|NCT02176967|PROCEDURE|Biopsy|Undergo biopsy
214996277|NCT02176967|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214996278|NCT02176967|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214996279|NCT02176967|DRUG|Carboplatin|Given IV
214996280|NCT02176967|OTHER|Clinical Observation|Undergo clinical observation
214996281|NCT02176967|PROCEDURE|Computed Tomography|Undergo CT
214996282|NCT02176967|DRUG|Cyclophosphamide|Given IV
214996283|NCT02176967|DRUG|Doxorubicin Hydrochloride|Given IV
214383313|NCT06265883|PROCEDURE|Len+DEB-TACE|Patients received TACE with drug-eluting beads. DEB-TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
214996284|NCT02176967|DRUG|Etoposide|Given IV
214996285|NCT02176967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214996286|NCT02176967|PROCEDURE|Ultrasound|Undergo ultrasound
214383314|NCT00003048|DRUG|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
214383315|NCT01731587|OTHER|Biological: MUC1 peptide specific immunotherapy|Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
214996287|NCT05879718|DRUG|Placebo|Placebo (intravenous infusion)
214996288|NCT05879718|DRUG|PF-06823859|PF-06823859 (intravenous infusion)
214996289|NCT05679895|BIOLOGICAL|CD1a-CAR T|Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach
214996290|NCT04002362|DRUG|Triamcinolone Acetonide|An intramuscular injection of triamcinolone acetonide (1 mg/kg, up to 40 mg maximum) is administered deep in the gluteal muscle by a trained registered nurse.
214996291|NCT04057365|DRUG|Nivolumab|Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
214383316|NCT01731587|DRUG|Cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
214383317|NCT01381874|DRUG|Exemestane|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
214996292|NCT04057365|DRUG|DKN-01|DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
214996293|NCT03976375|BIOLOGICAL|Pembrolizumab|IV infusion of pembrolizumab at 200 mg
214996294|NCT03976375|DRUG|Lenvatinib|Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.
214996295|NCT03976375|DRUG|Docetaxel|IV infusion of docetaxel at 75 mg/m\^2.
214996296|NCT04635423|BIOLOGICAL|V503|9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.
214996297|NCT04635423|OTHER|Placebo|0.9% sodium chloride (NaCL)
214996298|NCT05785078|BEHAVIORAL|Educational session about vaccinations|An educational session about maternal and childhood vaccinations was held in the context of the Childbirth Preparation Course held monthly at the FPG. In this occasion, on-site flu vaccination was offered to pregnant women attending the course and their partners, if present.
214996299|NCT06567678|DRUG|Colchicine 0.5 MG oral tablet twice daily|Blood samples will be collected from participants in 2 separate instances. Initially, a baseline VerifyNow P2Y12 PRU and Aspirin reaction unit test assay, followed by a subsequent repeat test 2-week after a 2-week, colchicine 0.5mg oral tablet twice-daily
214996300|NCT05822544|DRUG|TLC-6740 Oral Solution|Oral solution of TLC-6740
214996301|NCT05822544|OTHER|Placebo Oral Solution|Placebo-to-match oral solution TLC-6740
214996302|NCT05822544|DRUG|TLC-6740 Tablet|Tablet formulation of TLC-6740
214383318|NCT01381874|DRUG|Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
214383319|NCT01381874|DRUG|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
214383320|NCT03191357|OTHER|n/a observational|Observational study
214996303|NCT05822544|DRUG|Drug Metabolizing Enzyme|Oral dose of omeprazole, voriconazole, itraconazole, or rifampicin
214996304|NCT05822544|DRUG|Tirzepatide|Subcutaneous injection of tirzepatide
214996305|NCT05822544|OTHER|Placebo Tablet|Placebo-to-match tablet formulation of TLC-6740
214383321|NCT04071119|DRUG|Oxytocin nasal spray|Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days
214383322|NCT04071119|DRUG|Placebo|Participants administer the placebo (40 IU) twice a day for 5 - 7 days
214383323|NCT04142060|DRUG|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
214383324|NCT02247804|DRUG|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
214383325|NCT02247804|DRUG|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
214383326|NCT02247804|OTHER|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
214383327|NCT02247804|DRUG|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
214383328|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
214383329|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
214383330|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
214498810|NCT06744010|PROCEDURE|femoral block and popliteal block in ankle surgeries|"* All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4."
214996306|NCT05311527|DEVICE|Urolift|Urolift Implant
214498811|NCT06727448|OTHER|SRQ questionnaire|SRQ questionnaire administered at inclusion visit and 14 days after inclusion
214996307|NCT05311527|RADIATION|SABR|Stereotactic Body Radiation Therapy for prostate cancer
214383331|NCT00517075|DEVICE|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
214996308|NCT03628209|DRUG|Nivolumab|Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
214996309|NCT03628209|DRUG|Azacitidine|Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m\^2. Dose level 3: 75 mg/m\^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
214996310|NCT03628209|PROCEDURE|Post Treatment Surgery|Resection surgery at end of Cycle 1 treatment, day 28-35.
214996311|NCT06138821|DEVICE|ESG + lifestyle modification|Endoscopic sleeve gastroplasty - an endoscopic weight loss procedure where an endoscopic suturing device is utilized to reduce the size of the stomach by 70%.
214996312|NCT06138821|BEHAVIORAL|Lifestyle modification|Lifestyle modification program consisting of diet and exercise therapy
214996313|NCT02095366|DRUG|Morphine|"Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
215093192|NCT03748459|OTHER|Closure with Resorbable Suture|Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
215093193|NCT06261359|DRUG|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
215093194|NCT06261359|DRUG|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
215093195|NCT06261359|DRUG|Nab paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
215093196|NCT04256512|DEVICE|Medical Device Usage and Evaluation|Wear Elasto Gel Therapy Mittens and Foot Wraps
214996314|NCT02095366|DRUG|Sufentanil|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
214996315|NCT02095366|DRUG|Placebo|"Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
214996316|NCT02095366|DRUG|Placebo|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
214996317|NCT06070649|DRUG|0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion|Infusion
214996318|NCT06070649|DRUG|0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion|Infusion
214996319|NCT06070649|DRUG|25 mg Diphenhydramine (5 min) + Normal Saline|Infusion
214996320|NCT06974175|OTHER|Deprox_HP|Use of nutraceutic based on a compound of pollen extracts from pollen, mais and timothy
214996321|NCT06974175|OTHER|Peacist|Use of a nutraceutic based on palmitoilethanolamide + Bromelin + Horse Chestunt extract
214383332|NCT00664820|DIETARY_SUPPLEMENT|Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14|2 capsules daily for 3 months.
214383333|NCT05512728|DEVICE|VR|"The IVR environment was provided by Shinecon VR (Shinecon, china). Shinecon VR features, have a large field of view and high-quality display; with aspheric lens , lens diameter 40MM, view angle 108 , sharpness 99%, visibility 100%, color .38MM and pupillary distance adjustment 65 MM.~The shinecon VR setup was powered by a HUAWEI Y7 prime phone running the freely available IVR software.~Shinecon VR provides videos for nature, forest, wind, desert and animals. That included noise-cancelling headphones playing background sound from the IVR simulation."
214383334|NCT05512728|DRUG|Midazolam|• (titration of 0.05 mg/kg per dose) according to Modified Wilson sedation scale Score to achieve grade 1 (Oriented, eyes may be closed but can respond to 'Can you tell me your name?' 'Can you tell me where you are right now?'
214383335|NCT02979626|PROCEDURE|Respiratory nasal swab|Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
214383336|NCT00509158|BIOLOGICAL|arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant|
214383337|NCT00509158|BIOLOGICAL|arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant|
214383338|NCT03456167|OTHER|RecoverWell mobile app for follow-up care|The mobile app follow-up care is an application that can be loaded onto a smartphone. It allows the patient to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 6 weeks following surgery.
214383339|NCT02917265|DEVICE|TENS for vagus stimulation|TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.
214498812|NCT06745869|BEHAVIORAL|Diaphragmatic breathing exercise training|"At the end of the training, participants will be asked to do an exercise session and this session will be observed. Training will continue until participants learn and apply the exercise correctly.~5-minute warm-up and cool-down periods will be applied at the beginning and end of each exercise session. Exercises will be done twice a day, morning and evening, for 8 weeks.~In order to follow the exercise, participants will be given diaphragmatic breathing exercise tracking cards with date and session information. In addition, participants will be followed up weekly on one of the rehearsal days to ensure their adaptation to the exercise."
214498813|NCT06745869|BEHAVIORAL|Aerobic exercise training|The intensity of the aerobic exercise program will be calculated for each participant using the Karvonen formula. Accordingly, each participant will be given a brisk walking program on a suitable surface, which will be created specifically for the individual to reach the target heart rate range within the scope of the aerobic exercise program; they will apply a 45-minute session, 3 days a week, for 8 weeks.
214383340|NCT02917265|DEVICE|TENS for sham stimulation|TENS electrodes are applied on an area of the external ear devoid of vagus innervation.
214498814|NCT04257994|DIAGNOSTIC_TEST|obtaining a buccal smear sample|A sample will be taken from the inside of the participants' cheeks using a soft brush
214498815|NCT04273022|OTHER|Exercise|A single bout of standardized, moderate exercise
214498816|NCT06941766|DRUG|QL1706|5 mg/kg, IV infusion, Q3W (D1)
214498817|NCT06941766|DRUG|Chemotherapy|FAEV, EMA/EP, EMA/CO, or TP/TE.
214498818|NCT05754593|BIOLOGICAL|Anti-Mullerian hormone (AMH) level|Measure of Anti-Mullerian hormone (AMH) level by blood sample
214996322|NCT06965998|DRUG|Full dose rivaroxaban|The intervention group will receive full dose rivaroxaban for 90 days.
214996323|NCT06965998|DRUG|Low dose rivaroxaban|The comparator group will receive the standard treatment of low dose rivaroxaban.
214996324|NCT06965998|DRUG|Placebo|Since the treatment arm has an AM and PM dose of study drug from Day 1-21, the comparator group will take 1 placebo pill in the PM to keep the two arms blinded.
214996325|NCT06966375|OTHER|WYSH Web Application|Worldwide Yearly Screening for Hypospadias (WYSH) Web Application
214996326|NCT06347315|DIETARY_SUPPLEMENT|BrainXpert|sachet/stickpack of 25 g, has no preservatives, no flavors, no sweeteners, and no colorants.
214498819|NCT05754593|OTHER|Antral follicle count (AFC)|Measure of Antral follicle count (AFC) by ultrasound imaging
214498820|NCT05754593|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
214498821|NCT06942507|DRUG|Zanubrutinib|zanubrutinib 160mg po bid d1-28
214498822|NCT06942507|DRUG|Bendamustine + Rituximab|bendamustine 70-90mg/m2 ivgtt d1-2, rituximab 375mg/m2 ivgtt d1
214498823|NCT05653440|BEHAVIORAL|Accuracy-maximized condition|Naming treatment condition in which the target will be immediately provided for repetition at picture onset.
215093197|NCT04256512|OTHER|Questionnaire Administration|Ancillary studies
215093198|NCT02396394|BEHAVIORAL|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is \<95%.
215093199|NCT01799434|OTHER|treadmill run|
215093200|NCT02333890|DRUG|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
215093201|NCT02333890|DRUG|Placebo|
214383341|NCT03771157|DRUG|Shingrix vaccine|On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
214383342|NCT01419860|PROCEDURE|Elective colon resection|In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
214383343|NCT00128622|BIOLOGICAL|denileukin diftitox|
214383344|NCT00128622|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
214383345|NCT00128622|BIOLOGICAL|therapeutic autologous dendritic cells|
214383346|NCT01737996|DRUG|BI 207127 + faldaprevir|fixed dose combination
214383347|NCT02467322|DRUG|Albumin|MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
214383348|NCT02467322|DRUG|ascitic fluid|
214383349|NCT04752891|OTHER|AOM diagnosis with app|the diagnosis made by a senior physician using a traditional otoscope. the diagnosis made by the junior physician using an otoendoscope fixed on a connected smartphone
214383350|NCT04752891|OTHER|AOM diagnosis without app|the diagnosis made by a senior physician and by the junior physician, using a traditional otoscope
214383351|NCT04346550|OTHER|Suction drain|Post operatively, in both arms including drain group and no drain group, parameters of pain was assessed by visual analog scale (VAS) from 0 (no pain) to 10 (worst pain), assessed at 1st postoperative day by the duty doctor or the nurse. VAS \> 3 was considered as post surgical pain. The total number of hospital stay was noted from the day of operation till the day of discharge and discharge criteria was taken as a patient having pain as per VAS\<3, no fever and tolerating oral intake
214383352|NCT05268484|DEVICE|Perturbation-based Training with visual cues using Neurocom|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
214498824|NCT05653440|BEHAVIORAL|Effort-maximized condition|Naming treatment condition in which participants will have up to 10 seconds to respond before the target is provided for repetition.
215093202|NCT06030284|DEVICE|BurstDR-SCS|Spinal Cord Stimulation with a BurstDR-SCS system.
214383353|NCT00452413|DRUG|enzastaurin|Administered orally
214383354|NCT00452413|DRUG|erlotinib|Administered orally
214383355|NCT03438240|DRUG|Bupivacaine|patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%
214383356|NCT03438240|DRUG|Fentanyl|Plus 50 µg fentanyl
214383357|NCT03438240|DRUG|Dexmedetomidine|Plus 50 µg dexmedetomidine
214383358|NCT02419729|DEVICE|CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
214383359|NCT02419729|DRUG|Estrogen|Topical estrogen cream treatment: Estriol 1mg daily.
214383360|NCT02419729|DRUG|Placebo of Estrogen|Placebo of topical estrogen cream.
214383361|NCT02419729|DEVICE|Placebo of CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
214383362|NCT05083260|DRUG|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
214383363|NCT05083260|DRUG|placebo|Hard gelatin capsule containing only common excipients for oral formulations
214383364|NCT00985543|DRUG|lopinavir/ritonavir|Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
215093203|NCT06030284|DEVICE|BurstDR-SCS|BurstDR-SCS system turned off.
215093204|NCT04058548|DIAGNOSTIC_TEST|Sit to stand test|Participants will complete a sit to stand test in addition to a 6 minute walk test
215093205|NCT03737331|BEHAVIORAL|Fractal visual cueing|Walking to an external visual fractal (i.e., pink noise) stimulus.
215093206|NCT03737331|BEHAVIORAL|Periodic visual cueing|Walking to an external visual periodic (i.e., invariant) stimulus.
215093207|NCT03737331|BEHAVIORAL|Random visual cueing|Walking to an external visual random (i.e., white noise) stimulus.
215093208|NCT03239015|DRUG|Gefitinib|Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
215093209|NCT03239015|DRUG|Erlotinib|Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
214996327|NCT06347315|OTHER|Placebo|high-oleic acid sunflower oil as a calorie-equivalent, non-ketogenic vegetable oil, non added vitamin product will also be provided in a powder format in a sachet/stickpack of 25 g.
214996328|NCT06973785|DRUG|dispense of study drug|• Cohort Group 1 (Experimental): ketorolac 10mg with rescue medication oxycodone 5mg All patients will be given acetaminophen
214996329|NCT06973785|DRUG|Ketorolac|Patients will be randomized to either Ketorolac or Oxycodone
214383365|NCT03119610|DRUG|Oxytocin nasal spray|Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
214383366|NCT03119610|DRUG|Placebo nasal spray|Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
214383367|NCT02854358|DRUG|mixed powder of A. digitata and M. sylvestris|
214383368|NCT02854358|DRUG|Hypozalix spray (artificial saliva)|Hypozalix spray (artificial saliva)
214383369|NCT05808530|BEHAVIORAL|Cognitive Stimulation Therapy|"CST involves the use of standard tasks that focus on cognitive functions, designed to meet varying levels of difficulty in accordance with the individual's ability and rehabilitation. A detailed guide for CST is available for a range of health and care professionals, including care workers, occupational therapists, psychologists, and nurses (https://www.ucl.ac.uk/international-cognitive-stimulation-therapy/) publications/cst-manuals). The CST application consists of 14 sessions of 45-50 minutes, 2 days a week.~Intervention Group Week 1=Getting acquainted and applying pre-tests Week 2=Physical games and Sounds Week 3=Childhood and Food Week 4=Current events and Faces / Scenes Week 5=Word association and Creativity Week 6=Categorizing Objects and Orientation Week 7= Money usage and Games Week 8=Word Games and Team Competition Week 9=Closing and post-test application"
214383370|NCT00114634|DIETARY_SUPPLEMENT|Egg yolk preparation with cholesterol|Egg yolk preparation with cholesterol
214498825|NCT05653440|BEHAVIORAL|Effort-accuracy balanced condition|Naming treatment condition in which naming deadlines will be determined based on the balanced effort-to-accuracy benefit ratio formalized above, calculated on clinician-provided accuracy and response time ratings. Deadlines will be recalculated session-by-session to adjust to participant-specific treatment gains over time.
214498826|NCT06944795|DEVICE|SWIR device|A Short Wave Infrared (SWIR) Otoscope will record images for both the SWIR and white light video otoscopes. These images of the middle ear will be recorded in AVI format.
214687504|NCT07164014|OTHER|Mediterranean diet|Mediterranean Diet Total Calories: \~1,980 kcal Protein: \~110 g Carbohydrates: \~132 g Fat: \~117 g Diet Type: Mediterranean: Moderate-calorie, high in unsaturated fats, includes fermented dairy Omega-3 Sources: Present: Fish, Olive Oil, Nuts Oil/Fat Types: Olive oil, tahini, nuts (mostly monounsaturated \& polyunsaturated)
214687505|NCT07164014|OTHER|Hospital diet|Hospital diet Total Calories: \~3,100 kcal Protein: \~160 g Carbohydrates: \~280 g Fat: \~150 g Diet Type: High Protein, High Calorie: High in saturated fats, refined carbs, and animal proteins Omega-3 Sources: Minimal: Mostly absent Oil/Fat Types: Animal fats (saturated), dairy fat, minimal unsaturated fat
214996330|NCT05325281|DRUG|CPI-613® (Dose level -1.0 250 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
214996331|NCT05325281|DRUG|CPI-613® (Dose level 1.0 500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
214996332|NCT05325281|DRUG|CPI-613® (Dose level 2.0 1,000 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
214996333|NCT05325281|DRUG|CPI-613® (Dose level 3.0 1,500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
214996334|NCT05325281|DRUG|CPI-613® Maximum Tolerated Dose (MTD)|MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m\^2 and up to 1,500 mg/m\^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
215093210|NCT03239015|DRUG|Afatinib|Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
214383371|NCT00114634|DIETARY_SUPPLEMENT|Egg substitute, without cholesterol|Placebo control. Egg substitute, without cholesterol
214383372|NCT02476955|DRUG|ARQ 092 + carboplatin + paclitaxel (Closed)|Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.
214687506|NCT07162415|PROCEDURE|Open resection|A transverse or longitudinal incision is done depending on surgeon's preference. The ganglion and its pedicle are traced up to its origin. The pedicle is resected tangentially, usually, from the SL ligament for dorsal ganglions and depending on the site for volar ganglion. Wrist capsule is not closed.
214996335|NCT05325281|DRUG|Gemcitabine|Subjects will be administered 400 mg/m\^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
214996336|NCT05325281|RADIATION|Intensity-modulated Radiation Therapy|1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
214996337|NCT03133156|OTHER|Exercise Intervention|10-Week Aerobic Exercise Training
215093211|NCT03239015|DRUG|Trastuzumab|Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
215093212|NCT03239015|DRUG|Oxazolidine|Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
215093213|NCT03239015|DRUG|Olaparib|Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
215093214|NCT03239015|DRUG|Everolimus|Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
215093215|NCT03239015|DRUG|Cabozantinib|Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
215093216|NCT03239015|DRUG|Vemurafenib|Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
215093217|NCT03239015|DRUG|Dabrafenib|Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
215093218|NCT03239015|DRUG|Palbociclib|Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
214383373|NCT02476955|DRUG|ARQ 092 + paclitaxel (Closed)|ARQ 092 will be administered orally at 200 mg twice a day (BID) weekly (Cohort 1P) of a 28-day cycle in combination with an intravenous (IV) infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle.
214383374|NCT02476955|DRUG|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 mg QD, 5 days on/9 days of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously.
214383375|NCT03283696|DRUG|Olaratumab|Administered IV
214383376|NCT03283696|DRUG|Doxorubicin|Administered IV
214383377|NCT03283696|DRUG|Ifosfamide|Administered IV
214498827|NCT06180486|OTHER|Mindfulness Meditation Intervention|The mindfulness intervention is a scripted, \~12min audio recording based on core tenets of mindfulness meditation and contextualized for patients undergoing total knee arthroplasty. It teaches sustained attention on the present, body awareness, acceptance of the body's current state, and transformational strategies to cope with emotional or physical stimuli as they arise. It has been created by the study team based on the teachings of Jon Kabat Zinn (founder of mindfulness meditation) and the PI's history teaching yoga and meditation. Patients will be encouraged to review the audio recording once a week.
214498828|NCT06944548|BIOLOGICAL|Lipidomic analyses|"3 blood samples taken from 2 x 6 mL EDTA tubes for patients~* At baseline~* Week 5 of the adapted physical activity protocol~* Follow-up visit for adapted physical activity~  1 blood sample taken from 2 x 6 mL EDTA tubes for volunteers~* At baseline"
214498829|NCT06944548|OTHER|Adapted physical activity program|8-week adapted physical activity program. This program will be adapted to each group
214498830|NCT06945341|BEHAVIORAL|Focus-Group discussion|Focus-Group discussion on factors that could lead to an increase in the adoption of neuromuscular monitoring taking into account different country-specific contexts.
214498831|NCT06761625|DIETARY_SUPPLEMENT|SanProbi® Barrier capsules|The probiotic group received SanProbi® Barrier capsules
214498832|NCT06761625|OTHER|Placebo|The placebo group received capsules filled mainly with maize starch and maltodextrins.
214498833|NCT06043609|OTHER|This is an observational cohort study|This is an observational cohort study
214498834|NCT05292937|DIAGNOSTIC_TEST|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
214498835|NCT06768866|BEHAVIORAL|Gruop 1|To determine factors influencing Postsurgical acute pain
214498836|NCT06484517|DEVICE|Hugemed Videolaryngoscope|After general anesthesia induction, the first group of patients (Group M, n=20) was intubated with the McGrath videolaryngoscope. For the second group (Group H, n=20), the Hugemed videolaryngoscope was used. Patients were intubated using one of the appropriate blades numbered 1, 2, or 3 based on their height, weight, and age.
214498837|NCT06951334|DRUG|Vildagliptin 50 mg bid|Vildagliptin 50 mg bid for 12months
214687507|NCT07162415|PROCEDURE|Arthroscopic resection|Portals are selected by surgeon's preference. The pedicle of the ganglion is located and resected with a shaver. It is not necessary to remove all the ganglion walls. The portal incisions do not need to be sutured.
214996338|NCT05011656|DEVICE|Seraph-100 + State of the Art Care|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.
215093219|NCT03239015|DRUG|PD-1/L1 inhibitor plus anti-angiogenic agent|PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
215093220|NCT05318196|BIOLOGICAL|Biological samples collection|"SOT patients: samples will be collected at the time of the protocol follow-up visit (registration on the transplant list, on the day of the transplantation, and then at day 15, month 1-3-6-9-12 and then annually, as well as if complications or therapeutic modifications).~Dialysis patients: at the start of the dialysis and then at M3, M12, and if complications or modification of the dialysis protocol.~Non-dialysis or cancer patients: the sampling frequency will be individualized according to the pathology studied (acute or chronic) and the purpose of the sampling (diagnostic, mechanistic, prediction, evaluation of the therapeutic response). Samples for diagnostic and mechanistic purposes will be taken only once. Samples for prognostic purposes will be taken at regular intervals, adapted to the natural history of the disease while respecting the maximum volume of blood samples defined by the French law. Samples will be collected during a sampling performed as part of routine care."
215093221|NCT04773236|DRUG|sodium bicarbonate 8.4%|mixing the sodium bicarbonate with 2%lidocaine and 1:80.000 epinphrine using mixing pen (onset buffering system)
215093222|NCT04773236|DRUG|2%lidocaine with 1:80.000 epinphrine|injection
214383378|NCT03283696|DRUG|Mesna|Administered per standard of care
214383379|NCT03869515|OTHER|No intervention|It's an observational study, so no intervention will be carried out.
214383380|NCT00611117|OTHER|Physical Activity Level|High vs. low physical activity during a high fat diet consumption.
214383381|NCT02326350|DRUG|Aspirin 75mg|Active treatment
214383382|NCT02326350|DRUG|Lactose powder|Placebo
214383383|NCT05790226|DEVICE|Sentry System|any labelling or contrast agents. The Sentry System uses the Sentry Probe, a flexible cable that terminates in a stylus that delivers a small beam of light to the surface of the excised tissue specimen and collects the Raman spectrum of the light coming back from the same area of the specimen.
214383384|NCT04924764|OTHER|Conventional physical therapy.|Conventionally used intervention for subacute and chronic neck pain.
214383385|NCT04538924|OTHER|extended clinical, laboratory and instrumental examination; treatment options comparison|Multimodality investigation and different treatment comparison
214383386|NCT03290573|DEVICE|short peripheral venous catheter|short peripheral venous catheter for infusion therapy in adult patients
214383387|NCT05677737|OTHER|Education|"Educational program; It will be applied to the individuals in the experimental group for an average of 40 minutes in a time period they are suitable through the online platform prepared for the individuals in the experimental group in a three-month period. The literature will be scanned and appropriate educational materials will be created, and videos will be used to support education.~Educational program During the first interview, the individuals in the experimental group will be introduced to the online platform, their entrance will be provided, they will be informed about how to follow the trainings, and sample applications will be made.~Six main topics will be covered in the training program and will be completed every two weeks in three months."
214383388|NCT02583568|DRUG|Bevacizumab-800CW|three days prior to surgery bevacizumab-800CW will be administered
214383389|NCT00407784|DRUG|eplerenone|
214383390|NCT04780724|OTHER|Hypoxic gas mixture|Gas mixture of 12% O2 and 88% N2 for five minutes.
214383391|NCT04780724|OTHER|Hypercapnic and hypoxic gas mixture|Gas mixture of 12% O2, 5% CO2, and 88% N2 for five minutes.
214498838|NCT06951230|DRUG|Fentanyl injection|Fentanyl 1mcg/kg will be given before skin incision and Mayfield placement and followed up by fentanyl 1mcg/kg/hr, along the operation.
214498839|NCT06951230|PROCEDURE|scalp block|The scalp block procedure is performed with the patient in the supine position, utilizing surface landmarks for guidance. The local anesthetic is injected into the nerves after careful aspiration and under strict aseptic technique. The nerves that are typically injected include the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, as well as the lesser and greater occipital nerves, with or without the inclusion of the third occipital nerve. The volume of 0.5% bupivacaine injected should not exceed 2 ml at each site.
214498840|NCT06951074|BIOLOGICAL|Insulin producing stem cells infusion|"1. Liposuction of the anterior abdominal subcutaneous fat layer of participant~2. Characterization and Identification of mesenchymal stem cells~3. Differentiation of mesenchymal stem cells into insulin producing stem cells~4. In vitro detection of Insulin and c-peptide in differentiated MSC (Confirmatory tests for the insulin producing cells)~5. In vitro Insulin and c-peptide release detection in differentiated MSC in response to increasing glucose concentrations Differentiated MSCs injection in human subjects~6. Followup"
214498841|NCT06950463|OTHER|Group A (control group): It will be consisted of twenty two post menopausal women who will receive daily dosage of vitamin D3 supplement (600 IU/day) (Schleicher et al., 2016), for 6 week|1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl for scratch resistance and to provide them with a firm grip, even if their hands are sweaty. This dumbbell set consists of two dumbbells weighing 2 kg each, with dimensions of 21.7 x 15.7 x 8.5 cm; 4 kg.
214996339|NCT05011656|DEVICE|State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
214996340|NCT06391242|RADIATION|Standard Conventional Radiotherapy|20Gy in 5 fractions
214996341|NCT06391242|RADIATION|Stereotactic Body Radiotherapy|30 or 35Gy in 5 fractions
214996342|NCT05633654|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
214996343|NCT05633654|DRUG|Pembrolizumab|Administered intravenously
214996344|NCT05633654|DRUG|Capecitabine|Tablets administered orally
214996345|NCT06543576|BIOLOGICAL|Bevacizumab|Given IV
214996346|NCT06543576|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214996347|NCT06543576|RADIATION|Brachytherapy|Undergo brachytherapy
214996348|NCT06543576|DRUG|Cisplatin|Given IV
214996349|NCT06543576|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214996350|NCT06543576|DRUG|Paclitaxel|Given IV
214996351|NCT06543576|BIOLOGICAL|Pembrolizumab|Given IV
215093223|NCT04773236|DEVICE|Mixing pen (onset buffering system)|Premixing of the two solutions sodium bicarbonate and lidocaine with epinphrine before the local anesthesia adminstration to the patient
214383392|NCT04780724|OTHER|SpO2 measurement|Two SpO2 measuring devices are active simultaneously during measurement.
214383393|NCT02765490|DRUG|AL-335|AL-335 800 mg (2\*400) tablet will be administered once daily.
214383394|NCT02765490|DRUG|Odalasvir|Odalasvir 25 mg tablet will be administered once daily.
214383395|NCT02765490|DRUG|Simeprevir|Simeprevir 75 mg capsule will be administered once daily.
214383396|NCT01350505|BEHAVIORAL|White light exposure|\~200 lux of broad spectrum white light
214383397|NCT01350505|BEHAVIORAL|Dim white light exposure|\~28 lux of broad spectrum white light
214383398|NCT01350505|BEHAVIORAL|Very dim white light exposure|\<0.5 lux of broad spectrum white light
214383399|NCT01350505|BEHAVIORAL|Dim orange light exposure|\~28 lux of orange light
214383400|NCT01425164|DRUG|Ivabradine|ivabradine tablets, 5 to 7.5 mg bis-in-die.
214383401|NCT01425164|DRUG|Carvedilol|carvedilol tablets, 12.5 to 25 mg bis-in-die.
214383402|NCT04079283|DIAGNOSTIC_TEST|Clinical|Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)
214383403|NCT04079283|DIAGNOSTIC_TEST|Semantic|Semantic: A diagnostic model incorporating semantic radiological features (shape, location, border, density etc.)
214383404|NCT04079283|DIAGNOSTIC_TEST|Radiomic|Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)
214383405|NCT03147066|DRUG|Dezocine|Dezocine (0.1 mg/kg）will be infused during surgery
214383406|NCT03147066|DRUG|Flurbiprofen Axetil|Flurbiprofen Axetil (1 mg/kg）will be infused during surgery
214996352|NCT06543576|OTHER|Questionnaire Administration|Ancillary study
214996353|NCT05144503|DEVICE|SpherePVI™ Catheter|SpherePVI™ Catheter with the Affera Mapping and Ablation System
214996354|NCT05315700|DRUG|ORIC-114|ORIC-114 oral daily
214996355|NCT05315700|DRUG|Chemotherapy drug|21 days for up to 4 cycles
214996356|NCT06138743|DRUG|ARO-DM1 for Injection|single or multiple doses of ARO-DM1 by intravenous (IV) infusion
214996357|NCT06138743|DRUG|Placebo|calculated volume to match active treatment by IV infusion
214383407|NCT05096676|DRUG|Oxytocin: Including placebo|Individual received age-dependent dosing of oxytocin and placebo. Participants aged 13-18 years received a dose of 24 IU (3 puffs to each nostril), and younger participants (aged 12 years) received 16 IU.
214383408|NCT00007475|PROCEDURE|Plasma exchange|A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.
214383409|NCT00007475|DRUG|Cyclophosphamide|For GFR \> 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR \< 50 ml/min/1.73 m2 but \> 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
214498842|NCT06950463|DEVICE|1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl fo|1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl for scratch resistance and to provide them with a firm grip, even if their hands are sweaty. This dumbbell set consists of two dumbbells weighing 2 kg each, with dimensions of 21.7 x 15.7 x 8.5 cm; 4 kg.
214498843|NCT06951022|OTHER|Sujok therapy|Participants in the intervention group will receive seed therapy using apple seeds applied to specific hand points corresponding to the bladder area.
214498844|NCT06951204|PROCEDURE|Adductor Canal Block (ACB) Only|All patients will receive adductor canal block under complete aseptic conditions using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ). while patient is laying supine lower limbs will slightly abducted at the hips and flexed at the knees , using linear ultrasound probe(2.5-7.5MHZ) on the anterior aspect of the patient's thigh, At the level of mid-thigh, by moving probe medially until the boat shaped Sartorius muscle is visualized , at which the adductor canal is identified beneath the sartorius muscle, 20ml bupivacaine (0.25%) will be injected in the canal after a careful negative aspiration. The spread of the drug lateral and around the femoral artery will be seen real time on ultrasound
214498845|NCT06951204|PROCEDURE|Adductor canal block (ACB) combined with Genicular nerve block (GNB)|All patients will receive adductor canal block as described above under complete aseptic conditions then they will receive the genicular nerve block using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ), genicular nerve block will be done at three locations, i.e., superomedial, superolateral, and inferomedial locations of the condyle-shaft junction, while patient is lying supine linear ultrasound probe(2.5-7.5MHZ) will be used to target the superomedial, superolateral, and inferomedial genicular nerves,2ml bupivacaine (0.25%) will be injected in the 3 mentioned points after a careful negative aspiration
214498846|NCT06952101|PROCEDURE|Sparing Approach|Accurate staging with Pelvic MRI, CT scan, PET total body have to be performed before local excision in order to exclude false positive mesorectal lymph nodes. Subsequent Wait and See (W\&S) approach could be proposed.
214687508|NCT07162415|OTHER|Conservative treatment|Participant will be informed about the natural course of wrist ganglions. The conservative treatment may include needle aspiration of the ganglion, but it is not performed routinely. Participants are informed that wrist loading in extension may exacerbate the pain, and that the pain is not a sign of further injury to wrist joint. They can avoid heavy use it if they have too much pain, but they are advised to use hand as tolerated. Participants may use NSAIDs and acetaminophen for pain management as needed; however, the protocol does not specify a required course or dosage. A simple self-implemented exercise therapy instructions are given to every participant.
214687509|NCT07162519|DRUG|romiplostim N01|Eligible subjects who pass the screening will undergo a baseline visit and will receive romiplostim N01 administration once weekly for a maximum of 4 weeks. Dosing will be discontinued when the platelet count rises to ≥100×10⁹/L. When a subject resumes anti-tumor therapy, those with a baseline platelet count of \<50×10⁹/L will receive prophylactic administration of romiplostim N01 (administered 2 hours prior to anti-tumor therapy) before the anti-tumor drugs are given.
214687510|NCT05521074|DEVICE|Active tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.
214687511|NCT05521074|DEVICE|Sham tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid. tDCS will not be active in this condition.
214996358|NCT05748626|DEVICE|Anti-snoring device|For group 1, the study team will aid the subject in molding and preparing the device in the pre-operative area. They will wear the device throughout the entirety of the case.
214996359|NCT05748626|PROCEDURE|No anti -snoring device during their procedure.|For group 2 there will be no anti snoring device used during the case.
214996360|NCT05307250|BEHAVIORAL|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE|"In addition to the BSOC, ALHIV and their caregivers will participate in a family strengthening intervention plus a family economic empowerment intervention.~MFG is an evidence-based family-centered, group-delivered, evidence-informed, strength-based 10-session (weekly) intervention for children whose families struggle with poverty. Six additional sessions covering HIV stigma stigma-related issues will be added.~ALHIV will receive a YDA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate."
215093224|NCT05770037|DRUG|Alectinib|"Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric patients with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
214383410|NCT00247364|DRUG|Levetiracetam (Keppra)|
214383411|NCT00260819|DRUG|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
214383412|NCT00260819|DRUG|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
214383413|NCT03311022|DRUG|Nefopam Hydrochloride 30mg Tablets|
214383414|NCT03311022|DRUG|Acupan® 30mg Tablets|
214383415|NCT01512745|DRUG|apatinib|apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
214996361|NCT05307250|BEHAVIORAL|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR).|In addition to BSOC and MFG-HIVSR+FEE, ALHIV in this arm will receive the school-level HIV stigma reduction intervention targeting teachers, school nurses, matrons, and administrators (headteachers, director of studies) in their schools. GED-HIVSR seeks to impart educators in the intervention schools with HIV related knowledge, provide a safe space for educators to explore their personal values and bias that may promote or hinder their role of supportive individuals and systems for ALHIV, and empower them with knowledge and skills to act as change agents within their schools.
214996362|NCT05307250|OTHER|Bolstered Standard of Care (BSOC)|All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
214383416|NCT01512745|DRUG|placebo|placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
214383417|NCT04860414|BIOLOGICAL|Blood sampling|Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
214383418|NCT04860414|OTHER|Cognitive Assessment|QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
214383419|NCT04860414|OTHER|Subjective taste tests|Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
214383420|NCT04860414|OTHER|Objective taste tests|Recording of gustatory evoked potentials
214383421|NCT02665702|DRUG|NVB|25mg/m2 ，D1，8
214383422|NCT02665702|DRUG|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
214383423|NCT02665702|DRUG|Endostar|15mg/d，d1-d7 civ
214996363|NCT06620510|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
214996364|NCT06620510|BIOLOGICAL|No Interventions|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
214996365|NCT06473207|OTHER|Remote ischemic post conditioning sessions|Three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows: four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min (40 min total duration of the intervention), using an inflatable thigh tourniquet
214996366|NCT06473207|OTHER|Sham sessions|Three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows : application of a thigh tourniquet during 40 min without any inflation
215093225|NCT06203223|OTHER|Ova-max|use Ova-max 3 months prior to treatment initiation
215093226|NCT06203223|OTHER|placebo|use placebo 3 months prior to treatment initiation
215093227|NCT03632603|RADIATION|No intervention|No intervention during study period.
215093228|NCT05663957|DRUG|Evusheld|EVUSHELD users
214383424|NCT04406350|PROCEDURE|Intraoperative tight control of respiratory end-tidal gases|Control of ET CO2 and ET O2 during conduct of anesthesia.
214383425|NCT02548858|PROCEDURE|Perineorrhaphy|Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
214383426|NCT02548858|PROCEDURE|No Perineorrhaphy|Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
214383427|NCT01416701|DIETARY_SUPPLEMENT|Vitamin D (D3, cholecalciferol)|Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
214383428|NCT01416701|DIETARY_SUPPLEMENT|Placebo (cellulose)|Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
214383429|NCT02357810|DRUG|Pazopanib Hydrochloride|Given PO
214383430|NCT02357810|DRUG|Oral Topotecan Hydrochloride|Given PO
214383431|NCT02357810|OTHER|Laboratory Biomarker Analysis|Correlative studies
214383432|NCT03541772|DIETARY_SUPPLEMENT|Oncoxin-Viusid®|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments
214383433|NCT03541772|DIETARY_SUPPLEMENT|Placebo|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
214383434|NCT00258180|BIOLOGICAL|filgrastim|Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
214383435|NCT00258180|DRUG|cyclophosphamide|Administered IV over 1 hour on days 1-4
214383436|NCT04651400|DRUG|Antithrombin III|Antithrombin III
214383437|NCT01376960|PROCEDURE|elective forefoot surgery|Includes both soft-tissue and osseous procedures.
214383438|NCT03093857|DIAGNOSTIC_TEST|Determination of biomarker|Liquor, blood, and urine samples will be drawn and measured at different time points.
214383439|NCT01312987|DIETARY_SUPPLEMENT|Lipid-based nutritional supplement|"After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months"
214383440|NCT00728117|OTHER|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
214383441|NCT00728117|OTHER|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
214383442|NCT01878123|BIOLOGICAL|AMP-110|Dose levels 1 through 7: Single intravenous infusion on Day 0
214383443|NCT01878123|OTHER|Placebo|Dose levels 4 through 7: Single intravenous infusion on Day 0
214383444|NCT01229982|DRUG|Latanoprost-PPDS|Punctal Plug
214383445|NCT02218840|OTHER|Smoking topography|Evaluation of cigar smoking topography
214383446|NCT05538260|PROCEDURE|Repair of ocular trauma in children below 16 years old|Diagnosis and repair of pediatric ocular trauma
214383447|NCT00245401|DEVICE|CYPHERTM Sirolimus-Eluting Coronary Stent|
214383448|NCT03928145|DRUG|Chlorthalidone 25 mg|Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
214383449|NCT03928145|DRUG|Hydrochlorothiazide 50 mg|Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.
214383450|NCT03928145|DRUG|Amiloride 20 mg|Amiloride 20 mg taken orally in the morning for 12 weeks.
214383451|NCT03928145|DRUG|Amiloride 10 mg|Amiloride 10 mg taken orally in the morning for 12 weeks.
215093229|NCT06668389|DRUG|SGLT2 inhibitor (Dapagliflozin 10mg)|Subjects in SGLT2 inhibitor Group will take dapagliflozin 10mg once daily orally from Visit 1 (Week 1) to Visit 3 (Week 12 ± 1)
214383452|NCT00726349|OTHER|No intervention|Observational study.
214383453|NCT01406002|DRUG|darexaban|oral
214383454|NCT01406002|DRUG|Rifampicin|oral
214383455|NCT01339598|DEVICE|Transcranial direct current stimulation (Eldith DC Stimulator)|Eldith DC Stimulator (NeuroConn GmbH, Germany)
214383456|NCT02340702|OTHER|COPD|COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of \<0.7.
214383457|NCT05157516|PROCEDURE|erector spinea block|the patients will receive a single injection erector spinea block after induction of general anesthesia
214383458|NCT05157516|PROCEDURE|Caudal epidural block|the patients will receive caudal epidural block after induction of general anesthesia
214383459|NCT02733705|OTHER|Control|normal saline IV
214383460|NCT02733705|DRUG|Fentanyl|fentanyl 0.5 mcg/kg ideal BW
214383461|NCT02733705|DRUG|propofol|propofol infusion
214383462|NCT00278590|BIOLOGICAL|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation will be performed.
214383463|NCT01015313|OTHER|intensive sodium management|"1. dietary sodium restriction~2. avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms"
214383464|NCT01285284|OTHER|Music|A previously defined list of songs will be administered by headphones to these patients.
214996367|NCT05537116|BEHAVIORAL|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
214996368|NCT05537116|BEHAVIORAL|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
214996369|NCT05537116|BEHAVIORAL|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
215093230|NCT02413411|BEHAVIORAL|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
214383465|NCT01285284|OTHER|No music|No music will be administered by the headphones connected to the MP3 device.
214383466|NCT02378519|BEHAVIORAL|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
214687512|NCT05345691|BIOLOGICAL|Bmab 1000|60 mg administered as a single SC (subcutaneous) injection once every 6 months.
214996370|NCT06838325|OTHER|Prostate Cancer Screening|"The focus group will take about 2 hours to complete and will be led by the study Investigator and a research coordinator. A member of the research team will also take notes during the focus group, and the discussion will also be audio recorded and transcribed (written down word for word).~Additionally, participant demographic information will be collected (such as your age)."
215093231|NCT02413411|BEHAVIORAL|an educational program (an NIH-developed booklet)|
215093232|NCT06979973|DRUG|Midazolam|midazolam syrup
215093233|NCT06979973|DRUG|Rosuvastatin|Rosuvastatin
214383467|NCT02378519|BEHAVIORAL|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
215093234|NCT06979973|DRUG|CKD-508 Tablet|CKD-508
214383468|NCT00204308|DRUG|Combination tenofovir-emtricitabine|Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
214383469|NCT00242749|DRUG|Gefitinib, Cisplatin and Radiotherapy|
214383470|NCT05666414|PROCEDURE|sandwich interpositional bone grafting computer guided|performing the 2 vertical and the 1 horizontal osteotomies using a cutting patient specific guide and fixation of the vertically elevated bony segment after gap calculation using patient specific fixation guides
214383471|NCT05666414|PROCEDURE|conventional interpositional bone grafting|performing the conventional interpositional sandwich osteotomies free-hand and fixation of the mobilized bone segment free-hand
214687513|NCT05345691|BIOLOGICAL|Prolia®|60 mg administered as a single SC injection once every 6 months
214687514|NCT06367582|DEVICE|Vertebroplasty (VP)|Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
214383472|NCT03357367|DEVICE|TiVi system|"Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
214498847|NCT06952101|PROCEDURE|experimental chemoradiotherapy|Participants with cT2N0 rectal tumors are typically candidates for upfront surgical resection. The investigators propose an alternative approach based on experimental chemoradiotherapy (spCRT). Literature suggests that pathologic complete response (pCR) rates after CRT are significantly higher than the 25% described for intermediate-advanced tumors. The investigators will assess clinical complete response (cCR) or complete metabolic response (cMR) through a multidisciplinary restaging process, including MRI, PET, thorax-abdomen CT scan, ERUS, and rectoscopy. In participants achieving cCR or cMR, a Watch and Wait (W\&S) strategy or Local Excision/Transanal Minimally Invasive Surgery (LE/TAMIS) may be proposed to avoid the physical and psychological consequences of major surgery, followed by a rigorous surveillance program.
214498848|NCT06952101|PROCEDURE|Standard Chemotherapy|Tumors will be initially treated with standard CRT (stCRT). Patients who reach cCR-cMR at restaging they are already candidates to sparing approaches with W\&S/LE/TAMIS according to Multicentric Resarch Study Protocol
214498849|NCT06950164|OTHER|observation group|in the group, no intervention was given, and the preterm infants were diagnosed with respiratory distress syndrome(RDS)
214996371|NCT04046471|DIETARY_SUPPLEMENT|enhanced Stop Light Diet|Stop light diet enhanced with portion-controlled meals
214996372|NCT04046471|BEHAVIORAL|Group Remote|Participants will receive remotely delivered weight loss in a group setting.
215093235|NCT06980935|DEVICE|NervioX-2400|To design the individualized tTIS, each participant completed a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data were used to determine the tTIS montage and stimulation settings via computational modeling.
215093236|NCT06980194|DIAGNOSTIC_TEST|99mTc-4BOH SPECT myocardial perfusion imaging|Participants undergo myocardial perfusion imaging using the investigational radiotracer 99mTc-4BOH with SPECT. Imaging is performed according to a standardized protocol. Each participant receives both this SPECT imaging and a PET imaging procedure using 13N-ammonia, in a randomized sequence, within a 7-day interval.
215093237|NCT06980194|DIAGNOSTIC_TEST|13N-ammonia PET myocardial perfusion imaging|Participants undergo myocardial perfusion imaging using 13N-ammonia with PET as the active comparator. This procedure is performed according to standard clinical protocols. Each participant also receives 99mTc-4BOH SPECT imaging in a randomized sequence, with both tests completed within a 7-day window.
214383473|NCT04116944|BEHAVIORAL|Resistance exercise training|The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.
214383474|NCT04116944|OTHER|Wait-list|Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.
214383475|NCT04489420|BIOLOGICAL|CYNK001-IV|Planned Starting dose dor IV 1.2x10\^9 cells/dose
214383476|NCT04489420|BIOLOGICAL|CYNK001-IT|Planned starting dose for IT 200 x10\^6 +/- 50 x10\^6 cells dose
214383477|NCT03331029|DEVICE|transesophageal investigation|Comparison of 3D ultrasound with transesophageal echocardiography
214383478|NCT05284292|DEVICE|GUARDIAN platform|The enrolled elderly subjects and their caregivers will use at home the GUARDIAN platform consists of the Senior App, the Caregiver App and the Misty II robot.
214383479|NCT02476214|BEHAVIORAL|group prenatal care|"Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.~There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse."
214383480|NCT01617005|DRUG|Tocilizumab|Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
214383481|NCT05977920|OTHER|Caffeine|s. description
214383482|NCT02720289|OTHER|Video-based social learning class|Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.
214383483|NCT02720289|OTHER|Traditional didactic class|Child passenger safety lecture by a child passenger safety technician.
214996373|NCT04046471|BEHAVIORAL|Individual In-Person|Participants will receive a weight loss intervention during individual, at-home visits.
215093238|NCT06980857|OTHER|Control Group|In our study, this group will be placed in hyperextension position and immobilized on postoperative day 0. Postop 1-2. Foot pumping exercises, isometric quadriceps exercises, passive knee extension, straight leg raising, 0-40 degree passive knee flexion, partial/full weight ambulation, respiratory exercises and cold application will be performed daily. On postoperative days 3-6 (depending on discharge time), stretching in passive knee extension, active/assisted quadriceps exercises, isometric-isotonic exercise for leg and hip muscles, 90-0 knee extension, 0-90 degree passive knee flexion exercises will be performed.
214383484|NCT00547690|OTHER|Acupuncture and Strengthening|Acupuncture and strengthening
214383485|NCT00547690|OTHER|Strengthening Alone|Strengthening training program
214383486|NCT01698658|OTHER|ultrasound tomography|Undergo ultrasound tomography using SoftVue
214383487|NCT01698658|PROCEDURE|magnetic resonance imaging|Undergo MRI of the breast
214383488|NCT01159223|DRUG|ATV/r|All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
214383489|NCT03459313|OTHER|Active group|For this study, the Frisk.Friidrott (Healthy.Athletics/Track\&Field) website has been developed. The purpose of the website is to provide an easy-to-use tool that can assist coaches and parents involved in youth athletics with information how to structure training and recovery planning, provide guidance on possible injuries, and provide other information on health for youth athletes.
214383490|NCT06081335|DEVICE|EdgeEndo x7 continuous rotation files|endodontic files operating in continuous rotation
214383491|NCT06081335|DEVICE|EdgeOne Fire reciprocating files|endodontic files operating in reciprocating motion
214383492|NCT03555630|DIAGNOSTIC_TEST|Thromboelastogram|Blood sample processing for thromboelastogram
214383493|NCT00642837|DRUG|Tramadol/acetaminophen|Osteoarthritis, flexible dose depending on patients' pain relief
214383494|NCT00642837|DRUG|Tramadol/acetaminophen|Post surgical neurophatic pain, flexible dose depending on patients' pain relief
214383495|NCT00642837|DRUG|Tramadol/acetaminophen|Post traumatic neuropathic pain, flexible dose depending on patient pain relief
214996374|NCT06443541|BEHAVIORAL|High-intensity implementation strategies (HIS)-Students|Students in the HIS group will receive educational outreach in a pre-implementation in-person orientation to GlobalConsent, covering similar topics and three monthly one-hour learning sessions during implementation in which technical questions about program access or progression can be addressed; more intensive intervention to enhance adherence with more frequent email/Short Message Service (SMS), completion reminders; and demand generation encouraging program completion.
214498850|NCT06950164|OTHER|control group|in the group, no intervention was given, but the preterm infants were diagnosed without respiratory distress syndrome(RDS)
214498851|NCT06951503|DRUG|AK112|iv, q2w
214687515|NCT06367582|DEVICE|Kyphoplasty (KP)|Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
214687516|NCT06367582|DEVICE|Pedicular Screw Augmentation (PSA)|Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength
214687517|NCT05600400|RADIATION|Stereotactic Ablative Body Radiation|2 Fraction
214687518|NCT03721068|BIOLOGICAL|iC9.GD2.CAR.IL-15 T-cells|Three dose levels are being evaluated: 0.5 x 10\^6, 1.0 x 10\^6, 1.5 x 10\^6
214383496|NCT00642837|DRUG|Tramadol/acetaminophen|Spinal Cord Injury, flexible dose depending on patients' pain relief
214383497|NCT00642837|DRUG|Tramadol/acetaminophen|Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
214383498|NCT00642837|DRUG|Tramadol/acetaminophen|Diabetic Neuropathy, flexible dose depending on patients' pain relief
214383499|NCT00642837|DRUG|Tramadol/acetaminophen|Post stroke pain, flexible dose depending on patients' pain relief
214383500|NCT00642837|DRUG|Tramadol/acetaminophen|Low back pain, flexible dose depending on patients' pain relief
214383501|NCT00642837|DRUG|Tramadol/acetaminophen|Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
214383502|NCT00642837|DRUG|Tramadol/acetaminophen|Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
214383503|NCT00221286|DRUG|pegylated interferon alfa-2a|
214383504|NCT00221286|DRUG|tenofovir DF / emtricitabine combination therapy|
214383505|NCT00221286|DRUG|pegIFN / TDF / FTC combination therapy|
214383506|NCT02081235|PROCEDURE|surgery for congenital heart disease|surgery for congenital heart disease
214498852|NCT06951503|DRUG|Oxaliplatin|iv, q2w
214498853|NCT06951503|DRUG|Irinotecan|iv, q2w
214498854|NCT06951503|DRUG|Leucovorin and 5-FU|iv, q2w
214498855|NCT06951503|DRUG|Bevacizumab|iv, q2w
214498856|NCT06749353|DEVICE|Virtual reality|We will use a virtual reality glasses with the 'Lending Moments' program, where patients can experience a sunset on a paradise beach while listening to a soothing voice that guides them through the experience with relaxation and meditation techniques. During this time, we will proceed with the surgical intervention.
214687519|NCT03721068|DRUG|Cyclophosphamide|500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
214687520|NCT03721068|DRUG|Fludarabine|30 mg/m\^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
214687521|NCT05625360|OTHER|eHealth Mindful Movement and Breathing|The self-directed intervention includes an approximately 20-minute eMMB will teach synergistic components: (a) Mindful Meditation - 2 minutes of observing the current state of the body, emotions, thoughts, energy, and breath. Mindful attention may facilitate safe physical movements; (b) Mindful Movement - 10 minutes of gentle movements coordinated with and intended to enhance the breath; (c) Breathing and Relaxation - 3 minutes of placing the hands above the navel (rather than on the belly to avoid discomfort) and noticing them rise and fall with a focus on slightly extending the exhale, which will prepare participants for meditation); (d) Meditation - 5 minutes of observing the natural breath without reacting to it.
214996375|NCT06443541|BEHAVIORAL|Low-intensity implementation strategies (LIS) for Students|Students in the LIS group will receive basic implementation strategies of the GlobalConsent often used to deliver online programs at US universities with email/SMS completion reminders with a predetermined frequency for 12 weeks.
214383507|NCT05394233|DRUG|Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed|Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks, Pemetrexed, 500 mg/m2, intravenously every 3 weeks, Tislelizumab, 200 mg IV every 3 weeks
214383508|NCT05415033|OTHER|BREAST-Q|arabic version of breast questionnaire
214383509|NCT05431634|DRUG|Experimental drug: ESK-001|Multiple doses of ESK-001
214383510|NCT05431634|OTHER|Placebo|Placebo
214996376|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Faculty|"* Passive access to web-based educational materials~* Town halls (3) with general faculty to define sexual violence; rates in young people; acute/chronic effects over the life course; primary-prevention evidence-based interventions (EBIs)"
214996377|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Faculty|Passive access to web-based educational materials
214996378|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials~* Monthly emails from trained internal facilitators to university leaders with updates on implementation progress~* One post-implementation webinar to share anonymized findings (by IS group); discuss plan for sustainment (including guidance on how to handle reporting of sexual violence in existing university counseling centers)"
214996379|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials"
214383511|NCT01915433|OTHER|Wahls Paleo Plus|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
214383512|NCT01915433|OTHER|Wahls Diet|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
214996380|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual~* In-person leadership training to champion GlobalConsent with internal stakeholders (leaders, implementation teams, faculty, students); leadership styles; managing teams; influence without authority; managing conflict; emotional intelligence; negotiation; leading change~* Biweekly (six) 1-hr recorded quality-improvement team webinars to provide refresher training; assess implementation progress; assess modifications; build peer-network; provide anonymized data on implementation progress for discussion"
214996381|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual"
214383513|NCT01729234|DIETARY_SUPPLEMENT|Nitrate|Dietary Supplement
214383514|NCT01729234|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement
214383515|NCT01880372|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|Same as Arm description
214383516|NCT05353959|OTHER|No intervention|No intervention
214383517|NCT05436964|OTHER|saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
214383518|NCT05436964|DRUG|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
214383519|NCT01391351|OTHER|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy :~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy"
214383520|NCT01391351|OTHER|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy"
214383521|NCT05145946|BEHAVIORAL|Video Game Training Group 1|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week.
214383522|NCT05145946|BEHAVIORAL|Video Game Training Group 2|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week.
214383523|NCT01805882|DRUG|Sofosbuvir|
214383524|NCT01805882|DRUG|Ledipasvir|
214383525|NCT01805882|DRUG|GS-9669|
214383526|NCT01805882|DRUG|GS-9451|
214383527|NCT00002658|BIOLOGICAL|filgrastim|
214383528|NCT00002658|DRUG|amsacrine|
214383529|NCT00002658|DRUG|cyclophosphamide|
214383530|NCT00002658|DRUG|cytarabine|
214383531|NCT00002658|DRUG|daunorubicin hydrochloride|
214383532|NCT00002658|DRUG|etoposide|
214383533|NCT00002658|DRUG|idarubicin|
214383534|NCT00002658|DRUG|mitoxantrone hydrochloride|
214383535|NCT00002658|DRUG|thioguanine|
214383536|NCT00002658|DRUG|tretinoin|
214383537|NCT00002658|PROCEDURE|allogeneic bone marrow transplantation|
214383538|NCT00002658|PROCEDURE|autologous bone marrow transplantation|
214383539|NCT00002658|PROCEDURE|peripheral blood stem cell transplantation|
214383540|NCT00002658|RADIATION|radiation therapy|
214383541|NCT01225822|DRUG|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
214383542|NCT01225822|DRUG|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
214383543|NCT01225822|DRUG|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
214383544|NCT01225822|DRUG|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
214383545|NCT01225822|DRUG|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
214383546|NCT03987256|OTHER|Initial rehabilitation protocol|During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
214383547|NCT03987256|PROCEDURE|Needling with PRP|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
214383548|NCT03987256|PROCEDURE|Needling with saline solution|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
214383549|NCT01360567|DIETARY_SUPPLEMENT|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
214383550|NCT01360567|DIETARY_SUPPLEMENT|Placebo|500 mg . one capsule of placebo, 3 times per day
214383551|NCT02221245|PROCEDURE|Tumor Biopsy via Ultrasound Endoscopy|The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
214383552|NCT05769751|OTHER|Electronic medical record and hospital information system or other available resources|This is a non-interventional study. No study medication will be provided to the participants.
214383553|NCT00741715|DRUG|AVE5530|oral administration once daily in the evening with dinner
214383554|NCT00741715|DRUG|atorvastatin|oral administration once daily in the evening with dinner
214383555|NCT00741715|DRUG|placebo|oral administration once daily in the evening with dinner
214383556|NCT00023790|DRUG|silicon phthalocyanine 4|Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Pc 4.
214383557|NCT05867264|OTHER|Early drinking water|"After passing the evaluation by the anesthesiologist team in PACU, the EOF1 group drank 200ml of water.~The evaluation criteria for the anesthesiologist team are:~1. Steward's awakening score is ≥ 6 points.~2. Level of sobriety ≥ 3.~3. There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
214996382|NCT06573229|DIETARY_SUPPLEMENT|Aminolife Plus by Piemme Pharmatech, Italy|A nutritional supplement containing whey protein, vitamin D, carnitine, HMB, perilla, arginine, coenzyme Q10, inositol)
214996383|NCT06617884|OTHER|Gait and balance training|The training includes individually adapted, targeted, video-based coordination and balance training, which should lead to an improvement in gait and balance. It includes strength, coordination and flexibility exercises.
214996384|NCT05949086|BEHAVIORAL|Work Chat|Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
214996387|NCT03562572|PROCEDURE|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention
214383558|NCT05867264|COMBINATION_PRODUCT|Early consumption of carbohydrates|"After passing the evaluation by the anesthesiologist team in PACU, the EOF2 group had a drinking capacity of 200ml of 12.5% carbohydrates (100ml containing 12.5g of maltodextrin, fructose, and glucose).~The evaluation criteria for the anesthesiologist team are:~1. Steward's awakening score is 6 points.~2. Level of sobriety ≥ 3.~3. There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
214383559|NCT05867264|OTHER|Late feeding group|After observing the vital signs for 30 minutes after surgery, patients in Group C were sent back to the ward to continue fasting and drinking for at least 6 hours. After the anus exhausts, they began to gradually drink and eat
214383560|NCT01349894|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
214383561|NCT05644353|DRUG|Mirikizumab|Administered SC.
214383562|NCT03622879|BEHAVIORAL|MT|A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
214383563|NCT03622879|DEVICE|TENS|TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
214383564|NCT03622879|BEHAVIORAL|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
214383565|NCT02888067|DRUG|Rocuronium bromide 0.5 mg/kg|Moderate neuromuscular blockade with rocuronium bromide
214383566|NCT02888067|DRUG|Rocuronium bromide 1.0 mg/kg|Deep neuromuscular blockade with rocuronium bromide
214383567|NCT02888067|DRUG|Sugammadex sodium 2 mg/kg|Reversal with sugammadex sodium
214383568|NCT02888067|DRUG|Sugammadex sodium 4 mg/kg|Reversal with sugammadex sodium
214383569|NCT03361696|OTHER|Help to use the Interface System of Communication and Control of the Environment|the occupational therapist and the ergonomics engineers at the rate of 4 sessions per patient for periods of 2 to 3 hours help patient to use use the Interface System of Communication and Control of the Environment
214383570|NCT04778514|DRUG|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
214383571|NCT04778514|DRUG|PrEP and combined oral contraceptive (COC) as two separate tablets|PrEP tablet and a COC as two separate tablets
214383572|NCT02310698|DEVICE|contrast enhanced digital mammography (CEDM)|
214383573|NCT02310698|DEVICE|whole breast screening ultrasound (WBUS)|
214383574|NCT03173092|DRUG|Ixazomib|Ixazomib capsules.
214383575|NCT03173092|DRUG|Lenalidomide|Lenalidomide capsules.
214383576|NCT03173092|DRUG|Dexamethasone|Dexamethasone.
214383577|NCT03548805|PROCEDURE|ologen® Collagen Matrix|Ologen is a collagen matrix used to modulate wound healing in the postoperative period to promote diffuse blebs
214383578|NCT03548805|PROCEDURE|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC
214996388|NCT03562572|OTHER|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
214996389|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET|amlodipine/atorvastatin (5/20mg tablet) once a day
214996390|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|amlodipine/atorvastatin (5/10mg tablet) once a day
214996391|NCT04111419|DRUG|Allisartan Isoproxil|allisartan (240mg/tablet) once a day
214996392|NCT06179667|BEHAVIORAL|Mobile Application|"It is aimed to develop the mobile application to address the problems and training needs of informal caregivers regarding the caregiving process. In this context, in order to determine the needs of caregivers, face-to-face in-depth interviews will be held with caregivers using the Semi-Structured Questionnaire for Qualitative Interviews at the University of Health Sciences GTRH Geriatrics Department. The content of the mobile application will be created according to the topics determined as a result of qualitative research. Technical development of the application will be carried out by the web application designer."
214996393|NCT05626816|DEVICE|Genital Nerve Stimulation|Electrical stimulation applied to the genital nerve with surface electrodes using an off the shelf TENS unit (Ultima Plus). First, an amplitude threshold for the pudendo-anal reflex responses will be determined. Then, sham (1-2 Hz) and effective stimulation (20 Hz) will be briefly applied to record responses. Then, stimulation will be applied in random presentation order to record any changes in anorectal manometry outcomes due to both sham and effective stimulation.
214383579|NCT05889884|DEVICE|Extended maxillary fixed retainer|Bonding extended maxillary fixed retainer from right first maxillary premolar to left maxillary first premolar for 6 months then assessment of relapse using 3D superimposition , little index , lateral cephalometric assessment along with PDL assessment with quality of life ,function and speech assessment
214383580|NCT02820363|DEVICE|"CERAMENT|G"|"Surgical repair of tibia fracture, CERAMENT™\|G applied to bony voids."
214383581|NCT02820363|PROCEDURE|SOC treatment|surgical repair of tibial fracture
214383582|NCT05763784|DEVICE|Tightrope|Tightrope use special fiber and a set of metal buttons to fix diastasis of a joint.
214383583|NCT05851599|OTHER|SKF7® Labisia pumila standardized extract|Botanical extract of Labisia pumila (Kacip Fatimah)
214383584|NCT01407354|DEVICE|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
214383585|NCT01407354|OTHER|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
214383586|NCT05779306|DEVICE|IOL Master 700|Biometry using the IOL Master 700
214996394|NCT05626816|DIAGNOSTIC_TEST|Clinical exam|Examination by physician determines the presence of pelvic reflexes (pudendo-anal and bulbocavernosus) which are essential for GNS to have an effect.
214383587|NCT05779306|DEVICE|Casia-2|Anterior segment-OCT to evaluate lens tilt
214383588|NCT05779306|DEVICE|MS-39|Corneal Topography using the MS-39
214996395|NCT05626816|DIAGNOSTIC_TEST|Collection of SCI common data elements|Data regarding participant demographics, history of injury, and medical history will be collected.
214383589|NCT05779306|DEVICE|OSIRIS|Abberometry using the OSIRIS-Abberometer
214383590|NCT05779306|DEVICE|Autorefractor|Evaluation of Refraction using an Autorefractor
214383591|NCT05779306|DIAGNOSTIC_TEST|Subjective Refraction|Refraction performed by experienced staff
214383592|NCT02118662|OTHER|Energy Expenditure during seated in an office chair|You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
214383593|NCT02118662|OTHER|Energy Expenditure during seated and typing|You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
214383594|NCT02118662|OTHER|Energy Expenditure during Treadmill walking work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
214383595|NCT02118662|OTHER|Energy Expenditure during cycling work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
214383596|NCT04849221|OTHER|Tympanometry measurement in both ears|Measurement once or twice a day and at every change of more than 10 mmHg in ICP, over the entire period of time that ICP is measured by a probe or DVE
214383597|NCT04849221|OTHER|Collection of clinical and paraclinical data|"Patient: gender, weight/height, age, etiology of ICP entry, reason for ICP monitoring, presence of external (otoscopy), middle (otoscopy + CT) or internal (CT) ear abnormality, presence of inclusion and non-inclusion criteria, measurement of patient tilt.~healthy subjects: gender, weight/height, age, presence of abnormality of the external (otoscopy), middle (otoscopy) or internal ear (questioning), presence of inclusion and non-inclusion criteria..."
215093239|NCT06980857|OTHER|ERAS Group|In our study, this group of patients were informed about the surgical procedure to be performed by the orthopedist; detailed information about the postoperative rehabilitation process, prevention of possible complications, preoperative nutrition, smoking and alcohol cessation time will be given. The patient will stop eating solid food 6 hours before the operation and stop drinking fluids 2 hours before the operation. Necessary consultations will be completed before surgery. Preoperative preparation of the patient will be organized according to the ERAS protocol. The patient will be mobilized early, either in bed or in the room, within 6-7 hours after surgery. The exercises of the first group will be continued from the first postoperative day.
214383598|NCT04849221|OTHER|Intracranial pressure reading (ICP)|a single measure
214383599|NCT00930943|DRUG|Oxymorphone ER|40 mg qd twice
214383600|NCT02556151|PROCEDURE|Repetitive lumbosacral magnetic stimulation (rTLSMS)|Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
214383601|NCT00762840|DEVICE|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
214383602|NCT00762840|PROCEDURE|Conventional endodontic procedure|Standard root canal treatment
214383603|NCT02204579|DRUG|NPSP795|
214383604|NCT00723437|DRUG|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
214383605|NCT05762848|DEVICE|Mobile Phone Head Circumference App|Measurement of Head circumference of Babies/Infants with a mobile phone application.
214383606|NCT02778399|DRUG|Placebo|Placebo tablets for oral administration once daily
214383607|NCT02778399|DRUG|OBE2109|OBE2109 tablets for oral administration once daily
214383608|NCT02081456|OTHER|Soft Tissue Mobilization|Patients in the STM group received treatment in supine, with their head resting on one pillow and the involved UE positioned in abduction and external rotation to preload the neural structures of the upper limb. Manual pressure was applied to the soft tissues of the upper quadrant in a deep, stroking manner with the intention to improve the mobility of the soft tissues surrounding the pathway of the neural structures of the upper limb as well as any tender or tight tissues. The therapist spent approximately 7 minutes on the neck and scapular region, 4 minutes on the upper arm, and 4 minutes on the forearm and hand. The therapist was allowed to vary the time spent on each region according to his/her assessment of the patient's condition. The procedure lasted a total of 15 minutes.
214383609|NCT02081456|DEVICE|Therapeutic Ultrasound|Patients received therapeutic US applied for a period of 5 minutes to the most painful region of the neck, then a second 5-minute dose at the most painful region of the upper extremity. The US dose was 0.5 w/cm2, with sonation time 50% and frequency 1 MHz.40,52 The patient lay supine with the hand of the involved upper extremity placed on the abdomen and the elbow supported on a pillow. The two US doses and interaction time with the patient lasted a total of 15 minutes in an attempt to have equal patient/therapist contact between the two groups.
214996396|NCT05626816|DIAGNOSTIC_TEST|Bowel function survey completion|Two surveys will be conducted to assess the bowel function of the participant. The International SCI Bowel Function Basic Data Set (ISCI BF BDS v2.1) and the SCI Qulaity of Life Bowel Management Difficulties (SCI-QoL BMD) survey scales collect data on overall bowel function and how any difficulties impact the participants quality of life.
214996397|NCT05626816|DIAGNOSTIC_TEST|International Standard for Neurological Classification of SCI (ISNCSCI)|The physician will conduct the ISNCSCI to determine the level and severity of injury to the spinal cord. This is done by determining the ability to detect light touch and pinprick stimulation. Outcomes will be a Spinal Injury Association Impairment Scale (AIS) grade of A-D.
214996398|NCT05626816|DIAGNOSTIC_TEST|Response to genital nerve stimulation (GNS)|GNS will be applied to determine if there is a response in the participant. If the participant has no response to the stimulation they will be excluded from the second visit as it is dependent on the ability to respond to GNS.
214687522|NCT05625360|OTHER|Life Impacts Reflection|"This self-directed intervention will focus on active listening, reflection of statements, and avoiding negative judgments. Participants will write brief diary entries daily for four weeks postoperatively and as they choose thereafter. Participants will be given the option of completing diaries on the tablet computer or paper. The instructions for daily diary entries will be, What were some of the events or circumstances that affected you in the past day? Think back over the past day and write down on the lines below up to five events that had an impact on you. A study team member will call participants to encourage diary completion two days (Postop Day 3) and two weeks after the synchronous session."
214383610|NCT04268992|OTHER|Long-term exercise|All patients randomised to long-term exercise will perform exercise training at least three times a week for three months. The exercise is supervised and individualised.
214383611|NCT03027063|BEHAVIORAL|10,000 steps|Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
214383612|NCT03027063|BEHAVIORAL|Usual Care|Participants will receive the ACC/AHA exercise guidelines
214996399|NCT05626816|DIAGNOSTIC_TEST|Anorectal Manometry testing (ARM)|"The participant will be instrumented for ARM testing. This requires a special balloon catheter to be inserted into the anus and secured, surface electrode pads being applied to the anal sphincter, and electrode pads being applied to the genital nerve stimulation sites.~Once instrumented, the participant will be tested with the London Classification procedure. This procedure asks the participant to perform several actions (squeeze to withhold a bowel movement, push to have a bowel movement, and cough) as well as inflating the balloon on the catheter to determine reflex thresholds (RAIR, retroanal inhibitory reflex which relaxes the anal sphincter in response to rectal distension) and sensory thresholds (first senstation,"
214383613|NCT05528718|DRUG|Nitrous oxide gas for inhalation|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
214383614|NCT05528718|DRUG|Midazolam injection|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
214383615|NCT00612534|DRUG|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
214383616|NCT00612534|DRUG|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
214383617|NCT00612534|DRUG|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
214383618|NCT00612534|DRUG|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
214383619|NCT00049400|DRUG|BMS-247550|BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
214383620|NCT02572843|DRUG|MEDI4736 (anti-PD-L1)|fixed dosing 750 mg
214383621|NCT02952911|DEVICE|Smartphone and Smartwatch|Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
214383622|NCT00853281|OTHER|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
214383623|NCT00853281|OTHER|Standard vector control measures|Insectice-treated net
214383624|NCT05915390|DIETARY_SUPPLEMENT|walnuts|walnuts will provide 15% of the total energy
214383625|NCT05915390|DIETARY_SUPPLEMENT|Habitual diet|continue with habitual diet and abstain from walnuts
214383626|NCT06350292|BEHAVIORAL|SLEEP: COPE|Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
214383627|NCT00003216|DRUG|fluorouracil|
214383628|NCT00003216|DRUG|gemcitabine hydrochloride|
214383629|NCT00003216|RADIATION|radiation therapy|
214383630|NCT06476184|DRUG|Carboplatin|"Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy"
214383631|NCT06476184|DRUG|Paclitaxel|"Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy"
214383632|NCT00025584|DRUG|bortezomib|Given IV
214383633|NCT00025584|OTHER|laboratory biomarker analysis|Correlative studies
214383634|NCT01336985|DRUG|Irinotecan|
214383635|NCT01336985|PROCEDURE|Chemoembolization|
214383636|NCT01336985|DEVICE|Drug-Eluting Beads|
214383637|NCT01336985|PROCEDURE|Biopsy|
214383638|NCT00953303|DRUG|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
214383639|NCT00953303|DRUG|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
214383640|NCT02688465|DRUG|Apomorphine|
214383641|NCT03482856|BEHAVIORAL|MNA plus CBT-I|MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.
214383642|NCT03482856|BEHAVIORAL|MNA alone|MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.
214383643|NCT03916744|DRUG|Giredestrant|Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
214996400|NCT05928325|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessments
214383644|NCT03916744|PROCEDURE|Surgery|Breast cancer surgery will take place on Day 15 (+/-2 days).
214383645|NCT02223754|DEVICE|lotrafilcon B|Soft contact lens to be worn as daily wear, monthly replacement modality.
214498857|NCT06952582|BEHAVIORAL|The IMB model-based safer sexual dual protection educational intervention|The IMB model based safe sexual dual protection education was designed to provide factual information about sexual risks of STI/HIV and unwanted pregnancy and the benefits of safer sexual dual protection behaviors including abstinence and dual protection use, enhance motivation to practice primary sexual abstinence for sexually inexperienced youth and dual protection use for sexually experienced young women, and teach specific behavioral skills required for practicing abstinence and/or negotiate safer sex with partners to use condoms/dual protection for simultaneous prevention of both risks of STI/HIV and unwanted pregnancy among youth at risk.
214498858|NCT06953492|OTHER|PSQI|PSQI
214498859|NCT06951360|PROCEDURE|ENERGY questionnaire|Questionnaire including NASA Task Load Index, difficulty level of operation, patient and operation factors
214498860|NCT06443008|DEVICE|Observation Group|On the basis of myoelectric biofeedback treatment in the control group, the control group was trained alternately in each muscle group (triangle muscle, triceps brachii muscle group and forearm extensor muscle group). For example,After disinfection of the triangular, triceps and extensor muscles of the patient, the feedback electrode was attached to the area. The stimulation frequency was set at 50 Hz and the stimulation pulse width was set at 200 μs.During treatment, the patient is instructed to listen carefully to the device's password, drive the affected limb according to the specific password, and then perform tension and relaxation training.For each muscle group, the training time of each muscle group is about 0.5 h, 1 / d.In the later stage of treatment, the training intensity can be increased appropriately, so that the patient can carry out weight lifting during the feedback treatment, and listen to the password issued by the device to carry out muscle strength exercise.
214498861|NCT05374785|DRUG|CPL409116|CPL409116 contained in the tablet called PG242 (60 mg)
214498862|NCT05374785|OTHER|Placebo|Tablets without CPL409116 as an active substance
214498863|NCT04542031|OTHER|Questionnaire|Questionnaire to be completed at 6 and 12 months
214383646|NCT02223754|DEVICE|etafilcon A|Soft contact lens to be worn as daily wear, daily disposable modality.
214498864|NCT04318028|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7 Tesla MRI
214498865|NCT05108558|DRUG|CCH administration|Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
214498866|NCT05108558|DRUG|Control - Crossover to CCH|Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
214687523|NCT05625360|OTHER|PROMIS Questionnaires|Various PROMIS questionnaires will be completed by participants (Pain Interference, Sleep Disturbance, Physical Function, Anxiety and Depression)
214996401|NCT05928325|BEHAVIORAL|Health Education|Receive survivorship care education
214383647|NCT06062459|OTHER|Motor Control Exercise|Motor control exercises focusing on the activation and control of deep spinal muscles
214383648|NCT06062459|OTHER|Balance Training|Balance training exercises on to enhance proprioception and stability
214383649|NCT06062459|OTHER|Control Group|Participants received hot pack and stretching exercise
214383650|NCT00477061|DRUG|Morphine|
214383651|NCT01231139|DRUG|Paracetamol|Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).
214498867|NCT05108558|DEVICE|RestoreX|Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
214498868|NCT06454617|OTHER|Phantom|The patients will be simultaneously scanned with a QCT phantom
214498869|NCT05971342|DRUG|Gelatin sponge-loaded apoptotic vesicle complex（Kuaikang®)|The experimental group
214498870|NCT05971342|DRUG|Gelatin sponge only （Kuaikang®)|The positive control group
214687524|NCT03281889|RADIATION|Proton Beam|precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
214687525|NCT06826079|DRUG|Sorbitol|During the neoadjuvant treatment week, oral sorbitol 2-4g/ time, three times a day (with meals)
214687526|NCT06826079|OTHER|Placebo|During the neoadjuvant treatment week, oral placebo 2-4g/ time, three times a day (with meals)
214687527|NCT04145115|BIOLOGICAL|Ipilimumab|Given IV
214687528|NCT04145115|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214996402|NCT05928325|OTHER|Medical Device Usage and Evaluation|Wear activity tracking device
214996403|NCT05928325|OTHER|Supportive Care|Receive geriatric assessment-guided interventions
214996404|NCT05372484|DEVICE|Multimodal optical imaging|Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
214996405|NCT06517758|DRUG|Iptacopan|Hard gelatin capsule
214996406|NCT06517758|OTHER|Matching Placebo|Hard gelatin capsule
214996407|NCT06302543|PROCEDURE|autologous bone marrow cells injection|under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection
214996408|NCT06389240|OTHER|6 weeks post-operatively early weight bearing|Early mobilization 6 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
214996409|NCT06389240|OTHER|10 weeks post-operatively weight bearing (standard of care)|Standard of care mobilization at 10 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
214996410|NCT04886284|DRUG|Ertapenem|Adjunctive ertapenem
214996411|NCT04886284|DRUG|Placebo|Saline placebo
214687529|NCT04145115|BIOLOGICAL|Nivolumab|Given IV
214687530|NCT06113445|DRUG|Povorcitinib|Oral, Tablet
214383652|NCT01231139|DRUG|0.9% Sodium Chloride Schedule:|Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
214383653|NCT00722384|DRUG|bevasiranib|
214383654|NCT00722384|DRUG|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
214383655|NCT06028035|DIETARY_SUPPLEMENT|BB01|20 grams minimally processed form of Hemp hulls in the form of a bar/wafer.
214383656|NCT02553811|DIAGNOSTIC_TEST|accuracy diagnostic|effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
214383657|NCT05922839|DRUG|Zanubrutinib|Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months, and for effective patients, continue to use for 2 years after achieving optimal therapeutic effect.
214383658|NCT01431040|OTHER|No bowel prep|Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
214383659|NCT01431040|OTHER|Clear liquid diet and 2 Fleet's enemas|Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
214383660|NCT01194895|OTHER|protective ventilation|set tidal volume of 5ml/kg during one-lung ventilation
214498871|NCT06425614|PROCEDURE|Autotransfusion|"ANTIFIBRINOLYTIC THERAPY :~tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end~INTRAOPERATIVE MANAGEMENT :~* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter~* The general anaesthesia :~* propofol and Remifentanil or sufentanil both simultaneously administered .~* monitoring of the bispectral index~* Triple lumen central venous catheter~* Heparinization (300 UI/kg)~* Aortic and right auricular cannulations~TRANSFUSION PROTOCOL :~* During CPB, PRBC transfusion if necessary~* In the postoperative period if necessary~In bleeding patients:~The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center."
214996412|NCT05797155|BEHAVIORAL|CoQuit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips|CoQuit App (Cognitive Dissonance Based Smoking Cessation) Use of the CoQuit app, completion of cognitive dissonance activities, sharing of videos with online group, and providing support to other group members
215093240|NCT06980857|OTHER|Multimodal physiotherapy group combined with ERAS protocol|In our study, this group of patients who were informed about the surgery by the orthopedist will be examined by the anesthesiologist 1 week before surgery. Patients whose anesthesia preparation is completed will participate in a training program about pain, prevention of postoperative complications, auxiliary devices/equipment and exercises to be used, accompanied by a physiotherapist and a nurse. At the end of the program, patients will be given a 1-week home exercise program prepared by the physiotherapist. NMES device will be connected to the quadriceps muscles for 20 minutes half an hour before surgery, immediately after surgery and every day during hospitalization. Postoperatively, the patient will be mobilized early within 6-7 hours and the knee will be placed in hyperextension position. From the 1st day onwards, the exercises of the first group will be continued.
214383661|NCT01194895|OTHER|conventional ventilation|keep tidal volume at 8ml/kg during one-lung ventilation
214383662|NCT02480816|DIETARY_SUPPLEMENT|Mineral water|Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
214383663|NCT06560411|DEVICE|Non-Invasive Ventilation|Provide continuous or intermittent ventilatory support for the care of individuals who require mechanical ventilation
214383664|NCT00017940|GENETIC|Human Nerve Growth Factor|
214383665|NCT01008475|DRUG|EMD 525797 250 mg|EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
214498872|NCT05020496|DRUG|Diphenylcyclopropenone (DPCP)|Drug will be applied topically on the skin. It will cause contact hypersensitivity in patients
214498873|NCT02243800|OTHER|cholecalciferol versus placebo|
214498874|NCT01252420|DRUG|Enoxaparin|1.5mg/kg daily for 2 weeks
214498875|NCT02919787|DRUG|5-FU|Neoadjuvant treatment
214498876|NCT02919787|DRUG|Oxaliplatine|Neoadjuvant treatment
214498877|NCT02919787|DRUG|Irinotecan|Neoadjuvant treatment
214498878|NCT02919787|PROCEDURE|Pancreatic surgery|All patients
214498879|NCT02919787|DRUG|5-FU|Adjuvant treatment
214687531|NCT06113445|DRUG|Placebo|Oral, Tablet
214996413|NCT05797155|BEHAVIORAL|Tips for Smoking Cessation App|App containing daily tips for smoking cessation
214383666|NCT01008475|DRUG|EMD 525797 500 mg|"Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
214383667|NCT01008475|DRUG|EMD 525797 750 mg|EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
214498880|NCT02919787|DRUG|Oxaliplatine|Adjuvant treatment
214498881|NCT02919787|DRUG|Irinotecan|Adjuvant treatment
214498882|NCT06524882|DEVICE|Vivid Vision|dichoptic video games played through a virtual reality headset
214687532|NCT04038255|DRUG|Nicoderm C-Q Transdermal Product|6 weeks of nicotine replacement therapy patches
214996414|NCT02972840|DRUG|Acalabrutinib|Administered orally (PO)
214996415|NCT02972840|DRUG|Bendamustine|Administered intravenously (IV)
214996416|NCT02972840|DRUG|Rituximab|Administered intravenously (IV)
214996417|NCT02972840|DRUG|Placebo|Placebo comparator
214383668|NCT01008475|DRUG|EMD 525797 1000 mg|"Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
214498883|NCT06524882|DEVICE|Luminopia|dichoptic movies/shows shown through a virtual reality headset
214383669|NCT01008475|DRUG|Cetuximab|"Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
214383670|NCT01008475|DRUG|Irinotecan|"Safety part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
214383671|NCT02500459|DRUG|topotecan|intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
214383672|NCT02500459|DEVICE|Cleveland Multiport Catheter|The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
214383673|NCT01463280|DRUG|tumescent lidocaine infiltration|Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
214498884|NCT06524882|DEVICE|Optical Correction|Glasses prescribed at investigator discretion
214498885|NCT02588443|DRUG|RO70097890|
214498886|NCT02588443|DRUG|nab-paclitaxel|
214498887|NCT02588443|DRUG|gemcitabine|
214498888|NCT03002194|DEVICE|Cutometer|Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.
214498889|NCT03002194|OTHER|Photographs|Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
214498890|NCT01726998|OTHER|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
214498891|NCT01726998|OTHER|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
214498892|NCT00048932|DRUG|Double-blind Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.
214498893|NCT00048932|DRUG|Double-blind Placebo|Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
214498894|NCT00048932|DRUG|Open-label Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.
214498895|NCT03270709|DRUG|Vitamin D3 450,000 IU orally|Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
214498896|NCT02232737|OTHER|Very low nicotine content cigarettes|
214498897|NCT03971539|DRUG|BI 894416|BI 894416 film-coated tablet.
214498898|NCT03971539|DRUG|Placebo|Placebo film-coated tablet matching BI 894416.
214498899|NCT04559698|BEHAVIORAL|LGBTQ-affirmative CBT training|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.
214498900|NCT01147757|DRUG|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
214498901|NCT06492148|OTHER|Myofascial Release|The myofascial release technique is a widely used manual therapy method characterized by low-load, prolonged mechanical forces applied to manipulate the myofascial complex, aiming to restore optimal length, alleviate pain, and improve function.
214498902|NCT06492148|OTHER|Sham-Myofascial Release|The hands of the researcher applying the technique will be placed in the same areas as the myofascial release technique, with only the palms in light contact for the same duration. However, no intervention will be made to create any pressure or open the tissue barrier.
214498903|NCT03507504|OTHER|SCU-B|"SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home."
214498904|NCT05600114|DRUG|Cannabidiol oral solution|CBD 150 mg BID
215093241|NCT06981416|BEHAVIORAL|Digital education group|Digital training for home accidents and first aid based on the Theory of Planned Behavior (PBT) and the pre-test, post-test and follow-up results will be evaluated.
214383674|NCT00664638|DEVICE|Symplicty(TM) Catheter System|Renal denervation using the Symplicity Catheter System
214383675|NCT04472377|DEVICE|Self sampling kit for collecting discharge from vaginal fornix|A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.
214383676|NCT03556358|BIOLOGICAL|TX05 (trastuzumab)|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
214498905|NCT05600114|DRUG|Cannabidiol oral solution|CBD 300 mg BID
214498906|NCT05600114|DRUG|Placebo|Placebo BID
214996418|NCT04657289|DRUG|Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
214383677|NCT03556358|BIOLOGICAL|Herceptin®|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
214383678|NCT03556358|DRUG|Paclitaxel|175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
214383679|NCT03556358|DRUG|Epirubicin|75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
214383680|NCT03556358|DRUG|Cyclophosphamide|600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
214383681|NCT01550172|BEHAVIORAL|Sleep Behavioral Therapy A and NHMS|"The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments."
214383682|NCT01550172|BEHAVIORAL|Sleep Behavioral Therapy B and NHMS|"The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy B uses primarily behavioral adjustments."
214498907|NCT06385002|DRUG|Remimazolam|After tracheal intubation, the experimental group will maintain oxygen-air (O2-Air) at 2 liters/minute, and remimazolam will be infused at 1.0mg/kg/h, while adjusting the concentration of sevoflurane to maintain the depth of anesthesia with a bispectral index (BIS) of 40-60.
214498908|NCT05943795|DRUG|SI-B001|Administration by intravenous infusion
214498909|NCT05943795|DRUG|Docetaxel|Administration by intravenous infusion
214498910|NCT06385262|DRUG|Alirocumab|300 mg subcutaneously every 4 weeks prior to surgery
214498911|NCT06385262|DRUG|Cemiplimab|350mg IV every 3 weeks prior to surgery
214498912|NCT06385262|DRUG|Chemotherapy|Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
214687533|NCT04038255|BEHAVIORAL|Orientation session|This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide electronic informed consent which will be audio-recorded with their permission, and complete the baseline assessment.
214498913|NCT02963571|PROCEDURE|posterior percutaneous pedicle screw internal fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
214498914|NCT00715351|DRUG|insulin detemir|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
214498915|NCT00715351|DRUG|insulin NPH|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
214498916|NCT01872494|OTHER|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
214498917|NCT01872494|OTHER|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
214498918|NCT01872494|DRUG|0.33% ropivacaine 250ml|
214687534|NCT04038255|BEHAVIORAL|Craving-to-Quit app|The app is comprised of 22 modules for 22 days, 5-15 minutes each, designed to teach MT using audio, video, and animation. The app also includes other features such as social support (quit friend sign-ups, the tip of the week), activity feed (to track interaction with the app), and my morning stats (to track smoking).
214383683|NCT00737412|OTHER|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
214383684|NCT00737412|OTHER|Placebo|Matching capsules devoid of microorganisms
214383685|NCT04195880|OTHER|Interventions to Reduce Acute Care Transfers|Experimental CLCs were trained in INTERACT QI Intervention, containing tools, strategies and educational resources designed to catch and manage acute changes in conditions early that a Veteran may be experiencing, leading to a potential reduction in preventable hospital transfers from CLCs.
214383686|NCT02917941|DRUG|Ixazomib|Ixazomib capsules
214383687|NCT02917941|DRUG|Lenalidomide|Lenalidomide capsules
214383688|NCT02917941|DRUG|Dexamethasone|Dexamethasone Tablets
214498919|NCT01872494|DRUG|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
214498920|NCT06640231|OTHER|sealer activation after cleaning and shaping with XP-Endo Finisher|activation of sealer before the obturation of root canals
214498921|NCT06640231|OTHER|negative control where canals are obturated directly without sealer activation|sealer after cleaning and shaping before the obturation without using activation method
214498922|NCT03102853|OTHER|Nordic diet|
214498923|NCT03102853|OTHER|Control diet|
214498924|NCT03987581|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
214687535|NCT04038255|BEHAVIORAL|Two brief follow-up phone calls|The first phone call will occur one day before the quit date to remind participants about their quit date and provide support. The second will occur at the end of treatment (around day 60 after quit date) to review progress, provide support, and schedule the 3-month follow-up visit. Each phone call will last approximately 15 minutes.
214996419|NCT04657289|DEVICE|Port Delivery System with Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
214996420|NCT05094128|DRUG|Upadacitinib|Tablet; Oral
214383689|NCT02381990|PROCEDURE|FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY|"Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic cryoprobes/devices are employed to freeze and all circuled or noted cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins"
214383690|NCT01351025|DRUG|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
214383691|NCT01351025|DRUG|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
214383692|NCT01351025|DRUG|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
214383693|NCT05188755|OTHER|Indirect calorimetric test during submaximal exercise|"* metabolic evaluation by indirect calorimetry at rest and during exercise~* evaluation of cardiac output~* peripheral quantitative computed tomography (pQCT) of the muscle cross section~* evaluation of body composition~* assessment of physical capacity (chair test and 3 min step-test)~* blood test~* assess the level of physical activity"
214383694|NCT00515437|BIOLOGICAL|Botulinum Toxin Type B (Myobloc)|
214383695|NCT00515437|BIOLOGICAL|Matched placebo to Myobloc|
214383696|NCT04923308|OTHER|Triage results disclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will be communicated to the specialist using a standardized clinical note, prior to the patient's consultation and without further discussion.
214383697|NCT04923308|OTHER|Triage results undisclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will not be communicated to the specialist.
214383698|NCT05205317|DRUG|Metformin Hydrochloride Sustained-release Tablets|drug
214383699|NCT05205317|PROCEDURE|Vaginal repair|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
214383700|NCT03629652|OTHER|head-down position treatment|In the head-down position, the body is in the supine position with the head lowered to 30 degrees
214383701|NCT03629652|OTHER|Conventional Rehabilitation|The body is in the supine position without lowered head
214687536|NCT04038255|BEHAVIORAL|Group MT sessions|Total of eight group sessions (twice a week) during 4 weeks. The overarching theme of momentary awareness and acceptance of cravings and affect (e.g., stress, anxiety etc.) will be introduced and reinforced in complementary ways throughout the training. Each session will last 45-60 minutes.
214383702|NCT05296499|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing using cycle ergonomenter
214383703|NCT05296499|DIAGNOSTIC_TEST|Exercise cardiac MRI|Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET
214383704|NCT05296499|OTHER|6 minute walk test|6MWT
214383705|NCT05296499|DIAGNOSTIC_TEST|Blood tests|FBC, U\&E, LFTS
214383706|NCT05296499|OTHER|Quality of life questionnaires|SF36, EQ5D, VEINES-QoL/Sym
214383707|NCT05296499|OTHER|Repeat baseline assessments|repeat baseline
214383708|NCT05296499|DIAGNOSTIC_TEST|MR venogram|MRI scan of venous system
214383709|NCT05585138|OTHER|segmental breathing exercise|Group-A (interventional group) will receive segmental breathing exercises and deep breathing. segmental breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and in exhalation therapist will apply pressure on intercostal spaces at apical, lateral and posterior for one month 5 days a week and 2 sessions per day for 15 minutes for each patient. conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day.
214996421|NCT06496477|DEVICE|Ayo wearable|Primary study device - the Ayo wearable which are glasses that emit either bright blue-spectrum white light or dim blue-spectrum white light or Mini motion logger AAM-32 - an actigraphy device work during the first and last week of the study on the participants wrist throughout most of the day, measuring activity. This will be used as an indicator of sleep.
214996422|NCT05030818|DRUG|Polypill of acetylsalicylic acid, ramipril and atorvastatin|Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
214383710|NCT05585138|OTHER|deep breathing|conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.
214383711|NCT04842214|BEHAVIORAL|Oncological Rehabilitation|Multidimensional rehabilitation
214996423|NCT05030818|DRUG|Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin|Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
214996424|NCT05046353|DRUG|D-serine|Auditory remediation +/-D-serine
214996425|NCT05046353|OTHER|Placebo|Auditory remediation +/-D-serine
214996426|NCT06303739|DRUG|psilocybin|25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.
214996427|NCT06967415|OTHER|Pain, central sensitization,functional status and quality of life.|The patients' pain status, central sensitization functional status, and quality of life will be evaluated according to their stenosis grade.
214383712|NCT04665024|PROCEDURE|preoperative chest physiotherapy|"The patients were approached to partake in the investigation after they got full clarifications about the point of study. They were allocated into two groups and reassurance was achieved about the absence of any side effects.Furthermore, the examination was approved by the ethical committee.~Effects of preoperative chest physiotherapy were compared between two groups, by measuring the lung functions, oxygen saturation, pulmonary complications and length of hospital staying. Lung functions were completed by utilizing spirometry parameters, oxygen saturation was measured by pulse oximeter and pulmonary complications were diagnosed by specialist doctors."
214383713|NCT04665024|PROCEDURE|postoperative chest physiotherapy|"Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days."
214383714|NCT03373864|PROCEDURE|Unilateral spinal anesthesia|Unilateral spinal anesthesia with hypobaric local anesthesia allowing a lateralized anesthesia of the fractured limb.
214383715|NCT03373864|PROCEDURE|General anesthesia|General anesthesia following the latest recommendations for elderly patients (SFAR 2017)
214383716|NCT02149784|PROCEDURE|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy'
214383717|NCT01416233|PROCEDURE|autologous fat grafting to the orbit|subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
214383718|NCT05826015|DRUG|Paclitaxel|IV over 3 hours
214383719|NCT05826015|DRUG|Batiraxcept|IV over 60 minutes
214383720|NCT02603822|DIETARY_SUPPLEMENT|12C mannitol|12C mannitol 100 mg
214383721|NCT02603822|DRUG|Indomethacin|Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
214383722|NCT02603822|DIETARY_SUPPLEMENT|13C mannitol|13C mannitol 100 mg
214498925|NCT03987581|BEHAVIORAL|Mobile Contingency Management (mCM)|Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
214996428|NCT05813288|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
214996429|NCT05813288|DRUG|Placebo|Oral administration of placebo tablet
214996430|NCT05067491|BEHAVIORAL|Augmented reality exposure therapy|Virtual objects will be placed in the patient's visual field, superimposed on their real environment for exposure therapy.
214996431|NCT04336943|BIOLOGICAL|Durvalumab|Given IV
214383723|NCT02603822|DIETARY_SUPPLEMENT|Lactulose|lactulose 1 g
214383724|NCT01715610|DRUG|Clavulin|Patients will be randomized to the antibiotic or placebo arm via a random number generator.
214383725|NCT01715610|DRUG|Randomization to Placebo|Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
214383726|NCT01715610|DRUG|Clindamycin|Patients will be randomized to the antibiotic or placebo arm via a random number generator
214383727|NCT01407211|DIETARY_SUPPLEMENT|vitamin A|"25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
214383728|NCT04909580|BEHAVIORAL|Decision coaching with a patient decision aid|Decision coaching guided by the Ottawa Decision Support Framework
214383729|NCT04596033|BIOLOGICAL|GEN-011|Personalized neoantigen adoptive cell therapy (ACT)
214498926|NCT03987581|BEHAVIORAL|Long-term incentive|This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
214498927|NCT01087359|DRUG|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
214498928|NCT00416858|DRUG|cisplatin|
214498929|NCT00416858|DRUG|fluorouracil|
214498930|NCT00416858|PROCEDURE|adjuvant therapy|
214687537|NCT04038255|BEHAVIORAL|Brief advice on quitting smoking|Standard advice on how to quit smoking.
214687538|NCT04038255|BEHAVIORAL|Self-help smoking cessation materials|Written materials on how to quit smoking including contact info for state tobacco quitline.
214996432|NCT04336943|DRUG|Olaparib|Given PO
214996433|NCT04336943|OTHER|Quality-of-Life Assessment|Ancillary studies
214996434|NCT04336943|OTHER|Questionnaire Administration|Ancillary studies
214996435|NCT05707949|DRUG|Atogepant|Oral Tablet
214383730|NCT04596033|DRUG|IL-2|Cytokine
214383731|NCT04596033|DRUG|Fludarabine|Lymphodepletion drug
214383732|NCT04596033|DRUG|Cyclophosphamide|Lymphodepletion drug
214383733|NCT02630095|DRUG|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
214383734|NCT02630095|DEVICE|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
214383735|NCT05806944|DEVICE|TMS followed by Sham TMS|double blinded crossover schedule in which participants will undergo TMS and assessment in one visit, followed by sham-TMS and assessment the next visit.
214383736|NCT05806944|DEVICE|Sham TMS followed by TMS|double blinded crossover schedule in which participants will undergo sham TMS and assessment in one visit, followed by TMS and assessment the next visit.
214498931|NCT00416858|PROCEDURE|conventional surgery|
214996436|NCT05119569|DRUG|Fenebrutinib|Fenebrutinib will be administered orally.
214996437|NCT05119569|DRUG|Placebo|Placebo will be administered orally.
214996438|NCT05045612|OTHER|Stop antibiotic therapy|Stop antibiotic therapy instituted by the admitting physician
214996439|NCT03683030|DEVICE|Multi-Electrode RF Balloon Catheter|Multi-Electrode RF Balloon Catheter will be inserted
214996440|NCT06469385|BIOLOGICAL|ENS-002|"Live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria.~Low Dose ENS-002 High Dose ENS-002"
214383737|NCT03573908|DRUG|Linaclotide|Oral capsule
214383738|NCT03573908|DRUG|Placebo|Matching placebo oral capsule
214383739|NCT01222143|DRUG|NOVE-HiDAC|"NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12.~During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10."
214383740|NCT01222143|DRUG|Nilotinib|"The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study.~During induction, nilotinib will be given orally on Days 1-12.~During consolidation, nilotinib will be given orally on Days 1-10."
214383741|NCT05254639|DRUG|DONEPEZIL|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
214498932|NCT00416858|PROCEDURE|neoadjuvant therapy|
214498933|NCT00416858|RADIATION|radiation therapy|
214498934|NCT02746926|DRUG|tafamidis|
214498935|NCT03607175|DRUG|Triamcinolone-impregnated CMC foam|same information as included in the arm/group descriptions
214498936|NCT03607175|DEVICE|Propel Stent|same information as included in the arm/group descriptions
214498937|NCT04093609|GENETIC|XIST gene deletion|detection of XIST gene deletion by fluorescence in situ hybridization
214996441|NCT01242436|PROCEDURE|intravenous contrast administration|"The additional burden is restricted to a WB-DWI scan before and during therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
214498938|NCT05794841|DIAGNOSTIC_TEST|Tongue coating sample collection and multi-omics analysis|Tongue coating sample collection and multi-omics analysis for building a diagnostic model
214498939|NCT06065930|DEVICE|Subcutaneous microdialysis|"Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1."
214383742|NCT05254639|DRUG|PLACEBO|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
214498940|NCT02852252|DRUG|OTL38|Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.
214498941|NCT02852252|DRUG|ICG|Patients will be given imaging agent 24 hours before surgery to assist in imaging.
214498942|NCT04307056|PROCEDURE|Radical Prostatectomy|The surgical approach can be open or laparoscopic. The procedure begins with lymph node dissection for the intermediate risk groups (PSA \> 10 ng/mL and/or presence of grade 4 Gleason score). Total prostatectomy includes removal of the seminal vesicles. It can preserve 1 or 2 neurovascular bundles, depending on the cancer stage and/or the choice expressed by the patient. The vesicourethral suture is either a running or interrupted suture, and there is drainage by a bladder catheter for at least 5 days.
214498943|NCT04307056|PROCEDURE|High Intensity Focused Ultrasound (HIFU) Treatment|The treatment with High Intensity Focused Ultrasound (HIFU) evaluated in this study will be delivered by 2 types of medical devices currently available on the market, Ablatherm® and Focal One®. They are both computer-controlled and provided with an endo-rectal probe with integrated ultrasound, enabling planning and the monitoring of treatment of localized prostate cancer in realtime.
214687539|NCT03124173|OTHER|Training session|The subjects will be trained to realize several versions of a learning task of conditional visuo-motor associations.
214383743|NCT01551004|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
214383744|NCT01551004|OTHER|Placebo|Matching placebo capsules will be given to 2 subjects of each cohort.
214383745|NCT05586464|DRUG|Ban xia xie xin Decoction and bismuth quadruplicate group|Ban xia xie xin Decoction:10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
214383746|NCT05586464|DRUG|Bismuth quadruplicate group|Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
214383747|NCT04816019|BIOLOGICAL|ChAdOx1 nCov-19|A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)
214383748|NCT05249062|DEVICE|SHAPES app|Participants will be asked to use the app and connected devices daily for 3 months.
214498944|NCT00111631|DRUG|DPP-IV Inhibitor|Escalating doses po bid
214498945|NCT00111631|DRUG|Metformin|As prescribed
214498946|NCT00111631|DRUG|Placebo|po bid
214498947|NCT02455427|DEVICE|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
214498948|NCT02455427|OTHER|Physical Therapy|Physical therapy will be administered for 60 minutes
214498949|NCT02455427|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
214687540|NCT03124173|OTHER|First fMRI session|In this session (involving a condition specific to man and a condition that we are certain to obtain in the monkey), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and three Manual responses (3 MRI-compatible mouse buttons).
214996442|NCT03980223|DRUG|Doxycycline Hyclate Delayed-Release 200 mg|200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
214996443|NCT06239610|DEVICE|electromagnetic placement device|Daily use of an EMPD to verify FT position
214996444|NCT05136599|BIOLOGICAL|Bordetella pertussis D420|Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
214383749|NCT01525134|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
214383750|NCT01525134|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
214498950|NCT02433782|OTHER|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
214498951|NCT00139165|DRUG|Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks
214498952|NCT00139165|PROCEDURE|sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.
214498953|NCT05437770|OTHER|BFR (Blood-Flow Restricted exercise)|The BFR group performs unilateral training with the knee-OA diagnosed leg first. BFR exercise is performed with a pneumatic cuff placed at the top of the thigh on the leg being trained. The cuff will be inflated to 60-80 % of the total arterial occlusion pressure (AOP). The participant will afterwards perform training of the knee extensors in a leg press exercise machine and a leg extension exercise machine with a load corresponding to 30 % of the maximal load (1RM = Repetition Maximum).
214498954|NCT05437770|OTHER|Standard rehabilitation|The GLA:D programme involves a circuit training program with four stations. Each station involves two to six exercises where the participants perform 10-15 repetitions over 2-3 sets, which depends on the participants pain- and functional level. Following the 8 weeks GLA:D programme, participants will continue 4 weeks of team group training performing similar neuromuscular lower limb exercises as for the first 8 weeks.
215093242|NCT06981416|BEHAVIORAL|classical education group|"The training content prepared according to the Planned Behavior Theory will be given as classical training in the form of a flow chart."
215093243|NCT06979713|OTHER|yoga, pain education, yoga nidra|Participants will complete a series of yoga postures targeting the lower back combined with pain education. The session will conclude with either yoga nidra with pain acceptance intention. Interventions are completed at home 2x/week for 6 weeks.
215093244|NCT06979713|OTHER|yoga, pain education, relaxing music|Participants will complete a series of yoga postures targeting the lower back combined with pain education. The session will conclude with relaxing music depending on group assignment. Interventions are completed at home 2x/week for 6 weeks.
214498955|NCT04304937|OTHER|patient reported outcome measure|2 questionnaires are tested against each other
214498956|NCT03484741|BIOLOGICAL|MSC and PRP|MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.
214498957|NCT02821936|PROCEDURE|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
214498958|NCT04149132|DEVICE|pulse photoplethysmography (PPG)|PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
214498959|NCT04149132|DIAGNOSTIC_TEST|Measurements of nitric oxide (NO) and malondialdehyde (MDA)|On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
214996445|NCT06516575|BEHAVIORAL|sentence manipulations|Auditory stimuli (sentences) are manipulated to have key words masked by noise, or to have prosody (pitch contour) manipulated to be consistent or inconsistent with a specific inferred meaning. Participants repeat the sentences while a camera tracks changes in their eye movements and changes in pupil dilation.
214996446|NCT00434434|DRUG|omalizumab|Aged Liquid; subcutaneous repeating dose
215093245|NCT06981403|BEHAVIORAL|virtual escape room game-based pediatric medication management education|3 period aplied virtual escape room game-based pediatric medication management education
215093246|NCT06980415|DEVICE|Kay Pictures iSight|Tablet-based visual acuity measurement
214383751|NCT04655885|BEHAVIORAL|Optimization of cardiac flow by base water-electrolyte supply|optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
214498960|NCT00325000|BEHAVIORAL|Interpersonal Psychotherapy|
214498961|NCT00325000|DRUG|sertraline or amitriptyline|
214996447|NCT00434434|DRUG|omalizumab|Lyophilized; subcutaneous repeating dose
214996448|NCT00434434|DRUG|placebo|Subcutaneous repeating dose
214996449|NCT01922934|BEHAVIORAL|Commercial weight loss program|vouchers for Weight Watchers
214996450|NCT01922934|BEHAVIORAL|Colorado Weigh|Group behavioral weight loss program
214996451|NCT01922934|DIETARY_SUPPLEMENT|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
214383752|NCT04655885|BEHAVIORAL|Control arm|increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
214996452|NCT01922934|DRUG|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
214996453|NCT01922934|BEHAVIORAL|Recreation center passes|1 year pass to a Denver recreation center
214383753|NCT04466215|DRUG|Miricorilant|900 mg (6 x 150 mg) tablets taken orally once daily for two weeks
214383754|NCT04466215|DRUG|Placebo oral tablet|Six placebo tablets taken orally once daily for two weeks
214383755|NCT05154123|DRUG|Drug: AT-527 + rosuvastatin|"* Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single dose of AT-527 and rosuvastatin will be co-administered."
214383756|NCT05154123|DRUG|AT-527 + rosuvastatin|"* Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)"
214383757|NCT00134602|BEHAVIORAL|Needs assessment followed by tailored intervention|
214383758|NCT02669095|DEVICE|Investigational Contact Lenses (Test)|
214383759|NCT02669095|DEVICE|Marketed Contact Lenses (Control)|
214383760|NCT02949401|BEHAVIORAL|Use of Virtual Reality App|The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
214383761|NCT04994496|BEHAVIORAL|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
214498962|NCT04939909|DRUG|Botulinum toxin type A|Patients were treated with Botulinum toxin type A applications on the Orbicularis oculi and glabellar complex
214498963|NCT00180791|DRUG|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
214498964|NCT01641900|DRUG|eszopiclone|3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
214498965|NCT01641900|DRUG|placebo|placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
214498966|NCT04789759|DEVICE|Socket Preservation - Bond Apatite synthetic bone substitute|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth. If 1/3 of the buccal plate is missing, considered a class 2 alveolar socket.~Extraction of tooth and place 2/3 biphasic calcium sulfate cement matrix's with Hydroxyapatite (HA granules) , condensed , and covered with a resorbable membrane suture to the adjacent tissue.~At implant placement ,take bone for histological preparation and histomorphometric analysis of the healing pattern.~At T0, T1 and T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements, will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.~Primary and secondary stability will be measured by ISQ units with a RFA machine, that will include the machine to measure and the magnetic tip to be screwed in the implant platform."
214498967|NCT04789759|PROCEDURE|Socket healing - No Filler|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth, at extraction day, no flap opening , atraumatic extraction, no biomaterial filler, At T0, T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements will include an intramural scanner from all the stages , we will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material."
214498968|NCT04828096|OTHER|Orthodontic retention|The stability of the mandibular anterior teeth after two resp. 5 years of retention
214498969|NCT02810600|OTHER|Gallium-68 DOTA TATE PET scan|One PET/CT scan using Gallium-68 DOTA TATE
215094743|NCT04778800|DRUG|LM-first line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
214383762|NCT04994496|BEHAVIORAL|Two-week web-based text messages containing fun facts|"The web-based sham intervention consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham intervention, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
214383763|NCT00832195|DEVICE|Motion Controlling Running Shoe|Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
214383764|NCT00832195|DEVICE|Neutral Running Shoe|Standard running shoe with single density mid-sole foam.
214383765|NCT04803578|OTHER|Conventional physiotherapy|The subjects will receive rehabilitation according to the guidelines on the management of subjects after knee or hip arthroplasty, recovery of joint Range of Motion, recovery of lower limb strength, education to the crutches management, and stairs climbing and descending
214383766|NCT00370721|DRUG|bevacizumab|
214383767|NCT00377286|DIETARY_SUPPLEMENT|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
214383768|NCT00377286|OTHER|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
214383769|NCT02826967|PROCEDURE|Colonic Irrigation|
214383770|NCT05186337|BEHAVIORAL|FROA-BD programme|The experimental group (n=42) will receive a 4-month intervention consisting of 32 sessions of treatment.
214383771|NCT04446897|BIOLOGICAL|mesenchymal stem cells|autologous mesenchymal stem cells
214383772|NCT04446897|OTHER|standard treatment|standard treatment according to clinical protocols
214383773|NCT05474521|DEVICE|CODTimer test|The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.
214383774|NCT02456805|OTHER|Infant Formula 1|Feed ab libitum
214498970|NCT03209700|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
214498971|NCT04790331|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
214498972|NCT04790331|DRUG|Diltiazem|"Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina."
214498973|NCT04790331|DRUG|Placebo|Placebo oral tablet
214498974|NCT03723031|DRUG|Misoprostol|400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
214498975|NCT02330588|BEHAVIORAL|Eat It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's grain portion sizes and sugar sweetened beverage intake were presented."
214498976|NCT02330588|BEHAVIORAL|Move It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's moderate-to-vigorous physical activity (MVPA) and screen time were presented."
214498977|NCT02330588|BEHAVIORAL|eHealth Control|The eHealth Control group (1) screened children's weight status, and (2) provided parents with the opportunity select resources and services to help prevent obesity in children.
214498978|NCT04051333|DEVICE|ALS Nutrition App (MyDataHelps platform)|We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.
214498979|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
214996454|NCT04312100|OTHER|oxygen treatment|different kinds of oxygen treatments will be given to patients according to their state of illness
214996455|NCT03495518|OTHER|Symptom feedback to Health Care Provider|"These children will complete SPARK daily for 5 days in a row, daily symptom reports will be printed and provided in the patient chart. On days 1 and 3, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical"
214996456|NCT03495518|OTHER|Standard of care|A clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
214996457|NCT06032637|PROCEDURE|Pfannenstiel incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
214996458|NCT06032637|PROCEDURE|Supra-umbilical transverse incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision 3-4cm above the umbilicus, extending laterally to the semilunar lines, without panniculus retraction. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. The rectus sheath will be incised transversely using electrocautery for hemostasis, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually along the midline using blunt dissection. The peritoneum will be transversely incised and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
214996459|NCT00120978|DRUG|Advair|
214498980|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
214996460|NCT00120978|DRUG|Flovent|
214498981|NCT03220724|BIOLOGICAL|CH505TF|Administered by intramuscular (IM) injection in the thigh
214498982|NCT03220724|BIOLOGICAL|CH505w53|Administered by IM injection in the thigh
214498983|NCT03220724|BIOLOGICAL|CH505w78|Administered by IM injection in the thigh
214687541|NCT03124173|OTHER|Second fMRI session|In this session (involving a condition specific to man and a condition that we are almost certain to obtain in monkeys), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and Three orofacial responses (3 movements of the mouth).
214996461|NCT00608179|DRUG|Glimepiride|Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.
214996462|NCT00608179|DRUG|glyburide|Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.
214996463|NCT00608179|OTHER|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes
214383775|NCT02456805|OTHER|Infant Formula 2|Feed ab libitum
214383776|NCT05674630|DEVICE|Magic Touch drug eluting balloon based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the experimental arm will receive treatment with drug eluting balloon (Magic Touch®) followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
214498984|NCT03220724|BIOLOGICAL|CH505 M5|Administered by IM injection in the thigh
214498985|NCT03220724|BIOLOGICAL|GLA-SE adjuvant|Admixed with all CH505 gp120 proteins
214498986|NCT03220724|BIOLOGICAL|Placebo|Administered by IM injection in the thigh
214996464|NCT00608179|OTHER|glucose clamp|hypoglycemic glucose clamp procedure -120 minutes
214996465|NCT02422654|DRUG|eliglustat|"Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion"
215093247|NCT06981247|BEHAVIORAL|m-LIfE: mobile based lifestyle intervention for employees to increase their physical activity and promote healthy diet.|"The m-LIfE will primarily deliver healthy lifestyle educational content, provide customized strategies for PA, and offer participants the option to enter their daily intake of fruits and vegetables through Food Log feature. m-LIfE will track PA and diet, send tailored reminders, and provide motivational messages. Participants will receive two text messages daily: a goal reminder in the morning and feedback or reflection on their progress in the evening. Additionally, they will receive one motivational message at the end of each week to sustain their motivation. Personalized feedback will also be provided through the application, featuring graphs to illustrate daily, weekly, and monthly progress.~To support participants further, the application will enable two-way communication, allowing users to seek assistance and ask questions from the research team. A dedicated contact number will be made available within the app to facilitate direct communication."
214996466|NCT01053455|DEVICE|SiPAP|biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
214996467|NCT05081687|DRUG|Folfirinox|5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
214996468|NCT04235946|OTHER|accompanied and adapted water polo program|"Validated questionnaires in French will measure fatigue, quality of life, post-traumatic growth and the coach-athlete relationship. All questionnaires will be administered face to face before the sessions by a member of the social psychology research team.~The collection of qualitative data (semi-structured interviews) will be carried out by one of the members of the research team in social psychology on three occasions (inclusion, Week 10 and Week 20) in order to assess the psychological variables of interest (quality interpersonal relationships, self-esteem, post-traumatic growth) and their dynamics.~Physiological variables (weight, fat / lean mass, capacity of the operated arm) will be evaluated monthly. The physical measurement data will be recorded in an electronic case report form"
214996469|NCT04004182|DIETARY_SUPPLEMENT|Fruit bar with addition of polyphenols|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols
214383777|NCT05674630|DEVICE|Drug-eluting stent-based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the control arm will receive treatment with drug-eluting stent followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
214383778|NCT02565121|DRUG|corticosteroids|
214383779|NCT02565121|BEHAVIORAL|olfactory stimulation|stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
214383780|NCT03573661|DEVICE|Breast Cancer Locator (BCL)|This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
214383781|NCT04263103|OTHER|SJ-RS-WL2015 visual training program software|It is a software with perceptual learning methods for binocular functions
214383782|NCT03399162|BEHAVIORAL|PREHAB Workshop|PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
214383783|NCT03399162|BEHAVIORAL|PREHAB Exercise Program|An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
214383784|NCT04804995|OTHER|There is no intervention.|No intervention.
214383785|NCT03290612|DIETARY_SUPPLEMENT|Vitamin C|1.5g Ascorbic Acid
214383786|NCT03290612|OTHER|Placebo|Inactive placebo to mimic 1.5g ascorbic acid.
214383787|NCT02871830|BEHAVIORAL|Physical Activity|15 mins physical activity per day within the school setting.
214383788|NCT06437093|OTHER|TEACHING RELACTATION TECHNIQUES|"In our midwifery intervention, the mother was firstly educated about breastfeeding and relactation, using educational brochures prepared by the researchers. Afterwards, the mother was taught nipple stimulation, skin-to-skin contact and finger feeding method, and the first feeding of the baby was performed together with the mother. After this first intervention in the FHC, all interventions were performed at home. The follow-ups continued for 15 days with one day of telephone support and one day of home visit. Since the majority of mothers did not accept video calls (privacy, etc.), telephone support was provided only verbally."
214383789|NCT02778126|DRUG|[¹⁴C]Prexasertib|Administered IV Infusion
214383790|NCT02778126|DRUG|Prexasertib|Administered IV Infusion
214383791|NCT04547270|OTHER|Ultrasound scan|Volunteers will have an ultrasound scanning of both sides of their neck lying in supine position. Sequentially the scanning will start from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. Images will be recorded as video loops.
214383792|NCT00352898|BIOLOGICAL|MeMuRu-OKA (study vac)|
214383793|NCT00352898|BIOLOGICAL|MMR, Varicella vacc (control)|
214383794|NCT01424475|GENETIC|Healthy|Healthy Volunteers
214498987|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
214498988|NCT00743574|DRUG|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
214996470|NCT06072638|BEHAVIORAL|Eating in Absence of Hunger|Researcher gives child free access to palatable foods following a satiating meal.
214996471|NCT02290184|BEHAVIORAL|PilAm Go4Health Weight-loss Program|This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).
214996472|NCT02290184|BEHAVIORAL|Active Control|This is a 3-month active control using a pedometer only without any education related to wt loss, physical activity, health eating, or tracking healthy behaviors
214383795|NCT01424475|GENETIC|PKD Patients|PKS Patients
214383796|NCT01655602|PROCEDURE|Trichophytic closure upper edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
214383797|NCT01655602|PROCEDURE|Trichophytic closure lower edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
214383798|NCT01655602|PROCEDURE|Trichophytic closure both edge trimming|'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
214383799|NCT00926003|BEHAVIORAL|Full Computerized cognitive training|8 weeks of 3 times weekly intervention for 60 min per session with the full titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning
214498989|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
214996473|NCT06184282|DRUG|MEBO|MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
214996474|NCT06184282|DRUG|Lidocaine|Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
214996475|NCT06280651|OTHER|dietary preferences and their implications for oral health in children with Autism Spectrum Disorder|This study design typically does not involve interventions. Instead, it observes and analyzes existing conditions or behaviors-in this case, dietary preferences and their implications for oral health in children with Autism Spectrum Disorder (ASD)-without the researchers applying any specific treatment or experimental condition to the participants. The aim is to identify correlations or patterns at a specific point in time, rather than to assess the effects of an intervention.
214996476|NCT02354118|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
214996477|NCT02354118|OTHER|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
214996478|NCT04103008|DIAGNOSTIC_TEST|Speckle tracking echocardiography|assess left ventricular function on admission and after 40 days
214383800|NCT00926003|BEHAVIORAL|Limited computerized cognitive training|Locked Captain's Log CCRT that rotates randomly among simplest level of computer cognitive games training. 8 weeks of 3 times weekly intervention for 60 min per session with the non-titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning).
214383801|NCT05787158|OTHER|Muscle energy techniques|Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles. (21). Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes
214383802|NCT01204268|PROCEDURE|Sev-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
214383803|NCT01204268|PROCEDURE|Sevo continuous inhalation|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
214383804|NCT01589562|DRUG|Megace 800mg/20ml|Megestrol acetate 800mg/20ml, Suspension, Single dose
214383805|NCT01589562|DRUG|DW-ES(B) 625mg/5ml|Megestrol acetate 625mg/5ml, Nano suspension, Single dose
214383806|NCT01986361|DRUG|flurbiprofen|A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
214383807|NCT01986361|DRUG|placebo|A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
214383808|NCT00002760|DRUG|ketoconazole|400 mg PO tid for as long as treatment is effective
214383809|NCT00002760|DRUG|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
214383810|NCT00002760|OTHER|Withdrawal of antiandrogen therapy|no drugs given
214996479|NCT03345823|DRUG|Upadacitinib|Oral; Tablet
214996480|NCT03345823|DRUG|Placebo for Upadacitinib|Oral; Tablet
214996481|NCT01180062|DRUG|Latanoprost|"Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost."
214996482|NCT01180062|DRUG|Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
214383811|NCT02109198|DEVICE|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
214996483|NCT01180062|DRUG|Latanoprost SR insert|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
214996484|NCT04781062|DIAGNOSTIC_TEST|Blood and urine molecular analysis (Timing 0)|peripheral blood and urine sample collection
214383812|NCT02109198|DEVICE|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
214498990|NCT00743574|DIETARY_SUPPLEMENT|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
214687542|NCT03124173|OTHER|Third session of fMRI|In this session (involving a human-specific condition and a condition we hope to achieve in the monkey), subjects will have to learn by trial-error in successive trials, conditional associations between three abstract stimuli and three verbal or Vocals.
214996485|NCT04781062|DIAGNOSTIC_TEST|Blood and urine molecular analysis (Timing 1)|peripheral blood and urine sample collection
214996486|NCT01069939|DRUG|Esomeprazole|20mg, capsule, 72 weeks
214996487|NCT01069939|DRUG|Placebo|Placebo, capsule, 72 weeks
214996488|NCT05166876|DRUG|Brequinar Sodium|50 mg, 100 mg, 150 mg, 200 mg x 5 days
214498991|NCT00449774|DRUG|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
214498992|NCT00449774|DRUG|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
214498993|NCT03022968|DRUG|[18F]T807 PET|Imaging with \[18F\]T807 PET
214498994|NCT05085535|OTHER|Manual Therapy|Exercises for body mobility and muscle toning, Sophrology, musculoskeletal oscillatory manual therapy
214498995|NCT05085535|OTHER|Exercise|Exercises for body mobility and muscle toning, Sophrology
214996489|NCT05166876|DRUG|Dipyridamole 75 MG|75 mg TID for 5 days
214996490|NCT05166876|DRUG|Placebo|50 mg, 100 mg, 150 mg, 200 mg x 5 days
214996491|NCT05790590|DIAGNOSTIC_TEST|Double low dose CT|Simultaneous reduction of both radiation dose and contrast media dose
214996492|NCT05790590|DIAGNOSTIC_TEST|Standard dose CT|CT with standard radiation dose and contrast media dose
214996493|NCT03755817|DEVICE|SCENAR application|Active SCENAR application on the painful area
214996494|NCT03755817|DEVICE|SCENAR application with the device off|Placebo SCENAR application on the painful area
214996495|NCT01982864|DRUG|Gentamicin|"The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.~Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance…).~The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD)."
214996496|NCT05919134|DIETARY_SUPPLEMENT|Dentoblis|dissolve the tablets in the mouth once a day for 4 weeks
214996497|NCT05919134|DIETARY_SUPPLEMENT|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
215093248|NCT06981247|OTHER|Routine care arm|Participants in the routine care arm will receive educational material in the form of paper-based pamphlets to ensure they still benefit from basic health information on CVD risk prevention. They will continue their usual work routines without access to the app, but their PA and dietary habits will be assessed at baseline, post-intervention and at follow-up for comparative purposes.
215093249|NCT06575400|DRUG|BI 3804379|BI 3804379
215093250|NCT06575400|DRUG|Placebo matching BI 3804379|Placebo matching BI 3804379
215093251|NCT06979986|PROCEDURE|Endoscopic Submucosal Dissection with Systematically mediastinal Lymph Node Dissection|Participants will be evaluated for inclusion criteria and exclusion criteria, and then sign informal consent if desired. Participants will be randomly assigned to the intervention according to a prepared random tables. Participants in the SLND group will receive Endoscopic Submucosal Dissection with systematically mediastinal lymph node dissection
214996498|NCT01544231|BIOLOGICAL|Plasma NGAL level|The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
214996499|NCT01577914|DRUG|Carvedilol Tablets USP 12.5 mg|12.5mg tablet once a day
214996500|NCT01577914|DRUG|Carvedilol|12.5mg tablet once a day
214383813|NCT02801188|DRUG|Bupivacaine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
214996501|NCT02402062|DRUG|TH-302 + Sunitinib|"Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle."
214383814|NCT02801188|DRUG|Mixture of bupivacaine and dexmedetomidine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
214383815|NCT04555902|BEHAVIORAL|Postcard|The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.
214383816|NCT04555902|BEHAVIORAL|Small Gift|Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.
214383817|NCT04555902|BEHAVIORAL|Loss Frame and Fear Appeals|The postcard is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by stating the risks of breast cancer, while also stating that a mammogram screening is an accessible way to address those risks.
214383818|NCT06014138|DRUG|Propofol|Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
214383819|NCT06014138|DRUG|Isoflurane|Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
214996502|NCT01994031|DRUG|Paclitaxel liposome injection|
214996503|NCT01994031|DRUG|Paclitaxel injection|
214996504|NCT01890993|DRUG|liraglutide|Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
214996505|NCT01390506|DRUG|Sodium-selenite|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
214996506|NCT01390506|DRUG|Placebo|0,9% sodium chloride is administered intravenously
214996507|NCT00555854|BEHAVIORAL|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
215093252|NCT06979986|PROCEDURE|Endoscopic Submucosal Dissection without SLND|Participants will be evaluated for inclusion criteria and exclusion criteria, and then sign informal consent if desired. Participants will be randomly assigned to the intervention according to a prepare random tables. Participants in the non-SLND group will just receive Endoscopic Submucosal Dissection treatment, not undergo Systematically mediastinal Lymph Node Dissection.
215093253|NCT06980662|OTHER|laughter yoga|Laughter yoga is a type of complementary therapy that also includes some other components, including light physical exercises. This type of therapy combines unconditional laughter with yoga breathing exercises and yoga stretching positions, enabling patients to laugh in a different way from jokes or humour programmes. Laughter yoga steps; Warm-up exercises (5-10 minutes), Deep breathing exercises (10 minutes), Childish games (10 minutes), Laughter exercises (15 minutes). During laughter yoga, laughter is achieved without any jokes, comedy or humour and supports the realisation of a sincere laughter that does not involve cognitive thinking in individuals. Laughter yoga sessions should be done at home in a quiet and calm environment by making eye contact. Laughter yoga is applied in sessions that include warm-up, breathing and laughing exercises accompanied by applause and songs. The sessions take place in groups and last 45 minutes.
215093254|NCT06979622|OTHER|ultrasound combined with electromagnetic positioning guidance|TIPS procedure under ultrasound combined with electromagnetic positioning guidance
214996508|NCT00385840|BIOLOGICAL|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
215093255|NCT06980246|OTHER|Plyometric Exercise|The Plyo-Ex program was conducted for 45 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.
214996509|NCT00385840|BIOLOGICAL|FluarixTM|Single dose, intramuscular injection
215093256|NCT06980246|OTHER|Standard exercise program|The standard exercise program lasted for 45 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, coordination exercise, and functional training.
215093257|NCT06981169|DIAGNOSTIC_TEST|FeNO|FeNO measured with a NIOX VERO device before the respiratory test
215093258|NCT06981169|DIAGNOSTIC_TEST|blood sample|Blood sample for measuring the blood eosinophil count
215093259|NCT06979895|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
215093260|NCT06979895|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
215093261|NCT06979570|DEVICE|AttentivU|"A device for continuous brain and physiology monitoring. It includes up to 8 EEG sensors as well as EOG and accelerometry which can be monitored in real-time for changes in attention, sleepiness, alertness, cognitive load, stress, and related psychological traits. The EEG data is analyzed in real-time to identify these states and this information can then be used to modulate countermeasures to the state--to either increase or decrease alertness or help counteract cognitive load sleepiness or stress conditions."
214498996|NCT04383184|PROCEDURE|tracheoplasty|tracheoplasty and only left pulmonary artery transplantation
214996510|NCT04227834|BEHAVIORAL|Health hygiene education|A cartoon video explaining the etiology, risk factors, clinical symptoms, treatment and prevention of helminthiasis were given to the school-aged children
214996511|NCT04923451|DEVICE|Active Trans-cranial direct current stimulation (tDCS)|5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed
214996512|NCT04923451|DEVICE|Sham Trans-cranial direct current stimulation (tDCS)|5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed
214383820|NCT06017830|DEVICE|Physical treatment agents|Physical treatment agents such as TENS (transcutaneous electric nerve stimulation), hot pack and ultrasound will be applied to patients with low back pain. Sexual function will be assessed before, just after and 3 months later physical therapy.
214383821|NCT02837562|OTHER|Slit lamp eye examination|All participants in the trial will undergo a slit lamp eye examination
214383822|NCT00202774|DRUG|(capecitabine, oxaliplatin, 5-fluorouracil)|
214383823|NCT03791502|OTHER|Pilates Method Exercises|Pilates Method exercises performed on the apparatus, on the ground and with accessories. They will always be performed by a physiotherapist with teaching certification in the Pilates methodology and will be supervised by two properly trained physiotherapy trainees. Participants will start the exercise program in small groups of up to 8 people, twice a week for 60 minutes, for 12 weeks, totaling 24 sessions. The first day of intervention for both groups will be devoted to explaining the six principles described by Joseph Pilates: centralization, concentration, control, precision, fluidity and breathing, and some fundamentals such as the neutral position of the spine. And in all sessions, these principles will be remembered by the physiotherapist.
214383824|NCT02260076|DRUG|PEG 400|
214383825|NCT02260076|DRUG|Placebo|
214687543|NCT06226571|DRUG|SNDX-5613|Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
214687544|NCT06226571|DRUG|Chemotherapy Regimen|Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
214996513|NCT02823119|DEVICE|Mini-hysteroscopy|Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm. All of the procedures will be diagnostic.
214383826|NCT02430363|DRUG|MK - 3475|Administered Intravenously
214383827|NCT02430363|BIOLOGICAL|Suppressor of the PI3K/Akt pathways|Capsules orally with food
214383828|NCT02408237|DEVICE|Active tDCS Ambulatory|Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
214383829|NCT02408237|DEVICE|Sham tDCS Ambulatory|In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
214383830|NCT02408237|DEVICE|Active tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
214687545|NCT06226571|DRUG|HiDAC|Consolidation: Participants will receive HiDAC IV.
214687546|NCT05031910|OTHER|Medical Device Usage and Evaluation|Undergo virtual reality imaging via VR/3D-CEPs
214687547|NCT05031910|OTHER|Best Practice|Receive standard of care
214996514|NCT02823119|DEVICE|Conventional Office Hysteroscopy|. Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm. All of the procedures will be diagnostic.
214996515|NCT04587817|COMBINATION_PRODUCT|camrelizumab+hyperfractionated radiotherapy|Immunotherapy combined with hyperfractionated radiotherapy
214996516|NCT03982537|DRUG|N-Acetyl-L-Cysteine dietary supplement|Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
214996517|NCT03982537|RADIATION|Chemotherapy and Radiation|Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
214996518|NCT00692796|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
214996519|NCT02970045|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and other biological samples
214687548|NCT05031910|PROCEDURE|Resection|Undergo surgical resection
214687549|NCT01027910|DRUG|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
214687550|NCT01027910|DRUG|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
214687551|NCT01027910|DRUG|GCSF|Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
214687552|NCT05376345|BIOLOGICAL|LCAR-BCDR cells product|Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen
214996520|NCT02970045|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
214996521|NCT02970045|OTHER|Medical Chart Review|Review of medical chart
214996522|NCT02970045|OTHER|Quality-of-Life Assessment|Ancillary studies
214996523|NCT02970045|OTHER|Questionnaire Administration|Ancillary studies
214996524|NCT02414061|DIETARY_SUPPLEMENT|Whey Protein (Arla Foods Ingredients Group)|20 g whey protein isolate added to breakfast meal
215093262|NCT06979947|BEHAVIORAL|Structured Menopause Education Program|The structured education program was developed by midwifery researchers and delivered face-to-face by a certified midwife over four weekly sessions. Each session lasted approximately 20-25 minutes and covered topics such as menopausal symptoms, lifestyle changes, and coping strategies. Educational materials were individualized based on participants' MENQOL pre-test scores.
215093263|NCT06981377|DIAGNOSTIC_TEST|Analysis of cell free DNA, and extracellular vesicles (EVs) and EV-associated molecular components (including RNA, DNA, proteins)|"Plasma and buffy coat samples are shipped from the recruiting clinical sites to the lab of Professor Francesca Demichelis at the University of Trento (UniTN).~At UniTN, samples are stored in dedicated freezers with restricted access and subsequently used as follows:~* the plasma is used for the isolation of cell free DNA and extracellular vesicles (EVs);~* the buffy coat is used for the extraction of genomic DNA.~Nucleic acids sequencing library preparations and all downstream omics analyses are performed by Prof. Demichelis team."
215093264|NCT06983522|DEVICE|Toilet training booklet|Education on the subject of motherhood, the concept of motherhood and the role of motherhood. Education on parental attitudes, types of attitudes. Education on education in school, the age of starting education, the duration of education, signs of readiness for child toilet training, Brazelton's child-focused approach and characteristics of toilet training, the effects of parents' attitudes on toilet training and education on problems that may be encountered during toilet training. It covers the topics.
215093265|NCT06663046|BIOLOGICAL|Single dose injection of certain dose of UWD-00B|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-00B cells
215093266|NCT06658496|DEVICE|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 72 hours after birth to monitor regional tissue oxygenation.
215093267|NCT05445518|BEHAVIORAL|Jump Start Plus COVID Support|The Jump Start Plus COVID Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
215093268|NCT05445518|BEHAVIORAL|Healthy Caregivers-Healthy Children (HC2)|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom.
215093269|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength VitaJoy (ES/VJ)|Extra Strength VitaJoy Capsule, 2 capsules in the morning
215093270|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength Vita Calm (ES/VC)|Extra Strength Vita Calm Capsule, 2 capsules in the evening
215093271|NCT06579183|DIETARY_SUPPLEMENT|Placebo|Placebo Capsule, 4 capsules in the morning and evening respectively
215093272|NCT06981104|DRUG|0.05% cyclosporine eyedrops|0.05% cyclosporine, one drop each time, twice a day
215093273|NCT06981104|DRUG|0.1% sodium hyaluronate eye drop|0.1% sodium hyaluronate, one drop each time, three times a day
215093274|NCT06993974|DRUG|Mesalamine|Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.
215093275|NCT06993974|DRUG|Nitazoxanide|Nitazoxanide is an FDA-approved oral medication used to treat protozoal infections and is also effective against metronidazole-resistant Clostridium difficile colitis.
214383831|NCT02408237|DEVICE|Sham tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
214383832|NCT05720234|DRUG|avatrombopag|Patients with body weight ≥50kg were given 60mg/day and patients with body weight \< 50kg were given 40mg/day for 12 weeks.
214383833|NCT06129201|OTHER|Tongue image|Using intelligent imaging devices to collect subject tongue images
214383834|NCT05166525|OTHER|Medically tailored meals|Compare medically tailored meals vs. medically tailored meals with enhanced nutritional counseling vs. usual care
214383835|NCT03340558|BIOLOGICAL|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
214383836|NCT03340558|DRUG|Cobimetinib|MEK inhibitor
214383837|NCT04576364|DRUG|Magnesium sulfate for 12 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
214383838|NCT04576364|DRUG|Magnesium sulfate for 24 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
214383839|NCT00406224|DRUG|breathing 100% oxygen|
214383840|NCT00374660|DRUG|Oxaliplatin|Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 40 to 80 mg/m\^2 by dose escalations in 10 mg/m2 increments if no dose-limiting toxicity.
214383841|NCT00374660|DRUG|Irofulven|Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered as a 30-minute infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 0.30 to 0.40 mg/kg if no dose-limiting toxicity.
214383842|NCT06183814|BIOLOGICAL|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.
214383843|NCT04840277|DEVICE|Remote hearing aid adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
214383844|NCT02255396|OTHER|ESTRADIOL|
214996525|NCT02414061|OTHER|Breakfast meal|Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
214996526|NCT03504553|OTHER|Noise reduction|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
214996527|NCT01785901|OTHER|without interventions|without interventions
214996528|NCT00002129|DRUG|Vesnarinone|
214383845|NCT01736501|OTHER|Genetics education at baseline|
214383846|NCT01736501|OTHER|Hypothetical genomic scenarios at follow-up|
214498997|NCT01507506|RADIATION|Radiotherapy|"Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~\+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
214498998|NCT01507506|RADIATION|Experimental arm|"Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA\> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~\+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
214498999|NCT03529305|DEVICE|rTMS|Receive rTMS treatment to the primary motor cortex (M1)
214499000|NCT03529305|OTHER|Physical therapy|Receive physical therapy
214996529|NCT01017250|RADIATION|Stereotactic Radiosurgery (SRS)|Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
214996530|NCT01017250|DRUG|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
214996531|NCT05548894|DEVICE|stabilization splint|upper acrylic splint rest on the maxillary teeth and had flat surface
214996532|NCT05548894|DEVICE|laser therapy|The laser apparatus had a hand piece on which either a specially designed optic prism was attached to transfer laser energy to the tip of the prism
214383847|NCT02281526|DRUG|BIA 2-093|
214996533|NCT05548894|DEVICE|stabilization splint and laser therapy|the stabilization splint used in combination of treatment with laser therapy
214996534|NCT06652958|BIOLOGICAL|VH4527079|VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
214996535|NCT06978842|DEVICE|Wearable EEG headband for passive brain signal acquisition|This intervention involves the use of non-invasive, consumer-grade wearable EEG headbands to passively record brain activity from individuals with epilepsy in their natural home environments. The devices include BrainBit Headband, BrainBit Mindo, BrainBit Headphones, Muse 2, and Muse S. These devices transmit EEG signals via Bluetooth to a mobile application developed by the sponsor. The app provides real-time feedback on signal quality and securely uploads data to the cloud for offline analysis. The wearable devices are used solely for passive data acquisition and are not being evaluated for safety or therapeutic effectiveness in this study. No changes are made to clinical care or treatment.
214996536|NCT05406232|PROCEDURE|Biopsy|Undergo tumor punch biopsy
214996537|NCT05406232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214383848|NCT05171413|OTHER|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with soft tissue sarcoma.
214383849|NCT05958498|COMBINATION_PRODUCT|injectable platelet rich fibrin and microosteoperforation|i-PRF which second product of blood versus mops which is surgical procedure
214383850|NCT00077311|BIOLOGICAL|darbepoetin alfa|200 mcg sub Q on day 1 of each cycle if HgB \< or = 11 g/dL
214383851|NCT00077311|BIOLOGICAL|pegfilgrastim|6 mg sub Q day 2 of each cycle
214383852|NCT00077311|DRUG|cisplatin|75 mg/sq m IV over 1 hr Day 1 of each cycle
214383853|NCT00077311|DRUG|docetaxel|75 mg/sq m IV over 1 hr Day 1 of each cycle
214499001|NCT05421117|PROCEDURE|Laparoscopic adnexal mass extraction|Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
214499002|NCT03204032|DRUG|Tegafur|Tegafur 40-60mg po bid(d1-d14);
214499003|NCT03204032|DRUG|Temozolomide|200mg po qd(d10-d14)
214499004|NCT03204032|DRUG|Thalidomide|Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
214499005|NCT04819698|OTHER|Troponin I (cTnI ) monitoring|cTnI will be measured at baseline prior to surgery, as well as on 1h,12h, 24h and 72h after surgery for each patient in study B.
214499006|NCT05316259|DRUG|BPI-16350|Administered orally
214499007|NCT01664741|DRUG|Nicotine patch - transdermal|21 mg patch
214499008|NCT01664741|DRUG|placebo|
214499009|NCT04535856|DRUG|allogeneic mesenchymal stem cell|"Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)"
214499010|NCT04535856|OTHER|Placebo|Control group (placebo)
214996538|NCT05406232|RADIATION|Radiation Therapy|Undergo RT
214996539|NCT06827457|DRUG|GenSci120|Administered SC.
214996540|NCT06827457|DRUG|Placebo|Administered SC.
214383854|NCT00077311|DRUG|BNP7787|40 g IV over 30 min Day 1 of each cycle
214383855|NCT00267696|DRUG|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
214383856|NCT00267696|DRUG|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
214996541|NCT01858961|DRUG|BI 201335|Once a day
214996542|NCT01858961|DRUG|ribavirin|Twice a day
214996543|NCT01858961|DRUG|BI 207127|Twice a day
214996544|NCT01858961|DRUG|Telaprevir|Three times a day
214996545|NCT01858961|DRUG|ribavirin|Twice a day
214996546|NCT01858961|DRUG|Pegylated Interferon|Once a week
215093276|NCT06673407|BEHAVIORAL|Group Exposure for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears.
214499011|NCT02448069|DRUG|Argatroban|All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
214499012|NCT05132049|DRUG|DA-5211|single dose administration (DA-5211 one tablet once a day)
214499013|NCT05132049|DRUG|DA-5211-R1 + DA-5211-R2|single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
214499014|NCT03212885|DEVICE|Deep Brain Stimulation|Electrode that provides electrical stimulation to deep brain structures for relief of Parkinson's Disease symptoms.
214499015|NCT05211232|DRUG|Tislelizumab|GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
214499016|NCT05211232|DRUG|Placebo|GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
214499017|NCT01809457|OTHER|educational poster|educational poster for dental trauma
214499018|NCT05511545|OTHER|Patient Education Booklet|Excretory system organs, signs and symptoms to be seen in kidney and ureteral stones, treatment methods, ureteroscopy procedure, what to do before and on the morning of surgery, and surgery, using the training booklet prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. An average of 25-30 minutes of training was given in the patient's room in an encouraging language, allowing the patient to ask questions about the situations he would encounter in the clinic after the surgery. She started asking questions she didn't understand. Afterwards, the questions of the patients were answered and the patient was given a training booklet.
214499019|NCT04243200|OTHER|Hypos can strike twice|"The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover."
214499020|NCT06000800|OTHER|Group B|Umbilical cord clamping at 30 seconds
214499021|NCT06000800|OTHER|Group C|Umbilical cord clamping at 60 seconds
214499022|NCT06000800|OTHER|Group D|Umbilical cord clamping at 90 seconds
214499023|NCT06000800|OTHER|Group A|Umbilical cord clamping immediately after birth (5 second)
214499024|NCT01171638|DEVICE|Near infrared spectroscopy (NIRS)|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
214383857|NCT00267696|DRUG|Carboplatin|
214499025|NCT04433780|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC
214499026|NCT01131546|DRUG|Levamlodipine besylate|Once daily, 7AM - 10AM
214996547|NCT01235377|OTHER|Favor one of two thiazides for new prescriptions & attempt target dose|Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
214383858|NCT03034499|PROCEDURE|Single-port sacrocolpopexy|Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
214499027|NCT01131546|DRUG|Amlodipine maleate|Once daily, 7AM - 10AM
214499028|NCT00236847|DRUG|topiramate|
214499029|NCT05991804|OTHER|Transcutaneous spinal cord stimulation added to inpatient rehabilitation|Non-invasive electrical stimulation delivered over the spine, targetting movement of the upper limbs
214499030|NCT05991804|OTHER|Inpatient rehabilitation alone|Standard inpatient rehabilitation given at the Royal National Orthopaedic Hospital NHS Trust
214383859|NCT03034499|PROCEDURE|Multi-port sacrocolpopexy|Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
214499031|NCT04905784|BEHAVIORAL|Differential learning|The patient will be requested to perform different exercises, each exercise one time a day for 3 days in a row before moving to the next exercise. All patient will be asked to do the exercises in the same sequence.
214499032|NCT04905784|BEHAVIORAL|Usual toothbrushing|The patients in this group will be provided with the regular oral health instructions, including the traditional toothbrushing recommendations.
214499033|NCT06465550|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
214499034|NCT03936166|DRUG|CRN01941 Oral Solution|Investigational drug
214499035|NCT03936166|DRUG|CRN01941 Oral Capsule|Investigational drug
214996548|NCT03424148|DEVICE|Excel V™ Laser & Micro-Lens Array Attach|Subjects will receive laser treatments
214383860|NCT00305383|DRUG|Viramidine|
214383861|NCT00305383|DRUG|Peginterferon alfa-2b|
214499036|NCT03936166|DRUG|Placebo Oral Solution|Placebo
214499037|NCT03936166|DRUG|Placebo Oral Capsule|Placebo
214499038|NCT06415994|DRUG|Buprenorphine or Methadone Treatment|Pregnant mothers must be taking Buprenorphine or Methadone
214499039|NCT06415994|DIAGNOSTIC_TEST|Fetal and Placental MRI|"Two MRIs :~* Second Trimester~* Third Trimester"
214499040|NCT06415994|BEHAVIORAL|Child Developmental Assessment|At 1 year of life child will receive a developmental assessment
214499041|NCT06415994|BEHAVIORAL|Questionnaires|Participants will answer questionnaires on their medical history, pregnancy, substance use, and after birth: their child's development
214499042|NCT06415994|OTHER|Blood and Placental Samples|"At each MRI visit a blood sample will be collected for substances, DNA, RNA, epigenetics, and placental biomarkers.~At delivery: A sample of placenta will be collected for RNA, DNA, and epigenetic analysis."
214499043|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
214499044|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
214383862|NCT03697980|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
214383863|NCT02440984|PROCEDURE|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
214383864|NCT05821413|BEHAVIORAL|Data to care|Participants meet with a case manager who asks about health, basic needs such as housing and finances, and relationships and support systems. A score is assigned that reflects how much support is needed. A care plan is developed to address areas of need. The case manager meets regularly with participants to determine if needs are being met and identify strategies for meeting those needs. Participants with higher scores will receive more intensive contact with case managers, typically every month, until their level of need goes down. All participants will have their level and types of needs reassessed to determine if they need additional support or are moving toward self-management. Participants work with case managers for 6 months.
214383865|NCT05821413|BEHAVIORAL|Standard of Care|Participants can use standard case management and other services offered by the clinic.
214383866|NCT03696030|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given HER2-CAR T cells via intraventricular administration
214383867|NCT06423378|DEVICE|OSSIOfiber® Trimmable Fixation Nails|"Subjects will be treated with cannulated nails before or after arthroscopic management of their concomitant pathology at the discretion of the investigator. Technique described below. Following nail placement, tissue layers will be closed in standard fashion.~1. Preop MRI views used to estimate the proper depth \& location of nail placement on the femur and/or tibia~2. Exposure is gained to medial tibia~3. 1.4 mm K-Wire is placed through medial tibia parallel to the articular joint surface \~ 1 cm distal to the articular joint line~4. A depth gauge is placed over K-Wire to determine required length of cannulated nail~5. A 4.0 mm cannulated drill bit used over K-Wire to prepare the pilot hole~6. Tamp is used to insert pre-trimmed 4.0 mm cannulated nail into the pilot hole and K-Wire is subsequently removed~7. Intraop fluoroscopy can confirm adequate nail placement prior to removing K-wire~8. Repeat steps for additional nails"
214383868|NCT00539279|BEHAVIORAL|Prolonged Exposure Therapy (PE)|PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
214383869|NCT00539279|BEHAVIORAL|Relaxation Training (RT)|RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
214499045|NCT06835920|BEHAVIORAL|Front-of-package health warning|Participants will receive 3 different health warnings about alcohol consumption. The warnings will discuss health risks of alcohol including cancer, high blood pressure, and scarring of the liver. Labels will be placed on the front of participants' alcohol containers.
214499046|NCT06835920|BEHAVIORAL|Control label|Participants will receive a label displaying a barcode. Labels will be placed on the front of participants' alcohol containers.
214996549|NCT00535470|DRUG|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
214996550|NCT03603613|BEHAVIORAL|YRI|The YRI is designed to assist youth facing complex problems using evidence-based treatments that have been tested and shown to work well in other settings and cultures. The YRI has three specific goals: 1) develop emotion regulation skills for healthy coping; 2) develop problem-solving skills to assist with achieving goals, and; 3) improve interpersonal skills to enable healthy relationships and effective communication. It integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
214996551|NCT03603613|BEHAVIORAL|EPP|The youth capacity development component of GIZ's EPP includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use. Our YRI curriculum will be used for the psychosocial competency training module.
214996552|NCT03860155|BIOLOGICAL|allo-APZ2-ACLF|Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.
214996553|NCT01416779|BEHAVIORAL|Writing Intervention|Finding Balance Writing Intervention
214996554|NCT03913247|OTHER|Size Measurement using a measuring tape, a caliper and a metric|Each patient will have the following measure: measure of the span, the tibia, the ulna, the distance between the hill and the knee, the head, the trunk and the leg. The different measures will be done using a measuring tape and with a caliper. Before leaving the intensive care unit, each patients will be measured according to the WHO standard, that is to say strictly lengthened, using a metric for patient younger than 2 and stand up using a stadiometer for patient older than 2.
214996555|NCT00872742|BEHAVIORAL|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
214996556|NCT00872742|BEHAVIORAL|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
214996557|NCT06057857|OTHER|conventional oral examination|conventional oral examination
215093277|NCT06673407|BEHAVIORAL|Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from the investigators' previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during the investigators' quality improvement project, that are designed to enhance compassion.
215093278|NCT06673407|BEHAVIORAL|Peer-Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
214383870|NCT05485415|BEHAVIORAL|Multimodal intervention|Participants in the intervention group will receive personalised advice on sleep, light exposure, meal times and physical activity.
214996558|NCT06512987|OTHER|technology-driven, interactive ICU diary|Through the diary platform, patients can share their feelings and needs, while family members can send supportive messages, pictures, and videos. Healthcare providers will use the platform to connect with families and monitor patient conditions.
214996559|NCT02056132|OTHER|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
214996560|NCT05626088|OTHER|No Intervention|This is a non-interventional study.
214383871|NCT05485415|BEHAVIORAL|Control|General sleep advice
214383872|NCT02178644|DRUG|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
214996561|NCT02647177|OTHER|Pancreatic Cyst Aspiration|10 CC of pancreatic cyst aspiration
214383873|NCT01381419|DRUG|GSK1144814|Single dose.
214996562|NCT05899114|OTHER|Transitional Multidisciplinary Pharmacotherapeutic Care|"A structured medication review with improved transitional care and multidisciplinary collaboration.~TMPC consists of the following four elements:~1. A structured pharmacotherapeutic analysis~2. A transitional multidisciplinary discussion.The treating physician in the hospital will be involved. The general practitioner and community pharmacist will be consulted.~3. An interview and discussion with the patient and/or legal representative by a member of the Pharmacotherapy-team, which will be performed before the patient is discharged from the hospital.~4. A discharge note with the pharmacotherapeutic care plan. This will be sent to the community pharmacist and the general practitioner."
214996563|NCT06810973|BEHAVIORAL|SUCCESS-E|"SUCCESS-E is a previously developed intervention based on the evidence-based Antiretroviral Treatment and Access to Services (ARTAS) intervention, modified for those detained within a jail system. It is a manualized six-session program delivered by a case management team, composed of a professional case manager and paraprofessional peer navigators.~In Jail Sessions:~1. Build Trust~2. Assess Strengths~3. Explore life on ART~   Post-Release Sessions:~4. Link with care~5. Enhance self-efficacy for HIV care/PrEP~6. Future transitions"
214383874|NCT01381419|DRUG|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
214383875|NCT01381419|DRUG|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
214383876|NCT03408743|BEHAVIORAL|Knowledge Alone|Increase knowledge relate d STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.
214383877|NCT03408743|BEHAVIORAL|Self-efficacy alone|Increase self-efficacy to us e protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383878|NCT03408743|BEHAVIORAL|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214383879|NCT03408743|BEHAVIORAL|Benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383880|NCT03408743|BEHAVIORAL|Injunctive norms alone|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
214499047|NCT00686465|OTHER|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
214499048|NCT04516226|OTHER|Vaginal cleansing with chlorhexidine gluconate solution|Cleansing of the vaginal walls with chlorhexidine gluconate solution for women diagnosed with PPROM
214499049|NCT02432066|DRUG|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
214499050|NCT02432066|DRUG|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
214499051|NCT04178421|OTHER|Computerized training program|Eye-gaze fixation computer based training program
214499052|NCT04178421|OTHER|Placebo|Pac-Man, Zookeeper, Tetris
214383881|NCT03408743|BEHAVIORAL|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214499053|NCT03884842|BIOLOGICAL|Dupilumab/Dupixent|a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
214499054|NCT03884842|BIOLOGICAL|Placebo|Matched placebo
214499055|NCT04518709|PROCEDURE|Posterior Mitral Annulus Elevation Technique|Posterior mitral annulus elevation technique is performed using a large pledget and non-absorbable braided suture starting from the subvalvular section of the posterior mitral valve sutured to the ring annuloplasty (if in the process of repairing the mitral valve, ring implantation is performed; if without the use of ring annuloplasty, the suture is placed in the left atrial wall / supravalvular of PML), so that the posterior annulus is slightly attracted upward toward the cranial and the PML moves toward the center.
214499056|NCT04518709|PROCEDURE|Conventional Mitral Valve Repair|Conventional mitral valve repair in the pediatric patient using annuloplasty, leaflet resection and plication, sliding-plasty of chordae technique
214996564|NCT06810973|BEHAVIORAL|Enhanced Standard of Care|A list of referral sites for follow-up SUD care will be shared. This information sharing without strength-based, longitudinal case management will be an enhancement to treatment as usual. Also, information about HIV/PrEP follow-up in the community will be placed around the jail, such as affixed to the nurses' medication carts that they push from housing unit to unit, twice a day when residents are due for prescription medications.
214996565|NCT06810973|BEHAVIORAL|Key Informant Interviews|Key informant interviews (KII) will be conducted with jail staff and community stakeholders in the R61 phase to examine perceptions, barriers, and facilitators to SUD and HIV/PrEP service and treatment utilization, as well as document the experiences of SUCCESS-E participants from the pilot phase.
214996566|NCT03684889|BIOLOGICAL|SCRI-huCAR19v1|1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
214996567|NCT03684889|BIOLOGICAL|SCRI-huCAR19v2|Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
214996568|NCT06443632|BEHAVIORAL|WASPE Sleep Adjustment Protocol|Parents are instructed to implement the WASPE protocol (Watching videos, Activities outdoors, Stimulation to stay awake, Playing with toys, and Eating snacks) to keep the child awake from morning until the scheduled RT slot (14:00-16:00), thereby inducing natural deep sleep during RT without pharmacologic sedation. Treatment setup is verified with CBCT and monitored in real time using OSMS with a 5-mm motion threshold.
214996569|NCT06443632|DRUG|Chloral Hydrate|Oral or rectal chloral hydrate (typically 30-50 mg/kg, maximum 1 g) administered approximately 30 minutes before each RT fraction per institutional pediatric sedation protocol. Vital signs are monitored continuously. CBCT and OSMS are used as in the experimental arm.
214996570|NCT06811636|PROCEDURE|Lesion sterilization and tissue repair|Lesion sterilization and tissue repair therapy performed with a triple antibiotic mixture.
214996571|NCT06811636|PROCEDURE|Conventional pulpectomy|Conventional pulpectomy with calcium hydroxide-iodoform based root canal paste.
215093279|NCT06673407|BEHAVIORAL|Peer and Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from the investigators' previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during the investigators' quality improvement project, that are designed to enhance compassion. These groups are facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
215093280|NCT03298841|DEVICE|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:~Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
215093281|NCT03772054|DRUG|Sevoflurane|Inhalation anesthetic agent
214996572|NCT03872401|DRUG|Evolocumab|Administered subcutaneously using an autoinjector pen.
214996573|NCT03872401|DRUG|Placebo|Administered subcutaneously using an autoinjector pen.
214996574|NCT06815692|BEHAVIORAL|Psychoeducation|Focus on understanding mechanisms of concussion
215093282|NCT03772054|DRUG|Propofol|Intravenous anesthetic agent
215093283|NCT01399216|DIETARY_SUPPLEMENT|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
215093284|NCT01399216|DIETARY_SUPPLEMENT|Placebo|for 8 weeks
215093285|NCT03029507|BEHAVIORAL|ACT Enhanced ShipShape|The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.
215093286|NCT03029507|BEHAVIORAL|Standard ShipShape (SS)|The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
215093287|NCT06872749|OTHER|Placebo gel|will receive the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
215093288|NCT06872749|OTHER|KF2 (Potassium nitrate gel)|will receive application of potassium nitrate gel on hypersensitive dental surfaces, in an active way, for 10 minutes.
215093289|NCT06872749|OTHER|experimental Copaiba gel|will receive the application of the experimental desensitizing gel on the vestibular surfaces of the hypersensitive teeth in an active manner, for 10 minutes.
215093290|NCT05327972|DRUG|The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).|Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance.
215093291|NCT05327972|OTHER|PLACEBO|Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance.
215093292|NCT03606772|OTHER|Questionanniare|Filling printed questionnaire + Pelvic examination
215093293|NCT00309062|BIOLOGICAL|Recombinant birch pollen|
215094744|NCT04778800|DRUG|LM-second line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
214996575|NCT06815692|BEHAVIORAL|Physiotherapy|Gradual training and physical exercises
214996576|NCT06815692|BEHAVIORAL|Treatment of tinnitus and increased sound sensitivity|Treatment given individually or in groups
214499057|NCT02268708|PROCEDURE|Oncological pulmonary resection|Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
214996577|NCT06815692|BEHAVIORAL|Vision training and examination|Training and examination by a neuro-optometrist
214996578|NCT06815692|BEHAVIORAL|Sleep guidance and education|Counselling to achieve better sleep and reduce fatigue.
214996579|NCT06815692|BEHAVIORAL|Mindfulness with a cognitive therapeutic approach|Training by certified mindfulness instructor
214996580|NCT06815692|BEHAVIORAL|Employment-oriented intervention|The Concussion Team therapists work with a patient's employer to facilitate a gradual return to normal working hours.
214499058|NCT04082507|DIAGNOSTIC_TEST|Serum alpha-fetoproteine|Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
214499059|NCT01478594|DRUG|Tivozanib|Capsules for oral administration
214499060|NCT01478594|DRUG|Bevacizumab|Solution for intravenous infusion
214996581|NCT06815692|BEHAVIORAL|Energy management and graded exercise|Counselling to achieve more energy and vitality.
214996582|NCT06815692|OTHER|Neuropsychological counseling|Talks with a neuropsychologist about mTBI sequelae.
214996583|NCT06811038|DEVICE|iCanQuit Smartphone App Smoking Cessation Program|Receive access to iCanQuit app, with daily push notifications
214996584|NCT06811038|DRUG|Nicotine Gum|Receive nicotine replacement therapy gum
214996585|NCT06811038|DRUG|Nicotine Patch|Receive nicotine replacement therapy patch(es)
214996586|NCT06811038|DRUG|Nicotine Lozenge|Receive nicotine replacement therapy lozenge(s)
214996587|NCT06811038|OTHER|Survey Administration|Ancillary studies
214996588|NCT06811038|OTHER|Interview|Ancillary studies
214996589|NCT06597058|DRUG|MAR|Once-daily tablet
214996590|NCT06086054|BEHAVIORAL|Navigation and EMR referral to childcare facility|See arm description
214383882|NCT03408743|BEHAVIORAL|Injunctive norms and benefits|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383883|NCT03408743|BEHAVIORAL|Injunctive norms, benefits, self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383884|NCT03408743|BEHAVIORAL|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
214383885|NCT03408743|BEHAVIORAL|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214996591|NCT06983210|DRUG|Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy|To explore the efficacy and safety of the combination of tamivarotene (AM80), gemcitabine, cisplatin, and nivolumab in the treatment of patients with untreated unresectable or recurrent urothelial cancer
214383886|NCT03408743|BEHAVIORAL|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214383887|NCT03408743|BEHAVIORAL|Descriptive norms, benefits, self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383888|NCT03408743|BEHAVIORAL|Descriptive norms and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
214383889|NCT03408743|BEHAVIORAL|Descriptive and injunctive norms, self-efficacy|orrect misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383890|NCT03408743|BEHAVIORAL|Descriptive and injunctive norms, and benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214499061|NCT01478594|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
214499062|NCT05768282|DRUG|Oral prednisolone (30mg/day) for 28 days|Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
214499063|NCT04275583|DRUG|TQB3602|This is a kind of proteasome inhibitor.
214499064|NCT06158672|BEHAVIORAL|Emotional freedom technique group|Menopausal women in the emotional freedom technique group will be administered the emotional freedom technique by the researcher a total of 4 times at one week intervals.
214499065|NCT06158672|BEHAVIORAL|Sham emotional freedom technique group|Menopausal women in the sham emotional freedom technique group will be administered sham emotional freedom technique by the researcher a total of 4 times with one week intervals.
214499066|NCT01903902|DEVICE|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length \< 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
214499067|NCT05555095|BEHAVIORAL|digital health delivered multicomponent intervention|The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.
214499068|NCT05676931|DRUG|Domvanalimab|Administered as specified in the treatment arm
214996592|NCT05630066|DRUG|Alogabat|Alogabat will be administered QD with dose depending on cohort and age of the participant.
214996593|NCT06614127|DEVICE|Dexcom G7® sensor placed in upper arm and positioned over deltoid|"For the subjects with Dexcom G7® sensor placed in the upper arm and positioned over the deltoid cohort, study personnel will place the Dexcom G7® sensor on the subjects' deltoid and the electrodispursive pad on the thigh."
214996594|NCT06614127|DEVICE|Dexcom G7® sensor placed in anterior thigh|"For the subjects with Dexcom G7® sensor place in anterior thigh cohort, study personnel will place the Dexcom G7® sensor in the anterior thighs and the electrodispursive pad will be placed on the opposite thigh."
214996595|NCT06132802|PROCEDURE|Patients who received treatment involving ARS and arthrocentesis only|A 5mm acrylic anterior repositioning splint (ARS) with maxillary coverage was crafted from alginate impressions. After arthrocentesis, the ARS was worn incrementally over six months, starting at two hours and reaching 14 hours daily. In the second week, wear time was continuous, increasing to 24 hours daily (excluding meals) until the sixth month. The ramp was removed in the seventh week. Follow-ups involved grinding the splint by 1mm every four weeks. Arthrocentesis included anesthesia, betadine prep, and using two 18-gauge needles to inject Ringer's lactate solution (100-200 cc) for joint lavage, freeing the disc by moving the lower jaw in various orientations.
214383891|NCT03408743|BEHAVIORAL|Descriptive & injunctive norms, benefits, efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383892|NCT03408743|BEHAVIORAL|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
214383893|NCT03408743|BEHAVIORAL|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383894|NCT03408743|BEHAVIORAL|Expectancies and perceived benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214383895|NCT03408743|BEHAVIORAL|Expectancies, benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383896|NCT03408743|BEHAVIORAL|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
214383897|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383898|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214383899|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383900|NCT03408743|BEHAVIORAL|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
214383901|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, & self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383902|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214499069|NCT05676931|DRUG|Quemliclustat|Administered as specified in the treatment arm
214499070|NCT05676931|DRUG|Zimberelimab|Administered as specified in the treatment arm
214499071|NCT05676931|DRUG|Docetaxel|Administered as specified in the treatment arm
214499072|NCT05676931|DRUG|Platinum-Based Doublet|Administered as specified in the treatment arm
214499073|NCT02381028|OTHER|Human milk and emollient: Apobase creme® (Actavis Norway AS)|Topical application of human milk followed by emollient
214499074|NCT02381028|OTHER|Emollient: Apobase creme® (Actavis Norway AS)|Topical application of emollient
214499075|NCT00143286|DRUG|varenicline (CP-526,555)|
214499076|NCT02011360|OTHER|Low Carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein
214499077|NCT02011360|OTHER|Low Fat diet|Low Fat diet: 65%carb; 15%fat; 20% protein
214499078|NCT02927249|OTHER|Placebo|Given PO
214499079|NCT02927249|DRUG|Aspirin|Given PO
215094745|NCT05042180|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
214499080|NCT02639637|DRUG|Sitagliptin|Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
214499081|NCT02639637|DRUG|Placebo|Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
214499082|NCT02639637|DRUG|Neuropeptide Y|During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
214499083|NCT02639637|DRUG|Enalaprilat|Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
214499084|NCT02639637|DRUG|Valsartan 160mg|Valsartan 160 mg/d for 7 days prior to one of the study days.
215094746|NCT05042180|BEHAVIORAL|CBT|The active comparator receives 14 conventional cognitive behavioral therapy sessions with
215094747|NCT01829022|PROCEDURE|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
214383903|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214996596|NCT06132802|PROCEDURE|Patients who received treatment involving ARS, arthrocentesis, and an I-PRF injection|"A 5mm acrylic anterior repositioning splint (ARS) was crafted from alginate impressions, secured with Adam's clasps on upper first molars. After arthrocentesis, patients wore the splint incrementally over six months, starting at two hours and reaching 24 hours daily (excluding meals). The ramp was removed in the seventh week, and follow-ups included grinding the splint by 1mm every four weeks until it reached 3mm, guided by articulating paper.~Arthrocentesis involved administering anesthesia, prepping the area with betadine, and using two 18-gauge needles to inject 2-3 ml of Ringer's lactate solution for joint lavage. The lower jaw was moved to free the disc and release fibrous tissue. I-PRF preparation included centrifuging collected blood for 3 minutes at 700 rpm, and the resulting I-PRF was injected into the superior joint space of the lavaged joints."
214996597|NCT03966651|DRUG|PRRT with 177Lu-DOTATATE|Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
214383904|NCT03408743|BEHAVIORAL|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
214383905|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214383906|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
214383907|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
214499085|NCT06152640|DEVICE|Deep transcranial magnetic stimulation|"Neuronavigation: The coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC. The Brainways H7 coil with fluid cooling is used to obtain a greater depth of stimulation, up to about 6 cm below the cortex.~dTMS intervention: The intervention targets are at the left and right ACC, once per day, for 28 days. A total of 28 treatments are given. Stimulation mode: stimulation frequency 1Hz, stimulation intensity 100% RMT, number of pulses 150, sequence interval 20s, total 6 trials, 900 pulses."
214499086|NCT06152640|DEVICE|Sham deep transcranial magnetic stimulation|"Neuronavigation: The sham coil is positioned 4 cm in front of the scalp point and foot motor cortex, corresponding to the ACC.~Sham dTMS intervention: The intervention targets are at the left and right ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field), once per day, for 28 days. A total of 28 treatments are given."
214499087|NCT06152640|OTHER|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
214996598|NCT03412032|OTHER|assessment|different assessments in both arms
214996599|NCT02101853|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
214996600|NCT02101853|DRUG|Asparaginase|Given IM or IV
214996601|NCT02101853|BIOLOGICAL|Blinatumomab|Given IV
214996602|NCT02101853|DRUG|Cyclophosphamide|Given IV
214996603|NCT02101853|DRUG|Cytarabine|Given IT and IV or SC
214996604|NCT02101853|DRUG|Dexamethasone|Given PO or IV
214996605|NCT02101853|DRUG|Etoposide|Given IV
214996606|NCT02101853|DRUG|Leucovorin Calcium|Given IV or PO
214996607|NCT02101853|DRUG|Mercaptopurine|Given PO
214996608|NCT02101853|DRUG|Methotrexate|Given IT, IV, and PO
214996609|NCT02101853|DRUG|Mitoxantrone|Given IV
214996610|NCT02101853|DRUG|Mitoxantrone Hydrochloride|Given IV
214996611|NCT02101853|DRUG|Pegaspargase|Given IV
214996612|NCT02101853|OTHER|Pharmacological Study|Correlative studies
214996613|NCT02101853|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
214383908|NCT02490891|DEVICE|RGD K5 PET scan|PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
214383909|NCT03221660|DEVICE|F-Composite 2 system|Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
214383910|NCT02708433|DRUG|Lidocaine|Lidocaine
214383911|NCT06358040|DEVICE|Opioid-Dispensing Device|Addinex Opioid-Dispensing Device
214383912|NCT06358040|OTHER|App|Addinex App
214383913|NCT06358040|OTHER|Standard Opioid Pill Bottle|Standard Opioid Pill Bottle
214383914|NCT06527547|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Treatment using the Huatuo electronic acupuncture device (model SDZ-IIB) with electrodes placed on the auricular points related to the heart and kidney. Pulsed wave type is sparse-dense wave, with a frequency of 20Hz and intensity set to the highest level tolerable without pain. Patients will perform self-treatment at home for 30 minutes, twice daily, for 5 days a week over 4 weeks.
214383915|NCT06527547|DEVICE|Sham Stimulation|Treatment using the same Huatuo electronic acupuncture device with electrodes placed on different ear points (over the ear helix). The device settings (pulse type, frequency, intensity) are the same as the experimental group but do not correspond to traditional acupuncture points. Patients will also perform self-treatment at home as per the same schedule as the experimental group.
214383916|NCT05371509|DEVICE|Myofunctional therapy (MT) nozzle|Water bottle nozzle designed to allow the user to repeatedly perform the tongue suction, tongue press, and swallow exercise movements while also providing targeted resistance to train and improve tongue, soft palate, and pharyngeal muscle strength and endurance.
214383917|NCT05371509|OTHER|Placebo nozzle|The placebo bottle nozzle will look similar to the MT nozzle; but is not expected to function the same as the MT nozzle.
214383918|NCT05840861|DRUG|Vortioxetine|All MDD patients will receive 5mg of Vortioxetine per day at the start of this study, which will be gradually increased to 10mg per day within one week.
214383919|NCT05840861|DRUG|Quetiapine|All patients with bipolar disorder will receive 50mg of Quetiapine at day 1, 100mg of Quetiapine at day 2, 200mg of Quetiapine at day 3, and 400mg of Quetiapine per day since day 4.
214383920|NCT06660212|DEVICE|Photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. Doses will increase from 40%-100% power over the course of the intervention
214383921|NCT06660212|DEVICE|Sham photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants tolerance. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. . Doses will always be set to 1% power over the course of the intervention
214383922|NCT06660212|PROCEDURE|Multimodal physiotherapy|A total of 10 sessions of multimodal physiotherapy interventions will be provided to each of the participants in the multimodal physiotherapy (mPT) and multimodal physiotherapy combined with photobiomodulation treatment (mPT+PBM) groups. In general, each session will take place in the following order:1) Subjective assessment of the condition and screening for adverse effects or deterioration of the condition, 2)Education, 3) Relaxation Techniques, 4) Pelvic Floor Muscle Exercises, 5) Manual techniques, 6) exercises with accommodators, 7) Global exercises, 8) Assessment of the post-treatment condition and 9) adjustment of the weekly exercise program to be done at home. Each of these 9 treatments will be adjusted and tailored to each participant and progressed based on individual preference and response to treatment under the discretion of the study physiotherapist.
214383923|NCT01091402|PROCEDURE|autologous serum skin test, serum IL-18|
214383924|NCT06565169|BEHAVIORAL|Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training|Included in arm/group descriptions
214383925|NCT06565169|BEHAVIORAL|Care as Usual|Included in arm/group descriptions
214383926|NCT06924931|BEHAVIORAL|LCME training programme|A LCME training program was conducted from March 2017 to October 2017 in the CDR, inspired by the National English Laparoscopic Colorectal Surgery Course. All certified colorectal surgeons from three public hospitals in the CDR were invited. The training programme was conducted over 2-3 days, occurring twice within an 8-month period.
214383927|NCT06926582|DRUG|HS-10374 6mg tablets|Administered orally QD for 12 weeks
214383928|NCT06926582|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 12 weeks
214383929|NCT06926101|DEVICE|dental implants|dental implant placement by full or partial thickness flap
214383930|NCT06925048|DRUG|PD-1 inhbitor+SHR0302|PD-1 inhbitor+SHR0302 in the maintenance treatment
214383931|NCT06925048|DRUG|PD-L1 inhibitor+SHR0302|PD-L1 inhibitor+SHR0302 in second line
214383932|NCT06925763|DRUG|Nitroglycerin|cardiac disease treatment drug
214383933|NCT06926504|BEHAVIORAL|The care process S-TeamBirth|The intervention consists of the entire care team conducting huddles together with the birthing woman and her partner to plan the care, using the S-TeamBirth whiteboard to communicate and visualize decisions
214383934|NCT06926504|BEHAVIORAL|S-TeamBirth|Involving the entire care team including the woman and her partner in planning the care using team huddles and the S-TeamBirth whiteboard
214383935|NCT06926127|GENETIC|Whole Exome Sequencing (WES)|Blood samples, buccal swabs, and pathological tissue samples (skin/muscle) will be collected, and subsequently, DNA extracted from those tissues will be used for genomic analysis using Whole Exome Sequencing. The sample will follow the diagnostic pipeline already established inside the hospital. Moreover, the remaning aliquots of DNA extracted from the tissue (peripheral blood or tissue specimen) will be sent by the Genomics core facility to the Biobank for storage upon analysis completion.
214996614|NCT02101853|DRUG|Therapeutic Hydrocortisone|Given IT
214996615|NCT02101853|DRUG|Thioguanine|Given PO
214996616|NCT02101853|DRUG|Vincristine|Given IV
214996617|NCT02101853|DRUG|Vincristine Sulfate|Given IV
215094748|NCT02807870|DRUG|Methylphenidate|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).
214383936|NCT06925568|OTHER|No Intervention: Observational Cohort|"This is an observational study, so there is no direct intervention. However, the study involves documenting and analyzing the existing management strategies, including~* use of diagnostic tools ECG, troponin tests, etc~* Administration of medications such as antiplates and anticoagulants.~* Reperfusion therapies -thrombolysis, PCI"
214383937|NCT06925841|OTHER|Experimental|Two pre-selected mother-baby themed images to be used in the study will be printed separately on A4-sized papers (21.0 cm × 29.7 cm). Each participant will receive a new image every day.At the beginning of the study, each participant will be provided with a set of 12 colored pencils (orange, red, pink, purple, light blue, dark blue, light green, dark green, light brown, dark brown, black, and white). Colored pencils have been preferred over soft-tipped pencils due to their requirement for greater physical effort and their ability to facilitate a clearer expression of emotions. Participants in the intervention group will receive routine care and will engage in a 30-minute daily coloring activity.
214383938|NCT06925841|OTHER|routine care|The control group will receive routine care provided by the nurse.
214383939|NCT06926413|DRUG|Aumolertinib；midazolam|"Midazolam :~The enrolled subjects will receive a single oral dose of Midazolam 2 mg (2 mg/mL, 1 mL) on D1 of the run-in period and on C2D1.~Aumolertinib :~Starting from C1D1, the enrolled subjects will receive oral dose of aumolertinib 110 mg (55 mg/tablet, 2 tablets) once daily until the criteria for terminating treatment are met."
214383940|NCT06891937|BEHAVIORAL|Positive psychology|5-week positive psychology intervention
214383941|NCT06895317|BEHAVIORAL|Remote rehabilitation|To develop and validate a quantitative assessment system based on wearable sensors
214383942|NCT06895317|BEHAVIORAL|Rehabilitation face to face|Compare the validity of face-to-face physiotherapy with remote physiotherapy
214383943|NCT06810518|DEVICE|ALPCO Calprotectin CLIA|Measurement of calprotectin in feces
214996618|NCT06371274|DRUG|ATRA|ATRA is the main active metabolite of vitamin A. Studies have shown that ATRA can also reduce the number of MDSC in solid tumor patients, promote their differentiation and maturation, remove the immunosuppressive ability of MDSC, improve the tumor immune microenvironment, and thus improve the tumor treatment efficacy.
215093294|NCT05063201|DRUG|Cariprazine 1.5 MG|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
214383944|NCT06897670|OTHER|Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.|"Functional near-infrared spectroscopy (fNIRS) transcutaneously measures changes in oxyhemoglobin in the prefrontal cortex using light detection. It is designed to measure variations in cerebral hemodynamics on a real-time basis by radiating a near light beam, at two wavelengths of 780nm and 850nm of laser, into the cerebral cortex.~Participants will undergo a one-time functional near-infrared spectroscopy (fNIRS) procedure to measure cerebral hemodynamic patterns.~* Resting-State Measurement: 5-10 min resting-state scans.~* Task-Based Measurement: Participants will be shown an instruction video. Participants will complete a Verbal Fluency Task (VFT) during the fNIRS scan (15-20 min).~* During the fNIRS scan, optional basic vital signs will be measured using respiratory belts, photoplethysmography (PPG), and electrocardiogram (ECG).~* Each participant will complete 3 sets of resting-state and task-based measurements.~Total estimated time for fNIRS assessment: 45-60 min."
214383945|NCT05172206|OTHER|symptom-focused rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
214499088|NCT04144335|BIOLOGICAL|N-803 and bNAbs|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
215093295|NCT05063201|DRUG|Placebo|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
214499089|NCT04144335|BIOLOGICAL|haNK™ Cells|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
214996619|NCT06371274|DRUG|Toripalimab|Toripalimab is a fully human monoclonal antibody injection against PD-1 receptor. The NMPA has accepted the application of Toripalimab for a new indication for the treatment of initial metastatic or relapsed metastatic TNBC with PD-L1 positive (CPS≥1).
214996620|NCT06412601|BEHAVIORAL|RPM|remote patient monitoring by clinic staff
215093296|NCT06879171|PROCEDURE|Alveolar ridge preservation|Grafting of the socket with Autogenous tooth graft mixed with simvastatin immediately after tooth extraction
215093297|NCT06879171|PROCEDURE|Alveolar ridge preservation|Grafting the socket with Autogenous tooth graft immediately after tooth extraction
215093298|NCT00398203|DEVICE|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
215093299|NCT03048760|OTHER|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans \& 1 after approx. 2 weeks of radiotherapy treatment.
214383946|NCT05172206|OTHER|usual care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
214687553|NCT06315218|BEHAVIORAL|iTHRIVE 365 HIV care intervention|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) with mHealth interventions, iTHRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. iTHRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. iTHRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of Black SGLM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
214383947|NCT06899568|PROCEDURE|z mini plate with lingual extension|parasympheseal fracture model fixed with z mini plate with lingual extension
214383948|NCT06899568|PROCEDURE|two mini plates|parasympheseal fracture model fixed with conventional 2 mini plates
214383949|NCT06899672|OTHER|Alginate mixed with distilled water|Alginate will be mixed with distilled water only, without any disinfectant additive, to serve as the control for comparison
214383950|NCT06899672|OTHER|0.2% Chlorhexidine + Alginate|Alginate will be mixed with 0.2% Chlorhexidine solution to evaluate its effect on the linear dimensional stability of alginate impressions
214383951|NCT06899672|OTHER|1% Chitosan + Alginate|Alginate will be mixed with 1% Chitosan solution to assess its influence on the linear dimensional stability of alginate impressions
214687554|NCT06195280|RADIATION|Magnetic resonance imaging, 3DT1 sequence|The patient will have an exploration pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.
214687555|NCT06195280|PROCEDURE|Laparoscopy|After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.
214687556|NCT05183867|DEVICE|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
214996621|NCT06412601|BEHAVIORAL|app|use of Happy Bob phone app
214996622|NCT02112916|DRUG|Bortezomib|Given IV
214996623|NCT02112916|DRUG|Cyclophosphamide|Given IV
215093300|NCT06886542|OTHER|Dual task training|Dual task training is based on the simultaneous maintenance of motor-motor or cognitive-motor performance. The exercises given in single task training will be applied by combining them with cognitive and motor cognitive tasks.
214383952|NCT06899672|OTHER|0.2% Silver Nitrate + Alginate|Alginate will be mixed with 0.2% Silver Nitrate solution to determine its effect on the dimensional stability of alginate impressions
214383953|NCT06899672|OTHER|Green-synthesized Silver Nanoparticles + Alginate|Alginate will be mixed with a solution of green-synthesized Silver Nanoparticles to investigate its effect on the dimensional stability of alginate impressions
214383954|NCT06899672|OTHER|15% Povidone-Iodine + Alginate|Alginate will be mixed with 15% Povidone-Iodine solution to analyze its influence on the dimensional stability of alginate impressions
214383955|NCT06900517|DIETARY_SUPPLEMENT|Salvia officinalis Gel|From each participant, two sites of periodontal pockets ( ≥ 5 mm ) were selected and randomly allocated to either the test site (treated with scaling and RSD with S. officinalis gel) or the control site (treated with scaling and RSD alone).
214383956|NCT06899867|OTHER|Measure of cardiac index with thermodilution and transesophageal echocardiography|At 4 times of surgery, end-expiratory occlusion (EEO) test and measure of cardiac index before and after test with ETO and thermodilution
214383957|NCT06899867|OTHER|Surgical anastomosis echography|Visualisation of surgical anastomosis through transesophageal echocardiography : stenosis, doppler velocity, collar diameter
214687557|NCT04188405|DRUG|Decitabine|Given IV
214687558|NCT04188405|DRUG|Ponatinib|Given PO
214687559|NCT04188405|DRUG|Venetoclax|Given PO
214687560|NCT06672458|DEVICE|MyndMove Short Term Therapy|FES therapy will be provided in one visit (one hour duration) delivered within a 2 week period, in person. FES therapy uses surface electrical stimulation to produce muscle contractions in different combinations to achieve a wide range of reaching and grasping functions. To achieve these movements the single use electrodes will be placed in various combinations on the surface of the different upper arm muscles. Participants will perform hand and finger dexterity tests as well as arm functional mobility tasks while receiving FES.
214687561|NCT06672458|OTHER|Conventional Short Term Therapy|Therapy will be provided in one visit (one hour duration) delivered within a 2 week period, in person. Conventional therapy will consist of performance hand and finger dexterity tests as well as arm functional mobility tasks
214383958|NCT06899997|OTHER|Time-restrictred feeding|Time-restricted feeding pattern consisting of an 8 h eating window (from 6-8 am to 14-16 pm) followed by a 16 h fasting period
214383959|NCT06899997|OTHER|Non-time restricted feeding|14h eating window (from 6-8 am to 8-10 pm), followed by a 10 h fasting period
214996624|NCT02112916|DRUG|Cytarabine|Given IT, IV, or SC
214996625|NCT02112916|DRUG|Daunorubicin|Given IV
214996626|NCT02112916|DRUG|Daunorubicin Hydrochloride|Given IV
214996627|NCT02112916|DRUG|Dexamethasone|Given PO or IV
214996628|NCT02112916|DRUG|Doxorubicin|Given IV
214996629|NCT02112916|DRUG|Doxorubicin Hydrochloride|Given IV
214996630|NCT02112916|DRUG|Etoposide|Given IV
214996631|NCT02112916|DRUG|Hydrocortisone Sodium Succinate|Given IT
214996632|NCT02112916|DRUG|Ifosfamide|Given IV
214996633|NCT02112916|DRUG|Leucovorin Calcium|Given PO or IV
214996634|NCT02112916|DRUG|Mercaptopurine|Give PO
214996635|NCT02112916|DRUG|Methotrexate|Given IT, IV, or PO
214996636|NCT02112916|DRUG|Pegaspargase|Given IV
214996637|NCT02112916|RADIATION|Radiation Therapy|Undergo radiation therapy
214996638|NCT02112916|DRUG|Thioguanine|Given PO
214996639|NCT02112916|DRUG|Vincristine|Given IV
214996640|NCT02112916|DRUG|Vincristine Sulfate|Given IV
215094749|NCT02807870|BEHAVIORAL|Parental training|Weekly parental training conducted by behavioral psychologists.
214383960|NCT06900829|BEHAVIORAL|HIV team implementation|"A local hiv team will be implemented in a certain hospital. This will result in different activities, with a focus on:~* audit and feedback (reminding health care professionals to test for hiv)~* stigma reduction (raising awareness on existing hiv stigma towards hiv)~* education (increasing knowledge on hiv among health care professionals)~* linkage to prevention and care (improving pathways for hiv care and prevention)"
214383961|NCT05859165|DIETARY_SUPPLEMENT|Nutren Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
214383962|NCT05859165|DIETARY_SUPPLEMENT|Fresubin Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
214383963|NCT06899412|OTHER|self adhesive flowable composite|FIT SA is a self-adhesive, light-cured, flowable restorative with two discrete viscosities, F03 (low flow) and F10 (high flow) UDMA,HEMA,Phosphonic acid monomer, S-PRG filler based on fluoroboroaluminosilicate glass, Polymerizationinitiator,Pigments and others, Shofu's exclusive GIOMER technology gives FIT SA the ability to release and recharge fluoride and other beneficial ions for the life of the restoration.
214383964|NCT06899412|OTHER|Conventional flowable composite|Conventional flowable composite (bulk fil)
214499090|NCT06060119|DEVICE|microneedling|The operative sites will be anaesthetized with 2% lignocaine hydrochloride with adrenaline(1:80,000).Electric microneedling pen device model THAPPINKTM is used. Microneedling is carried out on the isolated site involving one tooth mesially and distally and 1.5mm apical to marginal gingiva each for 30-40 second intermittently. When pin point bleeding observed on the area of gingiva it is irrigated with sterile saline solution. Patient will be instructed to refrain from consuming hot beverage and brushing in that area for one day to avoid mechanical trauma. A total of 4 session of micro needling procedure will be carried out in one subject at 10 days intervals upto 40days
214499091|NCT00885313|DRUG|DHA250|DHA 250 mg/kg/d
214499092|NCT00885313|DRUG|DHA500|DHA 500 mg/kg/d
214499093|NCT00885313|DRUG|PLACEBO|placebo
214687562|NCT06672458|DEVICE|MyndMove Long Term Therapy|FES upper arm therapy will be provided in one-hour in-person sessions for a maximum of 40 sessions delivered no less than 3 times per week and up to 5 times per week during a period of up to 12 weeks. Over the course of 40 sessions, participants will progress through various movement sequences aimed at regaining natural, unassisted voluntary movements in the affected arms while receiving FES.
214687563|NCT06401642|DRUG|Zavegepant|10 mg intranasal
214687564|NCT04369053|DIAGNOSTIC_TEST|Freenome test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled. Participants will undergo blood collection and will then complete a standard-of-care screening colonoscopy.
214687565|NCT05299983|OTHER|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
214996641|NCT06794112|OTHER|Animated Educational Video|Both arms will receive standard care (written instructions), with the experimental arm receiving an additional animated video intervention.
214996642|NCT06794112|OTHER|Written Instructions|Standard written instructions for bowel preparation before colonoscopy
214996643|NCT06605963|DRUG|PPV-06|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
215094750|NCT02807870|OTHER|Psychoeducational groups for parents|Weekly psychoeducational groups conducted by educators.
214499094|NCT00885313|BEHAVIORAL|Lifestyle intervention|lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.
214499095|NCT01630226|DRUG|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
214499096|NCT02463448|BIOLOGICAL|Autologous Muscle Derived Cells|A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the sample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
214499097|NCT05838781|DIAGNOSTIC_TEST|Risk prediction model|A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
214996644|NCT06605963|DRUG|Placebo|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
214996645|NCT04501419|PROCEDURE|US-guided breast biopsy|During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
214996646|NCT04501419|OTHER|Ultrasound-guided breast biopsy training program|This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients
214996647|NCT04409002|DRUG|Niraparib|Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment
214996648|NCT04409002|DRUG|Dostarlimab|Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study
214996649|NCT04409002|RADIATION|Radiation|Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1
214996650|NCT05337241|DEVICE|Saline Enhanced Radiofrequency (SERF) Ablation|The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
214996651|NCT06816186|BEHAVIORAL|multimedia|When mothers and their spouses reported to the health classroom on the 37-week prenatal check-up day, the researcher explained the motivation and process of the research. After the women and their spouses agreed to join the study, they were randomly assigned to the experimental group and the control group. The control group will be given general care guidance, while the experimental group will receive general care and multimedia birth control education intervention, and the mothers and their spouses will download and watch the video through Line, an instant messaging software on their mobile phones.
214996652|NCT06816186|BEHAVIORAL|Usual Care|When mothers and their spouses reported to the health classroom on the 37-week prenatal check-up day, The control group will be given general care guidance,
214383965|NCT06900959|COMBINATION_PRODUCT|transcranial static field stimulation (tSMS) and transcranial (tDCS)|"* tSMS is a non-invasive brain stimulation (NIBS) technique that involves the application of a neodymium magnet to the scalp. Since the initial study introducing this method, numerous subsequent studies have confirmed that tSMS can lead to a reduction in corticospinal excitability.~* Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation (NIBS) technique that applies low-voltage electrical currents through surface electrodes on the scalp. Depending on the stimulation type (anodal or cathodal) tDCS can induce long-lasting increases or decreases in neuronal excitability and vascular-neuronal activity coupling. Cathodal stimulation leads to hyperpolarization and a reduction in excitability, whereas anodal stimulation induces depolarization and enhances excitability."
214383966|NCT06926166|OTHER|No intervention|No intervention
214383967|NCT06925711|DEVICE|Near-Infrared Spectroscopy (NIRS)|Controlled hypotensive anesthesia during orthognathic surgery with cerebral oxygen saturation monitoring using Near-Infrared Spectroscopy (NIRS). NIRS was used to continuously monitor regional cerebral oxygen saturation (rSO2) throughout the procedure to observe the effects of controlled hypotension on cerebral perfusion
214383968|NCT06926478|DRUG|Adalimumab Injection|10% (4.0mg/0.04ml) dissolved in sterile saline to be injected once during the time of the Boston Keratoprosthesis (Kpro) Surgery.
214383969|NCT06901180|PROCEDURE|short scar periareolar inferior pedicle reduction mammoplasty|reduction mammoplasty that minimizes scar with better cosmetic outcomes
214996653|NCT05714293|RADIATION|CT scan with contrast medium|Multi-detector CT scan (if possible with prospective-ECG gated sequential scan) with contrast medium injection of nonionic contrast agent. All CT datasets will be analysed for the qualitative and quantitative assessment of the aortic root. The coronary height will be assessed at baseline in relation to the aortic annulus and in relation to the stent of the bioprostheses after aortic valve replacement.
214996654|NCT04468711|DRUG|Vitamin D|Vitamin D plus topical 1% hydrocortisone cream twice daily
214996655|NCT04468711|DRUG|Placebo|placebo plus topical 1% hydrocortisone cream twice daily
214996656|NCT06656845|DEVICE|Genus, a self-management app for patients with knee osteoarthritis|The self-management app (Genus) will include weekly reminders with information videos on knee osteoarthritis and treatment options, exercise videos, quizzes, questionnaires, and a platform for remote monitoring by health professionals.
214996657|NCT02712515|PROCEDURE|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
214996658|NCT02712515|DEVICE|Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips|Ad-Tech Medical Instrumentation Corp. electrodes are intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
214996659|NCT02712515|DEVICE|FHC Guideline 4000+ system and/or Medtronic RC+S|Brain signals will be recorded using the clinical Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
214996660|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose A|altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169
215093301|NCT06886542|OTHER|Single task training|Single task training is a training approach that aims to improve the performance of individuals by focusing on only one task at a time.
215093302|NCT06886542|OTHER|Conventional physiotherapy|Range of motion, stretching, resistance exercises, isometric exercise, Before the treatment, a Hotpack will be applied to warm up the muscles, increase flexibility and improve performance. After exercise, transcutaneous electrical stimulation (TENS) will be used to relieve pain, reduce muscle tension and provide faster recovery.
215094751|NCT02807870|DRUG|Placebo pill|Placebo pill during 8 weeks.
214383970|NCT06900036|PROCEDURE|Platelet-Rich Fibrin (PRF) Application for Alveolar Preservation|This intervention involves the application of platelet-rich fibrin (PRF) in the extraction socket following premolar extraction to assess its effectiveness in alveolar bone preservation. PRF is a biological autologous material derived from the patient's own blood, promoting bone regeneration, wound healing, and tissue repair.
214383971|NCT06212908|OTHER|Basic Periodontal Therapy|All patients received oral hygiene instructions (interproximal cleaning with floss and interdental brushes, brushing instructions on the Bass technique). The patients were also encouraged to brush the back of the tongue once a day. Subsequently, all patients underwent supragingival scaling, prophylaxis, and polishing. Supragingival scaling was performed using manual instruments (Gracey curettes) and an ultrasonic device.
214383972|NCT04326413|PROCEDURE|Oral hygiene instruction and simple scaling|Monitor the changes of gum condition
214383973|NCT06925516|DRUG|Apatinib and Adebrelimab in Combination With chemotherapy|Patients would receive Adebrelimab (IV 1200mg q3w) and apatinib (PO 250mg qd) plus GEMOX (up to 6 cycles) in 21day cycles. Apatinib and Adebrelimab would be maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
214499098|NCT05838781|DIAGNOSTIC_TEST|14-days continuous ECG monitoring|14-days continuous ECG monitoring with an ECG patch.
214499099|NCT03789734|BIOLOGICAL|BLS-M22|BLS-M22 250mg/capsule
214499100|NCT03789734|OTHER|Placebo|BLS-M22 placebo 250mg/capsule
214499101|NCT05623436|BEHAVIORAL|Nursing students will be trained through virtual reality.|Nursing students will be trained through virtual reality.
214499102|NCT06195813|DIETARY_SUPPLEMENT|Asparagus capsule|Asparagus capsule is categorized as dietary supplement.
214499103|NCT06195813|OTHER|Placebo capsule|Placebo capsule is categorized as other.
214499104|NCT03253367|OTHER|Blood is obtained, mostly during routine venipuncture|
214499105|NCT05090631|GENETIC|DNA analysis|GWAS
214499106|NCT01594957|DRUG|LCQ908|Participants will receive a single oral dose of LCQ908
214499107|NCT00144040|BEHAVIORAL|Physician & patient education on appropriate antibiotic use|
214499108|NCT00144040|PROCEDURE|Rapid C-reactive protein testing to guide antibiotic treatment|
214499109|NCT01895582|OTHER|Blood samples|"4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)"
214383974|NCT06912061|PROCEDURE|Needle tendon lengthening technique|"Percutaneous Achilles tendon lengthening with the needle technique is performed by applying a series of microtenotomies to the tendon using needle pricks while the tendon is stretched. A withdrawal needle with a diameter of 1.1-1.2 mm is used. The needle pricks gradually weaken the tendon and stretch it to the desired length without opening the skin or tendon sheath. As a rule, it is desirable to achieve approximately 10-15 degrees of dorsiflexion before concluding the lengthening.~Local infiltration anesthesia is applied, followed by a simple bandage. The surgical procedure typically takes 3-4 minutes. Finally, a boot cast in soft plaster with the foot and ankle in neutral position is applied, and it can be fully weight-bearing immediately.~The cast is removed at the clinic after 4 weeks. After cast removal, the child/adolescent should be allowed gentle activity - not sports - for another 4 weeks, thereafter unrestricted activity.~Physical therapy may be utilized as needed, locally."
214996661|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose B|altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169
214383975|NCT06920667|DIETARY_SUPPLEMENT|Protein-Creatine-Omega-3-Vitamin D Supplement|Participants will receive a daily powdered supplement containing 30 g of whey protein isolate, 5 g of creatine monohydrate, 1 g of omega-3 fatty acids (EPA/DHA), and 1,000 IU of vitamin D3. The supplement will be taken once daily for 12 weeks, dissolved in water. It is designed to reduce glycemic variability and improve metabolic parameters in individuals with recently diagnosed type 2 diabetes.
214383976|NCT06920667|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Participants will receive a daily powdered placebo formulated with maltodextrin, without any active ingredients (no whey protein, creatine, omega-3, or vitamin D). It is identical in appearance, taste, and packaging to the active supplement. It will be taken once daily for 12 weeks and administered in the same conditions as the intervention group.
214383977|NCT06918223|BEHAVIORAL|Thyroid Informed Surgical Consent Augmenting Video (TISCAV)|Participants randomized to the intervention group will receive a surgeon-created Thyroid Informed Surgical Consent Augmenting Video (TISCAV). This 8-minute video includes animated visuals and a surgeon voiceover explaining thyroid anatomy, surgical options (lobectomy vs. total thyroidectomy), risks, benefits, and expectations. The TISCAV was designed and reviewed by an endocrine surgery team to improve patient comprehension, confidence, satisfaction, and reduce decision regret compared to standard verbal consent alone.
214383978|NCT06918223|BEHAVIORAL|Standard Consent|Participants receiving the Standard Consent intervention will undergo the routine informed consent process for thyroid surgery provided by their surgeon. This process includes a verbal discussion covering thyroidectomy procedure details, potential risks and complications, benefits, alternatives such as active surveillance, and an opportunity to ask questions.
214383979|NCT06473012|BEHAVIORAL|Cognitive Behavioral Therapy for Caregivers of Older Adults|Cognitive Behavioral Therapy Intervention for Caregivers of Older Adults is designed to be implemented in a group setting with 12 to 15 caregivers in a group. It consists of 6 weekly sessions, and each session lasts for 90 minutes to 120 minutes. The content of the intervention is based on lifestyle intervention, CBT and effective communication skills. Home practices will be assigned to the participants in between each weekly session.
214996662|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose C|altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169
214996663|NCT06663436|BIOLOGICAL|TYPHIBEV|TYPHIBEV administered intramuscularly on Day 1
214996664|NCT06663436|COMBINATION_PRODUCT|Infanrix hexa|Infanrix hexa administered intramuscularly on Day 169
214996665|NCT06663436|BIOLOGICAL|MR-VAC|MR-VAC co-administered subcutaneously on Day 1 and Day 169
214996666|NCT06663527|COMBINATION_PRODUCT|Fumigating-washing Therapy With CPD|All patients underwent anal fistulectomy based on the Parks classification. For postoperative infection prophylaxis, cefuroxime was used at a dosage of 2g per dose, twice daily. Commencing the day following surgery, a fumigating-washing therapy was conducted once daily either after defecation or two hours prior to intravenous infusion. In the study group, a medical solution used for fumigating-washing therapy was prepared by blending 200 ml of CPD with 2 liters of water at 40 °C. This medicinal solution was then transferred into the reservoir of an ultrasonic atomizing fumigating-washing device (Model:TM50-C, Xuzhou Tianma Medical Equipment Factory, China) that was classified by the FDA as Class II (special controls).
214996667|NCT06663527|COMBINATION_PRODUCT|fumigating-washing therapy with a placebo|fumigating-washing therapy with a placebo
214996668|NCT06666257|BEHAVIORAL|Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy|The intervention we are basing our adaptations on is a ecological momentary intervention, meaning it is integrated into participants daily lifestyle and schedule. Using an established framework for tracking daily body weight and physical activity, a gestational weight gain trajectory is estimated. Based on the data, recommendation prompts for exercise and diet will be discussed with participants during motivational interviewing. For the CGM piece, participants will wear unblinded CGM devices and have access to CGM linked app features that allow insights and reactivity to personal glycemic data
214996669|NCT02850835|OTHER|Video Decision Aid|A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
214996670|NCT00068185|DRUG|Black cohosh|
215093303|NCT01689545|BEHAVIORAL|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
215093304|NCT01689545|BEHAVIORAL|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
215093305|NCT01689545|BEHAVIORAL|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
215093306|NCT01689545|BEHAVIORAL|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
215093307|NCT07088250|DRUG|Atorvastatin Treatment|Atorvastatin 20 mg once daily for 21 days.
215093308|NCT07088250|OTHER|Best Medical Treatment|Patients in this group will receive best medical treatments in accordance with the guideline-directed management for ICH.
215093309|NCT07087431|BEHAVIORAL|Immediate disclosure of non-high CAD PRS|Participants receive their non-high CAD PRS result as soon as it is available after genotyping.
214383980|NCT06473012|BEHAVIORAL|Control intervention for Caregivers of Older Adults|The control group receives 6 weekly education sessions on useful healthcare information (mental health, physical health, health ageing and dementia). Each session lasts for 90 minutes to 120 minutes.
214383981|NCT06923189|BEHAVIORAL|Family Planning Intervention|"This multilevel intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community. The intervention is paired with health system strengthening elements implemented with the intervention health clinics (provider training, strengthening skip the queue policies, linkage of family planning services directly to dialogues)."
214383982|NCT06923189|BEHAVIORAL|Water, Sanitation, and Hygiene (WASH) Intervention|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (handwashing, food preparation) following an intervention manual that was developed for community groups in East Africa and tailored to the local Uganda context."
214383983|NCT06919445|OTHER|'Text Connect' text messages|The Text Connect message includes 1) a link to a FindHelp (an online social resource database available in over 100 languages) search tailored to the recipient's home ZIP code 2) information regarding applying for the Supplemental Nutrition Assistance Program (SNAP), and information regarding applying for the Special Supplemental Program for Women, Infants, and Children (WIC). All text message content was initially developed in consultation with caregivers of children with FI identified during an admission through a Community Engagement studio and was approved by the institution's Effective Health Communication Core. The investigators have adapted the content based on feedback from participants in the pilot study.
214383984|NCT06921616|PROCEDURE|Simple neuroendoscopic hematoma evacuation|For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, only simple neuroendoscopic evacuation of hematoma will be performed
214383985|NCT06921616|COMBINATION_PRODUCT|Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate|"For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, they will be treated with the combination of neuroendoscopic hematoma evacuation and sodium methylprednisolone succinate.~Administer sodium methylprednisolone succinate for injection by intravenous injection 6 hours after the onset of the disease. Specific administration: Intravenous injection at a dosage of 2 mg/kg, once daily, for three consecutive days."
214383986|NCT00297193|PROCEDURE|Autologous haematopoietic stem cell transplant|All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
214383987|NCT04542096|DEVICE|Lung electrical impedance tomography monitoring|A belt for recording changes in electrical impedance in the skin will be fastened for the purpose of this study with no other additional procedures
214383988|NCT06925152|DRUG|Bupivicaine intervention arm|TAP blocks in intervention group will include 0.5% bupivacaine in 30mL solution of 15mL normal saline and 15mL bupivacaine
214499110|NCT01359150|DRUG|CP-690,550|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
215093310|NCT07087431|BEHAVIORAL|Deferred Disclosure of non-high CAD PRS|Participants receive their non-high CAD PRS result after completion of the 12 month follow up period.
215093311|NCT07087899|OTHER|music|listening music
215093312|NCT07087405|DEVICE|Striae Distensae Treatment Device|One time deep skin treatment
214383989|NCT06925152|DRUG|Placebo arm|Placebo group TAP block syringe will include 30mL normal saline
214383990|NCT06925334|DRUG|Degludec insulin|The pre-mixed human insulin or insulin analogues were stopped, and the treatment was switched to Delgol insulin liraglutide injection. The initial dose was subcutaneous injection of 80% (not more than 16 units) of the full daily dose of medium-acting insulin in the original insulin, once a day, and the dose of Delgol insulin liraglutide injection was adjusted according to the fasting blood glucose level. Example 1: If the patient is currently using Novorin 30 20iu bid, the conversion calculation is 40\*70%\*80%=22.4 units, which should be 16 units; In example 2, the patient applied eubrine 50 20 IU bid, and the conversion calculation was 40\*50%\*80%=16 units.
214383991|NCT02805595|DRUG|23.4% Hypertonic saline|Saline Injections
214383992|NCT03491098|DRUG|Mometasone Furoate spray|"Mometasone Furoate spray one puff in each nostril daily for 8 weeks~hypertonic sea water solution spray one puff in each nostril daily for (8) weeks."
214383993|NCT03491098|DRUG|prednisolone sodium phosphate 15mg|three times per day for 1 week then gradual withdrawal over 2 weeks
214499111|NCT01359150|DRUG|placebo|Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
214499112|NCT03656042|DRUG|Filgrastim (75mcg/0.3ml)|"Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~1. 10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~2. Non-treatment"
214499113|NCT03504904|BEHAVIORAL|Internet-Delivered ACT and CFT|An 8-week internet-based intervention focused on acceptance and compassion. Psychological intervention based on Acceptance and commitment therapy and compassion focused therapy
214499114|NCT00569387|BIOLOGICAL|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
214499115|NCT04105387|PROCEDURE|Early Tracheostomy Change|The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
214499116|NCT05240794|DEVICE|ABM-01|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)
215093313|NCT03701997|DEVICE|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
214996671|NCT05676554|OTHER|An Enhanced Psychological Mindset Session for Adolescents|"It is a ten-minute psychoeducation video (animation) delivered on the internet, followed by five minutes of stories from fictional students about how they used the concepts. Participants then complete three multiple choice questions aimed to assess their understanding and ability to apply concepts from the video, followed by 'letter of advice' task where participants have to give advice to a fictional younger student based on the information presented in the animation and videos.~The intervention itself was developed by Perkins et al (2021) based on promoting a growth mindset. It was deemed to be a feasible and acceptable tool to promote mental health (Perkins et al., 2021) in their feasibility trial."
214383994|NCT03491098|DRUG|hypertonic sea water solution spray|one puff in each nostril daily for 8 weeks
214383995|NCT03073460|OTHER|Ultrasound examination|This exam is performed at 40 weeks gestation
214383996|NCT02981784|DRUG|Ponatinib (Iclusig®)|Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.
214383997|NCT02981784|PROCEDURE|allogeneic stem cell transplantation|
214383998|NCT03770013|DRUG|bupivacaine|bupivacaine 0.25% a total volume of 40 ml (20 ml each side
214383999|NCT03770013|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg
214384000|NCT03770013|DRUG|clonidine|1ug/kg clonidine
214384001|NCT03770013|DRUG|placebo|add placebo 9normal saline)
214384002|NCT05569824|DIAGNOSTIC_TEST|Lateral-flow Device|An additional amount of 0.1-0.2 ml (2-4 drops) of bronco-alveolar lavage (BAL) fluid will be collected during the bronchoscopy which is carried out as part of the standard of care. The LFD test will be carried out on the BAL fluid collected.
214384003|NCT02769065|DRUG|TAK-071|TAK-071 capsules
214384004|NCT02769065|DRUG|Donepezil|Donepezil over-encapsulated tablet
214384005|NCT02769065|DRUG|TAK-071 Placebo|TAK-071 placebo-matching capsules
214996672|NCT04166019|BEHAVIORAL|Peer-led self-management program|The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
214384006|NCT02769065|DRUG|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
214384007|NCT06228664|OTHER|foam rolling|Foam Rolling Technique on trapezius and suboccipital muscles.conventional therapy (15 min Hot pack, neck isometric exercises and cervical ROM exercises within pain free range). Patients will be treated 3 times per week for 6 consecutive weeks
214384008|NCT06228664|OTHER|bowen therapy|Bowen Therapy. conventional therapy (15 min Hot pack, neck isometric exercises and cervical ROM exercises within pain free range) will be given to both groups. Patients will be treated 3 times per week for 6 consecutive weeks
214384009|NCT00519246|DRUG|Saline|Saline 5 ml administrated intravenously
214384010|NCT00519246|DRUG|Opioid|Butorphanol tartrate 1 mg i.v.
214384011|NCT00519246|DRUG|Opioid|Butorphanol Tartrate 2 mg i.v.
214499117|NCT05240794|DEVICE|Digital Control|Placebo control for ABM-01
214996673|NCT04166019|BEHAVIORAL|Psycho-education group|The psycho-education group program is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
214384012|NCT00519246|DRUG|NSAID|Flurbiprofen Axetil 50 mg i.v.
214384013|NCT00519246|DRUG|NSAID|Flurbiprofen Axetil 100 mg i.v.
214384014|NCT00519246|DRUG|Opioid|Tramadol Hydrochloride 10 mg i.v.
214384015|NCT00519246|DRUG|Opioid|Tramadol Hydrochloride 20 mg i.v.
214384016|NCT00552786|DRUG|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
214384017|NCT00552786|DRUG|glucose|1 gm glucose capsule
214384018|NCT00003241|DRUG|phenylacetate|
214384019|NCT02764775|DEVICE|Headpod|Adaptive equipment to assist with active head movements
214384020|NCT02910518|DRUG|Insulin glulisine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214384021|NCT02910518|DRUG|Insulin glulisine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214384022|NCT02910518|DRUG|Insulin aspart|"Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous"
214384023|NCT02910518|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214384024|NCT02910518|DRUG|Glucagon|"Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous"
214384025|NCT02910518|DRUG|Glucose|"Pharmaceutical form: solution~Route of administration: intravenous"
214384026|NCT02910518|DRUG|Heparin|"Pharmaceutical form: solution~Route of administration: intravenous"
214384027|NCT00268619|DRUG|Ramipril|
214384028|NCT05544058|OTHER|Retrospective study|Retrospective study
214384029|NCT00933842|DRUG|LACTIC ACID(ND)|Treatment duration: 5 weeks
214384030|NCT03549234|DRUG|Erector Spinae (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
214384031|NCT03549234|DRUG|Paravertebral (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
214499118|NCT06175299|BEHAVIORAL|Adherence Promotion With Person-centered Technology (APPT) System with Social Functions|The system has seven games for cognitive training and two social interactions functions: a chat function and a leaderboard function.
214499119|NCT02477813|DRUG|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
214499120|NCT00690404|DRUG|AZD2066|single oral dose
214499121|NCT03113409|DRUG|Buprenorphine|Buprenorphine will be administered daily
214499122|NCT03113409|DRUG|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
214499123|NCT03113409|DRUG|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
214384032|NCT04142814|PROCEDURE|T-PEP|"First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist."
214384033|NCT04142814|PROCEDURE|IPV|IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
214996674|NCT04166019|BEHAVIORAL|Usual care|Routine care services consist of monthly psychiatric consultation and treatments prescribed by psychiatrist, nursing advice on community care, brief education (1-2 hourly sessions) about mental illness/treatments by psychiatric nurses, home visits by case managers, and/or referrals to community/welfare services.
214384034|NCT05878223|DEVICE|Extracorporeal shock waves|Both group received extracorporeal shock waves therapy
214384035|NCT05056064|OTHER|Oral exercise|exercise remain tongue
214384036|NCT05176782|DRUG|HTK cardioplegia|will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
214384037|NCT05176782|DRUG|Cold Cadioplegia|as the will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
214384038|NCT05696418|PROCEDURE|Total knee arthroplasty with a Mobile Bearing system.|The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Mobile Bearing system without resurfacing the patella.
214996675|NCT03923075|DRUG|Dexmedetomidine|INFUSION BEFORE INDUCTION OF ANAESTHESIA
214384039|NCT05696418|PROCEDURE|Total knee arthroplasty with a Fixed Bearing system.|The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Fixed Bearing system without resurfacing the patella.
214384040|NCT06285942|DRUG|Edoxaban|To use of Edoxaban via PEG in patients with an indication to anticoagulation therapy according to current guidelines
214384041|NCT06285942|DRUG|No Edoxaban|Other DOACs through PEG or subcutaneous heparin or LMWH
214384042|NCT00288197|DRUG|voriconazole|
214384043|NCT03396731|DEVICE|geko™ medical device|The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.
214996676|NCT03923075|OTHER|0.9% saline|INFUSION BEFORE INDUCTION OF ANAESTHESIA
215093314|NCT04495868|DRUG|Bacteriostatic Normal Saline|A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
215093315|NCT04495868|DRUG|1% Lidocaine|A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
215093316|NCT05080634|OTHER|Patients who underwent POEM|chalasia patients were recruited from a single center. The pre- and postoperative assessments included Eckardt scores, GerdQ questionnaire, high-resolution esophageal manometry, esophagogastroscopy and pH monitoring.
215093317|NCT04862728|OTHER|- Strong kids screening tool - Stamp screening tool - PYMS screening tool|Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP) evaluates patient's clinical diagnosis, nutritional intake during hospitalization and anthropometric measurements, developing a care plan based on the child's overall malnutrition risk (low, medium or high).Screening Tool for Impaired Nutritional Status and Growth (STRONG kids). It consists of four items: subjective clinical assessment, high-risk diseases, nutritional intake and losses, weight loss or poor weight gain. Patients classified at high nutritional risk have a longer hospitalization and a negative standard deviation score (SDS) for weight-for-height (WFH), which indicated a state of acute malnutrition.The Pediatric Yorkhill Malnutrition Score (PYMS) is adopted among medical and surgical patients between 1 and 16 years of age. The PYMS assesses four items: BMI, history of recent weight loss,
215093318|NCT01988545|OTHER|1,5 nmol/kg,GLP-1 sc injection|
214499124|NCT01016457|DEVICE|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
215093319|NCT01988545|OTHER|1,5 nmol/kg GLP-1 9-36amide, sc injection|
214384044|NCT00814515|DRUG|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
214996677|NCT05710679|BIOLOGICAL|Blood sample|"The intervention consist in a blood sample that will be taken twice :~* at the inclusion (before treatment)~* 3 months after the radiochemotherapy in case of incomplete response (PET-CT)"
214384045|NCT00814515|DRUG|NOVA22007|Vehicle
214384046|NCT03289390|DRUG|Acetaminophen|Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
214384047|NCT04853901|DRUG|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days
214384048|NCT04853901|DRUG|Standard of care_1|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days
214384049|NCT04853901|DRUG|Standard of care_2|Methylprednisolone 1-2mg/kg for 5-7 days
214384050|NCT00991159|BIOLOGICAL|RN316|Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
214499125|NCT03537326|DRUG|Budesonide|Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
215093320|NCT01988545|OTHER|Exendin-4 ;10 ug,sc injection|
215093321|NCT01988545|OTHER|saline|
215093322|NCT00300677|DRUG|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
215093323|NCT05096754|DEVICE|OCS Liver|Transplant with an OCS preserved liver.
214384051|NCT00767104|OTHER|Silk like Pillowcase|sleep on silk-like pillowcase each night
214384052|NCT00767104|OTHER|Cotton Pillowcase|Sleep on placebo cotton pillowcase each night
214384053|NCT05601713|OTHER|No cooling (control)|Participants are exposed to 38°C, 35% relative humidity for 6 hours without cooling interventions (control condition). Drinking water is available ad libitum.
214384054|NCT05601713|OTHER|Lower limb immersion|Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. Drinking water is available ad libitum.
214384055|NCT05601713|OTHER|Lower limb immersion + neck cooling|Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. During limb immersion, a towel soaked in cool water (\~20°C) is placed around the participants neck. The towel is re-wet half way through the 40-min limb immersion. Drinking water is available ad libitum.
214384056|NCT05860725|BEHAVIORAL|PSA Development|Health sciences students from a regional community college in Appalachian Virginia will be asked to to develop and submit a public service announcement (PSA) and to watch virtual training webinars that support the development of the PSAs. They will also be asked to complete surveys at three time points: before the PSA contest starts, after the PSA contest ends, and upon submitting a PSA.
214384057|NCT05860725|BEHAVIORAL|HPV vaccination focused social marketing campaign|Community members who use a regional health services focused non-profits rideshare buses and/or view their social media pages will be exposed to a 12-week social marketing campaign that uses PSAs developed in Phase 1. Community members will also complete surveys at three time points: before the start of the social marketing campaign, during the social marketing campaign, and after the social marketing campaign.
214384058|NCT02783820|DRUG|MMV390048 40 mg|
214499126|NCT05555901|DRUG|Fruquintinib+ chemotherapy|"Second-line treatment : Fruquintinib+FOLFIRI Drug: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off, q4w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Fruquintinib+Capecitabine Drug: Fruquintinib 4mg, orally, once daily, 2 weeks on/ 1 week off, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
214499127|NCT05555901|DRUG|Bevacizumab+ chemotherapy|"Second-line treatment : Bevacizumab+FOLFIRI Drug: Bevacizumab 5mg/kg on day 1, q2w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Bevacizumab+Capecitabine Drug: Bevacizumab 7.5mg/kg on day 1, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
214499128|NCT01487837|DRUG|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
214499129|NCT01544907|DEVICE|Conventional PTA|Use of conventional balloon for angioplasty only
214499130|NCT01544907|DEVICE|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
214499131|NCT02401932|OTHER|Hemophagocytosis|Best supportive care and immunosuppressive treatments
214384059|NCT02783820|DRUG|Placebo to match MMV390048 40 mg|
214384060|NCT02783820|DRUG|MMV390048 80 mg|
214384061|NCT02783820|DRUG|Placebo to match MMV390048 80 mg|
214384062|NCT02783820|DRUG|MMV390048 120 mg|
214499132|NCT00877019|DEVICE|Sonicare elite medium brush head|
214499133|NCT00877019|DEVICE|Sonicare elite mini brushhead|
214499134|NCT00877019|DEVICE|GABA Elmex sensitive extra soft toothbrush|
214499135|NCT00877019|DEVICE|ADA reference toothbrush|
215093324|NCT03434314|PROCEDURE|Minimally-Invasive Segmental Artery Coil-Embolization|During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
214384063|NCT02783820|DRUG|Placebo to match MMV390048 120 mg|
214384064|NCT04151693|BEHAVIORAL|Health Psychological Group Rehabilitation for Patients With Chronic Fatigue Syndrome (ME/CFS)|Adaptation (support own agency), rehabilitation and improvement of functional capacity.
214384065|NCT01315275|DRUG|Ranibizumab|
214499136|NCT04447898|DRUG|PPV-06 10 μg|Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
214499137|NCT04447898|DRUG|PPV-06 50 μg|High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
214499138|NCT04447898|DRUG|Placebo|Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
214499139|NCT02564705|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|
214384066|NCT00856934|BIOLOGICAL|Autologous Platelet Rich Plasma|Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
214384067|NCT00856934|BIOLOGICAL|Keratinocyte suspension|Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
214384068|NCT00856934|OTHER|Standard dressings|Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
214384069|NCT02668406|OTHER|Venous blood sampling (2 timepoints) (Phase A and B)|8.5ml at Day 1 + 8.5ml at Day 5
214384070|NCT02668406|OTHER|Venous blood sampling (1 timepoint) (Phase A and B)|8.5ml at Day 1
214384071|NCT02668406|OTHER|Voided urine sampling (first sample) (Phase A)|At least 20ml upon confirmation of being part of one of the 3 study groups
214384072|NCT02668406|OTHER|Voided urine sampling (second sample) (Phase A)|At least 20ml during routine hospital stay or routine follow-up visit
214499140|NCT02564705|PROCEDURE|Posterior Fusion|"* Posterolateral Fusion (PLF)~* Posterior Lumbar Interbody Fusion (PLIF)~* Transforaminal Lumbar Interbody Fusion (TLIF)"
214499141|NCT01536093|OTHER|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
214499142|NCT01536093|OTHER|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
214499143|NCT02851134|GENETIC|genetic analysis|genetic (Whole Exome Sequencing )
214499144|NCT02851134|BIOLOGICAL|blood and stools samples|biological collection
214996678|NCT04835441|DRUG|ALPN-101|Intravenous infusion via an infusion pump.
214384073|NCT03657381|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|Biological: F520 single-dose:0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 200mg/times, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 200mg/times, 10mg/kg, treat every 2 weeks; multiple dosing: 3mg/kg, 200mg/times, treat every 3 weeks.
214384074|NCT06230302|DIETARY_SUPPLEMENT|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
214384075|NCT06230302|DIETARY_SUPPLEMENT|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
214384076|NCT01186328|DRUG|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg
214384077|NCT01186328|DRUG|Cytarabine|"Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:~1-1.99 years: 30 mg 2-2.99 years: 50 mg~Greater than or equal to 3 years: 70 mg.~Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:~1. \- 1.99 years: 16 mg~2. \- 2.99 years: 20 mg~3. \- 8.99 years: 24 mg~Greater than or equal to 9 years: 30 mg"
214384078|NCT01186328|DRUG|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
214384079|NCT01186328|DRUG|Prednisone|40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.
214384080|NCT01186328|DRUG|Vincristine|1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
214384081|NCT01186328|DRUG|PEG-asparaginase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.
214384082|NCT01186328|DRUG|Methotrexate|"Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. \- 1.99 years: 8 mg~2. \- 2.99 years: 10 mg~3. \- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
214384083|NCT01186328|DRUG|Hydrocortisone|"Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. \- 1.99 years: 8 mg~2. \- 2.99 years: 10 mg~3. \- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
214384084|NCT03047174|OTHER|Mepitel® Film|Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.
214384085|NCT03047174|OTHER|Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily."
214384086|NCT06007079|DEVICE|CPM Device|Wearable monitor
214384087|NCT01265641|DRUG|AZD1981, 2000mg|Single oral dose, tablets
214384088|NCT01265641|DRUG|AZD1981, 200mg|Single oral dose, tablets
214384089|NCT01265641|DRUG|Moxifloxacin, 400mg|Single oral dose, capsule
214996679|NCT04835441|DRUG|Placebo|Intravenous infusion via an infusion pump.
214996680|NCT06590350|OTHER|Clinical nutrition counseling|"In the first phase, all patients admitted to the Departmental Simple Operating Unit Admission Room of Policlinico Universitario A. Gemelli will be screened for NRS-2002 upon admission.~Only patients with NRS-2002 ≥ 3 will subsequently be tracked via the Foundation's computer system (TrackCare®).~The patients will be managed by caregivers who may spontaneously request nutritional counseling, as is currently the case.~Patient data (laboratory tests, medical history, reason for admission, any instrumental test reports) and clinical outcomes (average length of hospitalization, complications, antibiotic therapy use, intensive care admission, mortality, re-hospitalization within 30 days) will be obtained from the Foundation's computer system (TrackCare®) and recorded in a dedicated Excel® spreadsheet.~Costs related to hospitalization and management of any complications will also be assessed."
214996681|NCT06590454|DRUG|Pyrvinium|Pyrvinium (2 mg/kg) per day for 14 days
214996682|NCT06590454|DRUG|Placebo|Placebo for 14 days
214996683|NCT06827938|DEVICE|YY-WRY-V01 Infrared thermotherapy apparatus|Infrared hyperthermia（44±1℃） device for 3 consecutive days (times / day), each treatment for 30 minutes After 7-10 days, the lesions of the same target were treated continuously for 2 days (times / day), and then treat every 7-10 days, the method was the same as before. Lesion changes were assessed after 15 treatments.
214384090|NCT01265641|DRUG|Placebo|Single oral dose, tablets
214996684|NCT06592352|DRUG|Modafinil Generis 100 mg|All participants enrolled in the study will receive the study intervention drug (Modafinil Generis 100 mg). Dose 200 mg once per day (2 tablets of 100 mg) in the morning for 3 months (84 days), Oral administration
214996685|NCT06839989|BIOLOGICAL|Mpox vaccination with MVA-BN|All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28.
214996686|NCT03672721|DRUG|IA Carbo+ Radiation|combination of intraarterial carboplatin + radiation in dose escalation
214996687|NCT05101226|BEHAVIORAL|Yoga attended in person|One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
214996688|NCT05101226|BEHAVIORAL|Yoga attended online|One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
214384091|NCT05114694|PROCEDURE|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
214384092|NCT05114694|PROCEDURE|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
214384093|NCT04278677|DIETARY_SUPPLEMENT|melatonin|Melatonin capsules to be taken for 6 weeks
214384094|NCT02890238|DRUG|Clomiphene citrate|50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
214499145|NCT00463502|DRUG|Metformin|
214499146|NCT04830124|DRUG|Nemvaleukin Alfa Subcutaneous|Subcutaneous injection of nemvaleukin every 7 days
214499147|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days
214499148|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous Less Frequent Dosing|Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)
214499149|NCT04830124|DRUG|Pembrolizumab|Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle
214499150|NCT05891132|DRUG|10 ml of lidocaine 2%|10 ml of lidocaine 2% for perineal infiltration at the time of crowning
214499151|NCT05891132|DRUG|lidocaine prilocaine cream 15gm|Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
214499152|NCT02169869|DEVICE|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
214499153|NCT02169869|DEVICE|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
214499154|NCT02420431|BEHAVIORAL|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
214499155|NCT02420431|BEHAVIORAL|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
214499156|NCT02275611|DRUG|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
214499157|NCT02275611|DRUG|Intranasal Placebo Spray|Intranasal Placebo Spray
214499158|NCT04110301|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).
214499159|NCT04110301|DRUG|Lenalidomide|Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction
214499160|NCT02209246|OTHER|PROMIS CAT Pain Interference|
214499161|NCT02209246|OTHER|PROMIS CAT Pain Behavior|
214499162|NCT02209246|OTHER|PROMIS CAT Physical Function|
214499163|NCT02209246|OTHER|MISS-21|
214687566|NCT05299983|OTHER|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites:~1. North American Menopause Society: https://www.menopause.org/for-women~2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
214384095|NCT02890238|DRUG|sildenafil citrate|20mg tab from 7th-11th day of the same cycle orally 3times/day
214384096|NCT02890238|DRUG|Placebo|tab from 7th-11th day of the same cycle orally 3times/day
214384097|NCT02473861|OTHER|Exercise|Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
214384098|NCT04172493|PROCEDURE|Hyperspectral Endoscopy (HySE)|Undergo hyperspectral endoscopy
214384099|NCT04172493|DEVICE|White Light Endoscopy (WLE)|Undergo white light endoscopy
214384100|NCT00665990|DRUG|Bevacizumab|Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose
214384101|NCT00665990|DRUG|Sorafenib|Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose
214384102|NCT00665990|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
214499164|NCT03911271|DRUG|0.1% atropine and 0.01% atropine|0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months
214499165|NCT03911271|DRUG|0.01% atropine|0.01% atropine for 24 months
214499166|NCT03911271|DRUG|0.9% Sodium-chloride|Placebo for 24 months
214499167|NCT03904069|DRUG|AMG 553|AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy
214499168|NCT06124573|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
214499169|NCT01391767|DEVICE|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
214499170|NCT04510324|OTHER|Red meat patties group|"1\. Baseline Visit: day -7 before randomization~* Clinical history~* Refrain from seafood, eggs, fish or meat, for 7-day (washout) prior to Day 1. 2. Day 1 Randomization~* Randomization to 1 of 2 interventions: plant-based or meat burgers~* 6 days-worth of burgers will be delivered to the participant's house 3. Day 1-6:~* The participant will be asked to eat a specific randomized diet for 6 days 5. Days 7~* Physical exam (weight, BP, HR)~* Food questionnaire~* Blood draw: Circulating TMAO, Total, LDL, and HDL cholesterol, Creatinine, High-sensitivity c-reactive protein~* Urine Collection - TMAO 6. Day 7-14: Washout 7. Day 14: Patties delivery 8. Day 14-20: Assigned diet for 6 days 9. Days 20: Same as day 7"
214499171|NCT04510324|OTHER|Plant-based patties group|Same as above
214499172|NCT05326789|DEVICE|REBOA catheter|balloon occlusion of the aorta during cardiac arrest to optimize coronary and cerebral perfusion.
214687567|NCT03561220|RADIATION|Standard of Care IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
214687568|NCT03561220|RADIATION|Standard of Care Proton Therapy|As this trial is pragmatic, all treatment will be standard of care.
214687569|NCT03561220|RADIATION|Proton Arm 1: Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions
214687570|NCT03561220|RADIATION|Proton Arm 2: Hypofractionated Proton Therapy|60.0 Gy (RBE) in 20 fractions
214384103|NCT03264768|DEVICE|endobronchial valves|A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.
214384104|NCT03264768|BEHAVIORAL|physical activity tele coaching|3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.
214384105|NCT03264768|PROCEDURE|Lung volume reduction surgery (LVRS)|Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.
214384106|NCT03015116|OTHER|Stretching|Daily foot and ankle stretching protocol
214384107|NCT03015116|OTHER|Cryotherapy|Daily cryotherapy in conjunction with stretching
214499173|NCT01354574|OTHER|High Glycemic Index meals|Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
214499174|NCT01354574|OTHER|Low Glycemic Index meals|Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
214499175|NCT03329482|OTHER|PULSE ULTRASOUND|For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.
214499176|NCT03329482|OTHER|KNEADING MASSAGE|Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
214499177|NCT04353089|OTHER|Basic life support courses|4 hours certified basic life support courses
214499178|NCT01756924|DRUG|CEM-102|
214996689|NCT06366347|DRUG|Abemaciclib|CDK inhibitor, tablet taken orally per protocol.
214996690|NCT06366347|DRUG|Letrozole|Aromatase inhibitor, tablet taken orally per protocol.
214996691|NCT06366347|DRUG|Pembrolizumab|Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
214384108|NCT03015116|DEVICE|Photobiomodulation Low Power|Photobiomodulation treatment with 10W power output
214384109|NCT03015116|DEVICE|Photobiomodulation High Power|Photobiomodulation treatment with 25W power output
214384110|NCT01015807|DRUG|Bupivacaine Placebo|2 x 20mL 0.9% NaCl
214384111|NCT01015807|DRUG|Clonidine Placebo|2 x 1mL 0.9% NaCl
214384112|NCT01015807|DRUG|Bupivacaine|2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
214384113|NCT01015807|DRUG|Clonidine|2 x 1ml Clonidine = 150 µg Clonidine
214384114|NCT02732093|PROCEDURE|stellate block|
214384115|NCT02732093|DRUG|Na.Cl 0.9% (placebo)|
214384116|NCT02732093|DRUG|lidocaine 2%|
214384117|NCT02075021|DRUG|Lenalidomide|
214499179|NCT01756924|DRUG|IV or Oral standard of care antibiotics|
214499180|NCT01756924|DRUG|Rifampin|
214499181|NCT01759862|DRUG|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
214499182|NCT01759862|OTHER|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
214499183|NCT01759862|DRUG|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
214499184|NCT02254759|DRUG|Midazolam, IV|2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).
214384118|NCT02075021|DRUG|nab-paclitaxel|
214384119|NCT02200939|DEVICE|Bioinductive implant|
214384120|NCT02200939|DEVICE|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
214384121|NCT02778191|DRUG|cisplatin|100 mg/m2 day 1, 22 and 43
214384122|NCT02778191|DRUG|carboplatin|carboplatin 300-350 mg/m2 day 1, 22 and 43
214384123|NCT02778191|DRUG|5-FU|5-FU 600 mg/m2 days 1-4, 22-25 and 43-46
214384124|NCT00783471|DRUG|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
214499185|NCT02254759|DRUG|Midazolam, oral|0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.
214499186|NCT02254759|DRUG|RO5186582|RO5186582 120 mg film-coated release tablet.
214499187|NCT01235806|RADIATION|MRI|MRI of the scaphoid bone fracture suspicion
214499188|NCT01082900|OTHER|Prophylactic CPAP Administration|"EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room"
214687571|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMRT
214996692|NCT02900651|DRUG|MAK683|Drug: MAK683
215093325|NCT02047097|DRUG|dimethyl fumarate|Provided under routine clinical care
215093326|NCT00757692|DRUG|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
214996693|NCT05360212|PROCEDURE|Anatomy-based fitting (ABF)|MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
214384125|NCT00783471|DRUG|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
214384126|NCT00361361|DEVICE|Excimer Laser Therapy|excimer laser is a UV 308nm laser. repeated sessions (10 sessions) needed. once per week.
214384127|NCT04748419|RADIATION|consolidative hypofractionated radiation therapy (hfRT)|Consolidative hfRT will start from 6.5Gy x 2 fractions and dose escalate to 10Gy x 2 fractions in a 3+3 design
214384128|NCT04748419|DRUG|Durvalumab 50 MG/ML|Durvalumab 10 mg/kg via a 60-minute iv infusion every two weeks ± 3 days for up to 12 months
214384129|NCT03053921|PROCEDURE|recession coverage|recession coverage done using Zuchellis technique
214384130|NCT03053921|PROCEDURE|recession coverage and membrane|recession coverage done using Zuchellis technique with placental membrane
214499189|NCT00731614|BEHAVIORAL|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
214499190|NCT00731614|BEHAVIORAL|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
214687572|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMPT
214687573|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMRT
214687574|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMPT
214384131|NCT02629068|BEHAVIORAL|PURPOSE|"The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.~Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together"
214384132|NCT05721443|DRUG|Dalpiciclib+cetuximab|"The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met."
214384133|NCT03924713|BEHAVIORAL|Supportive services|Assessment of behavioral, medical, and social needs, development of individual goals and action plan, follow-up to assist and work to ensure identified needs/goals are met. CHWs use their professional judgement to assess how long follow-up is required.
214384134|NCT02951910|DEVICE|Ophylosa tear supplement|Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
214384135|NCT01352143|DRUG|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
214499191|NCT00731614|BEHAVIORAL|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
214499192|NCT03214172|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
214499193|NCT06243770|DRUG|mRNA-0184|Intravenous infusion
214996694|NCT05360212|PROCEDURE|Standard Fitting|These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
214384136|NCT01352143|DRUG|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
214384137|NCT04066985|BEHAVIORAL|Growth Mindset Online Single-Session Program|30minute self-administered program for youths
214384138|NCT04066985|BEHAVIORAL|Self-Kindness Online Single-Session Program|30minute self-administered program for youths
214384139|NCT04066985|BEHAVIORAL|Supportive Therapy Online Single-Session Program (Control)|30minute self-administered active comparator program for youths
214499194|NCT03890289|DRUG|Idelalisib|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
214499195|NCT03890289|DRUG|Obinutuzumab|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
214687575|NCT01629498|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214687576|NCT01629498|RADIATION|Photon Beam Radiation Therapy|Undergo image-guided IMRT
214687577|NCT01629498|RADIATION|Proton Beam Radiation Therapy|Undergo image-guided IMPT
214687578|NCT01629498|OTHER|Questionnaire Administration|Ancillary studies
214687579|NCT06785038|BEHAVIORAL|EMPOWER Strategy|The EMPOWER Strategy will: 1) identify women in primary care; 2) deliver understandable, actionable, and non-stigmatizing PrEP education, in multiple formats and languages, directly and securely to women via the patient portal; 3) enable women to discreetly self-schedule a visit to discuss PrEP options via the patient portal, with either their own PCP or with a female PCP who has years of experience in PrEP delivery; and 4) support PCP counseling via clinical decision support that provides standardized, patient-centered language to guide PrEP discussions and via 'smart sets' to facilitate PrEP prescribing, when desired and appropriate.
215093327|NCT00757692|DRUG|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
214384140|NCT00634985|DRUG|eletriptan|40 mg oral tablet for migraine attack; additional 40 mg oral tablet \>2 hours from first dose if migraine reoccurred within 24 hours of achieving response
214384141|NCT02762981|DRUG|Relacorilant with nab-paclitaxel|Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.
214384142|NCT01821430|DRUG|Pregabalin|Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
214384143|NCT01821430|DRUG|Placebo|Placebo group will follow the same titration as the pregabalin group
214384144|NCT02384967|DRUG|Darunavir|to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
214384145|NCT01382940|DRUG|rituximab|1000 mg in 250 mL intravenous infusion
214384146|NCT01382940|DRUG|methotrexate|10 to 25 mg/week (oral or parenteral)
214384147|NCT01382940|DRUG|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
214384148|NCT01382940|DRUG|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
214384149|NCT01382940|DRUG|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
214384150|NCT02134210|DRUG|Etanercept|Head-to-head comparison
214384151|NCT02134210|DRUG|CHS-0214|
214384152|NCT00244374|BIOLOGICAL|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects\>18 years of age will receive the Twinrix vaccine and subjects\<18 years of age will receive the Engerix-B vaccine. Cohort subjects\>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
214384153|NCT00244374|BEHAVIORAL|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
214384154|NCT00244374|BEHAVIORAL|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
214384155|NCT00244374|BEHAVIORAL|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
214499196|NCT04929795|BEHAVIORAL|Rhythmic auditory stimulation (RAS)|"The song named 'Sign of The Times' is played and recorded by the research personnel beforehand. The beat of the song will serve as RAS. The computer software Audacity will be used to adjust tempi of RAS. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo. For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Participants in the experimental groups are required to use their right hand to pick up beads from source bowls to the target bowl when listening to the song. The 3-week intervention program will include 21 40-minute daily training sessions."
214499197|NCT04929795|BEHAVIORAL|no RAS|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
214499198|NCT04270734|PROCEDURE|EEG|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed
214499199|NCT04270734|PROCEDURE|NIRS|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
214499200|NCT06370988|DEVICE|iTBS Stimulation|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
214996695|NCT05360212|PROCEDURE|Standard fitting+ ABF|Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
215093328|NCT00487474|DEVICE|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
214384156|NCT02350920|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
214384157|NCT04944030|PROCEDURE|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
214384158|NCT01982877|BEHAVIORAL|Four Supports Intervention|The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.
214384159|NCT01982877|BEHAVIORAL|Educational Control Intervention|In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
214499201|NCT06370988|DEVICE|Sham iTBS Stimulation|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
214499202|NCT02610426|OTHER|Laboratory Biomarker Analysis|Correlative studies
214499203|NCT02075723|DIETARY_SUPPLEMENT|Overfeeding (130 % of energy requirements )|Overfeeding (130 % of energy requirements )
214499204|NCT02075723|BEHAVIORAL|Sleep restriction (4 hours per night)|Sleep restriction (4 hours per night)
214499205|NCT02867059|DRUG|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20\_SJ733\_Challenge Protocol\_v2.0\_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
214499206|NCT05159453|BIOLOGICAL|Human Insulin|International Unit for International Unit exchange of transdermally delivered Human Insulin for injected Human Insulin or combinations of basal and fast-acting insulins.
214499207|NCT05159453|DEVICE|Finger-actuated, Metered Pump Sprayer|Stock, pharmaceutical grade High Density Polyethylene (HDPE) bottle and HDPE nylon and stainless steel finger-actuated pump sprayer delivering 0.2 mL per pump.
214499208|NCT02806674|DEVICE|The eradication times of the patients|The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
214499209|NCT02806674|DEVICE|The result of 13C-urea breath test after treatment|The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
214499210|NCT00274261|DRUG|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
214499211|NCT00274261|DRUG|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
214499212|NCT03387189|OTHER|Quality Improvement Project|Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
214499213|NCT04071106|DRUG|Turmeric Extract|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
214384160|NCT03804996|DRUG|TG-1801|Intravenous infusion over 1 hour every 4 weeks
214384161|NCT03804996|BIOLOGICAL|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks"
214384162|NCT04360122|DRUG|Levamisole|Levamisole (150 mg/day for two days per week for 2 months
214499214|NCT04071106|DRUG|Turmeric Extract in Olive oil|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
214499215|NCT04071106|DRUG|Petrolatum|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
214499216|NCT04071106|DEVICE|NB-UVB|Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
214499217|NCT04071106|DRUG|calcipotriol/ Betamethasone|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
214499218|NCT00410254|DRUG|HCV-796|
214499219|NCT00410254|DRUG|midazolam|
214499220|NCT00371670|DRUG|balicatib (AAE581)|
214687580|NCT06785038|BEHAVIORAL|Attention Control|Women in this arm will be sent, via the patient portal, a CDC patient education material on benefits of physical activity. The material will be in English or Spanish based on patient's language.
215093329|NCT01798030|OTHER|Vitamin D|N/A, frozen specimen study
214384163|NCT04360122|DRUG|Isoprinosine|Isoprinosine (1 g 3 times per day daily) for two months
214384164|NCT04360122|DRUG|Levamisole and Isoprinosine|Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
214384165|NCT03622385|OTHER|DNA Methylation|No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
214384166|NCT03383796|PROCEDURE|Three dimensional laparoscopic resection for pCCA|Three dimensional laparoscopic resection for pCCA
214384167|NCT03383796|PROCEDURE|Open resection for pCCA|Open resection for pCCA
214384168|NCT01596283|PROCEDURE|Standard fluid management|The patient will receive standard fluid management
214384169|NCT01596283|DEVICE|Goal directed fluid therapy with the Edwards EV1000 system|This arm will have fluid therapy guided by the Edwards EV1000 system.
214687581|NCT06957431|DRUG|Zanzalintinib|Supplied by Exelixis, Inc.
214687582|NCT06957431|DRUG|Eribulin|1.1 mg/m\^2 dose.
214687583|NCT06785675|OTHER|Secukinumab|This is an observational study. There is no treatment allocation.
215093330|NCT00450073|DRUG|ergocalciferol (vitamin D2)|50,000 IU weekly
214384170|NCT04978610|BEHAVIORAL|Virtual Acceptance Commitment Therapy|"For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes."
214384171|NCT02308332|DRUG|Eviplera|switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
214996696|NCT06248268|OTHER|(Neuro-)psychological assessment|The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.
214384172|NCT05535140|OTHER|G8 Screening Tool|Determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients \>65y/o who are scheduled with the medical oncology department.
215093331|NCT00450073|DEVICE|Sperti Del Sol Lamp|5 times a week for 12 weeks
215093332|NCT00450073|DRUG|Vitamin D3|50,000 IU weekly
215093333|NCT06066073|DRUG|Lavender Oil|Twenty drops of lavender oil was added the distal water which fill the vaporizer which were placed in the waiting room. The patients inhaled the vapors of the lavender oil 20 minutes before starting the dental procedures
215093334|NCT06066073|DRUG|Distal Water|The patients inhaled vapors of the distal water in the waiting room 20 minutes before starting dental procedures
215093335|NCT01224444|OTHER|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
214384173|NCT00720902|PROCEDURE|Blood draws|Subjects will have serum cardiovascular markers assessed
214384174|NCT00720902|DRUG|growth hormone releasing hormone (GHRH) & arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
214384175|NCT00720902|PROCEDURE|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
214384176|NCT00720902|PROCEDURE|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
214384177|NCT00720902|PROCEDURE|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
214499221|NCT05549102|BEHAVIORAL|Cognitive Behavioural Therapy|In the Cognitive Behavioural Therapy group (N=87), patients will undergo CBT as part of their routine care in Step 3 of the IAPT programme. This will be administered by suitably trained clinicians. The specification of CBT is as recommended by the National Institute for Health and Care Excellence (NICE) guidelines (CG113 - Generalised anxiety disorder and panic disorder in adults: management). In these guidelines, patients are offered on average, 12-15 hourly, weekly sessions of CBT with a trained and competent practitioners. Therapy sessions involve discussions that identify patterns in thinking or behaviours which may be problematic, and therapists and patients work to set goals to reduce these using cognitive techniques. The principle is to teach the patient how to use CBT techniques in their day-to-day life to promote a lasting effect on mental health. We will test patients before (T1) and after (T2) a course of treatment.
214996697|NCT05860595|GENETIC|KL003 cell injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.
214996698|NCT05032196|DRUG|SAD: 30mg WVE-003|Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
214996699|NCT05032196|DRUG|SAD: 60mg WVE-003|Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
215093336|NCT03102567|DRUG|GLPG1205 50mg q.d.|oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
215093337|NCT03102567|DRUG|Placebo oral capsule|oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
215093338|NCT03102567|DRUG|GLPG1205 250 loading dose and 50mg q.d. maintenance dose|Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
214996700|NCT05032196|DRUG|SAD: 90mg WVE-003|Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
214996701|NCT05032196|DRUG|SAD: Pooled Placebo|Single dose of placebo
214996702|NCT05032196|DRUG|MD: 30mg WVE-003|Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure, antisense oligonucleotide (ASO)
214996703|NCT05032196|DRUG|MD: Placebo|Three doses of placebo Q8WK
214996704|NCT06983470|DEVICE|SNM based on visual-motor responses (VMRs)|SNM using parameters that elicited the best VMRs in the stage-1 implant procedure
214996705|NCT06983470|DEVICE|SNM based on sacral evoked responses (SERs)|SNM using parameters that elicited the best SERs in the stage-1 implant procedure
214996706|NCT06614374|DIETARY_SUPPLEMENT|Low-dose fish oil capsules|Patients in the low-dose group will receive four fish-oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs per day.
215093339|NCT06095167|DRUG|without concurrent cisplatin chemotherapy|IMRT without concurrent cisplatin chemotherapy
215093340|NCT06095167|DRUG|with concurrent cisplatin chemotherapy|IMRT with concurrent cisplatin chemotherapy
215093341|NCT04527939|PROCEDURE|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
214384178|NCT00782977|OTHER|Nasal oxygen therapy|Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
215093342|NCT05354193|OTHER|vasoplegic syndrome|"In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure \< 65 mmHg, cardiac index \< 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock"
214384179|NCT01486758|DRUG|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
214384180|NCT01486758|DRUG|Placebo|
214499222|NCT05549102|OTHER|Waiting List|In the control group (N=87), we will test patients who are currently seeking (but not undergoing) treatment before (T1) and after a wait (T2) of equivalent time (i.e. waiting list controls)
214499223|NCT03292133|DRUG|EGF816|EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
214499224|NCT03292133|DRUG|Gefitinib|Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
214499225|NCT02260024|OTHER|High fat, high caloric meal|
214499226|NCT02260024|DRUG|Pramipexole IR tablets|
214499227|NCT02260024|DRUG|Pramipexole SR C|
214499228|NCT02260024|DRUG|Pramipexole SR C2|
214499229|NCT02260024|DRUG|Pramipexole SR C2A|
214499230|NCT02260024|DRUG|Pramipexole SR C2B|
214384181|NCT02906085|DRUG|Endothelin-1|
214384182|NCT02906085|DRUG|Placebo|Isotonic saline
214996707|NCT06614374|DIETARY_SUPPLEMENT|High-dose fish oil capsules|Patients in the high-dose group will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day.
214384183|NCT04968262|OTHER|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis and sedation. Blood and urine samples were collected at the intensive care unit from this patient group at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. 24 patients were documented without sepsis and acute kidney injury as a control group.
214384184|NCT04968262|OTHER|Sepsis-related acute kidney injury therapy|Patient management of sepsis and sepsis-related acute kidney injury followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis, sedation and renal replacement therapy (if needed). In this patient group, blood and urine sampling was performed at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up.
214499231|NCT04381949|PROCEDURE|positive pressure extubation|"Two arms:~the first with classic extubation with disconnection of the ventilator and the second with an extubation without disconnection of the respiratory positive pressure"
214499232|NCT02813525|OTHER|ISI index on Doppler systolic flow in the aortic isthmus|Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
214996708|NCT06614374|DIETARY_SUPPLEMENT|Refined olive oil|Participants in the control group will receive 4 g refined olive oil daily
214996709|NCT06670976|PROCEDURE|Biopsy|Undergo tissue biopsy sample collection
215093343|NCT01442805|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
214499233|NCT04149119|DEVICE|Attractive Target Sugar Baits (ATSB)|Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
214499234|NCT00401479|DRUG|Placebo|
214499235|NCT00401479|DRUG|Solabegron (GW427353)|
214499236|NCT00343408|DRUG|cediranib maleate|
214499237|NCT00343408|DRUG|cisplatin|
214499238|NCT00343408|DRUG|fluorouracil|
214499239|NCT00343408|DRUG|gemcitabine hydrochloride|
214499240|NCT00343408|DRUG|leucovorin calcium|
214499241|NCT00343408|DRUG|oxaliplatin|
214499242|NCT02262299|DRUG|Pirfenidone|Receive tablets with pirfenidone
214499243|NCT02262299|DRUG|Placebo|Recieve tablets with placebo
214499244|NCT04217694|BEHAVIORAL|Cogstate Assessment Battery|Complete CogState testing
214499245|NCT04217694|DRUG|Memantine|Given PO
214499246|NCT04217694|DRUG|Memantine Hydrochloride|Given PO
214499247|NCT00853606|DRUG|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
214499248|NCT04415307|OTHER|Acupuncture|Acupuncture over acupoints.
214499249|NCT04415307|OTHER|Far-Infrared heat-patch attachment|Far-Infrared heat-patch attachment over acupoints.
214499250|NCT04415307|OTHER|Acupuncture and Fir-Infrared heat-patch attachment|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
214996710|NCT06670976|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214996711|NCT06670976|PROCEDURE|Computed Tomography|Undergo CT scan
214996712|NCT06670976|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214996713|NCT06670976|DRUG|Propranolol|Given PO
214996714|NCT06670976|RADIATION|Radiation Therapy|Undergo RT
214996715|NCT06670976|PROCEDURE|Surgical Procedure|Undergo surgery
214996716|NCT04740593|OTHER|Orthoptic care with the prescription of glasses from age 12-18 months onwards|Children assigned to the intervention group (group 1) will receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, and glasses, based on accurate determinations of refractive error by retinoscopy in cycloplegia by the study orthoptists at age 12-18 months. The spectacles for the children in this study will be provided by the study via their optician without costs.
214384185|NCT04835896|DRUG|M7824+paclitaxel|M7824 will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with paclitaxel 80 (or 70) mg/m2 once a week for 3 weeks (each cycle is 4 weeks)
214384186|NCT05480332|DEVICE|EndoPAT|"We will use the standard non-invasive EndoPAT finger probes to conduct the studies. A single finger on each hand will be placed into a probe equipped with pressure sensors. A baseline recording period will be obtained. After five minutes, an occlusion phase will start where a blood pressure cuff on the patient's non-dominant arm will be inflated to 60mmHg above the patient's systolic pressure, or 200mmHg, whichever is higher. This phase will be conducted in concert with the standard instructions provided with the EndoPAT system. The occlusion phase will last for five minutes, after which time the cuff will be deflated. There will then be a five minute post-occlusion recording period. The test will then be completed.~The baseline period, occlusion period, and post-occlusion period will then be analyzed. A reactive hyperemia index score will be the desired output from the EndoPAT computer software, and will become the primary data point."
214384187|NCT02655471|DRUG|"Raltegravir and Zidovudine"|Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
214499251|NCT04415307|OTHER|Far-Infrared heat-patch attachment over acupoints without electric current passing.|Far-Infrared heat-patch attachment over acupoints without electric current passing.
214499252|NCT00140491|DEVICE|Vision Restoration Therapy (NOVAVISION)|
214499253|NCT04204941|DRUG|Tazemetostat|400 mg, 600 to 800 mg of Tazemetostat will be administered twice daily.
214499254|NCT04204941|DRUG|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
214499255|NCT04204941|DRUG|Tazemetostat|800 mg administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.
214499256|NCT04204941|DRUG|Placebo|Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond
214499257|NCT04204941|DRUG|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
214499258|NCT04240613|DEVICE|TVT-O|TVT-O is one of the most popular treatments for urinary incontinence (UI). Its efficacy is well established in patients with pure stress urinary incontinence (SUI). Data reporting long-term outcomes of TVT-O for the treatment of mixed urinary incontinence (MUI) or recurrent SUI is scarce. The objective of this study was to evaluate the efficacy and safety and overall patient satisfaction of TVT-O in different subgroups of UI in a long-term follow-up.
214499259|NCT04958798|BEHAVIORAL|Culturally Centered MOUD Implementation Intervention|Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
214996717|NCT04740593|OTHER|Orthoptic care without the prescription of glasses from age 12-18 months onwards|Children with high refractive error in the control group (group 2) will also receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, but they will not receive glasses.
214996718|NCT04740593|OTHER|First measurement only|Children who have no or mild refractive error (group 3), the majority of all children, will be examined by the study orthoptists only once at the age of 12-18 months, after which youth health care (YHC) physicians and nurses will continue standard vision screening at CHCs, as part of screening for general health disorders and vaccinations. Visual acuity is measured routinely at 42-48 months as part of standard vision screening.
214996719|NCT05288985|DEVICE|Erector spinae plane catheter group in addition to Systemic Analgesia|Erector spinae plane catheter is placed in the post-interventional surveillance room in the operating theatre by an anaesthetist-intensive care physician or in the MIR department by the intensive care physician in charge of the patient within 2 hours after randomisation. The local anaesthetic injected into the catheter is Ropivacaine, prescribed according to a protocol of continuous flow, bolus and refractory period. The catheter is repositioned if a secondary displacement occurs.
214996720|NCT05288985|DRUG|Systemic Analgesia Only Group|Systemic analgesia alone consists only of the 3 levels of analgesic treatment
215093344|NCT01442805|BEHAVIORAL|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
214384188|NCT03366220|DRUG|Plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
214499260|NCT01855516|DRUG|Heparin|
214499261|NCT03980418|PROCEDURE|DaTSCAN SPECT/CT in VERITON-CT camera|the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
214996721|NCT06994988|DEVICE|A-Band (Smart Band-Aid)|The A-Band is a smart band-aid placed on the forearm or other designated site that collects interstitial fluid (ISF) from participants using a microneedle patch. ISF is a natural fluid found between your cells that can inform us on your bodily readings and health. A microneedle patch is a safe alternative to standard fluid collection which uses tiny needles to collect the ISF. The patches consist of single-use, sterile (clean) microneedles created from biocompatible materials. These microneedles penetrate the outermost skin layer without causing significant discomfort, pain, or bleeding.
215093345|NCT03120377|OTHER|Platform|Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.
214499262|NCT06561841|DRUG|HSK39297|HSK39297 tablets for 24 weeks
214687584|NCT06957535|BEHAVIORAL|Navigation|Navigation is provision of 1:1 support from a Diné peer-navigator
214687585|NCT06957535|BEHAVIORAL|TEAM|TEAM encompasses culturally tailored mammography education modules
214384189|NCT03366220|DRUG|Balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
214384190|NCT00871819|DEVICE|Precision Spinal Cord Stimulation (SCS)|Various SCS device programming parameters
214384191|NCT05260372|DIAGNOSTIC_TEST|Quantification of donor-derived cell-free DNA|Quantification of ddcfDNA on serial plasma samples during follow-up after lung transplantation
214384192|NCT02608489|DRUG|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
214499263|NCT06510790|DEVICE|Double J stent|Double J ureteral catheter has been used to prevent upper urinary tract obstructions or strictures and to facilitate stone clearance after procedures such as percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery (RIRS), and ureteroscopic lithotripsy (URSL).
214499264|NCT02794363|BIOLOGICAL|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
214384193|NCT02608489|DRUG|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
214384194|NCT03605160|PROCEDURE|traditional polish|After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.
214384195|NCT03605160|PROCEDURE|fluid-jet|After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
214384196|NCT02617264|PROCEDURE|SPOT|Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
214384197|NCT05134714|DEVICE|CAD/CAM zircon band and loop space maintainer|Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
214384198|NCT05134714|DEVICE|Conventional metal band and loop space maintainer|Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.
214384199|NCT03505450|OTHER|Population Sample|full sample of recruited participants
214499265|NCT02227706|BIOLOGICAL|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
214499266|NCT02227706|DEVICE|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
214499267|NCT02628626|DRUG|Colesevelam|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
214499268|NCT02628626|DRUG|Clonidine|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
214499269|NCT02628626|OTHER|Placebo|Placebo will be identical in appearance to the active drug.
215093346|NCT03120377|OTHER|Platform sham|will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
214384200|NCT03505450|OTHER|Purposive sample|purposive sample of recruited participants
214499270|NCT04932018|BEHAVIORAL|Virtual Community of Support|The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
214499271|NCT04932018|BEHAVIORAL|Mentorship Incubator|The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
214499272|NCT04231279|DRUG|synthetic human secretin|Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
214499273|NCT04197648|DEVICE|Exercise group|24 week supervised exercise program (strength and cardiovascular program).
214499274|NCT03186326|DRUG|FOLFOX regimen|"A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
214499275|NCT03186326|DRUG|FOLFIRI Protocol|"A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
214499276|NCT03186326|DRUG|Avelumab|"A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.~Then:~Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed"
214499277|NCT03186326|DRUG|Panitumumab|Administered at 6 mg/Kg
215093347|NCT03670784|OTHER|No intervention|No intervention, epidemiological investigation
214384201|NCT01752595|BEHAVIORAL|Preference Based Rhythmic Auditory Stimulation Music|"Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most."
214384202|NCT01752595|OTHER|Preference Based Music Intervention|
214384203|NCT04316728|DEVICE|VivaDiag™ COVID-19 lgM/IgG Rapid Test|VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma
214384204|NCT00003759|BIOLOGICAL|BCG vaccine|
214384205|NCT00003759|DRUG|valrubicin|
214384206|NCT00003759|PROCEDURE|conventional surgery|
214384207|NCT01496716|PROCEDURE|Hip arthroplasty|The purpose of hip arthroplasties is to reduce pain and increase mobility.
215093348|NCT07088237|BEHAVIORAL|Stress Feedback|The stress feedback draws on a skills-based model of emotion regulation that emphasizes the ability to identify and label emotions, followed by either actively modifying negative emotions or accepting negative emotions when necessary. Participants will receive a prompt to identify their current emotion, followed by questions regarding their current context.
214384208|NCT02859467|OTHER|Kinesio Taping and Inhibitory Treatment Techniques|"Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~* Release Technique of the trapezius muscle.~* Release Technique for scalene muscles.~* Technique suboccipital inhibition.~* Technique hands crossed for induction dorsal superficial fascia."
214384209|NCT02859467|OTHER|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
214384210|NCT03847038|PROCEDURE|Preventive strategies advice and dementia risk estimate disclosure|The BBRC-DemPrev-2018 study is a multimodal lifestyle-interventional, longitudinal, and prospective study of participants with a subjective perception of cognitive decline (SCD) or with mild cognitive impairment (MCI). Participants are disclosed their 5-year dementia risk estimate
214384211|NCT01334944|DRUG|Intravenous ibuprofen|400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
214384212|NCT02254408|DRUG|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
214384213|NCT02254408|DRUG|Placebo|Tablets administered orally or via nasogastric tube
214384214|NCT05697549|BEHAVIORAL|cognitive behavior language therapy|Cognitive behavior language therapy is an extensive form of Cognitive behavior therapy. and it is used in the management of speech-language related problems. It helps the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. and it also helps the individuals to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and Augmentative alternative communication.
214499278|NCT03186326|DRUG|Cetuximab|Administered at 500 mg/m²
214499279|NCT03186326|DRUG|Bevacizumab|Administered at 5 mg/Kg
214499280|NCT03186326|DRUG|Aflibercept|Administered at 4 mg/Kg
214499281|NCT04958317|OTHER|Early exercise|Participants will exercise for 30 minutes prior to an evening meal.
214499282|NCT04958317|OTHER|Late exercise|Participants will exercise for 30 minutes after an evening meal.
214499283|NCT04144868|DEVICE|Oxygen storage face masks and nasal catheter|Giving high-flow mask oxygen via oxygen storage face masks (100% O2, flow rate 8 L/min, 1 hour, four times daily, and 2 L/min via nasal catheter during intermittent periods, for 7 days) immediately at admission.
214499284|NCT04144868|DEVICE|Nasal catheter|Giving 2 L/min flow of 100% O2 via nasal catheter at admission for 24 hours daily for 7 days.
214499285|NCT02440672|DEVICE|JOURNEY™ II CR Total Knee System (J II CR TKS)|TKA with Journey II CR Total Knee System
214499286|NCT00575419|DRUG|N-acetylcysteine|"* Dose Level 1: 150 mg/kg/day~* Dose Level 2: 300 mg/kg/day~* Dose Level 3: 600 mg/kg/day~* Dose Level 4: 900 mg/kg/day~* Dose Level 5: 1200 mg/kg/day"
214499287|NCT00732966|DRUG|losartan|with losartan 50 mg once daily for one month
214499288|NCT00732966|DRUG|valsartan|valsartan 160 mg once daily
214499289|NCT01732120|PROCEDURE|Off-clamp partial nephrectomy|
214499290|NCT02645942|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine 1400 mg daily for 8 weeks
214499291|NCT02645942|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 8 weeks
214499292|NCT06321224|OTHER|Breathing exercises|Breathing exercises will be performed 3 days a week during 2 menstrual periods.
214499293|NCT06321224|OTHER|Control|No intervention will be made to the control group and they will be asked to continue their routine lives.
214499294|NCT00180934|PROCEDURE|Reirradiation with concomitant chemotherapy|
214499295|NCT02595346|DRUG|Hydroxychloroquine|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
214687586|NCT06433128|DRUG|Fosmanogepix solution for infusion|Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
214499296|NCT02595346|DRUG|placebo|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
214499297|NCT00370942|DRUG|GW823093C A|A=45 mg
214499298|NCT00370942|DRUG|GW823093C B|B=30 mg
214499299|NCT00370942|DRUG|GW823093C C|C=25 mg
214499300|NCT00023920|BIOLOGICAL|bevacizumab|Given IV
214499301|NCT00023920|DRUG|idarubicin|Given IV
214384215|NCT03550430|BEHAVIORAL|alpha/delta neurofeedback|neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.
214384216|NCT03550430|BEHAVIORAL|beta/theta neurofeedback|neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.
214384217|NCT03550430|OTHER|Diary completion|completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
214996722|NCT06994988|COMBINATION_PRODUCT|Empatica Smartwatch|A commercial smart band will be worn by participants for 22+ hours a day for approximately 7 days. The smart band collects biophysical data from the participant. This includes data on biomarkers, heart rate and heart rate variability, galvanic skin response, step count, and temperature fluctuations, among other biophysical data.
214384218|NCT03607201|OTHER|No intervention|Routine care
214384219|NCT06019013|DRUG|QLF3108|QLF3108 will be administered independent of body weight.
214384220|NCT01057030|DRUG|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
214499302|NCT00023920|DRUG|cytarabine|Given SC
214499303|NCT06514183|OTHER|Clinical diagnosis of recurrence|Clinical diagnosis of recurrence
214499304|NCT02143375|DEVICE|810 Diode Laser|The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
214384221|NCT01057030|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
214384222|NCT05417334|DEVICE|Resistive Capicitive Monopolar Radiofrequency|5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
214384223|NCT01526811|DEVICE|Endurant Stent graft|Endurant Stent graft implantation
214499305|NCT00032435|DRUG|PAL-40 Active|
214384224|NCT05126979|BIOLOGICAL|Inactivated Split Influenza Vaccine|
214384225|NCT05126979|BIOLOGICAL|Placebo|
214384226|NCT06255821|BEHAVIORAL|Exposure|One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.
214384227|NCT04199533|BEHAVIORAL|RUBI|Parent-mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
214499306|NCT00032435|DRUG|PAL-40 Placebo|
214499307|NCT02080585|BEHAVIORAL|Physical Activity advice.|Subjects receive advice regarding physical activities.
214384228|NCT04199533|BEHAVIORAL|RUBIES|School-staff mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
214384229|NCT02519647|DEVICE|Tracheal intubation with Gliderite|Tracheal intubation with Gliderite
214499308|NCT02190708|DRUG|PQ912|from day2 up to day6 twice daily oral dose of PQ912
214499309|NCT02190708|DRUG|Midazolam|single oral dose on day1 and day 6
214499310|NCT02190708|DRUG|Omeprazole|single oral dose on day1 and day6
214499311|NCT03329612|PROCEDURE|Remote Ischemic Preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions.
214499312|NCT01232959|DEVICE|Transvaginal Cholecystectomy|A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
214499313|NCT04379375|BEHAVIORAL|Nudge|Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
214499314|NCT00401869|DRUG|Epoetin alfa|
214499315|NCT00228475|DRUG|Pulmicort (budesonide) Turbuhaler|
214499316|NCT03699410|RADIATION|Neoadjuvant radiotherapy|Radiotherapy with total dose of at least 50 Gy on the tumor (cT) and the involved nodes (cN+) and with standard fractionation (1.8 Gy/fraction), 5 days/week.
214499317|NCT03699410|DRUG|Neoadjuvant chemotherapy|Oral Capecitabine, at the standard dose of 825 mg/m2 twice daily, concomitant to radiotherapy.
214499318|NCT03699410|PROCEDURE|Radical surgery|The time point of surgery is usually dependent on surgeon's and institutional habits and lies within 6 to 12 weeks after the end of nCRT. Surgeons participating in this study will be asked to operate patients on the 10th week after the end of nCRT.
214384230|NCT02519647|DEVICE|Tracheal intubation with S-guide|Tracheal intubation with S-guide
214384231|NCT01365533|DRUG|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
214384232|NCT01365533|DRUG|Placebo|Placebo, one tablet once daily, orally
214384233|NCT00298142|PROCEDURE|Usual Care provided by a medical doctor (GP or Neurologist)|
214384234|NCT00298142|PROCEDURE|Usual care plus Physio-/ Manual Therapy|
214384235|NCT01671839|DEVICE|Subcutaneous tissue release with the Cabochon System|Device: Subcutaneous tissue release
214384236|NCT04534413|DEVICE|composite optical fiberscope (COF)|Fiber Technology
214384237|NCT03297008|OTHER|No internvetion|No intervention, this is an observational study
214384238|NCT02914184|BIOLOGICAL|HRV PCV-free liquid vaccine|Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
214384239|NCT02914184|BIOLOGICAL|Rotarix|Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
214384240|NCT04861662|PROCEDURE|Free gingival graft procedure|Free gingival graft procedure applied to implants with KM\<2 mm to increase the width of keratinized mucosa surrounding them
214499319|NCT04646733|OTHER|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.
214499320|NCT04646733|OTHER|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
214499321|NCT04200287|BEHAVIORAL|Online decision aid tool|The decision aid intervention will be presented via a website
214499322|NCT00163046|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
214499323|NCT00163046|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
214687587|NCT06433128|DRUG|Fosmanogepix 400 mg tablets|Fosmanogepix 400 mg tablets for oral administration
214384241|NCT00798174|DEVICE|Standard configuration vs. azygos coil|Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
214384242|NCT00011024|PROCEDURE|Self Hypnosis|
214384243|NCT00011024|PROCEDURE|Acupuncture|
214384244|NCT00011024|PROCEDURE|Osteopathic Manipulation|
214384245|NCT01516775|OTHER|clear fluid ingestion|drinking of clear fluid in preoperative period
214384246|NCT00602186|DRUG|tamsolusin|0.4 mg /day
214499324|NCT05759260|OTHER|Observation|Observation
214499325|NCT02378649|DRUG|Sildenafil|Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
214384247|NCT00602186|DRUG|prazosin|1 mg/day
214384248|NCT03316417|OTHER|Renal Tolerance to Immunotherapy|The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.
214384249|NCT00005788|BIOLOGICAL|aldesleukin|
214384250|NCT06243107|BEHAVIORAL|Tai-chi|Participants will each receive a Tai Chi manual and have access to an instructional audio-visual material via a QR code. The instructional material is tailored specifically for cancer patients. Participants will receive individualized guidance and instructions from the researcher (YH) until they have completed all the executions on the checklist to the required standards.
214499326|NCT02378649|DRUG|Placebo|Placebo comparator concomitant with best practice usual care
214499327|NCT00056966|DRUG|ANTI-CD45|400ug/kg Day-5 through Day-2
214499328|NCT00056966|DRUG|CAMPATH-1H|Day -8 through Day -6 Dosed per Institutional SOP
214687588|NCT05232279|DRUG|Testofen 300mg|Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
214687589|NCT05232279|DRUG|Testofen 600mg|Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
214687590|NCT05232279|DRUG|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
214384251|NCT00674115|DRUG|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.
214384252|NCT00674115|DRUG|omeprazole magnesium|Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.
214384253|NCT00674115|DRUG|sodium bicarbonate|Sodium bicarbonate. Single dose.
214384254|NCT05072288|OTHER|Remote activity program|Participant will have to do exercise at home everyday (15min/day)
214384255|NCT04570553|PROCEDURE|surgical staging|Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
214687591|NCT06370715|DRUG|Insulin Lispro-aabc|Administered SC
214687592|NCT06370715|DRUG|Insulin Glargine|Administered SC
214687593|NCT03538652|OTHER|Formative Interviews (not an intervention)|One hour formative-interview session
214384256|NCT05907460|DEVICE|transesophageal echocardiography examination during cardiopulmonary resuscitation|Perform transesophageal echocardiography in patients with out-of-hospital cardiac arrest during cardiopulmonary resuscitation and adjust the chest compression site to compress the left ventricle and avoid left ventricular outflow tract.
214384257|NCT06305039|DIAGNOSTIC_TEST|Diagnostic tests of cochlear implant or acoustic hearing function|Because the cochlear implant participants in the study will use cochlear implant devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of cochlear implant or acoustic hearing function. This will include perceptual tests of sound localization, speech understanding in noise, binaural fusion, and loudness comparisons.
214384258|NCT06305039|BEHAVIORAL|Targeted aural rehabilitation of the poorer performing ear|Subjects will undergo listening practice on a tablet computer over headphones at home. For the test group, the aural rehabilitation will be targeted at the poorer ear. For the comparison control group, a sham aural rehabilitation will present speech to both ears.
214384259|NCT03020563|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine
214384260|NCT03020563|DRUG|Bupivacaine|Bupivacaine
214996723|NCT06994988|BEHAVIORAL|Questionnaires: Hospital Anxiety & Depression Scale, Central Sensitization Inventory, Pain Catastrophizing Scale, Somatic Symptom Scale-8, Pain Self-Efficacy Questionnaire-10, Athens Insomnia Scale|HADS- measures anxiety and depression (0-21, higher scores signify greater pathology); CSI- measures central sensitization (0-100, higher scores signify greater central sensitization, PCS- measures catastrophizing (0-52, higher scores signify greater catastrophization), SSS-8- measures somatization (0-32, higher scores signify greater somatization), PSEQ-10- measures self-efficacy (0-60, with lower scores signifying low self-efficacy), AIS- measures sleep (0-28, with higher scores signifying greater sleep dysfunction)
214996724|NCT06748066|BEHAVIORAL|RISE-ACL development|A meeting will be organized with all expert panel members to select relevant items. Before the meeting, experts will review a literature on ACL reconstruction return to sport processes. During round 1, the chairperson will ask panel members to suggest items to be included in the scale. Items with agreement from 5 or more members will be included in round 2. In round 2, redundant items will be identified and grouped, and new items will be added based on the literature and expert experience. Selected items will be randomly ordered to create a preliminary 6-level Likert scale (0 = strongly disagree, 5 = strongly agree).
215093349|NCT07088237|BEHAVIORAL|Music Listening|For the music recommendation component, our system suggests music that is tailored to the individual and the specific context. Because we will use machine learning to predict optimal music features based on physiological, contextual, and musical data, the music items will be naturally suggested based on current emotion and level of intensity as well as the current context and problem type. The music recommendation component is an adaptive playlist that is updated as changes in the user's stress level are detected. To provide personalized music recommendations, we use a supervised learning approach to design an algorithm, referred to as music feature prediction, which predicts optimal values of music features (e.g., energy, valence, instrumentalness, acousticness) that are hypothesized to result in reducing stress. These feature values, referred to as effective music features, are then used to generate a personalized music playlist.
215093350|NCT07089394|PROCEDURE|flexible urs|treating pediatric renal stones with flexible urs+holmium laser fragmentation
214384261|NCT05600725|OTHER|novel atrial pacing approach|See US Patent #10987516. An atrial pacing method that preserves atrioventricular and interventricular synchrony to reproduce an exercise-typical envelope of heart rate.
214384262|NCT05600725|OTHER|sham pacing approach|A pacemaker/ICD interrogator/programmer will be used to simulate changes in pacing rate over the same time period as the intervention group but the programming changes will not actually be implemented and not change in paced heart rate will occur.
214384263|NCT01179360|OTHER|Integrated FDG PET/CT|Optimized PET/CT imaging with dedicated head-and-neck protocol
214384264|NCT00525135|DRUG|Valproic Acid|"OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months."
215093351|NCT02591459|OTHER|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
214384265|NCT01642602|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
214499329|NCT00056966|DRUG|FK506|Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
214499330|NCT00056966|DRUG|Fludarabine|Day-8 through Day-5 30 mg/m2
214499331|NCT00056966|RADIATION|Total Body Irradiation|Day-1 single dose 450 cGy
214499332|NCT00056966|PROCEDURE|Stem cell infusion|Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.
214499333|NCT00754000|OTHER|Observation|AE monitoring and EPIC QOL survey
214499334|NCT06404723|DIAGNOSTIC_TEST|Fibrinogen to albumin Ratio and C-reactive to Albumin Ratio|to detect their relation to disease activity to use as predective and prognostic tools
214499335|NCT01780675|RADIATION|Radiation Prophylactic Cranial Irradiation|
214499336|NCT01780675|RADIATION|Radiation Hippocampal Avoidance PCI|
214384266|NCT02611050|BEHAVIORAL|The Multi-vessel Coronary Artery Disease Option Grid|The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
214384267|NCT02611050|BEHAVIORAL|Usual Care|In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
214384268|NCT01538108|DEVICE|PTA Balloon catheter with paclitaxel|patients treated by the NMB's PTA Balloon catheter with paclitaxel
214384269|NCT01538108|PROCEDURE|Plain Balloon angioplasty (PBA)|PBA
214384270|NCT04563390|BEHAVIORAL|Projection-based augmented reality exposure therapy (P-ARET).|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
214384271|NCT04563390|BEHAVIORAL|In vivo exposure therapy|"The intervention will be based on traditional in vivo exposure therapy to real cockroaches. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
214384272|NCT03165162|BEHAVIORAL|Food Order|randomly assigned orders of 7 bowls of granola, each with a different food label.
214384273|NCT00816387|PROCEDURE|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
214384274|NCT00816387|PROCEDURE|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
214384275|NCT05002374|OTHER|Vestibular rehabilitation with optokinetic stimulation|Vestibular rehabilitation incorporated with optokinetic stimulation in virtual reality environment for five consecutive days
214384276|NCT05002374|OTHER|Vestibular rehabilitation|Customized vestibular rehabilitation for five consecutive days
214384277|NCT06241261|DRUG|Silver diamine fluoride gel|Application of 38% SDF gel every 6 months
214384278|NCT06241261|DRUG|Silver diamine fluoride solution|Application of 38% SDF solution every 6 months
214384279|NCT00988546|OTHER|Computer based template for exam documentation|exam documentation performed using computer based template
214384280|NCT00988546|OTHER|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
214384281|NCT05601635|DIETARY_SUPPLEMENT|ButyraGen™|ButyraGen™ contains tributyrin as the primary active as well as Sunfiber®, a partially hydrolyzed guar fiber, and acacia fiber.
214384282|NCT03179800|DEVICE|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
214384283|NCT03179800|OTHER|Sham Implantation|Sham Implantation
214384284|NCT05203575|BEHAVIORAL|Fast-forwarding in Cycle 1|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 1 (first 14 weeks)."
214384285|NCT05203575|BEHAVIORAL|Goal-Setting plus Weekly Nudge in Cycle 1|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks)."
214499337|NCT01662154|DEVICE|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
214499338|NCT01662154|DEVICE|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
214499339|NCT02972359|DRUG|Neridronic acid|Neridronic acid administered as intravenous infusion.
214499340|NCT06033040|OTHER|MRI|Functional sequence imaging (MDME, IVIM) sequences were added to the routine MRI scan of patients with bladder tumor
214499341|NCT02063659|DRUG|Telotristat etiprate|Telotristat etiprate tablets
214499342|NCT02063659|DRUG|Placebo|Placebo-matching telotristat etiprate tablets
214499343|NCT06267300|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
214499344|NCT04518813|DEVICE|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
214499345|NCT04775667|OTHER|questionnaires for clinical assessments|questionnaires for clinical assessments
214687594|NCT03538652|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|In CBT, negative emotional states are viewed as problems to be solved, and the client learns skills to solve them.
214384286|NCT05203575|BEHAVIORAL|Fast-forwarding in Cycle 2|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 2 (second 14 weeks)."
214384287|NCT05203575|BEHAVIORAL|Goal-Setting plus Weekly Nudge in Cycle 2|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks)."
214384288|NCT01829893|DRUG|In combination of 0.2mg finasteride and 5mg tamsulosin|oral medication with 240 mL water
214384289|NCT01829893|DRUG|GL2701 capsule|oral medication with 240 mL water
214384290|NCT00958022|DRUG|LBH589 and carboplatin with etoposide|"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin \& mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."
214384291|NCT06355635|OTHER|Choice and Monitoring|current practive of vasoactive and inotrope drugs
214384292|NCT01460160|DRUG|Dasatinib|Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
214384293|NCT00100932|DRUG|E7389 28 Day Cycle|E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
214384294|NCT00100932|DRUG|E7389 21 Day Cycle|E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.
214384295|NCT00744328|DRUG|Transdermal Estradiol|Estradiol patch ranging in dose from 50 to 200 mcg/day
214384296|NCT00744328|DRUG|Sertraline|Sertraline dose will range from 50 - 200 mg/day
214384297|NCT00744328|OTHER|Placebo|Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
214384298|NCT00000508|BEHAVIORAL|smoking cessation|
214384299|NCT00000508|BEHAVIORAL|diet, reducing|
214384300|NCT00000508|BEHAVIORAL|exercise|
214384301|NCT00000508|BEHAVIORAL|diet, fat-restricted|
214384302|NCT02720822|DRUG|Placebo|Treatment with placebo is given as one double-blind capsule in the morning.
214384303|NCT02720822|DRUG|Morphine Sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
214384304|NCT02720822|DRUG|Plus laxative (Docusate with senna)|If patients are taking morphine, a laxative will be offered. This applies whatever the dose of morphine being taken (8mg, 16mg, 24mg or 32 mg).
214384305|NCT02720822|DRUG|Plus placebo laxative|If the patients are taking placebo, a placebo laxative will be offered.
214384306|NCT02720822|DEVICE|FitBit charge HR (Accelerometer)|A Fitbit will be worn by patients during week 1 and week 3.
214384307|NCT04229030|DRUG|RZL-012|small synthetic molecule for the treatment of Dercum's Disease lipomas
214499346|NCT04044781|DRUG|BPN14770, T2310|Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
214499347|NCT01532999|BEHAVIORAL|Mindfulness Based Stress Reduction|MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
214499348|NCT01532999|BEHAVIORAL|Present Centered Group Therapy|The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
214687595|NCT03538652|BEHAVIORAL|Acceptance and commitment therapy (ACT)|In ACT, negative emotional states are viewed as a necessary and potentially valuable component of a full life. When they occur, the goal is not to solve them, but to experience them in an observant, curious, nonjudgmental way-a practice referred to as mindfulness.
214687596|NCT03538652|OTHER|No intervention|Control group with no intervention administered
214687597|NCT05352893|DRUG|Imsidolimab high dose|intravenous
214687598|NCT05352893|DRUG|Imsidolimab low dose|intravenous
214687599|NCT05352893|OTHER|Placebo|intravenous
214687600|NCT06799845|DRUG|ATX101|ATX101 bupivacaine implants, total of 1,500 mg into the surgical site
214996725|NCT06748066|BEHAVIORAL|RISE-ACL scale validation|"The scale validation phase will involve 162 participants who have undergone ACL reconstruction within the past two years and are in the 'Return to Sport' process, with follow-up in the sports medicine department.~These participants will complete the final version of the RISE-ACL Scale in addition with the ACL-RSI scale and the IKDC Subjective Knee Form.~Validation will consist of testing face validity, construct validity, criterion validity (concurrent validity), and reliability, including internal consistency and test-retest reliability."
214996726|NCT03132792|GENETIC|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells
214996727|NCT00575081|DEVICE|Stereotactic brain procedures|Stereotactic brain procedures
214996728|NCT06249919|BIOLOGICAL|NS101|NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
214996729|NCT06249919|BIOLOGICAL|Placebo|Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
214996730|NCT06747247|DRUG|MT1013|MT1013 is a dual-agonist polypeptide, not only to control iPTH levels in SHPT patients on maintainence dialysis, but also promote bone formation.
214996731|NCT06747247|DRUG|Placebo|Appear similar to MT1013, but has no treatment effect.
214996732|NCT07008976|DRUG|TQB2102 Injection|TQB2102 Injection is a Human Epidermal Growth Factor Receptor 2 (HER2) bispecific antibody-drug conjugate.
214996733|NCT07008976|DRUG|Trastuzumab Emtansine for Injection|Trastuzumab Emtansine for Injection is HER2-targeting antibody-drug conjugate (ADC).
214996734|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
214996735|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
214996736|NCT05260008|DRUG|bupivacaine hydrochloride without epinephrine|bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
214996737|NCT07060755|OTHER|Peppermint oil footbath|This includes a footbath with peppermint oil for 30 minutes each day for 2 weeks
214996738|NCT07060755|OTHER|Warm Water Footbath|This includes a warm water footbath for 30 minutes each day dor 2 weeks
214996739|NCT05742360|DEVICE|CPAP therapy|CPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype
214996740|NCT07101783|DRUG|NNC0662-0419|Participants will receive NNC0662-0419 subcutaneously.
214996741|NCT07103538|BEHAVIORAL|Reflective practices|The intervention was implemented as part of a nursing course consisting of 4 hours of theoretical instruction, 4 hours of laboratory practice, and 8 hours of clinical practice. For 14 weeks, reflective practice was integrated into both the laboratory and clinical components. In the laboratory sessions, clinical scenarios were developed based on five common topics (e.g., infection control, vital signs) that students are likely to encounter during clinical practice. Students performed these scenarios by taking on different roles. Following each role-play, structured reflection sessions were conducted with the students. In the clinical setting, the final hour of each practice day was allocated for reflection. After completing an online reflection form, students had the opportunity to engage in group discussions if they wished to reflect further.
215093352|NCT02489812|BEHAVIORAL|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
214384308|NCT04229030|DRUG|Vehicle|Vehicle of RZL-012 drug product
214384309|NCT04066140|OTHER|No intervention|No Intervention. Observational Study.
214996742|NCT07103395|DRUG|Neoadjuvant therapy|The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.
214996743|NCT07103395|RADIATION|Radiotherapy|Definitive dose of hypofractionated radiotherapy was delivered to patients, with concurrent chemotherapy.
215093353|NCT01756443|DRUG|2% lidocaine/adrenaline and 0.5% bupivacaine|
215093354|NCT05314933|DRUG|2-Deoxyglucose|Intranasal administration
215093355|NCT05314933|OTHER|Placebo|Intranasal administration
214384310|NCT02387216|DRUG|MM-121|Investigational, fully human antibody targeting and inhibiting ErbB3
214384311|NCT02387216|DRUG|Docetaxel|approved chemotherapy treatment for NSCLC
214384312|NCT02724722|BEHAVIORAL|Assigned intervention|a simple flyer plus face-to-face health education and give one bag containing stainless steel-made tableware for eating out use
214384313|NCT02724722|BEHAVIORAL|No intervention|a simple flyer only with no face-to-face health education and give one bag not containing stainless steel-made tableware for eating out use
215093356|NCT05728073|PROCEDURE|ERCP|Patients separated to two groups according to having a ERCP history before the operation
215093357|NCT00443781|PROCEDURE|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
214384314|NCT04381936|DRUG|Lopinavir-Ritonavir|Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.
214384315|NCT04381936|DRUG|Corticosteroid|Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
214384316|NCT04381936|DRUG|Hydroxychloroquine|Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).
214384317|NCT04381936|DRUG|Azithromycin|Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
214499349|NCT04245995|DIAGNOSTIC_TEST|Feature Extraction Technology|The study´s aim was evaluation of the clinical applicability of the Feature Extraction Technology (FET) during a simulated blood loss scenario in comparison to visual estimation.
214384318|NCT04381936|BIOLOGICAL|Convalescent plasma|Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).
214384319|NCT04381936|DRUG|Tocilizumab|Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)
214384320|NCT04381936|BIOLOGICAL|Immunoglobulin|Intravenous immunoglobulin (IVIg) for children \>44 weeks gestational age and \<18 years with PIMS-TS only (see Protocol for dosage)
214996744|NCT07103395|DRUG|Consolidative therapy|Consolidation therapy consists of iparomlimab and tuvonralimab and thymosin alpha 1, for a total duration of 1 year.
214996745|NCT07104916|COMBINATION_PRODUCT|Psilocybin + MBCT therapy|The experimental arm has psilocybin with support and MBCT sessions.
215093358|NCT00443781|PROCEDURE|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
214384321|NCT04381936|DRUG|Synthetic neutralising antibodies|Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation
214384322|NCT04381936|DRUG|Aspirin|150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.
214384323|NCT04381936|DRUG|Colchicine|1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only
214384324|NCT04381936|DRUG|Baricitinib|UK \[age ≥2 years with COVID pneumonia\] and India \[age ≥18 years with COVID-19 pneumonia\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.
214384325|NCT04381936|DRUG|Anakinra|For children ≥1 \<18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \<10 kg in weight.
214384326|NCT04381936|DRUG|Dimethyl fumarate|Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).
214384327|NCT04381936|DRUG|High Dose Corticosteroid|Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.
214384328|NCT04381936|DRUG|Empagliflozin|Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).
214499350|NCT01432769|DIETARY_SUPPLEMENT|dietary supplement high in energy and protein|"patients in the standardized diet will receive extra 500 kcal from the dietary supplement"
214996746|NCT07104916|COMBINATION_PRODUCT|Active Comparator: Psilocybin with Support Only|The active comparator has psilocybin with support only.
215093359|NCT04066634|DEVICE|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
215093360|NCT04112979|BEHAVIORAL|Music|45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
215093361|NCT04112979|BEHAVIORAL|Mother's lap|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
215093362|NCT04112979|BEHAVIORAL|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 dB
215093363|NCT02077543|DEVICE|Brain Tissue Imprint - Medical Device (ProTool)|genomic, transcriptomic and proteomic studies.
214384329|NCT04381936|DRUG|Sotrovimab|UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.
214384330|NCT04381936|DRUG|Molnupiravir|Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.
214384331|NCT04381936|DRUG|Paxlovid|UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.
214384332|NCT04381936|DRUG|Baloxavir Marboxil|"Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4."
214384333|NCT04381936|DRUG|Oseltamivir|"Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)"
214384334|NCT04381936|DRUG|Low-dose corticosteroids: Dexamethasone|Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \<92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
214499351|NCT00914966|BIOLOGICAL|C1 inhibitor (human) [C1 INH]|
214499352|NCT00311714|DRUG|CS-8958 formulated as dry powder|
214499353|NCT00311714|OTHER|Placebo|
214499354|NCT00002095|DRUG|Ganciclovir|
214499355|NCT05454475|OTHER|Change the water injection temperature|Water injection is a routine procedure for endoscopy of small probe ultrasound, and our intervention is to change the water temperature and observe the effects of different water temperatures on patient safety and comfort.
214499356|NCT01298076|DRUG|bevacizumab|Anti-VEGF drug for intravitreal injection
214499357|NCT01298076|DRUG|dexamethasone|Slow-release steroid formulation for intravitreal injection
214996747|NCT07142005|OTHER|Interviews|"* Questionnaires/Survey Measures~* Qualitative Instruments"
214996748|NCT07142590|DIETARY_SUPPLEMENT|Stable Isotopes|15 mg of stable iron isotopes in the form of ferrous sulphate 57FeSO4 will be orally administered to each participant.
214996749|NCT07141589|DRUG|Lidocaine + Bupivacaine + Hyaluronidase|Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU diluted in normal saline to a total volume of 8 ml.
214384335|NCT04381936|DRUG|Low-dose corticosteroids: Dexamethasone|≥18 years old) with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
215093364|NCT00254683|DEVICE|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
215093365|NCT00539422|GENETIC|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
215093366|NCT05736003|PROCEDURE|Laparoscopic cholecystectomy|Removal of gallbladder laparoscopically
215093367|NCT03395561|DIETARY_SUPPLEMENT|green coffee|2 capsuls
214384336|NCT04891796|OTHER|No intervention|No intervention
214384337|NCT03389607|DIAGNOSTIC_TEST|spinal anesthesia|before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma
214384338|NCT00852826|PROCEDURE|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
214384339|NCT00852826|PROCEDURE|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
214384340|NCT05642273|DEVICE|oXiris membrane|oXiris membrane for 24h
214384341|NCT05642273|DIAGNOSTIC_TEST|Blood tests|Blood tests just after randomization (0 h) and at 24 h, 48 h and 7 days
214384342|NCT04919174|DRUG|Remimazolam|Sedation with remimazolam
214384343|NCT04919174|DRUG|Dexmedetomidine|Sedation with dexmedetomidine
214384344|NCT06108089|DIAGNOSTIC_TEST|[18F]MISO-PET/CT|18F\]MISO-PET/CT will be acquired in each patient as the standard of references of tumor hypoxia.
214384345|NCT03257423|DRUG|Ertapenem followed by levofloxacin and metronidazole|Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
214384346|NCT03257423|DRUG|Moxifloxacin|Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
214384347|NCT03257423|PROCEDURE|Appendectomy|Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
214384348|NCT03257423|OTHER|Placebo|Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
214384349|NCT01646684|DRUG|SOM230|
214384350|NCT05716789|PROCEDURE|CPR|CPR in cardiac arrest patients
214384351|NCT01336959|DRUG|BCT197 Part A|open label single dose administration of 10mg BCT197, 2 hours prior to surgery
214384352|NCT01336959|DRUG|Placebo|Single dose matching placebo administered 2 prior to surgery
214687601|NCT06799845|DRUG|bupivacaine hydrochloride|bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration
214384353|NCT01336959|DRUG|BCT197 Part B|BCT197 50mg single dose administered 2 hours prior to surgery
214384354|NCT05377970|OTHER|Thinkific Prehabilitation Exercise Program|Prehabilitation exercise program through the Thinkific platform
214384355|NCT03885804|DRUG|Quadratus lamborum dexmedetomidine intravenous|Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
214384356|NCT03885804|DRUG|Quadratus lamborum dexmedetomidine perineural group(|Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
214384357|NCT00452179|DRUG|APD125|
214384358|NCT02796781|BIOLOGICAL|Lung stem cells|Patients will receive clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
214687602|NCT06799845|DRUG|saline placebo|normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration
214687603|NCT05099172|DRUG|BAY2927088_formulation A|Oral administration
214996750|NCT07141589|DRUG|Fentanyl + Lidocaine + Bupivacaine + Hyaluronidase|Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU and fentanyl 20 μg diluted in normal saline to a total volume of 8 ml.
214996751|NCT07141589|DRUG|Ketorolac + Lidocaine + Bupivacaine + Hyaluronidase|Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, hyaluronidase 60 IU, and ketorolac 15 mg diluted in normal saline to a total volume of 8 ml.
214996752|NCT04021433|DRUG|Ketamine|Repeated doses of IM/SC ketamine up to 3 times a week
214996753|NCT05112432|DEVICE|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. Exercises continuously adjust difficulty level to user performance to maintain an approximately 80% current performance rate. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
215093368|NCT03395561|OTHER|control|2 capsuls
214996754|NCT05112432|BEHAVIORAL|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
214384359|NCT00557622|DRUG|paroxetine|BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
214384360|NCT00557622|OTHER|placebo|placebo
214384361|NCT01539863|OTHER|maintenance care|Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor
214384362|NCT01539863|OTHER|Treatment as needed|Participants may never receive treatment, there is no upper limit
214384363|NCT01097486|BIOLOGICAL|NeoFuse|Single Dose NeoFuse Surgical Implantation
214384364|NCT01097486|PROCEDURE|Allograft|Single Dose Allograft Surgical Implantation
214384365|NCT04962438|DRUG|Anti-VEGF|Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway
214384366|NCT05434221|OTHER|COPE|"The experimental group receives the COPE during their internships. The COPE consists of two part: (1) communication skills teaching and simulation practice; (2) clinical communication teaching: record the clinical treatment process of the interns and turn them into verbatim drafts. Experts then complied the strengths and weaknesses of the interns' communication skills based on the verbatim manuscripts and gave feedback on the interns' communication skills.~The interns in the experimental group will participate 1 time of the communication skills teaching and simulation practice, and 3 times of the clinical communication teaching in three months."
214384367|NCT01962025|PROCEDURE|Buttonhole needling technique|the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
214384368|NCT03450681|PROCEDURE|Pulsed radiofrequency of the saphenous nerve before knee replacement surgery|A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.
214384369|NCT03450681|PROCEDURE|Mock incision|A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
214384370|NCT04412590|OTHER|Vermont Family Based Approach|Comprehensive and individualized program to promote emotional health and wellbeing in families using evidence-based health promotion, prevention and intervention.
214384371|NCT04412590|OTHER|Treatment as Usual|Pediatric care as usual.
214687604|NCT05099172|DRUG|BAY2927088_formulation B_1|Oral administration
214687605|NCT05099172|DRUG|BAY2927088_formulation B_2|Oral administration
214687606|NCT05386394|DEVICE|Active tDCS + Language Therapy|Active tDCS stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 milliamps (mA)/cm2; estimated total charge 0.048 Coulombs (C)/cm2) in a ramp-like fashion for a maximum of 20 minutes. Language therapy will be conducted in conjunction with stimulation and will target oral and written naming.
214996755|NCT05112432|OTHER|Early Psychosis Coordinated Specialty Care|Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.
214384372|NCT01468922|DRUG|Pazopanib|Vascular endothelial growth factor (VEGFR) inhibitor
214384373|NCT01468922|DRUG|ARQ 197|Hepatocyte growth factor receptor (mesenchymal-epithelial transition factor \[c-MET\]) inhibitor
214384374|NCT02381002|OTHER|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
214384375|NCT02991144|GENETIC|scAAV8OTC|non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)
214384376|NCT02991144|DRUG|Reactive Corticosteroid Taper Regimen|"Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301."
214384377|NCT02991144|DRUG|Prophylactic Corticosteroid Taper Regimen|"Oral prednisone \[or oral prednisolone\] 60 mg/day at least 5 days prior to DTX301 administration, tapered over 9 weeks.~A prophylactic corticosteroid taper regimen will be administered to prevent or minimize transient vector-induced hepatic effects."
214384378|NCT06320873|OTHER|archery respiratory parameters|Evaluation of respiratory functions, respiratory muscle strength and shooting performance in archers
214687607|NCT05386394|DEVICE|Sham tDCS + Language Therapy|During sham stimulation, current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Language therapy targeting oral and written naming will be administered during sham tDCS stimulation.
214687608|NCT05233631|PROCEDURE|Therapeutic Endoscopic ultrasound|A minimally invasive procedure to assess digestive (gastrointestinal) and lung diseases. Procedure allows detailed imaging of the regional anatomy by approximating the frequency transducer to the region of interest.
214384379|NCT03591757|DRUG|Tolcapone|Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.
214384380|NCT05399095|BEHAVIORAL|Supine positioning: 5 days|Supine positioning for 5 days after DMEK
214996756|NCT06835751|BEHAVIORAL|Motivational Interviewing for PreP|Participants will receive MI-PrEP only will receive two 1-hour sessions with an intervention counselor. The first session will include information on PrEP and other HIV prevention and harm reduction strategies, and discussion on PrEP contemplation, importance, and confidence, and problem-solving around identified barriers to PrEP. The session will also include information on other available harm reduction strategies and services, including medications for opioid use disorder. The second session will focus on following up on any PrEP actions taken, challenges encountered, and problem-solving to address any challenges. Those ready to be linked to PrEP and/or harm reduction services will be offered an escort to a designated PrEP and/or opioid treatment clinic site or other harm reduction services.
214996757|NCT06835751|BEHAVIORAL|Common Elements Treatment Approach (CETA) + MI-PrEP|Participants will receive CETA+MI-PrEP will receive 7 to 14 weekly one-hour sessions from an intervention counselor. Similar to the MI-PrEP group, women in this study arm will receive the two 1-hour MI-PrEP sessions with an intervention counselor with linkages to PrEP and/or harm reduction services. Women will then begin CETA sessions. The CETA intervention component is a modular and flexible approach comprised of nine elements that can be combined in various ways, including different sequences, to address clients' presenting symptoms and problem areas. CETA currently includes key engagement strategies, including MI, throughout the intervention. The intervention counselor will determine the specific intervention component sessions, sequence of sessions, and dose, or frequency of sessions, based on the primary problem area identified by the participant and intervention counselor as reported in the baseline assessment survey and initial discussions.
214996758|NCT06122220|PROCEDURE|ONSD+AF|Measurement of the optic nerve sheath diameter and of sFLT-1/PGIF index
214996759|NCT06330701|DEVICE|Robotic-assisted mini-PCNL|This robotically enabled hybrid procedure called the MONARCH Mini-PCNL will allow the clinician to obtain retrograde and percutaneous access to participant's kidney under continuous visualization for therapeutic applications (i.e., stone removal).
214384381|NCT05399095|BEHAVIORAL|Supine positioning: 1 days|Supine positioning for 1 days after DMEK
214384382|NCT02172300|DRUG|Tiotropium inhalation capsules|
214384383|NCT02172300|DRUG|Placebo inhalation capsules|
214384384|NCT01472562|DRUG|lenalidomide|"Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle."
214384385|NCT01472562|BIOLOGICAL|rituximab|"Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
214384386|NCT01557621|BEHAVIORAL|Collaborative Pop-Based R/R: Phone/Mail Group|Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
214384387|NCT01557621|BEHAVIORAL|Collaborative Pop-Based R/R: Mail-Only Group|Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
214384388|NCT01557621|BEHAVIORAL|Practice-based Recall|All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
214384389|NCT03788902|DRUG|Ritalin|Single dose of Ritalin IR 0.3-0.5 mg/kg OR placebo
214384390|NCT06116201|OTHER|Estradiol|Estradiol
214384391|NCT06116201|OTHER|Estradiol and Anti-Androgen|Estradiol and Anti-Androgen
214384392|NCT06116201|OTHER|No intervention|No intervention
214384393|NCT00243828|DEVICE|Total Face Mask|
214384394|NCT03062098|DEVICE|ultrasound imaging|Ultrasound imaging during embryo transfer using a small vaginal probe.
214384395|NCT03866642|DEVICE|Cadence Total Ankle Replacment|Cadence Total Ankle prosthesis
214384396|NCT00813410|PROCEDURE|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
214384397|NCT04935723|OTHER|Reiki|The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.
214384398|NCT03354130|OTHER|Processed meat dietary intervention|Randomized cross-over dietary intervention with 5 different diets
214384399|NCT02563522|GENETIC|Engensis (VM202)|gene therapy
214384400|NCT02563522|DRUG|Placebo|Standard of care plus placebo
214384401|NCT03949660|DEVICE|Stimulation for blood pressure without stand|Consists of 80 daily training sessions using epidural stimulation optimized for blood pressure for up to 6 hours of stimulation a day.
214384402|NCT03949660|DEVICE|Stimulation for blood pressure with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
214384403|NCT03949660|DEVICE|Stimulation for trunk and core without stand|Consists of 80 daily training sessions using epidural stimulation optimized for trunk/core/voluntary function for up to 6 hours of stimulation a day.
214384404|NCT03949660|DEVICE|Stimulation for trunk or core with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
214384405|NCT02761460|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
214384406|NCT05296096|OTHER|Protein dosage and rehabilitation team delivered exercise prescription|"The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years.~The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions."
214499358|NCT04409470|DIAGNOSTIC_TEST|Blood gas sampling from artery and vein|Patients included in this study are treated according to clinical routine. After inclusion, sampling of an arterial blood gas and a venous blood gas is performed simultaneously or as close in time as possible. Because the venous blood gas analysis sample can be taken directly from the patient's peripheral venous catheter, no additional venous puncture is usually required and the additional amount of blood that may be required is approx. 1 ml (the assay requires about 500 µl). In the very rare cases where it is not possible to establish a peripheral venous catheter within a reasonable time, the sample will be acquired from a new venous puncture together with other venous routine samples.
214499359|NCT02910973|DEVICE|Vagus Nerve Stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
214499360|NCT02910973|DEVICE|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
214499361|NCT05979038|DRUG|Metformin|Patients in the intervention arm will take metformin 500mg three times a day
214499362|NCT00528320|DEVICE|Ovatio CRT|
214499363|NCT02355041|BEHAVIORAL|Meal Replacement-based Weight Loss Diet|
214996760|NCT06540170|BEHAVIORAL|A personalised self-care support program|A personalized care program consists of three 30-minute face-to-face sessions (once every 2 weeks) after patients' routine wound dressings to enhance self-efficacy, support emotional adjustments, and DFU self-care.
214499364|NCT02355041|BEHAVIORAL|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
214499365|NCT01084941|BEHAVIORAL|Lifestyle Intervention group|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
214499366|NCT01084941|BEHAVIORAL|Standard of Care|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
214499367|NCT01647932|DRUG|hydrochlorothiazide|hydrochlorothiazide according to clearance of creatinine; \>50ml/min 25mg daily, 20-50ml/min 50mg daily amd \<20ml/min 100mg daily.
214499368|NCT01647932|DRUG|Placebo|Placebo according to clearance of creatinine; \>50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd \<20ml/min 2 pills daily.
214499369|NCT04979715|PROCEDURE|physitherapy follow-up|preoperative patient informaiton, information leaflet and Physiotherapy meeting will be held every 2 weeks for 3 months
214499370|NCT04979715|OTHER|control|no intervention; preoperative patient informaiton and information leaflet
214499371|NCT05225376|OTHER|Physical activity sessions for pregnant women|"The physical activity sessions will take place once a week at the Estaing UHC, in the room used for the childbirth and parenting preparation classes of the outpatient obstetrics-gynecology clinic; and twice a week on Zoom. These sessions will be supervised by an APA professional (degree in STAPS and APA).~The measurement of the women's physical conditions will make it possible to adapt and individualize the PA sessions to each woman's level."
214996761|NCT01809808|PROCEDURE|Surgery for acromegaly|(non-experimental) standard procedure
214996762|NCT01809808|DRUG|Medications for acromegaly|(non-experimental) standard procedure
214996763|NCT01809808|DIAGNOSTIC_TEST|Total body magnetic resonance imaging|Subjects will undergo total body MRI with spectroscopy of the muscle and liver before and 3-6 months, 12 and 24 months after surgery or medical therapy for acromegaly.
214996764|NCT01809808|PROCEDURE|Adipose Tissue Biopsy|Subjects will undergo biopsy of subcutaneous adipose tissue before and 12 and 24 months after surgery or medical therapy for acromegaly.
214996765|NCT05511324|BEHAVIORAL|Questionnaires|Participants will be asked to complete this assessment on your own time, and it should take about 40 minutes.
214384407|NCT02007408|DRUG|Paracervical block|
214384408|NCT02007408|DRUG|Lidocaine spray|
214384409|NCT02007408|DRUG|Paracervical block + lidocaine spray|
214384410|NCT00668824|DRUG|Vasovist|
214384411|NCT01466296|DEVICE|Chaotic Perturbation|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the random shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will impose perturbations in the range tolerated by the subject. The therapist will make a written report of each session."
214384412|NCT01466296|DEVICE|Dummy not active shoes|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the dummy shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will not impose perturbations. The therapist will make a written report of each session."
214384413|NCT01466296|DEVICE|Treadmill training|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will exercise basic stretching and muscle strengthening, then walk on the treadmill. A physiotherapist according the subject's rate of improvement will determine the increase in treadmill velocity and slope. The therapist will make a written report after each session.
214384414|NCT01458184|BEHAVIORAL|PhoneCare system|"The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through virtual visits and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation)."
214384415|NCT02762838|BIOLOGICAL|BCD-055|BCD-055 is infliximab biosimilar
214384416|NCT02762838|BIOLOGICAL|Remicade®|
214499372|NCT03273894|DIAGNOSTIC_TEST|Coagulation testing|"* body temperature before the intervention~* body temperature during the intervention including the way of measuring, each 15 minutes~* body temperature at the end of surgery, signs of the patient's heat discomfort~* body temperature during resting time in the postanesthesia care~* standard coagulation tests + EXTEM, FIBTEM - after anesthesia induction~* blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM.~* if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C)."
214499373|NCT04910685|DRUG|Elenestinib|Elenestinib oral tablet
214499374|NCT04910685|DRUG|Placebo|Placebo oral tablet
214499375|NCT05556161|BEHAVIORAL|General Practitioners and Diabetes Specialists Co-management|"Self-monitoring of blood glucose: Participants will monitor blood glucose with a a free intelligent home blood glucose meter. Then, the intelligent blood glucose meter will upload data to the platform.~Glycosylated hemoglobin check:~Cooperative General Practitioner-Specialist Management: Based on the remote monitoring of blood glucose, general practitioners and specialists will jointly carry out management measures including health education, medication adjustment, outpatient consultation, referral, case discussion, etc. for participants."
214687609|NCT06039085|DEVICE|custom device to demonstrate a significant difference in electrical impedance signatures|Custom device will be used to measure electrical impedance signatures.
214687610|NCT06127407|DRUG|Ivosidenib 500mg|Provided as tablets, taken orally as two 250mg tablets once daily.
214687611|NCT06127407|DRUG|Placebo|Provided as tablets, taken orally once daily.
214687612|NCT04058457|DEVICE|DBS|Patients are tested pre-operatively and the post-operatively with their implanted neurostimulators ON and OFF. DBS implantation itself is part of routine care, and not part of the study.
214996766|NCT05511324|BEHAVIORAL|Caregiver Assessment|These sessions will involve simulation-based, caregiving skill training, and your caregiver will be taught skills to help support you (such as feeding, hygiene, mobility, medication administration, and care coordination).
214996767|NCT05696847|DRUG|Tirzepatide|Administered SC
214996768|NCT05696847|DRUG|Placebo|Administered SC
214996769|NCT04945369|OTHER|clinical and biological measurements and questionnaires|"Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.~Assessment of body composition by BOP-POD and by impedancemetry. Assessment of pulse wave by popmetre. Assessment of physical activity by accelerometer and by questionnaire Questionnaires for analysis of eating behaviour"
214384417|NCT02762838|DRUG|Methotrexate|All patients will receive methotrexate in a dose from 10 to 25 mg per week.
214384418|NCT02762838|DRUG|Folic acid|All patients will receive folic acid in a dose of 5 mg per week.
214384419|NCT00675506|DRUG|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
214996770|NCT03323502|BEHAVIORAL|APPROACHES ACP Specialist Program|The APPROACHES Advance Care Planning (ACP) Specialist will work with nursing home leaders (in intervention arm facilities) to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP Specialist Program with patients who have Alzheimer's disease/related dementias and their family caregivers.
214996771|NCT03323502|OTHER|Standard of care|Standard of care Advance Care Planning (ACP) procedures
214384420|NCT00675506|DRUG|Placebo|2-mg sub-cutaneous injections once daily for 12 months
214384421|NCT00936221|DRUG|AZD6244|oral capsules, 75mg twice daily
214384422|NCT00936221|DRUG|Dacarbazine|1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
214384423|NCT00936221|DRUG|Placebo|Placebo
214384424|NCT05425849|OTHER|rose oil aromatherapy|Aromatherapy refers to the medicinal or therapeutic use of essential oils absorbed through the skin or the olfactory system. The positive effects of social support, such as hand-holding, on anxiety and pain have been described
214384425|NCT03820323|DIAGNOSTIC_TEST|POC VL and targeted DRM testing.|Point-of-care Viral Load Testing will be done to ensure that providers and caregivers receive the results with in 24 hours study. Targeted DRM testing will be performed during the initiation of ART and when viremia (VL\>1000 copies/mL) is detected.
214384426|NCT03820323|DIAGNOSTIC_TEST|SOC VL testing|SOC VL testing is done at 6 months after ART initiation then every 3 months if unsuppressed, otherwise every 12 months. DRM testing is conducted only if failing 2nd line ART.
214384427|NCT03151395|OTHER|Sputum and blood sampling|Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
214384428|NCT00796432|DRUG|OROS paliperidone|
214384429|NCT05247827|OTHER|Targeted phantom limb motor execution (exercise)|The targeted phantom motor execution is a specific training program for people with TTA that has been designed to improve the muscles' strength, coordination, and flexibility at the amputated and contralateral intact sides. Such training consists of repeated short-term, short rest interval, and moderate-intensity exercises (Schoenfeld 2010, Krutki, Mrowczynski et al. 2017). Targeted phantom motor execution can improve the body image considering its induced muscular impacts. People with TTA will be trained to follow specific movements of their foot-ankle complexes simultaneously, in order to increase PLA, as well as induce muscular morphologic and brain neuroplastic changes (Moseley and Brugger 2009).
214384430|NCT02921373|BIOLOGICAL|19F Cell Sense-labeled PBMC|"Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging."
214384431|NCT02921373|DEVICE|MRI|Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
214384432|NCT01100060|DRUG|azithromycin (AZ) microsphere|AZ microsphere (2000 mg) single dose on Day 1.
214384433|NCT01100060|DRUG|test chloroquine (CQ) formulation|Test CQ formulation, 620 mg CQ base, single dose on Day 1.
214384434|NCT01100060|DRUG|azithromycin (AZ)|AZ IR 4 x 500 mg tablets, single dose on Day 1.
214384435|NCT01100060|DRUG|chloroquine (CQ)|CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
214384436|NCT05981963|DRUG|[14C]-BMS-986196|Specified dose on specified days
215093369|NCT00964301|OTHER|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
215093370|NCT00964301|OTHER|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
214384437|NCT00879996|DRUG|Methadone|Oral, 10-60 mg per day, 2-4 times per day, 6 months
214384438|NCT00879996|DRUG|Buprenorphine/naloxone|Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
214384439|NCT01141270|DRUG|AFOLIA|single sc injection, 225 IU
214384440|NCT01141270|DRUG|Gonal-f|single sc injection, 225IU
214384441|NCT02078505|BEHAVIORAL|diet|Carbohydrate poor diet
214384442|NCT01566929|DIETARY_SUPPLEMENT|Low calorie diet treatment|Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
214384443|NCT03811106|DEVICE|NeuromuscularElectricalStimulation+ConventionalPhysiotherapy|Sırt ekstansör kaslarına nöromusküler elektrik stimülasyonu uygulanacaktır
214384444|NCT03811106|OTHER|Conventional physiotherapy and rehabilitation|Konvansiyonel fizyoterapi ve rehabilitasyon uygulamaları yapılacaktır.
214384445|NCT04426084|OTHER|Hypertension|Exposure : Any registered diagnosis of I10 within 15 years or a registered pick-up of a prescription of antihypertensive treatment (ATC C02CA, C02DB02, C03, C07, C08, C09) within one year before index date in the Swedish prescribed drug register (exluding those with a registered diagnosis of other indications for betablocker (heart failure, atrial fibrillation) or ACE-inhibitor, ARB(heart failure) ) Exposures will be compared between cases and controls and between cases with different outcomes and controls
214384446|NCT04426084|OTHER|Diabetes type 2|"Exposure: Any registered diagnosis of E11 within 15 years or a registered pick-up of a prescription with any antidiabetic treatment (ATC A10) within one year before index date in the Swedish prescribed drug register.~Exposures will be compared between cases and controls and between cases with different outcomes and controls"
214384447|NCT04426084|OTHER|Obesity|Exposure: Diagnosis ICD E66 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes and controls
214384448|NCT04426084|DRUG|Antihypertensive Agents|"Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date.~Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls"
214384449|NCT04426084|DRUG|Statins (Cardiovascular Agents)|Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.
214384450|NCT04426084|OTHER|Chronic kidney disease|Exposure: Diagnosis ICD N18 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes (mechanical ventilation, continuous renal replacement therapy mortality) and controls. Exposures will thereafter be compared in subgroups by BMI at ICU-admission and in subgroups matched by history of type 2 diabetes.
214384451|NCT02597933|DRUG|Nintedanib|
214384452|NCT02597933|DRUG|Placebo|
214384453|NCT00001626|DRUG|antithymocyte globulin|antithymocyte globulin
214499376|NCT06571058|OTHER|Assistance|Assist patient with walking approximately 90 feet
214499377|NCT06571058|OTHER|Educational Intervention|Receive a short instructional session
214499378|NCT06571058|DEVICE|Medical Device Usage and Evaluation|Wear the B3 Buddy device
214499379|NCT06571058|OTHER|Medical Device Usage and Evaluation|Secure the urinary drainage bag to the patient using the B3 Buddy device
214499380|NCT06571058|OTHER|Questionnaire Administration|Ancillary studies
214499381|NCT06571058|PROCEDURE|Remove|Remove the device and return urinary drainage bag to the standard position
214499382|NCT06571058|OTHER|Walking|Walk approximately 90 feet
214499383|NCT06312254|DRUG|Topical lidocaine 5%|Drug is used to pharmacologically modulate peripheral sensory afferents
214499384|NCT06312254|DRUG|Topical Phenytoin 10%|Drug is used to pharmacologically modulate peripheral sensory afferents
214499385|NCT06312254|DRUG|Topical Mepyramine 2%|Drug is used to pharmacologically modulate peripheral sensory afferents
214499386|NCT06312254|OTHER|Topical Placebo|Drug is used as control
214499387|NCT06809907|DEVICE|Kintsugi Voice Device|The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression. The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs.
214499388|NCT05557006|PROCEDURE|left bundle branch pacing|In the procedure of left bundle branch pacing, various QRS morphologies are observed as penetrating the lead into the interventricular septum.
214499389|NCT00507884|PROCEDURE|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
214499390|NCT03169413|GENETIC|Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.|Gene study
214384454|NCT00001626|DRUG|cyclophosphamide|cyclophosphamide
214384455|NCT00001626|DRUG|cyclosporine|cyclosporine
214384456|NCT06469411|BIOLOGICAL|Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)|Patients in the intervention arm received 6 doses of secretome of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) 4 cc dissolved in albumin 20% every week for 6 weeks
214499391|NCT03657316|BEHAVIORAL|nutrition education|"The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages"
214499392|NCT06652750|OTHER|Routine Management|Conducting routine in-office follow-up for CIED paitents
214499393|NCT06652750|DEVICE|5G Cloud Follow-up|This study employed a 5G-cloud follow-up platform, a research tool that allows a device specialist to test, and program CIEDs in real-time from a remote location via an internet connection or mobile wireless network. Consistent with of the 5G remote support terminal externally connected to the programmer, a PAD was installed with a 5G-cloud follow-up app. The onsite medical staff began the cloud follow-up session by contacting the remote device specialist via video call. The connection to the CIED was made by the medical staff through the use of a standard programmer. He was in charge of turning on the programmer and applying the programmer wand to the patient's device. After an initial introduction, communication was established and continued via the wand connection. The remote device specialist logged into the 5G-cloud follow-up app with two-step verification. The remote device specialist then had complete control of the programmer to check and reprogram the device as needed.
214384457|NCT06469411|OTHER|4 cc distilled water dissolved in albumin 20%|Patients in the control arm received 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks
214687613|NCT01415037|PROCEDURE|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
214384458|NCT05424445|DRUG|Misoprostol|Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.
214384459|NCT01627080|OTHER|Cardiac Biomarker Blood Draws|Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
214384460|NCT01806519|BEHAVIORAL|Motor control intervention of head posture|"The tailored motor control intervention used for motor learning-procedure described by Fitts and Posner, further developed and adapted to rehabilitation of the spine by O´Sullivan.~The stages involved in the process was the Cognitive stage, Associative stage and the Autonomous stage"
214384461|NCT04205929|DRUG|Placebo|Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
214384462|NCT04205929|DRUG|Curcumin|Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
214384463|NCT00543660|PROCEDURE|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
214384464|NCT04035655|BEHAVIORAL|Coma Recovery Scale - revised|"Assessment of the level of consciousness by the dedicated Coma Recovery Scale - Revised, current gold-standard in consciousness level assessment.~Assessment before and after the tDCS session (immediately before and after the electrophysiological assessment, see below)."
214384465|NCT04035655|DIAGNOSTIC_TEST|Electrophysiological recordings|"The electrophysiological assessment consisted of:~* a 5 minutes resting state high-density EEG recording~* a approximately 6 minutes auditory oddball paradigm These two procedures were administered immediately before and after the tDCS session"
214384466|NCT00695747|PROCEDURE|2 Site procedure- Phacoemulsification/IOL and Trabeculectomy|2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
214384467|NCT03747770|BIOLOGICAL|Bivalent HPV vaccine CERVARIX®|Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04)
214384468|NCT04232189|OTHER|no intervention|no intervention, just specimen collection
214384469|NCT06031597|RADIATION|radiotherapy|"Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week."
214384470|NCT06031597|DRUG|Platinum-Based Drug|Cisplatin 25 mg/m2 once per week for a total of 5-6 cycles. For participants who have not completed 4 cycles of conversion chemotherapy in combination with immunotherapy, the original chemotherapy regimen may also be used, with the total number of chemotherapy cycles not exceeding 6 cycles.
214384471|NCT06031597|DRUG|Immunotherapy|Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.
214384472|NCT06031597|DRUG|Immunotherapeutic Agent|All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.
214384473|NCT02142582|DIETARY_SUPPLEMENT|WHO ORS|Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
214384474|NCT02142582|DIETARY_SUPPLEMENT|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
214499394|NCT06977984|BEHAVIORAL|Integrative Breathwork Intervention|The breathwork intervention involves a sustained conscious connected breathing pattern where there is no pause between inhale and exhale. During the breathing, a participant is guided to pay attention to the strongest sensation from moment-to-moment (e.g., mindfulness of somatic sensations) and relax unnecessary effort or tension. Participants lay supine throughout the 60 minute session. The session ends with spontaneous, relaxed breathing and an opportunity to briefly share one's experience.
214499395|NCT06613048|OTHER|Breathing exercise|"The researcher has a certificate in breathing exercises. Those who consent to participate in the study that meets the research criteria will be given training with a prepared training brochure about correct breathing technique, introduction and function of the diaphragm muscle, box breathing technique, diaphragm breathing technique and benefits of correct breathing before the exercise.~Box breathing technique will be applied in addition to standard treatment, 3 sets per day (morning, noon and evening) for 6 weeks, 10 repetitions in each set.~Diaphragm breathing exercise will be applied in addition to standard treatment, lasting 2 minutes in the first week, then increasing each week and reaching 12 minutes in the 6th week, as 3 sets (morning, noon and evening)."
214499396|NCT06232408|DRUG|RP-1664|RP-1664 will be supplied as immediate-release solid dosage form for oral self-administration.
214499397|NCT06109454|DRUG|Huaier granule|The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.
214384475|NCT03070509|DRUG|Lisdexamfetamine|lisdexamfetamine 50 mg single dose
214384476|NCT05561348|DEVICE|Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time. In the sham stimulation group, the electrodes were fixed at the same position without releasing current.
214384477|NCT04746651|OTHER|Guided Self Help|Guided self help appointments with prison staff - 4x 30 minute appointments.
214384478|NCT01920503|DRUG|Doxorubicin|Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
214384479|NCT01863927|OTHER|Research intervention|After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
214384480|NCT01107743|DRUG|Amlodipine/Atorvastatin|"Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.~Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.~For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.~Amlodipine~* Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.~* Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin~* Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.~* Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily."
214384481|NCT04227496|DEVICE|Auditory disturbances|A sound will be played from a portable device (smartphone) during movement
214384482|NCT00308737|DRUG|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
214384483|NCT00308737|DRUG|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
214384484|NCT04975828|DIAGNOSTIC_TEST|albumin creatinine ratio -EGFR-fundus examination- coronary angiography.|albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.
214384485|NCT02224482|BEHAVIORAL|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
214499398|NCT06109454|OTHER|Control|The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg/m2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg/m2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg/m2, intravenous injection, first day) every three weeks, with a maximum of four cycles.
214499399|NCT03643055|DIAGNOSTIC_TEST|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
214499400|NCT02460393|DRUG|Humanized TNFα monoclonal antibody|"Subcutaneous injection of different doses for healthy people~Subcutaneous injection of different doses in healthy people"
214499401|NCT02460393|OTHER|placebo|Subcutaneous injection of different doses for healthy people
214499402|NCT04797468|DRUG|HLX23|administered IV.
214499403|NCT06985342|DRUG|Rimegepant|Rimegepant 75 mg orally disintegrating tablet (ODT), administered as a single dose
214499404|NCT06985342|DRUG|Zavegepant|Zavegepant 10 mg nasal spray, administered as a single dose
214499405|NCT02544880|DRUG|Tadalafil|Tadalafil tablets administered by mouth. Dose will be between 10 to 20 mg adjusted depending on patient's body weight. On course 1, Tadalafil will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil will be administered daily for 14 consecutive days. No Tadalafil will be provided on Course 5.
214499406|NCT02544880|BIOLOGICAL|Anti-MUC1 Vaccine|300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
214996772|NCT06638619|BEHAVIORAL|Biofeedback Fixation Training|This training type involves the use of microperimetry. Microperimetry is a visual field test that incorporates perimetry and retinal imaging and is a standard ophthalmic clinical technology. It allows for direct observation of the fundus, but uses an eye-tracking system to compensate for involuntary eye movements. A program designed to train patients to direct and hold their gaze at an eccentric location programmed by the controller will be used. When the participant directs their gaze towards the pre-programmed location, a sound of increasing frequency is emitted to let them know they are approaching the correct location. The sound stabilizes into a solid tone when the patient is gazing directly at the trained location (biofeedback) and they are asked to attempt to hold their gaze at this location for as long as possible.
214384486|NCT00880321|DRUG|GSK2118436|Dose escalation with GSK2118436 may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached.
214384487|NCT00880321|DRUG|GSK2118436|Part 2 will use the recommended Part 2 dose of GSK2118436 identified during Part 1 of the study. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
214384488|NCT00880321|DRUG|Midazolam|Midazolam will be administered alone and with GSK2118436 in a sub-set of subjects in Part 2 to study the effect of GSK2118436 on CYP3A using midazolam as a probe.
214384489|NCT02218528|DIETARY_SUPPLEMENT|Plant-based ingredient|
214384490|NCT02218528|DIETARY_SUPPLEMENT|No Plant-based ingredient|
214499407|NCT02544880|BIOLOGICAL|Anti-Influenza Vaccine|300 uL Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
214499408|NCT02544880|OTHER|Tadalafil Placebo|Placebo tablets mimicking Tadalafil administered by mouth. On course 1, Tadalafil Placebo will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil placebo will be administered daily for 14 consecutive days. No Tadalafil Placebo will be provided on Course 5.
214499409|NCT02544880|OTHER|Anti-MUC1 Vaccine Placebo|Placebo for Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Placebo for Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5..
214499410|NCT02544880|OTHER|Standard of Care Treatment|Treatment according to prescribed standard of care regimen.
214384491|NCT05439577|DRUG|Mucopolysaccharide Polysulfate Cream|Patients using Hirudoid® alone
214384492|NCT05439577|DRUG|Mucopolysaccharide Polysulfate Cream and glucocorticoids|Patients using Hirudoid® and glucocorticoids (Combination therapy, but not always)
214384493|NCT00373932|BEHAVIORAL|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
214384494|NCT00373932|BEHAVIORAL|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
214384495|NCT00818064|DRUG|anti-IL-20|Single s.c. injection (per dose cohort)
214384496|NCT00818064|DRUG|placebo|Single s.c. injection (per dose cohort)
214384497|NCT04336423|DIAGNOSTIC_TEST|Obtain samples from sputum and feces|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
214384498|NCT02390063|BIOLOGICAL|ChAdOx1.5T4|A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
214384499|NCT02390063|BIOLOGICAL|MVA.5T4|A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
214384500|NCT02390063|DRUG|Cyclophosphamide|Metronomic cyclophosphamide (50mg bd)
214384501|NCT02225977|DRUG|Gilenya|
214384502|NCT06489691|OTHER|6-minute walk test (6MWT)|6-minute walk test (6MWT) will be performed according to clinical standards
214384503|NCT06568744|OTHER|Intervention resuscitation|"In fluid responsive patients, fluid intolerance will be checked.~Lung Ultrasound (LUS): Anterior LUS with 4-point assessment at each hemithorax. Min:0 and a max:24. Low risk: \< 10; intermediate risk: 10-14 or delta of 2 points. High risk: \>14, or an increase \>4 from baseline.~VExUS: Low risk: Grade 0-1. Intermediate risk: 2. High risk: 3 E/e' ratio: Low risk: \<8. Intermediate risk: 8-13. High risk \>14. Central venous pressure (CVP): Low risk \<12 mmHg. Intermediate risk: 12-15 mmHg or a delta of 3 mmHg. High risk \> 15 mmHg or \>5 mmHg increase after a fluid challenge.~In low-risk, a fluid challenge of 500 ml of balanced crystalloid will be performed in 30 minutes. If intermediate risk, a fluid challenge of 250 ml of balanced crystalloid in 30 minutes. If high-risk signals, alternative strategies (vasopressor and inodilator tests) will be deployed. After each challenge, peripheral perfusion, fluid responsiveness and intolerance will be re-assessed."
214384504|NCT06568744|OTHER|Standard of Care resuscitation|In fluid responsive patients, fluid challenges of 500 ml of balanced crystalloid will be performed in 30 minutes. After a fluid challenge, peripheral perfusion status and fluid responsiveness will be re-measured. If the patient persists with hypoperfusion, successive fluid challenges will be performed until hypoperfusion resolves or the patient becomes fluid unresponsive. If hypoperfusion signals persists and the patient becomes fluid unresponsive, alternative resuscitation interventions will be deployed, which include: 1) vasopressor titration to higher mean arterial pressure (MAP) targets in a MAP-test, and 2) addition of an inotrope to increase cardiac output in an inodilator test. If hypoperfusion fails to resolve, rescue therapies such as high-volume hemofiltration will be initiated.
214384505|NCT02735837|DRUG|Doxycycline Group|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
214499411|NCT02544880|OTHER|Anti-Influenza Vaccine Placebo|Placebo for Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Placebo for Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
214499412|NCT01939288|DEVICE|Neuromuscular stimulation, followed by intermittent pneumatic compression|
214499413|NCT01939288|DEVICE|Intermittent pneumatic compression, followed by neuromuscular stimulation|
214499414|NCT06812754|DRUG|Fezolinetant|oral
214499415|NCT06812754|DRUG|Placebo|oral
214499416|NCT06981208|OTHER|ChatGPT-generated patient education|This is created by entering the patient's age, medical history, social history, and case-specific details into Washington University ChatGPT Beta (HIPAA and FERPA compliant) by a study team member.
214499417|NCT06981208|OTHER|Usual patient education|Usual patient education will include description of breast reconstruction options, with further elaboration on which option are more suitable to the patient. This include also review of risk of complications and expected recovery after surgery.
214499418|NCT04724759|DRUG|Dexmedetomidine / Ketamine / Lidocaine|Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
214687614|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
214687615|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
214996773|NCT06638619|BEHAVIORAL|Saccadic Reading Training|Participants will be assigned to participate in an at-home reading program. The reading exercises consist of worksheets with letter and number combinations of increasing complexity and font sizes. They are intended to increase accuracy in identifying letters and numbers. Worksheets will initially be dispensed with larger font type and spacing and be graded at weekly intervals towards regular, newspaper-size print and spacing over the course of training.
214384506|NCT02735837|DRUG|placebo topical gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
214384507|NCT01946581|PROCEDURE|Cataract Surgery|
214384508|NCT04443387|DRUG|Vitamin D|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
214996774|NCT06300996|DEVICE|Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)|Spinal cord stimulation is FDA approved for treatment of pain. We are proposing utilizing the same technology to help restore motor control in people who have declining function due to the progression of SMA. These are 2-4 leads that are FDA-approved.
214384509|NCT04443387|OTHER|Placebo|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
214384510|NCT05242575|BEHAVIORAL|The information provided in the iVFT and control book parallel one another.|"An immersive virtual fled trip (iVFT) is a form of virtual reality (VR). The term immersive refers to an experience where the senses become heightened through multisensory input (e.g., visual, auditory, proprioceptive). When adding peripherals such as a head-mounted device (HMD) (e.g., goggles with 3D-lenses), a mobile phone becomes a pseudo-theater providing a 360-degree view that mimics the real world. For example, one can experience a simulated rollercoaster or visit the moon that may otherwise be inaccessible in day-to-day life. Also, a VFT provides for context and aids in background knowledge that is a crucial aspect of learning.~Participants will receive three interventions sessions each last 15-minutes."
214996775|NCT05842668|BEHAVIORAL|ESWL Group|Increasing comfort and reducing pain during ESWL
214996776|NCT05691283|DEVICE|trans cranial direct current stimulation (tDCS)|Three weeks of 20-minute tDCS stimulation
214384511|NCT04548271|DRUG|Camrelizumab|Anti-PD-1 targeted immunotherapy
214384512|NCT04548271|DRUG|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
214384513|NCT03757806|OTHER|Experimental group|"LiFE4D is an individualised programme, adapted to the participant's needs/preferences.~People with Dementia will receive assistance to increase their physical activity multiple times/day in their everyday tasks with the support/supervision of their caregivers.~The programme last for 12 weeks, with a lower face tracking over time with the health professional but replaced by caregivers. The intervention includes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt physical activity to everyday tasks, increase tasks frequency and intensity, monitor progress, clarify doubts, motivate and manage expectations. Phone calls aim to monitor motivation/evolution and clarify doubts."
214384514|NCT04078035|BEHAVIORAL|Socio-evaluative speech task|5-minute speech task designed to induce physiological arousal in a laboratory setting.
214384515|NCT04078035|BEHAVIORAL|Control, Quiet Rest|5-minute quiet rest period.
214384516|NCT05250258|OTHER|Telephone peer support by telephone|"Peer support by telephone from experienced father to new father with depressive symtoms.~4 times or more if requested during 4 months"
214384517|NCT00288028|DRUG|bortezomib|Dose of Bortezomib\* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
214384518|NCT00000942|DRUG|Nevirapine|
214384519|NCT00829361|OTHER|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
214384520|NCT04996199|DRUG|Oxcarbazepine|oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
214384521|NCT04996199|DRUG|Carbamazepine|carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks
214384522|NCT03767985|OTHER|Dichoptic video game therapy|Dichoptic video gaming for 1 hour per week, viewed through the Oculus Rift.
214384523|NCT03767985|OTHER|Occlusion therapy|Occlusion therapy for 2 hours per day, 7 days a week
214384524|NCT04642586|DIAGNOSTIC_TEST|multimodal magnetic resonance imaging|Brain MRI exam (without contrast injection)
214384525|NCT04642586|DIAGNOSTIC_TEST|blood test|Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .
214384526|NCT04642586|DIAGNOSTIC_TEST|neuropsychological assessment|neuropsychological assessment
214384527|NCT02164097|DRUG|ODSH|
214384528|NCT00189111|PROCEDURE|Cardiac Imaging + Treatment|
214384529|NCT01644396|BIOLOGICAL|Adalimumab|
214384530|NCT06495437|BIOLOGICAL|Intravenous infusion of extracellular vesicle preparation derived from Wharton's jelly mesenchymal stem cells.|The trial protocol includes a 3-week screening period and a 12-week study period after enrollment. The specific trial protocol is detailed in the figure above. Cell-derived extracellular vesicle formulation will be administered at week 0, with central visits conducted during the administration period. Central visits will also be conducted at weeks 1, 4, and 12 post-administration, with a phone visit at week 8. The entire study will last for 12 weeks. Following the final follow-up visit, further observation of the intervention's effects and safety will continue for an additional 3 months. During this 3-month period, there will be no artificial intervention or restriction on the medication and biological methods for the participants in each group.
214384531|NCT04192474|DEVICE|Flexible cystoscopy|Treatment with the investigational device: Ambu® aScope™ 4 Cysto
214384532|NCT06241196|DEVICE|implant|Implant will be placed through the surgical guide in the extraction socket
214384533|NCT06241196|PROCEDURE|Vestibular Socket Therapy|tunnel incision will be made in labial vestibule
214384534|NCT06241196|DRUG|Alloderm|allogenic soft tissue substitute
214996777|NCT05691283|DEVICE|Sham|Three weeks of sham stimulation
214996778|NCT05524883|DRUG|DYNE-251|Administered by IV infusion
214996779|NCT05524883|DRUG|Placebo|Administered by IV infusion
214996780|NCT02816021|DRUG|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
214996781|NCT02816021|DRUG|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
214996782|NCT03293524|GENETIC|GS010|GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
214384535|NCT06241196|DRUG|Xenogenic bone membrane shield|xenogenic bone membrane
214499419|NCT06856733|BEHAVIORAL|Person-centred team-based approach|"Phase 1 (investigation and assessment, week 1-3):~* A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.~* A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.~* A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.~* A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.~* A visit to a care manager~Phase 2 (treatment plan, week 3-4):~\- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.~Phase 3 (treatment and follow-up, week 4-24):~* Implementation of the individualized rehabilitation plan.~* Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.~* A second team consultation half-way"
214996783|NCT03293524|DRUG|Placebo|The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
214384536|NCT06241196|PROCEDURE|Connective tissue graft|soft tissue harvesting from palate
214384537|NCT06475287|DRUG|HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450|The combination therapy of HAIC with TQB2450 and Anlotinib was administered to enrolled patients in no particular order. Patients received routine hepatic artery catheterization via femoral artery puncture, followed by routine hepatic artery catheterization and infusion chemotherapy with 5% sodium bicarbonate 150ml + liposomal mitoxantrone (10mg) for 2-4 hours + Raltitrexed (2mg/m2) for 2-4 hours, every three weeks for at least two cycles. Systemic treatment was given every 21 days, with a fixed dose of 1200mg of TQB2450 injection on the first day of each systemic treatment cycle (1-7 days after HAIC treatment), administered intravenously over 60 minutes initially, followed by 30 minutes if tolerated. Anlotinib was administered orally once daily at a dose of 10mg, with a two-week break every three weeks. Treatment continued until unacceptable toxicity or loss of clinical benefit (as assessed by the investigator based on imaging, biochemical indicators, and patient clinical status).
214384538|NCT05825664|PROCEDURE|Endoscopic resection|Group 1: Polyps are resected by UEMR Group 2: Polyps are resected by CEMR
214384539|NCT00927043|OTHER|Epidemiological study according to clinical practice|Epidemiological study according to clinical practice.
214499420|NCT06864546|BEHAVIORAL|Physical activity intervention|"In the first week, patients will be asked to maintain their normal sedentary life, spending most of the waking day sitting. During the second week, participants will be asked to take at least 10,000 steps/day, with sitting replaced by standing and light-intensity walking.~See doi: 10.1007/s00125-016-4161-7"
214499421|NCT07013812|DRUG|Tranexamic Acid (IV)|One gram (10 ml) intravenous injection
214687616|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
214687617|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
214687618|NCT02251444|PROCEDURE|outpatient rehabilitation program|
214384540|NCT04394845|DIAGNOSTIC_TEST|[18F]GTP1|\[18F\]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]), with a maximum drug mass dose of 10 microgram (μg).
214384541|NCT04683523|OTHER|Exercise|Resistance training using dumbbells and therabands
214384542|NCT05453981|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention|Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy. It targets common sleep disturbances in disorders and has improved disorder-focused symptoms and sleep and circadian functioning in patients with Severe mental illness (SMI).
214384543|NCT05696314|DIAGNOSTIC_TEST|Transoral Ultrasound|The oropharynx is scanned using high-frequency, small-footprint ultrasound transducers placed onto the suspected oropharynx sub-locations (e.g. tonsils or tongue base). Lidocaine spray or gel will be applied prior to scanning to reduce the gag reflex.
214499422|NCT07013812|DRUG|Dextrose 5% (D5W)|5% dextrose water intravenously
214499423|NCT07012590|DRUG|Morphine|Patients received erector spinae plane block with morphine 2 mg as an adjuvant to bupivacaine 30 ml 0.25%.
214687619|NCT02251444|PROCEDURE|physical therapy|
214687620|NCT04237402|OTHER|Hair follicles sampling|The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
214687621|NCT04611763|DRUG|Flurbiprofen axetil preoperatively|give Flurbiprofen axetil 15 min before surgery
214687622|NCT04611763|DRUG|Flurbiprofen axetil postoperatively|give Flurbiprofen axetil at the end of surgery
214687623|NCT01640990|DRUG|Saline|30mins run-in period
214687624|NCT01640990|DRUG|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
214687625|NCT01640990|DRUG|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
214687626|NCT06346457|DRUG|Tamoxifen|Tamoxifen is 20 mg once daily for two to three weeks.
214687627|NCT06346457|DRUG|Letrozole|Letrozole (Aromatase inhibitor) is 2,5 mg once daily for two to three weeks.
214996784|NCT03295851|DRUG|Ferric carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
214996785|NCT03295851|DRUG|Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
214996786|NCT02278354|DRUG|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
214996787|NCT02278354|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post injection
214996788|NCT00562328|BIOLOGICAL|Alemtuzumab|"Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week."
214996789|NCT00562328|BIOLOGICAL|Rituximab|"Weeks 2-5:~375 mg/m\^2 by IV once weekly"
215093371|NCT05349383|DRUG|Antibody-Drug Conjugate|"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
214384544|NCT05696314|DIAGNOSTIC_TEST|Transcervical Ultrasound|Curved low-frequency ultrasound transducers will be placed on the submental region on the skin of the neck, and the tongue base will be visualized in the midline in transverse and sagittal planes. The tonsils will be visualized adjacent to the tongue base on either side in oblique transverse and oblique sagittal planes, deep to the submandibular glands.
214384545|NCT05482737|OTHER|no intervention|This is an observational retrospective study (meta-analysis)
215093372|NCT05349383|DRUG|Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate|We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
214384546|NCT05657444|DRUG|Tenecteplase|intra-arterial tenecteplase during endovascular treatment
214384547|NCT03535831|DIAGNOSTIC_TEST|18F-DCFPyL|The purpose of this study is to determine if use of 18F-DCFPyL would increase the detection of lesions and to better inform your oncologist on the best method of treatment for your disease.
214384548|NCT03312686|DIAGNOSTIC_TEST|endoflip|Resolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
214384549|NCT04937036|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
214384550|NCT00740103|DRUG|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
214384551|NCT04637165|OTHER|This is a non-interventional study|This is a non-interventional study
214384552|NCT04783298|OTHER|App|An application to deliver a series of behavioral questionnaires and decision-making game
214384553|NCT01181505|DRUG|Tolterodine|
214384554|NCT05324345|BEHAVIORAL|Prehabilitation group|All patients will be guided to use the network learning platform which including details in text, pictures and videos of their individualized prehabilitation strategy after a complete assessment. Multimodal prehabilitation strategy includes conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence), physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training), nutritional suggestion and optimization (whey protein supplement), and psychological therapy. All movements can be practiced with the reference to the standard videos in the network learning platform. Patients will check the prehabilitation content daily and form their own training tasks in the network learning platform. Standardized short message interviews will be sent to patients twice a week to optimize adherence and promote timely feedback.
214384555|NCT00526383|DRUG|Tricyclic antidepressants|antidepressant version medical dispositive
214384556|NCT03065114|OTHER|PGS|chromosome abnormality test from PGS and relationship between embryo development
215093373|NCT00582738|DRUG|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
215093374|NCT00582738|DRUG|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
214384557|NCT00960921|DRUG|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
214499424|NCT07012590|DRUG|Dexmedetomidine|Patients received erector spinae plane block with dexmedetomidine 100 µg as an adjuvant to bupivacaine 30 ml 0.25%.
214499425|NCT07012590|OTHER|Erector spinae plane block|Patients received erector spinae plane block with bupivacaine 30 ml 0.25% only.
215093375|NCT02634021|DRUG|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
214384558|NCT00960921|DRUG|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
214499426|NCT07013435|OTHER|Health Education Program|8 weekly sessions that include education on the co-occurrence of mental and physical problems, goal setting for health behavior change, and self-monitoring. Each session includes basic didactic information, interactive application of the information, and open discussion of didactic material.
214499427|NCT07013435|OTHER|SMART3RP-Lymphoma|The SMART3RP-lymphoma is a group program that, through a variety of mind-body approaches, such as imagery, relaxation, and yoga, seeks to buffer stress and promote psychological resiliency and physical well-being.
214499428|NCT07012044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214996790|NCT00562328|BIOLOGICAL|Sargramostim|"Week 1-6:~250 mcg subcutaneously three time as week"
214996791|NCT05191186|DRUG|Grass pollen extract - Alutard Phleum pratense, ALK|injection in lymph node
214996792|NCT04767750|OTHER|Blood sample collection|"5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~* Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~* Total RNA extraction from PBMCs by Trizol reagent and spin column.~* Reverse transcription to cDNA.~* The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR"
215093376|NCT02634021|DRUG|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
215093377|NCT02758301|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
215093378|NCT02484924|DRUG|Ticagrelor|No intervention- purely observational
215093379|NCT00364533|DRUG|Tapentadol IR (CG5503)|Fixed Dose 50, 75, \& 100 mg BID for 3 days
215093380|NCT00364533|DRUG|Placebo|Fixed Dose Matching placebo for 3 days
215093381|NCT00364533|DRUG|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
215093382|NCT00364533|DRUG|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
214384559|NCT06227962|DIAGNOSTIC_TEST|Neuropsychological assesment|Estimated intelligence (subtasks of Wechsler Intelligence Scale for Children - Fifth edition -Dutch version \[WISC-V-NL\] or Wechsler Adult Intelligence Scale - Forth edition - Dutch version \[WAIS-IV-NL\]); Vienna reaction time; Rey auditory verbal learning test; Word fluency; Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th Edition; Test of Everyday Attention for Children (TEA-Ch), subtask Score!/ or Test of Everyday Attention (TEA), subtask Elevator task; Trail making test; Word-color interference test
214384560|NCT06227962|DIAGNOSTIC_TEST|Psychosocial functioning and quality of life (questionnaires)|Anxiety (PROMIS); Depression (PROMIS); Peer-interaction (PROMIS); Perceived neurocognitive functioning (PROMIS); Participation and activity (PAY-CY); Trauma (KJTS/PCL-5); Health related quality of life (PEDSQL)
214384561|NCT06227962|DIAGNOSTIC_TEST|Parental psychosocial functioning (questionnaires)|Anxiety (PROMIS); Depression (PROMIS); Distress Thermometer-Parents (DT-P); Trauma (PCL-5)
214384562|NCT01291316|DRUG|Clonazepam|clonazepam, 1 mg, single oral dose
214384563|NCT01291316|DRUG|Tolterodine|Tolterodine 1,37mg, single oral dose
214996793|NCT02876081|DRUG|Afatinib|to evaluate the efficacy of afatinib, an EGFR TKI, on lung adenocarcinomas, EGFR wild-type, bearing the NTS/NTSR1 complex with a high level of expression
214384564|NCT01291316|DRUG|clobazam|clobazam 20 mg, single oral dose
214384565|NCT03116490|PROCEDURE|Anesthesia type|RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .
214384566|NCT04488367|DRUG|Tranexamic acid|10 mg/kg IV TXA in the ED, repeat doses before skin incision and in PACU
214499429|NCT07012044|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214996794|NCT05750706|OTHER|observation of invasive fungal infections|observation of invasive fungal infections during chemotherapy
214384567|NCT04488367|DRUG|Normal Saline|100 mL 0.9% normal saline in the ED, 10 mg/kg IV TXA before skin incision and in PACU
214384568|NCT03047772|DRUG|Atorvastatin|Routine dose of Atorvastatin therapy
214499430|NCT07012044|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214687628|NCT06346457|DRUG|Letrozole + GnRH|When they take Letrozole + GnRh, the GnRh is an injection once a month.
214996795|NCT05687110|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214996796|NCT05687110|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214996797|NCT05687110|PROCEDURE|Diagnostic Imaging Testing|Undergo medical imaging scans
215093383|NCT03675542|DRUG|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
215093384|NCT02611141|PROCEDURE|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack \& Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~1. Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~2. If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
215093385|NCT06406803|BEHAVIORAL|Dietary energy restriction|Patients enrolled in the dietary energy restriction group will reach an energy deficit of 40% only through reduced dietary intake.
215093386|NCT06406803|BEHAVIORAL|Daily exercise|Patients in the daily exercise group will reach an energy deficit of 40% through reduced dietary intake and increased physical activity (exercise).
215093387|NCT02152514|DRUG|Intrathecal Morphine/Sufentanil|
215093388|NCT02152514|DEVICE|PCA|
214384569|NCT03047772|DRUG|Intensive Atorvastatin|Intensive dose of Atorvastatin therapy
214384570|NCT03047772|DRUG|Low dose BMMSC|Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
214384571|NCT03047772|DRUG|Middle dose BMMSC|Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
214384572|NCT03047772|DRUG|High dose BMMSC|High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
214384573|NCT03047772|DRUG|Transplantation|Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
214384574|NCT02954458|DRUG|TED|0.05 mg/kg SC injection once daily.
214499431|NCT07012044|DRUG|Decitabine|Given PO
214499432|NCT07012044|DRUG|Decitabine and Cedazuridine|Given PO
214499433|NCT07012044|BIOLOGICAL|Filgrastim|Given SC or IV
214499434|NCT07012044|PROCEDURE|Imaging Procedure|Undergo diagnostic imaging
214499435|NCT07012044|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214499436|NCT03373968|DRUG|Givinostat|suspension of givinostat (10 mg/mL)
214499437|NCT06688370|DEVICE|Petit Drill|Day 1: 2-4 doses, including one of the daily doses taken at bedtime. Days 2 and 3: 3 to 4 doses on days 2 and 3, including one of the daily doses taken at bedtime.
214996798|NCT05687110|BIOLOGICAL|Novobiocin Sodium|Given PO
214996799|NCT05710640|DEVICE|Active tcVNS or Sham tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
214996800|NCT05710640|DEVICE|Active tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
214996801|NCT01601977|DEVICE|AVAPS-AE|Novel ventilation mode (Omnilab - AVAPS AE algorithm)
214996802|NCT01601977|DEVICE|Usual care|Non-invasive ventilation with standard ventilator
214996803|NCT00379041|BIOLOGICAL|bleomycin sulfate|
214996804|NCT00379041|DRUG|doxorubicin hydrochloride|
214996805|NCT00379041|DRUG|mechlorethamine hydrochloride|
214996806|NCT00379041|DRUG|prednisone|
214384575|NCT02954458|OTHER|SOC|Standard safety assessments and adjustments in nutritional support.
214384576|NCT02954458|DEVICE|Syringe|Teduglutide will be administered using syringe.
214384577|NCT02954458|DEVICE|Needle|Teduglutide will be administered using needle.
214384578|NCT05210556|OTHER|Diagnosed with Surgical Site Infection|As an observational study, this notates patients who were diagnosed with a deep organ/space surgical site infection within 30 days of surgery
214996807|NCT00379041|DRUG|procarbazine hydrochloride|
214384579|NCT04161040|BEHAVIORAL|Performance-based incentives|Participants will earn $1 per minute of engagement in physical activity.
214384580|NCT02130453|DRUG|Regadenoson|0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.
214384581|NCT05998837|DRUG|Dapagliflozin 10mg Tab|"Dapagliflozin will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
214384582|NCT05998837|DRUG|Placebo|"Placebo will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
214384583|NCT06850831|DRUG|Antipac|The first group is the NAC group, which will get intracoronary NAC 480 mg immediately after the lesion is opened during primary PCI. And the second group will have placebo immediately after the lesion is opened during primary PCI.
214384584|NCT05571384|BEHAVIORAL|high intensity body-weight circuit|"Bodyweight and suspension training equipment (TRX® Fit System) with modified movements. Modified Squats: participants will be instructed to hold the handles of the band with arms extended, participants will then lean back in a standing position and perform a squat within a comfortable range of motion while weight is being distributed to the band. Modified Rows: participants will grab the bands with arms and legs extended. They will find a comfortable angle by which to perform a row (pulling the handles to the rib cage) with arms at a 45-degree angle. Modified Push-Ups: perform push-ups on their knees with a flat back and hands underneath their shoulders. They will be instructed to lower their chest towards the ground in a controlled manner and as far as comfort will allow them. Modified Crunches: participants will lay on their back with feet approximately 8-10 inches from their buttocks, and asked to lift their shoulders slightly off the ground."
214384585|NCT04772885|DRUG|KT-474/Placebo|KT-474 or matching placebo oral tablet(s)
214384586|NCT04772885|DRUG|KT-474|KT-474 oral tablet(s)
214384587|NCT01960075|DRUG|Fosphenytoin|
214384588|NCT01960075|DRUG|Levetiracetam|
214499438|NCT04934995|OTHER|Blood Pressure Cuff|"After obtaining consent and confirming eligibility, Blood Pressure cuffs will be used as specified below:~Cuff size: large BP cuffs will be the default size for both arm and ankle measurements, but can be changed as clinically indicated based on circumferences of limbs Cuff location: BP cuffs will be placed on the contralateral arm to the main peripheral IV following standard procedures. Left ankle cuff will be placed underneath intermittent pneumatic compression cuffs Ankle blood pressure monitor screen will be covered. Thus, anesthesia providers will not be able to make any clinical decisions based on ankle blood pressures but arm blood pressure (standard) instead."
214996808|NCT00379041|DRUG|vinblastine sulfate|
214996809|NCT00379041|DRUG|vincristine sulfate|
214996810|NCT00379041|RADIATION|radiation therapy|
214996811|NCT05007925|DEVICE|Intravascular Lithotripsy|Localized peripheral intravascular lithotripsy
214996812|NCT01833182|OTHER|Tailored home intervention|The occupational therapist (OT) interventionist will develop a set of environmental modification choices to improve performance in problematic activities identified during the clinical evaluation. A plan for resolving the barriers identified during clinical assessment will be developed. The participant will review the barrier removal options and will make an informed choice resulting in a final treatment plan. Modification installation which will be provided, at no cost to the participant, by a contractor trained by the study PI. The tailored intervention includes training in the use of the new equipment or architectural changes. Photographs of identified barriers, study measures, and intervention plans will be reviewed by the principal investigator during team meetings to ensure treatment fidelity.
214996813|NCT01833182|OTHER|Sham intervention|We have developed a kit containing 12 standard adaptive equipment (AD) items (e.g., jar opener). The AD kit has been specifically designed to address fine motor function and will not influence fall outcomes. Two pieces of AD will be provided during each session, and the individual will be instructed to use each AD by the OT interventionist
214996814|NCT04031950|DEVICE|Novel wearable paediatric device|The patient will wear the novel wearable paediatric device at the same time as polysmnography
214384589|NCT01960075|DRUG|Valproic acid|
214384590|NCT00449241|DEVICE|Acupuncture|
214996815|NCT06059599|OTHER|active informed consent|new preoperative information method, based on multimedia tools and on the objective control of understanding by the patient candidate for vertebral or urological surgery.
214996816|NCT03354377|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.
214996817|NCT03354377|BEHAVIORAL|Physical Activity|Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.
214996818|NCT03354377|BEHAVIORAL|Podcasts/Mailings|Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
214996819|NCT03863912|OTHER|Disney movie|Disney movie on portable DVD Player.
214499439|NCT06697132|PROCEDURE|laparoscopic dismembered pyeloplasty|Modified antegrade stenting in laparoscopic pediatric pyeloplasty
214996820|NCT03863912|OTHER|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
214384591|NCT05487430|BEHAVIORAL|Positive Self-Affirmation|Each participant of the intervention group was given a set of earphones and an MP3 player which included an audio recording with a background sound of birds crowing and river-like flowing water together with the positive affirmation sentences. The self-affirmation sentences were created by the first author by paying special attention to not using negative predicates and words with negative meanings such as pain, nausea, and discomfort. In the audio recording, the affirmative sentences were verbalized by the first author with a soothing voice. Between each sentence, a pause is given so that the patient can repeat each sentence verbally or internally. The audio recording lasted 5 minutes 40 seconds and the patients were asked to listen to it at least once a day, however, they were encouraged to listen to it as much as they wanted.
214384592|NCT03033459|BEHAVIORAL|Motivational Interviewing|"Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill."
214384593|NCT03033459|BEHAVIORAL|Psychoeducation Control|Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
214384594|NCT03501329|COMBINATION_PRODUCT|Biological,Psychological and Social support|
214384595|NCT01621204|DRUG|Eltrombopag|Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
214384596|NCT01621204|DRUG|IVIG infusion|IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
214996821|NCT01976208|DRUG|Omalizumab|The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150\~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg\~750mg，then dosing interval is every 2 weeks.
214384597|NCT00161395|BEHAVIORAL|Instruction in the Creighton Model Fertility Care System|Instruction in the Creighton Model Fertility Care System.
214384598|NCT00161395|BEHAVIORAL|Preconception advice|Preconception advice for diet and frequency of intercourse.
214384599|NCT03347747|OTHER|Study Photography + Personal & Medical History Collection|3D facial images taken and complete a detailed study questionnaire
214384600|NCT04113681|PROCEDURE|Geniculate Artery Embolization|"1. Conscious sedation : midazolam and fentanyl~2. Local anesthesia : Lidocaine 2% subcutaneous~3. Retrograde or anterograde common femoral artery access - 4Fr introducer~4. Sub-therapeutic anticoagulation (heparin 2000 IU IA)~5. Lower extremity arteriography~6. Selective and supra-selective catheterization of geniculate arteries supplying painful region of the knee~7. If abnormal arterial blushes are demonstrated selective and supra-selective embolization will be performed with Embozene microspheres (100 microns to 200 microns) - cold saline or ice-packs sac to be applied to overlying skin if significant cutaneous arteries are demonstrated at angiography.~8. Angiographic end-points: embolization of abnormal blush while preserving the parent vessel~9. Arteriotomy closure (manual compression or closure device)"
214499440|NCT06698874|OTHER|ds-MCE and EGD examinations|Sequentially performing ds-MCE and EGD examinations on enrolled participants.
214499441|NCT03598907|OTHER|Fresh frozen plasma|Fresh frozen plasma will be used according to anaesthetist ,,blind,, decision
214499442|NCT07043842|OTHER|Shoulder circumference exercises|They are strengthening and stretching exercises that support the range of motion of the shoulder joint.
214499443|NCT07043842|OTHER|Scapular stabilization exercises|Changes in the biomechanics of the scapula affect the function of the shoulder. Biomechanical correction will be attempted with these exercises aimed at correcting the posture of the scapula.
214996822|NCT01976208|DRUG|placebo|
214996823|NCT04866160|DRUG|BI 1291583|BI 1291583
214996824|NCT04866160|DRUG|Placebo|Placebo
214996825|NCT02156661|DRUG|Oxytocin|
214996826|NCT05462873|BIOLOGICAL|QEQ278|Intravenous dosing of QEQ278
214996827|NCT02393625|DRUG|Ceritinib (LDK378)|
214996828|NCT02393625|DRUG|Nivolumab|
214996829|NCT03830606|DRUG|Nab-paclitaxel,S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
214996830|NCT02517489|DRUG|Hydrocortisone|Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
214996831|NCT02517489|DRUG|Placebo|Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
214996832|NCT03837704|OTHER|IQOS|AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.
214996833|NCT03837704|OTHER|Cigarette|AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
214996834|NCT03837704|OTHER|Smoking Cessation|AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
214996835|NCT06416644|DEVICE|Supera Vasculomimetic Stent|Femoral-popliteal revascularization with Supera Stent
214996836|NCT05776069|DRUG|VGA039|Single doses of VGA039
214499444|NCT07043842|OTHER|Thoracic mobility exercises|Changes in the biomechanics of the thoracic spine affect the function of the shoulder. Biomechanical correction will be attempted with these exercises aimed at correcting the posture of the thoracic spine.
214996837|NCT05776069|OTHER|Placebo|Single doses of Placebo
214996838|NCT05776069|DRUG|VGA039|Multiple doses of VGA039
215093389|NCT00493519|PROCEDURE|chocolate cake|
214996839|NCT06345079|DRUG|Cessation of somatostatin analogues|Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.
214384601|NCT03501043|DRUG|Dysport|Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
214384602|NCT02475525|DIETARY_SUPPLEMENT|Arginine enriched oral nutritional supplement|oral nutritional supplement containing arginine
214384603|NCT04189263|OTHER|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
214384604|NCT04189263|DRUG|standard of care aromatase inhibitors|standard of care aromatase inhibitors
214384605|NCT01396395|DRUG|Nicorandil|The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
214384606|NCT01396395|DRUG|Standard Treatment|The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
214384607|NCT04542408|DRUG|Anticoagulation Agents (Edoxaban and/or high dose LMWH)|In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until
214384608|NCT04542408|DRUG|Low dose Low molecular weight heparin or Placebo|In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
214384609|NCT05779553|DIAGNOSTIC_TEST|Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits|measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient
214384610|NCT01280734|DRUG|Circadin (R) 2 mg|One 2 mg tablet at 23:00
214384611|NCT01280734|DRUG|Stilnox (R) 10 mg|One 10 mg encapsulated tablet at 23:00
214384612|NCT01280734|DRUG|Placebo|One tablet or encapsulated tablet at 23:00
214384613|NCT00817375|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
214384614|NCT00817375|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
214384615|NCT06172608|OTHER|psychoeducational intervention|". Intervention group (I) will receive psychosocial education which will be consist of two parts. 1) Face to Face 2) Community based intervention.~1. Face to face: This face to face session will be consisting of 30-minute session soon after inclusion into the study. A leaflet consisting of all information will be provided to all the patents taking part in the study.~2. Community Based Intervention: In community based interventions prerecorded videos about all the topics covered in face to face session will be made available to parents via a secure online platform. Parents can easily browse it easily when they need it. These videos will be recorded in local language (Urdu), which is easy to understand for almost all the people."
214384616|NCT03428126|DRUG|Durvalumab|Dose Escalation and Dose Expansion Dose: 1500 mg by vein every 4 weeks in a 28 day cycle.
214384617|NCT03428126|DRUG|Trametinib|"Dose Escalation Starting Dose: 2mg by mouth daily in a 28 day cycle.~Dose Expansion Dose: MTD from Dose Escalation."
214384618|NCT01154894|OTHER|Aravita including arachidonic acid and docosaheaenoic acid|Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
214384619|NCT02703207|DEVICE|Positive airway pressure|CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
214384620|NCT02703207|DEVICE|NIPPV and /or oxygen|supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
214384621|NCT03317223|DRUG|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
214384622|NCT05523440|DRUG|Bevacizumab|Bevacizumab infusion.
214384623|NCT05523440|DRUG|Niraparib|Niraparib oral capsule.
214384624|NCT00914290|DRUG|IPX056|IPX056 ER capsule containing 10 mg baclofen
214384625|NCT00914290|DRUG|Baclofen IR|Encapsulated baclofen tablet 5 mg per capsule
214384626|NCT00914290|DRUG|Placebo IPX056|Placebo capsule for IPX056
214384627|NCT00914290|DRUG|Placebo IR|Placebo encapsulated baclofen placebo tablet
214384628|NCT03207646|OTHER|BrightHeart®|BrightHeart® has two components: smartphone mobile based application and a human coach. It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
214384629|NCT03492892|DEVICE|Acupuncture|Stimulate acupoint with filiform needles to restore the healthy condition of patients
214384630|NCT03492892|DEVICE|Sham Acupuncture|Stimulate non-acupoint with filiform needles to treat the condition of patients
214499445|NCT07044258|PROCEDURE|trans-tarsal stair-step lateral extension of the transconjunctival approach|patients presented with oribto-zygomaticomaxillary complex fractures that requires open reduction and internal fixation via trans-tarsal stair-step lateral extension of the transconjunctival approach
214499446|NCT07044258|PROCEDURE|transconjunctival approach|patients presented with oribto-zygomaticomaxillary complex fractures that requires open reduction and internal fixation via trans-tarsal stair-step lateral extension of the transconjunctival approach
214499447|NCT07044232|COMBINATION_PRODUCT|Nicardipine|Nicardipine infusion based acute blood pressure lowering treatment
214499448|NCT07044232|COMBINATION_PRODUCT|Glyceryl trinitrate|Glyceryltrinitrate based acute blood pressure lowering treatment
214996840|NCT06345079|DRUG|Continuation of somatostatin analogues|Patients randomised to continue SSA will receive a SSA injection ≥28 days prior to their first cycle of PRRT, during PRRT and will continue receiving SSA every 4 weeks after PRRT.
215093390|NCT00652899|BIOLOGICAL|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
215093391|NCT00652899|DRUG|Cyclophosphamide|60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
214384631|NCT06084559|OTHER|Supplemental oxygen therapy|Mobile oxygen via pressurized bottle or mobile oxygen concentrator will be applied
214384632|NCT06084559|OTHER|Sham Oxygen therapy|Patients will reveice pressurized air via a nasal cannula
214384633|NCT05536102|DRUG|PLD|20mg/m2, day 1, q3w
214384634|NCT05536102|DRUG|Oxaliplatin|130 mg/m2, day 1, q3w
214384635|NCT05536102|DRUG|Capecitabine|1000 mg/m2, days 1-14, q3w
214384636|NCT05536102|DRUG|Tislelizumab|200 mg, day 1, q3w
214384637|NCT04140253|BEHAVIORAL|Pelvic floor muscle training (PFMT) with lumbopelvic stabilization|"Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions~2. Training of pelvic floor muscles in different position~3. Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist."
214384638|NCT01834443|DEVICE|Direct current galvanic vestibular stimulation|
214384639|NCT04417387|OTHER|Observational|
214384640|NCT02420743|PROCEDURE|serum ferritin|serum ferritin will be measured serially at 26, 30 and 34 weeks gestation.
214384641|NCT02420743|PROCEDURE|MCA Doppler|MCA peak systolic value will be assessed at 26, 30 and 34 weeks gestation.
214384642|NCT04013412|DIETARY_SUPPLEMENT|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake \[any of 4 flavors\] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
214499449|NCT07043634|COMBINATION_PRODUCT|FDC (24 mg ER torsemide and 30 mg Spironolactone) without food|FDC without food
214996841|NCT06484114|DEVICE|Revita Duodenal Mucosal Resurfacing (DMR)|DMR is designed to ablate and re-epithelialize the duodenal mucosal surface, thus allowing nutrients to be exposed to a newly regrown and potentially normalized local mucosa. This implies that the duodenal mucosa surface is abnormal in participants associated with metabolic disorders. The Revita DMR procedure is performed endoscopically with supporting fluoroscopy.
214996842|NCT06484114|DEVICE|Sham|An endoscopic review with non active catheter introduction
214996843|NCT06378398|DRUG|Omeprazole|Two 20 mg/day omeprazole tablets taken before the first meal each day for 25-45 days.
214384643|NCT04662463|BEHAVIORAL|Cognitive Bias Modification for Interpretation (CBM-I)|Patients will receive CBM-I training by reading and imaging themselves in a series of emotionally ambiguous scenarios. Each scenario ends with an incomplete final word. Patients need to complete the final word to resolve the scenario in a positive direction.
214384644|NCT04662463|BEHAVIORAL|Placebo|Patients will receive placebo task which uses neutral rather than emotional material.
214384645|NCT01170416|OTHER|12-lead body surface mapping|An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
214384646|NCT02460263|DEVICE|Tablo Hemodialysis System|
214384647|NCT00884754|DEVICE|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
214499450|NCT07043634|COMBINATION_PRODUCT|FDC (24 mg ER torsemide and 30 mg Spironolactone) with food|FDC with food
214384648|NCT03176238|DRUG|everolimus|one 10 mg tablet or two 5 mg tablets of everolimus were administered orally once daily on a continuous dosing schedule starting on Day 1
214384649|NCT03176238|DRUG|exemestane|25 mg tablet was administered orally once daily on a continuous dosing schedule starting on Day 1
214384650|NCT06345001|DRUG|BAY3630942|IV, Single administration
214384651|NCT06345001|DRUG|BAY3547922|IV, Single infusion
214384652|NCT05043402|DRUG|navicixizumab|navicixizumab IV
214384653|NCT05043402|DEVICE|Xerna™ TME Panel|RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).
214384654|NCT00004062|DRUG|azacitidine|
214384655|NCT00004062|DRUG|liothyronine sodium|
214384656|NCT00004062|RADIATION|iodine I 131|
214384657|NCT04524598|DEVICE|Limbix Spark|The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.
214384658|NCT04524598|OTHER|Psychoeducation|The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.
214499451|NCT07042789|OTHER|Material source: AI generated ads vs existing ads by health agency|Each participant evaluated 50 ads in random order, of which 25 were AI-generated through youth co-design process, and 25 were existing ads from official health agencies.
214996844|NCT06378398|DRUG|Aspirin|Two 81 mg/day aspirin tablets taken before the first meal each day for 25-45 days.
214996845|NCT06571838|DEVICE|DAISY system|DAISY is a The humanoid robot with an ipad and attached peripheral devices capable of taking blood pressure and temperature
214996846|NCT06745297|DRUG|BI 3776528|BI 3776528
214996847|NCT06745297|DRUG|Placebo matching BI 3776528|Placebo matching BI 3776528
214996848|NCT06745297|DRUG|short-acting benzodiazepine|short-acting benzodiazepine
214996849|NCT05007821|DRUG|Linezolid 600 mg|One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26
214996850|NCT05007821|DRUG|Linezolid 1200 mg (QD)|Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4
214996851|NCT05007821|DRUG|Linezolid 1200 mg (TIW)|Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26
214996852|NCT05007821|DRUG|Bedaquiline 200 mg|Two 100mg tablets taken orally once daily in the morning during weeks 1-8
214996853|NCT05007821|DRUG|Bedaquiline 100 mg|One 100mg tablet taken orally once daily in the morning during weeks 9-26
214996854|NCT05007821|DRUG|Delamanid 300 mg|Six 50mg tablets taken orally once daily in the morning during weeks 1-26
214996855|NCT05007821|DRUG|Clofazimine 300 mg|Three 100mg capsules taken orally once daily in the morning during weeks 1-2
214996856|NCT05007821|DRUG|Clofazimine 100 mg|One 100mg capsule taken orally once daily in the morning during weeks 3-26
214996857|NCT06354257|DRUG|Microgynon|Participants received 1 dose of Microgynon (0.03 mg EE/0.15 mg LNG) on Day 1 of Treatment Period 1 and 1 dose co-administered with GSK3036656 20 mg on Day 15 of Treatment Period 3.
214384659|NCT04930237|DRUG|Relistor Injectable Product|12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days
214384660|NCT04930237|DRUG|Docusate Calcium|Standard of care
214384661|NCT04930237|DRUG|Bisacodyl|Standard of Care
214384662|NCT04930237|DRUG|Milk of magnesia|Standard of Care
214384663|NCT04930237|DRUG|Magnesium citrate|Standard of Care
214384664|NCT04930237|DRUG|Senna|Standard of Care
214384665|NCT04930237|DRUG|Enema|Standard of Care
214384666|NCT02558361|DRUG|Treatment with Apremilast|Standard dosing with apremilast (Otezla) will be used. \[30mg po BID after initial titration\]
214384667|NCT04395183|DRUG|5-Hydroxytryptophan 100 MG|5-HTP 100mg PO BID
214499452|NCT07042789|OTHER|source labelling conditions: control condition, AI condition, health agency condition, combined condition|"Participants were randomly assigned to one of four source labelling conditions: (1) Control (ads presented without any source labelling), (2) AI condition (ads labelled with the text Made with AI), (3) Health agency condition (ads labelled with the text Made by the World Health Organization (WHO)), and (4) Combined condition (ads labelled with the text Made with AI, by the World Health Organization (WHO))."
214499453|NCT06769919|RADIATION|Neoadjuvant radiotherapy|The experimental group will receive neoadjuvant systemic therapy combined with neoadjuvant radiotherapy before undergoing surgery
214499454|NCT06780488|OTHER|Real Visual-Vestibuar Rehabilitation|"The Real Visual-Vestibular Rehabilitation protocol will consist of specific exercises aimed at stimulating the visuo-vestibular function within immersive virtual reality environments replicating daily life situations. Patients will perform exercises in two types of contexts. In all exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the exercises can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation.The protocol will last 20 minutes, with 10 minutes dedicated to each exercise."
214996858|NCT06354257|DRUG|GSK3036656|Participants received 1 loading dose of 40 mg on Day 4 and a dose of 20 mg on Days 5 to 14 once daily in Treatment Period 2. In Treatment Period 3, participants received one 20 mg dose along with Microgynon (0.03 mg EE/0.15 mg LNG) on Day 15 after which a 20 mg dose on Days 17 and 18 once daily.
214996859|NCT06273852|DRUG|PBA-0405|Intratumoral microdose injection by the CIVO device.
214996860|NCT03168672|DEVICE|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
214996861|NCT06413927|BEHAVIORAL|Online Vehicle and Driver Safety Education|This online video education program provides education in vehicle and driver safety (e.g. vehicle maintenance, adjusting car seats and seatbelts). This online training will take up to 2 hours to complete and will have a short quiz at the end to determine compliance with this online training.
214996862|NCT06413927|BEHAVIORAL|Online Driver Skills Training|The online driver training is the Accelerated Curriculum to Create Effective Learning (ACCEL) is designed to enhance the ability to anticipate, recognize and respond to hazards and to maintain attention to the road. The training is delivered online via a computer and can be done from home or at a school or other site that has a computer with internet access. It requires up to two hours to complete, and will be hosted on a platform that will track progress and completion through the training (such as accuracy, duration in modules, time to complete) and a short quiz will be provided at the end to assess learning.
214996863|NCT06413927|BEHAVIORAL|Behind-the-Wheel Driver Training|The professional behind-the-wheel training course will be conducted in-person, delivered by local driving school partner Coastline Academy. The curriculum consists of 6 hours of training with assigned practice between lessons, and meets Pennsylvania and national standards. Post-lesson forms completed by the instructors will record adherence and consistency (intervention fidelity).
214996864|NCT03366246|DRUG|Lidocaine / Prilocaine Cream|according randomized this side received placebo or active product
214996865|NCT03366246|DRUG|placebo|according randomized this side received placebo or active product
214996866|NCT06208267|DRUG|Tranexamic acid|This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA
214996867|NCT05836948|DRUG|SHR-9839|Weekly fixed dose injection of SHR-9839
214384668|NCT04395183|DRUG|Creatine monohydrate|Creatine monohydrate 5g PO qday
214384669|NCT04395183|DRUG|placebo matched to 5-HTP|placebo matched to 5-HTP
214384670|NCT04395183|DRUG|Placebo|Dextrose either as loose powder (matched to creatine) or encapsulated (matched to 5-HTP)
214384671|NCT00497640|PROCEDURE|Artificial Neural Network|Use of a predicted optimal CPAP
214384672|NCT05029024|OTHER|30-minute mindful breathing|The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes.
214384673|NCT05029024|OTHER|control group|standard care alone
214996868|NCT02807922|DRUG|Zopiclone|
214996869|NCT02807922|DRUG|Placebo|
214996870|NCT01334099|BIOLOGICAL|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
214996871|NCT01334099|RADIATION|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
214996872|NCT00829153|DEVICE|U Clip|Interuppted nitional clips
214384674|NCT01233583|DRUG|Dovobet, neotigason, etanercept, adalimumab. infliximab|Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
214384675|NCT04771338|BEHAVIORAL|VR-JIT/KF-STRIDE|Treatment group will receive 12 sessions of job interview training protocol.
214384676|NCT00486135|DRUG|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
214384677|NCT00486135|DRUG|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
214996873|NCT00829153|PROCEDURE|Conventional prolene anastomosis|Continuous prolene anastomosis
214996874|NCT03930433|DRUG|Nebivolol|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
214996875|NCT03930433|DRUG|Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
214996876|NCT03930433|DRUG|Nebivolol+Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
214384678|NCT05651360|DIAGNOSTIC_TEST|low-dose CT|Low-dose CT scan will be performed, not exceeding 30% radiation dose of the standard CT. Low-dose CT images will be reconstructed with TrueFidelity high. The low-dose CT will be performed directly after the standard CT to avoid bias from differences in the timing of the contrast phase.
214384679|NCT02630524|BEHAVIORAL|eHealth Behavioral Lifestyle Intervention Device: Telecoach|Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
214384680|NCT00903734|DRUG|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
214384681|NCT00315588|DRUG|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
214384682|NCT02491021|OTHER|Rehabilitation Class|A 6 week programme of exercise and education in an out patient setting
214499455|NCT06780488|OTHER|Sham Rehabilitation|"The Sham Vestibular Rehabilitation protocol will involve the use of the same immersive virtual reality contexts and will aim to achieve the same objectives as the Real Visual-Vestibular Rehabilitation protocol, but without the unexpected stimuli. In both exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the session can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation. The protocol will last 20 minutes, with 10 minutes dedicated to each exercise."
214499456|NCT04525092|DEVICE|Online Pre-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>44L/session reinjected in pre-dilution mode. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
214499457|NCT04525092|DEVICE|Conventional Hemodialysis|Using the following parameters: maximum Blood flow rate allowed by vascular access, dialysate rate of 500 mL/min, no convection. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
214499458|NCT04525092|DEVICE|Online Post-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>22L/session reinjected in pre-dilution mode. The dialysate composition and net ultrafiltration rate will be prescribed according to participant's characteristics. Usage of intra-dialysis anticoagulation is mandatory.
214499459|NCT04021862|DRUG|Bermekimab Monoclonal Antibody|Bermekimab 400 mg or 800 mg will be administered subcutaneously.
214499460|NCT04021862|DRUG|Placebo|Placebo will be administered subcutaneously.
214996877|NCT02649699|OTHER|3D MRI Scans|Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
214687629|NCT06266390|DEVICE|Transcranial Magnetic Stimulation (TMS)|The TMS intervention will involve two sets of Intermittent Theta-Burst Stimulation (iTBS) delivered every weekday for 4-6 weeks. Each iTBS set consists of 40 trains and a total of 1200 pulses, delivered approximately 15 minutes apart, resulting in 2400 pulses per session.
215093392|NCT00652899|DRUG|Fludarabine phosphate|25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
214384683|NCT04121039|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
214384684|NCT04121039|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
214687630|NCT03280433|OTHER|Aortic valve replacement|
214687631|NCT02620462|DEVICE|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
214687632|NCT03087825|PROCEDURE|preoxygenation without inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
214996878|NCT03633708|DRUG|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
214996879|NCT06008002|PROCEDURE|M-TAPA block|ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (0.3 ml/kg , %0.25 bupivacaine) will be performed
214996880|NCT06008002|PROCEDURE|EXORA block|Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg , %0.25 bupivacaine) will be performed
214996881|NCT06008002|DRUG|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
214384685|NCT00061113|DRUG|Fluoxetine + outpatient cognitive behavioral therapy|single fixed morning dose 20 mg X 15 weeks
214384686|NCT00061113|DRUG|fluoxetine|20mg, QD x 16 weeks
214996882|NCT02295449|DEVICE|biopsy sample performed after the SonoVue® injection|
214996883|NCT00433537|DRUG|bortezomib|Given IV
214384687|NCT00061113|DRUG|placebo + CBT|single fixed morning dose X 16 weeks
214384688|NCT01252121|OTHER|Systane Ultra Lubricant Eye Drops|One drop in study eye, one time, during office visit.
214996884|NCT00433537|BIOLOGICAL|rituximab|Given IV
214384689|NCT01252121|OTHER|Hialid 0.1 Artificial Tears Eye Drops|One drop in study eye, one time, during office visit.
215093393|NCT00652899|RADIATION|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
215093394|NCT00652899|BIOLOGICAL|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
215093395|NCT00652899|BIOLOGICAL|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
214499461|NCT06832358|BEHAVIORAL|Routine nursing methods|According to their condition, they receive individualized drug treatment, including the main drugs of Parkinson's disease (such as dopamine replacement drugs) and combined antidepressant drugs. Secondly, regular follow-up evaluations will be conducted to monitor disease progression and drug side effects. At the same time, patients and their families will receive health education on Parkinson's disease and depression.The patients would receive basic psychological support. Medical staff will encourage patients to express their emotions and pay attention to their psychological state, which will help alleviate anxiety and depression. Medical staff will provide patients with information about local support organizations and social groups, and encourage patients to participate in related activities to increase social interaction and emotional support.
214996885|NCT00433537|DRUG|cyclophosphamide|Given IV
214384690|NCT01252121|OTHER|Unisol 4 Saline Solution|One drop in study eye, one time, during office visit.
214384691|NCT00280657|DRUG|Valette|1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
214499462|NCT06832358|BEHAVIORAL|PERMA positive psychological intervention mode|(1) Formation of an intervention team.(2) Development and execution of interventions.The study group participated in a series of positive psychology workshop involving interviews and exercises aligned with the PERMA model as part of their routine health education. Each participant took part in individualized interviews focused on two specific topics each week until all subjects were covered, with each session lasting between 30 to 50 minutes. This interview phase continued for one month, conducted in the hospital ward.
214499463|NCT06854432|OTHER|Biometrological measurements|Measurements will be taken from the scalp: on the vertex and occiput areas.
214996886|NCT00433537|DRUG|doxorubicin hydrochloride|Given IV
214996887|NCT00433537|DRUG|vincristine|Given IV
214384692|NCT00280657|DRUG|Diane|1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
214384693|NCT00280657|DRUG|Placebo|2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
214384694|NCT02569710|DRUG|AL-335|AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
214499464|NCT06854432|OTHER|Biological sampling|Samples will be taken from the scalp: on the vertex and occiput areas.
214996888|NCT00433537|DRUG|dexamethasone|Given IV
214996889|NCT00433537|BIOLOGICAL|filgrastim|Given SC
214996890|NCT00433537|BIOLOGICAL|pegfilgrastim|Given SC
214996891|NCT00433537|PROCEDURE|Autologous stem cell transplantation (ASCT)|
214996892|NCT01725399|OTHER|Apple Juice|
214384695|NCT02569710|DRUG|Odalasvir (ODV)|ODV capsules will be administered in a dose range of 25 to 50 mg.
214384696|NCT02569710|DRUG|Simeprevir (SMV)|SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
214996893|NCT01725399|OTHER|Water|
214996894|NCT04328194|DIAGNOSTIC_TEST|Serum Autotaxin|Marker
214996895|NCT04328194|RADIATION|chest x-ray|chest x- ray will be done for the study group
214996896|NCT04328194|DIAGNOSTIC_TEST|Breast ultrasound or mammography|Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer
214996897|NCT04328194|DIAGNOSTIC_TEST|Histopathological examination of breast mass specimens|by True cut or fine needle aspiration cytology
214996898|NCT04328194|RADIATION|Magnetic Resonance Imaging ( MRI) and Bone scan|will be done for the study group
214996899|NCT04328194|DIAGNOSTIC_TEST|Peripheral haemogram|blood sample will be taken from the patients
214996900|NCT04328194|DIAGNOSTIC_TEST|Renal and liver functions|to exclude any other morbidity
214996901|NCT04328194|DIAGNOSTIC_TEST|Prothrombin time and concentration|blood sample will be taken from the patients
214996902|NCT04328194|DIAGNOSTIC_TEST|Cancer Antigen 15-3 (CA15-3).|will be done for the 2 groups
214996903|NCT04328194|OTHER|Full medical history|full medical history will be taken from all patients
214996904|NCT04328194|OTHER|Full clinical examination|full clinical examination will be done for the patients
214384697|NCT04280822|DRUG|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, \>30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, \>30min, 3week (8 cycles at most)"
214384698|NCT00116402|DRUG|fluticasone and salmeterol|"1. will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~2. will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID."
214384699|NCT03545347|DRUG|Nandrolone Decanoate|Injections every 3 weeks, last injection at week 12. Women 50 mg, men with total testosterone ≥ 11 nmol/l will receive 100 mg, and men with total testosterone \< 11 nmol/l will receive a dose of 200 mg.
214996905|NCT00555191|BEHAVIORAL|diet restriction|each meal should contain less than 2 gm fructose
214996906|NCT05146765|DEVICE|Mobile application|Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.
214384700|NCT03545347|DIETARY_SUPPLEMENT|Protein-rich nutritional supplement|The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.
214996907|NCT05146765|OTHER|Treatment as usual|The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
214996908|NCT01757847|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
214384701|NCT03545347|OTHER|Physical therapy|The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.
214384702|NCT03545347|DRUG|Sodium Chloride 9mg/ml Injection|Placebo injection of 1 ml Sodium Chloride
214384703|NCT03848598|DIAGNOSTIC_TEST|Evaluation of local tendon deformation|Ultrasound-based speckle tracking to evaluate the local tendon tissue displacement during isometric exercise.
214996909|NCT01757847|BEHAVIORAL|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
214996910|NCT06166823|OTHER|EMR alert|EMR alert for medication optimization
214384704|NCT04402437|PROCEDURE|LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
214499465|NCT06597201|DRUG|amino acid (15) peritoneal dialysis solution|Subjects were treated with 1 bag of amino acid (15) peritoneal dialysis solution (2L) once every morning, and then with conventional glucose peritoneal dialysate (lactate).
214499466|NCT06597201|DRUG|glucose peritoneal dialysis solution|Subjects received conventional treatment with glucose peritoneal dialysis solution (lactate), which must include 1.5% glucose peritoneal dialysate (lactate) (2L) once.
214996911|NCT04175756|DEVICE|Caiman 5 articulating Maryland|Laparoscopic colorectal surgery
214996912|NCT03495388|DRUG|Oxycodone|Post-op pain management medication
214996913|NCT05239572|COMBINATION_PRODUCT|screening, prevention and counselling|Screening in Intergenerational solidarity clubs in Myanmar and Vietnam and in Posbindu programme in Indonesia
214499467|NCT05190172|RADIATION|Radiation therapy|Radiation therapy either with protons or photons
214499468|NCT06743581|DRUG|Cemiplimab|Cemiplimab 350 mg administered intravenously on day 1
214996914|NCT05458128|DRUG|Pitolisant|"Pitolisant 4.45 mg tablets~Pitolisant 17.8 mg tablets"
214996915|NCT05031897|DRUG|Fludarabine|Given IV
214996916|NCT05031897|RADIATION|Total-Body Irradiation|Undergo TBI
215093396|NCT02196428|OTHER|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
214499469|NCT06743581|DRUG|Dupilumab|Dupilumab 600 mg administered subcutaneously on day 1
214499470|NCT01574339|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a technical representative."
214499471|NCT05240352|DEVICE|active tDCS|Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
214996917|NCT05031897|PROCEDURE|Donor Lymphocyte Infusion|Undergo DLI
214996918|NCT05031897|DRUG|Cyclophosphamide|Given IV
214996919|NCT05031897|DRUG|Tacrolimus|Given IV
214996920|NCT05031897|DRUG|Mycophenolate Mofetil|Given IV
214996921|NCT05031897|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
214996922|NCT05031897|DRUG|Melphalan|Given IV
214996923|NCT05031897|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/ biopsy
214996924|NCT05031897|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
214996925|NCT05031897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214996926|NCT05436613|DEVICE|Transcranial Direct Current Stimulation|tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.
214996927|NCT06202183|BEHAVIORAL|Exercise Program|A 12 week, home-based, virtually supervised, aerobic and resistance exercise training program comprised of 36 sessions. Participants will be provided with a home stationary bike, resistance bands, and Fitbit. Virtually supervised sessions will be accessible via Zoom platform. For participants who do not have a device, a Wi-Fi-enabled tablet will also be provided.
214996928|NCT03188198|DRUG|rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim|
215093397|NCT02706028|DEVICE|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
215093398|NCT02706028|DEVICE|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
215093399|NCT05099159|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
215093400|NCT05099159|DRUG|Placebo|Matching placebo orally once daily
215093401|NCT03191877|DIETARY_SUPPLEMENT|coffee|"Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811"
215093402|NCT01702740|DRUG|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
215093403|NCT01702740|DRUG|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
215093404|NCT01702740|DRUG|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
215093405|NCT01702740|DRUG|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
215093406|NCT04100434|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
214384705|NCT04402437|PROCEDURE|QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
214384706|NCT05341102|DRUG|LY3556050|Administered orally.
214384707|NCT05341102|DRUG|Placebo|Administered orally.
214687633|NCT03087825|PROCEDURE|preoxygenation with inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
214384708|NCT04152343|DEVICE|RFA Physics Library -- a Planning and Guidance Platform (PGP)|Research software used to support liver RFA of HCC lesions \>2cm
214384709|NCT03158389|DRUG|APG101|weekly i.v.
214384710|NCT03158389|DRUG|Alectinib|twice daily (oral)
214384711|NCT03158389|DRUG|Idasanutlin|orally on 5 days of a 28 days cycle
214384712|NCT03158389|DRUG|Atezolizumab|i.v. every 3 weeks
214996929|NCT02904343|DEVICE|domestic hemodialysis machine|WEGO, DBB-27C
214996930|NCT02904343|DEVICE|imported hemodialysis machine|Fresenius, 4008s
214996931|NCT05886894|DEVICE|Lotrafilcon B multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
214996932|NCT05886894|DEVICE|Comfilcon A multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
214996933|NCT06371924|DEVICE|Machine Perfusion|The quality of DCD organs can be improved by replacing the icebox (static cold storage or SCS), which remains the main approach to preserve the livers after having been retrieved, by strategies that perfuse the livers in a machine (machine perfusion or MP). There are currently 3 MP strategies employed in the clinic: normothermic regional perfusion (NRP) is used in the donors by perfusing the liver with the donor's blood at 37 degrees Celsius, and normothermic (NMP) or hypothermic (HOPE) perfusion are used in the procured livers out of the body (using warm or cold perfusion fluids, respectively). To date, no controlled objective comparisons of these different MP strategies have been undertaken and the doctors do not have a good understanding of their mechanisms of action.
214996934|NCT05473507|DIAGNOSTIC_TEST|Digital Dermoscopy|Digital Dermoscopy will be performed every 3 months.
214996935|NCT05473507|DIAGNOSTIC_TEST|Reflectance confocal microscopy (RCM)|Reflectance confocal microscopy (RCM) will be performed every 3 months.
214996936|NCT05473507|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) will be performed every 3 months.
214996937|NCT05473507|DIAGNOSTIC_TEST|Dermtech tape-stripping|Dermtech tape-stripping for genetic analysiswill be performed every 6 months.
214996938|NCT05473507|DIAGNOSTIC_TEST|Total Skin Examinations|Total Skin Examinations will be performed every 12 months.
214996939|NCT06499519|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
214996940|NCT04738487|BIOLOGICAL|Pembrolizumab/Vibostolimab|Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
214996941|NCT04738487|BIOLOGICAL|Pembrolizumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
214996942|NCT05757856|DRUG|NDX-3315 and NDX-3324|Oral solution
214996943|NCT05029999|DRUG|PLD Chemotherapy|PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
215093407|NCT01522430|PROCEDURE|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
214384713|NCT03158389|DRUG|Vismodegib|daily orally
214384714|NCT03158389|DRUG|Temsirolimus|weekly i.v.
214384715|NCT03158389|DRUG|Palbociclib|orally on 21 days of a 28 days cycle
214384716|NCT02402088|BEHAVIORAL|Stress Imagery|"The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work."
214384717|NCT02402088|BEHAVIORAL|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
214384718|NCT02402088|BEHAVIORAL|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
214384719|NCT00893347|BEHAVIORAL|Treatment as usual|Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
214384720|NCT00893347|BEHAVIORAL|Cognitive-behavioural therapy|6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
214384721|NCT00550550|DRUG|Placebo|Placebo sublingual tablet, once daily
214384722|NCT00550550|BIOLOGICAL|SCH 697243|Grass sublingual tablet, once daily
214384723|NCT00550550|DRUG|Loratadine Syrup 1 mg/mL Rescue Treatment|Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to \<6 years of age and at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
214384724|NCT00550550|DRUG|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
214384725|NCT00550550|DRUG|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
214384726|NCT00550550|DRUG|Mometasone furoate 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to \<12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to \<18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
214384727|NCT00550550|DRUG|Albuterol 108 mcg Rescue Treatment|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to \<18 years with asthma symptoms .
214384728|NCT00550550|DRUG|Fluticasone 44 mcg Rescue Treatment|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to \<18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
214384729|NCT00550550|DRUG|Prednisone 5 mg Rescue Treatment|Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
214384730|NCT03323580|OTHER|GDFT|Target parameter will be titrated with fluid bolus, and thus individual amount varied depending on the parameter value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
215093408|NCT01522430|PROCEDURE|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
215093409|NCT06087978|DRUG|14C RPT193|Radiolabelled RPT193
214384731|NCT03323580|OTHER|traditional fluid therapy|Fluid therapy will be done without goal directed. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
214384732|NCT03952221|DEVICE|Continuous ultrasound therapy|continuous US therapy once a day, 9 minutes/session for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity
214384733|NCT03952221|DEVICE|pulsed ultrasound therapy|pulsed US therapy once a day, 9 minutes/session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle
214499472|NCT05240352|DEVICE|sham tDCS|"Subjects will receive a dose from a sham-tDCSthat is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later"
214499473|NCT06823635|DEVICE|Transcatheter device closure of perimembranous ventricular septal defects (PmVSDs)|Transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using an occluder device either specifically designed for this purpose or used off-label.
214499474|NCT06821724|DRUG|Casein phosphopeptide-amorphous calcium phosphate|Intervention
215093410|NCT04067778|DIAGNOSTIC_TEST|Intervention Group|Standard colonoscopy with targeted biopsies only
214384734|NCT03952221|DEVICE|US and electrotherapy (sonotens)|US and electrotherapy (transcutaneous electrical nerve stimulation) once a day, 10 minutes /session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, US: 3 MHz frequency, 0,5 W/cm2 SATA intensity, TENS: application in conventional mode at 100 Hz frequency and 100 μs wavelength
214996944|NCT05029999|DRUG|CDX-1140|CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
214996945|NCT05029999|DRUG|CDX-301|CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
214996946|NCT06965530|DIETARY_SUPPLEMENT|Clinic-Based Medically Tailored Groceries (CB-MTG)|Patients have the opportunity to pick up medically tailored groceries every other week at the Food Is Medicine Clinic or Market associated with their provider.
214996947|NCT06965530|DIETARY_SUPPLEMENT|Home Delivered Medically Tailored Groceries (HD-MTG)|Patient receive home delivered medically tailored groceries every two weeks during pregnancy and up to 6 months post-delivery.
214384735|NCT03952221|DEVICE|Sham ultrasound therapy|sham US therapy once a day for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 0 MHz frequency, 0 W/cm2 SATA intensity
214384736|NCT03322371|DEVICE|2-lead limited electroencephalography recording|The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.
214384737|NCT06076356|OTHER|Foam Rolling|Foam Roller for 90 seconds over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
214384738|NCT06076356|OTHER|Kinesio Taping|Kinesio taping over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
214384739|NCT03519243|BIOLOGICAL|BCD-131|subcutaneously monthly
214384740|NCT03519243|BIOLOGICAL|Mircera|subcutaneously monthly
214384741|NCT04740619|PROCEDURE|Natural Orifice Specimen Extraction|Natural Orifice Specimen Extraction via transanal
214384742|NCT01370681|DRUG|Period I : HKB0701 and SLM0807, Period II : CJ30001|
214384743|NCT01370681|DRUG|Period I : CJ30001, Period II : HKB0701 and SLM0807|
214384744|NCT05156502|DEVICE|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina and vestibule, following the IFU of the device.
214384745|NCT05156502|DEVICE|Fractionated Laser (Pixel CO.2-Alma)|Device: Fractionated Laser (Pixel CO2-Alma) The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina only, following the IFU of the device.
214384746|NCT03036059|DRUG|400 μg/kg Ivermectin + 400 mg Albendazole|400ug/Kg, tablet, given orally once or twice a year.
214384747|NCT01965938|DEVICE|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
214384748|NCT01965938|DEVICE|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
214499475|NCT06821724|DRUG|Casein phosphopeptide-amorphous calcium phosphate + fluoride|Intervention
214996948|NCT06965530|DIETARY_SUPPLEMENT|Home Delivered Medically Tailored Groceries plus Education (HD-MTG_PLUS)|Patients receive home delivered medically tailored groceries every two weeks during pregnancy and up to 6 months post-delivery, plus also receives additional nutrition and culinary education and support throughout the trial.
214996949|NCT06965010|BEHAVIORAL|Measurement-based care|Patients will complete MBC measures with their treatment provider and follow-up surveys conducted at baseline and monthly intervals. Both providers and patients will use the Greenspace Mental Health tools to regularly assess patient-reported symptoms, review results together, and collaboratively design individualized treatment plans. Providers will implement MBC to guide treatment adjustments based on these assessments.
214996950|NCT06965010|BEHAVIORAL|Measurement As Usual|Patients will participate in Measurement As Usual (MAU) via the existing processes available within treatment sites. Currently, patients are assessed and participate in semi-structured interviews at 6-month increments to assess progress and appropriateness of level of care.
214996951|NCT06205030|DRUG|anti-diabetic herbal drug|All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
214996952|NCT06263478|DRUG|INCA034176|IV infusion
214996953|NCT05344157|BIOLOGICAL|XSTEM-OA|XSTEM-OA is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of osteoarthritis.
214996954|NCT06292741|DEVICE|Sudoscan|recording of sudomotor function and pupillary reactivity
214996955|NCT05516498|DRUG|Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
214996956|NCT05516498|DRUG|Part A: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
215093411|NCT04067778|DIAGNOSTIC_TEST|Control Group|Standard colonoscopy with random AND targeted biopsies
214384749|NCT04946929|DRUG|Ticagrelor Oral Tablet [Brilinta]|Ticagrelor, 2-3mg/kg, 12h, p.o.
214384750|NCT04946929|DRUG|Low molecular weight heparin|half amount low molecular weight heparin
214384751|NCT03585101|DRUG|Elbasvir/grazoprevir|Daily fixed-dose combination (FDC) elbasvir (EBR) (50 mg)/grazoprevir (GZR) (100 mg) for 12 weeks
214384752|NCT02090634|BEHAVIORAL|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
214384753|NCT02090634|BEHAVIORAL|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
214499476|NCT06821724|DRUG|Nano hydroxyapatite paste|Intervention
214499477|NCT06821724|DRUG|Fluoride gel|Positive control
214499478|NCT05447208|DRUG|Growth Hormone|Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
214384754|NCT01465828|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).
214384755|NCT01465828|DRUG|prasugrel|Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
214384756|NCT01612325|DEVICE|Holmium-166 polylactic microspheres|Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
214384757|NCT01164228|DRUG|Gemcitabine|Given IV
214384758|NCT01164228|DRUG|Sunitinib|Given PO
214384759|NCT05354063|BIOLOGICAL|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
214384760|NCT05354063|BIOLOGICAL|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
214499479|NCT05447208|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
214499480|NCT06237673|DIAGNOSTIC_TEST|CT|CT-directed clinical management strategy
214996957|NCT05516498|DRUG|Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
214996958|NCT05516498|DRUG|Part B: placebo (matching zibotentan capsule) + dapagliflozin|"placebo capsule (matching zibotentan capsule)~dapagliflozin tablet"
214384761|NCT05354063|DRUG|Placebo|Placebo IM on day 0 and day 21.
214499481|NCT06237673|DIAGNOSTIC_TEST|invasive coronary angiography (ICA)|Standard clinical management directed by conventional invasive coronary angiography (ICA).
214499482|NCT06384521|BEHAVIORAL|Lifestyle MIND|Lifestyle MIND is implemented twice a week in the group format, including a physical activities class and a health class. The physical activity class lasts for 60 minutes. Participants engage in physical activities modified from the American College of Sports Medicine guidelines for diabetes. The health class lasts for about 2 hours and is delivered by occupational therapy faculty and students with light refreshments that are friendly for people with diabetes. The first hour of the health class involves psychoeducation and skills training for managing SMI and Type 2 Diabetes Mellitus (T2DM), including topics such as recognizing signs and symptoms of mental disorders and diabetes, goal setting, dealing with setbacks and resistance to change, celebrating culture and holidays, and establishing healthy habits and routines. The second hour of the health class is to address individual needs, social determinants of health, and any needed homework assistance.
214996959|NCT05516498|DRUG|Part B: zibotentan (dose A) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
214996960|NCT05516498|DRUG|Part B: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
214384762|NCT05995301|DRUG|Ropivacaine in Transversus abdominis plane|This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery
214384763|NCT05995301|DRUG|Ropivacaine in Local infiltration at port site|This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery
214384764|NCT01164462|BIOLOGICAL|blood test: rapid finger-stick blood specimen test|
214384765|NCT01164462|BIOLOGICAL|blood test: conventional test|
214384766|NCT00005837|DRUG|oxaliplatin|
214384767|NCT03804775|DIAGNOSTIC_TEST|Serum lipid profile|Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa
214384768|NCT00167830|BEHAVIORAL|Motivational Interviewing|Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.
214384769|NCT00167830|BEHAVIORAL|Strength and Cardiovascular Conditioning|Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.
214384770|NCT00167830|BEHAVIORAL|Food selection and portion control|Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
214384771|NCT01457235|OTHER|Cognitive Remediation|All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
214499483|NCT06420492|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug for four weeks.
214996961|NCT05516498|DRUG|Part B: zibotentan (dose C) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
214996962|NCT05535244|DRUG|Cevostamab|Cevostamab will be administered by IV infusion in 21-day cycles.
214996963|NCT05535244|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
214384772|NCT00987064|DEVICE|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
214996964|NCT05350202|DRUG|Empagliflozin|Empagliflozin was administered according to the approved product information.
214996965|NCT06576869|PROCEDURE|Upper extremity orthopedic surgeries.|Upper extremity orthopedic surgeries that require the use of a tourniquet.
214996966|NCT06967129|DEVICE|Investigational daily disposable, soft, toric lenses manufactured on 4th Generation Technology (4GT) lines with extended mini-stack hydration using propylene glycol (PG) as the hydration solvent.|Test Lens
214996967|NCT06967129|DEVICE|ACUVUE® Oasys 1-Day for Astigmatism (AO1DfA) soft contact lenses manufactured on 3rd Generation Technology (3GT) legacy lines using isopropyl alcohol (IPA) as the hydration solvent.|Control Lens
214384773|NCT00987064|DEVICE|Placebo TLA|TLA treatment with disabled filtration function
214384774|NCT02390856|DEVICE|Conventus DRS|The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.
214384775|NCT02390856|DEVICE|Volar Plate|A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
214499484|NCT06877208|OTHER|Glucagon (part C)|90 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).
214499485|NCT06877208|OTHER|Glucose clamp (part C)|90 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).
214499486|NCT06877208|OTHER|Saline (part C)|90 minutes intravenous infusion with isotonic NaCl.
214499487|NCT06877208|OTHER|Glucagon (part D)|210 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).
214499488|NCT06877208|OTHER|Glucose clamp (part D)|210 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).
214499489|NCT06877208|OTHER|Saline (part D)|210 minutes intravenous infusion with isotonic NaCl.
214499490|NCT05251363|DEVICE|Solia S lead|The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
214499491|NCT06814613|OTHER|Exercise|For the next 4 weeks, every night, 1 hour before the routine bedtime (or the time when the student planned to sleep), a video call (via the Google Meet application) was made with the student, and progressive relaxation exercises were performed. The exercise took approximately 20 minutes and followed the implementation protocol (Davis et al., 2008; Payne, 2000). Group interviews were conducted for students with similar sleep hours. They were asked to move to a ventilated room away from noise so that the exercises could be practiced comfortably and not interrupted.
214499492|NCT06764641|DIAGNOSTIC_TEST|Breath test|Participants must be fasted for a minimum of six hours prior to breath sample collection. Breath samples will be collected prior to the reference test for each participant (i.e. upper/lower gastrointestinal endoscopy, CT/MRI/ultrasound ± histological/cytology)
214499493|NCT01093612|PROCEDURE|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
214499494|NCT01093612|RADIATION|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
214499495|NCT01093612|PROCEDURE|Biopsy|Correlative Studies
214499496|NCT01093612|OTHER|Immunohistochemistry staining method|Correlative studies
214499497|NCT01093612|OTHER|laboratory biomarker analysis|Correlative studies
214499498|NCT01093612|GENETIC|mutation analysis|Correlative studies
214996968|NCT06543316|PROCEDURE|Low Thermal Plasma (LTP) Treatment|For patients randomized to the LTP group, the first LTP treatment will be administered during the initial esophagogastroduodenoscopy (EGD) using a single-use 2.3 mm filtered argon plasma coagulation (FiAPC probe). The argon plasma will be applied at low power settings (\~1 W) to the ulcerated areas using pulsed APC effect 0.1.
214384776|NCT00838799|DRUG|RGH-896|45 mg TID, capsules, 14 weeks.
214499499|NCT02928978|DRUG|Ruxolitinib|tablet (taken by mouth)
214499500|NCT02928978|DRUG|Placebo (for Ruxolitinib)|tablet (taken by mouth)
214499501|NCT06019247|OTHER|Individual placement support (IPS)|IPS is the most studied psychiatric rehabilitation intervention in the world. It is based on eight principles: inclusion of all clients who have declared a desire to work, no pre-vocational training, benefits counseling, rapid job search, treatment team-level integration of vocational and clinical services, consideration of client preferences in all decisions, assistance in job development, provision of follow-up supports after finding employment, and a focus on competitive employment. We propose to adapt and pilot the IPS to improve employment and health among people with severe mental disorders in Mexico.
214499502|NCT03253172|DIETARY_SUPPLEMENT|Potassium Chloride|Two potassium supplements with varying anions.
214499503|NCT03253172|DIETARY_SUPPLEMENT|Potassium Citrate|Potassium Citrate
214996969|NCT06543316|OTHER|Standard of Care Ulcer Treatment (typically PPI Administration)|Standard of care for treatment of ulcers is administration of a proton pump inhibitor (PPI). For patients in the SOC group whose ulcers have not healed completely by the second follow-up at 8 weeks, crossover to LTP treatment will be offered. This treatment will follow the same procedure as the initial LTP treatment.
214384777|NCT00838799|DRUG|RGH-896|30 mg TID, capsules, 14 weeks.
214499504|NCT03253172|DIETARY_SUPPLEMENT|Placebo|Placebo
214499505|NCT04982406|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
214499506|NCT03984565|DRUG|Cannabidiol|High-CBD, low-THC sublingual product formulated in palm oil
214499507|NCT03984565|DRUG|Placebo|Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.
214499508|NCT06356012|DRUG|Imiquimod|Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.
214499509|NCT06356012|PROCEDURE|Loop Electrosurgical Excision Procedure|Active comparator group will be treated with LEEP.
214499510|NCT03835754|DEVICE|OCS Heart System|The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
214499511|NCT05073003|DRUG|altSonflex Placebo|2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1\_Adults\_Placebo\_GR1 and ST1\_Adults\_Placebo\_GR2 groups in Stage 1 (Europe).
214687634|NCT00028561|DRUG|ixabepilone|Given IV
214687635|NCT00028561|DRUG|carboplatin|Given IV
214687636|NCT00028561|OTHER|laboratory biomarker analysis|Correlative studies
214687637|NCT00028561|OTHER|pharmacological study|Correlative studies
214384778|NCT00838799|DRUG|RGH-896|15 mg TID, capsules, 14 weeks.
214384779|NCT00838799|DRUG|pregabalin|100 mg, TID, capsules, 14 weeks.
214384780|NCT00838799|DRUG|placebo|TID, capsules, 14 weeks.
214384781|NCT02640391|OTHER|colonoscopy|
214384782|NCT02468635|OTHER|upper limb exercises|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESISTANCE STAGE: upper limb exercises with weight training equipment or dumbbells (the patient's adaptation) with 50% of maximum load reached the maximum repetition test. Series 2 minutes and rest interval between sets 1-2 minutes. RESPIRATORY TRAINING : Strengthening of the respiratory muscles 5-15 minutes with Threshold with load of 50% of the affected MIP (measure maximal inspiratory pressure) evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
214996970|NCT05411666|PROCEDURE|Saline solution maintenance of the CVC|"Saline solution maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun, according to local standard procedures."
214384783|NCT02468635|OTHER|without training for upper limb|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESPIRATORY TRAINING: Strengthening respiratory muscles 5-15 minutes with Threshold with load of 50% of MIP hit in the evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
214384784|NCT04152265|PROCEDURE|colonoscopy|colonoscopy
214384785|NCT04152265|OTHER|questionnaires|complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
214384786|NCT04152265|OTHER|demographic data collections|completing the demographic questionnaire
214384787|NCT04152265|OTHER|anthropometric data collections|For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
214384788|NCT04152265|PROCEDURE|Collecte the biological samples|blood and faeces collections
214384789|NCT04089098|DIAGNOSTIC_TEST|passive leg raising versus mini volume challenge|Blood samples will be collected and ultrasound evaluation of renal perfusion conducted in study participants immediately before conducting passive leg raising (PLR). PLR will then be carried out on study participants, followed by MVC. PLR- and/or MVC-responsive patients will receive a further 700 ml fluid immediately after the MVC. Renal perfusion will be further assessed 1 and 24 hours after the MVC.
214384790|NCT04129814|PROCEDURE|Non surgical periodontal therapy|single session full-mouth scaling and root planing
214384791|NCT05886322|DIAGNOSTIC_TEST|patient reported outcome measures|MIAH, mHI, Manotiba IBD Index, p-HBI/SCCAI, IBD-control
214384792|NCT05886322|DIAGNOSTIC_TEST|fecal calprotectin|fecal calprotectin point-of-care test and laboratory test
214384793|NCT05886322|DIAGNOSTIC_TEST|colonoscopy|endoscopic activity scores (SES-CD, UCEIS, MES)
214384794|NCT02456701|BIOLOGICAL|KTN3379|IV every 2 weeks
214384795|NCT02456701|DRUG|vemurafenib|960 mg po bid
214384796|NCT04269915|BIOLOGICAL|female Schistosoma mansoni cercariae|Viable female Schistosoma mansoni cercariae of the Puerto Rican strain
214384797|NCT03604822|PROCEDURE|Music therapy|ALS-specific, individualized MT protocol was delivered to study participants in their homes twice weekly for the duration of six weeks by the researcher. Facilitating music structures were composed by the researcher to support cueing, timing and intensity of breathing and vocalization exercises. These structures were regularly modified to suit the unique capabilities, current individual demands and progress of each participant. One familiar song, selected by the participant, was used for each participant in therapeutic singing exercise closing each session. Individualized exercises sets for independent practice were provided at session 3 to each participants. ALS-specific voice health guidelines were provided for participants prior to start of the treatment.
214384798|NCT02568579|PROCEDURE|blood sample/ stool sample|blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
214384799|NCT03583645|BEHAVIORAL|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
214384800|NCT03583645|OTHER|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
214384801|NCT05412810|OTHER|oxygen|oxygen exposure of more than 50% for 1.5 hours
214384802|NCT00697190|DEVICE|senofilcon A toric|silicone hydrogel contact lens for patients with astigmatism
214384803|NCT00697190|DEVICE|galyfilcon A toric|silicone hydrogel contact lens for patients with astigmatism
214384804|NCT04890795|DRUG|AL8326 tablets|10mg/tablet;Oral administration, once daily.
214384805|NCT01654081|DRUG|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
214384806|NCT00977769|DRUG|carbetocin 100 µg|Hemodynamic effect of
214384807|NCT00977769|DRUG|oxytocin 5 u|Hemodynamic effect of
214996971|NCT05411666|PROCEDURE|No maintenance of the CVC|"No maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun. Just visual inspection to local site of CVC insertion."
214996972|NCT06282861|DRUG|Trelegy Ellipta 100/62.5/25Mcg Inh 30D|Product to be used according to specifications. 1 inhalation daily for 12 months
214996973|NCT06282861|DRUG|Brimica|As per product specifications
214996974|NCT06282861|DRUG|Duaklir|As per product specifications
214499512|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose C|2 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to adults in the ST1\_Adults\_Dose C\_GR1 and ST2\_Adults\_Dose C groups in Stage 1 and 2 (Europe and Africa) and children in the ST2\_Children\_Dose C group in Stage 2 (Africa), and at Day 1 and Day 169 to adults in the ST1\_Adults\_Dose C\_GR2 group in Stage 1 (Europe); 3 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2\_Infants\_Dose C\_Safety and ST2\_Infants\_Dose C\_Dose find groups in Stage 2 (Africa).
214996975|NCT06282861|DRUG|Ultibro|As per product specifications
214996976|NCT06282861|DRUG|Ulunar|As per product specifications
214996977|NCT06282861|DRUG|Xoterna|As per product specifications
214996978|NCT06282861|DRUG|Anoro|As per product specifications
214384808|NCT00977769|DRUG|placebo (NaCl)|Hemodynamic effect of
214384809|NCT05917301|RADIATION|hypofractionation|This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.
214384810|NCT01586312|OTHER|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency
214384811|NCT01586312|DRUG|Hyaluronic Acid|Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
214384812|NCT00911313|DRUG|Letrozole tablets (Femara; Novartis Pharma, Switzerland)|2.5 mg letrozole daily from day 3 of the menses for 5 days
214384813|NCT00911313|DRUG|metformin HCl (Cidophage®; CID,Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks
214996979|NCT06282861|DRUG|Laventair|As per product specifications
214384814|NCT00911313|DRUG|CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)|150 mg CC for 5 days starting from day 3 of menstruation
214384815|NCT05232474|DEVICE|KomPas+|KomPas+ is a guideline-based clinical decision support system. With KomPas+, the aim is to integrate KomPas with the guideline recommendations for the conservative treatment process of patients with intermittent claudication. KomPas+ is a web-based tool, aimed to facilitate person-centered and participatory healthcare. Therapists have access to a tool that will help, for example, to improve consistency between patient-specific goals and the treatment plan. Using KomPas+, therapists are encouraged to discuss choices in the treatment plan with the patient. It is expected that the included topics in KomPas+ will not be burdensome for both patients and therapists. Topics to discuss are, for example, Frequency, Intensity, Time and Type (FITT) for drawing up a training schedule. KomPas+ is meant to facilitate therapists and patients in the SDM process. It does not force patients to take part in the SDM process against their will.
214996980|NCT06282861|DRUG|Spiolto Respimat|As per product specifications
214996981|NCT06282861|DRUG|Yanimo|As per product specifications
214996982|NCT06282861|DRUG|Foradil|As per product specifications
214996983|NCT06282861|DRUG|Broncoral|As per product specifications
214384816|NCT05232474|DEVICE|KomPas|KomPas is an online tool showing personalized outcome forecasts. These forecasts have been developed using real-world data of patients with intermittent claudication for physiotherapists in daily practice. The forecasts visualize the estimated outcome of supervised exercise therapy (walking distance and quality of life), for an individual patient with intermittent claudication. The information provided is based on patients similar to the individual patient from a large database. The actual outcome data of these similar patients are used to create an individual forecast. KomPas plots the estimated therapy outcome in time, thereby making personalized outcome forecasts. The forecasts are not used to direct the choices of treatment, but to motivate the patient, monitor the treatment process and to set realistic goals.
214384817|NCT01661556|DRUG|Miconazole|Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
214499513|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose B|2 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to children in the ST2\_Children\_Dose B group in Stage 2 (Africa); 3 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2\_Infants\_Dose B\_Safety and ST2\_Infants\_Dose B\_Dose find groups in Stage 2 (Africa).
214996984|NCT06282861|DRUG|Formoterol stada|As per product specifications
214996985|NCT06282861|DRUG|Oxis|As per product specifications
214996986|NCT06282861|DRUG|Formatris|As per product specifications
214996987|NCT06282861|DRUG|Formoterol Aldo|As per product specifications
214996988|NCT06282861|DRUG|Onbrez|As per product specifications
214996989|NCT06282861|DRUG|Oslif|As per product specifications
214996990|NCT06282861|DRUG|Hirobriz|As per product specifications
214996991|NCT06282861|DRUG|Striverdi|As per product specifications
214996992|NCT06282861|DRUG|Beglan|As per product specifications
214996993|NCT06282861|DRUG|Betamican|As per product specifications
214996994|NCT06282861|DRUG|Inaspir|As per product specifications
214996995|NCT06282861|DRUG|Serevent|As per product specifications
214996996|NCT06282861|DRUG|Soltel|As per product specifications
214996997|NCT06282861|DRUG|Eklira|As per product specifications
214996998|NCT06282861|DRUG|Bretaris|As per product specifications
214996999|NCT06282861|DRUG|Seebri|As per product specifications
214997000|NCT06282861|DRUG|Tovanor|As per product specifications
214997001|NCT06282861|DRUG|Enurev|As per product specifications
214997002|NCT06282861|DRUG|Spiriva|As per product specifications
214997003|NCT06282861|DRUG|Tavulus|As per product specifications
214997004|NCT06282861|DRUG|Sirkava|As per product specifications
214997005|NCT06282861|DRUG|Braltus|As per product specifications
214997006|NCT06282861|DRUG|Gregal|As per product specifications
214997007|NCT06282861|DRUG|Incruse|As per product specifications
214384818|NCT01661556|DRUG|Hydroquinone|Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
214384819|NCT01809041|DRUG|Sevoflurane|
214384820|NCT01809041|DRUG|propofol|
214384821|NCT01809041|DRUG|remifentanil|
214384822|NCT00799643|DRUG|Salsalate|Salsalate 3.5 g/d orally, divided dosing
214384823|NCT00799643|DRUG|Salsalate Placebo|
214384824|NCT06384612|BEHAVIORAL|use of pocket cards|Use of pocket cards of 22 cm x 11 cm size prepared by students every week in classes
214384825|NCT06926218|DRUG|HSK47388|cohort 1 to cohort 5
214384826|NCT06926218|DRUG|Placebo|cohort 1 to cohort 5
214384827|NCT06926543|DRUG|Chemoradiation|This intervention will consist of getting chemotherapy followed by radiotherapy, i.e, in a sequential manner
214384828|NCT06926543|DRUG|Chemoradiation|This intervention will consist of getting chemotherapy and radiotherapy at the same time, i.e, in a concurrent manner.
214384829|NCT06900686|DRUG|PD1 Inhibitor|PD1 Inhibitor
214384830|NCT06925958|DIAGNOSTIC_TEST|Flow cytometry|CD38 Flow cytometry testing
214384831|NCT06926452|PROCEDURE|Pontic site augmentation with sub-epithelial connective tissue graft.|Pontic site augmentation with sub-epithelial connective tissue graft.
214384832|NCT06926452|PROCEDURE|Pontic site augmenation using multi-layered platelet rich fibrin|Pontic site augmenation using multi-layered platelet rich fibrin
214997008|NCT06282861|DRUG|Rolufta|As per product specifications
214384834|NCT06925139|DEVICE|Non-ablative monopolar radiofrequency treatment|"Protocol for the experimental group:~Tissue preparation phase: 5 minutes with the circular resistive monopolar electrode, applying slow circular or semicircular movements in the perineal area. The temperature will be gradually increased based on the patient's temperature perception, ensuring it remains comfortable (approximately 5 out of 10).~Main phase: 10 minutes using the intracavitary capacitive electrode connected to the PLUMA handle, lightly resting it on the tissues and continuously moving the electrode. The temperature should reach 40-42°C in the tissue and be maintained for at least 10 minutes.~Final phase: 5 minutes with the circular resistive monopolar electrode, applying it similarly to the preparatory phase, with a subthermal effect, reaching a self-reported thermal sensation of 3 to 4 out of 10.~Protocol for the sham group: this group will receive the same treatment protocol that treatment group, but without the application of heat."
214384835|NCT06926322|DRUG|Conventional double antibiotic paste of Metronidazole 500 mg plus Ciprofloxacin 500 mg mixed with propylene glycol|The studied medicament will be placed onto the floor of the pulp chamber.
214384836|NCT06926322|DRUG|Double antibiotic paste of Metronidazole and Ciprofloxacin loaded chitosan-coated silver nanoparticles|The studied medicament will be placed onto the floor of the pulp chamber.
214384837|NCT06926322|DRUG|chitosan-coated silver nanoparticles|The studied medicament will be placed onto the floor of the pulp chamber.
214384838|NCT06508138|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus|"About 1 month before donating blood, donors are required to come to outpatient clinic once a week to receive the following vaccine series:~Week 1: PVX1 (1 of 3): intramuscular injection (IM) of 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 2: PVX1 (2 of 3): IM 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 3: PVX1 (3 of 3): IM TA-HPV vaccinia boost Pause for 2 weeks Peripheral blood collection and possible bone marrow harvest depending on randomization"
214384839|NCT01768546|BEHAVIORAL|Virtual Diabetes Prevention Program|Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
214384840|NCT01768546|BEHAVIORAL|Interactive tracking and problem solving web portal|
214384841|NCT05672212|DEVICE|ANI (Analgesia/Nociception Index) monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.
214384842|NCT05672212|DEVICE|standard monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.
214384843|NCT05672212|DRUG|Sufentanil|Sufentanil
214384844|NCT01829984|OTHER|Verbal and Written Instruction|"Pre-teaching Evaluation: Patient~* Pre-teaching Evaluation: Caregiver~  o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.~* Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection."
214384845|NCT01829984|OTHER|Verbal and Written Plus Simulation|"Post-injection Evaluation: Patient~* Post-injection Evaluation: Caregiver~  o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).~* Nurse Evaluation: Control~* Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study."
214384846|NCT06230991|DIETARY_SUPPLEMENT|SIM05|SIM05 contains a blend of food-grade Bifidobacterium and Lactobacillus strains plus prebiotics
214384847|NCT03657927|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
214384848|NCT03657927|DEVICE|McGrath MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
214384849|NCT04532242|BEHAVIORAL|Cognitive reappraisal|Participants will be trained to follow instructions to look/respond naturally or use cognitive reappraisal to reframe or reconsider a negative picture to decrease negative emotion.
214499514|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose A|3 doses of altSonflex1-2-3 Dose A administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2\_Infants\_Dose A\_Safety and ST2\_Infants\_Dose A\_Dose find groups in Stage 2 (Africa).
214499515|NCT05073003|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 to adults in the ST2\_Adults\_Control C group and children in the ST2\_Children\_Control B and ST2\_Children\_Control C groups in Stage 2 (Africa); 2 doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to infants in the ST2\_Infants\_Control A\_Safety, ST2\_Infants\_Control B\_Safety, ST2\_Infants\_Control C\_Safety and ST2\_Infants\_Control\_Dose find groups in Stage 2 (Africa).
214499516|NCT05073003|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to adults in the ST2\_Adults\_Control C group in Stage 2 (Africa).
214499517|NCT05073003|COMBINATION_PRODUCT|GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine|1 dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine administered intramuscularly, in the non-dominant arm, at Day 253 to infants in the ST2\_Infants\_Control A\_Safety, ST2\_Infants\_Control B\_Safety, ST2\_Infants\_Control C\_Safety and ST2\_Infants\_Control\_Dose find groups in Stage 2 (Africa).
214499518|NCT05073003|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to children in the ST2\_Children\_Control B and ST2\_Children\_Control C groups in Stage 2 (Africa).
214499519|NCT05073003|BIOLOGICAL|Serum Institute of India's Measles and rubella vaccine|2 doses of Serum Institute of India's Measles and rubella vaccine administered subcutaneously, in the non-dominant arm, at Day 29 and Day 281 to infants in the safety groups, and at Day 1 and Day 253 to infants in the dose-finding groups, in Stage 2 (Africa).
214384850|NCT01532180|DEVICE|aura6000 System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
214384851|NCT03739294|DRUG|Fluticasone Furoate/ Vilanterol Trifenatate|Asthma inhalation medication
214687638|NCT02261168|OTHER|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
214687639|NCT02811536|DEVICE|optical coherence tomography angiography|Imaging with optical coherence tomography angiography
214687640|NCT02165800|PROCEDURE|L-PANP-TME|
214687641|NCT02165800|PROCEDURE|O-PANP-TME|
214687642|NCT02486887|DEVICE|telemonitoring of weight, pulse and blood pressure|
214687643|NCT00074412|DRUG|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
214997009|NCT06370533|BEHAVIORAL|behavioral interventions|The investigators set diet, physical activity, and weight goals for each participant. During the lifestyle intervention period, the participants need to complete weekly self-monitoring of weight, weekly recording of diet behavioral goals, timely exercise logging, online health education course learning by using the WeChat public account. They will receive corresponding timely reminder and tailored feedback in the form of graphical illustration and text according to diet, physical activity, and weight data collected by WeChat public account and Huawei Wristband. They will receive individual face to face or telephone sessions every 2 weeks to complete health education, goal review, motivational interview as well as collecting adverse events.
214997010|NCT05556057|OTHER|mindfulness meditation(MM)|Participants will be provided with a unique invitation code that will allow them to download and use the free research version of the Mindfulness Coach app that is designed to deliver mindfulness training developed by the Veteran Affairs' National Center for PTSD.The app is tailored to users who may be skeptical about meditation practices by providing simple instructions and brief meditation exercises. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes, with an average length of 10 minutes
214997011|NCT05556057|OTHER|Health Education (active control)|Participants will be asked to download and use the free TED Talk app.Each participant's account will include a list of over 80 TED Talks related to the six broad categories of sleep, nutrition, mood, relationships, chronic pain, and health behaviors. These talks range from 4 to 18 minutes and were reviewed/selected by the investigator team. The research coordinator(RC) will instruct them to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week. The RC will ask participants to complete weekly logs of their TED Talk app use
214384852|NCT02936037|DRUG|MD1003 100mg capsule|
214687644|NCT00074412|DRUG|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
214687645|NCT02891798|DRUG|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
214687646|NCT02891798|DRUG|Bupivacaine Only (control arm)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
214687647|NCT02917551|OTHER|7 days of adequate antibiotic treatment|
214384853|NCT02936037|DRUG|PLACEBO|an inactive substance
214384854|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn5|Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement
214384855|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn10|Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement
214384856|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn0|20 g of LNS containing 0 mg of zinc and a daily placebo supplement
214687648|NCT02917551|OTHER|14 days of adequate antibiotic treatment|
214687649|NCT00924352|DRUG|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.
214997012|NCT05661331|DEVICE|Transjugular intrahepatic portosystemic shunt|The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.
214997013|NCT02842619|BIOLOGICAL|BonoFill-II|"Sinus augmentation - Surgery will be performed by either open or close sinus augmentation as per investigator discretion and as per common medical practice. After the elevation, BonoFill-II will be transplanted on the residual sub-antral bone.~Bone grafting after removal of cysts from jaws - Treatment will be performed according to the size of the cyst: in relatively small cyst total enucleation will be performed. In large cysts, a process of marsupialization will be performed. The entire cyst will be removed, including the epithelium layer, and the BonoFill-II product will be used for filling."
214997014|NCT03620669|DRUG|Durvalumab|Durvalumab 1500mg q4W until progression or unacceptable toxicity
214997015|NCT06026709|BEHAVIORAL|EmoEase|"The online interventionEmoEase integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program."
214997016|NCT06972056|DRUG|Atogepant 60 mg|Atogepant at a dose up to 60 mg daily.
214997017|NCT06972056|DRUG|Propranolol 160 mg|Daily propranolol up to 80 mg twice daily.
214997018|NCT06972056|DRUG|Topiramate 100 mg|Daily topiramate, up to 50 mg twice daily
214997019|NCT05153239|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
214997020|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
214997021|NCT05153239|DRUG|Irinotecan|For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk
214997022|NCT05153239|DRUG|Topotecan|Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk
214997023|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
214997024|NCT05116722|DEVICE|Shoulder Pacemaker|Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
214384857|NCT00944281|DIETARY_SUPPLEMENT|Suppl-Zn5|Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
214384858|NCT04057911|DEVICE|Active NIBS|Cathodal noninvasive brain stimulation will be given for 20 mins.
214384859|NCT04057911|DEVICE|Sham NIBS|The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
214499520|NCT05168384|COMBINATION_PRODUCT|Extracorporeal Photopheresis|"ECP procedures will be performed using a Therakos Cellex integrated, closed photopheresis system (Therakos, Inc., a Mallinckrodt Pharmaceuticals Company).~ECP will administered according to the following schedule (Group A):~Weeks 1-8: Twice per week (16 sessions). Weeks 9-16: Once per week (8 sessions). Weeks 17-24: Once every 2 weeks (4 sessions). Total: 28 sessions (within 24 weeks)."
214499521|NCT05168384|COMBINATION_PRODUCT|MS standard of care|Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN
214499522|NCT06749548|RADIATION|Group 1|the study is to emphasize the role of Computed Tomography Angiography (MDCTA) and Transthoracic Echocardiography (Echo) in the diagnosis of congenital cyanotic heart diseases.
214499523|NCT06777628|DRUG|Immunochemotherapy combined with antiangiogenic|Immunochemotherapy combined with antiangiogenic
214499524|NCT06763549|DEVICE|SUBPROTOCOL A|A 30-minute COR ECG recording will be performed, including 15 minutes of continuous sitting data used for clinical indication analysis through CardioMIND software. Data collection can occur in-clinic, via PHS, or using a shipped device with telehealth support. Sleep, HRV, and AFIB risk analysis will not be included.
214499525|NCT06763549|DEVICE|SUBPROTOCOL B|Subjects will undergo 24 hours of COR ECG recording, which must include at least one 15-minute unsupervised sitting session. Data analysis will include sleep patterns, HRV, and AFIB risk. ECG acquisition may take place in-clinic, via Patient Home Setup (PHS), or with a shipped device.
214499526|NCT06763549|DEVICE|SUBPROTOCOL C|COR 1.0 ECG recordings will be conducted over 2 to 7 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants subjects will also wear a cleared wrist or finger device to track SpO2 during sleep. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.
214687650|NCT00924352|DRUG|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
214687651|NCT05390424|DIAGNOSTIC_TEST|Blood collection using Dried Blood Spot|Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
214384860|NCT02405117|BEHAVIORAL|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
214384861|NCT03518528|DRUG|Estradiol 2 MG|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
214384862|NCT03518528|DRUG|Estradiol 100 µg|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
214384863|NCT04867876|BEHAVIORAL|Physical Therapy|Management of urinary incontinence by a physical therapist will include but is not limited to biofeedback, dietary management, alleviation of constipation, and neuromuscular re-education.
214384864|NCT04986735|DRUG|Empagliflozin|All subjects will have a baseline assessment and be prospectively followed up for 52 weeks to examine their outcome after receiving empagliflozin for neutropenia and neutrophil dysfunction.
214384865|NCT03672513|DIETARY_SUPPLEMENT|Placebo Comparator|Oral administration of 1 daily capsule containing lactose
214384866|NCT03672513|DIETARY_SUPPLEMENT|Zinc Supplement|Oral administration of 1 daily capsule containing 50 mg/day of Zn
214384867|NCT03672513|DIETARY_SUPPLEMENT|Magnesium supplement|Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
214384868|NCT06102031|DEVICE|ReDS-Guided|"ReDS™ measurements will be shared with the treating clinicians to guide diuretic treatment when discharge, home visit and outpatient follow-up, but blinded to the subjects.~At discharge:① If the ReDS™ reading \<36%, discharge as planned; ②ReDS™ reading ≥36%, increase the oral diuretic dose, discharge as planned.~When home visit and outpatient follow-up: ① If the ReDS™ reading \<20%, hold diuretics; ② If the ReDS™ reading was between 21-35%, maintain current diuretic dose and optimize GDMT. If the ReDS™ change ≥ 6% from the previous one, increase diuretic dose and optimize the GDMT; ③ If the ReDS™ reading was between 36-45%, increase diuretics and optimize the GDMT, then repeat ReDS™ test after 1 week(home visit); ④ If the ReDS™ reading was above 46%, consider intravenous diuretic therapy, and repeat ReDS™ test after 1 week(home visit) or hospitalization."
214384869|NCT06102031|OTHER|Usual care|ReDS measurements will not be shared with the treating clinicians and the subjects, diuretic treatment will only be guided using standard clinical care.
214384870|NCT00241137|DRUG|valsartan|
214384871|NCT04567693|OTHER|Early spaced-out appointments|Newly-diagnosed PLWH currently attend health centers monthly for ART pick-up and quarterly for clinical visits. In the intervention arms, participants will attend health centers quarterly for ART pick-up and semi-annually for clinical visits.
214384872|NCT00794001|BEHAVIORAL|Data analysis and Feedback|Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
214384873|NCT00749385|DRUG|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
214384874|NCT00749385|DRUG|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
214384875|NCT00749385|DRUG|EC naproxen|Enteric-coated naproxen tablet (500mg)
214384876|NCT00749385|DRUG|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
214384877|NCT02608762|RADIATION|standard adjuvant local radiation therapy or cranial radiation therapy|
214499527|NCT06763549|DEVICE|SUBPROTOCOL D|COR 2.0 (CORMDX) recordings will be conducted over 2 to 14 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants will also wear a cleared wrist or finger device to track SpO2 during sleep nights. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.
214499528|NCT06763549|DEVICE|SUBPROTOCOL E|Subjects will complete a 30-minute CORMDx (COR 2.0) ECG recording, with 15 minutes of continuous sitting data used for clinical indication analysis. Sleep, HRV, and AFIB risk analysis will not be performed.
214499529|NCT06763549|DEVICE|SUBPROTOCOL F|A 30-minute COR 2.0 ECG recording will be completed, along with a 12-lead resting ECG using an FDA-cleared reference device. Sleep, HRV, and AFIB analysis will not be performed.
214499530|NCT06763549|DEVICE|SUBPROTOCOL G|A 40-minute COR 2.0 recording will be conducted in two phases: 15 minutes of upright sitting and 15 minutes in a supine position. Hemodynamic monitoring, including blood pressure, cardiac output, and stroke volume variation, will be conducted using an FDA-cleared reference device. No sleep, HRV, or AFIB analysis will be performed.
214499531|NCT06763549|DEVICE|SUBPROTOCOL H|Subjects will undergo a 40-minute COR 2.0 recording, followed by a 40-minute COR 1.0 recording. Hemodynamic monitoring using an FDA-cleared reference device will be performed during both sessions. The transition between devices must occur within 60 minutes if the same adhesive is reused. Sleep, HRV, and AFIB analysis will not be performed.
214499532|NCT03706014|BEHAVIORAL|SIBS Program|Universal prevention program promoting positive sibling and family relationships conducted in an afterschool setting
214499533|NCT03706014|BEHAVIORAL|Control|Contact-equivalent attention control program in which students play educational games
214499534|NCT06753253|BEHAVIORAL|Cycling Exercise|Each arm will perform a 20-minute cycling intervention on an airdyne bike at different exercise intensity levels. Participants will perform the intervention three times over the course of one week.
215093412|NCT05892640|OTHER|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
215093413|NCT04519060|DEVICE|phototherapy eye shield|Phototherapy eye shields will be applied to the eyes of infants dilated for scheduled eye exam. They will be worn until four (4) hours after the last dose of dilating eye drops.
215093414|NCT02773654|OTHER|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
215093415|NCT02773654|OTHER|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
214384878|NCT03020329|DRUG|Paclitaxel liposome|"Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy.~Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.~Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily."
214384879|NCT03020329|DRUG|Cisplatin|Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.
214499535|NCT06016257|OTHER|Use of VirtuaCare™ for home program|Use of VirtuaCare™ system for the Home Program.
214499536|NCT06792227|BEHAVIORAL|FBT-H|"FBT is a structured treatment lasting 6-12 months, typically in an outpatient setting, with weekly sessions that gradually decrease in frequency over time (Lock \& Le Grange, 2015). It empowers parents to manage their child's recovery from the ED. The first phase focuses on weight restoration, with parents responsible for all eating decisions and restricting physical activity to reduce ED's influence. In the second phase, eating responsibility gradually shifts back to the adolescent. The final phase supports healthy adolescent development as ED symptoms subside.~The FBT-H adapts FBT to a home setting, with treatment led by family counselors and psychologists as part of a multidisciplinary team, including therapists, psychologists, a psychiatrist and a nurse specialist."
214499537|NCT05917860|DRUG|Degarelix|Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
214499538|NCT05917860|DEVICE|MRI-guided transurethral ultrasound ablation (TULSA)|MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) will be used to deliver whole-prostate gland treatment in accordance with the terms of TULSA marketing authorizations. The treating physicians will contour the entire prostate gland for a whole gland ablation.
214499539|NCT06735027|OTHER|intraarticular corticosteroid injection (IACI)|The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the glenohumeral joint. The injection site will then be disinfected with an alcohol wipe. A 21, 22, or 23-gauge needle (depending on provider preference) will be advanced into the glenohumeral joint under direct ultrasound visualization. After entry into the glenohumeral joint, a negative aspiration will be performed. At that time, up to 1 mL of 40mg/mL methylprednisolone acetate will be injected be injected into the joint space.
214997025|NCT05928247|BEHAVIORAL|Functional Communication Training (FCT)|During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. For participants with challenging behavior determined to be maintained by social-positive reinforcement (attention and/or tangible), the investigators also will typically recommend using a multiple schedule FCT (mult-FCT) to signal when reinforcement is available and to thin the schedule of reinforcement to render the treatment more practical for caregivers to implement. For participants with challenging behavior determined to be maintained by social-negative reinforcement (escape), the investigators will recommend using a chained schedule FCT (chained-FCT).
214997026|NCT05928247|BEHAVIORAL|Non-Contingent Reinforcement (NCR)|During NCR, the investigators will deliver the functional and competing reinforcers on time-based schedules and use multiple and chained schedules to signal when noncontingent reinforcement is available (similar to multiple- and chained-FCT).
214997027|NCT05928247|BEHAVIORAL|Competing Items and Response Blocking|The investigators will conduct a competing stimulus assessment (CSA) to identify items that produce at least an 80% reduction in challenging behavior when the participant is engaged with them. The investigators will evaluate conditions in which participants have free access to the item(s), when engagement with the item(s) is prompted, and when challenging behavior is physically blocked. Treatment will include one or more of the following components: non-contingent reinforcement informed by the CSA, reinforcing adaptive behavior, and blocking challenging behavior. The investigators will also use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of the this treatment. The ending duration of the S-delta component will be based on input from caregivers and the participant's school personnel.
214997028|NCT05928247|BEHAVIORAL|Research Units in Behavioral Intervention (RUBI) protocol|Caregivers of participants with mild challenging behavior will receive training on a variety of topics, such as prevention strategies and functional communication training, throughout implementation of the RUBI protocol.
214997029|NCT05278416|DEVICE|Lumoral treatment -device and Lumorinse tablets|Subjects will use Lumoral treatment -device and Lumorinse tablets daily as per protocol.
214997030|NCT03505281|BIOLOGICAL|Blood samples|"Patients:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml blood (EDTA)~* 2 tubes of 7 ml blood (EDTA) for 20 NET Covid patients~Healthy volunteers:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml of blood (EDTA)~* 1 tube of 4 ml (citrate)"
214997031|NCT04325022|DEVICE|Primary Total Hip Arthroplasty|Primary Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
214997032|NCT04325022|DEVICE|Revision Total Hip Arthroplasty|Revision Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
214997033|NCT04164979|DRUG|Cabozantinib|Given PO
214997034|NCT04164979|DRUG|Pembrolizumab|Given IV
214384880|NCT03020329|DRUG|5-fu|Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.
214384881|NCT03020329|RADIATION|Radical radiotherapy|Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.
214997035|NCT04903353|DRUG|Comparison of Risperidone and Aripiprazole|Comparing two FDA approved medications for treatment of irritability in autism
214997036|NCT04892953|DRUG|Carboplatin|Given IV
214997037|NCT04892953|BIOLOGICAL|Durvalumab|Given IV
214997038|NCT04892953|DRUG|Gemcitabine|Given IV
214997039|NCT04892953|PROCEDURE|Local Consolidation Therapy|Undergo LCT
214997040|NCT04892953|DRUG|Nab-paclitaxel|Given IV
214997041|NCT04892953|DRUG|Paclitaxel|Given IV
214384882|NCT06131996|OTHER|Volar supported splint|participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
214384883|NCT06131996|OTHER|elastic splint|participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week
214384884|NCT03462706|PROCEDURE|Cold Snare|Subjects randomized to Cold Snare Intervention will have any polyps sized 6mm to 15mm removed using cold snare techniques (no electrocautery, no submucosal injection.)
214384885|NCT03462706|PROCEDURE|Hot Snare|Subjects randomized to Hot Snare Intervention will have any polyps sized 6mm to 15mm removed using hot snare techniques (with electrocautery, no submucosal injection.)
214384886|NCT03462706|PROCEDURE|Cold EMR|Subjects randomized to Cold EMR will have any polyps sized 6mm to 15mm removed using cold EMR techniques (no electrocautery, with submucosal injection.)
214384887|NCT03462706|PROCEDURE|Hot EMR|Subjects randomized to Hot EMR will have any polyps sized 6mm to 15mm removed using hot EMR techniques (with electrocautery, with submucosal injection.)
214384888|NCT04805463|OTHER|Control group|The group that did not undergo any procedure after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied to the wound area.
214384889|NCT04805463|OTHER|PRF group|The group in which PRF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA)was applied over the PRF.
214997042|NCT04892953|DRUG|Pemetrexed|Given IV
214997043|NCT04892953|OTHER|Quality-of-Life Assessment|Complete questionnaire
214997044|NCT04892953|OTHER|Questionnaire Administration|Complete questionnaire
214384890|NCT04805463|OTHER|CGF group|The group in which CGF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the CGF.
214384891|NCT04805463|OTHER|AFG group|The group in which AFG is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the AFG.
214384892|NCT05568836|DIETARY_SUPPLEMENT|vitamin D supplementation|Intervention group will receive a single IM injection of 300000 IU vitamin D
214384893|NCT05568836|OTHER|control|control group will receive nothing
214384894|NCT03758820|BEHAVIORAL|Behavorial Cognitive Therapy (BCT)|"Check-in : review of the homewok Talk : Presentation of the aim of the session Group Activity : Relaxation and Execises Refreshment break Homework : exercises to practice at home and explanation about the forms to fill in.~Passout : session handbook and supports for exercises."
214997045|NCT06600152|DEVICE|MAP Wound Matrix|The MAP Wound Matrix is indicated for the management of full thickness wounds, including surgical sites, donor skin graft sites, wound dehiscence, lacerations, and draining wounds. The application of MAP Wound Matrix will occur immediately after Mohs surgery once hemostasis has been achieved
214997046|NCT06600152|DEVICE|DuoDerm|DuoDerm is a hydrocolloid dressing will be topically applied to the wound immediately following Mohs surgery according to the manufacturer\&#39;s instructions.
215093416|NCT05799989|PROCEDURE|Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
214384895|NCT01411501|OTHER|acupuncture|"Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks."
214384896|NCT01411501|DRUG|mosapride citrate|4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
214384897|NCT00749216|DRUG|Solanezumab|
214384898|NCT02468609|RADIATION|Ultralow-Dose-CT|Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
214384899|NCT05250713|DEVICE|Transcranial stimulation|Patients will receive either direct current stimulation or alternate stimulation.
214997047|NCT05735327|DRUG|No intervention|As this is an observational study, no intervention will be administered.
214997048|NCT05756530|OTHER|Affective touch paradigm|"Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm.~After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness.~As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch in close relationships."
215093417|NCT05799989|PROCEDURE|Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with atraumatic fixation
215093418|NCT04027270|OTHER|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
214997049|NCT05201534|OTHER|Interventions in Mathematics and Cognitive Skills - Experimental|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
215093419|NCT05990023|OTHER|Traditional vestibule rehabilitation training|"* Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~* Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~* Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~* Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~* During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements."
214384900|NCT05808335|DRUG|Standard of care|"The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)"
214384901|NCT03729102|BIOLOGICAL|Blood drawn after rabies vaccine booster vaccination|All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
214384902|NCT05904743|BIOLOGICAL|Afrezza|Pharmaceutical form: powder Route of administration: inhalation
214384903|NCT05904743|BIOLOGICAL|insulin degludec|Pharmaceutical form: solution for injection Route of administration: subcutaneous
214384904|NCT05904743|BIOLOGICAL|Rapid-acting Insulin Analog|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
214384905|NCT05904743|BIOLOGICAL|Basal Insulin|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
214384906|NCT00289237|BEHAVIORAL|Lifestyle intervention|
214384907|NCT03816241|OTHER|Frame|Vignette is framed in a way that nudges participant to leave a legacy
214384908|NCT03816241|OTHER|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
214384909|NCT03842462|OTHER|nCPAP|infants receive primary non-invasive respiratory support by mean of nCPAP
214384910|NCT03842462|OTHER|NIPPV|infants receive primary non-invasive respiratory support by mean of NIPPV
214384911|NCT03842462|OTHER|NHFOV|infants receive primary non-invasive respiratory support by mean of NHFOV
214384912|NCT01712243|OTHER|Light|
214384913|NCT05817435|BIOLOGICAL|efgartigimod PH20 SC as a prefilled syringe presentation|efgartigimod PH20 SC as a prefilled syringe presentation
214499540|NCT06735027|OTHER|suprascapular nerve block (SSNB)|The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the suprascapular nerve in its path at the suprascapular notch. After disinfection of the injection site with alcohol, anatomic landmarks for SSNB as described by Dangoisse et al. \[10\] will be marked with a marking pen. Ultrasound will be utilized to guide the tip of a 21, 22, or 23 gauge (depending on provider preference) needle to the floor of the suprascapular fossa while avoiding neurovascular structures. At that time, a mixture of up to 10 mL of 0.5% bupivacaine and 20 mg triamcinolone will be slowly injected to fill the fascial contents of the suprascapular fossa under direct ultrasound guidance.
214384914|NCT05817435|BIOLOGICAL|efgartigimod PH20 SC as a vial + syringe presentation|efgartigimod PH20 SC as a vial + syringe presentation
214384915|NCT02896816|OTHER|Surface EMG, MRI and PET Scan|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.
214384916|NCT02896816|OTHER|Surface EMG|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
214384917|NCT03729921|PROCEDURE|gastric variceal ligation|The highest point of the variceal vein was used as the primary ligation site. If the input vein was not obvious, the edge of the variceal vein was ligated. The variceal veins were ligated with a 6-ring ligation device, and more than 18 rings rubber bands could be applied in one session. GVL was performed regularly until varices were obliterated or reduced to residual small varices, which could not be ligated. The residual small varices was treated by cyanoacrylate injection.
214384918|NCT03729921|PROCEDURE|gastric variceal obturation|Gastric varices were uniformly treated via the sandwich technique, which starts with an injection of lauromacrogol, followed by N-butyl cyanoacrylate, then finished with flush of lauromacrogol. The number of injection sites and volume of lauromacrogol and cyanoacrylate used, directly correlated with the size of the varix. Multiple injection sites were chosen in attempt to obliterate the varix or varices in one session. Volume of lauromacrogol used ranged from 2-10ml, while that of cyanoacrylate ranged from 0.5-2ml, per injection site.
214499541|NCT05908227|OTHER|NHF high|Nasal high flow therapy 8L/min.
214499542|NCT05908227|OTHER|NHF low|Nasal high flow therapy 6L/min.
214384919|NCT06183086|DEVICE|Linovera®|Apply Linovera® at least twice a day (recommended every 12 h) on the pressure ulcer/injury until Category-1 pressure ulcer/injury is healed or until discharge.
214384920|NCT04130334|PROCEDURE|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
214384921|NCT04130334|PROCEDURE|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
214384922|NCT04105972|DRUG|ELX/TEZ/IVA|FDC tablet for oral administration.
214384923|NCT04105972|DRUG|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
214384924|NCT04105972|DRUG|IVA|Mono tablet for oral administration.
214384925|NCT00647634|DRUG|Alprazolam Extended-Release Tablets 3 mg|3mg, single dose fasting
214384926|NCT00647634|DRUG|Xanax XR® Tablets (3 mg|3mg, single dose fasting
214384927|NCT00764192|PROCEDURE|blood sample|blood sample before and after a single HD
214384928|NCT00764192|PROCEDURE|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
214384929|NCT02482272|DRUG|Lamivudine|Lamivudine 100mg/day orally
214384930|NCT02482272|DRUG|Adefovir|Adefovir 10mg/day orally
214384931|NCT02482272|DRUG|Entecavir|Entecavir 1mg/day orally
214384932|NCT01556815|PROCEDURE|Transarterial Chemoembolization (TACE)|Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
214384933|NCT01556815|OTHER|Sorafenib in combination with TACE|"Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.~Procedure: TACE~TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated ."
214384934|NCT04561882|DEVICE|Transcatheter exclusion of atrial septal aneurysm|"Through transseptal perforation, transcatheter reconstruction of atrial septum was achieved with PFO occluder to cover the whole ASA.~Device: Cardi-O-Fix™ patent foramen ovale occluder (Starway Medical Technology, Inc. Beijing, CN)"
214499543|NCT05908227|OTHER|NCPAP|Nasal continuous positive airway pressure 6 cm H20
215093420|NCT05990023|OTHER|Dual-task vestibule rehabilitation training|"* Adding a dual task of digit countdown and recitation to clinical balance training exercises.~* Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~* Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~* During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements."
214384935|NCT02313818|BEHAVIORAL|Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
214384936|NCT02621736|OTHER|blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.
214384937|NCT05402540|OTHER|STRAIN COUNTER STRAIN GROUP|"Strain Counterstrain Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~Therapist palpate surrounding and opposing tissues to locate trigger point by using one or two finger pads to monitor fasciculation and MTrP.~Hold the POC (position of comfort) until fasciculation decreases significantly or ceases. Average positions hold time while pressure is 90 s to 3 min.~Release tissue or joint slowly and reassess. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
214384938|NCT05402540|OTHER|ACTIVE RELESAE TECHNIQUE GROUP|"Active Release Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~The targeted muscle will be palpated while the therapist will looks for localized tenderness or trigger points with referred pain elicitation.~With the thumb therapist will relieve the trigger point. In ART the particular muscle is taken from shortened to lengthened position or from lengthened to shortened position.~Duration of treatment will be 8-15 minutes. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
214384939|NCT00365560|DRUG|tiotropium|
214384940|NCT00365560|DRUG|placebo|
214384941|NCT01161472|DRUG|4mg fesoterodine|4mg tablet once daily for 6 days
214384942|NCT01161472|DRUG|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
214499544|NCT06714240|DIETARY_SUPPLEMENT|Nutritionally complete Tube Feed with standard protein levels|Containing standard protein levels to target normal protein amount of 0.8 g of protein/kg body weight/day
214499545|NCT06714240|DIETARY_SUPPLEMENT|Nutritionally complete Tube Feed with higher protein levels|Containing higher protein levels to target elevated protein amount of 1.3 g of protein/kg body weight/day.
214499546|NCT02944500|DRUG|liraglutide|
214499547|NCT02944500|OTHER|Placebo|
215093421|NCT05077007|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma
215093422|NCT05077007|PROCEDURE|Extracorporeal Shock Wave Lithotripsy|Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.
215093423|NCT04246723|DRUG|Narlaprevir|100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
215093424|NCT04246723|DRUG|Ritonavir|100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
214384943|NCT01161472|DRUG|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
214384944|NCT01161472|DRUG|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
214384945|NCT03659643|DIAGNOSTIC_TEST|EEG with SPR analysis|qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
214384946|NCT03963947|BIOLOGICAL|Beltavac® Polymerized with house dust mites|Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice
214384947|NCT05039762|PROCEDURE|Extracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. When the right hemicolon is sufficiently mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated, a horizontal incision in the upper right quadrant is made. Through this incision the right hemicolon is extracted, the small bowel and the transverse colon are divided using staplers. The side-to-side ileocolic anastomosis is then handsewn.
214384948|NCT05039762|PROCEDURE|Intracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. The right hemicolon is mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated. The small bowel and the transverse colon are then divided using laparoscopic staplers. The side-to-side ileocolic anastomosis is formed by creating a small opening in the small bowel and the transverse colon, through which the laparoscopic stapler is used to join the bowel ends. The remaining opening is sutured laparoscopically. The specimen is retrieved through a Pfannenstiel incision.
214384949|NCT02163655|DRUG|FUROSEMIDE|Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
214384950|NCT02163655|DRUG|Placebo|Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
214384951|NCT00905502|DRUG|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
214384952|NCT00905502|DRUG|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
214384953|NCT01449240|OTHER|No treatment|
214384954|NCT01996072|DRUG|EC17|
214499548|NCT03880383|BEHAVIORAL|Coaching|Parents will interact and communicate regularly with a coach in person or by telephone. Coaches will be responsible for: identifying developmental concerns, proactive health promotion, guidance and training for developmental stimulation, parent support and education about child development, navigation of the health care system and self-management techniques. The frequency of coaching will be: once a month (minimum), for 18 months, at an average of 2.5 hours per month.
214499549|NCT03880383|BEHAVIORAL|Online parent education|Parents will be provided access to an online platform which will provide educational resources and access to parent-parent support. Online resources on child development are curated by researchers and representative of parent groups, and linked to this online platform. The themes covered in the online tool include resources on child development, accessing health care services and managing emotions and family dynamics. These topics range from: practical tips for managing day-to-day challenges, strategies to cope and support the child's transitions from one stage to another, practical tips when looking for developmental services for the child: knowing where and how to access services.
214499550|NCT03880383|BEHAVIORAL|Online peer support|Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge. This will put each family at the centre of each network (family, friends, health providers), allowing family networks to link with one another. Families will be able to find resources, create connections with the coach, health providers and other families, thus creating a network to support one another.
214499551|NCT06128980|DRUG|GDMT|Sequential weaning starting with SGLT2i - MRA - BB - ACEi/ARB/ARNi
214687652|NCT05656716|BEHAVIORAL|Nutritional intervention|The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants
214499552|NCT02413736|DRUG|Imatinib|Imatinib 400 mg/day
214499553|NCT02830204|DEVICE|Mitral Valve Replacement (MVR) with Sapien3|subjects with surgical MVR with Sapien3
215093425|NCT04246723|DRUG|Sofosbuvir|"400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle."
215093426|NCT00551291|DRUG|Mycophenolate mofetil|1 gm twice daily orally until end of study.
215093427|NCT00551291|DRUG|Prednisone|10 mg/day orally until end of study.
215093428|NCT00551291|DRUG|Erythropoietin Beta|Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
214384955|NCT01715337|OTHER|pulmonary rehabilitation|3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
214384956|NCT06004284|OTHER|control|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
214384957|NCT06004284|OTHER|exercise group|The exercise training program will be applied for 8 weeks, 3 days a week and for an average of 20-30 minutes. After the maneuver is taught, stretching exercises lasting 5 minutes for warm-up purposes and posture and core exercises lasting 25 minutes will be taught. Among the stretching exercises, quadratus lumborum stretching, hamstring stretching, erector spina stretching, hip extensor stretching exercises will be applied. Posterior pelvic tilt exercise will be performed as a control and smoothing exercise for the vertebrae of the lumbar and pelvic region. Among the core stabilization exercises, bridging, plank, plank in side lying, abdominal strengthening, cross arm leg lifting exercises in crawling position will be performed. Each exercise position will be required to be maintained for 8 seconds and to do 10-15 repetitions.
214499554|NCT05059223|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
214499555|NCT05059223|DRUG|Placebo|Placebo tablets, taken twice daily
214499556|NCT02291848|BIOLOGICAL|TAA-specific CTLs|"Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10\^6 cells/m2 and Day 14: 5 x 10\^6 cells/m2~Dose Level Two:~Day 0: 1 x 10\^7 cells/m2 and Day 14: 1 x 10\^7 cells/m2~Dose Level Three:~Day 0 2 x 10\^7 cells/m2 and Day 14 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
214499557|NCT02291848|BIOLOGICAL|TAA-specific CTLs- fixed dose|"Fixed dose of 2 infusions of 2 x 10\^7 cells/m2 administered 2 weeks apart.~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
214499558|NCT04225442|OTHER|Fatty meal to challenge the physiological chronobiome in healthy young and old|The intervention consists of a fatty meal
214499559|NCT02802423|DRUG|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
214384958|NCT00612222|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
214384959|NCT00612222|BIOLOGICAL|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
214499560|NCT05440448|DEVICE|Patch-free occlusion therapy|Use of filters in glasses to provide occlusion therapy
214499561|NCT05440448|DEVICE|Adhesive patch|Standard-of-care occlusion therapy with an adhesive patch
214499562|NCT00136006|BEHAVIORAL|Study to determine the burden of disease|
214499563|NCT05344339|PROCEDURE|Distal gastrectomy|Reconstruction after Distal Gastrectomy
214997050|NCT05201534|OTHER|Interventions in Mathematics and Cognitive Skills - Active Comparator|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
214997051|NCT06798324|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation. Active tDCS involves brief (e.g., 20-min) application of weak electric current (e.g., 2 mA) to the scalp. The tDCS device that will be used for this study is the Soterix 1x1 mini-CT.
214997052|NCT06798324|DRUG|Varenicline 1mg BID|"Varenicline is the most effective approved treatment for quitting smoking. Varenicline as per standard prescribing for dose escalation (i.e. Days 1 to 3: 0.5 mg once daily; Days 4 to 7: 0.5 mg twice daily; Days 8 to end of treatment: 1 mg twice daily) will be given concurrently over the same 2 weeks as the tDCS protocol and continue for an additional 10 weeks as per standard treatment duration recommended on the product monograph for a total of 12 weeks of varenicline treatment. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).~The target quit date for smoking cessation will be on the last day of the two weeks of daily tDCS which corresponds to the recommended quit date after starting varenicline treatment."
214384960|NCT00612222|BIOLOGICAL|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
214384961|NCT00612222|DRUG|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
214384962|NCT00612222|DRUG|fludarabine phosphate|25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
214499564|NCT04359732|OTHER|hybrid PET/MRI|An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
214499565|NCT02921555|DRUG|Methylprednisolone|Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
214499566|NCT02921555|DRUG|Prednisone|Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
214499567|NCT05753930|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
214499568|NCT02986243|OTHER|Exercise|6 months worth of exercise regimen
214499569|NCT02986243|DIETARY_SUPPLEMENT|Diet Plan|Each subject will receive a personalized diet plan from nutritionist.
214499570|NCT01690624|DRUG|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
214997053|NCT06798324|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS consists of 30s of 2 mA at the beginning and at the end of the 6 session (ramp up and down), then receiving 0 mA stimulation for the middle 19 min. The tDCS device that will be used for this study is the Soterix 1x1 mini-CT.
214997054|NCT06025838|BEHAVIORAL|positive feedback|The positive feedback game uses techniques relating to established therapies like Behavioral Activation and Acceptance and Commitment Therapy's valued living to encourage positive action in game and outside of the game.
214997055|NCT06147778|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
214384963|NCT03712540|DRUG|BMS-986278|Oral administration 30 mg
214499571|NCT05604326|BEHAVIORAL|Pathways Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers (in English or Spanish) in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual in English or Spanish, depending on the family's home language. Sessions will review information about autism, interactional strategies, and Applied Behavioral Analysis (ABA) techniques from the program manual, demonstrate intervention strategies, and provide caregivers with practice feedback and self-reflection.
214499572|NCT05604326|BEHAVIORAL|Parent Education Intervention (PEI)|Caregivers will access a 20-30-minute video lesson and associated handouts (in English or Spanish, depending on the parent's home language) every other week for 24 weeks. On the off week, the caregiver will meet with a trained clinician (in English or Spanish) for 30 minutes without the child. Lessons will cover autism, social attention delays, evidence-based interventions, self-regulation, talking with your child, playing with your child, principles of managing behavior, knowing your rights, and self-care. The first and last visit will occur in the family's home or another convenient location. All other visits will take place over Zoom videoconferencing software.
214499573|NCT02980510|DRUG|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil|
214499574|NCT02980510|DRUG|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan|
214499575|NCT03894215|DRUG|AGEN2034|PD-1 antibody
214499576|NCT03894215|DRUG|AGEN1884|CTLA-4 antibody
214499577|NCT04971785|DRUG|Semaglutide (SEMA)|Administered as subcutaneous (SC) injection
214499578|NCT04971785|DRUG|Cilofexor (CILO)/Firsocostat (FIR)|Tablets administered orally
214499579|NCT04971785|DRUG|PTM SEMA|Administered as SC injection
214997056|NCT06615258|BEHAVIORAL|Dynamic Neuromuscular Stabilization based breathing training and pelvic floor muscle training|"DNS-based breathing exercises will be taught to the women in this group using tactile biofeedback. To create tactile stimulation, one of the hard sponges placed within a belt will be positioned anteriorly in the inguinal region, and the other posteriorly in the Grynfeltt-Lesshaft triangle region. Breathing training will be provided in 3 different positions: sitting, crawling, and happy baby pose.~Pelvic floor muscle training: PFME will consist of 2 parts: relaxation training for pelvic floor muscles and pelvic floor muscle exercises.~Pelvic floor muscles will be given relaxation training in 3 different relaxation positions (modified butterfly pose, child pose and deep squatting position) suggested by Çeliker Tosun et al. PFME will be taught by the physiotherapist in the side-lying with external coccyx palpation. PFME will be applied in the hook-lying position, sitting position and standing position."
214997057|NCT06615258|BEHAVIORAL|Pelvic floor muscle training|Pelvic floor muscle training: PFME will consist of 2 parts: relaxation training for pelvic floor muscles and pelvic floor muscle exercises. Pelvic floor muscles will be given relaxation training in 3 different relaxation positions (modified butterfly pose, child pose and deep squatting position) suggested by Çeliker Tosun et al. PFME will be taught by the physiotherapist in the side-lying with external coccyx palpation. PFME will be applied in the hook-lying position, sitting position and standing position.
215093429|NCT05102968|BEHAVIORAL|Home-based rehabilitation supporting with the mobile application|For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.
214384964|NCT03712540|DRUG|Rifampin|Oral administration 600 mg
214384965|NCT02726776|OTHER|Suspension in a harness|
214384966|NCT02726776|OTHER|Climbing|
214384967|NCT00554983|BIOLOGICAL|recombinant birch pollen allergen|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
214384968|NCT00554983|BIOLOGICAL|placebo|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
214384969|NCT03117465|OTHER|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
214384970|NCT03117465|OTHER|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
214384971|NCT03326089|PROCEDURE|Pulmonary rehabilitation|Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
214384972|NCT05640739|BEHAVIORAL|Demonstration method for the use of the Metered Dose Inhaler|The effectiveness of the training given by the demonstration method for the use of the Metered Dose Inhaler (MDI)
214499580|NCT04971785|DRUG|PTM CILO/FIR|Tablets administered orally
214499581|NCT05953116|DIETARY_SUPPLEMENT|Nutrition supplementation|Blinded researchers will provide the randomly assigned supplement product to the trial participants for a period of 90 days. Used packaging will be collected at the end of every week from each trial participant to monitor compliance.
214499582|NCT05953116|OTHER|Exercise|Trained researchers will facilitate resistance-based exercises two to three times a week in an enclosed venue (gym). Trial participants will be assessed at baseline for one repetition maximum (1RM) which will serve as a basis for load progression. A target of 3 sets and 6-15 repetitions with at least 30 seconds rest in between sets will be performed by the trial participants under supervision of a trained researcher.
214499583|NCT05153668|DRUG|Everolimus Oral Tablet|Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
214499584|NCT01341301|RADIATION|Total Body Irradiation|Undergo TBI
214499585|NCT01341301|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
214384973|NCT05640739|BEHAVIORAL|Video watching method for the use of the Metered Dose Inhaler|The effectiveness of the training given by video watching method for the use of the Metered Dose Inhaler (MDI)
214384974|NCT03756454|BIOLOGICAL|Bezlotoxumab|Patients receiving Bezlotoxumab post-operatively.
214384975|NCT03756454|OTHER|Normal Saline|Placebo
214384976|NCT03755635|COMBINATION_PRODUCT|The WHO multimodal hand hygiene strategy|Comprises five essential elements; system change-availability of alcohol-based hand rub at the point of care and/ or access to safe continuous water supply and soap and towels; training and education of healthcare professionals; monitoring of hand hygiene practices and performance feedback; reminders in the workplace; and the creation of a hand hygiene safety culture with the participation of both individual healthcare workers and senior hospital managers.
214384977|NCT05920525|DEVICE|Electrical stimulation|A specific device will be used to stimulate the remodeling procedures in the alveolar bone.
214499586|NCT01341301|DRUG|Cyclophosphamide|Given IV
214499587|NCT01341301|DRUG|Tacrolimus|Given IV or PO
214499588|NCT01341301|DRUG|Mycophenolate mofetil|Given IV or PO
214499589|NCT01341301|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
214499590|NCT01341301|OTHER|Laboratory biomarker analysis|Correlative studies
214499591|NCT04332471|PROCEDURE|Radial shockwave therapy|Target intensity will be within a range of 3.5-5.0 bar at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
214499592|NCT04332471|PROCEDURE|Focused shockwave therapy|Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
214499593|NCT04332471|DEVICE|Shockwave therapy device|The shockwave therapy device will be used to administer either radial or focused shockwave therapy.
214499594|NCT04332471|OTHER|Home therapy|Stretching and ice massage
214499595|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)
214499596|NCT06138925|OTHER|Analysis of running|analysis of running on flat ground at different speeds (comfortable and fast)
214499597|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).
214499598|NCT06888284|BEHAVIORAL|Tui Jing therapy|Tui Jing therapy (Gua Sha + Meridian pressure) was utilized, a specialized form of Gua Sha that incorporates traditional techniques with targeted pressure on specific meridians.
214384978|NCT05920525|PROCEDURE|Traditional retraction of the front upper teeth|The retraction will be performed using coil springs which will help in moving the anterior teeth backward without the need to employ any additional procedure or device to accelerate this movement.
214384979|NCT01567943|BEHAVIORAL|Contingency Management|Behavioral reinforcement for alcohol abstinence
214384980|NCT00645216|DRUG|CP-945,598|Subjects take CP-945,598 alone for 21 days
214384981|NCT00645216|DRUG|CP-945,598|Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
214384982|NCT02436083|DRUG|antibiotic (use of penicilline, unacid, cefuroxime)|prophylactic antibiotics
214384983|NCT04033679|OTHER|Active TDCS|Participants will receive active TDCS stimulation.
214384984|NCT04033679|OTHER|Sham TDCS|Participants will receive sham TDCS stimulation.
214499599|NCT06888284|DEVICE|sham ultrasound intervention|Participants will receive a sham ultrasound intervention on the same meridians. To enhance comfort and prevent cold sensations from the metal probe, the ultrasound device will be pre-warmed to body temperature. A gel, mimicking the texture of the lubricant used in Tui Jing therapy, will be applied. The device will mimic the motion, direction, duration, and frequency of the Tui Jing therapy, but without activating the ultrasound's therapeutic mode. The participants will be informed that they are accepting low-intensity ultrasound mode, which will not produce any sensory perception, ensuring in distinguishing ability between active and sham interventions
214499600|NCT06507501|OTHER|Low Load Blood Flow Restriction Exercise Training (LL-BFRE)|Blood Flow Restriction exercise training, also known as occlusion training or KAATSU training, is a contemporary exercise training method based on partially restricting arterial and venous blood flow for short periods.
214384985|NCT03118375|DEVICE|super-power BAHA processor|The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
214384986|NCT05428904|OTHER|Virtual Reality Simulation|Virtual reality applications are a type of three-dimensional computer-based simulation that gives a sense of being anywhere and provides various data to the sense organs for this. However, virtual reality applications are a simulation model that creates a sense of reality for the participants and allows mutual communication with a computer-based dynamic environment.
214384987|NCT03181126|DRUG|Navitoclax|tablet
214384988|NCT03181126|DRUG|Chemotherapy|peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)
214499601|NCT06507501|OTHER|High Load Resistive Exercise Training (HL-RE)|HL-RE is a conventional, well known exercise method to enhance muscle strength and improve physical performance. It's performed by using resistance bands or weights applying on the extremity.
214499602|NCT05203198|BEHAVIORAL|Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training|Self-directed, technology-based, depression prevention program for adolescents and parents.
214499603|NCT05929794|DRUG|Metronidazole 0.75% Topical Gel|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
214997058|NCT04979247|DRUG|Oliceridine|Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.
214997059|NCT05268562|DRUG|Ketamine|1-2 mg/kg induction with additional medication administered as needed to achieve intubating conditions
214997060|NCT05268562|DRUG|Propofol|0.5-1 mg/kg induction with additional medication administered as needed to achieve intubating conditions
214997061|NCT04565054|DRUG|Abemaciclib 50 MG; 150mg 1-0-1 per os|Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
214997062|NCT04997902|DRUG|Tipifarnib|Oral administration
214997063|NCT04997902|DRUG|Alpelisib|Oral administration
214997064|NCT05634785|BIOLOGICAL|ATLCAR.CD30 Cells|The cellular product consists of ATLCAR.CD30 cells will be administered via intravenous injection, over 5 - 10 minutes after lymphodepletion. The expected volume will be 1 - 50 mL, the prescribed dose will be 2 × 108 CAR-T cells per meter square and the maximum dose will be 5 × 108 CAR-T cells per meter square.
214997065|NCT05634785|DRUG|Cyclophosphamid|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes 300 mg per square meter of intravenous cyclophosphamide.
214997066|NCT05634785|DRUG|Fludarabine|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes daily 30 mg per square meter of intravenous fludarabine infusion for 3 days.
214997067|NCT06358950|DRUG|ALKS 2680|Oral tablet of ALKS 2680 for once daily administration
214997068|NCT06358950|DRUG|Placebo|Oral tablet containing matching placebo for once daily administration
214384989|NCT03181126|DRUG|Venetoclax|tablet
214384990|NCT03355755|DEVICE|EksoGT with SmartAssist software|Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.
214384991|NCT04315025|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
214384992|NCT04315025|BIOLOGICAL|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
214384993|NCT04712201|PROCEDURE|En bloc transurethral resection of bladder tumor (TURBT)|En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy
214384994|NCT04712201|PROCEDURE|Conventional TURBT|Conventional transurethral resection of bladder tumor using monopolar and bipolar energy
214997069|NCT05748990|DRUG|Intranasal insulin|160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
214997070|NCT05748990|DRUG|Placebo|0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
214997071|NCT06226051|DEVICE|PEAPOD Infant Body Composition measuring device|PEAPOD is a device to that collects body composition measurements.
214997072|NCT06375733|DRUG|GFH009|administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
214384995|NCT01400230|PROCEDURE|diagnostic procedures CCTA, CAG, IVUS and FFR|Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
214384996|NCT04042285|DEVICE|Extracorporeal shockwave therapy in addition to standard care|Extracorporeal shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second. Participants will receive 3 sessions of shockwave therapy in a 7-day period. Standard care as per the NICE and IWGDF guidelines.
214384997|NCT04506008|RADIATION|Ultra-Hypo-fractionation Radiotherapy|Five fractions of pre-operative radiation
214384998|NCT04506008|PROCEDURE|Resection|Surgery
214384999|NCT04506008|OTHER|Questionnaire Administration|Ancillary studies
214385000|NCT04506008|RADIATION|Moderately-Hypo-fractionation Radiotherapy|15 fractions of pre-operative radiation
214997073|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
214385001|NCT05084222|DRUG|Buventol® Easyhaler® 200 µg/inhalation dmDPI|Two doses will be administered
214499604|NCT05929794|DRUG|Metronidazole 0.75% Topical Cream|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
214997074|NCT06375733|DRUG|GFH009|the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
214997075|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
214997076|NCT05853367|DRUG|MK-0472|Oral Administration
214997077|NCT05853367|BIOLOGICAL|Pembrolizumab|IV infusion
214997078|NCT05853367|DRUG|MK-1084|Oral Administration
214997079|NCT05457985|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.
214385002|NCT05084222|DRUG|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|Two doses will be administered
214385003|NCT05084222|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI|Four doses will be administered via Volumatic spacer
214997080|NCT05457985|BEHAVIORAL|Full Prolonged Exposure|Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.
214997081|NCT05457985|BEHAVIORAL|Clinician Supported PTSD Coach App|This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.
214385004|NCT04859439|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
214997082|NCT06648512|OTHER|No Interventions|No Intervention
214385005|NCT04095143|DIAGNOSTIC_TEST|Portal vein flow|Doppler assessment performed on day 0, 3 and 7.
214385006|NCT04095143|DIAGNOSTIC_TEST|Intra-renal flow|Doppler assessment performed on day 0, 3 and 7.
214385007|NCT04095143|DIAGNOSTIC_TEST|Hepatic vein flow|Doppler assessment performed on day 0, 3 and 7.
214385008|NCT04095143|DIAGNOSTIC_TEST|Pulmonary B-lines|Ultrasound assessment of performed on day 0, 3 and 7.
214385009|NCT04095143|DIAGNOSTIC_TEST|Dimensions of the inferior vena cava|Ultrasound assessment of performed on day 0, 3 and 7.
214385010|NCT04095143|DIAGNOSTIC_TEST|Left ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
214385011|NCT04095143|DIAGNOSTIC_TEST|Right ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
214385012|NCT00544063|DRUG|irinotecan hydrochloride|
214385013|NCT00544063|DRUG|oxaliplatin|
214385014|NCT00010439|DRUG|Alendronate|Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.
214385015|NCT01819025|BEHAVIORAL|4 face-to-face therapy session and a smartphone-app|An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
214385016|NCT01819025|BEHAVIORAL|CBT, treatment as usual|10 sessions of face-to-face therapy, full behavioral activation
214997083|NCT05077605|OTHER|Functional residual capacity measure by electrical impedance tomography|Patient functional residual capacity will be measured by electrical impedance tomography before extubation and then at 0, 10, 15 and 20 min after extubation.
214997084|NCT06128525|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214997085|NCT06128525|DEVICE|Microwave Ablation|Undergo transperineal MRI/US fusion guided transperineal targeted microwave ablation
214385017|NCT01073800|DRUG|atorvastatin 80 mg per os daily|atorvastatin 80 mg per os daily
214385018|NCT01073800|DRUG|placebo|placebo
214385019|NCT00975572|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
214385020|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
214385021|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
214385022|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
214385023|NCT00975572|BIOLOGICAL|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
214385024|NCT00975572|BIOLOGICAL|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
214385025|NCT00951262|BEHAVIORAL|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
214385026|NCT03804190|OTHER|questionaire|dutch musculoskeletal questionaire
214385027|NCT00067990|DRUG|Losartan 100mg|To be started within three months of transplant and continued for five years.
214385028|NCT00067990|DRUG|Placebo|No treatment with continued follow-up for five years.
214385029|NCT00421525|BIOLOGICAL|milatuzumab|twice weekly dosing for 4 weeks, total of 8 doses
214997086|NCT06128525|DEVICE|Multiparametric Magnetic Resonance Imaging|Undergo planning mpMRI of prostate
214997087|NCT06128525|OTHER|Questionnaire Administration|Ancillary studies
214997088|NCT06128525|PROCEDURE|Radical Prostatectomy|Undergo RP
214997089|NCT05200442|DRUG|VS-6766/avutometinib|An oral anti-cancer medication.
214997090|NCT05200442|DRUG|Cetuximab|A chemotherapy drug used to treat head, neck and colorectal cancer.
214997091|NCT05200442|OTHER|Pill Diary|A diary where participants in phase 2 of study will log their medications and times they are taken on study.
214997092|NCT06075264|DRUG|Artesunate ointment|topical ointment, as a non-surgical treatment
214997093|NCT06075264|DRUG|Placebo ointment|topical placebo ointment
214997094|NCT06624124|BEHAVIORAL|Gamified Training in Diversity Considerations in the Management of Pain and Opioid Use|Use of a video game-based training platform
214997095|NCT06624124|BEHAVIORAL|Traditional Training in Diversity Considerations in the Management of Pain and Opioid Use|Use of a traditional text-based training platform
214385030|NCT05304923|PROCEDURE|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV are: driving pressure (DP) 15psi, respiratory rate (RR) 20 bpm, inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply 100% oxygen.
214385031|NCT05304923|PROCEDURE|Nasal cannula oxygen supply|Oxygen supplementation at 2 liters min-1 is delivered via a nasal cannula
214385032|NCT02282410|DRUG|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
214385033|NCT05201911|DRUG|124I-AT03|IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
214997096|NCT06523634|RADIATION|Stereotactic body radiotherapy (SBRT)|5 fractions of SBRT to the prostate bed with or without whole pelvic radiotherapy Treatment every other day.
214997097|NCT06523634|RADIATION|SOC RT|"Standard salvage radiotherapy to the prostate bed with or without whole pelvic radiotherapy. Each participating centre can specify upfront which RT schedule will be used in the control arm, with the choice between the following schedules:~* Hypofractionated: 20 fractions (Daily treatment (OTT 4-5 weeks))~* Normofractionated: 32-35 fractions (Daily treatment (OTT 7-8 weeks))"
214997098|NCT06208241|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
214385034|NCT04157998|DRUG|normal saline|intrvenous administration of 10ml normal saline preoperative
214385035|NCT04157998|DRUG|Metoclopramide 10mg|intrvenous administration of 10mg metoclopramide diluted in 10ml normal saline preoperative
214385036|NCT01118455|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
214385037|NCT01118455|DRUG|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
214385038|NCT02576782|DRUG|Perineural Dexamethasone and bupivacaine|
214997099|NCT02990793|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/ECG resonance therapy (MeRT) treatment that is tailored specifically to each participant's EEG intrinsic alpha frequency (IAF). rTMS is applied at the participant's IAF.
214997100|NCT02990793|DEVICE|Sham MeRT Treatment|rTMS coil does not emit magnetic stimulation.
214499605|NCT05929794|DIAGNOSTIC_TEST|Transdermal water loss measurement|Baseline measurements of transepidermal water loss will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied).
214499606|NCT05929794|DIAGNOSTIC_TEST|Electrical Resistance|Baseline measurements of electrical resistance will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied). In all study periods the measurements will also be repeated at 48 hours and 96 hours, when metronidazole product and occlusive coverings are removed from the skin.
214385039|NCT02576782|DRUG|Systemic Dexamethasone plus perineural bupivacaine|
214385040|NCT02576782|DRUG|intravenous saline plus perineural bupivacaine|
214385041|NCT00543400|DRUG|M118|intravenous (IV) infusion
214385042|NCT00543400|DRUG|Unfractionated Heparin|IV infusion
214385043|NCT00477906|BIOLOGICAL|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
214385044|NCT06342895|DEVICE|Nutritional support prescription and delivery monitoring feedback|Real-time availability in an integrated computer interface (Nutrow) of all clinical and biological information related to nutritional support including recommended, prescribed, and delivered calories and proteins and enteral feed delivery transmitted by the Feedim medical device
214385045|NCT06342895|DEVICE|Usual care|Usual use of standard clinical and biological information related to nutritional support as available through the ICU electronic health record (i.e. without any calculated information on recommended, prescribed, or received calories and protein, only information on prescribed products and volumes as collected by and presented in the ICU EHR) In this arm, participants, investigators, and healthcare professionals will be blinded to real-time enteral feed volumes that will be collected by the Feedim medical device and transmitted to the electronic study case report form.
214385046|NCT04759742|DRUG|ropivacaine|According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).
214385047|NCT02139475|PROCEDURE|Colonoscopy|
214385048|NCT03327402|DRUG|SHP465|SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.
214385049|NCT03836508|DEVICE|Medium cut-off|"All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
214385050|NCT03836508|DEVICE|High-Flux|"All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
214385051|NCT01673074|DRUG|(PDT) Photodynamic therapy|photosensitizer
214385052|NCT02013973|OTHER|AMH-analysis|At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.
214385053|NCT00226564|DRUG|Alfentanil|
214385054|NCT04940182|DRUG|XC221|Participants will receive XC221 100 mg 2 times a day during 14 full days
214385055|NCT04940182|DRUG|Placebo|Participants will receive Placebo 2 times a day during 14 full days
214385056|NCT06257719|OTHER|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.
214385057|NCT00910637|DRUG|Gestodene/EE Patch (BAY86-5016)|55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles
214385058|NCT04563806|DEVICE|Magnetic Resonance Imaging|Undergo MRI-guided surgery
214385059|NCT04563806|PROCEDURE|Therapeutic Conventional Surgery|Undergo spinal surgery
214499607|NCT05929794|DIAGNOSTIC_TEST|Skin color measurement|Baseline measurements of skin color will be made at 3 sites on the upper arm.
214499608|NCT05929794|OTHER|Micropatch application|All subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm (color only measured at baseline). Two sites will have micropatch application + metronidazole product with occlusive covering. One site will have micropatch application + occlusive covering, no metronidazole product. Micropatch application will only occur on day 1 (a micropatch is a patch of 50 microneedles). Transepidermal water loss and electrical resistance are repeated after micropatch application and removal. At 48 hours occlusive coverings and metronidazole are removed; electrical resistance measurements are repeated. Metronidazole product and fresh occlusive patches are reapplied. At 96 hours patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis.
214385060|NCT01377415|DRUG|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
214385061|NCT01898143|OTHER|Whole body vibration|
214385062|NCT03810313|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
214385063|NCT03810313|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
214385064|NCT03810313|OTHER|Sham injection|Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
214997101|NCT05986188|OTHER|Pathways to Potential|Pathways to Potential stations MDHHS caseworkers, called success coaches, in local elementary, middle, and high schools. After identifying a social or material need that is a barrier to school attendance (e.g., transportation barriers, caregiver unemployment), success coaches connect students and families to community resources and public assistance.
214385065|NCT00595829|DRUG|XL019|XL019 capsules administered orally
214385066|NCT03580213|OTHER|Hand therapy MCPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices.
214499609|NCT05336344|BEHAVIORAL|ENCODE|a cognitive behavioral intervention for family caregivers to improve pain management skills and overall coping
214499610|NCT06828289|DRUG|Rivastigmine Mini-Tablet|Treatment group: Rivastigmine Mini-Tablet
214499611|NCT06828289|DRUG|Donepezil Hydrochloride|Control group: Donepezil Hydrochloride
214997102|NCT06974734|DRUG|PF-08046037|Given into the vein (IV; intravenous)
214997103|NCT06974734|DRUG|sasanlimab|Given under the skin (SQ; subcutaneous)
214997104|NCT06063486|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214687653|NCT05656716|BEHAVIORAL|Physical exercise intervention|Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
214687654|NCT05487716|BEHAVIORAL|High-intensity interval training (HIIT)|Included subjects who underwent an additional 36 sessions (2-3 sessions per week) of supervised bicycle ergometer (Ergoselect 150P, ergoline GmbH, Germany) training as in the previous protocol5 were classified as the HIIT participant. They exercised alternatively at 3-min interval of 80% VO2peak and 3-min interval of 40% VO2peak for 30 min each session.
214997105|NCT06063486|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214997106|NCT06063486|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214997107|NCT06063486|DIETARY_SUPPLEMENT|Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement|Given PO
214997108|NCT06063486|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
214997109|NCT06063486|DRUG|Placebo Administration|Given PO
214997110|NCT06063486|OTHER|Questionnaire Administration|Ancillary studies
214997111|NCT06975098|OTHER|Life balance intervention group program|Life balance intervention group program is a four-week group intervention program for individuals with depression, with sessions lasting two hours each week. The program will address life balance issues such as daily scheduling, time management, stress coping, emotional regulation, and social participation, and will be tailored to individual patient needs. Through group discussions and practical exercises, participants will learn to apply these skills in their daily lives. Telephone support will be provided during the intervention period to offer emotional support and enhance participation rates.
215093430|NCT05102968|BEHAVIORAL|Supervised rehabilitation by the therapist|For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd\~12th week and once two weeks at post-operative 13th\~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
215093431|NCT01943552|DRUG|placebo|normal saline
215093432|NCT01943552|DRUG|ipratropium bromide|ipratropium bromide
214385067|NCT03580213|OTHER|Hand therapy PIPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices. Possible additional splint and exercises specifically for the PIPJ extension.
214385068|NCT01678014|PROCEDURE|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
214385069|NCT01678014|PROCEDURE|Capsulotomy|
214385070|NCT00136812|BEHAVIORAL|stage-tailored intervention|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
214499612|NCT04686266|BEHAVIORAL|Health Information + Health Coaching|Virtual Health Coaching for You: The focus of these sessions is helping caregivers take care of themselves. These are virtual health coaching sessions by trained Health Coaches over 6 months with content based on the theoretical framework from our prior research
214499613|NCT06827665|BIOLOGICAL|DDA|: demineralized dentin allografts (DDA) allografts from human extracted teeth will be prepared and evaluated in a prospective clinical trial to assess their efficacy for alveolar ridge preservation. The reconstruction and preservation of the alveolar ridge after tooth extraction are essential for future prosthetic rehabilitation. Autogenous bone grafts, while effective, are limited by donor site morbidity and insufficient graft quantity. Allogenic dentin grafts, derived from healthy human donors, present a scalable solution.
214687655|NCT03617367|BIOLOGICAL|daxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
214687656|NCT01904734|DRUG|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
214997112|NCT06976229|BIOLOGICAL|Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells|"Description:~The Single Ascending Dose (SAD) and Muliple Ascending Dose (MAD) stages were built up in the study. XS228 in SAD and MAD following intrathecal injection through lumbar puncture in subacute spinal cord Injury participants.For SAD,the participants will single intrathecal injection with the dose level as 5×10\^7 cells 、1.5×10\^8 cells. For MAD, the participants will intrathecal injection of XS228 in Day 1, Day15, Day 29, Day 43 under the dose level of 5×10\^7 cells、1.5×10\^8 cells.Dose escalation followed a rule-based 3+3 design.~XS228 is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs). This advanced therapy medicinal product (ATMP) is being developed for the treatment of subacute spinal cord injury and represents a novel approach in regenerative medicine."
214997113|NCT06976710|BEHAVIORAL|Preoperative Exercise|Aerobic, Endurance, Respiratory, Muscle Strength, Education
214997114|NCT06976710|BEHAVIORAL|Postoperative Exercise|Aerobic, Endurance, Respiratory, Muscle Strength, Education
214997115|NCT06976710|DIETARY_SUPPLEMENT|Preoperative Nutrition|Malnutrition screening, Weight monitoring, Symptom management, Dietetic counselling, Nutrition support
214997116|NCT06976710|DIETARY_SUPPLEMENT|Postoperative Nutrition|Malnutrition screening, Weight monitoring, Symptom management, Dietetic counselling, Nutrition support
214385071|NCT05027399|BEHAVIORAL|Nursing teleconsultation for lifestyle changes|Guidance on better medication adherence, monitoring of signs and symptoms of exacerbation of heart failure, guidance on the need for fluid restriction.
214385072|NCT00439166|DRUG|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
214385073|NCT00439166|DRUG|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
214385074|NCT00439166|DRUG|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
214385075|NCT00439166|DRUG|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
214385076|NCT04283344|OTHER|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula
214385077|NCT04953013|DRUG|sodium bicarbonate|Drug exposure
214385078|NCT02738671|BEHAVIORAL|Cognitive assessment|
214385079|NCT02738671|OTHER|functional magnetic resonance imaging|
214385080|NCT02738671|OTHER|olfactory function measurement|
214687657|NCT03813745|OTHER|early denudation|COCs will be denudated in 30 min after oocyte retrieval
214385081|NCT02738671|PROCEDURE|bariatric surgery|Only a subgroup of the subjects will have the bariatric surgery.
214385082|NCT04439006|OTHER|Best Practice|Receive usual care
214385083|NCT04439006|DRUG|Ibrutinib|Given PO
214385084|NCT01079689|OTHER|needle stimulation|stimulation with acupuncture needles
214385085|NCT02294110|OTHER|spinal anesthesia|non diabetes mellitus
214385086|NCT03072381|BIOLOGICAL|Platelet Rich Plasma - Group 1|Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
214385087|NCT03072381|DRUG|Corticosteroid Control - Group 2|Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
214385088|NCT03019120|DRUG|Vitamin D|"1. Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~2. Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~3. Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~4. Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~5. At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery."
214385089|NCT00499850|DRUG|ZD6474 (vandetanib)|once daily oral dose
214385090|NCT00499850|DRUG|5-Fluorouracil|intravenous infusion
214385091|NCT00499850|DRUG|Leucovorin|intravenous infusion
214385092|NCT00499850|DRUG|Oxaliplatin|intravenous infusion
214385093|NCT01914367|BIOLOGICAL|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
214385094|NCT01914367|BIOLOGICAL|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
214385095|NCT00422799|DRUG|Bortezomib|Once weekly for 3 weeks
214385096|NCT00422799|DRUG|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
214385097|NCT04733911|OTHER|75 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 5 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
214687658|NCT03813745|OTHER|late denudation|COCs will be denudated 2 hr after oocyte retrieval
214687659|NCT00418834|DRUG|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
214997117|NCT06976710|BEHAVIORAL|Preoperative Psychology|CBT skills, Skills training, Emotional validation, Behavioural activation, Psycho-education
214997118|NCT06976710|BEHAVIORAL|Postoperative Psychology|CBT skills, Skills training, Emotional validation, Behavioural activation, Psycho-education
214997119|NCT06976710|OTHER|Preoperative Nursing|Risk management, Managing pain, Wound care, Bowel function, Surgical education
214997120|NCT06976710|OTHER|Postoperative Nursing|Risk management, Managing pain, Wound care, Bowel function/Stoma management, Education
214997121|NCT06976710|BEHAVIORAL|Preoperative Peer Support Group|"Fortnightly sessions moderated by a social worker including patients and carers:~Safe space, Share experiences/ideas, Support, Education"
214997122|NCT06976710|BEHAVIORAL|Postoperative Peer Support Group|"Fortnightly sessions moderated by a social worker including patients and carers:~Safe space, Share experiences/ideas, Support, Education"
214997123|NCT06976710|OTHER|Usual Care|All participants will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
214997124|NCT06974604|DRUG|Dexamethasone oral|Dexamethasone 10 mL daily for days 1-5 for each of the ﬁrst 3 cycles of therapy Datopotamab Deruxtecan 6.0 mg/kg IV on day 1 every 21 days
214997125|NCT06028464|DRUG|BI 1810631|BI 1810631
214997126|NCT06028464|DRUG|Carbamazepine|Carbamazepine
214997127|NCT05291234|DRUG|ABBV-916|Intravenous administration
214997128|NCT05291234|DRUG|Placebo|Intravenous administration
214997129|NCT06575348|DEVICE|YouControl-A-Fib mHealth Application|Participants will use the app for 3 months, includes 1 month phone call with Health Coach
214385098|NCT04733911|OTHER|150 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 10 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
214385099|NCT04733911|OTHER|300 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 20 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
214499614|NCT06827665|BIOLOGICAL|WTA|whole tooth allografts (WTA) allografts from human extracted teeth will be prepared and evaluated in a prospective clinical trial to assess their efficacy for alveolar ridge preservation. The reconstruction and preservation of the alveolar ridge after tooth extraction are essential for future prosthetic rehabilitation. Autogenous bone grafts, while effective, are limited by donor site morbidity and insufficient graft quantity. Allogenic dentin grafts, derived from healthy human donors, present a scalable solution.
214499615|NCT03697304|DRUG|BI 754091|Solution for infusion
214499616|NCT03697304|DRUG|BI 754111|Solution for infusion
214499617|NCT03697304|DRUG|BI 836880|Solution for infusion
214499618|NCT06831630|OTHER|Holmich protocol exercise|The treatment consisted of exercise therapy (ET) protocol suggested by Holmich et al and was started under the supervision of a trained sport physiotherapist who ensured that the exercise was carried out correctly and adhered to the original protocol. No treatment other than ET was applied. Although the ET protocol exactly mirrored the randomised clinical trial of Holmich et al, details such as the perceived resistance or weights (in exercise 3 in module 2) and the rest period between the exercise sets and repetitions, which were not defined in the Holmich study, were explained here for the athletes' benefit (tables 1 and 2). Treatment was administered three times a week (on even or odd days). The duration of each session was about 90 min for module 1 (first two weeks) and 120 min for module 2 (from the third week). From the third week, the athletes were asked to perform exercises from module 1 every other day, between the treatment sessions. Although adductor muscle stretching was for
214687660|NCT00418834|DRUG|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
214687661|NCT00418834|DRUG|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
214687662|NCT01953328|DRUG|Atorvastatin|Administered orally once a day
214687663|NCT01953328|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214687664|NCT01953328|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
214687665|NCT05279014|OTHER|Meal timing|A high-carbohydrate (1 g/kg body mass) meal to be consumed either 1.5-3 hours before or immediately after exercise. Those consuming the meal after exercise will have fasted for at least 8 hours before exercise.
214687666|NCT03300752|BEHAVIORAL|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
214687667|NCT03300752|BEHAVIORAL|Control Intervention|PCP will provide discussion of healthy lifestyles.
214997130|NCT04907799|BEHAVIORAL|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
214997131|NCT04907799|OTHER|Standard advice control|Initial nutrition consultation without subsequent counseling
214997132|NCT05993728|BEHAVIORAL|Body Project|The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.
214385100|NCT03874780|DEVICE|Vibe Delivery system|delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system
214385101|NCT04542226|DRUG|Polyoxidonium|Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
214385102|NCT01305746|DRUG|A-623|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
214385103|NCT01305746|DRUG|A-623|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
214997133|NCT05993728|BEHAVIORAL|Psychoeducational control|Participants randomized to the educational control condition will receive videos addressing body image and eating disorders
214997134|NCT06805461|DEVICE|RenovoCath®|Intra-arterial catheter delivery of chemotherapy agents for the collection of real-world data.
214997135|NCT05848908|OTHER|Telehealth Visit|telemedicine visit and follow-up surveys
214997136|NCT06619418|DEVICE|TENS device|will be using an FDA- cleared TENS device for electrical stimulation (TENS 7000, Compass Health Brands) in combination with commercially-available headphones for acoustic stimulation (AKG 845 BT).Will be shown how to use the device, trained on the multimodal stimulation procedure, and sent home with the device for 12 weeks.
214997137|NCT06619418|BEHAVIORAL|Integrative health modalities|will be instructed on the integrative health modalities for this study. They will be given a tablet that includes the videos for the visually guided deep breathing. They will also receive the reflective journal and be set up for health coaching visits. At the end of the 12 weeks, this group of participants will return to the U of M campus and complete an interview about satisfaction and usability of the IH modalities.
214997138|NCT01352520|DRUG|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
214997139|NCT04981093|DRUG|Dexamethasone Injection|"Intravenous injection after induction of anesthesia~Injection 0.15mg/kg dexamethasone (2ml)"
214499619|NCT06831630|OTHER|Joint Mobilization|"Focus of treatment was on reducing hip joint pain using joint mobilization techniques provided by the physical therapist and exercises performed in the HEP. Based on published literature, we developed a standard set of mobilizations to target hip joint motion limitations, defined as stiffness or pain that limited joint range of motion. Joint mobilization techniques were prioritized based on patient-specific tasks and the motion used during those tasks, followed by the hip motion limitations. The choice of joint mobilization techniques and grade used was based on direction of hip motion limitation and the relationship of pain and stiffness during hip motion assessment. The HEP included commonly used joint motion and stretching exercises to complement techniques performed during supervised sessions.~The exercises will be conducted over a period of 12 weeks, which is explained below Techniques will be prioritized based on restrictions noted on baseline examination.~1. Caudal glide~2. Lat"
214385104|NCT01305746|DRUG|A-623|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
214385105|NCT04695340|DIETARY_SUPPLEMENT|Psyllium|Psyllium is given to patients
214385106|NCT01217489|PROCEDURE|Breast scan - Electrical Impedance Mammography|Scanning of the breast on a non-invasive device, using harmless minute electrical currents
214385107|NCT04672512|DRUG|CORT125329 lipid capsule formulation|CORT125329 lipid capsule formulation 1 or 2 for oral administration
214385108|NCT04672512|DRUG|Placebo|Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
214385109|NCT04672512|DRUG|Prednisone|Prednisone tablet for oral administration
214385110|NCT03923361|DRUG|Diprivan|Similar to the high-intensity propofol treatments in Phase 1, the anesthesiologist will administer an induction dose of propofol followed by a continuous infusion, insert an airway, and begin mechanical ventilation. Propofol dosing will be adjusted with the goal of achieving a burst-suppression state with a SR of 40-60 for 12-15 minutes.
214385111|NCT05334121|DIETARY_SUPPLEMENT|Beta-alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
214385112|NCT05334121|OTHER|Control product consumption|Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
214385113|NCT06381440|DEVICE|Lokomat device (Hocoma AG, Volketswil, Switzerland).|Robot Assisted Gait Training device
214385114|NCT06381440|OTHER|Conventional walking training|Self-paced supervised walking training
214385115|NCT05749601|OTHER|Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid|Highlighting the influence of environment of origin on KOA incidence and corelated impact of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and body mass index (BMI). The analytes from synovial fluid were determined by fluorometric method.
214385116|NCT05749601|OTHER|The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis|Highlighting the influence of distal femoral torsion angle, patellofemoral congruence angle and sulcus angle, in KOA severity under the influence of sex and age.
214385117|NCT05749601|OTHER|The influence of ROS from the synovial fluid on the severity of KOA|Highlighting the influence of ROS from the synovial fluid in KOA severity under the influence of some biochemicals blood constants.
214385118|NCT01950117|PROCEDURE|Endoscopic mucosal resection|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.
214499620|NCT06832930|PROCEDURE|unicorn robotic bronchoscopy system|cryobiopsy with the help of robotic bronchoscopy system
214499621|NCT06832930|PROCEDURE|Conventional navigation bronchoscopy|cryobiopsy with the help of Conventional navigation bronchoscopy
214499622|NCT06827925|OTHER|Distance Digital Learning|receiving Distance Digital Learning of Flipped Education
214687668|NCT05164406|PROCEDURE|Blood salvage therapy|In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
214687669|NCT04671485|OTHER|Standard care|Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
214687670|NCT04671485|OTHER|Autohypnosis|"The patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
214385119|NCT01950117|PROCEDURE|Conventional polypectomy|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
214385120|NCT04571762|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT (a fraction dose adapted to the OAR geometry-of-the-day, 5 fractions) performed on the MR-Linac
214385121|NCT04746547|DRUG|Dolutegravir 50 MG|Twice daily dolutegravir with rifampicin containing TB treatment
214385122|NCT04746547|DRUG|Dolutegravir 10 MG|Twice daily dolutegravir with rifampicin containing TB treatment
214385123|NCT02546154|DRUG|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
214385124|NCT04037384|BEHAVIORAL|Eye yoga|Eye yoga exercises at home given by a trained instructor
214385125|NCT04037384|BEHAVIORAL|Passive Reading|Passive reading at home
214385126|NCT00157742|PROCEDURE|Spinal Cord Stimulation (SCS)|
214385127|NCT00157742|PROCEDURE|Percutaneous Myocardial Laser Revascularisation (PMR)|
214385128|NCT02802683|DRUG|Bupivacaine|spinal anesthesia with hyperbaric bupivacaine
214385129|NCT02802683|DRUG|Levobupivacaine|spinal anesthesia with isobaric levobupivacaine
214385130|NCT02802683|DRUG|Phenylephrine|continous infusion of phenylephrine
214385131|NCT02802683|DRUG|normal saline|continous infusion of normal saline
214385132|NCT04463784|DRUG|Efavirenz 400Mg Oral Tablet|The experimental arm will receive 400mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
214385133|NCT04463784|DRUG|Efavirenz 600Mg Oral Tablet|The active comparator arm will receive 600mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
214385134|NCT06530901|DIAGNOSTIC_TEST|Multidimensional ultrasound of the inferior vena cava|Cross-sectional parameters of the inferior vena cava include two-dimensional longitudinal diameter, cross-sectional length and short diameter, circumference, and cross-sectional area, as well as cross-sectional length and short diameter, circumference, and cross-sectional area in three-dimensional imaging
214385135|NCT02792985|BEHAVIORAL|Multisensory stimulation protocol|"Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.~An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room."
214385136|NCT02792985|BEHAVIORAL|Control protocol|"Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.~Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends)."
214385137|NCT02379559|BEHAVIORAL|Exercise|For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.
214385138|NCT02379559|BEHAVIORAL|Attention Control|We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
214385139|NCT04316767|BEHAVIORAL|App Intervention|Participants will receive access to a self-care app for use on their smartphone. The app provides a suite of tools based on cognitive behavioral therapy and mindfulness. The app guides users through a variety of short lessons (3-5 minutes) that teach users to self-manage stress, mood, anxiety, and depression. Participants will be encouraged to use the app on a daily basis and will be able to use the app at their discretion.
214385140|NCT03029780|BIOLOGICAL|Opdivo|Specified dose on specified days
214385141|NCT03029780|BIOLOGICAL|Yervoy|Specified dose on specified days
215093433|NCT04795700|BEHAVIORAL|MSC intervention|Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
215093434|NCT00329615|DRUG|Insulatard, flexpen|
214385142|NCT04323228|DIETARY_SUPPLEMENT|Oral supplement enriched in antioxidants|the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.
214385143|NCT04323228|DIETARY_SUPPLEMENT|cellulose-containing placebo capsules|The placebo group will receive an oral supplement at the same time in the same shape/size/color.
214385144|NCT00002901|DRUG|docetaxel|
214385145|NCT06275425|DRUG|Total intravenous anesthesia with Byfavo|General anesthesia is maintained with intravenous continuous administration of Byfavo.
214385146|NCT06275425|DRUG|Inhalation anesthesia with Sevoflurane|General anesthesia is maintained with Sevoflurane.
214385147|NCT00547287|DRUG|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
214385148|NCT00547287|DRUG|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
214385149|NCT00635765|DRUG|C2L-OCT-01 PR 30 mg|Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.
214687671|NCT04671485|OTHER|Musicotherapy|"the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
214385150|NCT02810314|BEHAVIORAL|neuropsychological battery|neuropsychological battery including cognitive and behavioural tests
214385151|NCT02810314|OTHER|resting state functional magnetic resonance image (rs-fMRI)|rs-fMRI
214687672|NCT04710862|BEHAVIORAL|Breathing training without a device|Breathing training without a mouth device
214687673|NCT04710862|BEHAVIORAL|Breathing training with a device|Breathing training with a mouth device
214687674|NCT05171569|DEVICE|Virtual care with remote automated monitoring (RAM)|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
214385152|NCT03008525|BIOLOGICAL|subcutaneous and visceral adipose tissue biopsies|Subcutaneous and visceral adipose tissue biopsies during operation
214687675|NCT04674618|DEVICE|US-assisted nusinersen administration|Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
214385153|NCT03008525|BIOLOGICAL|blood samples analysis|"Blood sampling is required to measure plasma cholecalciferol, calcidiol and calcitriol concentrations, as well as biological parameters of interest.~Another plasma/serum tube is used to measure pro- and anti-inflammatory cytokines and adiponectin."
214385154|NCT04985006|BEHAVIORAL|running at moderate intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 50-59% Heart rate reserve (HRR) for 30 minutes from the time the target intensity is reached.
214385155|NCT04985006|BEHAVIORAL|running at high intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 70-75% HRR for 30 minutes from the time the target intensity is reached.
214385156|NCT03560258|BIOLOGICAL|p24CE1/2 pDNA vaccine|4 mg administered by one injection/electroporation
214385157|NCT03560258|BIOLOGICAL|p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine|2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55\^gag pDNA administered by one injection/electroporation
214385158|NCT03560258|BIOLOGICAL|Full-length p55^gag pDNA vaccine|4 mg full-length p55\^gag pDNA vaccine administered by one injection/electroporation
214385159|NCT03560258|BIOLOGICAL|Placebo|1 mL placebo administered by one injection/electroporation
214385160|NCT00810758|DRUG|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
214385161|NCT00810758|DRUG|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
214385162|NCT00810758|DRUG|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
214385163|NCT03748602|PROCEDURE|Thoracic outlet decompression|TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
214385164|NCT03354325|BEHAVIORAL|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
214385165|NCT03354325|BEHAVIORAL|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
214385166|NCT04202744|OTHER|Shoulder and core evaluations|Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated.
214385167|NCT01291238|BEHAVIORAL|Healthier, Smarter, Happier|Increased physical activity and decreased sugar and fat intake during school hours
214385168|NCT06624943|DRUG|biosimilar insulin glargine|Once daily injection of biosimilar insulin glargine via reusable pen
214385169|NCT04498247|BIOLOGICAL|V591|1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.
214385170|NCT04498247|OTHER|Placebo|Placebo (0.9% sodium chloride) administered via IM injection.
214385171|NCT01797341|DRUG|Tacrolimus|
214499623|NCT06829940|OTHER|Baduanjin exercise training (BET)|Baduanjin Exercise Training (BET) is a traditional Chinese exercise focused on improving physical health, flexibility, balance, and mental well-being. It involves a 10-minute warm-up, a 40-minute core session practicing eight distinct postures, and a 10-minute cool-down. The postures, based on the Baduanjin form, target different body parts and promote strength, flexibility, and circulation. The exercises are synchronized with deep breathing to enhance relaxation and stress reduction. BET is especially beneficial for joint health, mobility, and mental clarity, making it suitable for individuals of all ages and fitness levels
214499624|NCT06138340|DRUG|Dexmedetomidine|Participants will be sedated and maintained by dexmedetomidine during the surgery.
214687676|NCT02364947|DRUG|Nalmefene hydrochloride|As-needed; tablets, orally
214687677|NCT02364947|DRUG|Placebo|As-needed; tablets, orally
214687678|NCT02527551|OTHER|Massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
214687679|NCT04940442|BEHAVIORAL|Outreach|Active: Outreach offering FIT or colonoscopy. Sequential: Outreach offering FIT first, and then offering colonoscopy to those still unscreened
214385172|NCT01797341|DRUG|Tacrolimus|
214385173|NCT00722995|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
214385174|NCT00722995|PROCEDURE|Gastric Bypass|Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
214385175|NCT02086162|BEHAVIORAL|Web-based motivational decision support system|
214385176|NCT02086162|BEHAVIORAL|NCI Education|
214385177|NCT00398775|PROCEDURE|antibiotic discontinuation|
214385178|NCT03326947|DRUG|docetaxel, cisplatin and 5-fluorouracil|"Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy"
214385179|NCT02746822|OTHER||
214385180|NCT06123572|OTHER|Placebo|Placebo Comparator
214385181|NCT06123572|OTHER|Anti-Ageing and Skin Brightening Gel|Anti-Ageing and Skin Brightening Gel.
214499625|NCT06138340|DRUG|Propofol|Participants will be sedated and maintained by propofol during the surgery.
214499626|NCT06138340|DRUG|Remimazolam Injection|Participants will be sedated and maintained by remimazolam during the surgery.
214997140|NCT04981093|DRUG|Normal saline|2ml of normal saline was injected intravenously after induction of anesthesia
214385182|NCT01248962|DRUG|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
214385183|NCT01248962|DRUG|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
214385184|NCT01027364|DRUG|Factor IX (rFIXFc)|
214385185|NCT01027364|DRUG|rFIX|
214385186|NCT00303563|DRUG|P38 Inhibitor (4)|50mg po qd
214385187|NCT00303563|DRUG|P38 Inhibitor (4)|150mg po qd
214385188|NCT00303563|DRUG|P38 Inhibitor (4)|300mg po qd
214385189|NCT00303563|DRUG|Placebo|po qd
214499627|NCT04306367|DRUG|Pembrolizumab|200 mg given intravenously.
214499628|NCT04306367|DRUG|Olaparib|300 mg given orally.
214499629|NCT06823063|BIOLOGICAL|MSC|a single injection dose i.v.
214499630|NCT04043117|OTHER|Body Image evaluation|"Evaluation of body image perception requires three assessment tools administered at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~1. Italian Body Image Concern Inventory: 19-items self-report instrument rated on a 5-points Likert scale (1 = never; 5 = always). It consists of two sub-scales to evaluate body image-related dissatisfaction and concern respectively.~2. Body Uneasiness Test: 71-item self-report questionnaire on a 6-points Likert scale (0 = never; 5 = always) that consists of two subscales: BUT-A (measuring weight phobia, body image concerns, avoidance, compulsive self-monitoring, detachment and body depersonalization) and BUT-B (measuring worries about specific body parts or functions).~3. Human Figure Drawing: qualitative measure of adolescent's body perception; participants are asked a free draw, representing themselves."
214499631|NCT04043117|OTHER|Self esteem evaluation|"Evaluation of body image perception is achieved administering TMA test at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~TMA (Multidimensional Self-Esteem Test): a 150-items self-report questionnaire for children and adolescents from 9 to 19 years old. It's made up of six subscales: interpersonal relationships, environmental control competence, emotionality, scholastic success, family life, body perception. Participants have to express their agreement with each item according to the following response options: absolutely true, true, false, absolutely false."
214499632|NCT04665297|BEHAVIORAL|International Guide for Monitoring Child Development|Monthly GMCD visits includes assessment of risk factors, open-ended exploration of caregiver concerns about development, assessment of functioning in seven developmental domains, and using mutual problem solving strategies to develop a nurturing care plan with the caregiver.
214499633|NCT06183619|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
214499634|NCT06183619|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation only
214499635|NCT06828341|BIOLOGICAL|CAR-T|allogeneic CAR-T targeting CD70 that cultured from heathy adults.
214499636|NCT06487819|PROCEDURE|Application of a rubber dam during dental treatments for varying durations.|Patients in each group will undergo dental procedures (either operative or endodontic treatment) with rubber dam isolation. The rubber dam will be applied for the specific durations mentioned in each group to evaluate the impact of mouth opening on the temporomandibular joint (TMJ).
214687680|NCT05525975|OTHER|Educational materials|Educational materials will be developed by our interdisciplinary research team. Will consist of a brochure and a video. Both materials highlight important information about opioid medications, explain proper disposal of excess of opioid medications and provide drug-free pain management tools for postoperative pain.
214997141|NCT06202638|DEVICE|HemoSphere monitor with Acumen Hypotension Prediction Index Software|Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
214997142|NCT03824158|BEHAVIORAL|Facilitated advance care planning (in-person or telephonic)|The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic, or telephonically. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.
214997143|NCT03824158|BEHAVIORAL|Web-based advance care planning|Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.
214385190|NCT04929366|PROCEDURE|Hypothermic dialysis followed with routine dialysis|Hypothermic dialysis (35.5 degrees Celsius dialysate) followed with routine dialysis (36.5 degrees Celsius dialysate)
214385191|NCT04929366|PROCEDURE|Routine dialysis followed with hypothermic dialysis|Routine dialysis (36.5 degrees Celsius dialysate) followed with hypothermic dialysis (35.5 degrees Celsius dialysate)
214385192|NCT04960553|DEVICE|Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex to 102 subjects who meet the study criteria for up to 12 weeks
214385193|NCT01711957|PROCEDURE|Liver transplantation|Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
214385194|NCT00692640|DRUG|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
214385195|NCT00692640|DRUG|Erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
214385196|NCT05763082|DRUG|roflumilast cream 0.3%|test product
214499637|NCT06753045|OTHER|Smartwatch|Sensors on the smartwatch will measure vitals such as heart rate, blood pressure, oxygen saturation, body composition, and electrocardio gram (ECG)
214499638|NCT06453018|DEVICE|Positional device, Rematee Bumper Belt or Night Shift|Positional device, Rematee Bumper Belt (Rematee, Blaine, Washington), or Night Shift (Advanced Brain Monitoring) on chest belt, will be used as the intervention
214499639|NCT05790018|DEVICE|PREGNANT PILLOW|First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
214499640|NCT06753461|PROCEDURE|intrahepatic blood flow occlusion|The specified blood vessel is temporarily clamped to achieve the intended blockage of blood flow.
214499641|NCT05794009|OTHER|Immersive Virtual Reality Exercise (IVRE)|The IVRE program will include aerobic exercise, muscle strengthening exercise, balance and flexibility exercise.
214499642|NCT05794009|OTHER|Home Exercise|Aerobic exercise, muscle strengthening exercise, balance and flexibility exercise at home.
214997144|NCT05007873|DRUG|Dasatinib|Given PO
214997145|NCT05007873|DRUG|Decitabine and Cedazuridine|Given PO
214997146|NCT05528419|DRUG|Sacubitril-valsartan|sacubitril valsartan 100mg initiated, and titrated to 200mg according to mean clinic blood pressure at 1-month follow-up
214997147|NCT05528419|DRUG|Valsartan|valsartan 80mg initiated, and titrated to 160mg according to mean clinic blood pressure at 1-month follow-up
214997148|NCT04046133|DRUG|Pembrolizumab|Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
214997149|NCT04123535|DEVICE|ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)|The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table
214499643|NCT03013946|BEHAVIORAL|Concomitant coaching|"The corner stones of the pro-active coaching are as follows:~* Patient education:~  * Information on nature and severity of treatment emergent AEs~ * information about remedies for TEAEs~ * propagation and explanation of tests and treatment decisions~ * Patient instruction on self-care and preventive measures~* Preemptive AE treatment strategies~* Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach"
214499644|NCT06832969|PROCEDURE|cryoablation|Lung cancer patients undergo treatment for peripheral malignant lung tumors using cryoablation technology under the guidance of bronchoscopy.
214997150|NCT04865770|DRUG|Semaglutide|Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
214997151|NCT04865770|DRUG|Placebo (Semaglutide)|Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
214499645|NCT06831500|DRUG|Administration of Carbidopa/levodopa|Participants will perform beat-by-beat orthostatic tests (Schellong tests) before and after intake of single doses of carbidopa:levodopa combinations at 3 different ratios
214499646|NCT02401815|DRUG|CGT9486|CGT9486 will be administered per dose and schedule specified in the arm.
214499647|NCT02401815|DRUG|Pexidartinib|Pexidartinib capsules will be administered per dose and schedule specified in the arm.
214687681|NCT06200740|DEVICE|Sonara|web application facilitating asynchronous observation of methadone dosing
214997152|NCT05453630|BEHAVIORAL|Patient Navigation|Patients will receive navigation from a trained lay navigator at a community-based nonprofit organization that supports access to high quality healthcare. The patient navigator will work with patients to schedule their colonoscopy and identify, explore, and overcome barriers. They will educate patients about the colonoscopy procedure and preparation, provide resources, and coach and motivate patients.
214997153|NCT05453630|BEHAVIORAL|Usual Care Control|Educational brochure about colonoscopy
214997154|NCT05589519|DEVICE|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis for partial rehabilitation of edentulous jaws.
214997155|NCT06967298|DEVICE|T30 Contact lenses|Individuals who have previously dropped out of Contact lenses (CL) due to discomfort will be refit into T30 contact lenses and their comfort with the product will be assessed.
214997156|NCT06505083|OTHER|modified stepping trainings|step-up on box texture difference
214385197|NCT05763082|DRUG|Zoryve|Reference Listed Drug product
214385198|NCT05763082|DRUG|Placebo|placebo
214385199|NCT02104830|BIOLOGICAL|Empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
214385200|NCT02104830|BIOLOGICAL|Filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
214499648|NCT02401815|DRUG|Sunitinib|Sunitinib will be administered per dose and schedule specified in the arm.
214499649|NCT06830915|OTHER|Observation only|No intervention made
214499650|NCT05427487|BIOLOGICAL|IVX037|Bioselected oncolytic RNA virus
214499651|NCT05427487|BIOLOGICAL|Sintilimab|An immune checkpoint inhibitor
214499652|NCT05203237|BIOLOGICAL|VK2735|Administered SC
214499653|NCT05203237|BIOLOGICAL|Placebo|Administered SC
214499654|NCT05203237|DRUG|VK2735 Placebo|Administered orally
214499655|NCT05203237|DRUG|VK2735 Drug|Administered orally
214687682|NCT04529551|OTHER|1601A|A filtered, king size cigarette with a menthol capsule in the filter.
214997157|NCT06344325|DRUG|fospropofol|The initial dose of fospropofol disodium in the youth group is 15mg/kg,the middle-aged group is 10mg/kg, the elderly group is 7.5mg/kg, and the concentration of adjacent intervals is 0.5mg/kg.
215093435|NCT06365983|PROCEDURE|Connective Tissue with Free Gingival Graft|The de-epithelialized free gingival grafting will begin with two horizontal incisions, 1.0 to 1.5 mm apical to the margin of the soft tissue of the adjacent teeth and two vertical incisions to delimit the area to be grafted. Along the coronal horizontal incision, the blade will be oriented almost perpendicular to the bone surface, and once an adequate thickness of soft tissue is obtained, it will be rotated to become almost parallel to the external surface of the palate. The graft thickness will be maintained uniform and the wound will be protected with absorbable collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) and maintained with compressive sutures with non-absorbable 5-0 monofilament thread (Microsuture, São Paulo), anchored to the soft tissue apical to the area of the palatal wound. Immediately after suture completion, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
215093436|NCT06365983|PROCEDURE|Connective Tissue with Linear Incision|The linear technique (Lorenzana ER, Allen EP 2000) will begin with a horizontal incision 2 mm apical to the gingival margin, perpendicular to the palate, which is deepened to the bone crest. Next, a second incision is made to divide the flap and expose the connective tissue bed. The thickness of the outer portion of the flap should be at least 1 mm, with uniformity throughout its extension to reduce the risk of epithelial tissue necrosis. Subsequently, internal lateral incisions (mesial and distal) and the base incision will be made, connecting the vertical incisions to delineate horizontal and vertical boundaries. Immediately after graft removal, an absorbable hemostatic collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) will be placed and sutured using non-absorbable 5-0 monofilament thread (Microsuture, São Paulo).Immediately after suturing is completed, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
214997158|NCT06326216|OTHER|Non-Interventional Study|Non-interventional study
214385201|NCT02104830|BIOLOGICAL|Placebo №1|Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
214385202|NCT02104830|BIOLOGICAL|Placebo №2|Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
214385203|NCT02104830|BIOLOGICAL|Empegfilrastim 7.5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
214385204|NCT03620682|BEHAVIORAL|Coaching sessions|Participants receive three 30-minute phone sessions with a doctorate-level therapist over the course of one month. These sessions are skills-based and focus on improving participants' problem solving through cognitive-behavioral techniques. Participants are allowed to text the therapist between sessions for information and support.
214385205|NCT03620682|BEHAVIORAL|Mobile applications|Participants will have access to 3 mobile apps for the duration of the study, and after it ends. One app will push participants a daily, self-reflective survey to complete, and a daily motivational or instructional tip to rate. Other apps will provide education and exercises on various aspects of mental health and wellness, such as sleep and relaxation.
214385206|NCT04530357|BIOLOGICAL|QazCovid-in® - COVID-19 inactivated vaccine|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
214385207|NCT04530357|OTHER|Placebo|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
214385208|NCT05606263|DRUG|Caldonirimab and Nimotuzumab|Subjects will receive caldonirimab (6mg/Kg, q2w) until disease progression or for a maximum of 12 months, and Nimotuzumab (400mg/time, q2w) for a total of 8 cycles
214385209|NCT00863889|DRUG|Depomedrol injection|1 cc of Depomedrol 80
214385210|NCT00863889|DRUG|Lidocaine, Marcaine|4 cc of each local anesthetic
214385211|NCT03895736|BIOLOGICAL|blood sampling|Sampling of 15 ml of blood during a blood test at Day 0, Day 1 and Day 3
214499656|NCT06329856|BEHAVIORAL|Administering of artificial hydration|Administering of artificial hydration to terminal cancer patients
214499657|NCT06826456|PROCEDURE|sub-ablative Er,Cr:YSGG laser|The irradiations will be done with an Er,Cr:YSGG laser device Er,Cr:YSGG Laser (Waterlase iPlus 2011,Biolase,Germany). This equipment emits photons at a wavelength of 2.78 µm. The repetition rate will be fixed at 20 Hz. The pulse duration will be fixed on 140 µs. The beam diameter at the focal area for the handpiece will be 600 µm. The tip will be positioned 1.0 mm from the enamel surface (focused mode). The handpiece will be positioned perpendicularly to the enamel. Power =0.25 Watt; energy density per pulse will be 62.5 J/cm2, Time = 20 seconds; Frequency = 20 Hz; without air/water. To ensure that each spot of a fissure was irradiated, each fissure will be irradiated for 2 min with overlapping irradiation
214997159|NCT05184842|DRUG|Venetoclax|Venetoclax 400 mg po on days 1, 8, 15 and 22 of each cycle (28-day cycle)
214997160|NCT05184842|DRUG|Decitabine|Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)
214997161|NCT02025543|DEVICE|MRI|R2 MRI scan
214997162|NCT06340581|DRUG|Treatment A: BGF MDI HFA|Participants will receive 4 oral inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
214997163|NCT06340581|DRUG|Treatment B: BGF MDI HFO|Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
214997164|NCT06340581|DRUG|Treatment C: BGF MDI HFO|Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose without spacer with charcoal.
214997165|NCT06340581|DEVICE|AeroChamber Plus Flow-Vu Spacer|Participants will receive 4 inhalations of BGF MDI HFA (treatment A) and BGF MDI HFO (Treatment B) as a single dose with AeroChamber Plus Flow-Vu spacer.
214997166|NCT03893955|DRUG|ABBV-927|Intravenous (IV) Infusion
214997167|NCT03893955|DRUG|ABBV-368|Intravenous (IV) Infusion
214997168|NCT03893955|DRUG|ABBV-181|Intravenous (IV) Infusion
214997169|NCT03893955|DRUG|Carboplatin|Intravenous (IV) Infusion
214997170|NCT03893955|DRUG|Nab-paclitaxel|Intravenous (IV) Infusion
214385212|NCT03524456|OTHER|Home blood pressure monitoring|Participants would use a blood pressure device at home, that sends the readings automatically to the health center via SMS. The physicians would use this tool for medication management or rescheduling visits.
214499658|NCT06826456|PROCEDURE|Fluoride varnish application|"The first permanent molar assigned for control group will receive fluoride varnish applications. Fluoride varnish will be applied to all teeth in the oral cavity, including the laser-treated as well as the control tooth at baseline and the 6-month recall.~Parents and children will be given age-appropriate oral hygiene instructions including proper teeth brushing with a 1100-ppm fluoride-containing dentifrice for at least 2 min twice daily especially before bedtime, as well as flossing if indicated."
214499659|NCT05104515|BIOLOGICAL|OVM-200|"The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer."
214499660|NCT06762405|RADIATION|radiotherapy|short course of radiotherapy (5 grays × 5 days)
214997171|NCT06460298|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
214997172|NCT06460298|DRUG|ProAgio Dose Expansion|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
214997173|NCT06101303|OTHER|Psychophysical assessment|"Thermal stimuli: The Thermal Sensory Analyzer will be used to deliver heat and cold stimuli. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water bath or an electronic electronic temperature-controlled water bath. Participants will be free to pull out of the water bath at any time.~Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer. These devices have a round probe that allows quantifying the amount of pressure that is being applied by real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.~Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture."
214997174|NCT06101303|BEHAVIORAL|Psychophysical assessments of experimental pain|"Pain ratings- Pain intensity and pain unpleasantness ratings will be assessed~Pain thresholds to heat, cold and/or pressure will be tested and participants will be instructed to press a button the first moment they feel pain.~Temporal summation- participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli.~Conditioned pain modulation (CPM) efficiency - CPM testing includes the application of a test stimulus without conditioning (heat or pressure stimuli) and a subsequent application of the same test stimulus together with a conditioning stimulus (cold stimulus).~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). During the OA paradigm, real time pain intensity ratings will be obtained~Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold water bath. Tolerance will be defined by the time of hand/foot withdrawal."
215093437|NCT01196962|DEVICE|Central venous catheter|Central venous catheter insertion to subclavian vein
214385213|NCT01149213|DEVICE|transcranial direct current stimulation|tDCS will be applied at 2mA/30 minutes, every other week during the first three months than once a month during the next three months.
214499661|NCT06762405|DRUG|Dostarlimab|dostarlimab 500 mg intravenous infusion every 3 weeks for 6 months (nine cycles)
214499662|NCT06762405|BIOLOGICAL|Biological study on circulating tumor DNA (optional for the patient)|"* Tissue collection (3 time points: baseline, w12 and 25) for:~* Exome (on tumor and normal tissue),~* 3'RNAseq,~* Hiplex Immunofluorescence~* In addition, 48 patients will be tested for Spatial transcriptomics assuming that 24 patients may have non-complete response and/or local recurrence and/or metastatic recurrence and will be paired with 24 patients with complete response and free of any disease at 2 years.~* Blood collection (5 time points: baseline, w3, 6, 12 and 24) for:~* ctDNA~* Cytokine dosage~* Proteomic analyses~* Stool collection (3 time points: baseline, w3 and 24) for:~Microbiota analyses"
214687683|NCT04529551|OTHER|1601B|A filtered, king size cigarette with a menthol capsule in the filter.
214687684|NCT01691872|DRUG|Retigabine|Retigabine
214687685|NCT04972071|OTHER|Knowledge translation (KT) of the CSRS based practice recommendations|The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g., troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; and 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. All the components of the practice recommendations will be applied by the ED physician treating the patient.
215093438|NCT02641522|DRUG|Siltuximab|Single infusion of siltuximab (11 mg/kg)
215093439|NCT05883618|OTHER|Exposure|Human Development Index of Country
215093440|NCT00517569|GENETIC|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
215093441|NCT00517569|DRUG|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
215093442|NCT01290900|DRUG|NXL104|IV Solution
215093443|NCT01290900|DRUG|Ceftaroline|IV Solution
215093444|NCT01290900|DRUG|Placebo Infusion|IV Saline
215093445|NCT01290900|DRUG|Ceftazidime|IV Solution
215093446|NCT01290900|DRUG|Moxifloxacin|Tablet (1)
214997175|NCT06101303|DIAGNOSTIC_TEST|Blood, urine and saliva samples|Blood (approximately 2 tablespoons), urine and saliva samples will be collected and sent to ZRT Laboratory, LabCorp, or internal Washington University lab for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone). Additional samples will be stored in a biobank for future processing.
214997176|NCT06101303|PROCEDURE|Biopsy and surgery-related data.|During the surgery, biopsies will be collected from the endometriosis lesions as well as from a healthy peritoneum. If there are no endometriosis lesions, biopsies will be taken of two common locations where endometriosis lesion grows (the infra-ovarian fossa). The lesions will be characterized based on their appearance and invasiveness of the lesions (i.e., powder-burn lesions, nonclassical red or white lesions, and superficially or deeply infiltrating (\>5mm) lesions). In addition, surgery-related data such as the incision size, type of anesthesia, pain ratings after the surgery, analgesic medication after the surgery, and side effects will be documented. Blood, saliva, urine, and samples will be collected for hormonal analyses or stored in a Biobank for future analyses.
214385214|NCT04402658|DRUG|Inhaled salbutamol|Participants will inhale 800 μg salbutamol (or placebo) using a standard metered dose inhaler used for asthma treatment, and a standard spacer device will be used to allow optimal delivery of the drug to the lung. The inhaler delivers 100 μg of salbutamol with each actuation (i.e., 8 puffs/actuations gives 800 μg) with inhalation time being approximately \~2 min (10 breaths) and the manufacturer's user instructions will be followed. Although complete uptake of salbutamol cannot be concluded as any salbutamol left in the spacer, mouth or remaining in the lung will be not measured. This dose of Salbutamol is chosen because it is the highest dose permitted by the World Anti Doping Agency (WADA).
214385215|NCT04654546|OTHER|Ultrasound abdominal scan|"A complete ultrasound scan of the abdominal organs using a clinical ultrasound device in the Imaging Institute at Haemek medical center. The ultrasound images will be visually coupled to previous CT images of the same patient at the time of the examination, using a Fusion system located in the ultrasound device mentioned above.~The coupled CT and ultrasound images will be encoded and be sent to the SAMPL laboratory in Weizmann institute, there it will serve as a learning platform for the artificial intelligence system."
214385216|NCT05924282|PROCEDURE|Curative intent surgery|Curative intent surgery means that surgeons intend to perform R0 resection.
214997177|NCT02633878|DRUG|"Chinese Herbal Medicine (New Shoutai Wan) plus Oral Progesterone"|"Chinese Herbal Medicine (New Shoutai Wan, one pack twice daily) + Oral Progesterone (100 mg thrice daily)"
214385217|NCT00332605|DRUG|Naltrexone plus N-Acetyl Cysteine|daily
214385218|NCT00332605|DRUG|Placebo|daily
214997178|NCT02633878|DRUG|"Chinese Herbal Medicine (New Shoutai Wan) plus Oral Progesterone Placebo"|"Chinese Herbal Medicine (New Shoutai Wan, one pack twice daily) + Oral Progesterone Placebo (100 mg thrice daily)"
214997179|NCT02633878|DRUG|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo) plus Oral Progesterone"|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo, one pack twice daily) + Oral Progesterone (100 mg thrice daily)"
214997180|NCT02633878|DRUG|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo) plus Oral Progesterone Placebo"|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo, one pack twice daily) + Oral Progesterone Placebo (100 mg thrice daily)"
214997181|NCT06438562|OTHER|Unfortified bouillon plus vitamin A in oil|Participants consume unfortified bouillon with vitamin A oil
214997182|NCT06438562|OTHER|Bouillon fortified with vitamin A #1 plus unfortified oil|Participants consume vitamin A #1 fortified bouillon plus unfortified oil
214997183|NCT06438562|OTHER|Bouillon fortified with vitamin A #2 plus unfortified oil|Participants consume vitamin A #2 fortified bouillon plus unfortified oil
214997184|NCT03229200|DRUG|Ibrutinib|Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
214997185|NCT02390284|DRUG|Latanoprost|Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
214499663|NCT04777084|DRUG|IBI318|IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
214385219|NCT01001780|DRUG|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
214385220|NCT00485056|DRUG|Pioglitazone|45mgs daily
214385221|NCT01054690|DEVICE|Bactiguard Infection Protection (BIP) Cathter.|
214997186|NCT02390284|DRUG|Bimatoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
214997187|NCT02390284|DRUG|Travoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
214997188|NCT02390284|DRUG|Timolol|Lower intraocular pressure by decreasing production of fluid
214997189|NCT02390284|DRUG|Dorzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
214997190|NCT02390284|DRUG|Brinzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
214997191|NCT02390284|DRUG|Acetazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
214385222|NCT01054690|DEVICE|Silicone Urinary Catheter|
214385223|NCT00245856|DRUG|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
214997192|NCT02390284|DRUG|Methazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
214997193|NCT01683526|PROCEDURE|Direct laryngoscopy|
214997194|NCT01683526|DEVICE|Video laryngoscopy (Glidescope)|
214997195|NCT01494558|OTHER|Chemoradiotherapy Regimen between PC and PE|etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
214385224|NCT00245856|DRUG|Warfarin|Titrated to INR 2-3 through study month 3
214499664|NCT06823128|DEVICE|RIC|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure,last for 7 to 10 days.
214385225|NCT04229680|OTHER|High Salt|Consumption of pills containing table salt for 10 days.
214385226|NCT04229680|OTHER|Recommended Salt|Consumption of pills containing dextrose for 10 days.
214385227|NCT03376503|DRUG|Pegfilgrastim|PK,PD and safety assessment
214385228|NCT03601104|OTHER|High intensity eccentric training|High intensity eccentric training group with 80% of isometric peak torque.
214499665|NCT06823128|DEVICE|Sham|RIC is given twice a day with 60mmHg pressure, last for 7 to 10 days.
214385229|NCT03601104|OTHER|High intensity eccentric training with BFR|Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
214385230|NCT03601104|OTHER|Low intensity eccentric training with BFR|Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
214385231|NCT03601104|OTHER|Low intensity eccentric training|Low intensity eccentric training group with 40% of isometric peak torque
214499666|NCT06823128|OTHER|Guideline-based therapy|Guideline-based therapy
214499667|NCT05605054|BEHAVIORAL|UCSD RELINK|UCSD RELINK coach-guided health literacy intervention and in-person service navigation assistance
214499668|NCT05605054|BEHAVIORAL|Self-study|Self-studying of programmatic information and list of service referrals
214499669|NCT05080777|BEHAVIORAL|Tele-Savvy|A low-risk, psychoeducational, group-based intervention, is grounded in social learning and stress process theory and its main goal is to produce improved caregiver mastery over the symptom management skills commonly encountered when supervising and caring at home for an older adult living with ADRD. Over the 7-week program, there are synchronous and asynchronous activities each week. The synchronous portion includes weekly scheduled videoconferences (60-80 min) that serve as an online classroom in which facilitators lead lectures and discussions. Daily, caregivers access online 6- to 15-min prerecorded videos, each focused on one main learning objective. Caregivers can watch the lessons whenever and as often as they wish.
214499670|NCT05080777|BEHAVIORAL|Caregiving During Crisis (Educational Program)|The attention control group will receive the self-guided Caregiving During Crisis program. Caregiving During Crisis is a fully online, asynchronous, professionally designed continuing education course aimed at developing the competency of informal caregivers of community-dwelling persons living with dementia to ensure the safety of that person and themselves during this time of the COVID-19 pandemic. The course, readily accessible by home computer or smartphone, describes methods of home infection control and prevention to create a Safe Home space, strategies for safely leaving and re-entering the home (e.g., to shop), additional strategies for safely allowing service personnel (e.g., home health aides or electricians) and select family members to enter the Safe Home space, and risk management strategies to frame decisions when/if COVID restrictions are relaxed or revoked.
214499671|NCT04705415|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
214499672|NCT04705415|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
214499673|NCT06230705|OTHER|Guided management|Guided Management
214687686|NCT02474940|BEHAVIORAL|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
214997196|NCT00003308|RADIATION|stereotactic radiosurgery|
214385232|NCT01003184|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once a week
214385233|NCT01003184|DRUG|insulin detemir|subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
214385234|NCT01280240|DRUG|Monofer(R)|Intravenous bolus injection given over app. 2 minutes only once
214385235|NCT06281262|DIAGNOSTIC_TEST|Peripheral blood collection|"The phenotypic characteristics of leukocytes will be compared between the groups to identify immunological markers of women at risk of preterm delivery.~Samples from the controls will be taken to define a baseline for the measured leukocyte populations."
214385236|NCT06281262|DIAGNOSTIC_TEST|Swab sample collection|Oral, vaginal and rectal swabs will be collected and stored for analysis of microbiota at the time of inclusion. At birth, oral, vaginal and rectal swabs and part of the placenta (placental tissue) will be collected for further analysis.
214997197|NCT02314013|DRUG|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
214997198|NCT03641157|OTHER|Easy Intubation|
214385237|NCT04114240|DRUG|Xybilun|Erectil dysfunction, Viagra generic (sildénafil)
214385238|NCT04535336|OTHER|Vitality acupunch (VA) exercise program|The VA had 3 phases and took 40 minutes to complete.
214385239|NCT04535336|OTHER|Control|Participants maintained their daily activities.
214385240|NCT02551744|DRUG|histamine-2 receptor antagonist group|famotidine tab 40 mg qd for 6 months.
214385241|NCT02551744|DRUG|proton pump inhibitor group|pantoprazole tab 40 mg qd for 6 months.
214499674|NCT06230705|OTHER|Self management|Self management
214997199|NCT01583088|DEVICE|phenique nerve stimulation NeurX™ (Synapse Biomedical)|phenique nerve stimulation NeurX™ (Synapse Biomedical)
214997200|NCT01583088|DEVICE|sham phrenic nerve stimulation|sham phenic nerve stimulation
214997201|NCT00658528|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
214385242|NCT04315714|OTHER|Yoga Program|Six-week, twice weekly, 60-minute private yoga program (delivered online/virtually via Zoom).
214385243|NCT01754883|DRUG|Lithium Carbonate|Oral Lithium carbonate to target serum levle of 0.6-0.8.
214997202|NCT00658528|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
214997203|NCT01937299|DRUG|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
214385244|NCT03662997|DEVICE|Bordered Five-Layer Foam Dressing|Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology
214385245|NCT03662997|DEVICE|Hydropolymer Foam Dressing|Hydropolymer, adhesive foam island dressing
214385246|NCT03662997|DEVICE|Hydrocellular Multi-Layer Foam Dressing|Multi-layered, hydrocellular foam dressing with silicone adhesive
214385247|NCT01719224|PROCEDURE|elevated body position|45 degrees elevated upper body position
214385248|NCT01719224|PROCEDURE|supine body position|non-elevated upper body position
214385249|NCT01777594|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
214385250|NCT01274065|GENETIC|Genetic analysis|The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
214385251|NCT04775121|OTHER|Deuterium Glucose|Oral administration of 20 g Deuterium Glucose on a 3-hour
214385252|NCT06272305|PROCEDURE|This research does not require any specific investigation and does not imply any modification of treatment.|Collection of data from the medical record for patients with a non specific carotid endarterectomy
214385253|NCT05602207|DRUG|Abrocitinib|100 mg Abrocitinib once daily (QD) for 12 weeks
214385254|NCT03767634|OTHER|Parenteral nutrition|Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
214385255|NCT00028860|BIOLOGICAL|filgrastim|
214997204|NCT01937299|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
214997205|NCT01937299|DRUG|Travoprost 0.004% ophthalmic solution|
214997206|NCT01918228|BEHAVIORAL|Talks about what science says about LBP|Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
214385256|NCT00028860|DRUG|carboplatin|
214385257|NCT00028860|DRUG|gemcitabine hydrochloride|
214385258|NCT00028860|DRUG|ifosfamide|
214997207|NCT03052621|PROCEDURE|Omental transposition|Harvesting the omentum to cover irradiated defects of breast cancer
214385259|NCT00028860|DRUG|paclitaxel|
214385260|NCT00028860|PROCEDURE|adjuvant therapy|
214385261|NCT03954457|BEHAVIORAL|A-CWS|The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.
214385262|NCT03954457|BEHAVIORAL|Standard Care Control|The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
214385263|NCT04848181|DRUG|cyproterone acetate|two weeks Cyproterone acetate administration before TURP
214385264|NCT04848181|DRUG|finasteride|two weeks finasteride administration before TURP
214385265|NCT04848181|DRUG|no treatment received|no treatment received before TURP
214499675|NCT06118138|COMBINATION_PRODUCT|Hyperbaric oxygen therapy (HBOT)|"HBOT is a medical treatment employed for various conditions. It entails breathing 100% oxygen within a pressurized chamber known as a hyperbaric chamber. This oxygen-rich environment promotes healing and aids in combating specific infections.~In this study, the investigators will administer HBOT using a hyperbaric chamber set to 2 times the normal atmospheric pressure, indicated as 2 atmosphere absolute (ATA). This pressure surge enhances oxygen dissolution into the bloodstream, surpassing levels achievable at sea level. The pressure will be raised incrementally, followed by HBOT sessions lasting for a total of 90 minutes. The 90-minute sessions include brief 5-minute intervals for ambient air every 20 minutes to ensure safety and comfort. Treatment will be conducted five days a week over eight weeks.~Supervised by competent healthcare professionals, HBOT is considered safe, with potential side effects primarily stemming from heightened pressure and, in rare cases, oxygen toxicity."
214499676|NCT06357468|OTHER|midwife-led births in low risk women in pregnancy|Pregnant women in the low-risk collective are cared for in a midwife-led delivery room if they wish to have a natural birth
214997208|NCT01550926|DRUG|120 mg orlistat|2 X60 mg capsule
214997209|NCT01550926|DRUG|60 mg orlistat|60 mg orlistat
214997210|NCT01550926|DRUG|orlistat experimental dose|experimental
214997211|NCT02835066|OTHER|Integrated Fitness Assessment|Undergo function/fitness assessment
214997212|NCT02835066|PROCEDURE|Psychosocial Assessment and Care|Undergo psychosocial health assessments
214997213|NCT02835066|PROCEDURE|Quality-of-Life Assessment|Complete EORTC QLQ-C30 and QLQ-LC13 questionnaires
214997214|NCT00051597|DRUG|SGN-30 (monoclonal antibody)|
214997215|NCT05808959|BEHAVIORAL|Education group|After the discharge training given at the clinic in the postoperative period, the participants will be given structured training on sexual health.
214997216|NCT03292302|DRUG|Placebo|Placebo comparator
214997217|NCT03292302|DRUG|ELX-02|Synthetic aminoglycoside
214997218|NCT00163059|DRUG|NMDA Antagonist, CP-101,606 (traxoprodil)|
214997219|NCT01276834|DRUG|everolimus|comparison of everolimus-based and CNI-based immunosuppression
214997220|NCT04801212|OTHER|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
214997221|NCT04801212|OTHER|core stability exercises|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
214385266|NCT05156463|COMBINATION_PRODUCT|PAI Tool and Exercise Coaching|Use of PAI tool and self-monitoring tools to increase physical activity and reduce sedentary behaviors. Participants will receive a personalized physical assessment and counseling from healthcare provider, exercise logs and a Garmin activity tracker to use between visits and 9 exercise coaching calls between clinical visits.
214385267|NCT04797325|DRUG|Vedolizumab|Repeatedly vedolizumab infusion at week 0, 2, 6, 14, 22
214385268|NCT04797325|DRUG|Prednisolone|tablet prednisolone plus infliximab in severe cases.
214385269|NCT02781896|DEVICE|pacing catheter|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the right ventricular pacing arm, rapid pacing is provided by a standard right ventricular pacing catheter.
214385270|NCT02781896|DEVICE|valve delivery guidewire|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the Left ventricular pacing arm, rapid pacing is provided via the valve-delivery guidewire inserted into the left ventricle. The cathode of an external pacemaker is placed on the external end of the guidewire using an alligator clamp. The TAVI catheter provides the necessary insulation. The anode is attached directly to the subcutaneous tissue at the femoral entry site (also using an alligator clamp).
214385271|NCT02183116|DRUG|Meloxicam|
214385272|NCT03462134|OTHER|Survey|Survey amongst orthopaedic surgeons
214499677|NCT06137768|DRUG|HRS-5965|HRS-5965
214499678|NCT06137768|DRUG|Placebo|Placebo.
214499679|NCT02473276|DRUG|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
214499680|NCT02473276|DRUG|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
214499681|NCT06474598|DRUG|MTX228|Tolimidone was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, tolimidone has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as Tolimidone, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabete
214499682|NCT06474598|DEVICE|DEXCOM G6|To monitor participants blood glucose levels continuously
214499683|NCT04721548|DRUG|Minoxidil Topical Foam|Apply 1 mL of solution twice a day.
214499684|NCT04721548|DRUG|Placebo|1 mL of solution twice a day.
214997222|NCT00056147|DRUG|denufosol tetrasodium (INS37217)|
214997223|NCT04017962|DRUG|Letermovir Pill|Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A). The maximum duration of LTV administration will be 14 weeks. Patients receiving oral medication will be administered a pill diary for drug compliance purposes. This will be administered and reconciled in clinic.
214997224|NCT04017962|OTHER|blood draw|Collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180.
214997225|NCT03183817|BEHAVIORAL|Person-centred care at distance|Person-centred care at distance through an eHealth platform
214997226|NCT01207960|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
214997227|NCT06381245|DIAGNOSTIC_TEST|PPG-based remote heart rhythm/rate monitoring|PPG-based remote heart rhythm/rate monitoring
214997228|NCT06381245|DIAGNOSTIC_TEST|ECG-based remote heart rhythm/rate monitoring|ECG-based remote heart rhythm/rate monitoring
214997229|NCT06381245|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography examination|Transthoracic and transesophageal echocardiography examination
214385273|NCT02641249|DEVICE|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
214385274|NCT02920151|OTHER|balance exercises circuit|Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
214385275|NCT03942380|DIAGNOSTIC_TEST|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA
214385276|NCT05739032|OTHER|Aerobic exercise and strength training|"Aerobic Exercise Training: The individuals in the study group were given aerobic exercise training at 70-80% of the 6MWT average speed. Patients performed exercise three days per week (twice under the supervision of a physiotherapist and once at home) for 30 minutes a day.~Strength Training: Lower and upper extremity strengthening training was performed three days a week, 3x10-12 repetitions per day, with the help of a resistance band suitable for muscle strength. Hip flexion, hip abduction, knee flexion, and knee extension exercises for the lower extremity, and shoulder flexion, shoulder extension, shoulder abduction, shoulder elevation, external rotation, horizontal shoulder abduction, and scapular adduction exercises for the upper extremity were performed."
214385277|NCT03853317|BIOLOGICAL|Avelumab|For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).
214385278|NCT03853317|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
214385279|NCT03853317|BIOLOGICAL|haNK™|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
214385280|NCT02289989|DRUG|Oregano extract cream|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
214385281|NCT02289989|DRUG|Hydrocortisone|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
214385282|NCT05342103|PROCEDURE|high flow oxygenation|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
214385283|NCT04885387|DEVICE|chest CT|chest CT pectus deformities diagnostic
214385284|NCT04885387|DEVICE|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device pectus deformities diagnostic
214385285|NCT01377558|OTHER|Aerobic endurance training intervention|"The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week"
214385286|NCT01377558|OTHER|Strength endurance training intervention|"The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week"
214385287|NCT01377558|OTHER|Combined aerobic endurance and strength endurance training|"week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week"
214385288|NCT00406419|DRUG|Methotrexate|Methotrexate tablet was administered orally at a dose 7.5-25 mg
214499685|NCT05742165|BEHAVIORAL|Time Restricted Eating (TRE)|TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.
214499686|NCT06760104|DIAGNOSTIC_TEST|Dental Plaque Detection Using AI Models|"1. AI Model Analysis:~   Description: Intraoral images of participants will be captured using standardized imaging techniques. These images will then be analyzed using various artificial intelligence models specifically designed for detecting dental plaque. The AI models will process the images to identify and quantify the presence of dental plaque.~2. Clinical Assessment:~Description: A qualified dentist will perform a traditional clinical examination of the participants to assess dental plaque using standard examination techniques. This will serve as the reference standard against which the AI models will be compared.~Study Procedures Image Acquisition: Intraoral images will be taken of each participant using \[ intraoral camera\].~AI Model Evaluation: The captured images will be analyzed using different AI algorithms, which may include."
214499687|NCT06719492|BEHAVIORAL|nutrition education|15 minutes of surgery specific nutrition education provided by a Registered Dietitian.
214499688|NCT06820827|OTHER|Myofascial release|The participants will receive myofascial release (MFR) on erector spinae, quadratus lumborum, piriformis and gluteus medius. The duration of MFR for each muscle will be 90 to 120 seconds, three times/week for eight weeks.
214385289|NCT00406419|DRUG|ocrelizumab|Ocrelizumab was administered via IV infusion at a dose specified in arm description
214499689|NCT06820827|DEVICE|High-power pain threshold ultrasound|The participants will receive high-power pain threshold ultrasound on sacroiliac joint, 20 minutes, three times/week for eight weeks.
214499690|NCT06763263|BEHAVIORAL|Experimental|Children and their parents in this group will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. Then, the child will be allowed to choose one of the superhero clothes he/she wants in his/her room and will be allowed to wear the clothes. The superhero figure will be shown to him/her and he/she will be allowed to play with the clothes and the figure for 2 hours.
214997230|NCT06381245|DIAGNOSTIC_TEST|Liver ultrasound examination|Liver ultrasound examination
214997231|NCT06381245|DIAGNOSTIC_TEST|Rotational angiography with three-dimensional reconstruction|Rotational angiography with three-dimensional reconstruction
214385290|NCT00406419|DRUG|Placebo|Matching placebo to ocrelizumab was administered via IV infusion
214997232|NCT06381245|DIAGNOSTIC_TEST|Blood-derived biomarker analysis|Blood-derived biomarker analysis
214997233|NCT06381245|DIAGNOSTIC_TEST|Mobile health-based spirometry|Mobile health-based spirometry
214385291|NCT01937637|BEHAVIORAL|Cognitive Behavioral Intervention for Breathlessness|Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
214385292|NCT03246243|DEVICE|nfant feeding solution|The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.
214385293|NCT01903343|DEVICE|shear wave elastography|ultrasound
214385294|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
214385295|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
214385296|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
214385297|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
214385298|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension BID
214385299|NCT06153940|DEVICE|Treatment|"The Everglade™ Stem, is a second generation cementless blade style hip stem Forged in Titanium and proximally Antero-Posterior (AP) flared with Titanium Plasma Spray + Hydroxyapatite (TPS + HA) coated for bone on-growth.~The stem has distal geometry and a polished anodized surface finish to minimize the stem hanging in Dorr A femurs.~The World Acetabular Cup is a porous coated and mated with the Cross-linked polyethylene World Liner"
214385300|NCT00099723|DRUG|VSL#3|
214385301|NCT06159413|DEVICE|VIRTUAL REALITY|LUMBAR MULTIFIDUS MUSCLES FUNCTION AMONG PATIENTS WITH LOW BACK PAIN: VIRTUAL REALITY VERSUS STABILIZATION EXERCISES.
214385302|NCT04911062|DRUG|Bupivacaine HCI without epinephrine|100 mg administered via injection into the surgical site.
214385303|NCT04911062|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
214385304|NCT04911062|DEVICE|Luer Lock Applicator|Applicator for instillation.
214385305|NCT01535274|OTHER|Inspired oxygen fraction / end tidal carbon dioxide|"Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~1. FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~2. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~3. FIO2 100%, PETCO2 30mmHg - beach chair position.~4. FIO2 100%, PETCO2 45mmHg - beach chair position.~5. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position."
214385306|NCT03679767|DRUG|Retifanlimab|Retifanlimab administered intravenously at 500 mg every 4 weeks
214499691|NCT06763263|BEHAVIORAL|Control|The children in this group and their parents will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. The children will be evaluated in terms of their reactions after their hospitalization, they will not be dressed in any clothing and no superhero figures will be used. Then the questionnaire will be filled out again and scoring will be done. In order to prevent ethical bias before discharge, the child will be dressed in a superhero costume and will be allowed to spend time with the clothing and figure.
214499692|NCT03324425|DRUG|Simvastatin 80mg|Participants will receive simvastatin 80 mg by mouth daily at bedtime
214499693|NCT05200572|BEHAVIORAL|Dyadic Life Review (DLR)|DLR will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes. Each session will facilitate a recall of each phase of life: childhood, adolescence, young adulthood, mid-life, earlier later life, and later life. While together, the patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life.
214499694|NCT06936410|DRUG|Lidocaine 2% Injectable Solution|patients received Lidocaine 2%, 1 mg/kg, IV bolus over 10 mins after the induction of anaesthesia , followed by Lidocaine infusion (2 mg/kg/h) diluted in 50 ml of normal saline with a maximum dose of 200 mg/h. The tourniquet was inflated 10 minutes after the start of the Lidocaine infusion then the Lidocaine infusion stopped at the time of tourniquet deflation
214499695|NCT06936410|DRUG|Dexmedetomidine HCL Injection|patients received a loading dose of Dexmedetomidine-Pfizer (0.8 μg·kg-1 over 10 min) followed by continuous infusion of Dexmedetomidine (0.4 μg·kg-1.h-1) diluted in 50 ml of normal saline. The tourniquet was inflated 10 mins after the start of Dexmedetomidine infusion then the Dexmedetomidine infusion stopped at the time of the tourniquet deflation.
214385307|NCT05014321|DEVICE|EC16 medical device (CE marked)|Application on brown spots located on the face (1 treatment during the study).
214385308|NCT05014321|DEVICE|device prototype (810A-v1)|Application on brown spots located on the face (4 treatments during the study).
214385309|NCT05014321|DEVICE|device prototype (810B-v1)|Application on brown spots located on the face (4 treatments during the study).
214385310|NCT05014321|DEVICE|device prototype (810C-v1)|Application on brown spots located on the face (4 treatments during the study).
214385311|NCT03646903|BEHAVIORAL|Cognitive Bias Modification|Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.
214385312|NCT03646903|BEHAVIORAL|Psychoeducation|Psychoeducation-based interventions rely on the premise that enhancing knowledge about psychiatric symptoms and treatment will facilitate treatment engagement.
214385313|NCT04730843|DRUG|ES102|ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
214385314|NCT03999268|BEHAVIORAL|I-START|Designed as a supplementary educational tool for patients on insulin therapy, I-START includes an injection plan to reinforce the knowledge and behaviors that users have been taught by their health care provider. This is done through eight modules created for the benefit of new and experienced insulin users, and those using pens or vial/syringes. The modules address a variety of topics pertinent to insulin therapy, including overcoming psychosocial barriers, injection techniques and best practices, managing hypo- and hyperglycemic events, monitoring blood glucose and troubleshooting and problem solving. At the end of each module, users can self-evaluate their confidence in mastering the information presented. This gives them the ability to move forward into the next module, repeat material already presented and/or save features of the modules that they would like to revisit at another time.
214385315|NCT03999268|BEHAVIORAL|Standard Insulin Administration Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
214499696|NCT06769789|OTHER|Drug free invitro activation Ovary|Drug free invitro activation Ovary
214499697|NCT06768892|OTHER|Dietary Intervention|Each study participant will offer a tailored diet regimen according to age, sex, health status, physical activity and type of work either (office work or physical demanding work) after A 24-hour Dietary recall to calculate average calories requirements for each study participant separately. The participants' meals will be based on Mediterranean Diet and The Dietary Approaches to Stopping Hypertension (DASH Diet) as they proved effectiveness in lowering the risk of cardiovascular disease, insulin resistance, hypertension, obesity and Metabolic Syndrome. Dietary intervention aimed to the extent that 5-10% reduction in body weight, following the guideline of prevention and treatment of obesity.
214499698|NCT06768892|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT method will be adapted and customized to facilitate a transition towards a heightened level of physical activity and to address the emotional and practical difficulties associated with weight loss. This encompassed assisting the participants in establishing attainable weight loss goals, identifying individualized approaches to manage appetite, sustaining healthy habits, and navigating social environments and circumstances related to food. The aforementioned factors were deliberated upon within the context of both group-based and individual settings, adhering to a meticulously customized guideline. This guideline encompassed the incorporation of positive thinking tactics, accompanied by assigned tasks to be completed between each session. The Cognitive Behavioral Therapy (CBT) intervention was administered as a 20-minute component within the weekly therapy sessions. cognitive-behavioral therapy (CBT) in conjunction with lif
214385316|NCT00061516|DRUG|BETAXON (levobetaxolol HCl)|levobetaxolol suspension, 0.5%
214687687|NCT02474940|BEHAVIORAL|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
214687688|NCT02474940|BEHAVIORAL|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
214687689|NCT04255186|DEVICE|Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
214687690|NCT04255186|DEVICE|Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
214687691|NCT04255186|DEVICE|Sham stimulation|a simulated stimulation protocol so that the device does not emit current
214687692|NCT03884660|DEVICE|remede System|Patients undergoing a remede System implant attempt. Study devices will be used per approved indications for use for each geography.
214385317|NCT00061516|DRUG|AZOPT (brinzolamide)|brinzolamide suspension, 1%
214385318|NCT05650944|DIAGNOSTIC_TEST|Hemogram|Sysmex XN-1000 hematological analyzer
214385319|NCT00852670|DRUG|ACT-128800|ACT-128800 administered orally once daily
214385320|NCT00852670|DRUG|Placebo|Matching placebo capsules administered orally once daily
214499699|NCT06768892|OTHER|Physical exercise training|A weekly session of physical exercise training lasting 10 to 20 minutes will be incorporated at the workplace. The primary objective of the sessions was to increase muscle mass in the lower limbs for the purpose of sustaining physical capacity and boosting quiescent metabolism. The exercises comprised squats involving one or two legs, performed with or without dumbbells and core balls, as well as lunges performed while strolling forward and to each side. Additional exercises that emphasized overall strength encompassed shoulder and arm movements, as well as abdominal and back extension exercises. Participants were encouraged to execute the strength training exercises depicted in the program's takeout pamphlets twice per week. Furthermore, participants will be motivated to engage in aerobic leisure activities for a duration of two hours per week, including bicycling, walking, running, swimming, or participating in various sports.
214687693|NCT03084575|PROCEDURE|Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy|Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.
214687694|NCT03084575|DRUG|hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)|L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.
214687695|NCT03084575|DEVICE|Thermal RF lesioning is done using Bailys RF generator|
215093447|NCT04129710|DRUG|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
214997234|NCT03907345|BEHAVIORAL|Exposure|The exposure session comprises a hierarchy of 7 steps, reaching from (1) holding a glass with the spider 30cm in from the body / face, to (7) letting the spider walk on the arm. The exposure session has a duration of 120 minutes. Prior to the exposure, participants receive psychoeducation on anxiety and phobias. A house spider (Tegenaria domestica) is used for the exposure.
214385321|NCT02538770|OTHER|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
214385322|NCT02538770|OTHER|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
214385323|NCT02400437|DRUG|Ixazomib|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
214385324|NCT02400437|DRUG|Dexamethasone|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
214385325|NCT02400437|DRUG|Rituximab|Doses given on Day 1 of induction and maintenance cycles.
214385326|NCT06199661|BEHAVIORAL|APEX|Three phases: warm-up, high-intensity interval training (HIIT) phase, cool-down. A 10-minute warm-up included deep breathing meditation and dynamic joint mobility exercises. Then, a 40-minute strength and balance workout in HIIT format with five different high-intensity (HI) exercises interspersed with five different postural stability recovery exercises. The HI intervals focused on enhancing cardiovascular fitness, muscle strength, and motor performance. The recovery intervals incorporated balance and mobility exercises. The HI exercises lasted 30 seconds for the first three weeks and then increased to 45 seconds in the fourth week while the recovery exercises lasted 60 seconds throughout the entire intervention. The HIIT phase was repeated three times in the 40 minute block. Lastly, a 10-minute cooldown consisting of standing and seated exercises similar to the warm-up.
214997235|NCT03793153|PROCEDURE|Uterine Cooling Technique|Standard LSCS will be done except immediatelyfollowing delivery of the fetus the uterus will beexternalized in the usual fashion and the body of theuterus cephalad to the hysterotomy incision will bewrapped in sterile surgical towels saturated in sterile,iced normal saline. These towels will come from asterile cooling pot set to 30 degrees Fahrenheit. Theskin of the abdomen will be draped to prevent contactwith the cold towels. Iced saline-soaked towels will bekept in place for a minimum of 5 minutes and replacedat the discretion of the attending obstetrician until thehysterotomy is closed and the uterus is replaced intothe patient's abdomen.
214997236|NCT05590468|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)
214997237|NCT05590468|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
214997238|NCT02071498|DEVICE|Pillbox app named ALICE|Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record
214997239|NCT02071498|OTHER|oral and written information|oral and written information about the most common errors of patients
214997240|NCT04311957|DRUG|Continuation of boosted PI|"Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs"
214997241|NCT04311957|DRUG|B/F/TAF|Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
214997242|NCT04165057|OTHER|Optimal muscle tension management|including TOF monitor and reversal of neuromuscular blockade agent : sugammadex
214997243|NCT00101959|DRUG|Rebif|
215093448|NCT04129710|DRUG|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
214385327|NCT02088632|BIOLOGICAL|Incobotulinumtoxina|Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.
214385328|NCT02088632|OTHER|Placebo Comparator|Normal saline is sterile sodium chloride without and preservatives.
214997244|NCT02061800|DEVICE|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
215093449|NCT04129710|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
215093450|NCT04129710|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
215093451|NCT04129710|DRUG|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
215093452|NCT04129710|DRUG|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
215093453|NCT03444012|DRUG|ticagrelor 90 mg|persistence and adherence on ticagrelor in ACS patients
214385329|NCT05646199|DRUG|Metformin|Participants will receive metformin
214385330|NCT05646199|DRUG|Semaglutide Injectable Product|Participants in this group will receive injectable Semaglutide
214385331|NCT00621816|DRUG|nitroprusside|nitroprusside continuous infusion, dose to be titrated to clinical effect
214385332|NCT00621816|DRUG|placebo infusion|blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
214385333|NCT00004202|DRUG|carboplatin|
214385334|NCT00004202|DRUG|chemotherapy|
214385335|NCT00004202|DRUG|efaproxiral|
214385336|NCT00004202|DRUG|paclitaxel|
214385337|NCT00004202|RADIATION|radiation therapy|
214385338|NCT03179813|PROCEDURE|Hydrocortisone|During the third molar extraction the hydrocortisone solution will be used in the test group
214385339|NCT03179813|PROCEDURE|Control|During the third molar extraction the saline solution will be used in the control group
214385340|NCT02101918|RADIATION|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
214385341|NCT02101918|OTHER|Laboratory Biomarker Analysis|Correlative studies
214385342|NCT02101918|BIOLOGICAL|Ziv-Aflibercept|Given IV
214385343|NCT00882921|BIOLOGICAL|Idursulfase|Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
214385344|NCT04845035|DRUG|Dasatinib|By mouth
214385345|NCT04845035|DRUG|Ponatinib|By mouth
214385346|NCT04845035|DRUG|Berlin-Frankfurt-Münster Chemotherapy|with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone
214385347|NCT04845035|DRUG|Methotrexate and Cytarabine|Intrathecal
214385348|NCT02009696|DEVICE|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
214385349|NCT02009696|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
214385350|NCT03581123|BEHAVIORAL|Supported-Self Management (SSM)|Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
214385351|NCT03581123|OTHER|Spinal Manipulation Therapy (SMT)|SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
214385352|NCT03581123|COMBINATION_PRODUCT|SMT + SSM|Combination Treatment
214385353|NCT03581123|DRUG|Standard Medical Care (SMC)|Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
214385354|NCT05907577|OTHER|Observational|No interventions.
214385355|NCT01364974|DRUG|ASP015K|oral
214385356|NCT01364974|DRUG|Placebo|oral
214385357|NCT04483934|BIOLOGICAL|Dermal fibroblasts|"Cultured autologous dermal fibroblasts.~For PR: The name dermal fibroblasts is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
214385358|NCT04483934|DEVICE|LED phototherapy|LED phototherapy
214385359|NCT01790360|BEHAVIORAL|Patient Navigation (PN) Intervention|Patient Navigation is defined as an individual relationship between a navigator and participant to promote retention in the continuum of HIV care . For this study, three experienced navigators will be hired. Their primary role will be to ensure that participants are linked to an HIV primary care provider, that they attend at least one scheduled visit within three months of receiving a confirmed HIV diagnosis, and that they are retained in care (as defined by attending three HIV visits within nine months of diagnosis). To promote linkage to HIV care, navigators will help participants identify material and other barriers to accessing care and will work with participants to overcome those barriers.
214385360|NCT01790360|BEHAVIORAL|Financial Incentives (FI) Intervention|After confirmation that they have completed their first HIV primary care visit, Financial Incentive participants will receive a gift card. Additionally, the coordinator will flip a coin and give participants a bonus gift card if the coin flip comes up heads. Participants who attend the second HIV primary care visit will receive a gift card. Patients who attend a third HIV primary care visit will receive a gift card. Study staff will be responsible for confirming participants' attendance at appointments.
214385361|NCT05903716|DIAGNOSTIC_TEST|Hormone|At baseline 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated from all patients
214385362|NCT05903716|DRUG|Isotretinoin|İn the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method
214385363|NCT05527730|DEVICE|Comparison of PRO-FIT or SELF-FIT fitting|add
214385364|NCT03910348|DEVICE|Whole-body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA).
214385365|NCT03910348|OTHER|High-impact exercise|In the high-impact exercise program, the patients were asked to jump using a jump-rope at the beginning of each session
214499700|NCT03773107|DRUG|Carfilzomib|Irreversible proteasome inhibitor
214499701|NCT03773107|DRUG|Ruxolitinib|Oral JAK inhibitor
214499702|NCT03773107|DRUG|Dexamethasone|glucocorticoid
214499703|NCT06759493|DIAGNOSTIC_TEST|Retinol isotope dilution technique|A group of 60 school children will be recruited through a stratified sampling. To this first group of 60 school children a retinol isotope dilution (RID) test for total body store assessment will be applied. The remaining 98 school children will be recruited according to stratified sampling and divided into two groups of 49 children (females and males). To these groups of children, the modified relative dose response (MRDR) test, a qualitative measure of vitamin A status will be used to investigate the absorption of 3,4-didehydroretinyl acetate in oil.
214499704|NCT00984815|DRUG|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
214499705|NCT06945809|DEVICE|WeFlow-EndoPatch Aortic Endovascular Patch System|The WeFlow-EndoPatch Aortic Endovascular Patch System for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
214499706|NCT06945809|OTHER|Conventional Treatment group|Doctors prescribe conventional medicines and regular imaging tests.
214499707|NCT05001139|DEVICE|Relizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
214499708|NCT06943950|DRUG|SYHX1901|Administered orally, once daily (QD)
214499709|NCT06952374|DEVICE|SmartWave Lithotripsy balloon|ntravascular lithotripsy is an approved adjunct interventional therapy in treating calcified lesions to facilitate stenotic lesion opening in peripheral vascular disease and coronary artery disease. The off-label use of current peripheral lithotripsy balloon in mitral valve as a compassionate treatment or as an adjunct treatment before mitral balloon valvuloplasty and transcatheter mitral valve replacement has been reported with success . A possible mechanism is that lithotripsy preferentially impacts hard tissue, disrupts calcium, and leaves soft tissue undisturbed, improving valve pliability, preventing leaflet damage, and making subsequent valvuloplasty safer.
214997245|NCT02061800|DRUG|Thiotepa|Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
214385366|NCT06534970|DEVICE|Three-dimensional stereophotogrammetry|Three stereoscopic photographs
214997246|NCT02061800|DRUG|Cyclophosphamide|Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
214997247|NCT02061800|DRUG|Alemtuzumab|Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
214385367|NCT06534970|OTHER|Questionnaires|"* SF-36 quality of life scale for general health inquiry~* Rosenberg Self-Esteem Scale~* Self-perception scale"
214385368|NCT03671733|DRUG|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
214499710|NCT06952036|PROCEDURE|Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C|Initiated Standard DAA treatment among HCV RNA positive patients.
214687696|NCT04009096|BIOLOGICAL|ChAd63 PvDBP and MVA PvDBP|one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
214997248|NCT02061800|DRUG|Tacrolimus|Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
214997249|NCT02061800|DRUG|Melphalan|Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
214385369|NCT03671733|DRUG|Exenatide|10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
214385370|NCT03671733|DRUG|Exenatide Microspheres for Injection|Exenatide 2 mg injection once weekly for 12 weeks.
214385371|NCT04844437|DIAGNOSTIC_TEST|Transperineal ultrasound|The fetal head station is evaluated by transperineal ultrasonography in valsalva.
214385372|NCT05545241|BEHAVIORAL|Neurofeedback + BART/EEG|"10 sessions of emotional neurofeedback (max of 2 sessions per week and max of 10 weeks).~Before (Baseline, Day 0) and at the study completion (after 10 neurofeedback sessions, Week 5), a EEG record is realized during the BART, assessing risk-taking behavior."
214687697|NCT06334822|DEVICE|Heartfelt Device installed|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
214687698|NCT06334822|OTHER|Standard care|Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation.
214997250|NCT02061800|DRUG|Busulfan|Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
214997251|NCT02061800|DRUG|Fludarabine|Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
214385373|NCT05545241|BEHAVIORAL|BART/EEG only|only the twice EEG record are realized during the BART, assessing risk-taking behavior (every corresponding to the pre and post-neurofeedback evaluations in arm I)
214385374|NCT02039661|DRUG|Lidocaine Spray|These patients received 2 puff lidocaine spray
214385375|NCT02039661|DRUG|Placebo|
214385376|NCT05115409|DRUG|Anti-PD-1 Antibody Plus Chidamide and Rituximab|Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks
214385377|NCT05490329|BEHAVIORAL|Tough Talks COVID|Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
214385378|NCT04407351|DEVICE|Green LED light|Investigators arrange 12 weeks green LED light phototherapy.
214385379|NCT04407351|DEVICE|Red LED light (placebo)|Investigators arrange 12 weeks red LED light phototherapy (placebo).
214385380|NCT00447954|COMBINATION_PRODUCT|High Dose NT-501 implant|High Dose NT-501
214385381|NCT00447954|COMBINATION_PRODUCT|Low Dose NT-501 implant|Low Dose NT-501
214385382|NCT00447954|OTHER|Sham|Sham Procedure
214385383|NCT04707339|PROCEDURE|Appendicectomy|Laparoscopic or Open Appendicectomy
214385384|NCT05363969|DEVICE|Fractionated laser resurfacing|Patients will receive 3-4 treatments with fractionated laser resurfacing
214385385|NCT00856661|DRUG|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
214385386|NCT00856661|DRUG|Placebo|IV, single bolus over 1 to 2 minutes on 1st day
214385387|NCT05480670|DIETARY_SUPPLEMENT|Berberine|550 mg Berberine supplement BDS for 3-months + changes in diet/life style.
214385388|NCT02120664|DRUG|Florbetapir (18F)|
214385389|NCT02120664|DRUG|11C-PiB|
214385390|NCT04966143|BIOLOGICAL|LY011|Targeting CLDN 18.2 Car-T injection
214687699|NCT06334822|OTHER|Questionnaires|Patients are presented with one or more optional questionnaires (some validated, some bespoke)
214687700|NCT06334822|DEVICE|Heartfelt Device in pharmacy|Device used monthly in the pharmacy, with the assistance of the pharmacist, and capturing foot volume data which are processed in the cloud.
214687701|NCT06334822|DEVICE|Heartfelt device alerting system|The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.
214687702|NCT05151471|DRUG|MT-1186|Oral edaravone
214385391|NCT06050902|DEVICE|Subclavian venipuncture for catheter placement using the needle-steering device|"1. Navigation software is implemented in an ultrasound machine.~2. A linear ultrasound probe (similar in appearance to a standard ultrasound probe) is used~3. Magnetization of the puncture needle after short introduction of the needle in a dedicated device.~4. Real time needle guidance on the ultrasound screen during the puncture."
214385392|NCT01473472|DRUG|Truvada|2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
214385393|NCT01473472|DRUG|Placebo|2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
214385394|NCT04321967|DRUG|Nitroglycerin Paste|1g of 2% Nitroglycerin paste topical application
214385395|NCT04321967|DRUG|Dermabond|Topical skin adhesive
214499711|NCT06948045|PROCEDURE|PLLA application to the mandibular angle|The investigator will mark the application area by palpating the inferior and posterior boundaries of the face and the mandibular ramus, approximately 1 cm from these anatomical landmarks. The second PLLA injection point will be marked 1 cm from the inferior bony border of the mandible, anterior to the mandibular ligament. The demarcated area will be anesthetized with a local infiltration of 0.3-0.5 mL of 1% lidocaine with epinephrine, using a 30G needle. PLLA will then be reconstituted in 10 mL of sterile water for injection. Administration will be performed with a 30G needle inserted perpendicularly into the marked area until the supraperiosteal plane of the mandibular angle is reached, delivering a 0.7 mL bolus of the reconstituted product. At the second site-1 cm from the inferior bony border of the mandible, anterior to the mandibular ligament-a 0.2 mL dose of the reconstituted product will be injected.
214499712|NCT06951724|DEVICE|Aspiration Catheter|Thrombus aspiration using Aspiration Catheter
214499713|NCT06951724|DEVICE|Export Advance Aspiration Catheter|Thrombus aspiration using Export Advance Aspiration Catheter
214499714|NCT06951841|DRUG|Liposome Irinotecan|Liposome irinotecan(50mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
214499715|NCT06951841|DRUG|Platinum|Carboplatin (AUC 4-5) or Cisplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
214499716|NCT06951841|DRUG|Tislelizumab|Tislelizumab (200mg) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
214499717|NCT06951841|DRUG|Anlotinib|Anlotinib (8mg) will be administered orally in a 3-week treatment cycle, once a day from day 1 to day 14 of each cycle
214499718|NCT06953258|OTHER|Home-based eccentric training at long muscle length|The training program will include conventional resistance exercises, with progressive increases in intensity and volume tailored to each participant's capabilities. In this condition, specific to the Arm #1, four specific exercises targeting the knee extensors and plantar flexors will be performed at long muscle lengths.
214499719|NCT06953258|OTHER|Conventional home-based training|The training program will include conventional resistance exercises, with progressive increases in intensity and volume tailored to each participant's capabilities. In this condition, specific to the Arm#2, four specific exercises targeting the knee extensors and plantar flexors will be performed in a conventional manner (i.e., at neutral or shorter muscle lengths).
214687703|NCT05151471|DRUG|Placebo|Oral
214687704|NCT00824187|DRUG|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
214997252|NCT02061800|DRUG|Methylprednisolone|Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
214997253|NCT02695407|OTHER|3 days cannulation|assessment of artery stenosis after 3 days of artery cannulation
214997254|NCT02695407|OTHER|5 days cannulation|assessment of artery stenosis after 5 days of artery cannulation
214385396|NCT05334927|BEHAVIORAL|Medicine Overuse Headache/New Daily Persistent Headache|At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
214385397|NCT05334927|BEHAVIORAL|Chronic Migraine|long-term follow-up
214385398|NCT05334927|BEHAVIORAL|Patients with other types of primary headache|No collection Brain imaging、Cognitive function test、Biological sample
214385399|NCT00105586|DRUG|Escitalopram|Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
214385400|NCT02306122|BEHAVIORAL|Pharmacist calls patient unless physician cancels call|
214385401|NCT02306122|BEHAVIORAL|Patient nonadherence information sent to physician|
214997255|NCT03517982|DRUG|Mycophenolate Mofetil|Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil
214997256|NCT03725553|DRUG|Intramyometrial Vasopressin|a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
214997257|NCT03725553|DRUG|Placebo|the group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)as soon as the umbilical cord was clamped.
214997258|NCT02013362|DRUG|Pralatrexate injection|
214997259|NCT02013362|DIETARY_SUPPLEMENT|Vitamin B12|
214997260|NCT02013362|DIETARY_SUPPLEMENT|Folic Acid|
214385402|NCT02306122|BEHAVIORAL|Pharmacist calls patient if physician requests call|
214385403|NCT02306122|BEHAVIORAL|Doctor receives information and may be allowed certain actions|
214385404|NCT00854516|PROCEDURE|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|"Procedure Schedule: The total duration for study participation will be 14 days (8 visits).~Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days."
214997261|NCT06418867|BEHAVIORAL|Mindfulness|Mindfulness Practice including 6 sessions with 1 hour for each
214385405|NCT02260505|DRUG|Imatinib maintenance|Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
214385406|NCT04011579|OTHER|MSFIT|MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
214385407|NCT02514421|DEVICE|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
214385408|NCT02514421|DRUG|gemcitabine|The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
214385409|NCT02514421|DRUG|nab-paclitaxel|The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
214385410|NCT01279733|GENETIC|Microarray analysis|"Microarray performed on prenatal specimen:~Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.~Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed."
214385411|NCT01534884|BIOLOGICAL|rituximab|1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
214385412|NCT02955121|OTHER|Prescriber Access to Genetic Information|
214385413|NCT05643820|DRUG|Permethrin 5% topical lotion|patients in group A prescribed with 5% topical permethrin lotion two overnight applications seven days apart
214385414|NCT05643820|DRUG|Ivermectin|patients in group B and weighing more than 15 kgs were given oral ivermectin 200 microgram/kg two doses seven days apart
214385415|NCT01606696|BEHAVIORAL|HIIT|Higher intensity interval training.
214385416|NCT01606696|BEHAVIORAL|Standard intensity non-interval training|Standard intensity non-interval training.
214385417|NCT01257659|PROCEDURE|STARR rectocele repair|The STARR transanal stapling system is used to repair a rectocele.
214385418|NCT01257659|PROCEDURE|Elevate mesh rectocele repair|A posterior Elevate mesh is placed transvaginally to repair a rectocele.
214687705|NCT00824187|DRUG|Placebo|Inert tablet
214687706|NCT01836575|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.
215093454|NCT03532217|BIOLOGICAL|PROSTVAC-V|-Replication-competent vaccinia virus which has been engineered to encode the sequences for a modified human prostate-specific antigen (PSA) and a triad of co-stimulatory molecules (TRICOM)
214385419|NCT00347516|PROCEDURE|IOL calculation formula|
214385420|NCT06335732|DIAGNOSTIC_TEST|Cross section study; single group related measurement design.|Two hundred pediatric physiotherapists from both genders were participated in the current study. They were selected randomly from the Outpatient Clinic of pediatric physiotherapists of Hospitals of Ministry of Health in Cairo-Egypt, the duration of this study was six months started from December 2022 to June 2023
214385421|NCT00671905|PROCEDURE|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
214687707|NCT01836575|DRUG|Carboplatin|Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\].
214385422|NCT00671905|PROCEDURE|PV isolation|Circumferential PV isolation
214385423|NCT05494229|OTHER|Pars-plana vitrectomy|Pars-plana vitrectomy
214385424|NCT01320423|PROCEDURE|Surgical Trial|Surgical Trial in Lobar Intracerebral Haemorrhage
214385425|NCT00886639|OTHER|6MWT with oxygen|2 liter per minute as continuous-flow
214385426|NCT00886639|OTHER|6MWT with medical air|2 liters as continuous-flow
214385427|NCT00308932|DRUG|HFA FP MDI|
214385428|NCT02974816|DEVICE|Glooko's mobile application|Standard of care and Remote monitoring
214385429|NCT03203694|BEHAVIORAL|Walking: Intervention arm in diabetics|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
214385430|NCT03203694|OTHER|Walking: No intervention in diabetics|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
214385431|NCT03203694|OTHER|Walking: Healthy cohort as reference controls|Subjects will be studied at one time only.
214385432|NCT03203694|BEHAVIORAL|Lower body heating: Intervention arm in healthy subjects|This intervention consists of 60 minutes of lower body heating (40-42 degree C).
214385433|NCT03203694|BEHAVIORAL|Lower body heating: Intervention arm in diabetics|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
214385434|NCT03203694|OTHER|Lower body heating: Healthy cohort as reference controls|Subjects will be studied at one time only.
214385435|NCT05932056|BEHAVIORAL|Miles de Manos (Thousands of Hands)|Miles de Manos (Thousands of Hands) is a school-based group intervention that incorporates elements of evidence-based behavior management interventions in parent, teacher, and parent-teacher joint sessions.
214385436|NCT04195529|GENETIC|presence of genetic variants|identification of the presence of genetic variants
214385437|NCT05603832|DRUG|F14|625 mg intra-articular sustained-release celecoxib
214385438|NCT05603832|DRUG|0.25 % Bupivacaine HCl|Local anesthetic
214385439|NCT05603832|DRUG|Acetaminophen|Analgesic
215093455|NCT03532217|BIOLOGICAL|PROSTVAC-F|-Fowlpox virus which does not replicate in human cells and has been engineered to encode the same sequences present in PROSTVAC-V.
215093456|NCT03532217|DRUG|Nivolumab|-Nivolumab is a human monoclonal antibody (mAb)
215093457|NCT03532217|DRUG|Ipilimumab|-Ipilimumab is a mAb blocking the inhibitory signal mediated by cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system.
215093458|NCT03532217|BIOLOGICAL|Neoantigen DNA vaccine|Each DNA vaccination will be 1 mL vaccine administered intramuscularly. At each vaccination time point, patients will receive two injections at separate sites.
214385440|NCT05603832|DRUG|Methocarbamol|Muscle relaxant
214385441|NCT03454425|DEVICE|Exablate Subthalamotomy|ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
214385442|NCT03454425|DEVICE|Sham Exablate Subthalamotomy|Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
214385443|NCT01215214|DRUG|midazolam|midazolam: 3mg iv
214385444|NCT02578914|DRUG|NS2 Ophthalmic Drops (0.5%)|
214385445|NCT02578914|DRUG|NS2 Ophthalmic Drops Vehicle (0.0%)|
214385446|NCT02377960|BEHAVIORAL|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
214385447|NCT02377960|BEHAVIORAL|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
215093459|NCT03532217|DEVICE|TriGrid Delivery System|-Electroporation device
214385448|NCT02377960|BEHAVIORAL|Usual care|Usual care
214385449|NCT00230139|DEVICE|SPECT/CT|
215093460|NCT03532217|PROCEDURE|Tumor biopsy|-Pre-treatment, post-treatment A (optional), and end of treatment
215093461|NCT03532217|PROCEDURE|Peripheral blood|-At the time of pre-treatment biopsy, mid-treatment of chemo-ADT, at time of enrollment (prior to POSTVAC administration), mid-treatment A, mid-treatment B (multiple)
214385450|NCT04670003|OTHER|users|Data of users of the web-application
214385451|NCT03265990|PROCEDURE|ligasure haemroidectomy|In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.
214385452|NCT03265990|PROCEDURE|Conventional haemorrhoidectomy|"According to the Ferguson technique~* Manual anal sphincter stretching up to 4 fingers~* Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.~* skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.~After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed."
214385453|NCT05727943|DRUG|Clioquinol|add on clioquinol to concomitant ASM
214385454|NCT02069574|PROCEDURE|non-surgical periodontal therapy|
214385455|NCT02291484|DEVICE|Cardiac CT scan|CT-guided management
214385456|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
214385457|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
214385458|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
215093462|NCT03532217|PROCEDURE|Fecal samples|-Post chemo/pre-treatment A, post-treatment A, pre-treatment B, post-treatment B
215093463|NCT03532217|PROCEDURE|Leukapheresis|"* Post-treatment A/pre-treatment B~* Mid-Treatment B, after Cycle 9 Day 1 and prior to Cycle 10 Day 1~* End of treatment"
214385459|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
214385460|NCT00735644|BIOLOGICAL|Hepatitis A vaccine|0.5 mL, Intramuscular
214385461|NCT02961374|DRUG|Erlotinib|Given PO
214385462|NCT02961374|DRUG|Erlotinib Hydrochloride|Given PO
214385463|NCT00003344|DRUG|irinotecan hydrochloride|
214385464|NCT00003344|RADIATION|radiation therapy|
214385465|NCT03386955|DRUG|BPI-7711 Capsule|Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)
214385466|NCT03178513|OTHER|Home visit|"The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:~* Medical assessment~* Psychosocial assessment~* Medication reconciliation~* Follow-up of inpatient primary team's specific recommendations~* Follow-up, as needed, with primary care team or inpatient team"
214385467|NCT05815901|DRUG|Epaminurad 6 mg|Epaminurad 6 mg tablet
214385468|NCT05815901|DRUG|Epaminurad 9 mg|Epaminurad 9 mg tablet
214385469|NCT05815901|DRUG|Febuxostat 40 mg|Febuxostat 40 mg tablet
214385470|NCT05815901|DRUG|Febuxostat 80 mg|Febuxostat 80 mg tablet
214385471|NCT05815901|DRUG|Epaminurad 6 mg placebo|Placebo tablet
214385472|NCT05815901|DRUG|Epaminurad 9 mg placebo|Placebo tablet
214385473|NCT05815901|DRUG|Febuxostat 40 mg placebo|Placebo tablet
214385474|NCT05815901|DRUG|Febuxostat 80 mg placebo|Placebo tablet
214385475|NCT03835936|OTHER|High frequency compression of the chest wall group|The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.
214687708|NCT00314756|DRUG|imiquimod|
214687709|NCT03163199|DEVICE|Translesional Hemodynamic Measurement|Measurement of hemodynamics using the NAVVUS catheter during endovascular therapy
214687710|NCT02364206|DRUG|LY2228820|
214687711|NCT02364206|DRUG|Temozolomide|
214687712|NCT02364206|RADIATION|radiotherapy|
215093464|NCT03889548|OTHER|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
214997262|NCT01428245|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
214997263|NCT01428245|DRUG|Estrace (estrogen)|oral estrace, 0.5-1 mg once a day for seven days
214385476|NCT03835936|OTHER|Manual maneuvers physiotherapy group|20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
214385477|NCT04032379|OTHER|Standard treatment|No intervention, some patients have additional neuro-psychological testing.
214385478|NCT00002536|DRUG|cisplatin|
214499720|NCT06951529|OTHER|Reproductive violence education|The training content, which was created by obtaining expert opinions based on literature, will cover the violence that women are exposed to or may be exposed to according to the cycles they experience during their reproductive years. Definition of Violence and Its Effects on Women's Health, Adolescence and Menstruation Period Violence, Family Planning and Infertility Violence, Pregnancy and Birth-Related Violence, Menopause-Related Violence, Legal Processes in Combating Reproductive Violence.
214499721|NCT05697068|BEHAVIORAL|COVID Prevention Program (CPP)|This project is a promotor/a-led COVID-19 Prevention Program (CPP) for Latino patients of a Federally Qualified Health Center (FQHC) who are recently diagnosed with SARS-CoV-2. The program will implement immediate risk reduction strategies to prevent household spread of COVID-19, followed by risk reduction strategies to prevent community spread. Patients and household members who agree to participate will be patients of the FQHC (the covered entity) and will have completed a broad consent that authorizes program activities (e.g., COVID-19 testing, individualized counseling). Patients are free to refuse to participate in the CPP without impact on other services they may receive at the clinic. Research activities will be managed by study's measurement team, which involves surveys conducted on index patients at baseline, 1-, 6-, 12-, and 24-months. Written informed consent will be obtained for all research activities occurring outside of clinical care.
214499722|NCT02511574|DRUG|natural progesterone|
214499723|NCT02511574|DEVICE|cervical pessary|
214499724|NCT04300270|DEVICE|Smartphone PPG recordings|Smartphone camera PPG recordings using a novel software application.
214499725|NCT04300270|DEVICE|Smartphone ECG|Smartphone connected one-lead ECG recordings.
214499726|NCT05864209|OTHER|Phthalate- and Bisphenol-free Baby Products|3-month supply. Products include wipes and diaper cream.
214499727|NCT05864209|OTHER|Cloth Diapers|Subscription to cloth diaper service.
214499728|NCT05864209|OTHER|Conventional Disposable Diapers|3-month supply.
214499729|NCT05864209|OTHER|Conventional Baby Products|Products include wipes and diaper cream.
214499730|NCT06554509|DRUG|SHR-1819 injection|SHR-1819 injection
214499731|NCT06554509|DRUG|Placebo|placebo
214499732|NCT04257747|OTHER|MRI acquisitions|MRI acquisitions will be performed on the ACHIEVA 3T TX DStream Philips® Research MRI of the GIE Faire Faces.
214499733|NCT04257747|OTHER|Doppler ultrasound procedure|The Doppler ultrasound procedure will be conducted in the traditional way in the Vascular Medicine Department of the Amiens-Picardie University Hospital
214499734|NCT05671510|DRUG|Gotistobart|Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
214499735|NCT05671510|DRUG|Docetaxel|Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
214687713|NCT06502470|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
214997264|NCT06157476|OTHER|Stretch-shortening exercise|The SSC-Ex program was conducted for 35 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.
214385479|NCT00002536|DRUG|vincristine sulfate|
214385480|NCT00002536|PROCEDURE|surgical procedure|
214385481|NCT00002536|RADIATION|radiation therapy|
214385482|NCT01639794|DRUG|Vesitirim™ (Solifenacin)|Oral
214385483|NCT03966612|OTHER|Questionnaires|"Questionnaires about:~* Socio-professional situation~* Lifestyle~* Health~* NME 1~* specific breast cancer survey~* Imaging"
214385484|NCT03716674|DEVICE|Metronome|Patients completed 4 walking sessions of at least 10 minutes each. During each session, no auditory rhythm was given, or the rhythm of a Rhythmic Auditory Stimulation (RAS) adapted to the pace of comfort of each patient using a metronome was broadcasted via headphones. In all, 4 conditions were tested: walk with no RAS or an isochronous RAS or a random RAS or a RAS with an autocorrelated metronome rhythm.
214385485|NCT00296387|DRUG|Rosuvastatin|
214385486|NCT00296387|DRUG|Atorvastatin|
214499736|NCT06566950|PROCEDURE|Low load-BFRt|The participants' two legs will be subjected to 70% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
214499737|NCT06566950|PROCEDURE|Sham Low load-BFRt|The participants' two legs will be subjected to 10% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
214687714|NCT01236612|DRUG|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
214687715|NCT01236612|BIOLOGICAL|Immunization|Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
214687716|NCT01236612|BIOLOGICAL|Plasmodium falciparum Bloodstage challenge|Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
214385487|NCT00119990|DRUG|Icodextrin (dialysate)|2 liter of extraneal are given with one fill for 4 hours.
214385488|NCT00119990|DRUG|Physioneal (dialysate) 1.36% and 2.27%|2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
214385489|NCT01325649|PROCEDURE|total mesorectal excision / long course radiochemotherapy|long course 5-FU based radiochemotherapy before total mesorectal excision
214385490|NCT01325649|RADIATION|long course 5-FU bases radiochemotherapy|
214385491|NCT05126043|DIAGNOSTIC_TEST|Triglycerides/high density lipoprotein ratio|Lipid profile
214385492|NCT02587559|PROCEDURE|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
214997265|NCT06157476|OTHER|Standard exercise program|The standard exercise program lasted for 35 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, manual guidance, and functional training.
214997266|NCT01034553|DRUG|Aurora A kinase inhibitor MLN8237|Given orally
214997267|NCT01034553|DRUG|bortezomib|Given IV
214997268|NCT00489580|DEVICE|SaeboFlex Dynamic Hand Orthosis|
214997269|NCT00489580|PROCEDURE|Saebo F.T.M. Arm Training Program|
214997270|NCT01260948|DRUG|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
214997271|NCT01260948|DRUG|Aricept®|10 mg Orally Disintegrating Tablet
214997272|NCT05085145|BIOLOGICAL|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
214997273|NCT01067300|PROCEDURE|Transplantation of unrelated cord blood unit(s)|Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
214997274|NCT04151459|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
214997275|NCT05000762|DIETARY_SUPPLEMENT|Zinc|Zinc gluconate 30 mg/day orally
214997276|NCT03534219|DEVICE|EarPopper|The EP device is 510(K) regulated (510(K) Number K073401) as a non-surgical, non-drug related treatment for middle ear pressure problems. The device is based on the Politzer Maneuver, and works by opening the Eustachian tube by delivering a safe, constant stream of air into the nasal cavity. In clinical studies funded by the National Institutes of Health (Grant#: 5R44DC003613-03), the EarPopper has proven to be effective in reducing chronic middle ear effusions. By regularly aerating the middle ear, we hypothesize that the EarPopper device will be an effective prophylactic measure to reduce incidence of AOM in children with recurrent OM. The device delivers a jet of air pressure from the nozzle at 5.2PSI, at a volume velocity of 1,524mL/min.
214997277|NCT04552093|DRUG|Floxuridine|Administration of intra-arterial floxuridine via the HAIP (HAIP chemotherapy) to the liver with concomitant Dutch standard of care systemic FOLFOX (5-FU, leucovorin and oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan).
214997278|NCT04552093|DEVICE|Tricumed IP2000V infusion pump|Surgical implantation of hepatic artery infusion pump (HAIP) followed by administration of the combined chemotherapy (HAIP and systemic).
214997279|NCT00462462|DRUG|Ethanol 96% Gel|
214997280|NCT00462462|DRUG|Ethanol 98% Solution|
214997281|NCT04607031|DIAGNOSTIC_TEST|measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke|7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications
214385493|NCT03661034|DEVICE|GammaSense Stimulation System (non-invasive, non-significant risk)|Non-invasive, non-significant risk audio-visual sensory stimulation device
214997282|NCT03365245|DEVICE|Microperimetry|Microperimetry is performed at three different days
214997283|NCT03365245|DEVICE|automated visual field|Automated visual field ist performed at three different days
214687717|NCT01236612|BIOLOGICAL|Plasmodium falciparum mosquito challenge|Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
214687718|NCT01236612|DRUG|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
214687719|NCT02814968|DRUG|Enzalutamide|
214997284|NCT05193487|OTHER|inferior alveolar nerve block|inferior alveolar nerve block using Articaine 4% with 1/200000 Adrenaline and a traditional needle injection
214997285|NCT05193487|OTHER|intra-osseous mandibular anaesthesia|intra-osseous mandibular anaesthesia using Articaine 4% with 1/200000 Adrenaline and a special intra-osseous injection device
214997286|NCT00017160|DRUG|doxorubicin|
214997287|NCT00017160|DRUG|filgrastim|
214997288|NCT00017160|DRUG|ifosfamide|
214997289|NCT00017160|PROCEDURE|biological response modifier therapy|
214385494|NCT05096468|DRUG|S-ketamine and pregabalin|"* Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
214385495|NCT05096468|DRUG|Normal saline and placebo capsule|"* Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
214687720|NCT02814968|DEVICE|18-FDG PET/CT|
214687721|NCT02814968|DEVICE|Whole body MRI|
214997290|NCT00017160|PROCEDURE|brachytherapy|
214997291|NCT00017160|PROCEDURE|chemotherapy|
214997292|NCT00017160|PROCEDURE|colony-stimulating factor therapy|
214997293|NCT00017160|PROCEDURE|conventional surgery|
214997294|NCT00017160|PROCEDURE|cytokine therapy|
214385496|NCT05914025|BEHAVIORAL|Behavioral Activation|Individuals will be provided with information about maladaptive patterns of behavior and how to correct these cycles with activity scheduling to elicit more positive emotional experiences. Participants will be provided with categories/lists of activities and a downloadable calendar after receiving the psychoeducation.
214385497|NCT03274219|BIOLOGICAL|bb21217|autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution
214499738|NCT06566950|PROCEDURE|High load-Eccentric training|The physical therapist will instruct the participants to complete eccentric exercises at a maximum of 70% repetitions, such as stairs, single leg squat, and single leg deadlift.
214499739|NCT03762395|DRUG|CXA-10|6 weeks of treatment with 150 mg/day of orally administered CXA-10
214499740|NCT03762395|DRUG|Matching Placebo|6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
214499741|NCT06314672|PROCEDURE|Accrual|Participate in AEP
215093465|NCT06312241|BEHAVIORAL|Metacognitive Training-Silver BeWell|Metacognitive Training- Silver BeWell is a cognitive behavioral based group intervention, which focuses on helping participants gain (metacognitive) distance from thought and behavioral patterns as well as behaviors and ER-strategies that are implicated in the onset of depression and reduced overall mental well-being. In 10 modules, MCT-Silver addresses issues specific to later life such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life, acceptance of negative feelings and resilience. In the training participants are made aware of information processing biases that have been shown to contribute to the onset of depression through engaging exercises using examples from daily life. Groups are comprised of up to 10 participants. Each session is 90 minutes.
215093466|NCT01304407|OTHER|Calcium stable isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
215093467|NCT00559130|DEVICE|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
215093468|NCT06031545|OTHER|Long peripheral venous catheters for use|Long peripheral venous catheters for use during the perioperative period in obese patients
214997295|NCT00017160|PROCEDURE|intraoperative radiotherapy|
214997296|NCT00017160|PROCEDURE|radiation therapy|
214997297|NCT00017160|PROCEDURE|surgery|
214997298|NCT03979404|DEVICE|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
214997299|NCT03024372|DEVICE|AV Fistula creation with sutures|End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
215093469|NCT06031545|OTHER|Midline catheter|Midline catheters for use during the perioperative period in obese patients
215093470|NCT06188299|OTHER|Restricted Fluid Administration|Restrictive fluid administration generally consists of partial or no replacement for the intravascular expansion from anesthesia, in which case vasopressors are usually administered, no replacement for the third space loss, and only partial replacement for deficits from preoperative fasting.
215093471|NCT01033318|DRUG|MK1809|single oral doses of MK1809
215093472|NCT01033318|DRUG|Comparator: Losartan|single oral doses of 100 mg Losartan
215093473|NCT01033318|DRUG|Comparator: Placebo|Placebo to MK1809
214385498|NCT00654134|BIOLOGICAL|Clinical Center Reference Endotoxin|20,000 EU inhaled
214385499|NCT01100047|DRUG|AZD5069|Oral suspension
214385500|NCT01100047|DRUG|Placebo|Oral suspension
214385501|NCT02780622|DRUG|Oseltamivir|Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.
214385502|NCT02780622|DRUG|Warfarin|Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
214385503|NCT02956434|BEHAVIORAL|Brief Family Intervention|Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
214385504|NCT01173640|DRUG|Midazolam|2 mg oral dose
214385505|NCT01173640|DIETARY_SUPPLEMENT|resveratrol (single dose)|1 g oral dose
214385506|NCT01173640|DIETARY_SUPPLEMENT|resveratrol (multiple dose)|1 g oral dose for 8 days
214385507|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly
214385508|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination and CHMI|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite
214499742|NCT06314672|PROCEDURE|Discussion|Participate in implementation discussions
214499743|NCT06314672|OTHER|Educational Activity|Participate in educational sessions/activities
214499744|NCT06314672|OTHER|Interview|Undergo interview
214499745|NCT06314672|OTHER|Review|Undergo data capture review
214499746|NCT06314672|OTHER|Survey Administration|Ancillary studies
214499747|NCT02465307|BEHAVIORAL|Confusion Assessment Method|Confusion Assessment Method (CAM) score
214499748|NCT02465307|DEVICE|Accelerometer|3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
214499749|NCT02465307|DEVICE|Commercially available camera|As part of facial recognition video system
214499750|NCT02465307|DEVICE|Internet Pod (iPod)|Monitors noise levels in the room
214499751|NCT02465307|DIAGNOSTIC_TEST|Cortisol Swab|Cortisol level collected through self administered salivary swab
214687722|NCT02814968|DEVICE|Bone scan|
214997300|NCT03024372|DEVICE|AV Fistula creation with clips|End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
214997301|NCT01163617|DEVICE|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
214997302|NCT01163617|DEVICE|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
215093474|NCT02776592|OTHER|Cow's milk-based formula with added nutrients|
215093475|NCT02776592|OTHER|Cow's milk-based formula|
214385509|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination booster|Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule
214385510|NCT05147727|DRUG|Fluconazole、Famitinib|Fluconazole, once daily on Days 12 to 24; Famitinib, once daily on Days 1 and 15
214385511|NCT04570241|BEHAVIORAL|Malaria toolkit|Knowledge, attitude, and practice on malaria
214385512|NCT03039439|PROCEDURE|Biospecimen Collection|Previously collected tumor tissue and blood samples
214385513|NCT03039439|OTHER|Laboratory Biomarker Analysis|Correlative studies
214385514|NCT04079530|DRUG|K-877 IR 0.2 mg/day|K-877 IR 0.1 mg tablet
214499752|NCT04398095|RADIATION|Hypofractionated radiotherapy|Resectable or marginally resectable tumors: preoperative hypofractionated 12x 3 Gy radiotherapy (4 days in a week, three weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.
214499753|NCT04398095|OTHER|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
214499754|NCT04398095|RADIATION|Hypofractionated radiotherapy with boost|"Non-resectable/inoperable tumors: definitive hypofractionated 12x 3 Gy radiotherapy prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with simultaneous integrated boost 3.5 Gy per fraction prescribed on boost planned target volume (tumor volume + setup/error margin), 4 days in a week, three weeks.~Radiotherapy with daily image guidance with cone beam-CT or kV-portal position verification."
214499755|NCT02303392|DRUG|Selinexor|Given PO
214499756|NCT02303392|DRUG|Ibrutinib|Given PO
214499757|NCT02303392|OTHER|Pharmacological Study|Correlative studies
214499758|NCT02303392|OTHER|Laboratory Biomarker Analysis|Correlative studies
214499759|NCT03937713|DRUG|eszopiclone|Eszopiclone is a nonbenzodiazepine benzodiazepine receptor agonists, effective for both sleep onset insomnia and sleep maintenance insomnia
214499760|NCT03937713|BEHAVIORAL|Brief behavioral therapy for insomnia|BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.
214499761|NCT03876288|DEVICE|GI Neuromodulation|The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
214499762|NCT03876288|DRUG|Immunotherapy|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
214499763|NCT03876288|PROCEDURE|Pyloric Therapies|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
214997303|NCT01163617|DEVICE|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
215093476|NCT00550901|DRUG|cisplatin|
214997304|NCT01163617|DEVICE|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
214997305|NCT01250938|BEHAVIORAL|ESI - Community Outreach|This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.
214997306|NCT02394756|DEVICE|Marketed Soft Contact lens|Replacement schedule every 2 weeks
214997307|NCT02394756|DEVICE|AIR OPTIX® AQUA|Replacement schedule every 4 weeks
214997308|NCT02394756|DEVICE|Biofinity®|Replacement schedule every 4 weeks
215093477|NCT00550901|DRUG|dexrazoxane hydrochloride|
215093478|NCT00550901|OTHER|high performance liquid chromatography|
215093479|NCT00550901|OTHER|laboratory biomarker analysis|
215093480|NCT00550901|OTHER|mass spectrometry|
215093481|NCT00550901|OTHER|pharmacological study|
214385515|NCT04079530|DRUG|K-877 CR 0.4 mg/day|K-877 CR 0.4 mg tablet
214385516|NCT04079530|DRUG|K-877 CR 0.8 mg/day|Two K-877 CR 0.4 mg tablet
214385517|NCT04826328|DRUG|FX301|FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain
214385518|NCT04826328|DRUG|Normal Saline|Single peripheral nerve injection
214385519|NCT06550349|OTHER|N/A - non-interventional study|N/A - non-interventional study. Data collection only.
214385520|NCT06411990|DEVICE|Fenestrated Endovascular Aneurysm Repair using the LIFE Device System|Fenestrated Endovascular Aneurysm Repair
214385521|NCT03884114|OTHER|High-fidelity simulation|The first evaluation modality studied is high fidelity (HF) simulation. In our study, this modality is considered to be the gold-standard assessment method of clinical assessment, because HF simulation corresponds to the modality which reflects the best clinical competence in hospital settings. The HF pediatric manikin used (SimBaby), is able to reproduce all the signs of an asthma exacerbation (coughing, wheezing, tachypnea, chest indrawing, seesaw respiration, cyanosis). In the simulation room, participants can use the same items that those present in the simulation game (a glass of water, paracetamol, short acting beta-agonist, controller treatment (Fluticasone), an asthma spacer with a facial mask, saline nose drops to perform nasal irrigation, oral steroids in tablets (prednisone), and a phone).
214385522|NCT03884114|OTHER|Simulation game|"EfficAsthme is a simulation game used on a tablet computer. This simulation game was developed to train parents on the management of asthma exacerbations of their children. For the purpose of the study, EfficAsthme is diverted from its original use to assess students' clinical skills. The training scenario A polluted atmosphere is used in this study. Participants need to observe the signs presented by the child, and to determine the severity of the asthma exacerbation. From a menu on the right of the screen, the participant can choose several actions, especially to provide the short acting beta-agonist."
214385523|NCT03884114|OTHER|Multiple choice questionnaire|The third evaluation modality corresponds to a multiple choice questionnaire (MCQ) including 15 questions. As for HF-simulation and the simulation game, the MCQ starts with the same briefing and continues with 15 questions regarding the management of a moderate asthma exacerbation.
214385524|NCT02617225|BEHAVIORAL|DHaAL Intervention|"This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors."
214385525|NCT02617225|BEHAVIORAL|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
214385526|NCT05014581|DRUG|Noradrenaline|Pre-emptive continuous infusion of noradrenaline during the peri-intubation period
214385527|NCT04196218|OTHER|Driving simulator|Computer simulated driving assessment
214385528|NCT01147692|BIOLOGICAL|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
214385529|NCT01518946|DRUG|Midodrine HCl|dose at the subject's current dose level
214385530|NCT01518946|DRUG|Placebo|single dose of matching placebo
214385531|NCT06645054|BEHAVIORAL|Standard rehabilitation|The patients will receive standard rehabilitation that comprises assessment performed by a multidisciplinary team (physical-and-rehabilitation-medicine specialist physician, physiotherapist, occupational therapist, psychologist, social worker, prosthetics-and-orthotics engineer).
214385532|NCT06645054|DEVICE|Lower-limb prosthesis|The patients from the LLL group will be fitted with an appropriate lower-limb prosthesis.
214385533|NCT06645054|DEVICE|Lower-limb orthosis|The patients from the LLO group will be fitted with an appropriate lower-limb orthosis.
214997309|NCT03972540|BEHAVIORAL|Mindful eating intervention|A Mindful Eating Workshop™ workbook was used for standardization and reproducibility of these sessions. The group sessions were focused on teaching applied strategies to consume food with intention and attention and aimed at improving emotional relationships with food. Intervention sessions were held once a week in the evening for 2 hours per session over 8 weeks. The intervention was delivered in a large conference room on the University of Georgia campus. Participants were required to attend seven out of eight sessions. If participants missed a session, they met with the instructor 30 minutes before the beginning of the following week's session to receive individual instruction on content of the missed session.
214385534|NCT01747590|DRUG|Zolpidem|
214499764|NCT00092534|BIOLOGICAL|Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|A 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
214499765|NCT00092534|BIOLOGICAL|Matching Placebo|A placebo 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
214997310|NCT03120793|DEVICE|Esophageal balloon catheter|Measurements obtained from mechanically ventilated patients with ARDS in the supine, upright and prone positions
214997311|NCT02907372|OTHER|neuropsychologic evaluation|
214385535|NCT01747590|DRUG|Alprazolam|
214385536|NCT01747590|DRUG|Caffeine|
214385537|NCT01747590|OTHER|Placebo|
214385538|NCT00384059|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
214385539|NCT00384059|BIOLOGICAL|7vPnC|Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
214385540|NCT00384059|BIOLOGICAL|Pediacel|concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
214385541|NCT00384059|BIOLOGICAL|NeisVac-C|concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
214499766|NCT05746429|BEHAVIORAL|Cognitive Behavior Therapy|Receive mobile CBT
214499767|NCT05746429|DEVICE|Transcranial Direct Current Stimulation|Undergo active tDCS
214499768|NCT05746429|OTHER|Interview|Attend virtual meetings and focus groups
214499769|NCT05746429|DRUG|Placebo Administration|Undergo sham tDCS
214499770|NCT05746429|OTHER|Questionnaire Administration|Ancillary studies
214997312|NCT02907372|OTHER|oncogeriatric evaluation|
214997313|NCT02763618|OTHER|Neurofeedback|Neurofeedback theta/beta ratio training. See 'Neurofeedback theta/beta ratio training' in detailed study description.
214385542|NCT00384059|BIOLOGICAL|Menitorix|concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
214385543|NCT04486391|DRUG|Tislelizumab|200 mg administered via intravenous (IV) infusion once every 3 weeks
214385544|NCT04486391|DRUG|Salvage Chemotherapy|Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
215093482|NCT01167166|DRUG|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
214385545|NCT06670781|DEVICE|Experimental: Intervention arm: Goal-Directed Valsalva maneuver|For the Goal directed Valsalva maneuver, the same method patients are instructed to blow into a plastic pipe connected to the manometer device, in order to reach a pressure of 40 mmHg for at least 5 seconds. Then patients are instructed to exhale quickly.
214385546|NCT06670781|DEVICE|Control - standard of care: Self-Directed Valsalva maneuver|The Valsalva maneuver is performed by the patient taking a normal (or deep) inspiration, followed by forceful expiration against a closed airway for up to 15 to 20 sec and then release of the expiratory effort on entry of saline into the right atrium.
214385547|NCT00914277|DRUG|SAR407899|Oral administration
214385548|NCT00914277|DRUG|Placebo|Oral administration
214385549|NCT00914277|DRUG|Sildenafil|Oral administration
214385550|NCT06166394|DRUG|Spinal hypobaric Mepivacaine Local Anesthetic Injection|• Administration of a hypobaric spinal mixture for Day-Surgery patients: 3.4ml of 1.5% mepivacaine created by 3ml 2% mepivacaine with 1ml sterile water, and then discarding 0.6ml
214499771|NCT06715033|DIAGNOSTIC_TEST|y balance and SLS|for assessment of static and dynamic balance
214499772|NCT00869232|DRUG|Velcade|1.0mg/m2 days 1, 5, 8, \& 11
214499773|NCT00869232|DRUG|Melphalan|10 mg/m2 day 3
214499774|NCT00869232|DRUG|Thalidomide|200 mg days 5-8
215093483|NCT05059977|BIOLOGICAL|TAK-881|Participants will receive subcutaneous infusion of TAK-881 on Day 1.
215093484|NCT03817073|DEVICE|Iowa Oral Performance Instrument (IOPI)|Using biofeedback to attain repetitions of 80% of baseline MIP.
215093485|NCT03465553|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
215093486|NCT02358915|DEVICE|FastStart neuromuscular electrical stimulator|
214385551|NCT06166394|DRUG|Spinal hypobaric Bupivacaine Local Anesthetic Injection|"Administration of a hypobaric spinal mixture for In-patients:~3ml of 0.33% bupivacaine created by 2ml 0.5% bupivacaine with 1ml sterile water"
214385552|NCT06611683|PROCEDURE|Inspiratory muscle training|A threshold inspiratory muscule device used a starting resistance set at 30% maximum inspiratory pressure, connecting to subject artificial airway. The subjects were then instructed to perform fast and forceful inspirations against added inspiratory resistance. The inspiratory muscle training was conducted twice daily over five consecutive days, followed by a two-day rest period. This regimen continued for three consecutive weeks or until the subject no longer required ventilator support.
214385553|NCT06611683|PROCEDURE|Routine care|Subjects received routine care without intervention.
214385554|NCT04601363|DEVICE|Patient Specific Rod|Posterior spinal fusion rod
214385555|NCT02714205|DRUG|transdermal nitroglycerin|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
214385556|NCT02714205|DRUG|Placebo|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
214385557|NCT01774071|DRUG|89Zr- DFO-MSTP2109A|"If you are enrolled onto Group 1:~Once you are given the diagnostic agent, the following procedures will be done:~PET scans at the approximate times:~* 1-4 hours after the injection~* 24 hours after the injection (the next day, Day 2)~* 48-120 hours after the injection (on either Day 3, 4, or 5)~* 144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,~* Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.~* At each time of your scheduled PET scan."
214499775|NCT00869232|DRUG|Dexamethasone|40 mg day 5-8
214499776|NCT00869232|DRUG|Cisplatin|10 mg/m2 day 5-8
214499777|NCT00869232|DRUG|Adriamycin|10 mg/m2 day 5-8
214499778|NCT00869232|DRUG|Cyclophosphamide|400 mg/m2 day 5-8
214499779|NCT00869232|DRUG|Etoposide|40 mg/m2 day 5-8
214499780|NCT05350371|DRUG|Pirfenidone Oral Tablet|Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.
214499781|NCT05350371|DRUG|Placebo|The placebo tablets will be an exact replica of the pirfenidone tablet.
214499782|NCT06784180|DRUG|Morphine|200 mcg intrathecal morphine
214499783|NCT06784180|DRUG|Bupivacaine|Intrathecal 0.75% bupivacine in 8.25% dextrose (Dose determined by weight, height, gestational age)
214499784|NCT06784180|DRUG|Fentanyl|15 mcg intrathecal fentanyl
214499785|NCT06784180|DRUG|Hydromorphone|100 mcg intrathecal hydromorphone
214385558|NCT01774071|DRUG|89Zr DFO-MSTP2109A|"If you are enrolled onto Group 2:~Once you are given the study drug, the following procedures will be done:~You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (\~ 3-7 days after injection).~No research blood work will be drawn in Group 2"
214385559|NCT00381641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
214385560|NCT00381641|OTHER|Pharmacogenomic Study|Optional correlative studies
214385561|NCT00381641|DRUG|Sunitinib|Given PO
214385562|NCT00381641|DRUG|Sunitinib Malate|Given PO
214385563|NCT04852588|PROCEDURE|Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)|Chest lymph node sampling procedure by EBUS
214385564|NCT04852588|PROCEDURE|Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)|Chest lymph node sampling procedure by EUS
214385565|NCT06519825|OTHER|Exercise|Inspiratory muscle strength training program will be applied to the FHP-C group for 7 days/6 weeks.
214385566|NCT02493049|DRUG|Domperidone|Addition of Domperidone to current Disease Modifying Therapy.
214385567|NCT05357560|BIOLOGICAL|Matrix-M with RH5.2 VLP and/or R21|3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints
214385568|NCT04632628|BEHAVIORAL|Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants will complete 4 web-based CBT- I sessions. Lesson 1: Sleep Hygiene and Stimulus Control Lesson 2: Sleep Restriction and Relaxation Strategies Lesson 3: Identifying and Restructuring Dysfunction Thoughts Lesson 4: Practical Recommendations, Review, and Maintenance of Change
214385569|NCT06919172|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
214385570|NCT06619730|DEVICE|Sedline Brain Function Monitor|The anesthesia provider will use the Sedline Brain Function Monitor information to affect their anesthetic dosing.
214385571|NCT00249743|DEVICE|FallSaver (formerly called NOCwatch)|
214385572|NCT05496322|DEVICE|Continuous Non Invasive Blood Pressure Monitoring|Continuous non-invasive arterial pressure monitoring
214499786|NCT05652218|DEVICE|LB-CRT|LB-CRT (DDD 60-130, LV lead turned off) (active intervention #1)
214499787|NCT05652218|DEVICE|BIV-CRT|BIV-CRT (DDD 60- 130, LV lead turned on) (active intervention #2).
214385573|NCT05496322|DEVICE|Intermittent Non Invasive Blood Pressure Monitoring|Intermittent non-invasive arterial pressure monitoring
214499788|NCT05044403|PROCEDURE|Extracorporeal support with haemoperfusion|Use of extracorporeal support with haemoperfusion
214997314|NCT02763618|OTHER|Placebo Neurofeedback training|The placebo training will be a previously recorded Neurofeedback session of a participant in group A
214385574|NCT06619782|OTHER|Practice Facilitation|Practice facilitation (PF) is a supplemental support to increase competence and and adoption of the National Institute of Mental Health (NIMH) youth suicide prevention. pathway in primary care. Practices will receive 6 months of PF which involves clinic- and provider- level data review and adoption data for the 5 components of the prevention pathway, clinical coaching around implementing the different components , logistical coaching in identifying multilevel contextual barriers to implementation and strategies to overcome them
214385575|NCT06619782|OTHER|Training in National Institute of Mental Health Youth Suicide Prevention Pathway|Training in the National Institute of Mental Health (NIMH) Youth Suicide Prevention Pathway involves a 2-hour in-person presentation created in consultation with NIMH, Zero Suicide and Substance Abuse and Mental Health Services Administration. It is delivered by a licensed professional counselor with content expertise to all primary care practice personnel involved in the prevention pathway. The first hour focuses on conducting Ask Suicide Screening Questions (ASQ) screening, identifying risk/protective factors, identifying warning signs and conducting a brief suicide safety assessment. The second hour covers safety planning, lethal means safety, behavioral health referrals and arranging follow-up. Didactic and interactive methods are used, including group discussion, activities, videos and case vignettes
214385576|NCT06621966|OTHER|Olive Oil Topical Oil|The IVG will receive standard PI prevention care along with a topical application of olive oil for 7 consecutive days. PI point prevalence and baseline risk assessments will be performed prior to the intervention. Post-intervention assessments will be conducted from days 3 to 8. Descriptive statistics and paired sample t-tests will be utilized for data analysis.
214499789|NCT05044403|PROCEDURE|Conventional treatment|Conventional treatment
214499790|NCT04367675|DRUG|INO-5401|INO-5401 contains genes which are active in human cancers (hTERT, PMSA, and WNT1) and are felt to be good targets for the immune system both people who have had cancer or for those at increased risk of getting cancer.
214499791|NCT04367675|DRUG|INO-9012|INO-9012 contains the gene for IL12, a part of your body's immune system. It is possible that adding this to INO-5401 will increase the immune response to the vaccine.
214499792|NCT04367675|DEVICE|Cellectra 2000|The device will deliver a small electric charge through 5 needles to increase the amount of the study vaccine taken up by the muscle.
214997315|NCT05188482|DEVICE|vibroacoustic therapy|Vibroacoustic respiratory therapy
214997316|NCT02552940|DRUG|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
214997317|NCT02335944|DRUG|Capmatinib|"In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state)."
215093487|NCT03833713|BEHAVIORAL|SMS Dialogue|Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support
214385577|NCT03768765|PROCEDURE|Holmium Laser Prostate Surgery|Patients will undergo standard of care holmium laser prostate surgery
215093488|NCT03833713|BEHAVIORAL|SMS Assessments|Once-weekly SMS assessments of motor vehicle risks
215093489|NCT06464523|BEHAVIORAL|Face to face education|In addition to the standard cervical cancer screening programme service, participants in this group received individual face-to-face health education on HPV and cervical cancer prevention through home visits and were given educational brochures. Participants in this group were interviewed a total of four times (four times face-to-face) during the research period.
214385578|NCT06623968|PROCEDURE|Dental implants|Long-term follow-up study on singel-tooth implants
214385579|NCT06679114|BEHAVIORAL|Acceptance and Commitment Therapy|The single-session ACT group intervention will involve a mixture of didactic instruction, discussion, metaphors, and experiential activities. ACT activities will help women notice and accept that negative thoughts, emotions, and experiences while being displaced by war are part of migratory and post-migratory life. ACT activities will also help them identify, reorient towards, and commit to values-consistent behaviors through effective goal-setting. The single-session will be approximately 3 hours long.
214385580|NCT06679114|BEHAVIORAL|Attention control|Usual care will be minimally enhanced by providing participants with an educational information session that provides information on health promotion.
214385581|NCT06624631|OTHER|Delivery strategy A|Delivery of PDMC at the primary admitting facility
214385582|NCT06624631|OTHER|Delivery strategy B|Referral to the closest peripheral facility for dispensing of PDMC two weeks post discharge
214385583|NCT06624384|DRUG|Group 1 drug|Group 1: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Lifitgrast . In one eye, cyclosporine 0.05% eye drops are randomly poured and in the opposite eye, Lifitgrast eye drops are poured.
214499793|NCT06550804|BEHAVIORAL|A-TEAM|Participants randomized to the intervention arm will receive the proposed intervention, which involves an electronic adherence device called Wisepill and triaged text alerts to the user, the social support, and the case manager for same day, two day, and seven day device non-openings.
214385584|NCT06624384|DRUG|Group 2: Drug and placebo|Group 2: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Artelac artificial tear as a placebo. In one eye, cyclosporine 0.05% eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
214385585|NCT06624384|DRUG|Group 3: Drug and palcebo|Group 3: In this group, the aim is to compare 2 drugs, Lifitgrast and Artelac artificial tear as a placebo. In one eye, Lifitgrast eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
214385586|NCT06624605|OTHER|Large Language Model-generated Plain Language Summary of Ophthalmology notes|Prospective, randomized Quality Improvement study with real-world implementation of Large Language Model-generated Plain Language Summaries of Ophthalmology notes.
214385587|NCT06689618|DEVICE|Exercise|The WB-EMS Device is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs. After donning a base layer consisting of fitted shorts and shirt, a vest, shorts, and arm straps with integrated electrodes mapped to major muscle groups (biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings) are donned. The suit connects to an impulse pack that communicates with the Katalyst iPad App to deliver the programmed stimulation to the participant. Within the Katalyst App, there are leveled exercise programs where low levels (i.e. Level 1 and 2) are simple movements and higher levels (i.e. Levels 3, 4, and 5) have more complex and dynamic movements. There is complete user control of the stimulation level of each individual muscle group to tailor to participant responses and tolerance.
214385588|NCT06875687|OTHER|Prostaglandin Analog-Based Eyelash Serum|This intervention consists of a prostaglandin analog-based eyelash serum applied once daily to the upper eyelid margin for six weeks. The serum contains dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE), a prostaglandin analog known to promote eyelash growth. The formulation also includes panax ginseng root extract, urtica dioica extract, panthenol, niacinamide, and biotinoyl tripeptide-1, which contribute to hair follicle nourishment. The study evaluates its effects on ocular surface integrity, tear film stability, and eyelash growth.
214499794|NCT06963476|DEVICE|repetitive transcranial magnetic stimulation (rTMS) for AUD|Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. To administer TMS, a stimulator equipped with a figure-8 coil will be used. Two separate coils will be used that are similar in appearance and acoustic properties. One active, unblinded, coil will be used to determine resting motor threshold (RMT) and deliver pulses for the recruitment curves; the other coil will be used to deliver rTMS. rTMS stimulation will be targeted using standard EEG electrode locations: FP1 for mPFC and F3 for l-dlPFC.
214997318|NCT02335944|DRUG|Nazartinib|"In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state)."
214997319|NCT05013801|OTHER|Cosmetic facial serum Q69|Cosmetic facial serum
214997320|NCT05013801|DRUG|2% Hydroquinone|2% Hydroquinone cream
214997321|NCT00398229|DRUG|s.c. human chorionic gonadotropin (Ovitrelle)|S.C. Ovitrelle 250 mcg once
214997322|NCT04374136|DRUG|AL001|Administered via intravenous (IV) infusion
214997323|NCT04374136|DRUG|Placebo|Administered via intravenous (IV) infusion
215093490|NCT06464523|BEHAVIORAL|Online education|In addition to the standard cervical cancer screening programme service, participants in this group received individual health education on HPV and cervical cancer prevention online via video call via WhatsApp application and were given a digital education brochure. Participants in this group were interviewed a total of four times (four times remotely) during the research process.
215093491|NCT00576472|DRUG|Methylphenidate|Please see detailed description for dosing information and study design.
214687723|NCT02810262|OTHER|Bone metastases biopsy|The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
214997324|NCT04374136|DRUG|Open label - AL001|Administered via intravenous (IV) infusion
215093492|NCT02478580|DRUG|Nuvigil|Patients will receive Nuvigil before the surgery
215093493|NCT02478580|DRUG|Placebo|Placebo will be given before surgery
215093494|NCT00116363|GENETIC|investigational drug INGN 241|
215093495|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
215093496|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
214385589|NCT06626438|OTHER|Treatable traits model of care|Embedded multidisciplinary clinic with treatable traits model of care.
214385590|NCT01598298|DRUG|duloxetine hydrochloride|Given PO
214385591|NCT01598298|OTHER|placebo|Given PO
214385592|NCT06691893|DEVICE|RELiZORB|RELiZORB (immobilized lipase) is a therapeutic device designed to enhance fat absorption in patients receiving enteral tube feedings. It works by hydrolyzing fats found in enteral formulas. RELiZORB is a single-use cartridge that connects in-line with enteral feeding sets. It contains lipase covalently bound to small polymer beads, forming a complex called iLipase, which remains within the cartridge. As the enteral formula passes through the cartridge, its fat content is hydrolyzed upon contact with iLipase. This process is especially beneficial for the absorption of long-chain polyunsaturated fatty acids, which require hydrolysis by pancreatic lipase for proper intestinal absorption. RELiZORB is compatible with a wide variety of commercially available enteral formulas.
214385593|NCT04287868|BIOLOGICAL|PDS0101|PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.
214997325|NCT04728256|BEHAVIORAL|Laughter therapy+Music listening+Keeping diary|"Laughter therapy was carried out by the researcher as a total of three sessions every 15 days, and each session lasted 30 minutes.~Participants listened to the types of music that they like (pop, Turkish folk music). In the meeting room in FHC, Two professional artists performed music recitals with a guitar and saz (qopuz) to pregnant women, and pregnant women actively participated in this process. The performance was carried out as three sessions, once every 15 days, and each session took 40 minutes.~In addition to music listening and laughter therapy, the pregnant women were asked to keep a diary to write down their emotions about their health status, pregnancy and baby. Then, each participant had an opportunity to explain her emotions or replies to the questions during the group therapy sessions every 15 days so that pregnant women were able to express their feelings."
214385594|NCT04287868|BIOLOGICAL|M7824|M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.
214385595|NCT04287868|BIOLOGICAL|NHS-IL12|NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.
214385596|NCT06701994|BEHAVIORAL|Innovative Kinesiotaping Bandage Group|This group will receive an innovative kinesiotaping bandage developed specifically for this study. The kinesiotape will be applied directly to the skin on the ankle, combining water resistance with restrictive properties to stabilise the joint while maintaining flexibility. Unlike traditional tape, the kinesiotape is designed to perform well in aquatic conditions, making it suitable for triathlon demands. It provides joint support while allowing a greater range of motion, aiming to enhance performance across all phases of the sport. To maintain blinding, the bandage will also be covered with an opaque stocking.
214499795|NCT06963476|DEVICE|repetitive transcranial magnetic stimulation (rTMS) for OUD|Description: Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. To administer TMS, a stimulator equipped with a figure-8 coil will be used. Two separate coils will be used that are similar in appearance and acoustic properties. One active, unblinded, coil will be used to determine resting motor threshold (RMT) and deliver pulses for the recruitment curves; the other coil will be used to deliver rTMS. rTMS stimulation will be targeted using standard EEG electrode location F3 for l-dlPFC.
214499796|NCT05592886|OTHER|SMT04 formula|The SMT04 formula is a synbiotic containing probiotics and prebiotics
214499797|NCT05592886|OTHER|Active placebo|The active placebo is 2 mg Vitamin C with an inert substance made of starch filler. The flavor, coloring and appearance are unidentifiable to the study product.
214499798|NCT06444607|PROCEDURE|Venepuncture|Blood draw in the context of routine patient care, when a venipuncture is already scheduled.
214499799|NCT06444607|PROCEDURE|Venepuncture|Volunteering for blood draw.
214499800|NCT06056193|PROCEDURE|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list
214997326|NCT03535415|DRUG|Recombinant Human Growth Hormone Injection (rhGH)|rhGH 0.05mg/kg/d by subcutaneous injection
214997327|NCT04685811|DRUG|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.
214997328|NCT03687424|DEVICE|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
214997329|NCT03687424|DEVICE|low-flow nasal oxygenation (LFNO)|Active comparator (LFNO): O2 flow 5L/min, FiO2 40%
214997330|NCT06319833|BEHAVIORAL|Physical activity interacting with a video|This experimental condition will be implemented five times a week, once per day, over 8 weeks. It will follow a structured format, including seven consecutive 40-second blocks of physical activity. The total video duration will amount to 9 minutes (40 seconds of activity followed by 20 seconds of rest, maintaining a 2:1 work-to-rest ratio). Additionally, participants will engage in 5 minutes of warm-up exercises and 5 minutes of cool-down activities. The experimental condition will consist of 10 videos, each centered around one of five different themes (a different one will be administered every day).
214997331|NCT02650583|OTHER|Educational Intervention|Receive Enhancing Connections Program
214997332|NCT02650583|OTHER|Questionnaire Administration|Ancillary studies
214997333|NCT01270659|DRUG|Fentanyl|Fentanyl buccal tablet 100 mcg once
214997334|NCT01270659|DRUG|Fentanyl|Fentanyl buccal tablet 200 mcg once
214997335|NCT01270659|DRUG|Oxycodone/acetaminophen|Oxycodone/acetaminophen 5/325 mg once
214997336|NCT01270659|DRUG|oxycodone/acetaminophen|Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
214499801|NCT05555628|OTHER|Mandibular Exercise|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
214499802|NCT05555628|OTHER|Mandibular Exercise and Postural Exercise Group|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
214385597|NCT06701994|BEHAVIORAL|Traditional Tape Bandage Group|Participants in this group will receive a traditional ankle bandage using functional tape. The bandage is applied directly to the skin and is designed to restrict ankle inversion and plantar flexion, providing stability to prevent recurrent injuries. Traditional tape bandages are widely used in sports due to their effective joint stabilisation. However, they have significant limitations in aquatic environments as they lack water resistance, which makes them less effective during the swimming phase of triathlons. The bandage will be covered with an opaque stocking to ensure blinding, preventing participants or evaluators from identifying the type of intervention.
214385598|NCT06701994|BEHAVIORAL|Placebo Bandage Group|Participants in this group will receive a placebo bandage consisting of a simple gauze wrap applied directly to the ankle. The gauze lacks stabilising or therapeutic properties and is used as a control to account for potential placebo effects. Although it mimics the application process of the other bandages, it does not provide functional or structural support to the ankle joint. An opaque stocking will cover the gauze to ensure that neither participants nor evaluators can distinguish the placebo bandage from the others, maintaining the integrity of the blinding process.
214385599|NCT06110962|DEVICE|Sleeptracker-AI|The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) is a commercially available, unobtrusive, and non-wearable home sleep monitoring device. It is either pre-installed in a mattress or can be purchased separately by consumers where it is placed under the mattress. The device uses piezo-electric sensors that register the forces exerted through the mattress by features such as the subject's motion, respiration, heartbeats, and snoring vibrations.
214385600|NCT05252819|DIAGNOSTIC_TEST|Magnetic Resonance Imaging and an optional blood test|One whole-Body MRI that takes approximately 35minutes One blood test, which it is an optional component at this stage
214385601|NCT04540302|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
214385602|NCT04540302|DEVICE|PTA|Target lesion treated with standard percutaneous transluminal angioplasty (PTA)
214385603|NCT05786781|DEVICE|Transarterial CT angiography|Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
214385604|NCT06707818|OTHER|Preoperative Interventions|During the initial surgical consultation, participants will provide informed consent. Demographic data and several validated assessment scales will be collected, including the Perceived Socioeconomic Status Scale (8), Ten-Item Personality Inventory (9), Pain Catastrophizing Scale (10), Hospital Anxiety and Depression Scale (11), Rosenberg Self-Esteem Scale (12), Quality of Recovery-15 (QoR-15) questionnaire (13), and the Visual Analog Scale (VAS) for pain (14).
214385605|NCT06707818|OTHER|Intraoperative Interventions|All surgical procedures will follow the standard general anesthesia protocol of the hospital. General anesthesia induction will involve propofol (1-2 mg/kg), fentanyl (1 mcg/kg), and rocuronium (0.6 mg/kg) for endotracheal intubation. Anesthesia maintenance will be performed with desflurane (4-6%) and remifentanil (0.1 mcg/kg/min), with adjustments as needed based on blood pressure and heart rate. Post-induction, dexamethasone (4 mg) will be administered for anti-inflammatory effects. To support postoperative pain management, tramadol (1 mg/kg), ibuprofen (400 mg), and paracetamol (1 g) will be administered before the end of the procedure. Ondansetron (4 mg) will be used for nausea prophylaxis. All intraoperative medications and dosages will be recorded without intervention.
214385606|NCT06707818|OTHER|Postoperative Interventions|"In the recovery room, analgesic interventions will follow the hospital's standard protocol: patients with VAS scores between 3 and 7 will receive 25 mcg of fentanyl, while those with scores above 7 will receive 50 mcg.~All patients will receive standard multimodal analgesia during the ward stay, including paracetamol (1 g, three times daily) and ibuprofen (400 mg, twice daily). Patient-controlled analgesia (PCA) devices will administer tramadol (10 mg IV per patient request, without continuous infusion)."
214997337|NCT03424642|BEHAVIORAL|Interactive 4D-ultrasound examination|Randomized controlled trial
214997338|NCT01680913|PROCEDURE|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
214997339|NCT01680913|PROCEDURE|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
214997340|NCT01680913|PROCEDURE|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
214997341|NCT02873663|PROCEDURE|Plasma and head hair collection|Plasma and head hair collection
214997342|NCT03236389|DEVICE|Q Collar|measuring changes in brain during MRI while wearing the Q collar
214997343|NCT02015156|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
214997344|NCT02015156|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
214997345|NCT04727008|BIOLOGICAL|CXCR4 modified anti-BCMA CAR T cells|intravenous infusion
214997346|NCT02530866|OTHER|Lower glycemic targets|Women will be randomized to either standard or lower glycemic targets.
214385610|NCT06710990|DRUG|SHR-A1811|SHR-A1811
214385611|NCT06710990|DRUG|Ritonavir|Ritonavir
214385612|NCT06710990|DRUG|Itraconazole|Itraconazole
214385613|NCT06713460|BEHAVIORAL|BEAM|Multicomponent intervention
214385614|NCT06716359|OTHER|Observational study without intervention|Observational study without intervention
214385615|NCT06882447|DRUG|Trial drug: QL1706, HPV 9-valent vaccine|QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on day 1 of each cycle and once every 3 weeks (21 days).
214385616|NCT01315730|DEVICE|Tactile Stimulation|See Arms
214385617|NCT06925880|DIETARY_SUPPLEMENT|Creatine Monohydrate|The intervention will consist of daily supplementation with micronized creatine monohydrate (FullGas Sport Creatine 200 mesh) for 12 weeks. The intervention will start at the time of hospital discharge with a loading dose of 20g/day for 1 week, divided into 4 intakes of 5g to favor digestive tolerance (breakfast, lunch, snack and dinner). Subsequently, a maintenance dose of 5g/day will be continued for 11 weeks (breakfast). Creatine should be consumed with food to improve its absorption.
214385618|NCT06925880|OTHER|Placebo|The control group will follow the same rehabilitation regimen as the intervention group and will receive a placebo with FullGas Sport microcrystalline cellulose. Its physical and organoleptic characteristics are the same as micronized creatine monohydrate. The dosage will be the same as that indicated for the study intervention: it will start at the time of hospital discharge with a loading dose of 20g/day for 1 week, divided into 4 intakes of 5g to favor digestive tolerance (breakfast, lunch, snack and dinner). Subsequently, a maintenance dose of 5g/day will be continued for 11 weeks (breakfast).
214385619|NCT06925360|DRUG|intravenous immunoglobulin|1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable 1\~2 times if necessary (5 days after the last infusion).
214385620|NCT06925230|PROCEDURE|arthroscopic assisted volar scapholunate capsulodesis|arthroscopic assisted volar scapholunate capsulodesis using PDS 2.00 sutures
214385621|NCT06925230|PROCEDURE|arthroscopic assisted dorsal scapholunate capsulodesis|arthroscopic assisted dorsal scapholunate capsulodesis using PDS 2.00 sutures
214385622|NCT06925230|PROCEDURE|arthroscopic assisted combined volar and dorsal scapholunate capsulodesis|arthroscopic assisted combined volar and dorsal scapholunate capsulodesis using PDS 2.00 sutures
214385623|NCT06924944|PROCEDURE|cataract surgery|cataract surgery treated with bilateral Clareon Vivity toric and non-toric IOL
214385624|NCT06925529|BEHAVIORAL|Cardio-Oncology Rehabilitation and Exercise Programme|Participants randomised to the CORE programme will receive exercise training that is analogous to cardiac rehabilitation, but Exercise Physiologists will individualise each training program using the participants baseline CPET results to maximise adherence and improve the effectiveness of the training program beyond typical cardiac rehabilitation programs. An Exercise Physiologist will supervise two training sessions a week and monitor adherence to one other independent session at home each week for the first 12 weeks of the training program whilst exercise frequency, intensity, and time is progressively increased. Supervision of the exercise training will then be stepped down gradually after 12 weeks to a fortnightly check-in to encourage intervention adherence. Patients will be provided with a training calendar and objective tools for tracking physical activity (e.g. heart rate monitor and diary). Adherence will be monitored in real-time using a research web-based platform.
214385625|NCT06926257|OTHER|Experimental group (B) - breathing training using VR|"The Flowborne VR - Biofeedback Breathing Meditation game is an interactive training environment that guides the participant through a series of breathing exercises. The app adjusts the difficulty level and pace of the workout in real time based on the participant's physiological parameters, such as breathing rhythm.~Types of exercises in the game:~1. diaphragmatic breathing - the participant takes slow, controlled breaths, inhaling into the diaphragm and exhaling at a set pace. The game visualizes breathing through animations of water waves and background color changes.~2. rhythmic breathing - the participant sts his breathing rhythm to the changing visual and audio stimuli, allowing for synchronous breathing control.~3. Controlled exhalation lengthening - the participant learns the technique of slow exhalation of air to improve relaxation and reduce tension."
214499803|NCT05555628|OTHER|Occlusal Splint Group|Patients will use occlusal splints for 6 weeks. The occlusal splints will be used only sleep time.
214499804|NCT04984837|DRUG|Lacutamab|750 mg/IV
214499805|NCT04984837|DRUG|Gemcitabine|1000 mg/m²
214499806|NCT04984837|DRUG|Oxaliplatine|100 mg/m²
214499807|NCT04891068|DRUG|Azacitidine|5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5
214499808|NCT05720117|DRUG|PYX-201|IV infusion
214499809|NCT05390411|BEHAVIORAL|SOCIAL HF|participate in SOCIAL HF training
214997347|NCT01197066|DRUG|Certolizumab Pegol|Certolizumab Pegol 200mg
214687724|NCT04664595|DRUG|Propofol Fresenius|final dose of Propofol (mcg/kg) to reach the target effect-site concentration
214687725|NCT00002789|DRUG|busulfan|
214687726|NCT00002789|DRUG|cyclophosphamide|
214997348|NCT01706328|DRUG|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
214997349|NCT01706328|DRUG|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
215093497|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
215093498|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
214687727|NCT00002789|DRUG|cyclosporine|
214687728|NCT00002789|DRUG|methotrexate|
214687729|NCT00002789|PROCEDURE|allogeneic bone marrow transplantation|
214997350|NCT01706328|DRUG|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
214997351|NCT01706328|DRUG|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
214499810|NCT03632343|OTHER|Pain Squad+ with Nurse Support|Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain \>3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
214499811|NCT03632343|OTHER|Pain Squad+|Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
214499812|NCT06183437|OTHER|Stopping Heart Failure Medication(s)|This group will stop their heart failure medication(s) under the supervision of the study team.
214499813|NCT04463979|OTHER|Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia|"Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points.~Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire."
215093499|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
214499814|NCT04773275|DEVICE|Pulsed electric field treatment using the Aliya system|Patients will undergo pulsed electric field (PEF) treatment of up to 5 tumors (new or progressing) measuring ≤ 2cm in longest diameter.
215093500|NCT06924658|OTHER|placebo|Placebo will have the same look of metformin
215093501|NCT06924658|DRUG|Metformin|Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
214499815|NCT05050266|BEHAVIORAL|EBQI|"EBQI is a systematic quality improvement method for engaging frontline practices in improvement that introduces best science and evidence in the service of operational goals. EBQI has been tested in several VA implementation trials. Sites randomized to EBQI will meet monthly with the implementation support team (i.e., high-intensity)."
214499816|NCT05050266|BEHAVIORAL|REP|The REP framework consists of 4 phases: pre-conditions, pre-implementation, implementation and maintenance/evolution. REP has a strong evidence-base and application in VHA health services research in promoting uptake of EBPs. Sites randomized to REP will meet quarterly with the implementation support team (i.e., low-intensity).
214997352|NCT01706328|DRUG|Salbutamol as needed|Salbutamol inhalation powder
214499817|NCT06520514|DRUG|Spesolimab|Spesolimab
214499818|NCT06431945|DIAGNOSTIC_TEST|Hepatitis C antibody (anti-HCV) test|Testing for hepatitis C antibodies determines whether or not you have been exposed to HCV at some point in your life. This testing will be performed in all 3,000 persons who inject drugs enrolled in the project.
214499819|NCT06431945|DIAGNOSTIC_TEST|Hepatitis C RNA test and genotype test|RNA is a type of genetic material from HCV that can be detected in the blood. This test will be used as a confirmation of the infection. This testing will be performed in all persons with positive antibody test who will come to clinical center.
214499822|NCT03032783|RADIATION|Total-Body Irradiation|Undergo Total Body Irradiation
214499823|NCT03032783|PROCEDURE|Donor Lymphocyte Infusion|Undergo Donor Lymphocyte Infusion
214997353|NCT01762189|PROCEDURE|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
214997354|NCT00825240|BEHAVIORAL|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
214499824|NCT03032783|DRUG|Cyclophosphamide|Given IV
214499825|NCT03032783|DRUG|Tacrolimus|Given IV
215093502|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the first 7 days|20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 7 days
214499826|NCT03032783|DRUG|Mycophenolate Mofetil|Given IV
214687730|NCT00002789|PROCEDURE|peripheral blood stem cell transplantation|
214997355|NCT00576082|OTHER|Cutaneous biopsy|Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample
214997356|NCT04651712|DIAGNOSTIC_TEST|POC-PCR|The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
214997357|NCT03160170|DEVICE|SISTER device|Use of the Suction-Integrated Surgical Tissue Elevator \& Retractor (SISTER) device during surgery
214997358|NCT03018938|DRUG|Insulin Analog Mid Mixture|Administered SC
214997359|NCT03018938|DRUG|Basal Insulin Analog|Administered SC
214997360|NCT00191100|DRUG|Gemcitabine|
214997361|NCT00191100|DRUG|Cisplatin|
214997362|NCT00191100|RADIATION|Brachytherapy|Brachytherapy, 30-35 Gy over 1 week
214997363|NCT00191100|RADIATION|Pelvic radiation|Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
214997364|NCT00580086|OTHER|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
215093503|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the first 5 days|20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 5 days
214385626|NCT06926257|OTHER|Experimental group (C) - breathing training using relaxation music|"* Diaphragmatic breathing - the conscious engagement of the diaphragm in the inhalation process.~* Controlled exhalation lengthening - a technique to lengthen the exhalation phase.~* Rhythmic breathing - synchronizing breathing with a set pace to improve breath control.~Structure of each session:~1. introductory phase (3 minutes)~   * Participants assume a comfortable sitting or lying position.~  * Brief instruction on proper breathing.~2. training phase (15 minutes).~   * Participants listen to relaxation music while focusing on the breathing techniques they learned before the session.~  * Breathing techniques used include those learned during the training: diaphragmatic breathing, controlled expiration lengthening, rhythmic breathing.~     3 Relaxation phase (2 minutes)~  * Gradual exit from the training session, focusing attention on the sensations of the body and mind."
214385627|NCT06925919|DRUG|IDB-011 dose level 1|IDB-774 + IDB-898
214385628|NCT06925919|DRUG|IDB-011 dose level 2|IDB-774 + IDB-898
214385629|NCT06925919|DRUG|IDB-011 dose level 3|IDB-774 + IDB-898
214385630|NCT06925919|DRUG|IDB-011 dose level 4|IDB-774 + IDB-898
214499827|NCT03032783|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo Hematopoietic Stem Cell Transplantation
214499828|NCT05317832|BEHAVIORAL|WI program|This 14-week web-based physical activity intervention (WI) program was developed by the National Center on Health, Physical Activity and Disability. The WI program was developed with guidance from literature and practice in health behavior change and internet-based health promotion programming. The content and features of the WI program include motivational resource, updated weekly resources, and customizable features.
214499829|NCT05317832|BEHAVIORAL|WI Program Reminder|Participants will be provided with reminders to use the WI program
214499830|NCT05317832|BEHAVIORAL|JITAI Goal Setting|Participants will be provided with standard, tailored, or no goal for the day. The goal will focus on recommending minutes of moderate-intensity (or higher) physical activity and a reminder to perform strength exercises.
214499831|NCT05317832|BEHAVIORAL|JITAI physical activity message|Participants will be provided with minutes of moderate-intensity (or higher) physical activity achieved, minutes of physical activity remaining, or no message.
214499832|NCT05317832|OTHER|Notification EMA|Participants will be inquired through an ecological momentary assessment (EMA) if they received a JITAI physical activity message.
214499833|NCT05317832|OTHER|End of day EMA|Participants will be inquired, through an ecological momentary assessment (EMA), if they performed aerobic and/or strength exercises for the day.
214499834|NCT05317832|OTHER|Wake up time EMA|Participants will be inquired, through an ecological momentary assessment (EMA), about the time they plan to wake up next day. This information will be used to provide a goal setting message for next day.
214499835|NCT05317832|OTHER|Weekly PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the last 7 days.
214499836|NCT05317832|OTHER|Daily PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the day.
214499837|NCT03852186|BEHAVIORAL|Cognitive behavioral therapy|Group based psychotherapy
214499838|NCT03852186|BEHAVIORAL|Acceptance and commitment therapy|Group based psychotherapy
214997365|NCT01769586|DRUG|Diphenhydramine|
214997366|NCT01769586|DRUG|Midazolam|
214385631|NCT06925919|DRUG|IDB-011 dose level 5|IDB-774 + IDB-898
214385632|NCT06925919|OTHER|Placebo|Normal saline
214687731|NCT02280928|OTHER|Balance exercise|Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
214385634|NCT06925412|PROCEDURE|MMC sponge application|Three micro swabs soaked in 0.03% MMC were subconjunctivally applied, followed by the creation of a fornix-based conjunctival flap. Subsequently, the standard trabeculectomy procedure was initiated without additional irrigation of the MMC application site
214499839|NCT06839937|BEHAVIORAL|REVISE - Virtual Reality Gender-Swap with Harassment Exposure|Participants will embody a virtual avatar of their female partner in a sexual harassment scenario using full-body tracking, and identity exchange in virtual reality (VR). The goal is to assess whether experiencing harassment from a first-person perspective increases empathy and decreases tolerance toward sexual harassment.
214499840|NCT06839937|BEHAVIORAL|REVISE - Virtual Reality Gender-Swap without Harassment|Participants will embody a virtual avatar of their female partner in a neutral social interaction scenario using VR-based identity exchange. This condition controls for the effect of perspective-taking alone, without exposure to harassment, to evaluate its impact on empathy and gender attitudes.
214499841|NCT05029284|BEHAVIORAL|teleABLE|Participants will be guided to self-monitor their daily activities, schedule personally meaningful non-sedentary activities, collaboratively problem solve to overcome barriers to the activity, and self-assess their progress. Participants may be asked to self-monitor their activity levels and complete planned activities between sessions.
214499842|NCT04297813|COMBINATION_PRODUCT|Advanced medicinal Therapy (MSC combined with biomaterial)|Augmentation of alveolar ridge with MSC and biomaterial
214499843|NCT04297813|PROCEDURE|Autologous bone graft|Augmentation of the alveolar ridge with bone graft
214499844|NCT02329704|PROCEDURE|Diff-Quik staining for morphology evaluation|"Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm."
214499845|NCT02329704|PROCEDURE|Motility Evaluation for grade A and B|"The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references."
214499846|NCT02329704|PROCEDURE|Concentration (mil/ml)|count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
214499847|NCT02329704|PROCEDURE|24 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
214997367|NCT02811159|DRUG|Telapristone acetate|Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.
214385635|NCT06925412|PROCEDURE|Sub-tenon MMC injection|MMC was administered via a sub-tenon injection. A 30-gauge needle was inserted into the conjunctiva and carefully advanced laterally along Tenon's capsule. A cannula was employed to minimize the excessive spread of MMC over the anticipated conjunctival incision site. After MMC delivery, a fornix-based conjunctival peritomy was performed, and both groups proceeded to undergo standard trabeculectomy
214385636|NCT06924996|PROCEDURE|Endovascular Thrombectomy (EVT)|A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire AB/FR device or aspiration. In case an atherosclerotic lesion is found underlying the occlusive lesion, angioplasty and subsequent stenting through detachment of the Solitaire device will be allowed
214385637|NCT06365411|DIAGNOSTIC_TEST|Biomarker discovery and validation - with focus on genomic biomarkers|Biomarker discovery and validation - with focus on genomic biomarkers
214385638|NCT05174793|OTHER|dehydration and rehydration|dehydration and rehydration
214385639|NCT05691361|DRUG|ADX-324|siRNA duplex oligonucleotide
214385640|NCT05691361|DRUG|Placebo|saline
214385641|NCT04259671|DEVICE|My Autism Passport (MAP) Application|Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. MAP is a mobile alternative to the paper version, and offers additional benefits such as the ability to set reminders, see regional developmental service agencies and other resources on a map, and directs the caregiver to information so that they may further their understanding about how to support their child.
214385642|NCT06574854|OTHER|DSW|Descending Stair Walking
214385643|NCT06574854|OTHER|ASW|Ascending Stair Walking
214385644|NCT06780566|DIAGNOSTIC_TEST|Point-of-care PCR testing for respiratory viruses|A nasal swab will be collected by trained research staff in full personal protective equipment (PPE) and placed into 3 mL of viral transport medium. The sample will be immediately processed and analysed in the ED using the Xpert® Xpress SARS-CoV-2/Flu/RSV test according to the manufacturer's instructions. The results of the test will be documented in the patient's paper or electronic case notes, and the clinical team will be directly informed of all results. The participant or legal guardian who signs the consent form will also be informed of the results when appropriate.
214385645|NCT06780566|DIAGNOSTIC_TEST|Laboratory PCR testing for respiratory viruses|The ordering of test for respiratory pathogens will be decided by the treating clinical team. All tests will be performed using the standard methods of the hospital laboratory.
214385646|NCT06899594|DRUG|Psilocybin 25 mg|25 mg administered orally (capsules)
214385647|NCT06900010|BIOLOGICAL|CM336 Injection|subcutaneous CM336 administration
214385648|NCT06899724|DRUG|Anesthetics, Inhalation|Inhaled analgesia
214385649|NCT06899724|DRUG|Intravenous Sedatives with or Without Analgesia|IV Fentanyl and midazolam
214385650|NCT06900166|DRUG|PegIFN alfa-2b|180 μg/ 0.5 ml ,hypodermic injection once a week
214385651|NCT06900166|DRUG|PegIFN alfa-2b and NUC|180 μg/ 0.5 ml ,hypodermic injection once a week, NUC drugs should be used according to the instructions of each drug
214385652|NCT06925997|DRUG|Colesevelam|Colesevelam is an approved drug with well known adverse events. Gastrointestinal side effects (Obstipation, flatulence, abdominal pain, diarrhea, nausea, meteorism, vomiting, chanced faeces) are very common (\>10%) or common (1-10%), but are mild and tolerable in most cases. All participants will be monitored closely, and colesevelam will be discontinued if the subject experience unreserved adverse events. All effects of colesevelam are transient (17-19) as the compound is not absorbed to the systemic circulation, i.e. treatment effects cease when the drug is excreted from the intestine. Specifically, no permanent metabolic effects of colesevelam has been observed in crossover experiments (27). Therefore, 8 weeks of colesevelam treatment as planned in the current study will have no long lasting positive or negative effects on the participants.
214385653|NCT06925126|OTHER|Not applicable- observational study|This is an observational cohort study with no planned interventions. Participants will be followed over multiple time points to evaluate treatment outcomes based on the standard care process.
214385654|NCT06926439|DRUG|Long chain lipid emulsion|For patients presenting with fat soluble drug overdose, administer a weight-based infusion of long-chain lipid emulsion at 0.05 ml/kg/min for 1 hour, not to exceed a total of 250 mL.
214385655|NCT06925425|OTHER|Task specific electrical stimulation ( TASES )|"Each child in group B receive the designed program plus the task specific electrical stimulation (TASES) for 20 minutes during the weight bearing exercises as push up , prone on hands on wedge and quadruped with weight shifting.~The electrical stimulation is applied with the following parameters. Pulse frequency 25-50 HZ, pulse duration 300 micro second, intensity to display a visible muscle contraction, for 20 minutes.~First channel, one electrode will be placed at the middle of triceps muscle, the second electrode will be placed more distal towards the elbow joint itself (about 3 cm above the olecranon process).~Second channel, one electrode will be placed over finger and wrist extensors motor point to allow activation of fingers and wrist extensors. The other electrode will be placed over the tendonous portion of the forearm between motor points of extensor carpi radialis and extensor carpi ulnaris muscles."
214997368|NCT05953467|OTHER|No intervention, observational.|None, observational study
214997369|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Bioequivalence
214997370|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Bioequivalence
214997371|NCT06646471|GENETIC|Bio-bank repository|Blood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years
214997372|NCT06646471|OTHER|Quality of Life (QoL)|"Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14:~* stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression.~* operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months.~* radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months."
214997373|NCT06646471|PROCEDURE|G-Code|G-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment.
214997374|NCT01675726|OTHER|questionary on quality of life|
214997375|NCT05184816|DRUG|Deferoxamine (DFO)|The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
214385656|NCT06925425|OTHER|Designed Physical therapy program|The program used a combination of open-and closed-chain exercises. Exercises for facilitating transitions as supine to sit with hand weight bearing , side lying to side sit , side sitting to quadruped, weight bearing exercises as prone on hands on wedge , quadruped with weight shifting and push up exercise for one hour.
214385657|NCT06900465|BEHAVIORAL|Caregiver Psychoeducation Group for Children and Adolescents with Emotional and Behavioral Disorders (CPG-CA)|The CPG-CA intervention is a group psychoeducational internvention for family caregivers of children and adolescents with E/BDs in China. It will consist of 10 to 15 family caregivers of children and adolescents with E/BDs, meeting once a week for 1.5 to 2 hours per session, for a total of 12 sessions over a 3-month period. The sessions will cover the following themes: (1) knowledge about child and adolescent emotional and behavioral disorders; (2) coping skills for common emotional and behavioral problems in children and adolescents; (3) problem-solving skills; (4) communication skills with children and adolescents; (5) positive parenting techniques; and (6) self-care techniques. A variety of facilitation techniques will be used in the intervention, including didactic teaching, group discussion, role-playing, and homework assignment.
214385658|NCT06900322|OTHER|Experimental Group (stimuli and handling; physical therapy [PediaSuit])|"Participants underwent a one-hour daily protocol (5 times a week) of stimuli and handling based on the neuroevolutionary concept, and motor physical therapy with therapeutic garments (PediaSuit).~During therapy based in PediaSuit protocol therapy suits were used to stimulate proprioception, muscle contraction, and postural stability.Traction bands were placed on the trunk to stimulate muscle control by stabilizing this area and the antigravity muscles.The ability exercise unit was also used to stimulate postural stability and muscle resistance, according to the functional ability of each child.~Neuroevolutionary concept is a problem-solving approach focused on the treatment of functional impairments, postural alignment and movement.~Therefore, Neuroevolutionary concept is an individualised approach aimed at improving functionality and, consequently, the quality of life of individuals with neurological deficits."
214385659|NCT06900322|OTHER|control group (conventional physical therapy)|Participants kept the therapeutic routine (conventional physical therapy).
214499848|NCT02329704|PROCEDURE|48 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
214499849|NCT02329704|PROCEDURE|HBA Testing|"The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm."
214997376|NCT06390904|DRUG|GnRH antagonist|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.
214997377|NCT06390904|DRUG|Letrozole 2.5mg|2.5mg po qd.
214997378|NCT06385353|OTHER|Quantification of deep vein thrombosis burden and assessment of post-thrombotic syndrome|"Post-thrombotic syndrome will be assessed by the Villalta score until 6 months of follow-up.~Data collected from colour doppler ultrasound will be used to calculate the Venous Volumetric Index to quantify deep vein thrombosis burden until 6 months of follow-up."
214997379|NCT05174624|OTHER|No intervention|No intervention
214997380|NCT05548374|DEVICE|Acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. Hwato-brand disposable acupuncture needles (size 0.30×40mm) will be inserted into the acupoints through the adhesive pads. Afterwards, the acupuncture will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance.
214997381|NCT05548374|DEVICE|Sham acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. The needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
215093504|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the second 7 days|20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 7 days
214997382|NCT05360706|GENETIC|AAV5-hFIX|AAV5 containing a codon-optimized human factor IX gene
214997383|NCT03990974|DRUG|postoperative antimicrobial prophylaxis|The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
214997384|NCT03990974|OTHER|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy unless necessary.
214997385|NCT00817791|DEVICE|Hyperbaric oxygen pretreatment (GR2200)|2 hours/day,5 days before surgery
214997386|NCT06064149|BEHAVIORAL|CARE-PC Web-Based Application|The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT.
215093505|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the second 5 days|20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 5 days
215093506|NCT06929962|DRUG|Vonoprazan and Amoxicillin for 14 days|20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 14 days
215093507|NCT03552588|DIAGNOSTIC_TEST|Continuous Electrocardiogram|A high-sensitivity, 14-day continuous ECG monitor.
214997387|NCT06532773|BEHAVIORAL|Nite2Day+|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
214997388|NCT03672162|PROCEDURE|Total abdominal hysterectomy|Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
214997389|NCT03619525|PROCEDURE|lung recruitment|During bypass, patients in this group will receive a lung protective design in the form of continuous positive airway pressure (CPAP) by closing APL valve at pressure of 5 Cm H2o combined with intermittent recruitment by sustained manual lung inflation at a pressure of 35 cmH2O for 30 seconds every (30-40) minute
214997390|NCT05618301|DRUG|Motixafortide|Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
214385660|NCT01830088|BEHAVIORAL|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
214385661|NCT01830088|BEHAVIORAL|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
214385662|NCT06025877|OTHER|PrecivityAD2(TM) blood test|The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
214385663|NCT06900738|DEVICE|Inflammometer|Patients wear an inflammometer for Photoplethysmography measurements.
214385664|NCT06900478|DRUG|Icariin Soft Capsules+TACE|"TACE: perform preoperative infusion chemotherapy, then selectively inject 2 to 5 mL of iodized oil and embolize.~Icariin Soft Capsules：take 6 tablets each time, orally, twice a day."
214385665|NCT06900075|DRUG|Efsubaglutide Alfa 3mg Q2W and 1mg QW|Efsubaglutide Alfa 3 mg administered once every two weeks for 8 weeks, followed by a switch to Efsubaglutide Alfa 1 mg administered once weekly for an additional 8 weeks of treatment.
214385666|NCT06900075|DRUG|Efsubaglutide Alfa 1mg QW and 3mg Q2W|Efsubaglutide Alfa 1 mg administered once weekly for 8 weeks, followed by a switch to Efsubaglutide Alfa 3 mg administered once every two weeks for an additional 8 weeks of treatment.
214385667|NCT05379712|OTHER|Resource® Support Plus|Nestlé Resource Support Plus® is a high energy- and protein-density Medical Food enriched with omega 3 polyunsaturated fatty acids. This is a nutritionally complete formula, in an easy to swallow, palatable, concentrated low volume, available in 2 flavours optimized for cancer patients undergoing chemotherapy and/or radiation in taste tests. It provides in a 125 mL serving: 250 kcal, 11.5 g protein and 0.95g of omega-3 fatty acid (eicosapentaenoic acid, EPA).
214385668|NCT03616067|DRUG|Botox® injection|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars)
214385669|NCT03616067|DRUG|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear.
214385670|NCT04000737|DRUG|Sorafenib+YIV-906|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.
214385671|NCT04000737|DRUG|Sorafenib+placebo|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
214385672|NCT03813147|DRUG|Azacitidine|Given IV
214385673|NCT03813147|DRUG|Cytarabine|Given intrathecally and IV
214385674|NCT03813147|DRUG|Fludarabine Phosphate|Given IV
214385675|NCT03813147|DRUG|Methotrexate|Given intrathecally
214385676|NCT03813147|DRUG|Pevonedistat|Given IV
214385677|NCT03813147|DRUG|Therapeutic Hydrocortisone|Given intrathecally
214385678|NCT06925607|DRUG|Mesenchymal Stem Cells (MSCs)|single dose injection (120 million cells)
214499850|NCT02329704|BIOLOGICAL|Bacterial contamination|Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
214687732|NCT02280928|OTHER|Cognitive training|Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
214997391|NCT05618301|DRUG|Natalizumab|Natalizumab will be administered as an IV infusion at a flat dose of 300 mg
214687733|NCT02280928|OTHER|Dual-task cognitive-cognitive training|The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
214687734|NCT03161938|DRUG|Dexamethasone|intravenous
214687735|NCT00016874|DRUG|cisplatin|
214687736|NCT00016874|DRUG|paclitaxel|
214687737|NCT00016874|DRUG|triapine|
214997392|NCT05618301|PROCEDURE|Leukapheresis|Leukapheresis consisting of a 1 Blood Volume procedure
214997393|NCT06010017|BEHAVIORAL|STEPP Intervention|Peer support intervention comprised of five learning modules on psychoeducation and supportive psychotherapy strategies, via virtual platform. If participants do not have a smart device, one will be provided by the study team.
215093508|NCT02887755|DEVICE|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
215093509|NCT01964677|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
215093510|NCT00519662|DRUG|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
214997394|NCT04323475|BIOLOGICAL|Bacteriophage cocktail spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages at a concentration of 1.4 x 10\^8 PFU/mL for an effective dosage of 2.5 x10\^5 PFU/cm\^2 of burned area. The study intervention will be applied in conjunction with standard of care.
214385679|NCT04009187|BEHAVIORAL|In-person wheelchair propulsion training program|The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.
214997395|NCT04323475|DRUG|Xeroform|Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
214997396|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
215093511|NCT04576078|DRUG|Oral nefopam|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
215093512|NCT04576078|DRUG|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
215093513|NCT05304312|DEVICE|Kegel Exercises guidebook|The Kegel exercises book is consisted of basic explanation about stress urinary incontinence and Kegel exercises, how to do Kegel exercises, table for them to write how many session they did in a day, and lastly their report progress (UDI-6, IIQ-7, periineometer, and 1-hour pad test) that we updated every four weeks
214385680|NCT04009187|BEHAVIORAL|30-minute education session|Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
214385681|NCT05899582|PROCEDURE|Extracranial-Intracranial Bypass Surgery|Extracranial-intracranial bypass surgery plus medical treatment
214385682|NCT05899582|OTHER|Medical treatment alone|Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.
214385683|NCT05371119|OTHER|Exercise Intervention|Training with light load with blood flow restriction (BFR)
214385684|NCT04343443|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
214385685|NCT04343443|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
214385686|NCT04343443|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
214385687|NCT04343443|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from hospital
214385688|NCT04343443|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
214385689|NCT03855163|BEHAVIORAL|Inspection visits|Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements
214385690|NCT03855163|BEHAVIORAL|Guidance workshops|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
214385691|NCT03855163|BEHAVIORAL|Online risk assessment tool|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
214385692|NCT05310201|BEHAVIORAL|Be Well Care Well|Be Well Care Well addresses teacher well-being through activities implemented in the classroom aimed at reducing teacher stress and improving physical activity. A subset of teachers involved in the program will complete classroom observations and cortisol testing to examine additional measures of stress.
214385693|NCT03499015|PROCEDURE|Balloon Eustachian Tuboplasty (BET)|A balloon catheter is used to dilate the cartilage part of the eustachian tube and is inserted through the nose to reach the opening of the tube, located in the nasopharynx.
214385694|NCT05121623|OTHER|Questionnaire|Online auto-administered Questionnaire
214385695|NCT02231229|OTHER|PCR-based strategy|Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
214385696|NCT02231229|DRUG|conventional therapy|Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
214385697|NCT05081505|BEHAVIORAL|Structural exercise course|12-week structured exercise class, team competition, social support, and incentive strategy
214385698|NCT05081505|BEHAVIORAL|Autonomous group class|12-week autonomous group class, team competition, social support, and incentive strategy
214385699|NCT05520502|OTHER|PILATES EXERCISE|12 WEEKS, 3 SESSIONS A WEEK 36 SESSIONS IN A TOTAL OF PLANNED MAT 1 PILATES EXERCISES
214385700|NCT00708721|DRUG|Clofarabine|Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
214385701|NCT05730738|DRUG|Dalfampridine ER, 10 Mg Oral Tablet, Extended Release|The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels
214385702|NCT05730738|DRUG|Placebo|placebo similar to Dalfampridine capsule
214385703|NCT01033292|DRUG|BSI-201|IV infusion, 5.6 mg/kg
214385704|NCT01464008|DRUG|Pegylated interferon alfa-2a and ribavirin|all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
214385705|NCT01392222|BEHAVIORAL|Focus groups|"The focus groups will cover the following issues~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option"
214385706|NCT01392222|BEHAVIORAL|Focus groups|"The focus groups will cover the following issues:~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option"
214385707|NCT00847821|DRUG|Bazedoxifene 10 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
214997397|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
214385708|NCT00847821|DRUG|Bazedoxifene 20 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
214385709|NCT00847821|DRUG|Bazedoxifene 40 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
214385710|NCT00847821|DRUG|Bazedoxifene 10 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
214385711|NCT00847821|DRUG|Bazedoxifene 20 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
214687738|NCT03531177|BEHAVIORAL|HEAL-D|HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.
214687739|NCT03531177|BEHAVIORAL|Control|Participants receive usual care from their healthcare team.
214997398|NCT06468462|DRUG|WHO-recommended periodic presumptive treatment|400 mg po cefixime plus 1 gram azithromycin po under direct observation
214997399|NCT06468462|DRUG|Doxycycline post-exposure prophylaxis|200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily
214997400|NCT02053116|DRUG|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
214997401|NCT02053116|DRUG|Placebo|Tablet, 0 mg, twice daily, 2 weeks
214997402|NCT05604950|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
215093514|NCT05250791|DRUG|Lidocaine hydrochloride 2% for injection|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
215093515|NCT05250791|DRUG|0.9% sterile Sodium Chloride solution for injection|Administered as lidocaine
215093516|NCT03233022|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
214385712|NCT00847821|DRUG|Bazedoxifene 40 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
214997403|NCT05841875|OTHER|C reactive protein algorithm|"Antibiotic therapy discontinuation will be encouraged under the following conditions:~If the peak CRP is below 100 mg/L: Consider stopping antibiotics when CRP falls below 35 mg/L, with a minimum treatment duration of 3 days.~If the peak CRP is above 100 mg/L or the patient meets criteria for sepsis or septic shock: Consider stopping antibiotics when CRP has decreased by 50%, after a minimum of 5 days.~If the patient does not meet the CRP criteria: Antibiotic discontinuation will be recommended after 5-7 days, provided there is clinical improvement.~Before discontinuing antibiotic therapy, physicians should confirm that the patient is clinically improving, with no signs of a persistent infectious focus. Additionally, they will be encouraged to verify that the Sequential Organ Failure Assessment (SOFA) score is stable or decreasing. These factors will assist in determining the appropriateness of stopping antibiotics."
214385713|NCT00847821|DRUG|Raloxifene 60 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as raloxifene tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
214997404|NCT02983656|BIOLOGICAL|live attenuated varicella vaccine|
214997405|NCT00637897|DRUG|docetaxel|
214997406|NCT00637897|DRUG|ixabepilone|
214997407|NCT00637897|DRUG|paclitaxel|
214997408|NCT00637897|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
214997409|NCT00637897|DRUG|paricalcitol|
214997410|NCT03016637|DEVICE|SharkCore (TM) FNB Exchange System|
214997411|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
214997412|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
214997413|NCT05593887|PROCEDURE|Hip reconstruction surgery.|This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction, pelvic osteotomy and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur, internal fixation
214997414|NCT05593887|PROCEDURE|Proximal femoral resection|Resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur
215093517|NCT04816383|OTHER|"Breastfeeding at AU Apple-Based Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
215093518|NCT01437527|BEHAVIORAL|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
214385714|NCT00847821|DRUG|Placebo|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
214385715|NCT03463915|DRUG|Bladder instillation WITH triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
214385716|NCT03463915|DRUG|Bladder instillation WITHOUT triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
214385717|NCT03743896|DRUG|Transdermal Glucosamine Cream|
214385718|NCT02712671|RADIATION|Chest radiograph|A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
214385719|NCT02712671|PROCEDURE|Blood interferon gamma release assay|Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).
214385720|NCT02712671|PROCEDURE|Tuberculin skin testing (TST)|An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.
214687740|NCT05504148|DRUG|crocin|Take saffron total glucosides tablets for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day.
214687741|NCT05504148|DRUG|Placebo|Take placebo piece during for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day
214997415|NCT05593887|PROCEDURE|Proximal femoral valgus ostetomy|The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate
214997416|NCT03463239|BIOLOGICAL|Autologous tissue engineered corpora|penile tissue construct
214997417|NCT03307356|OTHER|Uterine Transplant|Transplant of a uterus from a donor, deceased or living
214997418|NCT03590028|OTHER|Early Nephrology Consult (ENC)|The electronic risk prediction algorithm (ESTOP-AKI) will interface with electronic medical data to determine the likelihood for the patient to develop AKI. Early Nephrology Consult (ENC) will be implemented. A nephrologist will assess the subject and consult with their care team to advise a treatment plan during the hospitalization.
215093519|NCT01437527|BEHAVIORAL|therapy as usual|Body image therapy as usual
215093520|NCT05347940|OTHER|mirror therapy|A Mirror box will be used to easily create illusion. It' is a box with one mirror in the center where on each side of it, the hands are placed in a manner that the affected limb is kept covered always and the unaffected limb is kept on the other side whose reflection can be seen on the mirror.
214385721|NCT02712671|PROCEDURE|Sputum induction for mycobacterial microscopy and culture|Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.
214385722|NCT02712671|OTHER|Mycobacterium tuberculosis polymerase chain reaction testing|Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.
214385723|NCT02712671|PROCEDURE|Spirometry|Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
214385724|NCT04354766|OTHER|Blood sample|This study will require a blood sample (4 ACD tubes, 20 ml) at one time.
214385725|NCT04068363|OTHER|non interventional|non interventional study
214385726|NCT01732146|DRUG|erythropoietin Beta|erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
214385727|NCT01732146|DRUG|Placebo|
214385728|NCT03218332|DIAGNOSTIC_TEST|Biomarkers for detecting possible CTE invivo|Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
214385729|NCT00375141|DEVICE|Pulsed dye laser, Intense pulsed light|
214385730|NCT02803060|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formaulation number- SR15-62 -Z15-038).
214499851|NCT06090240|OTHER|MI-based ACP intervention|Motivational Interviewing on Advance Care Planning Intervention: Dyads of older adults and family caregivers will receive three MI-based ACP counselling sessions: (1) a preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions in weeks 2 and 3 will last 30-45 minutes each. Before each session, the nurse interventionist will first assess the dyad's readiness to engage in ACP based on the state of change algorithm. Participants who have never thought about ACP will be in the pre-contemplation state, those who are willing to discuss EOL care and preferences to be in the contemplation state, those ready to talk about EOL planning to be in the preparation state, and those in the action state have a confirmed action plan on signing up their ADs. Readiness-based ACP goals will be established, and state-matched MI counseling will be customized for each participant.
214499852|NCT05366088|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse."
214499853|NCT05366088|BEHAVIORAL|Health Enhancement Program|HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
214997419|NCT03590028|OTHER|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
214997420|NCT03713125|BEHAVIORAL|Reading Tutoring|20 hours of 1:1 reading tutoring intervention over 6 weeks
215093521|NCT05347940|OTHER|traditional physiotherapy protocol for flexor tendon repair|include stretching exercises and active ROM exercises
214385731|NCT03792321|DRUG|Testosterone Undecanoate|1000 mg i.m. every 10 weeks
214385732|NCT03792321|DRUG|Placebo|
214385733|NCT03164941|PROCEDURE|Selective Laser Trabeculoplasty|Laser treatment for glaucoma.
214385734|NCT06120517|COMBINATION_PRODUCT|emg- biofeedback|EMG activity shows the electrical activity measured during striated muscle contraction. The electrical activity of the muscle is in microvolts (1 volt = 1,000,000μV). Biofeedback units usually produce audio or visual feedback depending on the amount of electrical activity. Recording the bio-electrical activity of the muscle is a practical indicator of its contractility.
214385735|NCT02381743|BEHAVIORAL|Group 2 intervention daily SMS bullet point|Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.
214385736|NCT02381743|BEHAVIORAL|Group 3 intervention daily SMS bullet point|Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
214687742|NCT04358094|OTHER|Conversational hypnosis script|Conversational hypnosis during peripherical veinous catheter set up
214997421|NCT04429087|DRUG|BI 764532 - parenteral 1|BI 764532 - parenteral 1
214997422|NCT04429087|DRUG|BI 764532 - parenteral 2|BI 764532 - parenteral 2
214385737|NCT04380298|DRUG|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
214385738|NCT04380298|DRUG|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
214997423|NCT04573530|BEHAVIORAL|We Walk Plus Intervention|The frequency and content of weekly personalized SMS are based on each participant's preference. Prior to implementation of intervention, the investigators will conduct focus groups to learn participants' social network activities and preferences, strategies that can be used to encourage engagement via a private Fitbit community network.
214997424|NCT02916771|DRUG|Ixazomib|Oral, proteasome inhibitor
214997425|NCT02916771|DRUG|Lenalidomide|Oral, immunomodulatory agent
214997426|NCT02916771|DRUG|Dexamethasone|Oral, steroid
214997427|NCT00116909|DRUG|OSI 7904L|
214997428|NCT05675085|DIAGNOSTIC_TEST|Personalized screening protocol|"At the first screening round (recruitment) all participating women had the same tests;~* Two-view tomosynthesis of both breasts~* Calculation of volumetric breast density (VBD)~* Calculation of lifetime risk (LTR) using the Tyrer-Cuzick model~At subsequent rounds:~1. Women with non-dense breasts and low breast cancer risk are re-screened only with DBT every 2 years;~2. Women with dense breasts and low breast cancer risk are re-screened with DBT+US every 2 years;~3. Women with non-dense breasts and intermediate breast cancer risk are re-screened only with DBT every year;~4. Women with dense breasts and intermediate breast cancer risk are re-screened with DBT+US every year;~5. Women at high risk of breast cancer associated with a family history of breast cancer (w/wo hereditary factors) undergo DBT and MRI every year."
215093522|NCT01675362|DRUG|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
215093523|NCT01675362|DRUG|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
215093524|NCT01675362|DRUG|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
214385739|NCT04380298|DRUG|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
215093525|NCT01675362|DRUG|Placebo|They will receive placebo
214385740|NCT02341287|DEVICE|Warming hydrogel glove|Subjects wore the warming hydrogel glove in either the first or second two-week period.
215093526|NCT04608162|OTHER|Pulsed Electromagnetic Field (PEMF)|PEMF was administered to the whole body using a 1.8×0.6m mat
215093527|NCT04608162|OTHER|Exercise Program|Exercise program to facilitate bone health
215093528|NCT04608162|OTHER|Placebo PEMF|Patients received placebo PEMF
214385741|NCT02341287|DEVICE|Non-thermal glove|Subjects wore the non-thermal glove in either the first or second two-week period.
214385742|NCT02687412|PROCEDURE|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
214385743|NCT02687412|PROCEDURE|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
214499854|NCT04001829|DRUG|Docetaxel|Given IV
214499855|NCT04001829|DRUG|Paclitaxel|Given IV
214499856|NCT04001829|OTHER|Quality-of-Life Assessment|Ancillary studies
214997429|NCT05057637|DEVICE|Optical coherence tomography measurements|Optical coherence tomography measurements in femoropopliteal tract
214997430|NCT05899634|BEHAVIORAL|Defaults|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention). In addition, in this group, participants' online grocery shopping carts will be pre-filled with ingredients corresponding to the provided recipes. They will be told that their cart has been filled with items that can be used to make recipes from the provided recipe cards, and that they can modify it as they like.
214997431|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Materials Only|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment."
215093529|NCT05233345|BEHAVIORAL|Occupational Therapy|online occupational therapy sessions are based on the activity training
214499857|NCT04001829|OTHER|Questionnaire Administration|Ancillary studies
215093530|NCT03168100|DRUG|Elotuzumab|administered via IV infusion
215093531|NCT03168100|DRUG|Lenalidomide|taken by mouth
215093532|NCT03168100|DRUG|Dexamethasone|taken by mouth
215093533|NCT03168100|DRUG|Bortezomib|administered as a subcutaneous injection
215093534|NCT03547934|DEVICE|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
215093535|NCT00003447|DRUG|gemcitabine hydrochloride|
215093536|NCT00003447|DRUG|vinorelbine tartrate|
215093537|NCT04464824|OTHER|no intervention|no intervention
215093538|NCT04385225|OTHER|Longitudinal follow-up|Longitudinal hearing, vestibular and cognitive follow-up
215093539|NCT03226977|DEVICE|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
215093540|NCT03226977|DEVICE|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
215093541|NCT06175169|DEVICE|Information of Appendix (IA) model|Deep learning model
215093542|NCT04407104|DIAGNOSTIC_TEST|skin prick-test|retrospective study on data already collected
215093543|NCT02768753|PROCEDURE|The Axillary Bilateral-breast Approach|
215093544|NCT02768753|PROCEDURE|The bilateral Axillo-breast Approach|
215093545|NCT01583660|DRUG|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
215093546|NCT01583660|DRUG|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
215093547|NCT00112177|DRUG|Itopride Hydrochloride|
214385744|NCT02687412|PROCEDURE|bowel preparation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
214385745|NCT02687412|PROCEDURE|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
214385746|NCT02687412|PROCEDURE|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
214499858|NCT06552351|DEVICE|Needle-Free Jet Injection of 1 % lidocaine|The needle-free jet injection device delivers 1% lidocaine through high-pressure fluid without the use of a needle. This method aims to reduce the pain associated with needle-based anesthesia during infant lumbar punctures.
214499859|NCT06552351|OTHER|traditional needle infiltration of 1% lidocaine|Traditional needle infiltration involves injecting 1% lidocaine with a needle to provide local anesthesia before an infant lumbar puncture. This method is the standard practice for pain management in such procedures.
214499860|NCT03592888|DRUG|mDC3/8-KRAS Vaccine|Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
214687743|NCT04358094|OTHER|Standard script|Standard script during peripherical veinous catheter set up
215093548|NCT05107466|DIAGNOSTIC_TEST|P300 Visually evoked potential|Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.
215093549|NCT03984487|BEHAVIORAL|Surviving and Thriving in the Real World|The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
215093550|NCT03984487|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
215093551|NCT01065831|BEHAVIORAL|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
214385747|NCT02687412|PROCEDURE|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
214385748|NCT02687412|PROCEDURE|Postoperative glycaemic control|Postoperative glycaemic control;
214385749|NCT02687412|PROCEDURE|postoperative nausea and vomiting (PONV) control;|
214385750|NCT02687412|PROCEDURE|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
214997432|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Direct Training|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers."
215093552|NCT00370513|DRUG|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
215093553|NCT00269204|DRUG|niacin (+) laropiprant|Duration of Treatment - 24 weeks
215093554|NCT00269204|DRUG|ER-niacin|Duration of Treatment - 24 weeks
215093555|NCT03823950|DRUG|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
214385751|NCT02687412|PROCEDURE|pre-operative fasting at least 8h|
214385752|NCT02687412|PROCEDURE|bowel preparation for traditional surgery|Oral bowel preparations or mechanical bowl until liquid stool
214385753|NCT02687412|PROCEDURE|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
214385754|NCT03711864|BIOLOGICAL|IM21 CAR-T cells|fludarabine and cyclophosphamide Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
214385755|NCT00553202|BIOLOGICAL|anti-thymocyte globulin|Given IV
214385756|NCT00553202|DRUG|busulfan|Given IV
214385757|NCT00553202|DRUG|cyclophosphamide|Given IV
214385758|NCT00553202|DRUG|cyclosporine|Given IV or orally
214385759|NCT00553202|DRUG|methotrexate|Given IV
214385760|NCT00553202|DRUG|methylprednisolone|Given IV
214385761|NCT00553202|DRUG|tacrolimus|Given IV
214385762|NCT00553202|OTHER|laboratory biomarker analysis|Correlative studies
214499861|NCT04688684|BEHAVIORAL|Family-based diet and exercise intervention|The participants will meet together weekly as a family unit to receive education and planning to implement diet and lifestyle changes under the supervision of a health coach. This coach will also be available during the week by telephone or messaging for additional individualized support if needed.
214997433|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Local Supervision|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center."
214385763|NCT00553202|OTHER|pharmacological study|Correlative studies
214385764|NCT00553202|PROCEDURE|allogeneic bone marrow transplantation|allogeneic bone marrow transplantation
214385765|NCT00553202|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic SCT
214499862|NCT01632956|BEHAVIORAL|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
214499863|NCT01632956|BEHAVIORAL|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
214499864|NCT00489879|DEVICE|Mobile Health Care System (DrUB)|
214499865|NCT02541305|OTHER|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
214499866|NCT02541305|OTHER|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
214499867|NCT03678688|DRUG|10 mg OPC-167832|Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
214499868|NCT03678688|DRUG|30 mg OPC-167832|Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
214499869|NCT03678688|DRUG|90 mg OPC-167832|Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
214499870|NCT03678688|DRUG|3 mg OPC-167832|Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
214499871|NCT03678688|DRUG|RHEZ|"RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight:~* Participants weighing 30 to 37 kg received 2 tablets per day~* Participants weighing 38 to 54 kg received 3 tablets per day~* Participants weighing 55 to 70 kg received 4 tablets per day~* Participants weighing \> 70 kg received 5 tablets per day"
214499872|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.
214997434|NCT04249024|DEVICE|Laser treatment|The participants in the laser group are treated with a 970 nm diode laser and if calculus is present scaling and root planning (SRP). The peri-implant pocket will be radiated with the 970 nm laser, removing bacteria, diseased epithelium and granulation tissue. The laser will be used at a maximum of 20s intervals before water irrigation. Laser settings continuous wave mode and power between 1.0-1.3W. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
214997435|NCT04249024|PROCEDURE|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
214997436|NCT04249024|BEHAVIORAL|Oral hygiene instructions|Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.
214997437|NCT06147271|DRUG|SGLT2i|A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
214997438|NCT04280952|DEVICE|CONVIVO|tumor tissue with the CONVIVO system
214499873|NCT03678688|DRUG|30 mg OPC-167832 + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
214499874|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
214499875|NCT02959411|DRUG|Tolvaptan|Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
214499876|NCT02959411|DRUG|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
214499877|NCT04164446|DRUG|Placebos|The placebo that will be used contains starch and glucose.
214499878|NCT04164446|DIETARY_SUPPLEMENT|Oil Palm Phenolics|One capsule contains 250 mg OPP or 1 g OPP
214499879|NCT04072133|BEHAVIORAL|Meditative Movement|Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
214499880|NCT02343094|DRUG|PBA 7,5g/d|Treatment for 14 days with PBA
214499881|NCT02343094|DRUG|PBA 15g/d|Treatment for 14 days with PBA
214499882|NCT03349944|BEHAVIORAL|Training|The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
214499883|NCT01427517|DRUG|N-acetylcysteine|Single, intravenous administration of N-acetylcysteine
214499884|NCT02162082|DEVICE|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
214499885|NCT05845970|OTHER|Pamprin Botanicals|Participants will take Pamprin Botanicals only. Participants will take 450mg of Pamprin Botanicals two days before their predicted period and then take it every day during their period. Participants can also take Pamprin Botanicals two days after the bleeding has concluded.
214499886|NCT05845970|COMBINATION_PRODUCT|Pamprin Botanicals + Pamprin Menstrual Pain Relief|Participants will repeat taking Pamprin Botanicals two days before their second predicted period and continue to take it each day during their period. However, during the second period, participants will also take Pamprin Menstrual Pain Relief per the over-the-counter directions (2 tablets every 6 hours with water).
214385766|NCT04651114|BEHAVIORAL|Decision-making tool|"Women will be directed to a secure website to download a copy of the decision making tool and worksheets (they can download as many copies as they wish to). The women will use the tool and worksheets at their own pace for the pilot study period.~The decision making tool is a 23-page tool and set of 9 downloadable worksheets. The tool covers topics relevant to women with disabilities in considering or planning a pregnancy: 1) Overview of Pregnancy: 2) Knowing what is important; 3) Partners, family and important relationships; 4) Physical function and independence; 5) Health and wellbeing; 6) Caring for an infant; 7) Financial resources \& insurance; 8) How to find reliable information and resources; 9) Connecting with other women with physical disabilities; 10) Dealing with reactions of others, stigma and bias, pressure; and 11) Reaching a decision."
214385767|NCT01923896|BEHAVIORAL|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
214385768|NCT01923896|DRUG|d-cycloserine (DCS)|
214385769|NCT01923896|DRUG|Placebo|lactose powder
214385770|NCT01097395|DRUG|ribavirin|Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
214385771|NCT04071977|DRUG|Combined antioxidant therapy|It consists of a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1 mg), vitamin C (L-ascorbic acid 180 mg), vitamin E (DL-alpha tocopherol 30 mg), zinc (zinc oxide 20 mg), copper (copper sulfate 1 mg), taken once a day for 12 months
214499887|NCT02677766|OTHER|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
214499888|NCT02677766|OTHER|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
214499889|NCT05689606|BEHAVIORAL|Exercise|Exercise includes acute high-intensity interval training.
214499890|NCT01259570|DIETARY_SUPPLEMENT|Group 1|Skimmilk enriched with VD encapsulated in CM
214499891|NCT01259570|DIETARY_SUPPLEMENT|Group 2|VD will be dissolved in milkfat and homogenized into skimmilk
214499892|NCT01259570|DIETARY_SUPPLEMENT|group 3|3% fat milk wherein the VD will be in CM
214499893|NCT01259570|DIETARY_SUPPLEMENT|Group 4|Placebo: un-enriched skimmilk.
214997439|NCT03646617|RADIATION|Hypofractionated Radiation Therapy (HFRT)|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
214997440|NCT03646617|DRUG|Nivolumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.
214997441|NCT03646617|DRUG|Ipilimumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.
214997442|NCT05556343|DRUG|MYK-224|Specified dose on specified days
214997443|NCT06166303|DIAGNOSTIC_TEST|sFlt-1/PGIF|Index of sFlt-1/PGIF
214997444|NCT06005220|OTHER|SBD121|Medical Food
214997445|NCT06005220|OTHER|Placebo|Placebo
214997446|NCT06048445|DEVICE|intraoperative plancement of Biliary Drainage Stent|plancement of Biliary Drainage Stent in liver transplantation of pediatric patients
214385772|NCT04071977|OTHER|Placebo|It consists in a capsule with 100 mg of magnesium oxide
214385773|NCT00592319|DRUG|Celebrex|oral taking of Celebrex (100 mg, BID) for 9 months
214385774|NCT00592319|DEVICE|PDL|once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
214385775|NCT00592319|PROCEDURE|CO2 laser or microsurgery|once-time surgery to remove laryngeal papilloma
214385776|NCT03963323|DIETARY_SUPPLEMENT|Glucosamine Sulfate/Chondroitin Sulfate Tablet|Given PO
214385777|NCT03963323|OTHER|Placebo|Given PO
214385778|NCT00505726|PROCEDURE|Reflectance Confocal Imaging|Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
214385779|NCT02040272|PROCEDURE|(Extended) pleurectomy decortication|
214385780|NCT03707444|DEVICE|Scrambler Therapy Device|Superficial neuromodulation using EKG type electrodes \[Scrambler (MC5-A Calmare) Therapy\]
214499894|NCT05960669|PROCEDURE|3D model guided secondary resection|A prostate model was 3D printed from preoperative pelvic MRI data and used during robot-assisted radical prostatectomy to mark a positive surgical margin and guide secondary resection.
214499895|NCT06510140|BEHAVIORAL|Detection of the Post-operative delirium (POD)|Detection of the early Post-operative delirium (POD) to assess the performance of a new composite score with pre-operative frailty, and per-operative ElectroEncephaloGram (EEG).
214499896|NCT05479565|DIAGNOSTIC_TEST|venous blood sample for determining the value of highly sensitive C-reactive C protein from serum|The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.
214499897|NCT02192632|DRUG|Epiduo once daily with detailed instruction for how to apply it|
214499898|NCT02192632|DRUG|Epiduo- once daily, simple instruction for application|
214499899|NCT02192632|DRUG|BPO once daily|
214997447|NCT06547957|DRUG|EOS301984|Multiple doses of EOS301984
214997448|NCT06547957|DRUG|Anti-PD-1 monoclonal antibody|Multiple doses of EOS301984 in combination with Anti-PD-1
214499900|NCT00360191|DRUG|Buspirone|
215093556|NCT04807387|DEVICE|Vaginal Stent A|Ring stent
214385781|NCT02410967|BEHAVIORAL|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
214385782|NCT02410967|BEHAVIORAL|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
215093557|NCT04807387|DEVICE|Vaginal Stent B|Flower stent
215093558|NCT04807387|DEVICE|Vaginal Stent|Vaginal stent chosen from A or B that is the most comfortable
214385783|NCT02483013|OTHER|whitening dentifrices|Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
214385784|NCT02483013|OTHER|Placebo|One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
214385785|NCT00235443|DRUG|lacosamide|Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
214385786|NCT05217836|DIAGNOSTIC_TEST|ferritin; iron; transferrin; transferrin saturation; hemoglobin in reticulocyte; hepcidin|All patients will have the following laboratory parameters determined: ferritin, iron, transferrin, transferrin saturation, hemoglobin in reticulocyte, hepcidin. Patients with hemoglobin in reticulocyte below reference range will receive parenteral iron.
214385787|NCT02010697|BEHAVIORAL|Messages targeting nonsmokers|
214385788|NCT02010697|BEHAVIORAL|Messages targeting smokers|
214385789|NCT03906305|OTHER|Dry needling in a myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application over a myofascial trigger point by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into taut bands of the following shoulder spastic muscles (when a trigger point was present): upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy~Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
214499901|NCT00360191|PROCEDURE|Motivational enhancement therapy|
214499902|NCT01905566|DRUG|Clopidogrel|75mg once a day
214499903|NCT01905566|DRUG|Ticagrelor|90mg twice a day
214499904|NCT04196309|DRUG|low molecular weight heparin|LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)
214499905|NCT02162394|DEVICE|Observational ambulatory ECG monitoring|
214499906|NCT04436549|PROCEDURE|Stab Avulsion of varicose veins|Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.
214499907|NCT04436549|DIAGNOSTIC_TEST|Histopathologic evaluation of varicose veins|Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
214499908|NCT00502684|DRUG|Propranolol, etodolac|propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
214499909|NCT00985088|BIOLOGICAL|GSK2340274A|one or two intramuscular injections
214499910|NCT00985088|BIOLOGICAL|GSK2340273A|one or two intramuscular injections
214499911|NCT00985088|BIOLOGICAL|Saline placebo|One injection
214499912|NCT05346588|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
214499913|NCT05346588|OTHER|Anesthetic technique inhaled agent|must administer inhaled agent.
214499914|NCT04062578|BEHAVIORAL|Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature|The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
214687744|NCT03615755|OTHER|Hyperbaric Oxygen Therapy (HBOT)|The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
215093559|NCT01504204|DRUG|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
215093560|NCT01504204|DRUG|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
215093561|NCT00903331|DRUG|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
215093562|NCT00903331|DRUG|Placebo|matching placebo, once daily
215093563|NCT04369508|RADIATION|permanent brachytherapy|"Briefly, the patient had a general anesthesia and PPB was performed by using the real-time intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon."
215093564|NCT02107872|DRUG|REGN1500|
214997449|NCT06054347|OTHER|VINELAND II|Standardised questionnaire filled by the investigator during an interview with the parents or with the patient himself if capable of it. Duration 1 hour to 1 hour and a half.
214385790|NCT03906305|OTHER|Dry needling in a non myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application carried out over a non trigger point area by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into a non trigger point spastic muscle of the shoulder area: upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
214385791|NCT01401413|DRUG|ramelteon|8 mg nightly for 30 nights
214385792|NCT01401413|DRUG|placebo|placebo control i pill nightly for 30 nights
214385793|NCT04394520|OTHER|Modified Introduction|A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.
214385794|NCT04394520|OTHER|Active Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-in to the survey, if they do not respond, the survey will terminate.
214385795|NCT04394520|OTHER|Active Opt-out|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-out to the survey, if they do not respond, the survey will continue.
214385796|NCT04394520|OTHER|Passive Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to passively opt-in to the survey, if they do not hang-up, the survey will continue.
214385797|NCT00376051|DRUG|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
214385798|NCT00296842|BEHAVIORAL|Early psychological intervention|Psychoeducation, trauma narrative, provision of coping skills
214499915|NCT05141968|DIETARY_SUPPLEMENT|vitamin D supplements (2000 IU/day)|The interventional (experimental) group received vitamin D supplements (2000 IU/day). According to previous studies and after the direct supervision from the treating pediatrician and endocrinologist, the best preparation and dosage of vitamin D was used (According to FDA the recommended dose for children age 1 year and older is 2,000 IU/day).
214499916|NCT02824926|DRUG|Dapaconazole|
214499917|NCT02824926|DRUG|Ketoconazole|
214499918|NCT05795088|DEVICE|Continuous theta burst stimulation|Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease
214499919|NCT06445140|BEHAVIORAL|Collecting the variables and Implementation of a behavioural intervention|"The observational phase (during 15 days)~* Two measurements per day for motivational variables and physical activity and nutrition~* Two measurements per day for nutrition~* Three measurements per day for fatigue~* Continuous PA measurement by accelerometer~The interventional phase :~Part A (during 7 days)~* measuring physical activity (PA)~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue~Part B: BEHAVIORAL INTERVENTION (10 weeks),the APA teacher will call a patient once a week for follow-up.~Answer questionnaires and scales on the digital platform will be done :~* Motivational factors~* Self-evaluation of nutrition~* Self-assessment of fatigue~Part C : End of interventional phase(during 7 days)~* measuring physical activity~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue"
214499920|NCT03033667|DIETARY_SUPPLEMENT|G group|patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
214499921|NCT03033667|DIETARY_SUPPLEMENT|group L|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
214997450|NCT06409819|DRUG|phage therapy|phage therapy will consist of a combination of three lytic phages that are active against the participant's E. coli isolates and will be administered intravenously twice daily for 7 days.
214499922|NCT03033667|DIETARY_SUPPLEMENT|Group C|Over night fasting with no supplementation
214997451|NCT06409819|DRUG|control|Participants assigned to the control arm will start a 7-day course of intravenous sterile normal saline (placebo) administered twice daily.
214997452|NCT04274179|OTHER|Modified Atkins Diet|Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.
214997453|NCT04274179|DRUG|Absence epilepsy medications|At neurologist's discretion. \*OF NOTE\< THIS ARM IS COMPLETED
214385799|NCT04719403|OTHER|HealthPAL|Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.
214997454|NCT06804837|OTHER|Visual consent|Visual key information page
214997455|NCT06804837|OTHER|Standard consent|Summary text only
214997456|NCT05521958|PROCEDURE|Acute injury without compartment syndrome|"Acute tibial shaft or tibial plateau fractures who do not have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
215093565|NCT02107872|DRUG|placebo|
214385800|NCT05145842|PROCEDURE|floroscopy|After proper antiseptic dressing and draping, sacral hiatus was identified. the position of the needle was confirmed by lateral and anteroposterior fluoroscopic images. The needle was introduced up to S3 level for proper spread of the drug.
215093566|NCT02723175|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
215093567|NCT06421922|DIETARY_SUPPLEMENT|Group 1 received a regular constipation diet|Group 1 received only regular constipation diet, the constipation diet included 2 litres of water, 2 portions of vegetables, 3 portions of fruits and legumes 2 times a week. Followed 8 weeks.
215093568|NCT06421922|DIETARY_SUPPLEMENT|Group 2 received a constipation diet rich in soluble fiber|Soluble fiber (resistant starch) (5 g/day) was added to the constipation diet in group 2 as 1 sachet/day (5 g/day) during the initial 4 weeks and 2 sachets/day (10 g/day) in the following 4 weeks.
214997457|NCT05521958|PROCEDURE|Acute injury with compartment syndrome|"Acute tibial shaft or tibial plateau fractures who have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
214385801|NCT05145842|PROCEDURE|ultrasound+fluoroscopy|After proper antiseptic dressing and draping, the caudal region will be shown in the longitudinal section using sterile probe cover and gel. Under ultrasonographic imaging, the sacrococcygeal ligament will be crossed and the needle will not be advanced any further once the sacral canal is entered. The fluoroscopy phase of the combined imaging will be started and the needle position will be checked by taking an anteroposterior view. The needle tip will be positioned at the sacral 3 level. The needle will be repositioned until the proper position is achieved. The research will be terminated at this point and the time to this stage and the radiation exposure dose will be obtained.
214385802|NCT00474929|DRUG|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
214385803|NCT00474929|DRUG|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
214385804|NCT00819403|DRUG|simvastatin|Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
214385805|NCT00819403|DRUG|ezetimibe/simvastatin|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
214385806|NCT03746743|DIAGNOSTIC_TEST|score for neonatal sepsis|score for neonatal sepsis to predict morbidity
214385807|NCT00023842|BIOLOGICAL|BCG vaccine|
214385808|NCT00023842|DRUG|mitomycin C|
214385809|NCT00023842|PROCEDURE|adjuvant therapy|
214385810|NCT00023842|PROCEDURE|conventional surgery|
214385811|NCT03488290|BEHAVIORAL|LTP Plus TF-CBT|Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
214385812|NCT03488290|OTHER|Treatment as Usual|The Treatment as Usual group will receive routine care
214385813|NCT04905108|DRUG|Riboflavin|Administration of riboflavin one drop every 2 minutes during UVA exposure
214385814|NCT04905108|DRUG|Riboflavin|Administration of riboflavin one drop every 10 minutes during UVA exposure
214385815|NCT00421226|DRUG|ACZ885|
214385816|NCT03313219|DRUG|Gentuximab Injection|Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)
214499923|NCT05885620|DEVICE|drinking reminder and cognitive task (smartwatch-based application)|task A: prompt to drink some water task B: prompt to circle bells on a sheet
214499924|NCT03488459|BEHAVIORAL|Routine preoperative information from a nurse|Routine preoperative information from a nurse.
214499925|NCT03488459|BEHAVIORAL|Additional information support from a psychologist|Routine preoperative information from a nurse + additional information support from a psychologist.
214499926|NCT06504290|DRUG|VV119 Placebo （in healthy adult subjects）|"VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days."
214499927|NCT06504290|DRUG|VV119 （in healthy adult subjects）|"VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days."
214499928|NCT06504290|DRUG|VV119(in adult patients with schizophrenia)|VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily, VV119 6 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first three days,take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the forth day to the fifth day , take 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the sixth day to the seventh day , then 3 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.
214997458|NCT05521958|PROCEDURE|Exertional compartment syndrome|For patients with exertional compartment syndrome, a muscle biopsy will be obtained from affected extremity.
214687745|NCT02528500|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
214687746|NCT02712372|DRUG|AZD4831|AZD4831 1-50 mg/g oral suspension
214997459|NCT06032221|DEVICE|Thermidas Vista Telehealth App|Thermal camera with telemedicine app
214687747|NCT02712372|DRUG|AZD4831 placebo|AZD4831 placebo oral suspension
214997460|NCT05788029|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy
214997461|NCT05788029|PROCEDURE|open pancreaticoduodenectomy|open pancreaticoduodenectomy
215093569|NCT06421922|DIETARY_SUPPLEMENT|Group 3 received a constipation diet supplemented with probiotic yogurt.|"Bifidobacterium İnfantis 35624 (B. İnfantis 35624)\&#34; strain, which is specific to IBS, was added to yogurt in group 3, consumed before the lunch. The follow-up period was 8 weeks."
215093570|NCT04687423|DRUG|FCN-011|FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
215093571|NCT06089902|PROCEDURE|unroofing or other surgery if needed|unroofing of coronary artery
215093572|NCT03057470|DRUG|50% bolus insulin correction|Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
215093573|NCT03057470|DRUG|100% bolus insulin correction|Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
215093574|NCT03057470|DRUG|150% bolus insulin correction|Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
215093575|NCT03057470|OTHER|0% bolus insulin correction|Patients will receive no bolus insulin correction for post-exercise hyperglycemia
214997462|NCT05991713|BEHAVIORAL|Modifying Exploration|Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.
214385817|NCT05486429|COMBINATION_PRODUCT|Abdominal ultrasound and lipid profile|"All patients will be subjected to: -~* Complete history taking with stress on:~  * Age, sex, comorbid conditions (diabetes, hypertension, ischemic heart disease)~ * History of intake of lipid lowering drugs.~* Thorough clinical examination:~General examination, vital sign, height, weight, body mass index. Abdominal examination (hepatomegaly, splenomegaly, ascites)~* Laboratory Investigation:~  1.Lipid profile (total cholesterol, triglyceride, HDL, LDL, VLDL (~  .2Liver function tests (ALT, AST, Albumin, Bilirubin, PT, PC, INR) 3.Complete blood picture. 4.Serology for HBV, HCV. 5.Serum creatinine. 6.Fasting and postprandial blood sugar.~* Radiological Investigation:~  1.Abdominal ultrasound.~* FIB - 4 it combines platelets count, ALI, AST and age.~* AST/Platelets ratio index is calculated as (AST/upper limit of normal range) /Platelets count (10\^9/L) ×100."
214385818|NCT03029247|DRUG|Daprodustat|Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
214385819|NCT03029247|DRUG|Epoetin alfa|Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
214385820|NCT04906109|DRUG|Vemlidy Tab|1T
214385821|NCT04906109|DRUG|DA-2803 Tab|1T
214385822|NCT04914052|OTHER|Filming facial expressions|Study participants' facial expressions will be videoed by a camera placed in front of the patient's bed during their stay in the post anesthesia care unit.
214385823|NCT00206154|DRUG|Budesonide/formoterol pMDI|
214385824|NCT00206154|DRUG|Budesonide pMDI|
214385825|NCT00206154|DRUG|Formoterol Turbuhaler|
214385826|NCT01045122|DRUG|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
214385827|NCT01045122|DRUG|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
214687748|NCT06552598|DRUG|KD01(the recombinant oncolytic adenovirus)|"Phase Ia PART 1 (Dose Escalation Phase with Monotherapy): Subjects in each dose group will continue to undergo a 21-day assessment for Dose-Limiting Toxicity (DLT) after completing the first cycle of treatment (D1-5), totaling 26 days starting from D1.~Phase Ib PART 2 (Dose Expansion Phase with Monotherapy): Subjects will receive intratumoral injections, starting on D1. Further treatment will continue based on the patient's willingness, with a maximum of 5 administrations. The final administration will be followed by surgery 7-14 days later, until the patient is discharged."
214687749|NCT01057719|OTHER|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
214997463|NCT05932654|DRUG|BSI-045B|Patients will be treated with BSI-045B.
214997464|NCT04628507|OTHER|Spent media collection|Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
214997465|NCT07115108|DIETARY_SUPPLEMENT|High energy density enteral nutrition|High-energy-density enteral nutrition (100 cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted.
215093576|NCT02894450|OTHER|blood test|bioassay xaban
215093577|NCT02754960|DRUG|Thalidomide|Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
215093578|NCT02754960|DRUG|Placebo|Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
215093579|NCT04356482|BIOLOGICAL|convalescent plasma|"In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case.~In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated."
215093580|NCT01205477|DRUG|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
214385828|NCT00807521|DRUG|Dexamethasone|Single high dose bolus of dexamethasone before surgery
214385829|NCT00807521|DRUG|Placebo|Placebo for dexamethasone
214385830|NCT04981132|BEHAVIORAL|Pain Neuroscience education + Progressive therapeutic exercise training|The education group will have a comprehensive patient education which includes; description, transmission, representation of pain, central sensitization, neuroplasticity, its relation to body systems, psychosocial and emotional factors affecting pain, pain behavior, and lifestyle changes to cope with pain, etc. Plus, the group will have supervised progressive therapeutic exercises via the telerehabilitation method.
214385831|NCT04981132|BEHAVIORAL|Progressive therapeutic exercise training|The exercise group will have supervised progressive therapeutic exercises via the telerehabilitation method.
214385832|NCT03678259|DRUG|124I-p5+14 Injection|124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge
214385833|NCT01048645|DRUG|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
214385834|NCT01048645|OTHER|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
214385835|NCT01735357|DIETARY_SUPPLEMENT|EPA-rich triacylglycerol oil|
214385836|NCT01735357|DIETARY_SUPPLEMENT|Placebo - olive oil (BP specification)|
214385837|NCT01735357|DIETARY_SUPPLEMENT|DHA-rich triacylglycerol oil|
214385838|NCT02807740|OTHER|Virtual reality|Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
214385839|NCT02807740|OTHER|Conventional rehabilitation program|In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
214385840|NCT02606955|DEVICE|BIA DW|All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
214385841|NCT02593305|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g/day) for 4 weeks
214385842|NCT02593305|DIETARY_SUPPLEMENT|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 4 weeks
214385843|NCT06124742|DEVICE|clear aligners|taste perception will be evaluated before and after using clear aligners.
214385844|NCT02851966|PROCEDURE|mTESE|mTESE time may be postponed or advanced.
214385845|NCT01190215|BIOLOGICAL|FluarixTM|One Intramuscular injection
214385846|NCT01190215|BIOLOGICAL|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
214385847|NCT05883917|PROCEDURE|robot assisted gait training|Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.
214385848|NCT00586079|PROCEDURE|Deep brain stimulation surgery.|Deep brain stimulation surgery.
214385849|NCT05800808|PROCEDURE|High Intensity Intervals|8x4 min cycling bouts at 85% of VO2peak
214385850|NCT05800808|PROCEDURE|Moderate Exercise|81 minutes of cycling at 50% VO2peak
214385851|NCT00584701|DRUG|Risperidone|Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
214385852|NCT03369184|DRUG|Oxygen gas|The intervention is administered as previously described. The duration of intervention is 10 minutes.
214385853|NCT03369184|OTHER|Ambient air|Administered similarly to treatment arm, via an open face mask and during 10 minutes
214385854|NCT01279330|OTHER|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
214687750|NCT02890082|DRUG|Tamoxifen stim in early follicular phase|"Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3~* Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)~* Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH~* Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
215093581|NCT01205477|DRUG|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
215093582|NCT02259985|DRUG|Itasetron tablet|
214385855|NCT01279330|OTHER|Control|No intervention (Patients receive by mail the materials needed for stool samples).
214385856|NCT05264610|OTHER|Data collection (Laboratory tests, Radiologic diagnostics, Patient data taken from existing medical charts)|Data collection: Bone turnover laboratory parameters: alkaline phosphatase (AP), calcium (corrected for albumin), PTH, Calcidiol (25-OH-D3), N-terminales Kollagen Typ 1 -. Propeptid (P1NP), glomerular filtration rate (GFR), calcium/creatinine (in urine); Radiologic diagnostics: Bone densitometry (DEXA), X-rays, computer tomograms, MRI for analysis of time of the bone healing (or a non-union); Patient data taken from existing medical charts: side effects, tolerability of PTH, patient compliance, presence of previous illnesses as risk factors for the formation of pseudoarthrosis, indication for therapy, time at which therapy started and length of therapy with PTH, precise characterization of the operation (type and whether it is a revision or first operation).
214385857|NCT04811963|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
214385858|NCT00003511|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214385859|NCT01306721|DRUG|fexofenadine HCL (M016455)|Pharmaceutical form:tablet Route of administration: oral
214385860|NCT01306721|DRUG|pseudoephedrine|"Pharmaceutical form:tablet~Route of administration: oral"
214385861|NCT01306721|DRUG|fexofenadine HCL matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
214385862|NCT01306721|DRUG|pseudoephedrine matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
214385863|NCT01395043|PROCEDURE|Placing bilateral TAP-catheters preoperatively|Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
214385864|NCT01395043|DRUG|Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters|Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
214385865|NCT02342314|DRUG|LY3143753 (Part A)|Administered via SC injection
214385866|NCT02342314|DRUG|LY3185643 (Part B)|Administered via SC injection
214385867|NCT02342314|DRUG|Placebo (Part A and Part B)|Administered via SC injection
214385868|NCT02342314|DRUG|rGlucagon (Part B)|Administered via SC injection
214385869|NCT06457100|DRUG|Esmolol Injection|Before induction of anesthesia, 0.5 mg/kg of esmolol was pumped intravenously and infused within 1 minute, followed by a pumping rate of 3 mg/kg/h until the end of the procedure.
215093583|NCT02259985|DRUG|Itasetron infusion|
214997466|NCT07115108|DIETARY_SUPPLEMENT|General energy density enteral nutrition|General energy density enteral nutrition (60-88 cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted.
215093584|NCT02259985|OTHER|high fat breakfast|
215093585|NCT01081639|DRUG|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
215093586|NCT01081639|DRUG|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
215093587|NCT00784537|DRUG|ABVD|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)"
214385870|NCT06457100|DRUG|Lidocaine IV|Before induction of anesthesia, 2 mg/kg of lidocaine was pumped intravenously and infused within 10 minute, followed by a pumping rate of 2 mg/kg/h until the end of the procedure.
214385871|NCT02020499|DRUG|Somatuline Autogel® (lanreotide) 60, 90, 120 mg.|Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
214385872|NCT04275180|DRUG|Argatroban|Argatroban plus standard medical treatment
214385873|NCT01481155|PROCEDURE|ablative CO2 laser therapy|CO2 laser therapy
214385874|NCT01481155|PROCEDURE|photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²
214385875|NCT06210451|OTHER|Sterile water-based gel|Insertion of the speculum during ET will be performed using 5 gr of water-based, sterile gel
214385876|NCT01842737|PROCEDURE|Spinal treatment|This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
215093588|NCT00784537|DRUG|ABVD and Radiotherapy|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk)."
214385877|NCT01842737|PROCEDURE|Massage|The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
214385878|NCT02459184|OTHER|Income Security Health Promotion|"The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~* Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~* Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~* Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~* Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs."
214385879|NCT01983137|DRUG|Targinact® (oxycodone/naloxone)|
214385880|NCT02734108|DEVICE|Transcranial direct current stimulation|Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
214687751|NCT02890082|DRUG|Tamoxifen stim in late follicular phase|"Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14~* Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm~* Ovulation induction by OVITRELLE® 250μg.~* Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
214997467|NCT07120906|DEVICE|MRI guided procedure software evaluation|For the use of the MRI-needle guidance system (LUMENA) developed by CLEAR GUIDE MEDICAL during clinical MRI-guided needle placement procedures for patients undergoing a liver biopsy/procedure.
214997468|NCT05791357|DIAGNOSTIC_TEST|PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA|Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)
214997469|NCT00809627|DRUG|Caffeine|Caffeine 500 mg IV
214997470|NCT00809627|DRUG|saline|Normal saline
214997471|NCT06651788|OTHER|Ethyl Chloride|Topical anesthetic that rapidly cools the skin and underlying tissues
214997472|NCT06651788|OTHER|Cold Saline Spray|placebo application of cold saline spray
214997473|NCT06975319|BIOLOGICAL|V-212 (or Placebo) administered by i.m injection (3 vaccinations) - low dose|V-212 is a peptide antigen-based vaccine.
215093589|NCT05521321|BEHAVIORAL|Stanford Cannabis Awareness and Prevention curriculum|Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session course administered in a school classroom setting.
215093590|NCT05234203|DIETARY_SUPPLEMENT|HTB Rejuvenate|90 days of BID dosing of 2 capsules of HTB Rejuvenate
214385881|NCT02629055|OTHER|Respiratory EMG|Titration of non-invasive ventilation on surface respiratory muscle activity
214385882|NCT02696122|PROCEDURE|Local Group|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
214499929|NCT06504290|DRUG|VV119 Placebo （in adult patients with schizophrenia）|VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily, VV119 6 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first three days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the forth day to the fifth day ,take 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the sixth day to the seventh day, then 3 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
214499930|NCT01727167|DRUG|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
214499931|NCT01727167|OTHER|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
214499932|NCT03683849|OTHER|Training|One hour of training, twice a week, for six months.
214499933|NCT01278030|PROCEDURE|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
214499934|NCT05646407|DEVICE|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
214499935|NCT00885625|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart
214499936|NCT02133625|DRUG|carboplatin|
214499937|NCT02133625|DRUG|pioglitazone|
214499938|NCT00105170|DRUG|hCBE-11|
214499939|NCT04093115|DRUG|CX1106|administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
214499940|NCT02949297|DEVICE|Ovation Alto Abdominal Stent Graft System|Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
214499941|NCT00458783|BIOLOGICAL|Prolonged RBC storage|Transfusion with oldest available matching RBCs
214499942|NCT00458783|BIOLOGICAL|Short RBC storage|Transfusion with youngest available matching RBCs
214499943|NCT01737398|DRUG|Inotersen|
214499944|NCT01737398|DRUG|Placebo|
214499945|NCT06307457|DRUG|Palbociclib in combination with AI|Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI as first-line treatment, in Denmark.
214499946|NCT05462704|DRUG|Ferric derisomaltose|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.
214499947|NCT05462704|DRUG|Ferrous sulfate|325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.
214499948|NCT06375278|DEVICE|Intra-Ear Canal Cooling Catheter|Mild therapeutic hypothermia will be applied via the catheter device installed inside the ear canal by an experienced surgeon during cochlear implantation (CI) surgery.
214499949|NCT03293264|BEHAVIORAL|Exercise training group|"Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome."
214499950|NCT04580043|BEHAVIORAL|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
214499951|NCT04580043|DEVICE|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
214499952|NCT04580043|BEHAVIORAL|Sham Training|Computer-based task practice in a non-active/inert task.
214499953|NCT04580043|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
214499954|NCT02962284|DRUG|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
214499955|NCT06585124|DIAGNOSTIC_TEST|Flow Cytometry|Study of t cell population in flow cytometry
214499956|NCT06814171|OTHER|Low-carbohydrate breakfast|Daily low-carbohydrate breakfasts for one year.
214499957|NCT06814171|OTHER|Low-fat Control breakfast|Low-fat breakfasts for one year.
214499958|NCT05503446|OTHER|Peanut in common foods or supermarket-sourced cow's milk (CM)|Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol
214499959|NCT00061906|DRUG|celecoxib|Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
214997474|NCT06975319|BIOLOGICAL|V-212 (or Placebo) administered by i.m injection (3 vaccinations) - medium dose|V-212 is a peptide antigen-based vaccine.
214385883|NCT02696122|PROCEDURE|Spinal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
214385884|NCT00041756|DRUG|PG-530742|One 25 mg PG-530742 tablet, twice daily for for one year
214499960|NCT00677209|BIOLOGICAL|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
214499961|NCT02198417|DRUG|Metformin ER|Treatment with metformin ER for 12 weeks
214499962|NCT00259142|DRUG|Chloroquine, sulphadoxine-pyrimethamine|
214499963|NCT03284359|BEHAVIORAL|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
214499964|NCT01119651|DRUG|Tazarotene (Patch application in Challenge Phase)|There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated \& will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
214499965|NCT04011930|DRUG|cholecalciferol|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
214499966|NCT04011930|DRUG|Placebo oral capsule|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
214499967|NCT04169776|DEVICE|Transcutaneous Auricular Vagus Nerve (taVNS) stimulation|Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
214499968|NCT02078518|OTHER|Questionnaires|
215093591|NCT05879575|BEHAVIORAL|weight training|Pregnant women assigned to the intervention group will receive online weight training sessions twice a week, for 60 minutes per session, from the 16th to the 36th week of pregnancy. The Pelvic Girdle Questionnaire will be used to assess the condition of pelvic girdle pain during pregnancy, and to analyze whether weight training can improve this problem. Pelvic floor muscle structure will also be analyzed by pelvic ultrasound to determine whether it has been altered by weight training, leading to an improvement in pain.
215093592|NCT00766974|DEVICE|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
214385885|NCT00041756|DRUG|Placebo|One placebo tablet, twice daily for for one year
214385886|NCT00041756|DRUG|50 mg PG-530742|One 50 mg PG-530742 tablet, twice daily for for one year
214385887|NCT00041756|DRUG|100 mg PG-530742|100 mg PG-530742 tablet, twice a day for one year
214499969|NCT04566172|BEHAVIORAL|Inspiratory Muscle Training (IMT)|Participants will receive an inspiratory muscle training that they will do leading up to the day of their surgery.
214499970|NCT01746576|OTHER|Use of impedance threshold device during spontaneous ventilation|
214499971|NCT02945059|PROCEDURE|Selective reversible portal vein embolization|Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
214499972|NCT00357994|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
214499973|NCT00357994|DRUG|Placebo gel|
214499974|NCT00357994|DRUG|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
214499975|NCT00357994|DRUG|Placebo (PBO) oral capsules|
214499976|NCT00357994|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
214499977|NCT00357994|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
214499978|NCT00357994|DEVICE|J-tube|jejunal tube
214499979|NCT03211988|DRUG|Entinostat|Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
214499980|NCT03772132|BIOLOGICAL|mutation and signal pathway activation status analysis Drug: FORFIRINOX|Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
214499981|NCT01698541|DRUG|Tacrolimus|Tested generic
214499982|NCT01698541|DRUG|Tacrolimus|Original formulation used as comparator
214499983|NCT04126577|BIOLOGICAL|blood samples|4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
214499984|NCT02919748|OTHER|Choral Singing|Weekly sessions at 1 hour of choral singing.
214499985|NCT02919748|OTHER|Health Education Program|Weekly session at 1 hour of health education talk and group activities
215093593|NCT00766974|DEVICE|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
215093594|NCT04639817|DRUG|Levofloxacin|Levofloxacin administration
214385888|NCT00041756|DRUG|200 mg PG-530742|200 mg PG-530742 tablet, twice a day for one year
214385889|NCT01030978|BEHAVIORAL|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
214385890|NCT01030978|BEHAVIORAL|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
214385891|NCT00603265|DRUG|ADL5859|
214385892|NCT00603265|DRUG|Duloxetine|
214385893|NCT00603265|DRUG|Placebo|
214385894|NCT05192850|DRUG|Metformin use|As an observational study, this is past exposure to metformin that occurred during the study period
214499986|NCT02829398|PROCEDURE|CerebroSpinal fluid and plasma samples|CerebroSpinal fluid and plasma samples for biological markers
214499987|NCT05320289|DEVICE|AblaCare System|"The intervention includes the short-term use of the AblaCare System, which is comprised of three elements: (1) the AblaCare Needle-Catheter Ablation Device (NCAD) (the Device) a 16G echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secure onto a vaginal ultrasound probe; (2) the AblaCare Adapter which is clipped onto the ultrasound probe; and (3) the AblaCare Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use AblaCare NCAD for ovarian tissue ablation.~Once th patient is under conscious sedation, the physician guides the AblaCare system transvaginally with the use of a transvaginal ultrasound. Once the AblaCare device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue."
214499988|NCT02958696|DRUG|HTL0018318|Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
214499989|NCT03130894|OTHER|Plasma TMAO concentration|Plasma TMAO concentration
214499990|NCT03166085|DRUG|PU-H71|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
214499991|NCT03166085|DRUG|Nab-paclitaxel|nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
214499992|NCT03948295|DIETARY_SUPPLEMENT|Lipid Challenge|After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
214499993|NCT05304624|DEVICE|laser|these lasers are routinely used in dental practice
214499994|NCT01438034|DRUG|kisspeptin 112-121|0.24 nmol/kg
214499995|NCT01438034|DRUG|GnRH|75 ng/kg
214499996|NCT04402112|DRUG|Pitavastatin|1mg, 2mg, or 4mg, Once a day, at least 8 weeks
214499997|NCT06002867|PROCEDURE|SAPB (Serratus Anterior Plan) Block|The patient will be in the supine position. The area where the procedure will be performed will be cleaned with povidone iodine. Using a 22-gauge, 80 mm insulated Quincke needle with a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath, the latissimus dorsi muscle and the serratus muscle will be visualized at the level of the 4th and 5th ribs. After determining the fascia between the two muscles, the block needle will be advanced from caudal to cranial and 40 ml of 0.25% bupivacaine (local anesthetic) will be injected on the serratus muscle between the two muscles.
214499998|NCT01627314|BIOLOGICAL|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
214385895|NCT05798039|BEHAVIORAL|ENRICH|Participants will receive additional heart health-focused materials and guidance in sessions with their nurse home visitor. The nurse will help them choose and work towards behavior goals to support their health. This will include goals for activity, diet, weight, blood pressure, diabetes, smoking, social relationships, sleep, parenting, and getting health care.
214385896|NCT02002884|DRUG|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
214997475|NCT06975319|BIOLOGICAL|V-212 (or Placebo) administered by i.m injection (3 vaccinations) - high dose|V-212 is a peptide antigen-based vaccine.
214385897|NCT02002884|DRUG|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
214499999|NCT01627314|BIOLOGICAL|Untreated CB|Cord Blood
214500000|NCT02187536|DRUG|Telmisartan|
214500001|NCT02187536|DRUG|Simvastatin|
214500002|NCT02187536|DRUG|Telmisartan placebo|
214500003|NCT05739370|OTHER|Problem-Solving Therapy for Older Adults|"Problem-Solving Therapy for Older Adults (Ger-iPST) is an 8-week online psychotherapy program with online therapist support delivered through the Online Psycho Therapy Tool (OPTT). Ger-iPST has several evidence-based elements tailored to the specific needs of older adults, including relevant content (e.g. aging-related examples); process adaptations (e.g. more repetition); and digital usability modifications (e.g. high-contrast text).~Ger-iPST contains therapy modules assigned weekly and accessible at any time during the week. Modules begin with a brief, guided mindfulness relaxation exercise, followed by approximately 20 slides taking, on an average 1 hour to complete. Each module highlights a different step of Psychotherapy (PST) and includes an overview of a new skill, interactive activities and examples. A homework exercise designed to guide participants in applying a new PST skill exercise is submitted through the platform, and a clinician will provide personalized feedback."
214500004|NCT06244875|OTHER|Sampling|Blood and cerebrospinal fluid sampling during the diagnostic visit
214997476|NCT06978530|DEVICE|3D custom plate|Custom 3D plate will be designed using preoperative CT and virtual surgical planning.
214997477|NCT06978530|DEVICE|Standard titanium fixation plates|The fixation will be performed according to established surgical principles for managing displaced mandibular sub-condylar fractures without patient-specific planning or customization.
214997478|NCT06979388|DRUG|balcinrenone/ dapagliflozin|Participants will be receiving balcinrenone/ dapagliflozine in fasted or fed condition.
214997479|NCT06979388|DRUG|quinidine|Participants will be receiving quinidine orally in fasted condition.
215093595|NCT04639817|DRUG|trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole administration
215093596|NCT03132025|DRUG|"Apatinib and Capecitabine"|"Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
214997480|NCT07131384|DIETARY_SUPPLEMENT|Dietary Supplement: Inorganic Nitrate (Beetroot juice)|Participants will be supplemented with inorganic nitrate in the form of beetroot juice for 4 days (12.9 mmol of NO3/day), and their vascular health, insulin sensitivity, and exercise capacity will be measured post-supplementation. This is a randomized crossover design with 2 parallel groups (Group 1: Currently taking metformin, Group 2: Naive to metformin).
214385898|NCT02002884|DRUG|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
214385899|NCT02966002|DRUG|Aspirin|
214385900|NCT06261047|RADIATION|radiotherapy|radiotherapy
214385901|NCT06261684|DRUG|Intralesional Acyclovir|Intralesional Acyclovir in plantar warts
214385902|NCT06261684|DEVICE|Cryotherapy|Cryotherapy of plantar warts
214385903|NCT01052402|BIOLOGICAL|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
214385904|NCT00118625|BIOLOGICAL|Tree MATA MPL|
214385905|NCT01001481|OTHER|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
214500005|NCT05697835|BEHAVIORAL|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
214500006|NCT05697835|OTHER|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
214997481|NCT07131384|DIETARY_SUPPLEMENT|Dietary supplement: Placebo (Nitrate-depleted beetroot juice)|Participants will be supplemented with nitrate-depleted beetroot juice for 4 days (\<0.01 mmol NO3/day), and their vascular health, insulin sensitivity, and exercise capacity will be measured post-supplementation. This is a randomized crossover design with 2 parallel groups (Group 1: Currently taking metformin, Group 2: Naive to metformin).
214997482|NCT03617718|DRUG|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
214385906|NCT01226563|DEVICE|IK-5001|4 mL (+/- 0.2 mL) administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.
214385907|NCT01226563|DEVICE|Saline Solution|4 mL (+/- 0.2 mL) slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
214385908|NCT03311763|BEHAVIORAL|EIM Fitness Practitioners|Exercise is Medicine Practitioners will facilitate peer groups that attend twice-weekly exercise classes for 8 weeks, with clinical monitoring and advise regarding increasing physical activity.
214385909|NCT03311763|BEHAVIORAL|Counseling and wearable device|Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
214385910|NCT01342692|DRUG|Azacitidine|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks
214385911|NCT01342692|DRUG|Azacitidine associated with Valproic acid|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.~\- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)~\- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)"
214997483|NCT02738606|DRUG|Chemotherapy|
214997484|NCT02738606|OTHER|Laboratory Biomarker Analysis|Correlative studies
214385912|NCT01342692|DRUG|Azacitidine associated with Lenalidomide|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.~Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)"
214385913|NCT01342692|DRUG|Azacitidine associated with Idarubicine|Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above. Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of Azacitidine or day 10 if azacitidine was administered according to (5-2-2 regimen)
214385914|NCT00742820|DRUG|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
214385915|NCT00742820|DRUG|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
214500007|NCT05697835|OTHER|Care as usual|Care as usual, with written resources provided
214500008|NCT01354444|DRUG|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
214500009|NCT01354444|DRUG|Placebo|a pill that will look like the active drug but will not contain any carvedilol
214500010|NCT05352308|BEHAVIORAL|Common Sense Model Guided Narrative Video|The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
214500011|NCT06184321|BIOLOGICAL|Alteplase|Instilled into IPC
214385916|NCT00742820|DIETARY_SUPPLEMENT|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
214500012|NCT06184321|DRUG|Placebo Administration|Instilled into IPC
214997485|NCT02738606|PROCEDURE|Metastasectomy|Undergo lung metastasectomy
214997486|NCT02738606|OTHER|Quality-of-Life Assessment|Ancillary studies
214997487|NCT02738606|PROCEDURE|Therapeutic Conventional Surgery|Undergo hepatectomy
214500013|NCT05440058|DEVICE|Bispectral Index (BIS) monitoring system|Left and right sensors to record EEG activity and muscle reaction to anesthesia utilized in the operating room by anesthesia providers to assess the depth of sedation in patients with anesthesia.
214500014|NCT00982072|DRUG|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
214500015|NCT00982072|DRUG|prednisolone|Prednisolone 1mg/kg maximum 60mg od
214500016|NCT05783531|OTHER|VMood|VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
214500017|NCT05783531|OTHER|Enhanced treatment as usual|Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.
214500018|NCT02103556|OTHER|Mineral oil|4 ml daily (adjusted as needed), for 4 weeks
214500019|NCT02103556|DIETARY_SUPPLEMENT|Olive oil|4 ml daily (adjusted as needed), for 4 weeks
214500020|NCT02103556|DIETARY_SUPPLEMENT|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
214500021|NCT04210258|DEVICE|Etermis 3|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling facial moderate wrinkles (marionette lines) and/or to increase lip volume
214500022|NCT04210258|DEVICE|Etermis 4|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling deep and severe volume loss (nasolabial folds and/or marionette lines) and/or to increase lip volume
214500023|NCT04162210|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
214500024|NCT04162210|DRUG|Pom/dex (Pomalidomide plus low dose Dexamethasone)|Pomalidomide and Dexamethasone will be administered.
214385917|NCT02122341|DEVICE|BackStop|BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
214997488|NCT07130370|BEHAVIORAL|Acceptance and commitment therapy|Acceptance and Commitment Therapy (ACT) is a mindfulness-informed behavioral intervention that helps individuals accept difficult thoughts and feelings, clarify personal values, and commit to meaningful actions. It aims to improve psychological flexibility, enabling healthier coping with life's challenges.
214997489|NCT05812131|BEHAVIORAL|COPEWeb online training|COPE training delivered via online COPEWEb to providers
214997490|NCT05812131|BEHAVIORAL|COPE In Person|COPE training provided in person to providers
214997491|NCT06569186|BEHAVIORAL|Cue-based feedings|Speech therapists will use cue-based protocols to guide feeds
214385918|NCT04935138|GENETIC|cfDNA analysis|sequencing data from cfDNA analysis
214385919|NCT05905991|OTHER|Enhanced Stress Resilience Training|"The ESRT intervention will consist of 1) five weekly one-hour sessions (in-person or virtual) led by a certified instructor; 2) smartphone-based exercises that bring informal practice into daily life; 3) videos on principles and concepts taught each week; and 4) meditation recordings of various lengths and styles supporting the prescribed daily practice of up to 20 min/day. Weekly didactic and experiential activities will cover mindfulness-based intervention concepts and skills, such as cultivating resilience, awareness of the body, managing thoughts, responding versus reacting, transforming circumstances, and advocacy through mindful communication. The ESRT smartphone app (Mindful Brian) houses all course materials (pre-class materials and post-class materials) and sends class reminders and messages. Considering nurses' shifts, ESRT will be offered in two separate sessions each week."
214385920|NCT00002456|DRUG|cyclosporine|
214385921|NCT00002456|DRUG|methotrexate|
214385922|NCT00002456|PROCEDURE|allogeneic bone marrow transplantation|
214385923|NCT00004650|DRUG|conjugated estrogens|
214385924|NCT00004650|DRUG|Medroxyprogesterone|
214385925|NCT00724139|DEVICE|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
214385926|NCT03558958|DRUG|P-188 NF|Poloxamer administered daily via sc injection at 5 mg/Kg
214385927|NCT03971708|DRUG|Lidocaine|Local anesthetic
214385928|NCT03971708|DRUG|Ropivacaine|Local anesthetic
214500025|NCT05121636|DEVICE|MetaFix Collared Stem|Patients received the MetaFix Collared stem during there Total Hip Arthroplasty
214500026|NCT01437410|PROCEDURE|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
214997492|NCT05619627|DRUG|Dexmedetomidine|Participants will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI
214385929|NCT04595539|BEHAVIORAL|Behavioral Activation treatment with Attention Training Technique|"The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life."
214385930|NCT00529919|DIETARY_SUPPLEMENT|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
214500027|NCT04025255|DIETARY_SUPPLEMENT|Braini|A novel, neuro-protective and neuro-restorative dietary supplement composed of a combination of active ingredients which have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) status in 2018
214500028|NCT04025255|DIETARY_SUPPLEMENT|Placebo|Matched placebo
214500029|NCT01754051|DEVICE|PC 400 coils|
214385931|NCT06341426|DRUG|Single Psychedelic Dose Psilocybin|One psychedelic dose (1mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
214385932|NCT06341426|DRUG|Two Psychedelic Doses Psilocybin|Two psychedelic doses (25 mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
214385933|NCT03848364|BEHAVIORAL|Hip Hop Stroke 2.0|HHS2.0 is an innovative, multimedia program, a brief 3-hour (1hr/day for 3 days), school-based intervention designed to educate at-risk populations concerning stroke symptoms and calling 911 immediately in the event they occur (stroke literacy). HHS2.0 is accessed and delivered via a web link online as self-administered, interactive modules that target 4th and 5th grade children in the school system (ages 9-11) using narrative cartoons and multimedia games.
214385934|NCT04939636|DIETARY_SUPPLEMENT|Vitamin D3 capsules 4000IU/100µg.|Vitamin D3 supplementation
214385935|NCT04939636|DIETARY_SUPPLEMENT|Vitamin D3 capsules 600IU/15µg.|Vitamin D3 supplementation
214385936|NCT01432535|DRUG|PegIFN-2b (Sylatron®)|Single 4.5 μg/kg dose
214385937|NCT06028581|OTHER|breastfeeding support system|Using the breastfeeding support system
214385938|NCT01584492|DRUG|beclomethasone+formoterol 50/6 (1 inhalation)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
214385939|NCT01584492|DRUG|CHF 1535 50/6 (2 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
214385940|NCT01584492|DRUG|CHF 1535 50/6 (4 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
214385941|NCT01584492|DRUG|Formoterol + Beclomethasone dipropionate|"* Formoterol HFA pMDI 6 µg / actuation~* Extrafine BDP HFA pMDI 50 µg/actuation"
214500030|NCT03524755|OTHER|Exercise|
214500031|NCT05877872|PROCEDURE|Reduced-target resection|Patients receive surgery according to pSTV-post-IC.
214500032|NCT05877872|PROCEDURE|Full-target resection|Patients receive surgery according to pSTV-pre-IC.
214500033|NCT05877872|DRUG|Adjuvant immunotherapy|Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
214997493|NCT05619627|DRUG|General Anesthesia (control group)|Participants will receive general anesthesia for their MRI
214997494|NCT06040385|DEVICE|Implant supported hybrid prosthesis|For each patient, implant supported mandibular hybrid prosthesis will be fabricated digitally. Frameworks will be tried in patient's mouth, scanned intraorally by intraoral scanner (IOS).
214385942|NCT01584492|DRUG|Placebo (6 inhalations)|Matched placebo via pMDI
214385943|NCT04464616|PROCEDURE|spinal anaesthesia|spinal anaesthesia will be performed with the patient in sitting position at the L3-L4 or L4-L5 interspaces with a 25 or 27 G spinal tip needle with the study drug in the total volume of 3 ml.
214385944|NCT02291432|BIOLOGICAL|autologous muscle-derived cells (AMDC)|Cell treatment
214997495|NCT05121337|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
214997496|NCT05121337|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
214385945|NCT04977518|OTHER|no intervention|no intervention
214385946|NCT00790920|DRUG|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
214385947|NCT00790920|DRUG|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
214997497|NCT05643209|PROCEDURE|ablation|epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive patients undergoing catheter ablation
214997498|NCT06645015|DEVICE|AI augmented risk-stratification|A state-of-the-art artificial intelligence (AI) model called AIDPRO manual CRC is used as a decision support tool to estimate the 1-year mortality risk for each patient
214385948|NCT02618720|DRUG|ornidazole|
214385949|NCT02618720|DRUG|Placebo|
214385950|NCT04619953|OTHER|Dynamic Postural Stability Training|The dynamic postural stability training, will consist of marching on unstable surface and on treadmill both with open and with closed eyes.
214385951|NCT04619953|OTHER|Cognitive-Motor Training|The cognitive-motor training consisted of a dual task paradigm: each patient was asked to walk without stopping and was explained that, during the task, they might hear a sound, and in that case, they should have look at the stimulus 'side and recognize a visual target. This dual task was performed both marching on an unstable surface and marching on treadmill.
214385952|NCT04619953|OTHER|Conventional Therapy|The conventional neuromotor rehabilitation will consist in muscles stretching, active-assisted mobilizations, neuromuscular facilitations, gait training and balance exercises using swinging platforms
214500034|NCT00238485|DRUG|Licarbazepine|
214500035|NCT02610608|OTHER|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
214500036|NCT03021512|PROCEDURE|Phaco with Restor|Phacoemulsification with bilateral bifocal intraocular lenses implantation
214500037|NCT03021512|PROCEDURE|Phaco with Panoptix|Phacoemulsification with bilateral trifocal intraocular lenses implantation
214500038|NCT02031185|BEHAVIORAL|FitBit only|Participants will use the FitBit device
214500039|NCT02031185|BEHAVIORAL|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
214997499|NCT06645015|OTHER|Expert-based Risk-stratification|Experienced colorectal surgeons assess patient risk based on clinical judgment and national guidelines.
214997500|NCT05501691|OTHER|Placebo|Laser Simulation
214687752|NCT02890082|DRUG|Tamoxifen stim in luteal phase|"Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28~* 1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia"
214385953|NCT06167629|DIAGNOSTIC_TEST|PET 18F-PSMA|Subjects will be subjected to a PET examination according to international guidelines and where requested by the specialist. In particular, patients will be administered the radiopharmaceutical 18 F PSMA. Approximately two hours after administration, the patient is positioned on the PET/CT equipment table and image acquisition begins.
214385954|NCT04107623|DIAGNOSTIC_TEST|Indocyanine Green|Using Q-ICG perfusion of the remaining Gastric Conduit will be compared
214385955|NCT04693936|COMBINATION_PRODUCT|Nutraceutical Combination Plan|"Multivitamin (My Total Health) 1 tablet per day Vitamin C (My Immuno) 1 scoop per day Calcium-Magnesium combination (My Calmag) 1 scoop per day Omega 3-6-9 My Omega Krill. 1 capsule per day Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day Probiotics 40 billion 1 capsule per day~Nutraceuticals will be received daily along with the patient's customary psoriasis/Hashimoto's disease treatment."
214500040|NCT01480375|DEVICE|Smartbx™ system.|The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
214500041|NCT01697683|DRUG|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
214500042|NCT01697683|DRUG|Placebo|
214500043|NCT04618250|OTHER|SOFIA model|A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
214500044|NCT06509165|PROCEDURE|Modified coronally advanced flap technique|Subepithelial connective tissue graft was applied to the relevant areas with a modified coronally placed flap technique to cover the gingival recession.
214500045|NCT06509165|PROCEDURE|Tunnel technique|Subepithelial connective tissue graft was applied to the relevant areas with the tunnel technique to cover the gingival recession.
214687753|NCT05547763|PROCEDURE|surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates|under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
214997501|NCT05501691|RADIATION|445 nm Diode Laser Wavelength|Irradiated Using a 445 nm Diode Laser Wavelength
214385956|NCT04315103|COMBINATION_PRODUCT|a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP|All the injections were done by the same experienced physician using aseptic procedures.
214385957|NCT05985603|OTHER|CIMT Group|In this group of patients CIMT technique will be used for treatment
214385958|NCT05985603|OTHER|Mirror Therapy group|patient will perform movements in semi-reclined and sitting positions with the mirror placed between the two lower extremities.
214385959|NCT03009890|PROCEDURE|Surgery (Open Reduction Internal Fixation)|Either volar of dorsal plating or both
214385960|NCT03009890|PROCEDURE|Cast treatment|Hospitals may use their preferred protocol
214500046|NCT03244800|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously once daily for 49 days.
214500047|NCT03244800|DRUG|Placebo|Placebo will be administered subcutaneously once daily for 49 days.
214500048|NCT01935375|BEHAVIORAL|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
214500049|NCT01935375|BEHAVIORAL|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
214500050|NCT04718259|DRUG|intrathecal bupivacaine|The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
214687754|NCT00039273|BIOLOGICAL|panitumumab|
214687755|NCT02482363|RADIATION|UVA radiation|20 minutes of low dose UVA from a phototherapy unit
214997502|NCT05501691|RADIATION|660 nm Diode Laser Wavelength|Irradiated Using a 660 nm Diode Laser Wavelength
214500051|NCT04718259|DRUG|midazolam|midazolam
214500052|NCT04589975|PROCEDURE|laparoscopic surgery|
214500053|NCT02103166|DRUG|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
214500054|NCT02103166|DRUG|Physiological serum|100 ml of physiological serum (0.9% NaCl).
214997503|NCT05501691|RADIATION|970 nm Diode Laser Wavelength|Irradiated Using a 970 nm Diode Laser Wavelength
214997504|NCT00945737|DIETARY_SUPPLEMENT|Soy protein; 25 grams/day|Soy protein
214997505|NCT00945737|DIETARY_SUPPLEMENT|Control protein|Milk protein
214997506|NCT01331564|BEHAVIORAL|electronic intervention during pregnancy and postpartum|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention
214997507|NCT01331564|BEHAVIORAL|electronic intervention during pregnancy|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.
214997508|NCT01331564|BEHAVIORAL|Control|Control women will receive non-weight related content during both time periods at the project website.
214997509|NCT04748978|PROCEDURE|hysteroscopy|OPPIum and Myolysis
214997510|NCT01525589|DRUG|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
214997511|NCT03832478|DEVICE|Virtual Reality Headset Given|Samsung Gear VR Headset with guided mindfulness meditation app
214997512|NCT02383615|PROCEDURE|Saphenous nerve block|Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
214385961|NCT04684082|DEVICE|Colonic irrigation with the Colon Hydromat|"A designated health professional will administer to the patient the colonic irrigation procedure - using the Colon Hydromat device, a CE certified device for colonic irrigation and cleansing before endoscopic procedures."
214385962|NCT06099951|DRUG|Serplulimab + FOLFOXIRI|Starting from day 0, the patient will receive 8 cycles of FOLFOXIRI regimen at specific intervals. The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day for 46 hours. This regimen is repeated every 14 days.During radiotherapy (Monday to Friday), the patient will receive capecitabine 1650mg/m2/day orally twice daily. Serplulimab immunotherapy will be administered every 2 weeks during the FOLFOXIRI neoadjuvant chemotherapy period. Serplulimab will be given on the first day and the 14th day of radiotherapy, dissolved in 100ml normal saline and administered intravenously over 30-60 minutes at a dose of 200mg.
214385963|NCT06099951|RADIATION|Radiation therapy|Radiation therapy
214385964|NCT03377790|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
214385965|NCT03377790|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
214385966|NCT05565274|DRUG|Pentazocine plus placebo|30mg of pentazocine and 2milliLitre of injection water
214385967|NCT01200030|BEHAVIORAL|electrical stimulation with exercises|electrical stimulation with exercises
214385968|NCT01200030|BEHAVIORAL|placebo stimulation with exercises|placebo stimulation with exercises
214385969|NCT02770508|DRUG|darunavir/ritonavir|
214385970|NCT02770508|DRUG|Lamivudine|
214385971|NCT02770508|DRUG|emtricitabine-tenofovir(FTC/TDF)|
214385972|NCT02127827|DEVICE|Automated Ambulatory Glycemic Controller (AAGC)|
214385973|NCT04879758|GENETIC|Genetic Risk Estimate|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).
214385974|NCT04879758|OTHER|Genetic Risk Estimate + Fitbit Functions|"The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate."
214385975|NCT03200301|PROCEDURE|Intact Umbilical Cord Milking|Immediately after delivery, the infant will be placed at or ∼20 cm below the level of the placenta and about 20 cm of the intact umbilical cord will be milked towards the umbilicus three times. The technique consists of pinching the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 2-second pause between each milking motion. After completion of milking three times, the cord will be clamped close to the umbilicus and the neonate handed over to the neonatal team. The procedure of cord milking will be completed within 20 seconds.
214385976|NCT02632786|DRUG|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
214385977|NCT02632786|DRUG|Placebo|Saline Bag
214385978|NCT06381817|BIOLOGICAL|Haplo-cord HCT|Haploidentical hematopoietic cell transplantation will be performed with coinfusion of an unrelated cord blood unit
214385979|NCT06381817|BIOLOGICAL|Haplo-HCT|Hematopoietic cell transplantation will be performed with a haploidentical donor
214385980|NCT01768754|BEHAVIORAL|Usual and Fast Walking Speeds|Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
214500055|NCT01581216|OTHER|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
214500056|NCT01581216|OTHER|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
214500057|NCT01581216|OTHER|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
214500058|NCT02903875|OTHER|Patient therapeutic education (PTE) programme|
214687756|NCT02482363|RADIATION|Sham Control|20 minutes of sham control exposure
214687757|NCT02196194|DRUG|Tiotropium|
214997513|NCT00715611|PROCEDURE|Pleurectomy/Decortication|Pleurectomy/decortication will be performed as per standard technique
214997514|NCT00715611|DRUG|pemetrexed and cisplatin or carboplatin|The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
214997515|NCT00715611|RADIATION|Intensity Modulated Radiation Therapy|IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
214385981|NCT05539196|DEVICE|Exablate Pallidotomy, Unilateral|Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.
214385982|NCT02096614|DRUG|TBI-1201|TBI-1201(5\*10\^8 or 5\*10\^9) is administered.
214500059|NCT03136172|DEVICE|NIRS (near Infra-red spectroscopy)|"1. NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)~2. Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)~3. Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)"
214500060|NCT04129372|BEHAVIORAL|New Foods Take Time|New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
214500061|NCT00980213|DRUG|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
214500062|NCT03258398|DRUG|eFT508|eFT508 will be taken orally (PO) twice a day (bid).
214500063|NCT03258398|DRUG|Avelumab|Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
214500064|NCT02138994|DEVICE|Next Science Wound Gel|
214500065|NCT02138994|DRUG|Triple Antibiotic Ointment Neosporin|"Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~* Subject may continue the application of Neosporin until wound closure or~* Subject may cross over to the treatment group for 3 months"
214500066|NCT02897206|DRUG|Imipenem|A wide-spectre antibiotic from the carbapenem group
214500067|NCT02897206|DRUG|Placebo|An imipenem-matching placebo
214500068|NCT02803749|DRUG|Buspirone|
214500069|NCT02803749|DRUG|Placebo|
214500070|NCT01329406|DRUG|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
214500071|NCT01329406|DRUG|Placebo|1 tablet by mouth twice daily for 28 days
214500072|NCT01458600|DRUG|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
214500073|NCT01458600|DRUG|Methimazole|T Methimazole 5 mg 3x2 for 18 months
214500074|NCT01458600|DRUG|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
214500075|NCT01458600|DRUG|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
214500076|NCT01458600|DRUG|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
214500077|NCT03908606|PROCEDURE|Scaling and root planing|Supra and subgingival scaling and root planing.
214500078|NCT00369902|PROCEDURE|acupuncture|
214500079|NCT03842332|BEHAVIORAL|Life Skills and Resilience Program|The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
214500080|NCT00371345|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
214500081|NCT00371345|DRUG|Dasatinib 100 mg|Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)
214687758|NCT00174616|DRUG|Oxaliplatin, capecitabine, radiotherapy|"* Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~* Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~* Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks"
214500082|NCT02180815|DEVICE|ReVENT Sleep Apnea System|
214500083|NCT04456569|DEVICE|Geniculate Artery Embolization|All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.
214500084|NCT02378376|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|
214500085|NCT02378376|DIETARY_SUPPLEMENT|Dietary fiber enriched bran|
214500086|NCT05794594|DEVICE|3D printed personalized extendable prosthesis|3D printed personalized extendable prosthesis replacement for limb preservation in children
214500087|NCT02747537|DRUG|Sorafenib|
214500088|NCT02747537|DRUG|Irinotecan|
214500089|NCT06834282|DRUG|CER-1236|an autologous chimeric engulfment receptor T-cell
214500090|NCT06834282|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
214385983|NCT02096614|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
214385984|NCT02096614|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
214500091|NCT06834282|DRUG|Fludarabine|Lymphodepleting chemotherapy
214500092|NCT06834282|DRUG|Mesna|Chemoprotectant
214500093|NCT04860999|PROCEDURE|Osteopathic Manipulative Treatment|The osteopathic manipulations focused on treating the asymmetric postural dysfunction that was identified by the initial functional structural evaluation. The manipulation consisted of typical time-honored osteopathic treatments directed at the identified somatic dysfunction(s). These techniques were clinically directed and include: soft tissue, muscle energy, high velocity low amplitude, low velocity high amplitude as well as facilitated positional release as indicated.
214500094|NCT00713596|DRUG|Fibrinogen|One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
214500095|NCT00713596|PROCEDURE|Septorhinoplasty|Septorhinoplasty to correct nasal deviation.
214500096|NCT00713596|PROCEDURE|Taping after septorhinoplasty.|Simple taping over the nose following nasal surgery.
214500097|NCT00713596|PROCEDURE|Cast applied to the nose after nasal surgery|A molded cast will be placed on top of the nose following nasal surgery.
214500098|NCT00713596|OTHER|Saline|Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
214997516|NCT06986083|PROCEDURE|Prostate Biopsy|Transperineal prostate biopsy
214385985|NCT05276843|COMBINATION_PRODUCT|Qigong exercise program|Qigong is a low-impact, weight-bearing exercise characterized by gentle movements designed to dissipate force throughout the body while the subject changes poses, with well-coordinated sequences of both isometric and isotonic segmental movements in the trunk and 4 extremities.
214385986|NCT03197103|DRUG|N-Acetylcysteine (NAC)|For more information read Experimental Arm description
214385987|NCT03457285|OTHER|Physiotherapy|"Participants, with a confirmed diagnosis of AS, will be invited to participate. Once participants have provided informed consent, they will be required to complete the outcome measures provided. Participants will be set up to use the online exercise application and educated on its use.~Participants will then have access to videos of suitable exercises or exercise classes to follow and education material on their condition to read. Participants will be able to complete AS specific outcome measures and record their progress. Participants will also have a monthly video call with the senior rheumatology physiotherapist to discuss their exercise programme, symptoms and management. The participants will also record their compliance with their exercise programmes.~After the 6 month pilot period, participants will be required to complete the same outcome measures completed at the start of the study."
214385988|NCT02302950|DRUG|raltegravir|HIV therapy component
214385989|NCT01451736|DRUG|paliperidone palmitate|long-acting injectable
214385990|NCT01451736|DRUG|risperidone|oral
214500099|NCT01642719|BEHAVIORAL|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
214500100|NCT01642719|BEHAVIORAL|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
214500101|NCT05340738|OTHER|LyssnCBT|LyssnCBT is a technology that allows therapists and supervisors access to tools that assist with assessing CBT session fidelity, including speech-to-text transcription, annotation tools, and AI-generated metrics.
214500102|NCT06149299|PROCEDURE|Greater occipital nerve block|Greater occipital nerve block using ultrasound guidance
214687759|NCT06517615|BEHAVIORAL|Home Visit Supported Nursing Training Program|Individualized Nurse Education Program with Home Visit Support (• Walking and exercise programs, Disease self-management training for those with chronic diseases, techniques and practices that facilitate medication compliance, vital sign monitoring, • • • Nutrition charts and follow-ups, food characteristics information and weight tracking, cooking activities in the kitchen,• Helping to create family and friend systems, creating neighbor communication mechanisms
214687760|NCT05187806|BEHAVIORAL|motivational interview|After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions.The pretest and posttest Diabetes Self-Management Scale total scores and HbA1c values of the patients in the experimental and control groups were compared.
214385991|NCT05279430|BEHAVIORAL|Inspiratory muscle training|Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
214385992|NCT02265224|DRUG|N-acetylcysteine|The product was administered according to the randomisation list and cross-over design, with 150 mL of still mineral water under fasting conditions on study day 1 of periods 1 or 2 at 8:00±1 h.
214385993|NCT05389020|OTHER|Newly developed real-size infant's arm and leg manikin|The control group used conventional manikins made by Nasco; meanwhile, two newly designed real-size manikins were prepared for the intervention group: the right arm and right leg. Real-size manikins were developed based on the mean of anthropometric measurement of 50 Indonesian infants' arms and legs of healthy term neonates born in Dr Cipto Mangunkusumo Hospital. The manikins were made of Thermoplastic Polyurethane (TPU) filament using three-dimensional (3D) printing technology. The manufacturing process was carried out by the Medical Physics Department, Universitas Indonesia.
214385994|NCT04799860|BEHAVIORAL|health promotive work-way|"Clinical intervention: The patient is asked to fill in a screening form with life-style related questions. The caregiver takes adequate measures according to the recommendations of the national guideline and the filled in screeing form. The caregiver documents the measures taken.~Implementation intervention as described previously: using tailored strategies to support implementation of the gudieline-based recommendations"
214385995|NCT04767360|DEVICE|Bioness-300|Therapeutic treatment of foot drop with the electrical stimulation device Bioness L300.
214385996|NCT05950854|DIAGNOSTIC_TEST|Weight-bearing MRI|Four MRI scans with 0.25T scanner: weight-bearing and non-weight-bearing with flexed and extended knee
214385997|NCT01754454|BIOLOGICAL|Human Umbilical Cord Derived MSC|1×10\^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
214500103|NCT04545619|DEVICE|QDOT MICRO System|QDOT Micro Catheter with nGEN Generator
214500104|NCT03712371|DRUG|Chitosan|Increasing dose levels from 500mg twice daily to 2000mg twice daily for up to 85 days.
214500105|NCT02788981|DRUG|Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
214500106|NCT02788981|OTHER|Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
214500107|NCT02788981|DRUG|Nab-Paclitaxel|Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
214687761|NCT03913624|OTHER|Neuromuscular electrical stimulation|
214997517|NCT06986083|DRUG|Local anesthesia|Local anesthesia in addition to IV sedation
214997518|NCT06982820|DEVICE|Prism Training|Participants will complete 20 Prism training sessions. The Prism training sessions take place twice a week over a 10-week period, with a minimum of one night of sleep between sessions. Participants will also receive two single booster sessions, 4 weeks and 8 weeks after their last NF session completed.
214997519|NCT06811324|DRUG|Tirzepatide|Once weekly tirzepatide starting at 2.5 mg/weekly, with dose escalation monthly by 2.5 mg to a target dose of 10 mg/weekly or maximum tolerated
214997520|NCT06589245|DRUG|Alvesco Inhalant Product|Inhaled Alvesco will be administered daily for 14 days at escalating doses of 80mcg and 160mcg.
214997521|NCT06311383|DRUG|First-line Ribociclib + endocrine therapy|Ribociclib + letrozole, or Ribociclib + anastrazole, or Ribociclib + exemestane, or Ribociclib + fulvestrant
214997522|NCT06311383|DRUG|First-line endocrine therapy|As of physicians choice
214997523|NCT06311383|DRUG|First-line chemtherapy|As of physicians choice
214997524|NCT06657183|DEVICE|Alio Smart Patch™|"Alio Smart Patch is a non-invasive wearable biosensor that combines a unique, multi-sensor, wearable device with a provided- based portal to track sequentially the participant's physiologic, hematologic and electrolyte data. It works in conjunction with a home hub data relay system and an end-to-end cloud software data path. The system has been developed to enable home monitoring for multiple key metrics by healthcare provider caring for participants.~Enhanced Care Management (ECM) is a comprehensive, system-centric approach crafted to bridge the latent gaps in traditional care paradigms. ECM provides an exhaustive review of a participant's medical history and their personalized social needs, addressing both in a cohesive, participant-focused strategy.~This intervention couples Quantify Remote Care's Enhanced Care Management with the Alio Smart Patch technology."
214997525|NCT06649773|DRUG|Noiiglutide Injection|Experimental group
214385998|NCT03681795|DIAGNOSTIC_TEST|Experimental MRI exam and PET scan exam with radiotracer|MRI exam and PET scan exam with radiotracer
214385999|NCT01760018|DRUG|desflurane group|anesthesia is maintained with desflurane and remifentanil (Desflurane group)
214386000|NCT01760018|DRUG|TIVA group|anesthesia is maintained with fresofol and remifentanil (TIVA group).
214500108|NCT04098393|DRUG|Busulfan 3.2 mg/kg/day|Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
214997526|NCT06649773|DRUG|Noiiglutide Placebo|Placebo Comparator group
214997527|NCT06986967|PROCEDURE|Antegrade Perfusion|Procedure in which the surgeon accesses one of two arteries that branch off from the aorta to provide blood to the brain.
214997528|NCT06986967|PROCEDURE|Retrograde Perfusion|Procedure in which the surgeon accesses the superior vena cava to supply blood to the brain.
214997529|NCT03024008|BIOLOGICAL|BonoFill-II|"Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion.~A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed.~internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union."
214386001|NCT01232309|DIETARY_SUPPLEMENT|Chitin-Glucan|3 x 500 mg capsules (tid) = 4.5 mg daily dose
214386002|NCT01232309|DIETARY_SUPPLEMENT|Low Dose Chitin-Glucan|3 x 167 mg capsules (tid) = 1.5 g daily dose
214386003|NCT01232309|DIETARY_SUPPLEMENT|Low Dose Chitin-Glucan + Olive Extract|3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract
214386004|NCT01232309|DIETARY_SUPPLEMENT|Placebo|3 x 500 mg capsules (tid)
214500109|NCT04098393|DRUG|Fludarabine|Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
214997530|NCT02924376|DRUG|Pemigatinib|Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
214997531|NCT05996835|BIOLOGICAL|TIN816 70 mg lyophilisate powder|Immunotherapy Recombinant human CD39 enzyme
214997532|NCT05996835|OTHER|Placebo|0.9% sterile saline solution
214997533|NCT06824467|BIOLOGICAL|Sacituzumab tirumotecan|IV Infusion
214997534|NCT06824467|BIOLOGICAL|Bevacizumab|IV Infusion
214997535|NCT06824467|DRUG|H1 receptor antagonist|Rescue medication taken per approved product label before sacituzumab tirumotecan
214997536|NCT06824467|DRUG|H2 receptor antagonist|Rescue medication taken per approved product label before sacituzumab tirumotecan
214386005|NCT04572919|PROCEDURE|lateral advancement flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
214386006|NCT04572919|PROCEDURE|classic Limberg flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
214386007|NCT02724813|BEHAVIORAL|Cognitive Orientation to Occupational Preformance (COOP)|
214386008|NCT04922996|DRUG|Calcium Dobesilate|Dosage of calcium dobesilate in different tissues
214500110|NCT04098393|DRUG|Melphalan|Melphalan (70mg/m2/day) administered on days -6 and -5.
214500111|NCT04098393|DRUG|Antithymocyte globulin (ATG)|ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
214500112|NCT04098393|DRUG|Busulfan 0.8 mg/kg|Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
214500113|NCT04098393|PROCEDURE|Allogeneic hematopoietic cell transplantation (Allo-HCT)|Allogeneic hematopoietic cell transplantation following the conditioning regimen.
214997537|NCT06824467|DRUG|Acetaminophen (or equivalent)|Rescue medication taken per approved product label before sacituzumab tirumotecan
214386009|NCT03942913|OTHER|an observational study|this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
214386010|NCT02134119|DIETARY_SUPPLEMENT|Echinacea-based dietary supplement|Echinacea-based dietary supplement given at 8,000mg/day or 16,000 mg/day by mouth
214386011|NCT02134119|DRUG|Placebo|Sugar pill manufactured to mimic dietary supplement
214386012|NCT01127906|DRUG|PF-04531083 100mg|Oral PF-04531083 100mg suspension single dose
214386013|NCT01127906|DRUG|PF-04531083 2000mg|Oral PF-04531083 2000mg suspension single dose
214386014|NCT01127906|DRUG|Placebo suspension|Oral Placebo suspension (matched to PF-04531083 suspension)
214386015|NCT01127906|DRUG|Placebo tablet|Oral Placebo tablet (matched to Oxycodone)
214997538|NCT06824467|DRUG|Dexamethasone (or equivalent)|Rescue medication taken per approved product label before sacituzumab tirumotecan
214386016|NCT01127906|DRUG|Oxycodone 20mg|Oral Oxycodone 20mg (Oxycontin) controlled release formulation
214386017|NCT06450574|DRUG|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
214386018|NCT06450574|RADIATION|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
214386019|NCT06450574|PROCEDURE|Transanal Endoscopic Microsurgery (TEM)|10 weeks after Chemoradiotherapy
214386020|NCT06450574|PROCEDURE|Transanal Endoscopic Microsurgery|Standard surgical treatment of T1, N0, M0 rectal cancer. Early after diagnosis
214386021|NCT03709290|RADIATION|mri|mri brain \& spinal cord
214500114|NCT00229658|DRUG|pramlintide acetate|Subcutaneous injection prior to each major meal
214500115|NCT00249769|BIOLOGICAL|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
214687762|NCT01139385|PROCEDURE|Harmonic scalpel|The Cholecystectomy is performed using only Harmonic Scalpel to mobilize the Cholecystis and to close the cystic duct and the cystic artery
214687763|NCT01139385|PROCEDURE|Traditional|The cholecystectomy is performed using Harmonic Scalpel to mobilize the cholecystis and the cystic duct and the cystic artery are closed by titanium clips
214386022|NCT02710760|OTHER|Adoption Encouragement Treatment|Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.
214386023|NCT02710760|OTHER|Consumption Encouragement Treatment|Households in the Consumption Encouragement Treatment received the same guidance as households in the Adoption Encouragement Treatment, as well as additional guidance on the importance of specifically targeting foods made with QPM to young children and tools to help households keep the grain separate and remember to feed QPM-based foods to the young children.
214386024|NCT03693716|PROCEDURE|Dynamic Anterior Stabilization|All-arthroscopic trans subscapular Long Head of the Biceps tenodesis in the anterior-inferior glenoid with all-suture anchors
214386025|NCT01454830|BEHAVIORAL|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
214386026|NCT01454830|OTHER|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
214386027|NCT06345222|PROCEDURE|Prolotherapy|"The Modified Prolotherapy technique was applied in the study and 0.5cc 5% Dextrose injection was applied per injection to the tendon entesis and/or tendon of the patient's non-rheumatic chronic, myoskeletal knee-induced, pain-inducing sensation. The follow-up period was determined as 1 month after the last injection. The ligaments to be injected within the scope of the research (context knee pain) were determined as Lateral Collateral Ligament (LCL), AnteroLateral Collateral Ligament (ALL), Medial Collateral Ligament (MCL), Pes Anserius and Patellar Ligament."
214386028|NCT00982150|DRUG|Talampanel|50mg capsules tid
214386029|NCT03051126|OTHER|Tissue Samples|Fresh residual tissue samples will be obtained during parathyroid and/or pancreas tumor intervention (for pancreas tumor intervention in MEN1 patients with hyperparathyroidism and pancreatic lesions).
214386030|NCT02524132|BEHAVIORAL|Physical Activity|
214386031|NCT00780936|PROCEDURE|femoral nerve block|
214386032|NCT02663414|DEVICE|Atlas Knee System|The Atlas Knee System is an approved device (CE Marked) and is an extra-capsular knee implant specifically designed to treat patients with uni-compartmental, medial knee osteoarthritis (OA).
214997539|NCT06824467|DRUG|Steroid mouthwash (dexamethasone or equivalent)|Rescue medication taken orally 4 times daily
214997540|NCT04740307|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.
214386033|NCT03941314|DEVICE|Supera® Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
214386034|NCT03941314|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
214386035|NCT00152763|BEHAVIORAL|Cognitive Behaviour Therapy (CBT)|Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
214687764|NCT02305290|PROCEDURE|Endoscopic Mucosal Resection|
214997541|NCT04740307|DRUG|Lenvatinib|Lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or 8 mg (BW \<60 kg) administered orally every day (QD).
214997542|NCT04740307|BIOLOGICAL|Pembrolizumab|Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.
215093597|NCT03132025|DRUG|"Capecitabine"|"Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
215093598|NCT06004375|DIETARY_SUPPLEMENT|Neomune|Neomune containing 4.8 g arginine and 2 g glutamine
215093599|NCT03283436|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
215093600|NCT00257660|BIOLOGICAL|Botulinum toxin type A|500 units
215093601|NCT00257660|DRUG|Placebo|500 units
214386036|NCT00152763|OTHER|Usual Cardiac Care (UCC)|Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
214386037|NCT00902889|PROCEDURE|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
214386038|NCT00902889|PROCEDURE|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
214386039|NCT03006627|DRUG|postoperative morphine|Postoperatively, A loading dose of morphine will be given in incremental doses of 1 mg 5 min apart, till the VAS score reached ≤3. The dose of morphine required to reduce the VAS score to ≤3 will be recorded. Subsequently, PCA pump will be configured to deliver a bolus of 1 mg with a lock-out period lasting for 20 min.
214386040|NCT05693493|DEVICE|Proprioceptive knee brace|For the intervention group that randomly consisted of 15 subjects will be using a design of knee brace (Reaction Web®; DonJoy, Vista, CA). The elastomeric web design helps to reduce pain by dispersing load across the knee. The web acts like a spring to absorb shock and shifts the peak loads away from the painful area of the knee. Elastomeric web acts to dynamically stabilise the patella on all sides, bringing the patella into proper tracking position to reduce pain for patients with general patellofemoral instabilities. Reaction Web® has dual-axis hinges that are flexible, creating synergy with the elastomeric web for optimal fit and support, and providing energy dispersion to the knee.
214386041|NCT05799300|PROCEDURE|Intrathecal anaesthesia|Low dose 0.5% hyperbaric bupivacaine (1.3mls, 0.65mg) intrathecal anaesthesia.
214386042|NCT05843474|BEHAVIORAL|Take it Personal!|Take it Personal! is a six-week indicated prevention program for youth with a mild intellectual disability or borderline intellectual functioning. The program aims to teach youngsters skills to reduce their substance use (alcohol, cannabis, and other drugs). The prevention program differentiates four personality profiles associated with a higher risk for problematic substance use: sensation seeking, impulsivity, anxiety sensitivity and negative thinking. For each of the four personality profiles, different program outlines were developed that are similar in structure but have their own personality-specific materials, games and (psychomotor) exercises. There are weekly individual- and group sessions with three to four participants, led by a clinical psychologist and a psychomotor therapist. Motivational interviewing and cognitive behavioral therapeutic principles are applied, both of which have proven effectiveness in decreasing substance use the target group.
214386043|NCT04932382|DRUG|Misoprostol|will be used 3 h before IUD insertion
214386044|NCT04932382|DEVICE|IUD|a copper T380A IUD
214386045|NCT01824563|OTHER|Observational study|
214386046|NCT03930914|DEVICE|Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device|Daily use of Parasym (TM) device on tragus or ear lobe, as assigned treatment arm
214386047|NCT04683289|PROCEDURE|trabeculotomy|performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber
214386048|NCT00569803|DRUG|belatacept|single dose, 116 days
214386049|NCT00569803|DRUG|Placebo|Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
214386050|NCT04343781|OTHER|observation|observation of clinical symptoms related to COVID-19 disease
214386051|NCT01324479|DRUG|INC280|
214386052|NCT00695682|DRUG|intravitreal injection of infliximab|All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
214500116|NCT00249769|BIOLOGICAL|Measles Vaccine (MV)|"The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO).~SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979."
214500117|NCT04337944|PROCEDURE|Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
214997543|NCT02899052|DRUG|Carfilzomib|"Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 and beyond within 30 minutes to 4 hours after dexamethasone dosing.~Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16; Cycles 19 and beyond, for participants that have not previously transitioned to monotherapy: 27 mg/m2 on Days 1, 2, 15, and 16.~Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - onward: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 20 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16.~Cycles 2 - onward: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16."
214997544|NCT02899052|DRUG|Venetoclax|Venetoclax tablet administered orally once daily during Cycles 1 - onward. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.
214386053|NCT00994474|PROCEDURE|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
214386054|NCT00994474|PROCEDURE|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
214386055|NCT01235975|BIOLOGICAL|Meningococcal vaccine GSK 134612|Intramuscular injection
214386056|NCT01235975|BIOLOGICAL|MencevaxACWY TM|Subcutaneous injection
214386057|NCT05643417|DRUG|HAIC、Bevacizumab、Camrelizumab|HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
214386058|NCT03338205|DRUG|Ketamine|1 mg/kg ketamine bolus IV
214386059|NCT03304860|OTHER|Survey|Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
214386060|NCT02006420|DEVICE|ARFI-SVI Ultrasound|Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
214386061|NCT02580773|DRUG|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
214386062|NCT02580773|DRUG|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
214386063|NCT04883593|DRUG|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
214500118|NCT05408624|PROCEDURE|ultrasound transvaginal drainage|Ultrasound-guided transvaginal drainage of TOA by a puncture under simple sedation or analgesia with/or under general anesthesia
214500119|NCT05408624|PROCEDURE|laparoscopy|Laparoscopy for drainage of TOA under general anesthesia
214997545|NCT02899052|DRUG|Dexamethasone|Dexamethasone tablet administered orally during Cycles 1 - onward. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.
214997546|NCT06530576|DRUG|Thalidomide and methotrexate|Thalidomide at a dose of 50-100 mg/QN, Methotrexate 10 mg/m2 orally once a week.
214386064|NCT04883593|DRUG|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
214386065|NCT04989985|DRUG|Oxaliplatin+S-1|"Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w"
214386066|NCT04989985|DRUG|Sinitilimab+oxaliplatin+S-1|"Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w"
214386067|NCT01282671|OTHER|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months. A Positive expiratory pressure (PEP) device PEP ventil, System 22 (Rium Medical, Täby, Sweden) is used to create an expiratory resistance of +10 cm H2O.
214386068|NCT01907074|DRUG|Cholates|Cholates is given intravenously (IV push) and by mouth, once per study visit
214386069|NCT01933503|DRUG|OCA 5 mg|
214386070|NCT01933503|DRUG|OCA 10 mg|
214386071|NCT01933503|DRUG|OCA 25 mg|
214386072|NCT05261932|PROCEDURE|AI-assisted guided biopsy|The surface of the adenoma was classified and identified by the AI system, and different areas of the adenoma were marked by distribution to guide the endoscopist for biopsy to obtain the poorly differentiated portion of the lesion.
214386073|NCT00791921|DRUG|CDP870|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
214386074|NCT00791921|DRUG|Placebo of CDP870|Placebo given every 2 weeks until Week22 (SC)
215093602|NCT04109976|DRUG|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
214386075|NCT00389974|DRUG|sunitinib malate|Given PO
214386076|NCT04736589|DRUG|Inetetamab|Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.
214500120|NCT03389789|OTHER|Oral glucose solution + maternal holding|Infant will receive both the oral glucose solution and the contact with the mother
215093603|NCT02285530|DRUG|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.
214386077|NCT04736589|DRUG|Rapamycin|Oral 2mg, once a day.
214386078|NCT04736589|DRUG|Pyrotinib|Oral 400mg, once a day.
214386079|NCT04736589|DRUG|Chemotherapy|Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
214386080|NCT05496621|OTHER|Questionnaire|1st Stage Keele Start MSk tool translated into Turkish and its cultural adaptation, 2nd Stage Statistical analysis of reliability and validity of Turkish Keele start msk tool
214386081|NCT04825821|PROCEDURE|Clinical and ultrasonographic assessment|Routinely assessment by objective examination and transvaginal ultrasonographic scan 6, 12, and 24 months after the surgical procedures
214386082|NCT03188900|BIOLOGICAL|A collection of maternal plasma and serum|A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
214386083|NCT01197079|OTHER|Survey|Self administered anonymous survey
214500121|NCT03389789|OTHER|Breastfeeding|Infants will be breastfed
214500122|NCT03389789|OTHER|Oral glucose solution|Infant will receive only oral glucose solution without contact with the mother
215093604|NCT02285530|PROCEDURE|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
215093605|NCT02285530|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
214386084|NCT01175538|DRUG|Lactulose|In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
214386085|NCT01175538|DRUG|Lactulose|lactulose will be used in 30-60ml/day
214386086|NCT06110845|DEVICE|QPlasia OncoReader Breast (QPORB)|Automated diagnostic algorithm
214500123|NCT03389789|OTHER|Oral expressed breastmilk|Infant will receive only oral expressed breast milk without contact with the mother
214997547|NCT06361420|PROCEDURE|Driving pressure-guided positive end expiratory pressure|The positive end expiratory pressure setting rules are as follows: a 10-cycle experimental ventilation will be carried out at each level of positive end expiratory pressure after intubation, and the driving pressure of the last cycle will be recorded. The positive end expiratory pressure value corresponding to the lowest driving pressure is recognised as the optimal ventilation parameter. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
215093606|NCT04932291|DRUG|vafidemstat|1.2mg capsule
214386087|NCT01134133|OTHER|Anti-gurgling intervention|1\. head of bed 30 degrees or higher, 2. swallowing evaluation-based feeding, 3. sedatives titrated to minimal effective dose.
215093607|NCT04932291|DRUG|Placebo|placebo capsule
215093608|NCT01786460|OTHER|Blood draw at Days 0, 7, 14, and 21|
215093609|NCT03101007|DEVICE|ATTUNE Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
214386088|NCT01965158|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
214386089|NCT01965158|DRUG|Placebo|Placebo tablet taken orally once a day
214386090|NCT02025920|OTHER|Salmon Group|
214386091|NCT02025920|OTHER|Cod Group|
214386092|NCT02025920|OTHER|Meat Group|
214386093|NCT05297721|OTHER|Knowledge|Measuring the level of knowledge about skin tears
214386094|NCT00967174|DRUG|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
214386095|NCT00967174|DRUG|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
214386096|NCT00967174|DRUG|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
214386097|NCT00474175|DRUG|Placebo gel|single dose (less than 1g) of a matching placebo gel
214386098|NCT00474175|DRUG|benzocaine|single dose (less than 1g) of 10% benzocaine gel formulation
214386099|NCT00474175|DRUG|benzocaine|single dose (less than 1g) of 20% benzocaine gel formulation
214386100|NCT01620359|DEVICE|ExAblate MRgFUS|100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
214386101|NCT03848091|OTHER|Antibiotic pretreatment|a strategy with antibiotic pretreatment before one-step exchange arthroplasty in patients who bacteria responsible for the infection has been indentified (puncture, blood cultures,...)
214386102|NCT01047475|DRUG|MB-6|6# TID with meal
214386103|NCT01047475|DRUG|Placebo|6# TID with meal
214386104|NCT05255484|DRUG|LM-108|Administered intravenously
214386105|NCT05255484|DRUG|An Anti-PD-1 Antibody|Administered intravenously
215093610|NCT03101007|DEVICE|LCS Knee Prosthesis by DePuy|Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
215093611|NCT04855071|DEVICE|Non-ablative radiofrequency application|Non-ablative radiofrequency application will be applied with MJS intracavitary probe, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a frequency that will be individualized according to the maximum level of energy absorption by the patient's tissues (between 0.8-1.2MHz) and with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session). In addition, they will be applied 1 session per week. The treatment will last 8 weeks.
215093612|NCT04855071|OTHER|Usual intervention|The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
214386106|NCT04204213|BEHAVIORAL|Tai Chi Exercise|8 Section Brocade (Baduanjin) sitting Tai Chi classes + Healthcare Education seminars
214386107|NCT02456974|PROCEDURE|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care|
214386108|NCT02456974|PROCEDURE|blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.|
214386109|NCT02456974|PROCEDURE|blood sampling in patients receiving vancomycin as part of routine clinical care.|
214386110|NCT02456974|PROCEDURE|blood sampling in patients receiving teicoplanin as part of routine clinical care.|
214386111|NCT02456974|PROCEDURE|blood sampling in patients receiving meropenem as part of routine clinical care.|
214386112|NCT02456974|PROCEDURE|blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.|
214386113|NCT02456974|PROCEDURE|blood sampling in patients receiving amikacin as part of routine clinical care.|
214386114|NCT01818934|PROCEDURE|hip ultrasound|Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
214386115|NCT01152541|DRUG|Riboflavin/Dextran|Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
214386116|NCT01152541|DRUG|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
214386117|NCT01503541|GENETIC|DNA analysis|
214386118|NCT01503541|GENETIC|RNA analysis|
214386119|NCT01503541|GENETIC|gene expression analysis|
214386120|NCT01503541|GENETIC|mutation analysis|
214386121|NCT01503541|GENETIC|polymerase chain reaction|
214386122|NCT01503541|OTHER|laboratory biomarker analysis|
214386123|NCT05835193|OTHER|Diagnostic Test: Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity and reading capacity of pre-school students in Alexandroupolis, Greece will be examined via a web-based digital visual acuity chart
214386124|NCT00504465|DRUG|dinoprostone|
214500124|NCT01862016|PROCEDURE|APRV|Pressure ventilation mode allowing early spontaneous breathing
214997548|NCT06361420|PROCEDURE|Optimal oxygenation-guided positive end expiratory pressure|Positive end expiratory pressure will be maintained at the level facilitating optimal oxygenation during the off-pump period. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
215093613|NCT05485883|DRUG|Tislelizumab Lenvatinib|Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
215093614|NCT04093336|BIOLOGICAL|human umbilical cord mesenchymal stem cells|The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
214386125|NCT02728921|DRUG|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
214386126|NCT02728921|DRUG|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
214386127|NCT01430312|DRUG|azelaic acid pre-foam formulation|
214386128|NCT01430312|DRUG|Vehicle pre-foam formulation|
214386129|NCT01430312|DRUG|Water|
214386130|NCT01430312|DRUG|Sodium lauryl sulfate|
214386131|NCT06170957|OTHER|Modified pacifier|"In this project, a pacifier produced from a modified pacifier shield made of polypropylene (PP), a biocompatible polymer, which is made suitable for intubation tube in newborns connected to mechanical ventilator, will be used in the light of literature information. No study on the modification of the pacifier shield has been found in the literature, and a utility model application (file number 2020/03477 dated 06 March 2020) was made for this pacifier shield, which is planned to be modified, and the utility model application was accepted on 04.02.2022.~In the application of heel blood collection to newborns, a) before the procedure (20 minutes before), b) immediately before the procedure (20. minutes), c) during the procedure (between the 20th and 40th minutes), and d) 20 minutes after the procedure (40 minutes) will be evaluated once for each application, a total of four times."
214386132|NCT03169179|BEHAVIORAL|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
214386133|NCT02196493|DRUG|Azithromycin|250mg azithromycin three times per week for 12 weeks
214386134|NCT00684086|BEHAVIORAL|Diabetes Self Management Program|
214386135|NCT01109823|DRUG|intravenous administration of levofloxacin|Intravenous administration of levofloxacin is used.
214386136|NCT02672384|PROCEDURE|Dental examination and a point of care P. gingivalis test (Denka Seiken Co (Japan) )|Dental examination Study exams (oral and blood sample collection)
214386137|NCT05297643|DEVICE|Ekstracorporeal Shock Wave Therapy (ESWT)|Extracorporeal Shock Wave Therapy (ESWT); It is a treatment method in which high-intensity pressure waves are applied to the desired point in the body. It has been used in the treatment of kidney stones in previous years, and changes in bone tissue have been observed (12). Today, it is used in musculoskeletal system diseases such as plantar fasciitis, epicondylitis, achiltendinitis, osteoarthritis
214386138|NCT05297643|OTHER|complex decongestive therapy|Complex decongestive therapy consists of manual lymphatic degeneration, compression therapy, skin care and remedal exercise.
214386139|NCT01622543|DRUG|Folfox plus Bevacizumab and reolysin|FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
214386140|NCT01622543|DRUG|Folfox plus Bevacizumab|FOLFOX6/bevacizumab given every 14 days.
214386141|NCT00284869|DRUG|LPS|
215093615|NCT04093336|BIOLOGICAL|Placebo|Placebo
215093616|NCT04093336|OTHER|standardized treatment|standardized treatment
215093617|NCT03933176|PROCEDURE|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
214386142|NCT00831363|PROCEDURE|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
214386143|NCT00831363|PROCEDURE|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
215093618|NCT02983591|DRUG|Misoprostol after delivery|Patients will receive 1000 mcg Misoprostol per rectum
215093619|NCT02983591|DRUG|Oxytocin after delivery|Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h
215093620|NCT02983591|DRUG|Oxytocin before delivery|All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
215093621|NCT00930436|DRUG|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
215093622|NCT00381875|BIOLOGICAL|E1M184V peptide vaccine|
214386144|NCT00616564|DRUG|GM-CSF|Concomitant Priming with GM-CSF
214386145|NCT05016414|OTHER|Lower body negative pressure|lower body negative pressure at -20mmHg delivered via a custom designed sleeping sack
214386146|NCT03096171|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 16 weeks, with trainings of 20 minutes, four times a week.
214386147|NCT03486925|DRUG|oxytocin treatment|intranasal administration of oxytocin (24IU)
214386148|NCT03486925|DRUG|placebo treatment|intranasal administration of placebo
214386149|NCT03539367|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
214500125|NCT01862016|BIOLOGICAL|arterial blood gas measurement each morning|
214500126|NCT04558723|OTHER|ICD/CRT-D implantation|ICD/CRT-D implantation (if indicated)
215093623|NCT00381875|BIOLOGICAL|incomplete Freund's adjuvant|
215093624|NCT00381875|BIOLOGICAL|sargramostim|
215093625|NCT00381875|OTHER|immunoenzyme technique|
214997549|NCT06361420|PROCEDURE|Ventilation strategy|A Pressure regulated volume control mode is used in the patients before extubation. The ventilation target are: (1) a pulse oximetry ≥ 90% or a partial pressure of arterial oxygen ≥ 60mm Hg; (2) a partial pressure of arterial carbon dioxide: 35 \~ 50 mm Hg and (3) a pondus hydrogenii (pH) value \> 7.20. The ventilation parameters are: (1) tidal volume: 6 \~ 8 mL/Kg predictive body weight; (2) respiratory rate 10 \~ 15 cycles per minute; (3) inspiratory/expiratory ratio: 1:1.5 (1:2.5 - 1:3 in the patients with chronic obstructive pulmonary disease); positive end expiratory pressure: 0 \~ 8 cm centimeter water column. On-pump ventilation parameters are: (1) tidal volume: 4 mL/Kg predictive body weight; (2) respiratory rate: 4 circles per minute; (3) positive end-expiratory pressure: 4 cm centimeter water column; (4) inspiratory oxygen fraction: 21%.
214997550|NCT06361420|PROCEDURE|Management of hypoxemia|Management of hypoxemia will be initiated immediately through the following steps: (1) carefully checking anaesthesia apparatus malfunction, airway normality, and monitoring accuracy; (2) improving cardiac function, correcting fluid overload, and alleviating systemic inflammation; (3) performing alveolar recruitment manoeuvres as described above; (4) increasing the tidal volume and positive end expiratory pressure within the upper limits; (5) increasing the respiratory rate while addressing concurrent hypercapnia; (6) titrating the fraction of inspiratory oxygen until the pulse oximetry reaches or exceeds 90%; and (7) considering the use of extracorporeal membrane oxygenation if any following situations occurred 14: (a) a partial pressure of arterial oxygen \< 50 mm Hg for more than 3 hours; (b) a partial pressure of arterial oxygen to inspiratory oxygen fraction ratio \< 80 mm Hg for more than 6 hours; or (c) a critical respiratory acidosis for more than 6 hours.
214997551|NCT05912647|BEHAVIORAL|MTM|Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.
215093626|NCT03443232|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
215093627|NCT03443232|PROCEDURE|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
215093628|NCT01342614|DRUG|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
215093629|NCT01342614|DRUG|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
215093630|NCT02449018|DRUG|QBW251|QBW251 capsule(s) taken orally twice per day
215093631|NCT02449018|DRUG|Placebo|Matching placebo capsule(s) taken orally twice per day
214386150|NCT03539367|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
214386151|NCT02304016|BEHAVIORAL|Pelvic floor physical therapy|Patients in this arm will be receiving pelvic floor physical therapy
214386152|NCT00001202|DRUG|Spironolactone|
214386153|NCT00001202|DRUG|Testolactone|
214386154|NCT00001202|DRUG|Deslorelin|
214386155|NCT01798186|DRUG|Cannabis|Participants will be exposed to cannabis smoke present in ambient air
214386156|NCT02357043|DEVICE|Dario Blood Glucose Monitoring System|Finger-stick obtained with BGMS
214386157|NCT02357043|DEVICE|YSI|Finger-stick sample obtained by nurse/technician to be tested with YSI
214386158|NCT04699357|DRUG|Atropine|different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children
214386159|NCT01474616|OTHER|Sit-to-Stand Activity|Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
214386160|NCT05208385|PROCEDURE|video-assisted umbilical closure|video-assisted umbilical closure
214386161|NCT02091739|DRUG|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214386162|NCT02091739|DRUG|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214386163|NCT02091739|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
214386164|NCT00101660|DRUG|Dasatinib|Tablets; oral; 70 mg BID, depending on response
214997552|NCT05912647|BEHAVIORAL|CHW|Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one \~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive \~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.
214386165|NCT01321398|OTHER|Esophageal Pressure Monitoring|An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
214386166|NCT01948180|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T-cells
214386167|NCT01113658|DEVICE|SNaP Wound Care System|"The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician."
214386168|NCT05666544|OTHER|Web-based patient decision aid|After the clinic, use web-based patient decision aid of renal replacement therapy to conduct education.
214386169|NCT05666544|OTHER|Written health education leaflets|After the clinic, use a written health education leaflet on renal replacement therapy to conduct education.
214386170|NCT00713674|OTHER|Theraworx|Theraworx swab intranasal BID for 5 days
214500127|NCT01953224|BEHAVIORAL|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
214997553|NCT01471639|DRUG|intranasal ketorolac|15 mg
214500128|NCT01953224|DEVICE|Smartphone|
214997554|NCT00558545|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
215093632|NCT01471912|PROCEDURE|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
215093633|NCT00473525|DRUG|Placebo|Placebo QD
214386171|NCT00713674|DRUG|mupirocin antibiotic ointment|mupirocin antibiotic ointment swab intranasal BID for 5 days
214997555|NCT06816004|DEVICE|Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)|tDCS is a noninvasive brain stimulation device that modulates brain activity delivering a low-intensity electrical current.
215093634|NCT00473525|DRUG|PF-00734200 10 mg QD|10 mg QD
214386172|NCT00192023|DRUG|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
214386173|NCT00192023|DRUG|placebo|
214386174|NCT00192023|DRUG|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
214386175|NCT00192023|DRUG|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
214386176|NCT03213496|BEHAVIORAL|Walk prescription|30-40 minutes daily, for five days at the week, all weeks up to surgery.
214386177|NCT03213496|OTHER|Conventional care|Patient do not walk before surgery
214386178|NCT04337060|PROCEDURE|Single-injection ultrasound-guided bilateral erector spinae plane (ESP) block-Sham|"With the patient in the sitting position, 20 ml normal saline will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: after anesthesia induction, paracetamol 1 gr intravenous (IV)+ tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV morphine patient-controlled analgesia (PCA) of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
214500129|NCT04802018|DEVICE|Clinical decision support system based on non-invasive multimodal monitoring|Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
214500130|NCT03277404|PROCEDURE|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
214500131|NCT03277404|PROCEDURE|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
214500132|NCT00210275|BEHAVIORAL|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
214500133|NCT04886349|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma injection for first CMC OA
214500134|NCT04817059|DEVICE|Caseforge headcase|We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
214500135|NCT05515146|DIAGNOSTIC_TEST|near infra red fluorescence lymphatic imaging|ICG (0.2 ml from 25mg of ICG diluted by 5.0 ml of aqua ad injectabilia) was injected intradermally at the basis of the tattooed cutaneous area and at one point chosen so that the tracer had to flow under this area directly towards the root of the limb
214500136|NCT06226155|BEHAVIORAL|TENDAI4PrEP|An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
214386179|NCT04337060|PROCEDURE|Single-injection ultrasound-guided bilateral erector spinae plane block-Lidocaine/Bupivacaine|"With the patient in the sitting position, 10 ml 1% lidocaine + 10 ml 0.5% bupivacaine will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: After anesthesia induction, paracetamol 1 gr IV + tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV PCA of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
214386180|NCT04337060|OTHER|Pain follow-up and monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 15th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours with two different conditions which are at rest and while couching.If NRS score becomes ≥4 Dexketoprofen 50 mg will be administered (max 4 times).
214997556|NCT06816004|DEVICE|Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS)|taVNS is a noninvasive peripheral nerve stimulation device that modulates vagus nerve activity delivering a low-intensity electrical current (\< 5mA) through hydrogel electrodes to the left auricular branch of the vagus nerve.
214997557|NCT06816004|DEVICE|Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS)|tcVNS is a noninvasive peripheral nerve stimulation device that modulates vagus nerve activity delivering a low-intensity electrical current (\< 5mA) through cervical hydrogel electrodes to the left cervical branch of the vagus nerve.
214386181|NCT03788005|PROCEDURE|Early mobilization|Early mobilization as soon as possible and within a maximum of 12 hours following burr hole craniostomy for chronic subdural hematomas.
214997558|NCT06588283|DRUG|Ixekizumab|Administered SC
214997559|NCT06588283|DRUG|Tirzepatide|Administered SC.
215093635|NCT00473525|DRUG|PF-00734200 20 mg QD|20 mg QD
215093636|NCT00473525|DRUG|PF-00734200 5 mg QD|5 mg QD
215093637|NCT00473525|DRUG|PF-00734200 2 mg QD|2 mg QD
215093638|NCT00027911|BIOLOGICAL|NY-ESO-1 peptide vaccine|
215093639|NCT00027911|BIOLOGICAL|sargramostim|
215093640|NCT02505360|OTHER|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
215093641|NCT04764344|DRUG|Haloperidol|2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
215093642|NCT04764344|DRUG|Ondansetron|Ondansetron
214386182|NCT06381011|OTHER|Local Vibration|The patients in the study group will receive local vibration application including different frequency values on the neck and back regions for five consecutive days.
214386183|NCT02207439|DRUG|Nelfinavir (Viracept®) 1250 mg|Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).
214386184|NCT02207439|OTHER|Chemoradiation|Period 2: Concurrent Chemoradiation (70 Gy over 7 weeks) with Nelfinavir (1250 mg bid)
214386185|NCT00482222|BIOLOGICAL|cetuximab|
214386186|NCT00482222|DRUG|capecitabine|
214997560|NCT06980051|BEHAVIORAL|Virtual window|The virtual window, which displays 24h time-linked outdoor scene on a high-definition video monitor, will be on during working hours for three days each week.
214997561|NCT06610968|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|5000 IU Vitamin D (as cholecalciferol) capsules (Vitamin D3 125 mcg \[5,000 IU\], Pure Encapsulation, LLC) daily
215093643|NCT02153814|PROCEDURE|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
214386187|NCT00482222|DRUG|fluorouracil|
214386188|NCT00482222|DRUG|leucovorin calcium|
214386189|NCT00482222|DRUG|oxaliplatin|
214386190|NCT00482222|OTHER|study of socioeconomic and demographic variables|
214386191|NCT00482222|PROCEDURE|adjuvant therapy|
214386192|NCT00482222|PROCEDURE|neoadjuvant therapy|
214386193|NCT00482222|PROCEDURE|quality-of-life assessment|
214386194|NCT04878016|BIOLOGICAL|ZKAB001|Patients will receive ZKAB001 5mg/kg administered by IV infusion every 21days，
214386195|NCT04878016|DRUG|Placebo|Patients will receive placebo administered by IV infusion every 21days.
214386196|NCT04878016|DRUG|Carboplatin|Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
214997562|NCT06610968|DIETARY_SUPPLEMENT|Placebo Group|One placebo capsule (Zeebo Imagine, Zeebo) daily.
214997563|NCT06660732|DRUG|Rilonacept|320 mg subcutaneous (SC) loading dose delivered as two 2-mL, subcutaneous injections of 160 mg on the same day at different anatomical sites followed by once weekly 160 mg SC doses.
215093644|NCT02153814|PROCEDURE|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
215093645|NCT03831945|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
215093646|NCT03831945|BIOLOGICAL|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
214386197|NCT04878016|DRUG|Etoposide|"Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy."
214997564|NCT06859866|OTHER|Standard oral hygiene|Standard protocol includes oral hygiene instructions (OHI), professional supragingival and subgingival instrumentation, and air polishing. A combination of manual tools (scalers/curettes) and electric tools (sonic/ultrasonic instruments) will be used to remove plaque and tartar, with particular attention to avoid damaging the implant surface. Both supragingival and subgingival surfaces will be treated with the air polishing device using glycine powder. A local antiseptic (1% chlorhexidine gel) will be prescribed twice daily for 7 days after TNC. OHI will be reinforced at each follow-up visit.
214386198|NCT02912468|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
214386199|NCT02912468|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
214386200|NCT02912468|DRUG|Mometasone furoate 50 micrograms|"Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal"
214386201|NCT00476619|DRUG|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
214386202|NCT03485274|DRUG|Vortioxetine|oral medication taken once daily
214386203|NCT03485274|OTHER|Treatment as Usual|Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
214386204|NCT01876563|DIETARY_SUPPLEMENT|vitamin D|one tab 4000 IU/day vitamin D
214386205|NCT01876563|DIETARY_SUPPLEMENT|placebo|one tab per day placebo
214386206|NCT02826980|OTHER|questionnaire|Patients consultant in gynecology in the service of Doctor Sauvanet, for whom a diagnosis of endometriosis has been established (clinical history and imaging tests confirming the diagnosis) will be offered to fill a self-administered questionnaire during their consultation
214386207|NCT01570595|BEHAVIORAL|Web-Based Tailored Smoking Cessation Intervention|"The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
214500137|NCT06226155|OTHER|Enhanced treatment as usual|"Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy.~safety during pregnancy/postpartum, and PrEP availability at the ANC."
214997565|NCT06859866|DEVICE|The addition of home-based dual-light photodynamic therapy (Lumorinse® + Lumoral®)|Lumorinse® is an effervescent tablet that provides a final concentration of indocyanine green (ICG) of 250 μg/mL when dissolved in 30 mL of water. After rinsing the mouth for 1 minute, the Lumoral® device is used to activate the ICG. The device consists of 48 LED lights in the shape of a mouthguard, which simultaneously provide antibacterial blue light (aBL) at 405 nm and near-infrared (NIR) LED light at 810 nm. In combination with the ICG photosensitizer, the device delivers simultaneous aBL and aPDT action on dental plaque. After 10 minutes of use (30 J/cm2 radiant exposure), the device automatically shuts off. After treatment, patients will follow regular home oral hygiene procedures according to the OHI provided.
214997566|NCT06988033|BEHAVIORAL|Whole Body Vibration Therapy|Participants receive whole-body vibration therapy in a static upright position on a vibration platform (Power Plate My5). The intervention is applied 3 times per week for 8 weeks, progressively increasing frequency from 8 Hz to 40 Hz and amplitude from 2 mm to 5 mm. Each session lasts up to 15 minutes. No exercise is performed during the vibration.
214386208|NCT01570595|BEHAVIORAL|Standard of Care|advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
214386209|NCT02108145|PROCEDURE|bilateral metal stent insertion|
214386210|NCT02108145|PROCEDURE|unilateral metal stent insertion|
214386211|NCT00900081|OTHER|immunohistochemistry staining method|
214500138|NCT01085513|DEVICE|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
214386212|NCT00900081|OTHER|laboratory biomarker analysis|
214386213|NCT00900081|OTHER|medical chart review|
214386214|NCT04868643|DEVICE|The DIMI Renal Replacement Therapy (RRT) System|To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.
214386215|NCT00131859|PROCEDURE|Diffusion-tensor imaging|Obtain a Diffusion tensor MRI of brain.
214386216|NCT01122004|DRUG|Pregabalin|
214386217|NCT01122004|DRUG|Pregabalin|
214386218|NCT05666687|DRUG|MIJ821|MIJ821 will be administered as an i.v. infusion
214386219|NCT00344006|DRUG|chlorproguanil-dapsone-artesunate|
214386220|NCT00344006|DRUG|artemether-lumefantrine|
214386221|NCT01874106|OTHER|Diet Therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
214386222|NCT01874106|OTHER|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
214386223|NCT00111124|DRUG|Enbrel®|
214386224|NCT04842864|BEHAVIORAL|Fasting|23 hours fasting
214500139|NCT02188836|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
214386225|NCT02772575|PROCEDURE|Hepatic trans-arterial embolization (TAE)|
214386226|NCT02772575|DEVICE|MRI/CT scan|
214386227|NCT02772575|PROCEDURE|biopsy|
214386228|NCT02772575|OTHER|blood draw|
214386229|NCT02712697|DRUG|WM (Shentong Granules)|Shentong Granules with Prednisone
214386230|NCT02712697|DRUG|Hormone (prednisone)|Oral prednisone
214386231|NCT04353193|DRUG|Terlipressin|Terlipressin 1mg IV bolus
214997567|NCT06988033|BEHAVIORAL|Whole Body Vibration with Exercise|Participants perform lower extremity strengthening exercises on a vibration platform simultaneously with whole-body vibration. The protocol includes lunges, squats, heel raises, and ball squeezes. Vibration frequency ranges from 30 to 40 Hz and amplitude from 2 to 5 mm. Sessions are performed 3 times per week for 8 weeks, with duration progressing from 2 to 18 minutes depending on tolerance.
214997568|NCT06988033|BEHAVIORAL|Conventional Physiotherapy|Participants receive standard post-total knee arthroplasty physiotherapy 3 times per week for 12 weeks, lasting 40 to 70 minutes per session. In addition, a home-based exercise program is performed 3 times daily. The program includes range of motion, strengthening, and balance exercises. No vibration therapy is applied in this group.
214997569|NCT07050264|OTHER|Simulated burn injury via application of absorbent and impermeable material over 60% of the body|Simulated burn injury via application of absorbent and impermeable material over 60% of the body
214997570|NCT05285904|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab, that have started before inclusion of the patient into the study will be enrolled.
215093647|NCT03831945|BIOLOGICAL|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
215093648|NCT03530332|DIAGNOSTIC_TEST|PreTRM test|Blood test to determine risk of preterm birth
215093649|NCT03426631|DRUG|Placebo oral capsule|Placebo capsule 30 minutes before sleep
215093650|NCT03426631|DRUG|DAW1033B2 oral capsule|DAW1033B2 capsule 30 minutes before sleep
215093651|NCT04476394|DRUG|[14C]-Anaprazole Sodium enteric-coated capsule|\[14C\]-Anaprazole Sodium enteric-coated capsule
214386232|NCT04353193|DRUG|Terlipressin|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
214386233|NCT04353193|DRUG|Octreotide|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
214386234|NCT03290560|DRUG|Recombinant human tissue kallikrein|Recombinant human tissue kallikrein
214386235|NCT03290560|OTHER|Placebo|Placebo Comparator: Phosphate buffered saline
214386236|NCT04362657|DIAGNOSTIC_TEST|Computer Aided Diagnosis|Computer Aided diagnosis is an environment-enhancing technology developed to aid humans to improve their accuracy, speed and confidence by providing live feedback during the procedure, on request, or after the procedure has been completed.
214386237|NCT01953770|DRUG|PEG-L-asparaginase ind|1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour
214997571|NCT07060768|OTHER|Mandala Coloring|Mandala coloring at least 20 minutes each day. Totally 10 days intervention
215093652|NCT02659319|BEHAVIORAL|Family Lifestyle (FL)|12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
215093653|NCT02659319|BEHAVIORAL|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
215093654|NCT02659319|BEHAVIORAL|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
215093655|NCT04764110|DIETARY_SUPPLEMENT|Cyplexinol|partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)
215093656|NCT04764110|OTHER|Placebo|Maltodextrin
215093657|NCT03645317|DIAGNOSTIC_TEST|Blood tests & cardiac imaging|Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
214997572|NCT07056842|DRUG|Rifampin + VCT220|Participants will receive a single oral dose of VCT220 160 mg on Day 1. Rifampin 600 mg will be administered once daily from Day 4 to Day 10 and from Day 12 to Day 14. On Day 11, rifampin 600 mg will be administered followed 30 minutes later by VCT220 160 mg. All doses are administered under fed or fasting conditions with standardized restrictions on fluid and food intake.
215093658|NCT00099294|DRUG|Glufosfamide|
215093659|NCT02043119|BEHAVIORAL|Breastfeeding Clinic|
215093660|NCT05004974|DRUG|Sintilimab|Sintilimab is administered every 3 weeks (200mg, IV).
215093661|NCT05004974|DRUG|Pemigatinib|Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
215093662|NCT05729698|DEVICE|Baby warmer swaddle|Baby Swaddle with Heating System
215093663|NCT05729698|OTHER|polyethylene bag|polyethylene food bag
215093664|NCT03305380|OTHER|No interventions|As this is a patient registry, there are no interventions.
215093665|NCT01771614|BEHAVIORAL|Exercise|
215093666|NCT01771614|PROCEDURE|Hyperglycemia|
214386238|NCT01953770|DRUG|PEG-L-asparaginase cons|1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).
214386239|NCT01953770|DRUG|E.coli L-asparaginase|E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).
214386240|NCT01953770|DRUG|High-dose Methotrexate|2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.
214386241|NCT01953770|DRUG|Low-dose Methotrexate|30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
214386242|NCT01953770|DRUG|Triple intrathecal therapy|Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
214386243|NCT01953770|RADIATION|Cranial irradiation|12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients \>3 years of age
214386244|NCT01953770|DRUG|Daunorubicin|Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
214386245|NCT03713372|DRUG|Anti-EGFR monoclonal antibody|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
214386246|NCT03862196|BEHAVIORAL|Tailored text messages to improve retention in HIV care|Trained counselors will deliver the text messages. After a block randomization, the trained counselor (a nurse) will send the first welcoming message to participants in the intervention arm. The nurse will send 2 tailored text messages per week. In addition 2 to 4 days before an appointment, the nurse will send a message reminder. In addition, the nurse will have bilateral communication with participants using text messages according to their needs. The participants of the intervention arm will interact with the nurse during 3 months with a semi-structured strategy, that is, with template text messages (predesigned) and open messages (for which the nurse will be trained). Three and six months after started the intervention the variables of interest will be assessed.
214386247|NCT01290822|DEVICE|BiVP|Biventricular pacing
214386248|NCT01290822|DEVICE|AAI Pacing|Atrial pacing
214386249|NCT00101309|BIOLOGICAL|aldesleukin|
214997573|NCT07056842|DRUG|Itraconazole + VCT220|Participants will receive a single oral dose of VCT220 40 mg on Day 1. Itraconazole 200 mg will be administered once daily from Day 4 to Day 11 and from Day 13 to Day 14. On Day 12, VCT220 40 mg will be co-administered with itraconazole 200 mg after breakfast. All doses are administered under fed conditions with standardized fluid and fasting controls.
214997574|NCT01466868|DRUG|MK2206|"Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms."
214997575|NCT06795165|DRUG|Moxidectin 2 MG Oral Tablet|active medication
214997576|NCT06795165|DRUG|Placebo|placebo pills
214997577|NCT05569681|DRUG|Bemiparin 3500|"Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
214997578|NCT05569681|DRUG|Bemiparin 5000 IU|"Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
214997579|NCT07068932|DRUG|SHR-4506 Injection|SHR-4506 injection.
214997580|NCT04761588|DIETARY_SUPPLEMENT|Tyr sphere|"Tyr sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP) and docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
214997581|NCT06614192|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
214997582|NCT06614192|DRUG|Trifluridine/Tipiracil|Oral Tablet
214997583|NCT06614192|DRUG|Bevacizumab|IV Infusion
214997584|NCT06682364|BEHAVIORAL|Trauma-informed case management for women who use drugs|This intervention assesses the adequacy in which components of the gender-specific and trauma-informed intervention function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
214386250|NCT00101309|BIOLOGICAL|autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine|
214386251|NCT00101309|BIOLOGICAL|therapeutic autologous lymphocytes|
214386252|NCT06387589|PROCEDURE|Core stability exercises|"Core stability Exercises will include:~PLANK SIDE PLANK BIRD DOG MS GILL CURLUP PLANK + LEG RAISES SIDE PLANK + LEG RAISES PLANK + WALKS SIDE TO SIDE SIDE PLANK + TWIST BIRD DOG"
214386253|NCT06387589|PROCEDURE|Static Stretching of Iliopsoas|Static Stretching of Iliopsoas (Hold for 7-8s x 10 reps) Week 1 Lifting the leg while lying in a prone position with the knee bent Week 2 Lifting the leg in a prone position with a straight knee Week 3 Stretch in the modified Thomas test position Week 4 Modified launch stretch
214386254|NCT06387589|PROCEDURE|Post Facilitation Stretch of Iliopsoas|"Post Facilitation Stretch of Iliopsoas (5-10s x 10 reps) Patient's position supine at the edge of the table, non-effected hip and knee in flexion, experimental thigh and leg hang on the edge of table. Extend the hip of the opposite thigh up to the barrier. After that, the patient flexes the hip against maximal resistance (isometric) and breathes in for 5-10 seconds. Tell the patient Relax, whereas the therapist applies a rapid stretch to a new barrier and is held for 10 seconds."
214386255|NCT03501693|DEVICE|DBT plus S-View|DBT plus S-View images
214386256|NCT03501693|DEVICE|FFDM Alone|FFDM alone images
214386257|NCT00321204|PROCEDURE|TZD reducing the incidence of atrial arrhythmias|
214386258|NCT00089895|DRUG|Eptifibatide (Integrilin)|intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
214386259|NCT00089895|DRUG|Placebo|intravenous; delivery to match eptifibatide to maintain blind
214386260|NCT05330741|OTHER|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises, static muscle contraction, facilitation of trunk control from different positions, balance training from different positions on tilting board, facilitation of righting, protective and equilibrium reactions from different positions, facilitation of standing from different positions, gait training and, climbing stairs up and down.
214500140|NCT02188836|DEVICE|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
214500141|NCT01513616|OTHER|Pulmonary rehabilitation|8-week program, 3 supervised session per week
214997585|NCT06682364|BEHAVIORAL|CRS Only Intervention|This intervention assesses the adequacy in which components of the gender-specific case management by certified peer recovery specialists function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
214386261|NCT05330741|OTHER|Whole-Body Vibration|"The designed physical therapy program (mentioned before)~\+ Whole-body vibration (WBV) training, child will be asked to stand with slightly flexed knees (30 degrees of knee flexion), and both feet will be placed at an equal distance from the center of the platform to achieve an equal distribution of body weight over both feet. The device will set to produce a peak-to-peak sinusoidal vibration with an amplitude of 2 mm and a vibration frequency ranged from 25 to 30 Hz. WBV will applied for (30 sec. of WBV, 1 min rest, 10 repetitions), (45 sec. of WBV, 1 min rest, 10 repetitions), (60 sec. of WBV, 1 min rest, 10 repetitions) in the 1st, 2nd. and 3rd. months respectively."
214500142|NCT01513616|OTHER|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
214500143|NCT04767815|DRUG|Diet A group|Fasting + DWN12088 200 mg
214500144|NCT04767815|DRUG|Diet B group|30 minutes after a high-fat meal + DWN12088 200 mg
214500145|NCT04767815|DRUG|Diet C group|2 hours after a high-fat meal + DWN12088 200 mg
214500146|NCT06120218|PROCEDURE|Emergent Stenting|Emergent Stenting in acute ischemic stroke caused by tandem occlusions
214500147|NCT03542305|DRUG|Lorlatinib|Lorlatinib single oral dose
214500148|NCT02575924|DRUG|sequential medium|administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
214500149|NCT02575924|DRUG|1-step medium|administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
214997586|NCT03408353|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214997587|NCT03408353|PROCEDURE|Mammography|Undergo standard of care mammography
214997588|NCT03408353|OTHER|Questionnaire Administration|Complete questionnaires
214997589|NCT01125228|DRUG|Ziodovudine and Alpha Interferon|
214997590|NCT06646406|BEHAVIORAL|Patient letter and clinician communication|Single mailing to patients from practice with a reminder that the influenza and COVID-19 vaccines are due, and monthly emailing to the patients' clinicians with information about how to make a strong recommendation for those vaccines
215093667|NCT01965899|DEVICE|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
215093668|NCT01443832|DIETARY_SUPPLEMENT|Fe57 and Fe58-FeSO4 stable isotopes|\[57Fe\] and \[58Fe\]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
215093669|NCT06416293|OTHER|Questionnaire patients|Completion of a two-part questionnaire with a special focus on communication around the breast cancer diagnosis. Tumor stage and therapies received are also surveyed. The questionnaire can be answered online via a secure tool (REDCap) or in paper form.
214500150|NCT01760226|DRUG|DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|"Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved."
214500151|NCT01760226|DRUG|Methotrexate|"CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~* 2+ extranodal sites~* elevated LDH,~* MYC rearrangement OR~* bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6."
214500152|NCT01760226|DRUG|Etoposide|Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
214997591|NCT07084285|DRUG|Dexamethasone|A single 4mg (1mL) dexamethasone injection via the posterior intra-articular route, under CT guidance
214997592|NCT07084285|OTHER|Isotonic saline solution|1 mL isotonic saline solution, injectable, for a single posterior intra-articular injection, under CT guidance.
214997593|NCT07116733|DRUG|Desﬂurane group|"After routine induction, maintain anesthesia with inhaled desflurane , adjusting concentration as needed to sustain 0.5-2 MAC . To maximize the cardioprotective effects of inhaled anesthetics, adhere to this intraoperative strategy:~Maintain ≥1 MAC continuous desflurane for ≥30 minutes ; For on-pump CABG , discontinue desflurane 15 minutes before initiating cardiopulmonary bypass (CPB) ;~If intraoperative desflurane cessation is required, implement a wash-in/wash-out strategy (recommended but non-mandatory):~Perform 3 alternating cycles of:~Wash-in : ≥10 minutes of desflurane at ≥0.5 MAC, Wash-out : ≥10 minutes of complete cessation of inhaled anesthetics. Propofol is strictly prohibited for anesthesia maintenance throughout the procedure , except during CPB."
214997594|NCT07116733|DRUG|Propofol group|Administer total intravenous anesthesia (TIVA) using propofol infusion at 3-8 mg/kg/h . No inhaled anesthetics are permitted for maintenance. This may be delivered via:target-controlled infusion (TCI) systems, or manual adjustment of intravenous infusion rates.
215093670|NCT06416293|OTHER|Questionnaire physicians|Completion of a questionnaire with a special focus on communication around the breast cancer diagnosis
215093671|NCT01694979|OTHER|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
214386262|NCT05330741|OTHER|Gravity Force Stimulation|"The designed physical therapy program (mentioned before)~\+ Gravity force stimulation child will be asked to maintain his balance on GFS during each of the following positions as a progression (standing and walking on the surface of two beams connecting the two boxes - standing and walking crossly on the surface of one beam connecting the two boxes - standing and walking sideward on the surface of one beam connecting the two boxes - standing and walking on the edge of the two beams - standing and walking on the edge of one beam: most difficult)"
214386263|NCT00583232|DRUG|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
214386264|NCT00049998|DRUG|topotecan|
214386265|NCT05943314|BIOLOGICAL|CLL1/+CD33 CAR-T|CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.
214386266|NCT04023149|DRUG|recombinant human interleukin-2 (rhIL-2)|Drug: rhIL-2; Pharmaceutical form: solution; Route of administration: oral gargle.
214386267|NCT04023149|DRUG|placebo|Drug: placebo; Pharmaceutical form: solution; Route of administration: oral gargle.
214386268|NCT01569035|DRUG|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
214386269|NCT06055192|OTHER|Survey|Survey
214386270|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 1|1 x 10\^7 Inf.U MVA-BN-WEV vaccine
214386271|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 2|1 x 10\^8 Inf.U MVA-BN-WEV vaccine
214386272|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 3|2 x 10\^8 Inf.U MVA-BN-WEV vaccine.
214386273|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 1|
214500153|NCT01760226|DRUG|Doxorubicin|Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
214500154|NCT01760226|DRUG|Vincristine|Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
214500155|NCT01760226|DRUG|Rituximab|Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
214500156|NCT01760226|DRUG|Cyclophosphamide|Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
214997595|NCT07124741|DIAGNOSTIC_TEST|Serial VEXUS Ultrasound Evaluation|Ultrasound assessments will be performed by an experienced anesthesiologist at three time points (0-4 hours, 12-24 hours, and 72 hours)to determine the degree of venous congestion using the VEXUS Score. No treatment changes will be made based on the VEXUS findings. The scores will solely be used for prognostic correlation with mortality outcomes.
215093672|NCT01694979|OTHER|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
215093673|NCT01694979|OTHER|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
215093674|NCT06276790|PROCEDURE|ultrasound-guided/hysteroscopic curettage|ultrasound-guided/hysteroscopic curettage
215093675|NCT06276790|PROCEDURE|Procedure/Surgery: laparoscopic removal of the pregnancy lesion|laparoscopic removal of the pregnancy lesion
215093676|NCT04971941|DEVICE|Dental Vibe|Use of Dental Vibe during dental anesthesia intervention
215093677|NCT01567995|DRUG|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
214386274|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 2|
214386275|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 3|
215093678|NCT01567995|DRUG|Vehicle (base cream)|Vehicle (base cream)
214386276|NCT01980615|DRUG|Inhaled GFF (PT003)|
214386277|NCT01980615|DRUG|Inhaled Symbicort Dose 1|
214386278|NCT01980615|DRUG|Inhaled Symbicort Dose 2|
214386279|NCT02301156|DRUG|Ublituximab|Administered as an IV infusion
214386280|NCT02301156|DRUG|Ibrutinib|Administered orally
214386281|NCT03679195|DIETARY_SUPPLEMENT|NO Ultra|6-week supplementation period with 764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
214386282|NCT03679195|DIETARY_SUPPLEMENT|Placebo|"6-week supplementation period with placebo capsules (the active ingredients will be replaced by cellulose)~Participants will have to take 2 capsules of cellulose between breakfast and lunch and 2 capsules between lunch and dinner to match the number of capsules ingested daily by the NO Ultra group."
214500157|NCT01760226|DRUG|Prednisone|Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
215093679|NCT00787215|OTHER|observational: no treatment involved|observational: no treatment involved
214386283|NCT02811757|PROCEDURE|tenotomy|
214386284|NCT02811757|PROCEDURE|tenodesis|
214500158|NCT01760226|DRUG|G-CSF|G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
214500159|NCT02565966|OTHER|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
215093680|NCT04588181|BEHAVIORAL|cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
215093681|NCT05302622|OTHER|There is no intervention planning|There is no intervention planning
215093682|NCT06334614|DEVICE|iReach|The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.
214386285|NCT04380532|BIOLOGICAL|V-SARS|Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month
214386286|NCT03324503|DRUG|Glucocorticoid (prednisone or prednisolone)|≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
214386287|NCT03211715|OTHER|questionnaire|Rectal cancer patients who received sphincter saving surgery will be asked to fill up questionnaire related to bowel dysfunction
214386288|NCT02676908|OTHER|Compression socks for 2 weeks|Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
214500160|NCT03872063|OTHER|Experimental|The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects
214500161|NCT03872063|OTHER|Control|The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
214500162|NCT00857766|DRUG|ADVAIR DISKUS™ 250/50mcg|ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
214500163|NCT00857766|OTHER|Placebo|COPD subjects-Placebo DISKUS
214500164|NCT00690131|BEHAVIORAL|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
214500165|NCT02040870|DRUG|LDK378|750 mg once daily
214500166|NCT00775892|DEVICE|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
214500167|NCT04971733|DRUG|E2814|E2814 intravenous infusion.
214500168|NCT02450708|GENETIC|KIR genotyping|
214500169|NCT02450708|GENETIC|HLA genotyping|
214500170|NCT00858650|OTHER|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
214500171|NCT03792932|PROCEDURE|Laparoscopic distal pancreatectomy|Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
214500172|NCT03792932|PROCEDURE|Open distal pancreatectomy|Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
215093683|NCT00169221|DRUG|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
215093684|NCT00169221|RADIATION|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
215093685|NCT02975752|GENETIC|LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing
215093686|NCT03503981|OTHER|Psychotherapy|There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.
215093687|NCT01741337|PROCEDURE|Adaptive servo-ventilation post-operative treatment for 6 months|
214386289|NCT03236922|PROCEDURE|Pubococcygeus sling|The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.
214386290|NCT03236922|PROCEDURE|Rectus fascia sling|Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
214386291|NCT03368079|DEVICE|Negative Pressure Suction Catheter|The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
214386292|NCT02592200|DIETARY_SUPPLEMENT|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
214386293|NCT02592200|DIETARY_SUPPLEMENT|Placebo|Two doses per day for 28 days
214386294|NCT01805193|OTHER|Computed tomography myocardial perfusion imaging|
214386295|NCT01805193|OTHER|Oxygen 15 labelled water positron emission tomography|
214386296|NCT01326273|PROCEDURE|Lymphopheresis|Lymphopheresis
214386297|NCT01326273|PROCEDURE|CMV specific lymphocyte infusion|CMV specific lymphocyte infusion
214386298|NCT01326273|PROCEDURE|Peripheral blood for CMV DNA PCR|Peripheral blood for CMV DNA PCR
214386299|NCT01326273|PROCEDURE|Haematology/Blood chemistry|Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.
214386300|NCT00675415|DIAGNOSTIC_TEST|Capnography|Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
214386301|NCT00780182|DRUG|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
214386302|NCT00001266|DRUG|Suramin|
214386303|NCT00194480|DRUG|Pegylated Interferon|Weekly injections of pegIntereferon
214386304|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
214500173|NCT06175520|BEHAVIORAL|Preconception care (PCC)|The investigators will introduce PCC through the existing public health system. At the community level facility, healthcare providers will screen the women for some specific health problems and provide necessary supplements. Healthcare providers will screen for health problems such as- infectious diseases (e.g., Tuberculosis), Hypertension, Anaemia, Diabetes Mellitus, Thyroid problems, Sexually Transmitted Infection/Reproductive Tract Infection/Urinary Tract Infection, Nutritional status (e.g., Body mass index), Thalassemia symptoms, Thyroid symptoms, severe Dysmenorrhea, Immunization status, and Symptoms of acute Hepatitis B Virus infection, etc. The provider will also consider age, menstrual history, and reproductive history during preconception screening. If the provider finds any abnormality from the screening test which is a risk for a woman to become pregnant and for her newborn; the woman will be provided proper counseling, treatment, and referral to the appropriate facility.
214500174|NCT06364852|DRUG|LY007|FC and LY007 infusion
214386305|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
214500175|NCT03773549|OTHER|Virtual reality experience|Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
214500176|NCT00131209|DIETARY_SUPPLEMENT|fortified spread (RUTF)|
214500177|NCT00131209|DIETARY_SUPPLEMENT|maize and soy flour|
214386306|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 100 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
214386307|NCT04848883|BEHAVIORAL|Advanced AMS program|"1. \- Telephone acces to infectious disease experts to discuss patients' therpies during working days.~2. \- Biweeckly meetings with infectious diseases experts and antimicrobial stewardship group."
214386308|NCT04848883|BEHAVIORAL|Standard AMS program|"1. \- Educational materials.~2. \- Updated local antibiotic guidelines.~3. \- Promotion of delayed antibiotic prescription.~4. \- Promotion of Streptococcus pyogenes antigen test (Streptotest) if bacterial tonsillitis is suspected.~5. \- Daily report to GP of multiresistant bacteria isolates in urinary samples.~6. \- Quarterly reports to prescribers of AMS outcomes at the centre-level."
214386309|NCT01354834|DRUG|hMG|Patients with a condition
214500178|NCT06564194|BIOLOGICAL|JCXH-108|IM injection
214500179|NCT06564194|OTHER|Placebo|IM injection
214386310|NCT05730530|BEHAVIORAL|Nutrition education curriculum|This intervention consists of a 6-week-long nutrition education curriculum aimed at improving fruit and vegetable acceptance and consumption. Sessions will occur within the classroom 3 times per week for 6 weeks. Each week, the sessions will consist of 2 days of teaching activities and 1 day of taste-test activities designed for children to guess various common fruits and vegetables, assemble recipes including 2-4 different fruits and vegetables, and then taste the foods. These activities will be conducted in a full-classroom group setting.
214500180|NCT04477707|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
214500181|NCT04674813|DRUG|CC-95266|Specified dose on specified days
214500182|NCT04674813|DRUG|Fludarabine|Specified dose on specified days
214500183|NCT04674813|DRUG|Cyclophosphamide|Specified dose on specified days
214500184|NCT04674813|DRUG|Bendamustine|Specified dose on specified days
214500185|NCT04707001|OTHER|Catheterization based on ultrasound|Bladder volume ultrasound
214500186|NCT04707001|OTHER|Catheterization based on evaluation of symptoms|Ask for symptoms: Need to urinate, lower abdominal pain
214500187|NCT01672333|DRUG|TOX|oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
214500188|NCT00231699|PROCEDURE|Plastic wrap (study group) and cotton (control group) wrap.|
214500189|NCT01273610|DRUG|Lapatinib|250 mg tablets
214500190|NCT01273610|DRUG|Trastuzumab|Intravenous injection
214500191|NCT01273610|OTHER|laboratory biomarker analysis|
214500192|NCT01273610|OTHER|pharmacological study|
214500193|NCT05027906|DRUG|AT-1501|Investigative Arm
214500194|NCT06974383|OTHER|Training with Virtual Laparoscopic Hiatal Hernia Simulator (VLaHHS)|For the training phase, participants in Group 1 will perform the tasks on VLaHHS for an hour a day for a maximum of 15 sessions over 3 weeks.
214386311|NCT05373134|DRUG|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
214386312|NCT05373134|OTHER|Placebo|Placebo
214386313|NCT01394484|OTHER|Intervention I|Four servings of dairy foods (milk and yogurt) per day for 42 days.
214386314|NCT01394484|DIETARY_SUPPLEMENT|Intervention II|1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
214500195|NCT06971250|DRUG|Capsaicin only (7.6 ng)|Intradermal injection of 7.6 ng capsaicin (0.5 µM, 50 µL) in synthetic interstitial fluid (SIF) without Flupirtine. Used to induce experimental burning pain in the skin.
214500196|NCT06971250|DRUG|Capsaicin + Flupirtine 0.5 µg|Intradermal co-injection of 7.6 ng capsaicin (0.5 µM) and 0.5 µg Flupirtine in 50 µL SIF. Used to assess local analgesic effect of very low-dose Flupirtine on chemically induced pain.
214500197|NCT06971250|DRUG|Capsaicin + Flupirtine 1.2 µg|Intradermal co-injection of 7.6 ng capsaicin and 1.2 µg Flupirtine in 50 µL SIF. Part of dose-response evaluation for peripheral pain inhibition.
214500198|NCT06971250|DRUG|Capsaicin + Flupirtine 3.0 µg|Intradermal co-injection of 7.6 ng capsaicin and 3.0 µg Flupirtine in 50 µL SIF. Intermediate dose in microdose titration series.
215093688|NCT03691779|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet orally once daily in the morning.
215093689|NCT03691779|DRUG|IVA|IVA tablet orally once daily in the evening.
214386315|NCT03515057|DIAGNOSTIC_TEST|Single lead handheld electrocardiogram|Screening for atrial fibrillation during outpatient primary care office visits among patients 65 years and older
214386316|NCT00525603|DRUG|Cyclophosphamide|200 mg/m\^2/day 3-5 IV 5-30 minutes
214386317|NCT00525603|DRUG|Fludarabine|20 mg/m\^2/day 3-5 IV 5-30 minutes
214386318|NCT00525603|DRUG|Alemtuzumab|30 mg Days 1, 3, 5 IV 2-4 hours
214386319|NCT00525603|DRUG|Rituximab|375 mg/m\^2/day 2 IV 4-6 hours
214386320|NCT03734991|DRUG|Ibrexafungerp|Ibrexafungerp 300 mg BID for 1 day
214500199|NCT06971250|DRUG|Capsaicin + Flupirtine 7.6 µg|Intradermal co-injection of 7.6 ng capsaicin and 7.6 µg Flupirtine in 50 µL SIF. This is the highest Flupirtine microdose used in the capsaicin model.
214500200|NCT06971250|DRUG|Placebo (SIF only, no capsaicin or Flupirtine)|Intradermal injection of 50 µL synthetic interstitial fluid without capsaicin or Flupirtine. Used as negative control for capsaicin-Flupirtine co-injection conditions.
214500201|NCT06971250|DRUG|Room Temperature Injection (Control)|Intradermal slow infusion of SIF at \~23°C using a programmable pump. No capsaicin or Flupirtine included. Used as baseline control in heat model.
214500202|NCT06971250|DRUG|Heated injection without Flupirtine|Intradermal slow infusion of synthetic interstitial fluid preheated up to \~52°C. No Flupirtine included. Used to induce thermal pain in human skin.
214997596|NCT07085403|OTHER|Cognitive Orientation to daily Occupational Performance (CO-OP) is a cognitive problem-solving approach|Cognitive Orientation to daily Occupational Performance (CO-OP; CO-OP approach) is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need, to or are expected to perform. CO-OP is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the CO-OP approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the CO-OP Approach, are situated within a structured intervention format, and may involve the parent/significant other as appropriate.
214386321|NCT03734991|DRUG|Placebo|Matching placebo
214386322|NCT05825898|PROCEDURE|Surgery or Transcatheter tricuspid valve intervention|Isolated tricuspid valve surgery or Transcatheter tricuspid valve intervention
214386323|NCT02638623|DRUG|Lactated Ringer|2L Lactated Ringer administered prior to primary knee or hip arthroplasty
214386324|NCT02638623|DRUG|Placebo|No additional fluids will be administered
214386325|NCT02918929|DRUG|EDP 305|
214386326|NCT02918929|DRUG|Placebo|placebo to match EDP 305
214386327|NCT00735449|DRUG|Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
214500203|NCT06971250|DRUG|Heated Injection with Flupirtine 124 µg|Intradermal slow infusion of synthetic interstitial fluid up to \~52°C containing 124 µg Flupirtine. Used to test local analgesic effect of high-dose Flupirtine in heat pain model.
214500204|NCT04764175|BEHAVIORAL|Telephone All Nations Breath of Life|Same as described above.
214500205|NCT04764175|BEHAVIORAL|Comparison Program|Same as described above.
214386328|NCT00735449|DRUG|timolol maleate 0.5%|1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
214386329|NCT00735449|DRUG|latanoprost 0.005%|1 drop of latanoprost 0.005% once nightly.
214386330|NCT02932592|DEVICE|Continuous Glucose Monitoring System (i Pro 2 - Medtronic)|This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
214386331|NCT03513601|DRUG|(R)-CHOP regimen|(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
214386332|NCT03513601|DRUG|(R)-CVP regimen|The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
214386333|NCT02454829|OTHER|questionnaire|A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
214386334|NCT02975635|OTHER|Questionnaire|Patients are given a questionnaire with items related to personality and behaviour.
214386335|NCT03510624|DRUG|Rebaudioside A|Rebaudioside A 3g
214386336|NCT03510624|DRUG|Placebo|Empty capsules
214386337|NCT02010801|PROCEDURE|irreversible electroporation|
214386338|NCT02010801|DEVICE|nanoknife AngioDynamics US Ltd|
214500206|NCT02707198|DRUG|kefir|4 ounces of kefir 3 times a day, with or without food.
214997597|NCT06930040|OTHER|Action observation therapy protocol|The examined group got 30 minutes of a standard, selected physical therapy program in addition to 30 minutes of AOT on the upper limb (total session time: 1 hour), 3 sessions per week for three consecutive months (total therapy time: 3 hours/week). Action observation was executed with therapist guidance and repeated practice (3 repetitions for each task). The child has been requested to perform the watched task with the same tool after observing a 3-minute video for each task on an adjustable monitor screen positioned one meter in front of him or her from forward, sideways, and backward directions. The therapist sat beside the child to provide verbal comments during the excursion and to guide the child's movement. The AOT for the examined group included six unimanual tasks and six bimanual tasks. The unimanual tasks included pressing a rubber stamp, stacking cups, drinking water from a cup, grabbing a pen, flipping cards, and putting things on a stick.
214997598|NCT06930040|OTHER|Kenisiotaping|"Shoulder taping will done using two Kinesiotex tapes(2.5 · 7 cm), in the form of I shape. The tapes follow the line of pull of the anterior and posterior deltoid muscle fibers applied in order to assist the deltoid muscle action .~The tape was applied with the child in a sitting position by assistance from his care giver, while the therapist supported the child's arm. The first tape was initiated from the upper border of the lateral 1/3 of the clavicle to the deltoid prominence on the middle of the lateral side of the body of the humerus moving backward and lateralward while the arm was externally rotated and horizontally abducted. The second tape was initiated from the lower lip of the posterior border of the spine of the scapula towards also the humeral deltoid prominence moving forward and lateralward while the arm was horizontally adducted and internally rotated as if reaching to the outside of the contralateral hip."
214997599|NCT04253626|DRUG|Ferumoxytol Injection [Feraheme]|510mg intravenous ferumoxytol
214997600|NCT04253626|DRUG|Ferrous Sulfate|325mg oral ferrous sulfate
214997601|NCT07078773|PROCEDURE|peng block|A convex ultrasound probe (frequency 2-5 MHz) was positioned at the patient's inguinal ligament, with one end directed toward the anterior inferior iliac spine (AIIS), clearly visualizing the bony prominences of the iliopubic eminence and the AIIS. The needle tip was directed medially toward the pectineus muscle. Upon reaching the space between the pectineus muscle and the pubic bone, and after confirming the absence of blood on aspiration, 30 ml of 0.375% ropivacaine was injected.
214997602|NCT07078773|PROCEDURE|obturator nerve block|An ultrasound probe was positioned at the inguinal ligament, with the needle inserted parallel to the long axis of the probe. After confirming no blood upon aspiration, 15 ml of 0.375% ropivacaine was injected into the fascial plane between the adductor brevis and adductor magnus, as well as into the midportion of the adductor longus and adductor brevis muscles.
214997603|NCT06904404|PROCEDURE|Cataract surgery at high IOP|Cataract surgery at high IOP (conventional)
214997604|NCT06904404|PROCEDURE|Cataract surgery at low IOP|Cataract surgery at low IOP
214997605|NCT06905288|DRUG|Secukinumab|This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
214997606|NCT06812533|DEVICE|Alleviant ALV1 System|Creation of interatrial shunt
214997607|NCT06812533|OTHER|Sham-Control|Cardiac imaging
214997608|NCT06818968|DRUG|MK-6916|Oral administration
214386339|NCT02520648|OTHER|Neuro-lymphatic treatment|The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
214386340|NCT02520648|OTHER|Articulatory spinal manual therapy|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
214386341|NCT02520648|OTHER|Articulatory costal Manual therapy|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
214500207|NCT03383874|COMBINATION_PRODUCT|Probio-Tec BG-VCap-6.5|"The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10\^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10\^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally."
214500208|NCT03383874|OTHER|Placebo|This placebo is made almost identically to the Probio-Tec but without active microorganisms.
214500209|NCT04719936|PROCEDURE|inferior capsulotomy|inferior capsulotomy will be conducted during posterior approach.
214997609|NCT06818968|DRUG|Diltiazem|Oral administration
214997610|NCT06771206|DEVICE|Owlet pulse oximeter neonatal accuracy validation|This study specifically evaluates the Owlet pulse oximetry sensor, which is specifically designed and FDA cleared for for infants, and whose accuracy is specifically being validated in the neonate population.
214997611|NCT05701917|DEVICE|ClotTriever System|Mechanical thrombectomy
214500210|NCT04719936|PROCEDURE|superior capsulotomy|superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
214997612|NCT05701917|DRUG|Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.|Anticoagulants are a group of medications that decrease your blood's ability to clot.
214997613|NCT06821048|BIOLOGICAL|Intraperitoneal infusion of FAST CEA-targeted CAR-T|Intraperitoneal infusion of FAST CEA-targeted CAR-T (PTC13); Subjects will be treated with Fludarabine and Cyclophosphamide based lymphodepleting chemotherapy before CAR-T cell infusion.
214997614|NCT05763875|DRUG|Inclisiran|284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
214997615|NCT05763875|DRUG|Ezetimibe|10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
214997616|NCT05763875|DRUG|Matching Placebo for Inclisiran|0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
214386342|NCT04535622|BEHAVIORAL|A structured exercise|Exercise training will be conducted by a physical therapist which will take about 10 to 15 minutes. Patient education will include how to keep face down in various postures, and how to actively exercise the related muscles and joints while maintaining face-down posture through video clip and brochure. Patients will go through three times of self-exercise sessions everyday according to the training provided to the patients. Active exercise for the FDP patients will include exercise in a hands and knees position, limb exercise in an FDP, and exercise in a standing position. The exercises were performed within the range of individual muscle strength and fitness.
214997617|NCT05763875|DRUG|Matching Placebo for Ezetimibe|0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
214997618|NCT07082777|BEHAVIORAL|Narrative therapy|The intervention is structured around 4 central tasks focusing on different aspects of narrative repair. Task 1: Introduction to life story exploration and building alliance. Task 2: Explore and process the impact of mental illness on identity, externalizing negative narratives, and making sense of emotional responses such as guilt, grief, or shame. Task 3: Identify positive identity conclusions (e.g., strengths, values, skills) from past or current life experiences, and support their integration into the personal narrative. Task 4: Support the imagining of a realistic and hopeful future narrative, grounded in insights of previous sessions. Tasks 1-4 are addressed in a total of 8-12 sessions, depending on the specific user needs. Sessions will have an app. duration of 45-60 mins and will be delivered by the PI who is a trained therapist and psychologist (MSc. Psych.), receiving ongoing supervision. The intervention manual will be made freely available in relation to study publication.
214386343|NCT02874651|DRUG|Apatinib|Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
214997619|NCT07079332|OTHER|New Scale to evaluate ataxia motor symptoms|The Ataxia Trunk, Lower And upper extremity Scale (ATLAS) is a new scale. It differs from other Ataxia Scale by focusing on the assessment of coordination abilities of specific body segments: the trunk, lower limbs, and upper limbs.
214997620|NCT07086677|BIOLOGICAL|PG4 vaccine in Buffer 1 with low dose PA-001|Multivalent pneumococcal conjugate vaccine
214386344|NCT02874651|DRUG|Placebo|Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
215093690|NCT05027620|OTHER|Motor-cognitive exercise therapy in the home|"Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period."
215093691|NCT05625373|DRUG|Vancomycin|The powder will be placed within the surgical wound prior to skin closure.
214386345|NCT02743923|DRUG|carboplatin|AUC 6
214386346|NCT02743923|DRUG|paclitaxel|200mg/m2
214386347|NCT02743923|DRUG|Bevacizumab|15 mg/kg
214386348|NCT02743923|DRUG|Pemetrexed|500 mg/m2
214386349|NCT02743923|DRUG|cisplatin|75 mg/m2
214386350|NCT03810222|OTHER|N/A (Observational Study)|This is an observational study and does not include interventions. Exposure is TBI.
214386351|NCT05134402|DIAGNOSTIC_TEST|Sleepiz One Connect|Sleepiz One Connect measurements over 10 nights
214386352|NCT02390739|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).
214386353|NCT02390739|DRUG|Fludarabine|Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
214386354|NCT02390739|DRUG|Cyclophosphamide|Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
214386355|NCT02390739|BIOLOGICAL|Anti-Thyroglobulin mTCR PBL|On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
214386356|NCT01741454|DRUG|Tamsulosin|0.4 mg by mouth once per day.
214386357|NCT01741454|DRUG|Tolterodine ER|4 mg by mouth once a day.
214386358|NCT06056622|OTHER|Combined Exercises|"The treatment involving multisensory stimulation through active movement was structured into two distinct segments. The initial segment encompassed exercises executed on a wobble board, comprising tasks such as squats, passing a ball between hands and to another individual, maintaining a single-leg stance, and gently destabilizing each other's balance. The subsequent segment involved exercises performed on a soft mat, including activities such as jumping from a small box and landing with both knees flexed, passing the ball to a team member during a two-leg jump, executing a two-leg jump while rotating the trunk by 90 degrees, and leaping from a small box onto a soft mat while balancing on one leg. Each of these exercises was repeated ten times within each session.~Balance-related exercises were conducted with participants assuming a shoulder-width stance on both firm and soft surfaces."
214386359|NCT06056622|OTHER|Placebo Exercise|Participants allocated to the control group will receive placebo treatment sessions, which entailed a 10-minute exposure to a visual evoked potential (VEP) measurement screen while holding a mouse. During this time, participants were given instructions to click the mouse whenever the screen exhibited a change in color. These activities were carried out while seated in a chair equipped with arm support
214386360|NCT00650143|DRUG|Lenograstim (GRANOCYTE)=GCSF|10 µg/kg/d s.c. for 5 days divided in two dosages per day
214386361|NCT00650143|DRUG|Sitagliptin (Januvia)|100 mg p.o. per day for 28 days
214386362|NCT00650143|DRUG|Sodium Chloride (NaCl) 0.9 %|applied s.c. twice a day for 5 days
214386363|NCT00650143|DRUG|Gelatin|One capsule p.o. per day for 28 days
214386364|NCT03555825|DEVICE|Hocoma ArmeoSpring|A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.
214386365|NCT02440802|GENETIC|Saliva sample collection for genetic analyses|Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
214997621|NCT07086677|BIOLOGICAL|PG4 in Buffer 1 with low dose PA-002|Multivalent pneumococcal conjugate vaccine
214500211|NCT05555485|DEVICE|transcutaneous Auricular neurostimulation - Active|Active auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved
214386366|NCT05023135|DEVICE|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
215093692|NCT03156959|BEHAVIORAL|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
215093693|NCT03156959|BEHAVIORAL|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
214386367|NCT05710705|DEVICE|portable prototype of bioimpedance measurement|"The device will be installed during the patient's operation. It will be attached to the healthy skin of the flap (without wound or scar) by sterile glue. It will then be covered with a self-adhesive tegaderm type dressing. The wound will be isolated from the device with a hermetic silicone dressing of the Mepilex type, for example. There will therefore be no communication between the measuring device and the surgical wound."
214500212|NCT05555485|DEVICE|transcutaneous auricular neurostimulation - Sham|Sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX) but will not deliver prolonged stimulation.
214500213|NCT01858012|BEHAVIORAL|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
214500214|NCT03821506|DEVICE|Dynamic Light|Dynamic Lighting system
214500215|NCT03821506|DEVICE|Usual care|Standard lighting system
214500216|NCT06971042|RADIATION|Lung Ultrasound|Patients were examined in supine position, using a portable ultrasound machine equipped with a curvilinear transducer (5-3 MHz)
214500217|NCT06421285|BEHAVIORAL|Aerobic exercise, Strength training, Flexibility exercise|"Aerobic exercise: 30-40 minutes/time, 3-5 times a week, intensity of 4-6 points on the Rating of Perceived Exertion(RPE) 10-point scale(A simple conversation is possible during exercise, but the intensity is such that you feel out of breath) Strength training: 2-3 times a week, 3 sets of 10 repetitions per movement~* Upper extremities: Biceps brachii, triceps brachii, deltoid, pectoralis muscle exercise~* Lower extremities: gluteus maximus, hamstrings, quadriceps exercise Flexibility exercise: Stretching and mobility exercises reflecting post-surgery rehabilitation"
214687765|NCT01028651|DRUG|Treprostinil|"Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min."
214687766|NCT06271070|OTHER|Non-intervention|Non
214997622|NCT07086677|BIOLOGICAL|PG4 in Buffer 1 with high dose PA-001|Multivalent pneumococcal conjugate vaccine
214997623|NCT07086677|BIOLOGICAL|PG4 vaccine in Buffer 1 with high dose PA-002|Multivalent pneumococcal conjugate vaccine
214997624|NCT07086677|BIOLOGICAL|PG4 vaccine in Buffer 2|Multivalent pneumococcal conjugate vaccine
214997625|NCT07086677|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|(20vPnC)
214997626|NCT07086677|BIOLOGICAL|Saline injection|Placebo
215093694|NCT01864161|DRUG|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
215093695|NCT01864161|DRUG|Liposomal iron|Sideral forte 30 mg/die
214386368|NCT03846414|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
214386369|NCT03331185|BIOLOGICAL|Freeze Dried Bone Allograft|Human derived bone particles used in oral and periodontal grafting procedures
214997627|NCT07085819|DIETARY_SUPPLEMENT|Botanical Extract, 125mg|Two capsules per day (125 mg/day) before sleep, with or without food, for 8 weeks.
214997628|NCT07085819|DIETARY_SUPPLEMENT|Botanical Extract, 250mg|Two capsules per day (250 mg/day) before sleep, with or without food, for 8 weeks.
214997629|NCT07085819|DIETARY_SUPPLEMENT|Botanical Extract, 500mg|Two capsules per day (500 mg/day) before sleep, with or without food, for 8 weeks
214997630|NCT07085819|DIETARY_SUPPLEMENT|Pacebo|Two capsules per day before sleep, with or without food, for 8 weeks.
214997631|NCT07089901|DRUG|transdermal nicotine replacement therapy|All participants will receive transdermal nicotine replacement therapy (21 mg. patches)
214386370|NCT03331185|BIOLOGICAL|L-PRF clot|L-PRF is a second-generation platelet rich plasma obtained from autologous blood and contains several different growth factors, platelets and leucocytes in a complex fibrin matrix to accelerate the healing of soft and hard tissues.
214386371|NCT05694403|OTHER|Survey|Questionnaire
214500218|NCT05168085|DIETARY_SUPPLEMENT|Eggs|Providing 1 egg per day fo 6 months to infants
214500219|NCT04785950|DRUG|Low-dose levonorgestrel intrauterine systems (LNG-IUS)|Any low-dose intrauterine system (IUS) marketed in Spain
214500220|NCT01367236|DRUG|standard care|"* atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\*"
214500221|NCT01367236|DRUG|novel treatment|"* darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*~* maraviroc 150 mg once daily"
214386372|NCT01338922|DEVICE|Continuous subcutaneous insulin infusion therapy|Insulin is given continuously using an insulin pump. Devices are allowed having marketing approval. Insulins are permitted with marketing approval.
214386373|NCT01338922|DEVICE|Multiple daily injection therapy|Multiple daily injection therapy with different devices and insulin types. Devices and insulin types have to have marketing approval.
214500222|NCT03882450|PROCEDURE|Flexible fiberoptic laryngoscopy|Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.
214500223|NCT03882450|PROCEDURE|Laryngeal ultrasonography|Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.
214500224|NCT00679770|DRUG|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
214997632|NCT06551649|OTHER|Venous blood draw and skin biopsy|The skin tissue will be used to isolate fibroblasts, which will then be reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs will be differentiated to develop patient-specific and control organoids. The blood samples will be used to isolate peripheral blood mononuclear cells (PBMC) to study the contribution of inflammation in the in vitro models developed.
214997633|NCT07092254|DRUG|No drug|No study drug will be administered in this non-interventional study.
214997634|NCT04426214|DEVICE|tDCS|We will apply tDCS in combination with cognitive training. All participants receive cognitive training, and will be randomized to receive either active or sham tDCS
214386374|NCT06040034|DRUG|Lidocaine IV|Lidocaine given as bolus or continuous infusion.
214997635|NCT04426214|BEHAVIORAL|Cognitive Training|cognitive training on computer
214997636|NCT06340685|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin
214997637|NCT03907046|DRUG|Apixaban|Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.
214997638|NCT03907046|DRUG|Aspirin|Aspirin is an oral antiplatelet drug.
214386375|NCT02067234|OTHER|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
214386376|NCT02067234|BEHAVIORAL|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
214386377|NCT05999708|DRUG|GSK4381406|GSK4381406 will be administered.
214997639|NCT03997123|DRUG|Capivasertib|400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
214386378|NCT05999708|DRUG|Placebo|Placebo will be administered.
214386379|NCT05999708|DRUG|Indomethacin|Indomethacin will be administered.
214386380|NCT02122653|OTHER|Weight training|Participants will perform 4 weeks of Weight training for lower extremities.
214386381|NCT02122653|DEVICE|Electronic muscle stimulator|Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
214386382|NCT05024422|DRUG|Cabergoline|Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
214386383|NCT05024422|DRUG|Pyridoxine|Administration of Pyridoxine (200 mg X 3 per day for a week)
214386384|NCT05982704|DRUG|tixagevimab/cilgavimab 150+150 mg|Administration of tixagevimab/cilgavimab at a dose of 150+150 mg in patients with moderate/severe coronavirus infection.
214386385|NCT05982704|DRUG|tixagevimab/cilgavimab 300+300 mg|Administration of tixagevimab/cilgavimab at a dose of 300+300 mg in patients with moderate/severe coronavirus infection.
214386386|NCT05982704|DRUG|regdanvimab|Administration of regdanvimab at a dose of 40 mg/kg body weight in patients with moderate/severe coronavirus infection.
214386387|NCT02040558|DRUG|MNK-010|
214500225|NCT00679770|DRUG|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
214500226|NCT00679770|DRUG|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
214500227|NCT00679770|DRUG|Vehicle|Once daily application for 90 days and 3x weekly for 90 days
214500228|NCT04960813|BEHAVIORAL|Structured games|"Camp Kidpower - Structured Games is an interactive, child-friendly camp and is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 15 different exercises will be taught. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Playgroup intervention.~Parents will be asked to attend an approximately one-hour group meeting, during which information is presented regarding child anxiety, effortful control and the rationale for this treatment. Parents are asked to continue to utilize the intervention at home every day if possible with the child and will receive texts or emails to track the games that are played at home."
214687767|NCT01554956|BIOLOGICAL|Human Plasminogen|Eye Drops
214386388|NCT00984360|DRUG|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
214386389|NCT01720784|DIETARY_SUPPLEMENT|Alginate dietary fiber|
214386390|NCT01720784|DIETARY_SUPPLEMENT|Placebo|
214386391|NCT01744925|DRUG|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
214386392|NCT01744925|DRUG|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
214386393|NCT00628914|DRUG|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
214386394|NCT00628914|DRUG|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
214386395|NCT00628914|DRUG|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
214386396|NCT05854030|DIAGNOSTIC_TEST|collect plasma samples and clinical features|8ml of peripheral blood need to be collected from pre- and post-treatment advanced pulmonary squamous carcinoma separately
214386397|NCT01103960|DRUG|Telmisartan80mg+Amlodipine5mg|combination therapy
214500229|NCT04960813|BEHAVIORAL|Playgroup|"Camp Kidpower - Playgroup includes structured play activities. This will include art activities, dramatic play props, and a story time. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Kidpower intervention.~During the first week parents will attend an approximately one-hour group meeting, during which information is presented regarding the positive benefits of child-led play and special time with caregivers.~Parents well be asked to complete homework with their children during the week between sessions, and are shown how to track time spent in this activity. Parents will receive a daily text (or email) to to measure frequency of homework practice between sessions."
214500230|NCT04611373|DRUG|Acetazolamide Levamisole|Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
214997640|NCT03997123|DRUG|Paclitaxel|80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
214997641|NCT03997123|DRUG|Placebo|Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
214500231|NCT01596413|DRUG|Sancuso|granisetron transdermal system
214500232|NCT01596413|DRUG|IV granisetron|IV
214500233|NCT05777304|DEVICE|wearable device|IMU sensors and EMG sensors
214500234|NCT04010136|OTHER|Palliative care training|Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
214500235|NCT02792907|DEVICE|Compressive stocking|"After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.~Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking."
214500236|NCT02848560|DRUG|Hyperpolarized Xenon|Inhaled contrast for MRI occurring at each of 4 visits.
214500237|NCT01593020|DRUG|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
214997642|NCT06840535|DRUG|[68Ga]Ga-OncoACP3|Single intravenous bolus injection.
214386398|NCT01103960|DRUG|amlodipine 5mg|monotherapy
214386399|NCT01103960|DRUG|Telmisartan80mg+Amlodipine 5mg|combination therapy
214386400|NCT04100512|DEVICE|Oscillating Positive Expiratory Pressure Device|Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.
214386401|NCT04100512|DEVICE|Incentive spirometry|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
214386402|NCT04612816|OTHER|Prehospital ultrasound|Feasibility of real time PEU transmission in a university affiliated preclinical emergency system.
214386403|NCT00147225|DRUG|AMG 531|"Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).~1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)"
214386404|NCT00147225|DRUG|Carboplatin|AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
214500238|NCT01593020|DRUG|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
214997643|NCT07094724|BIOLOGICAL|Plasma|administration of IV high-titer WNV-neutralizing plasma
214386405|NCT00147225|DRUG|Adriamycin|75-90 mg/m\^2 IV
214386406|NCT00147225|DRUG|Ifosfamide|10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.
214386407|NCT03317028|DRUG|CS02 tablet and placebo tablet|Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
214386408|NCT03396432|DEVICE|Video Laryngoscopy for ET placement|Tracheal intubation performed with the Storz C-Mac Video Laryngoscope
214386409|NCT03396432|DEVICE|Direct Laryngoscopy for ET Placement|Tracheal Intubation performed with the Miller Blade
214386410|NCT05893680|OTHER|Group to play online games|Playing games in children is one of the non-pharmacological pain relief methods. In this study, the effect of playing an online game on pain level in children who underwent orthopedic surgery for pain management after the surgery was measured.
214386411|NCT05893680|OTHER|Group that received cold application|Previous studies have demonstrated that cold application has anti-inflammatory, muscle spasm reducing, and pain relieving properties. In this study, the effect of cold application on pain level in children who underwent orthopedic surgery was investigated.
214386412|NCT05893680|DRUG|Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)|The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
214386413|NCT05893680|OTHER|Group that played an online game and received cold application at the same time|To investigate the combined effect of online gaming and cold application as two separate non-pharmacological interventions, both interventions were applied together in this group
214500239|NCT01593020|DRUG|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
214500240|NCT01593020|DRUG|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
214997644|NCT06781788|OTHER|Making room for climate emotions in the classroom|"The Making room for climate emotions in the classroom program is designed to address emotions as students learn (formally or informally) about climate change. Each session features a drawing, photography, Lego sculpture, rock painting or collage/drawing workshop to address themes, explore emotions/feelings/experiences and initiate discussions on topics related to climate change."
214997645|NCT06880276|DRUG|1.5% QLM3003 ointment|QLM3003 topical cream; 1.5% cream applied twice daily (BID)
214997646|NCT06880276|DRUG|2% QLM3003 ointment|QLM3003 topical cream; 2% cream applied twice daily (BID)
214997647|NCT06880276|DRUG|QLM3003 Placebo|vehicle; vehicle applied twice daily (BID)
214997648|NCT07094269|OTHER|Occupational Therapy Intervention|"Participants in the intervention group will take part in the structured, manualized Packer Managing Fatigue Group Program (Packer et al.), delivered in groups of 8-10 by a licensed occupational therapist. The intervention will consist of six weekly sessions, each lasting 120 minutes, held in a dedicated outpatient room equipped with a whiteboard, group seating, and educational materials.~Each session will address a specific theme: (1) The importance of Rest, (2) Communication and Body Mechanics, (3) Tools, Technology, and ergonomics, (4) Priorities and Standard (5) Putting it all Together, (6) Some Closing Thoughts. Materials will include a participant workbook2, printed handouts, pens, markers, and name tags. All materials will be provided in Italian."
214997649|NCT07094269|BEHAVIORAL|Fact-sheets|Participants in the control group will receive six weekly fact sheets containing general information about Parkinson's disease. These fact sheets serve as a placebo intervention to control for attention and information exposure, without providing any structured fatigue management strategies. This approach helps isolate the specific effects of the active intervention compared to usual care.
214997650|NCT07092995|BEHAVIORAL|VR Freezing Task|Walking overground in immersive virtual reality (VR) environments that provoke freezing episodes
214997651|NCT07092995|BEHAVIORAL|Dual Task|Walking overground with and without concomitant performance of secondary cognitive or motor task
214997652|NCT07092995|BEHAVIORAL|External Cueing|Walking overground in immersive virtual reality (VR) environments that provoke freezing episodes with and without addition of visual and auditory cues.
214997653|NCT07091435|BEHAVIORAL|ChatGPT|Phase 2 Involves a quasi-experimental design with 174 participants identified as having low social frailty scores, randomly assigned to one of three groups: a ChatGPT intervention group engaging in daily 15-30-minute app-based conversations with emotional monitoring; a community social participation group attending regular social activities; and a control group maintaining routine activities. Outcomes related to emotional state, physical activity, social frailty, and prognosis will be assessed pre- and post-intervention.
214997654|NCT07091435|BEHAVIORAL|community social|Phase 2 involves a quasi-experimental design with 174 participants identified as having low social frailty scores, randomly assigned to one of three groups: a ChatGPT intervention group engaging in daily 15-30-minute app-based conversations with emotional monitoring; a community social participation group attending regular social activities; and a control group maintaining routine activities. Outcomes related to emotional state, physical activity, social frailty, and prognosis will be assessed pre- and post-intervention.
214997655|NCT07092280|DEVICE|Active tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation method used to modulate cortical excitability, which produces facilitatory or inhibitory effects on behaviors. The anodal electrode will be positioned at F3 (using the international 10-20 EEG system) to target the left dorsolateral prefrontal cortex (DLPFC). The cathodal electrode will be placed over the right DLPFC. Participants will undergo 20 active stimulation sessions, each lasting 20 minutes at a continuous 1.0 mA intensity.
214386414|NCT01032044|DEVICE|Standard endoscopic evaluation|Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy
214386415|NCT01032044|DEVICE|pCLE guided evaluation|Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
214386416|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
214500241|NCT01593020|DRUG|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
214500242|NCT01593020|DRUG|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
214500243|NCT00900900|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|one-time 400mg oral dose of DHEA
214500244|NCT00900900|DIETARY_SUPPLEMENT|pregnenolone|one-time 400mg oral dose of pregnenolone
214500245|NCT00900900|DRUG|Placebo|one-time dose oral dose
214500246|NCT02350634|DRUG|Flortaucipir F18|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of flortaucipir.
214500247|NCT04205487|BEHAVIORAL|Motivational Interviewing (MI)|Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
214500248|NCT04205487|BEHAVIORAL|Contingency Management (CM)|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
214997656|NCT07092280|DEVICE|Sham (No Treatment)|The anodal electrode will be positioned at F3 (according to the international 10-20 EEG system), targeting the left dorsolateral prefrontal cortex (DLPFC). The cathodal electrode will be placed over the right DLPFC. Participants will receive 20 sessions of sham stimulation, each 20 minutes long. At the start of each session, the current ramps up and remains active for 30 seconds. After 30 seconds, the current is DISCONTINUED (held at 0 mA) but the power indicator stays illuminated for the remainder of the 20-minute session to ensure effective blinding, as is standard in tDCS sham protocols
214386417|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
214386418|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
214386419|NCT02875834|DRUG|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
214386420|NCT04732429|DRUG|HST5040|Liquid solution
214386421|NCT04732429|DRUG|Placebo|Liquid solution
214386422|NCT00412633|BEHAVIORAL|Diet and physical activity interventions|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
214386423|NCT00412633|BEHAVIORAL|Computer technology to tailor, promote and sustain health behavior change & improve health care delivery.|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
214386424|NCT03311230|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
214386425|NCT03311230|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
214386426|NCT03311230|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
214500249|NCT06035809|BEHAVIORAL|SMART|A movement and body-based intervention in which participants are encouraged to explore the use of sensory equipment, which may help reduce symptoms related to psychological trauma/PTSD. Sensory equipment includes exercise balls, mini-trampoline, weighted blankets, and a hammock swing.
214997657|NCT06107946|OTHER|USD questionnaire|After a baseline screening symptom assessment, all eligible patients with at least 2 simultaneously occurring symptoms with a numeric rating score ≥4 on the 11 point scale on the Utrecht Symptom Diary, will be asked to fill out the Utrecht Symptom Diary during two weeks. In the first week twice daily (morning and evening), in the second week once daily (evening).
214997658|NCT07095101|BEHAVIORAL|Mobistudy Application|Treatment with mobile application
214997659|NCT07095101|DEVICE|Occlusal splint|Treatment with an occlusal splint
214997660|NCT07095842|DRUG|Ketamine|Intramuscular ketamine 2 mg/kg (max 90 mg)
214386427|NCT05309460|DRUG|Labetalol Oral Tablet|See Labetalol arm.
214386428|NCT05309460|DRUG|NIFEdipine ER|See Nifedipine arm.
214386429|NCT02973555|OTHER|PRP injection|autologous intrauterine infusion of PRP
214386430|NCT02998021|DEVICE|Vibrating Dumbbell|Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
214386431|NCT02998021|DEVICE|Standard Dumbbell|"Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks.~The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.~To obtain as much data as possible on resistance training with vibration within study timeline, a modification was recently approved by the Institutional Review Board (IRB) to cease enrolling subjects into standard dumbbell training."
214386432|NCT06180941|DRUG|magnesium sulfate.|magnesium sulfate as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
214386433|NCT06180941|DRUG|clonidine.|clonidine as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
214386434|NCT02057003|DRUG|DAA against HCV|
214386435|NCT01695733|BIOLOGICAL|trivalent influenza vaccine|
214500250|NCT02610413|OTHER|Laboratory Biomarker Analysis|Correlative studies
214500251|NCT06163391|DRUG|SOT201|intravenous infusion
214500252|NCT04241848|DEVICE|Keeogo|A new and novel type of robotic-device (Keeogo, B-temia, Inc.) was developed to provide powered assistance at the knee for persons with stroke. This device provides assistance for both knee extension and knee flexion during ambulation, transfers to standing and sitting, in addition to ascending and descending stairs. As this device isn't able to fully control the movement, it requires the ability of the patient to stand and initiate stepping. The approach the Keeogo uses to monitor the desired movement in order to appropriately provide assistance. This promotes intuitive learning for the user, minimizing the amount of instruction and practice needed to effectively ambulate allowing users to independently ambulate within one session. This device does not restrict leg movement, so the user can side-step and walk backwards. However, it does not provide assistance during these movements.
214687768|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact|The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
214386436|NCT00957164|BEHAVIORAL|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
214386437|NCT00957164|BEHAVIORAL|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
214386438|NCT00957164|BEHAVIORAL|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
214386439|NCT01302938|DRUG|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
214386440|NCT01302938|DRUG|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
214386441|NCT03342053|DRUG|RO7234292 (RG6042)|Intrathecal injection
214386442|NCT04904081|DRUG|Indocyanine green|The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
214386443|NCT03696719|DEVICE|BIS bispectral index monitoring device|In addition to the standard monitoring prescribed by the American society of Anesthesiologists, all study participants will be monitored with the BIS, a noninvasive monitoring device which measures the depth of anesthesia. The monitoring is performed using noninvasive electrodes placed on the forehead.
214386444|NCT03696719|BIOLOGICAL|NSE cerebral biomarker testing|Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.
214386445|NCT01233609|DRUG|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
214386446|NCT01233609|DRUG|Placebo|Dosage per subject weight- same schedule as the active comparator
214386447|NCT05884229|OTHER|Intra-operative analgesia guided by SPI|In the SPI-guided group, when SPI is higher than 50 for the first time and for more than 3 minutes, we will administer 1,0 μg/kg of fentanyl LBW. When SPI is again higher than 50 and for more than 5 minutes, we will re-administer 1,0 μg/kg of fentanyl LBW. We will repeat until SPI is between 20-50.
214386448|NCT01115543|DRUG|alfacalcidol and calcitriol|The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
214386449|NCT02319733|DEVICE|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
214386450|NCT05031676|OTHER|opioid free anesthesia|Maintenance of anesthesia was done with halothane. The incision was allowed at 1.2 MAC of halothane. This halogen was administered according to the hemodynamic parameters and the habits of the anesthesia team. Before waking up, all the patients benefited from preventive analgesia with 1 g paracetamol combined with 20 mg nefopam by slow intravenous injection over approximately 15 minutes.
214386451|NCT05505253|DRUG|Alfacalcidol 0.0005 MG|Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
214386452|NCT05505253|DRUG|Placebo|Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
214386453|NCT04398615|DEVICE|Wearable watch device|Every study participant will be given a wearable watch device at the beginning of the study and will be instructed on how to use the device and to wear it continuously throughout the duration of the study (6 months total follow-up). The device will register biometric data and automatically archived. During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.
214386454|NCT01067027|DIETARY_SUPPLEMENT|Lactobacillus reuteri|5 drops of study product 30 minutes before feeding.
214386455|NCT04453241|BIOLOGICAL|NBP615|Intramuscular injection, 0.5ml
214386456|NCT04453241|BIOLOGICAL|Gardasil|Intramuscular injection, 0.5ml
214386457|NCT00204126|DEVICE|Treadmill with partial body weight support|
214386458|NCT00204126|DEVICE|Surface Functional Electrical Stimulation|
214386459|NCT03881930|OTHER|Balance rehabilitation with modified visual input|Patients will perform the exercises alternatively: while keeping their eyes closed or their vision will be obstructed by a opaque mask or disturbed by moving luminous dots projected on the environment in a dark room without any visual reference cues.
214997661|NCT07095842|DRUG|Midazolam|Intramuscular midazolam 0.2 mg/kg (max 10 mg)
214386460|NCT03881930|OTHER|Balance rehabilitation with no modified visual input|Patients will perform the exercises while keeping their eyes openned
214386461|NCT03545373|DRUG|Azithromycin|Azithromycin tablet taken orally
214386462|NCT03545373|DRUG|Amoxicillin|Amoxicillin tablets taken orally
214386463|NCT01225913|DRUG|fluticasone/salmeterol in all asthmatics|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
214386464|NCT01225913|DRUG|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
214386465|NCT03664219|OTHER|isolation of IAN from implant with collagen membrane|comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
214386466|NCT01068301|DRUG|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
214386467|NCT01327118|DRUG|Prostaglandin F2alpha|intravenous injection
214386468|NCT01327118|DRUG|Isoton sodium chloride|intravenous injection
214386469|NCT03029260|OTHER|Neural mobilization - tension.|"Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.~The intervention will be delivered in one session only."
214386470|NCT03029260|OTHER|Neural mobilization - gliding|"Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.~The intervention will be delivered in one session only."
214500253|NCT04241848|OTHER|Ambulation training|Ambulation training will consist of mobility activities affecting daily life including: walking; squatting (or getting in and out of a chair); bending, kneeling or stooping (for picking an item up off of the floor); and ascending and descending stairs. Sessions will be monitored and tailored to the individual, based on their functional ability and to ensure their safety.
214500254|NCT04857983|DRUG|Memantine|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
214500255|NCT04857983|DRUG|Placebo|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
214500256|NCT02196623|OTHER|Hypoxic exercise|Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions
214500257|NCT02196623|OTHER|Normoxic Exercise|Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
214500258|NCT04472767|DRUG|Nivolumab|Given IV
214386471|NCT05036928|DIAGNOSTIC_TEST|Monocyte distribution width (MDW）|All enrolled patients will receive test with MDW.
214386472|NCT03346213|DRUG|MonoFer|Anaemic patients undergoing major surgery who would routinely be receiving intravenous iron 'MonoFer' will get this as part of routine care. They will then have a CPET repeated at least 10 days afterwards.
214500259|NCT04472767|DRUG|Ipilimumab|Given IV
214386473|NCT05996952|DRUG|RC48-ADC|Patients are treated with RC48-ADC at 2.0 mg/kg as an intravenous infusion over 30-90 minutes (60 minutes is recommended) once every 2 weeks for 12 weeks.
214386474|NCT04644640|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises for the knee, proprioception and balance training
214386475|NCT04644640|OTHER|In-person Rehabilitation Therapy|Range of motion exercises for the knee, proprioception and balance training
214500260|NCT04472767|DRUG|Cabozantinib|Given PO
214500261|NCT04472767|PROCEDURE|Transarterial Chemoembolization|TACE treatment will be administered using either the DEB-TACE or cTACE modality in a series of up to 3 individual procedures within the 9-12 weeks following Day 21 (= cycle 1 day 21) of a patient's first infusion of nivolumab/ipilimumab. The first TACE treatment should start no more than 7 working days after being cycle 1 day 21.
214500262|NCT06499441|OTHER|Myofascial induction in gastrocnemius|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
214386476|NCT04007445|BEHAVIORAL|Formally Directed Group (Exercise Group)|This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
214500263|NCT06499441|OTHER|Preassure release|Also called ischaemic pressure. Three cycles of pressure are applied to the trigger point of the gastrocnemius muscle until the pain disappears on pressure.
214500264|NCT02484599|BEHAVIORAL|Computerized attention training (CAT)|Three sessions of active computerized attention training.
214500265|NCT02484599|BEHAVIORAL|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
214500266|NCT03411941|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|IVT(Intravitreal) aflibercept treatment in routine clinical practice.
214500267|NCT06515457|DIETARY_SUPPLEMENT|Eye Empower|Participants will take three capsules of the Eye Empower supplement daily for three weeks.
214500268|NCT05423119|BEHAVIORAL|conventional therapy|upper limb rehabilitation with and without technologies
214500269|NCT05587699|DRUG|CKD-843 A 45mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
214500270|NCT05587699|DRUG|CKD-843 A 45mg|Single Injection
214500271|NCT05587699|DRUG|CKD-843 A 55mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
214997662|NCT07096388|PROCEDURE|endovascular repair|at first the iliac pathology main endovascular treatment was the graft stenting extended along the common and the external iliac artery with the embolisation of the internal iliac artery, with an high risk of pelvic ischemic complications, bowel ischemia, spinal cord ischemia, buttock claudication, erectile dysfunction. Nowadays, off-the-shelf endografts with a special design, the Iliac Branch Endoprosthesis, are available. These grafts, which preserve the hypogastric artery, avoiding complications due to its occlusion; they ensure better distal sealing by reducing the rate of type Ib endoleaks. The patient can be treated under local anesthesia and sedation or general anesthesia. Ultrasound-guided percutaneous access to one or both femoral arteries and, if needed, to the axillary or brachial artery is gained.
214386477|NCT04007445|OTHER|Self-Directed Group (Control Group)|This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
214386478|NCT06291935|DRUG|VG901|"Administered as specified in the treatment arm. Study Cohort 1 - Low dose; Study Cohort 2 - High dose~Other Names:~Gene Therapy (AAV2.NN-CNGA1)"
214386479|NCT03280134|PROCEDURE|axillary lymph node dissection (ALND)|If the patients had predictive nSLN+, need further axillary lymph node dissection.
214386480|NCT02961114|PROCEDURE|Microcannula Harvest Adipose|Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
214386481|NCT02961114|DEVICE|Centricyte 1000|Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
214386482|NCT02961114|BIOLOGICAL|IV Sterile Normal Saline|Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
214386483|NCT05694897|PROCEDURE|Erector spinae block using bupivacaine 0.25% and magnesium sulfate|"After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus 3.75 ml NS and 125 mg MgSO4 (1.25ml)."
214386484|NCT05694897|PROCEDURE|Erector spinae block using bupivacaine and dememdetomidine|"After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus dexmedetomidine 1ug/kg."
214386485|NCT04821739|DEVICE|AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.
214386486|NCT05917223|DIETARY_SUPPLEMENT|Milk protein ingestion|It's just an acute intervention, so the participant assigned to the Milk protein ingestion group will consume 20 g of milk protein during infusion protocol.
214386487|NCT05917223|DIETARY_SUPPLEMENT|Cron protein ingestion|It's just an acute intervention, so the participant assigned to the Corn protein ingestion group will consume 20 g of corn protein isolation during infusion protocol.
214386488|NCT05917223|DIETARY_SUPPLEMENT|Corn+Pea protein ingestion|It's just an acute intervention, so the participant assigned to the Corn+Pea protein ingestion group will consume 20 g of Corn+Pea protein isolation during infusion protocol.
214386489|NCT05917223|DIETARY_SUPPLEMENT|Non-protein, low energy|It's just an acute intervention, so the participant assigned to the Non-protein, low energy group will consume 20 g of carbohydrate during infusion protocol.
214386490|NCT06796699|DRUG|GH56 Capsule|GH56 capsule for oral administration at specified doses on scheduled days.
214386491|NCT06899373|DEVICE|Continuous glucometer|The continuous glucometer is a wearable device that measures interstitial glucose levels 24 hours per day and transmits readings every one minute.
214386492|NCT06899880|OTHER|Describe the perfusion parameters during a deresuscitation strategy and their association with the outcome.|Arterial lactate, pCO2 gap, SvO2, capillary refill time and mottling score anomalies will be described during the first 5 days of the deresuscitation strategy.
214386493|NCT06900309|OTHER|Specific exercise program|An 8-weeks specific exercise program based on lower limb plyomteric exercises
214386494|NCT06900309|OTHER|General exercise program|An 8-weeks of general exercise program focused on whole-body exercises
214386495|NCT06901050|OTHER|FAST HUGS WITH ICU approach|"FAST HUGS WITH ICU; It is an abbreviation of Feeding, Analgesia, Sedation, Thromboembolic prophylaxis, Head of bed elevation, Stress Ulcer prophylaxis and Glucose control Spontaneous breathing trial, Water Balance and constipation, Investigation and results, Therapy, Hypo-hyper delirium, Invasive devices, Check the daily infection parameters, Use a checlist. With this approach, patients will be followed up."
214386496|NCT06926309|OTHER|Peer mentoring|The peer mentor selected by the researchers will be given postpartum perineal care education and peer mentoring education. The peer mentor will prepare perineal care education materials under the supervision of the researchers. Then, the experimental group will be divided into small groups and given 4 hours of perineal care education to their peers.
214386497|NCT06769126|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
214386498|NCT06769126|DRUG|Ceralasertib|Given PO
214386499|NCT06769126|PROCEDURE|Computed Tomography|Undergo CT scan
214500272|NCT05587699|DRUG|CKD-843 A 55mg|Single Injection
214500273|NCT05587699|DRUG|CKD-843-R|0.5mg/day, 9 Month
214500274|NCT04091178|DIETARY_SUPPLEMENT|VITAMIN D|ORAL SOLUTION (2 ml) at 100.000 UI
214500275|NCT01400958|DRUG|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
215093696|NCT00894478|PROCEDURE|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
214997663|NCT07096388|PROCEDURE|open surgical repair|in case of surgical repair of aorto-iliac aneurysms, general anesthesia is required. Access to the aorta can be achieved through a transperitoneal or retroperitoneal approach. A bifurcated graft is usually used for reconstruction as it is more similar to the native anatomical conformation, but it is not the only option. Although not mandatory, it may be necessary to revascularize one or both internal iliac arteries. This is a very complex surgical technique, challenging even for the most experienced operators due to the location of the iliac arteries. It is a procedure with a high risk of bleeding and mortality, and a high risk of damaging nearby structures such as the ureters and great veins. At the end of the procedure the patient is awake and is usually monitored in the recovery room and then translated to the ward, with fewer than 20% of patients needing Intensive Care Unit (ICU) admission.
214997664|NCT07095660|DEVICE|Recana procedure|recanalization and debulking of obstructions and occlusions within stented and non-stented segments in veins
214997665|NCT06109272|DRUG|Livmoniplimab|Intravenous (IV) Solution
214997666|NCT06109272|DRUG|Budigalimab|Intravenous (IV) Solution
214997667|NCT06109272|DRUG|Durvalumab|Intravenous (IV) Solution
214997668|NCT06109272|DRUG|Atezolizumab|Intravenous (IV) Solution
214997669|NCT06109272|DRUG|Bevacizumab|Intravenous (IV) Solution
214997670|NCT06109272|DRUG|Tremelimumab|Intravenous (IV) Solution
214997671|NCT05828212|DRUG|CAR-T cells injection|CAR-T cells in the treatment of R/R neuromyelitis optica
214997672|NCT00000352|DRUG|Dextromethorphan|
214997673|NCT04943861|BEHAVIORAL|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
214997674|NCT04943861|OTHER|Usual Care|There is no peer navigation within usual care.
214997675|NCT06911060|DIETARY_SUPPLEMENT|Flaxseed|30 g/day for 12 weeks
214997676|NCT06911060|BEHAVIORAL|Diet|Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.
214997677|NCT07097324|BEHAVIORAL|Video- and Game-Based Oral Health Education|A video- and game-based oral health education intervention will be delivered to the participants in the intervention group over three weekly sessions. In the first session, participants will watch a video that highlights key messages on oral health, including the importance of oral health, the consequences of poor oral health and recommended oral health practices. This will be followed by an interactive quiz to reinforce the content of the video. In the second session, a video demonstrating proper tooth brushing and flossing techniques will be shown. Participants will then practice these techniques using tooth models. The third session will feature a video on cariogenic food consumption, followed by an interactive educational game in which participants identify non-cariogenic foods.
214997678|NCT07097324|BEHAVIORAL|Conventional Oral Health Talk|A conventional oral health talk will be delivered to participants in both the control and intervention groups. The talk will cover key messages on oral health, including the importance of oral health, consequences of poor oral health and recommended oral health practices.
214997679|NCT06774144|DRUG|Rezafungin|Rezafungin 400 mg IV once within 24 hours of liver transplant, followed by 200 mg IV weekly for 4 weeks.
214997680|NCT06774144|DRUG|Standard of care antifungal prophylaxis|UPMC uses a tiered approach to antifungal prophylaxis, based on risk factors for IFI. Fluconazole is used for recipients with risk factors for yeast infections: choledochojejunostomy, prolonged transplant time, receipt of \>40 units of blood products within 24 hours of transplant, and Candida colonization or infection within 3 months prior to transplant. Voriconazole is used for recipients with risk factors for mould infections: re-transplantation, renal failure requiring renal replacement therapy, fulminant hepatic failure as indication for transplant, intra-abdominal/thoracic re-exploration within the first month after transplant. No prophylaxis is given if there are no risk factors for yeast or mould infections.
214997681|NCT07103265|DEVICE|Transcranial focused ultrasound stimulation|Parameters Range of values Fundamental frequency 250 kHz Transducer diameter 15 cm Focal distance 13.5 cm (steerable +/- 5-10 mm from the center) Pulse repetition frequency 100 Hz Duty cycle 10% Duration 2 min for each of the 7 foci Peak spatial intensity (Isppa) 10.0 W/cm2 Peak temporal average intensity (Ispta) 1.2 W/cm2 Mechanical index (MI) 0.48 \* Thermal index (TI) 0.8oC \*\*
214997682|NCT07103265|DEVICE|Sham stimulation|Same set-up as for real stimulation but with without delivering any ultrasound stimulation
214997683|NCT07105358|DEVICE|transcranial random noise stimulation (tRNS)|Stimulation location: bilateral human middle temporal complex (hMT+). Stimulation parameters: 1 mA current intensity, with a frequency range of 101-640 Hz.
214997684|NCT07105358|DEVICE|Sham Stimulation|Stimulation location: bilateral human middle temporal complex (hMT+). Stimulation parameters: Ramp up stimulation at 1mA with a frequency range of 101-640Hz for the first 30 seconds followed by no current for the remainder of the duration.
214997685|NCT07105358|BEHAVIORAL|Perceptual learning-based training|A motion discrimination task, judging the global direction of moving dot stimuli with two different coherence levels.
215093697|NCT00894478|PROCEDURE|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
214386500|NCT06769126|BIOLOGICAL|Durvalumab|Given IV
214997693|NCT00217737|BIOLOGICAL|Bevacizumab|Given IV
214997694|NCT00217737|DRUG|Fluorouracil|Given IV
214386501|NCT06769126|DRUG|Etoposide|Given etoposide
214386502|NCT06769126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214386503|NCT06769126|BIOLOGICAL|Monalizumab|Given IV
214386504|NCT06769126|DRUG|Platinum Compound|Given platinum compound
214997695|NCT00217737|DRUG|Leucovorin|Given IV
214997696|NCT00217737|DRUG|Oxaliplatin|Given IV
214997697|NCT06240754|DRUG|Enasidenib|Provided by BMS.
214386505|NCT06769126|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
214500276|NCT01400958|DRUG|Placebo|Placebo x 42 days; THEN, No More Placebo
214997698|NCT07108777|DRUG|L-Carnitine Tartrate|L-carnitine 350 mg three times daily by oral.
214997699|NCT07108777|DRUG|Placebo|placebo tablet three times daily by oral.
215093698|NCT00267150|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
215093699|NCT03139799|BEHAVIORAL|Experimental - Puzzle Video Game Intervention|The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).
215093700|NCT03139799|BEHAVIORAL|Control - Tablet Newspaper Reading Intervention|The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.
214500277|NCT06499766|OTHER|Biodiversity intervention by inactivated microbial extract|Participants use the lotion including microbial extract on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
214500278|NCT06499766|OTHER|Placebo intervention by colored lotion|Participants use the lotion including safe, non-active coloring ingredient on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
214500279|NCT04219215|DEVICE|100% O2 in oxygen chamber|Application of 100% O2 in an hyperbaric oxygen chamber
214386506|NCT06769126|DRUG|Saruparib|Given PO
214386507|NCT06769126|RADIATION|Thoracic Radiation Therapy|Undergo thoracic radiation
214386508|NCT06901206|PROCEDURE|Neonatologist performed lung ultrasound|Neonatologist performed lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration. A comprehensive lung ultrasound examination will take 5 minutes or less to perform and involves minimal handling for the patient.
214386509|NCT06899529|PROCEDURE|Bevacizumab|Bevacizumab will be given immediately after surgery in the Treatment Group
214386510|NCT06899425|OTHER|Hot pack|The participants will be treated by hot packs on neck for 15 minutes, 3 times per weeks for 12 weeks.
214386511|NCT06899425|OTHER|Kinesio tape|The participants will be treated by hot packs and kinesio tape. The tape will be placed for several days (3-5 days of application) then it will be removed and repeated for 12 weeks.
214393857|NCT03385057|DRUG|Acetaminophen|Grape-flavored acetaminophen 160mg/5mL (Leader®) will be dispensed based upon the arm to which each participant has been randomized. Acetaminophen at 15mg/kg (max dose 650mg), dosing will be QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
214393858|NCT03702101|DEVICE|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
214500280|NCT04219215|DEVICE|21% O2 in oxygen chamber|Application of ambient air (21% O2) in an hyperbaric oxygen chamber
214997700|NCT07101302|BEHAVIORAL|App-Based Cognitive Behavioural Therapy for Insomnia|The iCANSleep app is based on an established CBT-I protocol. The core features of the iCANSleep app include 1) a modified CBT-I protocol for cancer survivors and 2) daily sleep diaries. Core components of CBT-I treatment to be implemented include sleep restriction, stimulus control, cognitive restructuring, and psychoeducation. These components will be modified into 7-weekly modules.
214997701|NCT07105904|DIAGNOSTIC_TEST|Viscoelastometric hemostatic assay|As part of usual care, when weaning the patient from CPB during cardiac surgery, blood samples are withdrawn from the patient to assess hemostasis: we test both Quantra viscoelastometric assay and biological hemostasis including QT, ACT, fibrinogen and platelet count
214997702|NCT05492955|BEHAVIORAL|Community Health Worker Care Model|Participants will be given a digital BP Cuff and a standardized training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week and record them in a logbook. CHWs will return to participant homes every 2-4 weeks to collect BP measurements and enter them into a data collection system, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. BP readings will be brought by the CHW to their assigned nursing supervisors at their local clinic, who will initiate and tailor medications based on a standardized clinical decision support algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors. Participants will either obtain medication(s) at the pharmacy or, as possible, have them delivered by a CHW.
215093701|NCT04157283|DIAGNOSTIC_TEST|MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)|"1. Neurophysiological Evaluation:~   Visual Evoked Potential (VEP).~2. Imaging Evaluation:~   Conventional MRI.~3. Cerebrospinal Fluid (CSF):~4. Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~5. Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~6. Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54)."
215093702|NCT05556213|PROCEDURE|laparoscopic examination|laparoscopic examination for staging of endometriosis
214386512|NCT00451841|DEVICE|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
215093703|NCT05556213|DIAGNOSTIC_TEST|Blood sampling|Blood sample to detect endometriosis
214386513|NCT06494319|BEHAVIORAL|Stress NAVIGATOR (Mobile Health Application)|Participants will be prompted to complete their assessments each week (or upon completion of each session) via the Stress NAVIGATOR mobile health app
214386514|NCT06494319|BEHAVIORAL|SIT NAVIGATOR|Participants will complete 11 self-paced virtual SIT sessions in the SIT-NAVIGATOR classroom. Participants will be asked to complete at least one session per week, in a minimum of 12 weeks and a maximum of 14 weeks.
214386515|NCT01167179|BEHAVIORAL|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
214500281|NCT03933137|OTHER|Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score|P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).
214500282|NCT02071316|DRUG|Hexacapron( Tranexamic acid)|1\. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
215093704|NCT02068560|DRUG|dDAVP infusion|
214500283|NCT02071316|DRUG|esomeprazole|2\. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
214500284|NCT02766517|DRUG|Capsaicin|Administered topically
214500285|NCT02700269|OTHER|mBEADS|Evaluate approaches using magnetic bead capture, isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of already approved malaria RDTs.
215093705|NCT05661045|PROCEDURE|low-flow anesthesia|Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
215093706|NCT04761744|DRUG|Nivolumab|Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
215093707|NCT03700814|DRUG|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
215093708|NCT04102722|DEVICE|MUST device|Imaging with MUST device
215093709|NCT02718040|DEVICE|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
215093710|NCT04499911|DRUG|Isotonic dextrose 5% in water solution|The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
215093711|NCT00521222|DRUG|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
215093712|NCT00521222|DRUG|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
214386516|NCT04161599|DRUG|Cefuroxime (750mg) I.V|Extra dosage
214386517|NCT04161599|PROCEDURE|Colonic Surgery|Colonic Surgery
214386518|NCT04161599|DRUG|Cefuroxime 750mg oral|Oral prophylaxis
214386519|NCT04161599|DRUG|Metronidazole 250 MG Oral Tablet [Flagyl]|Oral prophylaxis
214386520|NCT04161599|DRUG|Metronidazole 1 g Intravenous|IV prophylaxis
214386521|NCT04161599|DRUG|Cefuroxime 1,5 g Intravenous|IV prophylaxis
214386522|NCT04161599|DRUG|Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral|Laxative for bowel cleansing
214386523|NCT03017235|DRUG|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
214386524|NCT03017235|DRUG|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder|Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
214386525|NCT03990077|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
214386526|NCT03990077|DRUG|Docetaxel|Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
214386527|NCT05683236|OTHER|Health education|Doctors carried out health education for patients to avoid patients giving up their lives, encouraged them to actively cooperate with medical staff, and instructed patients on how to face the disease with a brave and strong attitude and actively fight the disease. Nurses conducted daily psychological counselling for patients, learnt their inner thoughts through communication with patients, and provided timely comfort and encouragement. An attention-shifting method can be used to alleviate the patient's attention to the disease, effectively improving internal depression and avoiding depression. For patients with anxiety and loneliness, family members were instructed to accompany and care.
215093713|NCT00521222|DRUG|Ipratropium HFA|Primary as-needed rescue medication in all treatment groups
215093714|NCT00521222|DRUG|Albuterol HFA|Secondary as-needed rescue medication in all treatment groups
214386528|NCT05683236|OTHER|Comfort care|Reasonable control of indoor temperature and humidity is necessary to ensure that warm, light conditions permit properly dressed patients to feel warm. Nurses need to ensure that patients are kept clean and tidy in personal hygiene. They would regularly assist patients in turning over while giving patients sufficient respect.
215093715|NCT04464525|DRUG|Omecamtiv mecarbil|Film-coated tablet administered orally.
215093716|NCT00876785|OTHER|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
214386529|NCT05683236|OTHER|Pain care|Clinicians should regularly evaluate the patient's physical pain and give reasonable analgesic drugs to patients. Nurses should closely observe the medication response of patients. At the same time, it is necessary to observe and record patients' physical pain daily and take effective pain control measures.
214386530|NCT05683236|OTHER|Dietary care|The clinical nutritionist formulated appropriate nutritional diets according to the nutritional status and personal preferences of patients, provided nutritional support for patients, and followed up with patients once a week after discharge to improve their nutritional status.
214386531|NCT05683236|OTHER|Psychological and social support care|"Two nurses with psychological counselling qualifications in the team used the anxiety and depression scale to evaluate the psychological and emotional status of patients and referred to The Questionnaire Survey on Awareness of Palliative Care by the Department of Elderly Section of the union medical college hospital. The content mainly included the patient's medical history and general situation, the needs and awareness of patients and their families for palliative care, the choice of patients and their families for the final treatment plan, and the needs of families for grief counselling. Timely professional counselling and intervention were undertaken to alleviate the patient's adverse emotions."
214500286|NCT00787709|BEHAVIORAL|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
214500287|NCT00062660|DRUG|Tipranavir|Tipranavir 250 mg soft elastic capsules
214687769|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact/breastfeeding/parental singing|Live parental infant-directed lullaby singing is an individually tailored, non-verbal, multisensory, multimodal and affective tool to regulate the infant before, during and after venipuncture. Direct breast-feeding has demonstrated efficacy that is equal to, or greater than, sweet taste interventions in reducing behavioral and physiological responses to pain in full-term infants undergoing venipuncture with no demonstrated adverse outcomes. Direct breast-feeding should be considered the preferred first-line analgesic intervention for painful procedures performed on full-term infants.
214997703|NCT05492955|BEHAVIORAL|Enhanced Community Health Worker-based with Mobile Health Blood Pressure Monitoring Model|Participants in this arm will also be given a BP Cuff, (but with cellular network capability, such that BP data can be directly transmitted to trial server), given training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week, which will be automatically uploaded onto the server to be made available by the nurse supervisors. CHWs will return to participant homes every 2-4 weeks to ensure functionality of the devices and transmission, collect BP measurements if the system is not functional, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. Nursing supervisors at the clinic will use the remotely collected BP data to initiate and tailor medications based on the same standardized clinical decision support (CDS) algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors.
214997704|NCT05492955|BEHAVIORAL|Standard of Care Model|Participants in the SOC arm will be referred to their clinic for active care as per standard clinical protocols. All care will be provided at the clinic. Routine care consists of regular visits to the clinic until BP is under control (\<140/90 mmHg) and then at 6 monthly intervals. BP measurements to guide management decisions will be made at the clinic using standard clinic equipment. Symptoms related to hypertension and/or medications will be assessed at each visit. Medications available will include medications on the South African Essential Drug list and which are available in the pharmacy. Prescriptions are picked up at the clinic pharmacy by patients as per routine protocol at the clinics. CHWs may also conduct monitoring as guided by clinical guidelines and as advised by their clinical supervisors during the study period to assess for adherence and provide education.
214997705|NCT06023225|BEHAVIORAL|Pain|Postoperative pain levels
214997706|NCT06023225|BEHAVIORAL|Opioid use|Postoperative opioid use
215093717|NCT00876785|OTHER|wheat bread based breakfast|Reference wheat bread breakfast
215093718|NCT03113604|OTHER|Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma|"Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib"
215093719|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail|
215093720|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
214386532|NCT05683236|OTHER|routine nursing intervention|The control group was given routine nursing intervention, strictly in accordance with a routine treatment process, monitoring the vital signs of patients, giving basic nursing, health education, diet guidance and so on.
214386533|NCT04602494|DRUG|Varenicline|varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
214386534|NCT04602494|DRUG|Placebo|Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
214386535|NCT00062621|PROCEDURE|Combined bone marrow and kidney transplant|
214386536|NCT00794625|DRUG|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
214386537|NCT00794625|DRUG|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
214386538|NCT00794625|DRUG|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
214386539|NCT00794625|DRUG|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
214386540|NCT00794625|BEHAVIORAL|Behavioral family counseling|Weekly behavioral counseling with a therapist
214386541|NCT04091906|DEVICE|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
214386542|NCT04822935|PROCEDURE|Vertebral Body Tethering|VBT surgery is a surgery performed by thoracotomy in adolescent idiopathic scoliosis patients.
214386543|NCT04118985|BEHAVIORAL|Cognitive rehabilitation and health behavior change intervention|Cognitive rehabilitation and health behavior change intervention in a group-based program intervention compared to self-implementation of techniques without these interventions
214386544|NCT04118985|BEHAVIORAL|Self-implementation|Self-implementation of cognitive rehabilitation and health behavior change recommendations
214386545|NCT00355407|DRUG|Darbepoetin alfa|
214386546|NCT02248961|DRUG|Fimasartan|"Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning."
214997707|NCT05388643|DIAGNOSTIC_TEST|Enhanced First Trimester GDM Screening|Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
214997708|NCT05388643|DIAGNOSTIC_TEST|Routine Gestational Diabetes Screening|Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
215093721|NCT03147794|DEVICE|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
214386547|NCT02248961|DRUG|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP \& DOHME B.V., Netherlands, tablets 50/100 mg
215093722|NCT05740319|OTHER|FMT|FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
215093723|NCT02983422|DRUG|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
214386548|NCT02142920|DRUG|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
214997709|NCT06619249|DIETARY_SUPPLEMENT|CoQ10 supplementation|Long-distance runners will be supplemented with CoQ10 for 4 weeks in cross-over manner with 4 weeks of wash out period.
214997710|NCT06619249|DIETARY_SUPPLEMENT|Placebo supplementation|Long-distance runners will be supplemented with placebo for 4 weeks in cross-over manner with 4 weeks of wash out period.
214997711|NCT05108519|OTHER|Electronic Health Record Review|Medical records are reviewed
214997712|NCT04132050|DRUG|R788|Oral administration
214997713|NCT04132050|DRUG|Placebo|Oral administration
215093724|NCT02983422|DRUG|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
215093725|NCT02983422|DRUG|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
215093726|NCT04762524|OTHER|CVVH vs CVVHD|Patients are initiated on CRRT in either the CVVH or CVVHD modality
215093727|NCT00475215|DRUG|Sugammadex|Sugammadex solution for injection.
215093728|NCT00475215|DRUG|Rocuronium|Rocuronium bromide solution for injection.
215093729|NCT06312033|DRUG|Estradiol Valerate|To elevate estradiol levels each woman has received 6mg on two consecutive days (total 12mg) of estradiol valerate (Progynova21©)
215093730|NCT06312033|DRUG|Placebo|Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
215093731|NCT04986280|DIAGNOSTIC_TEST|[18F]PSMA-1007|PSMA PET/CT using the intervention.
214386549|NCT01288781|DRUG|Acetazolamide|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
214386550|NCT01288781|DRUG|Lactose monohydrate|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
214386551|NCT01784315|DRUG|Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax|4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
214386552|NCT01784315|DRUG|Chloroquine and Primaquine|Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
214386553|NCT02746757|OTHER|Remote conditioning|
214386554|NCT02746757|DRUG|Exendin 9-39|
214386555|NCT00453310|DRUG|sunitinib malate|
214386556|NCT00892190|DRUG|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
214386557|NCT00892190|DRUG|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
214386558|NCT03045393|DRUG|Mirvetuximab Soravtansine (IMGN853)|Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
214386559|NCT03176095|DIETARY_SUPPLEMENT|Probiotic|
214386560|NCT03176095|DIETARY_SUPPLEMENT|Placebo|
214386561|NCT00650390|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
214386562|NCT05241561|DRUG|Cabozantinib|"Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety.~At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile."
214386563|NCT05241561|BIOLOGICAL|Blood sample|biomonitoring and pharmacokinetics
214386564|NCT05241561|OTHER|Questionnaires of quality of life|FKSI-19 and FKSI-DRS and EUROQOL EQ-5D-5L
214500288|NCT06856421|BEHAVIORAL|Auricular point compression|"Acupuncture Points: Endocrine, Sympathetic, Shenmen, Heart~Procedure Instructions:~Disinfect the areas with 75% alcohol as per standard precautions. Treatments use only ear patches without Vaccaria seeds applied to these specific acupuncture points.~Treatment sessions occur every Monday and Thursday. On Mondays, left ears are patched for three continuous days. Then on Thursdays, qualified medical personnel will remove the patches from the left ear and apply new patches to the right ear for four consecutive days. Any replacements must be performed at the hospital by qualified staff; patients should not attempt to do this themselves.~This procedure is repeated weekly over a span of four weeks, resulting in eight total applications. Importantly, patients in this group do not perform acupoint stimulation as part of their treatment."
214997714|NCT06850701|BEHAVIORAL|mbsr|In order to evaluate the effect of MBSR programme on stress, anxiety, self-compassion and prenatal attachment of pregnant women with perinatal pregnancy loss, MBSR will be applied for four weeks (two sessions per week) for a total of eight sessions in the experimental group. The intervention protocol of this study includes the entire MBSR programme consisting of two sessions per week for 1 month and homework assignments given throughout the programme. In all sessions, mindfulness exercises such as 3-minute breathing, body and breathing exercises, body scanning meditation, sitting meditation, mountain meditation, compassion meditation will be applied to the participants under the guidance of the researcher (H.G.Ö) who is trained and certified in the field of MBSR. It will be done in sessions and individual practices in an environment where pregnant women will not be disturbed at any time of the day. The live online MBSR programme will be provided through mobile communication tools. Sess
214997715|NCT03506477|DRUG|Enstilar® foam|for 4 weeks
214997716|NCT03506477|DRUG|Vehicle foam|for 4 weeks
214997717|NCT04487548|OTHER|Remote smoking cessation bundle|"The bundle is a remote version of what has previously been described in prior literature, which includes:~1. A brief (\<5 minutes) advice~2. Preoperative smoking cessation video prepared by QuitNow~3. Patients will be provided brochures on smoking cessation~4. A referral will be faxed (or internet-registered) to the Quitnow.ca Smokers' Helpline~5. All patients will be requested to participate in the provincial Smoking Cessation program that provides a free 12-week supply of NRT once per year."
214997718|NCT05974332|DIAGNOSTIC_TEST|Oncostatin M|Test to diagnosis of Ulcerative colitis
214997719|NCT01940848|DRUG|STW5 (Iberogast, BAY98-7411)|Applied orally over 28 days, 20 drops STW 5 three times daily
214997720|NCT01940848|DRUG|Placebo|Applied orally over 28 days, 20 drops placebo three times daily
214997721|NCT05833815|DRUG|Everolimus 10 mg|Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx
214997722|NCT05833815|DRUG|Standard of care|GemOx or CapOx
214386565|NCT05392140|BEHAVIORAL|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.
214386566|NCT05392140|BEHAVIORAL|Standart care|Standart care
214386567|NCT01228344|OTHER|Artemether-lumefantrine|
214386568|NCT02444988|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
214386569|NCT02444988|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
214386570|NCT02801474|PROCEDURE|direct fracture reduction and fixation|In the DR group, the posterior malleolar fracture was reduced and fixed in a direct way via a posterolateral approach with the patients in prone position.
214386571|NCT02801474|PROCEDURE|indirect fracture reduction and fixation|In the IR group, the posterior malleolus was reduced through ligamentotaxis following open reduction and internal fixation of lateral and medial malleolar fractures. Percutaneous cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
214386572|NCT04126096|DIAGNOSTIC_TEST|Skin Testing beta-lactams|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
214386573|NCT05706987|DRUG|Lidocaine|continuous lidocaine infusion perioperatively
214386574|NCT05706987|DRUG|Normal saline|normal saline
214997723|NCT06521242|OTHER|Patient Education|The intervention group was given 120 minutes of training.
214997724|NCT05873738|DRUG|Nicotine replacement|Nicotine patches
214997725|NCT01997580|DRUG|escitalopram|SSRI antidepressant
215093732|NCT03332160|DEVICE|Flexitouch head and neck lymphedema treatment system|Pneumatic compression device cleared for use by medical professionals and patients who are under medical supervision, for the treatment of many conditions such as: lymphedema; primary lymphedema; post mastectomy edema; edema following trauma and sports injuries; post immobilization edema; venous insufficiency; reducing wound healing time; treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers. The Flexitouch system and garments for head and neck are intended for use by medical professionals and patients who are under medical supervision for the treatment of head and neck lymphedema.
214386575|NCT02281175|BEHAVIORAL|Psychosocial intervention|Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
214386576|NCT02281175|BEHAVIORAL|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
214386577|NCT05689086|OTHER|Virtual Heart Failure Optimization Program|"Participants referred to the Virtual Heart Failure Optimization Program will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation.~Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well.~All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming."
214386578|NCT03481790|DRUG|Lactoferrin|(Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.
214386579|NCT03481790|DRUG|ferrous sulphate + folic acid (vitamin B9)|(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.
214386580|NCT02643719|BEHAVIORAL|Relaxation Therapy|Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
214386581|NCT02643719|DRUG|Topiramate|"Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)"
214386582|NCT02643719|DRUG|Standard of Care|Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
214500289|NCT06856421|BEHAVIORAL|No pressure on the ear point|"Acupuncture Points: Endocrine, Sympathetic, Shenmen, Heart~Procedure Instructions:~Disinfect the areas with 75% alcohol as per standard precautions. Treatments use only ear patches without Vaccaria seeds applied to these specific acupuncture points.~Treatment sessions occur every Monday and Thursday. On Mondays, left ears are patched for three continuous days. Then on Thursdays, qualified medical personnel will remove the patches from the left ear and apply new patches to the right ear for four consecutive days. Any replacements must be performed at the hospital by qualified staff; patients should not attempt to do this themselves.~This procedure is repeated weekly over a span of four weeks, resulting in eight total applications. Importantly, patients in this group do not perform acupoint stimulation as part of their treatment."
214500290|NCT06994559|OTHER|Preferred Music|The self-selected preferred music intervention will expose participants to music chosen based on personal tastes. Patients will be instructed to compile a playlist lasting approximately 1 hour, but preferably over 1 hour (to avoid repetition or moments without music) of their favorite music. They will be instructed to select songs that they find extremely pleasurable to listen to. Participants will be instructed to select songs that will have a higher likelihood to facilitate relaxation and introspection. This does not need to be an all-time favorite selection, but rather the music that they currently enjoy listening to the most.
214997726|NCT00952913|DRUG|Bosutinib|4 x 100-mg oral tablets, single dose
214997727|NCT00952913|DRUG|Bosutinib|4 x 100-mg oral tablets, single dose
215093733|NCT03332160|OTHER|Standard home lymphedema care|May include daily self manual lymphatic drainage, exercise, skin care, compression garments (as appropriate).
214997728|NCT00952913|DRUG|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
214997729|NCT02588287|OTHER|Blood draws for tenofovir PK, renal function|
214997730|NCT05948605|DEVICE|Empower Neuromodulation System|The Empower Neuromodulation System is designed to provide transcutaneous stimulation to the branches of a spinal nerve. The system comprised of three key components: (A) The Stimulator, (B) the Empower smartphone app, and (C) the Gel Patch. The smartphone application is used to coordinate treatment and record participant responses.
214997731|NCT00843882|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214997732|NCT00843882|BIOLOGICAL|Epoetin Alfa|Given SC
214997733|NCT00843882|OTHER|Laboratory Biomarker Analysis|Correlative studies
214997734|NCT00843882|DRUG|Lenalidomide|Given PO
214997735|NCT06833736|DEVICE|"The See Yourself Differently app"|As the app has not been evaluated before in terms of its impact on dietary change, the first intervention group will have the app as it stands. The overall aim of the syd is to improve general wellbeing across several health-related domains, which is achieved through engaging with its main features (the daily plan, journal, user profile, and chat function).
214997736|NCT06833736|DEVICE|"The See Yourself Differently app + messages"|The plant-forward recipes and information pages available on the app will be made more salient for app users in this group through sending them via targeted messages in the chat function at specific times. Each day, the information pages will be sent at 09:30 and the recipes will be sent at 13:00.
215093734|NCT02974894|DIETARY_SUPPLEMENT|Probiotic (Lactobacillus Plantarum)|
215093735|NCT02974894|DIETARY_SUPPLEMENT|Placebo|
215093736|NCT00837018|OTHER|physical exercise program|45 min, 3times a week
214386583|NCT02643719|DRUG|Abortive Medication (Naproxen and Sumatriptan)|All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
214386584|NCT00061230|BEHAVIORAL|biofeedback-monitored relaxation training|
214386585|NCT03321513|DRUG|intravitreous aflibercept|"Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique"
214386586|NCT03321513|DRUG|Bevacizumab + Deferred Aflibercept Group|"Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.~Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.~Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using a sterile technique."
214386587|NCT03669653|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
214386588|NCT03669653|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
214386589|NCT01176604|RADIATION|Yttrium Y 90 Glass Microspheres|Given via catheter
214500291|NCT06994559|OTHER|Therapist-selected Music|The therapist-selected music intervention will expose participants to a curated playlist specifically designed for psychedelic treatment by expert Music Therapists, which was used in a previous study to investigate the additive hemodynamic effects of music during ketamine infusions for depression. Patients will be randomly exposed to one of 9 available playlists, all containing songs without lyrics.
214500292|NCT06994559|OTHER|Silence|The silence intervention will expose patients to the same therapeutic procedures, in the same room and context, and with the same noise-cancelling headphones. The purpose is to cancel any potentially perturbing background noise, as no music will be played.
214500293|NCT06990542|RADIATION|Image-guided tumor-focused radiation therapy|Image-guided tumor-focused radiation therapy
214997737|NCT06833736|BEHAVIORAL|General information|The (no app) control group will be sent general health and sustainability information via email immediately after randomisation is done. To incentivise participation in both baseline and follow-up assessments, the control group will be offered lifetime access to the app and a summary of their self-reported food intake at week 10. The control group will be sent one email reminder halfway through (week 5) to remind them that they are involved in the study, provide them with instructions on the follow-up assessment, and that they will receive the intervention and dietary feedback at week 10.
214997738|NCT04652141|DIAGNOSTIC_TEST|AsthmaTuner|AsthmaTuner consists of a treatment-adjusting algorithm that gives patient immediate feedback on the status of symptom control (i.e. controlled, partly controlled or uncontrolled) and a treatment recommendation with an image of the correct inhaler or other type of medication and the dose based on lung function (FEV1) and symptom scores (0-4 points).
214997739|NCT06308562|DEVICE|Fuzzy Wale Compression Stockinet|EdemaWear is a tubular, circular knit elastic stockinet fabricated with elastic, vertically oriented fuzzy wales, with the compression provided by the elastic, horizontal oriented Lycra® spandex yarns knitted in between. The stockinet is applied from the foot to the popliteal crease, over the affected area. EdemaWear can be applied in direct contact with the skin or over a wound care dressing. Sizing is based on leg circumference. EdemaWear is indicated for edema management of various etiologies (lymphedema, chronic venous insufficiency, congestive heart failure), and optimizing wound healing. The stockinette is often combined with other boxed compression sets. The manufacturer's stated dosage of EdemaWear is 8-12mmHg when used alone.
214997740|NCT04926545|DRUG|Xiao Chai Hu Tang (XCHT)|"XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients."
214997741|NCT04926545|OTHER|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.
215093737|NCT00496132|DRUG|PRO131921|Escalating doses by IV infusion
215093738|NCT01760811|DRUG|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
215093739|NCT01561963|DRUG|Apremilast|Tablets for oral administration
214386590|NCT05208853|BIOLOGICAL|Anti CD30 CAR-T Cell Injection|"After enrollment, subjects complete the apheresis, then complete the lymphodepletion, and then receive the dose escalation test: 1.5×10\^7 cells，1.5×10\^8 cells，5× 10\^8 cells.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
214500294|NCT05361733|DRUG|XFB-19|XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).
214500295|NCT05361733|DRUG|Placebo|No active ingredient drug use to blind participants and investigators
214386591|NCT06307119|BEHAVIORAL|Occupational Therapy and Relaxation Group|"MOHO Based Intervention~The client-centered occupational therapy comprises five distinct stages:~1. Client-Centered Goal Setting:It involves collaboratively establishing goals the client's needs and aspirations.~2. Creating the Therapy Plan:Comprehensive therapy plan is devised from the findings from OSA and MOHOST results.~3. Implementing the Interventions:These interventions aimed addressing various personal challenges,financial management,stress management.~4. Evaluating the Results:It involves adjusting the therapy plan as needed based on the participant's responses and outcomes.~5. Receiving Feedback~Jacobson's Progressive Muscle Relaxation~Starting with the lower extremities,participants sequentially tensed and relaxed muscle groups,moving from distal to proximal regions,encompassing toes,ankles,thighs,buttocks,abdomen,fingers,triceps,shoulders,and face.During all these stages,it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds."
215093740|NCT01561963|DRUG|Rifampin Oral Capsules|Capsules for oral administration
215093741|NCT01561963|DRUG|Rifampin IV Solution|Intravenous (IV) solution
214500296|NCT06853782|DEVICE|High Frequency Linear Probe (GE Logic e R7 Ultrasonography Device, USA)|A high frequency linear probe (GE Logic e R7 Ultrasonography Device, USA) device will be used while blocking in both groups.
214997742|NCT04926545|DRUG|FOLFIRI regimen|Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
214997743|NCT05317546|DRUG|Cannabidiol|In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.
214997744|NCT03331250|DRUG|Eribulin|It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
214997745|NCT05215587|DEVICE|TEVAR|A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
214997746|NCT04590963|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
215093742|NCT01609413|DIETARY_SUPPLEMENT|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
215093743|NCT01609413|DIETARY_SUPPLEMENT|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
215093744|NCT02017561|BEHAVIORAL|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
214997747|NCT04590963|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
214997748|NCT04590963|OTHER|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
214997749|NCT05481151|DRUG|P1101 (Ropeginterferon alfa-2b-njft)|Ropeginterferon alfa-2b-njft
214997750|NCT05481151|DRUG|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft
214997751|NCT06556121|PROCEDURE|Saddle block|The injected solution will be comprised of 5mg of heavy Bupivacaine 0.75% plus 100mcg of Morphine will be injected into the intrathecal space.
214997752|NCT06556121|PROCEDURE|pudendal nerve block|As part of the analgesic plan, all patients will receive a multimodal analgesic regimen with acetaminophen, NSAIDs and opioids plus a surgeon-administered pudendal nerve block by anatomical landmarks with a mixture of Local Anesthetic as follows: 50mL of Normal Saline, 30mL of 0.25% Bupivacaine with epinephrine 1:200.000 and 20mL Lidocaine 1%. A volume of 20 mL of this mixture is used for the pudendal nerve block, and infiltration of the surgical incision and bilateral spermatic cord block is performed with an additional 20 mL of the same mixture of local anesthetic. 30ml of the solution is used to soak the vaginal plug made of gauze that is put inside the vaginal canal by the end of the procedure.
214997753|NCT06557772|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
214997754|NCT06557772|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: SC injection
215093745|NCT02017561|DRUG|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
215093746|NCT01008969|OTHER|SPECT-CT imaging|SPECT/CT for 3-dimensional mapping of 99mTc-sulfur nanocolloid in order to identify personalized lymphatic drainage patterns
215093747|NCT00318331|DRUG|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
215093748|NCT02286323|DEVICE|Bonfils|Bonfils Intubation Fiberoscope
215093749|NCT02286323|DEVICE|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
215093750|NCT01175395|DRUG|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
215093751|NCT04345094|OTHER|Hexylresourcinol|Emulsion containing hexylresorcinol as an active
214500297|NCT06853782|DEVICE|High Frequency Linear Probe (GE Logic e R7 Ultrasonography Device, USA)|A high frequency linear probe (GE Logic e R7 Ultrasonography Device, USA) device will be used while blocking in both groups.
214500298|NCT04088890|DRUG|Fludarabine|Fludarabine 30 mg/m2
214500299|NCT04088890|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2
214500300|NCT04088890|DRUG|CD22 CAR|Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR). Autologous CD22 CAR T cells will be administered intravenously at Dose Level 1 in subjects with ALL. Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) in subjects with aggressive B-cell NHL to determine MTD/RP2D
214386592|NCT06307119|BEHAVIORAL|Relaxation Group|Jacobson's Progressive Muscle Relaxation (JPMR) Participants underwent training in relaxation techniques involving mental visualization and Jacobson's progressive muscle relaxation method with the aid of music. Starting with the lower extremities, participants sequentially tensed and relaxed muscle groups, moving from distal to proximal regions, encompassing toes, ankles, thighs, buttocks, abdomen, fingers, triceps, shoulders, cervical muscles, and face. During all these stages, it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds.
214386593|NCT01976364|DRUG|Tofacitinib|Tofacitinib 5 mg tablet twice daily
214386594|NCT01976364|DRUG|Tofacitinib|Tofactinib 10 mg tablet twice daily
214386595|NCT01976364|DRUG|Methotrexate|Methotrexate 7.5-20 mg weekly
214500301|NCT07012252|PROCEDURE|Optical coherence tomography|Infants underwent optical coherence tomography.
214500302|NCT07013500|PROCEDURE|Conventional Gasserian Ganglion Radiofrequency|Conventional RFA was performed at the Gasserian ganglion under fluoroscopic guidance with thermal lesioning at 70-75°C for up to 90 seconds. Sensory and motor stimulation were used to verify needle placement.
214997755|NCT06557772|DIETARY_SUPPLEMENT|SIGE|Pharmaceutical form: Capsule Route of administration: Oral
214386596|NCT01976364|DRUG|Placebo Methotrexate|Placebo to match active methotrexate orally once a week
214386597|NCT02757521|DRUG|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
214500303|NCT07013500|PROCEDURE|Peripheral Pulsed Radiofrequency|PRF was applied to the peripheral branch of the trigeminal nerve at 42°C for two cycles of 120 seconds using fluoroscopic guidance. This technique was preferred in our clinic to avoid thermal complications such as hypoesthesia or motor dysfunction.
214500304|NCT07011784|OTHER|Blood flow restriction in combination with dance classes|Blood flow restriction in combination with online ballet and modern-style dance classes to test if the balance of older women can be improved. Participants will wear 5 centimetre elasticized blood flow restriction bands on their proximal thighs throughout the online ballet-modern dance classes. Tightness levels will be set at a 7/10 of the perceived tightness scale used by Wilson et al. (2013), with a total restriction time of approximately 60 minutes, twice per week.
214500305|NCT07011784|OTHER|Dance classes alone|Online ballet and modern-dance inspired classes will be held on Zoom twice per week for 75 minutes. The sessions will span a 12 week time frame. All classes will begin with a warm-up, 1 plie exercise, 1 tendu exercise, a travelling ballet-inspired exercise, 1 travelling Graham or Limón modern dance exercise and a seated cool-down.
214500306|NCT02520791|BIOLOGICAL|Anti-ICOS Monoclonal Antibody MEDI-570|Given IV
214500307|NCT02520791|OTHER|Laboratory Biomarker Analysis|Correlative studies
214500308|NCT02520791|OTHER|Pharmacological Study|Correlative studies
214997756|NCT06557772|DIETARY_SUPPLEMENT|Gluten-free product (GFP)|Pharmaceutical form: Capsule Route of administration: Oral
214997757|NCT02129543|PROCEDURE|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.
214997758|NCT04607421|DRUG|Encorafenib|75 mg capsules
214997759|NCT04607421|DRUG|Cetuximab|Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
215093752|NCT04345094|OTHER|Hydroquinone|Emulsions containing hydroquinone as an active
214386598|NCT02757521|DRUG|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
214386599|NCT02333929|DEVICE|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
214386600|NCT04853147|DRUG|palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,
214386601|NCT04853147|DRUG|palonosetron, dexamethasone, and 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
214500309|NCT07011758|DRUG|Medication for opioid use disorder|A medication treatment component delivered in Week 1 as part of a 2×2 factorial SMART design. The exact content (e.g., treatment modality or intensity) will be finalized based on model results from Aim 1, which identifies optimal dynamic treatment regimes.
214500310|NCT07011758|BEHAVIORAL|psychotherapy|A behavioral treatment component delivered in Week 1 as part of a 2×2 factorial SMART design. The exact content (e.g., treatment modality or intensity) will be finalized based on model results from Aim 1, which identifies optimal dynamic treatment regimes.
214500311|NCT06686667|BEHAVIORAL|Time Restricted Eating|The intervention arm will consist of a time-restricted eating protocol with fasting between 11:00 PM to 6:00 AM. Ad libitum eating will be allowed outside these times and the protocol will be administered during day and night shifts over a 2 week period.
214500312|NCT06699446|OTHER|pre rehabilitation|preoperative pre-rehabilitation (respiratory training, exercise therapy). Establish an individualized rehabilitation plan and postoperative communication via telephone or app
214997760|NCT04607421|DRUG|Oxaliplatin|Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
214997761|NCT04607421|DRUG|Irinotecan|Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
214997762|NCT04607421|DRUG|Leucovorin|Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
214997763|NCT04607421|DRUG|5-FU|Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
214997764|NCT04607421|DRUG|Capecitabine|150 mg or 500 mg Tablet
214997765|NCT04607421|DRUG|Bevacizumab|Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
215093753|NCT00668590|BEHAVIORAL|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
214386602|NCT05635136|OTHER|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy before conventional histopathological analysis
214386603|NCT06017687|DEVICE|OptiBP Study app|Each participant will use OptiBP Study app to measure their blood pressure optically by applying their fingertip to their smartphone camera, and subsequently enter the blood pressure values obtained by measuring it with their own blood pressure cuff.
214386604|NCT04829435|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
214386605|NCT04829435|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
214386606|NCT04291235|PROCEDURE|Airway Management Pathway|Patients in this group will receive several components that comprise airway management pathway: (1) daily spontaneous breathing trials (SBTs); (2) prompt extubation following successful extubation readiness criteria; (3) high-flow nasal oxygen for at least 24 hours following extubation.
214500313|NCT04834154|BEHAVIORAL|Mindfulness|6 weekly 2.0 hour video-conferenced group sessions with the following components: 1) short grounding meditation, 2) check in/review of prior weeks practice and symptoms, 3) educational topic, 3) main meditation, 4) reflection on meditation, and 5) action plan formation
214500314|NCT04834154|BEHAVIORAL|Control group|Wait list control
214500315|NCT06856265|PROCEDURE|radiofrequency ablation|Radiofrequency Ablation is a minimally invasive interventional technique performed via catheter guidance. It utilizes thermal energy (50-80°C) generated by high-frequency alternating current (typically 300-750 kHz) to induce coagulative necrosis or electrophysiological isolation in targeted tissues, thereby eliminating abnormal electrical activity or mechanical obstruction. In the treatment of cardiomyopathy, RFA is applied to ablate hypertrophied myocardial tissue (e.g., the ventricular septum) to alleviate left ventricular outflow tract (LVOT) obstruction.
214500316|NCT06856265|DRUG|Mavacamten|"Initial Dose: Both groups received a starting dose of Mavacamten 2.5 mg orally once daily.~Dose Titration: Adjustments were made based on a previously published titration protocol, guided by correlations among resting left ventricular ejection fraction (LVEF), LVOT gradient during Valsalva maneuver, and pre-dose Mavacamten plasma concentrations."
214997766|NCT06565962|OTHER|Educaiton group|The experimental group will be made to watch training videos prepared by AFAD on disaster preparedness, disaster moment and post-disaster by using virtual reality goggles.
214500317|NCT06778954|PROCEDURE|Arm I (Peritoneal application group)|At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is applied on space between peritoneum and fascia in Arm I.
214500318|NCT06778954|PROCEDURE|Arm II (Subcutaneous injection group)|At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is injected on subcutaneous area in Arm II.
214500319|NCT06411418|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio \< 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.
214500320|NCT03978962|DEVICE|Guided Tissue Regeneration|"Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction."
214997767|NCT06565962|OTHER|control group|The control group will receive standard care. The standard care programme will include brochures and guidance.
214997768|NCT05775289|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig for four 21-day cycles
214386607|NCT04291235|PROCEDURE|Usual Care|Patients in this group will be treated according to usual care, which may include extubation or tracheostomy timed according to treating physicians' discretion.
214386608|NCT03418870|BEHAVIORAL|Family Integrated Care|Parents of infants assigned to mFI-Care will be trained and treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches.
214386609|NCT01073839|DRUG|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
214500321|NCT05349292|OTHER|ANH|one group will be managed with ANH and the other without (control group)
214997769|NCT05775289|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab four 21-day cycles
214997770|NCT05775289|DRUG|Paclitaxel|Participants will receive IV paclitaxel Q3W for four 21-day cycles
214997771|NCT05775289|DRUG|Pemetrexed|Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
214997772|NCT05775289|DRUG|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles
214997773|NCT06433037|DIETARY_SUPPLEMENT|Chicory inulin|Chicory inulin (12g/day) divided over two dosages (6g per dose)
214997774|NCT06433037|DIETARY_SUPPLEMENT|Resistant dextrin|Resistant dextrin (14g/day) divided over two dosages (7g per dose)
214997775|NCT06433037|DIETARY_SUPPLEMENT|Seaweed polysaccharide|Seaweed polysaccharide (1g/day) divided over two dosages (0.5g per dose). Additionally contains 7g/day of placebo as a volumetric and isocaloric filler.
214997776|NCT06433037|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (7g/day) will be provided in two divided doses (3.5g per dose)
214997777|NCT06567847|OTHER|Neurocognitive Enriched Exercise|An intervention planned, progressed, and conducted under the supervision of a physiotherapist, which enriches strengthening, balance, range of motion, stretching, and mobilization exercises with neurocognitive elements.
214386610|NCT00768430|DRUG|Ketamine|Single dose .5 mg/kg IV (in the vein) infused over 40 minutes
214997778|NCT06567847|OTHER|Multimodal Exercise|Supervised and progressively advanced interventions that include strengthening, balance, range of motion, stretching, and mobilization exercises.
214386611|NCT00768430|DRUG|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
214386612|NCT02415920|DRUG|Oxytocin|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
214386613|NCT02415920|DRUG|Placebo|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
214386614|NCT02318719|DRUG|Placebo|Placebo
214386615|NCT02318719|DRUG|DS-5565|
214386616|NCT05327335|DEVICE|Intelligent robotics for elderly assistance - sarcopenia|Participants will use the robotics system and integrated environment to perform daily self-care to uncover problems in functionality, usability, and acceptance of the robotic device prototype. The system, connected to mobile apps and the Internet, will serve as a platform to measure and record data on how the participants engage in pre-specified activities. The experiment will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the design specifications for functionalities and reliability, user experiences, system security and privacy.
214386617|NCT02916082|PROCEDURE|Cervical length measurement|Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
214386618|NCT03054688|DEVICE|Somnotouch NIBP|Somnotouch NIBP in addition to standard blood pressure measurement
214386619|NCT02676752|PROCEDURE|Medical Examination|Evaluation of secondary lymphedema and fibrosis (LEF) status
214386620|NCT02676752|OTHER|Questionnaire Administration|Completion of questionnaires
214386621|NCT02676752|PROCEDURE|Shear Wave Elastography|Undergo ultrasound shear wave elastrography
214386622|NCT02430818|DRUG|ketamine|
214386623|NCT02430818|DRUG|morphine|
214687770|NCT04548089|BEHAVIORAL|Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)|Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
214997779|NCT03873831|BEHAVIORAL|Animal-assisted intervention|The therapy dog is present during the session.
214997780|NCT03873831|BEHAVIORAL|Social skills group|"The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists."
214997781|NCT05406778|DEVICE|SPARK Test|Thirty (30) minutes of resting state EEG data collection.
214997782|NCT06965478|BEHAVIORAL|Visual Training|Participants are asked to detect or discriminate visual stimuli.
214386624|NCT02342925|OTHER|Omnipaque 300|647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
214386625|NCT02342925|DRUG|RG1662|Oral administration twice daily
214997783|NCT06494761|DRUG|zongertinib|zongertinib, Hernexeos®
214997784|NCT06494761|DRUG|midazolam|midazolam
214386626|NCT02342925|DRUG|metformin|Single 850 mg dose of metformin
214386627|NCT05751538|OTHER|No intervention|No intervention
214386628|NCT02128256|DEVICE|Cerament G|
214386629|NCT05975502|OTHER|Epidemiological study|Study of epidemiological characteristics of women with syphilis during pregnancy and of children born from mothers with syphilis during pregnancy.
214386630|NCT03498222|DRUG|Atezolizumab|Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).
214386631|NCT03498222|DRUG|Pemetrexed|Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.
214386632|NCT03498222|DRUG|Carboplatin|Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.
214386633|NCT03498222|DRUG|ADI PEG20|Administered by intramuscular (IM) injection to patients once weekly.
214386634|NCT05340751|DIAGNOSTIC_TEST|Blood drawn|Hemoglobin and Hematocrit Levels
214386635|NCT04502056|BEHAVIORAL|Acknowledgement Racial Injustice AMA|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
214386636|NCT04502056|BEHAVIORAL|African American Sender Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
214386637|NCT04502056|BEHAVIORAL|African American Sender in Informational Videos.|Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
214386638|NCT04502056|BEHAVIORAL|Racial Inequality Highlighted|Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
214386639|NCT04502056|BEHAVIORAL|AMA Acknowledgement Drug Pricing|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
214386640|NCT04502056|BEHAVIORAL|White Sender in Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
214386641|NCT04502056|BEHAVIORAL|White Sender in Informational Videos|Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
214386642|NCT04502056|BEHAVIORAL|No Racial Inequality Highlighting|In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
214386643|NCT04502056|BEHAVIORAL|Placebo videos|Videos not related to covid-19 will be shown
214386644|NCT03880695|DRUG|Anlotinib+ Liposomal Doxorubicin|Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks
214386645|NCT00420134|PROCEDURE|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
214386646|NCT02961881|DRUG|blinatumomab|Blinatumomab used as both continuous IV infusion and subcutaneous injection
214386647|NCT06428149|PROCEDURE|Midline interproximal soft-tissue incision|Firstly, the marginal tissue will be elevated around the periodontal defect, through the tunneling of the tissues, entering through the gingival sulcus and the periodontal pocket of the teeth involved in the defect periodontal. Once the marginal tissues have been disinserted to full thickness, the soft supra-alveolar component of the defect to be reconstructed will be stretched, in a buccal direction, with a blunt instrument, applying pressure on the lingual aspect. Visualizing the midpoint of the interproximal tissue, the papilla will be dissected at its midpoint, entering through the mesial aspect, with the scalpel blade perpendicular to the central axis of the teeth.
214997785|NCT06494761|DRUG|omeprazole|omeprazole
214997786|NCT06494761|DRUG|repaglinide|repaglinide
214997787|NCT05065996|DIAGNOSTIC_TEST|Aortic MRI + 4D flow MRI|Together with routine aortic MRI specific 4D flow MRI sequence will be done.
214386648|NCT06428149|PROCEDURE|Marginal approach by palatal incision|First, an incision will be made in the palatal aspect of the interproximal papilla, at the base of the papilla, parallel to the axis of the tooth until touching the palatine alveolar crest, in order to detach and move the papilla from its base, attached to the vestibular flap. From the palatal incision the interproximal tissue will be elevated towards the buccal until the buccal bone crest is exposed.
214386649|NCT06428149|PROCEDURE|Minimally invasive surgical technique|The defect will be accessed through an incision at the base of the papilla on the vestibular aspect. Depending on the anatomy of the interproximal space, two types of incisions will be made: simplified papilla preservation flap (SPPF) when the width of the interproximal space is equal to or less than 2 mm, or modified papilla preservation technique (MPPT) when the width is greater than 2 millimeters. The interproximal incision will extend intrasulcular on the lingual and buccal aspect of the teeth adjacent to the defect, and mesio-distally it will extend as necessary to allow access to the defect and its debridement. The papilla will move from its base towards the palatine.
214500322|NCT03622021|DRUG|AK111 or Placebo|All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
214997788|NCT06255392|DRUG|Fluzoparib|Fluzoparib capsules appropriate dose oral, each treatment cycle defined as 3 weeks (21 days).
214997789|NCT06255392|DRUG|Apatinib Mesylate|Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
214997790|NCT06255392|DRUG|Capecitabine tablets|Capecitabine tablets, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
214997791|NCT06255392|DRUG|Vinorelbine Tartrate Oral|For the first three courses: reasonable dosage with reference to guidelines. After 3 courses of medication, it is recommended to increase the dose of vinorelbine tartrate once a week. Each treatment cycle defined as 3 weeks (21 days).
214386650|NCT02803567|BEHAVIORAL|Brief psycho-educational intervention|Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
214386651|NCT01973491|DRUG|ATX-MS-1467|Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
214386652|NCT05429658|DEVICE|Thrombectomy|The Route 92 Medical Reperfusion System is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within the internal carotid, middle cerebral, basilar and vertebral arteries.
214500323|NCT06735300|DRUG|Nirmatrelvir/Ritonavir (Paxlovid)|After providing the potential benefits and associated risks of antiviral treatment with Paxlovid, patients made well-informed decisions about whether or not to receive Paxlovid (300/100 mg nirmatrelvir/ritonavir, Pfizer Inc., New York, NY, USA) twice daily for 5 days.
214500324|NCT03260387|PROCEDURE|TPIAT|The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
214500325|NCT03595917|DRUG|ABL001|•ABL001 is administered daily per 28 day cycle
214500326|NCT03595917|DRUG|Dasatinib|Fixed doses oral once a day per 28 day cycle
214997792|NCT06255392|DRUG|Eribulin mesylate injection|Eribulin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
214997793|NCT06255392|DRUG|Gemcitabine Hydrochloride|Gemcitabine, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
214997794|NCT06255392|DRUG|Paclitaxel-albumin|Paclitaxel-albumin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
214997795|NCT05877846|DIETARY_SUPPLEMENT|Beta-hydroxymethyl butyrate supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
214997796|NCT05877846|DIETARY_SUPPLEMENT|Vitamin D supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
214997797|NCT05877846|DIETARY_SUPPLEMENT|Matching Beta-hydroxymethyl butyrate supplement without Vitamin D|Beta-hydroxymethyl butyrate (750 mg) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate per capsule. Frequency is 2 capsules twice daily (morning, evening)
215093754|NCT00668590|BEHAVIORAL|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
214500327|NCT03595917|DRUG|Prednisone|Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.
214500328|NCT03595917|DRUG|Blinatumomab|By intravenous continuous infusion beginning no earlier than cycle 2 day 1 of protocol therapy Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles
214500329|NCT05773365|OTHER|PENG block with or without local anaesthetic infiltration|As mentioned.
214386653|NCT00981396|BEHAVIORAL|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
214386654|NCT00981396|BEHAVIORAL|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
214386655|NCT02268617|OTHER|Treadmill Walking|Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
214386656|NCT05246072|DRUG|Ivermectin + colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
214386657|NCT05246072|DRUG|Colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
214386658|NCT04183634|DRUG|Rotigotine TTS (Test)|Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.
214386659|NCT04183634|DRUG|Neupro (Reference)|Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.
214386660|NCT00385853|DRUG|PTK787/ZK 222584|Twice daily for each 28-day cycle
214386661|NCT00385853|DRUG|Temozolomide|Daily for each 28-day cycle
214386662|NCT00385853|PROCEDURE|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
214386663|NCT01216891|BEHAVIORAL|Multi-element, team-oriented treatment|Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
214386664|NCT01928225|BIOLOGICAL|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
214386665|NCT06384378|DRUG|11C-ER176|ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.
214386666|NCT04923295|DRUG|Dapagliflozin 10Mg Tab|Effect of Dapagliflozin on ultrafiltration and PET results among peritoneal dialysis patients
214386667|NCT00953914|DRUG|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
214386668|NCT00953914|DRUG|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
214386669|NCT04679103|BIOLOGICAL|Eculizumab (JSC GENERIUM, Russia)|Eculizumab
214500330|NCT06424340|BIOLOGICAL|MB-dNPM1-TCR.1|T Cell Receptor (TCR) T cell therapy
214500331|NCT06402344|OTHER|Hormonal implant|History of at least 1 hormonal implant with gestrinone in the last 6 months, applied by the participant's private doctor.
214500332|NCT06402344|OTHER|Control group|Young women who never used any hormonal implant.
214500333|NCT02952144|DEVICE|Lixelle® treatment|The treatment will be performed with the Lixelle® column connected to upstream of the dialyzer in series on the routine HD circuit according to the description in the IFU. The dialyzer and the Kt/V urea in the conventional HD for each patient will be kept equal in Lixelle®-treatment. Since the maximum blood flow rate for Lixelle® is 250 ml/min, the dialysis time will be extended to achieve the target Kt/V urea. The study will not restrict the type of hemodialyzer and other conditions of HD as specified by the physician. However, any changes to the HD procedure should be recorded properly, and the Kt/V urea should be kept equal to that at the enrollment.
214687771|NCT00629694|PROCEDURE|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
214500334|NCT06103227|DRUG|Prednisone 5Mg|Prednisone administered for three weeks. If pregnant women weighs less than 90 kg , she will receive prednisone on altering days instead of every morning for pregnant women weighing more than 90 kg.
214500335|NCT04327635|DRUG|PEP|A biological drug made of certain parts of blood from living blood donors obtained from a certified blood bank. At the time of cardiac catheterization patients will undergo one-time intracoronary infusion of 10 milliliters of PEP dosage consisting of approximately 5%, 10%, or 20% PEP. PEP dose will be infused immediately distal to the newly placed stent over approximately 5 minutes.
214687772|NCT00629694|PROCEDURE|A-M|adenoidectomy and myringotomy alone
214687773|NCT00511589|OTHER|chagas disease diagnostic|
214386670|NCT04127084|DRUG|SGLT2 Inhibition|Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
214500336|NCT05777941|OTHER|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied.
214500337|NCT06113705|DIAGNOSTIC_TEST|18F-GE-180 PET|PET examination of glioblastoma using 18F-GE-180 PET radio-metabolic marker
214500338|NCT06113705|DIAGNOSTIC_TEST|Advanced MRI|MRI examination using advanced sequences to characterize tumor microstructure and function
214687774|NCT02273440|DRUG|BIIL 284 BS|
214687775|NCT02273440|DRUG|Theophylline|
214386671|NCT04250337|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
214386672|NCT04250337|OTHER|Placebo|Subcutaneous injection
214386673|NCT04250337|OTHER|Topical Corticosteroid|Topical Corticosteroid
214386674|NCT02874664|DRUG|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
214687776|NCT02273440|DRUG|Placebo|
214386675|NCT00393744|DRUG|pristinamycin|50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days
214386676|NCT00393744|DRUG|amoxicillin|50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
214997798|NCT05085873|DRUG|Sodium Oxybate injection|"* Induction dosage : 60 mg/kg by direct intravenous injection.~* Continuous dosage : 45 mg/kg/h by continuous intravenous injection.~* Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.~Sedation maintained until patient death."
214997799|NCT05085873|DRUG|Midazolam injection|"* Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).~* Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.~* Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).~Sedation maintained until patient death."
215093755|NCT01981889|DRUG|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
215093756|NCT04326686|OTHER|Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet|30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
214386677|NCT04765293|OTHER|Physical Therapy|Physical Therapy Gravity strengthening exercises vs standard physical therapy
214386678|NCT05969938|DIAGNOSTIC_TEST|MRD detection|Peripheral blood samples were collected for MRD detection before neoadjuvant chemoradiotherapy, during neoadjuvant chemoradiotherapy, and 3-4 weeks after radical surgery. For patients who achieved cCR after neoadjuvant therapy and adopted the W \& W strategy, the sampling time point was 3 months after the start of watching and waiting.
214386679|NCT06056986|DIAGNOSTIC_TEST|multimodal ultrasound|Dynamic contrast-enhanced ultrasound and shear wave elastography are perfomed on target intestinal loop
214386680|NCT01479686|PROCEDURE|iMRI|3.0TiMRI guided resection in adults with glioma
214386681|NCT01479686|PROCEDURE|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
214386682|NCT05294874|OTHER|gait training|walking forward, sideway and backward walking on balance board
214386683|NCT04720963|DRUG|Remimazolam|intranasal remimazolam
214386684|NCT04720963|OTHER|Distilled water for injection|intranasal distilled water for injection
214386685|NCT04720963|DRUG|Dexmedetomidine|Intranasal dexmedetomidine
214500339|NCT06113705|OTHER|Collection of hematopoietic stem cells|Hematopoietic stem cells will be collected by the aspiration of bone marrow during the surgical intervention for tumor resection
214500340|NCT06113705|OTHER|Blood withdrawal|blood withdrawal for evaluation of plasma biomarkers of inflammation, circulating microvesicles, and RNA
214500341|NCT06113705|OTHER|Collection of Cancer Stem Cells|Glioblastoma stem cells (GSCs) will be isolated from the tumor
214500342|NCT06818266|DRUG|Tocilizumab (RoActemra®, 20 mg/mL).|One single intravenous infusion at 8 mg/kg (up to a maximum of 800 mg) for patients ≥ 30 kg and 12 mg/kg for patients \< 30 kg
214500343|NCT06818266|DRUG|Placebo (NaCl 0.9%)|One single intravenous infusion
214500344|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a Low dose of ACI-35.030
214386686|NCT00003220|DRUG|bryostatin 1|
214500345|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a Medium dose of ACI-35.030
214687777|NCT05951738|PROCEDURE|Blood and saliva collection|Blood and saliva samples from pregnant women; saliva samples from babies.
214687778|NCT05951738|BEHAVIORAL|Psychometric scales|A battery of psychometric scales and questionnaires.
215093757|NCT00162240|DRUG|Muraglitazar|
214500346|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a High dose of ACI-35.030
214500347|NCT04445831|OTHER|Placebo|Administration of Placebo
215093758|NCT06263049|PROCEDURE|transurethral resection of prostate|resection of prostate by using bipolar cautarization
214500348|NCT04445831|BIOLOGICAL|JACI-35.054|Administration of a Low dose of JACI-35.054
214500349|NCT04445831|BIOLOGICAL|JACI-35.054|Administration of a Medium dose of JACI-35.054
214500350|NCT06636773|BEHAVIORAL|Diet|A reduced energy diet ranging from 1200-2100 kilocalories per day will be recommended for participants.
214386687|NCT04217993|DRUG|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
214386688|NCT04084782|DEVICE|Fungal Nail Treatment Kit|The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
214386689|NCT01365520|DRUG|turoctocog alfa|A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
214386690|NCT03022838|DRUG|Caffeine|From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
214386691|NCT02572336|DRUG|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
214386692|NCT02572336|DRUG|Placebo|Placebo is a THR-18 lookalike, to be administered with tPA.
214500351|NCT06636773|BEHAVIORAL|Aerobic Exercise|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress from an initial amount of 100 minutes per week to 300 minutes per week across the initial 6 months of the intervention, with this level of physical activity continuing to be recommended between months 7-12.
214500352|NCT06636773|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly group-based behavioral session for months 1-6, with these sessions being offered twice per month during months 7-12 to assist in supporting recommended changes in energy intake (diet) and physical activity.
214687779|NCT05951738|OTHER|Smartphone app|A smartphone application has been developed in the context of the study as a potential preventive and screening strategy.
214386693|NCT02572336|DRUG|Tissue Plasminogen Activator (tPA)|tPA is a thrombolytic agent. tPA is not an investigational drug.
214386694|NCT00005881|OTHER|Quality of Life Forms|Completion of the instrument \[Minneapolis-Manchester Quality of Life (MM-QOL)\] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
214386695|NCT05073744|DRUG|Nalbuphine|Nalbuphine hydrochloride injection or morphine hydrochloride injection is used for perioperative tumor ablation
214386696|NCT05073744|DRUG|Morphine|Morphine hydrochloride injection is used for perioperative tumor ablation
214386697|NCT00247624|DRUG|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
214386698|NCT00247624|DRUG|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
214386699|NCT00247624|DRUG|Placebo|Placebo every night for 8 weeks
214500353|NCT06636773|BEHAVIORAL|Aerobic + Yoga Exercise|Physical activity will be recommended in the form of a combination of aerobic types of activity, such as brisk walking, and yoga. Aerobic activity will progress from 60 minutes per week to 180 minutes per week across the initial 6 months of the intervention. Yoga will progress from 40 minutes per week to 120 minutes per week across the initial 6 months of the intervention. When combined this will progress from a total of 100 minutes per week to 300 minutes per week across the initial 6 months of treatment. This level of physical activity will continue to be recommended between months 7-12.
214500354|NCT05140967|OTHER|High Intensity Interval Training (HIIT)|High Intensity Interval Training
214500355|NCT05140967|OTHER|Moderate Continuous Intensity Training (MICT)|Moderate Intensity Continuous Training
214500356|NCT06828640|DEVICE|vaginal dilators|Evaluate the efficacy of vaginal dilators as an addition to Standard of Care in premenopausal or menopausal women, including breast cancer survivors
214500357|NCT06204250|DRUG|GS1-144|Oral tablets.
214500358|NCT06204250|DRUG|Placebo|Matching placebo tablets.
214386700|NCT02183870|DRUG|Crizotinib|250mg crizotinib bid until end of treatment
214386701|NCT03074812|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a commonly used non-invasive form of brain stimulation for studying motor functions in health and disease \[36\]. It involves the attachment of surface electrodes to the scalp through which very small electric currents (1 or 2mA) are applied via a current regulated device. The currents do not produce any sensation. The applied current affects excitability of underlying neural tissue.
214386702|NCT00000811|DRUG|Azithromycin|
214386703|NCT00000811|DRUG|Atovaquone|
214386704|NCT00000811|DRUG|Sulfamethoxazole-Trimethoprim|
214386705|NCT03531255|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
214386706|NCT03716544|DEVICE|Amplification with hearing aid|Use of hearing aids
214386707|NCT03716544|DEVICE|Customized music|Customized music delivered via an iPod
214386708|NCT03321006|DEVICE|Phonak Audeo B-R 90 hearing aid device (Active)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice
214386709|NCT03321006|DRUG|Duloxetine or escitalopram|We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
214386710|NCT03321006|DEVICE|Audeo B-R 90 hearing aid device (Sham)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies
214386711|NCT04131478|GENETIC|Pharmacogenetic testing|Pharmacogenetic testing for TNF alfa
214500359|NCT04002661|DRUG|Flibanserin|Flibanserin tablet
214500360|NCT04002661|DRUG|Placebo|Oral Tablet
214500361|NCT06474728|OTHER|Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus|Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus, with the dose of 100g per week,lasting for 12weeks.
214500362|NCT06047951|PROCEDURE|Stereotactic RadioSurgery (SRS)|"All treatments will be performed using the Gamma Knife Perfexion or Icon system (Elekta). The following treatment parameters will be used:~* The head will be immobilized using a stereotactic Leksell Model G frame, installed using local protocols~* Targeting will be performed by using a stereotactic CTA. No MRI will be performed.~* Only one aneurysm will be treated per patient~* The aneurysm, including its neck, will be contoured and targeted using a combination of 4mm isocenters as deemed appropriate by the treating team~* A prescription dose of 25 Gy at the margin of the target will be used~* The maximal dose on optic pathways will be kept below 10 Gy~* The brainstem 12-Gy volume will be kept below 1cc"
214500363|NCT06153693|DRUG|Placebo|Placebo once daily (QD) for 12 weeks
214500364|NCT06153693|DRUG|lorundrostat Dose 1|50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
214997800|NCT03890432|DEVICE|GLUCOSAFE 2|Use of GLUCOSAFE 2 software for nutrition management and insulin-therapy
214386712|NCT02095795|DEVICE|Technological Rehabilitation|The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.
214997801|NCT03890432|DEVICE|Local protocol control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
214997802|NCT03890432|DEVICE|Historical control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
214997803|NCT03502967|DRUG|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
214997804|NCT03502967|DRUG|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
214997805|NCT03678129|DRUG|AZD7325_10|Single oral dose (10mg)
214997806|NCT03678129|DRUG|AZD7325_20|Single oral dose (20mg)
214997807|NCT03678129|DRUG|Placebo|Single oral dose placebo (capsule)
214997808|NCT03678129|DRUG|Clobazam|Single dose (5mg)
214386713|NCT02095795|OTHER|Control Rehabilitation|When needed, more than one therapist are employed in the intervention for safety reasons.
214386714|NCT03337932|DRUG|Doxycycline 100 milligram Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
214386715|NCT03337932|DRUG|Doxycycline 100 milligram Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
215093759|NCT02900755|DRUG|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
214386716|NCT03337932|DRUG|Controls without a history of lyme disease.|No intervention.
214386717|NCT03719365|DEVICE|NAVAPSV|During the first trial, PSV will be set in order to obtain a Vt between 6 and 8 ml/kg; this support level will be defined as PSV100. Subsequently, the corresponding NAVA level (NAVA 100) will be determined using a dedicated ventilator function (NAVA Preview) which is able to estimate NAVA level in order to deliver an equivalent inspiratory peak pressure (Paw peak) compared to that obtained during PSV mode. Afterwards, PSV100 and NAVA100 will be first increased (PSV150 and NAVA150) during the second trial and then decreased during the third trial (PSV50 and NAVA150) by 50% from basal value. During the study period, PEEP and FiO2 will be kept equal to the values in use before patient enrollment.
214386718|NCT00365378|BIOLOGICAL|Comparator: HPV 16 L1 Vaccine|A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
214500365|NCT06153693|DRUG|lorundrostat Dose 2|50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
214687780|NCT00913978|DEVICE|Group 1: VitaHeat|Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
214997809|NCT06269900|DRUG|Dexamethasone|Dexamethasone phosphate injection is given as a slow injection or infusion (intravenous drip) into the veins.
214386719|NCT00365378|BIOLOGICAL|Comparator: Placebo|A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
214386720|NCT01502995|DEVICE|Laser light (U-Step Walking Stabilizer with laser light)|Use of a laser light on a rolling walker during episodes of freezing of gait.
214386721|NCT04499716|PROCEDURE|IPACK|25 milliliters of ropivacaine 0.3% will be injected between popliteal artery and femur.
214386722|NCT04499716|PROCEDURE|Femoral triangle block|25 milliliters of ropivacaine 0.3% will be injected on the lateral side of the femoral artery at the distal part of the femoral triangle.
214386723|NCT04499716|PROCEDURE|Obturator nerve block|20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.
214386724|NCT04499716|PROCEDURE|Femoral nerve block|20 milliliters of ropivacaine 0.3% will be injected in supine position under the fascia iliaca lateral to the femoral artery.
214386725|NCT04499716|PROCEDURE|Sciatic nerve block|25 milliliters of ropivacaine 0.3% will be injected in prone position in the subgluteal space by lateral approach.
214386726|NCT04499716|PROCEDURE|Lateral femoral cutaneous nerve block|5 milliliters of ropivacaine 0.3% will be injected laterally to the sartorius muscle.
214386727|NCT03296709|DEVICE|PPC z|Installation of a preformed pediatric zircona crown
214386728|NCT03296709|DEVICE|PPC m|Installation of a preformed pediatric metal crown
214500366|NCT06488274|DIETARY_SUPPLEMENT|New infant formula|The new formula will be given to infants during the 4-month study period.
214500367|NCT06813131|OTHER|Dietary counseling|This intervention uniquely focuses on the frequency of dietitian-led follow-up visits and their impact on metabolic syndrome-related parameters. The study includes three distinct groups with varying levels of follow-up intensity (control, intervention, and intensive intervention).
214500368|NCT06813131|OTHER|calling via telephone|"The intensive intervention group involves weekly diet adherence assessments via phone calls, setting it apart from other studies that typically rely on less frequent or standardized follow-up schedules. This design allows for the evaluation of how consultation frequency influences outcomes such as weight loss, blood sugar levels, lipid profile, and metabolic syndrome components."
214500369|NCT06775405|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
214500370|NCT06775405|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
214500371|NCT06169800|DEVICE|MPFL repair with Biobrace augmentation|MPFL repair with Biobrace augmentation
214997810|NCT06269900|DRUG|Placebo|Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
214997811|NCT05799352|DEVICE|Endoscopic lung volume reduction|a prospective monocentric study on hyperinflated COPD patients without collateral ventilation. Patients were evaluated before and 3 months after unilateral ELVR by transdiaphragmatic pressure (Pdi) measured at the functional residual capacity (FRC) after magnetic phrenic stimulation and by high-resolution computed tomography at the FRC allowing 3D modelling of the diaphragm for measurements of fibers length, length of the zone of apposition and radius of curvature of the diaphragmatic domes.
214997812|NCT05378204|OTHER|Main study:|"For each included patient, tumor biopsy specimen and blood samples will be collected at baseline visit (before the first dose of PARPi treatment).~During the treatment period: blood samples will be scheduled every 8 weeks (i.e. 2 cycles).~At the time of progression: tumor biopsy and blood samples will be collected."
214500372|NCT01535430|DIAGNOSTIC_TEST|Brain mapping|Brain mapping will be employed pre-, intra-, and post-operatively to evaluate specific functions.
214386729|NCT00310895|DRUG|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
214997813|NCT05378204|OTHER|Sub-study:|For each included patient, tumor biopsy specimen and blood samples will be collected as soon as possible after progression (before initiation of the post PARPi anti-tumoral treatment).
214997814|NCT06547255|DRUG|Bupivacaine liposome injectable suspension|At the end of the third molar extraction surgical procedure performed under general anesthesia and at least fifteen minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine nerve block (routine for this procedure), all patients will receive bilateral infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel) OR with 3mL of 0.5% bupivacaine with 1:200,000 epinephrine while they are still under general anesthesia.
214997815|NCT06542198|DIAGNOSTIC_TEST|Mannitol Infusion (blinded)|1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.
214997816|NCT06542198|DIAGNOSTIC_TEST|Placebo Infusion (blinded)|0.9% saline will be administered in the same amount as the mannitol dose infusion (= 5 ml/kg body weight), with a rate of 0.17 ml/kg/min in 30 minutes, with an upper limit of 400 ml (equivalent to a body weight of 80 kg).
214997817|NCT06542198|DIAGNOSTIC_TEST|Mannitol Infusion (open label)|1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.
214997818|NCT01063114|RADIATION|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
214500373|NCT06759129|BEHAVIORAL|Immediate-use of a mobile health application until completion|"Participants will use the RomSi app for approximately 14 days, completing all scheduled activities. Throughout the intervention, they will respond to ecological momentary assessments (EMA) designed to evaluate stigma, help-seeking intentions, and suicidal ideation.~The activities within the app will include interactive games aimed at fostering empathy and emotional understanding. Participants will also have continuous access to specialized help contacts to ensure their well-being during the study.~The protocol involves two groups that will receive tailored information based on their specific needs:~1. Individuals with low suicidal ideation and/or self-stigma, who will engage in activities focused on reducing personal stigma.~2. Individuals experiencing suicide bereavement, who will receive support tailored to address their loss and foster resilience.~A follow-up will be carried out one month and three months after the end of the intervention."
214997819|NCT06348225|BEHAVIORAL|Exercise|Participants will walk on a treadmill for 30 minutes at 55-60% of heart rate reserve. The treadmill will be set at 2mph and 2% grade, then be adjusted in the first 5 minutes to achieve target heart rate.
214997820|NCT06348225|OTHER|Heat Therapy|Participants will place their legs in a deep leg bath (mid-calf) set to 42C for 45 minutes.
214997821|NCT06348225|OTHER|Sham leg bath|Participants will place their legs in a deep leg bath (mid-calf) set to 36C for 45 minutes.
214997822|NCT04115098|DRUG|Celecoxib|Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
214997823|NCT04115098|DRUG|Naproxen|Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
214997824|NCT04115098|DRUG|Meloxicam|Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
214997825|NCT03346135|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo standard of care ASCT with a conditioning regimen of melphalan
214997826|NCT03346135|BIOLOGICAL|Daratumumab|Given IV
214687781|NCT00913978|DEVICE|Group 2: Bair Hugger|Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
214687782|NCT03446534|DRUG|Amoxicillin|Imacillin mixture
214687783|NCT03446534|DRUG|Placebos|Placebo manufactured to mimic amoxicillin mixture (Imacillin)
214997827|NCT03346135|OTHER|Laboratory Biomarker Analysis|Correlative studies
214997828|NCT03346135|DRUG|Melphalan|Undergo standard of care ASCT with a conditioning regimen of melphalan
214997829|NCT06084234|DIAGNOSTIC_TEST|GALAD|GALAD is a 3 biomarker panel incorporating AFP, AFP-L3% and DCP (all FDA approved), with patient age and sex.
214687784|NCT06475989|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214687785|NCT06475989|DRUG|Cabozantinib|Given PO
214687786|NCT06475989|PROCEDURE|Computed Tomography|Undergo CT scan
214687787|NCT06475989|DRUG|Dabrafenib|Given PO
214997830|NCT06084234|DIAGNOSTIC_TEST|Liver Ultrasound with or without AFP|This intervention consists of current standard of care ultrasound based surveillance with or without alpha-fetoprotein measurement.
214997831|NCT05473598|BEHAVIORAL|Stand Down app|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
214997832|NCT05473598|BEHAVIORAL|Peer-Supported Stand Down|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
214997833|NCT05473598|OTHER|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
214386730|NCT06456099|DRUG|Ultrasound-guided corticosteroid injection|Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus tendons on the greater trochanter of the hip at baseline, Prior to the beginning of exercises.
214386731|NCT06456099|BEHAVIORAL|Home exercise program|"Our exercise protocol is based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of eight weeks (see appendix 6, Træningsvejledning). Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled. Compliance to exercises are measured using a training diary that the participants must fill out during the study period (see appendix 7, Træningsdagbog)."
214500374|NCT06759129|BEHAVIORAL|Delayed use of a mobile health application until completion|"Participants assigned to the dApp group (delayed use) will not have access to the RomSi app during the first two weeks of the study. During this period, they will complete ecological momentary assessments (EMA) to evaluate stigma, help-seeking intentions, and suicidal ideation, without engaging in the intervention activities associated with the app.~After completing this initial control phase, participants in the dAPP group will begin using the RomSi app, following the same protocol as the iAPP group. This includes interactive activities, such as games designed to foster empathy and understanding, along with continuous access to specialized help contacts.~This crossover design allows for the immediate effects of the intervention to be compared between groups, while also evaluating changes in pre- and post-intervention measures across both conditions.~A follow-up will be carried out one month and three months after the end of the intervention."
214500375|NCT06893523|OTHER|Concentrated Growth Factor|Bilaterally impacted third molar of the patients areremoved surgically and concentrated growth factor isplaced in one of the extraction sockets.
214500376|NCT06893523|OTHER|Non-CGF|The other extraction socket is left empty for control purposes.
214500377|NCT05810285|DEVICE|GKS Prime Flex Mobile knee|Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis
214500378|NCT06113536|DIAGNOSTIC_TEST|Ultrasonographic evaluation|Ultrasonographic evaluation for assessment of possible meniscal extrusion
214500379|NCT06715514|DRUG|GLP-1 Receptor Agonist|Wegovy®
214386732|NCT06456099|BEHAVIORAL|Patient information leaflet|"In order to support self-management and modification of tendon load, participants will receive a handout at baseline that contains information about GTPS and advice on load management (see appendix 8, Folder - Smerter på ydersiden af hoften). The participants will be encouraged to read the leaflet regularly and follow the advice."
214500380|NCT06715514|DRUG|Menopausal Hormone Therapy|Estradot® and Utrogestan®\* (in women with intact uterus\*)
214500381|NCT05470114|DRUG|LEO 138559|LEO 138559 is an antibody given by subcutaneous injection.
214997834|NCT02717611|DRUG|ACP-196 (acalabrutinib)|ACP-196 100 mg to be administered orally (PO) twice a day BID.
214386733|NCT04452448|DEVICE|LASIK|All cases were operated upon using Wavelight Allegretto EX-500 excimer laser (Alcon Laboratories, Inc., Fort Worth, TX) with wave front optimized ablation profile WFO. The Moria II microkeratome (Moria, Anthony, France) was used in all cases.
214386734|NCT02733302|BEHAVIORAL|Hope theory|Adapted Physical Activity
214386735|NCT02019784|DRUG|Rifaximin-α|Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.
214386736|NCT02019784|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
214500382|NCT05470114|DRUG|Dupixent®|Dupixent® is an antibody given by subcutaneous injection.
214500383|NCT06773897|GENETIC|Saliva sample|Saliva sample is sent via prepaid US Mail for DNA extraction
214500384|NCT06773897|OTHER|Health Surveys|Health surveys are filled out online in the study portal.
214500385|NCT05325294|DEVICE|MiniMed 780G System|MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc
214997835|NCT05852054|BEHAVIORAL|OB Provider Clinical Decision Support (CDS)|When an eligible patients' chart is opened by a provider, the provider will be alerted to counsel patients about future risk for T2D and hypertension and the need to establish a primary care medical home. The alert will include a 'referral' to primary care and a brief guide with 'key points for counseling'. For patients with prior GDM, this will also include an option to order guideline-recommended oral glucose tolerance test (OGTT) with a single click.
214386737|NCT05960383|DIAGNOSTIC_TEST|BioFire Pneumonia Panel Plus|Assessment of sensbility and specificity of BioFire Pneumonia Panel Plus in lung transplantation
214386738|NCT03278886|DRUG|Low dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks
214386739|NCT03278886|DRUG|Nalmefene|18 mg of nalmefene taken once daily for 8 weeks
214386740|NCT03484338|BEHAVIORAL|Accelerated Resolution Therapy|ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
214393859|NCT01622101|DIETARY_SUPPLEMENT|Thermogenic properties of Zantrex-3®|The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by \>7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
214687788|NCT06475989|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214687789|NCT06475989|OTHER|Questionnaire Administration|Ancillary study
214386741|NCT01382485|OTHER|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
214386742|NCT01382485|OTHER|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
214687790|NCT06475989|DRUG|Trametinib|Given PO
214687791|NCT03610256|PROCEDURE|SADI-S|Laparoscopic SADI-S, recently described as an evolution of the BPD-DS, combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction, associating a sleeve gastrectomy and a duodeno-ileal bypass at 2.5 meters from the ileo-caecal valve if BMI ≥ 50 kg/m² or at 3 meters if BMI \< 50
214687792|NCT03610256|PROCEDURE|RYGB|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects"
214687793|NCT06368830|DIAGNOSTIC_TEST|3-ounce water swallow test|Bedside water swallow dysphagia screen where vocal quality of the participant is assessed before and after swallowing 3 ounces of water
214997836|NCT05852054|BEHAVIORAL|Patient Education (OB Visit)|A 1-page document will be printed or delivered electronically for eligible patients after every postpartum OB visit during the STEP-UP condition. The document will encourage patients to know the risk and will describe the importance of routine primary care and chronic disease evaluation and management. It will also provide tips for lowering risk through lifestyle changes. Patient materials will be delivered in English or Spanish based on the structured EHR variable for preferred language.
214997837|NCT05852054|BEHAVIORAL|Text messaging|At 3 months postpartum, all eligible patients who have not scheduled a primary care visit will receive a motivational text to prompt scheduling; a second text will be sent for those who still have not made an appointment. Among those who schedule a visit, a reminder text will be sent before the visit. Texts will be in English or Spanish based on patients' preferred language field in the EHR and written at a \<5th grade reading level.
214997838|NCT05852054|BEHAVIORAL|Patient Outreach|Patients who have not scheduled a primary care visit by 4 months postpartum will receive outreach from a trained coordinator who will assist with scheduling and help patients troubleshoot common barriers, such as concerns about transportation or cost.
214997839|NCT05852054|BEHAVIORAL|Primary Care Provider Clinical Decision Support (CDS)|The CDS will notify the provider that the patient had a recent high-risk pregnancy and signal the need to counsel the individual about their future risk for T2D and/or hypertension and the need for ongoing care. A brief guide with 'key points for counseling' described in plain language will be provided. For patients with prior GDM, the CDS will also include an easy to access 'smartset' to order appropriate testing (A1c, FG, or OGTT) based on time since delivery and provider discussions with the patient.
215093760|NCT05654688|OTHER|graston and muscle energy technique|"Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles."
215093761|NCT02204852|DRUG|Iloprost+eptifibatide|
214386743|NCT01190332|PROCEDURE|endoscopic sphincterotomy by conventional method|
214386744|NCT01190332|PROCEDURE|endoscopic sphincterotomy by rendezvous method|
214393860|NCT00432679|DRUG|Rosiglitazone (BRL49653C)|study drug
214393861|NCT01443429|DRUG|beraprost sodium(BPS)|
214393862|NCT02312505|DEVICE|COPFX|cardiac Output by semi-invasive pulse contour analysis
214393863|NCT00601718|DRUG|vorinostat|Given PO
214393864|NCT00601718|BIOLOGICAL|rituximab|Given IV
214393865|NCT00601718|DRUG|ifosfamide|Given IV
214393866|NCT00601718|DRUG|carboplatin|Given IV
214393867|NCT00601718|DRUG|etoposide|Given IV
214393868|NCT00601718|OTHER|pharmacological study|Correlative studies
214393869|NCT00601718|OTHER|laboratory biomarker analysis|Correlative studies
214393870|NCT00601718|GENETIC|gene expression analysis|Correlative studies
214393871|NCT02282319|DRUG|spinal dexmedetomidine 0.5 mcg|Administration of dexmedetomidine 0.5 mcg
214393872|NCT02282319|OTHER|spinal chloroprocaine 40 mg|spinal anesthesia with chloroprocaine 40 mg
214393873|NCT02282319|DRUG|IV dexmedetomidine 0.5 mcg/kg|intravenous administration of dexmedetomidine 0.5 mcg/kg
214393874|NCT05948462|DRUG|Lorlatinib|Participants will receive assigned dose of daily oral lorlatinib continuously for each cycle. Each cycle is 3 weeks.
214393875|NCT05948462|DRUG|Cisplatin or Carboplatin|Participants will receive standard of care intravenous Cisplatin or Carboplatin, both chemotherapy medications, on day 1 of each cycle every 3 weeks, for Cycles 1-4. Each cycle is 3 weeks.
214393876|NCT05948462|DRUG|Pemetrexed|Participants will receive intravenous Pemetrexed, a chemotherapy medication, on day 1 of each cycle. Each cycle is 3 weeks.
214393877|NCT05956938|DEVICE|Stroboscopic Glasses|"A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account a gradual increase in the difficulty of the task, divided into three visuomotor and anticipation components (ball size, type of trajectory and distance from the stimulus).~The training sessions will consist of 2 series, and will be based on passing a ball between two people. Every 60 passes the flicker level of the glasses will increase, starting with level 1 (6hz) and ending at level 6 (1.75hz)"
214386745|NCT04082091|BEHAVIORAL|SELECT mHealth Program|"Individuals will be screened via the telephone, using a mobile-based algorithm that prompts questions about hypertension, risk of Diabetes Mellitus, use of smokeless tobacco and smoking, level of physical activity, and main nutritional choices. These questions are based on tools that have been validated in studies undertaken in this population and will be directly administered by trained research staff of Aga Khan University. Screening will prompt triage into three categories: high - referred to the conveniently located integrated medical center for a medical teleconsultation and fasting glucose test; medium - receive fasting glucose test and BP measurement; and low risk. All subjects in each category will be enrolled in an e\_Prescription intervention for lifestyle change tailored to their individual risk profile."
214386746|NCT01316341|DRUG|BI10773|patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
214386747|NCT01316341|DRUG|Placebo|patient to receive two placebos
214386748|NCT01316341|DRUG|Placebo|patient to receive two placebos
214386749|NCT01316341|DRUG|Placebo|patient to receive two placebos
214997840|NCT05852054|BEHAVIORAL|Patient Education (Primary Care Visit)|A 1-page material will again be automatically printed or delivered electronically for eligible patients after their first primary care visit; it will replicate content from prior material provided after the OB visit.
214997841|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt and Suspenders|Endoscopic sleeve gastroplasty using belt and suspender plications.
214386750|NCT01316341|DRUG|BI10773|patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
214386751|NCT00717678|DRUG|Prograf-XL|oral
214997842|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt|Endoscopic sleeve gastroplasty using belt only plications.
214997843|NCT04083183|BIOLOGICAL|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given IV
214997844|NCT04083183|DRUG|Fludarabine|Given IV
214997845|NCT04083183|DRUG|Cyclophosphamide|Given IV
214997846|NCT04083183|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
214997847|NCT04083183|RADIATION|Total-Body Irradiation|Undergo TBI
214386752|NCT00717678|DRUG|Prograf|oral
214386753|NCT00717678|DRUG|MMF|oral
214386754|NCT05942352|DRUG|Ligustrazine by intravenously administration|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days
214386755|NCT05942352|DRUG|Ligustrazine by mouth|50 mg Ligustrazine tablet by mouth would be maintained for 1 year
214386756|NCT05942352|DRUG|Placebo by intravenously administration|Intravenous administration of 250ml saline per day for 15 days
214386757|NCT05942352|DRUG|Placebo by mouth|50 mg placebo tablet by mouth would be maintained for 1 year
214386758|NCT02355522|DRUG|Intrauterine lidocaine|
214386759|NCT02355522|DRUG|Lidocaine gel|
214386760|NCT02355522|DRUG|KY jelly|
214386761|NCT02355522|DRUG|Intrauterine normal saline|
214393878|NCT05956938|DEVICE|Action Video Game|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account an increase in the difficulty of the task gradually based on the nature of the video game. The video game selected will be ContraIII: Alien Wars, from the Nintendo Mini Classic console.
214393879|NCT03906981|OTHER|Plaque from each subject will be collected but there will be no intervention|No intervention
214393880|NCT00279279|DEVICE|Implanted Device|
214393881|NCT00600743|DRUG|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
214393882|NCT00600743|BEHAVIORAL|Instructions to binge eat|Subjects will be instructed to binge eat and will also be given either drug or placebo
214393883|NCT00600743|BEHAVIORAL|Instructions to eat normally|Subjects will be instructed to eat normally and will also be given either drug or placebo
214393884|NCT00600743|DRUG|Placebo|Drug one trial vs placebo
214393885|NCT02787720|OTHER|Family centered empowerment model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation
214393886|NCT02787720|OTHER|Continuous care model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
214393887|NCT00664664|DRUG|APD125|soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
214393888|NCT00664664|DRUG|APD125|soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
214393889|NCT00664664|DRUG|Placebo|soft gelatin capsule, daily dosing for up to 3 weeks
214393890|NCT05063643|OTHER|High altitude|High altitude is defined as \>2000m.
214393891|NCT01177813|DRUG|Placebo identical to BI10773 high dose|placebo tablets once daily
214393892|NCT01177813|DRUG|BI 10773|BI 10773 low dose tablet once daily
214393893|NCT01177813|DRUG|BI 10773 open label|Patients receive BI 10773 high dose tablets open label once daily
214393894|NCT01177813|DRUG|Placebo identical to BI10773 low dose|placebo tablets once daily
214393895|NCT01177813|DRUG|Placebo identical to BI10773 low dose|placebo tablets once daily
214393896|NCT01177813|DRUG|Placebo identical to BI10773 high dose|placebo tablets once daily
214393897|NCT01177813|DRUG|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
214393898|NCT01177813|DRUG|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
214393899|NCT01177813|DRUG|BI10773|BI 10773 high dose tablets once daily
214393900|NCT01177813|DRUG|Sitagliptin|Sitagliptin tablets 100 mg once daily
214393901|NCT01177813|DRUG|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
214393902|NCT01177813|DRUG|Placebo identical to BI10773 low dose|placebo tablets once daily
214386762|NCT02390843|DRUG|Simvastatin|The starting dose of simvastatin will be 140 mg/m\^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m\^2/dose BID, 225 mg/m\^2/dose BID, and 290 mg/m\^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
214386763|NCT02390843|DRUG|Cyclophosphamide|The dose of cyclophosphamide will be fixed at 250 mg/m\^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
214386764|NCT02390843|DRUG|Topotecan|The dose of topotecan will be fixed at 0.75 mg/m\^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
214386765|NCT02390843|DRUG|Myeloid growth factor|Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm\^3
214500386|NCT05758285|OTHER|AI-Based Prediction of Treatment Engagement and Outcomes|AI-based algorithms and prediction models of treatment engagement and outcomes based on data from the Online Therapy Unit by Prof. Heather Hadjistavropoulos will be trained to predict symptom improvement of patients from pre- to post-digital psychotherapy intervention and to predict patients' engagement with the digital psychotherapy intervention and to predict patient drop out probability. For prediction model estimation, state of the art AI-based algorithms, such as XGBoost, is used . XGBoost is a machine learning method developed by refining previously established decision-tree-based methodologies. Data is split into training and testing sets (e.g., 80/20 split).
214500387|NCT05391308|OTHER|Pre-polysomnography mesurement|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner), time spent sitting down (self-reporting)
214500388|NCT05391308|OTHER|Polysomnography measure|Apnea-Hypopnea Index
214500389|NCT05391308|OTHER|Post-polysomnography measurements|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner)
214500390|NCT05233072|OTHER|Blood sample|Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0
214500391|NCT02520544|DEVICE|Accolade stem|Total hip replacement
214500392|NCT02520544|DEVICE|Accolade II stem|Total hip replacement
214500393|NCT02520544|DEVICE|Trident/Tritanium cup|Total hip replacement
214500394|NCT05799794|BEHAVIORAL|Supervisor-led Implementation Coaching|Implementation coaching, support, or facilitation includes the support provided to supervisors and their organizations for successfully delivering an evidence-based practice (EBP). Implementation support can include consultation, supervision, and coaching.
214500395|NCT06285123|BEHAVIORAL|REP|"REP is a bundle of strategies designed to help hospitals implement an evidence-based clinical practice. REP's core components include 1) user-friendly packaging of the clinical guidance, 2) structured clinician training, 3) performance feedback, and 4) brief technical assistance."
214500396|NCT06285123|BEHAVIORAL|Facilitation|Facilitation is a process of interactive problem-solving via a supportive consultation relationship. Facilitation is delivered by an expert who meets regularly with site quality improvement leaders to support interactive problem-solving to address local barriers and unanticipated implementation challenges. In contrast to the group-based, brief technical assistance in REP, facilitation is individualized consultation with the site clinical champion that generates highly customized, local solutions that can potentially be sustained by the local providers and champions.
214500397|NCT05216276|PROCEDURE|TEP|Laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair
214500398|NCT05216276|PROCEDURE|rTAPP|robotic transabdominal preperitoneal (TAPP) inguinal hernia repair
214500399|NCT06938230|BEHAVIORAL|Health Education Initiative|Participants will receive a one time 45 minute intervention session. During the session participants will receive information regarding COVID-19 disease process and behavioral effects and had the opportunity to ask questions.
214386766|NCT00010686|DRUG|Dietary Phytoestrogens|
214386767|NCT04161807|DEVICE|Nerivio|The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
214386768|NCT04791202|DRUG|Dextrose|See arm descriptions
214386769|NCT04791202|DRUG|Methylprednisolone Acetate 40 MG/ML|See arm descriptions
214386770|NCT02006121|DRUG|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
214386771|NCT02006121|DRUG|Placebo|Sodium chloride 9 mg/ml
214393903|NCT01177813|DRUG|Placebo identical to BI10773 high dose|placebo tablets once daily
214500400|NCT03541902|DRUG|Cabozantinib|Given PO
214500401|NCT03541902|DRUG|Sunitinib Malate|Given PO
215093762|NCT02204852|DRUG|Placebo|
214393904|NCT05250804|OTHER|Helfer Skin Tap Technique|Helfer Skin Tap Technique is a technique in which the researcher taps the Dorso gluteal muscle by counting 1-15 with the palmar aspect of fingers (non-dominant hand) in rhythmic manner before inserting the injection intra muscularly at 90 degree and remove the needle quickly again by tapping and counting 1-3.
214500402|NCT04593407|PROCEDURE|Endoscopic mucosal resection (EMR)|"Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional lift-and-cut procedure or an underwater technique"
214500403|NCT04593407|PROCEDURE|Endoscopic submucosal dissection (ESD)|"Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.~The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation."
214500404|NCT06941961|DEVICE|intermittent theta burst stimulation|The iTBS delivered to the ipsilesional primary motor cortex (M1) at 80% resting motor threshold (RMT). Each session consists of 600 pulses (3-minute trains of 50 Hz triplets repeated every 10 seconds, twice daily with a 5-minute interval), administered for 7 consecutive days starting within 6 hours post-randomization.
214500405|NCT06941961|DEVICE|sham intermittent theta burst stimulation|Sham-iTBS is performed in the same way as the treatment group but uses 20% RMT.
214386772|NCT02875301|BEHAVIORAL|150 Minutes Week|This group will complete aerobic based exercise 150 minutes per week. Participants will obtain minutes through supervised on site exercise and home based exercise. An exercise duration of 30 minutes will be achieved by the forth week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise was been shifted to home based.
214393905|NCT00581256|RADIATION|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
214500406|NCT03255746|BEHAVIORAL|Sleep Enhancement|This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
214500407|NCT03255746|BEHAVIORAL|Health Education|This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
214500408|NCT06341933|OTHER|Duration of Surgery|Total surgery time in minutes
214500409|NCT06341933|OTHER|Volume of Fluid in Surgery|Fluid volume given during surgery in ml
214500410|NCT06341933|OTHER|Blood Loss|Blood loss during surgery in ml
214500411|NCT05672355|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214500412|NCT05672355|BIOLOGICAL|mRNA COVID-19 Vaccine|Given IM
214500413|NCT05672355|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM
214500414|NCT06260293|BEHAVIORAL|exercise|"A total of 4 exercise interventions.~Twice In-patient exercise interventions: exercises on the ward at POD1, and POD2, and Recommended walking and stretching.~Twice home-based exercise interventions: post-discharge, Recommended 30 minutes of low to moderate-intensity walking and daily bodyweight exercises per day(150 minutes each week). and remote exercises 1 per week."
214500415|NCT02891967|OTHER|bulk fill composite|cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
214500416|NCT02891967|OTHER|Nano resin composite (K Z350 xt)|cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
214500417|NCT06127810|DEVICE|CE MRI on 0.064T Scanner|Pt will undergo contrast enhanced images using Gadopiclenol on Hyperfine MRI
214500418|NCT06127810|DRUG|Gadopiclenol|Subjects will receive Gadopiclenol instead of standard of care contrast
214997848|NCT04083183|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
214997849|NCT04083183|DRUG|Mycophenolate Mofetil|Given PO or IV
214997850|NCT04083183|DRUG|Sirolimus|Given PO
214997851|NCT04083183|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214500419|NCT06344156|DRUG|Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy|Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines
214500420|NCT06411860|OTHER|Placebo|Participants will receive a subcutaneous (SC) injection of placebo.
214500421|NCT06411860|DRUG|Olpasiran|Participants will receive a SC injection of olpasiran at dose level 1 or 2.
214500422|NCT06411860|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
214500423|NCT06944951|DEVICE|Hydrophilic emulsion for the relief of haemorroidal symptoms|Administration for 2 weeks of PROCTOeze® PLUS - a soft and light hydrophilic emulsion able to provide symptomatic relief of haemorrhoids and anal irritation.
214997852|NCT04083183|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214997853|NCT06236932|DIETARY_SUPPLEMENT|Mediterranean diet|Hypocaloric Mediterranean Diet consist of a nutritional regimen with customized daily energy intake, calculated considering the Basal Metabolism and Physical Activity Level (LAF) of each patient. The distribution of macronutrients will be worked out as follows: ≃ 55-60% Carbohydrates (of which 80% are complex carbohydrates, pasta, bread, rice, whole grains and 20% simple sugars), ≃ 10-15% Proteins (of which the 60% of animal origin (meat, especially white) and 40% of vegetable origin (beans, chickpeas, lentils and legumes in general), ≃ 25-30% of lipids (predominantly olive oil).
214997854|NCT06236932|DIETARY_SUPPLEMENT|Melatonin supplementation|Melatonin (supplement formulation in capsules, 1mg/die one hour before sleep) will be associated with mediterranean diet for 12 w.
215093763|NCT05897697|OTHER|Interview|Structured interview
215093764|NCT04208087|DRUG|SI-722|SI-722 will be intravesically instilled.
215093765|NCT04208087|DRUG|Placebo|Placebo will be intravesically instilled.
215093766|NCT05487183|BEHAVIORAL|Medoc cutaneous probe|A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH
215093767|NCT05487183|BEHAVIORAL|Quantitative sensory testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
215093768|NCT05487183|BEHAVIORAL|Computer tasks|QST and computer tasks are used to measure changes in pain intensity
215093769|NCT01451190|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
215093770|NCT01531972|DRUG|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
215093771|NCT01531972|DRUG|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
214386773|NCT02875301|BEHAVIORAL|225 Minutes Week|This group will complete aerobic based exercise 225 minutes per week. Participants will obtain minutes through supervised on site exercise and home base exercise. A walking duration of 45 minutes will be achieved by the seventh week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise has been shifted to home based.
214386774|NCT02875301|BEHAVIORAL|Stretch and Tone|The control condition will focus on improving balance, flexibility, and strength. This group will obtain 150 minutes per week via in person sessions, zoom sessions and home based stretching. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.
214386775|NCT03337191|DRUG|Levobupivacaine|% 0,125 levobupivacaine
214386776|NCT03337191|DRUG|Morphine Sulfate|10 mq/kg morphine sulfate
214386777|NCT03337191|DEVICE|Ultrasound|Ultrasound guided caudal block
214386778|NCT04649827|OTHER|Clinical Observation|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, medications, and other risk factors such as the severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and main outcomes during hospitalization.
214386779|NCT00864526|DRUG|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
214386780|NCT00864526|DRUG|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
214500424|NCT06944197|OTHER|Standard Care Guidance Group|"Participants in this group will receive an individual, face-to-face consultation with a physiotherapist from the primary and community care service at the Primary Care Center. During the session, participants will be provided with an informational guide focused on the management of post-stroke conditions, as well as health promotion and secondary prevention strategies relevant to stroke recovery.~The document provided is titled Guide for People Affected by Cerebrovascular Disease, Their Families, and Caregivers, published in 2022 by the Department of Health of the Generalitat de Catalunya in collaboration with the Stroke Foundation. This group serves as the control group, as the intervention closely resembles the standard care currently implemented across Primary Care Centers in Catalonia for individuals in the chronic phase of stroke recovery."
214500425|NCT06944197|OTHER|Home-Based Therapeutic Exercise - Document Group|"Participants in this group will receive an individual, face-to-face consultation with a physiotherapist at the Primary Care Center. During the session, the Home-Based Therapeutic Exercise Program document will be explained and provided. This document outlines an exercise program to be followed over a 10-week period, with a frequency of three sessions per week.~The explanatory document includes three weekly exercise charts covering a total of 30 sessions. Each session is clearly described with detailed instructions to ensure proper execution, including dosage specifications such as repetitions, sets, and load. A checklist template is also included to help participants track their progress and completed activities.~The exercise program consists of strength exercises targeting the major muscle groups of the lower extremities (LE), upper extremities (UE), and trunk; stretching exercises focused on the most relevant flexor muscles of the lower and upper extremities; and exercises aimed"
214687794|NCT06368830|DIAGNOSTIC_TEST|Kayser-Jones Brief Oral Health Status Examination (BOHSE)|Scored assessment of the lymph nodes, lips, tongue, tissue inside of cheek, floor and roof of mouth, gums between teeth and/or under artificial teeth, saliva, condition of natural/artificial teeth, chewing position of teeth, and oral cleanliness
214687795|NCT06368830|DIAGNOSTIC_TEST|Tongue pressure|"Maximum isometric lingual pressure at the front and back of tongue will be measured by placing an air-filled pressure bulb on the surface of the oral tongue and having participants press the bulb as hard as possible against the hard palate"
214997855|NCT05502107|BEHAVIORAL|PRESS Intervention|The study intervention is PRESS protocol training and educational delivered to EMS providers, followed by protocol implementation. EMS providers will be trained to screen all EMS patients for protocol eligibility and will start using the protocol at the beginning of the intervention phase. The PRESS EMS protocol includes 2 major components: 1) an evidence-based sepsis screening tool, and 2) a prehospital sepsis alert call to the receiving hospital for participants who screen positive. Upon arrival to the ED, ED providers will provide immediate medical assessment to the patient to determine whether there is concern for sepsis. If the treating provider determines there is concern for sepsis, the provider will deliver usual sepsis care per local hospital protocols, workflows, or care pathways. Sepsis treatment interventions will not be specified by this study protocol.
214997856|NCT06113328|BIOLOGICAL|MK-6194|MK-6194 administered subcutaneously (SC)
214997857|NCT06113328|DRUG|Placebo|Placebo comparator to MK-6194 administered SC
214386781|NCT02420756|DEVICE|PET Scan|
214386782|NCT04745494|OTHER|OT administration|OT nasal administration
214997858|NCT06124196|DEVICE|wearable technology|Three wearable devices
214386783|NCT04745494|OTHER|Placebo administration|Placebo nasal administration
214386784|NCT04318730|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks, Apatinib was administered 250 mg p.o. qd.
214386785|NCT00946179|BIOLOGICAL|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
214386786|NCT00439829|DRUG|Gonal F|"* 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
214386787|NCT00439829|DRUG|Luveris|"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
214386788|NCT00439829|DRUG|Cetrotide|"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
214386789|NCT00439829|DRUG|hCG|"\- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o \> 3 follicles are \> 17 mm in diameter"
214386790|NCT06089174|OTHER|Ultra-trail|Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)
214386791|NCT01083420|DRUG|Minocycline|Minocycline 0.2% mouthwash
214687796|NCT06368830|DIAGNOSTIC_TEST|Test of Masticating and Swallowing Solids (TOMASS)|Measurement of bites, masticatory cycles, swallows, and time taken to consume a cracker
214997859|NCT04720898|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot provides optimized range of motion's movements and a visual feedback on the patient's performance. In addition, it may enhance neuroplasticity due to the increased number of movements repetitions which could influence motor learning.
214997860|NCT06965686|BEHAVIORAL|PERI-MIND|PERI-MIND will be informed by the focus group findings from phase one. However, the investigators anticipate including core components related to psychoeducation, psychological grounding, \& behavioral activation, which will be specifically adapted to the perimenopausal and menopausal population. Psychoeducation in this context will focus on menopausal symptoms like brain fog (e.g., how common they are, how long they typically last), information about dementia and its risk factors (e.g., most actionable risk factors in mid-life), and links between menopause and dementia (e.g., hormonal replacement therapy). Psychological grounding content will focus on practical training exercises in mindful monitoring of concerns about brain fog and other menopausal symptoms (e.g., meditation, deep breathing). Behavioral activation will focus on exercises to recognize and disrupt avoidant coping behaviors, and increase engagement in valued activities (e.g., social engagement, exercise, healthy eating).
215093772|NCT05378295|DIETARY_SUPPLEMENT|Fermentable oligosaccharide|Supplementation period 12 weeks
215093773|NCT05378295|DIETARY_SUPPLEMENT|Personalized fiber mixture|Supplementation period 12 weeks
215093774|NCT03825159|DEVICE|Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing|The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.
214386792|NCT01083420|DRUG|Dexamethasone|Dexamethasone 0.01% mouthwash
214386793|NCT06319235|DRUG|IMP|DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.
214386794|NCT06319235|DRUG|Placebo|0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C
214386795|NCT06489574|PROCEDURE|thoracic epidural with dexmedetomidine in patients undergoing thoracotomy surgery|"A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group A:~Patients will receive 50 μg dexmedetomidine with 10 ml of 0.125% bupivacaine followed by a continuous infusion of (10 ml bupivacaine + 25 μg dexmedetomidine + 39 ml saline with rate of 5 ml per hour)."
214386796|NCT06489574|PROCEDURE|thoracic epidural with fentanyl in patients undergoing thoracotomy surgery|"A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group B:~Patients will receive 50 μg fentanyl in addition to 10 ml 0.125% bupivacaine followed by a continuous infusion (10 ml bupivacaine + 100 μg fentanyl + 38 ml saline with rate of 5 ml per hour)."
214386797|NCT01915199|OTHER|Intensive Care|Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
214386798|NCT01205321|DRUG|Bombesin (68Ga) labeled (BAY86-7548)|Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
214687797|NCT06368830|DIAGNOSTIC_TEST|Respiratory function tests|Participants will take a maximum inhalation and forcefully exhale into a spirometer to measure maximum expiratory pressure (MEP), fully exhale their air and take a maximal inhalation into the spirometer to measure maximum inspiratory pressure (MIP), and produce a single strong cough into to spirometer to measure peak expiratory flow (PEF) and forced expiratory volume (FEV1)
214687798|NCT06246058|BEHAVIORAL|Partner support|The intervention group's survey vignette will include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
215093775|NCT03825159|DEVICE|spinal orthosis|The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
215093776|NCT05365737|OTHER|Oral rinse|Participants use mouthwasher for a given time.
215093777|NCT05365737|OTHER|Saliva harvest|Non-stimulated saliva harvesting
215093778|NCT01158690|OTHER|resource card|the intervention group receives an envelop with resource card
215093779|NCT01158690|OTHER|no resource card|the control group receives an envelop without resource card
214997861|NCT03848260|DEVICE|Magnetic device prototype|The device prototype comprises a near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and receiver (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet affixed to the paralytic upper eyelid, and a bio-signal acquisition module. The efficacy and safety of the device prototype was assessed using the device prototype.
214997862|NCT06967324|OTHER|Stepped care|Graduated palliative cross-sectoral care
214997863|NCT06967324|OTHER|Usual Care|Usual care at the outpatient respiratory clinic
214997864|NCT04199026|DRUG|Doxorubicin|Given via microdevice
214997865|NCT04199026|DRUG|Doxorubicin Hydrochloride|Given via microdevice
214386799|NCT01205321|DRUG|Bombesin (68Ga) labeled (BAY86-7548)|Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
214386800|NCT00458679|BIOLOGICAL|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10\^7) of IL-2 secreting B-cells together with (2 x 10\^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
214386801|NCT03203668|RADIATION|18F-choline PET/CT|18F-choline PET/CT imaging (neck, mediastinum)
214386802|NCT06082622|COMBINATION_PRODUCT|laxatives|triple therapy of drugs, behaviour and mental axis
214386803|NCT06321250|DRUG|JMKX003948|Subjects will receive JMKX003948 tablets until disease progression
214386804|NCT02676323|DRUG|Panobinostat|Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
214386805|NCT02676323|DRUG|Fludarabine|Fludarabine will be given intravenously (IV), 30 mg/m\^2/dose over 30 minutes, daily for 5 days (days 8-12).
214386806|NCT02676323|DRUG|Cytarabine|Cytarabine will be given IV, 2 gram/m\^2/dose over 4 hours, daily for 5 days (days 8-12).
214386807|NCT02676323|DRUG|Intrathecal Triples|Given intrathecally (IT).
214386808|NCT02676323|DRUG|Leucovorin|Leucovorin (5 mg/m\^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
214386809|NCT01356641|DRUG|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
214997866|NCT04199026|DEVICE|Drug Delivery Microdevice|Undergo percutaneous implantation of drug delivery microdevice
214997867|NCT04199026|DRUG|Everolimus|Given via microdevice
214997868|NCT04199026|BIOLOGICAL|Ganitumab|Given via microdevice
214997869|NCT04199026|DRUG|Ifosfamide|Given via microdevice
214997870|NCT04199026|DRUG|Irinotecan|Given via microdevice
215093780|NCT02064608|DRUG|AZD2014|mTOR inhibitor
215093781|NCT01977690|DEVICE|Clavicle Brace|
215093782|NCT04276974|OTHER|Organic diet|Organic plant-rich foods (2000kcal for women, 2500kcal for men)
214386810|NCT01356641|PROCEDURE|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
214386811|NCT04769713|PROCEDURE|Hepatic Hilar Nerve Block Needle placement|Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.
214386812|NCT04769713|DRUG|Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block|Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
214386813|NCT04769713|DRUG|Injection of normal saline in the hepatic hilum for the sham procedure|15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
214500426|NCT06944197|OTHER|Home-Based Therapeutic Exercise - Telerehabilitation Group|"Participants will have an individual consultation with a physiotherapist at the Primary Care Center, where an individualized therapeutic exercise program will be explained. The program spans 10 weeks with three sessions per week (totaling 30 sessions) and is delivered through the Physitrack telerehabilitation platform.~They will receive the Guide for the Use of the Physitrack Telerehabilitation Platform, which provides all necessary information for effective platform use. A brief tutorial will be given during the consultation to ensure familiarity with the tool.~The program mirrors the Therapeutic Exercise Document Group program, but with weekly progress monitoring via the platform. This allows the physiotherapist to adjust exercises or load based on progress. The platform also enables direct communication between participants and the physiotherapist, offering continuous support throughout the intervention."
214500427|NCT06943846|PROCEDURE|Platelet-rich fibrin (PRF)|Platelet-rich fibrin added to extraction socket
214997871|NCT04199026|DRUG|Pazopanib|Given via microdevice
214997872|NCT04199026|DRUG|Polyethylene Glycol|Given via microdevice
214997873|NCT04199026|DRUG|Temozolomide|Given via microdevice
214997874|NCT04199026|DRUG|Temsirolimus|Given via microdevice
214997875|NCT04199026|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214997876|NCT04199026|DRUG|Vincristine|Given via microdevice
214997877|NCT04431960|DRUG|blackcurrant (BC) extract|A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
214997878|NCT06646575|OTHER|Qualitative data, no intervention|This is a qualitative study
214997879|NCT05273190|DEVICE|Vibrotactile Stimulation|Small electric motors, similar to a vibrating cell phone or gaming joystick, deliver vibration to the throat. Participants will assess cough symptoms throughout the study period.
214997880|NCT02466971|RADIATION|Brachytherapy|Undergo brachytherapy
214997881|NCT02466971|DRUG|Cisplatin|Given IV
214997882|NCT02466971|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214997883|NCT02466971|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214997884|NCT02466971|OTHER|Laboratory Biomarker Analysis|Correlative studies
214997885|NCT02466971|RADIATION|Radiation Therapy|Undergo conventional RT
214997886|NCT02466971|DRUG|Triapine|Given IV
215093783|NCT04276974|OTHER|Non-organic diet|Likewise Non-organic plant-rich foods (2000kcal for women, 2500kcal for men)
215093784|NCT05729139|DRUG|Cemiplimab-Rwlc|350 mg via IV infusion over 30 minutes every 3 weeks for up to two years
214997887|NCT03169673|DIAGNOSTIC_TEST|Hyperpolarized Helium 3 Magnetic Resonance Imaging|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 3He gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
214997888|NCT06172907|BEHAVIORAL|Young Adults Coping with Cancer Together Intervention|This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.
214386814|NCT04696718|DIETARY_SUPPLEMENT|daily supplementation|the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days
214386815|NCT02934360|DEVICE|TR(ACE) Assay Testing|Serial plasma testing with TR(ACE) Assay
214386816|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 1|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
214386817|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 2|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.
214386818|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 3|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.
214386819|NCT04789577|BIOLOGICAL|AS03B|Participants received two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
214386820|NCT04789577|BIOLOGICAL|AS03A|Participants received two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
214386821|NCT04789577|DRUG|Placebo|Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.
214386822|NCT04102436|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
214386823|NCT04102436|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
214386824|NCT04102436|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg or 72,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
214386825|NCT04102436|BIOLOGICAL|Sleeping Beauty Transposed PBL|Day 0: Cells are to be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes or as clinically determined by an investigator for patient safety (between 2-4 days after the last dose of fludarabine).
214386826|NCT04905732|DEVICE|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
214386827|NCT04905732|DEVICE|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
214386828|NCT02096133|DRUG|Cholecalciferol|Vitamin D3 solution
214386829|NCT02096133|OTHER|Placebo comparator|Placebo comparator
214386830|NCT00387257|DRUG|Rilapladib (SB-659032)|
214386831|NCT04724356|OTHER|Virtual Reality|Intervention was led once per day, five days a week, over 8 weeks.
214386832|NCT04724356|OTHER|Resistance Exercise|Intervention was led once per day, five days a week, over 8 weeks.
214386833|NCT06286540|DEVICE|Lymphoblock|1 time per surgery with the exposition for 20 minutes.
214386834|NCT06286540|DEVICE|Placebo|1 time per surgery with the exposition for 20 minutes.
214386835|NCT05656443|DRUG|GST-HG171/Ritonavir|dose of 150 mg GST-HG171 with 100 mg ritonavir
214386836|NCT05656443|DRUG|Placebo|Placebo
214386837|NCT02493218|BEHAVIORAL|Mindfulness Instruction|Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
214386838|NCT02493218|BEHAVIORAL|Health Education|Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
214386839|NCT05170308|DEVICE|CO2 fractional laser|The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) to treat dyspigmentation in lichen planus pigmentosus
214386840|NCT01605734|PROCEDURE|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
214386841|NCT01605734|DRUG|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
214386842|NCT01381835|DRUG|TMC435|150 mg capsule once daily for 7 days
214386843|NCT05150587|DRUG|Rifaximin|Rifaximin tablets
214386844|NCT05150587|DRUG|Placebo|Placebo tablets
214386845|NCT00822003|DRUG|Oral GLP-1|GLP-1 tablet (2mg)
214386846|NCT00822003|DRUG|Placebo|Control tablet
214386847|NCT01674933|DRUG|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
214386848|NCT01674933|BEHAVIORAL|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
214386849|NCT00240838|DRUG|acetaminophen extended release caplets|
214393906|NCT00581256|RADIATION|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
214393907|NCT06063655|DIETARY_SUPPLEMENT|Control: Water|Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
214997889|NCT05007106|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
214386850|NCT05091944|DEVICE|web-based birth decision aid|Women in the intervention group receive both usual care and decision support (an interactive web-based birth decision aid). The innovative interactive web-based birth decision aid comprised five components: Component 1-a communication aid video involves 2 expert's talk about how to participate in SDM and prepare self with choice talk, option talk and decision talk(10 minutes )and practice communication skills with clinician(10 minutes); Component 2-overall of the function and features of birth decision aid. Component 3-introduce the benefits and risk of vaginal birth after cesarean; Component 4- the benefits and risk of elective repeat cesarean section; Component 5 -a quit to confirm women's knowledge regarding the two choices and confirm women's values.
214386851|NCT05706792|DEVICE|Nordic Sensi Chair|The Nordic Sensi Chair is an electrically operated rocking chair with built-in MusiCure music composed by Niels Eje. It is equipped with an integrated audio system with music recording based on more than 15 years of research on the calming and mentally stimulating effect of sound. The Nordic Sensi Chair has three different programs: Relax for deep relaxation, Refresh for recovery and Comfort for gentle relaxation. A 5 kg fiber blanket increases the feeling of security and relaxation, while helping users to perceive their own body. In addition to musical programming, the Nordic Sensi Chair provides predefined tactile stimulation and rocking motion, for a relaxing multi-sensory experience. All settings can be easily customized at the touch of a button. For the purposes of this study, the NSC deep relaxation program (Relax Program) was used.
214386852|NCT03900143|DEVICE|Tightra vaginal device|Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.
214386853|NCT01614847|DRUG|Artificial tears|At random, subjects will receive isotonic artificial tear or a control (normal saline).
214386854|NCT02190760|DRUG|Dexamethasone|
214386855|NCT02190760|DRUG|Bupivacaine|
214500428|NCT06946758|OTHER|Core stabilization exercises|Patients in the core stabilisation exercise group underwent a total of 24 sessions of core stabilisation exercise programme 3 days a week (with at least 1 day of rest between each session) for a total of 8 weeks. Each exercise session was performed under the supervision of a physician in the Department of Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine. Each session was arranged as 35-minute programmes with an average of 8-10 patients, 5 minutes of which was warm-up. Before starting the exercise, patients were taught to reduce lumbar lordosis by contracting and drawing in the abdominal muscles and to find a lumbar and pelvic neutral position by moving the pelvis forwards and backwards. In each session, the neutral position was found first and attention was paid to maintain the neutral position throughout the exercise. The exercises consisted of 3 levels. The exercise level was completed gradually
214500429|NCT06946758|OTHER|Aerobic Exercises|The aerobic exercise group underwent core stabilisation exercises applied to the control group. After the core stabilisation exercises, aerobic exercise was performed with a stationary bicycle at a speed of 50 rpm for approximately 40 minutes.
214500430|NCT05539209|BEHAVIORAL|OKquit|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys plus OKquit Smartphone App including tailored messages and on-demand content designed to assist participants in their cessation attempt.
214500431|NCT05539209|BEHAVIORAL|Standard Helpline Care|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys.
214687799|NCT06246058|BEHAVIORAL|Formal recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~FORMAL dress code of the recruiter is the intervention in this case, defined as clinical attire alluding to some clinical authority."
214997890|NCT05007106|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered via IV infusion Q3W.
214997891|NCT05007106|DRUG|Lenvatinib|Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
214386856|NCT02810730|PROCEDURE|Pancreatic MRI|Pancreatic MRI in the 6 months following the first consultation
214386857|NCT03266185|OTHER|Shorter PICT|Shorter post-infusion cooling time
214386858|NCT01643746|DEVICE|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
214386859|NCT01643746|DEVICE|Life Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
214386860|NCT04361513|DRUG|Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)|3 point genicular nerve block
214386861|NCT04361513|DRUG|triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)|intra-articular injection of triamcinilone
214687800|NCT06246058|BEHAVIORAL|Without Partner support|The intervention group's survey vignette will NOT include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
214997892|NCT05007106|DRUG|5-Fluorouracil|5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
214997893|NCT05007106|DRUG|Cisplatin|Cisplatin administered via IV infusion
214997894|NCT05007106|DRUG|Paclitaxel|Paclitaxel administered via IV infusion at investigator's choice of dose
214997895|NCT05007106|DRUG|Gemcitabine|Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
215093785|NCT05729139|DRUG|PEG-IFN alfa-2a|"Self-administered by the participant via subcutaneous injection in the abdomen or thigh weekly for up to one year. Participants will receive one of three doses:~Dose level 0: 45 mcg~Dose level 1: 90 mcg~Dose level 2: 135 mcg~Dose level 0 is considered the starting dose and sequential cohorts of three participants will be treated with escalated doses until the maximum tolerated dose is established."
214386862|NCT04393740|DIAGNOSTIC_TEST|scheimpflug imaging using pentacam|corneal tomography imaging using pentacam device (based on Scheimpflug principle )
214386863|NCT01764373|OTHER|Aerobic Exercise|Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
214386864|NCT01165840|DRUG|Dapsone|100 mg PO x 1 dose
214997896|NCT05007106|DRUG|Carboplatin|Carboplatin administered via IV infusion at investigator's choice of dose and frequency
214997897|NCT05007106|DRUG|Docetaxel|For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
214386865|NCT00249496|BEHAVIORAL|Contingency management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
214997898|NCT05007106|DRUG|Bevacizumab|Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
214386866|NCT00249496|BEHAVIORAL|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
214386867|NCT01247493|DRUG|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
214386868|NCT01088308|PROCEDURE|High rate atrial and vetricular stimulation|The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
214386869|NCT01088308|PROCEDURE|Ventricular Tachycardia induction|A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
214386870|NCT02693834|DEVICE|Posterior Leaf spring AFO|Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.
214386871|NCT02693834|DEVICE|Double adjustable AFO|Double adjustable AFO is a custom AFO with double action metal upright joints
214386872|NCT04707131|DRUG|LEM-S401|siRNA encapsulated in DegradaBALL®
214386873|NCT04707131|DRUG|Placebo|Placebo
214500432|NCT05223387|DEVICE|Axiom TL REG|"Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
214500433|NCT05223387|DEVICE|Axiom BL REG|"Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
214500434|NCT06950320|DEVICE|P-STIM (Biegler, Mauerbach, Austria) is a battery-operated micro-stimulation appliance|P-STIM (Biegler, Mauerbach, Austria) is a battery-operated micro-stimulation appliance weighing 5 grams, designed as a disposable product for a single use. P-STIM is placed behind the patient's ear and connected to stimulation needles (usually 3 needles) on the auricle. For the study, only one stimulation needle was needed. P-STIMTM offers regular therapy over several days. The appliance transmits low frequency electric pulses to exposed nerve endings. The built-in microchip creates periods of stimulation and rest, each lasting approximately 3 hours. Stimulation was performed with a frequency of 1Hz for 40min followed by a break of 20 min.
214500435|NCT06950320|DEVICE|Placebo|The placebo device is a look-a-like, that stimulates only for 1h hour and then stops.
214687801|NCT06246058|BEHAVIORAL|Casual recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~CASUAL dress code of the recruiter is the intervention in this case."
214997899|NCT05007106|DRUG|Capecitabine|Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
214386874|NCT04806412|DIAGNOSTIC_TEST|meassurement of PD-L1, ALK, EGFR|"PD-L1 test will be performed on cell-blocks using PD-L1 antibodies 22C3 and staining platform Dako Omnis (Agilent, Glostrup -Denmark).~ALK test will be performed on cell-blocks using staining platform Dako Omnis (Agilent, Glostrup- Denmark) and ALK antibodies Origene clone: OT1A4. Sample quality is assessed as for PD-L1.~EGFR mutation analysis will be performed as follows: after tumor content evaluation of hematoxylin and eosin stained slides, relevant regions are macrodissected and subjected to a standard genomic DNA extraction procedure using the GeneRead DNA FFPE Kit (Qiagen). Samples will be analysed using the GeneRead QIAact Actionable Insights Tumor Panel (Qiagen)"
214386875|NCT00000143|DEVICE|Ganciclovir implant and oral ganciclovir|oral ganciclovir, 1 gm three times daily
214386876|NCT00000143|DRUG|Cidofovir intravenous|intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
214386877|NCT02885727|DRUG|Durvalumab|Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
214386878|NCT02885727|RADIATION|Radiation Therapy|The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
214386879|NCT04848662|DRUG|BDA MDI (PT027) 160/180 μg|Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.
214386880|NCT04848662|DRUG|Pulmicort Respules 0.5 MG/ML Inhalation Suspension|Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.
214386881|NCT03802162|DRUG|CKD-355A (D797/Memantine HCl 20mg)|once a day
214997900|NCT05007106|DRUG|Oxaliplatin|Oxaliplatin administered via IV infusion Q3W up to 35 cycles
214997901|NCT03409367|OTHER|Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream|Lipid-rich emollient serving as skin barrier
214997902|NCT06335797|DIETARY_SUPPLEMENT|Senna Tab|Senna 8.6mg two tablets per day post operative day 1 and and if needed, then continue on the same dose regiment until post operative day 5.
214997903|NCT06335797|DIETARY_SUPPLEMENT|Dulcolax Suppositories|Dulcolax 1 suppository to be placed rectally on the evening of post operative day 1 and if needed, then continue using the same dose regiment until the post operative day 5.
214386882|NCT03802162|DRUG|CKD-355B (D797/Memantine HCl 20mg)|once a day
214386883|NCT03802162|DRUG|D797|once a day
214386884|NCT03802162|DRUG|D324 (Memantine HCl 10mg)|twice a day
214386885|NCT02827786|DEVICE|Electromagnetic Acoustic Imaging|Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
214386886|NCT03072082|DRUG|Danlou Tablet|Conventional western medicine \& Danlou Tablet
214386887|NCT03072082|DRUG|DanLou Tablet placebo|Conventional western medicine \& placebo (for Danlou Tablet)
214386888|NCT03072082|DRUG|Aspirin Enteric-coated Tablets|100 mg tablet, one tablet daily.
214386889|NCT03072082|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|One tablet daily. (for patients who can't use aspirin)
214500436|NCT06950931|DIAGNOSTIC_TEST|uPTM-FeA|In this monocentric prospective cohort study, we will measure uPTM-FeA by enzyme-linked immunosorbent assay (ELISA) kit DNLite IVD 103 in cooperation with PromedeusLab. Human uPTM3-DKD ELISA is a colourimetric immunoassay for quantitatively determining human unique Fetuin-A with specific post-translational modification (PTM) in urine.
214500437|NCT06952192|DEVICE|Virtual reality|VR application via a head-mounted display one minute before and throughout the SPT procedure. The VR intervention utilized a Samsung Gear VR headset (Samsung, Seoul, South Korea) in conjunction with a Samsung S7 or S8 mobile device to provide an immersive and engaging experience. Children were allowed to choose from a range of age-appropriate VR content designed to enhance engagement and relaxation. Prior to the procedure, children were trained on how to use the headset by study staff to ensure a smooth experience.
214500438|NCT06951516|BEHAVIORAL|Linguistic simplification|Children will participate in screen-based language processing and word learning tasks in which they hear utterances with different types and amounts of linguistic simplification (i.e., a within-group manipulation).
214687802|NCT05411198|DEVICE|XEN45 (Glaucoma Gel Stent)|Ab externo implant
214687803|NCT04472260|PROCEDURE|Verticalization and Prone position|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
214386890|NCT03072082|DRUG|Atorvastatin calcium|10 mg tablet, two tablets each night.
214687804|NCT06128551|DRUG|Assigned interventions|Drug: RMC-6291 and RMC-6236 Oral tablets
214997906|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration) in a HRT cycle, according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET."
214687805|NCT06398743|DEVICE|MRD|ctDNA MRD test
214386891|NCT03072082|DRUG|Isosorbide Mononitrate Tab 20 MG|One tablet two times daily.
214687806|NCT06501534|DRUG|Febuxostat|Tablets, Once a day (QD), Per oral
214997907|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration), according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET. In case of a non-receptive endometrium result, a second EB sample must be collected when indicated by the ERA report. Fluid sample collection will not be repeated in these cases."
214687807|NCT06501534|DRUG|IBI128|Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
214687808|NCT04261543|OTHER|High protein and early exercise|High protein is defined as protein prescription of ≥2.2 gram/kg body weight and early exercise is defined as starting cycle ergometry intervention within 24 hours of randomization
214386892|NCT03072082|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
214386893|NCT03072082|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
214386894|NCT00894582|PROCEDURE|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
214386895|NCT04479722|DEVICE|Left atrial appendage closure procedure|Implant LAAC system in LAA through percutaneous intervention
214386896|NCT03000673|DRUG|Enoxaparin|Specified dose of Enoxaparin on specified days
214386897|NCT03000673|DRUG|unfractionated heparin (UFH)|Specified dose of UFH on specified days
214386898|NCT03000673|DRUG|BMS-986177|Specified dose of BMS-986177 on specified day
214386899|NCT03903679|DEVICE|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway during the septal surgery.
214386900|NCT03903679|DEVICE|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
214687809|NCT04261543|OTHER|Usual Care|Usual care group has protein prescription of ≤1.2 gram/kg body weight and exercise at the discretion of attending clinicians
214687810|NCT01327651|DRUG|Daily dosing|A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
214687811|NCT01327651|DRUG|Time-driven dosing|TDF/FTC twice weekly with a post-exposure dose
214687812|NCT01327651|DRUG|Event-driven dosing|TDF/FTC as needed with a post exposure dose
214687813|NCT03708965|DRUG|JR-141|IV infusion (lyophilized powder)
214386901|NCT01121484|DRUG|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
214386902|NCT01121484|DRUG|placebo|Placebo tablets taken orally once daily.
214386903|NCT05983926|PROCEDURE|Subtotal colectomy was performed|"Colonic subtotal resection, also known as subtotal colectomy, is a surgical procedure used to treat colonic diseases such asconstipation, colon cancer, ulcerative colitis, and others.~The purpose of this surgery is to remove a portion of the colon in the patient's body. Unlike a total colectomy, which involves removing the entire colon, a subtotal colectomy only removes a portion of the colon. The procedure typically involves removing the diseased part of the colon and reconnecting the remaining colon. This allows for the preservation of some normal colonic function, enabling the patient to have regular bowel movements."
214386904|NCT00562978|BIOLOGICAL|filgrastim|
214386905|NCT00562978|DRUG|cyclophosphamide|
214386906|NCT00562978|DRUG|etoposide|
214386907|NCT00562978|PROCEDURE|AHSCT|
214386908|NCT00562978|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214386909|NCT01780129|DRUG|Polydatin Injectable|Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
214386910|NCT04299477|PROCEDURE|non-surgical periodontal treatment|supra- and subgingival scaling, and root planning
214386911|NCT04002219|DIETARY_SUPPLEMENT|beverage containing mushroom-extracts|Subjects recruited from both arms will receive treatment and be followed up clinically for 8 weeks.
214386912|NCT02378402|OTHER|Proton (1H-) magnetic resonance (MR) spectroscopy|PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
214386913|NCT00687336|OTHER|Empirical Hp eradication|Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
214386914|NCT00687336|OTHER|Eradication treatment guided by a positive test|Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
214386915|NCT00252213|DRUG|Human BNP|
214386916|NCT00299195|DRUG|sulindac|Sulindac 150 mg po bid x 24 weeks
214386917|NCT00299195|DRUG|Placebo|Placebo bid x 24 weeks
214386918|NCT04737317|DIAGNOSTIC_TEST|ECG, Echo, laboratory tests, CMR, PET-CT, Biopsy|ECG - 12 leads ECG Echo: transthoracic echocardiography laboratory tests: full blood count, electrolytes, creatinine, high sensitive cardiac troponin T, angiontesin converting enzyme, soluble interleukin-2 receptor, cardiac magnetic resonance imaging: 1.5 Tesla scanner, Conventional cine imaging and late gadolinium enhancement imaging PET-CT: 18F-fluorodeoxyglucose (FDG)- positron emission tomograph Biopsy: cardiac biopsy = endomyocardial biopsy, left and right ventricle, at least 5 specimens in formaldehyd and 3 specimens for testing of infectious agents Biopsy: extracardiac biopsy, as accessible according to imaging
214687814|NCT06361641|DIAGNOSTIC_TEST|Monocytes signatures in myeloproliferative neoplasms at diagnosis|The monocytes signatures will be perform from a peripheral blood sample. The signature will be derived from (i) surface marker expression, (ii) cytokines profiles, (iii) genes expression.
214687815|NCT00260585|PROCEDURE|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
214687816|NCT00260585|PROCEDURE|Blood specimen for non-DNA and DNA parts|Blood specimen is collected prior to surgery or at the time of scheduled routine surgical procedure(s), and at the time of routine follow-up visits
214386919|NCT05429437|BIOLOGICAL|Injectable platelet rich fibrin .|i-PRF with maxillary canine retraction that will be performed two times on intervention sides according to a standardized protocol.
214386920|NCT05429437|BIOLOGICAL|Injectable platelet rich fibrin .|i-PRF that will be performed four times on intervention sides according to a standardized protocol.
214386921|NCT04825444|DEVICE|Photoacoustic inspection|Use photoacoustic imaging system to image breast blood vessels
214386922|NCT01348776|DEVICE|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
214386923|NCT04785326|DRUG|DMB-3115|45mg or 90mg dose subcutaneous administration
214386924|NCT04785326|DRUG|Stelara|45mg or 90mg dose subcutaneous administration
214386925|NCT01463293|DIETARY_SUPPLEMENT|B. lactis HN019|Capsule containing 10 billion cfu B. lactis HN019 once a day
214386926|NCT01463293|DIETARY_SUPPLEMENT|B. lactis HN019|Capsule containing 1 billion cfu B. lactis HN019 once a day
214386927|NCT01463293|DIETARY_SUPPLEMENT|Placebo|Capsule containing no probiotic once a day
214386928|NCT01305278|OTHER|Use of Nintendo Wii Balance Gaming system|Use of Nintendo Wii Balance Gaming system
214386929|NCT03655990|DEVICE|Treatment with the JUVORA™ Dental Disc|treatment with the JUVORA™ Dental Disc
214386930|NCT01099930|OTHER|immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|"Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.~Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant"
214386931|NCT01099930|OTHER|Standard Therapy|Patient will receive standard therapy as decided upon by their treating neurologist.
214386932|NCT05243381|BIOLOGICAL|20 ml blood test|20 ml blood test
214386933|NCT02707523|DRUG|Azithromycin 10 mg|
214386934|NCT02707523|DRUG|Azithromycin 20mg|
214386935|NCT02707523|DRUG|Placebo|
214687817|NCT00260585|PROCEDURE|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
214386936|NCT05800782|BEHAVIORAL|Face Memory Training|Computer-based training using faces targeting face memory
214386937|NCT05800782|BEHAVIORAL|Face Perception Training|Computer-based training using faces targeting improving face perception
214386938|NCT05800782|BEHAVIORAL|Placebo control training|Computer-based training using faces not targeting improving face perception or memory
214386939|NCT03452605|DIETARY_SUPPLEMENT|cocoa flavanol supplementation|cocoa flavanols (containing 196 mg epicatechin)
214386940|NCT04723043|DEVICE|mechanical ventilation modes|ventilation with pressure controlled mode in laparoscopic abdominal surgery ventilation with volume controlled mode in laparoscopic abdominal surgery
214386941|NCT00967213|DRUG|ranibizumab|Lucentis® (ranibizumab) 0.3mg (0.05ml volume) intravitreal injection. Eligible patients will be initially received three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
214386942|NCT01440127|DRUG|Metformin|Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
214386943|NCT06205641|DRUG|Xuanfei Baidu Granule Placebo|Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.
214500439|NCT06950372|DRUG|Ropivacaine concentration low|Brachial plexus nerve block with ropivacaine 3.75 mg/ml
214500440|NCT06950372|DRUG|Ropivacaine concentration high|Brachial plexus nerve block with ropivacaine 7.5 mg/ml
214500441|NCT06950684|DIETARY_SUPPLEMENT|Whey Protein Supplement|Participants will take a daily supplement of whey protein powder (Easy Whey) providing 25 grams of protein each day for the duration of 6 months
214500442|NCT06950684|BEHAVIORAL|Resistance Training Program|Participants will engage in resistance training consisting of one guided online session each week and two additional independent resistance training sessions weekly, totaling three sessions per week, for a duration of 6 months.
214500443|NCT06951802|DRUG|Ketamine|Low-dose administration of ketamine during laparoscopic surgery
214386944|NCT06205641|DRUG|Xuanfei Baidu Granule|Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.
214386945|NCT06205641|DRUG|Baloxavir Marboxil Tablet|Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.
214386946|NCT01413230|DRUG|cholecalciferol|100 000 UI of cholecalciferol per week during 4 then 100 000 UI of cholecalciferol per month for 6 months
214386947|NCT04062435|DRUG|Drop application in the inferior fornix|See Arms
214386948|NCT04062435|DRUG|Drop application on the cornea|See Arms
214386949|NCT04230460|DRUG|Cannabis (THC) (Inhaled) Placebo|Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
214386950|NCT04230460|DRUG|Cannabis (High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
214386951|NCT04230460|DRUG|Cannabis (Very High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
214500444|NCT06951802|DRUG|Propofol|Control group
214500445|NCT06952283|BEHAVIORAL|Inducing mental fatigue|"During the mental fatigue induction phase, a 30-minute Stroop task will artificially induce mental fatigue, simulating the mental fatigue state that athletes experience during competitions or training sessions. The Stroop task is a classic cognitive control task widely used for inducing mental fatigue. Research in sports science has shown that a 30-minute Stroop task significantly increases subjective fatigue and reduces physical performance. This study will use a smartphone-based version of the Stroop task (with brightness and touch sensitivity standardised), where colour words (such as red and blue) are displayed continuously, but the font colour does not match the word's meaning. Participants must ignore the word's meaning and respond only based on the font colour. The Stroop task requires sustained attention, conflict resolution, and cognitive inhibition, leading to cognitive resource depletion and mental fatigue accumulation."
214687818|NCT00260585|PROCEDURE|Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies|Tissue from the biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushings are collected intraoperatively.
214386952|NCT04230460|DRUG|Alcohol (oral)|Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
214386953|NCT02779023|BEHAVIORAL|Cognitive-Behavior Therapy for Insomnia (CBT-I)|
214386954|NCT00811421|DRUG|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
214386955|NCT00811421|DRUG|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
214386956|NCT00811421|DRUG|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
214386957|NCT00811421|DRUG|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
214386958|NCT00811421|DRUG|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
214386959|NCT05146960|OTHER|Temporal summation|Temporal summation will be evoked in each predetermined area
214386960|NCT05146960|OTHER|Placebo|PPTs will be assessed once in each predetermined area
214386961|NCT03452176|DEVICE|Scrambler|Scrambler is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of nociceptive fibers with the intent of re-organizing maladaptive signaling pathways which has been investigated for treatment of peripheral neuropathy.
214386962|NCT03452176|DEVICE|Scrambler Sham Control|Sham control should be indistinguishable to the participants from experimental Scrambler therapy.
214386963|NCT02674360|BEHAVIORAL|SDM Training|
214386964|NCT00706784|DRUG|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
214386965|NCT03222258|BEHAVIORAL|Early palliative care|Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.
214386966|NCT03222258|BEHAVIORAL|Routine hospice care|Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
214386967|NCT01361620|DRUG|aspirin|aspirin 81mg, 7-10 days
214386968|NCT01615575|PROCEDURE|Transanal haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
214386969|NCT01615575|PROCEDURE|Stapler haemorrhoidopexy|Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
214386970|NCT01619046|BIOLOGICAL|GreenGene™ F and an approved recombinant Factor VIII product|one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate \< 10 mL/min
214386971|NCT01619046|BIOLOGICAL|GreenGene™ F|intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
214386972|NCT01619046|BIOLOGICAL|GreenGene™ F|"intra-venous infusion,~On-demand safety and efficacy substudy:~minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg"
214386973|NCT01619046|BIOLOGICAL|GreenGene™ F|"intra venous infusion,~Surgical substudy:~Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.~Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level."
214386974|NCT03176446|DEVICE|Local anesthesia with traditional technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
214386975|NCT03176446|DEVICE|Local anesthesia with computerized technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
214386976|NCT03176446|DEVICE|Local anesthesia with DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
214386977|NCT03176446|DRUG|Topic anesthesia|Application of topical anesthetic for 60 seconds with benzocaine
214386978|NCT03176446|DRUG|Local anesthetic|2% lidocaine with epinephrine 1: 100000 1.8 mL
214386979|NCT01989559|BIOLOGICAL|gp100:209-217(210M) Peptide Vaccine|Given SC
214386980|NCT01989559|BIOLOGICAL|HPV 16 E7:12-20 Peptide Vaccine|Given SC
214386981|NCT01989559|OTHER|Laboratory Biomarker Analysis|Correlative studies
214386982|NCT02811094|OTHER|polymerase chain reaction (PCR) technique of blood transcriptome analysis|this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
214386983|NCT05185518|DEVICE|Use of novel insulin injection port|use subcutaneous port into which glucose monitor is embedded
214386984|NCT02918240|PROCEDURE|Appointment intervals|
214386985|NCT02918240|DEVICE|fixed orthodontic braces|
214386986|NCT01710917|DRUG|Targinact® (oxycodon/naloxon)|
214386987|NCT05904860|OTHER|Backward Gait Training|Backward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
214386988|NCT05904860|OTHER|Forward Gait Training|Forward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
214386989|NCT04583683|BEHAVIORAL|Very low calorie diet with Fortimel (Nutricia) supplementation|Patients will undergo a very low calorie diet
214386990|NCT04583683|PROCEDURE|Metabolic Surgery|Patients will undergo metabolic surgery
214386991|NCT00195390|BIOLOGICAL|Prevenar|Prevenar 0.5ml/ Vial and PFS
214386992|NCT03965819|DIETARY_SUPPLEMENT|Pain Bloc-R|Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine
214386993|NCT03965819|OTHER|Active Comparator - Acetaminophen|DIN 02447479 Encapsulated for Blinding Purposes
214386994|NCT03965819|OTHER|Placebo|No active ingredients
214386995|NCT00779584|DRUG|MK-8776|IV infusion
214386996|NCT00779584|DRUG|Gemcitabine|IV infusion
214386997|NCT02276391|DRUG|Telmisartan/HCTZ combination|
214386998|NCT02276391|DRUG|Telmisartan|
214386999|NCT00817804|DEVICE|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
214387000|NCT01803230|DIETARY_SUPPLEMENT|creatine supplementation|creatine supplementation
214387001|NCT01803230|DIETARY_SUPPLEMENT|Placebo|
214387002|NCT00084734|DRUG|capecitabine|Oral
214500446|NCT06952283|BEHAVIORAL|Music intervention|During the music intervention phase, participants will listen to 15 minutes of classical music to facilitate mental fatigue recovery. This study selects Mozart's Eine Kleine Nachtmusik as the intervention music, a piece that has been applied in previous mental fatigue recovery studies and has been validated as an effective intervention. The intervention duration is set at 15 minutes, as multiple studies have confirmed this duration to be sufficient to produce recovery effects without causing additional cognitive load or auditory fatigue. The music will be played through a smartphone, with the intervention volume controlled at 50-60 dBA. Considering that the maximum volume of a smartphone is approximately 105-113 dBA, the standardised intervention volume is set at 50% (52.5-56.5 dBA) of the smartphone's maximum volume to ensure consistency among all participants.
214500447|NCT06952465|DRUG|Deucravacitinib|As per product label
214500448|NCT06952465|BIOLOGICAL|Any biologic treatment for psoriasis|According to the product label
214997908|NCT04649788|DEVICE|Ultrasound-guided axillary vein access|Venous access is performed through ultrasound-guided axillary vein puncture and Seldinger technique. After venous access is obtained, a guide-wire is advanced through the access needle, and the tip of the guide-wire is positioned in the right cardiac atrium.
214997909|NCT04649788|DEVICE|Cephalic vein access|Venous access is performed through a cephalic vein cutdown approach. After venous access is obtained, a guide-wire is advanced and the tip of the guide-wire is positioned in the right cardiac atrium.
214997910|NCT06298916|COMBINATION_PRODUCT|64Cu-LNTH-1363S|64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,
214997911|NCT06480032|DEVICE|Blood Flow Restriction band|Blood Flow Restriction (BFR) band operate by partially occluding arterial blood flow to distal structures, but more significantly impeding venous outflow from under the cuff, thereby also hindering venous return. The compression of vasculature proximal to the skeletal muscle leads to inadequate oxygen supply (hypoxia) within the muscle tissue, resulting in a localized hypoxic environment. Additionally, the reduction in venous blood flow causes blood to accumulate in the capillaries of the occluded limb, often manifesting as visible erythema. This temporary restriction will be maintained for a duration of 8 weeks.
214997912|NCT04518748|DRUG|Yttrium-90|Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)
214997913|NCT04518748|DEVICE|Selective Internal Radiation Therapy|SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres
214997914|NCT04518748|RADIATION|Stereotactic Body Radiation Therapy|3-5 fractions over 1-2 weeks, after Y-90 SIRT
214997915|NCT04518748|DIAGNOSTIC_TEST|PET/CT|Within 3 hours of completing Y-90 SIRT
214997916|NCT04518748|DEVICE|Therasphere|Glass microspheres containing Y-90, administered at day 0 by SIRT
214997917|NCT04818112|BEHAVIORAL|ATVV|A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.
214387003|NCT00084734|DRUG|cisplatin|IV
214387004|NCT00084734|DRUG|docetaxel|IV
214387005|NCT05386251|BEHAVIORAL|BPT/OST|See Arm description.
214387006|NCT05386251|BEHAVIORAL|Peer Support|See Arm description
214387007|NCT04760730|BIOLOGICAL|AZD1222|"Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles (nominal) per dose (unit dose strength \> 0.7 × 10\^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box"
214387008|NCT04760730|BIOLOGICAL|rAd26-S|"Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose (unit dose strength 1 × 10\^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers"
214387009|NCT05032118|DRUG|Ketamine Hydrochloride|Titratable ketamine infusion + low fixed-dose propofol.
214387010|NCT05032118|DRUG|Propofol|Standard of care titratable propofol infusion.
214387011|NCT05425030|DIETARY_SUPPLEMENT|Low-Sodium Salt Substitute|Tata SuperLite low-sodium salt substitute has 30% of the weight of the product replaced with potassium chloride (KCl) which is itself a non-prescription dietary supplement. Each household randomized to the intervention arm will receive one bag (1.5kg) per month to utilize instead of their usual table/cooking salt.
214387012|NCT05425030|BEHAVIORAL|Information/Education|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
214997918|NCT04818112|BEHAVIORAL|Attention control|Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.
214387013|NCT04833101|BIOLOGICAL|recombinant Ad5 vectored COVID-19 vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
214387014|NCT04833101|BIOLOGICAL|RBD-based protein subunit vaccine (ZF2001) against COVID-19|This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
214387015|NCT04833101|BIOLOGICAL|trivalent split influenza vaccine|This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
214387016|NCT01333085|DRUG|carboplatin|
214387017|NCT01333085|DRUG|RAD001|
214387018|NCT01333085|DRUG|paclitaxel|
214387019|NCT01458990|DRUG|Omeprazole|20mg PO BID for 20 days
214387020|NCT03603392|OTHER|Physical activity program|
214387021|NCT00873301|PROCEDURE|vestibulectomy|Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
214387022|NCT01743690|BIOLOGICAL|Probiotic lactobacilli reuteri|
214387023|NCT01743690|DRUG|Nystatin|
214387024|NCT01743690|DRUG|fluocinolone|
214393908|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV hydration multiplier|Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
214393909|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV sugar-free hydration multiplier|Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
214393910|NCT00109928|DRUG|cisplatin|
214393911|NCT00109928|DRUG|etoposide|
214393912|NCT00109928|DRUG|gemcitabine|
214393913|NCT00109928|DRUG|methylprednisolone|
214393914|NCT00003944|BIOLOGICAL|filgrastim|
214393915|NCT00003944|DRUG|carboplatin|
214393916|NCT00003944|DRUG|cyclophosphamide|
214393917|NCT00003944|DRUG|paclitaxel|
214393918|NCT00003944|DRUG|topotecan hydrochloride|
214393919|NCT00003944|PROCEDURE|peripheral blood stem cell transplantation|
214393920|NCT01196104|DRUG|Technosphere® Insulin Inhalation Powder|
214393921|NCT01196104|DRUG|Insulin Aspart|Usual Care
214393922|NCT01196104|DRUG|Insulin Glargine|
214393923|NCT02676986|DRUG|Enzalutamide|Anti-androgen
214393924|NCT02676986|DRUG|Exemestane|Hormonal therapy (Licenced)
214393925|NCT06359795|DIAGNOSTIC_TEST|18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT|Patients underwent 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT scans within 10 days.
214393926|NCT00471575|PROCEDURE|ultra sound examination|
214393927|NCT02688374|OTHER|Treatment A: Nicorette 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicorette
214393928|NCT02688374|OTHER|Treatment B: Nicotinell 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicotinell
214393929|NCT02688374|OTHER|Treatment C: Nicotinell 2 mg coated fruit flavor gum|Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
214393930|NCT06385912|PROCEDURE|lymphadenectomy|Systematic pelvic and para-aortic lymphadenectomy during IDS in lymphadenectomy group
214393931|NCT01023737|DRUG|Hydroxychloroquine|The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
214393932|NCT01023737|DRUG|Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
214393933|NCT06179589|DIETARY_SUPPLEMENT|VS002A|Amino acid based, glucose free ORS
214393934|NCT02478086|DIETARY_SUPPLEMENT|use amine acids parenteral 3.5g|"Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
214393935|NCT02478086|DIETARY_SUPPLEMENT|use amine acids parenteral 4g|"Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
214387025|NCT00986115|DRUG|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
214387026|NCT00986115|DRUG|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
214387027|NCT01442272|DRUG|Hidroferol®|Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
214387028|NCT01442272|DRUG|Paricalcitol: Zemplar®|Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
214387029|NCT01442272|DRUG|Habitual medication|Habitual medication
214387030|NCT06488391|BEHAVIORAL|Using a Portable Visualized Device for Self-Directed Breathing Training|Using a Portable Visualized Device for Self-Directed Breathing Training
214997919|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 1|Administration of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
214387031|NCT01086566|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
214387032|NCT02467413|DRUG|BAC|(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
214500449|NCT06951971|DRUG|dose-modified E-Ru|Emapalumab (1-2 mg/kg intravenously once weekly for 8 weeks) + Ruxolitinib (15-30 mg orally twice daily for 8 weeks)
214997920|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 2|Administration of concentration 2 of AAV2-hAQP1 via Stensen's duct to each parotid gland
214997921|NCT05926765|OTHER|Placebo|Administration of diluent via Stensen's duct to each parotid gland
214997922|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 3|Administration of concentration 3 of AAV2-hAQP1 via Stensen's duct to each parotid gland
214387033|NCT02467413|OTHER|BAC Matched Vehicle|BAC Matched Vehicle
214997923|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 4|Administration of concentration 4 of AAV2-hAQP1 via Stensen's duct to each parotid gland
214997924|NCT06174038|DEVICE|Hearing Intervention|"The hearing intervention includes an auditory needs assessment, hearing aid fitting, establishing Bluetooth connectivity from hearing aids to devices such as smartphones and computers, systematic orientation and instruction in device use, and provision and discussion of hearing toolkit materials for self-management and communication strategies. The hearing intervention is person-centered, focusing on identification of individual needs, setting of specific goals, engagement in shared-informed decision-making, and development of self-management abilities. Intervention-centric outcomes (e.g., hearing aid data logging, real ear measures) to verify the best-practices intervention will be gathered at all 5 intervention sessions as well as weeks 16 and 52. Additional visits to troubleshoot hearing aids or address concerns will be scheduled as needed."
214997925|NCT06174038|BEHAVIORAL|Health Education Intervention|"The evidence-based interactive health education program is designed for older adults and addresses chronic disease and disability prevention. Session content will be individualized for each participant based on a key, depending on his/her goals/interests. The curriculum includes didactics, activities, and goal setting led by staff trained/certified to deliver the intervention."
214387034|NCT03603015|DIAGNOSTIC_TEST|Penile cuff test|Comparison of invasive vs non-invasive urodynamics
214387035|NCT00536068|DRUG|Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo|"1. Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days~2. Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days~3. Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days~4. Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days"
214387036|NCT03122262|DRUG|Dolutegravir|DTG 50mg Oral Tablet once daily
214387037|NCT03122262|DRUG|Tenofovir Alafenamide|TAF/FTC 25/200mg Oral Tablet once daily
214387038|NCT03122262|DRUG|Truvada|
214387039|NCT03122262|DRUG|Atripla|
214387040|NCT04141072|DIAGNOSTIC_TEST|Shrunken Pore Syndrome|eGFR Cystatin C ≤ 60% of eGFR Creatinine
214387041|NCT04619342|DEVICE|GSMs-TACE|TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)
214387042|NCT04619342|PROCEDURE|Surgical Resection|Surgical Resection of PVTT
214387043|NCT02690636|RADIATION|radiotherapy|daily fractions, five fractions per week.
214387044|NCT02878213|DEVICE|D700 System|Atrial Fibrillation Ablation Procedure
214387045|NCT05179941|PROCEDURE|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion of the subscapularis tendon change after tenotomy vs peel technique and subsequent intra-operative repair.
214387046|NCT05564741|DRUG|Norepinephrine 1 MG/ML|As proxy for hypotension we record amount of Norepinephrine given during the study time of 30 minutes
214387047|NCT01913639|DRUG|Regorafenib|
214997926|NCT06740370|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
214387048|NCT01913639|DRUG|5-Fluorouracil|
214387049|NCT01913639|DRUG|Leucovorin|
214387050|NCT01913639|DRUG|Oxaliplatin|
214387051|NCT02109796|DEVICE|transcranial Direct current stimulation|
214387052|NCT04887181|OTHER|Teethmate Desensitizer|Powder and liquid contained in the material were mixed. It was applied to the buccal surface of the sensitive tooth. then it was washed away from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
214997927|NCT06740370|DRUG|Lenvatinib|(12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
214387053|NCT04887181|OTHER|Gluma Desensitizer|The material was applied to the buccal surface of the tooth with sensitivity. It was washed with water and removed from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
214387054|NCT04887181|OTHER|Hybrid Bond|It was applied to the buccal surface of the sensitive tooth with an applicator. It was cured with a LED light device. Dentin sensitivity was checked with evaporative air application. The process was repeated until the sensitivity disappeared.
214500450|NCT06951971|OTHER|Salvage treatment and follow-up|1\) for patients who did not respond to the E-Ru regimen after 7 days or who relapsed at any point during treatment, a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP) was administered; 2) for patients diagnosed with lymphoma after enrollment, chemotherapy was initiated; 3) for patients who completed 8 weeks of treatment without recurrence and had no detected HLH-related gene mutations, follow-up was initiated; and 4) for patients who met the criteria for allo-HSCT, allo-HSCT was performed.
215093786|NCT00513396|DRUG|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
215093787|NCT00513396|DRUG|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
215093788|NCT05514249|DRUG|CRD-TMH-001|Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
214387055|NCT04786522|DIAGNOSTIC_TEST|Bioimpedenziometry, Handgrip strenght evaluation|The measurement of body composition was performed using Bioimpedance (BIA 101, Akern srl, Pontassieve (FI), Italy). The handgrip dynamometer (Jamar, Sammons Preston, Bolingbrook, IL, USA) was used to determine the isometric force of the forearm.
214387056|NCT04786522|DIAGNOSTIC_TEST|Evaluation on blood specimens|Serum samples were assayed for calcium, phosphorus, magnesium, iron, lactate dehydrogenase (Ldh), creatine phosphokinase (Cpk), creatine kinase myocardial band (Ckmmb), myoglobin, thyroid stimulating hormone (TSH), 25(OH)-Vitamin D, osteocalcin, bone alkaline phosphatase (b-ALP), C-terminal telopeptide of type I collagen (CTX-I), haptoglobin, sclerostin, myostatin, and Irisin. Irisin serum concentrations were detected using a competitive ELISA kit (AdipoGen, Liestal, Switzerland)
215093789|NCT05793606|PROCEDURE|Deltoid ligament repair|Surgical repair for the deltoid ligament
215093790|NCT06252441|DRUG|Rectal Diclofenac|100 mg Rectal Diclofenac Before ERCP
215093791|NCT06252441|DRUG|Oral N-acetyl cysteine|1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
215093792|NCT02401204|OTHER|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected."
215093793|NCT03149952|OTHER|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
215093794|NCT01494519|PROCEDURE|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
214387057|NCT03706911|DRUG|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
214387058|NCT04985734|DIAGNOSTIC_TEST|Specific diagnostic work-up for ATTR-CM patients|Technetium-scintigraphy
214387059|NCT00264472|DRUG|ADH300004|5 mg
214387060|NCT05269537|RADIATION|Transthoracic Echocardiography|Measurement of cardiac output in supine position with left lateral tilt at baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection
214387061|NCT05269537|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 25-gauge spinal needle
214387062|NCT05269537|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
214387063|NCT05269537|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
214387064|NCT05269537|DRUG|Crystalloid Coload 1000 mL|Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
214387065|NCT05269537|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision and uterine exteriorization
214387066|NCT05269537|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
214387067|NCT05269537|DRUG|Oxytocin|Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
214387068|NCT05542732|DEVICE|CardioWatch 287-2|CardioWatch 287-2 (CW2 Test Device or CW2). This medical device is based on the precursor CardioWatch 287-1 approved by EU-MDR under number 20M00011CRT01, CW2 has two red, two infrared and two green LEDs, and two photosensors compared to its precursor.
214387069|NCT00493337|BEHAVIORAL|advanced adherence counseling+reminder|
214387070|NCT00493337|DEVICE|Compliance Card|
214387071|NCT05083624|BEHAVIORAL|rehabilation therapy|After comprehensive assessment by doctors, nurses and rehabilitation therapists, patients gradually begin rehabilitation treatment.IMS 0: no mobilisation or passively exercised by staff. IMS 1: sitting in bed and actively exercising .IMS 2: passively moved to chair without standing.IMS 3: sitting over edge of bed.IMS 4: standing in front of bed.IMS 5: transferring bed to chair.IMS 6: marching on spot.IMS 7: walking with assistance of more than one person.IMS 8: walking with assistance of one person.IMS 9: walking independently with a gait aid.IMS 10: walking independently without a gait aid.
214997928|NCT06740370|DRUG|PD-1 Inhibitors|Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
214997929|NCT03896737|DRUG|Daratumumab plus Velcade Cyclophosphamide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
214387072|NCT00974519|DRUG|Fuzheng 3|"Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
214387073|NCT00974519|DRUG|Fuzheng 1|"Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
214387074|NCT00974519|DRUG|Placebo|"Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
214387075|NCT05477706|OTHER|Personalized Support for Progress (PSP)|Personalized Support for Progress (PSP) is a Peer Specialist delivered intervention in which a peer supports Veterans in prioritizing their needs and attaining access to the Veterans' preferred services.
214387076|NCT05477706|OTHER|Tailored Referral (TR)|TR consists of detailed resource information and referral, consistent with standard practice.
214387077|NCT00886262|DRUG|Vasopressin|Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
214387078|NCT00886262|DRUG|Normal saline placebo|Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
214387079|NCT01610232|DEVICE|Photon stimulation by light-emitting diodes (LEDs)|Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
214387080|NCT01610232|OTHER|Treadmill training|Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
214393936|NCT00865475|DRUG|AZT+3TC+ABV (Trizivir)|Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
214997930|NCT03896737|DRUG|Velcade Thalidomide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
214997931|NCT06424275|DIAGNOSTIC_TEST|Risk-based screening algorithm|Risk-based screening algorithm
214997932|NCT06067399|DIAGNOSTIC_TEST|Glycated hemoglobin (HbA1C)|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
214997933|NCT06067399|DIAGNOSTIC_TEST|RDW|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
214997934|NCT06067399|DIAGNOSTIC_TEST|Lipid profile|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
214387081|NCT03959592|DRUG|Lutein, zeaxanthin and mesozeaxanthin|The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
214500451|NCT06950996|OTHER|Risk in prostate cancer|the prediction involves the classification of the prostate cancer according to the level of prostatic antigen (PSA), the biopsy classification of the aggressiveness of the tumour, and also the localisation of the tumour
214500452|NCT06950996|OTHER|Life expectancy in lung cancer|Clinicians will evaluate life expectancy in lung cancer using CTs, together with some clinical information.
214387082|NCT03959592|OTHER|Placebo|This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
214387083|NCT05164497|OTHER|Deliberate practice training|"The experimental condition consists of five weeks of deliberate practice training of non-specific psychotherapy skills organized as (1) classroom training and (2) homework. The classroom training consists of 15 hours (5 days x 3 hours) of deliberate practice training. Each day will be organized around a theme: (a) Empathy, (b) establishing the therapeutic alliance, (c) working with alliance ruptures, (d) formulation of an interpersonal focus, and (e) clinical expertise - a synthesis. The training will include theoretical introductions, students defining individual training goals, model responses of good psychotherapeutic skills, and student role-play. Regarding homework, after each of the five classes, the students will use Theravue to watch and respond to three therapy videos related to the theme of the previous class. The students have to deliver at least two new responses to each video informed by feedback from teachers and peers and a checklist describing a good response."
214387084|NCT05164497|OTHER|Theoretical teaching|The control condition will consist of five weeks of theoretical teaching of non-specific psychotherapy skills performed as (1) classroom teaching and (2) homework. Regarding classroom teaching, the 15 hours (5 days x 3 hours) of teaching will be organized around the same five themes as the experimental condition (see points a-d above). The class will consist of the teacher's presentation of theory and research findings, videos with master therapists defining core concepts, and group discussions of literature. Regarding homework, the participants will read literature and use a restricted version of Theravue to complete home assignments where they record their answers to three theoretical questions related to the theme of the preceding classroom teaching.
214387085|NCT03343405|BEHAVIORAL|Online Mind/Body Program for Fertility|The Mind/Body intervention involves (1) reducing physical symptoms of stress, (2) enhancing lifestyle behaviors related to fertility, (4) self-nurturing and coping skills, and (5) relaxation methods.
214387086|NCT03716622|DRUG|Furazolidone|bismuth-furazolidone-containing quadruple regimens
214500453|NCT06950996|OTHER|Histological subtype|An assessment by pathology of the subtype of breast tumour
214997935|NCT05997342|DRUG|TQB3912 tablets|TQB3912 is a small molecule Phosphorylated protein kinase inhibitor. Activation of the pathway plays an important role in cell survival, proliferation, migration, and differentiation.
214997936|NCT06321068|DRUG|carboplatin|the usage and dosage should be determined by the investigator
214997937|NCT06321068|DRUG|Paclitaxel|the usage and dosage should be determined by the investigator
214997938|NCT06321068|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
214997939|NCT06142383|BIOLOGICAL|Placebo|S.C. Injection
214387087|NCT03716622|DRUG|Clarithromycin|bismuth-clarithromycin-containing quadruple regimens
214387088|NCT05771584|DRUG|AST-301|100 μg
214500454|NCT06950996|OTHER|Staging of colon cancer|classify size, lymph node involvement and possibility of metastasis in medical images (computerized tomosynthesis) of thorax and pelvis region
214500455|NCT06950996|OTHER|invasion in rectum cancer|assess whether vascular extramural o mesorectal fascia has been invaded in the tumour using magnetic resonance medical images taken at diagnosis in the pelvic region
214500456|NCT06951633|OTHER|Subterranean, pulmonary rehabilitation|Pulmonary rehabilitation in the underground Health Resort of the 'Wieliczka' Salt Mine
214500457|NCT06950528|BEHAVIORAL|Control group|Control Group consists of six motion videos, including: crossover steps, high knees, lateral raises, punching movements, downward leg punches from a standing position, and elbow-to-chest expansions
214997940|NCT06142383|BIOLOGICAL|XXB750 Low dose|S.C. Injection
214997941|NCT06142383|BIOLOGICAL|XXB750 Medium Dose|S.C. Injection
214997942|NCT06142383|BIOLOGICAL|XXB750 High Dose|S.C. Injection
214997943|NCT06142383|DRUG|Sacubitril/valsartan|Tablet
214997944|NCT05323149|OTHER|Saline|Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
214997945|NCT05323149|DRUG|Tranexamic acid|Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
214997946|NCT03135327|DIETARY_SUPPLEMENT|Ocufolin|Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.
214997947|NCT06976892|DRUG|Dose Level 2 (starting dose)|Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 300 mg P.O. (days1-7, 15-21)
214997948|NCT06976892|DRUG|Dose Level 1|Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 200 mg P.O. (days1-7, 15-21)
214997949|NCT06976892|DRUG|Dose Level -1|Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 150 mg P.O. (days1-7, 15-21)
214997950|NCT06976892|DRUG|Dose Level 3|Idetrexed: 12 mg/m2 I.V. (days 1 \& 8) Olaparib: 200 mg P.O. (days1-7, 15-21)
214997951|NCT06976892|DRUG|Maximum Tolerated Dose|MTD of Olaparib in combination with idetrexed established from Dose Escalation
214997952|NCT04275648|DIAGNOSTIC_TEST|AsthmaTuner exercise field test|AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
214997953|NCT03006068|DRUG|Upadacitinib (ABT-494)|Upadacitinib (ABT-494) will be administered orally.
214997954|NCT03006068|DRUG|Placebo|Placebo will be administered orally.
214387089|NCT05771584|DRUG|rhuGM-CSF|100 μg
214387090|NCT04070053|OTHER|TheraPPP Pathway|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
214387091|NCT06023355|PROCEDURE|HYBRID|It involves the combination of a sternal sparing left internal mammary artery (LIMA) bypass and percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for non-left anterior descending (LAD) lesions. Through minimally invasive surgical techniques, HCR carries the potential for faster recovery postoperatively, fewer in-hospital complications, and lower utilization of healthcare resources, while providing the key benefits of LIMA-LAD grafting.
214387092|NCT04263090|DRUG|Rigosertib|Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).
214387093|NCT04263090|DRUG|Nivolumab|Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).
214387094|NCT01790321|DEVICE|LSF-filtering device|LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 NTU turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
214387095|NCT02498730|BEHAVIORAL|Interval Training|High Intensity Interval Training at 100% VO2Max
214387096|NCT02498730|BEHAVIORAL|Continuous Training|Continuous Stimulous at 60% VO2Max
214387097|NCT02498730|BEHAVIORAL|Control|Only Dependent Variables Measures
214387098|NCT06106074|DRUG|Tolebrutinib|Tablet, oral
214387099|NCT06106074|DRUG|Placebo|Tablet, oral
214500458|NCT06950528|BEHAVIORAL|Kinect group|Kinect Group features the same software functionality and design as the application based on bullet-screen cameras, but the hardware is built using a Kinect sensor. The gamified platform is primarily developed and presented using Unity software. The Kinect 3D motion-sensing camera incorporates real-time dynamic capture and image recognition capabilities, offering new possibilities for interactive approaches to motion therapy
214500459|NCT06950528|BEHAVIORAL|Monocular group|The game employs a virtual avatar to replicate users' movements, thereby fostering an immersive and engaging experience. A monocular camera captures users' movements in real time, which are analyzed through pose estimation algorithms and subsequently mapped onto the virtual avatar. Users interact with the game by following on-screen visual demonstrations, presented as either static images or animations, to perform the prescribed exercises. Movement accuracy is evaluated by the system, with scores awarded based on performance. To enhance user motivation and adherence, the game incorporates a reward system, where points earned through accurate execution can be redeemed for in-game rewards, such as unlocking background music, avatar customization options, and new virtual environments.
214687819|NCT03484533|BEHAVIORAL|HIV self-test kit|Women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
215093795|NCT01494519|PROCEDURE|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
215093796|NCT01803867|DRUG|rHIgM22|Administered via IV infusion
215093797|NCT01055483|DRUG|panobinostat/LBH589B|
215093798|NCT04044976|DRUG|Caffeine Citrate|Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
215093799|NCT03871972|DRUG|Umbilical Cord Blood Unit|3 infusions of umbilical cord blood (UCB) unit (TNC \> 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
214387100|NCT02660762|DRUG|Vincristine|induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years
214387101|NCT02660762|DRUG|Daunorubicin|induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；
214387102|NCT02660762|DRUG|Pegaspargase|induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
214387103|NCT02660762|DRUG|Prednisone|induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years
214387104|NCT02660762|DRUG|Intrathecal Methotrexate|induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
214387105|NCT02660762|DRUG|Cyclophosphamide|induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29
214387106|NCT02660762|DRUG|Cytarabine|induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41
214387107|NCT02660762|DRUG|6-Mercaptopurine|induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years
214387108|NCT02660762|DRUG|Methotrexate|Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
214387109|NCT02660762|DRUG|Etoposide|consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5
214387110|NCT02660762|DRUG|dexamethasone|consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28
214387111|NCT02660762|DRUG|thioguanine|consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42
214387112|NCT02660762|DRUG|intrathecal cytarabine|50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
214387113|NCT01245868|DRUG|Lidocaine|
214387114|NCT01245868|DRUG|bupivacaine|
214387115|NCT00114309|DRUG|131-I-TM-601|131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
214387116|NCT00114309|DRUG|131I-TM601|131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
214387117|NCT06115902|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
214500460|NCT06950333|OTHER|POCUS education curriculum|The training includes a 4-hour curriculum consisting of a 1-hour didactic session covering ultrasound principles and key applications, followed by 3 hours of hands-on practice using standardized models or phantoms under instructor supervision. Core scanning topics include Focused Assessment with Sonography for Trauma (FAST), lung ultrasound for dyspnea, carotid Doppler for suspected stroke, and focused cardiac ultrasound for cardiac arrest. Post-training assessments include a written test and an Objective Structured Clinical Examination (OSCE).
214687820|NCT03484533|BEHAVIORAL|Standard of Care (invitation letters for fast-track HIV testing in the clinic)|In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
214997955|NCT06395285|DRUG|DF-003|140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.
214997956|NCT05092542|BEHAVIORAL|Refugee and Immigrant Well-being Project (RIWP)|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
214997957|NCT03829384|BIOLOGICAL|mRNA-1944|mRNA encoding Chikungunya antibody
214997958|NCT03829384|OTHER|Placebo|Saline
214997959|NCT06417047|OTHER|Hand Holding|During the intramuscular injection, the aim is to draw the patients' attention elsewhere by holding their hand.
214997960|NCT00576537|BIOLOGICAL|Dendritic Cell Immunotherapy|Patients will receive four vaccines.
215093800|NCT02472236|DRUG|PEX168|200µg,injected subcutaneously,once a week.
214387118|NCT02562963|BIOLOGICAL|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10\^9 NKT cells in one course of treatment.
214387119|NCT02496403|BEHAVIORAL|Standard Medical Management (SMM)|SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
214387120|NCT02626702|OTHER|Observational|Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
214387121|NCT00002499|DRUG|asparaginase|
214387122|NCT00002499|DRUG|cytarabine|
214387123|NCT00002499|DRUG|daunorubicin hydrochloride|
214387124|NCT00002499|DRUG|dexamethasone|
214387125|NCT00002499|DRUG|methotrexate|
214387126|NCT00002499|DRUG|prednisone|
214387127|NCT00002499|DRUG|vincristine sulfate|
214387128|NCT00002499|RADIATION|radiation therapy|
214387129|NCT04454762|DRUG|Cabozantinib|oral administration (40 mg daily, reduced dose 20 mg daily)
214387130|NCT06007482|DRUG|ES009|ES009 is administered via intravenous infusion, once every 21 days.
214387131|NCT06547398|RADIATION|Adaptive radiotherapy +/- Margin Reduction|Radiotherapy using adaptive technology to recontour and replan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
214387132|NCT06547398|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for prostate cancer
214387133|NCT04986982|DRUG|Opicapone 50 mg|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
214387134|NCT04986982|OTHER|Placebo|Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
214387135|NCT05298098|DRUG|Hypertonic Saline Solution|Patients receive intravenous infusion of HSS (50ml of 10% NaCl) + Furosemide ( 250mg of furosemide) administered over one hour twice a day.
214387136|NCT05298098|DRUG|Placebo|Patients receive intravenous infusion of 5% Dextrose Solution (50ml of Dextrose 5%) + Furosemide (250mg of furosemide) administered over one hour twice a day.
214387137|NCT01155661|DRUG|LY2216684 (edivoxetine)|12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
214387138|NCT01155661|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
214387139|NCT01860014|DRUG|Poractant alfa|Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
214997961|NCT04428749|DIAGNOSTIC_TEST|Yale Swallow Protocol|The YSP is a three-step method consisting of an assessment of the patient's awareness, the patient's ability to follow simple instructions and finally the patient's ability to drink 90 ml water from a cup or by straw without stopping, choking or coughing.
214997962|NCT04428749|DIAGNOSTIC_TEST|FEES (fiberoptic endoscopic evaluation of swallowing)|"The FEES will be performed bedside by an experienced occupational therapists. The patient will be sitting upright in a chair and be given 1) 2 spoons of applesauce, 2) 2 spoons of water, 3) several sips of water, 4) 90 ml of water. All items colored blue.~The FEES will use a single-use AMBU rhino-laryngo scope slim and the AMBU monitor. the examination will be terminated in case of aspiration below the vocal cords."
215093801|NCT02472236|DRUG|Digoxin|0.5mg,oral,two times.
215093802|NCT00952614|DEVICE|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
215093803|NCT04023682|DRUG|Provodine Hand Sanitizer|Intervention with Provodine
214387140|NCT01860014|DRUG|Beractant|Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
214387141|NCT02901145|DRUG|Nivolumab,low dose cyclophosphamide|treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
214387142|NCT04513678|BEHAVIORAL|ImmunOncoTool Condition|Immunotherapy education + irAE monitoring + Facilitation of patient-provider communication
214387143|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 low dose
214387144|NCT01370005|DRUG|BI 10773|BI 10773 high dose once daily
214387145|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 low dose
214387146|NCT01370005|DRUG|BI 10773|BI 10773 low dose once daily
214387147|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 high dose
214387148|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 high dose
214387149|NCT00773058|DRUG|hydrocortisone|hydrocortisone 100mg q8h
214387150|NCT00773058|DRUG|placebo|normal saline 100ml q8h
214387151|NCT00641758|DRUG|Pycnogenol|Pycnogenol 100mg twice daily
214387152|NCT00641758|DRUG|Placebo|Placebo 100mg twice daily
214387153|NCT01317290|DIETARY_SUPPLEMENT|n-3 PUFA free olive oil|negative control
214387154|NCT01317290|DIETARY_SUPPLEMENT|linseed oil|
214387155|NCT02568332|BIOLOGICAL|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
214387156|NCT02568332|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
214387157|NCT04301440|DEVICE|The emission of electromagnetic with the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
214387158|NCT04301440|DEVICE|The emission of electromagnetic without the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
214387159|NCT04248842|DEVICE|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor (Meditech Blue BP-05), Nonin WristOx 3150 as well as departments standard monitors
214387160|NCT02302066|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
214387161|NCT02302066|BIOLOGICAL|TDV Placebo|Placebo-matching vaccine
214387162|NCT00412035|DRUG|Botulinum toxin A injection|10 units per kilo to maximum of 400 units
214387163|NCT00412035|DRUG|saline injection|10 units per kilo to maximum of 400 units
214387164|NCT02069769|BEHAVIORAL|communication with oncology team|Oncology team will contact patients and families via telephone at specific intervals
214387165|NCT05570682|PROCEDURE|TCI|General anesthesia will be induced with a TCI pump
214997963|NCT02717650|OTHER|A-STEP|"Study A) Study A) Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).~Feasibility/safety of a newly designed, incremental, maximal, standardised step test in adults with Cystic Fibrosis."
214997964|NCT02717650|OTHER|A-STEP (New Protocol)|Study B) Validation Study (random allocation of test order). Validity of an incremental, maximal, standardised incremental step test with breath-by-breath gas analysis using portable metabolic measurement equipment against CPET.
214997965|NCT02717650|OTHER|Comparator: CPET cycle ergometer (Gold Standard)|"Study B) Validation study (random allocation of test order) Gold standard CPET. An incremental, maximal standardised cycle ergometer exercise test (performed as per published protocol) using portable metabolic measurement equipment."
214387166|NCT05570682|PROCEDURE|Manual induction|General anestehsia will be induced and maintained using a pro kilo regimen.
214387167|NCT06480799|DIETARY_SUPPLEMENT|Fibre intervention|Inulin fibre (5g) and Pectin fibre (15g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
214387168|NCT06480799|DIETARY_SUPPLEMENT|Placebo intervention|Maltodextrin (10g) served as a control/ placebo to compare the effects observed with inulin and pectin.
214387169|NCT02586337|DRUG|Anlotinib|Anlotinib p.o. qd
214387170|NCT02586337|DRUG|Placebo|Placebo p.o. qd
214387171|NCT00385554|DRUG|UC-781 carbomer gel, 0.1% and 0.25%|
214387172|NCT06112223|DRUG|Gabapentin|Patients will receive oral gabapentin 600 mg 1 hour before the surgery.
214387173|NCT06112223|DRUG|Tramadol|Patients will receive oral tramadol 100 mg 1 hour before the surgery.
214387174|NCT01632943|DEVICE|Symplicity renal denervation system|"Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.~A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator."
214387175|NCT02139423|OTHER|CMV PCR|
214387176|NCT02698449|PROCEDURE|transcranial direct current stimulation|intensity provided will be 2 milliampere during 20 minutes using 2 electrodes (7x5cm). Anode electrode will be located on the right prefrontal dorsolateral area; cathode electrode will be located on the left supraorbital area.
214387177|NCT02698449|PROCEDURE|Specific cognitive rehabilitation|Specific cognitive rehabilitation will be personalized regarding the cognitive complaint and will include a training part and an ecological part.
214387178|NCT02698449|PROCEDURE|Nonspecific cognitive rehabilitation|Nonspecific cognitive rehabilitation will be focused on representation of body in space.
214387179|NCT02698449|PROCEDURE|transcranial direct current stimulation sham|the same operation that transcranial direct current stimulating but it is a sham surgery
214387180|NCT02698449|RADIATION|functional Magnetic Resonance Imaging n-back task|the n-back cognitive task was developed : 3 runs will be provided (0-back, 1-back and 2-back), each will be composed of 8 activation blocks and 8 resting blocks alternatively presented.
214387181|NCT02529878|DRUG|S1/Paclitaxel chemotherapy plus Apatinib|S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
214387182|NCT00381355|PROCEDURE|Written Action Plan for Acute Asthma|
214387183|NCT00371852|DRUG|lactoserum|
214387184|NCT00119925|BEHAVIORAL|patient education|patient leaflets about national guideline contents
214387185|NCT00119925|BEHAVIORAL|professional audit and feedback (guideline adherence)|feedback on current practice according to quality indicators
214387186|NCT00119925|BEHAVIORAL|professional education (communication/shared decision making)|educational tools for professionals concerning communication and shared decision making
214387187|NCT00119925|OTHER|information tools|tools and checklists to improve information provision
214387188|NCT03780270|DEVICE|Fluoride Varnish|Fluor Protector S (Ivoclar, 7'700 ppm F-)
214387189|NCT03780270|DEVICE|Curodont Repair|P11-4 (monomeric peptide) - for professional use
214387190|NCT03780270|DEVICE|Curodont Protect|Tooth gel (containing P11-4 assembled to a fibrillary matrix) - for home use (OTC)
215093804|NCT05304429|BEHAVIORAL|nutrition education|Educational sessions with topics that will address the management and prevention of frailty syndrome focusing on protein intake and physical activity
215093805|NCT05304429|BEHAVIORAL|nutritional counseling|nutritional counseling system based on the com-b model through three strategies: goal setting, self-monitoring and social support
214387191|NCT05510635|OTHER|interactive bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The researcher will read the story to the participant and then use the interview guideline to discuss it with him or her one by one. The interview guideline for interactive bibliotherapy is listed according to the mechanism of bibliotherapy, including identification, catharsis, and insight, and additional questions leading a reader to think deeply.
214387192|NCT05510635|OTHER|reading bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The participant can take 20 to 25 minutes to read the story. No one can bother the participant during the intervention.
215093806|NCT05226611|OTHER|Counterstrain|Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
215093807|NCT04185506|BEHAVIORAL|DBT+BWL|DBT skills include a focus on emotion regulation, distress tolerance, and mindfulness techniques. BWL includes a focus on monitoring of food intake, calorie reduction, and dietary and physical activity education.
215093808|NCT00077844|DRUG|Enoxaparin sodium|
214387193|NCT02021539|PROCEDURE|Cervical ultrasound +elastography 1|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
214387194|NCT02021539|BIOLOGICAL|Vaginal fibronectin measurement|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
214387195|NCT02021539|DRUG|Tocolytic treatment for 2 hours|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
214393937|NCT00865475|DRUG|Switching to LPV/r monotherapy (Kaletra)|Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
214393938|NCT00014950|PROCEDURE|CF newborn screening|
214393939|NCT04592328|OTHER|Bacterial cultures taken during surgery.|Cultures taken from skin, subcutaneous tissue, surigal materials and surgical gloves at incision and after two hours.
214393940|NCT02856919|DRUG|brimonidine tartrate|Mirvaso® gel (5 mg/g brimonidine tartrate)
214393941|NCT00983619|DRUG|MEDI-551|MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
214393942|NCT00983619|DRUG|Rituximab|Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
214393943|NCT03772314|DRUG|Modafinil|Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.
214393944|NCT03772314|DRUG|Amphetamine-Dextroamphetamine|Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.
214393945|NCT00749619|OTHER|Catheter Lock Solution Taurolidine and Citrate|
214393946|NCT00749619|OTHER|Catheter Lock Solution :Taurolidine and Citrate and Heparin|
214393947|NCT00749619|OTHER|Catheter Lock Solution : Heparin|
214387196|NCT02021539|PROCEDURE|Cervical ultrasound +elastography 2|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
214387197|NCT00004438|DRUG|leuprolide|
214387198|NCT06380634|BEHAVIORAL|Experimental group- Motivational Interview|Pregnant women who applied to the gynecology clinic and met the inclusion criteria were informed about the study. Those who agreed were informed about the purpose of the research. Firstly, the Informed Volunteer and Introductory Information Form was applied to the women, then the Personal Care Products Use Evaluation Form, Self-Efficacy Scale and Endocrine Disruptors Attitude Scale were applied. Then, the experimental group was informed about the motivational interviewing technique. A total of 3 interviews were held. The final test was made at the fourth meeting.
214387199|NCT06017674|PROCEDURE|Intra-articular Pulsed Radiofrequency|A 22-gauge 10 cm radiofrequency cannula with a 10-mm active tip was advanced to the mid-tibiofemoral joint under fluoroscopic guidance. After needle insertion, paresthesia-pain and motor stimulation tests were performed using sensory (50 Hz) and motor (2 Hz, 1 V) stimulation to confirm the absence of stimulation. Intra-articular Pulsed Radiofrequency (IAPRF) was applied at 45 V voltage for 20 ms pulse width for 360 s, followed by a 480 ms silent phase. The tissue temperature was adjusted to not exceed 42°C.
214387200|NCT06017674|DRUG|Steroid Injection|8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.
214387201|NCT02049710|BEHAVIORAL|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
214387202|NCT02049710|BEHAVIORAL|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
214387203|NCT02765022|DEVICE|Clip closure|Complete clip closure of secondary lesions after the endoscopic mucosal resection
214387204|NCT02765022|PROCEDURE|No clip closure|Observation: no clip closure of secondary lesions after the endoscopic mucosal resection
214500461|NCT05961995|BEHAVIORAL|Heartfulness meditation|Heartfulness meditation is a secular, specific, guided meditation technique that includes progressive relaxation with a concentrated focus on the heart. The HFN meditation will last 30 minutes. There will be a prescribed progressive relaxation technique which will last for \~ 5-10 minutes followed by the heart-based meditation.
214500462|NCT05650736|DRUG|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.
214500463|NCT06952296|DRUG|Dydrogesterone|"The duration of treatment with dydrogesterone is determined by the physician before inclusion in the study and will last for 6 menstrual cycles (Cycle used in the protocol refers to menstrual cycle. 1 cycle is 28 days on average)"
214500464|NCT06951867|DRUG|Tezepelumab|The exposure of primary interest is tezepelumab for severe asthma. Exposure will be assessed based on prescriptions or administrations depending on the data source. A comparable cohort of unexposed patients treated with high-intensity SOC will be identified based on the presence of a trigger exposure (i.e., augmentation or change of the non-biologic high-intensity treatment that does not represent treatment de-escalation) to mirror tezepelumab start in the exposed cohort. Due to the limited knowledge of the cardiovascular profile of biologics, SOC for comparative analyses will only include non-biologic high-intensity treatment.
214500465|NCT06950294|DRUG|High dose inhaled nitric oxide|Inhaled nitric oxide starting at 250-300 ppm, 40min, every 6 hours, from day 1 to day 5
214387205|NCT01283321|DRUG|Human fibrinogen concentrate|4 g IV once, within 30 minutes of ACT \< 155 seconds, post CPB, with evidence of significant microvascular bleeding
214500466|NCT06950294|OTHER|Sham treatment|Sham treatment with nitric oxide delivering and monitoring devices connected as the intervention group
214500467|NCT06950294|OTHER|standard therapy|Standard therapy pneumonia and critical illness
214387206|NCT01283321|OTHER|apheresis platelets|A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT \<155 seconds post CPB with evidence of significant microvascular bleeding.
214387207|NCT05778721|OTHER|respond to questionnaires by telephone|Seasonal Pattern Assessment Questionnaire (SPAQ) questionnaires and Sachs bipolarity index and Idiopathic Hypersomnia (IH) severity score
214387208|NCT05492812|OTHER|Sedation and Nursing Management in EEG Recording in Children|Evaluation of the effect of sedative agents applied during EEG recording in children
214387209|NCT05492812|DRUG|Chloral Hydrate|Chloral Hydrate
214387210|NCT05492812|DRUG|Hydroxyzine|Hydroxyzine
214387211|NCT05492812|DRUG|Melatonin|Melatonin
214500468|NCT06951880|DRUG|AZD4916|AZD4916 will be administered as oral solution.
214500469|NCT06951880|OTHER|Placebo|Placebo will be administered as oral solution.
214500470|NCT06950541|PROCEDURE|Myofascial therapy|The myofascial therapy in the form of Fascial Distortion Model (FDM) method is based on the idea that issues within the musculoskeletal system stem from deformations or distortions in the fascia. Once the type of deformation is identified, a specific technique is employed by the physiotherapist using their hands and pressure. FDM identifies six types of fascial distortions that can cause pain and other musculoskeletal issues. These distortions include triggerbands, continuum distortions, cylinder distortions, herniated triggerpoints, tectonic fixations, and folding distortions.
214687821|NCT03249792|DRUG|MK-2118 (IT)|IT injection
214997966|NCT04020172|DRUG|Dobutamine|intraoperative fluid administration will be guided by cardiac output monitoring
214997967|NCT02406612|DEVICE|X-Seal 6F Vascular Closure Device|
214997968|NCT05186155|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
214997969|NCT06059859|PROCEDURE|Augmented reality robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.
214500471|NCT06950541|PROCEDURE|Deep Tissue Massage|"A deep tissue massage is a therapeutic technique that focuses on realigning deeper layers of muscles and connective tissue. It is particularly beneficial for individuals dealing with chronic pain, muscle tension, or injury recovery.~The physiotherapist uses more intense pressure compared to other massage types, like Swedish massage. The goal is to reach deeper muscle layers to relieve tension and pain. The therapist employs various techniques, including long, slow strokes, deep finger pressure, and friction, also use elbows, knuckles, or forearms to apply pressure to specific areas."
214500472|NCT06951763|OTHER|stretching exrcise|The participants will receive stretching exercises program for 45 minutes, 3 days/week for 4 weeks.
214387212|NCT00721643|DIETARY_SUPPLEMENT|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
214387213|NCT00721643|DIETARY_SUPPLEMENT|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
214387214|NCT06000982|DRUG|PTCY|PTCY as 40mg/kg or 50mg/kg at day +3 and +4 for GVHD prophylaxis
214387215|NCT03762629|BEHAVIORAL|Exercise|Subjects were provided with energy-restricted diets of 1300-2200 kcal/day based on weight. The energy percentages provided by protein, fat and carbohydrate were 20%, 20% and 60%, respectively, while energy distributions at breakfast, lunch and dinner were 30%, 40% and 30%, respectively. Subjects performed a series of endurance exercise such as bicycling, walking, running, dancing and ball games for 5 hour/day, supplemented with resistance exercise. Training interventions were performed 5-6 day/week for 6 weeks. The exercise program was designed to result in an energy expenditure of 1500-2500 kcal/day.
214387216|NCT02415998|PROCEDURE|TEE|Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
214387217|NCT06204562|BEHAVIORAL|imitated laughter practice|"To imitate laughter, participants will practice Duchenne smile, which is reported to associate with positive emotion in people producing it If participants cannot imitate a Duchenne smile, they can hold a chopstick horizontally in their mouth tightly. To help timing the 3-minute and to enhance adherence, an audio recording with joyous music and vocal instruction will be played alongside the practice. Versions with or without laugh voice will be prepared for their preferences. A logbook will be given to each participant to record their practice. To remind participants to practise, a reminder will be made each day through the public announcement system of the respective nursing home, and the audio guide will be played."
214387218|NCT04140825|DEVICE|Resmon PRO FULL|Measurement of lung impedance by the Forced Oscillation Technique
214500473|NCT06951763|OTHER|myofascial release|The participants will receive the same stretching exercises program in addition to myofascial release of cesarean scar, abdominal fascia, diaphragm and psoas muscle for 30 minutes session twice a week for two weeks.
214500474|NCT06036316|BEHAVIORAL|Language assessment|"The proposed speech and language therapy assessment will consist of a battery of standardized tests that speech and language therapists can use to assess the language skills in reception and expression of adult patients.~Concerning the assessment of the interactions between working memory and semantic abilities, a complete protocol has been developed."
214500475|NCT06036316|BEHAVIORAL|TLC - Scale for the Assessment of Thought, Language, and Communication|This scale is frequently used in psychiatry and is used to measure formal thought disorders in patients suffering from psychosis. As part of this study, it will be intended for patients suffering from schizophrenia
214500476|NCT06036316|BEHAVIORAL|MINI - Mini International Neuropsychiatric Interview|This scale corresponds to a rapid assessment of the psychiatric and psychological state of patients. It helps detect any psychiatric disorders. Here, it will be offered to volunteers who are part of the control group.
214687822|NCT03249792|DRUG|MK-2118 (SC)|SC injection
215093809|NCT05777239|PROCEDURE|Dental Implant Approach for Crestal Sinus Elevation|Crestal Sinus Elevation by elevating the sinus membrane with a blunt ended dental implant approach
215093810|NCT00237263|DRUG|Entacapone|
215093811|NCT03495791|OTHER|YouTube Video|Educational Video
215093812|NCT00569868|DRUG|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
214387219|NCT04902417|OTHER|Dairy Foods (Yoghurt, Cheese, Milk)|Participants will be provided with a combination of dairy products (Yoghurt, Cheese, Milk) to be consumed daily, for a total of 3 servings per day
214387220|NCT04052191|BIOLOGICAL|MCRcI® stem cells|Intra-Coronary Administration of MCRcI® stem cells
214687823|NCT03249792|BIOLOGICAL|Pembrolizumab|IV infusion
214687824|NCT04702711|OTHER|No intervention|No intervention
214687825|NCT02284906|DRUG|Pioglitazone|Pioglitazone tablets
214687826|NCT02284906|DRUG|Placebo|Pioglitazone placebo-matching tablets
214687827|NCT03415477|DRUG|Denosumab (Xgeva)|Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.
214387221|NCT04850287|BEHAVIORAL|Digital Sensors for Population Awareness about Health Issues using Social Media|A clustered randomized control trial will be conducted and ZIP Codes from each demographic environment will be randomly assigned to control and intervention arms. Digital educational materials about organ donation will be exposed to online users in social media belonging to ZIP Codes assigned to the intervention arm
214387222|NCT04727476|DRUG|Lisdexamfetamine|Prescription of lisdexamfetamine sometime during til period from 1 April 2013 to 5 November 2019.
214500477|NCT06036316|COMBINATION_PRODUCT|CAST - Cannabis Abuse Screening Test|The purpose of this questionnaire is to approximate participants' cannabis consumption and to assess any disorders associated with cannabis consumption. It will be offered to all participants, patients and healthy controls
214500478|NCT04985539|DEVICE|Verily Study Watch|Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
214500479|NCT06371534|DRUG|QL2109|subcutaneous injection 3-5 min D1 (Day 1, single dose)
214387223|NCT00874432|DRUG|angiotensin converting enzyme inhibitor|Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
214500480|NCT06371534|DRUG|DARZALEX FASPRO®|subcutaneous injection 3-5 min D1 (Day 1, single dose)
214500481|NCT03896815|DRUG|INCB054329|
214500482|NCT05937594|GENETIC|Buccal swab saliva for further genetic testing|Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
214500483|NCT05179499|DRUG|Norepinephrine|Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
214500484|NCT05179499|OTHER|Balanced Crystalloid|IV fluids administered as per standard care
214500485|NCT05385588|OTHER|cognitive functional assessment|"* Self-administered questionnaire~* Cognitive and functional tests~* Medical questionnaire~* Sampling for biobank (28-32 ml will be collected)"
214500486|NCT06280885|BEHAVIORAL|Exercise|Participants will be randomised to either the FIERCE exercise programme involving supervised exercise prescription
214387224|NCT00874432|DRUG|lisinopril|1 x 40 mg per day
214500487|NCT06280885|BEHAVIORAL|Health Behaviour Change (Pedometer)|Participants in both arms will be provided with a pedometer as a health behaviour change intervention
214500488|NCT05611931|DRUG|Selinexor|Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
214500489|NCT05611931|DRUG|Matching Placebo for selinexor|Dose:60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
214500490|NCT01563185|DRUG|800 mg ibuprofen/26.6 mg famotidine|Oral tablet taken three time per day
214500491|NCT02259855|DRUG|Tipranavir|
214500492|NCT02259855|DRUG|Ritonavir|
214387225|NCT03713021|DEVICE|TraceIT Tissue Marker|The maximum injection volume of TraceIT hydrogel, for a single location, is 1mL.
214500493|NCT02259855|DRUG|Pegylated interferon|
214500494|NCT02259855|DRUG|Ribavirin|
214500495|NCT05994833|BEHAVIORAL|VPT|The VPT will be comprised of weekly virtual visits with the participant for one month. During the visits, the physical therapist will review the exercises that were prescribed, adherence, provide feedback to the participant as they execute the exercises onscreen and make corrections, make any progression or adjustments to the exercises, review running cues they learned from the testing session and answer any questions. The therapist will also review any new activities that are initiated during the previous week (to control for confounders), changes in musculoskeletal pain and participation in running volume.
214500496|NCT02843191|DRUG|Chemotherapy|5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
214500497|NCT06544291|DRUG|CBD 300mg|3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.
214500498|NCT06544291|DRUG|CBD 600mg|6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.
214500499|NCT06544291|DRUG|Placebo 0mg|6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.
214500500|NCT06264258|BEHAVIORAL|DVx-T1D™ app|The intervention group will be introduced to the DVx-T1D™ app and the participants will go home with the tablets that has the game installed. Participants will be asked to play the game for 20 mins or more daily. The aim of the app is to impart good behavioral changes in children with T1D in terms of diabetes education, on how to treat a low or a high blood sugar event and make healthy eating choices.
214500501|NCT04577651|DEVICE|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with 16-contact Directional Lead
214500502|NCT05480709|BEHAVIORAL|Psychocardiological Rehabilitation|Psychocardiological Rehabilitation: Regular cardiac rehabilitation with in-depth psychological and psychotherapeutic care, individual and group counseling, relaxation training, and interdisciplinary specialist psychiatric and psychosomatic visits.
214500503|NCT02076906|DEVICE|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
214500504|NCT06202079|DRUG|GZR4 Injection|GZR4 injection s.c., once-weekly, treat-to-target dose
214500505|NCT06202079|DRUG|Insulin Degludec|Insulin Degludec s.c., once-daily, treat-to-target dose
214500506|NCT06271330|DRUG|Faricimab|switch from previous anti-VEGF agents to faricimab
214387226|NCT05390398|BEHAVIORAL|Behaviour change guided lifestyle intervention|Participants in the intervention group receive personalized coaching from a lifestyle coach on adhering to the World Cancer Research Fund cancer prevention guidelines. The lifestyle coach is specialized in behaviour change techniques and uses these as the core of the lifestyle coaching. For each participant behavioural determinants will be assessed and targeted with specific applicable behaviour change techniques.
214387227|NCT01759615|OTHER|Early Enteral feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
214387228|NCT01759615|OTHER|Late enteral feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
214997970|NCT06059859|DEVICE|Mixed reality intraoperative frozen section analysis|Microsoft Hololens head-mounted display system will be used for inking prostate margins during intraoperative frozen section analysis
214387229|NCT05555160|DEVICE|PICC|Peripheral central venous catheterization (PICC) is mainly applied to patients with medium and long-term intravenous infusion, infusion of stimulant drugs and intermittent infusion of chemotherapy drugs. It is a catheterization technology to place PICC through peripheral veins and make its tip reach the central vein
214387230|NCT01076283|DRUG|Baclofen|Baclofen 10mg t.i.d.
214387231|NCT01076283|DRUG|Cyproheptadine|'active' placebo
214387232|NCT06396754|OTHER|AI-analysis on diagnostic and surgical specimens|The analysis will report a list of AI-based biomarkers to assess the tumour-immune spatial microenvironment as well as final spatial immune-ecology prognostic (SIPA) reports for every patient.
214387233|NCT04999371|BEHAVIORAL|Brief Alcohol Intervention|"The participants in the treatment group received free three-time counsel and constant multi-media messages about the topic of alcohol consumption for three months. One-to-one counseling services will be provided via a telephone call, which is based on World Health Organization (WHO) recommendations. A total of three counsels are conducted, which are set on the second week, sixth and tenth week after the baseline survey.~Brief intervention counselors are from the team of this study and trained by Hongkong University. All counselors are required to attend a full-day workshop before participant recruitment. The contents of the workshop include (1) knowledge of excessive drinking harms and benefits of controlling drinking; (2) overview of AUDIT; (3) alcohol reduction advice; (4) a standard procedure of brief intervention."
214387234|NCT04999371|BEHAVIORAL|Financial Incentive Intervention|The participants in financial Incentive intervention group were conducted by deducting money. Firstly, a certain amount of vouchers were given to the participants, which was equivalent to the reward for passing seven tests. Then, the voucher would be deducted according to every test result. Finally, the participants will receive cash according to the vouchers.
214387235|NCT06819319|DRUG|SHR-A2102 ; Adebrelimab injection|SHR-A2102 is administered intravenously, Adebrelimab is administered intravenously
214387236|NCT02671383|DRUG|Darunavir|Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
214387237|NCT02671383|DRUG|Lopinavir|Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
214387238|NCT06658340|BEHAVIORAL|Positivity in Post-COVID|A training to support well-being and self-management in patients with post-COVID-19 syndrome
214387239|NCT06661057|DEVICE|Vivally system stimulation|During the first month, participants will do the stimulation at different time points: 1) supine while in bed, 2) seated in the morning, 3) sitting in the afternoon, and 4) sitting in the evening. Participants will measure the circumference of their ankle prior to each use. Participants will use the System for an additional 2 months with the preferred stimulation parameters based on the study team's recommendations from the first month of use.
214387240|NCT03692715|DRUG|Ciprofloxacin|Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.
214500507|NCT00840047|DRUG|Methionine|Intravenous injection
214997971|NCT06059859|PROCEDURE|Robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction.
214997972|NCT01744821|DIETARY_SUPPLEMENT|Arm A: Vitamin D3 Group|
214387241|NCT03692715|DRUG|Placebo|identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
214387242|NCT01369134|DEVICE|Adper Easy Bond Self-etch dental adhesive|Bonding composite to restore Class I or Class II cavities
214387243|NCT06594679|DRUG|Niraparib Tosylate Monohydrate|Combination of niraparib and abemaciclib
214387244|NCT04235582|BEHAVIORAL|App + Inputs Contingency Management|The app has programmed contingencies whereby incentives can be earned for behaviors that are inputs to abstaining from drug use (e.g., attending psychotherapy or taking SUD psychopharmacology).
214387245|NCT04235582|BEHAVIORAL|App + Outcomes Contingency Management|The app has programmed contingencies whereby incentives can be earned for outcomes of abstaining from drug use (e.g., drug-negative saliva samples on saliva opioid tests).
214387246|NCT04991506|DRUG|ES102|The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
214387247|NCT04991506|DRUG|JS001|JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
214387248|NCT06613126|BEHAVIORAL|Symptom Management APP group|Based on symptom management theory and the relevant literature, the researcher designed a symptom management APP. The APP includes a symptom recording system, symptom management skills, and Tourette Syndrome knowledge information to facilitate parents' and children's joint learning.
214997973|NCT01744821|DIETARY_SUPPLEMENT|Placebo|
214997974|NCT01060176|DRUG|Tranexamic Acid|
214997975|NCT01060176|DRUG|Saline Solution|
214997976|NCT04608630|DRUG|Denosumab 60 MG/ML|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
214997977|NCT04608630|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.
214387249|NCT06613126|OTHER|health education instructions group|To receive outpatient verbal and paper health education guidance from healthcare providers.
214387250|NCT06291155|DRUG|SGLT2 inhibitor|All participants will be receive 100 mg/daily doses of Canagliflozin (INVOKANA) for 6 months. Canagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor
214387251|NCT03861507|DEVICE|Prostate Brachytherapy|High dose - rate (HDR) brachytherapy
214387252|NCT02763683|RADIATION|PiB and VAT|There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
214387253|NCT02269761|DEVICE|Nuvis Diagnostic Ultrasound System|Ultrasound of the chest
214387254|NCT06860529|DRUG|Serplulimab|Serplulimab is administered intravenously
214387255|NCT06860529|DRUG|Epirubicin|Epirubicin ivgtt
214387256|NCT06860529|DRUG|Albumin Paclitaxel|Albumin Paclitaxel ivgtt
214387257|NCT03367936|BEHAVIORAL|One-on-one Session|Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
214387258|NCT03367936|BEHAVIORAL|Self-monitoring|Participants will receive an orientation on how to self-monitor using the smartphone and other devises
214387259|NCT03367936|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
214387260|NCT06617104|OTHER|no intervention|no intervention
214387261|NCT06623214|DEVICE|nebulyft|Micro Radiofrequency Skin Treatment Device(nebulyft)
214387262|NCT06625840|DRUG|MK-1167|Oral Administration
214387263|NCT06625840|DRUG|Placebo|Oral Administration
214387264|NCT06624397|OTHER|CAREFREE Carer's Programme|This programme was developed to provide carers with an opportunity to develop an understanding of Anorexia from a Biopsychosocial framework, taking into account the complex array of biological, psychological and social/environmental factors associated with the development and maintenance of this disorder. CAREFREE programme is unique in its focus on providing a framework for understanding AN from a Schema - Compassion Focused framework, incorporating psychoeducation in regard to both Anorexia Nervosa and Carer Burnout. The programme has a relational focus, with an emphasis on improving emotional fluency, family communication skills and self-other compassion.
214387265|NCT06624683|DEVICE|Intelligent footbath basin|before night sleep, takes 30 mins, starting from the first day of the menstrual cycle (MC) and continuing for 28 days.
214500508|NCT05723107|DRUG|Chemotherapy|Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
214500509|NCT05723107|DEVICE|Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)|"EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes."
214500510|NCT05357144|BEHAVIORAL|Loyalty card program at drug shops & supply of HIVST and SRH products|"Consenting drug shops will receive:~* training on Malkia Klabu implementation;~* HIVST training (same as comparison drug shops);~* procedures for referring to youth-friendly HIV/SRH services;~* a monthly supply of HIVST reserved for free distribution to AGYW, with free price stickers and pre-packaged with referral information; and~* reimbursement for SRH products given to AGYW (e.g., birth control pills)."
214500511|NCT05357144|BEHAVIORAL|Comparison drug shops|Consenting drug shops in the comparison arm catchment areas will have access to the Maisha Meds inventory management application system for offline digital recording of HIVST, HIVST kits earmarked for free to AGYW, guidance on HIV care referral plan to facilitate linkage to nearby health facilities for AGYW. These control drug shops will not participate in Malkia Klabu (Queen Club) program implementation.
214500512|NCT03935750|PROCEDURE|Anterior cruciate ligament reconstruction (ACLR)|All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.
214387266|NCT00079456|DRUG|temsirolimus|Given IV
214387267|NCT00079456|OTHER|pharmacological study|Correlative studies
214387268|NCT00079456|OTHER|laboratory biomarker analysis|Correlative studies
214387269|NCT06625814|DRUG|Levothyroxine|single oral dose
214387270|NCT06625814|DRUG|Enlicitide Decanoate|single oral dose
214387271|NCT03478462|DRUG|CLR 131|IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
214387272|NCT05669573|PROCEDURE|Early feeding group|Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories.
214387273|NCT05669573|PROCEDURE|Standard fasting group|Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period.
214387274|NCT03190681|DRUG|Ritalin 10Mg Tablet|oral ingestion of 3 tablets in a single-dose
214387275|NCT03190681|DRUG|Placebo Oral Tablet|oral ingestion of 3 tablets in a single-dose
214387276|NCT02867657|BEHAVIORAL|Mindfulness|Five days MBSR curriculum with meditation and yoga
214387277|NCT06700226|DEVICE|AblaView® Unipolar PFA System|Patients with symptomatic paroxysmal atrial fibrillation will be treated with the AblaView® Unipolar PFA System system to achieve electrical isolation of the pulmonary veins. The AblaView® Unipolar PFA Catheter is a regular PFA irrigated catheter. The tip of the catheter has 7 holes distributed around that deliver at the same time irrigation and near infrared light for the OCR system, which will be processed and interpreted by the Console.
214387278|NCT05597956|PROCEDURE|white defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
214500513|NCT03935750|PROCEDURE|Lateral extra-articular tenodesis (LET)|Participants randomized to the BPTB or QT arms will be randomized a second time to a LET procedure or no additional surgery.
214997978|NCT04608630|DRUG|Sodium Chloride 0.9% or 5% Dextrose Intravenous|Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
214387279|NCT05597956|PROCEDURE|yellow defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
214387280|NCT05597956|PROCEDURE|brown defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
214387281|NCT03391960|DEVICE|Passive disinfection device|Add use of passive disinfection cap to existing central line needleless connector infection control procedure
214387282|NCT06715007|DRUG|Clopidogrel|Patients will take Clopidogrel
214387283|NCT06715007|DRUG|Aspirin|Patients will take Rivaroxaban
214387284|NCT06715007|DRUG|Cilostazol + Isosorbide Mononitrate|Patients will take Cilostazol plus Isosorbide Mononitrate
214387285|NCT06886737|OTHER|Virtual-reality convergence training game|The participant plays a custom virtual-reality game that is designed to train convergence.
214387286|NCT06889207|BEHAVIORAL|Physical exercise prehabilitation|Patients in the intervention group will have two supervised training sessions per week for eight weeks in group sessions supervised by a physiotherapist.
214387287|NCT06925308|BEHAVIORAL|Conversation|The design consists of two parts. In the first part, the researcher will have a conversation (with a formal and informal phase, where the subject will be given the idea that only the formal part is part of the study) with an adult with ASD during which covert recordings of the subject's eye behavior will be made, and in addition skin conductance and duration/frequency of eye contact of the subject will be recorded, without the subject knowing that this is intended for the purpose of studying eye contact. In the second part, the researcher and subject will watch the covert recording of the subject's eye behavior, during which the subject's skin conductance will be recorded and details of the subject's behavior as seen by the researcher.
214387288|NCT06925347|OTHER|medical adhesive tape|After the patients were assigned to the control and experimental groups, the tube of the patient in the control group was fixed with acrylic medical adhesive tape, and the tube of the patient in the experimental group was fixed with silicone medical adhesive tape.
214500514|NCT06023043|DRUG|Dexamethasone|Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
214500515|NCT03955627|BEHAVIORAL|Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)|Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks conducted by Zoom video, followed by an 8-week home-based version of the same program participants do on their own with bi-weekly coaching calls.
214500516|NCT03602859|DRUG|Niraparib|Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)
215093813|NCT06329024|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214997979|NCT04608630|DRUG|Sodium Chloride 0.9% Injection|Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180
214997980|NCT06078540|OTHER|USeeBP|"USeeBP is a low risk mobile medical app that proposes to do no more than:~* Help patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions;~* Provide patients with simple tools to organize and track their health information;~* Provide easy access to information related to patients' health conditions or treatments;~* Help patients document, show, or communicate potential medical conditions to health care providers;"
214997981|NCT06386042|OTHER|no intervention, observational study|no intervention, observational registry of the prescription of medical therapy according to the European Society of Cardiology Heart Failure guidelines (quality of care).
214997982|NCT02751905|DRUG|BIIB074|Administered orally as specified in treatment arm
214997983|NCT01143012|OTHER|Group eczema education session|Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
214997984|NCT01143012|OTHER|Control group|The control group will not attend the group eczema education session.
214387289|NCT06925386|DRUG|Standard therapy|The standard therapy for participants included a structured skincare regimen. A face wash was used once daily before bedtime to cleanse the skin. In the morning, a non-comedogenic sunscreen and a moisturizer were applied to protect and hydrate the skin. Additionally, a night cream containing clindamycin and tretinoin was applied once daily at night, specifically on acne-affected areas, to target inflammation and promote skin renewal.
214387290|NCT06925386|DIETARY_SUPPLEMENT|HEXBIO|The oral probiotics given are Hexbio®, an oral probiotic containing multiple beneficial bacterial strains, including Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium longum BCMC® 02120, and Bifidobacterium infantis BCMC®02129. This probiotic was administered in granule form and swallowed directly. Participants consumed the probiotic twice daily, after breakfast and dinner, for eight weeks to support gut microbiome balance and potential skin health benefits.
214387291|NCT06925386|BIOLOGICAL|Secretome|The topical secretome used is a hydrogel-based serum containing secretome components, including cytokines, growth factors, exosomes, microvesicles, and cell differentiation factors. The serum is formulated with a hydrogel base consisting of xanthan gum, sclerotium gum, 1% alginate, 2% glycerin, 1% caprylyl glycol, and 96% aqua. It is applied after cleansing the face with a facial cleanser, twice daily, in the morning and evening, for eight weeks
214387292|NCT06926569|DRUG|Amphotericin B|After enrollment, participants will be 1:1 randomly assigned into two groups for induction therapy after informed consent: single high-dose L-AmB group (10 mg/kg single intravenous dose of L-AMB) and control group (amphotericin B deoxycholate(AmBD) at 0.5-0.7 mg/kg/d intravenously for 14 days as the standard of care recommended by local guidelines).Thereafter, all participants in both groups will start consolidation therapy within 24 hours of the induction treatment, 200mg itraconazole(or voriconazole) q12h will be given for 10 weeks. After consolidation therapy, all participants will take oral itraconazole 200mg qd as secondary prophylaxis until their CD4+ cell counts are higher than 100cells/mm3 for at least 6 months. For the antiretroviral therapy, all participants will start B/F/TAF qd within 7 days after initiating antifungal therapy
214387293|NCT06926569|DRUG|AmBisome|After enrollment, participants will be 1:1 randomly assigned into two groups for induction therapy after informed consent: single high-dose L-AmB group (10 mg/kg single intravenous dose of L-AMB) and control group (amphotericin B deoxycholate(AmBD) at 0.5-0.7 mg/kg/d intravenously for 14 days as the standard of care recommended by local guidelines).Thereafter, all participants in both groups will start consolidation therapy within 24 hours of the induction treatment, 200mg itraconazole(or voriconazole) q12h will be given for 10 weeks. After consolidation therapy, all participants will take oral itraconazole 200mg qd as secondary prophylaxis until their CD4+ cell counts are higher than 100cells/mm3 for at least 6 months. For the antiretroviral therapy, all participants will start B/F/TAF qd within 7 days after initiating antifungal therapy.
214387294|NCT06734351|DEVICE|NOA VOLUME|Subcutaneous and/or Supraperiosteal Plane Injection
214387295|NCT06734351|DEVICE|VOLUMA XC|Subcutaneous and/or Supraperiosteal Plane Injection
214387296|NCT01919996|DRUG|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
214500517|NCT03602859|DRUG|Dostarlimab (TSR-042)|Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
214500518|NCT03602859|DRUG|Standard of care|Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
214687828|NCT04093739|DEVICE|G7 Freedom Constrained Liners|Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
214687829|NCT03181165|BEHAVIORAL|Low-carbohydrate Therapeutic Nutrition|The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
214687830|NCT00124267|DRUG|Intrarectal quinine|
214997985|NCT05660785|DRUG|Herombopag|"Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT.~Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA."
214997986|NCT00778180|DRUG|furosemide 80 mg tablets|
214997987|NCT05220345|DEVICE|colonoscopy assisted by both balloon-Behind The Folds visualizing and Computer assisted detection (CADe)|All participants will be subjected to a colonoscopy procedure, assisted by both G-eye balloon and the Discovery CADe system. Standard of care regarding the colonoscopy procedure will be applied to all study subjects. Any lesions detected during the procedure will be removed directly
214997988|NCT06651359|BEHAVIORAL|Surveys for Quality of Life|This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL).
214997989|NCT06651359|BEHAVIORAL|Surveys and mHealth App access|"This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL). Additionally, they will have a brief initial study visit, in-person or virtually, to review the app use. This arm of participants will use the mobile application at home for 12 months. During the first 12 weeks, the application will send daily surveys about symptoms, dietary and physical activities, weekly surveys about their mood, and an assessment of their overall QoL every 3 months. The app will provide tailored educational content, including short readings, videos, and audio recordings, to help users learn more about managing symptoms and improving their functioning. After 12 months of app use, an interview will be conducted to gather feedback about their experiences with the app. The information collected from these interviews will be analyzed to further enhance and improve the app's functionality."
214997990|NCT04667585|RADIATION|De-escalated radiation dose|Reduced dose of radiation applied to remaining radiation therapy when favorable interim PET-CT signature is produced
214997991|NCT04667585|RADIATION|Standard radiation dose|Standard dose of radiation applied to remaining radiation therapy when favorable PET-CT signature is not produced
214997992|NCT04667585|OTHER|18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)|The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
214997993|NCT05379556|DIAGNOSTIC_TEST|Assessment of andrological profile of LO-COCO-ANDRO male patients|"Assessment of serum prolactin (PRL), luteininzing hormone (LH), follicle stimulating hormone (FSH), 17β-estradiol, testosterone. Physical examination with measurement of body weight, height, body mass index, waist and hip circumference. Andrological physical examination with evaluation of testis volume with Prader orchidometer, testicular consistency and lesions, varicocele. Scrotal ultrasound performed in longitudinal, transverse and oblique scans using a high frequency linear probe with grayscale and color-doppler; transrectal prostate ultrasound performed with transverse, longitudinal and oblique scans using an end fire probe; basal penile ultrasound will be performed in longitudinal and transverse scans using a high frequency linear probe with grayscale and color-doppler; dynamic penile ultrasound performed as described for basal penile ultrasound after intra-cavernous infiltration of 10 mcg of prostaglandin-E1 (PGE1)."
214387297|NCT01413672|DEVICE|Use of CASTLE barrier|Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
214387298|NCT02358798|OTHER|3 years-assessment of respiratory function|
214387299|NCT03150927|DIETARY_SUPPLEMENT|Probiotic Microbial Composite|125mg (or 250 mg) of BiOWiSH Probiotic Microbial Composite™ is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
214387300|NCT03150927|DIETARY_SUPPLEMENT|Placebo|125mg (or 250 mg) of Placebo is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
214387301|NCT06130813|OTHER|increased perioperative communication program|Thanks to this communication program, informative content (8 times) will be shared with patients.
214387302|NCT06900972|DRUG|Gelafundin|Volunteers will undergo a comprehensive transthoracic echocardiography to measure left ventricular torsion, global longitudinal strain, left atrial strain and free wall right ventricular strain before any intervention. Initially, 500 ml of the specified but blinded solution will be administered, followed by a repeat of the echocardiographic process. Subsequently, an additional 500 ml will be given, totaling 1000 ml, and strain curves will be reacquired. After a washout period of 7 days, the same procedure will be repeated with the second solution.
214387303|NCT06900972|DRUG|Saline (NaCl 0,9 %) (placebo)|Volunteers will undergo a comprehensive transthoracic echocardiography to measure left ventricular torsion, global longitudinal strain, left atrial strain and free wall right ventricular strain before any intervention. Initially, 500 ml of the specified but blinded solution will be administered, followed by a repeat of the echocardiographic process. Subsequently, an additional 500 ml will be given, totaling 1000 ml, and strain curves will be reacquired. After a washout period of 7 days, the same procedure will be repeated with the second solution
214387304|NCT06900907|DEVICE|Diode laser|A single session was applied to three points of the tooth extraction site.
214687831|NCT04653909|OTHER|Rehabilitation|The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
214387305|NCT06900907|COMBINATION_PRODUCT|Hyaluronic acid|1 cc of hyaluronic acid gel was placed into the extraction socket, followed by suturing.
214387306|NCT06900907|COMBINATION_PRODUCT|Ozone|Topical ozone was applied to the extraction socket, followed by suturing.
214500519|NCT03602859|DRUG|Dostarlimab-Placebo|Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
214500520|NCT03602859|DRUG|Niraparib-Placebo|Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
214500521|NCT05562609|DRUG|Tranexamic acid|Ampoules and packaging for all arms will be identical in appearance.
214500522|NCT05562609|OTHER|Placebo|Ampoules and packaging for all arms will be identical in appearance.
214687832|NCT02840487|BIOLOGICAL|VRC-ZKADNA085-00-VP|VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
214997994|NCT05379556|DIAGNOSTIC_TEST|Assessment of reproductive function of LO-COCO-ANDRO male patients|Semen samples will be collected on site by masturbation directly into a sterile plastic container after 3-5 days of sexual abstinence. The sample will be analyzed according to World Health Organization (WHO) 2010 guidelines. Semen samples will be stored for biochemical and molecular evaluations.
214997995|NCT05379556|DIAGNOSTIC_TEST|Assessment of sexual function of LO-COCO-ANDRO male patients|Validated questionnaires to assess the prevalence of male sexual disorders, namely erectile dysfunction with International Index of Erectile function 15 (IIEF-15), premature ejaculation with premature ejaculation diagnostic tool (PEDT), hypoactive sexual desire disorder with andrological structured interview on erectile dysfunction (ANDRO-SIEDY). Patients will be also interviewed to evaluate lifestyle habits.
214387307|NCT06900907|DRUG|Methylprednisolone|In addition to the standard prescribed medication, 4 mg of oral methylprednisolone was prescribed postoperatively.
214387308|NCT06900907|PROCEDURE|Control|Only the standard prescribed medication was provided.
214387309|NCT06818032|OTHER|Negative control|Participants will be given a breakfast meal with 76 grams of bread and 60 grams of jam per 2000 daily calories.
214387310|NCT06818032|OTHER|Avocado|Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 84 grams of avocado per 2000 daily calories.
214387311|NCT06818032|OTHER|Fat and fiber addition|Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 13 grams of fat (mix of high-oleic safflower oil, safflower oil, palm oil, and macadamia nut oil) and 5.5 grams of fiber (mix of cellulose and pectin) per 2000 daily calories.
214387312|NCT06900491|OTHER|self-questionnaires|Patients will fill in these self-questionnaires on a tablet or on paper, depending on the availability of tablets in the centres, before and after consulting the doctor. These questionnaires assess the severity of the disease and quality of life.
214387313|NCT06900491|OTHER|unique collection of saddles|Stool samples will be taken at each visit, i.e. approximately every 6 months for patients
214387314|NCT06900660|DIETARY_SUPPLEMENT|Collagen Drinks|Dosage: 50 mL/day; duration: 8 weeks
214387315|NCT06899984|BEHAVIORAL|Patient Navigator|Patient Navigator will provide additional support to participants using their standard of care CGM device.
214387316|NCT06901271|DRUG|EMLA Cream|EMLA cream (2.5 grams) was applied to the treatment area 60 minutes before the procedure and covered with a transparent and impermeable dressing.
214387317|NCT06901271|DEVICE|Buzzy|The buzzy device was placed on the procedure area 60 seconds before the procedure and turned on. The cold and vibration application continued during the procedure.
214387318|NCT06901271|DRUG|Cold spray|Cold spray was applied to the procedure area for 5 seconds from a distance of 15 cm immediately before the procedure.
214387319|NCT06900088|DRUG|Selinexor|maintenance therapy with Selinexor combined with Azacitidine in patients with high-risk myeloid neoplasms after transplantation
214387320|NCT04086953|DIAGNOSTIC_TEST|6-minute walk test|This test is carried out in a 30-meter long walking corridor with two cones placed at the ends of the course and representing the turning zones
214500523|NCT06000410|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
214500524|NCT06000410|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
214500525|NCT04192773|DRUG|IV Lidocaine|IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
214500526|NCT06505759|DRUG|Bromelain gel|bromelain gel is prepared from bromelain capsules in laboratory
214500527|NCT06505759|DRUG|chlorhexidine gel|chlorhexidine gel is prepared from mouth wash
214500528|NCT06505759|PROCEDURE|SRP|Scaling and root planing was done with ultra sonic and hand scaling
214500529|NCT06075966|OTHER|Non-fusion group|Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
214387321|NCT04086953|DIAGNOSTIC_TEST|Walk-Time Limit Tes|Endurance test where the patient must walk at the same speed during the whole test (time limit). The test is carried out in a corridor 10 meter long.
214500530|NCT06075966|OTHER|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University
214687833|NCT02053272|DRUG|GWP42004|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
214687834|NCT02053272|DRUG|Placebo|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
214687835|NCT05701969|DIETARY_SUPPLEMENT|Melatonin|Melatonin
214687836|NCT05701969|OTHER|Placebo|Placebo control
214500531|NCT05986773|DRUG|Furosemide|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
214387322|NCT04086953|DIAGNOSTIC_TEST|Incremental shuttle walk test|Incremental walking test suitable for patients with chronic respiratory diseases. To perform this test, it is necessary to have a 10-meter walking corridor. The walking speed is dictated by a sound signal previously recorded. Every minute, the time between each beep is decreased and therefore the walking speed increased. The increment is 0.17m / sec every minute. Shifting to a higher speed is indicated by a triple beep. At most, the ISWT includes 12 speed levels.
214387323|NCT04086953|DIAGNOSTIC_TEST|Endurance shuttle walk test|"Constant load endurance running test performed on the same 10 meter run as the ISWT.~The patient is walking at a constant speed imposed by the audio beeps as for the ISWT. The objective of this test is to maintain the imposed walking speed as long as possible. The speed is calculated from the ISWT."
214500532|NCT05986773|DRUG|Metolazone|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
215093814|NCT06329024|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
214500533|NCT05986773|DRUG|Acetazolamide|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
214500534|NCT04202133|BEHAVIORAL|WW (formerly Weight Watchers)|The WW intervention will consist of weekly group workshops for 16 weeks with WW Coaches and Guides.
214500535|NCT04202133|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered the WW intervention
214500536|NCT04069754|BEHAVIORAL|Adapted Passport to Freedom|5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections.
214500537|NCT05507151|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
214500538|NCT06294795|PROCEDURE|congenital/pediatric cataract surgery|All procedures are performed under general anesthesia according to the standard technique of congenital/pediatric cataract surgery with an intraocular lens (IOL) implantation. Paracentesis is performed at 2.30 o\&#39;clock using a 20-gauge straight microvitreoretinal (MVR) knife; a high molecular weight ophthalmic viscosurgical devices (OVD) is injected into the anterior chamber. Then a 2.4 mm corneal tunnel incision is made at 11 o'clock with a disposable keratome knife 2.2 mm. Circular continuous capsulorhexis (≈ 5.5 mm). Сortical cleaving hydrodissection is followed by bimanual phacoaspiration in irrigation-aspiration mode. OVD is injected in the anterior chamber and an IOL is implanted in the capsular bag. Residual OVD is aspirated from the anterior chamber and behind the IOL and followed by IOL alignment. The surgery is completed with corneal hydration at the tunnel incision site.
214500539|NCT06294795|DEVICE|Non-Toric IOLs|A folding hydrophobic acrylic IOLs AcrySof IQ SN60WF and Clareon SY60WF for the non-toric group (Alcon Laboratories, Inc.) ARE implanted.
214687837|NCT00138931|PROCEDURE|Blood draw (genetic testing)|Blood draw (genetic testing)
214687838|NCT03127215|DRUG|Olaparib|Olaparib 150 mg tablet
214687839|NCT03127215|DRUG|Physician's choice|treatment according to current guidelines
214687840|NCT03127215|DRUG|Trabectedin|Trabectedin 1.1mg/m² infusional solution
214687841|NCT03632681|DRUG|Intranasal Insulin|Intranasal insulin
214687842|NCT03632681|DRUG|Intranasal Placebo|Intranasal placebo manufactured to mimic smell of insulin
214687843|NCT04017988|DIETARY_SUPPLEMENT|Ethanol Extracts of Porphyra Tenera(PTE10)|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
214687844|NCT04017988|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
214687845|NCT05605379|BIOLOGICAL|Next Generation Sequencing (DNA and RNA)|Targeted Next Generation Sequencing (DNA and RNA)
214687846|NCT02275689|PROCEDURE|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
214687847|NCT02275689|PROCEDURE|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
215093815|NCT03433534|OTHER|Pharmacokinetic of Nivolumab|Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
214687848|NCT03521167|DRUG|Ketamine|"Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.~Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg."
214687849|NCT03521167|DRUG|Lidocaine|Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
214687850|NCT03521167|DRUG|Dexmedetomidine|Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
214687851|NCT03521167|DRUG|Gabapentin|Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for \>65y or if patient having significant sedation/dizziness
215093816|NCT00637572|DRUG|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
215093817|NCT00637572|DRUG|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
214387324|NCT04086953|DIAGNOSTIC_TEST|Respiratory Functional Assessment|Forced vital capacity, total lung capacity, forced expiratory volume measured during the first second of forced expiration, and carbon monoxide diffusion capacity will be measured by plethysmographic examination and spirometry.
214387325|NCT06899399|PROCEDURE|Endovascular treatment|"Participants will receive carotid artery stenting as the primary intervention. The procedure will be performed via femoral artery access (radial access allowed for anatomically challenging cases) with mandatory use of an embolic protection device (EPD). Stent selection and EPD type will be determined by the operator based on lesion characteristics.~Pre-procedural dual antiplatelet therapy (DAPT: aspirin 100 mg/day + clopidogrel 75 mg/day) will be administered for ≥3-5 days. Post-procedural DAPT will continue for 3 months, transitioning to aspirin monotherapy (100 mg/day) thereafter. Statins and risk factor management (blood pressure、LDL-C, glycemic control) will align with standardized protocols."
214387326|NCT06899399|DRUG|Best medical treatment|Participants will receive intensive medical management, including aspirin (75-325 mg/day) or alternative antiplatelet agents (clopidogrel/dipyridamole) for intolerance. Statin therapy and risk factor control targets (blood pressure, lipids, glucose, lifestyle) will mirror the experimental group. Both groups will undergo regular follow-up for adherence monitoring.
214997996|NCT05379556|DIAGNOSTIC_TEST|Assessment of olfactory function of LO-COCO-ANDRO male and female patients|"Brief interview to collect patient's anamnesis relative to olfactory function, with particular reference to hypo / anosmia and hypo/ageusia onset timeline, duration and regression.~Interview for the self-assessment of chemosensory skills and for the evaluation of quality of life in relation to olfactory dysfunction.~Sniffin 'Sticks test for the evaluation of odor threshold (T), odor discrimination (D) and odor identification (I) (TDI score)."
214997997|NCT06815289|RADIATION|MR-informed stereotactic radiotherapy|MR-informed stereotactic radiotherapy for treatment of ultracentral lung tumours utilising a dedicated MR-simulator for daily adaptation followed by CBCT-guided treatment delivery.
214387327|NCT06848894|DRUG|Human urinary kallidinogenase (HUK)|HUK (0.15 PNA) and sodium chloride injection (100ml), once per day
214387328|NCT06848894|DRUG|Placebo|placebo (0 PNA) and sodium chloride injection (100ml), once per day
214387329|NCT06901232|BEHAVIORAL|Mindfulness Training|"All participants will complete a single 45-minute mindfulness training at Visit 2, with a refresher prior to the second mbNF session at Visit 3. Clinically trained study staff will conduct the training with the aim of teaching mental noting, a core mindfulness technique to be practiced and employed during neurofeedback. Mental noting is a major component of Vipassana (insight mindfulness meditation); its key principles include: concentration, observing sensory experience,'' not 'efforting', and contentment.Specifically, participants will be taught to mentally label/note whatever sensation is most prominent in their sensory experience from moment to moment (e.g., seeing, hearing, feeling, thinking). Training will be personalized to identify scenarios in which mental noting can be applied in the context of each person's daily life, explaining the goal of using these strategies to manage distress in daily life."
214387330|NCT06901232|BEHAVIORAL|Active mindfulness-based neurofeedback (Active mbNF)|Before the MRI scan, participants will practice mental noting by verbalizing their mental label with the study clinician providing feedback. Participants will then complete a silent practice of mental noting while viewing simulated neurofeedback. Participants will be trained until they feel competent to use mental noting in the scanner. During active mbNF (6 runs, 2.5 minutes each), participants will use mental noting with the aim of controlling visual feedback. Specifically, they will attempt to move the position of the white dot toward the (upper) red circle and away from the (lower) blue circle.
214387331|NCT06901232|BEHAVIORAL|Sham mindfulness-based neurofeedback|Before the MRI scan, participants will practice mental noting by verbalizing their mental label with the study clinician providing feedback. Participants will then complete a silent practice of mental noting while viewing simulated neurofeedback. Participants will be trained until they feel competent to use mental noting in the scanner. During sham mbNF, participants will view a visual display (white dot, red and blue circles) extracted from a previously acquired mbNF session. The display will be independent from brain activity in the sham condition and will simply mirror the stimuli observed by those in the mbNF group. This ensures participants across groups are viewing equivalent stimuli for the same amount of overall time.
214387332|NCT05965245|BEHAVIORAL|Suubi-Mhealth|Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
214500540|NCT06294795|DEVICE|Toric IOLs|A folding hydrophobic acrylic IOLs AcrySof IQ Toric SN6ATx and Clareon Toric CNW0Tx for the toric group (Alcon Laboratories, Inc.) were implanted.
214500541|NCT03214081|DRUG|Vonoprazan|Vonoprazan tablets
214500542|NCT00466037|BIOLOGICAL|Influenza vaccine|
214500543|NCT02577939|BEHAVIORAL|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
214687852|NCT03521167|DRUG|Tylenol|Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg
214687853|NCT03521167|DRUG|Gabapentin Pill|Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients \>65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea
215093818|NCT00809653|DEVICE|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
215093819|NCT00809653|DEVICE|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
214387333|NCT06900504|OTHER|Sleep hygiene education|A structured training booklet will be prepared to ensure sleep hygiene for individuals. In addition, sleep hygiene training will be provided to individuals.
214387334|NCT06831149|PROCEDURE|Removal of pharyngeal mucosa with decreased perfusion will be performed|Surgical removal of underperfused tissue versus nonremoval of tissue
214387335|NCT06831149|DEVICE|SPY-PHI|SPY Portable Handheld Imaging (SPY-PHI)
214387336|NCT06831149|DRUG|ICG (Indocyanine Green)|ICG will be used in conjunction with the SPY-PHI system for tissue imaging.
214387337|NCT04591977|DEVICE|HPV Self-Sampling Kit (Evalyn Brush)|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
214387338|NCT05164432|DIAGNOSTIC_TEST|MRI scan|Women will have an MRI scan during pregnancy to evaluate the fetus and placenta
214387339|NCT03271034|DIETARY_SUPPLEMENT|Weight loss|Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian and/or behaviorist weekly for \~4 months.
214387340|NCT03148977|PROCEDURE|Graft|Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
214387341|NCT00405353|DRUG|Androgel 10 grams of gel containing 100 mg of testosterone|testosterone gel
214997998|NCT05759338|DEVICE|Revian Red All LED cap|"The cap is a dual-band LED light therapy wireless smart cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women."
214997999|NCT06597006|DRUG|Inclisiran|Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg, inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg to ≥16 kg, or inclisiran sodium 100 mg s.c. for participants with body weight \<16 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
214387342|NCT02556905|DRUG|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
214387343|NCT02556905|DRUG|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
214387344|NCT06927180|DRUG|SHR-A1811|an anti-HER2 antibody-drug conjugate (ADC)
214500544|NCT02915315|DIETARY_SUPPLEMENT|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
214500545|NCT01343797|OTHER|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
214500546|NCT03842605|OTHER|Strength training|
214998000|NCT06597006|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
214998001|NCT04918173|DRUG|Atenativ|Antithrombin concentrate
214998002|NCT06596954|RADIATION|lymphocyte-sparing radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. While maintaining target coverage and traditional OAR (Organs At Risk) dose constraints, also address dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
214998003|NCT06596954|RADIATION|conventional radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. do not limit dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
214998004|NCT06785129|DEVICE|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time
214998005|NCT06785129|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
214387345|NCT06927180|DRUG|Pertuzumab|Pertuzumab
214387346|NCT06927180|DRUG|Albumin-Paclitaxel|Nab paclitaxel
214387347|NCT06927180|DRUG|Docetaxel|Docetaxel
214387348|NCT06927180|DRUG|Carboplatin|Carboplatin
214387349|NCT06927180|DRUG|Trastuzumab|Trastuzumab
214387350|NCT04683809|OTHER|Telerehabilitation|Patients will attend rehabilitation sessions through online programmes for rehabilitation
214387351|NCT03606941|DEVICE|electroacupuncture treatment|"Participants in the electroacupuncture group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of operation."
214500547|NCT00461019|PROCEDURE|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
214387352|NCT03606941|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle until the end of surgery."
214387353|NCT03161860|BEHAVIORAL|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
214387354|NCT00141882|DRUG|memantine|
214387355|NCT04961320|BEHAVIORAL|Occupational Therapy|Participate in OT session
214387356|NCT04961320|OTHER|Questionnaire Administration|Complete questionnaires
214387357|NCT00877903|DRUG|Prochymal®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
214687854|NCT03521167|DRUG|Tylenol Pill|Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
214687855|NCT01013948|OTHER|Non-Interventional|Non-Investigational Product (Survey Study)
214687856|NCT04332640|DEVICE|VERITAS Vision System|The investigators or designees will perform routine small-incision cataract surgery via phacoemulsification and use the VERITAS Vision system. The Investigator or designee will then complete a questionnaire regarding the clinical use of the VERITAS Vision system. The system log files automatically generated by the VERITAS Vision system after completion of each surgery will be collected.
214998006|NCT06785129|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
214998007|NCT06785129|BEHAVIORAL|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
214998008|NCT06785129|BIOLOGICAL|Hormonal assessment|Blood samples (approximately 2 tablespoons) and/or saliva and/or urine will be collected for analyses of sex hormone levels (e.g., prolactin, testosterone, estradiol).
214387358|NCT00877903|DRUG|Placebo|Intravenous infusion of excipients of Prochymal®
214998009|NCT06979362|DRUG|CDR132L|CDR132L will be administered intravenously once every 4 weeks.
214387359|NCT03598218|RADIATION|Hypofraction radiation|"Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
214387360|NCT03598218|RADIATION|Standard dose IMRT|"Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
214387361|NCT04474015|DEVICE|transcranial electric stimulation|NeuroConn® DC Plus stimulator: the NeuroConn® stimulator can be programmed with specific frequencies of stimulation ranging from 0.5 to 500 Hz. This device is therefore appropriate for the present study to stimulate only at 0.75 or 3.0 Hz. Also, the NeuroConn only allows low current intensities to be chosen. The maximum current intensity that can be delivered with this stimulator is 5 milliamps.
214387362|NCT02370290|OTHER|Medical Chart Review|Clinical and imaging information collected
214387363|NCT02370290|OTHER|Informational Intervention|Clinical and imaging data collected
214387364|NCT00747383|DRUG|Glimepiride|3mg oral tablet.
214387365|NCT00747383|DRUG|Sitagliptin|100mg oral tablet.
214387366|NCT00743990|OTHER|Ointment containing camphor, eucalyptus oil, and menthol|One time use
214387367|NCT00743990|OTHER|Petroleum jelly|One time use
214387368|NCT02709642|BEHAVIORAL|Deposit Contract|"A deposit contract (DC) is an agreement in which study participants puts their own money at risk, with the goal of earning it back by achieving a goal, in this case maintaining prior weight loss. If DC participants successfully maintain their weight, they get their money back. If they are not successful, they lose their money. For each 10 week period for one year, DC participants will make a deposit of at least $100 but will be allowed to increase their contribution if they would prefer."
214387369|NCT04361474|DRUG|Budesonide Nasal|Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
214387370|NCT04361474|OTHER|Physiological serum|Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.
214387371|NCT04910087|DIAGNOSTIC_TEST|Sonographic optic nerve sheath diameter measurement|With the linear ultrasound probe operating at 11 MHz in B mode, it will be measured in 2 planes, 3.0 mm behind the optic disc, the transverse plane where the probe is placed horizontally and the sagittal plane where the probe is placed vertically. Then, the average of these measurements will be recorded for both eyes every 10 minutes.
214387372|NCT05456815|OTHER|Standardized diet|During 9 weeks all food products will be standardized and provided by the Research Unit. The standardized diet is based on the average food composition in the Netherlands.
214387373|NCT01158378|DEVICE|Adherus Dural Sealant|In situ polymerizing sealant
214387374|NCT06275932|OTHER|Interventional group|Newborns will be covered with a thermal blanket during skin-to-skin contact in delivery room.
214387375|NCT06275932|OTHER|Standard of care group|Newborns will be covered with a bed wetting mat and cotton sheet during skin-to-skin contact in delivery room.
214387376|NCT02597205|BEHAVIORAL|physician-facing app and patient-facing messages|A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
214387377|NCT05189509|DRUG|TNK-Tissue Plasminogen Activator|0.25 mg TNK thrombolysis
214387378|NCT02892942|DRUG|Gonal-F®|225 to 450 IU/d; from day 2 of menstrual cycle onward
214387379|NCT02892942|DRUG|Cetrotide®|0.25 mg/day, starting on day 6 of Gonal-F®.
214387380|NCT02892942|DRUG|Cetrotide®|1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
214387381|NCT03731130|OTHER|EORTC QLQ C30|standardized questionaire
214387382|NCT03731130|OTHER|EORTC QLQ CR29|standardized questionaire
214387383|NCT03084419|DRUG|Abatacept|"The IV dose varies according to weight:~\<60kg=500mg~≥60 but≤100kg=750mg \>100kg=1g~This equates to approximately 10mg/kg."
214387384|NCT04675112|BEHAVIORAL|Cognitive Behavioral Treatment (CBT) and Tinnitus Retraining Therapy (TRT)|"CBT is a psychologically informed treatment. Depending on individual patient needs, relevant areas of tinnitus education and management/self-management strategies, such as managing the emotional consequences of tinnitus, rapid relaxation, managing fear and avoidance behaviors and changing unhelpful thoughts and beliefs, are applied in accordance to a published manual \[10\].~TRT is based on the neurophysiological model focusing more on education and sound therapy than on analytical cognitive and behavioral interventions. A TRT program is usually included in a management scheme with hearing aids."
214387385|NCT01919463|BEHAVIORAL|Abdominal Compression|Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
214387386|NCT01919463|DEVICE|Guidance of Magnetic Endoscopic Imaging (MEI) System|Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
214387387|NCT02593539|DRUG|Nemiralisib|Participants will be administered nemiralisib
214387388|NCT06208722|BEHAVIORAL|Testing a Mobile App to Improve Toothbrushing Skills and Habits in Teens With Autism|Information provided in arm descriptions.
214387389|NCT00259376|DRUG|Dronedarone (SR33589)|oral administration
214387390|NCT00259376|DRUG|placebo|oral administration
214387391|NCT02701322|BEHAVIORAL|Medical clown|
214387392|NCT00766896|DRUG|Aspirin (platelet sensitive versus platelet hyperreactivity)|"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."
214387393|NCT06043596|BEHAVIORAL|SafeSpace Sexual Health|The overall goal of the program is to prevent adolescent pregnancy and STIs by increasing sexual agency, increasing the use of condoms and contraception, and promoting healthy relationships and healthy life skills among adolescents.
214387394|NCT06043596|BEHAVIORAL|SafeSpace General Health|This arm represents the comparison group. SafeSpace General Health will act as the active comparator, while providing youth with lessons, facts, and resources about general health topics.
214387395|NCT01971320|DEVICE|Urostim I stimulation|Urostim I stimulation will be done during meals for 6 weeks
214387396|NCT03629873|DRUG|Chidamide|Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m\^2 IVD d-6; Etoposide 150mg/m\^2/d qd IVD d-5\~-2; Cytarabine 150mg/m\^2 q12h IVD d-5\~-2; Cyclophosphamide 1.0g/m\^2/d qd IVD d-5\~-2
214387397|NCT01282476|DRUG|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
214387398|NCT04324463|DRUG|Colchicine|oral medication
214998010|NCT06979362|DRUG|Placebo|Placebo will be administered intravenously once every 4 weeks.
214387399|NCT04324463|DRUG|Interferon-Beta|subcutaneous injection
214387400|NCT04324463|DRUG|Aspirin|oral medication
214387401|NCT04324463|DRUG|Rivaroxaban|oral medication
214387402|NCT02328157|DEVICE|Vitrectomy with cataract surgery and toric IOL|
214387403|NCT02328157|DEVICE|Vitrectomy with cataract surgery and common IOL|
214387404|NCT00366860|BEHAVIORAL|Soy bread|
214387405|NCT00743587|DRUG|Placebo|Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
214387406|NCT00743587|DRUG|Oxycodone|Oral, 1 x 20mg controlled-release tablets
214387407|NCT00743587|DRUG|Tramadol|Oral, 2 x 50mg immediate release capsules
214387408|NCT00743587|DRUG|Naproxen|Oral, 1 x 500mg enteric-coated
214387409|NCT03124680|COMBINATION_PRODUCT|Opioid free|Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
214387410|NCT03124680|COMBINATION_PRODUCT|opioid group|Opioid anesthesia will follow the current standard approach of our hospital.
214387411|NCT02377830|DEVICE|In-bed cycle ergometer (Restorative Therapies RT300 Supine)|
214387412|NCT02377830|OTHER|Routine physiotherapy|activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
214387413|NCT01336062|DRUG|Nanoparticle Albumin-Bound Paclitaxel|this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
214387414|NCT02320786|BEHAVIORAL|CoPILOT|Participants in both groups will receive twelve hours of training in a standard powered wheelchair however the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
214387415|NCT03552718|BIOLOGICAL|YE-NEO-001|Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
214387416|NCT03687268|DRUG|Naloxone HCl PR tablets|oral administration
214387417|NCT03687268|DRUG|Placebo Oral Tablet|Placebo
214387418|NCT03847779|OTHER|"Rest"|Cutaneous perfusion and vasomotion assessment at rest in supoine position
214387419|NCT03847779|OTHER|"Exercise"|Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test
214387420|NCT03847779|OTHER|"Foot lowering"|Cutaneous perfusion and vasomotion assessment after foot lowering
214387421|NCT03847779|OTHER|"Hyperthermia"|Cutaneous perfusion and vasomotion assessment during hyperthermia
214387422|NCT00437125|DRUG|Duloxetine hydrochloride|Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
214387423|NCT01542541|DRUG|Rifaximin|550mg BID for 2 days
214387424|NCT01817634|DIETARY_SUPPLEMENT|Fish powder corn-soy blend'+ Fish oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
214387425|NCT01817634|DIETARY_SUPPLEMENT|Fish powder corn-soy blend + corn oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
214387426|NCT01817634|DIETARY_SUPPLEMENT|Corn-soy blend + fish oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
214387427|NCT01817634|DIETARY_SUPPLEMENT|Corn-soy blend + corn oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
214387428|NCT06066489|OTHER|educational program about VAP|An educational program about VAP that includes VAP bundle from CDC as core measures , equipment related measures and general measures.
214387429|NCT03257592|DRUG|[11C]DPA-713|\[11C\]DPA-713 PET imaging
214387430|NCT05012215|PROCEDURE|Paravertebral|Ultrasound-guided paravertebral block
214387431|NCT05012215|PROCEDURE|Caudal block|Caudal block
214387432|NCT01628302|BEHAVIORAL|Lowering salt in diet|Low salt diet (50mmol)for three weeks.
214387433|NCT02468921|PROCEDURE|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
214387434|NCT01935960|OTHER|Laboratory Biomarker Analysis|Correlative studies
214387435|NCT01935960|OTHER|Pharmacological Study|Correlative studies
214387436|NCT01935960|OTHER|Placebo|Given PO
214387437|NCT01935960|DRUG|Retinoid 9cUAB30|Given PO
214387438|NCT06354621|DIETARY_SUPPLEMENT|Vitamin-D supplementation|Participants receiving a daily dose of vitamin D supplementation
214387439|NCT00165295|DRUG|Sildenafil citrate (Viagra)|
214387440|NCT00206960|DRUG|zuclopenthixol|Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
214387441|NCT00206960|DRUG|risperidone|Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
214387442|NCT04048070|DRUG|Flurbiprofen Axetil|One kind of NSAIDs, 200mg for 48 hours after surgery.
214387443|NCT04048070|DRUG|Sufentanil|One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery
214387444|NCT04048070|BEHAVIORAL|Extended perioperative counseling|The extended perioperative counseling contained additional information, including surgery procedures, importance of medicine treatment and medical help to relieve depression and anxiety about disease during peri-operation period.
214387445|NCT04048070|BEHAVIORAL|Shorter fasting food and water time before surgery|The patients in ERAS group were required to fast food for 6 to 8 hours and provided 12.6% maltodextrin carbohydrate supplement beverage for 2 hours before surgery
214387446|NCT04048070|BEHAVIORAL|Conventional perioperative counseling|THe conventional perioperative counseling included the risk of surgery and prognosis of disease and other things patients need to know.
214387447|NCT04048070|BEHAVIORAL|Regular fasting food and water time before surgery|The stricter control of preoperative fasting requirements, prohibiting solids and liquids from previous midnight to operation time.
214387448|NCT00763399|DIETARY_SUPPLEMENT|probiotics (antibiophilus(Lactobacillus casei), bio-three)|probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10\^8CFU/day
214387449|NCT02164162|DEVICE|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assistested Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
214387450|NCT02164162|OTHER|Conventional physical treatment|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation (PNF) concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
214387451|NCT02033460|OTHER|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
214387452|NCT02033460|OTHER|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
214387453|NCT02033460|OTHER|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
214387454|NCT01602952|DRUG|Radotinib|50mg, 100mg or 200mg Capsule BID
214387455|NCT00000611|DRUG|hormone replacement therapy|
214387456|NCT00000611|DRUG|estrogens|
214387457|NCT00000611|DRUG|progestins|
214387458|NCT00000611|DRUG|estrogen replacement therapy|
214387459|NCT00000611|BEHAVIORAL|diet, fat-restricted|
214387460|NCT00000611|DRUG|calcium|
214387461|NCT00000611|DRUG|vitamin D|
214387462|NCT00000611|BEHAVIORAL|dietary supplements|
214387463|NCT05297916|OTHER|enteral feeding|to intake oral feeding or delay it
214387464|NCT06071520|DRUG|Fostamatinib|Patient treated with fostamatinib in the period described
214387465|NCT00649389|DRUG|Olmesartan medoxomil|40mg olmesartan medoxomil
214387466|NCT00649389|DRUG|Amlodipine|Amlodipine 10mg
214387467|NCT00649389|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg
214387468|NCT03177889|COMBINATION_PRODUCT|Traditional Chinese Medicine (TCM)|"Traditional Chinese Medicine plus oral mucolytics \[ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid\];~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g~Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g"
214387469|NCT04662671|DEVICE|RD-X19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
214387470|NCT05245604|DRUG|TJO-087|Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
214387471|NCT05245604|DRUG|Cyclosporine ophthalmic solution 0.05%|Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
214387472|NCT02762344|DRUG|heparin|routinary heparin administration during coronary angiography/PCI
214387473|NCT01742637|DRUG|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
214387474|NCT01742637|DRUG|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
214387475|NCT01742637|DRUG|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
214387476|NCT05451381|DRUG|Propofol|sedation after cardiac surgery
214387477|NCT05451381|DRUG|Dexmedetomidine|sedation after cardiac surgery
214387478|NCT05451381|DRUG|Dexmedetomidine and Propofol|sedation after cardiac surgery
214387479|NCT03378843|OTHER|Spermidine content of natural diet|The exposure consists in the long-term average dietary intake of the polyamine spermidine
214387480|NCT03350113|DEVICE|Blood sampling for analysis|Blood Sampling for Analysis
214387481|NCT05664139|DRUG|Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel|"Recombinant Human Adenovirus Type 5 Injection:①the longest diameter of the lesion≥10mm and≤40mm, inject 1ml into the tumor each time;②the longest diameter of the lesion≥40mm and≤80mm, inject 2ml into the tumor each time. planned injections at D1. Every 3 weeks is a period, a total of 4 cycles; if there are visceral and superficial lesions at the same time, the injection lesions will be selected by the investigator based on possible benefits.~Camrelizumab:200mg/time.Intravenous within 48 hours after injection of recombinant human adenovirus type 5 injection. Every 3 weeks is a period, and the treatment is continued until the subject has disease progression or unacceptable toxicity or death.~Nab-paclitaxel:260mg/m2, D1, every 3 weeks as a period, a total of 4-6 cycles (determined by the investigator), or continue treatment until the subject has disease progression or Intolerable toxicity or death."
214387482|NCT01267825|DRUG|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
214500548|NCT03150875|DRUG|IBI308|Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
214500549|NCT03150875|DRUG|Docetaxel|As 2nd line treatment to subjects with squamous NSCLC
214387483|NCT01267825|DRUG|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
214387484|NCT01806740|DRUG|Gadoterate meglumine|Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
214500550|NCT01372085|DRUG|LY2584702 Reference Formulation|Administered orally
214387485|NCT03935464|BEHAVIORAL|PUMA|Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their adherence with provision of standard adherence counseling.
214387486|NCT05115019|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
214387487|NCT05115019|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
214387488|NCT04059393|OTHER|Internet-Based Intervention|Complete web-based legacy intervention
214387489|NCT04059393|OTHER|Best Practice|Receive standard of care
214387490|NCT04059393|OTHER|Quality-of-Life Assessment|Ancillary studies
214387491|NCT04059393|OTHER|Questionnaire Administration|Ancillary studies
214387492|NCT02049060|DRUG|Tivantinib|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
214387493|NCT03941613|PROCEDURE|SEEG guided RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.
214387494|NCT03941613|PROCEDURE|Anterior temporal lobectomy|classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere
214387495|NCT01562847|DRUG|Nilotinib|Patients will be treated with 800 mg nilotinib daily.
214387496|NCT04666922|DRUG|BI 765080|BI 765080
214387497|NCT04666922|DRUG|Placebo|Placebo; 0.9% saline for injection
214500551|NCT01372085|DRUG|LY2584702 Test Formulation|Administered orally
214500552|NCT01372085|DRUG|Placebo|Administered orally
214387498|NCT06429358|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|The probiotic supplement was delivered in the form of easy-to-swallow capsules.
214500553|NCT00732849|DRUG|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
214500554|NCT00309036|BIOLOGICAL|Recombinant grass pollen|
214500555|NCT00263159|PROCEDURE|Pharmaceutical care for asthma patients|
214500556|NCT00790569|DRUG|nicotine|Given transdermally and orally
214500557|NCT00790569|DRUG|varenicline|Given orally
214500558|NCT00790569|OTHER|placebo|Given orally
214500559|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection|Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.
214500560|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection placebo|Day 1: Tirofiban placebo will be injected at the same rate with experimental group.
214500561|NCT05310968|DRUG|Aspirin|Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
214500562|NCT02316301|DRUG|Long interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
214500563|NCT02316301|DRUG|Short interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
214500564|NCT04612868|DEVICE|AEYE Software Device|"Eligible participants will undergo the following procedures:~* Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis.~* Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis.~* All study subjects will have their pupils dilated using dilation drops."
214500565|NCT01448941|PROCEDURE|Temporary extraarticular plate fixation|Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1
214500566|NCT01448941|PROCEDURE|Primary arthrodesis|Primary arthrodesis
214998011|NCT06982352|DRUG|LPX-TI641|Oral solution administered QD for 28 consecutive days
214387499|NCT06429358|OTHER|Control Group|Participants in the control group were given a placebo that looked, tasted, and felt just like the probiotic pill.
214687857|NCT05356624|OTHER|Mulligan Mobilization|It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week
214998012|NCT06982352|DRUG|Placebo|Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
214998013|NCT05481931|DRUG|prabotulinumtoxinA|Botulinum toxin Type A powder for solution for injection
214998014|NCT06812325|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
214998015|NCT06812325|DRUG|Placebo|Placebo injections that appear identical to VRDN-003 injections but have no active drug.
214998016|NCT04880044|DIAGNOSTIC_TEST|EsoCheck/EsoGuard (EC/EG)|EC is a swallowed capsule on a tethered catheter that obtains a touch sample of the distal esophagus. The obtained sample is placed in a buffer and sent to a diagnostics lab for testing of methylated markers from extracted DNA. EG is a methylated DNA test . A positive EG is associated with Barrett's esophagus at all its stages.
214998017|NCT04880044|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|SOC diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum. Tissue samples collected.
214998018|NCT02745470|DRUG|Lixisenatide|Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)
214387500|NCT02571205|DRUG|Sustanon (testosterone)|Standard incremental regimen of Sustanon
214387501|NCT00153946|DRUG|Edaravone|30mg/20mL vial, twice per day, not longer than two weeks
214387502|NCT05878782|OTHER|MCRO+Occupational therapy|Experimental group A will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.
214387503|NCT05878782|OTHER|MCRO without intervention|Experimental group B will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
214500567|NCT01448941|PROCEDURE|Primary arthrodesis TMT 2 and 3|Primary arthrodesis TMT 2 and 3 when instability is present
214500568|NCT06509607|OTHER|Concentric Lower Limb Training Program|A specially designed 30-minute concentric lower limb training program (squats, lunges and leg extensions) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the coach, 2 days per week for 8 weeks.
214500569|NCT06509607|OTHER|Eccentric Lower Limb Training Program|A specially designed 30-minute eccentric lower limb training program (wall sit, sitting straddle single leg and full squat) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the same coach, 2 days per week for 6 weeks.
214998019|NCT02745470|OTHER|Placebo|Normal saline injection before performing fMRI
214387504|NCT00000343|BEHAVIORAL|counseling|
214387505|NCT03465449|BEHAVIORAL|CKD-EDU|Palliative Care based coaching intervention for support with dialysis-related decision making.
214387506|NCT03465449|OTHER|usual care|Nephrologist based usual care
214387507|NCT05046535|BEHAVIORAL|Sleep quality and physical activity|"Self-reported assessments will be used to measure the following: overall sleep quality, insomnia symptoms, Obstructive sleep apnea.~Physical activity will be measured objectively using the 6MWT, 9HPT, and cardiorespiratory fitness using the VO2 submaximal test on the recumbent stepper."
214387508|NCT05046535|GENETIC|Nicotine dependence|DNA sequencing for 20-25 subjects out of the whole sample will be performed. Sanger sequencing to all subjects will also be performed to identify related genes
214387509|NCT05046535|DIAGNOSTIC_TEST|Nicotine and cotinine serum levels|Cotinine serum level which is a major metabolite of nicotine and the preferred biomarker for measuring tobacco use will be measured together with nicotine levels using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
214500570|NCT05099419|DEVICE|Repetitive Transcranial Magnetic Stimulation|"rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles."
214500571|NCT06030960|DEVICE|Virtual Reality (VR)|Virtual Reality (VR) Stabilization Exercises
214500572|NCT06030960|OTHER|Regular Exercises|Regular Stabilization Exercises
214500573|NCT06030960|OTHER|patient instructions and education|a unified form of patient instructions and education in regards of LBP
214500574|NCT03376659|DRUG|Durvalumab|750mg IV q2 weeks
214500575|NCT03376659|BIOLOGICAL|CV301|"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."
214500576|NCT03376659|DRUG|Capecitabine|1000mg orally twice a day, Monday - Friday Weekly
214387510|NCT05046535|BEHAVIORAL|Smoking|Surveys that measure nicotine dependence and smoking behavior
214500577|NCT03376659|DRUG|Bevacizumab|5mg/kg IV q2weeks
214500578|NCT03107169|OTHER|FMT|Patients in the FMT group received FMT-FURM
214500579|NCT03107169|DRUG|Vancomycin|Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
214387511|NCT04551196|DRUG|Alternating Acetaminophen and Ibuprofen|Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
214387512|NCT04551196|DRUG|Combined Acetaminophen and Ibuprofen|Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
214500580|NCT04727294|BEHAVIORAL|Questionnaire|Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
214500581|NCT03955926|DIETARY_SUPPLEMENT|preoperative oral carbohydrate loading|Carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg) 800 mL is given to the NO-NPO group until 2 hours before surgery
214500582|NCT03339466|DEVICE|Inspiratory muscle therapy|6 weeks of inspiratory muscle therapy
214500583|NCT03473717|DEVICE|classic method|"* Put the Pozzi forceps to draw the uterus by the cervix to horizontalize it and align uterine cavity in the direct axis of cervix.~* Insert the hysterometer to measure the uterus depth.~* Locate the uterine depth on the inserter tube."
214500584|NCT03473717|DEVICE|direct method|"* Place the ring on the inserter tube 3 to 4 cm from the end as a marker.~* Insert the tube into the cervix until you feel the passage of the internal orifice of the cervix or until the ring is in contact with the external orifice of the cervix, the tube does not enter the uterine cavity"
214387513|NCT00563589|DRUG|mycophenolate mofetil, methotrexate, cyclosporin|
214387514|NCT00563589|DRUG|Methotrexate and cyclosporin|
214500585|NCT05786872|DEVICE|dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
214500586|NCT04121715|DEVICE|Fastigial Nucleus Stimulation|Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
214500587|NCT04121715|DRUG|Standard treatment|"Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition"
214998020|NCT05317351|DEVICE|Standard Colonoscopy|Subjects randomized into arm 1 will undergo standard colonoscopy using a standard colonoscope
214387515|NCT00000342|DRUG|Risperidone|
214387516|NCT01301768|OTHER|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
214387517|NCT00983489|BEHAVIORAL|video demonstration|video will be shown to mothers
214387518|NCT00983489|BEHAVIORAL|counselling|breast feeding counselling
214500588|NCT00491296|DEVICE|SYNERGO|
214500589|NCT00491296|DEVICE|SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
214500590|NCT00512252|DRUG|AMD3100|
214500591|NCT00512252|DRUG|Mitoxantrone|
214500592|NCT00512252|DRUG|Etoposide|
214500593|NCT00512252|DRUG|Cytarabine|
214500594|NCT02941094|DEVICE|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
214500595|NCT02941094|DEVICE|Ultrasound|Xario, Toshiba Tokyo Japan
214500596|NCT00705406|DRUG|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
214500597|NCT00705406|DRUG|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
214500598|NCT04412005|OTHER|No intervention|No intervention
214500599|NCT01079806|DRUG|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
214387519|NCT03083392|PROCEDURE|treatment of chronic maxillary sinusitis using DIVA system|chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
214387520|NCT03083392|DEVICE|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply saline lavage to the maxillary sinus
214387521|NCT01493661|OTHER|Chronic Sleep Restriction|All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
214387522|NCT03722264|DEVICE|OpalSeal|OpalSeal is a fluoride releasing orthodontic primer that is FDA approved for use during bonding of orthodontic brackets
214387523|NCT03722264|DEVICE|TransbondXT|Transbond is a primer used to bond orthodontic brackets that does not contain fluoride
214387524|NCT05193084|DEVICE|Heartfelt Device|"The Heartfelt Device is a CE marked device that measures the volume of the foot/lower leg. By positioning the Heartfelt device in the bedroom, automatic measurements can be made whenever the subject gets in and out of bed. Feet identification software, complemented by manual checks, ensures that photographs are only taken of the specified subject. Data is censored so that the part of the body which is 50cm above the floor is not stored. Encrypted, anonymised data is transmitted over the internet to the company's secure servers. For this study, no personal identifiable data will be stored on the device or on the servers used by the device.~The volume readings collected can be presented to the clinical team on a web interface. This is not presented against identifiable data, but only participant ID. However, in the current pilot, volume readings will not be reviewed by the clinical team until the point of data analysis, after the study period."
214387525|NCT05193084|DEVICE|Connected weighing scales|"The connected weighing scales are Xiaomi Smart Scales (CE marked, manufactured by Anhui Huami Informeyshn Technologies).~The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional(s) (the fact that a participant has not used scales regularly in the past is not an exclusion criteria). The weighing scales display weight so that the participants can record the weight in their own heart failure records (paper weight diary).~The study team will check the patient's paper weight diary in case they choose to use another set of scales.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will record patient weight as well as the date and time of the measurements."
214387526|NCT04178512|DRUG|Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control|prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
214387527|NCT06414564|DEVICE|Medtronic 780G insulin pump|Subjects on insulin infusion by 780G AHCL system
214500600|NCT01079806|DRUG|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
214500601|NCT03732807|DRUG|PF-06651600 Induction Dose|Oral tablets taken once daily (QD)
214500602|NCT03732807|DRUG|PF-06651600 Maintenance Dose #1|Oral tablets taken QD
214500603|NCT03732807|DRUG|PF-06651600 Maintenance Dose #2|Oral tablets taken QD
214500604|NCT03732807|DRUG|PF-06651600 Maintenance Dose #3|Oral tablets taken QD
214500605|NCT03732807|DRUG|Placebo|Oral tablets taken QD
214500606|NCT01972906|DEVICE|moxibustion|apply moxibustion according to traditional Chinese medicine
214500607|NCT01972906|DRUG|Ibuprofen Sustained Release Capsules|apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
215093820|NCT03668834|PROCEDURE|Dermabrasion with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~3. The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~4. With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~5. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
214500608|NCT04031365|PROCEDURE|Acupuncture|Use of sterile, disposable needles in acupuncture
214500609|NCT04031365|BEHAVIORAL|Cognitive Behavioral Therapy|psychotherapy
214500610|NCT01779700|DRUG|Fingolimod|0.5mg each day of 8 week cycle
214500611|NCT01779700|DRUG|placebo|1 tablet each day of 8 week cycle
214500612|NCT05884515|DIAGNOSTIC_TEST|SARS CoV-2 antigen tests|The intervention is to compare antigen tests
214500613|NCT03347409|OTHER|Changes in preoperative care|Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling
214500614|NCT03347409|OTHER|Changes in intraoperative care|Blended anesthesia is mostly carried out using Total Intra Venous Anesthesia (TIVA) with loco regional analgesia, in particular Thoracic Epidural Anesthesia (TEA) in open surgery and spinal morphine or Transversus Abdominis Plane (TAP) block or quadratus lumborum block for laparoscopic surgical approach, associated to NSAIDs or acetaminophen; control of deep neuromuscular blocking with Train-of-four (TOF) stimulation avoiding residual paralysis. Multimodal prevention of PONV (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.
214500615|NCT03347409|OTHER|Changes in postoperative care|Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV. According to the type of surgery TEA, TAP block , quadratus lumborum block or IT morphine is preferred. Patient is proposed to start drinking clear fluid 4 hours after surgery and to start eating the evening of the surgery, with the introduction of a normal free diet within 24 hours after surgery. It is proposed to chew gum three times daily for at least 15 minutes and eventually to use laxatives to promote a faster bowel function. Early mobilization is started from the evening of surgery.
214687858|NCT05356624|OTHER|Soft Tissue Mobilization|in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
214387528|NCT05764226|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia)was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.
214387529|NCT03815279|DRUG|Carfilzomib|Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
214500616|NCT06092476|DEVICE|Revita® DMR Treatment|"The Revita® System is an endoscopic treatment consisting of a single catheter and console designed to lift the duodenal mucosa with saline followed by controlled circumferential hydrothermal ablation of the mucosa. For this study Revita® DMR procedure will be conducted as follows:~DMR Treatment Paradigm 1- After initial 2 Lift and Ablate step, remaining Lift: Ablate steps will be conducted in 1:1 manner."
214387530|NCT03815279|DRUG|Lenalidomide|Lenalidomide PO once daily on days 1-21 of a 28 day cycle
214387531|NCT03815279|DRUG|Dexamethasone|Dexamethasone will be administered weekly
214500617|NCT06092476|OTHER|Sham procedure|The sham control for the Revita DMR procedure.
214998021|NCT05317351|DEVICE|Artificial Intelligence Aided Colonoscopy (GI Genius™)|Subjects randomized into arm 2 will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)
214387532|NCT00871351|DRUG|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
214387533|NCT00871351|DRUG|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
214387534|NCT00871351|DRUG|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
214387535|NCT00871351|DRUG|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
214387536|NCT05793710|BEHAVIORAL|The principle of laughter plus Qigong|"The intervention program include muscle stretching, breathing exercises, and closing exercises. The laughing practice method begins with a warm-up consisting of laughing to stretch the body, yawning, and exerting the voice, and ends with expelling all the qi in order to return to natural movements and return to taking care of your body and mind (He et al., 2021).~The LQP program meets once a week for 90 minutes and runs for 12 weeks. The program content: the laughter skills were 50-60 minutes, the feedback was 30 minutes, and relaxation was 10 minutes."
214500618|NCT00296790|DRUG|zolpidem tartrate|
214998022|NCT05317351|DEVICE|Combined Artificial Intelligence Aided Colonoscopy (GI Genius™) and G-EYE® Balloon Aided Colonoscopy|"Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™)."
214998023|NCT00590473|DEVICE|Interstim|Unilateral vs. Bilateral Placement of Interstim IPG
214998024|NCT03043781|OTHER|Continuous epidural infusion|Continuous infusion, 5 ml/h
214998025|NCT03043781|OTHER|Intermittent epidural bolus|Intermittent bolus 5 ml every hour
214998026|NCT06815471|DRUG|COR-1167|28-day treatment
214998027|NCT06815471|DRUG|Placebo|28-day treatment
214998028|NCT05287503|DRUG|Ambroxol Hydrochloride|Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.
215093821|NCT03668834|PROCEDURE|Dermaroller with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit.~2. Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~3. The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~4. The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~5. NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
214387537|NCT03992885|DRUG|Icotinib|"Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally~Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle"
214387538|NCT00291655|DRUG|Levetiracetam|500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
214387539|NCT02959671|DEVICE|Lower Anterior EXD-952 Self-ligating Brackets|Placement of EXD-952 Self-ligating Brackets on mandibular incisors
214500619|NCT03844685|DRUG|Promensil|1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months
214687859|NCT00793702|BIOLOGICAL|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
214687860|NCT01860053|BEHAVIORAL|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
214687861|NCT02307344|DIETARY_SUPPLEMENT|Nigella Sativa|
214998029|NCT05287503|DRUG|Placebo|Excipients
214998030|NCT05447806|DEVICE|Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support|This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
214998031|NCT05520359|DEVICE|Mobility Device|Use of mobility device during session.
214998032|NCT05520359|DEVICE|Spinal Stimulation|A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum
214998033|NCT04246879|OTHER|MRI|Subjects undergo one additional delayed MRI sequence
214387540|NCT03169192|DRUG|Zoledronic Acid|intravenous injections once every 3 months
214500620|NCT03844685|DRUG|Placebo Oral Tablet|Placebo tablet (80 mg) (without active principle) given once a day for 24 months
214998034|NCT06985121|OTHER|Placebo control|Placebo control (base formula without caffeine and panthenol). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
214387541|NCT02791490|DRUG|Sitagliptin|Oral tablet, 100 mg, once daily at approximately the same time each day
214387542|NCT02791490|DRUG|Placebo|Oral tablet, once daily at approximately the same time each day
214387543|NCT02791490|DRUG|Metformin IR|All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).
214500621|NCT05416476|DRUG|Anisodine Hydrobromide|Anisodine Hydrobromide 1 mg oral tablet, twice times a day
214500622|NCT05416476|DRUG|Anisodine Hydrobromide placebo|Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
214998035|NCT06985121|OTHER|Base formula only|Base formula consisting of active ingredients caffeine and panthenol. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
214500623|NCT01046292|DRUG|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
214387544|NCT03693274|BEHAVIORAL|BreathAware for Pain Management|Patients will be given access to a BreathAware, a 16- week web-based mindfulness course, which will be initiated at their enrollment. BreathAware is a self-paced course comprised of 2-3 minute lessons delivered via video, audio and technology-based guided instruction, and is available on a phone or tablet.
214500624|NCT02708394|DRUG|olanzapine|atypical antipsychotic
214500625|NCT02708394|DRUG|placebo|placebo control
214500626|NCT02745990|DRUG|Recombinant human erythropoietin|rhEPO is administered 500IU/kg, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
214500627|NCT02745990|DRUG|Normal saline|Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
214500628|NCT05616494|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
214500629|NCT04242524|BEHAVIORAL|Circadian Clock Alignment|Use timed lights and meals to align the circadian clock
214387545|NCT00054964|DRUG|Albuterol HFA-BOI|Albuterol HFA breath operated inhaler, 90 mcg/sprau
214387546|NCT00054964|DRUG|Albuterol HFA-MDI|Albuterol HFA multi-dose inhaler
214500630|NCT04242524|BEHAVIORAL|Circadian Clock Control|No circadian clock alignment
214500631|NCT05300672|DRUG|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
214500632|NCT01115140|DRUG|metformin plus placebo|metformin 850 mg cp, 2 cps daily
214500633|NCT01115140|DRUG|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
214500634|NCT01115140|DRUG|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
214500635|NCT01115140|DRUG|placebo alone|placebo cp, 2 cps daily
214500636|NCT03441490|BEHAVIORAL|Guided-ICBT for adolescents with anxiety|Internet-based cognitive behavioural therapy with therapeutic guidance through mail, 8 weeks.
214500637|NCT03441490|BEHAVIORAL|Guided-ICBT with chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat, 8 weeks.
214500638|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail, 8 weeks.
214500639|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat, 8 weeks.
214500640|NCT01697228|DIETARY_SUPPLEMENT|Vitamin D|
214687862|NCT02307344|DIETARY_SUPPLEMENT|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
214687863|NCT00426114|DRUG|Administration of an IV glucose-injection|
214687864|NCT03219593|DRUG|Apatinib mesylate tablets|Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
214998036|NCT06985121|OTHER|Base formula plus IGF-1 and FGF-7|Base formula plus insulin growth factor 1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
214998037|NCT06985121|OTHER|Base formula plus Centella asiatica extracellular vesicles|Base formula plus Centella asiatica extracellular vesicles. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
214998038|NCT06985121|OTHER|Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7|Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
214998039|NCT06982066|BEHAVIORAL|ReSPECT|ReSPECT is an interactive, web-based digital platform that integrates (1) an AYA-centered pre-visit questionnaire (PVQ) that will discretely alert clinicians to relevant SRH questions/concerns, (2) targeted patient education on PVQ selections, and (3) clinician-centered guidance for addressing SRH issues. At enrollment, all participants will complete a baseline survey (T1). AYAs will have access to the ReSPECT digital platform and will receive the first prompt to complete the PVQ 3-5 days before their next clinic appointment. Once completed, AYAs will receive an email/text with a link to tailored information based on their PVQ selections for review. Clinicians will receive an email with a link to the patient's PVQ results on the ReSPECT platform along with clinical management recommendations. All participants will complete a brief virtual survey (T2) and interview within 48 hours of the first postintervention clinic visit and a follow-up survey 2 months after study enrollment (T3).
214387547|NCT00836173|DRUG|RICE|RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
214387548|NCT00836173|DRUG|GaRD Treatment|After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
214500641|NCT00853255|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
214500642|NCT05081804|DIETARY_SUPPLEMENT|Carbohydrate Preoperative Drink|Patients randomized to the intervention will drink the preoperative drink two hours prior to surgery
214500643|NCT02220452|OTHER|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
214500644|NCT02220452|OTHER|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
214500645|NCT01517503|BEHAVIORAL|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
214500646|NCT01517503|BEHAVIORAL|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
214500647|NCT03246750|DRUG|B-MAD chemotherapy|B-MAD chemotherapy
214500648|NCT04569526|DEVICE|use of intraoperative ultrasound|Ultrasonography guided brain lesions resection intra operatively for good localization
214500649|NCT03944200|DRUG|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229\_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
214500650|NCT03944200|DRUG|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229\_01(A)) together with 150 mL of water containing 30 g sugar."
214500651|NCT04163562|DRUG|INP20|Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.
214500652|NCT04163562|DRUG|Placebo|Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
214687865|NCT04368806|DRUG|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
215093822|NCT03668834|PROCEDURE|Liquid nitrogen induced blister with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. The site to be grafted is outlined with a surgical marking pen.~3. To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~4. The patient is asked to visit 24 hours later.~5. The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
215093823|NCT00428207|DRUG|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
214387549|NCT01984424|DRUG|Atorvastatin|Atorvastatin was supplied as over-encapsulated 20 mg tablets
214500653|NCT04278989|DRUG|Anti-tumor B|1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).
214387550|NCT01984424|DRUG|Placebo to Atorvastatin|Placebo matching to atorvastatin supplied as over-encapsulated tablets
214387551|NCT01984424|OTHER|Placebo to Ezetimibe|Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
214387552|NCT01984424|DRUG|Ezetimibe|Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
214500654|NCT06950450|BEHAVIORAL|EMOTİONAL FREE TECHNIQUE|"Intervention Group Procedure Steps:~Pre-Procedure:~Nursing students in the intervention group will be informed about Emotional Freedom Techniques (EFT), and after explaining the purpose and method of the study, their consent will be obtained using the Volunteer Consent Form.~They will be asked to complete the Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI) (state-trait version) forms.~Afterwards, information about EFT will be provided, including how to perform the technique and how to carry out the tapping procedure. After a discussion that is expected to last about 20 minutes, the EFT session will begin. Before the procedure, nursing students will complete the Descriptive Information Form, the State-Trait Anxiety Inventory (STAI-I), and the VAS score forms.~1\. EFT Procedure Sequence: Nursing students who meet the inclusion criteria, including first-year nursing students with no previous clinical experience, will have an initial meeting before their first clinic"
214687866|NCT04368806|OTHER|Placebo Control|Normal Saline with autologous Serum
214687867|NCT03105440|OTHER|Virtual reality|"This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
214500655|NCT06950710|OTHER|NAFLD|This study is an observational one with no intervention
214500656|NCT05596994|DEVICE|Lighting Intervention Therapy|The LIT will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The TLI intervention will remain in place and will be delivered to participants for 10 weeks each in a counterbalanced manner. Combining spectrum and light level, LIT will allow the research team to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The research team will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater) and about 50 lux at the eye during the evening hours (CS of less than 0.1) and when the control lighting intervention is used.
214500657|NCT05596994|DEVICE|Sham LIT|A placebo comparison lighting intervention will be used. The comparison lighting intervention will remain in place and will be delivered to participants for 10 weeks.
214500658|NCT00504023|DRUG|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
214500659|NCT00504023|PROCEDURE|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
214500660|NCT00504023|PROCEDURE|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
214500661|NCT04174339|DRUG|Camrelizumab|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
214500662|NCT04174339|DRUG|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
214500663|NCT04174339|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
214500664|NCT00204685|DRUG|dornase alfa|
214387553|NCT01984424|OTHER|Placebo to Evolocumab|Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
214387554|NCT01984424|DRUG|Evolocumab|Evolocumab supplied as single-use prefilled autoinjector/pen(s)
214387555|NCT01551316|DRUG|MN-221|This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
214387556|NCT01551316|DRUG|Placebo|This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
214387557|NCT01123460|OTHER|enzyme-linked immunosorbent assay|
214387558|NCT01123460|OTHER|laboratory biomarker analysis|
214387559|NCT05516368|BEHAVIORAL|TF-CBT|Modular TF-CBT therapy programme of 16 weekly individual sessions, each lasting 60-90 minutes.
214500665|NCT02150616|BEHAVIORAL|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
214500666|NCT02150616|BEHAVIORAL|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
214500667|NCT02150616|DRUG|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
214500668|NCT02150616|DRUG|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
214500669|NCT02230137|BEHAVIORAL|Text message arm|Text message sent before each injection of insulin
214500670|NCT04587219|BIOLOGICAL|Gam-COVID-Vac|combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
215093824|NCT00428207|DRUG|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
215093825|NCT05571774|OTHER|collection data|collection data
215093826|NCT01181674|DRUG|insulin glargine|sc injection
215093827|NCT01181674|DRUG|metformin|oral administration
214387560|NCT02532959|DEVICE|Diagnostic Breath Analysis|Conduct exhaled breath samples
214387561|NCT00077636|DRUG|Copegus|400mg po bid for 16 weeks
214387562|NCT00077636|DRUG|Copegus|400mg po bid for 24 weeks
214387563|NCT00077636|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 16 weeks
214387564|NCT00077636|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks
214387565|NCT04944394|OTHER|online questionnaire|"Administration of an online questionnaire (Limesurvey platform) at M0~\- This questionnaire includes a characterization of the professional (center, profession, usual department and department during the health crisis, family situation). Generic stress factors, the traumatic impact of the crisis and collective and individual coping strategies are also collected."
214387566|NCT04944394|OTHER|questionnaire survey|A questionnaire survey of the chief physician of the intensive care unit of each hospital will make it possible to characterize the support provided by the institution and how it changed over time
214387567|NCT05284305|OTHER|Pregnancy|DT with a history of concomitant or subsequent pregnancy.
214387568|NCT02133482|DRUG|Placebo|placebo solution
214500671|NCT05491135|BIOLOGICAL|HMB002|The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.
214500672|NCT02695264|DEVICE|HS-1000 recording|
214500673|NCT01809275|DRUG|QBECO|
214500674|NCT01809275|DRUG|Placebo|
214500675|NCT00651859|DRUG|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
215093828|NCT01181674|DRUG|acarbose|oral administration
215093829|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
215093830|NCT01181674|DRUG|insulin glargine|sc injection
215093831|NCT01181674|DRUG|metformin|oral administration
215093832|NCT01181674|DRUG|acarbose|oral administration
214387569|NCT02133482|DRUG|BI 639667|oral solution BI 639667, single rising doses
214387570|NCT02032173|DRUG|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
214387571|NCT01643941|BIOLOGICAL|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
214387572|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
214387573|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
214387574|NCT01643941|BIOLOGICAL|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
214387575|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
214387576|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
214387577|NCT01643941|BIOLOGICAL|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
214387578|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
214387579|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
214387580|NCT01643941|BIOLOGICAL|SA3Ag vaccine|Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
214387581|NCT01643941|PROCEDURE|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
214387582|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
215093833|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
215093834|NCT01181674|OTHER|Standard glycemic care|as informed by the current clinical practice guidelines
215093835|NCT02530996|DRUG|BH4|BH4 10 mg/kg/day given once to a total of 12 SSc patients
215093836|NCT02530996|DIAGNOSTIC_TEST|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
215093837|NCT02530996|DRUG|Placebo|On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
215093838|NCT00311909|DEVICE|Thalamic deep brain stimulation|
215093839|NCT06499883|BEHAVIORAL|Pocket Ark|Pocket Ark (PA) is a mobile e-learning and assessment platform for use by flood remediation workers in the field. The purpose of this mobile application is to provide workers with real-time data to assist with making safe decisions during the planning phase in the flooded zone and provide a communications platform to improve logistics between operational bases and workers during and after the deployment to the flooded zone. Pocket Ark incorporates an action planner, scenario-based PPE training content, assessments (both knowledge and health-risk), personal security protection, and resource location features for workers involved in disaster rescue and recovery. Individual construction worker's readiness to be safely deployed to flooded and post-flood environments will be assessed.
215093840|NCT04268745|BEHAVIORAL|Balance training|Progressive balance training within virtual environments
215093841|NCT04268745|BEHAVIORAL|Traditional Vestibular Rehabilitation|Progressive balance training and gaze stability exercises
215093842|NCT01086852|BIOLOGICAL|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
215093843|NCT02062203|DRUG|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
215093844|NCT02062203|DRUG|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
215093845|NCT02062203|DRUG|Placebo|Single oral dose of placebo
215093846|NCT02062203|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
215093847|NCT00221494|DRUG|citalopram + tiodothyronine, or + pindolol, or + placebo|
215093848|NCT00447122|DRUG|Gemcitabine 1000mg/m2 30 minutes|1000mg/m2 30 minutes
215093849|NCT00447122|DRUG|Lapatinib 1000mg/d|1000mg/d
214387583|NCT01643941|BIOLOGICAL|Placebo|Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
215093850|NCT00447122|DRUG|Lapatinib 1500mg/d|1500mg/d
215093851|NCT00447122|DRUG|Gemcitabine 1000mg/m2 100minutes|1000mg/m2 100minutes
214387584|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
214387585|NCT01643941|PROCEDURE|Colonization swab samples|Colonization swabs will be collected from all subjects at various timepoints.
214387586|NCT05082142|DRUG|Tranexamic acid|Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
215093852|NCT00447122|DRUG|Oxaliplatin 100mg/m2|100mg/m2
214387587|NCT05149781|PROCEDURE|Standardized diagnosis and treatment|Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.
214387588|NCT01163110|DIETARY_SUPPLEMENT|Realbuild|Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
214387589|NCT03431051|OTHER|Healthy Beverage Initiative|A Healthy Beverage Initiative will be instituted at two hospital campuses.
214387590|NCT03661996|DRUG|CNTX-4975-05|Osteoarthritis (OA) intra-articular injection of CNTX-4975-05
214387591|NCT03661996|DRUG|Lidocaine without epinephrine|15 mL lidocaine intra-articular injection
214387592|NCT03661996|DEVICE|ElastoGel|Cooling Device
214387593|NCT03661996|DEVICE|Breg Ice Water Pump|Cooling Device
214387594|NCT03785457|OTHER|Repetitive Trunk Extension|Subjects will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds (Figure 2), repeated five times with 15-second rest breaks.
214387595|NCT03785457|OTHER|Sustained Trunk Extension|Subjects will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks.
214387596|NCT04639921|DIAGNOSTIC_TEST|positive test followed by gluten-free diet|DBPCFC with gluten
214387597|NCT04639921|DIETARY_SUPPLEMENT|Placebo|Placebo
214387598|NCT02814474|OTHER|Na-3-hydroxybutyrate|Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
214387599|NCT02814474|OTHER|Saline|Infusion of 0.9 % saline
214387600|NCT05414838|DIETARY_SUPPLEMENT|Curcumin, Omega-3 and Vitamin-D (COD)|"Acumin™ Turmeric Complex (Dr. D's Ultra BioTurmeric) 500 mg daily (NPN 80087842)~Omega-3 supplements (combination of DHA and EPA) 900 mg daily (NPN 80019234)~Vitamin D3 supplements 2500 IU daily (NPN 80108995)"
214387601|NCT01694810|DRUG|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
214387602|NCT01694810|DRUG|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel applied once daily 4 weeks
214387603|NCT01694810|DRUG|8% NVN1000 Topical Gel|8% NVN1000 Topical Gel applied once daily for 4 weeks
214387604|NCT01694810|DRUG|Vehicle Topical Gel|Vehicle Topical Gel applied once daily
214387605|NCT01993017|OTHER|Cognitive Behavioral Therapy (CBT)|"The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement ."
214387606|NCT01993017|DRUG|Antidepressant Medication|"The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated."
214387607|NCT01993017|OTHER|Standard Care|Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
214387608|NCT01993017|OTHER|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
214387609|NCT01993017|OTHER|No intervention|
214387610|NCT02280057|DRUG|Metformin|Metformin 1500 mg (=2 pills) per day in six months
214387611|NCT02280057|DRUG|Placebo|2 pills per day in six months; pills look like metformin pills
214387612|NCT00068380|DRUG|imatinib mesylate|Given orally
214387613|NCT00068380|OTHER|laboratory biomarker analysis|Correlative studies
214387614|NCT01619657|DRUG|6% Hypertonic Saline (HS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
214387615|NCT01619657|DRUG|0.9% Isotonic Saline (IS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
214387616|NCT00462722|DRUG|Ibuprofen|400 mg with each exercise session (up to 5 days per week) for 9 months
214387617|NCT00462722|DRUG|Placebo|with each exercise session (up to 5 days per week) for 9 months
214387618|NCT00462722|BEHAVIORAL|musculoskeletal-loading exercise|Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
214387619|NCT02800824|DRUG|Budesonide|
214387620|NCT02800824|DRUG|Uceris|
214387621|NCT01508299|PROCEDURE|skin test|skin test with the Suspected raw food
214387622|NCT06219343|DEVICE|Non-invasive vagus nerve stimulation|Patient undergoes non-invasive vagus nerve stimulation during tachycardia episodes to see if reentry is possible
214387623|NCT02419547|DRUG|Versed|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
214387624|NCT02419547|DRUG|Fentanyl|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
214387625|NCT02419547|DRUG|Propofol|Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
214387626|NCT02419547|DRUG|Sevoflurane|Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
214387627|NCT05990920|BIOLOGICAL|SNK02|SNK02 is ex vivo expanded allogeneic NK cells for IV injection, is a light-yellow cryopreserved cell suspension consisting of NK cells isolated from healthy donor's peripheral blood mononuclear cells.
214387628|NCT02949674|DRUG|Ropivacaine|It will be used as a analgesic dose in surgical site before surgery.
214387629|NCT02949674|DRUG|Bupivacaine|It will be used as a analgesic dose in surgical site before surgery.
214500676|NCT00651859|DRUG|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
215093853|NCT03083145|DIETARY_SUPPLEMENT|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
215093854|NCT03083145|DIETARY_SUPPLEMENT|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
215093855|NCT03083145|BEHAVIORAL|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
214387630|NCT05591625|BEHAVIORAL|Eye Movement Desensitisation and Reprocessing|"EMDR is a trauma-focussed, psychological talking therapy whereby the participant verbally relates a narrative of an emotionally disturbing memory, in brief sequential doses, while simultaneously focusing on an external stimulus, most commonly side-to-side finger movements of the psychological therapist. EMDR aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR is widely practiced, so is scalable. It is also protocolised, so can be taught and tested, and allows for fidelity assessment in controlled studies.~The number of sessions will depend on ongoing presence of disturbing memories. This will be determined by the psychological therapist and participant."
214387631|NCT03355963|OTHER|saline injection|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
215093856|NCT01048450|RADIATION|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
215093857|NCT01048450|PROCEDURE|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
215093858|NCT01048450|PROCEDURE|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
215093859|NCT02540291|DRUG|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
214387632|NCT03355963|BIOLOGICAL|Botulinum toxin type A 50 units|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
214387633|NCT03355963|BIOLOGICAL|Botulinum toxin type A 100 units|The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
214387634|NCT00027638|DRUG|thalidomide|
214387635|NCT02569450|BEHAVIORAL|Surgical outcomes monitoring using Shewhart control chart|"* Assistance by a local surgeon responsible for the implementation of intervention within his/her department~* Quarterly team meeting to interpret variations in observed outcomes on the control charts~* Restitution of surgical outcomes based on wall posters in operating room~* Training sessions provided to local surgeon for appropriate control chart utilization"
214387636|NCT02835456|DEVICE|Sharklet Catheter insertion|
214387637|NCT02835456|DEVICE|Silicone Foley Catheter insertion|
214387638|NCT06529900|BEHAVIORAL|oral mastication training|Through specific exercises and techniques aimed at enhancing masticatory function and overall oral health.
214387639|NCT06529900|BEHAVIORAL|texture and diet education|Teach the knowledge and techniques of softening food textures.
214387640|NCT00404534|DRUG|Amoxicillin, Clarythromycin, Omeprazole for ten days|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
214387641|NCT01708889|BIOLOGICAL|BMS-914143 (Peginterferon Lambda-1a)|
214387642|NCT00917267|DRUG|exenatide once weekly|2.0mg subcutaneous injection, once a week
214387643|NCT00917267|DRUG|exenatide twice daily|5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
214387644|NCT03376841|DRUG|Cenicriviroc|1 tablet; single-dose oral administration
214387645|NCT00823550|DRUG|Entecavir|entecavir 0.5 mg QD
214387646|NCT00823550|DRUG|Lamivudine|lamivudine 100 mg QD
214387647|NCT05980429|OTHER|Music Therapy, prescribed|"All music pieces selected for the prescribed intervention contain compositional elements of relaxation analyzed, prepared, and recorded by professional concert artists and a Grammy-nominated composer. The compositional elements included Accentuation, Articulation, Dynamic Range, Familiarity, Interpretive Expertise, Melodic Shape, Meter, Recording Quality, Repetition, Register, Rubato, Tempo, Texture, Timbre, Transition, and Tonality. These 15 repertoire-selecting parameters were used to choose the prescribed music play list for this study. Music used for the study was downloaded from a password-protected Google Drive accessible to the study participants assigned to the prescribed music intervention group."
214387648|NCT05980429|OTHER|Music Therapy, self-selected|All music pieces were self-selected by the participant
214387649|NCT02858765|OTHER|Application of white polychromatic light for 2h30 at different times of day|
214387650|NCT06171906|BIOLOGICAL|mesenchymal stromal cells|On the basis of conventional PGF treatment for poor implantation, the enrolled patients were injected with 1×10\^6/kg mesenchymal stem cells of cord blood weekly for 4 consecutive weeks
214387651|NCT01863602|DRUG|Lamotrigine tablets|Administered for long-term according to the prescribing information in the locally approved label by the authorities.
214500677|NCT00651859|DRUG|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
214500678|NCT02526576|BIOLOGICAL|Stromal Vasular Fraction|The stromal vascular fraction obtained from adipose tissue will be added to the graft
214500679|NCT02526576|PROCEDURE|Biopsy|A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
214500680|NCT02220959|OTHER|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
214500681|NCT05573724|DRUG|AZD5305|"In Part A, the participants will receive a single dose of AZD5305 on Day 1 and Day 7.~In Part B, the participants will receive AZD5305 once daily."
214500682|NCT05573724|DRUG|Itraconazole|In Part A, the participants will receive Itraconazole twice daily on Day 4 and once daily on Days 5-12
215093860|NCT01149902|BIOLOGICAL|Cyclophosphamide, Docetaxel, Dendritic cells, OK-432|Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35
214387652|NCT03063970|DEVICE|Dynamic Lycra Orthosis|Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.
214387653|NCT03063970|OTHER|Usual Rehabilitation|Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
214387654|NCT02960763|DRUG|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
214387655|NCT02960763|DRUG|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
214387656|NCT02960763|DRUG|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
214387657|NCT02960763|DRUG|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
214387658|NCT02960763|DRUG|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
214387659|NCT02348398|DRUG|Pazopanib|600 mg by mouth daily in a 28 day cycle.
214387660|NCT02348398|DRUG|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
214387661|NCT02348398|BEHAVIORAL|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
214387662|NCT05985057|OTHER|Artificial intelligence|Prediction of carbapenem resistance via deep machine learning model
214387663|NCT00335725|DRUG|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
214387664|NCT00335725|DRUG|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
214387665|NCT01935921|BIOLOGICAL|Cetuximab|Given IV
214387666|NCT01935921|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215093861|NCT04293367|OTHER|High Intensity Interval Training (HIIT)|"HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery)."
215093862|NCT00359723|DRUG|methylphenidate|
214387667|NCT01935921|BIOLOGICAL|Ipilimumab|Given IV
214387668|NCT01935921|OTHER|Laboratory Biomarker Analysis|Correlative studies
214387669|NCT02250521|DEVICE|McGrath MAC enhanced direct laryngoscope|"The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct laryngoscopy with an inline video camera for an enhanced view.~All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The LCD monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist."
214387670|NCT00312858|BIOLOGICAL|Comparator: VAQTA™ (Hepatitis A vaccine)|VAQTA™ 0.5 mL injection
214387671|NCT00312858|BIOLOGICAL|Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)|ProQuad™ 0.5 mL injection
214387672|NCT00312858|BIOLOGICAL|Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)|Prevnar™ 0.5 mL injection
214387673|NCT00204659|DRUG|Rituximab + CHOP chemotherapy|standard Rituximab + CHOP chemo-immunotherapy
215093863|NCT04140981|DEVICE|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
215093864|NCT02476123|BIOLOGICAL|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
215093865|NCT03661086|DEVICE|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
215093866|NCT05538351|DEVICE|Body Composition Monitor (BCM)|The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
214387674|NCT02604836|DRUG|Ibandronate|Film-coated oral ibandronate tablet (150 mg) once-monthly
214387675|NCT05051332|DRUG|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
214687868|NCT03105440|OTHER|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
215093867|NCT03907033|DRUG|Liposomal bupivacaine|Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
215093868|NCT03907033|DRUG|Bupivacaine Hydrochloride|We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
215093869|NCT04147546|DIAGNOSTIC_TEST|Additional screening using ultra sensitive RDTs|At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm
214687869|NCT03105440|OTHER|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
214387676|NCT05051332|PROCEDURE|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate
214387677|NCT01200537|DRUG|Estradiol|This group of patients will receive estradiol patches prior to the IVF cycle.
215093870|NCT04147546|DRUG|Dihydroartemisinin-piperaquin|All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home
215093871|NCT04147546|OTHER|Reminders|Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
215093872|NCT02576808|DRUG|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
215093873|NCT02576808|DRUG|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
214387678|NCT01200537|DRUG|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
214387679|NCT02360839|DEVICE|EUS-guided fine needle biopsy sampling (EUS-FNB)|Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
214387680|NCT04134858|OTHER|The nurse-led health coaching program|The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
214387681|NCT04161417|OTHER|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
214387682|NCT03406793|DIETARY_SUPPLEMENT|Standard MNP|Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.
214387683|NCT03406793|DIETARY_SUPPLEMENT|High zinc, low iron MNP|Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.
214387684|NCT03406793|DIETARY_SUPPLEMENT|High zinc, low/no iron on alternating days|Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.
214387685|NCT03406793|DIETARY_SUPPLEMENT|Dispersible zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.
214387686|NCT03406793|DIETARY_SUPPLEMENT|Intermittent zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.
214387687|NCT03406793|DIETARY_SUPPLEMENT|Placebo powder|Daily provision of a placebo powder for 24 weeks.
214387688|NCT01668433|DRUG|Regimens (Primaquine, Methylene blue)|Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
214387689|NCT01868035|DRUG|tositumomab and iodine I-131 tositumomab|"Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass."
214387690|NCT02767635|DRUG|Botox-Epic|injected 20 units of Botox into lateral epicondyle in Botox-Epic group
214387691|NCT02767635|DRUG|Botox-Tend|injected 20 units of Botox into tender point of muscles in Botox-Tend group
214387692|NCT02767635|DRUG|triamcinolone acetonide (Steroid)|injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
214387693|NCT02492646|PROCEDURE|Saline group|After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
214387694|NCT02492646|PROCEDURE|Dry group|After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
214387695|NCT03656484|DRUG|Tetracycline-Metronidazole (TM) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
214387696|NCT03656484|DRUG|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
214387697|NCT03103022|DRUG|Acetaminophen|Oral acetaminophen \[160 mg/5ml concentration\] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses
214387698|NCT03103022|DRUG|ibuprofen|Oral ibuprofen \[100 mg/5 ml\] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
214387699|NCT00432835|DEVICE|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
214387700|NCT05707650|PROCEDURE|reverse breech extraction technique or push technique|using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix
214387701|NCT06037174|PROCEDURE|minimally invasive procedure|different minimally invasive approach to complete thyroidectomy, including endoscopy-assisted subclavian approach, robot-assisted transaxillary or transoral approach (not leaving scar on the neck)
214387702|NCT06037174|PROCEDURE|Conventional Open Surgery|Conventional Open Surgery
214387703|NCT04853862|OTHER|questionnaire|Questionnaire for health-related quality of life evaluation
214387704|NCT00164853|PROCEDURE|endoscopic balloon dilatation|Refer to description under arms
214387705|NCT00164853|PROCEDURE|Standard sphincterotomy|Refer to under arms
214387706|NCT03393299|PROCEDURE|STOPP/START criteria|software which helps to do the drug reconciliation
214387707|NCT03959774|DEVICE|IPC NET|a digital pack with connected bracelet and connected balance will be given to the patient. IPC NET and Nokia Health applications will be downloaded. Pairing between connected objects and the smartphone will be done during the inclusion visit
214387708|NCT01704885|BEHAVIORAL|Play Intervention|
214387709|NCT01704885|OTHER|Questionnaires|
214387710|NCT03685032|DRUG|Dexamethasone|The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
214387711|NCT03685032|DRUG|Ondansetron|The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
214387712|NCT03685032|DRUG|0.9% Sodium Chloride Injection|The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
214387713|NCT04130711|OTHER|Visual virtual Conditions|"The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background."
214387714|NCT04130711|OTHER|Standard EEG|Twenty healthy volunteers test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order.
214387715|NCT04130711|OTHER|Neurofeedback Training Stroke Patients|The post-stroke subject is evaluated on clinical tests (FMA, ARAT, MAL, NHPT, Finger Tapping test) during the first visit. Then, he performs 12 sessions of NFB (on his deficit member) lasting 45 minutes, spread over 6 weeks, depending on the feedback modality that has been drawn randomly (visual or visuo-vibratory). A second visit after the first NFB session and a third visit after the last NFB session evaluates the motor skills of the trained upper limb (FMA, ARAT, MAL, NHPT, Finger Tapping test) and a satisfaction questionnaire is given to the subject for evaluate tolerance and satisfaction with the feedback modality assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
214387716|NCT00423293|DRUG|fluorouracil|1000 mg/m\^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
214387717|NCT00423293|DRUG|mitomycin C|10 mg/m\^2 intravenous therapy on day 1 and day 29 of radiation therapy.
214387718|NCT00423293|RADIATION|Intensity-modulated radiation therapy|"Prescription dose depends on tumor staging.~T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.~T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.~For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes \> 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx."
214387719|NCT02486549|PROCEDURE|Supraclavicular Block|Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
214387720|NCT02486549|PROCEDURE|Interscalene Block|Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
214387721|NCT02486549|DRUG|Bupivacaine|20ml 0.25% bupivacaine will be injected for brachial plexus block
214387722|NCT02486549|DEVICE|Ultrasound|The Ultrasound will be used for brachial plexus visualization
214387723|NCT01862458|BIOLOGICAL|tPA alone|
214687870|NCT03105440|OTHER|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
215093874|NCT06526156|DRUG|Bupivacaine injection|A 3 mL hypobaric (0.33%) solution of bupivacaine, prepared by mixing 2 mL of isobaric (0.5%) bupivacaine with 1 mL of sterile water. Dural puncture will be performed using a 25 or 27G (gauge) spinal needle at the L5-S1 intervertebral space, and the 3 mL of 0.33% bupivacaine will be injected into the intrathecal space.
215093875|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
215093876|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
215093877|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
214387724|NCT01862458|BIOLOGICAL|tPA plus dornase|
214387725|NCT03902938|BIOLOGICAL|Biodesign Otologic graft|Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.
214387726|NCT03902938|OTHER|Autograft temporalis fascia|Patient's mastoid cavity will be covered with covered with autograft.
214387727|NCT01912222|DRUG|IXAZOMIB|
214387728|NCT01727492|DRUG|Antioxidantia|
214387729|NCT03051490|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
214387730|NCT03051490|DRUG|porcine PERT|oral, enterically-coated, pig-derived, pancreatic enzyme replacement
214998040|NCT06605508|PROCEDURE|Autologous Adipose Tissue-Derived Stem Cell Injection for Erectile Dysfunction|This intervention involves the use of autologous adipose tissue-derived stem cells (ADSC) to treat erectile dysfunction. The process begins with a minimally invasive liposuction procedure to harvest fat tissue from the participant\&#39;s own body. The harvested fat is then processed to isolate stem cells, which are subsequently injected directly into the erectile tissue of the penis. This approach aims to enhance erectile function by promoting tissue regeneration and improving blood flow. Unlike other treatments for erectile dysfunction, this intervention uses stem cells derived from the participant\&#39;s own fat, which may reduce the risk of immune rejection and offer a novel regenerative therapy option. The treatment is designed to address ED in patients who have not responded adequately to conventional therapies like PDE-5 inhibitors.
214387731|NCT03904537|BIOLOGICAL|anti-PD-1 antibody-activated TILs|Participants would received one dose anti-PD-1 antibody-activated TILs at the final cycle of XELOX regimen chemotherapy
214387732|NCT05112341|RADIATION|radiation therapy|the patient first is simulated then delineation is done
214387733|NCT03529448|DRUG|TN-TC11G|"TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered."
214387734|NCT03529448|DRUG|Temozolomide Oral Product|"During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
214387735|NCT03529448|RADIATION|Radiotherapy|All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
214387736|NCT01138930|DRUG|Berberine|1.5g daily for 3 month
214387737|NCT01138930|DRUG|Placebo|placebo daily
214387738|NCT03535402|DRUG|Sarilumab|SC administration of 200 mg twice a week
214387739|NCT06365307|COMBINATION_PRODUCT|"Osteoplastic material based on octacalcium phosphate and biologically active nucleic acids for bone tissue regeneration Nucleostim-VEGF (Histograft)"|Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
214687871|NCT03105440|OTHER|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
214998041|NCT06605508|PROCEDURE|Stem cell-derived Exosomes Injection for Erectile Dysfunction|This intervention involves the use of stem cell-derived exosomes to treat erectile dysfunction. Exosomes are nano-sized extracellular vesicles secreted by stem cells, containing bioactive molecules such as growth factors and signaling proteins that promote tissue repair and regeneration. Unlike therapies requiring the transplantation of live cells, this cell-free approach eliminates the need for invasive harvesting procedures. The exosomes are carefully purified from cultured stem cells and prepared for direct injection into the erectile tissue of the penis. This approach aims to enhance erectile function by stimulating tissue regeneration, reducing inflammation, and improving blood flow. Unlike other treatments for erectile dysfunction, exosome therapy offers a novel regenerative option, potentially benefiting patients who have not responded adequately to conventional therapies such as PDE-5 inhibitors.
214998042|NCT06985043|DEVICE|Auricular vagus nerve stimulation (AVNS)|Auricular vagus nerve stimulation (AVNS) will be applied to both ears simultaneously, using a biphasic, asymmetric waveform with pulses of 300 microsecond duration and a frequency of 25 Hz, continuously for 20 minutes. The application will be performed in a single session and the follow-up time will be determined as 30 minutes.
214998043|NCT06984484|DEVICE|Afluxin®|Afluxin® stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.
214998044|NCT06984484|DRUG|Placebo|Inactive control stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.
214998045|NCT06605560|OTHER|Platelet Rich Plasma|PRP contains a high concentration of platelets obtained by centrifugation of autologous blood. After degranulation of platelets, various growth factors and cytokines are released and accelerate cartilage matrix synthesis, restrain synovial membrane inflammation and promote cartilage healing.
214998046|NCT06593314|BEHAVIORAL|Message with EchoGo|This alert will inform the provider that the patient has subclinical HFpEF
214998047|NCT06593314|BEHAVIORAL|Standard Message|This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.
214998048|NCT06590961|DRUG|UBX-303061|UBX-303061 oral dosage
215093878|NCT02393053|PROCEDURE|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
215093879|NCT02393053|PROCEDURE|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
214387740|NCT06365307|OTHER|Synthetic osteoplastic material based on β-TCP or bone autograft|Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
214387741|NCT05815927|DRUG|Pembrolizumab|Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).
214387742|NCT05815927|RADIATION|stereotattic ablation radiotherapy (SABR)|Total dose and number of fractions will depend on the site of the disease. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
214387743|NCT02328092|DEVICE|rSMS in treatment of Nocturnal Enuresis|Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
214387744|NCT02421900|OTHER|radio-frequency catheter ablation of atrial fibrillation|radio-frequency catheter ablation of atrial fibrillation
214387745|NCT04399551|DRUG|CAB OLI|CAB will be available as 30 milligrams (mg) tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
214387746|NCT04399551|DRUG|CAB LA|CAB LA 600 mg will be administered as intramuscular (IM) injection.
214387747|NCT04399551|DRUG|RPV OLI|RPV will be available as 25 mg tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
214387748|NCT04399551|DRUG|RPV LA|RPV LA 900 mg will be administered as IM injection.
214387749|NCT04399551|OTHER|Continuous Quality Improvement (CQI) calls|CQI will be attended by the enhanced arm (Arm-E). The CQI calls will be conducted to identify problems/challenges, generate plans to address the challenges, and identify how to measure the change that results from the plan.
214387750|NCT05469542|DEVICE|Everbeat Ring|The primary objective of this study is to assess the concordance of specific ECG parameters obtained in the everbeat nine-lead ECG waveform with those obtained in the comparable leads from a standard 12-lead ECG recorder.
214387751|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
214387752|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
214387753|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
214998049|NCT06811896|BEHAVIORAL|Stress Management and Resiliency Training Program|The Stress Management and Resiliency Training Intervention is an evidence-based intervention to reduce physiologic responses to stress that may contribute to cardiovascular disease risk. The intervention is typically delivered over an 8-week period and works to decrease stress responses by improving psychological resiliency to structural and social stressors and decreasing sympathetic nervous system activation. Eliciting the relaxation response through meditation, mindfulness, and autogenic training are core components.
214998050|NCT06811896|OTHER|Usual Care|Usual social and clinical services provided to patients at the recruiting clinic
214998051|NCT06605924|OTHER|Tobacco-free|Ad contains baseline language + language that product is tobacco-free
214998052|NCT06605924|OTHER|Discrete|Ad contains baseline language + language that product is discrete
214998053|NCT06605924|OTHER|Convenient|Ad contains baseline language + language that product is convenient
214387754|NCT05012449|PROCEDURE|Arthrography-assisted joystick technology.|Arthrography-assisted joystick technology.
214387755|NCT01336634|DRUG|Dabrafenib|Dabrafenib study treatment was provided as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt)
214387756|NCT01336634|DRUG|Trametinib|Trametinib study treatment was provided as 0.5 mg and 2 mg tablets. Each tablet contained 0.5 mg or 2 mg of trametinib parent (present as the dimethyl sulfoxide solvate)
214387757|NCT01446263|PROCEDURE|Radial access versus femoral access for coronary angiography and intervention|Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
214387758|NCT05518292|OTHER|rhomboid intercostal block|Ultrasound guided RIB will apply with 10-12 MHz linear ultrasound transducer, in plane technique. Patients will placed in the sitting position. 22G spinal needle needle will be inserted to plane between the rhomboid muscle and intercostal muscles over the T5-6 ribs 2 cm to 3 cm medially from the medial border of the scapula. 20 ml of bupivacaine 0.25% will inject into the fascial plane.
214387759|NCT05518292|OTHER|serratus anterior plane block|Patients will placed in the lateral position with the diseased side up. A 10-12 MHz linear ultrasound transducer is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The fifth rib is identified in the mid-axillary line. The following muscles are identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). As an extra-reference point, the thoracodorsal artery is used to aid the identification of the plane superficial to the serratus muscle. The needle (22G spinal needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance, 20 ml of bupivacaine 0.25% will inject.
214387760|NCT00947037|DRUG|AP-CD/LD|
214393948|NCT03708419|OTHER|Optimal diet|Based on a 7-points OGTT, participants will be classified as MIR or LIR. The hypothesized optimal diet for MIR has a moderate fat content which is high in mono- unsaturated fatty acids (HMUFA) with a macronutrient breakdown of 38 E% from fat (20% MUFA, 10% polyunsaturated fatty acids (PUFA), 8% saturated fatty acids (SFA)), 48 E% from carbohydrates (CHO, 35% complex), and 14 E% from protein (35-40% plant protein). The hypothesized optimal diet for LIR is low in fat, high in protein (LFHP) and increased fiber with a macronutrient breakdown of \<28 E% from fat (10% MUFA, 10% PUFA, 8% SFA), 48 E% from CHO (35% complex), and 24 E% from protein (35-40% plant protein), and an additional supplement of 6g of soluble fiber per day. Participants wil be randomly allocated to one of the two diets.
214998054|NCT06295406|OTHER|Neuropsychological assessment|Neuropsychological tests assessing reading abilities, skills of motor coordination, postural stability, manual dexterity, including graphomotor skills, and estimation of time will be performed
214998055|NCT05637294|DEVICE|splinting|neutral-positioned wrist orthosis
214998056|NCT06817720|DRUG|olverembatinib|GIven by PO
215093880|NCT00007644|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
215093881|NCT01174173|DRUG|Ranolazine|ranolazine 1000 mg PO BID for 3 months
215093882|NCT02648672|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
215093883|NCT02648672|DRUG|Placebo|
215093884|NCT05491434|DIETARY_SUPPLEMENT|Protein supplement|One líquid brick every day during 3 weeks
214387761|NCT04289701|OTHER|Health Services for Systematic Hypertension Management|"The systematic hypertension management health services from the Hypertension prevention and control initiative in China project. Main services are as follows:~1. Healthcare provider training and patient education.~2. Standardized guideline-based hypertension diagnosis, treatment and management recommendation.~3. Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform.~4. Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs.~5. Outcome and performance evaluation quarterly.~6. Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients.~7. Certification for Honorary Hypertension Centers at county levels and establishment for hypertension clinics at primary care centers."
214387762|NCT04532021|DIAGNOSTIC_TEST|matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements|These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
214387763|NCT03579797|BEHAVIORAL|Screening, referral, follow-up and health management|Field screening, remote diagnosis, comprehensive assessment, referral, and eye health management of diabetics were the main study processes. The community health service centers (CHSC) are responsible for the field screening. The designated medical institutions (DMI) of each district are responsible for the remote diagnosis and comprehensive assessment of diabetic eye diseases, especially diabetic retinopathy (DR), based on comprehensive evaluation through the remote reading system (RRS) and Shanghai eye health information service system (SEHISS). The staff of CHSC urged the referral objects promptly for further diagnosis and treatment in DMI. According to the diagnosis after clinically confirmed, all the study participants will be recommended appropriate eye health management.
214387764|NCT01863043|PROCEDURE|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
214387765|NCT01863043|PROCEDURE|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
214387766|NCT03301688|BIOLOGICAL|Toripalimab|To compare the different drug batch number with different process
214387767|NCT01068314|OTHER|Repetitive arm exercise|After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
214387768|NCT04232098|OTHER|Heat to ankle|Heat administered via hot water to ankle level
214387769|NCT04232098|OTHER|Heat to calf|Heat administered via hot water to calf level
214387770|NCT03376802|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214387771|NCT03376802|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
214387772|NCT03720782|DEVICE|LEGION Porous HA Tibial Baseplate and/or the LEGION Porous HA CR Femoral Component|LEGION Porous HA Tibial Baseplate (with and without holes) and/or the LEGION Porous HA CR Femoral Component
214387773|NCT01971580|DRUG|Ambrisentan|
214500683|NCT00507494|DRUG|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
215093885|NCT05077332|DRUG|Famotidine|80 mg tablet, QID for 14 days
215093886|NCT05077332|DRUG|Celecoxib|400 mg (initial dose) then 200 mg capsule, BID for 5 days
215093887|NCT05077332|OTHER|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
214387774|NCT00854295|DEVICE|NexGen LPS-Flex Mobile Bearing Knee|Total Knee Replacement
214387775|NCT04808128|OTHER|Drink A + SC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with simple carbohydrates.
214387776|NCT04808128|OTHER|Drink B + SC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with simple carbohydrates.
214387777|NCT04808128|OTHER|Drink C + SC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with simple carbohydrates.
214387778|NCT04808128|OTHER|Drink A + CC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with complex carbohydrates.
214387779|NCT04808128|OTHER|Drink B + CC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with complex carbohydrates.
214387780|NCT04808128|OTHER|Drink C + CC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with complex carbohydrates.
214387781|NCT03154359|DRUG|Atomoxetine Hydrochloride|Atomoxetine dose adjusted to achieve pre-defined concentration
214387782|NCT04856943|PROCEDURE|Smartconsent application|Patients asigned to smartconsent group will sign informed consent through a Tablet.
214387783|NCT04856943|OTHER|Control group|Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice
214387784|NCT04743375|OTHER|wound dressing application|Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.
214387785|NCT03929419|DRUG|intranasal insulin|application of 160 units human insulin
214387786|NCT03929419|DRUG|Placebo spray|nasal spray containing placebo solution
214387787|NCT00003284|BIOLOGICAL|filgrastim|
214387788|NCT00003284|DRUG|carboplatin|
214387789|NCT00003284|DRUG|etoposide|
214387790|NCT00003284|DRUG|ifosfamide|
214387791|NCT00003284|DRUG|paclitaxel|
214387792|NCT00003284|PROCEDURE|peripheral blood stem cell transplantation|
214387793|NCT00003284|RADIATION|radiation therapy|
214500684|NCT01082575|DEVICE|Oxygen Monitoring|No intervention
214500685|NCT00683800|DRUG|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
214500686|NCT00683800|DRUG|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
215093888|NCT05293496|BIOLOGICAL|vobramitamab duocarmazine|Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.
214387794|NCT04208360|DEVICE|StethoMe stethoscope|Assessing whether use of the StethoMe AI lung sounds analysis software provides clinical benefit by improving the identification of abnormal lung sounds.
214387795|NCT03077373|BEHAVIORAL|Counseling letter|"The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).~The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters."
214387796|NCT00462436|BEHAVIORAL|Consumption of Dietary Portfolio|The study involves following an aggressive low fat diet that is high in viscous fiber, nuts and soy protein. The diet is individually tailored to meet individual participants needs.
214387797|NCT05033743|DRUG|Secnidazole 2 GM Oral Granules|Once weekly 2g oral secnidazole for 18 weeks
214387798|NCT00356486|DRUG|Peginterferon alfa-2a, Ribavirin, epoetin-β|Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
214500687|NCT05610787|DEVICE|EXCOR Active Driving System for Pediatric VAD|The EXCOR Active Driving System - will be used with the EXCOR Pediatric VAD.
214500688|NCT02036112|PROCEDURE|conventional ELAPE|device
214500689|NCT02036112|PROCEDURE|Individual ELAPE|device
214500690|NCT00229970|DRUG|montelukast sodium|7 mg or 14 mg single injection
214500691|NCT00229970|DRUG|Comparator: Placebo|Placebo single injection
214500692|NCT05502094|OTHER|Heart Rate Variability Measurement|The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.
214500693|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit # 1
214500694|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit #1
214998057|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
214998058|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3, plerixafor (0.24mg/Kg) subcutaneously every 12 hours on days -3 and -2 and low dose total body irradiation (TBI) 200 cGY on days -2 and -1 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be cyclophosphamide (50mg/Kg) intravenously on days +3 and +4 and sirolimus with a loading dose 3 mg/m2 starting on day +5. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
214998059|NCT06814496|DRUG|Tarlatamab|Tarlatamab will be administered at a step-up dose of 1mg on Cycle 1 Day 1 and then 10 mg on Cycle 1 Day 8 and Cycle 1 Day 15 and every 2 weeks thereafter. For cycle 2 onwards, tarlatamab infusion will occur every 2 weeks on days 1 and 15 of each cycle.
214998060|NCT06814496|RADIATION|Concurrent Radiation Therapy|Standard of care RT can begin as early as Cycle 1 Day 16 and as late as Cycle 2 Day 28, assuming there is no ongoing CRS (extracranial)/ICANS (cranial).
214387799|NCT00356486|DRUG|Peginterferon alfa-2a + Ribavirin for 12 weeks|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
214387800|NCT02591420|BIOLOGICAL|VRC01|40 mg/kg of VRC01 will be administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
214387801|NCT02591420|BIOLOGICAL|Placebo for VRC01|Administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
214500695|NCT01700205|OTHER|Type of Formula|infant formula
214500696|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (1)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
214500697|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (2)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
214500698|NCT03642366|OTHER|Sham LiST Device + 5mg Tadalafil|Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
214500699|NCT02535221|DRUG|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
214500700|NCT02535221|DRUG|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
214500701|NCT05834452|PROCEDURE|The Epley Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotated 90° towards the unaffected side around the yaw axis~4. Rotate a further 90° toward the unaffected side around the yaw axis~5. Rotates back to an upright position with a 135° backward rotation around the pitch axis."
214500702|NCT05834452|PROCEDURE|The 360 Degree Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotate a further 90° backward around the pitch axis (total 225°)~4. Rotate a further 90° backward around the pitch axis (total 315°)~5. Rotate back to an upright position with an additional 45° backward rota-tion around the pitch axis (total 360°)."
214500703|NCT05834452|DEVICE|Mechanical rotational chair|TRV chair
214387802|NCT02591420|DRUG|Antiretroviral therapy (ART) (regimen will vary within countries and by patient)|ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
214387803|NCT03305302|PROCEDURE|Sample of cancerous epithelium from the tongue|Harvesting and culture of cancerous epithelium from the surgical piece
214387804|NCT00345384|DRUG|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
214500704|NCT05230966|DEVICE|Remote Ischemic Conditioning (RIC)|RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
214998061|NCT06814496|RADIATION|Sequential Radiation therapy|Standard of care radiation therapy can occur prior to Cycle 1 Day 1 (if radiation treatment is completed \<7 days prior to the start of tarlatamab) or be interdigitated with tarlatamab with a 7-day washout between RT and infusion, with RT to begin as early as Cycle 1 Day 22 and as late as cycle 2 Day 28, assuming no ongoing CRS (extracranial)/ICANS (cranial).
214998062|NCT06821269|PROCEDURE|Robotic assisted total knee arthroplasty|Total knee arthroplasty with robotic assisatance
214998063|NCT06821269|PROCEDURE|Manual total knee arthroplasty|Total knee arthroplasty without robotic assistance
214998064|NCT06821269|PROCEDURE|Robotic assisted revision total knee arthroplasty|Revision total knee arthroplasty with robotic assistance
214998065|NCT06821269|PROCEDURE|Manual revision total knee arthroplasty|Revision total knee arthroplasty without robotic assistance
214998066|NCT06819111|DRUG|Potassium Citrate Extended Release Oral Tablet|In this crossover study, patients will serve as their own controls. Patients will receive slow-release potassium citrate (UroCit-K), potassium magnesium citrate (powder), or potassium magnesium citrate (tablets). The study period will last approximately 6 weeks for each participant. Patients will be instructed to take one form of potassium citrate for one week at a time followed by a washout period for one week. This process will be completed a total of three times as we seek to study the effects of three forms of potassium citrate.
214998067|NCT06127732|DIETARY_SUPPLEMENT|Phytosterol supplements|Participants were randomized into two groups to receive diet plus phytosterols (DP) for 12 weeks, followed by a 7-day washout period with a second period of intervention, where treatments were switched, and participants received diet alone (D) and were followed for another 12 weeks.
214998068|NCT06401434|DIAGNOSTIC_TEST|On-site radiologist|All participants in this arm will be screened by CXR. All CXR images will be interpreted by only an on-site radiologist. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
214998069|NCT06401434|DIAGNOSTIC_TEST|CAD-based triage (with INSIGHT CXR software)|All participants in this arm will be screened by CXR. All CXR images will first be processed with the INSIGHT CXR CAD software (Lunit, South Korea) to identify the totally normal/clear CXR images; only those with the possibility of containing an abnormality (abnormality score ≥ 20) will be sent to the on-site radiologist for reading/interpretation. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
214998070|NCT06651593|DRUG|SAR444881|Given by IV
214998071|NCT06651593|DRUG|Cemiplimab|Given by Iv
215093889|NCT05293496|BIOLOGICAL|lorigerlimab|Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
214998072|NCT06983392|BEHAVIORAL|Abstain from smoking/vaping|They may be asked to stop smoking cigarettes or vaping during the study for 21 days. If they are asked to abstain from their product use they will be given nicotine patches and/or lozenges to help with abstinence during the study.
214998073|NCT04665206|DRUG|VT3989|25, 50, 100,150 or 200 mg capsules for oral administration.
215093890|NCT05164614|COMBINATION_PRODUCT|RT-102 (80 μg)|RaniPill capsule containing PTH with doses of 20 and 80 μg
215093891|NCT05164614|DRUG|Forteo|A commercial formulation of PTH for SC control (20 µg)
214387805|NCT00345384|OTHER|Placebo (Normal Saline)|
214387806|NCT03036501|DRUG|[^14C]-Risdiplam|\[\^14C\]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries \[μCi\]) of \[14C\]-labeled Risdiplam.
214500705|NCT05481346|PROCEDURE|Multidomain training|"The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training.~All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members."
214500706|NCT00022165|DIETARY_SUPPLEMENT|selenium|
214500707|NCT03726593|DRUG|Artesunate and Pyronaridine|Standard weight based dosing
214500708|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Pyronaridine|Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
214500709|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Mefloquine|Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
214387807|NCT00885352|DRUG|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
214387808|NCT00885352|DRUG|Comparator: Placebo|Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
214387809|NCT00885352|DRUG|Pioglitazone|Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
214387810|NCT00885352|DRUG|Metformin|Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
214387811|NCT00885352|DRUG|Glipizide|Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
214387812|NCT02508922|DIETARY_SUPPLEMENT|Vitamin D3|2,000iu vitamin D drops will be taken daily for 20 weeks
214500710|NCT03677037|OTHER|Short-term MBT|Short-term mentalization-based therapy
214500711|NCT03677037|OTHER|Long-term MBT|Long-term mentalization-based therapy
214998074|NCT04665206|DRUG|Nivolumab & Ipilimumab|"Nivolumab infusion - 360 mg every 3 weeks, 30-minute intravenous infusion~Ipilimumab infusion - 1 mg/kg every 6 weeks, 30-minute intravenous infusion"
214998075|NCT04665206|DRUG|Osimertinib|40 or 80 mg tablets for oral administration
214998076|NCT06985888|DEVICE|SpeediCath® Standard male new coating|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male new coating CH12 by HCP
214998077|NCT06985888|DEVICE|SpeediCath® Standard male|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male CH 12 by HCP
214998078|NCT06821113|BEHAVIORAL|COVID-19 Group Problem Solving|"Participants will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a personal commitment called Mi Promesa to implement COVID mitigation practices. Navigation Component will consist of providing information and linking LDLs with social service providers and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support."
214998079|NCT06821113|BEHAVIORAL|Standard of Care|Participants will receive a COVID-19 prevention flyer and social resources list only
215093892|NCT05164614|COMBINATION_PRODUCT|RT-102 (20 μg)|RaniPill capsule containing PTH with dose of 20μg
215093893|NCT03631134|DRUG|SGLT2 inhibitor|Patients will be gave SGLT2 inhibitor 10mg per day
214387813|NCT02508922|DIETARY_SUPPLEMENT|Placebo|Matching placebo drops will be taken daily for 20 weeks
214387814|NCT02312180|BIOLOGICAL|Plasminogen (Human) Intravenous|Plasma-derived purified plasminogen formulated for intravenous administration
214387815|NCT04822480|BEHAVIORAL|Diabetes Prevention Program (DPP)|Individuals with prediabetes can mitigate the risks and costs of diabetes by taking preventative action, such as participation in a National Diabetes Prevention Program (DPP). The DPP began as a multisite randomized controlled trial demonstrating the effectiveness and cost-benefit of a 12-month intensive lifestyle intervention over pharmaceutical treatment for preventing or delaying diabetes among prediabetic participants. In 2010, Congress authorized the Centers for Disease Control and Prevention to lead the dissemination of the DPP as a targeted approach (high risk populations) and population-based strategy to reduce the incidence of diabetes and diabetes-related healthcare costs. The goal is to achieve modest weight loss (7%) by developing and implementing behavior change skills resulting in lifestyle modifications such as physical activity (150 minutes per week) and dietary and nutritional practices.
214387816|NCT04307498|BEHAVIORAL|Intensive Outpatient Program - Prolonged Exposure|Prolonged Exposure for Posttraumatic Stress Disorder (PE for PTSD; Foa, Hembree, \& Rothbaum, 2007) is an empirically supported behavioral therapy that utilizes exposure-based interventions to target the psychological mechanisms (i.e., avoidance; maladaptive cognitive changes) thought to maintain trauma-related symptoms. IOP-PE includes 15 days of PE treatment delivered over three consecutive weeks. The standard outpatient PE protocol has modified with seven treatment augmentations to meet the unique needs of post-9/11 veterans.
214387817|NCT03290157|DEVICE|ColoprAPP|Additional downloaded SPA for reminding the crucial steps of colonoscopy preparation
214387818|NCT04386226|DIETARY_SUPPLEMENT|Ambrotose LIFE|Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.
214387819|NCT04386226|DIETARY_SUPPLEMENT|Advanced Ambrotose|Advanced Ambrotose contains aloe vera extract inner leaf gel, arabinogalactan, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, and rice starch
214387820|NCT04386226|OTHER|Placebo|Maltodextrin
214387821|NCT02848261|BEHAVIORAL|Developmental Demands|Education and training related to use of CGM in this age group
214387822|NCT02848261|BEHAVIORAL|Distress Reduction|Education and training on reducing distress
214387823|NCT02848261|BEHAVIORAL|Remote Monitoring|Education and training on the use of remote monitoring
214387824|NCT02848261|BEHAVIORAL|Fear of Hypoglycemia|Education and training on reducing fear of hypoglycemia
214387825|NCT02848261|BEHAVIORAL|No intervention|No intervention - serves as the control group
214387826|NCT03740880|OTHER|Dual trigger|dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
214387827|NCT02252458|DRUG|Fentanyl|
214500712|NCT05316766|OTHER|Physical rehabilitation|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on conventional therapy
214687872|NCT03105440|OTHER|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
214687873|NCT00137774|DRUG|Bevacizumab|Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
214687874|NCT00137774|DRUG|Temozolomide|Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.
214687875|NCT04443127|DEVICE|Virtual Reality Training Session|VR based motor priming intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
214687876|NCT04443127|BEHAVIORAL|Motor-Relearning Program|Motor-Relearning Program intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
214387828|NCT00068874|BEHAVIORAL|Coping skills and cognitive restructuring techniques|This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.
214387829|NCT00068874|BEHAVIORAL|Educational training|Participants will attend five study visits that will include disease-appropriate education materials.
214687877|NCT00127556|PROCEDURE|Label applied to blood bag|
214998080|NCT06821113|BEHAVIORAL|Booster session|"Participants in this group will also receive a booster phone call 10 to 15 days after the small group intervention to provide brief prompts to encourage participants to act on their personal commitments and encourage them to seek community resources."
214998081|NCT06305026|DIAGNOSTIC_TEST|Muscle- and skin biopsies|RA patients with and without concomitant fibromyalgia will be examined with muscle and skin biopsies.
214387830|NCT03491748|DRUG|ETX0282|Oral Gelatin capsules
214387831|NCT03491748|DRUG|Cefpodoxime proxetil|Oral tablets
214387832|NCT03491748|DRUG|Placebo|Oral Gelatin capsules
214387833|NCT05445856|DRUG|Methadone|Methadone is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
214998082|NCT06389513|BIOLOGICAL|MCV4|4 doses of vaccine on Day 0, Day30, Day 60 and Month 12
214998083|NCT00327093|DRUG|cetuximab|indication : second intention treatment
214998084|NCT00327093|DRUG|bevacizumab|Indication: first intention treatment
214387834|NCT05445856|DRUG|Fentanyl|Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
214387835|NCT03523182|DIETARY_SUPPLEMENT|Spirulina|"Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.~Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.~We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend."
214387836|NCT03523182|DIETARY_SUPPLEMENT|Control|Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.
214393949|NCT03708419|OTHER|Suboptimal diet|"The optimal diet for the other metabolic phenotype will be considered as suboptimal/ control diet. For the MIR phenotype this is the high protein, high fiber, low fat diet; for the LIR phenotype this is the high monounsaturated fatty acid diet. See the description above."
214393950|NCT05264233|DIETARY_SUPPLEMENT|Coconut oil|50 g of coconut oil will be added to the test meal for breakfast and 30 g of coconut oil will be added to the test meal for lunch
214393951|NCT05264233|DIETARY_SUPPLEMENT|Butter|50 g of butter will be added to the test meal for breakfast and 30 g of butter will be added to the test meal for lunch
214393952|NCT05264233|DIETARY_SUPPLEMENT|Vegetable oil|50 g of vegetable oil will be added to the test meal for breakfast and 30 g of vegetable oil will be added to the test meal for lunch
214393953|NCT02757222|RADIATION|Escalated Dose|"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
214393954|NCT02757222|RADIATION|Standard Dose|"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
214393955|NCT01333540|DRUG|TD-1211|Escalating doses
214393956|NCT01333540|DRUG|Placebo|Placebo once daily
214393957|NCT02444234|DRUG|Tedizolid PO|Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
214393958|NCT02444234|DRUG|Tedizolid IV|Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
214393959|NCT05668364|OTHER|Outdoor cold air exposure|Exposure to outdoor cold air (\<10°C or \<50°F, intervention group) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
214393961|NCT05539521|DRUG|Remimazolam Besylate|sedation drugs
214387837|NCT01129505|BEHAVIORAL|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|"Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.~Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.~Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies."
214387838|NCT03263234|OTHER|8 weeks of circadian adjusted LED-based lighting (CALED)|The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
214387839|NCT05842460|BEHAVIORAL|Nutrient warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, to images of food products.
214387840|NCT05842460|BEHAVIORAL|Nutrient and ultraprocessed warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, and an experimental ultraprocessed warning label to images of food products.
214387841|NCT04946955|OTHER|Application and website with or without promotion|Development of an application and a website to de-stigmatise mental health and support the user in seeking help
214387842|NCT02254837|DEVICE|Zilver PTX Drug-Eluting Stent|
214387843|NCT01170884|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.
214387844|NCT01170884|DRUG|bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops|1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
214387845|NCT00773955|DRUG|R-(-)-gossypol acetic acid|Given orally
214387846|NCT00773955|OTHER|pharmacological study|Correlative studies
214387847|NCT00773955|OTHER|laboratory biomarker analysis|Correlative studies
214387848|NCT01199458|DRUG|alfentanil|20 mikrogr/kg
214387849|NCT01199458|DRUG|saline|The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
214387850|NCT02267720|PROCEDURE|Occlusal-proximal ART restorations - Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
214387851|NCT02267720|PROCEDURE|Occlusal-proximal ART restorations - Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
214387852|NCT03961113|OTHER|Assessment by questionnaire|"At diagnosis a gerontological evaluation will be carried out including the following tests: ADL, iADL, MNA, SF 36, SPPB, FRIED criteria and GDS. The set of scales and scores of the procedure is commonly used in geriatrics to assess the fragility of the patient.~A monthly telephone reassessment conducted by an ARC will collect ADL and iADL from the first month to the eleventh month. The end-of-study consultation will be conducted by a geriatrician at the 12th month and will include the following tests: ADL, iADL, MNA, SF 36, the SPPB, the criteria of FRIED and the GDS"
214387853|NCT00840372|PROCEDURE|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
214387854|NCT02223065|DRUG|Saxagliptin|
214387855|NCT02223065|DRUG|Dapagliflozin|
214387856|NCT02783118|OTHER|Self administered online CBT|"The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.~The following exercises are included in the app:~1. The Emotional Pulse exercise~2. The Sticky Notes exercise~3. The Find Irrational Thoughts~4. The Change Irrational Thoughts"
214387857|NCT06442813|BEHAVIORAL|EFT GROUP|One times one pregnancy
214387858|NCT06222008|OTHER|no Intervention|Observational study, no intervention
214387859|NCT01634958|BIOLOGICAL|Depigoid Phleum|Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
214387860|NCT03758027|BEHAVIORAL|CARESS|"The goals of each component are as follows:~* Communicate alternatively - a method to bring the brain back and remove the individual from his/her limbic system;~* Release endorphins - a release for the internal stress created by the emotion; and~* Self-soothe - a method of quelling and containing."
214393962|NCT05539521|DRUG|Propofol|Propofol
214393963|NCT01183650|DRUG|Tadalafil|5 mg, administered orally, daily for 10 days
214393964|NCT06393686|OTHER|yoga|The yoga intervention will be implemented every two weeks, with each session lasting 45 minutes and implemented for 10 weeks. Sessions will always be led by the same certified yoga instructor. Each session will include a variety of different yoga poses, as well as breathing techniques and deep relaxation methods.
214393965|NCT00037557|DRUG|BeneFIX|
214393966|NCT05092243|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
214387861|NCT03758027|BEHAVIORAL|Isometric Exercise|5-minute protocol for cravings management and affect regulation
214387862|NCT03947359|DIAGNOSTIC_TEST|Fibroscan Touch 502 M probe|Measurement of liver stiffness
214998085|NCT06587139|BEHAVIORAL|Teen Connection Project (TCP)|The Teen Connection Project (TCP) includes seven 90-minute sessions facilitated by transgender and/or gender minority (TGM) adults. Each transgender and/or gender minority youth (TGMY) will be paired with a TGM adult mentor based on TGMYs' rank-ordered preference for mentors. The research team seeks to match mentors \& mentees such that each TGMY is matched with one of their top 3 preferred mentors. Mentors and mentees participate together in each session along with other mentors \& mentees. Facilitators direct activities/discussion to promote TGMY social-emotional skills acquisition and facilitate mentor-mentee conversations. TCP sessions also include mentor-mentee breakout sessions where mentors share challenges they personally faced as TGMY and how they overcame them. Break-out discussions focus on self-acceptance, coming out, dating questions, hopes and goals for the future, \& how other marginalized social identities, such as race and ethnicity, intersect with identifying as TGMY.
214387863|NCT03947359|DIAGNOSTIC_TEST|Fibroscan Touch 502 S probe|Measurement of liver stiffness
214387864|NCT03068806|DIAGNOSTIC_TEST|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
215093894|NCT02156778|BEHAVIORAL|Active Comparator: Extended Standard Care (Stroke Card)|"Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment."
214387865|NCT00152971|DRUG|Dabigatran Dose 1 - day 2 to completion|low dose regimen taken once daily
214387866|NCT00152971|DRUG|Dabigatran Dose 1 - day 1|low dose regimen taken once daily
214387867|NCT00152971|DRUG|Dabigatran Dose 2 - day 2 to completion|high dose regimen taken once daily
214387868|NCT00152971|DRUG|Dabigatran Dose 2 - day 1|high dose regimen taken once daily
214387869|NCT00152971|DRUG|Enoxaparin|30 mg subcutaneously twice daily
214387870|NCT03292146|DRUG|Denosumab 60 MG [Prolia]|Denosumab 60mg injection at baseline and 6 months
214387871|NCT03292146|DRUG|Placebo Injection|Placebo Injection at baseline and 6 months
214387872|NCT03292146|DRUG|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at Month 12 through 24 months.
214387873|NCT01058434|DRUG|TKI258|
214387874|NCT05983744|OTHER|0 Hz Control|Lower body negative pressure (LBNP) applied to -60 mmHg for 10-min
214387875|NCT05983744|OTHER|0.1 Hz PPT|Lower body negative pressure (LBNP) applied at a frequency of 0.1 Hz from -30 mmHg to -90 mmHg
214387876|NCT05983744|OTHER|0.05 Hz PPT|Lower body negative pressure (LBNP) applied at a frequency of 0.05 Hz from -30 mmHg to -90 mmHg
214393967|NCT00649493|DRUG|Rabeprazole Sodium Tablets 20 mg|20mg, single dose fed
214393968|NCT00649493|DRUG|Aciphex® Tablets 20 mg|20mg, single dose fed
214393969|NCT05743764|DRUG|HU007|cyclosporine 0.02%, trehalose 3%
214393970|NCT05743764|DRUG|Restasis|cyclosporine 0.05%
214393971|NCT05743764|DRUG|Moisview Eye drop|trehalose 3%
214393972|NCT00466674|DRUG|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
214393973|NCT02971059|DIETARY_SUPPLEMENT|Phenylalanine intake|Phenylalanine will be provided as graded intakes ranging from 7-40 mg/kg/day
214393974|NCT01284140|BEHAVIORAL|Sleep and circadian rhythm promotion|This multifaceted intervention attempts to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. The intervention began the morning after enrollment and enforced a specific period of enhanced light exposure from 9:00 a.m. to noon. The initial target of 5,000 lux administered by light box (Sunsation, SunBox Co.) was reduced to 400-700 lux after the first 10 subjects were enrolled in the study.
214393975|NCT01284140|BEHAVIORAL|Usual care|Usual care.
214393976|NCT04595734|OTHER|No intervention due to observational methods of study|No intervention due to observational methods of study
214393977|NCT00088205|DRUG|enzastaurin|500 milligrams (mg), oral, daily, up to six 28-day cycles
214393978|NCT03192215|DRUG|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
214393979|NCT03192215|DRUG|Aspirin|Aspirin 81 mg by mouth once daily.
214393980|NCT02593032|DEVICE|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
214393981|NCT00110513|BIOLOGICAL|Recombinant human antithrombin (rhAT)|Up to 24 hours prior to the scheduled elective surgical procedure, caesarean section, or delivery induction, each patient will receive an initial intravenous loading dose followed by a continuous intravenous infusion of recombinant human antithrombin (rhAT) that will target and maintain an AT activity that is \> 80% and \< 120% of normal. The dosing objective for all study patients is maintenance of the AT activity at \> 80% and \< 120% of normal during the high-risk period for thromboembolic events. Dosing and dose adjustments will be based on the results of AT activity determinations performed prior to and during treatment.
214393982|NCT03856021|PROCEDURE|Microfracture with Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate harvested and prepared from the iliac crest
214387877|NCT01070823|DRUG|Tysabri® (natalizumab)|Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
214387878|NCT05799937|PROCEDURE|Non Surgical Root Canal Treatment|After administration of LA and rubber dam isolation, access cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with rotary instruments . 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
214387879|NCT02231437|DRUG|Berodual®|
214387880|NCT04017390|DRUG|Theraworx Foam|Apply Theraworx Foam alone
214387881|NCT04017390|DRUG|Placebo Foam|Apply placebo foam alone
214387882|NCT04017390|OTHER|Theraworx Foam and night splint|Apply Theraworx Foam and night time splint
214387883|NCT04017390|OTHER|Placebo Foam and night time splint|Apply placebo foam and night time splint
214387884|NCT01197820|DEVICE|MRI|"Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96\*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.~In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128\*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.~Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed"
214387885|NCT00366301|DRUG|Insulin glargine injection|Once daily for 14 weeks
214387886|NCT00366301|DRUG|metformin|Up to 4 pils per day (2g per day) maximum
214387887|NCT00366301|DRUG|Placebo pill|Up to 4 pills per day
214387888|NCT05351645|BEHAVIORAL|Treatment|"Once per day for a 14-day trial period, participants in the Treatment group were assigned to read a first-person narrative about a past issue with suicidal thoughts or behaviors. These narratives each contained positive elements, such as providing details about how the author had overcome issues with suicide, suggesting that people with suicidal thought are not alone, or encouraging people with suicidal thoughts/behaviors to have hope."
214387889|NCT03792217|OTHER|1.3% NaOCl|Endodontic irrigant
214387890|NCT03792217|OTHER|5.25% NaOCl|Endodontic irrigant
214387891|NCT00179712|DRUG|CC-5013|
214387892|NCT00179712|DRUG|topotecan|
214387893|NCT02354963|PROCEDURE|In vitro fragmentation of the ovarian tissue|Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
214387894|NCT03976895|PROCEDURE|Supine position (SP)|"Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.~Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
214387895|NCT03976895|PROCEDURE|Prone position (PP)|"Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.~Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
214387896|NCT00955734|OTHER|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
214387897|NCT00955734|OTHER|Immobilization|This set of patients will be casted for 6 weeks after surgery.
214387898|NCT01896115|DEVICE|Vercise DBS settings|Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
214387899|NCT02796287|PROCEDURE|achieving a neuropsychological examination in the acute amnesic phase|achieving a neuropsychological examination in the acute phase in addition to the normal protocole
214387900|NCT02796287|PROCEDURE|Neurological consultation with neuropsychological evaluation|Neurological consultation with neuropsychological evaluation one year after the acute amnesic phase
214387901|NCT02796287|RADIATION|MRI|Brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium, one year after the acute amesic phase
214387902|NCT01253122|DRUG|TRx0037|
214387903|NCT02843958|DEVICE|HEMOPTIC|
214387904|NCT01280318|PROCEDURE|head and neck surgery|Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.
214387905|NCT01830192|OTHER|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
214387906|NCT01830192|OTHER|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
214387907|NCT01607385|DRUG|GSK2330672|BID, repeat doses
214387908|NCT01607385|DRUG|Placebo|BID, repeat doses
214387909|NCT01607385|DRUG|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
214387910|NCT05947123|BEHAVIORAL|Patient health care observational follow up after 2 prophylactic tratments|Real-life, observational, single-center cohort study to describe the efficacy of prophylactic treatment in patients after failure of at least 2 prophylactic treatments. Patients included in the study will be followed up in consultations or day hospitals according to their usual care, and will be asked to complete the MIDAS, HIT-6, PGIC, HAD and WPAI questionnaires at each visit. Data describing their care will be extracted from computerized patient records.
214393983|NCT03856021|PROCEDURE|Microfracture|All surgeons will use a 2 mm microfracture pick to perform the microfracture procedure. Using the 2 mm pick, surgeons will make 5 holes per 10 cm2.
214393984|NCT02061761|BIOLOGICAL|BMS-986016|Specified Dose on Specified Days
214387911|NCT06475716|BEHAVIORAL|Internet-based guided programme Spring|Spring is an online guided self-help programme based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps designed for delivery over 8 weeks. The steps cover psychoeducation, grounding techniques, management of anxiety, behavioral activation, imaginal exposure, cognitive restructuring, in vivo exposure, and prevention of relapse. The user of the programme also receives up to 3 hours of therapist guidance.
214387912|NCT02827942|DRUG|vonoprazan 20 mg bid|Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
214387913|NCT02827942|DRUG|Amoxicillin 500 mg tid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
214387914|NCT02827942|DRUG|Amoxicillin 750 mg bid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
214387915|NCT02827942|DRUG|Clarithromycin 200 mg bid|Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
214387916|NCT02827942|DRUG|Metronidazole 250 mg bid|Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
214387917|NCT06255093|BEHAVIORAL|Community-based recreation program referral|Provide referral to local Parks and Recreation for programs of interest and participation. Participants will have the option to join a program (up to 4months) and have access to additional resources via study webpage to identify support services.
214387918|NCT06255093|BEHAVIORAL|Pre-surveys only|Receive online wellness education and anxiety treatment options information
214387919|NCT02811900|PROCEDURE|Roux en Y gastric bypass|Laparoscopic RYGB is performed as following: a gastric pouch of approximately 30mL was obtained using successive firings of the Endo GIATM linear stapler, followed by the creation of an antecolic alimentary limb of 150cm and of a biliopancreatic limb of 75cm. A gastrojejunal anastomosis was fashioned with the PCEEA™ 28 circular stapler until 2012, and using the Endo GIA™ linear stapler afterwards. The mesenteric defect and Petersen's defect were closed using a non-absorbable running suture.
214387920|NCT02811900|PROCEDURE|Sleeve gastrectomy|Laparoscopic SG is performed as following: after greater curvature mobilization, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using successive firings of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
214998086|NCT06825897|OTHER|Conventional Triage for Mechanical Thrombectomy|Participants undergo the conventional standard-of-care triage process. Upon arrival at the thrombectomy-capable center, patients first undergo an initial evaluation in the emergency department (ED), which includes diagnostic imaging (CT or MRI) to confirm eligibility for mechanical thrombectomy (MT). If the patient is found to have a large vessel occlusion (LVO) suitable for thrombectomy, they are transferred to the neurointerventional suite for treatment.
214387921|NCT02811900|PROCEDURE|Gastric banding|Laparoscopic gastric banding is performed as following: a perigastric tunel is performed by blunt dissection and the banding is calibrated over the stomach.
214387922|NCT02811900|PROCEDURE|Intragastric balloon|Flexible endoscopy is used to place intragastric balloon for a maximum interval of six months.
214387923|NCT05448586|DRUG|Opioid|Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
214387924|NCT04071470|BEHAVIORAL|Storytelling|Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP
214387925|NCT04071470|DRUG|PrEP|Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
214387926|NCT06141304|DRUG|Plerixafor|Plerixafor was injected subcutaneously to participants twice per day for five consecutive days ten days post DLI.
214387927|NCT01076088|DRUG|Sitagliptin 50 mg|Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
214387928|NCT01076088|DRUG|Metformin 500 mg|Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
214387929|NCT01076088|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
214387930|NCT01076088|DRUG|Placebo|Matching placebo tablets to sitagliptin or metformin for 24 weeks.
214387931|NCT01076088|DRUG|Metformin 850 mg|Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
214387932|NCT05937009|OTHER|Orienteering exercise program|Orienteering exercise program running for 12 weeks (30-45 minutes, 3 sessions/week). Sessions will have 4 phases: 1) Signature of attendance sheet; 2) warm-up exercises for 5 minutes; 3) Start of orienteering proofs, where the departs will occur individually, with 3 interval minutes between participants; 4) stretches session, to return to a calm state.
214393985|NCT02061761|BIOLOGICAL|BMS-936558|Specified Dose on Specified Days
214998087|NCT06825897|OTHER|Direct Transfer to Angiography Suite (DTAS|Patients who arrive at the thrombectomy-capable center (from home, mobile stroke units, or interfacility transfer) are immediately transferred to the neurointerventional suite, bypassing the emergency department (ED). Upon arrival in the neurointerventional suite, initial neuroimaging (typically using flat panel CT or other imaging modalities) is conducted to confirm the presence of a large vessel occlusion (LVO). If the patient is eligible for mechanical thrombectomy (MT), treatment is initiated directly in the angiography suite. This approach aims to reduce delays in care and improve clinical outcomes by providing faster access to thrombectomy treatment.
214393986|NCT04415697|DIAGNOSTIC_TEST|Gene expression test using nanostring technology.|Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology
214393987|NCT02337478|DRUG|Vincristine Sulfate Liposome|Given via injection
214393988|NCT02337478|OTHER|Laboratory Biomarker Analysis|Correlative studies
214393989|NCT02258464|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update)
214393990|NCT02258464|DRUG|Placebo (saline)|Up to 6 cycles of saline injection
214387933|NCT03676920|BEHAVIORAL|Discussions of Cost App (DISCO App)|The DISCO App is an app-based and patient-focused intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions. The DISCO App allows patients to provide basic demographic information (e.g., employment status, insurance status, etc), and uses that information to provide patients with an individually-tailored list of treatment cost questions they can ask their provider.
214500713|NCT05316766|OTHER|Physical rehabilitation interactive table|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on multi-user touch surface
214500714|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
214500715|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
214387934|NCT02926508|DIETARY_SUPPLEMENT|Bimuno (BGOS)|"The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink."
214387935|NCT02926508|OTHER|Maltodextrin|"Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention."
214387936|NCT03143335|PROCEDURE|Retropectoral immediate breast reconstruction|Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.
214387937|NCT03143335|PROCEDURE|Prepectoral immediate breast reconstruction|Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
214387938|NCT03411889|DIAGNOSTIC_TEST|MRI scanning|MRI scanning during tear drainage
214387939|NCT02383511|DRUG|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
214387940|NCT02383511|DRUG|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
214500716|NCT03653897|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
214687878|NCT05115279|PROCEDURE|breast conservative surgery for post chemotherapy tumour size|"* Skin preparation by povidine iodine.~* Excision of the mass with safety margin.~* Sentinel axillary lymph node or complete axillary clearance depend on axillary lymph node status~* All specimens were oriented with sutures~* A frozen section examination of the specimen was performed intraoperative~* When the margin status was inadequate, a re-excision was performed~* Closure as drawn by different oncoplastic technique"
214387941|NCT02383511|DRUG|SMT C1100|Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
214500717|NCT03653897|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
214500718|NCT05912218|BIOLOGICAL|MEI6570|Saline Control
214687879|NCT02096146|PROCEDURE|TMT Fusion plate|Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
214687880|NCT02096146|PROCEDURE|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
214687881|NCT05565300|OTHER|Cycling exercise|30 minutes of cycling (90 rpm).
214687882|NCT05565300|OTHER|Cognitive tasks|30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
214387942|NCT06100601|BEHAVIORAL|ANS regulation therapy|innovative intervention for functional dysphonia
214387943|NCT06100601|BEHAVIORAL|conventional voice therapy (CVT)|conventional voice therapy traditionally provided for functional dysphonia
214500719|NCT02251652|DRUG|Ingenol Mebutate|Ingenol mebutate 0.05% gel
214500720|NCT02251652|PROCEDURE|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
214500721|NCT00494949|DRUG|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
214500722|NCT00494949|DRUG|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
214500723|NCT01644994|COMBINATION_PRODUCT|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
214500724|NCT03496883|BIOLOGICAL|Recombinant Activated Factor VII (rFVIIa)|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
214998088|NCT06988176|DIAGNOSTIC_TEST|Frailty assessment, nutrition assessment, cognition assessment, muscle strength testing|"Participants will undergo a structured frailty and muscle-strength assessment battery performed during their routine preoperative evaluation. These assessments serve as the primary exposure measures of interest and include:~Clinical Frailty Scale (CFS) evaluation (functional frailty assessment) Respiratory muscle strength assessment (Maximal Inspiratory Pressure (MIP) and Maximal Expiratory Pressure (MEP) using a MicroRPM handheld respiratory pressure meter) Hand-grip strength measurement (using Jamar dynamometer) Physical performance evaluation (Timed Up-and-Go (TUG) test) Skeletal muscle mass estimation (Bioelectrical impedance analysis, InBody 120) Muscle thickness measurement (Rectus femoris muscle thickness using portable ultrasound) Cognitive function screening (Mini-Cog test) Nutritional risk screening (Perioperative Nutrition Screen \[PONS\]) No additional interventions beyond these observational assessments will be conducted."
214998089|NCT06610838|OTHER|Health Assessments|Participants will complete the blood tests, questionnaires, cardiovascular tests, and pulmonary test at visits 1, 2, and 4. Non-Contrast Chest CT and cardiopulmonary treadmill (VO2 max) stress tests will occur at visits 1 and 4. Visit 3 will not include cardiovascular and pulmonary tests.
214998090|NCT06859008|PROCEDURE|Biopsy|Undergo biopsy
214687883|NCT03085641|DEVICE|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
214687884|NCT00069576|BEHAVIORAL|nutritional counseling|
214387944|NCT06100601|BEHAVIORAL|ANS regulation therapy + CVT|combination of ANS regulation therapy and CVT
214387945|NCT00771875|DRUG|Rabbit Antithymocyte Globulin (RATG)|All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
214387946|NCT00771875|DRUG|Rituximab|Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
214387947|NCT00771875|DRUG|Bortezomib|Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
214387948|NCT00771875|DRUG|Acetaminophen|Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
214387949|NCT00771875|DRUG|Antihistamine|Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
214387950|NCT00771875|DRUG|Methylprednisolone|Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
215093895|NCT02156778|BEHAVIORAL|Active Comparator: Standard Care|"In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment."
214387951|NCT02032667|BEHAVIORAL|Multi-player condition|Children in the multi-player condition will be able to play with and compete against other children in real time.
214387952|NCT00941538|DIAGNOSTIC_TEST|Experimental: Screening with EBV VCA/EBNA1-IgA testing|Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.
214387953|NCT01534455|DRUG|Lapatinib + 1,23 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
214387954|NCT01534455|DRUG|Lapatinib + 1,76 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
214387955|NCT03306043|DRUG|Mepolizumab|Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
214387956|NCT04089774|BEHAVIORAL|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
214500725|NCT03496883|BIOLOGICAL|Placebo|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
214500726|NCT03414645|BIOLOGICAL|CAM-101 10%|fibrinogen-depleted human platelet lysate
215093896|NCT04083950|BIOLOGICAL|Vivotif Typhoid Oral Vaccine|One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
215093897|NCT04083950|DRUG|Aspirin (Positive Control)|Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
215093898|NCT01918332|DRUG|Valsartan 160mg|
215093899|NCT01918332|DRUG|Rosuvastatin 20mg|
215093900|NCT01918332|DRUG|Valsartan 160mg placebo|
215093901|NCT01918332|DRUG|Rosuvastatin 20mg placebo|
215093902|NCT02408523|DRUG|Lacosamide Tablet|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
215093903|NCT02408523|DRUG|Lasosamide Oral Solution|"* Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
215093904|NCT02408523|OTHER|Placebo Tablet|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
215093905|NCT02408523|OTHER|Placebo Oral Solution|"* Active Substance: Placebo~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
215093906|NCT03964792|GENETIC|DREPAGLOBE drug product|Each patient will receive a single IV infusion of DREPAGLOBE drug product
215093907|NCT05216029|OTHER|Best Practice|Receive standard of care
215093908|NCT05216029|OTHER|Informational Intervention|View oncology dashboard
215093909|NCT05216029|OTHER|Questionnaire Administration|Ancillary studies
215093910|NCT06426849|OTHER|Liuzijue Exercise|"LiuzijueExercise includes inhalation and exhalation through various mouth patterns to manage and control the rise and fall of the breath in the body. It is performed by delivering 6 distinct sounds, (xū,hē, hū sī, chuī, and xī) through termination along with comparing body activities.~The following are 6-8 vital parts of body movements:~1. Swaying and twisting~2. Hip rotations~3. Arm movements~4. Knee bends~5. Foot pivots~6. Spine elongation~7. Hand gestures~8. Breath synchronization Frequency: 1 session per day for a week Intensity:In first week 1 set of Luizijue exercise will be performed then progressively increase to 4 sets till 6th week .~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Luizijue Exercise."
215093911|NCT06426849|OTHER|Tai Chi Chuan Exercise|"Tai Chi Chuan Exercise combines deep diaphragmatic breathing and relaxation with many fundamental postures.~Names of the 10 Movements in Sequence~1. Commencing Form~2. Repulsing the Monkey~3. Brush Knee~4. Parting the Horse's Mane~5. Cloud Hands~6. Golden Cockerel Standing on the Left, then the Right~7. Kick Out Right, Kick Out Left~8. Grasping the Bird's Tail~9. Cross Hands or Embrace the Tiger~10. Closing Form Frequency: 3 sessions / week Intensity: Initially each posture will be performed 3 times then progressively leads to 6 or 10 reps according to patient tolorance.~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Tai Chi Chuan Exercise."
214387957|NCT04475848|DRUG|RO6953958|"Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD)."
214387958|NCT04475848|DRUG|Placebo|"Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg."
214387959|NCT04475848|DRUG|Midazolam|Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
214387960|NCT05245799|BEHAVIORAL|Speech Language Therapy|Children who are deaf/hard of hearing will receive typical speech and language therapy with a speech pathologist. Reading time is prescribed 20 min, 3x/week.
214387961|NCT05245799|BEHAVIORAL|Digital Software Application|The Hear Me Read app is an IOS-based software application that enables parents and speech-language pathologists to partner together to help deaf/hard of hearing children (D/HH) achieve reading, speech and language goals through interactive digital storybook reading.
214387962|NCT02685371|BEHAVIORAL|Breathing|Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
214387963|NCT00516750|DRUG|cisplatin|
214387964|NCT00516750|DRUG|doxorubicin hydrochloride|
214387965|NCT00516750|DRUG|methotrexate|
214387966|NCT00516750|DRUG|vinblastine|
214387967|NCT00516750|GENETIC|gene expression profiling|
214387968|NCT00516750|PROCEDURE|neoadjuvant therapy|
214387969|NCT06441058|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
214387970|NCT00508339|BEHAVIORAL|Questionnaire|Toronto Extremity Salvage Score (TESS) questionnaire.
214387971|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period."
214387972|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
214387973|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
214387974|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
214387975|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
214387976|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
214387977|NCT05565235|DRUG|patients will receive intraoperative serratus block with bupivacaine|no additives
215093912|NCT05800275|DRUG|Tucatinib Oral Tablet|300 mg, twice daily
215093913|NCT05800275|DRUG|Capecitabine tablets|1000 mg/m², twice daily on days 1-14 of each 21-day cycle
214387978|NCT05565235|DRUG|serratus block with bupivacaine /magnesium|magnesium added
214387979|NCT05565235|DRUG|serratus block with bupivacaine with nalbuphine|nalbuphine added
214387980|NCT02529397|BEHAVIORAL|Adaptive Working Memory Training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.
214387981|NCT02529397|BEHAVIORAL|Non-adaptive cognitive training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
214387982|NCT02494206|DRUG|QBX258|Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
214387983|NCT04276090|DEVICE|Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.|Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
214387984|NCT04276090|DRUG|Hepatic artery infusion pump floxuridine and dexamethasone|Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump
214387985|NCT04276090|DRUG|Systemic chemotherapy for colorectal liver metastases|Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)
214387986|NCT04276090|DRUG|Systemic chemotherapy for intrahepatic cholangiocarcinoma|Patients will receive disease-appropriate systemic chemotherapy for intrahepatic cholangiocarcinoma (gemcitabine/oxaliplatin or gemcitabine alone)
214387987|NCT01799720|DIETARY_SUPPLEMENT|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
214387988|NCT01799720|DIETARY_SUPPLEMENT|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
214393991|NCT02258464|OTHER|Background hormonal therapy|Prescribed by PI and was provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
214393992|NCT03381508|DEVICE|Brizzy continuous positive pressure device|Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.
214393993|NCT05112211|DRUG|Doxycycline Hyclate|patients administrated with doxycycline tablets 100mg orally per day
214393994|NCT03012789|PROCEDURE|Surgery|Surgical excision
215093914|NCT05800275|DRUG|Trastuzumab Injection|Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
215093915|NCT02915913|BEHAVIORAL|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
214387989|NCT01799720|DRUG|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
214387990|NCT04440644|BEHAVIORAL|BBI|administration of psychometric test
214387991|NCT04465058|OTHER|COVID19|viral infection
214387992|NCT01234649|DRUG|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
214387993|NCT01234649|DRUG|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
214387994|NCT02904109|DRUG|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
214387995|NCT02904109|DRUG|Placebo|Once daily oral administration of placebo mannitol for 8 days.
214387996|NCT00515398|OTHER|Observation|Ex vivo administration of AT2220
214387997|NCT00318149|BIOLOGICAL|Fluarix|1 dose administered intramuscularly in the deltoid region of the non-dominant arm
214387998|NCT00318149|BIOLOGICAL|Fluarix-AS25|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
214387999|NCT00318149|BIOLOGICAL|Fluarix-AS50|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
214388000|NCT00318149|BIOLOGICAL|Fluarix-AS01B|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
214388001|NCT00318149|BIOLOGICAL|Fluarix-AS01E|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
214388002|NCT03948425|RADIATION|spectral CT|Head spectral CT
214388003|NCT02916004|DEVICE|Measurement of NFR and PDR|Feasibility testing of NFR and PDR in sedated, ventilated patients. Comparison of NFR and PDR with standard routine care of pain assessment
214388004|NCT04663568|DEVICE|Levonorgestrel-releasing intrauterine system|Levonorgestrel-releasing intrauterine system will be inserted during the menstrual cycle
214388005|NCT06428838|BIOLOGICAL|Eptinezumab|The study treatment consists of a single infusion of eptinezumab (100mg/mL).
214388006|NCT06428838|OTHER|Standard of Care|SoC may include a combination of Toradol, Metoclopramide, and/or Benadryl. Ketamine and/or Midazolam may also be used, according to a stepwise approach, at the discretion of the treating physician. The timing and dose of all medication(s) administered in the ED will be recorded.
214388007|NCT01269008|DEVICE|Medtronic ePID 2.0|Closed loop system is an automated insulin delivery system based on body blood sugar. It consists of an Insulin pump, glucose sensor, and a device presently a laptop with all the algorithms.
214388008|NCT06220383|PROCEDURE|Hall technique|Prepless crown technique
214388009|NCT06220383|PROCEDURE|Conventional technique|1 or 1,5 mm preparation on mesial, distal and occlusal of the tooth
214388010|NCT02591680|OTHER|Neuromuscular training|
214388011|NCT02591680|OTHER|Muscle strengthening|
214388012|NCT02591680|DEVICE|Sensorimotor|
214388013|NCT06312293|DEVICE|Transcutaneous Vagus Nerve Stimulation|All techniques used to stimulate the vagal nerve are called vagus nerve stimulation.
214388014|NCT04324255|PROCEDURE|LT|Liver transplantation
214388015|NCT04524572|BEHAVIORAL|Motion sensor|To explore the role of a motion sensor with accompanying web application on step counts, energy balance, and metabolic markers in nurses
214388016|NCT03093740|DRUG|Zepatier|Based on negative viral resistance testing of the donor treatment will be Zepatier
214388017|NCT03093740|DRUG|Zepatier plus Sofosbuvir|Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
214388018|NCT05291221|DRUG|intratracheal saline|At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients
214388019|NCT05291221|DRUG|intratracheal Dexmedetomidine|At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
214388020|NCT05291221|DRUG|intratracheal Lidocaine|At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
214388021|NCT01805817|DRUG|YASMIN® (Drospirenone/Ethinyl Estradiol)|oral contraceptive pills
214388022|NCT01805817|DEVICE|The Copper-T is an intrauterine device (IUD)|intrauterine device for contraception
214388023|NCT01805817|DEVICE|levonorgestrel-releasing system|intrauterine device
214388024|NCT03572855|COMBINATION_PRODUCT|Scoliosis Brace|Brace will be fitted to each subject by a spine orthopedic surgeon before the testing. The subject will wear the fitted brace for 2 months.
214388025|NCT01633216|BIOLOGICAL|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
214388026|NCT01633216|BIOLOGICAL|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
214388027|NCT01633216|BIOLOGICAL|Monovalent OPV 2 week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
214388028|NCT01633216|BIOLOGICAL|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
214388029|NCT01633216|BIOLOGICAL|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
214388030|NCT05518422|DRUG|Hyperinsulinemic, euglycemic infusion|60 minute infusion
214388031|NCT06481852|DRUG|MTT with antibiotic preconditioning + fiber supplementation|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
214500727|NCT03414645|BIOLOGICAL|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
214388032|NCT06481852|DRUG|MTT with antibiotic preconditioning + placebo supplementation|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
214388033|NCT06481852|OTHER|MTT with placebo + placebo supplementation.|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
214388034|NCT04362592|DEVICE|In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique|The percutaneous approach uses endoscopes through a closed maternal abdomen and closed uterus to perform the spina bifida correction.
214388035|NCT04362592|DEVICE|In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique|The laparotomy/uterine exteriorization technique uses endoscopes through an open abdomen and closed, exteriorized uterus to perform the spina bifida correction.
214388036|NCT01898637|OTHER|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
214388037|NCT01898637|DEVICE|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
214388038|NCT05724056|DEVICE|Idroflog®|"The study intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
214388039|NCT05724056|DEVICE|Sodium Hyaluronate 0.18% (Vismed®)|"The control intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
214388040|NCT01266694|DRUG|Colchicines|oral form, 1 mg, once a day during 14 days
214388041|NCT01266694|DRUG|Placebo|oral form, placebo
214388042|NCT02008968|DRUG|allopurinol 300 mg./day|
214388043|NCT02008968|OTHER|No intervention|
214388044|NCT02008968|DRUG|Normouricemic|
214388045|NCT02215733|DRUG|ARB|other than telmisartan
214388046|NCT02215733|DRUG|ACEI|
214388047|NCT02215733|DRUG|Beta-blockers|
215093916|NCT02915913|BEHAVIORAL|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
215093917|NCT02915913|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
215093918|NCT02915913|OTHER|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
214388048|NCT02215733|DRUG|Diuretics|
214500728|NCT03414645|BIOLOGICAL|CAM-101 30%|fibrinogen-depleted human platelet lysate
214500729|NCT03741621|DIETARY_SUPPLEMENT|Viscous Fibre Blend|High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
214500730|NCT03741621|DIETARY_SUPPLEMENT|Psyllium|Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
214500731|NCT03741621|DIETARY_SUPPLEMENT|Wheat Bran|All Bran cereal (All Bran®; Kellogg Company)
214500732|NCT05014035|BEHAVIORAL|Resistance Exercise|This is an 8-week exercise program, delivered using a hybrid approach of in-person, in-home supervised exercise, and virtual delivery of exercise via zoom. Individuals will participate in resistance exercise 3 days per week for 8 weeks.
215093919|NCT00185601|BEHAVIORAL|Internet Diabetes Self-Management Program|
214388049|NCT02215733|DRUG|Telmisartan|
214388050|NCT03581877|DRUG|Alteplase|As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.
214388051|NCT03581877|DEVICE|EKOS|As stated before, the EKos device will be used for ultrasound assisted catheter directed thrombolysis or ACDT, same dose t-tpa will administered through the pulmonary catheter. It will be given at a fixed dose over 24 hours.
214388052|NCT00538174|DRUG|Dapagliflozin|Tablets, Oral, once daily up, to 14 days
214388053|NCT00538174|DRUG|placebo|Tablets, Oral, 0 mg, once daily, up to 14 days
214388054|NCT01028079|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
214388055|NCT01028079|DRUG|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
214388056|NCT01028079|DRUG|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
214388057|NCT05518760|OTHER|no intervention|no intervention
214388058|NCT01177839|OTHER|Screening sheets|Reviewing screening sheets
214388059|NCT00274690|DRUG|GW679769|
214388060|NCT05738460|DRUG|antibiotics|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
214388061|NCT02974530|OTHER|Neurological evaluation|
214388062|NCT02974530|OTHER|Laryngological evaluation|
214388063|NCT02974530|OTHER|MRI evaluation|
214388064|NCT02974530|OTHER|Breathing investigation|
214388065|NCT02974530|OTHER|MRI and articulatory investigation|
214388066|NCT02974530|OTHER|Postural investigation|
214388067|NCT02974530|OTHER|Voice and soundscape investigation|
214388068|NCT04527848|DRUG|small amount of undiluted C3F8|vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
214388069|NCT05598177|DRUG|dexmedetomidine|The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
214388070|NCT05598177|DRUG|Placebo|The participant will pump saline without dexmedetomidine at the same speed as group D.
214500733|NCT03190850|OTHER|Intervention|The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
214500734|NCT03190850|OTHER|Control|The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
214687885|NCT00069576|BEHAVIORAL|self blood glucose monitoring|
214388071|NCT03001232|BEHAVIORAL|Movement-oriented Dementia Care|The intervention is a new multidisciplinary approach that focuses on optimizing physical activity and independence in daily care and activities. MDC intended to incorporate all persons surrounding the patients. The nursing staff was intensively trained by an expert in MDC, and played a central role in continuously stimulating patients to function as independently as possible. Geriatric physicians and physiotherapists advised the nursing staff about participants' medical and physical limitations to ensure safe stimulation. Consequently, a plan was created for each resident to determine the daily routines they were capable of performing themselves. Caregivers and volunteers were informed about the benefits of an active lifestyle during several open meetings.
214388072|NCT00128245|DRUG|Pimecrolimus|
214388073|NCT00128245|DRUG|Vehicle|Placebo
214388074|NCT04022005|DRUG|Chidamide, Rituximab, Gemcitabine,Oxaliplatin|"All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy."
215093920|NCT01751139|PROCEDURE|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
215093921|NCT01751139|OTHER|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
214388075|NCT03904511|OTHER|Souroubea-Platanus Preparation|Extracts of S. Sympetala and P. occidentalis.
214388076|NCT03904511|OTHER|Placebo|Placebo
214388077|NCT03132623|DRUG|andrographolide sulfonate|Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
214388078|NCT03132623|DRUG|andrographolide sulfonate simulation|Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
214388079|NCT05958329|BEHAVIORAL|HRV Biofeedback|5 minute daily sessions of HRV biofeedback
214388080|NCT04287049|DRUG|Azithromycin|Azithromycin 250 mg PO daily
214388081|NCT00240292|DRUG|Rosuvastatin|
215093922|NCT02923076|OTHER|CCR5 delta32/delta32 cord blood transplantation|
214388082|NCT05127798|OTHER|Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.|Evaluation of first line treatment with intensive treatment outcome (or event free survival and overall survival and toxicity) in adult patients between 18 and 70 years old with AML.
214388083|NCT02322814|DRUG|Cobimetinib|Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
214388084|NCT02322814|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
214388085|NCT02322814|DRUG|Placebo|Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
214388086|NCT02322814|DRUG|Atezolizumab|Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
214388087|NCT02322814|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
214388088|NCT04875832|BEHAVIORAL|Eye Movement Desensitization and Reprocessing - EMDR|"EMDR is a comprehensive psychotherapy approach, originally developed to treat the victims of trauma. EMDR is guided by an information processing model known as the Adaptive Information Processing (AIP) model. One of the key assumptions of the AIP model is that dysfunctionally stored (disturbing) memories are the cause of several mental pathologies. EMDR is therefore used to address a range of complaints that follow distressing life experiences and it~is characterized by an eight-phase psychotherapy approach. The intervention is based on the use of bilateral stimulation (e.g., taps, tones, or eye movements), which aims to stimulate the information processing system of the brain in combination with other methods of established psychotherapies. EMDR is widely recognized as an empirically supported treatment for post-traumatic stress disorder (PTSD) and it is one of the best psychological treatment focused on the ri-processing of recent traumatic experiences"
214388089|NCT02462525|DRUG|ABBV-838|Varying doses of ABBV-838
214388090|NCT02462525|DRUG|Pomalidomide|Administered orally per the label.
214388091|NCT02462525|DRUG|Dexamethasone|Administered orally per the label.
214388092|NCT03493763|DIAGNOSTIC_TEST|5hmC profile in plasma cell-free DNA after liver resection|Peripheral blood is drawn every 3 months after liver resection for 5hmC test (Time frame: 2 years or until tumor recurrence).
214388093|NCT05907486|DRUG|N-acetyl-cysteine|8g/d (\>=45kg); 200mg/kg.d (\<45kg), intravenously for at least 4 hours, day -9 to day +45
214388094|NCT05907486|DRUG|Busulfan|3.2mg/kg, day-7 to day -5, intravenously
214388095|NCT05907486|DRUG|Cytarabine|2g/m2, day -8, intravenously
214388096|NCT05907486|DRUG|Cyclophosphamide|1.8g/m2, day -4 to day -3, intravenously
214388097|NCT02290002|DRUG|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
214388098|NCT02290002|OTHER|coasting|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
214388099|NCT02310451|BIOLOGICAL|blood test|blood test to J0-M3-M6-M12
214388100|NCT03668262|DRUG|Cis-atracurium|Different concentration of cis-atracurium
214388101|NCT00238732|DRUG|Bazedoxifene/Conjugated Estrogen|
215093923|NCT01867086|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
214388102|NCT04506749|DIETARY_SUPPLEMENT|Dietary supplement consumption|The consumption time was 56 days. Consumed 100 grams daily to consume during the day.
214998091|NCT06859008|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
214998092|NCT06859008|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
214998093|NCT06859008|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
214998094|NCT06859008|PROCEDURE|Computed Tomography|Undergo CT
214998095|NCT06859008|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214998096|NCT06859008|OTHER|Questionnaire Administration|Ancillary studies
214998097|NCT06859008|DRUG|Sonrotoclax|Given PO
214388103|NCT00118092|DRUG|tanespimycin|Given IV
214388104|NCT00118092|OTHER|laboratory biomarker analysis|Correlative studies
214388105|NCT03646630|PROCEDURE|Quadratus Lumborum Block|Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%
214388106|NCT03646630|PROCEDURE|Caudal Block|caudal block with 1 ml/kg of bupivacaine 0.25%.
214388107|NCT02459093|DEVICE|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
214388108|NCT02459093|DEVICE|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
214388109|NCT00591864|DEVICE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
214388110|NCT05095363|BEHAVIORAL|PCplanner|A mobile app platform that will display participant survey results to clinicians to facilitate communication on specific needs as well as provide resources on advance care planning to participants.
214388111|NCT04247399|OTHER|Simulation-based learning|Pre-clinical simulation-based learning at Simbionix GI-mentor II virtual reality simulator and OGI CLA 4 phantom.
214388112|NCT04337086|DEVICE|T4k Appliance|The pre-fabricated, hard, polyurethane, pink T4K™ (Myo functional research Co., Australia) was used in the study. It consisted of: facial bows, lingual bows / tongue guard, lingual tag / tongue tag, dental channels with a pre-determined bite position and a lip bumper. In the first week, the patients were instructed to gradually increase the wearing time of the appliance during the daytime. By the second week, the patients were instructed to wear the appliance achieving at least 8 hours during sleeping. The Trainer usually needs no adjustments. The patients were asked to place it themselves inside their mouths. The distal ends of the appliance were trimmed 2-3 mm with an acrylic bur on a straight hand piece if they were too long or the patient could not keep his lips together. By the end of the first 4 weeks, the patients were wearing the appliances minimum of 1 hour during the day plus the overnight wear following the manufacturer's instructions.
214388113|NCT04337086|DEVICE|Twin block appliance|The twin block was used, and instructions were given to wear the appliance nearly full-time. Selective sequential inter-occlusal trimming was done monthly after the 2nd month in the occlusal surface of the maxillary bite blocks to clear over the mandibular molars allowing their eruption in a more favourable mesial direction and to increase the vertical dimension. Trimming was done in the fitting surface over the maxillary and mandibular premolars whenever needed to allow their full eruption and to level the occlusal plane
214388114|NCT04714437|BEHAVIORAL|F|The participant will be asked to chew the latex bag naturally.
214388115|NCT04714437|BEHAVIORAL|R|The participant will be asked to chew the latex bag unilaterally on the right-side.
214388116|NCT04714437|BEHAVIORAL|L|The participant will be asked to chew the latex bag unilaterally on the left-side.
214500735|NCT00421759|DEVICE|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
214998098|NCT06859008|DRUG|Zanubrutinib|Given PO
214388117|NCT04714437|BEHAVIORAL|A1|The participant will be asked to chew the latex bag changing the side once.
214998099|NCT06857370|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1)|Three doses of basic immunization were completed at 2, 4 and 6 months of age
214998100|NCT06857370|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 2)|Three doses of basic immunization were completed at 2, 4 and 6 months of age
214998101|NCT06857370|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 3)|Three doses of basic immunization were completed at 2, 4 and 6 months of age
214998102|NCT05415774|DEVICE|1 : S-C1-C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
214998103|NCT05415774|DEVICE|2 : S-C2-C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
214998104|NCT05415774|DEVICE|3 : C1 - S - C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
214998105|NCT05415774|DEVICE|4 : C1 -C2 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
214998106|NCT05415774|DEVICE|5 : C2 - S - C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
214998107|NCT05415774|DEVICE|6 : C2 - C1 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
214998108|NCT05589532|DEVICE|Prosthetic single-tooth prosthesis using PEEK|A single tooth implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis.
214388118|NCT04714437|BEHAVIORAL|A3|The participant will be asked to chew the latex bag changing the side three times.
214388119|NCT04714437|BEHAVIORAL|A5|The participant will be asked to chew the latex bag changing the side five times.
215093924|NCT01867086|DRUG|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
214388120|NCT05089435|DEVICE|EZYPRO® ECG Recorder|EZYPRO is an ECG monitoring patch designed to enhance the arrhythmia detection rate by applying 14 days in a home setting environment.
214388121|NCT05893199|DEVICE|Clinical monitoring using the Ti.Care app (https://ti.care/es)|Clinical monitoring using the Ti.Care app (https://ti.care/es)
214388122|NCT05893199|OTHER|Usual care|usual follow-up in primary care both arms
214388123|NCT02601716|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
214388124|NCT02601716|BIOLOGICAL|CHMI (7G8)|CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
214388125|NCT02601716|BIOLOGICAL|CHMI (NF135.C10)|CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
214388126|NCT03579264|BEHAVIORAL|My Viva Plan|Use of the online platform, My Viva Plan, to support health and wellness.
214388127|NCT01222923|DRUG|Risperidone|1 mg orally disintegrating tablets
214388128|NCT05053243|DEVICE|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V2 and V4 in a sequential fashion along with the Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 7 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
214388129|NCT04598893|BIOLOGICAL|Teplizumab|Received teplizumab in PROTECT Study
214388130|NCT04598893|OTHER|Placebo|Received placebo in PROTECT study
214388131|NCT03412968|PROCEDURE|Polysulfone Filter|The intervention for this group consisted using a Polysulfone filter in order to hemofiltration in the procedure involving Cardiopulmonary Bypass (CPB).The perfusionist's role is essential during the procedure, as they control both Cardiac Output (CO) and gas exchange, depending on their action, will affect blood lactate levels.
214388132|NCT03412968|PROCEDURE|Procedure/ Surgery: without Polysulfone Filter|In this group, no intervention is performed during the procedure involving Cardiopulmonary Bypass (CPB)
214388133|NCT02873026|DRUG|Triamcinolone Acetonide|Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
214388134|NCT02028832|PROCEDURE|PIM consult and service provision|If service is requested, treatment options include acupuncture/acupressure, massage, and reiki
214388135|NCT02028832|PROCEDURE|Usual care|Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
214388136|NCT01978366|DRUG|HT-100|May be administered in either fed or fasted state
214998109|NCT03896334|BEHAVIORAL|Supervised Isometric Handgrip Training|The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.
214998110|NCT03896334|BEHAVIORAL|Sham comparator - stretching and relaxation exercises|The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
215093925|NCT01867086|DRUG|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
214998111|NCT06481579|BIOLOGICAL|IVX-A12|IVX-A12 IM injection.
214388137|NCT01871558|DRUG|Vildagliptin|50 mg b.i.d
214998112|NCT06481579|BIOLOGICAL|Licensed RSV Vaccine|Licensed RSV Vaccine (AREXVY) IM injection.
214998113|NCT05492994|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test
214388138|NCT01871558|DRUG|Metformin|metformin is to be kept unchanged
214388139|NCT01871558|DRUG|sulfonylurea (SU)|
214388140|NCT01871558|DRUG|Basal Insulin|
214388141|NCT05984316|OTHER|Exercise|"Dual task exercises are defined as the appropriate direction of attention during two activities performed at the same time. Dual task performance is required during many activities in daily life. Multitasking is complicated to understand because it is divided into social, physical, and psychological branches.~The simultaneous occurrence of movement and cognitive processes is seen as a part of social participation. Considering that one task affects the other, dual task is defined as the simultaneous performance of two tasks that can be performed independently, can be evaluated separately, and have different purposes.~Each task must be incompatible and measurable, achievable alone or in different combinations. The increased need for information processing alone does not constitute dual-tasking."
214388142|NCT05265455|DIETARY_SUPPLEMENT|Plant sterols 2.5 g/day|Daily consumption of one stick (2.5 g of plant sterols) during lunch or dinner for 3 weeks
214388143|NCT05265455|DIETARY_SUPPLEMENT|Placebo|Daily consumption of one stick (the same matrix without plant sterols) during lunch or dinner for 3 weeks
214388144|NCT05876611|DEVICE|New type of self stabilizing atlantoaxial fusion cage|Using the above-mentioned new fusion cage for the treatment of atlantoaxial dislocation
214388145|NCT01676948|DRUG|ACZ885|
214998114|NCT05492994|DIAGNOSTIC_TEST|Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Pulmonary function test
215093926|NCT06584253|OTHER|Musculoskeletal System Health Questionnaire Scale|It is a 14-item scale that evaluates pain intensity, physical function, sleep, fatigue, emotional state, physical activity level, impact on work and social life, independence, self-management ability and general impact.
214388146|NCT01676948|DRUG|Canakinumab|
214388147|NCT01676948|DRUG|Canakinumab|"Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients"
214388148|NCT01676948|DRUG|Canakinumab|Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
214388149|NCT03233178|OTHER|Non-interventional|
214388150|NCT02698683|OTHER|lymphocyte count|lymphocyte count
214388151|NCT00502034|DRUG|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
214388152|NCT00502034|DRUG|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
214388153|NCT05403060|BEHAVIORAL|ALIADA: Alimentación, Adolescencia y Ambiente|The objective of the educational nutritional intervention is to promote in adolescents an increase in their consumption of vegetables and fruits and a decrease in their consumption of ultra-processed foods, through the application of the TSC constructs, with the use of education by pairs as the main strategy (peer leaders). It lasts two months, includes three exclusive sessions for peer leaders and five sessions for all participants, where the leaders, together with the researchers, will lead the activities of the sessions, as well as a general event for all high school students. Intervention activities include: electronic presentations, videos, food preparation and label reading workshops, individual and team reflection activities, goal setting and monitoring, board games, contests, among others. In addition, each participant is given a workbook, which contains key messages and activities for each educational session.
214388154|NCT02401308|PROCEDURE|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery: awake vs. asleep
214388155|NCT01294501|OTHER|Medication administration educational module|The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
214388156|NCT02641457|DRUG|Aflibercept|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
214388157|NCT02641457|DRUG|Ranibizumab|12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
214388158|NCT02736968|DRUG|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules
214388159|NCT02736968|OTHER|Placebo|Placebo
214388160|NCT03798704|DIAGNOSTIC_TEST|IFA, LIAISON|Comparison of two diagnostic serological tests - IFA and LIAISON.
214388161|NCT01335295|DRUG|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
214388162|NCT01861457|OTHER|Nozin® Nasal Sanitizer®|The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.
214998115|NCT05492994|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging
214998116|NCT05492994|DIAGNOSTIC_TEST|Chest Computer Tomography|Chest Computer Tomography
215093927|NCT06584253|OTHER|International Physical Activity Questionnaire (short form)|"International Physical Activity Questionnaire (short form) -~The IPAQ assesses a range of physical activities, including leisure-time physical activities, indoor and outdoor activities, work-related physical activities, and transportation-related physical activities."
215093928|NCT06584253|OTHER|Pittsburgh Sleep Quality Index|It is a questionnaire that evaluates sleep quality with questions asked under 7 main headings: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disorders, use of sleep aids and daytime functions.
214388163|NCT01861457|OTHER|Placebo|The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).
214998117|NCT05492994|DIAGNOSTIC_TEST|Blood biomarker analysis|Blood biomarker analysis
214998118|NCT05064631|DRUG|Bacterial Lysate|Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system.
214388164|NCT06038890|PROCEDURE|Holmium laser enucleation of the prostate using the veil-sparing technique|Holmium laser enucleation of the prostate using the veil-sparing technique
214388165|NCT00319059|DRUG|systemic administration of 99mTc-HYNIC-Annexin A5|
214388166|NCT00319059|BEHAVIORAL|10 minutes of ischemic handgripping|
214388167|NCT05185596|DEVICE|Transesophageal Echocardiography|transesophageal Echocardiography during advanced life support
214388168|NCT00216450|DRUG|rabeprazole sodium|
214388169|NCT04737213|DRUG|SGM-101|Fluorescence guided surgery
214388170|NCT02324764|DEVICE|Glidesheath Slender|testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
214388171|NCT02324764|DEVICE|standard 6- French radial sheath|
214998119|NCT06991257|DRUG|Placebo|ARM 1
214998120|NCT06991257|DRUG|Low Dose PF-07328948|ARM 2
214998121|NCT06991257|DRUG|Medium Dose PF-07328948|ARM 3
214998122|NCT06991257|DRUG|High Dose PF-07328948|ARM 4
214388172|NCT02041923|BEHAVIORAL|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
214388173|NCT02041923|OTHER|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
214388174|NCT00932334|BEHAVIORAL|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
214388175|NCT00932334|BEHAVIORAL|TALK Standard|Participants receive and educational video and booklet about living kidney donation
214388176|NCT00932334|BEHAVIORAL|Usual Care|Participants receive their usual care
214388177|NCT02372864|BEHAVIORAL|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
214388178|NCT02687490|DRUG|Abraxane|125 mg/m2, D1, D8, D15
214998123|NCT06988202|PROCEDURE|Pulmonary Vein Isolation (PVI) without Left Atrial Posterior Wall Isolation (PWI)|"A doctor inserts a thin, flexible tube (called a catheter) through a blood vessel, usually in the groin, and guides it to the heart.~Once the catheter is in place, the doctor uses pulsed field electroporation, heat (radiofrequency) or cold (cryoablation) to create small scars in the area where the pulmonary veins connect to the left atrium of the heart.~These scars block the faulty electrical signals that cause AF, helping the heart maintain a normal rhythm."
214388179|NCT02693301|OTHER|Exercise program|
214388180|NCT04275843|DIETARY_SUPPLEMENT|Traditional Diet|Consuming an traditional whole foods based diet for 4 weeks.
214388181|NCT04275843|DIETARY_SUPPLEMENT|Modern Diet|Consuming an processed formulation of the traditional diet for 4 weeks.
214388182|NCT00460148|DRUG|Ropinirole|
214388183|NCT05690542|OTHER|blood tests|evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;
214388184|NCT05287516|OTHER|Breakfast meal|A meal consisting of breakfast biscuits and water.
214388185|NCT03798834|DRUG|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
214388186|NCT03798834|OTHER|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
214388187|NCT00517309|BIOLOGICAL|V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|
214388188|NCT00517309|BIOLOGICAL|Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years|
214388189|NCT04921969|DRUG|Ruxolitinib|The study cream will be applied topically twice a day for up to 52 weeks.
214388190|NCT04921969|DRUG|Vehicle Cream|Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
214388191|NCT06900608|BEHAVIORAL|Acceptance and Commitment Therapy|A 6-session ACT intervention was implemented targeting Cognitive Defusion (CD) and Values-Based Activity Scheduling (VBAS). During the first 3 sessions, the therapist taught participants how to defuse from negative self-thoughts using didactic and experiential techniques and emphasized the relationship between negative thoughts and the self and learning to observe negative thoughts for what they are - thoughts, words, ideas, and evaluations. During sessions 4-6, the therapist used similar techniques to focus on behaving in meaningful ways without letting negative thoughts dictate behavior. During these VBAS sessions, the participant identified their values and worked with the therapist to decide on goals that were values-consistent, and focused on those foals without letting negative thoughts and emotions get in the way of living toward them.
214388192|NCT06900608|BEHAVIORAL|Treatment as usual|"The 6-session supportive therapy (ST) condition emphasized the exploration of feelings; helping the client to become aware of and talk about emotional experiences with no attempt to change thoughts, behaviors, or the client's experiences directly (Greenberg et al., 1998). Psychoeducation emphasized the untoward effects of not acknowledging or exploring feelings and benefits of identification and talking about feelings. The therapist used open-ended questions, reflective listening, empathy, and clarification questions. Therapists did not give advice, offer solutions, make interpretations, or disagree with/confront the client. For homework, the participants were asked to complete awareness homework, involving monitoring of presence, intensity, and duration of emotions with no prescription to change them or do anything differently."
214388193|NCT06901219|BEHAVIORAL|Running Fatigue Protocol|The experimental group went through a fatigue protocol, in which speed and incline increase one unit each minute passing, and stopped when rate of perceived exertion level reached ≥ 18, and the plasma lactate level differed from the baseline by ≥ 4mmol/L.
214388194|NCT06828549|BEHAVIORAL|MOSAIC|All MOSAIC PWD participants receive monthly phone coaching following a semi-structured protocol plus daily automated text message support. MOSAIC uses the mobile phone-delivered structure and functionality developed for FAMS (NCT04347291). Tailoring rules novel to MOSAIC determine phone coaching protocol content, text message content, and the involvement of a SP. Semi-structured protocols used in prior studies (and in the case of NCT04334109 adapted for mobile phone-delivery) are employed. Per tailoring rules, enrolled SPs may be invited to participate in monthly coaching calls with the PWD and/or receive text messages about supporting the PWD. The study will not assess outcomes or effects among SPs.
214388195|NCT06828549|BEHAVIORAL|Print Materials|Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters
214388196|NCT02043730|DRUG|Nab-paclitaxel and Gemcitabine|Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
214388197|NCT02043730|DRUG|Gemcitabine|gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
214388198|NCT02885519|BEHAVIORAL|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment"
214388199|NCT02885519|BEHAVIORAL|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
214388200|NCT03335930|BEHAVIORAL|a 12-week moderate-intensity exercise training|a 12-week, aerobic, moderate-intensity exercise training
214388201|NCT00338767|BEHAVIORAL|Directly Observed Therapy (DOT)|DOT includes storefront directly observed therapy of prescribed anti-depressants. Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
214388202|NCT00338767|DRUG|Fluoxetine|Medication treatment includes flouxetine for treatment of depression.
214388203|NCT01340482|DRUG|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
214388204|NCT02671721|OTHER|Maximal Compliance|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
214388205|NCT02671721|OTHER|Transpulmonary Pressure|We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
214388206|NCT00226473|DRUG|Cisplatin, Vindesine, Dacarbazine (drugs)|
214388207|NCT02044237|BEHAVIORAL|Decoupling|
214388208|NCT02044237|BEHAVIORAL|Progressive relaxation|
214388209|NCT03518658|OTHER|Evaluation Group|Patient receiving exposure to the MyCareLink Heart App during device pairing
214388210|NCT03518658|OTHER|Control Group (Historical)|Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C). The patients' data will be extracted from Medtronic de-identified CareLink™ database.
214388211|NCT05755230|OTHER|No intervention|No intervention
214388212|NCT04842994|DEVICE|IONM tube|The standardized technique of IONM-RLNs (bilaterally) will be used, including indirect vagal response evaluation at the beginning and also at the end of surgery according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group (INMSG) (Randolph GW, Dralle H. 2011).
214998124|NCT06988202|PROCEDURE|Pulmonary Vein Isolation (PVI) with Left Atrial Posterior Wall Isolation (PWI)|PVI with an additional step where the doctor also isolates the back wall (posterior wall) of the left atrium.
214998125|NCT06991114|DRUG|Allogeneic NK Cells|AlloNK, dosed after a conditioning regimen, combined with Rituximab.
214998126|NCT06989437|DRUG|ponsegromab|Double-Blind ponsegromab Treatment
214998127|NCT06989437|DRUG|placebo|Double-Blind placebo Treatment
214388213|NCT01316146|DRUG|CAR.CD30 T cells|"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2~Group Two, 1x10\^8 cells/m\^2~Group Three, 2x10\^8 cells/m\^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc."
214500736|NCT00826995|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
214998128|NCT06170827|DRUG|AIO-001|AIO-001 Solution for SC injection.
214998129|NCT05796089|RADIATION|Thoracic Radiotherapy|"Participants will receive thoracic radiotherapy to a dose of 30 Gray (Gy) in 10 fractions (3 Gy per day) concurrently with cycle 3 or 4 of chemo-immunotherapy (Group 1).~Participants who are unsuitable for concurrent radiotherapy may receive consolidation radiotherapy. Consolidation thoracic radiotherapy will be administered to a dose of 30 Gy in 10 fractions, following 4 cycles of chemo-immunotherapy (Group 2).~Treatment fractions will be delivered daily, where treatment should be completed within 15 days (9-10 fractions a fortnight)."
214998130|NCT05796089|DRUG|Etoposide with Carboplatin or Cisplatin|"The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre.~Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles."
214998131|NCT05796089|DRUG|Durvalumab|"The immunotherapy in this study is a standard treatment for ES-SCLC.~Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy.~A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy)."
214998132|NCT05253807|DRUG|Pemigatinib|13.5 mg tablet
214998133|NCT06174402|DRUG|Fenofibrate|Fenofibrate 200 mg/day
214998134|NCT06174402|DRUG|Placebo|1 tablet/ day
214998135|NCT06174402|DRUG|UDCA|UDCA 13-15mg/kg/day
214998136|NCT06081244|DRUG|Sacituzumab govitecan|10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
214998137|NCT06081244|DRUG|Pembrolizumab|200 mg every 3 weeks (q3w)
214388214|NCT01419145|OTHER|Multimodal intervention|Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
214388215|NCT01419145|OTHER|Standard care|Standard cancer care
214388216|NCT00670462|BEHAVIORAL|Standard Behavioral Treatment (SBT)|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
214388217|NCT00670462|BEHAVIORAL|Maintenance-Tailored Treatment (MTT)|
214388218|NCT05155592|BIOLOGICAL|reduction or discontinuation of Adalimumab|For patients with non-infectious uveitis whose inflammation stabilizes after treated with Adalimumab, extended dosing intervals to once a month, during which inflammatory status is monitored. If there was no recurrence within 6 months, Adalimumab was discontinued, and whether inflammation recurred after withdrawal was observed.
214388219|NCT00864838|DRUG|Acetazolamide|250 mg 1 hour before intravitreal injection
214388220|NCT00864838|DRUG|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
214388221|NCT00864838|PROCEDURE|Anterior chamber paracentesis|Immediately after bevacizumab injection
214388222|NCT01339988|DRUG|Busulfan/Cyclophosphamide|"Conditioning regimen:~Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days."
214388223|NCT01549522|BEHAVIORAL|bulletin board or telephone depth interview (TDI)|experiential based research. anonymous participation.
214388224|NCT01549522|BEHAVIORAL|interview regarding experiences and opinions as to condition and treatment|not a drug trial. experential/opinion based research.
214388225|NCT05386186|DRUG|Glimepiride|Initiate glimepiride 1-4mg once daily as an add-on therapy to metformin and adjust the glimepiride dosage to 1-6 mg once daily in the first 12 weeks according to the diabetes management guideline recommended by the Chinese Diabetes Society.
214998138|NCT06989970|COMBINATION_PRODUCT|Active tDCS on the DLPFC + Cognitive Intervention(s)|"Combination Product: Active tDCS and cognitive training intervention. Participants will receive cognitive training paired with active tDCS for 3 weeks, followed by follow-up sessions immediately after and 2 months later, during which the patient's performance on the cognitive training exercises and executive functions will be assessed. Cognitive training exercises have been drawn from a computer-aided cognitive training program (BrainHQ).~For the active tDCS, stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to the left DLPFC at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes."
214388226|NCT05386186|DRUG|Sitagliptin|Add sitagliptin 100mg once daily in all patients randomized to this arm.
214388227|NCT03706157|DRUG|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
214388228|NCT03706157|DRUG|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
214388229|NCT04152785|BEHAVIORAL|Information regarding GHG and/or nutrition|Participants will have to select a meal from a menu.
214388230|NCT02790593|DEVICE|Juxta-Cures™|Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
214388231|NCT02790593|DEVICE|Standard Compression|Compression bandaging
214388232|NCT02790593|DEVICE|PicoPress®|Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
214388233|NCT02790593|DEVICE|Silhoutte® 3D wound imaging system|Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
214388234|NCT02391870|BEHAVIORAL|MBCT-PD|Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
214388235|NCT02448836|DEVICE|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
214388236|NCT02448836|DEVICE|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
214500737|NCT02463214|OTHER|Engineered Room|"Touchless devices:~Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors~Copper products:~Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.~Titanium dioxide paint:~Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote"
214388237|NCT05140811|DRUG|IMM01|IMM01 is intravenously once a week, every 28 days for a treatment cycle;
214388238|NCT05140811|DRUG|Azacitidine|Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
214388239|NCT06081374|DEVICE|simulation implication|Breastfeeding education is planned by dressing pregnant women with simulation models.
214388240|NCT04373915|BEHAVIORAL|Remote Bedside Rounding|Parents of infants on the medical team utilizing remote rounding will have the opportunity to participate in rounds by video conferencing at the infant's bedside. Participation will be tracked and surveys regarding stress, satisfaction, and attachment will be completed by parents in both groups.
214388241|NCT01040767|OTHER|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
214388242|NCT00196989|DRUG|Pioglitazone|
214388243|NCT00196989|DRUG|GW677954|
214388244|NCT01517243|DRUG|Sunitinib|Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
214388245|NCT01517243|DRUG|Temsirolimus|Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
214388246|NCT01728038|BEHAVIORAL|Cessation Counseling|Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
214388247|NCT02105636|DRUG|Nivolumab|
214388248|NCT02105636|DRUG|Cetuximab|
214388249|NCT02105636|DRUG|Methotrexate|
214388250|NCT02105636|DRUG|Docetaxel|
214388251|NCT03413410|DRUG|Metoprolol|Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
214500738|NCT03809949|DRUG|Fentanyl Opioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
214998139|NCT06989970|COMBINATION_PRODUCT|Sham tDCS on the DLPFC + Cognitive Intervention(s)|"Combination Product: Sham tDCS and cognitive training intervention~Participants will receive cognitive training paired with sham tDCS for 3 weeks, followed follow-up sessions immediately after and 2 months later, during which the patient's performance on the cognitive training exercises and executive functions will be assessed. Cognitive training exercises have been drawn from a computer-aided cognitive training program (BrainHQ).~For the sham tDCS, electrodes will be placed in the same area as in the active tDCS condition, but current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds."
214388252|NCT03922802|DEVICE|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will receive up to 45 minutes of AIH prior to receiving transcutaneous electrical spinal cord stimulation delivered by a Transcutaneous Spinal Cord Neurostimulator while performing locomotor activities.
214388253|NCT03922802|OTHER|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
214388254|NCT03922802|OTHER|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with sham transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
214500739|NCT03809949|DRUG|Saline Nonopioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
214500740|NCT06004765|DRUG|Lenalidomide|10mg/d \*21 days, 28 days for 1 course
214500741|NCT06004765|DRUG|Azacitidine|75mg/m2/d\*5 days, 28 days for 1 course
214500742|NCT02419300|DEVICE|ultrasoungraphy|pelvic ultrasonography and Doppler
214500743|NCT05783843|BEHAVIORAL|Pictorial Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different pictorial warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
214500744|NCT05783843|BEHAVIORAL|Text Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different text-only warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
214388255|NCT06286579|DEVICE|Immediately implant placement|After atraumatic tooth extraction immediate implant placement with SOI surface and loading will be performed with temporary restoration. After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered
214388256|NCT06286579|DEVICE|Delayed|"After atraumatic tooth extraction, the extraction site will be left to heal for 4 months, just grafting with A-Oss and suture, according to a socket preservation procedure. Four month later, implant will be place and immediate loadind with temporary restoration will be performed.~After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered"
214388257|NCT04453670|PROCEDURE|autopsy|autopsy
214388258|NCT00744237|DRUG|Nebivolol|"* Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~* Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~* Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~* Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration"
214388259|NCT00744237|DRUG|Metoprolol ER|"* Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~* Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~* Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~* Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration"
214388260|NCT00744237|DRUG|HCTZ|"* HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~* HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration"
214388261|NCT02640599|OTHER|Vestibular Rehabilitation + Aerobic Exercise|Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
214388262|NCT02640599|OTHER|Vestibular Rehabilitation|The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
214388263|NCT01743300|DRUG|Sunitinib|All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
214388264|NCT01743300|DRUG|Midazolam|All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
214388265|NCT01743300|OTHER|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
214388266|NCT01743300|OTHER|Grapefruit juice|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
214388267|NCT03240536|OTHER|Choosing Wisely form|"The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.~The three guidelines included will be:~1. Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).~2. Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology~3. Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management."
214388268|NCT01175772|DRUG|Cytophosphan, Celecoxib, Methotrexate|"Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~* Cytophosphan tab 50 mg -1x1 per day, continuous~* Celecoxib tab 200 mg - 1x2 per day, continuous~* Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly"
214388269|NCT00771693|DRUG|Insulin aspart (Novorapid®)|a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.
214388270|NCT05197257|DRUG|Ga-PSMA-11|The PSMA Sterile Cold Kit, is a kit comprising all needed materials (lyophilized PSMA for PSMA reconstitution, elution vial for Ga and ancillary materials for transfer between vials) to perform a room-temperature radiolabelling of PSMA-11 with Ga. Ga is not part of the kit and should be provided in the form gallium chloride solution following the requirements of the relevant local regulations. PSMA-11 radiolabelled with Ga is administered in patients with prostate cancer recurrence after radical treatment.
214388271|NCT03780595|DRUG|Passiflora incarnata|Passiflora pills administration up to 6 pills per day
214388272|NCT03780595|DRUG|Control|Control pills administration up to 6 pills per day
214388273|NCT06313996|DRUG|Cyclophosphamide|Specified dose on specified days
214388274|NCT06313996|DRUG|Doxorubicin|Specified dose on specified days
214388275|NCT06313996|DRUG|Vincristine|Specified dose on specified days
214388276|NCT06313996|DRUG|Rituximab|Specified dose on specified days
214388277|NCT06313996|DRUG|Prednisone|Specified dose on specified days
214388278|NCT06313996|DRUG|Bendamustine|Specified dose on specified days
214388279|NCT06313996|DRUG|Lenalidomide|Specified dose on specified days
214388280|NCT06313996|DRUG|Fludarabine|Specified dose on specified days
214388281|NCT06313996|DRUG|Liso-cel|Specified dose on specified days
214388282|NCT02686541|DEVICE|Atherectomy followed by Drug Eluting Balloon (DEB)|"Patient will undergo an intervention under anaesthesia. After pre-arthrectomy Intravascular ultrasound (IVUS) of the affected arterial segment, patient will undergo treatment with Arthrectomy, followed by post-arthrectomy IVUS analysis.~Following arthrectomy, the affected vessel will be treated by supplementary Ranger Drug Eluting Balloon (DEB).~During post-procedure, patients will be started on dual antiplatelets for 3 month post intervention followed by Aspirin for life unless contraindicated. Clinical follow-up, duplex ultrasound (to assess for re-stenosis) and Ankle Brachial Pressure Index (ABPI) will be performed at 1-month, 6-month and 12-month. Assessment of the symptoms, pulse, and clinical patency will be performed at each visit."
214388283|NCT01422681|DEVICE|minimally invasive extracorporeal carbon dioxide removal|"The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).~Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min)."
214500745|NCT05783843|BEHAVIORAL|No Warnings (Control)|Participants will be shown a single package without a warning. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study.
214998140|NCT06992258|DRUG|Fruquintinib+ Lonsurf (trifluridine and tipiracil)|Experimental arm
214998141|NCT06992258|DRUG|Fruquintinib|Standard Of Care Arm
214388284|NCT02762383|DRUG|Peginterferon Alfa-2|Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
214388285|NCT05412459|DRUG|99mTc-DARPinG3|Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.
214388286|NCT06030453|COMBINATION_PRODUCT|SMART HOME strategy|Sleep hygiene: quiet and dim environment for 6 hours to facilitate sleep (Score: 0-100%).Multidisciplinary collaboration: pharmacists, respiratory therapists, rehabilitation therapists, and physical therapists (Score: ≥20%).Assessment : Evaluating and assessing the levels of pain, anxiety, and agitation (Score: 0-100%).Release of tracheal tubes and restraints: relieving pressure from tracheal tubes and restraints (Score: 0-100%).Time and schedule: Orienting the patient to time and a schedule (Score: 0-100%).Home-like environment and Hearing: A comfortable environment similar to home and music (Score: 0-100%).Orientation support: assisting with a sense of person, time, and place (Score: 0-100%).Medication review : Reviewing and adjusting medications (Score: ≥20%).Early mobilization and nutrition(Score: 0-100%).
214388287|NCT06030453|COMBINATION_PRODUCT|PADIS nursing intervention|pharmacological treatments for pain, agitation, delirium, immobility, and sleep disruption as well as nursing interventions
214388288|NCT05707832|DRUG|Amphotericin B cholesteryl Sulfate Complex for Injection|Intravenous injection (IV), once a day after reaching the recommended dose of 3.0-4.0 mg/kg for treatment. Subjects will receive ABCD intravenous therapy for at least 2 weeks, and the longest course of treatment will not exceed 6 weeks.
214388289|NCT04343482|DEVICE|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing
214388290|NCT02100540|DRUG|I placebo capsule|I placebo capsule
214388291|NCT02100540|DRUG|II RDC 0.3mg capsule|II RDC 0.3mg capsule
214388292|NCT02100540|DRUG|III RDC 0.6mg capsule|III RDC 0.6mg capsule
214388293|NCT00802659|RADIATION|Stereotactic radiotherapy|This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
214388294|NCT05140187|BIOLOGICAL|CMV-TCR-T cells|The patients with CMV infection after HSCT will receive one to three doses of donor-derived CMV-TCR-T cells, with the escalated doses including 1×10\^3/kg, 1×10\^5/kg, and 5×10\^5/kg CMV-TCR-T cells per dose.
214388295|NCT00157651|DRUG|warfarin|Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9
214388296|NCT00157651|DRUG|placebo|matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
214388297|NCT04821999|DEVICE|a 940-nm diode laser|a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
214388298|NCT06781281|DRUG|Serplulimab|Serplulimab
214388299|NCT06781281|DRUG|NabPE|Epirubicin 75mg/m2 ivgtt +Albumin Paclitaxel 260mg/m2
214388300|NCT06523738|DIAGNOSTIC_TEST|1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation|1\. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation
214388301|NCT00861926|DRUG|Ventolin|Ventolin : salbutamol sulfate 100µg
214388302|NCT00861926|DRUG|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
214998142|NCT06991842|PROCEDURE|Permanent dental restoration|In both study arms, permanent dental restorations are made with resin-based composite in permanent anterior teeth. Both study arms will use identical materials for the resin-based composite restoration (Tetric Plus Flow and Tetric Plus Fill) and universal adhesive (Adhese Universal), with the only difference being the duration of the phosphoric acid etching step. All other aspects of the restorative procedure, such as isolation of the operative field, application techniques, and final polishing, will remain consistent across both arms.
214998143|NCT06992999|DRUG|Low Dose Psilocybin|10mg dose of psilocybin
214388303|NCT02721641|DRUG|Herceptin|Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
214388304|NCT03901560|OTHER|Music Therapy|
214388305|NCT06441825|OTHER|Increased multimodal observation including digital monitoring|Digital monitoring combined with repeated clinical assessments and retrospective analysis of serological markers
214388306|NCT04041752|BEHAVIORAL|SOLID|condition with a classical meal served using solid food items
214388307|NCT04041752|BEHAVIORAL|LIQUID_P|condition with a liquid meal served using a powder solution
214388308|NCT04041752|BEHAVIORAL|LIQUID_L|condition with a pre-prepared meal served using a liquid solution.
214388309|NCT01912781|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
214388310|NCT01912781|DEVICE|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
214388311|NCT01912781|DEVICE|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
214998144|NCT06992999|DRUG|High Dose Psilocybin|30mg dose of psilocybin
214998145|NCT06992778|DEVICE|Remote fine-tuning of hearing aids|"Remote Fine-Tuning of Hearing Aids allows patients to adjust their hearing aids remotely, without having to visit a clinic. Using a mobile app on the patient's device, real-time adjustments are made based on their feedback, with immediate changes during the session.~Unlike traditional face-to-face adjustments, this approach lets patients stay in their own familiar surroundings. This helps create a more accurate listening environment, as the adjustments are made based on the sounds they experience in their everyday life."
214998146|NCT06992778|DEVICE|Face-to-face fine-tuning of hearing aids|In the clinic, the standard procedure for fine-tuning hearing aids (HAs) involves a face-to-face consultation with an audiologist, typically lasting 30 minutes.
214998147|NCT05513560|DRUG|Ibudilast|10mg pills, 2 pills twice per day
214388312|NCT04396223|DRUG|Avelumab Injection|Avelumab administration at 800mg a 1 hour IV infusion once every 14 days during 4 months ½ (median)
214388313|NCT04396223|DRUG|Methotrexate 1 GM Injection|methotrexate administration at 1mg/kg/day during 4 months ½ (median)
214388314|NCT04974814|DRUG|Rosuvastatin 40mg|patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI
214388315|NCT04974814|DRUG|Atorvastatin 80mg|patients in active arms will be preloaded with a single 80 mg atorvastatin in ER before PCI
214388316|NCT04974814|DRUG|Control Test|patients in control arm will not preloaded with statin in ER before PCI
214388317|NCT01855581|DRUG|pediatric sedation (propofol, ketamine, etc)|"Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively."
214388318|NCT06122532|PROCEDURE|Stem cell preparation combined with Reticular skin|The dose of transplanted stem cells per wound (100cm2) is 1×10\^6, then cover the wound with autologous regular skin.
214388319|NCT06122532|PROCEDURE|Stem cell preparation combined with MEEK skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 \^ 6, then cover the wound with autologous MEEK skin.
214388320|NCT06122532|PROCEDURE|Stem cell preparation combined with split-thickness skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 \^ 6, then cover the wound with autologous split-thickness skin.
214388321|NCT06122532|PROCEDURE|autologous skin grafting|After cleaning the wound, use autologous skin (Reticular skin/MEEK skin/split-thickness skin) grafting and cover the wound surface。
214388322|NCT01982214|DEVICE|sedentary|No intervention
214998148|NCT05513560|DRUG|Pentoxifylline|400mg pill 3 times per day
214998149|NCT05513560|OTHER|Placebo|Placebo matching ibudilast, 2 pills twice per day OR placebo matching pentoxifylline 1 pill 3 time per day.
214998150|NCT06585462|DRUG|AMG 513|AMG 513 will be administered by SC or IV injection.
215093929|NCT06584253|OTHER|Cognitive Failures Questionnaire|The questionnaire aims to measure daily cognitive errors. It assesses simple errors made over the last 6 weeks, as well as perception (e.g., are there times when you can't see something you need at the supermarket even though it's there?), memory (e.g., have you ever forgotten people's names?) and motor functioning (e.g., have you ever bumped into anyone?).
214998151|NCT06585462|DRUG|Placebo|Placebo will be administered by SC or IV injection.
214998152|NCT06585462|DRUG|AMG 513|AMG 513 will be administered by SC injection.
214998153|NCT06585462|DRUG|Placebo|Placebo will be administered by SC injection.
214998154|NCT03786081|DRUG|Tisotumab Vedotin|Given into the vein (IV)
214998155|NCT03786081|DRUG|Bevacizumab|Given via IV
214998156|NCT03786081|DRUG|Pembrolizumab|Given via IV
214998157|NCT03786081|DRUG|Carboplatin|Given via IV
214998158|NCT03698162|OTHER|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo STAR DCE-MRI
214998159|NCT03698162|OTHER|Bevacizumab Injection|Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
214998160|NCT06597175|DEVICE|ORIGO|The device measurement is first performed on the breast area with the lesion, followed by the measurement of the corresponding area in the contralateral breast for comparison.
214998161|NCT04871321|DRUG|nab-paclitaxel plus gemcitabine-cisplatin|\- gemcitabine 800mg/m2 + cisplatin 25 mg/m2 + nab-paclitaxel 100mg/m2 on day 1 and day 8, every 21 days
214998162|NCT04375631|DRUG|Cladribine|Given IV
214388323|NCT01982214|DEVICE|Vibration|Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
214998163|NCT04375631|DRUG|Cyclophosphamide|Given IV
214998164|NCT04375631|DRUG|Cyclosporine|Given IV then PO
214500746|NCT06100198|OTHER|nutrition and exercise program|Nutrition courses include understanding malnutrition and sarcopenia; understanding the six major food categories and their requirements; and understanding protein-rich food sources. Exercise courses include understanding exercise types, flexibility exercises, and muscle strength training exercises.
215093930|NCT06584253|OTHER|Jamar hand dynamometer|Jamar hand dynamometer - students will perform grip strength assessments with their dominant hand while seated. As recommended by the American Association of Hand Therapists protocol, students will sit in a comfortable chair with their shoulders neutrally rotated and adducted, elbow flexed to 90°, and wrist and forearm in neutral positions.
214500747|NCT05782699|DEVICE|BP monitoring during tilt testing|BP measure at various times during tilt testing
214500748|NCT00367874|DRUG|Buprenorphine|
214500749|NCT00367874|DRUG|Valproate|
214500750|NCT00005869|DRUG|gemcitabine hydrochloride|
214998165|NCT04375631|DRUG|Cytarabine|Given IV
214998166|NCT04375631|BIOLOGICAL|Filgrastim|Given SC
214998167|NCT04375631|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
214998168|NCT04375631|DRUG|Mitoxantrone|Given IV
214998169|NCT04375631|DRUG|Mycophenolate Mofetil|Given IV or PO
214998170|NCT04375631|DRUG|Mycophenolate Sodium|Given PO
214998171|NCT04375631|RADIATION|Total-Body Irradiation|Undergo TBI
214998172|NCT04375631|DRUG|Idarubicin|Given IV
214998173|NCT04375631|DRUG|Fludarabine|Given IV
214998174|NCT04375631|DRUG|Cytarabine|Given IV
214998175|NCT04375631|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214998176|NCT04375631|PROCEDURE|Echocardiography Test|Undergo ECHO
214998177|NCT04375631|PROCEDURE|X-Ray Imaging|Undergo x-ray
214998178|NCT04375631|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
214998179|NCT04375631|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
214998180|NCT04375631|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214998181|NCT06860906|PROCEDURE|V-Y advancement flap|anal stenosis treated by removal of scarring tissue and cover the defect using V-Y advancement flap
214998182|NCT06859515|OTHER|No intervention, only for observational studies|No intervention, only for observational studies
214998183|NCT06061341|DIAGNOSTIC_TEST|TruGraf®|TruGraf® is a non-invasive blood-based test to assist the clinician in lowering immunosuppression in liver transplant patients. It is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients.
214998184|NCT03351348|DRUG|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
214388324|NCT01515904|BEHAVIORAL|STOMP Clinic|"A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions."
214388325|NCT01973894|PROCEDURE|Blood and urine sampling|"Blood and urine sampling will follow this schedule:~* 24h: blood (3ml)~* 48h: blood (3ml) and urine~* End of infusion: blood (3ml)~* 6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
214388326|NCT00701337|DRUG|oestradiol|oestradiol 2 mg oral route 30 days
214388327|NCT00701337|DRUG|oestradiol|oestradio transdermal patch 60ug by 24 hours 30 days
214388328|NCT05691348|PROCEDURE|Ambulatory appendectomy|Appendectomy will be performed in outpatient surgery unit. Patient will be discharge from the hospital the same day as surgery
214388329|NCT05691348|PROCEDURE|Conventional appendectomy|Appendectomy will be performed in digestive surgery department. Patient will be discharge from the hospital the day after surgery: he will spend a night under observation
214388330|NCT01014221|OTHER|Acupuncture|acupuncture administered in 8 sessions over 4 weeks
214388331|NCT01014221|DRUG|Prednisolone|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
214388332|NCT02301637|DEVICE|Eeva™ Test|The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.
214388333|NCT00026897|PROCEDURE|Gamma-camera imaging|
214388334|NCT00026897|PROCEDURE|Low-risk biopsy|
214388335|NCT06391814|BIOLOGICAL|EBV-specific T cells|Consolidative cellular immunotherapy consisting of one (or up to 4) infusion of ex vivo expanded T cells
214388336|NCT02611310|OTHER|No intervention|No intervention administered in this study.
214388337|NCT03497494|PROCEDURE|2 cm away from the pylorus edge|2 cm away from the pylorus edge
214388338|NCT03497494|PROCEDURE|4 cm away from the pylorus edge|4 cm away from the pylorus edge
214388339|NCT03497494|PROCEDURE|6 cm away from the pylorus edge|6 cm away from the pylorus edge
214998185|NCT03351348|BEHAVIORAL|patient-reported pain scores|Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain. Patients may be discharged when table either on the day of surgery or post-operative day 1 (on pill diary for same-day discharge patients).
214998186|NCT03351348|OTHER|saline|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 ± 30 minutes hours postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
214998187|NCT06613451|OTHER|Mobile Application|Mobile Application Use on the Intravenous, Intramuscular and Subcutaneous Drug Administration
214998188|NCT05360186|DEVICE|MateRegen® gel (BioRegen)|Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation.
214998189|NCT06994065|DRUG|Ferric Carboxymaltose (FCM)|This study will dose each patient according to their calculated iron deficit through Ganozi formula Iron deficit(mg) = bodyweight(kg) x (target Hb - actual Hb) (g/dl) x 2.4 + Iron storage depot(mg)
214388340|NCT03497494|PROCEDURE|LRYGB|laparoscopic Roux-en-Y gastric bypass
214998190|NCT06994065|DRUG|Iron Sucrose injection|This study will dose each patient according to their calculated iron deficit through Ganozi formula Iron deficit(mg) = bodyweight(kg) x (target Hb - actual Hb) (g/dl) x 2.4 + Iron storage depot(mg)
214388341|NCT01582880|DRUG|Riboflavin|Used to treat donor cornea before implantation
214388342|NCT03219203|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
214388343|NCT02027363|DRUG|Capecitabine|maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
214388344|NCT02027363|OTHER|Observation|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
214388345|NCT01418612|DRUG|Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited|
214388346|NCT03984019|DIAGNOSTIC_TEST|Cardiac condition measurements|Cardiac MRI, ECG, echocardiography, cardiac blood markers
214388347|NCT00969345|OTHER|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
214388348|NCT00969345|OTHER|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
214388349|NCT02566070|OTHER|Continuous Gastric Feeding|
214388350|NCT02566070|OTHER|Bolus Gastric Feeding|
214500751|NCT00005869|DRUG|rubitecan|
214500752|NCT00002281|DRUG|Filgrastim|
214500753|NCT00002281|DRUG|Epoetin alfa|
214500754|NCT00002281|DRUG|Zidovudine|
214500755|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
215093931|NCT06584253|OTHER|Depression Anxiety Stress Scale - 21 Short Form|DASÖ-21 consists of 3 subcategories (depression, anxiety and stress). Each category consists of 7 separate questions and a total of 21 questions.
214388351|NCT00872430|OTHER|Placebo|In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.
214388352|NCT00872430|OTHER|Klein Laxative Tea|The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
214388353|NCT02951351|DRUG|Proparacaine|Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
214388354|NCT02951351|PROCEDURE|Conjunctival culture|Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
214500756|NCT00983294|DRUG|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
214500757|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
214388355|NCT01478815|BEHAVIORAL|contingency management|Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
214388356|NCT01478815|OTHER|Standard Care|Standard Care
214388357|NCT00641849|BEHAVIORAL|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
214500758|NCT06508749|DRUG|PGDM1400LS|IV Antibody Infusion based on subject's weight
214388358|NCT00641849|BEHAVIORAL|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
214500759|NCT06508749|DRUG|VRC07-523LS|IV Antibody Infusion based on subject's weight
214500760|NCT06508749|DRUG|PGT121.414.LS|IV Antibody Infusion based on subject's weight
214500761|NCT06508749|DRUG|ART Regimen prior to enrolling in Step 1a|Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1a.
214500762|NCT06508749|DRUG|ART Regimen prior to enrolling in Step 1b|Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1b.
214500763|NCT06508749|OTHER|Analytic Treatment Interruption|(all anti-HIV agents are discontinued)
214500764|NCT03978065|DIAGNOSTIC_TEST|Confocal microscopy|"For this purpose live stains will be combined with a confocal imaging setup equipped with 6 laser lines. A major advantage of this technique is that tissue specimens do not need to be fixed prior to analysis. Such an approach does not only allow tissue viability and integrity assessment in an unprecedented speed and accuracy, but also promises to shed new light into quality assessment and prognosis in kidney transplantation. The investigators herein wish to establish the predictive values of this technology in kidney transplantation.~The methodology used in this trial is referred to as BIOPSYCHRONOLOGY - as a reference to dendrochronology, or tree ring dating. Leaving the biopsy sample intact facilitates its analysis, just as drills are used for tree-ring counting."
214500765|NCT06434584|OTHER|without AI assistance|provide insulin dosage and confidence score without AI assistance
214500766|NCT06434584|OTHER|with AI dosage assistance|provide insulin dosage and confidence score with AI dosage assistance
214500767|NCT06434584|OTHER|with explainable AI assistance|provide insulin dosage and confidence score with explainable AI assistance
214500768|NCT06434584|OTHER|with faulty explainable AI assistance|provide insulin dosage and confidence score with faulty explainable AI assistance
214500769|NCT01456156|RADIATION|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
214500770|NCT01779245|DIETARY_SUPPLEMENT|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
214500771|NCT01779245|DIETARY_SUPPLEMENT|Placebo|
214500772|NCT05615220|DRUG|Ecopipam Hydrochloride|Selective dopamine D1 and D5 receptor antagonist
214500773|NCT04000516|BEHAVIORAL|Time restricted feeding|Restricting the eating window to about 8 hours a day, during waking hours.
214500774|NCT03927196|BEHAVIORAL|extended counseling|Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
214500775|NCT04003324|BEHAVIORAL|Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults|Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
214500776|NCT05841407|DIETARY_SUPPLEMENT|High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
214500777|NCT05841407|DIETARY_SUPPLEMENT|No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
214388359|NCT00692055|DRUG|PN400|naproxen 375 mg / esomeprazole 20 mg
214388360|NCT00692055|DRUG|Naproxen|naproxen 375 mg
214388361|NCT02662803|OTHER|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
214388362|NCT02662803|OTHER|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
214388363|NCT04537897|DRUG|BI 474121|BI474121
214388364|NCT04537897|DRUG|Midazolam|Midazolam
214388365|NCT04537897|DRUG|Placebo|Placebo
214388366|NCT02936154|DRUG|PF-06650833|
214388367|NCT02936154|DRUG|placebo|
214388368|NCT04966780|PROCEDURE|acute abdominal surgery|Acute surgery for acute abdominal disease
214500778|NCT03805672|DRUG|Low Dose Enoxaparin|
214500779|NCT03805672|DRUG|High Dose Enoxaparin|
215093932|NCT06584253|OTHER|Body Awareness Questionnaire|The questionnaire aims to determine the level of body composition sensitivity.
215093933|NCT06584253|OTHER|SF-12|This questionnaire consists of two general components related to physical and mental function, consisting of 12 questions and 8 scales measuring physical function (2 questions), bodily pain (1 question), role limitations due to physical problems (2 questions), general health (1 question) vitality (40).
214388369|NCT00642928|DRUG|Placebo|1 capsule per day during 4 weeks
214388370|NCT00642928|DRUG|BF 2.649 5 mg|one BF 2.649 capsule of 5 mg per day during 4 weeks
214388371|NCT00642928|DRUG|BF 2.649 10 mg|One BF 2.649 capsule of 10 mg per day during 4 weeks
214388372|NCT00642928|DRUG|BF 2.649 20 mg|One BF 2.649 capsule of 20 mg per day during 4 weeks
214388373|NCT00642928|DRUG|BF 2.649 40 mg|One BF 2.649 capsule of 40 mg per day during 4 weeks
214388374|NCT03136250|OTHER|Group A (Control Group - Static Stretching + Standard Treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Conventional Static Stretching 15-30 seconds hold 3-5 repetitions (Page P, 2012) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles.
214388375|NCT03136250|OTHER|Group B (Autogenic Inhibition - PIR + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Post Isometric Relaxation MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles. (Chaitow L, 2006)
214388376|NCT03136250|OTHER|Group C (Reciprocal Inhibition - RI + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Reciprocal Inhibition MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid,Levator Scapulae and Upper Trapezius Muscles (Chaitow L, 2006)
214388377|NCT05816148|OTHER|Questionnaire survey|On leisure physical activity, barriers to physical activity and quality of life.
214388378|NCT01580098|OTHER|Self-monitoring for patients with Diabetes mellitus type 2|Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
214388379|NCT01580098|OTHER|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are submitting the vital parameters of the patient via mobile device.
214388380|NCT04384458|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.
214388381|NCT04384458|DRUG|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
214388382|NCT00197028|BIOLOGICAL|RTS,S/AS02D|3-dose intramuscular injection in the thigh
214388383|NCT00197028|BIOLOGICAL|TETRActHib™|3-dose intramuscular injection in the thigh.
214388384|NCT00197028|BIOLOGICAL|Engerix-B®|3-dose intramuscular injection in the thigh.
214388385|NCT05637411|OTHER|Predictive model|We will define and validate predictive models of risk of exacerbations in asthmatic patients
214388386|NCT03308058|BEHAVIORAL|Breastfeeding computer education|Breastfeeding computer education
214388387|NCT00992537|DRUG|insulin degludec|Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
214388388|NCT00992537|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
214388389|NCT00992537|DRUG|insulin aspart|Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
214500780|NCT00775866|PROCEDURE|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
214500781|NCT06294249|DEVICE|Laser-induced Incision|On the treatment side, an incision was made on the crest of the alveolar soft tissue using the laser.
214500782|NCT06294249|PROCEDURE|Punch Incision|On the control side, a punch incision was made on the crest of the alveolar soft tissue using using a punch.
215093934|NCT01786395|DRUG|UF-021|
215093935|NCT01786395|DRUG|Placebo|
214388390|NCT02093039|DEVICE|decision aid group|The paper-based leaflet DECIDEO is a 12-page pocket leaflet providing scientific information about the advantages and disadvantages of participating in the national breast screening program, understandable by all, constructed to conform with the International Patient Decision Aid Standards
214388391|NCT05839353|OTHER|SBAR training by serious game|SBAR training by serious game
214388392|NCT04607824|BEHAVIORAL|Duchenne Muscular Dystrophy group|Assessment of heart rate variability at rest and during computational task in people with Duchenne muscular dystrophy
214388393|NCT04607824|BEHAVIORAL|Typical Development group|Assessment of heart rate variability at rest and during computational task in people with typical Development
214388394|NCT01602757|DRUG|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
214388395|NCT03383562|PROCEDURE|operation in different stages of the day|operation was arranged in the morning ,afternoon or at night
214388396|NCT04738721|BEHAVIORAL|Evaluation|"Within the scope of the course, the demographic information of the students (such as height, weight, body mass index) is recorded and the physical activity status is recorded with International Physical Activity Questionnaire Short Form (UFAA). Cardiovascular endurance with 6-Minute Walking Test, flexibility and circumference of waist, hip and neck with the Sit and Lie Test and body composition and Body Fat Ratio will be evaluated. After a full year of quarantine, the same students who were previously evaluated and accepted to participate in the current study will be evaluated with online remote video viewing methods (Teams, Zoom, etc.) and, with the same tests and measurements under supervision by the researchers."
214388397|NCT01899274|DEVICE|bant iPhone application|
214388398|NCT01705808|DRUG|Protein C concentrate|
214388399|NCT01852656|BEHAVIORAL|Postcard and IVR Reminder Group|"IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.~Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012."
214388400|NCT01852656|BEHAVIORAL|Postcard Only Reminder Group|Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
214388401|NCT01852656|BEHAVIORAL|IVR Only Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
214388402|NCT04997044|OTHER|Concomitant physical rehabilitation|Children of this group will receive a regular exercise rehabilitation program including starching exercises, functional strength training and static and dynamic balance exercises.The program will be conducted by six licensed pediatric physical therapists for one hour/session, 3 times/week, and six successive months.
214388403|NCT04997044|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis was prescribed with a hinge at the level of the medial malleolus extends distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured straps. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day.
214388404|NCT04997044|OTHER|selective dorsal rhizotomy|The surgical procedures were tailored to each child according to preoperative assessment plan. All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact.
214388405|NCT03254160|DRUG|DNS-3379|DNS-3379
214500783|NCT06294249|PROCEDURE|Implant Placement|Implant placement was done in both laser and punch arms. The drilling was performed based on the company (Straumman) protocol. On each side, a dental implant (Straumman SP, Basel, Switzerland) and healing abutment were placed. Patients were visited at 24, 48, 72 hours, and 7 days after insertion.
214500784|NCT04597866|BEHAVIORAL|Multimodal rehabilitation|A combination of exposure in vivo and interventions directly targeting the cortical reorganization for treating CRPS.
214500785|NCT05071300|DRUG|Eplontersen|Eplontersen will be administered by SC injection.
214500786|NCT01130285|GENETIC|Lung Cancer Risk Test|Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
214500787|NCT03758742|BEHAVIORAL|High-Fruit Diet|In this supervised controlled feeding study, participants will consume a diet rich in whole fruit. During the Ramp-Up Phase (Weeks 1-4), participants will gradually increase the amount of whole fruit they consume, eventually reaching 50% of calories from whole fruit. In the Main Phase (Weeks 5-12), participants will consume a whole fruit-rich, eucaloric diet that provides 50% of calories in the form of whole fruit. The non-fruit portion of the diet will be styled as a Mediterranean Diet. Participants will be required to approximately keep their weight stable throughout the intervention.
214500788|NCT00734877|DRUG|M-VTD-PACE|2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
214998191|NCT06445725|BEHAVIORAL|Acceptance Based Coping (ABaCo)|The educational ABaCo protocol consists of core Acceptance \& Commitment Therapy (ACT) interventions, culturally and contextually-tailored for this population, and in accordance with clinician-led versions of ACT for diabetes to include (a) identification of patient values, (b) teaching acceptance and brief mindfulness skills, and (c) techniques for engaging in valued activities while coping with difficult experiences (e.g., sugar cravings, distress). It is delivered by a community health worker (promotor/a) over 6 consecutive weeks over the phone, followed by a booster call at week 10.
214998192|NCT06992960|DEVICE|ChitoCare® medical Scar Healing Gel (Örsáragel)|ChitoCare® medical Scar Healing Gel is a topical gel indicated for the treatment of new and old scars. The Scar Healing Gel provides a soothing effect and support to the scar tissue to heal in an orderly manner. It protects against infections, stimulates cell proliferation in old and new scars, as well as correct tissue organization with proper collagen alignment for a better aesthetic appearance and skin flexibility. Ideal for treating scars after accidents, surgery, C-section and cosmetic surgery. For smoother and less visible scars. May be used by the whole population, also elderly and children.
214388406|NCT03254160|DRUG|Placebo|Placebo
214388407|NCT04931459|DRUG|ACU193|Intravenous ACU193
214388408|NCT04931459|DRUG|Placebo|Intravenous Placebo
214388409|NCT04139148|DEVICE|Ture Transcranial Direct Current Stimulation (tDCS)|Ture 1-2 mA current of tDCS intervention in patients' binary brain DLPFC areas(20 mm).
214388410|NCT04139148|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS intervention in patients' binary brain DLPFC areas(20 mm).
214388411|NCT05992714|DEVICE|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using VR head device
214500789|NCT00734877|DRUG|TT3-LITE Regimen (L-TT3)|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
214500790|NCT06062875|DRUG|Adalimumab|Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
214500791|NCT02457936|BEHAVIORAL|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
214500792|NCT03229408|DRUG|Salsalate|Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
214500793|NCT03229408|OTHER|Placebo|Appears identical to experimental drug
214500794|NCT01553942|DRUG|Afatinib|induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
214388412|NCT05992714|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using phone
214388413|NCT03562546|OTHER|Strength From Within|A 12 week at home structured resistance exercise programme using resistance bands. Participants will also receive a walking programme, a warm up and cool down, and ankle range of motion exercises.
214998193|NCT06992960|DEVICE|Amoena CuraScar Mammilla Circles Silicone Scar Patch and Amoena CuraScar Anchors Silicone Scar Patch|Amoena CuraScar Mammilla Circles Silicone Scar Patch and Amoena CuraScar Anchors Silicone Scar Patch are silicon-based, single-patient, multi-use scar patches intended for use as scar reduction therapy in surgical breast scars. The silicone creates a moist environment on the scar, which prevents the scar from drying out. It keeps the scar soft and has a positive effect on scar tissue. The devices are specifically designed for breast scarring and are shaped to fit the normal surgical scars experienced after breast surgery.
214998194|NCT04611126|DRUG|Ipilimumab|Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.
214388414|NCT06153823|OTHER|virtual reality glasses|child behavior management will be done by using VR glasses distraction
214388415|NCT06153823|OTHER|Tell Show and Do|child behavior management will be done by using tell show and do technique
214388416|NCT06184490|PROCEDURE|Prone position with thoraco-abdominal cushion|Prone position with cushions positioned laterally on the chest, abdomen, and pelvis
214388417|NCT04316390|DIETARY_SUPPLEMENT|Control|study drink (two weeks)
214388418|NCT04316390|DIETARY_SUPPLEMENT|Hesperidin|study drink + Hesperidin 600 mg (two weeks)
214388419|NCT04316390|DIETARY_SUPPLEMENT|Vitamin C|study drink + Vitamin C 250 mg (two weeks)
214388420|NCT04316390|DIETARY_SUPPLEMENT|Hesperidin + Vitamin C|study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)
214388421|NCT00151918|DRUG|Lanthanum carbonate|
214388422|NCT04015791|OTHER|NOCISCAN-LS Disc MR Spectroscopy|The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain
214388423|NCT02490618|OTHER|Probiotic tablet- Biogaia|
214388424|NCT02490618|OTHER|Placebo tablet|
214687886|NCT04060667|COMBINATION_PRODUCT|Wireless physiologic monitoring|The intervention in this study is the use of a wireless monitor to perform physiologic monitoring of women undergoing emergency cesarean delivery for the first 24 hours after completion of the cesarean and send alerts to responding clinicians should vital signs fall out of a pre-specified range.
214687887|NCT01107522|DRUG|CTO|Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
214998195|NCT04611126|DRUG|Cyclophosphamid|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
214998196|NCT04611126|DRUG|Fludarabine Phosphate|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
214998197|NCT04611126|BIOLOGICAL|Tumor Infiltrating Lymphocytes infusion|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
214998198|NCT04611126|DRUG|Nivolumab|Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
214998199|NCT04611126|DRUG|Relatlimab|Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
214998200|NCT03884374|BEHAVIORAL|Focused Breathing and Attention Training (BAT)|Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.
214388425|NCT00624325|DRUG|interferon alfa-2b|12 MU daily continuously subcutaneous
214388426|NCT00624325|DRUG|interferon alfa-2b|9 MU daily continuously subcutaneous
214388427|NCT00624325|DRUG|interferon alfa-2b|6 MU daily continuously subcutaneous
214388428|NCT00082602|DRUG|galantamine ER|
214388429|NCT00282815|DEVICE|continuous positive airway pressure or CPAP|RemStar Pro (Respironics, Inc.) The CPAP is applied through a nasal mask during the hours of sleep. Positive air pressure holds the naso-oro-pharyngeal airway open during sleep.
214388430|NCT00282815|DEVICE|sham CPAP|sham CPAP
214388431|NCT04955704|DEVICE|InferRead CT Pneumonia.AI|InferRead CT Pneumonia.AI reads chest CT DICOM images from medical imaging storage devices and triages cases by detecting pneumonia lesions and then flagging suspected cases in the study list. InferRead CT Pneumonia.AI is a tool to assist clinicians and it does not replace the interpretation and diagnosis by clinicians.
214388432|NCT01471158|DRUG|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
214500795|NCT01553942|RADIATION|Radiation|Daily, Monday-Friday
214500796|NCT01553942|DRUG|Cisplatin|Day 1 of each cycle, IV infusion over 60 minutes
214500797|NCT01553942|DRUG|Pemetrexed|Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
214500798|NCT01553942|PROCEDURE|Surgery|Surgery to remove tumor
214500799|NCT04934943|DIAGNOSTIC_TEST|mini_FC|100 ml of Crystalloids infused over 1 minute - data recording and new baseline - FC 4 ml/kg in 10 minutes - data recording
214388433|NCT01471158|DRUG|Dorzolamide/timolol Maleate Fixed Combination (COSOPT)|Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
214388434|NCT03312179|DEVICE|PCI and DES stenting|Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.
214388435|NCT03312179|DRUG|Incretins|Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
214388436|NCT00669903|DRUG|AZD0328|
214388437|NCT00669903|DRUG|Placebo|
214500800|NCT05682950|RADIATION|online adaptive radiotherapy|CTV covers pelvis.
214500801|NCT05115864|DEVICE|PFMT with device|The wearable PFMT device (XFT-0010CK) is made by two parts. One part is the screen device which is able to show the real-time vaginal resting pressure and voluntary contraction pressure in units of mmHg. The other part is a vaginal air-filled probe. The two parts are combined with a thin air tube. The whole device is connected to a smartphone app by Bluetooth to record the progress of PFMT. There are two modes of the device, one is assessment mode, when it comes to the assessment mode that the device is able to assess the grade of type I and II pelvic floor muscle fiber strength by the patients themselves, the other mode is practice mode by displaying real-time visual pressure value according to the completeness of the PFMT program.
214500802|NCT05806515|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214500803|NCT05806515|DRUG|Carboplatin|Given IV
214500804|NCT05806515|PROCEDURE|Chest Radiography|Undergo chest X-ray
214500805|NCT05806515|PROCEDURE|Computed Tomography|Undergo CT
214500806|NCT05806515|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214500807|NCT05806515|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
214500808|NCT05806515|PROCEDURE|Surgical Procedure|Undergo surgery
214500809|NCT04200664|DIAGNOSTIC_TEST|Hearing assessment|All study participants will undergo hearing tests, including hearing-specific questionnaires
214500810|NCT04200664|DIAGNOSTIC_TEST|Vestibular/balance assessment|Siderosis group participants will undergo vestibular/balance tests, including gait assessment and balance-specific questionnaires
214500811|NCT04200664|OTHER|Quality of life assessment|All study participants will be asked to complete a set of quality of life questionnaires
214998201|NCT03884374|BEHAVIORAL|Standard Breathing and Attention Training (BAT)|Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.
214500812|NCT04200664|DIAGNOSTIC_TEST|Olfactory (smell) function testing|Siderosis group participants will undergo a formal smell identification testing by means of self-administered smell chart to identify the revealed scents
214500813|NCT04200664|GENETIC|DNA bio-banking|Siderosis group participants will be asked to provide a saliva sample for DNA bio-banking
214998202|NCT03884374|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges
214998203|NCT03884374|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
214998205|NCT06948695|OTHER|Warm-up|5-minute warm-up run on treadmill at a freely chosen speed
214500815|NCT06545344|OTHER|Best Practice|Receive usual care
214500816|NCT06545344|PROCEDURE|Palliative Care Consultation|Attend a palliative care visit
214500817|NCT06545344|OTHER|Survey Administration|Ancillary studies
214500818|NCT06545344|OTHER|Tumor Board Review|Undergo evaluation by tumor board
214500819|NCT06253546|DRUG|TV-44749|"Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection"
214500820|NCT06253546|DRUG|Oral Olanzapine|"Pharmaceutical form:~tablet~Route of administration:~oral"
214500821|NCT06778187|DRUG|Oral arsenic trioxide|"Patients will be treated in 28-day cycles.~Each cycles will comprise:~Oral arsenic trixoide (10mg/day or 0.15mg/kg/day in patients \< 50kg) from Days 1-14~PLUS:~* Oral ascorbic acid (1000mg/day) from Days 1-14~* Azacitidine (75mg/m2/day s.c. or i.v.) from days 1-7; OR Decitabine (20mg/m2/day i.v.) from days 1-5; OR Oral-decitabine-cedazuridine (1 tablet/day) from days 1-5.~* Venetoclax (100mg-400mg/day) from Days 1-14 (if used)"
214500822|NCT06433115|OTHER|Lean (≥90%) Grass-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
214500823|NCT06433115|OTHER|Lean (≥90%) Grain-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
214500824|NCT06433115|OTHER|Plant-Based Meat|Plant-based meat would be macronutrient matched to the same quantities of meat prescribed for a given energy level.
214500825|NCT02811510|DRUG|Placebo|Placebo pill (no active cannabinoids)
214500826|NCT02811510|DRUG|Dronabinol|10 mg capsule of Dronabinol will be administered orally.
214500827|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Clarithromycin tablets|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and clarithromycin tablets are administered twice from D1 to D10.
214500828|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Cyclosporine softgels|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and cyclosporine sofgels are administered once at D4.
214500829|NCT05312671|DRUG|Atezolizumab|Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)
214500830|NCT05312671|DRUG|Carboplatin|Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
214500831|NCT05312671|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
214500832|NCT05312671|DRUG|Etoposide|Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)
214500833|NCT05312671|PROCEDURE|Cystectomy|Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).
214500834|NCT01488968|RADIATION|Standard Radiation Treatment|39 radiation treatments
214500835|NCT01488968|RADIATION|Hypofractionated radiation treatment|25 radiation treatments
214388438|NCT06031909|DIAGNOSTIC_TEST|Multimodal frailty assessment|"Different domains are assessed during hospital stay, these include:~* Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI)~* Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging~* Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers~* Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS)~* Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle."
214388439|NCT00504296|DRUG|HDAC inhibitor SB939|SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
214388440|NCT00504296|OTHER|immunoenzyme technique|
214388441|NCT00504296|OTHER|immunohistochemistry staining method|
214388442|NCT00504296|OTHER|immunologic technique|
214388443|NCT00504296|OTHER|laboratory biomarker analysis|
214388444|NCT00504296|OTHER|liquid chromatography|
214388445|NCT00504296|OTHER|mass spectrometry|
214388446|NCT00504296|OTHER|pharmacological study|
214388447|NCT01082172|DEVICE|Implant Thoracic Stent Graft|Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
214388448|NCT02419430|BEHAVIORAL|MBRT ClassRoom and Phone Application|2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
214388449|NCT02419430|BEHAVIORAL|Phone application only|"Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:~* Joys of Life~* Count your blessings~* Think differenc, feel better~* Exercising --\> Happier~  \+ Exercising --\> Sleep~* Pre-Sleep routine~* Eat that frog~* Mindful Meditation"
214998206|NCT06948695|OTHER|Random blade test|4-minute run on a treadmill with a flat incline.
214998207|NCT06948695|OTHER|Random blade test|4-minute run on treadmill with a 10% gradient
214998208|NCT06948695|OTHER|Comfort speed test|1 min running test on an instrumented treadmill (Gaitway, H/P/Cosmos, Nußdorf, Germany) at comfort speed.
214998209|NCT06948695|OTHER|Outdoor random blade test|100-metre outdoor run at a comfort speed
214998210|NCT07000227|BEHAVIORAL|Low FODMAP diet|High FODMAP foods are swapped for low FODMAP alternatives, for two weeks (Elimination phase)
214998211|NCT07000227|BEHAVIORAL|Gentle FODMAP diet|Key High FODMAP foods will be identified from patients' food diaries and swapped with low FODMAP alternatives. (Elimination phase)
214998212|NCT07000227|BEHAVIORAL|Traditional Dietary Advice|Subjects are required to follow a set of healthy eating guidelines set by NICE guidelines for IBS for two weeks a. Have regular meals and take time to eat b. Avoid missing meals or leaving long gaps between eating c. Drink at least eight cups of fluid a day, especially water or other non-d. caffeinated drinks, such as herbal teas d. Restrict tea and coffee to three cups a day e. Reduce intake of alcohol and fizzy drinks . Limit intake of high-fibre food g. Reduce intake of resistant starch h. Limit fresh fruit to three portions a day
214388450|NCT02419430|BEHAVIORAL|Questionnaires|At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
214388451|NCT05597800|DRUG|Nivolumab and Ipilimumab|"Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~* Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~* Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles)."
214388452|NCT05402800|OTHER|FSFI questionnaire|The FSFI is a reliable test for the assessment of sexual function in women. The Arabic version of this test, was used. The FSFI is comprised of six domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) with score ranges of 0 (or 1) to 5. The total FSFI score ranges from 2.0 to 36. The translated version of the FSFI test was used in this study. All questions in the FSFI questionnaire were explained by the physician one by one, and they were filled in a suitable and silent environment where patients could comfortably share such intimate information
214388453|NCT00837525|PROCEDURE|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
214388454|NCT03316612|DIETARY_SUPPLEMENT|Vaccinium Myrtillus L. extract|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
214388455|NCT03316612|DIETARY_SUPPLEMENT|Placebo|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
214388456|NCT02696330|DRUG|clopidogrel|clopidogrel 75mg tablets with 300mg loading dose followed by 75mg oral tablets daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
214388457|NCT02696330|DRUG|enoxaparin|enoxaparin 40 mg by subcutaneous injection once daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
214388458|NCT02696330|DRUG|placebo|starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
214388459|NCT00683280|BEHAVIORAL|contingency management|Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
214388460|NCT00683280|OTHER|Standard of Care|varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
214998213|NCT06865222|PROCEDURE|Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) - 2 weeks|"The Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) will be administered through an FDA-approved Transcranial Magnetic Stimulation (TMS) medical device. Results of the baseline EEG will be uploaded to NoetherTech's EMBP software on the Mayo Clinic campus, and transferred to Noethertech servers for TMS parameter determination~TMS treatment will be one 30 min session per day, 5 days per week (Monday-Friday), for 2 weeks."
215093936|NCT03305315|OTHER|Measurements of jaw movement|Jaw mobility will be measured during simple movements of the mouth (opening the mouth, side-to-side and backwards-and-forwards movement of the jaw). These movements will be measured using a specific apparatus, part of which will be placed on the head like a helmet with the other part placed in the mouth and stuck to the teeth using a dental adhesive. The part in the mouth is specifically designed for this purpose. Measurements using this apparatus will take around 30 minutes.
215093937|NCT03305315|OTHER|Measurement of natural electrical activity of facial muscles|Natural electrical activity of the facial muscles will be measured using electrodes placed on the skin.
215093938|NCT02472704|DIETARY_SUPPLEMENT|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
215093939|NCT02472704|DIETARY_SUPPLEMENT|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
214388461|NCT00683280|OTHER|Standard of Care|Twice weekly brief counseling based on public health service guidelines for quitting smoking.
214388462|NCT00058019|DRUG|ixabepilone|Given IV
214388463|NCT02443662|OTHER|Catheterization|Routine catheterization during follow up.
214388464|NCT06098495|GENETIC|search for epigenetic profile of infertility|examine the epigenetic profile of DNA extracted from MGCs and blood sample
214388465|NCT03967990|OTHER|Refined cornmeal flour|48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
214388466|NCT03967990|OTHER|50/50 refined cornmeal-bran mix|48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
214388467|NCT03967990|OTHER|Whole grain cornmeal flour|48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
214388468|NCT01827254|OTHER|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
214388469|NCT01561092|DRUG|Escitalopram|5 or 10 mg escitalopram tablets administered orally once daily
214388470|NCT01561092|DRUG|Placebo|Tablets
214388471|NCT06392672|BEHAVIORAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
214388472|NCT06174935|DRUG|0.01% atropine ophthalmic drop|0.01% atropine ophthalmic drop will be applied daily to the affected eye
214388473|NCT00078104|PROCEDURE|Extraction of wisdom teeth|
214388474|NCT05231564|OTHER|hybrid training|The experimental group trained two to three sessions of 45 to 50 minutes a week with a recovery of 24 to 48 hours between each session to burn 500 kcal. The first three weeks held hybrid training with a metabolic program and the other three weeks held a strength training program.
214388475|NCT02364232|BEHAVIORAL|bilateral training with and without mirror feedback|
214388476|NCT05947773|OTHER|Learning to walk with a robot|The patients completed a 1-hour learning to walk program using a soft exoskeleton. The protocol includes several difficult parts of the walk. (Walking protocol)
214388477|NCT05947773|OTHER|Walking group|The walking protocol was performed without robotic assistance for 1 hour every day for 3 weeks.
214388478|NCT05947773|OTHER|Control group|The control group performed the physiotherapy treatment for 3 weeks.
214388479|NCT04561011|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
214388480|NCT02066350|PROCEDURE|Single pancreas transplantation|
214500836|NCT04233567|DRUG|Infigratinib|Given PO
214500837|NCT03584711|COMBINATION_PRODUCT|FOLFOX + panitumumab|"FOLFOX + panitumumab according to a stop and go strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment"
214500838|NCT06192433|DEVICE|High-frequency repetitive transcranial magnetic stimulation (40Hz)|Participants in this group receive high-frequency TMS at 40 Hz. The TMS intervention is applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient undergoes this TMS treatment for a course of 10 consecutive working days. The specific parameters for TMS include pulses at 40 Hz with an intensity set at 40% of the maximum intensity. Each pulse lasts for 2 seconds, followed by a 58-second rest period. On each treatment day, patients receive 30 sets of stimulation, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
214500839|NCT06192433|DEVICE|Moderately high-frequency repetitive transcranial magnetic stimulation (10Hz)|Participants in this group receive moderately high-frequency TMS at 10 Hz. Similar to the high-frequency group, the TMS intervention targets the bilateral dorsolateral prefrontal cortex (DLPFC) and is administered for a course of 10 consecutive working days. The TMS parameters for this group involve pulses at 10 Hz with an intensity set at 90% of the maximum intensity. Each pulse lasts for 4 seconds, followed by a 56-second rest period. As in the high-frequency group, patients in this group also receive 30 sets of stimulation per treatment day, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
214500840|NCT04825743|DRUG|zalunfiban|zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
214500841|NCT04825743|DRUG|Placebo|A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
214500842|NCT04541589|DRUG|Iscalimab|Iscalimab 600 mg or 300 mg was administered subcutaneously weekly for the first 3 weeks. Subsequently, iscalimab was administered subcutaneously bi-weekly (every other week or Q2W).
214500843|NCT04541589|OTHER|Placebo|Placebo (1 injection of 2 ml) administered to participants in the iscalimab 300 mg arm to maintain blinding until the final database lock of the core study
214500844|NCT04280289|DRUG|cannabidiol extract|"The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials"
214500845|NCT04026776|DRUG|Allopurinol|Study Part 2- Preterm group only: After Visit 5 preterm born participants will start allopurinol 200 mg daily PO for 6 weeks. The 1 week high and low salt diets and assessments will be repeated while on allopurinol.
214500846|NCT04026776|OTHER|Dietary Intervention|High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
214500847|NCT06181435|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
214500848|NCT06181435|DRUG|Placebo|"Pharmaceutical form:~Injection solution Route of administration: SC injection"
214500849|NCT06546553|DRUG|PF-07826390|PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors
214500850|NCT06546553|BIOLOGICAL|sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
214998214|NCT06865222|PROCEDURE|Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) - 4 weeks|"The Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) will be administered through an FDA-approved Transcranial Magnetic Stimulation (TMS) medical device. Results of the baseline EEG will be uploaded to NoetherTech's EMBP software on the Mayo Clinic campus, and transferred to Noethertech servers for TMS parameter determination~TMS treatment will be one 30 min session per day, 5 days per week (Monday-Friday), for 4 weeks."
214998215|NCT06670937|OTHER|Induced sputum|Patients will provide 1) an induced sputum sample after inhaling 15 ml of 0.9% NaCl solution
214998216|NCT06670937|OTHER|Blood sample|Patients will provide 2) a blood sample.
214998217|NCT07002528|BEHAVIORAL|sucrose solution|apply sucrose solution to evaluate pain among local anesthesia
214998218|NCT07002528|BEHAVIORAL|Cryotherapy|apply cryotheraby to evaluate pain among local anesthesia
214998219|NCT07002528|BEHAVIORAL|topical anesthesia|apply topical anesthesia to evaluate pain among local anesthesia
214500851|NCT06546553|OTHER|SOC (anti-PD-1 + platinum -based chemo)|Standard of Care (anti-PD-1 + platinum -based chemo)
214500852|NCT04594564|PROCEDURE|Total hip arthroplasty with Delta TT cup|Total hip arthroplasty using Delta TT cup and ceramic bearings
214500853|NCT04753190|BEHAVIORAL|Baseline Sleep Satiation and Phase Stabilization|All participants will be assigned a 9-h sleep opportunity for the first week of the 2-week study. This will ensure that adolescents are not sleep restricted before living in the laboratory during the second week of the study. The 9-h sleep schedule will be individually timed from his/her averaged wake time (± 15 mins) before the study begins. Assigned bedtime will be 9 h before wake.
214998220|NCT03414008|DRUG|BI 1291583|Single dose
214998221|NCT03414008|DRUG|Matching placebo: Tartaric acid|Single dose
214998222|NCT07003425|DRUG|APG777|APG777 subcutaneous injection
214998223|NCT07003425|DRUG|APG777|APG777 subcutaneous injection every 12 weeks
214998224|NCT07003425|DRUG|APG777|APG777 subcutaneous injection every 24 weeks
214998225|NCT05865886|DRUG|BI 1291583|BI 1291583
214998226|NCT05865886|DRUG|Placebo to BI 1291583|Placebo matching BI 1291583
214998227|NCT06602258|DRUG|E2814|E2814 IV infusion.
214998228|NCT06602258|DRUG|Lecanemab|Lecanemab SC injection.
214998229|NCT06602258|DRUG|Placebo|Placebo IV infusion.
214998230|NCT03459846|DRUG|Durvalumab|Durvalumab 1500 mg IV q4w
214998231|NCT03459846|DRUG|Olaparib|Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
214998232|NCT03459846|DRUG|Placebo|Matching placebo for oral tablet BID
214388481|NCT04639089|DRUG|platlet rich plasma on sternal healing post median sternotomy|"Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery"
214388482|NCT04874376|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection
214388483|NCT05531019|DIETARY_SUPPLEMENT|Echinochrome A|Dietary Supplement with Echinochroma A Simple randomized design, in this arm patients will take 6ml of a 0.025% Echinochroma A solution twice a day for 90 days. 3 mg of Echinochroma A will be consumed per day.
214388484|NCT05531019|OTHER|Control|Simple randomized design, in this arm patients will take 6ml of an fructose aqueous solution twice a day for 90 days with the same flavor as the treatment
214388485|NCT01738893|DRUG|Gabapentin 300 mg|Test product
214388486|NCT01738893|DRUG|Gabapentin 300 mg|Reference product
214500854|NCT04753190|BEHAVIORAL|Gradually Shifted Sleep|For all participants, their assigned baseline sleep/wake schedule will gradually shift earlier over 3 days in the laboratory to facilitate the phase advance shift of the circadian system.
214500855|NCT04248322|BEHAVIORAL|Semi-structured interview|Using iterative, semi-structured interviews or focus groups to explore the lived experience with CC and usual customary care (UCC) of catheter users with NLUTD and their caretakers to generate user-defined themes regarding bladder function and catheter-related barriers and the daily impacts on one's life.
214500856|NCT05516992|DRUG|SB-01 For Injection|Intradiscal injection
214500857|NCT05516992|DRUG|Sham Needle|Sham needle placement
214500858|NCT05208567|DIAGNOSTIC_TEST|Echocardiogram|Cardiac Ultrasound Scan - using an abbreviated protocol
214500859|NCT06042751|BEHAVIORAL|Exercise Therapy|Six online consultations will take place on the basis of the sports medicine assessment every two weeks, resulting in 300 min in 3 months. For the home-based implementation, participants receive wearables with which the activity and training data are collected. In conjunction with feedback, the goal is to ensure that the interventions lead to improvements in self-control, reduced resilience, and fatigue without overwhelming participants with volume or intensity. Due to the expected large differences in personal performance, determined in the initial assessment, the exercise plan is individually designed and regularly adjusted. This includes control of everyday activity as well as moderate endurance and strengthening exercises totalling up to 30min daily. The individual training intensity is below the aerobic lactate threshold so that overload is avoided. The average training heart rate is planned to be in the range between 50 and 70% of the maximum heart rate.
214687888|NCT01107522|DRUG|CTO and Temodar®|"Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.~Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.~Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle"
214388487|NCT05923593|DIETARY_SUPPLEMENT|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil.
214388488|NCT00044460|DRUG|rosiglitazone|
214388489|NCT02456337|DEVICE|Mucograft|Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.
214388490|NCT02456337|DEVICE|Emdogain|Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.
214687889|NCT01107522|DRUG|CTO, Temodar®, Radiation therapy|Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
214998233|NCT05423756|OTHER|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
214998234|NCT05423756|OTHER|Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having a skin/soft tissue infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
214998235|NCT07126938|DRUG|Alcoholic beverage|Participants in the experimental group consumed self-selected amounts of alcohol, monitored by study staff to ensure safety and compliance with protocol guidelines. Participants then filled out the remainder of the general health questionnaire, including how many drinks they consumed, and whether or not they feel too impaired to drive a vehicle or go to work.
215093940|NCT06456073|BIOLOGICAL|E-CEL UVEC cells (AB-207)|Allogeneic (consented-maternal donor) E4ORF1+ (pro-survival gene transduced) human umbilical vein endothelial cells (percutaneous injection formulation)
215093941|NCT04279613|DRUG|NNC0361-0041|Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.
214388491|NCT02456337|PROCEDURE|Coronally Advanced flap|Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
214388492|NCT01923389|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
214388493|NCT01923389|DRUG|100 mg PF-05231023|100 mg IV infusion twice a week for 4 weeks
214388494|NCT05901415|PROCEDURE|Combined anterior lumbar plexus and lateral sacral plexus block in a semi-supine position|We proposed a modified approach of combined anterior LPB and lateral SPB with the patients posed in a semi-supine position aiming to reduce the pain and discomfort induced by position changing effectively.
214388495|NCT05901415|PROCEDURE|Combined anterior lumbar plexus and lateral sacral plexus block in a classical position.|Patients posed in a classical position and received combined anterior LPB and lateral SPB.
214500860|NCT06042751|BEHAVIORAL|Psychotherapy|Six online consultations will take place based on the psychosocial assessment and the initial psychosomatic interview every two weeks, resulting in 300 min in 3 months. A structured, telemedicine-supported, modularized, brief psychosomatic intervention is planned with a focus on psychoeducational elements, promotion of self-management, improvement of illness acceptance, modification of self-monitoring, and learning to cope with altered performance levels. The six modularized telemedical sessions taking into account the specific deficits identified in the psychosomatic evaluation. Within the sessions, starting points are identified with the patients, which the patients can work on independently between the sessions.
214500861|NCT05302115|DEVICE|S-ICD|Implantation of an S-ICD
214500862|NCT04815993|DRUG|SYN-020 delayed release capsule|SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
214500863|NCT06787469|OTHER|Resin Cement|Bioactive self adhesive resin cement (SHOFU BeautiLink) used to cement indirect restorations to endodontically treated molars.
214500864|NCT06787469|OTHER|Resin Cement|Self adhesive resin cement
214500865|NCT04763759|DRUG|TRL1068, a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
214500866|NCT06285864|BEHAVIORAL|Interoception-based intervention|Intervention will include body awareness, sensorial, and relaxation exercises, plus homework.
214500867|NCT05896865|RADIATION|Whole breast / chest wall & regional lymph node irradiation|Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions
214500868|NCT05896865|RADIATION|Internal mammary or supraclavicular lymph node boost|Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy
214500869|NCT01981603|OTHER|navigator|
214998236|NCT05509218|BEHAVIORAL|Mobile-delivered personalized feedback|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.
214998237|NCT06867640|OTHER|Forgiveness-Based Group Psychoeducation|The effect of forgiveness-based group psychoeducation applied to cancer survivors on fear of cancer recurrence, forgiveness and psychiatric conditions.
215093942|NCT04279613|OTHER|Placebo|Placebo
214388496|NCT05575674|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
214388497|NCT03354520|BEHAVIORAL|Tailored Videos|web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).
214388498|NCT03354520|BEHAVIORAL|OSA Treatment|Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.
214388499|NCT03354520|BEHAVIORAL|Standard Videos|Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website
214388500|NCT01887314|DIETARY_SUPPLEMENT|Standardized Ginger extract|
214388501|NCT00649740|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fasting
214500870|NCT01226316|DRUG|AZD5363|Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
214500871|NCT01226316|DRUG|AZD5363|Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
214998238|NCT04488224|DEVICE|Nano-X Patient Rotation System|"The Nano-X prototype is a horizontal patient rotation system that immobilises participants while being rotated on the horizontal axis.~This device will be used to rotate patients horizontally while cone-beam Computed Tomography (CBCT) projections are acquired."
214998239|NCT04488224|RADIATION|Conventional CBCT scan|A conventional cone-beam Computed Tomography (CBCT) scan is acquired on standard radiotherapy machinery.
215093943|NCT06597695|DRUG|Ketamine-assisted psychotherapy|Ketamine-assisted psychotherapy delivered in a group format
215093944|NCT06422338|OTHER|IMCI-enhanced by suPAR levels (SoC + suPAR POC)|IMCI-guidelines (standard of care) + Point-Of-Care (POC) based on suPAR quantification
215093945|NCT06548932|DRUG|GZR33 Injection|A single dose
215093946|NCT06548932|DRUG|GZR101 Injection|A single dose
215093947|NCT06548932|DRUG|Placebo|A single dose
215093948|NCT04428151|DRUG|Lenvatinib|20 mg once daily, taken as oral capsules
215093949|NCT04428151|BIOLOGICAL|Pembrolizumab|200 mg 30-minute IV infusion on day 1 of each 21-day cycle
215093950|NCT04428151|DRUG|Docetaxel|75 mg/m\^2 administered as an IV infusion on day 1 of each 21-day cycle
215093951|NCT04428151|DRUG|Capecitabine|1250 mg/m\^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets
214388502|NCT00649740|DRUG|Topamax® Sprinkle Capsule 25 mg|25mg, single dose fasting
214388503|NCT01989598|OTHER|Laboratory Biomarker Analysis|Correlative studies
214388504|NCT01989598|OTHER|Pharmacological Study|Correlative studies
214388505|NCT01989598|DRUG|Trametinib|Given PO
214388506|NCT01989598|DRUG|Uprosertib|Given PO
214388507|NCT06349122|DIAGNOSTIC_TEST|Vaginal flora abnormalities screening and quantification using molecular biology technique|Vaginal self-sampling is a simple and validated method of sampling used for the molecular biology technique and the quantification of microorganisms involved in vaginal flora imbalance bacteriosis.The patient performs a self-sampling with a cotton swab transferred into a transport medium tube. The sample is sent to the laboratory where Multiplex Point of Care polymerase chain reaction (PCR) is performed.
214388508|NCT06349122|DRUG|Azithromycine|In case of Chlamydia trachomatis infections, as well as significant increase of Fannyhessea vaginae: 1 g per os in a single dose; In case of Neisseria gonorrhoeae infection: 2 g per os in a single dose (associated to ceftriaxone 1g IM)
214388509|NCT06349122|DRUG|Ceftriaxone|In case of Neisseria gonorrhoeae infections, 1g, associated to azithromycin 2 g per os in a single dose
214388510|NCT06349122|DRUG|Metronidazole|Metronidazole ovules: In case of Trichomonas vaginalis infection during the 1st trimester of pregnancy: 1 ovule morning and evening for 14 days (French Society of Dermatology Recommendations 2016); Metronidazole 500 mg tablets in case of Trichomonas vaginalis infection during the 2nd or the 3rd trimester of pregnancy in a single dose of 2 g
215093952|NCT04428151|DRUG|Paclitaxel|80 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
214388511|NCT06349122|DRUG|Clotrimazole, Vaginal|In case of Candida albicans infection in a single dose to be repeated up to 6 times if necessary.
214388512|NCT06349122|OTHER|Usual Care|Patients will not be screened using molecular biology techniques in this group. The management of these patients is a matter of routine for health professionals. They will be free to prescribe a standard vaginal swab if symptoms are present and to treat their patients according to their usual protocols. No routine sampling is recommended in the absence of a history
214388513|NCT04132570|DRUG|Budesonide|Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days.
214388514|NCT04132570|OTHER|Placebo|Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days.
214388515|NCT03979950|BEHAVIORAL|Survey|Solid Organ Transplant patients will be recruited via social media. Co-investigators will reach out to the administrators of various social media networks to share information regarding the study with their networks on our behalf. Potential participants who are interested in participating, can then follow the link to the online survey tool, which includes the participant demographic information (age, ethnicity and highest level of education) and questionnaire. The questionnaire is 30 questions long and takes approximately 15 minutes to complete. This questionnaire will be a single, cross-sectional survey. No personal information will be documented on the questionnaire. All responses will be anonymous. Participants will be recruited for 6 months.
214388516|NCT00652262|DRUG|Levitra (Vardenafil, BAY38-9456)|Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
214500872|NCT01226316|DRUG|AZD5363|Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
214998240|NCT04488224|OTHER|Psychometrically validated questionnaires|The Claustrophobia Questionnaire (CLQ), Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaires administered. CLQ only once before the first session, STAI and FMS both before and after each Nano-X CBCT session.
214998241|NCT06260956|BEHAVIORAL|Consumption|Subjects consume peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.
214998242|NCT06260956|BEHAVIORAL|Avoidance|Subjects avoid eating peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.
214998243|NCT06680778|DEVICE|Proactive Monitoring|Proactive monitoring of vital signs for the duration of the first two cycles of chemotherapy by using a Fitbit
214998244|NCT05154513|OTHER|Cohort 1|No intervention provided in this study
214998245|NCT03579771|DRUG|Cisplatin|Given IV
214998246|NCT03579771|DRUG|Gemcitabine|Given IV
214998247|NCT03579771|DRUG|Nab-paclitaxel|Given IV
214998248|NCT05583071|DRUG|Tafasitamab|IV
214998249|NCT05583071|DRUG|Lenalidomide|Oral
214998250|NCT05583071|DRUG|Rituximab|IV
214998251|NCT05583071|DRUG|Methotrexate|IV
214998252|NCT07005206|BEHAVIORAL|Six Hats Thinking|A total of 6 sessions of thinking training were given once a week for 6 weeks.
214998253|NCT07005206|DEVICE|No Intervention (Control)|No intervention was made to this group.
214998254|NCT04822766|PROCEDURE|Hematopoietic stem cell transplantation|patients will undergo allo-HSCT after consolidation therapy (or completion of other appropriate non-palliative strategy) according to standard procedures of the transplant center (choice of donor, conditioning regimen, GVHD and infection prophylaxis). The use of novel therapies (such as sorafenib, midaustorine, venetoclax, etc.) will be allowed as post-transplantation maintenance strategy.
214998255|NCT04822766|DRUG|Best chemotherapy treatment|patients will be treated according to the standard procedures of the treating center for this type of population. Patients will receive the best available treatments (including additional conventional chemotherapy or other non-palliative therapies such as 5-azacytidine, decitabine, venetoclax, midaustorine, enasidenib, etc.).
215093953|NCT04428151|DRUG|Cetuximab|400 mg/m\^2 loading dose, followed by 250 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
215093954|NCT04428151|DRUG|Lenvatinib|24 mg once daily, taken as oral capsules
215093955|NCT01754298|PROCEDURE|Retro-articular drilling|"* Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~* Use a 0.045 K-wire for drilling.~* Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
214388517|NCT02530138|DIETARY_SUPPLEMENT|synbiotic|2 symbiotics capsules per day for 28 weeks
214388518|NCT02530138|DIETARY_SUPPLEMENT|Placebo|2 placebo capsules per day for 28 weeks
214388519|NCT06339294|DRUG|Clotrimazole Cream|Single time application of clotrimazole ointment was done after aural toilet in external auditory canal via IV catheter
214388520|NCT06339294|DRUG|Povidone-Iodine|Gelfoam soaked pyodine solution was placed in external auditory canal after aural toilet
214500873|NCT01226316|DRUG|AZD5363|Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
214500874|NCT02227134|PROCEDURE|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
214500875|NCT05251844|OTHER|receiving an email|The email informed that the employee has had been identified as having accessed a patient's electronic medical record without a known work-related purpose and that unauthorized access is a privacy violation.
214500876|NCT05273944|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
214500877|NCT05895786|DRUG|PF-06823859|anti-interferon beta therapy
214500878|NCT05895786|DRUG|Placebo|Placebo for PF-06823859
214500879|NCT02426138|OTHER|Medically Tailored Meal Delivery (MTM)|Patients will receive delivery of medically tailored meals for 12 weeks
214500880|NCT02426138|OTHER|Usual Care + Choose MyPlate|Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
214500881|NCT00238901|DRUG|Basiliximab|
214500882|NCT06967597|PROCEDURE|Cholecystoscopy and gallbladder cleaning|"Upper gastrointestinal endoscopy and cholecystoscopy are performed 4 weeks after GB drainage. A standard gastroscope is used to inspect the gallbladder cavity with retrieval or lithotripsy of residual stones until complete cleaning of the GB is achieved. Several procedures may be required to achieve complete stone clearance.~Finally, the LAMS is retrieved and replaced with a double pigtail plastic stent."
214500883|NCT04633148|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion for 3 days
214500884|NCT04633148|DRUG|Fludarabine (Non-IMP)|Intravenous infusion for 3 days
214998256|NCT06819371|OTHER|Single Task Exercise|Patients will follow the exercises in a way to focus on only one task during the exercise sessions. In the creation of the exercise programme, the principles of the exercise prescription recommended by the American Sports Medicine Association for individuals with adult Type 2 diabetes will be taken into consideration. In this context, planning will be made by considering the progression of stretching, balance and walking exercises from simple to difficult.
214998257|NCT06819371|OTHER|Dual Task Exercise|Patients enrolled in the dual-task exercise group will perform a second task during the exercise sessions along with the exercises in the single-task exercise group. This second task will be determined individually according to the level and progress of the patient.
214998258|NCT01462448|PROCEDURE|Blood Draw|Single blood draw of 30 ml
214998259|NCT05708924|DRUG|FT538|FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.
214998260|NCT05708924|BIOLOGICAL|Enoblituzumab|Enoblituzumab 15 mg/kg IV begin on Day -6 and continuing once every 3 weeks beginning on Day 22 until disease progression or unacceptable toxicity - refer to Section 7.2.1 for timing of the enoblituzumab dose on Day 22 if steroid pre-meds are needed due to an infusion reaction with the 1st enoblituzumab dose as there is a 14 day ban on corticosteroid use after the last dose of FT538
214998261|NCT05374590|BIOLOGICAL|Efgartigimod IV or Efgartigimod PH20 SC|Intravenous infusion of Efgartigimod or Subcutaneous injection of Efgartigimod PH20 SC
215093956|NCT01754298|PROCEDURE|Trans-articular drilling|"* Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~* Use a 0.045 K-wire for drilling~* A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
215093957|NCT05036200|DEVICE|pulsed dye laser|four pulsed dye laser sessions were administered every eight weeks in the 21 patients
214500885|NCT04633148|DRUG|UniCAR02-T-pPSMA|Intravenous Infusion for 21 days
214500886|NCT04633148|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
214500887|NCT00003459|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
214500888|NCT03088800|DRUG|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
214500889|NCT03088800|DRUG|APAP|Oral APAP at 15mg/kg dose
214500890|NCT06294756|OTHER|Inhalation of Sulfurous Thermal Water|Active Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a conventional thermal water aerosolization Faset™system (Faset Spa, Trezzano sul Naviglio, Milan, Italy) delivering particles of TW with a diameter between 0.6 µm \<MMAD \< 5 µm. Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs.
214500891|NCT06294756|OTHER|Inhalation of Sterile Distilled non-pyrogenic Water|Placebo Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a modified thermal water aerosolization Faset™system, previously disconnected from the hydraulic circuit that supplied TW and connected to non-pyrogenic sterile water reservoirs (Highly depurated water- Pharmaceutical grade FU-for external and internal use, Makeitlab, Canosa di Puglia, BT, Italy). Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs delivering particles of SDW with a diameter between 0.6 µm \<MMAD \< 5 µm.
214687890|NCT06439875|DIETARY_SUPPLEMENT|effect of L-arginine and liposomial vitamin C on pulmonary rehabilitation|Patients with a certified diagnosis of COPD and chronic respiratory failure will be randomized in a 1:1 ratio into the interventional arm or the placebo controller arm. All patients will undergo multidisciplinary intensive pulmonary rehabilitation for 28 days. The patients in the interventional group will receive a twice-daily oral supplementation with either a combination of 1.66 g l-arginine plus 500 mg liposomal vitamin C
214687891|NCT06439875|OTHER|placebo|Patients in this arm will undergo multidisciplinary intensive pulmonary rehabilitation without any dietary supplementation.
215093958|NCT02704689|DEVICE|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
215093959|NCT00759525|DRUG|Glycyrrhetic Acid|130 mg daily for fourteen days
215093960|NCT00759525|DRUG|Placebo|Placebo daily for fourteen days
215093961|NCT02212678|DRUG|N-acetylcysteine capsule|N-acetylcysteine capsule
215093962|NCT02337634|DRUG|Placebo|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
215093963|NCT02337634|DRUG|Milk Thistle|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
214388521|NCT04099381|BIOLOGICAL|ASD CB-MNC infusion low level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 3 or fewer by A, B, DRB1 loci.
214388522|NCT04099381|BIOLOGICAL|ASD CB-MNC infusion high level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 4 or more by A, B, DRB1 loci.
214500892|NCT00091988|BEHAVIORAL|Lifestyle & Behavioral Change Program|Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
214500893|NCT00091988|BEHAVIORAL|Structured Education Program|Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
214500894|NCT01765374|DEVICE|ESAOTE MyLab60|US evaluation at different time points
214388523|NCT04099381|OTHER|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
214388524|NCT03562169|DRUG|Ixazomib, thalidomide, & dexamethasone (ITD) re-induction|"4 - 6 ITD 28-day cycles as follows:~* Ixazomib 4mg capsule on days 1, 8 and 15~* Thalidomide 100mg capsule on days 1-28~* Dexamethasone 40mg tablets on days 1, 8, 15 and 22"
214500895|NCT01765374|DRUG|Rituximab|
214500896|NCT06067776|BIOLOGICAL|Cetuximab|Given IV
214500897|NCT06067776|DRUG|Osimertinib|Given PO
214500898|NCT06067776|DRUG|Tucatinib|Given PO
214500899|NCT00291694|DRUG|celecoxib|Celecoxib 400 mg BID
214500900|NCT00291694|OTHER|placebo|placebo
214500901|NCT03658109|DRUG|Lidocaine Bolus Infusion|Patients will undergo Lidocaine Bolus infusion.
214500902|NCT03658109|PROCEDURE|QL block|Patients will undergo a posterior QL block pre-operatively
214500903|NCT03658109|DRUG|Saline Bolus Infusion|Patients will undergo Saline Bolus infusion.
214500904|NCT03658109|PROCEDURE|Simulated QL block|Patients will undergo a simulated posterior QL block pre-operatively.
214500905|NCT06466512|BEHAVIORAL|Midwifery-embodied care|The midwife will provide ANC, delivery and PNC. The Community Healthcare Provider, Health Assistants will act as auxillary staff. Local transports will be integrated into the system. Coordination committee will see through that the interventions are carried out properly.
214687892|NCT06053606|DEVICE|cryoablation of atrial fibrillation using only 28 mm size balloon|all applications in all PVs are done with 28 mm balloon
214998262|NCT03922776|PROCEDURE|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~* at diagnosis, before chemotherapy (pre-CT)~* after chemotherapy (post-ct) Collection of two blood samples (5mL),~* before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~* and then, after chemotherapy (post-CT), up to 3 months after enrollment"
214998263|NCT06797687|DIAGNOSTIC_TEST|Cardiac computed tomography|Mitral valve annulus measurements in the enrolled patients obtained will be obtained from: coronary CT scan, intraoperative transesophageal echocardiography and the ring surgically implanted during surgery.
214998264|NCT06455111|OTHER|Keenoa|Keenoa is an artificial intelligence-enhanced, image-assisted tool, is a newly designed mobile application that may facilitate collection of dietary data. Serving as a visual food diary, individuals can upload a picture of their meal, choose the food items eaten using a preselected food list available by the app, and confirm the portion size with the presented visual aids.
215093964|NCT05797662|DRUG|Propranolol|Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks
215093965|NCT03680729|BEHAVIORAL|Adapted Brothers Saving Brothers (aBSB)|This information is listed in the arm description.
215093966|NCT03680729|BEHAVIORAL|Standard Street Outreach|This information is listed in the arm description.
214500906|NCT03440996|OTHER|Clinpro™ 5000|Clinpro™ 5000 with 1.1% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
214500907|NCT03440996|OTHER|Clinpro™ Tooth Crème|Clinpro™ Tooth Crème with 0.21% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
214500908|NCT03440996|OTHER|MI-Paste Plus|MI-Paste Plus is a widely used anti-cavity toothpaste on the market and it is used as a control group in this study.
214687893|NCT06053606|DEVICE|cryoablation of atrial fibrillation using expandable balloon (28 / 31 mm)|first applications in LSPV and RSPV are done with 31 mm balloon
214388525|NCT03562169|DRUG|Conventional autologous stem cell transplant (ASCT-con)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
214388526|NCT03562169|DRUG|Augmented autologous stem cell transplant (ASCT-aug)|Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
214388527|NCT03562169|DRUG|ITD consolidation and ixazomib maintenance vs. No further therapy|"Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression."
214388528|NCT00099489|DRUG|Interferon Beta-1a|
214388529|NCT03917810|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
214500909|NCT06487702|DRUG|fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium|"Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w"
214500910|NCT03582475|DRUG|Carboplatin|Given IV
214500911|NCT03582475|DRUG|Cisplatin|Given IV
214500912|NCT03582475|DRUG|Docetaxel|Given IV
214500913|NCT03582475|DRUG|Etoposide|Given IV
214500914|NCT03582475|BIOLOGICAL|Pembrolizumab|Given IV
214500915|NCT04346875|PROCEDURE|Regularly changing of dressing|Conventional dressing
214998265|NCT06455111|OTHER|ASA24|The Automated Self-Administered 24-Hour (ASA24) dietary recall or record is a free, web-based tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries.
214998266|NCT06364956|DRUG|Tislelizumab combined with two predefined dose groups of palbociclib|Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.
214998267|NCT06364956|DRUG|RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.|After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
215093967|NCT05841498|DEVICE|Immunoadsorption|Immunoadsorption (IA) is a well-established extracorporeal therapy for several autoimmune diseases such as systemic lupus. Its therapeutic effect is based on the removal of antibodies (ABs) from the plasma including auto-ABs and it is used if an immediate response to therapy is necessary. Side effects (SE) of the IA are rare, but angiotensin-converting enzyme (ACE)-inhibitors are prohibited concomitant medication. Notable SE may include increased susceptibility to infection, transient disorders of blood coagulation, or allergic reactions to materials of the adsorber or tubing system. To ensure an effective therapy, a blood flow of at least 45 ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins but in most patients is the placement of a central venous catheter necessary. Central venous catheter placement carries potential risks such as injury to the lung or mispuncture of the carotid artery.
215093968|NCT05841498|DEVICE|Sham-apheresis|Sham-apheresis is a procedure without any known therapeutic effects. As there are no known therapeutic effects there are also no known side effects excepted the risk of an allergic reaction to materials of the tubing system or to citrate, which is necessary to prevent clotting inside the extracorporeal system. To ensure a smooth operation a blood-flow of at least 45ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins. However, in most patients, placement of a Shaldon catheter into the internal jugular vein is necessary. Shaldon catheter placement carries other potential risks such as injury to the lung resulting in pneumothorax or mispuncture of the carotid artery. However, since the catheter placement is sonography-guided, the risks for such adverse events are minimized.
215093969|NCT04068610|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
214500916|NCT04346875|PROCEDURE|No application|No dressing change
214500917|NCT02972424|DRUG|Teriparatide Prefilled Syringe|TPTD 20 mcg
214500918|NCT02972424|DRUG|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
214500919|NCT03363945|BIOLOGICAL|MDR-101|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
214500920|NCT00464893|DRUG|Catumaxomab|10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
214500921|NCT00464893|DRUG|catumaxomab|10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
214500922|NCT06510829|DEVICE|Diode laser|Application of laser waves on the lesion
214500923|NCT01706159|DRUG|catridecacog|Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
214500924|NCT01706159|DRUG|placebo|Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
214687894|NCT04083430|DRUG|Yellow Fever Vaccine|"STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution."
214388530|NCT02169947|BEHAVIORAL|Weight loss core|The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
214500925|NCT04505358|DRUG|PU-AD|active vs placebo
214687895|NCT03057834|BEHAVIORAL|Pelvic floor muscle exercise|Standardized pelvic floor muscle exercise regimen
214687896|NCT02388516|DIETARY_SUPPLEMENT|Vitamin D3|
214388531|NCT02169947|BEHAVIORAL|Weight loss core plus maintenance|The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
214500926|NCT04505358|DRUG|Placebo|active vs placebo
214500927|NCT06199557|DRUG|Hydroxyurea, Hydroxycarbamide|Hydroxyurea (HU/hydroxycarbamide) is a hydroxylated analogue of urea which prevents DNA synthesis by inhibiting the activity of ribonucleotide reductase (RNR). HU has been used to treat a variety of diseases. As an antineoplastic drug, HU has some advantages. It may be used by ambulatory patients and has relatively few side effects, which are relieved almost immediately after withdrawal of the drug. The drug is readily absorbed from the gastrointestinal tract following oral administration. At present, HU has an important role as standard of care for treating hyperleukocytosis in chronic and acute myeloid leukemia.
214500928|NCT06199557|DRUG|Valproic acid|Valproic acid (VPA) has been used clinically as an anticonvulsant and mood-stabilizing drug. During the last two decades, VPA has been described as a histone deacetylase (HDAC) inhibitor and gained increased interest for use in cancer therapy. VPA is administered orally with available routine measurements of serum levels and has a low toxicity profile.
214388532|NCT01406561|DRUG|OMS103HP-S|Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
214388533|NCT01406561|DRUG|Vehicle|3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
214388534|NCT02869269|DEVICE|Early stage|patients who classed as clinical stage 1 and 2
214388535|NCT02869269|DEVICE|Late stage|patients who classed as clinical stage 3 and 4
214388536|NCT06529354|BEHAVIORAL|Moderate-intensity Group|In water aerobics sessions, the exercises are performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
214998268|NCT06869148|OTHER|Prioritized assessment for older patients living with frailty|In the beginning of 2025, the Emergency department of University hospital of Linköping launched a clinical guideline which stated that patients aged 65 years or older should be assessed with CFS as early as possible, preferably in connection to triage. If the patients were assessed as living with frailty, the frailty score should be stated in the electronical overview of ED patients. The patient's needs of care should be met according to frailty level and the responsible clinical team should aim to decrease the ED length of stay for older patients living with frailty.
214998269|NCT06871111|BIOLOGICAL|Commensal Bacteria Strains|7 doses containing 8 capsules will be administered over 7-10 days
214998270|NCT06865534|OTHER|Local language model|Group will be given access to local language model first after using ChatGPT and then will get access to pdf file
214998271|NCT06865534|OTHER|Guideline pdf|Group will be given access to pdf file after ChatGPT and then to a local language model
214998272|NCT06868355|OTHER|No intervention (observational study)|This is an observational study
214998273|NCT06608277|PROCEDURE|Group A active comparator|Group A placebo comparator. Stellate Ganglion Block plus placebo (.9 normal saline) infusion
214998274|NCT06608277|DRUG|Group B active comparator|Active Comparator: Group B = Sham Stellate Ganglion Block plus ketamine infusion
214998275|NCT06608277|COMBINATION_PRODUCT|Group C Experimental|Group C experimental Stellate Ganglion Block plus ketamine infusion
214998276|NCT06608277|OTHER|Group D Placebo Comparator|Group D Placebo Comparator: Sham Stellate Ganglion Block plus placebo normal saline
214998277|NCT06138886|DEVICE|Pulsed electromagnetic therapy|The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.
214998278|NCT06138886|OTHER|calisthenics exercises|This group includes 30 burned patients who will perform calisthenics exercises program for 3 months (3times/week) in addition to their traditional physical therapy program and medical treatment.
214998279|NCT07010497|DRUG|irpagratinib|Patients will receive oral administration of ABSK-011 capsules in a repetitive dosing regimen for a period of 21 consecutive days as a cycle, either once daily or twice daily, until the investigators make a comprehensive assessment of imaging examinations, laboratory data, and the clinical condition of the patients, and determine that there is intolerable toxicity or disease progression.
214998280|NCT07010471|DRUG|1.0mg/kg/day PRAX-562|Once daily orally or gastronomy/jejunostomy
214998281|NCT07010471|DRUG|1.5mg/kg/day PRAX-562|Once daily orally or gastronomy/jejunostomy
214998282|NCT07010471|DRUG|Placebo|Once daily orally or gastronomy/jejunostomy
214998283|NCT05186272|BEHAVIORAL|Stress reduction program 'A'|Participants will use stress reduction program 'A' app 10-20 min per day for 6 weeks.
214998284|NCT05186272|BEHAVIORAL|Stress reduction program 'B'|Participants will use stress reduction program 'B' app 10-20 min per day for 6 weeks.
214998285|NCT07009717|OTHER|No intervention (observational study)|No intervention; observational study
214388537|NCT06529354|BEHAVIORAL|High-intensity Group|In water aerobics sessions, the exercises are performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
214388538|NCT04112940|OTHER|Starch-based Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
214388539|NCT04112940|OTHER|Xanthan-gum Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
214388540|NCT06196580|DRUG|repaglinide; midazolam; SHR4640|repaglinide; midazolam; SHR4640
214388541|NCT06196580|DRUG|repaglinide; midazolam; SHR4640; SHR4640 placebo|repaglinide; midazolam; SHR4640; SHR4640 placebo
214388542|NCT06196580|DRUG|repaglinide; midazolam; SHR4640 placebo|repaglinide; midazolam; SHR4640 placebo
214388543|NCT04957732|DEVICE|Standard of Care (SoC)|SoC consisted of irrigation with normal saline, using the same proprietary abscess irrigation tip as the Irrisept arm. SoC was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
214687897|NCT02388516|DIETARY_SUPPLEMENT|Placebo|
214687898|NCT06138795|DRUG|AZD2389|Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.
214687899|NCT06138795|DRUG|Placebo|Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
215093970|NCT04068610|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
215093971|NCT04068610|DRUG|FOLFOX|Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
215093972|NCT04068610|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
215093973|NCT06292039|OTHER|Human-Centered Injury Thrivorship Pathway|Enrollment in the human-centered injury thrivorship pathway.
215093974|NCT06832579|DEVICE|Wearable|semi-continuous heart rhythm monitoring with Wearable
215093975|NCT02428205|DRUG|Propranolol|Participant will receive Propranolol prior to each EIBI session
215093976|NCT02428205|DRUG|Placebo|Participant will receive placebo prior to each EIBI session
214388544|NCT04957732|DEVICE|Irrisept Delivery System|Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression. The device had an option for use with an Irriprobe applicator or an abscess irrigation tip. Irrisept was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
214388545|NCT03148847|OTHER|Baseline care|
214388546|NCT03148847|OTHER|Referential's dissemination|
214388547|NCT01035333|DRUG|Orlistat|60mg capsule three times a day for up to 6 months
214388548|NCT04310943|DRUG|Tislelizumab|Tislelizumab, 200mg, Q3W ,use until disease progression
214388549|NCT00994786|DRUG|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
214388550|NCT00994786|DRUG|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
214500929|NCT06199557|DRUG|6-Mercaptopurine (6-MP)|In 1953, 6-MP was an approved antileukemic agent resulting in remissions in children with acute lymphocytic leukemia (ALL). After adding 6-MP to methotrexate and prednisolone in the treatment regimen, the one-year mean survival of children with ALL was increased from 29% to 50%. 6-MP, even about 70 years after its discovery, remains the standard maintenance therapy once the children are in complete remission.
214388551|NCT03034213|DEVICE|Gentrix™ Surgical Matrix (Treatment)|Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
214500930|NCT03362190|DRUG|Avacincaptad Pegol|Avacincaptad Pegol in combination with Lucentis
214500931|NCT03362190|DRUG|Lucentis|Avacincaptad Pegol in combination with Lucentis
214500932|NCT04968587|PROCEDURE|Sustained Low-Efficiency Dialysis|All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate
214500933|NCT06212297|GENETIC|LX101|Subretinal administration of LX101 to the contralateral, previously uninjected eye
214998286|NCT07011264|BEHAVIORAL|The BAJJAJJA intervention|"The BAJJAJJA intervention is composed of:~The IGA COMPONENT which is intended to promote economic empowerment by improving household income based on available resources. The component will consist of a series of 1-hour sessions with 3 separate GMC participant groups (8 GMCs per group). Two IGA experts will lead these sessions, weekly for the first two months and later monthly for the remaining 10 months of the 12-month intervention period.~The HEALTH COACHING COMPONENT will be informed by theChronic Disease Self-Management Education (CDSME) framework.54 This community-based, person-centered care model will be used to empower GMCs to manage their health through goal-setting, problem-solving, and chronic disease self-monitoring. I (PI) will leverage the community networks that I developed during my preliminary work to (1) recruit interventionists (two nurses) and (2) ensure their adequate training and adherence to the intervention manuals and procedures."
214998287|NCT06588088|OTHER|Dietary|The diet of these healthy volunteers was such that no calories were consumed after 19.30 in the evening in the first week, and in the second week, 25% of the daily calorie need calculated according to the Harris - Benedict formula was taken, taking into account the nighttime eating syndrome (NES) criteria, after 20.30 in the evening.
214998288|NCT07013643|DRUG|AZD6234|AZD6234 will be administered as a subcutaneous injection in the abdomen.
214500934|NCT00687219|BIOLOGICAL|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
214500935|NCT00687219|DRUG|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening \>=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening \>=12g/dL and \<14g/dL; treatment duration is 48 weeks
214500936|NCT04047641|DRUG|Cladribine|Given Intravenous
214998289|NCT07013643|DRUG|Ethinyl estradiol/Levonorgestrel (EE/LEVO)|EE/LEVO will be administered as combined oral tablets.
214998290|NCT07013643|DRUG|Acetaminophen (APAP)|APAP will be administered orally as a solution.
214998291|NCT07013643|DRUG|AZD9550|AZD9550 will be administered as a subcutaneous injection in the abdomen.
214500937|NCT04047641|DRUG|Cytarabine|Given Intravenous
214998292|NCT07010835|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 and CD3.
215093977|NCT00412594|DRUG|Cladribine|Given IV
215093978|NCT00412594|OTHER|Laboratory Biomarker Analysis|Correlative studies
214388552|NCT03034213|DEVICE|Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)|A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
214388553|NCT01613027|BIOLOGICAL|Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
214388554|NCT02348853|BEHAVIORAL|Healthy Weight for Living (HWL)|
214500938|NCT04047641|DRUG|Idarubicin|Given Intravenous
214500939|NCT04047641|DRUG|Quizartinib|Given by mouth
215093979|NCT00412594|BIOLOGICAL|Rituximab|Given IV
215093980|NCT06426914|OTHER|Clinical Pilates|"Warmup: 5-10 minutes Pilates Clinical (Introductory program) The Hundred modified The Roll-up modified The roll-over modified Spine twist modified Single-leg circle modified Rolling like a ball Shoulder Bridge modified~For every Step emphasizing:~FOCUS: On muscle involved REPETITIONS: 3-5 VISUALIZATION: Imagination process (Different for each step) Cool down: 5 minutes Total Time: 30 minutes"
214998293|NCT07013968|BEHAVIORAL|culturally tailored, trauma-informed mindfulness smoking cessation intervention|"Eight weekly in-person group sessions, each 90 minutes long. From the second half of PY01 to PY04, sessions will be performed in closed in groups of 7-10 participants (with a total of 6 groups). The curriculum is grounded in Lakota values and trauma-informed care. Each of the eight sessions will begin and end with a Lakota serenity prayer and wazílya (smudging of sage), and the meaning and relevance of one of the Lakota values will be discussed. Through a storytelling approach, which is central to Lakota culture, the participants will learn about their value as a Lakota woman, the role of caŋṡaṡa, the association between unresolved trauma and smoking, and the importance of Lakota mind-based and mindfulness strategies in their lives."
214998294|NCT02141113|DRUG|Guanfacine Hydrochloride|"1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)"
214998295|NCT02141113|OTHER|Placebo|Placebo of matching mg
214998296|NCT07013110|DRUG|dnaJP1|The study drug is dnaJP1 peptide. It is a manmade short protein that can be taken easily as a pill. dnaJP1 works to restore the body's immune tolerance by improving its ability to self-adjust - helps to restore the immune system and improve controls on inflammation that has been lost.
214998297|NCT07013110|DRUG|Placebo|This is the control.
214998298|NCT07013578|BEHAVIORAL|Healing Circuits™ sessions|Treatment of the Study group will involve 12-weekly 50-minute sessions with a social worker who has been trained in the Healing Circuits™ Methodology - a structured mental health support delivered by a therapist in a one-on-one model.
214998299|NCT07013578|BEHAVIORAL|self-directed Healing Circuits™ curriculum|Treatment of the Control group will involve 12 weekly online modules of a self-directed Healing Circuits™ curriculum - structured mental health support being delivered in an web-based video instruction model.
214998300|NCT05536739|DEVICE|Robotic hip exoskeleton|The intervention is an experimental robotic hip exoskeleton in a powered state providing assistance to the user that has been previously developed by the team. It is used to improve walking gait performance.
214998301|NCT05536739|OTHER|No hip exoskeleton|The intervention will serve as a baseline where participants will be asked to perform the tasks without wearing a hip exoskeleton.
214998302|NCT05536739|DEVICE|Unpowered hip exoskeleton|The intervention is an experimental robotic hip exoskeleton in an unpowered state that has been previously developed by the team. It is used to improve walking gait performance.
214998303|NCT07014618|OTHER|Pre & Post Surveys|As part of this intervention, patients will complete a pre-treatment questionnaire at the time of consent, which can be administered in person, over the phone, or through the mHealth mobile app, based on their preference. One month after treatment, patients will complete a post-treatment questionnaire using their chosen method. At the six-month mark, patients will complete an additional post-treatment questionnaire along with the COST-Functional Assessment of Chronic Illness Therapy (COST-FACT) survey.
215093981|NCT06426914|OTHER|Cardiac Rehabilitation|"Chest Physical therapy (Chest percussions and active huffs as per need) Breathing strategies (Diaphragmatic and purse lip 1-3 sets \* 5 Reps/Day)~Functional mobility (walk /cycling as per patient tolerance)~Patient education and Wound care Sternal Precaution guidance"
215093982|NCT06971757|OTHER|Routine Follow-Up (RFU)|Standard follow-up care with scheduled X-ray and clinical visit at 3 months and 1 year after surgery.
215093983|NCT06971757|OTHER|Check-Up on Demand (COD)|Follow-up care with scheduled X-ray and clinical visit at 3 months and only at 1 year if requested.
215093984|NCT06545643|DEVICE|Dreem headband|The Dreem headband is an EEG-based wearable tool that can be used to reliably assess the relationship between sleep and epilepsy over extended observation periods.
215093985|NCT05958199|DRUG|NPX267|NPX267 will be administered by intravenous infusion every three weeks until documented disease progression or participant withdrawal
215093986|NCT00068094|DRUG|Probiotic-containing powder|
215093987|NCT04373629|BEHAVIORAL|attentional modulation|Attentional instructions when viewing faces will be given
215093988|NCT04373629|OTHER|perceptual modulation|Faces will be presented of varying durations
214388555|NCT02348853|BEHAVIORAL|Current Best Practice (CBP)|
214388556|NCT00545363|DRUG|Ibandronate|Participants will receive ibandronate 150 mg QM orally for 6 months.
214388557|NCT00707213|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|FDG-PET/CT scan-The scans that will be done with a radioactive sugar (\[18F\]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
214388558|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with normal renal function
214388559|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with mild renal impairment
214388560|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
214388561|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with severe renal impairment
214388562|NCT06495255|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMOs)|HMOs will be applied as a neutral-flavoured powder
214388563|NCT06495255|DIETARY_SUPPLEMENT|Control|will be applied as powder
214388564|NCT02265081|PROCEDURE|ultrasound|pelvic floor ultrasound
214388565|NCT02265081|PROCEDURE|uroflow-meter|uroflow meter: measurement of passed urine volume
214388566|NCT02579018|BEHAVIORAL|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
214388567|NCT06289634|BEHAVIORAL|Man-made sounds|Participants will be asked to listen to the assigned sounds (relaxing music) for 30 minutes a day for 15 days.
214388568|NCT06289634|BEHAVIORAL|Natural sounds|Participants will be asked to listen to the assigned sounds (birds, ocean, wind) for 30 minutes a day for 15 days.
214388569|NCT03917641|BIOLOGICAL|Khat leaves|One of the two compressions (one per each eye) the patient will use will contain the Khat leaves.
214388570|NCT00951509|OTHER|Power Mobility Road Test (PMRT)|All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
214388571|NCT04453501|DRUG|favorable outcome|Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
214998304|NCT07014618|OTHER|Opt Out of Questionnaire|As part of this intervention, patients declined to participate in the optional questionnaire. However, their data will still be collected through chart review and will be compared to the data of patients who accepted both the questionnaire and navigation services.
214388572|NCT04930328|DRUG|Oxbryta® (voxelotor) 500-mg Tablets|Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
214388573|NCT02454036|BEHAVIORAL|BBI intervention|Psychological intervention designed to reduce stress and enhance quality of life
214500940|NCT01613053|DRUG|Glivec|800 mg per day
214500941|NCT06212479|DIAGNOSTIC_TEST|MRI Scan|Whole Body MRI Scan
214500942|NCT04816955|BEHAVIORAL|Dietary recommendations|Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
214500943|NCT01121965|PROCEDURE|Pars plana vitrectomy with ILM peeling|Pars plana vitrectomy with ILM peeling
214500944|NCT03775486|DRUG|Durvalumab|Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
214500945|NCT03775486|DRUG|Placebo for Olaparib|Matching tablet
214500946|NCT03775486|DRUG|Olaparib|150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
214500947|NCT03775486|DRUG|Nab-paclitaxel+carboplatin|Standard of Care chemotherapy (squamous and non-squamous patients)
214500948|NCT03775486|DRUG|Gemcitabine+carboplatin|Standard of Care chemotherapy (squamous patients only)
214500949|NCT03775486|DRUG|Pemetrexed+carboplatin|Standard of Care chemotherapy (non-squamous patients only)
214500950|NCT03775486|DRUG|Gemcitabine+cisplatin|Standard of Care chemotherapy (squamous patients only)
215093989|NCT04373629|OTHER|naturalistic viewing|Faces will be viewed without specific instructions
214388574|NCT06038903|OTHER|caffeine consumption expectation|The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption.
214388575|NCT01832103|DRUG|MK-7145|
214388576|NCT01290536|DEVICE|Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery
214500951|NCT03775486|DRUG|Pemetrexed+cisplatin|Standard of Care chemotherapy (non-squamous patients only)
214500952|NCT02055742|DEVICE|illumigene CT and NG assays, illumipro-10|
214500953|NCT02000089|DRUG|Secretin|inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
214500954|NCT02000089|DIAGNOSTIC_TEST|MRI|MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
214500955|NCT02000089|OTHER|Tumor marker gene test with CA19-9|A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
214500956|NCT04562675|BEHAVIORAL|LHA intervention|For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.
214388577|NCT01167686|DIETARY_SUPPLEMENT|Gardemont Goldtrain Plus (GT+)|Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
214388578|NCT06236360|BEHAVIORAL|Mediterranean Diet Intervention|The primary goal is to evaluate whether tele-intervention can elevate the level of flavonoids, anthocyanins, proteins, omega-3 fatty acids, short fatty acids, fruits and vegetables, and fibers (all previously associated with a better response to immunotherapy) and limit foods with added sugars.
214500957|NCT04562675|OTHER|brochure-only|brochure-only for control group (CG)
214500958|NCT02019459|OTHER|Very low nicotine content cigarettes|
214500959|NCT02019459|OTHER|standard nicotine content cigarettes|
214500960|NCT04008316|DRUG|Colchicine|colchicine 1mg/day
214388579|NCT05987501|DIAGNOSTIC_TEST|Multimodal ultrasound|Contrast enhanced ultrasound and shear wave elastography on target intestinal loop are perfomed before and at different timepoints after treatment induction
214388580|NCT04896125|DRUG|Lumigan PF; Xalatan|Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.
214500961|NCT04420767|DEVICE|tDCS|Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
214500962|NCT04420767|DEVICE|Sham brain stimulation|Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
214500963|NCT04420767|BEHAVIORAL|Go-No GO task|During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
214500964|NCT06101875|OTHER|Health Coach (Health coaching)|Patients will be assigned a health coach and be eligible to 8 times, 1 hour sessions over a 12 week period. The health coach will use techniques to increase their ability to self-manage, motivation levels and commitment to change their behaviour.
214500965|NCT06101875|OTHER|Digital Toolkit (Control)|This is an online website, unsupervised, 12-week self-management programme.
214500966|NCT00767741|DEVICE|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
214998305|NCT07016178|BEHAVIORAL|Acceptability and Feasibility of Twistle messaging for PDM+ patients|PC patients identified by the PDM as high risk for developing or having undetected MCI or ADRD will receive the patient-informed message developed in Aim 2. The patient-informed message will include instructions for completing validated questions about subjective memory concerns. In addition, interested patients will have the option to schedule a visit with the BHN, or enroll in research opportunities.
214998306|NCT04878263|OTHER|Conventional hospitalization|Conventional care pathway : patients will be hospitalized as long as necessary and then followed according to High Health Authorities recommendations and usual practices.
215093990|NCT06980610|PROCEDURE|digestive stoma closures|"Both surgical techniques (Collatamp interposition and directed healing) are routinely used in the CVMC and Digestive Cancer Surgery departments for stoma closure or restoration of digestive continuity. The choice of technique is at the surgeon\&#39;s discretion.~Specific procedures related to the research:~Procedures that differ from standard management are randomization and patient completion of a questionnaire."
214388581|NCT04358796|DEVICE|Hyperbaric oxygent treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 2 ATA. They will breath 100% oxygen while solving cognitive tests designed to assess their cognitive capacities
214388582|NCT04358796|DEVICE|Control hyperbaric oxygen treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 1.2 ATA for a short while and the decreased back to 1 ATA. They will breath air while solving cognitive tests designed to assess their cognitive capacities
214388583|NCT03125941|DRUG|Dexamethasone|pre-operative intravenous administration
214388584|NCT03103230|DEVICE|Cortical magnetic stimulation|Motor Evoked Potentials of lips and hand recorded after cortical magnetic stimulation
214388585|NCT02753725|DRUG|Fentanyl|The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
214388586|NCT02753725|DRUG|Normal saline|the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
214500967|NCT01333605|DRUG|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
214500968|NCT00406887|DRUG|Difluprednate Ophthalmic Emulsion|
214500969|NCT03134300|DIAGNOSTIC_TEST|Cytokine from blood|Blood draw- one intraoperative, one 3 weeks postoperative
214998307|NCT04878263|OTHER|FIL-EAS ic care pathway|Organized care pathway with a maximum 4 working day long conventional hospitalization followed by hospitalization at home with a follow up combining hospital and private practice competences.
214998308|NCT06627296|OTHER|Exercise Training|"Individuals in the NMES group will have a total of 24 sessions of NMES application with 15 repetitions 3 days a week for 8 weeks and then exercise programs will be performed face-to-face. They will also be given home exercises to continue at home.~In the NMES group, NMES training will be performed for extensor carpi radialis longus (ECRL), extensor carpi radialis brevis (ECRB), abductor pollicis longus (APL), flexor carpi radialis (FCR) muscles. The pencil electrode will be used to stimulate the ECRL, ECRB, FCR and APL muscles in such a way that 30+30+30=90 contractions will be obtained from each muscle. According to the morphologic characteristics of each muscle, different current and will be applied.~P11th program to ECRL and APL : 65 Hz. 200 μs, P13th program to ECRB and FCR 50 Hz, 200 μs will be applied. Exercises includes intrinsic and extrinsic muscle strengthening, stabilization exercises and dart exercises, wrist neuromuscular exercises and perturbation exercises."
214998309|NCT06627296|OTHER|Exercise Training (Control Group)|"Patients in the control group will have face-to-face exercise programs with a physiotherapist for a total of 24 sessions of 15 repetitions 3 days a week for 8 weeks. Exercises will be performed 3 days a week with a physiotherapist. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises.~Exercise training includes intrinsic and extrinsic muscle strengthening, wrist stabilization exercises, dart exercises, wrist neuromuscular exercises using different materials, reactive muscle control, perturbation exercises.~Exercises will be at the limit of pain. Until the 6th month, overloading, strong gripping, weight transfer, rotations and lifting heavy objects should be avoided. Rehabilitation with functional range of motion is important. Exercises will be performed with a physiotherapist 3 days a week. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises."
214998310|NCT06627296|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation
214998311|NCT07011849|DRUG|Pembrolizumab|Given by IV
214998312|NCT07011849|DRUG|Lenvatinib|Given by mouth
214998313|NCT07018570|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered via intravenous infusion over 30 minutes, twice at 21-day intervals.
214998314|NCT07018570|DRUG|Docetaxel|Docetaxel 50 mg/m2 will be administered over 60 minutes.
214998315|NCT07018570|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 will be administered over 2 hours.
214998316|NCT07018570|DRUG|Levofolinate|Leucovorin 200 mg/m2 will be administered over 2 hours.
214998317|NCT07018570|DRUG|Fluorouracil (5-FU)|5-FU 2600 mg/m2 will be administered over 24 hours.
215093991|NCT03553186|DRUG|Tranexamic Acid 100 MG/ML|TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
214500970|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.
214500971|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses
214500972|NCT03784105|DRUG|Codeine Phosphate|30 mL of codeine phosphate 10mg/5mL
214998318|NCT07018570|RADIATION|Radiation Therapy|25Gy (5Gy×5fr)
214998319|NCT00357565|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
214998320|NCT00357565|DRUG|busulfan|Administered 1.1 mg/kg if \<12 kg intravenous (IV) every 6 hours (0.8 mg/kg if \>12 kg IV every 6 hours on Days -8 through -5.
214500973|NCT03784105|DRUG|Siripus simplex|Sugar syrup
214500974|NCT03874169|DEVICE|E4 wristband|A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
214500975|NCT00000127|PROCEDURE|Optic Nerve Sheath Decompression Surgery|
214388587|NCT05768724|BEHAVIORAL|intervention diet|"The Resmena diet: It was characterized by a higher meal frequency, consisting of seven meals/d (including breakfast, lunch, dinner, and two snacks in the morning and two snacks in the afternoon), and by a different macronutrient distribution; 40% total energy value from CHO, 30% from proteins and 30% from lipids. This pattern tried to reinforce high n-3 polyunsaturated FA (n-3 PUFA) and high natural antioxidant food consumption and promoted low GL CHO intake as well as a high adherence to the Mediterranean diet. It also maintained a healthy FA profile and a cholesterol content of less than 300 mg/day.~* Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked."
214388588|NCT05768724|BEHAVIORAL|control diet|"Control diet: It was based on the American Heart Association (AHA) guidelines, including 3-5 meals per day, a macronutrient distribution of 55% total energy value from carbohydrates, 15% proteins, and 30% lipids, a healthy fatty acids (FA) profile and a cholesterol consumption lower than 300 mg/day.~\- Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked"
214388589|NCT04825860|DRUG|SEP-363856 50 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
214388590|NCT04825860|DRUG|SEP-363856 75 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
214388591|NCT04825860|DRUG|Placebo|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
214388592|NCT00582491|DRUG|Modafinil|Modafinil 400mg orally every day for 16 days
214388593|NCT00582491|DRUG|Placebo|Placebo orally everyday for 16 days
214388594|NCT00040092|DRUG|Virulizin®|
214388595|NCT03692221|DRUG|MSC Treatment group 1 (low dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
214500976|NCT03058757|DRUG|intravesical mitomycin-C 40mg/20ml instillation|"neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation~* one day before surgery~* four hours before surgery"
214500977|NCT01536366|DRUG|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
214500978|NCT01536366|DRUG|Repaglinide|0.5 mg repaglinide (single-dose)
214500979|NCT03987646|PROCEDURE|Non-staged vestibular fresh socket therapy|a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
214687900|NCT05139498|PROCEDURE|Conservative management for placenta accreta spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
214998321|NCT00357565|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \>200 ng/mL. For children \< 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
214998322|NCT00357565|DRUG|fludarabine phosphate|Administered 25 mg/m\^2 intravenous (IV) over 60 minutes on Days -4 through -2.
214998323|NCT00357565|DRUG|melphalan|Administered 60 mg/m\^2 intravenous (IV) over 30 minutes on Days -4 through -2.
214998324|NCT00357565|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients \<45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
214998325|NCT00357565|PROCEDURE|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
215093992|NCT03553186|DRUG|Placebo|Placebo solution (200 cc sterile normal saline + placebo TXA ampule (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
214998326|NCT05694364|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
214388596|NCT03692221|DRUG|MSC Treatment group 2 (high dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
214500980|NCT02940249|DIETARY_SUPPLEMENT|Apple polyphenols|Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
214500981|NCT02940249|DIETARY_SUPPLEMENT|Placebo|
214998327|NCT05694364|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
214998328|NCT05694364|BIOLOGICAL|PRGN-3007|PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
214388597|NCT03692221|OTHER|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
214388598|NCT04817917|BIOLOGICAL|Japanese Encephalitis Vaccine (Vero Cell), Inactivated;|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. For participants from Group 1 and Group 2 who haven't completed the JE immunization schedules, a booster dose of JEV-I will be administered at 6 years old.
214388599|NCT04817917|OTHER|No prospective interventions|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.
214388600|NCT00781534|DRUG|Ginseng|Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
214388601|NCT00781534|DRUG|Ginseng|
214388602|NCT00781534|DRUG|ginsenoside RE|active metabolite of ginseng
214388603|NCT00781534|DIETARY_SUPPLEMENT|Placebo (sugar pill)|placebo group
214388604|NCT06266702|OTHER|Experimental Oil with Phospholipids|Consumed on white bread
214388605|NCT06266702|OTHER|Control Polyunsaturated Oil Blend|Consumed on white bread
214388606|NCT04876651|OTHER|177Lu-DOTA-rosopatamb|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC
214687901|NCT05139498|PROCEDURE|Cesarean hysterectomy for placenta accreta spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
214388607|NCT04876651|DRUG|Standard of Care|enzalutamide or abiraterone \[+ prednisone/prednisolone)\] or docetaxel
214388608|NCT00089713|DRUG|alagebrium chloride (ALT-711)|
214388609|NCT02327273|DRUG|BMS-963272|
214388610|NCT02327273|DRUG|Placebo|
214388611|NCT02829333|OTHER|general anesthesia and patient controlled intravenous analgesia|Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation
214388612|NCT02829333|OTHER|spinal anesthesia and continuous postoperative epidural analgesia|Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation
214388613|NCT03698760|DIAGNOSTIC_TEST|Olfactory test|"Olfactory test:~All fragrances tested are kept in an airtight case protected from cold and heat.~The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way."
214388614|NCT03791203|BEHAVIORAL|Calorie restriction (MACR)|This was a randomized, single-blind controlled trial with modified alternate-day calorie restriction (MACR) as the active intervention and normal habitual diet as control at Hospital University of Sains Malaysia.
214388615|NCT01933386|DEVICE|SoundBite|Non-surgical removable bone conduction device via the teeth.
214388616|NCT03820791|DEVICE|Placement of a poster in patients' rooms|Patients and their caregivers will be exposed to the poster for one month
214388617|NCT03941743|DRUG|Fingolimod|Given PO
214388618|NCT03941743|DRUG|Fingolimod Hydrochloride|Given PO
215093993|NCT06981442|BEHAVIORAL|Community-based environmental management|This intervention will be performed by the local community, who will have been previously informed and trained on the appropriate environmental management methods for the control of the Aedes mosquito. It will be based on the following elements: i) identification and removal of all artificial sources of reproduction of the Aedes mosquito inside and around the house (i.e. covering abandoned containers and/or storage containers to avoid water accumulation); ii) regular collection and disposal of household waste; iii) identification and resolution of all artificial sources of reproduction of the Aedes vector in or around the house (i.e. natural cavities such as tree holes will be filled to prevent water accumulation). This intervention will be carried out as a single intervention in Arm 1, in combination with a larvicidal intervention in Arm 2 and in combination with the intervention against the adult stage of the Aedes mosquito in Arm 3.
214388619|NCT03941743|OTHER|Questionnaire Administration|Ancillary studies
214388620|NCT04192630|DEVICE|CVisc50 OVD|Bausch + Lomb CVisc50 Cohesive OVD
214388621|NCT04192630|DEVICE|ProVisc OVD|ProVisc OVD
214388622|NCT04192630|PROCEDURE|Cataract Surgery|Cataract Surgery
214388623|NCT01683240|DEVICE|cholangioscopy (Frimberger)|cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
214388624|NCT03154840|DRUG|Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU|Investigate the Relative Bioavailability among Different Eutropin Formulations
214388625|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~4 doses starting from 121 to \< 212 days of age"
214388626|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~3 doses starting from 212 days to \< 12 months of age"
214388627|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~2 doses starting from 12 months to \< 24 months of age"
214388628|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~1 dose starting from 24 months to \< 72 months of age"
214388629|NCT02328976|OTHER|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
214388630|NCT02110524|DEVICE|Percutaneous Transluminal Angioplasty|
214388631|NCT05196048|OTHER|No Intervention|No Intervention
214388632|NCT01425632|DRUG|TAU-284|TAU-284 Low
214388633|NCT01425632|DRUG|TAU-284|TAU-284 High
214388634|NCT01425632|DRUG|Placebo|Placebo
214388635|NCT01812538|DRUG|DIC075V|"Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments."
214388636|NCT03145467|DRUG|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
214388637|NCT03145467|DRUG|Zolmitriptan|Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
214388638|NCT04894461|DEVICE|Moxibustion|The moxibustion treatment sessions are three times per week for eight weeks. Indirect moxa stick will be used.
214687902|NCT05673005|DEVICE|MED3000 topical gel|Topical gel that has been shown to improve erectile dysfunction when used as needed.
214687903|NCT01665417|DRUG|Experimental|Icotinib: 125mg, oral administration, three times per day.
214388639|NCT05199805|BEHAVIORAL|Mindfulness-based pain management|The structured program will include mindfulness exercises, meditation, a gentle body exercise series, and body awareness exercises, as well as information about pain, mindfulness-based pain management, and pain regulation methods suitable for everyday life. During the 8 weeks, treatment as usual is allowed.
214388640|NCT05911490|BEHAVIORAL|Prolonged sitting|In the laboratory, after consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
214388641|NCT05911490|BEHAVIORAL|Breaking prolonged sitting|In the laboratory, after consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
214388642|NCT04055168|DRUG|AZD6615|AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
214388643|NCT04055168|DRUG|Placebo|Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
214388644|NCT00240526|BIOLOGICAL|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
214388645|NCT00240526|BIOLOGICAL|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
214388646|NCT02976597|DRUG|Bupivacaine 0.25% 20ml on each side Sonar guided TAB|Bupivacaine 0.25% 20ml on each side Sonar guided TAP block. After careful aspiration injection of 20ml of 0.25% bupivacaine will be performed and hypoechoic layer will be detected on ultrasound then the maneuver will be repeated on the other side
214388647|NCT02976597|DRUG|Morphine 10mg|Morphine 10mg will be added to bupivacaine in sonar guided- TAP block divided into 5mg on each side.
214388648|NCT02976597|DRUG|Morphine 15mg|Morphine 15mg will be added to bupivacaine in sonar guided- TAP block divided into 7.5mg on each side.
214500982|NCT00873782|OTHER|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
214500983|NCT05359796|BIOLOGICAL|Chronic hyperglycemia|For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.
214500984|NCT05359796|BIOLOGICAL|Residual islet function|For each follow-up, fasting and stimulated C-peptide levels will be measured.
214388649|NCT05575115|BEHAVIORAL|Peer Comparison|"Peer comparison was an email-based intervention. Clinicians were ranked from highest to lowest inappropriate prescribing rate within each region using EHR data. Clinicians with the lowest inappropriate prescribing rates (the top-performing decile) were told via monthly email they were Top Performers. The remaining clinicians were told that they were Not a Top Performer in an email that included the number and proportion of antibiotic prescriptions they wrote for antibiotic-inappropriate acute respiratory tract infections, compared with the proportion written by top performers."
214388650|NCT03550586|OTHER|Questionaires|Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS)translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire . Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire .
214500985|NCT05359796|GENETIC|Genetic variation|Genetic variations of interest will be detected with the blood sample collected at baseline.
215093994|NCT06981442|OTHER|Vector control against immature stages of Aedes|Larvicidal control will be carried out through pyriproxifen-based autodissemination stations combined with Beauveria bassiana, implemented according to the manufacturer's recommended procedures.
214388651|NCT03664037|DRUG|Dexamethasone phosphate|each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline \[NS\]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
214388652|NCT03664037|DRUG|Placebo|each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
214388653|NCT02307110|OTHER|cross-sectional observation|cross-sectional opthalmic examination
214388654|NCT01716208|DRUG|Ofatumumab + Fresh Frozen Plasma|
214500986|NCT05359796|DIETARY_SUPPLEMENT|Dietary constitutes|For each follow-up, the dietary constitutes for the past 3 days will be recorded.
214500987|NCT05359796|GENETIC|Microbiome composition and function|For each follow-up, the fecal and oral samples will be collected for measurement.
214500988|NCT05359796|BIOLOGICAL|Metabolome composition|For each follow-up, the serum and urine samples will be collected for measurement.
214500989|NCT05359796|BIOLOGICAL|Composition of peripheral blood immune cells|For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
214500990|NCT02533232|DRUG|Minocycline|Minocycline 200mg per day
214500991|NCT04366193|DIAGNOSTIC_TEST|Oximetry|Validation of a high-resolution wireless oximeter for OSA diagnosis comparing with a well established and validated method (home sleep test).
214500992|NCT01484743|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
215093995|NCT06981442|OTHER|Vector control against the mature stages of Aedes|The control of the adult Aedes mosquitoes will be carried out through mass trapping using BG-GAT traps implemented according to the manufacturer's recommended procedures. In each household, three traps will be deployed.
215093996|NCT06980870|DRUG|Anti-inflammatory drug (ibuprofen)|Effect of pre-medication with anti-inflammatory drugs(ibuprofen and dexamethasone)on Post-Endodontic pain
215093997|NCT06980870|DRUG|Anti-inflammatory drug (dexamethsaone)|Effect of pre-medication with anti-inflammatory drugs(ibuprofen and dexamethasone)on Post-Endodontic pain
215093998|NCT00527319|DRUG|VT-122 low dose|VT-122 low dose, dose escalated
215093999|NCT00527319|DRUG|VT-122 high dose|VT-122 high dose, dose escalated
214388655|NCT02958618|PROCEDURE|"30 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 30 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
214388656|NCT02958618|PROCEDURE|"60 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 60 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
214388657|NCT02958618|PROCEDURE|"180 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18 ) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 180 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
214388658|NCT00450320|DRUG|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
214388659|NCT04797819|DIAGNOSTIC_TEST|Coronary plaque components|Coronary plaque components were detected by CCTA method
214388660|NCT02450864|OTHER|ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD \>270degrees.
214388661|NCT01061918|DEVICE|Tecnis MF|20 patients in the Tecnis MF group.
214388662|NCT01061918|DEVICE|ReSTOR|20 patients in the ReSTOR group.
214388663|NCT00517426|DRUG|acetazolamide|i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
214388664|NCT01885273|PROCEDURE|Pressurized irrigation method|The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.
214388665|NCT01885273|PROCEDURE|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
214388666|NCT00664703|DRUG|Lobeline sulfate|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
214388667|NCT00664703|DRUG|Methylphenidate HCl|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
214388668|NCT00664703|DRUG|Placebo|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
214388669|NCT04901364|BEHAVIORAL|Sensitivity and specificity of risk factors for degeneration of IPMNs|Measurement of high-grade dysplasia or invasive cancer on the histological analysis of the surgical specimen
214388670|NCT01339364|OTHER|Didactic Lecture|2 sessions of didactic lecture with PowerPoint presentations each delivered by a special lecturer. whole education period lasts 3 hours.
214388671|NCT01339364|OTHER|Interactive Lecture|2 sessions of brief interactive lectures followed by case discussion sections.
214388672|NCT01339364|OTHER|Lecture plus Small Group Education|A 1.5 hours session of didactic lecture followed by a session of small group education with 3 simulated patients.
214388673|NCT03632434|DEVICE|transcranial direct current stimulation|tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.
214388674|NCT01751113|DRUG|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
214388675|NCT01751113|DRUG|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
214388676|NCT01751113|DRUG|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
214500993|NCT06191458|DRUG|Primaquine|Primaquine 0.5 mg/kg (Government Pharmaceutical Organization, Thailand) will be given once daily with food for 14 days. This is the dose recommended by the World Health Organization for radical cure of P. vivax in tropical regions. Doses will be directly supervised (DOT).
214500994|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
214500995|NCT05026970|DEVICE|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
215094000|NCT06980883|OTHER|Dry Needling|dry needles Administered to patients in Group 1 as part of their treatment regimen( 2 days per week).
214388677|NCT04831008|OTHER|Figure-of-eight suture|Using the figure-of-eight closure technique when closing access for structural heart therapies.
214388678|NCT04831008|OTHER|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
214388679|NCT00325936|DRUG|Cilnidipine|10\~20mg, qd, po for 3 months or 12 months.
214388680|NCT03162757|PROCEDURE|Central venous catheterization|Central venous catheterization via either internal jugular vein or subclavian vein up to a maximum of two attempts.
214388681|NCT06022718|OTHER|Taping|Kinesio taping and Rigid taping was applied.
214388682|NCT04021992|DRUG|gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab|All patients enrolled in the study will accept gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab as their salvage chemotherapy.
214388683|NCT04855292|DRUG|TG103 injection|TG103 injection, SC, once weekly
214388684|NCT04855292|DRUG|Placebo|Placebo control, SC, once weekly
214388685|NCT02965118|DRUG|PAC-14028 cream 1.0%|topical application
214388686|NCT02965118|DRUG|PAC-14028 cream Vehicle|topical application
214388687|NCT06110741|OTHER|Blood and saliva sampling|Collecting blood and saliva sample
214388688|NCT06110741|OTHER|Survey|Collecting data on infectious diseases during the study period
214388689|NCT03403777|DRUG|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks.
214388690|NCT06461013|BEHAVIORAL|Blood flow restriction|A common clinical tourniquet (7cm \* 50cm in size) is placed in the middle section of the patient's thigh on the affected side, connected to a pressure gauge, observed and gradually pressurized to 160-170mmHg for about 10 minutes, then depressurized for 1 minute, and then re pressurized to 160-170mmHg. Each training session lasts for 20 minutes, once a day, five times a week, for a total of 8 weeks.
214500996|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Kegel|Biofeedback+Kegel exercises
214500997|NCT06515210|DIETARY_SUPPLEMENT|Acacia Gum|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
214388691|NCT02654093|DRUG|Cholecalciferol|
214388692|NCT02654093|DRUG|Raloxifene|
214388693|NCT02654093|DRUG|Cholecalciferol and Raloxifene co-administration|
214388694|NCT02969980|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
214388695|NCT04420546|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
214388696|NCT04420546|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding self-harm
214388697|NCT03783481|DEVICE|Mobile community|Install an application (app) on subjects' smartphone. Subject's will join the mobile community using the application through which they can check their own and other members daily steps and communicate with each other.
214388698|NCT03783481|OTHER|No Mobile community|No Mobile community
214388699|NCT01606956|PROCEDURE|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
214388700|NCT01606956|PROCEDURE|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
214388701|NCT01551303|DRUG|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
214388702|NCT01551303|DRUG|Placebo|Matched nasal spray placebo
214500998|NCT06515210|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
214500999|NCT06515210|DIETARY_SUPPLEMENT|Placebo|Participants (n=23) incorporate the placebo into their usual diet daily.
214501000|NCT06051799|OTHER|Myofascial trigger points pressure release|Patient lying down in the supine position, Therapist do a first and second finger pincer grasp is performed on the myofascial trigger points located on the upper trapezius muscle and sternocleidomastoid muscle, this pressure will be increased as the therapist perceives a reduction in soft tissue resistance under the finger over a period of 90 seconds. Previous studies indicate no difference between 60 and 90 seconds of pressure. It will be performed on as many trigger points as we find in each muscle associated with the study.
214687904|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
214388703|NCT03487718|BIOLOGICAL|Leukocyte platelet rich fibrin plug + d-PTFE membrane|Following tooth extraction, an autologous leukocyte platelet rich fibrin plug will be placed in the socket and covered with a d-PTFE membrane
214388704|NCT03487718|DEVICE|d-PTFE membrane|Following tooth extraction, the socket will be covered with a d-PTFE membrane
214388705|NCT01115023|OTHER|iron cooking pot|the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
214388706|NCT02218385|DEVICE|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
214388707|NCT04047381|OTHER|Measurement of Quality of Life|Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
214388708|NCT02701751|OTHER|Exercise session|A blood sample and fat biopsy will be obtained before and after the 60 minute moderate exercise session. There is no drug or device intervention in this study.
214388709|NCT01208415|DEVICE|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
214388710|NCT06360003|PROCEDURE|Right Ventricular Outflow Tract Posterior Septum Pacing|The Right Ventricular Outflow Tract (RVOT) posterior septum pacing is routinely performed to observe the QRS complex characteristics of the 12 lead ECG (with a focus on comparing their differences with the R-wave amplitude of spontaneous ventricular arrhythmias in the right chest (V1\~V3) leads). When the pacing-induced R-wave amplitudes are all lower than spontaneous VAs in V1\~V3, we predict the origin of Left Ventricular Outflow Tract (LVOT), mapping and ablation in LVOT; otherwise we predict the origin of RVOT, mapping and ablation in RVOT.If fails, go to the opposite site to do mapping and ablation. If still fails, go to distal great cardiac vein (DGCV) to do mapping and ablation.
214388711|NCT06360003|PROCEDURE|systemic mapping and ablation|The TC or ST ablation catheter is delivered to ventricular outflow tract (VOT) to perform systemic mapping and ablation.
214687905|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
214687906|NCT04906655|DRUG|Glycopyrronium 2.4 % Medicated Cloth|The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.
214687907|NCT01631279|DRUG|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
214687908|NCT04697472|DEVICE|LIFT System|The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
214687909|NCT00075348|GENETIC|mutation analysis|
214998329|NCT06863012|DIAGNOSTIC_TEST|Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement|Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) measurement is a minimally invasive, ultrasound-based diagnostic procedure designed to assess portal hypertension in patients with chronic liver disease. Using an endoscopic ultrasound (EUS) probe, and a fine-needle aspiration (FNA) needle (EchoTip® Insight™) is used to directly measure intravascular pressures. Unlike the standard hepatic venous pressure gradient (HVPG) measurement, EUS-PPG provides direct pressure readings, does not require catheterization of the hepatic vein, and eliminates the need for radiation, iodinated contrast, and interventional radiology. This study aims to evaluate the accuracy, feasibility, and safety of EUS-PPG compared to HVPG.
215094001|NCT06980883|OTHER|myofascial release|"Myofascial Release: Provided to patients in Group 2 along with traditional treatment( 2 days per week).~Evaluation of fascial restriction was assessed using the therapists elbow. Any restrictions felt were assessed and given treatment.Myofascial chain release- Position of the patient- Supine lying, prone lying and side lying Position of the therapist- Side of the patient limb to be treated~\- Technique-Using the therapist elbow a vertical release proximal to the attachment of the muscle belly or fascia was applied. Once an end-feel was reached a slow stroke down the length of the target tissue was performed along with monitoring the indirect feedback and tissue tension to identify any additional restrictions. The long stroke was repeated in a line parallel to the first stroke. It was continued until an end-feel is reached throughout the entire muscle belly or fascia on the most restricted/ painful points."
215094002|NCT06980883|OTHER|(traditional exercises)|comprising straight leg raising and isometric quadriceps exercises (2 days per week).
215094003|NCT06663722|BIOLOGICAL|Axatilimab|Axatilimab will be administered intravenously (IV) at a dose of 0.3 mg/kg, beginning as a pre-phase dose two weeks prior to initiation of Extracorporeal Photopheresis (ECP) therapy. Thereafter, Axatilimab will be administered with a frequency of one treatment session bi-weekly during each treatment cycle.
214388712|NCT06291532|DEVICE|Rehabilitation with VRRS|"The patients underwent an experimental intervention lasting two months (9 sessions lasting about 40 minutes) integrated into the regular activity of a semi-residential center for autistic adolescents and young adults.~The proposed exercises were 2D and the patient interacted with the scenarios through the touch screen. For all participants, the tasks were the same, but difficulty and duration varied according to the needs and goals to be achieved."
214388713|NCT04645524|DRUG|AD182|Oral capsule administered before bed
214388714|NCT04645524|DRUG|AD504|Oral capsule administered before bed
214388715|NCT04645524|DRUG|Placebo|Oral capsule administered before bed
214388716|NCT04645524|DIAGNOSTIC_TEST|Polysomnography|for all arms
214388717|NCT03648593|BEHAVIORAL|work recovery intervention|Recover! app: one hour weekly for two months
214388718|NCT03648593|BEHAVIORAL|waiting list control|no treatment during 6 months,then Recover! app
214501001|NCT06051799|OTHER|Therapeutic exercise and postural hygiene|"Therapeutic exercise and postural hygiene: A progression of exercises with contraction of the deep neck flexor muscles will be included in the first session. Subjects will be taught to perform a slow and controlled craniocervical flexion. Subjects will then be trained to be able to progressively maintain craniocervical flexion through feedback from an air device (Stabilizer™, Chattanooga Group Inc., Chattanooga, TN) placed behind the neck. This sensor monitors the slight flattening of the cervical curve that occurs with contraction of the craniocervical deep flexor musculature. It should be performed at least once a day during the treatment regimen.~Also Postural correction exercises carried out regularly throughout the day, especially when seated. Indications are given to avoid pelvic retroversion and maintain a natural lumbar lordosis while performing retraction and adduction of the scapulae and gently lengthening the spine."
214501002|NCT02744066|DEVICE|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
214501003|NCT03163563|DEVICE|Easywarm|Warming blanket
214501004|NCT03163563|DEVICE|BairHugger|Patient warming mattress with continuous warm air.
214501005|NCT04705649|OTHER|Treatment de-escalation|De-escalation from standard treatment based on molecular profile
214501006|NCT04350619|OTHER|Genetic screening. No therapeutic intervention|Genetic screening using NGS technique. No therapeutic intervention
214501007|NCT00623337|BEHAVIORAL|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy \& 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify \& refer sick babies
214501008|NCT04571437|DRUG|Capecitabine|Capecitabine metronomic combined with Letrozole
214501009|NCT04571437|DRUG|Letrozole 2.5mg|Letrozole daily alone
214501010|NCT02170337|DRUG|AMG 282|AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
214501011|NCT02170337|DRUG|Placebo|Contains no active drug
214501012|NCT00874588|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
214501013|NCT01475110|DRUG|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
214501014|NCT02454959|DEVICE|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
214501015|NCT02454959|DEVICE|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
214501016|NCT04039776|DIAGNOSTIC_TEST|"Cone Beam Computed Tomography (CBCT)"|"Cone Beam Computed Tomography (CBCT), a machine that use a low dose of radiation compared to traditional CT systems, and allows the examination in supine and standing position knee . In this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism."
214501017|NCT01603836|BIOLOGICAL|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
214501018|NCT01156155|RADIATION|Digital xray of jaw and teeth|one time xray of jaw and teeth
214501019|NCT01156155|PROCEDURE|Blood draw|Three to four tablespoons of blood drawn.
214998330|NCT06863012|DIAGNOSTIC_TEST|Hepatic Venous Pressure Gradient (HVPG) Measurement|Hepatic Venous Pressure Gradient (HVPG) measurement is the current gold standard for assessing portal hypertension in patients with chronic liver disease. The procedure involves catheterization of the hepatic vein via the jugular or femoral vein, where free hepatic venous pressure (FHVP) and wedged hepatic venous pressure (WHVP) are measured using a pressure transducer. HVPG is an indirect measure of portal pressure and requires fluoroscopy, radiation exposure, and specialized interventional radiology equipment. While widely used in clinical practice, HVPG has limitations, including the need for a hospital setting, potential patient discomfort, and limited feasibility in certain cases. This study will compare HVPG to EUS-PPG to determine whether EUS-PPG can serve as a less invasive and more accessible alternative.
214998331|NCT05880836|DEVICE|nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen|nebulized delivery of bronchodilator via in-line drug delivery maintaining high-flow nasal cannula oxygen
214998332|NCT05880836|DEVICE|standard jet nebulization (SJN) with face mask|standard jet nebulization delivery of bronchodilator
214998333|NCT07019909|BIOLOGICAL|20vPnC|20 valent pneumococcal conjugate vaccine
214501020|NCT01156155|OTHER|questionnaires|completed questionnaires regarding patient's health and functional ability.
214501021|NCT01156155|PROCEDURE|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
214501022|NCT01156155|OTHER|Bilateral digital xray of hands|One time digital xray of hands
214501023|NCT05931510|OTHER|Myofscual release|I will apply myofascial release on group A patients and observse its effects on shin splint
214501024|NCT05931510|OTHER|Post isometric relaxation.|I will apply post isonetric relaxation on group b patients and observe effects on shin splint
214501025|NCT04502472|BIOLOGICAL|Convalescent plasma transfusion|Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.
214998334|NCT07019909|BIOLOGICAL|13vPnC|13 valent pneumococcal conjugate vaccine
214998335|NCT06626256|BIOLOGICAL|Aldesleukin|Given SC
214998336|NCT06626256|PROCEDURE|Biopsy|Undergo biopsy
214388719|NCT01115491|DRUG|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
214388720|NCT01115491|DRUG|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
214388721|NCT02708589|DIETARY_SUPPLEMENT|probiotic|
214501026|NCT02378779|OTHER|Questionary SF12 and PEDT (Premature Ejaculation Diagnostic Tool)|The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
214501027|NCT02378779|OTHER|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
214501028|NCT02378779|OTHER|Humour|Use the humour to approach the subject of premature ejaculation
214388722|NCT02708589|OTHER|Placebo|
214388723|NCT05914831|RADIATION|Ultra-fractionated WBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast where the tumor was located.
214388724|NCT05914831|RADIATION|Ultra-fractionated PBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the part of the breast where the tumor was located.
214501029|NCT02378779|OTHER|Take the drama out|Take the drama out to approach the subject of premature ejaculation
214501030|NCT02378779|OTHER|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
214501031|NCT02378779|OTHER|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
214501032|NCT02378779|OTHER|Help to verbalize|Help for the patient to speak about premature ejaculation
214998337|NCT06626256|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214501033|NCT04444804|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Dosage at the discretion of the treating physician
214501034|NCT04444804|DRUG|LMWH and Phenprocoumon|Dosage at the discretion of the treating physician
214998338|NCT06626256|PROCEDURE|Computed Tomography|Undergo CT
214501035|NCT05111951|BEHAVIORAL|Mobile health-delivered physical exercise and support for physical activity|Mobile health-delivered physical exercise sessions, prescription of an individual exercise-regime and support for physical activity through behavior change techniques.
214501036|NCT05111951|BEHAVIORAL|Mobile health-delivered behavior change techniques.|Mobile health-delivered behavior change techniques following the core elements of the Swedish model for physical activity on prescription.
214501037|NCT05986305|BEHAVIORAL|Go Act|Go Act sessions address becoming a parent who can 'Go Act,' caring for one's self as a parent, understanding and managing youth health needs, working with health providers as partners, and working with other service providers such as schools and vocational services. The intervention uses motivational interviewing, story-telling with self-disclosure, psycho-education introduced with a know-want to know-learned strategy, problem-solving, role play, and practice outside of class.
214501038|NCT05986305|BEHAVIORAL|Peer|During Peer sessions facilitators lay ground rules for respectful and confidential sharing and encourage group discussion. The group provides a format to make personal connections through shared identity. Participants may discuss strategies for individualized advocacy, so that they learn from the experiences of others.
214501039|NCT00121849|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
214501040|NCT00177177|DRUG|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
214501041|NCT02338024|BEHAVIORAL|Modified Antiretroviral Treatment Access Study intervention|
214501042|NCT00986375|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
214998339|NCT06626256|DRUG|Cyclophosphamide|Given IV
214998340|NCT06626256|PROCEDURE|Excisional Biopsy|Undergo excisional biopsy
214998341|NCT06626256|DRUG|Fludarabine|Given IV
214998342|NCT06626256|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214998343|NCT06626256|PROCEDURE|Standard Treatment|Receive standard of care therapy
214998344|NCT06626256|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Given STIL101 for injection IV
214388725|NCT02930642|BEHAVIORAL|Mindful Eating|Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.
214388726|NCT02930642|OTHER|Nutrition DVD|Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
214388727|NCT00786201|DRUG|Placebo|Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
214388728|NCT00786201|DRUG|CNTO 888 1 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
214388729|NCT00786201|DRUG|CNTO 888 5 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
214388730|NCT00786201|DRUG|CNTO 888 15 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
214388731|NCT00322608|DRUG|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
214388732|NCT03436160|DRUG|WR826647|100 mcg Carbon-14 radio labeled WR826647 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
214388733|NCT03436160|DRUG|WR909388|100 mcg Carbon-14 radio labeled WR909388 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
214388734|NCT03436160|DRUG|WR909390|100 mcg Carbon-14 radio labeled WR909309 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
214388735|NCT00828906|DRUG|DuoTrav|DuoTrav Eye Drops
214388736|NCT04297241|DRUG|Isosorbide Dinitrate|All patients will be given a 6 week titration regimen of study medication. Patients will begin at a 5mg dosage and titrate up to 30mg three times per day if each subsequent dose is tolerated.
214501043|NCT00986375|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
214501044|NCT03019835|DRUG|Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery|
214501045|NCT03019835|OTHER|Spontaneous recovery|just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
214501046|NCT01022125|DRUG|TMC435|
214501047|NCT02587169|DRUG|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
214501048|NCT05871658|BEHAVIORAL|electroacupuncture|electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.
214501049|NCT03391024|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while navigated with clinically approved system.
214501050|NCT03619642|OTHER|Robotic assessment of finger proprioception|The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .
214998345|NCT07018960|PROCEDURE|Chest wall reconstruction with 3D printed titan custom prothesis|"Dynamic Chest Wall Reconstruction with Patient-Specific 3D-Printed Titanium Prostheses~1\. Intervention Overview~A custom-designed, 3D-printed titanium prosthesis is surgically implanted to reconstruct chest wall defects following oncologic resection or traumatic injury. The prosthesis is engineered to:~Restore structural integrity of the thoracic cavity Preserve physiological chest wall dynamics during respiration Provide long-term biomechanical stability"
214998346|NCT07020559|DRUG|allogeneic platelet plasma|Al-PRP derived from healthy blood donors
214998347|NCT07020559|DRUG|autologous platelet plasma|Autologous platelet-rich plasma from the patient themselves
214998348|NCT07016971|DRUG|CBG/CBD Oil|Participants will receive a commercially available high CBG/CBD hemp extract oil that also contains small amounts of cannabichromene (CBC). The product is formulated as a sublingual oil and administered twice daily. Participants will take 0.5 mL of the oil sublingually twice daily during the first week, followed by 1 mL sublingually twice daily for the remaining 11 weeks. The oil has a defined and independently verified cannabinoid and terpene profile and is marketed as a dietary supplement.
214998349|NCT05341284|OTHER|Questionnaire Survey and Cervical Cancer Screening|"A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36."
215094004|NCT06663722|PROCEDURE|Extracorporeal Photopheresis|"Mandatory ECP therapy will be administered at a frequency of two treatment sessions per week during Cycles 1 through 3, two treatment bi-weekly during Cycles 4 through 6, and two treatments during week 1 of Cycle 7.~Optional ECP therapy will be administered at a frequency of two treatment sessions during weeks 2 and 4 of Cycles 4 through 6, when mandatory ECP is not administered. Optional ECP therapy will also be administered as two treatment sessions during week 3 of Cycle 7.~After Cycle 7, participants may receive ECP therapy only at the Investigator's discretion for a maximum Treatment Period of 12 months."
214501051|NCT00034489|DRUG|pemetrexed|
214501052|NCT00034489|DRUG|gemcitabine|
214388737|NCT03856996|BIOLOGICAL|Stable CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
214388738|NCT03856996|BIOLOGICAL|Transient CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
214388739|NCT03856996|BIOLOGICAL|Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)|Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
214687910|NCT02198287|DRUG|BIIX 1 XX inhalation solution|single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
214687911|NCT02198287|DRUG|Placebo|
214687912|NCT02683616|DEVICE|CPAP|Continuous Positive Airway Pressure in cases of moderate/severe OSA
214687913|NCT00934557|DRUG|ATG Fresenius|
214388740|NCT04075799|OTHER|high-intensity interval training|The HIIT protocol consists of 8 weeks using stair climbing three times per week. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will comprise 6-12 x 30-seconds bouts of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. Post-exercise the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks. The first (week 1) and final week (week 8) of the exercise program will be monitored by a trained exercise physiologist. During supervised visits, heart rate and rating of perceived exertion (OMNI scale) will be measured at the end of each bout and after active recovery. Subjects will have the option to request further monitoring if desired.
214388741|NCT06158308|PROCEDURE|Laproscopic Appendicectomy|A type of surgery done without a large incision. Instead, from 1 to 3 tiny cuts are made. A long, thin tube called a laparoscope is put into one of the incisions. It has a tiny video camera and surgical tools.
214388742|NCT06158308|PROCEDURE|Open Appendicectomy|A cut or incision about 2 to 4 inches long is made in the lower right-hand side of your belly or abdomen. The appendix is taken out through the incision.
214388743|NCT04694729|OTHER|videoconference-based|Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.
214388744|NCT04694729|OTHER|video-based|The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
214388745|NCT03349372|PROCEDURE|Hematopoietic stem cell transplantation|Hematopoietic stem cell transplantation
214388746|NCT01003639|DRUG|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
214501053|NCT01044888|DRUG|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
214501054|NCT04693949|OTHER|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
214501055|NCT04693949|OTHER|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
214501056|NCT01767350|PROCEDURE|Blood withdrawal for DNA|"Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up."
214501057|NCT03293914|BEHAVIORAL|Lifestyle Redesign|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
214501058|NCT04776096|DRUG|Bepotastine Besilate 1.5% PF|Bepotastine besilate 1,5% Preservative free ophthalmic solution
214501059|NCT04776096|DRUG|Olopatadine Hydrochloride 0.2% BAK|Olopatadine hydrochloride 0.2% with BAK as preservative
214501060|NCT02448524|DEVICE|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
214998350|NCT07017010|BEHAVIORAL|phonemic awareness intervention (PA)|All 12 weeks of lessons will exclusively focus on instruction at the phoneme level (i.e., the individual sounds in words), with activities addressing the blending of sounds to form short words. Other activities may include counting the number of sounds heard in a word, matching letter tiles to the sounds heard in the word, and separating short words into their component sounds.
214998351|NCT07017010|BEHAVIORAL|phonological sensitivity + phonemic awareness intervention (PSPA)|The first six weeks of intervention will include a focus on being able to manipulate (separate and blend) parts of words larger than the individual sounds. This will include manipulating compound word components, syllables, and initial sounds and rhyming components of words. Activities may include matching pictures of words, assembling/disassembling puzzle pieces that represent words, and sorting pictures (words) by their first or ending sounds. The second six weeks of intervention will focus on phonemic awareness, as described for the PA intervention condition, and be the same as what the children in the DPA intervention condition experience.
214998352|NCT07017010|BEHAVIORAL|delayed onset phonemic awareness intervention (DPA)|The six weeks of intervention will focus on phonemic awareness, as described for the PA intervention condition, and be the same as the second six weeks of lessons that the children in the PSPA intervention condition experience.
214998353|NCT07011797|DRUG|CX11|CX11 tablets administered orally once daily (QD) with meals
214998354|NCT07011797|OTHER|Placebo|Matching placebo tablets administered orally once daily (QD) with meals
214388747|NCT01003639|DRUG|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
214388748|NCT01003639|BEHAVIORAL|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
214687914|NCT00934557|DRUG|ATG Fresenius|
214388749|NCT01918319|BEHAVIORAL|Lifestyle intervention|Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
214501061|NCT02448524|DEVICE|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
214501062|NCT00171769|DRUG|Certoparin|
214501063|NCT05309200|DRUG|OCE-205|The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.
214501064|NCT05309200|DRUG|Placebo|Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
214501065|NCT00459524|BEHAVIORAL|Questionnaire|Questionnaires taking about 30 minutes to complete.
214501066|NCT00459524|BEHAVIORAL|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
214501067|NCT03693066|OTHER|Ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
214501068|NCT03693066|OTHER|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
214501069|NCT03693066|OTHER|Control|
214501070|NCT02481466|BEHAVIORAL|Portfolio diet and structured exercise|"Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily."
214687915|NCT00934557|DRUG|ATG Fresenius|
214687916|NCT00934557|DRUG|ATG Fresenius|
214687917|NCT00934557|DRUG|ATG Fresenius|
214687918|NCT00934557|DRUG|ATG Fresenius|
214687919|NCT00934557|DRUG|ATG Fresenius|
214998355|NCT07018362|OTHER|restricted fetal growth|The fetus is of abnormal size and has not reached its genetic growth potential in utero. Fetal birth weight is less than two standard deviations from the average weight for the same gestational age, or less than the 10th percentile of normal weight for the same age.
214998356|NCT04430699|DRUG|Cisplatin|Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.
214388750|NCT04503382|OTHER|Kindness Media|As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.
214998357|NCT04430699|DRUG|Pembrolizumab|Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.
214388751|NCT02092038|DRUG|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
214998358|NCT04430699|RADIATION|Radiation Therapy|Standard of care radiation therapy 1x daily up to 8 weeks.
214998359|NCT06875180|OTHER|Tele-rehabilitation exercise|For this group, McKenzie extension exercises were applied to 50 patients online via the zoom platform.
214388752|NCT02092038|RADIATION|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
214687920|NCT00934557|DRUG|ATG Fresenius|
214998360|NCT06875180|OTHER|Face-to-face exercise|For this group, 50 patients face-to-face in the clinical environment under the supervision of a physiotherapist in charge.
214998361|NCT06866132|DEVICE|Investigational Noninvasive Neuromodulation Device|The investigational noninvasive neuromodulation device will be setup by the patient at bedtime and will be used every night. The IRB has established that the investigational device is non-significant risk.
214998362|NCT06859320|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy is one of the popular bariatric surgeries known for weight reduction
214998363|NCT06612294|BEHAVIORAL|PEF Interventional Session|3 sessions over 6 weeks for asthma management
214998364|NCT06612294|BEHAVIORAL|Control Sessions|3 sessions over 6 weeks for asthma management
214998365|NCT06612294|BEHAVIORAL|Control Booster|A single booster session after the 6-months assessments are completed.
214998366|NCT06612294|BEHAVIORAL|Active booster|A single booster session after the 6-months assessments are completed.
214998367|NCT04278898|DRUG|N-Acetylcysteine|N-acetylcysteine Single Dose 2700 mg taken orally
214998368|NCT07023302|DRUG|Upadacitinib|Oral Tablets
214998369|NCT07023302|DRUG|Upadacitinib Placebo|Oral Tablets
214998370|NCT07022054|DEVICE|iCare IC1000 measurement|Measurement of intraocular pressure with iCare IC1000
214998371|NCT06632600|DRUG|LXE408|LXE408 administered by oral route
214388753|NCT02092038|PROCEDURE|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
214388754|NCT02092038|PROCEDURE|craniotomy and tumor resection|maximal safe resection
214388755|NCT01903408|RADIATION|Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB|The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
214388756|NCT05171140|PROCEDURE|Triangular Nail Placement of Femoral Neck|Triangular Nail Placement of Femoral Neck in arm A Femoral Neck Inverted Triangle Nail Surgery in arm B
214388757|NCT05811429|OTHER|Aerobic exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
214388758|NCT05811429|OTHER|Pilates exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
214388759|NCT04362137|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets
214388760|NCT04362137|DRUG|Placebo|Matching-image placebo
214388761|NCT04851860|DRUG|sublingual immunotherapy|sublingual immunotherapy is the only disease modifying therapy preventing the evolution of AR to asthma
214388762|NCT00253786|OTHER|Intensive multifactorial therapy|Blood glucose control: HbA1c \< 6.2% Blood pressure control: SBP \< 125 mmHg, DBP: \< 75 mmHg Lipid profile: T-cho \< 180 mg/dl, LDL-cho \< 100 mg/dl, HDL-cho \>40 mg/dl Dietary intervention: TDEI \< 30 kcal/kg/day, sodium \< 5 g/day, protein \< 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care
214388763|NCT00253786|OTHER|Standard therapy|Blood glucose control: HbA1c \< 6.9% Blood pressure control: SBP \< 130 mmHg, DBP: \< 80 mmHg Lipid profile: T-cho \< 200 mg/dl, LDL-cho \< 120 mg/dl, HDL-cho \>40 mg/dl, Dietary intervention: TDEI \< 25-30 kcal/kg/day, sodium \< 6 g/day, protein \< 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)
214998372|NCT06632600|DRUG|Placebo|Placebo administered by oral route
214998373|NCT06632600|DRUG|Benznidazole|Benznidazole administered by oral route (administered as standard of care)
214388764|NCT03497884|DEVICE|rTMS|For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).
214388765|NCT00566943|DEVICE|PSD Veritas Collagen Matrix|Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.
214998374|NCT06692114|DEVICE|Deep Transcranial Magnetic Stimulation, DTMS active|The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Each treatment stimulates at a frequency of 20 Hz for 2 seconds, with a sequence interval of 20 seconds. Each treatment consists of 50 sequences, for a total of 2000 pulses.
214998375|NCT06692114|DEVICE|Deep Transcranial Magnetic Stimulation, DTMS sham|The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Compared with active treatment, the sham stimulation coil only produced sound and scalp vibration.
214388766|NCT00566943|PROCEDURE|Roux-en-Y gastric by-pass surgery with no buttress|Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
214388767|NCT05713760|DRUG|Tirbanibulin Ointment 1%|Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
214388768|NCT01304082|DRUG|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
214388769|NCT01304082|DRUG|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
214388770|NCT01304082|DRUG|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
214388771|NCT05148832|DRUG|Administration of Systemic Corticosteroid|10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery.
214388772|NCT01015222|DRUG|Dasatinib|Starting dose of 50 mg daily PO for 28 day cycle
214388773|NCT01015222|DRUG|Bevacizumab|Starting dose 5 mg/kg IV Day 1 and 15
214388774|NCT01015222|DRUG|Paclitaxel|Starting dose 40 mg/m2 IV Day 1, 8 and 15
214388775|NCT01779479|DRUG|Cabacitaxel|Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
214388776|NCT01779479|DRUG|Paclitaxel|Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
214998376|NCT06704932|DRUG|SAR446959|Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
214998377|NCT06704932|DRUG|Placebo|Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
215094005|NCT06587230|BEHAVIORAL|Teachers Leading the Frontlines|"1. During 3-day training, Knowledge and attitudes toward child mental health care are measured pre-training, post-training, and post-intervention.~2. The teachers select students whom they believe have the highest mental health needs to receive care.~3. Teachers analyze chosen students' symptoms.~4. Teachers analyze students' behavior with the AABC Chart.~5. Teachers develop a targeted response using a behavior plan called the 4Cs plan (Cause, Change, Connect, and Cultivate). In the 4Cs, teachers select therapeutic techniques to deliver from a menu of evidence-based therapeutic options for each category of behavior.~6. Throughout the year, teachers receive supervision through monthly site visits supplemented by as-needed telephone and digital discussions to guide their care from the study team. Teachers encourage the use of the 4Cs plan at home."
214388777|NCT03267290|DIAGNOSTIC_TEST|Sonazoid- CEUS, CEMRI, CECT|Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
214501071|NCT02481466|BEHAVIORAL|DASH-like diet and structured exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers."
214998378|NCT07039305|BEHAVIORAL|Physical capacity training for chronic stroke - building aerobic capacity and muscle strength|The general format of each exercise session includes assessment of resting heart rate (HR), blood pressure (BP), and rating of perceived exertion (RPE) followed by a 5-minute warm-up, a minimum of 30 minutes of aerobic exercise followed by 25 minutes of resistance exercise. Aerobic exercise will always include a minimum of 10 minutes of walking (overground or treadmill) at the prescribed intensity followed by cycle, arm or rowing ergometry. Sessions will begin at a target intensity of \~60% heart rate reserve (HRR) determined from the exercise tolerance test performed at baseline and calculated using Karvonen's formula. The goal will be to increase training intensity by \~5% HRR every \~3 weeks and progressed as tolerated. Resistance exercise will target all major muscle groups and include multiple sets dosed at the 10-repetition to fatigue level (\~75% of the 1-repetition maximum). Resistance exercises will be progressed with improvements in strength or as tolerated.
214388778|NCT00054925|BEHAVIORAL|Personal contact (PC)|This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.
214388779|NCT00054925|BEHAVIORAL|Interactive technology (IT)|The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
214388780|NCT05341375|PROCEDURE|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
214388781|NCT05341375|DRUG|Esketamine|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
214388782|NCT05341375|BEHAVIORAL|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery
214388783|NCT05341375|BEHAVIORAL|The assessment of cognitive function|Participants were assessed for MMSE at the same period as the group C
214388784|NCT01358838|DEVICE|ablative 10600 nm fractional laser therapy|"Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.~Half of the scar, or one of two comparable scars, will receive no treatment at all."
214388785|NCT01719601|DRUG|No intervention|This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
215094006|NCT06587230|BEHAVIORAL|Responding to Students' Emotions Through Education|"All processes for RE-SEED are the same as in Tealeaf except...~1. Teachers receive only 1 day of training~2. The study team does not provide supervision to the teachers, allowing only the school counselor to provide supervision~This less resource-intensive approach will allow for an ethical comparator to Tealeaf, where the schools would like for teachers to have some skills to support identified students."
215094007|NCT06980675|DEVICE|Activated Ozonized Olive Oil Gel|It is a natural oil which has been ozonized to improve the antimicrobial activity against periodontopathogenic bacterias
215094008|NCT06980675|OTHER|Placebo gel|Placebo gel with same texture, color, way of administration and taste of Activated Ozonized Olive Oil Gel
215094009|NCT06980064|DIAGNOSTIC_TEST|Smartwatch + GP|Participants in the intervention group will be required to wear a smartwatch continuously for 24 hours. After this period, the collected data will be processed using a pre-trained foundational model for disease diagnosis, generating preliminary diagnostic suggestions. GPs will then integrate these smartwatch-derived findings with clinical interviews and aforementioned baseline examination results to formulate a final diagnosis.
215094010|NCT06980064|DIAGNOSTIC_TEST|GP only|GPs will make diagnosis with clinical interviews and aforementioned baseline examination results to formulate a final diagnosis.
214998379|NCT06714279|DRUG|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
214998380|NCT06714279|DRUG|Intraperitoneal infiltration to liver|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
214388786|NCT01143623|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
214388787|NCT01143623|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
214388788|NCT01143623|OTHER|Placebo|Placebo
214388789|NCT05097768|DRUG|Dexamethasone 0.5mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
214388790|NCT05097768|DRUG|Ketorolac 10 Mg Oral Tablet|The patients will be randomly given the medication by mouth 60 min before administering IANB.
214388791|NCT05097768|DRUG|Meloxicam 7.5 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
214388792|NCT05097768|DRUG|Ibuprofen 600 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
214388793|NCT05097768|DRUG|Placebo|The patients will be randomly given the medication by mouth 60 min before administering IANB.
214388794|NCT02262260|DRUG|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
214388795|NCT02262260|DRUG|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
214388796|NCT00198601|DRUG|Gentamicin in Uniject Pre-filled syringe|
214501072|NCT02481466|BEHAVIORAL|Portfolio diet and routine exercise|"Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
214998381|NCT07044908|DRUG|TQB2922 injection ± TAS-102 tablets|TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis by natural killer cells and macrophages, thus killing tumour cells.
214998382|NCT07044908|DRUG|TQB2922 injection+TAS-102 tablets ± Bevacizumab|TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype IgG1. TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis by natural killer cells and macrophages, thus killing tumour cells.
214388797|NCT03387241|DRUG|Fluticasone/ Formoterol|See above
214388798|NCT03387241|DRUG|fluticasone/ salmeterol|See above
214388799|NCT01642082|BIOLOGICAL|Dalantercept|Given SC
214388800|NCT01642082|OTHER|Laboratory Biomarker Analysis|Correlative studies
214388801|NCT03547284|DRUG|sugarless gum|81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours
214388802|NCT01761539|OTHER|Aggressive Hydration|Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
214388803|NCT01761539|OTHER|Moderate Hydration|Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
214388804|NCT02581176|DRUG|Apixaban|
214388805|NCT02312674|DIETARY_SUPPLEMENT|Oral nutritional supplement|Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
214388806|NCT01794117|DRUG|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
214388807|NCT06391216|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052 and Bifidobacterium longum R0175|8-week supplementation (56 days); 3 × 10\^9 CFU/day
214388808|NCT06391216|DIETARY_SUPPLEMENT|Placebo|8-week supplementation (56 days)
214388809|NCT04779905|DIAGNOSTIC_TEST|urinary albumbin/creatinine ratio|detection of microalbuminuria in nafld patients
214388810|NCT03343860|PROCEDURE|AT case 1.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
214388811|NCT03343860|PROCEDURE|AT case 2.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
214388812|NCT03343860|PROCEDURE|AT case 1.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
214388813|NCT03343860|PROCEDURE|AT case 1.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps"
214998383|NCT06886165|BEHAVIORAL|My Avenue to HelP|"The MAP intervention is based on AMBIT principles. A MAP team, consisting of designated employees from CAMHS and two municipalities, will be trained in AMBIT. A Key-Worker and a Mentalizing Case Manager will be assigned to each participant and step into the existing network, taking responsibility for integrating AMBIT principles into all aspects of the work with and around the young person. The Key-worker from the MAP team is responsible for reaching out to the young person at least once a week during the intervention. The Mentalizing Case Manager ensures that mentalization is upheld in the professional network. CAMHS will offer treatment as usual in accordance with the existing evidence-based clinical guidelines and best practice for any specific mental health disorder.~The MAP team members will meet once a week to work as a team and collaborate closely with family members and other potential informal caregivers. The network of helpers will meet and coordinate monthly."
214388814|NCT03343860|PROCEDURE|AT case 1.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
214388815|NCT03343860|PROCEDURE|AT case 2.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, ablation of the subsequent AT will be performed until sinus rhythm restoration. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
214388816|NCT03343860|PROCEDURE|AT case 2.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
214388817|NCT03343860|PROCEDURE|AT case 2.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
214388818|NCT03343860|PROCEDURE|SR Case 1|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
214998384|NCT06886165|BEHAVIORAL|Management as Usual|"Participants in the control group will receive non-manualized, standard treatment in CAMHS in collaboration with their municipality of residence, following local practice and guidelines. The MAU will be slightly enhanced compared to standard treatment: a) the young people will have an open case file during one year of participation in the MAP project (and longer if indicated), and b) the standard care services will receive feedback from the research assessment at baseline (after approval of the specific content from parents and the young person) in order to help the young person's caseworker to coordinate the support. These enhancements are made to improve the cohesion of care for the young person, yet without applying the mentalization-based AMBIT principles and MAP teams of the MAP treatment condition.~principles applied in the MAP treatment condition."
214998385|NCT07043946|DRUG|Budoprutug|Single IV dose of study product on Day 1 and Day 15
214998386|NCT06883695|DRUG|SHR-3045 Injection|SHR-3045 injection.
214998387|NCT06883695|DRUG|SHR-3045 Placebo Injection|SHR-3045 placebo injection.
214388819|NCT03343860|PROCEDURE|SR Case 2|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 10 consecutive AT)"
214388820|NCT06576115|DRUG|Nab paclitaxel|125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
214388821|NCT06576115|DRUG|Gemcitabine|1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
214388822|NCT06576115|DEVICE|TheraBionic P1|This treatment consists of delivering preset low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
214388823|NCT01849900|OTHER|Knowing your body|"Women will receive the Knowing your body kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits."
214388824|NCT01849900|BEHAVIORAL|Healthy Lifestyle|Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
214388825|NCT06493136|DRUG|lidocaine gel|questionnaire
214388826|NCT03587298|PROCEDURE|Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)|"The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the hardest appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded."
214388827|NCT04963894|OTHER|Home functional balance physiotherapy|Experimental physiotherapy program is carried out at home to improve the balance of people with Parkinson's disease through exercises that simulate everyday functional contexts.
214388828|NCT04963894|OTHER|Conventional physiotherapy|Conventional control physiotherapy program is carried out face-to-face in a rehabilitation gym and in groups of 6 people. The conventional program of physiotherapy includes conventional therapeutic goals of rehabilitation in people with Parkinson's disease.
214388829|NCT04137614|PROCEDURE|Drug coated balloon (DCB)|Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.
214388830|NCT04137614|PROCEDURE|Digital substraction angiography (DSA)|DSA was used to evaluated the stenosis of renal artery
214388831|NCT02820584|BIOLOGICAL|GSC-loaded autologous dendritic cells|
214388832|NCT03885466|BEHAVIORAL|Nordic Walking exercise|Participants will initially train 3 times per week for 3 months. Training sessions will be led by trained peer- and/or student-instructors. Nordic walking sessions (starting at 20 and progressing to 60min/session) will include a warm-up, strengthening, and dynamic balance and stretching exercises in addition to Nordic walking, as per the Saskatoon Health Region guide (Saskatoon Health Region, 2014). Training (distance and intensity) will be progressive and individually set.
214388833|NCT05997121|DEVICE|Transforaminal lumbar interbody fusion|Transforaminal Lumbar Interbody Fusion indicates a surgical approach in the lumbar spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height. Screws and rods are also added to maintain the level secure while the bones fuse together.
214388834|NCT03729024|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments
214388835|NCT00070993|DRUG|creatine monohydrate|
214388836|NCT06442540|PROCEDURE|Physical Agents|Hot pack
214388837|NCT06442540|PROCEDURE|Manipulation|HVLA manipulation of SI joint
214388838|NCT06442540|PROCEDURE|Core Stability Exercises|Supine abdominal draw-in Hold 8s 3s off x 2 Abdominal draw-in, with one knee drawn to the chest. Hold 8s 3s off x 2 Abdominal draw-in, with the heels sliding backward one after the other. 10 reps 3s off x 2 Abdominal draw-in, with both knees drawn to the chest. Hold 8s 3s off x 2 Supine twist 15 reps 3s off x 3 Prone bridging on elbows Hold 8s 3s off x 3 Side bridging on elbows Hold 8s 3s off x 3 Quadruped opposite arm-leg lift Hold 8s 3s off x 3 Advance to the stage 2 when the patient can hold 30 reps for an 8-sec hold.
214388839|NCT06442540|PROCEDURE|Intramusular electrotherapy|Intramuscular electrotherapy/ 3 sessions per week
214501073|NCT02481466|BEHAVIORAL|DASH-like diet and routine exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
214388840|NCT06442540|PROCEDURE|Soft tissue mobility|Stretching and Myofacial Release of piriformis and erector spinae
214388841|NCT03030937|DRUG|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
214388842|NCT03030937|DRUG|Irinotecan|Irinotecan was used as second line treatment with AGC.
214388843|NCT04688593|DEVICE|MobileLink|Patients who receive a MobileLink hip prosthesis system will be followed-up for 10 years.
214388844|NCT03301090|OTHER|Placebo|Placebo
214388845|NCT03301090|BIOLOGICAL|REGN3048|REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
214388846|NCT03301090|BIOLOGICAL|REGN3051|REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
214388847|NCT04871035|DEVICE|Immunoadsorption|1 cycle, consisting of 5 sessions on 5 consecutive days with processing of the 0.7-fold individual plasma volume (maximum 2.5 l) each days with tryptophan adsorbers.
214388848|NCT04871035|DEVICE|Plasma Exchange|1 cycle, consisting of 5 sessions on 5 consecutive days with exchange of 0.7-fold plasma volume (maximum 2.5 l) each day with albumin solution as volume replacement solution.
214388849|NCT00610701|DEVICE|Anterior pin placement|Anteriorly-placed (front of the leg) femoral external fixator pins
214388850|NCT00610701|DEVICE|Lateral pin placement|Laterally-placed (side of the leg) femoral external fixator pind
214388851|NCT01152294|BEHAVIORAL|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
214388852|NCT03329521|OTHER|Multicomponent intervention|Patients in 13 of the 26 CKD programs will receive a multicomponent intervention or usual care. The intervention has four main components: (1) support for local quality improvement teams and administrative needs; (2) tailored education and resources for staff, patients, and living kidney donor candidates; (3) support from kidney transplant recipients and living kidney donors; and (4) program-level performance reports and oversight by program leaders.
214388853|NCT01022801|DRUG|Entecavir|Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
214388854|NCT06461819|RADIATION|Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.|this researcher used a biodegradable material injection technique. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
214388855|NCT06451315|PROCEDURE|Analyze CTscans pre-operatively by Nurea System|CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by system develop by Nurea
214388856|NCT06451315|PROCEDURE|Analyze CTscans pre-operatively by hospital practitioner|CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by an hospital practitioner
214388857|NCT05760976|DRUG|Cisatracurium|Advanced intravenous injection of cisatracurium before the succinylcholine injection
214388858|NCT05639621|PROCEDURE|Accompaniment|presence of a person freely chosen by the patient, who will escort in a visual and tactile way during the endoscopic procedure
214388859|NCT02500563|OTHER|Amino acid based infant formula|
214388860|NCT02500563|OTHER|Extensively hydrolyzed casein infant formula|
214388861|NCT02500563|OTHER|Mother's own breast milk|
214388862|NCT03620643|DRUG|Crizotinib Oral Capsule [Xalkori]|Crizotinib 250 mg Crizotinib 200mg
214501074|NCT03875066|OTHER|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
214501075|NCT03875066|OTHER|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
214501076|NCT01797666|DRUG|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
214501077|NCT05609149|PROCEDURE|total mesorectal excision|patients must underwent total mesorectal excision
214501078|NCT07012096|BEHAVIORAL|counseling, leaflet and mhealth education for hypertension|Investigators will develop 6 leaflets and 24-SMSs containing messages on the burden of hypertension, consequences, and the benefits of preventing of hypertension, and the healthy practices for preventing hypertension, tobacco, physical inactivity, dietary salt intake, inadequate fruits and vegetables, overweight and obesity, and the use of trans fat. It will be written in plain and simple Bengali. Leaflets will be received by CG-1, CG-3, IG-1 and IG-3. 24-SMSs. Face-to-face counselling (approximately 20 min/session). A total of 20 sessions (1 cycle) will be provided. The session will be repeated if the cycle is over.
214388863|NCT03620643|DRUG|Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]|Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
214388864|NCT05315284|PROCEDURE|the Use of Titanium Elastic Nail in The Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle|Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle
214388865|NCT00514046|DRUG|Vandetanib|once daily continuously (28 day cycles)
214388866|NCT00641173|DRUG|paroxetine|treatment with SSRI paroxetine
214388867|NCT00641173|DRUG|placebo|treatment with placebo
214388868|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
214388869|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
214388870|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
214388871|NCT05989165|DRUG|Minoxidil 5% Topical Solution|Patient will be given minoxidil 5% topical solution, twice a day for 12 weeks
214388872|NCT05989165|DEVICE|microneedling|Patient will be given microneedling treatment every 4 weeks
214388873|NCT01800708|DRUG|Triamcinolone acetonide|
214388874|NCT01800708|DRUG|Prednisolone syrup|
214388875|NCT00847990|OTHER|Maternal blood screening test for fetal aneuploidy|One blood draw of 20 to 30 mL
214388876|NCT00549887|DRUG|Analog or Human Insulin|prescribed in accordance with usual clinical practice
214388877|NCT00265707|DEVICE|Blood pressure measurement|
214388878|NCT03218696|DEVICE|Cough Syrup for adults and children|The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.
214388879|NCT03218696|DEVICE|Placebo|The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
214501079|NCT07012096|BEHAVIORAL|Leaflets and mhealth education|"Participants will receive 6 leaflets containing messages on the burden of hypertension, consequences, and benefits of prevention of hypertension, and the healthy practices for preventing hypertension.~Participants will receive 24 SMSs containing the burden of hypertension, consequences, and benefits of prevention of hypertension, and the healthy practices for preventing hypertension.~And additionally receive a dummy counselling of 5 to 10 minutes informal discussion with the participants, which will not include any health messages that will be received by the participants of the intervention group."
214501080|NCT07012096|OTHER|Dummy Placebo|Participants will only receive a dummy counselling of 5 to 10 minutes informal discussion with the participants, which will not include any health messages that will be received by the participants of the intervention group.
214501081|NCT07012785|DRUG|Bismuth quadruple therapy|Bismuth quadruple therapy
214501082|NCT07012785|DRUG|Saccharomyces boulardii|Saccharomyces boulardii
214501083|NCT07036744|BEHAVIORAL|MIND-over-MIRROR|An eight session (plus one follow-up booster session) on Acceptance and Commitment Therapy (ACT) with compassion developed specifically for BDD, in a group setting and applied remotely or in hybrid format.
214501084|NCT07036627|OTHER|study of microbiota|"* Drug: Esomeprazole, a proton pump inhibitor commonly used in pediatric gastroenterology.~* Administration: Oral, once daily, 30 minutes before meals.~* Dosage: Personalized dosing according to body weight, with an average of approximately 0.6 mg/kg/day.~* Treatment duration: Minimum 45 days, maximum 60 days.~* Comparator: None. This is a within-subject design; each participant serves as their own control with baseline samples (t0) compared to follow-up (t1-t2).~* Monitoring: Adherence to therapy and sample collection timeline will be verified during scheduled clinical follow-up."
214501085|NCT07032051|DEVICE|Continuous Passive Motion|Continuous passive motion was applied to the left ankle joint for 30 minutes twice a day using a motorized CPM device.
214501086|NCT07036874|DIAGNOSTIC_TEST|transient elastography and oesophagogastroduodenoscopy|Liver and spleen stiffness will be measured by transient elastography. Varices will be identified by oesophagogastroduodenoscopy.
214501087|NCT07043621|PROCEDURE|Early Scalp Block Group|"Following induction of general anesthesia and prior to head pinning (Mayfield clamp placement), a scalp block was performed under aseptic conditions using 20 mL of 0.25% bupivacaine.~The block targeted six sensory nerves that innervate the scalp: Supraorbital nerve, Supratrochlear nerve, Auriculotemporal nerve ,Zygomaticotemporal nerve, Greater occipital nerve, Lesser occipital nerve.~Each nerve was infiltrated subcutaneously at its anatomical location using a 25-gauge needle, with the total volume distributed evenly or proportionally across the injection sites."
214998388|NCT06883097|BEHAVIORAL|Learn to Quit-HIV (LTQ-H) App|LTQ-H consists of 319 screens divided into: (a) HIV-tailored smoking cessation ACT skills, (b) education about tobacco dependence and treatment (USCPG), and (c) NRT psychoeducation and adherence. Content is gradually presented across 28 modules (14 education and 14 skills) that can be completed in 14 days.
214388880|NCT00941564|OTHER|Infant Formula milk based|Consume ad lib
214388881|NCT00941564|OTHER|Infant formula milk based|consume ad lib
214388882|NCT05660915|PROCEDURE|Intermediate approach|The area between superior mesenteric vein and superior mesenteric artery was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.
214388883|NCT05660915|PROCEDURE|Standard approach|The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
214388884|NCT00876460|DRUG|BIBF 1120 M + docetaxel M|BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
214388885|NCT00876460|DRUG|BIBF 1120 M + docetaxel H|BIBF 1120 Medium dose bid + docetaxel 75mg/m2
214388886|NCT00876460|DRUG|BIBF 1120 H + docetaxel H|BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
214388887|NCT00876460|DRUG|BIBF 1120 L + docetaxel M|BIBF 1120 Low dose bid + docetaxel 60 mg/m2
214388888|NCT00876460|DRUG|BIBF 1120 H + docetaxel M|BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
214388889|NCT00179530|BEHAVIORAL|Relaxation Response|Relaxation training
214388890|NCT03135704|DEVICE|"Re Spine"|A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
214388891|NCT03135704|OTHER|Physiotherapy|Usual protocol for treatment of low back pain
214388892|NCT04536571|DEVICE|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
214388893|NCT04536571|DEVICE|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
214388894|NCT00599547|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
214388895|NCT03152045|BEHAVIORAL|Communication Intervention|In this study, Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
214388896|NCT00278382|DRUG|sorafenib tosylate|Given orally
214388897|NCT00278382|OTHER|laboratory biomarker analysis|Correlative studies
214388898|NCT02061696|DEVICE|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
214388899|NCT02061696|PROCEDURE|Standard Manual Compression|Closure procedure by Manual Compression
214388900|NCT04340908|DRUG|Dapagliflozin 10 MG|10 mg tablet, oral, once daily, 1-year treatment, postoperation
214388901|NCT04340908|DRUG|Placebos|matching placebo tablet, oral, once daily, 1-year treatment, postoperation
214388902|NCT03987230|DRUG|Sensitive Eyes® Plus Saline Solution|Sensitive Eyes® Plus Saline Solution
214388903|NCT03987230|OTHER|Oust™ Demodex® Wipes™|Oust™ Demodex® Wipes™
214388904|NCT03987230|OTHER|I-LID N LASH PLUS® Eyelid Cleanser|I-LID N LASH PLUS® Eyelid Cleanser
214388905|NCT03987230|OTHER|Blephadex Lid Wipes|Blephadex Lid Wipes
214388906|NCT03987230|OTHER|Eye Cleanse Lid Wipes|Eye Cleanse Lid Wipes
214388907|NCT03987230|OTHER|Blephademodex|Blephademodex
214388908|NCT02141958|DRUG|Fenretinide|Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
214388909|NCT02141958|DRUG|Placebo|A matching placebo will be used to keep the study double-blind.
214388910|NCT01567865|BIOLOGICAL|Vaccine produced in existing facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
214388911|NCT01567865|BIOLOGICAL|Vaccine produced in new facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
214388912|NCT02750176|OTHER|Closed chain exercises|Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
214388913|NCT02762734|OTHER|MEDIA|"The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent."
214388914|NCT01476488|DRUG|tacrolimus|
214388915|NCT05596357|OTHER|questionnaires|The patient must answer questionnaires before and after reconstructive surgery
214388916|NCT00309608|DRUG|Linagliptin|Linagliptin medium dose tablet once daily
214388917|NCT00309608|DRUG|Linagliptin|Linagliptin high dose tablet once daily
214501088|NCT07043621|PROCEDURE|Late Scalp Block Group|"In the pre-emergence group, the scalp block was performed at the end of surgery but before emergence from general anesthesia, while the patient was still under deep anesthesia.~Under strict aseptic conditions, 20 mL of 0.25% bupivacaine was administered to block the following six sensory nerves innervating the scalp: Supraorbital nerve, Supratrochlear nerve, Auriculotemporal nerve, Zygomaticotemporal nerve, Greater occipital nerve, Lesser occipital nerve.~The local anesthetic was injected subcutaneously at the anatomical landmarks of each nerve using a 25-gauge needle. The total volume was distributed evenly or proportionally depending on the area. No additional surgical stimulation occurred after the block, and extubation followed routine emergence from anesthesia."
214501089|NCT07043517|OTHER|RDC/TMD|TMJ functions were assessed using the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).
214388918|NCT00309608|DRUG|Linagliptin|Linagliptin low dose tablet once daily
214388919|NCT00309608|DRUG|Placebo|Placebo tablets once daily
214388920|NCT00309608|DRUG|Glimepiride|Glimepiride tablets once daily
214388921|NCT04613882|DEVICE|Soft Toric Custom Made Contact lens|Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.
214388922|NCT04613882|DEVICE|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.
214388923|NCT04613882|DEVICE|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
214388924|NCT04426344|DEVICE|ensoETM device|Core warming will be performed using standard technique per instructions for use for the esophageal heat transfer device. The esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment. It is expected that patient temperature will increase from baseline by 1°C to 2°C, but due to ongoing heat loss from the patient, the expected maximum patient temperature is below 39°C. The time course of illness of COVID-19 is such that most patients no longer have fever by the time of mechanical ventilation.\[41\] If patient temperature increases above this range and reaches 39.8°C, the device will be set to an operating temperature of 40°C, thereby preventing any further increase in patient temperature (ambient heat loss precludes patient from reaching device operating temperature).
214388925|NCT00621296|DRUG|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
214388926|NCT02810067|PROCEDURE|Tunnel + AlloDerm|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm).
214998389|NCT06883097|BEHAVIORAL|QuitStart|This DTx, QuitGuide was adapted from the National Cancer Institute Smokefree.gov Initiative's QuitGuide's 5 modules have the following intervention components: (a) psychoeducation about the impact of smoking on health, (b) setting up a quit date and a quit plan, (c) selecting reasons for quitting, (d) tracking triggers and smoking habits, and (e) tips for quitting.
214998390|NCT06734364|DEVICE|buddy tape|Buddy-taping a finger dynamically splints one finger to an adjacent, uninjured finger.
214388927|NCT02810067|PROCEDURE|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
214388928|NCT03643146|BEHAVIORAL|Lifestyle Management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
214388929|NCT03643146|BEHAVIORAL|Control Group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
214388930|NCT00101335|DRUG|celecoxib|
214388931|NCT04723849|DIETARY_SUPPLEMENT|Auxilie® Immuplus, Envicon Medical, Verona, Italy|"Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. Height (cm) and weight (kg) were measured for each child at every visit. Endothelial function was assessed using two methodologies: a post occlusive release hyperemic test (PORH) and a heat provocation test (HPT)."
214388932|NCT01440582|DRUG|Panobinostat|"Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.~Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.~Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.~Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle."
214388933|NCT01440582|DRUG|Bortezomib|"Induction Therapy (Part A, 21-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8."
214501090|NCT07043933|BEHAVIORAL|Mobile-Compatible Web-Based Hydration Tracking Program|"Intervention Description:~The SIVI Hydration Application is a mobile-compatible, web-based behavioral intervention designed specifically for older adults. It supports self-monitoring and self-management of daily fluid intake through features such as personalized fluid goals, visual drink-logging with icons, daily reminders, progress graphics, educational videos, and motivational digital badges. The app was developed using gerotechnology and universal design principles to accommodate cognitive and sensory changes common in aging. Its unique focus on hydration behavior, combined with usability features like large fonts, high contrast, and voice-assisted guidance, distinguishes it from general health or diet tracking apps. Participants use the app for 8 weeks as part of a structured intervention with training and weekly follow-up."
214501091|NCT07043283|DRUG|Ebronucimab|Ebronucimab subcutaneous injection.
214501092|NCT07043205|BEHAVIORAL|Coastal walk|A 40-minute walk with psychophysiological monitoring in Ostend (along the beach)
214501093|NCT07043205|BEHAVIORAL|Urban walk|40' walk in Ghent (urban)
214501094|NCT07042698|OTHER|Glomerular Filtration Rate measurement with iohexol clearance|After performing a 4-phase CT urography (or 3-phase CT scan, with the addition of a 4th phase for research purposes), performed for clinical indications as part of the patient's care, and using iohexol as a contrast agent, patients will undergo a biological measurement of iohexol clearance, based on serum and urine samples taken over 4 periods of 1 hour, between 3 and 7 hours after the CT scan. No iohexol will be reinjected to measure GFR. The CT scan images will be segmented by the investigator to determine the CT-measured GFR.
214501095|NCT07042750|OTHER|Eccentric cycling exercise|Patients perform eccentric cycling exercise instead of normal cycling exercise in addition to standard car during a cardiopulmonary rehabilitation
214501096|NCT07042750|OTHER|Standard Care Arm|Patients perform cardiopulmonary rehabilitation according to standard care
214501097|NCT07042581|DRUG|Revaree Plus|Revaree Plus is a hyaluronic acid vaginal suppository
214388934|NCT01440582|DRUG|Lenalidomide|"Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.~Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle."
214501098|NCT07043010|DEVICE|Near-Infrared Parathyroid Tissue Sensor Imaging (PTS)|FDA-cleared imager (e.g., Fluobeam LX/PTeye) providing real-time autofluorescence to identify parathyroid tissue during surgery; no dye or radiation.
214501099|NCT07043010|PROCEDURE|Rim-Preservation Technique|Surgical excision of adenoma while leaving the NIRAF-positive rim of normal parathyroid tissue in situ; minimal defatting to ensure perfusion.
214501100|NCT07043010|PROCEDURE|En-bloc Resection Technique|Surgical excision of adenoma together with the surrounding NIRAF-positive rim; autotransplant fragment if \< 2 normal glands remain in neck.
214501101|NCT07043413|DIAGNOSTIC_TEST|thrombus analysis|Detailed expression pattern of RNA and histological characteristics will be investigated.
214501102|NCT07043075|DEVICE|TAVR using a guidance software|TAVR procedure with TAVIPILOT augmented reality guidance software operating in parallel on a separate screen in a blind setup, enabling clinicians to assess the analysis and recommendations provided by the software, either immediately after valve deployment or following the completion of the procedure.
214501103|NCT07043049|DRUG|Tramadol|Tramadol 1 mg/kg IV given 5 minutes after spinal anesthesia for prevention of post-anesthesia shivering
214998391|NCT06734364|DEVICE|splint|Short arm splint immobilize and maintain stability of the injured finger, the hand is immobilized in the intrinsic plus position with syndactyly of the injured finger and adjacent finger
214998392|NCT06736405|OTHER|Pericapsular nerve group block|Pericapsular nerve group block will be applied to patients in addition to standard treatment to prevent postoperative pain
214998393|NCT06736405|OTHER|No Pericapsular nerve group block|Patients will be given standard treatment to prevent postoperative pain
214388935|NCT01440582|DRUG|Dexamethasone|"Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle."
214388936|NCT01440582|BEHAVIORAL|Symptom Questionnaire|Completed on day 1 of each cycle.
214388937|NCT03918954|DEVICE|Virtual sensory room|A pair of virtual reality glasses (Oculus Go) with installed the program Calm Place, a program designed for anxiety reduction.
214388938|NCT03918954|OTHER|Sensory room|A room with calming elements that patients can use to feel calm.
214388939|NCT03150524|DIAGNOSTIC_TEST|TCD- cerebral blood flow velocities|Participants will undergo daily TCD for monitoring of cerebral blood flow.
214388940|NCT03150524|BEHAVIORAL|Headache pain score|Participants will be evaluated by nurses for headache frequency and severity every shift.
214388941|NCT03150524|OTHER|Neurological examination|Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.
214388942|NCT03150524|DIAGNOSTIC_TEST|Repeat Neuroimaging|All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.
214501104|NCT07043049|DRUG|Ketamine|Ketamine 0.5 mg/kg IV administered 5 minutes after spinal anesthesia for prevention of post-anesthesia shivering.
214501105|NCT07044154|OTHER|Tai Chi (Sun Style)|The Sun Tai Chi intervention will be conducted by a Sun Tai Chi instructor with 7 years of teaching experience and will take place in an exercise room at the Catholic University of Maule. The intervention will last for 12 weeks, with a frequency of twice per week, and each class will last 60 minutes. Each session will begin with 10 minutes of warm-up exercises, followed by 20 minutes of basic Sun Tai Chi exercises, including lower limb movements, overall body mobility at a slow pace, precise movements of the hands and feet, and proper body alignment. This will be followed by 20 minutes of practice of the basic movement sequence of Sun Tai Chi (Taolú), and will conclude with 5 minutes of meditation and 5 minutes of relaxation exercises.
214501106|NCT07044154|BEHAVIORAL|Health lifestyle education|The control group will receive guidance on a healthy physical and mental lifestyle.
214501107|NCT07042737|BEHAVIORAL|animation-based breast cancer education|The animation-based humorous application consists of four videos, each lasting 40-45 minutes, which separately explain the signs and symptoms of breast cancer, self-breast examination, clinical breast examination, and mammography through animation.
214501108|NCT07042737|OTHER|Control group (placebo)|No intervention will be applied to the control group.
214501109|NCT07042373|BEHAVIORAL|Control|In the control condition, participants will purchase tobacco/nicotine products in the ETM. Cigarettes will increase in price across trials.
214501110|NCT07042373|BEHAVIORAL|Product Category Score|In the product category score condition, participants will purchase tobacco/nicotine products in the ETM where the percentage of taxes applied to each product category will be distributed between 0% and 100% proportional to their abuse liability score. Abuse liability scores will be scaled such that the product category with the highest abuse liability will be taxed at 100%.
214998394|NCT04251416|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
214388943|NCT03150524|DRUG|Nimodipine|Participants will be administered nimodipine every 4 hours.
214388944|NCT03150524|DRUG|Verapamil ER|Participants will be administered long acting verapamil every 12 hours.
214388945|NCT04922190|BEHAVIORAL|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
214998395|NCT03634241|BIOLOGICAL|Pembrolizumab|Given IV
214998396|NCT03634241|OTHER|Quality-of-Life Assessment|Ancillary studies
214388946|NCT02671318|DRUG|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
214388947|NCT02671318|DRUG|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
214388948|NCT02844491|OTHER|additional biological samples|blood and tissue samples
214388949|NCT03244293|OTHER|no intervention|
214388950|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
214388951|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
214388952|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
214388953|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
214388954|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
214501111|NCT07042373|BEHAVIORAL|Product Category Rank|In the product category rank condition, participants will purchase tobacco/nicotine products in the ETM where the tax percentage applied to each product category will be determined by the number of categories and their position in the ranking. The product category with the highest abuse liability will be taxed at 100%; the product with the lowest abuse liability will be taxed at 0%. All other tax rates will be equally spaced across other products based on ranking.
214501112|NCT07042373|BEHAVIORAL|Product Tiers|In the product tiers condition, participants will purchase tobacco/nicotine products in the ETM where tobacco products will be placed in tax tiers to simplify the existing complex tobacco tax system. The investigators will use three tax tiers (i.e., high tax, medium tax, and no tax), as adopted by four states. Products will be placed into tiers depending on their average score (i.e. no tax: \< 0.33, medium tax: 0.33-0.66, and high tax: \>0.66). Products in the high tax tier will be taxed at 100% and products in the medium tax tier will be taxed at 50%.
214388955|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
214388956|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
214388957|NCT03230383|DRUG|Placebo|Matching Placebo for PF-06865571 for each cohort.
214388958|NCT03402373|DIETARY_SUPPLEMENT|Lycoderm|soft gel contains nutritional supplement
214998397|NCT03634241|PROCEDURE|Computed Tomography|Undergo CT
214998398|NCT03634241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214998399|NCT07056244|DRUG|Dexmedetomidine|as adjuvant to bupivacaine in caudal epidural block for postoperative analgesia
214388959|NCT03402373|DIETARY_SUPPLEMENT|Placebo|soft gel without active ingredients
214388960|NCT03399149|OTHER|Systematic evaluation by an intensivist|implementation of a standardized procedure for patient care in ICU
214388961|NCT02327819|DIETARY_SUPPLEMENT|Branched-chain amoni acids (BCAA)|
214388962|NCT02327819|DIETARY_SUPPLEMENT|non-BCAA protein supplement|
214388963|NCT03453827|OTHER|no intervention|no intervention
214388964|NCT05501171|BEHAVIORAL|DREAMLAND|"DREAMLAND is self-administered psychological app for patients with AML that includes four modules, focused on:~1. Supportive psychotherapy strategies to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance.~2. Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social support.~3. Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty.~4. Self-care to promote positive health behaviors and enhance patients´ sense of control especially as they transition from the hospital to outpatient care.~Each module takes 20 minutes to complete. DREAMLAND also includes three optional models that also take 15 minutes to complete.~Other names BNT200"
214998400|NCT07056244|DRUG|Dexamethasone|as adjuvant to bupivacaine in caudal epidural block for postoperative analgesia
214998401|NCT04404283|DRUG|Brentuximab vedotin|1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks
214998402|NCT04404283|DRUG|Rituximab|375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
214998403|NCT04404283|DRUG|Lenalidomide|20 mg given by mouth (orally) daily
214998404|NCT04404283|OTHER|Placebo|Administered via intravenous infusion every 3 weeks
214998405|NCT06749912|DEVICE|Low back pain wrap|The low back pain wrap device includes heat, vibration, and red light to assist with reducing pain sensation, improving function.
214388965|NCT05501171|BEHAVIORAL|CERENA|"CERENA is a self-administered physical health app that includes 4 modules focused, focused on:~1. Education about general wellness.~2. Nutrition.~3. Exercise.~4. Cancer prevention.~Each module takes 20 minutes to complete. CERENA also includes three optional modules that also take 15 minutes to complete."
214388966|NCT05023967|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
214998407|NCT05113381|DEVICE|CerebroFlo™ EVD Catheter|The CerebroFlo™ EVD Catheter is indicated for temporary insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid (CSF) in those patients with elevated intracranial pressure (ICP), intraventricular hemorrhage, or hydrocephalic shunt infections.
214998408|NCT06872645|DRUG|5% Dextrose/Water|Patients will be randomized to undergo up to two-hour dwell with 5% dextrose in sterile water for 5 days
214388967|NCT05023967|DRUG|Extended Release Metformin Hydrochloride|Given PO
214388968|NCT05023967|OTHER|Monitoring|Use continuous glucose monitoring system
214388969|NCT05023967|OTHER|Nutritional Assessment|Receive nutritional counseling
214388970|NCT05023967|OTHER|Short-Term Fasting|Perform intermittent fasting
214388971|NCT01051063|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular injection
214388972|NCT01420263|PROCEDURE|Re-feeding residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
214388973|NCT01420263|PROCEDURE|Fresh Feeding Breastmilk or Formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
214388974|NCT02274649|BEHAVIORAL|one-to-one peer mentoring|Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge
214388975|NCT02274649|BEHAVIORAL|general peer support|General (traditional) peer support includes introduction and provision of support services upon request
214998409|NCT06872645|DRUG|1.5% standard PD fluid|Patients will be randomized to undergo up to two-hour dwell with 1.5% standard PD fluid for 5 days
214388976|NCT01393041|DEVICE|Angio-Seal VIP|Vascular Closure Device
214388977|NCT06390930|OTHER|Acute Intermittent Hypoxia|During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
214388978|NCT06390930|OTHER|Sham Acute Intermittent Hypoxia|During Sham AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The Sham AIH intervention involves alternating breathing cycles. One cycle involves breathing air closely resembling room air (\~21% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
214388979|NCT00231660|DRUG|topiramate|
214388980|NCT01928680|DRUG|Cisplatin/Capecitabine|Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
214501113|NCT07043439|OTHER|Mobilization|"Participants receiving this intervention will undergo Grade 3 joint mobilization targeting the first metatarsophalangeal (1st MTP) joint. The technique will be administered by a licensed physiotherapist with the participant lying in the prone position and the foot in a neutral position.~Mobilization will be performed according to the Maitland concept, which defines Grade 3 as large-amplitude, rhythmic oscillatory movements applied within the range of motion but up to the limit of tissue resistance, without entering the paraphysiological space.~The goal of this technique will be to increase joint play and mobility, reduce stiffness, and potentially improve biomechanical alignment. The mobilization will last approximately 5 minutes, and outcome measures will be collected before and immediately after the session."
214998410|NCT06551402|DRUG|Dabigatran Etexilate 150mg|100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
214998411|NCT06551402|DRUG|Rivaroxaban 20 MG Oral Tablet|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
214998412|NCT06789510|OTHER|Autologous Platelet Rich Plasma|10 mL PRP intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
214388981|NCT00192140|BIOLOGICAL|FluMist|A single intranasal dose of FluMist will be administered to approx. 300 subjects.
214388982|NCT00836654|BIOLOGICAL|Catumaxomab (Removab)|Puncture free survival
214388983|NCT00836654|PROCEDURE|paracentesis|
214388984|NCT04049292|OTHER|Better and safer return to sport (BEAST)|The RTS assessment includes a Lachman test, modified stroke test, side hop test, triple hop test, and quadriceps muscle power test. The sport-specific progression plans have 6 participation levels in practice and 6 participation levels in match play. A minimum of 2 weeks and 4 training sessions without pain or effusion must be completed before the athlete progresses to the next level. Criteria for full, unrestricted participation in practice: (1)at least 9 months from ACLR, (2)modified stroke test grade 0, (3)completed previous levels in the sport-specific progression plan, (4)negative Lachman test, (5)side hop test limb symmetry at least 90%, (6)triple hop test limb symmetry at least 90%, (7)quadriceps power symmetry at least 90%. The strength training and knee control exercise protocols each have 3-4 different exercises of 3-4 sets that are performed 3 days per week.
214998413|NCT06789510|OTHER|Saline solution|10 mL saline solution intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
214998414|NCT00578526|DRUG|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
214998415|NCT00578526|DRUG|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
215094011|NCT06981364|DIETARY_SUPPLEMENT|Fish Oil|Upon completion of baseline testing both groups will be instructed not to alter their normal diet and activity levels throughout the study period. Zach Townsend, an individual who will not be directly involved with the data analysis, will create a spread sheet containing the weight of the subjects and separate identifier generated via algorithm. The spread sheet will be provided to the principle and co-investigators who will partition the supplements out into 42 separate sealable bags per subject. The bags will be dispersed by Mr. Townsend to maintain the double-blind standard. Subjects will either consume 4 g/day GNC Triple Strength Fish Oil Mini, General Nutrition Corporation, Pittsburgh, PA, or placebo (dextrin) of equal volume for six weeks. They will be instructed to consume fish oil or the placebo with a glass of water at the same time every day. These protocols are similar to ones used in previous investigations1-7.
215094012|NCT06086483|DRUG|Ropivacaine 0.2% Injectable Solution|"20 mL 0.5% ropivacaine was injected into the PENG block~20 mL 0.5% ropivacaine was injected into the Adductor Canal block"
214388985|NCT04049292|OTHER|Usual care|Usual care is determined by the treating health care professional
214388986|NCT01474837|BEHAVIORAL|Intervention: Exercise and motivational interviewing|12 sessions of exercise with MI
214388987|NCT02675140|DRUG|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
214388988|NCT02675140|DRUG|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
214388989|NCT01815814|OTHER|Rolfing / Myofascial Structural Integration|"Rolfing is similar to deep massage. It is also known as myofascial structural integration."
214388990|NCT04213586|DIETARY_SUPPLEMENT|Whey protein supplementation|35 g of whey protein (7 d/wk) during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
214388991|NCT04213586|DIETARY_SUPPLEMENT|Collagen supplementation|35 g of collagen (7 d/wk) + 2 g of leucine during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
214388992|NCT00790114|DRUG|AZD7325|Oral, day 1-12
214388993|NCT00790114|DRUG|Midazolam|single dose, twice during treatment
214388994|NCT00790114|DRUG|Caffeine|single dose, twice during treatment
214388995|NCT01783353|DIETARY_SUPPLEMENT|Zinc gluconate|
214388996|NCT01783353|DIETARY_SUPPLEMENT|Corn starch pill|
214388997|NCT02678325|OTHER|Standardized high protein enteral nutrition|A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
214388998|NCT02678325|OTHER|Standardized normal protein enteral nutrition|double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
214388999|NCT05324930|DEVICE|Piscean collagen dressing|Piscean collagen dressing
214389000|NCT05324930|DEVICE|Saline infused dressing|Saline infused dressing
214389001|NCT02320643|DEVICE|Seratom® PA mesh|Partially absorbable mesh
214389002|NCT03857841|BIOLOGICAL|UNEX-42|UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.
214389003|NCT03857841|BIOLOGICAL|Phosphate-buffered saline|Phosphate-buffered saline
214389004|NCT02149602|RADIATION|Intensity modulated radiotherapy|Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
214389005|NCT03055611|DRUG|ELOCTA|Extended half-life factor VIII product
214501114|NCT07043439|OTHER|High-Velocity Low-Amplitude (HVLA) Manipulation|"This intervention will involve the application of a high-velocity, low-amplitude (HVLA) thrust manipulation to the first metatarsophalangeal (1st MTP) joint. A licensed physiotherapist will perform the procedure with the participant positioned prone and the foot placed in a neutral alignment.~The therapist will stabilize the 1st metatarsal bone with one hand and apply a quick, controlled thrust to the proximal phalanx of the hallux in a dorsal direction using the other hand. The technique will be delivered with minimal amplitude and maximal speed, aiming to restore joint motion, reduce soft tissue tension, and stimulate neuromechanical reflexes.~The manipulation procedure will take approximately 2-3 minutes, including setup and execution. Pre- and post-intervention outcome measures will be used to assess its immediate effects."
214998416|NCT06461754|OTHER|Sonographic evaluation of diaphragm and lung|While the patient in a semi-sitting position (20-40 degree), by ultrasound, the diaphragm thickness was measured in the zone of apposition, on the mid-axillary line among the 8th and 10th intercostal spaces, using a 7-10 MHz linear probe in (M) mode. at the end of expiration and at the end of inspiration by capturing nearly three images during spontaneous patient breathing. The average of three DTI measurements was calculated In lung ultrasound, 2-4 MHz convex ultrasound probe in (B) mode was employed. We implemented a modified LUSm in our investigation, which assessed four lung regions on each side.
215094013|NCT06086483|DRUG|0.9%sodium chloride|"20 mL 0.9% sodium chloride was injected into the PENG block~20 mL 0.5% sodium chloride was injected into the Adductor Canal block"
214389006|NCT03055611|DRUG|ALPROLIX|Extended half-life factor IX product
214389007|NCT02625194|DRUG|Oxygen|Oxygen is supplied through suction port during bronchoscope-guided intubation.
214389008|NCT06617234|OTHER|Nurse-led Intervention Program|"Nurse-led Intervention Program: This intervention consists of a face-to-face educational session led by a nurse, focusing on the importance of cardiac rehabilitation. The session lasts 15-20 minutes and is tailored to the patient's medical condition and lifestyle, with follow-up reminders and personalized guidance for rehabilitation participation.~LINEbot Automated Robot System: This intervention uses the LINEbot system to send automated push notifications to participants, including educational messages, reminders for cardiac rehabilitation appointments, and health tracking prompts. Participants can log their daily health data through the system, which offers personalized advice on diet, exercise, and medication management."
214389009|NCT06617234|OTHER|LINEbot Automated Robot System|Participants in this group will use the \&amp;#34;LINEbot\&amp;#34; automated robot system, which sends push notifications through the LINE app. The system delivers education messages, exercise guidance, and health tracking prompts. It provides daily reminders for cardiac rehabilitation participation, as well as customized messages on health management, such as diet, medication, and self-care. The system also allows users to log health data like blood pressure and heart rate.
214393995|NCT02699541|BEHAVIORAL|Diabetes Self-Management Education|"This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.~Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight."
214393996|NCT06100380|OTHER|Survey|Questionnaire
214393997|NCT04265443|DEVICE|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
214389010|NCT06897020|OTHER|(Group A: Bioflx crowns)|"prepartion:1.The mesiodistal width of the tooth will be measured using calipers and a closely fitted crown will be selected based on the measurements.~2.The tooth will be prepared similarly to stainless steel crowns (SSCs): • Occlusal reduction of approximately 1-1.5 mm will be done using a diamond bur.Mesial and distal reduction of no more than 1 mm will be performed using a No. 169L diamond bur.Depending on the tooth anatomy, either no buccal and lingual reduction will be needed, or a minimal reduction will be done. 3.All sharp line angles and corners will be smoothed to ensure proper crown fit. 4.The crown will be checked for proper fit before cementation. It will be positioned to extend 1 mm below the gingival margin. 5.The crown will be cemented using luting glass ionomer cement (GIC). The crown will be held with firm, constant pressure until the cement sets initially.~6.The marginal fit will be evaluated, and necessary adjustments will be made. 7.The occlusion will be checked."
215094014|NCT06825546|DRUG|Icaritin|"Icaritin soft capsules, 600 mg, taken twice daily, should be swallowed with warm water within 30 minutes after breakfast and dinner. If a patient misses a dose and cannot take it within 2 hours after a meal, they should continue with the next scheduled dose without needing to make up for the missed dose.~Gemcitabine, 1000 mg/m², is administered on days 1 and 8, followed by a 14-day pause, constituting a 21-day treatment cycle. Nab-paclitaxel, 125 mg/m², is also administered on days 1 and 8, with a 14-day pause, making up a 21-day treatment cycle."
214389011|NCT06897020|OTHER|(Group B: Preformed Zirconia crown|"1. Crown Selection: The mesiodistal dimension of the corresponding tooth will be measured . to select the appropriate size.~2. Occlusal Reduction: The marginal ridge of adjacent teeth will be used as a reference point and a 1.5-2 mm of occlusal reduction will be performed to allow proper crown seating.~3. Bucco-Lingual Reduction: The bucco-lingual wall will be reduced by approximately 1-1.5 mm using a flame-shaped diamond bur.~4. Interproximal Reduction: 1mm of interproximal reduction will be performed using a flame-shaped diamond bur such as a .368 or .330tapered carbide bur.~5. Feather Margin Preparation: Subgingival reduction of 1-2 mm will be done using a flame-shaped diamond bur, creating a feathered margin to achieve a passive fit.~6. Trial Fitting of the Crown: The crown will be tried in to ensure proper adaptation. until the crown fits passively and extends sub gingivally by 1-2 mm wit.~7. Glass ionomer cement will be used for cementation."
214389012|NCT05905497|DRUG|Bemnifosbuvir (BEM)|BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)
214389013|NCT02751736|DIETARY_SUPPLEMENT|CJLP243|Perioperative administration till postoperative weeks 3
214389014|NCT02751736|DIETARY_SUPPLEMENT|Placebo|Perioperative administration till postoperative weeks 3
214389015|NCT02446093|BIOLOGICAL|Aglatimagene besadenovec|Three courses of CAN-2409 + prodrug (valacylovir or acyclovir) will be delivered and timed with different phases of therapy: 1) after induction chemotherapy 2) during CR or post-SBRT, and 3) at time of surgery. Up to 2 additional courses of CAN-2409 + prodrug, if feasible, for subjects with disease progression or metastases.
214389016|NCT02446093|RADIATION|Chemoradiation|CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.
214389017|NCT02446093|RADIATION|Stereotactic body radiation therapy|SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.
214389018|NCT02446093|PROCEDURE|Surgery|Surgical resection should be performed within 8 weeks after completing CR or SBRT.
214389019|NCT00386308|DRUG|Tranexamic acid tablets|3900 mg/Day
214389020|NCT00386308|DRUG|Placebo tablets|
214389021|NCT01828307|BEHAVIORAL|Motivational enhancement therapy (MET)|MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
214389022|NCT01828307|BEHAVIORAL|Contingency management|Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
214389023|NCT01828307|BEHAVIORAL|Standard Aftercare Treatment|Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
214389024|NCT03649269|DIETARY_SUPPLEMENT|PC-300 tea.|Patients had to drink one cup of the tea half an hour before breakfast, main meal and dinner.
214389025|NCT03649269|DRUG|Bezafibrate|Patients were prescribed 200 mg/day at night.
214389026|NCT02906683|DRUG|TAS-303|Oral administration for 8 weeks, once daily.
214389027|NCT02906683|DRUG|Placebo|Oral administration for 8 weeks, once daily.
214389028|NCT04377022|OTHER|Combined Therapy (Aerobic Exercise in addition to conventional therapy)|"There are two intervention arm in the study~1. Combined therapy~2. Conventional Therapy"
214389029|NCT02546687|OTHER|Venous blood sampling|"The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood."
214389030|NCT01352234|DRUG|Acetylsalicylic Acid 160 mg|Capsule containing Acetylsalicylic Acid 160mg pill with lactose
215094015|NCT06825546|DRUG|AG chemotherapy|"Gemcitabine (1000 mg/m²) + saline (100 mL), infused intravenously over 30 minutes, followed by a 100 mL saline flush.~Nab-paclitaxel (125 mg/m²) + saline (100 mL), infused intravenously over 30 minutes, followed by a 100 mL saline flush"
214389031|NCT01352234|DRUG|Acetylsalicylic Acid 80 mg|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
214389032|NCT01976611|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
214389033|NCT02781506|DRUG|Nivolumab|Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist
214998417|NCT07069361|BEHAVIORAL|Mindfulness-Based Cognitive Therapy - Life Course Adaptation (MBCT-L)|MBCT-L (Mindfulness-Based Cognitive Therapy for Life) Is a structered, group-based intervention developed for use with healthy adults. The programs runs for 8 consecutive weeks, with sessions lasting 2 hours and 15 minutes. It includes formal and informal mindfulness practices, exercises to develop cognitive and emotion awareness, with elements adapted from cognitive therapy. The course was designed to support participants in cultivating habits that increase emotion regulation and psychological well-being. Home practice is assigned daily using audio-guided meditations. The intervention is standardized and delivered by a instructor trained under Oxford Mindfulness Centre (OMC) protocols. MBCT-L is distinct from the clinical MBCT model used for relapse prevention. And it is also disting from other Mindfulness-Based interventions as it uses different exercises than, for example, Mindfulness-Based Stress Reduction which emphasis stress theories in the intervention.
214389034|NCT02781506|RADIATION|SAbR|SAbR (1-3 lesions)
214389035|NCT04917549|OTHER|detection of oral lesions|oral lesions in patient diagnosed with COVID-19
214389036|NCT02351440|DRUG|duloxetine|patients will be randomized to receive either duloxetine or placebo
214389037|NCT02351440|DRUG|placebo|placebo
214389038|NCT04346641|DIAGNOSTIC_TEST|Facial Measurements and Tooth Size and Pulp Volume|Radiographic images of patients who have been indicated for cone-beam computed tomography for the upper jaw for various reasons (such as impacted teeth, sinusitis, skeletal anomalies) will be reviewed retrospectively. Facial measurements (lower face height, midface height, inter-zygomatic distance, inter-pupillary distance, inter alar distance, epicanthus distance, the distance between commissures) of the patients who received cone beam computed tomography will be measured in the clinic. Mesiodistal distance, buccal palatal distance, root length, pulp volume of maxillary sixth tooth will be measured using cone beam computed tomography. The data obtained will be compared.
214389039|NCT01662622|DRUG|Sevoflurane|"The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted."
214389040|NCT01396928|PROCEDURE|Colonic reservoir|Type of reservoir to be performed
214389041|NCT02074540|OTHER|Questionnaire|Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty
214389042|NCT05741970|PROCEDURE|Scaling and root planing|Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.
214389043|NCT06439290|PROCEDURE|Phonosurgery|Gender-affirming voice surgery (such as glottoplasty, cricothyroid approximation, thyroplasty and chondrolaryngoplasty), in addition to gender-affirming voice training and hormone therapy, plays an important role in achieving a gender-congruent voice in transgender and gender diverse people. In addition, these interventions are sometimes performed on cisgender men or women who wish to change their voice. However, the impact of these interventions on broad voice characteristics needs to be further investigated.
214501115|NCT07043439|OTHER|Sham Manipulation|"Participants in the control group will receive a sham (placebo) intervention designed to mimic the real treatment in setup and duration, without applying any therapeutic mechanical stimulus. The sham procedure will be conducted by the same physiotherapist with participants lying prone and their foot in a neutral position.~The physiotherapist will place their hands around the 1st MTP joint as if a manipulation were to be performed and will maintain static contact for the same duration as in the experimental group. However, no thrust, traction, or mobilization force will be applied.~The sham intervention will also last approximately 10 minutes, ensuring consistency across groups. All assessments will be conducted immediately before and after the intervention to evaluate potential placebo effects."
214501116|NCT06890208|OTHER|No intervention|No intervention
214501117|NCT07042308|DIAGNOSTIC_TEST|Transient elastography|Liver stiffness and spleen stiffness from transient elastography
214501118|NCT06737354|GENETIC|IVB103 Injection（Low dose）|Single intravitreal injection
214998418|NCT07068607|DRUG|Vonoprazan|Vonoprazan - amoxicillin dual therapy: Vonorazon 20 mg daily for 14 days # amoxicillin 1000 mg by mouth three time daily for 14 days; Vonoprazan-tetracycline dual therapy:Vonorazon 20 mg daily for 14 days # tetracycline 500 mg by mouth three time daily for 14 days; Vonoprazan-minocycline dual therapy:Vonorazon 20 mg daily for 14 days # minocycline 100 mg by mouth two time daily for 14 days; Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
214389044|NCT06439290|PROCEDURE|Mastectomy/breast augmentation|Control group of PFAB and PMAB persons undergoing a mastectomy or breast augmentation surgery.
214389045|NCT05723848|DEVICE|Smartwatch (Withings Scanwatch)|All-day monitoring of patients via smartwatch
214389046|NCT04854538|DRUG|Ekmasonid|1 extended release tablet contains 9 mg Budesonide
214389047|NCT04854538|DRUG|Uceris (first dose)|1 extended release tablet contains 9 mg Budesonide
214389048|NCT04854538|DRUG|Uceris (second dose)|1 extended release tablet contains 9 mg Budesonide
214389049|NCT06109506|PROCEDURE|Conservative treatment with antibiotics and eventual percutaneous image-guided drainage of the abscess|Patients with acute diverticulitis and abscess formation are commonly treated with a conservative approach that includes endovenous antibiotics and, for abscesses \> 4-5 cm, percutaneous image-guided drainage.
214389050|NCT00259818|DRUG|EM-1421|
214389051|NCT01242176|DRUG|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
214389052|NCT01242176|DRUG|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
214389053|NCT04651270|DEVICE|SurroundScope|The study will evaluate standard laparoscopic surgery using the 270Surgical system. The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
214389054|NCT00612703|DRUG|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
214389055|NCT03010579|DRUG|erythropoietin|Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
214389056|NCT03010579|DRUG|iron supplementation|If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
214389057|NCT04014478|DEVICE|Endovascular Denervation|A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
214389058|NCT01614977|DRUG|Methylprednisoline|Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
214389059|NCT02329106|DEVICE|Irreversible electroporation (IRE)|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
214389060|NCT02240589|DRUG|Memantine|Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.
214389061|NCT02240589|DRUG|Placebo|Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
214389062|NCT02471859|DRUG|GDC-3280|GDC-3280 at various doses, depending on the cohort and treatment period
214389063|NCT02471859|DRUG|Placebo|Placebo at various doses, depending on the cohort and treatment period
214389064|NCT02802319|DEVICE|Porcine Xenograft (Zcore)|Ridge preservation bone grafting after tooth extraction
214389065|NCT02802319|DEVICE|Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting after tooth extraction
214389066|NCT05641142|OTHER|monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease|"Monitoring:~* hemoglobin and ferritin levels~* transfusion or intravenous iron~* hospitalization for bleeding or thrombose~* digestive bleeding and/or another haemorrhagic accident~* severity of epistaxis~* quality of life"
214389067|NCT00027521|BIOLOGICAL|bleomycin sulfate|
214389068|NCT00027521|DRUG|electroporation therapy|
214389069|NCT05826522|OTHER|observationnal|cohort of blood collection and severals exams
214389070|NCT03545113|PROCEDURE|Upper arm arteriovenous graft surgery|Creation of arteriovenous graft vascular access for hemodialysis
214389071|NCT03545113|PROCEDURE|Upper arm arteriovenous fistula surgery|Creation of arteriovenous fistula vascular access for hemodialysis
214389072|NCT03938064|DRUG|Prontogest 400 mg vaginal pessaries|natural progesterone in the form of vaginal suppositories 400 mg
214389073|NCT05634122|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weeks of 90 minutes sessions Session 1: Presentation of the general ACT therapy concept. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis third Session 5: Values and feelings. Session 6: Drink one direction. Session 7: Dare and change. Session 8: Ready to act with ACT. Treatment as usual (TAU) Standard pharmacological treatment for patients with chronic pain.
214389074|NCT05634122|BEHAVIORAL|Treatment as Usual (TAU)|Standard pharmacological treatment for patients with chronic pain
214389075|NCT05442567|DRUG|Vedolizumab IV|Vedolizumab IV infusion
214389076|NCT05442567|OTHER|No Intervention|Participants will not receive any intervention in the Observational Cohort.
214389077|NCT01463774|DRUG|Treatment A: Canagliflozin tablet|Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
214389078|NCT01463774|DRUG|Treatment A: Metformin IR tablets|Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
214389079|NCT01463774|DRUG|Treatment B: Canagliflozin/metformin fixed dose combination tablets|Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
214998419|NCT07068607|DRUG|Tetracycline 500mg tid|Vonoprazan-tetracycline dual therapy:Vonorazon 20 mg daily for 14 days # tetracycline 500 mg by mouth three time daily for 14 days
214389080|NCT04762173|DEVICE|Online self-help intervention|Access to two online, self-guided programs available on the SilverCloud Health website.
214389081|NCT03472287|DRUG|Diacerein 1% Ointment|Diacerein 1% Ointment administered topically
214389082|NCT03428061|OTHER|Integrated care for cardiovascular risk management|Disease management program for the prevention of cardiovascular diseases
214389083|NCT00650221|DRUG|Pravastatin|Single-dose 80 mg immediate-release oral tablet
214389084|NCT00650221|DRUG|Pravastatin|Single-dose 80 mg immediate-release tablet
214389085|NCT02262611|DRUG|Micardis®|
214389086|NCT02262611|DRUG|MicardisPlus®|
214389087|NCT01656603|BIOLOGICAL|unlicensed CBU|infusion of unlicensed cord blood units
214389088|NCT01339611|BEHAVIORAL|Educational program|Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
214389089|NCT04520958|BEHAVIORAL|Mindfulness of Breath|Mindfulness of Breath consisted of instruction in focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
214389090|NCT04520958|BEHAVIORAL|Mindfulness of Pain|Mindfulness of Pain consisted of instruction in how to (1) zoom in to deconstruct pain into its constituent physical sensations and precisely map each sensation's spatial location, (2) use mindful breathing to zoom out and broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that were absent of sensation and pleasant sensations), and (3) shift attention from unpleasant sensations to neutral/pleasant sensations or experiences.
214998420|NCT07068607|DRUG|Minocycline|Vonoprazan-minocycline dual therapy Vonorazon 20 mg daily for 14 days # minocycline 100 mg by mouth two time daily for 14 days
214998421|NCT07068607|DRUG|Bismuth|Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
215094016|NCT06980207|DRUG|LY03017|administered orally
215094017|NCT06980207|DRUG|LY03017-Placebo|administered orally
214389091|NCT04520958|BEHAVIORAL|Cognitive-Behaviorally Based Pain Psychoeducation|Cognitive-Behaviorally Based Pain Psychoeducation consisted of psychoeducation about the link between thoughts, emotions, and behavior and provided instruction in the use logic to dispute maladaptive thoughts about pain that might otherwise exacerbate pain and distress.
214389092|NCT03932448|OTHER|The proposed study is not interventional.|The proposed study is not interventional. However, if a treatable microorganism is detected, e.g. Borrelia or Anaplasma, suitable therapy, e.g. doxycycline, will be in initiated if appropriate.
214389093|NCT03945110|DEVICE|iAluRil® intravesical instillations|50ml of a sterile solution of sodium hyaluronate (1.6% 800mg/50ml) and sodium chondroitin sulphate (2% - 1 g/50ml) is administered intravesically (directly into the bladder) via a pre-filled syringe connected to a catheter and held in the bladder for at least 30 minutes.
214389094|NCT01314781|DRUG|solifenacin|solifenacin 5mg tablet once daily
214389095|NCT01314781|PROCEDURE|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
214389096|NCT01683994|DRUG|Cabozantinib|Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
214389097|NCT01683994|DRUG|Docetaxel|75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
214389098|NCT01683994|DRUG|Prednisone|5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
214389099|NCT01026376|DRUG|decitabine|Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
214389100|NCT01026376|DRUG|decitabine|Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
214389101|NCT03347864|DRUG|68Ga-NOTA-RM26|1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
214389102|NCT02723279|BEHAVIORAL|EPNS|Electrical pudendal nerve stimulation Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
214389103|NCT02723279|DRUG|TT|Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
214389104|NCT03342781|DEVICE|high flow nasal oxygen therapy|Oxygen therapy using a high-flow nasal cannula (HFNC) is a high-flow oxygen delivery system that enhances the efficiency of respiration by using high flow rates to clear dead space and provide fresh oxygen. This system supplies oxygen at a high flow rate through a loose nasal cannula.
214389105|NCT03342781|DEVICE|Diffuser oxygen mask|diffuser mask is a low-flow delivery system, which is capable of delivering up to 90% of the fraction of inspired oxygen (FiO2) with low CO2 retention. In this system, the FiO2 can be adjusted by modifying the flow velocity to deliver the quantity of oxygen that the patient requires. Oxygen is supplied to the patient in a jet that flows from a device mounted on the oxygen mask. This ensures that a high concentration of oxygen is provided at a low flow rate.
214501119|NCT06737354|GENETIC|IVB103 Injection（Intermediate dose）|Single intravitreal injection
214501120|NCT06737354|GENETIC|IVB103 Injection（High dose）|Single intravitreal injection
214998422|NCT07068607|DRUG|Clarithromycin 500 mg|Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
214998423|NCT07068607|DRUG|Amoxicillin|Vonoprazan - amoxicillin dual therapy:Vonorazon 20 mg daily for 14 days # amoxicillin 1000 mg by mouth three time daily for 14 days; Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
214389106|NCT03135132|BEHAVIORAL|Control group|Recommend to consume usual diet during 12-week study period
214389107|NCT03135132|BEHAVIORAL|LCD group|Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day
214389108|NCT01750593|PROCEDURE|Radiofrequency ablation of the thyroid nodule|Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
214389109|NCT00003534|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214389110|NCT03979261|DIAGNOSTIC_TEST|evolution of sex ratio according to age|Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
214501121|NCT06782009|OTHER|Calorie restriction|Participants will be provided with a food menu guide for fifteen days with a 30% energy restriction (kcal) according to their usual diet, with a macronutrient distribution of 20-30% protein, 50-60% carbohydrates and 20-30% fat.
214501122|NCT06782009|OTHER|Intermittent fasting 16/8|Participants will be provided with a food menu guide for fifteen days with an energy intake according to the energy expenditure determined by indirect calorimetry with normal distribution of macronutrients. Intermittent fasting will be used with a time-restricted model of 16:8. For 16 hours, they will not be able to eat or drink calories. In the other 8 hours, they need to adhere to the energy-restricted diet.
214501123|NCT06782009|OTHER|Ketogenic diet|Participants will be provided with a food menu guide for 15 days with an energy intake according to the energy expenditure determined by indirect calorimetry, with the following distribution of macronutrients: 20-25% protein, 5-10% carbohydrates, 70-80% fat.
214998424|NCT06334016|PROCEDURE|Biospecimen Collection|Undergo blood collection
214998425|NCT06334016|DRUG|Cannabis sativa Extract|Vape THC
214998426|NCT06334016|DRUG|Nicotine|Vape active nicotine
214998427|NCT06334016|DRUG|Placebo Administration|Vape placebo nicotine
214998428|NCT06334016|OTHER|Questionnaire Administration|Ancillary studies
214998429|NCT06845553|DRUG|Vutiglabridin|Once-daily oral administration
214389111|NCT04868474|BEHAVIORAL|Training program and decision aid|1\) a one-time, in-person, 2.5-hour training program encouraging participating GPs to present quitting smoking with a quit aid as the default choice to their eligible patients, and 2) access to an electronic decision aid that presents available quit aids. The 2.5-hour training program consists of: 1.5 hours of didactic teaching, with information about pharmacologic quit aids, electronic cigarettes, presenting quitting as a default choice, the decision aid, and a video of a model consultation. This is followed by 1 hour of role plays to practice presenting quitting as a default choice using the decision aid.
214389112|NCT04868474|BEHAVIORAL|Refresher course|A 45-minute refresher training about smoking cessation that does not aim to change GP behaviour. It will include the same information about pharmacologic quit aids and electronic cigarettes.
214389113|NCT03140917|DIAGNOSTIC_TEST|Multimodal liver function assessment|HBS, MRI, CE-CT and ICG
214389114|NCT05010694|DRUG|GH35 Tablet|GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
214389115|NCT01084928|BEHAVIORAL|Lifestyle Intervention Classes|The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
214389116|NCT06349785|DEVICE|rehabilitation of mechanically ventilated patients|"1. mechanical ventilation~2. silicon resuscitation bag (500ml) connected to pressure manometer with an oxygen flow of 10 l.min-1~3. Endotracheal closed suction with pressure control ventilation (PCV)"
214389117|NCT06349785|PROCEDURE|supportive care|\- Children in study group B will receive standard Physical therapy program including suction, percussion and vibration with total duration of session in group a will be 15 minutes, daily for successive two weeks
214389118|NCT06500182|OTHER|hippotherapy sessions|Patients benefit from the hippotherapy sessions in additional to continuing to receive traditional care.
214389119|NCT03442023|DRUG|Chlorhexidine gluconate at 2%|Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
214389120|NCT03442023|DRUG|Chlorhexidine gluconate at 0.12%|Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
214389121|NCT00164177|DRUG|HalfLytely|
214389122|NCT05313009|DRUG|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly
214389123|NCT05313009|DRUG|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).
214389124|NCT06548685|PROCEDURE|Bone Grafting|Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites
214389125|NCT06548685|OTHER|Vegetable Derived|Tooth extraction followed by socket preservation with vegetable ivory
214998430|NCT06845553|DRUG|Placebo|Once-daily oral administration
214389126|NCT05583747|DEVICE|iTBS|rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. iTBS is a briefer form of patterned rTMS that has been shown to be effective against MDD, despite a stimulation period of 1-3 min rather than 30-40 min.
214389127|NCT02621567|DEVICE|Bright Light Therapy Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.
214389128|NCT02621567|DEVICE|Modified Dim Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
214389129|NCT02891590|DRUG|DTRMWXHS-12|
214389130|NCT03507543|DRUG|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
214389131|NCT00268931|BEHAVIORAL|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
214389132|NCT00268931|BEHAVIORAL|Social Training|This group underwent special social interactions with their parents two times each day.
214389133|NCT03157024|DEVICE|Ring Sham (RS)|
214389134|NCT03157024|DEVICE|Real Needle (RN)|
214389135|NCT03157024|DEVICE|Kim Sham (KS)|
214389136|NCT03859375|OTHER|microbial skin counts in the disinfection area after paints of skin disinfectants|microbial skin counts in the disinfection area after 2 and 3 paints of skin disinfectants (chlorhexidine in alcohol \[CHX\] and povidone iodine in alcohol \[PI\])
214389137|NCT02213419|DRUG|Endoscopic ultrasonography-guided double ethanol lavage|"A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes."
214389138|NCT00243555|PROCEDURE|allergy skin testing|
214389139|NCT00243555|PROCEDURE|venepuncture|
214389140|NCT00719602|DRUG|Lamivudine|Taken orally twice daily
214998431|NCT06892847|PROCEDURE|Transcranial Magnetic Stimulation|Participants will receive TMS for treatment measures as determined by referral and presentation.
214998432|NCT07071766|BEHAVIORAL|Proud of Baby and Me|The original Baby \& Me curricula was adapted to be delivered in outpatient substance use treatment settings to newly postpartum women receiving medications for opioid use disorder (MOUD) for this study.
214998433|NCT06774625|DRUG|LTG-001 High Dose|LTG-001 High Dose
214998434|NCT06774625|DRUG|LTG-001 Mid Dose|LTG-001 Mid Dose
214998435|NCT06774625|DRUG|LTG-001 Low Dose|LTG-001 Low Dose
214998436|NCT06774625|OTHER|Placebo|Placebo
214998437|NCT06774625|DRUG|Suzetrigine|Active comparator - Nav1.8 inhibitor
214389141|NCT00719602|DRUG|Lopinavir/Ritonavir|Taken orally twice daily
214389142|NCT00719602|DRUG|Nevirapine|Taken orally twice daily
214389143|NCT00719602|DRUG|Zidovudine|Taken orally twice daily
214389144|NCT04037111|DEVICE|Transcutaneous electrical vagus nerve stimulation|The patient received active VNS and escitalopram oxalate tablets for 2 months.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
214389145|NCT04037111|DEVICE|Sham vagus nerve stimulation|The patient received sham VNS.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
214501124|NCT05381480|BEHAVIORAL|In-home Preventive Health Visits by Advanced Practice Nurse|Elements of Comprehensive Geriatric Assessment used as a preventive, health risk assessment, with recommendations tailored for health risks identified and offered to building tenants
214501125|NCT05381480|BEHAVIORAL|On-site Evidence-based Physical Activity, Health and Wellness Classes|Weekly calendar of health promotion and injury/illness prevention classes offered to building tenants.
214501126|NCT05320692|DRUG|TACE+Camrelizumab+Apatinib mesylate|TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.
214389146|NCT04037111|DRUG|drug treatment|Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg
214501127|NCT05320692|PROCEDURE|TACE|TACE Alone.
214389147|NCT02606669|DIETARY_SUPPLEMENT|Meal Replacement|Using a Meal Replacement product, supplemented by protein powder and multivitamin
214389148|NCT00656461|DRUG|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
214389149|NCT02774408|DEVICE|Saturation sensitive backup ventilation|
214501128|NCT06828952|DRUG|ceftriaxone|ceftriaxone 1 gm/12 hourly and IV metronidazole 500 mg/8 hourly
214501129|NCT06828952|DRUG|ceftriaxone 1 gm/12 hourly and IV metronidazole 500 mg/8 hourly|Conservative management
214501130|NCT06066619|DIETARY_SUPPLEMENT|Cranberry Juice A|Cranberry juices will be provided by Ocean Spray Company.
214389150|NCT00548041|OTHER|HIV test by oral swab|Eligible subjects underwent rapid HIV testing by oral swab.
214389151|NCT03638635|DRUG|Bupivacaine|Abdominal injection of bupivacaine into fascial layer.
214389152|NCT03638635|DRUG|Bupivacaine liposome|Abdominal injection of bupivacaine liposome into fascial layer.
214389153|NCT01603420|DRUG|Luteinizing hormone-releasing hormone (LHRH)|Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
214389154|NCT01603420|DRUG|Docetaxel|Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
214389155|NCT01603420|OTHER|Conformal Radiation Therapy (RT)|1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
214501131|NCT06066619|DIETARY_SUPPLEMENT|Cranberry Juice B|Cranberry juices will be provided from Ocean Spray Company.
214501132|NCT06066619|DIETARY_SUPPLEMENT|Placebo Juice|Placebo juice will be provided from Ocean Spray Company to match the appearance, taste, and calories of the cranberry juice.
214501133|NCT04252677|BEHAVIORAL|Obesity Prevention|This intervention includes content specific to obesity behaviors-related health information, motivation, and behavioral skills.
214501134|NCT04252677|BEHAVIORAL|Health Literacy|This intervention includes content specific to improving health literacy.
214501135|NCT04900597|OTHER|Elecare Jr|Elecare Jr is a standard pediatric elemental formula
214501136|NCT04900597|OTHER|Nourish|Nourish is a commercially prepared blenderized tube feed that is formulated for pediatric use
214501137|NCT04900597|OTHER|Real Foods Blends|Real Foods Blends is a commercially prepared blenderized tube feed that is formulated for pediatric use
214998438|NCT07041151|OTHER|At-home Foley Catheter Self-Removal with Passive Void Trial|Participants will remove their foley catheter at home and perform a passive void trial. They will be instructed to drink fluids and attempt to void within a designated time frame. Instructions and support will be provided to ensure safety and follow-up, including clinic contact if voiding is unsuccessful.
214998439|NCT07041151|OTHER|In-Office Foley Catheter Removal and Backfill Void Trial|Participants will return to clinic for removal of their foley catheter and undergo a backfill void trial. Standard protocols for instillation and assessment of urinary retention will be followed.
214998440|NCT06772077|DEVICE|Rehabilitation treatment with ATLAS2030|10 sessions of Rehabilitation Treatment with ATLAS2030 with With an evaluation session before the first session and another one after 10 sessions.
214998441|NCT06898125|OTHER|Extracorporeal Shockwave Therapy|Shock wave therapy is a new modality for the improvement of cellulite and lipedema; it is an easy, noninvasive, local therapy, without side effects, with short periods of application. Its original idea was the stimulation of lipid mobilization and improved lipolysis in areas with edema.
214389156|NCT06108115|BEHAVIORAL|CueToSleep (Full Intervention Package)|Individuals will be randomly allocated to receive the full Health Rhythms package (CueToSleep) program on their smartphones. The package includes 24/7 behavioral sensing from the participant's smartphone using the global positioning system, accelerometer, and screen on/off state, as well as a series of psychoeducational learning screens about the relationship among alcohol, mood disturbance and sleep, and personalized suggestions for behavior change to improve sleep that will be sent to the participant every 3 to 4 days. These suggestions will be based on behaviors indicated by the individual participant's sensor data over the previous 3 to 4 days.
214389157|NCT03379064|BEHAVIORAL|Culturally adapted Cognitive Behavior Therapy for IBS|Culturally adapted Cognitive Behavior Therapy for IBS
214389158|NCT05625581|DRUG|tofacitinib|All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.
214389159|NCT00125580|BEHAVIORAL|Infant sleep instruction|
214389160|NCT00313911|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
214389161|NCT00313911|BIOLOGICAL|Tritanrix-HepB/Hib|0.5 mL, Intramuscular
214389162|NCT04192513|DRUG|J. lividum|Investigational Product
214389163|NCT03350659|DRUG|Midodrine|Midodrine single 5mg/day
214389164|NCT03350659|DRUG|Atomoxetine|Atomoxetine single 18mg/day
214389165|NCT02193802|DEVICE|PillCam® COLON 2 and PillCam Crohn's capsules|"Patient preparation for PillCam® COLON 2 and PillCam Crohn's capsule procedure:~Patients will drink only clear liquids beginning 12 noon the day prior to the procedure,12 hour fast prior to the procedure and 1 L of PEG on the morning two hours before the capsule ingestion.~Patients can drink clear liquids 2 hours and eat 4 hours post ingestion. Eight hours post ingestion the data recorder should be removed. Patients will confirm excretion of the capsule or as required by the investigator."
214501138|NCT06823440|DEVICE|Compression using surgical gloves and compression knee socks|Compression therapy will be applied using surgical gloves and compression knee socks. The compression itself will take place on the principle of compressing the limbs, which will narrow the blood vessels and thereby limit the flow of cytostatics to the peripheral parts of the body. This is believed to reduce damage to nerve fibers. Special knee socks with compression of 20-30 mm Hg and latex/nitrile surgical gloves will be used for pressure therapy. The size of the compression aids will be determined by the nursing staff (gloves will be a tight-fitting size; they will not cause discomfort). The patients will wear the compression aids for a specific amount of time before administering paclitaxel, throughout paclitaxel infusion, and after the infusion.
214389166|NCT04706741|DRUG|Izokibep|Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously
214389167|NCT04706741|DRUG|Prednisone/Prednisolone|Background Corticosteroid
214389168|NCT03384953|BEHAVIORAL|Clinical Hypnosis - Group Treatment|group treatment
214501139|NCT03713879|DEVICE|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
214998442|NCT06898125|OTHER|Complex Decongestive Therapy|Complex decongestive therapy (CDT) is one of the most important treatment modalities of choice for patients with this clinical condition. CDT has two phases: treatment and maintenance. The first stage consists of skin care, manual lymph drainage, kinesiotherapy and bandaging of the limb. Drainage can facilitate the return of lymphatic flow by stimulating the cisterna chyli. Next, kinesiotherapy is applied, which aims to activate the lymph. Finally, the limb is moistened and then a compressive bandage is applied aimed at creating a pressure gradient towards the areas where lymph absorption is greater. The second phase continues skin care, physical exercises and external compression applications using bandages with varying degrees of elasticity.
214998443|NCT06898151|PROCEDURE|CEA/CAS plus best medical treatment|Timing of CEA/CAS plus best medical treatment
214998444|NCT06781307|OTHER|skin to skin|Intervention measures include 1 hour of skin-to-skin contact between mother and baby every day from day 1 to day 30 postpartum.
214998445|NCT06822517|DRUG|VENT-02|Orally administered capsules
214998446|NCT06822517|DRUG|Placebo|Orally administered capsules
214998447|NCT06733363|BEHAVIORAL|Behavioral Dietary Intervention|Participate in POW-R Health Only/Core program
214998448|NCT06733363|BEHAVIORAL|Telephone- Based Intervention|Receive live phone calls
214389169|NCT03384953|BEHAVIORAL|Clinical Hypnosis - Individual Treatment|individual treatment
214389170|NCT01574430|PROCEDURE|PDT|30% or 50% verteporfin dose PDT was given to patients with CSC
214389171|NCT00884858|DRUG|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
214389172|NCT00462046|DRUG|Berberine|
214389173|NCT06364241|OTHER|Focus group|During the focus group, the investigators will explore the cognitive deficits that people with lived experience with psychosis and their carers consider to be the most impairing.
214998449|NCT04643002|DRUG|Isatuximab|Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
214998450|NCT04643002|DRUG|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
214998451|NCT04643002|DRUG|Pomalidomide|Pharmaceutical form: Capsule; Route of administration: Oral
214998452|NCT04643002|DRUG|Belantamab mafodotin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
214998453|NCT04643002|DRUG|Pegenzileukin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
214998454|NCT04643002|DRUG|SAR439459|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
214998455|NCT04643002|DRUG|Belumosudil|Pharmaceutical form: tablet; route of administration: oral
214389174|NCT00004203|DRUG|oxaliplatin|
214389175|NCT00087789|GENETIC|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10\^10 vg, CERE-110 1.0 x 10\^11 vg, CERE-110 2.0 x 10\^11 vg
214389176|NCT00818415|DRUG|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
214389177|NCT00818415|DRUG|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
214389178|NCT06001281|OTHER|plasma collection|Plasma samples will be prospectively collected at relevant time points during patient treatment.
214389179|NCT00002708|PROCEDURE|surgical procedure|
214389180|NCT00002708|RADIATION|radiation therapy|
214389181|NCT00002708|RADIATION|stereotactic radiosurgery|
214389182|NCT04367402|OTHER|BioMedomics COVID-19 IgM-IgG Rapid Test|Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
214389183|NCT01987596|BIOLOGICAL|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
214389184|NCT01219803|DRUG|High Dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,5 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
214389185|NCT01219803|DRUG|Mild dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,3 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
214501140|NCT03713879|DRUG|Indomethacin|rectally administered indomethacin before or after ERCP
214998456|NCT04643002|DRUG|Evorpacept|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
214998457|NCT05521373|DEVICE|ultrasound cervical selective nerve root block|"A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance"
214998458|NCT05521373|DEVICE|ultrasound and fluoroscopy-guided cervical selective nerve root block|The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
214998459|NCT06760182|DRUG|TQH2722 injection|TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
214389186|NCT01219803|DRUG|Low dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc, 150ml/bag, twice in a day
214389187|NCT01219803|DRUG|Placebo|The placebo was a kind of decoction,which including 4.5% low dose GGQL Decoction to feel bitter taste as other drugs, 150ml/bag, twice in a day
214389188|NCT02328196|BEHAVIORAL|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
214501141|NCT06675149|DEVICE|Diacutaneus fibrolysis|Material : Stainless steel large angle and small long angle: length 22cm x height 6cm x width 2cm. Weight: 70 grams
214501142|NCT06675149|DEVICE|Transcutaneous electrical nerve stimulation|physical therapy electrical modality
214998460|NCT06760182|DRUG|TQH2722 Placebo|Placebo without drug substance.
214998461|NCT02905591|DRUG|Radiation Therapy|Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days
214998462|NCT02905591|DRUG|Paclitaxel|"Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered~* the dose is 45 mg/m2 (standard dose)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standardized dose reductions are used"
214501143|NCT06675149|PROCEDURE|Massage|manual therapy intervention
214501144|NCT03915106|DEVICE|Brace|Wear a rigid brace
214501145|NCT03915106|PROCEDURE|Surgical correction using implants|Surgical correction of spine using implants (metallic rods and metallic screws)
214501146|NCT06282081|DIAGNOSTIC_TEST|Serum Neurofilament Light|The purpose of this research is to investigate a biomarker, called serum neurofilament light (sNfL), which is measured in blood. This study will attempt to investigate whether or not sNfL is a useful tool for clinicians in patients diagnosed with relapsing remitting multiple sclerosis.
214998463|NCT02905591|DRUG|Carboplatin|"Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.~* Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standard dose reductions are used"
214998464|NCT02905591|DRUG|Ascorbic Acid|"Administered intravenously~* 75 grams per infusion; each infusion is about 2 hours~* 3 infusion per calendar week~* The infusion is actively running for at least 20 minutes when radiation begins~* May be given while chemotherapy is delayed due to low counts~* Dose reductions are not used~* Given for 6 to 7 weeks, depending on when radiation starts"
214389189|NCT04633083|OTHER|Data collection|"Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data."
214501147|NCT06444516|OTHER|FID123300 ocular lubricant|Investigational ocular lubricant
214501148|NCT06799351|DRUG|Ozone therapy|Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
214501149|NCT06799351|DRUG|Oxygen (placebo)|Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
214501150|NCT06810466|DIETARY_SUPPLEMENT|Test Product A|Innovative formulation of a dietary supplement for mild hypercholesterolemia. Test Product A will be admistered daily for 8 weeks. After the fist 8 weeks, this arm will continue with the intake of the Product Test A for other 8 weeks.
214501151|NCT06810466|DIETARY_SUPPLEMENT|Test Product B|Classic formulation of a dietary supplement for mild hypercholesterolemia. After the fist 8 weeks, this arm will continue with the intake of the Product Test A for other 8 weeks.
214501152|NCT06810466|DIETARY_SUPPLEMENT|Placebo|"Placebo does not contain functional components and is indistinguishable from Product Test B.~After the fist 8 weeks, this arm will continue with the intake of the Product Test A for other 8 weeks."
214389190|NCT01936129|DRUG|Copaxone|
214501153|NCT06100952|COMBINATION_PRODUCT|Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment|"Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source"
214501154|NCT06100952|COMBINATION_PRODUCT|Placebo and sham treatment|"Drug: placebo ophthalmic solution~Device: UV-3000 light source"
214501155|NCT05571553|OTHER|Recommendations and reorientation towards healthcare resources|"Phase 1~* After completing the CARE© questionnaire, participants will be given recommendations.~* After the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments made.~Phase 2~* After completing the CARE© questionnaire, participants will be given recommendations.~* If their health status is judged fragile by the CARE© score, and after the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments.~For both phases, after 3 (6) months, the participants of the Control group will benefit from the recommendations following the CARE© assessment done at M3 (M6), and if necessary from the ESOGER© assessment and the Red Cross intervention. Throughout the study, they will continue to receive their conventional care."
214501156|NCT03641664|BEHAVIORAL|Family Centered Treatment|Family Centered Treatment® (FCT) is a promising practice for providing home-based services to families at-risk for their children being removed from home.
214501157|NCT03641664|BEHAVIORAL|Level II or Level III Out of Home Placement|Residential care for children with emotional, behavioral, and/or mental health in North Carolina who have experienced a level of dysfunction that makes it impossible to function at an age appropriate level in their own homes or in a lower level of care. These services can be provided in a variety of locations from urban to rural, from facility based to community based and from public sector to private sector. This service provides a structured and supervised environment for the acquisition of skills necessary to enable the child to improve level of functioning to achieve and/or to maintain the most realistic level of independent function where earlier treatment gains are somewhat fragile and the child is subject to regression.
214501158|NCT06619977|DEVICE|Analgesia nociception monitoring (ANI)|Analgesia nociception index (ANI; MetroDoloris Medical Systems, Lille, France) is a noninvasive tool for monitoring the intraoperative state of the autonomic nervous system, in particular - the parasympathetic nervous system. The ANI algorithm uses data from one lead ECG trace. Heart rate variability, or the beat-to-beat alterations in heart rate, is a well-known and recognised noninvasive indicator of autonomic nervous system activity.
214389191|NCT01936129|DRUG|Placebo (buffered normal saline w/v)|
214389192|NCT03223272|DRUG|Reserpine|Open label reserpine 0.1 mg pill orally
214389193|NCT03636360|DEVICE|Light|15 hours of light exposure
214389194|NCT00245375|DRUG|Tylenol #3|
214501159|NCT06163625|DEVICE|Repetitive Transcranial Magnetic Stimulation|For those with depression where medication and psychotherapy have limited benefit, repetitive transcranial magnetic stimulation (rTMS) is an effective treatment. rTMS is a treatment that involves stimulating certain areas of the brain with magnetic field pulses. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region. This can be helpful in treating some kinds of psychiatric and neurological disorder, including MDD.
214389195|NCT00245375|DRUG|Combination Tylenol and Ibuprofen|
214389196|NCT01533714|BIOLOGICAL|CDP6038 (olokizumab)|Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection
214389197|NCT02351596|OTHER|Physiotherapy Core Stability Group Programme|"The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this."
214501160|NCT06163625|BEHAVIORAL|Research Interview, Questionnaires|"Research Interview: A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 30 minutes.~Research Questionnaires: A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. Questionnaires will be completed via pen and paper at each visit. These questionnaires will take approximately 90 minutes to complete."
214998465|NCT07075835|PROCEDURE|Enhanced external counterpulsation|20 (5 days a week for 4 weeks) one-hour procedures (compression pressure 220-280 mmHg) of enhanced external counterpulsation (device: LUMENAIR EECP, Vasomedical Inc., USA, registration certificate №2018/6915 dated 15.03.2018). The systolic deflation/diastolic inflation sequence of enhanced external counterpulsation leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
214389198|NCT02351596|OTHER|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
214998466|NCT05797740|DRUG|Mavenclad|This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.
214998467|NCT06013722|DIAGNOSTIC_TEST|18F-Na PET Scan|For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.
214389199|NCT02500212|DRUG|ENVARSUS®|
214389200|NCT02500212|DRUG|ADVAGRAF®|
214389201|NCT03978754|DIAGNOSTIC_TEST|ICG lymphography、CM、VD、Bioelectrical impedance technology、self-report|All of these methods are used for patients visiting the lymphedema clinic to assess whether they have developed lymphedema.
214389202|NCT03978754|DIAGNOSTIC_TEST|Bioelectrical impedance technology、CM|These two methods are routine evaluation methods for breast cancer patients before surgery
214389203|NCT03664739|DRUG|IDP-120 Gel|IDP-120 Gel, once-daily application
214389204|NCT03664739|DRUG|IDp-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
214389205|NCT03634137|DRUG|Afamelanotide Group 1|One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
214389206|NCT03634137|DRUG|Afamelanotide Group 2|One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
214389207|NCT03989635|DRUG|QAW039|QAW039 450mg
214389208|NCT03475719|DRUG|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
214389209|NCT03475719|DRUG|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
214389210|NCT04381767|DEVICE|EYE-SYNC|Evaluation of oculomotor performance using visual presentation and eye tracking analysis
214389211|NCT02917044|PROCEDURE|Atrial Fibrillation Ablation|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
214389212|NCT02917044|DEVICE|Catheters used to isolate pulmonary veins|Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
214998468|NCT06077201|OTHER|HBCR hands-off|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance.
214998469|NCT06077201|OTHER|HBCR interactive|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
214389213|NCT02917044|PROCEDURE|Atrial Fibrillation Ablation with HD mapping to isolate PVs|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
214389214|NCT02917044|DEVICE|Rhythmia HD mapping|Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
214389215|NCT00599989|PROCEDURE|adjuvant therapy|
214389216|NCT00599989|PROCEDURE|conventional surgery|
214389217|NCT00599989|RADIATION|3-dimensional conformal radiation therapy|
214389218|NCT00599989|RADIATION|brachytherapy|
214389219|NCT00599989|RADIATION|intracavitary balloon brachytherapy|
214389220|NCT00599989|RADIATION|proton beam radiation therapy|
214389221|NCT01241253|OTHER|Whole cooked beans with rice meals|Three types of bean-and-rice meals all equal to 50 grams available CHO. Control treatment was 50 grams available CHO in the form of white rice alone.
214389222|NCT05540743|DRUG|biologic DMARDs|follow up the clinical response in Egyptian population to the drug
214389223|NCT04147182|DRUG|Hypertonic Saline 3%|3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
214389224|NCT02997839|BEHAVIORAL|sleep disruption|"Group two will have interrupted sleep at time periods of 2 hours post operatively.~Group two will be woken every 2 hours, which is the standard NCCU protocol."
214389225|NCT03173781|DRUG|droxidopa|medication
214389226|NCT03173781|DRUG|Placebo|medication
214998470|NCT06162377|DRUG|Methylnaltrexone|Given by SC (injection)
214998471|NCT07075679|DIAGNOSTIC_TEST|Group with AI iCAD version 3|Reading mammograms by one radiologist with AI support
214998472|NCT07075679|DIAGNOSTIC_TEST|Group without AI|Standard double reading by two radiologists without AI.
214389227|NCT04924686|OTHER|Observational studies, no intervention|Observational studies, no intervention
214389228|NCT05158439|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214389229|NCT02176681|DRUG|Vildagliptin (Galvus)|Use Vildagliptin (50 mg/day) added to insulin during 3 months
214389230|NCT02176681|DRUG|Insulin|Insulin
214389231|NCT01448720|DRUG|Paliperidone palmitate|Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
214389232|NCT03748836|DRUG|ALPN-101|Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
214389233|NCT03748836|DRUG|Placebo|Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
214389234|NCT01808976|OTHER|Problem Solving Therapy|this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
214998473|NCT07078786|DRUG|Betamethason Sodium Phosphate|Intramuscular injection of Betamethasone 12mg will be administered on 2 consecutive days
214389235|NCT01808976|BEHAVIORAL|Evolution|This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.
214389236|NCT01808976|BEHAVIORAL|Basic health push app|This is an app that send daily tips for improving your mood.
214389237|NCT00323713|BEHAVIORAL|Very low protein diet|0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids
214389238|NCT00323713|BEHAVIORAL|Low protein diet|0.6 g of protein per kilo of body weight per day
214389239|NCT04408547|DEVICE|embryo transfer catheter|undergoing embryo transfer
214389240|NCT06356727|DIAGNOSTIC_TEST|Thermodilution based assessment of coronary microcirculation|Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
214389241|NCT02293525|DEVICE|ReLeaf catheter|Continuous infusion rate 10ml/hr (5ml/side)
214389242|NCT02293525|DRUG|Ropivacaine|
214389243|NCT02293525|DRUG|Saline|
214389244|NCT02293525|DRUG|Morphine|Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
214389245|NCT02293525|DRUG|Oxycodone|10mg every 4-6 hours
214389246|NCT05124834|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
214389247|NCT05124834|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
214389248|NCT01421589|DRUG|Growth hormone treatment|Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.
214389249|NCT00385450|DRUG|Nelfinavir/placebo|1250mg/twice each day/four days.
214501161|NCT06163625|BEHAVIORAL|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes, and there will be a recovery period for 40 minutes. The participant will be given instructions about these tasks outside of the scanner. This brain scan will happen at St. Michael's Hospital.
214389250|NCT01311362|DRUG|St. Johns wort|"* Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~* Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
214389251|NCT03790514|OTHER|Heat Wrap|Commercially heat tapes ( without drugs) will be applied to patients.
214389252|NCT00251927|DRUG|esomeprazole|40 mg oral tablet administered daily
214389253|NCT00251927|PROCEDURE|Laparoscopic fundoplication (surgery)|Surgery
214501162|NCT06163625|BIOLOGICAL|Saliva Samples|The participant will be asked to provide six 1mL saliva samples during the MRI scan and recovery period so that the investigators can measure molecular markers associated with depression. In order to provide the sample, the investigators will collect their saliva using a cotton swab and test tube. Each sample should take no more than 5 minutes.
214998474|NCT07078786|DRUG|Dexamethasone|two doses of 12mg of IM Dexamethasone given 24 hours apart
214998475|NCT06192602|BEHAVIORAL|AIM_AT|The program consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team.
214998476|NCT06192602|BEHAVIORAL|CPG|Psychoeducation group program (12-18 members/group) consists of 10 two-hour sessions, weekly/biweekly (similarly, 4-month duration) and is guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psychoeducation programs for psychosis.
214998477|NCT06192602|BEHAVIORAL|TAU|Routine/Usual care only (control) group participants (and the two treatment groups) will receive usual community mental healthcare services.
214998478|NCT07080567|DRUG|Maraviroc|Maraviroc (300mg) twice daily for 90 days
214998479|NCT07080567|DRUG|Mannitol|Placebo intervention
214998480|NCT06406010|DRUG|Ropivacaine 5mg/ml 20ml|administered in a pericapsular nerve group (PENG) block
214389254|NCT05303597|DIAGNOSTIC_TEST|ultrasound-guided diagnostic nerve block with lidocaine|Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment.
214389255|NCT05388994|OTHER|Exercise|The initial implementation for the 8-week combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike (Ergoline Ergoselect 200; Ergoline GMBH, Bitz, Germany). All sessions are individually supervised and conducted. Training intensity was started at 70% of maximum aerobic capacity and training intensity was increased by 5% of VO2peak every two weeks. Pedal speed was fixed at 50 rpm throughout 8 weeks of training. Exercise sessions; It started with a 5 minute warm-up period (30% of VO2peak), followed by a total of 40 minutes with a 30-minute load period and a 5-minute cool-down period (without resistance).
214389256|NCT04204772|BIOLOGICAL|Activated charcoal and Tap Water|12 grams of AC mixed with Tap water or 25 grams of AC mixed with Tap water
214389257|NCT04204772|BIOLOGICAL|Activated Charcoal and Apple Juice|12 grams of AC with Apple Juice or 25 grams of AC with Apple Juice
214389258|NCT02153021|RADIATION|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
214389259|NCT01039350|DRUG|Darbepoetin alfa|Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
214998481|NCT06406010|DRUG|Saline 0.9%|administered in a pericapsular nerve group (PENG) block
214998482|NCT04506151|BEHAVIORAL|Sleep-Opt|12-week behavioral intervention
214389260|NCT06526377|DRUG|Natrunix|Natrunix is a monoclonal antibody preparation. Natrunix antibody is indistinguishable from a natural antibody isolated from a healthy human. Natrunix is expected to be the safest, most effective therapy for alleviating inflammatory pain and mitigating damage, mainly in the spine and sacroiliac joints, in AxSpA patients.
214389261|NCT06526377|DRUG|Placebo|Placebo
214389262|NCT02909023|BIOLOGICAL|blood samples are performed to measure active T cellular immune response during a routine visit|"During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.~The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit."
214389263|NCT00047983|DIETARY_SUPPLEMENT|Canola oil|
214389264|NCT00047983|DIETARY_SUPPLEMENT|Arginine|
214389265|NCT00047983|DIETARY_SUPPLEMENT|Fish oil emulsion|
214389266|NCT02632019|DRUG|Gemcitabine|Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
214389267|NCT02632019|BIOLOGICAL|Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment|"Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.~PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63."
214389268|NCT05819060|DRUG|Fuzuloparib Combination with Bevacizumab|For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT\>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.
214389269|NCT00936520|DRUG|SAR 1118 0.1%|Daily eye drops (twice daily, \~50 microliter \[uL\] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
214389270|NCT00936520|DRUG|SAR 1118 1.0%|Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
214389271|NCT00936520|DRUG|SAR 1118 5.0%|Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
214389272|NCT00857376|DIETARY_SUPPLEMENT|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
214389273|NCT01224808|BIOLOGICAL|Biostate|Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
214389274|NCT00990301|DRUG|Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.|test drug
214389275|NCT00990301|DRUG|Uniretic® 15mg/25mg Tablets|reference drug
214389276|NCT00849082|DRUG|cyproterone acetate|
214389277|NCT00849082|DRUG|goserelin acetate|
214389278|NCT00849082|RADIATION|radiation therapy|
214389279|NCT06442072|BEHAVIORAL|guided online self-help program|16 weeks of training and application of psychotherapeutic methods
214389280|NCT00071240|DRUG|Somatropin (recombinant human growth hormone)|3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
214389281|NCT01832415|DRUG|Bevacizumab|Observation of bevacizumab administration in first line ovarian cancer treatment
214389282|NCT04004572|DRUG|LEAP regimen|Patients will be given LEAP regimen every 3 weeks for 8 cycles.
214389283|NCT06106841|DRUG|400mg of TQB3909 tablets|TQB3909 tablets 400mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
214389284|NCT06106841|DRUG|600mg of TQB3909 tablets|TQB3909 tablets 600mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
214389285|NCT01044342|DRUG|AZD1446|capsule; single oral dose
214389286|NCT01044342|DRUG|AZD1446|capsule, single oral dose
214389287|NCT01044342|DRUG|donepezil|capsule, single oral dose
214389288|NCT01044342|DRUG|Placebo|capsule, single oral dose
214389289|NCT04432402|DRUG|Lenalidomide|Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
214389290|NCT02406261|DRUG|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
214389291|NCT02406261|DRUG|Simvastatin|20 mg simvastatin will be administered orally as 1 × 20-mg tablet
214389292|NCT02406261|DRUG|Midazolam|500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
214389293|NCT02406261|DRUG|Midazolam|250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
214389294|NCT02406261|DRUG|Donepezil|5 mg donepezil will be administered orally as 1 × 5-mg tablet
214389295|NCT02406261|DRUG|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
214389296|NCT03753711|PROCEDURE|Multifidus muscle biopsy during minimally invasive back surgery|Bilateral biopsy of the multifidus muscle in patient with a unilateral disc hernia.
214389297|NCT03379714|DEVICE|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.
214389298|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg
214389299|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg
214389300|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
214998483|NCT04506151|BEHAVIORAL|Healthy Living|Healthy Living
214389301|NCT03154203|OTHER|No intervention in this study|No intervention in this study
214389302|NCT01193543|DIETARY_SUPPLEMENT|calanus oil|1 gram twice daily
214389303|NCT01193543|DIETARY_SUPPLEMENT|olive oil|1 gram twice daily
214389304|NCT00227760|DRUG|Cediranib Maleate|Given PO
214389305|NCT00227760|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
214389306|NCT00227760|OTHER|Laboratory Biomarker Analysis|Correlative studies
214389307|NCT00227760|OTHER|Pharmacological Study|Correlative studies
214389308|NCT00742105|DRUG|BGT226|
214389309|NCT03410914|DEVICE|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery.
214389310|NCT04005937|DIAGNOSTIC_TEST|H-reflex|Electrical stimulation of Group Ia afferent of muscle spindle
214389311|NCT00497965|PROCEDURE|Chiropractic Manipulation|
214389312|NCT00497965|BEHAVIORAL|Balance Exercises|
214389313|NCT03575689|DEVICE|Doyle Splint|Using Doyle splints following septoplasty is the standard of care and may help with stability of the septum in the immediate post op period. owever these splints are associated with morbidity in the post-op period. The quilting technique was developed to prevent complications and stabilize the septum. This study examines the efficacy of these splints in stabilizing the septum and preventing complications after septoplasty
214389314|NCT02439177|DEVICE|Blood glucose monitoring system (Omnitest 3)|
214389315|NCT02439177|DEVICE|Blood glucose monitoring system (Omnitest 5)|
214389316|NCT05428462|OTHER|Psychoeducation day on borderline personality disorder|Transmission of latest knowledge on borderline personality disorder
214389317|NCT04227860|OTHER|Balance exercise program|"Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
214389318|NCT04227860|OTHER|Strengthening exercise program|"Patients will be engaged in strengthening exercise program 3 time per week for 6 weeks.~Divided into 3 stages, stage 1, 2 and 3, each stage 2 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
214389319|NCT01991249|OTHER|blood draw|
214389320|NCT04961736|OTHER|no intervention|This is an observation study, with no intervention
214389321|NCT03013686|PROCEDURE|Interval appendectomy|Laparoscopic appendectomy
214389322|NCT03013686|PROCEDURE|Follow-up with MRI|Abdominal MRI
214389323|NCT00152490|DRUG|Certolizumab Pegol (CDP870)|
214998484|NCT06795451|DEVICE|transcutaneous spinal direct current stimulation|transcutaneous spinal direct current stimulation
214998485|NCT06705478|DRUG|Pramipexole ER|Tablets self-administered orally
214389324|NCT02332330|DEVICE|VEST|
214389325|NCT03319186|PROCEDURE|EDIT Management|"EDIT management~1. Volumetric Pleural MRI for pre-aspiration pleural cavity volume~2. Large volume pleural aspiration with recording of intra-pleural pressure during aspiration~3. Volumetric Pleural MRI for post-aspiration pleural cavity volume~4. Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.~   MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 \< 14.5 cm H2O/L: allocated to 1st-line TP~5. EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion."
214389326|NCT03319186|PROCEDURE|Chest drain and talc pleurodesis|Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
214389327|NCT03729895|DEVICE|Adjustable Oral Appliance|Adjustable Oral Appliance consist of plastic maxillary occlusal splint，mandible occlusal splint and adjustable connecting rod.It could offer a non-invasive form of treatment but also achieve a good therapeutic effect
214389328|NCT01488864|BEHAVIORAL|Applied Relaxation (AR)|"AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.~During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.~The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation."
214389329|NCT03918538|BEHAVIORAL|Home rehabilitation exercise program|After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual. The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers.
214389330|NCT05504213|DRUG|HS-10352 combined with fulvestrant (Stage 1)|"Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
214389331|NCT05504213|DRUG|HS-10352 combined with fulvestrant (Stage 2)|"Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
214389332|NCT02222896|DRUG|Chlorhexidine Gluconate|2% CHG solution on cloth
214389333|NCT02222896|OTHER|Vehicle|Excipients of CHG product only
214389334|NCT02222896|DRUG|DynaHex-2|2% CHG solution
214389335|NCT02677363|OTHER|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
214389336|NCT02441946|DRUG|Abemaciclib|Administered orally
214389337|NCT02441946|DRUG|Loperamide|Administered orally
214389338|NCT02441946|DRUG|Anastrozole|Administered orally
214389339|NCT05435235|DRUG|Dapagliflozin 10mg Tab|One tablet daily starting 48h prior to PCI and continuing for 48h post-PCI.
214998486|NCT06705478|DRUG|Escitalopram|Tablets self-administered orally
214389340|NCT05034224|DEVICE|Swan-Ganz catheter placed in the coronary sinus - deflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be kept deflated during sham intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
214389341|NCT05034224|DEVICE|Swan-Ganz catheter placed in the coronary sinus - inflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be inflated to obtain coronary sinus occlusion during the active intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
214389342|NCT05298462|DIAGNOSTIC_TEST|Livzon Rapid Antibody Test for COVID-19|Point-of-care Rapid Antibody Test for COVID-19
214389343|NCT00874289|OTHER|NGAL kit|Kit to test NGAL levels in heart failure patients
214389344|NCT04392440|BEHAVIORAL|DIAL-SDM|Communication intervention for nephrologists and coaching intervention for patients.
214389345|NCT04392440|OTHER|usual care|regular nephrology care
214389346|NCT00179348|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214389347|NCT00179348|PROCEDURE|Yoga|Undergo a yoga-based rehabilitation program
214389348|NCT02111213|BEHAVIORAL|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
214389349|NCT02111213|BEHAVIORAL|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
214389350|NCT06477367|OTHER|Video-Based Breathing Exercises|Researchers will present a 5-7 minute instructional video aimed at helping participants recall the technique for performing the exercises. These instructional videos will be sent to the researchers' mobile phones via WhatsApp. Participants will be instructed to perform the exercises three times a day for 15 minutes each, for a period of 30 days. To encourage regular exercise, participants will be provided with an exercise diary, and researchers will send reminder SMS messages at the same time every day. The control group will receive the clinic's routine dyspnea care protocol. After thirty days, final tests will be administered to both groups, and the research will be concluded.
214389351|NCT03190863|BEHAVIORAL|Motor imagery combined with neurofeedback (MINF)|"7 individuals with C6-C7 tetraplegia randomize in the experimental group consisting in motor imagery practice combined with visual neurofeedback (NF - i.e. performance of the imagined movement).~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. After each imagined movement, the NF based on brain activity measured by electroencephalography is display on a screen."
214389352|NCT03190863|BEHAVIORAL|Motor imagery (MI)|"7 individuals with C6-C7 tetraplegia randomized in the active comparator group consisting in motor imagery practice alone without visual NF. This means that the performance of the imagined movement is not displayed to the participants.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
214389353|NCT03190863|BEHAVIORAL|Control (C)|"7 individuals with C6-C7 tetraplegia randomized in the sham comparator group consisting in imagining geometric shapes by visualization. Shapes are successively displayed on a screen.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
214389354|NCT05690061|DIETARY_SUPPLEMENT|Grain-Fed Beef Hamburger|Bowl of grain-fed beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
214389355|NCT05690061|DIETARY_SUPPLEMENT|Grass-Fed Beef Hamburger|Bowl of grass-fed, grass-finished beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
214389356|NCT05690061|DIETARY_SUPPLEMENT|Impossible BurgerTM|Bowl of plant-based Impossible burger cooked without seasonings. 250 grams of uncooked Impossible burger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
214389357|NCT02058420|DRUG|Low tocotrienols group|300 mg tocotrienols daily
214389358|NCT02058420|DRUG|High tocotrienols group|600 mg tocotrienols daily
214389359|NCT00002802|DRUG|carboplatin|
214389360|NCT00002802|DRUG|cisplatin|
214389361|NCT00002802|DRUG|cyclophosphamide|
214389362|NCT00002802|DRUG|dacarbazine|
214389363|NCT00002802|DRUG|doxorubicin hydrochloride|
214389364|NCT00002802|DRUG|etoposide|
214389365|NCT00002802|DRUG|ifosfamide|
214389366|NCT00002802|DRUG|melphalan|
214389367|NCT00002802|DRUG|mesna|
214389368|NCT00002802|DRUG|vincristine sulfate|
214389369|NCT00002802|DRUG|vindesine|
214389370|NCT00002802|PROCEDURE|autologous bone marrow transplantation|
214389371|NCT00002802|PROCEDURE|conventional surgery|
214389372|NCT00002802|RADIATION|low-LET cobalt-60 gamma ray therapy|
214389373|NCT00002802|RADIATION|low-LET electron therapy|
214389374|NCT00002802|RADIATION|low-LET photon therapy|
214389375|NCT00002802|RADIATION|radioisotope therapy|
214389376|NCT04815486|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS in 10 daily sessions in two weeks of sequential application of: 90% RMT at 1Hz, 1000 pulses/day, 25s inter train on M1 of lesioned hemisphere and 90% RMT at 10Hz, 1000 pulses/day, 50s inter train on M1 of healthy hemisphere.
214389377|NCT04815486|DEVICE|Motor Imagery (MI) through a Brain-Computer Interface (BCI) training platform in Virtual Reality (VR) with NeuRow|It will consist of a combination of the bilateral rTMS protocol and the MI-neurofeedback training. During this therapy, the patient received 10 consecutive daily sessions of bilateral rTMS (Monday to Friday, two weeks), with the same stimulation parameters as another therapy, and 12 non-consecutive sessions of MI-neurofeedback (three times a week for four weeks). The first 6 MI-neurofeedback sessions were carried out after bilateral stimulation with rTMS (i.e., rTMS as a priming method during the first two weeks), and the last 6 sessions, without rTMS as prior priming during the last two weeks.
214389378|NCT02220335|PROCEDURE|Pulmonary arterial denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
214389379|NCT02220335|DRUG|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
214389380|NCT04503538|OTHER|Telemedicine visit|Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit.
214389381|NCT00759772|DRUG|Placebo|sc daily for 6 months
214389382|NCT00759772|DRUG|Teriparatide|20 mcg sc daily for 6 months
214389383|NCT04241575|DIAGNOSTIC_TEST|Simple fibrosis scores and electronic reminder messages|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
214389384|NCT06229184|DIAGNOSTIC_TEST|Fecal Calprotectin Test|Fecal samples are taken fom obese and healthy adolescents for study
214389385|NCT01568827|DIETARY_SUPPLEMENT|Blackraspberry Slurry|Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
214389386|NCT02265029|OTHER|Immediate spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
214389387|NCT02265029|OTHER|Late spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
214389388|NCT05351138|DEVICE|TENS|In the study, CE certified tens device with Biolito brand, which is used specifically for incontinence treatment, will be used. The electrodes used during the intervention will be placed to the parasacral region (S2-S4). While the current is given, the power of the device will be gradually increased in 1 mA intervals. The lower value of the stimulation will be 10 mA and the upper value will be 25 mA, and the treatment will be continued with any value that the child can tolerate in this range.
214389389|NCT05351138|OTHER|Massage|The massage will be applied to the abdominal area between the subcostal lower border and the anterior superior of the spina iliaca. Massage techniques are as follows: Abdominal patting, colon patting, colon kneading, colon patting again, abdominal patting again. It will be advanced with deep abdominal strokes, then the starting point will be returned with transverse superficial strokes for the transversus abdominis muscle and oblique superficial strokes for the rectus abdominis muscle, and these strokes will be repeated 3 times each, a total of 6 times. Afterwards, 3 times column brushing, 3 times column kneading and 3 times column plastering will be done, respectively. At the end, a total of 6 abdominal strokes will be performed for both the transversus abdominis and oblique abdominal muscles as in the beginning.
214389390|NCT00213330|PROCEDURE|rectal distension|
214389391|NCT02978313|DRUG|Cetuximab|anti-EGFR monoclonal antibody
214389392|NCT02978313|DRUG|mFOLFOX6|Oxaliplatin+LV5FU2
214389393|NCT02978313|DRUG|FOLFIRI|Irinotecan+LV5FU2
214389394|NCT00002474|DRUG|carboplatin|
214389395|NCT00002474|DRUG|cyclophosphamide|
214389396|NCT00002474|DRUG|mitoxantrone hydrochloride|
214389397|NCT00002474|PROCEDURE|autologous bone marrow transplantation|
214389398|NCT00002474|PROCEDURE|bone marrow ablation with stem cell support|
214389399|NCT03306407|OTHER|Improved hand hygiene|The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
214389400|NCT03782896|OTHER|acute postoperative pain|All patients assessed postoperative pain score in the recovery room and postoperative 2 month
214389401|NCT02226172|DRUG|Glasdegib (PF-04449913)|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
214389402|NCT02226172|DRUG|Placebo|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
214389403|NCT01865617|BIOLOGICAL|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
214389404|NCT04724720|DRUG|Famotidine|Standard or care treatment plus prescribed famotidine
214389405|NCT04724720|DRUG|Placebo|Standard of care treatment plus placebo
214389406|NCT02161601|PROCEDURE|Cricoid Pressure|Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
214389407|NCT03646227|OTHER|Standard of Care|There is no prescribed intervention for this study. Standard of care will be captured in the eCRF.
214389408|NCT03851874|PROCEDURE|Bariatric surgery|Bariatric surgery
214389409|NCT00000700|DRUG|Zidovudine|
214389410|NCT05445024|PROCEDURE|nalbuphine group|nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
214389411|NCT05445024|PROCEDURE|sufentanil group|sufentanil (1/1000\* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
214389412|NCT05468125|PROCEDURE|guidance|either follow the care bundle or the best evidence practice
214389413|NCT00380341|PROCEDURE|Instrument-applied spinal manipulative therapy|
214501163|NCT06883149|BIOLOGICAL|PIN +anti-PD1|"1. Initial treatment phase:~   PIN injection frequency: day0 and day 3, per 3 weeks for 8 cycles;~   PIN injection dosage:~   Cycle1: 4e9 or 8e9 viral particles of PIN based on the number of injectable lesions, their longest diameter, and the tumor volume capacity .~   Cycle 2\~8: 4e9 or 8e9 viral particles of PIN based on the tumor volume's capacity.~   Anti-PD1: day -3, per 3 weeks for 8 cycles;~2. Maintenance treatment phase:~   No injection lesion: Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~   Have injection lesion:~   PIN: 4e9 or 8e9 viral particles based on the tumor volume's capacity, per 6 weeks (within first 24 weeks), then per 8 weeks till 2 years unless unavailability of injection lesion, PD or serious intolerable AEs.~   Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~3. Salvage treatment phase:~Dosage and frequency of administration refer to the initial treatment phase and maintenance treatment phase."
214998487|NCT06751784|DRUG|Fampridine SR|Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.
214501164|NCT05667805|DRUG|Platelet Concentrate|Liberal use (standard treatment)
214501165|NCT05667805|DRUG|Prothrombin Complex Concentrate|Liberal use (standard treatment)
214998488|NCT06751784|OTHER|Placebo|no active substance
214389414|NCT04548531|BEHAVIORAL|Shared Decision Making|"The decision aid is a paper information sheet presenting the pros and cons of three screening options (colonoscopy, stool-based tests, and postponing cancer screening until next year).~The decision coaching is a structured interview to help patients clarify their preference for screening test and to support them in implementation (whether scheduling colonoscopy, ordering stool test or seeking additional advice from specialist)."
214501166|NCT05667805|OTHER|Restricitve Use|Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
214501167|NCT06742047|BEHAVIORAL|Professional development programme|The professional development programme include dialogue groups facilitated by registered nurses (RN) who are expert and experienced supervisors that received a three day training before conducting the groups. Then including education days with joint lectures and simulations with experts in the field with experience. The programme provides NGNs with regular opportunities for reflection for learning from experiences of care to enhance personal and professional growth.
214501168|NCT05373017|OTHER|DANE Recovery Program|Virtual visits with care coordinator to carry out an individualized recovery plan
214501169|NCT05373017|OTHER|Questionnaires|Physical, cognitive, and psychological assessments
214501170|NCT04601428|BIOLOGICAL|IA therapy of HCC with CSR02-Fab-TF|Intra-Arterial Infusion of CSR02-Fab-TF
214501171|NCT05886530|OTHER|No intervention|Observational data collection only.
214501172|NCT06910020|OTHER|Active Cycle of Breathing Technique|"* Patients will assume the sitting position and relax their shoulders, then perform the following:~  1. Breathing control (abdominal breathing)~ 2. Chest expansion (thoracic breathing)~ 3. Huff cough (forced expiratory technique)~* After completing the above actions, patients will be asked to cough up the residual deep sputum to promote pulmonary expansion.~* The ACBT intervention will be performed for three days, each day two sessions, each session three courses, with 10 minutes of rest between them as needed."
214998489|NCT07084350|DRUG|lactulose|"1. Two days before the colonoscopy: The patients should respectively take 30mL of lactulose orally on an empty stomach in the morning and at 8:00 PM of the same day, respectively.~2. One Day Before the Colonoscopy: The patients should take 30mL of lactulose orally at 7:00 PM.~3. On the Day of the Colonoscopy:~For Morning Appointments:The patients should take 30mL of lactulose orally at 2:00 AM.~For Afternoon Appointments:The patients should take 30mL of lactulose orally at 7:00 AM."
214998490|NCT07084350|DRUG|PEG (solution given 4 L)|"1. One Day Before the Colonoscopy: The patients should take 2000mL of PEG solution at 8:00 PM, and drink the entire solution within 2 hours.~2. On the Day of the Colonoscopy:~For Morning Appointments: The patients should take 2000mL of PEG solution at 3:00 AM and drink the entire solution within 2 hours.~For Afternoon Appointments: The patients should take 2000mL of PEG solution at 7:00 AM and drink the entire solution within 2 hours."
214998491|NCT07083232|DIETARY_SUPPLEMENT|standard normal diet|Group I: formed of normal animals. They were allowed standard normal diet and water. They received no drugs
214998492|NCT07083232|DRUG|low dose Streptozotocin|Non-treated diabetic rats; diabetes was induced by administration of 20% fructose solution in drinking water for 2 weeks, then intra peritoneal injection of a low dose STZ (40 mg/kg b.w.), was done
214998493|NCT07083232|DRUG|Sitagliptin (Novartis, USA)|Sitagliptin treated diabetic group sitagliptin was administered by gastric gavage in a dose 10mg/ kg /day for 4 weeks
214389415|NCT05445596|BEHAVIORAL|Functional communication training|Functional communication training (FCT) is a behavioral approach to treating problem behavior. During FCT, children learn to use communication to access reinforcers, instead of using problem behavior.
214389416|NCT01466764|DRUG|Anakinra|An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
214389417|NCT01466764|OTHER|Normal Saline|An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
214389418|NCT05366049|OTHER|using a medicine pacifier to give acetaminophen|While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
214501173|NCT06730386|DRUG|AK138D1|Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.
214501174|NCT06770764|DRUG|ODC-IL2|ODC-IL2 as a single agent infused IV over 60 minutes on Days 1 and 15 of a 28 day cycle.
214501175|NCT06509191|DRUG|Intervention 1|Melatonin 5mg/day
214501176|NCT06509191|DRUG|Intervention 2|Melatonin 8 mg/day
214501177|NCT06509191|OTHER|Control|Placebo
214501178|NCT06776952|DRUG|XNW5004 ; Chidamide placebo|XNW5004 + Chidamide placebo
214501179|NCT06776952|DRUG|XNW5004 placebo; Chidamide|XNW5004 placebo + Chidamide
214501180|NCT06758219|OTHER|There is no intervention in the study.|There is no intervention in the study.
214501181|NCT06779578|PROCEDURE|Bipolar pulsed radiofrequency|Bipolar pulsed radiofrequency ablation: the active comparator
214998494|NCT07083232|DRUG|Pioglitazone hydrochloride (Unipharma., Egypt)|Pioglitazone treated diabetic group (G4); Pioglitazone was administered by gastric gavage in a dose 10 mg/ kg /day for 4 weeks
214389419|NCT05693467|DRUG|Dexamethasone palmitate emulsion(DXP) plus ropivacaine|The local infiltration solution in the dexamethasone palmitate emulsion(DXP) plus ropivacaine group will consist of ropivacaine and dexamethasone palmitate emulsion(DXP). For local infiltration, a total of 30mL solution will be prepared for each group, which will include 2mL of DXP(4mg per 1mL) added to 20.5 mL of saline and 7.5mL of 1% ropivacaine added to 15mL of saline for Group A . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
214389420|NCT05693467|DRUG|Ropivacaine alone|The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone. For local infiltration, a total of 30mL solution will be prepared for each group, which will include 7.5mL of ropivacaine added to 22.5mL of saline for Group B . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
214389421|NCT05036889|DIAGNOSTIC_TEST|Mind.Px Report|Use of Mind.Px report as a reference for potential better matching of biologics to patients.
214501182|NCT06779578|PROCEDURE|Mopolar pulsed radiofrequency|Monopolar pulsed radiofrequency ablation: the placebo
214501183|NCT03024866|PROCEDURE|Electronic Brachytherapy|A group receives High-dose-rate electronic brachytherapy (EBT) which provides a non-surgical treatment option and the other group receives Mohs surgery. This matched-pair cohort study compared the outcomes of treatment with EBT to those of Mohs surgery in patients with NMSC.
214501184|NCT04932577|BIOLOGICAL|Faecal microbiota transplantation|All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
214501185|NCT04932577|BIOLOGICAL|Placebo|Placebo
214501186|NCT06347432|OTHER|Power wheelchair skills training using the IndieTrainer system|The IndieTrainer system will be used to provide the power wheelchair (PWC) skills training sessions. The IndieTrainer is comprised of a mobility device and an array of video-based gamified training modules designed to facilitate PWC training. The IndieTrainer mobility device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. Principles outlined in the Assessment of Learning Powered mobility use (ALP) Facilitating Strategies for each ALP Assessment phase will guide the intervention sessions.
214389422|NCT04746274|BEHAVIORAL|Online large-group one-session multicomponent positive psychological intervention|The intervention is aimed at enhancing positive mental health by using components from positive psychology or positive psychotherapy. These include for exapmle using character strengths, savoring the moment, goal setting and goal attainment. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
214998495|NCT07083232|DRUG|Dapagliflozine hemihydrate (Janssen, USA)|Dapagliflozine treated diabetic group (G5); Dapagliflozine was administered by gastric gavage in a dose 1mg/ kg /day for 4 weeks
214998496|NCT07121439|DRUG|a combination serum containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES|Subjects were randomized to receive a combination serum The combination serum contained Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES. applied twice daily, following QS-Nd:YAG 1064 nm low-fluence laser treatment. Clinical evaluations were conducted at baseline and at Weeks 1, 2, and 4 post-laser to assess pigmentation improvement, erythema, and overall skin condition.
214998497|NCT07121439|DRUG|2% hydroquinone cream|Subjects were randomized to received 2% hydroquinone cream, applied once daily at night, following QS-Nd:YAG 1064 nm low-fluence laser treatment. Clinical evaluations were conducted at baseline and at Weeks 1, 2, and 4 post-laser to assess pigmentation improvement, erythema, and overall skin condition.
214998498|NCT07120464|OTHER|Observation Only|All participants will receive post-exposure rabies vaccination using either the Zagreb or Essen regimen, in accordance with national immunization guidelines.
214998499|NCT07121335|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).
214389423|NCT04746274|BEHAVIORAL|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|The intervention is aimed at reducing dysfunctional thoughts by applying strategies known from the cognitive therapy of depression. These include for example identification of automatic thoughts and cognitive biases as well as evaluating evidence for and against automatic thoughts. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
214389424|NCT06012565|DRUG|KAND567|2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).
214501187|NCT04651010|OTHER|Multimodal MRI|Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
214501188|NCT06355310|DRUG|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
214501189|NCT06355310|DRUG|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
214501190|NCT05487820|DEVICE|IscAlert|Insertion of a CO2- and temperature sensor(s) in the reconstructed flap.
214501191|NCT06215144|DRUG|NRCT-101SR|NRCT-101SR is a sustained release formulation.
214501192|NCT06054854|BIOLOGICAL|Extra blood sampling, Non-invasive or leftover samples or medical waste|"Extra blood sampling, Urine, Saliva, Stool, Superficial nasal swamp sampling. Bronchoalveolar lavage fluid, Mediastinal node or mass, Peripheral nodule aspiration supernatant, Pleural fluid, Cerebrospinal fluid collection (leftover samples or medical waste).~Blood will be collected in larger quantity during a blood test planned as part of the patient's care.~Non-invasive or leftover samples or medical waste will be collected on top of the usual diagnosis and during follow-up, depending on the case."
214501193|NCT05695027|DRUG|Dietary supplements - Nicotinamide and Pyruvate|Nutritional supplements
214389425|NCT06012565|DRUG|Microcrystalline cellulose|Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).
214389426|NCT03225521|BEHAVIORAL|HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.|HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
214389427|NCT00432575|DRUG|surinabant (SR147778)|oral administration
214389428|NCT00432575|DRUG|placebo|oral administration
214389429|NCT01621958|BEHAVIORAL|Repeated perturbation training|One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
214389430|NCT01621958|BEHAVIORAL|Minimal perturbation training|One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
214389431|NCT04879498|DRUG|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia fixed partial dentures
214501194|NCT05695027|DRUG|Placebo|Placebo
214501195|NCT06828276|BEHAVIORAL|Culturally adapted i-CBT|A culturally and language adapted i-CBT intervention for Farsi/Dari speaking youth migrants and refugees. The intervention targets mild to moderate common mental health problems.
214501196|NCT04230395|BEHAVIORAL|HATHI Intervention|4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.
214501197|NCT04230395|OTHER|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
214501198|NCT06628674|BEHAVIORAL|core muscle exercise|Patients in experiment group will do core muscle exercise with online interactive videos
214501199|NCT06628674|BEHAVIORAL|pelvic muscle exercise|Patients in experiment group will do pelvic muscle exercise without online interactive videos
214501200|NCT06828731|DRUG|Empagliflozin 10mg daily|This intervention will assess recruitment and retention (feasibility trial).
214501201|NCT06828731|OTHER|Lifestyle education|This intervention is considered standard care for prediabetes.
214501202|NCT06381622|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)
214389432|NCT04879498|OTHER|Veneered zirconia|To assess the clinical performance and survival of posterior veneered zirconia fixed partial dentures
214501203|NCT06381622|DRUG|Lidocaine epinephrine|20 mL Ropivacaine 5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg) / ml (= 100 mg Ropivacaine + 200 mg Lidocaine)
214501204|NCT06381622|DRUG|Ropivacaine 0.75% Injectable Solution|20 mL Ropivacaine 7,5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg)/mL (= 150 mg Ropivacaine + 200 mg Lidocaine)
214501205|NCT06784830|OTHER|Effects on Image Quality and Patient Satisfaction|Effect of nursing intervention on image quality and patient satisfaction during PET/CT imaging in Alzheimer's patients
214501206|NCT06784830|OTHER|Anxiety degree of patients after nursing|Self Rating Anxiety will be used Scale (SAS) to assess the degree of anxiety after care
214501207|NCT06098040|DEVICE|flash glucose monitoring continuous|Group 2 (FGM continuous): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion continuously for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
214998500|NCT07119658|BEHAVIORAL|Composite intervention to address MetS|"The composite intervention includes six components: 1. All patients will be provided a Fitbit Charge device at ED discharge with instructions to wear on their wrist for study duration. 2. Participants in the intervention group will first watch a brief (\~5 minute) educational video outlining the adverse effects of MetS and the benefit of walking, via iPad tablet. 3. Participants in the intervention group will also be given accompanying written exercise prescription encouraging them to walk 150 minutes per week. 4. Reminder texts encouraging continued walking behavior (i.e. Remember to get in your steps!) will be sent to the intervention group, at approximate 2-3x/week intervals for the 3-month follow-up period. 5. The intervention group will also be provided written resources for healthy eating practices upon ED discharge. 6. All intervention group participants will receive referrals into primary care clinic and the Eskenazi Health Healthy Me Program for follow-up."
214501208|NCT06098040|DIAGNOSTIC_TEST|capillary blood test|Group 1 (SMBG): will be asked to test capillary blood glucose as recommended by subjects' usual provider for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
214501209|NCT06098040|DEVICE|flash glucose monitoring intermittent|Group 3 (FGM intermittent): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion 1 week off/2 weeks on for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
214389433|NCT04879498|OTHER|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic fixed partial dentures
214389434|NCT06362343|DRUG|Rivaroxaban|Rivaroxaban
214389435|NCT04065282|DRUG|Sintilimab|3 cycles before radical surgery
214389436|NCT04065282|DRUG|Oxaliplatin|85mg/m2 Q3W, 3 cycles perioperation
214389437|NCT04065282|DRUG|Capecitabine|1000mg/m2 bid po D1\~14 Q3W, 3 cycles perioperation
214501210|NCT04800367|DRUG|Romosozumab Prefilled Syringe [Evenity]|2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit
214501211|NCT04800367|DRUG|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|1 subcutaneous injection of 60 mg/mL every six months from study 12 month visit through the 24 month visit. Injections occur at the 12 and 18 month visits.
214501212|NCT06827847|PROCEDURE|Traditional polychromatic layering dental composite technique|patient received composite restoration done by layering technique
214501213|NCT06827847|PROCEDURE|Contemporary monochromatic single shade dental composite technique|patient received composite restoration done by single shade composite
214389438|NCT00258440|DRUG|Weekly procrit dosing|The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
214998501|NCT07120022|OTHER|Self-efficacy training|The primary goal of this study is to determine whether self-efficacy training can increase the probability of taking cold showers regularly over a three-month period.
214998502|NCT07119996|DRUG|Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3|"1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W.~4. Vitamin B3 tablet(also known as nicotinic acid tablet) supplementation daily(300mg QD or 500mg QD) after antibiotic treatment."
214998503|NCT07115134|DEVICE|Bearables Gastrostomy Tube Dressing|"The gastrostomy tube dressing in its current design is composed of two parts, both of which are external to the patient: one part is rigid and holds the gastrostomy at a fixed position, this is a 3D printed design that is produced here. The second part is a 3 x 3 flexible, cushioned, biocompatible adhesive bandage designed to fit around the skin opening (Silicone Foam Dressing, NH NeuHeils, USA). The design is subject to minor changes including the number of parts and location with the structure of the padding and securement but will continue to be designed with comfort as a priority. After assembly, the device is packaged (sterilization pouches, Plastcareusa, USA), sealed, and sanitized using UV light prior to patient use."
214389439|NCT00258440|DRUG|Interval Dosing|The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
214389440|NCT04676711|DRUG|GFH312|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
214389441|NCT04676711|DRUG|Placebo|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
214389442|NCT01713790|DEVICE|Stochastic resonance whole-body vibration|Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.
214389443|NCT01713790|DEVICE|Exergame|training program over 10 weeks, three times a week.
214501214|NCT06831747|PROCEDURE|Bilateral salpingo-oophorectomy - S-LPS|In standard laparoscopy (S-LPS), the initial laparoscopic access was performed at the umbilical level using open laparoscopy (Hasson technique). The subsequent accesses were carried out in the right and left iliac fossa. In the S-LPS, these accesses are performed using a 5mm trocars. Finally, a 5mm ancillary trocar was placed in the suprapubic region to use instruments such as bipolar forceps, irrigators, and scissors. The subsequent surgical steps were identical for both techniques.
214998504|NCT06511297|DIAGNOSTIC_TEST|comprehensive metabolic phenotyping|The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
214998505|NCT07081516|PROCEDURE|temperature|Adjusting the temperature of the local anesthetic drugs injected intrathecally
214998506|NCT07087015|PROCEDURE|Cervical sympathetic nerve block|Patients will receive a CSB.
214998507|NCT07087015|PROCEDURE|Subcutaneous sham injection|Patients will receive a subcutaneous sham injection of saline.
214998508|NCT07087015|DRUG|Ropivacaine|The CSB group will receive ropivacaine 0.5% 10ml.
214998509|NCT07087015|DRUG|Normal Saline|The control group will receive 3 ml of normal saline in the sham injection.
214389444|NCT01713790|DEVICE|Leg press|training program over 10 weeks, three times a week.
214389445|NCT00737061|DEVICE|Adiana Transcervical Sterilization System|Implantation of silicone matrix in fallopian tubes
214389446|NCT04205175|DRUG|Feiba|This is a single center, open label, dose escalation study of in vivo administration of Feiba in congenital hemophilia A patients with inhibitors who are on emicizumab.
214389447|NCT01804543|DRUG|Ranolazine|ranolazine 500 mg, then 1000 mg twice a day
214389448|NCT02397486|DRUG|Pentoxifylline|
214389449|NCT02397486|DRUG|Vitamin E|
214389450|NCT02397486|DRUG|Cisplatin|
214389451|NCT02397486|RADIATION|Radiation therapy|
214389452|NCT01347853|DRUG|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
214389453|NCT01347853|DRUG|Placebo|Intranasal post-surgery for up to 5 days total
214393998|NCT06092541|DRUG|Intervention Group: pericervical anesthesia|"Patients assigned to the Intervention Group will receive Pericervical anesthesia before performing Hysteroscopy.~Specifically, for the administration of pericervical analgesia, Mepivacaine/Lidocaine 1.5% 10/15 ml (max dose 7 mg/kg) will be used and pericervical infiltration will be performed at 0.5 cm depth at 3 and 9 hours."
214393999|NCT06092541|OTHER|Nitroux Oxide anesthesia|Patients assigned to the Control Group will receive Nitrous Oxide anesthesia before hysteroscopy
214394000|NCT03766893|DRUG|Buprenorphine / Naloxone Oral Product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly (buprenorphine/naloxone) basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
214394001|NCT03766893|DRUG|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
214394002|NCT03766893|OTHER|Pharmacy maintenance addiction care|Patients on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for one month. Patients will visit weekly for check-ins with a pharmacist. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it once by the pharmacist during the pilot. All patients will visit the pharmacy at least weekly for addiction care (assessment, toxicological testing).
214394003|NCT03044262|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid) that is part of an ostomy device
214394004|NCT03044262|OTHER|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
214998510|NCT06930872|DRUG|Part 1|ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)
214998511|NCT06930872|DRUG|Part 2|ZYN002 (transdermal), VPA (oral)
214998512|NCT05448365|DIETARY_SUPPLEMENT|Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol|The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D
214389457|NCT04039178|DEVICE|BQ|The BQ device (BrainQ Technologies Ltd., Israel), a Brain Computer Interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in EEG measurements of healthy/non healthy subjects. These patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.
214389458|NCT04039178|DEVICE|Sham|Sham BQ device
214389459|NCT00115219|DRUG|Etanercept|
214389460|NCT03748238|PROCEDURE|Endometrial Injury with Hysteroscopy|All office hysteroscopy procedures will be done transvaginally under sedation with a 5 mm 30 degree lens supplied with a 5 F working channel continuous flow office hysteroscope (Bettocchi office hysteroscope, Karl Storz, Tuttlingen, Germany) without speculum or tenaculum. Briefly, following cervical passage and initial endometrial cavity investigation endometrial injury will be performed without energy modality (i.e. with scissors). Endometrial injury will perform first on the fundus by cutting into the endometrium (without injuring the myometrium) transversally. Later, vertical incisions will perform 0,5 cm apart each other, on the anterior and posterior walls of the uterus, 1-1.5 cm away from the fundus and one cut for each lateral wall
214389461|NCT06400680|DEVICE|Spine Kinematic Assessment with Optoelectronic system|"All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 100 Hz.~The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of spinous and transversal processes, by manual identification.~During the data acquisition protocol, the subject perform five trial of walking barefoot on a 6 m distance at a self-selected normal-pace speed.~Every subject repeated this operations 2 times with 2 different operators."
214389462|NCT01474447|BEHAVIORAL|Grinberg Method|The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
214501215|NCT06831747|PROCEDURE|Bilateral salpingo-oophorectomy - PSS|In the MiniLap® Percutaneous Surgical System (PSS), the initial laparoscopic access was performed at the umbilical level using open laparoscopy (Hasson technique). The subsequent two accesses were carried out in the right and left iliac fossa. These latter accesses are directly performed using MiniLap® with a 2.4mm incision. Finally, a 5mm ancillary trocar was placed in the suprapubic region to use instruments such as bipolar forceps, irrigators, and scissors. The subsequent surgical steps were identical for both techniques.
214501216|NCT05598398|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|"The V.A.C.Ulta™ Negative Pressure Wound Therapy System is a 510(k) - cleared, Class II device (K100657) with the following indication for use: the V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option."
214501217|NCT05598398|OTHER|Standard of Care (Wet-to-dry dressings)|Wet-to-dry dressings
214501218|NCT03922256|OTHER|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
214389463|NCT00636584|DRUG|sodium nitroprusside|sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations
214389464|NCT00636584|DRUG|placebo|placebo
214501219|NCT05606341|DRUG|CpG1018|"0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
214998513|NCT05448365|DIETARY_SUPPLEMENT|Placebo|Maltodextrines
214998514|NCT06879574|OTHER|Measuring dietary intake|During 5-week study, participants will monitor their usual dietary intake during two 3-day periods (on weeks 1 and 5). During week 3 (calibration week) participants will consume a test diet. Wearable camera technology, self-collected blood and urine samples, and online FFQ (eNutri) will be used to monitor food intake during study weeks. Study tools as well as foods/drinks for the test diet will be delivered to each participant and they will be asked to comply with the study procedures in their home or working environment. Participants will post study samples and the study equipment/logs at designated times using pre-paid envelopes or a courier collection, respectively.
214998515|NCT00453505|DEVICE|TMS|\<=1 Hz TMS for up to 30mins and up to 115% of resting motor threshold intensity (MT).
214998516|NCT00453505|DEVICE|tDCS|tDCS up to 2 mA for up to 60mins.
214998517|NCT00453505|DEVICE|tACS|tACS up to 1 mA for up to 10 minutes.
214998518|NCT00453505|DEVICE|CPNS|CPNS alone with intensities below 130% of the peripherally-elicited-motor-threshold for up to 2 hours.
215094018|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy without suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access.
214389465|NCT00075569|BIOLOGICAL|HspE7|500 micrograms of SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7.
214389466|NCT05929365|PROCEDURE|colonoscopy|determine the mutation profile of resected colorectal neoplasia
214389467|NCT00439179|DRUG|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
214389468|NCT00439179|DRUG|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
214389469|NCT00439179|DRUG|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
214998519|NCT07087795|DRUG|NNC0194-0499|Participants will receive subcutaneous NNC0194-0499 once weekly.
214389470|NCT00439179|DRUG|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
214389471|NCT05908890|DEVICE|Experimental Denture Adhesive|Adhesive will be applied to the partial denture(s) by a dental professional separate from the examiner and subject.
214389472|NCT05908890|DEVICE|Fixodent True Feel Denture Adhesive|Adhesive will be applied to the partial denture(s) by a dental professional separate from the examiner and subject.
214389473|NCT00088179|DRUG|pexelizumab in conjunction with CABG|
214389474|NCT03855410|BEHAVIORAL|S4E|The face-to-face version of S4E (i.e., Storytelling for Empowerment) is registered as a best-practice with the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-Based Practices and Programs.The S4E mHealth app was developed in collaboration with youth in Southeast Michigan. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol and drug use, HIV and STIs. We now propose to develop modules focused on tobacco prevention and cessation. S4E aims to increase self-efficacy and communication about health risk behaviors. The face-to-face version of S4E has been shown to prevent and reduce substance use, including cigarette use, as well as increase (1) substance use prevention knowledge, (2) communication about health risk behaviors, and (3) perception of harm and self-efficacy in refusing licit and illicit substances.
214389475|NCT03855410|BEHAVIORAL|Attention-Matched Control Group|Participants in the Attention-Matched Control group will receive a PDF version of the tobacco module material, an enhancement to the usual care they would receive should they not join the study. Participants in this group will also receive usual care. The Clinic's usual care includes standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services.
214389476|NCT04570345|DRUG|ticagrelor monotherapy|• Drug: ticagrelor monothearpy after first 3 months dual therapy
214389477|NCT04570345|DRUG|Aspirin with P2Y12 receptor inhibitor|• Drug: aspirin plus ticagrelor dual therapy during 12 months
214389478|NCT05761145|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection
214389479|NCT03999905|BEHAVIORAL|Counseling training|Online training using Moodle.
214389480|NCT03395834|DEVICE|O3|O3 TM and INVOS® monitoring simultaneously in single patient during 3 min of vascular occlusion test
214389481|NCT01844115|DRUG|Placebo|
214389482|NCT01844115|DRUG|Vilazodone|Viibryd
214389483|NCT03191929|OTHER|HIT Intervention|"Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.~Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD."
214389484|NCT03191929|OTHER|Minimal Intervention Control Arm|"Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.~Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website."
214389485|NCT01072123|OTHER|Quest for the Code|interactive asthma-based computer program
214389486|NCT00758160|DRUG|OROS Methylphenidate|Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
214389487|NCT01873547|BIOLOGICAL|cell therapy|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
214389488|NCT01873547|OTHER|rehabilitation|Patients only receive rehabilitation of limb function.
214389489|NCT00715663|DRUG|biphasic insulin aspart 30|No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
214998520|NCT07087795|DRUG|Placebo|Participants will receive placebo matched to NNC0194-0499 subcutaneously.
214998521|NCT07087795|DRUG|Semaglutide|Participants will receive subcutaneous semaglutide once weekly.
214998522|NCT06043427|DRUG|Paclitaxel|80 mg/m²
214998523|NCT06043427|DRUG|Ramucirumab|8 mg/kg
214998524|NCT06043427|DRUG|Zanidatamab|Dose and schedule to be assigned at enrollment
214998525|NCT06420219|OTHER|Non-Interventional Study|Non-interventional study
214998526|NCT06821321|BEHAVIORAL|Plyometric Training|Participants will receive a total of twenty-four 45-minutes in-person resistance-training sessions, twice per week, using three sets of eight repetitions per set on five upper body exercises. During resistance-training participants will be allowed 1-minute rests between sets. Participants will also perform two jump training exercises on a horizontal Pilates reformer, the leg plyometric and ankle plantar plyometric jumps.
214998527|NCT06821321|BEHAVIORAL|Power Training|Participants will receive a total of twenty-four 45-minutes in-person training sessions, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include five upper-body exercises and two lower-body exercises.
214389490|NCT05686915|DIAGNOSTIC_TEST|MARS MRI|metal artifact reduction sequence (MARS) MRI to assess for fluid collections, ATLRs or other abnormalities
214389491|NCT05686915|DIAGNOSTIC_TEST|Titanium Labs|Labs to look at titanium levels in blood
214389492|NCT05686915|DIAGNOSTIC_TEST|Cobalt Labs|Labs to look at cobalt levels in blood
214389493|NCT05686915|DIAGNOSTIC_TEST|Chromium Labs|Labs to look at chromium levels in blood
214389494|NCT01982396|DRUG|ABC Twice Daily|
214389495|NCT01982396|DRUG|ABC Once Daily|
214389496|NCT01982396|DRUG|3TC Once Daily|
214389497|NCT01982396|DRUG|3TC Twice Daily|
214389498|NCT00038441|DRUG|DTI-015|DTI-015 injected through a catheter into center of brain tumor.
214389499|NCT05100719|DRUG|alverine-citrate + simethicone and lactase|Patients who randomized in the first arm are treated with alverine-citrate + simethicone and lactase.
214501220|NCT05606341|DRUG|CpG1018|"0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
214501221|NCT05606341|DRUG|CpG1018|"0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
214501222|NCT05606341|DRUG|Placebo|Sterile saline injection supplied by the NYU Investigational Pharmacy.
214501223|NCT06506422|DRUG|Empagliflozin 10 MG|10mg Empagliflozin daily for 12 weeks
214501224|NCT06506422|DRUG|Placebo|10mg Placebo daily for 12 weeks
214501225|NCT06034353|BEHAVIORAL|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
214998528|NCT06461143|DRUG|%4 articaine with 1:200 000 adrenaline|For intraosseous anesthesia SleeperOne5 device is going to be used.
214389500|NCT05100719|DRUG|alverin-citrate + simethicone with placebo|Patients in the second arm receive alverin-citrate + simethicone with placebo without lactase.
214389501|NCT02220504|OTHER|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients.
214389502|NCT02220504|OTHER|Maintenance antipsychotic treatment|Maintenance antipsychotic medication to stabilized patients.
214389503|NCT05912114|DRUG|Mannitol|Mannitol, as an osmotic laxative, increases the colloid osmotic pressure in the intestinal lumen, which results in a hyperosmolar state in the intestine, thus allowing easy elimination of stools.
214389504|NCT05912114|DRUG|Polyethylene glycol electrolyte|Polyethylene glycol electrolyte is an inert polymer that cannot be absorbed by the body itself. Due to its high permeability, it retains water in the intestinal tract, increasing the amount of fluid retained in the intestine and softening the stool, thus acting as a diuretic.
214389505|NCT02084719|DEVICE|Oraquick HCV Rapid Antibody Test|
214389506|NCT02084719|DEVICE|Standard algorithm|
214389507|NCT03305224|DRUG|Ra-223 in combination with enzalutamide|Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
214501226|NCT06916637|RADIATION|18F-HER2 Affibody PET scan|HER2 Affibody, labeled with PET radio-nuclide 18F will be used as a molecular imaging tracer for PET scan. All participants will undergo 18F-HER2 Affibody PET scan.
214389508|NCT00993317|DRUG|Placebo of CDP870|Given every 2 weeks until Week22 (SC)
214389509|NCT00993317|DRUG|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
214389510|NCT00993317|DRUG|Methotrexate|"Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly."
214389511|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 100|
214389512|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 300|
214389513|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 1000|
214389514|NCT02712593|OTHER|Placebo|
214389515|NCT05774405|DRUG|Climara 0.1Mg/24Hr Transdermal System|Transdermal estradiol patch is used.
214389516|NCT05774405|OTHER|Hydrogel patch|Adhesive Hydrogel patch
214389517|NCT00002215|DRUG|Emivirine|
214389518|NCT00002215|DRUG|Nelfinavir mesylate|
214389519|NCT02691351|OTHER|Prospective Registry|"Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~1. Regimen~2. Response Evaluation~3. SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection"
214501227|NCT05819619|DRUG|Prophylactic use of ibuprofen and ondansetron post misoprostol administration|Prophylactic use of ibuprofen and ondansetron post misoprostol administration
214501228|NCT05819619|DRUG|Use of ibuprofen and ondansetron at symptom onset post misoprostol administration|Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
214501229|NCT03804372|DRUG|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
214501230|NCT03804372|DRUG|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
214501231|NCT03804372|DRUG|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
214501232|NCT06892769|OTHER|telehealth counseling|Patients in the intervention group will be called every week (for 4 weeks) and will be trained in line with the determined guide and scales will be filled.
214501233|NCT04268277|DRUG|Rituximab|100 mg concentrate for solution for infusion
214501234|NCT04268277|DRUG|Pembrolizumab|100 mg/ 4mL concentrate for solution for infusion
214501235|NCT06825377|DIETARY_SUPPLEMENT|Whey protein|Whey protein powder will be provided with nutritional support in both groups if needed to meet the target protein intake.
214501236|NCT06529848|OTHER|Exercise training|"The training sessions are consist of cycling and as follows: a 10 min warm-up at a light intensity, 20-35 min of cycling exercise in intervals at varying intensities from light (\~60% of max heart rate) to more intensive (80-90% of max heart rate) and ending with 5 min of warm-down at a light intensity. The training intensity will be progressive during the course of the intervention period. The cycling training sessions are supervised .~Home training is allowed up to once a week if participants are able to adhere to the prescribed intensity levels.~Training sessions are closely monitored to ensure effectiveness and safety. This includes heart rate monitoring, perceived exertion assessment."
214501237|NCT05793034|DIAGNOSTIC_TEST|Biological biomarker assessment|IHC, PCR, NGS, methylome
214501238|NCT04279158|BEHAVIORAL|"experience 1 The negative priming task"|The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.
214998529|NCT07094789|DEVICE|Next Generation Dome Helmet (NGDH)|Participants will receive two sessions of Magnetic Resonance-guided focused ultrasound neuromodulation, spaced four weeks apart, using the Next Generation Dome Helmet device. Treatments will target regions within the CSTC circuit identified by advanced MRI scans. Each session will include pre-treatment assessments, precise sonications of deep brain structures, real-time safety monitoring, and post-treatment imaging.
214389520|NCT05075343|DEVICE|Custom foot orthoses|"3D printed custom foot orthoses (CFO) were designed by the same experimented podiatrist based on a detailed clinical and biomechanical examination and a 3D foot scan obtained for each participant. The degrees and types were adjusted at the CFO delivery according to each patient's comfort and tolerance.~The intervention period was 7weeks. The participants were taught to wear the CFO progressively during the first two weeks to allow for the lower limbs' muscles and structures to adjust to the CFO, and to wear the orthoses for the next 5 weeks, 7 days a week as often as they could."
214389521|NCT02710695|BEHAVIORAL|Control|This group will receive a standardized 10 minute discussion.
214389522|NCT02710695|BEHAVIORAL|Intervention|This group will receive a standardized 10 minute discussion
214389523|NCT00747526|DRUG|Rabeprazole sodium 5 mg|Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
214389524|NCT00747526|DRUG|Rabeprazole sodium 10 mg|Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
214998530|NCT07094256|DEVICE|Peritorq|Novel torque device specifically designed for electrophysiology and ablation catheters
214998531|NCT03506451|OTHER|Demographics questionnaires and the FACT HN questionnaire|Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
214998532|NCT06908967|DEVICE|EyeMirage device|This is a novel, smartphone-based device powered by artificial intelligence that will be used for virtual and remote routine eye examinations.
214389525|NCT00624663|DRUG|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
214389526|NCT02238197|DRUG|Atrovent® Inhalation Solution|
214501239|NCT04279158|BEHAVIORAL|"experience 2 Stop signal task"|The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
214501240|NCT04279158|BEHAVIORAL|"experience 3 Anti-saccades"|The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
214998533|NCT07097506|DRUG|bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester)|25 g C8 ketone di-ester taken daily for approximately 6-weeks
214998534|NCT07097506|OTHER|Placebo|25 g Placebo taken daily for approximately 6-weeks
215094019|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy with suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access. At this point, it is applied running seromuscular stitches at the proximal third of the stapled line using unidirectional 2/0 barbed sutures to invaginate the staple line completely.
214389527|NCT02153359|DEVICE|High Efficiency Particulate Air Cleaner|
214389528|NCT02153359|DEVICE|Sham air cleaner|
214389529|NCT05024149|OTHER|infrared thermography (IRT)|The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
214389530|NCT00056758|BIOLOGICAL|Autologous Dendritic Cell HIV Vaccination|
214501241|NCT06061107|BEHAVIORAL|"The cartoon version of the ACP for Seniors brochure"|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention."
214501242|NCT03036462|DRUG|Iron|i.v. iron administration
214501243|NCT03036462|DRUG|Saline|i.v. NaCl administration
214389531|NCT05892523|PROCEDURE|THA|positioning the acetabular cup regarding abduction and anteversion angles with or without concern to spinal deformity
214389532|NCT04422639|RADIATION|SRS/SRT|Comparing pre-operative SRS/SRT to post-operative SRS/SRT
214389533|NCT01964521|DEVICE|Mepilex Transfer Ag|A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
214389534|NCT03377868|DIAGNOSTIC_TEST|Optic coherence tomography|Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.
214389535|NCT03377868|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.
214389536|NCT05391360|DRUG|Freethiadine tablets(part I)|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
214389537|NCT05391360|DRUG|Freethiadine tablets (part II)|once or twice daily for consecutive 28 days
214389538|NCT05391360|DRUG|Freethiadine placebo tablets|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
214389539|NCT05391360|DRUG|entecavir tablets|once daily for consecutive 28 days
214389540|NCT05434299|DRUG|TFX05-01|TFX05-01 for intravenous
214389541|NCT01372605|OTHER|Measurement-Based Care collaborative depression management|Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications
214998535|NCT07095764|OTHER|Manual Lymphatic Drainage|Specific manual lymph drainage techniques including stationary circles, rotary circles, pumping, and scooping will be applied to both lower extremities using gentle, rhythmic skin movements in accordance with the direction of the lymphatic flow.
214998536|NCT07095764|OTHER|Cardiac Rehabilitation|An individualized program consists of progressive, low-intensity exercises including respiratory exercises, range of motion exercises for major joints, postural exercises, flexibility exercises, and gradual mobilization exercises such as sitting and walking will be applied.
214998537|NCT06906497|DRUG|lebrikizumab|"Patients will receive lebrikizumab with a 500 mg loading dose administered subcutaneously at baseline and Week 2 followed by 250 mg every 2 weeks until Week 24.~At week 24, patients with ≥ Eczema Area and Severity Index (EASI) 50 will continue in the study and begin receiving lebrikizumab 250mg every 4 weeks (Q4W), while patients with \<EASI 50 will be discontinued from the study.~At week 36, patients with EASI ≥50 to \<90 will remain on Q4W through W60 (do not enter withdrawal arm), while patients with sustained low disease activity (IGA 0/1 or EASI≥90 response for at least 3 months assessed at W24 and W36) will withdraw from lebrikizumab treatment"
214998538|NCT07098572|DEVICE|Cyclic single channel neuromuscular stimulation|Cyclic single channel neuromuscular stimulation is used to trigger repetitive muscular contractions
214998539|NCT07098572|DEVICE|Electromyogram-triggered 4 channel neuromuscular stimulation|EMG-MES provides biofeedback by using electromyographic signals to trigger muscular contractions
214998540|NCT06911346|DIETARY_SUPPLEMENT|Diet supplementation|Healthy plant-based diet (plus supplemental foods) as part of a hypocaloric diet.
214998541|NCT06911346|DIETARY_SUPPLEMENT|Polyphenol-rich supplement|Hypocaloric diet with polyphenol-rich supplement. Polyphenol-rich sachets containing ≈30g/day of a combination of plant extracts rich in polyphenol. Frequency: 2 sachets a day. Duration: 12 weeks
214998542|NCT06911346|OTHER|Placebo|Hypocaloric diet plus Placebo. The placebo is a sachet (≈30g/day) with similar appearance, taste, and texture but without active polyphenols. Frequency: 2 sachets a day. Duration: 12 weeks
215094020|NCT07002645|OTHER|Web-based conflict resolution training program|"Researchers developed the content of the web-based conflict resolution training program. First, ten experts were consulted to check the program's clarity and suitability. Second, the program was revised and finalized according to the experts' feedback.~A web page was obtained from the World Wide Web (www) by using hosting and domain services. Technical support and consultancy were received from a professional web design company during the implementation of the website. The content of the training program, for which expert opinions were obtained, was transferred to the web page. Web-based conflict resolution training program will be applied to the intervention group for 2 week."
214389542|NCT01372605|OTHER|Enhanced Usual Care|
214389543|NCT01108510|DRUG|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
214389544|NCT01108510|DRUG|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
214389545|NCT01108510|DRUG|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
214389546|NCT01108510|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
214389547|NCT01108510|DRUG|COBI placebo|Placebo to match COBI administered orally once daily
214389548|NCT01108510|DRUG|RTV placebo|Placebo to match RTV administered orally once daily
214389549|NCT03650660|OTHER|Trans-thoracic ultrasound|Trans-thoracic ultrasound performed by an expert and a non-expert
214389550|NCT04924972|PROCEDURE|Blepharoplasty|90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.
214389551|NCT02796963|BEHAVIORAL|Crowdsourced intervention|The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.
214389552|NCT02796963|BEHAVIORAL|Traditional intervention campaign|The pre-intervention period will include conventional HIV testing campaigns organized by local CDC, Community-Based Organization (CBO), and partners. These are typically designed by experts and social marketing companies.
214389553|NCT03741244|DRUG|apatinib|Apatinib is an oral small molecule antiangiogenic targeted drug developed in China. More and more studies found that antiangiogenic drugs have outstanding performance in treating glioma. From the perspective of clinical and molecular mechanism, the combination of Temozolomide and apatinib may have synergistic effect especially to TMZ insensitivity patients(MGMT gene promoter unmethylated) and poor prognosis (IDH1 wild type) population
214998543|NCT07095023|DRUG|Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab|"Patients who meet the inclusion criteria will be enrolled and given paclitaxel oral solution and subcutaneous pertuzumab/trastuzumab for neoadjuvant treatment.~Paclitaxel oral solution: 200mg/m2 po bid, D1,D8,D15, q3w. Subcutaneous pertuzumab/trastuzumab: 1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL, q3w."
214998544|NCT07099690|PROCEDURE|Perineal massage|"Perineal massage will be performed during labor, either between or during contractions, regardless of the position chosen by the laboring woman.~The researcher, wearing gloves, will insert one or two fingers (index and middle) into the participant's vaginal canal and move them from side to side in a U-shaped motion, for approximately one second in each direction. Light downward pressure will be applied toward the rectum, according to the woman's tolerance, until relaxation of the massaged perineal muscles is observed.~A water-based lubricant will be used to facilitate the procedure. The massage will last no longer than 5 minutes."
215094021|NCT03668990|OTHER|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
214389554|NCT03741244|DRUG|Temozolomide|Temozolomide，alkylating agent， is the standard first-line chemotherapy of glioma.
214389555|NCT04246515|DEVICE|Blood Flow Restriction Training|Vascular occlusion of the injured limb.
214389556|NCT04246515|DEVICE|Sham Blood Flow Restriction Training|Blood Flow Restriction material will be attached to the limb without vascular occlusion.
214389557|NCT04246515|OTHER|Classic rehabilitation|Classic rehabilitation protocol after a hamstring injury consisiting out of stretching, strength, core stability,...
214389558|NCT00003415|DRUG|amifostine trihydrate|
214389559|NCT00003415|DRUG|topotecan hydrochloride|
214998545|NCT07099443|OTHER|Non-Interventional Sample Collection and Analysis|This study is observational. Biological samples are collected as part of standard care or for research purposes and analyzed to characterize resistance mechanisms. No treatment or intervention is administered as part of the study protocol.
214389560|NCT03096301|DEVICE|Low-intensity laser|Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
214389561|NCT03096301|DEVICE|occlusal plates|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
214389562|NCT03096301|DEVICE|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
214389563|NCT06072820|DEVICE|Salivary Sampling|"Inclusion visit: After signature of the informed consent, all subjects will perform 3 consecutive Endotest® Diagnostic during the visit and 1 at-home.~Circadian circle visit: 6 included subjects will be asked to come back for a full day. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit.~Repeatability-intermediate fidelity-stability-interferences visit: a maximum of 16 included subjects will be asked to come back for this visit. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit."
214501244|NCT06463366|DEVICE|3D-MRE,MRI-PDFF|3D-MRE(storage modulus, ., loss modulus and damping ratio \[DR\] for liver inflammation and fibrosis) MRI-PDFF(liver fat content)
214501245|NCT06492083|OTHER|traditional Chinese medicine hot bag|traditional Chinese medicine hot bag
214501246|NCT06826898|DEVICE|DEFEHERE Absorbable Adhesion Barrier|DEFEHERE Absorbable Adhesion Barrier, 1.0 mL/syringe
215094022|NCT05660213|DRUG|Targeted drugs combined with anti-PD-1/PD-L1 antibodies|Targeted drugs combined with anti-PD-1/PD-L1 antibodies
215094023|NCT05660213|DRUG|TACE (transarterial chemoembolization) combined with targeted/immunotherapy|TACE (transarterial chemoembolization) combined with targeted/immunotherapy
215094024|NCT05660213|DRUG|Lenvatinib monotherapy|For patients weighing less than 60 kg, the recommended daily dose of this product is 8 mg (2 capsules of 4 mg), once daily; For patients weighing ≥ 60 kg, the recommended daily dose of this product is 12 mg (3 capsules of 4 mg), once daily. Treatment should be continued until disease progression or intolerable toxic reactions occur.
215094025|NCT05660213|DRUG|Huaier granules combined with any of the above Cohorts for treatment|Oral administration of Huaier granules, 10g each time, 3 times a day, until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that there is no longer any benefit.It is recommended that the date of first use of Huaier granules be determined by the researchers, and after disease progression, the researchers and patients should jointly decide whether to continue receiving Huaier granules treatment.
215094026|NCT06680440|DRUG|ASC30|Tablet, QD
215094027|NCT06680440|OTHER|Placebo|Tablets, QD
214389564|NCT00592046|DRUG|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
214501247|NCT06826898|DEVICE|Sham (No Treatment)|conventional therapy without using any antiadhesion product
214501248|NCT02492074|DRUG|Delta-9-tetrahydrocannabinol|oral administration of delta-9-tetrahydrocannabinol
214501249|NCT02492074|DRUG|Cannabidiol|oral administration of cannabidiol
214501250|NCT02492074|DRUG|Placebo|oral administration of placebo
214501251|NCT05418491|OTHER|No intervention is used in the current study. Interventions were given in the original A.R.T. study|The current study is a post-intervention study; interventions were given in the original A.R.T. study
214501252|NCT05870787|DIAGNOSTIC_TEST|Swede score colposcopy|New colposcopy method: with application of acetic acid, supplemented with a systematic scoringsystem (Swede score) including Lugols iodine, and collection of cervical biopsies.
214998546|NCT07098390|BEHAVIORAL|Progressive Muscle Relaxation Exercise|"When patients are admitted to the Orthopedics and Traumatology Clinic for arthroplasty and agree to participate in the study, they will be informed about the research process and written informed consent will be obtained. The Descriptive Information Form, Numeric Rating Scale (NRS), The Fear of Falling Scale, and the State-Trait Anxiety Inventory (STAI) will be administered through face-to-face interviews by the researcher. After the pre-tests are completed, patients will be randomly assigned to the intervention and control groups.~In the preoperative period, upon admission to the clinic, patients in the intervention group will receive progressive muscle relaxation exercises (PMRE). To enhance concentration and minimize the impact of ambient noise, patients will listen to the exercises using headphones.~On the first postoperative day, the patient will be revisited by the researcher. After the physician explains that the patient will be mobilized, the State-Trait Anxiety Inventory will"
214998547|NCT07131969|OTHER|blood draw|Venous blood sampling into Tempus tube for RNA-sequencing
214389565|NCT01900574|DRUG|Golimumab|Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
214389566|NCT01258660|DRUG|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
214389567|NCT01258660|DRUG|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)\] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
214389568|NCT01356992|DRUG|Enoxaparin|Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
214389569|NCT02867969|OTHER|Motor training|The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
214389570|NCT02952573|DRUG|JNJ-42756493|Once daily dosing
214389571|NCT02952573|DRUG|Dexamethasone|Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
214389572|NCT04330014|BEHAVIORAL|vaccine|affect vaccination on children
214389573|NCT02963688|GENETIC|Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform|BRCA1,2 Germline /Somatic mutation test
214389574|NCT00765427|DRUG|QLT091001|7-day repeated dose
214389575|NCT00350701|DRUG|androgel|androgel 5g
214389576|NCT00350701|DRUG|androgel 10g|androgel 10g
214389577|NCT00350701|DRUG|placebo|placebo
214389578|NCT03364439|DRUG|Treatment plan|R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
214389579|NCT03209401|DRUG|Niraparib|an oral PARP inhibitor
214389580|NCT03209401|DRUG|Carboplatin|a platinum-based injection
214394005|NCT02800603|BEHAVIORAL|Family Check Up|"The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings."
214394006|NCT06330636|OTHER|D-Allulose|Test breakfast
214998548|NCT06859307|PROCEDURE|intra-abdominal instillation of corticosteroids|after adhesiolysis, peritoneal lavage with diluted corticosteroids will be instillated intra-abdominally
214998549|NCT06859307|PROCEDURE|intra-abdominal instillation of fresh frozen plasma|after adhesiolysis, peritoneal lavage with diluted FFP will be instillated intra-abdominally
214998550|NCT06755450|DRUG|AUR112|Once daily
214998551|NCT07097025|DEVICE|vagus nerve stimulation|VNS is a neuromodulatory treatment involving implantation of a subcutaneous device that delivers intermittent electrical stimulation to the vagus nerve, modulating central pathways associated with mood regulation.
215094028|NCT06123754|DRUG|Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection|The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.
215094029|NCT06123754|DRUG|placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection|The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
214389581|NCT00953095|BEHAVIORAL|Joint Attention Intervention|Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.
214389582|NCT02459080|DRUG|TD-4208|
214389583|NCT02459080|DRUG|Placebo|
214389584|NCT03562351|OTHER|Verbal Instructions Educational Intervention|Caregivers will undergo training with verbal instructions
214389585|NCT03562351|OTHER|Video Educational Intervention|Caregivers will undergo training with an educational video
214389586|NCT03562351|OTHER|Mannequin Educational Intervention|Caregivers will undergo training with a mannequin
214389587|NCT01448421|DEVICE|Keystone Heart Embolic Deflection Device|The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.
214389588|NCT04800523|DEVICE|UroMonitor System|Implantable device to wirelessly and without catheters monitor the neurogenic bladder on an ambulatory basis
214389589|NCT01775930|DRUG|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
214389590|NCT01182727|DRUG|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
214389591|NCT00846833|BIOLOGICAL|Haploidentical NK cell|"1. Collection of PBMCs by leukapheresis~2. CD3+ depletion of apheresis product using CliniMACS®"
214389592|NCT00363896|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
214389593|NCT00363896|DRUG|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
214389594|NCT05142410|DIAGNOSTIC_TEST|Analysis of post-translational histone modifications via mass spectrometry|"During the GrossHist study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company \[Bouvier and Fortier et al. 2021\]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4)."
214389595|NCT01572324|DRUG|Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine|HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
214389596|NCT02351882|DRUG|Nabilone|Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).
214389597|NCT02351882|DRUG|Placebo|Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
214389598|NCT03657264|DRUG|P03277 0.1 mmol/kg|Single intravenous bolus injection at 2 mL/sec
214389599|NCT03657264|DRUG|Moxifloxacin 400mg|One tablet per os
214389600|NCT03657264|DRUG|NaCl 0.9%|Single intravenous bolus injection at 2 mL/sec
214389601|NCT03657264|DRUG|P03277 0.3 mmol/kg|Single intravenous bolus injection at 2 mL/sec
214389602|NCT02424552|DRUG|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.
214389603|NCT02424552|DRUG|Placebo|Filling material: lactose monohydrate, cellulose, magnesium stearate
214389604|NCT04466423|BEHAVIORAL|Small group meetings (COMPASS: COlleagues Meeting to Promote And Sustain Satisfaction)|The first 15 minutes of each session will be semi-structured discussion involving i) check in and ii) dialogue about the assigned question. Group leaders will be provided 3-4 discussion questions for each session. The group (or the leader) can choose the one they are most interested in and will then spend 10-15 minutes discussing the question together. Questions will touch on key themes for discussion (see the attached topics list) and are derived from our previous intervention studies. The remainder of the time can be used for socializing and building relationships with colleagues.
214389605|NCT05089058|BEHAVIORAL|Brief, digitally delivered imagery-competing task intervention package, comprised of:|"Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) task procedure: a memory cue followed by playing imagery-competing computer game task with mental rotation instructions. Monitoring of intrusive memories to select hotspot cue, and which intrusion to target.~(ii) accompanying information, including rationale for the brief cognitive task.~(iii) option to use the brief cognitive task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
214394007|NCT06330636|OTHER|Sodium Saccharin|placebo breakfast
214394008|NCT02488382|DRUG|Lonquek|Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
214394009|NCT02210910|DEVICE|InSpace™ system over repair|
214394010|NCT02210910|PROCEDURE|Best Repair of torn Rotator Cuff|
214394011|NCT00910806|DRUG|TMC207; nevirapine|
214394012|NCT03978390|BEHAVIORAL|behavioral priming|Priming the children with images of superheroes in order to behave desirably during the dental injection
214389606|NCT05089058|BEHAVIORAL|Brief, digitally delivered relaxation task intervention, comprised of:|"Brief, digitally delivered relaxation task intervention, comprised of:~Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) relaxation exercise task using instruction components from progressive muscle relaxation~(ii) accompanying information, including rationale for the brief relaxation exercise task.~(iii) option to use the brief relaxation exercise task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
214389607|NCT01168063|DRUG|Molecular detection of antibiotic resistance|Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
214389608|NCT01168063|DRUG|standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)|"2 lines of treatments :~1\) PPI + Amoxicillin + Clarithromycin for 7 days~1\) PPI + Amoxicillin + Metronidazole for 14 days"
214389609|NCT04003662|DEVICE|Vital Signs Measurement|Vital signs are measured twice with standard of care equipment while recording digital video data at the same time.
214389610|NCT06420674|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|"The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders is a psychological intervention that focuses on a wide range of emotional disorders (i.e., anxiety, depression and related disorders). It allows care for comorbid disorders, subclinical or unspecified symptoms reducing associated costs and improving response to treatment.~In our study, the Unified Protocol preventive program will be applied throughout 10 online modules. Women will have access to a web-page (moodle version) that includes audiovisual materials (e.g., written manual, videos, editable registers) and psychological assessments."
214389611|NCT04600297|DEVICE|ELS Even Stronger (3D Printed Resin Composite)|Missing of one premolar cases will be restored using the 3D Printed resin composite (ELS Even Stronger, Saremco, Switzerland). The steps of the procedure: Preparation, scanning, colour determination, design of the restoration, printing the restoration, adjusting occlusion, finishing and polishing, cementation.
214389612|NCT04974879|DRUG|Osimertinib Oral Tablet|Osimertinib, 80mg, oral daily; bevacizumab (avastin), 15mg/KG body weight, erery 21 days, intravenously.
214389613|NCT02715895|DIETARY_SUPPLEMENT|Friso|Friso formula feeding on demand for 3 months
214389614|NCT02715895|DIETARY_SUPPLEMENT|Wyeth|Wyeth formula feeding on demand for 3 months
214389615|NCT02715895|DIETARY_SUPPLEMENT|Breast milk|Breast milk feeding on demand
214389616|NCT04519541|DEVICE|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
214389617|NCT02433548|PROCEDURE|Fascia iliaca block|injection of 30 mLs below the fascia iliaca
214389618|NCT02433548|PROCEDURE|Sham injection|subcutaneous of 5 cc of normal saline
214389619|NCT05938725|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
214389620|NCT05938725|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
214389621|NCT03005093|OTHER|CAREGIVERS|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
215094030|NCT07031804|OTHER|Saline Nasal Spray|A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)
215094031|NCT07031804|OTHER|Saline Nasal Spray|A saline nasal spray will be introduced as oxytocin on the first day (induced positive expectations) and as saline on the second day (no induced positive expectations)
214389622|NCT03005093|OTHER|CHILDREN OF CAREGIVERS|Chewing performance with Karaduman Chewing Performance Scale, tongue control with Tongue Thrust Rating Scale, dysphagia symptom severity with the Pediatric version of the Eating Assessment Tool will be evaluated. These assessments will be done before and after swallowing rehabilitation program.
214389623|NCT01598428|PROCEDURE|anterior capsule polishing|polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
214389624|NCT00924469|DRUG|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
214389625|NCT00924469|DRUG|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
214389626|NCT00924469|DRUG|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
214389627|NCT04573413|DEVICE|Inhibitory repetitive transcranial magnetic stimulation|"r-TMS Parameters: International 10/20 system for the location of the target area (left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
214389628|NCT04573413|DEVICE|Sham Group|Sham stimulation and Visual scanning training Intervention: Device: SHAM
214389629|NCT01625624|OTHER|Carbohydrate Food Bar|Control Food Bar containing carbohydrate
214389630|NCT01625624|OTHER|Modified Carbohydrate Food Bar|Test Food Bar containing modified carbohydrate
214389631|NCT04913818|BEHAVIORAL|BUDPA Program|The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies (e.g. shoulders, elbows, wrists, hips, knees and ankles), and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The Research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements. The training session will end with a 10-minute cool down session with walking exercise and stationary trunk and limb mobilizing exercise involving joints of shoulders, elbows, wrists, hips, knees, and ankles.
214389632|NCT04913818|OTHER|Control arm (Usual care)|Active Comparator: Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training
214389633|NCT02473887|DRUG|Ondansetron with1:1 ORA - sweet.|single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
214501253|NCT04104022|BEHAVIORAL|Prolonged Exposure Therapy|Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.
214501254|NCT04104022|BEHAVIORAL|Attendance-based monetary incentives|Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
214389634|NCT01350622|DRUG|PENNSAID|active treatment with PENNSAID and oral placebo. Subjects will apply 40 drops of Pennsaid to the affected ankle joint once, and will take a single placebo pill.
214389635|NCT01350622|DRUG|Diclofenac hydroxyethylpyrrolidine|active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
214389636|NCT02465021|OTHER|Dietary intervention|All arms are given to all participants, in a randomized order
214389637|NCT03044353|DRUG|GSK2315698 (CPHPC)|20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
214389638|NCT03044353|BIOLOGICAL|GSK2398852 (anti-SAP mAb)|Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
214389639|NCT04788069|DIETARY_SUPPLEMENT|Wholemeal bread|180g wholemeal bread/day + fixed portion at test day
214389640|NCT04788069|DIETARY_SUPPLEMENT|Sourdough bread|180g sourdough bread/day + fixed portion at test day
214501255|NCT05256797|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
214501256|NCT05256797|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
214501257|NCT01976260|DEVICE|Fractional Radiofrequency|
214501258|NCT01976260|DEVICE|1550-nm Fractional Photothermolysis|
214389641|NCT04788069|DIETARY_SUPPLEMENT|Bread with sourdough|180g bread with sourdough/day + fixed portion at test day
214998552|NCT07095725|DIAGNOSTIC_TEST|Record EMG maximum amplitude from rectus abdominis, erector spinae L3 level|"EMG Electrode Placement and Muscle Assessment:~Electrodes for the rectus abdominis were placed longitudinally at the umbilical level. For the erector spinae, L3 was located using a line between the posterior superior iliac crests, and electrodes were placed \~3 cm lateral to the L3 spinous process.~Assessment:~Rectus Abdominis: In the crook-lying position, participants performed a slow curl-up (\~35-40°), holding for 10 seconds.~Erector Spinae: In the prone position with a 10-cm pad under the abdomen, participants lifted the upper body with neutral cervical alignment for 10 seconds.~Each test was repeated three times with 2-minute rest intervals."
214998553|NCT07097532|PROCEDURE|Radiofrequency|Under sterile conditions and fluoroscopic guidance, pulsed radiofrequency treatment was applied unilaterally to the dorsal root ganglia at the L4-L5 and L5-S1 spinal levels. Sensory and motor stimulation were performed to confirm appropriate electrode placement. Pulsed radiofrequency was delivered at 45 volts for 300 seconds at 42°C using standard radiofrequency equipment. Patients were monitored for three hours following the procedure, and cutaneous silent period (CSP) recordings were obtained on the same day and during follow-up assessments.
214998554|NCT07097532|PROCEDURE|Transforaminal Epidural Steroid Injection|Using a fluoroscopic C-arm device, transforaminal epidural steroid injection (TFESI) was performed at the L4-L5 and L5-S1 foraminal levels. At each level, a total of 4 mL of solution containing 16 mg of dexamethasone and sterile saline was administered following confirmation of appropriate contrast spread. Negative aspiration was verified prior to injection. Cutaneous silent period (CSP) measurements were conducted on the same day and at designated follow-up intervals.
214998555|NCT06908629|OTHER|Implementation of social determinants of health screening and referral|Participants will be referred to community-based resources in response to their answers on the screening tool.
214998556|NCT07093359|PROCEDURE|Laparoscopic or robotic LINX procedure|Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.
214501259|NCT03633604|BIOLOGICAL|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
214998557|NCT07093359|PROCEDURE|Laparoscopic or robotic fundoplication|Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.
214998558|NCT07100912|OTHER|Mitopure Topical Formula 5|Topical skin cream containing Mitopure
214998559|NCT07100912|OTHER|Mitopure Topical Formula 6|Topical skin cream containing Mitopure
214998560|NCT07100912|OTHER|Mitopure Topical Formula 7|Topical skin cream containing Mitopure
214389642|NCT01079143|DRUG|Certican®|Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
214501260|NCT06516887|DRUG|bemcentinib|Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
214501261|NCT06516887|DRUG|pacritinib|For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.
214389643|NCT01079143|DRUG|Neoral|Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
214389644|NCT01079143|DRUG|Myfortic|"Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days."
214389645|NCT01079143|DRUG|Simulect®|The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
214389646|NCT01079143|DRUG|Corticosteroids|An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
214389647|NCT06528561|PROCEDURE|Sef-care program with exercise|Self-care program with physical exercise with aerobic and muscular strength components implemented progressively according to the participant's clinical evolution
214389648|NCT02162992|OTHER|No intervention|Observational
214389649|NCT02821832|PROCEDURE|Saliva collection|For biomarker assessments
214389650|NCT02821832|PROCEDURE|Urine collection|For biomarker assessments
214389651|NCT02821832|PROCEDURE|Sputum collection|For primary endpoint assessments and other biomarker assessments
214389652|NCT02821832|PROCEDURE|Blood Collection|For biomarker and eligibility assessments
214389653|NCT02821832|RADIATION|PET/CT Scan|Imaging of the lungs to establish disease extent and severity
214389654|NCT02821832|DRUG|Isoniazid, Rifampicin, Pyrazinamide and Ethambutol|Treatment-standard of care
214389655|NCT02825953|DRUG|surfactant|the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
214389656|NCT02825953|DEVICE|nasal continuous positive airway pressure|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
214389657|NCT02825953|DEVICE|non-invasive intermittent positive-pressure ventilation|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
214389658|NCT02825953|DEVICE|Neopuff|Fisher and Paykel, Auckland, New Zealand
214389659|NCT02825953|DEVICE|neonatal ventilator|GE Healthcare, Madison, USA
214389660|NCT03745794|OTHER|Best Practice|Given standard of care
214389661|NCT03745794|DRUG|Quadratus Lumborum Block|Undergo QL block
214998561|NCT07100912|OTHER|Mitopure Topical Formula 8|Topical skin serum containing Mitopure
214998562|NCT07100912|OTHER|Mitopure Topical Formula 9|Topical skin exfoliator containing Mitopure
214998563|NCT07100912|OTHER|Mitopure Topical Formula 10|Topical skin cleanser containing Mitopure
214389662|NCT03745794|OTHER|Quality-of-Life Assessment|Ancillary studies
214998564|NCT07104864|DIAGNOSTIC_TEST|histopathological confirmation|histopathological confirmation
214389663|NCT03745794|OTHER|Questionnaire Administration|Ancillary studies
214998565|NCT07103564|OTHER|Immediately placed implant in maxillary premolars with local melatonin application|Patients will receive immediately placed implants with local melatonin powder (3mg) application.
214389664|NCT05139641|BEHAVIORAL|Counseling to preserve fertility|Counseling to preserve fertility VS Control group
214389665|NCT04448431|DRUG|Vortioxetine|10 or 20 mg/day, capsules, orally
214998566|NCT07103564|OTHER|Immediately placed implant in maxillary premolars without local melatonin application|Patients will receive immediately placed implants without local melatonin application.
214389666|NCT04448431|DRUG|Desvenlafaxine|50 mg/day capsules, orally
214389667|NCT02520180|DEVICE|Firehawk™ stent system|MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent
214389668|NCT02520180|DEVICE|Abbott Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
214501262|NCT05245877|DRUG|enoxaparin/tinzaparin/dalteparin|Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
214501263|NCT06951282|DIETARY_SUPPLEMENT|Selenium|200 microgram selenium was given daily for 3 months
214501264|NCT06951282|DRUG|Methotrexate|0.4 mg/kg/week sub cutaneous methotrexate for 3 months
214501265|NCT06950567|OTHER|psycho-educational intervention and therapeutic activity|"The objective is to provide knowledge and skills to tolerate/reduce discomfort so that they can begin to reduce or discontinue medication (BZD).~The focus is on the effect of combined care, but the implementation of this approach is also evaluated, which will provide valuable knowledge for further health developments in Primary Care."
214501266|NCT06950567|OTHER|Control|"Sending a Benzocarta to each person's postal address-a personalized letter signed by their Family Doctor, an explanatory sheet on how to gradually reduce medication, and infographics on sleep hygiene, stress, or anxiety."
214501267|NCT06950281|DRUG|Low Sodium Oxybate|Low sodium oxybate (LXB) will be administered as a twice nightly regimen. All subjects will undergo an 8 week Treatment Titration and Optimization Phase. Titration should proceed in an increment of 1.5g per night each 7 days until a 50% reduction in nocturnal headache frequency is achieved or a maximum dose (9g per night) is reached. If a subject is unable to titrate to a higher dose, they may stay at the highest tolerated dose for the duration of the study. Subjects may stop titration or have dose reduction at any time for safety and tolerability reasons.
214501268|NCT06950281|DRUG|Placebo|Placebo with equal appearance
214389669|NCT01356173|DRUG|GDC-0349|Oral escalating dose
214389670|NCT05104918|DRUG|Vortioxetine|10 mg tablets
214389671|NCT05104918|DRUG|Venlafaxine|75 mg tablets
214389672|NCT01498913|DRUG|repaglinide|Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
214389673|NCT02861391|DEVICE|CO2 AcuPulse Laser|Each subject will receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
214501269|NCT06950918|OTHER|Experimental|"This study is a quasi-experimental parallel group design comparing Flipped Classroom (FC) and Flip-Jigsaw models in a theoretically-oriented public health course. Both groups used the same pre-prepared video lectures to standardize content, but differentiated in-class strategies: The FC group used instructor-led discussions, while the Flip-Jigsaw group used Jigsaw technique and peer teaching (students learning subtopics in expert groups and teaching them in master groups). Unlike traditional FC, this hybrid model includes systematic peer collaboration and role-based accountability mechanisms. Theoretical knowledge acquisition, motivation and engagement outcomes were assessed through quantitative tests (pre-post-retention tests) and qualitative interviews, and objectivity was ensured in practical exams with single-blinded assessors. The study brings innovation to the literature as it is the first study to demonstrate the unique effect of Flip-Jigsaw in theoretical courses in the fie"
214501270|NCT05434598|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
214501271|NCT03496766|DRUG|Tipifarnib|Tipifarnib 600 mg will be administered until progression
214501272|NCT05825885|DRUG|E2|micronized E2 at a daily dose of 4-6mg,
214501273|NCT05454826|OTHER|Exercise|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
214501274|NCT05454826|OTHER|Cold Application|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
214501275|NCT05231018|OTHER|Psychotherapy|8-sessions psychotherapy
214501276|NCT05387564|BEHAVIORAL|SCT Documentation and Disclosure Toolkit (SCT-DD)|A toolkit of implementation strategies
214501277|NCT05941013|DEVICE|Ultrasound detectable cuffed endotracheal tube (USD-ETT)|Intubation with a novel ultrasound-detectable endotracheal tube
214389674|NCT02861391|DEVICE|Sham Laser|Each subject will receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
214389675|NCT03587792|PROCEDURE|stapedectomy|Stapedectomy as described in literature with stapes removal, Carbon Dioxide (CO2) laser platinectomy and placement of a prothesis(piston) between the incus long process and the stapes footplate
214501278|NCT00647387|DEVICE|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
214389676|NCT02646306|OTHER|shoulder proprioceptive rehabilitation tool|"Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the reaching of an object."
214389677|NCT01464255|DEVICE|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
214389678|NCT01464255|DEVICE|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
214389679|NCT05276323|DRUG|Medihoney Derma Cream|applied topically, twice a day, on all affected areas in the body for two weeks.
214389680|NCT05276323|DRUG|Hydrocortisone 1% cream|applied topically, twice a day, on all affected areas in the body for two weeks.
214389681|NCT03051659|DRUG|Eribulin Mesylate|Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
214389682|NCT03051659|DRUG|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
214389683|NCT03535051|DEVICE|fractional carbon dioxide laser|Monthly fractional carbon dioxide laser sessions
214998567|NCT07102992|DEVICE|High intensity laser therapy|"High intensity Laser Therapy :A standard handpiece endowed with fixed spacers will used to provide the same distance to the skin and perpendicularly to the zone to be treated with a laser beam diameter of 5 mm. Three phases of treatment will be performed for every session. The total energy that will be delivered to the patient during one session will be 1275 J through three phases of treatment.~Frequency of treatment: Treatment will be given 5 times / week for 20 sessions."
214998568|NCT07102992|DEVICE|Shock Wave therapy|"radial extracorporeal shock wave therapy (2,000 shots, 4 Bar, 5 Hz) (once a week) will be administered to the ulnar nerve at the proximal cubital tunnel region.~Frequency of treatment: Treatment will be given 1 time / week for 4 sessions"
214998569|NCT07102992|OTHER|Ulnar nerve gliding exercises.|"While keeping patients head in a neutral position, will teach the patient to:~1. Begin with your arm out, palm side of the hand facing up.~2. Bend the elbow toward you, palm side facing you.~3. Rotate the palm of your hand outward and bend your wrist so that the fingers are pointing towards you.~4. Twist your wrist so that the palm of your hand is now facing upward.~5. While your wrist remains bent, stretch out your arm into a straight position, with your fingers bent towards the floor.~Hold each position for 5 seconds, repeat series 3-5 times. Frequency of treatment: Treatment will be given 5 times / week for 20 sessions."
214998570|NCT07104877|DRUG|SYS6010|Administered via intravenous infusion at the dose of 3.2-4.8 mg/kg
214998571|NCT07104877|DRUG|SYH2051|Administered via oral at the dose of 40-80 mg
214998572|NCT07100600|DRUG|Trastuzumab Rezetecan|Trastuzumab Rezetecan：4.8mg/kg Q3W
214998573|NCT07100600|RADIATION|FSRT or WBRT|FSRT （8Gy/3-5 fx）or WBRT（30Gy/10fx）
214389684|NCT03535051|DRUG|Tacrolimus Oint 0.03%|topical daily tacrolimus ointment application
214394013|NCT03978390|BEHAVIORAL|endowment effect|Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure
214394014|NCT03978390|BEHAVIORAL|Positive reinforcement|Giving rewards to the children at the end if they cooperate desirably during the treatment
214394015|NCT04505995|DRUG|Azacitidine and homoharringtonine|Concommitant use of azacitidine and homoharringtonine
214394016|NCT03314623|BEHAVIORAL|Weight bearing as tolerated|If fracture is deemed stable the subjects will be allowed to weight bear immediately after surgery.
214394017|NCT02475044|BEHAVIORAL|Cognitive-Behavioral Therapy|16 Sessions of CBT.
214394018|NCT06226428|OTHER|Bed cyclo-ergonometry|The MotoMed Letto 2 device will be used, with a progressive pattern, starting at 5 minutes and lasting up to 30 minutes. It will be performed once a day, during weekdays (Monday to Friday) until discharge from the intensive care unit, and at a modified Borg intensity of 2-3 (Light).
214394019|NCT06226428|OTHER|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.
214394020|NCT06226428|OTHER|Progressive upper and lower limb strength training|Performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells.
214394021|NCT02348320|BIOLOGICAL|Personalized polyepitope DNA vaccine|
214394022|NCT05923177|DRUG|SPECT|One single injection of \[123I\] I-(HE)3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6, 24 and 48 hours.
214394023|NCT03948087|DEVICE|Vacuum Removable Rigid Dressing (VRRD)|Intra-operative application of device.
214394024|NCT00798356|OTHER|Yoga training|Yoga training for 12 weeks
214394025|NCT05943275|DEVICE|Magnetic sensor|During the right heart catheterization procedure, measurement of hemodynamic pressures by the non-invasive experimental method (Magnetic sensor) and the invasive control method
214394026|NCT00459303|DEVICE|aspherical intraocular lens|implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
214394027|NCT00459303|DEVICE|spherical intraocular lens|implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
214394028|NCT00416871|BIOLOGICAL|aldesleukin|
214394029|NCT00416871|BIOLOGICAL|recombinant interferon alfa|
214394030|NCT03018743|DRUG|Dapoxetine|Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
214394031|NCT04418414|DRUG|Gene therapy|CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
214394032|NCT04418414|OTHER|Biological|G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.
214394033|NCT04906590|DRUG|[18F] PI-2620|Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
214394034|NCT00451568|DRUG|Metformin|500 mg 2 tablets 2 times a day
214389685|NCT05818059|DIAGNOSTIC_TEST|Diagnosis of Tuberculosis with computer-aided detection (CAD) software|"After enrolment, each subject will be assessed according to ARM 1 (assessment by clinician #1 without CAD) or ARM 2 (assessment by clinician #1 with CAD). Allocation to sequence ARM 1 or ARM 2 will be performed using a computer-generated random assignment list (with a 1:1 ratio), and assignments will be included in sealed opaque envelopes sequentially numbered.~Clinicians cannot be masked to the assessment method (with or without CAD) and cannot be masked to the further assessment (referral for microbiological diagnosis with stool and sputum Xpert) due to care process. However, the statistician will be masked to the assessment during data analysis."
214389686|NCT00786474|DRUG|Placebo|Normal saline solution, dosage determined by weight, self-administered by patient twice a day
214998574|NCT07103590|PROCEDURE|single Sagittal Split plate|patients will be treated using a single Sagittal Split plate at the neutral zone of mandible
214998575|NCT07103590|PROCEDURE|two conventional miniplates|patients will be treated using two conventional miniplates according to Champy's osteosynthesis lines.
214998576|NCT07103174|BIOLOGICAL|MG-K10 placebo|Administer the drug once every 4 weeks for a total of 6 times
214389687|NCT00786474|DRUG|Dalteparin|Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
214389688|NCT00029575|DEVICE|Surgi-Vision Guidewire Coil|
214389689|NCT02378064|DRUG|6-month treatment|
214389690|NCT00492804|PROCEDURE|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
214389691|NCT00492804|PROCEDURE|Neurectomy|Neurectomy
214389692|NCT01501422|DRUG|Estrogen patch|50 microgram estrogen patch weekly
214389693|NCT01501422|DRUG|Placebo|Placebo patch for 8 weeks
214389694|NCT05344989|DRUG|APNmAb005|Administered by IV infusion
214389695|NCT05344989|DRUG|Placebo|Administered by IV infusion
214389696|NCT01428804|DEVICE|transcranial Direct Current Stimulation (tDCS)|Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
214389697|NCT05754138|DEVICE|Sport SICD|Follow up
214501279|NCT02842749|DRUG|everolimus|Participants were instructed to take everolimus at a starting dose of 10 mg orally once daily. However, dose adjustments were permitted in order to allow the participant to continue the study treatment.
214501280|NCT06216249|PROCEDURE|Computed Tomography|Undergo PSMA PET/CT, SPECT/CT, PET/CT and CT
214998577|NCT07103031|BEHAVIORAL|Behavioral therapy|Patients in PedMIDAS stage 1-2 (score ≤ 30) received behavioral therapy including lifestyle counseling, stress management techniques, sleep hygiene education, and individualized headache triggers review. Additionally, each patient was provided with a headache report card to self-monitor symptoms, triggers, and medication use over a 3-month period.
214998578|NCT07103031|DRUG|Propranolol|Patients in PedMIDAS stage 3-4 (score \> 30) received oral propranolol treatment at a dose of 1-3 mg/kg/day, adjusted by weight and tolerance, for a total of 3 months. The medication was prescribed and monitored by a pediatric neurologist. Patients were followed with routine check-ups and adverse effects were recorded.
214998579|NCT05467527|BEHAVIORAL|Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice|The PACT group will receive a combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks. The modules will cover real-life scenarios of daily parenting challenges in caring for a child with SHCN, followed by age-appropriate positive parenting advice based on the Centers for Disease Control and Prevention guidelines. After going through the scenarios, parents will be audio/visually guided to participate in ACT activities, including mindfulness exercises, ACT metaphors and experiential exercises, which will be used to increase psychological flexibility.
214389698|NCT02394899|BEHAVIORAL|Play therapy|Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
214389699|NCT02394899|OTHER|Problem solving skills|Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
214389700|NCT02733042|DRUG|Durvalumab|Administered as an IV infusion (250 mL) over approximately 1 hour in duration
214389701|NCT02733042|DRUG|Lenalidomide|Administered orally
214389702|NCT02733042|DRUG|Rituximab|Administered by intravenous infusion
214389703|NCT02733042|DRUG|Ibrutinib|Administered orally
214389704|NCT02733042|DRUG|Bendamustine|Administered as a 30-minute intravenous infusion
214389705|NCT03489005|DRUG|BIA 5-1058|"Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets"
214389706|NCT03489005|DRUG|Placebo Oral Tablet|"Matching placebo tablets administered as follows:~\- placebo, as 12 × 0-mg tablets"
214501281|NCT06216249|OTHER|Gallium Ga 68 Gozetotide|Given IV
214501282|NCT06216249|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
214501283|NCT06216249|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214501284|NCT06216249|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT
214389707|NCT03489005|DRUG|Moxifloxacin 400 mg|"Administered as follows:~\- 400 mg moxifloxacin, as 1 × 400-mg tablet"
214389708|NCT04412252|DRUG|Tofacitinib|10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days
214389709|NCT04412252|OTHER|Placebo|Tofacitinib-matching placebo administered as tablets or solution taken orally twice daily for 14 days
214389710|NCT01967264|DRUG|Udenafil|Udenafil tablets
214501285|NCT06216249|OTHER|Questionnaire Administration|Ancillary studies
214501286|NCT06216249|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
214998580|NCT05467527|BEHAVIORAL|Positive parenting advice|The Control Group will receive a total of 6 online modules and 4 group-based video conferencing sessions in a closed group of 6-8, 60 minutes per session guided by a trained facilitator via the mobile app across 12 weeks. The online modules will provide identical contents to those in the PACT group, but no guided ACT metaphors or experiential exercises. The interaction sessions serve to review and discuss the contents of online modules, but without the contents related to ACT/prosociality.
214998581|NCT06913595|DRUG|Direct Oral Anticoagulant.|Direct Oral Anticoagulant AFTER BARIATRIC SURGERY
214998582|NCT06913595|DRUG|Low Molecular Weight Heparine|Low molecular weight heparin after bariatric surgery
214998583|NCT07105657|OTHER|Rehabilitation|Three weeks intensive rehabilitation where patients undergo group-based and individualised rehabilitation focusing at improving pain, function and quality of life for the patient
214998584|NCT07103447|DRUG|AK112, Carboplatin, Paxlitaxel|The combination of AK112, a platinum-based chemotherapy agent, and Paxlitaxel is administered every three weeks as a neoadjuvant treatment for triple-negative breast cancer. After completing six cycles of this regimen, the participant undergoes surgical treatment.
214998585|NCT07103291|OTHER|Respiratory muscle endurance training|Respiratory muscle endurance training program over 5 weeks.
214998586|NCT07103291|OTHER|Sham respiratory muscle endurance training|Respiratory muscle endurance training program over 5 weeks following a sham training procedure that is meant to elicit no physiologic changes.
214998587|NCT07103577|PROCEDURE|Island osteoperiosteal flap|Crestal incision using no. 15 blade on a bard parker no. 3. Two blind lateral vertical ostotomies at about 1.5 to 2 mm from the adjacent tooth roots to preserve subpapillary and root bone coverage. These cuts are to ensure the complete fracture of buccal plate while being attached to the overlying periosteum.
214998588|NCT07103577|PROCEDURE|Conventional ridge splitting|Crestal incision and 2 vertical releasing incisions will be made using a no.15 blade mounted on a Bard Parker no.3. Then, a full mucoperiosteal flap reflection to expose bone.
214998589|NCT07102680|OTHER|L Max|L Max proprietary formulation
214998590|NCT07102680|OTHER|Placebo|Lactohale 300
214389711|NCT01967264|DRUG|Placebo|Placebo tablets
214389712|NCT05067946|BIOLOGICAL|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
214389713|NCT05067946|OTHER|Placebo|GX-19N formulation buffer
214389714|NCT04540484|OTHER|Screening|Blood test screening for covid
214389715|NCT05753423|DIAGNOSTIC_TEST|Interview-based questionnaires & Clinical examination|Interview-based questionnaires will be conducted among Egyptian mothers attending Pediatric Dentistry and Dental Public Health outpatient clinic at Faculty of Dentistry, Ain Shams University by the principal investigator. Clinical examination of the oral health status of their preschool children aged 3-5 years will be conducted by the principal investigator.
214389716|NCT04011332|OTHER|Integrated Care Model|The patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led integrated care model for three months. The model constitutes a bundle of interventions that are commonly known as key elements in COPD management. In addition, the ANP-Team (Advanced Nursing Practice-Team) will coordinate the different health professionals within the hospital and across transitions within the three months.
214389717|NCT03949088|OTHER|UF and Na profiling|Modulation of UF and dialysate sodium
214389718|NCT06329674|DRUG|AJU-A51|Subjects take the investigational products once a day for 24 weeks.
214389719|NCT06329674|DRUG|A51R2|Subjects take the investigational products once a day for 24 weeks.
214389720|NCT06329674|DRUG|A51R3|Subjects take the investigational products once a day for 24 weeks.
214389721|NCT06329674|DRUG|AJU-A51 Placebo|Subjects take the investigational products once a day for 24 weeks.
214394035|NCT00451568|DRUG|Desorelle|1 tablet/day in 21 days
214394036|NCT05929508|OTHER|Ischemic Preconditioning|A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
214394037|NCT01278108|DRUG|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
214394038|NCT01278108|DRUG|placebo|single dose, oral solution or capsule (matching corresponding study medication)
214394039|NCT01278108|DRUG|GLPG0778|multiple dose, capsule, 7 days
214394040|NCT01278108|DRUG|placebo|multiple dose, capsule, 7 days
214394041|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 1
214394042|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 2
214394043|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 3
214394044|NCT01688960|DRUG|aflibercept (ziv-aflibercept)|Dose level 1
214394045|NCT01688960|DRUG|aflibercept (ziv-aflibercept)|Dose level 2
214394046|NCT06625736|DRUG|Xenical|The Xenical group will receive identical capsules 120mg (one capsule) to be taken three times daily with meals, equaling 360mg total daily dose, which aligns with the usage in adult female patients
214394047|NCT06625736|DIETARY_SUPPLEMENT|The dandelion extract|The dandelion extract group will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals.
214394048|NCT04703803|COMBINATION_PRODUCT|1% lidocaine injection in trigger points|The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
214394049|NCT03455296|OTHER|fluid therapy; crystalloid|maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A \& group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.
214998591|NCT07103460|COMBINATION_PRODUCT|Essential Oil Diffusion Combined with Respiratory Training|three commonly used essential oils (wintergreen, peppermint, and eucalyptus) will be integrated into IS respiratory training
215094032|NCT06876740|BEHAVIORAL|Project Safe Guard - Trauma|Project Safe Guard-Trauma (PSG-T) is a brief (15- to 20-minute), single-session lethal means safety counseling intervention (LMSC) for firearm-owning individuals with posttraumatic stress disorder (PTSD). PSG-T is designed to promote secure firearm storage practices by (1) using motivational interviewing techniques and (2) addressing the functional link between PTSD symptoms and unsafe firearm storage practices. In motivational interviewing-based LMSC, the clinician uses a guided approach to help individuals identify their values and motivations for secure firearm storage, rather than prescribing a certain set of actions. The focus is on respecting patients' autonomy and normalizing responsible firearm ownership by developing discrepancies, amplifying ambivalence, expressing empathy, rolling with resistance, and supporting self-efficacy. PSG-T combines PSG-proven motivational interviewing techniques with PTSD- and firearm-specific psychoeducation.
214389722|NCT06329674|DRUG|A51R2 Placebo|Subjects take the investigational products once a day for 24 weeks.
214389723|NCT04517422|DIETARY_SUPPLEMENT|Probiotics|Combination of Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483
214389724|NCT04517422|OTHER|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0
214389725|NCT01863641|DRUG|calcitriol|Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
214389726|NCT01863641|DRUG|placebo|Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
214998592|NCT07103798|OTHER|College Park ICON|Subjects will be fitted and trained on the College Park ICON MPK. An accommodation period of 2 months will be provided prior to evaluation with the knee joint.
214389727|NCT03016793|DRUG|Puerarin|purabone (puerarin) is a bone graft used for surgical repair of bony defects.
214389728|NCT03016793|DRUG|β- tricalcium phosphate|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
214998593|NCT07103798|OTHER|Conventional NMPK|Subjects will be tested walking with their conventional, mechanical prosthetic knee prior to being fitted with the MPK.
214389729|NCT03016793|DRUG|β- tricalcium phosphate alone|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
214389730|NCT00467922|DRUG|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
214389731|NCT00467922|DRUG|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
214389732|NCT00960752|DRUG|gp100|1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
214389733|NCT00960752|DRUG|R848 gel|Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
214389734|NCT00960752|DRUG|MAGE-3|1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
214389735|NCT04020159|OTHER|Patient Registry|No intervention/treatment
214389736|NCT05259774|DEVICE|Relizema cram|Relizema cream is a CE marked, Class IIa medical device, dermatological cream for topical use indicated for symptomatic treatment of dermatitis and erythema. Relizema cream is indicated for the treatment of itching and flushing associated with different types of dermatitis, including atopic dermatitis.
214389737|NCT00461292|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection \> Week 12; injections into detrusor
214389738|NCT00461292|BIOLOGICAL|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor
214389739|NCT00461292|OTHER|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection \> 12 weeks; injections into detrusor
214998594|NCT07104305|BEHAVIORAL|High-contact communication strategy|Patients will have contact with their clinician more frequently. The communication strategy may utilize text, email, portal, phone, video or other options as agreed on. The frequency will be at least once a week. All patients will complete a set of questionnaires at the end of the visit.
214389740|NCT00461292|OTHER|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor
214389741|NCT02180438|DRUG|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
214389742|NCT02926664|OTHER|measurement of qSOFA|qSOFA will be measured at H0, H1 and H3
214389743|NCT05232435|OTHER|pilate mat exercise will be performed|pilate group:1- bridging 2- shoulder bridge 3- front support 4- spine stretch forward 5- spine twist plus standard treatment(stretch hamstring -stretch lower back - strength abdominal muscles - electrical heat pad)
214389744|NCT05232435|OTHER|MET|Will receive MET for hamstring and erectorspinae plus standard treatment
214389745|NCT05232435|OTHER|control group receive standard treatment|electrical heat pad - stretch hamstring - stretch lower back muscles - stregth abdominal muscles
214389746|NCT03176589|DEVICE|positive expiratory pressure (PEP)|Patients take a deep inspiration followed by PEP expiration with an expiratory pressure of 10-15 cm H2O
214389747|NCT03176589|DEVICE|Placebo comparator, Deep inspiration and expression in a placebo tube without resistance|Deep inspirations 3 times 10 and expiration in a placebo tube without expiratory resistance
214389748|NCT03176589|OTHER|Deep breathing maneuvers|deep breathing maneuvers 3 times 10 breahs without any device at expiration
214389749|NCT01811940|DRUG|Adderall-ER|MAS-ER 60mg/day
214389750|NCT01811940|DRUG|Topiramate|Topiramate 100 mg bid.
214389751|NCT01811940|OTHER|Placebo|Placebo
214389752|NCT03115008|BEHAVIORAL|Video-based terminal feedback|Terminal feedback is given after skill performance using video-based coaching coupled with a validated polypectomy assessment tool
214389753|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg BID
214389754|NCT01057108|OTHER|FOSTRAP Chewing Gum|40 mg BID
214389755|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg TID
214389756|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg TID
214389757|NCT01057108|OTHER|Placebo chewing gum|
214389758|NCT00042796|DRUG|decitabine|Given IV
214389759|NCT00042796|OTHER|pharmacological study|Correlative studies
214389760|NCT00042796|OTHER|laboratory biomarker analysis|Correlative studies
214389761|NCT01267981|DRUG|Standard diet|"After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy."
214501287|NCT05273463|BEHAVIORAL|Video-Based Intervention|15-minute video about what to expect before, during, and after your surgery
214501288|NCT05273463|BEHAVIORAL|Classroom-Based Intervention|Virtual 30-minute course with an Orthopedic nurse about what to expect before, during, and after your surgery
214501289|NCT05393024|DRUG|Belantamab mafodotin|MMRR patients included in Named Patient Program e Expanded Access Program
214501290|NCT05876338|OTHER|CRCaSSM|The intervention group will receive face-to-face training, giving patient education booklet and telephone counseling based on the symptom management model. After the training, it is planned to provide telephone counseling for a total of 6 times, once every 2 weeks for 3 months.
214998595|NCT07104006|BEHAVIORAL|Multi-Theory Model (MTM)-Based Smoking Cessation Program|"Multi-Theory Model (MTM)-Based Smoking Cessation Program: A four-week online smoking cessation program based on the Multi-Theory Model (MTM). It uses behavior change strategies including participatory dialogue, building confidence, emotional transformation, practice for change, and changes in physical and social environment. Activities include storytelling, role-playing high-risk situations, emotional regulation, social support, stress management, reflection, and commitment exercises. The goal is to help young adults initiate and maintain quitting smoking.~Knowledge-Based Smoking Risk Education and Quit Strategies Program: A four-week, online educational program providing information on smoking risks, benefits of quitting, barriers, and practical quit strategies. This control arm focuses on increasing knowledge and awareness but does not include MTM-based behavior change techniques."
214998596|NCT04132440|OTHER|Interview|Complete interview
214389762|NCT01267981|DRUG|Standard Diet + 500 ml of polyethyleneglycol|Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
214501291|NCT06389110|DRUG|Alleance®|Atropine sulfate 0.01%, ophthalmic solution.
214501292|NCT06389110|DRUG|Placebo|Ophthalmic solution.
214501293|NCT06117124|RADIATION|Digital X-Ray Radiogrammetry|An x-ray of the left hand will be taken by a Radiographer. This will be uploaded to PACS and analysed using BoneXpert software. This calculates bone density as a 'Bone Health Index', and provides a standard deviation score for age, gender and bone age.
214998597|NCT04132440|OTHER|Questionnaire Administration|Complete questionnaire
214998598|NCT07108894|BIOLOGICAL|ABCL575|Participants will receive SC injection of ABCL575
214998599|NCT07108894|BIOLOGICAL|Placebo (Normal Saline 0.9%)|Participants will receive SC injection of placebo (Normal Saline 0.9%)
214998600|NCT07108335|OTHER|PROvider ReMote ObsTetric-Related Employment Education (PROMOTE)|An on-demand 30-minute web-based training for clinical team members that provides a high-level summary of federal employment laws, work note templates embedded into the electronic health record (EHR) that prompt the clinician team member to include relevant information, and a patient-facing infographic designed to facilitate clinician counseling.
214998601|NCT06910397|DRUG|Probiotic Arm|one tablet daily for 28 days
214998602|NCT06910397|OTHER|Placebo|placebo tablet once daily for 28 days
214389763|NCT01267981|DRUG|Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol|apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
214389764|NCT02737020|DRUG|Rhodiola|Rhodiola rosea 200mg pill up to four times a day
214389765|NCT02737020|DRUG|Placebo|up to four times a day
214389766|NCT04484766|OTHER|Primary data collection|"Primary data collection takes place via questionnaires outside the study centre.~All other investigations take place at the study centre:~* Physical examination: height, weight, BMI, blood pressure~* Cardiac examination: cardiac output~* Vascular measurements: Carotid intima media thickness, total peripheral resistance, blood pressure, flow-mediated vascular dilatation, critical flicker frequency, pulse wave velocity, augmentation index~* Serum analysis: basic laboratory, multiplex analysis (human vascular inflammation, human angiogenesis and adhesion molecule panel)"
214389767|NCT03784534|OTHER|Imaging|high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan
214389768|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor recovery progress|NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth
214389769|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor skills|the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
214389770|NCT05365113|PROCEDURE|alveolar recruitment maneuver|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
214998603|NCT07107529|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
214998604|NCT07107529|DRUG|Talquetamab|Talquetamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
214998605|NCT07107529|DRUG|Daratumumab|Dartumumab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
214998606|NCT07101458|BEHAVIORAL|Promoting Resilience in Stress Management intervention|PRISM is a manualized, skills-based training program comprised of three 60-minute, one-on-one sessions designed to build resilience resources (stress management, goal-setting, cognitive-reframing, and meaning-making) in adolescents and young adults (AYAs). The sessions are scheduled every 1-2 weeks based on participant preference. In this study, the PRISM sessions will be facilitated by trained nurses who hold bachelor's degrees in Nursing Science with a specialisation in mental health.
214389771|NCT02664779|OTHER|Arrhythmia diagnosis with the 10 steps method|
214389772|NCT02664779|OTHER|Arrhythmia diagnosis with the 6 steps method|
214389773|NCT02664779|OTHER|Arrhythmia diagnosis with the 4 steps method|
214389774|NCT00180713|DRUG|Simvastatin|Simvastatin 40mg od for 1 month, then 80mg od for 11 months
214389775|NCT00180713|DRUG|Placebo|Placebo tablet once daily.
214389776|NCT04103554|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID
214389777|NCT04103554|DRUG|Standard of care|standard of care used for treating BP
214389778|NCT04124874|OTHER|There will be no intervention|There will be no intervention
214389779|NCT05711888|BEHAVIORAL|Semantic Recognition Procedure|A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.
214389780|NCT06574828|DRUG|BIIB091|Administered as specified in the treatment arm.
214389781|NCT06574828|DRUG|Moxifloxacin|Administered as specified in the treatment arm.
214389782|NCT06574828|DRUG|BIIB091-matched Placebo|Administered as specified in the treatment arm.
214389783|NCT06574828|DRUG|Moxifloxacin-matched Placebo|Administered as specified in the treatment arm.
214389784|NCT05923086|DRUG|ORE001|Administration before major meal
214389785|NCT05923086|DRUG|Placebo|Administration before major meal
214389786|NCT06206616|BEHAVIORAL|Gluten-free diet|"Pediatric patients affected by newly diagnosed Celiac Disease (CD) according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will start a gluten-free diet (GFD), as normally expected for all CD patients. The assessment of adherence to the GFD will be carried out through the monthly compilation, by the children and/or their parents, of a specifically created and validated questionnaire.~Before and after the start of GFD enrolled patients will undergo an abdominal ultrasound to establish the presence and degree of hepatic steatosis."
214389787|NCT03761082|OTHER|NA(observation study)|NA(observation study)
214389788|NCT05536778|OTHER|Realization of the 3 tests|The participants will have to perform the isokinetic evaluation during one session and the two functional tests during another session. Those sessions will be separated by 14 days.
214389789|NCT05254444|BEHAVIORAL|Social marketing|Multi-tiered nutrition social marketing intervention focused on sustainable fish nutrition, dietary diversity and food safety.
214389790|NCT05254444|BEHAVIORAL|social marketing + gear modification|Multi-tiered nutrition social marketing intervention plus fishing gear modification (basket trap) and training.
214389791|NCT04943263|OTHER|Tracheal Temperature|Temperature measured from the endotracheal tube compared with the esophageal temperature
214389792|NCT05315661|DRUG|ET-STEM|mesenchymal stem cells preconditioned with ethionamide
214389793|NCT01979731|OTHER|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
214389794|NCT01979731|OTHER|Guidelines ergonomics|Orientation about manual material handling, posture, furniture, rest break and others in general.
214389795|NCT00964457|DRUG|cetuximab|cetuximab 500mg per meter square every second week
214389796|NCT01628627|DEVICE|Frequency Modulated Neural Stimulation (FREMS) (Aptiva)|FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly \~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
214389797|NCT01628627|DEVICE|sham treatment (Aptiva)|The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
214389798|NCT00507221|DRUG|Albendazole|"Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days"
214389799|NCT00507221|DRUG|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
214389800|NCT00507221|DRUG|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
214389801|NCT03251560|DRUG|Fuke Qianjin capsule|Fuke Qianjin capsule 0.8g pills by mouth, three times daily
214389802|NCT03251560|DRUG|Placebo oral capsule|Placebo oral capsule 0.8g pill by mouth, three times daily
214389803|NCT05191641|OTHER|Individualized nursing care|Individualized nursing care based on the Professional Values Model for parents of pediatric oncology patients
214389804|NCT04022460|DIAGNOSTIC_TEST|Video clip assessment|Parents will take short video clips of their child sleeping at night. They will be asked to review the video clips and rate whether they think their child has obstructive sleep apnea (OSA), and if so, how severe it is. Two clinicians will review the video clips on a separate night.
214389805|NCT04022460|DIAGNOSTIC_TEST|Polysomnography (sleep study)|Children will undergo a polysomnography as the gold standard test to assess for OSA.
214389806|NCT04022460|OTHER|Educational webinar|After evaluating the video clips of their child sleeping, parents will watch an educational webinar on OSA in children with Down syndrome and how to recognize symptoms.
214389807|NCT01411722|DEVICE|Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)|Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
214389808|NCT00591123|DRUG|FOLFOX|Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions
214389809|NCT00591123|DRUG|5-FU|5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home.
214389810|NCT00591123|DRUG|Erlotinib|All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
214389811|NCT05626972|DRUG|Tenecteplase|Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK (0.25mg/kg) before endovascular therapy (EVT)
214389812|NCT05591560|DRUG|Itraconazole capsule|Oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group II
214389813|NCT05591560|DRUG|Placebo|4 placebo capsules for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group I
214389814|NCT05438225|BEHAVIORAL|Automated text message reminder|Participants in the intervention group will receive monthly automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
214389815|NCT01007240|DEVICE|polyethylenimine (PEI) nanoparticles.|
214389816|NCT06272019|OTHER|Iodine gargle|Iodine gargle 0.2 %
214389817|NCT03075956|DRUG|5 mg E4 single-dose|A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
214389818|NCT03075956|DRUG|15 mg E4 single-dose|A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
214389819|NCT03075956|DRUG|45 mg E4 single-dose|A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
214389820|NCT03075956|DRUG|15 mg E4 multiple-dose|15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
214389821|NCT06114563|OTHER|Spirulina yogurt|High cardiometabolic risk volunteers will be asked to consume 2 yogurts with spirulina, each containing 2 g spirulina, daily for 8 weeks, without any other change in their dietary habits and physical activity.
214389822|NCT06114563|OTHER|Conventional yogurt|High cardiometabolic risk volunteers will be asked to consume 2 conventional yogurts (without spirulina), daily for 8 weeks, without any other change in their dietary habits and physical activity.
214389823|NCT01052909|DRUG|Glimepiride|Glimepiride tablets 1 mg
214389824|NCT06622785|BEHAVIORAL|Physical activity|Data were collected using a International Physical Activity Questionnaire-Short Form (IPAQ-SF)
214389825|NCT06622785|BEHAVIORAL|Exercise Benefits|Data were collected using a Exercise Benefits/Barriers Scale .
214389826|NCT00000692|DRUG|Butyldeoxynojirimycin|
214389827|NCT02326844|DRUG|BMN 673 (talazoparib)|1 mg by mouth (p.o.) once daily on 28-day cycles until disease progression
214389828|NCT00004928|DIETARY_SUPPLEMENT|calcitriol|
214389829|NCT00004928|DRUG|zoledronic acid|
214389830|NCT06280963|BEHAVIORAL|muscle energy technique|in muscle energy technique, the target is gluteus maximus muscle ( hip extension ) and repeat the method from three to five times .
214501294|NCT06117124|DIAGNOSTIC_TEST|Quantitative Ultrasound (QUS)|The MiniOmni Bone Densitometer will be used to measure bone density at three peripheral sites on both sides of the body (left and right): the distal radius (lower arm), mid-tibia (lower leg) and phalynx (hand). The speed of ultrasound (speed of sound) through the bone will be measured and converted to a standard deviation score.
214389831|NCT06280963|BEHAVIORAL|posterior innominate mobilization|in posterior innominate mobilization ( grade 3 mobilization ) , frequency of mobilizations is 30 oscillations , 3 sets per session ( every set has 30 oscillations )
214389832|NCT06280963|BEHAVIORAL|conventional treatment|"conventional treatment include~* TENS ( 45 minutes of conventional TENS )~* Ultrasound (pulsed mode 1:1 ,5 min .1.5W/cm2 )~* Stretching exercises ( hamstrings ,hip flexors and hip adductors)~* Strengthening exercises (lower abdomen and glutes muscles )~* Lumpopelvic stabilization exercise"
214389833|NCT05685771|DEVICE|Phase-targeted auditory stimulation|Bursts of pink noise (50 ms) played during deep non-REM sleep at specific phases of sleep slow waves.
214389834|NCT02339649|PROCEDURE|Blood Sample|Blood Sample
214389835|NCT02339649|BEHAVIORAL|Neurocognitive Assessment|Neurocognitive Assessment
214389836|NCT02339649|OTHER|Resting State EEG|10-20 Minutes of Resting State EEG
214389837|NCT02339649|PROCEDURE|Lumbar Puncture|Lumbar Puncture
214389838|NCT02339649|OTHER|MRI|60 Minutes MRI
214501295|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
214501296|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
214501297|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
214501298|NCT02969356|BIOLOGICAL|Botulinum toxin type A|Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs).
214389839|NCT03630562|PROCEDURE|Aqueous humor samples collection|In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
214389840|NCT04348682|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Imaging|A single dose activity of 5 mCi (accepted range of 3-7 mCi) of 68Ga-PSMA-11 will be intravenously administered to patient as a bolus injection. After 50-100 minutes of uptake time, the patient will undergo a whole body (skull to mid-thighs) PET/CT imaging.
214389841|NCT01091428|DRUG|Alisertib|Alisertib tablets
214389842|NCT01091428|DRUG|Paclitaxel|Paclitaxel intravenous infusion
214501299|NCT02969356|OTHER|GSC|The GSC is a motivational tool. The physiotherapist will teach each subject the stretching postures and exercises to perform on a daily basis throughout the study. These will be tailored to the individual subject's needs and will form the GSC therapy.
214501300|NCT04152408|DEVICE|FiberSense System|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
214501301|NCT03187223|DRUG|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
214998607|NCT07103252|OTHER|Blood Flow Restriction Therapy|Personalized Blood Flow Restriction Therapy uses an an inflatable cuff (Delfi PTS system) around the upper thigh which partially restricts arterial inflow during exercise. BFR allows for similar improvements of muscular strength and muscle mass as traditional heavy load strength training while using significantly lower loads. The reduced stress on supporting tissues ( tendons, joints, bones and ligaments) allows people who normally couldn't tolerate high loads to enhance their strength and muscle mass.
214998608|NCT07104591|BIOLOGICAL|HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)|Banked, partially HLA-matched virus-specific T cells (VSTs) directed against EBV, CMV, adenovirus, and BK virus.
214998609|NCT07104253|DEVICE|Ex vivo cryo-ablation|With informed consent obtained prior to transplantation, explanted lungs from patients undergoing lung transplantation will be obtained. The organs will be placed in an acrylic box and will be perfused at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 7 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon. The cryocatheter will be inserted in the lungs and cryoablation will be performed with varying freeze-thaw cycles to confirm design and operating specifications of the device.
214998610|NCT07111637|DEVICE|AI software|icobrain ms is an Artificial Intelligence (AI)-assistive software which quantifies brain Magnetic Resonance Imaging (MRIs) and summarises clinically relevant findings for patients with Multiple Sclerosis in structured electronic radiological reports and annotated images.
214998611|NCT06979466|DEVICE|Q Therapeutic System (BQ 3.0) - Active|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
214389843|NCT03863743|OTHER|integrated care pathway|Incidence of POUR after undergoing total hip or knee replacement and integrated care pathway will be evaluated.
214389844|NCT03863743|OTHER|physician's standard of care|Incidence of POUR will be evaluated in standard of care treatment.
214389845|NCT03386695|OTHER|Education by Pamphlets|Distribution of pamphlets with information of prevention and early detection of cervical cancer and written as well as pictorial depiction on how to collect cervical self sample for HPV detection.
214389846|NCT03386695|OTHER|Health education programme|Health education program explaining about prevention and early detection of cancer and education on method of collection of cervical self sample for HPV.
214389847|NCT06115850|PROCEDURE|Music|In the music intervention group, the patients received music intervention during RT for 10 consecutive days and listened to music for approximately 10-15 minutes in each session.
214389848|NCT04468243|OTHER|Nurse-led diabetes care|Nurse-led brief diabetes education, instructions on glucometer and Metformin use, patients receive prescriptions for Metformin and blood glucose testing kit
214389849|NCT05507489|DRUG|Jinzhen oral liquid or Jinhuaqinggan granules|Jinzhen oral liquid, for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day.The dosage and usage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition. The drugs were medicated for 14 days.
214998612|NCT07103499|BEHAVIORAL|Pilates-Based Core and Breathing Exercise Program|An 8-week supervised Pilates-based exercise program for overweight and obese women, focusing on abdominal endurance and core stabilization. Sessions (3/week) include diaphragmatic breathing, use of reformer and cadillac equipment, and structured warm-up, main, and cool-down phases.
214998613|NCT07103655|DRUG|mavacamten|Add Mavacamten to guideline-directed standard medical therapy for patients with hypertrophic cardiomyopathy (HCM) and mid-to-apical left ventricular obstruction.
214389850|NCT06134245|DEVICE|Entia Liberty|Home monitoring
214389851|NCT02531295|DRUG|Euphorbia kansui extract powder prepared as tea|1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
214389852|NCT01154023|BEHAVIORAL|stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)|Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 \& 6 were delivered individually by phone.
214389853|NCT01167270|BEHAVIORAL|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
214501302|NCT03187223|DRUG|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
214501303|NCT04302233|OTHER|New pharmaceutical support (NPS)|The only difference between these 2 groups is that patients in the NPS group benefit from additional visual and oral information on the characteristics of their implant and on medical device vigilance during their hospitalization.
214998614|NCT07103655|DRUG|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Administer an appropriate dose of beta-blockers according to the patient's tolerance.
214389854|NCT01167270|BEHAVIORAL|Parenting Insights|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
214389855|NCT01315743|BEHAVIORAL|Team COOL|1\) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
214389856|NCT01060020|DRUG|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
214389857|NCT04424290|DRUG|BI 764524|BI 764524
214389858|NCT04424290|DRUG|Sham control of BI 764524|Sham control of BI 764524
214389859|NCT03298607|DIETARY_SUPPLEMENT|Placebo|2 months treatment
214501304|NCT06413979|BEHAVIORAL|Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID)|(1) Family Engagement of caregivers and primary supports in treatment planning and services; (2) Relational Reframing of family constraints, resiliencies, and social capital connected to the youth's ID symptoms; (3) Functional Analysis of the youth's ID symptoms and related behaviors; (4) Cognitive-behavioral therapy (CBT) core techniques to address the youth's ID symptoms and functional needs, featuring three transdiagnostic interventions (emotion acceptance, emotional exposure, behavioral activation) to address negative affect and emotional dysregulation underlying both depression and anxiety; and (5) Family Psychoeducation and Safety Planning focused on education about comorbid SUD/ID and prevention of youth self-harm. All interventions featured in each module have strong empirical support.
214501305|NCT06414577|DRUG|Irinotecan Liposomal combined With Nituzumab|Irinotecan liposomal: 70mg/m2, ivgtt, d1; Nituzumab: 400 mg, igvtt, d1 One treatment cycle every two weeks for up to 8 cycles, or until disease progression, intolerable toxicity, death, and investigator judgment of no further benefit
214501306|NCT05157581|DEVICE|Extracorporeal photopheresis (ECP)|Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
214501307|NCT05157581|DRUG|Methoxsalen Injection|Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
214501308|NCT06148506|OTHER|Ribociclib|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with ribociclib+ET by prescription within the study enrollment timeline will be recruited.
214501309|NCT06148506|OTHER|Combination chemotherapy|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with CT by prescription within the study enrollment timeline will be recruited.
214501310|NCT03614299|OTHER|Ecological symptom measurements using a webapp|A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)
214998615|NCT07103655|DRUG|diltiazem|Administer an appropriate dose of diltiazem according to the patient's tolerance.
214998616|NCT06919757|DIAGNOSTIC_TEST|fetal ultrasound to assess lungs, heart and diaphragm|The potential association between fetal ultrasound parameters (estimation of lung volumes, diaphragmatic thickness and contractility, cardiac thickness and kinetics), perinatal complications and respiratory function in the first years of life will be studied. Variables include: neonatal complications, non-invasive markers of respiratory status during neonatal admission (e.g. peripheral oxygen saturation/rfaction of inspired oxygen ratio among others), lung function tests in the first two years of life.
214998617|NCT02266576|BEHAVIORAL|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.
214998618|NCT02266576|BEHAVIORAL|Enhanced DPP|Enhanced DPP components consist of access to a mental health counselor, active referrals to mental health services, and traditional healing workshops such as the use of talking circles, a modified photo voice and digital storytelling to address specific psychosocial issues that are a result of historical trauma, stress, and grief.
214998619|NCT06245239|DEVICE|perfusion index|measurement of perfusion index
214998620|NCT07124260|DIAGNOSTIC_TEST|gut microbiota|Fresh fecal samples were collected from patients during the non-menstrual period and subjected to 16S rDNA sequencing.
214998621|NCT07124260|DIAGNOSTIC_TEST|tongue coating microbiota|Tongue coating samples were collected under fasting conditions between 6:00-9:00 AM on the same day as fecal specimen collection and subjected to 16S rDNA sequencing.
214998622|NCT07124260|DIAGNOSTIC_TEST|tongue picture|Tongue images were captured under fasting conditions between 6:00-9:00 AM on the same morning as fecal specimen collection.
214998623|NCT07142408|DRUG|Chlorhexidine gluconate (4%)|Chlorhexidine 4% solution will be applied from the neck down (avoiding the face, penis, and vagina), allowed to sit on the skin for one minute, then rinsed off in the shower every day for 5 days prior to surgery.
214998624|NCT07142408|DRUG|Mupirocin 2% Ointment|Mupirocin 2% ointment will be applied to the inside of the nostrils twice daily, in the morning and evening, for 5 days prior to surgery. A small amount of the ointment will be placed on the tip of a cotton swab to facilitate application to each nostril.
214389860|NCT03298607|DIETARY_SUPPLEMENT|Serelys PMS|2 months treatment
214389861|NCT04671290|OTHER|Any intervention|No intervention
214389862|NCT03966690|DEVICE|Isokinetic leg extension/-flexion on a legpress device|Maximum strength and rate of leg-flexion /-extension during legpress exercise
214501311|NCT03614299|DIAGNOSTIC_TEST|Interferometry|Evaluation of the mebomian function using the LipiView methodology
215094033|NCT06876740|BEHAVIORAL|Project Safe Guard|Project Safe Guard-Trauma (PSG) is a brief (15- to 20-minute), single-session lethal means safety counseling intervention (LMSC) for firearm-owning individuals. PSG-T is designed to promote secure firearm storage practices by using motivational interviewing techniques. In motivational interviewing-based LMSC, the clinician uses a guided approach to help individuals identify their values and motivations for secure firearm storage, rather than prescribing a certain set of actions. The focus is on respecting patients' autonomy and normalizing responsible firearm ownership by developing discrepancies, amplifying ambivalence, expressing empathy, rolling with resistance, and supporting self-efficacy.
214501312|NCT04200196|PROCEDURE|"fabrique à histoire"|"Fabrique à histoire is a participatory entertainment method. Children of this arm going to create and listening a story before and during the venous puncture."
214501313|NCT04200196|PROCEDURE|Usual care|It is a passive entertainment method. Children of this arm going to do habitual activities before and during the venous puncture, like to sing, blow up a balloon, to play with recreational thing, etc.
214501314|NCT01850355|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
214501315|NCT04994301|DIAGNOSTIC_TEST|Lung T1 MRI|Evaluation of lung T1 MRI to Assess Lung Disease
214501316|NCT04692532|OTHER|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
214501317|NCT04692532|OTHER|Calorie restriction|25% energy restriction every day
214501318|NCT05475015|DEVICE|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
214501319|NCT05475015|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.
214501320|NCT06256393|OTHER|Collection of biological samples|Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse
214998625|NCT07142200|DRUG|Disitamab Vedotin|Each patient will receive Disitamab Vedotin injection \[2.0 mg/kg, Q2W, iv\], with an expected total of 12 courses of treatment. The specific number of treatment cycles is determined by researchers based on the patient's response to the treatment, tolerance to the treatment plan, and comprehensive assessment of the condition. Patients with safety intolerance caused by any drug treatment should reduce or discontinue the medication according to the dosage adjustment plan specified in the plan. The medication is diluted with physiological saline and administered intravenously for one hour.
214998626|NCT07142200|DRUG|PD-1 inhibitor|Each patient will receive Triprolizumab injection \[3mg/kg, Q2W, iv\], with an expected total of 12 courses of treatment. The specific number of treatment cycles is determined by researchers based on the patient's response to the treatment, tolerance to the treatment plan, and comprehensive assessment of the condition. Patients with safety intolerance caused by any drug treatment should reduce or discontinue the medication according to the dosage adjustment plan specified in the plan. The medication is diluted with physiological saline and administered intravenously for one hour.
215094034|NCT06713616|DRUG|Racemic ketamine|Ketamine will be given intravenously. Per FDA guidance, the max dose of ketamine will be 60mg per day, with a total lifetime limit of 8 doses. Ketamine will be infused over 40 minutes.
215094035|NCT06713616|DRUG|Spravato (Esketamine)|Spravato® (Esketamine) will be given intranasally. For esketamine, the dose will be between 56 and 84mg, according to the FDA label for the drug. Allowances will be made for patients who have difficulty tolerating these doses to be dosed at 28mg in subsequent treatment sessions.
215094036|NCT07037381|OTHER|KN95 mask|AIR+ KN95 mask
215094037|NCT02074813|OTHER|Inspiratory muscle training|Inspiratory muscle training
215094038|NCT00783913|OTHER|Visumotor Upper Extremity Training|Control
215094039|NCT00783913|OTHER|Anodal/Sham tDCS|Condition
214501321|NCT04858412|DIETARY_SUPPLEMENT|β-hydroxy β-methyl butyrate (HMB) enriched amino acid|β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.
214501322|NCT04858412|DIETARY_SUPPLEMENT|Balanced amino acid|Balanced amino acid is the balanced mixture of the various essential amino acids.
214501323|NCT04148742|DRUG|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
214501324|NCT05396638|BEHAVIORAL|Contingency Management|Participants will be paid for abstinence at each study visit.
214501325|NCT06217588|OTHER|Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.|The study will collect extensive historical health data (retrospective), and at baseline will conduct an extensive characterization of the disease progression using the parameters described above.
214501326|NCT06282913|BEHAVIORAL|Mindfulness Meditation|Mindfulness Meditation application will be implemented online by the researcher in 20-minute group sessions once a week for 8 weeks. Participants will be asked to provide a quiet, ventilated, dimly lit environment for the practice. The researcher will start the application when the participants take their places as they feel comfortable. In the first stage, the researcher will teach physicians and nurses to take deep diaphragmatic breaths through the nose and out through the mouth.
214501327|NCT02808468|BEHAVIORAL|Brief Cognitive Therapy|Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
214501328|NCT05405140|OTHER|Shock wave therapy with multiphasic neuroplasticity based training protocol|Interventions program will be based on Activity dependent neuroplasticity targeting relevant impairments included: task specific practice, motor learning, strengthening, postural awareness, Balance training, aerobic and conditioning exercises, range of movement with Shock wave therapy for most of time of the day .
214501329|NCT05405140|OTHER|Conventional physical therapy|The CP program focused on the facilitation of movements on the paretic side, range of motion, stretching exercises, upper and lower limb strengthening exercises, and improving balance, standing, sitting, transferring, patients received a program for at least 30 sessions, 5 times per week for 6 or more weeks.
214501330|NCT05887531|OTHER|Prehabilitation|Patients will be included in a prehabilitation program
214501331|NCT01434251|OTHER|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
214501332|NCT04906057|BEHAVIORAL|Forced Aerobic Exercise (FE)|High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer
214501333|NCT04906057|BEHAVIORAL|Voluntary Aerobic Exercise (VE)|Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer
214501334|NCT04266236|PROCEDURE|L3 LPB|ultrasound-guided L3 lumbar plexus block
214501335|NCT04266236|PROCEDURE|L4 LPB|ultrasound-guided L4 lumbar plexus block
214501336|NCT04266236|PROCEDURE|T12 block|ultrasound-guided thoracic 12th segment nerve block
215094040|NCT06175156|PROCEDURE|Controlled analgesia/sedation|During the pre anesthesia assessment, explain in detail to the patient the usage of the self-control pump and confirm that each patient can master it. Firstly, connect the self-control analgesic pump with a loading dose of 3 ml. Then, continuously pump in a mixture of propofol and remifentanil at a speed of 0.1 ml/kg/h. After the loading dose is completed, the examination can begin. During the operation, press the self-control handle according to the patient's sensation. Each press can quickly push 1ml of the medication, with a locking time of 1 minute
215094041|NCT06175156|PROCEDURE|Intravenous combined anesthesia|Intravenous slow infusion of fentanyl 1 μ G/kg, midazolam 0.02mg/kg, slowly administer propofol 0.8-1mg/kg after 2 minutes (time greater than 60 seconds), and start the examination when the patient's consciousness disappears and they do not respond. During the surgery, propofol is interrupted to maintain the auditory evoked potential index (AAI) between 30-40.
215094042|NCT01650272|DRUG|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
215094043|NCT01650272|DRUG|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
214389863|NCT03966690|DEVICE|Isokinetic leg extension/-flexion on a legcurl device|Maximum strength and rate of leg-flexion /-extension during legcurl exercise
214501337|NCT04266236|PROCEDURE|L3 QLB|ultrasound-guided quadratus lumborum block at L3 level
214501338|NCT04266236|DRUG|0.375%ropivacaine 25 ml (Raropin)|0.375%ropivacaine (Raropin) 25ml will be given
214501339|NCT04266236|DRUG|0.375%ropivacaine 40 ml (Raropin)|0.375%ropivacaine (Raropin) 40ml will be given
214501340|NCT04266236|PROCEDURE|General anesthesia with tracheal intubation|General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation
214501341|NCT04908358|OTHER|Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Stimulation of vagus nerve in the outer ear
214687921|NCT04077970|BIOLOGICAL|Intrauterine flushing of follicular fluid with granulosa cells|All patients in case and control groups will receive agonist and antagonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
214389864|NCT02477891|DRUG|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram \[mg/kg\]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
214389865|NCT02011256|DEVICE|Implantable loop-recorder|All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
214501342|NCT04908358|OTHER|Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Sham stimulation of vagus nerve in the outer ear
214501343|NCT06006117|DRUG|Mosunetuzumab + Lenalidomide|"* Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~  * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~ * C2 to C12: 45 mg D1 28-days cycles~* Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)"
214501344|NCT06006117|DRUG|- Rituximab + Lenalidomide (28-days cycles|"* Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12"
214501345|NCT06006117|DRUG|- Rituximab + Bendamustine (28-days cycles)|"* Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6."
214501346|NCT06006117|DRUG|- Rituximab + CHOP (21-days cycles)|"* CHOP, IV standard dose from cycle 1 to 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)"
214501347|NCT06448624|DRUG|Ampicillin sulbactam 3 days|Ampicillin sulbactam 1.5 gram IV BID for 3 days after CIED implantation
214501348|NCT06448624|DRUG|Placebo 3 days|Placebo for 3 days after CIED implantation
214389866|NCT03393403|DRUG|Dexmedetomidine|0.5mcg/kg intravenous(IV)continuous infusion for 30 minutes, or 0.5mcg/kg adding to local anesthetic for subcostal TAP block
214389867|NCT03393403|DRUG|0.9% Sodium-chloride|0.125ml/kg intravenously infusion in Dexmedetomidine\_adj group and control group
214389868|NCT03408834|OTHER|pulse variability index|fluid management with pulse variability index or conventional
214389869|NCT04544228|PROCEDURE|Serratus Anterior Plane Block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
214389870|NCT04544228|PROCEDURE|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes."
214389871|NCT04544228|DRUG|bupivacaine +ketamine|30 ml bupivacaine 0.25% + 1 ml ketamine (50mg) in Serratus Anterior Plane Block.
214389872|NCT04544228|DRUG|bupivacaine + neostigmine|30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.
214389873|NCT04544228|DRUG|bupivacaine +saline|30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
214389874|NCT06306560|DRUG|adebrelimab|adebrelimab IV
214389875|NCT06306560|DRUG|famitinib|famitinib PO
214389876|NCT06306560|DRUG|chemotherapy|chemotherapy IV
214389877|NCT01899118|RADIATION|Preoperative irradiation|50.4Gy/28F/5.5w
214389878|NCT01899118|DRUG|Nimotuzumab|400mg/w，0-5w
214389879|NCT01899118|DRUG|Oxaliplatin|130mg/m2 d1
214389880|NCT01899118|DRUG|Capecitabine|825mg/m2 bid d1-5/w,1-5w
214389881|NCT03434236|DIETARY_SUPPLEMENT|low dose Lipinova (30 mL daily)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
214389882|NCT03434236|DIETARY_SUPPLEMENT|Placebo|Placebo will have a similar appearance, smell and taste as the nutritional supplement
214389883|NCT03434236|DIETARY_SUPPLEMENT|high dose Lipinova (60mL)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
214389884|NCT05078684|PROCEDURE|Left ganglion stellate block|Ultrasound-guided anesthetic block of left ganglion stellate using 8ml of 5% bupivacaine.
214389885|NCT05078684|PROCEDURE|Sham left ganglion stellate block|Subcutaneous application of 0.5-1ml of 5% bupivacaine to the site of expected LGSB
214998627|NCT07142200|RADIATION|radiotherapy|"1. Whole bladder treatment, recommended scope of application: T2 Suggestion: The total bladder radiotherapy dose is 2Gy/day, five times a week, up to a dose of 50Gy/25 times, to cover at least 95% of the planned target volume (PTV full bladder).~   The radiation dose for shrinking the field to bladder tumors is 2Gy/day, five times a week, with a total dose of 14Gy/7 times, to cover at least 95% of the planned target dose (PTV bladder tumors).~2. Whole pelvic radiotherapy (whole bladder+selective pelvic lymph node radiotherapy), applicable range: T3-T4a Suggestion: Whole pelvic radiotherapy at 2Gy/day, five times a week, up to a dose of 46Gy/23 times, to cover at least 95% of the planned target dose.~Reduce the dosage to 2Gy/day for the entire bladder and up to 4Gy/twice. Bladder tumor (PTV bladder tumor) 2Gy/day, five times a week, with a total dose of 14Gy/7 times, to cover at least 95% of the planned target volume.~The above radiotherapy plan is a suggestion, and the specific plan will"
214998628|NCT07141823|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid) regularly has been taken|
214389886|NCT03452020|DEVICE|Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer|Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
214389887|NCT03636945|OTHER|PET at 18F-FDOPA|18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET imaging
214389888|NCT03013699|BEHAVIORAL|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
214501349|NCT03469791|PROCEDURE|Surgical treatment of Degenerative Spondylolisthesis|
214998629|NCT07141069|OTHER|Art therapy combined with Exercise|one hour of expressive art intervention followed by one hour of exercise training. The art therapy will be conducted in small groups of eight participants, facilitated by a part-time registered expressive art therapist. Each session begins with a 5-minute introduction and check-in, welcoming participants and inviting them to share their current status. This is followed by a 10-minute brief mindfulness exercise to help center participants and promote relaxation, setting the stage for the creative activities that follow. The core of each session consists of a 20-minute art-making process centered around specific themes that guide participants in exploring their pain and personal narratives.
214998630|NCT07141069|OTHER|Exercise|each one-hour session in the exercise control group will involve progressive back and general reconditioning exercises, along with back care education to support self-management of LBP.
215094044|NCT05757167|DIAGNOSTIC_TEST|Malaria High-Sensitivity Rapid Diagnostic Test (HS-RDT)|"Detection of Plasmodium falciparum HRP-II antigen1~Method: Lateral Flow; Time to Result: 20 minutes; Sample Type: Fingerstick Whole Blood; Sample Volume: 5µl; Storage Conditions: 1-30°C; Shelf Life: 12 months; Sensitivity/Specificity: 99.0%/98.6%"
215094045|NCT05757167|DRUG|Artemether-lumefantrine (AL)|oral tablets: 6 doses of 80/480 mg over 3 days
215094046|NCT06074458|OTHER|Glucosano|Glucosano is a remote patient monitoring diabetes dashboard with a patient facing Smartphone application
215094047|NCT06074458|BEHAVIORAL|Community Health Worker diabetes technology coach|Community Health Workers will work with participants as a diabetes technology coach during scheduled and as needed visits
215094048|NCT03922087|OTHER|No intervention|No intervention
214389889|NCT03013699|BEHAVIORAL|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
214389890|NCT02527837|DRUG|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
214998631|NCT07142174|DEVICE|cervical facet implant will be introduced into the cervical levels that were mobile on flexion-extension x-ray and exhibited foramen stenosis or spondylolisthesis|"The patients will be managed according to the current practice for posterior cervical spine surgical approaches regarding patient positioning, surgical exposure, and neural decompression. The patients will be positioned prone with the head in a Mayfield headrest, All patients will be monitored using intraoperative motor evoked potentials (MEP) and somatosensory evoked potentials (SSEP). Intra-operative X-rays (antero-posterior and lateral) will be used to identify the index cervical level and to guide facet preparation and CeLFI insertion. Exposure of the posterior surface of the lateral mass at the index level of the cervical spine will be done either through a midline open technique or para-midline; inter-muscular approach (MIS). The facet joint-space (FJS) will be opened using a monopolar cautery with careful attention to preserve the joint's capsule on the lateral and medial boundaries.~The FJS will be prepared using sequential dilators; designed for this purpose. Each dilator me"
215094049|NCT06900920|DRUG|TQB3473 Tablets|TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.
214389891|NCT02527837|DRUG|Sodium chloride|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
215094050|NCT06900920|DRUG|TQB3473 Placebo|Placebo contains no active substance.
215094051|NCT06929676|PROCEDURE|Periodontal Treatment|Non-surgical periodontal treatment with scaling and root planing and dental splinting
214389892|NCT05444400|OTHER|Strengthening|Strengthening
214389893|NCT05444400|OTHER|Conventional protocol|Conventional protocol
215094052|NCT06929676|OTHER|assessment of tooth mobility before and after periodontal treatment|Evaluation of dental mobility with a customized device before and after non-surgical periodontal therapy and after stabilization by periodontal splints
214389894|NCT02127320|DRUG|Rosuvastatin 20mg|
214389895|NCT02127320|DRUG|Ezetimibe 10mg|
214389896|NCT02127320|DRUG|Rosuvastatin 20mg + Ezetimibe 10mg|
214389897|NCT05769699|PROCEDURE|blood sample|blood sample
214389898|NCT02612896|DRUG|Mass drug administration, praziquantel 10mg/kg|see previous, in elimination study arm only
214389899|NCT02612896|BEHAVIORAL|Health education|in all study arms, using village meetings, posters, pamphlets.
214389900|NCT04103320|OTHER|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
214389901|NCT01074632|DRUG|Lurasidone HCl|
214501350|NCT06247904|DEVICE|Active rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be determined from individual MRI-modeled e-field, to achieve approximately motor threshold in the target area.
214501351|NCT06247904|DEVICE|sham rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be close to zero (negligible) since sham coil will be used for the intervention
215094053|NCT06929676|OTHER|Evaluation of Clinical Parameters|Periodontal: probing depth, bone loss, CAL (clinical attachment level) Clinical: occlusal prematurities and collection of gingival crevicular fluid Questionnaire: quality of life (OHIP-14)
215094054|NCT05215730|DEVICE|MedCu wound dressings with copper oxide (COD)|Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
215094055|NCT06653023|BIOLOGICAL|Universal CAR-T cells injection for treating HCC and NSCLC|A novel universal CAR-T platform to treat cancer patients
215094056|NCT04023123|OTHER|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
215094057|NCT04473365|OTHER|Intestinal parasite|Pre-existing intestinal parasite infection present or absent at time of admission
215094058|NCT07089004|DIAGNOSTIC_TEST|No intervention (observational study)|Observational - Biochemical, Hematological and Clinical Scoring Assessments
215094059|NCT01646203|BIOLOGICAL|IMC-TR1|Administered intravenously
214389902|NCT01183702|PROCEDURE|LASIK surgery|Participants have received LASIK surgery and their eyes are healthy.
214389903|NCT01183702|OTHER|No Intervention|Participant has healthy eyes not altered by LASIK surgery.
214389904|NCT02443922|DRUG|Glimepiride|Glimepiride 2mg qam
214389905|NCT02443922|DRUG|Sitagliptin|Sitagliptin 100mg qam
214389906|NCT02443922|DRUG|Metformin|Metformin as prescribed
214389907|NCT01801553|OTHER|Spinal manipulation|"-In the intervention group :~True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:~If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.~-In the control group:~Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body."
214501352|NCT04986930|RADIATION|SBRT+mFOLFIRINOX|Stereotactic body radiotherapy: 3500 cGy (5 fractions) mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
214998632|NCT07140835|DEVICE|SurgiStep Platform|The Surgistep (pedal-controlled, adjustable platform) allows real-time height adjustment during surgery. The surgeons can adjust the height of the platform.
214998633|NCT07140835|DEVICE|Standard Foot stool|Foot stool is considered as the standard of care during surgery.
214998634|NCT07140822|DEVICE|Coronary Cutting Balloon Catheter|This product uses a pressure device to pressurize the balloon to expand it. The blades designed on the surface of the balloon produce a cutting effect on the vascular lesions, allowing it to better embed into the plaque.
214389908|NCT01801553|OTHER|sham spinal manipulation|
214389909|NCT01801553|OTHER|Usual medical care|
214389910|NCT05461105|DRUG|rencofilstat, 75 mg|1 softgel capsule
214389911|NCT05461105|DRUG|rencofilstat, 150mg|2 softgel capsules
214389912|NCT05461105|DRUG|rencofilstat, 225 mg|3 softgel capsules
214389913|NCT05713812|PROCEDURE|Kinesiotaping|Kinesiotape will be applied
214389914|NCT05713812|PROCEDURE|Control Treatment|IFC + Hot pack for 20 minutes MDT (prone positioning) for 10 minutes. Lumbar SNAGs + lumbar rotation mobilization. Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.
214389915|NCT00167986|DRUG|vancomycin-resistant enterococci and ESBL|
214389916|NCT03273140|DEVICE|Gamification Diabetes Education Program (GDEP)|"Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform."
214389917|NCT02423590|DRUG|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
214389918|NCT02423590|DRUG|Gemcitabine|"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
214389919|NCT02423590|DRUG|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
214389920|NCT03621722|OTHER|Elequil Aromatabs|There will be a variety of different Aromatabs such as orange/peppermint or lavender
214389921|NCT02354924|DEVICE|Biofinity soft contact lens|Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
214501353|NCT04986930|DRUG|mFOLFIRINOX|mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
214998635|NCT07140822|DEVICE|VesscideTM Cutting Balloon System|This product utilizes a pressure mechanism to inflate the balloon, causing it to expand. The blades on the balloon's surface create a cutting action on the vascular lesions, enabling the device to penetrate the plaque more effectively.
214998636|NCT07140744|DIAGNOSTIC_TEST|P-tau217|Blood biomarker testing
214998637|NCT07140744|OTHER|Standard of Care|Standard of care
214998638|NCT07141186|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|Enrolled patients will receive intravenous infusion of QL1706 once every 3 weeks at a dose of 5.0 mg/kg until disease progression, death, intolerable treatment toxicity, or withdrawal from the clinical trial for any reason.
214389922|NCT02354924|DEVICE|Visco soft contact lens|Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
214389923|NCT01849120|DEVICE|EQUANOX Advance 8004CB sensor|The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
214389924|NCT01432015|DRUG|fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
214389925|NCT01432015|DRUG|aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
214389926|NCT01432015|OTHER|Oral Placebo|One pill administered on days 1-3 in conjunction with Fosaprepitant.
214998639|NCT07141420|BEHAVIORAL|Routine Care|Participants receive standard post-ICU follow-up care according to hospital protocols . This includes routine health assessments and general rehabilitation guidance at designated intervals (discharge, 1/3/6 months post-discharge). No structured PICS management program or AI technology is provided.
214998640|NCT07141420|BEHAVIORAL|Health Promotion Model-Based Optimized Program|"An evidence-based, multidisciplinary rehabilitation protocol for Post-Intensive Care Syndrome (PICS) management, developed using the Health Promotion Model (HPM). It includes:~Personalized rehabilitation plans addressing physical, cognitive, and psychological recovery.~Structured follow-up at discharge, 1/3/6 months post-discharge. Components: Physical function training, cognitive exercises, anxiety/depression coping strategies, and sleep hygiene education.~Delivery: Clinician-guided (no AI/technology involved). Developed via literature review and validated by ICU physicians and nursing experts ."
214389927|NCT01432015|OTHER|IV placebo|100 cc of IV placebo administered on day in conjunction with Aprepitant
214389928|NCT00263120|BEHAVIORAL|Pain Questionnaire|
214394050|NCT07032311|DEVICE|Behavioral Treatment|Description: ARM-2-G1: Patient subjects receiving standard care services without GLP-1 medication as part of the treatment regimen, and SIPPA Health behavioral intervention/therapy. ARM-2-G2: Patient subjects receiving standard care services that includes GLP-1 medication as part of the treatment regimen, and SIPPA Health behavioral intervention/therapy.
214394051|NCT07032324|DRUG|CAR T cells|chimeric antigen receptor T cells
214389929|NCT06268639|PROCEDURE|Osseodensification|The intervention, osseodensification, involves a surgical technique using specific drills (e.g., Densah burs) rotated in a counterclockwise direction to compact bone rather than remove it, thereby increasing bone density around the implant site. This method is aimed at improving the primary stability of dental implants by creating a denser bone environment, which theoretically should lead to better osseointegration and long-term success of the implant. The technique distinguishes itself from traditional drilling by preserving and enhancing bone structure, which is crucial for the success of dental implants in patients.
214389930|NCT05351060|OTHER|Custom Fabricated Splint|Participants will wear a customized splint on their affected hand(s)during the hours of sleep for the duration of the study.
214389931|NCT06104072|DEVICE|REHACOM Software|"It is a computer-based cognitive rehabilitation test that includes 32 cognition training tasks for attention/concentration, reaction behavior, memory , logical reasoning \& executive functioning with graded difficulty . It is composed of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patientenpult (1990-1997) EN/ISO-13485-certified).~* For each Cognitive training domain there is one hundred levels of difficulty.~* Each patient is evaluated from level one(1) ang gradually increase the difficulty till we reach the level that will be used in the treatment sessions as the patient's performance improve we can proceed to the next level.~* The period of the session was chosen to be maximum (60 minutes) for each patient with five minutes rest in between each level."
214389932|NCT06104072|OTHER|A Designed Physical Therapy Program|A designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, postural correction, gait training, balance training on different base of supports using static and dynamic balance training with reciprocal and weight shifting exercises.
214389933|NCT06076473|DIAGNOSTIC_TEST|Untargeted metabolomics|Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.
214389934|NCT03849872|DRUG|ONO-5788|Investigational Drug
214389935|NCT03849872|DRUG|[14C]-ONO-5788|Investigational Drug
214389936|NCT06475560|DIAGNOSTIC_TEST|CCE arm|Twice a week, patients will attend the in-hospital clinic in groups of five persons. They will bring their completed FIT sample, questionnaire, and the signed consent form. A project nurse will administer the capsules in the morning, and the patients can leave after. When the capsule investigation is completed, patients must return their belt and receiver to the Department of Surgery, OUH. After a few days, the patient will receive an electronic letter with the results and information regarding upcoming steps. Those with positive findings or an incomplete investigation will be given a new appointment according to the current clinical routine. A second questionnaire will be sent to the patient 2 weeks after the completed procedure.
214389937|NCT06475560|DIAGNOSTIC_TEST|OC arm|Patients will start bowel cleansing according to the instructions. They will bring their completed questionnaire and the signed consent form to the scheduled colonoscopy. They will continue to follow the routine clinical setup for outpatient colonoscopy and will only receive, by digital post, after 2 weeks from the procedure, an extra second questionnaire.
214389938|NCT02755454|DEVICE|Perfusion CT Imaging|
214389939|NCT03620903|DRUG|Ibrutinib / Bortezomib / Rituximab|Induction (Rituximab / Bortezomib / Ibrutinib), Maintenance I (Ibrutinib / Rituximab), Maintenance II (Ibrutinib)
214389940|NCT00398398|DRUG|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
214389941|NCT04647019|DIETARY_SUPPLEMENT|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder consumed daily with 250 ml water. The powder is sealed in sachets and stored at -24 °C, except when transported. Participants are asked to store the sachets in a freezer until consumption.
214389942|NCT04647019|DIETARY_SUPPLEMENT|Placebo powder|22 g placebo powder matched for macronutrients, color, and flavor consumed daily with 250 ml water. The powder is sealed in sachets and participants are asked to store the sachets in a freezer until consumption.
214389943|NCT04782310|DRUG|Pregabalin|Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
214389944|NCT04782310|DRUG|Duloxetine|Duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
214389945|NCT03976310|DRUG|48 weeks of Benralizumab|Benralizumab is administered for 48 weeks (week 0 to week 48) every 4 weeks for the first 3 injections (30 mg sc per injection), and then every 8 weeks for the following 5 injections.
214389946|NCT03976310|OTHER|Computed tomography|Computed tomography of the thorax is performed at the beginning (week 0), middle (week 24) and towards the end (week 48) of Benralizumab therapy. A sinus scan is also added on weeks 0 and 48.
214389947|NCT02338713|DRUG|Calcichew D3|Calcium 500 mg and vitamin D3 1000 IU chewable tablets
214389948|NCT02338713|DRUG|Noncarbonated Water|Noncarbonated water 200 mL
214998641|NCT07141420|BEHAVIORAL|LLM-Enhanced Optimized Program|"Combines the HPM-Based Optimized Program with Large Language Model (LLM) technology for dynamic personalization:~AI-generated rehabilitation plans: ChatGPT-4 synthesizes patient data (baseline + follow-ups) to create/update monthly plans, reviewed by a multidisciplinary expert team.~Patient-facing LLM tool: Kimi Smart Assistant installed for daily health queries under strict safety protocols (all outputs validated by nurses via WeChat).~Phased implementation:~Pre-discharge: LLM training + baseline plan generation. 1/3/6 months: Plan updates + outcome tracking. 3/6 months: Semi-structured interviews on LLM experience. Includes LLM usage guidelines and expert validation safeguards ."
214998642|NCT07141368|OTHER|Curcumin Dispersome formulation|75% BLG (600 mg (2 capsules of 300 mg each, containing 90 mg curcumin per capsule
214998643|NCT07141368|OTHER|Non-formulated Curcumin|dose: 90 mg, 1 capsule
214998644|NCT07141368|OTHER|Benchmark Formulation 1 - Turmipure Gold™|recommended daily dose: 300 mg, 1 capsule
214998645|NCT07141368|OTHER|Benchmark Formulation 2 - Qunol, Turmeric, Curcumin Complex, Extra Strength|recommended daily dose: 1000 mg, 2 capsules of 500 mg each
214389949|NCT05232149|DRUG|Orelabrutinib( lower dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia
215094060|NCT07088770|BEHAVIORAL|Community Coalition CLS Workgroup/Network of Providers|Community Coalition/Network of Providers TechMPower forms the foundation of community engagement in this approach, with membership including PLWH and SUD, sheriffs, within-jail staff, community service providers or other partners who are able to advance the adoption of EBPs within jail and service settings. All coalitions are trained and prepared to drive a planning process at the local level for efficient identification and allocation of resources needed to link people from CLS to a network of community providers for HIV and SUD care and retention. Community coalitions integrate evidence-based (ERIC) strategies: Build coalition; Promote network weaving; Identify/train champions; Conduct consensus discussions that support needed services.
215094061|NCT07088770|BEHAVIORAL|Tech-mediated Training and Service Delivery|Researchers will train all staff, healthcare providers and peer navigators to recognize and reduce stigma in CLS and healthcare settings using a training program informed by MPI Frye and colleagues in the CHHANGE (MH102182-01) intervention, which developed an anti-intersectional stigma training program for CBOs and offers comprehensive training to healthcare and social service organizations. Additionally, researchers will train staff and support protocol enhancements as needed to utilize tech mediated service delivery for NCM in-reach and services coordination in the community. These integrate 5 evidence-based (ERIC) implementation strategies: promote consultation; provide clinical/technical supervision; centralize technical assistance; change physical structure and equipment.
214389950|NCT05232149|DRUG|Orelabrutinib( higher dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia
214389951|NCT02444585|DRUG|Denosumab|Intended to prevent periprosthetic loss of bone mineral density
214389952|NCT00806624|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
214389953|NCT00806624|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
214389954|NCT00806624|DRUG|Warfarin tablets|Warfarin tablets taken once daily for up to 3 months
214389955|NCT01905579|PROCEDURE|Paracentesis of the anterior chamber|Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
214389956|NCT02550132|PROCEDURE|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
214389957|NCT02550132|DEVICE|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
214389958|NCT01617083|DRUG|Azithromycin|Antibiotic used to treat infections
214389959|NCT01617083|DRUG|Placebo|Thickening compound with sugar and flavoring
214389960|NCT00899587|DRUG|enalapril|enalapril 5 mg every night
214389961|NCT00899587|OTHER|oxygen|oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
214389962|NCT00899587|DRUG|placebo|
214394052|NCT02527070|DEVICE|RESPeRATE (Paced Breathing)|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
214394053|NCT02527070|DEVICE|Quantum Warp10 (Red LED)|
214394054|NCT02527070|DEVICE|Omnilux new-U (Near Infrared LED)|
214394055|NCT02527070|OTHER|Heat/cold provocation|Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
214394056|NCT06718322|OTHER|Primary Cancer Prevention Implementation Toolkit (PCP-IT)|The PCP-IT is an online implementation support toolkit which aims to support implementation teams in improving the implementation of primary cancer prevention programs (PCPs). The PCP-IT builds upon the theory-base and the proven to be effective ItFits tool. The PCP-IT encompasses a total of six modules which are designed to guide implementers through the process of selecting and adapting PCP programs, identifying and addressing barriers, and developing and applying tailored implementation strategies. The toolkit includes: (1) a repository of PCP programs, (2) a repository of determinants of practice, (3) a repository of implementation strategies, (4) stakeholder consultation at all stages, (5) an online community of implementation practitioners, and (6) structured stepped process flows, instructions, examples and worksheets for working with the materials. https://global.itfits-toolkit.com/
214394057|NCT04315415|DEVICE|Silk Voice|Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)
214389963|NCT04534335|DEVICE|SNOO Smart Sleep from Happiest Baby, Inc|Data related to the use of the SNOO itself (collected electronically) such as the amount of movement provided by the SNOO, etc., will be examined with the hemodynamic data obtained during the use of the SNOO. Clinical care data as it relates to the child will also be evaluated as it pertains to the use of the SNOO (this information will focus on the amount and frequency of narcotics administered to the infant). feasibility of use is the device intervention.
214389964|NCT01812343|OTHER|Exercise test|
214389965|NCT00255658|DRUG|sorafenib tosylate|Given orally
214389966|NCT00255658|DRUG|temsirolimus|Given IV
214389967|NCT00255658|OTHER|laboratory biomarker analysis|Correlative studies
214389968|NCT02484560|DRUG|Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell|
214389969|NCT00467142|BIOLOGICAL|bevacizumab|
214389970|NCT00467142|DRUG|fluorouracil|
214389971|NCT00467142|DRUG|irinotecan hydrochloride|
214389972|NCT00467142|DRUG|leucovorin calcium|
214389973|NCT00467142|GENETIC|polymorphism analysis|
214389974|NCT05385328|DEVICE|EYEFUL: healthy people|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
214394058|NCT00994487|OTHER|High Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
214394059|NCT00994487|OTHER|Low Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
214394060|NCT06494553|OTHER|cervical stabilization exercises|Neck stabilization exercises included the following: Chin tuck, cervical extension, Shoulder shrugs, Shoulder rolls, Scapular retraction
214394061|NCT06494553|DEVICE|Ultrasound therapy|The Chattanooga Intelect ultrasound made in America. Year of production: 2013. It was clinically proven to provide the best possible treatment outcomes by utilizing a high-quality transducer to ensure maximum ultrasound delivery to the treatment area. The output is a clean, culminated beam with the lowest available beam non-uniformity ratio
214394062|NCT06494553|OTHER|traditional treatment program|US, IR and therapeutic exercise program that consisted of Stretching exercises included the following: 1) stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up, and performing arm abduction and external rotation. 2) Stretching the cervical extensors, placing both hands on the occipital area in a sitting position followed by a flexed neck posture with the head down to stretch the cervical extensors.
214394063|NCT06494553|DEVICE|Infrared therapy|Infrared therapy is a non-invasive treatment modality that uses infrared light to promote healing, reduce pain, and improve circulation. It involves the application of infrared light, which penetrates deep into the tissues, providing therapeutic benefits.
214394064|NCT04714216|DEVICE|The Omnipod 5/Horizon HCL system|"The Omnipod 5/Horizon HCL system, consists of a disposable insulin infusion pump (or pod), a built-in model predictive control (MPC) insulin dosing algorithm, and a remote Personal Diabetes Manager (PDM) interface, that interact with a Dexcom G6 continuous glucose monitor (CGM) to automatically control insulin delivery based upon real-time glucose values. The PDM component also enables remote interaction with the system, including glucose monitoring as well as insulin dosing management and adjustments."
214394065|NCT04615858|DIETARY_SUPPLEMENT|Genepro Generation 3 Protein|Generation 3 Genepro Protein. Micronized protein. Zero lactose. No gluten. All Natural. No flavor. No Sugar. FODMAP Certified protein. 11g in weight, scoop.
214394066|NCT04615858|DIETARY_SUPPLEMENT|Whey Protein|Nutrition industries number 1 selling whey protein powder. No flavor. Gluten Free. 30g scoop.
214394067|NCT06484764|PROCEDURE|CT-fluoroscopy guided robot-assisted biopsy of thoracic and abdominal lesions|"During the procedure, the participant first undergoes a CT scan the radiologist plans the needle trajectory based on the registered preoperative CECT (contrast-enhanced computed tomography~) and intraoperative CT. After the participant is manually sterilised and given local anaesthesia, the radiologist will remotely control the robot to finish the needle insertion process under the CT-fluoroscopy guidance and simultaneously adjust the angular needle if necessary. The radiologist confirms whether the needle has reached the target area by CT-fluoroscopy image."
214394068|NCT06484764|PROCEDURE|Freehand CT-guided percutaneous needle biopsy of thoracic and abdominal lesions|Radiologists following the current clinical practice guidance to finish the freehand biopsy procedure under the CT guidance.
214394069|NCT05764603|DRUG|MRI|MR ARTHROGRAPHY AND CT ARTHROGRAPHY IN PATIENT WITH KNEE OSTEOARTHRITIS
214394070|NCT05084261|DRUG|BT051 200 mg|Oral BT051 200 mg once daily for 28 days.
214394071|NCT05084261|DRUG|BT051 800 mg|Oral BT051 800 mg once daily for 28 days.
214394072|NCT05084261|DRUG|BT051 3200 mg|Oral BT051 3200 mg once daily for 28 days.
214394073|NCT05084261|DRUG|Matching Placebo|Placebo Matching BT051
214389975|NCT05385328|DEVICE|EYEFUL: people with pathology|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
214389976|NCT01982344|DEVICE|mini-exchange-room|
214389977|NCT05622890|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
214389978|NCT02654223|BIOLOGICAL|MG56 Mannosylated 500 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
214389979|NCT02654223|BIOLOGICAL|MG56 Mannosylated 1000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
214389980|NCT02654223|BIOLOGICAL|MG56 Mannosylated 3000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
214389981|NCT02654223|BIOLOGICAL|MG56 Mannosylated 5000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
214389982|NCT02654223|BIOLOGICAL|MG56 Mannosylated 500 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml sublingual
214389983|NCT02654223|BIOLOGICAL|MG56 Mannosylated 1000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml sublingual
214389984|NCT02654223|BIOLOGICAL|MG56 Mannosylated 3000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml sublingual
214389985|NCT02654223|BIOLOGICAL|MG56 Mannosylated 5000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml sublingual
214389986|NCT02654223|BIOLOGICAL|Subcutaneous placebo|Comparison between placebo and active group
214389987|NCT02654223|BIOLOGICAL|Sublingual placebo|Comparison between placebo and active group
214389988|NCT05809349|DEVICE|transcranial magnetic stimulation|The stimulation intensity will be 80% resting motor threshold (RMT). The theta burst stimulation (cTBS) with a frequency at 50Hz, repeated at 5Hz, are delivered in a duration of 33.2s with the number of stimulation pulses of 600. Two groups of stimulation will be repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. The treatment will last for 2 weeks, with 5 times per week.
214389989|NCT02771210|BIOLOGICAL|Secukinumab|Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
214389990|NCT02771210|DRUG|Secukinumab Placebo|Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
214389991|NCT01576055|DEVICE|TIGRIS Vascular Stent|Implant
214389992|NCT01576055|DEVICE|BARD LifeStent|Implant
214389993|NCT03048032|PROCEDURE|Blood sampling|Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.
214389994|NCT03048032|PROCEDURE|Echocardiography exam|A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
214501354|NCT06429449|DRUG|Venetoclax|Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.
214389995|NCT05056090|PROCEDURE|Patients will receive MV in PP|Putting the patient in a prone position
214389996|NCT01269814|PROCEDURE|Gastroscopy|Gastroscopy
214389997|NCT03650595|DEVICE|"The TRANBERGCLS|Thermal Therapy"|"MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS\|Thermal Therapy"
214501355|NCT06429449|DRUG|Azacitidine|An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
214501356|NCT06429449|DRUG|Mitoxantrone|Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.
214501357|NCT05395351|DRUG|rt-PA|Intravenous recombinant tissue plasminogen activator (IV rt-PA)
214501358|NCT05006482|OTHER|Best Practice|Receive usual follow-up survivorship care
214501359|NCT05006482|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessment
214389998|NCT04506996|BEHAVIORAL|Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management|see arm/group descriptions
214389999|NCT04506996|BEHAVIORAL|Monday-Focused Written Messages for Weight Management|see arm/group descriptions
214390000|NCT04506996|BEHAVIORAL|Educational Materials|After the baseline assessment and the 1st follow-up (\~8 weeks post randomization), participants received educational materials regarding physical activity and healthier diets. The study staff reviewed these materials with the participants
214390001|NCT03652194|OTHER|in vitro evaluation of epithelial immune response during C. glabrata infection|"1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~2. study of protein expression by the Western-Blot method"
214390002|NCT03652194|OTHER|study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates|"1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~2. in vivo evaluation measured by a survival study on a CD-1 mouse model."
214390003|NCT02932969|DRUG|BMS-986231|
214501360|NCT05006482|OTHER|Educational Intervention|Participate in survivorship health education sessions
214390004|NCT02932969|DRUG|BMS-986231 Placebo|
214390005|NCT02694640|BEHAVIORAL|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
214390006|NCT02694640|BEHAVIORAL|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
214390007|NCT02694640|BEHAVIORAL|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
214390008|NCT04017702|DEVICE|Expiron respirator|Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
214390009|NCT04496414|DEVICE|Bactiseal Catheter|Bactiseal Catheter manufactured by Codman \& Shurtleff, Inc. in the United States is a silicon catheter impregnated in rifampicin and clindamycin.
214390010|NCT05689814|DEVICE|Paraffin based Denture Fixative|Denture fixative applied in strips to secure dentures in place
214390011|NCT02125032|DEVICE|Transcranial low voltage pulsed electromagnetic fields (T-PEMF)|
214390012|NCT02125032|DEVICE|Placebo Transcranial low voltage electromagnetic fields|
214390013|NCT03165006|PROCEDURE|Mode of detection: Cancer detected at screening|Cancers detected as a result of screening mammograms.
214390014|NCT03165006|PROCEDURE|Mode of detection: Interval cancer|Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
214390015|NCT00684762|DRUG|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
214390016|NCT00684762|DRUG|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
214501361|NCT05006482|OTHER|Exercise Intervention|Participate in EXCAP program
214501362|NCT05006482|OTHER|Questionnaire Administration|Ancillary studies
214501363|NCT05006482|PROCEDURE|Tailored Intervention|Participate in GEM consultation
214501364|NCT05696821|DIAGNOSTIC_TEST|Educational intervention|The educational intervention includes a 3-months training program in the use of point-of-care ultrasound tailored to meet the educational needs of general practitioners. The training programs consists of three teaching seminars over a three month time period, a curriculum of 10 POCUS applications, and an online learning platform providing educational support before, during and after the teaching sessions.
214390017|NCT02572817|BIOLOGICAL|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
214390018|NCT02572817|BIOLOGICAL|Low-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
214390019|NCT00368862|DRUG|Ebixa (memantine hydrochloride)|
214390020|NCT00368862|DRUG|Cipralex (escitalopram)|
214390021|NCT04562103|DRUG|Epinephrine / Ropivacaine|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
214390022|NCT04562103|DRUG|Ropivacaine|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
214390023|NCT04443439|DEVICE|GE Discovery MR750 3.0t superconducting MRI|T2WI, FLAIR, DWI, 3D BRAVO, 3D-ASL, rs-fMRI, DKI sequences to exclude other organic lesions
214390024|NCT03781232|DEVICE|Prototype 0.3|Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
214501365|NCT05295108|OTHER|Caring Connections|peer-based letter writing social connectedness intervention to improve social health outcomes
214501366|NCT05295108|OTHER|Attention control|informational materials provided to educate on life domains that are important to social health
214501367|NCT04172675|DRUG|Erdafitinib|Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.
214390025|NCT04215393|DRUG|Conbercept eye drop|In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.
214390026|NCT04215393|DRUG|Placebo|In the second stage, subjects will be receive Conbercept eys drop or a placebo.
214390027|NCT05462652|DEVICE|Active Intervention|The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
214390028|NCT05092048|OTHER|questionnaire|PHQ-9 and GAD-7 questionnaire
214390029|NCT04112472|DEVICE|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The intervention are optical, non-contact examinations with the investigational device EYESTAR 900 and comparative device(s). Results of the examinations serve to compare the performance data of the investigational device with those of the comparative devices.
214390030|NCT02605382|DRUG|Chlorhexidine gluconate|
214390031|NCT02605382|DRUG|placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
214390032|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
214390033|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
214390034|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
214390035|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
214390036|NCT04579120|DRUG|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
214390037|NCT04579120|DRUG|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
214390038|NCT02293174|DEVICE|Topcon TRC-NW400|Retinal Fundus Camera
214390039|NCT02293174|DEVICE|TRC-NW8|Retinal Fundus Camera
214390040|NCT02293174|DEVICE|TRC-NW400|Retinal Fundus Camera
214390041|NCT02293174|DEVICE|Canon-CR2|Retinal Fundus Camera
214390042|NCT02293174|DEVICE|Zeiss Visucam PRO|Retinal Fundus Camera
214390043|NCT02693886|OTHER|doctor experience|
214390044|NCT05086822|DRUG|Irinotecan liposome|Irinotecan liposome
214390045|NCT05015660|DEVICE|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
214390046|NCT05015660|DEVICE|Right ventricular active fixation lead|Active fixation lead (standard)
214390047|NCT02214823|DEVICE|FES-Cycling|
214390048|NCT02214823|OTHER|Standard Care|standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
214390049|NCT00077350|DRUG|triapine|Given IV
214390050|NCT00077350|DRUG|gemcitabine hydrochloride|Given IV
214390051|NCT00077350|OTHER|laboratory biomarker analysis|Correlative studies
214390052|NCT01948271|DRUG|Trichuris Suis Ova|During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
214390053|NCT03324542|DRUG|Aflibercept [Eylea]|Anti-vascular endothelial growth factor (VEGF)
214390054|NCT03103932|OTHER|Biomarker guided discharge algorithm|participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
214390055|NCT00406120|PROCEDURE|Fine needle aspiration biopsy|
214390056|NCT05540093|OTHER|high power pain threshold ultrasound|After explaining the procedure, and the trigger points will be marked by a physical therapist that . Then, the hand placed next to the prone position with the head in the neutral position, and the hands placed next to the body. The frequency was set to 1 MHz, and the intensity increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe will be held there for 4 s; then, the intensity was reduced by 50%, and the probe was moved over and around the trigger point. This process is done several times for three minutes.
214390057|NCT05540093|OTHER|traditional therapy|the patients will receive traditional therapy in the form of postural correction exercise, active range of motion and stretching exercise for cervical muscles
214998646|NCT07141615|COMBINATION_PRODUCT|Qingwei Huazhuo Decoction: Mulberry leaf powder, lotus leaf powder, malt powder, hawthorn powder, Poria cocos powder, gardenia powder, dried tangerine peel powder, licorice powder, momordica grosvenor|"On the basis of receiving dietary and exercise education, the pediatric patients were given the Qingwei Huazhuo Decoction orally.~Composition:Mulberry Leaf Powder, Lotus Leaf Powder, Germinated Barley Powder, Hawthorn Powder, Poria Mushroom Powder, Cape Jasmine Fruit Powder, Tangerine Peel Powder, Licorice Root Powder, Monk Fruit Powder.~Administration Method:Take one sachet each time, add 150ml of warm boiled water, stir well, and drink.~Treatment Course:The first-stage course lasts for 12 weeks.For participants in the experimental group who have completed the first 12-week stage, they may continue to take the Qingwei Huazhuo Decoction orally for another 12 weeks"
214998647|NCT07141615|BEHAVIORAL|diet and exercise education|"① Dietary Education With reference to the Balanced Diet Pagoda for School-Age Children Aged 6-10 Years in the Chinese Dietary Guidelines for School-Age Children (2022), the children were required to record their daily diet and complete a dietary diary.~② Exercise Education~Children were advised to accumulate at least 60 minutes of moderate-to-vigorous physical activity (MVPA) daily, mainly consisting of aerobic exercise. The specific requirements were as follows:~1.3-5 sessions of aerobic exercise per week; 2.2-3 sessions of resistance exercise per week; 3.Daily screen time limited to less than 2 hours. The parents were asked to record their children's daily completion of the above requirements."
214998648|NCT07142434|DEVICE|neonatal Umbilical Catheter Pathway Simulator|evaluate the quality of simulator
214390058|NCT05706181|OTHER|Home-based leg heat therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
214998649|NCT07142421|DRUG|Combination therapy (COMB)|Trifluridine/tipiracil combined with Anlotinib in treatment
215094062|NCT07088770|BEHAVIORAL|Multidisciplinary Implementation Team with Champion|The multidisciplinary Implementation Team will be comprised of a correctional health nurse, social worker and discharge planner or counselor and corrections officer from the jail. A representative from the community coalition and peer and case manager from NCM will join the team using a tech-mediated platform for conducting the training and for on-going weekly case conferencing addressing system and client level barriers and service planning. The role of the champion from the correctional setting will be to convene meetings focused on fidelity to the intervention components, engagement in shared problem-solving and mediation of administrative issues that may inhibit effective implementation of TechMPower. The champion and implementation team may request technical assistance (TA) or implementation facilitation at any point during implementation. This TA may be provided by the investigative team or outside providers from federal programs.
214390059|NCT05706181|OTHER|Home-based sham therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
214390060|NCT03443596|BIOLOGICAL|Early intensive BP control|Participants in the early intensive BP control arm are treated with BP lowering medications, with an aim to bring the systolic BP to 140-160mmHg and maintain this level for 72 hours post-ictus
214390061|NCT02479035|DIETARY_SUPPLEMENT|Red raspberry meal 1|\~125 g fresh weight (1 cup equivalent)
214390062|NCT02479035|DIETARY_SUPPLEMENT|Red raspberry meal 2|\~250 g fresh weight (2 cup equivalent)
214390063|NCT02479035|DIETARY_SUPPLEMENT|Control meal|0 g red raspberry
214394074|NCT02471846|DRUG|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle with the exception of biopsy cohort A, where atezolizumab administration will start on Cycle 2 Day 1.
214394075|NCT02471846|DRUG|GDC-0919|Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, 400, 600, and 1000 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
214998650|NCT07142226|GENETIC|Circulating Tumor DNA (ctDNA) Testing (ctDNA-based Next-Generation Sequencing (NGS))|Peripheral blood will be collected from patients with advanced biliary tract cancer for circulating tumor DNA (ctDNA) testing. Next-generation sequencing (NGS) will be performed to detect clinically relevant genomic alterations, including IDH1 mutations, FGFR2 fusions, ERBB2 amplifications, and MSI-H/dMMR. The ctDNA results will be compared with tissue-based genomic profiling to evaluate concordance and clinical utility.
214998651|NCT07142096|DIETARY_SUPPLEMENT|MitoQ (mitoquinol mesylate)|Dietary supplement course before surgery or chemo/radio-therapy
214394076|NCT00913679|PROCEDURE|Surgical approach (ReCap Hip Resurfacing System)|two different surgical approaches in hip resurfacing arthroplasty
214394077|NCT01222832|DRUG|Bacitracin|Bacitracin soaked nasopore sponge
214394078|NCT01339325|PROCEDURE|Cholecystectomy|"Standard laparoscopic cholecystectomy The first cannula is inserted with an open laparoscopy technique. LCs are performed with either HF or US energized dissection, standard or fundus-first gallbladder dissection, closure of the artery by ligature/clip or US, closure of cystic duct by ligature/clip.~Laparo-endoscopic single site cholecystectomy~The TriPort device is inserted at the navel site through a 15 to 25 mm incision with an open laparoscopy technique. Two working instruments are inserted (one grasper and one energised device) through the TriPort. A further 1.8 or 3 mm instrument inserted through the larger gel valve, parallel to a 5 mm dissecting instrument, is used in some cases to enhance exposure. Gallbladder dissection is accomplished either after preparation of the cystic duct and artery or with a fundus-first technique, by means of HF electrosurgery or US shears.The cystic artery is divided between clips or by US scissors. The duct is divided between clips."
214394079|NCT00968838|PROCEDURE|White Blood Cell Transfusion|"4 Transfusions, each taking approximately 1 hour:~Patients \<50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients \>50 years of age are randomized to receive either radiated or non radiated transfusions."
214394080|NCT02746536|OTHER|Slow chest compression|"During the SCC, the patient will remain in the sitting position; a bimanual slow compression on his/her upper chest will be performed always by the same evaluator, who will stand behind the patient. This compression will be done only in the expiratory phase, during one minute, in all respiratory cycles, respecting the chest mobility of each patient.~A standardized verbal command will be given: Exhale all the air."
214394081|NCT02746536|OTHER|No slow chest compression|"The patient will remain seated at rest for one minute after the 6MST. A standardized verbal command will be given: Exhale all the air."
214394082|NCT01755689|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the right arm.
214394083|NCT01755689|BIOLOGICAL|Cervarix®|Three doses administered intramuscularly (IM) in the deltoid of the left arm.
214394084|NCT01755689|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the left arm.
214394085|NCT02816047|OTHER|Registry|Observational study to describe WCD indications, event rates, inappropriate shock rates and follow up (including ICD rate, shock rate, morbidity and mortality) in all Austrian WCD patients
214394086|NCT01327547|DRUG|Maraviroc|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
214394087|NCT01327547|DRUG|Placebo|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
214394088|NCT03257488|DEVICE|type IV portable monitoring (Somnocheck micro Weinmann)|Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.
214394089|NCT03493113|DIAGNOSTIC_TEST|EEG|
214394090|NCT00385905|DEVICE|Excel Drug-eluting stent|
214394091|NCT03918915|DRUG|SYD-101 Dose 1|Sterile topical ophthalmic solution
214394092|NCT03918915|DRUG|SYD-101 Dose 2|Sterile topical ophthalmic solution
214394093|NCT03918915|DRUG|Vehicle|Sterile topical ophthalmic solution without active ingredient
214394094|NCT04277741|DIETARY_SUPPLEMENT|RS4 bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber.
214394095|NCT04277741|DIETARY_SUPPLEMENT|Control bar|The control group will consume one native wheat starch bar per day.
214394096|NCT04846205|DIAGNOSTIC_TEST|systematic etiological|"Theses following tests are made as usual practice :~* Ventilator polygraphy, or polysomnography between 1 month and 1 year after cryptogenic ischemic stroke.~* Transoesophageal ultrasound"
214394097|NCT03864289|BEHAVIORAL|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
214394098|NCT04545294|DEVICE|Theta tACS|See detail in arm/group descriptions regarding the intervention.
214394099|NCT04461925|PROCEDURE|Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|i/v infusions
214394100|NCT04461925|DRUG|Antibiotics|per os
214394101|NCT04461925|DRUG|Hormones|a moderate amount of dexamethasone i/v
214394102|NCT04461925|DRUG|Anticoagulant Therapy|Sub-Q
214390064|NCT02314741|PROCEDURE|POEM Procedure|The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually \~6cm long \& averages 8-10cm. After the myotomy is performed the scope is withdrawn \& inserted into the lumen to inspect the mucosa, ensure mucosal integrity \& confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, \& is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
214390065|NCT00095030|DRUG|muraglitazar|
214390066|NCT03806504|OTHER|PEEP|performing 35 cm/H2O PEEP and 2-3 ml/kg tidal volume
214390067|NCT03806504|OTHER|control group|performing 6 cm/H2O PEEP and 6-8 ml/kg tidal volume
214501368|NCT04172675|DRUG|Investigator Choice (Gemcitabine)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
214501369|NCT04172675|DRUG|Investigator Choice (Mitomycin C)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
214998652|NCT07141524|OTHER|Physiology measurements|Measurement of lung perfusion (via EIT) and transpulmonary pressure (via esophageal manometry) during decremental PEEP trial
214390068|NCT01629680|DRUG|Moxaverine|Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
214390069|NCT01629680|DRUG|Placebo|coated tablets identical in number and appearance as the study drug
214998655|NCT07141290|DEVICE|Silent fish and bunny game|Participants play two levels of a computer game. In one level they need to squat at different levels to make a bunny jump and catch some carrots. In the other level they need to catch fiches by adjusting the extension of their leg.
214998656|NCT07141290|DEVICE|Sound supported fish and bunny game|In the auditory feedback group sound is used to transfer the Knowledge of Results. The sound is linked to the joint position.
214501370|NCT05641766|DRUG|THC|Participants will receive THC into a rapidly flowing IV infusion.
214998657|NCT07140887|OTHER|Bone Ring|"Patients in this group will be treated with the bone ring technique. An implant drill will be used next to prepare central osteotomies corresponding to the final implant diameter to be placed in the center of the disc converting it to a bone ring."
214998658|NCT07140887|OTHER|Split Bone block|Patients of this group will be treated with split bone block with simultaneous implant technique. The bone shell will be split into two bone shells each 1 \~ 2 mm in thickness using a disc.
214998659|NCT07142070|OTHER|Saliva, serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, serum were then stored at -80 °C until analysis.
214998660|NCT07142070|DRUG|oral isotretinoin|oral isotretinoin
214998661|NCT07141394|DRUG|Medication for Addiction Treatment (MAT)|MAT includes medications for alcohol use disorder (MAUD) and medications for opioid use disorder (MAUD). It reduces substance use, increases SUD treatment engagement, enhances quality of life, and reduces overdoses.
214390070|NCT06435949|DRUG|Fentanyl (as Citrate)|intravenous anesthesia with propofol with fentanyl (group Fentanyl) and propofol with oxycodone (group Oxycodone)
214390071|NCT01144221|PROCEDURE|Intramyocardial Cell therapy|Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation
214390072|NCT01359618|DRUG|TC-5214|Single dose, oral tablets
214390073|NCT01359618|OTHER|Placebo comparator|Single dose, oral tablets
214390074|NCT01359618|DRUG|Moxifloxacin|Single dose, oral encapsulated tablet
214501371|NCT05641766|OTHER|Placebo|Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
214998662|NCT07141394|BEHAVIORAL|Cognitive Behavioral Therapy for Substance Use Disorders (CBT-SUD)|An evidence-based psychotherapy that uses cognitive behavioral therapy to further recovery goals across SUD diagnoses.
214390075|NCT01359618|OTHER|Moxifloxacin placebo comparator|Single dose, oral encapsulated tablet
214390076|NCT01570179|DRUG|ideal BW based sugammadex reversal of moderate block|2 mg/kg sugammadex (based og ideal body weight)
214390077|NCT01570179|DRUG|real body weight based sugammadex reversal of moderate block|2 mg/kg sugammadex (based on real BW)
214390078|NCT01570179|DRUG|real body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on real BW)
214390079|NCT01570179|DRUG|ideal body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on ideal BW)
214390080|NCT04159116|OTHER|Prophylactic suctioning when clinically indicated|Suctioned prophylactically when clinically indicated by copious secretions, coughing, choking or desaturatation
214390081|NCT01694992|OTHER|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
214390082|NCT02444299|DEVICE|Shoulder hemi-arthroplasty|
214390083|NCT00034645|DRUG|Posaconazole oral suspension|
214390084|NCT00957788|DRUG|NST-001|Comparison of different dosages of drug.
214998663|NCT07141810|DRUG|Antifibrotic drugs (nidanib or pirfenidone)|One group received primary therapy, and another group received an antifibrotic drug (nidanib or pirfenidone) in addition to primary therapy.
214998664|NCT07142330|PROCEDURE|Atherectomy|Two different techniques : rotational atherectomy or thromboendarterectomy
214998665|NCT04903795|DRUG|hEGFRvIII-CD3 (BRiTE)|Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
214998666|NCT04523961|DRUG|2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion|Topical anesthetic used to numb the skin prior to laser procedures
214998667|NCT04523961|DRUG|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion|Topical anesthetic used to numb the skin prior to laser procedures
214998668|NCT06187077|BEHAVIORAL|DHA-Enhanced FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Weekly educational modules provide information on components of cardiovascular health (CVH). Participants are given a Fitbit to track physical activity, which will automatically synch to the app and will be asked to track their daily fruit and vegetable intake on the app. DHAs will promote CVH and digital health readiness as peer mentors by guiding participants through the educational modules and encouraging use of the additional interactive app features. During the guided intervention phase, they will facilitate weekly visits with participants in their church, which will follow the FAITH! App modules and integrate a digital health topic. Following the 11-week guided intervention, participants will have a 12-month maintenance phase with access to use the app as they wish.
214998669|NCT06187077|BEHAVIORAL|FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Each week, an educational module is completed in the app, which provides information on a component of cardiovascular health. Participants will be given a Fitbit to track their physical activity, which will automatically synch to the app, and will be asked to track their daily fruit and vegetable intake on the app as well. Following the 11-week guided intervention, participants will have a 12-month maintenance phase in which they will have access to use the app as they wish.
214998670|NCT05578872|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
214390085|NCT01714102|DIETARY_SUPPLEMENT|Placebo|Placebo manufactured to mimic resveratrol tablet
214390086|NCT01714102|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol PO BID for 30 days
214390087|NCT01476436|OTHER|Low carbohydrate dietary advice|Dietary advice
214390088|NCT01476436|OTHER|Continue usual diet|Dietary advice
214390089|NCT00119262|DRUG|doxorubicin hydrochloride|Given IV
214390090|NCT00119262|DRUG|cyclophosphamide|Given IV
214390091|NCT00119262|BIOLOGICAL|bevacizumab|Given IV
214998671|NCT04959513|PROCEDURE|LPRF bone block|Guided bone regeneration using an L-PRF bone block (composite graft composed of a xenograft, a membrane from the patient's blood and a collagenous membrane) after a short healing period of 6 to 8 weeks after tooth extraction
214998672|NCT05954871|DRUG|GDC-1971|GDC-1971 capsules or tablets will be administered as specified in each treatment arm.
214390092|NCT00119262|DRUG|paclitaxel|Given IV
214390093|NCT00119262|BIOLOGICAL|filgrastim|Given SC
214390094|NCT00119262|BIOLOGICAL|pegfilgrastim|Given SC
214390095|NCT00119262|RADIATION|radiation therapy|Undergo radiation therapy
214390096|NCT00119262|DRUG|tamoxifen citrate|Given orally
214390097|NCT00119262|DRUG|aromatase inhibition therapy|Receive aromatase inhibition therapy
214390098|NCT00734214|DRUG|0.9% NaCl|"Intravenous Fluid~Isotonic Parenteral Fluid"
214390099|NCT00734214|DRUG|0.45%NaCl|"Intravenous Fluid~Hypotonic Parenteral Fluid"
214390100|NCT00431639|BEHAVIORAL|Animal Assisted Therapy|Every subject will be exposed to both treatment and comparison conditions.
214390101|NCT03653663|DRUG|Simvastatin 20 mg|Subjects are treated with 20 mg simvastatin for 8 weeks
214390102|NCT03653663|DRUG|Placebo Oral Tablet|Subjects are treated with placebo for 8 weeks
214390103|NCT01684995|BEHAVIORAL|Brief physician advice|Brief physician advice to quit smoking
214390104|NCT01684995|DRUG|nicotine patch|nicotine patch
214390105|NCT01684995|BEHAVIORAL|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
214998673|NCT05954871|DRUG|Osimertinib|Osimertinib tablets will be administered as specified in each treatment arm.
214998674|NCT05954871|DRUG|Cetuximab|Cetuximab, solution for infusion will be administered as specified in each treatment arm.
214998675|NCT05419518|BIOLOGICAL|EXTERNAL BEAM RADIATION|A minimum of three daily radiation therapy treatments are required in any given week. Any missed radiation treatments will be made up at the end of the treatment schedule, such that the total number of delivered 5 Gy fractions remains ten.
214390106|NCT00679484|DRUG|olmesartan medoxomil + candesartan cilexetil placebo|Dosage form: tablet; frequency: daily; duration: 24 weeks
214390107|NCT00679484|DRUG|olmesartan medoxomil placebo + candesartan cilexetil|Dosage form: tablets; frequency: daily; duration: 24 weeks
214390108|NCT02029040|DRUG|3% Hypertonic Saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
214390109|NCT02029040|DRUG|0.9 % normal saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
214390110|NCT02035813|DRUG|Ribociclib|Ribociclib/Everolimus in combination with endocrine therapy
214390111|NCT02035813|DRUG|Eribulin|
214390112|NCT03590665|OTHER|Hand grip exercise and lower body negative pressure|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
214390113|NCT03593993|PROCEDURE|Surgical Cohort|Blood, cerebrospinal fluid, and surgical tissue collected during procedure
214390114|NCT01910727|BEHAVIORAL|Together on Diabetes-Hopkins|The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
214390115|NCT02179372|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.
214390116|NCT02179372|DIETARY_SUPPLEMENT|Medium chain fatty acid (placebo)|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
214390117|NCT01472913|DRUG|Fibrin sealant|Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
214390118|NCT01472913|DRUG|Saline water|Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
214390119|NCT06042868|OTHER|Nursing protocol|Emergency nursing protocol
214390120|NCT05658835|OTHER|Thrombi and blood analyses|Thrombi and blood will be collected during thrombectomy
214390121|NCT03562260|PROCEDURE|bipolar release|the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture
214394103|NCT04461925|DEVICE|Оxygen therapy|Оxygen therapy, mechanical ventilation and other supportive therapies
214998676|NCT06968403|BEHAVIORAL|Community emotional intelligence network|This intervention focuses on developing emotional intelligence (EI) to tackle climate change-induced mental health challenges like eco-anxiety, solastalgia, and stress from displacement and natural disasters. It is community-centered, utilizing local resources and volunteers for EI training and mental health support, unlike traditional clinical interventions that depend on centralized healthcare systems. A mobile app is integrated to facilitate communication, learning resources, and participant connections, offering remote support and continuous engagement, even during climate events like floods or cyclones. Targeting coastal communities in Bangladesh, this program addresses the mental health impacts of frequent natural disasters, saltwater intrusion, and displacement. Unlike other mental health programs, it not only treats symptoms but also builds resilience against environmental stressors, empowering communities to cope with climate-induced mental health challenges.
214998677|NCT02487576|OTHER|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
214998678|NCT02487576|OTHER|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
214998679|NCT06971887|OTHER|Clear Communication of Lab Test Result letter|The Clear Communication of Lab Test Result letter (CCLR) was designed using clear communication and health literacy best practices to explain test done, meaning of results, and any future action recommended.
214390122|NCT05900219|DRUG|HL-085+Vemurafenib|The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration for 21 days per cycle. The primary efficacy endpoint in this study was the ORR assessed by the Independent Review Committee (IRC) according to the RECIST 1.1
214390123|NCT05348408|DRUG|platelet rich plasma|perineural PRP injection under ultrasound guidance in addition to medical treatment
214390124|NCT01518660|BEHAVIORAL|Training|Bi-weekly progressive resistance training
214390125|NCT01017653|DRUG|Irinotecan|Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
214390126|NCT01017653|DRUG|Panitumumab|Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
214390127|NCT01042990|OTHER|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
214390128|NCT02590068|DRUG|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
214390129|NCT00862953|DIETARY_SUPPLEMENT|Normal protein energy-restricted|Normal protein diet energy restricted
214390130|NCT00862953|DIETARY_SUPPLEMENT|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
214501372|NCT06358755|DEVICE|Defocus Incorporated Multiple Segments lenses|Defocus Incorporated Multiple Segments lenses that provide optical defocus for myopia control will be given to this group of participants.
214501373|NCT06358755|DEVICE|single vision spectacle lenses|Single vision spectacle lenses will be given to this group of participants.
214501374|NCT06358755|DRUG|Low dose atropine|0.01% atropine administrated twice per day (1 drop in the morning and 1 drop at night before bedtime) will be given as intervention.
214501375|NCT03945773|DRUG|Cabozantinib|Oral tablets of 60mg, 40mg and 20 mg.
214501376|NCT03013218|DRUG|Evorpacept (ALX148)|Evorpacept (ALX148)
214998680|NCT05115214|DEVICE|SpherePVI™ Catheter|Affera SpherePVI™ Multi-Ablation System
214501377|NCT03013218|DRUG|Pembrolizumab|Keytruda
214501378|NCT03013218|DRUG|Trastuzumab|Herceptin
214390131|NCT02826148|OTHER|RAADS-R scale|This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
214390132|NCT00211341|DIETARY_SUPPLEMENT|Vitamin A|Weekly single oral dose 7000 micrograms
214390133|NCT05833243|OTHER|modified diaphragmatic training|Modified diaphragmatic strength training prescriptions will be given based on the result of baseline assessment. The intensity is 60% from the maximum respiratory muscle strength from baseline and weekly remeasurement. Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist.
214390134|NCT05833243|OTHER|standard diaphragmatic training|"standard diaphragmatic strength training prescriptions will be given as daily routine, 3 times a day.~Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist."
214390135|NCT03422458|DEVICE|Alveolar Ridge Preservation|Insertion of a bone substitute material (BioOss Collagen) within the bony envelope at least to the level of the palatal/ lingual bone plate. Adaptation of a collagen matrix (Mucograft Seal) to the soft tissue borders.
214390136|NCT04814927|DRUG|Copper IUD|Participants randomized to Copper IUD will receive Paragard IUD at Visit 2.
214390137|NCT04814927|DRUG|Etonogestrel implant|Participants randomized to ETG implant will receive the implant at Visit 2.
214390138|NCT04814927|DRUG|Levonorgestrel IUS|Participants randomized to LNG intrauterine system will receive the IUS at Visit 2.
214390139|NCT04814927|DRUG|DMPA Sub-cutaneous|Participants randomized to DMPA SC will receive the injection at Visit 2.
214390140|NCT02385578|OTHER|an educational intervention|"the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on"
214501379|NCT03013218|DRUG|Rituximab|Rituxan
214501380|NCT03013218|DRUG|Ramucirumab + Paclitaxel|Standard of care chemotherapy
214501381|NCT03013218|DRUG|5-FU + Cisplatin|Standard of care chemotherapy
214501382|NCT04400188|DRUG|Fluzoparib|Given PO
214501383|NCT04400188|DRUG|temozolomide|Given PO
214501384|NCT04400188|BIOLOGICAL|SHR-1316|Given injection
214501385|NCT06830681|DIETARY_SUPPLEMENT|New generation eHF|New generation of a whey-based eHF formula intended for the dietary management of infants with CMPA.
214501386|NCT06830681|DIETARY_SUPPLEMENT|Commercial eHF|Commercial whey-based eHF formula intended for the dietary management of infants with CMPA.
214390141|NCT03555604|DIAGNOSTIC_TEST|Gastric ultrasound|Gastric ultrasound to measure antrum cross sectional area
214390142|NCT02619227|OTHER|Livelihood intervention|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
214390143|NCT02443025|BEHAVIORAL|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
214390144|NCT04950556|OTHER|Exercise|Pelvic floor muscle exercise will be given to the exercise group
214390145|NCT04950556|OTHER|Control|No intervention
214390146|NCT03623880|BEHAVIORAL|Unified Protocol|The unified protocol is a form of cognitive behavior therapy focused on helping the person reduce emotional distress through cognitive changes and behavioral skills. Exercises included confronting emotional-driven behaviors and mindfulness activities.
214390147|NCT03623880|BEHAVIORAL|Supportive Therapy|Supportive therapy seeks to improve self-esteem, aid the patient with problem solving, and provide structured support using empathetic listening.
214390148|NCT01013532|DRUG|Cilostazol|Cilostazol 100mg bid
214390149|NCT01013532|DRUG|Probucol|Probucol 250mg bid
214390150|NCT01013532|DRUG|Aspirin|Aspirin 100mg qd
214390151|NCT01013532|DRUG|placebo of cilostazol|same shape and size of active cilostazol
214390152|NCT01013532|DRUG|placebo of aspirin|same size and shape of active aspirin 100mg
214390153|NCT01013532|DEVICE|ankle-brachial index (ABI)|measurement of ABI every years during follow up
214998689|NCT02600949|DRUG|Imiquimod|Applied topically
214998690|NCT02600949|BIOLOGICAL|Pembrolizumab|Given IV
214998691|NCT02600949|BIOLOGICAL|Sotigalimab|Given IV
214390154|NCT01013532|DEVICE|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
214390155|NCT01013532|DEVICE|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
214390156|NCT01013532|DEVICE|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
214390157|NCT04526405|DIAGNOSTIC_TEST|SARS-CoV-2 S1/S2 IgG|SARS-CoV-2 S1/S2 IgG analysis
214390158|NCT06488560|DIETARY_SUPPLEMENT|commercial blenderized tube feed (CBTF)|Based on assessment by a dietician the participant will be fed the commercial blenderized formula to meet their caloric needs
214390159|NCT06488560|DIETARY_SUPPLEMENT|commercial formulas (CF)|Participant will be fed the commercial formula to meet their caloric needs per standard of care
214390160|NCT04171830|OTHER|modified Hospital One-year Mortality Risk (mHOMR)|"Every inpatient will automatically be given the intervention (an mHOMR/HOMR Now! score) upon admission to hospital and considered for secondary interventions based on their score. Baseline threshold will be set as \>0.21 (59% sensitivity and 90% specificity for 12-month mortality with mHOMR).~At minimum each individual identified by the tool will receive two assessments to screen for severe symptoms and desire to engage in advance care planning (ACP):~1. Edmonton Symptom Assessment System Revised: scores \>6 will be flagged as severe. Clinical teams will address the symptoms as appropriate for the patient.~2. 4-item Advanced Care Planning Engagement Survey: Scores of 3-4 indicate readiness to discuss ACP. Clinical teams may choose to discuss ACP and goals of care themselves, activate a local ACP intervention, or distribute ACP documentation.~Both of these assessments will be done by a member of the treating team within 72 hours of the patient's hospital admission."
214501387|NCT06786351|PROCEDURE|Right atrial balloon occlusion|Thoracic endovascular aortic repair with right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3
214390161|NCT02638610|DEVICE|Cochet-Bonnet aesthesiometer|"The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.~This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface."
214390162|NCT03504735|BEHAVIORAL|Therapeutic Lifestyle Change|Monthly consult with a dietitian and fitness instructor.
214390163|NCT03504735|DRUG|Caduet Pill|Take once daily.
214390164|NCT03504735|DRUG|Placebo|Take once daily.
214501388|NCT06786351|PROCEDURE|Non right atrial balloon occlusion|Thoracic endovascular aortic repair not using right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3
214501389|NCT04786262|BIOLOGICAL|VX-880|Infused into the hepatic portal vein.
214687922|NCT01750398|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
214687923|NCT01750398|DRUG|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
214687924|NCT01750398|DRUG|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
214998692|NCT02600949|BIOLOGICAL|Synthetic Tumor-Associated Peptide Vaccine Therapy|Given SC
214998693|NCT02600949|PROCEDURE|Computed Tomography|Undergo CT
214998694|NCT02600949|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214390165|NCT00630058|DRUG|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
214390166|NCT00630058|DRUG|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
214390167|NCT02848612|DRUG|anticoagulation by unfractionated heparin|anticoagulation by unfractionated heparin
214390168|NCT01993537|DRUG|Vitamin D|
214390169|NCT04058821|DIAGNOSTIC_TEST|Novel MRI scan - 7 days post injury|"* A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
214390170|NCT04058821|DIAGNOSTIC_TEST|Novel MRI scan - 14 days post injury|"* A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
214390171|NCT04058821|DIAGNOSTIC_TEST|Functional MRI scan - 6 months post brachial plexus exploration|"* Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)"
214390172|NCT04058821|DIAGNOSTIC_TEST|Functional MRI scan - 12 months post brachial plexus exploration|"* Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)"
214390173|NCT00361075|DRUG|transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)|
214390174|NCT01651936|DRUG|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
214390175|NCT01651936|DRUG|Methotrexate|MTX dosed at the stable dose received upon study entry
214390176|NCT01651936|DRUG|Dose-match placebo|Dose-matched placebo dosed orally BID
214390177|NCT02512510|DRUG|TD-4208|
214390178|NCT02512510|DRUG|Placebo|
214390179|NCT04276662|DRUG|DS-3201b|1 dose of 50 mg DS-3201b
214390180|NCT06442020|PROCEDURE|Tadalafil (PDE5i)|Tadalafil at a dose of 5mg/day
214390181|NCT04173312|COMBINATION_PRODUCT|Bupivacaine infusion|Local systemic Infusion of anesthetic
214390182|NCT04173312|COMBINATION_PRODUCT|Saline|Local systemic infusion of saline
214390183|NCT04001764|PROCEDURE|The radial artery cannulation over 2 cm of the wrist|The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.
214687925|NCT00525148|DRUG|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
214390184|NCT04001764|PROCEDURE|The radial artery cannulation in the distal 3/4 area of the forearm|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
214390185|NCT04001764|PROCEDURE|The radial artery cannulation in the distal 1/2 area of the forearm|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
214390186|NCT02141659|DRUG|TAK-385|TAK-385 Tablets.
214390187|NCT02053428|PROCEDURE|percutaneous image-guided gastrostomy|
214390188|NCT03893864|DIETARY_SUPPLEMENT|Administration of a product with Fitosomed Ubiquinone|Healthy runner athletes, \> 50 years old, without any chronic illness, without any other nutritional supplementation or drug intervention, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions.
214390189|NCT03893864|PROCEDURE|Coenzyme Q10 level in muscle biopsies|Determination of the muscle Ubiquinone concentration, the metabolic and structure characteristics of the muscle before and after one month of supplementation
214390190|NCT03893864|DIAGNOSTIC_TEST|Coenzyme Q10 level in plasma, blood cells, urine cells|Determination of Ubiquinone concentration in different tissues before and after one month of supplementation or not
214390191|NCT03893864|DIAGNOSTIC_TEST|Total antioxidant capacity after strenous exercise|Determination of the Total Antioxidant Capacity after strenous exercise in the Climate Chamber
214390192|NCT04708288|DEVICE|ARCHIMEDES Biodegradable Biliary and Pancreatic Stent|Pts that will receive ARCHIMEDES Biodegradable Biliary and Pancreatic Stent
214390193|NCT02857803|PROCEDURE|Virtual Reality|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
214390194|NCT02857803|PROCEDURE|Paper and Pencil|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
214390195|NCT02857803|PROCEDURE|Conventional Therapy|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
214394104|NCT04086979|BEHAVIORAL|Parental Friendship Coaching|In this condition, therapists instructed parents in ways to coach their children to display better friendship behaviors using skills teaching, role play, active practice, and homework. This is a 10 week group intervention.
214394105|NCT04086979|BEHAVIORAL|Coping with ADHD through Relationships and Education|In this condition, the therapist provided parents with psychoeducation about ADHD and friendship difficulties, and encouraged them to apply this information to their child and to support one another with tips about how to address these problems. This is a 10 week group intervention.
214394106|NCT05266105|DRUG|Palazestrant|Complete Estrogen Receptor Antagonist
214394107|NCT05266105|DRUG|Palbociclib|Palbociclib is an approved CDK 4/6 Inhibitor drug
214394108|NCT06581640|BIOLOGICAL|CAR-T treatment|Peripheral blood lymphocyte collection, PBMC separation, BCMA CAR-T cell preparation/storage, lymphodepletion chemotherapy pretreatment for the subject, and BCMA CAR-T cell infusion.
214394109|NCT01807143|OTHER|laboratory biomarker analysis|Correlative studies
214394110|NCT01490515|PROCEDURE|non-invasive metabolomic profiling|non-invasive metabolomic profiling of IVF human embryos
214394111|NCT01490515|OTHER|morphological evaluation|Simple microscopic observation of embryos and evaluation of morphological characteristics
214394112|NCT02462083|DRUG|IDP-118 Lotion|IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
214998695|NCT06127563|OTHER|creation of a clinical pathway to increase vaccination coverage in frail patients|creation of a clinical pathway to increase vaccination coverage for frail patients, integrating hospital and local health units through an automated algorithm
214390196|NCT03877705|DRUG|Listerine ready tabs|Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
214390197|NCT01062412|DEVICE|LensAR Laser System|Laser treatment of the crystalline lens
214390198|NCT02954900|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
214390199|NCT02954900|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
214390200|NCT01315405|BEHAVIORAL|Emotional facial expression recognition tests|"20 patients with an Idiopathic Parkinson's disease~\+ 20 paired healthy volunteers (on sex, age, and education)~After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)~Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)"
214390201|NCT03558464|DIETARY_SUPPLEMENT|Intervention (integrated package)|"During whole study (pregnant women and offspring):~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* Life stage-appropriate (pregnancy, lactation, IYCF) monthly nutrition and WASH trainings~During pregnancy and up to when offspring turns 6 months old:~* LNS (Enov' Mum, 20g sachet daily)~* Anthelminthic treatment (single-dose mebendazole (500mg), once during second trimester of pregnancy)~Children 6-24 months of age~* MNP (MixMe, 1g sachet every three days)~* ORS + zinc~* 1 egg per day~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group. All women will follow regular antenatal care as provided by the Kenyan government as part of their routine health system (e.g. intermittent preventive malaria treatment and iron-folic acid-supplements)."
214390202|NCT03558464|OTHER|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. This agriculture focused package consists of: - Agricultural training (every 2 weeks on average) for all - Free to enrol for the following products on credit: o Compost boosters~* Cook stoves o Seeds (onions, maize, indigenous greens, beans) o Maize storage bags o Drying tarps~* Trees o Solar lights o Fertilizer o Actellic dust (insecticide) o Re-usable sanitary pads"
214390203|NCT02886546|PROCEDURE|pneumoperitoneum|
214390204|NCT02886546|DEVICE|oesophageal Doppler monitor|
214390205|NCT01247441|OTHER|Clinical data|
214390206|NCT02406989|DRUG|MS-553|Study Drug
214390207|NCT02406989|DRUG|Placebo|Matching placebo to MS-553
214390208|NCT00326768|DRUG|Telmisartan 40 mg/HCTZ 12.5 mg|
214390209|NCT00326768|DRUG|Telmisartan 40 mg|
214390210|NCT00326768|DRUG|Telmisartan 80 mg/HCTZ 12.5 mg|
214390211|NCT06278116|OTHER|Aligners cleansing with water|The product is masked in a spraying bottle without any labels. Once a day, for 14 days, the patient sprays the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
214390212|NCT06278116|OTHER|Aligners cleansing with dish soap Svelto|the product is masked in a transparent bottle without any labels. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
214998696|NCT05836870|OTHER|Enhanced Usual Care|Participants will receive general recommendations to maintain physical activity.
214998697|NCT05836870|BEHAVIORAL|Tele-supervised resistance exercises|Participants will take part in a monitored exercise program.
214687926|NCT02486510|DRUG|Maraviroc|"Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours"
214998698|NCT06286982|OTHER|Oral Symptom Assessment Scale|The Oral Symptom Assessment Scale is a patient-rated oral (or mouth) symptom assessment tool
214998699|NCT04598828|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
214390213|NCT06278116|OTHER|Aligners cleansing with Polident Antibacterial Denture Cleaner|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the tablet in a glass full of warm water (30-35 °C), then the aligner is placed inside it for 5 minutes. Afterward the aligner is rinsed under fresh running water.
214390214|NCT06278116|OTHER|Aligners cleansing with Invisalign Cleaning Crystals|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the crystals in a glass full of warm water (30-35 °C) mixing with a spoon for 20 seconds; then, the aligner is placed inside the glass for 15 minutes. Afterward, the aligner is rinsed under fresh running water.
214390215|NCT06278116|OTHER|Aligners cleansing with Geldis|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
214390216|NCT01002664|DRUG|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
214390217|NCT01002664|DRUG|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
214687927|NCT03308084|DRUG|Methylprednisolone|Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
214687928|NCT03308084|DRUG|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
214501390|NCT05176756|BEHAVIORAL|Gamification and Social Support|Participants will be entered into a points and levels-based game designed to help them meet their step count goals. At the start of each week, the participant will receive a set amount of points. Each day their step goal is not met, they lose points. If the participant meets a certain point value at the end of the week, they will either advance one level (of five total levels); if they do not, they will drop one level. Each participant will also select a family member or friend or the study coordinator to serve as a support partner. At the beginning of the intervention, the participant and support partner will identify at least 3 ways in which they can help the participant meet their step goals. This partner will receive a weekly email reminding them of these approaches and updating them on the participant's progress.
214998700|NCT06069479|PROCEDURE|craniofacial surgery|Surgical treatment, either stripcraniectomy or fronto-orbital advancement
214501391|NCT05176756|BEHAVIORAL|Attention control|Participants will receive a daily text message with their step count from the day prior.
214501392|NCT06242015|OTHER|Carbohydrate-first meal|Rice (150 grams) eaten first, followed by broccoli (150 grams) and chicken (100 grams)
214998701|NCT06598462|DRUG|Solrikitug Low Dose|Solrikitug low dose subcutaneous injection
214998702|NCT06598462|DRUG|Solrikitug Mid Dose|Solrikitug mid dose subcutaneous injection
214998703|NCT06598462|DRUG|Solrikitug High Dose|Solrikitug high dose subcutaneous injection
214998704|NCT06598462|OTHER|Placebo|Placebo subcutaneous injection
214998705|NCT05725421|PROCEDURE|Donor Radical and Partial Nephrectomy|Donor participants will undergo laparoscopic radical nephrectomy (RN) . Donor kidney then will undergo cold perfusion and ex-vivo partial nephrectomy (PN) with cold ischemia. During PN, careful inspection of tumor will be performed to ensure it is well-encapsulated. If any infiltrative features (versus well encapsulated tumor) are noted intraoperatively then transplant will not be performed. Multiple surgical margins will be sent (either frozen section or standard with priority). If final margins are positive or concerning, then transplant will not be performed. Biopsies of the tumor will be performed and sent to pathology (either frozen section or standard with priority).
214390218|NCT02543021|DEVICE|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
214390219|NCT02543021|PROCEDURE|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
214390220|NCT02569320|DRUG|Dexamethasone|Given PO
214998706|NCT05725421|PROCEDURE|Kidney Transplantation|The donor kidney will remain on ice while pathologic analysis is performed, and transplant recipient surgery is initiated (if pathologic analysis satisfactory). Cold ischemia with delay for pathology will have minimal functional impact in this setting based on extensive prior experience with renal transplantation where kidneys are routinely kept hypothermic for several hours prior to transplantation.
214998707|NCT05725421|PROCEDURE|Laparoscopic Radical Nephrectomy|Radical nephrectomy consists of the removal of the kidney together with the perirenal fat and regional lymph nodes. The transperitoneal approach allows early control of the renal vessels.
214998708|NCT06408857|DRUG|MAM01 300 mg SC|MAM01 300 mg will be administered SC
214998709|NCT06408857|DRUG|MAM01 300 mg IM|MAM01 300 mg will be administered IM route
214998710|NCT06408857|DRUG|MAM01 2000 mg IV|MAM01 2000 mg will be administered IV
214998711|NCT06408857|DRUG|MAM01 190 mg SC|MAM01 190 mg will be administered SC
214998712|NCT06408857|DRUG|MAM01 225 mg SC|MAM01 225 mg will be administered SC
214998713|NCT06408857|DRUG|MAM01 150 mg SC|MAM01 150 mg will be administered SC
214998714|NCT06408857|DRUG|MAM01 150 mg IM|MAM01 150 mg will be administered IM
214998715|NCT06408857|DRUG|MAM01 150 mg IV|MAM01 150 mg will be administered IV
214998716|NCT06408857|DRUG|Placebo SC|Placebo will be administered SC
214390221|NCT02569320|DRUG|HDAC Inhibitor AR-42|Given PO
214501393|NCT06242015|OTHER|Carbohydrate-last meal|Broccoli (150 grams) and chicken (100 grams) eaten first, followed by rice (150 grams)
214501394|NCT05317689|DRUG|Psilocin|17.5mg oral psilocin with psychological support and physiological monitoring
214998717|NCT06408857|DRUG|Placebo IV|Placebo will be administered IV.
214998718|NCT06408857|DRUG|Placebo IM|Placebo will be administered IM
214998719|NCT02379416|DRUG|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
214998720|NCT04310826|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary magnesium intervention
214998721|NCT04310826|OTHER|Media Intervention|Undergo video interviews
214390222|NCT02569320|OTHER|Laboratory Biomarker Analysis|Correlative studies
214390223|NCT02569320|DRUG|Pomalidomide|Given PO
214390224|NCT00724425|DRUG|IPI-493|Capsules, Multiple Schedules
214390225|NCT01598974|PROCEDURE|Traditional Acupuncture|
214390226|NCT01598974|PROCEDURE|Laser Acupuncture|
214390227|NCT00762684|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
214390228|NCT00762684|DRUG|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
214390229|NCT06240858|PROCEDURE|Laparoscopic transabdominal preperitoneal hernia repair.|The TAPP group used self-gripping mesh for laparoscopic transperitoneal preperitoneal hernia repair.
214390230|NCT06240858|PROCEDURE|Lichtenstein hernia repair.|The Lichtenstein group used self-gripping mesh for Lichtenstein hernia repair.
214998722|NCT04310826|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
214501395|NCT05317689|DRUG|Psilocybin|25mg oral psilocybin with psychological support and physiological monitoring
214998723|NCT05777681|PROCEDURE|Aortic Surgery|open surgical repair with resection of infected aortic segment, debridement of surrounding tissue and in situ graft replacement.
214390231|NCT05136911|BEHAVIORAL|SALT-Intervention|Participants in the intervention group will have access to all standard care as provided to the usual care group participants. In addition, participants in the intervention group will receive the SALT-intervention developed by the principal investigator in the form of a SALT-intervention consist of the Salt Intervention manual, five online modules which include a virtual cooking demonstration and five ten-minute weekly telephone calls delivered by the principal investigator.These strategies aim to increase knowledge, enhance self-management abilities and provide social support.
214390232|NCT02324023|DEVICE|Endoscopic ultrasound|All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
214390233|NCT04408027|BEHAVIORAL|Virtual-Care Cognitive Behavioural Therapy|The feasibility, participation barriers, and acceptability of the intervention, virtual-care cognitive behavioural therapy (VC-CBT), will be evaluated for children with anxiety. The VC-CBT protocol will involve 12 sessions (of one hour in duration) delivered by a CBT therapist using PHIPA (Personal Health Information Protection Act) compliant Zoom. An initial session will review therapy goals and psychoeducation about anxiety. Sessions 2 and 3 will focus on feeling identification and will introduce relaxation strategies. Sessions 4 and 5 will introduce cognitive distortions and restructuring strategies. Sessions 6 and 7 will introduce exposure tasks. Sessions 8 to 11 will involve practicing cognitive restructuring skills and completing exposures. The final session will review relapse prevention. Parents will participate in the first and last sessions, as well as join at the end of each session for a brief review of the skills learned during the session.
214390234|NCT03411824|OTHER|no intervention|Non applicable
214390235|NCT04149041|DIAGNOSTIC_TEST|ultrasound|POCUS is applied to adult patients in an emergency department.
214390236|NCT02582164|DEVICE|Duke Biomedical Engineering's Long-working distance OCT|The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
214390237|NCT02085837|OTHER|Education|Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
214390238|NCT02085837|OTHER|Daily weight measurement and monitoring|Monitor weight to avoid problems related to hypervolemia.
214390239|NCT02085837|OTHER|Universal Dietary education|To improve diet and health
214390240|NCT02085837|OTHER|Medication review|Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.
214390241|NCT02085837|OTHER|Focused advanced directive program|Education will be provided to increase awareness and encourage patients to have advanced directive.
214390242|NCT02085837|OTHER|Countdown to fistula program|To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
214390243|NCT02340520|DRUG|Theophylline|Oral
214390244|NCT02340520|DRUG|Roflumilast|Oral
214390245|NCT03259282|BIOLOGICAL|Analysis of gamma globulin|Electrophoresis of proteins
214390246|NCT05174104|PROCEDURE|Vestibular Rehabilitation|The home exercise schedule consists of a patient-tailored association of adaptation (without and with the target moving on pitch and yaw planes for 1 min each three times per day), substitution, habituation, and balance and gait exercises. All the unilateral vestibular hypofunction patients will be followed in the clinic twice a week for 4 weeks for 30-45 min and evaluated for adherence. Between supervised sessions, patients will perform a twice-daily home exercise plan for a total of 30-40 min/day
214394113|NCT04082182|BIOLOGICAL|Dendritic cell immunotherapy|Intravenous infusions of MIDRIX4-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
214394114|NCT04082182|BIOLOGICAL|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIX4-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
214998724|NCT06974058|DIETARY_SUPPLEMENT|Nasafytol® (Quercetin/Curcumin Supplement)|Participants in this group will receive Nasafytol®, a combined dietary supplement containing quercetin (65 mg) and curcumin (42 mg). Participants will take two capsules (single administration) twice a day for a duration of 8 weeks. The supplement is intended to alleviate mild to moderate symptoms of Long COVID-19, including but not limited to fatigue, cognitive function, generalized body pain, low mood, sleep disturbance, and overall quality of life.
214998725|NCT03439735|DRUG|Endocrine Therapy and a CDK 4/6 inhibitor|Participants with untreated metastatic disease receiving ET and a CDK 4/6 i as first line therapy.
214998726|NCT03439735|DRUG|Endocrine Therapy and a CDK 4/6 inhibitor|Participants initiating a CDK 4/6 i after progression on ET.
214998727|NCT06973525|DRUG|Patients will initially receive trastuzumab, pyrotinib, and albumin-bound paclitaxel. Those who do not achieve a radiological response after Cycle 2 will switch to SHR-A1811 (a HER2-targeted antibody|Drug: SHR-A1811 Drug: Pertuzumab
214390247|NCT01231503|BIOLOGICAL|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=\<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =\< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
214998728|NCT06973525|DRUG|Patients will initially receive trastuzumab, pyrotinib, and nab-paclitaxel. Those who achieve a partial response (PR) or complete response (CR) after cycle 2 will continue on the same regimen.|Patients will initially receive trastuzumab, pyrotinib, and nab-paclitaxel. Those who achieve a partial response (PR) or complete response (CR) after cycle 2 will continue on the same regimen.
214998729|NCT06187909|PROCEDURE|PECS II BLOCK|The patient laid supine with the ipsilateral arm abducted and externally rotated. The high-frequency linear probe was placed transversely between the clavicle medially and above and the shoulder joint laterally. After identifying the pectoralis major and minor muscles and the plane between them, the probe was angled caudally to look for the pulsating pectoral branch of the thoraco-acromial artery. After that, the block needle was inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine were administered. Then probe was moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The third and fourth ribs were detected. The needle targeted the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 10 mL of 0.25% bupivacaine was done.
214998730|NCT06187909|PROCEDURE|MTP BLOCK|The block was performed with the patient in a sitting position. A high-frequency linear probe was placed in a vertical orientation 3 cm lateral to the midline at the T2 level in the parasagittal plane. The distance between the parietal pleura and the transverse process was measured using ultrasound guidance. The block needle was inserted out of plane to the probe and advanced to a depth equivalent to half of the measured distance beyond the transverse process. Then, 10 mL of 0.25% bupivacaine was injected. A similar injection was performed at the T6 level, with sonographic identification and level determination achieved by counting from the second rib.
214998731|NCT05544929|DRUG|KFA115|Immunomodulatory agent
214998732|NCT05544929|DRUG|pembrolizumab|Anti-PD-1 antibody
214390248|NCT01231503|BIOLOGICAL|Engerix-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=\< 7 days of age)
214390249|NCT01231503|BIOLOGICAL|Tritanrix HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
214390250|NCT01231503|BIOLOGICAL|BCG|1 dose, intradermal route, in shoulder at birth (=\< 7 days of age)
214390251|NCT01231503|BIOLOGICAL|OPV|4 doses, orally, at birth (=\< 7 days of age) and at 6, 10 and 14 weeks of age
214390252|NCT01231503|BIOLOGICAL|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
214390253|NCT02552433|DIETARY_SUPPLEMENT|protein intake assessment and optimisation|
214390254|NCT03126032|OTHER|GlycoCheck™-System|"Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay."
214390255|NCT01586338|DRUG|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
214390256|NCT03803020|OTHER|fractional flow reserve and SPECT detection|fractional flow reserve and SPECT detection
214390257|NCT00284089|DRUG|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
214390258|NCT04237974|DEVICE|computed tomography pulmonary angiography|The radiological severity of pulmonary embolism will be assessed by using the computed tomography pulmonary arterial obstruction index (CT-PAOI)
214390259|NCT03942874|BEHAVIORAL|Group Reward Retraining|Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated
214390260|NCT01146574|BIOLOGICAL|Sotatercept|Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
214390261|NCT01146574|BIOLOGICAL|Placebo|Placebo
214390262|NCT05926128|DRUG|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment with a scheduled molecular monitoring until month 24.
214390263|NCT02055573|OTHER|Ready To Learn (RTL)|See arm description
214390264|NCT02055573|OTHER|All Babies Cry (ABC)|See arm description
214390265|NCT01604811|DRUG|Permixon® 160 mg|Oral administration - 160 mg twice daily.
214390266|NCT01604811|DRUG|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
214390267|NCT01604811|DRUG|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
214390268|NCT01604811|DRUG|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
214390269|NCT03053492|DEVICE|Duck Duck Punch Play|The behavioral intervention will include playing a hands-free video game custom designed for stroke survivors.
214390270|NCT03053492|BEHAVIORAL|Commercially Available Game Play|The behavioral intervention will include playing a hands-free video game available off-the-shelf.
214390271|NCT00004399|DRUG|magnesium sulfate|
214390272|NCT00004399|DRUG|nimodipine|
214390273|NCT01868074|DEVICE|Insole|Custom-molded arch-supporting insole
214390274|NCT02663375|DEVICE|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
214501396|NCT05317689|DRUG|Sublingual Psilocin|2.18mg - 4.36mg sublingual psilocin with psychological support and physiological monitoring
214390275|NCT06425978|DRUG|Cellular Matrix / A-CP-HA Kit|"For infiltration, a prior preparation of the region with anesthetic cream is performed, procaine 25 mg/g + lidocaine 25 mg/g (Emla 5% cream) in the vulvar area and vaginal introitus. Occlusion of the area with plastic film is performed for 20 minutes. After asepsis and antisepsis, infiltration is performed with mesotherapy needles 31G 4mm, using the technique of superficial point-to-point mesotherapy microinjections, in the vestibule and the first 3 cm of the posterior wall of the vagina."
214390276|NCT06425978|DRUG|Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)|Blissel®, Estriol vaginal gel 50 micrograms/g, daily application for 15-21 days in a row, then two times a week for 24 weeks (6 months). Application instructions will be explained to the patients. The gel should be applied in the vagina using an applicator with the marked dose, the full applicator should be inserted into the vagina and emptied, preferably at night.
214998733|NCT05600907|BIOLOGICAL|JSP191|A monoclonal antibody that targets human CD117
214998734|NCT06097507|BEHAVIORAL|Educational intervention|The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler.
214998735|NCT05960773|DRUG|Decitabine/cedazuridine|Decitabine/cedazuridine (INQOVI) oral tablet (35 mg decitabine and 100 mg cedazuridine) taken 3 consecutive days during the first week of every cycle (1 cycle=28-days) for 6 cycles (i.e., 1 course). Additional 6 cycles (i.e., Course 2) for subjects with stable disease or disease regression. Max (total) of 2 treatment courses.
214998736|NCT00929006|DRUG|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
214998737|NCT00929006|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
214998738|NCT02364713|BIOLOGICAL|Bevacizumab|Given IV
214998739|NCT02364713|DRUG|Gemcitabine Hydrochloride|Given IV
214390277|NCT03835637|DRUG|ORIC-101|Capsule or oral suspension
214390278|NCT04574154|PROCEDURE|FIB|FIB with ultrasound: Ropivacaine 0.5% 40 ml
214390279|NCT04574154|PROCEDURE|ESPB|ESPB (L4) with ultrasound: Ropivacaine 0.5% 40 ml
214390280|NCT04574154|PROCEDURE|spinal anesthesia|bupivacaine 0,5% 2.2 ml
214390281|NCT00334425|DRUG|MENOPUR; GONAL-F|
214390282|NCT01544491|DRUG|RAD001|Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
214390283|NCT01544491|DRUG|MMF|MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
214390284|NCT02521324|DEVICE|DGB2|DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
214390285|NCT03982888|PROCEDURE|Deep Brain Stimulation|Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.
214390286|NCT03982888|DEVICE|DBS|"Use of the Medtronic DBS device. DBS device consists of 2 parts:~1. DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~2. Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses"
214390287|NCT01763528|OTHER|nutrition intervention|high protein diet
214390288|NCT05592535|PROCEDURE|Coronary revascularization|Coronary revascularization performed by PCI in a vessel investigated with FFR or indication for surgery
214390289|NCT02290717|DEVICE|Fractional CO2 laser|
214390290|NCT02290717|OTHER|NB-UVB therapy|NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
214390291|NCT02290717|DRUG|Fluticasone Propionate Cream 0.05%|4 times a week (standard IPD protocol)
214390292|NCT06083103|DIAGNOSTIC_TEST|18-FDG PET-MRI|For this trial, 18-FDG PET-MRI will be conducted directly after PET-CT using a single dose of radiotracer
214390293|NCT00160160|DRUG|eprosartan/HCTZ|
214390294|NCT05130788|BEHAVIORAL|WeChat Quit Coach|"WeChat Quit Coach intervention will be delivered via WeChat private groups for 6-12 weeks (\<30 seconds per day). During the intervention period, participants will receive a text message at a fixed point of time every day (e.g., 8:00 am). The messages are designed to build motivations and skillset to quit smoking. Participants will also receive a daily group discussion question (e.g., If you are to give one piece of advice to someone who has not made the decision to quit smoking, what would you say to his/her?), and be encouraged to respond to the question. Participants can comment on group members' responses and ask questions related to smoking and quitting either in group (so everyone in the group can see the message) or directly to the coach (so only the coach can see the message). The coach will respond to the questions within 24 hours. The PI and the RA will moderate group discussions."
214390295|NCT05130788|BEHAVIORAL|Leaflet|Participants in the control group will receive a leaflet with information about existing smoking cessation programs targeting Chinese American smokers.
214998740|NCT02364713|OTHER|Laboratory Biomarker Analysis|Correlative studies
214998741|NCT02364713|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
214998742|NCT02364713|DRUG|Paclitaxel|Given IV
214998743|NCT02364713|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214998744|NCT02364713|OTHER|Quality-of-Life Assessment|Ancillary studies
214998745|NCT02364713|DRUG|Topotecan Hydrochloride|Given IV
214998746|NCT06084741|OTHER|Omitting of usage of intraabdominal drains after repair of peptic ulcer perforations|omitting the intraabdominal drains
214998747|NCT06084741|OTHER|Using intraabdominal drains|The investigators will put intraabdominal drains
214998748|NCT04941300|OTHER|Mailed FIT Outreach|We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.
214390296|NCT05130788|DRUG|Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges|Participants in both groups will be offered a 4-week supply of NRT patches and lozenges but not forced to use the medications. The medications are free to participants. If participants want to try or use the medications, the study team will mail the patches and lozenges (with a Chinese version of the instruction) or deliver in person.
214390297|NCT00967018|DRUG|Degarelix|
214390298|NCT00857441|DEVICE|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
214390299|NCT00857441|DEVICE|Liberté|Bare metal stent
214390300|NCT00857441|DEVICE|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
214390301|NCT00857441|DEVICE|Taxus|Paclitaxel eluting stent
214390302|NCT03897205|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
214390303|NCT03897205|OTHER|Plasma Exchange|The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.
214390304|NCT05364918|DRUG|Jeksung combined with anti-radiation spray|Treat radiation stomatitis with Jeksung combined with anti-radiation spray
214390305|NCT05515718|OTHER|Standard pain management|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician, under strict aseptic conditions After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
214501397|NCT04228991|RADIATION|Locoregional radiation treatment - Conventional fractionation|40 Gray in 15 daily fractions over 3 weeks
214501398|NCT04228991|RADIATION|Locoregional radiation treatment - Hypofractionation|26 Gray in 5 daily fractions over 1 week
214501399|NCT04948645|DRUG|Fosigotifator|Oral
214501400|NCT04948645|DRUG|Placebo|Oral
214501401|NCT06963437|OTHER|Diet|A four-stage dietary program will be implemented in accordance with ASMBS guidelines. To the best of our knowledge, there is currently no study comparing the dietary approach following revisional bariatric surgery with ketogenic and intermittent fasting diets
214998749|NCT04941300|OTHER|Standardized navigation|"The standardized navigation includes, but is not limited to, the following key components:~1. Identification of individuals with abnormal FIT~2. Results review and colonoscopy order by provider~3. Results reporting to patient~4. Insurance approval for colonoscopy~5. Colonoscopy scheduling~6. Bowel preparation \& colonoscopy completion~7. Colonoscopy results provided to patient and CHC~8. Referral-to-Care for patients with CRC (if necessary)"
214998750|NCT02676973|PROCEDURE|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
214998751|NCT02676973|PROCEDURE|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
214998752|NCT02676973|PROCEDURE|Uphold™ LITE|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
214998753|NCT06144606|DRUG|Tecartus|Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
214390306|NCT05515718|OTHER|Femoral nerve block|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician under strict aseptic conditions, immediately after oral informed consent is obtained. After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
214390307|NCT03268460|DIAGNOSTIC_TEST|Arterial blood gases|blood PH, HCO3
214390308|NCT03268460|DIAGNOSTIC_TEST|Blood anion gap|(Na+) - (Cl- + HCO3-)
214390309|NCT03268460|DIAGNOSTIC_TEST|serum electrolytes|Na+ , K+ , Cl- and calcium
214390310|NCT03268460|DIAGNOSTIC_TEST|renal function test|blood urea and serum creatinine
214390311|NCT03268460|DIAGNOSTIC_TEST|urine analysis|urine PH, specific gravity, aminoaciduria, glycosuria, phospaturia and 24 hr urine calcium
214390312|NCT01272882|DEVICE|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
214501402|NCT06963437|OTHER|Ketogenic diet|A high-protein Very Low-Calorie Ketogenic Diet (VLCKD) will be implemented as the nutritional intervention. In line with previous studies, the daily energy intake of the ketogenic diet will be planned as 600-800 kcal, with approximately 10% of energy from carbohydrates (\<30 g/day), 40-45% from protein, and 40-50% from fat. Total carbohydrate intake will be restricted to less than 30 g per day, primarily from vegetables, while fat intake will derive from natural protein sources and 10 g of olive oil per day.
214501403|NCT06963437|OTHER|Fasting|Patients in this group will follow a time-restricted eating pattern (16/8) for a duration of 6 weeks, with food intake limited to an 8-hour window each day. Intermittent fasting will preferably be observed between 6:00 PM and 10:00 AM; however, patients may choose alternative 16-hour fasting periods such as 7:00 PM-11:00 AM or 8:00 PM-12:00 PM, depending on their individual routines. During the 8-hour feeding window, patients will adhere to the stage 4 post-bariatric dietary guidelines in accordance with ASMBS recommendations
214501404|NCT06963437|OTHER|Control|No individualized diet will be planned
214687929|NCT03644940|DIAGNOSTIC_TEST|CustomSight|Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
214687930|NCT05674045|DRUG|EG017 3mg|EG017 3mg/day Oral administration for 12 weeks, once daily
214687931|NCT05674045|DRUG|EG017 6mg|EG017 6mg/day Oral administration for 12 weeks, once daily
214390313|NCT02646111|DRUG|12 weeks without Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.
214998754|NCT06524349|DEVICE|3D printed knee extender device|Participants will receive a 3D printed knee extender device with sealed water bottles and an at-home rehabilitation program designed to be used with the 3D printed knee extender device.
214390314|NCT02646111|DRUG|12 weeks with Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.
214390315|NCT02646111|DRUG|24 weeks with Ribavirin|24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.
214390316|NCT01454180|DRUG|gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.|"* Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
214390317|NCT01454180|DRUG|Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI|"* Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
214390318|NCT00820820|BIOLOGICAL|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (\>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
214390319|NCT00820820|BIOLOGICAL|placebo|Vehicle (water for injection), 0.5 ml, once
214390320|NCT03739320|DRUG|Mepolizumab 100 MG Injection [Nucala]|100 milligrams subcutaneously once every 4 weeks
214390321|NCT03414697|OTHER|Control group|The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy.
214390322|NCT03414697|PROCEDURE|UC-MSCs|Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10\^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.
214390323|NCT05214014|BIOLOGICAL|Autologous Regulatory Т-cells|Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs
214390324|NCT05214014|OTHER|Standard treatment according to the clinical protocols|Standard treatment of Systemic Sclerosis according to the clinical protocols
214687932|NCT00114283|DRUG|lapatinib ditosylate|Given PO
214390325|NCT00002720|DRUG|tamoxifen citrate|
214390326|NCT00002720|PROCEDURE|conventional surgery|
214390327|NCT02112058|BEHAVIORAL|A Family-Strengthening Program for Low-Income Families|"The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.~Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.~The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program."
214390328|NCT00580229|DRUG|prednisone|prednisone 40mg by mouth 30-60 minutes prior to rituximab
214687933|NCT00114283|OTHER|laboratory biomarker analysis|Correlative studies
214687934|NCT06461611|BEHAVIORAL|Health Diary Program|The health diary is constructed based on the theory of health action process approach, which is used to plan and clock for self-management behaviors of adolescent patients during fixed orthodontic treatment.
214998755|NCT05619614|DEVICE|eye-tracking glasses|endoscopists wear eye-tracking glasses during real-time colonoscopy
214687935|NCT06461611|BEHAVIORAL|Traditional Health Education|Traditional health education is that the nurse orally teaches the patient about fixed orthodontic knowledge, and the patient obtains a paper information.
214998756|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy|The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
214998757|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes|The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
214390329|NCT06237374|BEHAVIORAL|Digital Vaccine Education Training & Patient-facing Chatbot Tool|The first part of the intervention is a digital training provided to CHWs, which includes videos and job aids on vaccine education to support patient communication. The second part of the intervention is a patient-facing chatbot designed to provide key information about routine immunization that CHWs can share with their patients through the social media and messenger application, WhatsApp.
214390330|NCT06237374|BEHAVIORAL|Standard Training|All CHWs in the study will receive the standard CHW training that is provided on an ongoing basis by Lwala Community Health Alliance.
214390331|NCT00301002|DRUG|Alefacept|
214390332|NCT01839968|OTHER|Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma|
214390333|NCT01429506|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy
214390334|NCT01429506|DRUG|Intensive medical management|Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
214390335|NCT04131959|DEVICE|CytoSorb 300 mL device|Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass
214501406|NCT04182646|DEVICE|Spartz Balloon|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required
214501407|NCT02815917|DRUG|[18F]FTP PET/CT|All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.
214501408|NCT03432000|OTHER|Performances of patients and controls on temporal task|To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)
214501409|NCT06305884|PROCEDURE|Bioelectric Impedance Analysis|Undergo BI
214998758|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub|The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
214998759|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub|The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
214390336|NCT02359591|OTHER|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
214390337|NCT04642469|DRUG|Durvalumab|Intravenous administration of Durvalumab
214390338|NCT04642469|OTHER|Placebo|Placebo Comparator
214390339|NCT02767700|GENETIC|NGS|Next generation sequencing
214390340|NCT04924140|DRUG|Aducanumab|Administered as specified in the treatment arm
214390341|NCT02773706|OTHER|Automated Psychology Services|The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.
214390342|NCT02773706|OTHER|Notification of Subspecialist|The automated screening tool determines a positive or negative screen, then informs the clinician.
214390343|NCT04658732|DRUG|Administration of Alprazolam , Gabapentin , Dexmedetomidine|Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.
214390344|NCT02622633|DEVICE|Epidural Electrode|Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.
214390345|NCT05592080|RADIATION|MRI|MRI-mDIXON-Quant examinations, anthropometric measures, body composition, hormonal and biochemical assays were performed in all participants, and the liver fat fraction (LFF) and muscle fat fraction (MFF) represented the fat content in the liver and skeletal muscle, respectively.
214501410|NCT06305884|OTHER|Exercise|Pedal an exercise bike
214501411|NCT06305884|PROCEDURE|Photoplethysmography|Undergo PPG
214501412|NCT06305884|BEHAVIORAL|Questionnaire Administration|Ancillary studies
214501413|NCT06432881|DEVICE|RD SET Sensor|All subjects are enrolled into this arm and will have Sp02 measurements obtained.
214501414|NCT05663710|DRUG|177Lu girentuximab|Given by IV (vein)
214501415|NCT05663710|DRUG|Nivolumab|Given by IV (vein)
214501416|NCT05663710|DRUG|Cabozantinib|Given by PO
214501417|NCT05663710|DRUG|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV (vein)
214501418|NCT05635643|DRUG|CHS-114|CHS-114
214501419|NCT05635643|DRUG|toripalimab|toripalimab-tpzi
214501420|NCT00570999|DRUG|Palifermin|60 mg/kg/day
214501421|NCT00570999|OTHER|Placebo|1,2 mL once daily
214501422|NCT02562937|BEHAVIORAL|text messages related to sedentary behaviour|texts sent twice daily encouraging reduced sedentary behaviour
214390346|NCT01355874|DRUG|Iferanserin|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
214390347|NCT01355874|DRUG|Placebo|Placebo ointment BID for 14 days during double blind.
214390348|NCT01355874|DRUG|Iferanserin + Placebo|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
214390349|NCT00719303|BEHAVIORAL|Behavioral Dietary Intervention|Receive dietary intervention
214390350|NCT00719303|BEHAVIORAL|Compliance Monitoring|Complete daily fat gram and step diaries
214390351|NCT00719303|OTHER|Counseling|Undergo face-to-face and telephone counseling
214390352|NCT00719303|OTHER|Educational Intervention|Receive educational materials
214390353|NCT00719303|BEHAVIORAL|Exercise Intervention|Undergo physical activity intervention
214390354|NCT00719303|OTHER|Laboratory Biomarker Analysis|Correlative studies
214390355|NCT00719303|OTHER|Quality-of-Life Assessment|Ancillary studies
214390356|NCT00719303|OTHER|Questionnaire Administration|Ancillary studies
214390357|NCT02228525|DRUG|selinexor (KPT-330)|
214390358|NCT00680056|DRUG|Formoterol plus Placebo (Tiotropium)|Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
214390359|NCT00680056|DRUG|Formoterol plus Tiotropium|Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
214390360|NCT03333174|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
214390361|NCT05522920|OTHER|Therapy with and without spinal cord stimulation|Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.
214390362|NCT00403975|DRUG|diquafosol tetrasodium ophthalmic solution, 2%|
214390363|NCT00823732|OTHER|educational intervention|Undergo individualized interdisciplinary palliative care intervention
214390364|NCT00823732|OTHER|medical chart review|Ancillary studies
214390365|NCT00823732|OTHER|questionnaire administration|Ancillary studies
214390366|NCT00823732|PROCEDURE|end-of-life treatment/management|Undergo end-of-life treatment/management
214390367|NCT00823732|PROCEDURE|psychosocial assessment and care|Undergo psychosocial assessment and care
214390368|NCT00823732|PROCEDURE|quality-of-life assessment|Ancillary studies
214390369|NCT00823732|PROCEDURE|management of therapy complications|Undergo management of therapy complications
214390370|NCT00823732|PROCEDURE|assessment of therapy complications|Undergo assessment of therapy complications
214390371|NCT05047796|OTHER|Intervention Protocol|The intervention protocol will consist of visceral osteopathic techniques and will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy.
214390372|NCT05047796|OTHER|Sham Protocol|The sham protocol will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy. The sham protocol will consist of simulation of therapy, where the therapist will place his hands in the same regions of the intervention protocol, without therapeutic intent
214390373|NCT04763135|DRUG|Mirtazapine|"Orally disintegrating tablets of mirtazapine introduced at the dose of 15 mg and increased up to 45 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
214390374|NCT04763135|DRUG|Escitalopram|"Orally disintegrating tablets of escitalopram introduced at the dose of 10 mg (or 5 mg for patients older than 65) and increased up to 20 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
214390375|NCT06058871|BEHAVIORAL|Regular messages|The EMI-I messages will be delivered in sequence over three months. The content, frequency, and timing of the messages will be determined by participant preferences, as determined during the baseline evaluation, as personalisation is central to such cognitive and behavioural changes. The messages will mainly be text-based, but other forms such as videos will also be used, depending on the needs of the participants.
214390376|NCT06058871|BEHAVIORAL|Nurse-led real-time support messages (chat type)|The nurse will initiate 10-15-minute chats via an online platform (e.g., WhatsApp) after all instant messages for each session have been delivered. The nurse will guide the participants to set goals for breastfeeding. Any anticipated barriers will be discussed. The participants can also initiate the chats. While there is no limit to the number of chat messages, nurse-led real-time support messages will be provided during working hours (i.e., 9 am-6 pm on weekdays).
214390377|NCT03522987|DRUG|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
214390378|NCT01673360|DEVICE|Elevate PC|List of AMS prolapse products
214390379|NCT01673360|DEVICE|Mini Arc Pro|List of AMS Urinary Incontinence devices
214390380|NCT01673360|DEVICE|RetroArc|List of AMS Urinary Incontinence devices
214390381|NCT03957135|PROCEDURE|Laparoscopic distal pancreatectomy|Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer
214390382|NCT03957135|PROCEDURE|open distal pancreatectomy|Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
214390383|NCT01088529|DRUG|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
214390384|NCT01088529|DRUG|Prednisone|5 mg orally daily.
214687936|NCT05378425|DRUG|NTX-1088|IgG4 mAb targeting the poliovirus receptor (PVR, CD155).
214390385|NCT01088529|DRUG|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
214390386|NCT02595177|PROCEDURE|Cataract surgery with intraocular lens implantation.|Phacoemulsification under topical anesthesia with intraocular lens implantation.
214390387|NCT05372887|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
214390388|NCT05372887|DRUG|Placebo|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
214390389|NCT06233123|BEHAVIORAL|the Medisafe android application (https://www.medisafe.com).|software for Android mobile phones that can remind the patient of his treatment on time
214998760|NCT05958381|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
214390390|NCT06231290|OTHER|Adult full pulpotomy procedure|The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.
214390391|NCT01264029|BEHAVIORAL|Mindful Tai Chi Intervention|
214390392|NCT01264029|BEHAVIORAL|Mindfulness Meditation|
214501423|NCT02714777|DEVICE|Autonomic nervous system activity|Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
214501424|NCT06522165|OTHER|Analysis|analysis and review of imaging and clinical data
214998761|NCT05958381|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
214998762|NCT04452526|OTHER|Best Practice|Receive usual care
214998763|NCT04452526|OTHER|Educational Intervention|Receive educational materials
214390393|NCT01264029|BEHAVIORAL|Mall Walking|
214390394|NCT01264029|BEHAVIORAL|Weekly Discussion|
214501425|NCT06465017|DIAGNOSTIC_TEST|standard-of-care imaging (18F-FDG and 68Ga-FAPI PET/CT), 68Ga-THP-Trop2 VHH PET/CT|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG and 68Ga-FAPI) and 68Ga-THP-Trop2 VHH, and undergoes PET/CT imaging within the specified time.
214998764|NCT04452526|OTHER|Questionnaire Administration|Ancillary studies
214998765|NCT04452526|OTHER|Reminder|Receive reminder letter
214501426|NCT04432584|DRUG|Crovalimab|"Dosing depends on body weight. Participants will be dosed as follows:~* 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study~* 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study~* 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study~* 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study~* 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study~* 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study."
214998766|NCT04558619|BEHAVIORAL|Kōmmour Prenatal|Centering Pregnancy, a group prenatal care model, is a promising intervention that challenges the standard model of one-on-one counseling of prenatal care. The model, is currently implemented at the UAMS, but as of yet to be adapted for Pacific Islanders. Centering Pregnancy replaces the individual prenatal care visit with a group model for obstetrically low-risk women. This model provides substantially more health promotion content than the traditional one-on-one prenatal care model. The intervention occurs from week 14 of pregnancy through birth, following the same same schedule as individual care. Group visits are 90-120 minutes each and follow a unique structured curriculum that incorporates standards of care. In the group setting, credentialed prenatal providers conduct a one-on-one assessment with each patient (30 min) and then facilitate group discussions on the topics of pregnancy, using adult learning principles (60-90 min).
214998767|NCT05357612|DRUG|Pimavanserin|PD related Psychosis
214998768|NCT06975696|PROCEDURE|Standard endovascular thrombectomy with Fusion|Standard endovacular procedure with the addition of Fusion imaging according to the intended use of the ARTIS Icono Biplane.
214998769|NCT06975696|PROCEDURE|Standard EVT without Fusion|Standard endovacular procedure without the use of Fusion imaging on the ARTIS Icono Biplane.
214998770|NCT02580604|DRUG|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
214390395|NCT00802828|DRUG|Famotidine Tablets, 40 mg|
214390396|NCT05244590|OTHER|Consultation model for patients with palliative care needs|"Training in PC for GPs The training program for GPs will meet the main training needs of GPs according to our previous study and feedback from elements of the Palliative Care Study Group of the Portuguese Association of General and Family Medicine (GESPal). The training program will have a total duration of 24 hours and will consist of two modules.~Consultation model for patients Consultations will take place every 3 weeks for a total period of 12 weeks. The consultation model will be divided into five areas (Summarize clinical information, Objective symptoms' management, Assessment and coding of chronic diseases and symptoms, planning clinical approach, (other) problems/concerns) to be addressed during the assessment. The five areas were constructed to be intuitive for GPs, following the records' structure used in Portuguese primary care."
214501427|NCT04432584|DRUG|Eculizumab|Eculizumab will be administered at a dose of 900 mg Q2W, as per the dosing schedule described above.
214390397|NCT05273086|BEHAVIORAL|Sleep Intervention Group|"The intervention group will acquire skills to improve their quality of sleep such as:~* Acquisition of notions of chronobiology.~* Location of the nervous structures involved in biological rhythms.~* Awareness of the existence of three times that direct our biological rhythms, and of the need for them to be synchronized.~* Self-knowledge of the chronotype and the degree of adjustment of the three times.~* Knowledge of the variables that determine a good quality of sleep.~* Applications of chronobiology to the field of nursing. Recommendations for nurses and patients.~* Self-knowledge of the quality of sleep and the health status of the circadian system."
214390398|NCT03432949|DRUG|Dexamethasone plus Radium-223|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
214390399|NCT05975437|OTHER|personalized surveillance plans (PSP) and personalized aftercare plans (PAP)|The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the 'Breast Cancer Surveillance Decision Aid' including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision-making is supported by a patient decision aid.
214390400|NCT01821898|DRUG|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
214390401|NCT01821898|OTHER|Elimination diet|This group will receive an elimination diet
214390402|NCT04976595|DRUG|Natesto|Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.
214390403|NCT03016117|PROCEDURE|Pecs II block and parasternal block|The Pecs II block will be performed under ultrasound guidance, at fourth rib level, on the axillary line, into the fascial plane between pectoralis minor muscle and serratus muscle. The parasternal block will be performed under ultrasound guidance, at the second and fourth intercostal space, between the pectoralis major muscle and the intercostal muscles, near to the external intercostal membrane.
214390404|NCT04587531|DEVICE|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
214390405|NCT03772106|DRUG|Propofol Fresenius|Propolipid 1% : IV
214390406|NCT03772106|DRUG|sevorane|sevorane Quick fill (sevoflurane) : inhalation
214687937|NCT05378425|DRUG|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
214998771|NCT02580604|DRUG|Half-Normal Saline|This is the placebo comparative infusion. Half-normal saline will be infused at the second collection visit following the identical infusion schedule determined during the calcium infusion visit.
214998772|NCT05438199|DEVICE|Toilet seat that measures waste output|Participants will use a toilet that includes a apparatus designed to measure waste output.
214390410|NCT04133428|DRUG|Sacubitril-Valsartan|"Evaluation of the Sacubitril-Valsartan treatment effectiveness.~As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment.~Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made."
214390411|NCT05451511|OTHER|Door-In-The-Face Technique|Sequential request strategies will be applied as an intervention. For the Door-In-The-Face Technique, participants first receive a large request they are unlikely to accept, followed by a smaller request that is the true behavior of interest.
214390412|NCT05451511|OTHER|Foot-In-The-Door Technique|Sequential request strategies will be applied as an intervention. For the Foot-In-The-Door Technique, participants are shown an easier first request that they are likely to accept, followed by a larger request that is not the behavior of interest.
214390413|NCT02817620|DIETARY_SUPPLEMENT|Spirulysat®|
214390414|NCT02817620|DIETARY_SUPPLEMENT|Placebo|
214390415|NCT05177731|DRUG|Venetoclax|Orally by mouth
214390416|NCT05177731|DRUG|Decitabine for Injection|Intravenous infusion
214390417|NCT05177731|DRUG|Cytarabine|Intravenous infusion
214390418|NCT05177731|DRUG|Idarubicin|Intravenous infusion
214998773|NCT06119607|DEVICE|TRIFLO Heart Valve|Surgical Aortic Valve Replacement - Mechanical Valve
214390419|NCT05177731|DRUG|Gilteritinib|Orally by mouth
214390420|NCT02917577|BIOLOGICAL|Avaxim Pediatric®|2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.
214390421|NCT02917577|BIOLOGICAL|Avaxim ® (adult)|2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.
214390422|NCT04938115|BIOLOGICAL|CD7 CART|Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
214390423|NCT05171868|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|Each participant in the intervention group will receive 8 individual, weekly EMDR sessions over 8 weeks. Each session will take approximately 60-90 minutes. The sessions will be delivered at a place convenient to the participant. Trained EMDR therapists will deliver the intervention.
214390424|NCT03696875|OTHER|Multilevel Guided Discharge Planning|Clinical recommendations and resources activations + scheduling of early visit with the specialist + communication with primary care + written instruction sheet to the patient
214390425|NCT03696875|OTHER|Standard of care|Standard of care
214390426|NCT02222519|DRUG|Rocuronium|Rocuronium 0.6mg/kg iv single dose
214390427|NCT01424059|OTHER|WEDQ-B (questionnaire)|Questionnaires are answered after delivery; within 48 hours and after five weeks
214390428|NCT04882761|DEVICE|Dental implant|Comparative
214390429|NCT04980768|PROCEDURE|Root canal treatment|Patients with apical periodontitis will undergo root canal treatment.
214390430|NCT05410236|OTHER|3D bronchial tree model|A detachable 3D printed bronchial tree model
214390431|NCT03511872|OTHER|Basic life support training|"A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group."
214998774|NCT05840484|OTHER|Active Surveillance|Participants will be asked to complete questionnaires, have physical and rectal examinations, have prostate biopsies, and have imaging scans (such as MRIs). These visits will be done between every 6 months and every 2-3 years, depending on the test/procedure.
214998775|NCT06136403|DRUG|deucravacitinib|treatment by deucravacitinib in two phases of challenge
214390432|NCT00662493|BEHAVIORAL|Motor control retraining program|Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated
214501428|NCT06840496|DRUG|Bionetide|Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
214501429|NCT06840496|DRUG|Placebo|"Placebo~• Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks"
214501430|NCT05905926|DRUG|Tenapanor|Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study. Doses can be titrated to either 50 mg BID or 25 mg BID
214501431|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.1mg/kg|Remimazolam Tosilate for Injection 0.1mg/kg at induction
214998776|NCT06424509|OTHER|High degree of long (>5 days) and/or compulsory psychiatric inpatient care|High degree of long (\>5 days) and/or compulsory psychiatric inpatient care
214998777|NCT00870506|BEHAVIORAL|video|5-minute video compared (intervention) to no video and no other intervention (control)
214390433|NCT00662493|BEHAVIORAL|Quadriceps strengthening program|4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
214394115|NCT04082182|BIOLOGICAL|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
214394116|NCT03635138|OTHER|Metal nanoparticles ( O Zn and Cu)|Np of OZn nanoparticles mixed with dental adhesive
214394117|NCT03635138|OTHER|Dental Adhesive pure|Dental Adhesive with commercial preparation
214394118|NCT01004419|DRUG|ZD6474 (vandetanib)|vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
214394119|NCT01004419|DRUG|Faslodex (Fulvestrant)|Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
214394120|NCT06232499|DEVICE|Intravenous Laser Irradiation of Blood|The different color lights for Intravenous Laser Irradiation of Blood are red light at 808nm and blue light at 415nm
214394121|NCT03244592|DRUG|Minocycline|200 mg/day
214394122|NCT03244592|DRUG|Sugar pill|Matched placebo
214394123|NCT01304524|BIOLOGICAL|VGX 3100|1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
214394124|NCT01304524|BIOLOGICAL|Placebo|1ml of placebo delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
214394125|NCT01304524|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
214394126|NCT00003238|DRUG|perillyl alcohol|
214394127|NCT01915147|DRUG|OXN PR followed by OxyPR tablets|
214394128|NCT01915147|DRUG|OxyPR followed by OXN PR tablets|
214394129|NCT03076359|BEHAVIORAL|Traditional Healer Support Program|"Traditional Healers will provide the traditional healer support program assistance, as previously described, to all newly diagnosed patients."
214394130|NCT03076359|DRUG|Standard of Care|First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
214394131|NCT01545362|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
214394132|NCT03891459|BEHAVIORAL|spray+ manipulation|Participants in spray+ group received placebo manipulation and were told they sprayed was oxytocin (in fact, it was saline);
214394133|NCT03891459|BEHAVIORAL|control manipulation|Participants in control group were told they sprayed saline (in fact, it was saline).
214394134|NCT06223477|OTHER|Platelet-rich Fibrin|PRF will be injected distal to the canine on the experimental side.
214394135|NCT06223477|OTHER|Vitamin D3|Vitamin Dꝫ will be injected distal to the canine on the experimental side
214394136|NCT03597893|DRUG|Oxytocin|intranasally administrated
214394137|NCT03597893|DRUG|Placebo|intranasally administrated
214394138|NCT03188328|DRUG|AvidinOX|"AvidinOX vial containing 22.5 mg AvidinOX~\+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume"
214394139|NCT03188328|DRUG|177Lu-ST2210|177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
214394140|NCT03188328|DRUG|177Lu-ST2210|Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
214394141|NCT05568485|OTHER|Telerehabilitation was applied to the group with rheumatism|Telerehabilitation was applied to the group with rheumatism in 3 sessions a week for 24 weeks via a social texting program. The intervention sessions consisted of 10 minutes of dance therapy-authentic movement, 40 minutes of exercises, and 10 more minutes of dance therap
214394142|NCT06190158|DIAGNOSTIC_TEST|Oral sodium suppression test|Oral sodium suppression test (\~2 grams of supplemental sodium for 3 days)
214394143|NCT06190158|DIAGNOSTIC_TEST|Saline suppression test|Saline suppression test (2 liters of saline)
214394144|NCT06190158|DIAGNOSTIC_TEST|Captopril suppression test|Captopril suppression test (50mg of captopril)
214394145|NCT06190158|DIAGNOSTIC_TEST|Dexamethasone suppression test|1mg of dexamethasone
214394146|NCT06190158|DIAGNOSTIC_TEST|Cosyntropin stimulation test|250mcg of cosyntropin
214394147|NCT01642186|DRUG|everolimus|
214394148|NCT01642186|DRUG|letrozole plus leuprolide|
214394149|NCT01642186|DRUG|combination of everolimus, letrozole and leuprolide|
214390434|NCT03656731|OTHER|Breast cancer exercise intervention|"The exercise-based intervention is comprised of:~1. Supervised and group-based exercise training at the hospital setting two times a week. Each session will last approximately 60 minutes.The program consists of warm-up, exercises for balance and flexibility, progressive resistance training (seven resistance training exercises targeting the large muscle groups), and stretching and relaxation.~2. Home-based walking with activity tracker assessment. Evaluation and goal-setting in relation to activity (step counts) will be conducted once weekly.~3. Serving of a protein supplement (protein drink or bar) after each supervised training session."
214390435|NCT05321706|DRUG|Dapagliflozin 10 mg|Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin
214390436|NCT05321706|DRUG|Placebo|Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
214390437|NCT02631421|PROCEDURE|Blood Sampling|
214998778|NCT05936437|DEVICE|Subjects treated with Newest medical device|"Newest is a sterile, non-pyrogenic, viscoelastic gel for single use for intradermal infiltrations. Newest is a medical device containing 2ml of the original association of polynucleotides (10mg/ml) and hyaluronic acid (10mg/ml).~Total number of treatments will consist in 4 Newest administrations: at T0 - basal, at T1- 2 weeks, at T2 - 4 weeks, at T3- 6 weeks."
214998779|NCT06023953|DEVICE|Nerivio device|REN treatment with Nerivio device
214390438|NCT02631421|OTHER|Cardiac MRI|
214390439|NCT00002502|DRUG|busulfan|
214390440|NCT00002502|DRUG|cyclophosphamide|
214390441|NCT00002502|DRUG|cytarabine|
214390442|NCT00002502|PROCEDURE|allogeneic bone marrow transplantation|
214390443|NCT03383003|DRUG|Nexium|Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy
214390444|NCT03383003|DRUG|Amolin|Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy
214390445|NCT03383003|DRUG|Klaricid|clarithromycin 500 mg bid daily for 7 days in the non-bismuth quadruple therapy
214390446|NCT03383003|DRUG|Flagyl|Metronidazole (Flagyl) 500 mg tid daily for 7 days in the non-bismuth quadruple therapy
214390447|NCT02481843|OTHER|2 hours of hyperoxia (FiO2 = 1)|Patients received 2 hours of hyperoxia at FiO2 = 1
214390448|NCT02011425|DEVICE|mandibular advancement appliance|mandibular advancement appliance
214390449|NCT00337662|DRUG|olanzapine|10-20 milligrams (mg), oral, daily, 10 weeks.
214390450|NCT00337662|DRUG|risperidone|2-6 mg, oral, daily, for 10 weeks.
214390451|NCT00337662|DRUG|risperidone|2-6 mg, oral, daily, 10 weeks
214390452|NCT00073385|DRUG|Pivanex|
214390453|NCT00073385|DRUG|Docetaxel|
214390454|NCT00132379|DRUG|ABR-217620|10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles
214390455|NCT00132379|DRUG|docetaxel|75mg/m\^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
214501432|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.15mg/kg|Remimazolam Tosilate for Injection 0.15mg/kg at induction
214501433|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.2mg/kg|Remimazolam Tosilate for Injection 0.2mg/kg at induction
214501434|NCT02407808|DRUG|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
214998780|NCT04549636|OTHER|V/Q SPECT-CT|At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
214998781|NCT04549636|OTHER|St. George's Respiratory Questionnaire (SGRQ)|At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
214998782|NCT04549636|OTHER|mMRC (Modified Medical Research Council) Dyspnea Scale|At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
214998783|NCT04549636|OTHER|Six-minute walk test (6MWT)|At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
214998784|NCT04549636|OTHER|Spirometry|At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
214390456|NCT00994773|DRUG|Simvastatin|daily doses for 14 days
214390457|NCT00994773|DRUG|Tenofovir|
214390458|NCT00994773|DRUG|Entecavir|Entecavir
214390459|NCT00410787|DRUG|OROS hydromorphone HCI (slow release)|
214390460|NCT02173730|DRUG|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
214390461|NCT02173730|DRUG|Pantoprazole|Pantoprazole tablet 40 mg
214390462|NCT03402880|BIOLOGICAL|Pembrolizumab|Given IV
214390463|NCT03402880|DRUG|Epacadostat|Given PO
214390464|NCT03402880|OTHER|Laboratory Biomarker Analysis|Correlative studies
214998785|NCT04549636|OTHER|Plethysmography & DLCO|At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
214998786|NCT04549636|OTHER|Airwave Oscillometry|At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
214998787|NCT06122077|DIAGNOSTIC_TEST|blood draw|Subjects who provide informed consent and meet the eligibility criteria will have 50 ml of blood collected and sent to Freenome or Freenome's designee for processing, testing, and storage, and will then complete a standard-of-care screening LDCT.
214998788|NCT06300138|DRUG|Itraconazole|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months
214998789|NCT06300138|DEVICE|Infrared thermotherapy apparatus|infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
214501435|NCT02407808|DRUG|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
214390465|NCT01381952|RADIATION|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.|Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
214390466|NCT01381952|RADIATION|Normal dose DSA with conventional X-ray technology|Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
214390467|NCT03691948|OTHER|Responsible Opioid Prescriber Education (ROPES)|The ROPEs intervention is a self-guided, web-based continuing dental education intervention. Consistent with ADA recommendations, ROPEs consists of seven modules of active content: (1) Overview; (2) Background on the Opioid Epidemic; (3) Dental Pain Management and the Role of Opioids; (4) Universal Precautions Approach; (5) Screening, Monitoring, and PDMP use; (6) Providing Patient Education; and, (7) Case Vignettes. All key intervention content is delivered via video-based platform and includes downloadable practice aides and resources.
214390468|NCT03691948|OTHER|Active Comparator Control|An online PDF version of the Center for Disease Control Guideline for Prescribing Opioids for Chronic Pain.
214501436|NCT05349721|DRUG|PTC857|PTC8657 will be administered as an oral solution twice a day.
214501437|NCT05349721|DRUG|Placebo|Matching placebo will be administered as an oral solution twice a day.
214501438|NCT03070392|BIOLOGICAL|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
214501439|NCT03070392|DRUG|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
214501440|NCT03070392|BIOLOGICAL|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
214501441|NCT03070392|BIOLOGICAL|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
214501442|NCT02276443|DRUG|Chemotherapy|Receive standard chemotherapy
214501443|NCT02276443|OTHER|Immunotherapy|Receive standard immunotherapy
214501444|NCT02276443|OTHER|Laboratory Biomarker Analysis|Correlative studies
214501445|NCT02276443|PROCEDURE|Lymph Node Biopsy|Undergo baseline lymph node evaluation
214501446|NCT02276443|PROCEDURE|Ultrasonography|Undergo standard ultrasound
214501447|NCT05718245|DEVICE|HEPA filter|HEPA filters with the capacity to reduce PM2.5 levels
214501448|NCT05718245|DEVICE|Sham filter|sham filters without the capacity to reduce PM2.5 levels
214501449|NCT04762758|DRUG|(RS)-baclofen, naltrexone hydrochloride and D-sorbitol|oral fixed dose combination
214501450|NCT04762758|DRUG|Placebo|liquid oral solution
214998790|NCT06300138|OTHER|Itraconazole and Infrared thermotherapy apparatus|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months, while infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
214501451|NCT04675294|DRUG|evorpacept|IV Q3W
214998791|NCT05020743|OTHER|No intervention|Not applicable for a Natural History Study
214998792|NCT04730921|DEVICE|Left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
214501452|NCT04675294|DRUG|pembrolizumab|IV Q3W
214501453|NCT05994014|DIAGNOSTIC_TEST|PET/CT|Experimental test for detecting atherosclerosis
214501454|NCT06267729|BIOLOGICAL|AZD0754|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.~During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion."
214501455|NCT02976961|OTHER|Supportive care|Information, guidance, supportive care, and psychological intervention
214501456|NCT02972034|DRUG|MK-8353|PO capsule
214501457|NCT02972034|BIOLOGICAL|Pembrolizumab|IV infusion
214501458|NCT05812976|OTHER|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
214501459|NCT05812976|OTHER|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
214501460|NCT05327608|OTHER|Time Restricted Eating|Undergo intermittent fasting
214501461|NCT00466869|DRUG|Betahistine|
214501462|NCT05424666|PROCEDURE|Harvesting method and Fat graft preparation method|"The procedure begins by identifying the areas where the fat will be collected Then the sample is collected by micro-incision using a fine suction cannula or during conventional liposuction. The fat cells are taken from an area of the body where there is a reserve (generally, in the abdomen, hips, knees, inner thighs, buttock) The collected fat cells are then subjected to a sterile centrifugation for a few minutes so as to separate the cells that will be injected (intact fat cells) from the elements that must not be injected (fat cells destroyed by the sample, non-fat cells such as than blood cells).~Injection of fat cells into the breasts The reinjection of fat (lipofilling) is performed using micro-cannulas allowing incisions of the order of 1-2 mm in different angles and in multiple directions so as to increase the contact area between the grafted cells and the recipient tissues allowing a good grip of the injection."
214998793|NCT04730921|DEVICE|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
214998794|NCT03488524|DRUG|AMX0035|Combination therapy of PB and TURSO
214998795|NCT05786664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214390469|NCT04795817|DEVICE|Transoral Robotic Surgery|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA. Concomitant non-robotic surgical procedures may also be performed as part of the subject's treatment for OSA, and can include one or more of the following: uvulopalatopharyngoplasty (UPPP), lateral pharyngoplasty, expansion sphincter pharyngoplasty, palatine tonsillectomy, or a modified uvulopalatoplasty. Nasal surgery such as septoplasty or turbinoplasty can be combined if it is needed.
214998796|NCT05786664|OTHER|Electronic Health Record Review|Review of records
214998797|NCT05786664|OTHER|Quality-of-Life Assessment|Complete quality-of-life questionnaires
214390470|NCT04325464|DEVICE|PEAR-003A|PEAR-003A delivers CBT-I through a decentralized clinical trial open to participants with chronic insomnia
214390471|NCT02478125|DRUG|Burixafor Hydrobromide|Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
214390472|NCT02478125|DRUG|Docetaxel|Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
214390473|NCT02478125|DRUG|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
214390474|NCT02344537|BEHAVIORAL|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
214390475|NCT01031472|DRUG|GSK2248761 formulation 1|100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
214390476|NCT01031472|DRUG|GSK2248761 reference formulation|GSK2248761 100mg Gelucire reference capsule with food
214390477|NCT01031472|DRUG|GSK2248761 formulation 3|100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
214390478|NCT01031472|DRUG|GSK2248761 formulation 2 or 4|100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
214390479|NCT05877300|COMBINATION_PRODUCT|Cellspan™ Esophageal Implant-Adult (CEI)|The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stromal cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.
214390480|NCT01494714|DRUG|JNJ 10229570-AAA 1.2% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
214390481|NCT01494714|DRUG|JNJ 10229570-AAA 2.4% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
214390482|NCT01494714|DRUG|JNJ 10229570-AAA 3.6% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
214390483|NCT01494714|DRUG|Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
214390484|NCT01494714|DRUG|Petroleum jelly|A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
214390485|NCT00798486|DEVICE|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
214390486|NCT03274154|DIETARY_SUPPLEMENT|Pre-Hyaluron 465 Innēov|Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
214390487|NCT04446780|PROCEDURE|Mediolateral episiotomy|Cutting of the perineum during vaginal delivery in order to avoid obstetric anal sphincter injury
214390488|NCT03857412|PROCEDURE|Capsular polishing|Capsular polishing taking place during cataract surgery
214390489|NCT03857412|OTHER|Non capsular polishing|No capsular polishing taking place during cataract surgery
214390490|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
214390491|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
214501463|NCT03861052|DRUG|Tirzepatide|Administered SC
214501464|NCT03861052|DRUG|Dulaglutide|Administered SC
214998798|NCT05786664|OTHER|Survey Administration|Complete surveys
214998799|NCT04787679|PROCEDURE|Hip replacement surgery|After hip replacement surgery the sponsor obtains femoral head samples for the study
214998800|NCT06177301|DRUG|Tislelizumab combined with GX|"Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity."
214998801|NCT06177301|DRUG|Tislelizumab combined with GP|"Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 \~ 6 cycles."
214998802|NCT06379113|DRUG|GnRH antagonist|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.
214998803|NCT06379113|DRUG|Letrozole 2.5mg|2.5mg po qd.
214390492|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
214390493|NCT04264234|DIAGNOSTIC_TEST|Vaginal Ultrasonography|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.
214390494|NCT04264234|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.
214390495|NCT02611830|DRUG|Vedolizumab 300 mg IV|Vedolizumab intravenous infusion
214390496|NCT02611830|DRUG|Placebo IV|Vedolizumab intravenous infusion placebo
214390497|NCT02611830|DRUG|Vedolizumab 108 mg SC|Vedolizumab subcutaneous injection
214390498|NCT02611830|DRUG|Placebo SC|Vedolizumab subcutaneous injection placebo
214390499|NCT01755520|DRUG|Ticagrelor|90mg twice daily dose
214390500|NCT01755520|DRUG|Aspirin|Aspirin 100mg once daily
214390501|NCT01755520|DRUG|Placebo - Ticagrelor|Placebo
214390502|NCT01755520|DRUG|Placebo - Aspirin|Placebo
214390503|NCT04733196|DRUG|Essential oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
214390504|NCT04733196|DRUG|Essential oils in combination with chlorhexidine 0,12%|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
214390505|NCT04733196|DRUG|Placebo mouthwash|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
214390506|NCT04733196|DRUG|Chlorhexidine 0,20 % in combination with aroma oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
214390507|NCT04733196|DRUG|Prebiotic|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
214390508|NCT04733196|DRUG|Hydrogen peroxide 0,8 %|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
214390509|NCT03826134|DRUG|[11C]PXT012253|Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
214390510|NCT05389527|DRUG|Pembrolizumab+Lenvatinib|"After enrollment, subjects receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 9 weeks: Lenvatinib 8 mg (body weight \<60 kg) or 12 mg (body weight ≥60 kg) orally once daily for 9 weeks.~Subjects conduct surgery 1 week after the last dose of Lenvatinib. 4 weeks after surgery, Pembrolizumab and Lenvatinib will restart as adjuvant treatment for up to 1 year."
214390511|NCT06144268|DEVICE|ZyMōt Multi (850µL)|An amount of 850 µl untreated semen sample will be loaded into the inlet chamber with a help of a sterile insulin-type syringe. A volume of 750 µl of Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution medium will be placed on top of the membrane (outlet chamber). After 30 min of incubation in a humidified incubator (37°C), 500 µl of medium, containing the selected spermatozoa, will be retrieved from the upper side of the membrane (retrieval chamber). An amount of 400 µl will be necessary for the IUI procedure.
214390512|NCT06144268|OTHER|Density Gradient Centrifugation|"The gradient columns will be prepared by placing 1 ml 80% gradient media in a centrifuge tube and an additional 1 ml of 40% gradient layered on top.~The raw semen sample will be placed on top of the gradient (1ml semen/gradient tube) and centrifuged at 300xg for 20 minutes. The sperm pellet will be collected and washed 2 times for 5 min at 800xg in Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution.~The resulted pellet will be resuspended in the washing solution in a volume that will provide at least 1x106 forward motile spermatozoa in 400 µl, as this amount is necessary for IUI procedure."
214390513|NCT04842396|OTHER|Experimental:Motorized cycle ergometer|Cycling training on the MOTOmed Muvi for 20 minutes 3 days per week for 6 weeks. Moreover, control of adverse events throughout the trial was measured through the assessment and monitoring of vital signs before, during (within the first 10 minutes), and after the intervention sessions. Vital signs \[heart rate (per minute), systolic and diastolic blood pressure (in millimeters of mercury, mm Hg), and oxygen saturation (in percentage)\] were monitored by a nurse and a medical doctor using mobile finger pulse oximeters.
214390514|NCT00188318|PROCEDURE|hyperfractionated accelerated radiotherapy|
214390515|NCT00865111|DRUG|Bupropion 150 mg Extended-Released Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
214390516|NCT00865111|DRUG|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
214501465|NCT04378205|PROCEDURE|0.014-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.014-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
214501466|NCT04378205|PROCEDURE|0.016-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.016-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
214501467|NCT04180943|DRUG|interscalene nerve block|intra and post-operative analgesia
214998804|NCT05224726|OTHER|Platelet Rich Plasma|Injection of 5cc of PRP preparation at the myometrium around the uterine incision after it has been sutured.
214998805|NCT05224726|OTHER|Placebo|Injection of 5cc of 0.9% Normal Saline at the myometrium around the uterine incision after it has been sutured.
214998806|NCT06620406|DIETARY_SUPPLEMENT|Synbiotic IVS-1|A mixture of the prebiotic potato resistant starch (RS, Bobs Red Mill) and the probiotic IVS-1 (Bifidobacterium adolescentis).
214998807|NCT06620406|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin, a carbohydrate packaged similarly to the study intervention
214998808|NCT01078662|DRUG|olaparib|Tablets Oral BID
214501468|NCT03823703|DRUG|Miricorilant|Tablets taken orally
214998809|NCT05614115|DRUG|Empagliflozin|is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
214998810|NCT05614115|OTHER|Placebo|Placebo comparator
214998811|NCT02351141|OTHER|Hyperpolarized Noble Gas MRI|"Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
214998812|NCT05546814|PROCEDURE|Sodium algorithm|Infants will receive sodium and follow a sodium supplementation schedule or algorithm. This means that based on the sodium levels collected from the samples (stool and urine) they will receive an increase or maintain the same amount to help
214998813|NCT03636438|OTHER|No Intervention|No Intervention
214998814|NCT04186832|DEVICE|FitBit|Wear FitBit
214390517|NCT05228093|PROCEDURE|Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap|"Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. And the reconstruction of the nasopharyngeal defect use the nasal septum and floor mucoperiosteum flap. Antibiotic therapy based on the result of bacterial cultivation before the surgery was administered for 5-7 days after surgery. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid, and endoscopic nasal cleanup was performed every 2-4 weeks until the flap was completely epithelialized and the entire defect was relined.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
214390518|NCT05228093|PROCEDURE|Conservative treatment|"Debridement guided by nasopharyngeal endoscopy and excision of the radiation-induced necrotic tissues were performed every 1 or 2 weeks. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid. Other conservative treatment included daily nasopharynx rinsing with 2% aquae hydrogeniidioxide (5-10 mL each time) or saline (50-100 mL each time) and antibiotic therapy (metronidazole or ornidazole) guided by the culture results was also performed synchronously. Intravenous nutrition and systematic antibiotic therapy were also performed if indicated and necessary. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
214390519|NCT02653924|OTHER|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
214390520|NCT02653924|OTHER|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
214390521|NCT02653924|OTHER|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
214998815|NCT04186832|DEVICE|Pedometer|Wear pedometer
214998816|NCT04186832|OTHER|Quality-of-Life Assessment|Ancillary studies
214998817|NCT04186832|OTHER|Questionnaire Administration|Ancillary studies
214501469|NCT03823703|DRUG|Placebo|Placebo tablets
214501470|NCT03265756|DEVICE|Multimometer|A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
214501471|NCT03072810|BEHAVIORAL|Positive mindfulness program|4 week program consisting of 8 modules. Each module comprises an introduction video (approx. 10 minutes), a daily meditation (approx. 10 minutes) and a daily activity.
214998818|NCT05171647|DRUG|Mosunetuzumab|Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).
214501472|NCT03617575|DIETARY_SUPPLEMENT|apo-Lactoferrin|1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf \[total of 1.5 mg iron\]) in a maize porridge (extrinsically labeled)
214501473|NCT03617575|DIETARY_SUPPLEMENT|holo-Lactoferrin|1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
214501474|NCT03617575|DIETARY_SUPPLEMENT|FeSO4|1.5 mg FeSO4 as 54Fe in a maize porridge
214501475|NCT03617575|DIETARY_SUPPLEMENT|1. FeSO4|10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
214501476|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 1 day break|10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
214501477|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 2 day break|10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
214501478|NCT01451359|DEVICE|EndoBronchial Valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
214501479|NCT00151866|PROCEDURE|platelet transfusion|
214501480|NCT01491815|DRUG|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
214998819|NCT05171647|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).
214998820|NCT05171647|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.
214998821|NCT05171647|DRUG|Rituximab|Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
214998822|NCT05171647|DRUG|Gemcitabine|Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
214998823|NCT05171647|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
214501481|NCT01491815|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
214998824|NCT05013138|BEHAVIORAL|Training for ACEs and study procedures|"The providers will lead a resilience-based conversation discussion regarding the impact of caregiver ACEs, after receiving training for ACEs and study procedures.~The first training component will provide an overview of ACEs using the ACE Interface Training. The second training component will address the implementation of the caregiver ACEs screening in the clinic."
214998825|NCT05013138|BEHAVIORAL|Training on study procedures|Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination.
214998826|NCT05611970|DEVICE|Vaginal pessary|A reusable vaginal pessary for stress urinary incontinence
214998827|NCT06462976|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
214390522|NCT02653924|OTHER|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
214390523|NCT00547105|DRUG|Erlotinib|Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
214501482|NCT01491815|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
214501483|NCT01491815|BIOLOGICAL|RoActemra|"Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week"
214998828|NCT05185440|BEHAVIORAL|GIFTSS Training|training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)
214501484|NCT00664599|DRUG|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
214501485|NCT00664599|DRUG|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
214501486|NCT04557566|BEHAVIORAL|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
214501487|NCT03137459|BEHAVIORAL|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
214501488|NCT03137459|OTHER|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
214501489|NCT05944094|DEVICE|Clorhexidine|Antiseptic treatment aimed at reducing potential bacterial overgrowth consisted of 10 days (1 box) of vaginal ovules of CLX (CumLaude CLX ® , CLX digluconate 0.2%) always starting between 10+0 and 16+0 weeks.
214501490|NCT01970878|DRUG|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
214501491|NCT01970878|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
214501492|NCT01970878|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
214501493|NCT01970878|DRUG|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
214501494|NCT06317610|OTHER|growth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI|biopsy or puncture: Patients received biopsy or puncture to obtain tumor tissues or Malignant effusion for organoids establishment
214998829|NCT05185440|BEHAVIORAL|Learning Collaborative|learning collaborative (anticipated meeting monthly) with college health center staff and clinicians to address common barriers to implementation of GIFTSS intervention, reinforce GIFTSS training
214998830|NCT05185440|BEHAVIORAL|Provider Scripts|scripts and prompts for college health center staff and clinicians to encourage implementation of GIFTSS intervention
214998831|NCT00325416|DRUG|melphalan|(Days -4,-3,-2) 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2)
214998832|NCT00325416|DRUG|topotecan (TPT)|"Phase I Dose Escalation: Level 1 - 20 mg/m\^2; Level 2 - 30 mg/m\^2; Level 4 - 54 mg/m\^2; Level 5 - 72 mg/m\^2; Level 6 - 96 mg/m\^2; Level 7 - 127.8 mg/m\^2; Level 8 - 170.1 mg/m\^2~Phase II: Treatment at maximum tolerated dose (MTD)"
214998833|NCT00325416|PROCEDURE|Autologous Stem Cell Rescue|Day 0
214998834|NCT05847790|DEVICE|Invu monitoring belt|INVU monitoring belt used for remote NSTs
214998835|NCT05847790|OTHER|Standard of care|In-clinic NSTs - standard of care
214390524|NCT00547105|RADIATION|SBRT|SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body
214998836|NCT04608552|BEHAVIORAL|OMT Exercises|Oral and oropharyngeal exercises
214998837|NCT04608552|BEHAVIORAL|Nasal Breathing Exercises|Nasal breathing exercises each week
214998838|NCT04608552|OTHER|Use of Nasal Lavage|Use of nasal lavage with application of 10ml of saline in each nostril two times per day
214998839|NCT06429241|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|single dose injection (120 million cells)
214501495|NCT01840085|DRUG|0.03% DSC127 topical gel|
214501496|NCT02412540|BEHAVIORAL|Comprehensive Lifestyle Intervention|Dietary, behavioral and activity interventions designed to reduce weight.
214501497|NCT00925548|BIOLOGICAL|Tecemotide (L-BLP25) and Hormonal Treatment|"Investigational Arm:~Pretreatment (Single Dose) 300 mg/m\^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~\*calculated as mass of lipopeptide (antigen)"
214687938|NCT01734512|DRUG|Everolimus|Everolimus tablet will be taken daily by mouth with water. All participants will be given a dose of 5 mg/m2/dose daily.
214687939|NCT05100199|DRUG|OnabotulinumtoxinA X|Injection
214687940|NCT05100199|DRUG|Placebo|Injection
214998840|NCT04742751|DRUG|Metformin|To begin week 12 for participants who remain prediabetic after 12 week lifestyle run-in. Dosage and Route of Administration: 500 mg dose/ day to be taken orally, increased to 1000 mg dose/ day at week 14 through week 24. The dose should be taken immediately following the evening meal and at approximately the same time daily
214501498|NCT00925548|BIOLOGICAL|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|"Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD)."
214501499|NCT00925548|DRUG|cyclophosphamide|300 mg/m\^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
214501500|NCT00925548|DRUG|sodium chloride (NaCl)|NaCl 9 g/L infusion
214501501|NCT01619007|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
214501502|NCT01619007|DRUG|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
214501503|NCT03050931|DEVICE|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
214998841|NCT04742751|BEHAVIORAL|Digital Intervention|"Lifestyle Change Digital Intervention - This is a digital platform that will include a core curriculum focused on diet, exercise, and behavioral strategies for goal setting and self-monitoring to improve diet including a weight loss On Day 1, participants will begin their digital lifestyle intervention using their smart-phone application with their lifestyle coach and peer group.~On day 14, participants will be contacted by phone (+/- 4 days, day 10 to 18) and adherence assessed using virtual pill counts via phone calls.~At weeks 4, 8, 16 and 20 a phone-based pill count for adherence and adverse event symptom log will be completed and study medication dispensed.~At week 12 (interim assessment) and 24 (study-end), the participant will return to St. Jude Children's Research Hospital (SJCRH) for an in-person assessment.~The digital lifestyle change program will complete at week 24."
214998842|NCT05368649|OTHER|Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
214390525|NCT00594789|OTHER|Information letters|Information letters under Manitoba Health letterhead will be sent out to physician(s) and/or patient connected with a fracture that meets specific criteria. To address concerns over discontinuous care of patient seen at the time of fracture and for subsequent follow-up, the physician notification will specifically target the individual involved in the initial report to Manitoba Health as well as the primary care physician (using an algorithm developed by the Manitoba Centre for Health Policy). The notification will provide a general recommendation for osteoporosis assessment in addition to a copy of the BMD testing requisition since BMD testing is usually justified in this setting. The notification will not dictate what testing or treatment needs to be performed.
214390526|NCT05745428|OTHER|molecular and cellular analyses|sample blood
214390527|NCT02014090|OTHER|Hemodynamic and biological measurements|by MCE, PWA, Doppler, Multiplex, FACS
214390528|NCT05240833|DIAGNOSTIC_TEST|VExUS Score|"The VExUS-Guided Arm care team will be informed of the Day 0 VExUS immediately after the ultrasound is performed and given a suggested target for the following 48 hours as follows:~* VExUS 0: There is no evidence of venous congestion.~* VExUS 1: There is evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: There is evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis.~* If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
214390529|NCT01755624|DEVICE|NovoTTF-100A device|
214390530|NCT01755624|OTHER|Best Standard of Care|
214390531|NCT00552773|DRUG|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
214390532|NCT00006432|PROCEDURE|very low fat diet|
214390533|NCT00220961|DRUG|Pioglitazone|Pioglitazone tablets - 45 mg/day
214390534|NCT00220961|DRUG|Placebo|Placebo tablets similar to pioglitazone tablets - 1 tablet/day
214390535|NCT04398693|DIETARY_SUPPLEMENT|Prebiotic|It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of SCFA (acetate and butyrate) in a sachet with a powder that must be dissolved in a glass of liquid to your choice, during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study.
214390536|NCT02380508|DRUG|BCG SSI|Intradermal injection
214390537|NCT02380508|OTHER|No vaccination|
214501504|NCT00374998|BIOLOGICAL|FP9-PP (FP9 polyprotein)|
214501505|NCT00374998|BIOLOGICAL|MVA-PP (Modified Virus Ankara polyprotein)|
214501506|NCT00837044|DRUG|Treximet|Treximet
214501507|NCT00837044|DRUG|Migraine rescue medication of choice|Migraine rescue medication of choice
214998843|NCT04589650|DRUG|Alpelisib|Adult participants (group 1) will receive 125 mg of alpelisib oral tablets once daily. Pediatric participants (Group 2: 6 to 17 years old) will receive 50 mg of alpelisib oral tablets once daily. Pediatric participants (Group 4: 2 to 5 years old) will receive 50 mg of alpelisib oral tablets once daily, Pediatric participants (Group 3: 0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose and maximum dose levels ranging from 20 mg every other day to 50 mg once daily. Pediatric participants (Group 5: 6 to 17 years old) will receive 125 mg of alpelisib oral tablets once daily.
214390538|NCT02380508|DRUG|BCG Sii|intradermal injection
214390539|NCT03651232|BEHAVIORAL|yoga|once weekly group yoga class for 12 weeks
214390540|NCT03651232|BEHAVIORAL|support group|once weekly group support class for 12 weeks
214390541|NCT04081519|DEVICE|active rTMS over DLPFC|15 sessions of active rTMS over DLPFC
214390542|NCT04081519|DEVICE|Add-on active rTMS over DLPFC|15 additional sessions of active rTMS over DLPFC
214390543|NCT04081519|DEVICE|Add-on active rTMS over LPC|15 additional sessions of active rTMS over LPC
214390544|NCT04081519|DEVICE|Add-on sham rTMS|15 additional sessions of sham rTMS over DLPFC or LPC
214390545|NCT02058290|DRUG|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
214390546|NCT02058290|DRUG|EXPAREL|"Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
214390547|NCT03923010|DRUG|Itraconazole|Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
214390548|NCT05902221|DRUG|amoxicillin or moxifloxacin|Antibiotic treatment back bone during 12 weeks
214998844|NCT04589650|DRUG|Placebo|Participants will receive matching placebo once daily up to week 16.
214998845|NCT04993261|PROCEDURE|Dual-Energy Computed Tomography|Undergo dual energy CT scan
214998846|NCT02404571|DRUG|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
214390549|NCT05902221|DRUG|amoxicillin or moxifloxacin + rifampicin|Antibiotic treatment back bone during 12 weeks + rifampicin
214390550|NCT06559943|OTHER|Traditional Physiotherapy + Placebo Kinesio Tape|"Following a total of 15 sessions of electrophysical agent and exercise training, 5 days a week, for 3 weeks, each session lasting 45 minutes, followed by traditional physiotherapy, 2 days a week, for 3 weeks, a total of 6 times, with 0% tension applied to the trapezius muscle in the neck region (I). Kinesiotape will be applied.~The tape will be applied twice a week in total, staying for 3 days and leaving one day free after each application."
214390551|NCT06559943|OTHER|Traditional Physiotherapy + Kinesio Tape Treatment with Inhibition Method|In addition to a total of 15 sessions of electrophysical agents and exercise training, 5 days a week for 3 weeks, each session lasting 45 minutes, kinesio tape will be applied 6 times in total, 2 days a week. Kinesiotape will be cut into an (I) shape (15 cm) with 50% tension and adhered laterally to the C7 joint. In acute cases such as overuse and muscle spasm, it is recommended to apply an inhibition technique that will inhibit the muscle. In the inhibition technique, the direction of the tape should be from the entry point of the muscle to the starting point and the application should be done with very light or light (15 - 25%) tension. In chronic cases, a facilitation technique should be applied to stimulate the weak muscle. The direction of the tape should be from the starting point of the muscle to the attachment point and the application should be done with light or moderate tension (25 - 50%).
214390552|NCT03091101|DEVICE|Scleral lens wearing keratoconics|Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
214390553|NCT01629056|PROCEDURE|ablation|RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
214390554|NCT01629056|PROCEDURE|RF ablation|RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
214390555|NCT05667779|DRUG|QRL-101|Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
214390556|NCT05667779|OTHER|Placebo|A placebo comparator will be administered at all dose levels.
214390557|NCT02626858|DEVICE|extra treatment planning CT-scan|Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
214998847|NCT00639184|OTHER|Early intervention counseling|Bi-monthly home visits by counselor
214998848|NCT00639184|OTHER|Health education counseling|World Health Education health education counseling program at home visits,twice per month
214998849|NCT04156698|DRUG|Docetaxel|Docetaxel is a chemotherapy drug.
214998850|NCT04156698|DRUG|Cisplatin|Cisplatin is a chemotherapy drug.
214998851|NCT04156698|DRUG|Capecitabine|Capecitabine is a chemotherapy drug.
214998852|NCT04156698|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
214998853|NCT02324153|DRUG|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
214998854|NCT02324153|DRUG|Microcrystalline Cellulose|Placebo Comparator
214998855|NCT02324153|DRUG|Riboflavin 100 mg|Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
214998856|NCT01267578|BIOLOGICAL|vaccination|Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
214998857|NCT01563081|DRUG|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old
214390558|NCT02571946|RADIATION|Proton beam therapy|
214390559|NCT01246180|DRUG|Diclofenac|diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
214390560|NCT01246180|DRUG|Amiloride|amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
214390561|NCT00335205|DRUG|ropinirole|
214390562|NCT05582096|DRUG|LY3457263|Administered SC.
214390563|NCT05582096|DRUG|Tirzepatide|Administered SC.
214501508|NCT06505382|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous neuromodulation|Percutaneous ultrasound-guided neuromodulation of the saphenous nerve in subjects with patellofemoral pain to assess its positive effects on pain and functionality.
214998858|NCT01563081|DRUG|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
214998859|NCT01814540|DIETARY_SUPPLEMENT|Bovine Milk Oligosaccharide|The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
214998860|NCT01814540|DIETARY_SUPPLEMENT|Placebo Glucose Polymer|
214998861|NCT03122106|BIOLOGICAL|Personalized neoantigen DNA vaccine|-Personalized polyepitope inserts integrating the prioritized neoantigens and mesothelin epitopes will be designed and then synthesized and cloned into the pING parent vector
214998862|NCT03122106|DEVICE|TDS-IM Electrode Array System|-Ichor Medical Systems
214998863|NCT03122106|PROCEDURE|Peripheral blood draws|-Enrollment, mid adjuvant chemotherapy, end of chemotherapy, week 1, week 5, week 9, week 13, week 17, week 21, week 25, and week 77
214998864|NCT01214278|DRUG|rTG|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
214390564|NCT05582096|DRUG|Placebo|Administered SC.
214998865|NCT01214278|DRUG|GArTG|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
214390565|NCT04180735|PROCEDURE|Liver transplantation|Liver transplantation
214501509|NCT04407247|BIOLOGICAL|Infliximab|Given IV
214998866|NCT01214278|DRUG|EE|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
214998867|NCT01214278|DRUG|KPL|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
214390566|NCT03612518|BEHAVIORAL|Text and Voice Messages|Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
214390567|NCT03612518|BEHAVIORAL|Interactive Phone Call|Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
214390568|NCT04263298|DRUG|Fulvestrant|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
214390569|NCT04263298|DRUG|Capecitabine Oral Product|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
214390570|NCT04109742|DRUG|phosphatidylcholine-curcumin complex supplement|a dietary curcumin supplement given at two different doses
214390571|NCT04109742|DRUG|Placebo curcumin capsule|matching placebo to active curcumin capsules
214390572|NCT00405704|DRUG|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
214390573|NCT00405704|DRUG|Placebo|Cherry flavored liquid suspension matched to active comparator.
214390574|NCT05728567|OTHER|whether the participants had T2DM|whether the participants had T2DM
214390575|NCT03012061|DRUG|Placebo|Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.
214390576|NCT03012061|DRUG|UMEC|UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.
214501510|NCT04407247|BIOLOGICAL|Vedolizumab|Given IV
214687941|NCT06233435|BEHAVIORAL|PADSS|Observe PADSS after total knee arthroplasty at 6 and 24 hours
214687942|NCT04992013|DRUG|Niraparib|Capsule taken by mouth
214687943|NCT04258059|DEVICE|Active household UV water treatment device|This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
214687944|NCT04258059|DEVICE|Inactive household UV water treatment device|This sham device will use a lamp not emitting germicidal UV.
214687945|NCT00347711|DRUG|Intravitreal injection|
214998868|NCT05237375|OTHER|The MIDWIZE model|"So-called MIDWIZE ambassadors are planned to be appointed to lead the clinical implementation of the quality improvement components.~Initial training workshops will be held with the ambassadors on practical aspects of the chosen components and how to explain their benefits to the units' staff. Training will also be provided on how to enhance interdisciplinary teamwork and coordinate quality improvements. The workshops will be held onsite at Naguru hospital and online via the project's MIDWIZE virtual platform. The ambassadors will themselves hold training workshops to support midwives and other healthcare providers at the clinics during the implementation of the quality improvements components. The virtual MIDWIZE platform will contain videos, posters, presentations, and other training material that the ambassadors can utilise to enhance the units' capacity and engage their colleagues."
214390577|NCT03012061|DRUG|Fluticasone Furoate|FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
214390578|NCT03012061|DRUG|Albuterol/salbutamol|Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
214390579|NCT03859401|DEVICE|EnMPC (Ensemble Model Predictive Control) AP Controller|This AP controller has the ability to anticipate exercise activity by use of trends seen during the Data Collection Period.
214390580|NCT03859401|DEVICE|rMPC (Naïve Model Predictive Control) AP Controller|This AP controller does not have the ability to anticipate exercise activity.
214390581|NCT02696902|DRUG|MEDI3902|Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
214390582|NCT02696902|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
214998869|NCT06310863|DEVICE|LASBEAU Strong or Restylane Lyft injection as hyaluronic acid fillers|"Subjects will be randomized to receive LASBEAU Strong or Restylane Lyft injections into each of the nasolabial folds on both sides.~LASBEAU Strong or Restylane Lyft Injection Box"
214998870|NCT04961359|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
214998871|NCT04961359|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
214390583|NCT00000664|DRUG|Interleukin-2, Polyethylene Glycolated|
214390584|NCT00000664|DRUG|Zidovudine|
214390585|NCT01228422|BIOLOGICAL|Interferon alpha 2a|3MUI
214390586|NCT00601003|DRUG|Nifurtimox|30mg/kg/day PO divided into TID dosing q day
214390587|NCT00601003|DRUG|Cyclophosphamide|250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
214998872|NCT03279458|DEVICE|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
214998873|NCT05413421|DRUG|ORIC-944|Oral, once daily, continuous
215094063|NCT07088770|BEHAVIORAL|Tech-mediated Peer Navigation Enhanced Case management (NCM)|Navigation-Enhanced Case Management (NCM) uses Project START, a CDC best evidence intervention as its HIV risk reduction framework. Prior to release, a case manager and peer navigator via telehealth and in-person provide discharge planning and patient education and serves as a liaison to the courts. After release, patient navigators facilitate reentry into community care and provide referrals to HIV medical and SUD care as appropriate (e.g., ART, PrEP, MOUD) and assistance with food, housing, transportation, employment, substance dependence, mental health treatment, and legal issues. TechMPower planned to enhance tracking of linkage during NCM services by integrating reporting along with a web-based platform that tracks assignment of providers and peers and follows for 6 months to capture PRISM linkage and retention in MOUD, HIV and ancillary care.
214390588|NCT00601003|DRUG|Topotecan|0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
214390589|NCT04707911|BEHAVIORAL|Social Media Intervention|Social media based intervention using Instagram with up to 3 posts per day for 30 days
214390590|NCT03341663|COMBINATION_PRODUCT|Coronary angiography,Canadian Cardiovascular Society angina pectoris classification for the severity of angina and electronic Von Frey instrument for testing the degree of acupoint sensitization|All the interventions were tested for only once
214390591|NCT04959149|DEVICE|AirTraq videolaryngoscope|intubation of morbidly obese patient using Airtraq videolaryngoscope
214390592|NCT01291225|OTHER|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
214390593|NCT01291225|BEHAVIORAL|Educational campaign|Educational materials will be developed and distributed in Ross County.
214390594|NCT01267253|DRUG|Brivanib Alaninate|Given PO
214390595|NCT01267253|OTHER|Laboratory Biomarker Analysis|Correlative studies
214390596|NCT00014196|DRUG|cisplatin|
214390597|NCT00014196|DRUG|docetaxel|
214390598|NCT00014196|RADIATION|radiation therapy|
214687946|NCT03229915|BEHAVIORAL|cognitive processing therapy|Group therapy for PTSD patients
214687947|NCT00830037|DRUG|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
214998874|NCT05413421|DRUG|Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets|Oral, 1000 mg once daily, continuous
214998875|NCT05413421|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|Oral, 240 mg once daily, continuous
214998876|NCT05413421|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|Oral, 600 mg twice daily, continuous
214998877|NCT05413421|DRUG|Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets|Oral, 160 mg once daily, continuous
214390599|NCT04444687|DIAGNOSTIC_TEST|Test for SARS-CoV-2|"* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)~* After intubation samples are acquired in the OR~  1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)~ 2. blood sample (as part of standard operation procedures for CoVID-19 patients)~ 3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy~ 4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)~* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR."
214390600|NCT05291182|DRUG|SY-4835|WEE1 inhibitor
214390601|NCT03470714|OTHER|Force Irradiation|For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
214501511|NCT06572189|GENETIC|Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)|Receive administration of 100μg of CD-801 via hepatic arterial injection every 14 ± 3 days (the dosing interval will be adjusted based on the tolerability, safety, and therapeutic effect of the subjects), for one treatment cycle. Treatment will continue until the occurrence of disease progression, death, intolerable toxicity, voluntary withdrawal of informed consent, loss to follow-up, initiation of new antitumor treatment, or termination of the study by the investigator (whichever comes first), and completion of the final follow-up and assessment 14 days after the last administration.
214501512|NCT06296940|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a brief, evidenced based intervention for PTSD. WET is generally delivered individually across 5 sessions in which the therapist guides the patient through writing exercises. Across exposure sessions, participants experience habituation so that their symptoms decrease by the end of treatment. WET has an established evidence base in general outpatient psychotherapy for PTSD, but has not been adapted or tested in residential SUD treatment settings.
214687948|NCT00830037|DRUG|Ferrous Sulfate|Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
214998878|NCT04673734|DIAGNOSTIC_TEST|myelin sensitive MRI scan|"Acquisition of 3 myelin sensitive MRI scans as follows: 1. Two MRI during 1 day; the second after 30 min interval and a repositioning.~2\. One MRI within one week after the first one.~The total scan time will be \~ 1 hour. T1 maps will be calculated after magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE6) acquisition based on a product sequence. Magnetization Transfer (MT) sat maps will be calculated. Quantitative susceptibility mapping (QSM) maps will be reconstructed using an in-house implementation of the structural feature based collaborative reconstruction algorithm (SFCR). For the reconstruction of multi-shell diffusion data, AMICO10 Accelerated Microstructure Imaging via Convex Optimization (AMICO) from diffusion MRI data will be used. Myelin Water Fraction maps will be fitted voxel-wise using a Non-Negative Least Squares fitting."
214998879|NCT04477863|OTHER|Follow-up Interview|Non Applicable
214998880|NCT05806970|OTHER|Email Nudge|An email to UCLA Health Cardiology clinic managers with a list of MRA-eligible HFrEF patients and a request to schedule or change cardiology appointments.
214998881|NCT00933153|DIETARY_SUPPLEMENT|Ensure Plus|Ensure plus supplement with meals
214998882|NCT00933153|DIETARY_SUPPLEMENT|Meals on Wheels|Two Meals on Wheels twice daily
214998883|NCT03820232|DEVICE|temperature monitoring|In every patient observed in this prospective observational study, body core temperature will be contemporaneously monitored through the oesophageal probe and the heated controlled servo sensor. Both are routinely used for this purpose in clinical practice
214390602|NCT03470714|OTHER|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
214390603|NCT02768558|RADIATION|Radiation Therapy (RT)|2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
214998884|NCT02352194|OTHER|Rehabilitation|Physiotherapy and physical activity
214998885|NCT06387017|DIAGNOSTIC_TEST|blood sampling|blood collection
214390604|NCT02768558|DRUG|Cisplatin|Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
214998886|NCT06387017|DIAGNOSTIC_TEST|stool collection|stool collection
214998887|NCT06387017|RADIATION|low dose CT scan|low dose CT scan evaluation
214998888|NCT04243668|PROCEDURE|ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)|"In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry,reflux questionnaire."
214998889|NCT04260113|DRUG|Apatinib Mesylate|Apatinib orally 500mg once daily half an hour after meal
214390605|NCT02768558|DRUG|Etoposide|Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
214390606|NCT02768558|DRUG|Nivolumab|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
214390607|NCT02768558|OTHER|Placebo|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
214501513|NCT06296940|BEHAVIORAL|Treatment as Usual|Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on their substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)
214501514|NCT02781519|DRUG|THC|Active THC (0.015mg/kg) administered over 10 minutes
214501515|NCT02781519|DRUG|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
214390608|NCT02626221|OTHER|Non Interventional Study|Non Interventional Study
214390609|NCT03018301|DRUG|Ketamine|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
214390610|NCT03018301|OTHER|Normal saline|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
214501516|NCT05472532|PROCEDURE|Patient sampling.|"One or several bio-specimens will be sampled depending on the cohort :~* Blood (40 ml)~* Pleural Fluid (40 ml)~* Peritoneal liquid (40 ml)~* Solid tumors"
214501517|NCT05512819|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
214501518|NCT05512819|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
214501519|NCT05971979|OTHER|No intervention|No intervention
214501520|NCT06292689|DRUG|Cardunolizumab|"1. Not systematically treated:~   Cardunolizumab (10mg/kg) + Cisplatinum (50mg/m2)/ Carboplatinum (AUC 4-5) + Paclitaxel (175mg/m2) ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.~2. Previous systematic treatment:~Cardunolizumab (10mg/kg) + Chemotherapy regimen selected by the investigator ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment."
214501521|NCT04636138|OTHER|Exercise|Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.
214501522|NCT04589624|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
214501523|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214687949|NCT05909514|BEHAVIORAL|PelvicSense(R)|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
214687950|NCT06357975|PROCEDURE|Biopsy Procedure|Undergo biopsy
214687951|NCT06357975|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214687952|NCT06357975|DRUG|Crizotinib|Given PO
214390611|NCT03222544|COMBINATION_PRODUCT|methylene blue|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
214687953|NCT06357975|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
214687954|NCT04434053|DEVICE|MIETHKE M.blue®|The programmable shunt will be adjusted through the MIETHKE M.blue® valve.
214390612|NCT03222544|COMBINATION_PRODUCT|Photon therapy instrument|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
214390613|NCT03219268|BIOLOGICAL|tebotelimab 1 mg|1 mg IV every other week
214390614|NCT03219268|BIOLOGICAL|tebotelimab 3 mg|3 mg IV every other week
214501524|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo hpMRI
214501525|NCT04606264|DRUG|Neuraxial Analgesia|This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
214501526|NCT04606264|DRUG|Regional Block 1: Paravertebral|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
214501527|NCT04606264|DRUG|Perphenazine|This randomized group will receive 8 mg of perphenazine orally preoperatively.
214501528|NCT04606264|DRUG|Aprepitant|This randomized group will receive 40 mg of aprepitant orally preoperatively.
214390615|NCT03219268|BIOLOGICAL|tebotelimab 10 mg|10 mg IV every other week
214390616|NCT03219268|BIOLOGICAL|tebotelimab 30 mg|30 mg IV every other week
214390617|NCT03219268|BIOLOGICAL|tebotelimab 120 mg|120 mg IV every other week
214390618|NCT03219268|BIOLOGICAL|tebotelimab 300 mg|300 mg IV every other wee
214390619|NCT03219268|BIOLOGICAL|tebotelimab 400 mg|400 mg IV every other wee
214390620|NCT03219268|BIOLOGICAL|tebotelimab 600 mg|600 mg IV every other week
214390621|NCT03219268|BIOLOGICAL|tebotelimab 800 mg|800 mg IV every other week
214390622|NCT03219268|BIOLOGICAL|tebotelimab 1200 mg|1200 mg IV every other week
214390623|NCT03219268|BIOLOGICAL|margetuximab|15 mg/kg IV every 3 weeks
214501529|NCT04606264|DRUG|Dimenhydrinate|This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
214501530|NCT04606264|DRUG|Ondansetron 4 MG|This randomized group will receive 4 mg of ondansetron orally.
214501531|NCT04606264|DRUG|Dexamethasone|This randomized group will receive 4-5 mg of dexamethasone intravenously.
214501532|NCT04606264|DRUG|Regional Block 2: QL1|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
214687955|NCT04434053|DEVICE|MIETHKE proGAV 2.0® (with SA 2.0®)|The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
214687956|NCT01433458|DRUG|RLX030A|RLX030 is administered as a continuous 24 hour infusion
214687957|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS A|High-whey protein, leucine-rich, low-caloric ONS in powder format
214687958|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS B|High casein-protein, low-caloric control product (isocaloric to product A)
214687959|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS C|High casein-protein, high-caloric control product.
214687960|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS D|high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
214687961|NCT04425772|DRUG|FNC+Standard of Care|FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
214390624|NCT03851913|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
214390625|NCT02216747|DRUG|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
214390626|NCT02216747|DRUG|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
214390627|NCT02216747|DRUG|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
214390628|NCT05719623|OTHER|CUEVAS MEDEK EXERCISES|stretchings/strengthening
214390629|NCT05719623|OTHER|BALANCE AND POSTURAL|BALANCE AND POSTURAL
214390630|NCT01647308|DRUG|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
214390631|NCT01647308|DRUG|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
214390632|NCT01664936|RADIATION|Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I|We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
214390633|NCT01409421|BEHAVIORAL|motivational interviewing|counseling intervention
214390634|NCT01409421|BEHAVIORAL|three phone calls to remind patients to take their eye drops|reminder phone calls
214501533|NCT05255172|OTHER|Supervised Exercise|12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
214501534|NCT03447509|DEVICE|iTMS|Small magnetic pulse will be given to the brain in a non invasive manner.
214390635|NCT03308760|OTHER|Questionnaire|Interview concerning the post-operative rehabilitation programme and a functional analysis using the American Orthopaedic Foot and Ankle Society questionnaire
214390636|NCT03308760|OTHER|Static stabilometry|on a force plate, in a double- then single-foot stance, with the eyes open and then closed
214390637|NCT03308760|OTHER|Isokinetic test|Isokinetic test of the flexors/extensors and invertors/evertors of the ankle
214390638|NCT02855164|DRUG|Tropifexor (LJN452)|Comparison of different doses of drug
214390639|NCT02855164|DRUG|Placebo|Comparator
214390640|NCT03229434|BEHAVIORAL|Mountain hiking|Compare arm description
214390641|NCT03101124|DRUG|Tranexamic Acid 25 mg/ml for wound surface moistening|Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure
214390642|NCT03101124|DRUG|Tranexamic Acid 5 mg/ml as bolus in wound cavity|200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later
214390643|NCT03101124|DRUG|Tranexamic Acid Injectable Solution|1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
214390644|NCT00715572|DRUG|thyroxine|monotherapy with thyroxine
214390645|NCT00715572|DRUG|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
214390646|NCT03313115|BEHAVIORAL|Sleep/Wake Protocol|"Day RN observes if completed per pt: no caffeine after 3 pm, encourage activities to prevent napping (chart % day spent napping), Lights on blinds/door open, Reasonable effort for some noise in room, Eye glasses hearing aids applied, Chair position/mobility at least 2x30 minutes.~Night RN observe if completed per pt: Appropriate pain control, Optimize room temp, Warm bath before 2200, TV off by 2200, Prevent extra alarms after 2200, Close room curtain by 2200, Dim room lights by 2200, Family out by 2200, Door half/fully closed after 2200, # RN interruptions after 2200, Offer eye mask/ear plugs, Meds administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other), Dim hallway lights by 2200, Nurses station quiet"
214390647|NCT00004430|DRUG|Dihematoporphyrin derivative|
214390648|NCT00004430|DRUG|prednisolone|
214390649|NCT00004430|PROCEDURE|Laser surgery|
214390650|NCT02989896|DEVICE|perfusion index|
214390651|NCT05437042|OTHER|Medial calcaneal wedge|Immediate effect of medial calcaneal wedge for static balance and weight distribution
214390652|NCT00383240|DRUG|mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
214390653|NCT00383240|DRUG|Mometasone furoate MDI (MF MDI) 200 mcg|MF 200 mcg via metered dose inhaler twice daily for 26 weeks
214390654|NCT00383240|DRUG|formoterol fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
214501535|NCT03447509|OTHER|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
214501536|NCT03447509|DEVICE|Sham iTMS|Sham or fake stimulation will be given to the brain in a non invasive manner.
214501537|NCT03447509|OTHER|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
214390655|NCT00383240|DRUG|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
214390656|NCT03842553|OTHER|No Intervention: anonymous online survey|
214390657|NCT02692950|OTHER|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
214390658|NCT02692950|BEHAVIORAL|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
214501538|NCT03410589|OTHER|Sinlge arm|application of scales for evaluation of sleep, fatigue and quality of life - Observational study
214501539|NCT04921358|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks
214501540|NCT04921358|DRUG|Docetaxel|75 mg/m\^2 intravenously once every 3 weeks
214501541|NCT04921358|DRUG|Sitravatinib|100 mg orally once daily
214390659|NCT03625505|DRUG|Venetoclax|tablet, oral
214390660|NCT03625505|DRUG|Gilteritinib|tablet, oral
214390661|NCT06625827|DRUG|Digoxin|Oral administration
214390662|NCT06625827|DRUG|Nemtabrutinib|Oral administration
214390663|NCT02601937|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
214998890|NCT05265572|BEHAVIORAL|Domestic Hygiene and household hygiene Intervention|A demonstration on the domestic hygiene intervention will be conducted where participants will be guided on optimal cleaning of windowsills, floors and other surfaces with water and detergent, and advised on appropriate method of cleaning. Participants will be provided with a package of cleaning materials (mop, bucket, detergent, hand wash liquid soap and cloth for wet dusting) which will be used during the demonstration, and retained by participants to facilitate sustainability of the intervention during and after the study. Participants will be further engaged in an educational discussion, with the aid of a specially designed educational pamphlet containing information about health effects potentially associated with dust lead exposure from mine dumps and the personal hygiene and domestic hygiene steps that may be followed to reduce dust lead exposure.
214998891|NCT05645991|DIETARY_SUPPLEMENT|Coconut Sap Powder (CSP)|CSP was given once daily (1.5 g/day) for 8 weeks.
214998892|NCT05645991|DIETARY_SUPPLEMENT|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
214998893|NCT06335199|PROCEDURE|Unilateral Left tVNS stimulation|Electrical stimulation to the cymba concha or tragus (depending on the ear dimension) of the outer ear on the left side after successful trials.
214998894|NCT06335199|PROCEDURE|Bilateral tVNS stimulation|Electrical stimulation to the cymba concha or tragus (depending on the ear dimension) of the outer ear on both sides after successful trials.
214998895|NCT06335199|PROCEDURE|Unilateral Left Sham stimulation|Electrical stimulation to the earlobe of the outer ear on the left side after successful trials.
214998896|NCT06335199|PROCEDURE|Bilateral Sham stimulation|Electrical stimulation to the earlobe of the outer ear on both sides after successful trials.
214998897|NCT06335199|PROCEDURE|Unilateral Right tVNS stimulation|Electrical stimulation to the cymba concha or tragus (depending on the ear dimension) of the outer ear on the right side after successful trials.
214998898|NCT06335199|PROCEDURE|Unilateral Right Sham stimulation|Electrical stimulation to the earlobe of the outer ear on the right side after successful trials.
214998899|NCT05507177|OTHER|communication training programme for healthcare providers|the communication training programme is specifically designed to help Dutch primary care healthcare providers facilitate adequately deprescribing cardiometabolic medication in older patients
214998900|NCT01913353|BIOLOGICAL|MVA BN®|0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection
214998901|NCT01913353|BIOLOGICAL|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
214998902|NCT02871102|PROCEDURE|Recruitment Maneuver with PEEP and Tidal Volume Optimization|A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
214390664|NCT03233061|DIAGNOSTIC_TEST|cardiorespiratory fitness and daily physical activities evaluations|"The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine."
214390665|NCT02140346|DRUG|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
214390666|NCT02140346|DRUG|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
214390667|NCT02924389|DRUG|dolutegravir|Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.
214998903|NCT03167918|DRUG|Calcium Dobesilate|gave each patient 0.5 g bid，
214998904|NCT03167918|DRUG|Xuefuzhuyu Decoction|gave each patient100 ml bid，po
214998905|NCT03167918|DRUG|Xuefuzhuyu Decoction & Calcium dobesilate|gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
214998906|NCT03167918|DRUG|metformin|gave each patient 1000 mg, bid, PO
214998907|NCT03167918|DRUG|Mecobalamin Tablets|gave each patient 0.5 mg bid, PO
214998908|NCT03834090|DEVICE|rESWT|rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.
215094064|NCT06853314|BEHAVIORAL|PrEP for WINGS|The PrEP for WINGS intervention involves three sessions of a self-paced and self-directed intervention delivered via a mobile health platform. Session 1 will focus on HIV risk reduction and provide the PrEP Decision Aid, where participants will learn information about PrEP to help them decide if it is appropriate for them. Sessions 2-3 will involve integrated Screening, Brief Intervention, Referral to Treatment (SBIRT) modules focused on IPV and alcohol reduction. The PrEP for WINGS intervention will also involve peer navigation sessions with Community Health Advocates to help intervention participants trouble shoot any barriers to achieving goals they set during the self-paced sessions. The PrEP for WINGS intervention will take place over a 30 day period and Sessions 2-3, and the peer navigation sessions may be delivered using smart phones or using tablets available at study data collection sites.
214390668|NCT02924389|DRUG|Triumeq|Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
214998909|NCT03834090|OTHER|Supervised exercises|A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
214390669|NCT02924389|DRUG|Truvada|Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
214390670|NCT00582530|OTHER|Whole Blood Draw|The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
214390671|NCT06826066|OTHER|Blood samples|We propose to include patients who have been treated with radiotherapy and did not experience severe radiation-induced toxicity, after obtaining their informed consent. A blood sample will then be collected by the nursing staff from the Oncology-Radiotherapy department at Henri Mondor University Hospital. After the patient signs the consent form, each patient will have their clinical information recorded and a blood sample taken. The blood samples will be immediately transported, at room temperature, to the INSERM U955 i-Biot unit at Henri Mondor (serum, plasma, and PBMC). All samples will be frozen at -80°C for later analysis.
214501542|NCT04632290|DEVICE|STIMO-BSI system implantation|Participants are implanted bilaterally with epidural electrocorticography devices. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
214998910|NCT04343144|DRUG|Nivolumab Injection|Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).
214998911|NCT03290768|DEVICE|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
214998912|NCT03290768|DEVICE|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
214998913|NCT03290768|BEHAVIORAL|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
214998914|NCT00065871|BEHAVIORAL|Contraceptive Screening by Pharmacist|
214998915|NCT00065871|BEHAVIORAL|Contraceptive Prescribing by Pharmacist|
214390672|NCT00896623|GENETIC|mutation analysis|
214390673|NCT00896623|GENETIC|polymorphism analysis|
214390674|NCT00896623|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
214390675|NCT05952401|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (patient smoking cessation handout and brief advice).
214501543|NCT04632290|DEVICE|ARC-BSI Lumbar System|ARC-BSI Lumbar System for participants entering the optional extension with system upgrade: replacement of the neurostimulator, and upgrade of the WIMAGINE system and STIMO system wearable devices.
214501544|NCT05091255|PROCEDURE|Cryotherapy|The procedure involves general or peripheral anesthesia and percutaneous treatment under CT control with probes capable of forming ice spheres of up to 3 cm that will be used in sufficient number to treat the neoplasm completely.
214501545|NCT05120804|BEHAVIORAL|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
214998916|NCT04055870|PROCEDURE|EUS-guided liver biopsy at MDMC|Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
214998917|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
214998918|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
214998919|NCT01147458|DRUG|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
214998920|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
214998921|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
214998922|NCT01147458|DRUG|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
214998923|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
214998924|NCT01147458|DRUG|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
214998925|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
214998926|NCT01147458|DRUG|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
214998927|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
214998928|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
214998929|NCT02603900|DRUG|ropivacaine|15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
214998930|NCT02603900|DRUG|bupivacaine|20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
214998931|NCT02603900|DEVICE|Sham Adductor Canal Catheter|Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
214998932|NCT02603900|DEVICE|Adductor Canal Catheter|Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
214998933|NCT05718596|OTHER|sweeps laser to use irrigation activation|The SWEEPS fiber tip (25 µs ultra-short dual pulse mode-Auto SWEEPS mode) was inserted into the Er:YAG laser source (2,940 nm, 20 mJ per pulse, 15 Hz, 0.3 W power, and 50 µs pulse frequency). 3% NaOCl solution was activated in three periods of 20 s. Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
214998934|NCT05718596|OTHER|PUI to use irrigation activation|The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 2 mm behind the working length without touching the canal walls.
214390676|NCT05952401|BEHAVIORAL|"Nudges"|"Patients in the experimental arm will receive practice guidelines (patient smoking cessation handout and brief advice) and Nudges to Quit, guideline-informed messages immediately following patient tobacco treatment needs assessment."
214390677|NCT02743715|DEVICE|Active tDCS (transcranial direct current stimulation)|An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
214390678|NCT02743715|DEVICE|Sham tDCS|The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
214390679|NCT06010511|OTHER|3T MRI scan|Conventional (3T) brain MRI scans will be used to determine global and functional markers of cerebral SVD, like WMH volume and presence of lacunes, microbleeds and superficial siderosis (3D T1, 3D FLAIR, SWI, DWI), hemodynamics (arterial spin labelling \& flow territory mapping) and white matter structural integrity (diffusion tensor imaging (DTI)). Furthermore, we want to measure structural integrity with a novel MR fingerprinting sequence and an inhomogeneous magnetization transfer (ihMT) MRI scan. We also want to apply a fMRI scan technique to measure CSF fluctuations in the 4th ventricle as a measure of brain glymphatics. Also the flow-territory mapping sequence is a non-standard sequence. Heart rate and respiratory signal will be measured during the scans (3T and 7T MRI) with standard vendor-supplied equipment.
214390680|NCT06010511|OTHER|7T MRI scan|Ultra-high field (7T) brain MRI scans will be used to determine WMH shape and other markers of cerebral SVD in or surrounding the WMH, like local enlarged perivascular spaces, (cortical) microinfarcts and microbleeds (T1, T2, FLAIR and T2\*) and vascular pulsatility (phase contrast MRI). Moreover, a recently implemented MRI technique to measure glymphatic flow in perivascular spaces will be used.
214390681|NCT06010511|BEHAVIORAL|Neuropsychological assessment|"* Mini-mental state examination~* Clock drawing~* 15-Word Verbal Learning Test, immediate and delayed~* Visual Association Test~* Stroop Color Word Test, 40 item version~* Trail Making Test A\&B~* Letter Digit Substitution Test~* Animal fluency test~* Hospital anxiety and depression scale~* Informant Questionnaire on Cognitive Decline in the Elderly"
214501546|NCT05120804|BEHAVIORAL|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus relationship skills training
214501547|NCT02278796|DRUG|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
214687962|NCT04425772|DRUG|FNC dummy tablet+Standard of Care|FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
214687963|NCT03519945|DRUG|Mirikizumab|Administered SC.
214998935|NCT00143572|DRUG|Magnesium Pidolate, Hydroxyurea|Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
214390682|NCT06010511|OTHER|General baseline data|"Baseline data, such as age, sex, psychiatric comorbidity and medication lists will be extracted from the patient files.~Age (Year of birth); Years of education; BMI (height \& weight); Sex; Verhage scale (education); Smoking status; Blood values; Sleep habits; Waste-hip ratio; Blood pressure; Current/general cardiovascular health; Psychiatric comorbidity; medical history related to cardiovascular health."
214390683|NCT03661229|DEVICE|CVInsight Monitoring|All participants (n=50) will receive CVInsight non-contact device and CVInsight contact device application during two of their regularly scheduled dialysis sessions.
214390684|NCT05718648|DRUG|BI 1015550|BI 1015550
214390685|NCT05416775|DRUG|SHR-8068；Adebrelimab|SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion
214390686|NCT05416775|DRUG|SHR-8068；adebrelimab and platinum-based chemotherapy|SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
214998936|NCT03550209|DRUG|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
214998937|NCT03550209|DIETARY_SUPPLEMENT|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
214998938|NCT06319118|DRUG|Placebo|placebo + usual care, placebo 5 mg daily; 2.5mg 2 times daily, after breakfast and dinner.
214998939|NCT06319118|DRUG|dihydroergotine mesylate sustained-release tablets|Dihydroergotine mesylate extended-release tablets + conventional treatment, dihydroergotine mesylate sustained-release tablets 5mg daily; 2.5mg 2 times daily, after breakfast and dinner.
214390687|NCT05416775|DRUG|Adebrelimab；platinum-based chemotherapy|Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
214390688|NCT00966862|OTHER|Other: Dietary Fibers|
214390689|NCT02366208|DRUG|PEG-Tα1|1.6 mg/ml, once a week, taken subcutaneously
214390690|NCT02366208|DRUG|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
214390691|NCT02366208|DRUG|Adefovir|10 mg, once daily, taken orally for 48 weeks
214390692|NCT02338258|DEVICE|Anti-rotational plate|
214390693|NCT02338258|DEVICE|Exchanged Intramedullary nailing|
214390694|NCT06251726|DIAGNOSTIC_TEST|Immunoscore Colon Test|"Immunoscore Colon is an in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer.~The test uses immunohistochemistry, digital pathology techniques and a dedicated image analysis software to determine CD3+ and CD8 + cell densities in the tumor ant in the invasive margin of the tumor."
214390695|NCT03435458|COMBINATION_PRODUCT|Balloon catheter + oral misoprostol|The pharmacological cervical ripening will be administered just after the balloon catheter insertion (after coming back in her room) and will consist of misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
214501548|NCT02278796|DRUG|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
214501549|NCT03546829|DRUG|Vancomycin|125 mg, 4x daily for 5 weeks
214501550|NCT03546829|RADIATION|Precision hypofractionated radiation|Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression and will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
214501551|NCT04926857|OTHER|Non-Interventional|Non-Interventional
214501552|NCT05923684|BEHAVIORAL|NLP-based Feedback|Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.
214501553|NCT06130046|BIOLOGICAL|MR-proADM dosage|Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U
214501554|NCT04578834|DRUG|Placebo|Placebo to LNP023 200mg b.i.d
214501555|NCT04578834|DRUG|LNP023|LNP023 200mg b.i.d
214501556|NCT06358625|OTHER|Pre-treatment biopsy|"A breast biopsy is performed just before the clip is placed in the tumour and additional blood samples are performed."
214501557|NCT06578949|DRUG|Ravulizumab|Ravulizumab will be administered by intravenous (IV) infusion.
214998940|NCT04254757|PROCEDURE|Two different treatment|One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery
214998941|NCT02555878|DRUG|Rivaroxaban|Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
214390696|NCT03435458|DRUG|Oral misoprostol alone|Patients will receive a pharmacological cervical ripening alone that consist of Misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
214501558|NCT04350502|PROCEDURE|chest tube drainage|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day).
214998942|NCT02555878|DRUG|Placebo|Placebo tablet will be administered orally once daily for 180 days.
214998943|NCT05234671|OTHER|Exercise programme|12-week exercise programme. The estimated session's duration of 55 minutes. For the prescription of high intensity interval training (HIIT) and the collection of individualised peak power output (PPO) a baseline peak oxygen uptake on an arm crank ergometer will be performed. Each session will consist of 5 minutes warm up performing light to moderate intensity arm cranking (55-65% PPO), 30-minutes' high intensity interval training (HIIT; 30s 100% PPO/ 30s passive recovery) on an arm crank ergometer. The HIIT protocol will be combined with resistance training (RT) lasting for a total of 15 min.The intensity will be at 75-80% of one repetition maximum. Following each exercise session, patients will undertake a 5 min cool-down period.
214998944|NCT00765076|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK2186877A|One intramuscular injection at Day 0
214998945|NCT00765076|BIOLOGICAL|GSK Biologicals' Fluarix|One intramuscular injection at Day 0
214998946|NCT00632294|PROCEDURE|Tissue Sample|A leftover sample of the removed allograft bone will be collected.
214998947|NCT02100787|OTHER|TheraTears lubricating drops|A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
214998948|NCT00594139|BIOLOGICAL|Autologous neobladder construct|provision of an autologous neo-bladder construct
214998949|NCT05948488|OTHER|Questionnaires|The questionnaires focus on anxiety, fear and quality of life.
214998950|NCT06251947|DRUG|Efbemalenograstim Alfa|Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
214998951|NCT02701491|DIETARY_SUPPLEMENT|Ginger|ginger
214998952|NCT02701491|OTHER|Placebo|Placebo
214998953|NCT02875080|DRUG|OPC-34712|
214998954|NCT06439680|OTHER|"HASCV-R Health Programme"|"HASCV-R program Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
214998955|NCT05042297|PROCEDURE|Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention|Reduction of the posterior ring was either closed reduction in SI joint dislocations \& fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach. Anterior pelvic ring reduction and fixation in the combined APR fixation group was done via the classic Pfannenstiel approach or extension more lateral \& completing the anterior intrapelvic approach. Fixation was via pubic rami plating.
214998956|NCT01812915|DEVICE|Cylindrical-shape cuff ETT (Group C)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt Hi-Lo(TM) endotracheal tube.
214998957|NCT01812915|DEVICE|Tapered-shape cuff ETT (Group T)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt TaperGuard(TM) endotracheal tube.
214390697|NCT02382510|DRUG|TRN-157|
214390698|NCT02382510|OTHER|Placebo|
214998958|NCT06069089|RADIATION|Dexa scan|No intervention
214998959|NCT02756897|DRUG|Ibrutinib|Given PO
215094065|NCT06853314|BEHAVIORAL|PrEP Decision Aid|The PrEP Decision Aid will be delivered to participants in the control condition, and focus on helping study participants decide if they should initiate PrEP. This single session will focus on HIV risk reduction, and then launch the patient-centered PrEP Decision Aid. This individual session will be identical to the first session of the PrEP for WINGS three session intervention, and will also be delivered through an online survey platform. In addition, study participants in the control condition will also have one peer navigation session with a Community Health Advocate at the end of the self-paced session to help facilitate linkage to care.
215094066|NCT04886258|DRUG|DFV890|DFV890
215094067|NCT04886258|DRUG|Placebo|Placebo
214390699|NCT02382510|DRUG|Tiotropium|
214390700|NCT03917160|DEVICE|EMS device|EMS treatment will be performed
214390701|NCT03918239|DRUG|SHP643|Participants will receive injection of SHP643.
214390702|NCT05672082|DRUG|[18F]DPA-714|Participant received one injection of 200 MBq of \[18F\]DPA-714
214390703|NCT04448236|DEVICE|Blood flow restriction resistance exercise|"Application the Blood flow restriction device over the proximal thigh to have 80% of the limb occlusion pressure to accumulate the metabolite generated during knee extension"
214390704|NCT02840396|DEVICE|rTMS|repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.
214501559|NCT04350502|BIOLOGICAL|antibiotic concentration in pleural fluid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
214501560|NCT04350502|DRUG|Amoxicillin + clavulanic acid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
214501561|NCT04920253|DEVICE|Study Device Debridement|debritom+ water jet debridement
214998960|NCT02756897|OTHER|Laboratory Biomarker Analysis|Correlative studies
214998961|NCT02756897|DRUG|Venetoclax|Given PO
214998962|NCT02066116|PROCEDURE|Kinect-based rehabilitation plus occupational therapy|The developed kinect-based rehabilitation system will be used for 30min/session. Conventional 30min occupational therapy also will be applied for the patient enrolled.
215094068|NCT01359605|DRUG|varespladib methyl|500 mg oral suspension
214998963|NCT02066116|OTHER|sham virtual rehabilitation education plus occupational therapy|For the sham virtual rehabilitation, computer-based cognitive rehabilitation program will be used. Patients will be encouraged to use their affected arm to push the button but the motion will be minimal and not related to the concept of upper extremity rehabilitation.
214998964|NCT00304577|PROCEDURE|Bilateral recession|
214998965|NCT00304577|PROCEDURE|Unilateral recession and resection|
214390705|NCT02840396|DEVICE|Sham rTMS|Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
214390706|NCT04890522|DRUG|Triprilimab(JS001)|Maximum 6 cycles for combined therapy and maintenance for up to 2 years.
214390707|NCT04890522|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
214390708|NCT04890522|DRUG|5-Fluorouracil|Maximum 6 cycles for combined therapy.
214390709|NCT04890522|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
214390710|NCT05828225|DRUG|CD19 CAR-T cells injection|CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
214390711|NCT02292810|DEVICE|Inspiratory muscle exercise|For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
214390712|NCT02292810|DEVICE|Inspiratory muscle exercise placebo|For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
214390713|NCT04249336|DRUG|Fluoro-Calcium-Phospho-Silicate based dentifrices|Bio-Active glass based formulation
214390714|NCT04249336|DRUG|8% Arginine based dentifrices|Tubular occluding formulation
214390715|NCT04249336|DRUG|8% Strontium Acetate|Tubular occluding formulation
214390716|NCT04249336|DRUG|Sodium Fluoride|No claim of relieving Dentin Hypersensitivity
214390717|NCT02930122|DRUG|anakinra (150mg)|intraarticular administration
214998966|NCT00768053|DRUG|Etanercept|Etanercept 50 mg once a week
214998967|NCT01164475|DRUG|Granulocyte-colony stimulating factor (G-CSF)|
214998968|NCT01164475|DRUG|Fixed Dose Plerixafor|
214998969|NCT01164475|DRUG|Weight-Based Plerixafor|
214390718|NCT02930122|OTHER|Saline intraarticularly|intraarticular administration
214390719|NCT03069820|DRUG|docetaxel and cisplatin|Patients receive TP (docetaxel and cisplatin) chemotherapy
214390720|NCT01941550|DRUG|Cabazitaxel chemotherapy|given in 6 cycles
214390721|NCT00231998|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
214501562|NCT04920253|DEVICE|SOC Debridement|Sharp Scalpel
214501563|NCT05646719|DRUG|Phentolamine Opthalmic Solution 0.75%|phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
214501564|NCT05646719|OTHER|Placebo|Vehicle for Phentolamine Ophthalmic Solution
214501565|NCT05646719|DRUG|Low dose pilocarpine|Pilocarpine hydrochloride ophthalmic solution 0.4%
214501566|NCT05646719|OTHER|Low dose pilocarpine vehicle|Vehicle for low dose pilocarpine
214501567|NCT05554159|BEHAVIORAL|Standard Fitbit Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
214998970|NCT05991817|PROCEDURE|Surgery/general anesthesia|Adult patients between the ages of 30 and 50 who are to undergo elective surgery under general anesthesia will have their spatial memory tested and interleukin 1beta and alpha tumor necrosis measured before and after surgery.
214390722|NCT04228549|DEVICE|MyPADMGT|Online tracking and feedback to help patients adopt healthy lifestyles
214390723|NCT04228549|DEVICE|MyPADMGT + Nudging|Online tracking and feedback to help patients adopt healthy lifestyles plus nudging support to assist in making decisions
214501568|NCT05554159|BEHAVIORAL|Virtual Exercise Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
214501569|NCT06362200|DEVICE|40 Hz tACS intervention|The central electrode is placed in the CP6 and the other four electrodes are placed around the CP6. 40 Hz tACS group participants will receive alternating current stimulation (40Hz, 2.0mA, 20min/time, three times a day, 21 times in total) for 1 week. Subjects in the placebo comparator group will receive sham tACS for 1 week, which mimics the tACS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs.
214390724|NCT05857579|PROCEDURE|Microblepharoexfoliation|MBE was performed using the yokefellow instrument (Youke Electronic Corporation, Guangzhou, China), which contains a handpiece with a 1.80 mm diameter medical-grade diamond bur. Patients underwent MBE on the upper and lower lid margin of both eyes at 500 rpm until complete removal of accumulated biofilm debris, epithelial keratinization or capped meibomian glands. MBE was carried out only in the first combined treatment session.
214390725|NCT05857579|PROCEDURE|Intense pulse light|IPL treatment was carried out with Thermaeye Plus (MDS Medical Technologies SL, Barcelona, Spain). The procedure began by applying an ultrasound gel (Carmado SL, Alicante, Spain) to the patient's periocular areas and upper eyelids. In the periocular areas, 6 light pulses were applied; 4 light pulses on the skin below the lower eyelid (with handpiece placed horizontally in the first pass and vertically in the second pass) and 2 light pulses on the canthal area (with handpiece placed vertically in first and second pass). The parameters were as follows: (1) Filter: 650 nm; (2) fluence: 9 j/cm2; (3) pulses: 2; (4) duration: 3 ms; (5) Delay: 20 ms; and (6) Cooling: 70%. In the upper eyelids, 4 light pulses were applied; 2 light pulses in the first and second pass, respectively. The parameters were as follows: (1) Filter: 650 nm; (2) Fluence: 5 j/cm2; (3) pulses: 1; (4) duration: 3 ms and (5) Cooling: 70%.
214390726|NCT05857579|PROCEDURE|Meibomian gland expression|Finally, the MGX was performed on both upper and lower eyelids of each eye with a Collins forceps (Medi Instrument Inc, New York, USA).
214390727|NCT05857579|DRUG|Home-based therapy|Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
214390728|NCT00000174|DRUG|Rivastigmine|
214390729|NCT05978648|DRUG|Trilaciclib|240 mg/m2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day
214390730|NCT05978648|DRUG|Epirubicin|90 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
214390731|NCT05978648|DRUG|Cyclophosphamide|600 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
214501570|NCT05305365|DRUG|QBS72S|QBS72S 18mg/m2 injection given intravenous once a month.
214501571|NCT05980507|DRUG|ICI201|ICI201 CAR-T cell injection
214501572|NCT00418652|DEVICE|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
214501573|NCT00418652|DEVICE|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
214501574|NCT00418652|DEVICE|TMS over the vertex|10Hz TMS for over vertex.
214501575|NCT02021396|PROCEDURE|Embolization|this arm of the study was interventional (splenic artery embolization)
214998971|NCT02349880|BEHAVIORAL|shared decision making training|
214998972|NCT02959268|DEVICE|Al-Sense|Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests
214998973|NCT02574091|DRUG|1% icotinib hydrochloride cream|Topical administration for twice daily
214998974|NCT02574091|DRUG|2% icotinib hydrochloride cream|Topical administration for twice daily.
214501576|NCT01205633|PROCEDURE|venous angioplasty|catheter venous angioplasty via femoral vein approach
214501577|NCT05773235|DIAGNOSTIC_TEST|Combined 3- and 7 Tesla-MRI|7 Tesla-MRI including the following sequences: susceptibility weighted imaging (SWI), T1, T2, FLAIR, quantitative mapping sequences (T1mapping, qSM)
214501578|NCT03115099|DRUG|LY3325656|Administered orally
214501579|NCT03115099|DRUG|Placebo|Administered orally
214501580|NCT03115099|DRUG|Liraglutide|Administered subcutaneously
214998975|NCT02574091|DRUG|Placebo|Topical administration for twice daily.
215094069|NCT05502666|BEHAVIORAL|¡Salud! Por la Vida|Lay health worker (LHW) delivered educational intervention for colorectal cancer screening (CRCS). The intervention consisted in having the participant complete a tailored interactive multimedia intervention (TIMI). TIMI consisted of a series of educational videos that addressed common barriers to colorectal cancer screening as well as provided information about colorectal cancer (CRC) and CRCS tests. Participants were able to tailor the TIMI for sex (male/female) and CRC family history. After TIMI completion, the LHW provided participant with a copy of the SPLV newsletter and printed infographics on CRC, CRCS, and an action plan tailored by type of CRCS (FOBT/FIT or colonoscopy). The Intervention Group subject participation took approx. up to 2 hours and Control Group up to 1 hour (half hour for each: baseline and follow-up interview). Follow-up data was collected 6 months post education session (intervention group) or post-baseline survey (control group).
215094070|NCT01293981|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
215094071|NCT03860363|DEVICE|Blood drainage post cardiac surgery|Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
215094072|NCT02066415|BIOLOGICAL|Erenumab|Administered once a month subcutaneously by authorized investigational site study staff.
215094073|NCT02066415|DRUG|Placebo|Administered once a month subcutaneously by authorized investigational site study staff.
215094074|NCT00430937|DRUG|Daptomycin|4 mg/kg intravenous once daily
215094075|NCT00430937|DRUG|Vancomycin|1 g intravenous twice daily
215094076|NCT00430937|DRUG|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
215094077|NCT06190327|BEHAVIORAL|Blended indoor and outdoor multicomponent structured exercise|Participants will receive a 16-week blended indoor and outdoor multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Session 1/week will conduct in indoor setting, while session 2/week will conducted in outdoor setting (park). Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
214501581|NCT03115099|DRUG|Sitagliptin|Administered orally
214501582|NCT02372799|DRUG|Vilazodone|
214390732|NCT05978648|DRUG|Paclitaxel|80 mg/m2, intravenous drip, d1,8,15, Q3W, 4 cycles.
214390733|NCT05978648|DRUG|Docetaxel|75 mg/m2, intravenous drip, d1, Q3W, 6 cycles.
214390734|NCT05978648|DRUG|Carboplatin|area under curve(AUC) = 6, intravenous drip, d1, Q3W, 6 cycles.
214390735|NCT05978648|DRUG|Trastuzumab|8 mg/kg in Cycle 1, 6 mg/kg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
214390736|NCT05978648|DRUG|Pertuzumab|840mg in Cycle 1, 420mg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
214501583|NCT02372799|DRUG|Placebo|
214390737|NCT01465139|DRUG|CDX-301|"CDX-301, administered in multiple dosages and frequencies depending on arm:~n=3-6 at between 1-75 μg/kg over 5 days~n=3-6 at 25 μg/kg over 7 days~n=3-6 at 25 μg/kg over 10 days"
214501584|NCT02372799|DRUG|Fluoxetine|
214501585|NCT00000388|BEHAVIORAL|Psychosocial treatment|
214390738|NCT03390036|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
214390739|NCT03390036|DEVICE|Monovisc|Hyaluronic Acid
214501586|NCT00000388|DRUG|Anti-ADHD medication|
214501587|NCT00000388|BEHAVIORAL|Assessment-and-Referral|
214501588|NCT03706261|DRUG|18F-MK-6240|Administration of 5 mCi of 18F-MK-6240 for tau PET.
214501589|NCT03706261|DRUG|18F-Florbetaben|Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.
214501590|NCT05650125|OTHER|Biosampling|Biosampling of blood/tumour/adjacent normal tissue
214501591|NCT03799588|DEVICE|Biphasic Chest Cuirass|Patients will have a esophageal manometer placed after intubation and before initiation of negative pressure ventilation.
214501592|NCT00004807|DRUG|dextromethorphan|
214390740|NCT03390036|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
214390741|NCT06349200|BEHAVIORAL|432 Hz music|Music tuned to the 432 Hz frequency, as compared with other frequencies, has the advantage of providing utter calm, pleasure, and peace to its listeners. It has proven to be effective for reducing stress and improving sleep quality
214390742|NCT06349200|BEHAVIORAL|Binaural beats|Binaural beats are defined as the sound that is born when two sounds of constant intensity but different frequencies are presented to both ears separately. The resultant sound perceived in the brain has a single tone and a frequency equivalent to the difference between the frequencies of the carrier sounds
214390743|NCT06349200|BEHAVIORAL|White noise|White noise is a type of random sound characterized by equal intensity across all frequencies within the audible range, resulting in a steady, uniform sound similar to the static from a television or radio tuned to an unused frequency.
214501593|NCT00004807|DRUG|topiramate|
214501594|NCT00004807|DRUG|Donepezil|
214501595|NCT03983642|DEVICE|Wii balance board|"Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level."
214501596|NCT06642584|DRUG|Semaglutide B|Semaglutide B will be administered subcutaneously.
214501597|NCT06642584|DRUG|Semaglutide J|Semaglutide J will be administered as oral tablets.
214501598|NCT06642584|DRUG|Semaglutide L|Semaglutide L will be administered as oral tablets.
214501599|NCT06642584|DRUG|Semaglutide M|Semaglutide M will be administered as oral tablets.
214501600|NCT06642584|DRUG|Semaglutide N|Semaglutide N will be administered as oral tablets.
214501601|NCT05284643|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Participants will receive radiation therapy delivered via intensity modulated proton therapy (IMPT) simultaneous integrated boost technique over a period of 10 days, 5 days per week for approximately 2 weeks.
214501602|NCT05284643|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.
214501603|NCT02637063|BEHAVIORAL|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
214501604|NCT02637063|BEHAVIORAL|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
214390744|NCT06018597|DRUG|Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL|No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
214390745|NCT01958177|BIOLOGICAL|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)|Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
214390746|NCT04971616|OTHER|Demographic data and range of motion.|The body parameters (BMI, age, gender), daily activities (daily steps, sedentary), work and rest time (sleep time, quality) were collected through wearable devices. The range of motion of neck and waist was collected through hand-held devices.
214501605|NCT02637063|OTHER|Usual care|No intervention beyond participants' own medical care.
214501606|NCT05868837|DRUG|Rituximab|Rituximab 1000 mg IV on RCP days 1 and 15
214501607|NCT05868837|OTHER|Placebo|Placebo 1000 mg IV on RCP days 1 and 15
214501608|NCT06417008|DRUG|HS-20117|Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)
215094078|NCT06190327|BEHAVIORAL|Indoor-only multicomponent structured exercise|Participants will receive a 16-week indoor-only multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Both two sessions will conducted in indoor setting. Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
215094079|NCT04354272|OTHER|Questionnaire|Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
215094080|NCT05822050|DRUG|Selinexor|XPO1 inhibitor
215094081|NCT02580786|BEHAVIORAL|Breastfeeding peer support|
215094082|NCT05511350|DRUG|TJ210001|
214390747|NCT01745315|DEVICE|Advanced bipolar devices|
214390748|NCT02171364|PROCEDURE|Virtual ablation in based 3D CT of patient who diagnosed AF|
214390749|NCT02171364|PROCEDURE|conventional ablation based on physician's personal experience|
214501609|NCT06417008|DRUG|Aumolertinib|110 mg orally once daily.
214501610|NCT00447837|DRUG|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
214390750|NCT03126305|OTHER|OC-Go|OC-Go, a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices
214390751|NCT00358215|DRUG|Darbepoetin alfa|Administered by subcutaneous injection
214501611|NCT03028389|PROCEDURE|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
214501612|NCT04363112|BEHAVIORAL|Mini Kid II|Mini Kid II (Mini International Neuropsychiatric Interview ) is a standardised, hetero mental health questionary for children, according to DSM IV. Mini Kid II will be administered to children between day 3 and 7 during the study.
214501613|NCT01084525|DRUG|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
214501614|NCT01084525|DRUG|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
214390752|NCT00358215|DRUG|Placebo|Placebo subcutaneous injection
214390753|NCT00410631|BIOLOGICAL|filgrastim|
214390754|NCT00410631|DRUG|carboplatin|
214390755|NCT00410631|DRUG|cisplatin|
214390756|NCT00410631|DRUG|cyclophosphamide|
214390757|NCT00410631|DRUG|dacarbazine|
214390758|NCT00410631|DRUG|doxorubicin hydrochloride|
214501615|NCT01084525|DRUG|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
214501616|NCT00491400|DRUG|Fenofibrate|140 mg/day for 8 weeks
214501617|NCT00491400|DRUG|Atorvastatin|20 mg/day for 8 weeks
214501618|NCT00353691|DRUG|glimepiride|
214501619|NCT00353691|DRUG|metformin|
214390759|NCT00410631|DRUG|etoposide phosphate|
214390760|NCT00410631|DRUG|ifosfamide|
214998976|NCT05267457|OTHER|Plasma vanadium concentration|Plasma vanadium concentrations were measured using inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 7700 Series, United States)
214998977|NCT01634594|DRUG|Group R|
214998978|NCT01634594|DRUG|Group N|
214998979|NCT01634594|DRUG|Group D|
214998980|NCT00437762|DRUG|Botulinum Toxin A Injection|Botulinum Toxin A Injection
214998981|NCT00437762|DRUG|Placebo injection|Placebo Injection
214998982|NCT04733885|DEVICE|Experimental|Current application will be made in the frequency range of 20-50 Hz. The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh.ES applications will be performed in the supine position with head and knee pillow supported.
215094083|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
214390761|NCT00410631|DRUG|isotretinoin|
214390762|NCT00410631|DRUG|melphalan|
214390763|NCT00410631|DRUG|topotecan hydrochloride|
214390764|NCT00410631|DRUG|vincristine sulfate|
214390765|NCT00410631|DRUG|vindesine|
214390766|NCT00410631|PROCEDURE|autologous hematopoietic stem cell transplantation|
214390767|NCT00410631|PROCEDURE|conventional surgery|
214390768|NCT00410631|PROCEDURE|peripheral blood stem cell transplantation|
214390769|NCT00410631|RADIATION|iobenguane I 131|
214390770|NCT00410631|RADIATION|radiation therapy|
214390771|NCT04261738|DEVICE|Hyperbaric Oxygen|Volunteers will be given a standard hyperbaric oxygen treatment (2.4 ATA x 90 minutes)
214390772|NCT03743363|OTHER|Exergame 2/week|virtual training 2 times a week(8 week-long)
215094084|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet|Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)
214390773|NCT03743363|OTHER|Exergaming 3/week|virtual training 3 times a week(8 week-long)
214390774|NCT03743363|OTHER|Healthy control / Exergaming 1/week|In the first 8 week-long only control group. For the next 8 weeks, the control group will do 1 workout per week.
214390775|NCT00030368|DRUG|bortezomib|Given IV
214390776|NCT00030368|DRUG|paclitaxel|Given IV
214390777|NCT00030368|OTHER|laboratory biomarker analysis|Correlative studies
214390778|NCT06031168|OTHER|Metformin gel coated implants|Patients will be treated with 1% concentrated metformin gel coated hydrophilic dental implant.
214390779|NCT06031168|OTHER|uncoated hydrophilic dental implants|Patients treated by uncoated implants
214390780|NCT04235868|BIOLOGICAL|Stem cell-derived derived pleiotropic factor|After debridement, the wounds in experimental group apply stem cell-derived lyophilized powder, and use foam dressing to wrap the wound; apply once every 2-3 days.
214390781|NCT04235868|BIOLOGICAL|fibroblast growth factor|After debridement, the wounds in control group apply fibroblast growth factor to the wound surface, and use foam dressing to wrap the wound; apply once every 2-3 days.
214390782|NCT04020003|DRUG|Levosimendan|General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
214390783|NCT04328363|BEHAVIORAL|Intervention|Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.
214390784|NCT04529720|BIOLOGICAL|Biological/Vaccine: Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
214390785|NCT04529720|BIOLOGICAL|Biological/Vaccine: Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TdaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
214390786|NCT04529720|BIOLOGICAL|Biological/Vaccine: Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
214390787|NCT00285181|DRUG|Simvastatin|
214501620|NCT06341959|PROCEDURE|Oral screening|The participants in the intervention group will receive an oral examination. Subsequently, information about any identified problem will be given. Lastly, participants will receive a referral letter for their dentist and a report for the general practitioner. If the participants don't have a regular dentist, they will also be given a list with contact information of dentists in the area.
214501621|NCT00981552|RADIATION|IMRT planning|
214501622|NCT00981552|RADIATION|4-Field Radiation Planning|
214501623|NCT01270282|DRUG|AM-101 0.81 mg/mL|
214501624|NCT01270282|DRUG|Placebo|
214390788|NCT02352662|OTHER|Perioperative blood samples collection|Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
214390789|NCT00631384|BEHAVIORAL|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
214501625|NCT03929471|OTHER|Target weight correction protocol|The intervention group will undergo target weight correction process based on time averaged fluid overload measurement (by bio-impedance).
214501626|NCT04388865|BEHAVIORAL|Control|Subjects will engage with their providers as is standard of care.
215094085|NCT01714258|PROCEDURE|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
215094086|NCT03968783|OTHER|Monofilament suture|1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision
215094087|NCT03968783|OTHER|Multifilament suture|1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
214998983|NCT04733885|DEVICE|Control|The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh. The same device used in ES application to the sham group will be attached to the patients, however, active ES will not be issued from the device and only vacuum will turn on. ES applications will be performed in the supine position with head and knee pillow supported.
214998984|NCT04235855|DEVICE|Endoscopic USG guided Liver biopsy|Diagnostic yield with EUS guided liver biopsy - Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed.
214998985|NCT04235855|DEVICE|Percutaneous Liver Biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
214998986|NCT01719328|BEHAVIORAL|Vinyasa yoga|
214998987|NCT01859091|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
214998988|NCT02205021|OTHER|No intervention|
214998989|NCT02247544|DRUG|Trabectedin|Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
214998990|NCT04455932|DIAGNOSTIC_TEST|Abbreviated non-contrast MRI of the liver|every 6 months
214998991|NCT04455932|DIAGNOSTIC_TEST|Ultrasound surveillance|every 6 months
214998992|NCT04455932|DIAGNOSTIC_TEST|Multiphase contrast-enhanced liver MRI|screening
215094088|NCT02179541|OTHER|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
215094089|NCT05235919|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|30 minutes rTMS session 5 days/week for 3 weeks.
214390790|NCT00631384|BEHAVIORAL|Individual VCT|Women to receive individual VCT
214390791|NCT01936610|OTHER|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
214390792|NCT01936610|OTHER|lecture|Describe advantages and disadvantages in one 90-min session
214390793|NCT04692844|DRUG|Propranolol|Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
214390794|NCT04692844|DRUG|Primidone|Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
214390795|NCT05097118|DRUG|Ketamine Versus Bupivacaine|Drugs Ketamine versus Bupivacaine
214501627|NCT04388865|BEHAVIORAL|Text-based Clinical Hovering|Subjects will receive remote monitoring via text messaging of clinical symptoms and medication adherence reminders with feedback to social support.
214501628|NCT04726657|DRUG|Premixed Human Isophane Insulin Suspension + Human Insulin Injection|premixed human insulin
214998993|NCT06645847|OTHER|Ketone ester|"Ketone ester (KE) (Chemical name: Bis-octanoyl-(R)-1,3-butanediol, Common name: C8 ketone di-ester) formulated as a dietary supplement.~KE 12.5 g per day for 1 week; followed by KE 25 g per day for 1 week; followed by KE 37.5 g per day split into two doses for 1 week; followed by KE 50 g per day split into two doses for 17 weeks"
215094090|NCT05235919|OTHER|Sham stimulation|30 minutes sham stimulation 5 days/week for 3 weeks.
215094091|NCT03826199|DRUG|TDF-FTC|We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
214390796|NCT02387437|BEHAVIORAL|SI recruitment|SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
214998994|NCT06645847|OTHER|Placebo Comparator: Non-ketone placebo|Placebo oil (non-ketogenic canola oil) formulated as a dietary supplement. Placebo oil 12.5 g per day for 1 week; followed by Placebo oil 25 g per day for 1 week; followed by Placebo oil 37.5 g per day split into two doses for 1 week; followed by Placebo oil 50 g per day split into two doses for 17 weeks
214998995|NCT05306353|DRUG|Placebo for VIB4920|26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)
214998996|NCT05306353|DRUG|VIB4920 with TNFi|52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)
214998997|NCT05306353|DRUG|VIB4920 without TNFi|Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
214390797|NCT02387437|BEHAVIORAL|IP recruitment|Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
214390798|NCT02387437|BEHAVIORAL|PCV recruitment|PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
214501629|NCT04726657|DRUG|Premixed Insulin|Premixed Insulin Analog Biphasic Aspart 30
214998998|NCT04603066|DRUG|Ondansetron 16 mg with Tariquidar|In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
214998999|NCT04603066|DRUG|Ondansetron 16 mg with Placebo|In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
214999000|NCT02363660|BIOLOGICAL|GINI|
214999001|NCT00649948|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
214999002|NCT00649948|DRUG|Glucophage XR 500 mg|500mg, single dose fed
214390799|NCT04216979|PROCEDURE|laparoscopy entry policy|"Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.~Group (B):- The umbilicus is the primary entry site."
214390800|NCT06531135|BEHAVIORAL|T-CBSM|A 10-week remotely-delivered group, lasting about 120 minutes each session.
214390801|NCT06531135|BEHAVIORAL|Support group|Participants will receive weekly supportive-expressive group intervention for two hours per week for five weeks total.
214390802|NCT02523313|DRUG|Nivolumab + Placebo|Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
214390803|NCT02523313|DRUG|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
214390804|NCT02523313|DRUG|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
214390805|NCT04658160|BEHAVIORAL|Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients|access to/use of the tracking platform
214390806|NCT05731882|DEVICE|E-SeaLA, CardioPulse PFA system|First, pulmonary vein isolation(PVI) was performed with the novel hex spline PFA ablation catheter( CardioPulseTM PFA system, Hangzhou Dinova EP Technology Co., Ltd), then, pulsed field ablation and mechanical closure of the left atrial appendage were achieved by E-SeaLATM(Hangzhou Dinova EP Technology Co., Ltd) implantation.
214390807|NCT04169919|DRUG|Povidone-Iodine|Povidone-Iodine 5% eye wash
214390808|NCT04169919|DRUG|Normal Saline Flush|Normal Saline eye wash
214390809|NCT03953404|DIAGNOSTIC_TEST|SPLA2-IIA|bedside blood test
214390810|NCT05141981|DEVICE|inbody device|measure muscle mass
214390811|NCT05744050|BEHAVIORAL|Low energy density lunch|Particpants will be provided with a lunch low in energy density (\~1.1kcal/g)
214390812|NCT05744050|BEHAVIORAL|Medium energy density lunch|Participants will be provided with a lunch medium in energy density(\~1.7kcal/g)
214390813|NCT05744050|BEHAVIORAL|High energy density lunch|Participants will be provided with a lunch high in energy density (\~3kcal/g)
214999003|NCT06666452|BEHAVIORAL|COMFI - a COMbined Fatigue Intervention|The COMFI intervention is a 24-week group-based outpatient fatigue intervention consisting of 1) Six group sessions based on CBA covering topics such as fatigue and related factors, PA, trying out PA, energy management, and enhancing peer support 2) a seventh group session intended as a booster session in week 24, 3) one optional individual session in week 6-9 of the intervention, and 4) a support line in week 13-23 of COMFI.
214999004|NCT04939597|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214999005|NCT04939597|PROCEDURE|Cognitive Assessment|Complete cognitive testing
214999006|NCT04939597|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214390814|NCT00262288|DRUG|i.v. recombinant human C1 inhibitor|
214390815|NCT05889819|DIETARY_SUPPLEMENT|Almond orange potato cookies for stunted under-five children|"Trained enumerator distributed 50 g cookies three times a week during 30 days to the treatment group.~Anthropometry measurement: weight and height measured at pre study, during study (once a week), and post study."
214390816|NCT04262492|DRUG|Rivaroxaban|Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID
214390817|NCT04645238|OTHER|Static Stretching|Static hamstring stretching exercise lasting 30 seconds and 10 repetitions under the supervision of the physiotherapist
214390818|NCT04645238|OTHER|PNF Stretching|PNF hold-relax stretching technique that consists of 10 seconds isometric contraction, 30 seconds hamstring stretching and 10 repetitions under the supervision of the physiotherapist
214390819|NCT04765592|DEVICE|WeFlow-Arch Modeler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
214999007|NCT04939597|DRUG|Memantine Hydrochloride|Given PO
215094092|NCT03826199|BEHAVIORAL|Counselling on PrEP in antenatal and postnatal care|Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.
214390820|NCT01562002|PROCEDURE|Stem Cell with Amniotic Membrane Transplant|Single stem cell expansion in amniotic membrane transplant
214390821|NCT04329104|BIOLOGICAL|VRC-MALMAB0100-00-AB (CIS43LS)|Administered via one-time intravenous infusion
214390822|NCT04329104|OTHER|Normal saline|Administered via one-time intravenous infusion
214390823|NCT05932459|DRUG|Deuremidevir Hydrobromide for Suspension 100mg|Take it with 240ml water in fasted condition.
214390824|NCT05932459|DRUG|Deuremidevir Hydrobromide for Suspension 300mg|Take it with water in fasted condition or after taking infant formula.
214999008|NCT04939597|DRUG|Placebo Administration|Given PO
214999009|NCT04939597|OTHER|Questionnaire Administration|Ancillary studies
214999010|NCT05761249|OTHER|HeartInsight activation|HeartInsight is activated at enrollment. The attending physicians are free on how to integrate HeartInsight in the patient care. Any treatment is based on routine care according to guidleines. Only documentation occurs on how the physicians use HeartInsight and actions taken in response to HeartInsight alerts
214999011|NCT05609864|OTHER|Quantification of injectable drugs wastage|Drugs are prescribed at discretion of physicians. For each patient who have anesthesia in the operating room, all labelled syringes having contained drugs (name + dilution) are collected and analyzed.
214999012|NCT06386029|BEHAVIORAL|Power Down bedtime manipulation|The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for autistic children). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Participants (caregivers and their child) will be educated in the Power Down protocol and data collection methods for the 2 week intervention trial. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.
214999013|NCT05993546|DEVICE|vacuum assisted sheath|allows for simultaneous suction with continuous irrigation throughout the case to enhance visibility and facilitate stone retrieval
214999014|NCT05993546|DEVICE|passive suction via conventional sheath|conventional access sheath for stone retrieval using current technique via passive suction
214999015|NCT04937387|DRUG|FF/VI|FF/VI will be administered.
214999016|NCT04937387|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
214999017|NCT04937387|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
214999018|NCT02708836|PROCEDURE|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
214999019|NCT02708836|DEVICE|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
214999020|NCT02708836|DEVICE|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
214999021|NCT02708836|PROCEDURE|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
214999022|NCT02708836|PROCEDURE|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
214999023|NCT02708836|PROCEDURE|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
214999024|NCT02708836|PROCEDURE|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
214999025|NCT02708836|PROCEDURE|Emergence from anesthesia|"At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand)."
214999026|NCT05197426|DRUG|Oral Azacitidine|Specified dose on specified days
214999027|NCT05197426|OTHER|Placebo|Specified dose of specified days
214999028|NCT06254274|DRUG|RAY1225|Administered SC
214999029|NCT06254274|DRUG|Placebo|Administered SC
214999030|NCT06665633|DRUG|Oxygen 100 % Gas for Inhalation|Oxygen 100% Gas for Inhalation in Hyperbaric Oxygen Therapy Chamber at 1.5 ATA
214999031|NCT06665633|DEVICE|Hyperbaric Oxygen Therapy Chamber|Hyperbaric Oxygen Therapy, 40 treatments, at 1.5 ATA and 100% Oxygen
214999032|NCT04134845|DRUG|Dantrolene/Ryanodex|muscle relaxant
214999033|NCT04134845|DRUG|Placebo|Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
214999034|NCT06668090|BEHAVIORAL|Moderate intensity bike exercise|Participants will do moderate intensity bike exercise for up to one hour thrice weekly for 12 weeks.
214390825|NCT05932459|DRUG|Deuremidevir Hydrobromide for Suspension 25mg|Take it with 240ml water on an empty stomach.
214390826|NCT05932459|DRUG|Deuremidevir Hydrobromide tablets 100mg|Take it with 240ml water in fasted condition.
214501630|NCT00747006|DRUG|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
214999035|NCT06809582|PROCEDURE|The T-Tilt position|"The T-Tilt position is a modified lithotomy position used during retrograde intrarenal surgery (RIRS). In this position:~The patient is placed in a 30-degree Trendelenburg position, meaning the head is slightly lower than the feet.~The surgical side is elevated at a 30-degree angle to improve access to the kidney.~This modified positioning is designed to enhance stone clearance, particularly by facilitating the movement of stone fragments away from the lower kidney calyces, where residual stones often remain. Researchers will compare this position to the standard lithotomy position to determine its impact on stone-free rates and surgical outcomes."
214999036|NCT05010122|DRUG|Decitabine and Cedazuridine|Given PO
214999037|NCT05010122|DRUG|Gilteritinib|Given PO
214999038|NCT05010122|DRUG|Venetoclax|Given PO
214999039|NCT05973045|PROCEDURE|Operative Hysteroscopy 24 Centigrade Degree|Operative hysteroscopy will be performed at room temperature distention medium.
214999040|NCT05973045|PROCEDURE|Operative Hysteroscopy 37 Centigrade Degree|Operative hysteroscopy will be performed using a heated distention medium.
214999041|NCT05102019|DEVICE|Arm 1: treatment with Shockwave Reducer|Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
214999042|NCT05102019|OTHER|Arm 2 (control): Implantation procedure with no device implanted|No device is implanted
214999043|NCT05102019|DEVICE|Arm 3 (unblinded, non-randomized): Single arm registry|Shockwave Reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
214999044|NCT06810583|DRUG|Dalbavancin|3 doses of q28 days dalbavancin (12 weeks).
214999045|NCT06810583|DRUG|Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)|28 days dalbavancin plus fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician) for up to 3 doses (12 weeks).
214999046|NCT07113587|DRUG|Application of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis|
214390827|NCT06768957|OTHER|Single leg hop for distance|"Patients will have to perform a Single leg hop for distance.~A 10-minute warm-up is required beforehand, followed by three single-leg hop round trips over a distance of 6m to ensure that they are able to perform the exercise.~You start on the healthy side to understand the principles and reassure yourself. The distance covered is measured. This tells us something about the strength of the lower limb. The landing should be assessed qualitatively.~1\. Patient balanced on 1 foot, hands crossed over shoulders. 2. Jump as far as possible.~3\. Stabilise 1 time, keeping hands on shoulders."
214999047|NCT07113587|DRUG|Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis|
214999048|NCT07113587|DRUG|Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis|
214390828|NCT06768957|OTHER|Single leg hop for distance plus cognitive task|"Patients were asked to perform a single leg hop for distance in addition to a cognitive task.~A 10-minute warm-up is required beforehand, followed by three single-leg hop round trips over a distance of 6m to ensure that they are able to perform the exercise.~You start on the healthy side to understand the principles and reassure yourself. The distance covered is measured. This tells us something about the strength of the lower limb. The landing should be assessed qualitatively.~1. Patient balanced on 1 foot, hands crossed over shoulders.~2. Observe a sequence of 5 digits, appearing every 4 seconds, on the computer in front of you.~3. As soon as the 5th digit appears, jump as far as you can.~4. Stabilise 1 time, keeping your hands on your shoulders.~5. Replay the sequence of 5 numbers that appear on the screen, in reverse order."
214390829|NCT05285917|DRUG|Hydroxyurea|Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.
214390830|NCT03884231|DEVICE|Infinity DBS System with MR Conditional labelling|Patients implanted with the Infinity DBS system with MR Conditional labeling
214390831|NCT00559910|DRUG|PH-797804|PH-797804 at four dose levels
214390832|NCT00559910|DRUG|Placebo|Placebo
214390833|NCT06345209|DEVICE|Sirolimus-coated Coronary Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Sirolimus-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
214390834|NCT06345209|DEVICE|Drug-coated Coronary Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Drug-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
214390835|NCT01349010|DRUG|Probucol|250mg (1 tablet) bid. p.o for 8 weeks
214390836|NCT01349010|DRUG|Placebo|1 tablet bid. p.o for 8 weeks
214501631|NCT00747006|DRUG|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
214501632|NCT01724905|DIETARY_SUPPLEMENT|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
214390837|NCT00911924|DEVICE|iStent|Glaukos iStent, medication
214999049|NCT07113587|DRUG|Application of intraperitoneal and intravenous ciprofloxacin in automated peritoneal dialysis patients without peritonitis|
214999050|NCT07114887|BEHAVIORAL|Virtual reality for vocational recovery|Intervention is an immersive virtual reality (VR) intervention, delivered through a VR headset, supported by a trained vocational specialist. Intervention content was co-designed with young people with mental health and vocational challenges, and vocational specialists with experiencing supporting this population. Content was guided by goals of vocational programs, including Individual Placement and Support.
214999051|NCT06827054|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
214390838|NCT01548014|DIETARY_SUPPLEMENT|VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).
214390839|NCT00145717|DRUG|Plant sterol enriched milk tea|
214501633|NCT01724905|DIETARY_SUPPLEMENT|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
214501634|NCT01053650|DRUG|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
214999052|NCT06827054|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
214999053|NCT06827054|OTHER|Interview|Ancillary studies
214999054|NCT06827054|DRUG|Psilocybine|Given PO
214999055|NCT06827054|BEHAVIORAL|Psychotherapy|Attend psychotherapy sessions
214999056|NCT06827054|OTHER|Questionnaire Administration|Ancillary studies
214999057|NCT07119333|DEVICE|Air purifiers|Air purifiers
214999058|NCT07119333|DEVICE|Sham air purifiers|Sham air purifiers
214999059|NCT07121530|PROCEDURE|HPV infection in infertile males|To investigate the status of HPV infection in infertile males in Qena government, and to Analyse the effects of HPV infection on semen parameters.
214999060|NCT07121244|DRUG|68Ga-R11228|68Ga-R11228 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions
214999061|NCT07121244|DRUG|177Lu-R11228|177Lu-R11228 is a lutetium-labeled small molecule radioligand designed to treat tumor lesions
214999062|NCT07119567|OTHER|Multimodal Sleep and Biomarker Assessment|Participants will undergo non-invasive sleep assessments including polysomnography recordings (using the Somfit® device), actigraphy, self-reported questionnaires (on sleep, substance use), and urinary biomarker collection (for cortisol and melatonin levels) at three distinct stages of their substance use/withdrawal timeline.
214999063|NCT07120841|BEHAVIORAL|Telephone Education|Participants in this group will receive telephone follow-up education by a nurse during the two weeks after discharge
214687964|NCT00752609|DRUG|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
214999064|NCT07120841|BEHAVIORAL|Standard Care (in control arm)|Participants in this group will receive standard post-discharge care without any follow-up telephone education
214999065|NCT07120334|BEHAVIORAL|PortionSize Ed + MedDiet Support|Full PortionSize Ed app access with personalized dietary feedback, educational videos, 3 virtual sessions with a registered dietitian (RDN), standard of care (for post-stroke with pre-diabetes or T2D) over 12 weeks.
214999066|NCT07120334|BEHAVIORAL|Standard of care for Stroke and Prediabetes or T2D|Uses a basic version of the PortionSize Ed app without feedback or RDN support and receives usual care for stroke recovery and prediabetes or T2D for 12 weeks.
214999067|NCT04597008|DRUG|Treatment group|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed, which is placed right before wound closure at the final stafe of definitive fracture fixation.
214999068|NCT04597008|DRUG|Control group|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed, which is placed right before wound closure at the final stage of definitive fracture fixation.
214999069|NCT06653218|OTHER|No interventions|It is a observational study
214999070|NCT06653218|OTHER|Not have interventions|It is a observational study
214999071|NCT06977555|BEHAVIORAL|Communication Course and skills training|"A multi module intervention where the nurses will learn about communication with mechanically ventilated patients will be developed. The investigators hypothesize that this intervention will:~1. make it easier for mechanically ventilated ICU patients to communicate their needs and symptoms during mechanical ventilation and to improve their symptom burden.~2. improve ICU nurses' skills in communicating with ICU patients who are unable to speak. This will potentially contribute to better communication with critically ill patients, including those being delirious.~3. improve ICU nurses´ satisfaction with their communication."
214999072|NCT06653842|DRUG|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% Rapamycin Anhydrous Gel
214999073|NCT06653647|BEHAVIORAL|Guided Imagery Therapy|Participants will be asked to listen to a pre-recorded, 10 to 15 minute guided imagery therapy (GIT) session via mobile application 5 out of 7 days per week for 8 weeks in addition to their usual care for their abdominal pain.
214999074|NCT06977711|DRUG|Loncastuximab|Intravenous (IV) administration 0.15 mg/kg day 1 cycles 1-2, and 0.075mg/kg day 1, cycles 3-5
214999075|NCT06977711|DRUG|Roflumilast|Oral administration of 500mcg days 1-21, cycles 1-8
214999076|NCT06977711|DRUG|Rituximab|IV administration of 375mg/m2 day 1, cycles 1-8
214999077|NCT06977711|DRUG|Cyclophosphamide|IV administration of 750mg/m2 day 1, cycles 3-8
214999078|NCT06977711|DRUG|Vincristine|IV administration 1.4mg/m2 (max 2mg) day 1, cycles 3-8
214999079|NCT06977711|DRUG|Doxorubicin|IV administration 50mg/m2 day 1, cycles 3-8
214999080|NCT06977711|DRUG|Prednisone|Oral administration 100mg/days 1-5, cycles 3-8
214999081|NCT06978088|DRUG|LP-168|Patients will receive LP-168 200 mg daily beginning day 1 of therapy for 12 cycles.
214999082|NCT06978088|DRUG|Obinutuzumab|Patients will with LP-168 and then receive obinutuzumab for a total of 6 cycles, beginning cycle 7, days 1, 2, 8 and 15, and then day 1 of cycles 8-12. A minimum of 12 cycles of therapy will be administered.
214999083|NCT06976476|DRUG|IgPro20|Will be administered in addition to Standard of Care treatment. IgPro20 is intended for subcutaneous administration using an infusion pump
214999084|NCT03124355|DRUG|placebo sugar pill|placebo single oral dose
214999085|NCT03124355|DRUG|Pyridostigmine Pill|pyridostigmine bromide 30 mg single oral dose
214999086|NCT03124355|DRUG|Galantamine Pill|Galantamine hydrobromide 8mg single oral dose
214999087|NCT03124355|DEVICE|Vagal stimulation|Vagal stimulation will be given at 50 Hz during the tilt table tests
214999088|NCT03124355|DEVICE|Sham vagal stimulation|Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
214999089|NCT07125248|PROCEDURE|Bilateral chest tube placement|Bilateral chest tubes will be passed in this intervention group through intercostal spaces
214999090|NCT07125248|PROCEDURE|Single drain placement|A single transhiatal drain will be placed in mediastinum in this group
214999091|NCT06979128|PROCEDURE|PICC placement|Patient scheduled for PICC placement
214999092|NCT06084247|DEVICE|Curved KARL STORZ fetoscope|The KARLZ STORZ curved scope is used to see the inside of a pregnant person's uterus during minimally invasive surgery, similar to conventional scopes. The curved scope is rounded and thought to help visualize the anterior placenta because of its position on the uterus.
214999093|NCT06084247|DEVICE|Conventional Scopes|The conventional scopes are regularly used during laser photocoagulation of placental anastomoses.
214999094|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
215094093|NCT03242252|DRUG|Placebo|"Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral"
214390840|NCT04917380|OTHER||Retrospective clinical study，no intervention
214390841|NCT01853254|DRUG|Peginterferon alfa-2a|Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
214687965|NCT06286319|DEVICE|Angel Cooler|Device that provides cooled oxygen (between 4-8°C) directly to the lung airways along with external cooling to lung surfaces using cold preservation solutions.
214390842|NCT01853254|DRUG|Ribavirin|For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing \< 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
214999095|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium gluconate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
214390843|NCT02359149|PROCEDURE|intravitreal injections given by a nurse|
214390844|NCT02359149|PROCEDURE|intravitreal injections given by a physician|
214390845|NCT02359149|PROCEDURE|Intravitreal injections|
214390846|NCT02359149|DRUG|Anti-VEGF agents|
214390847|NCT03420235|OTHER|Home monitoring program|The home monitoring program consists of 1) the use of an interactive internet tool to coach patients and enhance self-management 2) home-based pulmonary function testing with a handheld spirometer and 3) recording of patient-reported outcomes (PROs).
214390848|NCT02653014|DRUG|KBP-5074|
214390849|NCT02679768|BEHAVIORAL|Circadian Reinforcement Therapy|Circadian reinforcement therapy plus electronical monitoring. Circadian reinforcement therapy is a specialized psychoeducation working with strengthening of circadian rhythms.
214390850|NCT02679768|BEHAVIORAL|Standard treatment|Standard treatment plus electronical monitoring
214390851|NCT04055506|DRUG|BMS-986165|Dose 1
214390852|NCT04055506|DRUG|Ritonavir|100 mg
214390853|NCT06469073|PROCEDURE|Transversus thoracic muscle plane block or Erector spinal plane block|Transversus thoracic muscle plane block or Erector spinal plane block
214390854|NCT01854294|DRUG|GM604|GM604 treated group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
214390855|NCT01854294|DRUG|Placebo comparator|Placebo comparator group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
214390856|NCT03753282|OTHER|questionnaires for patient reported outcome|"questionnaires with respect to outcomes:~* Reoperations~* Short term complications~* Long term complications~* EQ-5D (current)~* HOOS (current)~* disease related change of occupation~* use of walking aids~* comorbidities~* medication"
214501635|NCT03926026|DRUG|Fluticasone Propionate|NCX 4251 Ophthalmic Suspension, 0.1%
214501636|NCT03926026|DRUG|Placebo|NCX 4251 Ophthalmic Suspension, 0%
214501637|NCT01681563|DRUG|Pentostatin|Lyophilized powder for intravenous administration.
214501638|NCT01681563|DRUG|Cyclophosphamide|IV
214501639|NCT01681563|DRUG|Ofatumumab|Liquid concentrate for solution for infusion.
214501640|NCT03055598|DRUG|Ferric Citrate|Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
214390857|NCT03753282|OTHER|questionnaire for course of the disease|"questionnaires to assess course of the disease:~* from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA)~* therapeutic interventions"
214390858|NCT02903628|BEHAVIORAL|eye health education|give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
214390859|NCT03823976|OTHER|Types of the dental procedures in general anaesthesia|Analysis of the mean number of preventive, prophylactic, therapeutic and rehabilitation procedures
214390860|NCT05471869|DIAGNOSTIC_TEST|Aneurysm diagnosis|Intelligent detection and diagnosis of aneurysm diagnosis by CTA
214390861|NCT03279705|DEVICE|Water jet channel|The separate water jet channel was used for infusing water.
214390862|NCT03279705|DEVICE|Accessory channel|The accessory channel was used for infusing and/or suctioning water
214390863|NCT03674606|DRUG|Low dose aspirin|One 75 mg aspirin dose taken daily
214390864|NCT03106961|DEVICE|Bioresorbable vascular scaffolds, OCT, non-compliant ballooning|Measure the effect of high-pressure, NC ballooning on scaffold embedding by OCT
214390865|NCT05760729|DIAGNOSTIC_TEST|Cognitive testing|Cognitive tests will be carried: MOCA, trail making test, digit symbol substitution, forward and backward digit testing.
214390866|NCT04176133|DRUG|Entolimod|Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
214390867|NCT04176133|DRUG|Placebo|Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
214390868|NCT04176133|DRUG|Influenza vaccine|Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
214501641|NCT05964023|DEVICE|pBFS rTMS|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
214501642|NCT05964023|DEVICE|5-cm rTMS|"Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be localized by 5-cm rule."
214501643|NCT05917236|PROCEDURE|hepato-portoentostomy|the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation)
214501644|NCT01035372|DIETARY_SUPPLEMENT|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
214501645|NCT06159959|DRUG|Carbetocin|To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
214501646|NCT03106259|DRUG|FURESTEM-RA Inj.|Non-interventional observational study
214501647|NCT00345046|DRUG|Pred Forte|Four drops daily decreasing to once daily over four weeks.
214501648|NCT00345046|DRUG|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
214501649|NCT00345046|DRUG|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
214999096|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
215094094|NCT03242252|DRUG|Sotagliflozin|"Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral"
214999097|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
214999098|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
214999099|NCT06237712|DIETARY_SUPPLEMENT|Placebo caps|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
214999100|NCT04616313|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
214390869|NCT04327908|OTHER|Questionaire TESS and MSTS|answering TESS and MSTS questionnaire
214390870|NCT06480643|OTHER|High load exercise type|Heavier load, fewer reps
214390871|NCT06480643|BEHAVIORAL|Low load exercise type|Lighter load, more reps
214999101|NCT04616313|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
214390872|NCT05687617|DRUG|Indocyanine green|0,25mg/kg IV at the start of the surgery,
214390873|NCT01645332|DRUG|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
214999102|NCT04616313|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
214999103|NCT04616313|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity
214999104|NCT04616313|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
214999105|NCT04616313|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
214999106|NCT04616313|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
214999107|NCT06258447|DEVICE|Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system|the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization.
214999108|NCT05583877|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
215094095|NCT01983124|DRUG|Fotemustine + Vemurafenib|"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."
214390874|NCT01645332|DRUG|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
214390875|NCT01645332|OTHER|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
214390876|NCT01890902|DRUG|Ketoprofen 10% Cream|
214390877|NCT01890902|DRUG|Placebo|
214390878|NCT01755286|DRUG|OTO-201|Single intra-operative injection
214390879|NCT01755286|DRUG|Placebo|Single intratympanic injection
214390880|NCT01755286|DRUG|Sham|Simulated single intratympanic injection
214390881|NCT00280423|DRUG|GW679769|
214390882|NCT01730781|RADIATION|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
214390883|NCT00210665|DRUG|Trabectedin|Type= exact number, unit= mg/m2, number= 1.5, form= intravenous infusion, route= intravenous use. 1.5mg/m2 as 24hr infusion on day 1 of each 21 day cycle
214390884|NCT00380887|DRUG|Premarin|
214390885|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)|Blood pass through infusion set without external pressure.
214390886|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg|Blood pass through infusion set under external pressure (150mmHg)
214390887|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg|Blood pass through infusion set under external pressure (200mmHg)
214390888|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg|Blood pass through infusion set under external pressure (250mmHg)
214390889|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg|Blood pass through infusion set under external pressure (300mmHg)
214390890|NCT03652480|DRUG|MethylPREDNISolone Acetate 40 MG/ML|
214390891|NCT00936338|BEHAVIORAL|splint and joint mobilization self exercise|
214390892|NCT06458829|BEHAVIORAL|SEARCH-AF|SEARCH-AF program will include opportunistic screening among old adults during primary care visits and promoting strategies. Promoting strategies will be developed based on the Consolidated Framework for Implementation Research framework which may include leadership engagement, policy support, providing screening resources, atrial fibrillation screening and management training. General practitioner or nurse in each health care center will implement point-on-care screening. The intervention will last for six months and followed up for another six months.
214390893|NCT02977065|DRUG|Atorvastatin 20mg|PO daily for 4weeks
214390894|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 50 mg|PO daily for 4weeks
214390895|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 100 mg|PO daily for 4weeks
214390896|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 200 mg|PO daily for 4weeks
214390897|NCT02977065|DRUG|Rosuvastatin 10 mg|PO daily for 4weeks
214390898|NCT02977065|DRUG|Rosuvastatin 10 mg + CKD-519 100 mg|PO daily for 4weeks
214999109|NCT05583877|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
215094096|NCT04821323|DRUG|Indomethacin|Indomethacin capsules will be administered orally.
215094097|NCT04821323|DIAGNOSTIC_TEST|Lactulose-mannitol|Lactulose-mannitol solution will be administered orally.
215094098|NCT02805231|OTHER|Vitamin D receptor polymorphic analysis|
215094099|NCT05323071|OTHER|Sucrose 24%|"According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, \>37 weeks : 1 mL"
215094100|NCT01659255|DRUG|Tirabrutinib|Capsules administered orally
215094101|NCT02192229|DRUG|50.000 IU vitamin D3 (Biodal 50,000 IU)|
215094102|NCT02192229|DRUG|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
215094103|NCT00012363|DRUG|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 \& 8, q 21 days
215094104|NCT00012363|DRUG|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 \& 8, q 21days
215094105|NCT05019989|BEHAVIORAL|Intervention group on diet and physical activity|"The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~1. Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~2. Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~3. Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)"
215094106|NCT05019989|BEHAVIORAL|Control group: only public recommendation an lifestyle|"1. Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~2. Dissemination of the information on the study by media~3. Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
214390899|NCT04402593|BEHAVIORAL|Modified Heidelberg Model of Neuro-Music Therapy|6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
214390900|NCT05200390|DEVICE|Continuous glucose monitor|FreeStyle Libre 2 system
214390901|NCT00061620|DRUG|Tezacitabine (FMdC)|7.5 mg/m2 bolus infusion daily x 5
214390902|NCT01169259|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
214390903|NCT01169259|DRUG|omega-3 fatty acids (fish oil)|Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
214390904|NCT01169259|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
214390905|NCT01169259|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
214390906|NCT03728153|DRUG|Fluoxetine 20 MG Oral Tablet|Once-daily dosing for 90 days
214390907|NCT00555204|DRUG|ABT-089|10 mg - capsules once daily for 12 weeks
214501650|NCT03667833|OTHER|Shoulder brace|Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
214501651|NCT04707170|DEVICE|MRI with gadolinium injection|"Patients presenting for imaging for whom an MRI examination with gadolinium injection has been prescribed and who meet the inclusion and non-inclusion criteria will be offered to participate in the study.~The patients included, hospitalized at the A. de Rothschild Foundation Hospital for at least 24 hours, may be included in the ancillary study to meet secondary objective number 5."
214687966|NCT04246528|BEHAVIORAL|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
214687967|NCT03115333|DIAGNOSTIC_TEST|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
215094107|NCT00131651|DRUG|ATN-161|
215094108|NCT04397965|DEVICE|Cascade Continuous Glucose Monitor|Continuous Glucose Monitoring
215094109|NCT05962359|BEHAVIORAL|Parent-Implemented Communication Treatment|The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
214687968|NCT03969706|DRUG|Abemaciclib 200 MG|Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
214390908|NCT00555204|DRUG|ABT-089|5 mg - capsules once daily for 12 weeks
214390909|NCT00555204|DRUG|ABT-089|15 mg - capsules once daily for 12 weeks
214390910|NCT00555204|DRUG|ABT-089|20 mg - capsules once daily for 12 weeks
215094110|NCT00066547|BIOLOGICAL|monoclonal antibody HuHMFG1|
214390911|NCT00555204|DRUG|ABT-089|30 mg - capsules once daily for 12 weeks
214390912|NCT00555204|DRUG|ABT-089|35 mg - capsules once daily for 12 weeks
214390913|NCT00555204|DRUG|placebo|placebo - capsules once daily for 12 weeks
214390914|NCT06530524|DRUG|OnabotulinumtoxinA|Injection of onabotulinumtoxinA into the at-risk major salivary glands
214390915|NCT06530524|DRUG|Placebo|Injection of normal saline into the at-risk major salivary glands
214390916|NCT05612776|OTHER|HIIT|HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.
214390917|NCT05612776|OTHER|HRV|The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.
214501652|NCT05608070|DRUG|Oxytocin|Oxytocin 30 IU in 500 ml IV at a rate of 5 IU/h (83.33 ml/h). The infusion will be started intra-operative once the uterus is removed and will continue to run until completion of the medication or discharge from PACU criteria are met, whichever occurs first.
215094111|NCT04637919|BIOLOGICAL|IN-B001 EV71 A dose|Inactivated vaccine against EV71, three doses, 28 days interval
214390918|NCT05054127|OTHER|foiiow up patients|observational study
214390919|NCT01017120|DRUG|Tazarotene Foam|Tazarotene foam once a day application to the face
214999110|NCT05584059|BEHAVIORAL|Focused Acceptance and Commitment Therapy|This is an individual-based FACT counselling programme which composes of 4-6 sessions on a weekly basis (45-60mins/session). All the sessions are delivered by a trained FACT interventionist via either video-conferencing (e.g., Zoom or Windows Teams) or face-to-face format. The programme aims to increase the psychological flexibility of the parent, so that he/she is able to (i) experience the present moment and take perspective on self (i.e., Awareness); (ii) detach the distressing private experiences and associated rules and to take a non-judgemental, accepting stance toward the painful experiences (i.e., Openness) and (iii) exhibits strong connection with values and commit to values-consistent actions. The trained interventionist will use different ACT strategies in these sessions, including ACT metaphors, experiential exercises, guided mindfulness exercises, guided imagery exercises and values clarification exercises to reinforce the above principles.
214687969|NCT05079841|DEVICE|Electric breast pump|Participants randomized to the intrapartum nipple stimulation will use electric breast pump or nipple stimulate by hand (if preferred) (intervention) to induce labor for at least 2 hours
214999111|NCT06980480|BIOLOGICAL|IGI, 10%|IGI, 10% IV infusion.
214999112|NCT06980012|PROCEDURE|Pharmaceutical consultation|The pharmaceutical interview is a structured way of carrying out an optimized medication review with the patient. This interview takes place at the time of the first prescription of oral anti-cancer treatment.
214999113|NCT06980012|PROCEDURE|Pharmaceutical consultation and follow-up|After the first prescription and at the treatment renewal date (+/- 2 days), the hospital pharmacist will contact the dispensing pharmacist to inform him/her of the patient's treatment, and then as part of the follow-up to detect any problems with treatment compliance (non-renewal of treatment by the patient, lack of follow-up, complaints of adverse effects by the patient). These events will be recorded in the observation book.
214999114|NCT06979583|DEVICE|4.8 Fr Ureteral stents|After surgery, patients will have the Boston Scientific 4.8 Fr ureteral stent placed.
214999115|NCT06979583|DEVICE|7 Fr Ureteral stents|After surgery, patients will have the Bard 7 Fr ureteral stent placed.
214999116|NCT06106477|BEHAVIORAL|Intermittent Fasting|"Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of:~* An approximately fourteen-hour nightly fasting period that is followed by~* An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM)."
214999117|NCT05744479|DRUG|Metformin|Metformin oral, 2000mg/day, for 24 weeks.
214999118|NCT05744479|DRUG|Placebo|Oral placebo for 24 weeks
214999119|NCT05744479|BEHAVIORAL|Lifestyle Intervention|Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
214999120|NCT05879146|DRUG|Nirogacestat|Given by PO
214999121|NCT06815627|DRUG|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
214390920|NCT01017120|DRUG|Vehicle Foam|Vehicle Foam once a day application to the face
214390921|NCT00284375|PROCEDURE|Registration of all big toe prostheses in Ghent University Hospital|Registration of all big toe prostheses in Ghent University Hospital.
214390922|NCT04764929|DEVICE|Helmet CPAP|Vyatil nonpowered oxygen tent system
214390923|NCT05620030|OTHER|Univentricular Heart|Prevention of complications when discovered
214390924|NCT04539119|DRUG|Tenofovir|Participants will be given tenofovir 300mg (1 capsule) qd po two weeks before the first cycle of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Tenofovir will be given until the copy count of HBV DNA drops below 1\*10\^3/L.
214390925|NCT04539119|DRUG|Entecavir|Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
214687970|NCT05079841|DRUG|Exogenous oxytocin intravenous infusion without nipple stimulation.|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor as current standard of care
214999122|NCT06815367|DEVICE|Pneumatic Compression|Following downhill running protocol, participants will complete 20 minutes of pneumatic compression at 100 mmHg.
214999123|NCT06815367|DEVICE|Blood Flow Restriction|Following the downhill running protocol, participants will complete 4 rounds of treatment: 3 minutes at 100% resting limb occlusion pressure, 2 minutes of 0% resting limb occlusion pressure.
214999124|NCT06841562|BEHAVIORAL|TRAINERa intensive exercise training|Remotely-delivered exercise training intervention
214999125|NCT06814977|PROCEDURE|Acupuncture|Acupuncture is a non-pharmacological intervention that does not involve the use of any therapeutic agents or devices. Participants will receive 10 weekly treatments over 10 weeks.
214999126|NCT06587282|DEVICE|Bloom Micro Occluder System|Percutaneous transcatheter closure of PDA using Bloom Micro Occluder System
214999127|NCT06587113|OTHER|Visual tasks|In the experiments, participants sit in front of a computer screen with their head in a chinrest to control for distance from the monitor and eye-tracking equipment. For the visual search task, participants will search for a visual target among distractors and make a response regarding its orientation. For the stop-signal task, participants will make an eye movement to a target that appears on the screen, except on trials where a visual signal appears indicating they should cancel this behavior. In the useful field of view task, participants will report the location of a briefly-presented and masked target, while also responding to the identify of a central target in some blocks.
214999128|NCT01371981|DRUG|Asparaginase|Given IM
214999129|NCT01371981|DRUG|Bortezomib|Given IV
214999130|NCT01371981|DRUG|Cytarabine|Given IT or IV
214999131|NCT01371981|DRUG|Daunorubicin Hydrochloride|Given IV
214999132|NCT01371981|DRUG|Etoposide|Given IV
214999133|NCT01371981|OTHER|Laboratory Biomarker Analysis|Correlative studies
214390926|NCT01087723|DRUG|Bivalirudin|
214390927|NCT01087723|DRUG|Heparin|
214390928|NCT01095705|PROCEDURE|Conventional procedure|Local anaesthesia (Lidocaïne)
214390929|NCT01095705|PROCEDURE|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
214390930|NCT02717013|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing calcium lactate similar to the HMB capsules.
214390931|NCT02717013|DIETARY_SUPPLEMENT|HMB|HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
215094112|NCT04637919|BIOLOGICAL|IN-B001 CVA16 B dose|Inactivated vaccine against CVA16, three doses, 28 days interval
214390932|NCT00252590|BEHAVIORAL|Health Motivational Feedback|Personalized feedback on health status
214390933|NCT00252590|BEHAVIORAL|Health Education|Generalized health education related to alcohol use
214390934|NCT00252590|BEHAVIORAL|Control - treatment as usual|Control group with no additional intervention
214390935|NCT00079794|DRUG|Iscar|
214390936|NCT00079794|DRUG|mistletoe|
214390937|NCT05332574|BIOLOGICAL|GB263T|Participants will receive IV infusions of GB263T at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive GB263T at predefined dose levels and frequency, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days.
214999134|NCT01371981|DRUG|Mitoxantrone Hydrochloride|Given IV
214999135|NCT01371981|OTHER|Pharmacological Study|Correlative studies
215094113|NCT04637919|BIOLOGICAL|IN-B001 Bivalent C dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
215094114|NCT04637919|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
215094115|NCT05455177|OTHER|Digital first-line intervention for osteoarthritis including exercise and education|The digital OA management programme was delivered by a smartphone application, including education and exercises based on a face-to-face osteoarthritis self-management programme provided nationwide in Sweden and designed according to national and international guidelines. Over 12 weeks, which is the recommended minimum duration of a self-management intervention for OA, a total of 163 exercise sessions and 31 educational sessions are provided.
215094116|NCT00958932|BEHAVIORAL|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
214390938|NCT03188614|DRUG|Fluid resuscitation|The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
214390939|NCT04873622|BEHAVIORAL|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
214390940|NCT00289770|BIOLOGICAL|Twinrix™|Intramuscular injection, 3 doses
214390941|NCT03836898|DEVICE|Presbyopic posterior chamber phakic intraocular lens IPCL|Presbyopic posterior chamber phakic intraocular lens IPCL (EyeolUK, United Kingdom) has a refractive optic and diffractive trifocal pattern on its anterior optical surface to correct both distance and near refractive errors. Presbyopic addition is manufactured in a range of +1.0 to + 4.0 diopters (D) in 0.5 D steps.
214390942|NCT02054312|BEHAVIORAL|Family Based Interpersonal Psychotherapy (FB-IPT)|
214390943|NCT02054312|BEHAVIORAL|Client Centered Therapy (CCT)|
214390944|NCT00893568|OTHER|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
214390945|NCT05993195|DEVICE|Conduit Titanium Interbody Graft|The Concorde Bullet Device is compared with Conduit Titanium Interbody Graft for lumber fusion in terms of reoperation rates at 2 years.
214390946|NCT05993195|DEVICE|Concorde Bullet Device|This traditional device is to compare the clinical results of the new Conduit Titanium Interbody device for lumbar fusion
214390947|NCT04746430|DRUG|Dexamethasone|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
214390948|NCT01918293|DEVICE|SMART ARM|The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
214390949|NCT01508143|DRUG|Misoprostol 400 micrograms|Misoprostol 400 micrograms each 6 hours for 8 dose
214390950|NCT01508143|DRUG|Misoprostol 800 micrograms|Misoprostol 800 micrograms each 12 hours for 4 doses
214390951|NCT01565018|DRUG|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
214999136|NCT01371981|OTHER|Quality-of-Life Assessment|Ancillary studies
214999137|NCT01371981|OTHER|Questionnaire Administration|Ancillary studies
214999138|NCT01371981|DRUG|Sorafenib Tosylate|Given PO
214999139|NCT06590974|DRUG|Freeze-dried Human Protein C Concentrate|Freeze-dried Human Protein C Concentrate (TAK-662) intravenous injection
215094117|NCT05394480|DIAGNOSTIC_TEST|Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.|Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
214501653|NCT05608070|DRUG|Placebo|0.9% saline infusion at the rate of 83.3 ml/h.
214390952|NCT01565018|DRUG|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
214390953|NCT03134378|DRUG|Rabeprazole Sodium 20mg|Twice daily
214390954|NCT03134378|DRUG|Clarithromycin 500mg|Twice daily
214390955|NCT03134378|DRUG|Amoxicillin 500 Mg|Twice daily
214390956|NCT01615588|DIETARY_SUPPLEMENT|Manuka Honey|honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
214390957|NCT01158430|BEHAVIORAL|ACT group therapy|Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions \& 1 booster session 1 month after 9th session, a total of 35.5 hours
214390958|NCT00498836|DRUG|CP-4055|CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion
214390959|NCT00498836|DRUG|Sorafenib (Nexavar)|Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing
214390960|NCT02916992|RADIATION|CT scan of the thorax|A low dose CT scan of the thorax (2mSv) wil be performed once.
214390961|NCT02916992|GENETIC|blood sample for FLCN mutation analyses|A venous punction in order to withdraw 16ml blood is undertaken once.
214501654|NCT00387075|PROCEDURE|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, \[123I\]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
214999140|NCT06593886|DEVICE|BabyG|This involves wearing a harness connected to the overhead device while in a 10 X 10 play area filled with toys and equipment commonly used for infants to promote mobility skills (e.g. crawling and walking). Families can choose to come for 3 30-minute or 2 45-minute sessions per week. Half of the children will participate in the training immediately after enrollment in the study, the others will wait for 12 weeks before starting training. All will receive a comprehensive assessment at 0, 12 and 24 weeks, with additional developmental assessments at 6 and 18 weeks
214999141|NCT06590727|OTHER|Distress Thermometer|Enrolled patients will be given a clinical psychological interview. Then they will be given an anamnestic interview and the aforementioned questionnaires will be administered.
214390962|NCT01702428|BIOLOGICAL|Priorix|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
214390963|NCT01702428|BIOLOGICAL|M-M-R II|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
214390964|NCT01702428|BIOLOGICAL|Varivax|Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
214390965|NCT01702428|BIOLOGICAL|Havrix|Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
214390966|NCT01702428|BIOLOGICAL|Prevnar 13|US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
214390967|NCT05491343|DRUG|MedroxyPROGESTERone Injection [Depo-Provera]|The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
214390968|NCT05491343|DEVICE|Other|Follow up using US
214999142|NCT06502860|OTHER|skin to skin with sling|In the intervention group, skin-to-skin contact will be facilitated using a specially designed sling. This approach aims to enhance the quality and duration of skin-to-skin contact between the mother and the newborn.
214390969|NCT04995497|DRUG|Intravenous Administration of Lidocaine Post Cardiac Surgery|Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
214390970|NCT04995497|DRUG|Administration of Lidocaine Post Cardiac Surgery via ESP Catheter|Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
214390971|NCT04958928|PROCEDURE|Catheter ablation|All patients received radiofrequncy ablation.
214390972|NCT00154063|DRUG|E2007|
214390973|NCT00154063|OTHER|Placebo|
214390974|NCT00807690|DRUG|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
214390975|NCT04155437|BEHAVIORAL|Health Facility Level Interventions|"* Intensified counseling on maternal dietary diversity and quality using job aids~* Counseling on purpose of IFA supplementation, managing side effects, and importance of adherence to daily consumption~* Distribution/prescription of IFA tablets at each ANC visit~* Use of pill card/reminders for pregnant women and their spouses~* Monthly IFA tablet stock monitoring to assure sufficient supplies~* Measurement of weight gain during each ANC visit and advise on healthy weight gain~* Checks for functioning scales and use of monitoring sheets~* Intensified counseling on early initiation of breastfeeding and exclusive breastfeeding using job aids~* Reminder on importance of early ANC attendance and 4+ visits"
214501655|NCT00387075|DRUG|[123I]β-CIT|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
214501656|NCT02824198|BIOLOGICAL|CYD Dengue Vaccine (5 dose formulation)|0.5 mL, Subcutaneous
214501657|NCT02824198|BIOLOGICAL|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
214501658|NCT00562094|DRUG|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
214999143|NCT06986512|PROCEDURE|bronchoscopy|We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF)
214999144|NCT06857344|PROCEDURE|AI Controlled General Anesthesia|During gastrointestinal endoscopy, anesthesia will be induced using ciprofol, and controlled by an AI model.
214999145|NCT06857344|PROCEDURE|General Anesthesia (GA)|Anesthesia will be induced using ciprofol, and controlled by experienced anesthesiologists.
214999146|NCT03472092|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
214999147|NCT03472092|DRUG|Placebo|The placebo pill will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study.
214390976|NCT04155437|BEHAVIORAL|Community Level Interventions|"* Advocacy among community leaders (traditional and religious leaders, local associations, etc.) about ANC~* Gatherings among grandmothers, husbands, and other influencers about ANC and their roles~* Promotion of ANC service utilisation and the importance of early ANC visit during the first trimester.~* Early identification of pregnant women~* Support women's group discussions~* 2-3 home visits per pregnant woman by community health workers (Agent de santé a base communautaire; ASBC) which will include counseling on diet quality, breastfeeding, importance on adherence to daily IFA consumption and side effect management, etc."
214390977|NCT04155437|BEHAVIORAL|Health System Level Interventions|"* Training on nutrition interventions during ANC for all ANC providers and community health workers~* Semi-annual supervision by the Regional Health Directorate (Direction Regionale de la Santé; DRS)~* Quarterly supportive supervision of health facility staff by the health district management team~* Monthly supportive supervision of ASBCs~* Monthly review between health facilities and ASBCs~* Training and use of data registers~* Training and use of mother's cards to record up to 8 ANC visits and nutrition services~* Training on data utilization to improve coverage and quality"
214390978|NCT05756452|DIAGNOSTIC_TEST|Anamnesis and clinical evaluation|All partecipants will undergo a global echocardiographic evaluation, a 24-hour ECG Holter recording to assess HRV and blood samples collection for neurotransmitter measurements, platelet activation and reactivity evaluation and inflammatory profile assessment by proteomics analysis, inflammasome activity evaluation, NLRP3, pro-IL-18 and pro-IL-1β expression level by qPCR and epigenetic analysis.
214390979|NCT00072852|DRUG|Irinotecan|
214390980|NCT00839774|OTHER|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
214390981|NCT00839774|OTHER|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
214390982|NCT00839774|OTHER|White wheat flour|White wheat flour will be administered at 50 g/day
214390983|NCT02091869|OTHER|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
214390984|NCT02091869|DEVICE|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
214390985|NCT05293288|DEVICE|EEG-guided general anesthesia|pEEG monitoring will start with the beginning of induction of general anesthesia and will end with the end of surgery (surgical suture). In the EEG-guided group, depth of anesthesia will be adjusted to target PSI values between 25 and 50 and spectral edge frequency between 10 and 15. In case of contradictory values, the raw EEG waveforms, ARTF, EMG, as well as the overall clinical situation will be evaluated for decision making.
214390986|NCT01403389|DRUG|Eculizumab|1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
214390987|NCT01403389|DRUG|Placebo|240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
214501659|NCT03944694|DIAGNOSTIC_TEST|Delirium assessment.|Full blood count analysis.
214501660|NCT01144559|PROCEDURE|Continuous Infusion|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
214501661|NCT01144559|PROCEDURE|Bolus Administered|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
214999148|NCT03472092|DRUG|Amitriptyline|Amitriptyline will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study. For this study, a dose of 0.25 mg/kg/day will be provided for the 1st 2 weeks, followed by a dose of 0.5 mg/kg/day for 2 weeks, 0.75 mg/kg/day for 2 weeks and a maximum dose of 1.0 mg/kg/day for 2 weeks based on tolerability. Participants experiencing tolerability issues, may be held a current dose rather than titrated to the next dosage if deemed appropriate by the study doctor.
214999149|NCT03472092|BEHAVIORAL|Biofeedback-Assisted Relaxation Training (BART)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
214999150|NCT03472092|BEHAVIORAL|Cognitive Reappraisal Training (CR)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
214999151|NCT06855810|DRUG|Venetoclax|All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. For all ETP/near-ETP T-ALL patients, venetoclax will replace daunorubicin in induction therapy. CAT will replace CAT+ during early intensification. Venetoclax will replace daunorubicin in interim therapy 2 and 4. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
214687971|NCT03334617|DRUG|Durvalumab|Durvalumab given IV at 1500 mg Q4W ±2 days
214501662|NCT01600482|DEVICE|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
214687972|NCT03334617|DRUG|AZD9150|AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
214687973|NCT03334617|DRUG|AZD6738|AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
214999152|NCT06855810|DRUG|Dasatinib|All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. All non-ETP T-ALL patients will receive dasatinib after initial window phase in induction therapy. For non-ETP T-ALL patients with MRD \<0.01% on day 46, CAT will replace CAT+ during early intensification, and patients will be continuously subjected to dasatinib combined with chemotherapy during early intensification, interim tharapy, reinduction therapy and maintenance therapy. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
214999153|NCT06855810|DRUG|homoharringtonine|All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. All non-ETP T-ALL patients will receive dasatinib after initial window phase in induction therapy. For non-ETP T-ALL patients with MRD ≥0.01% on day 46，CAT+ will be replaced with randomized doses of homoharringtonine (HHT) during early intensification, and HHT will be administrated during reinduction therapy. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
214999154|NCT06483737|DRUG|Human albumin infusion at a modified dosage|Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.
214999155|NCT06483737|DRUG|Human albumin infusion at a routine dosage|Participants receive intravenous infusion of human albumin according to the current clinical practice.
214999156|NCT06483737|DRUG|Lactulose|All participants will receive standard treatment of overt HE according to the current practice guideline.
214999157|NCT06483737|DRUG|Rifaximin|All participants will receive standard treatment of overt HE according to the current practice guideline.
214999158|NCT06483737|DRUG|Ornithine Aspartate|All participants will receive standard treatment of overt HE according to the current practice guideline.
214999159|NCT06483737|DRUG|Branched-Chain Amino Acids|All participants will receive standard treatment of overt HE according to the current practice guideline.
214999160|NCT06483737|DRUG|Arginine|All participants will receive standard treatment of overt HE according to the current practice guideline.
214999161|NCT06661655|DEVICE|Liver ultrasound|Hepatoscope is a point of care ultraportable ultrasound device that is capable of conventional grayscale ultrasound imaging, of 2D transient elastography (imaging + liver stiffness measurement), and of quantitative ultrasound properties measurement (ultrasound attenuation, backscattering coefficient, sound speed) related to liver steatosis.
214999162|NCT06662539|DRUG|Petrelintide|Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
214999163|NCT06662539|DRUG|Placebo|Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
214999164|NCT06659757|DRUG|KIT2014|KIT2014 will be administered by inhalation with a nebuliser
214390988|NCT01177202|BIOLOGICAL|HAC1 Vaccine|Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
214501663|NCT03689946|DRUG|Evolocumab|"Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector."
214501664|NCT03689946|DIAGNOSTIC_TEST|18F-NaF PET|18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
214501665|NCT03689946|DIAGNOSTIC_TEST|CCTA|CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
214501666|NCT03689946|DRUG|Omnipaque|contrast agent for CCTA
214501667|NCT03689946|DRUG|Metoprolol|beta blocker to optimize heart rate during CCTA
214501668|NCT03689946|DRUG|Nitroglycerin|premedication for CCTA
214501669|NCT01555138|DRUG|Indacaterol|Indacaterol is delivered via a SDDPI.
214501670|NCT01555138|DRUG|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
214501671|NCT02893969|BEHAVIORAL|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
214501672|NCT02893969|BEHAVIORAL|Rest|Complete physical rest until asymptomatic.
214999165|NCT06659757|OTHER|Placebo|Placebo will be administered by inhalation with a nebuliser
214999166|NCT06210919|BIOLOGICAL|TRTP-101|Intradermal injection of the each of four sites
214999167|NCT06557356|DRUG|LY3532226|Administered SC
214999168|NCT06557356|DRUG|Placebo|Administered SC
214999169|NCT04396808|DEVICE|Decipher|The Decipher test (GenomeDx Biosciences) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
214999170|NCT04396808|DEVICE|Prolaris|The Prolaris test (Myriad Genetics, Inc.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
214999171|NCT04396808|DEVICE|Oncotype Dx Genomic Prostate Score (GPS)|The Oncotype Dx GPS test (Exact Sciences corp.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
214999172|NCT04396808|OTHER|Standard of care (askMUSIC score)|AskMUSIC is a risk calculator based on standard clinical and pathologic variables (https://ask.musicurology.com/) and is generally included as part of routine clinical care.
215094118|NCT02534116|PROCEDURE|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
215094119|NCT02534116|PROCEDURE|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
214999173|NCT06449989|DIAGNOSTIC_TEST|Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI|"For molecular genetic research, archival formalin-fixed and paraffin-embedded tumor blocks will be used. Research method - HRM-PCR sequencing to determine mutation status of KRAS, NRAS and BRAF (RotorGene 6000, ABI Prism 3500) and fragmentation analysis to determine MSI (ABI Prism 3500) Subject to study: mutations in the KRAS, NRAS, BRAF genes, as well as MSI status and HER2neu expression (± amplification) Somatic mutations in the RAS family genes are planned to be studied in exons 2 (codons 12 and 13), exon 3 (codon 61) and exon 4 (codon 146). In the case of the BRAF gene - exon 15 (codons 597-601). Determination of microsatellite instability is planned using five markers: BAT25, BAT26, NR21, NR24, NR27, associated with structural and functional disorders of the DNA unpaired base repair system.~Assessment of HER2 gene status is planned by immunohistochemical (IHC) screening of HER2neu expression. IHC-screening of HER2-status will be performed using an antibody clone 4B5 (Ventana)."
214999174|NCT06606743|BEHAVIORAL|High-Intensity Interval Training|Participants will receive a total of 20 in-person sessions of 45 minutes duration. Subjects perform high-speed movements with minimal recovery between movements. Hand weight will be used to increase intensity as training progresses.
214999175|NCT06606743|BEHAVIORAL|High-Velocity Circuit Resistance Training|Participants in this group will perform a total of 20 in-person training sessions using 12 resistance exercises performed in 3 circuits with minimal recovery between exercises.
214390989|NCT01804673|DRUG|Fentanyl-ITS|Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
214390990|NCT04563442|OTHER|complication|complication co morbidities
214390991|NCT00239629|DRUG|Teriparatide|
214390992|NCT00239629|DRUG|Strontium ranelate|
214390993|NCT00239629|PROCEDURE|Transiliac bone biopsy|
214390994|NCT03483077|DRUG|BI 730460|tablets
214501673|NCT04694937|DEVICE|heart rate variabilty measured by pulse oximetry|"Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points."
215094120|NCT04863196|OTHER|Laser therapy Treatment Group|laser in gastric mucosa lesion
215094121|NCT04863196|OTHER|Barrier Dust Treatment Group|barrier powder in gastric mucosa lesion
215094122|NCT01291693|BEHAVIORAL|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
214390995|NCT03483077|DRUG|Placebo|tablets
214390996|NCT05258747|DRUG|Olaparib tablets, 150 mg|Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia
214390997|NCT05258747|DRUG|Lynparza® (olaparib) tablets 150 mg|Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).
214501674|NCT05381519|BIOLOGICAL|DXP604|1800mg，IVgtt
214390998|NCT06060834|DIETARY_SUPPLEMENT|Topical Botanical Agent|Cayenne Pepper, Coconut Water, Kelp, Lemon Juice, Oxynex LM, Potassium Sorbate, Red Palm Oil, Rose Water, Saw Palmetto, vitamin C
214390999|NCT02161900|OTHER|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
214391000|NCT02451501|DEVICE|AKITA|
214687974|NCT03334617|DRUG|Vistusertib|Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
214391001|NCT01677780|DRUG|RO5045337|Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m\^2) to 1800 mg/m\^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
214391002|NCT00172081|DRUG|placebo|Daily subcutaneous injection with placebo
214391003|NCT00172081|DRUG|ALX1-11|PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
214391004|NCT04392232|DRUG|Convalescent Plasma|"• Investigational Product~o COVID-19 convalescent plasma will be obtained from an FDA-registered blood establishment (Hoxworth) that follows donor eligibility criteria and donor qualifications as outlined in section III.C.I of the Investigational COVID-19 Convalescent Plasma Guidance for Industry."
214391005|NCT00000517|DRUG|warfarin|
214391006|NCT00431002|BEHAVIORAL|Resistance training|See Detailed Description.
214391007|NCT00451217|DRUG|Sugammadex|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered
214391008|NCT00451217|DRUG|Neostigmine|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
214391009|NCT05778331|PROCEDURE|Antagonist protocol for induction of ovulation|Full labs will be revised to exclude women with any chronic disease. Ultrasound to exclude any anatomical uterine problem.HSG.Women who will be categorized as Poseidon group 3 and Poseidon group 4.They will be given after that antagonist protocol with dose of HMG/FSH 300-450 I.U. per day: (Gonapure 150 I.U -follicle stimulating hormone FSH preparation of recombinant DNA technology- MinaPharm pharmaceuticals-Egypt) will be given from 2nd day of menstruation per day as starting dose then on 7th day (Cetrotide 0.25 -Cetrorelix, an anti-gonadotropin releasing hormone- MERCK SORONO-Germany) will be given daily till triggering . US will be done to evaluate follicular size from 7th day if it will be 1.8 cm or more for at least 2 follicles then (Chorimon 5000 i.u-Choriogonadotropin Alfa-IBSA-Switzerland )of total dose 10000 I.U. will be given then ovum pick up with be done after 35 h of triggering ovulation .Assessment of embryo quality
214391010|NCT00436176|BEHAVIORAL|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
214391011|NCT06315764|PROCEDURE|Reflexology|"Following four weeks of treatment (post-1) and additional four weeks of treatment (post-2) the post evaluation was used (post-2).Before and after the foot reflexology, blood pressure was checked twice. Around 20 minutes is spent on foot reflexology .~Each patient in this study did 20 minutes of peddler aerobic training, with the first 5 minutes serving as a warm-up with intensity set at 60 - 65 percent of maximal heart rate, followed by another 10 minutes of peddler training with intensity gradually increased up to 70 - 75 percent, and the last 5 minutes serving as a cooling down with intensity set at 60 - 65 percent of maximal heart rate. After the warm-up and at the end of each training phase, the participants' heart rates were monitored. Finally, if the individual experienced pain, fainting, or shortness of breath, the training was promptly terminated as well as reflexology three times each week for eight weeks"
214501675|NCT00943969|PROCEDURE|gastric bypass|gastric bypass combines restrictive and malabsorptive procedures
214501676|NCT05543005|OTHER|maternal voice intervention|maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time after routine care period
214391012|NCT00505167|DRUG|Memantine|Patients randomized to receive either memantine or donepezil
214391013|NCT00505167|DRUG|Donepezil|Patients randomized to receive either memantine or donepezil
214999176|NCT06649032|OTHER|No intervention|no difference: both cohorts are followed in the same way
214999177|NCT06979921|DEVICE|Blood test|Blood test
214999178|NCT06606730|DRUG|Pembrolizumab|Administration of pembrolizumab for 6 months
214999179|NCT06606730|OTHER|Deescalation|Patients will be followed up according to standard practice for 4 years
214999180|NCT06459869|DRUG|NG-350A IV administration|a tumour-selective anti-CD40-expressing adenoviral vector
214999181|NCT06459869|DRUG|Capecitabine oral administration|chemotherapy
214999182|NCT06459869|RADIATION|Radiotherapy|long-course intensity-modulated radiotherapy
214501677|NCT01255514|DRUG|high dose dexamethsone|high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
214501678|NCT01673399|DRUG|Atosiban|Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
214999183|NCT06618040|BEHAVIORAL|Bedtime Stories Sleep Health Education Program for Caregivers (BTS-C)|The BTS-C includes 6 educational modules on different topics related to sleep health: principles of healthy sleep practices include sleep routines, the sleep environment, considerations for screen time, timing of sleep and activities surrounding sleep, expectations for healthy sleep and sleep duration. Caregivers will also receive a combination of tailored messages or prompts to explore progress, identify strategies for change, and goal setting.
214501679|NCT01673399|DRUG|placebo|
214501680|NCT00252005|DRUG|Apixaban|
214687975|NCT03334617|DRUG|Olaparib|Olaparib (AZD2281) given orally at 300 mg BD
214687976|NCT03334617|DRUG|Oleclumab|Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
214687977|NCT03334617|DRUG|trastuzumab deruxtecan|Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only \& trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days
214687978|NCT03334617|DRUG|cediranib|cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1
214687979|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.
214687980|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28
214999184|NCT06595290|OTHER|High intensity care|This arm follows a structured algorithm for initiating and uptitrating all four pillars of HFrEF oral medications post-randomization (pre-discharge) and during at least 4 visits over 6 weeks post-discharge.
214391014|NCT00358150|DRUG|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067\[active moiety of eliglustat in plasma\] trough plasma concentration was greater than or equal to \[\>=\]5 nanogram per milliliter \[ng/mL\] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than \[\<\] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
214391015|NCT03747289|OTHER|performing exercises in a weight bearing posture|20 participants will perform exercises in a weight bearing posture
214391016|NCT03747289|OTHER|performing exercises in a non weight bearing posture|20 participants will perform exercises in a non weight bearing posture
214391017|NCT02364453|DRUG|PACAP38|Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
214391018|NCT04403958|PROCEDURE|PRC|Total wrist arthrodesis with dorsal plate using proximal row of the wrist as bone graft
214391019|NCT04403958|PROCEDURE|TWA|Total wrist arthrodesis with dorsal plate using iliac crest as bone graft
214391020|NCT06249620|DIETARY_SUPPLEMENT|Inmunoferon|The dosage regimen is two capsules (with the active ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
214391021|NCT06249620|DIETARY_SUPPLEMENT|Placebo|The dosage regimen is two capsules (with inert ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
214391022|NCT04668989|DEVICE|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week.
214501681|NCT04061759|OTHER|Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.|Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
214501682|NCT04895670|BEHAVIORAL|Empowering Youth Aging out of Foster Care|App that allows storage of health information, and access to reputable health information and community resources.
214501683|NCT04788810|OTHER|Administration of d12-Cl2BPA|Administration of d12-Cl2BPA
214501684|NCT01681823|DIETARY_SUPPLEMENT|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
214999185|NCT06595290|OTHER|Usual care|Patients will be managed by their cardiologist according to their usual practice. Follow-up appointments will be scheduled as per the cardiologist\&#39;s instructions. Participants will return to the recruiting study site for clinical outcome assessment by study investigators at 90 and 180 days post-discharge.
214999186|NCT06123338|DRUG|Pembrolizumab|Pembrolizumab will be administered on an every 3-week dosing schedule
214999187|NCT06123338|DRUG|Trastuzumab|Trastuzumab will be administered on an every 3-week dosing schedule
214999188|NCT06123338|DRUG|Oxaliplatin|Oxaliplatin every 3 weeks, +/-7 days
214999189|NCT06123338|DRUG|Capecitabine|Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks
214999190|NCT06123338|DRUG|5-Fluorouracil|5-Fluorouracil administered as a 24 hour IV continuous infusion once every 2 weeks
214999191|NCT06123338|DRUG|Docetaxel|Docetaxel administered intravenously once every 2 weeks.
214999192|NCT06590857|DRUG|RYZ101|Ac-225
214999193|NCT06587061|DRUG|HRS-4642+AG|HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel will be administrated per dose level in which the patients are assigned.
214999194|NCT06597721|DRUG|ADCE-T02|Administered intravenously
214999195|NCT03244189|BEHAVIORAL|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
214999196|NCT03244189|BEHAVIORAL|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
214999197|NCT03244189|BEHAVIORAL|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
214999198|NCT06990724|OTHER|Videogame Intervention|No Baby No video game
214999199|NCT06990724|OTHER|Commercial game control|Commercial video game
214999200|NCT06997094|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214999201|NCT06997094|DRUG|Chemotherapy|Given concurrent chemotherapy
214999202|NCT06997094|DRUG|Decitabine|Given IV
214999203|NCT06997094|RADIATION|External Beam Radiation Therapy|Undergo EBRT
214999204|NCT06997094|OTHER|Questionnaire Administration|Ancillary studies
214391023|NCT04668989|DEVICE|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week.
214391024|NCT01929330|DRUG|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
214391025|NCT01929330|DRUG|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
214391026|NCT00991614|DEVICE|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
214391027|NCT01980901|DEVICE|Ovation™/Ovation Prime™ Abdominal Stent Graft System|Single occurence permanent implant of AAA device.
214391028|NCT04386590|OTHER|Manual Therapy Plus Pulmonary Rehabilitation|Manual therapy combined with Pulmonary Rehabilitation
214391029|NCT04386590|OTHER|Sham Intervention|Detuned US plus Pulmonary Rehabilitation
214391030|NCT04550273|BEHAVIORAL|aerobic treadmill exercise|The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
214391031|NCT01714973|BIOLOGICAL|ST266|Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
214391032|NCT04882020|DIAGNOSTIC_TEST|cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha|compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.
214391033|NCT01622348|DRUG|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
214391034|NCT01622348|DRUG|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
214391035|NCT01622348|DRUG|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
214391036|NCT00179010|DRUG|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
214391037|NCT00179010|DRUG|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
214391038|NCT06054620|DIETARY_SUPPLEMENT|Collagen and Vitamin C|Collagen-modelled crystalline amino acids (30g total, 8g glycine) and vitamin C (500 mg).
214391039|NCT06054620|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Iso-caloric Placebo (30g maltodextrin).
214391040|NCT04466332|DEVICE|LifeCath-CT PICC easy™ (Vygon)|"ECG electrodes are placed on patient's chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify a suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The PICC is advanced into the central circulation and used as an intracavitary electrode (connection with Vygocard2™). Saline water instilled through the catheter ensures conductivity.~The ECG is then used until displayed intracavitary P-wave has a maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The PICC hub side is then trimmed and the catheter part connected. The PICC is caped with a neutral bidirectional valve.~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess the position."
214391041|NCT04466332|DEVICE|PowerPICC-SOLO® (C.R. Bard)|"ECG electrodes are placed on patients chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The catheter's free end is cut to the anticipated length using anthropometric measurements (insertion/axillary crease+axillary crease/sternal notch+13cm) and the preloaded magnetic-tipped stylet (serving as intracavitary electrode) is put inside.~The PICC is advanced into central veins until intravascular ECG displays a P-wave with maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess position."
214391042|NCT01942655|OTHER|Blood sample and recto-colic biopsies|
214391043|NCT03765762|DRUG|GRF6019|GRF6019 for IV infusion
214391044|NCT03765762|OTHER|Placebo|Placebo for IV infusion
214501685|NCT02108574|DEVICE|Placebo Filter|
214501686|NCT02108574|DEVICE|Rhinix Nasal Filter|
214501687|NCT00942344|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
214501688|NCT00942344|DRUG|Amlodipine|amlodipine 5mg, 10mg
214999205|NCT06997094|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
214999206|NCT05330442|BEHAVIORAL|Written Exposure Therapy (WET)|The WET protocol for primary care settings consists of six, 30-minute sessions. The first session consists of psychoeducation of PTSD and treatment rationale. Written narratives are conducted in sessions 2-6, following specific writing instructions and 20 minutes of writing in each session.
214999207|NCT06002282|BEHAVIORAL|Tailored messages|Messages will be individually tailored to parents' responses to a baseline survey (child gender, vaccination status) and real-time responses to interactive prompts about vaccine hesitancy determinants with links to additional information (e.g., CDC, NJ Department of Health) and community resources to overcome barriers.
214999208|NCT06002282|BEHAVIORAL|Standard messages|Generic reminder/recall HPV vaccination messages.
214999209|NCT05732818|DEVICE|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
214999210|NCT06603285|DRUG|Treprostinil|sc/iv continuously
214999211|NCT06865417|DRUG|Filgotinib|IP will be provided as commercially developed film-coated tablets (100 and 200 mg strength) or reduced-strength (65 mg) age-appropriate film-coated tablets for use in pediatric subjects aged at least 8 years and needs to be taken orally q.d. at approximately the same time every morning (with or without food).
214999212|NCT06863233|DRUG|Zirconium Zr 89 crefmirlimab berdoxam|Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab), conjugated with deferoxamine (Df, berdoxam) and radiolabeled with Zirconium-89.
214999213|NCT06863233|DIAGNOSTIC_TEST|PET/CT Scan|Each patient will undergo up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam followed by PET/CT 24 hours later (+/- 3 hours).
214999214|NCT06857955|OTHER|Saline|0.9% sodium chloride saline solution
214999215|NCT06857955|DRUG|QCZ484|Solution of Injection
214501689|NCT00942344|DRUG|Losartan|Losartan 50mg, 100mg
214501690|NCT05135234|BEHAVIORAL|Muscular Exercise|Sedentary time (muscular inactivity when sitting) will be replaced with low effort muscular activity
214501691|NCT01801800|PROCEDURE|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
214501692|NCT01613417|DRUG|gadoteridol|ProHance 0.1 mmol/kg
214391045|NCT00007293|DEVICE|UV-B Lightsource and Fiber Optic Comb|
214391046|NCT05162807|BEHAVIORAL|Psychoeducational Video on Palliative Care|The intervention is a psychoeducational video introducing palliative care and discussing its purpose, structure, benefits, and efficacy.
214391047|NCT05162807|BEHAVIORAL|Educational Video on Nutrition|The attention control is a video on nutrition and healthy eating during cancer survivorship.
214391048|NCT00956540|PROCEDURE|Deflating tracheal cuff|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support.
214391049|NCT00956540|PROCEDURE|Deflating tracheal cuff 2|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate manage the airway.
214391050|NCT02392767|DIETARY_SUPPLEMENT|Verum|2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.
214391051|NCT02392767|DIETARY_SUPPLEMENT|Placebo|corn starch
214391052|NCT05125042|PROCEDURE|Amiodarone hydrochloride tablet + acupoint catgut embedding|Patients with persistent AF after undergoing catheter ablation take receive acupoint catgut embedding in Neiguan and Zusanli twice after and one month after surgery combined with amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
214391053|NCT05125042|DRUG|Amiodarone hydrochloride tablet|Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
214391054|NCT02167152|OTHER|Ischemic preconditionin|Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
214501693|NCT01613417|DRUG|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
214501694|NCT01227746|PROCEDURE|Tumor biopsies|
214501695|NCT03412266|DRUG|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
214501696|NCT04365959|PROCEDURE|Prone position|The objective of the study is to value the ability of the prone position to increase the oxygenation of the patient with SARS-cov-2 pneumonia as a lung recruitment index; the PP also prevents the need for intubation and the consequent risk deriving from the procedure itself and from the predisposition to develop superinfections (VAP).
214501697|NCT01223274|DEVICE|CPAP/PEEP|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
214501698|NCT01223274|DEVICE|Standard management practices|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
214999216|NCT06864689|BEHAVIORAL|Video-log (vlog) series with videos tailored to cisgender Black women or to healthcare providers|This intervention is a video-log (vlog) series based health communication intervention that will be disseminated through community health centers (CHCs) and social media to increase willingness for and use of PrEP among cisgender Black women and to increase willingness to prescribe and refer PrEP among healthcare providers.
214501699|NCT06547125|DEVICE|JUVÉDERM® VOLITE™|Injection, intradermal
214501700|NCT06547125|OTHER|Control|No-treatment control
214501701|NCT05079984|BEHAVIORAL|Graded exposure treatment (GET)|Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.
214501702|NCT00077935|DRUG|Civamide|Cream 0.075%, TID for 52 weeks
214501703|NCT00385606|DRUG|gemcitabine|
214501704|NCT00385606|DRUG|prolonged continuous infusion gemcitabine|
214501705|NCT00385606|DRUG|cisplatin|
214999217|NCT06863740|DRUG|Cannabis oil|5:1 CBD:THC oral formulation with a concentration of 25 mg/g CBD and 5 mg/g THC in a pharmaceutical grade medium chain triglyceride (MCT) oil.
214999218|NCT06863740|DRUG|Cannabis placebo|Placebo oil
214999219|NCT06503614|DRUG|Durvalumab|Durvalumab 1500mg IV
214999220|NCT06503614|DRUG|Monalizumab|Monalizumab 1500mg IV
214999221|NCT03240211|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV
214391055|NCT01805765|DRUG|Qing'E pills|composed of eucommia, psoralen, walnuts and garlic
214391056|NCT01805765|DRUG|Placebo|Containing 2% of Qing'E pills
214391057|NCT01762163|DRUG|Qizhitongluo Capsule|
214391058|NCT01762163|DRUG|Naoxintong Capsule|
214391059|NCT01762163|DRUG|Aspirin Enteric-coated Tablets|
214391060|NCT01762163|BEHAVIORAL|the routine recovery training|
214501706|NCT00385606|DRUG|rofecoxib|
214391061|NCT01762163|DRUG|placebo|
214391062|NCT04877704|OTHER|Symprove (probiotic)|Symprove's unique water-based formula is packed full of live, active bacteria. It is a probiotic, not a drug.
214391063|NCT04877704|OTHER|Placebo|Matched placebo to Symprove probiotic
214391064|NCT01592695|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
214391065|NCT01592695|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
214501707|NCT03676569|BIOLOGICAL|ADRC transplantation in autoimmune refractory epilepsy|
214999222|NCT03240211|DRUG|Pralatrexate|Pralatrexate 20 or 30 mg/m2 IV push
214999223|NCT03240211|DRUG|Decitabine|Decitabine 10 mg/m2
214999224|NCT03561376|DRUG|Topical zinc oxide vs. petrolatum post-surgical scars|"Following linear closure on non-scalp skin with scar length \> 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery."
214999225|NCT04172779|DRUG|Erlotinib Hydrochloride|Oral administration of erlotinib 25mg tablet
214999226|NCT05482971|DRUG|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft (P1101)
214999227|NCT06860035|OTHER|Dementia Caregivers' Link to Assistance and Resources (DECLARE)|The intervention for treatment branches includes two parallel processes: (1) calling eligible caregivers to field a self-assessment instrument and upload caregiver responses to the patient record, and (2) identifying and flagging cases for expedited social work access with dementia-trained social workers.
214391066|NCT01592695|BEHAVIORAL|Tobacco quit line referral|Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
214391067|NCT01592695|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
214391068|NCT01592695|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
214999228|NCT06861543|BIOLOGICAL|TMT101 Injection|Three dose levels are planned to be explored: 0.1 mg, 0.2 mg, and 0.4 mg. The initial dose is 0.1 mg with a dose reduction for safety reasons, the level of dose reduction will be discussed jointly between the investigator and the sponsor. TMT101 will be injected intramuscularly, Once a week,a total of 9 times
214391069|NCT01592695|DRUG|Bupropion Sustained Release|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
214391070|NCT01592695|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
214391071|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
214391072|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
214391073|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
214391074|NCT01592695|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
214391075|NCT01592695|BEHAVIORAL|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
214391076|NCT01592695|BEHAVIORAL|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
214391077|NCT00698321|BEHAVIORAL|HIV/STD prevention curriculum|The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
214391078|NCT00698321|BEHAVIORAL|General health promotion curriculum|The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
214687981|NCT03334617|DRUG|AZD6738 (ceralasertib) (240 mg or 160 mg)|AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
214999229|NCT06860321|DEVICE|Adjunct antibacterial home-use dual-light medical device|Crossover active intervention.
214391079|NCT05401422|OTHER|treatment|types
214391080|NCT02584764|BEHAVIORAL|Cognitive behavior therapy|
214999230|NCT06860321|OTHER|Regular oral self care|Crossover regular intervention.
214999231|NCT06042283|BEHAVIORAL|Metacognitive Training-Silver|"The Metacognitive Training-Silver program includes the following topics: Thinking and Reasoning 1 (module 1), Memory (module 2), Thinking and Reasoning 2 (module 3), Self-Esteem (module 4), Thinking and Reasoning 3 (module 5), Behaviors and Strategies (module 6), Thinking and Reasoning 4 (module 7) and Perception of Feelings (module 8).~Each session is planned to last 45-60 minutes. Materials will be used in the Metacognitive Training-Silver program are PPT (Power Point Presentations) slides, videos, homework exercises, and yellow-red cards.~Metacognitive Training-Silver is planned to be applied face-to-face in 3 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group. In order to increase compliance with the Metacognitive Training-Silver program, the sessions will be applied during the routine treatment period."
214999232|NCT07000006|BEHAVIORAL|Home-based Core Stability Exercise|The online exercise program aims to improve trunk stability and reduce low back pain. A clinical exercise physiologist will deliver real-time exercise sessions, with each session lasting 40-45 minutes, three days a week for 12 weeks. Participants will join private group sessions using a free video platform.
214391081|NCT02584764|BEHAVIORAL|Internet support|
214391082|NCT01629654|BEHAVIORAL|Health promotion program|"A 13 weeks organized program:~* One group session about poststroke fatigue involving both patient and relatives~* Two personal meetings, involving both patient and relatives~* Three telephone meetings, involving only patient"
214391083|NCT02381860|OTHER|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
214391084|NCT02381860|DIETARY_SUPPLEMENT|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
214391085|NCT04758221|OTHER|Treatment by composite coronal build-up|A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
214391086|NCT01554943|OTHER|cardiac MRI|Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
214687982|NCT03334617|DRUG|AZD6738 (ceralasertib) 7 days monotherapy|AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
214391087|NCT04241874|OTHER|Mechanical Ventilation|Respiratory support through mechanical ventilator
214391088|NCT00432861|DRUG|PANCRECARB® (pancrelipase)|Capsules
214391089|NCT00432861|DRUG|Placebo|Capsules
214391090|NCT05663983|BEHAVIORAL|Description of therapeutical results|Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
214391091|NCT00563992|DRUG|Lithium|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
214391092|NCT00563992|DRUG|Valproic acid|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
214391093|NCT04515160|DIAGNOSTIC_TEST|Clinical Frailty Scale|Clinical fragility scale will be recorded in the first 24 hours of intensive care admissions.
214391094|NCT04515160|DIAGNOSTIC_TEST|Modified Frailty Index|Modified Frailty Index will be recorded in the first 24 hours of intensive care admissions.
214391095|NCT01085929|PROCEDURE|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
214391096|NCT01085929|PROCEDURE|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
214391097|NCT02766673|DRUG|Albuterol Sulfate|Subjects will receive a dose of study medication every 4 hours for 24 total hours
214391098|NCT02766673|DRUG|Sterile Saline|Subjects will receive a dose of study medication every 4 hours for 24 total hours
214391099|NCT00279994|PROCEDURE|Exercise therapy|
214391100|NCT00279994|DEVICE|Accelerometer (PAM; Personal Activity Monitor)|
214501708|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
214501709|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
214501710|NCT04969666|DRUG|IPED2015|Active treatment
214501711|NCT04969666|DRUG|Placebo|Placebo
214501712|NCT06100185|DEVICE|PeakSleep|The PeakSleepTM is a constant current device which delivers stable stimulation as a function of the impedance measured across the electrodes (e.g. it varies voltage to produce a steady current). The device gradually ramps up the current as the impedance decreases during the stimulation session. The device uses stimulation amplitudes in the range of 100uA to 500uA at each electrode pair. Devices will be configured to deliver 100 stimulation trains over 30 minutes where each train is 6 pulses of 0.75Hz trapezoidal stimulation (each train lasts 8 seconds). The inter-train interval is 10 seconds leading to a total stimulation time of \<14 minutes with a maximum dose of 1mA (500uA per electrode pair).
214501713|NCT06100185|DEVICE|Sham|Sham is delivered with the same devices which are alternatively configured to deliver a trivially low amplitude (e.g. 100uA) waveform of a different frequency (e.g. 25 Hz) for the same treatment duration. Beyond differences in amplitude and frequency of stimulation, devices will be operated in exactly the same way during sham treatment.
214999233|NCT06999629|DIETARY_SUPPLEMENT|Relaxation Placebo Control|Participants will use their Relaxation Placebo Control as directed for a period of 6 weeks.
214391101|NCT00279994|PROCEDURE|Oral Exercise Therapy advise|
214501714|NCT01784328|DEVICE|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
214501715|NCT02622698|DIETARY_SUPPLEMENT|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
214501716|NCT02622698|OTHER|Placebo|Placebo- Patients did not take any protein supplementation after surgery
214501717|NCT02413138|DRUG|Somavaratan (VRS-317)|Long acting recombinant human growth hormone
214501718|NCT02861820|DEVICE|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
214999234|NCT06999629|DIETARY_SUPPLEMENT|Relaxation Active Product 1|Participants will use their Relaxation Active Product 1 as directed for a period of 6 weeks.
214999235|NCT06999629|DIETARY_SUPPLEMENT|Relaxation Active Product 2|Participants will use their Relaxation Active Product 2 as directed for a period of 6 weeks.
214999236|NCT07002112|BIOLOGICAL|LVIVO-TaVec100 product|Prior to infusion of the LVIVO-TaVec100 product, subjects will receive bridging therapy if needed.
214999237|NCT06994325|BEHAVIORAL|Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention|The Conversations Helpful for Awareness of illness Trajectory (CHAT) intervention will incorporate 4 health-coach sessions, supplemented by 7 educational videos. Each session will be up to 60 minutes long and will be conducted remotely. During the health coach sessions, a trained health coach will work with subjects, reviewing the content of each video and emphasizing key learning content.
214999238|NCT06994325|BEHAVIORAL|Standard of Care (SOC)|The Standard of Care Group will not have access to the Health Coach or video-based educational content. This group will have no study activities during Weeks 1-7 but will participate in follow-up assessments.
214999239|NCT07000110|DRUG|Anifrolumab|Anifrolumab prescribed per local practice
214391102|NCT03179631|DRUG|Ataluren|10, 20 mg/kg
214391103|NCT03179631|DRUG|PLACEBO|10, 20 mg/kg
214391104|NCT01034579|OTHER|Blood sampling|Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
214391105|NCT01034579|OTHER|Blood sampling|Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
214391106|NCT05050474|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
214391107|NCT00453479|DRUG|GSK233705B|
214391108|NCT03498079|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound will be done to females complaining from primary infertility with mullerian anomalies
214501719|NCT01687920|DRUG|BAY94-8862 (1.25mg)|
214501720|NCT01687920|DRUG|BAY94-8862 (2.5mg)|
214501721|NCT01687920|DRUG|BAY94-8862 (5mg)|
214501722|NCT01687920|DRUG|BAY94-8862 (7.5mg)|
214501723|NCT01687920|DRUG|BAY94-8862 (10mg)|
214501724|NCT02663804|DEVICE|Total Knee Arthroplasty|
214501725|NCT03041961|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
214501726|NCT03041961|DIETARY_SUPPLEMENT|Aronia full spectrum|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
214501727|NCT03041961|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa)
214501728|NCT06297057|OTHER|Neurophysiological Recordings|"Eyes-open resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes open and staring at a white cross in the center of a light grey screen to limit their eye movements.~Eyes-closed resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes closed.~ASSR: this block will last approximately 6 minutes. Stimuli will consist of a train of sounds presented repeatedly at high frequency.~MMN: this block will last approximately 3 minutes. Stimuli will consist of a train of equal sounds presented alternating with a 'deviant' (rarer frequency) sound."
214391109|NCT04873778|DEVICE|Kinesio taping|Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints
214391110|NCT04873778|DEVICE|Dynamic taping|Dynamic taping: Invented by Kendrick,elasticised with multi-directional rebound and with strong elastic resistance and recoil than KT
214501729|NCT05485116|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
214501730|NCT02168998|BEHAVIORAL|Clown|Comparison of routine venipuncture with a distraction technique by a medical clown
214999240|NCT05984381|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) orally
214999241|NCT05984381|DRUG|Dapsone|Dapsone 100 mg/day
214391111|NCT06115278|OTHER|survey|survey
214391112|NCT01763788|DRUG|Necitumumab|Administered IV
214391113|NCT01763788|DRUG|Gemcitabine|Administered IV
214501731|NCT03185793|DRUG|Placebo|Placebo once daily for 5 weeks
214501732|NCT03185793|DRUG|SHR4640|1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
214501733|NCT03185793|DRUG|benzbromarone|25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
214501734|NCT06566092|BIOLOGICAL|LN-145/LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
214391114|NCT01763788|DRUG|Cisplatin|Administered IV
214391115|NCT01803295|DEVICE|40 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
214391116|NCT01803295|OTHER|Standard of care MMC mixed with water|Standard of care 40mg MMC mixed with water
214391117|NCT01803295|DEVICE|80 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
214501735|NCT00001752|DRUG|L-arginine|
214501736|NCT00001752|DRUG|Estrogen|
214999242|NCT05984381|DRUG|Methotrexate|Methotrexate 15 mg weekly
214999243|NCT06652841|DEVICE|transShield Embolic Protection System|Patient undergoing TAVR procedure will receive the transShield EPS with the intent to capture and remove debris dislodged during the interventional procedure.
214999244|NCT04193891|OTHER|Modified Atkins Diet|The ketogenic diet, where individuals restrict their carbohydrate intake and significantly increase their intake of fats, was initially primarily used in children with severe epilepsy, often due to genetic syndromes. Recently, with the advent of slightly less restrictive forms of ketogenic dietary therapy (e.g. the modified Atkins diet), it has begun to be used in adults with intractable seizures who are not surgical candidates.
214999245|NCT05779930|BIOLOGICAL|CD19 specific Chimeric Antigen Receptor T Cell|Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy
214999246|NCT07003932|OTHER|Remote monitoring|The remote monitoring group will be more closely followed than the control group in order to detect any deterioration over time. This group will not be scheduled for a face-to-face consultation unless it is deemed necessary by a physiotherapist or if the patient contacts the hospital themselves.
214999247|NCT07003932|OTHER|Usual Care|The control group will follow usual care with face-to-face consultation with a physiotherapist at 2 and 12 months. They will also anwer questionnaires at 2, 6 and 12 months, but these will not be monitored.
214999248|NCT07003685|DEVICE|GDD in posterior chamber|GDD in posterior chamber
214999249|NCT07003685|DEVICE|GDD in aterior chamber|GDD in anterior chamber
214999250|NCT07003542|DRUG|Sitagliptin|"Sitagliptin will be self-administered orally by participants.~Dose level - sitagliptin~* 1 100 mg daily~* -1 50 mg daily~* -2 25 mg daily"
214999251|NCT02956291|DEVICE|Magnetic Resonance Fingerprinting|Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes
214999252|NCT06892340|DEVICE|Transcutaneous Auricular Neurostimulation device|The Sparrow Ascent device will be programmed to the preset stimulation parameters. Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region 1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set to 250 #s for all participants. The stimulation intensities (mA) will be set to 1.0 and 1.4 (for Region 1 and 2, respectively) based on the median values observed in the previous data set. If the participant states that the stimulation intensity is discomforting, the research coordinator will gradually decrease/increase until a comfortable stimulation intensity is achieved
214999253|NCT06892184|BEHAVIORAL|hypnotic communication|During local anaesthesia, the operator will not remain silent, nor will he describe to his patient the anaesthesia he is performing, nor warn his patient of possible future pain. When performing anesthesia, the operator will use a dissociative, hypnotic language, standardized across all patients.
214391118|NCT03567954|DIAGNOSTIC_TEST|Ultrasound examination of the rotator cuff tendons|An ultrasound scan of the rotator cuff tendons will be performed to determine the presence of a rotator cuff tear or not
214999254|NCT06892184|BEHAVIORAL|conventional communication|suggestions typically uttered by the practitioner, who describes what he is doing and warns of possible pain.
214999255|NCT07044414|DEVICE|Manual Acupuncture|Manual acupuncture is administered at bilateral ST36 Zusanli, SP6 Sanyinjiao, and midline points CV4 Guanyuan and CV6 Qihai using sterile, single-use 0.25 × 25 mm acupuncture needles. The insertion depth follows standard clinical practice and safety guidelines, with twirling stimulation performed at minutes 0 and 10. Each session lasts approximately 20 minutes and is conducted three times per week for a total of 21 sessions. Participants continue to receive their standard chemoradiotherapy for head and neck cancer.
214999256|NCT07044414|DEVICE|Sham Manual Acupuncture|Sham Manual acupuncture uses Park sham needles with telescopic tips that do not penetrate the skin, applied at the same acupoints (ST36, SP6, CV4, CV6) with identical procedure and appearance to mimic real acupuncture. Adhesive bases are used to fix the sham needles. Stimulation is mimicked at minutes 0 and 10. Sessions last the same duration and frequency as the intervention group. Participants also continue their standard chemoradiotherapy.
214999257|NCT06892314|BIOLOGICAL|Exposure to hyperglycemia (type 2 diabetes)|Exposure to hyperglycemia, in the context of type 2 diabetes, as measured by continuous glucose monitoring
214999258|NCT06740487|BEHAVIORAL|Traditional Exposure Therapy (ET) Treatment|Traditional exposure therapy (ET) includes the following components: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), and (d) relapse prevention strategies and further treatment planning (session 10).
214999259|NCT06740487|BEHAVIORAL|Traditional Exposure Therapy (ET) Treatment with addition of Augmented Reality (AR) Component|Traditional exposure therapy (ET) with addition of Augmented Reality component includes the following: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), (d) relapse prevention strategies and further treatment planning (session 10), and (e) 30 minutes of each 90 minute session dedicated to augmented reality exposure therapy (ARET). During ARET, the clinician guides participant, who is wearing augmented reality (AR) goggles, through preset scenarios during which characters mingle with each other (e.g., grocery store, social gathering), as well as custom scenarios where participant can interact with the character.
214999260|NCT06743776|DRUG|MN-166|MN-166 will be taken orally at a dose of 10 mg in the morning and 20 mg in the evening for the first 2 weeks, whereafter dose of 30 mg BID will be taken.
214999261|NCT06739447|OTHER|Consumer Wearable Device Vital Sign Measurement|Consumer Wearable Devices such as the Fitbit, are durable devices that can provide vital sign data.
214999262|NCT06743074|OTHER|foot exercise|foot exercise
214999263|NCT06743074|OTHER|hip exercise|hip exercise
214999264|NCT06743074|OTHER|control|control
214999265|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under High Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
214391119|NCT03893825|DRUG|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm description.
214391120|NCT03893825|DRUG|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm description.
214391121|NCT01006317|BEHAVIORAL|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
214391122|NCT01006317|BEHAVIORAL|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
214391123|NCT01006317|OTHER|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
214391124|NCT00332683|PROCEDURE|Maintaining low (15mmHg) ETT cuff pressure|Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg
214501737|NCT01703546|PROCEDURE|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band \& Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
214501738|NCT01100151|DRUG|RDC-1036 (ALKS 37)|Capsules for oral administration
214501739|NCT01100151|DRUG|Placebo|Capsules for oral administration
214501740|NCT00790699|DEVICE|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
214999266|NCT05666245|BEHAVIORAL|No Intervention - Under High Air Hygiene|"No intervention~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
214391125|NCT00332683|PROCEDURE|Maintaining a normal pressure in the ETT cuff|No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
214391126|NCT02354859|DRUG|Gallium nitrate|Study subjects will receive an infusion of either placebo or gallium nitrate.
214501741|NCT00790699|OTHER|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
215094123|NCT01291693|BEHAVIORAL|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
215094124|NCT01116427|BIOLOGICAL|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
214391127|NCT02354859|DRUG|Normal Saline|Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
214999267|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under Low Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~Low air hygiene is achieved with minimal ventilation."
214999268|NCT05666245|BEHAVIORAL|No Intervention - Under Low Air Hygiene|"No intervention~Low air hygiene is achieved with minimal ventilation."
214999269|NCT07051668|OTHER|Pediatric Sepsis Diagnostic Toolkit|The toolkit consists of the following items: 1) a recommendation to request and report vital signs in all pediatric hospital/ED transfers, 2) dissemination of evidence based pediatric sepsis diagnostic criteria to accepting and referring providers and transfer nurses, and 3) accepting physician education in conversational strategies to promote improved diagnostic accuracy during pediatric transfer conversations.
214999270|NCT07052630|OTHER|Internet-Based Intervention|Interact with PACT website
214999271|NCT07052630|BEHAVIORAL|Patient Navigation|Receive a patient navigation session
214999272|NCT07052630|OTHER|Best Practice|Receive standard/usual care
214999273|NCT07052630|OTHER|Survey Administration|Ancillary studies
214391128|NCT03008421|DIETARY_SUPPLEMENT|Astarte® (HSO Health Care GmbH, Vienna, Austria)|oral intake of Astarte® (HSO Health Care GmbH, Vienna, Austria) as described
214999274|NCT02996773|DRUG|Bendamustine|After transplant, given intravenously on day +4 as part of Phase Ib.
214999275|NCT02996773|DRUG|Cyclophosphamide|After transplant, given intravenously on day +3 as part of Phase 1b.
214999276|NCT04042844|BIOLOGICAL|BRTX-100|Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.
214999277|NCT04042844|DRUG|Saline|Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution
214999278|NCT07054281|DEVICE|UNITY Vitreoretinal Cataract System (VCS)|UNITY VCS is a commercially approved surgical system that facilitates the management of fluid and gases, as well as removal, grasping, cutting, illumination, and coagulation of ocular materials during eye surgery. In this study, the UNITY VCS posterior segment functionalities will be used to perform posterior segment (i.e., vitreoretinal) ophthalmic surgery.
214999279|NCT07054281|DEVICE|CONSTELLATION Vision System|CONSTELLATION is a commercially approved, multifunctional surgical instrument used during ophthalmic surgery to cut vitreous and tissues, emulsify the lens, illuminate the posterior segment of the eye, and apply diathermy to stop bleeding.
214999280|NCT07054281|PROCEDURE|Vitreoretinal ophthalmic surgery|Ophthalmic surgery performed in the posterior segment of the eye
215094125|NCT01116427|DRUG|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
214391129|NCT03008421|OTHER|Placebo|Identical-looking oral potato-maltodextrin-based placebo
214391130|NCT05406960|DIETARY_SUPPLEMENT|Tea infusion|Herbal tea infusion will be administrated by the oral route before food
214391131|NCT06371365|PROCEDURE|Free Flap surgery|No intervention, this is an observational study
214391132|NCT02086552|OTHER|Laboratory Biomarker Analysis|Correlative studies
214391133|NCT02086552|DRUG|Lenalidomide|Given PO
214391134|NCT02086552|DRUG|Sonidegib|Given PO
214391135|NCT02735733|DEVICE|Cold Bakri Balloon|In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
214501742|NCT06180226|DIAGNOSTIC_TEST|PET CT with 18 FDG .|Impact exerted by the use of 18FDG PET in the process of functional monitoring of the patient undergoing radiotherapy treatment.
214999281|NCT07051993|DRUG|ZN-A-1041|Participants will be administered either a ZN-A-1041 capsule or a tablet orally.
214999282|NCT07051993|DRUG|Rabeprazole|Participants will be administered rabeprazole BID.
214999283|NCT07055113|BEHAVIORAL|Individual-based Virtual Physical Therapy Program|"Twelve-week virtual physical therapy that includes one-on-one visits with a physiotherapist.~Multi-modal Self-management program comprises:~* Education to understand OA and its management: 'Understanding \& Managing OA'; 'Activity \& Exercise'; 'Managing Pain'; 'Healthy Eating'; 'Mental \& Emotional Well-being'; 'General Wellness'.~* Personalized Goal Setting in partnership with therapist to promote patient activation.~* Progressive neuro-muscular exercises of the core and lower extremity, customized to patient capacity with participants encouraged to perform exercises at least 2 times/week between PT sessions to improve strength and function; 2 levels of resistance bands will be provided to progress resistance.~* Physical activity goals using FitBit step count, to increase daily activity as tolerated."
215094126|NCT00601913|DRUG|erlotinib hydrochloride|
215094127|NCT00601913|GENETIC|protein analysis|
215094128|NCT00601913|GENETIC|western blotting|
215094129|NCT00601913|OTHER|immunohistochemistry staining method|
215094130|NCT00601913|OTHER|laboratory biomarker analysis|
215094131|NCT00601913|OTHER|liquid chromatography|
215094132|NCT00601913|OTHER|mass spectrometry|
215094133|NCT00601913|PROCEDURE|neoadjuvant therapy|
215094134|NCT00601913|PROCEDURE|therapeutic conventional surgery|
214391136|NCT06152523|DRUG|Monalizumab/MEDI5257|Phase II trial using an A'Hern design with a safety lead-in cohort to assess the safety/tolerability of the combination of monalizumab and MEDI5752 in patients with metastatic MSI/dMMR cancer
214391137|NCT06436963|BEHAVIORAL|narrative medicine training combined with CBL training|The experimental group received narrative medicine training combined with CBL training.
214391138|NCT06436963|BEHAVIORAL|CBL training|The control group received normal CBL training.
214391139|NCT04139915|DRUG|Dactolisib|TORC1 inhibitor
214391140|NCT04139915|DRUG|Placebo|Placebo capsule
214391141|NCT01380301|DRUG|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
214391142|NCT01380301|DRUG|Miltefosine alone|short course (half)
214391143|NCT03088358|DRUG|TeaRx|
214391144|NCT03088358|DRUG|Enoxaparin|
214391145|NCT00708305|DRUG|Sodium Fluoride (NaF)|Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
214391146|NCT00708305|DRUG|Placebo|Fluoride free toothpaste (0ppmF)
214391147|NCT02761174|DRUG|Brimonidine|Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control
214391148|NCT02761174|OTHER|IPL+air-cooling|IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
214501743|NCT02357966|BIOLOGICAL|514G3 (2 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
214501744|NCT02357966|BIOLOGICAL|514G3 (10 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
214501745|NCT02357966|BIOLOGICAL|514G3 (40 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
214999284|NCT07055113|BEHAVIORAL|Group-based Virtual Physical Therapy Program|"Twelve-week virtual physical therapy that includes group classes (4-5 participants) with two physiotherapists. In each session, each participant will also have a 10-12 min one-on-one interaction with one of the physiotherapists.~Multi-modal Self-management program comprises:~Education to understand OA and its management: 'Understanding \& Managing OA'; 'Activity \& Exercise'; 'Managing Pain'; 'Healthy Eating'; 'Mental \& Emotional Well-being'; 'General Wellness'.~Personalized Goal Setting in partnership with therapist to promote patient activation.~Progressive neuro-muscular exercises of the core and lower extremity, customized to patient capacity with participants encouraged to perform exercises at least 2 times/week between PT sessions to improve strength and function; 2 levels of resistance bands will be provided to progress resistance.~Physical activity goals using FitBit step count, to increase daily activity as tolerated."
214999285|NCT07053618|DEVICE|Implantation of the VADLINK Percutaneous Left Ventricular Assist Device|To implant VADLINK percutaneous left ventricular assist device during percutaneous coronary intervention (PCI).
214999286|NCT07053618|DEVICE|VA-ECMO|Received venous arterial extracorporeal membrane oxygenation (VA-ECMO) during PCI.
214999287|NCT06896201|DIAGNOSTIC_TEST|Neuropsychological Assessments and Other Questionnaires|A brief assessment of the cognitive status will be performed by the means of Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale (CDR-SB), Activities of the Daily Living (ADL) and Instrumental Activities of the Daily Living (IADL) scales. Moreover, extended neuropsychological assessments assessing memory, language, executive functions, attention and visuospatial perception will be conducted by trained neuropsychologists, as per clinical practice. Concerning depression and behavioural / neuropsychiatric symptoms, which are known to be relevant in cognitive decline and ageing, data will be collected by the means of Neuropsychiatric Inventory (NPI). Additional questionnaires about subjective cognitive decline, quality of sleep (Pittsburgh scale) and cognitive reserve (CRIq) will be conducted on some subgroups of subjects.
215094135|NCT02989805|BEHAVIORAL|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
215094136|NCT04037150|DIAGNOSTIC_TEST|Circulating tumor DNA|Circulating tumor DNA
214391149|NCT04711460|BEHAVIORAL|Younger participants|Younger Participants 19-29 years received TAU + Tx over 5 weeks
214391150|NCT04711460|BEHAVIORAL|Older participants|older participants 30-54 years received TAU + Tx over 5 weeks
214391151|NCT04711460|BEHAVIORAL|TAU|Participants received TAU or Treatment As Ususal, Cognitive Behavior Therapy only
214391152|NCT04711460|BEHAVIORAL|TAU + MIndfulness practice|Participants received TAU + mindfulness training
214391153|NCT04942860|DRUG|1% Methotrexate gel|1% methotrexate gel applied onto a predefined limb
214501746|NCT02357966|OTHER|Placebo plus standard IV antibiotic treatment|Sterile isotonic formulation buffered at pH 6.2 - 6.5 plus standard IV antibiotic treatment
214391154|NCT04942860|DRUG|0.5% Methotrexate gel|0.5% methotrexate gel applied onto a predefined limb
214391155|NCT02186080|DRUG|Gemigliptin|
214391156|NCT02186080|DRUG|Placebo|
214391157|NCT06143657|DIAGNOSTIC_TEST|Automated Gram Staining Machine analysis|Measure urine and sputum specimens using this device.
214391158|NCT01810627|RADIATION|MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
214391159|NCT03786120|DRUG|Zolpidem|PO sleep aid in various doses
214391160|NCT02823964|DRUG|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
214391161|NCT03996941|BEHAVIORAL|Harm reduction of informal PrEP use|"Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.~Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit."
214391162|NCT03996941|OTHER|PrEP follow up based on point of care testing|The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.
214501747|NCT02357966|BIOLOGICAL|514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II|A single dose of 514G3 plus standard IV antibiotic therapy
214501748|NCT02357966|OTHER|Placebo plus standard IV antibiotic treatment: Phase II|A single dose of placebo plus standard IV antibiotic therapy
214391163|NCT05973318|DRUG|Dorzotimol eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
214391164|NCT05973318|DRUG|Cosopt eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
214391165|NCT04422366|BIOLOGICAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
214391166|NCT04422366|BIOLOGICAL|GARDASIL®|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule
214391167|NCT01324219|BEHAVIORAL|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
214391168|NCT01324219|BEHAVIORAL|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
214391169|NCT02851160|OTHER|semi-structured interview conducted by a clinical psychologist|semi-structured interview conducted by a clinical psychologist
214391170|NCT02851160|OTHER|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
214391171|NCT01737060|DEVICE|Reverse total shoulder arthroplasty|
214391172|NCT03180879|DRUG|Test - RB ibuprofen acid orodispersible tablets|RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
214391173|NCT03180879|DRUG|Reference - RB Nurofen ibuprofen acid tablets|RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
214391174|NCT03180879|DRUG|Comparator - Dolormin ibuprofen lysine tablets|Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
214501749|NCT06509022|DIAGNOSTIC_TEST|PEPTEST test|Quantitative determination of gastric salivary amylase。
214687983|NCT06514352|OTHER|Skin contact immediately after birth|In the immediate skin-to-skin contact group after birth, if the newborn does not need any intervention, he will be placed on the mother's chest immediately (without cord clamping) and skin-to-skin contact will begin. An average of 60 minutes of skin contact will be made until the first breastfeeding occurs. All routine practices for the newborn in the delivery room (except weight measurement) will be performed on the mother's chest. (n=48)
214999288|NCT06896201|BIOLOGICAL|Blood Exams, Fluid Biomarkers, Genetics|All patients will undergo a blood samples collection at T0 and T4, as per clinical practice. Additional blood samples will be collected stored and processed according to literature recommendation-based standardized operating procedures.. Blood will be collected into EDTA tubes and will be immediately refrigerated and centrifugated at 2000x g for 10 minutes. Plasma will then be aliquoted in 0.5 ml polypropylene vials and frozen at -80°C. Levels of blood biomarkers of amyloidopathy, tauopathy, neurodegeneration and neuroinflammation will be measured using the Lumipulse G assays (Fujirebio) and the Multiplex assays for Ella (Biotechne). Whole blood samples will be used for genetic analysis, which will include the determination of APOE genotype
215094137|NCT00329927|BIOLOGICAL|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
214391175|NCT03577808|OTHER|Biopsy|Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.
214391176|NCT03424486|OTHER|Questionnaires|Evaluation of the prevalence of anxiety, depression and quality of life
214391177|NCT02489825|PROCEDURE|Augmentation vertebroplasty|Cement augmentation of fractured vertebral body
214391178|NCT02489825|PROCEDURE|Augmentation and prophylactic vertebroplasty|Cement augmentation of fractured vertebral body and prophylactic augmentation of both adjacent vertebral bodies
214391179|NCT00139022|DEVICE|Continuous Positive Airway Pressure|
214391180|NCT01211236|OTHER|application of wound dressing made of bio-bags (vitapads) containing maggots|
214391181|NCT01211236|OTHER|application of classical hydrogel/alginate wound dressing|
214391182|NCT03132493|DRUG|Nivolumab 10 MG/ML|nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression
214391183|NCT00002793|DRUG|fluorouracil|
214391184|NCT00002793|DRUG|leucovorin calcium|
214391185|NCT00402545|DRUG|Cetuximab|Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
214391186|NCT00402545|DRUG|Docetaxel|Given intravenously on day 1 of each 21-day cycle for 3 cycles
214391187|NCT00402545|DRUG|Cisplatin|Intravenously on day 1 of each 21-day cycle for 3 cycles
214391188|NCT00402545|DRUG|5-Fluorouracil|Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
214391189|NCT01930435|DEVICE|Sterile Humidification Device|This is a personal humidification device. It is hand held and produces sterile warm vapor.
214391190|NCT02826018|DRUG|ALN-HBV|Ascending doses of ALN-HBV by subcutaneous (sc) injection
214391191|NCT02826018|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
214391192|NCT00334867|DRUG|cyclophosphamide|Given IV
214391193|NCT00334867|DRUG|dexrazoxane hydrochloride|Given IV
214501750|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
214501751|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
214501752|NCT01332552|DRUG|GSK2485852 70 mg|single dose
214501753|NCT01332552|DRUG|GSK2485852 420 mg|single dose
214501754|NCT01332552|DRUG|placebo|single dose
214501755|NCT01332552|DRUG|placebo|Repeat dose, once daily for 3 days
214501756|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
214687984|NCT06514352|OTHER|Very Early Skin contact|In the very early skin-to-skin contact group, skin-to-skin contact will begin within the first 30-40 minutes after birth, after the first and emergency intervention is given to the newborn in need of intervention, and skin-to-skin contact will be carried out for an average of 60 minutes until the first breastfeeding occurs.(n=48)
214391194|NCT00334867|DRUG|doxorubicin hydrochloride|Given IV
214391195|NCT00334867|DRUG|etoposide|Given IV
214391196|NCT00334867|DRUG|ifosfamide|Given IV
214999289|NCT06896201|OTHER|Connectivity Analysis|"Functional Magnetic Resonance Imaging (fMRI) and/or high-density electroencephalography (EEG) will be used to assess connectivity in selected group of subjects. EEG data will be collected during four 5-minute runs of alternating eyes-open and eyes-closed conditions using a 128-electrode high-density EEG system.~The EEG spectral coherence analysis will evaluate the functional coupling between the brain areas under study. Brain connectivity measures will be computed for each frequency band and for each subject, to be used as measure of weight of the graph in a graph analyses.~A subsample of subjects will be also investigated with connectivity measures of MRI by applying FA e DTI technique. All the data will be collected both at baseline and after a 2-years-period during which the prevention and intervention strategies will be performed."
214999290|NCT06896201|DEVICE|Physical Activity|Participants will be proposed an unsupervised, monitored exercise program consisting of three 60-minute sessions of moderate-intensity aerobic exercise (40%-85% of their maximum heart rate) each week. To track exercise intensity. The activity will be personalized according to specific attitude of each subjects including walking session, bike sessions or swim sessions. The type, frequency and intensity of the activity will be recorded by means of a commercially available wearables (Garmin Vivosmart 4, Garmin Vivosmart 5) and the Healthentia application. Those non using the wearables will keep a diary of the activity. Study investigators will ensure both protocol adherence and participant safety through regular follow-up telephone contacts.
214999291|NCT06896201|DEVICE|Healthentia|Healthentia, developed by Innovation Sprint, is a Software as a Medical Device (SaMD) designed for remote patient monitoring, virtual coaching, and automatic alerts using real-world data. It has been successfully used in over 20 studies and integrates features like teleconsultations, activity tracking, medication management, and support for wearable devices. It provides a patient companion app, offering remote patient monitoring and self-reporting, personalized advice or content in the form of dialogues. It is designed to optimize and improve patient engagement and ensure data integrity. The software facilitates daily self-reporting, providing information to patients and collecting other current data through self-reported questionnaires (health status, physical activity, quality of life, etc.), which will be crucial in order to control the adherence of patients to the program
214391197|NCT00334867|DRUG|topotecan hydrochloride|Given IV
214391198|NCT00334867|DRUG|vincristine sulfate|Given IV
214391199|NCT00334867|PROCEDURE|conventional surgery|Patients undergo surgery in week 18
214391200|NCT00334867|PROCEDURE|radiation therapy|Patients undergo radiation therapy in week 19
214391201|NCT05765097|DEVICE|Artificial pancreas treatment|five to seven days treatment by artificial pancreas system
214391202|NCT04718714|DRUG|Midazolam|loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.
214999292|NCT06896201|DEVICE|Eligence|Based Platform exercising the brain and the cognitive skills through 35+ games and activities designed by specialized health experts. It offers over 30 games focusing on cognitive skills such as memory, reasoning, attention, orientation, executive functions, construction skills, and language. It allows healthcare professionals to create personalized training sessions, monitor performance in real-time, and generate detailed evaluation reports. Accessible from any device, it is aimed at individuals in early stages of dementia or rehabilitation phases. In our clinical study, subjects will be trained on seven cognitive programs, which can be executed at home with or without assistance and supervision of a Health Professional (who can easily create personalized sessions to follow-up at distance) and/or an informal carer
215094138|NCT02211313|DEVICE|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
214391203|NCT04718714|DRUG|Propofol|loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.
214391204|NCT04718714|DRUG|Dexmedetomidine|loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
214391205|NCT00723424|DRUG|AZD5672|50 mg, for 13 days
214391206|NCT00723424|DRUG|Digoxin|0.5mg dose
214391207|NCT05239416|PROCEDURE|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
214391208|NCT01495182|OTHER|Dietary fiber|A proprietary fiber will be given to subjects
214391209|NCT05013996|BEHAVIORAL|MIDSA|Multidimensional Inventory of Development, Sex, and Aggression
214391210|NCT05013996|BEHAVIORAL|Usual methods of evaluation|Usual methods of evaluation of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
214391211|NCT03017989|DEVICE|NIRF imaging|By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
214391212|NCT03394261|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
214391213|NCT05856240|BEHAVIORAL|Managing Stress & Emotions Group (MSEG)|The intervention consists of 6, 90-minute weekly sessions and includes the following components: providing education about psychological and emotional reactions to stress, introducing and practicing coping skills (e.g., mindfulness, emotional awareness, flexible thinking, behavioral modification), decreasing psychological avoidance using emotional exposure, and facilitating group support and discussion (see De Paul \& Caver, 2021 for original protocol description).
214391214|NCT00464919|DRUG|Sorafenib|
214391215|NCT00464919|DRUG|tegafur/uracil (UFUR®)|
214391216|NCT00004003|DRUG|cisplatin|
214391217|NCT00004003|DRUG|fluorouracil|
214391218|NCT00004003|DRUG|gemcitabine hydrochloride|
214391219|NCT00441051|DRUG|Diclofenac sodium 1mg/g|
214391220|NCT03940235|DRUG|Androgen deprivation therapy (ADT)|SBRT + ADT
214391221|NCT03940235|RADIATION|SBRT|SBRT to all radiological documented lesions (bone or lymphnodes)
214501757|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
214391222|NCT03324737|DEVICE|Interactive Smartphone App|"There are six main components to the APP.~* Goal Setting: personalizes diet, activity, and weight loss goals for patients based on their starting point.~* Food choices and recommendations: App has an automated and immediate recommendation of foods if the choice selected from food database is not optimal. It has a calorie and nutrients tracker to enable patients to track their food intake.~* Activity and steps tracker: App has a pedometer to count physical activity and steps to enable patients to track their progress towards goals.~* Interactive video lessons: App has video lessons pushed weekly to the patient according to her needs. The videos encompass aspects of diet, lifestyle and behavior management.~* Healthcare Professionals Support: App has a chat channel to enable interaction between participants and healthcare professionals."
214391223|NCT02325232|DEVICE|Capsule endoscopy, double balloon enteroscopy sequential use|Small bowel capsule endoscopy followed by double-balloon enteroscopy with histological sampling in case of mucosal alterations
214391224|NCT00326690|DEVICE|Blue Egg Device|
214391225|NCT01560377|DEVICE|PINPOINT Endoscopic Fluorescence Imaging System|The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
214391226|NCT02796547|DRUG|Levobupivacaine|Infiltration of the banks of the episiotomy done with Levobupivacaine
214391227|NCT02796547|OTHER|Physiological serum|Infiltration of the banks of the episiotomy done with physiological serum
214391228|NCT00872469|DRUG|Tranexamic acid|1-2 grams by intravenous injection
214391229|NCT00872469|DRUG|Placebo [Saline]|Matched to active comparator
214391230|NCT00003143|DRUG|Amifostine|
214391231|NCT00003143|DRUG|DHAP|
214391232|NCT04506580|PROCEDURE|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) vs subcuticular nylon suture|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and subcuticular nylon suture are applied for each knee
214391233|NCT04012814|DEVICE|Venus Bliss|The FDA cleared device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
214391234|NCT00390455|DRUG|Fulvestrant|Given IM
214391235|NCT00390455|OTHER|Laboratory Biomarker Analysis|Correlative studies
214391236|NCT00390455|DRUG|Lapatinib Ditosylate|Given PO
214391237|NCT00390455|OTHER|Placebo Administration|Given PO
214391238|NCT02891044|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-040)
214391239|NCT01148342|DRUG|MDMA|
214391240|NCT01148342|DRUG|(+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules|0, 1.0 \&amp; 1.6 mg/kg
214501758|NCT01332552|DRUG|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
214391241|NCT03022240|DRUG|Propofol|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
214391242|NCT03022240|DRUG|Sevoflurane|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
214391243|NCT03022240|DRUG|Ametop|Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.
214391244|NCT03022240|DRUG|Ondansetron|Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
214391245|NCT04397523|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
214391246|NCT02089581|DRUG|Active comparator MR2XXX|comparison of two new oral formulations with existing formulation
214391247|NCT02089581|DRUG|MRXXX|MRXXX
214391248|NCT02089581|DRUG|MR1XXX|
214391249|NCT02089581|DRUG|MRXXX and MR1XXX|MRXXX and MR1XXX in fed and fasted state
214391250|NCT02183428|DRUG|BI 1356|
214391251|NCT02183428|DRUG|Glyburide|
214391252|NCT02183428|DRUG|BI 1356 + Glyburide|
214391253|NCT02810691|DIETARY_SUPPLEMENT|Soluble fiber supplementation|Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.
214391254|NCT02810691|DIETARY_SUPPLEMENT|Placebo (for fiber supplementation)|Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
214391255|NCT04555915|OTHER|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
214391256|NCT05206864|OTHER|Medical Food: SBD111|One capsule administered twice daily with morning and evening meals for 28 days
214391257|NCT05206864|OTHER|Placebo|One capsule administered twice daily with morning and evening meals for 28 days
214501759|NCT01332552|DRUG|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
214501760|NCT01332552|DRUG|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
214501761|NCT01332552|DRUG|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
214501762|NCT02554006|BEHAVIORAL|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
214391258|NCT01275196|DRUG|Nilotinib|
214391259|NCT01275196|DRUG|Imatinib|
214391260|NCT00562068|BIOLOGICAL|alemtuzumab|
214391261|NCT00562068|DRUG|cyclophosphamide|
214391262|NCT00562068|DRUG|doxorubicin hydrochloride|
214391263|NCT00562068|DRUG|prednisolone|
214391264|NCT00562068|DRUG|vincristine sulfate|
214391265|NCT00562068|GENETIC|polymerase chain reaction|
214391266|NCT00562068|OTHER|flow cytometry|
214391267|NCT00562068|OTHER|laboratory biomarker analysis|
214391268|NCT00562068|OTHER|pharmacological study|
214501763|NCT02554006|BEHAVIORAL|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
214501764|NCT01420497|DRUG|intra-articular infiltration|intra articular infiltration
214391269|NCT00535743|DRUG|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.
214391270|NCT00535743|DRUG|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,
214391271|NCT00535743|DRUG|Esmeron®|Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
214391272|NCT02636894|DEVICE|Restylane Silk|
214391273|NCT02864043|DEVICE|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
214501765|NCT01420497|DRUG|epidural infiltration|epidural infiltration
214391274|NCT02864043|PROCEDURE|esophagogastroduodenoscopy (EGD)|Standard of care EGD
214391275|NCT03923218|OTHER|LL-37 levels in Gingival crevicular fluid|Collected gingival crevicular fluid
214391276|NCT03923218|OTHER|Serum Vitamin D3 levels|Collected serum
214501766|NCT04388137|OTHER|No intervention.|No intervention.
214501767|NCT03605732|BEHAVIORAL|self help sleep hygiene intervention application|This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.
214501768|NCT03605732|OTHER|patients education|Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
214999293|NCT06896201|OTHER|Nutrition|Participants will follow a personalized nutrition plan, as per clinical practice, receiving dietary advice derived by the same scheme already used in the FINGER project on prevention. The plan focuses on balanced, nutrient-rich meals, based on the reduction of carbohydrate assumption and stable inclusion of seeds, vegetables, fish and omega 3 aliments in the diet that may protect the brain through anti-inflammatory and antioxidant properties. A diary of the meals will be recorded in a diary included in the Healthentia application. No integrated meals or nutraceutical product will be used.
214999294|NCT06739655|RADIATION|Preoperative radiotherapy|"In this study the patients assigned to the experimental treatment arm will receive preoperative radiotherapy instead of postoperative radiotherapy.~This preoperative radiotherapy will follow the standard of care (SoC) principles as they are defined for postoperative radiotherapy in breast cancer, as defined by international guidelines."
214999295|NCT06739655|RADIATION|Postoperative radiotherapy|Standard of care (SoC) postoperative radiotherapy, as defined by international guidelines.
214999296|NCT06739655|PROCEDURE|Immediate breast reconstruction|In the experimental arm of the PRADAIIBE, the participants will undergo immediate breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery. Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.
214999297|NCT06739655|PROCEDURE|Immediate or delayed breast reconstruction|In the standard arm of the PRADAIIBE, the participants will undergo immediate or delayed breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery (immediate), or at a later time (delayed). Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.
214999298|NCT06740721|DEVICE|False Lumen Embolization System, IMPEDE-FX RapidFill|Embolization of the false lumen of an aortic dissection
214999299|NCT06840548|DRUG|[68Ga]Ga-OncoCAIX|Single intravenous bolus administration.
214999300|NCT07055555|BEHAVIORAL|Acute Stress|Participants randomized to the acute stress condition will complete the Trier Social Stress Test (TSST), a validated experimental method for inducing acute psychosocial stress. The TSST consists of a brief anticipation period followed by a 5-minute mock job interview and a 5-minute surprise mental arithmetic task, performed in front of a neutral panel of judges in professional attire.
215094139|NCT03528005|BEHAVIORAL|Multi-domain intervention|60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
214687985|NCT06514352|OTHER|Early Skin contact|For newborns who need intervention after birth and whose skin-to-skin contact cannot be started in the delivery room, skin-to-skin contact will begin within the first 24 hours after birth, after the newborn becomes stable.(n=48)
214391277|NCT03923218|OTHER|Clinical parameters|Recorded plague index, gingival index, probing depth, clinical attachment level
214391278|NCT03257293|BEHAVIORAL|Modified Cystoscopy|The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.
214391279|NCT03257293|BEHAVIORAL|Routine Cystoscopy|Routine cystoscopy as done as part of routine clinical practice
214391280|NCT00362102|DRUG|Cetuximab|
214391281|NCT03937323|OTHER|Blood lymphocyte subtypes and serum cytokines|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine the proinflammatory cytokines
214501769|NCT00729898|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
214501770|NCT00019604|PROCEDURE|computed tomography|Scan to assess the effects of ablation.
214501771|NCT00019604|PROCEDURE|magnetic resonance imaging|Imaging used to assess the effects of this ablative therapy on tumor vascular density.
214501772|NCT00019604|PROCEDURE|positron emission tomography|Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
214687986|NCT06804850|DRUG|Tislelizumab|200mg IV Q3W
214687987|NCT06804850|DRUG|Afatinib|30mg PO QD
214687988|NCT06804850|RADIATION|Low dose radiotherapy|4Gy / 2f. Intensity-modulated radiotherapy was used for radiotherapy.
214391282|NCT02546063|OTHER|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
214391283|NCT03034317|DEVICE|NeuRx DPS|Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.
214391284|NCT03862651|DRUG|Cangrelor|Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.
214999301|NCT07055555|BEHAVIORAL|Non-Stress Control Task|Participants randomized to the control condition will complete a non-stressful task designed to parallel the structure of the Trier Social Stress Test without eliciting acute stress. They will have a brief anticipation period followed by a 5-minute description of their typical day or favorite hobby. This task is conducted without an evaluative panel, minimizing the potential for stress or anxiety.
214999302|NCT03157635|DRUG|Crovalimab|Crovalimab will be administered as per schedule described in individual arm.
214999303|NCT03157635|DRUG|Placebo|Placebo will be administered as per schedule described in Part 1 placebo arm.
214999304|NCT07056400|PROCEDURE|First Ejaculate for ICSI|Intervention 1: First Ejaculate for ICSI In this intervention, sperm collected from the first ejaculate will be used in Intracytoplasmic Sperm Injection (ICSI). The sperm will be analyzed for motility, morphology, and concentration before being used in fertilization and embryo culture. This arm will evaluate the quality of sperm obtained from the first ejaculate
214999305|NCT07056400|PROCEDURE|Second Ejaculate for ICSI|In this intervention, sperm collected from the second ejaculate (obtained within 1-2 hours after the first ejaculate) will be used in Intracytoplasmic Sperm Injection (ICSI). The sperm will be analyzed for motility, morphology, and concentration before being used for fertilization and embryo culture. This arm will evaluate the quality of sperm obtained from the second ejaculate and its impact on fertilization rates and embryo development
214999306|NCT07057115|PROCEDURE|vNOTES Salpingectomy Group.|Participants will undergo salpingectomy using the vaginal natural orifice transluminal endoscopic surgery (vNOTES) technique. This minimally invasive procedure is performed transvaginally without abdominal incisions, offering potential benefits such as less postoperative pain, faster recovery, and better cosmetic outcomes.
214999307|NCT07057115|PROCEDURE|Laparoscopic Salpingectomy|Participants will undergo conventional laparoscopic salpingectomy, a minimally invasive surgical technique performed through small abdominal incisions using a laparoscope. This method is the current standard approach for managing ectopic pregnancies.
214999308|NCT06786533|DRUG|Anti-FLT3 CAR-T cells|Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.
214999309|NCT06742346|BEHAVIORAL|Non Tailored Messages|Generic messages promoting a plant-based diet were developed, with each message addressing one of the three most commonly mentioned motives for plant-based eating (Miki et al., 2019; Miki et al., 2020): health motives, environmental motives, and animal welfare motives. All messages were designed to be factual (including science-based statistics), concise (4-5 sentences), relevant to teens (e.g., addressing health concerns like acne), and autonomy-supportive (offering suggestions and tips rather than directives) (Hingle et al., 2013). The messages were intentionally crafted in a neutral linguistic style, avoiding highly emotive language, non-standard syntax, or emojis. These messages are delivered from Monday to Friday for two weeks.
215094140|NCT04622904|DRUG|lidocaine-magnesium infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 0.2 mg/kg/h of ketamine will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
214391285|NCT04657549|PROCEDURE|Tonsillectomy|Tonsillectomy is done by monopolar electrocautery, bipolar scissors or cold instruments. First the mucosa of the anterior palatinal arch is incised and tonsillar capsule identified, then tonsillar tissue is removed along the capsule. Any bleeding is coagulated either with monopolar or bipolar electrocautery.
214391286|NCT04657549|PROCEDURE|Tonsillotomy|Tonsillotomy is done using monopolar electrosurgery, bipolar scissors or coblator device. Most of the tonsillar tissue is removed, exceeding the removal behind the line between anterior and posterior palatinal arch so that only thin layer of tonsil tissue is left over the tonsillar capsule.
214391287|NCT00199030|DRUG|Alemtuzumab (MabCampath)|
214391288|NCT00199030|DRUG|Cladribine|
214501773|NCT00019604|PROCEDURE|radiofrequency ablation|Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.
214501774|NCT00019604|PROCEDURE|radionuclide imaging|Imaging following injection of a radioactive material.
214501775|NCT00019604|PROCEDURE|ultrasound imaging|An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.
214391289|NCT04022837|DRUG|Pantoprazole 40mg|effect of this drug on renal function
214391290|NCT00832338|DRUG|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
214391291|NCT00832338|DRUG|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
214391292|NCT00239785|DRUG|FTY720|
214391293|NCT05776082|OTHER|Questionnaire survey and specimen collection|Questionnaire survey, clinical follow-up and specimens collection.
214501776|NCT00019604|RADIATION|fludeoxyglucose F 18 (FDG-PET)|FDG PET scans rely on metabolic changes to evaluate response to therapy.
214501777|NCT00019604|RADIATION|gadopentetate dimeglumine|Food and Drug Administration approved contrast agent.
214501778|NCT05986994|OTHER|Metabolic acidosis|Metabolic acidosis at birth with umbilical cord arterial pH at birth \< 7.12
214501779|NCT05986994|DIAGNOSTIC_TEST|microRNA|Evaluation of microRNA levels
214501780|NCT05986994|OTHER|Hypothermia|Therapeutic induced hypothermia refers to a lowering of the central body temperature for therapeutic purposes
214501781|NCT02013115|DRUG|Budesonide|Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
214999310|NCT06742346|BEHAVIORAL|Linguistically tailored health messages|Linguistically tailored messages are generated using a Large Language Model. Generic messages promoting a plant-based diet were customized to align with participants' linguistic style, including their preferred choice of words, expressed valence, syntax, and emoji use. These messages are delivered from Monday to Friday for two weeks.
214999311|NCT05979935|DIAGNOSTIC_TEST|tongue diagnosis|The tongue image of participants will be collected via camera, and tongue images will be used for AI deep model learning analysis.
214999312|NCT01786265|DRUG|Abiraterone Acetate|Given PO
214999313|NCT01786265|DRUG|Bicalutamide|Given PO
214999314|NCT01786265|DRUG|Degarelix|Given via injection
214999315|NCT01786265|DRUG|Flutamide|Given PO
214391294|NCT04329858|PROCEDURE|silver modified glass ionomer|occlusal cavity filled with silver modified
214391295|NCT04329858|PROCEDURE|zinc modified|occlusal cavity filled with zinc modified
214391296|NCT04329858|PROCEDURE|conventional glass ionomer|occlusal cavity filled with conventional glass ionomer
214391297|NCT02125123|OTHER|Nutritional Supplement and Counseling|Ready-to-feed nutritional supplement and dietary counseling
214391298|NCT02125123|OTHER|Counseling|Dietary counseling
214391299|NCT00981825|DRUG|Fluoride|Whole mouth brushing for 7 days
214391300|NCT00981825|DRUG|Triclosan/Fluoride|Brush whole mouth twice daily for 7 days
214391301|NCT05887804|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
214391302|NCT05887804|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
214391303|NCT05887804|DRUG|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
214391304|NCT03119571|PROCEDURE|Initial CCL admission|Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions
214391305|NCT03119571|DIAGNOSTIC_TEST|Initial ICU admission|Evaluate for additional testing and/or procedures
214391306|NCT03969082|BEHAVIORAL|Bibliotherapy|Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
214391307|NCT02342587|DRUG|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
214391308|NCT05390138|BEHAVIORAL|Smart Sleep Apnea Self-management Support Programme (4S)|The experimental group will receive usual care and Smart Sleep Apnea Self-management Support Programme (4S). The 4S includes two interview sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to self-management. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
214391309|NCT05390138|BEHAVIORAL|General Hygiene Information (GH)|The control group will receive usual care and general hygiene information (GH). The GH includes two GH sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to general hygiene information. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
214391310|NCT03056859|DEVICE|Extravascular blood pressure transducer|Listed device is included in central venous catheter placement apparatus for consenting patients, according to manufacturer directions
214501782|NCT04203966|DIAGNOSTIC_TEST|12-item General Health Questionnaire (GHQ-12)|Structured validated screening tools to assess for the presence of CMDs, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
214391311|NCT06116214|OTHER|Vachellia Nelotica|As a root canal irrigant (herbal)
214501783|NCT04203966|DIAGNOSTIC_TEST|WHO AUDIT (World Health Organization- Alcohol Use Disorders Inventory Tool)|Structured validated screening tools to assess for the presence of alcohol use disorders, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
214999316|NCT01786265|DRUG|Goserelin Acetate|Given via injection
214999317|NCT01786265|DRUG|Leuprolide Acetate|Given via injection
214999318|NCT01786265|DRUG|Nilutamide|Given PO
214999319|NCT01786265|DRUG|Prednisone|
214999320|NCT06213831|DRUG|Ruxolitinib Cream 1.5%|Ruxolitinib Cream 1.5%
214999321|NCT06004882|OTHER|PNS therapy|PNS therapy-NS is a 60-day therapy targeting chronic pain. The procedure involves implanting a small piece of wire next to the nerve causing pain, and the wire is connected to an external device that is then used to apply electric pulses to the nerve, blocking pain signals, for 60 days
214999322|NCT06004882|DRUG|Triamcinolone|Given by Injection
214999323|NCT06004882|DRUG|Bupivacaine|Given by Injection
214999324|NCT06004882|OTHER|Placebo|Given by Injection
214999325|NCT03324646|DRUG|[11C]PS13|A novel PET ligand to selectively image COX-1
214999326|NCT07061340|BEHAVIORAL|Therapeutic Touch|no Therapeutic Touch
214999327|NCT07059767|DRUG|ETH47|single intranasal dose of ETH47
214999328|NCT07059767|DRUG|Placebo|single intranasal dose of placebo
214999329|NCT07057089|DRUG|Capecitabine|Capecitabine: 825mg/m2, bid;
214999330|NCT07057089|DRUG|Camrelizumab|Camrelizumab: 200mg
214999331|NCT07057089|DRUG|CAPOX|CAPOX
214999332|NCT07057089|RADIATION|Involve-field irradiation|Involve-field irradiation: Primary rectal tumor + metastatic or suspicious pelvic lymph nodes, mesorectal region, and presacral region
214999333|NCT07057089|RADIATION|Elective nodal irradiation|Elective nodal irradiation: Large pelvic field
214999334|NCT07057089|PROCEDURE|TME surgery|TME surgery
214391312|NCT06116214|OTHER|sodium hypochlorite|As a root canal irrigant
214391313|NCT02838628|DRUG|50 mg of KX2-391 Ointment 1%|Dose: 50 mg; Route of administration: Topical
214391314|NCT02838628|DRUG|50 mg of KX2-391 Ointment 1%|Dose: 50 mg; Route of administration: Topical
214391315|NCT05045911|PROCEDURE|Endoscopic Barbed-clips Suturing|Endoscopic Barbed-clips Suturing
214391316|NCT02547571|DRUG|High volume PEG split-dose|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
214391317|NCT02547571|DRUG|Low volume PEG split-dose|Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
214391318|NCT02547571|DRUG|High volume PEG non split, day before|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
214391319|NCT02547571|DRUG|Low volume PEG non split, same day|Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
214391320|NCT02547571|OTHER|Clear liquid diet|
214391321|NCT02547571|OTHER|Low residue diet|
214999335|NCT05888857|DRUG|MEDI5752|A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
214999336|NCT01838538|DRUG|Bevacizumab|
214999337|NCT01838538|DRUG|TC:paclitaxel + carboplatin|
214999338|NCT06757205|DIAGNOSTIC_TEST|Using a structured questionnaire to collect quantitative and qualitative data on adolescents' experiences and perceptions. The Italian version of the Mentalization Questionnaire (MZQ) was develop|"Using a structured questionnaire to collect quantitative and qualitative data on adolescents' experiences and perceptions.~* The Italian version of the Mentalization Questionnaire (MZQ) was developed as a self-rated instrument to assess mentalization. It consists of 15 items with responses ranging from 1 = 'no agreement at all' to 5 = 'total agreement' on a 5-point Likert scale. Calculated sum scores for the total scale range from 15 to 75 with higher scores indicating lower mentalization capacities.~* The Toronto Alexithymia Scale (TAS) is a measure of deficiency in understanding, processing, or describing emotions (alexithymia). It has twenty statements rated on a five-point Likert scale. The total score ranges from 40 to 200 and the higher score indicates a greater level of alexithymia."
214999339|NCT05387642|DRUG|10 mg PRAX-114, 20 mg PRAX-114, and Placebo|Single dose with a washout period between doses
214999340|NCT05387642|DRUG|10 mg PRAX-114 or 20 mg PRAX-114|Once daily oral treatment for 28 days
214999341|NCT07053787|BEHAVIORAL|Standard Yoga|Weekly hatha yoga for 12 weeks augmented by home practice guided by yoga instructional videos.
215094141|NCT04622904|DRUG|lidocaine-ketamine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
214391322|NCT02547571|OTHER|Early colonoscopy (stratified)|"Early appointments: 7:30 AM to 10h30 AM"
214501784|NCT05897905|BEHAVIORAL|Personalised, holistic follow-up appointments underpinned by self determination theory|"Appointment 1 (two weeks after discharge):~* Address participants knowledge gaps as regards their stroke, medication and secondary prevention.~* Detailed biopsychosocial review.~* Understand participant priorities and jointly set goals.~* Agreeing onward referrals if needed.~* Written summary sent to GP with copy to participant.~Appointment 2 (six weeks):~* Review priorities identified in post stroke review checklist.~* Review goals and plans from first appointment.~* Address any new or persistent information gaps.~* Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being.~* Agreeing onward referrals and action plan.~* Written summary and plan sent to GP."
214391323|NCT02547571|OTHER|Later colonoscopy (stratified)|"Later appointments: 10:30 AM to 4:30 PM."
214391324|NCT05490693|OTHER|Experimental group|Experimental group: 26 control group group: 26
214391325|NCT04000932|DRUG|Local platelet rich plasma (PRP) injection-T-Lab PRP kit|Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.
214391326|NCT04000932|DRUG|Local steroid injection-Diprospan ®, Schering Plough|The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
214391327|NCT02228473|DRUG|Glycopyrrolate|Glycopyrrolate will be administered.
214391328|NCT02228473|DRUG|Atropine|Atropine will be administered.
214391329|NCT02323893|DRUG|[18F]F-AraG|
214999342|NCT07053787|BEHAVIORAL|Enhanced Yoga|"Weekly hatha yoga for 12 weeks augmented by home practice guided by yoga instructional videos ...~plus six weekly 50-minute 1-on-1 coaching sessions starting week 10 of the standard yoga intervention and ending week 15 (3 wks after end of standard yoga). During this transition, participants are supported with development and execution of their plan for continuing their yoga practice. Participants will be offered 1 additional ad-hoc coaching session to help them re-start yoga if they get off track and/or experience major life events such as moving, job change, medical issues, etc."
214391330|NCT04374929|DEVICE|StealthTrac Temporary Pacing Lead Plus Negative Pressure Wound Therapy|Following fixation of the StealthTrac Lead, Negative Pressure Wound Therapy is applied over the incision site.
214391331|NCT04374929|DEVICE|StealthTrac Temporary Pacing Lead Plus Anti-Inflammatory Glucocorticoid|"• Methylprednisolone 125 mg administered over 30 minutes beginning at least 30 minutes prior to the incision and StealthTrac Lead insertion procedure. This intravenous dose can be repeated every 8 hours on day one of the insertion from 1-3 doses depending on the patient's ability to take oral medications. It can be administered daily thereafter until the patient is able to take oral dosing. In normal circumstances, post op day 2, commence oral glucocorticoid (see below for recommended oral dosing).~Oral (PO) glucocorticoid preparations and dosing:~* Prednisone 40-60 mg orally daily based on BMI category. BMI categories: Low (\<18); Medium (18-30); High (\>30). Low and medium are assigned 40 mg daily. High BMI is assigned 60 mg daily dose. This while the StealthTrac lead remains in place.~* Methylprednisolone 16-32 mg daily based on BMI (low, medium and high) while the StealthTrac Lead remains in place."
214391332|NCT04374929|DEVICE|Two StealthTrac Temporary Pacing Leads (Increased Electrode Spacing)|"Once the first StealthTrac Lead is placed using the procedure described in the AtaCor Temporary Pacing System Instructions for Use (DOC-10085), load a second StealthTrac Lead into the same MACH I Delivery Tool, unless it was damaged during insertion of the first StealthTrac Lead, in which case a new MACH I Delivery Tool should be used.~Insert the second StealthTrac Lead through (1) a different intercostal muscle path within the same intercostal space or (2) within an adjacent intercostal space. Increased electrode spacing is achieved by pacing between the leads."
214391333|NCT04374929|DEVICE|StealthTrac Lead Only (Control)|A single StealthTrac Lead is placed with no additional treatment.
214391334|NCT05447793|DEVICE|Fitostimoline plus|Formulation in gauzes and cream
214391335|NCT05447793|DEVICE|Connettivina bio plus|Formulation in gauzes and cream
214391336|NCT04676828|DIAGNOSTIC_TEST|Single-photon-emission CT scan|SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung
214391337|NCT02689791|DIETARY_SUPPLEMENT|Resistant Starch Type 4|single dose 26g fiber given at the breakfast meal
214391338|NCT02518724|PROCEDURE|RIPC intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
214391339|NCT02518724|PROCEDURE|placebo intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
214391340|NCT02341144|PROCEDURE|Pre-op percutaneous rectus sheath block|After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
214391341|NCT02341144|PROCEDURE|Intra-operative rectus sheath block|After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
214391342|NCT02341144|DRUG|Ropivacaine|
214391343|NCT02349464|OTHER|Specialized Preterm Infant/Mother Dyad Lactation Support|Mother will receive home equipment and pediatric clinic lactation support.
214391344|NCT05882084|DIETARY_SUPPLEMENT|Astaxanthin 6 mg daily|Astaxanthin at 6 mg is given for daily ingestion and compared against placebo.
214391345|NCT05882084|DIETARY_SUPPLEMENT|Placebo|Placebo
214391346|NCT02579356|DRUG|Telmisartan|
214391347|NCT02579356|DRUG|Atorvastatin|
214391348|NCT02885493|BEHAVIORAL|tests|
214391349|NCT01416896|PROCEDURE|Hemodialysis using the standard venous needle|Hemodialysis using the standard venous dialysis needle
214391350|NCT01416896|PROCEDURE|"Hemodialysis using a new venous needle, the BME needle"|"Hemodialysis using a new venous dialysis needle or the BME needle"
214391351|NCT01416896|PROCEDURE|"Hemodialysis using a new venous needle, the BME needle"|"One hemodialysis using a new venous needle, the BME needle"
214391352|NCT01416896|PROCEDURE|Hemodialysis using the standard venous needle|One hemodialysis using the standard venous needle
214391353|NCT00282360|DRUG|Trimetazidine|
214391354|NCT04221061|DRUG|18F-FluorThanatrace|18F-FluorThanatrace is a novel radiopharmaceutical which measure PARP-1 expression using a Positron Emission Tomography (PET/CT) scan.
214391355|NCT00714350|BEHAVIORAL|New ICU Display Visualization|
214391356|NCT05033080|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
214999343|NCT05164978|DRUG|DEP combine with PD-1 antibody|Doxorubicin hydrochloride liposome injection 25 mg/m2 day 1 Etoposide 100 mg/m2 day1 Methylprednisolone 1.5 mg/kg days 1 to day 3, 0.25mg/kg days 4 to 14 Sintilimab Injection 200mg d4
214999344|NCT06602479|DRUG|MEDI0618|MEDI0618 per protocol
214999345|NCT06602479|DRUG|Placebo|Volume-matched placebo for all arms
214999346|NCT06603779|DEVICE|Ultasound Therapy|a device that transmit ultrasound waves to the participant through direct contact
214999347|NCT06603779|OTHER|Integrated Neuromuscular technique|Integrated Neuromuscular technique is a kind of Manual therapy which include Ischemic Compression, Strain counter-strain and muscle energy technique
214999348|NCT06603779|OTHER|Cervical and Scapular Stabilization exercises|Cervical and Scapular Stabilization exercises are a group of therapeutic exercises.
214391357|NCT05033080|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
214391358|NCT05033080|DRUG|IVA|Tablet for oral administration.
214391359|NCT05033080|DRUG|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
214391360|NCT05033080|DRUG|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
214391361|NCT05033080|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
214391362|NCT06033651|RADIATION|x-ray|AP view of pelvis
214999349|NCT06842017|DEVICE|Passive Exoskeleton.|The passive exoskeleton is used to assist patients with shoulder musculoskeletal disorders during the performance of activities of daily living (ADLs), such as overhead reaching and lifting. The device helps reduce biomechanical load and muscle strain, providing support for the shoulder joint.
214999350|NCT06842017|PROCEDURE|Shoulder Rehabilitation with Passive Exoskeleton.|The rehabilitation protocol involves the use of a passive exoskeleton during physical tasks to improve shoulder function and reduce pain. Patients perform specific exercises while wearing the exoskeleton, which is tailored to their individual needs.
214999351|NCT06842017|OTHER|Usability Assessment and Patient Satisfaction.|The usability of the passive exoskeleton is evaluated using validated scales, such as the System Usability Scale (SUS), to assess its comfort, effectiveness, and overall satisfaction. The assessment also includes patient feedback on the ease of use and perceived benefits of the device during rehabilitation sessions.
214999352|NCT06740760|BEHAVIORAL|Genetic counselling|Behavioral: genetic counselling
214999353|NCT06740760|BEHAVIORAL|Leaflet|Genetic information as a form of a leaflet
214391363|NCT03499379|DEVICE|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
214391364|NCT03499379|DEVICE|Paraguard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
214391365|NCT01566305|DIETARY_SUPPLEMENT|Buttermilk without added egg-yolk|Buttermilk without added egg-yolk
214391366|NCT01566305|DIETARY_SUPPLEMENT|Buttermilk with added egg yolk|Buttermilk with added egg yolk
214391367|NCT01566305|DIETARY_SUPPLEMENT|Skimmed milk with added egg-yolk|Skimmed milk with added egg-yolk
214391368|NCT01566305|DIETARY_SUPPLEMENT|Skimmed milk without added egg yolk|Skimmed milk without added egg yolk
214391369|NCT00181038|DEVICE|Peri-Neuronal Catheter|
214391370|NCT03560245|DRUG|Bryostatin|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
214391371|NCT03560245|OTHER|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the experimental drug
214391372|NCT05401435|OTHER|Resting measurement of blood pressure and heart rate|Simultaneous blood pressure and heart rate measurement every morning and evening during the duration of the experiment (28 days).
214391373|NCT03270813|BEHAVIORAL|Relaxation training plus RAGE-Control|RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
214999354|NCT04628624|DIETARY_SUPPLEMENT|Placebo control|8 week supplementation period, with participants consuming 2 capsules per day containing potato starch
215094142|NCT04622904|DRUG|lidocaine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of normal saline 100 mL will be administered preoperatively within 10 minutes. Followingly, normal saline will be administered intraoperatively at a rate of 20 mL/h
215094143|NCT06079151|DEVICE|Nasal high-flow|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary
214999355|NCT04628624|DIETARY_SUPPLEMENT|GTE 1|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)
214999356|NCT04628624|DIETARY_SUPPLEMENT|GTE 2|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
214999357|NCT06631417|DRUG|BI 1291583|formulation 1
214999358|NCT06631417|DRUG|BI 1291583|formulation 2
214999359|NCT06631417|DRUG|BI 1291583|formulation 3
214999360|NCT06796738|DIAGNOSTIC_TEST|HPV testing|This study will use the Roche Cobas® 8800 system for HPV testing. The Roche Cobas HPV test is a PCR test that detects 14 hrHPV types and specifically identifies types 16 and 18.
214391374|NCT03270813|BEHAVIORAL|Relaxation training plus Sham Videogame|The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
214391375|NCT03675074|DEVICE|Neujia|Neujia devices endoscopically deployed for jejunoileal compression anastomosis
214391376|NCT01265823|BIOLOGICAL|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
214391377|NCT05053217|PROCEDURE|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
214391378|NCT06448455|OTHER|Observation|Collect relevant data of patients
214391379|NCT01850082|PROCEDURE|Vein Harvesting Procedures|"Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH."
214999361|NCT06840600|BEHAVIORAL|Public safety rationale|Rationale provided for policy is to increase community safety.
214391380|NCT01756820|PROCEDURE|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
214391381|NCT01756820|PROCEDURE|Knifelight|A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
214391382|NCT00715741|OTHER|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
214391383|NCT00715741|OTHER|FiO2 0.3 without PEEP|FiO2 0.3 without PEEP
214391384|NCT00715741|OTHER|FiO2 >0.9 with 3-5 cm water PEEP|FiO2 \>0.9 with 3-5 cm water PEEP
214391385|NCT00715741|OTHER|FiO2 >0.9 without PEEP|FiO2 \>0.9 without PEEP
214391386|NCT03178084|DRUG|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
214391387|NCT03178084|DRUG|Efavirenz QD + Zidovudine/Lamivudine BID|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
214391388|NCT03178084|DRUG|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
214391389|NCT04181840|DIAGNOSTIC_TEST|Blood and faeces tests|During V1 - Laboratory tests, particularly for calprotectin concentration assessment
214391390|NCT04181840|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of anal sphincter muscles will be measured
214391391|NCT04181840|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 and V2 - Examination with a gynecological speculum, Two-handed examination, Rectal examination, and Anoscopy
214391392|NCT04181840|DIAGNOSTIC_TEST|Transanal ultrasonography|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
214391393|NCT04181840|DIAGNOSTIC_TEST|Anorectal manometry|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
214391394|NCT04181840|OTHER|Determining the degree of sphincter injury|During V2 - conducting the examination will finally determine the extent of sphincter damage, present the patient with therapeutic options and decide on the treatment or rehabilitation of sphincter.
214391395|NCT02349724|BIOLOGICAL|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
214391396|NCT02191384|DRUG|Orcinoside|oral, twice per day
214391397|NCT01356667|BEHAVIORAL|DARTNA|3-hour protocol provided 2x/week over 12 weeks
214999362|NCT06840600|BEHAVIORAL|Right-to-health rationale|Rationale provided for policy is to support humans' right to healthy food.
214391398|NCT01356667|BEHAVIORAL|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
214391399|NCT03228017|DRUG|Aspirin and/or Atorvastatin|This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.
214391400|NCT01018563|DRUG|MORAb-003|Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
214391401|NCT00447044|BEHAVIORAL|Resistance Exercise|Subjects will lift weights with their legs.
214391402|NCT00447044|DIETARY_SUPPLEMENT|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
214391403|NCT00447044|DIETARY_SUPPLEMENT|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
214391404|NCT02477397|DRUG|Spiromax Budesonide/formoterol|1\. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
214999363|NCT06840600|BEHAVIORAL|Cost-saving rationale|Rationale provided for policy is to save the government money.
214999364|NCT06840600|BEHAVIORAL|No rationale (Control)|In this arm, no rationale is provided for the policy.
214999365|NCT06346899|OTHER|No intervention|This is a non-interventional study.
214999366|NCT04994132|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214999367|NCT04994132|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214999368|NCT04994132|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214999369|NCT04994132|PROCEDURE|Bone Scan|Undergo bone scan
214391405|NCT02477397|DRUG|Diskus Fluticasone/salmeterol|2\. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
214391406|NCT03781765|DRUG|Methylphenidate|stimulant medication
214391407|NCT03781765|DRUG|Atomoxetine|non-stimulant medication
214391408|NCT02332018|RADIATION|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
214391409|NCT02161861|OTHER|cFFE increase the fusiogenic capacities of a gamete|
214391410|NCT03106519|DRUG|Liposome bupivacaine + bupivacaine|
214391411|NCT03441113|DRUG|MMB|Tablet(s) administered orally once daily
214391412|NCT03341650|BEHAVIORAL|High Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (at least 5 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
214501785|NCT06272591|OTHER|Preliminary search in the patient's file|"Details of the information previously sought in the patient's file :~age profession gender/parity physiological or pathological pregnancy indication for induction of labour gestational age at time of induction"
214999370|NCT04994132|PROCEDURE|Computed Tomography|Undergo CT
214999371|NCT04994132|DRUG|Cyclophosphamide|Given IV or PO
214999372|NCT04994132|BIOLOGICAL|Dactinomycin|Given IV
214999373|NCT04994132|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214999374|NCT04994132|PROCEDURE|Positron Emission Tomography|Undergo PET
214999375|NCT04994132|RADIATION|Radiation Therapy|Undergo radiation therapy
214999376|NCT04994132|DRUG|Vincristine Sulfate|Given IV
214999377|NCT04994132|DRUG|Vinorelbine Tartrate|Given IV
214999378|NCT04994132|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
214999379|NCT06586957|DRUG|NKT3964|Oral CDK2 Degrader
214999380|NCT05295407|GENETIC|Genetic Assessment|The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
214391413|NCT03341650|BEHAVIORAL|Low Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (no more than 3 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
214391414|NCT02947607|PROCEDURE|Colon biopsies|
214391415|NCT01706224|PROCEDURE|Blood sample|Samples will be tested to determine the presence of anti-pertussis antibodies.
214391416|NCT01706224|OTHER|Data collection|Electronic Case Report Forms (eCRF)
214391417|NCT01706224|OTHER|Data collection|Questionnaires, active questioning.
214391418|NCT04410887|DRUG|PIPAC+SOX+OLAPARIB|SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg BID PO
214391419|NCT02798029|RADIATION|Frameless Fractionated Stereotactic Radiation Therapy|
214391420|NCT01378520|DRUG|ketoconazole|600 mg capsule oral once
214391421|NCT01378520|DRUG|inert powder|oral once
214391422|NCT06420596|OTHER|Conventional Physiotherapy|Conventional physiotherapy is one prescription of 9 in person physiotherapy sessions (according to FMH Switzerland guidelines). The frequency of the physiotherapy sessions are at the discretion of the treating clinician, but the recommendation is 1 to 2 sessions per week.
214501786|NCT06272591|OTHER|A posteriori research in the patient's file|Data on maternal and foetal morbidity and mortality following childbirth will be collected.
214501787|NCT06272591|OTHER|First questionnaire : choice of induction method reason for choice|Given on arrival at the maternity unit to begin induction.
214999381|NCT06763952|OTHER|AI-BRIDGE|AI-based eye screening program
214999382|NCT06768320|DRUG|Lomaira 8Mg Tablet|8 mg tablet up to three times a day
214999383|NCT07058558|BEHAVIORAL|Nutrition Education and Community Gardening|Participants will be presented with 16 nutrition education modules based on the Portfolio Diet, through group-based virtual sessions delivered by the investigators for one year. In addition, participants will take part in two community gardening sessions during growing season, and will grow Portfolio Diet foods such as eggplant, okra, and temperate climate fruit.
214999384|NCT07059819|DEVICE|Local hyperthermia device|Local hyperthermia at 44℃ for 30 mins on cervical region, at days of 1,2,3 and 17, 18.
214999385|NCT06758388|OTHER|home exercise program|The prepared home exercise program is a program that includes gradual strengthening exercises that participants will do once a day, 5 days a week, for 8 weeks. The exercises will be performed as 1 set for the first 2 weeks, 2 sets in the 3rd and 4th weeks, and 3 sets in the last 4 weeks.
214999386|NCT06758388|BEHAVIORAL|home exercise program + brisk walking exercise|In addition to the home exercise program applied by the control group, a brisk walk will be performed. The brisk walking exercise will be done for 30 minutes, 5 days a week for 8 weeks. The intensity of the exercise will be adjusted according to the Borg CR-10 scale and the Speech test. Moderate intensity exercise is recommended for participants. The participant will walk rhythmically for 30 minutes at a speed where he/she will give 4-6 points on the Borg CR-10 Scale, and can speak a few sentences without getting out of breath according to the Speech test, but cannot sing. Before and after the brisk walk, he/she will be asked to walk at a slow speed for 5 minutes (warm-up-cool down).
214999387|NCT07104526|DRUG|Propranolol + Bleomycin|Oral propranolol at 1 mg/kg/day for 6 months plus intralesional bleomycin (1 mg/mL solution) injected once monthly. The bleomycin dose was 0.2-0.5 mg per injection site, not exceeding a total of 1 mg/kg per session or a cumulative dose of 10 mg.
215094144|NCT06368934|PROCEDURE|sub-lobectomy|Combined with previous research and our team's precise neurosurgery concept, we define the surgical strategy based on lobectomy and further preserving the brain parenchyma in functional areas according to anatomical landmarks and electrophysiological boundaries as sub-lobectomy.
215094145|NCT06368934|PROCEDURE|imaging total resection|Imaging total resection (T1-enhanced borders) will met the RANO criteria
215094146|NCT02955459|DRUG|VNRX-5133|
214391423|NCT06420596|DEVICE|Akina Cloud|Akina Cloud is a digital health application that supports therapeutic exercises in people with musculoskeletal disorders. It is the first app-supported physiotherapy solution available in Switzerland.
214391424|NCT05544552|DRUG|TYRA-300|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
214391425|NCT04437147|DIETARY_SUPPLEMENT|Placebo|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets
214391426|NCT04437147|DIETARY_SUPPLEMENT|3 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 3 billion CFU strains of probiotics
214391427|NCT04437147|DIETARY_SUPPLEMENT|8 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 8 billion CFU strains of probiotics
214391428|NCT04023097|DEVICE|Toothwave toothbrush|Subjects get the device's box with the user manual and the device. However, they don't use the device, but only read the user manual and fill questionnaires.
214501788|NCT06272591|OTHER|Second questionnaire : experience of induction|Given post-partum in the maternity unit.
214501789|NCT05271994|PROCEDURE|endoscopic biliary drainage|endoscopic biliary drainage
214501790|NCT06509412|DEVICE|LANAP surgical protocol using ND:YAG 1064 laser|A free running pulsed, 1064 nm wavelength-specific ND:YAG laser (Light walker AT)\* with an attached 320 µm diameter optical glass fiber attached to a metallic hand piece with a flexible tip, which will be set at 3:4 -watt average power, 20 HZ, and a 100-600 µs pulse duration
215094147|NCT02955459|DRUG|Placebo|
215094148|NCT02514005|OTHER|Manual therapy|\- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
214391429|NCT03791385|BEHAVIORAL|Picture Exchange Communication System (PECS)|A communication system frequently used with non-verbal children with autism spectrum disorders (ASD) that uses a series of pictures that describe how a certain activity is done, in our case showing a structured method and technique for teeth brushing.
214391430|NCT06823557|DIETARY_SUPPLEMENT|Psychobiotic treatment|The dietary supplementation will follow established guidelines, recommending an intake of 16 g of prebiotic per day, distributed across three meals, for a duration of 12 weeks.
214391431|NCT06823557|OTHER|Placebo treatment|The control group will receive identical packaging that matches the experimental treatment in taste and appearance and will follow the same guidelines for consuming the placebo. For ethical reasons, after the end of the RCT, the control group will be given the option to receive the same prebiotic supplement.
214391432|NCT00903786|DRUG|perampanel|Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
214391433|NCT03806868|OTHER|voucher for ordering foods (ONLY omega-3 rich foods)|A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.
214391434|NCT03806868|OTHER|voucher for ordering foods in general (any type of foods)|A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
214391435|NCT06017388|BEHAVIORAL|Hypnosis|We will propose a hypnotic induction followed by a suggestion of mystical experience (based on Lynn \& Evans, 2017).
214391436|NCT06017388|BEHAVIORAL|Control|We will propose the neutral reading of a mystical expetience suggestion (based on Lynn \& Evans, 2017).
214391437|NCT01496508|DEVICE|mechanical ventilation (SLE 5000, Servo-i-Maquet)|Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
214391438|NCT02312401|DEVICE|multi-parametric MRI(MP-MRI)|
214391439|NCT02312401|DEVICE|dynamic contrast-enhanced MRI (DCE)|
214391440|NCT02312401|PROCEDURE|biopsy|
214391441|NCT05295914|DIAGNOSTIC_TEST|TREAT-B score|TREAT-B score: ALT(alanine transferase), HBeAg REACH-B score: sex, ALT, HBV viral load, age WHO-simplified score: ALT, cirrhosis
214391442|NCT00458913|DRUG|bortezomib|
214391443|NCT00458913|DRUG|cisplatin|
214391444|NCT05956548|PROCEDURE|external securement of scs leads during the scs trial period|two groups- one group will have an anchor device used alone to secure the leads, the second group will have an anchor device with a suture to secure the leads
214391445|NCT05240378|OTHER|Surgery|Surgery for cancer as per the stage of the disease and protocol
214391446|NCT00032344|PROCEDURE|Colonoscopy|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
214391447|NCT03295266|DRUG|MK-3866|Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
214391448|NCT02578511|DRUG|Ixazomib|Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
214999388|NCT07104526|DRUG|Propranolol|Oral propranolol hydrochloride solution administered at a dose of 1 mg/kg/day for 6 months.
214999389|NCT07104708|PROCEDURE|The Child-Parent- Trainer exercise program|The Child-Parent-Trainer exercise program is a 12-week exercise training program, which is based on the sensory and cognitive needs of children with ASD, multiple game forms are integrated to form a multi-sensory intervention model. The exercise program is developed according to the types of exercise recommended in the Exercise Guidelines for Preschool Children of China, including the development of basic motor skills, such as physical movement, posture control, object control; development of important physical qualities, such as agility, balance, coordination. The training program for different age group consists of physical movement items, object control items and limb coordination items. The exercise intensity is moderate.
215094149|NCT02514005|DEVICE|Dry needling|"* Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~* Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps."
215094150|NCT04028466|DRUG|Vonoprazan|Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
215094151|NCT04028466|DRUG|Omeprazole|Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
214391449|NCT05605717|RADIATION|Fibroscan|Liver fibroscan and ultrasonography
214391450|NCT00210522|DRUG|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
214391451|NCT06480682|RADIATION|Dual x-ray scan|Annual whole body scan monitoring bone mineral density for whole body, radius, L1-4 and femur and body composition
214391452|NCT06480682|DIAGNOSTIC_TEST|Blood screen|Three times a year blood samples will be taken to measure: full blood count, ferritin, B12, folate, erythrocyte sedimentation rate (ESR), renal function, liver function, thyroid stimulating hormone (TSH), Free thyroxine (T4), luteinizing hormone (LH), oestradiol, testosterone, follicle-stimulating hormone (FSH), coeliac screen, vitamin D (25(OH)D), Leptin and Ghrelin
214391453|NCT06480682|OTHER|Questionnaires|Informed consent; Low energy availability questionnaires for males and females; General health including menstrual status (females)
214391454|NCT06480682|OTHER|Anthropometric measurements|Three times a year participant's measurements will be taken: stature, body mass and body composition (bio-impedence)
214391455|NCT06480682|PROCEDURE|Resting Metabolic rate|Resting metabolic rate will be measured by resting gas analysis. Each participant will lie down for a period of 15 minutes, in the final 5 minutes their expired gases are analysed using a breath-by-breath gas analyser (Cortex).
214391456|NCT06480682|OTHER|Energy expenditure|Energy expenditure was estimated using accelerometery (Genieactive) and activity logs in the participants' normal environment, assessed during 3 weekdays of scheduled dance training and 2 weekend days without scheduled dance training. Focus is on daily energy expenditure
214391457|NCT06280287|DIAGNOSTIC_TEST|FAPI PET|68Ga-FAPI PET/MR with high-resolution cardiovascular magnetic resonance vessel wall imaging for patients with carotid stenosis; 18FAl-FAPI PET/CT for patients with coronary artery disease
214391458|NCT02857660|OTHER|Whole body Electromyostimulation (exercise)|1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
214391459|NCT02857660|DIETARY_SUPPLEMENT|Protein|up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
214391460|NCT05295303|DEVICE|Remote integrated post-MI management system|The home-based remote integrated post-MI management system comprises (1) a patch-based long-term Holter monitoring system HC3A250 (BISA Technologies (Hong Kong) Limited, Hong Kong SAR, China), (2) a handheld single-lead electrocardiogram (ECG) recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China), (3) a blood pressure monitor, (4) a patient-facing smartphone application specially designed for the study, and (5) a web-based clinical management system for clinicians
214391461|NCT03933332|OTHER|Diaphragm thickness|measured at apposition zone using ultrasonography in mm
214391462|NCT03933332|OTHER|Cross-sectional area of rectus femoris muscle|measured at lower one-third line between Spina iliaca anterior inferior (SIAI) and upper border femur patella using ultrasonography in cm\^2
214391463|NCT03933332|OTHER|Cross-sectional area of biceps brachii|measured at biceps brachii muscle using ultrasonography in cm\^2
214501791|NCT06509412|DEVICE|LANAP surgical protocol using diode 940 laser|Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm was attached with a power average set at 0.5-1 watt, in continuous mode, and 20 HZ
214501792|NCT06509412|PROCEDURE|Scaling and root planing (SRP)|Scaling and root planing (SRP) using ultrasonic device (Woodpecker USD-P Led Ultrasonic Scaler Ende) at moderate setting and with appropriate tips and also hand curettes will be used for root planning.
214501793|NCT00220532|DRUG|Folic acid with riboflavin|
214501794|NCT05150093|PROCEDURE|Deep Brain Stimulation|Clinically indicated DBS treatment for dystonia or tremor with simultaneous research electrocorticography (ECoG).
214999390|NCT07104708|PROCEDURE|The regular physical training|The regular physical training courses will last for 12 weeks. It is training in motor skills and fine motor skills. The items include passing the ball, lifting small dumbbells, running, handicrafts, etc. There is no requirement for the intensity of the exercise.
214501795|NCT04654390|DRUG|DWP16001 Amg|Tablets, Orally, Once daily
214501796|NCT00364975|BEHAVIORAL|gourmet cooking workshop|
214501797|NCT04274790|PROCEDURE|Scheduled and planned surgery|Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.
214501798|NCT04608409|DRUG|Lapatinib and Paclitaxel|Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
214501799|NCT00599196|DRUG|Rotigotine|"Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours."
214501800|NCT00703352|DRUG|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
214999391|NCT07105150|BEHAVIORAL|video-based education program|"The video-based education program will include 4 workshops of 20 minutes each, at a rate of 1 video per week:~Video 1: Anatomy and physiology of the pelvic floor; Video 2: Physiology of the urinary tract; Video 3: Physiology of the digestive tract; Video 4: Pathophysiology of urinary incontinence and other pelvic floor disorders (genital prolapse and anal incontinence) and preventive measures in daily activities."
214999392|NCT07105150|OTHER|written information|The control group will receive a paper information document (containing the same information as the intervention group) during the 4-week period
214391464|NCT03933332|DIAGNOSTIC_TEST|C-Reactive Protein (CRP) Level|quantitative CRP using ELISA method in mcg/mL
214391465|NCT03250351|OTHER|Neural mobilization group|See arm/group descriptions
214391466|NCT03250351|OTHER|Control group|See arm/group descriptions
214391467|NCT02693340|BIOLOGICAL|sampling|"• Sampling period(s):~* Blood: W0, W6, W14, W30 and W52 and relapse.~* Biopsies and fecal: W0, W14 and M52 and relapse."
214391468|NCT04725630|BEHAVIORAL|Healthy food incentive|$10.50/week/household member for 12 months to purchase healthy foods in participating supermarkets.
214391469|NCT04725630|BEHAVIORAL|Healthy food prescription|A one-time healthy food prescription pamphlet
214391470|NCT00479089|DRUG|Docetaxel|25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
214391471|NCT00479089|DRUG|ZD1839|250 mg by mouth daily, without break.
214391472|NCT00479089|DRUG|Dexamethasone|"Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment."
214501801|NCT02683174|DEVICE|Novel ambulatory patch (ZIO® XT Patch)|All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
214501802|NCT02683174|BIOLOGICAL|BNP and hs-troponin I at 0 and 3 hours post ED attendance|All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
214501803|NCT03912909|DRUG|Empagliflozin Oral Tablet [Jardiance]|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
214501804|NCT03912909|DRUG|Placebo Oral Tablet|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
214501805|NCT05488405|DRUG|Mesalamine Oral Product|Mesalamine oral suspension for oral use
214501806|NCT04038190|BEHAVIORAL|behavioral activation|Behavioral activation (BA) is an intervention that indirectly addresses psychopathy by guiding individuals to identify goals in their lives, and encouraging individuals to engage in reinforcing activities that align with their goals (Lejuez et al, 2001). While initially used to treat depression, BA has been efficaciously applied to substance use because BA acts on the same reinforcement system common to many disorders (Daughters et al., 2018).
214501807|NCT01204996|DRUG|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
214501808|NCT01204996|DRUG|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
214501809|NCT01204996|DRUG|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
214687989|NCT04591912|BEHAVIORAL|mind. body. voice|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
214999393|NCT07103421|DIAGNOSTIC_TEST|Non-Surgical Periodontal Therapy|Non-surgical periodontal therapy involves the removal of bacterial plaque and calculus from tooth surfaces and root surfaces beneath the gum line using manual or ultrasonic instruments. This treatment is performed for patients with periodontitis to improve gum health and reduce inflammation. Serum cystatin C levels will be compared before and after treatment between healthy patients and those with renal impairment.
214999394|NCT07104890|BEHAVIORAL|Enhanced Recovery After Surgery (ERAS) Protocol, which includes early oral intake, early mobilization, opioid-sparing multimodal analgesia, prophylactic antiemetics, early urinary catheter removal, an|The Enhanced Recovery After Surgery (ERAS) Protocol for elective cesarean section includes a multimodal perioperative care approach aimed at accelerating postoperative recovery. Key components are early oral intake, early mobilization, opioid-sparing multimodal analgesia, prophylactic antiemetics, early removal of the urinary catheter, and gum chewing to stimulate bowel function. This protocol is compared with Standard Perioperative Cesarean Care, which involves overnight fasting, delayed oral intake until bowel function returns, conventional analgesia, later mobilization, and routine catheter removal.
214999395|NCT07103226|RADIATION|Hyperthermia|Hyperthermia will be applied for a period of 15 to 20 minutes in the area to be treated, maintaining a thermal sensation of gentle heat for the patient and accompanied by active-assisted or passive mobilization of the structures adjacent to the plantar fascia.
214999396|NCT07103226|OTHER|Physical Exercise|The therapeutic physical exercise focused on the flexor muscles of the foot will consist of 3 periods of isometric contraction of 15 seconds, with a rest period of 30 seconds, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
214501810|NCT01204996|DRUG|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
214687990|NCT02154750|DEVICE|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
214687991|NCT02154750|DEVICE|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
214687992|NCT04111276|DEVICE|Breg Osteoarthritis Brace gait fluoroscopy|Gait under fluoroscopy surveillance with brace
214391473|NCT03784352|DEVICE|Virtual Reality|A calming virtual reality game will be played
214391474|NCT03751163|DRUG|Tranexamic Acid Oral Product|Encapsulated tranexamic acid 250 mg
214687993|NCT04111276|OTHER|Gait fluoroscopy without brace|Gait under fluoroscopy surveillance without brace
214687994|NCT04111276|DIAGNOSTIC_TEST|JointVue ultrasound|JointVue ultrasound procedure to reconstruct 3D femoral and tibial bones
214687995|NCT04111276|DIAGNOSTIC_TEST|Computer Tomography|Computer Tomography scan limited to the study knee and will image 6 inches distal on the tibia and 6 inches proximal on the femur
214687996|NCT02648412|DRUG|ketamine|bolus 1 mg/kg
214687997|NCT02648412|PROCEDURE|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
214391475|NCT03751163|DRUG|Hydroquinone 4% Cream|Hydroquinone 4% Cream
214391476|NCT03751163|OTHER|Sunscreen|Sunscreen SPF 30
214391477|NCT03751163|DEVICE|Placebo|Encapsulated placebo
214391478|NCT02323503|DEVICE|CRT-D device replacement|
214391479|NCT03133949|OTHER|Establish the clinical, biological and radiological characteristics of patients|Establish the clinical, biological and radiological characteristics of patients
214501811|NCT01894399|DRUG|HM61713|Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
214501812|NCT06961305|DEVICE|Cross-linked Hyaluronic Acid Gel|This intervention involves the injection of Alexa Medium, a sterile, cross-linked hyaluronic acid gel (17.5 mg/mL). The gel is administered into the mucous membrane of the lips for aesthetic restoration of lip volume loss. The product is supplied in a pre-filled 1 mL syringe and injected by a trained medical professional. One or two injections were administered per participant, with the second injection performed at the investigator's discretion at Visit 2. The device is manufactured by Diaco Biofarmaceutici S.r.l., Italy.
214501813|NCT03311880|BEHAVIORAL|Cognitive remediation|Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
214501814|NCT00849238|DRUG|mycophenolate mofetil|
214501815|NCT03819543|DEVICE|Transcranial Direct Current Stimulation|Application of transcranial direct current stimulation via scalp electrodes over presumed epileptogenic focus for 20 minutes at 2.0 mA.
214501816|NCT05283018|DEVICE|Electroencephalogram recording|Brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
214501817|NCT05283018|OTHER|Auditory stimulation|Monotonous sounds are sent via binaural headphones: a standard item and a distractor item (rough sound). Each stimulus lasts about 300 ms and they are separated by 1.5 to 2 seconds between them; the deviant sound/standard sound ratio is fixed between 1/5 and 1/6.
214501818|NCT05283018|DEVICE|Transcranial Doppler|Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography. For all patients, CFV (unit cm/s) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at inspired oxygen fraction (FiO2) of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period.
214687998|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every other day.|6mg/kg of oral iron as ferrous sulfate administered every other day instead of 6 mg/kg of oral iron daily supplementation.
214999397|NCT07103226|OTHER|Stretching|The plantar fascia stretch will be performed with the patient in the supine position. Maximum dorsiflexion will be achieved, and the lower limb will be elevated with the knee extended as tolerated. This procedure will be performed three times in a row for 30 seconds, with a 1-minute rest between each stretch.
214999398|NCT07103226|OTHER|Orthopedic insole|Imposition of an orthopedic insole
214999399|NCT07103694|DRUG|anti-CGRP monoclonal antibodies|erenumab, fremanezumab, galcanezumab, eptinezumab
214687999|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every day.|6 mg/kg of oral iron as daily ferrous sulfate instead of 6mg/kg of oral iron supplementation administered every other day.
214999400|NCT07103694|DRUG|gepants|atogepant, rimegepant
214999401|NCT07103694|DRUG|combination of sumatriptan and naproxen|combination of sumatriptan and naproxen
214999402|NCT07103694|DRUG|ditan|lasmiditan
214999403|NCT07104396|OTHER|Cogito digital therapeutics development platform|Cogito will provide a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics for the prevention, treatment and/or management of any disease or disorder. This platform will allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide all the components for building a digital therapeutic for any health condition and population. Overall, Cogito offers great promise to markedly accelerate the pace and impact of science based digital therapeutics.
214999404|NCT07102758|PROCEDURE|L-PRF with dental implant and customized healing abutment|L-PRF with dental implant and customized healing abutment
214999405|NCT07102758|PROCEDURE|Connective tissue with dental implant and customized healing abutment|Connective tissue with dental implant and customized healing abutment
214391480|NCT03666884|DRUG|COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
214391481|NCT03666884|BIOLOGICAL|AS 50% eye drops 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
214391482|NCT06358911|OTHER|Poly amido amine dendrimer (PAMAM)|"Desensitizing agents was applied once after the bleaching procedure,as follows:~1-Bleaching/PAMAM group, patients received bleaching followed by the application of PAMAM for 30 minutes according to previous studies."
214391483|NCT06358911|OTHER|Manufacturer's desensitizing agent, Ultra EZ|"Desensitizing agents was applied once after the bleaching procedure, as follows:~2-Control group, where patients received hydrogen peroxide in-office bleaching followed by the application of manufacturer recommended desensitizing agent ( Ultra EZ) once for 60 minutes."
214391484|NCT06358911|OTHER|MI paste plus, desensitizing agent|"Desensitizing agents was applied once after the bleaching procedure, as follows:~3-Bleaching/MI Paste Plus group, patients received bleaching followed by the application of MI paste plus according to the manufacturer's instructions once for 3 minutes."
214391485|NCT06358911|OTHER|Hydroxyapatite and F (ReminPro), desensitizing agent|"Desensitizing agents was applied once after the bleaching procedure, as follows:~4-Bleaching/Hydroxyapatite and F (ReminPro), patients received bleaching followed by the application of Hydroxyapatite and F (ReminPro) according to the manufacturer's instructions once for 3 minutes"
214391486|NCT02574676|OTHER|non-interventional|
214391487|NCT02484079|PROCEDURE|Polypectomy|
214391488|NCT03421496|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
214391489|NCT03421496|DRUG|Placebo|Matching oral solution
214391490|NCT03421496|DRUG|Vigabatrin|Powder suspension
214391491|NCT06035614|DEVICE|exciplex|exciplex, excimer lamp 308nm produced by clarteis
214999406|NCT07103434|BEHAVIORAL|VR Mindfulness intervention|Parallel randomized controlled trial
214999407|NCT07103434|BEHAVIORAL|Audio-based MBI|Parallel randomized controlled trial
214999408|NCT07103434|BEHAVIORAL|Waitlist control|Parallel randomized controlled trial
214999409|NCT07104045|OTHER|Reduced light color temperature|reduced light color temperature on postpartum mothers' well-being, breastfeeding motivation, and psychological well-being after a cesarean section
214999410|NCT07103915|DRUG|Lidocaine 10% Spray|This study evaluates whether intranasal 10% lidocaine spray reduces pain and improves first-pass success during nasogastric tube (NGT) insertion compared to placebo.
214391492|NCT06035614|DRUG|Tacrolimus ointment|tacrolimus monohydrate ointment 0.1% TACRUS
214391493|NCT01003600|BEHAVIORAL|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
214391494|NCT01357330|DRUG|SAR245408 (XL147)|Pharmaceutical form:capsule and tablet Route of administration: oral
214391495|NCT01357330|DRUG|MSC1936369B|Pharmaceutical form:capsule Route of administration: oral
214391496|NCT04810039|OTHER|Predict the outcome of the Glasgow Outcome Scale|Predict the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
214391497|NCT05822921|BEHAVIORAL|In-person Psychoeducation (IP)|Parents will attend two 60-minute (i.e. one day per week, for the next two weeks), in-person psychoeducation sessions on the MAC, in or near their hometown. During these sessions, a clinician will discuss a series of psychoeducation topics supplemented with PowerPoint slides. Across the two sessions, the following topics will be covered: (1) signs/symptoms and epidemiology of ASD, (2) risk factors associated with developing ASD (e.g., genetics, neurobiology, environment, social motivation), (3) navigating the IEP process, and (4) evidence-based best practices recommended for their child's profile of ASD symptoms and co-occurring conditions. This delivery method will allow parents to ask questions and receive immediate, live, and detailed answers from an expert clinician, to focus on specific examples relevant to their child, and to foster ASD knowledge and efficacy in helping their child.
214391498|NCT05822921|BEHAVIORAL|Telehealth Psychoeducation (TH)|Parents in this group will attend two 60-minute sessions, remotely via a live video chat platform, rather than in-person. Otherwise, it will follow the same format and PowerPoint materials as the IP Group. Sessions will still be facilitated by a clinician, thus maintaining the option to ask questions, discuss personalized examples, etc. For families without computer and internet access, the family will be assisted with to connecting to internet access at a private and convenient location (e.g., a church, library, or local community services agency). In the event that this is not possible, the family will be randomized to one of the other two groups.
214501819|NCT05283018|DEVICE|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at FiO2 of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period."
214501820|NCT02798900|OTHER|Functional task-training|The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
214501821|NCT02798900|DEVICE|Therapeutic Ultrasound|Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
214501822|NCT02301806|OTHER|dieting|
214501823|NCT02301806|DRUG|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
214688000|NCT00045682|DRUG|Paclitaxel Poliglumex|Given IV
214999411|NCT07103915|OTHER|Placebo|Drug: Placebo Spray (Ethanol-matched solution without lidocaine)
214999412|NCT07103980|DRUG|Mesenchymal stem cell derived exosome nebulization combined with compound methoxyphenamine capsule|"Mesenchymal stem cell derived exosome nebulization (FITCELL 5ml nebulization QD) was combined with compound methoxyphenamine capsule ( Asmei 2 capsules oral TID) for cough treatment."
214999413|NCT07103980|DRUG|Normal saline nebulization combined with the compound methoxyphenamine capsule|"Normal saline nebulization (0.9% sodium chloride 5ml nebulization QD) was combined with the compound methoxyphenamine capsule (Asmei 2 capsules oral TID) for cough treatment."
214501824|NCT02301806|DRUG|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
214501825|NCT01824225|DRUG|Aflibercept|
214501826|NCT00431054|DRUG|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
214688001|NCT06986122|BEHAVIORAL|Pain Threat Manipulation|Participants receive brief thermal pain stimuli in certain virtual environments to examine how threat influences perception and physiological responses.
214688002|NCT06986122|BEHAVIORAL|Pain Controllability Manipulation|In some contexts, participants can reduce or avoid pain using a button; in others, no action changes the outcome. This manipulation is used to study the effects of perceived control over pain.
214999414|NCT07104994|DEVICE|Dental implant|insertion of dental implants after surgical tranlocation of the inferior alveolar nerve.
214999415|NCT07105267|DRUG|FMT Protocol|FMT protocol Samples (urine, blood, stool) collection Psychological examination Pediatric quality of life Scale Bristol Stool form Scale
214999416|NCT07102667|BEHAVIORAL|Protein intake 1.2 g/kg/day and resistance exercise|Protein intake of 1.2 g/kg/day in combination with resistance exercise using resistance bands
214999417|NCT07102667|BEHAVIORAL|Protein intake 1.0 g/kg/day and resistance exercise|Protein intake 1.0 g/kg/day in combination with resistance exercise using resistance bands
214999418|NCT07104734|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 2 weeks (2 capsules per day)
214999419|NCT07104734|OTHER|Hesperetin (Hesperetin trial)|The Hesperetin capsule supplement was taken for 2 weeks, with a daily dosage of 500 mg of Hesperetin (equivalent to 2 capsules per day, each containing 250 mg of Hesperetin and 50 mg Pycnogenol®).
214999420|NCT07105332|DEVICE|OMI and Photometer|A glucose sensitive ocular mini insert (OMI) is placed sub-conjunctivaly. When exited by photometer the glucose concentration is measured.
214999421|NCT07104630|BEHAVIORAL|Pulmonary Rehabilitation (PR)|"Participants will complete an 8-week course of PR, administered by certified respiratory therapists. For each week of the course, participants will attend two PR sessions. Each session will review topics such as physical function, nutrition, and psychosocial health. Participants will also be given an exercise prescription to complete throughout the 8-week course. The exercise prescription will include individualized cardiopulmonary activities."
214501827|NCT00431054|DRUG|Docetaxel|75 mg/m\^2 by vein over 1 hour every 4 weeks
214501828|NCT01379651|OTHER|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
214501829|NCT02160119|OTHER|MRI-based techniques|fMRI, DTI
214501830|NCT02160119|OTHER|EEG|ERP
214501831|NCT05985265|PROCEDURE|Fat grafting|Nano fat grafting followed by fractional carbon dioxide laser resurfacing
214501832|NCT00224835|BEHAVIORAL|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
214999422|NCT07104630|OTHER|No intervention: Usual care|Participants will receive standard-of-care, publicly available education on Nutrition and Cancer Survivors and Physical Activity and Cancer Survivors published by the American Institute for Cancer Research.
214999423|NCT07103837|OTHER|Reactive Skill Test|The Reactive Skill Test will be conducted using a setup consisting of four pods, white cones, and balls that match the colors of the light signals During the test, a ReactionX device configured with four distinct light colors (red, green, blue, and yellow) will be used. The test protocol is programmed via the ReactionX mobile application to control the sequence and display of lights. Each LED light is illuminated in a randomized order with zero delay time. Upon illumination, the participant is required to select the ball corresponding to the color of the light, place it on the matching cone, and then deactivate the LED light of the same color as the last placed ball. The test concludes once this sequence is completed for all four lights. Performance is evaluated based on parameters such as reaction time, accuracy, and total completion time. This protocol is specifically designed to assess cognitive skills such as color recognition, reaction time, motor coordination, and attention.
214999424|NCT07103473|DEVICE|Interactive Binocular Treatment|Patients in the intervention group will be asked to play the games which will be designed based on the Interactive Binocular Treatment System and the patients in the placebo group will be asked to play games without the Interactive Binocular Treatment System.
214999425|NCT07104032|DRUG|Tirabrutinib|Administered orally.
214999426|NCT07104032|DRUG|Rituximab|Administered intravenously (IV).
214999427|NCT07104032|DRUG|Temozolomide|Administered orally.
214501833|NCT00224835|BEHAVIORAL|Cardiac Education Class|"Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format."
214501834|NCT03775252|DIETARY_SUPPLEMENT|Ketogenic diet|Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
214501835|NCT00252382|DRUG|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
214501836|NCT04097509|BIOLOGICAL|AFG application on palatinal wound healing|9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.
214501837|NCT04097509|BIOLOGICAL|i-PRF application on palatinal wound healing|10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.
214501838|NCT04097509|OTHER|control|no application
214501839|NCT01545583|DRUG|LY3016859 intravenous|Administered intravenously
214501840|NCT01545583|DRUG|Placebo intravenous|Administered intravenously
214501841|NCT01545583|DRUG|LY3016859 subcutaneous|Administered subcutaneously
214501842|NCT01545583|DRUG|Placebo subcutaneous|Administered subcutaneously
214501843|NCT02522104|DRUG|Siklos|
214501844|NCT03489811|OTHER|Test Essential Oil Blend|The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
214688003|NCT04611685|DRUG|NSAID|Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.
214999428|NCT07103213|BEHAVIORAL|IMPACTREEL programme|The IMPACTREEL programme is a school-based intervention designed to promote positive body image in adolescents. It combines social media literacy education with third-wave strategies, including mindfulness, self-compassion, and psychological flexibility. The intervention consists of 7 weekly group sessions lasting 55 minutes each, delivered by trained psychologists facilitators during school hours. The content targets appearance ideal internalisation, critical thinking about social media, and healthier body image attitudes.
214688004|NCT04611685|DRUG|Tramadol|Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
214999429|NCT07103135|DEVICE|MagVenture X100 Pro transcranial magnetic stimulation system|The study intervention involves the use of the MagVenture X100 Pro transcranial magnetic stimulation system to deliver accelerated intermittent theta burst stimulation (aiTBS) to personalized targets within the somato-cognitive action network (SCAN) and action motor network (AMN) for the treatment of chronic pain.
214391499|NCT05822921|BEHAVIORAL|Psychoeducation as Usual (PAU)|Parents in this group will receive basic paper psychoeducation resources, distributed at their feedback session. It will be up to each parent how frequently and diligently these resources are reviewed. This should be akin to what a family might have access to at their pediatric or primary care office. To be consistent across study groups, the materials produced for these parents will be comprehensive and will include the same span of content as the PowerPoint slides used in the other two groups, but without structured sessions facilitated by a clinician. Upon distribution of materials, parents will be provided with our contact information and encouraged to reach out if any questions occur. Parents in the paper informational materials group will have the option to complete two in-person or video conference psychoeducation sessions after the end of the study, if preferred (i.e., 6 months later).
214391500|NCT05830435|BEHAVIORAL|Trier social stress test|TSST-VR-friendly: The assistant behind the desk asks the participant to prepare a small talk on their favourite holiday within 5 minutes. Then the participant is asked to tell about his holiday for 5 minutes. Then the participant is asked to do a simple math task: adding the number 5 to 0 for 5 minutes. The research assistant gives friendly gestures and verbal encouragements. TSST-VR-neutral: The assistant asks the participant to prepare a speech for a job interview in the upcoming 5 minutes. Then the participant is asked to deliver the speech for 5 minutes in front of two panelists and camera. Then the participant is asked to do a math task, subtracting the number 13 from 1022 for 5 minutes. During the performance the two panellist have neutral gestures and give neutral verbal instructions. TSST-VR unfriendly: The procedure of the TSST-VR unfriendly is the same as the neutral TSST-VR, with the addition that the two panellist give unfriendly gestures such as tapping on the table.
214391501|NCT02853266|OTHER|laboratory biomarker analysis|Archived serum samples are analysed for measurement of biomarker NCRA
214391502|NCT00826163|DRUG|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
214391503|NCT03406702|DRUG|CX-8998|T-type calcium channel blocker
214391504|NCT03763955|BEHAVIORAL|MIRT|"4 week MIRT provide:~1. front to front treatment (1 hour/day for 5 days/week)~2. treatment with robotic devices (1 hour/day for 5 days/week)~3. occupational therapy (1 hour/day for 5 days/week)"
214999430|NCT07104552|DRUG|Course of amoxicillin|Oral amoxicillin per os at 50 mg/kg/day
214999431|NCT07102745|BEHAVIORAL|HomeLink|HomeLink is a structured post-discharge home-based care program for people living with HIV, designed to improve health outcomes after hospital discharge. Starting one week after discharge, trained nurse-clinician and counselor teams conduct regular home visits every two weeks for up to six visits. During these visits, the team will provide clinical assessments, medication adherence support, psychosocial counseling, specimen collection, and home safety evaluations. The intervention aims to offer personalized, continuous care that addresses medical, psychological, and social needs in the participant's home environment, enhancing recovery and reducing post-hospital mortality.
214999432|NCT07102745|BEHAVIORAL|HomeLink Plus Nutritional Support|This intervention combines the HomeLink home-based care program with the provision of nutritional support through food parcels. Participants receive food parcels designed to address nutritional needs and support overall health and recovery. The combined approach aims to improve post-discharge outcomes by addressing both medical and nutritional factors contributing to patient well-being.
214999433|NCT07104656|PROCEDURE|Inferior Osteotomy made by border saw|Inferior border saw used to make the inferior border osteotomy
214999434|NCT07104656|PROCEDURE|Inferior Osteotomy made with reciprocating saw|reciprocating saw used to make the inferior osteotomy
214391505|NCT01857622|DRUG|DU-176b 15mg|oral DU-176b 15mg once daily
214501845|NCT03489811|OTHER|Active Essential Oil Blend|The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
214501846|NCT03489811|OTHER|Control Blend|The control blend consists of inert vegetable oils which are produced from plant matter.
214501847|NCT04839809|DRUG|CC-92480|Oral
214501848|NCT04839809|OTHER|Placebo|Oral
214501849|NCT01989052|DRUG|CTO|
214999435|NCT05199948|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
214999436|NCT05199948|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
214391506|NCT01857622|DRUG|DU-176b 30mg|oral DU-176b 30mg once daily
214391507|NCT01857622|DRUG|DU-176b 60mg|oral DU-176b 60mg once daily
214391508|NCT04866862|DRUG|Combination of Fruquintinib and Camrelizumab|Fruquintinib 5mg d1-21+Camrelizumab 200 mg d1
214391509|NCT00420758|DIETARY_SUPPLEMENT|Food supplement: fortified spread|Provision of fortified spread
214391510|NCT00420758|DIETARY_SUPPLEMENT|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
214501850|NCT01989052|DRUG|Lomustine|
214501851|NCT01747538|DRUG|Placebo|Solution for subcutaneous injection
214501852|NCT01747538|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
214501853|NCT01747538|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
214501854|NCT03314259|DRUG|Tamsulosin|Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
214501855|NCT03314259|DRUG|Placebo Oral Tablet|placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
214501856|NCT04497415|OTHER|Video-Based intervention|Three minutes video of a nurse that shares her personal story
214501857|NCT03813524|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
214501858|NCT01354145|DRUG|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
214501859|NCT01354145|DRUG|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
214501860|NCT03703414|DIAGNOSTIC_TEST|Fecal microbiota composition analysis and blood cytokine level analysis|Fecal microbiota composition analysis and blood cytokine level analysis
214391511|NCT03100994|DRUG|Bupivacaine|injecting anesthetics to different local
214391512|NCT03100994|DEVICE|Ultrasound|Ultrasound guided nerve block
214391513|NCT04381260|OTHER|No intervention|There is no intervention for patients included in this group as this is a retrospective data registry only.
214501861|NCT00734578|DRUG|SPD503-AM|SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
214501862|NCT00734578|DRUG|SPD503-PM|SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
214999437|NCT07103785|OTHER|Mobile game app|The mobile game designed to modify attentional bias toward alcohol-related cues was developed by integrating game elements into a modified version of the dot-probe task. This gamified intervention was installed on the smartphones of participants assigned to the experimental group, and each participant was provided with a unique username and password for access. Participants were instructed to engage with the mobile game every other day over one month.
214391514|NCT04381260|OTHER|Interview|Key Informant Interview
214391515|NCT04381260|OTHER|Survey|Stakeholder survey
214501863|NCT00734578|DRUG|Placebo|Placebo matched to Guanfacine Hydrochloride Extended Release
214501864|NCT03735459|BEHAVIORAL|Patient reminders and accountability questionnaires|Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
214501865|NCT06829199|BIOLOGICAL|Pembrolizumab|Neoadjuvant therapy - 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 24 weeks Adjuvant therapy - 200 mg IV infusion Q3W or 400 mg IV infusion every 6 weeks (Q6W) for up to approximately 30 weeks.
214501866|NCT06829199|DRUG|Paclitaxel|80 mg/m\^2 by IV infusion every week for up to 12 weeks.
214391516|NCT04750993|DIAGNOSTIC_TEST|musculoskeletal ultrasonography|The presence of subclinic synovitis findings in the hand joints was evaluated with musculoskeletal ultrasonography.
214391517|NCT01234766|DRUG|Bendamustine|90mg/m2, IV - Days 1 and 2 of every cycle
214391518|NCT01234766|DRUG|Rituximab|375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
214501867|NCT06829199|DRUG|Carboplatin|AUC 1.5 mg/mL/min by IV infusion every week for up to 12 weeks.
214501868|NCT06829199|DRUG|Doxorubicin (hydrochloride)|60 mg/m\^2 by IV infusion Q3W for up to 12 weeks.
214501869|NCT06829199|BIOLOGICAL|Boserolimab|30 mg by IV infusion every 6 weeks (Q6W) for up to 12 Weeks.
214501870|NCT06829199|DRUG|Epirubicin Hydrochloride|90 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.
214501871|NCT06829199|DRUG|Cyclophosphamide|600 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.
214999438|NCT07103785|DRUG|Akamprosat or Naltrekson or combined medical treatment (Akamprosat and Naltrekson)|Medicines prescribed by a doctor for the treatment of Alcohol Use Disorder (Akamprosat or Naltrekson or combined medical treatment (Akamprosat and Naltrekson))
215094152|NCT03567018|DEVICE|MRI Scan|Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
214391519|NCT01234766|RADIATION|Y-90 ibritumomab|0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
214391520|NCT02495896|DRUG|Cisplatin|Given IV
214391521|NCT02495896|DRUG|Docetaxel|Given IV
214391522|NCT02495896|DRUG|Gemcitabine Hydrochloride|Given IV
214391523|NCT02495896|OTHER|Laboratory Biomarker Analysis|Correlative studies
214391524|NCT02495896|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
214391525|NCT02495896|OTHER|Pharmacological Study|Correlative studies
214391526|NCT02495896|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
214391527|NCT00554333|BIOLOGICAL|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
214391528|NCT00554333|BIOLOGICAL|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
214391529|NCT04138342|DRUG|Quantum dots coated with veldoreotide|The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
214391530|NCT04138342|DRUG|Topical approved placebo|The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
214391531|NCT04667845|DEVICE|Home Ovulation Test|Digital read home ovulation test
214391532|NCT06512103|DIAGNOSTIC_TEST|Apical periodontitis group|Radiography of the patients were taken. Blood samples and gingival crevicular fluid samples were collected from those patient
214391533|NCT02386917|PROCEDURE|Gastric bypass|Weight loss surgery
214391534|NCT02386917|BEHAVIORAL|Very low calorie diet|Non-surgical weight loss procedure
214501872|NCT06829199|DRUG|Capecitabine|1000 mg/m\^2 to 1250 mg/m\^2 by oral administration twice a day (2 weeks on and 1 week off) for up to approximately 24 weeks.
214501873|NCT06829199|DRUG|Olaparib (if approved/available locally)|300 mg by oral administration twice a day for up to approximately 52 weeks.
214501874|NCT01556594|DRUG|Nasal Glucagon 1 mg|
214501875|NCT01556594|DRUG|Nasal Glucagon 2 mg|
214501876|NCT01556594|DRUG|SC Glucagon|
214501877|NCT01556594|DRUG|Nasal Glucagon 3 mg|
214501878|NCT02085941|DEVICE|Cryoablation|Cryoablation using 17G Galil cryoprobe
214501879|NCT02085941|DEVICE|Biopsy|Biopsy using 18G Temno core biopsy needle
214501880|NCT04169828|DRUG|Methotrexate|Children in both the intervention and control group will receive Methotrexate dosed as prescribed by the attending rheumatologist
214501881|NCT04169828|DRUG|Ondansetron|"Children in the intervention group will be prescribed premedication with oral ondansetron.~Children in the control group will be prescribed ondansetron ONLY if the child reports nausea/vomiting during regular treatment care with Methotrexate"
214501882|NCT04169828|DRUG|Folic/folinic acid|Children in both intervention and control group will receive folic acid or folinic acid dosed as prescribed by the attending rheumatologist.
214501883|NCT05418868|DRUG|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be administered.
214391535|NCT03417037|DRUG|BMS-986205|Administered orally daily, 100 mg
214391536|NCT03417037|BIOLOGICAL|Nivolumab|Specified dose on specified days
214391537|NCT03417037|DRUG|Chemotherapy|Platinum-based doublet chemotherapy
214391538|NCT01133574|DRUG|SLV354 capsules|20 mg
214391539|NCT01133574|DRUG|SLV354 capsules|60 mg
214391540|NCT01133574|DRUG|SLV354 capsules|120 mg
214391541|NCT01133574|DRUG|SLV354 capsules|250 mg
214391542|NCT01133574|DRUG|SLV354 capsules|500 mg
214391543|NCT01133574|DRUG|SLV354 capsules|750 mg
214391544|NCT01133574|DRUG|SLV354 capsules|1000 mg
214391545|NCT01133574|DRUG|SLV354 capsules|1250 mg
214391546|NCT01133574|DRUG|Placebo capsules|placebo
214391547|NCT01133574|DRUG|SLV354 capsules|low dose group 1
214391548|NCT01133574|DRUG|SLV354 capsules|high dose group 1
214391549|NCT01133574|DRUG|SLV354 capsules|low dose group 2
214391550|NCT01133574|DRUG|SLV354 capsules|high dose group 2
214391551|NCT01133574|DRUG|Placebo capsules|placebo
214391552|NCT00006040|BIOLOGICAL|filgrastim|
214391553|NCT00006040|DRUG|etoposide|
214391554|NCT00006040|PROCEDURE|autologous bone marrow transplantation|
214391555|NCT00006040|PROCEDURE|peripheral blood stem cell transplantation|
214391556|NCT00006040|RADIATION|yttrium Y 90 monoclonal antibody M195|
214391557|NCT00911963|DRUG|VCH-222 or matching placebo|capsule, oral, 4 doses once daily or twice daily, 3 days
214391558|NCT00911963|DRUG|VCH-222 or matching placebo|capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks
214391559|NCT00911963|BIOLOGICAL|peginterferon alfa-2a|subcutaneous injection, 180 μg, once weekly, 48 weeks
214501884|NCT05418868|DRUG|Cabotegravir >=400 mg/mL|CAB \>=400 mg/mL will be administered by IM or SC injection.
214501885|NCT05418868|DRUG|Cabotegravir Formulation I|CAB Formulation I will be administered by IM injection.
214501886|NCT05418868|DRUG|CAB Formulation J|CAB Formulation J will be administered by IM injection.
214391560|NCT00911963|DRUG|ribavirin|tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
214391561|NCT05486208|DRUG|LY3844583|Administered SC and/or IV.
214391562|NCT05486208|DRUG|Placebo|Administered SC and/or IV.
214391563|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
214391564|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
214391565|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
214391566|NCT00632710|OTHER|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
214391567|NCT00632710|OTHER|phototherapy placebo|disconnected laser (same device - experimental group)
214391568|NCT04213989|DEVICE|Flexitouch Plus and Conservative Care|A segmental, programmable, gradient advanced pneumatic compression device. The system consists of a controller unit and garments, and provides in-home manual lymphatic drainage therapy in the legs for approximately 1 hour daily. Conservative care may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
214391569|NCT04213989|OTHER|Conservative Care|May include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
214391570|NCT03660722|OTHER|blood and urinary samples|blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks
214391571|NCT00150410|DRUG|Inhaled insulin|
214391572|NCT04857190|DEVICE|Parker Flex-it Directional Stylet|Parker Flex-it Directional Stylet
214391573|NCT04857190|DEVICE|Conventional Malleable Stylet|Conventional Malleable Stylet
214391574|NCT00030433|DRUG|gemcitabine hydrochloride|
214391575|NCT00030433|DRUG|irinotecan hydrochloride|
214391576|NCT04399187|DRUG|Sodium hypochlorite gel application|Patients treated by scaling and root planing and Sodium hypochlorite gel application, meanwhile in patients of control group scaling and root planing alone was performed.
214391577|NCT02971384|DRUG|Echinaforce|
214391578|NCT02835443|DEVICE|Deep Brain Stimulation|Electrical stimulation of the dentate nucleus area of the cerebellum.
214391579|NCT03936296|PROCEDURE|mpMR guided MR-US fusion transrectal prostate biopsy|mpMR images will be loaded to US fusion platform and registration of the will be performed. Suspicious lesions on MR which have PIRADS score 3 and above are targeted. Additional 2-4 cores biopsies will be taken them
214391580|NCT03936296|PROCEDURE|12 core standard transrectal prostate biopsy|Under the guidance of transrectal ultrasonography, 12 core biopsies taken from apex, apex lateral, mid, mid lateral, base and base lateral of right and left prostate lobe
214391581|NCT06077916|DRUG|Azithromycin|azithromycin is reconstituted and administered according to standard prescription indications in 250 mL saline solution
214391582|NCT06077916|DRUG|Saline solution|placebo consisting of saline solution 250 mL is administered
214391583|NCT01402167|PROCEDURE|Kyphoplasty|Patients will be treated via a balloon kyphoplasty surgical procedure
214391584|NCT01402167|PROCEDURE|Vertebroplasty|Patients will be treated via a transcutaneous vertebroplasty procedure.
214391585|NCT04532151|DIAGNOSTIC_TEST|Non-invasive skin imaging assessment|"Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~* an examination on LC-OCT~* an examination on LC-OCT-doppler~* a fluid silicone molding~* an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable."
214501887|NCT05418868|DRUG|rHuPH20|rHuPH20 will be administered.
214501888|NCT05418868|DRUG|RPV|RPV will be administered by IM injection.
214501889|NCT06107933|OTHER|Observational only|Exposure to micro and nano plastics
214501890|NCT05791162|OTHER|Blood collection|Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)
214501891|NCT05791162|OTHER|Urine sample|Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)
214391586|NCT05009706|OTHER|Self-care in Older frail Persons with Heart failure Intervention (SOPHI)|Patients who are randomized to the Self Care group will receive oral and written information, advice and support on following activities: excercise (from physiotherapist), nutrition (dietician) and symptom management (nurse), based on patient´s individual needs and abilities. The Self Care group will perform the activities daily at home. Once a week, patients come to the hospital to exercise with the support of a physiotherapist. Once a week or every other week patients will meet (at hospital or by phone) the dietician and nurse to solve possible problems and to follow-up food/nutrition intake and symptoms/symptom management.
214501892|NCT03168750|DEVICE|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
214501893|NCT05462912|DEVICE|custom foot orthotic|The goal of this study is to find out whether the use of software generated custom-made orthopedic foot orthoses improves pain in the long term.
214501894|NCT06554431|BEHAVIORAL|Self-Driven Repetitive Artmaking|Three (3) art kits which all use repetitive artmaking processes (e.g., materials for mandalas, stamp making kit, weaving kit)
214501895|NCT04812314|BEHAVIORAL|Exercise|Participants will complete a moderate intensity continuous exercise 4 days/week.
214501896|NCT04812314|BEHAVIORAL|No exercise|Participants will remain sedentary throughout the duration of the study.
214999439|NCT07103928|BEHAVIORAL|Impart Assisted Partner Notification|Participants randomized to the Impart arm may choose per partner either a) sell-tell notification or b) having an Impart-trained APN notifier team locate, notify, and offer HIV testing to their partners without revealing the identity of who had named them. Impart notifiers initially contact named partners by telephone and identify themselves as health service providers with important information about the partner's health that needs to be shared in person. Partners who agree to meet are asked to choose a location. Notification by telephone is only delivered as a last resort when circumstances prevent in-person notification or a partner insists on learning the reason for the telephone call. Once contact is made at a private location, partners will be advised of their possible shared exposure to HIV. APN notifiers never reveal participant names or identifying information during this meeting. All notified partners are offered immediate HIV testing and treatment referral, if HIV-positive.
214391587|NCT01666054|OTHER|PSV|Pressure Support Ventilation will be used until patient is extubated
214391588|NCT01666054|OTHER|PAV|Proportional Assist Ventilation will be used until patient is extubated.
214391589|NCT05964881|PROCEDURE|sacrospinous hysteropexy|sacrospinous hysteropexy
214391590|NCT01086605|DRUG|pixantrone dimaleate|Given IV
214501897|NCT06478290|COMBINATION_PRODUCT|curcumin, omega-3, and vitamin D (COD)|Combination of curcumin, omega-3, and vitamin D supplements (COD). Theracurmin Double Strength/Natural Factors Canada 180 mg/day (oral, 3 tablets of 60 mg taken by mouth) Vitamin D: 2000 IU/day LipoMicel/Natural Factors Canada (oral, 1 tablet taken by mouth) Omega-3: 900 mg day (oral, 1 tablet taken by mouth)
214501898|NCT04495257|DRUG|Nivolumab|Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
214501899|NCT04495257|DRUG|Ipilimumab|Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
214501900|NCT04495257|DRUG|APX005M|APX005M 0.3mg/kg intravenously (IV) every 3 weeks
214688005|NCT02228278|BEHAVIORAL|Group A|"Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.~Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals."
214999440|NCT07103928|BEHAVIORAL|Self-Tell Notification|"Participants who wish to self-notify one or more partners are coached to do so either in person or by telephone. APN counselors confirm the names of partners for whom participants provide contact information before giving the phone to the participant to explain the reason for the call: I want to speak with you because I was diagnosed with HIV and I believe we shared an exposure. Alternately, participants who wish to notify partners in person are coached to inform partners that they have a serious health matter that they wish to discuss, and ask the partner to visit them in jail/prison. Either way, the APN counselor is present to record the names of partners whom participants self-notify, and offers to speak with the partner immediately afterwards to answer their questions about HIV and to provide information about HIV testing and contact information should the partner wish to contact an HIV provider on their own to learn more about HIV testing or to schedule an HIV test."
214999441|NCT07102888|DRUG|RSS0393 Ointment|RSS0393 ointment.
215094153|NCT05521633|DRUG|Metformin and Pioglitazone|Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
215094154|NCT02668029|DRUG|oxygen|information already included in arm/group descriptions.
215094155|NCT02668029|DRUG|medical air|Placebo
214391591|NCT00000206|DRUG|Buprenorphine|
214391592|NCT03464214|DEVICE|Neck Muscle Vibration|Local vibration device applied on neck muscles for 8 weeks
214391593|NCT03464214|BEHAVIORAL|Cervical Stabilization Exercises|Cervical stabilization exercises performed by healty individuals for 8 weeks
214391594|NCT06082531|DRUG|Sodium hyaluronate injection|The control group was injected into the joint cavity with sodium hyaluronate injection..
214391595|NCT06449885|OTHER|patients receive optimal treatment or follow-up according to the characteristics of the disease|Patients with MZL who are eligible for enrollment will be evaluated by the investigator and the enrolled patients will receive long-term follow-up after collecting medical history information, biological samples, and oncology data according to the study protocol. This study does not specify a detailed treatment modality, and patients receive optimal treatment or follow-up according to the characteristics of the disease.
214391596|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
214688006|NCT02228278|OTHER|Group B|"Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.~Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals."
214391597|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
214391598|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
214391599|NCT04691882|BEHAVIORAL|Diaphragmatic contraction|Sequential periods (30 s) of voluntary diaphragmatic contraction after meal ingestion
214391600|NCT04691882|BEHAVIORAL|Diaphagmatic relaxation|Sequential periods (30 s) of voluntary diaphragmatic relaxation after meal ingestion
214391601|NCT04560205|DRUG|Tocilizumab|"4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation."
214391602|NCT00824174|BEHAVIORAL|Questionnaire|1 questionnaire, about 15-20 minutes.
214391603|NCT03172117|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
214391604|NCT03172117|OTHER|Normal saline 2mL|Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
214391605|NCT01718236|DRUG|Rocuronium + sugammadex|Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
214391606|NCT01718236|DRUG|Succinylcholine + Neostigmine|1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
214391607|NCT01270997|BIOLOGICAL|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
214391608|NCT01270997|BIOLOGICAL|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
214391609|NCT03554161|BIOLOGICAL|Tocilizumab (TCZ)|Patients with refractory BD associated uveitis will receive Tocilizumab therapy, the efficacy and corticosteroids-tapering effects will be evaluated.
214391610|NCT01281553|DRUG|Placebo|Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
214391611|NCT01281553|DRUG|Cisapride|0.2 mg/kg suspension q.i.d.for 8 weeks.
214391612|NCT00422370|DEVICE|lipid based additives based on vegetable oil & lecithin|
214391613|NCT05909293|DRUG|Venclexta 100 MG Oral Tablet|"When there is a deficiency of neutrophils, G-CSF treatment may be necessary. The treatment is continued until the absolute neutrophil count (ANC) reaches either \>0.5×109/L and remains at that level for 3 consecutive days, or \>2×109/L. The purpose of G-CSF therapy in this context is to stimulate the production of neutrophils and restore their levels to a sufficient and stable range. This helps to strengthen the immune system and reduce the risk of infections associated with low neutrophil counts.~When experiencing Grade 3-4 thrombocytopenia, subcutaneous injection of IL-11 can be administered as a treatment.~When symptoms of infection occur, aggressive antimicrobial therapy and other supportive treatments should be administered.~All blood products should undergo irradiation when transfused, and all blood products must be filtered before infusion.~If gastrointestinal adverse reactions occur, antiemetic medications can be administered to alleviate symptoms."
214391614|NCT00001010|DRUG|Zidovudine|
214391615|NCT00001010|DRUG|Acyclovir|
214391616|NCT01024959|OTHER|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
214391617|NCT04375982|DIAGNOSTIC_TEST|Venepuncture|Blood tube will be collected from standard venepuncture
214999442|NCT07104019|PROCEDURE|Biofiller Injection|Biofiller will be prepared by heating the platelet-poor plasma (PPP) component obtained from peripheral blood, which is then mixed with concentrated PRF (c-PRF). After creating a surgical tunnel in the mandibular anterior region (canine to canine), 0.5 mL of the prepared biofiller will be injected into each tooth region under the gingiva. The procedure is performed under local anesthesia and aims to increase gingival thickness in patients with a thin periodontal phenotype.
214999443|NCT07104019|PROCEDURE|connective tissue graft|A connective tissue graft will be harvested from the palatal donor site and placed under the gingiva using a minimally invasive tunneling technique in the mandibular anterior region (canine to canine). The procedure will be performed under local anesthesia and aims to increase gingival thickness. No biomaterials or adjunctive agents will be used.
214999444|NCT05164172|DRUG|Eptinezumab|Concentrate for solution for infusion
214391618|NCT04375982|DIAGNOSTIC_TEST|Fingerstick|Capillary blood will be collected by fingerstick
214391619|NCT00636792|DRUG|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
214391620|NCT00636792|DRUG|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
214501901|NCT04566861|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) for anxiety during pregnancy|Women who are randomized to the intervention group will receive six core Cognitive Behavioral Therapy (CBT) sessions for anxiety during pregnancy (and possible booster sessions) to treat symptoms of anxiety.
214501902|NCT05590494|PROCEDURE|Ultrasonic tenotomy|Ultrasonic procedure as part of standard of care, as clinically indicated, to stimulate healing of the partial tear. The procedure uses ultrasound guidance that allows a needlelike device to gradually break up and remove tendinopathic tendon tissue.
214501903|NCT01562834|DRUG|somatropin|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
214391621|NCT00636792|DRUG|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
214391622|NCT01414413|OTHER|Home assessment and initiation of ART|Home-based ART eligibility assessment (WHO staging, CD4 count measurement and educational treatment preparation) and initiation.
214391623|NCT01414413|OTHER|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor.
214501904|NCT01562834|DRUG|placebo|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
214501905|NCT04652726|DRUG|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
214501906|NCT04652726|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
214501907|NCT02157116|DRUG|cisplatin|
214999445|NCT06408259|DRUG|Ozanimod|Specified dose on specified days
214391624|NCT01231685|DRUG|Raltegravir|Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
214391625|NCT01231685|DRUG|Ritonavir-boosted protease inhibitor|Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
214391626|NCT04295746|OTHER|Serious Game ShopAut|"The serious game ShopAut, is a three-dimensional game conceptually based on classic 3D life simulation games. ShopAut aims to teach players the procedure of a shopping activity; to reinforce object categorization and recognition in a supermarket; to improve attention, orientation, and problem-solving skills; and to help the player engage in simple economic transactions.~The intervention provides a virtual training with ShopAut to train, experiment, and practice behaviours and actions that can be then transferred in real-life contexts."
214391627|NCT04813757|OTHER|exercise|each group will perform 2 shoulder strength exercise at the therapy session and 3 exercise at home session-2 strength exercise and one stretching exercise. they will perform the exercises 5 times per week
214391628|NCT04813757|OTHER|manual therapy|on each treatment session both group will receive 15 minutes of manual therapy which will include: massage,3-4 trigger point treatment posterior capsule stretch and mobilization with movement
214999446|NCT06408259|DRUG|Fingolimod|Specified dose on specified days
214999447|NCT06408259|OTHER|Placebo|Specified dose on specified days
214391629|NCT00902941|DRUG|Azilect 1mg|1 mg daily orally for 120 days
214391630|NCT00902941|DRUG|Placebo|1 mg daily orally for 120 days
214391631|NCT00709592|BIOLOGICAL|Thymoglobulin|Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
214391632|NCT00709592|RADIATION|Total-Body Irradiation|Undergo TBI
214501908|NCT02157116|DRUG|Docetaxel|
214501909|NCT02157116|DRUG|Pegfilgrastim|
214501910|NCT04739137|DIAGNOSTIC_TEST|DDiVAT Testing|Participants will self examine his/her distance visual acuity via application in a simulation room of our department with certain predetermined environmental lighting conditions using the same smart devices.
214501911|NCT04739137|DIAGNOSTIC_TEST|Distance visual acuity assessment via ETDRS chart|The distance visual acuity of each participant will be measured with the conventional method via ETDRS chart
214501912|NCT00370383|DRUG|Erlotinib|erlotinib 150 mg/day once daily
214501913|NCT00370383|DRUG|Satraplatin|"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
214501914|NCT00093496|DRUG|gemcitabine hydrochloride|Given IV
214501915|NCT00093496|DRUG|tanespimycin|Given IV
214501916|NCT03936192|DRUG|glucosamine sulphate 1500mg and meloxicam 15mg|glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
214501917|NCT03936192|DRUG|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
214501918|NCT03936192|DRUG|Placebos|Placebo administered once daily for 12 weeks.
214999448|NCT05019885|DRUG|Ketamine Hydrochloride|Three times a week (M, W, F) for 2 consecutive weeks.
214999449|NCT01237093|OTHER|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda
214999450|NCT01237093|OTHER|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish
214999451|NCT01237093|OTHER|3. Meat and fish, no soda|weight maintaining diet with meat and fish but no soda
214999452|NCT01237093|OTHER|4. Meat and fish and soda|weight maintaining diet with meat, fish and soda
214999453|NCT01237093|OTHER|5. Fish, no meat or soda|weight maintaining diet with fish but no meat or soda
214999454|NCT01237093|OTHER|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat
214999455|NCT01237093|OTHER|7. No meat, fish or soda|weight maintaining diet with no meat, no fish, and no soda (vegetarian)
214391633|NCT00709592|PROCEDURE|Allogeneic PBSCT or BMT|Undergo allogeneic PBSCT or BMT
214391634|NCT00709592|DRUG|Tacrolimus|Given PO
214391635|NCT00709592|DRUG|Mycophenolate Mofetil|Given PO
214391636|NCT05391321|OTHER|administration of the 4 quality of sexual life questionnaires|administration of the 4 quality of sexual life questionnaires
214391637|NCT06220786|DEVICE|Low-level laser therapy|Low-level laser therapy ca. 72 Joules per cm2
214391638|NCT06220786|DEVICE|"Fake low-level laser therapy"|Identical laser pen without production of low-level laser therapy
214391639|NCT00079443|DRUG|romidepsin|Given IV
214391640|NCT00079443|BIOLOGICAL|rituximab|Given IV
214391641|NCT00079443|DRUG|fludarabine phosphate|Given IV
214391642|NCT00079443|OTHER|laboratory biomarker analysis|Correlative studies
214391643|NCT04773886|DRUG|Mineral trioxide aggregate|Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
214391644|NCT04773886|DRUG|Biodentine|Vital Pulpotomy will be done using Biodentine as pulp capping agent
214391645|NCT04773886|BIOLOGICAL|Platelet rich fibrin|"10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~* Acellular platelet plasma- top most layer~* Platelet rich fibrin -middle layer~* Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece"
214391646|NCT03375684|OTHER|Conventional chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
214391647|NCT03375684|OTHER|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
214501919|NCT04115423|DRUG|Tocilizumab|A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
214501920|NCT04115423|DRUG|Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)|Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
214688007|NCT03202316|DRUG|Atezolizumab|Given IV
214688008|NCT03202316|DRUG|Cobimetinib|Given PO
214688009|NCT03202316|DRUG|Eribulin|Given IV
214391648|NCT02161328|OTHER|EIT belt|
214391649|NCT00821132|OTHER|Genetic study of ALS families|Collection and analysis of genetic material, medical and family histories from families with ALS
214391650|NCT00722813|OTHER|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
214391651|NCT01950273|DRUG|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
214391652|NCT01950273|DRUG|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
214391653|NCT05583851|DEVICE|Acceptance and Commitment Therapy|Smartphone app guided and manualized version of acceptance and commitment therapy.
214391654|NCT05583851|OTHER|Psychoeducation Active Control|Set of 11 public seminar videos regarding depression and anxiety. Each are 15 minutes long.
214391655|NCT01770249|PROCEDURE|Per-oral Endoscopic Esophagomyotomy (POEM)|The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
214391656|NCT00472186|DRUG|Lansoprazole|If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
214391657|NCT00472186|DRUG|Placebo|Placebo will also be administered based on weight.
214391658|NCT01254565|DRUG|Etelcalcetide|Administered intravenously (IV) at the end of hemodialysis
214391659|NCT01254565|DRUG|Placebo|Administered intravenously at the end of hemodialysis
214391660|NCT01389063|DRUG|Maraviroc|HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
214391661|NCT00492843|DRUG|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
214391662|NCT04016051|DRUG|Clarithromycin DST (125 mg)|Clarithromycin DST (125.0 mg clarithromycin / straw).
214391663|NCT04016051|DRUG|Clarithromycin DST (187.5 mg)|Clarithromycin DST (187.5 mg clarithromycin / straw).
214391664|NCT04016051|DRUG|Clarithromycin DST (250 mg)|Clarithromycin DST (250.0 mg clarithromycin / straw).
214391665|NCT04016051|DRUG|Clarithromycin Syrup (125 mg)|Clarithromycin Syrup 2.5 ml (125 mg).
214391666|NCT04016051|DRUG|Clarithromycin Syrup (187.5 mg)|Clarithromycin Syrup 3.75 ml (187.5 mg).
214391667|NCT04016051|DRUG|Clarithromycin Syrup (250 mg)|Clarithromycin Syrup 5 ml (250 mg).
214391668|NCT05604287|DRUG|ID119031166M|The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.
214391669|NCT05604287|DRUG|Placebo|The participant will receive a oral dose of Placebo.
214391670|NCT06208072|DRUG|Irbesartan 150mg|Irbesartan group will be treated with Irbesartan 150mg once daily for a total of 8 weeks.
214391671|NCT06208072|DRUG|Eplerenone 25 mg|Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks
214391672|NCT01379820|DEVICE|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
214391673|NCT03871049|DRUG|Bupivacaine with dexamethasone|bupivacaine with dexamethasone
214501921|NCT01370928|DEVICE|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
214501922|NCT01370928|DEVICE|Standard colonoscope|Screening colonoscopy
214501923|NCT03187678|DRUG|i.v. selexipag|Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
214688010|NCT03202316|OTHER|Laboratory Biomarker Analysis|Correlative studies
214688011|NCT03202316|OTHER|Pharmacological Study|Correlative studies
214999456|NCT01237093|OTHER|8. Soda, no meat or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda)
214501924|NCT03187678|DRUG|oral selexipag (Uptravi)|Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
214501925|NCT04811924|DRUG|Application of 0.02% MMC over 60 seconds post corneal crosslinking.|Topical application of 0.02% MMC on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after MMC application.
214501926|NCT04811924|DRUG|Corneal crosslinking without the application of 0.02% MMC|Topical application of placebo on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after placebo application.
214501927|NCT03932513|DRUG|inarigivir soproxil|Inarigivir 200mg and 400mg oral tablets, once daily
214501928|NCT01499316|PROCEDURE|High Flow oxygen|10 minute shigh flow oxygen
214501929|NCT01499316|PROCEDURE|Room Air|Room air breathing
214501930|NCT04105816|DEVICE|892.1550 Ultrasonic pulsed doppler imaging system|Use of the ultrasound to measure quadriceps volume
214501931|NCT04105816|DIAGNOSTIC_TEST|Thigh circumference measurement|Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
214391674|NCT03871049|DRUG|Bupivacaine|bupivacaine
214688012|NCT06992804|OTHER|NirsCure with Lecanemab|Near-infrared light therapy (one session per day, 30 minutes per session, 6 sessions per week) combined with lecanemab (10mg/kg).
214688013|NCT06992804|OTHER|sham NirsCure with Lecanemab|Sham near-infrared light therapy (where only the equipment appearance is consistent with the true near infrared light device, one session per day, 30 minutes per session, 6 sessions per week) in combined with lecanemab (10mg/kg).
214391675|NCT04376411|DIAGNOSTIC_TEST|Flow-cytometric assay|100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.
214391676|NCT04376411|DIAGNOSTIC_TEST|2D Echocardiographic analysis|Trans thoracic echocardiographic examination was performed through (PHILIPS -33) echocardiography device with broadband S5-1 transducer
214391677|NCT04376411|DIAGNOSTIC_TEST|Two-Dimensional speckle tracking echocardiography|Two-Dimensional speckle tracking echocardiography was performed on grey scale images of the left ventricle. For offline analysis digital storage software (Qlab 10.4) was used. The frame rate was adjusted to be 60-90 frame/second.
214391678|NCT06527651|DRUG|Genicular blocks (dexamethazone and lidocaine)|Genicular blocks were applied bilaterally by another physiatrist who was experienced in ultrasonographic (US) interventional procedures more than 5 years. Total of 6mL solution consisting of 0.5 mg/2mL dexamethazone and 4mL %1 lidocaine for three branches of genicular nerves (superomedial, superolateral and inferomedial branches) was divided into three branches for each knee. Total of 12 mL solution was applied for each patient.
214391679|NCT00921297|PROCEDURE|Immediate Cataract Surgery|Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
214501932|NCT00753493|DRUG|intravenous topiramate|Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
214501933|NCT05209555|DIAGNOSTIC_TEST|MoCA|MoCA test to identify Mild Cognitive Impairment
214501934|NCT05209555|DEVICE|BAMCOG|Three games, compared to the MoCA to identify Mild Cognitive Impairment
214501935|NCT05209555|DIAGNOSTIC_TEST|DeltaScan|EEG to detect acute encephalopathy
214501936|NCT05209555|DIAGNOSTIC_TEST|Salivette|To collect saliva for cortisol analysis
214501937|NCT05209555|DIAGNOSTIC_TEST|Pilocarpine iontophoresis|To collect sweat for cortisol analysis
214501940|NCT02920034|DEVICE|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
214501941|NCT02920034|DEVICE|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
214501942|NCT02920034|DEVICE|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
214501943|NCT06008236|BEHAVIORAL|Progressive Muscle Relaxation and Breathing Exercises|Progressive relaxation exercise is a method that provides relaxation in the whole body by voluntary, regular relaxation of large muscle groups in the human body. Exercise helps individuals to be able to feel the difference between tension in the muscles and relaxation, and to learn to relax on their own in case of tension. Deep breathing exercise supports the maximum ventilation of the lung by correct breathing using the diaphragm.
214501944|NCT03274076|DRUG|Tofacitinib|Oral medication tofacitinib 5 mg twice a day for 24 weeks.
214501945|NCT03274076|DRUG|Placebo Oral Tablet|Oral Placebo 5 mg twice a day for 24 weeks
214501946|NCT02446340|DRUG|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
214501947|NCT02446340|DRUG|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
214501948|NCT00000852|PROCEDURE|Allogeneic lymphocyte transfer|
214501949|NCT00975585|DEVICE|senofilcon A|soft contact lens, 2-week replacement indicated
214501950|NCT00975585|DEVICE|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
214501951|NCT00310973|BEHAVIORAL|Social Network Intervention|
214501952|NCT03973034|DIAGNOSTIC_TEST|Low depth whole genome sequencing|Low depth whole genome sequencing of the peripheral blood samples from different groups.
214501953|NCT03640299|PROCEDURE|ERAS procedure|Optimized preoperative, intraoperative and postoperative procedures.
214688014|NCT06992804|OTHER|NirsCure with Lecanemab|Near-infrared light therapy (one session per day, 30 minutes per session, 6 sessions per week) combined with lecanemab (10mg/kg).
214688015|NCT00552539|OTHER|'educational video'|'educational video'
214391680|NCT05675917|DEVICE|MacuTest platform|"The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet)."
214391681|NCT05119413|DRUG|New trio de Kligman|Once daily application in addition to the same sunscreen
214501954|NCT00795184|DEVICE|Imaging procedures (NBI)|"Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites."
214501955|NCT00795184|DEVICE|HDWLE|
214501956|NCT00795184|DEVICE|pCLE|
214501957|NCT05031234|DRUG|anaesthesia without opiates|Anaesthesia without opiates for patients undergoing laparoscopic colectomy
214501958|NCT05031234|DRUG|anaesthesia with morphine|anaesthesia with morphine for patients undergoing laparoscopic colectomy
214501959|NCT04595461|OTHER|Video Education|Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
214501960|NCT04595461|OTHER|Control|Standard patient education with verbal and written education
214501961|NCT04379557|PROCEDURE|Catheter Ablation|Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
214501962|NCT05276999|OTHER|Healthcare provider education|Mix of training and educational activities within the district continuing medical education system targeting community health workers and frontline providers focused on the importance of sore throat and it's link to RHD, clinical guidelines to differentiate patients at high or low risk for GAS pharyngitis and guideline based care for treating GAS pharyngitis
214501963|NCT05276999|OTHER|Community Awareness campaign|A district wide public health campaign to increase community awareness of sore throat, including school based education, VHT community sensitization, education of parents and patients, radio messaging, posters, signs and billboards.
214688016|NCT06991153|DEVICE|Lung Boost Device Training|Patients in the experimental group will train with the Lung Boost Respiratory Trainer (MD800) for 8 weeks, three times weekly, totaling 24 sessions. The procedure will be explained, and equipment sanitized before use. Training begins in strength mode at level 1, where patients inhale deeply through a mouthpiece, with feedback provided via on-screen balls. If level 5 is easily reached, resistance increases using a cone, restarting at level 1. Sessions include 15 repetitions of 2-3 second inhalations and exhalations, performed in three sets with 15-second rests to prevent fatigue. In endurance mode, patients inhale or exhale as long as possible, progressing gradually from level 1. Each session lasts 15 minutes, divided into three sets of five breaths with 15-second rests. This structured program enhances respiratory muscle strength and endurance.
214688017|NCT06991153|OTHER|Traditional physical therapy program|Patients in both groups will receive a traditional physical therapy program for the chest in form of diaphragmatic breathing exercise and pursed-lip breathing exercise for 8 weeks.
214999457|NCT07108660|BEHAVIORAL|Infection Preventionist Led Best Practices Reminders|Infection preventionists at each study hospital review a dashboard on a daily basis that contains predictions for the infection preventionist's hospital. If a patient is predicted to have a possible CLABSI by the ML model, the infection preventionist reviews the case and recommends next steps to the care team based on Providence's CLABSI prevention best-practices bundle, which include reviewing the line for necessity and recommending alternate IV access when appropriate. If line-removal isn't possible, the infection preventionist collaborates with the direct care team to ensure that the line maintenance best practices are observed, including maintaining a clean, dry and intact dressing and using daily chlorhexidine baths.
214999458|NCT06828328|BIOLOGICAL|GC203 TIL|the candidates will be assigned to GC203 TIL(gene-edited TIL) group
214999459|NCT06448754|DRUG|Volrustomig|Participants will receive volrustomig via intravenous (IV) infusion.
214999460|NCT06448754|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion.
214999461|NCT06448754|DRUG|Pemetrexed|Participants will receive pemetrexed via IV infusion.
214999462|NCT06448754|DRUG|Ramucirumab|Participants will receive ramucirumab via IV infusion.
214391682|NCT05119413|DRUG|Trio Kligman|Once daily application in addition to the same sunscreen
214391683|NCT02786043|DRUG|Propionyl-L-Carnitine Hydrochloride|1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
214501964|NCT03014518|OTHER|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
214688018|NCT06991153|DRUG|Medical Treatment|Patients in both groups will receive medical treatment for 8 weeks.
214688019|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
214688020|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
214688021|NCT00923910|DRUG|WT1 Peptide-Pulsed Dendritic Cells|
214688022|NCT00923910|DRUG|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
214999463|NCT06448754|DRUG|Paclitaxel|Participants will receive paclitaxel via IV infusion.
214391684|NCT03254693|COMBINATION_PRODUCT|1-step self-etch approach (SE)|Application mode - Do not use etchan. According to the manufacturer's instructions.
214501965|NCT03014518|OTHER|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
214501966|NCT02553889|DRUG|ISIS 416858|subcutaneous injection
214501967|NCT02553889|DRUG|Placebo|subcutaneous injection
214501968|NCT01928459|DRUG|BGJ398|BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
214501969|NCT01928459|DRUG|BYL719|BYL719 will be administered orally once daily on each day of the 28-day cycle.
214501970|NCT04053270|DRUG|Afamelanotide|16mg subcutaneous implant
214501971|NCT04053270|DRUG|Placebo|Placebo subcutaneous implant
214501972|NCT00205179|DRUG|Novasoy|100mg/day soy isoflavones
214501973|NCT00205179|DRUG|Placebo|100mg/day matching placebo
214501974|NCT02763449|BEHAVIORAL|Self-monitoing|Participants will self-monitor their physical activity level via activity monitors
214501975|NCT00093353|DRUG|cefixime|
214501976|NCT00093353|DRUG|irinotecan hydrochloride|
214501977|NCT00093353|DRUG|temozolomide|
214501978|NCT00586313|DEVICE|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
214501979|NCT00586313|PROCEDURE|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
214501980|NCT00227175|BEHAVIORAL|Semi-structured, open ended interview|
214501981|NCT02247375|DRUG|Low dose of BIIL 284 BS tablets|
214501982|NCT02247375|DRUG|High dose of BIIL 284 BS tablets|
214688023|NCT00923910|DRUG|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
214688024|NCT00923910|DRUG|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
214688025|NCT00923910|DRUG|WT1 Peptides|dendritic cell vaccine
214391685|NCT03254693|COMBINATION_PRODUCT|selective enamel etching (SEE)|Application mode - Etch only on enamel for 15 s. Rinse for 15s. Air dry to remove excess water.According to the manufacturer's instructions.
214391686|NCT03254693|OTHER|1-step self-etch for double time (SE2X)|Application mode - Do not use etchan. According to the manufacturer's instructions, but for the double time (20 s) in the each application.
214391687|NCT03254693|OTHER|1-step self-etch additional layer (SE1+)|Application mode - Do not use etchan. According to the manufacturer's instructions, but apply tree times.
214391688|NCT06010121|DIETARY_SUPPLEMENT|Liposomal Vitamin D|2000 IU of cholecalciferol in liposomal formulation
214501983|NCT02247375|DRUG|Placebo|
214501984|NCT00203554|GENETIC|Poly methylmetacrylate, PMMA|
214501985|NCT02831231|DRUG|xanomeline tartrate|xanomeline tartrate, 75 mg capsule, TID
214501986|NCT02831231|DRUG|Trospium chloride|trospium chloride, over encapsulated 20 mg tablet, BID
214501987|NCT02079649|DRUG|AL-53817 Ophthalmic Solution, 0.1%|
214501988|NCT02079649|DRUG|AL-78843 Ophthalmic Solution, 0.03%|
214501989|NCT02079649|DRUG|Dexamethasone Ophthalmic Suspension, 0.1%|
214501990|NCT02079649|DRUG|AL-53817 Vehicle|Inactive ingredients used for masking purposes
214501991|NCT04941703|DRUG|Magnesium Citrate plus probiotic|296 ml magnesium citrate
214501992|NCT05346094|OTHER|No intervention|No intervention
214501993|NCT00622856|BEHAVIORAL|psychological intervention|Psychological intervention
214501994|NCT00622856|BEHAVIORAL|Diabetes education|5 sessions with diabetes nurse
214501995|NCT03305445|DRUG|Ipilimumab|Ipilimumab (1mg/kg)
214501996|NCT03305445|DRUG|Nivolumab|Nivolumab (3mg/kg)
214501997|NCT01578941|OTHER|Diary|"Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (\>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM."
214501998|NCT00806767|BIOLOGICAL|therapeutic immune globulin|
214501999|NCT00806767|DRUG|busulfan|
214502000|NCT00806767|DRUG|fludarabine phosphate|
214502001|NCT00806767|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214502002|NCT03760913|DRUG|OLP-1002 (Test): Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
214502003|NCT03760913|DRUG|OLP-1002 (Test): Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
214502004|NCT03760913|OTHER|Placebo: Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
214502005|NCT03760913|OTHER|Placebo: Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
214502006|NCT00344916|DRUG|Ng-monomethyl-L-arginine (drug)|
214502007|NCT02974322|DRUG|GED-0301|GED-0301
214502008|NCT02974322|DRUG|Placebo|Placebo
214502009|NCT05800236|PROCEDURE|Gastrectomy|Patients operated on for curative purposes at the Bordeaux University Hospital for gastric adenocarcinoma of any type or stage and Collection of two venous blood tubes
214502010|NCT03813472|DEVICE|Hydration Sensor|This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.
214502011|NCT06079242|DEVICE|Resin microspheres containing yttrium-90 (Y-90)|SIR-Spheres Y-90 resin microspheres are permanent implant and for single use only
214502012|NCT01798667|DRUG|DA-8031|
214502013|NCT01798667|DRUG|Placebo|Placebo of DA-8031, undistinguishable
214688026|NCT00923910|DRUG|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
214688027|NCT00923910|DRUG|Diphenhydramine|Pre-medication
214688028|NCT00923910|DRUG|Acetaminophen|Pre-medication
214688029|NCT00009594|PROCEDURE|Naturopathic Medicine|
214999464|NCT07110142|OTHER|Tongueometer|The Tongueometer device features an air-filled bulb that is placed against the roof of the mouth by the tongue for resistance training. This setup allows for an initial measurement of the patient's maximum tongue strength and endurance, which helps establish goals that are specific to each patient. The device connects to a mobile application that provides visual biofeedback, ensuring consistent monitoring as the patient completes exercises using the tongue bulb for resistance. Once the patient's goals are set based on their initial measurements, the app offers two exercise modules designed to improve both tongue strength and endurance.
214391689|NCT06010121|DIETARY_SUPPLEMENT|Traditional Vitamin D|2000 IU of cholecalciferol in traditional formulation
214391690|NCT02565355|OTHER|Dietary Exclusion|The IgG antibody results will be disclosed ONLY to the patients in the lifestyle modification group by phone approximately one week after clinic visit.. 'Dietary Exclusion' will be advised by a dietitian. Patients are advised to eliminate a maximum of two foods as identified by high IgG antibody titres.
214999465|NCT07110285|OTHER|Artificial intelligence-based algorithm|Trigger day timing decision by an artificial intelligence-based algorithm
214391691|NCT02565355|OTHER|Standard Treatment|The standard therapy group will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relievers as appropriate.
214391692|NCT05153278|BIOLOGICAL|Packed red blood cells|Standard treatment for iron deficiency anemia (control)
214391693|NCT05153278|DRUG|Intravenous drug|Experimental treatment for iron deficiency treatment
214391694|NCT00179283|DRUG|sertraline|
214391695|NCT00179283|DRUG|venlafaxine XR|
214391696|NCT00549419|DRUG|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
214391697|NCT00549419|DRUG|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
214391698|NCT00549419|DRUG|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
214391699|NCT01705470|DRUG|furosemide|
214502014|NCT06075017|PROCEDURE|dental implant placement|Comparing the amount and type of biofilm on zirconia vs. titanium implants
214688030|NCT00009594|PROCEDURE|Traditional Chinese Medicine|
214999466|NCT07102914|BEHAVIORAL|Screening, Brief Intervention and Referral for Treatment (SBIRT)|A single-arm, open pilot design maximizes the ability of the investigators to work collaboratively with NHAEC staff and administration to tailor the implementation strategy, establish the feasibility and acceptability of study methods and interventions (e.g., recruiting students, training SRSs to deliver SBIRT with integrity, response rates to assessment measures, student receipt of SBIRT, retention of SRSs and students), address the structural barriers within the AEC setting, identify the needs of the populations of interest, and gather data that points to best approaches to ensuring the study's success.
214999467|NCT07104448|BEHAVIORAL|Standardized Perioperative Care Protocol|A multi-component protocol involving preoperative patient education, nutritional screening, standardized anesthesia, goal-directed fluid therapy, multimodal opioid-sparing analgesia, and a structured physiotherapy-led mobilization schedule starting on postoperative day 1.
214391700|NCT01705470|DRUG|placebo normal saline|
214391701|NCT03817346|DRUG|GT-002|Single ascending dose
214391702|NCT03817346|DRUG|Placebo oral capsule|Comparator single ascending dose
214391703|NCT05674084|DIAGNOSTIC_TEST|Capillary refill time|CRT will be measured by applying firm pressure to the ventral surface of the index finger distal phalanx with a glass microscope slide. The pressure will be increased until the skin is blank and then maintained for 10 seconds. The time for return of the normal skin color will be registered with a chronometer, and \> 3 seconds is defined as abnormal. Light and ambient temperature will be the same for all individuals.
214391704|NCT05773131|DEVICE|VR collaborative visualization system|Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
214391705|NCT00242463|DRUG|Nandrolone (anabolic steroid)|
214391706|NCT00242463|DRUG|Placebo|
214391707|NCT03866772|DRUG|Misoprostol Oral Tablet|50 mcg oral consumption
214391708|NCT03866772|DEVICE|double balloon device for cervical ripening|insertion for 6 hours and followed by the above mentioned protocol
214391709|NCT03774992|DEVICE|Orthokeratology lenses|Custom fit, form stable contact lenses
214391710|NCT00178256|DRUG|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
214391711|NCT00178256|PROCEDURE|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
214391712|NCT02123537|DEVICE|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System during waking hours for 12 weeks.
214391713|NCT00960102|DEVICE|cochlear implant|Multichannel Nucleus cochlear implant
214391714|NCT00960102|DEVICE|hearing aid|Phonak hearing aid
214391715|NCT02544269|PROCEDURE|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
214391716|NCT02544269|PROCEDURE|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
214391717|NCT02406313|OTHER|CTS|Standardized Thermal Cure
214391718|NCT02406313|OTHER|ETP|Patient Therapeutic Education
214502015|NCT03387254|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
214502016|NCT03387254|DEVICE|VR + sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
214502017|NCT04389385|BIOLOGICAL|COVID-19 Specific T Cell derived exosomes (CSTC-Exo)|The virus-specific T-cells (VSTs) are body's natural immune defense against various disease-causing viruses. Donor originated COVID-19 specific T-cells (CSTC) are in vitro activated and expanded by exposing to viral peptide fragments in the presence of natural immune stimulant proteins called cytokines. These Covid-19 specific fragment peptides activate specific T-cells and stimulate the secretion of potent mediators including IFN gamma in forms of exosomes. We propose treatment of Covid-19 patients -who are at early stages of pulmonary disease- with CSTC-exomes to control disease progression.
214688031|NCT01096550|BEHAVIORAL|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
214688032|NCT01096550|BEHAVIORAL|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
214391719|NCT03808441|OTHER|ctDNA analysis|Regular ctDNA analysis, which upon a decrease in mutant BRAF VAF (variant allele frequency) level of ≥80% the switch to N+I is triggered.
214391720|NCT00539903|BEHAVIORAL|Physical activity (PA) and immigrants|
214391721|NCT04800757|BEHAVIORAL|individual -Brief Motivational Intervention (BMI)|"A baseline survey will be administered prior to the session.Sessions will be initiated by exploring working conditions and psychosocial factors that may influence risk for work related injuries. If the LDL is motivated to change the target behavior, a 'change plan' will be developed which involves identifying reasons for change, goals in making change, specific actions and timelines, and others who may help the person change. The final step will be the development of a personal safety plan to reduce work place risks and a discussion of the following topics: (a) how they will know if their plan is successful, (b) potential obstacles, and (c) what the worker can do if the plan does not work. Finally,each worker will be asked to write and sign a personal pledge (Mi Promesa) to implement his own safety plan.Follow-up surveys will be conducted 4 weeks after the baseline survey."
214391722|NCT04800757|BEHAVIORAL|Group (Group Problem Solving)|Participants will be administered a baseline survey prior to session. The GPS intervention consists of a discussion between 2-5 LDLs and a trained group facilitator. The sessions will last 30-45 minutes and are intended to encourage and support Latino day laborers (LDL) to act to reduce work-related hazards and promote worksite safety. The intervention combines four participatory and group problem solving activities to engage in collaborative learning: an icebreaker, the risk identification, action planning, and Nuestra Promesa (Our Pledge). The last activity requires LDL to select a risk reduction behavior and then to fill out and sign a card detailing a pledge to implement a safety plan. Follow up surveys will be conducted four weeks post intervention, to assess participants' change in attitudes, beliefs, and risk reducing behavior and their implementation or their safety plan.
214391723|NCT04800757|BEHAVIORAL|Standard of Care (OSHA 10 Safety Cards)|Participant will be administered a baseline survey prior to the session.Participants in this standard of care control group will receive four wallet size cards with information about risk reduction strategies to deal with the four hazards responsible for most workplace fatalities in Texas: falls, struck by, heat exposure and cuts. The laminated cards are adapted from OSHA's website publicly available materials in Spanish for workers with limited literacy.
214391724|NCT00671632|DRUG|Ramelteon, triazolam, and placebo (56 possible combinations total)|"Randomized sequence over eight consecutive days to include the following:~Ramelteon 16 mg, tablets, orally, one day only;~Ramelteon 80 mg, tablets, orally, one day only;~Ramelteon 160 mg, tablets, orally, one day only;~Triazolam 0.25 mg, capsules, orally, one day only;~Triazolam 0.50 mg, capsules, orally, one day only;~Triazolam 0.75 mg, capsules, orally, one day only;~Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;~Additional dose of study medication or placebo, tablets or capsules, orally, one day only."
214391725|NCT03542448|DEVICE|Swept source optical coherence tomography|Measurement of choroidal thickness in myopic patients
214391726|NCT02043262|BEHAVIORAL|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
214391727|NCT02043262|BEHAVIORAL|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
214391728|NCT02474511|OTHER|general anesthesia and local anesthesia|the patient received generalanesthesia and local anesthesia randomly
214391729|NCT04198532|OTHER|Contrast bath|Contrast bath (hot and cold therapy)
214502018|NCT05926674|OTHER|Myofascial Release|Myofascial release is a manual therapy technique commonly used by clinicians and bodyworkers to provide effects such as decreased pain, improvement in flexibility, ROM, and quality of life. It combines non-gliding fascial traction with varying amounts of stretching to produce a tensional force on the muscle and its associated fascia resulting in viscoelastic lengthening and deformation.
214502019|NCT05926674|OTHER|Light Touch Contact|The sham treatment of light touch will be applied to the lumbar spine and this form of contact is not therapeutic. It is only meant to only mimic a manual therapy technique.
214999468|NCT07104448|OTHER|Conventional care|Standard, non-protocolized institutional perioperative care, with management decisions based on the discretion of the attending surgeon and care team.
214999469|NCT07103148|BIOLOGICAL|Yellow fever vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
214391730|NCT02966535|DEVICE|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
214999470|NCT07103148|BIOLOGICAL|Yellow fever vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
214999471|NCT07103148|BIOLOGICAL|Yellow fever vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
214999472|NCT07103148|BIOLOGICAL|Measles, combinations with mumps and rubella, live attenuated|Powder, lyophilized, for suspension for reconstitution Subcutaneous or intermuscular
215094156|NCT04922905|OTHER|NEURO +|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed."
214502020|NCT00964236|DRUG|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
214502021|NCT02398487|DEVICE|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
214502022|NCT02398487|DEVICE|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
214688033|NCT00275405|DRUG|Garlic Oil Macerate|
214688034|NCT00170157|DRUG|Bicalutamide|Given orally
214688035|NCT00170157|DRUG|Flutamide|Given orally
214688036|NCT00170157|DRUG|Goserelin Acetate|Given SC
214688037|NCT00170157|DRUG|Ipilimumab|Given IV
214688038|NCT00170157|DRUG|Leuprolide Acetate|Given IM
214688039|NCT00170157|OTHER|Pharmacological Study|Correlative study
214391731|NCT02966535|DEVICE|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
214999473|NCT07099326|OTHER|Educational Method Using Interactive Video|"Phase 1 - Interactive Video-Based Training (10 sessions of 30 minutes each):~Patients will access the platform via the website https://spotplayer.ir/ and watch a comprehensive interactive video related to end-stage renal disease (ESRD) and its replacement therapies. This video consists of ten 30-minute sessions, uploaded at the rate of one session per day. During the viewing, pop-up questions will appear, which patients are required to answer. Different response options will lead to the presentation of different educational scenarios. In addition, multiple-choice questions related to the content will be included throughout the video, and patients must record their answers in the system. The instructor will be able to review these responses through a management dashboard. It is worth noting that all patients will have previously received the necessary training to use the interactive videos, including Q\&A sessions designed to ensure sufficient skill acquisition in utilizing the interact"
214999474|NCT07099326|OTHER|Educational Method Using Conventional Video|"This educational intervention will be carried out in two phases with a total duration of six hours. A total of 55 patients will participate in this study, organized into groups of five and guided by an experienced instructor familiar with the interactive video-based educational system.~Phase 1 - Conventional Video-Based Training (10 sessions of 30 minutes each):~Patients will access the platform through the website https://spotplayer.ir/ and watch in-depth educational videos related to end-stage renal disease (ESRD) and its replacement therapies. The video content consists of ten 30-minute sessions, which will be uploaded for the patients at the rate of one session per day.~Phase 2 - Consolidation and Reinforcement Session (1 hour):~After completing the ten video sessions, patients will participate in group discussions to analyze the scenarios, topics, and questions presented in the videos. The instructor will facilitate the discussions, summarize the outcomes, and assess the over"
214999475|NCT07104201|DRUG|Fenofibrate|Fenofibrate 200mg
214999476|NCT07104851|BEHAVIORAL|Resilience-Satir Hybrid Intervention|A structured, 12-week, group-based psychological intervention integrating principles from Resilience Theory and the Satir Model to enhance coping skills, self-esteem, communication, and family dynamics.
214999477|NCT07104851|OTHER|Treatment as Usual (TAU)|Standard care for adolescent depression, including pharmacotherapy and routine nursing support, without structured psychotherapy.
214999478|NCT07108465|DRUG|Bupivacaine 0,5%|Injection of bupivacaine 0,5% in group A
215094157|NCT04922905|OTHER|NEURO -|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)"
214391732|NCT04188483|DIETARY_SUPPLEMENT|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days.
214391733|NCT04188483|BIOLOGICAL|Influenza vaccination|Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
214391734|NCT04708691|OTHER|Aerobic exercise|aerobic exercise
214502023|NCT00853580|DRUG|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
214502024|NCT00853580|DEVICE|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
215094158|NCT04190004|DRUG|Vasopressins|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
214391735|NCT04350476|DIAGNOSTIC_TEST|VitalConnect Vital Sign Patch|"This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.~This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication)."
214391736|NCT04076020|BEHAVIORAL|Relational agent/AliveCor Kardia - Intervention|Use of the relational agent and Kardia daily for 120 days.
214391737|NCT04076020|BEHAVIORAL|Usual Care|Use of the WebMD app daily for 120 days.
214391738|NCT06172218|OTHER|Flo|sterile, micronized human amniotic membrane product derived from placenta and umbilical cord
214391739|NCT06172218|OTHER|Saline|sterile, preservative free 0.9% NaCl
214391740|NCT05022602|DEVICE|Imagio|Imagio - both ultrasound probe and Duplex OA probe
214391741|NCT02811289|DRUG|Mirbetriq (Mirabegron)|50mg of Mirabegron will be administered orally at time 0 in protocol A.
214391742|NCT02811289|OTHER|cold exposure|Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
214391743|NCT02811289|RADIATION|injection of 18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
214391744|NCT02811289|RADIATION|injection of 11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
214391745|NCT02811289|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
214391746|NCT02811289|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
214502025|NCT05011955|BEHAVIORAL|Mindfulness, compassion and intercare based Intervention|"The mindfulness based intervention was a short version of the Mindfulness based intercare program (IBAP). The intervention consists of four synchronic group sessions via ZOOM of one hour each, one peer week and home practice. A total of four groups were conducted of 15 students each.~The IBAP program was inspired by first and second generation mindfulness based interventions, such as Mindfulness based cognitive training, Self-Compassion and Cognitive based Compassion training. Also compassionate communication, conservation of resource theory and habits theory.~Each module consists in meditation practices, inquiry and self or group reflections on different topics such as mindfulness, automatic pilot, mind wandering , acceptance, gratitude and compassion, care resources and intercare."
214688040|NCT02226614|DEVICE|University of Edinburgh head cooling device|head cooling
214688041|NCT00001693|DRUG|Celecoxib (SC-58635)|
214688042|NCT00518453|BIOLOGICAL|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
214999479|NCT07108465|DRUG|Ropivacaine 0,75%|Injection of ropivacaine 0,75% in group B
214391747|NCT02811289|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
214391748|NCT03870178|DEVICE|Transcranial direct current stimulation (tDCS)|The noninvasive and nonpharmacological weak electrical current applied to the scalp to modulate cortical excitability.
214391749|NCT01510613|DRUG|Pomalidomide and Dexamethasone|Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
214391750|NCT02310126|DEVICE|etafilcon A (multi-focal)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
214502026|NCT05011955|BEHAVIORAL|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work base on psychoeducation about stress, anxiety, selfcare and effective communication. Plus general curricular intervention. Delivered by psychologist.
214502027|NCT05011955|OTHER|General curricular intervention|"All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams."
214502028|NCT02629224|DRUG|ASP8825|Oral
214502029|NCT02394106|DRUG|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
214502030|NCT02394106|OTHER|Placebo|Normal saline, 1000 ml, administered once
214502031|NCT05866575|OTHER|escitalopram|Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
214502032|NCT05866575|OTHER|vortioxetine|Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
214502033|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Oxide|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients
214688043|NCT02114632|DIETARY_SUPPLEMENT|Eye Q|3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
214391751|NCT02310126|DEVICE|etafilcon A (sphere)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
214999480|NCT07112482|BEHAVIORAL|Standard Oncological Care + Tailored Dietary Counseling + Nutritional Monitoring|"Participants in this group will receive:~Standard oncological care (e.g., chemotherapy and routine cancer treatments)~Individualized dietary counseling: Nutrition plans tailored by a clinical dietitian to meet energy needs (25-30 kcal/kg/day) and protein needs (1.2-1.5 g/kg/day), adapted to clinical status, dietary tolerance, and treatment side effects.~Regular nutritional monitoring: Counseling sessions every 15-21 days over a period of six months.~Dietary adherence tracking: Through structured food records and goal adherence checklists.~Light physical activity guidance: Encouragement to engage in low-intensity activity suited to patient capacity.~Psychosocial support: Sessions with a certified clinical psychologist addressing emotional distress, fatigue, and anorexia.~Adherence criteria: Defined as attending ≥75% of sessions and meeting ≥80% of dietary goals."
214999481|NCT07112118|OTHER|data collection|Collect the facial expressions, audio, text and postural behavior data of the respondents using electronic devices.
214391752|NCT06451575|DIAGNOSTIC_TEST|Blood collection|Blood collection
214391753|NCT00230321|DRUG|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
214391754|NCT00590993|OTHER|MRI and MRSI|Compare treatment impact when using MRI and MRSI
214391755|NCT00271869|PROCEDURE|Extracorporeal photoimmunotherapy|
214391756|NCT02220686|BEHAVIORAL|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
214391757|NCT01578096|BEHAVIORAL|stress management|The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
214391758|NCT01948362|DRUG|Sulforadex|Active compound
214688044|NCT00355004|OTHER|counseling intervention|
214688045|NCT00355004|PROCEDURE|fecal occult blood test|
214391759|NCT01948362|DRUG|Alpha cyclodextrin|Placebo control
214391760|NCT00855868|DRUG|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
214391761|NCT00855868|DRUG|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose \[11C\]-PIB
214391762|NCT03901469|DRUG|ZEN003694|PO QD
214391763|NCT03901469|DRUG|Talazoparib|PO QD
214502034|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Sulphate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients
214502035|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients
214502036|NCT02714075|OTHER|Ferric Pyrophosphate, ZnSO4, CA/TSC|Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients
214502037|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, CA, EDTA|Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients
214688046|NCT00355004|PROCEDURE|screening colonoscopy|
214688047|NCT02434315|DEVICE|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
214502038|NCT02714075|OTHER|Ferrous Sulphate|Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
214502039|NCT06511284|OTHER|High protein dose|High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition
214391764|NCT05769270|BEHAVIORAL|Peer Navigation and Coping Skills|Participants will receive 6 sessions of peer navigation and coping skills
214391765|NCT05769270|BEHAVIORAL|Treatment as Usual|Participants will receive referrals for PrEP and services
214502040|NCT06511284|OTHER|Usual protein dose|Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition
214502041|NCT02884245|DRUG|Estrogens|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
214502042|NCT03712150|DEVICE|tdcs|application of optimised parameters of tDCS (anodal stimulation, 1.5 mA, 10 min) over the unconditioned hemisphere reverses the brain and behavioural consequences of inhibitory pre-conditioning
214502043|NCT00748982|DRUG|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
214502044|NCT00748982|DRUG|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
214502045|NCT00000215|DRUG|Pergolide|
214502046|NCT01968967|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
214502047|NCT01968967|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
214502048|NCT04624139|BEHAVIORAL|Internet-based cognitive behavioral therapy + physiotherapy|"Combined intervention of stress reducing I-CBT and physiotherapy. The intervention consists of two components; I-CBT and physiotherapy aiming to reduce symptoms of stress.~I-CBT: Designed to reduce stress, during 8 weeks. Physiotherapy: A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
214502049|NCT04624139|BEHAVIORAL|Physiotherapy only|"A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
214688048|NCT02434315|DEVICE|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
214391766|NCT00000484|DRUG|chlorothiazide|
214391767|NCT00000484|DRUG|Rauwolfia alkaloids|
214391768|NCT05251441|DIETARY_SUPPLEMENT|Breast Milk Fortifier supplements|Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
214688049|NCT02434315|DEVICE|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
215094159|NCT04190004|DRUG|Placebo|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
215094160|NCT03247959|BEHAVIORAL|Video game distraction and video distraction|video game distraction and video distraction will be advocated during the extraction procedure
214391769|NCT00932490|BEHAVIORAL|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
214391770|NCT03953729|DRUG|Ibuprofen|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
214391771|NCT03953729|DRUG|Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
214502050|NCT02408913|BIOLOGICAL|VRC-EBOMVA079-00-VP (MVA-EbolaZ)|Ebola Modified Vaccinia Virus Ankara Vaccine
214502051|NCT02408913|BIOLOGICAL|VRC-EBOADC069-00-VP (cAd3-EBO)|Ebola Chimpanzee Adenovirus Vector Vaccine
214502052|NCT04352400|DRUG|Nafamostat Mesilate|administered intravenously as a continuous infusion
214502053|NCT04352400|DRUG|Placebo|administered intravenously as a continuous infusion
214502054|NCT00144235|DRUG|Pharmaton PHL 00749|
214502055|NCT00144235|DRUG|Placebo|
214502056|NCT01170208|DEVICE|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
214502057|NCT01351376|DEVICE|Low Level Laser Therapy|Placebo LLL combined with CDT
215094161|NCT03973905|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
214391772|NCT02803320|DRUG|SPF 50 Y65 110 (BAY 987516)|Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
214391773|NCT05223842|BEHAVIORAL|Family Promoting Positive Emotions (F-PPE)|F-PPE is an 8-session dyadic intervention designed to enhance positive emotionality and buffer against the effects of stress on anhedonia in children. The intervention will be administered online through videoconferencing sessions with a clinician to mothers and their children.
214391774|NCT05223842|BEHAVIORAL|Written Information|Mothers assigned to the Written Information condition will receive email newsletters providing resources relevant to depression.
214391775|NCT00654329|DRUG|Saline|Normal saline, given intranasally
214391776|NCT00654329|DRUG|Fentanyl|Fentanyl, nasal transmucosal, 2 micrograms/kilogram
214391777|NCT00654329|DRUG|Dexmedetomidine|Dexmedetomidine, transmucosal, 1 microgram/kilogram
214391778|NCT00654329|DRUG|Dexmedetomidine|Dexmedetomidine, 2 microgram/kilogram, transmucosal route
214999482|NCT07105241|OTHER|VR therapy|Patients in the VR intervention group receive a VR 'relax and distract' intervention in addition to standard care. This type of VR utilizes video's, relaxation exercises and cognitive games to immerse patients in a novel, calming and distracting environment, enhancing the patient's ability to manage anxiety, stress and pain. The VR set is introduced to the patient in the cardiology day care unit prior to the procedure allowing for familiarization with the device. After moving the patient to the catheterization laboratory, the VR set is re-offered to the patient and the VR intervention is started. The intervention ends with the conclusion of the procedure, or when the patient indicates that they would like to discontinue the therapy earlier.
215094162|NCT01471210|DRUG|Urelumab (BMS-663513)|
214391779|NCT02264496|BEHAVIORAL|Exercise|
214391780|NCT00974636|DIETARY_SUPPLEMENT|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
214391781|NCT00974636|DIETARY_SUPPLEMENT|Usual Salt Diet|Usual salt intake (approximately \>180-200 mmol/day in the average American diet).
214391782|NCT00074763|BIOLOGICAL|Platelet Transfusion|All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
214391783|NCT03237962|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.
214391784|NCT03237962|DEVICE|Nasal Cannula|Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
214391785|NCT04876885|OTHER|Educational video|Three two-minute educational videos about COVID-19 vaccine development and dissemination
214391786|NCT02651285|OTHER|G-CSF medium|incubation of IVF embryos with a specific medium containing G-CSF
214391787|NCT02651285|OTHER|Control|incubation of IVF embryos with a medium without G-CSF
214391788|NCT02761629|DRUG|Peg-Interferon Alpha-2A|Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
214391789|NCT02761629|DRUG|Ribavirin|Ribavirin will be administered as either 1000 milligrams (mg) (2\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing less than (\<) 75 kilograms (kg) or as 1200 mg (3\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing greater than or equal to (\>/=) 75 kg.
214502058|NCT01351376|DEVICE|Low Level Laser|Active LLL combined with CDT
214502059|NCT02322372|DRUG|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
214502060|NCT02322372|DRUG|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
214502061|NCT01116206|DRUG|Prucalopride|2 mg tablet, orally once daily, for 12 weeks
214502062|NCT01116206|DRUG|Placebo|1 tablet, orally once dailyfor 12 weeks
214688050|NCT02492750|BIOLOGICAL|Anakinra|Given SC
214688051|NCT02492750|DRUG|Dexamethasone|Given PO
215094163|NCT00599508|DIETARY_SUPPLEMENT|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
215094164|NCT00599508|DIETARY_SUPPLEMENT|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
215094165|NCT00599508|DIETARY_SUPPLEMENT|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
215094166|NCT00599508|DIETARY_SUPPLEMENT|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
215094167|NCT00599508|DIETARY_SUPPLEMENT|berry placebo powder|berry placebo powder administered daily for 16 weeks
214391790|NCT06500520|OTHER|Resisted Exercise group|The resisted exercise training program targeted trunk, upper, and lower body segments with 10-12 repetitions at 30-65% intensity, lasting 50-60 minutes per session, 3 times weekly for 8 weeks. Participants determined their maximal repetition through trial training. Maximal power was assessed using concentric 1-maximal repetition (MT). Following a 2-3 minute rest and a 5-minute warm-up (walking), participants performed the 1-MT test to establish their heaviest lift with the correct technique, adjusting resistance levels accordingly. The circuit-style training spanned 9 stations with 2-3 sets per station, each circuit lasting 2-3 minutes with 90-second rests between sets. A 5-minute warm-up and cool-down (walking) preceded and followed each session. Exercises included bilateral elbow flexion, chest press, bilateral shoulder abduction, bilateral knee extension, back extension, sit-ups, knee flexion, hip abduction, and hip adduction.
214391791|NCT06500520|OTHER|Stretching Exercise group|The participants were made to perform stretching exercises, selected by reviewing the literature, under supervision 3 days a week for 8 weeks, and they were asked not to do any other exercises during this intervention period. They were asked to do exercises such as trunk flexion, pelvic elevation, squatting, trunk lateral flexion, lumbar extensor stretching, lower abdominal stretching, hip adduct stretching, piriformis stretching, and trunk flexor stretching (cobra pose). The holding time was 5 seconds, the rest time was 1 second, and the exercises were applied in 10 repetitions.
214391792|NCT02933463|OTHER|Embrace Wetbond|not require an additional bonding agent hydrophilic, fluoride releasing
214391793|NCT02933463|OTHER|Clinpro sealant|
214502063|NCT00766909|DRUG|cyclosporine|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days."
214999483|NCT07105241|OTHER|360 degree education videos|Prior to the procedure, patients in the VR intervention group are additionally offered an educational video consisting of a virtual tour of the EP laboratory with a visual explanation of the upcoming procedure. These videos will be recorded as 360ͦ videos to support an optimal immersive experience when viewed on the VR set. In this way, the videos will serve simultaneously as additional educational measures for the procedure, as well as a way to familiarize patients with the VR set. Use of the educational videos is not obligatory, but is offered optionally according to patients' preference.
214999484|NCT07102706|DRUG|GR1803 injection|weekly dose up to week 24 , biweekly dose from week 24 to week 36, and triweekly dose from week 36 to week 52
214999485|NCT02145390|PROCEDURE|Transurethral Resection of the Bladder Tumor & Cystoscopy|"TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~* Cystoscopic evaluation~* Bimanual examination under anesthesia,~* Transurethral resection of the bladder tumor,~* Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop."
214391794|NCT01084590|BEHAVIORAL|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
214391795|NCT01084590|BEHAVIORAL|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
214391796|NCT03300089|PROCEDURE|General anaesthesia|General anaesthesia
214391797|NCT03300089|PROCEDURE|Regional anaesthesia|Regional anaesthesia
214391798|NCT04843813|DIETARY_SUPPLEMENT|Lutein|Participants will consume daily soft gels containing the lutein supplement.
214391799|NCT04843813|DIETARY_SUPPLEMENT|Placebo|Participants will consume daily soft gels containing the safflower oil.
214391800|NCT04039802|PROCEDURE|Single-stage surgery|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
214391801|NCT04039802|OTHER|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
214391802|NCT00922844|DRUG|Sevoflurane and isoflurane|Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
214391803|NCT00238862|PROCEDURE|Amniotic membrane transplantation|
214391804|NCT00238862|DRUG|Autologous serum/BSS 20%|
214391805|NCT05701722|DEVICE|Flourish HEC Vaginal Care System|BioNourish, a component of the Flourish HEC system, is a class II medical device. In addition to BioNourish, the system includes Balance intimate wash and BiopHresh homeopathic vaginal suppository with probiotics. All products are available over the counter and have been on the market for several years.
214391806|NCT03326817|OTHER|Control Group|Patients receive standard care
214391807|NCT03326817|DEVICE|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
214391808|NCT02132533|DRUG|Nifedipine|Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
214502064|NCT00766909|DRUG|tacrolimus|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days."
214688052|NCT02492750|OTHER|Laboratory Biomarker Analysis|Correlative studies
214688053|NCT02492750|DRUG|Lenalidomide|Given PO
214688054|NCT02492750|OTHER|Placebo|Given SC
215094168|NCT02648217|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
215094169|NCT02648217|DRUG|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
215094170|NCT05023148|PROCEDURE|Electroacupuncture|Stimulating acupoints using electric stimulator
215094171|NCT05023148|PROCEDURE|Thread embedded acupuncture|Stimulating acupoints using thread embedded
214391809|NCT02132533|DRUG|Placebo|Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
214391810|NCT02132533|OTHER|Usual care|Usual evaluation, monitoring and care for women with preterm labor.
214502065|NCT00766909|OTHER|Capsules and isotonic saline|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days."
214502066|NCT04877756|DRUG|OLX10010|Lyophilized cake reconstituted with WFI and injected intradermally
214502067|NCT05230264|OTHER|Elective AAA Repair|Elective AAA Repair - Observation of Stress Response
214502068|NCT03773471|BEHAVIORAL|Mobile Health App|ArthritisPower App
214502069|NCT03208465|DRUG|Empagliflozin|In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
214502070|NCT03208465|DRUG|Sitagliptin|In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
214502071|NCT05141539|DEVICE|Rehabilitation assessment software|"In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability."
214502072|NCT05141539|DEVICE|VFSS and FOIS|In phase 3, this study applies VFSS and FOIS for the head and neck cancer patients for comparison with the developed rehabilitation assessment software for criterion-related validity.
214502073|NCT06369220|DIAGNOSTIC_TEST|cobas® liat CT/NG/MG nucleic acid test|The cobas® CT/NG/MG nucleic acid test for use on the cobas® Liat® System is an investigational, automated, qualitative in vitro nucleic acid diagnostic test that utilizes real-time polymerase chain reaction (PCR) for the direct detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) nucleic acid in male/female urine and vaginal swabs (clinician-collected and self-collected) in cobas® PCR Media.
214502074|NCT06369220|OTHER|Standard of Care (SOC): Clinician's Standard Practice|Standard of care (SOC) is defined as the traditional/typical diagnosis and treatment steps in practice recommended by the CDC guidelines that rely upon clinical syndromic presentations and/or external laboratory testing.
214502075|NCT04884165|DEVICE|Remote monitoring of home mechanical ventilation (NIV) using SRETT|Patients will use the SRETT device attached to their home ventilator.
214502076|NCT04884165|OTHER|Home mechanical ventilation (NIV) without remote monitoring|Usual care
214502077|NCT04309552|DRUG|18F-FMISO PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
214688055|NCT05110898|DRUG|fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg|Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.
214999486|NCT02145390|RADIATION|Intensity Modulated Radiation Therapy|"For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~* Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~* Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~* Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~* Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume."
214688056|NCT05110898|DRUG|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
214999487|NCT02145390|BEHAVIORAL|Expanded Prostate Cancer Index Composite Short Form 12|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
214999488|NCT02145390|BEHAVIORAL|International Prostate Symptom Score|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
214999489|NCT07104149|DRUG|Cadonilimab combined with cisplatin|Neoadjuvant chemotherapy plus cadonilimab for locally advanced cervical cancer
214999490|NCT07103759|BEHAVIORAL|Refrain from caffeine techniques|Participants will be asked to refrain from drinking caffeinated beverages in the late afternoon and evening.
214999491|NCT07103759|BEHAVIORAL|Project REST Platform|Participants will use the Project REST platform
214391811|NCT03160300|DEVICE|Music with Binaural Beats|Relaxing music with embedded binaural beats at a frequency of 5 Hz
214999492|NCT07110051|DRUG|Nalbuphine|this group will a single dose of nalbuphine (0.2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours)
214999493|NCT07110051|DRUG|Tramadol|this group will receive a single dose of tramadol (2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours).
214391812|NCT03160300|DEVICE|Music|Relaxing music without a binaural beat component
214391813|NCT01603563|BEHAVIORAL|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
214999494|NCT07103707|PROCEDURE|open cholecystectomy|standard open cholecystectomy performed under general anesthesia
214999495|NCT07103707|PROCEDURE|Laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy using minimally invasive technique
214391814|NCT01603563|BEHAVIORAL|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, \& trauma narrative etc.).
214391815|NCT02001974|DRUG|Paclitaxel+Reparixin|Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
214391816|NCT06316219|DRUG|Nomegestrol Acetate/Estradiol 2.5mg/1.5mg|hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol 2.5mg/1.5mg at any time of the menstrual cycle
214391817|NCT00478764|DRUG|intraocular triamcinolone and gatifloxicin|
214391818|NCT05374759|DIAGNOSTIC_TEST|neutrophil gelatinase-associated lipocalin|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, blood samples will be taken and NGAL levels will measured.
214391819|NCT05374759|DIAGNOSTIC_TEST|renal resistive index|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, renal resistive index will measure and record.
214391820|NCT00672958|DRUG|Vortioxetine|Encapsulated immediate-release tablets.
214391821|NCT00672958|DRUG|Placebo|Vortioxetine placebo-matching capsules.
214391822|NCT01380990|GENETIC|Infusion of autologous EFS-ADA LV CD34+ cells|Autologous EFS-ADA LV CD34+ cells (OTL-101\*) are infused intravenously
214391823|NCT01380990|OTHER|Haematopoietic Stem Cell Transplantation (HSCT)|Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from GOSH will be collected as comparator group.
214688057|NCT03699982|OTHER|Daily calorie target based on resting energy expenditure|"Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.~Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake."
214688058|NCT06514469|DRUG|Sufentanil intravenous administration followed consultation of remote physician|Intravenous administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
214688059|NCT06514469|DRUG|Sufentanil intravenous administration based on paramedic competency|Intravenous administration of sufentanil to patients with acute injury by paramedics based on their competencies
214999496|NCT07105293|OTHER|PEEP 5 cmH2o applied group|A standardized anesthesia protocol involved volume-controlled ventilation with a tidal volume of 6-8 mL/kg and a frequency of 10-12 breaths/min, PEEP:5 cmH2o
214999497|NCT07105293|OTHER|PEEP 10 cmH2o applied group|A standardized anesthesia protocol involved volume-controlled ventilation with a tidal volume of 6-8 mL/kg and a frequency of 10-12 breaths/min, PEEP:10 cmH2o
215094172|NCT03316950|DEVICE|IntraGen RF|IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
215094173|NCT03316950|DEVICE|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
214391824|NCT01380990|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
214391825|NCT01380990|DRUG|Peg-Ada|Peg-Ada enzyme replacement therapy is discontinued at Day +3- (-3/+15 days) after successful engraftment
214391826|NCT01836627|OTHER|Hyperinsufflation therapy|15 minutes twice a day of hyperinsufflation with Cough Assist® device
214391827|NCT03482817|DRUG|Ze 117|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
214391828|NCT03482817|DRUG|Probe drug cocktail|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
214391829|NCT02240719|DRUG|everolimus|Given PO
214391830|NCT02240719|DRUG|bendamustine hydrochloride|Given IV
214391831|NCT02899871|OTHER|diagnosis of joint|"The diagnosis of joint pain will be established by a rheumatologist and completed:~* If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~* serum assays of the anti-TNF administered, as well as screening for associated antibodies."
214391832|NCT03121534|DRUG|Blinatumomab|"Patients will receive blinatumomab as a continuous IV infusion, commencing on day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week .~blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28. This will be followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days.blinatumomab treatment-free interval."
214391833|NCT03121534|DRUG|Dexamethasone|Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for \>4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
214688060|NCT01280123|DRUG|Pioglitazone|"Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated."
214391834|NCT03121534|DRUG|Ibrutinib|Ibrutinib treatment will commence on cycle 1, day 1 at 420mg/d. Dose reductions to 280mg/d or 140mg/d are allowed per treating physician discretion, but the reason must be documented in the medical record. Ibrutinib will be given continuously until disease progression or toxicity.
214391835|NCT03121534|DRUG|Nivolumab|Patients will receive nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.
214391836|NCT02374593|DRUG|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
214391837|NCT02374593|DEVICE|Ultrasound|
214391838|NCT04267614|DRUG|Etanercept|Patients who received etanercept for RA
214391839|NCT02526056|OTHER|Physiotherapists|This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.
214688061|NCT01280123|DRUG|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
214999498|NCT07106593|BEHAVIORAL|Cognitive Processing Therapy|CPT (Resick, Monson, \& Chard, 2024) consists of 12 50-minute sessions conducted over a 6- to 12-week period (Resick, Monson, \& Chard, 2008). The three phases of CPT include psychoeducation, processing, and challenging beliefs and assumptions related to the trauma, oneself, and the world.
214999499|NCT07106593|BEHAVIORAL|CBT-t|The standard CBT-t protocol is gathered from the Progressive Tinnitus Management (PTM) program, and includes psychoeducation about how tinnitus can develop. CBT-t includes using behavioral principles to help manage tinnitus reactions, including the use of sounds: soothing sounds, background sound, and interesting sound. CBT-t teaches relaxation exercises, scheduling pleasant activities, and learn how to modify thoughts related to tinnitus. Therapists will also provide basic education on how to protect hearing health among participants in order to prevent worsening of tinnitus and to prevent exacerbation of any hearing loss.
214999500|NCT07103746|DRUG|Ublituximab|Initial dose includes 150 mg dose followed by 450 mg two weeks later; maintenance dose is 450 mg
214999501|NCT07103746|DRUG|Placebo for Ublituximab|0.9% sodium chloride injection
215094174|NCT03316950|DEVICE|Placebo (DIVA/IntraGen combined)|"(DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner."
215094175|NCT05693454|DRUG|Infiltration with NaCl|Local wound infiltration at the end of spine surgery with NaCl
215094176|NCT05693454|DRUG|Infiltration with Ropivacain|Local wound infiltration at the end of spine surgery with Ropivacain
214391840|NCT02526056|OTHER|elderly people|In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
214391841|NCT03097003|DRUG|Apremilast|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
214391842|NCT04622137|PROCEDURE|Kinesiotaping therapy|The investigators used kinesiotaping strips in formations such as the Y, I, X, fan, web, and donut formations ove fractured clavicula.
214391843|NCT01197989|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
214391844|NCT01197989|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
214391845|NCT03118544|DEVICE|DyeVert System|The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
214391846|NCT02554630|OTHER|Adjuvant|Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.
214391847|NCT02554630|OTHER|Blood Collection|Blood collection will be performed on all groups.
214391848|NCT03514407|DRUG|INCB059872|Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
214391849|NCT00210119|DRUG|Glivec|
214391850|NCT02507882|BIOLOGICAL|IL28B Polymorphism|SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
214391851|NCT02507882|BIOLOGICAL|miRNA quantification|"RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen)."
214391852|NCT03458559|DRUG|Radium-223 chloride|Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
214391853|NCT03458559|DRUG|Rhenium-188-HEDP|Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
214391854|NCT04610762|DIAGNOSTIC_TEST|GeneXpert HCV VL Fingerstick test|The participants will have a molecular test (GeneXpert HCV VL Fingerstick, Cepheid) that quantifies hepatitis C virus (HCV) RNA levels directly from a fingerstick blood sample.
214391855|NCT02603315|OTHER|marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment
214999502|NCT07104955|OTHER|MDT referral and review software|Use of the multi-disciplinary team (MDT) meeting software to submit, review and discuss referrals
214999503|NCT07105072|PROCEDURE|Vitrectomy|vtrectomy is a surgical procedure to remove vitreous humor and can be used in case of viritis and as a debulking procedure for ciliary body granuloma.
214999504|NCT06914726|OTHER|Patient Centered Clinical Decision Support (PC-CDS)|The intervention provides patient specific recommendations on managing cancer risk due to hereditary cancer gene variants that is integrated into an existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and all subsequent primary care encounters using the most up to date available clinical information.
214999505|NCT07105969|OTHER|Strontium Incorporated Hydroxyapatite [Sr-HA] coated mini-screws purchased from Dentarum company|Maxillary canine retraction by mini-screw loaded with 150g Niti coil spring
214999506|NCT07111390|DEVICE|60Hz Intermittent Light Therapy|Intermittent 60 Hz flickering white light delivered via a wearable headset.
214999507|NCT07111390|DEVICE|Sham Light Therapy|Constant white light delivered via a wearable headset.
215094177|NCT05693454|DRUG|Infiltration with a combination of Levobupivacaine and Tramadol|Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
215094178|NCT06130982|BEHAVIORAL|Health Qigong·Yijinjing|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Yijinjing:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
214391856|NCT00865891|DRUG|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
214391857|NCT00865891|DRUG|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
214391858|NCT01330693|DRUG|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
214391859|NCT01330693|DRUG|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
214391860|NCT03971812|BIOLOGICAL|Blood sample|A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
214391861|NCT01161004|DRUG|Sugammadex - Nacl 9/00|"* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~* Nacl 9/00: same volume as Sugammadex"
214391862|NCT01161004|DRUG|Nacl 9/00 - sugammadex|"* Nacl 9/00: same volume as Sugammadex~* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses."
214391863|NCT03684720|OTHER|Discover followed by direct instruction [DD]|The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.
214391864|NCT01018641|BIOLOGICAL|SA3Ag vaccine|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1."
214391865|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
214391866|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
214391867|NCT01018641|BIOLOGICAL|SA3Ag followed by Placebo|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo."
214688062|NCT05791799|DRUG|Etonogestrel|Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year
214999508|NCT07116161|OTHER|Exercise Therapy Arm (ET)|Consists of a self-supervised individualized exercise prescription by the rehabilitation professional consisting of aerobic (e.g. brisk walking / cycling) and resistance training exercises, customized by patient preference.
214999509|NCT07116161|OTHER|Experimental: Exercise Therapy (ET) plus Cognitive Behavioural Therapy (CBT)|Consists of four major components adapted from previous studies,13,15,16 and delivered by qualified and trained study psychologists. First, the ABC model of cognitive behavioural therapy (A: activating events, B: beliefs, C: consequences) will be taught and applied to identify negative, unhelpful beliefs and the emotional, behavioural and physical consequences of those beliefs. Second, patients were taught behavioural strategies to manage fatigue (e.g. sleep hygiene, activity scheduling). Lastly, participants will be guided to reformulate dysfunctional cognitions regarding fatigue, improve coping strategies in relation to significant others (e.g. family, friends) and set goals.
214999510|NCT07115693|BEHAVIORAL|Telerehabilitation-Based Resistance Exercise Program|Participants received synchronous telerehabilitation sessions three times per week for six weeks. Each session lasted 45 minutes and included supervised resistance exercises for upper extremity muscle groups. Exercise bands were chosen based on baseline strength. Pulse oximeters were used to monitor heart rate and oxygen saturation.
214391868|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
214688063|NCT05379361|BEHAVIORAL|Emotional Intelligence Development Program|It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.
214688064|NCT05379361|BEHAVIORAL|Plasebo Training Group|It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
214391869|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
214391870|NCT01018641|BIOLOGICAL|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
214391871|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
214391872|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
214391873|NCT01018641|BIOLOGICAL|SA3Ag with no booster in stage 2|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive no vaccine."
214391874|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
214391875|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
214391876|NCT01018641|PROCEDURE|Placebo with no booster in stage 2|"In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.~In stage 2 the subject will receive no vaccine."
214391877|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
214391878|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
214391879|NCT05404867|OTHER|fMRI|fMRI scan for 1 hour
214391880|NCT03847623|DIETARY_SUPPLEMENT|Curcumin|Natural compound, active ingredient of turmeric, in bi-daily dosing
214391881|NCT03847623|OTHER|Placebo|Placebo tablets at bi-daily dosing
214391882|NCT00003329|GENETIC|gene mapping|
214391883|NCT04827134|DRUG|TRIUMEQ|TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
214391884|NCT04827134|DRUG|DOVATO|DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
214391885|NCT02861898|DRUG|Intra-arterial Cetuximab|
214391886|NCT02861898|DRUG|Intra-arterial Mannitol|
214391887|NCT01830881|DRUG|Midazolam|5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
214391888|NCT01830881|DRUG|Ibuprofen|800 mg oral ibuprofen 30-60 minutes prior to procedure
214391889|NCT01830881|OTHER|Placebo-Cherry syrup|5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
214391890|NCT01830881|DRUG|Lidocaine|injection of 20 mL 1% lidocaine without epinephrine
214391891|NCT01231243|PROCEDURE|in-office bleaching with/without light|Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
214391892|NCT01475916|BEHAVIORAL|Educational program: consultation with paediatric pulmonologist|Longitudinal prospective study
214391893|NCT00988351|DEVICE|Continuous positive airway pressure|continuous positive airway pressure determined by polysomnography titration
214391894|NCT00988351|DEVICE|Auto-adjusting positive airway pressure treatment|Pressure range 4-18 centimeters of water (cm H2O)
214391895|NCT04874324|DRUG|WCK 2349 Oral|1 dose given orally twice daily at 12 hourly interval for five days.
214391896|NCT04874324|OTHER|Placebo Oral|Subjects will receive matching placebo
214391897|NCT02038764|DRUG|Placebo|Placebo
214391898|NCT02038764|BIOLOGICAL|PF-06342674 Dose A|Multiple SC Doses
214391899|NCT02038764|BIOLOGICAL|PF-06342674 Dose B|Multiple SC Doses
214391900|NCT02038764|BIOLOGICAL|PF-06342674 Dose C|Multiple SC Doses
214391901|NCT02038764|BIOLOGICAL|PF-06342674 Dose D|Multiple SC Doses
214391902|NCT05046977|PROCEDURE|Single osteotomy|Single tibial osteotomy
214391903|NCT05046977|PROCEDURE|Double Osteotomy|Double Tibial Osteotomy
214391904|NCT04845295|OTHER|resistance training|Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.
214391905|NCT01306175|DRUG|Digoxin plus BI 10773|Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
214391906|NCT01306175|DRUG|Digoxin|Digoxin 0.5 mg as single dose
214391907|NCT02136498|DRUG|Varenicline|Standard 12 week course of varenicline, provided in both arms
214391908|NCT02136498|BEHAVIORAL|Cognitive-behavioral self-help|Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
214391909|NCT02136498|BEHAVIORAL|MyMAP (My Mobile Advice Program)|Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
214391910|NCT04844918|DRUG|Tirzepatide|Administered SC
214391911|NCT04844918|OTHER|Placebo|Administered SC
214391912|NCT03477786|COMBINATION_PRODUCT|drug adjustment and behavioral modification|anti-hypertension drug prescription by physician and case management by health educator
214999511|NCT07115693|BEHAVIORAL|Home Exercise Program|Participants were given a home-based, unsupervised exercise program to follow three times per week for six weeks. The exercises were taught at the beginning, and adherence was monitored using a physical activity diary. No tele-supervision was provided.
214999512|NCT07114861|DRUG|Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX|KN510 120mg/day + KN713 90mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks
214999513|NCT07114861|DRUG|Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX|KN510 120mg/day + KN713 120mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks
214999514|NCT07114328|OTHER|hand massage|The hand massage was applied to both hands for 5-6 minutes, for a total of 10-12 minutes
214999515|NCT07115082|DRUG|Climen 21 Tablets|Climen is commonly used clinically as a hormone replacement therapy and was administered to all patients in both the control and experimental groups in this project.
214999516|NCT07115082|BIOLOGICAL|hA-MSCs|The patients who were part of the experimental group were administered oral Clomid medication in conjunction with a combined intravenous injection of human amniotic MSCs.
214999517|NCT07115797|OTHER|arthrocentesis - PRP injection -ARS|oarthrocentesis then PRP injection and then ARS
214999518|NCT07115797|OTHER|ARS|Insertion Of ARS Only
214999519|NCT07115004|DRUG|VGA039|VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.
214999520|NCT06912633|BIOLOGICAL|human retinal progenitor cells|Single intravitreal injection of 8.8 million retinal progenitor cells (RPCs)
214999521|NCT06912633|OTHER|Mock injection|Pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection. Subjects randomized to the sham control group will undergo identical preparation as the active treatment group immediately prior to treatment, including application of anesthetics.
214999522|NCT06923605|DRUG|Epoetin 4000|Erythropoietin hormone
214999523|NCT06923605|OTHER|Placebo|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl) 4 times daily
214999524|NCT07115992|PROCEDURE|RARP±SRT|Participants will undergo robot-assisted radical prostatectomy (RARP). Upon biochemical recurrence, they will receive salvage radiotherapy: 52.5-62.5 Gy in 20-25 fractions/2.5-3.0 Gy per fraction, per 2025 AUA/ASTRO/SUO guidelines.
214999525|NCT07115992|PROCEDURE|RARP+ePLND|Participants will undergo robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (ePLND), encompassing bilateral removal of obturator, external iliac, internal iliac, and common iliac lymph nodes. The dissection field extends laterally to the genitofemoral nerve, medially to the bladder wall, proximally to the ureter crossing the common iliac vessels, and distally to the deep circumflex iliac vein and femoral canal.
214999526|NCT07116187|OTHER|Train-Your-Brain (TYB) Stroke Recovery Programme|The intervention involves a structured brain health programme delivered by clinical neuropsychologists in three phases: an initial needs assessment, a multi-session intervention, and follow-up support. Participants will receive assessments, attend group sessions covering topics such as lifestyle, mood, cognition, and return-to-work strategies, and be supported with workbooks and referrals to community services. The programme combines in-person and online formats.
214999527|NCT06923293|DEVICE|Utilization of motorized orthosis|While part of this study, participants will be fitted for the motorized orthosis and will complete walking tests with and without the AFO.
214999528|NCT07130591|OTHER|Cogniplat game platform|The Cogniplat gaming platform is designed to improve cognitive function in geriatric individuals, with or without mild cognitive impairment. Participants played the Cogniplat games face-to-face with a physiotherapist twice a week on non-consecutive days for 10 weeks, sessions lasting about 30-45 minutes. Scores from the platform were recorded to evaluate progress.
214999529|NCT07130591|OTHER|Control group|Individuals in this group did not participate in any regular play program. Demographic data were recorded. For evaluation purposes, a single session of Cogniplat game platform was applied in the first interview and in the second interview 10 weeks later. Initial and final evaluations were recorded.
214999530|NCT07138768|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be performed to all patients
214999531|NCT07141030|DRUG|GZR18 injection|GZR18 injection:3mg
215094179|NCT06130982|BEHAVIORAL|Health Qigong·Wuqinxi|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Wuqinxi:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
214688065|NCT03288779|DEVICE|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
214999532|NCT07141212|DEVICE|Virtual reality glass|"Virtual reality (VR), with its immersion and interactivity, offers the possibility to amplify the effectiveness of breathing techniques in promoting mental health by creation of relaxing scenarios and has been successfully employed in promoting relaxation and stress reduction. Virtual reality can turn breathing exercises into an interactive experience that feels more like a fun activity than a tedious task. It consists of VR headset, two touch controllers, glasses spacer with adjustable straps for good vision as follows:~1. Colour Breathing VR program (Box Breathing) :~   Patient sit in comfortable position with relaxed both shoulders. Breath in for 4 second, Hold breath for 4 sec, Breath out for 4 sec, Hold for 4 sec, Inhalations and exhalations move a 3D cloud shaped object closer and farther away from the user.~2. LAMINAL VR (Calm): Inhalations and exhalations grow and shrink a 2D circle with bubbles in between, changing in color."
214391913|NCT01990820|DEVICE|Acclarent Relieva Balloon Sinuplasty|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner."
214391914|NCT01990820|PROCEDURE|Adenoidectomy + Maxillary Sinus Irrigation|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.~After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home."
214999533|NCT07141212|PROCEDURE|Buteyko Breathing|"1. The ''Control pause (CP)'' breathing test: Hold his nose on the out breath, with empty lungs but not too empty and count how many seconds that he can comfortably last before the need to breathe in again.~2. Shallow breathing Sit up straight: breathe air slightly into the tip of the nostrils. Concentrate on calming his breath to reduce the amount of warm air he feel on his finger, try to maintain the need for air for about 4 min.~3. Putting it together Take Control pause:~Reduced breathing for 4 min. Wait 2 min and take Control pause. Reduced breathing for 4 min. Wait 2 min and take Control pause."
214391915|NCT00183456|BEHAVIORAL|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
214391916|NCT00183456|BEHAVIORAL|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
214391917|NCT01971190|DRUG|Intravitreal Aflibercept injection|"2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
214391918|NCT01971190|DRUG|Sham injection|"Sham injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
214391919|NCT01971190|PROCEDURE|Half-fluence photodynamic therapy|"At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
214391920|NCT04516421|DIETARY_SUPPLEMENT|Protein supplementation|The experimental group contained 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
214391921|NCT04516421|DIETARY_SUPPLEMENT|Placebo oat drink|placebo oat drink contained 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
214391922|NCT00004221|DRUG|Carboplatin|Given IV
214391923|NCT00004221|DRUG|Cyclophosphamide|Given IV
214391924|NCT00004221|BIOLOGICAL|Filgrastim|Given SQ
214391925|NCT00004221|DRUG|Paclitaxel|Given IV
214391926|NCT00004221|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplantation
214391927|NCT00004221|DRUG|Topotecan Hydrochloride|Given IV
214391928|NCT00575068|DRUG|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A \& II-B - Dosage start at the MTD (up to 375 mg/m2)
214391929|NCT03853122|OTHER|Best current practice exercise programme|"Therapeutic Physical Exercise programme based on the protocol of Afredson (for Achilles and patellar tendinopathies) and LEAP (for gluteal tendinopathy).~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetitions of two eccentric exercises~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetions of one eccentric exercise~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL: an exercise programme divided into stages with progression in different exercises, volumes and loads"
214391930|NCT03853122|OTHER|Experimental exercise programme|Therapeutic Physical Exercise programme structured in five stages oriented to specific neuromuscular adaptations based on the characteristics of the neuromuscular system, once daily, three times/week, sets, repetitions and load based on individually performed tests.
214391931|NCT06117748|OTHER|Pressure controlled ventilation-volume guaranteed|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
214502078|NCT04309552|DRUG|18F-FLT PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
214502079|NCT06315985|OTHER|Experimental group: Listenning to the Turkish Classical Music to pregnant women diagnosed with preeclampsia|The music to be used in the research will be applied together with midwifery practices and is not a treatment option, tool or treatment option for any disease. Although listening to Classical Turkish music has no effect on treatment and care, it does not have a harmful effect on pregnant women. The participant can withdraw from the study at any time without giving any reason. The Personal Information Form, Perceived Stress Scale, and Pittsburgh Sleep Quality Index (PSQI) will be administered to the pregnant women in both groups participating in the study by face-to-face interviews with the individuals on the first day of their admission to the clinic. At the end of the third day, the Perceived Stress Scale and Pittsburgh Sleep Quality Index (PSQI) scales will be re-administered to both groups.
214502080|NCT04033315|DEVICE|L-PLUS meter|Blood Glucose Monitoring System
214502081|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^4 pfu delivered intramuscularly
214502082|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^5 pfu delivered intramuscularly
214502083|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^6 pfu delivered intramuscularly
214999534|NCT07141095|DRUG|maribavir|Maribavir tablets are administered orally at a dose of 0.4 g per administration (2 tablets of 0.2 g each), twice daily. The recommended duration of treatment is 8 weeks; however, the specific treatment duration should be individualized based on the clinical characteristics of each patient.
214999535|NCT07142629|PROCEDURE|Selective caries removal|Selective carious removal to firm dentine. Subsequently, 2 mm of Biodentine will be placed as a liner over the pulpal wall leaving the peripheries of the cavity available for bonding of the subsequent restoration.
214999536|NCT07142629|PROCEDURE|Non-Selective caries removal|Complete caries excavation will be done to hard scratchy dentine, with the aid of caries detector dye.If no pulp exposure is evident 2 mm of Biodentine will be placed and the cavity will be restored. If pulp exposure occurred, and it is bleeding normally and uniformly red with no zones of degeneration or necrosis then direct pulp capping will be attempted with Biodentine as a capping material. If no hemostasis is achieved, then the procedure will be modified to either partial pulpotomy, full pulpotomy or RCT depending on the clinical assessment.
214999537|NCT07141407|OTHER|Supportive Care|Attend TAC telephone-based coaching sessions
214999538|NCT07141407|BEHAVIORAL|Telephone-Based Intervention|Attend TAC telephone-based coaching sessions
214999539|NCT07141407|OTHER|Survey Administration|Ancillary studies
215094180|NCT06130982|BEHAVIORAL|Health Qigong·Baduanjin|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Baduanjin:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
214502084|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^7 pfu delivered intramuscularly
214502085|NCT04794218|OTHER|Placebo/Diluent|N/A delivered intramuscularly
214502086|NCT03552276|DRUG|SUNPG18_07 I (Tildrakizumab 200 mg)|injection
214502087|NCT03552276|DRUG|SUNPG18_07 II (Tildrakizumab 100 mg)|injection
214502088|NCT00984048|OTHER|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
214688066|NCT04120792|BEHAVIORAL|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
214999540|NCT07141407|OTHER|Educational Intervention|Receive an ACP brochure/handout
214391932|NCT06117748|OTHER|Volume controlled ventilation|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
214391933|NCT01693003|DRUG|Indacaterol|150 µg d.o. during the first 3 weeks
214391934|NCT01693003|DRUG|Tiotropium|150 µg d.o. during 3 weeks
214391935|NCT05858489|OTHER|Mini-Mental State Examination (MMSE)|Each patient will be evaluated by MMSE then by the adapted version of MMSE
214391936|NCT01908673|BEHAVIORAL|HRV biofeedback|
214391937|NCT01908673|BEHAVIORAL|ASTM|
214391938|NCT02731313|BIOLOGICAL|Trastuzumab|Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
214391939|NCT05752422|DEVICE|Niraxx G1 Headband Device including sham|Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
214391940|NCT03410238|BEHAVIORAL|Saferteens Brief Intervention|A 30 minute private one-on-one brief motivational interviewing intervention administered by clinic staff. The goal of the intervention is to reduce and prevent youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on-one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior. In the 2 months following the intervention, participants will receive booster text messages tailored to their responses during the intervention.
214391941|NCT04357002|DRUG|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
214391942|NCT04357002|DRUG|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
214999541|NCT07142122|PROCEDURE|Total laparoscopic proximal gastrectomy with preservation of both the hepatic and celiac branches of the vagus nerve, followed by double-tract reconstruction.|Total laparoscopic proximal gastrectomy with meticulous preservation of the hepatic branch of the vagus nerve (via fenestration of the lesser omentum) and the celiac branch (via skeletonization of the left gastric artery). The esophagus was transected ≥3 cm proximal to the tumor, preserving \>50% of the residual stomach. Double-tract reconstruction was then performed: an end-to-side esophagojejunostomy was created first, followed by a side-to-side gastrojejunostomy between the residual stomach and jejunum, and finally a side-to-side jejunojejunostomy approximately 40 cm distal to the gastrojejunal anastomosis. This approach achieves oncological resection while maximizing preservation of digestive physiology (gallbladder contraction, reduced dumping syndrome, and partial gastric reservoir function).
214999542|NCT07142122|PROCEDURE|Total laparoscopic proximal gastrectomy with preservation of the hepatic branch of the vagus nerve but deliberate resection of the celiac branch, followed by double-tract reconstruction.|Total laparoscopic proximal gastrectomy with meticulous preservation of the hepatic branch of the vagus nerve (via lesser omentum fenestration adjacent to the liver edge), while deliberately not preserving the celiac branch (by direct transection at the root of the left gastric artery). The esophagus was transected ≥3 cm proximal to the tumor with preservation of \>50% gastric remnant. Double-tract reconstruction was then executed: end-to-side esophagojejunostomy (circular stapler) → side-to-side gastrojejunostomy (linear cutter) → side-to-side jejunojejunostomy approximately 40 cm distal to the gastrojejunal anastomosis. This technique achieves oncological resection while utilizing the residual stomach and dual-pathway design to minimize postoperative dumping syndrome and preserve partial gastric function.
214999543|NCT07141706|DRUG|DB-1317|Administered I.V.
214391943|NCT04357002|DRUG|vaginal placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
214391944|NCT06489054|OTHER|Peer education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the experimental group (peer-based education). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
214391945|NCT06489054|OTHER|Conventional education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the control group (dentist lecture). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
214391946|NCT02861677|OTHER|pharmaceutical care|
214391947|NCT01429519|DRUG|RPh201, botanical drug product|topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
214391948|NCT00651443|DRUG|Galiximab|Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
214391949|NCT03806946|DIAGNOSTIC_TEST|electroencephalography|diagnosis epileptic discharge
214391950|NCT03806946|DIAGNOSTIC_TEST|psychometric scales to diagnosis psychiatric disorders|to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.
214391951|NCT03806946|OTHER|psychometric scales for assesment socioeconomic and behaviour problems|to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden
214391952|NCT04596787|PROCEDURE|Bilateral Thoracic paravertebral block|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
214391953|NCT03905590|PROCEDURE|Periapical surgery with amniotic membrane|periapical surgery will be done followed by amniotic membrane placement over the defect
214391954|NCT03905590|PROCEDURE|periapical surgery without amniotic membrane|periapical surgery will be done without placement of membrane over the defect.
214999544|NCT07142616|OTHER|03 - Summaries of and clinical notes from several providers|Access to all clinical notes across three providers: General practitioner, Social services and Specialist care, like in arm 02. In addition, access to information management features, such as summaries of patient's priorities, and clinical summaries of key health problems, including links to source documents.
214999545|NCT07142616|OTHER|01 - Clinical notes from one provider|Access to all clinical notes available to the provider in the patient's case. The provider is General practice in two patient cases, and hospital in one patient case.
214999546|NCT07142616|OTHER|02 - Access to notes from primary and secondary care|Access to all clinical notes across three providers: General practitioner, Social services and Specialist care.
214999547|NCT07141264|DRUG|Adebrelimab combined with Etoposide Capsules|Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Adebrelimab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Etoposide Capsules is given orally at a dosage of 50mg or 25mg daily, every 3 weeks. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
214999548|NCT07141797|OTHER|Executive functions assessment|"Inhibition: Emotional (hot) and logical (cold) inhibition using Emotional and Classic Stroop tests. Participants identify the color of words or emotion in photos while inhibiting automatic responses. Inhibition scores are based on the difference in response times between congruent and interference conditions.~Working Memory: Participants recall a sequence of points on a grid, first in the original order, then in reverse. The working memory score is the difference between the two tasks.~Cognitive Flexibility: A task requiring alternation between identifying numbers as greater/less than 5 or even/odd based on color cues. Flexibility is scored by comparing response times for alternating and non-alternating tasks.~Visuospatial abilities are assessed with a global-local task. Raven's Progressive Matrices will assess general intelligence, and socio-economic data will be collected."
214999549|NCT07142499|BEHAVIORAL|Memory Support System|Participants and study partners in the MSS treatment group will work with a study trainer to learn the MSS and eventually adapt the skills to support functioning in their daily life. The MSS trainer will follow a 10-session MSS Training Workbook as the standardized protocol for training. Additional sessions beyond the standard 10 sessions can be added if needed to support mastery of the MSS (up to a maximum of 15 total sessions). Participants and study partners will also receive a copy of the brain health education workbook that contains the same educational information for the control group at the 8-week follow up.
215094181|NCT06130982|BEHAVIORAL|Walking|1-8weeks:While the experimental group received intervention, the control group underwent walking exercise. The intervention frequency is the same as the experimental group: 1 time/day, 5times/week,30 minutes/time, the total duration controlled within 50 minutes, and includes 3 contents.Warm up activity:head movements,neck movements,shoulder movements, chest expansion exercise,waist rotation,body rotation, lunge movements,leg movements,knee joint movements,ankle movements(15 min).Walk around the track and field (30 min).Cool down (5min) 8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
215094182|NCT02133365|BEHAVIORAL|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
215094183|NCT05614921|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side
214391955|NCT05261503|OTHER|HEP|The Homeostasis-Enrichment-Plasticity (HEP) intervention group will receive 45 minutes of face-to-face environmental enrichment-based intervention one day per week and online home support once a week for 12 weeks.
214391956|NCT05261503|OTHER|Traditional Phsical Therapy|The Traditional Physical Therapy group will receive a 45-minute intervention, two days a week for 12 weeks.
214391957|NCT02649322|DEVICE|J-Tip|"After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic pop and hissing sounds inherent to the J-tip injector."
214391958|NCT02649322|DEVICE|Syringe and 25 gauge needle|The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
214391959|NCT01618396|DRUG|Sedation drug (Propofol and Midazolam)|Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
214391960|NCT00245336|BIOLOGICAL|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
214391961|NCT00245336|DRUG|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
214391962|NCT03380884|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
214391963|NCT02708238|DIETARY_SUPPLEMENT|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
214391964|NCT02708238|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 (108 CFU)|
214391965|NCT02708238|DRUG|Simethicone|
214391966|NCT05134389|PROCEDURE|One Anastomosis Gastric Bypass|Exposure to One Anastomosis Gastric Bypass
214502089|NCT01401218|OTHER|Electronic Medical Record (EMR) Review|"measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.~potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,"
214502090|NCT00176202|DRUG|Divalproex Sodium|Divalproex sodium is a mood stabilizer
214502091|NCT00176202|DRUG|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
214502092|NCT00378300|DRUG|Oral Probiotics|
214502093|NCT02873559|DRUG|testosterone|Testosterone supplemented in 5 months
214502094|NCT02873559|OTHER|Progressive muscle training|Progressive muscle training during 4 months
214502095|NCT05657210|GENETIC|Mutation|
214502096|NCT04623554|BEHAVIORAL|Prehabilitation program|The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
214502097|NCT04989296|DIAGNOSTIC_TEST|Peripheral blood samples were obtained following the standard procedures.|Taking 4 ml of peripheral blood from patients on an empty stomach.
214502098|NCT05957510|DRUG|Serplulimab|serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.
214502099|NCT05957510|DRUG|SOC|the treatment recommended by the investigator
214502100|NCT04514718|DEVICE|Holmium laser|low energy holmium laser
214502101|NCT01160354|DRUG|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
214502102|NCT01160354|DRUG|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
214502103|NCT04876495|DIETARY_SUPPLEMENT|Whey protein isolate|"Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the whey protein shake:~* Tropicana Trop50 Orange Juice 207mL~* Water 43 mL~* Sucralose 0.5g~The total energy 233.47Kcal.~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
214502104|NCT04876495|DIETARY_SUPPLEMENT|Potato protein isolate|"Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.~Other ingredients in the potato protein shake:~* Tropicana Trop50 Orange Juice 250mL~* Sucralose 0.5g~The total energy 233.46Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
214502105|NCT04876495|DIETARY_SUPPLEMENT|Rice protein isolate|"Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the rice protein shake:~* Tropicana Trop50 Orange Juice 183mL~* Water 67mL~* Sucralose 0.5g~The total energy 233.43Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
214502106|NCT05483088|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected for analysis with the NEPHROCLEAR CCL14 Test
214502107|NCT03440086|DEVICE|abdominal Jackson-Pratt drain|One-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
214502108|NCT05999682|OTHER|apigenin|Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
215094184|NCT05614921|OTHER|Wound infiltration|5 ml local anesthetic for each trocar side
214391967|NCT00676975|DRUG|Traditional Chinese Medicine|"A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale"
214391968|NCT00676975|DRUG|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
214502109|NCT05999682|OTHER|sterilized water|Intragastric tube injection of 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
214502110|NCT01918176|DRUG|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
214502111|NCT01918176|DRUG|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
214502112|NCT03636854|OTHER|Concentric exercises|Resistance concentric straight leg raise and knee extension will be done.
214502113|NCT03636854|OTHER|Eccentric exercises|Resistance eccentric straight leg raise and knee extension will be done.
214502114|NCT05035329|OTHER|Outcome measurements|Outcome measurements were applied.
214502115|NCT01025128|DRUG|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
215094185|NCT02882100|BIOLOGICAL|adjuvanted trivalent influenza vaccine|Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
215094186|NCT02882100|BIOLOGICAL|trivalent influenza vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
215094187|NCT02133976|BEHAVIORAL|cognitive therapy|
214999550|NCT07142499|BEHAVIORAL|Brain Health Education|Participants and study partners in the control group will be provided with the MSS guidebook and day planner for self-study of the MSS system. They will also meet with a study trainer to complete 10 sessions of a brain health education course that is tailored for individuals with MCI. The trainer will use a HABIT-based brain health education workbook to provide the content. Additional sessions beyond the standard 10 sessions can be added up to a maximum of 15 total sessions. Participants and study partners will receive a copy of the brain health education workbook at the 8-week follow up.
214999551|NCT07141979|DEVICE|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in left DLPFC
214999552|NCT07141979|DEVICE|Sham tDCS|20 min, left DLPFC Sham tDCS
214999553|NCT07141329|DRUG|SPN-817|SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
214999554|NCT07140978|DIETARY_SUPPLEMENT|Green Chef Meal Delivery Program|Participants will receive Green Chef meals for lunch and dinner, delivered weekly for 16 weeks. Meals include organic produce, responsibly sourced protein, and nutritionist-approved recipes. Participants will also receive guidelines for preparing healthy breakfasts and will use smart devices to record biomarker data.
215094188|NCT02133976|BEHAVIORAL|mindfulness training|
214391969|NCT01898520|DRUG|Sativex|Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
214391970|NCT01898520|DRUG|Placebo|Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
214391971|NCT04731103|DRUG|Abacavir (ABC)|Tablets or oral solution
214391972|NCT04731103|DRUG|Lamivudine (3TC)|Tablet or oral solution
214391973|NCT04731103|DRUG|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Tablet or oral solution
214502116|NCT03849066|OTHER|Parent-Reported Symptom Assessment|As the basis for PRSA, the investigator will use the PediQuest Memorial Symptom Assessment Scale (PQ-MSAS), which is an adapted pediatric-specific version of the validated adult MSAS that assesses 28 physical and psychological symptoms over the past week. The study instrument is designed to be completed by a full-proxy parent, and 2 versions tailored for specific age groups are available (0-3, 3-18 years-old). Spanish versions are available for both instruments. The PQ-MSAS contains 28 symptom items, each with 4-point scores for domains of frequency, severity, and extent of bother. Based on these components, a global symptom score and individual symptom scores can be calculated (0-100 scale, with 100 being the worst).
214502117|NCT04439500|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
214502118|NCT04439500|BEHAVIORAL|Brain Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
214999555|NCT07141927|OTHER|Measurements|First, the demographic characteristics of all participants were recorded. For those who met the inclusion criteria, primary and secondary outcome measurements were performed by the same physical therapist in a single session
214999556|NCT07141875|OTHER|No intervention|This is an observational study without any interventions.
215094189|NCT02133976|BEHAVIORAL|behavioral therapy|
215094190|NCT02133976|OTHER|treatment as usual|
215094191|NCT02087722|DRUG|KI1001|
215094192|NCT02087722|DRUG|Placebo|
215094193|NCT04545463|DIETARY_SUPPLEMENT|FIBRACEP|A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
215094194|NCT04545463|DIETARY_SUPPLEMENT|INSOLUBLE|A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
215094195|NCT04545463|DIETARY_SUPPLEMENT|SOLUBLE|A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
215094196|NCT02392403|DEVICE|Nucleus CI532 cochlear implant|
215094197|NCT05664802|BEHAVIORAL|e-HERO: Ending the HIV Epidemic in Rural Oklahoma|A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.
214391974|NCT04110366|BIOLOGICAL|Live attenuated influenza vaccine|Vaccination with live attenuated influenza vaccine (LAIV)
214391975|NCT04110366|OTHER|Vehicle control|Vehicle control nasal challenge
214391976|NCT05939817|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
214391977|NCT05939817|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
215094198|NCT02541786|DRUG|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
215094199|NCT02541786|DRUG|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
215094200|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
215094201|NCT00678834|DIETARY_SUPPLEMENT|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
214391978|NCT05939817|DRUG|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
214391979|NCT03675841|DRUG|Pazufloxacin Mesilate ear drops|Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
214391980|NCT01927731|DRUG|Eltrombopag Olamine|Given PO
214391981|NCT01927731|OTHER|Laboratory Biomarker Analysis|Correlative studies
214391982|NCT00275496|PROCEDURE|Sentinel Lymph Node Dissection|Subject has wide excision and sentinel lymph node dissection for primary melanoma.
214391983|NCT00275496|PROCEDURE|Complete Lymph Node Dissection|Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
214391984|NCT00275496|PROCEDURE|Wide Excision|Subject has wide excision only for primary melanoma.
214391985|NCT04723251|BEHAVIORAL|taking photographs|"Participants will photograph images (using a cell phone) that invoke a feeling of gratitude. At least 1 photograph (at any time of the day) should be taken for a period of three weeks.~Once the photo images are captured, the participant should spend a moment looking at the image and reflecting on why they are grateful for the subject of the photograph."
214391986|NCT01388530|DEVICE|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
214391987|NCT01812005|DRUG|alisertib|Given PO
214391988|NCT01812005|BIOLOGICAL|rituximab|Given IV
214391989|NCT01812005|OTHER|laboratory biomarker analysis|Laboratory correlative studies will be performed
214391990|NCT00432510|DRUG|C1 esterase inhibitor [human] (C1INH-nf)|
214391991|NCT00976079|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
214391992|NCT00976079|DEVICE|Placebo TENS|Placebo TENS use
214391993|NCT02761889|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Previously untreated patients with prostate cancer will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
214391994|NCT02761889|PROCEDURE|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
214391995|NCT02761889|DEVICE|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
214391996|NCT02761889|DEVICE|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
214391997|NCT00114153|DRUG|capecitabine|
214391998|NCT00114153|DRUG|carboplatin|
214391999|NCT00114153|PROCEDURE|conventional surgery|
214392000|NCT00114153|RADIATION|radiation therapy|
214392001|NCT02743793|PROCEDURE|Blood Draw|
214392002|NCT03627611|DRUG|Levothyroxin|3 months
215094202|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
214392003|NCT03627611|DRUG|Liothyronine|3 months
214392004|NCT02065570|DRUG|Adalimumab|
214392005|NCT02065570|DRUG|Placebo|
214392006|NCT03543722|BEHAVIORAL|National Career Coach Program|Intensive employment services as described above.
214392007|NCT03543722|BEHAVIORAL|Local Community Resources Program|Usual employment services as described above.
214392008|NCT02697006|DEVICE|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
214392010|NCT04160611|DRUG|Midazolam 7.5mg|The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
214392011|NCT02059772|DRUG|ranibizumab|
214392012|NCT02059772|PROCEDURE|micropulse diode laser|
214392013|NCT06187571|OTHER|CT+MWM|The MWM technique was applied to the MWM group in addition to the CT. The MWM technique was applied in flexion, abduction, internal rotation, and external rotation directions. The MWM technique was performed with 3 sets of 10 repetitions.
214392014|NCT06187571|OTHER|CT|Cold packs, electrotherapy modalities, scapular mobilization, stretching, and strengthening exercises were applied to the CT group.
214392015|NCT01648179|DRUG|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
214392016|NCT01648179|DRUG|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
214392017|NCT01648179|DRUG|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
214392018|NCT01648179|DRUG|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
214392019|NCT02293837|DRUG|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
214392020|NCT02293837|DRUG|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
214392021|NCT02293837|OTHER|Standard of Care|Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])
214392022|NCT01880060|BEHAVIORAL|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; \>20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
214392023|NCT01880060|BEHAVIORAL|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
214392024|NCT05310032|DRUG|HSG4112|Once-daily oral adminstration
214392025|NCT05310032|DRUG|Placebo|Once-daily oral adminstration
214392026|NCT06160713|DRUG|Itraconazole 65 MG|Two capsules of suba-itraconazole 65 mg twice daily for 6 months
214999557|NCT07142187|OTHER|electro-thumbtack needle|The treatment acupoints include bilateral ovarian acupoints, Guan Yuan (CV4), bilateral Shen Shu (BL23), bilateral waist and eye acupoints (EX-B7), bilateral San Yin Jiao (SP6), and bilateral Zu San Li (ST36), totaling 11 acupoints. Among them, the bilateral ovarian acupoints and bilateral waist eye acupoints (EX-B7) were treated with electro-thumbtack needle. Other acupoints were treated with thumbtack needle.Choose a sparse and dense waveform, adjust the intensity to the maximum patient can tolerate, and stimulate for 30 minutes each time. After the stimulation is completed, remove the electrode patch and electroacupuncture device, and keep the electric needle at the acupoint for another 3 days.During the needle retention period, the electric needles at the bilateral ovarian acupoints and bilateral waist and eye acupoints were alternately stimulated once every other day using an electroacupuncture device for 30 minutes each time.
214392027|NCT06160713|OTHER|Standard care|Standard care for bronchiectasis
214392028|NCT04779242|DRUG|Omadacycline|IV for injection, oral tablets
214392029|NCT04779242|DRUG|Moxifloxacin|IV solution, oral tablets
214392030|NCT02480686|DRUG|SOF+PEG+RBV|Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
214392031|NCT01757067|DEVICE|PVC ablation|This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
214999558|NCT07142187|OTHER|placebo electro-thumbtack needle|The control group selected acupoints that were the same as the treatment group. Bilateral ovarian acupoints and bilateral waist and eye acupoints are treated with placebo electro-thumbtack needle, while other acupoints are treated with placebo electro-thumbtack needle. The treatment methods for placebo electro-thumbtack needle and placebo thumbtack needle are the same as those for the treatment group.
214999559|NCT07140926|DEVICE|Recovery Connect|"Recovery Connect is a white-labeled version of the Recovery Path platform, rebranded to maintain partner organizations' brand identity while leveraging its established digital infrastructure. Recovery Path is a HIPAA-compliant remote patient monitoring system that supports a blended model of care for medication for opioid use disorder (MOUD), integrating in-person treatment with continuous digital engagement.~The app provides patients with daily check-ins, access to evidence-based resources and coping strategies, and secure messaging with their care teams. Clinicians receive real-time data on patient progress, risks, and setbacks. Between visits, clinicians can recommend tailored coping tools and psychoeducational content, reinforcing accountability and enhancing continuity of care.~RC is also integrated into the clinic's electronic medical record system to streamline workflows, reduce administrative burden, and improve documentation accuracy through auto-generated case notes."
214392032|NCT01223222|DRUG|LTX-109|Topical administration. 3 times daily. 5 days.
214392033|NCT03053674|OTHER|Oral and written explanation|Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
214392034|NCT03053674|OTHER|Follow-up questionnaire|Follow-up questionnaire to determine whether participants have receive post-partum vaccination
214392035|NCT02438150|BEHAVIORAL|Hospital fire video training|Participants will watch a video about hospital fire training which last for 30 minutes
214392036|NCT02438150|BEHAVIORAL|Non hospital fire video training|Participants will watch a video about volcanic eruption which last for 30 minutes
214392037|NCT03285113|DEVICE|GiMer Medical MN 1000 External Stimulator|Trial stimulator to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
214392038|NCT02643979|DRUG|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
214392039|NCT02643979|DRUG|Propofol|100mg of Propofol
214392040|NCT02643979|DRUG|Saline|1mL of saline
214392041|NCT03518164|PROCEDURE|Allograft|Bone graft
214392042|NCT00849680|OTHER|Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine|Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
214392043|NCT00849680|BIOLOGICAL|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Monovalent MRKAd5 HIV-1 gag vaccine (1x10\^9 vp/dose)
214392044|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^6 vp/dose)
214392045|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^7 vp/dose)
214392046|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^8 vp/dose)
214392047|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^9 vp/dose)
214392048|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^10 vp/dose)
214392049|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10\^11 vp/dose)
214392050|NCT00849680|BIOLOGICAL|Comparator: Placebo to MRKAd5 HIV-1 gag vaccine|Placebo to the MRKAd5 HIV-1 gag vaccine.
214999560|NCT07141017|OTHER|Initial standardized global review|"The intervention under study will be the initial standardized global review, which will be performed as soon as axial spondyloarthritis is diagnosed (less than 12 months from diagnosis is mandatory) and only at the baseline visit.~This review includes both the assessment of different domains of the disease, but also the education and information on such different domains of the disease and its management~The domains assessed during the intervention will be: diagnosis of spondyloarthritis, spondyloarthritis phenotype, disease activity, disease severity and function, treatment adherence and comorbidities.~At the end of the intervention, a detailed medical report on this initial standardized global review will be produced and sent to the patient, their rheumatologist, their general practitioner, and their dispensing pharmacist."
214999561|NCT04527419|PROCEDURE|No mediastinal lymph node dissection|No mediastinal lymph node dissection will be performed.
215094203|NCT06464965|BIOLOGICAL|CB CAR-NK182|To study the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 in patients with advanced gastric cancer and advanced pancreatic cancer
214392051|NCT04103424|BEHAVIORAL|Short-term Exercise Training|Participants will perform 2-weeks of supervised exercise training on a stationary bike.
214392052|NCT03892369|OTHER|Ethanol|Ethanol administration
214392053|NCT00282230|DRUG|FK778|
214392054|NCT05233722|OTHER|Exercise|1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
214392055|NCT05233722|PROCEDURE|Insulin infusion|2 hours of Euglycemic Hyperinsulinemic Clamp
214392056|NCT05233722|DRUG|Placebo|Administration of 800 mg of calcium tablets
214392057|NCT05233722|DRUG|Rapamycin|Administration of 16 mg of Rapamycin tablets
214392058|NCT05500027|DIAGNOSTIC_TEST|serum test|serum test of sCD58 and TGFbeta1
214392059|NCT04017741|DRUG|Combined Depo-Medrone and Lidocaine|"Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm."
214392060|NCT04017741|DRUG|Sodium Chloride 0.9% Inj|Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
214392061|NCT04267575|DEVICE|Canady Helios Cold Plasma Scalpel|Device used to distribute cold plasma energy at the resected tumor margins.
214392062|NCT01049074|OTHER|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
214392063|NCT01049074|OTHER|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
214392064|NCT01387503|PROCEDURE|Liver transplantation|Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
214392065|NCT04262102|BEHAVIORAL|SD_SF|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
214392066|NCT04262102|BEHAVIORAL|SD_BLW|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
214392067|NCT04262102|BEHAVIORAL|HFV_SF|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
214999562|NCT06932315|DRUG|HRS-9190 for Injection|Subject will receive the HRS-9190 injection at different dose levels.
215094204|NCT01277315|DRUG|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
215094205|NCT03665116|DIETARY_SUPPLEMENT|L-arginine|L-arginine capsule
215094206|NCT04382417|OTHER|Observational study|Not required
215094207|NCT04890015|PROCEDURE|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
215094208|NCT06438796|DRUG|Blinatumomab|Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation
214392068|NCT04262102|BEHAVIORAL|HFV_BLW|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
214392069|NCT00115362|DRUG|venlafaxine|
214392070|NCT01254175|BIOLOGICAL|rHPIV3cp45 Vaccine|10\^5 TCID\^50 of rHPIV3cp45 vaccine, delivered as nose drops
214392071|NCT01254175|BIOLOGICAL|Placebo Vaccine|Placebo vaccine, delivered as nose drops
214392072|NCT05892835|OTHER|Educative|A 2-hour training workshop was held where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Manikin for CPR practices Little Anne QCPR). Laerdal and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
214392073|NCT03108963|DRUG|L-carnitine and Metformin|L-carnitine plus Metformin was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
214392074|NCT03108963|DRUG|placebo|placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
214392075|NCT01721395|DIETARY_SUPPLEMENT|Agave Syrup|
214688067|NCT04120792|BEHAVIORAL|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
215094209|NCT05044624|PROCEDURE|retroperitoneal mass excision|retroperitoneal mass excision
214392076|NCT01902589|OTHER|Helicobacter Pylori Culture|"Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.~The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.~4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere."
214392077|NCT01461993|BIOLOGICAL|rLP2086 and Gardasil|Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.
214392078|NCT01461993|BIOLOGICAL|rLP2086|Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.
214392079|NCT01461993|BIOLOGICAL|Gardasil|Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
214392080|NCT03309163|DRUG|Tramadol|Patient-controlled intravenous analgesia with Tramadol
214392081|NCT03309163|DRUG|Hydromorphone|Patient-controlled intravenous analgesia with Hydromorphone
214392082|NCT03309163|DRUG|Ropivacaine (Epidural analgesia)|Patient-controlled epidural analgesia with Ropivacaine.
214392083|NCT03395938|BEHAVIORAL|Proactive engagement|The engagements would include (1) a sealed envelope containing a cancer information sheet and an invitation letter directed towards siblings for them to contact the research team, (2) weekly phone reminders to the participants for a total of 4 weeks in a bid to remind participants of the need to convey the screening message to their siblings. The envelope will contain information on the various means for the siblings to contact the research team. These include communication means such as electronic mails (emails), telephone, hard copy returned mails through pre-paid envelopes, short messaging services (SMSs) or clinic consult.
214392084|NCT03395938|BEHAVIORAL|Current practice|This intervention depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation. The research team would highlight that we would be happy to assist if necessary. The research team would then contact the patients in 4 weeks to check if they have communicated with their siblings and if they have gone for screening. We would also find out which method did they adopt to communicate with their siblings.
214999563|NCT06943443|DEVICE|Miniscrew-Assisted Rapid Palatal Expansion (MARPE) Treatment|"Vitamin D Supplementation: Vitamin D plays a crucial role in calcium absorption, bone health, immune system function, and cellular growth. It is primarily obtained through sunlight exposure, certain foods, and supplements. In the context of your study, Vitamin D supplementation will be used to improve the Vitamin D levels in patients undergoing Miniscrew-Assisted Rapid Palatal Expansion (MARPE) treatment.~Key Points:~Purpose: To correct Vitamin D deficiency, which may affect bone metabolism and orthodontic treatment outcomes.~Administration: Vitamin D supplementation is typically provided in the form of oral tablets or soft gels, with a usual dosage of 800-2000 IU per day, depending on the individual's baseline levels.~Measurement: Vitamin D levels will be measured at the beginning and end of treatment using 25-hydroxyvitamin D (25(OH)D tests to assess the effectiveness of supplementation.~Effect on MARPE: Adequate Vitamin D levels may support better bone remodeling and healing, pote"
214999564|NCT06938685|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
214392085|NCT00787722|PROCEDURE|Hematopoietic Stem Cell Transplantation|Infusion of participant's own stem cells
214392086|NCT00787722|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
214392087|NCT00787722|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
214392088|NCT00787722|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
214392089|NCT00787722|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
214392090|NCT00787722|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
214392091|NCT00787722|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
214392092|NCT05581238|OTHER|TRACK-TCT|An extra variable will be added to an existing prediction model. It is hypothesized that the predictive ability will improve and that better distinction could be made between patients with an increased risk for receiving blood transfusions.
214392093|NCT00219141|DRUG|Aliskiren 150/300 mg|Aliskiren 150 mg tablets
214392094|NCT00219141|DRUG|Losartan 50/100 mg|Losartan 50 or 100 mg capsules
214999565|NCT06938685|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
214999566|NCT07141784|DEVICE|C-Mill® Treadmill Training Combined with Conventional Physiotherapy|Participants received a 4-week integrated rehabilitation program consisting of 10 C-Mill® treadmill training sessions in addition to individualized conventional physiotherapy. C-Mill® sessions incorporated virtual reality and gamified tasks to improve static and dynamic balance, gait speed, stride regulation, and safe obstacle negotiation. Conventional physiotherapy targeted mobility, muscle strength, and functional skills to enhance walking performance and independence.
214999567|NCT07141316|DEVICE|Blood flow restriction combined with electrostimulation.|Participants will perform 30 minutes of blood flow restriction once a day during electrostimulation of the quadriceps of the operated limb.
214999568|NCT07141693|PROCEDURE|NIRS-guided management|NIRS-guided management where a predefined 6-step intervention protocol (volume optimization, vasoactive drugs, inotropes, heart rate management, transfusion, and FiO₂ increase)
214999569|NCT07141693|PROCEDURE|Standard anesthesia management|Standard anesthesia management
214999570|NCT07141771|DRUG|Serplulimab|Serplulimab: 4.5mg/kg, ivgtt, 21 days/cycle
214999571|NCT07141771|DRUG|Fluzoparib|100mg BID oral
214999572|NCT07141771|DRUG|Topotecan/Irinotecan/Paclitaxel/Temozolomide|second-line chemotherapy options: Topotecan/Irinotecan/Paclitaxel/Temozolomide etc.
214999573|NCT07141771|DRUG|Etoposide/Carboplatin/Cisplatin|First-line chemotherapy: the original first-line chemotherapy regimen, recommended Etoposide 100mg / m2 d1-3, Carboplatin AUC = 5 d1 / Cisplatin 75mg / m2 d1 q21d
214392095|NCT00219141|DRUG|Aliskiren placebo|Aliskiren 150 mg placebo tablet
214392096|NCT00219141|DRUG|Losartan 50/100 mg placebo|Losartan 50/100 mg placebo capsules
214392097|NCT03368924|OTHER|SCA patients (SS genotype)|"The clinical data relative to the patients will be collected in each of these stages (CVO, basic state).~Besides, to estimate the severity of the CVO, we shall use an index of severity of the episode ( IS2) adapted from the one who was validated by our group to stratify the severity of vasoocclusifs episodes at the drepanocytic child SS.~Main clinical parameters: taken of analgesic at home (level), temperature in the admission, SaO2 in the admission, number of painful sites, thoracic pain with or without associated cough, score EVA in the entrance, feeling of the patient of bigger gravity of the CVO with regard to its crises previous, heart rate to the admission, … Main biological parameters: rate of leukocytes, of polynucléaires neutrophiles, of réticulocytes, Lactate déshydrogénase, of haemoglobin, C-reactive Protein … The biological data can be studied according to their raw rate or according to their difference with their basic value (in the stable state)."
214392098|NCT04864821|DRUG|Targeting CD276 CAR T cells|Targeting CD276 autologous chimeric antigen receptor T cells
214392099|NCT05039775|DEVICE|EROS device|Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.
214392100|NCT05039775|BEHAVIORAL|Psychosexual support|Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.
214502119|NCT01543893|BEHAVIORAL|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
214502120|NCT01543893|BEHAVIORAL|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
214502121|NCT04913103|DRUG|Polatuzumab vedotin|treatment by a study drug polatuzumab-vedotin, i.v.
214502122|NCT04913103|DRUG|Bendamustine Hydrochloride|treatment by a study drug bendamustin i.v.
214999574|NCT07141771|DRUG|Lurbinectedin|2.6mg/m2 (3 patients, if safe, in the 3.2mg / m2 dose group) or 3.2 mg / m2, ivgttd,21d / cycle .
215094210|NCT06245538|BEHAVIORAL|Seated rest|Participants will be resting while seated on a comfortable chair for 20 minutes
214392101|NCT00253279|PROCEDURE|PET Scans|Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
214502123|NCT04913103|DRUG|Rituximab|treatment by a study drug rituximab, i.v.
214502124|NCT06210152|DEVICE|Radial Extracorporeal Shockwave Therapy|Radial Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. Each session involved the delivery of 1000 pulses at a frequency of 10Hz and an air pressure setting of 1.0 bar.
214502125|NCT06210152|DEVICE|Sham Extracorporeal Shockwave Therapy|Sham Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. In each session, the device was held against the achilles tendon without being powered on.
214688068|NCT04120792|BEHAVIORAL|Cognitive Training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
214688069|NCT04120792|BEHAVIORAL|Neutral video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
214999575|NCT07141771|DRUG|Temozolomide|150mg/m2, oral, on days 1-5,28d / cycle
214999576|NCT07140965|PROCEDURE|Pegulicianine Fluorescence-Guided Surgery|Given by Surgery
214999577|NCT07140965|PROCEDURE|Digital Breast Tomosynthesis|Given by Procedure
214999578|NCT07140965|PROCEDURE|Breast Conserving Therapy|Given by Procedure
214999579|NCT07142057|BIOLOGICAL|23-valent pneumococcal vaccine|Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine
214999580|NCT07141667|PROCEDURE|Erector spinae plane block with liposomal bupivacaine|In the anesthesia induction suite, the anesthesiologist administers an ultrasound-guided erector spinae plane (ESP) block under local anesthesia prior to the induction of general anesthesia. The procedure involves the sequential injection of 10 mL of normal saline, followed by the administration of 20 mL of 1.33% liposomal bupivacaine.
214999581|NCT07141667|PROCEDURE|Erector spinae plane block with bupivacaine HCL|In the anesthesia induction suite, the anesthesiologist administers an ultrasound-guided erector spinae plane (ESP) block under local anesthesia prior to the induction of general anesthesia. The procedure involves the sequential injection of 10 mL of normal saline, followed by the administration of 20 mL of 0.5% bupivacaine HCL.
215094211|NCT06245538|BEHAVIORAL|Exercise at moderate intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)
215094212|NCT06245538|BEHAVIORAL|Exercise at vigorous intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)
214392102|NCT01400464|DRUG|Prednisone therapy and pharmacokinetic|Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
214392103|NCT05617547|DIAGNOSTIC_TEST|Pulse Oximeter (Massimo)|The Massimo LNCS (low noise cabled sensors) pulse oximeter will be used to estimate the oxygen saturation and compared to the gold standard, the arterial oxygen saturation in the blood as measured by co-oximetry. The pulse oximeters is FDA cleared for this purpose so patients will not be exposed to any interventions that are not standard of care.
214392104|NCT03660033|DIAGNOSTIC_TEST|ECG in delivery room|See arm/group discussions
214392105|NCT05392075|BIOLOGICAL|Pfizer COVID-19 mRNA vaccine|vaccinated people who received the Pfizer COVID-19 mRNA vaccine
214392106|NCT05392075|BIOLOGICAL|Moderna COVID-19 mRNA vaccine|vaccinated people who received the Moderna COVID-19 mRNA vaccine vaccine
214392107|NCT00004811|DRUG|itraconazole|
214392108|NCT06480669|OTHER|Time Restricted Feeding|8 participants who practiced a 12/12 TRF (12 hours of fasting, from approximately 20:30 to 8:30 the following day).
214392109|NCT06480669|OTHER|Mediterranean Diet|A control group consisting of 9 participants who followed a standard Mediterranean diet.
214392110|NCT02903784|DEVICE|fMRI|Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)
214392111|NCT02903784|PROCEDURE|tractography|Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)
214392112|NCT02903784|OTHER|neuropsychological examination|Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination
214392113|NCT02923219|BIOLOGICAL|Adipose-derived stem cells|The adipose-derived stem cells therapy involve injection of patient's own adipose-derived stem cells. Local anesthetic will be applied to the face prior to the injection. For adipose-derived stem cells preparation, proper volume of fat cells will be collected from each patient just before each procedure. The stem cells will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing.
214502126|NCT03176056|DIETARY_SUPPLEMENT|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
214502127|NCT03176056|DIETARY_SUPPLEMENT|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI \> 24 and 30 kcal/day for underweight subjects with a BMI \<18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
214502128|NCT06272188|OTHER|web-based online preconceptional counselling|web-based online preconceptional counselling
214502129|NCT03693807|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
214502130|NCT03693807|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
214999582|NCT07141173|BEHAVIORAL|Individual lifestyle management|Manage the diet, exercise, weight and healthy lifestyle of pregnant women
214999583|NCT07142460|BEHAVIORAL|Intervention|The students in the experimental group were shared the digital stories prepared for drug applications from the WhatsApp group and were asked to watch them for two weeks. Students were able to watch the stories on their mobile phones at the time and frequency they wanted. During 2 weeks, the researchers met with the students twice in the classroom environment and received feedback on the digital stories. Feedbacks about the real meaning of the stories and their contribution to education were obtained by using discussion and question-answer methods. Each student explained their opinions about the stories and had the opportunity to think deeply about them by receiving feedback from their classmates.
214999584|NCT03855800|DIAGNOSTIC_TEST|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
214392114|NCT03728192|OTHER|mangosteen extract|For Mangosteen group :DNA fragmentation assay is used to identify apoptosis.1×106 cells were harvested and treated with mangosteen pericarp extract for 48 h For Camptothecin group : Cells were also treated with standard anticancer drug Camptothecin to act as a positive control.
214392115|NCT03912220|DRUG|Nicotinamide riboside|The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.
214392116|NCT03912220|DRUG|Placebo Oral Tablet|Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
214502131|NCT03693807|DRUG|Gemcitabine|Please see Detailed Description.
214502132|NCT03693807|DRUG|Oxaliplatin|Please see Detailed Description.
214502133|NCT03693807|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
214502134|NCT03693807|DRUG|Fluorouracil|Please see Detailed Description.
214502135|NCT03693807|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
214999585|NCT03855800|PROCEDURE|Pancreatic Surgery|Surgical resection of pancreatic cyst
214999586|NCT03855800|PROCEDURE|Endoscopy Exam|Clinically indicated endoscopic ultrasound
214999587|NCT07138781|DRUG|Ketamine|Patients will receive 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg).
214999588|NCT07138781|DRUG|29 ml bupivacaine 0.25% + 1 ml saline|Patients will receive 29 ml of bupivacaine 0.25% + 1 ml of saline.
214392117|NCT00675545|DRUG|Docetaxel, Carboplatin|"Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available."
214392118|NCT01780493|PROCEDURE|The Direct Nipple Ureteroneocystostomy Technique|
214392119|NCT02930564|OTHER|CDED + milk fat and gluten|CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)
214392120|NCT03263182|BEHAVIORAL|Introduction of the Safe Childbirth Checklist|"1. Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.~2. Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.~3. Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.~4. Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training."
214502136|NCT05715684|OTHER|Exercise Training|Virtually supervised exercise training for four weeks prior to cystectomy
214999589|NCT07142538|OTHER|exercises|Exercise training was provided to both groups.
214999590|NCT07141680|PROCEDURE|Replantation|Root canal treatment Tooth extraction and replacement Splinting
214999591|NCT07141680|PROCEDURE|Splint|Root canal treatment Splinting
214392121|NCT00581633|OTHER|normal saline (0.9%)|liter normal saline over 30 minutes x 1 dose
214392122|NCT03862989|PROCEDURE|Radiofrequency catheter ablation|A catheter is inserted into the heart and signals are recorded from the heart whilst at rest or whilst being stimulated by a catheter, in order to determine the site to ablate. Radiofrequency is then delivered to the target site in order to disrupt the pathological electrical activation which is causing the abnormal heart rhythm.
214392123|NCT04930458|OTHER|Nanosilver fluoride|Nanosilver fluoride will be applied to the affected tooth in single application and then follow up after one and three months
214392124|NCT04930458|OTHER|Sodium fluoride with casein phosphopeptides amorphous calcium phosphate|Sodium fluoride with casein phosphopeptides amorphous calcium phosphatewill be applied to the affected tooth in single application and then follow up after one and three months
214392125|NCT04930458|OTHER|Sodium fluoride varnish|Sodium fluoride varnish will be applied to the affected tooth in single application and then follow up after one and three months
214392126|NCT03973138|DRUG|Ranibizumab|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA) under the pro re nata (PRN) treatment regimen. The retreatment were conducted if BCVA was reduced by 0.1 logarithm of the minimal angle of resolution (logMAR) value or more from maximum acuity or if OCT central subfield thickness was more than 300μm.
214392127|NCT05342116|OTHER|Nestle Preload|1 sachet of Preload (50g) diluted with 400ml of water, to be consumed 2 to 4 hours prior to the endoscopy.
214392128|NCT05342116|OTHER|Water|400ml of water to be consumed 2 to 4 hours prior to the endoscopy.
214392129|NCT02004743|BEHAVIORAL|Intervention|"Psychological guidelines and PET~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD."
214392130|NCT02004743|OTHER|Treatment as usual|"Participants will experience treatment as usual.~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD"
214502137|NCT05715684|DIETARY_SUPPLEMENT|Nutritional Intervention|Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively
214502138|NCT01524497|DRUG|Trazodone|75mg tablet/150 mg tablet
214502139|NCT01524497|DRUG|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
214502140|NCT04139304|DRUG|Cyclophosphamide|Given IV
214502141|NCT04139304|BIOLOGICAL|Daratumumab|Given IV
214502142|NCT04139304|DRUG|Doxorubicin|Given IV
214502143|NCT04139304|DRUG|Doxorubicin Hydrochloride|Given IV
214502144|NCT04139304|DRUG|Etoposide|Given IV
214502145|NCT04139304|DRUG|Prednisone|Given PO
214502146|NCT04139304|DRUG|Vincristine|Given IV
214502147|NCT04139304|DRUG|Vincristine Sulfate|Given IV
214999592|NCT07142213|PROCEDURE|ALPPS|In recent years, Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) provides new hope for the solution of large/unresectable hepatobiliary malignancies. This technique promotes the rapid proliferation and regeneration of the remaining liver by separating the liver and ligation of the portal vein, so that the patients whose original liver function is not enough to tolerate large-scale liver resection can complete liver regeneration in a short time, so as to perform secondary resection. Compared with traditional two-stage hepatectomy, ALPPS significantly speeds up the rate of liver regeneration, shortens the waiting time for a second surgery, and provides a safer radical treatment for tumors in high-risk patients.
215000423|NCT07124806|COMBINATION_PRODUCT|Botulinum toxin guided by ultrasonography and anatomical references|The botulinum neurotoxin (BoNT) will be calculated according to the weight of each patient. It will be injected in four places: two of them into the medial gastrocnemius and the other two into the lateral gastrocnemius. For medial gastrocnemius muscle, ¼ of the dose will be injected into the muscle belly at the 25% of the distance between the popliteal fossa and the intermalleolar line. Another ¼ will be injected into the muscle belly at the 35% of the previously mentioned distance. For lateral gastrocnemius, ¼ of the dose will be injected into the muscle belly at the 20% of the distance between the popliteal fossa and the intermalleolar line. The remaining ¼ of the dose will be injected into the muscle belly at the 30% of the previously described distance. All patients will conduct the same physical therapy program and under the direction of the same team of physical therapists. This program will begin two weeks after receiving the BoNT injection.
214392131|NCT05963867|DRUG|BI 764532|BI 764532
214392132|NCT05963867|DRUG|[89Zr]Zr-BI 764532|\[89Zr\]Zr-BI 764532
214392133|NCT05514574|OTHER|Music|"hussoni duseni  music"
214392134|NCT05514574|OTHER|Stress ball|Stress ball squeeze
214502148|NCT03067948|BEHAVIORAL|Patient Designated Positive Screen Shared with Provider|Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
214502149|NCT00082836|BIOLOGICAL|rituximab|
214502150|NCT00082836|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214502151|NCT04197037|PROCEDURE|Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.|Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
214999593|NCT02799524|OTHER|comparison of screening scales|Concordance degrees Assessment of each of 2 scales ( HADS and GDS ) from the DSM- V , for diagnostic confirmation of major depressive episodes in elderly patients with cancer or haematological malignancies
214999594|NCT05592197|DRUG|Lenvatinib|Lenvatinib will be initially provided to patients first (dose: 8 mg qd for patients \< 60 kg, and 12 mg qd for patients ≥ 60 kg)
214999595|NCT05592197|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
214999596|NCT05592197|RADIATION|External beam radiation (RT)|RT will be given within 4 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-6000 cGy in 25 fractions.
214999597|NCT03421561|DEVICE|"Stellarex 0.035 OTW Drug-coated Angioplasty Balloon"|"The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
214999598|NCT03421561|DEVICE|EverCross™ 0.035 PTA Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
214392135|NCT00702182|DRUG|Vinorelbine (Navelbine)|Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
214392136|NCT00702182|DRUG|Vinorelbine (Navelbine)|Metronomic Schedule Oral Vinorelbine 3 times a week
214999599|NCT05112120|DRUG|Olumiant|Olumiant (4mg) will be administered in line with standard of care guidance.
214392137|NCT00702182|DRUG|Erlotinib|Daily Oral Erlotinib 100 mg
214392138|NCT01609530|PROCEDURE|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
214392139|NCT01609530|PROCEDURE|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
214392140|NCT01885260|DRUG|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks
214392141|NCT01885260|DRUG|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks
214392142|NCT01885260|DRUG|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks
214392143|NCT01421082|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)|Lung Volume Reduction Coil (LVRC)
214392144|NCT00224523|DRUG|GW685698X|
214392145|NCT00224523|DRUG|mometasone furoate|
214392146|NCT02384005|OTHER|Self-anal exam arm|After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
214502152|NCT00139360|DRUG|Bevacizumab|Anti angiogenesis treatment
214502153|NCT02743819|DRUG|Pembrolizumab|Pembrolizumab given every 3 weeks (200 mg) by IV infusion.
214502154|NCT02743819|DRUG|Ipilimumab|Ipilimumab given every 3 weeks (200 mg) by IV infusion for total of 4 doses.
214502155|NCT05869734|BEHAVIORAL|Sleep health promotion|We will provide sleep hygiene related adjustments in the intervention group A; and brief behavioral treatment for insomnia (BBTI) in the intervention group B.
214502156|NCT05869734|BEHAVIORAL|Urologic health promotion|We will provide information related to urologic health promotion in three groups (2 experimental groups and 1 comparison group).
214502157|NCT05869734|BEHAVIORAL|Pelvic floor muscle training|We will provide information related to pelvic floor muscle training in three groups (2 experimental groups and 1 comparison group).
214502158|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with whole dose blood-stage inoculum (neat)
214999600|NCT06219005|BEHAVIORAL|ultrasound education and simulation workshop|workshop testing emergency physician knowledge and technical skills in performing ultrasound-guided nerve blocks in a simulation model
214999601|NCT00524498|DRUG|OPC-18|OPC-18: 500IU \* 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
214392147|NCT02066532|DRUG|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
214392148|NCT02066532|DRUG|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab \> 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
214392149|NCT04415385|DRUG|Camrelizumab|200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.
214392150|NCT04415385|DRUG|Apatinib|250 mg, orally once a day. Take about half an hour after a meal with warm water.
214999602|NCT00524498|DRUG|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
214999603|NCT04316715|BEHAVIORAL|Lifesteps for PrEP|Four weekly nurse delivered counseling sessions plus two optional booster sessions. Sessions last approximately 40-50 minutes each. Sessions employ cognitive behavioral (CBT) techniques, motivational interviewing (MI), and psychoeducation.
214999604|NCT04316715|BEHAVIORAL|Daily text message reminders|Participants get daily text messages on their cell phone reminding them to take their PrEP medication.
214392151|NCT05725187|DEVICE|MobiCare|It is a 9.2g wearable electrocardiogram device, mobiCARE, in the form of a patch, and the model name is MC200M.
214392152|NCT04801745|OTHER|Healthy vegan diet|Participants will attend group lessons and individual nutrition counseling to help them adopt a healthy vegan diet.
214392153|NCT04801745|OTHER|My Plate - Low Purine|Participants will attend group lessons and individual nutrition counseling to help them adopt a balanced diet in accordance with my plate, and emphasis on choosing low purine options from the protein food groups.
214392154|NCT04801745|OTHER|Amla fruits|Participants will be provided with powdered amla fruits, and will be instructed to take 3g per day.
214392155|NCT03216902|DRUG|Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
214392156|NCT03216902|DRUG|Topical ultra-low dose of DE-126 Ophthalmic Solution|Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
214999605|NCT04949451|DIETARY_SUPPLEMENT|Whey protein supplement|Participants consume whey protein at the beginning of the eating period.
214999606|NCT04949451|DIETARY_SUPPLEMENT|Ketogenic aid|Participants consume ketogenic aid upon waking.
214999607|NCT04949451|OTHER|Control group - time restricted feeding only|Time restricted feeding.
214999608|NCT00001073|DRUG|Isotretinoin|
214999609|NCT03772873|PROCEDURE|minimally invasive pilonidal excision|MIPE procedure with trephine excision of pits and sinuses
214999610|NCT00119704|DRUG|Botulinum toxin A injection or normal saline|
214999611|NCT05008770|OTHER|No intervention|No intervention
214999612|NCT05853068|DEVICE|Mechanical ventilation|Need for endotracheal intubation and invasive mechanical ventilation
214999613|NCT04706338|DEVICE|TMS treatment|Using TMS to stimulate (5 Hz, 90%\~110% resting motor threshold) patients' primary motor area and SMA.
214999614|NCT05403918|OTHER|conventional physiotherapy|Hot pack, TENS, and therapeutic ultrasound will be applied for 10 minutes. Then glides will be given 30 x 3 times in grades III and IV. The rest of the exercises will be prescribed as 3 sets for 10 repetitions with 2 minutes of rest between sets for 6 weeks with respect to 3 sessions per week.
214999615|NCT05403918|OTHER|scapular stabilization exercises along with conventional physiotherapy|Each stretch will be repeated 3 times. Each active exercise will be progressed from 3 sets of 10 reps to 3 sets of 15 reps. If the subject easily completed 3 sets of 15 reps of active exercise, they will go on to resisted exercises. These will be performed once a day, for 6 weeks, 3 sessions per week.
214999616|NCT00000142|DRUG|Cidofovir|"Three groups:~1. the deferral group, treatment deferred until retinitis progressed~2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
214999617|NCT02199587|BEHAVIORAL|Presence of medical clown during endocrine test|
214392157|NCT03216902|DRUG|Topical low dose of DE-126 Ophthalmic Solution|Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
214392158|NCT03216902|DRUG|Topical medium dose of DE-126 Ophthalmic Solution|Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
214392159|NCT03216902|DRUG|Topical high dose of DE-126 Ophthalmic Solution|Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
214392160|NCT03216902|DRUG|0.005% Latanoprost Ophthalmic Solution|0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
214392161|NCT04834778|DRUG|HC-5404-FU|HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.
214392162|NCT03009721|DRUG|Other: Not applicable-observational study|
214392163|NCT04632732|DIAGNOSTIC_TEST|COVID-19 test|Nasal pharyngeal swab
214999618|NCT02805491|OTHER|meconium|to evaluate internal exposure to pesticide
214999619|NCT02805491|OTHER|self questionnaires to parents|to evaluate external exposure to pesticide
214999620|NCT05319470|DIAGNOSTIC_TEST|Intraocular pressure (IOP)|Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.
214999621|NCT05319470|DIAGNOSTIC_TEST|Tear Break-up Time (TBUT)|TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.
214999622|NCT05319470|DIAGNOSTIC_TEST|Conjuctival Hyperemia|Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.
214999623|NCT05319470|DIAGNOSTIC_TEST|Schirmer Test|Schirmer test will be performed on both eyes to asses tear production.
214392164|NCT04632732|DIAGNOSTIC_TEST|Blood sampling|20cc of blood will be collected each 7 days during 28 days.
214392165|NCT03082833|DRUG|AZD2014|AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
214999624|NCT05319470|DIAGNOSTIC_TEST|Visual Fields and OCT RNFL|Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.
214999625|NCT03119311|DIAGNOSTIC_TEST|Video-oculography|Diagnostic Method for Exotropia Using Video-oculography
214999626|NCT03119311|DIAGNOSTIC_TEST|APCT|alternative prism cover test
214999627|NCT03260400|DEVICE|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
214999628|NCT05690516|BEHAVIORAL|Wearing face masks|Participants are asked to wear face masks in public spaces.
214999629|NCT01684605|DRUG|NESP 60μg|Administrated NESP 60μg once intravenously
214999630|NCT01684605|DRUG|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
214999631|NCT02590315|OTHER|Invitation for breast screening and random allocation|Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.
214999632|NCT02590315|DEVICE|DBT|Combo-mode DBT. DBT participants will have an additional radiation exposure for breast tomosynthesis.
214392166|NCT02543190|BEHAVIORAL|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
214392167|NCT03135457|PROCEDURE|Autologous RBC transfusion|Autologous RBC transfusion 300ml 10 ml/min
214392168|NCT03135457|PROCEDURE|Saline transfusion|Saline transfusion 300ml 10ml/min
214392169|NCT04096573|DRUG|LC51-0255|LC51-0255
214392170|NCT04096573|DRUG|Placebo|Placebo
214392171|NCT01263106|DRUG|LY2216684|18-mg LY2216684 oral dose
214502159|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:5 dilution blood-stage inoculum
214502160|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:10 dilution blood-stage inoculum
214999633|NCT02590315|DEVICE|Conventional digital mammography.|Conventional digital mammography.
214999634|NCT00077194|DRUG|romidepsin|
214999635|NCT01503801|DRUG|Nitric Oxide|The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
214999636|NCT01503801|DEVICE|respiratory support|Routine respiratory support.
214999637|NCT03907423|DRUG|Rosuvastatin10 mg tablet|Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
214999638|NCT03907423|DRUG|Placebo Oral Tablet|Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
214999639|NCT02653820|OTHER|Reflexology|
214999640|NCT05217264|OTHER|Assesment|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
214392172|NCT01263106|DRUG|Theophylline|200-mg theophylline oral dose
214392173|NCT00150384|DRUG|Amlodipine/Atorvastatin|
214999641|NCT00884065|OTHER|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
214999642|NCT00884065|OTHER|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
214999643|NCT01732783|OTHER|Panitumumab + Chemotherapy|Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.
214999644|NCT00176332|DRUG|rosuvastatin|
214999645|NCT06056609|OTHER|Yoga|An 8 week online mother and baby yoga programme to include daily diary completion and questionnaires at designated study timepoints
214392174|NCT02913521|DRUG|Diclofenac Sodium Gel 1%|
214392175|NCT02913521|DRUG|Voltaren Gel|
214392176|NCT02913521|DRUG|Placebo|
214392177|NCT03939247|OTHER|Active Tecaretherapy|"The Tecaretherapy: consists of using a specific device providing high frequencies (between 300 kHz and 1 MHz) supposed to accelerate the tissues healing process"
214392178|NCT03939247|OTHER|Inactive Tecaretherapy|"Inactive Tecaretherapy: the device will not provide any current."
214392179|NCT03939247|OTHER|CPT|Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
214392180|NCT03662360|OTHER|essential oils|Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
214392181|NCT00170937|DRUG|valsartan plus hydrochlorothiazide|
214392182|NCT04707690|DEVICE|Intraurethral laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
214392183|NCT04707690|DEVICE|Intraurethral SHAM laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
214392184|NCT03996044|OTHER|Teeth brushing and flossing|All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.
214392185|NCT03996044|OTHER|Tongue scraping|Tongue scraping will be performed by the same operator on all participants. Posterior-anterior movements will be performed with the scraper over the tongue dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
214392186|NCT03996044|RADIATION|Antimicrobial Photodynamic Therapy (aPDT)|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
214392187|NCT03996044|BIOLOGICAL|Probiotics|Pharmacy-manipulated capsules containing strains of Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg) will be used. Forty-two capsules will be delivered for each patient, who should take 1 capsule 3 times a day after meals for 14 days.
214392188|NCT04356339|DRUG|Interferon-beta-1b (BETASERON, BAY 86-5046)|Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician
214392189|NCT05281003|DRUG|Pembrolizumab|Biological: Pembrolizumab 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
214392190|NCT05281003|DRUG|Paclitaxel|Drug: Paclitaxel 150 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
214392191|NCT05281003|DRUG|Cisplatin|Drug: Cisplatin 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
214392192|NCT01985477|DRUG|Lenalidomide|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.~Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.~Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment."
214999646|NCT03960827|OTHER|EE Training|Participants randomized to EE engage in four center-based EE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. Each week, two of the sessions occur on a cycle ergometer and two involve treadmill exercise (4 total sessions per week). During all sessions, the participant's heart rate is monitored to ensure they maintain exercise intensity at 70% of heart rate reserve (± 5%). Periodically during training sessions perceptual data from participants are recorded, which is used to track the subjective experience of participants and in interpreting adherence data.
214999647|NCT03960827|OTHER|RE Training|Participants randomized to RE engage in four center-based RE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. The prescription is a 2-day split, meaning approximately half of the major muscle groups are exercised each session and each muscle group is exercised twice per week. Two sessions per week include seven exercises that focus on the hips/thighs, back and biceps, and the other two sessions per week include seven exercises that focus on the chest, shoulders, triceps, calves and abdominal muscles. The first set per muscle group is a warm-up performed at 50-70% of prescribed loads that are based on 10-repetition maximum (10RM). Three sets per exercise are then performed at 10RM intensity. Load increases when a participant can perform 12 repetitions for 2 of 3 sets of an exercise. During all sessions, heart rate is monitored and perceived exertion is recorded.
214999648|NCT04545177|DEVICE|NICO Myriad and Tissue Preservation System (TPS)|Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
215094213|NCT00521664|BIOLOGICAL|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
215094214|NCT00521664|BIOLOGICAL|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
215094215|NCT06398717|PROCEDURE|adductor canal block|"group C will receive a unilateral adductor canal block alone, using an ultrasound to identify the location of the nerve.~group H will receive unilateral peri-hamstring injection combined to adductor canal block, After the adductor canal block, the transducer will be moved posteriorly till identifying the site of injection group O will receive unilateral anterior obturator nerve block combined with adductor canal block, The anterior branch of the obturator nerve is located using ultrasound"
214392193|NCT01985477|DRUG|Dexamethasone|"Phase I All Patients - Induction: Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22.~Phase II Group A: Dexamethasone starting dose: Dose previously on when progressing prior to study entry.~Maintenance Therapy: Phase I and Phase II Group A: Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22."
214392194|NCT01985477|DRUG|All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: ATRA starting dose: MTD from Phase I.~Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.~Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days."
214392195|NCT05962593|OTHER|Telephone call|The patients will be randomized for a postoperative telephone call
214392196|NCT03936140|DRUG|Inhaled iloprost|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
214502161|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:20 dilution blood-stage inoculum
214502162|NCT03165734|DRUG|Pacritinib|Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
214392197|NCT03936140|DRUG|Distilled water|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
214392198|NCT01424436|BIOLOGICAL|GSK933776|1mg/kg dose group
214999649|NCT06567691|PROCEDURE|EUS Gastrojejunostomy|Endoscopic Ultrasound (EUS) Gastrojejunostomy. Under live real-time EUS visualization, a solution of normal saline or water and dilute methylene blue will be infused through the nasobiliary drainage catheter to mechanically distend the small intestine and create a suitable, expanded fluid-filled target for transgastric access. Once a suitable target has been identified, a lumen apposing metal stent (LAMS) will then be deployed securely across the newly created gastroenterostomy tract. Appropriate stent placement will be confirmed.
215094216|NCT05808517|BEHAVIORAL|Tai Chi|Tai Chi (TC) is a traditional Chinese exercise, also known as a mind-body exercise. It is suitable as an alternative or supplementary form of routine physical exercise for older adults. TC focuses on gentle and rhythmical movements while maintaining a meditative state. Low to moderate activities have benefits to improve sleep disturbances in older adults. In addition, growing evidence widely supports meditation as a potential intervention to improve sleep disturbances through reducing repetitive negative thoughts such as worry and rumination.
215094217|NCT05808517|OTHER|repetitive transcranial magnetic stimulation|The brain stimulation technique repetitive transcranial magnetic stimulation (rTMS) provides the opportunity to non-invasively modulate cortical excitability. In general, low-frequency rTMS (≤ 1 Hz) is thought to inhibit cortical excitability.
214392199|NCT01424436|BIOLOGICAL|GSK933776|3mg/kg dose group
214392200|NCT01424436|BIOLOGICAL|GSK933776|6mg/kg dose group
214392201|NCT04879316|OTHER|Resting Energy Expenditure measurement|Resting Energy Expenditure measurement using indirect calorimetry
214392202|NCT04324294|DRUG|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
214392203|NCT00005028|DRUG|bryostatin 1|
214392204|NCT00005028|DRUG|paclitaxel|
214392205|NCT01680458|DRUG|Fluconazole|"Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.~Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.~Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.~Absolute doses exceeding 600 mg/day are not recommended."
214392206|NCT00738452|OTHER|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
214392207|NCT00738452|OTHER|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
214392208|NCT00738452|PROCEDURE|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
214392209|NCT00738452|PROCEDURE|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
214392210|NCT00738452|RADIATION|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
214392211|NCT00738452|RADIATION|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
214392212|NCT03915119|OTHER|GFT AI training|navigates a cluttered environment of stationary and moving/pursuing virtual obstacles to reach a way-point as quickly and efficiently as possible. Block order and difficulty, as well as the behavior of the obstacles in each block, will be driven by the AI and statistically weighted to specifically target the perceptual-motor and neuromechanical mechanisms based on each athlete's visit 1 performance
214392213|NCT01007968|DRUG|LBH589|
214392214|NCT05666375|PROCEDURE|Percutaneous translumbar and transhepatic permcath|For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access
215094218|NCT03782441|DEVICE|Prototype 0.5|Investigational Medical Device collecting spectral Raman data from tissue
214392215|NCT02401958|OTHER|Resistance training|17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
214502163|NCT03165734|DRUG|Physician's Choice medications|Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
214502164|NCT06344481|DEVICE|Surgical (Hyalex Cartilage Knee Implant)|Implantation of Hyalex Cartilage Knee Implant.
215094219|NCT02149017|RADIATION|SNUBH-NM-333(18F)|5-10 mCi
215094220|NCT02335424|BIOLOGICAL|pembrolizumab|IV infusion
215094221|NCT03386409|BEHAVIORAL|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
215094222|NCT03386409|BEHAVIORAL|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
215094223|NCT02694952|BIOLOGICAL|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
214392216|NCT00819065|DRUG|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
214392217|NCT00819065|DRUG|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
214392218|NCT04107896|DRUG|Silodosin|Cap silodosin
214392219|NCT04107896|DRUG|Tamsulosin|Cap tamsulosin
214392220|NCT03344822|DIAGNOSTIC_TEST|68Ga-PSMA-11|radioactive tracer for PET-CT (68Ga-PSMA-11)
214392221|NCT03344822|DIAGNOSTIC_TEST|18F-Choline PET-CT|radioactive tracer for PET-CT (18F-Choline PET-CT)
214392222|NCT01397565|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
214999650|NCT06567691|PROCEDURE|Surgical Gastrojejunostomy|Gastrojejunostomy will be performed via an open technique using an upper midline or left sub-costal incision (at the discretion of the surgeon). An antecolic, pro-peristaltic, gastrojejunostomy will be performed using one of two standard techniques: 1) hand-sewn: 2-layer anastomosis using absorbable suture or 2) stapled: single-layer anastomosis using a surgical stapler with closed staple height ranging from 1.0 - 1.5 mm and suture closure of the common enterotomy. Feeding tube placement will be at the discretion of the operating surgeon and if performed, will be performed via a Stamm technique. Abdominal fascial closure will be performed with absorbable, monofilament, suture and skin will be closed using staples or suture at the discretion of the surgeon.
214392223|NCT01397565|PROCEDURE|Minilaparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using minilaparoscopic instruments
214392224|NCT04992936|DIETARY_SUPPLEMENT|Extract from the wine industry|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
214392225|NCT04992936|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
214392226|NCT04545216|OTHER|Long-distance mountain running|Impact of a mountain race on the knee cartilage
214392227|NCT06167551|OTHER|mother lullaby group|mother's lullaby: the mother will be made to sing her own lullaby 5 minutes before the heel prick.
214392228|NCT06167551|OTHER|white noise group|white noise: 5 minutes before taking heel prick blood, white noise will be started to be played on an MP3 player with white noise. The MP3 player will be placed in the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
214392229|NCT06167551|OTHER|classical music group|classical music: 5 minutes before heel prick, classical music will be started to be played from the MP3 player with white noise. The MP3 will be placed inside the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
214999651|NCT06567691|OTHER|Gastric Outlet Obstruction Scoring System (GOOSS)|A previously validated instrument for assessing tolerance of oral intake.
214999652|NCT06310239|OTHER|Collection of biologic samples and data|"* collection of skin flora samples via swabs~* data collection regarding subject's medications See Detailed Description in Study Description section above for more details"
214999653|NCT01806792|DRUG|risedronate combine|
214999654|NCT01806792|DRUG|Risedronate|
214999655|NCT01806792|DRUG|Placebo(for Risedronate)|
214999656|NCT01806792|DRUG|Placebo(for risedronate combine)|
214999657|NCT00189384|DRUG|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
214999658|NCT00908778|DRUG|Vitreosolve|intravitreal injection
214999659|NCT00908778|DRUG|Vitreosolve|intravitreal injection
214999660|NCT02995889|DEVICE|FLT-PET|
214999661|NCT04939584|DEVICE|MultiPulse Therapy|Electrical Stimulation
214999662|NCT00370708|PROCEDURE|Oral Intake following admittance to the postpartum ward|
214999663|NCT03358953|DEVICE|Electron Cigarette|Blended Tobacco flavour, 18mg/ml
214999664|NCT03358953|DEVICE|Nicotine Replacement Patch|NiQuitin 21mg
214999665|NCT01808742|DEVICE|Treatment with CryoTouch III Device|Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
214999666|NCT04056026|BIOLOGICAL|Fecal Microbiota Transplant|Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
214392230|NCT06167551|OTHER|Contol Group|No intervation
214999667|NCT02802475|BIOLOGICAL|vena punction|
214999668|NCT04615507|DEVICE|JJVC Investigational Multifocal Contact Lens|TEST Lens
214999669|NCT04615507|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL Lens
214999670|NCT05044988|DRUG|HS-10342|HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle
214999671|NCT04474821|OTHER|Educational Intervention|Receive educational materials on HPV
214999672|NCT04474821|OTHER|Survey Administration|Ancillary studies
215094224|NCT02694952|BIOLOGICAL|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
214999673|NCT05057013|DRUG|HMBD-001|Participants with advanced solid tumours will receive their assigned dose level of HMBD-001 diluted in 0.9% sodium chloride, administered once a week as a 120-minute intravenous (IV) infusion. Cycles are 28 days with no break in between; administration may continue for up to 6 cycles but may continue for longer if the participant is deemed to be benefitting.
214392231|NCT04456335|GENETIC|Collection of supragingival plaque from caries free children|Supragingival plaque samples were collected from posterior molar teeth
214392232|NCT01468532|DRUG|docetaxel|Given IV
214392233|NCT01468532|DRUG|pasireotide|Given IM
214392234|NCT01468532|DRUG|prednisone|Given PO
214392235|NCT05504382|DEVICE|naproxen phonophoresis|transmission of naproxen molecule by therapeutic ultrasound
214392236|NCT01476917|DEVICE|Attune Sleep Apnea System|Observation of Attune Sleep Apnea System for use during sleep.
214392237|NCT05222425|DRUG|Xagrotin|A herbal compound
214392238|NCT05222425|DRUG|Green tea|Normal green tea
214392239|NCT03665883|PROCEDURE|Monopolar energy|Monopolar energy in TEP for inguinal hernia
214392240|NCT03665883|PROCEDURE|Blunt dissection|Blunt dissection in TEP for inguinal hernia
214392241|NCT05175534|PROCEDURE|monitoring|peroperative transesophageal echocardiography for monitoring in liver transplant surgery
214392242|NCT00589550|BIOLOGICAL|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
214392243|NCT00589550|DRUG|Sorafenib|
214392244|NCT00589550|GENETIC|gene expression analysis|
214392245|NCT00589550|GENETIC|polymerase chain reaction|
214392246|NCT00589550|GENETIC|reverse transcriptase-polymerase chain reaction|
214392247|NCT00589550|OTHER|flow cytometry|
214688070|NCT02015598|DRUG|Carbocysteine|carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
214688071|NCT02015598|DEVICE|Continuous Positive Airway Pressure|Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
215094225|NCT04322825|DEVICE|TENS incorporated into the Mollii suit|trans cutaneous electric stimulation,
215094226|NCT04316000|OTHER|Initial Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
215094227|NCT04316000|PROCEDURE|Endoscopic band ligation without resection of the subpetihelial tumour.|Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
214392248|NCT00589550|OTHER|immunoenzyme technique|
214392249|NCT00589550|OTHER|laboratory biomarker analysis|
214392250|NCT03777865|BIOLOGICAL|13vPnC|All subjects receive a single dose (0.5mL) of 13vPnC
214392251|NCT03508336|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|"Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected four stimuli: 1) only a command (as recommended in CRS-R), which was open your mouth; 2) only a spoon without a command; 3) a spoon and a command, the command was there is a spoon and open your mouth; 4) a spoon with water and a command, the command was there is a spoon with water and open your mouth. In brief, we presented these stimuli orderly in front of the patient's mouth and presented any one of them over 4 trials at 15 second intervals."
214392252|NCT04694482|OTHER|Psychometric scale administration|PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups
214392253|NCT04529603|DEVICE|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
214392254|NCT01931579|DEVICE|confocal endo-microscopy|The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
214392255|NCT00671996|DRUG|Mangafodipir|"Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.~Formulation content: MnDPDP 10 mmol/ml~Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy."
214392256|NCT00671996|DRUG|Placebo treatment (0.9% NaCl)|Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
214392257|NCT06192355|DEVICE|Endoscopic hemostasis using a Esophagogastroduodenoscopy|performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
214392258|NCT04650971|BIOLOGICAL|UniFluVec|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
214392259|NCT04650971|BIOLOGICAL|Placebo|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
214392260|NCT05741905|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
214688072|NCT02883465|PROCEDURE|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~* a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~* a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
214392261|NCT05741905|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
214392262|NCT01743794|DRUG|Ropivacaine|wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
214392263|NCT01743794|DRUG|Saline solution 0.9%|wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
214392264|NCT02146222|DRUG|VEGFR/PDGFR dual kinase inhibitor X-82|Given PO
214392265|NCT02146222|DRUG|docetaxel|Given IV
214999674|NCT05057013|DRUG|HMBD-001 and enzalutamide|Participants with metastatic castration resistant prostate cancer (mCRPC) confirmed as HER3 positive with no PTEN loss or with a NRG1 fusion rearrangement will receive the HMBD-001 recommended Phase 2 dose (RP2D) as determined in Part A, diluted in 0.9% sodium chloride and administered once a week as a 120-minute IV infusion, in combination with enzalutamide administered at a fixed dose of 160 mg once daily, in 28-day cycles with no break between cycles. Immediately before commencing combination therapy, participants may receive one 28-day cycle of enzalutamide monotherapy to confirm that their disease does not respond to enzalutamide alone. HMBD-001 may be administered for up to 6 cycles; enzalutamide may be continued until disease progression or unacceptable toxicity.
214999675|NCT06224257|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
214392266|NCT02146222|OTHER|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
214392267|NCT02146222|PROCEDURE|positron emission tomography/computed tomography|Undergo FLT PET/CT
214392268|NCT02146222|OTHER|pharmacological study|Correlative studies
214392269|NCT02146222|OTHER|laboratory biomarker analysis|Correlative studies
214392270|NCT03584776|DEVICE|Virtual Reality|Participants randomized to the VR condition will experience an an immersive guided relaxation VR experience during research visits in the post-operative period. They will also have the opportunity to choose additional VR games and relaxation experiences during their inpatient stay.
214392271|NCT00401102|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
215094228|NCT04316000|OTHER|1-2 Months Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
215094229|NCT04316000|OTHER|1 Year Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
215094230|NCT02772900|OTHER|Beetroot-based nutritional gel|100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
215094231|NCT02772900|OTHER|Placebo|100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
214392272|NCT04281433|OTHER|Activa Bioactive|Before cavity preparation and restoration, masticatory muscles activity will be evaluated by using electromyography. An electromyography detects the electrical potential generated by muscle cells. A total of 40 posterior teeth will be selected for this study and grouped into 2 main groups (20 for each group)) according to presence of caries in one or both side in patient (unilateral or bilateral). Split mouth technique will be used. The affected teeth will be treated by removing the caries and restored tooth with bulk fill composite material, after restoring the affected teeth. Masticatory muscles activity will be evaluated by using electromyography to detect any changes in masticatory muscles activity before and after restoration.
214392273|NCT04959760|DIAGNOSTIC_TEST|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2 in fingestick capillary blood and plasma samples.
214392274|NCT05493384|OTHER|Telerehabilitation Group|The program will include stretching, strengthening, breathing, posture, proprioceptive, relaxation exercises and segmental extremity movements. Each exercise will be performed 10 times in a session for the first 4 weeks and 15 times for the last 4 weeks. Exercises will be performed progressively on the patients.
214392275|NCT00544544|DRUG|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
214392276|NCT03032354|DRUG|Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12|Combination therapy of probiotics during 6 months
214688073|NCT04473443|OTHER|FEops HEARTguideTM|A patient-specific computer simulation that aims to improve the outcomes after TAVI by suggesting THV platform, THV size and implantation depth with the use of the pre-procedural CT-scan.
214688074|NCT00668434|DRUG|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
214688075|NCT00668434|DRUG|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
214688076|NCT06671093|GENETIC|Tune-401|Epigenetic gene silencing therapy
214688077|NCT04290962|BEHAVIORAL|Lifestyle Therapy|Complete web-based lifestyle intervention
214392277|NCT03032354|OTHER|Placebo, (Placebo group)|Placebo during 6 months
214688078|NCT04290962|OTHER|Quality-of-Life Assessment|Ancillary studies
214688079|NCT04290962|OTHER|Questionnaire Administration|Ancillary studies
214688080|NCT03017924|DEVICE|Q collar|q-collar concussion prevention device
214999676|NCT07125820|OTHER|Experimental Group|There are two groups: a study group and a control group. Both groups will continue taking their doctor-prescribed medications for migraine attacks. After the initial assessment, both groups will receive a 30-minute education and brochure containing lifestyle recommendations to address migraine triggers. The brochure will include recommendations for nutrition, environment, sleep, physical activity, and stress. Additionally, a Chattanooga Cefar® TENS device will be used. The frequency will be set at 100 Hz and the transition time will be set at 100 µs. The session will last 20 minutes. Individuals in the study group will be assigned an exercise program. Patients in this group will exercise in-person three days a week for eight weeks under the supervision of a physical therapist. The program will include cervical stabilization exercises, stretching, and balance exercises. The program is planned with a progression from easy to more difficult every two weeks.
214392278|NCT06474689|OTHER|EMDR|EMDR is based on the Adaptive Information Process (AIP) model, which posits that the traumatic event experienced by a subject is stored in memory along with the disturbing emotions, perceptions, cognitions, and physical sensations that characterized that moment. All this information is stored in a dysfunctional way within neural networks and unable to connect with other networks with useful information. The information enclosed in the neural networks, not being able to be processed, continue to cause discomfort in the subject, up to the onset of pathologies such as post-traumatic stress disorder (PTSD) and other psychological disorders. The goal of EMDR is to restore the adaptive processing of information in order to achieve the adaptive resolution by creating new and more functional connections.
214392279|NCT06474689|OTHER|CBT|CBT-E is based on the transdiagnostic theory for eating disorders. According to this theory, there is an overvaluation of shape, weight, eating and their control that people use to judge themselves which represents the core feature of maintaining eating disorder symptoms including binge eating. The goals of CBT-E are to increase the understanding of eating disorders, reduce weight concerns, and establish a pattern of regular eating by addressing the mechanisms that have been maintaining the eating disorder psychopathology including body image disturbances and reactions to life events and emotions. The goals of CBT-OB are to help patients to reach, accept and maintain a healthy weight loss by adopting a healthy lifestyle.
214392280|NCT00004390|DRUG|desipramine|
214392281|NCT00004390|DRUG|methadone|
214392282|NCT00004390|DRUG|morphine|
214392283|NCT00004390|DRUG|nortriptyline|
215094232|NCT01779635|DEVICE|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
215094233|NCT01779635|DEVICE|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
214392284|NCT04520555|DEVICE|Laryngeal mask airway|LMA Flexible is a supraglottic airway device, which can be moved out of the surgical field without displacement of the cuff, or loss of seal for the anesthetist
214392285|NCT04520555|DEVICE|Endotracheal tube|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
214392286|NCT00762021|DEVICE|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
214392287|NCT00762021|DEVICE|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
214392288|NCT01414426|DRUG|vandetanib|Given PO
214392289|NCT01414426|OTHER|placebo|Given PO
214392290|NCT01414426|OTHER|immunohistochemistry staining method|Correlative studies
214392291|NCT01414426|OTHER|laboratory biomarker analysis|Correlative studies
214392292|NCT01414426|PROCEDURE|biopsy|Correlative studies
214392293|NCT01414426|OTHER|pharmacological study|Correlative studies
214392294|NCT05222035|DRUG|Camrelizumab|PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
214392295|NCT05222035|DRUG|G-CSF|G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
214392296|NCT06087562|DRUG|Ropivacaine 0.5% Injectable Solution 20mL|Ultrasound-guided iPACK block with 20mL of 0,5% ropivacaine
214392297|NCT06087562|DRUG|0,9% normal saline 20mL|Ultrasound-guided placebo block with 20mL of 0,9% normal saline
214392298|NCT05266014|DRUG|tinlarebant|"Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months."
215094234|NCT02747511|DRUG|Haloperidol|
214392299|NCT00749801|DRUG|Nattokinase|2 capsules in the morning and before bed-time daily
214392300|NCT06140563|OTHER|anticoagulation dosing|In one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm.
214392301|NCT01450605|DRUG|No Intervention|Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
214392302|NCT04318093|DRUG|BMS-986259|Specified dose on specified days
214688081|NCT02928406|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
215094235|NCT02747511|DRUG|Placebo|
215094236|NCT04185415|DRUG|bepranemab|"bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous"
215094237|NCT04185415|DRUG|Placebo|"* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous"
214392303|NCT04318093|OTHER|Placebo|Specified dose on specified days
214392304|NCT03254953|BEHAVIORAL|self-monitoring of body weight|\- weigh daily for 3 months and track their weight using the MyFitnessPal mobile app
214392305|NCT03254953|BEHAVIORAL|self-monitoring of diet|"* track their diet (food and drinks) daily using the MyFitnessPal mobile app~* when they are asked to track diet will vary based on the arm"
214392306|NCT03254953|BEHAVIORAL|weekly personalized feedback + lessons + action plans|\- these are additional evidence-based intervention components
214392307|NCT00786890|OTHER|observational, no intervention needed|observational, no intervention needed
214392308|NCT01156077|DRUG|TR-701 FA|Oral TR-701 FA 200 mg will be given as a single oral dose
214392309|NCT01156077|DRUG|TR-701 FA|TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
214392310|NCT03004313|PROCEDURE|Pet Scan|Subjects will undergo Pet Scanning for 90 minutes
214392311|NCT03004313|PROCEDURE|MRI scan|
214392312|NCT03004313|PROCEDURE|Quantitative Sensory Testing (QST)|
214392313|NCT03112200|PROCEDURE|Subchondroplasty with Arthroscopy|The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
214392314|NCT03112200|PROCEDURE|Arthroscopy Alone|An endoscopic examination, therapy and surgery of the knee joint.
214392315|NCT00446940|DRUG|rosuvastatin|
214392316|NCT00446940|DRUG|atorvastatin|
214392317|NCT02042638|DRUG|hCG 1500 IU three times a week|
214392318|NCT02042638|DRUG|Pregnyl (hCG) ampule 1500 IU/three times a week|
214392319|NCT02397265|DEVICE|Bi-hormonal closed loop pump|Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
214392320|NCT02397265|DEVICE|Standard opened loop pump|Using a standard opened loop pump
214392321|NCT02397265|DEVICE|Insulin closed loop|Using a closed loop
214392322|NCT02225821|DRUG|Cephalozin|1000 mg Cephalozin
214392323|NCT02225821|OTHER|Sodium chloride|10 cc of NaCl 0.9%
214392324|NCT04282590|DRUG|TRK-750/Placebo|Powder for oral solution
214392325|NCT04282590|DRUG|Placebo/TRK-750|Powder for oral solution
214999677|NCT07125820|OTHER|control group|Individuals in the control group will receive a single session of placebo Chattanooga Cefar® TENS application and home exercise program in addition to drug treatment and patient education.Patients in this group will receive a single session of placebo TENS. Electrodes will be placed as in the study group. The physiotherapist will turn on the device but will not increase the current. Thus, the stimulation light of the device will be on but no current will be delivered. Patients will be told that they will not feel anything during the treatment and that this is a feature of the application. The application will be performed for 20 minutes.Home Exercise Program After the initial evaluation and patient education, patients will be offered an exercise program to be performed at home. This program will only consist of stretching exercises for the trapezius and levator scapula muscles. The exercises will be recommended to be performed once a day, 3 days a week, for 8 weeks with 10 repetitions.
214999678|NCT07124702|BEHAVIORAL|Simultaneous cessation intervention|This simultaneous cessation intervention group will target CCs and ECs at the same time. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.
214392326|NCT00136032|DRUG|Somatropin|Stratified based on age and estrogen status from 3 to 6 mcg/kg/day
214392327|NCT00136032|DRUG|Placebo|Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
214392328|NCT02443506|DRUG|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
214392329|NCT02443506|DRUG|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
214392330|NCT06250543|DRUG|AbobotulinumtoxinA 300 UNT|20 evenly distributed intradetrusor injections, 1 ml per site, were performed
214392331|NCT06250543|DRUG|IncobotulinumtoxinA 100 UNT|20 evenly distributed intradetrusor injections, 1 ml per site, were performed
214392332|NCT06250543|DRUG|Lidocain|30 minutes before the procedure the bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter
214392333|NCT06250543|OTHER|placebo|30 minutes before the procedure the bladder was instilled with 40 ml of 0.9% NaCl solution
214392334|NCT00467064|BEHAVIORAL|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
214392335|NCT00467064|OTHER|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
214392336|NCT05976113|OTHER|Observation only|Just obsrevation following standard of care (including surgery, chemotherapy and radiation when appropriate)
214392337|NCT00610064|RADIATION|Baseline neuroimaging|Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
214392338|NCT00610064|RADIATION|Neuroimaging during sacral neuromodulation|Neuroimaging during sacral neuromodulation using PET
214392339|NCT00127413|BEHAVIORAL|Cognitive Behavioral Therapy - Pain|Pain treatment
214392340|NCT00127413|BEHAVIORAL|Cognitive Behavioral Therapy-Integrated|Integrated treatment
214392341|NCT00127413|BEHAVIORAL|Cognitive Processing Therapy - PTSD|Cognitive processing therapy
214392342|NCT00127413|BEHAVIORAL|Treat as Usual|Treatment as usual
214392343|NCT01515345|DRUG|prasugrel or ticagrelor|prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
214392344|NCT01515345|DRUG|Clopidogrel|clopidogrel 75mg od for 12 month
214392345|NCT04100161|DIETARY_SUPPLEMENT|Protein supplementation|Daily dose of 40 g whey protein for 3 months
214392346|NCT04100161|DIETARY_SUPPLEMENT|Carbohydrate supplementation|Daily dose of 40 g maltodextrin for 3 months
214392347|NCT04100161|PROCEDURE|Active rehabilitation|Progressive rehabilitation following a muscle strain injury for 3 months
214392348|NCT04394091|DEVICE|ultrasensitive PET CT|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.
214392349|NCT00618462|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.
214392350|NCT00618462|BEHAVIORAL|Contingency management (CM)|CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.
214392351|NCT00618462|BEHAVIORAL|Psychoeducation therapy|Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.
214392352|NCT00618462|BEHAVIORAL|Case management|Case management will assist participants in obtaining additional services from the community as needed.
214392353|NCT00618462|BEHAVIORAL|Gamblers Anonymous (GA)|All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
214392354|NCT04485650|OTHER|music therapy|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group.
214392355|NCT04485650|OTHER|sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
214392356|NCT04485650|OTHER|non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
214392357|NCT00547911|DRUG|Droxidopa|
214502165|NCT04111510|DRUG|Tumor infiltrating lymphocytes (TIL) LN-145|"The TIL autologous therapy with LN-145 is comprised of the following steps:~1. Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;~2. LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;~3. A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);~4. Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);~5. Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization)."
214502166|NCT06193590|DEVICE|Carevix|Cervical stabilization device that uses vacuum
214502167|NCT06193590|DEVICE|Tenaculum|standard of care cervical stabilization device
214999679|NCT07124702|BEHAVIORAL|Stepwise cessation intervention|This stepwise cessation intervention group will first target CCs and then target ECs after quitting CCs. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.
214999680|NCT07124702|BEHAVIORAL|Behavior counseling only|Participants assigned to the control group will receive behavior counseling only. They will complete the same number of study visits as their counterparts in the intervention groups.
214999681|NCT07124364|BEHAVIORAL|Benson Relaxation Technique|The Benson Relaxation Technique is a structured relaxation method involving the repetition of a word, sound, or phrase while sitting quietly in a comfortable position with eyes closed, combined with passive muscle relaxation. In this study, it will be delivered in weekly 30-minute group sessions for 8 weeks by a trained instructor. Participants will be instructed to practice the technique daily at home for 10-15 minutes.
214999682|NCT07124364|BEHAVIORAL|Mindfulness-Based Stress Reduction Meditation|Mindfulness-Based Stress Reduction meditation is a practice focusing on cultivating awareness of the present moment through seated meditation and mindful breathing. In this study, participants will attend weekly 30-minute group sessions for 8 weeks, guided by an experienced instructor. They will also be encouraged to perform daily mindfulness meditation at home for 10-15 minutes.
214999683|NCT07124364|BEHAVIORAL|Breathing Therapy|Breathing therapy consists of guided breathing exercises designed to promote relaxation, reduce stress, and improve psychological well-being by regulating breathing patterns. In this study, participants will attend weekly 30-minute group sessions for 8 weeks, led by a trained facilitator. Daily home practice of slow deep breathing techniques for 10-15 minutes will be encouraged.
214502168|NCT04205903|DRUG|Nilotinib|Given PO
214502169|NCT04205903|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO on cycle 1 Days 7, 14, 15 once a day 24 hours prior to the paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on days 8, 15.
214392358|NCT00547911|DRUG|Carbidopa|
214392359|NCT00547911|DRUG|Entacapone|
214392360|NCT02254096|DRUG|BIRT 1696 BS|
214392361|NCT02254096|DRUG|Placebo|
214392362|NCT02254096|OTHER|Grapefruit juice (GFJ)|
214392363|NCT02254096|OTHER|High fat meal (HFM)|
214392364|NCT01539174|BIOLOGICAL|rituximab|Given IV
214392365|NCT01539174|DRUG|cyclophosphamide|Given IV
214392366|NCT01539174|DRUG|doxorubicin hydrochloride|Given IV
214392367|NCT01539174|DRUG|vincristine sulfate|Given IV
214392368|NCT01539174|DRUG|prednisone|Given PO
214392369|NCT01539174|OTHER|laboratory biomarker analysis|Correlative studies
214392370|NCT01539174|OTHER|pharmacological study|Correlative studies
214392371|NCT00655330|DRUG|Valsartan|Valsartan (160mg/day)
214392372|NCT00655330|DRUG|Placebo|Placebo
214502170|NCT04205903|DRUG|Paclitaxel|Given IV weekly on days 1, 8, 15, of every 21 days, at a starting dose of 80mg/m2
214502171|NCT04205903|OTHER|Questionnaire Administration|Ancillary studies
214502172|NCT03684993|DRUG|Arabic, Gum|natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
214502173|NCT03684993|DRUG|Licorice Root|natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
214502174|NCT03684993|DRUG|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
214999684|NCT07124208|DEVICE|Biophoton Generators|Biophoton Generators will be placed around the subject's bed and used during the night sleep during the entire study period.
214999685|NCT07124936|DRUG|HDM2005|HDM2005 will be administered as an intravenous injection.
214392373|NCT00655330|DRUG|Probucol|Probucol (750mg/day)
214392374|NCT05372679|DEVICE|Renal denervation|The TIVUS system will be used for renal denervation
214392375|NCT03241524|OTHER|Exercise program for pelvic muscle floor|Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
214392376|NCT01550835|DEVICE|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Standard of care use of an embolic protection device
214392377|NCT01550835|DEVICE|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
214392378|NCT01483157|OTHER|vascular occlusion with exercise trainig|twelve weeks of resistance training with vascular occlusion twice a week
214392379|NCT01483157|OTHER|high intensity resistance training|twelve weeks of resistance training twice a week
214999686|NCT07124936|DRUG|Rituximab or Rituximab biosimilar|Rituximab or Rituximab biosimilar will be administered as an intravenous injection.
214999687|NCT07124936|DRUG|Gemcitabine|Gemcitabine will be administered as an intravenous injection.
214999688|NCT07124936|DRUG|Oxaliplatin|Oxaliplatin will be administered as an intravenous injection.
214999689|NCT07124936|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous injection.
214999690|NCT07124936|DRUG|Doxorubicin|Doxorubicin will be administered as an intravenous injection.
214999691|NCT07124936|DRUG|Prednisone|Prednisone will be administered orally.
214392380|NCT01644474|DRUG|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
215094238|NCT02220751|DRUG|non-surgical periodontal therapy + systemic doxycycline|"A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group."
215094239|NCT02220751|PROCEDURE|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
214392381|NCT01644474|DRUG|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
214392382|NCT01644474|DRUG|Placebo (for Alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
214392383|NCT01644474|DRUG|Placebo (for Ezetimibe)|One capsule orally once daily at approximately the same time of the day with or without food..
214999692|NCT04972760|DRUG|Baricitinib|Baricitinib, 4 mg/d, oral route for 24 weeks
214999693|NCT04972760|DRUG|Placebo|Placebo, 4 mg/d, oral route for 24 weeks
214999694|NCT06611813|DRUG|Neoadjuvant Chemotherapy in Combination with Toripalimab|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
214999695|NCT06611813|DRUG|HR+ HER2 breast cancer|During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant therapy and postoperative adjuvant therapy for a total of 1 year.
214999696|NCT06675864|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
214999697|NCT06857435|PROCEDURE|Full Thickness Skin Graft (FTSG)|Full thickness skin in FTSGs are harvested by different means by surgeon preference and standard of care. Typically an area of skin with matching color and texture to the site which needs reconstruction is identified from a hidden and/or non-cosmetic area and collected via excision. After excision the donor site is closed and the graft is thinned by using a scalpel or scissors to remove excess fat or other soft tissues from the deep surface before being placed in the donor site.
215094240|NCT01264614|BEHAVIORAL|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
215094241|NCT00273845|BEHAVIORAL|Motivational interviewing|One session
215094242|NCT00273845|BEHAVIORAL|Strengths-Based Case Management|5 sessions
214392384|NCT02604732|PROCEDURE|Laparoscopic inguinal hernia repair with perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
214392385|NCT02604732|PROCEDURE|Laparoscopic inguinal hernia repair without perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
214392386|NCT04286230|BEHAVIORAL|Adherence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
214392387|NCT04286230|BEHAVIORAL|Persistence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
214392388|NCT03787290|DRUG|Tocilizumab|participants will receive a single subcutaneous injection of tocilizumab (162 mg)
214392389|NCT03787290|DRUG|Placebo|participants will receive a single subcutaneous injection of saline
214392390|NCT03787290|DEVICE|Whole-Body Hyperthermia|subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
214392391|NCT04898842|OTHER|Dietary intervention|To determine whether a 4 stage bowel obstruction diet as a means of managing oral intake in patients symptomatic with malignant sub-acute bowel obstruction (SBO) is deliverable and effective in clinical practice.
214392392|NCT03457272|OTHER|New risk assessment|"Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles."
214999698|NCT06857435|PROCEDURE|Base of wound fat graft with Split Thickness Skin Graft (STSG) Reconstruction (Autologous Layered Composite Grafting).|Autologous Layered Composite Grafting consists of the layered strategy of simultaneous fat and skin grafting. Fat is harvested by minimally invasive liposuction and applied directly to the wound base without any chemical or biologic processing. Skin is harvested as a split thickness skin graft by dermatome and applied over the layer of adipose tissue.
214999699|NCT06998875|DRUG|Tofacitinib and Acitretin Capsules.|The same with Arms.
214392393|NCT05783674|OTHER|Brain Breaks® Video Exercises|A total of at least 140 Brain Breaks® videos, each 3-4 minutes long, aerobic exercises including wide joint movements, movements specific to different sports branches such as yoga and volleyball, basketball, football, tennis, karate, judo, and warm-up-cooling movements. It includes national dances of different cultures. Horon, Zeybek, Scarf dance, morning gymnastics in Ürgüp Göreme, dribbling (volleyball, basketball), Pilates ball, and core area exercises. In each session, 2 videos will be applied and each will be repeated 2-3 times, and a 3-minute rest break will be given between each video. The total session will last for 20-30 minutes on average and physical activity will be performed twice a week, for a total of 8 weeks, 16 sessions.
214392394|NCT05783674|OTHER|Posture training|All participants, as the BB Video Exercise and Control Group, will be given a 20-minute hands-on training on the importance of proper posture once at the beginning of the study, and breathing control training will be given to maintain proper sitting, standing, lying postures, and proper posture.
214392395|NCT04453397|DRUG|TNB-383B|TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
214999700|NCT06998875|DRUG|Acitretin Capsules.|The same with Arms.
214999701|NCT07002125|OTHER|Whole Body Vibration|Each exercise session will be performed with a frequency of 30 Hz and an amplitude of 2 mm. Participants are in a 110° squat position on the platform (the degree will be adjusted using a goniometer). Participants will exercise for 16 minutes from week one to week three, 20 minutes from week four to week six and 24 minutes from week seven to week eight, respectively (8 iterations and 1 minute of vibration with 1 minute interval between each iteration)
214999702|NCT07002125|OTHER|Aerobic Exercise|From week one to week three, from week four to week six and from week seven to week eight, the participants will exercise for 30 minutes (5 minutes of running at 60-70% of heart rate and 5 minutes of active rest at 30-45% of maximum heart rate), 42 minutes (7 minutes of running at 60-70% of heart rate and 7 minutes of active rest at 30-45% of maximum heart rate) and 60 minutes (10 minutes of running at 60-70% of heart rate and 10 minutes of active rest at 30-45% of maximum heart rate). The exercise sessions consist of warm-up, main program and cool-down phases.
214999703|NCT07001241|BEHAVIORAL|Telehealth Exercise Program|BfitBwell-TP is a 12-week telehealth exercise intervention. Exercise prescriptions are created, personalized, and delivered by Cancer Exercise Specialists. Exercise content is delivered using a combination of videoconference sessions and a commercial personal training application (accessible via smartphone or internet browser). Patient-reported symptoms (specifically cancer-related fatigue) are assessed every two weeks via emailed surveys. Survey scores are compared to a reference chart of predicted improvements during the program, developed from an established clinical exercise oncology program. Additional videoconference sessions are initiated for participants demonstrating lower than expected symptom improvement, with the goal of adapting the current exercise prescription to improve symptom response.
214999704|NCT03194893|DRUG|Alectinib|Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
214999705|NCT03194893|DRUG|Crizotinib|Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
215094243|NCT02776033|DRUG|GSK2982772|GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
215094244|NCT02776033|DRUG|Placebo|Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
214392396|NCT02751463|DRUG|Sunscreening Sport Spray Rest (BAY987519)|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
214392397|NCT02751463|OTHER|Untreated skin|One site is patched without treatment as control
214392398|NCT02023879|DRUG|Alirocumab|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
214392399|NCT02023879|DRUG|Placebo (for Alirocumab)|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
214392400|NCT02023879|DRUG|Non-statin LMT|Ezetimibe or Fenofibrate at stable dose as background therapy.
214392401|NCT02023879|OTHER|Diet Alone|Stable cholesterol-lowering diet as background therapy.
214392402|NCT02101099|DEVICE|Colonoscopy Force Monitor|Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
214392403|NCT01404611|DRUG|DF289|Ear drops
214392404|NCT01404611|DRUG|DF277|Ear drops
214392405|NCT01404611|DRUG|DF289 plus DF277|Ear drops
214392406|NCT05433402|DRUG|ChlorproMAZINE 50 MG|The experimentall group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours) plus choloropromazine 50 mg daily for 6 months
214392407|NCT05433402|DRUG|Control|The control group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours)
214392408|NCT02758574|PROCEDURE|CDT without ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.
214392409|NCT02758574|PROCEDURE|CDT with ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.
214392410|NCT06382909|DIETARY_SUPPLEMENT|Inflammatory level|Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage
214392411|NCT06382909|DIETARY_SUPPLEMENT|Cognitive assessment|Neurological assessment Psychiatric assessment
214392412|NCT06382909|DIETARY_SUPPLEMENT|Pedagogical assessment|Sociopedagogical assessment
214392413|NCT02044458|DEVICE|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
214392414|NCT03363659|DRUG|Disulfiram|Disulfiram is taken orally, twice daily.
214392415|NCT03363659|DIETARY_SUPPLEMENT|Copper gluconate|Copper gluconate is taken orally, twice daily
214392416|NCT03363659|DRUG|Temozolomide|Temozolomide is taken once daily
214392417|NCT00880308|DRUG|LDE225|
214392418|NCT03141710|DIETARY_SUPPLEMENT|20 ml of prebiotic per day|12 volunteers will take 20ml of prebiotic per day for 12 weeks
214392419|NCT06625164|OTHER|exercise|core stabilization exercises
214392420|NCT06625541|DRUG|AJ302-IM|7 cohorts (7 dose levels) of participants are planned to be dosed.
214392421|NCT06625541|DRUG|Placebo|Matching placebo
214999706|NCT06277258|OTHER|Patient Empowerment model|"Session I~* Knowledge about the disease, calories \& diet distribution, physical activities, symptoms of hypoglycemia, Blood Glucose target etc.~* Training on use of glucometer and record keeping Session II~* Evaluation and interpretation of sugar level based on the sugar chart.~* Tuning of diet and exercise if needed.~* Discussion about the challenges faced by the patient during maintenance of sugar level.~Session III \& ongoing~* Tuning of the diet based on calories, evaluation of the understanding~* Assessment of patient satisfaction~* Assessment of patients' knowledge and skill to designate her as Empowered~Assurance and counseling of patient and family will be rendered in each session."
215094245|NCT00531583|DRUG|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
215094246|NCT02792998|DRUG|IW-1701|IW-1701 Tablet
214392422|NCT06625996|DIETARY_SUPPLEMENT|carbohydrate loading|Preoperative carbohydrate loading
214392423|NCT03872388|DRUG|Atorvastatin|"Patients will receive Atorvastatin per ASCVD guidelines dosed as either a moderate intensity (20mg/day) or high intensity statin (80mg/day). Tablets are available in either 20mg or 80mg and will be dispensed as per standard of care for up to 24 months as part of the study.~Patients may also receive capecitabine concurrently with Atorvastatin per physician discretion as standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day."
214392424|NCT03872388|DRUG|Capecitabine|Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
214392425|NCT06624917|PROCEDURE|Green Breast Surgery Protocol|A perioperative protocol aiming at reducing environmental impact of surgery, and fast recovery protocol to reduce hospitalization.
214392426|NCT05929846|OTHER|Back to Living Well Program|The Back to Living Well program (BLW), a sustainable community-based program for persons with persistent mild to moderate LBP. The goal of the intervention is to provide an opportunity for community dwelling persons with persistent mild to moderate LBP to learn how to safely engage in exercise and become active self-managers. The 12-week program will engage participants in weekly exercise sessions, education and self management sessions, and encourage independent exercise at least 1x per week. All participants will be encouraged to complete an action plan and watch online education videos weekly.
215094247|NCT02792998|DRUG|Placebo|Matching Placebo Tablet
214392427|NCT01040780|DRUG|Icotinib|125 mg three times daily (375 mg per day) by mouth
214392428|NCT01040780|DRUG|Gefitinib|250 mg every 24 hours by mouth
214392429|NCT05407168|OTHER|Best Practice|Receive standard of care
214392430|NCT05407168|OTHER|Health Promotion and Education|View decision aid
214392431|NCT05407168|OTHER|Questionnaire Administration|Ancillary studies
214392432|NCT04876560|OTHER|Application of CDSS to provide nutritional care in breast cancer patients from home|A personalised dietary plan was implemented by the CDSS. The CDSS estimated body mass index (BMI) and Total daily Energy Expenditure (TEE) according to individual's incorporated data. For overweight and obese patients, the CDSS produced a hypocaloric diet, in which daily energy intake was less than TEE by approximately -500 kcal/day. Nutrient distribution was in line with the Mediterranean dietary pattern. Patients received individual login passwords to CDSS allowing access to their personal profile from home. During the trial, patients were instructed to record food diaries in the CDSS every week, which were also made available to the dieticians. Visiting the CDSS, patients had the opportunity to track their progress e.g. monitoring goals of body weight, physical activity, consumption of fruits, vegetables, legumes.
214999707|NCT05984537|DRUG|Bivalirudin|Participants in the bivalirudin group received a one-time intravenous injection of 0.75 mg/kg during PCI, and then received a continuous intravenous infusion of 1.75 mg/kg/h for 4 hours according to the participants' condition after PCI.
214999708|NCT05984537|DRUG|standard heparin|Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.
214999709|NCT05743140|DIAGNOSTIC_TEST|CaIMR|Investigators diagnose CMD with CaIMR. Investigators use OCT and OCTA to analyze the fundus microcirculation quantitatively.
214999710|NCT02487134|DEVICE|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
214999711|NCT02487134|DEVICE|Control|Closure of the abdomen with conventional technique
215094248|NCT00584571|PROCEDURE|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
214999712|NCT05628324|BEHAVIORAL|practice muscle activation patterns|practice upper limb muscle activation patterns using EMG-controlled games
214999713|NCT05628324|BEHAVIORAL|task practice|practice functional upper limb tasks
215094249|NCT00584571|DRUG|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
215094250|NCT05956509|BIOLOGICAL|ABBV-950|Intramuscular (IM) Injection
214392433|NCT04876560|OTHER|General lifestyle advice to breast cancer patients by phone|General lifestyle guidelines were provided by phone and food diaries were sent via emails.
214392434|NCT00802737|DRUG|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
214392435|NCT02711072|DRUG|control group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
214392436|NCT02711072|DRUG|infiltration group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
214392437|NCT02955433|OTHER|Rideshare-based transportation|
214392438|NCT03677128|OTHER|mNavigator|Allied health providers at BMC will use mNavigator to facilitate compliance with protocol-driven treatment and reduce patient abandonment for patients diagnosed with Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.
215094251|NCT05956509|BIOLOGICAL|BOTOX|Intramuscular (IM) Injection
215094252|NCT05956509|DRUG|Placebo for ABBV-950|Intramuscular (IM) Injection
214392439|NCT00890643|DRUG|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
214392440|NCT00890643|DRUG|placebo|placebo
214392441|NCT05793762|DEVICE|Left virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual left hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
214999714|NCT06693661|OTHER|Kidney Health Coaching|"The intervention entails support from a KHC that includes:~* An initial rapport-building call~* Ongoing telephone support at least twice a month for six months~* Meeting the patient at all in-person clinic appointments~* Documenting interactions in the EMR using a customized platform~Telephone support begins with a social determinants of health (SDoH) screening tool to identify barriers and facilitators to CKD self-management and appointment adherence. This tool provides access to local resources based on the patient's ZIP code. Subsequent calls will follow up on resource usage, review CKD educational materials and treatment options, complete the Decision Aid for Renal Therapy tool, and facilitate communication through the patient portal. Each call will start with specific goals (e.g., review National Kidney Foundation CKD materials) and conclude with goals for the next session."
214999715|NCT06693661|OTHER|Usual Care|"ER Discharge (d/c): Patients may receive consultations and support from Care Management in the ER such as transportation or medication assistance. Follow-up by a social worker varies post-discharge.~Hospital d/c: All hospitalized patients are assessed by the care management team to identify psychosocial needs and begin discharge planning, which may include follow-up appointments and resources. High-risk patients receive additional follow-up from a care transitions coordinator for 30 days post-discharge.~Primary Care: Patients in primary care clinics have access to various support services. Those recently hospitalized or identified as high-risk receive care coordination from social workers. Internal referrals are managed by referral coordinators, while external referrals come from clinic staff. Discharge information is provided after visits.~Nephrology: There are no coordinated support services for chronic kidney disease (CKD) patients receiving nephrology care."
214999716|NCT06683352|BIOLOGICAL|Investigational Influenza Vaccine|Investigational Influenza Vaccine
214999717|NCT06683352|BIOLOGICAL|COVID-19 Vaccine|Pfizer-BioNTech COVID-19 Vaccine
214999718|NCT06683352|COMBINATION_PRODUCT|Influenza and COVID Combination Vaccine|Combined investigational influenza and Pfizer-BioNTech COVID-19 Vaccine
214999719|NCT06683352|BIOLOGICAL|Licensed Influenza Vaccine 1|Licensed Influenza Vaccine 1
215094253|NCT02391532|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
215094254|NCT02391532|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
214392442|NCT05793762|DEVICE|Right virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual right hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
214999720|NCT06683352|BIOLOGICAL|Licensed Influenza Vaccine 2|Licensed Influenza Vaccine 2
214999721|NCT06683352|OTHER|Placebo|Saline
214392443|NCT01706211|DRUG|BRL 49653C|BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
214392444|NCT01706211|DRUG|Placebo|
214392445|NCT04435795|DRUG|Normal Saline intranasal and placebo inhaler|Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
214392446|NCT04435795|DRUG|Ciclesonide|Ciclesonide 600mcg BID inhaled with aero chamber
214999722|NCT06696053|OTHER|Transversal therapeutic education|Additional patient consultation for therapeutic education with nurses.
214392447|NCT04435795|DRUG|Ciclesonide nasal|intranasal ciclesonide 200 mcg DIE
214392448|NCT03864926|DRUG|Envarsus XR|"Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR."
214392449|NCT03864926|DRUG|Tacrolimus|Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
214502175|NCT06623773|DRUG|Chondroitin sulfate|Chondroitin sulfate (CS) is a natural biomacromolecule belonging to the class of glycosaminoglycans and is an unbranched complex polysaccharide consisting of a repeating disaccharide structure of glucuronic acid and N-acetyl-D-glucosamine \[18\]. It is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans. Oral bioavailability of CS has been demonstrated \[19\], and its use for the treatment of OA has been established in animal models \[20\], as well as in clinical trials \[21, 22\]. CS, is available as a pharmaceutical grade drug (Structum®), meaning that the product is manufactured under Good Manufacturing Practices (GMP) conditions, and is in excess of 99% purity with no binders, fillers, excipients, dyes, or unknown substances. According to the Instructions for Use (IFU), the recommended posology for Structum® is 500 mg twice daily.
214502176|NCT06346093|PROCEDURE|Fecal Microbiota Transplantation Capsules|FMT Capsules in Combination with Chemotherapy and Anti-PD1/PD-L1 Therapy
214999723|NCT04950686|BEHAVIORAL|Media Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.
214999724|NCT04950686|BEHAVIORAL|Health Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
214999725|NCT06627504|BEHAVIORAL|Sleep Health and Circadian Timing Intervention|Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.
214392450|NCT00445601|DRUG|gemcitabine hydrochloride|Given intravesically
214392451|NCT00445601|OTHER|placebo|Given intravesically
214392452|NCT05377710|PROCEDURE|sinus lift with lateral approach|Maxillary sinus floor augmentation or sinus lift is a surgical procedure, which provides a solution to the problem of sinus bone loss (too thin), and thus increases the thickness of the bone for immediate or subsequent implant placement in the premolars and molars (4). It consists of the elevation of the sinus mucosa that lines the maxillary sinus. The space thus freed will be filled with a bone filling material
214502177|NCT06346093|PROCEDURE|Placebo|Mainly composed of starch, the appearance, shape, color, and size are exactly the same as FMT capsules
214502178|NCT03199404|DEVICE|TRAP|Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
214999726|NCT06827509|DIAGNOSTIC_TEST|Ultrasound-based flow imaging|Ultrasound-based flow imaging (based on blood speckle tracking) of the carotid artery will be acquired at 6-8 weeks after surgery.
214999727|NCT05849740|DRUG|Daratumumab and corticosteroid treatment|Daratumumab and corticosteroid treatment
214999728|NCT07021443|OTHER|non-interventional|non-interventional
214999729|NCT07024563|DRUG|Ravulizumab|Participants will receive Ravulizumab via intravenous (IV) infusion.
214999730|NCT02184013|PROCEDURE|Catheter ablation|Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).
214999731|NCT05931380|DRUG|Orforglipron|Administered orally
214999732|NCT05931380|DRUG|Placebo|Administered orally
214999734|NCT07029568|DRUG|NNC0705-0001|NNC0705-0001 will be administered orally.
214999735|NCT07029568|DRUG|Placebo|Placebo matching NNC0705-0001 will be administered orally.
215094255|NCT05516849|DRUG|Oxandrolone|Oxandrolone is a synthetic anabolic androgenic steroid that induces its responses by binding to androgen receptors which modulates gene expression to increase protein synthesis and efficient utilisation of amino acids. Oxandrolone was first synthesized in 1962 through 17alpha-alkylation of testosterone resulting in a formal composition of (4bS,7S,9aS,9bR,11aS)-tetradecahydro-7-hydroxy-4aS,6aS,7-trimethyl- cyclopentanaphthopyran-2(1H)-one and molecular formula of C19H30O3.
215094256|NCT05516849|OTHER|Placebo|As there is currently no approved medication to aid in soft-tissue regeneration, we will be using a placebo control.
215094257|NCT04159532|DIETARY_SUPPLEMENT|MAG-EPA/MAG-DHA|monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
214392453|NCT03764358|DEVICE|Arteriovenous Fistula|Surgical implantation of an arteriovenous fistula for hemodialysis
214392454|NCT03764358|DEVICE|Tunneled Cuffed Catheter|Placement of a tunneled cuffed catheter in surgical theatre
214999736|NCT07024082|OTHER|Land-based Liuzijue exercise|This group includes 40 patients.Will be Performed twice a week from 9:00 to 10:00 a.m. in the rehabilitation department of Shanghai Yue-Yang Hospital under the guidance of an experienced instructor. The LG exercise program consisted of three parts: (1) Warm ups: 5-10 min of stretching and joint activity covering the limbs, neck, and trunk; (2) Land-based Liuzijue exercise: Liuzijue exercise consist of six distinct sounds (xu, he, hu, si, chui, and xi) and corresponding movements was performed with the knees in a semi-flexed position for 45 min; and the time to complete an intact Liuzijue exercise lasts 12-15 min; (3) Cool down: regulate breathing and relax muscles including flap and stretch muscles for 5-10 min.
214999737|NCT07024082|OTHER|Water-based Liuzijue exercise|"This group includes 40 patients. Water-based Liuzijue exercise will be performed twice a week, from 1:00-2:00 p.m., between June and September 2016, in the thermostatic swimming pool located at Shanghai University of Sport (Shanghai, China). The temperature of swimming pool was between 26°C and 30°C, while the temperature of air was between 30°C and 34°C, and the relative humidity was between 60% and 80%. Circulating water purification and disinfection equipment coordinated with chlorine disinfectant was used to sterilize the pool water. The participants were immersed in water to a level between their xiphisternum (lowest part of the sternum) and clavicles. Water-based Liuzijue exercise requires that participants remain awake and have eaten no sooner than 1 h prior to entering the pool to exercise. The WG exercise program consisted of three parts similar with LG:~(1) Warm ups; (2) Water-based Liuzijue exercise; and (3) Cool down."
214999738|NCT05504811|DEVICE|FitMi AD|Exercise using the motion sensing devices and a tablet computer
214999739|NCT05504811|OTHER|Conventional exercise program|Exercise following printed sheets or booklet
214999740|NCT06004830|DRUG|Spironolactone|All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
214999741|NCT06698796|DRUG|Dazukibart|anti-interferon beta therapy
214999742|NCT06160531|DRUG|CC-42344|Anti-influenza A agent
214999743|NCT06160531|DRUG|Placebo|Matching placebo
214999744|NCT06141005|DIAGNOSTIC_TEST|Ultrathin bronchoscopy with intratumoral washing|Each subject suspected or diagnosed of lung cancer will undergo bronchoscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
214999745|NCT05856331|DRUG|SAR447537|A1PI, Recombinant, Bivalent Fc Fusion Protein
214999746|NCT05856331|DRUG|Zemaira|Alpha1-Proteinase Inhibitor (Human)
214999747|NCT05935410|BEHAVIORAL|DM Social Needs|6-monthly sessions of telephone delivered, manualized education and skills training on diabetes management, and problem solving and resolution of social needs.
214999748|NCT05935410|BEHAVIORAL|Usual Care|Diabetes education materials in accordance with recommendations from the American Diabetes Association (ADA) will be mailed monthly.
214392455|NCT04944225|OTHER|Opioid Reduction Strategy|The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
214392456|NCT02026713|OTHER|quit smoking for a 2 weeks period|evaluate the platelet reactivity after 15 days by quit smoking
214392457|NCT00074074|BIOLOGICAL|infliximab|
214392458|NCT04378634|BEHAVIORAL|Exercise|Sub-maximal exercise test
214392459|NCT04378634|OTHER|Mental Stress Test|Computerised mental arithmetic challenges and social evaluative threat tasks
214999749|NCT07030959|DRUG|AUBE00|AUBE00 as an oral administration
214999750|NCT07030452|DEVICE|Laser Acupuncture|Laser acupuncture irradiation was performed using an RJ Laser laserpen with a wavelength of 785 nm and an output power of 50 mW. The laser probe was positioned perpendicularly to the skin surface, using a continuous wave mode with a dose of 4 Joules. The acupuncture points targeted were EXB1 and CV17, as well as BL13 and ST36 on both sides of the body. Each point received irradiation for 1 minute and 20 seconds. During the therapy session, subjects wore a headset playing music and protective glasses. The treatment was administered twice a week for a total of 8 sessions.
214999751|NCT07030452|DEVICE|Sham Laser Acupuncture|Sham laser acupuncture irradiation was conducted using an RJ Laser laserpen with a wavelength of 785 nm and an output power of 50 mW at the acupuncture points EXB1 and CV17, as well as BL13 and ST36 on both sides of the body. However, the laser device was not activated, and no radiation was delivered to the patient. The laser probe was positioned perpendicularly to the skin surface at the same acupuncture points, but without activating the laser. During the session, subjects wore a headset with music and protective glasses, similar to the active treatment group. The sham treatment was administered twice a week for a total of 8 sessions.
215094258|NCT04159532|DIETARY_SUPPLEMENT|TG-EPA/TG-DHA|Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
215094259|NCT04159532|DIETARY_SUPPLEMENT|EE-EPA/EE-DHA|Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
214392460|NCT01345643|OTHER|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
214392461|NCT01345643|OTHER|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
214392462|NCT03260361|OTHER|Hypnosis, kinesitherapy, MEOPA|classical intervention
214392463|NCT03260361|OTHER|Usual practice|Usual practice with treatments and physio
214392464|NCT00341640|PROCEDURE|Blood testing|
214392465|NCT04683471|DEVICE|Stimulator|Neuromodulation
214392466|NCT04683471|DEVICE|Sham|Sham
214392467|NCT01150578|DRUG|No intervention|No intervention
214392468|NCT03340155|OTHER|Photo(chemo)therapy|Treatment with photo(chemo)therapy, including UVB, UVA, PUVA and photopheresis
214392469|NCT05638880|DRUG|Valsartan 80 mg|Valsartan is an angiotensin receptor blocker.
214392470|NCT05638880|DRUG|Empagliflozin 10 MG|Empagliflozin is an oral hypoglycemic drug.
214392471|NCT05638880|DRUG|Levocetirizine|Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
214392472|NCT02895490|OTHER|educational intervention|Receive a DVD containing educational information and communication skills
214392473|NCT02895490|OTHER|communication skills training|Receive a DVD containing educational information and communication skills
214999752|NCT06877624|DRUG|QRL-101|This cross-over design study will evaluate three formulations (Formulations 1, 2, and 3) of QRL-101, beginning in a fasted condition before moving to a fed cross-over design.
214999753|NCT06693843|DRUG|Aleniglipron or Placebo|Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
214392474|NCT02895490|OTHER|educational intervention|Receive information about the LINC group
214392475|NCT02895490|OTHER|questionnaire administration|Ancillary studies
214392476|NCT02895490|OTHER|quality-of-life assessment|Ancillary studies
214392477|NCT03450213|DEVICE|Pentacam|Pentacam will be used to measure the magnitude and axis orientation of anterior and posterior corneal astigmatism.
214392478|NCT04481516|OTHER|Yoga|SKY Yoga
214392479|NCT05924490|BEHAVIORAL|Real-time strategy-based videogame training|Rise of Nation is a complex strategy-based video game, in which individualized-adaptive feedbacks are constantly given to players based on their performance.
214392480|NCT05924490|BEHAVIORAL|Semantic Knowledge training|Packages of various cross-word puzzles include word search, word ladder, and word wheel.
214392481|NCT02543723|BEHAVIORAL|Nurse Coach Intervention|Participants randomized to the intervention 2 group a tailored nurse coach component. Participants will receive an initial session conducted by the nurse coach, via phone or in-person. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
214392482|NCT04238221|DRUG|Doxofylline|Patients will receive a 4-week treatment with doxofylline 400 mg bid, in addition to their chronic usual inhalation therapy.
214392483|NCT01300429|GENETIC|obtain tissue specimens|One core biopsy specimen will be placed in formalin and processed for cytogenetic and FISH analyses as well as DNA for ALK sequencing. The second core biopsy specimen will be immediately frozen in liquid nitrogen and stored in a -80 degree freezer for research specimen. Collection will be performed on-site at the time of the procedure.
214392484|NCT02259920|DRUG|KUC 7483 CL, immediate release tablet|
214392485|NCT02259920|DRUG|KUC 7483 CL, particulate formulation|
214392486|NCT02259920|DRUG|KUC 7483 CL, solution formulation|
214392487|NCT02259920|DEVICE|Enterion™ capsule|
214392488|NCT01326793|OTHER|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
214392489|NCT02083003|DIETARY_SUPPLEMENT|Polyamine low-diet|
214392490|NCT02083003|DIETARY_SUPPLEMENT|Liberal alimentation|
214392491|NCT00273962|DRUG|ipratropium plus salbutamol UDV|
214392492|NCT00273962|DRUG|salbutamol UDV|
214392493|NCT02348437|PROCEDURE|Repair|An on-going suture technique with minimum four stitches.
214392494|NCT02348437|PROCEDURE|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
214392495|NCT00730990|OTHER|Positron Emission tomography|Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
214502179|NCT06061744|OTHER|Minimally invasive surgery|laparoscopic or robotic surgical approach for the treatment of gallbladder cancer
214999754|NCT06693843|DRUG|Aleniglipron or Placebo|Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
214999755|NCT06693843|DRUG|Aleniglipron or Placebo|Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
214392496|NCT00730990|DRUG|PET Scan with PF-03654746|If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
214392497|NCT00730990|DRUG|PET Scan with PF-03654746|If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
214392498|NCT00730990|DRUG|PET Scan with PF-03654746|"Part 2 of the study will have 3 possible interventions:~1\) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg)."
214392499|NCT02450773|DRUG|Furosemide|40 mg furosemide on postpartum day 1-6
214392500|NCT02450773|DRUG|Potassium chloride|20 meq potassium chloride on postpartum day 1-6
214392501|NCT02450773|DRUG|Placebo #1|Placebo (for furosemide)
214392502|NCT02450773|DRUG|Placebo #2|Placebo (for KCl)
214392503|NCT03840837|DRUG|Rivastigmine transdermal patch|Titration of transdermal rivastigmine, as per arm description.
214392504|NCT01877096|BEHAVIORAL|Motivational Interviewing|A brief motivational interviewing session
214392505|NCT01877096|BEHAVIORAL|Attention Control|Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
214392506|NCT04157790|OTHER|CARE score|CARE score calculation
214999756|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
214999757|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
214999758|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
214999759|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
215094260|NCT04788771|PROCEDURE|Tracheal intubation in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
214392507|NCT00556348|DRUG|bevacizumab|1.25mg
214392508|NCT01506492|BEHAVIORAL|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
214392509|NCT01456858|OTHER|Insecticide Treated Polyethylene Sheeting|Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
214392510|NCT01456858|OTHER|Untreated Plastic Sheeting|Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
214392511|NCT06203444|DRUG|Tenapanor|The study drug will be administered in dose of 50 mg bid
214502180|NCT01605409|PROCEDURE|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
214502181|NCT01605409|PROCEDURE|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
214502182|NCT01728974|OTHER|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
214502183|NCT06294223|DEVICE|Exercise follow up with near-infrared spectroscopy|Exercises will be followed by near-infrared spectroscopy. Fatigue protocol will be applied.
214502184|NCT06492304|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
214502185|NCT00002748|BIOLOGICAL|gene-modified tumor cell vaccine therapy|
214502186|NCT00002748|BIOLOGICAL|interleukin-2 gene|
214999761|NCT07032077|DRUG|HRS-7058|HRS-7058 combimed with antitumor drugs
214999762|NCT06877533|DRUG|EOS006215|Multiple doses of EOS006215
214999763|NCT06877533|DRUG|Anticancer agent|Multiple doses of EOS006215 in combination with other anticancer agents
214999764|NCT06701006|OTHER|Integrated skills and safety planning app|This is a digital app that includes supported safety planning resources in clinic as well as coping skills and lived experience videos for adolescents, young adults and parents/caregivers that can be accessed in clinic or at home.
214999765|NCT06703983|OTHER|Low Glycemic index therapy|In intervention arm, patients will receive a low glycemic index diet(LGIT). The LGIT is a modified form of the ketogenic diet that restricts carbohydrate intake to sources with a glycemic index of less than 50. This diet provides approximately 60% of total calories from fat, 30% from protein, and 10% from carbohydrates.In the LGIT arm, there will be 20 participants who will follow a LGIT diet under the care of a Registered Dietitian and a Pediatric Neurologist. After three months, seizure outcomes will be categorized into the following groups: At the end of the study period, seizure outcomes will be analyzed and categorized into four groups: Seizure-free participants. Participants with \>90% seizure reduction. Participants with \>50% seizure reduction. Participants with \<50% seizure reduction (non-responders). Results will be analyzed and compared with Classic Ketogenic diet which serves as the standard dietary therapy for epilepsy.
214999766|NCT06703983|OTHER|Classic Ketogenic Diet|"This study includes two interventions: Low Glycemic Index Therapy(LGIT) and Classic Ketogenic diet(CKD) with the CKD used as a comparison.~There will have a total of 40 participants, randomly divided into two groups and each group would have 20 participants.~The randomization process will use the block randomization technique and will be conducted via a website.~Participants will first have a session with a pediatric neurologist and then meet with a Dietitian who will explain the ketogenic diet in detail for them.~The participants in the CKD group will follow a Classic Ketogenic diet where 90% of calories come from fats, 6% from proteins, and 4% from carbohydrates.~Patients receive the diet, and investigators will remain in online contact throughout the 3-month study, with monthly in-person visits for assessment and to ensure proper adherence to the diet.~The primary outcome will be the reduction in seizures, as reported by the participants' parents."
215094261|NCT02355951|OTHER|blood draw|
214392512|NCT04861922|DRUG|Unfractionated Heparin|10 unit/kgBW/hour continuous infusion for 5 days
214392513|NCT02064621|DRUG|Candesartan 32mg|Candesartan 32mg 1T, PO, QD for 9days
214392514|NCT02064621|DRUG|Candesartan 32mg/Amlodipine 10mg|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
214392515|NCT01625910|BEHAVIORAL|Behavioral counseling|Counseling of parents to improve their child's diet and physical activity
214392516|NCT02873299|OTHER|10 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
214392517|NCT02873299|OTHER|20 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
214392518|NCT02959138|DRUG|Lanraplenib.|20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1
214392519|NCT02391038|DRUG|MLN0264|MLN0264 IV.
214392520|NCT03024320|BEHAVIORAL|M2M|An eHealth platform has been designed to deliver a home-based package using the extensive set of movement patterns that have been adapted for people with a range of physical/mobility disability, called Movement-To-Music (M2M). The M2M prescription will be based on the participant's baseline level of health, function and fitness. Each movement pattern will be available in three different positions - standing, standing with support (chair) and seated. The duration of each M2M session will be gradually increased during the Adoption phase from three 20-minute sessions (10 min. aerobic \& 10 min. strength) during weeks 1 to 3 (60 min/wk), to 45-min sessions (30 min. aerobic \& 15 min. strength) during weeks 4 to 6 (135 min/wk), and to 50-min sessions (150 min/week) during weeks 7 to 12 (excluding 5-min warmup and 5-min cool down).
214392521|NCT03024320|BEHAVIORAL|Attention Control|Telecoaching on health-based topics, not including physical activity.
214502187|NCT03565484|DRUG|susceptibility guided therapy|Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
214502188|NCT03565484|DRUG|personal medication history guided therapy|Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
214502189|NCT03565484|DRUG|salvage treatment for failed eradication|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
214999767|NCT06703398|BIOLOGICAL|GC101 TIL|Patients with advanced melanoma (excluding uveal melanoma) who have failed to PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed; if NRAS mutation is present, tunlametinib have failed) and are ineligible for resection
214999768|NCT06703398|DRUG|dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin|monotherapy or combination of dacarbazine, temozolomide, paclitaxel, platinum or cisplatun, and the chemotherapy's dosage could refer to the drug label or the relevant treatment guideline, the final decision is up to investigator
214999769|NCT06878430|OTHER|Functional and Cognitive scores|We will collect information about prior neurological symptoms, including prior symptoms suggestive of TIA or stroke, cognitive or motor symptoms, blood pressure and other known vascular risk factors, medicines, frailty, functional status, education, and employment status We will collect a baseline validated function and cognitive score, and take a sample of speech. Speech will be measured at assessment, in collaboration with the NeuroCARE Clinical and Digital Measures Module (22/SS/0010 IRAS No. 310885).
214999770|NCT07032649|DRUG|Benzoyl Peroxide 10% Bar|Active ingredient for drug included. Blind identification by package number
214999771|NCT07032649|OTHER|Placebo|Placebo that looks like active treatment, blinded but available to ID via package number
214999772|NCT07033689|DEVICE|Suizenji (an ultrasound-guided HIFU therapy system)|Suizenji (an ultrasound-guided HIFU therapy system)
214999773|NCT07033689|DRUG|Nal-IRI/FL|Standard of care
214999774|NCT07033689|DRUG|mFOLFIRINOX adjuvant chemotherapy|standard of care
214999775|NCT07033689|DRUG|Gem/nab-PTX|standard of care
214999776|NCT07034677|DRUG|Indapamide 1.5 MG SR|14 days treatment with indapamide 1.5 mg/day compared to placebo
214999777|NCT07034677|DRUG|Placebo|14 days treatment with placebo
214999778|NCT07033897|BEHAVIORAL|Adapted HARP|The adapted HARP intervention includes two to three in-home visits conducted by an OT practitioner over approximately 5 weeks in the homes of PwD. At the end of the first home visit, solutions to remove the identified fall hazards will be determined collaboratively with the participant, using motivational interviewing to establish hazards and shared-decision making and tailoring to help the participant brainstorm solutions to remove the hazards. Participants will then receive one to two additional visits from the OT, and a contractor if needed, to implement solutions using a self-management approach, identifying any additional hazards and subsequent modifications if necessary. All adaptive equipment and modifications will be provided at no cost to the participant. Booster visit(s) will be completed 3-6 months after the initial treatment sessions to ensure the home modifications are still appropriate, troubleshoot any equipment issues and review the self-management process.
214999779|NCT07033663|DRUG|Monoclonal antibody|non-intervention. Drug used in clinical practice as per practitioner decision
214999780|NCT06711991|DRUG|TQC3927 powder for inhalation|TQC3927 is a targeted inhibitor
214392522|NCT02158650|BEHAVIORAL|Video-Based Informed Consent|
214392523|NCT02880449|BEHAVIORAL|Intervention|A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
214392524|NCT01463917|DRUG|Hypertonic solution|Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
214392525|NCT01463917|DRUG|Isotonic|Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
214392526|NCT06455761|DRUG|68Ga-DOTA-NI-FAPI04|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.
214999781|NCT06711991|DRUG|TQC3927 powder for inhalation placebo|A placebo without drug substance.
214999782|NCT06712316|DRUG|BNT327|Intravenous infusion
214999783|NCT06712316|DRUG|Pembrolizumab|Intravenous infusion
214999784|NCT06712316|DRUG|Carboplatin|Intravenous infusion
214999785|NCT06712316|DRUG|Pemetrexed|Intravenous infusion
214392527|NCT06455761|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
214999786|NCT06712316|DRUG|Paclitaxel|Intravenous infusion
214392528|NCT04880915|OTHER|surgical smoke affects|The study, experimental type, was conducted to investigate the effects of five different methods on surgical smoke protection.
214392529|NCT05360758|OTHER|Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia|Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia using laboratory tests, abdominal ultrasound, general condition of the patient and bone marrow
214392530|NCT02464111|OTHER|Treatment 1: Control|No supplement provided.
214392531|NCT02464111|DIETARY_SUPPLEMENT|Treatment 2: Bolus (LNS)|One LNS supplement provided in a single bolus dose in the morning
214392532|NCT02464111|DIETARY_SUPPLEMENT|Treatment 3: Divided Dose (LNS)|One LNS supplement provided in 3 separate portions throughout the study visit
214392533|NCT02873286|BIOLOGICAL|MVA-BN-RSV|MVA-mBN294B
214502190|NCT03637296|OTHER|Critical time intervention|Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
214392534|NCT02873286|OTHER|Placebo|Tris Buffered Saline, sterile
214392535|NCT03055585|BIOLOGICAL|Wolbachia-infected Aedes aegypti mosquitoes|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
214502191|NCT03604146|BEHAVIORAL|Medical quality control intervention strategy|Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
214502192|NCT03074656|OTHER|Therapeutic drug monitoring|Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
214502193|NCT03074656|OTHER|Standard care|Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
214502194|NCT03839550|COMBINATION_PRODUCT|Apatinib Mesylate +SHR-1210|"Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection."
214502195|NCT03839550|PROCEDURE|Hepatic Arterial Infusion(HAI)|Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
214502196|NCT04873206|OTHER|routine stain by H&E.|formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.
214999787|NCT06712641|DRUG|Gentamicin + narrow spectrum betalactam|Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
214999788|NCT06712641|DRUG|Cefotaxime|Empirical therapy for suspected community-acquired sepsis with cefotaxime
214392536|NCT03055585|OTHER|standard practice dengue control|standard practice dengue control activities conducted by dengue control program
214502197|NCT00124254|PROCEDURE|Silicone metacarpophalangeal joint arthroplasty|Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
214502198|NCT00124254|OTHER|Usual care|Non-surgical usual care
214502199|NCT03683576|DRUG|GB001|film-coated oral tablet
214502200|NCT03683576|DRUG|Placebo|film-coated oral tablet
214999789|NCT06712641|DRUG|Piperacillin-tazobactam|Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam
214999790|NCT06710509|BEHAVIORAL|Three Messaging Nudges|Patients in the Experimental Condition will receive a set of up to three email and text messages over the course of five days, while also receiving usual care which could include messaging from their practice or the electronic health record.
214999791|NCT06709053|DIAGNOSTIC_TEST|standing hight-based|The model equation for predicting double-lumen tube insertion depth using standing hight -based: Depth = 1.083 + 0.166×standing hight (cm)
214999792|NCT06709053|DIAGNOSTIC_TEST|sitting height-based|The model equation for predicting double-lumen tube insertion depth using sitting height ( depth = 0.32 × sitting height)
214999793|NCT06709053|DIAGNOSTIC_TEST|CT-based|The model equation for predicting double-lumen tube insertion depth using CT depth = 1.543 + 0.155\*standing hight,cm + 0.202\*Ds-c,cm
214392537|NCT05392387|OTHER|Standard antiviral therapy|pegylated interferon or/and nucleos(t)ide analogues
214392538|NCT01946243|DRUG|Florbetapir F18|No Florbetapir F 18 will be administered in this study.
214392539|NCT03149263|BEHAVIORAL|distraction|Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
214392540|NCT02023138|OTHER|Focus group|Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
214999794|NCT06710886|BEHAVIORAL|Augmented Theme|The music is augmented by embedding the natural rhythms of bodily functions (e.g. breathing, heart rate variability, vascular tone, etc) that signal the body to calm.
214392541|NCT02023138|OTHER|Wiki|A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
214392542|NCT05794919|DRUG|Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g|A generic product manufactured by Hainan Linheng Pharmaceutical Co., Ltd.
214392543|NCT05794919|DRUG|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®）produced by OM pharma S.A.
214392544|NCT05762536|DRUG|Darolutamide|Darolutamide 600 mg b.i.d. until the end of the last taxane cycle
214392545|NCT05762536|DRUG|Docetaxel or cabazitaxel|Docetaxel or cabazitaxel Q3W
214392546|NCT05103813|DRUG|Beraprost Sodium Tablets|Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial infarction
214392547|NCT00351923|BIOLOGICAL|MeMuRu-OKA (study vaccine)|
214392548|NCT00963989|DEVICE|Penumbra System|The Penumbra System is used to revascularize clotted cerebral blood vessels.
214392549|NCT01439087|DEVICE|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Colonic Polyps with OFDI system
214999795|NCT06710886|BEHAVIORAL|Mozart Theme|The selected Mozart composition consists of: Composition Eine kleine Nachtmusik, K. 525 (5 minutes 30 seconds), Andante from Piano Concerto No. 21, K. 467 (6 minutes 30 seconds), and Ave verum corpus, K. 618 (3 minutes).
214392550|NCT00003792|BIOLOGICAL|MART-1 antigen|
214392551|NCT00003792|BIOLOGICAL|filgrastim|
214392552|NCT00003792|BIOLOGICAL|flu matrix peptide p58-66|
214392553|NCT00003792|BIOLOGICAL|gp100 antigen|
214392554|NCT00003792|BIOLOGICAL|recombinant MAGE-3.1 antigen|
214392555|NCT00003792|BIOLOGICAL|tyrosinase peptide|
214392556|NCT00003792|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214392557|NCT04284761|COMBINATION_PRODUCT|Bicalutamide implant|Biolen bicalutamide implant
214392558|NCT03414788|BIOLOGICAL|PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
214392559|NCT03414788|BIOLOGICAL|[124I]IB PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
214392560|NCT06044220|BEHAVIORAL|Intervention|The intervention group was given training on male reproductive health and testicular self-examination after the pretest. Posttest was administered after the training. He was reminded to perform TSE for 3 months after the training. After the reminders, a follow-up test was applied.
214392561|NCT06044220|OTHER|Control|Pretest and posttest were administered to the control group at the same time as the intervention group. After reminding the intervention group to perform TSI for 3 months, a follow-up test was performed in the control group.
214392562|NCT05827666|DIETARY_SUPPLEMENT|2% milk beverage|Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.
214392563|NCT05827666|DIETARY_SUPPLEMENT|Almond milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.
214999796|NCT07028398|BEHAVIORAL|Nurse Nudge|Nurses will be nudged to call the patients, which may increase the likelihood that the patient receives a post- appointment follow-up call.
214999797|NCT07102797|BEHAVIORAL|ActiveGirls Physical Activity Program (Full)|Participants in the ActiveGirls Full Intensity intervention group will receive a series of 6 health coaching visits delivered via telemedicine. These visits will address physical activity goal setting within the family. Participants will also receive the ActiveGirls education messaging which will include 3-4 text messages per week (Months 1-6 of their study participation).
214999798|NCT07102797|BEHAVIORAL|ActiveGirls Physical Activity Program (Delayed Lower Intensity)|Participants in this group will only receive the ActiveGirls education messaging which will include 3-4 text messages per week (Months 7-12 of their study participation)
214999799|NCT07114133|OTHER|Environmental Probiotic Spray Intervention|The probiotic strains include Bacillus subtilis YHX001J, Bacillus amyloliquefaciens YHX002J, and Bacillus velezensis YHX003J
214999800|NCT07114133|OTHER|Purified water spray (containing no active ingredients) as the placebo control|Purified water spray
214392564|NCT05827666|DIETARY_SUPPLEMENT|Soy milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.
214392565|NCT05827666|DIETARY_SUPPLEMENT|Rice milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.
214392566|NCT01681368|DRUG|Birinapant (TL32711)|47mg/m\^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
214392567|NCT01428921|BEHAVIORAL|Theory based education and brief motivation interview|"* Standard education programme as described above,~* Plus~  1. Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~ 2. Follow-up phone call would be arranged within 1 week after using CPAP.~ 3. Video, slides and booklets would be used as education media."
214392568|NCT01189890|DRUG|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
214392569|NCT01189890|DRUG|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
214392570|NCT01189890|DRUG|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
214392571|NCT01189890|DRUG|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
214392572|NCT06542757|RADIATION|1.5 T Elekta Unity MR-Linac system|Patients will receive 9 Gy/fraction (45 Gy total) for five fractions to the DIL, while the remainder of the prostate will be treated to 30 Gy in 5 fractions.
214392573|NCT06542757|DEVICE|Hydrogel rectal spacer (SpaceOAR)|A rectal spacer will be placed one week prior to simulation to achieve a separation of approximately 1 cm between the prostate and anterior rectal wall to further minimize rectal toxicity in these patients. The hydrogel will remain in the body for about 12 weeks.
214392574|NCT06320522|DIETARY_SUPPLEMENT|Ketone Monoester|Commercial dietary supplement intended raise blood ketone body levels
214392575|NCT06320522|DIETARY_SUPPLEMENT|Placebo|Placebo drink (2mM sucrose octaacetate) taste and volume matched to the ketone monoester drinks
214392576|NCT02140294|DIETARY_SUPPLEMENT|Polymeric nutritional supplements|
214392577|NCT02140294|DIETARY_SUPPLEMENT|Standard Nutrional Treatment|
214392578|NCT05928715|OTHER|Finger feeding|The newborn will receive every expressed breast milk or formula support during the day with the finger feeding method.
214392579|NCT05406037|BIOLOGICAL|Venous sample|at Day 0, Day 3, Day 7, Day 14, Day 28 (7 ml blood sample collecting on dry tube) D0 = Diagnostic day
214392580|NCT04358419|DIAGNOSTIC_TEST|Aspergillus specific proteins in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
214392581|NCT04358419|DIAGNOSTIC_TEST|Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
214392582|NCT04896944|OTHER|No intervention|No intervention
214392583|NCT02831309|BEHAVIORAL|Light-Intensity Condition|The light-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, light--intensity activity breaks performed at 25% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
214392584|NCT02831309|BEHAVIORAL|Moderate-Intensity Condition|The moderate-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, moderate-intensity activity breaks performed at 50% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
214502201|NCT01687751|DRUG|Dexmedetomidine|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
214502202|NCT01687751|DRUG|Midazolam|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
214502203|NCT01818869|DRUG|AZD8848|Multiple doses inhaled IMP via a nebulizer
214999801|NCT07116070|OTHER|Clinical Assessments|"Participants will undergo the following assessments:~* Muscle strength: Handgrip strength test (using a digital dynamometer),~* Muscle mass: Bioelectrical impedance analysis (BIA) or DXA,~* Physical performance: 6-minute walk test, 5-repetition sit-to-stand test,~* Fatigue: Modified Fatigue Impact Scale (MFIS),~* Disability: EDSS,~* Nutritional status: Mini Nutritional Assessment (MNA),~* Physical activity: Godin Leisure-Time Exercise Questionnaire,~* Quality of life: MSQoL-54."
214999802|NCT07115199|PROCEDURE|Remote Patient Monitoring|The patients randomized to this intervention will get set up with remote patient monitoring. For these patients, blood pressure management and medication adjustment will be based on remote blood pressure measurements.
214999803|NCT07113795|PROCEDURE|TCM dummy therapy combined with mesenchymal stem cell injection therapy|Combines TCM dummy therapy with mesenchymal stem cell injection, integrating traditional local stimulation and modern stem cell regenerative mechanisms.
214999804|NCT07113795|PROCEDURE|Dummy Line Therapy Group|Utilizes traditional thread-embedding techniques, placing specialized threads at specific sites to effectively drain inflammatory exudates and necrotic materials.
214999805|NCT07113795|PROCEDURE|MSC Group|Administers mesenchymal stem cell injections directly to target areas, leveraging their differentiation and anti-inflammatory properties to enhance tissue repair.
215094262|NCT00657371|DEVICE|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
214392585|NCT02831309|BEHAVIORAL|High-Intensity Condition|The high-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, vigorous-intensity activity breaks performed at 75% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
214392586|NCT02831309|BEHAVIORAL|Sedentary Condition|The sedentary condition consisted of 8 hours of sitting interrupted with 2-minutes of screen time every 18 minutes. Standardized meals were provided.
214392587|NCT03093519|DRUG|KHK6640|Intravenous administration
214392588|NCT03093519|DRUG|Placebo|Intravenous administration
214392589|NCT03906513|DEVICE|OMK2|OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).
214392590|NCT06297629|DRUG|ASTX727|Given by PO
214392591|NCT06297629|DRUG|Donor Lymphocyte Infusion|Given by Infusion
214392592|NCT02891239|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
214502204|NCT01818869|DRUG|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
214502205|NCT01827839|BIOLOGICAL|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
215094263|NCT02712424|BIOLOGICAL|DAR-901|
215094264|NCT02712424|BIOLOGICAL|Sterile saline placebo|
215094265|NCT00724529|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
215094266|NCT04033874|OTHER|kangaroo care|kangaroo care
215094267|NCT04033874|OTHER|holding on the mother's lap|holding on the mother's lap
215094268|NCT04033874|OTHER|white noise listening|white noise listening
215094269|NCT04033874|OTHER|ambient sound listening|ambient sound listening
215094270|NCT00537407|DRUG|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
215094271|NCT00537407|DRUG|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
214999806|NCT07119164|OTHER|Laughter yoga|Laughter yoga is a mind-body practice that combines unconditional laughter with yogic breathing techniques (known as pranayama). Developed by Dr. Madan Kataria in 1995, the practice is based on the principle that voluntary laughter can provide similar physiological and psychological benefits as spontaneous laughter. It is typically conducted in group sessions involving eye contact, playful behavior, and laughter exercises, which aim to reduce stress, enhance mood, and promote overall well-being.
214999807|NCT07114952|BEHAVIORAL|alternative nasal breathing|The alternate nasal breathing exercise involves breathing in and out through both nostrils in a certain pattern and for a certain period of time. For example, an individual who breathes in through the right nostril for 5 seconds with the left nostril closed, then closes the right nostril and exhales through the left nostril for 5 seconds. Then he/she inhales through the left nostril for 5 seconds and exhales through the right nostril. A total of 6 breaths are taken per minute. The application is applied for 5 minutes, the patient rests in a calm environment for two minutes and the application is performed for another 5 minutes. In order to increase the compliance of individuals with the application, a sample video was watched and application instructions were given by the researcher. The application was performed while the patients were in an upright sitting position.
214999808|NCT07114237|PROCEDURE|Opioid Free Anesthesia|patients will receive opioid free anesthesia and bilateral ultrasound guided transversus abdominus plane block.
214999809|NCT07114237|PROCEDURE|Control group (general anesthesia)|patients will receive conventional general anesthesia
214999810|NCT07116252|PROCEDURE|EDTA|17% EDTA as a final rinse after instrumentaion (sequential chelation)
214999811|NCT07116252|PROCEDURE|Etidronate|9% HEBP as a final rinse after instrumentation (sequential chelation)
214999812|NCT07116252|PROCEDURE|clodronate|0.26 M (7.6%) clodronate as a final rinse after instrumentation (sequential chelation)
214999813|NCT07116252|PROCEDURE|Etidronic acid /sodium hypochlorite|(2.5% NaOCl + 9% HEBP) during instrumentation and as a final rinse after instrumentation (continous chelation)
214999814|NCT07116252|PROCEDURE|clodronate + sodium hypochlorite|2.5% NaOCl + 0.26 M (7.6%) clodronate during instrumentation and as a final rinse after instrumentation (continuous chelation)
214999815|NCT07114770|DEVICE|Theta Burst Stimulation (TBS, an advanced variant of repetitive transcranial magnetic stimulation)|Participants will receive a single session of either iTBS or cTBS (600 pulses) targeting the right cerebellar Crus I/II. One week after the initial TBS, they will receive another single session of iTBS or cTBS (600 pulses) at the same site.
214999816|NCT07120880|PROCEDURE|AD + SHR + active LT and extended-release melatonin 2mg|Patients will receive an SSRI antidepressant (e.g., Fluoxetine, Sertraline, Paroxetine, Escitalopram) or SNRI (e.g., Venlafaxine, Duloxetine) antidepressant (as clinically appropriate), combined with sleep hygiene education, daily morning LT (10,000 lux for 30 minutes between 7-8 a.m. using the Dayvia Slim Style 3 lamp), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
214999817|NCT07120880|PROCEDURE|AD + SHR + active LT and placebo melatonin|Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily morning bright LT (10,000 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
214999818|NCT07120880|PROCEDURE|AD + SHR + placebo LT and extended-release melatonin 2mg|Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps in non-therapeutic mode), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
214999819|NCT07120880|PROCEDURE|AD + SHR + placebo LT and placebo melatonin|Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and oral placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
215094272|NCT00537407|DRUG|Ribavirin|Ribavirin supplied as 200 mg tablets
214392593|NCT02025452|OTHER|Rapid diagnostic|Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
214392594|NCT02025452|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
214392595|NCT02025452|OTHER|Placebo|Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
214392596|NCT00593554|RADIATION|Total Body Irradiation|8 Gy on Day -9
214392597|NCT00593554|DRUG|Thiotepa|5 mg/kg/d on Day -8 to -7
214392598|NCT00593554|DRUG|Fludarabine|40 mg/m2/d on Day -6 to -3
214392599|NCT00593554|BIOLOGICAL|Rabbit ATG|2.5 mg/kg/d on Day -5 to -2
214392600|NCT00593554|DRUG|Palifermin|60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2
214392601|NCT03985163|OTHER|Patient Reported Outcomes Electronic Survey|This study does not include a drug, test, behavioral or medical procedure intervention; participants will be asked to complete three surveys
214392602|NCT02854306|PROCEDURE|Bariatric surgery|With mindfulness programm
214392603|NCT02854306|PROCEDURE|Bariatric surgery|Without mindfulness programm
214392604|NCT01649596|DEVICE|Warming Gown|Forced air warming Gown and portable warming unit that follows patient from pre-operative through surgery and into post-operative recovery.
214392605|NCT01649596|OTHER|Standard of care warming|The intervention is standard of care, placing warm blankets on the patient at time of pre operative preparation through the procedure and into recovery.
214392606|NCT04122560|DRUG|Fluconazole 200mg tab|PO dose of 400mg
214392607|NCT04122560|DRUG|Fluconazole 2 MG/ML|IV dose of 400mg
214392608|NCT06146309|DRUG|aflibercept (2mg/0.05ml)|Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
214999820|NCT07121101|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 2 tablets and Placebo 4 tablets for the first time ，TRD205 1 tablets and Placebo 2 tablets each for the other three times
214999821|NCT07121101|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 4 tablets and Placebo 2 tablets for the first time ，TRD205 2 tablets and Placebo 1 tablets each for the other three times.
214999822|NCT07121101|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 6 tablets and Placebo 0 tablets for the first time ，TRD205 3 tablets and Placebo 0 tablets each for the other three times.
214999823|NCT07121101|DRUG|placebo|Administered orally every 12 hours for a total of four times；Take Placebo 6 tablets for the first time ，Placebo 3 tablets each for the other three times.
214999824|NCT07119346|PROCEDURE|EOI block|EOI block with 0.25% ropivacaine 1 mL/kg (max 40 mL) bilaterally under ultrasound guidance
214999825|NCT07119346|PROCEDURE|sham block|Sham block with equal volume of normal saline bilaterally under ultrasound guidance
214999826|NCT07120867|DIAGNOSTIC_TEST|Pleural manometry|Pleural manometry will be performed during the first thoracentesis using a water column connected to the pleural drainage system. Pleural pressure will be measured at baseline and at intervals during fluid removal to evaluate lung expandability. The water column manometer allows estimation of pressure changes in real time. Based on the pressure curve and indicators of non-expandable lung (such as early pressure drop, plateauing, or sustained negative pressures), the treatment plan will be adapted. If adequate lung re-expansion is observed, pleurodesis will be considered. If the pressure pattern suggests a non-expandable lung, pleurodesis will be avoided due to the high risk of failure, and a tunneled pleural catheter will be recommended instead.
214999827|NCT07119203|PROCEDURE|Robotic cholecystectomy|Robotic multiport cholecystectomy
214999828|NCT07119203|PROCEDURE|Laparoscopic cholecystectomy|Conventional multiport laparoscopic cholecystectomy
214999829|NCT07121010|DIETARY_SUPPLEMENT|Animal-Based Protein Smoothie|This smoothie is formulated to deliver 50% of its total caloric content from high-quality animal-based protein, such as whey protein isolate or pasteurized egg whites. It is designed to evaluate the postprandial metabolic and immune response to animal-derived protein sources. The smoothie does not contain any added free amino acids and is prepared in a food-safe certified kitchen under standardized conditions. All participants consume the smoothie after an overnight fast to ensure consistency in metabolic assessment.
214999830|NCT07121010|DIETARY_SUPPLEMENT|Plant-Based Protein Smoothie|This smoothie is formulated to deliver 50% of its total caloric content from plant-based protein, such as pea or rice protein isolate. It is designed to evaluate the postprandial metabolic and immune response to plant-derived protein sources. The smoothie does not contain any added free amino acids and is prepared in a food-safe certified kitchen under standardized conditions. All participants consume the smoothie after an overnight fast to ensure consistency in metabolic assessment.
214999831|NCT07121010|DIETARY_SUPPLEMENT|Plant-Based Protein Smoothie with Leucine|This smoothie is formulated to deliver 50% of its total caloric content from plant-based protein, using sources such as pea or rice protein isolate. In addition, it is supplemented with pharmaceutical-grade leucine to match the leucine content typically found in animal-based protein sources. The smoothie is designed to assess whether leucine supplementation can modulate the postprandial metabolic and immune response to plant-derived protein. It is prepared in a food-safe certified kitchen and consumed after an overnight fast to maintain consistency across study conditions.
214999833|NCT07120529|OTHER|CT scan|CT chest, abdominal, pelvis during follow-up
214999834|NCT07120529|PROCEDURE|Ultrasound scan (Transvaginal or Transabdominal)|Transvaginal and transabdominal ultrasound scan during follow-up
214999835|NCT07120529|PROCEDURE|Gynecological examination|Gynecological standard examination during follow-up
214999836|NCT07121062|OTHER|Online parent administered questionnaire|Unsettled Infant Questionaire (UnIQue)
214999837|NCT07123818|DEVICE|AI software|AI software that will verify brain NECT scans on the presence of unruptured intracranial aneurysms (UIA). Brain NECT scans will be send to the AI software which will detect possible unruptured intracranial aneurysms (UIA). NECT scans on which a possibe UIA has been detected will be send to a platform on which involved radiologist can verify the AI result(s).
214502206|NCT06939491|DEVICE|Ultrasound guided electrolysis therapy|"Ultrasound-guided galvanic electrolysis (USGET) is a technique most commonly used on chronically affected tissue. A galvanic current flows through an acupuncture needle producing an inflammatory reaction in the tissue. The inflammatory reaction will trigger a host of biological processes in the body. These will ultimately start the generation of new immature collagen fibres. The fibres become mature by means of training stimulus.~The technique shows good results on tendons in the chronic phase, and may be used for injuries, such as long-standing muscle injury and treatment of myofascial pain syndrome and trigger points."
214502207|NCT06939491|DEVICE|Sham Electrolysis|The same intervention as the electrolysis group with the device turned on but the current intensity turned to 0 mA (e.g., no galvanic current).
214392609|NCT05666700|BIOLOGICAL|Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent|Cilta-cel is a cellular immunotherapy derived from autologous CD3+ T-cells that have undergone ex vivo modification to target B-Cell Maturation Antigen (BCMA) on the surface of plasma cells. Cilta-cel will be administered as two IV infusions, ≥70% unlabeled and ≤30% labelled. The dose will be based on the patient's weight (kg) at apheresis
214392610|NCT02254421|DRUG|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
214999838|NCT07125404|RADIATION|Low-level laser auriculotherapy (LLLT-AT)|Low-Level Laser Auriculotherapy (LLLT-AT) is a non-invasive, painless treatment that applies infrared laser (class IIIb, 905 nm) to specific auricular acupuncture points. It aims to reduce musculoskeletal pain and anxiety by stimulating mitochondrial cytochrome c oxidase, increasing ATP production, promoting tissue repair, and modulating inflammation. LLLT also reduces nerve excitability and triggers β-endorphin release, aiding in pain control. Auricular stimulation may influence autonomic nervous system activity, impacting both physical and emotional symptoms. The intervention consists of two sessions per week over three weeks, following standard laser safety procedures.
214392611|NCT02254421|DRUG|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
214392612|NCT02743286|BEHAVIORAL|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 15 2-minute standing interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
214392613|NCT02743286|BEHAVIORAL|Walking breaks|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 2-minute walking interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
214392614|NCT02743286|BEHAVIORAL|Stand more|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 10-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
214392615|NCT02279147|DRUG|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
214392616|NCT05235763|OTHER|activity coach|The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.
214392617|NCT05235763|OTHER|sham activity coach|The visual appearance of Optilogg is changed as to make the patient aware that something has happened to it, hence not knowing if it is the real activity coach or not. No new functionality is added, however.
214392618|NCT04328558|OTHER|Clavipectoral fascia plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
214392619|NCT01037959|DRUG|Norfloxacin|400 mg/day (per os) for 6 months
214392620|NCT01037959|DRUG|Placebo|1 pill/day (per os) for 6 months
214392621|NCT03896451|DEVICE|Total knee endoprothesis|Total knee endoprosthesis after knee joint osteoarthritis
214502208|NCT05787106|OTHER|Cyberball task|"The game consists of ball throws between animated characters lasting about 50 throws. In the rejection condition, after 2 or 3 throws, the participant no longer receives the ball (no more passes). In the control conditions (all included), the participant receives the ball as often as the others."
214502209|NCT06951061|PROCEDURE|IVF/ICSI|In vitro fertilization with or without ICSI with ejaculated and surgically retrieved sperm.
214502210|NCT00491894|DRUG|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
214502211|NCT06952205|OTHER|Experimental group|McKenzie exercises, Transcutaneous Electrical Nerve Stimulation (TENS), Hot Pack (HP) and pulsed ultrasound treatments were applied.To experimental group, functional taping were applied in addition of these treatments.
214502212|NCT06952205|OTHER|only exercises|McKenzie exercises, Transcutaneous Electrical Nerve Stimulation (TENS), Hot Pack (HP) and pulsed ultrasound treatments
214502213|NCT03427463|DRUG|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
214502214|NCT03427463|DRUG|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
214502215|NCT06341023|BEHAVIORAL|Functional Balance Intervention|Participants in the intervention group will undergo a multi-component FBI exercise program, both in a lab setting (Study 1) and at home (Study 2), for 2 days/week over 4 months. This evidence-based protocol, previously piloted with chronic stroke patients, older adults with mild cognitive impairment, and pre-frail older adults, focuses on improving physical (endurance, strength, balance, and gait) and cognitive function (processing speed, attention, and memory). The program consists of functional agility, functional strength, dual-task, and vestibular exercises, with each 1-hour session including 10 minutes dedicated to each component. The exercise order will be randomized for each session, preceded by a warm-up with gentle self-stretching exercises.
214999839|NCT07125404|OTHER|Sham Low-level laser auriculotherapy (sham LLLT-AT)|Sham LLLT-AT replicates the active procedure using the same laser device and parameters, but without light emission. The probe will be deactivated and applied to the same auricular points twice weekly for three weeks. As LLLT is painless and athermal, participants are unlikely to distinguish the sham condition. Standard safety protocols will be maintained.
214392622|NCT04037995|OTHER|No intervation|No intervation
214392623|NCT04375696|DRUG|Polyglucosamine L112|Polyglucosamine; Ascorbic Acid; Tartaric Acid
214392624|NCT04375696|OTHER|Placebo|Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide
214392625|NCT06341517|DEVICE|iTBS|Intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses for up to 8 sessions daily for 5 days
214392626|NCT00861796|DRUG|CYR-101|Experimental arm
214392627|NCT00861796|DRUG|Placebo|Placebo comparator
214392628|NCT03492619|BEHAVIORAL|Intensive Intervention|an intervention focused on alleviating discouragement, food insecurity, and excess weight in women and targeted at the individual, family, and community levels
214392629|NCT03492619|BEHAVIORAL|Non-Intensive Intervention|Group sessions for healthy lifestyle
214392630|NCT03092960|BEHAVIORAL|Minimal intensity intervention|The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
214392631|NCT03092960|BEHAVIORAL|HOMBRE|HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
214392632|NCT04621136|DRUG|Ripasudil ophthalmic solution 0.4%|"Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin.~Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks."
214999840|NCT07125404|OTHER|Myofascial release|Myofascial release is a manual therapy applied bilaterally to the masseter and temporalis muscles as a baseline intervention. Each session includes 1 minute of ischemic pressure, 1 minute of myofascial release, 30 seconds of positional release, and 30 seconds of general mobilization per muscle. The protocol consists of two sessions per week for three weeks (six sessions total), aiming to reduce muscle tension and improve mandibular function.
214999841|NCT06712914|DEVICE|MagPro X100 by MagVenture|Participants will receive 5 session per day of TBS for 6 days (30 sessions total). Six treatment days have to occur within a 2 week period. Each session will be comprised of 1800 pulses, using a MagVenture MagPro X100.
214999842|NCT07035197|DRUG|Eptinezumab|"Eptinezumab 100 mg IV q 3 months~* Baseline visit: Within 24 hours of receiving eptinezumab (duration of IDI \~30 - 45 minutes)~  * Semi-structured In-depth interview~ * MMD (days)~ * Thai version MIDAS (total score, grading)~ * Thai version EQ-5D-5L (5 domains \& 5 levels of severity; index score)~* 3-month follow-up visits (duration of interview: \~10 minutes):~  * Semi-structured brief interview~ * MMD (days)~ * Thai version MIDAS (total score, grading)~ * Thai version EQ-5D-5L (5 domains \& 5 levels of severity; index score)~* 6-month follow-up visit:~  * no interview~ * MMD (days)~ * Thai version MIDAS (total score, grading)~ * Thai version EQ-5D-5L (5 domains \& 5 levels of severity; index score)"
214392633|NCT02415218|BIOLOGICAL|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
214392634|NCT00272766|DRUG|pegaptanib sodium|
214392635|NCT01972334|BIOLOGICAL|FMT|as explained in study arm
214392636|NCT01972334|BIOLOGICAL|placebo|salt water or saline will be given as placebo
214392637|NCT00839917|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
214392638|NCT00839917|BIOLOGICAL|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
214999843|NCT07035197|OTHER|Sham (No Treatment)|"\*\* No intervention, neither eptinezumab nor placebo, was given~* Baseline visits: Within 24 hours of giving eptinezumab administration (duration of IDI \~30 - 45 minutes) - Semi-structured in-depth interview"
214999844|NCT07034924|DEVICE|Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S)|The AAJT-S is a non-invasive, externally applied medical device designed to achieve temporary occlusion of the abdominal aorta and inferior vena cava by inflating a pneumatic bladder to 250 mmHg. In this study, the device will be used as a temporizing measure for patients with severe postpartum hemorrhage unresponsive to standard uterotonics and balloon tamponade. The device will be applied horizontally over the upper abdomen and inflated using a built-in pressure gauge. The intended effect is to reduce pelvic blood flow and allow time for mobilization of surgical resources and blood transfusion. Maximum application time will not exceed 60 minutes, in accordance with established safety guidelines.
214999845|NCT07035886|OTHER|No intervention|As this is an observational study, no intervention will be administered.
214999846|NCT07036406|BEHAVIORAL|Semantic Feature Analysis (traditional)|This treatment involves naming pictures of objects, describing the objects' features (e.g., category membership, physical attributes, etc.), and creating sentences using the objects' names. It does not include direct metacognitive strategy training.
214999847|NCT07036406|BEHAVIORAL|Semantic Feature Analysis + Metacognitive Strategy Training|This treatment involves metacognitive teaching and practice, naming pictures of objects, describing the objects' features (e.g., category membership, physical attributes, etc), creating sentences using the objects' names, debriefing on overall performance, and discussing recent and future opportunities for strategy implementation in real life.
214999848|NCT06876909|DIETARY_SUPPLEMENT|barley green|Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day
214999849|NCT06704022|DIETARY_SUPPLEMENT|Oral nutritional supplement|Consumption of the oral nutritional supplement
214999850|NCT04539041|DRUG|antisense oligonucleotide|solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
214999851|NCT04539041|DRUG|placebo|placebo for each dose level
214999852|NCT06877962|BEHAVIORAL|Home-based Tele Exercise|The participants in the study group will be given an online personalized exercise program at home in hemodialysis (HD) days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of tele-exercises will be private, and the professional will send the link for each training session and will control the access of the participants.
214999853|NCT07031687|DEVICE|Active TIBS|Participants receive active TIBS targeted at the bilateral hippocampus. Stimulation parameters include a 5 Hz (Theta band) low-frequency modulation envelope, generated by two high-frequency current pairs (e.g., f1=2000 Hz, f2=2005 Hz). Peak-to-peak current intensity for each pair will be 2 mA (or 1 mA per electrode). Stimulation is delivered daily for 40 minutes, 6 days/week, for a total of 2 weeks. Individualized targeting and initial intensity optimization are guided by baseline sMRI and DTI. Real-time high-density EEG monitoring during each daily session (D2-D11) provides feedback on brain activity
214999854|NCT07031687|DEVICE|Sham TIBS|Participants receive sham stimulation designed to mimic the sensation of active TIBS without therapeutic output. This involves using a sham coil or a device mode with extremely low current intensity (e.g., 0.1-0.2 mA) or brief ramp-up/ramp-down sensations at the beginning and end of sessions, with no effective current delivery during the main stimulation period. The stimulation position and apparent parameters are identical to the active TIBS group to maintain blinding.
214999855|NCT07037121|BEHAVIORAL|Whole Food Plant Based Diet Jumpstart|"Participants receive personally-tailored support by a research nutritionist during five total visits: (1)baseline visit to collect surveys on health status, current home kitchen-based habits, kitchen inventory, food preferences, and clinical measures, followed by assessing health goals, obstacles, and opportunities. At least two breakfast, three lunch, and five dinner WFPB recipes will be selected. (2) A kitchen-centered visit will target the fridge, pantries, and cabinets to assist participants in cleaning out ultra-processed junk foods. These foods will be stored in a large tote during the study. (3) The day before the intervention starts will be a grocery shopping trip to purchase the WFPB heart-healthy groceries together. (4) Intervention day 1 will focus on jumpstarting meal prep. After day 1, weekly 30-min telehealth nutrition consultations will provide additional support. (5) Clinical measures and postintervention surveys will be collected on day 29."
214999856|NCT07038785|DIAGNOSTIC_TEST|Breath test|Breath sample collection using a sample collection kit
214999857|NCT06705933|OTHER|Core stability exercise|Lumbo-pelvic stabilizing exercises (posterior pelvic tilt, bilateral hip abduction, bilateral knee raise, bridging, hip shrugging) will be performed three times per week for eight weeks.
214999858|NCT06705933|OTHER|Myofascial release|The participants will receive myofascial release technique for 20 min for 3 times per week for 8 weeks.
214999859|NCT06705933|OTHER|Kinesiotaping|The participants will receive Kinesio-Taping over the sacroiliac joint and the hip region. Following a test trial of a small patch for 24 hours, they will be instructed to keep the tape on for 48 hours (it will be replaced after 48 hours) . It will be applied for 8 weeks.
214999860|NCT06704867|OTHER|High flow nasal cannula|Subjects undergoing endoscopic ultrasound will receive high flow nasal cannula during the procedure
214999861|NCT06720636|DEVICE|EndoSign|"The EndoSign cell collection device is a non-endoscopic capsule sponge device used to collect pan-esophageal samples.~The Endosign procedure consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Seven minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter is retrieved by pulling on the string. Upon retrieval the capsule-sponge scrapes against the surface of the top of the stomach and esophagus and collects epithelial cells. The capsule-sponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests."
214999862|NCT06721793|DIETARY_SUPPLEMENT|carbohydrate electrolyte drink|2% carbohydrate solution with 1,020 mg/L of Sodium
214999863|NCT06721793|DIETARY_SUPPLEMENT|no-sugar electrolyte drink|1% carbohydrate solution with 1,060 mg/L of Sodium
214999864|NCT06721793|DIETARY_SUPPLEMENT|Caffeinated Carbohydrate and electrolyte drink|2% carbohydrate solution with 1,000 mg/L of Sodium, and 200mg/L caffeine
214999865|NCT06721793|DIETARY_SUPPLEMENT|Water (Placebo)|flavored water with non-caloric, non-sodium-containing sweetner
214999866|NCT07040592|DRUG|semaglutide|All participants will receive a prescription for semaglutide and will meet with a clinical pharmacist and addiction psychiatrist for further support
214999867|NCT07041177|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
214999868|NCT06702462|DRUG|HFA-152A propellant|HFA-152A propellant is administered via oral inhalation
214999869|NCT06702462|DRUG|HFA-134A propellant|HFA-134A propellant is administered via oral inhalation
214392639|NCT02701946|PROCEDURE|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)
214392640|NCT02701946|PROCEDURE|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
214999870|NCT06878703|DRUG|Midazolam|Continuous intravenous administration with a loading dose of 10 µg/kg over 30 min, followed by a maintenance dose (from 10 to 40 µg/kg/h)
214999871|NCT06878703|DRUG|Dexmedetomidine|Continuous intravenous administration with a loading dose of 0.05 μg/kg over 30 minutes followed by a maintenance dose (from 0.05 to 0.2 μg/kg/h)
214392641|NCT01129336|DRUG|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
214999872|NCT03421808|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS
214392642|NCT01129336|DRUG|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
214392643|NCT00867490|DRUG|Candesartan+HCTZ - Phase 1|4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.
214392644|NCT00867490|DRUG|Aliskiren+HCTZ - Phase 2|Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
214392645|NCT00867490|DRUG|Aliskiren+HCTZ+amlodipine - Phase 3|The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
214392646|NCT05521295|OTHER|no intervention|no intervention in this study
214392647|NCT03389685|BIOLOGICAL|Platelet Rich Plasma|Pure PRPII®, leukocyte-poor, platelet rich plasma
214392648|NCT03389685|OTHER|Saline Placebo|saline solution
214392649|NCT03246425|OTHER|Ventilator mode change|The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
214392650|NCT03246425|DEVICE|Monitoring of blood pressure variation|The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
214392651|NCT01428674|OTHER|Interpersonal Mindful Compassion with Touch|A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
214392652|NCT01428674|OTHER|Reading while extending loving kindness|The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
214392653|NCT05238532|GENETIC|CT303|"Once a time, intravenous injection~* CT303 Starting Dose : 1.0\*10\^6 cells/kg~* CT303 Increasing Quantity Dose : 2.0\*10\^6 cells/kg"
214392654|NCT02230150|BEHAVIORAL|Adhesion-HF|The hypothesis that was investigated is whether the nursing consultation improves therapeutic strategies for membership, adherence to self-care, improved levels of NT-proBNP improves performance in 6-minute walk test, monitoring of biomarkers of laboratory tests (sodium , potassium, urea, creatinine and NT-proBNP) frequent occurrence of readmissions and mortality in patients with heart failure after 1 month.
214999873|NCT07037134|OTHER|Natural soundscape exposure|Participants receive a standardized 20-minute auditory exposure to curated natural soundscapes via high-fidelity open-back reference headphones powered by a DAC/amplifier and corrected for frequency response using calibration software. Participants are randomly assigned one of 22 recordings. Each includes 10-second fade-in/out effects and are calibrated to 45-55 dB. The stereo recordings (320-kbps MP3, 48 kHz/24-bit) feature biophony (e.g., bird vocalizations) and geophony (e.g., rainfall), free of urban sounds and selected for ecological validity based on predefined criteria: (i) recognizable/context-specific sounds; (ii) culturally neutral; (iii) foreground presence and depth; (iv) no prolonged silence; (v) no technical artifacts. During exposure, they lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active, causal listening under continuous researcher supervision.
214999874|NCT07037134|OTHER|Urban soundscape exposure|Participants receive a standardized 20-minute auditory exposure to curated urban soundscapes, using the same equipment and technical specifications as all other intervention conditions. Each participant is randomly assigned one of 22 recordings, calibrated to 45-55 dB (Leq,20min). The recordings feature anthropophony (e.g., unintelligible background speech) and technophony (e.g., transportation-related sounds), free of natural sounds and selected for ecological validity based on the same predefined criteria as the natural soundscapes. To prevent semantic processing, participants are pre-screened and post-session reconfirmed to ensure they do not understand the languages used. During exposure, participants lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active listening in a causal mode and is conducted under continuous researcher supervision.
214392655|NCT02418299|DEVICE|IncontiLase Er:YAG laser treatment|Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
214392656|NCT04345198|PROCEDURE|Adrenal Artery Ablation|Intervention with adrenal artery ablation is performed in PA patients with resistant hypertension.
214392657|NCT04684927|DEVICE|MID-C System -Minimal invasive deformity correction system for the treatment of AIS|"A 5 years follow-up will be performed for all patients who underwent AIS repair surgery using the MID-C System. The follow-up in order to assess safety and efficacy measurments. Eligible Patients will be followed and assessed at the following time points: Immediate Post-op up to 6 weeks, 6 months, 12 months, and then annually out to 5 years post-implantation.~During the study, the following rating scales and assessments will be conducted to assess the probable benefit and safety of the treatment: Physical exam,X-rays,Cobb angle measurements,Adverse Events (AEs) and Scoliosis research society (SRS-22) questionnaire: The questionnaire is commonly used to assess health related quality of life in children with AIS."
214392658|NCT02653040|OTHER|Dynamic lighting|"Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:~07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity"
214392659|NCT02367014|DRUG|elamipretide (low dose)|elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
214392660|NCT02367014|DRUG|elamipretide (intermediate dose)|elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
214392661|NCT02367014|DRUG|elamipretide (high dose)|elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
214392662|NCT02367014|DRUG|Placebo|placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
214392663|NCT02961855|DRUG|anesthesics plus antiinflammatory, CLIFE1|anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
214392664|NCT02961855|DRUG|local anesthesics, CLIFE2|local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
214392665|NCT05872828|OTHER|No intervention|Observational study. No intervention will be adopted.
214392666|NCT02642718|DRUG|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
214502216|NCT06341023|BEHAVIORAL|Stretching|Participants in the control group will undergo a 4-month lab-based stretching program, with the same frequency and session length as the intervention group (1 hour/session for 2 days/week). The stretching regimen will include progressive stretches targeting upper and lower-limb muscles, core, and back muscles, followed by a 10-minute cool-down comprising relaxation and breathing exercises. These stretches are designed to improve performance in daily living activities. In Study 2, stretching participants will receive a detailed printed exercise manual for home-based training, ensuring consistency with the lab-based program. No additional equipment, such as computers or tablets, is required for the home stretching program.
214502217|NCT06532136|DRUG|Deucravacitinib|Deucravacitinib 6 mg orally once daily.
214502218|NCT06532136|DRUG|Placebo|Matching placebo orally once daily.
214502219|NCT03110809|DIETARY_SUPPLEMENT|Capsinoid|Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.
214392667|NCT02642718|OTHER|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
214392668|NCT02502305|BEHAVIORAL|liveonline course|physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
214502220|NCT03110809|DIETARY_SUPPLEMENT|Placebo|Placebo for capsinoid. Capsule contains no active ingredients.
214502221|NCT06196853|DRUG|Aminophylline|Give aminophylline for 5 days to keep serum theophylline level 5-15 mg/dl
214999875|NCT07037134|OTHER|Broadband sound exposure|Participants receive a standardized 20-minute auditory exposure to broadband sounds (i.e., white or pink noise), using the same equipment and technical specifications as all other intervention conditions. Each participant is randomly assigned to one of the two noise types, with equal distribution across conditions. The stimuli are generated using professional audio software and calibrated to 50 dB (Leq,20min). During exposure, participants lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active listening in a causal mode and is conducted under continuous researcher supervision.
214392669|NCT03354637|DRUG|ATI-50002 high dose|Topical solution
214392670|NCT03354637|DRUG|ATI-50002 low dose|Topical solution
214502222|NCT04716517|OTHER|Alkasite bioactive restorative material.|"Alkasite restorative is a category of filling material, like compomer, and is essentially a subgroup~of the composite resin. Cention N is a urethane dimethacrylate (UDMA)-based, self-curing powder/liquid restorative with optional additional light curing. The liquid comprises of dimethacrylates and initiators, while the powder contains various glass fillers, initiators, and pigments. It is radio opaque and contains alkaline glass fillers capable of releasing fluoride, calcium, and hydroxide ions. Due to the sole use of cross-linking methacrylate monomers in combination with a stable, efficient self-cure initiator, Cention N displays a high polymer network density and degree of polymerization over the complete depth of the restoration."
214502223|NCT04716517|OTHER|Resin Modified Glass Ionomer|The resin-modified glass ionomer materials are hybrid materials of traditional glass ionomer cement with a small addition of light-curing resin, and hence exhibit properties intermediate to the two, with some characteristics superior to conventional glass ionomer materials
214392671|NCT03354637|DRUG|Placebo|Topical solution
214392672|NCT05334823|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214392673|NCT02726399|DRUG|Ramucirumab|Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
214392674|NCT02726399|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
214392675|NCT02726399|DRUG|Capecitabine|Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
214392676|NCT02726399|DRUG|Cisplatin|Cisplatin 80mg/m2 administered as an IV infusion every 21 days
214392677|NCT01427621|PROCEDURE|remote ischemic pre and postconditioning (RIPC)|RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
214392678|NCT02851836|BEHAVIORAL|image visualization and quotation|"two sets of 60 pictures are shown to the adolescents. we ask them to quote for their valence, hedonicity, arousal and to characterize the emotion elicited in each picture.~This evaluation takes approximately 1hour."
214392679|NCT01327937|DEVICE|Apligraf|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
214392680|NCT01327937|OTHER|Standard of Care Dressing Group|Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
214392681|NCT02564055|DRUG|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
214392682|NCT02564055|DRUG|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
214392683|NCT02564055|DRUG|Vehicle cream|White to off-white vehicle cream base to be applied topically
214392684|NCT04027205|OTHER|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
214392685|NCT04027205|PROCEDURE|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation
214392686|NCT00773071|DEVICE|SPECT/CT guided LM/SL|Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
214502224|NCT02761499|DEVICE|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
214502225|NCT00003167|BIOLOGICAL|Ad5CMV-p53 gene|Given intravesically
214502226|NCT05678725|DEVICE|tACS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.
214999876|NCT07037134|OTHER|Blank tape attention placebo control|Participants receive a standardized 20-minute exposure to blank audio (silence), using the same equipment and technical specifications as all other intervention conditions. At study onset, participants are informed they will hear a range of environmental sounds, including some that may be inaudible (i.e., present but beyond the range of human hearing). During the placebo condition, a blank recording is played, producing silence, while participants remain unaware of whether they are receiving an active or placebo stimulus. This attention-control condition ensures procedural consistency while delivering no auditory stimulation. During exposure, participants lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active listening in a causal mode and is conducted under continuous researcher supervision.
214392687|NCT01599416|DIETARY_SUPPLEMENT|U-relax|Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
214392688|NCT04747275|DRUG|Liquid stable levothyroxine (L-T4) Tirosint-SOL|Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
214392689|NCT04747275|DRUG|Oral tablet levothyroxine (L-T4)|Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
214392690|NCT00615602|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
214392691|NCT00615602|DRUG|Trastuzumab|Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months
214392692|NCT00615602|DRUG|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
214392693|NCT00615602|DRUG|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
214392694|NCT00615602|DRUG|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
214392695|NCT00615602|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
214392696|NCT00615602|DRUG|Trastuzumab|Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
214392697|NCT05912530|OTHER|no intervention|there is no intervention will done
214392698|NCT05351736|DRUG|Lurasidone|Treatment with lurasidone
214392699|NCT00447330|DRUG|capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)|"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."
214502227|NCT05678725|DEVICE|tDCS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.
214502228|NCT05678725|DEVICE|sham|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The stimulation lasted for 20 minutes and included a 10-second ramp-up and 10-second ramp-down.
214502229|NCT03181100|DRUG|Atezolizumab|Given IV
214502230|NCT03181100|BIOLOGICAL|Bevacizumab|Given IV
214502231|NCT03181100|DRUG|Cobimetinib|Given PO
214502232|NCT03181100|DRUG|Nab-paclitaxel|Given IV
214502233|NCT03181100|DRUG|Paclitaxel|Given IV
214392700|NCT06002061|DEVICE|NovaResp MAPR System|"Baseline measurements will be taken while the subject is awake. Genioglossus activity with maximal tongue protrusion will be measured as well as the response to 1 to 2 pressure routines. Once the subject is sleeping, the operator will observe the PSG recording and determine sleep stage and respiratory phase (inspiration, expiration, between breaths). Test routines will be performed for each sleep stage and each respiratory phase. If the operator notices an apnea occurring, one of the routines will be applied. When all manual tests are complete, an automatic mode will be engaged for the remainder of the night. During this mode, a previously developed and trialled AI model will be used to predict if an obstructive apnea is upcoming. The operator will input which routine to test, and the routine will be automatically applied when a prediction occurs. There will be a minimum of 60 seconds between pressure routine applications."
214392701|NCT05498766|DRUG|Huaier granule|Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.
214392702|NCT05498766|DRUG|Oxaliplatin|Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.
214392703|NCT05498766|DRUG|Tegafur, Gimeracil and Oteracil Potassium|Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
214392704|NCT00531011|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
214502234|NCT03181100|DRUG|Vemurafenib|Given PO
214502235|NCT03542747|DEVICE|Time to ventilation with the iLTS|Time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
214502236|NCT03542747|DEVICE|Time to ventilation with the Fastrach|Time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
214502237|NCT06951295|PROCEDURE|Thyroidectomy operation is a surgical removal of thyroid, injury of recurrent laryngeal nerve one of common complications of thyroidectomy Which can affect Vocal cords mobility|Assessment of vocal cords mobility at thyroidectomy operation is very important and life saving for patient, during thyroidectomy one of common complications, injury of recurrent laryngeal nerve unilateral or bilateral, unilateral injury may complicate to dysphonia, bilateral injury may complicate to dyspnea
214502238|NCT02304809|DRUG|Vemurafenib|Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
214688082|NCT02149836|DRUG|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
214999877|NCT05793060|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine 50 Mcg
214999878|NCT05793060|DRUG|Dexamethasone Phosphate|Dexamethasone 4 mg
214999879|NCT06550882|DRUG|OBIZUR|OBIZUR injection.
214502239|NCT03499964|DEVICE|Optilume Drug Coated Balloon (DCB)|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
214502240|NCT03499964|DEVICE|Control Treatment|A control subject may be dilated with either a rod, uncoated balloon or DVIU until the desired result is reached, based on standard of care for the clinical site and treating physician
214502241|NCT06016400|DRUG|Alfacalcidol Oral Solution|Alfacalcidol Oral Solution 1ug a day
214502242|NCT06016400|DRUG|Placebo|Placebo
214502243|NCT03071354|DIETARY_SUPPLEMENT|HMB protein supplement (3g)|HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.
214999880|NCT06723743|OTHER|Transcutaneous vagus nerve stimulation for attention in veterans with TBI|taVNS does not require surgery or medication, offering a safe and accessible treatment option. Each participant undergoes both an active taVNS session and a sham (placebo) session. Sham stimulation mimics the sensory experience of taVNS but does not deliver electrical currents to the vagus nerve, ensuring blinding and providing robust comparisons. The study is completed in a single visit lasting 2.5 to 3 hours, minimizing participant burden.
214502244|NCT03071354|DIETARY_SUPPLEMENT|Nutritional Supplement|Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
214392705|NCT00531011|DEVICE|TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
214392706|NCT03268590|DRUG|Oxygen|Persons will undergo MRI, EEG, and complete computerized cognitive testing in baseline room air. Persons will then breathe 100% pure oxygen and undergo MRI, EEG, and complete computerized cognitive testing. Persons will serve as their own controls.
214502245|NCT02909959|DRUG|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
214502246|NCT02909959|DRUG|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
214502247|NCT02596919|OTHER|photography|photography of meibomian glands
214502248|NCT04160741|OTHER|Radiation and warm environment|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
214502249|NCT04160741|OTHER|Warm environment|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
214502250|NCT04160741|RADIATION|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
214392707|NCT05719285|DRUG|Single-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 1: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure~Second line:~Arm 1: cefalexin 500 mg once pre-procedure~Third line:~Arm 1: nitrofurantoin 100 mg once pre-procedure~Fourth line:~Arm 1: ciprofloxacin 500 mg once pre-procedure"
214392708|NCT05719285|DRUG|Multi-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses"
214392709|NCT02971891|DRUG|CLS006 (Furosemide) Topical Gel|
214392710|NCT02971891|DRUG|Vehicle Topical Gel|
214392711|NCT04592536|DRUG|CVL-865 High dose|High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)
214502251|NCT04160741|OTHER|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
214502252|NCT03615612|OTHER|QuickSee refractive error assessment + glasses|QuickSee refractive error assessment + glasses
214502253|NCT05390905|DRUG|HSK21542 Injection|1μg/kg/dose
214502254|NCT05390905|DRUG|Tramadol hydrochloride|50mg/dose
214502255|NCT05390905|DRUG|placebo|placebo
214502256|NCT01515241|DRUG|CER-001|Weekly injection
214502257|NCT03363984|DRUG|Midazolam|Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times
214502258|NCT03363984|DRUG|ID-082|Administration of ID-082 under fasted conditions/outside of meal times
214502259|NCT06038695|DEVICE|Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB|"* Fibro-Gide is the Volume-Stable Collagen Matrix.~* Recombinant human platelet-derived growth factor-BB will be found within the device of GEM21S."
214502260|NCT01979276|DRUG|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
214502261|NCT01979276|DRUG|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
214502262|NCT01979276|DRUG|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
214392712|NCT04592536|DRUG|Alprazolam 1mg XR|Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)
214392713|NCT04592536|DRUG|Placebo|Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
214392714|NCT04592536|DRUG|CVL-865 low dose|Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)
214392715|NCT01096199|DRUG|TS-ONE, Cisplatin, RAD001|
214392716|NCT03262337|OTHER|none, this is an observational study|none, this is an observational study
214392717|NCT02919943|PROCEDURE|Percutaneous Coronary Intervention|OCT-guided Percutaneous Coronary Intervention.
214392718|NCT06475196|DRUG|Sintilimab (PD-1 inhibitor)|to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.
214392719|NCT02774343|DRUG|Pioglitazone|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
214392720|NCT02774343|DRUG|Placebo|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
214392721|NCT02774343|BEHAVIORAL|Therapy|Cognitive-behavioral therapy 1 hour per week
214392722|NCT02774343|BEHAVIORAL|Contingency Management|Prize-based contingency management for attendance
214392723|NCT02120846|OTHER|Flywheel leg-press resistance exercise|
214392724|NCT03912480|BIOLOGICAL|Stem cells from human exfoliated teeth|Intravenous infusion of pulp mesenchymal stem cells
214392725|NCT06067529|DRUG|hormone replacement therapy|hormone replacement therapy
214392726|NCT03318952|DRUG|lidocaine|A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.
214392727|NCT03318952|DRUG|articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered
214502263|NCT02546531|BIOLOGICAL|Defactinib|
214502264|NCT02546531|BIOLOGICAL|Pembrolizumab|
214502265|NCT02546531|DRUG|Gemcitabine|
214502266|NCT02238041|DEVICE|GlucoClear System|
214392728|NCT00919893|DRUG|Cernilton|Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
214502267|NCT03213145|DRUG|intraconazole|Subjects will receive itraconazole once daily from Day 5 through Day18
214502268|NCT03213145|DRUG|Rifampin|Subjects will receive rifampin once daily from Day 5 through Day 16
214502269|NCT03213145|DRUG|EDP 305|Subjects will receive EDP 305 once daily on Day 1 and Day 14
214688083|NCT03566108|PROCEDURE|VISTA|Vestibular incision supraperiosteal tunnel access (VISTA) incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
214999881|NCT06723743|DEVICE|Soterix Medical Vagus Nerve Stimulation mini-CT|Soterix Medical min-CT VNS device is used for non-invasive stimulation procedures and trials. It has blinding features such as single-blind for this study in which patients will either receive active or shame taVNS.
214999882|NCT06886204|BEHAVIORAL|YEAH: Youth Empowered Advocating for Health|"The Youth Empowered Advocating for Health (YEAH) program is a Youth Participatory Action Research (YPAR) intervention aimed at addressing community violence by fostering youth and community healing. It combines photovoice and theater arts performances.~In photovoice sessions, Black youth explore structural determinants of community violence through a participatory research process. Guided by trained facilitators, youth learn the method after obtaining parental consent and youth assent. Using the structured SHOWED framework, they analyze and discuss images, generating ideas for social action. During the photovoice sessions, photo assignments will be completed, with discussions recorded, analyzed for themes, and shared for validation.~The final four sessions will integrate these themes into theater arts performances, allowing youth to creatively express insights and experiences, fostering empowerment and social change."
214999883|NCT06704126|OTHER|Passive movement|This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes.
214999884|NCT06704126|OTHER|Passive movement with blood flow restriction|This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes. During the 60 seconds on of passive movement training, blood flow restriction cuffs which will be applied to the legs, will be inflated to cause 80% arterial blood flow occlusion.
214999885|NCT06184152|DIAGNOSTIC_TEST|CEUS imaging|Contrast-enhanced ultrasound (CEUS)
214999886|NCT06184152|DIAGNOSTIC_TEST|aMRI imaging|contrast enhanced abbreviated MRI (AMRI)
214392729|NCT00919893|DRUG|Placebo|Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
214392730|NCT01375959|DIETARY_SUPPLEMENT|resveratrol|resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks
214392731|NCT01375959|DRUG|Placebo|3 placebo capsules orally twice a day for 6 weeks
214392732|NCT04254679|DRUG|Opioid analgesics|"Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
214392733|NCT04254679|DRUG|Non-opioid analgesics|"Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
214502270|NCT03739866|DRUG|Lenacapavir|Administered subcutaneously in the abdomen
214502271|NCT03739866|DRUG|Placebo|Administered subcutaneously in the abdomen
214502272|NCT03739866|DRUG|B/F/TAF|50/200/25 mg tablets administered orally once daily
214502273|NCT03739866|DRUG|TAF|Tablets administered orally
214502274|NCT01503372|DRUG|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
214502275|NCT01503372|DRUG|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
214392734|NCT05408000|DRUG|ketofol vs propofol|Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia
214688084|NCT03566108|PROCEDURE|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
214688085|NCT06682793|BIOLOGICAL|A2B395|Allogeneic logic-gated Tmod CAR T cells
214999887|NCT07043452|DRUG|Blinded Study Medication - Condition 1|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
214999888|NCT07043452|DRUG|Blinded Study Medication - Condition 2|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
214999889|NCT07043452|DRUG|Blinded Study Medication - Condition 3|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
215094273|NCT02977845|BEHAVIORAL|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
215094274|NCT05577637|DRUG|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
215094275|NCT03474198|DRUG|Rifampicin|10mg/kg
215094276|NCT03474198|DRUG|Isoniazid|5mg/kg
215094277|NCT03474198|DRUG|Pyrazinamide|25mg/kg
214392735|NCT00794820|DRUG|Fludarabine Phosphate|25 mg/m\^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
215094278|NCT03474198|DRUG|Ethambutol|15mg/kg
215094279|NCT03474198|DRUG|Linezolid|600mg
215094280|NCT03474198|DRUG|Clofazimine|200mg
215094281|NCT03474198|DRUG|Rifapentine|1200mg
214392736|NCT00794820|DRUG|Cyclophosphamide|250 mg/m\^2 by vein over 60 minutes daily for 3 days (days 2-4)
214392737|NCT00794820|DRUG|Rituximab|375 mg/m\^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m\^2 on days 2-3
214392738|NCT00266474|OTHER|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
215094282|NCT03474198|DRUG|Levofloxacin|1000mg
215094283|NCT03474198|DRUG|Bedaquiline|400mg once daily for 2 weeks then 200mg 3x a week
215094284|NCT03474198|DRUG|Rifampicin|35mg/kg
215094285|NCT02694497|OTHER|Chlamydia care as usual|
215094286|NCT01160432|DRUG|Methadone, naloxone|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient's individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week's periods for four weeks.
214392739|NCT02905019|BIOLOGICAL|R21 with Matrix-M1|Vaccine
214502276|NCT05202366|DRUG|CGB-400 Topical Gel|CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
214502277|NCT03090711|DEVICE|Transcranial Magnetic Stimulation (TMS)|The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.
215094287|NCT03594214|DIAGNOSTIC_TEST|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
215094288|NCT05839704|PROCEDURE|Bilateral Erector Spinae Plane Block|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the erector spinae plane at the level of T8.
215094289|NCT05839704|PROCEDURE|Abdominal Wall Blocks|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the subcostal transversus abdominus plane bilaterally and the serratus plane on the left side
215094290|NCT02713867|BIOLOGICAL|Nivolumab|
215094291|NCT03251586|DIAGNOSTIC_TEST|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
214392740|NCT02905019|BIOLOGICAL|ChAd63 ME-TRAP|Vaccine
214999890|NCT07043452|DRUG|Blinded Study Medication - Condition 4|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
215094292|NCT03251586|DIAGNOSTIC_TEST|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
215094293|NCT05385445|BEHAVIORAL|Audit and Feedback|The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit \& Feedback interventions to change prescribing and laboratory ordering.
215094294|NCT03652467|DRUG|Conventional TACE|Conventional chemoembolization drugs are injected through hepatic artery.
215094295|NCT03652467|DRUG|Deferoxamine and conventional TACE|Deferoxamine is injected before conventional transarterial chemoembolization.
215094296|NCT01656226|DEVICE|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
215094297|NCT01656226|OTHER|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
215094298|NCT03107923|DIAGNOSTIC_TEST|Dobutamine stress test|Test of myocardial reserve
215094299|NCT04569994|DRUG|NNC0363-0845|A single dose administered s.c. (subcutaneously, under the skin)
215094300|NCT04569994|DRUG|Placebo (NNC0363-0845)|A single dose administered s.c.
215094301|NCT04569994|DRUG|Insulin degludec|A single dose administered s.c.
215094302|NCT04040842|DIAGNOSTIC_TEST|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
214392741|NCT02905019|BIOLOGICAL|MVA ME-TRAP|Vaccine
214392742|NCT02870504|PROCEDURE|Corneoscleral limbus group|Laser spot locates on the corneoscleral limbus
214392743|NCT02870504|PROCEDURE|one spot group|Laser spot locates on one spot away from the corneoscleral limbus
214392744|NCT02870504|PROCEDURE|two spots group|Laser spot locates on two spots away from the corneoscleral limbus
214392745|NCT00011830|DRUG|G-CSF|
214392746|NCT00011830|PROCEDURE|Apheresis|
214392747|NCT02208882|DRUG|BMS-986120|
214392748|NCT02208882|DRUG|Placebo|
214392749|NCT02208882|DRUG|Midazolam|
214392750|NCT00466258|DRUG|R-CHOP|"* Cyclophosphamide 750 mg/m2 i.v. day 1~* Adriamycin 50 mg/m2 i.v. day 1~* Vincristine 1,4 mg/m2 i.v. day 1~* Prednisone 100 mg i.v or oral. days 1-5."
214392751|NCT00466258|DRUG|Highly active antiretroviral therapy|Combined antiretroviral treatment (TARGA) wich include at lest 3 drugs. The combination should be accepted as an initial or rescue treatment.
214392752|NCT00466258|DRUG|Central nervous system (CNS) prophylaxis|methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
214392753|NCT00466258|DRUG|Prophylaxis of opportunistic infections and support treatment|Pegfilgrastim
214392754|NCT05542992|DIAGNOSTIC_TEST|CT-based deep learning model|CT-based deep learning model for pure-solid nodules classifications
214999891|NCT07043452|DRUG|Blinded Study Medication - Condition 5|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
214999892|NCT07043452|DRUG|Placebo|Double blind administration of placebo.
214999893|NCT07038668|PROCEDURE|Using of viscoelastic during the operation|Using of viscoelastic during the operation
214999894|NCT07038668|PROCEDURE|No using of viscoelastic during the operation|No using of viscoelastic during the operation
214999895|NCT07042945|DRUG|MK-4646|MK-4646 in capsular form administered orally
214999896|NCT05420207|OTHER|No intervention|No intervention included
214999897|NCT06719713|BEHAVIORAL|Store Safely|"The Store Safely intervention occurs online and is self-administered. Once directed to the Store Safely website, participants are welcomed and instructed to complete each step of the online program. Upon clicking Start, participants are taken to Step 1 of the intervention and instructed to review a brief video. Step 2 involves a review of a data infographics. Participants are then directed to the Decision Aid in Step 3. In Step 4, participants are instructed to complete the Family Firearm Storage Action Plan. In Step 5, participants will review another brief video. There will also be an optional step, consisting of a resource page that details local options for obtaining safe storage devices. At the end of each step, participants mark a checkbox to indicate they have completed the intervention activity which facilitates website analytics of participant engagement. Lastly, participants are thanked and provided with details about the final steps of the trial."
214999898|NCT07044674|DEVICE|UNITY Vitreoretinal Cataract System|UNITY VCS is a commercially approved surgical system that facilitates the management of fluid and gases, as well as removal, grasping, cutting, illumination, and coagulation of ocular materials during eye surgery. It consists of a console, remote control, foot controller, video overlay, and compatible anterior segment devices. In this study, it will be used for the removal of cataracts.
214999899|NCT07044674|DEVICE|CENTURION Vision System with Active Sentry|CAS is a commercially approved surgical system for use during anterior segment ophthalmic surgery. It consists of a console, foot controller, remote control, video overlay, and compatible anterior segment devices. The Active Sentry handpiece will be used.
214999900|NCT07044674|PROCEDURE|Anterior segment ophthalmic surgery|Cataract surgery during which the crystalline lens (often cloudy) is broken into small pieces and gently removed from the eye with suction (phacoemulsification)
214999901|NCT07045493|DRUG|A single dose of Albendazole 400mg + Ivermectin (200 µg/ kg) combination therapy|Children will receive the medication after being randomly assigned to either treatment arm. Albendazole will be administered as a syrup and ivermectin tablets as powdered tablets because ivermectin suspension is not available in Bangladesh. The commercially available 6 mg unscored Ivermectin tablets will be crushed, the tablet fragments ground into a powder, and stored in an airtight plastic container in a dry, cool environment after all aseptic procedures. According to the weight of the children, the investigators will provide the needed amount (weighted by microgram scale) of the drug mixed with 5 ml of water. The study field staff will help the parents to give the medicine to the child by the direct observation therapy (DOT) method. The parents will be advised to bring the children on an empty stomach in the morning. Ivermectin will be given first, and a light snack will be provided 30 minutes after taking ivermectin. Then albendazole will be given to the children.
214999902|NCT07045493|DRUG|A single dose of 400 mg Oral Albendazole monotherapy|Albendazole will be given in syrup form. The study field staff will help the parents to give the medicine to the child by the direct observation therapy (DOT) method. The parents will be advised to bring the children on an empty stomach in the morning. Ivermectin will be given first, and a light snack will be provided 30 minutes after taking ivermectin. Then albendazole will be given to the children. Both drugs will be given using direct observation at the field clinic. Parents will be advised to report any adverse effects, including vomiting, after taking the medication. If vomiting occurs within one hour of medication, a redosing will be provided.
214999903|NCT06887010|DRUG|ABBV-101|Oral: Tablet
214999904|NCT07043322|PROCEDURE|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
214999905|NCT07043322|DRUG|Cabergoline|Cabergoline is used to treat different types of medical problems that occur when too much of the hormone prolactin is produced. It can be used to treat certain menstrual problems, fertility problems in men and women, and pituitary prolactinomas
214999906|NCT06382480|OTHER|Diet with specific macronutrient composition.|The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat.
214999907|NCT07047209|DRUG|Digoxin|Digoxin tablets will be administered orally in a once daily dosage. Each tablet is scored and is of 125 mcg strength. Participants will take 1 tablet, two tablets or half a tablet depending on the dosing tier they are in during study participation.
214999908|NCT06728358|DIAGNOSTIC_TEST|Molecular analyses|Search for molecular alterations that correlate with patient prognosis
214999909|NCT06729463|DRUG|Humira|Assess the pharmacogenetic association between IKBKB gene polymorphism (SNPs) in psoriatic patients taking systemic biologic therapy
214999910|NCT01688492|DRUG|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
214392755|NCT06445855|BEHAVIORAL|Interpersonal relationship-based intervention program|An interpersonal relations-based intervention program will be implemented with an online intervention platform.
214392756|NCT04064554|DEVICE|BCG vaccination with MicronJet600|BCG vaccination with MicronJet600
214392757|NCT04064554|DEVICE|BCG vaccination with conventional needle|BCG vaccination with conventional needle
214392758|NCT02300480|PROCEDURE|CTB group|CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
214999911|NCT06734858|DEVICE|SAT014|SAT-014 in Combination with Baseline Conventional Treatment Participants in this arm will use the SAT-014 application for 6 weeks in combination with their baseline conventional treatment, which may include pharmacological therapy or simple counseling (excluding cognitive behavioral therapy and psychoanalytic counseling therapy). The aim of this study is to assess the efficacy and safety of SAT-014 for alleviating symptoms of trauma and stressor-related disorders, such as PTSD and adjustment disorder.
214999912|NCT06734858|OTHER|Control|Baseline Conventional Treatment Participants in this arm will receive only conventional treatment, which includes the medication they were taking at baseline for the indication or the basic counseling therapy they were receiving at baseline.
214999913|NCT07049341|DEVICE|MemorEM|The MemorEM device delivers 915MHz electromagnetic waves to the head via 8 emitters in a cap worn on the head and powered by a control box and battery worn on the arm.
214999914|NCT02769273|DEVICE|Percutaneous Transluminal Angioplasty|
214999915|NCT06726096|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection|"The drug was administered once every 4 weeks.~Other Names:~Tocilizumab Injection placebo control"
214999916|NCT02790515|DRUG|Anti-thymocyte globulin (rabbit)|Given intravenous (IV) prior to transplant on Days -14, -13, -12.
214999917|NCT02790515|DRUG|Blinatumomab|Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
214999918|NCT02790515|DRUG|Cyclophosphamide|Given by IV infusion prior to transplant on Day -9.
214999919|NCT02790515|DRUG|Fludarabine|Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
214999920|NCT02790515|DRUG|G-CSF|Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
214999921|NCT02790515|DRUG|Melphalan|Given IV prior to transplant on Days -2 and -1.
215094303|NCT04634942|DEVICE|Cryos REF 0971 Cold Spray|Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
214392759|NCT02300480|PROCEDURE|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
214392760|NCT01210235|BEHAVIORAL|FLU-FIT Program|In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
214392761|NCT05444673|DRUG|Paprizumab combined with cisplatin and 5-FU|Patients with advanced temporal bone cancer were treated with pabulizumab combined with cisplatin and 5-FU
214392762|NCT02524054|DRUG|Furosemide|80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
214392763|NCT02524054|DRUG|Aerosolized saline|8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
214392764|NCT04314063|OTHER|nasal swap|nasal swap to detect prevalence of staph aureus in food handlers
214688086|NCT06682793|DIAGNOSTIC_TEST|xT CDx with HLA-LOH assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
214688087|NCT06683014|DRUG|MDMA|Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).
214688088|NCT07015983|DRUG|CC-97540|Specified dose on specified days
214688089|NCT07015983|DRUG|Fludarabine|Specified dose on specified days
214999922|NCT02790515|DRUG|Mesna|Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
214999923|NCT02790515|DRUG|Rituximab|Given IV prior to transplant on Day -1.
214999924|NCT02790515|DRUG|Tacrolimus|Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
214999925|NCT02790515|DRUG|Thiotepa|Given IV prior to transplant on Day -3.
214999926|NCT02790515|BIOLOGICAL|HPC,A Infusion|Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
214392765|NCT04932720|BEHAVIORAL|chıld yoga programme|"Yoga sessions were in the form of 6 sessions and were held as 2 sessions per week. The program was given by an expert yoga instructor who has an international Yoga Alliance approved child and adolescent yoga certificate.Consisting of the components of Hatha Yoga (HY), one of the yoga types known and widely practiced all over the world; Sessions consisting of asanas (yoga postures), pranayamas (breathing techniques), relaxation, relaxation exercises and meditation were prepared. Sessions are 45 minutes; For those who are new to yoga for the first 15 minutes; mental and physical preparation; asanas, pranayamas were taught, drama followed by breathing exercises and asanas in the next 30 minutes, relaxation techniques (imaginary journey) and meditation in the last 15 minutes."
214392766|NCT05421520|DEVICE|Artificial intelligence assisted system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
214392767|NCT01581879|DRUG|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
214392768|NCT02300389|RADIATION|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
214999927|NCT02790515|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
214999928|NCT02790515|DRUG|Sirolimus|Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
214999929|NCT06732154|DRUG|HRS-5632|HRS-5632 Injection
214999930|NCT06732154|DRUG|Placebo|Sodium chloride injection
214999931|NCT06886464|DRUG|Cilastatin Sodium|Intravenous cilastatin reconstituted in normal saline solution
214999932|NCT06886464|DRUG|Placebo-Saline|Identical looking normal saline solution
214999933|NCT06760546|DRUG|Setmelanotide|Solution for daily subcutaneous injection
214999934|NCT06760546|DRUG|Placebo|Placebo matched to setmelanotide for daily subcutaneous injection
214999935|NCT07048496|OTHER|BCG delivery at home|The BCG at home project will be a single-arm prospective pilot, to evaluate the feasibility, scalability and effectiveness of home treatment, and utilize the BB-Bot (chatbot) for PRO and adverse event measurement.
214999936|NCT06752213|DEVICE|Vagus nerve Stimulation|Vagus nerve Stimulation
214999937|NCT06752213|OTHER|Manual therapy|Manual therapy
214999938|NCT06769022|BEHAVIORAL|Goal Setting and Exercise Intensity Intervention|Participants' goal-setting and exercise intensity are manipulated based on group assignment.
214999939|NCT06827002|DRUG|Dichrostachys glomerata|DGE were procured from Gateway Health Alliances, Fairfield in 400 mg and 300 mg capsules.
215094304|NCT04634942|DEVICE|ShotBlocker BIONIX Press Firmly USA|ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
214999940|NCT06827002|DRUG|Cissus quadrangularia|CQR-300® were procured from Gateway Health Alliances, Fairfield in 400 mg and 300 mg capsules.
214999941|NCT06827002|DRUG|Dextrin|Placebo capsules containing 400 mg of dextrin, looking identical to DGE and CQE were also procured from Gateway Health Alliances, Fairfield, California, USA.
214999942|NCT06827002|DRUG|Semaglutide (Rybelsus®)|Oral semaglutide (Rybelsus®) was purchased and then repackaged into capsules looking identical to DGE, CQE and placebo capsules.
214999943|NCT00632359|DRUG|Lenalidomide|10 mg daily given for 12 months
215094305|NCT00628147|DEVICE|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
215094306|NCT04356079|DIAGNOSTIC_TEST|International Headache Society Test|Thorough History of Patients and families
215094307|NCT06386679|BIOLOGICAL|allogenic amniotic fluid mesenchymal stem cell|Intra-articular AFCC injection will be given for single knee for each patient in single dose, 20 million of AFCC in each dose
215094308|NCT02411929|DRUG|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
214999944|NCT07064616|DEVICE|Catheter ablation using pulsed field ablation|"PulseSelect™ Pulsed Field Ablation System:~This intervention uses the PulseSelect™ system to perform pulsed field ablation (PFA) for pulmonary vein isolation in patients with persistent atrial fibrillation. PFA delivers short, high-voltage electrical pulses that selectively affect myocardial cells while minimizing damage to surrounding tissues such as the esophagus or phrenic nerve. This technique is designed to reduce procedural complications and improve safety compared to traditional thermal ablation methods."
214999945|NCT07064616|DEVICE|Catheter ablation using cryoballoon ablation|"Cryoballoon Ablation:~This intervention uses a cryoballoon catheter to perform pulmonary vein isolation by freezing tissue around the pulmonary veins. The balloon delivers extreme cold temperatures to create transmural lesions that block abnormal electrical signals responsible for atrial fibrillation. Cryoballoon ablation is widely used and considered effective for atrial fibrillation treatment but may carry risks related to collateral tissue injury."
214999946|NCT07066891|DRUG|CSII in the prediction model group|"1. Everyday insulin dosage decided by AI prediction model.~2. CSII treatment continues for 1 to 2 weeks based on whehter or not the patient is newly diagnosed or with different disease duration."
214999947|NCT07066891|DRUG|CSII in the empirical group|"1. Everyday insulin dosage decided by clinicans' experience.~2. CSII treatment continues for 1 to 2 weeks based on whether or not the patient is newly diagnosed or with different disease duration."
214392769|NCT02300389|RADIATION|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
214392770|NCT03936413|DEVICE|Bay Labs EchoGPS Echcoardiogram|An echocardiogram will be performed in this arm using the Bay Labs EchoGPS. The Bay Labs EchoGPS system is an ultrasound system which uses the techniques of computer vision to analyze echocardiography images in real time. It then provides feedback to the user to optimize the images, and once they meet a specific level of quality it automatically records the images.
214392771|NCT03936413|DEVICE|Native Terason Echocardiogram|An echocardiogram will be performed in this arm using a native Terason echocardiography system. This system will not have any artificial intelligence assistance in image optimization or selection.
214502278|NCT03090711|DEVICE|Transcranial Alternating Current Stimulation (tACS)|TACS stimulation involves two electrodes placed on either side of the desired site of cortical stimulation. The mode of stimulation used in this experiment is identical to previous studies using tACS in sleep ( Marshall et al., 2006; Prehn-Kristensen et al., 2014 ). Stimulation follows a sinusoidal pattern from 0 to 260 μA. This pattern is delivered at 0.75 Hz and is repeated for 225 cycles; a total of 5 minutes of stimulation. This 5 minute pattern is again repeated 5 times, with a minute of no stimulation between each; thus for a total of 30 minutes.
214502279|NCT03090711|DEVICE|sham Transcranial Magnetic Stimulation (TMS)|Sham coil will be used to exclude possible nonspecific effects of the TMS. The sham coil is shielded i.e., the magnetic field output is weakened and therefore insufficiently powerful to stimulate the cortex.
214999948|NCT07065058|DRUG|Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin|Single dose of Repaglinide at Day 2, Rosuvastatin and Digoxin at Day 3 Orally VCT220 once daily from Day 9 to Day 78, titrated from 20mg to 160mg. Co-administrated Repaglinide at Day 72, co-administrated Rosuvastatin and Digoxin at Day 73
214999949|NCT07064005|DRUG|Gamma- glutamylcysteine|400 mg (two times) per day
214999950|NCT07066202|OTHER|No intervention is planned in this study. Only the assessment of a specific condition.|No intervention is planned in this study. Only the assessment of a specific condition.
214999951|NCT04753515|DRUG|dexmedetomidine combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.
214999952|NCT04753515|DRUG|propofol combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.
214999953|NCT06776341|OTHER|GEMIN5-Related Neurodevelopmental Disorder|This is an observational study. The investigators will collect data from participants' medical records regarding neurodevelopmental outcomes (eg. cognitive, speech and language, motor skills, developmental skills, vision, hearing), Time to event (Acquistion and loss of developmental milestones), and, if available, data regarding MRIs (presence of cerebellar atrophy), survival, visiion, hearing, and biomarkers of disease.
214999954|NCT06769490|DRUG|Ziftomenib|Participants will receive treatment in tablet form
214392772|NCT03075293|OTHER|Determination of pain management|Determine of pain management given to children with appendicitis in ER according to their medical records
214392773|NCT00003288|BIOLOGICAL|filgrastim|
214999955|NCT06769490|DRUG|Quizartinib|Participants will receive treatment in tablet form
214999956|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
214999957|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
214999958|NCT02872714|DRUG|pemigatinib|Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
214999959|NCT02872714|DRUG|pemigatinib|Pemigatinib once a day by mouth continuously.
215094309|NCT02411929|DRUG|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
215094310|NCT02411929|DRUG|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
214502280|NCT03090711|DEVICE|sham Transcranial Alternating Current Stimulation (tACS)|Sham stimulation will be used to exclude possible nonspecific effects of the tACS. Sham tACS stimulation will involve actual stimulation for the first 30 seconds of the ramp-up period (stimulation power is gradually increased until its final level), and then immediately gradually decreased until zero (without the intermediate 4 minutes of actual stimulation). This procedure will be repeated 5 times every 6 minutes and shall induce similar cutaneous sensations as real stimulation.
214502281|NCT01728324|DRUG|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
214502282|NCT01728324|DRUG|Ribavirin: 24-week treatment|24 weeks of active treatment
214502283|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
214502284|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
214502285|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
214502286|NCT01728324|DRUG|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
215094311|NCT01276002|PROCEDURE|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
215094312|NCT05764174|BEHAVIORAL|Factual messages|Messages with descriptive data on COVID-19 vaccines
215094313|NCT05764174|BEHAVIORAL|Narrative message|Messages with emotional descriptions on COVID-19 vaccines
214392774|NCT00003288|DRUG|cyclophosphamide|
214392775|NCT00003288|DRUG|tirapazamine|
214392776|NCT05812703|BEHAVIORAL|Cognitive Behavioral Therapy|The participants will attend one of the behavioral group treatments programs offered by the Stanford Pain Management Center. This class may be held online via Zoom, or in person based at the Stanford Pain Management Center. The class may be recorded for training purposes. No names or images/faces will be recorded for privacy reasons. The behavioral groups are 3 types, with or without exercise/movement. Current Evidence Based treatments that are provided as standard practice include: Cognitive Behavioral Therapy Group, with movement, Acceptance and Commitment Therapy Group, with or without movement. Group participants will learn different skills in each group and develop a personalized plan to use the skills after group ends. At the end of group participants will be given an anonymous survey about the class to evaluate satisfaction of the treatment. Movement in this portion of class is designed to low impact and restorative/gentle, with no significant increases in HR \> 50% HRmax.
214392777|NCT05812703|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a 6 week behavioral group program led by a psychologist to improve psychological flexibility and reduce pain interference in patients with chronic pain.
214392778|NCT05812703|BEHAVIORAL|Moderate to high Intensity Group Exercise|Group exercise led by supervised clinician with Cardiovascular focus to increase HR into zones to see adaptations to improve cardiovascular fitness.
214392779|NCT03537261|BEHAVIORAL|Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)|Parents of children with ASD will be randomly assigned to the 6-hour P-CPI group training session, which includes nonverbal, paraverbal, verbal, and physical intervention techniques. Baseline measures will be administered on the day of training and follow-up measures at 2-week, 1-month, 2-month, and 3-month post baseline. The treatment group will also participate in an in-person follow-up group qualitative interview.
214392780|NCT03760822|DRUG|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
214392781|NCT03760822|DRUG|Paclitaxel|IV paclitaxel at 80 mg/m² on D1, D8 and D15
214688090|NCT07015983|DRUG|Cyclophosphamide|Specified dose on specified days
214999960|NCT06475547|OTHER|Descriptive|This study is observational and does not involve any clinical intervention. The primary procedure involves the collection of epicardial fat tissue samples. The collected samples are then processed and analyzed to compare inflammatory gene expression between the two groups. The analysis includes RNA sequencing to identify differentially expressed genes associated with atrial fibrillation and inflammation.
214999961|NCT07062965|DRUG|PF-07248144|KAT6 inhibitor
214999962|NCT07062965|DRUG|Fulvestrant|Endocrine therapy
214999963|NCT07062965|DRUG|Everolimus|mTOR inhibitor
214999964|NCT07062965|DRUG|Exemestane|Endocrine therapy
214999965|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 1
214999966|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 2
214999967|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 3
214999968|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
214999969|NCT01434316|DRUG|Dinaciclib|Given IV
214999970|NCT01434316|DRUG|Veliparib|Given PO
214392782|NCT03237013|BEHAVIORAL|Facial Morphing Intervention|Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
214392783|NCT03237013|BEHAVIORAL|Mindfulness Intervention|Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
214392784|NCT00123513|BEHAVIORAL|Diet|Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.
214999971|NCT06392126|DRUG|nL-CHCHD-001|Personalized antisense oligonucleotide
214999972|NCT04905901|DRUG|Tranexamic acid|Tranexamic acid nebulization 15 minutes before sinus surgery
214999973|NCT04905901|OTHER|Saline placebo|Normal saline placebo nebulization 15 minutes before sinus surgery
214999974|NCT06788509|DRUG|JNJ-75348780|Participants from the parent study (75348780LYM1001 \[NCT04540796\]) who are deriving benefit from study treatment will continue to receive subcutaneous JNJ-75348780.
214999975|NCT06788509|DRUG|JNJ-67856633|Participants from the parent studies (64264681LYM1002 \[NCT04657224\], 67856633LYM1002 \[NCT04876092\] and 67856633LYM1001 \[NCT03900598\]) who are deriving benefit from study treatment will continue to receive JNJ-67856633 orally.
214999976|NCT06788509|DRUG|JNJ-54179060|Participants from the parent study (67856633LYM1002 \[NCT04876092\]) who are deriving benefit from study treatment will continue to receive JNJ-54179060 orally.
214999977|NCT06788509|DRUG|JNJ-64264681|Participants from the parent studies (64264681LYM1001 \[NCT04210219\], 64264681LYM1002 \[NCT04657224\]) who are deriving benefit from study treatment will continue to receive JNJ-64264681 orally.
214999978|NCT06788509|DRUG|JNJ-74856665|Participants from the parent study (74856665AML1001 \[NCT04609826\]) who are deriving benefit from study treatment will continue to receive JNJ-74856665 orally.
214999979|NCT06788509|DRUG|JNJ-70218902|Participants from the parent study (70218902EDI1001 \[NCT04397276\]) who are deriving benefit from study treatment will continue to receive JNJ-70218902 orally.
214999980|NCT06788509|DRUG|JNJ-64619178|Participants from the parent study (64619178EDI1001 \[NCT03573310\]) who are deriving benefit from study treatment will continue to receive JNJ-64619178 orally.
214999981|NCT07070973|DEVICE|Assisted Fluid Management|Intraoperative fluid infusion will be regulated according to the Assisted Fluid Management (AFM) software and on Hypotension Prediction Index (HPI) will be used to titrate vasopressors and inotropes.
214392785|NCT00123513|BEHAVIORAL|Exercise|Increase routing physical activity, walking routes, stairs intervention, etc.
214688091|NCT07015151|DIAGNOSTIC_TEST|Low-dose Chest CT Screening|Participants undergo a low-dose chest CT scan to screen for early lung cancer and assess associated conditions (emphysema, coronary calcifications, osteoporosis).
214688092|NCT07015151|DIAGNOSTIC_TEST|Spirometry|Assessment of lung function through spirometry, with optional plethysmography and diffusion testing to detect COPD and PRISM patterns.
215094314|NCT05764174|BEHAVIORAL|Mixed message|Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
214392786|NCT00123513|BEHAVIORAL|Environment|Cafeteria and vending machine changes and identification of opportunities of physical activity.
214392787|NCT00288873|DRUG|Ergocalciferol|
214392788|NCT00288873|DRUG|Cholecalciferol|
214392789|NCT00237562|PROCEDURE|Large loop electrosurgical excision|
214392790|NCT04266743|DEVICE|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
214392791|NCT05508347|DRUG|Nituzumab/placebo|"Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy"
214392792|NCT02269618|OTHER|Home-based telehealth program|"Home-based telehealth program~* Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.~* Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms~* Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor~* Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need~* Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises."
214392793|NCT02269618|OTHER|Home-based rehabilitation|"Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer~* Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)~* Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient."
214392794|NCT02269618|OTHER|Usual care|Usual care All patients will be followed also in usual care manner by their GPs.
214392795|NCT01861756|OTHER|Diabetes Medication Choice decision aid|The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.
214999982|NCT07070973|OTHER|Goal Directed Fluid Therapy (GDT)|Institutional goal directed therapy protocol used to optimize SVI and reduce intraoperative hypotension
214999983|NCT07071779|OTHER|Alcohol-specific inhibition training|Twelve sessions of alcohol-specific inhibition training
214999984|NCT07071779|OTHER|Control training|Twelve sessions of unspecific inhibition training
214999985|NCT07071402|PROCEDURE|Ultrasound-guided vacuum-assisted excision combined with surgical treatment|Patients undergoing VAE surgery （EnCor® vacuum-assisted minimally invasive rotary system）are placed in an appropriate position, undergo routine disinfection and blanching, and the tumor location is located by ultrasound. After local anesthesia, a vacuum-assisted rotary cutting needle is percutaneous punctured beneath the tumor. Under ultrasound guidance, the tumor tissue is gradually resected until the ultrasound shows complete tumor resection. The resected tissue is sent for pathological examination. After the patient is confirmed to have breast cancer through VAE resection biopsy, depending on the patient's specific condition, they are hospitalized for radical mastectomy. The surgical methods can be breast-conserving surgery or mastectomy. At the same time, sentinel lymph node biopsy is performed, and the resected tissue is sent for pathological examination. The surgical process follows the surgical treatment norms for breast cancer.
214392796|NCT00502996|DRUG|Methotrexate|\>=15 mg po/week
214392797|NCT00502996|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
215094315|NCT03583736|BEHAVIORAL|Virtual visit|Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
215094316|NCT03583736|BEHAVIORAL|Office visit|Scheduled office visit with oncologist following uterine cancer diagnosis.
215094317|NCT05614284|DEVICE|Virtuos|Use of autograft or Virtuous Lyograft as an adjunct to spinal fusion in TLIF.
215094318|NCT02001584|DRUG|Baclofen|
215094319|NCT02001584|DRUG|Memantine|
214392798|NCT01729728|DRUG|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
214392799|NCT06228729|PROCEDURE|Endotracheal intubation|Inserting endotracheal tube into the trachea
214392800|NCT03569917|OTHER|Rectal swab collection|Rectab swab collection will be performed at inclusion and 5 and 30 days later.
215094320|NCT02001584|DRUG|Placebo|
215094321|NCT02179814|DRUG|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
215094322|NCT02179814|DRUG|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
215094323|NCT02179814|DRUG|Placebo|Placebo at the second, third and fourth medication intake time point
215094324|NCT03133923|BIOLOGICAL|≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥3.0 lgCCID50/ml but \<3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
214392801|NCT02500979|DRUG|Pramlintide acetate|Pramlintide acetate administered by a separate pump
214392802|NCT02500979|DRUG|Placebo|Placebo administered by separate pump
214502287|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
214502288|NCT01728324|DRUG|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
215094325|NCT03133923|BIOLOGICAL|≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
214502289|NCT01728324|DRUG|Faldaprevir: 16-week treatment|16 weeks of active treatment
214392803|NCT02500979|DRUG|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
214392804|NCT02500979|DRUG|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
214392805|NCT03688789|OTHER|Hydrocortisone supplementation|"* Cortisol at T0 and T30 mins less than 550 nmol / L after ACTH 250 μG achieved during the last chemotherapy session~* Hydrocortisone supplementation in patients with biological adrenal insufficiency~* scale of quality of life estimated by EORTC QLQ-C30"
214392806|NCT04149262|DRUG|Fiasp|Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
214392807|NCT04149262|DRUG|Novorapid|Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
214392808|NCT04149262|DEVICE|640G pump|MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
214392809|NCT00610675|DRUG|Org 50081|One tablet daily
214392810|NCT05905887|DRUG|Rivoceranib Mesylate, Paclitaxel|"Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).~Rivoceranib 400 mg orally once a day."
214392811|NCT00799734|DRUG|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
214392812|NCT04126473|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
214392813|NCT04126473|DRUG|Ivacaftor|CFTR potentiator
214502290|NCT01728324|DRUG|Ribavirin: 16-week treatment|16 weeks of active treatment
214502291|NCT01728324|DRUG|RBV: 24-week treatment|24 weeks of active treatment
214502292|NCT01728324|DRUG|BI 207127: 16-week treatment|16 weeks of active treatment
214999986|NCT07071259|OTHER|TMS Stimulation|For the TMS session, participants will be positioned on a chair, in a seated position. They will be equipped with an EEG cap 64 active electrodes, using gel to ensure good measurements of brain activation, and a sensor on the forehead to measure the location of the head in space for the neuronavigation system. They will also wear headphones generating white noise to mask the TMS coil noise. Preparation time for the EEG acquisitions is estimated at 30 min. The TMS coil will be shaped in 8 for good spatial resolution. It will be positioned on the participant's head using a robot (approved medical CE) allowing good targeting accuracy and stability during the experiment. The stimulation target will be defined beforehand on the participant's MRI, and the robot will read this information to position itself.
214502293|NCT01335867|DRUG|Vigabatrin|Vigabatrin escalated to 3 grams daily for 8 weeks
214999987|NCT07071337|DRUG|SKB264|5mg/kg, IV on Day 1 and Day 15 of each 28 day cycle
214999988|NCT07071337|DRUG|Nab-paclitaxel|100 mg/m\^2, IV, on Days 1, 8, and 15 every 4 weeks
215094326|NCT03133923|BIOLOGICAL|Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)|Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day
215094327|NCT01833000|DEVICE|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
215094328|NCT02372422|OTHER|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
215094329|NCT02372422|OTHER|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
215094330|NCT02544997|DRUG|Poziotinib|12mg P.O. for 2wks q21days
214392814|NCT00267111|DRUG|Eucerin plus|1g, single application
214502294|NCT01335867|DRUG|Placebo|Placebo pills
214999989|NCT07071337|DRUG|Paclitaxel|90 mg/m\^2, IV, on Days 1, 8, and 15 every 4 weeks; or 80 mg/m\^2, IV, weekly, every 3 weeks
214999990|NCT07071337|DRUG|Capecitabine|1000-1250 mg/m\^2, orally, Days 1-14, twice daily, every 3 weeks
215094331|NCT03343600|DRUG|Imatinib|Imatinib 100 mg/tablet, 2 tablets daily
214392815|NCT00267111|DRUG|Amethocaine gel 4%|1 g, single application
214392816|NCT02862847|OTHER|stool samples|
214392817|NCT01822028|DRUG|Treatment A|Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
214392818|NCT01822028|DRUG|Treatment B|"Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day)."
214392819|NCT01316692|OTHER|laboratory biomarker identification and analysis|Correlative studies
214392820|NCT01316692|PROCEDURE|biopsy|Correlative studies
214392821|NCT01316692|OTHER|immunohistochemistry/tissue microarrays|Correlative studies
214392822|NCT01316692|GENETIC|TdT-mediated dUTP nick end labeling assay|Correlative studies
214392823|NCT01316692|OTHER|mass spectrometry|Correlative studies
214502295|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
214502296|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
214502297|NCT00831506|DRUG|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
214502298|NCT02604251|DEVICE|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
215094332|NCT03343600|DRUG|Placebo|Placebos 2 tablets daily
215094333|NCT00301288|PROCEDURE|Autologous stem cell transplant|
215094334|NCT02095509|DRUG|Enoxaparin|Drug class: Low-molecular weight heparin
214999991|NCT07070700|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706 will be administered by IV, 5 mg/kg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214392824|NCT02368002|BEHAVIORAL|Behavioral weight loss therapy|All participants start with behavioral weight loss therapy which consists of 20 weekly meetings wtih a weight loss coach. Session components will include weekly weigh-in, discussion of progress and challenges and discussion of scheduled session topic. Dietary goals and physical activity goals are set. After their first session, participants are randomized to have their weight assessed at either their 3rd session or their 7th session. Both the participant and their coach are blinded to the randomization. If the participant has lost the expected amount of weight, they continue with behavioral weight loss therapy for the full 20 session.
214392825|NCT02368002|BEHAVIORAL|Portion-controlled meals|"Participants continue with behavioral weight loss therapy, but this is augmented with portion-controlled meals (PCM). Adherence to energy intake goals is facilitated by consuming pre-prepared meals specifically designed to meet caloric intake guidelines. PCMs reduce individuals' motivationally- and self-regulatory-dependent planning and decision making around eating. PCMs also serve as a teaching tool regarding the amount and type of food people should eat in order to produce weight loss."
214502299|NCT02604251|DEVICE|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
214502300|NCT02520674|OTHER|optic nerve head ophthalmoscopy|Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
214502301|NCT03057600|DRUG|Paclitaxel|standard weekly paclitaxel in 28-day cycles
214502302|NCT03057600|DRUG|CB-839|CB-839 administered as oral tablets twice daily (BID)
214502303|NCT05642806|BIOLOGICAL|Mepolizumab|Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
214502304|NCT05642806|OTHER|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
214502305|NCT04288167|DIAGNOSTIC_TEST|Sample collection|Samples of urine and saliva will be collected from participants using customary sample collection means.
214999992|NCT07070700|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214392826|NCT02368002|BEHAVIORAL|Acceptance-based treatment|Switching the therapeutic approach to an enhanced behavioral weight loss therapy teaching acceptance-based behavioral skills theoretically addresses the root problem of many weight loss challenges and boosts long-term capacity for self-regulation. Acceptance based strategies are designed to help participants identify and internalize values and lasting commitment to behavior consistent with these values. The strategies focus on increasing people's ability to forgo more pleasurable options (e.g., hedonic pleasure of food) in favor of behavior that is distinctly less pleasurable or even aversive (remaining hungry, anxious, bored). The inability to tolerate such distress is directly associated with failure of self-regulation.
214392827|NCT04967625|DRUG|Sintilimab|A humanized anti-PD-1 monoclonal antibody
214392828|NCT04967625|DRUG|Anlotinib hydrochloride|A tyrosine kinase inhibitor selectively targeting VEGFR-2
214502306|NCT04305197|DRUG|ICP-022|Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
214502307|NCT04305197|DRUG|ICP-022|Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
214502308|NCT04305197|DRUG|ICP-022|Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
214999993|NCT07070700|PROCEDURE|cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. Lenvatinib plus QL1706 will be administered 1-3 days after cryoablation.
214999994|NCT06383611|COMBINATION_PRODUCT|VT-X7 Treatment System|Local antibiotic irrigation via the VT-X7 Treatment System adjuvant to two-stage exchange arthroplasty per standard of care.
214999995|NCT06214507|OTHER|No intervention|No intervention
214999996|NCT07073274|DIAGNOSTIC_TEST|EEG analysis|All patients will have a continous recording of their EEG during anesthesia
215094335|NCT03027232|OTHER|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
214502309|NCT04305197|DRUG|Placebos|Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
214502310|NCT04715815|OTHER|No intervention (only interview)|Interview
214502311|NCT00076115|DRUG|Risperidone|
214502312|NCT03489369|DRUG|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
214999997|NCT07070349|DRUG|HRS-6213|HRS-6213 IV administered as imaging agent for PET scan.
214999998|NCT03973229|DRUG|Estradiol patch|Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
214999999|NCT03973229|OTHER|Placebo patch|Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
215000000|NCT05813873|OTHER|Triflow|Triflow
215000001|NCT05813873|OTHER|Control|Exercise
215000002|NCT06632951|DRUG|Livmoniplimab|Intravenous (IV) Infusion
215000003|NCT06632951|DRUG|Budigalimab|IV Infusion
215094336|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
214502313|NCT00002437|DRUG|Cidofovir|
214502314|NCT00002437|DRUG|Probenecid|
215000004|NCT06632951|DRUG|Docetaxel|IV Infusion
215000005|NCT06632951|DRUG|Paclitaxel|IV Injection
215000006|NCT06632951|DRUG|Docetaxel|IV Injection
215094337|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
215094338|NCT04452773|DIETARY_SUPPLEMENT|Manremyc|Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli
215000007|NCT06632951|DRUG|Paclitaxel|IV Infusion
215000008|NCT06632951|DRUG|Gemcitabine|IV Infusion
214392829|NCT01536145|DRUG|CP-751,871|CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
214392830|NCT04683302|DEVICE|3DUS biplanar catheterization|biplanar view of both short and long axis view of the internal jugular vein improves anatomical awareness and potentially improves safety of venous catheterization
214392831|NCT04683302|DEVICE|2D US catheterization|2D short axis internal jugular vein catheterization
214392832|NCT01257139|PROCEDURE|Dual-agent therapy or docetaxel alone or best supportive care|"ARM B: (245 patients)~Treatment if the SGS screening test is negative:~* non epidermoid tumor:~* Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.~* epidermoid tumor:~* Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management."
214392833|NCT06207643|PROCEDURE|carotid endarterectomy|removing carotid artery atheromatous plaque surgically
214502315|NCT05558072|GENETIC|Toll-like receptor 4|Toll-like receptor 4
214502316|NCT03044457|PROCEDURE|TKA|"femoral and tibial positioning using the reversed gap technique"
214502317|NCT05340452|DRUG|Klaribact 125mg/5ml Suspension|one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
214502318|NCT05340452|DRUG|Klaricid 125mg/5ml Suspension|one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
214502319|NCT06510569|DEVICE|U lab aligners|Aligner group change the aligner every 10 days
214502320|NCT06510569|DEVICE|oramco bracket|changing orthodontic wire every one month
214502321|NCT04154007|DIAGNOSTIC_TEST|kidney function tests - urine output|"AKI was classified based on the worst of either creatinine or urine output criterion as follows:~Stage I 1.5-1.9 times baseline OR ≥0.3 mg/dl increase in the serum creatinine, OR urine output \<0.5 ml/kg per hour for 6 to 12 hours.~Stage II 2.0-2.9 times baseline increase in the serum creatinine OR urine output \<0.5 ml/kg per hour for ≥12 hours.~Stage III 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to ≥4.0 mg OR urine output of \<0.3 ml/kg per hour for ≥24 hours, OR anuria for ≥12 hours OR the initiation of renal replacement therapy."
214502322|NCT06104618|DRUG|Enfortumab Vedotin|Given IV
214502323|NCT06104618|PROCEDURE|Computed Tomography|Undergo CT
214392834|NCT03869645|DEVICE|CAPERE Thrombectomy System|Mechanical thrombectomy of acute thrombus in peripheral vasculature with the CAPERE Thrombectomy System
214392835|NCT00579982|DRUG|Lamotrigine|Experimental formulation
214392836|NCT03184090|DRUG|Palbociclib|palbociclib in combination with endocrine therapy (investigator's choice)
214392837|NCT03184090|DRUG|Endocrine therapy (non IMP)|Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
214392838|NCT02361060|DRUG|Neostigmine|40mcg/kg
214392839|NCT02361060|DRUG|Sugammadex|4mg/kg
214392840|NCT02361060|DRUG|Atropine|10 mcg/kg
214392841|NCT06026722|BEHAVIORAL|cognitive behavioral therapy for insomnia|CBT-I is a 4-session program built around 3 main axes: psychoeducation on sleep hygiene, cognitive therapy and behavioral stimulus control, sleep restriction and relaxation. Each of the 3 axes will be worked on over 3 sessions, the last one being a summary and consolidation session of the first 3. For ethical reasons, it has been decided that patients in the control arm will also follow CBT-I (on a waiting list). The control group will have the same follow-up as the experimental group, but will start the intervention 6 months after the experimental group. This will enable all patients to access CBT-I.
214392842|NCT06420102|DIAGNOSTIC_TEST|Biophysical and biochemical skin assessment|Measurements are taken from the skin surface including transepidermal water loss, skin hydration and pH. In addition, non-invasive biofluid (sebum) is sampled from the skin to profile local inflammation. Skin surface cells were also stripped to assess corneocyte properties over the pressure ulcer and surrounding healthy skin.
214502324|NCT06104618|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214502325|NCT03937765|PROCEDURE|PRP harvest and preparation|"The PRP harvest and preparation will be done in the operating room with the help of the hospital blood bank. The skin graft surgery will be completed by Dr. Jason Lowe and/or one of the Orthopaedic Surgery residents. Follow up will also be completed by Dr. Lowe or one of the residents. Data analysis will be done by Drs. Lowe and Manoharan.~Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage."
214502326|NCT04181099|OTHER|Implant neck surface|The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
214502327|NCT06635759|OTHER|Upper trapezius low-load endurance exercise|Participants in the EE group will perform the overhead shrug exercise for the affected side using a green Thera-Band Elastic Band. To perform this exercise, the subject will stand and place one arm of the affected side in an overhead position against the wall. The middle portion of the theraband will be placed on the floor, and the subject will stand on the middle portion of the theraband to fixate it in place with both feet shoulder-width apart. Then, the subject grasp both tails of the theraband and perform the shoulder shrug movement for the affected side with a 3-second elevation, hold at the end range for 5 seconds, and then return back to the starting position with a 3-second depression. The subject will perform this exercise for 20 repetitions per set, 3 sets a day with 1-minute rest between sets, 3 alternate days a week, for 5 weeks. They will be instructed to record all training sessions in a diary.
214688093|NCT07015151|DIAGNOSTIC_TEST|Cardiovascular Risk Assessment|Cardiovascular risk is evaluated using SCORE2/SCORE2-OP tools, based on blood pressure and cholesterol levels.
215094339|NCT04452773|DIETARY_SUPPLEMENT|Placebo|Same excipients than active arm without bacilli.
214392843|NCT01160120|DRUG|generic FDC of TDF/3TC/EFV|Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
214392844|NCT05199233|DEVICE|Muse S™ Headband system|Clinical grade, headband style, wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (smartphone or tablet).
214392845|NCT01358448|BEHAVIORAL|growth monitoring|Caretakers will be encouraged to monitor child growth monthly.
214392846|NCT01358448|BEHAVIORAL|Growth Monitoring plus Family-based Behavioral Counseling|Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
214392847|NCT00736073|DRUG|aprepitant|one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
214392848|NCT00736073|DRUG|Placebo|one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
214392849|NCT04399239|COMBINATION_PRODUCT|AuriNovo|AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
214392850|NCT03244241|DRUG|Insulin Degludec 100 UNT/ML [Tresiba]|Basal-bolus insulin regime
214392851|NCT01305096|OTHER|Yoga intervention|6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
214392852|NCT02669303|DRUG|platelet-rich plasma group|"Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the Recover(TM) Platelet Separation Kit (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder."
214392853|NCT02669303|DRUG|Methylprednisolone group|Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
214392854|NCT06226142|PROCEDURE|Percutaneous dilatational tracheostomy|Percutaneous dilatational tracheostomy
214392855|NCT06207370|DRUG|Tafenoquine|Oral Tafenoquine
214392856|NCT06207370|OTHER|Placebo|Placebo
214392857|NCT04037241|BIOLOGICAL|Anti-CEA CAR-T cells|Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
214392858|NCT04037241|DRUG|gemcitabine/nab paclitaxel|systemic chemotherapy regimen
214392859|NCT04037241|DRUG|NLIR+FU/FA|systemic chemotherapy regimen
214392860|NCT04037241|DRUG|Capecitabine|systemic chemotherapy regimen
214392861|NCT05989867|DIAGNOSTIC_TEST|blood test|"Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors"
214392862|NCT05989867|DEVICE|Continuous Glucose Monitor|blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control )
214392863|NCT00110760|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
214392864|NCT00110760|DRUG|Placebo Peel|Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
215094340|NCT02350738|OTHER|Period I MCET (8 wks)|MCET\_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock\_MCET group: mock-therapy (3 sessions/wk)
215094341|NCT02350738|OTHER|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
214392865|NCT05270317|PROCEDURE|Bone Graft Cultivation and Harvesting|Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.
214392866|NCT02795260|BIOLOGICAL|Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
214392867|NCT02795260|BIOLOGICAL|placebo of Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
214688094|NCT07015151|BEHAVIORAL|Smoking Cessation Support|Active smokers receive a structured smoking cessation intervention, including a baseline consultation and up to two follow-up sessions (which may be remote).
215094342|NCT02350738|OTHER|Period II MCET (8 wks)|MCET\_Mock group: mock therapy (MCET) (3 sessions/wk) Mock\_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
214688095|NCT07015151|OTHER|Optional Biospecimen Collection (Bio-ILYAD)|Optional collection of blood and exhaled breath condensate for future analysis of biomarkers in lung cancer detection.
215094343|NCT02557984|DRUG|Placebo|Placebo Pill
215094344|NCT02557984|DRUG|Amisulpride|400 mg Amisulpride
215094345|NCT02557984|DRUG|Naltrexone|50 mg Naltrexone
215094346|NCT03031119|DRUG|Placebo|Tablets administered once or twice daily, with food, in Part A.
215094347|NCT03031119|DRUG|PF-06835919|Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
215000011|NCT05063162|DRUG|Rozanolixizumab|"* Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive pre-specified doses of rozanolixizumab."
215000012|NCT05063162|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive placebo."
215000013|NCT05046080|OTHER|Electronic Health Record Review|Medical records reviewed
214392868|NCT03614884|BEHAVIORAL|Gambling and Smoking Treatment|The treatment condition will have access to 7 treatment modules on content surrounding both gambling and smoking behaviours. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling and smoking behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially. Participants in this condition will also be provided with nicotine replacement therapy (NRT) in the form of nicotine patches to use for the duration of the study.
214392869|NCT03614884|BEHAVIORAL|Gambling only treatment|The control condition will have access to 7 treatment modules on content surrounding gambling only. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
214392870|NCT03027505|DRUG|Ready to Use Therapeutic Food (RUTF)|"MUAC used as the primary admission and exit criteria for children with MUAC \<125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~* MUAC \<115 mm: 175 kcal /kg/day~* 115 \<MUAC \<120mm: 125kcal/kg/day~* 120 \<MUAC \<125mm: 75kcal/kg/day"
214392871|NCT02443103|DRUG|Guanabenz acetate|
214392872|NCT05624723|DRUG|INCB054707|INCB054707 75 mg will be administered orally
214392873|NCT03669094|DIETARY_SUPPLEMENT|Lactobacillus salivarius V4II-90|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the Lactobacillus salivarius V4II-90 (1\*10E9 CFU) probiotic supplement over a 12 weeks period. A visit will then be completed one month after delivery.
214392874|NCT03669094|DIETARY_SUPPLEMENT|Placebo|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the placebo supplement over a 12 weeks period. A visit will then be completed one month after delivery.
214392875|NCT02878070|BEHAVIORAL|Calls from a Peer Health Coach for 6 months|Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
215000014|NCT05046080|OTHER|Laboratory Biomarker Analysis|Correlative studies
215000015|NCT07073170|DRUG|LY3549492|Administered orally
214392876|NCT01630590|DRUG|Cabozantinib|Starting dose of 60 mg by mouth every day of a 21 day cycle.
214392877|NCT01630590|DRUG|Androgen Ablation Therapy|Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
214392878|NCT02366936|DEVICE|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
214392879|NCT02067351|BEHAVIORAL|Mindfulness|Meditation, body scan, yoga.
214392880|NCT03069560|DEVICE|SMS|SMS contact from the caregiver with patient after discharge in intervention group
214392881|NCT02978989|PROCEDURE|nonsolo LC|This patient is scheduled to undergo nonsolo laparoscpic cholecystectomy.
215000016|NCT07073170|DRUG|Placebo|Administered orally
215000017|NCT07066189|BEHAVIORAL|Exercise and Medical Nutrition|10, 30-minute sessions spread out over the course of their neoadjuvant therapy and in the weeks leading up to surgery. On weeks counseling is not scheduled an exercise session will be observed.
215000018|NCT07069244|DIAGNOSTIC_TEST|Complete Blood Count Test|Complete blood count test provides data on total white blood cell count, neutrophil count, neutrophil percentage, lymphocyte count, lymphocyte percentage, monocyte count, monocyte percentage, eosinophil count, eosinophil percentage, basophil count, basophil percentage, platelet count, platelet distribution width (PDW), mean platelet volume (MPV), plateletcrit (PCT), erythrocyte count, hemoglobin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and red blood cell distribution width (RDW). In addition, neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet-leukocyte ratio (PLR), Pan-Immune-Inflammation Value (PIV), Systemic Immune-Inflammation Index (SII), Hemoglobin-to-Red Cell Distribution Width Ratio (HRR) values are also formulated from these parameters.
215000019|NCT07069244|DIAGNOSTIC_TEST|Periodontal examinations|With periodontal evaluation, plaque percentage, probing pocket depth, percentage of bleeding on probing, clinical attachment level, number of teeth, periodontal inflammatory surface area (PISA) parameters are recorded.
215000020|NCT07069244|DIAGNOSTIC_TEST|Clinical Dementia Rating scale|Stage I: mild Alzheimer's disease, Stage II: moderate Alzheimer's disease, Stage III: severe Alzheimer's disease
215000021|NCT07069244|DIAGNOSTIC_TEST|Standardized Mini-Mental Test|Cognitive status is assessed with the Standardized Mini-Mental Test.
215000022|NCT07073235|DEVICE|Intermittent Theta Burst Stimulation|iTBS protocol: 600 pulses at 80% of AMT for 190 sec on the contralesional cerebellum, targeted with the support of a neuronavigational system, 15 sessions over a period of 5 weeks
215094348|NCT03031119|DRUG|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
215094349|NCT05105815|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
215094350|NCT01233388|OTHER|Text message surveillance|Text message surveillance for vaccine adverse events
215094351|NCT02715726|DRUG|Alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
214392882|NCT02978989|PROCEDURE|solo LC|This patient is scheduled to undergo solo laparoscpic cholecystectomy.
214392883|NCT00656916|DRUG|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
214392884|NCT00287248|DRUG|[123I] IMPY & SPECT Imaging|Subjects will be injected with 7mCi of \[123I\]IMPY, followed by SPECT imaging
214392885|NCT03352063|BEHAVIORAL|Prolonged sitting with exercise|Subjects will commit to sitting more than 11 hours per day and taking less than 5000 steps per day while participating in exercise training.
214392886|NCT03352063|BEHAVIORAL|Active walking with exercise.|Subjects will commit to sitting less than 5 hours per day and taking more than 10000 steps per day while participating in exercise training.
214392887|NCT03358329|COMBINATION_PRODUCT|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
214392888|NCT01313923|DRUG|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
214392889|NCT06393218|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214392890|NCT06393218|BEHAVIORAL|Diaphragm Training|Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
214392891|NCT06393218|BEHAVIORAL|Routine rehabilitation|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214392892|NCT02471404|DRUG|Dapagliflozin|10 mg, orally Green, plain, diamond-shaped, film-coated tablet
215000023|NCT07073235|DEVICE|Sham Intermittent Theta Burst Stimulation|It is identical to its active version, replicates operational sounds, and delivers a very shallow magnetic field to mimic the sensation of magnetic stimulation.
214392893|NCT02471404|DRUG|Saxagliptin|5 mg, orally Plain, yellow, biconvex, round, film-coated tablet
214392894|NCT02471404|DRUG|Glimepiride|1, 2, or 4 mg, orally Opaque gray capsule
214392895|NCT02471404|DRUG|Placebo for dapagliflozin|Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet
215000024|NCT07073248|DEVICE|Intermittent Theta Burst Stimulation|iTBS protocol: 600 pulses at 80% of AMT for 190 sec on the ipsilesional motor cortex, targeted with the support of a neuronavigational system, 15 sessions over a period of 5 weeks
215000025|NCT07073248|DEVICE|Sham Intermittent Theta Burst Stimulation|It is identical to its active version, replicates operational sounds, and delivers a very shallow magnetic field to mimic the sensation of magnetic stimulation
215000026|NCT07071883|BEHAVIORAL|Holotropic breathwork|HB is the practice of self-directed hyperventilation while lying down with the support of a selected music set and trained facilitators. Participants may experience an expanded state of consciousness with altered cognition, perception, and emotions.
215000027|NCT07071883|BEHAVIORAL|Multiple modality|Multiple Modality (MM) intervention (yoga, meditation, and a film/discussion)
215000028|NCT05993884|DRUG|iEPCs|Patients receive iEPCs IV with the single dose
215000029|NCT05993884|DRUG|Placebo|Patients receive placebo IV with a single dose
214392896|NCT02471404|DRUG|Placebo for saxagliptin|Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet
214392897|NCT02471404|DRUG|Placebo for glimepiride|Does not contain active ingredient, orally. Opaque gray capsule
214392898|NCT04994041|OTHER|Pelvic floor muscle plus adductor strengthening|20 sessions of pelvic floor muscle strengthening plus adductor is strengthening
215000030|NCT06794866|DRUG|OnabotulinumtoxinA|Intramuscular Injections
214392899|NCT04994041|OTHER|Pelvic floor muscle exercises|20 sessions of pelvic floor muscle strengthening
214392900|NCT03417882|BIOLOGICAL|GRN-1201 + Pembrolizumab|GRN-1201 will be administered in combination with Pembrolizumab
215000031|NCT06794866|DRUG|Placebo|Intramuscular Injections
215000032|NCT04610866|DRUG|Mitapivat|Investigational drug mitapivat (also known as AG-348, AGI-1480 and AGX-0841) is an orally bioavailable, broad-spectrum allosteric activator of alleles of the RBC-specific form of pyruvate kinase (PKR), as well as liver-type pyruvate kinase (PKL) and muscle pyruvate kinase (PKM1 and PKM2).
215000033|NCT06797713|PROCEDURE|Esophageal doppler|Fluid/inotrope decisions will be made with parameters such as stroke volume (SV), stroke volume variation (SVV), pulse pressure variation (PVV), systemic vascular resistance (SVR), and cardiac output (CO) on the Doppler monitor screen.
215000034|NCT06797713|PROCEDURE|Conventional method|Fluid therapy is performed by monitoring parameters such as blood pressure, urine output, lactate...
214688096|NCT05412212|OTHER|LTBI video intervention|3-minute educational video about latent tuberculosis and importance of taking and completing treatment
214392901|NCT02088827|OTHER|Inactivity|Subjects will remain inactive (lying on a bed) for 4 hours.
214688097|NCT04626245|BEHAVIORAL|Mindfulness training|Phone-delivered brief mindfulness training based on principles of MBSR
215000035|NCT06874361|DEVICE|Mi-Helper|The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
215000036|NCT06680128|BIOLOGICAL|GBP560-A|"injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"
215000037|NCT06680128|BIOLOGICAL|GBP560-B|"injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"
215000038|NCT06680128|BIOLOGICAL|IXIARO|injection volume of 0.5mL on V2(1day) and V5 (29day) in stage1 and stage2
215000039|NCT06680128|BIOLOGICAL|IMOJEV|injection volume of 0.5mL on V5 (29day) in stage1 and stage2
214392902|NCT02088827|OTHER|Activity|Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
214392903|NCT01682564|DRUG|Candemore tablet|"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
214392904|NCT01682564|DRUG|Atacand tablet|"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
214392905|NCT05197686|DEVICE|Oxygen theraphy with high flow nasal cannule|Oxygen theraphy with high flow nasal cannule
214392906|NCT05197686|DEVICE|Oxygen theraphy with mask with reservoir|Oxygen theraphy with mask with reservoir
214392907|NCT00401674|DRUG|carboplatin|
214392908|NCT00401674|DRUG|paclitaxel|
214392909|NCT02982720|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously.
214392910|NCT02982720|DRUG|Sylatron|Sylatron will be administered subcutaneously.
214392911|NCT03418935|DRUG|Remaxol (succinate + methionine + inosine + nicotinamide)|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
214392912|NCT03418935|DRUG|Ringer's Solution|Intravenous infusion, 400 or 800 ml
214392913|NCT01952964|OTHER|JUC spray dressing|"Intervention group Care of Tenckhoff catheter exit site using spray dressing. The detailed procedures will be introduced by the nurse according to the protocol of the unit. Please refer to Appendix III for details.~Skin test with JUC spray will be carried out prior to the usage of JUC spray dressing for caring the exit site. For the first three days after patient has been discharged, study team members will perform telephone follow up. Patients are reminded to report for signs and symptoms of infection or physical damage of catheter noted. A routine follow up at the Renal Unit will be arranged at eight weeks intervals."
214392914|NCT05993286|BEHAVIORAL|Exposure Therapy|"At Week 0, the homework was to expose oneself to these sounds for 20 minutes a day, three days a week for three weeks.~At the Week 3 interview, the frequency and severity of the homework were adjusted based on the degree of improvement in the symptoms and the person's adherence to the instructions."
214392915|NCT05993286|OTHER|Sound Therapy|Participants were asked to listen to specifically modulated music for twenty minutes a day, three days a week, for the first three weeks. At the Week 3 assessment, if the patient reported no or little benefit in their misophonia symptoms, the instruction was modified (intensified) to listening to the same music for forty minutes a day, three days a week.
214392916|NCT05993286|OTHER|Psychoeducation|A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.
214392917|NCT01676025|PROCEDURE|PRA|
214392918|NCT01676025|PROCEDURE|LA|
214392919|NCT06339125|OTHER|Fall prevention algorithm|Algorithm generates fall prevention alerts to nurses in real time, using evidenced based electronic health record information regarding changes in care that may suggest the need for additional fall prevention strategies
214392920|NCT06339125|OTHER|Inspiren camera visualization|The Inspiren computer camera visualization is an additional strategy for nurses to employ when there is a change in a patient's fall risk.
214392921|NCT02144519|BEHAVIORAL|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
214392922|NCT05295563|OTHER|Evaluation|Gastrocnemius muscle morphology (cross-sectional area, muscle thickness, fascicle length, pennation angle), muscle stiffness, muscle vascularization and functionality of children with CP will be evaluated.
215000040|NCT06680128|BIOLOGICAL|Normal Saline (Placebo)|injection volume of 0.5mL on V2 (1day) in stage1 and stage2 (This is for IMOJEV placebo)
215000041|NCT06771323|DRUG|Valbenazine|To assess if valbenazine 80mg daily improves motor symptoms in idiopathic CD patients with persistent symptoms despite current treated with botulinum toxin injections.
215000042|NCT06771323|DRUG|Placebo|Placebo
215000043|NCT06419608|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 6 weeks
215000044|NCT06419608|DRUG|Placebo|Matching placebo taken once daily for 6 weeks
214392923|NCT00633737|BEHAVIORAL|Stress reduction intervention|In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
214392924|NCT00305864|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
214392925|NCT00305864|DRUG|Motexafin Gadolinium|Given IV
214392926|NCT00305864|DRUG|Temozolomide|Given orally
214392927|NCT02912156|DRUG|Vaway FC Tablets 200mg (Voriconazole)|
214392928|NCT02912156|DRUG|VFEND FC Tablets 200mg (Voriconazole)|
214392929|NCT05586854|PROCEDURE|Hydrolink NV membrane|"patient dialysis on a Hydrolink-NV® membrane with an anticoagulant dose decrease protocol.~Period 1 : conventional membrane with his usual anticoagulant for 4 weeks. Period 2 : Hydrolink-NV® membrane with maintenance of the previous doses of Orgaran® Period 3 : Hydrolink-NV® membrane with a decrease in Orgaran® Period 4 : Hydrolink-NV® membrane with the minimum effective dose of Orgaran® or without Orgaran® for a period of 3 months (M4, M5, M6)."
214392930|NCT00171405|DRUG|aliskiren|
214392931|NCT01435044|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
214688098|NCT06875479|DIAGNOSTIC_TEST|Five Seasons [5S] Sleep Tracking Mat|The Five Seasons \[5S\] Sleep Tracking Mat consists of a main control box, monitoring mat, temperature/humidity sensor, power adapter, and light sensor. It utilizes Ballistocardiogram (BCG) technology to detect heartbeat, respiration, body movements, and snoring. The collected data is analyzed by a proprietary pre-trained AI model, enabling automatic detection of respiratory events, calculation of the Apnea-Hypopnea Index (AHI), and sleep stage interpretation. Compared to other sleep monitoring devices, it is non-contact and requires no wearable components, making it particularly suitable for long-term, daily home use.
214688099|NCT06713642|DEVICE|SPOTFIRE ST System|Polymerase chain reaction (PCR) test that identifies up to 13 different viral and bacterial pathogens in about 20 Minutes
214392932|NCT01435044|DRUG|GS-0938|GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily
214392933|NCT01435044|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
214392934|NCT01435044|DRUG|Placebo to match sofosbuvir|Placebo to match sofosbuvir administered orally once daily
214392935|NCT01435044|DRUG|Placebo to match GS-0938|Placebo to match GS-0938 administered orally once daily
214392936|NCT02018237|BEHAVIORAL|High fructose corn syrup diet|Subjects will consume a high fructose corn syrup diet for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
214392937|NCT02018237|BEHAVIORAL|Standard diet (low in high fructose corn syrup)|Subjects will consume a standard diet (low in high fructose corn syrup) for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
214392938|NCT02276378|DRUG|Telmisartan low|
214392939|NCT02276378|DRUG|Telmisartan high|
214392940|NCT02276378|DRUG|Hydrochlorothiazide (HCTZ)|
214392941|NCT02276378|OTHER|Japanese meal|
214392942|NCT02836613|BIOLOGICAL|Galcanezumab|Administered SC
214392943|NCT05071274|DEVICE|Skinpen Prescision System|Skinpen Precision is an automated nonsurgical micro needling device designed for use by licensed health care practitioners or individuals directed by practitioners. The device incorporates a sterile Microneedle cartridge and Biosheath for single use only.
214392944|NCT03881059|OTHER|BMS-986165 Placebo|Participants will receive BMS-986165 matching placebo QD
214392945|NCT03881059|DRUG|BMS-986165 Dose A|Participants will receive BMS-986165 Dose A QD.
214392946|NCT03881059|DRUG|BMS-986165 Dose B|Participants will receive BMS-986165 dose B QD.
214392947|NCT03881059|DRUG|Ustekinumab|Participants will receive ustekinumab SQ injection QD.
214392948|NCT03881059|OTHER|Ustekinumab Placebo|Participants will receive ustekinumab SQ matching placebo QD
214392949|NCT05335772|BEHAVIORAL|Action Observation and following Action Execution|VR-AOT patients will observe, rehearse and execute specific upper limb motor task belonging to activities of daily living.
214392950|NCT05335772|BEHAVIORAL|Landscape Observation and following Action Execution|VR-LO participants will observe virtually explorable landscapes lasting for a matched duration. Then, they will be asked to actively perform the same set of hand actions requested to VR-AOT experimental groups.
214392951|NCT03499626|DRUG|ASLAN001|"Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD"
214392952|NCT05284019|DRUG|Eptinezumab|Concentrate for solution for IV infusion
214392953|NCT05284019|DRUG|Erenumab|Solution for SC Injection
214392954|NCT05284019|DRUG|Onabotulinumtoxin-A|Solution for IM Injection
215000045|NCT06035120|DEVICE|AeriSeal System|The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
215000046|NCT04890834|OTHER|Best Practice|Receive standard care
215000047|NCT04890834|OTHER|Exercise Intervention|Participate in yoga sessions
215000048|NCT04890834|OTHER|Questionnaire Administration|Ancillary studies
215000049|NCT06401538|DRUG|BMB-101|BMB-101 liquid administered orally twice a day for 3 months
215000050|NCT05495464|DRUG|Acalabrutinib|Given by PO
215000051|NCT05495464|DRUG|Rituximab|Given by IV (vein)
215000052|NCT05495464|OTHER|Brexucabtagene Autoleucel|Given by IV (vein)
215000053|NCT05495464|DRUG|Cyclophosphamide|Given by IV (vein)
215000054|NCT05495464|DRUG|Fludarabine Phosphate|Given by IV (vein)
214392955|NCT05284019|DRUG|Fremanezumab|Solution for SC Injection
214392956|NCT05284019|DRUG|Galcanezumab|Solution for SC Injection
214392957|NCT00035503|DRUG|etiprednol dicloacetate|
214688100|NCT01911182|OTHER|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
215000055|NCT06891547|DIETARY_SUPPLEMENT|Spark Placebo Control 5.1|Participants will use their Radicle Spark Placebo Product 5.1 as directed for a period of 6 weeks.
215000056|NCT06891547|DIETARY_SUPPLEMENT|Spark Active Study Product 5.1 Usage|Participants will use their Radicle Spark Active Study Product 5.1 as directed for a period of 6 weeks.
215000057|NCT06764927|BIOLOGICAL|Cryoprecipitate Intercept Fibrinogen Complex (IFC)|INTERCEPT Fibrinogen Complex is a pathogen-reduced cryoprecipitated fibrinogen complex derived from human plasma. It contains fibrinogen, Factor XIII, and von Willebrand factor to achieve stable clot formation and restore hemostasis1. Recently approved by the US Food and Drug Administration, it is used for the treatment of bleeding associated with fibrinogen deficiency.
215000058|NCT06764927|BIOLOGICAL|Cryoprecipitate Antihemophilic Factor (AHF)|Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma. It is used for fibrinogen supplementation, particularly for hypofibrinogenemia fibrinogen, anemia associated with bleeding or congenital deficiency.
215000059|NCT06901310|DEVICE|Hyberbaric Oxygen Therapy|Treating participants with 100% Oxygen at 2.4 Atmospheres for 90 minutes at 10 treatments.
215000060|NCT06692322|DRUG|Zongertinib (BI 1810631)|Film-coated tablet
215000061|NCT03858322|DRUG|Paclitaxel|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
215000062|NCT03858322|DRUG|Cyclophosphamide|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
215000063|NCT03858322|DRUG|Carboplatin|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
215000064|NCT07073469|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
215000065|NCT07073469|OTHER|Standard medical treatment|Standard medical treatment according to local guidelines
215000066|NCT07071428|PROCEDURE|Regular acupuncture|Primary acupoints: Baihui (GV20), Hegu (LI4, bilateral), Fengchi (GB20, bilateral), Taichong (LV3, bilateral), Jinsuo (GV8), and Ganshu (BL18, bilateral). Operational procedures: Preoperative preparation identical to the treatment group; for Baihui (GV20), perform subcutaneous insertion backward (0.5 cun); for Fengchi (GB20), apply oblique insertion toward the nasal tip (0.8 cun); for Hegu (LI4) and Taichong (LV3), use perpendicular insertion (0.5 cun); for back-shu points (Ganshu BL18), rapid needling is applied due to low safety and inconvenience of retaining needles. Needle manipulation for qi activation, cycle, and frequency align with the treatment group. Treatment protocol: 3 sessions per week, 10 sessions constituting one course, totaling 20 sessions.
215000067|NCT07071428|PROCEDURE|the Nourishing the vital energyand Regulating the spirit needle technique|Primary points: Zhongwan (RN12), Xiawan (RN10), Qihai (RN6), Guanyuan (RN4), Taixi (KI3/bilat.), Baihui (GV20), Sishencong (EX-HN1), Shenting (GV24), Benshen (GB13/bilat.). Supplemental points: Blinking: Zanzhu (BL2) + Taiyang (EX-HN5/affected); Mouth twitch: Dicang (ST4) + Jiache (ST6/affected); Neck twitch: Fengchi (GB20) + Shangqu (KI17/affected); Limb twitch: UL-Waiguan (SJ5) + Quchi (LI11/affected), LL-Futu (ST32) + Yanglingquan (GB34/affected); Vocal tics: Tongue Three Needles (HN23). Post-disinfection: Calm child pre-needling. Sequence: Scalp → abdomen → limbs. Techniques: Scalp points-subcutaneous backward 0.5in; Taixi (KI3)-perpendicular 0.5in, mild lift-thrust/twirl to deqi; Abdomen-abdominal acupuncture (linea alba ref.), adipose/fascial layer insertion (no muscle/deqi), 30min retention no manipulation; Rapid withdrawal with pressure. Protocol: 3 sessions/week, 10-session course, 20 sessions total.
215000068|NCT06750276|DRUG|AZD2389|Doses of AZD2389 or placebo will be administered orally.
215000069|NCT07073001|OTHER|Telephone interview|A structured telephone interview at three months will assess the degree of implementation, explore associated barriers (administrative, cognitive, organizational, ...), and investigate any potential link with hospital readmissions or changes in patients' living situations.
215000070|NCT07074327|DRUG|VX-407|Suspension for oral administration.
215000071|NCT07074327|DRUG|LNG/EE|Combination Tablets for Oral Administration.
215000072|NCT07074327|DRUG|NGM/EE|Combination Tablets for Oral Administration.
215000073|NCT07074327|DRUG|NET/EE|Combination Tablets for Oral Administration.
215000074|NCT07074327|DRUG|DRSP/EE|Combination Tablets for Oral Administration.
215000075|NCT07073950|DRUG|Budesonide/Glycopyrronium/Formoterol Fumarate|BGF will be administered as 2 inhalations via oral route of administration
215000076|NCT07073950|DRUG|Placebo|Matching placebo will be administered as 2 inhalations via oral route of administration
215000077|NCT07073950|DEVICE|Metered dose inhaler|Participants will receive BGF and matching placebo via metered dose inhaler in treatment periods of the study.
215000078|NCT06345339|DRUG|Armour Thyroid|Oral Capsule or Tablet
215000079|NCT06345339|DRUG|Levothyroxine|Oral Capsule
215000080|NCT07129187|DRUG|SHR-A1811|Drug: SHR-A1811 4.8mg/kg
214392958|NCT05463614|DRUG|Propafenone and Propranolol|Propafenone Hydrochloride Tablets, 100-200mg, 1 or 2 times per day; Propranolol Hydrochloride Sustained-Release Capsules, 40mg, 1 times per day
214392959|NCT05318846|DRUG|HRS4800 tablets|Dosing frequency: single dose; Route of administration: oral
214392960|NCT05318846|DRUG|Placebo tablets|Dosing frequency: single dose; Route of administration: oral
214392961|NCT03989713|DRUG|MRD-triggered arm|"1. Salvage therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / \>-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~2. Consolidation therapy:~   Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / \>-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3~3. Observation therapy:~No treatment"
214392962|NCT03989713|DRUG|Prophylactic Arm|"1. Salvage therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / \>-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~2. Consolidation therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / \>-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3;~3. Maintenance therapy:~Quizartinib: Cycle 1, Days 1-15: 40mg, p.o. and Day 16-28: 60mg, p.o."
214392963|NCT01465503|DRUG|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR \<30 ml/min/1.73 m2.
214392964|NCT01465503|DRUG|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
214392965|NCT02325726|PROCEDURE|Renal Resistive Index compared with NephroCheckTM|
214392966|NCT04577742|RADIATION|106 Ruthenium plaque brachytherapy|All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation
214392967|NCT03728114|DEVICE|RIC|Adults allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
214392968|NCT03728114|DEVICE|sham RIC|Adults allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
214392969|NCT01013935|OTHER|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
214392970|NCT01013935|OTHER|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
214392971|NCT04315246|BIOLOGICAL|radiolabeled DPTA-omburtamab|Biological, radiolabeled DPTA-omburtamab
215094352|NCT02715726|DRUG|Placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
215094353|NCT02715726|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
215094354|NCT02715726|DRUG|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
215094355|NCT02715726|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
215094356|NCT02715726|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
214392972|NCT04870619|OTHER|High Intensity Gait Training|The intervention provided in this project is routinely delivered as a standard of care at the participating sites for patients after stroke that have a goal of walking improvement. The intervention consists of 45-60 minute, physical therapy sessions that occur five days per week (not weekends), focusing on prioritizing stepping practice at higher aerobic intensities during scheduled treatments (target training zone of 70-85% heart rate max (HRmax). Stepping is performed on treadmills and over ground, with safety harness systems and body weight support only as needed to ensure successful stepping. Tasks are progressed by increasing task difficulty as determined by the therapist. Accordingly, practice of non-walking tasks performed during physiotherapy, including bed mobility, transfers, and standing balance/ pre-gait activities, is limited.
214392973|NCT01215708|DRUG|Tamsulosin|tamsulosin 0,4mg every night for 30 consecutive days
214392974|NCT05359731|DRUG|Bupivacaine Hydrochloride|Patients will receive a total volume of 30 ml of bupivacaine 0.5% in an axillary block with a double puncture.
214392975|NCT05359731|DRUG|Bupivacaine Hydrochloride with Dexamethasone|Patients will receive a total volume of 30 ml of bupivacaine 0.5% with Dexamethasone 4 mg in an axillary block with a double puncture.
214392976|NCT02247414|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
214392977|NCT02247414|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
214392978|NCT02247414|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
214392979|NCT02247414|DRUG|Low Molecular Weight Heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
214392980|NCT00287469|BIOLOGICAL|Hepatitis E vaccine, recombinant (Sar 56 kDa)|20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)
214688101|NCT00540176|DRUG|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
215094357|NCT02715726|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
215000081|NCT06927245|DEVICE|PTeye Device|Near infrared stimulation of parathyroid tissue using light at a wavelength of approximately 690 - 770 nm results in autofluorescence of parathyroid tissue. Near infrared autofluorescence detection devices, such as PTEye have been developed with probe-based methods, displaying quantitative real-time information to aid surgeons in detection of parathyroid tissue relative to surrounding tissue.
215000082|NCT05486182|DRUG|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
215000083|NCT06382272|DEVICE|Bionic Breast implant|A small medical device will be temporarily implanted in one of the breasts at the time of the mastectomy. This device is capable of sending very small electrical currents to the nerves that can deliver sensory stimulation in response to touch and pressure applied to the breast
215000084|NCT07072091|OTHER|Total body physiotherapy|This intervention consists in 5 weeks of 2 x week 60 min sessions of physiotherapy consisting in active exercise performed in upper limb, trunk, and lower limb muscles, in a whole-body approach.
215000085|NCT07072091|OTHER|Focus shoulder physiotherapy|This intervention consists in 5 weeks of 2 x week 60 min sessions of physiotherapy consisting in active exercise performed only in the shoulder district, focusing on the trunk-arm muscles.
215000086|NCT07072091|OTHER|Education|Single education session providing information about posture hygiene and proper warm-up
215000087|NCT07076069|DRUG|Multimodal Pain Regimen|"Preoperatively: One dose of Pregabalin 100mg and Celecoxib 400mg along with interscalene block~Intraoperatively: Intravenous Dexamethasone 0.1mg/kg (maximum dose of 8mg), Magnesium 2g, Acetaminophen 1000mg, and local infiltration of 0.5% Ropivacaine 20ml~Postoperatively (Discharge): Acetaminophen 975mg every 4 hours, Meloxicam 7.5mg once per day, Pregabalin 50mg twice per day, Magnesium 400mg once per day, along with rescue Oxycodone 5mg every 4 hours, as needed"
215000088|NCT07076069|DRUG|Standard of Care Pain Regimen|No preoperative medications. Interscalene block in the preoperative holding area. Alternating Acetaminophen 975mg and Ibuprofen 600mg every 4 hours, with rescue Oxycodone 5mg every 4 hours, as needed
215000089|NCT07073924|BEHAVIORAL|Implementation strategy bundle|The anticipated strategy bundle will include integrated patient-, provider-, and system-level interventions to support sustainable implementation. At the patient level, this may involve education, peer support, and navigation services; at the provider level, training, decision-support tools, and workflow enhancements; and at the system level, policy changes, electronic health record integration, and organizational alignment to promote and maintain prescribing of PrEP and injection equipment.
214392981|NCT00287469|OTHER|Placebo|PBS buffer placebo containing alum
215000090|NCT07076355|DRUG|Botulinum Toxin type a (Botox)|A single dose of 25 units of botulinum toxin type A (BTX-A) was injected into the lateral pterygoid muscle using ultrasonography-guided technique. The injection was performed under local anesthesia with patient monitoring.
215000091|NCT04725539|PROCEDURE|hypoxic exposure|"Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5\*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4\*4min (FiO2 = 12%) and 3\*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5\*5min (FiO2 = 10%) and 4\*3 min (FiO2 = 21%)~one night at 1900m"
215000092|NCT07079189|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
215000093|NCT06455189|OTHER|Control Group - Standard of care neurosurgical resection|The control group will include only standard of care tools. - Standard of care neurosurgical resection will include the use of all standard neurosurgical instruments and techniques (eg, microscope, intraoperative ultrasound, 5-ALA fluorescence guided surgery and neuronavigation system).
214392982|NCT03876938|DRUG|aprepitant|aprepitant 125 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
214392983|NCT03876938|DRUG|olanzapine 10 mg|olanzapine 10 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 10 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
214392984|NCT03876938|DRUG|olanzapine 5 mg|olanzapine 5 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 5 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
214392985|NCT02903589|OTHER|observational|
214392986|NCT00259324|BEHAVIORAL|Diet and Activity|Diet and Activity
214392987|NCT05699902|PROCEDURE|PECs block during mastectomy|The patients were randomised to receive a PECS block consisting of 30 ml of levobupivacaine 0.25% after induction of anaesthesia (PECS group) or a saline mock block (control group). The patients answered a 40-item QoR questionnaire (QoR-40) before and 1 day after breast cancer surgery. MAIN OUTCOME MEASURES
214392988|NCT05699902|PROCEDURE|Sham block|Female undergone mastectomy and have received conventional analgesic methods
214392989|NCT00332215|DRUG|Inhaled Sodium Pyruvate|
214392990|NCT04479293|OTHER|Post COVID-19 Functional Satus Scale|scale from 0-64 assessing functional limitation
214392991|NCT01436123|OTHER|Stenting and micro-infusion of NP|Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
214392992|NCT01436123|DEVICE|Implantation of everolimus-eluting stent|Put stent in ischemia-related coronary artery by indications for PCI
214392993|NCT03169270|OTHER|Exercise training|All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
214392994|NCT01844193|DEVICE|Compex Rehab|"Participants in this arm will use a Compex® Rehab unit for neuromuscular electrical stimulation starting with postoperative at-home day 1 and continue using the unit twice a day, every day, until a 10-week follow-up is reached. The unit produces a 380 microsecond biphasic curve and utilizes a four phase process for the treatment (Warm-up, Work, Relaxation, and Recovery) for a total treatment time of 20 minutes and 5 seconds per session. All frequencies are delivered at the maximum subjective tolerable intensity. Participants will control this intensity and be asked to select a level that is tolerable although mildly uncomfortable; they will be instructed to increase this intensity as tolerated."
214392995|NCT01266993|BIOLOGICAL|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
214392996|NCT01266993|BIOLOGICAL|Menjugate|Intramuscular, 1 dose
214392997|NCT02749695|DRUG|Melsmon|Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
214392998|NCT02749695|OTHER|Placebo|2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
214392999|NCT03398915|PROCEDURE|Transpedicular Instrumentation|Transpedicular screw placement and instrumentation
214393000|NCT02942004|DRUG|Placebo|Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
214393001|NCT02942004|DRUG|SAGE-547 60 μg/kg/h|Intravenous infusion of SAGE-547.
214393002|NCT02942004|DRUG|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547.
214393003|NCT02532322|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
214393004|NCT02532322|DRUG|normal saline|normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
214393005|NCT01272986|DEVICE|ALOA IgG-Elisa|measurement of IgG Level in blood
214393006|NCT01272986|DEVICE|ALOA IgG-AtheroAbzyme|measurement of IgG in blood
214393007|NCT03146858|DRUG|Enoxaparin|Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
214393008|NCT04866914|BEHAVIORAL|Acceptance and Commitment Therapy for Insomnia|ACT-I treatment group: Participants diagnosed with chronic insomnia will receive group treatment. The six sessions will be aimed at psychoeducation about sleep added to the therapeutic processes of acceptance, mindfulness, availability, values, defusion and commitment, used in ACT.
214393009|NCT04866914|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Active control group CBT-I: Participants diagnosed with chronic insomnia will receive treatment in a group. The six sessions will be aimed at cognitive-behavioral components, such as education and sleep hygiene, stimulus control, sleep restriction and demystification / restructuring of belief beliefs.
214393010|NCT04001140|BEHAVIORAL|Enhancement of emotion regulation skills|Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
214393011|NCT00206388|DRUG|Zolendric acid|IV, 2mg/m2/dose on day 0
214393012|NCT00206388|DRUG|Cyclophosphamide|fixed dose of 25mg/m2/dose days 0-27
214393013|NCT02310893|BEHAVIORAL|Combined Contingency Management and Peer Navigation|
214393014|NCT02310893|BEHAVIORAL|Contingency Management|
214393015|NCT02310893|BEHAVIORAL|Peer Navigation|
214393016|NCT06190574|OTHER|Telephone follow-up|Telephone follow-up
214393017|NCT04276818|PROCEDURE|PRP group|Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns
214393018|NCT04276818|PROCEDURE|conventional treatment group|The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.
214393019|NCT03382600|BIOLOGICAL|Pembrolizumab|200 mg Q3W on Day 1 by IV infusion
214393020|NCT03382600|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
214393021|NCT03382600|DRUG|TS-1|40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
214393022|NCT03382600|DRUG|Cisplatin|60 mg/m\^2 Q3W on Day 1 by IV infusion
214393023|NCT04206137|OTHER|Group A (PNF rhythmic initiation group )|Lifting of arms and push the head back through the pattern of flexion -abduction-external rotation and neck in extension to the left in opposition of therapist hand resistance will be asked to do. At the end range of motion extensor muscles of back will start to contract.Then, reversing of that movement pattern to extension-adduction-internal rotation and neck flexion to right against the therapist resisting hands will be asked. this will be repeated on both sides
214393024|NCT04206137|OTHER|Group B (Swiss ball exercises)|"Supine position: A ball will be placed under patient neck, and will be asked to bend hip and knee up to 90°. 5 times, 10 seconds hold Supine position: With a ball below the pelvis, knees bent, the ball press will be done with pelvis. 5 times, for 10 seconds hold.~Crawling position: With a ball below one knee while keeping toes away from contact with the floor, the patient will balance first to stabilize the posture and slowly raise the other lower limb. This exercise will be performed in turn for the two lower limbs 10 times, with 10 seconds hold.~Prone position: the patient will place a ball in front of pelvis and will repeatedly raise and lowered the two lower limbs alternately. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set."
214393025|NCT00543218|DRUG|teriparatide 20 micrograms/day subcutaneous|
214393026|NCT00543218|DRUG|calcitonin 100 IU/day subcutaneous|
214393027|NCT01448044|DRUG|BMS-790052 (NS5A Replication Complex Inhibitor)|
214393028|NCT01448044|DRUG|Placebo matching BMS-790052|
214393029|NCT01448044|DRUG|Pegylated-interferon alfa 2a|
214393030|NCT01448044|DRUG|Ribavirin|
214393031|NCT03111758|DEVICE|Flow augmentation|Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome
214393032|NCT00780442|DRUG|D-cycloserine|50 mg DCS
214393033|NCT00780442|DRUG|Placebo|Placebo
214393034|NCT01000376|DRUG|Eribulin alone|Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m\^2 alone on Day 1, then eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
214393035|NCT01000376|DRUG|Eribulin plus Ketoconazole|Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m\^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
214393036|NCT05235295|PROCEDURE|Ultrasound-guided sacroiliac joint injection|Using ultrasound the sacral hiatus in transverse position was identified. Then, sliding laterally and cephalad in transverse position, the posterior superior iliac spine and the posterior sacroiliac joint were identified. The needle was advanced toward the posterior joint space from medial to lateral, using an in-plane technique.
214393037|NCT05235295|PROCEDURE|Flouroscopy-guided sacroiliac joint injection|Using anterior posterior and contralateral oblique view the posterior joint line and inferior joint margin were identified and a needle was advanced at the point the posterior inferior joint line was most clearly seen.
214393038|NCT00507026|DRUG|IV Diclofenac|IV Diclofenac q6h
214393039|NCT00507026|DRUG|IV ketorolac|IV ketorolac q6h
214393040|NCT00507026|DRUG|Placebo|Placebo q6h
214393041|NCT02126436|OTHER|Acupuncture|"Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:~using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks."
214393042|NCT02126436|OTHER|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
214393043|NCT00035945|DRUG|ISIS 14803|
214393044|NCT05008159|BEHAVIORAL|3 month community-based mobility and health intervention|"12 weekly GROUP (10-15 adults per cohort) sessions + 3 INDIVIDUAL tailored system navigation sessions at beginning, midpoint, and end of program.~The 3-month GROUP program will include the following fixed components:~i) weekly interactive group-based health education sessions focused on:~* increasing knowledge, skills, and behaviours related to physical activity, healthy eating, and available community supports for older adults;~* socialization to foster peer and community connections, co-learning, and decrease social isolation~* skill-building to support independence and quality of life; and~ii) INDIVIDUAL tailored system navigation support"
214393045|NCT00715507|DEVICE|medication monitor|the medication monitor will aid in expertise and decision-making.
215000094|NCT06455189|PROCEDURE|MRF/MRI infiltration guidance for extended resection|Magnetic resonance imaging, MRI, is a procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body
214393046|NCT02189096|OTHER|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
214502328|NCT06635759|OTHER|Upper trapezius stretching exercise|Participants in the SE group will perform static upper trapezius stretching exercise for the affected side. To perform the stretch, participants will be asked to sit upright on a chair and look straight ahead. To reduce scapular elevation and upward rotation, the ipsilateral hand should be placed below the buttock. The subject will then be asked to perform deep neck flexion, neck rotation towards the affected side, and contralateral side flexion using the opposite hand in a diagonal direction until the position of 'mild discomfort' is attained. They should maintain the deep neck flexion when performing the stretch. The stretch will be held for 30 seconds each set, 3 sets a day, daily for 5 weeks.
214393047|NCT02189096|OTHER|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
214393048|NCT06259162|PROCEDURE|LAG-3 expression / immune checkpoint protein expression|Evaluate the tissue and blood before and after chemotherapy
214393049|NCT00896454|DRUG|denosumab|120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
214393050|NCT00658736|DRUG|Triamcinolone|Injection of bupivacaine and triamcinolone
214393051|NCT00658736|DRUG|Bupivicaine alone|Injection of bupivacaine
214393052|NCT00397267|DRUG|inhalation of corticosteroids|
214502329|NCT02432898|DEVICE|3D OCT-1|Spectral Domain OCT Device
214502330|NCT02432898|DEVICE|3D OCT-2000|Spectral Domain OCT Device
214502331|NCT02432898|DEVICE|DRI OCT-1|Swept Source OCT Device
214502332|NCT02432898|DEVICE|NW-300|Fundus Camera
214502333|NCT02432898|DEVICE|CT-1P|Tonometry
214502334|NCT02432898|DEVICE|TRK-2P|Tonometry, Corneal Topography
214502335|NCT02432898|DEVICE|SP-1P|Specular Microscopy
214502336|NCT02432898|DEVICE|SL-D701|Slit Lamp Imaging
214502337|NCT02432898|DEVICE|MC-4S|Visual Acuity Testing
214688102|NCT04832841|DIAGNOSTIC_TEST|anti-spike SARS-CoV-2 IgG|Immunochemiluminescent assay by DiaSorin S.p.A. Italy
214688103|NCT06686030|DRUG|AK112 low dose|10mg/kg, Q3W, ivgtt
214393053|NCT04387838|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
214393054|NCT04387838|OTHER|Questionnaire|"Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age~* Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital~* Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures"
214688104|NCT06686030|DRUG|Chemotherapy|ivgtt
214393055|NCT05759312|DRUG|Zimberelimab|Zimberelimab 240mg IV every 2 weeks
214393056|NCT05759312|DRUG|Metformin Hydrochloride|Metformin 2000mg PO QD
214393057|NCT03693599|DRUG|carbetocin|single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
214393058|NCT03693599|DRUG|Syntometrine|one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
214393059|NCT06274580|DEVICE|embolization of the middle meningeal artery|Embolization of the MMA is occluded with PVA particles or liquid embolizing materials
214393060|NCT05193721|DRUG|SHR-1901|SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
214393061|NCT03688711|DRUG|Dasiglucagon|Glucagon analogue
214393062|NCT03688711|DRUG|Placebo|Placebo for dasiglucagon
214393063|NCT03041454|OTHER|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
214393064|NCT06122181|DRUG|HS-10384 tablets|Multiple dosing of HS-10384 orally in a fasting state
214393065|NCT06122181|DRUG|HS-10384-matched placebo tablets|Multiple dosing of HS-10384-matched placebo orally in a fasting state
214393066|NCT00253409|DRUG|chemotherapy|
214393067|NCT00253409|PROCEDURE|adjuvant therapy|
214393068|NCT00253409|PROCEDURE|conventional surgery|
214393069|NCT00253409|PROCEDURE|neoadjuvant therapy|
215000095|NCT03986034|DRUG|During Venetoclax|Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
214393070|NCT00253409|RADIATION|radiation therapy|
214502338|NCT02233556|DRUG|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~1. Mismatch negativity(MMN)~2. P50"
215000096|NCT07066098|DRUG|IBI343|Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle
215000097|NCT07066098|DRUG|Placebo|Subjects in the control arm will receive placebo 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle
215000098|NCT02157324|DRUG|acalabrutinib|
215000099|NCT02157324|DRUG|ACP-319|
215000100|NCT07076472|DRUG|Aminolevulinic Acid Intravenous Formulation SONALA-001|Given IV
214393071|NCT02749058|PROCEDURE|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
214393072|NCT02749058|PROCEDURE|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
214393073|NCT00604929|DIETARY_SUPPLEMENT|carbohydrate and protein|The intake of carbohydrate and protein during endurance type exercise
214393074|NCT04695158|DRUG|COVID-19 group (Group I)|Routine COVID-19 treatment
214393075|NCT04695158|DRUG|Type II Diabetes Mellitus and COVID-19 group (Group II)|Routine Type II Diabetes Mellitus and COVID-19 treatments
215000101|NCT07076472|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215000102|NCT07076472|PROCEDURE|Computed Tomography|Undergo CT
214393076|NCT02053545|DRUG|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF"
214393077|NCT01410461|DEVICE|quantitive sensory testing|Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
214393078|NCT01410461|DEVICE|Ultrasound testing|Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
214393079|NCT03262090|DRUG|0.2ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
214393080|NCT03262090|DRUG|0.4ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
214393081|NCT03262090|DRUG|0.6ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
214393082|NCT03262090|DRUG|0.8ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
214393083|NCT03262090|DRUG|1.0ug/kg dexmedetomidine|subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
214502339|NCT02168309|DRUG|Labetalol|Titrate up for blood pressure control
214502340|NCT02168309|DRUG|Nifedipine|Titrate up to achieve blood pressure control
214502341|NCT04934033|OTHER|Neurological assessments|The participants will have a MRI, and language and cognitive assessments.
214502342|NCT04422392|DRUG|Carboplatin|(IV, Q3W)
214502343|NCT04422392|DRUG|Pemetrexed or Nab-paclitaxel|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
214502344|NCT04422392|DRUG|PD-1 antibody|(IV, Q3W)
214502345|NCT03989310|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle
214502346|NCT03989310|DRUG|nab-paclitaxel|Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
214502347|NCT03989310|DRUG|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
214393084|NCT02441205|BEHAVIORAL|High Intensity Interval training|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (\~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
214393085|NCT04396353|OTHER|Electronic questionnaire|Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).
214393086|NCT04193293|DRUG|Duvelisib|Phosphoinositide 3-kinase (PI3K) Inhibitor
214393087|NCT04193293|BIOLOGICAL|Pembrolizumab|Immunotherapy (programmed cell death protein 1 \[PD-1\] inhibitor)
214502348|NCT03989310|DRUG|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
214393088|NCT06369961|DRUG|transdermal fentanyl|Adult cancer pain patients switched from oral opioid to TDF
214393089|NCT03454217|DRUG|Oxycodone|Postoperative pain treatment with oxycodone
214393090|NCT03454217|DRUG|Tramadol|Postoperative pain treatment with tramadol
215000103|NCT07076472|OTHER|Electronic Health Record Review|Ancillary studies
215000104|NCT07076472|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215000105|NCT07076472|PROCEDURE|MRI-Guided Focused Ultrasound Ablation|Undergo transcranial MRgFUS
215000106|NCT06717399|OTHER|Mindfulness meditation|Each mindfulness meditation session will be 30 minutes long, consisting of a 5-minute introduction, 15 minutes of guided mindfulness meditation, and 10 minutes of educational discussion.
215000107|NCT06882057|DRUG|Blinatumomab|All LR-B-ALL patients will be treated with 14 days of blinatumomab (Blina-14) as early intensification to replace CAT+ (historically given in LR-B-AL with MRD19\>0.1% in the 2020 protocol). Additionally, second 14 days of blinatumomab will be given after completion of HDMTX consolidation treatment.
215000108|NCT06882057|DRUG|Reinduction-2 omission|Reinduction-2 will be omitted for patients with NGS-MRD46\<10\^-6 who have receive the two courses of Blina-14.
215000109|NCT06882057|DRUG|Chemo-light Maintenance 2|Patients with FCM-MRD19\<0.01% and IgH rearrangement NGS MRD 46\<10\^-6 will receive chemo-light maintenance-2 with 4 cyles of 8-week course of MTX + 6MP (totally 32 weeks).
215000110|NCT07080528|DRUG|Sevofluorane|Investigation of the effect of Sevoflurane on muscle relaxation
215000111|NCT07080528|DRUG|Propofol|Investigation of the effect of Propofol on muscle relaxation
214393091|NCT01110720|DRUG|Davunetide|Davunetide Nasal Spray 30 mg BID IN 52 weeks
214393092|NCT01110720|DRUG|Placebo|Placebo Nasal Spray BID IN 52 weeks
214393093|NCT04675242|DRUG|NCX 4251|NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily
214393094|NCT04675242|DRUG|Placebo|Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily
214393095|NCT02874066|DRUG|PTV/r/OBV/DSV|Viekirax/Exviera for 12 weeks
214393096|NCT05975866|DIETARY_SUPPLEMENT|curcumin|Daily consumption of three 500 mg curcumin capsules with breakfast, lunch, and dinner
214393097|NCT05975866|BEHAVIORAL|Anti-inflammatory diet|The anti-inflammatory diet will be personalized based on each person's calorie intake in five meals. Achieving the goals of an anti-inflammatory diet by consuming only one type of food or following its principles in one meal is impossible and must be implemented consistently and regularly in a meal plan.
214393098|NCT02030275|DRUG|RXI-109|surgery.
214393099|NCT02030275|DRUG|Placebo|surgery.
214393100|NCT00918216|GENETIC|fluorescence in situ hybridization|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
214502349|NCT00691691|RADIATION|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
214393101|NCT00918216|OTHER|immunohistochemistry staining method|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
214393102|NCT00918216|OTHER|medical chart review|Patients' medical charts are reviewed to obtain clinical information
214393103|NCT00918216|PROCEDURE|fluorescence spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
214393104|NCT00918216|PROCEDURE|histopathologic examination|Hematoxylin and eosin stained sections of the tissue samples are examined by light microscopy for histopathological analysis.
214393105|NCT00918216|PROCEDURE|light-scattering spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
214393106|NCT05108727|DEVICE|Diode Laser|DL with a wavelength of 810±5 nm, a 400micron diameter, and a power of 1 watt in continuous mode was applied to the MWF at the test sites.
214393107|NCT05108727|PROCEDURE|Modified Widman Flap|Periodontal Surgery Technique
214393108|NCT03549611|DRUG|Multimodal Oral Drug Regimen|Regimen of 4 pharmacologic agents that provides analgesia by acting on 4 different physiologic pain pathways
214502350|NCT05146635|DRUG|Intravesical Bcg|Patients will receive induction and maintenance BCG after complete TURBT.
214502351|NCT05146635|DRUG|Intravesical chemotherapy (epirubicin)|Patients will receive induction and maintenance epirubicin after complete TURBT.
215000112|NCT06878846|OTHER|Correlation Study|Assessment of correlation
215000113|NCT05061888|OTHER|Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables|Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.
215000114|NCT05061888|OTHER|Smart Intervention for Stress Management|Will receive a Smart Intervention on stress management practices and strategies.
214393109|NCT03549611|DRUG|Acetaminophen|Acetaminophen 975mg
214393110|NCT02361593|PROCEDURE|assistance of a transparent cap|Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
214393111|NCT02361593|PROCEDURE|without a transparent cap|Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
214393112|NCT00068666|DRUG|temozolomide|
214393113|NCT00068666|RADIATION|radiation therapy|
214393114|NCT00320879|DRUG|irbesartan|
214393115|NCT02221895|OTHER|Postpartum follow up appointment 2-3 weeks after delivery|experimental arm
214393116|NCT02221895|OTHER|Postpartum follow up 6-8wk after delivery|control arm
214502352|NCT00592891|DRUG|Hyperbaric oxygen therapy|Total body pressurized oxygen
214502353|NCT04318691|BIOLOGICAL|Blood sampling|Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.
214502354|NCT04318691|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage at admission to the ICU with analysis of cytological, bacteriological, viral and anatomopathological, and test of NETs.
214502355|NCT05925335|DEVICE|Transseptal Transcatheter Mitral valve-in-valve Replacement|Transcatheter transfemoral mitral valve-in-valve replacement is an alternative surgery in patients with severe dysfunction of a degenerated mitral bioprosthesis and high surgical risk for repeat operation. The procedure is performed via femoral vein access. All procedures were carried out using intra-procedural TEE guidance to aid in transseptal puncture. After balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle and expanded in the mitral position during rapid ventricle pacing.
214502356|NCT06630325|DRUG|Abemaciclib|Given PO
214502357|NCT06630325|PROCEDURE|Biopsy|Undergo tumor biopsy
214502358|NCT06630325|PROCEDURE|Bone Scan|Undergo bone scan
214502359|NCT06630325|DRUG|Carboplatin|Given IV
214502360|NCT06630325|PROCEDURE|Echocardiography|Undergo echocardiography
215000115|NCT06828432|DEVICE|CRUISE CTICU CareTaker Vitalstream Device|The CareTaker Vitalstream device is a patented PDA technology and artificial intelligence algorithms derive continuous hemodynamic parameters by analyzing reflective pulse wave analyzes the pulse pressure waveform at 500 times per second, isolates the individual central aortic pulses that give rise to the observed pulse shape, reads central aortic measurements therefore eliminating the effects of hydrostatic pressure, and tracks vascular tone.
215000116|NCT06828432|DEVICE|CRUISE CTICU CNAP Device|The CNAP Monitor provides advanced hemodynamic information from the non-invasive reusable CNAP finger sensor. It supports your Goal Directed Therapy whenever an arterial line is not indicated. Patient-friendly, easy-to-use, cost-efficient. CNAP Monitor offers a unique set of parameters to support your daily routine - all non-invasive \& continuous allowing for perioperative fluid management even in low and moderate-risk surgeries and patients.
215000117|NCT06828432|DEVICE|CRUISE CTICU Edwards Clearsight Device|The Edwards ClearSight system provides continuous blood pressure and advanced hemodynamic parameters from a noninvasive finger cuff. Continuous data offered by the ClearSight system enables you to proactively optimize perfusion through hemodynamic management.
215000118|NCT03842007|DIAGNOSTIC_TEST|Rectal Barostat Study|Contractions will be recorded with a balloon inserted into the rectum and inflated
215000119|NCT03842007|DIAGNOSTIC_TEST|Fecoflowmetry|Rectum will be filled with a small amount of paste.Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Subjects will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.
214393117|NCT04401553|DRUG|cephalosporin|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
215000120|NCT06773975|DIETARY_SUPPLEMENT|Oral nutritional supplementation|The oral nutritional supplement is a locally made plant based formulation targeted to improve the nutritional status of the elderly
215000121|NCT07080957|PROCEDURE|Mesh-free laparoscopic uterus-preserving pectopexy|Laparoscopic pectopexy without synthetic mesh was performed by utilizing native tissue fixation techniques. The uterus was suspended to the iliopectineal ligaments using permanent sutures without mesh implantation. The procedure aimed to provide apical support and avoid mesh-related complications. Postoperative follow-up included assessments of anatomical correction, functional recovery, and patient satisfaction.
214393118|NCT04401553|DRUG|Second tier antibiotic (Vancomycin)|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam (standard of care)
214502361|NCT06630325|DRUG|Exemestane|Given PO
214502362|NCT06630325|DRUG|Fulvestrant|Given IM
214393119|NCT03213015|DIAGNOSTIC_TEST|Ankle dorsiflexion measurement|It was used the test with WB, called Lunge Test, in which each evaluator marked a point 15 cm distal to the anterior tuberosity of the tibia (TAT) with a felt tip pen. After that the smartphone (app iHand) will be placed at this point. Between each measurement, the mark was removed with alcohol 70% The demarcated point served as a guide for positioning the smartphone. In order to standardize the smartphone positioning, BHome (home button on the iPhone), was aligned with the TAT pen mark. To ensure the same distance from the foot to the test, the distance of the hallux to the wall was measured (tape measure), recorded and reused for each test.
214393120|NCT02327910|OTHER|TOF unit TcPCO2 group|The patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
214393121|NCT02327910|OTHER|TOF group|The patients of T group were extubated when TOF ratio greater than 0.9.
214393122|NCT01037205|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
214393123|NCT01037205|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
214393124|NCT03141528|OTHER|Self-learning|Training without supervision
214393125|NCT03141528|OTHER|Instructor-led learning|Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
214393126|NCT01165346|RADIATION|Fiducials|Implantation of fiducials
214393127|NCT01165346|RADIATION|CyberKnife|3 fractions over 8 to 10 days, 15 Gy/fraction
214502363|NCT06630325|DRUG|Gefitinib|Given PO
214502364|NCT06630325|DRUG|Gemcitabine|Given IV
214502365|NCT06630325|DRUG|Letrozole|Given PO
214502366|NCT06630325|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214502367|NCT06630325|DRUG|Olaparib|Given PO
214502368|NCT06630325|DRUG|Osimertinib|Given PO
215000122|NCT07080957|PROCEDURE|Mesh-based laparoscopic uterus-preserving pectopexy|Laparoscopic pectopexy was performed using a synthetic mesh to provide apical support while preserving the uterus. The mesh was bilaterally fixed to the iliopectineal (Cooper's) ligaments, and the uterus was suspended in a tension-free manner. This technique is designed to restore pelvic anatomy and improve symptoms of prolapse. Patients were followed postoperatively to assess anatomical success, complications, and functional outcomes.
215000123|NCT07083583|DRUG|IV Iron (standard of care)|Participants will receive IV iron therapy as part of standard management for iron deficiency
214393128|NCT02667444|DRUG|SB204 4%|Applied topically once daily
214393129|NCT02667444|DRUG|Vehicle Gel|Applied topically one daily
214502369|NCT06630325|DRUG|Paclitaxel|Given IV
215000124|NCT07084142|OTHER|Online, patient-facing decision-making aid (app) with personalized risk information.|"The online, patient-facing decision-making aid will have the following features:~1. Clinical Data Input,~2. Introduction via Animated Video,~3. Common Questions,~4. Check-In Quiz,~5. Risk and Values Exploration based on patient specific information,~6. Wrap-Up,~7. Patient-Physician Worksheet,~These steps will be completed by the patient in advance of a provider visit where a shared-decision making process will decide whether an ICD is an appropriate sudden cardiac death-prevention strategy to pursue."
215000125|NCT07084142|DEVICE|Implantable Cardioverter Defibrillator (ICD)|Some participants, in their course of medical care unrelated to the study intervention, will undergo implantation of an ICD.
215000126|NCT07084142|OTHER|Online, patient-facing decision-making app without personalized risk information.|The online, patient-facing decision-making aid will have the following features: 1) Clinical Data Input, 2) Introduction via Animated Video, 3) Common Questions, 4) Check-In Quiz, 5) Generic Risk and Values Exploration without patient specific information, 6) Wrap-Up, 7) Patient-Physician Worksheet, These steps will be completed by the patient in advance of a provider visit where a shared-decision making process will decide whether an ICD is an appropriate sudden cardiac death-prevention strategy to pursue.
214393130|NCT05851911|BIOLOGICAL|sars-cov-2 vaccine or infection|Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2
214393131|NCT04719013|DEVICE|Evoke radiofrequency device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments,
214393132|NCT05018429|PROCEDURE|nerve sparing|When resect the bladder and prostate, the neurovascular bundles around the prostate will be preserved.
214502370|NCT06630325|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214502371|NCT06630325|DRUG|Pemetrexed|Given IV
215000127|NCT06372145|DRUG|Tolebrutinib|Pharmaceutical form:Tablet-Route of administration:oral
215000128|NCT06372145|DRUG|Placebo|Pharmaceutical form:Tablet-Route of administration:oral
215000129|NCT06372145|DRUG|Teriflunomide|Pharmaceutical form:Tablet-Route of administration:oral
215000130|NCT07121374|DRUG|Neoadjuvant chemo-immunotherapy|Neoadjuvant chemotherapy (2 cycles of cisplatin OR carboplatin accord healthcare- investigator's choice - PLUS pemetrexed fresenius AND immunotherapy (2 cycles of Opdivo PLUS 1 cycle of Yervoy for inoperable T2-T3 TNM 9 patients with PM
215000131|NCT07121374|PROCEDURE|Extended pleurectomy/decortication in case of reaching operability|After the systemic treatment the surgery will follow if patient is operable.
215000132|NCT07116863|DRUG|KDF1901-R0|Fixed-dose combination tablet containing valsartan 80 mg and amlodipine 5 mg. Orally administered once daily for 4 weeks during the run-in period, and for 2 weeks during Treatment Period 1(Dual Therapy group).
214393133|NCT01632332|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
214393134|NCT01632332|OTHER|laboratory biomarker analysis|Correlative studies
215000133|NCT07116863|DRUG|KDF1901-L|"Fixed-dose combination tablet containing valsartan 80 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg.~Orally administered once daily for 2 weeks during Treatment Period 1."
214393135|NCT06096220|PROCEDURE|Enucleation|Enucleation is complete removal of the cyst from the bony defect of the jaw affected by the lesion. Osteotomy is performed to allow access to the cyst, cystic wall is detached from the bone and removed completely.
214393136|NCT06096220|DIAGNOSTIC_TEST|incisional biopsy|Lesions clinically abd radiographically consistent with OKC will be submitted for histological examination to confirm the diagnosis of OKC
214393137|NCT06096220|DRUG|Application of 5-fluorouracil|5% 5-fluorouracil cream will be applied immediately after the enucleation to the cystic cavity for 24 hours
214393138|NCT06096220|DRUG|Application of Carnoy solution|Carnoy solution will be applied during the enucleation as described previously
214393139|NCT02500316|DRUG|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
214502372|NCT06630325|OTHER|Survey Administration|Ancillary studies
214502373|NCT06630325|DRUG|Tamoxifen|Given PO
214502374|NCT06630325|DRUG|Temozolomide|Given PO
214502375|NCT06630325|PROCEDURE|Biospecimen Collection|Biological Sample Collection, Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection
214502376|NCT02423642|PROCEDURE|Continuous renal replacement therapy with regional citrate anticoagulation|"CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)"
214502377|NCT02423642|PROCEDURE|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
214502378|NCT01722409|DRUG|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
214502379|NCT01722409|DRUG|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
214502380|NCT02980588|DEVICE|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
214688105|NCT06686030|DRUG|Olaparib|bid, oral
214688106|NCT06686030|DRUG|AK112 high dose|20mg/kg, Q3W, ivgtt
214688107|NCT02684240|DRUG|Nitazoxanide|nitazoxanide 1000 mg orally twice daily with food for 14 days
215000134|NCT07116863|DRUG|KDF1901|"Fixed-dose combination tablet containing valsartan 160 mg, amlodipine 10 mg, and chlorthalidone 25 mg.~Orally administered once daily for 6 weeks during Treatment Period 2."
214502381|NCT02483468|BEHAVIORAL|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
214393140|NCT03696277|RADIATION|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
214393141|NCT05216926|OTHER|Timing of preventive action based on prediction model|Timing of preventive action based on prediction model
214393142|NCT05216926|OTHER|Hypoglycaemia treatment at hypoglycaemia (usual care)|Hypoglycaemia treatment at hypoglycaemia (usual care)
214502382|NCT02483468|DEVICE|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
214502383|NCT02483468|DEVICE|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
215000135|NCT07116863|DRUG|KDF1901-R1|Fixed-dose combination tablet containing valsartan 160 mg and amlodipine 10 mg. Orally administered once daily for 6 weeks during Treatment Period 2.
214502384|NCT06495970|DEVICE|Gradient Denervation System|The Gradient Denervation System delivers ultrasound ablation to planned locations in the pulmonary artery to down-regulate the sympathetic nervous drive. The system includes a sterile, single-use catheter that is designed to centrally position the transducer within the arterial target zone for consistency of ablation.
215000136|NCT07113808|DEVICE|contrast-enhanced ultrasound examination|to evaluate the the application of contrast-enhanced ultrasound examination in children with intra-abdominal diseases that require clear diagnoses aged from 29 days to 18 years old
215000137|NCT07113808|DRUG|SonoVue®|perform contrast enhanced ultrasound (CEUS) using Sonovue as the contrast agent
215000138|NCT06183476|BEHAVIORAL|Amplify-RHYTHM|Amplify-RHYTHM will have two main components: 1) timed light exposure (increase light in the morning, blue light reduction in the evening and eye masks at night), 2) weekly remote coaching session by psychologist to optimize circadian and sleep behaviors
214502385|NCT03335488|DRUG|RAVICTI|RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
214502386|NCT03335488|DRUG|NaPBA|"* NaPBA in patients weighing \< 20 Kg - 600 mg/Kg, maximum total daily dose~* NaPBA in patients weighing \> 20 Kg - 13 g/m2, maximum total daily dose"
214502387|NCT03771066|BEHAVIORAL|bisphenol A|Vanilla wafer cookie with bisphenol A administered
214502388|NCT03771066|BEHAVIORAL|Placebo|Vanilla wafer cookie with no bisphenol A
215000139|NCT07124728|BEHAVIORAL|Technology-enabled Telehealth Care Plan|Participants receive a 6 month personalized telehealth intervention via a multidisciplinary care team, delivering care via a secure digital platform, including education, risk assessment, lifestyle coaching, medical history review, and stroke risk reduction planning. The Healthie EHR is used for communication, documentation, and data integration. Syntrillo Navigators and neurology providers conduct onboarding, telemedicine visits, and coordination with patient's primary care providers and care team.
215000140|NCT07124728|DEVICE|Blood Pressure Monitoring Device|Participants will receive a cellular-enabled, FDA-cleared blood pressure monitor supplied by Tenovi. Blood pressure is measured twice daily during baseline and at least once daily throughout the 6-month intervention. Data is transmitted via a secure gateway to the Healthie EHR for real-time monitoring and analysis.
215000141|NCT07124728|DEVICE|Tenovi Smart Pillbox|Participants receive a connected 7-day smart pillbox that detects compartment openings and refills. Medication adherence data is uploaded in real time to a secure dashboard and integrated into the EHR.
215000142|NCT07124728|DEVICE|Wearable Activity Trackers (Fitbit or Apple Watch)|Participants will utilize a commercially available wearable activity tracker to monitor step counts, resting heart rate, and heart rate variability. This data is integrated into the EHR. Devices will be provided if participants do not already own one.
215000143|NCT07124728|OTHER|Healthie EHR|HIPAA-compliant electronic medical record system used for participant management, secure communication, clinical documentation, and device data integration, consisting of custom workflows used for risk tracking and care planning.
214393143|NCT01222611|DRUG|Fosamprenavir|HAART including fosamprenavir boosted with ritonavir
214393144|NCT01406717|DRUG|SPIL1033|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
214393145|NCT01406717|DRUG|Placebo|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
214393146|NCT01375894|DEVICE|"imitation assessment using the 5-dt data glove."|measuring the speed of the hand during imitation
214502389|NCT05328466|DEVICE|The engineer-built system, video-game based Kinect sensor|The games were developed by the researcher team.
214502390|NCT00856362|DRUG|Moxidectin|
214502391|NCT00856362|DRUG|Midazolam|
214688108|NCT02684240|OTHER|Control|The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
214688109|NCT06445504|DEVICE|Robotic-Assisted Surgery (RAS) Hernia Repair Surgery|Patients indicated for Robotic-Assisted Surgery (RAS) for ventral and inguinal hernia repair will have the RAS surgery using the Medtronic Hugo RAS system
215000144|NCT07124728|OTHER|Secure Messaging Platforms (TigerConnect, Weave, AirCall)|Participants and providers may communicate using secure messaging platforms for appointment reminders, assessments, and care support, to enhance participation engagement and care coordination.
214393147|NCT04091776|RADIATION|CT scan|"1. Quantitative CT scan to measure localized osteoporosis and detection of cortices comminution.~2. Blinded surgeon decision as regard to replace or to fix using DHS or PFN (depending on x-rays data only).~3. Pathological assessment of osteoporosis in retrieved bone in patients whom hip replacement was decided.~4. Assessment of fixation failure in fixed fractures if occurred.~5. Fixation failure is defined as:~5.1. Lag cut through 5.2. Lag cutout 5.3. Z-effect (lag penetration) 5.4. Non-union (within 6 months) 5.5. Loss of reduction with progressive varus deformity 5.6. Femoral fracture 5.7. Intra-operative fracture of lateral wall or anterior cortex"
214393148|NCT00596024|DIETARY_SUPPLEMENT|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
214393149|NCT00596024|DIETARY_SUPPLEMENT|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
214393150|NCT03257995|DRUG|Indacaterol maleate|150 μg via Concept1 device
214393151|NCT03257995|DRUG|Indacaterol acetate|150 μg via Concept1 device
214393152|NCT03257995|DRUG|Placebo|Capsule containing no active ingredients delivered via Concept1 device
214393153|NCT05895968|PROCEDURE|posterior cervical surgery|The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.
214393154|NCT06211387|PROCEDURE|Resistance Exercise Training|Resistance Exercise Training for knee
214393155|NCT06211387|PROCEDURE|Joint Mobilization|Tibiofemoral and Patellofemoral Joint Mobilization
214393156|NCT03120208|BEHAVIORAL|• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.|The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
214393157|NCT03120208|BEHAVIORAL|The GAD-7 with a discrimination threshold ≥10.|The GAD-7 with a discrimination threshold ≥10.
214393158|NCT03120208|BEHAVIORAL|• Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46|Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
214393159|NCT03120208|BEHAVIORAL|The IES-R, validated in French, with a discrimination threshold ≥ 30.|The IES-R, validated in French, with a discrimination threshold ≥ 30.
214393160|NCT03120208|BEHAVIORAL|EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)|For the partners
214393161|NCT03355105|OTHER|Objective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|The exsufflation pressures will be progressively increased starting from -20 cmH2O with 10 cmH2O increments up. 3 coughing operations will be realised for each level, until obtention of 10% of AUC decrease or a PCF collapse of at least 10% over the last 2 levels and without exceeding -70 cmH2O. The selected landing will be the one allowing the largest PCF without presence of collapse. An intermediate bearing between 2 bearings may be tested in order to approach an optimum adjustment threshold less than 5 cmH2O.
214393162|NCT03355105|OTHER|Subjective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|"The exsufflation pressures will be gradually increased from -20 cmH2O, with 10 cmH2O increments up to a maximum of -70 cmH2O. The selected level will be the one selected both by the patient and the clinician therapist and considered as making it possible to obtain the most effective cough according to the return of the patient."
214393163|NCT00346996|DRUG|insulin levemir / aspart|for subcutaneous injection
214393164|NCT00346996|DRUG|human insulin /insulin isophane|for subcutaneous injection
214393165|NCT01112696|DEVICE|Sensor wear|All subjects to wear sensors
214393166|NCT01642069|OTHER|laboratory biomarker analysis|Correlative studies
214393167|NCT05291884|DEVICE|Impella BTR|Subjects will be prepared for pump insertion procedure according to clinical site standard of care. Procedural preparations for insertion of the Impella BTR are identical to the insertion of the Impella 5.0/5.5 via the axillary artery. The Impella BTR remains in situ until the patient is sufficiently recovered for removal or is transitioned to another form of support. It is expected that the Impella BTR is in situ for a maximum of 28 days.
214393168|NCT04478513|DRUG|AZD4635|During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
214502392|NCT03696056|BEHAVIORAL|Kirtan Kriya meditation|The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
215000145|NCT07124728|DRUG|Antihypertensive Medication Management|Participants may be prescribed or have existing antihypertensive regimens adjusted (ACE inhibitors, beta blockers, calcium channel blockers, diuretics, etc) by neurologists or nurse practitioners based on individual risk assessments and clinical findings during the study. Changed will be recorded in EHR.
215000146|NCT07124728|DRUG|Statin Medication Management|Lipid-lowering medications, including statins, may be initiated or adjusted as part of participants' care plans. Medication use is guided by cardiovascular risk and AHA guidelines. Changed will be recorded in EHR.
214393169|NCT04478513|DRUG|Fluvoxamine|Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
214393170|NCT03677882|BEHAVIORAL|Mind Body Bridging Group Session|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
214393171|NCT02969031|BEHAVIORAL|Enhanced SCOPE training|Intervention is integrated into the American Board of Internal Medicine (ABIM) Maintenance Of Certification (MOC) process.
214393172|NCT02969031|BEHAVIORAL|Standard Communication training|Standard Communication training
214393173|NCT04758234|DRUG|LY3549492|Administered orally.
214393174|NCT04758234|DRUG|Placebo|Administered orally.
215000147|NCT07124728|DRUG|Antiplatelet or Anticoagulant Therapy|Participants with atrial fibrillation or elevated cardiovascular risk may be started on or have changes to antiplatelet or anticoagulant therapy. Medication decisions are made by neurologist or nurse practitioners during telemedicine visits. Changed will be recorded in EHR.
215000148|NCT07124728|PROCEDURE|Laboratory Blood Test Collection|Blood samples may be collected at baseline and at 6 months to assess inflammation through high-sensitivity C-reactive protein.
214393175|NCT04903834|DIAGNOSTIC_TEST|Soton hyperinflammation score|Score for hyperinflammation defined by blood parameters and other physiological measurements
214393176|NCT04903834|DIAGNOSTIC_TEST|HScore|Score for secondary haemophagocytic lymphohistiocytosis validated in prior publications
214393177|NCT04809792|RADIATION|SBRT on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
214393178|NCT02973360|DRUG|Docosahexaenoic Acid|Oral Capsule
214502393|NCT03696056|BEHAVIORAL|Music listening program|"The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log."
214502394|NCT00388726|DRUG|E7389|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
214502395|NCT00388726|DRUG|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
215000149|NCT07122609|DRUG|Pirtobrutinib|Dose:200mg，d1-21
215000150|NCT07122609|DRUG|R-GemOx|Dose: Rituximab: 375mg/m2, d1; Gemcitabine: 1000mg/m2, d2; Oxaliplatin:100mg/m2, d2
215000151|NCT07122609|DRUG|Polatuzumab Vedotin|Dose: 1.8mg/kg，iv，d1 (For patient who is CD79b positive and has not previously received polatuzumab Vedotin)
215000152|NCT07122583|DEVICE|CoolSculpting Elite System|CoolSculpting Elite Applicator
215000153|NCT07122037|DEVICE|DosMedical Smell Training Set|Olfactory training with four different odorants (e.g., rose, eucalyptus, lemon, and cloves) for approximately 10 seconds each, twice a day, in the morning and in the evening
215000154|NCT07122037|BEHAVIORAL|Nasal Airflow Inducing Maneuver|"Repeated generation of an underpressure in the oral cavity by simultaneously lowering the jaw, the floor of the mouth the tongue, the base of the tongue and soft palate with securely closed lips. This negative pressure created in the oral cavity generates an airflow through the nose."
215000155|NCT07119541|BEHAVIORAL|Alliance-Focused Dialectical Behavior Therapy plus Deliberate Practice|The alliance-focused DBT training plus deliberate practice is a 4-session weekly intervention delivered to therapists working with individuals with borderline personality disorder or emotion dysregulation. This training intervention involves a didactic component, video analysis, and case-based learning. Deliberate practice methods (e.g., setting individualized training goals, skills coaching, feedback, and opportunities for repeated practice) will be integrated both within and between training sessions.
215000156|NCT07119541|BEHAVIORAL|Alliance-Focused Dialectical Behavior Therapy plus Reflective Practice|The alliance-focused DBT training plus reflective practice is a 4-session weekly intervention delivered to therapists working with individuals with borderline personality disorder or emotion dysregulation. Trainings will involve a didactic component, video analysis, and case-based learning. Reflective practice methods (i.e., thinking about past experiences to gain insight for future actions) will be integrated both within and between training sessions.
215094358|NCT05141955|OTHER|Group Erector Spinae Plane Block (ESPB)|"Patients will receive general anesthesia initially then bilateral ESPB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed (not exceeding toxic dose) 150 mg "
215094359|NCT05141955|OTHER|Group Quadratus Lumborum Block (QLB)|"Patients will receive general anesthesia initially then bilateral QLB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed not exceeding toxic dose150 mg "
214393179|NCT02973360|DRUG|Placebo|Oral Capsule
214393180|NCT03259529|DRUG|Bendamustine hydrochloride|70 mg/m2 by intravenous (IV) infusion for up to 2 cycles
214393181|NCT03259529|DRUG|Gemcitabine 500 mg|500 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
214393182|NCT03259529|DRUG|Gemcitabine 700 mg|700 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
215000157|NCT07123571|BEHAVIORAL|Contagious Laughter|Contagious laughter videos
215000158|NCT07123675|DEVICE|Device: AI Clinical Decision Support System|An AI-based software system that provides real-time, on-screen recommendations to the anesthesiologist regarding drug administration and adjustments to maintain optimal patient physiological parameter
215000159|NCT07123675|PROCEDURE|Procedure: Standard of Care Anesthesia|Standard anesthesia management according to institutional guidelines. The attending anesthesiologist makes all clinical decisions based on their expertise and judgment without input from the investigational AI system.
215000160|NCT06868082|BIOLOGICAL|Solrikitug|Solrikitug Formulation 1
215000161|NCT06868082|BIOLOGICAL|Solrikitug|Solrikitug Formulation 2
215000162|NCT05504291|PROCEDURE|Biospecimen Collection|Undergo aqueous humor, tissue, and blood sample collection
215000163|NCT05504291|DRUG|Carboplatin|Given IV
215094360|NCT05141955|OTHER|Group (C) (Control group)|Where patients will be operated under general anesthesia.
215094361|NCT01378611|DEVICE|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
215094362|NCT03536026|PROCEDURE|Conventional bronchoscopy|-Standard of care
215094363|NCT03536026|DEVICE|VIDA Pulmonary Workstation 2|-Virtual bronchoscopic navigation system
215094364|NCT03536026|PROCEDURE|Biopsy|-Standard of care
214393183|NCT03259529|DRUG|Gemcitabine 1000 mg|1000 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
214393184|NCT03259529|DRUG|Nivolumab|1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles
214393185|NCT03259529|DRUG|Rituximab|375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles
214393186|NCT01556763|DRUG|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
214393187|NCT01556763|DRUG|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
214393188|NCT01556763|DRUG|Placebo|Matching placebo was administered as one capsule per day for 21 days.
214393189|NCT01556763|DRUG|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
214393190|NCT04723160|DIAGNOSTIC_TEST|Software assisted imaging diagnosis|In the test group, diagnoses are given with the help of the software.
214393191|NCT04170296|DRUG|EN3835|Collagenase Clostridium Histolyticum (CCH)
214393192|NCT04581902|DEVICE|rTMS therapy|rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.
214502396|NCT04346914|BIOLOGICAL|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide|ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1\~3，q3w
215000164|NCT05504291|DRUG|Etoposide|Given IV
215000165|NCT05504291|PROCEDURE|Examination Under Anesthesia|Undergo imaging of the eye during EUA
215000166|NCT05504291|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215000167|NCT05504291|DRUG|Melphalan|Given I-VITRE
215000168|NCT05504291|PROCEDURE|Ultrasound Biomicroscopy|Undergo UBM during EUA
215000169|NCT05504291|DRUG|Vincristine|Given IV
215000170|NCT04919824|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.
215000171|NCT04919824|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.
215000172|NCT05105841|DRUG|Venetoclax|Oral Tablet
215000173|NCT05105841|DRUG|Ibrutinib|Oral Capsule
215000174|NCT05105841|DRUG|Obinutuzumab|Intravenous (IV) Infusion
215000175|NCT04851119|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215000176|NCT04851119|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
215000177|NCT04851119|DRUG|Tegavivint|Given IV
215000178|NCT04851119|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
215000179|NCT06908590|BEHAVIORAL|Education, Providing and Engaging Social Support and Assistance with Health System Navigation|"1. Introduction to Program and Cardiac Rehab Needs Assessment Education about Cardiac Rehab~2. Education about CVD and how Cardiac Rehab can help in the participants recovery~3. Social Support Module~4. Health System Navigation Module"
215000180|NCT07096076|OTHER|Thoracolumbar fascia inhibition|Soft tissue mobilization: Participants will be asked to lie on their backs without a pillow in a hook-lying position, placing a foam roller under the inferior part of the scapula and clasping their hands behind the cervical region. Then, they will be instructed to lift their hips off the ground and roll the foam roller in a cranial and caudal direction from the inferior scapular region to the sacral area for 30 seconds, performing flexion and extension movements with their knees. This application will be performed in a total of 4 sets.
215000181|NCT07096076|OTHER|Suboccipital inhibition group|Soft tissue mobilization: Participants will be asked to lie in a supine position on an appropriate surface and keep their knees in extension. Then, they will be instructed to hold both ends of a sheet and place the middle part of the sheet on the plantar surface of one foot. Using the sheet and by dorsiflexing the ankle, they will pull the extended leg toward themselves. This position should be maintained for 30 seconds (8). It is important that the opposite knee does not flex during the exercise. The application will be performed bilaterally.
215000182|NCT07096076|OTHER|hamstring stretching|Participants performed passive hamstring stretching using a sheet for self-assistance. Participants will be asked to lie supine on an appropriate surface and keep their knees in extension. Then, they will be instructed to hold both ends of a sheet and place the middle part of the sheet on the plantar surface of one foot. Using the sheet and performing ankle dorsiflexion, they will pull the leg-kept in knee extension-toward themselves. This position should be held for 30 seconds (8). It is important that the opposite knee does not move into flexion during the exercise. The application will be performed bilaterally.
215000183|NCT07087951|DEVICE|Gamma auditory stimulation device (active setting)|Participants will receive auditory stimulation using the gamma auditory stimulation device (active setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.
215000184|NCT07087951|DEVICE|Gamma auditory stimulation device (sham setting)|Participants will receive auditory stimulation using the gamma auditory stimulation device (sham setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.
215000185|NCT07093034|DEVICE|Extended nocturnal use of auricular vagus nerve stimulator device|Patients will wear the ParasymTM device with an ear clip on the tragus that provides stimulation at sub-detection threshold.
214393193|NCT01139905|OTHER|lopinavir/ritonavir|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
214393194|NCT05158881|DEVICE|Near-infrared spectroscopy|Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion. Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.
214393195|NCT00195715|BIOLOGICAL|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
214502397|NCT03741023|PROCEDURE|Blood draw (venipuncture or fingerstick)|Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
214502398|NCT05038839|DRUG|Cabozantinib|Given PO
214502399|NCT05038839|DRUG|Pamiparib|Given PO
214393196|NCT05805306|BEHAVIORAL|Entre Herman@s|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
214393197|NCT05805306|BEHAVIORAL|Vaccines for Health|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
214393198|NCT06193759|BIOLOGICAL|Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)|Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse. In this study, individualized TSA-T cells will be generated against proteogenomically determined tumor-specific antigens after standard of care treatment in children less than 5 years of age with embryonal brain tumors.
214393199|NCT00845871|DRUG|deferasirox:|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
214393200|NCT02076074|RADIATION|accelerated partial breast irradiation|Undergo HG-PBI
214393201|NCT01542060|DRUG|biphasic insulin aspart 30|Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
214393202|NCT00345787|DRUG|Placebo|Corresponding placebo is applied for 12weeks
214393203|NCT00345787|DRUG|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
214393204|NCT03694314|DIETARY_SUPPLEMENT|Omega-3 fatty acids|200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).
214393205|NCT03694314|DIETARY_SUPPLEMENT|Placebo|200 mL placebo fruit juice with no effect on the hypothesized outcome.
214393206|NCT04424875|DRUG|3 mg melatonin|patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
214393207|NCT04424875|DRUG|Placebo|patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
214393208|NCT00406458|DRUG|SB-509|60 mg dose
214393209|NCT00406458|OTHER|Normal Saline|
214393210|NCT02500914|DRUG|SC-002|SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
215000186|NCT07096427|BEHAVIORAL|Virtual Reality-Based Prenatal Education|This intervention involves prenatal education based on Pender's Health Promotion Model delivered using immersive 360-degree virtual reality (VR) videos. The content focuses on healthy lifestyle behaviors during pregnancy, including nutrition, physical activity, stress management, and health responsibility. Participants view the videos via VR headsets in three weekly sessions, each lasting approximately 20 minutes. Motivational follow-up calls are conducted after the sessions.
214393211|NCT00841516|OTHER|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
214393212|NCT00841516|BIOLOGICAL|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
214393213|NCT01370603|DRUG|Atorvastatin|40 mg tablet administered orally once daily
214393214|NCT01370603|DRUG|Ezetimibe|10 mg tablet administered orally once daily
214393215|NCT01370603|DRUG|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily
214393216|NCT01370603|DRUG|Placebo to atorvastatin|Administered orally once daily
214393217|NCT01370603|DRUG|Placebo to ezetimibe|Administered orally once daily
214393218|NCT01370603|DRUG|Placebo to ezetimibe/atorvastatin|Administered orally once daily
214393219|NCT06177236|DIAGNOSTIC_TEST|cervical cancer screening|The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.
214393220|NCT03723135|DRUG|CC-486|Oral azacitidine administered as directed by treating physician.
214393221|NCT05179044|DEVICE|Guardian Sport Rehabilitator knee brace|The Guardian Sport Rehabilitator knee brace has pneumatic condyles that can be used to support and control the knee joint as well as an extension swing assist design which automatically assists in extending the knee when the patient themselves may guard against it. The Guardian Rehabilitator Knee Brace is considered by the FDA as a Class I external medical device. It is used on label and therefore exempt from IDE requirements.The Guardian Brace FDA registration to manufacturer external limb devices is attached for reference.
214393222|NCT02905123|BEHAVIORAL|Check Your Drinking|
214393223|NCT00798031|DEVICE|A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.|A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
214502400|NCT06336590|BEHAVIORAL|Morning Exercise|Exercise is changed from normal (6pm-11pm) exercise to morning (6am-11am) exercise.
214502401|NCT01953692|BIOLOGICAL|Pembrolizumab|IV infusion
214502402|NCT01953692|DRUG|Lenalidomide 20 mg|oral capsule
214502403|NCT01953692|DRUG|Lenalidomide 25 mg|oral capsule
214502404|NCT02662205|OTHER|Psychotherapy Group|Traditional process group
214393224|NCT00798031|DEVICE|Placement of dental implant|"Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.~A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis."
214393225|NCT00798031|DEVICE|dental implant|Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
214393226|NCT00417014|DRUG|chlorambucil|
214393227|NCT00417014|DRUG|prednisolone|
214502405|NCT02662205|OTHER|Yoga class|Yin yoga class
215000187|NCT07096427|BEHAVIORAL|Booklet-Based Prenatal Education|This intervention includes prenatal education based on Pender's Health Promotion Model delivered through printed booklets. The educational content is identical to that of the VR group and covers healthy behaviors in pregnancy. The booklets are discussed in three face-to-face sessions, held once per week for three weeks. Each session lasts about 20 minutes. Participants receive motivational follow-up phone calls after the sessions.
215000188|NCT05629091|DEVICE|FibDex|Nanofibrillar cellulose wound dressing
215000189|NCT05629091|DEVICE|Epicite hydro|Wound dressing
215000190|NCT05629091|DEVICE|Epiprotect|Wound dressing
215000191|NCT07098858|DEVICE|The Wise System|The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
215000192|NCT06910540|OTHER|Acu-TENS|This protocol makes use of the acu-TENS treatment on the acupoints Hegu (LI4), Zusanli (ST36), Sanyinjiao (SP6), and Taichong (LR3). After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTR+ Myolito Multifunctional Stimulator MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 3-5 mA, and pulse width of 300µS will be delivered continually during TUGOR.
215000193|NCT06910540|OTHER|Sham acu-TENS|In the sham acu-TENS, within the same time interval, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current.
215000194|NCT07099222|DRUG|Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks|Low, non-weight based dose of Dexamethasone and Dexmedetomidine adjunct with Ropivacaine (local anesthetic) for use in peripheral nerve blocks to look for synergistic effects of the combination in extending the duration of the block while limiting any potential side effects of each additive.
215000195|NCT07099222|DRUG|Ropivacaine with low, non weight based Dexamethasone additive|Very accepted, standard peripheral nerve block with steroid adjunct solution used to increase the duration of local anesthetic by 4-6hrs.
215000196|NCT07094035|DIETARY_SUPPLEMENT|food supplement based on a mixture of green tea extract and a pool of probiotics.|two capsules of food supplement (verum) or placebo, daily for 56 consecutive days. The daily consumption of the food supplement provides: green tea extract (Camellia sinensis (L.) Kuntze - folium) 300 mg, as a green capsule, and a pool of probiotics (Lactobacillus rhamnosus LRH020 2x10\^9 UFC, Bifidobacterium lactis BL050 2x10\^9 UFC, Lactobacillus plantarum PBS067 2x10\^9 UFC), as a white capsule.
215000197|NCT07094035|DIETARY_SUPPLEMENT|Placebo|1 capsule/day of maltodextrin (500 mg) with a green shell, and 1 capsule/day of maltodextrin (500 mg) with a white shell for 56 days. The two colours are applied to maintain the binding.
214393228|NCT00417014|DRUG|procarbazine hydrochloride|
214393229|NCT00417014|DRUG|vinblastine sulfate|
214393230|NCT00417014|RADIATION|radiation therapy|
214393231|NCT03636035|DIETARY_SUPPLEMENT|Tregocel®|Coated tablet (oral)
214393232|NCT06280456|DRUG|Tranexamic Acid Powder|10 mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation with different drainage clamping time.
214393233|NCT01630343|DRUG|Paracetamol tablet and Tramadol capsule|Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
214393234|NCT01630343|DRUG|Panadol 500mg tablet, tramadol 50mg capsule|Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
214393235|NCT01097460|DRUG|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
214393236|NCT01233167|DRUG|clopidogrel|clopidogrel 75 mg po per day for 12 months
214502406|NCT02662205|OTHER|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
214502407|NCT03905278|BEHAVIORAL|Parental guidance|A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.
214502408|NCT00324948|DRUG|Topical alprostadil (PGE-1)|
215094365|NCT04790292|DRUG|group M|10mg morphine in 5ml normal saline + 10ml of 0.25% bupivacaine ( total volume 15 ml) were injected intra-articularly
215000198|NCT07097961|BEHAVIORAL|Pulmonary Rehabilitation|The intervention includes twice-weekly walking and wall sit exercises, guided by a physiotherapy assessment. Participants use a pedometer, receive written instructions, and are monitored weekly by phone or home visit. Caregivers supervise the exercises and sessions are logged in a participant workbook.
215000199|NCT05279300|DRUG|CS5001|The dose and dosing schedule is decided by the Safety Monitoring Committee.
215094366|NCT04790292|DRUG|group MD|10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly
215094367|NCT01472744|BEHAVIORAL|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
215000200|NCT05279300|BIOLOGICAL|Rituximab|IV infusion
215094368|NCT01472744|BEHAVIORAL|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
215094369|NCT01472744|BEHAVIORAL|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
215094370|NCT01472744|BEHAVIORAL|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
215094371|NCT01642758|DRUG|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
214393237|NCT01233167|DRUG|placebo|placebo 75mg po per day for 12 months
214393238|NCT01233167|DRUG|clopidogrel and placebo|clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
214393239|NCT04039503|DRUG|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
214393240|NCT04039503|DRUG|Placebo|Administered SC as add-on to the pre-trial background medication.
214393241|NCT01163747|BIOLOGICAL|tocilizumab|Intravenous repeating dose
214393242|NCT01163747|DRUG|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
214393243|NCT01163747|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
214393244|NCT01163747|BIOLOGICAL|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
215000201|NCT05279300|DRUG|Gemcitabine|IV infusion
215000202|NCT05279300|DRUG|Oxaliplatin|IV infusion
215000203|NCT05279300|DRUG|Lenalidomide|PO
214393245|NCT04970095|DEVICE|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
214393246|NCT04970095|DEVICE|Petit Face Mask|"The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion.~consist of forehead cap chin cap cross bar"
215000204|NCT05279300|DRUG|Cyclophosphamide|IV infusion
215000205|NCT05279300|DRUG|Doxorubicin|IV infusion
215000206|NCT05279300|DRUG|Vincristine|IV infusion
215000207|NCT05279300|DRUG|Prednisone|PO
215000208|NCT06862115|DRUG|ACE-I and/or ARB antihypertensive treatment|When the ACE-I and/or ARB duration of action is ≥24 hours, the drug will be stopped 48 hours prior to surgery. All other ACE-I and/or ARB will be stopped 24 hours before surgery.
215000209|NCT06795126|OTHER|Little NIRVANA|Augmented reality (AR) digital solution where children interact with the game using a magic wand
215000210|NCT07096674|DRUG|ORX750|Oral ORX750
215094372|NCT02445573|OTHER|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
214393247|NCT02392884|BEHAVIORAL|Cognitive Rehabilitation|Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
214502409|NCT05841342|OTHER|No intervention|No intervention
214688110|NCT05673811|DRUG|Nab-paclitaxel|Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
215000211|NCT07096674|DRUG|ORX750|Oral ORX750
215000212|NCT07096674|DRUG|ORX750|Oral ORX750
215000213|NCT07095868|BIOLOGICAL|EVM14|Cancer Vaccine
215000214|NCT07095868|COMBINATION_PRODUCT|Pembrolizumab|Anti-PD1 antibody
215000215|NCT05997576|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
215000216|NCT05997576|DRUG|Placebo|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.
214393248|NCT02244099|OTHER|Controlled Substance|Patients will be identified using the reporting workbench in the EMR if they have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months by one of the consenting resident physicians from Martha Morehouse General Internal Medicine Resident Continuity Clinic. Once identified, a comprehensive chart review for other important parameters based on best practice recommendations as described in the research protocol will be conducted in order to characterize the patient population for which the recommendations are being made to the physicians. Improvement in controlled substance, carisoprodol, and tramadol prescribing and adherence to the CSTA by the resident physicians will be tracked using a pre/post intervention comparison.
214393249|NCT03109340|OTHER|Supervised treadmill group (Group I)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70% VO2max (moderate-intensity) was determined by the submaximal treadmill test.The participants were instructed walking exercise at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY).During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
214393250|NCT03109340|DEVICE|ECE PEDO pedometer (Group II)|Following a 10-minute rest after treadmill test, the participants were instructed to walk on the treadmill while maintaining their target heart rate. The number of steps taken in a minute was calculated using a criterion pedometer when target HR responses were reached. In this way, we determined the steps per minute required to moderate intensity walking for each participant. Detected individual step numbers were recorded to ECE PEDO for each person. Then participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from the range of steps per minute.During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
214393251|NCT00991822|DRUG|Dorzolamide 2%|
214393252|NCT00991822|DRUG|Timolol 0.5%|
214393253|NCT06625749|DEVICE|Accurasee™ IOPCL|Intraocular pseudophakic capsular lens (IOPCL)
215000217|NCT06910774|OTHER|Dosage of serotonin and tryptophan metabolites levels in serum|These measurements will be performed on residual blood samples in the laboratory, after blood collection carried out as part of routine care. Patients will not need to undergo an additional blood draw.
215000218|NCT03105102|DRUG|Placebo for Risankizumab SC|Placebo for Risankizumab SC Subcutaneous (SC) Injection
215000219|NCT03105102|DRUG|Risankizumab IV|Risankizumab IV Intravenous (IV) infusion
215000220|NCT03105102|DRUG|Placebo for Risankizumab IV|Placebo for Risankizumab IV Intravenous (IV) infusion
215000221|NCT03105102|DRUG|Risankizumab SC|Risankizumab SC Subcutaneous (SC) injection
215000222|NCT03105102|DRUG|Risankizumab On-Body Injector (OBI)|Subcutaneous (SC) injection; on-body injector (OBI)
215000223|NCT07102524|DRUG|TSHA-105|AAV9/SLC13A5
214393254|NCT03681639|DIAGNOSTIC_TEST|Serum Metal ion levels determined to monitor changes in chromium and cobalt levels|Analyses was performed pre-operatively, 6 months, 1 year, 2 years and 5 years post-operatively for all study subjects enrolled in this study, as well as, all revision study subjects receiving the Metasul LDH™ total hip system. To prevent intra-observer variation the metal ion concentrations was analysed by an approved Central Laboratory. The Central Laboratory provided specimen collection kits for the transfer of blood specimens to the Laboratory for analysis. The Laboratory provided the results to the Investigators. The cobalt and chromium was measured by induced coupled plasma mass spectrometry (ICP-MS). BUN, creatinine and GFR will be determined locally.
214393255|NCT00654940|DRUG|Pregabalin (Lyrica)|Oral, 75mg or 150mg capsules, BID
215000224|NCT07101575|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography with bubble test, by intravenous infusion of agitate saline solution
215000225|NCT06744322|PROCEDURE|Fast discharge strategy|Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.
215000226|NCT02180867|DRUG|Doxorubicin|Given IV
215000227|NCT02180867|DRUG|Doxorubicin Hydrochloride|Given IV
214393256|NCT00654940|DRUG|Placebo|Oral, matched capsules, BID
215000228|NCT02180867|DRUG|Ifosfamide|Given IV
215000229|NCT02180867|DRUG|Pazopanib|Given PO
215000230|NCT02180867|DRUG|Pazopanib Hydrochloride|Given PO
215000231|NCT02180867|RADIATION|Radiation Therapy|Undergo radiation therapy
215000232|NCT02180867|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
215000233|NCT07104266|DRUG|Celecoxib (Celebrex)|The participants will take one capsule celecoxib (100 mg) or placebo after breakfast and one after supper, starting 7 days before radiotherapy and ending 14 days after radiotherapy.
215000234|NCT07104266|DRUG|Placebo|Participants will take one capsule of placebo after breakfast and one after supper, starting 7 days before radiotherapy and ending 14 days after radiotherapy.
215000235|NCT07103902|BEHAVIORAL|Moderate-Intensity Exercise|Participants will engage in 20 minutes of cycling at approximately 70% max heart rate with a 2.5 minute warm up and a 2.5 minute cool down.
215000236|NCT07103902|BEHAVIORAL|Low-Intensity Exercise|Participants will engage in 20 minutes of cycling at approximately 40-50% max heart rate with a 2.5 minute warm up and a 2.5 minute cool down.
215000237|NCT07105202|DRUG|levosimendan|Participants randomized to to the intervention will receive levosimendan. The infusion is administered over 24 hours, starting at a dose of 0.1 µg/kg/min. After 4 hours, the dose may be increased to 0.2 µg/kg/min if tolerated, based on clinical judgment. A maximum of four treatment cycles may be given if the patient is not successfully weaned from mechanical ventilation within 7 days.
215000238|NCT07105202|DRUG|Soluvit|Participants randomized to this arm will receive a placebo consisting of Soluvit diluted in glucose 5%, administered as an intravenous infusion over 24 hours. The infusion will mimic the Levosimendan administration protocol, starting at 0.1 µg/kg/min and potentially increasing to 0.2 µg/kg/min after 4 hours, to maintain blinding. A maximum of four placebo treatment cycles may be administered if the patient is not successfully weaned from mechanical ventilation within 7 days.
215000239|NCT07105202|OTHER|Standard care|All patients in this arm will receive standard ICU care, including daily assessments for readiness to wean from invasive ventilation.
215000240|NCT07103681|PROCEDURE|Ventriculoperitoneal Shunt (VP)|VP Shunt surgery involves surgical insertion of a catheter (tube) to divert brain fluid from the cerebral ventricles to the abdominal peritoneum. This will be performed in Group 1 patients as clinically indicated.
214393257|NCT06058689|DRUG|Pomalidomide 4 MG Oral Capsule|A single dose of 4 mg Pomalidomide per os, capsule, 4 mg, per period
214393258|NCT00092170|DRUG|MK0826, ertapenem sodium|
214393259|NCT00092170|DRUG|Comparator: Ticarcillin/Clavulanate|
214393260|NCT05155280|OTHER|PET imaging using [11C]DASB radioligand.|Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.
215000241|NCT07103681|PROCEDURE|Brain and Skin Biopsy|Brain and skin biopsy's may be taken during the VP shunt to assist in histological analysis for neurodegenerative changes.
215000242|NCT07103681|DIAGNOSTIC_TEST|MRI Brain|MRI brain with diffusion imagining will be performed before and after shunt surgery.
215000243|NCT07104136|BEHAVIORAL|COPD-care seminar|"A two day seminar which will include:~Lecture: Understanding COPD and Current Guidelines Overview of COPD pathophysiology. Review of the latest GOLD guidelines and treatment strategies Hands-on Session: Inhaler Technique and Device Selection Practical demonstration of different inhaler devices. Evaluating patient inspiratory effort and selecting suitable devices. Understanding advantages of each device and molecule. Motivational interview seminar- On line pre-course lectures about the theory behind motivational interview. Two workshops for simulation and practice of the technic through clinical cases with relevance to COPD patients including smoking cessation counseling techniques.~Panel Discussion: Multidisciplinary Approach to COPD Management Involving respiratory specialists, physiotherapists, and primary care physicians.~Discussion on referral practices and collaborative care."
215000244|NCT07105410|OTHER|Aim #1: The effect of post-exercise circulatory occlusion on H-reflex and V-wave|Aim #1 follows a randomized and crossover design in which 16 young and healthy males are evaluated during thigh circulatory occlusion performed after a submaximal isometric plantar flexion contraction (PECO day). In the other session, participants are evaluated during free-flow conditions and without previous fatiguing contraction (no-PECO day). In PECO day, participants complete a 3-min contraction at 40% of maximal force. Then, for testing, blood flow from lower-leg is blocked during 4 min, by an inflatable cuff around the ipsilateral thigh before task termination, during which H- reflex is tested. At the end of recordings, the cuff is deflated. Participants ware allowed to rest for 5-10 min. Then, they are requested to perform a new 3 min contraction with the cuff being inflated before task termination. The cuff remains inflated for \~ 2 min during which V-wave recordings are obtained. In both days, leg pain intensity is reported by participants and brachial AP is measured.
214393261|NCT05155280|BEHAVIORAL|Eye Tracker|"The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach."
214393262|NCT00141687|PROCEDURE|Early ECV between 34 0/7 and 35 6/7 weeks|Early external cephalic version between 34 0/7 and 35 6/7 weeks of gestation
214393263|NCT00141687|PROCEDURE|Delayed ECV at or after 37 0/7 weeks|Delayed external cephalic version at or after 37 0/7 weeks of gestation
214393264|NCT02965209|PROCEDURE|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
214393265|NCT05921630|OTHER|Education|Patient education before pulmonary function test
215000245|NCT07105410|OTHER|Aim #2: The hypoalgesic effects of acute exercise of different modalities|Aim #2 follows a randomized and crossover-controlled design, consisting on two experimental sessions. 24 healthy male (all diferent from Experiment 1) are randomly allocated to one of the following exercising regimens: aerobic, anaerobic or dynamic resistance (8 participants for each exercise group). In one of the experimental days, participants are evaluated for pain sensitivity and neuromuscular responses both before and after a lower-limb acute exercise protocol (exercise day) and in the other day before and after 15 min of quiet rest (non-exercise day). In both sessions, participants are evaluated for rectus femoris, upper trapezius and biceps brachiis muscles pressure pain threshold, followed by the application of a cold pain tolerance test on the foot. The intensity of pain is reported by a 0-100mm VAS and AP and HRV continously measured. Then, participants are tested for H-reflex and V-wave excitability during PECO, with leg pain intensity (0-10) and brachial AP recorded.
215000424|NCT07124806|COMBINATION_PRODUCT|Botulinum neurotoxin guided by ultrasonography and in vivo location of innervation zones guided by high-density electromyography|The botulinum neurotoxin (BoNT) will be calculated according to the weight of each patient. It will be injected in eight places: four will be located in vivo for gastrocnemius medialis and four for gastrocnemius lateralis. These places will correspond to innervation zones located by high-density electromyography in different zones of each muscle. Thus, each of the eight located innervation zones will receive 1/8 of the calculated dose for the gastrocnemius muscle. All patients will conduct the same physical therapy program and under the direction of the same team of physical therapists. This program will begin two weeks after receiving the BoNT injection.
214393266|NCT01941992|DRUG|SAMITAL®|
214393267|NCT01941992|DRUG|Placebo sachets|
214393268|NCT00590070|DRUG|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
214393269|NCT00590070|DRUG|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
214393270|NCT00590070|DRUG|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
214393271|NCT03541811|DIAGNOSTIC_TEST|3-d gait examination (level walking)|"Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2.~Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured."
215000246|NCT07105410|OTHER|Aim #3: The hypoalgesic effects of chronic training of different modalities|Aim #3 follows a randomized-controlled design. 32 healthy male (all the 24 participants from Experimental 2 plus 8 new subjects) are randomly allocated to one of the following groups: aerobic, anaerobic, dynamic resistance training and no-training (control) (8 participants for each group). Each intervention group perform 6 weeks of exercise training (3x week). Participants allocated to each training group are evaluated before and after training (2 assessment days in each time-point). On one day participants are tested for pressure pain threshold and cold pain tolerance with concomitant measures of pain ratings (0-100mm VAS), AP and HRV. The influence of metaboreflex activation on H-reflex and V-wave is also measured (during PECO). In addition, during PECO ischemic pain rating and AP are obtained. On another day, participants are evaluated for motor performance (maximal oxygen uptake, maximal voluntary contraction and peak power) and neuromuscular adaptations (i.e. H-reflex and V-wave)
215000247|NCT07105059|DRUG|Teclistamab|After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
215000248|NCT07105059|DRUG|Mezigdomide|Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
215000249|NCT07105124|DRUG|Sibeprenlimab|Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.
215000250|NCT07103824|OTHER|Upper Extremity Neurocognitive Tests|The validity and test-retest reliability of the Reactive Neurocognitive Upper Extremity Tests (Reactive CKCUEST and Reactive 90/90 Wall Throws Test) will be analyzed through this protocol. Participants will undergo three assessment sessions spaced one week apart: measurements will be conducted using the Catchpad device during the first and third weeks, and the BlazePod™ device during the second week. To ensure blinding, the personnel responsible for conducting the assessments, recording the data, and performing the statistical analyses will be distinct individuals. Participants will be familiarized with the devices one week prior to testing, and a standardized 5-minute free walking warm-up will be administered at each session. All assessments will be performed under similar environmental conditions and at consistent times of day.
215000251|NCT07103616|DRUG|Randomization of Propofol or Dexmedetomidine|This intervention is a randomization of Propofol or Dexmedetomidine. Each group will receive three minutes of research images, followed by induction of anesthesia and immediately followed by three minutes of imaging. The subject will receive standard care clinical magnetic resonance imaging for 45 minutes and three minutes of research images at the end of the scan.
215000252|NCT07104435|OTHER|Artmaking and exergaming|Weekly visual artmaking and exergaming
215000253|NCT07104071|OTHER|reduced light brightness|reduced light brightness
215000254|NCT07103109|OTHER|Proximal stabilization exercises|Patients will receive Scapular mobilization in five manners, superior glide, inferior glide, up-ward rotation, down-ward rotation, and distraction. Each mobilization will be done ten times. A thirty second break will be given between each set. Also scapular strengthening exercises composed of diagonal two (D2) flexion pattern to augment the upper, middle, lower, and serratus anterior muscles' activity level. To activate upper trapezius muscle, shoulder shrug exercise will be used. To activate serratus anterior muscle, Wall slide exercise will be used. Scapular retraction exercise for rhomboids and middle trapezius activation will be done. Strengthening exercises will be performed using weights were initiated with two sets of ten repetitions, beginning with a weight of 0.5 kg and progressed to 0.75, and1kg, it will be applied 5 days per week for 6 weeks
215000255|NCT07103109|OTHER|Conventional physical therapy|Patients will receive shoulder joint mobilization, posterior capsular stretching, and ROM exercises in form of Codman/pendulum exercise. To mobilize the shoulder joint, distraction of the glenohumeral joint, posterior glide and caudal glide will be performed to the patients in a supine lying position at a frequency of two to three oscillations/second for one to two minutes. Every direction was repeated three to four times. At the resting position rhythmic oscillations grade I and II will be applied. In posterior capsule stretching each stretch will be repeated ten times for 20 seconds, between each stretching a 30-second break will be given. Pendulum exercise will be demonstrated to the patient at first, then they will performed it in the forward-backward direction, side-to-side direction, and circular pattern, for two to three minutes in each direction, it will be applied 5 days per week for 6 weeks
215000256|NCT07104331|DRUG|nab-Sirolimus|nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle.
214393272|NCT03541811|DIAGNOSTIC_TEST|Anthropometrics and body composition assessment|Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.
214502410|NCT03336892|BEHAVIORAL|Mental Health Care Coordination|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
214502411|NCT06013124|OTHER|Work environment, well-being, customer satisfaction|Evaluation hospital work environment, staff well-being features and patients/caregivers satisfaction and perceived quality of care
215000257|NCT07105306|OTHER|Buteyko Breathing Technique Training|Buteyko Breathing Technique (BBT), developed in the 1950s, which focuses on reducing dysfunctional hyperventilation patterns through breath control and extended breath-holding phases called control pauses
215000258|NCT07104747|PROCEDURE|Static Exercise Intervention|Static exercises generally involve maintaining a fixed position without movement-such as standing on one leg or holding a specific posture-emphasizing isometric muscle control and stability.
215000259|NCT07104747|PROCEDURE|(Dynamic Exercises Group|Dynamic exercises were structured across three progressive stages-basic, moderate, and advanced-each increasing in complexity and difficulty. These exercises were performed in various positions, including sitting, standing, and walking.
215000425|NCT07125937|DRUG|38% Silver Diamine Fluoride|A topical ammonia solution containing silver and fluoride ions applied directly to enamel caries lesions. Application will follow the UCSF protocol: lesions will be cleaned, isolated, and treated with SDF for 2 minutes using a microbrush applicator.
214393273|NCT03541811|DIAGNOSTIC_TEST|Biomarkers|"Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C.~All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method)."
214393274|NCT03541811|DIAGNOSTIC_TEST|Clinical examination|Hemophilia joint health score (HJHS) will be assessed. Height will be measured with a stadiometer (SECA 213), weight with a medical scale (Marsden M-420) and leg length according to the Plug-in-Gait protocol with a measuring tape from the Anterior Spina Iliaca Superior to the distal aspect of the Medial Malleolus. Further anthropometrical parameters taken will be knee distance and malleoli distance by using a caliper. Gait relevant passive joint ROM of the knee, hip and ankle will be assessed by means of a handheld goniometer. The flexibility of hamstring muscles will be expressed as Popliteal Angle measured with a goniometer with the subjects supine and the hip in 90° flexion.
214393275|NCT03541811|DIAGNOSTIC_TEST|Habitual physical activity tracking (accelerometer based)|Participants will be instructed to wear an Actigraph wGT3X-BT tri-axial accelerometer permanently over a period of seven consecutive days with an elastic band on right hand sided hip. Data will be process with software ActiLife version 6.13. Cut-offs of at least 10 hours daily wear-time and a minimum of three valid weekdays and one valid weekend day will be applied for data cleaning. Count sampling epoch will be set at one minute. The so called Freedson Adult VM2 Cut-Offs will be applied to categorize physical activity intensities. The so called Freedson VM3 Combination will be applied for the estimation of activity energy expenditure.
214393276|NCT01238783|DRUG|AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension|Topical ocular dosed 3 times per day for 3 days
214502412|NCT04316494|DRUG|Hydroxychloroquine|"White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900"
214502413|NCT04316494|DRUG|Placebo|"Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate"
214502414|NCT01347294|DRUG|Bleomycin|Intralesional
214502415|NCT01347294|DRUG|Fibrovein|Intralesional
214502416|NCT01347294|DRUG|Bleomycin + Fibrovein|Intralesional
214502417|NCT04638816|DEVICE|Restylane Volyme|Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).
214502418|NCT04638816|DEVICE|Restylane Lyft Lidocaine|Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).
214502419|NCT03852082|PROCEDURE|percutaneous coronary intervention|Patients with coronary heart disease co-morbid depression post percutaneous coronary intervention.
214502420|NCT06394947|OTHER|Fluid administration (any type)|The fluid challenge (FC) (bolus) is defined as the administration of any bolus of fluid (crystalloid or colloid) which is expected to affect pressure/flow/perfusion variables. The FC is expected to be completed within 30 min.
214502421|NCT06230731|OTHER|Oxygen saturation|Measure oxygen levels in 5 proximal colon mucosa locations.
214502422|NCT00824642|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
215000260|NCT07103005|PROCEDURE|Intensive behavioral change with physical activity and diet. A single-group pre-post design|"The group of 43 participants recieved a lifestyle intervention, and was measurred before and after the intervention.~The intervention was intensive physical activity with focus om muscle strength and dietary advice from dietition, with focus on more fruits, vegetables, proteins and fiber.~Body composition was measurred using Bioelectrical impedance, DEXA and WRIC. Health related quality of life was measured using the questionnaire RAND-36, and diet was registered with the questionnaire DIGIKOST."
215000261|NCT07105033|BEHAVIORAL|FACT Session|Participants will participate in 4 weekly, 35-45 minute sessions
215000262|NCT07105033|BEHAVIORAL|Enhanced Usual Care and Assessments|Participants will complete a symptoms questionnaire
214393277|NCT01238783|DRUG|AL-15469A 0.5%|Topical ocular dosed 3 times per day for 3 days
214393278|NCT01238783|DRUG|AL-6515 0.3%|Topical ocular dosed 3 times per day for 3 days
214393279|NCT01238783|DRUG|Vehicle|Topical ocular dosed 3 times per day for 3 days
214393280|NCT01924403|PROCEDURE|Staple Closure|
214393281|NCT01924403|PROCEDURE|Vertical Mattress Closure|
214393282|NCT01924403|PROCEDURE|Running Subcuticular Closure|
214502423|NCT00824642|DEVICE|placebo|placebo TENS applied prior to exercise
214502424|NCT01964781|DRUG|Tranexamic Acid|Topical administration - does it reduce surgical bleeding?
214502425|NCT01964781|DRUG|Bupivacaine|Topical Bupivacaine- does it reduce surgical pain?
214502426|NCT01964781|DRUG|Adrenaline|Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
214502427|NCT01964781|DRUG|tranexamic acid plus saline|
214502428|NCT01964781|DRUG|saline|
214502429|NCT06218745|OTHER|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
214502430|NCT04366024|OTHER|other|clinical diagnosis
214502431|NCT06090513|COMBINATION_PRODUCT|Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation|TSO500; detect single nucleotide variants (SNV), INDELs, copy number alterations (CNAs), microsatellite instability (MSI), and tumor mutation burden (TMB) in eligible patients; ELIA software to interface clinic EMR to lab; Consultations and molecular tumor boards by molecular genetic pathologist (MGP)
214502432|NCT06090513|DIAGNOSTIC_TEST|limited genetic testing or no testing|Minimal genetic testing for eligible patients or treatment without testing
214502433|NCT05313412|DEVICE|Lens A (comfilcon A lens)|6 hours
214502434|NCT05313412|DEVICE|Lens B (lehfilcon A lens)|6 hours
214502435|NCT00109031|DRUG|palifermin|Administered as one daily intravenous bolus.
214502436|NCT00109031|RADIATION|Total Body Irradiation|To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
214502437|NCT00109031|DRUG|Cyclophosphamide|Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
215000263|NCT07105345|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Participants will receive 12 weekly 90-minute individual sessions of Cognitive Processing Therapy (CPT) following the Resick manual. The intervention includes cognitive restructuring, trauma-related belief processing, and structured behavioral assignments. Sessions are delivered by trained therapists.
214393283|NCT03506217|DEVICE|Vigileo Flo-trac device|A Vigileo Flotrac pulse counter invasive arterial cardiac output meter was used for cardiac output measurement. Heart rate, blood pressure, cardiac output, stroke volume variance (SVV), systemic vascular resistance (SVR) values were recorded.
214393284|NCT00608361|DRUG|Dasatinib|Given PO
215000264|NCT07105345|OTHER|Treatment as Usual (TAU)|Participants will receive routine outpatient psychiatric care as determined by clinicians. This may include medication, general supportive therapy, or psychoeducation, but will not include structured CPT sessions.
215000265|NCT07105007|BEHAVIORAL|Exercise Intervention|After completing the education sessions, the participants will start 8 weeks of a hybrid exercise intervention, three days/week, being one supervised session in the exercise center and two unsupervised sessions at home. Sessions at the exercise center will be supervised by experienced exercise trainers in a 1:1 ratio. The intervention is designed to meet the recommendation of at least 150 minutes of MVPA per week and the recommendations on exercise intensity and volume from the ACSM. Each exercise session will be composed of aerobic and resistance exercises at moderate intensity (i.e., combined exercise training), which is the best exercise model for the needs of PLWH. Additionally, poor muscle strength has been associated with lower VO2peak among PLWH, suggesting that appropriate muscle-strengthening exercises can improve the aerobic performance of these patients. The aerobic exercise will be performed in a continuous manner and prescribed using the heart rate reserve.
214393285|NCT00608361|OTHER|Pharmacological Study|Correlative studies
214393286|NCT01884987|DRUG|GM1|This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
214393287|NCT00581113|RADIATION|Radiotherapy|Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
214393288|NCT05291013|PROCEDURE|Gastric byspass|Test will be before and 9-12 month after gastric bypass
214393289|NCT05466474|BIOLOGICAL|Tislelizumab Injection|Efficacy of tislelizumab or tislelizumab combined with dacarbazine in the treatment of advanced malignant melanoma.
214393290|NCT03428568|OTHER|Herbal Melanin|Herbal melanin extracted from Nigella sativa seeds
214393291|NCT03428568|DRUG|Nexium|omeprazole
214393292|NCT03428568|DRUG|Amoxil|Antibiotic
214393293|NCT03428568|DRUG|Clarithromycin|Antibiotic
214393294|NCT03428282|PROCEDURE|VR Box|Distraction will be made during the injection of the drug using this method.
214393295|NCT03428282|PROCEDURE|Tablet Device|Distraction will be made during the injection of the drug using this method
214393296|NCT03428282|DRUG|Anesthesia|Anesthesia will be obtained by injecting the drug into the oral mucosa before performing the dental treatment.
214393297|NCT06306950|DEVICE|Near infrared spectroscopy neuromonitor to prevent cerebral desaturation|patients were assigned into active treatment (intervention) or usual care (control) groups with cerebral oximetry monitoring using NIRS bilaterally (Root; Prime Medical Corporation, MASIMO, USA) \[17\]. After cleansing the adjacent skin area with alcohol, an adhesive optode pad was placed over each frontal to temporal area. Resting baseline rSO2 values were obtained after waiting at least 1 minute after the placement of the sensors.
214393298|NCT02810119|DRUG|LO2A|
214393299|NCT02810119|DRUG|Placebo|
214393300|NCT01625936|DRUG|CRLX101 (Cerulean)|CRLX101 is an innovative tumor-targeting nanopharmaceutical.
214393301|NCT01625936|DRUG|Bevacizumab|
214393302|NCT03139838|BEHAVIORAL|EHR-Based Intervention A|Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
214502438|NCT00109031|DRUG|Etoposide|Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
214393303|NCT03139838|BEHAVIORAL|EHR-Based Intervention B|Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
214393304|NCT02864511|PROCEDURE|Nefertiti lift|
214393305|NCT06365606|DEVICE|iStatis Syphilis Ab Test|Capillary (fingerstick) blood, venous whole blood and plasma samples prospectively collected from the participants will be tested on the iStatis Syphilis Ab Test.
214393306|NCT02775747|BIOLOGICAL|platelet rich plasma gel|Platelet rich plasma is prepared from fresh whole blood which is collected from a peripheral vein stored in acid citrare dextrose solution A (ACD-A)anticoagulant and processed to increase platelets by separating various components of blood
214393307|NCT02775747|BIOLOGICAL|saline|64 controlled women with recurrent cesarean section and fullfit to all inclusion and exclusion craiteria will reseve saline injection at time of wound closure
214393308|NCT01818141|DRUG|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
214502439|NCT00109031|DRUG|Placebo|Administered as one daily intravenous bolus.
214502440|NCT02426229|DRUG|dabigatran etexilate|dabigatran etexilate 75mg orally twice a day for 6 months
214502441|NCT05966012|DRUG|Tranexamic acid|Recent data suggests that antifibrinolytics like tranexamic acid (TXA) might be able to lessen the inflammation of the nervous system caused by surgery and CPB through the inhibition of plasmin production, thereby stabilising the blood brain barrier.
214502442|NCT01822756|DRUG|ruxolitinib|
214502443|NCT01822756|DRUG|gemcitabine|Other names: Gemzar®
214393309|NCT01818141|DRUG|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
214502444|NCT01822756|DRUG|nab-paclitaxel|Other names: Abraxane®
214502445|NCT01822756|DRUG|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
214393310|NCT04814017|PROCEDURE|Radial Shock-Wave Therapy|Radial shock-wave therapy was applied in 1.0-4.0 bar intensity, 10-15 hz frequency interval. 300-700 pulse for a trigger point, 1500-3000 pulse for a muscle. Intensity, frequency and pulse increased every session regularly beginning from minimal taking patients tolerance into consideration. Trigger points in the upper, middle and lower trapezius, supraspinatus, infraspinatus and levator scapula muscles were treated. Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
214393311|NCT04814017|PROCEDURE|Control|Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
214393312|NCT00619476|DRUG|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
214393313|NCT00619476|DRUG|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
214393314|NCT00619476|DRUG|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
214393315|NCT00619476|DRUG|Placebo|placebo
214393316|NCT04329143|PROCEDURE|open completion cholecystectomy|open excision of cystic duct remnant
214393317|NCT04329143|PROCEDURE|lap completion cholecystectomy|lap excision of cystic duct stone
214393318|NCT01062906|DRUG|Lidocaine|1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
214393319|NCT01062906|DRUG|Fentanyl|Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
214393320|NCT03753321|DIETARY_SUPPLEMENT|Whey protein|Whey protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
214393321|NCT03753321|DIETARY_SUPPLEMENT|Soy protein|Soy protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
214502446|NCT06028308|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone mounted with earphones) during movement
215000266|NCT07105007|BEHAVIORAL|Education sessions|At the beginning of the program, the participants will receive two face-to-face group education sessions, consisting of 90 minutes of exercise and cardiovascular health education. The material for the education sessions will be developed by the study team (a diverse team including exercise scientists, nurse, cardiologist, and infectious disease specialist). The focus of the sessions will be to increase the participants' knowledge and self-efficacy. The education sessions will occur prior to the start of the exercise intervention, to teach the participants how to safely perform the home-based exercises. An interventionist, who will possess a degree in a health profession, will present the content following the completion of standard training using material and guidance developed for this purpose. The content of the sessions will include a self-assessment on exercise and physical activity, and incorporate the ACSM recommendations for quantity and quality of exercise
214393322|NCT03753321|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Isoenergetic placebo (maltodextrin) for 10 days (7 days pre-loading and 3 days during trials 1 and 2
214393323|NCT04444375|DIAGNOSTIC_TEST|balance test|balance test
214393324|NCT03444220|BIOLOGICAL|Anaerobically Cultivated Human Intestinal Microbiota|30ml ACHIM will be administrated at week 0 and 2 with 14 days apart
214393325|NCT03444220|BIOLOGICAL|Anaerobically Cultivated medium|30ml medium will be administrated at week 0 and 2 with 14 days apart
214393326|NCT06301659|BEHAVIORAL|routine rehabilitation therapy|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
214393327|NCT06301659|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
214393328|NCT01062815|DIETARY_SUPPLEMENT|Parenteral Nutrition|Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
214393329|NCT01820468|BEHAVIORAL|Adapted critical time intervention team|
214688111|NCT05673811|DRUG|Gemcitabine|Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
214393330|NCT02711176|DRUG|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
214393331|NCT02711176|DRUG|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
214393332|NCT02711176|DRUG|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
214393333|NCT02711176|DRUG|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
214393334|NCT02711176|DRUG|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
214393335|NCT02711176|DRUG|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
214393336|NCT01783093|OTHER|Data Collection|Collection of data from existing medical records
214502447|NCT03177941|OTHER|Eviderma Smart Phone Teledermatology Application (Eviderma)|First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
214393337|NCT01554982|DRUG|ferric citrate|Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
214393338|NCT01564082|DEVICE|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
214393339|NCT04084743|OTHER|Virtual reality intervention|Virtual reality intervention includes: Maze game software
214393340|NCT04084743|OTHER|Dual task intervention|The intervention combined both motor and cognitive training which includes, walking 10 meter (1) Free walking (2) Walking carrying an emptying tray (3) Walking carrying a tray with 4 empty glasses (4) Digit calculations (Counting forward and backward, addition, subtraction, multiplication and division) during walking.
214393341|NCT04084743|OTHER|Conventional physiotherapy|"1. Gait training in parallel bar~2. Balance activities which includes, a. Forward direction activity b. Backward direction activity c. Sideways direction activity"
214393342|NCT00678444|OTHER|Educational video|Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
214393343|NCT02127905|BIOLOGICAL|CD34+ selected cells|Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
214393344|NCT02986737|DEVICE|ACURATE neo™ and ACURATE TA™ LP|ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
214502448|NCT04738656|DIETARY_SUPPLEMENT|Diet plan|Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
214502449|NCT03972046|DRUG|Talimogene laherparepvec (T-Vec)|Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
214502450|NCT03972046|DRUG|Dabrafenib (BRAF Inhibitor)|Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
215000267|NCT07105007|BEHAVIORAL|Behavioral coaching|At the end of their weekly in-person exercise sessions, the participants will receive a 20 minute coaching session to address their attitudes, self-efficacy, and behavioral self-management skills towards exercise. During the sessions, the trainers will be taught to use motivational interviewing, an evidence-based communication strategy that identifies and enhances patients' own motivations and reasons for health behavior change. Motivational interviewing is an approach to assessment and intervention based on the Stages of Motivational Readiness for Change model, which has been shown to increase physical activity in people with chronic health conditions. According to the Stages of Motivational Readiness for Change Model, individuals move through a series of stages (i.e., Precontemplation, Contemplation, Preparation, Action, and Maintenance) as they adopt and maintain a new habit. The coaching session will also address barriers from the home-based sessions, discuss HIV-specific barriers
214393345|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #1 PO for at least 7 days
214393346|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #2 PO for at least 7 days
214502451|NCT03972046|DRUG|Trametinib (MEK Inhibitor)|Trametinib (MEK Inhibitor) 2 mg by mouth once a day
214502452|NCT01006538|DEVICE|Epimacular Brachytherapy|Strontium-90. The device delivers 24 Gray of beta radiation to the choroidal neovascular membrane (CNV) lesion. Each device is calibrated for a set duration.
214502453|NCT01006538|DRUG|Ranibizumab|intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
214502454|NCT06452069|OTHER|IMMUNO19|"280 participants will be divided into 2 groups. There will be 140 participants in the groups.~The 1st group will receive IMMUNO19 10 mL one time, The 2nd group will receive Placebo 10 mL for one time."
214393347|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #3 PO for at least 7 days
214502455|NCT03777566|DIAGNOSTIC_TEST|sonohysterography|sonohysterography with measuring the uterine cavity volume
214502456|NCT04070963|OTHER|HbA1C|To take additional blood test of HbA1C once patient consented to the study
214502457|NCT03492021|OTHER|Diet Intervention_AP-CPT|Adequate Protein\_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
214502458|NCT03492021|OTHER|Diet Intervention_PP-PPT|Optimal Protein\_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
214502459|NCT00562614|DRUG|SLx-2101|
214502460|NCT01203943|DRUG|CC-930|CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
214502461|NCT01203943|OTHER|Placebo|Placebo
214393348|NCT04218760|DRUG|Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
214393349|NCT04218760|OTHER|Blood sample|3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
214502462|NCT01203943|DRUG|CC-930|CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
214502463|NCT01203943|DRUG|CC-930|C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
214502464|NCT02139813|PROCEDURE|Laparoscopic Mini-gastric bypass|"The laparoscopic Omega Loop Bypass will consist of:~* a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His~* a narrow gastric tube will be calibrated to be approximately 1.5 cm wide~* an Omega loop of 200 cm~* a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler"
214688112|NCT05673811|GENETIC|VCN-01|VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.
214393350|NCT03059693|DRUG|HAT1 topical cream|
214393351|NCT03059693|DRUG|Vehicle cream|
214393352|NCT04170660|DIAGNOSTIC_TEST|Diagnostic test|During a vascular check-up usually prescribed, an additional blood sample is taken to allow the determination of the sFlt1/PlGf ratio.
214393353|NCT03673371|OTHER|Questionnaire|This is a questionnaire developed by DoD and VA researchers specifically for this study.
214393354|NCT05398354|BEHAVIORAL|Active retirement|"During the intervention, the sensorimotor training program will have a progressive increase in load, the exercises will be divided into 3 levels of intensity: easy (without external load, during the first 8 weeks), intermediate (application of external load: elastic bands, shin guards and free weights, from the 9th to the 16th week) and advanced (increased external load compared to the previous level, from the 17th to the 24th week).~During the sessions we will still assess the intensity through the subjective perception of effort (RPE) scale. In addition, adherence and control of the level of control through the Physical Activity Enjoyment (PACES) survey applied to participants."
214393355|NCT00027690|DRUG|Gefitinib|Given orally
214393356|NCT00027690|OTHER|Laboratory Biomarker Analysis|Correlative studies
214393357|NCT03242603|BIOLOGICAL|Anti-GD2 in combination with NK cells|Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
214502465|NCT02139813|PROCEDURE|Procedure of reference in bariatric surgery|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects"
214502466|NCT04547764|DRUG|triple antibiotic paste (TAP)|root canal treatment of pulpally involved teeth.
214502467|NCT04547764|DRUG|Vitapex (calcium hydroxide/iodoform paste)|root canal treatment of pulpally involved teeth.
214502468|NCT03110536|DIAGNOSTIC_TEST|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.~The questionnaire also contains clinical cases that require triage coding."
214502469|NCT03110536|OTHER|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
214502470|NCT04897633|DEVICE|transcranial electric stimulation|Simon's task assessment when under tDCS
214502471|NCT02233998|OTHER|Mouth Rinse 1|
214502472|NCT02233998|OTHER|Mouth Rinse 2|
214502473|NCT02233998|OTHER|Mouth Rinse 3|
214502474|NCT01328496|DRUG|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
214502475|NCT06282354|OTHER|Type of post-operative appointment|remote post-operative appointment for small or medium urooncology procedures
214502476|NCT03914885|GENETIC|ATLCAR.CD30|Administered at a dose of 2 x 10\^8 cells/m2
214393358|NCT06139484|DEVICE|Transcranial Magnetic Stimulation|The stimulations were performed by Magstim RAPID.
215000268|NCT07105007|BEHAVIORAL|Mobile health support|At the beginning of the program the participants will receive a fitness activity tracker (e.g., Fitbit or similar) to help in achieving their PA goals. Contemporary activity trackers provide reliable information on heart rate, steps count, and amount of PA performed, that will help the participants to monitor the intensity and amount during the home-base sessions. Heart rate monitoring will also be used to assess compliance with the home-based exercise prescription. Trackers also include gamification, awarding badges and trophies when goals are attained, that is demonstrated to be motivating.
214502477|NCT03914885|DRUG|Bendamustine|Administered as a dose of 70mg/m2/day over 3 consecutive days; maybe dose reduced per treating physician discretion based on prior toxicities and the patient's clinical status
214502478|NCT03914885|DRUG|Fludarabine|Administered at a dose of 30mg/m2/day over 3 consecutive days; given concomitantly with bendamustine
215094373|NCT02445573|OTHER|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
214502479|NCT02245529|DRUG|Tamsulosin|
214502480|NCT00297349|DRUG|Topiramate|Individualization of the treatment should begin from 25 mg for 1 week.
214502481|NCT03243006|DRUG|Paracetamol|2 tablets of 500mg of paracetamol
214502482|NCT03243006|DRUG|Tramadol/Paracetamol combination|2 tablets of tramadol/paracetamol combination (32.5mg/325mg)
214502483|NCT03243006|DRUG|Placebo Oral Tablet|2 tablets of placebo
214502484|NCT04318483|OTHER|survey|parents' telephone interview to collect medical history
214502485|NCT06002087|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The current researchers adapted the Unified Protocol (UP) treatment and used the adapted version in this study. UP outlines two complimentary modules for goal setting and psychoeducation followed by five core treatment modules: mindful emotion awareness, cognitive flexibility, countering emotional behaviors, awareness and tolerance of physical sensations, and emotion exposures, and an optional relapse prevention module to help people maintain their gains after treatment.
214688113|NCT05281523|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) was administered using a pre-filled syringe.
214688114|NCT05281523|DRUG|Placebo|Placebo was administered as normal saline using a pre-filled syringe.
215000269|NCT07103161|DEVICE|Uresta bladder support device|The Uresta bladder support device is an intravaginal device indicated for adult women over 18 years of age who experience stress urinary incontinence, including urine leakage during exercise and non-exercise activities such as coughing and laughing. The device is FDA-cleared and licensed by Health Canada. Participants receive the entire kit that includes the three most common sizes which fit 90% of women. Two additional sizes are available in the lab if needed. Participants will be instructed to self-insert the Uresta prior to running, following the manufacturer instructions with researcher guidance as needed. The device aims to provide mechanical support to the urethra and bladder neck to prevent urine leakage during activities that provoke leakage.
214393359|NCT03749382|OTHER|AprilAge- facial morphing appearance based intervention for smoking|"Appearance-based intervention: The intervention is a software that ages an individual's face with and without the effects of smoking. Participants have their photo taken on a laptop webcam, they are then asked to report their age and ethnicity in order to calibrate the software, the participants picture is then matched to a stock image. The participants will see two images on the screen, on the left is there face aged without the effects of smoking and one the right aged with the effects of smoking. Participants will be led through a series of morphing sequences (1-5). In-between each of the morphing sequences (Morph1 to Morph5) the participant will be asked to comment on the differences they can see between the two images.~General stop smoking intervention: The General stop smoking intervention comes in the form of a NHS stop smoking information leaflet. The participants will be given the leaflet on a laptop screen and asked to read through the whole document."
214393360|NCT02011958|DRUG|Liposomal Amphotericin B|"40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)"
214393361|NCT02011958|DRUG|Miltefosine|"Orally taken every day during 28 days~* 1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)"
214393362|NCT02358590|BEHAVIORAL|HAPA menu-based mini-video|The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis
214393363|NCT02358590|BEHAVIORAL|Standard care|The treating physician will advice participants to take vitamin D
214393364|NCT03715374|PROCEDURE|Periodontal Surgery with PRF+ABB|Patients will be treated by periodontal surgical flaps with the addition of PRF+ Anorganic Bovine Bone filling material
214393365|NCT03715374|PROCEDURE|Periodontal Surgery with Collagen Membrane +ABB|Patients will be treated by periodontal surgical flaps with the addition of Collagen Membrane + Anorganic Bovine Bone filling material
215000270|NCT07103161|DEVICE|Sportex regular tampon|Participants will use a regular absorbency Sportex tampon as a conservative intravaginal support to potentially reduce stress urinary incontinence (SUI) symptoms during running. Participants will be instructed to insert the tampon prior to running into the mid-to-upper vaginal canal while standing or sitting.
215094374|NCT04274803|DRUG|Intralipid, 20% Intravenous Emulsion|intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
214393366|NCT01801384|BEHAVIORAL|Voucher-based incentives|
214393367|NCT06121518|DRUG|D064 and D702, QD|Experimental Group Subjects assigned to this group are treated with D064, D702
214393368|NCT06121518|DRUG|D064 and Placebo of D702, QD|Comparator Group Subjects assigned to this group are treated with D064, placebo of D702
214393369|NCT06121518|DRUG|Placebo of D064 and D702, QD|Comparator Group Subjects assigned to this group are treated with D702, placebo of D064
214393370|NCT03079115|DRUG|High-dose Atorvastatin|high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
214393371|NCT03079115|DRUG|Conventional-dose Atorvastatin|conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
214393372|NCT02626403|DEVICE|Anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
214393373|NCT02626403|DEVICE|Sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
214393374|NCT05475938|OTHER|Painting therapy and psychoanalysis|Pathologically confirmed children with malignant bone tumors, painting therapists to explain the requirements and purpose of painting. After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
214393375|NCT03204695|DEVICE|Percutaneous LAA Closure|LAA Closure with the WaveCrest LAA Occlusion System (study device)
215000271|NCT05765500|DRUG|Relugolix|Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
214393376|NCT03204695|DRUG|Anticoagulation or Clopidogrel|Subjects either continue on anticoagulation or receive clopidogrel
215094375|NCT04274803|DRUG|Conventional therapy of antiphospholipis syndrome|the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
215094376|NCT06487728|DIAGNOSTIC_TEST|Urinary titin|Urinary titin and skeletal muscle index as predictor of muscle wasting in critically ill patient
214393377|NCT03800966|OTHER|Leaflet|Leaflets for both groups will be printed in colour. Leaflet in each group contains 8 pictures and 8 statement, whose sequences will be scrambled. Primary school students need to do the matching, to ensure they read the statements.
214502486|NCT01708278|DRUG|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
215000272|NCT05765500|DRUG|Leuprolide|Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
215000273|NCT07105826|OTHER|Prebiotic Soda 1|A single dose of 12 ounces of Olipop will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
215094377|NCT03797092|BIOLOGICAL|Allogeneic adipose-derived stromal cells (CSCC_ASC)|Active group
215094378|NCT03797092|OTHER|Control group|No treatment
214393378|NCT04019600|OTHER|Echocardiography|Demographic data and health risk factors will be collected on day of screening, together with the above tests. Right heart catheterization will be separately arranged in patients with a high echocardiographic probability of PAH. For those with a low-intermediate echocardiographic probability, screening will be repeated within 1 year to ensure true negativity of the original scan.
214393379|NCT03241043|DRUG|Treatment 2 weeks Envarsus followed by 2 weeks Advagraf|
214393380|NCT03241043|DRUG|Treatment 2 weeks Advagraf followed by 2 weeks Envarsus|
214393381|NCT04834362|DRUG|Analog Insulin|"For a patient who is known to have diabetes but were not getting insulin previously (or previous insulin dosage is not known), insulin therapy will be started at a total daily dose of 0.3-0.4 units/kg/day for an admission BG between 10-15 mmol/L or 0.5-0.6 units/kg/day for a BG \>15 mmol/L. In previously insulin treated patients, ongoing total daily dose of insulin will be started. If there is history of poor glycemic control with ongoing insulin dose, then 10-20% increase of daily dose of insulin will be considered.~For a patient who is not known to have diabetes, insulin therapy will be started if admission BG is \>10 mmol/L in two or more occasions. A total daily dose of 0.3-0.4 units/kg/day will be started if admission BG is 10-15 mmol/L and 0.5-0.6 units/kg/day for a BG \>15 mmol/L."
214393382|NCT04834362|DRUG|Human insulin|Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm.
214393383|NCT03990714|PROCEDURE|Right hemicolectomy|It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal
214393384|NCT01868789|RADIATION|Weightbearing CT|
214393385|NCT06458660|BEHAVIORAL|LPP+: Mindfulness Meditation Delivered|During the 6-week intervention period, participants will receive reminder SMS text messages at a time selected by the participant at 48 and 24-hrs before each scheduled study visit. Within 24 hours after every session, participants will receive an SMS text reminder to complete a session satisfaction survey. If the satisfaction surveys are not completed within 48 hours after each session, participants will receive an additional SMS text message once per day for three consecutive days after each planned study visit. Twenty-four hours before each scheduled study visit after study visit number 1, participants will an SMS text requiring a one-character response (1= yes, 2=no), asking if participants practiced any mindfulness meditation techniques since the last session. Participants who have not interacted with the app during the previous week will receive an accountability call to assess barriers to participation.
214393386|NCT06458660|BEHAVIORAL|LP|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
214393387|NCT05536674|BEHAVIORAL|SMS reminder for the HPV vaccination|A BI-informed SMS reminder to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination and share information about the vaccine.
214393388|NCT03788148|DEVICE|Stent, red blood cell transfusion|BMS (Bare Metal Stent) and DES (drug-eluting stent) transplants with periprocedural red blood cell transfusion
214393389|NCT01349829|BIOLOGICAL|HAVpur Junior|"≥12 International Units (IU) hepatitis A antigen coupled to virosomes, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
214393390|NCT01349829|BIOLOGICAL|Havrix 720 Junior|"≥720 ELISA Units (EU) hepatitis A antigen adsorbed to aluminium hydroxide, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
214393391|NCT01859650|OTHER|MR and CT imaging|
214393392|NCT00104182|DRUG|insulin detemir|
214393393|NCT00104182|DRUG|insulin NPH|
214393394|NCT03095599|BIOLOGICAL|IVACFLU-S|"IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~* NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~* NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~* NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA"
214393395|NCT03095599|OTHER|Placebo|Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
214393396|NCT00299689|DRUG|Denileukin diftitox|12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.
214502487|NCT01708278|OTHER|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
214502488|NCT01122914|DRUG|Anakinra|
214502489|NCT03011047|PROCEDURE|endoscopic trans-antral approach|new surgical approach to repair the orbital floor fractures through the maxillary sinus
214688115|NCT05513391|BIOLOGICAL|Recombinant influenza vaccine (RIV4)|Pharmaceutical form: solution for injection Route of administration: intramuscular
215000274|NCT07105826|OTHER|Prebiotic Soda 2|A single dose of 12 ounces of Poppi will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
215000275|NCT07105826|OTHER|Diet Soda|A single dose of 12 ounces of Diet Coke will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
215000276|NCT07105826|OTHER|Regular Coke|A single dose of 12 ounces of Regular Coke will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
215000277|NCT06911541|DEVICE|Wireless respiratory rate monitor|This sensor is being fasten on the chest of the patients and measures respiratory rate with the help of an accelerometer. Data is being sent wireless to a backend monitor.
215000278|NCT07106138|DEVICE|Conventional syringe injection|Manual injection using a conventional dental syringe and needle to deliver local anesthetic.
215000279|NCT07106138|DEVICE|Star Pen|A computer-controlled local anesthetic delivery system designed to provide slow, controlled injection with improved comfort.
214393397|NCT05830916|DIAGNOSTIC_TEST|Antiphospholipid antibodies|Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies with high affinity for phospholipids such lupus anticoagulant (LA), β2glycoprotien І (β2GPІ), and anticardiolipin (anti-CL). They interfere with physiological mechanisms of coagulation and fibrinolysis, leading the haemostatic balance towards coagulation. Moreover, it seems to affect the physiological function of various cells such as platelets and endothelial cells
214393398|NCT01379235|OTHER|Pilatis exercise|12 weeks of pilatis exercise 3 times a week.
214393399|NCT02334319|DRUG|Ganetespib|Given IV
214393400|NCT02334319|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214393401|NCT02334319|OTHER|Laboratory Biomarker Analysis|Correlative studies
214393402|NCT05733923|PROCEDURE|Traditional Escavation|"Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling.~\- Group 6: 15 carious teeth will be excavated chemo-mechanically using Selecti-solve."
214393403|NCT05733923|PROCEDURE|Excavation with Sodium Hypochlorite Gel 2.5%.|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using Sodium Hypochlorite Gel 2.5%.
214393404|NCT05733923|PROCEDURE|Excavation with Papacarie Duo|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Papacarie Duo.
214393405|NCT05733923|PROCEDURE|Excavation with Brix3000|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Brix3000.
214393406|NCT05733923|PROCEDURE|Excavation with Selecti-solve|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Selecti-solve.
214393407|NCT00931203|DRUG|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
214393408|NCT01096732|DRUG|GDC-0449|Gelatine capsules of 150mg.Taken O.D. for 14 days.
215000280|NCT07106138|DEVICE|Comfort-In|A needle-free injection system that delivers anesthetic through high-pressure jet injection, reducing injection-related discomfort.
215000281|NCT07106138|DEVICE|Vibraject|A vibrating attachment for dental syringes that provides vibrotactile stimulation during injection to distract from pain perception
215000282|NCT05363865|BEHAVIORAL|Virtual Community Intervention|Modules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems
214393409|NCT00807222|DRUG|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
214393410|NCT04616274|DRUG|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
214393411|NCT00742885|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
214502490|NCT03011047|PROCEDURE|trans-orbital surgical approach|through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
214502491|NCT00853593|DEVICE|Pacing Lead|implant and follow-up of study device
214502492|NCT02193932|OTHER|EEG Triggered fMRI using Micro Maglink|
214502493|NCT00191542|DRUG|Atomoxetine|
215000283|NCT05363865|BEHAVIORAL|Standard of Care|health websites and county information provided to participants
215000284|NCT07106775|BEHAVIORAL|Family Intervention Program (PIF)|Home psychoeducational intervention in an individual format driven by a practitioner where caregivers learn parenting competences and children learn autonomy and emotional regulation skills
215094379|NCT03230292|DRUG|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
214502494|NCT00191542|DRUG|Placebo|
214502495|NCT06195345|DIAGNOSTIC_TEST|MR Imaging|MR imaging pertaining to the patient and project (ICHOR 1)
215000285|NCT07106385|DEVICE|rtms|Participants will undergo a treatment protocol involving six sessions of rTMS using the EXOMIND™ device, administered once or twice a week. Each session will deliver 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total duration of 24 minutes and 30 seconds. The target site would be left dorsolateral prefrontal cortex (DLPFC), determined by the most common used 5-cm rule. The procedure would be conducted in our research centre with medical staff supported.
215000286|NCT07104903|OTHER|Data collection from medical records|Data are collected from the information system and medical records, including demographic characteristics, presence of surgical site infection, comorbidities, data regarding neoadjuvant oncological therapy, preoperative laboratory findings, type and duration of surgical intervention, perioperative complications, and SENIC and NNIS scores are calculated.
215000287|NCT06630091|DRUG|Golidocitinib|150 mg once per day by PO
215000288|NCT06630091|DRUG|Cyclophosphamide|750 mg/m2 by IV
215000289|NCT06630091|DRUG|Doxorubicin|50 mg/m2 by IV
215094380|NCT04024904|DEVICE|OncomfortTM device|The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
214502496|NCT00953355|DRUG|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
214393412|NCT05071066|OTHER|ADHD+|"The group-based intervention is designed to reduce participants' ADHD and related symptoms. The content of the treatment will follow an established manual which is developed by an expert group comprised of psychiatrists and clinical psychologists. Core treatment components include internet use/addiction intervention, cognitive training, emotion management, social skills training, occupational training, emotion support/befriending, parenting training, and career guidance.~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months. The post- intervention assessments (3-month \[T1\], and 6-month \[T2\]) will be administered to all participants. During the period of intervention, all participants shall be clean from other forms of interventions to reduce any other possible confounders."
214393413|NCT04781647|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily
214393414|NCT04781647|DRUG|ETV|Participants will receive ETV 0.5 mg tablets orally once daily
214393415|NCT04781647|BIOLOGICAL|Peg-IFNα|Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
214393416|NCT00489723|DRUG|tamsulosin 0.4mg|
214393417|NCT04934774|BIOLOGICAL|CD7 CAR T cells|Non-gene edited anti-CD7 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
214393418|NCT01912820|DIETARY_SUPPLEMENT|green tea extract|Given PO
214393419|NCT01912820|DRUG|quercetin|Given PO
214393420|NCT01912820|OTHER|placebo|Given PO
215000290|NCT06630091|DRUG|Vincristine|1.4 mg/m2 (max: 2 mg) by IV
215094381|NCT03407885|OTHER|Bundled payments for knee and hip replacement|"The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices."
215094382|NCT04191785|DIAGNOSTIC_TEST|plasmatic NGAl and MRI|Determination of plasma NGAL protein during routine blood test Realization of a reno vesical MRI at 48 hours of inclusion
215094383|NCT04467125|DRUG|Eutectic Lidocaine Prilocaine|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
214393421|NCT01912820|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy
214393422|NCT01912820|OTHER|laboratory biomarker analysis|Correlative studies
214393423|NCT04641624|OTHER|ultrasound assessment|soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
214393424|NCT03693820|DRUG|the infiltration group|"* 15-20 ml periportal,~* 50 ml in gallbladder bed,~* The rest (about 150 ml in 70 Kg patient) will be intraperitoneal"
214393425|NCT03693820|DRUG|the control group|the 50 ml prepared for gallbladder bed infiltration will be replaced by saline.
214393426|NCT04535739|RADIATION|prophylactic cranial irradiation|25Gy/2.5Gy/10f were given for PCI patients
214393427|NCT02940769|DEVICE|light glasses|light glasses
214393428|NCT02940769|DEVICE|sham glasses (placebo)|sham light glasses
214393429|NCT01811563|DEVICE|Zimmer|
214393430|NCT01811563|DEVICE|Stryker|
214393431|NCT00050414|DRUG|Trabectedin|Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.
214393432|NCT00050414|DRUG|Dexamethasone|Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
214393433|NCT05299489|OTHER|Direct restoration|Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration, bonding, applying composite and assessment of occlusion.
214393434|NCT05299489|OTHER|Indirect restoration|"Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. Preparation walls were vertical according to the longitudinal axis of the tooth and the occlusal depth 2 mm. The impressions were taken for both jaws and the bite were recorded for the using red wax. The cavity in example were painted with insulating material. Indirect composite resin were applied, finishined and polished.~Cementation:~Tooth surface: The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration: application of silane coupling agent to enhance the formation of resin tags.~Dual cure resin cement was used for final cementation followed by an assessment of occlusion."
214393435|NCT00047710|DRUG|Bevacizumab|Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
214393436|NCT00047710|DRUG|Capecitabine|650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.
214393437|NCT00047710|RADIATION|Radiotherapy|Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
214393438|NCT05221203|BEHAVIORAL|TR-30|Bodyweight training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
214393439|NCT05221203|BEHAVIORAL|TR-45|Bodyweight training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
215000291|NCT06630091|DRUG|Prednisone|100 mg by PO
215000292|NCT05145595|DEVICE|Thermal Sensory Analyzer|Thermal stimuli: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
214393440|NCT04989530|DEVICE|Extracorporeal Shock Wave Therapy|different energy levels of ESWT
214393441|NCT04433793|BEHAVIORAL|Yoga therapy|"One yoga session will last one hour. It consists of physical exercises (asanas), conscious breathing (Pranayama) and deep relaxation (Savasana). The subsequent body exercises are structured from lying to sitting to standing. The following sequence of exercises will be repeated in each yoga unit: 1) Relaxation: conscious breathing, body scan, mindfulness 2) Vein pump 3) Pelvis and back rotation (adapted variation of the nakrasana) 4) Pelvis opening (adapted variation of the supta baddha konasana) 5) Shoulder bridge (setu bandha sarvangasana) 6) Forward folds (Paschimottanasana and variations with Pranayama) 7) Backbend: intense east stretch (Purvottasana) 8) Diagonal static yoga cat (Majariasana 1 and resting pose) 9) Standing exercise 10) Upward Salute(Urdhva Hastasana) 11) Warrior 1 (Virabhadrasana 1) 12) Warrior 3 (Virabhadrasana 3) 13) Tree (Vrkasana variation) 14) Relaxation (Savasana)."
214502497|NCT00953355|DRUG|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
214502498|NCT04171011|DEVICE|Stimulator device|The stimulator device will be used to electrically stimulate the NVB
214502499|NCT04251923|DEVICE|Retro pubic sling|patient after hysterectomy will undergo retropubic sling surgery in the same setting. Retropubic sling will be inserted vaginally in the retropubic area following standard protocol.
214393442|NCT00329719|PROCEDURE|Conventional Surgery|Undergo surgery
214393443|NCT00329719|OTHER|Laboratory Biomarker Analysis|Correlative studies
214393444|NCT00329719|DRUG|Sorafenib Tosylate|Given PO
214393445|NCT00329719|DRUG|Temsirolimus|Given IV
214502500|NCT00540111|DIETARY_SUPPLEMENT|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
214502501|NCT03800212|DRUG|treatment for ampullary adenocarcinoma|all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
214502502|NCT06098482|DEVICE|Mobile Research App (MRA)|The MRA (research tool) is a platform used for the delivery of speech perception material in-clinic outside the sound booth or in the home of the hearing-impaired recipients. The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.
215000293|NCT05145595|DEVICE|Pressure Stimuli|Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
215000294|NCT05145595|DEVICE|Mechanical Stimuli|Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture.
214393446|NCT00832143|BEHAVIORAL|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
214393447|NCT05305937|DEVICE|MRI scan|All patients will be scanned twice during the same MRI session, before and 2 hours after taking glucosamine orally. In addition to the CEST scans with glucosamine, patients will undergo MRI scans with the standard contrast agent of gadolinium. This procedure will be done following the CEST scan
214393448|NCT04800835|DEVICE|Gastric Balloon|implantation of two types of gastric balloons. Spatz3 Adjustable balloon will be implanted for 12 months and 6-month non adjustable balloon will be implanted for 6 months
214393449|NCT05030935|DEVICE|mHealth App|In short, mHA contains three main functions for the user: a) a reminder for switching the patient position, b) training for preventive care habits and c) the possibility for patient evaluation in order to determine the need for the use of support surfaces.
214393450|NCT03218761|DIAGNOSTIC_TEST|NET mRNA level|quantification of mRNA to the Norepinephrine Transporter (NET)
214393451|NCT03218761|DIAGNOSTIC_TEST|Plasma catechols|plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
214393452|NCT03218761|DIAGNOSTIC_TEST|Urine Catechols|urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
214393453|NCT06783621|DRUG|OnabotulinumtoxinA|Intramuscular Injections
214393454|NCT06783621|DEVICE|JUVÉDERM|Injections
214393455|NCT06783621|DEVICE|CoolSculpting Elite System|CoolSculpting Elite Applicator
214502503|NCT06098482|OTHER|SOC/validated delivery of the speech perception test material|This involves the delivery of speech perception test material in the sound booth in a clinic.
214688116|NCT05513391|BIOLOGICAL|Quadrivalent influenza vaccine (IIV4)|Pharmaceutical form: suspension for injection Route of administration: intramuscular
214688117|NCT07051915|DRUG|Avatrombopag|Daily tablets
214688118|NCT07051915|DRUG|Rituximab (Arm B)|I.V.
214688119|NCT07051954|OTHER|Core Stabilization|12-week supervised core stabilization training, 3 sessions per week, 45 minutes per session.
215000295|NCT05145595|BEHAVIORAL|Pain Ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
215000296|NCT05145595|BEHAVIORAL|Thermal pain thresholds|Cold and heat pain thresholds (CPT and HPT, respectively) will be determined \[22; 55\]. Thresholds are determined by continuous ramping of temperature from 32°C baseline temperature until the participant press a button at the first moment he/she feels pain from the stimulus. Cut-off temperatures are 0°C and 50°C, to minimize potential damage to the skin. The baseline temperature to which the thermode returns before each test is 32°C. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
214393456|NCT06783621|OTHER|SkinMedica Products|Skincare Product
214393457|NCT06783621|DRUG|KYBELLA|Injections
214393458|NCT02552680|OTHER|Exercise|Physical Exercise
214393459|NCT02552680|OTHER|Guideline|Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
214393460|NCT02552680|OTHER|Brochure|Manual/brochure containing information about general health
214393461|NCT00008437|DEVICE|high-intensity focused ultrasound ablation|
214393462|NCT05271682|DRUG|FHND6091|FHND6091 capsules
214502504|NCT02138123|PROCEDURE|IOL-shell technique|Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
214502505|NCT02138123|PROCEDURE|Conventional procedure|In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
214502506|NCT04468412|DIAGNOSTIC_TEST|Carotid Artery Reactivity Testing|The carotid artery reactivity (CAR) test assesses macrovascular endothelial function by measuring the carotid artery diameter in response to sympathetic stimulation. Participants are in the supine position with the neck extended for assessment of the carotid artery. Left carotid artery diameter is recorded continuously during baseline (30 seconds) and during immersion of the right hand up to the wrist in icy water (4°C) for 3 minutes. CAR can either represent a dilatory response (normal endothelial function) or a constrictive response (endothelial dysfunction) of the carotid artery.
214502507|NCT04230941|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.
214502508|NCT03104530|OTHER|Brown crabmeat|Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
214502509|NCT05541289|BIOLOGICAL|BBV152|Single Arm; BBV152 (COVAXIN™)
214502510|NCT00600353|DRUG|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
215000297|NCT05145595|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
214393463|NCT02809508|DIETARY_SUPPLEMENT|Oily fish|A selection of oily fish, including salmon, herring and mackerel, provided for dinner and lunch
214393464|NCT02809508|DIETARY_SUPPLEMENT|Poultry|A selection of poultry, mainly chicken, provided for dinner and lunch
214393465|NCT04788290|OTHER|Observational|Rabone D®, Once daily administered per the locally approved product information
214393466|NCT01373710|DRUG|Trastuzumab|One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg
214393467|NCT00440180|DRUG|Anastrozole|1 mg qd for 4 months
214393468|NCT00440180|DRUG|Placebo|Placebo Comparator
214393469|NCT00231270|DEVICE|Cordis Nitinol Stent|
214393470|NCT00231270|DEVICE|PRECISE tapered stent|
214393471|NCT00231270|DEVICE|ANGIOGUARD XP Emboli Capture Guidewire (ECGW)|
214393472|NCT06080230|BEHAVIORAL|Participants in the 8-week program|Psychological resilience program based on positive psychotherapy was applied to nurses
214393473|NCT05303038|COMBINATION_PRODUCT|Cryoablation Combined with Tirelizumab and Bevacizumab|"Cryoablation of 1-2 typical metastatic lesions will be performed on D1 under general anesthesia and ultrasound guidance for two cycles.~200mg Tirelizumab ( IV Q3W) + Bevacizumab 7.5mg/kg ( IV Q3W) will be administered at D14 after cryoablation."
214502511|NCT00600353|DRUG|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
215094384|NCT04467125|DRUG|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.
215094385|NCT01639755|DEVICE|new texture shaped breast implants|breast implant surgery
215094386|NCT00473408|DEVICE|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
215094387|NCT00473408|PROCEDURE|Blood sample|See protocol.
215094388|NCT00473408|PROCEDURE|Tumor sample|See protocol.
215094389|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
214393474|NCT05172830|DEVICE|Ovation Alto™ Abdominal Stent Graft System|Single occurrence permanent implantation of AAA device
214393475|NCT01714596|OTHER|PO versus IV antibiotics Route of administration evaluation|This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
214393476|NCT02106689|DEVICE|Needle free system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
214393477|NCT02106689|DEVICE|Standard needle injection system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
214393478|NCT05774496|OTHER|Estimation of the occurrence of retinochoroiditis in women with congenital toxoplasmosis and previous retinochoroiditis lesions (recurrence) during pregnancy and postpartum.|All fundus examinations completed during pregnancy and postpartum in women with congenital toxoplasmosis and previous retinochoroiditis lesions are going to be checked.
214502512|NCT00600353|DRUG|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
215000298|NCT05145595|BEHAVIORAL|Mechanical temporal summation|A pinprick stimulus with standardised intensity (#6.10 or #6.45 von Frey filament) and a flat contact area of 0.25mm diameter will be used. In this test, participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli. The 10 identical pinprick stimuli are applied with a frequency of 1 s-1 within an area of 1 cm2. Immediately following the single stimulus and series of stimuli, an evaluation of the pain will be collected. The difference in pain ratings evoked with the one stimuli vs. the 10 stimuli is the temporal summation value.
215000299|NCT05145595|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information. CPM testing includes the application of a test stimulus without conditioning (control run) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run). Heat-CPM and pressure-CPM. Heat and pressure CPM will be tested in random order.~The difference between the pain ratings/thresholds of the test stimulus with vs. without the concomitant conditioning stimulus is the CPM magnitude. CPM\<0 (reduction in pain) implies efficient inhibitory pain modulation of spatial filtering."
215000300|NCT05145595|BEHAVIORAL|Offset analgesia efficiency|"Offset analgesia (OA) paradigm assesses endogenous inhibitory pain modulation efficiency of temporal filtering of nociceptive information. The mechanisms underlying OA are distinct from the CPM mechanisms \[41\]. OA is characterized by a disproportionately large reduction in pain perception after a small decrease in temperature during noxious thermal stimulation.~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). The T1 will be noxious heat (44-48°C) delivered to the hand or leg. During the OA paradigm, real time pain intensity ratings will be obtained using the computerized VAS.~The difference between the pain ratings of the 10-20 seconds noxious stimulus in the OA paradigm compared to a control paradigm (30 seconds of T1) is the OA magnitude. OA\<0 (reduction in pain) implies efficient inhibitory pain modulation of temporal filtering."
215000301|NCT05145595|BEHAVIORAL|Cold pain tolerance|Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold (4-12°C) water bath. Tolerance will be defined by the time of hand withdrawal. VAS ratings of cold pain intensity might be obtained periodically, and both pain intensity and pain unpleasantness will be recorded upon hand withdrawal. Limb immersion in the cold water bath will be terminated after 120 s if participants do not withdraw their hand before then.
215000302|NCT02337686|OTHER|Laboratory Biomarker Analysis|Correlative studies
215000303|NCT02337686|BIOLOGICAL|Pembrolizumab|Given IV
215000304|NCT02337686|OTHER|Pharmacological Study|Correlative studies
215000305|NCT02337686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
215000306|NCT06762808|DRUG|Atezolizumab|Given by IV infusion
215000307|NCT06762808|DRUG|Talazoparib|Given by IV infusion
215000308|NCT06082037|DRUG|Belumosudil|Tablet, Oral
214502513|NCT06498414|DRUG|rifampin standard arm|120 doses daily self-administered rifampin at 10mg/kg/day (max 600mg/day)
215000309|NCT06082037|DRUG|Azithromycin|Depends on pharmaceutical presentation, Oral
215000310|NCT06082037|DRUG|Placebo|Tablet, Oral
215000311|NCT06448637|DEVICE|Drug Coated Balloon (DCB)|Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI)
215000312|NCT06448637|DEVICE|Drug Eluting Stent (DES)|Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI)
215000313|NCT07108296|OTHER|cardiopulmonary exercise testing (CPET)|In this study, the cardiopulmonary exercise testing (CPET) system used breath-by-breath continuous analysis for gas exchange and ventilation variables. The protocol included spirometry with an 8-breath data collection method. The cycle ergometer workload ranged from 10 to 40 W/min using a RAMP protocol. The standard CPET protocol comprised a 3-min rest, 3-min warm-up, 8 - 12 min incremental exercise phase, and 3-min each of active and passive recovery.
215000314|NCT07108387|DRUG|Tocilizumab|"Participants will continue Tocilizumab (TCZ) at a lower dose of either 4 mg/kg IV monthly or 162 mg SC every 2 weeks~Participants randomized to the stepped-down treatment arm will receive TCZ on their current route of administration. The route of administration may change if needed during study participation at the discretion of the investigator"
214393479|NCT00781742|DRUG|AZD6765|IV once per dosing day, multiple times during the treatment period
214393480|NCT00781742|DRUG|Placebo|0.9% saline IV once per dosing day multiple times during the treatment period
214393481|NCT02256774|DRUG|BILR 355 BS|
214502514|NCT06498414|DRUG|rifampin double dose|60 doses daily self-administered rifampin at 20 mg/kg (max. 1200 mg/day)
214502515|NCT06498414|DRUG|levofloxacin and rifapentine|30 doses daily self-administered levofloxacin (15 mg/kg, max 750mg/day and rifapentine (10mg/kg, max: 600mg)
214502516|NCT05966155|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
214502517|NCT05966155|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
214502518|NCT05985915|DRUG|Ianalumab (VAY736)|Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use
214502519|NCT05985915|OTHER|Placebo|Placebo 0 mg/2 mL PFS or AI, once monthly between doses of Ianalumab 3 monthly , solution for injection for subcutaneous Use
214502520|NCT04378790|OTHER|Patching|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
214502521|NCT04378790|OTHER|Glasses|Eye Glasses are created and worn by patient to improve vision
214502522|NCT05948813|DRUG|TY-9591|The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
215094390|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
214393482|NCT02256774|DRUG|Combivir®|
214393483|NCT02256774|DRUG|Ritonavir|
214393484|NCT02319343|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
214393485|NCT02319343|DRUG|Isotonic Sodium Chloride|Placebo
214502523|NCT05948813|DRUG|Osimertinib|The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
214502524|NCT05886920|DRUG|D3S-002|Oral
214502525|NCT00870064|PROCEDURE|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
215000315|NCT07108387|DRUG|Discontinue Tocilizumab|"Participants will discontinue Tocilizumab and will have visits at Week 2, Month 1 and 2, and then every 2 months during the TCZ Withdrawal Phase until the Month 18 Visit.~Participants who remain in remission will enter the Follow-Up Phase for an additional 12 months at Month 18 and will continue withdrawal at that time."
215000316|NCT07104643|DRUG|TYK-00540|Take the specified dose (20mg or 30mg) orally twice a day. Take it on an empty stomach in the morning with about 200 mL of warm water.
215000317|NCT07104643|DRUG|Enzalutamide|Take orally, 160mg each time, once a day. Take orally with or without meals.
215000318|NCT07109557|OTHER|Baduanjin|Baduanjin exercise
215000319|NCT07109895|OTHER|Standard Care Only|Standard care includes routine wound debridement, moist wound dressings infection control, glycemic management, vascular assessment, and patient education in line with international DFU management guidelines.
215000320|NCT07109895|OTHER|TENS plus Standard Care|This experimental group will receive the same intervention plus Transcutaneous Electrical Nerve Stimulation (TENS) in burst mode (1-4 Hz at 100 Hz) applied around the wound site for 30 minutes, along with standard care.
215000321|NCT07109895|OTHER|Custom Insole + Standard Care|The experimental group will receive customised polyethene foam insoles with a Poron top layer along with standard care.
215000322|NCT07109895|OTHER|TENS + Custom Insole + Standard Care|Participants in this group will receive a combination of transcutaneous electrical nerve stimulation (TENS), custom-made insole therapy, and standard care for diabetic foot ulcers (DFUs).
215000323|NCT05948761|OTHER|Hypoxia through modified hypoxic generator|Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants.
215000324|NCT05948761|OTHER|Normoxia through hypoxic generator without active elements|Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants, without active elements.
215000325|NCT07111494|DRUG|GLP-1 agonists|GLP-1, any assigned drug
215000326|NCT07111494|OTHER|Nutrition Counseling|Nutrition Counseling in PsA
214393486|NCT05645289|DRUG|Minodronate|The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
214502526|NCT00870064|PROCEDURE|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
215000327|NCT07102836|DRUG|Zinc sulfate|Oral zinc sulfate syrup in a dose providing 5mg elemental zinc daily as adjuvant to phototherapy.
215000328|NCT07102836|DRUG|Probiotic lactobacillus rhamnosus GG|Oral Probiotic Lactobacillus rhamnosus GG drops daily as adjuvant to phototherapy.
215000329|NCT00080626|BIOLOGICAL|pegfilgrastim|6 mg injection on day 1 of each cycle
215000330|NCT00080626|DRUG|docetaxel|100 mg per meter-squared, every 14 days for 4 cycles
215000331|NCT00080626|PROCEDURE|conventional surgery|lumpectomy or mastectomy at end of treatment
215000332|NCT00080626|PROCEDURE|neoadjuvant therapy|treatment prior to definitive breast surgery
215000333|NCT07106879|OTHER|Blood Work|Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.
214393487|NCT05645289|DRUG|Alendronate|The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
214393488|NCT01391143|BIOLOGICAL|MGA271|"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
214393489|NCT03751540|PROCEDURE|ostap|this block is performed under general anesthesia in this patients for postoperative analgesia.
214502527|NCT04605055|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
214502528|NCT04605055|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
214502529|NCT00597636|BEHAVIORAL|Questionaire, blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
214502530|NCT00597636|BEHAVIORAL|Questionaire, Blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
215000334|NCT07103954|OTHER|McKenzie Exercises plus Conventional Physical Therapy|"First of all conventional physical therapy is applied. For this we will use transcutaneous electrical nerve stimulation (TENS) and hot pack, positioned over the neck region, for 15-20 minutes. This will help in improving blood flow and increasing muscle activation.~For McKenzie exercises, the participant will be in a comfortable sitting posture with proper back support. He will be asked to perform the following exercises:~1. Retraction in supine and sitting positions~2. Retraction with patient and therapist overpressure~3. Retraction with extension and rotation~4. Rotation with patient and therapist overpressure~5. Lateral flexion~6. Lateral flexion with patient and therapist overpressure • All these exercises will be done with a hold of one or two seconds and the movement is then repeated for five to six times."
214393490|NCT03751540|PROCEDURE|SIPB plus rectus sheath block|this block is performed under general anesthesia in this patients for postoperative analgesia.
214393491|NCT01054872|BIOLOGICAL|HIV-1 DNA plasmid vaccine|4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
214393492|NCT01054872|BIOLOGICAL|HIV-1 recombinant Ad5 vaccine|1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
214502531|NCT06097091|OTHER|Self-management education|A self-management of the FM handbook will be provided. SME will be delivered via weekly video calls over a 6-week period. The video call lasting for 15 minutes, will consist of reviewing the weekly self-management content (5 min), questioning and answering related to the content of the self-management handbook (5 min), and a debriefing session (5 min).
214502532|NCT06097091|BEHAVIORAL|pain neuroscience education|"Participants in the experimental group will receive a 6-week PNE program. The PNE program that is designed to explain pain to the participants will be implemented via 6 individual face-to-face sessions, each lasting for 45 minutes over a 6-week period. Printed take-home materials will be provided to the participants to enhance learning. The goal of PNE is to increase participants' knowledge about pain to help them reconceptualize their beliefs about pain and decrease perceived threats of pain. The content will be composed according to the second edition of the book, Explain Pain by Butler and Mosley (2013) as well as etiologies of fibromyalgia. Accordingly, the PI has developed the preliminary PNE content."
214502533|NCT06151964|DRUG|AZD9550|Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks
214502534|NCT06151964|DRUG|Placebo|Matching administration volumes for SC injection
214502535|NCT06477653|BIOLOGICAL|dupilumab|Dupilumab is an interleukin-4 receptor alpha antagonist. Dosing for an individual will be determined based on the nature of their residual symptoms and the FDA-approved dosing for that indication.
214502536|NCT06052332|RADIATION|Short course radiotherapy|Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.
214502537|NCT06052332|DRUG|Adjuvant chemotherapy (optional)|The choice of the adjuvant chemotherapy is to the investigator's discretion.
214502538|NCT06052332|PROCEDURE|Total mesorectal excision|"Surgery must be performed according to the principles of total mesorectal excision. A watch \& wait approach is allowed for those subjects who have clinical complete response according to the local assessment."
214502539|NCT06052332|COMBINATION_PRODUCT|Total neoadjuvant therapy|"The choice of the TNT is left to the investigator's discretion.~If RAPIDO:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If RAPIDO light:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If OPRA with induction chemotherapy:~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~If OPRA with consolidation chemotherapy:~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine) followed by~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)"
214502540|NCT00553332|DRUG|selumetinib|Given orally
214502541|NCT00553332|OTHER|laboratory biomarker analysis|Correlative studies
214502542|NCT06363617|OTHER|FLI|Health professionals will use the FLI test in their clinical practice
214502543|NCT04340752|DRUG|Indocyanine Green|ICG is an injectable fluorescent pigment that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision. The ICG will not affect the course of the operative or postoperative period, and will be injected intravenously prior to the actual repair
214502544|NCT06648122|OTHER|laboratory results|evaluation of laboratory results (hemogram results:WBC, RBC, Hematocrit, Monocyte count, Neutrophil count, Lymphocyte count, Platelet count, PDW, MPV, MLR, NLR, NMR, PLR, PMR, PNR, PWR, SII)
214502545|NCT04560946|BEHAVIORAL|Personalized Augmented Cognitive Training (PACT)|Personalized Augmented Cognitive Training (PACT) group. Intervention: Behavioral: The study neuropsychologist will use a portion of the TBI education session to describe available treatment modules and make recommendations for module selection based on results from baseline assessment. After discussion, five 60-minute CogSMART modules will be selected. PACT participants will receive guidance to complete 2 modules per week of the CogSMART app. PACT participants will also receive guidance to complete BrainHQ exercises of their choice for 30 minutes a day, 5 days per week, for a total training time of 15 hours.
215000335|NCT07103954|OTHER|Mulligan Mobilization with Conventional Physical Therapy|"First of all conventional physical therapy is applied. For this we will use transcutaneous electrical nerve stimulation (TENS) and hot pack, positioned over the neck region, for 15-20 minutes. This will help in improving blood flow and increasing muscle activation.~The Mulligan mobilization, the patient will be seated in a comfortable position on a chair and the therapist stood behind to perform the mulligan mobilization. A gliding force will be applied by the therapist on the patient's spinous process or on the facet joint of the superior vertebra of the target segment for treatment. This gliding force will be maintained by the therapist. Then the patient will move his head towards the painful side (flexion, extension, rotation, and lateral flexion), and more pressure will be applied by the patient at the end of active movement. The Mulligan mobilization will be repeated 10 times for 3 sets."
214393493|NCT03923296|DEVICE|Blood measurement and monitoring|Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters.
214393494|NCT03923296|BEHAVIORAL|Interviews|Focus group interviews
214393495|NCT04575649|OTHER|Gastrointestinal anomalies|Infants born late preterm (at or above 35 weeks gestation) and term infants admitted to the NICU with congenital gastrointestinal anomalies, including gastroschisis, omphalocele, esophageal and bowel artesias, tracheoesophageal fistulas, Hirschsprung's disease, or congenital diaphragmatic hernias.
214393496|NCT01995357|DEVICE|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
214393497|NCT01995357|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
214393498|NCT01995357|DEVICE|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
214393499|NCT04384679|DEVICE|Hydrophilic polymer and potassium ferrate powder|Application with pressure until hemostasis is achieved
214393500|NCT01026909|DRUG|Aristospan 20mg|Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
214393501|NCT03146481|DRUG|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
214393502|NCT03146481|OTHER|Placebo|Placebo tablet given one hour before starting the root canal treatment
214393503|NCT04732715|BEHAVIORAL|CaRE Course|Participants will complete the CaRE Course over a 6-8 week time period. The curriculum of the CaRE course will include topics addressing caregiving for a PLWD during a pandemic, navigating the healthcare system for a PLWD, guiding and managing daily life, and self care.
214393504|NCT01184001|DRUG|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
214393505|NCT01184001|DRUG|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
214393506|NCT01184001|DRUG|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
214393507|NCT01184001|DRUG|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
214393508|NCT05107245|DIAGNOSTIC_TEST|1test1|Loss of bacterial diversity diagnosis
214393509|NCT01807221|DRUG|Finerenone (BAY94-8862)|
214502546|NCT04560946|BEHAVIORAL|Enhanced Treatment As Usual|"Enhanced Treatment As Usual (ETAU) group. Intervention: Behavioral: The ETAU condition was designed to replicate treatment as usual following neuropsychological assessment of post-TBI cognitive problems. Treatment as usual for mTBI patients at the VA hospital usually consists of: 1) A general evaluation by the polytrauma clinic, 2) Possible neuropsychological assessment evaluation by the TBI Cognitive Rehabilitation Clinic, and 3) If impairments are present, cognitive rehabilitation is offered. The current study's condition is considered enhanced treatment as usual because standard of care for chronic mTBI does not always involve neuropsychological assessment with feedback and psychoeducation or the provision of self-directed tools such as the CogSMART app or BrainHQ cognitive training software."
214393510|NCT01807221|DRUG|Placebo|
214393511|NCT01807221|DRUG|Inspra (eplerenone)|
214502547|NCT04119063|DEVICE|powered orthosis|Novel powered leg brace to provide assistance during walking.
214393512|NCT02609659|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
214393513|NCT02609659|DRUG|ribavirin|Tablet
214393514|NCT05063305|DIETARY_SUPPLEMENT|Probiotic|The probiotic to be used in the study is in capsule form and consists of 12 bacterial strains and 10-billion colony forming unit (CFU). The product consists of the following bacterial strains and species: Bifidobacterium infantis ATCC SD 6720, Bifidobacterium bifidum ATCC SD 6576, Bifidobacterium breve ATCC SD 5206, Bifidobacterium lactis ATCC SD 5220, Bifidobacterium longum ATCC SD 5588, Lactobacillus acidophilus DSM 32754, Lactobacillus casei ATCC SD5213, Lactobacillus paracasei ATCC SD 5275, Lactobacillus plantarum ATCC SD 5209, Lactobacillus reuteri ATCC SD 6689, Lactobacillus rhamnosus ATCC 53103, Lactobacillus salivarius ATCC SD 5208) in combination with the prebiotic, xylooligosacharide (XOS).
214393515|NCT05063305|DIETARY_SUPPLEMENT|Placebo|A placebo, that will be indistinguishable in appearance to the probiotic, will be provided to half of all study participants for the length of the trial. It will contain the following ingredients: Microcrystalline cellulose, magnesium stearate, a vegetarian capsule, and silicon dioxide. The probiotic will be manufactured by MeriCal.
214393516|NCT00542841|PROCEDURE|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
214393517|NCT00376441|PROCEDURE|Vaginal Surgery|patients undergoing vaginal surgery
214393518|NCT04963673|OTHER|calcineurin inhibitor dosage|The dosage of calcineurin inhibitors will be done as usual by the toxicology pharmacology laboratory of the CHU Amiens-Picardie. If the patient does not object, the determination of protein-bound uremic toxins from the rest of the collected blood tube will be performed using high performance liquid chromatography.
214393519|NCT04607915|BEHAVIORAL|Intervention for TECC Model|The Care Coordinator (CC) will provide brief coaching sessions (15 to 20 minutes) to each participant once per week for 8 weeks. Participants can identify topics for discussion and the CC and participant can decide if a video session via WebEx is required versus a phone call. Also, participants will be given peer support and will be indirectly monitored by a virtual care team of experts.
214393520|NCT01662427|OTHER|Questionaire to assess Noctural Parkinson's Disease Symptoms|Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
214393521|NCT00001955|DRUG|Etanercept|
214502548|NCT03844919|DEVICE|rTMS + CBIT|"Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10."
214502549|NCT03844919|BEHAVIORAL|Sham rTMS + CBIT|Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
214502550|NCT01847534|OTHER|Supplemental PN|
214502551|NCT01847534|OTHER|Standard Care|
214688120|NCT07051954|OTHER|Functional Inspiratory Muscle Training (IMT)|IMT using a portable inspiratory muscle training device at 60% MIP, progressively increased over 12 weeks.
215094391|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
214393522|NCT00001955|DRUG|Celecoxib|
214393523|NCT05534880|OTHER|Binaural beats|Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.
214393524|NCT03198793|DRUG|QGC001|Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]) over 8 weeks.
214393525|NCT00519259|DRUG|Lobeline|
214393526|NCT01155388|DRUG|Ferumoxytol|Experimental: Ferumoxytol
214393527|NCT01155388|DRUG|Oral Iron|Active Comparator: Oral iron
214393528|NCT03710213|BEHAVIORAL|Text Message-based Intervention|The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
214393529|NCT01004250|DRUG|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
214393530|NCT01004250|DRUG|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
214393531|NCT01004250|DRUG|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
214393532|NCT04192214|DRUG|BC 007|1350 mg of BC 007
214502552|NCT05473416|OTHER|McKenzie back extension exercise|McKenzie's back extension exercise consists; start with your belly facing down on the mat. Angle your legs in line with your hips, point your toes, and breathe into the next movement. Gently bending your elbows, push yourself up off the floor, until you feel the extension in your back. Be mindful not to lock your elbows as you support your weight with your hands and wrists for 10 seconds. Take deep inhales and exhales as you move in and out of the pose. Patients will be performed these activities under the supervision of physiotherapist.
214688121|NCT06751056|DEVICE|Cervical Traction Device|"Participants will use their home neck traction devices daily for 12 weeks, while continuing their prescriptions for gabapentin or pregabalin.~At study initiation and every 2 weeks thereafter for a total of 12 weeks, they will receive an electronic survey assessing their itch score. Based on survey results, they will receive a call from the study team to adjust their dosage of gabapentin or pregabalin by up to 33%."
214688122|NCT06896513|OTHER|Isthmus|The neck skin thickness from the thyroid isthmus to the skin will be measured in millimeters using a linear ultrasound probe (3-13 Hz) in the supine position with neck hyperextension. Measurements will be taken in a transverse view at the level of the 2nd-3rd tracheal rings, and the average of three measurements will be recorded.
214688123|NCT06895408|OTHER|Intravenous Infusion|Glucose-dependent Insulinotropic Polypeptide
214688124|NCT06895408|OTHER|Intravenous Infusion|Glucagon-Like Peptide 1
214688125|NCT06895408|OTHER|Intravenous Infusion|Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide 1
214688126|NCT06895408|OTHER|Intravenous Infusion|Saline
214688127|NCT00005051|DRUG|carboplatin|
214688128|NCT00005051|DRUG|cisplatin|
215094392|NCT02108665|RADIATION|Radiographic hysterosalpingography|
214393533|NCT04258085|OTHER|Early diagnosis program combined with electronic medical record|Implementation of early diagnosis approach targeting symptomatic women, combined with use of electronic medical record to facilitate documentation, patient tracking across levels of the health care system, and patient contact
214393534|NCT03943589|DRUG|Imlifidase|All subjects will receive imlifidase (Day 1) prior to standard care IVIg
214393535|NCT02710331|DRUG|Active Dronabinol|10 mg capsule of Dronabinol will be administered orally.
214393536|NCT02710331|DRUG|Placebo|Control: no alcohol, administered for \~80 minutes.
214393537|NCT02710331|DRUG|Placebo|Control: Placebo pill (no active cannabinoids) administered orally.
214393538|NCT02710331|DRUG|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
214688129|NCT00005051|DRUG|paclitaxel|
214688130|NCT00005051|DRUG|topotecan hydrochloride|
214688131|NCT04182659|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
214688132|NCT04182659|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
214393539|NCT00889382|DRUG|OSI-906|Administered orally
214393540|NCT00889382|DRUG|Paclitaxel|Administered intravenously
214393541|NCT03675724|DIETARY_SUPPLEMENT|Fisetin|Flavonoid Family
214393542|NCT03675724|DRUG|Placebo oral capsule|Placebo
214393543|NCT01875835|DEVICE|Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)|
214393544|NCT01875835|DEVICE|Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)|
214393545|NCT02338921|DRUG|Sitagliptin|"100mg qd per oral during 24months~compared with other treatment groups"
214393546|NCT02338921|DRUG|Dapagliflozin|"10mg qd per oral during 24months~compared with other treatment groups"
214393547|NCT02338921|DRUG|Lobeglitazone|"0.5mg qd per oral during 24months~compared with other treatment groups"
214393548|NCT02338921|DRUG|Glimepirde|
214393549|NCT02338921|DRUG|Metformin|
214393550|NCT03806049|DRUG|Niraparib|given orally once daily
214393551|NCT03806049|DRUG|Bevacizumab|given as iv infusion every three weeks
214393552|NCT03806049|DRUG|TSR042|Given as IV infusion every three weeks
214393553|NCT03806049|DRUG|Carboplatin|given as iv infusion every three weeks
214393554|NCT03806049|DRUG|Paclitaxel|given as iv infusion every three weeks
214688133|NCT06899204|DRUG|Abrocitinib|Study Drug for Observational Data Collection.
214688134|NCT06897475|DRUG|LY3457263|Administered SC
214688135|NCT06897475|DRUG|Placebo|Administered SC
214688136|NCT05100056|OTHER|No Intervention|This is a non-interventional study.
214688137|NCT06771674|DRUG|Pembrolizumab|Given as monotherapy.
214688138|NCT06771674|DRUG|Nivolumab|Given in combination with chemotherapy.
214688139|NCT06771674|DRUG|Nivolumab|Given without chemotherapy.
214688140|NCT06771674|DRUG|Pembrolizumab|Given in combination with chemotherapy.
214688141|NCT06771674|DRUG|Pembrolizumab|Given without chemotherapy.
215094393|NCT02108665|RADIATION|Magnetic resonance imaging hysterosalpingography|
214393555|NCT05599880|DRUG|Bortezomib|Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
214393556|NCT04096807|OTHER|Standard TEE exam including measurement of left upper pulmonary vein diameter and collapsibility, compared with PCWP measured continuously by a pulmonary arterial catheter|TEE takes part of the standard perioperative hemodynamic monitoring in cardiac surgery. Patients enrolled in the study are also monitored by a pulmonary arterial catheter
214393557|NCT03813095|DRUG|APH-1501|The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
215000336|NCT07112781|RADIATION|Single Dose Radiotherapy|Procedure: external-beam radiotherapy (EBRT) on a linear accelerator with a dose 24 Gy in one session using technique of image-guided volumetric intensity modulation arc therapy (VMAT-IGRT) and a set of dedicated devices that ensure target immobilization and reproducibility of prostate anatomical localization during treatment. A special air-filled endorectal balloon will be used for immobilization of the prostate and anatomical reproducibility of organs at risk during treatment. A Foley catheter will be used to ensure reproducibility of the urethral position and online tracking of the prostate gland position during treatment. A special external immobilization system, including patient positioning on a patient transfer trolley, which allows for patient transfer without removing the endorectal balloon and urinary catheter from the table at all stages of pre-radiation preparation (MR, CT, Positron emission tomography (PET) / CT simulation) and during the treatment.
215000337|NCT07111533|PROCEDURE|Open Flap Debridement (OFD)|Under Local Anesthesia , intrasulcular incisions using surgical blade #15c Then, a full thickness mucoperiosteal flap will be raised . Then, the granulation tissue in the intrabony defect will be debrided and the root will be planned using manual and ultrasonic instruments followed by saline and chlorohexidine irrigation till obtaining a healthy sound bone surface.
215000338|NCT07111533|PROCEDURE|Bone Graft|Bovine Xenograft material packed into the debrided defect.
215000339|NCT07111533|PROCEDURE|Autogenous Periosteal Pedicle Graft (PPG)|"* Vertical releasing incisions will be used if necessary for better access.~* The periosteal membrane will be separated from this flap and released with one vertical incision mesially and one horizontal incision apically . Posteriorly, the periosteum remained attached to the mucoperiosteal flap for adequate blood supply.~* periosteal membrane will be turned over to cover this defect completely and sutured with the lingual flap with a synthetic 6-0 bioabsorbable Vicryl suture. \*The soft tissue flap will be sutured with 5-0 nonabsorbable prolene suture material and a periodontal dressing was given."
215000340|NCT07111533|PROCEDURE|Pericardium Membrane|A pericardium membrane was adapted for defect coverage and sutured with the lingual flap with a synthetic 6-0 bioabsorbable Vicryl suture.
215000341|NCT04391556|DRUG|Firmagon|120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
215000342|NCT06736821|DIETARY_SUPPLEMENT|Open sinus augmentation with melatonin gel mixed with xenograft|"All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the melatonin gel which was mixed with xenograft as an augmentation material.~Preclinical studies proved the direct action of melatonin in enhancing the differentiation and proliferation of bone-forming osteoblasts. In addition to increasing bone mass, melatonin also facilitates new bone growth and osteointegration, making melatonin a particularly attractive molecule for use in bone implants when used alone or in combination with other growth factors"
215000343|NCT06736821|PROCEDURE|Open sinus augmentation with xenograft|All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
215000344|NCT07104188|DIETARY_SUPPLEMENT|A non-active placebo supplement.|Placebo powder mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.
215000345|NCT07104188|DIETARY_SUPPLEMENT|Caffeine|220 mg caffeine powder mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.
215000346|NCT07104188|DIETARY_SUPPLEMENT|Energy Drink|A supplement containing 220 mg caffeine, 1800 mg anserine extract, and 400 mg elderberry extract, mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.
215000347|NCT07103278|DRUG|AD-116|AD-116 Oral Tablet
215000348|NCT07103278|DRUG|AD-1161|AD-1161 Oral Capsule
215000349|NCT07104344|BIOLOGICAL|CM355|CM355 injection
215000350|NCT07103525|BEHAVIORAL|INSPIRE Initiative|Culturally relevant, multi-level intervention designed to increase HIV testing through reducing intersectional stigma. Intervention includes series of four one-on-one conversations (45 minutes each over a six-week period) via mobile phone between the Hunter peer advocates and FSWs, which are reinforced through weekly text messages from the peer advocates and through role-model stories shared online.
215000351|NCT07103525|BEHAVIORAL|Standard of Care|Standard HIV prevention information with no tailored components via one mobile phone verbal conversation with peer advocates.
215000352|NCT07103330|DEVICE|Metallic fixation hardware|Control
215000353|NCT07103330|DEVICE|Cranial flap placement and fixation using only Montage Flowable Settable Bone Paste|Experimental
215000354|NCT07105046|OTHER|Interviews|A 30 to 45-minute in-depth semi-structured interview by phone will be administer, following a semi-structured interview guide.
215000355|NCT07105046|OTHER|Focus Groups|45 to 60 minutes video conference
215000356|NCT07108283|DRUG|Zasocitinib|Zasocitinib capsules.
215000357|NCT07108283|OTHER|Placebo|Zasocitinib matching placebo capsules.
215000358|NCT07107243|DIAGNOSTIC_TEST|Speaking valve combined with airway pressure|All patients wore speaking valves for 30 minutes, during which the transtracheal end-expiratory pressure was measured to assess the patency of the upper airway.
215000359|NCT07107243|DIAGNOSTIC_TEST|Bronchoscopy|The same examiner performed bronchoscopy on all patients to assess upper airway patency.
215094394|NCT06382935|OTHER|Probin Pocket Depth reduction|Probin Pocket Depth reduction in millimetres before and after treatment
214394150|NCT01511627|DRUG|General Anesthesia + Spinal anesthesia combined|"All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Patients will receive a spinal anesthetic with:~* Bupivacaine 0.5% 10 mg~* Fentanyl 10ug~* Epidural Morphine 150ug~After the spinal, a general anesthetic will be induced using:~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU)."
214394151|NCT01511627|DRUG|General Anesthesia (control group)|"All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Group I (General anesthetic) patients will receive a general anesthetic :~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously~Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU)."
214394152|NCT04802642|OTHER|Survey|Survey
214394153|NCT00321256|PROCEDURE|human pancreatic islet transplantation|
214394154|NCT02590133|DRUG|Recombinant Human Endostatin Injection (Endostar)|15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
214394155|NCT02590133|DRUG|Fluorouracil (5-Fu)|200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
214394156|NCT02590133|DRUG|Nedaplatin|80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
214394157|NCT01668147|DRUG|[11C] desmethyl-loperamide|IV administration of 10-14 mCi of \[11C\] desmethyl-loperamide with PET/CT imaging
214394158|NCT01668147|OTHER|Control - no pretreatment|Session 1: IV administration of 10-14 mCi \[11C\] desmethyl-loperamide (dLop) with PET/CT imaging and brain MRI
214502832|NCT07031271|BEHAVIORAL|Tangram game|Tangram game; It is a very old intelligence and attention game of Chinese origin. This game stands out with its both entertaining and educational aspects. Tangram consists of seven geometric pieces formed from a square shape. These 7 pieces; 2 large right triangles, 1 medium right triangle, 2 small right triangles, 1 square and 1 parallelogram. The aim is to create various shapes (animals, people, objects, letters, etc.) with these pieces. The aim of the Tangram game is to recreate the same appearance with a given shape (silhouette) using the pieces. All 7 pieces must be used in the game, the pieces must not be overlapped, the pieces must not be cut or divided, the pieces can be rotated or turned according to the selected shape. For example, the person is asked to create a cat figure with these 7 pieces in accordance with the rules. This game is one of the non-pharmacological pain management techniques by diverting the attention of the patients. It is easy to apply and cheap.
214394159|NCT01668147|DRUG|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI
214394160|NCT01668147|DRUG|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI
214394161|NCT04316455|OTHER|Integrative Yoga Therapy|Participants having an hour in-person weekly session with qualified yoga therapist for 6-weeks. At each session, the personalised yoga practices including straightening and relaxing posture of yoga, yoga breathing, Combinations of sound and imagery yoga practices were given and asked to continue practice at home during the week.
214394162|NCT03498755|BEHAVIORAL|Mobile phone audio messaging|"Audio messages will be pushed to participants' mobile phones twice weekly on a set schedule in discrete modules that include basic information related to each of the four behavioral domains followed by an integration of the information across behaviors through relatable, character-driven narratives that enable message recipients to engage with the content through a real-world context."
214394163|NCT03498755|BEHAVIORAL|Peer-to-peer learning|Women participants in each community will meet twice monthly for peer-to-peer learning sessions to reinforce the content of audio messages. These sessions will further use women's empowerment approaches including critical examination of gender dynamics, and discussions of solutions for equitable decision-making and control of resources within households. These discussions will be facilitated with male household members and grandmothers in separate learning sessions that will be held three times throughout the intervention period.
214394164|NCT03498755|BEHAVIORAL|Conditional cash transfer|Participants will receive a conditional cash transfer to support their fish smoking business. The payment will be conditional on their participation in entrepreneurship trainings and the use of the investment into their fish smoking business.
214502833|NCT07038135|DIETARY_SUPPLEMENT|Novel Natural Supplement (NNS)|Multi-ingredient formula including whey protein, pea protein, oats, sweet potato, flaxseed, chia seeds, spinach powder, cardamom, green tea extract, beetroot powder, and stevia. Administered daily for 8 weeks.
215094752|NCT05663671|DIAGNOSTIC_TEST|Diagnostic Test|30% of IBD patients are misdiagnosed. This affects surgical care of patients. Investigators have unveiled a signature discriminator between UC\&CC that also predicts the outcome of IC patients into authentic UC/CC. This is a bioassay that is specific, sensitive, linear, affordable, minimal risk, non-invasive and constitutes an inexpensive, simple to use, point-of-care test format. Investigators published data which have shown robust presence of DEFA5 in the colon crypt mucosa with aberrant expression of apparent crypt-cell-like cells (CCLCs) in areas identified with ectopic colon ileal metaplasia consistent with CC. Investigators propose to validate that UC/CC, the two unsolved medical sub-types of pathology can accurately be distinguished among IC patients by examining CCLCs secreted DEFA5 levels in endoscopy biopsies instantly. Diagnostics relies on the expression/localization/activation of DEFA5 and the ectopic CCLCs in the mucosal crypt of CC patients.
214502834|NCT07038135|DIETARY_SUPPLEMENT|Placebo|A placebo containing maltodextrin, microcrystalline cellulose, and beetroot powder, matched in appearance, flavor, and texture to the NNS. Administered daily for 8 weeks.
214394165|NCT03498755|BEHAVIORAL|Entrepreneurship training|Entrepreneurship training will focus on commonly lacking business knowledge, with an emphasis on establishing fundamental entrepreneurial skills (i.e., customer care, accounting), sound business management and decision-making, building strong and sustainable business relationships, and encouraging the use of loans for their intended purposes. This training will be introduced during the credit and savings group (CSG) meetings that will occur twice per month.
215000426|NCT07124637|BEHAVIORAL|Multicomponent Social Cognitive Theory-Based Educational Program to Increase Fruit and Vegetable consumption in Students|"This multilevel blended educational intervention applies Social Cognitive Theory (SCT) to increase fruit/vegetable (F/V) intake among female middle school students. The 8-week program includes:~A) Student Components:~* Seven 60-minute sessions (4 in-person, 3 WhatsApp-delivered)~* Interactive activities: cooking demonstrations, goal-setting workshops, and educational games~* SCT-focused content: self-efficacy building, outcome expectation modification~B) Parental Engagement:~* Weekly SMS nutrition tips~* Two virtual workshops on creating F/V-supportive home environments~* School Environment Modifications:~* Cafeteria redesign to promote F/V accessibility~* Peer-led 'Healthy Eating Ambassador' program~Unique aspects distinguishing this intervention:~* First SCT-based program specifically adapted for Iranian adolescent females~* Dual delivery (in-person + digital) optimized for school settings~* Simultaneously targets individual, social, and environmental determinants."
215000427|NCT07124715|DEVICE|Rough Surface Zygomatic Implant|Surgical placement of a zygomatic implant with a fully roughened surface from apex to collar. Used for the control arm.
215000428|NCT07124715|DEVICE|Partially Machined Surface Zygomatic Implant|Surgical placement of a modified zygomatic implant with a smooth machined coronal portion, a non-threaded machined middle section, and a rough apical portion. Used for the test arm.
215000429|NCT07125118|BEHAVIORAL|The OurRelationship Program|A guided self-help program for couples delivered online over 10 weeks. Participants complete structured learning modules and engage in planned couple conversations focused on improving communication, problem-solving, and emotional connection. Each couple receives support from a trained coach through five scheduled telephone or video calls. The program is designed to be flexible and completed at the couple's own pace within the 10-week period.
215000430|NCT07125118|BEHAVIORAL|Bibliotherapy|"An unguided self-help program for couples using the Danish book Take Care of Your Relationship \[Pas på Parforholdet\] and an accompanying reading guide. Couples are encouraged to read assigned sections, engage in planned couple conversations, and apply strategies for improving relationship functioning. The intervention is self-paced and completed over 10 weeks without guidance from a coach or therapist."
215000431|NCT07125833|DEVICE|Cryoneurolysis|Cryoneurolysis of the suprascapular nerve
215000432|NCT07125833|OTHER|No cryoneurolysis|Control Group
215000433|NCT07124988|PROCEDURE|regional flap|regional flap reconstruction for palatomaxillary defects
214502835|NCT06718127|BIOLOGICAL|blood samples collection|blood samples collected at D0 ,W1, W5, M3 and M6
215000434|NCT07124988|PROCEDURE|distant flap|Distant flap reconstruction for palatomaxillary defects
215000435|NCT07124663|OTHER|Breastfeeding education|Women will receive education on breast milk and breastfeeding during pregnancy.The education program consists of two sessions, with a total duration of 60 minutes.
215000436|NCT07123311|BEHAVIORAL|Online Stress Management Program|"This is an online pilot stress management program tailored for health students, combining cognitive-behavioral therapy and guided mindfulness meditation. Over eight sessions, participants engage with interactive psychoeducation modules, videos, and practical exercises to understand stress and develop coping strategies.~The sessions cover stress awareness, mindfulness meditation (basic and advanced), breathing techniques, time management using the Eisenhower matrix, and cognitive-behavioral methods to foster positive thinking and problem-solving.~The final session helps participants create a personalized action plan to integrate learned skills into daily life. Throughout the program, a support group encourages interaction and provides ongoing guidance to enhance well-being and stress management."
215000437|NCT07138794|OTHER|Subtransverse process interligamentary|Patients will receive subtransverse process interligamentary (STIL) block using 20ml of bupivacaine 0.25%.
215000438|NCT07138794|OTHER|Thoracic paravertebral block|Patients will receive a thoracic paravertebral block (TPVB) using 20ml of bupivacaine 0.25%.
215000439|NCT07141628|DIAGNOSTIC_TEST|lipoprotein A level dosing|Plasma levels measured in mmol/l
215000440|NCT07142304|DEVICE|The Lilac Device|The Lilac Glove and Boot devices are wearable, non-sterile device for patients undergoing cancer treatment who wish to reduce the risk of peripheral neuropathy. Treatment with the Lilac Glove and Boot devices is administered by the healthcare professional in the healthcare environment. The Lilac Glove and Boot devices are designed for continual use; the devices must be fitted and turned on before infusion begins; the devices must be used without interruption during infusion, and for up to two (2) hours after infusion is complete.
215000441|NCT07142304|DEVICE|Sham device|The sham device will look, appear to function and worn for the same duration as the Lilac Device. The only difference between the devices is the level of compression applied.
215000442|NCT07142577|OTHER|Mandala coloring|Mandala coloring activities will be carried out by the certified researcher 3 days a week for 8 weeks.
214502836|NCT03562741|PROCEDURE|Fecal Microbiota Transplantation|Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
215094753|NCT04043468|OTHER|Audit and feedback|Audit and feedback (A\&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
215094754|NCT04707248|DRUG|DS-6000a|Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
215094755|NCT04707248|DRUG|DS-6000a|Intravenous administration at RDE on Day 1 of Cycle 1
215094756|NCT02166268|DRUG|AVANZ Phleum pratense 15,000 SQ+|
215094757|NCT02166268|DRUG|Placebo|
215094758|NCT00255528|DRUG|metoprolol succinate|
215094759|NCT00707954|DRUG|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
215094760|NCT00707954|DRUG|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
214693794|NCT05310994|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
214693795|NCT05310994|DIETARY_SUPPLEMENT|Wasabi Leaf Extract Drink|consume 1 bottle per day
215000443|NCT07141056|OTHER|Psychological Stress Status|Psychological stress status will be assessed using both self-reported and clinician-rated measures. Participants will be categorized into stressed and non-stressed groups based on the following criteria: Self-reported measures (either): PHQ-9 score ≥ 5 (depression symptoms) and/or; GAD-7 score ≥ 5 (anxiety symptoms) Clinician-rated measures (either): HAMD score ≥ 7 (mild depression) and/or HAMA score ≥ 7 (mild anxiety) Additional assessments: Clinical Global Impression Scale (CGI) EORTC QLQ-C30 (quality of life) Assessment timing: Baseline (before starting immunotherapy) After 2-3 cycles of treatment Every 3 months during follow-up.
215000444|NCT07141056|OTHER|Psychological Stress Status|Psychological stress status will be assessed using both self-reported and clinician-rated measures. Participants will be categorized into stressed and non-stressed groups based on the following criteria: Self-reported measures (either): PHQ-9 score ≥ 5 (depression symptoms) and/or; GAD-7 score ≥ 5 (anxiety symptoms) Clinician-rated measures (either): HAMD score ≥ 7 (mild depression) and/or HAMA score ≥ 7 (mild anxiety) Additional assessments: Clinical Global Impression Scale (CGI) EORTC QLQ-C30 (quality of life) Assessment timing: Baseline (before starting immunotherapy) After 2-3 cycles of treatment Every 3 months during follow-up.
214394166|NCT03498755|BEHAVIORAL|Market price information|Average market prices for fresh and processed fish at community, district, and regional markets will be disseminated via audio message calls (using Viamo's Infoline platform) to the mobile phones of women with the price information in their preferred language. These market prices will be collected twice weekly by Viamo field enumerators and sent to regional coordinators for validation. A second, independent validation will be carried out to ensure that there are no discrepancies.
214394167|NCT03498755|BEHAVIORAL|Improved smoke ovens|Local private sector artisans will construct and serve as suppliers of the new ovens. The promotion, uptake and impact of these improved Ahotor ovens will be tested among study participants. Awareness-raising workshops held in each community will promote the Ahotor in concert with a public retrofitting of a Chorkor stove. Immediately following this event, one month later, and three months later, study participants will receive additional one-on-one counseling to provide further support on the proper use of the smoke oven, as well as on optimal handling and smoking practices to enhance product quality.
214394168|NCT06168656|BEHAVIORAL|Mobile Application|"The mobile application will include the following features:~Direct Message Section: This section will allow expectant fathers to ask specialized questions directly to experts or specialists.~Forum Section: Expectant fathers can use this section to engage in discussions and connect with each other.~Education Section: This section is specifically designed to cater to the educational needs of expectant fathers."
214394169|NCT02040792|DRUG|TD-4208|
214394170|NCT02040792|DRUG|Placebo|
214394171|NCT01842087|OTHER|Control Food|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
214394172|NCT01842087|OTHER|Fiber Fortified Food|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
214394173|NCT03557983|DRUG|Fenofibrate|Fenofibrate is dissolved in Saline and topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
214394174|NCT03557983|DRUG|Saline|Saline is topically spread three times per day at the irradiated areas for one week.
214394175|NCT00451997|DRUG|Gleevec|600 mg (capsules) by mouth once daily
214394176|NCT00451997|DRUG|Ara-C|10 mg as an injection under the skin daily for 21 days of every 28 day cycle
214394177|NCT05652855|DRUG|MHB088C for Injection|MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
214394178|NCT04141111|DEVICE|Continuous Glucose Monitoring (CGM)|"On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review."
214394179|NCT03760315|DIAGNOSTIC_TEST|blood mNGS (IDSeqTM Ultra); blood Culture|take blood samples for mNGS and Culture at the same time in sepsis patients. No intervention on the treatment of the patients.
214394180|NCT00124800|BEHAVIORAL|Tinnitus retraining therapy|Sound therapy and counseling
214394181|NCT00124800|DEVICE|Sound therapy|sound therapy and counselling
214394182|NCT01025661|OTHER|Chiropractic care|Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.
214394183|NCT03693261|PROCEDURE|Coronary artery bypass grafting (CABG)|CABG, as part of the standard medical care
214394184|NCT03693261|PROCEDURE|Valve replacement|cardiac surgery for aortic or mitral valve replacement as part of their standard medical care
214394185|NCT02372331|OTHER|ERAS perioperative management|"* Preop Counseling~* Preop biliary drainage (X) when Serum Total bilirubin \< 14.62mg/dl and cholangitis (-)~* Preop enteral nutrition~* Oral bowel preparation (mechanical bowel preparation ) (X)~* Preop fasting \< 6 hours~* Prevention of postoperative nausea and vomiting (PONV) (O)~* Nasogastric intubation (X)~* Near-zero fluid balance~* Somatostatin analogues (X)~* Postop routine artificial nutrition (X), soft diet at POD #2~* Audit~* Other items are same as conventional"
214394186|NCT03459820|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
215121343|NCT02046707|OTHER|Concentric and eccentric exercise sessions|
214522589|NCT05364541|DEVICE|MyoVista wavECG|A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
214394187|NCT06040463|BEHAVIORAL|Diabetes Self-Management Training (DSMT)|The American Diabetes Association endorses the use of small-group diabetes self-management training (DSMT), for people living with diabetes to improve lifestyle, HbA1c levels, and overall quality of life. A certified diabetes care and education specialist will teach a four-part series of one-hour sessions providing culturally competent group education and discussion for groups of 5-8 patients: Session 1 - Living with diabetes - physiology of diabetes, integrating diabetes into your daily life, long term outcomes of diabetes; Session 2 - Culturally competent food education \& portion control; Session 3 - Tips \& Tricks for dining out and special occasions; Session 4 - Advanced tools and psychosocial implications of living with diabetes. While patients will be encouraged to move through the series together as a cohort, there will be make-up sessions and flexibility to ensure high-quality participation.
214522590|NCT00912275|DRUG|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
215000445|NCT07141056|OTHER|Psychological stress status|Psychological stress status will be assessed using both self-reported and clinician-rated measures. Participants will be categorized into stressed and non-stressed groups based on the following criteria: Self-reported measures (either): PHQ-9 score ≥ 5 (depression symptoms) and/or; GAD-7 score ≥ 5 (anxiety symptoms) Clinician-rated measures (either): HAMD score ≥ 7 (mild depression) and/or HAMA score ≥ 7 (mild anxiety) Additional assessments: Clinical Global Impression Scale (CGI) EORTC QLQ-C30 (quality of life) Assessment timing: Baseline (before starting immunotherapy) After 2-3 cycles of treatment Every 3 months during follow-up.
215000446|NCT07141433|OTHER|LLM-Assisted Public Health Emergency Training Program|"A hybrid training program integrating the hospital's standard public health emergency (PHE) curriculum with Large Language Model (LLM) technology as an auxiliary learning tool. Participants receive:~* Standardized PHE training (online lectures + offline simulations) covering professional knowledge, skills, and emergency drills (e.g., infectious disease response, trauma management).~* LLM-enabled interactive support: Structured guidance to use LLMs for:~Reviewing session content Resolving knowledge uncertainties via Exploring unfamiliar PHE concepts~• Duration: 1 month, with 20-minute sessions. Distinguishing feature: Uses LLMs to dynamically adapt to individual learning needs, enabling on-demand knowledge reinforcement and overcoming spatiotemporal limitations of traditional training."
215000447|NCT07141433|OTHER|Standard Public Health Emergency Training Program|"The hospital's existing public health emergency (PHE) training program without AI augmentation. Participants receive:~* Identical core content as the experimental group: Professional knowledge, skills training, and emergency drills for PHE response (e.g., disaster protocols, infection control).~* Explicit restriction: Prohibited from using LLMs or any AI tools for learning support.~* Delivery: Hybrid format (online + offline), 1-month duration, 20-minute sessions.~Distinguishing feature: Represents traditional training methods reliant on instructor-led content without personalized, on-demand AI-driven reinforcement."
215000448|NCT07141550|OTHER|Clinical Pilates Group|Participants will be introduced to the principles of Pilates, the workout program, and its five key elements: neutral spine, lumbopelvic and scapular stabilization, focus, and breathing. Clinical Pilates sessions will be held twice weekly for 8 weeks, 60 minutes each, via synchronous telerehabilitation (Zoom/WhatsApp). Each session includes a 10-minute warm-up, 40 minutes of Pilates exercises, and a 10-minute cool-down. The physiotherapist will provide visual and verbal guidance to ensure correct posture and breathing. Exercises start with 6-8 repetitions in the first week, increasing progressively according to participant ability and advancing to higher-level positions.
215000449|NCT07141550|OTHER|Kinesthetic Brain Exercises Group|16 sessions, approximately 40 minutes each, will be administered twice a week for eight weeks by a physical therapist via video chat programs such as Zoom or WhatsApp. Kinesthetic brain exercises consist of three phases: a warm-up phase, an exercise phase, and a cool-down phase. The warm-up and cool-down phases consist of hand-eye coordination and relaxation exercises. The exercise phase consists of independent and dependent movements, as well as a combination of both.
215000450|NCT07141160|OTHER|Combined: Mobile app + 6WELLS|Mobile based digital toolkit for cognitive health, remote assessment and multi-component intervention, comprising the 4 key pillars of assessment; cognitive training and stimulation; cognitive wellness; and dual-task training. Together with onsite 6 WELLS Group-Based Activity is a structured, group-based, cognitive health promotion programme that aims to build communities of practice, stimulate goal attainment, and drive behavioural change towards cognitive health and wellbeing. The curriculum is delivered via a 10-week onsite programme comprising weekly facilitated small-group activities centred on six key components.
215000451|NCT07141160|OTHER|Remote mobile based app|Mobile based digital toolkit for cognitive health, remote assessment and multi-component intervention, comprising the 4 key pillars of assessment; cognitive training and stimulation; cognitive wellness; and dual-task training.
215000452|NCT07141121|DEVICE|Histolog Scan|Upon prostate removal, the prostate is taken to the Histolog scanner, dipped in proprietary fluorescent dye, rinsed with saline, and then scanned on five different sides. This involves simply placing the prostate on the surface of the scanner and acquiring images on each side, giving a high-resolution (cellular level) microscopic imaging of the prostate's surfaces. Once images are collected, the prostate is returned to the pathology lab to undergo the NeuroSafe procedure, which is standard of care (SOC).
215000453|NCT07141355|DIAGNOSTIC_TEST|microcirculation using the video microscopy tool.|"The study intervention is the assessment of microcirculation using the video microscopy tool.~This study's primary purpose is to perform this specific diagnostic procedure-measuring microcirculatory parameters with the CytoCam-IDF device-at two distinct time points: at inclusion (H0) and again 48 hours later (H48).~The administration of empagliflozin (or not), which is pa and 48 hours after initiating empagliflozin treatment, microcirculatory data will be collected using a videomicroscope. A camera, roughly the size of a large pen, is placed under the patient's tongue for a few seconds to acquire images of the sublingual microcirculation. The entire image acquisition process takes less than 5 minutes and is unaffected by whether the patient is intubated.~Images are then analyzed in real-time by the MicroTools software, which calculates key microcirculatory parameters.~All anonymized images are stored on a dedicated, password-protected computer accessible only to the investigators."
214693796|NCT01044420|DRUG|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
214394188|NCT06040463|BEHAVIORAL|Remote Glucose Monitoring (RGM)|Remote Glucose Monitoring (RGM) is an automated process of transmitting glucose levels directly from a personal smartphone device to a healthcare provider using a remote data transmitter. Since 2020, Sinai has worked with Glooko Inc. to provide the RGM platform and technical assistance to patients and for Sinai providers to access data remotely. Via the app, patients can: document their glucose levels; sync data from a meter, insulin pump, pen or continuous glucose monitoring device; track their weight; log food and meals; access educational resources; track steps; and track blood pressure. Remotely uploading data provides patients with a direct line to their provider for regular feedback on progress and answers to questions between clinic visits. Patients also receive one one-hour education session on RGM and the Glooko application.
214394189|NCT06040463|BEHAVIORAL|Community Health Worker tailored support|CHWs are frontline public health workers who are trusted members of and/or have an unusually close understanding of the community served. The Center has two bilingual (Spanish/English) CHWs; additional bilingual CHWs will be added to the team to support the proposed study. While approaches will differ slightly depending on the patient and study condition, all patients paired with a CHW will be screened for social needs utilizing a standard social determinants of health (SDoH) screening tool, receive referrals to resources to address unmet social/health needs, and aided in navigating health and social systems.
214394190|NCT04640480|DRUG|SNB-101|SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
214394191|NCT04399564|DEVICE|temporary hemodialysis catheters|Vascular access using temporary vs.long-term hemodialysis catheters
214394192|NCT04399564|DEVICE|long-term hemodialysis catheters|long-term hemodialysis catheters
214394193|NCT00401466|DEVICE|Implantable Cardioverter Defibrillator|ICD with Biotronik Home Monitoring capability
214394194|NCT04071691|DIAGNOSTIC_TEST|PET-MRI|SST2 PET-MRI scan
214394195|NCT04107103|DRUG|Combination Product: Nivolumab with Pemetrexed|Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.
214394196|NCT03839472|PROCEDURE|CBI|CBI with 5 liters normal saline in 1 liter increments up to 2 hours after TURBT procedure.
214394197|NCT03699124|BIOLOGICAL|FD MVA-BN|Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)
214394198|NCT01346761|BEHAVIORAL|Telephone Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
214394199|NCT01346761|BEHAVIORAL|In-Person Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
215000454|NCT07140757|OTHER|Questionnaire|This questionnaire includes twenty-four questions covering patients complaints ranging from 0 to 4. Patients will be asked about the presence and severity of each item currently on the medical appointment.
214394200|NCT01691989|DRUG|aleglitazar|150 mcg orally once a day for 26 weeks
214394201|NCT01691989|DRUG|placebo|oral doses once a day for 26 weeks
215000455|NCT07142564|OTHER|Carrier Care (CC)|Carrier care uses an infant carrier to secure the infant to the caregiver, while SSC does not have a securing device. The caregiver holds the infant with their arms.
215000456|NCT07141563|DRUG|Nivolumab + platinum-based chemotherapy|According to the product label
214394202|NCT05218122|OTHER|cross-sectional study without intervention|cross-sectional study without intervention
214394203|NCT00699543|DEVICE|Coroflex Please stent implantation|Use Coroflex Please stent in the treatment of coronary stenosis
214394204|NCT00699543|DEVICE|Taxus stent implantation|Use Taxus stent in the treatment of coronary stenosis
214394205|NCT02127684|DRUG|ranibizumab|ranibizumab 0.3mg intravitreally monthly
214394206|NCT02127684|DRUG|ranibizumab|ranibizumab given every 2 weeks for 8 weeks then monthly as needed
214394207|NCT00506285|DRUG|Methylphenidate Transdermal System (MTS)|MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
214394208|NCT00506285|OTHER|placebo patch|This patch is designed to appear identical to the actual intervention patch
215000457|NCT07141576|OTHER|Erbium laser (2940 nm): Infrared light energy|The lasers emit light energy in the infrared and visible spectrum, which is fundamentally different from ionizing radiation (like X-rays or gamma rays) that can damage DNA. Dental lasers work through photobiomodulation and thermal effects, not through radiation exposure.
215000458|NCT07141576|OTHER|Diode laser (650 nm): Visible red light energy|Non-ionizing radiation or more accurately as optical energy devices, not ionizing radiation.
215000459|NCT07141576|DRUG|Fluoride varnish|Biological Intervention
214394209|NCT06150677|OTHER|Voluntary apnoea|Static apneas at high lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).
214394210|NCT02749708|DRUG|IRX5183|IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 \[DL1\] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
214394211|NCT05054829|BEHAVIORAL|PEERS®: program for the education and enrichment of relational skills|providing evidence-based social skills treatment to preschoolers, adolescents, and young adults with autism spectrum disorder (ASD)
214394212|NCT01089556|DRUG|Duloxetine|Administered orally
214394213|NCT01089556|DRUG|Pregabalin|Administered orally
214394214|NCT01089556|DRUG|Placebo|Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
214394215|NCT00487422|DRUG|prucalopride|2 mg o.d.
215000460|NCT07140952|BEHAVIORAL|Strong SC|The Strong SC intervention combines the StrongPeople StrongHearts program with a supplemental medically tailored grocery program. The StrongPeople StrongHearts program is a 12-week group program, with two meetings per week, that incorporates education on nutrition and physical activity for weight management and cardiovascular health, as well as strength training and aerobic exercises. The supplemental MTG program will utilize a grocery delivery platform(s) to deliver a weekly medically tailored grocery box of produce worth approximately $30 (costs covered by grant funds). Box contents will be tailored by the PI, who is a registered dietitian licensed in South Carolina, to participants' nutrition needs and functional abilities (e.g., pre-cut vegetables for participants with limited hand functionality). Participants will receive an allotment of produce each week, as well as a recipe(s) and virtual cooking demonstration providing practical strategies on incorporating each week's produce.
215000461|NCT07140952|BEHAVIORAL|StrongPeople StrongHearts|The StrongPeople StrongHearts program is a 12-week group program, with two meetings per week, that incorporates education on nutrition and physical activity for weight management and cardiovascular health, as well as strength training and aerobic exercises. Participants of this intervention will receive a systematically adapted version of this program tailored to the physical capacities of the target population (chronic stroke survivors). The systematically adapted version of StrongPeople StrongHearts will be used across both experimental arms in this study.
215000462|NCT07141108|DEVICE|Paindrainer Care system|Self management digital tool for chronic pain
215000463|NCT07142343|DRUG|Pozelimab|Administered per the protocol
215000464|NCT07141940|OTHER|Indonesian-language application-based auditory guided imagery therapy|This study used a mobile application developed by researchers using Indonesian language to deliver an auditory guided imagery therapy
215000465|NCT07141940|OTHER|Psychoeducation|Psychoeducation consists of sleep hygiene and relaxation therapy (breathing exercise, progressive muscle relaxation, and guided imagery)
215000466|NCT07142447|BEHAVIORAL|Multi-Component Behavioral intervention|"A multicomponent behavioral intervention during pregnancy and up to the first 18 months after delivery, composed by:~1. Digital tool called App Hypiend Digital Tool aimed at promoting lifestyle habits to reduce EDC exposure by providing personalized recommendations~2. Telephone monitoring~3. Workshop about environmental health education"
214394216|NCT00487422|DRUG|Prucalopride|4 mg o.d.
214394217|NCT00487422|OTHER|Placebo|o.d.
215000467|NCT07142447|BEHAVIORAL|Control group|Minimal behavioral intervention. Usual care
214394218|NCT05373602|DIAGNOSTIC_TEST|LARS questionnaire|Eligible participants were issued with LARS questionnaire (Chinese version) by E-mail, message, phone or face to face interview.
215000468|NCT07141758|DIAGNOSTIC_TEST|ELISA|Unstimulated saliva samples will be non-invasively collected from participants in this study to measure the concentrations of E-cadherin, Calprotectin, and MMP-9. These protein concentrations will be quantified using commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits.
215000469|NCT07141953|BEHAVIORAL|Yoga|Participants in the intervention group will take part in an 8-week yoga program designed for women who have entered surgical menopause after gynecological cancer surgery. The program will consist of two 60-minute sessions per week, one delivered online and one delivered face-to-face, conducted in small groups (5-6 participants) or individually, depending on participant availability. The sessions will include physical postures, breathing exercises, and relaxation/meditation techniques. The program will be delivered by a certified yoga instructor.
215000470|NCT07141511|DRUG|BG-71332|Administered orally
215000471|NCT07141511|DRUG|Zanubrutinib|Administered orally
215000472|NCT07141511|DRUG|Sonrotoclax|Administered orally
214394219|NCT00855192|BEHAVIORAL|mindful meditation|interpersonal and psycho-educational
214394220|NCT00855192|BEHAVIORAL|interpersonal therapy|psycho-educational
214394221|NCT06239974|DRUG|Vericiguat|Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group
214394222|NCT06239974|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|All patients will have stress CMR examinations at recruitment and at the end of trial.
214394223|NCT01238575|OTHER|placebo|Administered for up to 8 weeks.
214394224|NCT01238575|DRUG|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
215000473|NCT07141602|DIAGNOSTIC_TEST|lateral cephalometric x- ray and dental panoramic tomogram|lateral cephalometric x- ray and dental panoramic tomogram
215121344|NCT00760682|PROCEDURE|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
215121345|NCT00183131|BEHAVIORAL|Brief Personalized Feedback|
215121346|NCT05488639|OTHER|Registration of football exposure and occurrence of injuries and illnesses only|"Injury \& illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days."
215121347|NCT04363879|PROCEDURE|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
214394225|NCT01093261|DRUG|Placebo|"Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days."
214394226|NCT01093261|DRUG|Hydrocortisone Fludrocortisone|HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
214394227|NCT02128503|OTHER|HBV DNA level monitoring|HBV DNV level being monitoring regularly
214394228|NCT02687503|DIETARY_SUPPLEMENT|Probiotic|All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
214394229|NCT05440799|DRUG|BI 1819479|BI 1819479
214394230|NCT05440799|DRUG|BI matching placebo|BI matching placebo
215094761|NCT01834079|BIOLOGICAL|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
215094762|NCT05976347|DRUG|Fluoxetine 20 MG|Fluoxetine 20 mg once daily
215000477|NCT07142161|DRUG|RD13-02 cell infusion|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphami
215000478|NCT07140848|BEHAVIORAL|CGM-DPP|Participants in the DPP who receive personalized CGM coaching.
214394231|NCT03148080|PROCEDURE|Cognitive Assessment|Complete CogState
214394232|NCT03148080|OTHER|Questionnaire Administration|Complete Self-Report Questionnaire
214394233|NCT03405662|DEVICE|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
214394234|NCT03405662|OTHER|Sham Vielight Neuro Gamma|The Sham Vielight Neuro Gamma headset is identical to the active Vielight Neuro Gamma headset and intranasal light emitting diode (LED) except it has a power output of 0.
214394235|NCT02158624|DRUG|Intravitreal Lucentis 0.5mg|
214394236|NCT01608438|DEVICE|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
214394237|NCT02415075|BEHAVIORAL|medical rehabilitation|Participants who will take part in the study are asked to fill out a questionnaire when arriving at the rehabilitation clinic and will be invited to participate in two motivational telephone interviews after six and 12 months.
214394238|NCT05350085|DRUG|Remimazolam besylate|① initial dose: use a micro injection pump to pump remimazolam at the rate of 50mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation ; ② Maintenance dose: maintain the pump speed at 5 \~ 10mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
214394239|NCT05350085|DRUG|Midazolam|① initial dose: use a micro injection pump to pump remazolam at the rate of 30mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation; ② Maintenance dose: maintain the pump speed at 3 \~ 6mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
215000479|NCT07140848|BEHAVIORAL|Control|Participants in control group will be referred to DPP.
215000480|NCT07142239|DIAGNOSTIC_TEST|• Complete blood count , MPV|CBC report
215000481|NCT07142239|DIAGNOSTIC_TEST|Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:|CBC report
215094763|NCT05976347|DRUG|Duloxetine 30 MG|Duloxetine 30 mg once daily
215094764|NCT05976347|OTHER|Observation|Referral to behavioral health and resources for addressing depressive symptoms
215094765|NCT06041698|OTHER|Planned Notification|Receive text notification
215094766|NCT06041698|OTHER|Survey Administration|Complete surveys
215094767|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in TXT-Chatbot
215094768|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
215094769|NCT06041698|OTHER|Interview|Ancillary studies
215094770|NCT06041698|OTHER|Survey Administration|Complete surveys
215000482|NCT07142239|DIAGNOSTIC_TEST|Antiphospholipid antibody profile|Patient record
215000483|NCT05922085|OTHER|Ultrasound|performed within 3 hours prior to extubation
215000484|NCT05922085|OTHER|nasofibroscopie|performed within 24 to 36 hours after extubation
215000485|NCT01435941|DRUG|Non-steroidal anti-inflammatory drug (NSAID)|Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
215000486|NCT01435941|DRUG|Triptan|Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
214394240|NCT05649488|DEVICE|Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus|"Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle.~Therapeutic apparatus specification: IVL-HVG-C01； Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015"
214394241|NCT05649488|DEVICE|Dragonfly Opstar Imaging Catheter|OCT (optical coherence tomography) measurement using Dragonfly Opstar Imaging Catheter was performed in the OCT subgroup before or after the treatment of intracoronary lithotripsy balloon catheter and intracoronary lithotripsy therapeutic instrument, or after stent placement.
214394242|NCT00588003|DRUG|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
214394243|NCT00588003|OTHER|Placebo|No medication before surgery
214394244|NCT06120062|OTHER|swaddled|the 1st experimental group were swaddled
214394245|NCT06120062|OTHER|mother's breast milk odor|the 2nd experimental group were made to inhale mother's breast milk odor
214394246|NCT06120062|OTHER|both swaddled and made to inhale mother's breast milk odor|the 3rd experimental group were both swaddled and made to inhale mother's breast milk odor
215000487|NCT00676884|DRUG|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)|30 mgs s.c. b.i.d.
214394247|NCT06120062|OTHER|No procedure|No procedure was applied to the infants in the control group.
214394248|NCT05489029|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
214394249|NCT01010893|BIOLOGICAL|Vaccination with Fluval P and Fluval AB influenza vaccines|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
214394250|NCT01010893|BIOLOGICAL|Vaccination with Fluval P monovalent influenza vaccine|Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
214394251|NCT06034574|DEVICE|Continuous glucose monitoring|Assessment of accuracy of two different continuous glucose monitoring devices during exercise
214394252|NCT02265380|DEVICE|Placement of IV catheter|
214394253|NCT00014339|DRUG|Wobe-Mugos E|
214394254|NCT00014339|DRUG|melphalan|
214394255|NCT00014339|DRUG|prednisone|
214394256|NCT00014339|PROCEDURE|quality-of-life assessment|
214394257|NCT04340674|OTHER|Telerehabilitation based on aerobic exercise|To perform different whole body aerobic exercises moderately intense according to Borg scale.
214394258|NCT00187317|BEHAVIORAL|Balance training (exercise)|Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
214394259|NCT00187317|OTHER|Flexibility and relaxation exercise|30-minute sessions, three times per week for six weeks.
214394260|NCT05884021|OTHER|Postoperative analgesia|In patients who used intravenous PCA after surgery
215000488|NCT00676884|DRUG|placebo|1.5 mL s.c. b.i.d.
215000489|NCT05892198|PROCEDURE|surgery|surgery with primary closure, Rhomboid flap , or Rotational flap
215000490|NCT00639093|BEHAVIORAL|psychoeducational / motivational combined with crushing|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
215000491|NCT00639093|BEHAVIORAL|psychoeducational / motivational combined with control|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
215000492|NCT00128388|OTHER|PFPP|Psychoanalytic Psychotherapy for panic disorder
215000493|NCT00128388|OTHER|ART|Applied Relaxation Training
215000494|NCT02742688|DIETARY_SUPPLEMENT|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)
215000495|NCT02742688|DIETARY_SUPPLEMENT|Placebo|Placebo(4g/day)
215000496|NCT00376844|RADIATION|External Beam Radiation Therapy|
215000497|NCT00376844|RADIATION|Vaginal Brachytherapy|
215000498|NCT04709887|PROCEDURE|Wound treatment|According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.
215000499|NCT04709887|PROCEDURE|Vascular intervention surgery|Segmented distal angiography under the guidance of digital subtraction angiography (DSA) were perform after local anesthesia. The superficial artery is expanded by a 3-4 mm balloon.
215094771|NCT06041698|OTHER|Planned Notification|Receive email notification
215094772|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in MyChart/Patient Portal
214394261|NCT00830986|DEVICE|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation
214394262|NCT00830986|DEVICE|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
214394263|NCT03763188|OTHER|Use of daily urinary urea excretion|Weaning dialysis catheter
214394264|NCT06235164|DRUG|immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab|"Drug: Sintilimab, Nivolumab, and Camrelizumab，One course will last 21 days.Given once every 3 weeks at a dose of 200 mg. Drug: nab-paclitaxel nab-paclitaxel one course will last 21 days#Given twice every 3 weeks at a dose of 125 mg/m2. Drug:oxaliplatin Oxaliplatin one course will last 21 days#Given once every 3 weeks at a dose of 130 mg/m2.~Drug:docetaxel docetaxel one course will last 21 days#Given once every 3 weeks at a dose of 40mg/m2.~Drug:fluorouracil fluorouracil one course will last 14 days#Given once every 2 weeks at a dose of 2800mg/m2.~Drug: Capecitabine Capecitabine was calculated according to body surface area every 3 weeks at a dose of 1000 mg/m2, P.O., bid, d1-d14 Drug: S1 S-1 was calculated according to body surface area, P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg everytime;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time"
214394265|NCT05293535|OTHER|Prognostic study|No intervention... as it is a prognostic study and no intervention done on patients.
214394266|NCT03857581|DRUG|Clozapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
214394267|NCT03857581|DRUG|Olanzapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
214394268|NCT06081530|DRUG|BI 3802876|BI 3802876
215028957|NCT04719312|PROCEDURE|Y modification of transconjunctival approach|"Section of the orbital septum is done at the Arcus Marginalis and subperiosteal dissection done to expose the infraorbital rim and orbital floor.~Subsequently, canthotomy of the superficial limb of the lateral canthal ligament is performed and subperiosteal dissection is carried out to expose the fracture at the frontozygomatic region.~The cutaneous Y will transform into a box when retracting its corners, increasing the working area and allowing access of the frontozygomatic (FZ) suture, lateral orbital wall, body of the zygoma, infraorbital rim, and floor of the orbit with a single approach.~A small upper vestibular incision is placed to expose the fracture at the zygomatic buttress. Reduction and fixation of fractures in a regular fashion are accomplished."
214394269|NCT06081530|DRUG|Placebo matching BI 3802876|Placebo matching BI 3802876
214394270|NCT03568721|DRUG|Ibuprofen|prescription of ibuprofen 400 mg
214394271|NCT03568721|DRUG|Acetaminophen|prescription of acetaminophen 500 mg
214394272|NCT03568721|OTHER|Chewing gum|prescription of one tablet of chewing gum
214394273|NCT02556515|PROCEDURE|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
214394274|NCT02556515|PROCEDURE|Total joint replacement|Total joint replacement
214394275|NCT02556515|DEVICE|Elektra prosthesis|Elektra prosthesis
214394276|NCT02092246|DEVICE|Ultrasound machine|Use of ultrasound machine guidance for accurate needle placement into the knee joint
214394277|NCT02092246|DEVICE|Unguided injection|Needle placement will take place without ultrasound machine guidance
215094773|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
215094774|NCT06041698|OTHER|Interview|Ancillary studies
215094775|NCT05873855|BEHAVIORAL|Para ti, para mi, para nosotros (P3)|From day 1 to day 180 (i.e., entire 6-month duration, post baseline) of the pilot trial, participants randomized to the intervention arm will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
214394278|NCT01654822|DRUG|topical application cervical spray|one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
214394279|NCT01654822|DRUG|topical spray on the cervix|one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
214394280|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T0|
214394281|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T1|
214394282|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T0|
214394283|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T1|
214394284|NCT02587689|BIOLOGICAL|anti-MUC1 CAR T Cells|
214394285|NCT01776684|DRUG|EGFR TKIs (gefitinib, erlotinib, afatinib, et al)|
214394286|NCT04830605|BEHAVIORAL|Internet-based treatment|The intervention is an internet-based psychotherapy treatment with eight modules based on acceptance and commitment therapy and with written therapist contact through eight weeks.
214394287|NCT01161693|DEVICE|TROOP® elevation pillow|Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
214394288|NCT01161693|DEVICE|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
214394289|NCT01161693|DEVICE|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
214394290|NCT01914978|OTHER|Food allergy handbook for parents|The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.
214394291|NCT01914978|OTHER|Food allergy treatment as usual|
214394292|NCT02340754|BEHAVIORAL|Mindfulness-based Stress Reduction|
214394293|NCT02340754|BEHAVIORAL|MS Education Control|
214394294|NCT03562455|OTHER|VRSim 3.0|VRSim 3.0 is a virtual reality training module.
214394295|NCT03562455|BEHAVIORAL|In-Person Wheelchair Training|A therapist will be used to train power wheelchair users.
214394296|NCT06545396|OTHER|Half-dose illumination protocol|Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 18,5J/cm2, with the illumination intensity being less than 200 mW/cm2.
214394297|NCT06545396|OTHER|Full-dose illumination protocol|Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 37J/cm2, with the illumination intensity being less than 200 mW/cm2.
214394298|NCT02571621|DEVICE|Combitube|Intubation with Combitube
214394299|NCT05765188|OTHER|loop electrosurgical excision procedure|A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.
214394300|NCT01219595|OTHER|Sweetened, dried cranberries|Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
214394301|NCT01219595|OTHER|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
214394302|NCT01219595|OTHER|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
214394303|NCT01219595|OTHER|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
214394304|NCT01219595|OTHER|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
214394305|NCT01219595|OTHER|Observation|Subjects in the non-UTI susceptible group will have one visit where one vaginal and one rectal swab will be collected.
214394306|NCT02343588|BEHAVIORAL|The Health Lifestyles Interventions|"1. Creating supportive school and family environment, whole intervention periods;~2. Health lifestyles educational strategies, 30min/week for education lessons and six times education activities;~3. Instruct and promote school physical education, whole intervention periods;~4. The monitoring and instruction of obesity related behaviors, once a week for physical activity and dietary behavioral log and once a month for parental monitor"
214394307|NCT01654237|OTHER|questionnaires|185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
215000500|NCT04709887|PROCEDURE|Tibial transverse transport surgery|In the anteromedial area of the proximal tibia of the affected limb, the external fixation frame was compared with the area along the midline of the medial longitudinal axis of the proximal tibia. Subsequently, two 3.0 Steinmann pins were inserted through the single layer of cortical bone. The skin was cut along the long axis with the 3.0 Steinmann pin as the centre, and the subcutaneous tissue was separate bluntly to expose the periosteum. The Steinmann pins were used as the centre point for the drilling on four sides with a 2.0 drill bit and use of a rapid osteotomy device; the length of each side was 2.5 cm. Subperiosteal osteotomy was performed with a 5-mm narrow bone knife at an angle of 15°-30° to the bone surface. The surgeons should pay attention to protect the blood supply of the periosteum during this procedure. The external fixators were fixed with 4.0 Steinmann pins at the distal and proximal ends. The subcutaneous tissue and skin were sutured.
215000501|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
215000502|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
215000503|NCT02210754|OTHER|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
215000504|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
215000505|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
215000506|NCT02210754|OTHER|Marlboro Cigarette|cigarettes
215000507|NCT04681872|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
215000508|NCT04681872|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
215000509|NCT04681872|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus
215000510|NCT00084253|DRUG|Atazanavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
215000511|NCT00084253|DRUG|Atazanavir-Ritonavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD\*, Once daily, 96 weeks.
215000512|NCT01626716|OTHER|care management|patients who assigned to the intervention group will take 7 times phone calls from case manager
215000513|NCT06403059|DIAGNOSTIC_TEST|Cervical Length|trans vaginal ultrasound
215000514|NCT06403059|DIAGNOSTIC_TEST|Uterocervical Angle|by trans vaginal ultrasound
214394308|NCT01101139|DRUG|Sugammadex|Sugammadex (single intravenous injection 0.25 mg/kg)
214394309|NCT01101139|DRUG|Placebo|Placebo: single intravenous injection Saline 0.9%
214394310|NCT01426490|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C, 100 mg/d
214394311|NCT01426490|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6, 50mg/d
214394312|NCT01426490|DIETARY_SUPPLEMENT|Folic acid|Folic acid 400 microgram/d
214394313|NCT01426490|DIETARY_SUPPLEMENT|Vitamin B6 plus folic acid|Vitamin B6, 50 mg; folic acid, 400 microgram
214394314|NCT00158522|DRUG|pegylated interferon alpha2a|
215000515|NCT03606824|DRUG|Pitavastatin and placebo|The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.
214394315|NCT04454905|DRUG|Camrelizumab|Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
215094776|NCT05873855|BEHAVIORAL|Waitlist Control Para ti, para mi, para nosotros (P3)|From day 91 to day 180 (i.e., starting after 3-month assessment) of the pilot trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
214394316|NCT04454905|DRUG|Apatinib|Apatinib is a novel angiogenesis inhibitor vascular endothelial growth factor 2.
214394317|NCT04980716|DRUG|"Multiple cardiovascular drugs related to Golden Triangle"|Based on impedance cardiography results at each timepoints, cardiovascular drug treatment and exercise plan will be given in the intervention group.
214394318|NCT01555021|GENETIC|Genotyping assays|"Patients will provide blood samples at the beginning of the study. If the patient is in the AGT group (as opposed to the TAU group), their blood samples will be sent for genotyping immediately. AGT psychiatrists will be given the results of genotyping within 3-5 days in order to decide which antidepressants to use long-term and at what doses. Patients in the Treatment as Usual group will have their blood samples stored for future analysis. Both groups will provide saliva samples for GWAS analysis at a alter date; however, since the study was terminated early, GWAS testing for both groups and genotyping for the TAU group were not performed.~Patients will receive questionnaires to measure their mood, side effects, and symptoms.~Patients will be asked to participate in 3 follow-up phone calls (1 month, 3 months, and 6 months) to measure their mood."
215000516|NCT03606824|DRUG|Pitavastatin and levothyroxine|The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
215000517|NCT01614418|DEVICE|Endoscopic radiofrequency ablation catheter|Endoscopic radiofrequency ablation
215000518|NCT06231121|DRUG|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
215000519|NCT02807090|OTHER|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
215000520|NCT02807090|OTHER|Circular dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
215000521|NCT04168489|DEVICE|active rTMS|(rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.
215000522|NCT04168489|DEVICE|sham rTMS|The sham rTMS is inactive and similar to placebo effect.
215094777|NCT04236791|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
215094778|NCT04236791|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
215094779|NCT05469139|DIAGNOSTIC_TEST|Portable MRI acquisition|Patients on ECMO will undergo a portable MRI of the brain
215094780|NCT01306656|DRUG|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week"
215094781|NCT01306656|OTHER|Placebo|"Month 1: Placebo once a week~Months 2-6: Placebo once a week"
215094782|NCT01306656|DIETARY_SUPPLEMENT|Vitamin D|Daily multivitamin with 400 IU vitamin D.
215094783|NCT05010447|DEVICE|Virtual Coach App|The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
215094784|NCT03057080|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
215000523|NCT00687518|DRUG|Erythropoietin|Intravenous injection of 50 U/kg of erythropoietin
215000524|NCT00687518|DRUG|Placebo|Intravenous injection of equivalent volume of saline serum
215000525|NCT00358514|DEVICE|Continuous Compartment Pressure Monitoring|See Detailed Description.
215094785|NCT00331188|DRUG|Sanvar® (vapreotide)|
215094786|NCT04806802|DEVICE|APIOC Sphere and APIOC Astigmatism|Single Vision Contact Lenses
215094787|NCT00017290|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
215094788|NCT00017290|BIOLOGICAL|keyhole limpet hemocyanin|
215094789|NCT00017290|BIOLOGICAL|sargramostim|
215094790|NCT00017290|DRUG|cyclophosphamide|
215094791|NCT00017290|DRUG|prednisone|
215094792|NCT00017290|DRUG|vincristine sulfate|
214394319|NCT01366651|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to \<1 year of age.
214394320|NCT01366651|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients \<12 weeks of age.
214394321|NCT06339151|DRUG|Dexamethasone before surgery|Dexamethasone 0.15 mg/kg IV before surgery
214394322|NCT06339151|DRUG|Dexamethasone before and 12 hours after surgery|Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 12 hours post operation
214394323|NCT06339151|DRUG|Dexamethasone before and 24 hours after surgery|Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 24 hours post operation
214394324|NCT01191684|OTHER|laboratory biomarker analysis|Correlative studies
214394325|NCT01191684|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214394326|NCT01191684|OTHER|flow cytometry|Correlative studies
214394327|NCT01191684|OTHER|immunoenzyme technique|Correlative studies
214394328|NCT01191684|BIOLOGICAL|modified vaccinia virus ankara vaccine expressing p53|Given SC
214394329|NCT04093141|PROCEDURE|IRE|in situ irreversible electroporation
214394330|NCT01448525|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
214394331|NCT01448525|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
214394332|NCT03875911|DRUG|Mitomycin C|Three delivery methods of Mitomycin-C in Trabeculectomy
214394333|NCT02117674|PROCEDURE|standard forward-viewing colonoscopy|examination of the colon with a conventional colonoscope
214394334|NCT02117674|PROCEDURE|full-spectrum colonoscopy|examination of the colon with full-spectrum colonoscope
214394335|NCT02117674|PROCEDURE|right colon retroflexion|examination of the right colon with scope retroflexion (both with conventional and fuse scope)
214394336|NCT03519698|OTHER|Warm water|Footbaths were prepared with 12 liters of warm water (40 °C)
214394337|NCT03519698|OTHER|Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour (Sinapis nigrea semen plv.)
215000526|NCT05372770|DEVICE|Flourish Vaginal Care system|Flourish includes Restore® vaginal moisturizing gel, a Class II medical device cleared by the FDA, in addition to two other kit components
215000527|NCT04519775|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
215000528|NCT02826473|OTHER|BRAINCHECK|Subjects of the Intervention-Group will undergo a brief cognitive assessment, using the BRAINCHECK, during hospital admission assessments. Subjects with positive results will then be referred to a Memory Clinic undergoing subsequent interdisciplinary comprehensive diagnostic examinations. Patients with established diagnosis will be invited to counselling services of the Alzheimer Association (providing social counselling).
215094793|NCT03086902|DEVICE|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
215094794|NCT03086902|DEVICE|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
214394338|NCT03519698|OTHER|Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour (Zingiberis rhizoma plv.)
214394339|NCT00119119|DRUG|pentoxyphilline|
214394340|NCT00119119|DRUG|tocopherol|
214394341|NCT01121718|DRUG|ICG Intervention|NIR-guided sentinel lymph node mapping with indocyanine green (ICG)
214394342|NCT02343575|DRUG|Valproic Acid|"1\.~Start:~VPA PO/NGT 500 mg BID~2\.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3\.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4.If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS"
214394343|NCT02343575|DRUG|Placebo|Placebo 500 mg matched to VPA BID PO/NGT
214394344|NCT02343575|DRUG|Haloperidol|Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
214394345|NCT02374190|OTHER|Standard Hospital Care|We described patient characteristics using percentages for categorical data, means and SD or medians and IQRs for normally and non-normally distributed continuous variables, respectively. Statistical comparisons for differences in baseline characteristics among patients admitted during regular hours and off-hours were performed using χ2 tests for categorical variables, t-tests and Wilcoxon rank sum tests for normally and non-normally distributed continuous variables, respectively. DTB times were described using median and IQR based on time of admission. All p values were calculated as two-tailed analyses, using a significance level of 5%.
214394346|NCT00750893|BIOLOGICAL|Rotarix or Rotarix liquid formulation|GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine (oral suspension or prefilled syringe).
214394347|NCT03824938|DRUG|Aspirin 650mg Oral Capsule|A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
214394348|NCT03824938|DRUG|Acetaminophen Tablet 650mg|A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
214394349|NCT03824938|OTHER|Placebo|A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
214394350|NCT05480033|BEHAVIORAL|Imagery Technique|The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
214394351|NCT03885856|OTHER|single row repair technique|single row repair technique
214394352|NCT03885856|OTHER|double row repair technique|double row repair technique
214394353|NCT03498326|DRUG|Gemcitabine|One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.
214394354|NCT03498326|DRUG|Gemcitabine|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.
214394355|NCT05126459|COMBINATION_PRODUCT|Regimen 1|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg) In combination with oral drugs stated above, administeration via inhalation of Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
215000529|NCT00083278|DRUG|MDX-010|
215000530|NCT01177176|OTHER|Extended Care Management|Telephone-based care management of tobacco cessation for 3 months after hospital discharge that features 2 innovations: (1) to increase medication use, smokers receive a free refillable 30-day sample of their choice of FDA-approved smoking cessation medication (nicotine replacement, bupropion, or varenicline) at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers seeking or most likely to benefit from continued counseling after hospital discharge.
215000531|NCT01177176|OTHER|Standard Care|Usual care provided to hospitalized smokers during their inpatient stay, with no post-discharge care management plan
215000532|NCT05992727|DIAGNOSTIC_TEST|Galectin 3 measurement in serum and saliva by ELIZA|Galectin 3 measurement in serum and saliva by ELISA in the two groups
215000533|NCT02886663|OTHER|stimulation of the blind visual field|
215000534|NCT00742677|PROCEDURE|nutritional support|Given orally
215000535|NCT00177671|DRUG|Escitalopram|Escitalopram, 10mg to 20mg daily.
215000536|NCT00177671|DRUG|Donepezil|Donepezil, 5mg to 10mg daily.
215000537|NCT00177671|DRUG|Venlafaxine|Venlafaxine, 150mg to 300mg daily.
215000538|NCT00177671|DRUG|Placebo|
215000539|NCT00177671|DRUG|Duloxetine|
215000540|NCT04462679|OTHER|COMMIT mHealth application|We will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and youth living with HIV (YLWH).The tool will be used by community CHWs in Achham, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
215000541|NCT04410822|OTHER|Clinical tests|Semi-qualitative interviews and questionnaire FITAS
214394356|NCT05126459|COMBINATION_PRODUCT|Regimen #2|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Meperidine (1.5 -2 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
215000542|NCT01644929|PROCEDURE|transcranial direct current stimulation (tDCS)|Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
215000543|NCT01644929|PROCEDURE|Sham stimulation, then tDCS|Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks
215000544|NCT01644929|PROCEDURE|Sham stimulation|Sham stimulation for 30 seconds on 15 days during 6 weeks
215000545|NCT02852083|DRUG|Pioglitazone|Pioglitazone 25 mg once daily, p.o.
215000546|NCT02852083|DRUG|nivolumab|3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
215094795|NCT03846609|DEVICE|double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is used for removal of colonic polyp
214522591|NCT00658801|RADIATION|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:~1. Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.~2. Group 2: 5cm \<Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
214522592|NCT00796640|DRUG|ER Paliperidone|
214522593|NCT01878188|DRUG|BC-819/PEI|Intravesical instillation
215000547|NCT02852083|DRUG|Treosulfan|Treosulfan 250 mg twice daily, p.o.
215094796|NCT03846609|DEVICE|no double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is not used for removal of colonic polyp
215094797|NCT00299117|BEHAVIORAL|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
215094798|NCT05265897|OTHER|CAQ|Informational document
214394357|NCT05126459|COMBINATION_PRODUCT|Regimen #3|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Midazolam (0.5- 0.75 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
214394358|NCT01304043|DRUG|chemotherapies protocols|Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
214394359|NCT04874064|OTHER|Liquid Biopsy|Blood collection and access to residual tumor.
214394360|NCT01196130|BEHAVIORAL|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
214522594|NCT01878188|DRUG|BCG Vaccine|intravesical instillations
215000548|NCT02852083|DRUG|Clarithromycin|Clarithromycin 250 mg twice daily p.o.
215000549|NCT01723059|DRUG|Standard Triple Therapy|for 10 days
215000550|NCT01723059|DRUG|Sequential Therapy|total 10 days
215000551|NCT01323218|DRUG|25 OH vitamin D|After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
215000552|NCT05861271|DRUG|Capecitabine，Pyrotinib|Pyrotinib and Capecitabine for half a year
215000553|NCT00475046|BEHAVIORAL|Motivational Interviewing|
215000554|NCT05389696|DRUG|Single subcutaneous administration and Blood collection|Single subcutaneous administration and Blood collection
215000555|NCT05389696|DRUG|Single subcutaneous administration and then IV injection.|Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.
215000556|NCT05389696|DRUG|MIT-001 20mg and 40mg_Multiple administration|Multiple subcutaneous administration for 7 days and then blood collection
214394361|NCT01196130|OTHER|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
214394362|NCT02420327|DRUG|Placebo patch & placebo capsule|On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
214394363|NCT02420327|DRUG|Placebo patch & galantamine capsule|On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
214394364|NCT02420327|DRUG|Nicotine patch & placebo capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
214394365|NCT02420327|DRUG|Nicotine patch and galantamine capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
214394366|NCT03600038|BEHAVIORAL|Experimental smoking cessation smartphone app|The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.
214394367|NCT03600038|BEHAVIORAL|Standard of care smoking cessation smartphone app|The control intervention uses a standard of care smartphone smoking cessation app.
214394368|NCT01467258|DRUG|Amantadine|Single dose
214394369|NCT05280847|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
214394370|NCT01674595|BIOLOGICAL|AVANZ olea|Immunotherapy Olea europaea
214394371|NCT05853757|DRUG|Zzowin Nutra Tablet|1 Tablet daily half an hour before going to bed
214394372|NCT06062576|DRUG|Yunnan Baiyao|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
215000557|NCT03947034|DRUG|Drugs inducing hyperammonemia|Drugs susceptible to induce metabolic toxicities such as hyperammonemia
215000558|NCT02293499|BEHAVIORAL|PLASMA|"A structured asthma self-management manual (Let's Talk about Asthma \[LTAA\],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site."
215000559|NCT00690898|DRUG|Lanreotide autogel 120 mg|12 months
215094799|NCT00278616|BIOLOGICAL|Stem Cell Transplantation|Autologous Stem Cell Transplantation
215094800|NCT00005949|BIOLOGICAL|aldesleukin|Given SC
215094801|NCT00005949|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|Given SC
215094802|NCT00005949|OTHER|laboratory biomarker analysis|Correlative studies
215094803|NCT03105349|DRUG|elbasvir/grazoprevir|16 weeks treatment
215094804|NCT03105349|DRUG|Sofosbuvir|16 weeks treatment
215094805|NCT03105349|DRUG|Ribavirin|16 weeks treatment
215094806|NCT06011369|PROCEDURE|Fluorescence in thyroid surgery|Fluorescence in thyroid surgery
215094807|NCT05310812|DIAGNOSTIC_TEST|Biochemical evaluation.|Blood will be taken for biochemical evaluation-ELISA.
215094808|NCT05014997|OTHER|no intervention|this study was designed as retrospective observational study
215094809|NCT02353195|OTHER|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
215094810|NCT01286077|DRUG|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
214394373|NCT00004736|DRUG|Nelfinavir mesylate|
214394374|NCT00004736|DRUG|Ethambutol hydrochloride|
214394375|NCT00004736|DRUG|Isoniazid|
214394376|NCT00004736|DRUG|Pyrazinamide|
214394377|NCT00004736|DRUG|Lamivudine|
214394378|NCT00004736|DRUG|Rifabutin|
214394379|NCT00004736|DRUG|Stavudine|
214394380|NCT00004736|DRUG|Zidovudine|
214394381|NCT00614198|OTHER|Gluten- and casein-free diet|Removal of foods containing gluten (cereal produce) and casein (dairy produce)
214394382|NCT01381744|BIOLOGICAL|Flagellin/F1/V|Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.
214394383|NCT01381744|OTHER|Placebo|Phosphate buffered saline (PBS) used as diluent and placebo.
214394384|NCT04517370|DEVICE|Fractional/Pixel CO2 laser|"The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation)."
214394385|NCT05690789|OTHER|No treatment given|No treatment given
214394386|NCT04048252|OTHER|Focus group creation|Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention
214394387|NCT04048252|OTHER|Workshop|Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
214394388|NCT02088775|PROCEDURE|PET scan|Undergo PET-CT scan
214394389|NCT02088775|PROCEDURE|CT Scan|Undergo PET-CT scan
214394390|NCT02088775|PROCEDURE|hepatic artery embolization|Undergo standard radioembolization
214394391|NCT05011916|DRUG|KDR2-2 suspension eye drops|All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.
214394392|NCT00827151|DRUG|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
214394393|NCT02578225|OTHER|Non interventional study|
214394394|NCT03741205|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
214394395|NCT02666586|OTHER|Faba bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder (300g).
214394396|NCT02666586|OTHER|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
214394397|NCT02666586|OTHER|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
214394398|NCT02666586|OTHER|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
214394399|NCT02666586|OTHER|Non-pulse smoothie smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
214394400|NCT01169181|DEVICE|AMES + brain stimulation|Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.
214394401|NCT00065468|DRUG|Interferon Alfa|Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
215000560|NCT05783973|DIAGNOSTIC_TEST|Next generation sequencing|Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.
215000561|NCT05732545|BEHAVIORAL|enteral nutrition program for patients with abdominal hypertension guided by abdominal pressure|There are 4 aspects of intra-abdominal pressure monitoring, source control and treatment for the etiology of increased abdominal pressure, enteral nutrition program, enteral nutrition tolerance evaluation and treatment
215000562|NCT03483753|DRUG|Vasopressin|"Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.~Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min"
215000563|NCT03483753|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.
215000564|NCT06398288|OTHER|Dermal matrix (Oracell, LifeNet, USA)|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health) + dermal matrix on the buccal aspect (Oracell, Lifenet Health)
215000565|NCT06398288|OTHER|No dermal matrix|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health)
215000566|NCT03527602|PROCEDURE|Foraminal enlargement|After determining the working length, a rotary file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
214394402|NCT00065468|DRUG|CCI-779|25 mg of CCI-779 given Intra Venously once per week
214394403|NCT00065468|DRUG|Interferon Alfa and CCI-779|15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
214394404|NCT01874574|DRUG|Hylan G-F 20|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
214394405|NCT01874574|DRUG|Corticosteroid|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
214394406|NCT03309124|OTHER|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
214394407|NCT03309124|OTHER|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
214394408|NCT03309124|OTHER|Mashed potatoes|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
214394409|NCT03309124|OTHER|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
214394410|NCT03309124|OTHER|Meal skipping|No food given
214394411|NCT01225835|DRUG|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
214394412|NCT01225835|DRUG|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
214394413|NCT01225835|DRUG|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
214394414|NCT01225835|DRUG|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles \>+17 mm diameter as shown by pelvic ultrasound examination.
214394415|NCT01225835|DRUG|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
214394416|NCT05315830|BIOLOGICAL|HER2 Tumor Vaccine|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28
214693797|NCT05690334|DRUG|Crystalloid - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
215000567|NCT01360476|DIETARY_SUPPLEMENT|cholecalciferol (Vitamin D)|50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
214394417|NCT05315830|BIOLOGICAL|HER2 Tumor Vaccine+ Standard of Care chemotherapy|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28 Standard of Care Chemotherapy cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle) or other standard of care chemotherapy
214394418|NCT04745104|DRUG|SHR-1707|SHR-1707 will be administered through IV infusion
214394419|NCT04745104|DRUG|Placebo|Placebo will be administered through IV infusion
214394420|NCT03085550|PROCEDURE|Fat grafting|Single treatment fat grafting infiltrated into diabetic ulcer wound
215000568|NCT01360476|DIETARY_SUPPLEMENT|Placebo|chewable wafer every 2 weeks for 52 weeks (27 total doses)
215000569|NCT00782093|DRUG|volociximab|volociximab intravitreal injection
214394421|NCT03085550|PROCEDURE|Fat grafting + platelet rich plasma|Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
215000570|NCT05285449|DIETARY_SUPPLEMENT|Cannabidiol (CBD) powder formulation|30 mg CBD in the form of 300 mg of 10% CBD isolate
215000571|NCT05285449|DIETARY_SUPPLEMENT|Matching Placebo Cannabidiol (CBD) powder formulation|Matching Placebo
215000572|NCT00417222|DRUG|olmesartan medoxomil|5 to 40mg P.O. daily until the end of the study
215000573|NCT05139147|DEVICE|DAISe Thrombectomy System|DAISe Thrombectomy System for mechanical thrombectomy
215000574|NCT03118882|BEHAVIORAL|Diet group|A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.
215000575|NCT03118882|BEHAVIORAL|Physical activity group|A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.
215000576|NCT03118882|BEHAVIORAL|Physical activity and diet group|A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
215000577|NCT05259215|OTHER|physiotherapy|Standard usual care physiotherapy after stroke
215000578|NCT05370326|OTHER|Enhanced Opioid Stewardship Program|The goal of the enhanced opioid stewardship intervention is to manage chronic pain while reducing risk of inappropriate/risky opioid use and preventing harms of opioid use.
215000579|NCT04320537|OTHER|abstinence from use of marijuana and other abused drugs|abstinence from use of marijuana use and other abused drugs
215000580|NCT06461884|OTHER|Percussions|Group A: Percussions and diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
215000581|NCT06461884|OTHER|, Diaphragmatic breathing exercise|Group B: Diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
215000582|NCT01369303|DRUG|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
215000583|NCT03138681|DRUG|Placebo|placebo is given intravenously twice a day for 14 days
215000584|NCT03138681|DRUG|ATP|ATP (100mg) is given intravenously twice a day for 14 days
214394422|NCT00307099|DRUG|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
214394423|NCT00307099|DRUG|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
215000585|NCT03138681|DRUG|Phosphocreatine|Phosphocreatine (1g) is given intravenously twice a day for 14 days
214394424|NCT04349410|DRUG|Hydroxychloroquine, Azithromycin|FMTVDM Planar, SPECT, PET
214394425|NCT04349410|DRUG|Hydroxychloroquine, Doxycycline|FMTVDM Planar, SPECT, PET
214394426|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin|FMTVDM Planar, SPECT, PET
214394427|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin, Primaquine - low dose.|FMTVDM Planar, SPECT, PET
214394428|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin, Primaquine - high dose.|FMTVDM Planar, SPECT, PET
214394429|NCT04349410|DRUG|Remdesivir|FMTVDM Planar, SPECT, PET
214394430|NCT04349410|DRUG|Tocilizumab|FMTVDM Planar, SPECT, PET
214394431|NCT04349410|DRUG|Methylprednisolone|FMTVDM Planar, SPECT, PET
215000586|NCT06005376|OTHER|Breakfast rolls consisting of wheat flour with and without a E304i/zinc additive|The participants were provided with two Breakfast rolls (a 40 g) a day during the intervention week. In addition, they were provided with gluten-free foods during the whole trial.
215000587|NCT03877809|DRUG|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
215000588|NCT05447832|DEVICE|Lung function monitoring equipment at home - 2 weeks|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once daily for 2 weeks.
215000589|NCT05447832|DEVICE|Lung function monitoring equipment at home - 4 months|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once weekly for 4 months.
214394432|NCT04349410|DRUG|Interferon-Alpha2B|FMTVDM Planar, SPECT, PET
214394433|NCT04349410|DRUG|Losartan|FMTVDM Planar, SPECT, PET
214394434|NCT04349410|DRUG|Convalescent Serum|FMTVDM Planar, SPECT, PET
214394435|NCT01479491|OTHER|Data collection|Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
214394436|NCT02589392|OTHER|Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash|
214394437|NCT02589392|OTHER|Cetaphil® Restoraderm® body wash|
214394438|NCT04280471|DRUG|Fecal Microbiota Transplantation Capsule|Receive OpenBiome FMT Capsule DE PO
214394439|NCT04676009|OTHER|Exercise arm :|"Patients will receive physical activity recommendations at inclusion.~At each treatment cure, patients will receive pre-exercise nutritional recommendations and an acute physical exercise prior to immunotherapy and chemotherapy. The acute physical exercise will last 35 minutes and will be intermittent and individualized based on the results obtained by the patient during an endurance test on a ergocyle performed prior to treatment.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3).~A nutritional assessment will be carried out during the first and last treatment cure.~They will also benefit a home walking program. These patients will have to wear an activity tracker tracker during all intervention (3 months).~They will have a phone follow-up every 10 days (± 3 days) after each treatment cure for the study duration."
214394440|NCT02965144|OTHER|no treatment|no treatment
214394441|NCT05987618|DEVICE|Oral appliance with elastic bands|"The elastic bands are attached to hooks on both the upper and lower appliance, and on both sides. The elastic bands will be carefully selected not to interfere with retention of the oral appliance. The strongest elastic bands that do not interfere with retention of the oral appliance will be chosen, probably within the range of 85-170 grams (3/8 - 3/16)."
214394442|NCT05987618|DEVICE|Oral appliance without elastic bands|The oral appliance without the elastic bands.
214394443|NCT03299062|DIAGNOSTIC_TEST|Cytology and Immunohistochemistry|Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
214394444|NCT03978026|BEHAVIORAL|Nap|Each participant is compared to himself in 4 conditions,
214394445|NCT03572829|DRUG|Aprepitant|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1. AND then patients received aprepitant 80mg, dexamethasone 8mg on day 2-5 at every chemotherapy cycle.
214394446|NCT01566786|DRUG|activated recombinant human factor VII|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
214394447|NCT01566786|DRUG|placebo|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
214693798|NCT05690334|DRUG|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
215000590|NCT05447832|DIAGNOSTIC_TEST|Inflammation and remodelling from clinical indicted bronchoscopy|For patients who are undergoing clinically indicated bronchoscopy, consent will be obtained to use any surplus clinical samples for this study. The samples to be collected are broncho-alveolar lavage and endobronchial biopsies. Both of these are taken from the airways during clinical bronchoscopy.
215000591|NCT00025142|DRUG|FOLFOX regimen|
215000592|NCT00025142|DRUG|fluorouracil|
214394448|NCT02938936|OTHER|Pre-natal visit scheduling|This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
214394449|NCT01141335|DEVICE|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using a polypropylene mesh will be fixed by sutures in Polypropylene 2/0.
214394450|NCT01141335|DEVICE|Infinit® PTFE mesh (WL Gore)|A Lichtenstein tension-free hernioplasty is performed using a PTFE mesh will be fixed by sutures in PTFE 2/0.
214394451|NCT05515679|BEHAVIORAL|The BRAIN App|The BRAIN App will be the first-ever artificial intelligence enabled cognitive stimulation therapy app, specifically designed for PWD. The goal of the app is to foster positive relationships between the care triad.
215000593|NCT00025142|DRUG|gefitinib|
215000594|NCT00025142|DRUG|leucovorin calcium|
215000595|NCT00025142|DRUG|oxaliplatin|
215094811|NCT02908789|RADIATION|Antimicrobial photodynamic therapy (aPDT)|Selective caries removal + Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms + tooth restauration
215094812|NCT02908789|OTHER|Without Antimicrobial phothodynamic therapy|Selective caries removal + tooth restauration
215094813|NCT00136552|DRUG|rituximab|
215000596|NCT03307850|OTHER|Observation During Exercise and Stress|"Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study."
215000597|NCT05181722|OTHER|Patient navigator support|Support of a patient navigator for patients who have experienced an abnormal screening mammogram
215000598|NCT01847209|PROCEDURE|Video-Assisted Thoracic Surgery (VATS) wedge resection|
214394452|NCT01579617|BEHAVIORAL|BUtiful.|8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.
214394453|NCT01579617|BEHAVIORAL|DIVAS.|Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
214394454|NCT00274170|DRUG|Octreotide|
214394455|NCT02522338|DRUG|iohexol|10 ml de l'iohexol (300 mgI/ml)
214394456|NCT04509830|OTHER|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator
214394457|NCT04509830|OTHER|quadriceps strengthening, stretch hamstring,cuff muscles|multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch
214394458|NCT02989363|PROCEDURE|Device O-Arm in DBS|Deep brain stimulation surgeries with device O-Arm
214394459|NCT02989363|PROCEDURE|Device O-Arm in RAQUIS|Complex back surgeries with the device O-Arm
214394460|NCT02989363|PROCEDURE|Not device O-Arm in DBS|Deep brain stimulation surgeries without the device O-Arm
214394461|NCT02989363|PROCEDURE|Not device O-Arm in RAQUIS|Complex back surgeries without the device O-Arm
214394462|NCT03509376|PROCEDURE|Suture repair|The diastasis is repaired with continous nylon suture
214394463|NCT03509376|PROCEDURE|Rolled mesh repair|Continuous nylon suture is done over a narrow strip of self gripping Rolled mesh to repair the diastasis
214394464|NCT01187290|RADIATION|neoadjuvant chemoradiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
214394465|NCT03360279|DEVICE|Regular balloon|Randomization: to use regular balloon to treat stent graft restenosis
215000599|NCT02880176|OTHER|Financial Incentive to Increase Ambulation|Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
215000600|NCT03956706|RADIATION|Stereotactic Radiosurgery|Stereotactic radiosurgery dose escalation by either 18, 20, or 22 Gy to the subventricular zone in addition to standard of care
215000601|NCT02606305|DRUG|Mirvetuximab soravtansine|
215000602|NCT02606305|DRUG|Bevacizumab|
215000603|NCT02606305|DRUG|Carboplatin|
215000604|NCT02606305|DRUG|Pegylated Liposomal Doxorubicin|
215000605|NCT02606305|DRUG|Pembrolizumab|
215000606|NCT00984945|BIOLOGICAL|H5 VLP pandemic influenza vaccine 5 µg|0.5 mL, IM, 2 injections 21 days apart
215000607|NCT00984945|BIOLOGICAL|H5 VLP pandemic influenza vaccine 10 µg|0.5 mL, IM, 2 injections 21 days apart
215094814|NCT00172341|DRUG|Staloral TM|
215094815|NCT02331498|DRUG|Pazopanib|Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
215094816|NCT02237638|BIOLOGICAL|hVEGF26-104/RFASE|Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
215094817|NCT05476523|OTHER|NeuraLight|NeuraLight is an investigational software-based platform used for measuring eye movements in response to visual stimuli and captured using a simple webcam
214394466|NCT03360279|DEVICE|DCB (paclitaxel-coated balloon)|Randomization: to use DCB (paclitaxel-coated balloon, Ranger, Boston-Scientific) to treat stent graft restenosis. The paclitaxel dose is 2 ug/mm2 delivered with the Ranger drug-coated balloon.
214394467|NCT05239871|DIAGNOSTIC_TEST|Ultrasound|Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.
214394468|NCT05287334|DEVICE|Electrical impedance tomography measurement|During standard blood donation, donors' chest bioimpedance will be measured using electrical impedance tomography.
214394469|NCT02829710|BEHAVIORAL|Nurse-driven sedation protocol|The nurse-driven sedation protocol included the COMFORT-B scale. Initial doses were chosen by the physicians then all changes were made by the nurses with the aim of attaining an optimal range of analgesia and sedation, which was defined as values from 11 to 17 on the COMFORT-B score.
214394470|NCT00807027|DRUG|Activated T lymphocyte(Immuncell-LC)|"Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109\~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)"
214394471|NCT02207374|DRUG|semaglutide|Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.
214394472|NCT02207374|DRUG|DPP-4 inhibitor|Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
214394473|NCT01040286|DRUG|Flurbiprofen|2.0 mg
214394474|NCT01040286|DRUG|Chlorhexidine|2.5mg
214394475|NCT02087150|DEVICE|Acclarent Eustachian Tube Balloon Catheter (ETBC)|
214394476|NCT00124774|PROCEDURE|Nucleoplasty|
214394477|NCT03862703|DEVICE|mHealth intervention, PTSD Help app.|Experimental group will receive the app, PTSD Help.
215000608|NCT00984945|BIOLOGICAL|H5 VLP pandemic influenza vaccine 20 µg|0.5 mL, IM, two injections 21 days apart
215000609|NCT00984945|BIOLOGICAL|Placebo|0.5 mL, IM, two injections 21 days apart
215000610|NCT00865605|DRUG|Halobetasol Propionate 0.05% Ointment, single exposure|A: Other Subjects received Alpharma/Purepac USHP formulated products
215000611|NCT00865605|DRUG|Ultravate® 0.05% ointment, single exposure|Subjects received Bristol-Myers Squibb Company formulated products
215000612|NCT01610193|PROCEDURE|Appendicectomy|Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
215000613|NCT01330927|DRUG|VA106483|"Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above"
215000614|NCT03233750|BEHAVIORAL|Stress Inoculation Training|see description in arm/group descriptions
214394478|NCT06395389|BEHAVIORAL|Health Education (HealthEdu)|The Health Education condition is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session focuses on providing in-depth information on good sleep hygiene and habits to improve sleep and information on positive eating habits, nutrition, and physical activity/functional exercise. The second session focuses on providing information about stress and social connection.
214394479|NCT06395389|BEHAVIORAL|Bloom|Bloom is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session encourages participants to ask themselves what is important to them. This discussion emphasizes identifying values and ways to live in line with their values, as well as why they use cannabis and providing personalized feedback related to their reasons for use. The second session asks participants to reflect on information from session one and consider what they would like to do next to live in line with their values.
214394480|NCT02763891|OTHER|Intervention group (Body body suspension and tilting exercises)|The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises. The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method. During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles. Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation. Each session lasts 30 minutes.
214394481|NCT02763891|OTHER|Control group (global muscle stretching)|Subjects receiving submitted a global muscle stretching session twice a week for eight weeks. During this period. All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
214394482|NCT00955006|BIOLOGICAL|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
214394483|NCT00955006|BIOLOGICAL|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
214394484|NCT02273505|DRUG|Asasantin (ER)|
214394485|NCT02273505|DRUG|Persantin|
214394486|NCT02273505|DRUG|Acetyl salicylic acid (ASA)|
214394487|NCT06130839|OTHER|Rocker board training|Then intervention will be applied to the perturbation group as mention below at Rocker board (50 x 45 cm).the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after8th week (pre, mid and post intervention). Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between.
214394488|NCT06130839|OTHER|Stable surface training|the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after 8th week (pre, mid and post intervention).
215094818|NCT01563016|DIETARY_SUPPLEMENT|glucose drink|participants will receive a drink rich in glucose
214394489|NCT02501135|PROCEDURE|Femoral nerve block with ropivacaine or bupivacaine|
214394490|NCT00688090|BIOLOGICAL|Biological: MKC1106-MT|Cancer Vaccine, Immunotherapy
214394491|NCT00688090|BIOLOGICAL|Biological: MKCC1106-MT|Cancer Vaccine, Immunotherapy
214394492|NCT04531072|DRUG|Artemether-lumefantrine|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
215000615|NCT03233750|BEHAVIORAL|Crisis Resource Management|During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
215000616|NCT03735576|BEHAVIORAL|Psychotherapy|15-session individually-delivered CBT specific for LLD in comparison with a supportive unspecific intervention (SUI) of the same quantity
215094819|NCT00015951|BIOLOGICAL|bevacizumab|
215094820|NCT00015951|DRUG|cytarabine|
215094821|NCT00015951|DRUG|mitoxantrone hydrochloride|
215094822|NCT02606357|DRUG|INSULIN GLARGINE|"Pharmaceutical form:Solution~Route of administration: Subcutaneous"
215094823|NCT00056446|DRUG|Vatalanib|
215094824|NCT01841255|DEVICE|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
215094825|NCT01841255|DEVICE|facemask|
215094826|NCT06453291|DRUG|NSAIDs (Nonsteroidal Anti-Inflammatory Drugs):|"Objective: To reduce pain and inflammation associated with chronic low back pain.~Medications: Ibuprofen, Naproxen, or Diclofenac.~Dosage:~Ibuprofen: 400-600 mg every 6-8 hours as needed. Naproxen: 250-500 mg twice daily as needed. Diclofenac: 50 mg three times daily as needed. Administration: Oral tablets. Duration: Daily use as prescribed, for the duration of the study. Monitoring: Regular follow-up visits to monitor pain levels, side effects, and adherence."
215000617|NCT03735576|DIAGNOSTIC_TEST|Questionnaires|There will be a total of four assessments (see primary \& secondary endpoints). The first visit of the study will be a screening and baseline (T0) visit. After the baseline assessment, the subjects will be randomized to either of the two treatment arms. Within one week, the first of the successive bi-weekly 50-minute individual face-to-face treatment sessions will be performed by a study therapist. After 7 therapy sessions, the primary and secondary outcomes will be obtained in week 5 (T1) by the blinded rater. This will be followed by the treatment sessions 8 to 15 which will be carried out by the therapist. End-of-treatment primary and secondary outcomes will be obtained in week 10 (T2). The final follow-up assessment (T3) will be performed 6 months after randomization by the blinded rater.
214394493|NCT04531072|DRUG|Atazanavir-ritonavir 300/100 mg|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
214394494|NCT04864041|OTHER|Evaluation of global longitudinal strain using routinely recorded echocardiography images|There are no particular intervention performed in patients in this study, because echocardiography is part of the standard of care of patients hospitalised in the ICU for vaso occlusive crisis.
214394495|NCT02342184|DRUG|GB-0998|
214394496|NCT01034241|DIETARY_SUPPLEMENT|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
214394497|NCT01034241|DIETARY_SUPPLEMENT|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
214394498|NCT01034241|DIETARY_SUPPLEMENT|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
214394499|NCT01034241|DIETARY_SUPPLEMENT|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
215000618|NCT03735576|OTHER|Magnetic Resonance Imaging|Underlying mechanisms are examined using neuroimaging. MRI data are acquired at four scanning sites and will be performed at baseline, end-of-treatment and follow-up to obtain a high-resolution structural T1-weighted image, a T2-weighted FLAIR image, a resting state fMRI, and diffusion tensor imaging (DTI) of the subjects' brain.
215000619|NCT03735576|OTHER|Blood analysis|Blood sampling will be acquired in order to investigate the underlying mechanisms in LLD and the specific effects of psychotherapy. Blood samples are acquired at five sites at baseline (T0), T1, T2 and T3 for genetic and epigenetic analyses, measurement of Amyloid-β, Neurofilament light chain (NFL), Peripheral Blood Mononuclear Cells (PBMCs), Metabolomics, Proteomics and miRNA analyses.
215000620|NCT04462146|BEHAVIORAL|Internet-based Self Applied Treatment Program|"It is a self-applied treatment for PGD through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is up to 8-10 weeks. A weekly support call will be made (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
215000621|NCT04462146|BEHAVIORAL|Videoconference treatment with a therapist|"It is a treatment for PGD applied by a therapist composed of 8-10 treatment sessions. Each session lasts approximately 60 minutes. No weekly support call will be provided.~The sessions will take place by videoconference. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention."
215000622|NCT04355273|DRUG|Heparin|heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
214394500|NCT01021163|DRUG|N-acetylcysteine, saline|Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
214394501|NCT04256590|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to measure the tongue surface areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue surface areas.
214394502|NCT06091618|PROCEDURE|new technique of ejaculatory preserving laser prostatectomy|"laser will be employed to preform vaporization. The ejaculatory preserving procedure will be done in the following steps:~Setting a mark cut 1 cm proximal of the verumontanum as orientation. Complete resection of the middle lobe to the abovementioned mark. Vaporization of lateral lobes to the capsule and the ventral side to the level of the verumontanum with avoidance of paracollicular digging.~Circular resection of the internal bladder neck. Apical resection utilizing the colliculus seminalis as a distal resection border and maintaining a 1cm safety area for preservation of ejaculation.~Total removal of prostate cuts and final check to confirm that there are no obstructive components."
214394503|NCT06091618|PROCEDURE|conventional technique of laser vaporization of the prostate|conventional laser vaporization of the prostate
215000623|NCT04355273|DRUG|Heparin|heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
215094827|NCT06453291|PROCEDURE|Standard Physical Therapy|"Objective: To improve mobility, strength, and reduce pain.~Techniques:~Stretching exercises. Strengthening exercises for core and back muscles. Manual therapy techniques. Postural training. Frequency: Twice a week sessions. Duration: 45-60 minutes per session. Monitoring: Progress will be assessed during each session and adjusted as necessary"
214394504|NCT01584830|DRUG|Regorafenib (BAY73-4506)|Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
214394505|NCT01584830|DRUG|Placebo|Placebo will be given 3 weeks on/1 week off (160 mg od po.)
214394506|NCT01857830|BEHAVIORAL|Meditation Retreat|The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
214394507|NCT01857830|BEHAVIORAL|Active Comparator Relaxation Group|Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
214394508|NCT06381362|PROCEDURE|Minimally invasive pancreatic surgery|Minimally invasive pancreatic surgery
214394509|NCT02372058|DEVICE|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
215000624|NCT04355273|DRUG|normal saline|normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
215000625|NCT06339840|DIETARY_SUPPLEMENT|Low-carbohydrate diet group|During the initial 8-week weight loss phase, participants will adopt a low-carbohydrate dietary pattern (with carbohydrate energy ratio of 20-30%, protein energy ratio of 30-40%, and fat energy ratio of 40-45%), with a caloric intake approximately 75% of their usual daily intake, but not less than 1200 kcal. Throughout the intervention period, participants will receive a daily nutritionally balanced meal replacement for 8 weeks to substitute for staple foods and control carbohydrate intake. Nutritionists will reinforce interventions by setting health goals, providing health education, implementing dietary and exercise interventions, and monitoring through a combined approach using a mobile platform. During the subsequent 4-week transition phase, participants' diets will gradually transition to a balanced dietary pattern (with carbohydrate energy ratio of 45-60%, protein energy ratio of 20-30%, and fat energy ratio of 20-25%) under the guidance of nutritionists.
215000626|NCT06339840|BEHAVIORAL|Health Education Group|Upon enrollment, nutritionists will provide lifestyle guidance to patients, including personalized adjustments such as limiting total energy intake to \<1600 kcal/day, adjusting macronutrient distribution to 45-55% for carbohydrates, 20-30% for fats, and 20-30% for protein. Participants are advised to accumulate at least 150 minutes of moderate-intensity aerobic exercise per week (achieving 50%-70% of maximum heart rate). At enrollment, nutritionists will educate participants on healthy lifestyle principles, train them on nutritional intervention tools, and assist in food selection for weight management planning. Throughout the intervention, nutritionists will conduct follow-ups with patients via phone or mobile platforms to monitor weekly dietary and exercise habits, weight changes, and address any participant concerns promptly.
215000627|NCT02008370|DRUG|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
214394510|NCT05449574|DIAGNOSTIC_TEST|Scale for the Assessment of Sensory Integration in Adults|In people with MS and people with health of similar age, a test was performed to assess sensory integration in adults
214394511|NCT00255697|PROCEDURE|psychosocial assessment and care|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
214394512|NCT00255697|PROCEDURE|quality-of-life assessment|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
214394513|NCT01952301|DEVICE|Xenogeneic Collagen Matrix|A type I and III porcine collagen matrix, as cleared by FDA (K012423)
214394514|NCT01952301|DEVICE|Free Gingival Graft|Autogenous, full-thickness soft tissue graft harvested from patient's palate.
214394515|NCT03049657|DEVICE|Angiolite|Percutaneous coronary intervention
215000628|NCT00601627|BIOLOGICAL|panitumumab|
215000629|NCT00601627|DRUG|capecitabine|
215000630|NCT00601627|DRUG|fluorouracil|
215000631|NCT00601627|DRUG|gemcitabine hydrochloride|
215000632|NCT00601627|RADIATION|radiation therapy|
215000633|NCT04999787|DRUG|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
215000634|NCT04999787|DRUG|Placebo|Placebo
215000635|NCT02479490|DRUG|Prednisone + Everolimus|"Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.~A treatment cycle consists of 28 days."
215000636|NCT02749734|PROCEDURE|Subretinal transplantation|Transplant hESC-RPE into subretinal space of patients with macular degeneration
215000637|NCT04884568|DEVICE|Exufiber|Wound dressed with Exufiber for up to 21 days.
215000638|NCT01858948|DRUG|Omega|Omega-3 supplements
215000639|NCT01858948|DRUG|Placebo|Similar in shape and color to Omega supplements
215000640|NCT01858948|DRUG|Quetiapine fumarate|Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
215000641|NCT03317496|DRUG|Avelumab 800 mg in combination with pemetrexed / carboplatin|Avelumab Pemetrexed Carboplatin
215000642|NCT03317496|DRUG|Avelumab 800 mg in combination with gemcitabine / cisplatin.|Avelumab Gemcitabine Cisplatin
215000643|NCT03317496|DRUG|Avelumab 1200 mg in combination with pemetrexed/carboplatin|Avelumab Pemetrexed Carboplatin
215000644|NCT03317496|DRUG|Avelumab 1200 mg in combination with gemcitabine/cisplatin|Avelumab Gemcitabine Cisplatin
215000645|NCT02737618|DEVICE|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
215000646|NCT00977418|BEHAVIORAL|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
215000647|NCT00977418|OTHER|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
214394516|NCT03049657|DEVICE|Xience|Percutaneous coronary intervention
214394517|NCT01482650|DEVICE|supraglottic airway placement and use|The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
214394518|NCT01642134|DRUG|aspirin+clopidogrel (Duoplavin)|100 mg aspirin ;75 mg clopidogrel 3º months
214394519|NCT05175482|OTHER|Virtual Education|health belief model based virtual education
215000648|NCT03568903|OTHER|Comprehensive physical therapy|Each session included exercises for posture, strength, range of motion, balance. In addition, different transfers and gait training was performed. Each session began with exercises in laying position (15 minutes), thereafter exercises in sitting were performed for 10 minutes. Then different exercises in standing position were performed for 15 minutes, followed by 10 minutes of gait training. 10 minutes of exercises for manual dexterity and upper limb function ended the session.
214394520|NCT03266341|DIAGNOSTIC_TEST|Cultures|Take different samples anddetection of anaerobes on enriched blood agar and other selective anaerobic cultures
214394521|NCT04406337|DEVICE|Low intensity pulsed ultrasound|Low intensity pulsed ultrasound therapy will use ultrasound with frequency of 1.5 MHz, power intensity of 30 mW/cm\^2 (0.03 W/cm\^2 ) and 20% duty cycle.
214394522|NCT04406337|DEVICE|High intensity continuous ultrasound|High intensity continuous ultrasound therapy will use ultrasound with frequency of 1 MHz, power intensity of 3 W/cm\^2 and 100% duty cycle.
214394523|NCT00972179|DRUG|Placebo|Administered by subcutaneous or intravenous injection.
214394524|NCT00972179|DRUG|Tezepelumab|Administered by subcutaneous or intravenous injection
214394525|NCT04166695|DEVICE|Monolithic / facially veneered zirconia fixed partial denture|Participant receives one monolithic / facially veneered zirconia fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
214394526|NCT04166695|DEVICE|Completely veneered CoCr fixed partial denture|Participant receives one completely veneered CoCr fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
214394527|NCT02054078|DRUG|Bevacizumab|Bevacizumab200mg by intrapleural administration
215000649|NCT00049829|DRUG|Zoledronic Acid|
215000650|NCT00620607|DRUG|huC242-DM4|dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks
215000651|NCT03014362|DEVICE|Neuronetics NeuroStar XPLOR magnetic stimulator - Active|"Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
215000652|NCT03014362|DEVICE|Neuronetics NeuroStar XPLOR magnetic stimulator - Sham|Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
215000653|NCT01007877|OTHER|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
215000654|NCT02716285|DRUG|Ileocolonic release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
215000655|NCT02716285|DRUG|Placebo|Placebo capsule, containing microcrystalline cellulose
215000656|NCT02716285|DRUG|Small intestinal release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
215000657|NCT00038415|BIOLOGICAL|CLL vaccine using DNA plasmid vector|
215000658|NCT05220735|DIETARY_SUPPLEMENT|Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA)|"3 three fish oil capsules providing 2.1 g n-3 PUFA; 1.27 g Docosahexanoic acid (DHA) and 0.86 g Eicosapentanoic acid (EPA) capsules.~The absorption study test meals will consist of white bread with butter and honey, 6mg of labeled iron as ferrous sulfate and 300 g of distilled water. The meal will be given on two days without and with ascorbic acid. The test meals without ascorbic acid will contain 6 mg 57Fe as ferrous sulfate whereas the meals containing ascorbic acid will contain 6 mg 58Fe as ferrous sulfate."
215000659|NCT00989027|DRUG|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
215000660|NCT00989027|DRUG|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
215000661|NCT00989027|DRUG|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
215000662|NCT00989027|DRUG|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
215094828|NCT06453291|PROCEDURE|Neuromodulation via Dorsal Root Ganglion (DRG):|"Objective: To modulate excitatory pathways and reduce pain through targeted stimulation.~Procedure:~Placement of electrodes near the DRG. Application of pulsed radiofrequency (RF) at 42°C for 3-20 minutes.~Frequency:~Initial treatment: Once a week for the first month. Maintenance: Monthly sessions if needed. Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels and functional improvement will be assessed before and after each session."
214394528|NCT02054078|DRUG|Pulvis talci|Pulvis talci 4g by intrapleural administration
214394529|NCT03906487|BEHAVIORAL|Assessment measures MINI, PCL5 and BDI-II and definition of 5 SDM|"This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing assessment measures called MINI, PCL-5, BDI-II ;~* the last to characterize the SDM by defining 5 personal memories"
214394530|NCT03906487|BEHAVIORAL|Assessment measures MINI and definition of 5 SDM|"This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing MINI questionary;~* the last to characterize the SDM by and defining 5 personal memories"
214394531|NCT00100139|DRUG|Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)|
214394532|NCT00100139|DRUG|Paclitaxel for injection (Taxol)|
214693799|NCT05690334|DRUG|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
215000663|NCT00989027|DRUG|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
215000664|NCT00817063|DRUG|alitretinoin|Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
214394533|NCT04610151|OTHER|guided imagery|Guided Imagery CD: A guided imagery CD was prepared by a web designer with the recommendations of the researcher to include relaxing, soft and slow-paced, mixed nature sounds and photographs towards reducing pain in lower extremity surgical operation patients. The directives used for guidance, the audio recordings created as a result of literature review and the video lasted for 13 minutes (
215000665|NCT00817063|DRUG|Placebo|Patients receive matching placebo for up to 24 weeks
215000666|NCT01773369|BEHAVIORAL|Early leg training|Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therapist in the clinical setting.
215000667|NCT01773369|BEHAVIORAL|Delayed leg training|The training activity will be exactly the same as the Early leg training group, except that it will occur \~3 months after recruitment.
215000668|NCT01773369|BEHAVIORAL|Parent leg training|Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
215000669|NCT01374737|DRUG|Dexmedetomidine|dexmedetomidine, 0.1ug/kg up or down
215000670|NCT06413407|BEHAVIORAL|Tai Chi Exercise|Tai Chi Exercise will be applied to this group.
215000671|NCT06413407|BEHAVIORAL|Receptive Music Therapy|Receptive Music Therapy will be applied to this group.
215000672|NCT06413407|BEHAVIORAL|Experimental|Tai Chi Exercise and Receptive Music Therapy techniques will be applied together to this group.
215000673|NCT04650620|DEVICE|Plenhyage® thin|0.75%
215000674|NCT04650620|DEVICE|Plenhyage® medium|2%
215000675|NCT04650620|DEVICE|Plenhyage® strong|2.5%
215000676|NCT02362451|BIOLOGICAL|Autologus elutriated monocyte placebo vaccine|20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
215000677|NCT02362451|BIOLOGICAL|Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine|20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
215000678|NCT03425370|PROCEDURE|Closure of surgical wounds using buried sutures or tissue adhesive on aesthetic outcome.|Effect of replacing buried sutures with tissue adhesive on aesthetic outcome of surgical wounds will be measured using the POSAS.
215000679|NCT03139201|DEVICE|OxyAqua|OxyAqua (olifilcon D) silicone hydrogel soft contact lens
215000680|NCT03139201|DEVICE|Si-Hy|Si-Hy (oliflcon B) silicone hydrogel soft contact lens
215000681|NCT06018168|OTHER|Skincare Routine|"Morning:~1\. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~1. VITAMINSCRUB - Wet your face with lukewarm water \& apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~2. CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~3. CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~4. HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face"
215000682|NCT06018168|DIETARY_SUPPLEMENT|MINDBODYSKIN Supplement|Participants will take 3 capsules daily with a meal. The MINDBODYSKIN acne supplement contains Vitamin A (6,100mcg per serving of 3 capsules), Vitamin B12, Vitamin B-5, 5-Hydroxytryptophan (5-HTP), 3,3'-Diindolymethane (DIM), a proprietary liver blend of milk thistle, dandelion extract and L-glutathione, turmeric root extract, a proprietary digestive blend of protease and betaine hydrochloride, and silicon dioxide.
215000683|NCT00308776|PROCEDURE|Cholecystokinin (CCK) infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.
214394534|NCT03810079|DEVICE|Anodal transcranial direct current stimulation|Neuromodulation of bilateral prefrontal areas using 2 mA tDCS delivered during 20 minutes via sponge electrodes on the scalp
215000684|NCT00308776|PROCEDURE|Saline infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.
215000685|NCT04324320|DIAGNOSTIC_TEST|medical assessment|"medical assessment includes the collection of~* sociodemographic data~* anthropometric data (weight, height, body mass index)~* medical data~* psycho-oncologic basis assessment (PO-BADO questionnaire)~* pain assessment (VAS: visual analogue scale)~* 3 functional tests:~  * handgrip strength~ * 6 Minute Walking Test~ * Timed Get up and Go Test"
215000686|NCT04324320|DIAGNOSTIC_TEST|psychological assessment|"psychological assessment includes several standardized screening and assessment questionnaires and tools:~* quality of life: SF-36~* anxiety, depression, stress: Hospital Anxiety and Depression Scale (HADS-D)~* subjective stress perception: Perceived Stress Scale (PSS-10)~* resilience: resilience scale (RS-13)~* fatigue: Brief Fatigue Inventory (BFI)~* disability related to pain: Pain Disability Index (PDI)~* workability: Work Ability Index - short version (WAI-K)~* psychological assessment based on the checklist of the International Diagnoses (IDCL) for ICD-10 and the ICD-10 checklist of symptoms for psychological disorders (SCL))"
215000687|NCT01879852|BEHAVIORAL|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
215094829|NCT06453291|PROCEDURE|Platelet-Rich-Plasma Therapy|"Objective: To promote healing and reduce inflammation through the application of concentrated platelets.~Procedure:~Blood draw from the patient. Centrifugation to separate platelets. Injection of PRP into the affected area of the lower back.~Frequency:~Initial treatment: Once a week for the first three weeks. Follow-up: Additional injections may be given based on patient response and clinical judgment.~Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels, inflammation markers, and functional improvement will be assessed before and after each injection."
215121348|NCT04363879|PROCEDURE|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
214394535|NCT01793246|DEVICE|probe based laser endomicroscopy (pCLE)|pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
215000688|NCT01879852|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
215000689|NCT05124678|DRUG|Isoniazid Tablets|High dose of isoniazid
215000690|NCT02648906|DRUG|Choline alfoscerate|
215000691|NCT02648906|DRUG|Placebo|
215000692|NCT02111980|DEVICE|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
215000693|NCT02696616|DRUG|BI 655088|
215000694|NCT02696616|DRUG|Placebo|
214394536|NCT02019433|DEVICE|Structan®|
214394537|NCT01594658|PROCEDURE|Foam sclerotherapy|Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.
214394538|NCT01594658|PROCEDURE|conservative|This arm only has medical standard handling (healings performed by the nurse group)
214394539|NCT04349761|DRUG|MyMD1|Isomyosamine 5mg capsules
214394540|NCT04349761|DRUG|Placebo|Placebo
214394541|NCT01924143|DRUG|TD-9855|radiolabeled (100 µCi \[14C\]-Labeled) TD-9855 (20 mg)
214394542|NCT01575782|DRUG|Chloroquine|Daily intake of Chloroquine during radiotherapy
214394543|NCT00306514|BIOLOGICAL|CYT004-MelQbG10|
215094830|NCT06558877|BEHAVIORAL|pharmacist-led multifaceted intervention|"Based on the blood pressure management model of pharmacist-led multifaceted intervention, clinical pharmacists who have received unified training provide pharmaceutical intervention and lifestyle guidance to subjects in the intervention group according to standard protocol.~Pharmaceutical interventions include health education, medication adherence (medication consultation, medication reminder), medication reorganization, and rational use of medication. At the same time, clinical pharmacists supervise the subjects to change their lifestyle (including reasonable diet, quitting smoking and drinking, moderate exercise, weight control and ensuring sleep, etc.), and guide the subjects to conduct home blood pressure monitoring."
214394544|NCT04374565|DRUG|High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma|Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; \~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.
214394545|NCT04015882|OTHER|Exercise therapy|The exercise therapy group will make by physiotherapist supervision.
214394546|NCT04982965|DRUG|Active Cannabis|400 mg of vaporized and inhaled active cannabis (5.1%)
214394547|NCT04982965|DRUG|Placebo Cannabis|400 mg of vaporized and inhaled placebo cannabis (\<.1%)
214394548|NCT04777188|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
214394549|NCT04291170|OTHER|QDASH|completing the tasks on the QDASH: open jar, wash wall, carry shopping bag, wash back, cut food, hammer wood
214693800|NCT02543398|PROCEDURE|Ridge preservation|Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
214394550|NCT04291170|OTHER|KOOSJR|completing tasks on the KOOSJR: pivot, straighten, go up/down stairs, stand upright, rise from sitting, bend over
214693801|NCT06091020|BIOLOGICAL|IncobotulinumtoxinA|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
215000695|NCT06208332|BEHAVIORAL|Photo-Narrative|Photo-Narratives include 1-3 photos of the pediatric patient and their family to tell a story about palliative care topics that are shared with the child's clinicians.
215000696|NCT00138970|DRUG|Zenapax®, CellCept® and prednisolone|
215000697|NCT00138970|DRUG|Sandimmun Neoral®, CellCept® and prednisolone|
215000698|NCT04553315|PROCEDURE|chest expansion exercises|Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.
215000699|NCT01500083|DRUG|Bendamustine at a dose of 100 mg/m2|Bendamustine will be administered intravenously over 30 minutes.
215000700|NCT01500083|DRUG|Bendamustine at a dose of 120 mg/m2|Bendamustine will be administered intravenous (i.v.) over 60 minutes.
215000701|NCT03035539|OTHER|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
215000702|NCT03035539|OTHER|Standard treatment|Standard treatment
215000703|NCT03415256|OTHER|passive vibration|The passive vibration is delivered using a Physio Plate (Domino S.R.L, San Vendemiano, Italy). The frequency delivered is 50 Hz for a total number of ten cycles for a period of ten minutes approximately (one cycle= 60seconds working time with 2 seconds rest time).
215000704|NCT03415256|OTHER|no passive vibration|The control group will not receive any treatment and continue their usual lifestyle.
215000705|NCT01346553|DEVICE|ESVV device|wearing the ESVV device for 6 hours
215000706|NCT00429247|DRUG|Trastuzumab|Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
215000707|NCT02744768|DRUG|Dasatinib|Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
215000708|NCT02744768|DRUG|Blinatumomab|"Upon induction:~patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary."
215000709|NCT02200081|DRUG|MGN1703|
215000710|NCT02200081|OTHER|Standard of care|Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
215000711|NCT01555931|DRUG|Levonorgestrel-releasing intrauterine system|Placement within 48 hours of delivery
215000712|NCT04791826|BEHAVIORAL|On-screen electronic alert|On-screen computer-based alert notifying the provider that the patient is at an increased risk of developing HF based on the WATCH-DM risk score and associated guideline recommendation for preventive management of these patients.
215000713|NCT02499315|DRUG|AMG 357|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
215000714|NCT02499315|DRUG|Placebo|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
215000715|NCT01922011|DRUG|Daptomycin|IV daptomycin Infusion A in 12 to \<18 years old (7 mg/kg); in 7 to \< 12 year olds (9 mg/kg); in 24 months to \<7 year olds (12 mg/kg); in 12 to \<24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
214394551|NCT00972387|DIETARY_SUPPLEMENT|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
214394552|NCT00972387|DIETARY_SUPPLEMENT|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
214693802|NCT06091020|BIOLOGICAL|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
215000716|NCT01922011|DRUG|Vancomycin (or equivalent)|IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
215000717|NCT01922011|DRUG|Nafcillin (or equivalent)|IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
214394553|NCT00972387|DIETARY_SUPPLEMENT|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
215000718|NCT01063907|DRUG|KW-2478|Administered Days 1, 4, 8 and 11 of a 21 day cycle
215000719|NCT01063907|DRUG|Bortezomib|Administered on Days 1, 4, 8 and 11 of a 21 day cycle
215000720|NCT04831658|DRUG|the dose-escalation phase|"The study adopts the 3+3 design,The dose planned to be explored is the daily oral dose of the BTK inhibitor abutinib, which is 100 mg, 150 mg and 200 mg, respectively.Orelabrutinib continues to be taken orally until the tumor is relieved for 3 months; PD-1 monoclonal antibody is used by intravenous drip, 21 days as a treatment cycle, and a total of 1 year of observation; formustine is used by intravenous drip for 21 days It is a treatment cycle, a total of 6 cycles of observation; after 2 cycles, the efficacy is evaluated, and adverse reactions are recorded. At the same time, MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath, and intrathecal injection once per treatment cycle, a total of 6 times."
215000721|NCT05256264|DRUG|Ketamine|Ketamine infusion at different dose to observe EEG DSA changes
215000722|NCT04575012|PROCEDURE|Deferred invasive strategy|PCI on 7 to 10 days after symptom onset
215000723|NCT04575012|PROCEDURE|Early invasive strategy|Primary PCI
215000724|NCT00918307|DRUG|Varenicline|Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily
214693803|NCT01830543|DRUG|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
215000725|NCT00918307|DRUG|Placebo|Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
215000726|NCT02299167|DRUG|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
215000727|NCT02333032|OTHER|Inclined treadmill training|
215000728|NCT03956875|OTHER|yoga|yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
215094831|NCT06558877|BEHAVIORAL|conventional health education|The subjects receive conventional hypertension health education, standard blood pressure measurement training and regular follow-up in the control group.
215094832|NCT06222034|DRUG|Filgotinib|Film-coated mini-tablets administered orally once daily
215094833|NCT06222034|DRUG|Filgotinib|Commercially developed film-coated tablet administered orally once daily
215094834|NCT05771675|DRUG|Simvastatin|40Mg Oral Tablet
215094835|NCT05771675|DRUG|Placebo|Matching Simvastatin Placebo tablet
215094836|NCT05623683|OTHER|Intermittent Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will walk on the treadmill for 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
215121349|NCT03138421|DRUG|ABX-1431 HCl|ABX-1431 HCl, capsules, 20 mg
215121350|NCT03138421|DRUG|Placebo|Matching placebo
214693804|NCT01830543|DRUG|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
214394554|NCT00972387|DIETARY_SUPPLEMENT|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
214394555|NCT01298180|DRUG|Growth hormone (Genotonorm® or Omnitrope®)|drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.
215000729|NCT06135259|DRUG|erythropoietin|erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan(5%) and glycerophosphate (20%).
215000730|NCT06135259|DRUG|Triamcinolone acetonide|Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
215000731|NCT01540734|DRUG|Marketed paracetamol|Marketed formulation
215000732|NCT01540734|DRUG|Experimental paracetamol formulation|Experimental formulation
215000733|NCT00248053|DRUG|curcumin|curcumin 500 mg by mouth, three times a day for 9 months
215000734|NCT04373070|COMBINATION_PRODUCT|CAir|The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 \[2017\], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
215000735|NCT03184272|PROCEDURE|baseline alert 1|measurement in supine position
215000736|NCT03184272|PROCEDURE|Anti-Trendelenburg-position (ATB)|measurement under ATB
215000737|NCT03184272|PROCEDURE|ATB in narcosis|measurement under ATB in narcosis
215000738|NCT03184272|PROCEDURE|baseline in narcosis 1|measurement in supine position in narcosis
215000739|NCT03184272|PROCEDURE|passive leg raising|measurement under passive leg raising
215000740|NCT03184272|PROCEDURE|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
215000741|NCT03184272|PROCEDURE|baseline in narcosis 2|measurement in supine position
215000742|NCT03184272|PROCEDURE|start capnoperitoneum|measurement in supine position
215000743|NCT03184272|PROCEDURE|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
215000744|NCT03184272|PROCEDURE|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
215000745|NCT03184272|PROCEDURE|ATB loss of capnoperitoneum|measurement under ATB
215000746|NCT03184272|PROCEDURE|baseline|measurement in supine position
215094837|NCT05623683|OTHER|Continuous Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will rest for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
215094838|NCT01571232|DRUG|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
215094839|NCT01571232|DRUG|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
215000747|NCT03184272|PROCEDURE|baseline alert 2|measurement in supine position
215000748|NCT03184272|PROCEDURE|torso position rising 30° at the beginning|measurement in the recovery unit
215000749|NCT03184272|PROCEDURE|torso position rising 30° at the end|measurement in the recovery unit
215000750|NCT00473499|DEVICE|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
215000751|NCT02920658|DRUG|NAVS Naphthalan|
215000752|NCT02920658|DRUG|0.05% Betamethasone dipropionate|
215000753|NCT05695313|DRUG|OnLife®|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. The OnLife supplement will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
215000754|NCT05695313|OTHER|Placebo|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. Placebo will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
215000755|NCT02198638|BIOLOGICAL|A nasal swab|A nasal swab was performed by a research assistant and influenza virus infection was confirmed by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction on viral cultures
215000756|NCT01502891|OTHER|Decision Aid|The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
215000757|NCT04412421|PROCEDURE|Gastric Bypass, Sleeve Gastrectomy|Lifelong vitamin and Mineral supplementation
215000758|NCT01294813|DEVICE|Electrical Impedance Tomography (EIT)|EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.
215000759|NCT03212937|DRUG|Selinexor|Oral KPT-330 is administered on Day 3, 5, and 7 of each 21-day cycle. Starting dose is 40mg will be adjusted according to toxicity
215000760|NCT03212937|DRUG|ICE Chemotherapy|"IV Ifosfamide 5g/m\^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle~IV Carboplatin AUC 5 on Day 2 (inpatient) or D1-3 (outpatient) of each 21-day cycle~IV Etoposide 100 mg/m\^2 on Days 1-3 of each 21-day cycle"
214394556|NCT01298180|PROCEDURE|DEXA, blood tests, H.G.P.O, osseous age.|"SPW, GHD, SPW-B :~blood tests : centralized dosage H.G.P.O : adjusted to children's age."
214394557|NCT01298180|PROCEDURE|biopsy|Biopsy : Cutaneous and fat tissue biopsy.
214394558|NCT02647047|PROCEDURE|Spinal analgesia|Administration of morphine 0.2 mg in subarachnoid space.
214394559|NCT02647047|PROCEDURE|Epidural analgesia|Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space
214394560|NCT02647047|PROCEDURE|Transversus Abdominis Plane block|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
214394561|NCT02647047|PROCEDURE|Surgical wound infiltration|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
214394562|NCT02647047|DRUG|Acetaminophen|Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
214394563|NCT02647047|DRUG|Ketorolac|Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
214394564|NCT02647047|DRUG|Ropivacaine|Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL
214394565|NCT02647047|DRUG|Sufentanil|Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
214394566|NCT02647047|DRUG|Ropivacaine|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
214394567|NCT02647047|DRUG|Ropivacaine|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
214394568|NCT03124628|OTHER|Flywheel resistance exercise|Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.
214394569|NCT03124628|OTHER|Weight-stack resistance exercise|Conventional weight-stack resistance exercise
214394570|NCT01168674|DRUG|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
214394571|NCT01168674|DRUG|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
215000761|NCT00058591|BIOLOGICAL|Intravenous injection of EBV specific CTLS|"The dose levels for this study are as follows:~Level Dose~1. 2 x 107 CTLs/m2~2. 5 x 107 CTLs/m2~3. 1 x 108 CTLs/m2~If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals."
214394574|NCT00127972|DRUG|stavudine|
214394575|NCT00127972|DRUG|lamivudine|
214394576|NCT00127972|DRUG|nevirapine|
214394577|NCT00127972|DRUG|efavirenz|
214394578|NCT00127972|DRUG|trizivir|
214693805|NCT01830543|DRUG|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
214693806|NCT01830543|DRUG|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
214394579|NCT03479190|PROCEDURE|ultrasound guided injection of Platelet rich plasma|Platelet rich plasma (PRP) injection into trochanteric area under ultrasound guidance
214394580|NCT03479190|PROCEDURE|ultrasound guided injection of Normal Saline|ultrasound guided injection of Normal Salineinto trochanteric area under ultrasound guidance
214394581|NCT02584855|DRUG|Ixekizumab|Administered SC
214394582|NCT02584855|DRUG|Placebo|Administered SC
214394583|NCT00747318|DRUG|SKP FlutiForm HFA pMDI|Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
214394584|NCT05401370|PROCEDURE|Methylene blue dye|For MB group, the staining of the glandular tissue will be obtained with 3-4 mL of 1% MB that will be introduced into the gland via the salivary duct several minutes before the surgery.The trans-oral catheterization of the Stensen's duct will be performed and the solution will be injected via intravenous cannula.The glandular tissue will turn dark blue.
214394585|NCT05208619|PROCEDURE|Regional anaesthesia|Patients receive either a thoracic epidural analgesia or paravertebral block as an regional anaesthetic adjunct to general anaesthesia for thoracic surgery
214394586|NCT00039156|DRUG|ortataxel|
214394587|NCT05509712|BEHAVIORAL|Focus Groups to Refine MobileMen App Content|Participants are shown a clickable wireframe of the proposed new app features, including competition, animated badges, leaderboard, and incentives. Focus group members discuss perceptions, ease of use, and interest in the app design/features and identified additional or unnecessary features for adopting and maintaining physical activity (PA).
214394588|NCT05509712|BEHAVIORAL|Beta testing of MobileMen App Prototype|Project staff present the clickable wireframe prototype and have men navigate and test features using a structured script. Staff track participant responses in notes, as well as through both recording via a side profile and the device screen. At the conclusion of the session, participants complete surveys measuring satisfaction, helpfulness, and usability.
214394589|NCT02107248|BEHAVIORAL|Sleep position: no restrictions|during the first eight weeks after total hip replacement following a posterolateral surgical approach
214693807|NCT01830543|DRUG|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
214693808|NCT01830543|DRUG|clopidogrel|One 75 mg tablet once daily for up to twelve months
214394590|NCT02107248|BEHAVIORAL|Sleep position: supine|during the first eight weeks after total hip replacement following a posterolateral surgical approach
214394591|NCT02779595|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day
214394592|NCT05970835|OTHER|Control group|Participants assigned to control group will receive the usual care provided by clinicians and physiotherapists from the Complexo Termal de Caldelas. Participants will have an educational session conducted by one of the researchers, and a paper sheet will be distributed with exercises and a written explanation of how to perform those exercises and the number of sets and repetitions. data collection will be conducted in moments t2 and t3 by a phone call.
214394593|NCT05970835|OTHER|Experimental group|"Experimental group evaluation: balance, functionality- 30 Second Sit To Stand Test, Modified Medical Research Council and functional status questionnaire, pain using VAS, cognitive variables-Montreal Cognitive Assessment and self-reported thermal water effects.After evaluation the App will display exercises related to data collected. Outcome measures will be collected at baseline, and 1 week, 1 month and 3 months after baseline.~After evaluation the App will display exercises related to data collected concerning participants condition improvement."
214394594|NCT02138747|DRUG|Mirabegron|Oral
214394595|NCT02138747|DRUG|Tolterodine ER|Oral
214394596|NCT00932646|DRUG|BI 1744 (Olodaterol) Low Dose|BI1744 Respimat low dose once daily and placebo Foradil
214394597|NCT00932646|DRUG|BI 1744 (Olodaterol) Medium Dose|BI1744 Respimat medium dose once daily and placebo Foradil
214394598|NCT00932646|DRUG|Placebo|Placebo Respimat once daily and placebo Foradil
214394599|NCT00932646|DRUG|Foradil|12 mcg twice daily and placebo Respimat
214394600|NCT02833662|OTHER|Measure of ODI and heart rhythm|Record nocturnal respiratory and cardiac parameters before and after surgery.
214394601|NCT04963972|BEHAVIORAL|Behavioral Intervention|Participate in Lucid Lane therapy program
215000762|NCT05731765|DIAGNOSTIC_TEST|Machine Learning Model|Automated machine learning system for the detection of spontaneous venous pulsations and quantification of intracranial pressure
215000763|NCT01813175|OTHER|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
215000764|NCT01813175|OTHER|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
215000765|NCT01813175|OTHER|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
214394602|NCT04963972|OTHER|Best Practice|Receive standard of care opioid education
214394603|NCT04963972|OTHER|Questionnaire Administration|Ancillary studies
214394604|NCT01272713|OTHER|Oxygen therapy|"* Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~* In-hospital oxygen as per hospital protocol"
214394605|NCT01272713|OTHER|No oxygen therapy|No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
214394606|NCT00183443|DRUG|Divalproex-extended release (DVP-ER)|Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
214394607|NCT00183443|DRUG|Lithium|Extended release lithium will be provided in 300 mg capsules. Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.
214394608|NCT00183443|DRUG|Quetiapine|Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
214394609|NCT05282849|PROCEDURE|ultrasound guided fascia iliaca block|ultrasound guided fascia iliaca block anesthetizes variable combinations of the femoral nerve , lateral femoral cutaneous nerve , and obturator nerve, and is effective for many painful hip surgeries making it potentially useful for analgesia following Developmental Dysplasia of Hip (DDH) surgery.
214394610|NCT05282849|PROCEDURE|ultrasound guided quadratus lumborum block|ultrasound-guided quadratus lumborum (QL) block provides perioperative somatic, even visceral analgesia for patients including pediatrics, undergoing abdominal or hip surgery. The local anesthetic injected adjacently into the quadrates lumborum muscle spreads in a medial and cranial direction under the crura and arcuate ligaments of the diaphragm, then into the thoracic paravertebral space anesthetizing the hip region
214394611|NCT02640976|DRUG|Human menopausal gonadotrophin (HMG)|\[Merional® 75 IU ampoules, IBSA institut\]
215000766|NCT06036095|DRUG|Sevoflurane|Inhalational maintenance of anesthesia group using sevoflurane
215094840|NCT04137250|PROCEDURE|Hamstring|The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
215121351|NCT05899140|DRUG|Clindamycin|Clindamycin will be administered at a dose of 450 mg TDS (oral) or 10 mg/kg/dose QID iv (maximum 600mg QID iv) for a maximum of 7 days
215121352|NCT05899140|OTHER|Standard of care|Standard of care
214394612|NCT02640976|DRUG|GnRH antagonist Cetrorelix|\[Cetrotide® 0.25 mg syringes, Merck Serono\]
214394613|NCT02640976|DRUG|Human chorionic gonadotrophin (hCG)|\[Choriomon® 5000 IU ampoules, IBSA institut\]
214394614|NCT05909787|OTHER|Auto-questionnaire|MCH (Montreal Children's Hospital) self questionnaire completed by the parents
214394615|NCT00737984|PROCEDURE|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
214394616|NCT06493123|OTHER|Conventional Cardiopulmonary Rehabilitation|Conventional cardiopulmonary applications including positioning, chest physiotherapy, in-bed normal joint movement exercises, sitting and walking, posture exercises
214693809|NCT01830543|DRUG|prasugrel|One 10 mg tablet once daily for up to twelve months
214693810|NCT01830543|DRUG|ticagrelor|One 90 mg tablet twice daily for up to twelve months
214693811|NCT01566643|DRUG|RA5-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
215000767|NCT06036095|DRUG|Propofol|Intravenous maintenance of anesthesia group using propofol
215121353|NCT00263874|DRUG|UK-500,001|
215000768|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
215000769|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
215000770|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 1 dose Intramuscular
214394617|NCT06493123|OTHER|Bottle P.E.P. (Pozitive Expiratory Pressure)|"The device will be built according to the optimal design parameters for a positive expiratory pressure therapy bottle device established by Mestriner et al. According to this~Bottle-P.E.P. device:~* PEP: 10-20 cmH2O~* Inspiration: Expiration Ratio: 1:3-4~* Material Used: Open top plastic bottle, plastic pipe.~Plastic Bottle Specifications:~I. Material-Hard Plastic II. Dimensions-Weight- 40grams; Height- 25cm; Width- 10cm; Perimeter- 20cm III. Water column height- 13cm~Plastic Pipe Properties:~I. Material-Pipette II. Inner Diameter- ≥8mm III. Pipe Length- 30cm IV. Depth in the water column - 10cm; 3 cm above the bottom of the bottle surface.~\- The distal end of the tube used in the Bottle P.E.P. will be placed 10 cm below the surface, i.e. 10 cm water column and 3 cm above the bottom of the bottle, and the device will be placed on a table in front of the participant."
214394618|NCT06493123|OTHER|Early Mobilization|"The Maebashi mobilization protocol will be followed for early mobilization program. According to this protocol, the hemodynamic and respiratory parameters of the patient will be evaluated first and the patient who meets the criteria for the mobilization program will be started to the mobilization program according to the appropriate stage of the 5-stage mobilization protocol.~In Maebashi Mobilization protocol:~Level 1: No mobilization and in-bed passive exercise Level 2: Supported in-bed sitting and in-bed active/assistive-active exercise Level 3: Unassisted sitting on the edge of the bed Level 4: Active transfer to chair Level 5: Standing, stepping in place and supported walking about 10 meters (with support of 2 people)"
214394619|NCT00316030|DRUG|Bexarotene|
214394620|NCT04826874|BEHAVIORAL|Affect labeling|Short behavioral intervention teaching affect labeling
214394621|NCT03129529|DEVICE|Focused shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
214394622|NCT03129529|DEVICE|Radial shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
214394623|NCT01352702|DRUG|Dabigatran|Patients assigned to this group will receive Dabigatran
214394624|NCT01352702|DRUG|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
214394625|NCT02379065|DEVICE|The Aerogen Aeroneb Solo©|
215000771|NCT05869474|PROCEDURE|Iodine125-Seeds implantation|Endoscopic ultrasound-guided intratumoral iodine125-Seeds implantation
215000772|NCT05869474|DRUG|Gem/nab-P Chemotherapy|nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8 every 3 weeks
215000773|NCT05172570|DRUG|Gabapentin|Gabapentin is a common medication used preoperatively and postoperatively as part of multimodal analgesia to help with acute pain.
215000774|NCT05632991|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 20 ml local anesthetic each side
215000775|NCT05632991|OTHER|Subcostal Transversus Abdominis Plan Block Group|ultrasound guided Subcostal Transversus Abdominis Plan Block Group 20 ml local anesthetic each side
215000776|NCT02157090|OTHER|Herpes Patch SOS (Hansaplast®)|
215000777|NCT02157090|OTHER|Herpes vesicle patch of Compeed®|
215000778|NCT00942851|DRUG|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
215000779|NCT00942851|DRUG|placebo|topical treatment NOT containing AH-8
215000780|NCT06530810|DRUG|HS-10382+Flumatinib|Drug:HS-10382+Flumatinib HS-10382 is administered orally BID Drug:Flumatinib Flumatinib 400mg once daily
215000781|NCT00229801|RADIATION|MRI|
215000782|NCT02627716|PROCEDURE|SOS Plan|"It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.~The booklet outlines four avenues to consider:~* Contact details / contact person~* Treatment and current follow-ups~* Medical care in the event of a crisis~* Practical aid in the event of a crisis~Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks."
214394626|NCT02379065|DEVICE|Phillips Respironic© mask|
214394627|NCT06442644|OTHER|Live music in the intensive care unit|To test a patient-tailored live music intervention's effect on stress reduction in adult, critically ill patients admitted to the intensive care unit.
214394628|NCT00811746|DRUG|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
214394629|NCT00811746|DRUG|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
214394630|NCT00811746|OTHER|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
214394631|NCT04499339|DRUG|SLAMF7 CAR-T|Single infusion of autologous SLAMF7 CAR-T cells
214693812|NCT01566643|DRUG|RA3-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
215000783|NCT05319704|OTHER|Test of effort on cycle on concentric or excentric mode|participants may receive 4 interventions sequentially during the protocol
215000784|NCT05319704|OTHER|Kinetics on concentric or excentric mode during test of effort|participants may receive 4 interventions sequentially during the protocol
215000785|NCT07113717|OTHER|virtual Hospital at Home|telemedicine set-up, virtual Hospital at Home
215000786|NCT07115420|DEVICE|Fully covered self expanding metal stent (FCSEMS) within LAMS|In those randomised to FCSEMS, size will depend on the size of the LAMS with a 6mm LAMS to be stented with 8mm diameter FCSEMS and an 8mm LAMS to be stented with a 10mm FCSEMS, 4cm or 6cm length. The aim is to have at least 3cm of FCSEMS in the duodenal lumen If unable to place FCSEM through LAMS, crossover to DPS is allowed with plan for both intention to treat and per protocol analysis to be undertaken after completion of the study
215121354|NCT01822197|DEVICE|Phototherapy|light will be administered at a minimum distance of 12 inches away to provide 10,000 lux
214394632|NCT04441424|BIOLOGICAL|Convalescent plasma|400 ml of convalescent plasma (plasma taken 2 weeks from the recovered COVID-19 patients) and was transfused over 1-2 hours to the recipients by blood donation set.
214394633|NCT04441424|DRUG|Hydroxychloroquin with Azithromycin|The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
214394634|NCT02285595|DEVICE|Sonendo GentleWave™ System|
215094841|NCT04137250|PROCEDURE|Quadriceps tendon|orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
215094842|NCT01854268|DRUG|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
215094843|NCT03147443|DRUG|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
214394635|NCT00284908|DRUG|S-Tenatoprazole-Na (STU-Na)|30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
214394636|NCT06548789|DIETARY_SUPPLEMENT|Prebiotic Xnack Packouts|Prebiotic snack packouts (distributed every two weeks) and diet counseling to support increased consumption of prebiotic foods which provide dietary fiber, plant-based protein and other nutrients selectively fermented by the microbiome (e.g., pulses and legumes).
214394637|NCT01157741|BEHAVIORAL|C-C|Mx as H-C plus positioning follow up in the community clinic
214394638|NCT01157741|OTHER|C-SF|As C-C but with additional supplementary food (SF) (C-SF)
214394639|NCT01157741|OTHER|As C-C with additional psychosocial stimulation (PS) (C-PS)|Giving psychosocial stimulation
214394640|NCT01157741|OTHER|As C-C but with both SF & PS (C-SF+PS)|Giving both SF \& PS
214394641|NCT01157741|OTHER|H-C|Follow-up at Hospital
214394642|NCT01058330|OTHER|Plyometric training program|The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of five lower extremity exercises and five upper extremity exercises
214394643|NCT05716841|OTHER|Ballistic exercises|stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 Sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
214394644|NCT01535131|PROCEDURE|palatoplasty|procedure to close cleft palate
214394645|NCT04380896|OTHER|Blood test|Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.
214394646|NCT04380896|OTHER|Standardised questionnaires|It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.
215121355|NCT02398240|DRUG|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
215121356|NCT02398240|DRUG|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
214394647|NCT02075190|OTHER|Therapeutic Computerized intervention|Remediation training intervention
214394648|NCT02075190|OTHER|Nontherapeutic computerized intervention|Online gaming intervention
214394649|NCT00188396|DRUG|Citalopram|
215000787|NCT07115420|DEVICE|Double pigtail stent (DPS) within LAMS|In those randomised to DPS, a double pigtail will be placed through the LAMS. The size of the stents will be left to the discretion of the proceduralist though 7Fr calibre with 7cm length is the recommended size
215000788|NCT07121348|PROCEDURE|Platelet rich fibrin|platelet rich fibrin is obtained by removing the middle layer from a centrifuged blood sample and is rich with platelets that plays an important role in tissue regeneration mesoporous silica nanoparticles are high surface area and excellent biocompatibility and enhance the outcome hyalurnic acid nanoparticles are high water capacity and involved in cell proliferation and adhesion and help in tissue regeneration pomegranate nanoparticles has anti-inflammatory and antibacterial effect and also help in tissue proliferation and regeneration
214394650|NCT00284999|DRUG|Soothe|
214394651|NCT00284999|DRUG|Refresh Tears|
214394652|NCT03844321|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
214394653|NCT03844321|BEHAVIORAL|Brief Mindfulness|3 sessions of online mindfulness therapy
214394654|NCT05140213|DEVICE|Anti-infectious prescription support tool|"implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
214394655|NCT00230815|DEVICE|Follitropin alfa injected by Pen device|Follitropin alfa will be injected subcutaneously by Pen device at a dose of 75 International Unit (IU) and 150 IU in subjects aged 18-34 and 35-40 years, respectively, for 5 days. Dose will be adjusted on stimulation Day 6 until ovulation triggering criteria will met.
214394656|NCT00230815|DEVICE|Recombinant Human Choriogonadotropin (r-hCG)|Recombinant Human Choriogonadotropin (r-hCG) injection will be administered as a single dose of 250 microgram subcutaneously when at least 1 follicle, but not more than 3 follicles, reached a mean diameter greater than or equal to (\>=)17 mm and estradiol levels are approximately 150 picogram per milliliter (pg/mL) per mature follicle.
214394657|NCT00660920|DRUG|Ponatinib|Comparison of different dosages of drug given orally once per day.
214394658|NCT05387486|PROCEDURE|Anatomical Landmark technique|anatomical landmarks (sternocleidomastoid muscles, sternal notch, cricoid cartilage, carotid artery and clavicle) will be palpated. A 3cc syringe with 21 gauge needle (locator) will be used first to locate IJV at the apex of the triangle formed by the two heads of the sternocleidomastoid muscle. After successful location, an introducer needle of 18 gauge, attached with a 5 ml syringe, will be inserted at the same point. The introducer needle will be directed towards the ipsilateral nipple at an angle of 20-30° with the skin
214394659|NCT05387486|PROCEDURE|Ultrasound-guided pre location technique|In Group Ultrasound-guided pre location technique, venipuncture site will be determined using ultrasound probe which will be then removed and locator needle of 21 gauge will be used first to confirm IJV location. The cannulation or venipuncture will be performed at the marked point of locator needle by the use of 18 gauge introducer needle.
214394660|NCT05387486|PROCEDURE|Ultrasound-guided real-time technique|In Group Ultrasound-guided real-time technique, cannulation or venipuncture will be performed under real-time imaging using 18 gauge needle i-e ultrasound will be used for prelocation and puncturing of IJV and locator needle will not be used
214394661|NCT00002015|DRUG|Ganciclovir|
214394662|NCT05088967|DRUG|IBI110|R2PD d1 IV every 3 weeks
214394663|NCT05088967|DRUG|sintilimab|200mg d1 IV every 3 weeks
214394664|NCT04773249|DEVICE|Lateral Epicondylitis Bandage|The lateral epicondylitis bandage was first used by Ilfeld in 1965, and it is a non-elastic band that prevents the expansion of the muscles in the proximal forearm. A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
214394665|NCT04773249|DEVICE|Wrist Extension Splint|Wrist extension splint is an upper extremity orthosis that keeps the wrist at 15-20 degrees of extension with the polyethylene bar it contains. A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
214394666|NCT05752643|OTHER|Online follow up|The online follow up will include screening for HIV and STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Treponema pallidum (TP)) based in a self-sampling strategy
214394667|NCT01597661|DRUG|Exposure to any bupropion during the first trimester|"The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
214394668|NCT01597661|DRUG|Exposure to bupropion alone during the first trimester|"The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
214394669|NCT01597661|OTHER|Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy|"The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
214394670|NCT02452866|DRUG|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
214502837|NCT07040605|OTHER|Deep cervical flexors muscle training and sensorimotor training|"deep cervical flexor muscle training will be performed according to the protocol of Jull and Falla using a pressure biofeedback unit. Participants will be positioned in a supine crook-lying posture with the neck in a neutral position, and the air bag of the pressure biofeedback unit will be placed beneath the cervical lordosis and inflated to a baseline of 20 mmHg. Patients will be instructed to perform a gentle nodding action, increasing the pressure by 2 mmHg increments up to 30 mmHg. Each increment will be held for ten seconds, repeated in three sets of ten repetitions, with a two-minute rest between sets. To enhance activation of the deep flexors, patients will be instructed to keep their mouth open during the exercise.~Proprioception training will include head relocation practice, oculomotor exercises, and eye-head coordination exercises."
215094844|NCT03147443|DRUG|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
215094845|NCT03147443|DRUG|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
215094846|NCT06581172|DIAGNOSTIC_TEST|D_dimer|DIC score including FDPs,D\_dimer
214394671|NCT03467308|GENETIC|Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)|"The followings markers will be investigated in tissue samples:~1. TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~2. TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis.~* Akt expression using western blot.~* GSH using chemical methods."
215000789|NCT07120230|PROCEDURE|Tubeless Lung Transplantation Surgery|Patients undergoing this surgery receive lung transplantation surgery without standard tracheal intubation. Instead, they will breathe on their own using a special airway device called a laryngeal mask airway (LMA), combined with a bronchial blocker to separate lung ventilation during surgery. Sedation is maintained with intravenous medications (propofol, remifentanil, and dexmedetomidine), and participants will remain spontaneously breathing or receive minimal breathing assistance as needed. The surgical incision will be numbed using local anesthesia with lidocaine and ropivacaine injections. After surgery, the LMA will be removed in the operating room, and participants will transition directly to non-invasive breathing support before being monitored in the ICU.
215000790|NCT07121686|DEVICE|Red light exposure|Patients in the red light group received red light therapy concurrently with standard care.
214394672|NCT05080881|DIAGNOSTIC_TEST|phonocardiographic measurement: InnoVital Systems|The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.
214394673|NCT05080881|DIAGNOSTIC_TEST|phonocardiographic measurement: ThinkLabs StethOne|This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
214394674|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: BIOPAC|Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.
214394675|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: Masimo Radical-7|A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.
214394676|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: CoVa Monitoring System 2|This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.
214394677|NCT05080881|DIAGNOSTIC_TEST|Thoracic impedance|Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
214394678|NCT01374802|DRUG|Darunavir|400 mg tablet for oral administration
214394679|NCT01374802|DRUG|Ritonavir|tablet for oral administration
214394680|NCT01374802|DRUG|BI 201335|
215000791|NCT07121686|DEVICE|Red-blue light exposure|Patients in the red and blue light group received combined red and blue light therapy concurrently with standard care.
215000792|NCT07121322|DRUG|dornase alfa i.v. and cisplatin|Cisplatin 100mg/m2 day 1, every 3 weeks, Dornase alfa 125 microgram/kg day 1-5 i.v. push over 30 seconds±5 seconds
215000793|NCT07121634|DRUG|Misoprostol 25 µg Vaginal|The Misoprostol group (n=40) were Misoprostol cases, a synthetic PGE1 in the form of vaginal tablets of 25 µg (Vagiprost; ADWIA Co/Egypt) applied locally to the posterior fornix every 4 hours for cervical ripening before induction of labor is started (up to 3-doses).
215000794|NCT07121634|DRUG|Isosorbide Mononitrate|"The Isosorbide Mononitrate group (n=40) were nitric acid donor cases applied to the posterior fornix prior to induction of labor. Isosorbide mononitrate (IMN) (Monomack; Mack Pharmaceutics; Jordan) in a vaginal dose of 40 mg was used every 4 hours (up to 3 doses).~Women who scored a BS of \> 6 from the assigned time were labelled as (1), after the passage of 40 hours, while those women whose BS was less than 6 were labelled (0) for construction of the Kaplan Meier curve for both groups."
215000795|NCT07119216|BEHAVIORAL|Peer Mentorship|The iPeer2Peer intervention is a peer support mentorship program that will provide modelling and reinforcement by pre-screened and trained peer mentors to the mentees. The mentorship program will encourage mentees to develop and engage in self-management and transition skills and support the participants; practice of these skills. The mentors will provide information and support to mentee participants via 5-10 calls (using WhatsApp) of 20-30 minute durations and text messaging (using WhatsApp) for 12 weeks to encourage participation in self-management skill building tailored to their needs.
215094847|NCT01646242|PROCEDURE|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
215094848|NCT01646242|PROCEDURE|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
214394681|NCT03061448|BEHAVIORAL|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
214394682|NCT03313258|DEVICE|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
214693813|NCT01566643|DRUG|RA7-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
215000796|NCT07120113|OTHER|cupping massage|This group will receive cupping massage three sessions per week for four weeks
215000797|NCT07120113|OTHER|Myofascial release technique|This group will receive the myofascial release technique three sessions per week for four weeks
215000798|NCT07120113|OTHER|Traditional exercises|This group will receive traditional exercises three sessions per week for four weeks
215094849|NCT02563938|DRUG|AK001|Given parenterally.
215000799|NCT07119944|OTHER|Not Related|This observational study does not involve any therapeutic intervention. Instead, all participants undergo gait analysis using two different measurement methods-2D pose estimation algorithms and an inertial measurement unit (G-Walk system)-to compare their outputs. Both assessments are performed on the same individuals under standardized conditions without altering their routine care.
214394683|NCT03313258|DEVICE|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
214394684|NCT04070677|COMBINATION_PRODUCT|Ziverel|Patients in treatments with radiotherapy alone (RT) or radiochemotherapy (RT-CH) with acute radiation-induced esophagitis grade 2 or superior according to the most recent CTCAE will received support treatment with ZIVEREL®
214394685|NCT01117753|BEHAVIORAL|OutPatient Treatment for Adolescents (OPT-A)|
215000800|NCT07121673|BEHAVIORAL|Dental appointment message|Patients receive a WhatsApp message offering a preventive dental check-up for $19,990.
214394686|NCT01117753|BEHAVIORAL|Treatment As Usual|
214394687|NCT03380663|PROCEDURE|Remote Ischemic Conditioning (RIC)|"Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery.~High intensity traditional resistance training (TRT) is performed by sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes)."
214394688|NCT01719900|DIETARY_SUPPLEMENT|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
214394689|NCT01719900|DIETARY_SUPPLEMENT|Control|Control biscuit with no yellow pea hull fibre.
214394690|NCT03164915|BIOLOGICAL|LIV-GAMMA SN Inj.|
214394691|NCT04908124|DEVICE|Lubricant A|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
214394692|NCT04908124|DEVICE|Lubricant B|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
214394693|NCT04908124|DEVICE|Lubricant C|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
214394694|NCT04908124|DEVICE|Lubricant D|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
214394695|NCT04908124|DEVICE|Lubricant E|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
214394696|NCT02559609|BEHAVIORAL|Contingency management for alcohol abstinence|Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.
214502838|NCT07040605|OTHER|conventional physical therapy exercise|"will include stretching exercises targeting the sternocleidomastoid, upper trapezius, levator scapulae, scalene, Rhomboids and pectoralis muscles, performed in three repetitions, holding each stretch for thirty seconds, strengthening exercises will be provided Isometrically for the cervical flexors, extensors and at sides using a prescription of three sets of ten repetitions with a ten-second hold and two minutes of rest between sets.~TENS and Hot back."
214502839|NCT06724471|DEVICE|Human ovarian tissue cryopreservation using thermosoldered or screwed cryovials|Human ovarian tissue Cryopreservation: immediately after cyst resection, pericystic ovarian cortex will be cut into 1mm3 fragments and cryopreserved in screwed or thermosoldered cryovials using a slow programmable freezing device (Nano Digitcool, Cryo Bio System).
215000801|NCT07121673|BEHAVIORAL|Dental appointment message with price discount|Patients receive a WhatsApp message offering a preventive dental check-up for $990.
215000802|NCT07121673|BEHAVIORAL|Bundling frame|The message includes language indicating they can schedule the dental appointment on the same day as their upcoming medical appointment to save time.
215000803|NCT07120711|PROCEDURE|EGR2/NLRP3 pathway activity|"Peripheral blood collection \& PBMC isolation:~Children: 3 mL venous blood drawn from the right antecubital vein preoperatively; Adults: 3 mL fasting venous blood drawn the morning after PSG.~Collected in EDTA tubes; PBMCs separated via Ficoll-Paque density gradient. Flow cytometry: 1×10⁶ PBMCs stained for CD14/CD16, HLA-DR, CD11b, CD80/CD86, CD163/CD206.~RNA extraction: Remaining PBMCs lysed in TRIzol and stored at -80 °C for RT-qPCR of EGR2, NLRP3, and downstream genes Serum/plasma: Within 1 h of collection, centrifuge at 400 × g for 10 min at 4 °C; 1 mL used for ELISA quantification of TNF-α, IL-6, IL-1β, CCL2, IL-17, CRP; remainder stored at -80 °C for future proteomic or metabolomic assays~Saliva sampling \& processing:~2-3 mL unstimulated saliva expectorated into sterile tubes, kept at 4 °C, processed (centrifuged, aliquoted) within 2 h, then stored at -80 °C."
214394697|NCT02559609|BEHAVIORAL|Contingency management for completing job related activities|Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.
214693814|NCT03487900|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
214693815|NCT04513834|OTHER|GP will receive the educational outreach visit by a DAM (healthcare representative).|GP will receive the educational outreach visit by a DAM (healthcare representative).
215094850|NCT02563938|DRUG|Placebo|
214693816|NCT04513834|OTHER|Patient education material on PPI deprescribing will be sent to the patients|Patient education material on PPI deprescribing will be sent to the patients
214693817|NCT05806047|DRUG|chidamide combined with fulvestrant|chidamide combined with fulvestrant
214693818|NCT03510611|DRUG|Ensartinib with fed or fasting|The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.
214693819|NCT03157973|OTHER|Education intervention|eHealth tool and standardized nurse-led follow-up.
214693820|NCT00120120|DRUG|Lenalidomide (CC-5013)|Lenalidomide 2-5 mg capsules taken one time per day
214394698|NCT02559609|BEHAVIORAL|Job relelated activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
214394699|NCT02281396|BIOLOGICAL|2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
214394700|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
214394701|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
214394702|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
214394703|NCT03772951|OTHER|Cognitive Remediation Therapy|Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.
214394704|NCT03772951|DRUG|Clozapine|the course of disease is more than 2 years, the condition is stable for more than one month
214394705|NCT02155959|DEVICE|toric intraocular lens|toric intraocular lens
214394706|NCT04376294|DEVICE|Extracorporeal Shockwave Therapy(ESWT)|Each session of Extracorporeal Shockwave Therapy(ESWT) consists of 2000 pulses with a pressure of 3 bars (equals an energy flux density of 0.1 mJ/mm²), and treatment frequency of 8 pulses/sec
214502840|NCT07042360|DIAGNOSTIC_TEST|ReDs Pro|"The basic principle invovles emitting low-power electromagnetic sgnals into the lungs and measuring the dielectric properties of lung tissue~The varing dielectric constants of these components result in differences in the impedance values for electromagnetic waves. Therefore, using the impedance method allows the estimation of the dielectric properties of lung tissue, which can be further converted into lung fluid content data through calculations."
214502841|NCT07042360|DIAGNOSTIC_TEST|Fibroscan|Using external ultrasound scanner to check fo rliver stiffness using acoustic energy
215000804|NCT07120711|PROCEDURE|fatty tissue|"Subcutaneous fat biopsy (adults undergoing surgery):~100-200 mg obtained intraoperatively, placed in RNAlater at 4 °C for 24 h, then frozen at -80 °C for downstream RNA-seq, RT-qPCR, and Western blot analyses of EGR2, NLRP3, and related inflammatory markers"
215000805|NCT07122960|OTHER|Visual ICF|This visual ICF fully represents all the content of the standard, text-only ICF using cartoon characters, graphics and easy text.
215000806|NCT07122960|OTHER|Text-only ICF|Text-only ICF
215000807|NCT07119528|OTHER|AF application enhancing AF education|This group will use AF-application. The app will include content related to anticoagulation therapy, such as: medication reminders or intake confirmation for anticoagulants, the importance of anticoagulation therapy in stroke prevention, the role of antiarrhythmic and rate-control medications in symptom management, the necessity of controlling risk factors such as hypertension, diabetes, and hyperlipidemia, and quality of life and cognitive function assessments through questionnaires.
214394707|NCT04376294|OTHER|Eccentric training of the calf muscle:|The patients were asked to stand with all their body weight on the injured leg on a wooden step. From an upright body position and standing with all body weight on the forefoot, with the ankle joint in plantar flexion. The calf muscle is loaded by having the patient lower the affected limb down by dorsiflexion the ankle until the plantar aspect of the heel lay below the level of the step, and the ankle is in maximum dorsiflexion.
214394708|NCT04376294|OTHER|Gastrocnemius, soleus, and hamstring stretch|Stretching every muscle for 30 seconds. Each stretch was performed 3 times (holding for 30 seconds and rest for 30 seconds). All these stretches were performed directly after the eccentric exercises twice/day for 7 days/week for weeks
214394709|NCT03116503|OTHER|diagnosis of bipolar disorder and comorbid depression|Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
214394710|NCT01849796|DEVICE|tDCS|TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
214502842|NCT07043231|OTHER|Creative materials|This intervention provides professionals with co-created creative materials specifically designed to facilitate structured, safe conversations about suicidality with children and adolescents. Unlike standard tools, it offers three flexible pathways-Conversation, Drawing, and Walking-allowing a personalized approach tailored to the young person's preferences and context. The materials guide professionals through the assessment of suicidal intent, risk and protective factors, and help formulate a risk assessment and Safety Plan. The content is aligned with national clinical guidelines but uniquely integrates experiential insights from youth with lived experience, ensuring both theoretical grounding and practical applicability.
215000808|NCT07119528|OTHER|AF application without enhancing AF education and drug adhrence|This group will use AF-application. However, this application will not contain materials enhancing AF education and adherence.
215000813|NCT07122089|DEVICE|Selective Internal Radiotherapy|SIRT will use Yttrium-90 glass-microspheres (TheraSphereTM). SIRT needs two steps: the treatment simulation (diagnostic angiography and scintigraphy of hepatic perfusion with 99mTc-MAA) and the administration (during a therapeutic angiography).
214394711|NCT04152850|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and Traditional Chinese Medicine
214394712|NCT01091896|DRUG|Bevacizumab|1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
214394713|NCT01091896|DRUG|bevacizumab|1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
214394714|NCT04096989|OTHER|Traditional Chinese medicine regimen-based lifestyle mobile health APP|The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.
214394715|NCT04096989|OTHER|Lifestyle mobile health APP|Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
214394716|NCT01865123|BEHAVIORAL|Transcendental Meditation|A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
214394717|NCT01865123|BEHAVIORAL|Prolonged Exposure|Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
214394718|NCT01865123|BEHAVIORAL|Educational control|This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
214394719|NCT02333734|OTHER|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces \~ 90% of the maximum heart rate. The time spent per session is expected to last \~ 25 minutes.
214394720|NCT00354133|DEVICE|Kinetra and Soletra (neurostimulator, Medtronic)|Patients in this arm were implanted with a neurostimulator (Kinetra and Soletra from Medtronic) are stimulated. Additionally the get best medical treatment.
214394721|NCT00354133|DRUG|Best Medical Treatment|Patients in this arm get best medical treatment only
214394722|NCT00064025|OTHER|Laboratory Biomarker Analysis|Correlative studies
214394723|NCT00064025|DRUG|Medroxyprogesterone|Given IM
214394724|NCT00064025|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical hysterectomy
214394725|NCT00095823|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
214394726|NCT00095823|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
214394727|NCT01209481|BEHAVIORAL|nutritional education group action|The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
214394728|NCT03277378|DEVICE|lead placement followed by BurstDR stimulation|lead placement followed by BurstDR stimulation
214394729|NCT04641195|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|180,000 international units (IU) of vitamin D3 at enrollment, followed by 2000 IU once per day from enrollment to 8 weeks
214394730|NCT04641195|DIETARY_SUPPLEMENT|Zinc (zinc gluconate)|40mg of zinc gluconate taken once per day from enrollment to 8 weeks
214394731|NCT04641195|DIETARY_SUPPLEMENT|Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|180,000 IU of vitamin D3 at enrollment, followed by 2000 IU of vitamin D3 and 40mg of zinc gluconate once per day from enrollment to 8 weeks
214394732|NCT04641195|OTHER|Placebo|Placebo vitamin D bolus at enrollment followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
214394733|NCT02468934|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
215000814|NCT07122089|DRUG|Tremelimumab|Tremelimumab should be done 1 to 3 weeks after SIRT and is administrated according to the Summary of Product Characteristic (SPC).
214394734|NCT00450515|DRUG|capecitabine|
214394735|NCT00450515|DRUG|vinflunine|
214502843|NCT07042620|DEVICE|SonoClear(R) System|The SonoClear(R) System is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
214502844|NCT07042282|DEVICE|Nighttime Splinting|Nighttime splinting for 6 weeks.
214693821|NCT04521348|DRUG|multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody|Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
215000815|NCT07122089|DRUG|Durvalumab|After the end of the tremelimumab infusion, patient receive durvalumab then one injection every 4 weeks until further progression upon investigator decision. Also administrated according to the Summary of Product Characteristic (SPC).
215000816|NCT07113600|OTHER|Nerve Block|"Ilioinguinal/ Iliohypogastric nerve block:~In the supine position, the ultrasound probe probe is positioned in a transverse manner, superior to the anterior superior iliac spine. The three anterior abdominal muscle layers are identified, and the two nerves are identified in the abdominal neurovascular plane.~A echogenicneedle is inserted in a medial-to-lateral direction. After negative aspiration, 5 ml saline is injected to ensure correct needle tip position then 20 ml of bupivacaine 0.25% is injected gradually close to the nerves.~Erector spinae plane block:~In a lateral position, the erector spinae is visualized about 3 cm lateral to T7-T9 spinous processes on the target side. A echogenic needle (50 mm/22 gauge) is advanced in a cephalad to caudad direction until the tip reaches the plane deep to the erector spinae muscle immediately lateral to the transverse process. A 20 ml bupivacaine 0.25% is injected gradually into this plane."
215121357|NCT02398240|DRUG|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
214394736|NCT06024629|DEVICE|cOCT and LC-OCT|"cOCT: conventional optical coherence tomography (cOCT) is an established imaging modality within dermatology that enables visualization of the architecture of the skin with a penetration depth of 1.0 - 1.5mm.~LC-OCT: Line-field confocal optical coherence tomography (LC-OCT) is a new emerging diagnostic modality within the field of dermatology. LC-OCT enables tridimensional imaging of the skin with a cellular resolution and BCC features on LC-OCT have been described. However, the penetration depth of LC-OCT (500µm), is limited compared to the penetration depth of cOCT (1.0-1.5mm)"
214394737|NCT02500875|DEVICE|PTNiA|
214394738|NCT02500875|DEVICE|PTNiB|
214394739|NCT02500875|DEVICE|PTN|
214394740|NCT04570813|OTHER|Artistic activies|12 workshops of artictic activities during 12 weeks
214394741|NCT03424720|DEVICE|PLE and BIS|Investigators attach the PLE and BIS sensors on the forehead of the patients undergoing facial nerve integrity monitoring during general anesthesia using total intravenous anesthetics
214394742|NCT00613613|DRUG|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
214394743|NCT00613613|DRUG|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
214394744|NCT01097213|DRUG|Ethanol|Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
214394745|NCT01097213|DRUG|Placebo - half-normal saline|Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
214394746|NCT00829608|BIOLOGICAL|Human Papillomavirus Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
214394747|NCT01212406|DRUG|Vitamin D|Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
214394748|NCT02963051|DRUG|Copper|1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15
214394749|NCT02963051|DRUG|Disulfiram|"80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals"
214394750|NCT02963051|DRUG|Copper gluconate|"1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals"
214502845|NCT07042282|DRUG|Corticosteroid Injection|Local corticosteroid injection (triamcinolone acetonide 40mg). A single injection of triamcinolone acetonide 40mg mixed with an equal volume of 1% lidocaine is administered. The injection is performed under ultrasound guidance and anatomical landmarks to target the proximal carpal tunnel. With the wrist extended, the needle is typically inserted on the ulnar side of the palmaris longus tendon, approximately 1 cm proximal to the wrist crease. If blood is aspirated or the patient reports paresthesia (which usually indicates nerve irritation), the injection site should be adjusted.
214502846|NCT07042282|OTHER|Evaluation and Dynamic Adjustment|6 weeks later, all patients will undergo evaluation of their initial treatment. Further therapeutic decisions will be made based on physician assessment, including: continuing nighttime splinting, administering corticosteroid injections to patients who initially received only the splint, adding nighttime splinting for patients initially received only corticosteroid injections, and transitioning from nighttime splint use to continuous wear. Subsequently, evaluations will be conducted every 6 weeks, with dynamic adjustments to the treatment plan. Throughout the study period, physicians will perform electrophysiological examinations according to changes in patients' clinical status.
214502847|NCT07043894|DRUG|Romiplostim N01|Participants receive weekly subcutaneous injections of romiplostim N01 (250 μg/vial; Qilu Pharmaceutical) starting at 2 μg/kg. Doses are adjusted weekly based on platelet counts: increased by 2 μg/kg if platelets are \<50 × 10⁹/L, by 1 μg/kg if 50-99 × 10⁹/L, up to a maximum of 10 μg/kg. Treatment continues for up to 2 weeks but stops early if platelets reach ≥100 × 10⁹/L or increase by ≥30 × 10⁹/L from baseline.
214693822|NCT01321931|DRUG|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
215000817|NCT07125963|PROCEDURE|Custom-made positioning appliance-assisted mandibular segment repositioning|A patient-specific surgical guide designed using STL-based digital planning in Blender and produced via 3D printing with biocompatible surgical resin (Formlabs SLA printer). Used to guide and stabilize the proximal mandibular segment during sagittal split ramus osteotomy.
215000818|NCT07125963|PROCEDURE|Conventional Manual Positioning|The proximal mandibular segment is positioned manually by the surgeon based on visual and tactile feedback without the use of a positioning guide. This technique represents the standard method in sagittal split ramus osteotomy.
214394751|NCT04774822|PROCEDURE|Color Fundus Photography|Stereoscopic Fundus photography
215094851|NCT01373320|BEHAVIORAL|Lay health advisor interactions|"For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening."
215094852|NCT03517969|DRUG|Berzosertib|Given IV
215094853|NCT03517969|DRUG|Carboplatin|Given IV
215094854|NCT03517969|DRUG|Docetaxel|Given IV
214394752|NCT04774822|DRUG|Mydriatics Agent|Eye dilating agent
214394753|NCT04774822|PROCEDURE|Optical Coherence Tomography (OCT)|Optical Tomographic imaging of retina
214394754|NCT00997256|DRUG|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
214394755|NCT00997256|DRUG|film-coated sugar-pill|3 x 2 tablets / day over 3 days
214394756|NCT00518713|DRUG|Clobazam Low Dose|0.25 mg/kg/day; tablets; orally; for 15-18 weeks
214394757|NCT00518713|DRUG|Clobazam Medium Dose|0.5 mg/kg/day; tablets; orally; for 15-18 weeks
214394758|NCT00518713|DRUG|Clobazam High Dose|1.0 mg/kg/day; tablets; orally; for 15-18 weeks
214394759|NCT00518713|DRUG|Placebo|tablets; orally; daily for 15-18 weeks
214394760|NCT01722136|BEHAVIORAL|Low Dosage|Exercise dose of 8kcal/kg/week
214394761|NCT01722136|BEHAVIORAL|High Dosage|Exercise dose of 14kcal/kg/week
214394762|NCT04396925|OTHER|Point-of care Ultrasonography|GPs using POCUS and how it affects clinical judgement
215000819|NCT07125456|OTHER|Postmortem Care Teaching Simulation|"The participants in the experimental group will be administered the Informed Consent Form, Demographic Characteristics Form, Postmortem Care Knowledge Test for Nursing Students (PCKTNS), and End-of-Life and Postmortem Care Self-Efficacy Scale for Nursing Students (ELPMCSESN) prior to the theoretical education. Following the pre-tests, it is planned to provide theoretical education for approximately 4 class hours (with each class hour lasting 45 minutes). The first 2 hours of the theoretical education will cover topics related to Death and General Aspects of Death, while the remaining 2 class hours will be delivered as a PowerPoint presentation focusing on postmortem care application content.~Following the theoretical education, the experimental and control groups will be shown the Postmortem Care Skills Video. Additionally, prior to the teaching simulation for postmortem care, the experimental group will be shown the Scenario Case Video, after which the scenario prepared fo"
214394763|NCT03027713|PROCEDURE|weaning protocol|The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group
214394764|NCT01939782|OTHER|No Breakfast (NoB)|In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
214394765|NCT01939782|OTHER|Yes Breakfast (YesB)|In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
214394766|NCT00391014|DRUG|liposomal Amphotericine B|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
214394767|NCT00641186|DRUG|sodium oxybate|4.5 to 9.0 grams per night
215000820|NCT06661668|DEVICE|Gastric pacemaker (Enterra system) implantation|Laparascopic implantation of a gastric pacemaker (Enterra system) for patients with therapy refractive gastroparesis
214394768|NCT01991444|OTHER|TAVI|no Intervention planned, Observation only
214394769|NCT00687661|DRUG|Bisphosphonate|35mg given orally once weekly for 24 months
214522595|NCT01509040|OTHER|Standard Care|"Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours."
214693823|NCT01321931|DRUG|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
215000821|NCT06162403|OTHER|Peripheral Nerve Stimulation|The leads are inserted through a needle. If needed, the study team may give participants anesthetic (for example, as a cream/gel on your skin and/or as an injection) to numb the area where the leads will be injected.
215000822|NCT06364865|DEVICE|laparoscopic procedure|Not applicable, subject requiring procedure will have a laparoscopic procedure performed according to the institutions standard of care procedures. There are no clinical procedures performed on the subject as part of this registry study. Surgeon will answer questionnaires regarding use of the device upon completion of the laparoscopic procedure.
215000823|NCT06869967|PROCEDURE|Auricularis Magnus Nerve Block|Auricularis Magnus Nerve block will be performed using 5 mL of %0.5 bupivacaine
215000824|NCT06869967|PROCEDURE|Control Group|Intravenous analgesics 1 gram paracetamol, 20 mg tenoxicam, 8 mg ondansetron will be administered.
215000825|NCT06672016|DRUG|Transdermal system containing progestin|MR-130A-01 transdermal system, patch to be used for female contraception
214394770|NCT00687661|DRUG|Placebo|identical placebo pill once weekly for 24 months
215000826|NCT06867094|DRUG|SAR441566|Pharmaceutical form: Tablet Route of administration: Oral
215000827|NCT06867094|DRUG|SAR441566 matching Placebo|Pharmaceutical form: Tablet Route of administration: Oral
214394771|NCT04623411|BEHAVIORAL|Neonatal resuscitation training with classical method and serious game simulation method|"After the theoretical training, the participants will be given technical information on the use of web-based neonatal resuscitation serious game simulation method.~Each participant will be asked to apply this method at least three times."
214394772|NCT04623411|BEHAVIORAL|Control Group|Neonatal resuscitation training with classical method
214394773|NCT02922985|DRUG|Intravenous acetominophen|One dose if 1 gram intravenous to be given pre-surgery
214394774|NCT02922985|DRUG|Ketorolac, intramuscular|One dose of 60 mg Intramuscular to be given at time of skin closure
214394775|NCT02922985|DRUG|Bupivacaine, subcutaneous|Inject 20 mL of 0.25% bupivacaine at the site of anticipated skin incision.
214394776|NCT02922985|DRUG|Normal saline|Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
214394777|NCT03119337|OTHER|Text-based follow-up|2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
214394778|NCT01099540|DRUG|Pazopanib|Pazopanib 800 mg qd daily
215000828|NCT05300139|OTHER|Color Doppler Ultrasound|Comparison between D90±5 and baseline CDUS
215000829|NCT06436209|BEHAVIORAL|Multitask Practice Intervention (MPI)|Multitask practice intervention (MPI) includes multiple behavioral testing sessions during which participants receive practice with multitasking two tasks using the psychological refractory period procedure.
214394779|NCT02218489|DRUG|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
215094855|NCT03517969|OTHER|Laboratory Biomarker Analysis|Correlative studies
214394780|NCT02218489|DRUG|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
214394781|NCT00063817|DRUG|Conditioning Regimen|Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
214394782|NCT02404493|DEVICE|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
214394783|NCT02404493|DRUG|1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
214394784|NCT00214032|DRUG|Pycnogenol|pycnogenol 300 mg daily
214394785|NCT00214032|DRUG|Placebo|placebo 3 capsules daily
214394786|NCT06077435|DEVICE|AI|AI system
214394787|NCT00019006|DRUG|Detox-B adjuvant|
214394788|NCT00019006|DRUG|ras peptide cancer vaccine|
214394789|NCT00571779|DEVICE|AtriCure Bipolar System|
214502848|NCT07043985|DIAGNOSTIC_TEST|biopsy|Diagnosis of the HGF and healthy tissues depends on pre-described criteria; gingival overgrowth covering one third of the crown length as a minimum, systemically free, no history of drug uptake causing gingival overgrowth (nifedipine, phenytoin, cyclosporine, oral contraceptive pills). Before sampling, written consents were obtained from all patients. Using light microscope, haematoxylin and eosin (H\&E) stained sections were precisely examined and histopathological features were reported. All specimens were assessed semi-quantitatively, on a graded scale, under ×100 magnification power and a fixed grid for the following parameters. Three to four fields of each gingival specimen were randomly selected. A blinded evaluation was done by two independent observers. If a debate was reported regarding a specimen, a consensus was reached following re-evaluation. The most representative areas were selected to be morphometrically analyzed using Leica QWin 500 analyzer computer system (Germany).
214394790|NCT03240939|DRUG|Dutasteride 0.5 mg|single dose
214394791|NCT03240939|DRUG|Tadalafil 5 mg|single dose
214394792|NCT03240939|DRUG|YY-201|single dose
214394793|NCT01207050|DRUG|Ramelteon|8mg capsule taken within one half hour of bedtime each night over the three night study period.
214394794|NCT01207050|DIETARY_SUPPLEMENT|Placebo|Control treatment
214394795|NCT01235130|DRUG|OMEGA-3|600mg, 2 caps, twice a day
214502849|NCT07043127|OTHER|Sham-BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
214394796|NCT01235130|DRUG|Placebo soybean oil|600mg, 2caps twice a day
214394797|NCT03435601|DRUG|Anifrolumab|"IV Administration of Anifrolumab 300 mg every 4 weeks from week 0 to week 20 for a total of 6 doses.~At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
215094856|NCT00358969|DRUG|guanfacine (Tenex)|
215094857|NCT03060954|DEVICE|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
215094858|NCT03060954|DEVICE|FINE VISION®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
214394798|NCT03435601|DRUG|Placebos|"Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
214394799|NCT01487304|DRUG|Marketed low dose hormone replacement therapy|A low dose of marketed HRT products prescribed at the discretion of the treating physician
214394800|NCT05172882|PROCEDURE|Wound site infiltration|Block fluids that were prepared as 20 ml 0.25% bupivacaine before the intervention, will be applied through the upper and lower incision lips on the suprainguinal surgical site.
214394801|NCT05172882|PROCEDURE|Transversalis fascia plane block|External, internal oblique, and transversus abdominis muscles will be visualized by the ultrasound device. After transversalis fascia will be seen, transversalis fascia plane block will be performed. As a block fluid 20 ml 0.25% bupivacaine will be applied.
214394802|NCT03037879|OTHER|SPT|Participants in the SPT group will receive 10 training sessions over 5 weeks.
214394803|NCT03037879|OTHER|SPT Control|Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
214394804|NCT03037879|OTHER|mSMT|Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
215000830|NCT06436209|BEHAVIORAL|Single-task Practice Intervention (SPI)|Single task practice intervention (SPI) includes multiple behavioral testing sessions during which participants receive separate practice on two tasks.
215000831|NCT05419024|OTHER|Acute Treatment Interruption|Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
215000832|NCT03485794|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215000833|NCT03485794|OTHER|Laboratory Biomarker Analysis|Correlative studies
215000834|NCT06874933|DRUG|Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart|"Group A: Epirubicin + cyclophosphamide + Benmelstobart are administered by intravenous drip once every 3 weeks for a total of 2 cycles, followed by nab-paclitaxel + Benmelstobart administered by intravenous drip once every 3 weeks for a total of 2 cycles. During the treatment period, Anlotinib is simultaneously combined. It is taken orally once a day, before breakfast. Take the medicine continuously for two weeks, then stop taking it for one week. One cycle is 21 days, and there are a total of 3 cycles.~Group B: Nab-paclitaxel + Benmelstobart are administered by intravenous drip once every 3 weeks for a total of 2 cycles, followed by Epirubicin + cyclophosphamide + Benmelstobart, which are administered by intravenous drip once every 3 weeks for a total of 2 cycles. During the treatment period, Anlotinib is also used in combination. It should be taken orally once a day before breakfast, continuously for two weeks, then stop taking it for one week."
215000835|NCT06626399|DIAGNOSTIC_TEST|Diagnosis of SSI|Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
215000836|NCT07021027|DRUG|Whole Egg - 4|Participants will be asked to consume 4 medium Eggland's Best eggs per day for 5 months.
215000837|NCT07021027|DRUG|Whole Egg - 2|Participants will be asked to consume 2 medium Eggland's Best eggs per day for 5 months.
215000838|NCT07014826|DRUG|HRS-5965|HRS-5965
215000839|NCT07014826|DRUG|Placebo|Placebo
215000840|NCT07021794|DRUG|Placebo|A single dose of placebo (saline) indistinguishable from the active drug in appearance
215000841|NCT07021794|BIOLOGICAL|Sipavibart|A single intramuscular dose of Sipavibart, 300 mg
215000842|NCT07023081|BIOLOGICAL|20vPnC|20vPnC vaccine
215000843|NCT06686121|BEHAVIORAL|Home Based Exercise|This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention
215000844|NCT06686121|DRUG|Nitrate Rich Beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.
215000845|NCT06686121|BEHAVIORAL|Attention Control|"Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging age pages relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D."
215000846|NCT06686121|DRUG|Placebo Beetroot Juice Without Nitrate|Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.
215000847|NCT06629584|DRUG|Asciminib|Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.
215000848|NCT06686784|BEHAVIORAL|After School Plus|"The afterschool program as usual runs M-H and consists of a variety of clubs from which middle school students chose to enroll for a semester (\~4 months). Clubs are offered on either a M/W or T/H schedule. Students receive a snack in the cafeteria each day before attending their class.~Afterschool plus is the same as Afterschool as Usual with the addition of young adult mentors. Following snack, mentors will lead students in a short emotion regulation exercise including physical activity and breathing exercises. Mentors will prompt students to identify how they are feeling and make connections between the activities they are doing and their mood and then do activities with students in each class. On T/H, \~4 mentors will lead a new DiscoverU  club which is based on behavioral activation principles and spends more time helping students identify and do more activities that improve their mood. The class promotes physical activity as an important strategy for mental health."
215000849|NCT06631144|BEHAVIORAL|Spanish-language Caregiver-Enabled Care Program (CECP)|CECP is a nonmedical digital population health intervention to support and engage family caregivers of persons with dementia. CECP consists of digital content, including health education videos and tutorials, that is delivered to caregivers on a dedicated tablet based on their specific needs. Caregivers are supported by a proactive human coach who provides support, access to resources, and performs risk mitigation measures as necessary. Alerts are shared with providers and/or care management teams via a data hub that makes it easy to track, manage and resolve alerts. CECP is delivered over a 6-month period via a dedicated tablet that is shipped to the caregiver's home at no cost to the caregiver or person with dementia. This study's CECP is in Spanish.
215000850|NCT06690346|OTHER|Systematic oral health education|Provide systematic oral health education to patients in experimental group, including oral hygiene instruction and dietary instruction
215000851|NCT06690346|OTHER|Routine oral health education|Provide routine oral health education to patients in control group, including routine oral self-care instruction
214394805|NCT03037879|OTHER|mSMT Control|Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
214394806|NCT04840888|DRUG|LY3484356|Administered orally.
214394807|NCT04840888|DRUG|Omeprazole|Administered orally.
214394808|NCT04840888|DRUG|Itraconazole|Administered orally.
214394809|NCT04840888|DRUG|Carbamazepine|Administered orally.
214394810|NCT00474721|DRUG|ibuprofen|
214394811|NCT00474721|DRUG|acetaminophen with codeine|
214693824|NCT01321931|DRUG|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
214394812|NCT01265589|DRUG|surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
214394813|NCT01265589|DRUG|surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
214394814|NCT02388074|DEVICE|CyPath®|CyPath® diagnostic assay for the early detection of lung cancer using sputum
214394815|NCT05787938|DEVICE|MRI|A procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body. A contrast agent, such as gadolinium, may be injected into a vein to help the tissues and organs show up more clearly in the picture. MRI may be used to help diagnose disease, plan treatment, or find out how well treatment is working. It is especially useful for imaging the brain and spinal cord, the heart and blood vessels, the bones, joints, and other soft tissues, the organs in the pelvis and abdomen, and the breast. Also called magnetic resonance imaging, NMRI, and nuclear magnetic resonance imaging.
214394816|NCT00000782|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
214394817|NCT00000782|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214394818|NCT06493838|DRUG|intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.|intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
214394819|NCT06493838|DRUG|Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.|Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.
214394820|NCT03464604|DIAGNOSTIC_TEST|active|Pre-screening for melanoma by qualified nurse
214394821|NCT00003458|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
214394822|NCT02133924|DRUG|natalizumab|Natalizumab 300mg on days 0 and 14.
214394823|NCT02133924|DRUG|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
214394824|NCT01254890|DRUG|Azacitidine|75 mg/m\^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
214394825|NCT01254890|DRUG|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
214394826|NCT02773264|DEVICE|Ultrasound|Ultrasound Elastography of soft tissue and organ lesions
214394827|NCT03320460|DRUG|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
214394828|NCT03320460|DEVICE|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
214394829|NCT03320460|OTHER|Placebo gel|Placebo gel for 30 consecutive days to mask the treatment
214502850|NCT07043127|OTHER|BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
214693825|NCT02704676|OTHER|marker(CA-125)|measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
215000852|NCT06690970|DIAGNOSTIC_TEST|68Ga/18F-PSMA/PSFA|Each subject receive a single intravenous injection of 68Ga/18F-PSMA/PSFA, and undergo PET/CT imaging within the specificed time.
215000853|NCT01290835|RADIATION|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
215000854|NCT01290835|RADIATION|stereotactic radiotherapy|
215000855|NCT07023354|DRUG|BI 1291583|BI 1291583
215000856|NCT07023731|DRUG|ARV-806|Intravenous infusion at assigned dose and dosing schedule
215000857|NCT07023640|DIAGNOSTIC_TEST|68Ga-DOTA-mPNE|PET/CT examination was performed after intravenous injection of 68GA-DOTA-mPNE tracer
215094859|NCT06298201|OTHER|E-Based Physical Exercise Intervention|The intervention comprises a 6-months home-based resistance training for the lower extremities, conducted twice weekly.
215094860|NCT01091818|DRUG|dexmedetomidine|Dexemedethomidine is given as major sedative drug
214394830|NCT03320460|OTHER|Placebo Photobiomodulation|Laser device will be positioned over the lesion but will be switched off to mask the treatment.
214394831|NCT01213862|BEHAVIORAL|Home Based Education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
214394832|NCT01340911|DRUG|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
214394833|NCT01340911|DRUG|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
214394834|NCT03746977|DIETARY_SUPPLEMENT|Protein|Protein supplementation 1.2 or 1.5 g/kg body mass/d
214394835|NCT03746977|BEHAVIORAL|Walking|Walking with a volume corresponding to 250 kcal/d
214394836|NCT03746977|BEHAVIORAL|WB-EMS application|WB-EMS application 1.5x 20 min/week
214394837|NCT05178264|DRUG|SARS-CoV-2 vaccines|All patients treated at least with 1 SARS-CoV-2 vaccine
214394838|NCT04183673|PROCEDURE|Laser therapy-cryo thermal therapy|5 days per week, 3 weeks, sessions including laser therapy + cryo therapy followed by usual rehabilitation
214394839|NCT04183673|PROCEDURE|Usual care|5 days per week, 3 weeks, sessions of usual rehabilitation
214394840|NCT04364321|DRUG|Clonazepam 0.5 MG|Clonazepam 0.02 mg/kg only one dose
214394841|NCT04364321|DRUG|Diazepam Tablets|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)
214394842|NCT01185054|OTHER|½ strength apple juice|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.
214502851|NCT07042477|BEHAVIORAL|Integrated Telemedicine Program|The integrated telemedicine program is short-term bridge support provided by a virtually accessible team, including a behavioral health provider (Health Psychologist or Licensed Clinical Social Worker \[LCSW\]) and Community Health Worker (CHW). Once stabilized, members transition from bridge support to ongoing care with a Geisinger Health System Primary Care Provider and Behavioral Health Provider.
214502852|NCT07042919|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
214502853|NCT07042919|PROCEDURE|Computed Tomography|Undergo CT
215000858|NCT07023393|DEVICE|Intraoperative spinal measurement system|The design is a prospective study to evaluate the effectiveness of a novel intraoperative spinal measurement tool to assist the surgeon with achieving preoperatively planned alignment-related parameters during surgery.
215000859|NCT02244073|DRUG|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
215000860|NCT07026266|OTHER|Water|"Calcium-bicarbonate mineral water Lete"
215000861|NCT07026266|OTHER|Water|"Oligomineral water Sorgesana"
215000862|NCT06696781|PROCEDURE|Pacemaker stimulation|We deactivate the pacemaker to establish baseline measurements of NOL, bispectral index (BIS), mean arterial pressure (MAP), and heart rate (HR), recorded every minute for 5 minutes. We then adjust the pacemaker to 90 bpm and 110 bpm in subsequent 5-minute phases to assess the physiological responses. After deactivating the pacemaker to analyze washout effects, we reactivate it at 110 bpm to observe any changes. A temporary disconnection of the NOL monitor for 1 minute tests system reliability, followed by continued monitoring at the same rate for an additional 5 minutes. Each measurement phase averages data from the last 10 seconds each minute to ensure accuracy and reduce artifacts.
215000863|NCT07027488|DRUG|AB821|AB821 will be administered via IV infusion using weight-based dosing. Patients will receive the drug at a dose escalation every two weeks for up to 52 cycles.
215000864|NCT06700070|DRUG|PBA-0111|Intratumoral microdose injection by the CIVO device.
215000865|NCT07026331|PROCEDURE|balloon angioplasty|Balloon angioplasty treatment followed by standard medical therapy post-procedure.
215000866|NCT07026331|PROCEDURE|Stent|Patients will receive either balloon-assisted stenting or direct stenting, followed by standard medical therapy after the endovascular treatment.
215000867|NCT07026344|PROCEDURE|Stent placement|For patients who fail thrombectomy, perform stent placement.
215000868|NCT07026344|PROCEDURE|Continued Thrombectomy|For patients with failed thrombectomy, perform at least one additional thrombectomy attempt
215000869|NCT07026344|PROCEDURE|balloon angioplasty|For patients who fail thrombectomy, perform balloon angioplasty.
214394843|NCT01185054|OTHER|Pediatric Electrolyte|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
214394844|NCT01398501|DRUG|Sorafenib|Oral, 200 to 400 mg QD or BID
214394845|NCT01845948|BEHAVIORAL|parental training programme|In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.
214394846|NCT01845948|BEHAVIORAL|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
214394847|NCT03176043|PROCEDURE|IV Fluid Administration|Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
214394848|NCT02585791|OTHER|Propylene Glycol|inhaled Propylene Glycol (PG) by vaporing
214394849|NCT02585791|OTHER|vegetable glycerin|inhaled vegetable glycerin (VG) by vaporing
214394850|NCT02585791|OTHER|PG+VG|inhaled PG+VG by vaporing
214394851|NCT04157686|DRUG|MT10109L Dose 1|MT10109L Dose 1 will be injected into the GL area
214394852|NCT04157686|DRUG|MT10109L Dose 2|MT10109L Dose 2 will be injected into the LCL area
214394853|NCT04157686|DRUG|MT10109L Dose 1 + Dose 2|MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area
214502854|NCT07042919|PROCEDURE|Echocardiography Test|Undergo ECHO
214502855|NCT07042919|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214502856|NCT07042919|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214502857|NCT07042919|DRUG|Zanzalintinib|Given PO
214502858|NCT07042438|BIOLOGICAL|Axicabtagene Ciloleucel|Given CAR-T cells
215000870|NCT07032597|DEVICE|HArmonyCa Lidocaine Injectable Gel|Subdermal or Deep Dermal or Supraperiosteal Injection
215000871|NCT07032597|DEVICE|Restylane® Perlane® Lidocaine|Subcutaneous to Supraperiosteal Implantation Injection
215000872|NCT07124039|DRUG|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using the EHR data from the Tianjin Healthcare and Medical Big Data Platform (China) database.
214394854|NCT01564745|OTHER|Functional respiratory evaluation|Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
214394855|NCT00218803|BEHAVIORAL|Nurse asthma education intervention|Asthma Education
214394856|NCT00218803|BEHAVIORAL|Control Group|Asthma Education
214394857|NCT02377713|DRUG|KHK6640|Single ascending dose administration
214394858|NCT02377713|DRUG|Placebo|Single ascending dose administration
214394859|NCT03122756|DRUG|Dexamethasone|Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.
214394860|NCT03122756|OTHER|Normal Saline|Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
214394861|NCT05668936|DRUG|Cotadutide|Participants will receive a subcutaneous injection of cotadutide.
214394862|NCT05668936|DRUG|Cotadutide-placebo|Participants will receive a subcutaneous injection of cotadutide-placebo.
214394863|NCT05668936|DRUG|Moxifloxacin|Participants will receive a single oral dose of Moxifloxacin film-coated tablet.
214394864|NCT05668936|DRUG|Moxifloxacin-placebo|Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.
214394865|NCT03753776|DRUG|Placebo pills of Radium bromatum|Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
214394866|NCT03753776|DRUG|Radium bromatum pills|Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
214394867|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna placebo pills|Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
214394868|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna pills|Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
215094861|NCT01091818|DRUG|Midazolam|Midazolam is given as major sedative drug
214394869|NCT03609554|OTHER|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
214394870|NCT01216293|DRUG|Dexlansoprazole|Dexlansoprazole 60 mg capsules
214394871|NCT01216293|DRUG|Esomeprazole|Esomeprazole 40 mg capsules
214394872|NCT01216293|DRUG|Placebo|Placebo-matching capsules
214394873|NCT01080651|DRUG|Voriconazole|Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
214394874|NCT04496843|DIAGNOSTIC_TEST|HWA09 Measurement|Simultaneous recording of Withings HWA09 Device and PSG devices for the reference.
214394875|NCT01243073|DRUG|Imetelstat|
214394876|NCT04590859|PROCEDURE|Block performed|Comparing block performed with penile blood flow
214394877|NCT04590859|DEVICE|LMA placement|Placement of LMA for airway securement
214394878|NCT02679534|OTHER|hand massage|
214394879|NCT02679534|OTHER|hand holding|
214394880|NCT02679534|OTHER|application of unscented hypoallergenic cream|
214394881|NCT02679534|OTHER|environmental adjustments|
214394882|NCT06394661|DRUG|Serplulimab+NabPE|Serplulimab plus neoadjuvant nab-PE: Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serplulimab 4.5mg/Kg ivgtt on Day 3）
214394883|NCT05280405|DRUG|Infliximab|Infliximab
214394884|NCT05632536|PROCEDURE|SACRAL ESP AND CAUDAL BLOCK|Application of ultrasound-guided sacral erector spinae plane (ESP) block or ultrasound-guided caudal block with 1mL/kg 0.25% bupivacaine (local anesthetic) to patients
214394885|NCT06609330|BEHAVIORAL|Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)|Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.
214394886|NCT01338558|DRUG|bevacizumab [Avastin]|5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
214394887|NCT01338558|DRUG|cetuximab|400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
214394888|NCT01338558|DRUG|mFOLFOX6|Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
214394889|NCT06376981|DRUG|Hyaluronic acid injection|An injection of 2 ml of Acid hyaluronic
214394890|NCT06376981|DRUG|Corticosteroid injection|An injection of 1 ml of corticosteroids
214394891|NCT06376981|DRUG|Placebo injection|An injection of 2 ml of placebo (physiological serum)
214394892|NCT00608725|RADIATION|DAXOR|131-I-Human Serum Albumin Blood Volume Assessment Kit
214394893|NCT00608725|PROCEDURE|QSweat|Quantitative Sweat Testing
214394894|NCT00608725|DRUG|Intrinsic Heart Rate|Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
214394895|NCT00697554|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection
214394896|NCT00697554|BIOLOGICAL|Engerix™-B|3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
214394897|NCT01779713|GENETIC|Case-control transcriptomic study|No intervention
215094862|NCT04336852|PROCEDURE|Flow mediated dilation (brachial and femoral arteries)|Assessment of vascular function of the brachial and femoral arteries.
215094863|NCT04336852|PROCEDURE|Cerebral vascular reactivity to carbon dioxide (CO2)|Cerebral blood flow responses to increasing partial pressure of CO2
215094864|NCT04336852|PROCEDURE|Cerebral vascular function test|Cerebral blood flow responses to a reactive hyperemia stimulus
215094865|NCT04318327|BIOLOGICAL|PHE885|Infusion
214394898|NCT06618105|DRUG|Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations|Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.)
214394899|NCT06618105|DRUG|Test Placebo|Matching Placebo of T inhalation aerosol
214394900|NCT06618105|DRUG|Reference Placebo|Matching Placebo of R inhalation aerosol
214394901|NCT06618105|DRUG|Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations|Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.)
214394902|NCT06622278|BEHAVIORAL|Flipped Classroom|The flipped classroom educational model requires participants to independently review educational material before class, and class time with the health educator is spent engaging in group and individual skills-based activities and problem-solving assignments. The theoretical basis for the development of active learning is to elicit higher cognitive learning, according to the revised Bloom's taxonomy and shift independent student time to passive learning (remembering and understanding) and collaborative student and educator time to active learning (applying, analyzing, evaluating, and creating). Thus, the weight management education will include: case vignettes, group debates/discussions, think-pair-share activities, gamification of health-related topics, creation of meal and physical activity, problem-solving barriers to a healthy diet and physical activity, and hands-on worksheets.
214394903|NCT05516017|DEVICE|Vestibular Electrical Stimulator and Pinhole Glasses|"It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.~The pinhole glasses are made of 2 pieces of opaque black plastic material with a total of 113 holes on each side. The opaque black plastic is 1.7 mm thick, 4.5 cm wide, and 5.5 cm long.~The holes in the opaque black material are arranged horizontally in 11 rows from top to bottom. The diameter of each hole is 1.1 mm, the horizontal distance of the holes from each other is 4.5 mm, and the vertical distance is 3.5 mm."
214394904|NCT05516017|DEVICE|Vestibular Electrical Stimulator|It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.
214394905|NCT06626178|DIAGNOSTIC_TEST|Computed tomography (CT) scan low dose|The radiological investigation will be done with multi-detector-row (64 or more) computed tomography (CT) scanners at low-dose protocol. The low-dose spiral CT consists of a CT study of the chest, without the need for injection of contrast medium, characterized by less radio exposure than the standard CT of the chest with high sensitivity in detecting pulmonary nodules.
214394906|NCT06626178|PROCEDURE|Blood sampling|Peripheral venous blood sampling (20 ml)
214394907|NCT06626178|PROCEDURE|Tissue sampling (lung)|sampling of tumor and healthy tissue during surgery
214394908|NCT06626178|OTHER|Spirometry|Spirometry measurement using spirometer
214394909|NCT06626178|OTHER|Questionnaires|Compilation of epidemiological questionnaire, quality of life questionnaires
214394910|NCT06626178|OTHER|Smoking cessation program|Study guarantee valid support for quitting smoking, which for a smoker is a more effective intervention to reduce the risk of developing lung cancer, myocardial infarction and other smoking-related diseases
214394911|NCT06626178|OTHER|Carbon monoxide measurment|Measurment of Carbon monoxide (CO)
214394912|NCT06626178|OTHER|Cardiovascular primary prevention|Intervention done in order to find the presence of coronary calcifications
214394913|NCT06624423|OTHER|corn silk tea|Corn Silk Tea
214394914|NCT05244148|DEVICE|IP1 - Stérimar BLOCKED NOSE Baby nasal spray|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
214394915|NCT05244148|DEVICE|IP2 - Stérimar Stop & Protect Cold Baby + standard of care|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
214394916|NCT05244148|BEHAVIORAL|Standard of Care|hydration + rest at home + if needed paracetamol
214394917|NCT02104856|DEVICE|Alair System (Bronchial Thermoplasty)|
214394918|NCT00130650|DEVICE|Pain Ease|
215000873|NCT07125729|PROCEDURE|Biospecimen Collection|Undergo archival tissue and/or blood sample collection
215000874|NCT07125729|OTHER|cfDNA or ctDNA Measurement|Undergo Haystack MRD and Signatera ctDNA/cfDNA testing
215000875|NCT07125729|OTHER|Electronic Health Record Review|Ancillary studies
214394919|NCT01949675|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
214394920|NCT01949675|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
214394921|NCT01949675|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
214394922|NCT03750279|OTHER|Exercise therapy|"* 5 min. warm up with light exercises for the lower limb prior to strength/endurance exercise therapy.~* Strength/endurance exercise therapy including level 1 or 2 per session:~Level 1: Pelvic lifts (2x15 rep.), one-legged knee bends (2x10 rep. per leg), hip abductions (2x10 rep. per leg). The participants may progress from level 1 to level 2.~Level 2: Pelvic lifts (3x15 rep.), one-legged knee bends (3x10 rep. per leg), hip abductions (2x10 rep. per leg), sideways slide (2x10 rep. per leg), and backwards slide (2x10 rep. per leg). The participants may regress from level 2 to level 1."
215000876|NCT07036666|DIETARY_SUPPLEMENT|Active Product|Women's (vaginal) Health Active Product
215000877|NCT07123636|DIETARY_SUPPLEMENT|Hair Care Products|"Daily oral intake of 2 tablets (Not Today, Grey). Twice-daily application of 3-4 pumps of To The Root serum. Wash and Smooth used according to hair type (daily or every other day)."
215000878|NCT07122336|PROCEDURE|PVI|PVI
215000879|NCT07122336|PROCEDURE|PWI|PWI
215000880|NCT07122336|PROCEDURE|EGM|EGM
215000881|NCT07114575|OTHER|Gait Analysis|All participants will undergo gait analysis at three different walking speeds.
215000882|NCT07122440|OTHER|acute mastoiditis|retrospective data collection from clinical charts
214394923|NCT03750279|OTHER|LLLT|\- LLLT (60 mW mean output per probe, 904 nm wavelength) applied to the knee in adherence with the recommendations by World Association for Laser Therapy, in terms of dosage per treatment spot.
214502859|NCT07042438|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215094866|NCT00687102|DRUG|tamoxifen|oral tamoxifen plus placebo daily for 5 years
215094867|NCT00687102|DRUG|raloxifene|oral raloxifene plus placebo daily for 5 years
215121358|NCT02398240|DRUG|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
214394924|NCT03750279|OTHER|Sham LLLT|\- Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
214394925|NCT03359681|DRUG|Metformin Hydrochloride|metformin 500mg three times a day 20 days before colon cancer surgery and 10 days after.
214394926|NCT03359681|DRUG|Placebo oral capsule|placebo 500mg three times a day 20 days before colon cancer surgery and 10 days after.
214394927|NCT00897611|PROCEDURE|DNA methylation analysis|
214394928|NCT00897611|PROCEDURE|polymerase chain reaction|
214394929|NCT00897611|PROCEDURE|computed tomography|
214394930|NCT00897611|PROCEDURE|magnetic resonance imaging|
214394931|NCT02309528|OTHER|Educational computerized digital stories|computerized digital stories made by American Indians
214394932|NCT01295346|OTHER|Head CT scan and blood draw|
214394933|NCT01492517|OTHER|Ozone exposure|Exposure to 0.3ppm ozone for 2 hours
214394934|NCT01492517|OTHER|Diesel exhaust|Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3
214394935|NCT01492517|OTHER|Ozone18|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
214394936|NCT01492517|OTHER|Clean Air|Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
214394937|NCT00225420|DRUG|docetaxel|Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
214394938|NCT00225420|DRUG|leuprolide acetate|Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
214394939|NCT00225420|RADIATION|radiation therapy|The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
214394940|NCT00360555|DRUG|flibanserin|flibanserin 25 mg b.i.d
214394941|NCT00360555|DRUG|flibanserin 50mg|flibanserin 50mg qhs/b.i.d.
214394942|NCT00360555|DRUG|flibanserin 100mg|flibanserin 50 mg b.i.d/100mg qhs
214394943|NCT00360555|DRUG|placebo|placebo comparator
214394944|NCT02836977|DRUG|tegafur-uracil|Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
214394945|NCT05140993|BEHAVIORAL|extended emotional and orientation support|extended emotional and orientation support
214394946|NCT06228235|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"rTMS: rTMS is a form of non-invasive brain modulation. High-frequency rTMS will be administered. Pulses will be delivered at the frequency of 20Hz, in 50 trains of 40 pulses, 2000 pulses in total.~Behavioral priming with regulation of craving: During rTMS, participants will look at pictures either related or unrelated to smoking. When looking at pictures related to smoking, participants will either upregulate cravings by thinking about the immediate positive experience of smoking or downregulate cravings by thinking about long-term negative consequences of smoking. When looking at neutral pictures unrelated to smoking, participants will not regulate their cravings."
214394947|NCT01109303|PROCEDURE|TightRope System- Arthrex® / Dynamic Implant|Patients are operated on using a dynamic implant, the TightRope System by Arthrex®. The ankle is immobilized in a plaster boot for 6 weeks.
214394948|NCT01109303|PROCEDURE|Screw fixation - Synthes® / Static Implant|Patients are operated on using a static implant, the rigid four-cortices 3,5 mm screw fixation by Synthes®. The ankle is immobilized in a plaster boot for 6 weeks.
214394949|NCT03664167|DIETARY_SUPPLEMENT|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
214394950|NCT06186505|DEVICE|AirGlove|AirGlove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intraveneous drugs by gently heating the patients arm up as it forces warm air through a double walled polythene glove. In this study, the device will be used on the leg of the participants as means of encouraging circulation to the area.
214394951|NCT04122053|BEHAVIORAL|Intervention group with genotype information|Results of genotyping will be translated into personalised dietary recommendations. Subjects will be informed about their genotypes from the beginning of the study. The importance of personalised recommendations will be explained.
214394952|NCT04122053|BEHAVIORAL|Control group without genotype information|Subjects will receive personalised dietary recommendations, but at the beginning they will not be informed about their genotypes and the meaning of personalisation. Information about their genotype will be given to the participants at the and of study.
214394953|NCT05484258|BEHAVIORAL|Shared Medical Visit|Group visit wherein physician and Social Worker, would be discussing topics relevant to the population.
214394954|NCT00000556|DRUG|amiodarone|
214394955|NCT00000556|DRUG|sotalol|
214394956|NCT00000556|DRUG|propafenone|
214394957|NCT00000556|DRUG|flecainide|
214394958|NCT00000556|DRUG|quinidine|
214394959|NCT00000556|DRUG|moricizine|
214394960|NCT00000556|DRUG|disopyramide|
214394961|NCT00000556|DRUG|procainamide|
214394962|NCT00000556|DRUG|adrenergic beta antagonists|
214394963|NCT00000556|DRUG|verapamil|
214394964|NCT00000556|DRUG|diltiazem|
214394965|NCT00000556|DRUG|digoxin|
214394966|NCT00000556|PROCEDURE|catheter ablation|
214394967|NCT00000556|DEVICE|pacemaker, artificial|
214394968|NCT01023308|DRUG|Panobinostat|Panobinostat was administered 3x week ( 2 weeks on 1 week off)
214394969|NCT01023308|DRUG|Bortezomib|Bortezomib was administered 2 x week ( 2weeks on 1 week off)
214394970|NCT01023308|DRUG|Dexamethasone|Dexamethasone was adminstered on day of Bortezomib and the day after Bortezomib administration
214394971|NCT01023308|DRUG|Placebo|Placebo was administered 3x week ( 2 weeks on 1 week off)
214394972|NCT00551213|BIOLOGICAL|Robatumumab|
214394973|NCT00551213|DRUG|Irinotecan|
214394974|NCT00551213|BIOLOGICAL|Cetuximab|
214394975|NCT00551213|DRUG|Capecitabine|
214394976|NCT00551213|DRUG|FOLFOX|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
214394977|NCT00551213|DRUG|CAPEOX/XELOX|Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)
214394978|NCT00551213|DRUG|FOLFIRI|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
214502860|NCT07042438|DRUG|Chemotherapy|Receive chemotherapy
214394979|NCT03350477|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
214394980|NCT03350477|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
214394981|NCT00255814|RADIATION|radiation therapy|
214394982|NCT01015573|DEVICE|magnetic sensor system to measure the movements of finger tapping|
214394983|NCT04612114|DIAGNOSTIC_TEST|Belun Ring|Simultaneous recording of Belun Ring data (pulse oximeter, pulse rate and actigraphy) and standard of care PSG will be performed for one night.
214394984|NCT03801720|OTHER|Ultrasound|Using ultrasound stimulation to induce micturition.
214394985|NCT04653896|DEVICE|Keeogo|The Keeogo is the only commercially available (in Canada) robotic exoskeleton for a non-paralyzed population who can stand and initiate a stepping action, but have impaired mobility for functional tasks. Keeogo provides active assistance during stance and swing phases and assists users to perform functional mobility tasks including walking, stair climbing, sit-to-stand, bending, squatting, and kneeling.
214394986|NCT02809027|DRUG|Ginger|
214394987|NCT02809027|DRUG|Placebo|
214394988|NCT01383993|DRUG|Voriconazole|"Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
214394989|NCT01383993|DRUG|Voriconazole|"Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
214394990|NCT03251404|OTHER|Injury prevention exercise programs|The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
214394991|NCT02928094|BIOLOGICAL|Ad5FGF-4|Ad5FGF-4 administered via intracoronary infusion using standard balloon catheter, and under conditions of transient ischemia.
214394992|NCT02928094|BIOLOGICAL|Placebo|Placebo buffer administered via intracoronary infusion using standard balloon catheter, without transient ischemia.
214394993|NCT05545969|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
214394994|NCT05545969|DRUG|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET)
214394995|NCT04689022|BEHAVIORAL|Mississippi Scale for Combat-Related PTSD (M-PTSD)|The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).
214394996|NCT04689022|DIAGNOSTIC_TEST|visual analogue scale (VAS)|pain intensity
214394997|NCT04689022|DIAGNOSTIC_TEST|Douleur Neuropathique 4 questions (DN4)|neuropathic pain component
214394998|NCT00414869|DRUG|NCX-1000|500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days
214394999|NCT00414869|DRUG|Placebo|Inactive powder matching NCX-1000
214395000|NCT01093300|DEVICE|Paclitaxel-eluting balloon catheter|
214395001|NCT01093300|DEVICE|Everolimus-eluting stent|
214395002|NCT03010735|DIETARY_SUPPLEMENT|probiotics|Daily take 4.0E+10 CFU of probiotics
214395003|NCT03010735|DIETARY_SUPPLEMENT|Placebo|
215000883|NCT07124689|OTHER|Treatment outcome|Patients will be evaluated for their central sensitization scores before the injection, the pain they experienced during the injection 1 hour after the injection, their daytime and nighttime pain intensity before and 1 month after the injection, their pain thresholds for tactile sensation around the shoulder, and their pain and disability levels.
215121359|NCT00001002|DRUG|Zidovudine|
215121360|NCT00001002|DRUG|Foscarnet sodium|
214395004|NCT03544528|PROCEDURE|Regeneration|Apical bleeding will be induced by passing a hand instrument beyond the apical foramen to allow blood filling in the canal. Mineral trioxide aggregate will be placed directly over the coagulated blood clot.
214395005|NCT00218985|BEHAVIORAL|Exercise training|Intensity controlled exercise training before the scheduled bypass surgery
214395006|NCT03572010|DIETARY_SUPPLEMENT|FeFum fortified maize test meal|Maize porridge extrinsically labeled with 2 mg ferrous fumarate (58FeFum); only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L); cereal staple foods, like maize, depending on milling, may be high in phytic acid, a potent iron absorption inhibitor
214395007|NCT03572010|DIETARY_SUPPLEMENT|FeSO4 fortified LNS|self-made Lipid-based nutritional supplement (LNS) extrinsically fortified and labeled with 6 mg ferrous sulfate (57FeSO4); only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L); LNS may be a better food matrix for iron supplementation compared to maize-based porridge; contains canola oil, peanut paste, milk powder, sugar, maltodextrin and palm stearin
214395008|NCT03572010|DIETARY_SUPPLEMENT|FeSO4 supplement|170 mg iron tablets as FeSO4 (containing 55 mg of elemental iron) with 6 mg extrinsically labeled 57Fe; will be given together with a glass of water; only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L);
214395009|NCT03572010|DIETARY_SUPPLEMENT|FeSO4 fortified fruit juice|Fruit juice labeled with 12 mg 57Fe as FeSO4; in the group for iron sufficient children
214395010|NCT01492855|PROCEDURE|Arthroscopy|Arthroscopy is offered for the patients who do not benefit from conservative treatment.
214502861|NCT07042438|PROCEDURE|Fecal Microbiota Transplantation|Given PO
214395011|NCT01492855|BEHAVIORAL|Non-invasive treatment|All patients will receive information and supervised exercises by a physiotherapist.
214395012|NCT04964765|DIAGNOSTIC_TEST|Mapping|CardioInsightTM Cardiac Mapping System is a non-invasive single beat cardiac mapping system that provides three-dimensional electroanatomic maps of the heart. The CIT vest is attached to the patient's torso for non-invasive mapping. To ensure correct and rapid mapping of the NOAF by the CIT device, it is essential to briefly slow down the patient's heart rate below 50bpm for a few seconds. Therefore 6mg adenosine as a rapid i.v. bolus will be administered. The adenosine application will slow down the patient's heart rate and allow for correct mapping by the CIT device. Medical therapy of atrial fibrillation is started immediately according to local protocol. Since non-invasive mapping is performed within a few minutes, the therapy of atrial fibrillation will not be critically delayed. Consecutively, a low-dose thoracic computed tomography (CT) scan (neck to upper abdomen) will be performed independent from the patient's rhythm.
214395013|NCT04964765|DIAGNOSTIC_TEST|Computed tomography scan|The CT scans will follow a standardised protocol as predefined by the manufacturer of the CIT vest, Medtronic (Dublin, Ireland). After the sensor array has been placed on the patient, the patient is ready to undergo a CT scan to register each electrode's locations with respect to the body surface. All CT scans cover a body region from neck to the upper abdomen, have no cardiac gating performed or any contrast agent given. The CT scans are acquired on 3 CT scanners manufactured by Siemens Corporation (Berlin, Germany) with a fixed tube voltage of 80 kVp and 250 effective mAs (=mAs/pitch). The reconstruction parameters are of 3 mm slice thickness and of 1.5 mm increment (slice overlap) The estimated effective dose (ED) is 3.2 mSv per patient.
214395014|NCT02646553|OTHER|Children refered to the obesity clinic|Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
214395015|NCT03796689|DEVICE|Smartphone-linked HBPM and associated app|Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publicly available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.
214395016|NCT03796689|DEVICE|Standard HBPM|Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publicly available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
214395017|NCT03642002|OTHER|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
214395018|NCT03642002|OTHER|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
214395019|NCT03642002|OTHER|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
214395020|NCT03642002|BEHAVIORAL|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
214395021|NCT03642002|OTHER|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
214395022|NCT06297824|BEHAVIORAL|ERGT-A|Emotion regulation group therapy for adolescents
214395023|NCT04201522|OTHER|Normocapnic hyperpnoea intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
214395024|NCT04201522|OTHER|Sham intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
214395025|NCT02561455|DRUG|Gilteritinib|oral tablet
214395026|NCT01050075|OTHER|acupuncture therapy|acupuncture therapy
214395027|NCT01050075|OTHER|questionnaire administration|Ancillary study
214395028|NCT01050075|OTHER|management of therapy complications|To be determined by the treating physician
214395029|NCT05049044|OTHER|Quality of Life Questionnaire-Core 30 (QLQ-C30)|The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
214395030|NCT01577030|DIETARY_SUPPLEMENT|Non-fat dairy|Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
214395031|NCT01577030|DIETARY_SUPPLEMENT|Add 4 servings fruit|Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
214395032|NCT05969522|DRUG|GlucoCorticoid|The high-risk group: methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)\*3 days , with 2 courses, interval 5-7 days;Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage, with the first reduction after 2-4 weeks. The dose was reduced once every 3 weeks in the first 3 months, and once every 4 weeks in the next 3 months, with a reduction of 5-10mg/ day each time; Rituximab：375 mg/m2/ time, once a week for 4 times;Intravenous cyclophosphamide 7.5-10mg/kg.d\*2 days(Max.500mg/d), once every 4 weeks, twice in total, at the 8th and 12th week.The medium-low risk group: methylprednisolone was the same dose as before, but only with 1 course, then followed by oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d), divided into three times for 3 weeks, and then changed to morning daily; The dose was reduced as the high-risk group ;Rituximab was the same dose as before.
215000884|NCT07122050|DEVICE|Prizvalve® system Transcatheter valve-in-valve replacement|Transcatheter valve-in-valve replacement procedure was performed according to standard clinical practice. Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system will be attempted.
215000885|NCT07124481|BEHAVIORAL|Mindfulness based stress reduction|8 weekly sessions of 2.5 hour per session, face-to-face in a group consisting of maximum 15 participants, supervised by a certified mindfulness trainer
215000886|NCT07123090|DRUG|Sasanlimab|Recombinant humanized monoclonal antibody, prefilled syringe, subcutaneous (under the skin) injection per protocol
214395033|NCT03482674|BEHAVIORAL|DIMINI lifestyle intervention|DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.
214395034|NCT00521872|PROCEDURE|STARR Operation|
214395035|NCT04925921|DEVICE|SR-1 Laser|3-4 treatments at 4-6 week intervals
214395036|NCT00337116|DRUG|iso sorbide dinitrate iv bolus or s/l|
214395037|NCT05545462|DRUG|Doxycyclin|THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
215000887|NCT07123090|DRUG|Palbociclib|Cyclin-dependent kinase (CDK) 4/6 inhibitor, tablet taken orally per protocol
214395038|NCT05545462|OTHER|COMMON SALT|THE USE OF COMMON SALT IN TREATMENT OF UMBILICAL GRANULOMA
214395039|NCT02580682|DRUG|Sanfu herbal patch|The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
214395040|NCT02580682|DRUG|Sanfu moxibustion|Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
214395041|NCT02580682|DRUG|Sanfu herbal patch and moxibustion|use Sanfu moxibustion followed by Sanfu herbal patch
214395042|NCT03112122|BIOLOGICAL|autologous bone marrow concentrate|injection of autologous bone marrow concentrate
214395043|NCT03112122|BIOLOGICAL|bone substitute i-FactorTM|subchondral injections of i-FactorTM
214395044|NCT03112122|PROCEDURE|core decompression|subchondral anterograde drilling
214395045|NCT04708184|DRUG|GLPG3970 oral solution|GLPG3970 for oral administration
214395046|NCT04708184|DRUG|GLPG3970 tablet|GLPG3970 for oral administration
214395047|NCT03623711|DRUG|Escitalopram|participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
214395048|NCT03623711|DRUG|Duloxetine|participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.
214395049|NCT03623711|DRUG|Bupropion|participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.
214395050|NCT03623711|OTHER|Healthy control|Healthy control take placebo tablets
214395051|NCT03749356|DRUG|TacroBell SR cap.|"* Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment."
215094868|NCT02227394|DRUG|Z7200|"Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)"
214395052|NCT05193942|BEHAVIORAL|Intervention Our Plan|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the intervention arm will be granted access and instructed to use the Our Plan program as directed. The Our Plan program includes modules covering topics of communication, decision-making, HIV/STI prevention, and stigma and discrimination. Each module contains content, questions, and activities for the participant and couple to complete. One goal of OurPlan is to help both partners of the couple create and use a risk- reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own confidence, intention, and perceived ability to use these strategies.
215094869|NCT02227394|DRUG|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
214395053|NCT05193942|BEHAVIORAL|Internation Informational Control|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the informational control condition will receive a webpage that contains information about HIV/STI prevention options and resources. This control condition represents the current equivalent of a standard of care for online HIV resources.
214395054|NCT03206294|OTHER|pharmacist assessment|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
214395055|NCT04372511|DEVICE|Binaural Beats|Device: Sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
214395056|NCT05727683|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (25 mg/m2/day for 3 days) plus cyclophosphamide IV (250 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JWCAR029 cells infusion. Phase 1 will evaluate up to 4 JWCAR029 cells dose levels.
215094870|NCT05443724|DRUG|CVL-231 30 mg|Oral tablets
215094871|NCT06972095|PROCEDURE|EVAR|endovascular repair of the AAA with the endurant stent graft
214395057|NCT06550830|BIOLOGICAL|Sinovac PCV24 formulation 1|One dose of Sinovac PCV24 formulation 1(0.5mL)
215000888|NCT07123090|DRUG|Axitinib|Vascular endothelial growth factor (VEGF) inhibitor, tablet taken orally per standard of care
215094872|NCT06585150|DRUG|Obeldesivir|Tablet administered orally
215094873|NCT06585150|DRUG|Obeldesivir Placebo|Tablet administered orally
215094874|NCT06567704|BEHAVIORAL|Interviews|Interviews
215094875|NCT06493240|RADIATION|radiation|45 Gy radiation dose in 25 fractions to the pelvis
215094876|NCT06493240|DRUG|PD-1 Monoclonal Antibody|200mg Sintilimab after radiation (3 times, 2-week interval)
215094877|NCT06493240|PROCEDURE|TME surgery|TME surgery for 6\~8 weeks after radiation
215094878|NCT05138549|DRUG|Astaxanthin|12 mg oral astaxanthin supplement
215094879|NCT05138549|OTHER|Placebo|Oral placebo identical to astaxanthin supplement
215121361|NCT02454023|DEVICE|Portable sleep monitor (ApneaLink Air)|Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
215121362|NCT02454023|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
215121363|NCT01896024|BEHAVIORAL|Psychiatric Management|
215000889|NCT07122115|BEHAVIORAL|Mindfulness-Based Childbirth and Parenting Education|"The intervention was an 8-week mindfulness-based childbirth and parenting education program specifically adapted for pregnant women experiencing prenatal distress. The program included weekly 120-minute online sessions combining formal mindfulness practices (such as mindful breathing, body scan, and sitting meditation), informal exercises (e.g., mindful eating, mindful walking), psychoeducation, group sharing, and guided reflections.~Participants were also asked to complete daily home practice assignments using audio recordings. The content was adapted from the Mindfulness-Based Childbirth and Parenting (MBCP) curriculum and integrated with prenatal education. The intervention was delivered by a trained instructor and tailored to meet the emotional and cognitive needs of expectant mothers."
215000890|NCT07123363|DRUG|bitopertin|bitopertin 60 mg will be taken once daily by mouth
214395058|NCT06550830|BIOLOGICAL|Sinovac PCV24 formulation 2|One dose of Sinovac PCV24 formulation 2(0.5mL)
214395059|NCT06550830|BIOLOGICAL|Prevenar13®|One dose of PCV13 manufactured by Pfizer
214395060|NCT06213012|DEVICE|Transcutaneous Spinal cord Stimulation|Delivered using a constant-current stimulator
214395061|NCT06213012|DEVICE|Epidural Spinal Stimulation (ESS)|"The device used for ESS, the CoverEdgeX 32 Surgical Lead system (Boston Scientific, USA), is a device approved by the FDA used in the treatment of severe pain and is approved for individuals to manage chronic pain when other treatments have not been effective.~If you are in the ESS group, you will have surgery to have the stimulator placed and the stimulator will be removed at an office visit towards the end of the study."
214502862|NCT07042438|PROCEDURE|Leukapheresis|Undergo leukapheresis
214502863|NCT07042438|DRUG|Placebo Administration|Given PO
214502864|NCT07042269|BEHAVIORAL|Aerobic Exercise|Performed daily 10,000-step walking (5 days/week)
214502865|NCT07042269|BEHAVIORAL|Respiratory Muscle Training|Performed 12-week progressive resistance training using the Lung Fitness® breathing trainer (initial/moderate/high resistance levels)
214502866|NCT07044024|COMBINATION_PRODUCT|CeraVe|"Patients with GEA classification 1 will be assigned to use CeraVe Blemish Control Cleanser in combination with CeraVe Blemish Control Gel.~Patients in GEA Class 2 will be assigned to use CeraVe Blemish Control Cleanser in combination with CeraVe Facial Moisturising Lotion in combination with topical medications.~Patients with GEA classification 3 will be assigned to use CeraVe Foaming Facial Cleanser in combination with CeraVe Facial Moisturising Lotion in combination with topical medications.~Patients with a GEA classification of 4 and above will be assigned to use CeraVe Hydrating Facial Cleanser in combination with CeraVe Moisturising Cream in conjunction with a commonly used sunscreen product in combination with an oral medication."
214502867|NCT07043062|PROCEDURE|Open surgical Interference|to compare the outcomes of Laparoscopic repair versus Open surgical repair of Genitovesical fistula in females.
214502868|NCT06538077|DRUG|Oral Branched chain Amino acid|The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 12 weeks
215000891|NCT07122063|DRUG|SYS6045|SYS6045, IV Q3W
215000892|NCT07125417|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Monotherapy with oral anticoagulants (OAC) including direct oral anticoagulants (DOAC) and vitamin K antagonist oral anticoagulants (VKA) for 45 days after left atrial appendage closure (LAAC), followed by aspirin-directed antiplatelet monotherapy (Single Antiplatelet Therapy: SAPT) through the end of the observational period.
214395062|NCT03172741|DRUG|Medical Marijuana|1-gram marijuana cigarette smoked once per day for 3 months
214395063|NCT03172741|DRUG|Placebo|Matching 1 gram placebo cigarette smoked once per day for 3 months
214395064|NCT05828784|DEVICE|Intersomatic arthrodesis|"Arthrodesis is an operative modality also used in the treatment of multiple recurrences of herniated discs, stenosis (narrowing) of the spinal anal, degenerative and malformative spondylolisthesis.~The procedure can be performed with different surgical techniques, but in all cases it aims to achieve the same goal: to re-establish, through the use of spacers, the correct distance between two vertebral somes, in cases of disc degeneration, that are no longer able to fulfill their function; that is, they no longer absorb mechanical stresses and/or compress the nerve structures of the spine causing almost always unbearable (disabling) pain."
214395065|NCT00805636|DRUG|2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10)|\[18F\]-ML-10 will be radiolabeled at the PET Radioactive Drug Production (RDP) facility at or in close proximity to each clinical site, and will be administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The dose concentration selected for \[18F\]-ML-10 will be 7 MBq/Kg or 0.19 mCi/Kg. The radioactivity dosage of \[18F\]-ML-10 administered at each PET/CT session will be at least 300 MBq (8.1 mCi) and not more than 500 MBq (13.5 mCi).
214395066|NCT00805636|RADIATION|Stereotactic Radio-Surgery (SRS) therapy|SRS will be administered according to the standard of care using a radiation dose of 14-24 Gy to each lesion.
214395067|NCT00805636|PROCEDURE|Positron Emission Tomography|Each patient will undergo 2 PET/CT sessions, each following intravenous administration of \[18F\]-ML-10, to assess tracer uptake by the brain metastases treated by SRS. The PET/CT scan will be directed to the brain and will include one bed position. The PET/CT sessions will be performed at baseline, i.e., before the radiation treatment, and on the day after, within 24h after SRS treatment.
214395068|NCT00262743|BIOLOGICAL|Polyphenon E|"Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day~Phase II: 2000 mg orally twice a day"
215000893|NCT07125417|OTHER|Non-Antithrombotic Therapy|Monotherapy with OAC for 45 days after LAAC, followed by no antithrombotic therapy (Non-Antithrombotic Therapy: NAPT) from enrollment through the end of the observational period.
215000894|NCT07125716|DEVICE|1 inch|1 inch suture length
214502869|NCT06538077|DRUG|Rifaximin 550 MG|Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 12 weeks
214502870|NCT06538077|DRUG|Lactulose|Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day
214502871|NCT06538077|DRUG|Placebo for BCAA|A placebo comparator of 15 gm of skimmed milk powder will be used.
215000895|NCT07125716|DEVICE|0.5 inch|0.5 inch suture length
215000896|NCT06718218|BEHAVIORAL|Mindfulness Pain Management|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice.
215121364|NCT01896024|BEHAVIORAL|Motive-oriented therapeutic relationship/Plan Analysis|
214395069|NCT02040233|DRUG|BAY1067197 (10 mg)|10 mg BAY1067197 for 7 d treatment once daily as oral application
214395070|NCT02040233|DRUG|BAY1067197|The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
214395071|NCT02040233|DRUG|Placebo (10 mg)|10 mg Placebo for 7 d treatment once daily as oral application
214395072|NCT02040233|DRUG|Placebo|5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
214395073|NCT02818816|DRUG|brimonidine tartrate 0.2%|Alpha adrenergic receptor agonist
214395074|NCT02818816|OTHER|Carboxymethylcellulose Eye Drops|Ocular lubricants
214395075|NCT04218136|BIOLOGICAL|Blood samples|A minimum of 4 blood samples and a maximum of 6 blood samples will be collected. Venous return blood samples collected as part of routine monitoring of patients for bioclinical parameters. Samples will be collected before start of the infusion and end of the infusion
214395076|NCT00895479|PROCEDURE|Graft placement surgery plus Trinam therapy|"Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.~Control arm: graft placement surgery"
214395077|NCT00372307|DRUG|Application of pimecrolimus|
214395078|NCT06431698|DEVICE|Custom-made silicone device|Correction of deformation using the custom-made silicone device
214395079|NCT06431698|DEVICE|adjustable Earwell device|Correction of deformation using the adjustable Earwell device
214395080|NCT04236128|OTHER|Mobile App|"The app will be provided to patients in hospital on post-operative day 3. On the day of discharge, the patient will be emailed a Daily Health Check and receive subsequent Daily Health Check emails on Day 1-14, 21 and 30 days following discharge. The Daily Health Check is a tailored questionnaire to elicit their symptoms and status of post-operative recovery. After the patient has completed the Daily Health Check, a Daily Health Check Summary is emailed to the patient that summarizes their responses and provides appropriate action recommendations based on their responses ranging from: (i) suggestions for educational modules, (ii) expect a call from your health care team in the next 24 hours, (iii) call your surgeon's office today or (iv) go to the nearest emergency room. The patient's Daily Health Check responses are displayed in real time on a secure website that automatically red flags extreme responses to alert the health care team to contact the patient by telephone."
214395081|NCT04474964|RADIATION|Low dose Craniospinal Irradiation plus Focal Radiotherapy|The intervention arm of the study is to prospectively evaluate disease-related outcomes of low-dose CSI plus focal radiotherapy without concurrent chemotherapy followed by standard 6-cycles of adjuvant systemic chemotherapy in WNT-pathway medulloblastoma.
214395082|NCT06388070|DRUG|HUC3-053|drops in each eye five to six times a day for 12 weeks
214395083|NCT06388070|DRUG|Hyalein Mini Drops|drops in each eye five to six times a day for 12 weeks.
214395084|NCT05801159|DIAGNOSTIC_TEST|Positron Emission Tomography-Computerised Tomography (PET-CT)|Injection of the 18F-fluoropivalate (18F-FPIA) radiotracer followed by a whole brain static PET-CT scan.
214693826|NCT00509496|DRUG|fludarabine phosphate|25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days.
214395086|NCT05691569|OTHER|doll therapy|empathy dolls
214395087|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
214395088|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
214395089|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
214395090|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
214395091|NCT03498014|OTHER|Pharmacogenetic analysis allowing personalized opioid prescription|Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
214395092|NCT03498014|OTHER|Standard opioid prescription|Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
214395093|NCT02701582|DRUG|Phenylephrine|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \>=2.2 Phenylephrine is administered
214395094|NCT02701582|DRUG|Epinephrine|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \< 2.2 Epinephrine is administered
214395095|NCT02701582|OTHER|Albumin|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
214395096|NCT02701582|OTHER|Voluven|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
214395097|NCT02701582|OTHER|Normal Saline|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
214395098|NCT02701582|OTHER|Packed Red Blood Cells|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
214395099|NCT02701582|DEVICE|FloTrac Monitor|FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.
214395100|NCT00005991|DRUG|gemcitabine hydrochloride|
214395101|NCT00005991|DRUG|pegylated liposomal doxorubicin hydrochloride|
214395102|NCT00778063|DRUG|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
214395103|NCT00778063|DRUG|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
214395104|NCT05582213|DIAGNOSTIC_TEST|induction of anesthesia|This group includes (20) patients will receive induction by sevoflurane 3% using open circuit (modified Ayre's T-piece) till loss of consciousness and will be maintained on oxygen mask on the same concentration of sevoflurane and connected to capnogram
214502872|NCT06538077|DRUG|Placebo for Rifaximin 550mg|Identical placebo sugar pills will be used as a placebo.
214395105|NCT01406860|DRUG|Droperidol|Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
214693827|NCT00509496|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenous
214395106|NCT01406860|DRUG|Metoclopramide + diphenhydramine|Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
215000897|NCT06718218|BEHAVIORAL|Mindfulness Recording With Sustained Tone|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice, that is accompanied by a sustained low C tone at 65.41 Hertz.
215000898|NCT06718218|BEHAVIORAL|Mindfulness Recording with Binaural Beats|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice that is accompanied by binaural beats resulting from the delivery of a sustained 65.41 Hertz tone in the left ear and a sustained 69.41 Hertz tone in the right ear.
214395107|NCT00931450|DRUG|exemestane|Given orally
214395108|NCT00931450|DRUG|sunitinib malate|Given orally
214395109|NCT00931450|OTHER|placebo|Given orally
214395110|NCT02391285|DEVICE|dynamometer (Auckland vaginal elastometer)|"The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.~I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.~II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.~III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings."
214395111|NCT00763932|BIOLOGICAL|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
214395112|NCT02727868|GENETIC|blood samples|
214395113|NCT01734837|DEVICE|DS-Ligature Clip|
214395114|NCT04572490|DIAGNOSTIC_TEST|periapical radiograph|alveolar bone loss measurement on standardized parallel periapical radiograph
214395115|NCT00126204|DRUG|Doxycycline|
215000899|NCT06718218|BEHAVIORAL|Mindfulness Recording with Binaural Beats and Theta Music|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice that is accompanied by binaural beats resulting from the delivery of a sustained 65.41 Hertz tone in the left ear and a sustained 69.41 Hertz tone in the right ear as well as instrumental theta wave music.
214395116|NCT03930966|DIAGNOSTIC_TEST|PDEQ, PCL-5 and demographic survey|Questionnaires
214395117|NCT04507672|DRUG|Fluid resuscitation|Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
214395118|NCT00948259|DRUG|NP031112|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
214395119|NCT00948259|DRUG|Placebo|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
214395120|NCT03030547|DEVICE|SenseWear activity monitor|Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
214395121|NCT02640651|DEVICE|DC-Stimulator (PLUS version)|transcranial direct current stimulation
214395122|NCT04554485|DRUG|Blinatumomab|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
214395123|NCT06378502|DRUG|Amoxicillin Short|Short Span
214395124|NCT06378502|DRUG|Amoxicillin Long|Long span
214395125|NCT02774265|DRUG|VTE prophylaxis with Enoxaparin 30mg BID|Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
214395126|NCT02774265|DRUG|VTE prophylaxis with Aspirin 81mg BID|Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
214395127|NCT01613820|DRUG|Ketamine|ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.
214395128|NCT01613820|DRUG|Scopolamine|Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
215000900|NCT06712355|DRUG|BNT327|Solution for intravenous infusion
215000901|NCT06712355|DRUG|Atezolizumab|Concentrate for solution for intravenous infusion
215000902|NCT06712355|DRUG|Etoposide|Solution for infusion
215000903|NCT06712355|DRUG|Carboplatin|Solution for infusion
215000904|NCT07042022|DEVICE|Development of digital defocus vision training (DDVT)|During a six-month follow-up period, participants received 10 minutes of DDVT twice a day (once in the morning, and the other in the afternoon) using a head-mounted VR display. In daily life during non-training sessions, participants were required to wear frame glasses with complete correction.
215000905|NCT06882889|DEVICE|Domestic hearing aids|The domestic hearing aids used in this study are from the Bigsound brand. Using domestic hearing aids for intervention, one first evaluates the patient's hearing condition through pure-tone audiometry. Subsequently, by thoroughly understanding the patient's hearing needs, lifestyle, and other relevant factors, the most suitable type and functions of hearing aids are selected to best meet the individual's specific situation.
215000906|NCT06882889|DEVICE|Imported hearing aids|The imported hearing aids used in this study are from the Phonak brand. Using imported hearing aids for intervention, one first evaluates the patient's hearing condition through pure-tone audiometry. Then, by thoroughly understanding the patient's hearing needs, lifestyle, and other relevant factors, the most suitable type and functions of hearing aids are selected to best meet the individual's specific situation.
215000907|NCT06703606|DRUG|MARSTACIMAB|Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)
215000908|NCT06883175|DIAGNOSTIC_TEST|FLIP|Functional Lumen Impedance Planimetry
215094880|NCT06870526|BEHAVIORAL|Food box delivery|"* Time Needed: 12 weeks (duration of intervention)~* Description: Participants will receive grocery boxes containing a selection of food items tailored to their cultural and nutritional needs. They will be asked to utilize the groceries provided and provide feedback on the quality and quantity of items received. The pilot study will partner with Instacart, utilizing Instacart Care Carts for the medically tailored grocery delivery in which researchers order and deliver groceries on behalf of participants. Although families are not able to modify the order, they select when and where they want the grocery box delivered."
215094881|NCT07011043|DRUG|Budoprutug|Single IV dose of study product on Day 1 of study
214395129|NCT02291224|BEHAVIORAL|Interactive multimedia platform|An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
214395130|NCT02291224|BEHAVIORAL|Intervention arm counseling|Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.
214395131|NCT02291224|BEHAVIORAL|Standard of care counseling|Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
214395132|NCT04672109|DEVICE|Transcranial direct current stimulation|Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
214395133|NCT05640076|OTHER|24/7 Telephonic Palliative Care Service availability|"Metropolitan Palliative Care Service-implemented 24/7 telephonic availability service for the patients, their relatives, the EMS and Primary Care physicians taking care of them.~After consultation, if the information and medical suggestions are not sufficient, an urgent ambulatory or home visit could be planned."
214395134|NCT00573950|DRUG|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
214395135|NCT00573950|DRUG|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
214395136|NCT01388374|OTHER|Other, care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
214395137|NCT00912821|DRUG|6 L dialysate|6 L peritoneal dialysis solution
214395138|NCT00912821|DRUG|8 L dialysate|8 L peritoneal dialysis solution
214502873|NCT02136654|BEHAVIORAL|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
214502874|NCT02773225|DRUG|Eltrombopag|"* CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> partial or complete remission Eltrombopag and slow tapering of CSA~* 12 month after therapy start --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment"
214502875|NCT02773225|DRUG|Placebo (for Eltrombopag)|"* CSA + Placebo, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --\> dose escalation~* 12 month after start of eltrombopag --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment"
214502876|NCT06469554|BEHAVIORAL|MEP-only group|Participants in this group will receive a Multicomponent Exercise Program (MEP) consisting of: Supervised aerobic training on a stationary bike Progressive resistance/strength training using weight machines Balance training exercises The MEP sessions will be 30-40 minutes long and conducted over 4 consecutive days.
214502877|NCT06469554|BEHAVIORAL|MEP-VR group|"Participants in this group will receive the same MEP intervention as the MEP-only group.~Additionally, they will use an immersive virtual reality (IVR) system during the exercise program"
214502878|NCT06749119|PROCEDURE|Free gingival graft operation|Free gingival graft was harvested from palatal region and stabilized on the maxillary anterior recipient bed with sutures .
214502879|NCT06768411|DRUG|PEG-rhGH|1= 0.2mg/kg/week Initial doses of PEG-rhGH 2=0.22mg/kg/week Initial doses of PEG-rhGH
214502880|NCT06768411|DRUG|GnRHa|"1. pubertal children of short stature without GnRHa treatment~2. pubertal children of short stature with GnRHa treatment"
215000909|NCT06883175|DIAGNOSTIC_TEST|HRM|HIgh Resolution Manometry
215094882|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery Day 1 of Cycle 3: avelumab (10mg/kg)
215000910|NCT06883175|OTHER|Prucalopride|Medication
215000911|NCT06717451|DEVICE|Control-IQ Technology v1.5|"Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ technology v1.5.~Every month participants will receive a survey to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment. Participants will also complete surveys related to patient reported outcomes at baseline, 6 months, and 12 months."
215000912|NCT06714526|GENETIC|Point-of-Care CYP2C19 Testing|Genetic testing with the Genomadix cube to determine P2Y12 inhibitor
215000913|NCT06714526|DRUG|ticagrelor + aspirin|If patients are poor or intermediate metabolizers of clopidogrel, they will receive ticagrelor (90 mg PO BID) + aspirin (81 mg PO daily)
214395139|NCT05586191|OTHER|Action observation at home|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
214395140|NCT05586191|OTHER|Action Observation therapy at hospital|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
214395141|NCT03373474|OTHER|local distribution points association|"Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm."
214395142|NCT03373474|OTHER|local-distal points association|"Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9."
214395143|NCT00002214|DRUG|Capravirine|
214395144|NCT03565770|OTHER|individual coaching|coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.
214395145|NCT03565770|OTHER|Standard care|completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
214395146|NCT01300559|DEVICE|Tissuelink device|Tissuelink device plus Unipolar electrocautery
214395147|NCT04773574|DEVICE|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA)|"Ocular investigations were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks"
214395148|NCT01286974|DRUG|[14C]linifanib|\[14C\]linifanib, single administration, oral liquid
214395149|NCT01286974|DRUG|ABT-869, linifanib|linifanib once a day (QD), oral tablet
214395150|NCT01284777|GENETIC|blood sample, thoracocentesis|20ml of blood only one thoracocentesis (the same that one for diagnostic)
214395151|NCT04910906|DEVICE|Ectoin® Vaginal Gel|"Ectoin® Vaginal Gel is a clear, non-hormonal moisturizing gel containing only active ingredient Ectoin® for the relief of vaginal dryness/vaginal atrophy.~Other excipients in the formulation include:~Hydroxyethylcellulose (Gelling agent) Lactic acid (90 %) (pH stabiliser) DL-Sodium lactate (Buffer substance) Sodium benzoate (preservative) Propylene glycol (Humectant)"
214395152|NCT05313893|BIOLOGICAL|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
214395153|NCT00999401|DRUG|sapacitabine and seliciclib|sequential or concomitant administration of sapacitabine and seliciclib
214395154|NCT04004793|BEHAVIORAL|Intensive lifestyle intervention|Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500\~750 kcal/day) for 3 months, with \<35% as fat, \>15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).
214395155|NCT04004793|DRUG|Dapagliflozin 10 MG Oral Tablet|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
214395156|NCT04004793|DRUG|Placebo Oral Tablet|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
214395157|NCT02071563|DIETARY_SUPPLEMENT|CSB14|
214395158|NCT02071563|DIETARY_SUPPLEMENT|RUSF1|
214395159|NCT02071563|DIETARY_SUPPLEMENT|SC+|
214395160|NCT04668287|BEHAVIORAL|Increasing self-esteem|During 5 weeks, participants will be part of one of the working groups in which they'll be taught by a counselor about how a low self-esteem develops and what have to be done for improving self-esteem, based on the Melanie Fennel' model.
214395161|NCT03748979|DRUG|TAK-925|TAK-925
214395162|NCT03748979|DRUG|Placebo|TAK-925 Placebo
214395163|NCT02026973|DRUG|Fulvestrant|
215000914|NCT06714526|DRUG|clopidogrel + aspirin|Normal, rapid, and ultra-rapid metabolizers of clopidogrel will receive 75 mg PO daily of clopidogrel and 81 mg PO daily of aspirin.
215000915|NCT07043478|OTHER|Bragg ACV Liquid|Apple Cider Vinegar
215000916|NCT07043478|OTHER|Placebo|Water
215000917|NCT06723457|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215000918|NCT06723457|PROCEDURE|Computed Tomography|Undergo PET/CT
215000919|NCT06723457|BIOLOGICAL|Epcoritamab|Given SC
215000920|NCT06723457|DRUG|Lenalidomide|Given PO
215000921|NCT06723457|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215000922|NCT06723457|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215000923|NCT07038915|DRUG|Tiragolumab|Given by IV
214395164|NCT02026973|DRUG|Anastrozole|
214395165|NCT02026973|DRUG|Placebo|
214395166|NCT02026973|DRUG|Somatostatin|
214395167|NCT01335308|BEHAVIORAL|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
214395168|NCT01335308|BEHAVIORAL|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
214395169|NCT01335308|BEHAVIORAL|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
214395170|NCT03249376|DRUG|Lumateperone|Lumateperone 42 mg (ITI-007 60 mg tosylate)
214395171|NCT03249376|OTHER|Placebo|Placebo
214395172|NCT00002813|DRUG|cisplatin|
214395173|NCT00002813|DRUG|vinorelbine tartrate|
214395174|NCT00189176|DRUG|Tetrathiomolybdate|
214395175|NCT02809586|BEHAVIORAL|SMI + I|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. Participants will earn incentives for interaction during the intervention (8 weeks).
214395176|NCT02809586|BEHAVIORAL|SMI|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. This group will NOT receive incentives for their participation in the secret group.
214395177|NCT04127305|OTHER|No Intervention|No Intervention
214395178|NCT04397302|DIAGNOSTIC_TEST|Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction|Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study
214395179|NCT01064583|OTHER|cocoa|dissolved in water twice-daily intervention
214395180|NCT04916899|DRUG|Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
214395181|NCT01958762|OTHER|Invitation for oral cavity cancer screening|
214395182|NCT05506267|DEVICE|Trachea Sound Sensor (TSS)|Use the TSS and commercial vital sign monitors to develop a diagnostic algorithm that detects and predicts hypoventilation due to opioids and anesthetic medication
214395183|NCT01650675|BEHAVIORAL|WIDUS computer-delivered, indirect brief intervention|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
215000924|NCT07038915|DRUG|Ivonescimab|Given by IV
215000925|NCT06717477|PROCEDURE|Changes to the care pathway for carpal tunnel syndrome (The Carpal Tunnel Plus Pathway)|Changes to the care pathway for carpal tunnel syndrome. Features of the CTS+ pathway include new referral form, care map for mild, moderate and severe CTS established, point or care ultrasound with steroid injection introduced, and expedited referral to surgeons.
215000926|NCT06727253|DIETARY_SUPPLEMENT|Glycan|The post-operative CD patients will receive an orally administered glycan.
215000927|NCT03496129|BEHAVIORAL|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
215000928|NCT03496129|BEHAVIORAL|Personalized feedback and text messages|"Experimental: Personalized feedback and text messages~Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions."
215000929|NCT03496129|BEHAVIORAL|Information Only|"Active Comparator: Information Only~Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message."
215000932|NCT03084757|DIAGNOSTIC_TEST|research of druggable molecular alterations on tumor biopsy|The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations
215000933|NCT07050433|DIAGNOSTIC_TEST|CXCR2 as a biomarker|CXCR2 biomarker expression will be measured in tumor and immune cell samples
215000934|NCT07044440|OTHER|digital outpatient follow-up|In addition to routine outpatient follow-up visits on day 14 and 28 post-operative, digital follow-up by questionnaire on their health status and general well-being are provided. Possibility to request an interaction with a doctor from our department at any time during the 28 days following discharge
215000935|NCT07044440|OTHER|standard follow-up|routine outpatient follow-up visits on day 14 and 28 post-operative
215000936|NCT05934838|DRUG|Tazemetostat Pill|Participants will take 800 mg of tazemetostat twice a day starting 7 days before apheresis and continue to take tazemetostat until lymphodepletion, which is chemotherapy given prior to receiving the CAR T cells. Participants will stop taking tazemetostat after lymphodepletion until after CAR T cell infusion. Once lymphocyte counts increase, tazemetostat will be resumed and tazemetostat will be taken for 6 - 12 months, depending on participant response.
215000937|NCT05371613|DRUG|tividenofusp alfa|Intravenous repeating dose
215000938|NCT05371613|DRUG|idursulfase|Intravenous repeating dose
215000939|NCT06891066|DRUG|ISL|ISL 1mg oral capsule will be administered as 2mg orally (each capsule 1mg) as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks.
214395184|NCT01650675|BEHAVIORAL|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
214395185|NCT03692988|BEHAVIORAL|Dignity Therapy|Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
214395186|NCT01154036|DRUG|ezetimibe 10 mg|
214395187|NCT01154036|DRUG|atorvastatin|
214395188|NCT01154036|DRUG|Comparator: rosuvastatin|
214395189|NCT05475769|DRUG|Clinical evaluation|Patients will receive treatments under the criteria of the responsible physician and the response to these treatments will be prospectively collected.
214395190|NCT06359665|DRUG|Curcumin|500 mg capsule twice daily
214395191|NCT06359665|DRUG|Placebo|capsule twice daily
215000940|NCT06891066|DRUG|ULO|ULO 100mg oral tablet will be administered as 200mg (2 tablets) orally as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks.
215000941|NCT06891066|DRUG|BIC/FTC/TAF|BIC 50mg oral tablet/FTC 200mg oral tablet/TAF 25 mg oral tablet administered orally to group 2 participants for 48 weeks in part 1 of the study.
215000942|NCT06670534|DRUG|JMKX003142 tablets|JMKX003142 tablets for experimental groups.Take the JMKX003142 tablets（on empty stomach） once daily for seven days.
215000943|NCT06670534|DRUG|Torasemide tablets|Torasemide tablets for active comparator group.Take the torasemide tablets once daily for seven days.
215000944|NCT04968496|OTHER|Food Secure Group|Weekly meals (five breakfast and five lunch meals) will be provided to all children randomized to this group to prevent the onset of summertime food insecurity
215000945|NCT02207608|DRUG|Hyaluronic Acid|Add hyaluronic acid to BCG Treatment
215000946|NCT02207608|DRUG|BCG (Immucist®)|Usual BCG treatment
215000947|NCT06864832|OTHER|Mirror image postural exercises|Patients will recieve mirror image postural exercise on the 3D postural analysis
215094883|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery
215094884|NCT01137019|DEVICE|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
215094885|NCT01137019|DEVICE|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
215000948|NCT06864832|OTHER|Back exercises|Exercises in the form of back muscles stretching exercises and abdominal muscles strengthening exercises.
215000949|NCT06767059|OTHER|Walking Group|Patients will be asked to walk for 30 minutes at least 3 times for 8 weeks. In order to ensure regular follow-up, patients will be asked to write on the walking tracking form when they walk and the number of steps before they start walking and the number of steps after walking using the application.
215000950|NCT06767059|OTHER|Grounding Group|Patients will be asked to walk with a grounding stick for 30 minutes at least 3 times for 8 weeks. Patients will be asked to fill in the walking follow-up form and grounding follow-up form for regular follow-up.
215094886|NCT05092373|BIOLOGICAL|Atezolizumab|Given IV
214395192|NCT06352515|DIAGNOSTIC_TEST|Flow cytometry|flow cytometry to study distribution of T lymphocyte subsets in ulcerative colitis patients
214395193|NCT00623415|DRUG|Flupirtine|300 mg daily (divided in two doses)
214395194|NCT00623415|DRUG|Placebo|twice daily
214395195|NCT00165620|DRUG|Iomeprole|
215094887|NCT05092373|DRUG|Cabozantinib S-malate|Given PO
215094888|NCT05092373|DRUG|Nab-paclitaxel|Given IV
214395196|NCT00283738|DEVICE|BioSTAR Septal Repair Implant System|PFO Closure
214395197|NCT00283738|PROCEDURE|Sham Procedure|Catheterization
214395198|NCT05679700|OTHER|Rigid Taping|Rigid taping was applied to stroke patients with knee hyperextension.
214395199|NCT01537653|DRUG|SAR231893 (REGN668)|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
214395200|NCT01537653|DRUG|placebo|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
214395201|NCT06048874|PROCEDURE|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
214395202|NCT06048874|DRUG|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
214395203|NCT06048874|DRUG|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
214395204|NCT03069794|DIAGNOSTIC_TEST|Use of stable force platform|Use of stable force platform to appreciate the posture before and after spinal surgery
214395205|NCT01985698|PROCEDURE|Robotic-assisted resection.|Robotic-assisted abdominoperineal resection.
214395206|NCT01985698|PROCEDURE|Laparoscopic resection|Laparoscopic abdominoperineal resection
215094889|NCT05092373|PROCEDURE|Tumor Treating Fields Therapy|Receive TTF
215094890|NCT06747871|BEHAVIORAL|Very Low Nicotine Cigarettes (VLNC)|Spectrum NRC 102/103 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco.
215094891|NCT06747871|BEHAVIORAL|Normal Nicotine Cigarettes (NNC)|Spectrum NRC 600/601 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco.
214395207|NCT03086122|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
214395208|NCT00655395|DRUG|Laromustine (VNP40101M) and Ara-C|"1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
214395209|NCT01979055|BEHAVIORAL|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
214395210|NCT01979055|BEHAVIORAL|Telephone follow-up|Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
214395211|NCT01235273|DRUG|Growth Hormone|growth hormone administration
214395212|NCT01235273|OTHER|Placebo|standard placebo
214395213|NCT01349907|DRUG|Asenapine|One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
214395214|NCT01349907|DRUG|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam \[up to 4 mg/day\] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
214395215|NCT02460081|DRUG|PDA-002|
214395216|NCT02460081|DRUG|Placebo|
214395217|NCT05511740|RADIATION|Afternoon Radiation|Melatonin, a hormone of the pineal gland, which levels are characteristic of circadian patterns, regulated with low levels of excretion in the afternoon, rises gradually during the night, peaks at dawn, and falls back in the afternoon and late afternoon. Many studies prove the function and potential of melatonin as circadian biomarkers and well correlated with the development of cancer.The function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.
214395218|NCT03226457|DRUG|Empagliflozin 25mg|Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks
214395219|NCT03226457|DRUG|Placebo oral capsule|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
214395220|NCT03226457|DRUG|Frusemide|Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.
214502881|NCT06751186|BEHAVIORAL|Teté Dance Guided Support|A culturally tailored behavioral intervention combining physical activity and community engagement to support breastfeeding practices.
214502882|NCT06759441|BEHAVIORAL|Reframe-It+|Reframe-IT+ is an individual intervention based on cognitive behavioral therapy, with a problem-solving and help-seeking approach, which is carried out at the Educational Establishment with a trained psychologist. It consists of 13 weekly sessions of 25 minutes each, of which 5 sessions have a face-to-face component and 8 sessions have a face-to-face-digital component where students use a computer always in the company of a psychologist facilitating the program.
214502883|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 1|Step 1 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 25% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
214502884|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 2|Step 2 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 50% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
214693828|NCT00509496|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
215000951|NCT05628350|OTHER|No UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% total energy) for 6 weeks. Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein) and matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality.
215000952|NCT05628350|OTHER|High UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet with high UPF intake (81% total energy) for 6 weeks. Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein) and matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality.
215000953|NCT05016596|DIETARY_SUPPLEMENT|turmeric|Turmeric supplement
214395221|NCT01591460|DRUG|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
214395222|NCT01591460|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
214395223|NCT01591460|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
214395224|NCT01591460|DRUG|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
214395225|NCT01591460|DRUG|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
214395226|NCT00524238|DRUG|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
214395227|NCT03413358|DRUG|Sheng Bai oral liquid|"Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy.~Subjects will be treated for 2 courses"
214395228|NCT03413358|DRUG|Platinum-based two medicine (carboplatin / cisplatin) .|Using Platinum-based two medicine (carboplatin / cisplatin)
214395229|NCT05886686|DEVICE|Validation of the accuracy of a combined oximeter, thermometer and heart rate measurement device|Validation of the combined device measurements compared with standard of care devices
214395230|NCT00859508|DEVICE|SyntheCel|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
214395231|NCT00859508|DEVICE|Other FDA cleared dura replacements|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
214395232|NCT00739635|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
214395233|NCT00739635|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo
214395234|NCT01541618|OTHER|MSDX Complex-1 Biomarker test|MSDX Complex-1 Biomarker test
214395235|NCT03763396|DRUG|Ketoconazole (KCZ)|Oral Tablet
214395236|NCT03763396|DRUG|Posaconazole (PCZ)|Delayed Release Oral Tablet
214395237|NCT01528644|DIETARY_SUPPLEMENT|alginate beads containing ferrous gluconate|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
214395238|NCT01528644|DIETARY_SUPPLEMENT|ferrous gluconate in a capsule|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
215000954|NCT05016596|DIETARY_SUPPLEMENT|placebo|Placebo
214395239|NCT01528644|DIETARY_SUPPLEMENT|ferrous gluconate in a capsule in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
214502885|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 3|Step 3 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 75% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
215000955|NCT06884033|BEHAVIORAL|Cinematherapy|Cinematherapy, also known as cinema therapy and movie therapy, involves therapist-directed viewing of movies for specific therapeutic purposes.
215000956|NCT02279953|DRUG|Vortioxetine 10-20 mg|
214502886|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 4|Step 4 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 100% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
215000957|NCT02279953|DRUG|Placebo|
215000958|NCT02279953|DRUG|SSRI|escitalopram, citalopram or sertraline
215000959|NCT04611087|BEHAVIORAL|Discussion|Attend focus groups
215000960|NCT04611087|OTHER|Interview|Attend interviews
215000961|NCT04611087|OTHER|Survey Administration|Ancillary studies
215000962|NCT02643277|BEHAVIORAL|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
215000963|NCT02643277|OTHER|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
214395240|NCT01528644|DIETARY_SUPPLEMENT|alginate beads with ferrous gluconate in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
214395241|NCT04102540|OTHER|Infographic intervention|Information visualizations (infographics) will be used to teach participants about HIV during study visits immediately following their normal clinic visits.
214395242|NCT03790930|DIAGNOSTIC_TEST|deep learning|manually labeled samples will be used to train, validate and test deep learning algorithm, and then realize automatic classification.
214395243|NCT01611103|PROCEDURE|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
214395244|NCT00229476|DRUG|sertraline (Zoloft)|
214395245|NCT00431977|PROCEDURE|coronary computed tomography angiography|
214502887|NCT06647979|BIOLOGICAL|autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein|autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein
214502888|NCT06647979|DEVICE|Sequencing Assay for Variant rs114518452|Device used to carry out the diagnostic testing for exclusion criteria number 12
214395246|NCT04171804|DEVICE|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
214395247|NCT04676230|PROCEDURE|Experimental group|Caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
214395248|NCT04676230|PROCEDURE|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
214395249|NCT03507829|DRUG|Human insulin isophane, Humulin N (Eli Lilly)|Human insulin isophane, Humulin N (Eli Lilly)
214502889|NCT06821373|BEHAVIORAL|Chatbot|The intervention includes five modules based on the five stages of Stages of change. Chatbots will build up a rapport with the participants, monitor their stage with a few simple questions based on previous Stages of Change studies, and provide stage-tailored packages of response, advice, and feedback (one of the five modules) accordingly to enhance their motivation and self-efficacy each week. For those who click 'yes' to a question assessing the first stage of change (PC), Chatbot will make a record and automatically ask questions assessing the next stage; for those who click 'no', Chatbot will automatically send them the module corresponding to their SoC via WhatsApp. Each module will take 10-15 minutes. In total, it will take 1 hour to complete all the modules.
214502890|NCT06821373|BEHAVIORAL|Control|The intervention includes five modules based on the five stages of Stages of change. Chatbots will build up a rapport with the participants, monitor their stage with a few simple questions based on previous Stages of Change studies, and provide stage-tailored packages of response, advice, and feedback (one of the five modules) accordingly to enhance their motivation and self-efficacy each week. For those who click 'yes' to a question assessing the first stage of change (PC), Chatbot will make a record and automatically ask questions assessing the next stage; for those who click 'no', Chatbot will automatically send them the module corresponding to their SoC via WhatsApp. Each module will take 10-15 minutes. In total, it will take 1 hour to complete all the modules.
214502891|NCT02864550|DRUG|Doxycycline|doxycycline 100mg orally daily
214502892|NCT02864550|OTHER|Placebo|placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
215000964|NCT02206347|BEHAVIORAL|attention focus|
215000965|NCT03630991|DRUG|Edetate Calcium Disodium|Given IV
215000966|NCT03630991|DIETARY_SUPPLEMENT|Multivitamin|Given PO
215000967|NCT03630991|DRUG|Succimer|Given PO
215000968|NCT07070830|DEVICE|Active Comparator: Omnipod M System with lower starting dose|Omnipod M Automated Insulin Delivery System with Dexcom G6 continuous glucose monitoring system
215000969|NCT07070830|DEVICE|Active Comparator: Omnipod M System with higher starting dose|Omnipod M Automated Insulin Delivery System with Dexcom G6 continuous glucose monitoring system
215000970|NCT06854328|DEVICE|Prism|Prism is using an amygdala-fMRI-guided model for processing EEG signals. The model, termed EEG fMRI pattern (EFP), uses several electrodes EEG-signal to produce a real time amygdala-EFP biomarker signal. GrayMatters' product, Prism, is used to train patients in downregulating the amygdala-derived-EFP biomarker during therapy sessions.
215000971|NCT07068581|PROCEDURE|Maternal voice|"Mothers of the infants in the intervention group will be asked to read aloud the lyrics of a designated in a calm tone of voice in a quiet environment, and their voices will be recorded. The recorded maternal voice will then be played to the infants in the NICU using the same Bluetooth-enabled device with built-in speakers. The audio device will be placed inside the incubator or open warmer, approximately 20-30 cm from the infant.~Each infant will be assigned an individual audio device, which will be used exclusively for that infant. Maternal voice playback will begin 20 minutes before morning and evening oral feedings and will continue throughout the feeding session, twice daily, for a maximum of 5 days. If the infant is discharged earlier, the intervention will be discontinued.. During the playback of the maternal voice, monitor sounds in the NICU will be minimized, and the staff will be instructed to speak quietly to maintain a calm environment."
215000972|NCT07068581|OTHER|Control Group (standard feeding )|The control group will not be exposed to maternal voice, and standard feeding procedures will be applied.
215000973|NCT06843070|PROCEDURE|PENILE BLOCK ARM|P arm: Patients who underwent Dorsal Penile Block after circumcision surgery
215000974|NCT06843070|PROCEDURE|SACRAL ESP BLOCK ARM|S arm: Patients who underwent Sacral Erector Spinae Plane Block after circumcision surgery
215000975|NCT07120243|PROCEDURE|Toothpaste Product|Administration ofa toothpaste
215000976|NCT07120243|PROCEDURE|Varnishes, Fluoride|The tooth will be dried, and cotton roll isolated. According to manufacturer instructions, thin coat of the varnish will be applied on the teeth for 10 - 20 s using a microbrush in a horizontal sweeping motion , then drying with air will be done.
215000977|NCT07121114|OTHER|No treatment given|No treatment given
214395250|NCT03507829|DRUG|Standard of care|Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT
215000978|NCT07117214|DRUG|[68Ga]Ga-DWJ155|Radioligand imaging agent
215000979|NCT07124793|DRUG|IBI363+IBI305|Each treatment cycle lasts for 21 days (the first treatment cycle is 28 days). Subjects will receive IBI363 Q3W in combination with bevacizumab Q3W until 2 years of treatment, PD, intolerable toxicity, start of new anti-tumor treatment, withdrawal of informed consent, death, or study termination (whichever occurs first).
215000980|NCT07122635|DRUG|Diquafosol Sodium 3%|Diquafosol Sodium 3% ophthalmic solution, 1 drop each time, 6 times daily, from baseline (1 week after the surgery) to 12 weeks
214395251|NCT03507829|DRUG|Insulin lispro, Humalog (Eli Lilly) in insulin pump|Insulin lispro, Humalog (Eli Lilly) in insulin pump
214395252|NCT02037867|DEVICE|Fibrosis Biomarkers|Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
214395253|NCT01744496|DRUG|Rotigotine|Patches will contain 4 mg / 24 h (20 cm\^2), 6 mg/ 24 h (30 cm\^2), or 8 mg /24 h (40 cm\^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
214395254|NCT01744496|DRUG|Placebo|Placebo patches match the size of active patches 20 cm\^2, 30 cm\^2, or 40 cm\^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
214395255|NCT03987568|OTHER|Blood draws|Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
214395256|NCT03987568|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|At the beginning of study magnetic resonance imaging MRI will be completed.
214395257|NCT00649974|DRUG|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fasting
214395258|NCT00649974|DRUG|Valtrex® Tablets 1000 mg|1000mg, single dose fasting
214502893|NCT06683989|OTHER|Pilates training|One hour of Pilates training was conducted for eight weeks, two days a week. Every training session was carried out by a certified and experienced physiotherapist from the Australian Institute of Pilates and Physiotherapy. The one-hour session was structured as a warm-up, a cool-down, and Pilates exercises.
215000981|NCT07124286|OTHER|Abdominal Bracing Training|The group underwent an abdominal bracing maneuver training. Following the training, they performed the Closed Kinetic Chain Upper Extremity Stability Test and the Seated Medicine Ball Throw Test in 2 conditions: with abdominal bracing and without abdominal bracing.
215000982|NCT07123545|BIOLOGICAL|iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine|Administered subcutaneously at 0.3 mg/peptide on Days 1, 4, 8, 15, 22, 52, and 82, followed by booster immunizations every 2-3 months.
214395259|NCT05140174|OTHER|Radical Healing and Internalized Stigma (RHIS) Training|8-hour RHIS training includes, readings that discuss radical healing and internalized stigma, access to didactic information regarding radical healing and internalized stigma. Therapists will role play certain scenarios that may involve minority stress experiences and discuss with the trainers different types of responses that could be therapeutic. The training will focus on the most up to date research regarding transgender mental health, minority stress, radical healing, and role-plays that focus on these processes.
215094892|NCT06584448|OTHER|Deuterium Metabolic Imaging with deuterated acetate tracer|Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.
215094893|NCT06892639|BIOLOGICAL|D-Fi|D-Fi is composed of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
214395260|NCT05220124|DRUG|Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)|420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 4 treatment cycles.
214395261|NCT01426906|DRUG|Ketoconazole|Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
214395262|NCT01426906|DRUG|rifampicin|Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
214395263|NCT04131868|BEHAVIORAL|Typical sleep opportunity|Typical sleep opportunity with consistent sleep timing for 1 week
214395264|NCT04131868|BEHAVIORAL|Extended sleep opportunity|Extended sleep opportunity by 90 min per night with consistent sleep timing for 1 week
214395265|NCT02369315|BEHAVIORAL|Treatment (Invited entry 2012)|Entry to music program offered in September 2012
214395266|NCT02369315|BEHAVIORAL|Control (Invited entry 2013)|Entry to music program offered in September 2013
214395267|NCT01038674|DRUG|anti-IL-20|Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
214395268|NCT01038674|DRUG|placebo|Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
214395269|NCT03630081|DRUG|WCK 4282 (FEP-TAZ) 4 g|WCK 4282 (FEP-TAZ) 4 g \[2 g FEP and 2 g TAZ\] IV q8h, infused over 90 min
214395270|NCT03630081|DRUG|Meropenem|1 g IV q8h, infused over 45 min
214502894|NCT06683989|OTHER|Prenatal care|Regular prenatal care for participants in the CG included standard nursing and medical treatments.
214502895|NCT04162873|DRUG|Celecoxib|Given PO or via feeding tube
214502896|NCT04162873|OTHER|Placebo|Given PO or via feeding tube
214502897|NCT04162873|OTHER|Quality-of-Life Assessment|Ancillary studies
214502898|NCT04162873|OTHER|Questionnaire Administration|Ancillary studies
215000983|NCT07123545|BIOLOGICAL|iNeo-Vac-T01 Personalized T Cell Injection|Administered via intravenous infusion: Dose Level 1: 5×10⁹ to 10×10⁹ cells; Dose Level 2: 1×10¹⁰ to 5×10¹⁰ cells.
215000984|NCT07121998|PROCEDURE|Core needle biopsy|Core needle biopsy of metastatic lesions
215000985|NCT07121998|PROCEDURE|Phlebotomy|Phlebotomy of peripheral vein
215000986|NCT06901544|DIAGNOSTIC_TEST|Serum C Reactive Protein|values for serum albumin is 35 to 55 g/l and for CRP is less than 6 mg/dl CLI will be calculated as CRP divided by serum albumin and multiplied by 100
215094894|NCT07080944|PROCEDURE|SLN identification using technetium-99m|SLN Biopsy after pre-surgery positive SLN visualization.
215094895|NCT07080944|PROCEDURE|SLN intra-operatory identification with radioguided surgery|SLN biopsy after no pre-surgery SLN visualization using technetium-99m and intra-surgery SLN identification.
214395271|NCT03630081|DRUG|ciprofloxacin 500 mg Optional Oral Switch|ciprofloxacin 500 mg PO q12h
214395272|NCT03630081|OTHER|Infusion of normal saline|Infusion of normal saline over 45 min
214395273|NCT00001450|DRUG|paclitaxel|
214395274|NCT00001450|DRUG|cisplatin|
214395275|NCT05950048|OTHER|The web-based breastfeeding counseling|To the web-based breastfeeding counseling/experimental group (n =33), during the first 6 months after birth, they will be directed to the web-based breastfeeding consultancy website. On this page, mothers will receive counseling on breastfeeding (written, visual, audio materials and telephone counseling) from birth. In addition, the Web-based breastfeeding counseling/experimental group will fill out data collection forms in the first 24 hours, 1st, 2nd, 4th and 6th months after delivery.
214395276|NCT05951699|DEVICE|minimally invasive preoperative image-guided vacuum-assisted biopsy|minimally invasive preoperative image-guided vacuum-assisted biopsy of the breast and needle biopsy of axillary lymph node
214395277|NCT02244593|OTHER|FAST MRI and mammography screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram.
214395278|NCT03670147|DEVICE|PF-SCS programming|In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
214395279|NCT03113162|BIOLOGICAL|Autologous Hematopoietic Stem Cell|
214395280|NCT03113162|DRUG|BEAM Regimen|Reduced-intensity BEAM for Immunoablation
214502899|NCT03909347|BEHAVIORAL|PLAN|The study intervention, PLAN is a multifaceted intervention led by trained CHW. It consists of two main components: dementia literacy education and phone counseling with navigation assistance through (1) 1-hour visit for dementia literacy education and (2)monthly counseling with navigation assistance
214502900|NCT03909347|BEHAVIORAL|Standard of Care|The investigators will refer control group participants to participants' primary physicians for follow-up and provide an Alzheimer's Association brochure about signs of dementia and dementia treatment, which is publicly available in Korean.
214502901|NCT05878405|OTHER|Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Given PO
214502902|NCT05878405|OTHER|Methylene Blue Oral Rinse|Given PO
214502903|NCT03343704|DRUG|Idarucizumab|Intravenous
214502904|NCT06754059|DRUG|Pyrotinib|In this study, after at least 4 cycles of taxoid chemotherapy combined with trastuzumab ± pertuzumab, the evaluation result reached SD, CR or PR, and capecitabine combined with pyrotinib + trastuzumab was given successively in the later period (capecitabine was used for 4-6 cycles
214502905|NCT06757686|DEVICE|Mousetrap appliance|two mini-implant will be inserted in the palate. then, the mousetrap appliance will be inserted on the mini-implant and activated with power chain.
214502906|NCT05200416|DEVICE|Heylo|Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
214502907|NCT05200416|DEVICE|Standard of Care|Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
215000987|NCT06901739|DIETARY_SUPPLEMENT|Synbiotic|The synbiotic supplement contains both tannins (350mg) and probiotic strains (Lactobacillus acidophilus, Lactobacillus casei, y Bifidobacterium lactis 2×10 9 UFC/g each) that have already demonstrated a positive health effect in obesity. Besides, participants will follow a dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.
215000988|NCT06901739|DIETARY_SUPPLEMENT|Placebo|Subjects will recieve a placebo supplement, contained in an identical capsule form as the synbiotic, along with the same dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.
214395281|NCT02578420|OTHER|open-label placebo|"Placebo Cream, openly described as Placebo"
214395282|NCT02578420|OTHER|deceptive placebo|"Placebo Cream, described as Voltaren, containing Diclofenac"
214395283|NCT01567163|BIOLOGICAL|Ramucirumab|ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
214395284|NCT01567163|DRUG|Docetaxel|docetaxel 75 milligrams/square meter (mg/m\^2) intravenous infusion administered on Day 1 of each 3-week cycle
214395285|NCT02937844|BIOLOGICAL|Anti-PD-L1 CSR T cells|Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.
214395286|NCT02937844|DRUG|Cyclophosphamide|250 mg/m\^2, d1-3
214395287|NCT02937844|DRUG|Fludarabine|25mg/m\^2, d1-3
214395288|NCT02339389|OTHER|Labor analgesia|Measuring maternal ventilation after placement of epidural analgesia compared to baseline
214395289|NCT01821443|OTHER|Stereotactic radiosurgery (SRS)|"Dose \& prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% \[maximum=100%\]), as defined by target delineation on the imaging studies.~The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL)."
214502908|NCT06508437|BIOLOGICAL|Influenza Vaccination|Standard Dose QIV (15µg Hemagglutinin) - VaxigripTetra Suspension for injection, 0,5ml prefilled syringe
214502909|NCT06756386|DEVICE|extra corporeal shock wave therapy (ESWT )|Using wound area measurements and histological/immunohistochemical analysis of wound biopsies, we show ESWT enhanced healing of chronic ulcers associated with improved wound angiogenesis ), significantly decreased-positive macrophages per biopsy area and generally increased macrophage activity ,this activity prevent bacterial infection which delay healing
214502910|NCT06756386|DEVICE|Low Level Laser Therapy|"Low-level laser therapy (LLLT) has been used as an adjuvant to conventional therapy with promising results,improve healing by delivering nutrient substances , especially in patients with acute and bloody ulcers.~Positive effects include acceleration of tissue repair, increased formation of granulation tissue, wound contraction, inflammation modulation, and pain reduction The biochemical effects of LLLT are associated with the release of preformed substances (histamine, serotonin, and bradykinin), which stimulate the production of ATP and inhibit the production of prostaglandins."
214502911|NCT06756386|OTHER|conservative treatments|( compression pandaging, lifestyle changes, physical activities)
215000989|NCT06902961|OTHER|Game-based exercise group|Game-based exercise group
215000990|NCT06902961|OTHER|control group|control group
215000991|NCT06905171|OTHER|Auditory Stimulation|A tone at a 1000 Hz frequency, delivered through speakers at a comfortable volume
214502912|NCT06929286|DRUG|Nadofaragene Firadenovec|For patients randomized to receive nadofaragene firadenovec, the patient will receive nadofaragene firadenovec as of normal saline instilled intravesically every 3 months for up to 12 months.
214395290|NCT05952115|OTHER|lumbar motor control exercises|"the patients will receive lumbar motor control exercises in the form of three exercises (Abdominal draw in maneuver, side-bridge, and quadruped) and the level of difficulty increased each week. For all exercises, the number of repetitions stayed the same, but the difficulty increased each week, and we progressed to the advanced level of each of the three exercises.~This training achieves co-contraction of the local/deep stabilizing muscles (Transversus abdominis and multifidus) and strengthening the global/large spinal stabilizers (erector spinae and obliques)."
214395291|NCT05952115|OTHER|Cervical stabilization exercises|The exercise program consisted of an axial elongation exercise, cranio-cervical flexion exercise, cervical extension exercise, and cervical-scapulothoracic strengthening exercise. The exercise program progressed based on the exercise tolerance of the patients by increasing the repetition of the exercise (10 reps to 15 reps to 20 reps). And for the resistive exercise, the participants change to an elastic band with greater resistance (progress to the next color resistance band). Exercises were performed for 20 min/session, and an exercise log recording the date and repetition of the exercises was maintained by the therapist for each participant.
214395292|NCT04079374|DRUG|Etanercept|Subcutaneous injections
214395293|NCT04079374|DRUG|Enbrel|Subcutaneous injections
214395294|NCT05349396|DRUG|Eszopiclone 3mg Test Drug T-1 Coated Tablets|Participants will receive one tablet of the test formulation T-1 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
214395295|NCT05349396|DRUG|Eszopiclone 3mg Test Drug T-2 Coated Tablets|Participants will receive one tablet of the test formulation T-2 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
214395296|NCT05349396|DRUG|Eszopiclone 3mg Reference Product Coated Tablets|Participants will receive one tablet of the Rerefence Product containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
214395297|NCT06418035|BEHAVIORAL|Video modeling by scanning Qr code|The protocol activity carried out by the experimental group will involve the use of the QR Code: in the operator's presence, the child scans the code through a technological device and watches the video of the activity to be played later in the HomeLab.
214395298|NCT06418035|BEHAVIORAL|Modeling traditional method|The control group will carry out the protocol activities in a traditional way, without technological tools. The child observes the operator who shows the live activity inside the HomeLab.
214395299|NCT05674942|OTHER|Patients with urinary tract infection and chronic kidney disease|The data that will be collected from the electronic patient records at the clinics through a google form will include sociodemographic (age, sex, weight and occupation), comorbidities (e.g., HTN, DM), medications used, renal functions (serum creatinine, and CKD stage calculated by 2021 CKD-EPI creatinine equation), and in case of positive urine culture (type of microorganism and antibiogram).
214395300|NCT00003009|BIOLOGICAL|aldesleukin|
214395301|NCT01225042|DIETARY_SUPPLEMENT|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
214395302|NCT01225042|DIETARY_SUPPLEMENT|placebo|placebo consisting of carrier material powder of identical appearance
214395303|NCT02334943|BIOLOGICAL|Blood test|Blood test
214395304|NCT01423864|DRUG|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
214395305|NCT01423864|DRUG|solumedrol|Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 \> FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
214395306|NCT03951935|OTHER|Oswestry Disability Index (ODI) questionnaire|Participant's level of low back pain and the extent to which the pain impacts his/ her daily life activities and social life are estimated with the standardized Oswestry Disability Index questionnaire
214395307|NCT03951935|DIAGNOSTIC_TEST|self-paced walking test (SPWT)|walking back and forth at a self-selected pace along a hallway at the University Hospital until the onset of claudication, pain or until reaching the time limit of 30 minutes. Kinematic and electromyographic (EMG) data will be recorded every 3 minutes.
214395308|NCT01048606|BEHAVIORAL|Placebo + exercise|"Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
214395309|NCT01048606|DIETARY_SUPPLEMENT|Phytoestrogens without exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions."
214502913|NCT06929286|DRUG|Gemcitabine|gemcitabine instilled intravesically for 1 h, then drained completely out of the bladder
214502914|NCT06929286|DRUG|Docetaxel|followed by docetaxel instilled intravesically for 1 h. This is given once weekly for 6 weeks for induction. Those who have a complete response typically proceed with once-monthly instillations of GemDoce for up to 24 months as maintenance therapy
214502915|NCT07087145|DIAGNOSTIC_TEST|Mail-based Saliva Sample Kit|Sent via United States Postal Service and returned via FedEx
214502916|NCT07087145|OTHER|Study-related Surveys|Online surveys will be administered
214502917|NCT06743568|DEVICE|Transcatheter aortic valve replacement|Eligible patients will be randomized 1:1 to self-expandable valve group or balloon-expandable valve group.
214502918|NCT06890117|DEVICE|Ultrasonic Scalers with EMS PI tip and Saline Irrigation|Control Group: Non-surgical peri-implantitis treatment using ultrasonic scalers and EMS PI tips designed for implants, combined with saline irrigation to remove plaque and biofilm from implant surfaces.
214395310|NCT01048606|OTHER|Phytoestrogens + exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
214395311|NCT00057603|PROCEDURE|Deep Brain Stimulation|Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.
214395312|NCT02563834|DRUG|thiapalmitate tracer|Radiolabeled tracer infusion; occurs in all treatment arms
214395313|NCT02563834|DRUG|Saline|Saline infusion for control
214395314|NCT02563834|DRUG|Insulin|Insulin infusion for insulin/glucose clamp procedure
214395315|NCT05853874|OTHER|Nutrition intervention (dietary protocol)|The nutrition intervention sought to improve participants' overall diet quality, taking into account a sufficient intake of carbohydrates, lipids, fibres and micronutrients (vitamins and minerals), promoting proper fruits and vegetables consumption and variety. About water intake, considering the high dehydration risk in older persons highlighted by the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines, its adequate consumption is recommended and encouraged.
214395316|NCT05853874|OTHER|Hospital standard of care|The standard clinical procedures following the malnutrition diagnoses will be implemented according to the routine of the two hospitals
214395317|NCT00319605|DRUG|Levetiracetam|
214395318|NCT03300375|OTHER|Home exercise program|Home-based, progressive exercise program using resistance bands
214395319|NCT03300375|OTHER|Post Op instructions|Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time.
214395320|NCT01364727|DRUG|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
214395321|NCT05072522|DRUG|SKLB1028|SKLB1028 capsules, oral, once daily in continuous 28-day cycles
214395322|NCT00163891|BEHAVIORAL|Chest physiotherapy|
214395323|NCT00005973|DRUG|BMS-214662|Given IV
214395324|NCT00005973|OTHER|laboratory biomarker analysis|Correlative studies
214395325|NCT03681483|DRUG|RO5126766|RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.
214502919|NCT06890117|DEVICE|Er:YAG (2940nm) and Diode (808nm) Laser|Experimental Group: Non-surgical peri-implantitis treatment using Er:YAG laser (2940nm) and Diode laser (808nm) for decontamination of the implant surface and surrounding tissues. The Er:YAG laser is used for mechanical debridement and biofilm removal, while the Diode laser has biostimulatory effects.
215000992|NCT06905171|OTHER|Visual Stimulation|A checkerboard pattern displayed on a monitor, with colors alternating every 25 ms
214395326|NCT04513457|OTHER|Liver resection and Neoadjuvant chemotherapy|
214395327|NCT04513457|OTHER|Liver resection and Adjuvant chemotherapy|
214395328|NCT04513457|OTHER|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy|
214395329|NCT04513457|PROCEDURE|Liver resection|
214395330|NCT01927718|DRUG|Thalidomide|100 mg by mouth daily for 28 days in a 28 day cycle.
214395331|NCT01927718|DRUG|Lenalidomide|Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
214395332|NCT01927718|BEHAVIORAL|Questionnaires|Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
214395333|NCT01601444|DEVICE|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
214395334|NCT02246829|PROCEDURE|Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
214395335|NCT01165710|OTHER|Patients with Atrial Fibrillation (AF)|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
214395336|NCT05771194|DRUG|Routine preoperative and postoperative anti-infection therapy|received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.
214395337|NCT05771194|DRUG|artificial tear therapy|given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery.
214502920|NCT04564547|DRUG|Islatravir|ISL capsule taken by mouth.
214502921|NCT04564547|DRUG|Ulonivirine|Ulonivirine tablet taken by mouth.
214502922|NCT04564547|DRUG|BIC/FTC/TAF|BIC/FTC/TAF tablet taken by mouth.
214502923|NCT04564547|DRUG|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
214502924|NCT04564547|DRUG|Placebo to Ulonivirine|Placebo tablet matched to ulonivirine taken by mouth.
214502925|NCT04564547|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
214502926|NCT03728335|DRUG|Enasidenib Mesylate|Given PO
214502927|NCT05496686|DRUG|4.7 microCi 225Ac-MTI-201|4.7 microCi intravenous solution
214502928|NCT05496686|DRUG|9.5 microCi of 225Ac-MTI-201|9.5 microCi intravenous solution
215000993|NCT06905171|OTHER|Somatosensory Stimulation|A train of three electrical stimuli, each lasting 1 ms, separated by 8 ms, at an intensity that clearly elicits a pricking sensation
215000994|NCT06905171|OTHER|Auditory-Visual Stimulation|Stimulation using auditory and visual stimuli concomitantly
214395338|NCT05771194|PROCEDURE|Cleaning, hot compresses and massage of the meibomian gland|Group B used a steam eye mask (Your Ga Run Fang, Shang Hai Run Mu Industrial Co., Ltd.) for 20 minutes 3 days before surgery. Sterile cotton swabs were used to apply physiological saline to the eyelid for local cleaning, and the secretions and phosphorus debris on the surface of the eyelid margin were removed to fully expose the meibomian gland. Meibomian gland tweezers were used to squeeze from the root of the gland toward the opening to expel the secretions; each gland was expressed twice. After the operation, an appropriate amount of gatifloxacin cream (Shen Yang Xing Qi Pharmaceutical Co., Ltd.) was applied to the conjunctival sac to prevent infection. Hot towels (40°C) were applied to the eyes for 10 minutes every morning and evening for 3 days before the operation.
214395339|NCT00399425|DRUG|bemiparin (low molecular weight heparin)|
214395340|NCT02984956|DEVICE|pleth variability index|
214395341|NCT02430922|DEVICE|iVolution nitinol stent|
214395342|NCT04328818|DIAGNOSTIC_TEST|indwelling device biofilm identification|performance of the NGS-based identification technique in comparison with the conventional culture-based one, for the same indwelling device biofilm sample
214395343|NCT04730063|DEVICE|VQm PHM™|Procedure: Non-invasive measurements obtained with the VQm PHM™
214395344|NCT01009047|DRUG|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
214395345|NCT01009047|DRUG|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
214395346|NCT00064272|DRUG|ginger extract|Given orally
214395347|NCT00064272|OTHER|placebo|Given orally
214395348|NCT04380818|RADIATION|Low-dose radiotherapy|Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later
214395349|NCT04380818|DRUG|Hydroxychloroquine Sulfate|200 mg/12h for 5 days
214395350|NCT04380818|DRUG|Ritonavir/lopinavir|400/100 mg/12h for 7-10 days
214395351|NCT04380818|DRUG|Tocilizumab Injection [Actemra]|600 mg/day for 1-2 doses
214395352|NCT04380818|DRUG|Azithromycin|500 mg/24h for 3 days
214395353|NCT04380818|DRUG|Corticosteroid|Corticosteroids (methylprednisolone/dexamethasone/prednisone)
214395354|NCT04380818|DRUG|Low molecular weight heparin|low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
214395355|NCT04380818|DEVICE|Oxygen supply|Oxygen
214395356|NCT02500485|DRUG|SHR3824, SP2086|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
214395357|NCT01322438|DRUG|Regorafenib (BAY73-4506) + rifampin|Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
214395358|NCT02618057|DRUG|Prednisolone|PO prednisolone, 1 mg/kg/day, for 5 days
214395359|NCT02618057|DRUG|Levofloxacin|Levofloxacin, 10mg/kg/day, IV, for 5days
214395360|NCT06303336|OTHER|NMES with Dynamic Bracing|The group will receive NMES along with dynamic bracing
214395361|NCT06303336|OTHER|NMES without Dynamic Bracing|The participants will receive NMES on the lower extremity
214395362|NCT06303336|OTHER|Dynamic Bracing Only|This group will receive dynamic bracing only on the lower limb.
214395363|NCT03137602|DEVICE|ATOMIC mobile app|(a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
214395364|NCT04716881|DRUG|Naltrexone 380 MG|Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days
214502929|NCT05496686|DRUG|19 microCi of 225Ac-MTI-201|19 microCi intravenous solution
214395365|NCT04435392|DRUG|Jaktinib Hydrochloride Cream|Subjects in each group were scheduled to give the drug for 8 weeks.
214395366|NCT04435392|DRUG|Placebo|Placebo
214395367|NCT05758363|DIETARY_SUPPLEMENT|Consumption of dietary supplement.|Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.
214395368|NCT05758363|OTHER|Consumption of control product|Consumption of 1 capsule per day of control product of identical appearance with breakfast.
214395369|NCT01085565|DEVICE|ExAblate 2100|Conformal Bone System
214395370|NCT01369056|BEHAVIORAL|Advanced Adherence Counseling (AdvAdh)|AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
214502930|NCT05496686|DRUG|38 microCi of 225Ac-MTI-201|38 microCi intravenous solution
214502931|NCT05496686|DRUG|76 microCi of 225Ac-MTI-201|76 microCi intravenous solution
214502932|NCT05496686|DRUG|152 microCi of 225Ac-MTI-201|152 microCi intravenous solution
214502933|NCT05496686|DRUG|254 microCi of 225Ac-MTI-201|254 microCi intravenous solution
214502934|NCT05496686|DRUG|424 microCi of 225Ac-MTI-201|424 microCi intravenous solution
214502935|NCT05496686|DRUG|564 microCi of 225Ac-MTI-201|564 microCi intravenous solution
214502936|NCT05496686|DRUG|750 microCi of 225Ac-MTI-201|750 microCi intravenous solution
215000995|NCT06905171|OTHER|Visual-Somatosensory Stimulation|Stimulation using visual and somatosensory stimuli concomitantly
215000996|NCT06905171|OTHER|Auditory-Somatonsensory Stimulation|Stimulation using auditory and somatosensory stimuli concomitantly
215000997|NCT06905171|OTHER|Auditory-Visual-Somatosensory Stimulation|Stimulation using auditory, visual and somatosensory stimuli concomitantly
215000998|NCT04455698|BEHAVIORAL|Remote Telegenetic Counseling by Phone|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor by Telephone.
214395371|NCT04398784|DIETARY_SUPPLEMENT|Freeze Dried Blueberry Powder - 71717|Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.
214395372|NCT04398784|DIETARY_SUPPLEMENT|USHBC Blueberry Placebo Formula #114|Blueberry flavor- and color-matched placebo powder.
214395373|NCT03173443|DEVICE|single lumen tube and bronchial blocker|fiberoptic intubation with single lumen tube and bronchial blocker
214395374|NCT03173443|DEVICE|double lumen tube|fiberoptic intubation with double umen tube
214395375|NCT04299633|DRUG|Vadadustat|2 x 150 mg oral tablets
214395376|NCT04299633|DRUG|Sevelamer carbonate|2 x 800 mg oral tablets
214395377|NCT04299633|DRUG|Calcium acetate|2 x 667 mg oral gelcaps
214502937|NCT05496686|DRUG|998 microCi of 225Ac-MTI-201|998 microCi intravenous solution
215000999|NCT04455698|BEHAVIORAL|Remote Telegenetic Counseling by Videoconferencing|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor using Videoconferencing Technology.
215094896|NCT07080944|PROCEDURE|Axillary Limph Node Dissection (ALND)|Axillary Limph Node Dissection (ALND) after no pre-surgery SLN visualization using technetium-99m and no intra-surgery SLN identification.
214395378|NCT04299633|DRUG|Auryxia®|2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
214395379|NCT04394741|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
214395380|NCT04394741|DEVICE|Control-Dry Needling|"Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles~1 session in upper trapezius muscle moving the needle up and down ten times."
214395381|NCT03575637|DRUG|Olanzapine|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
214502938|NCT05496686|DRUG|1327 microCi of 225Ac-MTI-201|1327 microCi intravenous solution
214502939|NCT06892600|DRUG|Combined Spinal anesthesia (heavy bupivacaine 0.5%) and General anesthesia|Combined spinal and general anesthesia Spinal anesthesia with Bupivacaine heavy 0.5% 10 mg General anesthesia with Lidocaine 1.5mg/kg, Fentanyl 2 mcg/kg, propofol 2 mg/kg, Rocuronium 0.6 mg/kg
214502940|NCT06892600|DRUG|General Anesthesia (control group)|Lidocaine 1.5mg/kg, fentanyl 2 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg
214502941|NCT06191302|PROCEDURE|blood sample|Blood sample collected in the post-acute period (follow-up visit) will be analysed for biomarkers predictive for diseases related to and disease progression in various organ systems (e.g., cardiovascular, pulmonary, and renal systems), including e.g., Pro-BNP, NGAL, and interleukins.
214502942|NCT06191302|OTHER|Online questionaire|The participants will complete an online questionnaire related to disease and health issues associated with COVID-19 and COVID-19 post-acute sequalae's and existing Non-Communicable Disease.
214502943|NCT05826977|BEHAVIORAL|CASI-Plus|See arm description
214502944|NCT06909799|DRUG|N-Acetyl Cysteine (NAC)|NAC will be provided as 600 mg capsules from NOW Healthgroup. Standard TB treatment will be provided as fixed dose combination tablets.
215001000|NCT04455698|BEHAVIORAL|Usual Care Arm|Participants in the usual care arm will receive usual care services depending on which referral method they choose and if they initiate services. After a 6 month status survey, if they have not had genetic services through usual care they will be offered services and re-randomized to ARM A/ARM B.
215094897|NCT06745583|DRUG|EI-1071 tablet, oral|Dose: 448.2 mg BID for 28 days
215094898|NCT07079982|OTHER|Freeze-dried whole grape powder|Studying the effects of freeze-dried whole grape powder on immune profiles in healthy aging adults
215094899|NCT07079982|OTHER|Control grape-free powder|Studying effects of a control grape-free powder on immune profiles in healthy aging
214395382|NCT01752413|DIETARY_SUPPLEMENT|Ferrous gluconate 325mg|Participants with low ferritin (\<30 micrograms/L (males) or \<20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.
214395383|NCT01752413|BEHAVIORAL|Nutrition counseling|All blood donors receive current dietary counseling recommending iron rich foods
214395384|NCT02561351|OTHER|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
214395385|NCT04100460|DIETARY_SUPPLEMENT|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
214395386|NCT04100460|DIETARY_SUPPLEMENT|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
214395387|NCT04100460|DIETARY_SUPPLEMENT|Control - No Arabinoxylan|Participants are given no Arabinoxylan
214395388|NCT01557972|PROCEDURE|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
214395389|NCT01557972|PROCEDURE|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
214395390|NCT04288362|OTHER|Intervention Group|Participants in this arm will undergo the new care model for management of diabetes mellitus polyclinics.
214395391|NCT04288362|OTHER|Control Group|Participants in this arm will continue to undergo the existing care model for management of diabetes mellitus in the polyclinics.
214502945|NCT06909799|DRUG|Standard TB treatment|Standard TB treatment will be provided as fixed dose combination tablets.
214502946|NCT05261581|PROCEDURE|Erector Spinae Plane Block|Erector spinae block (ESB) is an ultrasound-guided interfascial plane block. The local anesthetic is injected using ultrasound guidance superficial to transverse process and deep to erector spinae muscle group
215001001|NCT07093541|DRUG|ecopipam HCl ~2mg/kg/day|Saily oral tablet taken every evening before bedtime.
215001002|NCT07093476|DRUG|Metformin|tablets, QD, oral administration
215001003|NCT07093476|DRUG|Alogliptin|tablets, QD, oral administration
214395392|NCT05943418|BEHAVIORAL|Wysa for Worry|"The Wysa for Worry cCBT program is a week-based cCBT programme consisting of specialised cognitive behavior therapy (CBT) interventions delivered through a conversational agent.~Each week of the programme focuses on a different CBT technique or intervention, which is explained in a short weekly video. Following each video, the technique or intervention is discussed and practiced with Wysa's AI chatbot."
214395393|NCT05943418|BEHAVIORAL|App-based Psychoeducation|The control will include the weekly delivery of active psychoeducational resources.
214395394|NCT02934113|BEHAVIORAL|iOTA|The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
214395395|NCT02934113|BEHAVIORAL|HWPP|Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
214395396|NCT02892682|OTHER|BLOOD TEST|
214395397|NCT02223247|DRUG|TVB-2640|
214395398|NCT01558674|DRUG|MK-7145|
214395399|NCT01558674|DRUG|Furosemide|
214395400|NCT01558674|DRUG|Torsemide|
214395401|NCT04147260|DRUG|BI 730357|Film-coated tablet
214395402|NCT04147260|DRUG|Placebo to match BI 730357|Film-coated tablet
214395403|NCT04147260|DRUG|Ciprofloxacin|Film-coated tablet
214395404|NCT06275672|OTHER|Adapted version of the mhGAP-IG|An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.
214395405|NCT05918315|PROCEDURE|Buccal mucosa substitution urethroplasty|Use of buccal mucosa as a substitution for urethroplasty
214395406|NCT03479749|DEVICE|RegenoGel-OSP, RegenoGel|RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
214395407|NCT02242240|DRUG|Formoterol twice daily|
214395408|NCT02242240|DRUG|Formoterol once daily|
214395409|NCT02242240|DRUG|Tiotropium once daily|
214395410|NCT02242240|DRUG|Placebo|
214395411|NCT04136652|PROCEDURE|CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch|women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
214395412|NCT01531192|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
214395413|NCT01531192|DRUG|Nystatin|50000 unit/3 times a day, both for orally and by orogastric route
214395414|NCT00259493|PROCEDURE|Off-Pump Coronary Artery Bypass Graft Surgery|
214395415|NCT00445263|DRUG|TIROFIBAN|intravenous infusion
214395416|NCT00445263|PROCEDURE|CORONAROGRAPHY|standard procedure of coronarography
214395417|NCT00000719|DRUG|Zidovudine|
214395418|NCT00000719|DRUG|Zalcitabine|
214395419|NCT02869113|DRUG|BAY98751 (Y65-110)|10 µL in one eye
214395420|NCT02869113|DRUG|BAY 98751 (Y65-102)|10 µL in one eye
214395421|NCT02869113|DRUG|BAY 98751 (Y65-106)|10 µL in one eye
214395422|NCT02869113|DRUG|Standard shampoo mixture (Control)|10 µL in other eye
214395423|NCT01872780|DRUG|Rosiglitazone|single oral administration of 4mg of rosiglitazone
215001004|NCT07093476|DRUG|empagliflozin|tablets, QD, oral administration
214395424|NCT01872780|GENETIC|CYP2C8 genotype|CYP2C8\*11.
214395425|NCT03508804|DRUG|Lidocaine-Prilocaine Cream|10ml of vaginally self-administered cream composed of an eutectic mixture of 2.5% lidocaine, 2.5% prilocaine
215001005|NCT06903702|DRUG|Azacitidine (AZA)|given daily for 7 days starting on Day 1 of each Cycle
215001006|NCT06903702|DRUG|Venetoclax|orally daily for 28 days
215001007|NCT06903702|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|After the conditioning treatment, the HSCT procedure is part of standard care on Day 0.
215001008|NCT07096921|DRUG|Mosapride citrate 5 mg + DA-9701 30 mg|Experimental: Mosapride citrate 5 mg + DA-9701 30 mg, Oral, 3 times/day, 30 min before meals for 4 weeks
214395426|NCT03508804|DRUG|Placebo Cream|10ml of vaginally self-administered placebo cream
214395427|NCT03508804|DRUG|1% Lidocaine Paracervical Block|Paracervical block of 10ml of 1% lidocaine
214395428|NCT01734850|DRUG|Busulfan|Intravenous busulfan
214395429|NCT01734850|BIOLOGICAL|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
214395430|NCT01734850|BIOLOGICAL|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
214395431|NCT06109844|OTHER|Standard of Care|Patients enrolled in this observational study receive standard of care. Treatment, ointments, compression and bandages will be registered at every visit.
215001009|NCT07096921|DRUG|Mosapride citrate 5 mg + DA-9701 30 mg placebo|Placebo Comparator: Mosapride citrate 5 mg + DA-9701 placebo, Oral, 3 times/day, 30 min before meals for 4 weeks
215001010|NCT07092384|DRUG|Remifentanil|Observe the incidence of pruritus and paresthesia after different doses of remifentanil and fospropofol disodium
215001011|NCT07092384|DRUG|Sufentanil|Observe the incidence of pruritus and paresthesia after sufentanil and fospropofol disodium
215001012|NCT06911931|OTHER|EEG measure of visual processing|Non-invasive scalp EEG measure of early cortical visual processing.
215001013|NCT07092826|OTHER|Psychopathological assessment and non-invasive multisensory stimulation|This intervention consists of a non-invasive, cross-sectional assessment involving standardized psychopathological interviews and multisensory stimulation tasks (auditory, tactile, and combined). It is designed to explore formal and content-related features of obsessive-compulsive symptoms, insight levels, and trauma-related correlates in patients with OCD and schizophrenia spectrum disorders. No pharmacological treatment or experimental therapy is administered as part of this study.
215001014|NCT07091747|OTHER|Cannabis 50 mg of CBD and 5 mg of THC|Cannabis 50 mg of CBD and 5 mg of THC
215001015|NCT07099885|DIAGNOSTIC_TEST|Standard of Care (SOC)|Diuretic treatment per attending physician.
215001016|NCT07099885|DIAGNOSTIC_TEST|Algorithhm-based decongestion|Patient will receive standarized furosemide dosing based on the result of the algorithm-estimated 6h urine output (profiles of diuretic response).
215001017|NCT00980460|DRUG|Cisplatin|Given IV
215001018|NCT00980460|DRUG|Dexrazoxane|Given IV
215001019|NCT00980460|DRUG|Doxorubicin Hydrochloride|Given IV
214395432|NCT05955521|PROCEDURE|exosome and ctDNA evaluation|Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.
215001020|NCT00980460|DRUG|Fluorouracil|Given IV
215001021|NCT00980460|DRUG|Irinotecan Hydrochloride|Given IV
215001022|NCT00980460|OTHER|Laboratory Biomarker Analysis|Correlative studies
215001023|NCT00980460|PROCEDURE|Liver Transplantation|Undergo liver transplant
215001024|NCT00980460|DRUG|Temsirolimus|Given IV
215094900|NCT03259815|PROCEDURE|P.I.O.S.|Physiologically-Guided Incremental Optimisation Strategy
215094901|NCT03259815|DIAGNOSTIC_TEST|Pre and post-PCI coronary physiology measurements|Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
215094902|NCT06856330|PROCEDURE|furlow with buccal myomucosal flap|patients were treated with furlow with buccal myomucosal flap
215094903|NCT06856330|PROCEDURE|two flap palatoplasty|patients were treated with two flap palatoplasty
215094904|NCT07081256|DRUG|QLM2010 for injection；dexamethasone|QLM2010 for injection；Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
214395433|NCT05595330|BEHAVIORAL|Lymphedema prevention protocols|"Coming for surgery: A PPT lecture; 2. A seminar; 3. Patients were given a lymphedema prevention brochure; 4. Diary cards for exercise is given and instruct patients to fill out daily; 5. Establish a WeChat group.~The first chemotherapy:1. Review diary card and provide guidance and education. 2. A PPT lecture; 3. A seminar; 4. Play functional exercise videos in the recovery room; 5. Rehabilitation volunteers come to the ward to form mutual help groups with patients under the guidance of subject team members; 6. Instruct regular exercise and avoid behaviors that can lead to lymphedema. 7. Ask about the exercise and whether there is any swelling and discomfort and give guidance.~The second chemotherapy: 1. A PPT lecture; 2. A seminar; 3. Play functional exercise videos in the recovery room.~The third chemotherapy: 1. Routine nursing; 2. Assess patients' knowledge of lymphedema prevention and exercise compliances; 3. Play functional exercise videos in the recovery room."
214395434|NCT00747058|DRUG|PF-3864086|The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
214395435|NCT00747058|DRUG|Placebo|Placebo
214395436|NCT02204293|DRUG|Canakinumab|Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
214395437|NCT02204293|DRUG|Placebo|Matching placebo administered subcutaneously.
214395438|NCT01990300|DRUG|Alogliptin/Pioglitazone|Alogliptin/Pioglitazone combination tablets
214395439|NCT00720005|DEVICE|Aspheric Acrysof ReSTOR intraocular lens|Bilateral implantation of Aspheric Acrysof ReSTOR
214395440|NCT02462785|BEHAVIORAL|In-person Carbohydrate Counting Class|An in-person carbohydrate counting class led by a registered dietician. The in class session covers topics including the role of CHO in nutrition and diabetes, sources of CHO, different CHO and non-CHO foods, resources for CHO counting, label reading, and meal planning. This is the standard procedure for CHO counting education at SickKids.
214502947|NCT05261581|DRUG|NSAID|Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation.
215001025|NCT00980460|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
215001026|NCT00980460|DRUG|Vincristine Sulfate|Given IV
215001027|NCT05609344|BEHAVIORAL|SBIRT|Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
215001028|NCT06908538|DEVICE|cryoablation|Cryoanalgesia, also known as Cryoablation, Cryoneurolysis, or Cryonerve Block, has been used for decades to treat chronic pain and has recently been employed for the management of Phantom Limb Pain. Cryoanalgesia involves the use of a probe to apply extreme cold (approximately -70◦C) to induce reversible axonal injury and Wallerian degeneration to produce a temporary conduction block that is sustained until regeneration of the axon and sensation is restored, typically weeks to months later.
215001029|NCT06911294|BEHAVIORAL|Polygenic Risk Score|genetic test for the evaluation of cardiovascular risk
215001030|NCT06911294|BEHAVIORAL|Digital app and wearable device|a wearable device connected with its app
215001031|NCT07098377|DIAGNOSTIC_TEST|nasopharyngeal swab for biological sample analysis|nasopharyngeal swab for biological sample analysis
215094905|NCT07081256|DRUG|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
215121365|NCT04440878|BEHAVIORAL|Static stretching|Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 15 seconds of rest with 10 repetitions, and the individuals will be asked to participate in the exercise actively.
215121366|NCT04440878|BEHAVIORAL|Mulligan TSLR technique|Mulligan TSLR will be applied by a physiotherapist in 3 repetitions with the patient in the supine position.
215121367|NCT03999515|DRUG|Abiraterone Acetate|Given PO
214395441|NCT02462785|BEHAVIORAL|Online Carbohydrate Counting Tutorial|A web-based CHO counting tutorial that covers the same concepts reviewed during the standard in-person instructional session held at SickKids. A teen delivers the educational messages in short segments using techniques designed to maintain the viewer's attention (e.g., visuals of food portions and short segment highlights to emphasize important points). The online module includes brief interactive question/answer components for reinforcement. The secure online tutorial will be accessible for one week through a link provided by REDCap. Users will be able to repeat sessions, log on and off during sessions, and choose specific modules for repetition/review. The investigators will be able to capture the number of times patients log on and detail frequency and specifics of usage.
214395442|NCT01405794|DRUG|32ppm Silver Particle|Oral silver dose of 32ppm
214395443|NCT01405794|DRUG|Placebo|Sterile Water No Silver
214395444|NCT02576834|BEHAVIORAL|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
214395445|NCT02576834|OTHER|Services as Usual|Services as usually provided in the community
214395446|NCT02019602|PROCEDURE|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
214395447|NCT02019602|PROCEDURE|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
214395448|NCT02019602|PROCEDURE|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
214395449|NCT02019602|BIOLOGICAL|Certolizumab Pegol|"Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous Use"
214395450|NCT00322374|DRUG|Ixabepilone|Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.
214395451|NCT00322374|DRUG|Epirubicin|Infusion, intravenous (IV): 75 mg/m\^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
214395452|NCT03085121|PROCEDURE|Distal femoral resection in total knee arthroplasty|EM and IM alignment systems are used to make the distal femoral cut in a random order.
214395453|NCT03124030|PROCEDURE|simple dental extraction|dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied
214395454|NCT06381037|BEHAVIORAL|"How to improve your strengths and quality of life."|"The intervention program How to improve your strengths and quality of life consists of 8 individual sessions. The sessions take place weekly, so the total duration of the program is 8 weeks. Each session lasts approximately 1 hour. The sessions will be held both in person and online.~The sessions are:~* Session 1: Introduction to quality of life and personal strengths.~* Session 2: Self-fulfillment.~* Session 3: Pleasure.~* Session 4: Autonomy and control.~* Session 5: Family functioning and assertive communication.~* Session 6: Resilience.~* Session 7: Experiential acceptance.~* Session 8: Gratitude and closing of the workshop."
214395455|NCT03869060|BIOLOGICAL|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
214395456|NCT00925782|DRUG|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
214395457|NCT00925782|DRUG|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
214395458|NCT03133468|DRUG|AJM347|Oral administration
214395459|NCT03133468|DRUG|Placebo|Oral administration
214395460|NCT02503462|DRUG|Darunavir|darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).
214502948|NCT05261581|BEHAVIORAL|Home Exercise Programme|Home exercise programme will include some stretches that aid in pain relief by helping take stress off the low back and hips, core stabilization exercises and postural exercises.
215001032|NCT07099534|DRUG|IV Ketamine (0.5 mg/kg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder|Participants receive two intravenous (IV) infusions of ketamine at a dose of 0.5 mg/kg over 40 minutes. The first infusion is administered at Hour 0 (H0) and the second at Hour 24 (H24). Vital signs and potential adverse effects are closely monitored before, during, and after each infusion. This intervention aims to assess the short-term efficacy and safety of ketamine in reducing symptoms of severe borderline personality disorder.
215001033|NCT07111052|BEHAVIORAL|Lock and Protect is a self-administered, web-based decision aid for caregivers of adolescents at risk for suicide.|Lock and Protect is a user-friendly web-based decision aid that identifies preferences and explores options for removing or storing lethal means safety through: (a) education on home means of suicide, such as firearms, medications, and other potentially dangerous home and external items/situations (e.g., poisons, methods/ligatures used in suffocation/hanging), and community hazards (e.g., subways, heights); (b) safe storage options; and (c) protective monitoring and supervision as a means of increasing adolescent safety during a time of elevated risk.
214395461|NCT02503462|DRUG|ritonavir|ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).
214502949|NCT05986617|DEVICE|InBody Band 2|Wearable bioimpediance monitor similar to a fitness watch.
214502950|NCT06161285|OTHER|Sampling|Single-time sampling of respiratory virus-infected children
215121368|NCT03999515|DRUG|Enzalutamide|Given PO
215121369|NCT03999515|DRUG|Erdafitinib|Given PO
215121370|NCT00003279|BIOLOGICAL|BCG vaccine|
215121371|NCT00003279|BIOLOGICAL|monoclonal antibody BEC2|
214395462|NCT02503462|DRUG|cobicistat|cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
214395463|NCT03001401|OTHER|iDesign|One group will under go standard LASIK using iDesign platform (J\&J, USA). Visual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
215001034|NCT07105761|BEHAVIORAL|Body-Mind-Spirit|The experimental group participated in a 10-week BMS group intervention, with weekly 130-minute sessions. The intervention combined Eastern philosophy and Western psychotherapy to enhance emotional balance and psychological resilience. Core components included observing merits (recognizing strengths), cultivating gratitude, and practicing forgiveness. Physical activities such as finger dexterity training, diaphragmatic breathing, and stretching supported autonomic regulation and flexibility. Psychological strategies involved positive thinking, emotional expression, and life story sharing. All materials were adapted with audio descriptions for accessibility. Participants with visual impairment received orientation training and volunteer support for transportation and on-site assistance.
214395464|NCT03001401|OTHER|SMILE|The other group will undergo SMILE for treatment refractive error (Carl Zeiss, Germany). isual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
214693829|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes."
214395465|NCT05956977|DEVICE|resection with help of 3D ultrasound|see above
214395466|NCT00463541|DRUG|solifenacin succinate|oral
214395467|NCT03548636|BEHAVIORAL|Single-Arm Feasibility Study|Groups of 8 to 12 participants, consisting of \>50% breast cancer survivors, were invited to apply for up to $2000 to enable access to equipment, resources, facilities, instruction and/or transportation to implement a physical activity intervention. Applicants were assessed by a Grant Review Panel. Successful applicants were informed that they would receive an additional $500 incentive if they increased their group's mean physical activity at six month follow-up (assessed via accelerometry).
214395468|NCT06460415|DEVICE|photobiomidulação|The volunteers in the GFBM group will undergo 8 sessions of a combined red and infrared laser protocol with 4J of infrared power and 4J of red power. Being applied at 8 points (4 red and 4 infrared) in the vulvar region and 8 points (4 red and 4 infrared) points in the intravaginal pelvic floor region. The MMO semiconductor laser device (GaA1As and InGaAlP) will be used with an area of the output laser beam at the NOZZLE of the laser pen of 3mm2 and wavelengths of 660nm (Red Laser) and 808nm (Infrared Laser) with a power of 100mW. The application will be carried out with the volunteers on a stretcher, in the supine position, gynecological position, with the knees and hips flexed and in abduction, feet supported on the stretcher.
214395469|NCT06460415|OTHER|Placebo|The placebo control will be administered using the same device as the GFBM, but without any therapeutic dose delivery. Furthermore, the irradiated sites and irradiation time will be the same as PBMT. Volunteers will receive a total dose of 0 J in placebo mode. This treatment was also carried out in 8 sessions.
214395470|NCT06410378|PROCEDURE|Erector Spinae Plane Block|Patient will receive 20 ml of bupivacaine 0.25 % through Erector Spinae Plane Block approach
214395471|NCT06410378|PROCEDURE|Serratus Anterior Plane Block|Patient will receive 20 ml of bupivacaine 0.25 % through Serratus Anterior Plane Block approach.
214395472|NCT06410378|PROCEDURE|controll group|patient will receive general anesthesia
214395473|NCT04388930|OTHER|Pre-operative assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing"
214395474|NCT04388930|OTHER|Post-operative day 3 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
214395475|NCT04388930|OTHER|Post-operative week 4-6 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
214395476|NCT04388930|OTHER|Post-operative 3 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
214395477|NCT04388930|OTHER|Pre-operative 6 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
214395478|NCT04388930|OTHER|Post-operative month 12 recipient assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
215121372|NCT04933071|BEHAVIORAL|Podcast|A list of podcasts that are specified for each rotation
215121373|NCT05887921|PROCEDURE|Inguinal Lymphadenectomy|arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
215121374|NCT00330759|BIOLOGICAL|Denosumab|120 milligrams by subcutaneous injection every 4 weeks
214395479|NCT05345912|DRUG|CG-745 IV Solution|CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
214395480|NCT05345912|DRUG|CG-750 125mg capsule|CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
214395481|NCT05345912|OTHER|PO Placebo|PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
214395482|NCT05345912|OTHER|IV Placebo: 0.9 % normal saline|IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
214395483|NCT00166634|PROCEDURE|Ambulatory Blood Pressure Monitoring (ABPM)|
214395484|NCT06279754|DRUG|Recombinant Human Endostatin Injection|Recombinant Human Endostatin Injection：210 mg, intravenous infusion for 72 hours, once every three weeks cycle Evafolimab Injection：Subcutaneous injection on day 1, 8, and 15, once every three weeks cycle
214693830|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes."
214395485|NCT01276249|DEVICE|Fortevo Endograft|The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
214395486|NCT05490069|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and real-time chat-based support messages, delivered according to participants' preferences.
214395487|NCT02397460|DRUG|Gefapixant|Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)
214395488|NCT02397460|DRUG|Placebo|
214395489|NCT05286515|OTHER|Hybrid Peroperative PT|The intervention will consist of an in-person evaluation assessing the subject's functional level, lower and upper extremities range of motion, strength and endurance. The remaining sessions will be conducted via telehealth. The program will consist of two sessions per week up to six weeks. The program will start approximately 8 to 7 weeks before the scheduled surgery date.
214395490|NCT05286515|OTHER|Standard Clinical Practice PT|This group will follow the protocols established by the PT facility they chose. They will finish treatment two to three weeks before the surgery date, similar to the intervention group.
214395491|NCT02213055|DRUG|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
214395492|NCT02213055|DRUG|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
214395493|NCT04268836|DEVICE|Optimal Acuity Clear-K® Low Vision Aid System treatment|The treatment involves irradiation of the cornea with low energy light in a treatment pattern that produces corneal shape change.
214395494|NCT02986828|DRUG|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
214395495|NCT02986828|DRUG|Normal saline|Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
214395496|NCT02986828|DEVICE|Ultrasound|
214395497|NCT02631083|OTHER|Breakfast, lunch, snack and dinner|These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
214395498|NCT01531140|DRUG|polyethylene glycol +Bisacodyl|Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
214395499|NCT01531140|DRUG|Polyethylene glycol|Polyethylene glycol p.o.: 60 ml/kg/days
214395500|NCT01531140|DRUG|Sennosides|Sennosides 1tbl/8kg for 2 days
215001035|NCT07111702|DRUG|Cefazolin|A single 2g intravenous dose administered once before surgery.
215001036|NCT07111403|PROCEDURE|SAP fluoride plus|The agent was applied by removing the safety clip, activating the applicator and squeezing out the sponge above the lesion and the solution was left to diffuse for 5 min.the patients were instructed to eat only soft foods and avoid hot liquids for two hours. Also, they were educated and motivated about the importance of oral hygiene.
215001037|NCT07111403|PROCEDURE|10% n-HAp.|the pastes were applied using micro brushes. The excess was removed after four minutes with a cotton swab. The subjects were advised not to drink or eat for 30 minutes after the treatment. The treatment was applied once every week for a period of four weeks.they instructed to adhere to oral hygiene measures.
214395501|NCT06381635|DIETARY_SUPPLEMENT|Manuka honey mixed with aloe vera gel|a mix gel of manuka honey and with aloe vera honey (1:1) mixed in water bath to get a homogenous mix is then packed in unmarked bottles.
214395502|NCT04181541|PROCEDURE|Provider type: Physicians|In this cohort, women will receive second trimester medical abortion care from physicians
214395503|NCT04181541|PROCEDURE|Provider type: Midlevel Providers|In this cohort, women will receive second trimester medical abortion care from midlevel providers.
214395504|NCT03375814|DRUG|Crocin|This group (osteoarthritic patients) can receive crocin with conventional therapy
214395505|NCT03375814|DRUG|Placebo Oral Tablet|The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
215121375|NCT00330759|DRUG|Zoledronic Acid|4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
215121376|NCT03976258|DRUG|buprenorphine/naloxone|This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
215121377|NCT03976258|DRUG|Methadone|This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
214395506|NCT04415892|OTHER|Cinnamaldehyde and capsaicin|Topical application of cinnamaldehyde and capsaicin on the fingers
214395507|NCT06320275|BEHAVIORAL|Storytelling Intervention|A storytelling fertility awareness video intervention, approximately 10 minutes in length, guided by a situation-specific theoretical framework and storytelling/narrative communication theory, was developed by the researchers.
214395508|NCT05181943|DEVICE|Simpler diode laser|Non-contacting irradiation for 30 seconds on three intraoral sites repeated four times
214395509|NCT05181943|DRUG|Conventional symptomatic treatment|Conventional treatment using oracure, BBC spray, miconaz three times daily
214395510|NCT05517720|OTHER|Aria Trio complete Facial System|Renew Serum, Brighten Serum, and Refine Serum.
214395511|NCT00114842|PROCEDURE|MR colonography|
214395512|NCT03415087|PROCEDURE|sequential intrathecal injection|intrathecal injection of fentanyl and hyperbaric bupivacaine
214395513|NCT03415087|DRUG|hyperbaric bupivacaine|intrathecal injection of intrathecal bupivacaine
214395514|NCT03415087|DRUG|fentanyl|intrathecal injection of fentanyl
215001038|NCT07111403|PROCEDURE|10% n-BAG.|the pastes were applied using micro brushes. The excess was removed after four minutes with a cotton swab. The subjects were advised not to drink or eat for 30 minutes after the treatment. The treatment was applied once every week for a period of four weeks. patients instructed to adhere to oral hygiene measures.
215001039|NCT07111403|PROCEDURE|Flour Protector S|After application of varnish, the patient was instructed to avoid abrasive diet for the rest of the day and not brush or floss until the next morning. The treatment was done at baseline and after 6 months.
215001040|NCT07113496|BIOLOGICAL|Allogeneic CAR-T|Patients will receive lymphodepletion chemotherapy followed by a single intravenous infusion of Allogeneic CAR-T cells. In select cases, CAR-T infusion may be administered post-autologous hematopoietic stem cell transplantation (auto-HSCT)
215001041|NCT06480539|DRUG|Placebo|The comparator is a placebo, namely pure saline (NaCl 0.9%), which will be administered following the same regimen as the intervention.
214395515|NCT04558086|DEVICE|Virtual reality|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
214395516|NCT04558086|DEVICE|Photo book|To develop the intervention strategies of hospitalized school-age children with IV placement, using Photo book to further examine the effectiveness of reducing IV pain and fear.
214395517|NCT01024751|DEVICE|Bausch & Lomb Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
214502951|NCT06909942|DIAGNOSTIC_TEST|Psoas Muscle Index|The PMI is typically calculated using cross-sectional imaging (CT or MRI) at the level of the third lumbar vertebra (L3).The total psoas area is normalized to patient height: PMI = Total psoas muscle area (cm²) / height² (m²).The PMI is particularly valuable in hospital settings where patients may have difficulty performing functional tests like handgrip strength measurements, offering an objective assessment of muscle status from readily available imaging data.
215001042|NCT06480539|DRUG|Dexmedetomidine|Nocturnal administration of dexmedetomidine (0.2-1.0 mcg/kg/h) during the first night after surgery. Dexmedetomidine infusion, not preceded by a bolus administration, will be started at 0.4 mcg/kg/h in the intervention group at 8 p.m. the day of surgery. Dexmedetomidine infusion will be titrated every 30 minutes with 0.1 mcg/kg/h steps until a RASS of -1 to -3 (drowsy, light to moderate sedation) is reached. The infusion will be discontinued at 6 a.m. the next morning.
215001043|NCT07104409|OTHER|virtual reality hypnosis device|VRH group, in which patients will receive conventional sedation (remifentanil 0.1 mcg/kg/min and propofol 0.5 mg/kg if necessary) and a Virtual Reality headset with an environment chosen by the patient and hypnosis support with suggestions to reduce their anxiety.
215001044|NCT07105397|OTHER|Conversational AI system|The conversational AI intervention utilizes interactive dialogue to collect patient medical histories. Powered by advanced Large Language Models (LLMs), the system engages participants in open-ended, natural language conversations. A Dialogue Manager coordinates the dialogue, ensuring conversations remain medically relevant, personalized, and safe. Clinicians monitor the interactions in real-time, validating and ensuring accuracy of antidepressant recommendations informed by an evidence-based Antidepressant Knowledgebase.
215001045|NCT07105397|OTHER|Structured Survey Questionnaire|"The structured questionnaire intake utilizes a predefined, multiple-choice survey that systematically collects patient medical history without conversational interaction. Questions are algorithmically selected based on the patient's earlier responses to maximize information efficiency, typically requiring fewer than 13 items. Patients select from standardized responses (including options like I do not know or I do not want to say). Contextual help messages are provided as needed. Upon completion, the system generates antidepressant recommendations using the same Antidepressant Knowledgebase as the Conversational AI system, clearly explaining its rationale. A prototype version is available at http://MeAgainMeds.com, with ongoing development to enhance features and usability."
215001046|NCT07104097|PROCEDURE|spinal anesthesia|spinal anesthesia at L3-L4 plain bupivacaine 0.5% 2.2 ml
215001047|NCT07104097|PROCEDURE|superficial erector spinal plane block (ESPB)|Lidocaine 1% + ropivacaine 0.25% 30 ml with adrenaline 1:200.000 on top of L3 transverse process, between bone and erector spinae muscle
215001048|NCT07104097|PROCEDURE|deep (inter laminar) erector spinal plane block (ESPB)|Lidocaine 1% + ropivacaine 0.25% 30 ml with adrenaline 1:200.000 between L3 and L4 transverse process, between erector spinae muscle and deep muscles
215094906|NCT07088939|BEHAVIORAL|dialectical behavior therapy|This internet-delivered dialectical behavior therapy (iDBT) intervention consists of an e-learning course with 4 modules based on the 4 areas of skills training in dialectical behavior therapy: mindfulness, emotion regulation, distress tolerance, and interpersonal effectiveness. Participants can work through the modules at a self-guided pace to learn more than 30 specific skills using psychoeducational materials. The intervention incorporates psychoeducational elements of skills training with introductory videos, interactive quizzes, practice and homework suggestions, as well as quotes and videos from individuals with lived experience. In preliminary testing, it was estimated to take approximately 8-10 hours to complete all material.
215001049|NCT07104097|DRUG|Dexamethasone|8 mg iv preoperatively
215001050|NCT07104097|DRUG|Ibuprofen 400 mg|preoperatively and postoperatively (every 8 hours)
215001051|NCT07104097|DRUG|Paracetamol|1000 mg preoperatively and postoperatively (every 8 hours)
215001052|NCT07104097|DRUG|Morphine|Patient Controlled Analgesia
215001053|NCT06395519|DRUG|ETX-19477|Oral medication taken daily
214395518|NCT01024751|DEVICE|Ciba's Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
214395519|NCT04779164|DIAGNOSTIC_TEST|knee ultrasonography|The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
214502952|NCT06909942|DEVICE|Handgrip Dynamometer|Handgrip strength (HGS) is one of the key diagnostic criteria for sarcopenia according to several international consensus guidelines, including those from the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Asian Working Group for Sarcopenia (AWGS).Men: \<27 kg and women: \<16 kg values indicates sarcopenia for each patient.Handgrip strength measurement with a dynamometer provides a standardized, reliable, and clinically relevant assessment that helps identify individuals with sarcopenia who may benefit from early intervention strategies.
214395520|NCT04243161|OTHER|Experimental|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.~The intensity of the treatment will be 50% of the PIM and PEM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
214395521|NCT04243161|OTHER|Control|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.~The intensity of the treatment will be 30% of the PIM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
214395522|NCT01564719|BEHAVIORAL|Holistic health|The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
214395523|NCT01470378|PROCEDURE|Thigh Surgery|Circumferential thigh surgery post bariatric surgery
214395524|NCT03574701|DIETARY_SUPPLEMENT|Vitamin A|The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
214395525|NCT01141660|DEVICE|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
214395526|NCT01141660|DEVICE|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
214395527|NCT00305201|DRUG|pravastatin|
214395528|NCT01219621|PROCEDURE|Symphony Dual Chamber Rate Responsive Device|Echocardiography ANP/BNP measurements
214395529|NCT00515164|DRUG|Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel|20 mL Hydrogel
214395530|NCT01643395|OTHER|vertebroplasty|Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
214395531|NCT01643395|OTHER|conservative therapy|The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
214395532|NCT03487003|DRUG|rocuronium|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg rocuronium is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues.
215001054|NCT07116564|DRUG|Enhanced Recovery After Surgery|Preoperatively ERAS protocol includes, No solid food for 6 hours before procedure; 800 ml (fantomalt powder) Carbohydrate drink 8 hours before surgery; 400 ml (fantomalt powder) 2 hours before surgery; Celecoxib 200g 1 hour before surgery . Intraoperatively, on induction lidocaine 1.5 mg/kg and Fentanyl 1 to 2 mcg/kg followed by IV lidocaine infusion at 1.5 mg/kg/h.
215001055|NCT07116564|DRUG|Control|Preoperatively, NPO 6 hours before the procedure Intraoperatively, on induction Nabuphine 0.1mg/kg
215001056|NCT07113964|DRUG|QL1706 + olaparib|"QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies.~Other Names: Iparomlimab and Tuvonralimab Injection Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor with biologic activity in ovarian cancer as well as other solid tumors..~Other Names: NA"
214395533|NCT03487003|DRUG|saline|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg saline is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues
214395534|NCT04943900|DRUG|BMS-986416|Specified dose on specified days
214395535|NCT04943900|DRUG|Nivolumab|Specified dose on specified days
215001057|NCT07115446|DRUG|HS-20093|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
215094907|NCT07087444|BEHAVIORAL|Health education intervention to improve knowledge and uptake of personal protective equipment and visibility materials among commercial motorcycle riders and passengers|This intervention consists of a structured health education program targeting commercial motorcycle riders and passengers in the Limbe Health District. It includes interactive group sessions focused on the importance, benefits, and correct use of personal protective equipment (helmets, reflective jackets) and visibility materials (reflective strips, lights). Educational materials such as leaflets and posters are distributed to reinforce learning. Additionally, participants receive follow-up SMS reminders to encourage consistent and proper use of protective gear. The goal is to increase awareness and uptake of safety measures to reduce road traffic injuries. This intervention is community-based and tailored to the local context in Cameroon.
215094908|NCT07088263|DRUG|Gemcitabine, Vinorelbine, Eribulin, or Utidelone|Gemcitabine, Vinorelbine, Eribulin, or Utidelone is recieved every 28 days. The chemotherapy interval is one cycle every 28 days.
215001058|NCT07115446|DRUG|HRS-5041|HRS-5041 was given oral administration, QD, at a 21-day cycle.
215001059|NCT07114523|PROCEDURE|collagen membrane|collagen membrane apply to distal surface of second molar after third molar surgery
215001060|NCT07114523|PROCEDURE|third molar surgery|standard third molar surgery without any additional application
215001061|NCT07115550|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib|Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib
215001062|NCT07113938|DEVICE|Ambient AI Scribe|Software that records audio of a clinical interaction and generates a clinical note.
214395536|NCT06029361|DEVICE|Selfit Device group|During 21 days, intervention group will receive physical therapy of 45 minutes which 15 minutes out of the 45 minutes will be with the SELFIT system
214395537|NCT06029361|OTHER|Control Group|Conventional physical therapy of 45 minute
214395538|NCT05197075|DRUG|DRV/COBI FDC|DRV/COBI FDC tablet dispersed in water will be administered orally.
214395539|NCT05352451|BEHAVIORAL|Interventional Survey|Complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member. The first interview, will ask about some basic information. In the second and last interview, will ask about experience of the coaching sessions and about how you feel about your decisions regarding your treatment and care. At each of the two time points, you and your caregiver will be interviewed separately. The video-conferencing, will be conducted through Zoom, which is a secure, widely used software which allows people to communicate remotely with computers, tablets, or smart phones. The software is available free of charge to you if you have a computer or other suitable device and internet.
214395540|NCT06195241|DRUG|DaxibotulinumtoxinA|Patients with Benign Essential Blepharospasm (BEB) or Hemifacial spasms (HFS) will be treated with DaxibotulinumtoxinA-Lanm (Daxxify) using a 2:1 conversion rate of Daxxify to Botox.
214502953|NCT06909942|OTHER|SARC-F Score|"The SARC-F is a simple screening tool used to identify individuals at risk for sarcopenia, which is the progressive loss of muscle mass and strength typically associated with aging.~The SARC-F questionnaire consists of 5 components that assess key aspects related to muscle function:~Strength: Difficulty lifting and carrying 10 pounds Assistance with walking: Difficulty walking across a room Rising from a chair: Difficulty transferring from a chair or bed Climbing stairs: Difficulty climbing a flight of 10 stairs Falls: Frequency of falls in the past year~Each component is scored from 0-2 points:~0 = No difficulty~1. = Some difficulty~2. = A lot of difficulty or unable to do~The total score ranges from 0-10, with higher scores indicating higher risk:~A score of 4 or greater suggests risk of sarcopenia A score of less than 4 suggests low risk"
215001063|NCT07114250|PROCEDURE|spinal anesthesia|Spinal Anesthesia group: Patients included in this group will undergo supine Percutaneous nephrolithotomy under spinal anesthesia
215001064|NCT07114250|PROCEDURE|General Anesthesia|General Anesthesia : Patients included in this group will undergo supine Percutaneous nephrolithotomy under general anesthesia
215094909|NCT07087522|BEHAVIORAL|Stress Ball Use|Participants will perform hand exercises using a rubber stress ball for 5 minutes, 3 times daily, for 3 days prior to radial angiography.
215094910|NCT07088289|BEHAVIORAL|TRIPP|In this study, participants will use TRIPP with a VR headset at home, engaging in short mindfulness sessions 3+ times per week for 4-12 weeks.
215094911|NCT07089030|PROCEDURE|Standard endoscopic evaluation|Examinations of the gastrointestinal (GI) tract (including the stomach, small intestine, and colon) will be performed to identify the source of bleeding. These examinations may be repeated based on the treating physician's assessment. Iron supplementation (ferrous sulfate) will be administered either orally (per os) or intravenously (IV), and blood transfusions will be provided if necessary.
214395541|NCT05577065|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
214395542|NCT05577065|DIETARY_SUPPLEMENT|Placebo|Matching placebo in the form of a sachet once daily for 26 weeks
214693831|NCT04766502|OTHER|Blood sample (20 ml) and EORTC QLQC30 survey|"Blood sample (20ml) will be taken before and 24h after PIPAC procedure~EORTC QLQC30 during pre operative consultation and at each post operative consultations"
215001065|NCT07116343|DRUG|Ropivacaine|The patient will receive 0.2% ropivacaine (20.0 ml) into the pleural cavity intraoperatively before sternal closure. A continuous infusion of 0.2% ropivacaine will be administered through a microcatheter into the drained pleural cavity, with titration of the infusion rate. The initial infusion rate is set at 10 ml/hour.
215094912|NCT07089030|PROCEDURE|Conservative Medical Management|The investigational intervention involves a conservative treatment approach guided by a decision-making algorithm based on iron deficiency anemia values. This algorithm, developed from guidelines by the British Society of Gastroenterology and the American Gastroenterological Association, determines whether patients receive oral or IV ferrous sulfate or a blood transfusion. Laboratory parameters (hemoglobin, ferritin) will be monitored at weeks 4, 12, 38, and 64. After iron therapy, hemoglobin response will be assessed at 4 weeks, and treatment will continue for \~3 months post-normalization to ensure iron store repletion. Blood tests will be repeated every 6 months to detect recurrence.
214693832|NCT04846751|BEHAVIORAL|TYPE OF EXERCISE (OR REST)|continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
215001066|NCT07116343|DRUG|0.9 % NaCl|The patient will receive 20.0 ml of a 0.9% sodium chloride solution into the pleural cavity intraoperatively, prior to sternal closure. A continuous infusion of 0.9% sodium chloride solution will then be administered through a microcatheter into the drained pleural cavity. The initial infusion rate is set at 10 ml/hour.
215121378|NCT03976258|DRUG|Naltrexone Injection|This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
215121379|NCT03976258|DRUG|Heroin|This is an observational study. Participants using heroin will be enrolled into this group.
214693833|NCT02059213|DRUG|Ibrance|
214693834|NCT02059213|DRUG|Bicalutamide|
214693835|NCT02059213|DRUG|Zoladex|
214693836|NCT02059213|DRUG|Lupron Depot|
214395543|NCT04517656|OTHER|Blood samples|"A peripheral blood sample will be taken and will include 2 EDTA tubes of 5 mL, for a total volume of 10 mL:~* Samples before the allograft,~* Samples at different times post-allograft: 15 days, 30 days, 60 days, 90 days, 180 days, 360 days,~* Samples in the event of the occurrence of concomitant events during the 12-month follow-up period: occurrence of acute Graft Versus Host Disease, chronic Graft Versus Host Disease, or relapse of the disease before the initiation of a new treatment."
215001067|NCT07116538|OTHER|Nishauri mHealth Intervention|The Nishauri mHealth intervention, developed by Palladium with Kenya's Ministry of Health and funded by PEPFAR/CDC, is a client-centered digital platform designed to enhance HIV care in Kenya. It supports appointment scheduling, ART referrals, and patient engagement through features such as automated medication and appointment reminders, tailored health education, two-way communication, and behavior-change strategies. Interoperable with national health systems like KenyaEMR and Ushauri, it enables real-time data exchange and continuity of care. Despite national scale-up, uptake remains low and varies across facilities, providers, and patients, particularly among men, who face unique sociocultural barriers. Addressing gender norms and contextual factors is key to improving implementation and achieving sustained engagement and better outcomes.
215001068|NCT07116655|BEHAVIORAL|Single-session solution focused consultation|"In the SSC, the interventionist first sets expectations, explaining that the session is a means of providing short-term support. The interventionist will then praise the participant for agreeing to receive support and introduce the Action Plan, which will guide the session's structure. The interventionist will then work with the participant to (1) identify a specific, modifiable issue they are facing; (2) use the miracle question to envision their ideal outcome where the problem is resolved, and rates their current proximity to that; (3) determine the smallest possible step they can take towards this outcome through a scaling exercise; and (4) develop a personalized action plan that leverage on their current resources to begin addressing the problem. Upon ending the SSC, the interventionist writes a personalized note to the participant, highlighting their strengths and expressing confidence in their ability to follow through."
215001069|NCT07116655|BEHAVIORAL|Single-session supportive intervention|In the supportive consultation session, the interventionist will allow the participant to decide what they wish to discuss during the session and listen empathetically, validate their feelings and offer reassurance to the patient. The exact wording or questions will vary depending on the client's needs and sharing.
215001070|NCT07114809|DEVICE|Experimental group (EG) performing Anodal-tDCS (A-tDCS) and VR|"Patients in the EG group will undergo a simultaneous A-tDCS over the left DLFPC. The tDCS will be delivered by a battery-driven, constant current simulator, two holding bags of plant cellulose (7x5 cm) and two electrodes of conductive silicone. The active (anodal) electrode will be placed by means of a cap on the scalp overlying the left DLPFC (46 Brodmann Area). The reference electrode will be located over the right shoulder. The choice of the left DLPFC as the site of stimulation relies upon the evidence that this region has a critical role in the top-down control of the task-relevant stimuli processing (Miller 2001).The DLPFC contributes to increase cognitive control through its connections with the anterior cingulate cortex and has been shown to enhance working memory and executive function. During the cognitive training (on-line procedure), A-tDCS (current of 1,5 mA) will be delivered for 20 minutes, while maintaining the current density (0.06 mA/cm2) below the safety limits."
215001071|NCT07114809|DEVICE|Sham Comparator: Control group (CG) performing sham-tDCS (S-tCDS) and VR|CG will receive a S-tDCS over the DLPFC. In the S-tDCS session, the current will be turned off 30 sec after the beginning of the stimulation and turned on for the last 30 sec. By doing this, the patient feels an itching sensation below the electrodes at the beginning and at the end of stimulation, making this condition indistinguishable from the real A-tDCS stimulation. Doing this, all the subjects will be blinded on the type of stimulation. As well as in the EG, CG performs cognitive training including motor and cognitive exergames that incorporate enjoyment, technology, and health care.
215001072|NCT07114432|DRUG|BCMA/CD19-targeted allogeneic CAR-T|Lymphodepletion chemotherapy followed by allogeneic CAR-T cell (RN1201) infusion
215001073|NCT07114211|DIAGNOSTIC_TEST|99mTc-HYNIC-FAPI-04 SPECT-CT|Perform quantitative SPECT/CT with 99mTc-HYNIC-FAPI-04 on selected patients. Acquire whole-body images in a planar format and SPECT/CT images of two or more sites in a tomographic format.
215001074|NCT07114107|DEVICE|VPAT (Vibratory Positive Pressure Therapeutic Apparatus）|"VPAT (Vibratory Positive Pressure Therapeutic Apparatus）is a physical solution which can relieve nasal congestion and discomforts by applying acoustic vibration and oscillatory positive expiratory pressure. Clinical research has shown that low-frequency vibration at approximately 130 Hz promotes the production of the highest concentration of Nitric Oxide (NO) in the paranal sinuses, which helps to regulate the nasal mucosal blood, restoring the mucous membrance-cilia mechanism, clean up the bacteria, viruses and allergenic particles in the respiratory tract.~Combined with Oscillatory Positive Expiratory Pressure and Transnasal Breathing, it can help to cultivate the habit of nasal breathing and slow breathing, as well as to restore the function of lungs."
215121380|NCT03780335|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
215121381|NCT04493996|BEHAVIORAL|Cognitive training|The cognitive training involves a standardized, paper-and-pencil-based cognitive training that will be performed by the patients at home for approximately 40 minutes per day over a preoperative period of 2-3 weeks
215121382|NCT06014346|OTHER|Psychological strategy|"* flyer given at the interview presenting the 4 most frequent fears as well as a description of the recommended muscular and breathing exercises,~* then realization accompanied by a training of these exercises"
215121383|NCT06014346|OTHER|Physiological strategy|\- ingesting a salty snack
214693837|NCT00362791|BEHAVIORAL|"Enhanced HIV/STD Counseling: 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model"|
214693838|NCT00362791|BEHAVIORAL|"Brief Counseling (aka client-centered counseling): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior"|
214395544|NCT05125211|DRUG|GB001 recombinant peptide spray|administrated oral spray
214395545|NCT05125211|DRUG|Placebo|administrated oral spray
214693839|NCT00362791|BEHAVIORAL|"HIV Prevention Education: 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies"|
215001075|NCT07114107|DRUG|basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA|"All participants need basic control drugs contains antihistamines(Ebastine 10 mg once daily for 2 weeks), mometasone furoate nasal spray(Spray 2 puffs into each nostril, each puff contains 50 μg of mometasone furoate, i.e., 100 μg per administration, once daily for 2 weeks).~Asthma participants should added Inhaled corticosteroids-long-acting beta-agonists (ICS-LABA) therapy. For mild to moderate asthma: budesonide/formoterol (160μg/4.5μg) , with 1 inhalation each time, twice daily, or salmeterol/fluticasone propionate (50μg/100μg) with 1 inhalation each time, twice daily. For moderate to severe asthma: Budesonide/Formoterol (320μg/4.5μg), with 1 inhalation each time, twice daily; or salmeterol/fluticasone propionate (50μg/250μg or 50μg/500μg) with 1 inhalation each time, twice daily. Dosage adjustments should be evaluated and determined by the physician based on the patient's disease control status."
214395546|NCT05382858|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
214395547|NCT06275035|DRUG|Memantine Oral Tablet|Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
214395548|NCT05977946|DEVICE|Volta System|The Volta System is a wearable, battery-operated, neurostimulation system designed to deliver tAN or taVNS. The device will be used to deliver two 30-minute sessions of active or sham therapy according to the participant's randomization group (taVNS or tAN).
214395549|NCT05125016|DRUG|REGN4336|Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
214395550|NCT05125016|DRUG|Cemiplimab|Administered concomitantly every 3 weeks (Q3W) by IV infusion
214395551|NCT05125016|DRUG|REGN5678|Administered concomitantly QW by IV infusion
214395552|NCT05125016|DRUG|Sarilumab|Administered once by IV infusion as prophylaxis prior to REGN4336 IV
214395553|NCT06610682|DRUG|Plixorafenib|Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
214502954|NCT06909942|DEVICE|Train-of-Four(TOF)|"A Train of Four (TOF) device is a specialized neuromuscular monitoring tool used primarily in anesthesiology and critical care to assess the degree of neuromuscular blockade in patients who have received neuromuscular blocking agents (NMBAs).The device delivers four sequential electrical stimuli (hence train of four) at 0.5-second intervals to a peripheral nerve, typically the ulnar nerve at the wrist. It then measures the resulting muscle contractions, usually of the adductor pollicis muscle (thumb).Modern TOF devices provide a numerical value called the TOF ratio or count, which compares the strength of the fourth twitch to the first twitch.~Ratio of fourth twitch to first twitch amplitude \<0.7: Significant residual blockade 0.7-0.9: Moderate recovery 0.9: Adequate recovery for extubation"
214502955|NCT06909942|DEVICE|Bispectral Index(BIS)|"A Bispectral Index (BIS) device is a specialized monitoring system used primarily in anesthesiology and critical care to assess a patient's level of consciousness during sedation and general anesthesia.Uses a sensor placed on the patient's forehead to capture electroencephalogram (EEG) signals from the brain.Employs advanced algorithms to analyze the raw EEG data, examining frequency, power, and phase relationships.Processes the EEG information into a dimensionless number (the BIS value) ranging from 0 to 100.~BIS Scale:~100-80: Awake, normal consciousness 80-60: Light to moderate sedation 60-40: General anesthesia (surgical level of hypnosis) 40-20: Deep hypnotic state 20-0: Burst suppression to flatline EEG (very deep anesthesia)"
215121384|NCT02863614|DRUG|Ibuprofen 600 mg|
214395554|NCT06610682|DRUG|Cobicistat 150 MG [Tybost]|Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
214395555|NCT01544621|OTHER|Smoking cessation|Smoking cessation
215121385|NCT02863614|DRUG|Lorazepam 1 mg|
215121386|NCT02863614|DRUG|Placebo|
215121387|NCT04585724|DRUG|Abemaciclib|Given PO
215121388|NCT04585724|DRUG|Palbociclib|Given PO
215121389|NCT04585724|OTHER|Quality-of-Life Assessment|Ancillary studies
215121390|NCT04585724|DRUG|Ribociclib|Given PO
214395556|NCT04025372|DRUG|Bicalutamide|Bicalutamide is categorized as an antiandrogen. Antiandrogens are substances that block the effects of testosterone. Cancer of the prostate depends on the male hormone testosterone for its growth. If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.
214395557|NCT04025372|DRUG|GnRH Agonist|In men, GnRH agonists cause the testicles to stop making testosterone. Some GnRH agonists are used to treat prostate cancer.
214395558|NCT04025372|RADIATION|Radiation Therapy|Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
214395559|NCT04025372|DRUG|Darolutamide|Darolutamide belongs to a class of drugs called androgen receptor inhibitors. In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
214395560|NCT06218589|DIAGNOSTIC_TEST|Velacur|Velacur is a liver ultrasound that measures hepatic fat and fibrosis through the propagation of a continuously, externally conducted shear wave. An enrolled participant may choose to do the ultrasound at the time of a clinic visit, or research visit or a scheduled radiology visit according to manufacturer's instructions by trained study staff. Fibrosis and steatosis measures will be collected from all scans.
214395561|NCT06218589|DIAGNOSTIC_TEST|MRI|Participants who have not had an MRI within the past two years will be offered a research MRI (no contrast or sedation will be used) to measure hepatic fat and hepatic stiffness (if required). Participants who have had an MRI or liver biopsy in the past two years will use historical data comparison data. MRI data will include the PDFF hepatic fat, any assessment of fibrosis and notes of other abnormalities.
214395562|NCT06218589|DIAGNOSTIC_TEST|Blood sample collection for biomarkers|Biomarkers are metabolic thumbprints of how the body is behaving to different health or disease processes, some of the biomarkers can be studied from plasma or serum combined with other demographics. A lipid profile and comprehensive metabolic panel (CMP), if not obtained clinically within 4 weeks, will be collected as a standard of care.
214395563|NCT06218589|DIAGNOSTIC_TEST|Liver biopsy|Liver biopsy data will be collected only if liver biopsy is done clinically when available and scored using the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) approach.
214395564|NCT01083966|DRUG|Bevacizumab (Avastin)|"Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS"
215001076|NCT07114107|DEVICE|OPEP（Oscillating Positive Expiratory Pressure device）|Oscillating Positive Expiratory Pressure (OPEP) device contain a inner ball that creates a resistance and oscillates when the patient blows through the device. This resistance helps splint the airways open during exhalation whilst the oscillation loosens the mucous within the airways. This makes it easier for some patients to clear their sputum.
215001077|NCT07115654|DRUG|CM336 (BCMA/CD3 bispecific antibody)|CM336 is a bispecific antibody targeting BCMA and CD3, designed to redirect T cells to eliminate abnormal plasma cells.
215001078|NCT07114627|DRUG|Blood sampling for pharmacokinetics|Extra blood samples are collected for assement of the pharmacokinetics of capecitabine.
215001079|NCT07114289|PROCEDURE|Spontaneous breathing trial using pressure support ventilation|Patients will receive low level pressure support ventilation for 1 hour before extubation
215001080|NCT07114289|PROCEDURE|Spontaneous breathing trial using T-Piece|Patients will receive a T-piece with oxygen for 1 hour before extubation
215001081|NCT07114029|PROCEDURE|Mesh-free Sacrocolpopexy via VNOTES|Mesh-free sacrocolpopexy is performed via the VNOTES technique to treat pelvic organ prolapse. Outcomes will be evaluated before and 6 months after surgery.
215001082|NCT07115160|OTHER|Training following a predefined protocol.|Training following a predefined protocol.
214395565|NCT02210819|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"
214395566|NCT02210819|DRUG|Recommended VTE pharmacological treatments according to international guidelines|"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."
214395567|NCT01824914|DEVICE|McGrath Videolaryngoscope|A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
214395568|NCT01848834|BIOLOGICAL|Pembrolizumab|IV infusion
214395569|NCT02257255|PROCEDURE|Pfannenstiel cesarean section|Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment
215094913|NCT07087457|BEHAVIORAL|The digital stimulus command|"The digital stimulus command: Providing information on the harms of inactivity and sedentary lifestyle on online, digital platforms. The individual will take the HRV measurement in a sitting position for 5 minutes every morning (before consuming tobacco products for smokers) as taught and will send the screenshot of the data to the researcher via WhatsApp. Ensuring that the digital stimulus commands that will remind the activity in line with TTM are followed by reminders sent to the computer screen or mobile phones. Taking a break from sitting when the command It's time for activity comes (taking a total of 6 breaks in the working hours of 08:30 - 17:30, 1 every 60 minutes recording the activity as completed in the digital diary and survey form) \*Activities of office workers other than the time they spend sitting; Recording the number of steps and activities in the office, its surroundings and in daily life in a digital diary."
215094914|NCT07087457|BEHAVIORAL|5 day 30-minute walking program|5 day 30-minute walking program. This group was also defined as the human stimulus group because, in addition to the digital stimulus command, they will be invited by the researcher and will participate in the walking program with the researcher. This group will first receive the activity program and simultaneously will also receive the digital stimulus command interventions.
214395570|NCT02257255|PROCEDURE|Misgav-Ladach cesarean section|Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
214395571|NCT01342029|DRUG|Ranolazine|"This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.~500-1,000 mg po bid for 2 weeks"
214395572|NCT01342029|DRUG|Placebo|500-1,000 mg po bid for 2 weeks
214395573|NCT06348537|DIETARY_SUPPLEMENT|Olive Polyphenols|Patients with fibromyalgia of Group 1 will consume Olive Polyphenols daily during 60 days.
214395574|NCT06348537|DIETARY_SUPPLEMENT|Placebo|Patients with fibromyalgia of Group 2 will consume a placebo daily during 60 days.
214395575|NCT05796960|PROCEDURE|Thyroidectomy with or without lymphadenectomy or multivisceral resection|Lymph node dissection, as well as its surgical extension, was performed according to the surgeon's discretion. Multivisceral operations involved oesophagus, trachea and larynx.
214395576|NCT02865057|PROCEDURE|Vaginal assessment|Vaginal assessment of position prior to delivery
214395577|NCT03981536|DRUG|AP-101|Administered by intravenous infusion (IV)
214395578|NCT01050101|DIETARY_SUPPLEMENT|No fiber|"The High GI low fiber meal consists of 0 grams fiber with total kcal of 573 with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein.~Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
214502956|NCT06758076|DEVICE|Lens 1 (ocufilcon D)|15 minutes of daily wear
215094915|NCT07089251|DRUG|low-dose epinephrine and tranexamic acid|low-dose epinephrine and tranexamic acid
214395579|NCT01050101|DIETARY_SUPPLEMENT|Low GI high fiber viscous meal|"Test meal consists of 12 grams of fiber (9 grams soluble and 3 grams insoluble). The ratio is 80:20 ratio of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
214502957|NCT06758076|DEVICE|Lens 2 (somofilcon A)|15 minutes of daily wear
214502958|NCT06830460|OTHER|Training|"The training will consist of a four-hour session, including a 30-minute lecture on ocular anatomy and ultrasound techniques, a real-time demonstration, and supervised hands-on practice with at least 20 measurements.~Participants must achieve a score of at least 70% on a multiple-choice test to proceed to practical verification, where they will measure the ONSD in five healthy volunteers. These measurements will be compared to those taken by an expert tutor."
214693840|NCT01573507|OTHER|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
214395580|NCT01050101|DIETARY_SUPPLEMENT|Low GI high fiber non-viscous|"Test meal consists of 11 grams of fiber (3 grams soluble and 8 grams insoluble). The ratio is 20:80 of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
214395581|NCT00992160|DRUG|GW597599|GW597599 15mg tablet
214395582|NCT00992160|DRUG|Placebo|Placebo to match GW597599 15mg tablet
214395583|NCT05851690|PROCEDURE|Surgical treatment of pilonidal sinus disease|Advancement flap techniques in surgical treatment of pilonidal sinus disease.
214395584|NCT01005628|DRUG|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
214395585|NCT03086824|DEVICE|magnetic resonance-guided focused ultrasound|
214395586|NCT03037229|DEVICE|Smartphone ECG|
214395587|NCT03037229|DEVICE|Standard 12-lead ECG|
214395588|NCT02040090|DRUG|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
214395589|NCT00001493|GENETIC|peripheral blood progenitor cells carrying MDR1|
214395590|NCT04915703|PROCEDURE|Flushing of PTBD catheter|flushing of internal external PTBD catheter 3 times a day
214395591|NCT00999973|DRUG|Mitomycin C 0.02%|
214395592|NCT00999973|DRUG|Placebo|
214395593|NCT01978275|DEVICE|stimulong 100, pajunk, germany|simulating catheter
214395594|NCT01978275|DEVICE|plexolong 100, pajunk, germany|nonstimulating catheter
214395595|NCT04908436|DRUG|Finerenone (BAY94-8862)|10 mg BAY94-8862 immediate release (IR) tablet, administered orally
214395596|NCT00972946|BIOLOGICAL|Administration of autologous Endorem-labelled mononuclear cells intravenously|single dose
214395597|NCT00972946|DRUG|Administration of Endorem|single dose, intravenous
214395598|NCT03591861|PROCEDURE|Ketogenic diet|"* Children under 2 years will immediately start on a full calorie classical 3:1 ketogenic diet. The 3:1 ratio indicates that the diet contains 3 g of fat for every 1 g of protein + carbohydrate, which results in about 87% of calories coming from fat.~* Children 2 years or older will skip breakfast and lunch on the day of admission but start a full calorie 3:1 ketogenic diet at dinner."
214395599|NCT03591861|DRUG|BCNU|-Standard of care
214395600|NCT03567356|OTHER|"MAT-PLUS Helping Hands"|"1\) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
214395601|NCT05850286|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, double infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
214395602|NCT05850286|DRUG|VRD-based Regimen|Bortezomib, Lenalidomide and Dexamethasone
214395603|NCT06282549|DRUG|Telmisartan/Amlodipine/Chlorthalidone(Truset)|Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/25 mg
214395604|NCT00514007|DRUG|OSI-906|OSI-906 administered orally
214395605|NCT06250309|DIETARY_SUPPLEMENT|Dietary assignment|A total of 48 subjects will be randomized by a computer program into one of two groups: MD or WD. Participation in each dietary arm lasts 8 weeks, with a 6 week washout period in between each arm.
214395606|NCT05205720|PROCEDURE|Celiac plexus block|The surgeon is instructed to perform a single celiac plexus block under direct vision. 10ml 0.5% ropivacaine is injected into the nerve in both sides.
214395607|NCT05205720|DRUG|Ropivacaine|Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
214395608|NCT03967405|DEVICE|MolecuLight PID|Hand-held, real-time fluorescence imaging device
214395609|NCT04813146|OTHER|SLP|Synchronization of dietary intake with circadian rhythm of the body
214395610|NCT04813146|OTHER|SLP along with Physiotherapy|Synchronization of dietary intake along with Physiotherapy (aerobic, flexibility, resistance and balance exercises)
214395611|NCT04813146|OTHER|Physiotherapy|Physiotherapy given only (aerobic, flexibility, resistance and balance exercises)
214395612|NCT04894903|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring \& preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
214395613|NCT06386653|DRUG|Diagnostic injection of [123I]I-DARPIN-Ec1|A single intravenous injection of \[123I\]I-DARPIN-Ec1
214395614|NCT06386653|DIAGNOSTIC_TEST|Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1|Gamma camera-based whole-body planar scintigraphy imaging 2, 4, 6, and 24 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
214395615|NCT06386653|DIAGNOSTIC_TEST|Whole-body SPECT with [123I]I-DARPIN-Ec1|Whole-body SPECT at 2, 4, and 6 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
214395616|NCT06238648|PROCEDURE|Biopsy|Undergo biopsy
214395617|NCT06238648|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214395618|NCT06238648|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
214395619|NCT06238648|BIOLOGICAL|Epcoritamab|Given SC
214395620|NCT06238648|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214395621|NCT06238648|OTHER|Patient Observation|Undergo observation
214395622|NCT06238648|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214395623|NCT06247826|PROCEDURE|Blood sampling|Blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis.
214395624|NCT05580159|BIOLOGICAL|SW-BIC-213|The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.
214395625|NCT05580159|BIOLOGICAL|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|The patient will take a third dose of COVID-19 Inactivated vaccine.
214693841|NCT03605719|DRUG|Carfilzomib|Given IV
214693842|NCT03605719|DRUG|Dexamethasone|Given IV
215001083|NCT07115251|BEHAVIORAL|Plans4Care|Caregivers assigned to treatment condition will receive: 1) access to the web-app; 2) an orientation to the web-app involving initial set up; and 3) a brief video explaining use of the web-app. Caregivers will be guided through accessing the platform, creating an account and completing a brief set of background questions.
215001084|NCT07115901|OTHER|Guaranteed Income|Participants will receive guaranteed income (GI) to the amount of $6,750 over the study period. While all participants will receive the GI intervention, there will be variation in the method of disbursement. Some participants will receive the GI as a one-time lump sum payment whereas other participants will receive the same GI amount split into 9-monthly installments.
215001085|NCT07114783|DEVICE|Dual-function semi-rigid thoracoscopy|Patients received pleural biopsy via dual-function semi-rigid thoracoscopy.
215001086|NCT07114783|DEVICE|Rigid thoracoscopy|Patients received pleural biopsy via rigid thoracoscopy.
215001087|NCT07114705|DIAGNOSTIC_TEST|Transvaginal ultrasound|This is the only method
215001088|NCT07114497|DIAGNOSTIC_TEST|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|During surgery, degenerated intervertebral disc tissues will be collected under sterile conditions and stored at -80°C in cryotubes. miRNA expression profiles will be analyzed using rt-PCR. Candidate miRNAs are selected based on databases such as miRBase, miRTar, and miRDB.
215001089|NCT07114497|DIAGNOSTIC_TEST|excised|Intervertebral disc tissues that are not degenerated will be collected during surgery and stored in the same manner as in the IVDD group. These samples will be used for comparative analysis of miRNA expression via rt-PCR to serve as the control baseline.
215001090|NCT07114497|DIAGNOSTIC_TEST|Diagnostic work up|During surgery, degenerated intervertebral disc tissues will be collected under sterile conditions and stored at -80°C in cryotubes. miRNA expression profiles will be analyzed using rt-PCR. Candidate miRNAs are selected based on databases such as miRBase, miRTar, and miRDB.
215001091|NCT07115498|BEHAVIORAL|iTAG|Participants in this intervention start by receiving a brief (15 minute) in-person standard-of-care counseling session focused on increasing their knowledge of HIV treatment adherence and strategies to improve adherence. Following this session, they will then receive daily or less frequent text messages (SMS) over the course of three months. Messages are primary two-way, automated, and have preprogrammed response options. Message content includes HIV medication reminders, motivational messages, information on topics relevant to HIV treatment (e.g., HIV disclosure) in the form of quizzes, opportunities to reach out for support from clinic staff or peer mentors, and game-based messages including story messages, a weekly scoreboard, point system progress, and peer interactions.
214693843|NCT03605719|BIOLOGICAL|Nivolumab|Given IV
215001092|NCT07116551|DEVICE|Abbott BE TAVI System|Abbott BE TAVI System
215001093|NCT07116356|DIAGNOSTIC_TEST|Antibiotic administration|different samples were collected from patients admitted at oncology center at sohag
215001094|NCT07116356|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|"Molecular detection of carbapenem resistant genes:~* Extraction of nucleic acid from isolated organisms by boiling.~* Primers will be used for detection of carbaenem resistant genes"
215001095|NCT07115485|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 2.0mg/kg
215001096|NCT07115485|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 2.5mg/kg
215001097|NCT07115485|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 3.0mg/kg
215001098|NCT07113756|DRUG|topical metformin 30% cream|"each patient will use topical metformin 30% cream twice daily for 12 weeks.~o Preparation of metformin 30% cream: Weighing 30 gm standard metformin ( E. Merck ) supplied by chemtech. Using digital balance then Grinding the powder by pestle \& Morter then Adding 30 ml propylene glycol and alcohol to reach a total 100 gm weight then adding parabens mix as preservative with 0.5 gm then mix thoroughly followed by Levegating \& mixing then divide to smaller well tighten closure with labels"
215001099|NCT07113756|DRUG|betamethasone valerate.1% cream|"each patient (age, sex and BMI matched) will use topical betamethasone valerate 0.1% cream twice daily for 12 weeks.~o Manufactured by Egyptian international pharmaceutical industries co. E.I.P.I.C.O. and will be purchased from local pharmacy, Sohag, Egypt."
214693844|NCT03605719|BIOLOGICAL|Pelareorep|Given IV
215001100|NCT07114588|DIETARY_SUPPLEMENT|ETHANWELL BALANCED|A nutritional powder providing 250 kcal, 13.5 g protein (including 6.75 g whey protein and 2740 mg BCAAs), and 166.953 mg POLYCAN® (β-glucan) per serving. Administered 3 times daily for 8 weeks.
215001101|NCT07114588|BEHAVIORAL|Elastic Band Training|Participants perform 5 specific resistance exercises (push up \& press down, straight arm lift, seated rowing, squat, seated leg raise). Each exercise is done in 3 sets of 10 reps, 3 times per week, for 8 weeks.
215001102|NCT07115056|DRUG|Tranexamic Acid (TXA)|Oral tranexamic acid (TXA) is administered at a dose of 1.95 grams per day, divided into three 650 mg capsules taken once daily, starting on postoperative day (POD) 1 through POD 10 (10 total doses; 30 capsules) to the treatment group.
215001103|NCT07115056|DRUG|Placebo|Participants in this arm will receive oral placebo capsules (microcrystalline cellulose), 3 capsules daily from postoperative day (POD) 1 to POD 10, for a total of 10 doses (30 capsules).
214395627|NCT02875561|DEVICE|Sonopet Ultrasonic Aspirator|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
214395628|NCT02875561|DEVICE|CO2 Laser Ablation|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
214395629|NCT00563849|DRUG|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
214395630|NCT04334785|DEVICE|cryo-ablation|Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.
214395631|NCT00039182|DRUG|erlotinib hydrochloride|Given orally
214395632|NCT00039182|OTHER|laboratory biomarker analysis|Correlative studies
214395633|NCT04395768|DIETARY_SUPPLEMENT|Vitamin C|In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)
214395634|NCT04395768|DRUG|Hydroxychloroquine|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
214395635|NCT04395768|DRUG|Azithromycin|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
214395636|NCT04395768|DIETARY_SUPPLEMENT|Zinc Citrate|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
214395637|NCT04395768|DIETARY_SUPPLEMENT|Vitamin D3|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
214395638|NCT04395768|DIETARY_SUPPLEMENT|Vitamin B12|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
214395639|NCT02406118|PROCEDURE|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
214395640|NCT02988206|BEHAVIORAL|Personalized Objects|personalized objects are based on the observation or the reports from family
214395641|NCT02988206|BEHAVIORAL|non-personalized Objects|non-personalized objects are based on the suggestion in CRS-R,which are comb and cup
214395642|NCT01722318|DRUG|Plecanatide|
214395643|NCT01722318|DRUG|Placebo|
214395644|NCT00776100|OTHER|clinical observation|Patients undergo observation for 6 weeks.
214395645|NCT00776100|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 6 weeks.
214395646|NCT00049686|DRUG|laromustine|
214395647|NCT03687450|BEHAVIORAL|RISE yoga-based program|The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga \& Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
214395648|NCT06189430|OTHER|Yoga|Yoga practice was standardized throughout the study to avoid the risk of intervention variability. The basic structure of each yoga session is meditation, breathing exercises (pranayama), and after a warm-up, yoga practice includes asanas (postures) for strength, balance and mobility, and finally ends with relaxation. The yoga intervention we recommend was created within the framework of the asanas that the elderly can do in the literature and by taking the expert opinion of a sports physician.
214395649|NCT06189430|OTHER|Standard exercise|It is a type of exercise similar in intensity to vinyasa yoga. (50-70% MHR: maximum pulse rate)
214395650|NCT02126787|BEHAVIORAL|Intensive Group Analytic Psychotherapy|The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes \& Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.
214395651|NCT02126787|BEHAVIORAL|Intensive transdiagnostic cognitive-behavioral group therapy|GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, \& Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, \& Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
214395652|NCT00004220|DRUG|gemcitabine hydrochloride|
214395653|NCT00004220|DRUG|oxaliplatin|
214395654|NCT05093751|OTHER|Observation|This study does not involve any intervention to subjects.
214395655|NCT04196374|GENETIC|Genomic Sequencing|Whole Genome Sequencing and reporting of actionable genomic results for genes included on the ACMG secondary findings list.
214395656|NCT03567993|BEHAVIORAL|Comparison|Participants randomized to the comparison arm will receive twice-monthly abstinence assessments from the text messaging system, with no motivational feedback. Those in the comparison arm are neither offered nor encouraged to participate in the intervention.
215094916|NCT07089251|DRUG|Tranexamic Acid (TXA) treatment|Tranexamic Acid
214502959|NCT05829629|BIOLOGICAL|FluBHPVE6E7|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule
215001104|NCT07115316|OTHER|Exercises|"1. Nordic hamstring curls~2. Seated leg curls~3. Prone leg curls~4. Knee Straightening (Extension)~5. Knee Bend (Flexion)~6. Inner Range Quads~7. Straight Leg Raise~8. Lunge to Split Lunge~9. Single Leg Sit to Stand~10. Standing Hamstring Curls~11. Double/Single Leg Bridge~12. Side Lie Hip Abductions~13. Crab Walks~14. Forward Step Ups~15. Calf Raises~16. Single Leg Balance~17. Clock Face Mini Squat~18. Arabesque Clock~19. Two-Legged Jump / Single-Legged Hop"
215001105|NCT07114978|DEVICE|Echocardiography|simple, bedsided, non-invasive
215001106|NCT07113548|BEHAVIORAL|Personalized iCBT for depression|"Participants receive 12 sessions of personalized treatment in an online iCBT program. The treatment includes the option for weekly written feedback from a psychologist, or video-based interventions depending on the participant's current status. The content of the 12-week program is tailored to the participant's individual symptom profile.~The treatment incorporates elements from standard Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Compassion-Focused Therapy (CFT), and Positive Activity Interventions (PAT).~The program consists of nine modules, each targeting a specific area:~Rumination,~Anhedonia,~Tearfulness and emotional regulation,~Sleep problems,~Difficulty concentrating,~Eating issues,~Low energy,~Social withdrawal,~Self-critical thinking,~The treatment concludes with support aimed at preventing relapse."
215001107|NCT07113548|BEHAVIORAL|Standard iCBT|"Standard iCBT consisting of a one size fits all progression of cognitive behavioral therapy over 12 weeks. This includes:~Introduction to Online Cognitive Behavioral Therapy~Start of Treatment~Rumination~Activity Monitoring~Activity Planning~Cognitive Restructuring~Behavioral Experiment I~Behavioral Experiment II~Core Beliefs I~Core Beliefs II~Relapse Prevention"
214395657|NCT03567993|BEHAVIORAL|Intervention|"Participants randomized to the intervention arm will receive:~1. Motivational Messages~2. Abstinence and Motivation to Use Services Assessments~3. Encouragement to access the Quitline~4. Encouragement to use Nicotine Replacement Therapy (NRT)~5. Provision of NRT, if requested~Intervention subjects are encouraged to access the Quitline and use NRT. However, these are not mandatory components of the intervention and subjects can choose if they would like to engage with the Quitline or use NRT."
214395658|NCT05858203|OTHER|ATAC-seq and ChIP-seq|CD138+ cells will be isolated from the bone marrow of MM patients and will be subjected to ATAC-seq and ChIP-seq analyses, by useing specific antibodies, to better understand the involvment of Che-1 in MM tumorogenesis.
214395659|NCT00203905|DRUG|5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
214395660|NCT00203905|DRUG|5-Fluorouracil, Hydroxyurea-[FHX]|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
214395661|NCT04793464|BEHAVIORAL|Promotores de Salud|The Promotores de Salud intervention is delivered by a paid Promotor(a) who is a trusted member of the community where the testing site is located. The intervention includes: (1) psychoeducation to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores are on-site at testing events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
214395662|NCT04793464|BEHAVIORAL|Services as usual|Services as usual, our control condition, includes strategies that are typically conducted by county and community-based organizations that serve under-represented groups to notify people of testing opportunities related to COVID-19. These include Facebook advertisements, email announcements, circulation to other community-based organizations and state agencies (e.g., Oregon Health Authority, county public health), and other flyer distribution means. This condition also includes a pamphlet about health behaviors and community resources handed out by testing facilitators at testing events.
214502960|NCT05829629|DRUG|Placebo|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at determined schedule
214502961|NCT05835219|DRUG|REBYOTA™|REBYOTA™ is administered in the rectum
214502962|NCT04578938|DRUG|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
214502963|NCT04578938|BEHAVIORAL|Cognitive training|8 sessions of computer-based cognitive training
214502964|NCT04578938|BEHAVIORAL|Sham Training|8 sessions of computer-based sham training
214502965|NCT03789656|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
214502966|NCT05909995|DRUG|INCB 99280 with Ipilimumab|Dose Escalation and expansion of INCB 99280 with Ipilimumab
214502967|NCT04287647|DEVICE|Transpyloric stent|See arm/group descriptions
215001108|NCT07109713|DIETARY_SUPPLEMENT|Active|Cranberry Beverage
215001109|NCT07109713|DIETARY_SUPPLEMENT|Placebo|Placebo Beverage
215001110|NCT07111546|DRUG|LBL-024 for Injection|Intravenous infusion.
215001111|NCT07111546|DRUG|Durvalumab Injection|Intravenous infusion.
215001112|NCT07111546|DRUG|Cisplatin Injection|Intravenous infusion.
215001113|NCT07111546|DRUG|Gemcitabine Hydrochloride for Injection|Intravenous infusion.
215001114|NCT07111546|DRUG|Bevacizumab Injection|Intravenous infusion.
215001115|NCT07115862|OTHER|pomegranate juice -> habitual diet|237 ml of pomegranate juice for the first 8 weeks -\> habitual diet for the second 8 weeks
215001116|NCT07115862|OTHER|habitual diet -> pomegranate juice|habitual diet for the first 8 weeks -\> 237 ml of pomegranate juice for the second 8 weeks
215001117|NCT06914713|DRUG|Jin-shui Huan-xian granule|"Jin-shui Huan-xian Granules: on the basis of treatment guided by Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , the experimental group was given Jin-shui Huan-xian Granules for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks."
215094917|NCT06904235|DRUG|IV NEPA (fosnetupitant/palonosetron)|"In NEPA-22-01, different body weight-based dosages of IV NEPA will be applied to patients below and over 3 months of age:~Formulation A (for patients ≥3 months of age; 235 mg fosnetupitant/1.5 mg palonosetron per vial) or Formulation B (for patients \<3 months of age; 235 mg fosnetupitant/2.5 mg palonosetron per vial)."
214502968|NCT04287647|OTHER|Sham|Sham
214502969|NCT06486051|DRUG|Fludarabine|30 mg/m\^2/day IV for three consecutive days
214395663|NCT05656638|BEHAVIORAL|Speech and language therapy|"The treatment focuses on grammatical time marking. The aim of the treatment is to train underlying grammatical time marking processes, which were identified as deficient during a preliminary evaluation. The intervention is composed of 4 steps inspired by models and hypotheses from the literature on the subject. Step 1: temporal adverbial selection, subject must identify the tense encoded in sentences and select the correct adverbial among those proposed. Step 2: selection of inflected verb forms, subject must identify the tense encoded in the sentence and select the correct verb form among those proposed. Step 3: production of inflected verb forms, subject must identify the tense encoded in the sentence and produce inflected verbs. Step 4: semantic narration, subject must describe scenes using verbs inflected according to the previously defined reference time."
215001118|NCT06914713|DRUG|Jin-shui Huan-xian granule placebo|"Jin-shui Huan-xian granule placebo: on the basis of treatment guided by Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , the experimental group was given Jin-shui Huan-xian Granules placebo for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks.The Jin-shui Huan-xian granules and their placebo are identical in appearance, weight, color and smell."
214395664|NCT02337205|DRUG|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
214395665|NCT02513992|PROCEDURE|intra-arterial injection of tracer|intra-arterial ictal injection of perfusion tracer
214395666|NCT02513992|DRUG|99m-Technetium Ethyl Cysteinate Dimer|administration of perfusion tracer 99m Tc-ECD during epileptic seizure
214395667|NCT02513992|DEVICE|intra-arterial catheter|placement of intra-arterial catheter via femoral artery
214395668|NCT02513992|DEVICE|pressure injector|the injection of the perfusion tracer will be delivered with a pressure injector
214395669|NCT02624206|DIETARY_SUPPLEMENT|Juice A|Subjects to be given juice daily for 3 weeks.
214395670|NCT02624206|DIETARY_SUPPLEMENT|Juice B|Subjects to be given juice daily for 3 weeks.
214395671|NCT02290366|RADIATION|Focal prostate brachytherapy with Cesium-131|
214395672|NCT05274308|PROCEDURE|Blood sampling|Blood sampling from all eligible transplantation patients according to the protocol
214395673|NCT03698864|DRUG|PCS499|PCS499 900mg twice a day with food
214395674|NCT02934477|OTHER|Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
214395675|NCT04253197|DEVICE|Ultrasound|Pregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.
214395676|NCT03380780|DRUG|Emicizumab|Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
214395677|NCT04660019|OTHER|Scalp and auricular acupuncture|Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of scalp and auricular acupuncture treatment on day 1, 5, 9 and 14.
214395678|NCT04660019|OTHER|Seed acupressure|Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of seed acupressure treatment on day 1, 5, 9 and 14.
214395679|NCT03032874|PROCEDURE|Colonoscopy|They all had screening colonoscopy
214395680|NCT03183557|DRUG|"Zoledronic acid, Reclast®"|To examine the efficacy of zoledronic acid in osteoporosis
214395681|NCT03183557|DRUG|"Zoledronic acid, Reclast® and active vitamin D, alfacalcidol®"|To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
214395682|NCT05221749|DRUG|Nanosilver Fluoride (NSF)|Optimized synthesis of Nanosilver Fluoride
214395683|NCT05221749|DRUG|Silver diamine fluoride|Silver Diamine Fluoride
214395684|NCT05896917|DEVICE|3D Printed Foot Orthosis|3D printed foot orthoses designed and fabricated at the Taibah University
214395685|NCT05896917|DEVICE|Prefabricated Foot Orthosis|Generic foot orthoses available commercially
214395686|NCT00519636|DRUG|FPNS|fluticasone propionate nasal spray
214395687|NCT00519636|DRUG|FFNS|fluticasone furoate nasal spray
214395688|NCT00519636|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
214395689|NCT00519636|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
214395690|NCT03449537|DIETARY_SUPPLEMENT|extensively hydrolyzed casein formula + LGG|Hypoallergenic formula based on extensively hydrolyzed casein supplemented with the probiotic Lactobacillus rhamnosus GG
214395691|NCT03449537|DIETARY_SUPPLEMENT|Hypoallergenic formula based on amino-acid based formula|Hypoallergenic formula for cow milk allergy treatment based on amino acids
214502970|NCT06486051|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for three consecutive days
215001119|NCT07111507|DRUG|Tarlatamab|Patients receive lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequent cycles.
215001120|NCT07114939|DRUG|[18F]FluorThanatrace|Intravenous injection of ≤ 12 mCi of \[18F\]FTT for whole-body PET CT dynamic imaging and subsequent static scan.
215001121|NCT07114510|OTHER|OPTI-VENT Bundle|"Provider Education: During a brief (\<2 minute) bedside education, the educator will 1) review the CPR ventilation rate targets for age, and 2) ensure the provider has a cue card of current rate recommendations on his/her person. Compliance will be defined as performance of at least 30 trainings per unit per month. We will record provider discipline and time since last training as a surrogate of training spread. Educators will leverage these two-minute trainings to review the patient's current ventilator settings as an initial target during CPR to ensure adequate chest rise.~Additionally, a focus on CPR ventilation rates will be integrated into resuscitation education or quality meetings for all disciplines. Report cards detailing unit-level performance will be generated by the study team for review during site monthly presentations.~Point-of-Care Guidance: A metronome will be deployed to all cardiac arrests using a smart phone application."
215001122|NCT07114510|OTHER|Transition|There will be a 2-month transition period for study sites beginning study enrollment using standard ICU practices as they onboard to the study intervention.
215001123|NCT07114510|OTHER|None - control|Control - no intervention
214395692|NCT03085251|DEVICE|Blood glucose monitoring systems for self-testing (BGMS)|"Measurement procedure~* Subjects will be asked to wash and dry their hands before the measurements.~* The measurement procedure for each reagent system lot of a BGMS will be as follows:~* Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~* Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~* Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~* The sample will be applied to the reagent system units following specifications in the manufacturer's labelling."
214395693|NCT02071550|DEVICE|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
215001124|NCT07114822|BEHAVIORAL|Harnessing Online Peer Education|This group will have peer leaders that will engage participants in the groups. These peer leaders are those with type II diabetes that have over the recommended amount of exercise each week.
214395694|NCT02071550|DEVICE|FORESIGHT and INVOS monitor|
215001125|NCT07115810|OTHER|No additional drugs(control Group)|No intervention
215001126|NCT07116239|DRUG|Edoxaban 60 mg|film-coated tablet, manufactured by Daiichi Sankyo Europe GmbH
215001127|NCT07116239|DRUG|Enoxaparin 40 mg|enoxaparin sodium, prefilled syringe of 0.4mL injectable solution, manufactured by SANOFI WINTHROP INDUSTRIE
215001128|NCT07113639|PROCEDURE|Injection|US-guided subacromial-subdeltoid injection with 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 8 mL normal saline (10 mL total)
215001129|NCT07113639|PROCEDURE|Injection|US-guided subacromial-subdeltoid injection with 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 1 mL normal saline (3 mL total)
215001130|NCT07114926|DIETARY_SUPPLEMENT|Taiwanese green propolis|"Intervention Details:~Experimental Group: Take two capsules of Taiwan Green Propolis (each containing 500 mg/mL of propolis) before breakfast and dinner daily, totaling four capsules/day for 12 consecutive weeks.~During the intervention period, both groups will maintain their usual diet and activity levels and receive the same health education on nutrition and exercise."
215001131|NCT07114926|DIETARY_SUPPLEMENT|placebo|Take placebo capsules identical in appearance, smell, and content, with the same dosage and frequency.
215001132|NCT07115186|BEHAVIORAL|Psychoeducation|Psychoeducation sessions for adolescents focus on essential topics like stress, emotional distress, and mental disorders, offering foundational knowledge to enhance their understanding and ability to manage these challenges effectively.
215094918|NCT06904235|DRUG|Reference Treatment: IV ondansetron infusion|"IV Ondansetron Dosing Regimen~* Day 1 (before start of chemotherapy): One 30-min infusion of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration)~* Day 1 at 4 h and 8 h after the end of first administration: Two 30-min infusions of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration)"
214395695|NCT01611818|OTHER|Low Intensity Internet-delivered psychotherapy|Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
214395696|NCT01611818|OTHER|Self-guided Internet delivered psychotherapy|No contact with the therapists over the treatment period will be done.
215094919|NCT06904235|DRUG|Reference Treatment: IV fosaprepitant infusion|"Fosaprepitant IV Dosing Regimen~* Patients aged 12 years to \<18 years: a single dose of IV fosaprepitant 150 mg~* Patients aged 2 years to \<12 years: a single dose of IV fosaprepitant 4 mg/kg (maximum dose: 150 mg)~* Patients aged 6 months to \<2 years: a single dose of IV fosaprepitant 5 mg/kg (maximum dose: 150 mg)"
215094920|NCT07088523|DRUG|Xintong Oral Liquid (Sequential Phase)|Xintong Oral Liquid (Lunan Pharmaceutical), 10 mL tid po from week 5 to 52.
215094921|NCT07088523|DRUG|Xintong Oral Liquid (Intensive Phase)|Xintong Oral Liquid (Lunan Pharmaceutical), 20 mL tid po for 4 weeks.
215094922|NCT07088523|DRUG|TCM Syndrome Differentiation Decoction|Individualized herbal decoction based on TCM diagnosis (four diagnostic methods), administered for 14 days during intensive phase.
215094923|NCT07088523|DRUG|Standard Treatment (Guideline-Based)|Combination therapy including: 1. Antiplatelet: aspirin 100 mg/day + clopidogrel 75 mg/day. 2. Lipid-lowering: atorvastatin 20 mg/day. 3. Antidiabetic: metformin 500 mg bid (max 2000 mg/day). \*Doses may be adjusted per local guidelines or patient tolerance.
215094924|NCT07089680|DRUG|Nirmatrelvir/Ritonavir|Participants aged 60 years or older residing in long-term care hospitals (LTCHs) in Korea who were diagnosed with COVID-19 and received Paxlovid (Nirmatrelvir/Ritonavir) as part of their clinical care. This group will be assessed for multiple outcomes including mortality, progression to severe disease, worsening of activities of daily living (ADL), and frailty.
215094925|NCT06403878|DRUG|Carboplatin|neoadjuvant chemotherapy，2cycles.
215094926|NCT06403878|DRUG|Nab paclitaxel|neoadjuvant chemotherapy，2cycles.
215094927|NCT06403878|DRUG|Sintilimab|neoadjuvant immunotherapy，2cycles.
215094928|NCT07087613|DEVICE|Eko CORE 500 Digital Stethoscope|The FDA-cleared Eko CORE 500 digital stethoscope is used to collect phonocardiogram (PCG) and three-lead ECG recordings from participants. This observational study uses these recordings to develop and validate artificial intelligence algorithms to detect pulmonary hypertension and low left ventricular ejection fraction. No modifications to the device or device functionality are being tested.
215094929|NCT07089602|OTHER|Standard of Care DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215094930|NCT07089602|OTHER|Tri-Membrane Wrap™ DFU|Participants will receive weekly applications of Tri-Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215094931|NCT07089602|OTHER|Membrane Wrap™ DFU|Participants will receive weekly applications of Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215094932|NCT07089602|OTHER|Membrane Wrap-Lite™ DFU|Participants will receive weekly applications of Membrane Wrap-Lite™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215094933|NCT07089602|OTHER|Membrane Wrap-Hydro™ DFU|Participants will receive weekly applications of Membrane Wrap-Hydro™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215094934|NCT07089602|OTHER|Standard of Care VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215094935|NCT07089602|OTHER|Tri-Membrane Wrap™ VLU|Participants will receive weekly applications of Tri-Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215094936|NCT07089602|OTHER|Membrane Wrap™ VLU|Participants will receive weekly applications of Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
215094937|NCT07089602|OTHER|Membrane Wrap-Lite™ VLU|Participants will receive weekly applications of Membrane Wrap-Lite™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214395697|NCT01611818|OTHER|Improved treatment as usual|Any kind of treatment administered by the GP to the patient with depression
214395698|NCT01159639|DRUG|Clopidogrel|patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
214395699|NCT00915902|DRUG|Omega-3-acid ethyl esters|Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks
214395700|NCT00915902|DRUG|Placebo|Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
215094938|NCT07089602|OTHER|Membrane Wrap-Hydro™ VLU|Participants will receive weekly applications of Membrane Wrap-Hydro™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214395701|NCT00003050|DRUG|cyclophosphamide|
214395702|NCT00003050|DRUG|doxorubicin hydrochloride|
214395703|NCT00003050|DRUG|paclitaxel|
214395704|NCT00003050|DRUG|tamoxifen citrate|
214395705|NCT00003050|PROCEDURE|surgical procedure|
214395706|NCT00003050|RADIATION|radiation therapy|
214395707|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
214395708|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
214395709|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
214688171|NCT06926764|PROCEDURE|Intertransverse process block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle. ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 25 ml 0.25% levobupivacaine is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same v
214395710|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
214395711|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
214395712|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
214395713|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
214395714|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
214395715|NCT03499574|BEHAVIORAL|Dysphagia therapy using surface EMG as biofeedback|10 x 45 minute sessions over 14 days
214395716|NCT03499574|BEHAVIORAL|Usual Care|Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
214395717|NCT01615991|DRUG|Radiosynoviorthesis|Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
214395718|NCT02881177|DRUG|Oxytocin|40 IU
214395719|NCT02881177|DRUG|Placebo|40 IU
214395720|NCT04112264|PROCEDURE|Monopolar radiofrequency ablation|a radiofrequency cannula is advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia along the area of knee joint supplied by that respected genicular nerve by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
214395721|NCT04112264|PROCEDURE|Bipolar radiofrequency ablation|Two radiofrequency cannula are advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
214395722|NCT04156152|OTHER|DEENSIBILIZING TOOTHPASTE BASED ON NANOCRISTALS OF HYDROXIAPATITA / 5% POTASSIC NITRATE / SODIUM MONOFluORPHOSPHATE 1450 PARTS PER MILLION|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
214395723|NCT04156152|OTHER|5% POTASSIC NITRATE / SODIUM FLUORIDE 1426 PARTS PER MILLION TOOTHPASTE|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
215001133|NCT07115186|BEHAVIORAL|guided written therapy|In the guided writing intervention, students are asked to write about a recent event that triggered strong emotions on paper and, based on the requirements of each session, attempt to regulate their emotions. This approach aims to enhance students' abilities in emotional identification and emotion regulation.
215001134|NCT07115186|BEHAVIORAL|wait-list condition|Participants will engage in their regular school activities, and after the intervention group completes the program, they will receive the same intervention content as the intervention group.
215001135|NCT06920745|DEVICE|The TriClip System|The TriClip System
215001136|NCT07114263|DRUG|Group F (fentanyl group)|Group F (fentanyl group):will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5% and 0.5 ml (25 mcg) Fentanyl and 1 ml glucose 5% with total volume of 3ml.
215001137|NCT07114263|DRUG|Group D :Dexmedetomidine group|Group D :Dexmedetomidine group: will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5% and 1 ml (4 mcg) Dexmedetomidine and 0.5 ml glucose 5% with total volume of 3ml.
214395724|NCT00651469|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
214395725|NCT00651469|DRUG|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
214395726|NCT05088837|OTHER|muscle energy technique|MET was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles. the limb was taken very slightly beyond the restriction barrier and was held there for 10-30 seconds, it was done 3 times per session for 12 sessions.
214395727|NCT05088837|OTHER|ice and heat packs|Applying 20 minutes: 10 minutes hot,10 minutes cold on sacroiliac area, 3 times per week for 12 sessions
214395728|NCT05867485|OTHER|COVID-19 Discharge Education|"A discharge education brochure has been developed based on information from the literature to complement the verbal information provided to patients. The content of the education brochure includes the following:~1. Information about the spread of the virus and precautions to be taken.~2. Guidelines for cleanliness and disinfection of the environment.~3. Precautions regarding personal and wearable items.~4. Information about food and beverages.~5. Guidelines for personal hygiene practices.~6. Information about quarantine and isolation.~7. Guidelines for maintaining health and care (e.g., respiratory hygiene, cough etiquette, movement, range of motion exercises) (CDC, 2019; Ministry of Health of Turkey, 2020; CDC 2019 A-B-C-D)."
214395729|NCT04823559|OTHER|ThinkCancer workshop|The proposed intervention, the ThinkCancer! Workshop, is practice-based and consists of themed sessions for both clinical and non-clinical staff, the co-production of a Cancer Safety Netting Plan (CSNP) and the appointment of a Cancer Safety Netting Champion (CSNC). The workshop aims to raise awareness and increase knowledge around current cancer diagnosis guidance and will be delivered over half a day during GP protected time in the form of face-to-face educational sessions. Sessions will consist of a series of interactive activities exploring existing processes within practices and developing plans for change to implement each component.
214395730|NCT01542021|DRUG|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
214395731|NCT01542021|DRUG|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
214395732|NCT01542021|DRUG|androgen deprivation therapy|
214395733|NCT05271838|DIETARY_SUPPLEMENT|Magnesium acetate mixture (30 mmol/ml)|Patients with a magnesium retention test \>25% and randomized to intervention receive magnesium acetate oral mixture (30 mmol/ml) 20 ml x 3/day for a period of three weeks.
214395734|NCT05271838|DIETARY_SUPPLEMENT|High-protein diet (2 g/kg/day)|Nutritional counseling and protein supplementation to establish an intake of 2 g protein kg/day during admission and three weeks after discharge.
214395735|NCT05835622|DEVICE|Keeogo|Keeogo is exoskeleton for walking assistance
214395736|NCT05835622|OTHER|adviced home practice|health tips for regular and appropriate physical activity
214395737|NCT02307747|OTHER|blood samples|Blood samples will be collected every 4 hours during 24 h
214502971|NCT06486051|BIOLOGICAL|WZTL-002 CAR T-cells|"WZTL-002 comprises autologous T-cells transduced to express the third-generation 1928T2z chimeric antigen receptor, which recognises the CD19 antigen present on malignant and normal B-cells. The chimeric antigen receptor (CAR) incorporates an extracellular scFv specific for CD19, the intracellular signalling domains of CD28 and CD3ζ, and an intracellular co-stimulatory domain derived from TLR2 interposed between CD28 and CD3ζ.~On Day 0, the WZTL-002 CAR T-cell product is administered intravenously two days after completing lymphodepleting chemotherapy."
214502972|NCT04069247|BEHAVIORAL|e-CBT-I|The e-CBT-I will be delivered through a mobile application (eSleep) with a personal password.
214502973|NCT04069247|BEHAVIORAL|e-HE|The e-HE will be delivered in control though a mobile application (eSleep) with a personal password.
214502974|NCT05833724|DRUG|Chidamide|Subjects will receive a single dose of 30 mg chidamide. Twice a week.
214502975|NCT04604197|OTHER|Angiography and Clinical Follow up|Angiography and Clinical Follow up
214502976|NCT04604197|OTHER|Clinical Follow up|Clinical Follow up
214502977|NCT02882620|BEHAVIORAL|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
214502978|NCT02882620|BEHAVIORAL|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
215001138|NCT07114263|DRUG|Group DF :Fentanyl and Dexmedetomidine group|Fentanyl and Dexmedetomidine group:will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5%, 0.5 ml (25 mcg) Fentanyl and 1 ml (4 mcg) Dexmedetomidine with total volume of 3ml.
215001139|NCT07113704|PROCEDURE|Conventional Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy technique starting at Calot's triangle. Used as the comparator group in this study.
214395738|NCT04088474|DIETARY_SUPPLEMENT|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
214395739|NCT04088474|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo
214395740|NCT03663777|OTHER|Isometric handgrip training|Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
214395741|NCT03663777|OTHER|Control Group|Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
214395742|NCT04676490|OTHER|RECORD-ED Card|Low-cost and low-tech recordable audio card containing language-concordant discharge instructions for families of children under age 10 presenting to the ED for asthma exacerbations with no or public insurance and a preference for English or Spanish. Recordable cards allow for multiple audio reviews of the instructions by multiple caregivers without dependence on access to the internet or smartphone technologies.
214395743|NCT04676490|OTHER|RECORD-ED Patient Portal|Audio recorded, language concordant discharge instructions via patient portal
215001140|NCT07113704|PROCEDURE|Fundus-First Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy technique initiated at the gallbladder fundus and carried out retrogradely toward Calot's triangle. This method was applied to difficult gallbladders (Nassar Grade 3-4) to improve operative safety and avoid conversion to open surgery.
215001141|NCT07114354|OTHER|PDCogniCare platform|Digital platform designed to support early and accurate detection of dementia in people living with Parkinson's disease
215001142|NCT07116603|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|Participants completed the International Continence Questionnaire-Short Form (ICIQ-SF) and the Incontinence Impact Questionnaire (IIQ-7) form were completed
215001143|NCT07116226|OTHER|Medical Keto Education Program|4 hour asynchronous educational class
214395744|NCT01671748|DEVICE|MIST ultrasound therapy|Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
214395745|NCT01671748|OTHER|Standard Care|Compression bandaging, non-adherent dressing, and debridement if required.
214395746|NCT06524505|DEVICE|deep Transcranial Magnetic Stimulation (dTMS) -active|with the H1-coil device included 20-min sessions of 18 Hz (2-s trains separated by 20-s inter-train intervals, 55 trains totaling 1980 pulses/session).
214395747|NCT06524505|DEVICE|deep Transcranial Magnetic Stimulation (dTMS) -sham|The sham stimulation was performed using the same procedures, with the sham coil.
214395748|NCT01017978|PROCEDURE|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
214395749|NCT01974466|OTHER|Goal A|controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
214395750|NCT01974466|OTHER|Goal B|"controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:~1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
214395751|NCT06626386|DIAGNOSTIC_TEST|PSA testing|PSA Testing in venipunctate and capillary blood
214395752|NCT06625294|PROCEDURE|Task -oriented training with bilateral functional task training exercises|"Task oriented training approach with BFTT will consists of different tasks including:~Hand Movements:~1. Fold a small cloth towel with both hands with initially putting the towel flat on the table and gradually folding it into a large towel roll.~2. Put a small amount of putty on patient's table and instruct to roll it with the help of rolling pin moving it back and forth using both the hands.~3. Place a jar with a removable lid on the table and instruct the patient to remove lid from the jar completely by holding the jar with either hand and remove the lid with the alternate hand.~4. Pouring water: Pour water from jug while holding the jug in unaffected hand to cup/glass that is held in affected hand and activity can be done the other way round as well.~5. Pour water from one hard plastic cup to another while alternatively involving both the hands (we must not allow deformation of the cup)~6. Plunging action with coffee maker against water resistance:Fill the coffee maker with water."
214395753|NCT06625294|PROCEDURE|Task Oriented Training with CIMT|"• Hand Movements:~1. Sitting at a table (Wrist Extension): Affected forearm resting on table. Place cylindrical object in palm of patient's hand. Patient asked to move the hand towards the forearm (dorsiflexion) by extending the wrist - no elbow flexion allowed.~2. Sitting at a table (Radial Deviation of Wrist): Therapist should place forearm with ulnar side on table in mid-pronation / supination position. Thumb in line with forearm and wrist in extension. Fingers around cylindrical object. Patient is asked to lift hand off table. No wrist flexion or extension.~Advanced Hand Activities:~1. Have the patient reach forward to pick up the top of a pen with their affected hand, bring the affected arm back to their side and put the pen cap down in front of them.~2. Place (beans), in a teacup an arm's length away on the affected side. Place another teacup an arm's length away on the intact side. Have the patient pick up one beans with their affected hand and place the beans in the cup on the"
214395754|NCT06687148|OTHER|Manual manipulation|The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.
214502979|NCT02882620|BEHAVIORAL|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
214502980|NCT05173415|DEVICE|Sirius Pintution|The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
214502981|NCT05173415|DEVICE|HydroMARK (C) Clip|The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
215001144|NCT07115225|OTHER|Analytical test - Shoulder Range of Motion (ROM)|Passive external rotation in supine position with arm in 90° abduction - passive internal rotation in supine position with arm in 90° abduction.
215001145|NCT07115225|OTHER|Analytical test - Shoulder Strength|Shoulder external rotation and internal rotation measured with a hand held dynanometer in supine lying
215001146|NCT07115225|OTHER|Modified-Athletic Shoulder Test (M-AST)|Shoulder strength in the antero-posterior plane measured with a hand held dynanometer in prone lying
214502982|NCT06035744|DRUG|CLN-617|Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences
214502983|NCT06035744|DRUG|Pembrolizumab|Humanized IgG4 anti-PD-1 monoclonal antibody
214502984|NCT06172946|DEVICE|powerbreath|Previous studies have confirmed the efficacy of implementing IMT as part of a RR program in a certain profile of patients with COPD, showing improvements in maximum inspiratory pressure, perception of well-being, and other respiratory diseases, and dyspnea during exercise. (Gandullo et al., 2022)
214502985|NCT06172946|DEVICE|TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION|Transcutaneous electrical diaphragmatic stimulation (TEDS) has been used to improve respiratory muscle strength in patients with respiratory muscle weakness. A previous study reported that patients with chronic obstructive pulmonary disease (COPD) showed increased lung volume and oxygen saturation after a single session of TEDS. (Hsin et al., 2022)
214502986|NCT01086241|PROCEDURE|2D Mammogram|Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
214502987|NCT01086241|PROCEDURE|Tomosynthesis|Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
215001147|NCT07115225|OTHER|Physical performance test - Unilateral Seated Shot-Put Test (USSPT)|Set up requires that the subject is placed in a seated position (knees bent at 90° degrees) with their back against the wall, and a 3 kg medicine ball held at height of the shoulder. When ready, the subject will perform a shot put motion to push the medicine ball as far as possible in a horizontal direction. The average of three trials is recorded for each arm.
214502988|NCT01054287|OTHER|Multifactorial falls prevention program|
215094939|NCT07089121|DRUG|Descartes-08|In part 1, three different doses will be administered to 3 participants with either disease indication to establish maximum tolerated dose In part 2, the MTD established in Part-1 will be administered as six once-weekly infusions to up to 10 participants per each of four baskets (cSLE, AAV, JDM and JMG) in an outpatient setting.
215094940|NCT07088302|DRUG|lactase administration|1 drop for each 10 ml of formula milk for 14 days
215094941|NCT07088302|OTHER|placebo|10 ml milk without lactase
214502989|NCT01054287|OTHER|No falls prevention intervention|
214502990|NCT06214052|DRUG|VH4524184|VH4524184 was administered as tablets orally at Day 1.
214502991|NCT06214052|DRUG|Matching Placebo|VH4524184 Matching Placebo was administered as tablets orally at Day 1.
214502992|NCT06214052|DRUG|Antiretroviral therapy|Antiretroviral therapy was administered as available and as per investigator's recommendation.
214502993|NCT06387199|DRUG|Semaglutide with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
214502994|NCT06387199|DRUG|Placebo with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
214502995|NCT06758323|DIETARY_SUPPLEMENT|Beetroot juice combined with caffeine (COM)|"* 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session~* 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session"
214502996|NCT06758323|DIETARY_SUPPLEMENT|Beetroot juice placebo with caffeine (CAF)|\- 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session
214502997|NCT06758323|DIETARY_SUPPLEMENT|Beetroot juice with caffeine placebo (BRJ)|\- 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
214395755|NCT06687148|OTHER|Sham manipulation|The participants will receive one session of sham manipulation if in the sham group. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation, the physiotherapist will pretend to execute a thrust.
214395756|NCT06710535|OTHER|Manual Manipulation|The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.
214395757|NCT06710535|OTHER|Sham Manipulation|The participants will receive one session of sham manipulation if in the sham group. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation, the physiotherapist will pretend to execute a thrust.
214395758|NCT05438615|OTHER|Corneal Refractive Therapy-spherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
214395759|NCT05438615|OTHER|Corneal Refractive Therapy-aspherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
214395760|NCT06328062|DRUG|Mirogabalin|Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
214395761|NCT06328062|DRUG|Pregabalin|Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
214395762|NCT06893055|OTHER|Strength-Endurance Training|"The intervention for the experimental Strength-Endurance group includes warm-up, three laps of strength and endurance exercises and cool-down.~The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions."
214395763|NCT06893055|OTHER|Endurance Training|The intervention for the control Endurance training group includes warm-up, three laps of endurance exercises and cool-down. The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions.
214395764|NCT05623137|DEVICE|Acu-TENS|A dual-channel TENS stimulator will be used (ECS300A; Neurotrac, Verity Medical LTD, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
214395765|NCT05623137|DEVICE|Sham Acu-TENS|A dual-channel TENS stimulator will be used (ITO Physiotherapy \& Rehabilitation, Co, Ltd, Tokyo, Japan). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
214502998|NCT06758323|OTHER|Beetroot placebo with caffeine placebo (PLA)|\- 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
214502999|NCT06940960|DRUG|JY231 Injection|This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with relapsed refractory B-cell lymphoma/ leukemia. Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 2 years to determine if the disease is under control.
214503000|NCT06942806|OTHER|HF-SCS parameter settings: Frequency 1000 Hz, pulse width 60-180 μs, amplitude 0.5-3.0 V|HF-SCS parameter settings: Frequency 1000 Hz, pulse width 60-180 μs, amplitude 0.5-3.0 V
215094942|NCT07088835|DEVICE|SeizEAR|The in-ear electrode is a two-electrode device that fits snugly into the ear canal of the user. The device electrodes consist of a Ag/AgCl layer over a substrate. In one iteration, the substrate is a silicone rubber. In another iteration, the substrate is copper. The copper iteration consists of a Ag/AgCl ink that is manually applied to the copper, whereas the other iteration is purchased in a finished state with the Ag/Agel already adhered to the silicone. The electrodes are attached to a foam earpiece during the molding process. The foam earbud is made in-house and can be designed to be more firm or less firm.
214395766|NCT05623137|OTHER|SHP|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
214395767|NCT00153387|BEHAVIORAL|Women's health|
214395768|NCT05574374|DRUG|DWP14012|Potassium-competitive acid blocker
214395769|NCT05574374|DRUG|DWC202202|Clopidogrel Bisulfate
214395770|NCT05574374|DRUG|DWC202203|Proton pump inhibitor
214395771|NCT05018650|DEVICE|Route 92 Medical Reperfusion System|Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.
214395772|NCT05359900|OTHER|Pain neuroscience education|Pain neuroscience education lecture
214395773|NCT05359900|OTHER|Red Flag Education|Red Flag education lecture
214395774|NCT02229903|DEVICE|Active DTMS Treatment|H-coil Deep TMS 29 TMS treatments over 6 weeks.
214395775|NCT02229903|DEVICE|Sham Treatment|29 treatments over 6 weeks.
214395776|NCT06180252|DIAGNOSTIC_TEST|PET with 11C MP4|Each subject will undergo a PET exam using 11C MP4 as a tracer. This is a specific ligand for the acetyl-choline esterase enzyme already used abroad both in healthy volunteers and in various patient groups.
214395777|NCT03670186|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Participants perform high-intensity interval training (HIIT) on a cycle ergometer. The HIIT protocol consists of a 3-minute warm-up at 50W, ten 60-second high-intensity cycling intervals interspersed with 90 seconds of active recovery at 30% of their peak power output and a 2-minute cool-down at 50W for a total of 17.5 minutes.
214395778|NCT02725281|OTHER|Stress ball|"The patients in this group were given stress ball into both their palms 5 minutes before ESWL. Participants were instructed to squeeze the balls twice after counting up to ten and repeat it until the end of the procedure. This ball was medium hard and has been made of high quality silicon."
214395779|NCT02725281|OTHER|Music|The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
214395780|NCT05400720|BEHAVIORAL|Mentoring|At least one meeting between the mentor and mentee will occur to share experiences and see if the mentee would like to continue meeting with a mentor
214395781|NCT02112734|DRUG|Vitamin D|400 IU/daily until age 12 months
215001148|NCT07115225|OTHER|Physical performance test - modified-Closed Kinetic Chain Upper Extremity Stability Test (m-CKCUEST)|The test is performed in a push-up position with the hands one half-arm span apart on strips of athletic tape. The person reaches with alternating hands across the body to touch the piece of tape under the opposing hand. The number of cross-body touches performed in 15 seconds is recorded. In total, three 15-s test trials were performed, with 45 s rest between each trial.
214395782|NCT02112734|DRUG|placebo|identical placebo daily
214395783|NCT06474117|OTHER|Gait analysis coupled with ultrasound|Measure the lengths of the Achilles tendon and gastrocnemius medialis muscle
214395784|NCT06474117|OTHER|Isokinetic dynamometer with simultaneous ultrasound|Measure the force/length profile of the gastrocnemius medialis muscle
214395785|NCT03403933|DRUG|Didrogyl|"Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels\> 30 ng / ml are obtained.~Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study."
214395786|NCT02358460|DEVICE|Ventilation delivered by SLE5000 ventilator|"In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
214395787|NCT01461616|DRUG|NPH|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
214395788|NCT01461616|DRUG|Detemir|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
214395789|NCT01461616|DRUG|Glargine|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
214395790|NCT05188963|PROCEDURE|Intermittent catheterization|Intermittent catheterization is performed as treatment for urinary retention. Treatment is stopped when postvoid urinary retention volume is below the threshold of each group.
214395791|NCT04319003|BEHAVIORAL|Sugar-reduction intervention|The intervention consisted of a) installation of a water filter at the school. b) each participant received a metal water bottle. c) a registered dietitian gave a 30-minute presentation on sugar reduction for the purposes of type 2 diabetes prevention
214395792|NCT02169830|DRUG|nortriptyline|The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
215001149|NCT07115225|OTHER|Supine moving apprehension test (SMAT)|The beginning position of the participant is lying in a supine position while holding the weight just over their chest. Participants move their shoulder to 135° of abduction with the elbow extended, then returning to the starting position, and immediately move their shoulder to 180° of abduction with the elbow fully extended and finally return to the starting position. This cycle is repeated as much as possible for 1 minute.
215121391|NCT05107895|BEHAVIORAL|online coping skills training|Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
215121392|NCT00930891|DRUG|Standard Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles"
214395793|NCT02169830|DRUG|Topiramate|Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
214395794|NCT02169830|BEHAVIORAL|Diet Modification|Emphasis will be given to cessation of known migraine triggers such as caffeine, sodas, chocolates, alcohol (especially red wine) and aged cheeses. Patients who have complete control of their symptoms with diet and behavior modification alone will be followed for a total of 4 months to determine the durability of symptom relief.
214395795|NCT04596527|DRUG|18F-FMPP|18F-FMPP were injected into the patients at rest (2.5 mCi) and during stress (6.0 mCi) for an individual subject before PET/CT scans.
214395796|NCT06396195|OTHER|bioflx crown|The Bioflx crowns are characterized by their flexibility, durability, and adaptability. These crowns are preformed pediatric crowns designed for aesthetics, combining properties found in both stainless steel and zirconia crowns.
214395797|NCT06396195|OTHER|stainless steel crown|"Stainless steel crowns continue to be considered the Gold Standard for posterior full coverage restorations in primary molars"
214395798|NCT00081471|DRUG|darbepoetin alfa|0.45 micrograms/kg sc (starting dose) weekly
214395799|NCT00081471|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.6 micrograms/kg sc (starting dose) once every 2 weeks
214395800|NCT01316497|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC was performed by applying a blood pressure cuff around the child's leg. The cuff was inflated to 40 mmHg above the systolic pressure in 4 cycles of 5 minutes. Every cycle of ischemia was followed by 5 minutes of reperfusion. The first RIPC cycle started after anesthesia induction when invasive arterial blood pressure was monitored. Appropriate cuff size was used choosing between four sizes. For reproducibility RIPC was performed on the right leg with only a few exceptions, when the leg was used for invasive catheters.
214395801|NCT01316497|PROCEDURE|Control|The cuff was applied on the leg without inflation in the control group.
214503001|NCT06942806|OTHER|LH-SCS parameter settings: Frequency 30-100 Hz, pulse width 100-300 μs, amplitude 0.5-5.0 V|LH-SCS parameter settings: Frequency 30-100 Hz, pulse width 100-300 μs, amplitude 0.5-5.0 V
214503002|NCT01804166|DRUG|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
214503003|NCT01804166|DRUG|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
214503004|NCT02434328|DRUG|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
214395802|NCT02555371|BIOLOGICAL|Mepolizumab 100mg|Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.
214503005|NCT02434328|DRUG|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
214503006|NCT05529472|DEVICE|Peripheral Orbital Atherectomy System (OAS)|Treatment with Orbital Atherectomy System (OAS) followed by Percutaneous Old Balloon Angioplasty (POBA), pre-dilation and Drug Coated Balloon (DCB) - Medtronic IN.PACT™ Admiral™
214503007|NCT06951373|PROCEDURE|Multiple Percutaneous Needle Aspiration (MPNA)|A minimally invasive technique involving repeated needle aspiration of breast abscess fluid without making an incision.
214503008|NCT06951373|PROCEDURE|Incision and Drainage (ID)|A surgical procedure involving an incision in the abscess to allow drainage of pus, followed by wound care.
214395803|NCT02555371|DRUG|Placebo|The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
214503009|NCT06947876|OTHER|Enrolment 3T MRI research scan|Enrolment research scan performed with 3T magnetic resonance imaging scanner.
214503010|NCT06947876|OTHER|Enrolment Field-cycling Imaging research scan|Enrolment research scan performed with Field-Cycling Imaging scanner.
214503011|NCT06947876|OTHER|Enrolment ultra-low field MRI research scan|Enrolment research scan performed with ultra-low field MRI scanner
214395804|NCT04784273|PROCEDURE|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
214395805|NCT04784273|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
214395806|NCT03116763|BEHAVIORAL|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype calls conducted over 5-12 weeks.
214395807|NCT03116763|OTHER|Active Comparator: Control Group|The control group will receive standard care but without the iPeer2Peer program.
214395808|NCT00513019|DRUG|Lamictal (lamotrigine)|once daily from beginning to end of study. Dosage varies.
214395809|NCT00513019|DRUG|Placebo|daily
214395810|NCT03184714|DEVICE|NIPPV|BiPAP treatment for 3 years
214395811|NCT00058903|DRUG|sertraline|
214395812|NCT05180747|OTHER|Frequency of physical therapy sessions|Physical therapy sessions consisted of standard of care practice at our center of excellence i two different frequencies. All patients in both groups received 12 physical therapy sessions. Patients in the burst group received 2 physical therapy sessions per week in 6 weeks, while patients in the spaced group received 1 session every 2 weeks for 6 months.
214503012|NCT06947876|OTHER|Follow up 3T MRI research scan|Follow up research scan performed with 3T magnetic resonance imaging scanner, 18-months after baseline scans.
214503013|NCT06947876|OTHER|Follow up Field-cycling Imaging research scan|Follow up research scan performed with Field-Cycling Imaging scanner, 18-months after baseline scans.
214503014|NCT06947876|OTHER|Follow up ultra-low field MRI research scan|Follow up research scan performed with Ultra-low field MRI scanner, 18-months after baseline scans.
214503015|NCT06947876|OTHER|Enrolment cognitive assessment interview|Enrolment interview performed to complete cognitive assessment scoring of Montreal Cognitive Assessment, EQ-5D, Trail making test, Animal naming test, controlled oral word association test, and Hopkins Verbal Learning Test.
215001150|NCT07115225|OTHER|Physical performance test - Posterior shoulder endurance test (PSET)|The participant is positioned prone, with the test shoulder off the table and the arm in 90° of horizontal abduction, the point at which the participant is to hold the arm as long as possible until fatigue. The participant holds a weight equal to 2% of his body weight (rounded to the nearest 0.5 kg).
215001151|NCT07115225|OTHER|Patient-reported outcome measure - The Shoulder Instability-Return to Sport after Injury (SIRSI)|Psycho-social questionnaire assessing the psychological readiness of athletes to return to sport following traumatic shoulder instability and conservative or surgical management. The SIRSI includes 12 questions with an 11-point Likert scale in the form of blocks to be ticked from 0 to 10. The total score is equal to the sum of the values of the 12 responses then determined in relation to 100 to obtain a percentage. High scores correspond to a positive psychological response.
214395813|NCT05926856|DRUG|Indocyanine green|Indocyanine Green 25mg kit for injection
215001152|NCT07115225|OTHER|Patient-reported outcome measure - Numeric Pain Rating Scale (NPRS)|"Patient's shoulder pain will be measured using an 11-point NRS, with a minimum value of zero (no pain) and a maximum score of 10 (the worst pain possible)"
215001153|NCT07115225|OTHER|Modified Tampa-Scale of Kinesiophobia for Anterior Shoulder Instability (TSK-SI)|"modified Tampa Scale of Kinesiophobia (TSK) to make it suitable for application in patients with anterior shoulder instability. The TSK-SI contains 18 items and the total score can range from 18 to 72, with 18 being the best score (no fear of movement/kinesiophobia) and 72 being the worst score (severe fear of movement/kinesiophobia)"
215001154|NCT07113652|DEVICE|TI stimulation device (nerviox-1000）|"The TI stimulation device (nerviox-1000) delivers temporally interfering electrical fields with a 130 Hz envelope frequency, generated by high-frequency carrier waves. The stimulation is applied for 20 minutes per session, with a peak current of 3-4 mA per channel, adjusted based on individual tolerance. The stimulation targets include the nucleus accumbens, bed nucleus of the stria terminalis, amygdala, caudate nucleus, and putamen. Stimulation is administered twice daily, with each treatment phase lasting 7 consecutive days.~Sham stimulation uses identical electrode placement and setup as active stimulation. A brief 30-second ramp-up is applied to mimic real stimulation, followed by rapid reduction to 0 mA or minimal current. A 1 mA tail current is delivered in the final 30 seconds to simulate the tapering effect of active stimulation."
215001155|NCT07116135|DEVICE|hearing instruments|Participants will be fit with three different models of hearing instruments.
215001156|NCT07113834|DRUG|Adalimumab|A tumor necrosis factor-alpha (TNF-α) inhibitor used as a biologic agent for the treatment of ankylosing spondylitis. Administered subcutaneously as part of systemic immunomodulatory therapy.
215001157|NCT07113834|DRUG|Systemic corticosteroids|Oral or intravenous corticosteroids (e.g., prednisolone) used to suppress systemic inflammation in cases of active AS or severe uveitis.
215001158|NCT07116005|BEHAVIORAL|Mandala Coloring|"Participants in this group receive the Mandala Art Therapy intervention, a creative, mindfulness-based activity rooted in complementary and alternative medicine. The intervention is designed to reduce exam-related anxiety by fostering visual focus, emotional calm, and self-expression. The Mandala protocol includes the following components:~* Distribution of printed Mandala outlines on A4 paper~* Provision of six colored pencils (red, orange, yellow, green, blue, and purple)~* A 20-minute individual coloring session in a quiet and relaxed setting~* No prescribed patterns-participants color freely to encourage self-directed engagement The Mandala coloring session is conducted exactly one hour before the Objective Structured Clinical Examination (OSCE). The activity is supervised by the researcher to ensure a supportive and distraction-free environment. Participants are encouraged to concentrate on the process of coloring to promote psychological grounding and reduce pre-exam stress."
215001159|NCT07114159|DEVICE|Sacral nerve stimulation|Device: G132 system, Beijing PINS Medical Co., China Neuromodulation was performed according to the usual protocol
215001160|NCT07113847|BIOLOGICAL|Resin-Based Desensitizer|resin desensitizing agent
215001161|NCT07113847|DEVICE|Laser Desensitizer|Low-power Diode laser
215001162|NCT07113847|BIOLOGICAL|Fluoride-Based Desensitizer|Fluoride-based varnish
215001163|NCT07116447|BEHAVIORAL|Health messages - existing Swedish legislation|Textual health warning messages currently mandated for use in printed alcohol advertisements under the Swedish Alcohol Ordinance, focusing on communicated various alcohol harms
214395814|NCT06508099|DRUG|Vitamin A|300 000 IU single dose orally
214395815|NCT06508099|DRUG|Vitamin D3|100 000 IU single dose orally
214395816|NCT06003101|BIOLOGICAL|Bone marrow aspirate concentrate (BMAC)|Bone marrow aspiration from the body of the ilium will be performed through one of the arthroscopic portals.
214395817|NCT06003101|PROCEDURE|Control|Standard of care hip arthroscopy without bone marrow aspiration will be performed in these patients.
214395818|NCT06224426|OTHER|Normobaric high-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=80% through endotracheal intubation, with a gas flow rate set at 4 L/min.
214395819|NCT06224426|OTHER|Normobaric low-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=30% through endotracheal intubation, with a gas flow rate set at 4 L/min.
215001164|NCT07116447|BEHAVIORAL|Health messages - pictograms|Pictograms indicating no alcohol use during pregnancy and while driving
215001165|NCT07115628|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive brain stimulation technique
214395820|NCT04860128|BEHAVIORAL|Sports technology application|Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.
214395821|NCT04201951|DRUG|Tranexamic acid injection|Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
214395822|NCT04201951|OTHER|Glucose water 5%|Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
214395823|NCT04793932|DRUG|PAXG|Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days
214395824|NCT04793932|DRUG|mFOLFIRINOX|Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days
214395825|NCT04793932|DRUG|short-course chemotherapy|other two months of chemotherapy after surgery
214395826|NCT04793932|DRUG|long-course chemotherapy|other two months of chemotherapy before surgery
214395827|NCT06116110|OTHER|Long-term Follow-Up|No intervention
214395828|NCT02455479|BIOLOGICAL|dAd5GNE Vaccine|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
214395829|NCT02455479|BIOLOGICAL|Placebo|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
214395830|NCT06452706|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug conjugate (ADC).
214395831|NCT02156362|OTHER|follow up visit|At least 1 follow up visit per year will be done and an additional visit if needed.
214395832|NCT06267274|DRUG|Bimatoprost Ophthalmic Solution, 0.01%|1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
214395833|NCT06267274|DRUG|LUMIGAN® (bimatoprost ophthalmic solution) 0.01%|1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
214395834|NCT00798395|DRUG|Org 50081|1.5 mg on day 1-7
214395835|NCT00798395|DRUG|Org 50081|4.5 mg on Day 1-7
214395836|NCT00798395|DRUG|Placebo|Once daily on Day 1-7
214395837|NCT00798395|DRUG|zopiclone|Single dose of 7.5 mg
214395838|NCT01548443|DEVICE|Medifoam H dressing|"Cover medifoam H on the wound for a week."
214395839|NCT01548443|DEVICE|Duoderm THIN dressing|"Cover Duoderm THIN on the wound for a week"
214395840|NCT00005611|DRUG|BMS-188797|
214395841|NCT03615482|BIOLOGICAL|V114|Single 0.5 mL injection
214395842|NCT03615482|BIOLOGICAL|QIV|Single 0.5 mL injection
214395843|NCT03615482|BIOLOGICAL|Matching Placebo for V114|Single 0.5 mL injection
214395844|NCT03987035|DEVICE|BeGraft Peripheral (BGP) Stent Graft System as bridging stent|BGP Stent Graft System as bridging stent
214503016|NCT06947876|OTHER|Follow up cognitive assessment interview|Follow up interview performed to complete cognitive assessment scoring of Montreal Cognitive Assessment, EQ-5D, Trail making test, Animal naming test, controlled oral word association test, and Hopkins Verbal Learning Test. Performed 18-months after baseline interview.
214503017|NCT06952335|PROCEDURE|Phrenic nerve stimulation at 8mA|Phrenic nerve stimulation (PNS) at 8mA is applied.
214503018|NCT06952335|PROCEDURE|Phrenic nerve stimulation at 15mA|Phrenic nerve stimulation (PNS) at 15mA is applied.
214395845|NCT05798728|PROCEDURE|Outpatient transcervical foley balloon|These participants will receive a 16-French Foley catheter which will be placed by a physician present in the clinic. The balloon will be inflated with 40 mL of sterile water, and the catheter will then be gently withdrawn so that the balloon applies pressure against the internal os. The catheter will then be taped to the inner thigh.
214395846|NCT05798728|PROCEDURE|Inpatient Vaginal Misoprostol|These participants will receive 25 micrograms of Misoprostol (100- microgram tablet cut into fourths by the hospital pharmacist) inserted vaginally into the posterior fornix every 4 hours and repeated up to a maximum of six doses per our standard hospital protocol.
214395847|NCT02845505|OTHER|Intravascular Ultrasound, coronary computed tomography angiography|
214395848|NCT03521921|DEVICE|Mitraclip|Edge-to edge mitral valve repair
214395849|NCT04576780|OTHER|Integrated Large Complex Polyp Referral Pathway|"The referring doctor will use a standardized template to send the referral along with its associated video or high-resolution photographs.~Referrals will be reviewed in a consensus fashion by at least 2 expert physicians at St. Michael's Hospital (SMH) on a bi-weekly basis. Polyps will be scored using a standardized evaluation form that documents relevant polyp features to assist the determination of whether a lesion is amenable to curative endoscopic resection.~Cases will be triaged as being: (1) a standard polyp suitable for local removal in the community; (2) a complex polyp requiring expert removal at SMH with priority assigned based on the suspected risk of invasive disease; (3) a polyp that is not amenable to endoscopic resection or that is suspicious for cancer will that be recommended for surgical resection."
214395850|NCT02922413|BIOLOGICAL|Hemin for injection|Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.
214395851|NCT02922413|OTHER|Placebo|Saline infusion
214395852|NCT03078387|DIAGNOSTIC_TEST|imaging|imaging before and after treatment
214395853|NCT00979173|DRUG|AC480|Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
214395854|NCT05491005|BEHAVIORAL|Total diet replacement|Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
214395855|NCT05491005|BEHAVIORAL|eHealth|All follow-up through an eHealth application and video meetings.
214395856|NCT05491005|BEHAVIORAL|Face-to-face|All follow-up through face-to-face meetings.
214395857|NCT01161017|DRUG|Amitriptyline|Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
215001166|NCT07115277|DRUG|Flotufolastat F-18 Injection|All patients will receive one injection of Flotufolastat F-18 Injection, a PET radiopharmaceutical selective for PSMA. For the injection, subjects will receive a target dose of 8 mCi (296 MBq) ± 20% IV as a bolus injection. Flotufolastat F-18 Injection will be followed by a 10 ml saline flush.
215001167|NCT07116577|RADIATION|Palliative radiotherapy|Conventional fractionation, low-dose hypofractionated radiotherapy, or high-dose hypofractionated radiotherapy may be employed.
214395858|NCT01161017|DRUG|Topiramate|For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
214503019|NCT06952335|PROCEDURE|Phrenic nerve stimulation at 15mA combined with phrenic-abdominal stimulation at 15mA|Phrenic nerve stimulation (PNS) at 15mA combined with phrenic-abdominal stimulation at 15mA is applied.
214395859|NCT02377765|DEVICE|Transcutaneous Stimulation|TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.
214395860|NCT02377765|PROCEDURE|Percutaneus Stimulation|PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
214395861|NCT05616182|OTHER|LARS ligament and bone prosthesis replacement was performed|To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
214395862|NCT01500226|DRUG|Rolapitant|(4 X 50 mg capsule) 200 mg PO
214395863|NCT01500226|DRUG|Granisetron|2 mg PO
214395864|NCT01500226|DRUG|Dexamethasone|20 mg PO
214395865|NCT01500226|DRUG|Placebo|(4 X 0 mg capsules) 0 mg PO
214395866|NCT06176456|DIAGNOSTIC_TEST|rTMS|Active regiment
214395867|NCT06176456|OTHER|Placebo|Tactile artefacts without magnetic pulses
214395868|NCT05096390|DRUG|Axitinib Oral Tablet [Inlyta]|Axitinib 5 up to 10mg twice a day
214395869|NCT05096390|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
214395870|NCT02955277|OTHER|TECH: Tablet Enhancement of Cognition and Health protocol|Cognitive training using touchscreen tablets (TECH protocol)
214395871|NCT02955277|OTHER|Standard care or active standard care|standard occupational therapy or 6-weekly group sessions playing board games and puzzles.
214395872|NCT02754609|OTHER|Gluten micro-challenge|From week 12 to week 24, all participants will start a gluten micro-challenge from 10mg/day for the first 2 weeks escalating over the this period to 50mg/day at the end of week 24.
214395873|NCT02754609|OTHER|Inadvertent gluten challenge|From week 24 to week 36, all participants will be on gluten 50mg/day and 1g twice weekly.
214395874|NCT02754609|OTHER|Moderate gluten challenge|From week 36 to week 42, all participants will be on gluten 2g/day.
214395875|NCT02754609|OTHER|Liberal diet|From week 42, all participants will be unblinded and those who have received hookworm therapy have the option to go on a liberal diet of more than 10g of gluten/day from week 42 to week 94.
214395876|NCT02754609|OTHER|Necator americanus-hookworm larvae L3-10|A total of 40 participants at week 0 and week 8 will have hookworms L3-10 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
214395877|NCT02754609|OTHER|Tabasco® Sauce|Arm: Placebo Comparator: Tabasco® Sauce A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing
214395878|NCT02754609|OTHER|Necator americanus-hookworm larvae L3-20|A total of 40 participants at week 0 and week 8 will have hookworms L3-20 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
214503020|NCT06950827|PROCEDURE|laparoscopic right hemihepatectomy|Laparoscopic surgery has many advantages, such as small surgical incision and fast postoperative recovery. In recent years, more and more centers have gradually transitioned to performing right hemihepatectomy through laparoscopy as much as possible.
215001168|NCT07116577|DRUG|Iparomlimab and tuvonralimab|5 mg/kg, intravenously infused on Day 1 of each cycle, administered every 3 weeks (with each cycle defined as 21 days).
214395879|NCT02754609|OTHER|Gluten free diet|From week 0 to week 12, all participants will be on a gluten free diet.
214395880|NCT05729815|OTHER|Relaxation|Sessions focused on relaxations activities (Jacques Choque Method).
214395881|NCT05729815|OTHER|Loose parts play|Loose parts play-based sessions, with open-ended materials.
214395882|NCT05729815|OTHER|Combined|Sessions focused on loose parts play and relaxation activities.
214395883|NCT01973465|BIOLOGICAL|Stool|Implanting fecal matter via colonscope
214395884|NCT01603940|DRUG|Benazepril|Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.
214395885|NCT01603940|DRUG|Losartan|Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.
214395886|NCT00147979|DEVICE|Bridging by PTFE with bounded heparin|Bridging by PTFE with bounded heparin
214395887|NCT00147979|DEVICE|Bridging by PTFE without bounded heparin|Bridging by PTFE without bounded heparin
215001169|NCT07116577|DRUG|TAS-102|35 mg/m², orally twice daily on Days 1 to 5 and Days 8 to 12 of each cycle, with each cycle spanning 28 days (4 weeks).
214395888|NCT02748564|BIOLOGICAL|Aldesleukin|Given IV
214395889|NCT02748564|OTHER|Laboratory Biomarker Analysis|Correlative studies
214395890|NCT02748564|BIOLOGICAL|Pembrolizumab|Given IV
214395891|NCT00005594|DRUG|ISIS 2503|Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
214395892|NCT03135353|DEVICE|3D saline infusion sonohysterography|instillation of saline in the uterine cavity using pediatric foley's catheter, then performing 3D ultrasound scan of the uterus and adenexae
214395893|NCT03135353|DEVICE|Office Hysteroscopy|an outpatient procedure done to assess the uterine cavity using the office hysteroscopy
214395894|NCT02529865|BIOLOGICAL|Periurethral injection of autologous ADRCs and adipose tissue|1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.
214395895|NCT01809210|DRUG|selumetinib|2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
214395896|NCT01809210|DRUG|gemcitabine|1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
214395897|NCT01809210|DRUG|cisplatin|75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
215001170|NCT07116577|DRUG|Bevacizumab|7.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
214395898|NCT01809210|DRUG|carboplatin|If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
214395899|NCT01809210|DRUG|pemetrexed|Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
214395900|NCT00791622|DRUG|Paliperidone ER|
214395901|NCT03567083|BEHAVIORAL|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialized workers or lay people, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
214395902|NCT01808443|OTHER|Cryotherapy|up to a maximum of four treatments every 21-28 days
214395903|NCT01808443|OTHER|laser|up to a maximum of four treatments every 21-28 days
214395904|NCT02717598|PROCEDURE|cold snare polypectomy|CSP was performed by using a disposable oval snare with a diameter of 10 mm under gentle suction to reduce colon wall tension. The tip of the endoscope was deflected toward the polyp base to ensnare 1 to 2 mm of normal mucosa surrounding the polyp. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding.Cross-sections of the EMR specimens were collected at 1-mm intervals.
214395905|NCT02717598|PROCEDURE|hot snare polypectomy|HSP, which is using electrocoagulation on the basis of using cold snare.After HSP, another independent endoscopic surgeon judged whether the endoscopic eradication was successful. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding, the specimens were retrieved and stored in formalin. Cross-sections of the EMR specimens were collected at 1-mm intervals; accurate tissue section of the marked site was ensured.
214395906|NCT00192283|BIOLOGICAL|CAIV-T|The total single-dose volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
214503021|NCT06951243|DRUG|MHB088C for Injection (B7-H3 ADC)|MHB088C for Injection, an antibody drug-conjugated molecule (ADC), is conjugated from a humanized monoclonal antibody targeting the B7-H3 molecule and a DNA topoisomerase I inhibitor (TOP1i) via protease-hydrolyzable linkers.The intervention will be administered intravenously at a dose of 2.0 mg/kg every 2 weeks (Q2W) until disease progression, withdrawal from the study, or death.
214503022|NCT06952088|OTHER|Training on Neonatal Resuscitation|Improve training of health care personnel (physicians, nurses and midwives) on neonatal resuscitation through manikin simulation using two different devices: a face mask and a laryngeal mask. Before the simulations begin, each participant will receive a brief introduction on the technical characteristics of the manikin and how to use the two masks. A stopwatch will be used to record the time required to achieve effective ventilation, defined by the expansion of one-third of the newborn manikin's rib cage. Consideration will also be given to whether corrective maneuvers will need to be performed during the use of each mask and the timing with which these maneuvers will be applied. Finally, a pseudonymous questionnaire will be administered to participants to assess their perceptions of the ease of use of each mask.
214503023|NCT06950216|OTHER|IONM|The probe needle electrodes were inserted into the corpus cavernosum penis, ischiocavernosus muscle, bulbocavernosus muscle, anal sphincter, etc., and each monitoring electrode was connected to the nerve monitor. The changes of electromyography of each effector during the operation were monitored in real time. The stimulation electrode was placed in the abdominal cavity during the operation. During the resection of the prostate, electrical stimulation was performed on the possible running area of the NVB, and the stimulation site where the signal was monitored was protected from resection and burning under the premise of safe surgery.
214503024|NCT06951854|DRUG|Drug: NV01-A02|NV01-A02 will be administered orally at a different dose once daily for 8 weeks. The formulation is a white, film-coated tablet, designed for use in patients with mild to moderate cognitive impairment.
215001171|NCT07119060|PROCEDURE|Cystectomy|Surgical removal of the endometrioma by gently pulling the cyst wall away from the ovarian tissue (divergent traction technique)
215001172|NCT07119060|PROCEDURE|plasma vaporization|It consists of destroying the cyst wall (vaporization) using plasma energy
215001173|NCT07119060|PROCEDURE|Sclerotherapy|Ethanol sclerotherapy destroys the endometriotic tissue lining the inner wall of the cyst through prolonged contact with 96% alcohol
215001174|NCT07117760|DRUG|225Ac-LNC1011|administered intravenously once every 8-10 weeks (1 cycle) for 4 cycles
215001175|NCT07117760|DRUG|68Ga-PSMA-11|Intravenous dose of approx. 150 MBq at screening and at time of centrally confirmed radiographic progressive disease
215121393|NCT00930891|DRUG|Experimental Treatment (PCDE or PE + bevacizumab)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression"
215121394|NCT00930891|DRUG|Prerandomization Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles"
214395907|NCT00192283|OTHER|Placebo|A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
214395908|NCT04574245|PROCEDURE|Gastrectomy; Hepatectomy|
214503025|NCT06951854|DRUG|Drug: Placebo (ZP8396)|ZP8396 is a matching placebo tablet administered orally once daily for 8 weeks. The placebo is identical in appearance to NV01-A02 but contains no active ingredient.
214503026|NCT05436665|PROCEDURE|UT-DSAEK|"The main incision (3.5-5mm) is created at the corneal limbus or via a cornea-scleral tunnel with 2-3 smaller (approx. 1mm) paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber, according to the surgeon's preference. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed. Once the anterior chamber is prepared, OVD or air has been removed, then the eye is ready for the new corneal graft.~The pre-cut corneal tissue delivered by the bank is then gently rinsed and may be stained with 0.06% trypan blue if required. The tissue is loaded into a glide or injector, and pulled into the anterior chamber using a smooth-tipped micro-forceps (e.g., Busin forceps). Once the graft enters the eye, it is lifted to the posterior cornea. The graft is further centred using air (or SF6 Gas) in the anterior chamber."
214503027|NCT05436665|PROCEDURE|DMEK|"The main incision (2.8-3mm) is created superior or temporally at the corneal limbus and is accompanied by 2-3 smaller paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed.~The DMEK roll is poured into a basin and rinsed. The graft is then stained with 0.06% trypan blue to aid in graft visualization. The graft is loaded into an injector and introduced into the anterior chamber. The graft is unrolled using external manoeuvres and once unrolled, it is lifted to the back of the cornea. The eye is then pressurised with a full air fill from 10 to 120 minutes. The pressure is then reduced and the case is completed by suturing any incisions required."
214503028|NCT02370797|RADIATION|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
214503029|NCT00604890|DRUG|API 31510 3% Topical Cream|Topical treatment 3% active cream applied to the lesion
214503030|NCT00604890|DRUG|API 31510 1.5% Topical Cream|Topical treatment 1.5% active cream applied to the lesion
214503031|NCT00604890|OTHER|Placebo|Topical treatment placebo applied to the lesion
214503032|NCT06132737|DRUG|[90Y]Y-PentixaTher|\[90Y\]Y-PTT i.v. injection
214503033|NCT06525077|DRUG|FT218|Sodium oxybate for extended-release oral suspension
214503034|NCT06525077|OTHER|Placebo|Matched placebo equivalent for oral suspension
214503035|NCT05587764|DIAGNOSTIC_TEST|Standard of Care|Standard of care for emergency events per local guidelines.
214503036|NCT00302211|DRUG|Inhaled Iloprost (5 μg)|iloprost inhalation solution (Ventavis) (5 μg)
215001176|NCT07118267|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum|containing 60 billion CFU (administered as two capsules per day)
215001177|NCT07118501|DEVICE|Total Ankle Replacement|Incompass™ Total Ankle System
214395909|NCT00061100|BEHAVIORAL|Behavior Therapy-RISE|manually-guided HIV intervention RISE: Reduce high risk Intravenous drug use and unsafe Sexual Encounter
214395910|NCT00061100|BEHAVIORAL|Standard prevention Education|standard psychosocial Education for HIV/hepatitis prevention
214395911|NCT00504348|DRUG|Tacrolimus|Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
214395912|NCT05852769|DRUG|BMS-986196|Specified dose on specified days
214503037|NCT00302211|DRUG|Inhaled Placebo|inhaled placebo
214503038|NCT00302211|DRUG|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
214503039|NCT00302211|DRUG|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
214395913|NCT05852769|DRUG|Caffeine|Specified dose on specified days
214395914|NCT05852769|DRUG|Montelukast|Specified dose on specified days
215001178|NCT07118657|OTHER|Vegan Diet|"Vegan diet would be defined as a diet based solely of plant products with exclusion of all animal products including meat, fish, dairy, honey and eggs.• Additional supplementation of vitamin B12 (500 µg/day) in the vegan diet group along with calcium (50-75 mg/kg/day), vitamin D (800-1600 IU/day) and iron supplementation (3-6 mg/kg/day) as per requirement.~o Monitoring- Based on vitamin B12 levels, 25(OH) vitamin D3 levels, serum calcium, and serum iron studies (complete hemogram, ferritin, iron, transferrin saturation, total iron binding capacity)."
214395915|NCT05852769|DRUG|Flurbiprofen|Specified dose on specified days
214395916|NCT05852769|DRUG|Omeprazole|Specified dose on specified days
214503040|NCT04716101|OTHER|Massage therapy technique|The massage therapy technique consists of manual deep and slow compression and shearing forces applied on the lumbar spine muscles and thoracolumbar fascia in a distal to proximal direction.
214503041|NCT04716101|OTHER|Sham massage technique|For the sham massage technique the massage therapist will put the right palm at the participant's right lower back along erector spinae and likewise left palm at left lower back without applying force, holding the palm during 2 minutes and half.
215001179|NCT07118657|OTHER|Standard Diet|Standard Diet
215001180|NCT07117526|DEVICE|Aneurysm occlusion with an intrasaccular device|Intervention with HARBOR Occlusion Device
215001181|NCT07118319|DRUG|Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)|Injection, once, 6 months
215001182|NCT07118319|DRUG|Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)|Injection, every two weeks for four doses, 6 months
215001183|NCT07117461|BEHAVIORAL|NCCN Distress Thermometer|A tool used to determine on a number scale the amount of distress for the past week
215001184|NCT07116954|PROCEDURE|Twenty-Two adult Patients who indicated for bilateral maxillary first premolar extraction will be randomly assigned into two equal group.|Group1: Elastomeric chains will be used on the right side, and NiTi closed-coil springs will be used on the left side. Group2: NiTi closed-coil springs will be used on the right side, Elastomeric chains will be used on the left side.
215001185|NCT07116954|PROCEDURE|Canin retraction with NiTi Closed-Coil Springs and elastomeric chains|Comparison between canine retraction using NiTi closed-coil springs versus elastomeric chains
215001186|NCT07118761|BEHAVIORAL|Home-based walking training|Patients enrolled in the experimental group will undergo an exercise-based intervention at home guided by a smartphone application. Each exercise session will encompass 8 walking minutes at home at a fixed slow speed to be repeated twice per day. Every week the speed will be slightly increased to maintain an adequate training stimulus.
215001187|NCT07117006|DEVICE|miniscrew- supported maxillary posterior segments' intrusion using clear aligners|maxillary posterior segments will be intruded with the aid of miniscrews and clear aligners
215001188|NCT07117799|DRUG|PF-07248144|Period 1: Participants received Form 1 in a single dose of tablet fasted Period 2: Participants received Form 5 in a single dose of tablet fasted
215001189|NCT07117799|DRUG|PF-07248144|Period 1: Participants received Form 5 in a single dose of tablet fasted Period 2: Participants received Form 1 in a single dose of tablet fasted
214395917|NCT05852769|DRUG|Midazolam|Specified dose on specified days
214395918|NCT05852769|DRUG|Digoxin|Specified dose on specified days
214395919|NCT05852769|DRUG|Pravastatin|Specified dose on specified days
214395920|NCT05248464|OTHER|The Patient Dignity Inventory instrument (PDI)|The PDI is an instrument made up of 25 items integrated into 5 factors that include: symptoms, existential anguish, dependency, peace of mind, and social support, prior to its application, adaptation, and validation will performer
214503042|NCT06272110|OTHER|System level Language Access (LA) intervention|Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.
214503043|NCT06397235|DRUG|DEB-TACE+HAIC|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~RALOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; Raltitrexed, 3 mg/m2 infusion for 0.5 hour."
214503044|NCT06397235|DRUG|DEB-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
215001190|NCT07117799|DRUG|PF-07248144|Period 1: Fasted participants received a single dose of tablet of Form 1 orally Period 2: Participants received a single dose of tablet orally of Form 5 in a fed state
215001191|NCT07117045|DIAGNOSTIC_TEST|Diagnostic Evaluation for Positive AI Findings|MDT will review positive AI findings (including PDAC, pancreatic precursor lesions and benign lesion) cases to determine next steps: (1) Suspected PDAC and pancreatic precursor lesions are referred for hospital examination with diagnostic results collected; (2) Benign lesion cases receive personalized monitoring until endpoint events or study end; (3) Cases with positive AI findings but MDT-confirmed normal pancreatic issues receive at least one year of follow-up. If any abnormal results arise, management will transition to either plan (1) or (2).
215001192|NCT07118670|DRUG|Aflibercept 8mg|Solution in Vial, intravitreal (IVT) injection
215001193|NCT07119034|DIAGNOSTIC_TEST|Total cholesterol (TC), random blood glucose (RBG), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)|Blood samples were collected from the antecubital vein and processed at the TrueLab medical laboratory. The whole blood was initially collected in plain tubes, and subsequently centrifuged to obtain serum samples. Total cholesterol (TC), random blood glucose (RBG), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) Thioredoxin and 4-Hydroxynonenal quantification, malondialdehyde levels
215001194|NCT07117370|BEHAVIORAL|Coach Mpilo|Peer support for treatment navigation. Peer supporters (coaches) with TB and HIV treatment experiences are trained in listening, support, and action planning to assist men in navigating and staying on treatment.
215001195|NCT07118163|OTHER|Other|No intervention was applied in this study.
215121395|NCT05555303|DRUG|Amikacin|"In addition to the all-oral RR-TB treatment, add two intramuscular doses each consisting of 30 mg amikacin/kg, a first dose on day 1 and a second dose on day 4, all in the first week of treatment.~The amikacin solution will be admixed with a lidocaine solution in the syringe before administration."
215001196|NCT07118163|OTHER|No intervention; Observational study|No intervention
215001197|NCT07115719|OTHER|No Intervention: Observational Cohort|NO INTERVENTION
215001198|NCT07115641|DRUG|Huoluo Pills|Huoluo Pills: Orally take 1 pill once, twice a day (swallow with warm water)
215121396|NCT03110471|BEHAVIORAL|West Wales Adverse Drug Reaction (WWADR) Profile|Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement
214395921|NCT05248464|OTHER|WHOQOL-BREF (quality of life) instrument|The WHOQOL-BREF is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment, it consists of 24 items.
214395922|NCT05435183|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
214395923|NCT05435183|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
214395924|NCT00260156|DRUG|vildagliptin|
214395925|NCT00260156|DRUG|placebo|
214395926|NCT04773002|OTHER|Different anesthesia methods|Total intravenous anesthesia (TIVA)and volatile anesthesia
214503045|NCT02921711|DEVICE|LVIS®|Low-profile Visualized Intraluminal Support device
214503046|NCT01961063|DRUG|busulfan|Given IV
215121397|NCT03110471|BEHAVIORAL|usual care|usual care
215121398|NCT04546035|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.
215001199|NCT07115641|DRUG|Iguratimod Tablets|Iguratimod Tablets: Orally take 1 tablet once, twice a day (one tablet in the morning and one in the evening, after meals)
215001200|NCT07114419|DRUG|Efsubaglutide Alfa 20 mg QW|Efsubaglutide Alfa 20 mg QW
215001201|NCT07114419|DRUG|Efsubaglutide Alfa 40 mg QW|Efsubaglutide Alfa 40 mg QW
215001202|NCT07114419|DRUG|Efsubaglutide Alfa 40 mg Q2W|Efsubaglutide Alfa 40 mg Q2W
215001203|NCT07114419|DRUG|Efsubaglutide Alfa 80 mg QW|Efsubaglutide Alfa 80 mg QW
215001204|NCT07114419|DRUG|Efsubaglutide Alfa 80 mg Q4W|Efsubaglutide Alfa 80 mg Q4W
214395927|NCT01118962|DRUG|Lacosamide|Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
214395928|NCT03708380|BEHAVIORAL|Dietary intervention|Over a 60-day period, participants will receive healthy lunches that provide a hand-delivered healthy alterative to their current diets.
214395929|NCT04689165|BIOLOGICAL|Experimental Group A meningococcal polysaccharide vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
214395930|NCT04689165|BIOLOGICAL|Control Group A meningococcal polysaccharide vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
214395931|NCT05931562|OTHER|Fermented Foods|Participants will recieve dietary education to include 4 to 6 portions of fermented foods to their normal diet.
214395932|NCT05931562|OTHER|High Fibre|Participants will recieve dietary education to increase their fibre intake to 24-35g/day in their normal diet.
214395933|NCT05931562|OTHER|Combined Diet|Participants will recieve dietary education to increase their fibre intake to 25-30g/day and include 3 to 4 portions of fermented foods to their normal diet.
214395934|NCT05931562|OTHER|Control|Participants will recieve dietary education based on the Irish healthy food pyramid.
214395935|NCT03478423|DRUG|Codeine|30mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
214395936|NCT03478423|DRUG|Oxycodone|5mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
215001205|NCT07114419|OTHER|Placebo|Placebo
215001206|NCT07116018|BEHAVIORAL|Psychoeducation|The intervention comprises 8 individual psychoeducational sessions over 12 weeks, as an adaptation of the Psychoeducation, Paced Respiration, and Relaxation (PEPRR) (Laudenslager et al., 2015). The adaptation in the current study involves delivery by a trained nurse and omission of the biofeedback component.
215001207|NCT07115849|BEHAVIORAL|Physical training|Aerobic and resistance training three times per week. Two supervised training sessions.
215094943|NCT07088822|BIOLOGICAL|V4020|The V4020 vaccine was prepared using an iDNA® infectious clone that encodes the full-length rearranged genomic RNA downstream from the optimized CMV promoter. Compared to the wild type VEEV, V4020 contains genetic rearrangement within the genomic RNA, with the capsid gene placed downstream from the glycoprotein genes. V4020 also includes attenuating mutations from the VEE TC83 vaccine, nucleotide A at position 3 in the untranslated region and E2-120Arg in the E2 glycoprotein. Notably, the E2-120Arg attenuating mutation was genetically engineered in V4020 to prevent reversion mutations. The E2-120Arg was encoded in V4020 by a CGA codon instead of AGA in the TC83 virus. Therefore, in the V4020 vaccine, at least two mutations would be needed to revert to the wildtype ACA (E2-120Thr). In contrast, in the TC83 vaccine, an AGA codon encodes the attenuating mutation E2-120Arg, and a single point mutation would be sufficient to revert to the 213 VEEV wild type ACA (E2-120Thr).
214395937|NCT03478423|DRUG|Hydromorphone|1mg tablets.Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
215001208|NCT07115147|DEVICE|Blue diode laser|All procedures would be performed under spinal or general anaesthesia. Blue diode laser vaporization would be performed according to the standard approach for the obstructing prostate
215001209|NCT07114393|BEHAVIORAL|Liberal use of intracoronary imaging during complex PCI|A new protocol regarding use of intracoronary imaging will be implemented in multiple PCI centers in the Netherlands. Main goal of this protocol will be to increase the use of imaging in complex PCI in the Netherlands. Moreover operators will be trained according to the new protocol and on site training will be organized to improve the skills in using imaging during complex PCI.Operators are requested to use of intracoronary imaging preferentially in all complex coronary lesions, but at least increase their use with at least 50% and minimum of 25% of the cases. Throughout the second phase, individual participating operators will receive personalized feedback on their use of intracoronary imaging at multiple intervals. Based on this result, the implementation process will be refined as necessary. These intermediate measurements will also be shared with all participating centres anonymous.
215001210|NCT07113873|OTHER|ultra-translucent monolithic multi layered zirconia|laminate veneer
215001211|NCT07113873|OTHER|lithium disilcate ceramics|laminate veneer
215001212|NCT07116460|DEVICE|Austin Air Cleaner|The Austin Air Purifier consists of 4 stages, a large particle pre-filter, medium pre-filter, a medical grade HEPA filter and a high efficiency gas arrestance carbon cloth to reduce air pollution in homes.
215094944|NCT07087873|DEVICE|Neuroelectrical modulation group|Participants received transcranial electrical stimulation using the Spanish Neuroelectrics StarStim 32 device.
214395938|NCT00514605|OTHER|Behavioral counseling|Standard-of-Care counseling at the Point-of-Care.
214395939|NCT00514605|DEVICE|HIV-1 Antibody Test Kit|Assay to detect HIV antibodies
214395940|NCT00772798|DRUG|Paclitaxel, Carboplatin and Vorinostat|Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
215094945|NCT07087873|DEVICE|Pseudo-neuromodulation group|Pseudo-stimulation is performed using the same equipment and procedures as in the neuromodulation group.
215094946|NCT02209974|DRUG|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
215001213|NCT07114991|BEHAVIORAL|E-Bike Commuting|Participants in the intervention group will receive a pedal-assist electric bicycle (e-bike), a helmet, safety training, and a cycling computer. They will be asked to use the e-bike for commuting or personal travel at least four times per week for 12 weeks. E-bike usage will be monitored using a Garmin Edge device. Participants will also complete baseline, 12-week, and 24-week assessments including fitness testing, blood tests, body composition, surveys, and wearable activity monitoring.
215001214|NCT07115173|DRUG|This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.|This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.
214395941|NCT01043731|PROCEDURE|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
214395942|NCT01635894|BEHAVIORAL|Training|Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
214395943|NCT01305356|DEVICE|Augment® Injectable Bone Graft|Implantation of up to 9cc of Augment® Injectable Bone Graft
214395944|NCT01305356|PROCEDURE|Autologous bone graft|Implantation of up to 9cc of autologous bone graft
214395945|NCT01409174|DRUG|Ipilimumab|"Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.~Phase II dose: Maximum tolerated dose (MTD) from Phase I."
214395946|NCT01409174|DRUG|Temozolomide|200 mg/m\^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
214395947|NCT01409174|DRUG|Cisplatin|25 mg/m\^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
214395948|NCT01409174|DRUG|Interferon Alfa-2b|5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
214395949|NCT01409174|DRUG|Interleukin-2|9 million IU/m\^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
214395950|NCT01697761|OTHER|Treatment Group|patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
214395951|NCT01697761|OTHER|Control Group|patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
214395952|NCT02152436|OTHER|Simulation - based curriculum|Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
214395953|NCT00337415|DRUG|MK0354|
215001215|NCT07114094|OTHER|Deprescribing Tool|"Deprescribing Tool will be used for medication review during patient consultation. The prescriber will be encouraged to refer to the tool for medication review of elderly patients aged ≥ 60 years and take deprescribing decision if indicated.~Deprescribing may take place in any of the following ways-~1. Immediate discontinuation of a drug, e.g., a duplicate drug~2. Initiation of gradual tapering of a drug e.g., an anxiolytic, which is no longer indicated~3. Reduction in dose of a drug, e.g., lower dose of an NSAID for relief of symptoms of rheumatoid arthritis Only 1-3 medicines will be deprescribed at a time. Medicines with overlapping indications will not be deprescribed at the same time so it is clear which medicine is responsible if withdrawal effects occur."
214395954|NCT02772250|BEHAVIORAL|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by one investigator at 15:00-17:00 on the day before colonoscopy.
214395955|NCT02772250|BEHAVIORAL|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
214395956|NCT03437798|OTHER|Disease status|Women who reported periodontal disease diagnosis/condition
214503047|NCT01961063|BIOLOGICAL|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
214503048|NCT01961063|OTHER|pharmacological study|Correlative studies
214503049|NCT01961063|OTHER|laboratory biomarker analysis|Correlative studies
214503050|NCT05621174|DRUG|Dexamfetamine|Magisterial Dexamfetamine
215001216|NCT07114848|DRUG|Tamsulosin|Tamsulosin 0.4 mg once daily for 14 days
215001217|NCT07114848|DRUG|solifenacin|Solifenacin 5 mg once daily for 14 day
214503051|NCT05621174|DRUG|Dexamfetamine|Tentin
214503052|NCT03445689|OTHER|Assessment of oxygenation instability|Recordings of SpO2 and heart rate will be analyzed by dedicated software to obtain frequency, duration and severity of episodes of hypoxemia and hyperoxemia.
214503053|NCT03445689|OTHER|Determination of mechanisms of hypoxemia episodes|Recordings of SpO2, heart rate, esophageal pressure, tidal volume, minute volume, respiratory rate and transcutaneous PCO2 will be analyzed to determine the prevalence, severity and duration of hypoxemia episodes produced by the different mechanisms.
214503054|NCT03445689|OTHER|Assessment of respiratory instability|Recordings of tidal volume, minute volume and respiratory rate will be analyzed to determine frequency of apnea, periodic breathing, distribution of inter-breath intervals.
215094947|NCT02209974|DRUG|Inhaled Placebo|
215001218|NCT07113925|DRUG|TQB2101 for Injection|TQB2101 for Injection is an ROR1 ADC, an antibody-drug conjugate. It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.
215001219|NCT07115030|BEHAVIORAL|PCT+2HOPE|"Each PCT+ group follows the same structure and starts with the group setting an agenda. Clients identify issues to work on using these steps: 1) Identify an issue and if/how it relates to their PTSD or substance use, 2) Brainstorm ideas that may help, 3) Evaluate how useful each idea is, and 4) Choose a plan. Clients are encouraged to implement and evaluate the effectiveness of the plan and share the outcome at their next group. At the end of the group, clients process their experiences of the discussion.~HOPE is a flexible, module-based individual treatment where the ordering and emphasis of each module are determined by client priorities. HOPE is trauma-focused; clients relate their current symptoms to their experience of IPV, but do not process traumatic memories. Modules focus on 1) Establishing safety, providing information and skills that enhance empowerment, 2) Cognitive behavioral therapy skills, and 3) Improving relationships and establishing healthy boundaries."
215001220|NCT07114757|PROCEDURE|Renal denervation after stroke|Renal sympathetic denervation (RDN) is a minimally invasive catheter-based procedure targeting renal sympathetic nerve fibers to achieve sustained reductions in blood pressure.
215001221|NCT07115017|DRUG|[18F] FZTA|Participants will receive a single intravenous bolus injection of 7 ± 20% milliCurie (mCi) of the investigational radiotracer \[18F\]-FZTA. Participants will then undergo a brain \[18F\]-FZTA PET scan
215001222|NCT07114718|DEVICE|Ductus Arteriosus Stent|The eligible subjects will proceed to implantation of the Lifeline Ductus Arteriosus Stent to maintain patency of the PDA.
214503055|NCT03445689|OTHER|apneic threshold of CO2|In mechanically ventilated infants the apneic threshold of CO2 will be measured by transcutaneous PCO2 following a step wise increase in ventilator rate until spontaneous breathing ceases transiently. In spontaneously breathing infants the apnea threshold of CO2 will be measured during episodes central apnea.
214503056|NCT03445689|OTHER|Assessment of peripheral chemoreceptor function|The Dejours test will be used to assess peripheral chemoreceptor function by measuring the immediate ventilatory response to high-inspired oxygen.
215001223|NCT07114913|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
214503057|NCT03445689|OTHER|Assessment of central chemo-receptor function|Central chemo-receptor function will be assessed by measuring the ventilatory response to inspired CO2.
215001224|NCT07114913|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
215001225|NCT07114913|DIAGNOSTIC_TEST|Pressure pain threshold|Pain pressure threshold is used to measure deep muscular tissue pain sensitivity.
215001226|NCT07118384|DRUG|Cefoperazone-sulbactam injection|Two grams of Cefoperazone/sulbactam IV are administered every 8 hours, and each dose is administered as an extended infusion over 4 hours. The solution is diluted with a compatible solution (normal saline 0.9%) with a maximum final concentration of 250 mg/ml
215001227|NCT07118384|DRUG|Ampicillin - Sulbactam Injection|Two grams of Ampicillin/sulbactam IV are administered every 8 hours, and each dose is administered as an extended infusion over 4 hours. The solution is diluted with a compatible solution (normal saline 0.9%) with a final concentration not exceeding 45mg/ml.
215001228|NCT07115381|BEHAVIORAL|Therapeutic Horticulture|Therapeutic Horticulture uses plant cultivation and related gardening activities as the medium of action, allowing patients to participate in gardening activities such as planting, maintenance, and harvesting of plants.
215094948|NCT04670783|PROCEDURE|Surgery|Orthopedic surgery (i.e. tenotomy, tendon transfer) or percutaneous neuroablative procedures (i.e. cryoneurotomy) which will be done for upper limb refractory spasticity after being triaged by DNB.
215094949|NCT03144869|BEHAVIORAL|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
215094950|NCT00676910|DRUG|JNJ-26854165|
215094951|NCT02214745|OTHER|Questionnaire|Questionnaire developed for this purpose by the investigators
215094952|NCT02707796|PROCEDURE|Hemicolectomy|
215094953|NCT00562562|OTHER|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
214503058|NCT05655949|DRUG|Gemcitabine|Intravenous infusion
214503059|NCT05655949|DRUG|Cisplatin|Intravenous infusion
214503060|NCT05655949|DRUG|Durvalumab|Intravenous infusion
214503061|NCT05655949|RADIATION|Yttrium-90|Injection of radiation microsphere beads
214503062|NCT05908773|DRUG|TTX-MC138-NODAGA-Cu64|TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging.
214503063|NCT04380805|BIOLOGICAL|AK104|All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.
214503064|NCT03869476|DIAGNOSTIC_TEST|Non-invasive diagnosis score|"* spleen fibrosis by elastography~* plasma cytokines levels~* mutationnal landscape by NGS~* CD34 circulating cells"
215001229|NCT07115381|OTHER|Routine treatment and nursing|The conventional treatment mainly involves the use of antidepressant drugs, supplemented by physical therapy, psychological therapy, and rehabilitation training, etc. The routine care includes admission introduction, health education (manifestations, hazards, treatment methods of depression and non-suicidal self-harm, as well as the importance of following medical advice for treatment), medication guidance, discharge guidance, and psychological care, etc.
215001230|NCT07117721|PROCEDURE|Endoscopic Band Ligation (ENDOBAND-DM)|Endoscopic band ligation of the second through fourth parts of the duodenum, from just distal to the ampulla of Vater to the ligament of Treitz. The aim is to induce localized mucosal remodeling that may enhance enteroendocrine signaling (GLP-1, GIP) and improve glycemic control in patients with type 2 diabetes mellitus.
215001231|NCT07113665|DEVICE|ExAblate Neuro 4000|The ExAblate Neuro 4000 is an MRI-guided focused ultrasound (MRgFUS) system designed to perform noninvasive thermal ablation of targeted brain tissue. In this study, the ExAblate Neuro 4000 will be used to perform a bilateral capsulotomy by ablating the anterior limb of the internal capsule (ALIC) in patients with treatment-refractory anorexia nervosa (AN) and comorbid obsessive-compulsive disorder (OCD) and/or major depressive disorder (MDD). The procedure will be conducted under real-time MRI guidance and thermometry to ensure accurate targeting and controlled thermal delivery. This study aims to evaluate the safety, feasibility, and preliminary clinical benefit of MRgFUS in improving psychiatric symptoms and quality of life in this patient population.
215001232|NCT07116174|BIOLOGICAL|Xcell Amnio Matrix|A lyophilized amniotic membrane allograft
215001233|NCT07116395|DRUG|Tranexamic Acid (TXA)|orthopedic trauma patients who are on anticoagulation
215001234|NCT07117175|DRUG|Anti-human CD7 CAR-NK cell injection|Administer anti-human CD7 CAR-NK cell injection on D0
215001235|NCT07104110|DRUG|QLH12016|oral AR PROTAC
215001236|NCT07104110|DRUG|abiraterone acetate|oral CYP17 inhibitor
215001237|NCT07104110|DRUG|enzalutamide|oral androgen receptor inhibitor
215001238|NCT07121127|COMBINATION_PRODUCT|FSN+Vitamin supplement|Fu's subcutaneous needling with oral Vitamin C and vitamin E supplements
215001239|NCT07121127|DRUG|Vitamin Supplements|oral Vitamin C and vitamin E supplements
215001240|NCT07121257|DEVICE|VENTIJET system|The Ventijet system is an investigational ventilation device delivering continuous high-velocity gas flow through a proximal nozzle. The system is designed to maintain alveolar recruitment with low driving pressures, acting as an expiratory brake. Patients received continuous flow ventilation using Ventijet for 1 to 24 hours after baseline assessment with conventional mechanical ventilation.
215001241|NCT07121231|OTHER|Motor Support Program|The MSP was implemented over 12 weeks, two days a week, 50 minutes per session. Based on pre-test results, 30% (15 minutes) of each session was devoted to individualized activities, and 70% (35 minutes) to group activities supporting peer interaction. This structure allowed for both personalized support and social engagement. The program was carried out by the research team and eight special education teachers at the children's rehabilitation centers. Each child received one-on-one support from at least one teacher. Activities were aligned with preschool motor development goals and followed a four-phase structure: (1) Warm-up (5 min): rhythmic movements (e.g., walking, running, jumping); (2) Preparation (5 min): functional exercises for flexibility and joint mobility; (3) Main activity (35 min): individual and group exercises to enhance motor, social, and pre-academic skills; (4) Cool-down (5 min): group games reinforcing learned skills and social interaction.
215001242|NCT07119619|PROCEDURE|Regenerative Endodontic Treatment Using a Blood Clot as a Scaffold|During the initial visit, the teeth were anesthetized using inferior alveolar block anesthesia. The endodontic access cavity was then opened. Each canal was irrigated with 2.5% NaOCl and saline. The canals were dried with paper points. Ca(OH)2 was placed in the canals with the objective of achieving an antimicrobial effect. After the application of root canal disinfectant, the opened cavity was sealed with a temporary filling material.The patient has been scheduled for a follow-up appointment within one to four weeks. During the second appointment, local anesthesia was performed using an anesthetic agent that did not contain a vasoconstrictor. The canals were irrigated with 17% EDTA and dried with paper points. Bleeding was induced by instrumentation with a K-type file, at 2 mm past the apical foramen, thus creating a blood clot within the canal. MTA was applied on the scaffold as capping material.
215001243|NCT07119619|PROCEDURE|Regenerative Endodontic Treatment Using a Chitosan as a Scaffold|"During the initial visit, the teeth were anesthetized using inferior alveolar block anesthesia. The endodontic access cavity was then opened. Each canal was irrigated with 2.5% NaOCl and saline. The canals were dried with paper points. Ca(OH)2 was placed in the canals with the objective of achieving an antimicrobial effect. After the application of root canal disinfectant, the opened cavity was sealed with a temporary filling material. The patient has been scheduled for a follow-up appointment within one to four weeks.~During the second appointment, local anesthesia was performed using an anesthetic agent that did not contain a vasoconstrictor. The canals were irrigated with 17% EDTA and dried with paper points.Chitosan in gel form was placed into the root canal space with the help of an injector.MTA was applied on the scaffold as capping material."
215001244|NCT07119619|PROCEDURE|Regenerative Endodontic Treatment Using a Platelet Rich Fibrin as a Scaffold|During the initial visit, the teeth were anesthetized using inferior alveolar block anesthesia. The endodontic access cavity was then opened. Each canal was irrigated with 2.5% NaOCl and saline. The canals were dried with paper points. Ca(OH)2 was placed in the canals with the objective of achieving an antimicrobial effect. After the application of root canal disinfectant, the opened cavity was sealed with a temporary filling material.The patient has been scheduled for a follow-up appointment within one to four weeks. During the second appointment, local anesthesia was performed using an anesthetic agent that did not contain a vasoconstrictor. The canals were irrigated with 17% EDTA and dried with paper points.Ten milliliters of venous blood was collected from the patient and immediately placed in a centrifuge at 3000 rpm for 10 minutes. The prepared PRF was placed in the canal space. MTA was applied on the scaffold as capping material.
215001245|NCT07119749|OTHER|Stable isotope tracer consumption|Daily consumption of oral deuterium oxide (0.3 ml per kg of lean body mass) to equilibrate in body water and become slowly incorporated into muscle protein, enabling measurement of muscle protein synthesis rates
214395957|NCT06373848|DRUG|Receive 30 mg of Coq10|A total of 120 individuals diagnosed with chronic periodontitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a daily dose of Coq10 at 30 mg, while Group B received a daily dose of Vitamin E at 400 mg; Furthermore, group C did not receive any supplements. The periodontal examination involved a total of 300 teeth across the three groups. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total antioxidant capacity and determine if there were any changes over time.
214503065|NCT06518486|OTHER|Foot-ankle exercise|Foot-ankle exercise group will receive usual care provide by public health center and intervention through health education, leaflets, and videos about foot-ankle exercise. At the first meeting, participants will be taught how to do foot exercises and practice them in front of the instructor. Afterwards, participants will practice foot exercises independently without supervision for 12 weeks. One foot exercise session takes 10-15 minutes, while the physical activity target is for participants to fulfil a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do foot exercises for 2-3 sessions every day. The minimum duration of each session is 10 minutes, and two consecutive days without foot exercise are not allowed. Participants are asked to document all foot exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for ±5 minutes/week.
214503066|NCT06518486|OTHER|Walking exercise|Participants in the walking exercise group will receive usual care provide by public health center and intervention through health education and leaflets about walking exercise. Participants will practice walking exercises independently without supervision for 12 weeks. Participants walked at the same speed as they did every day. The physical activity target to be achieved is for participants to be able to engage in a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do walking exercises with a minimum duration of 10 minutes for each session. Two consecutive days without walking exercise are not allowed, and a minimum of 150 minutes/week is allowed. Participants are asked to document all walking exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for ±5 minutes/week.
214503067|NCT06518486|OTHER|Usual care and health education|Participants in the control group will receive the usual care provided by the community health center and intervention in the form of health education about DM in general.
214503068|NCT05253781|DRUG|Low-dose aspirin|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
214503069|NCT05253781|OTHER|Placebo|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
214503070|NCT06017505|DIAGNOSTIC_TEST|electronic self administered gerocognitive examination (eSAGE)|A self-administered digital assessment that evaluates multiple cognitive domains: orientation, language, memory, executive function, calculations, abstraction, and visuospatial abilities, through multiple questions. Additionally, it includes the collection of six clinical variables: education, gender, race, family history of dementia, stroke, and emotion.
214503071|NCT02294461|DRUG|Enzalutamide|Oral
214503072|NCT02294461|DRUG|Placebo|Oral
214503073|NCT00237016|DRUG|doxycycline treatment|
214503074|NCT06464016|DEVICE|Ventricular Assist Device with Berlin Heart EXCOR|"The Berlin Heart® EXCOR is a type of artificial heart pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body."
214503075|NCT06470503|BEHAVIORAL|Exercise Program|8-week program and four-week short maintenance period.
214503076|NCT05326646|DIETARY_SUPPLEMENT|Low FODMAP diet|After the realisation of a wireless motility capsule, patients will underwent 6 weeks of low FODMAP diet after dietician education. Symptomatic scores (IBS-SSS, GIQLI, HAD) and stools samples (metabolomic and lipidomic) will be performed before and after the low FODMAP diet.
214395958|NCT00675727|BIOLOGICAL|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
214395959|NCT06424379|OTHER|Histopathological analysis|"Morphological analysis will include the description of architectural patterns and cytological features on formalin-fixed and paraffin-embedded (FFPE) tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud.~A panel of immunohistochemical staining will be analyzed including CD20, CD3, CD10, Bcl-6, Bcl-2, CD5, CD23, CD38, MUM1, Ig kappa, Ig lambda, MEF2B, LMO2, MNDA, IRTA1, P53, CMYC and Ki67 . /MIB1. Diffuse large B-cells lymphomas will be classified into two distinct subgroups: centro-germinative (GC) and non-centro-germinative (nGC), using the Hans algorithm."
214503077|NCT04153682|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples
214503078|NCT04153682|DIAGNOSTIC_TEST|Antimicrobial stewardship|After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
214503079|NCT03508232|DRUG|Placebo|Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
215001246|NCT07119749|RADIATION|DXA scan|Whole body DXA scan to assess lean body mass for prescription of deuterium oxide tracer
215001247|NCT07119749|BEHAVIORAL|Controlled diet|Participant will be asked to consume a provided 6-day diet package that will be prepared by the research team. This package will include 3 meals per day plus snacks
215001248|NCT07119749|OTHER|Saliva sample|Obtained from participants by asking them to spit into a tube each day during the study, for 11 days in total.
215001249|NCT07119749|OTHER|Blood sample|Resting venous blood sample from a forearm vein on 6 separate occasions
214395960|NCT06424379|GENETIC|Molecular analysis|"Next-generation sequencing (NGS) analysis will be performed on FFPE tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud. A panel of 73 genes dedicated to lymphoma diagnosis determined by a consensus of French Lysa experts will be used. The identification of genetic variants will be followed by the attribution of pathogenicity class in accordance with the guidelines for validation of NGS-based oncology panels.~RNA extraction will classify DLBCLs into two distinct subgroups: germinal-centre B-cell-like (GCB-DLBCL) and activated B-cell-like (ABC-DLBCL)."
214395961|NCT04485780|BIOLOGICAL|botulinum toxin type A|In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.
214395962|NCT05536427|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
214395963|NCT05205447|DRUG|LY3410738|Oral LY3410738
214395964|NCT05205447|DRUG|Itraconazole|Oral Itraconazole
214395965|NCT05205447|DRUG|Carbamazepine|Oral Carbamazepine
214395966|NCT04234243|PROCEDURE|cytoreduction and HIPEC|cytoreduction CCR 0-1, and HIPEC close technique
214395967|NCT05572151|PROCEDURE|lymph node number|Lymph nodes were harvested during surgical resection of rectal cancer
214395968|NCT00839228|DRUG|Perhexiline|100mg o bd for 3 months
214503080|NCT03508232|DRUG|Doxycycline Hyclate|Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.
214503081|NCT05432986|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
214503082|NCT06075121|OTHER|Abdominal massage|Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening. Enteral nutrition will be interrupted twice a day for 5 days, between 09.30-10.00 in the morning and 21.30-22.00 in the evening, and patients will receive an abdominal massage for 15 minutes.
214503083|NCT05791227|DIAGNOSTIC_TEST|Sonographer Evaluation|A sonographer will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
215001250|NCT07119749|PROCEDURE|Muscle biopsy|A highly experienced researcher will sample a small section of muscle (\~200 mg) from the vastus lateralis muscle under local anaesthetic (5 ml, 1% Lidocaine)
214503084|NCT05791227|DIAGNOSTIC_TEST|AI Evaluation|An AI model will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
214503085|NCT05581953|OTHER|Omnivorous|Pork-added plant-forward diet
215001251|NCT07119749|BEHAVIORAL|Resistance exercise|participants will complete 8 sets of 10 repetitions of unilateral eccentric knee extensions on an isokinetic dynamometer.
215001252|NCT07119749|OTHER|Isometric strength test|Bilateral isometric strength will be measured using a well-established protocol on an isokinetic dynamometer.
215001253|NCT07119749|DIETARY_SUPPLEMENT|Supplement|Consumption of 3 supplements a day for 3 days following resistance exercise. All supplements are commercially available.
215094954|NCT03779503|DEVICE|midafilcon A|midafilcon A 1 day daily disposable contact lens
214395969|NCT00839228|DRUG|Placebo|Placebo one tablet bd for 3 months
214395970|NCT03677024|PROCEDURE|SLN arm|Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
214395971|NCT01330043|DRUG|Bupropion|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
214395972|NCT01330043|DRUG|Nicotine patch|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
214503086|NCT05581953|OTHER|No meat|Plant-forward no meat
214503087|NCT03753555|DRUG|Atorvastatin Calcium|20mg Qd for 12 months
214503088|NCT03753555|DRUG|Atorvastatin Calcium|40-80mg Qd for 6 months
214503089|NCT03753555|DRUG|Probucol|0.5g Bid for 6 months
214503090|NCT03753555|DRUG|PCSK9 inhibitor|Evolocumab 140mg subcutaneously injected, twice each month
214503091|NCT03357562|DEVICE|lung MRI|lung MRI without contrast injection
215001254|NCT07120659|OTHER|soft touch massage|Soft superficial massage which follows the anatomy of the body without penetrating into the deeper tissues
215094955|NCT03779503|DEVICE|somofilcon A|somofilcon A 1 day daily disposable contact lens
215094956|NCT03393507|DRUG|Apatinib|500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
215094957|NCT03393507|DRUG|Taxus + platinum|Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time\> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
214503092|NCT06027996|DEVICE|Absorbable Antibacterial Matrix|Soft tissue support coated with antibiotics
214503093|NCT02200276|BIOLOGICAL|Influenza|
215001255|NCT07120659|OTHER|vacuum massage|Intense stimulation through suction of the skin and deeper layers
215001256|NCT07119671|OTHER|HOPAIR Intervention: Meeting between Peer Helper and Concerned Individual in Psychiatric Crisis Unit|This intervention begins with an initial discussion focused on the individual's lived experience, followed by an explanation of the Hope Box's principle, utility, and use. After each intervention, the peer supporter will complete a satisfaction self-questionnaire to provide feedback.
215001257|NCT07117656|BEHAVIORAL|Project Vuselela|A four session intervention with people who inject drugs and family members. Delivered three group sessions and one dyad session. Session content designed to improve coping and communication skills that will in turn improve treatment outcomes.
215001258|NCT07117851|DRUG|Disitamab Vedotin combined with Bicalutamide|Single Group Assignment
215001259|NCT07118865|OTHER|Online Pilates exercise|Participants will be asked to do their Pilates practice while watching the videos (not from memory) to ensure that they are performing techniques optimally. Each module lasts 25 minutes, but includes some resting activities so modules are not vigorous or fatiguing for most people. Nonetheless, subjects will be instructed to omit activities that they feel they cannot do safely. Participants can pause a session to add more rest breaks, if needed, or stop and complete a session later. Participants will attempt to do 3 Pilates modules per week, for a total of 75-90 minutes/week (depending on the exact length of the modules they do).
215001260|NCT07117682|DEVICE|Autologous Adipose-Derived Regenerative Cells (ADRCs) Intraovarian Injection|Under general anesthesia, patients undergo lower abdominal liposuction (aspirate: 100-360 mL). ADRCs are immediately prepared bedside using the Celution® system (Cytori Therapeutics): Lipoaspirate is processed in a sterile container with automated separation, centrifugation, and resuspension (90-120 min). From the 5mL ADRCs suspension obtained, 0.5mL is reserved for QC (cell count/viability/surface markers); 4.5mL is injected bilaterally into ovarian stroma (2-2.5mL/ovary). Post-procedure, patients are monitored supine for 30 min for local/systemic reactions before discharge if stable.
215001261|NCT07117071|OTHER|collection of medical data|collection of medical data : Age, Sex, Previous cataract surgery, Cellularity, Dermatological pathology, results of screening of Fuchs endothelial corneal dystrophy by Specular microscopy
215001262|NCT07117747|OTHER|Healthy volunteers|All subject belong to the same arm and ther is no intervention
215001263|NCT07119411|OTHER|ICU Beacon|Availability of a proprietary clinician awareness for potential organ deterioration software to treating clinicians (ICU Beacon) in addition to the standard of care.
215001264|NCT05911269|OTHER|TiMBRe|"1 \& 2 Music Listening~* Live music played by the music therapist (e.g., guitar, voice) and AYA selected music will be used to facilitate attention to the present moment and provide cues for breathing/relaxation.~  3 \& 4 Music Facilitated Breathing~* The therapist will lead participants in music facilitated breathing exercises using rhythmic features of the music to cue structured breathing for relaxation and self-awareness~  5 \& 6 Music Facilitated Progressive Muscle Relaxation for Stress Reduction~* Using music as a structured auditory cue for tensing and releasing of muscles.~  7 Body Percussion~* The therapist will lead participants in a hands-on body percussion activity to bring attention to the sound of rhythm, sensation in their hands and body.~  8 Participants Choice~* will be selected by the participant."
215094958|NCT00994591|DRUG|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
214503094|NCT06269263|BEHAVIORAL|Home-based cardiac rehabilitation|Guided by physiotherapists, patients will receive different trainings regrading endurance/balance/resistance,/coordination at home
215001265|NCT05911269|OTHER|Control|Standard of care study staff calls and cancer survivorship resources
215001266|NCT07121881|DEVICE|Bar Attachment|A bar attachment supported by three mandibular implants (placed in the midline and canine regions) is used to retain a mandibular overdenture. The bar provides rigid splinting across the implants and allows retention using friction or clips, without additional attachment components. This serves as the control group.
215001267|NCT07121881|DEVICE|Bar with OT Equator Attachment|A bar attachment supported by three mandibular implants is combined with two OT Equator attachments to enhance denture retention and allow slight vertical and rotational resilience. The OT Equator system includes metal housings and retentive nylon caps, intended to reduce cap wear and improve patient comfort. This is the experimental arm.
215001268|NCT07123714|PROCEDURE|Nebulization of magnesium sulfate|patient will be nebulized with 5 mg magnesium sulfate (5 ml) 15 minutes before induction of anesthesia
215001269|NCT07123233|BEHAVIORAL|Pain Reprocessing Therapy|"One cohort of 30 patients (PRT+TAU group) will receive eight sessions of Pain Reprocessing Therapy (PRT) in addition to Treatment-as-Usual (TAU). PRT is a cognitive-behavioral-inspired approach aimed at helping patients reinterpret chronic pain as brain-generated rather than structurally caused.~A second cohort of 30 patients (TAU group) will undergo the same assessment phases but will receive only Treatment-as-Usual without PRT.~Use this module to add a description of each group or cohort in the study and to list any interventions of interest."
215001270|NCT07123233|BEHAVIORAL|Usual Therapy|Patients undergo yhe usual pharmacological tretment as prescrived by neurologist
215001271|NCT05988190|BEHAVIORAL|Contextual Word Learning Intervention|Metalinguistic intervention consisting of meaning generation, explanation and feedback, with semantic diversity varying (no, medium, high).
215001272|NCT07105085|PROCEDURE|living donor liver transplantation|other intervention cannot be applied.
215001273|NCT07120178|OTHER|slit lamp examination|data collected: tumor size, pigmentation, vascularization, cells
215001274|NCT07120178|OTHER|dermatoscopy examination x20 and x400|data collected: tumor size, pigmentation, vascularization, cells
215001275|NCT07120178|OTHER|confocal microscopy examination|data collected: tumor size, pigmentation, vascularization, cells
215094959|NCT07088432|DRUG|Dexamethasone|Single intravenous injection of 8 mg dexamethasone (2 mL) administered 5 minutes before spinal anesthesia. This intervention was tested for its effect on prolonging the duration of sensory and motor blocks induced by hyperbaric bupivacaine combined with sufentanil. The drug was administered under sterile conditions by an anesthesiologist blinded to group allocation.
215121399|NCT00989001|DRUG|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
215121400|NCT00989001|DRUG|Placebo|Injection
215121401|NCT05020509|PROCEDURE|medial branch block|lumbar medial branch block
214503095|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
214503096|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
215001276|NCT07120698|DRUG|Sintilimab|"Patients who met the inclusion criteria were treated with adaptive adjuvant sintilimab therapy guided by MRD.~Patients should test twice at postoperative days 3 to 7 and again at postoperative day 28 (±3 days). The results of these two tests will be used to determine the subsequent treatment pathway. Participants with two consecutive positive MRD tests or a single positive MRD test will be enrolled in the MRD+ treatment cycle：they will receive adjuvant treatment with sintilimab (200 mg, intravenous infusion, every 3 weeks). Follow-up visits will be conducted every 3 months, during which chest CT scans and MRD testing will be performed. If MRD becomes negative, treatment will be discontinued and the participant will be monitored. If MRD remains positive, treatment with sintilimab will continue.~Participants with two consecutive negative MRD tests will be enrolled in the MRD- treatment cycle：they will undergo follow-up observation only. Follow-up visits will be conducted every 3 months"
215001277|NCT07116616|DRUG|mRNA-2808|intravenous
215001278|NCT06937476|DRUG|Escitalopram|Escitalopram will be administered orally at a fixed dose of 20 mg/day for 8 weeks. This SSRI antidepressant is used as baseline pharmacological treatment for patients with major depressive disorder (MDD), either as monotherapy or in combination with aripiprazole. No other psychotropic medications are allowed during the study period.
214395973|NCT01330043|DRUG|Varenicline|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
214395974|NCT01290016|BEHAVIORAL|2 servings dairy + exercise|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
214395975|NCT01290016|BEHAVIORAL|4 servings dairy + exercise|Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.
214395976|NCT01290016|BEHAVIORAL|Control|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
214395977|NCT06117995|OTHER|Assessment the pre-washed sperm motility before IUI|The pre-washed sperm motility will be assessed by using WHO 2021 guidelines, stratified into four groups.
214395978|NCT06493500|DRUG|Eggshell derived Nano-hydroxyapatite (n-HAp) with a Fluoride containing toothpaste|patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
214395979|NCT06493500|DRUG|Eggshell derived Nano-hydroxyapatite (n-HAp) without a Fluoride containing toothpaste|patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
214503097|NCT05649137|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
215001279|NCT06937476|DRUG|Aripiprazole 5mg|Aripiprazole will be administered as an adjunctive treatment to escitalopram at an initial dose of 2.5 mg/day, titrated up to 5 mg/day based on tolerability. Treatment will last 8 weeks, after which aripiprazole will be tapered and discontinued. This intervention aims to evaluate the efficacy of dopaminergic augmentation in reducing pathological rumination symptoms.
215001280|NCT06766292|PROCEDURE|primary intervention|In the study group: 2.0 mm screws were fixed to the lateral wall of the sinus above the superior osteotomy and placed buccopalatally where the schneiderian membrane was elevated and maintained. this technique will suspends the membrane in position to allow the blood clot to organized and formation of bone.
214395980|NCT06174974|OTHER|Education|The education was designed to cover the environmental stressors of the intensive care unit and the practices performed to reduce these stressors. The education content was created according to the Activities of Daily Living (ADL) Theory based on the institution's cardiovascular surgical intensive care unit protocols (Cardiovascular surgical intensive care unit visitor entry-exit rules information form) and the literature (included at the end of the presentation). Expert (intensive care nurses, ward nurses, cardiovascular surgeons and academic nurses) opinions were obtained. Patient-friendly and simple language was used to ensure that the content of the information presentation was acceptable and interesting.
214395981|NCT06478823|OTHER|Stools donation|"Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects.~Donors will be followed from their selection until 6 months after their last valid stool donation."
214395982|NCT04443920|DRUG|Tranexamic acid (TXA)|Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
214395983|NCT04443920|DRUG|Placebo Normal Saline (NS)|Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
214503098|NCT03997786|DRUG|Tildrakizumab|Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
214503099|NCT03997786|DRUG|Placebo|(Weeks 0 to 16)
214503100|NCT03997786|DRUG|Tildrakizumab|(Weeks 16 to 52)
214395984|NCT05656313|DEVICE|Measures of speech intelligibility in a noisy situation with speech from the side and from behind (measured with CC-OLSA Test)|"The Concurrent OLSA test (CC-OLSA) is a speech recognition test with three turn-taking talkers presenting sentences of the Oldenburg sentences test at fixed signal-to-noise ratios.~CC-OLSA is the only one-talker-at-a-time speech test that is sensitive at the desired SNR and uses sentences with an intelligibility function with slopes of 10-17 %/dB."
214395985|NCT05656313|DEVICE|Measures of the subjective speech recognition threshold in a noisy situation with speech from the side and from behind (measured with HEISS test)|The measure of the subjective speech recognition threshold is an alternative procedure to evaluate the subjective speech intelligibility in different listening conditions. The subjective speech recognition threshold is defined as the speech presentation level of running speech needed to just follow conversation. Subjects have to adjust the presentation level of speech so that they are just able to understand the speech, using a slider on a touch screen. This adjustment is repeated 10 times. Each adjustment results in a value for the subjective speech recognition threshold in dB SNR. The outcome measure is the mean value of the 10 repetitions. The HEISS-Test will be repeated four times for the secondary objective: test for 2 test conditions (Reference, novel approach) against 2 target directions (better ear side, back).
214395986|NCT05656313|DEVICE|Ability to multitask in the auditory and visual domains in noisy situation with speech from the side and from behind (Multitask test)|This test uses a dual-task-paradigm assessing vigilance for auditory and visual triggers concurrently. The primary task is to listen to a novel (Harry Potter) and respond on two trigger words by pressing the appropriate button (one in each hand). The secondary task is to observe a monitor showing a sequence of random signs and respond on a target sign by pressing both buttons. The test includes at least 100 triggers (50 auditory, 50 visual) and takes 10 minutes per condition (side vs. back; novel approach vs. reference; 40 minutes in total). The multitask test will be repeated four times for the secondary objective: 2 conditions (Refrence, novel approach) against 2 target directions (better ear side, back). Following data are provided from each multitask Test measure: (1) subjective rating of the perceived ability to perform the visual and the auditory test simultaneously. (2) reaction times to auditory and visual tasks, and (3) accuracy.
214503101|NCT03997786|DRUG|Tildrakizumab|at every 12 weeks in open label fashion till 5 years (240 weeks).
214503102|NCT03997786|DRUG|Tildrakizumab|(Weeks 0 to 16)
214503103|NCT03997786|DRUG|Etanercept|(Weeks 0 to 16)
214503104|NCT03997786|DRUG|Placebo|(Weeks 16 to 52)
215001281|NCT06766292|PROCEDURE|open sinus lifting with xenograft only|ll Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
215001282|NCT06142682|DEVICE|Cochlear Implant|cochlear implantation with dexamethasone eluting electrode
215001283|NCT06299761|DRUG|BBI-825|Oral RNR inhibitor
215001284|NCT06105437|OTHER|BE-EMPOWERed program|The BE-EMPOWERed program entails a group program for older people, workshops for healthcare professionals and a 6-steps implementation plan for primary care areas. The group program for older people is based on the main principles of the Australian multifactorial falls prevention program 'Stepping On'. The workshops for healthcare professionals focus on the multifactorial falls prevention approach, reimbursement of healthcare costs, referrals to other healthcare professionals and motivational interviewing. The Implementation plan consists of 6-steps: 1. enable support, 2. map baseline situation, 3. define objectives and priorities, 4. plan implementation, 5. implementation and 6. evaluation, adjust and work towards sustainability. Last, to support the primary care areas, implementation facilitators were trained.
215001285|NCT03850106|DIETARY_SUPPLEMENT|Placebo|Placebo
215001286|NCT03850106|DIETARY_SUPPLEMENT|Indus810|Active product
215001287|NCT05983406|DEVICE|Doppler investigation|Doppler investigation
215001288|NCT03869437|DRUG|Cefiderocol|2 grams intravenously administered over 3 hours every 8 hours for a period of 5 to 14 days (dosage adjustment is necessary based on renal function).
215001289|NCT03869437|OTHER|Best Available Therapy|Standard of care was determined by the investigator
215001290|NCT06002113|OTHER|GOCD Tool|Web-based tool with 4 components; pre-admission health status; current illness prognosis for hospital survival; in-hospital cardiorespiratory arrest prognosis; values and goals of care
215001291|NCT06002113|OTHER|Usual care|Attending physicians responsible for GOCD during hospitalization using their usual approaches
215001292|NCT05845593|OTHER|Decision Support Test|LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE
215001293|NCT06213974|OTHER|No Intervention|This is non-interventional study.
215001294|NCT02749955|BEHAVIORAL|PS-PrEP Intervention Group|This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.
215001295|NCT02749955|BEHAVIORAL|PrEPLine Control Group|This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
215001296|NCT05020912|DRUG|ALA|At first visit, ALA applied to one BCC lesion
215001297|NCT05020912|PROCEDURE|PDT|PDT with blue light (for 30 min (\~20 mJ/cm2))
215001298|NCT05944549|BEHAVIORAL|Financial coaching using TrustPlus|Participants will be assigned a financial coach, who will, prepare a budget, conduct a soft pull of their credit report and score to analyze the credit score. Based on the participant's goals and financial limitations as highlighted by the, the participant and financial coach will create a personalized financial action plan comprising of strategies, follow-up actions, and resources, which includes unlimited access to one-on-one sessions with the financial coach. After the intensive financial coaching, participants will maintain access to the TrustPlus Portal and can continue to connect with their financial coach as needed throughout the 6-month intervention period. Participants will also have ongoing access to educational webinars and Trust+Ed, an interactive resource that provides self-guided content on many financial topics of interest, such as credit building and debt management.
214395987|NCT05656313|DEVICE|Measure of subjective speech intelligibility and listening effort in noisy situation with speech from the side and from behind (subjective assessment; 100-point scale)|"In addition to the tests mentioned above a subjective assessment will be used to determine the subjective perception as this measure is often a good indication for clinical relevance.~For this purpose, the same speech material as used in the HEISS-test is presented by a loudspeaker in the same noisy environment as in the other three tests. The subjects rate his/her perception of the presented speech using a questionnaire on the dimensions listen effort and speech intelligibility. The subject will rate his perception on the 100 point scale with pencils with different colors to get either absolute and relative ratings.~The subjective assessment will be repeated four times for the secondary objective: 2 test conditions (Rference and novel approach) against 2 target directions (better ear side, back). Following data are provided from assessment: rating on a 100-point scale per condition and per dimension."
214395988|NCT04463082|PROCEDURE|Intravenous administration of fluids|Intravenous administration of fluids (20ml/kg, but the maximum volume will be limited up to 500ml) within 60 minutes.
214395989|NCT00002730|DRUG|buthionine sulfoximine|
214395990|NCT00002730|DRUG|melphalan|
214395991|NCT00936494|PROCEDURE|Cold ablation inferior turbinate reduction|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
214395992|NCT03685708|BIOLOGICAL|HEPLISAV-B|HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
214395993|NCT03988374|DRUG|Dentifrices|Dentifrice on plaque, gingivitis, and bleeding.
214395994|NCT05743192|OTHER|Stop performing an antibiotic susceptibility test|Intervention = Stop performing an antibiotic susceptibility test for enterococcus faecalis in urine cultures. It defines two groups : one before and one after the intervention
214395995|NCT05530967|OTHER|TT|"This intervention uses questionnaire at three-time intervals (i.e., days 5, 10, and 30) and abstraction of PAP use data (days 1 - 35). Consecutive adults with moderate-severe OSA and recommended to PAP treatment will be invited to the study. Once the patient has been prescribed PAP therapy a research associate will call the patient before receiving their new PAP device. The research associate will utilize an IRB approved telephone script to discuss study details, conduct eligibility screening (inclusion/exclusion criteria), and to ask whether the patient is interested in participating.~The research associate will then send the patient an IRB approved digital information sheet. The information sheet will provide the patient an option to mark Yes if they are willing to participate in the study or No if they are not willing. Patients who indicate their willingness to participate will receive the Triage Tool in accordance with the study protocol."
214395996|NCT05530967|OTHER|VE|A randomly selected sub-group of participants (n=30) will also receive an animated education video that provides targeted information and encouragement for self-managing your PAP problem(s). Patients in this sub-group will be asked to view a maximum of 2 different videos that are less than 2 minutes in duration. These videos are aligned with practice guideline recommendations for addressing PAP problems early in treatment. The videos will be sent digitally from Somnoware™.
214395997|NCT00627042|BIOLOGICAL|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
214395998|NCT00583180|DRUG|Capsaicin|instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.
215001299|NCT05944549|BEHAVIORAL|Brighter Bites|Families receive a weekly distribution of fresh fruits and vegetables for 24 weeks, there will be Nutrition education in school throughout the school year using the evidence-based CATCH (Coordinated Approach to Child Health) program and weekly healthy recipe tastings and cooking skill demos for families during produce pick-up time.Fruit and vegetable access is complemented by CATCH, an evidence based, Texas Education Agency-approved, coordinated school health program designed to promote healthy nutrition, physical activity, and prevent obesity in schoolchildren. In addition, the Brighter Bites website and mobile app are freely available in English and Spanish.
214395999|NCT03641833|DIAGNOSTIC_TEST|blood sample for brain biomarkers|Transcranial Doppler will be performed to evaluate a.cerebri media blood flow speed during surgery.
214396000|NCT01842243|PROCEDURE|Apical pacing|Pacemaker set to pace at right ventricular apex initially.
214396001|NCT01842243|PROCEDURE|Septal pacing|Pacemaker set to pace at right ventricular septum initially.
214396002|NCT01842243|DEVICE|Pacemaker|MR conditional Pacemaker implanted in all study patients
215094960|NCT07088432|DRUG|Placebo|Single intravenous injection of 2 mL isotonic saline (0.9% NaCl) administered 5 minutes before spinal anesthesia. This placebo was used to mimic the dexamethasone injection in the control group. The preparation, volume, and timing were identical to the intervention group to maintain blinding. The saline was administered under sterile conditions by an anesthesiologist blinded to group allocation.
215094961|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
214396003|NCT04499742|RADIATION|Using Isotope (Tc99m-Sulfur Colloid) to label glucose and administer this directly into duodenum.|Patients will be undergoing Standard of Care procedure EAGBT for collection of duodenal fluid (aspirate and culture) and placement of a catheter into the duodenum. This catheter will be used for infusion of glucose isotope into the small bowel. Subsequently Standard of Care nuclear medicine imaging will be used to track the location of the isotope in the gut.
214396004|NCT04963764|DRUG|Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (10 days)
214396005|NCT04963764|DRUG|Placebo|Participants will be randomized to receive oral placebo for a standard course (10 days)
214396006|NCT02557906|PROCEDURE|Breast reconstruction - implant and an ADM (SurgiMend)|Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
214396007|NCT02557906|PROCEDURE|Breast reconstruction- autologous tissue|Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
214396008|NCT02557906|PROCEDURE|Breast reconstruction- implant + dermal sling/LD flap|Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
214396009|NCT03993899|DEVICE|FineHearing strategy or HDCIS strategy|Cochlear implant with FineHearing strategy or HDCIS strategy
214396010|NCT00344370|DRUG|Pitavastatin|Pitavastatin 4 mg QD
214396011|NCT00344370|DRUG|Atorvastatin|Atorvastatin 40 mg
214396012|NCT03086915|DRUG|Neuromuscular Blocking Agent|Administration of neuromuscular blockers during anesthesia
214396013|NCT04980235|DIAGNOSTIC_TEST|transperineal 3D ultrasound|All ultrasound volumes were acquired 7days after delivery and another examination 6weeks post-delivery by one experienced sonographers using a GEVoluson p8 (GE Healthcare) equipped with a 4-8-MHz curved array 3Dultrasound transducer
214396014|NCT05316168|DRUG|Bupivacaine HCl 0.5% Injectable Solution|During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%
214396015|NCT05316168|DRUG|Dexamethasone|During adductor canal block participants will receive 2mg Dexamethasone
214396016|NCT05316168|PROCEDURE|Infiltration between Popliteal Artery and Capsule of the knee (iPACK)|Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone
214396017|NCT05316168|DRUG|Percocet 5Mg-325Mg Tablet|Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control
214396018|NCT03583541|BEHAVIORAL|HIV Risk Reduction|This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.
214396019|NCT03583541|BEHAVIORAL|Financial Literacy|This evidence-based Financial Education Core Curriculum addresses the importance of savings, banking services, budgeting debt management. Undarga adaptation for FSWs included shortening and simplifying sessions while retaining core elements; adding weekly check-ins due to safety concerns FSWs share related to intervention participation, and safety planning as needed. We will further adapt sessions in months 1-6 to assure language and illustrative examples are culturally consonant, and to infuse BE principles consistent with HIVRR. During sessions 1 \& 2 we will include information on delay discounting, for example, learning to understand the tendency to prefer small immediate rewards over larger available at a later time; sessions 3 \& 4 will include details on economic utility; sessions 5 will contain information on salience (e.g. understanding occasions when women may minimize triggers to unsafe sex); and session 6 will address loss aversion.
214396020|NCT03583541|BEHAVIORAL|Mentorship|Mentorship. Mentorship to bridge the transition from FL and savings to a vocational change is a critical component of this intervention. These sessions are intended to support the transition -equipped with financial literacy and savings -to vocational, educational, employment or small business development training using matched savings. The mentorship sessions are adapted from the pilot study and integrate components (e.g., referral and linkage, coaching, exchange visits to model farmers) from income-generating activities provided by our collaborating partner, RTY. All sessions include check-in and individual attention. The first 4 sessions focus on identifying options for vocational, educational, employment or business development training. The second 4 sessions include invited experts in identified areas of interest by group members for more intensive time and attention to individualized needs to make the transition.
214396021|NCT03583541|BEHAVIORAL|Matched savings individual development account|A matched savings individual development account (hereafter IDA) is a savings account held at a local bank whereby deposits made by the woman are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce women to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each woman will receive an IDA held in her own name. Women will be allowed and indeed encouraged to contribute up to 50,000 shillings (\~15 USD) per month towards their IDAs. The maximum amount of women's contribution to be matched will be an equivalent of US$15 per month for 10 months. During the intervention, monthly account statements will be generated for women to note their accumulated savings. During the intervention, women will have direct access to both their personal savings deposited in the accounts and the match provided by the study.
214396022|NCT00176865|PROCEDURE|Stem Cell Transplant|IV on Day 0
214396023|NCT00176865|DRUG|Fludarabine|30mg/m\^2 IV Day -7 through Day -3
214396024|NCT00176865|DRUG|Melphalan|140 mg/m\^2 IV Day -1
214396025|NCT00176865|DRUG|Anti-thymocyte globulin (ATG)|30 mg/kg IV Day -5 through Day -1
214396026|NCT00176865|DRUG|Campath 1H|0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
214396027|NCT00176865|DRUG|Cyclosporin A|2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children \<40 kg) maintaining a level of \>200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181
214396028|NCT00176865|DRUG|Mycophenolate mofetil|15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present
214396029|NCT00176865|DRUG|Intravenous immunoglobulin (IVIG)|500 mg/kg IV weekly beginning on Day +7 until Day +100
214396030|NCT04537104|DEVICE|Coala Heart Monitor|ECG monitoring
214396031|NCT05218564|DRUG|Oxygen Therapy|During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
214503105|NCT05355792|DEVICE|OmniTaper EV implants|Partially edentulous subjects in need of one implant in the maxilla or mandible (2nd and 3rd molars excluded) will receive an OmniTaper EV implant system. The study will be done in accordance with standard dental practice using a one- or two-stage surgical protocol and immediate or delayed placement and/or loading.
214503106|NCT05098171|BIOLOGICAL|Signal Switch Receptor Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
214396032|NCT05218564|OTHER|Compressed Medical Air|During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
215001300|NCT05944549|BEHAVIORAL|Noom|Participants will get access to Noom which is a mobile app for weight loss that shifts the paradigm from dieting to a digitally supported and artificial intelligence (AI)-driven cognitive behavioral therapy approach to support personalized behavior changes towards eating, physical activity and stress management. The Noom Healthy Weight curriculum covers foundations in weight loss, nutrition, physical activity, sleep and stress management.Daily tasks (e.g., weight and food logs, readings) are organized vertically in simple cards on the phone screen, allowing users to easily scroll through what needs to be done. It will pull physical activity data (e.g., steps) directly from the health app on smartphones or apps associated with external devices such as Fitbit. Furthermore, Noom stands out from other app-based programs by assigning a personal coach to each user, helping users navigate the emotional and physiological experiences of the Noom weight loss experience.
215001301|NCT04445415|DIAGNOSTIC_TEST|COVID-19 antibodies testing|antibodies aganist COVID-19 detected in the serum of patients
215001302|NCT06112145|OTHER|rehabilitation program|All fingers of the injured hand are fitted with a dorsal blocking orthosis. Early passive mobilization exercises in the form of passive flexion and extension and edema massage will be taught and it will be recommended to be applied every two hours during the day.
215001303|NCT04392804|PROCEDURE|scaling and root planing|one appointment for scaling and root planing of selected periodontal pockets, with periodontal curette (HuFriedy, Chicago, IL, USA), rinsing with saline solution
215001304|NCT02124174|DRUG|Vidaza and Valproic Acid|"Days 1-5: 5-Azacytidine 40 mg/m\^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily~\*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days."
215001305|NCT01292902|OTHER|inspiratory muscle exercise|To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 \< 88%.
215001306|NCT01292902|OTHER|inspiratory muscle exercise|Equal to the group with chronic heart failure.
215094962|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
215094963|NCT02482402|DRUG|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
215094964|NCT02482402|DRUG|Placebo|inhalation solution placebo
214396033|NCT05397938|DRUG|JMT103|JMT103, subcutaneous injection, once every 6 months (Q6M)
214396034|NCT05397938|DRUG|Alendronate sodium|Alendronate sodium tablet, once every week (QW)
214396035|NCT05397938|DRUG|JMT103 placebo|JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)
214396036|NCT05397938|DRUG|Alendronate sodium placebo|Alendronate sodium tablet placebo, once every week (QW)
214396037|NCT02542514|DRUG|Ibrutinib|p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)
214396038|NCT06121115|DRUG|Norepinephrine|Norepinephrine administered in midline catheter according to clinical routine
214396039|NCT05676398|DIAGNOSTIC_TEST|Ambulatory rhythm recording|Ambulatory rhythm recording by use of a wearable patch-type device.
214396040|NCT00534911|BEHAVIORAL|Cognitive Behavioral Therapy|"Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.~Other Name: Primary and secondary coping enhancement training (PASCET)"
214396041|NCT00534911|BEHAVIORAL|Supportive Non-directive Therapy (SNDT)|SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
214396042|NCT04153513|DRUG|Lanolin|Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
214396043|NCT04153513|OTHER|Mother's milk|After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
214396044|NCT06364319|DRUG|anti-CD25 rhMAb|1 mg/kg/day administered IV day 1, 4, and 8, then weekly for 6 doses. For patients achieving partial remission, an extra dose of Anti-CD25 rhMAb can be given on days 39 and 49.
214396045|NCT06364319|DRUG|Prednisone|Maintain pre-screening dose
214396046|NCT06364319|DRUG|Ruxolitinib|10mg, BID PO
214396047|NCT06364319|DRUG|Cyclosporine|1.25mg/kg, BID PO/IV, target:150-250ng/ml
214396048|NCT00654693|OTHER|Rapid Response Team|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
214396049|NCT03490890|OTHER|Microwave ablaton|Patients with pathology verified GGO were treated with MWA.
214396050|NCT06343441|DEVICE|intraoral scan|intraoral scanning of the edentulous arch and scan body
214396051|NCT06343441|DEVICE|open tray impression|conventional method of impression making with silicone rubber material
214396052|NCT02426385|DEVICE|FineVision Toric|Posterior chamber IOL which consists in a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye
214396053|NCT05015777|OTHER|Emil Jaques-Dalcroze's Eurhythimcs Exercise Program|"Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece."
214396054|NCT00279422|DRUG|visilizumab|
214503107|NCT06082518|DEVICE|Monoplace Hyperbaric Chamber (Class III medical device).|"40 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2 atmospheres (ATM) per treatment), scheduled daily from Monday to Friday (i.e., 5 treatments per week) until treatments are completed (approximately 8 weeks). Treatments will be delivered in a medical grade, Health Canada-approved monoplace hyperbaric chamber and overseen by specialist hyperbaric physicians and a Certified Hyperbaric Technologist.~Device is being used in manner consistent with approved usage in Canada."
214503108|NCT06453681|OTHER|bilateral PECS|ectoralis nerve (Pecs) block, which is novel, less invasive regional analgesic technique.
214503109|NCT06453681|DRUG|Dexmedetomidine|Dexmedetomidine is a potent α2 agonist. In our practice, dexmedetomidine is administered as an additive to regional anesthesia to improve the duration and quality of analgesia
214503110|NCT05405101|PROCEDURE|Thermal ablation of aldosterone producing adenoma.|"On the left side, Radiofrequency ablation of aldosterone producing adenoma(s) will be undertaken via the stomach (endoscopically), under transgastric ultrasound guidance.~On the right side, either Radiofrequency or Microwave Ablation of aldosterone producing adenoma(s) will be performed via a percutaneous approach, under CT guidance."
214503111|NCT05405101|PROCEDURE|Unilateral adrenalectomy|Unilateral total adrenalectomy for aldosterone producing adenoma. This will be laparoscopic in the vast majority of patients, with open conversion if surgically indicated (unlikely in \>1-2 patients)
214503112|NCT04680481|DEVICE|Transcranial alternating current stimulation|Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.
214503113|NCT05683457|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).
214503114|NCT05683457|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214503115|NCT05830825|PROCEDURE|Vertebral Body Tethering (VBT)|Vertebral Body Tethering surgery with the Tether™ in UK
214503116|NCT05392556|DIETARY_SUPPLEMENT|Probiotic|Cerebiome (Lallemand Health Solutions): probiotic supplement containing Bifidobacterium longum R0175, Lactobacillus helveticus R0052, and maltodextrin. Dosing: Oral, 3.6 g/d containing 3x10\^9 CFU/d (powder form)
215001307|NCT04926415|DEVICE|taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 30 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
215001308|NCT04926415|DEVICE|Sham taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
214396055|NCT00279422|DRUG|visilizumab|
214396056|NCT05452629|BEHAVIORAL|Mindfulness induction (MI)|In the MI condition, participants were guided to focus on present experiences regarding the thoughts, emotions and sensations through the three classic mindfulness exercises (i.e., focused breathing, meditation, and body scanning). The duration of MI was 30-minutes.
214503117|NCT05392556|DIETARY_SUPPLEMENT|Prebiotic|Bimuno-GOS (Clasado Biosciences): Dosing: Oral; 3.6 g/d containing 2.75 g active GOS/d (powder form)
214396057|NCT05452629|BEHAVIORAL|Relaxation (RI)|In the RI condition, participants were guided to relax each muscle group following the audio for 30-minutes.
214503118|NCT05392556|OTHER|Placebo|Maltodextrin 3.6 g/d (powder form)
214503119|NCT04931225|DRUG|Landiolol|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
215001309|NCT01089595|DRUG|Nilotinib|Nilotinib 400 mg po bid
215001310|NCT01089595|DRUG|Nilotinib with Imatinib|Nilotinib 400 mg po BID Imatinib 400 mg po daily
215001311|NCT02159638|DEVICE|Guardian Enlite sensor|Sensor insertion
215001312|NCT02159638|DEVICE|Dexcom G4 platinum sensor|Sensor insertion
215001313|NCT01816607|PROCEDURE|new functional magnetic resonance imaging (MRI) protocols|diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
215001314|NCT06515730|DRUG|Apixaban|5 mg tablet twice a daily with dose reduction according to label
215001315|NCT06515730|DRUG|Warfarin|2.5 mg tablet once daily, with individual dosing according to coagulation tests
215001316|NCT01692015|OTHER|Questionnaire on dietary history|
215001317|NCT01692015|OTHER|Questionnaire on nosebleed severity|
215001318|NCT01692015|OTHER|One week food diary generated by weighing foods|
214396058|NCT04463043|DEVICE|SelfBACK app|The selfBACK is an evidence-based and data-driven decision support system (DSS) to support self-management of low back and neck pain delivered via a smartphone app. The selfBACK app provides individually tailored self-management plans to participants on a weekly basis by matching the participant's health information with targeted educational messages, physical activity advices and exercise recommendations via the DSS.
214396059|NCT04463043|OTHER|e-Help webpage|The e-Help is an evidence-based web-based resource to support self-management of low back and neck pain. The e-Help webpage provides evidence-based self-management content equivalent to the selfBACK including educational messages, physical activity and exercise recommendations. Instructions on how to compose exercise programs will be given to participants, however no tailored self-management support will be offered in this solution.
214396060|NCT04463043|OTHER|Usual care|Usual care refers to seeking care or receiving treatments or help as usual.
214396061|NCT01190384|OTHER|Couscous plus fiber|Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.
214396062|NCT01190384|DIETARY_SUPPLEMENT|Grape seed extract|300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.
214396063|NCT01190384|OTHER|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
214396064|NCT06396390|DRUG|Progestin|In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
214396065|NCT06396390|DRUG|GnRH antagonist|In this regimen, Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
214396066|NCT06024499|DRUG|HY209GEL Active|Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1
214396067|NCT06024499|OTHER|Placebo|Placebo
214396068|NCT01686932|DRUG|Vildagliptin|vildagliptin 50mg BID for 8 weeks
214396069|NCT01686932|DRUG|Sitagliptin|sitagliptin 100mg QD for 8 weeks
214396070|NCT06564025|BEHAVIORAL|Pilot program study|To assess program feasibility, acceptability, and preliminary efficacy, we will pilot the intervention with a purposive sample of 50 father-teen pairs (100 participants total). All participants will receive the program.
214396071|NCT06566482|DRUG|Dexmedetomidine-esketamine combination|Patient-controlled analgesia is established with dexmedetomidine (1 μg/ml), esketamine (1 mg/ml), and sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
214396072|NCT06566482|DRUG|Placebo|Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
214396073|NCT01782040|OTHER|Auriculotherapy group|It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
214396074|NCT04571632|DRUG|Avelumab|"Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required."
214396075|NCT04571632|DRUG|Ipilimumab 5 MG/ML|"Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size"
215001319|NCT01692015|PROCEDURE|Blood tests for full blood count, albumin, and indices of nutritional status|
215001320|NCT05002751|OTHER|UCSD Vaginal Dilator Questionnaire|14 question survey
215001321|NCT05002751|OTHER|EORTC Sexual Health Questionnaire|22 question survey
215001322|NCT01415076|PROCEDURE|Insufflation with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
215001323|NCT01680172|DRUG|Ketamine|Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
215001324|NCT01680172|DRUG|Placebo|Single dose of liquid placebo solution taken by mouth
215001325|NCT00992888|DEVICE|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
215001326|NCT02981589|DEVICE|Invasive mechanical ventilation|Invasive ventilation was performed to all eligible patients. When patients met predefined criteria, spontaneous breathing trial was performed. Given spontaneous breathing trial passed, patients were extubated; on the contrary, patients would continue to receive invasive ventilation. If patients had respiratory failure after extubation, reintubation and invasive ventilation were necessary.
215001327|NCT02408822|DEVICE|PTA Balloon dilatation catheter Advance® (Cook® Medical)|2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
215001328|NCT02408822|DEVICE|Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®|2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
215001329|NCT02109224|DRUG|Ibrutinib|Given PO
215001330|NCT02109224|OTHER|Laboratory Biomarker Analysis|Correlative studies
214396076|NCT04571632|DRUG|Pembrolizumab 100 MG in 4 ML Injection|The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.
214396077|NCT04571632|OTHER|CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC|"CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions \< 0,5 cm to 4.0 mL for lesions \> 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size."
214396078|NCT05426382|DEVICE|A digital care solution for patients with NAFLD|A digital solution that provides remote symptom monitoring and support of healthy lifestyle choices through tasks that are made more attractive with gamification and rewards.
214396079|NCT06237868|DEVICE|rTMS Active|The participants undergo Active rTMS, approximately 10-15 min and then complete tasks and questionnaires.
214396080|NCT06237868|DEVICE|rTMS Sham|The participants undergo Sham rTMS, approximately 10-15 min and then complete tasks and questionnaires.
214396081|NCT02338518|DRUG|oxaliplatin|"oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.~Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group."
214396082|NCT02338518|DRUG|etoposide|etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
214396083|NCT02338518|DRUG|pharmorubicin|pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
214396084|NCT02338518|DRUG|S-1|80\~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
214503120|NCT06023927|OTHER|Clinical observation, diagnostic testing|Glaucoma evaluation including structural and functional diagnostic testing at baseline and 3 subsequent follow-up visits over a period of 9 months
214503121|NCT05567016|OTHER|Active case detection using molecular testing (ACDm)|In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.
214503122|NCT05567016|OTHER|Passive case detection using molecular testing (PCDm)|With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.
214503123|NCT05567016|OTHER|Control (standard of care)|With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
214503124|NCT06449521|BEHAVIORAL|BECOME intervention|The intervention, BECOME, includes: a) Evidence-based stress reduction (EBSR): as recommended in the WHO mhGAP guidelines, diaphragmatic breathing and body scan will be used to manage stress and anxiety. b) Behavioral activation (BA): as recommended in the mhGAP guidelines, this evidence-based strategy will increase the time that patients spend engaging in pleasurable activities to both treat depression and increase physical activity, depending on their cognitive and physical capabilities (e.g., going to a neighbor's house for tea or walking to the local market). c) Motivational interviewing (MI): an evidence-based patient-interaction strategy that increases the patient's internal motivation to engage in healthy behaviors (e.g., quit tobacco) both to prompt change (if they are not engaging in healthy behaviors) and maintain them (if they are already engaged in healthy behaviors), as recommended by Package of Essential Noncommunicable disease interventions) PEN protocols.
214503125|NCT05707013|DEVICE|HP Arize 3D-Printed Orthotics|Custom 3D-printed orthotics manufactured by HP.
214503126|NCT05707013|DEVICE|Traditional Orthotics|Traditionally fabricated custom orthotics manufactured by a local supplier.
214503127|NCT06118086|DRUG|REM-422|"* REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~* REM-422 will be administered orally once daily"
214396085|NCT01965964|PROCEDURE|Questionnaire|
214396086|NCT00472537|PROCEDURE|Retromuscular Mesh repair of midline incisional hernia|
214503128|NCT06335511|PROCEDURE|microsurgical decompression|decompression of neurological structures
214503129|NCT06335511|PROCEDURE|decompression and instrumented fusion|decompression of neurological structures and spine stabilization
214503130|NCT05741229|DRUG|Nebulized nitroglycerine as adjunctive therapy|Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy
215001331|NCT02109224|OTHER|Pharmacological Study|Correlative studies
214396087|NCT00472537|PROCEDURE|Laparoscopic repair of midline incisional hernia|
215094965|NCT03678831|PROCEDURE|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
215094966|NCT05515289|DRUG|SHR6390|SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.
215094967|NCT00324441|DEVICE|Iratherm® 1000|
215094968|NCT04628065|BEHAVIORAL|#BabyLetsMove|This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (\<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
214396088|NCT00953420|DRUG|Docetaxel|60 mg/m2 IV on Day 1
214396089|NCT00953420|DRUG|Carboplatin|Target AUC of 5 (mg/ml x min) on Day 1
214396090|NCT00953420|DRUG|Dexamethasone|5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
214396091|NCT00953420|BIOLOGICAL|EBV-specific cytotoxic T lymphocytes|1 x 10e8 cells/m2 IV over 1 to 5 min
214396092|NCT00953420|BIOLOGICAL|G-CSF or Peg-GCSF|If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for \> 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC \> 2500 cells/ul x 2 days after nadir.
214396093|NCT04538807|DIAGNOSTIC_TEST|electromyography|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
214396094|NCT04976569|DEVICE|STN-DBS stimulation pattern change|Deep brain stimulation (DBS) is an elective surgical procedure in which electrodes are implanted into certain brain areas.We use specific STN-DBS stimulation pattern to regulate sleep architecture.
214396095|NCT00255229|DRUG|Glutamine|Glutamine 10 g four times daily starting two days before treatment for six days in total
214396096|NCT00255229|OTHER|Placebo|Glutamine placebo
214396097|NCT03296618|DRUG|NSI-566|Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
214396098|NCT02571439|PROCEDURE|Surgical TAP block|surgeon administered TAP block
214396099|NCT02571439|PROCEDURE|Conventional TAP block|Anesthesiologist administered TAP block
214396100|NCT02571439|DRUG|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
214396101|NCT00393094|BIOLOGICAL|Bevacizumab|10 mg/kg intravenous injection
214396102|NCT00393094|DRUG|Irinotecan hydrochloride|125 mg/m\^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m\^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
214396103|NCT06392061|DIETARY_SUPPLEMENT|Trilac|Trilac® is a dietary supplement developed by Surveal Pharma to support digestive health and overall well-being. This probiotic contains 4 strains of naturally-occurring bacteria including: Lactobacillus acidophilus, LA-5®, Bifidobacterium animalis, BB-12®, Streptococcus thermophiles, STY-31 and Lactobacillus delbrueckii subsp. Bulgaricus LBY-27 in concentration of 4.5 milliards CFU/capsule. Patients in the probiotic group will be instructed to take one tablet per day for a period of 8 weeks.
214396104|NCT03160482|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
214396105|NCT04607473|DEVICE|automated breast ultrasound (ABUS)|Both HHUS and ABUS will be performed on each patient for preoperative staging. Breast radiologists each independently will read HHUS and ABUS images obtained from one patient. The radiologists will be blinded to the findings of the other US mode.
214396106|NCT00652925|DRUG|Celecoxib|Higher dose, 6 mg/kg/dose BID
214503131|NCT05741229|DRUG|conventional therapy for PPHN|patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
214503132|NCT05835466|DRUG|reparixin|reparixin at 1200mg TID three times per day.
215001332|NCT01035788|BEHAVIORAL|Mindfulness Based Cognitive Behavioral Conjoint Therapy|This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
215001333|NCT01035788|BEHAVIORAL|CBCT for PTSD - Communication Skills|This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
214396107|NCT00652925|DRUG|Celecoxib|Active drug at lower dose
215001334|NCT04691934|PROCEDURE|Anesthesia management|Patients who underwent cesarean section and had positive PCR nasopharyngeal swabs for COVID-19 were included in the study. Patients who tested negative and were clinically suspicious were excluded from the study. PCR test was not performed on all elective and emergency pregnant women to be taken for cesarean section in our hospital. It was only applied to patients with symptoms or patients who were suspected. All patient demographics and information about anesthesia were analyzed retrospectively from the patient files.
215001335|NCT05304325|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
215001336|NCT05304325|OTHER|Blood sampling|Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants
215001337|NCT05304325|OTHER|Blood pressure|Systolic and diastolic blood pressure will be measured.
215001338|NCT05304325|OTHER|Anthropometric measurements|Body weight, height and waist circumference will be measured.
215001339|NCT05304325|OTHER|Body composition|Body composition will be evaluated by dual-energy X-ray absorptiometry.
215001340|NCT05304325|OTHER|Resting metabolic rate|Resting metabolic rate will be measured by indirect calorimetry.
215001341|NCT05304325|OTHER|Food intake|Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.
214396108|NCT00652925|DRUG|Naproxen|Control comparator, 15 mg/kg/dy target dose
214396109|NCT04537338|GENETIC|1. Characterize the immune response after infection with SARS-CoV-2|1\. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens
214396110|NCT05407532|PROCEDURE|Group with oral management|The investigators provided information on oral health care plus oral exercises before meals, including salivary glands massage methods.
214503133|NCT05465941|PROCEDURE|Biopsy|Undergo biopsy
214503134|NCT05465941|DRUG|Pegylated SN-38 Conjugate PLX038|Given IV
214503135|NCT05465941|PROCEDURE|Computed Tomography|Undergo CT
214503136|NCT05465941|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
215001342|NCT05304325|PROCEDURE|Adipose tissue biopsy|A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
215001343|NCT06049342|BIOLOGICAL|NCR100 injection|Subjects will receive a one-dose intra-articular NCR100 injection.
215001344|NCT00704353|DRUG|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
215001345|NCT00704353|DRUG|Standard Medical Care (SMC)|Per product label
214396111|NCT05407532|PROCEDURE|Group with oral care|The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
214396112|NCT00555789|DRUG|AEB071|200mg oral b.i.d.
214396113|NCT00555789|DRUG|mycophenolic plus tacrolimus|720mg b.i.d. 2yrs
214396114|NCT01710774|PROCEDURE|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
215001346|NCT02748031|PROCEDURE|slit-lamp-adapted anterior segmental photography|The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
215001347|NCT06552195|OTHER|learning with augmented reality|"Study presentation: participants will be given a 10-minute general introduction on the study followed by a 20 minutes tutorial to introduce the HoloLens 2 and the TEACHANATOMY learning platform.~* Study session: The study session consists of three learning blocks of approximately 20 minutes each, plus a repetition block to assess the acquired knowledge. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test at the end of the study and after three months.~* Final questionnaire: At the end of the study session participants will be given a questionnaire to assess adverse health symptoms and user experience."
214396115|NCT06531148|OTHER|Chemo-mechanical caries removal|Chemo-mechanical were be used as a Chemo-mechanical caries removal agent for one side of the bilateral carious teeth (selected randomly). Application of the material were be done according to the manufacturer's instructions (20). The material will be applied with a blunt spoon excavator and left for 2 minutes allowing the chemistry to work. The decayed dentin which becomes soft (due to the action of the material) was being scraped away using a blunt excavator in a pendulum movement without pressure. If necessary, the procedure will be repeated to get healthy dentin. The cavity will be visually inspected by caries detector dye to assess the complete removal of the carious dentin.
214396116|NCT03386760|DEVICE|Laser Utilisation PicoSecond|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
214396117|NCT03386760|DEVICE|Laser Utilisation Nano-second|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
214396118|NCT00925340|BEHAVIORAL|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
215094969|NCT01647334|RADIATION|Adaptive radiotherapy|
215094970|NCT05729984|BEHAVIORAL|Paula exercises|The patients will perform Paula exercises after the cesarean delivery
214396119|NCT00925340|BEHAVIORAL|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
214396120|NCT02712840|PROCEDURE|Freeze-All Protocol|All good morphologic quality blastocysts are vitrified on day 5 or 6. The best quality vitrified blastocyst frozen on day 5 will be warmed and transferred in a subsequent cycle.
214396121|NCT02712840|PROCEDURE|Fresh Protocol|Participants receive fresh embryo transfer of best morphologic quality blastocyst on day 5 and vitrification of all good quality supernumerary blastocysts.
214396122|NCT04311242|OTHER|Diet|Ketogenic diet
214396123|NCT03559439|BIOLOGICAL|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
214396124|NCT04598737|PROCEDURE|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
214396125|NCT04598737|PROCEDURE|Lithium disilicate|Lithium disilicate laminate veneer treatment
214396126|NCT02298205|OTHER|Asthma controller medication (Beclomethasone) adjustment strategy|The participant will adjust the dose of Beclomethasone based on symptoms
214396127|NCT02298205|OTHER|Provider-based adjustment|The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
214396128|NCT05349318|DEVICE|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
215094971|NCT05729984|BEHAVIORAL|Gum chewing|The patients will be given chewing gum and will be asked to chew it after the cesarean delivery
215094972|NCT05095857|DRUG|S-ketamine|S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
215094973|NCT05095857|OTHER|Isotonic saline (placebo)|Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
214396129|NCT05349318|DEVICE|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
214396130|NCT01162941|OTHER|Steroid refractory ITP|a platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)
214396131|NCT02514980|DRUG|Bupivacaine|Infraorbital nerve block using bupivacaine 0.25% on each side.
214396132|NCT02514980|DRUG|Ketamine|Infraorbital nerve block using 0.5mg/kg ketamine on each side.
214396133|NCT03615625|BEHAVIORAL|Power Training Session|"3 sets of 8-10 repetitions of 5 exercises performed in the following order: leg press, bench press, knee extension, upright row, and knee flexion, using an intensity corresponding to 50 % of 1-RM and two-minute intervals between sets and exercises. The concentric phase of exercises during each repetition was performed as fast as possible while the eccentric phase lasted 1-2 seconds."
214396134|NCT02329990|DIETARY_SUPPLEMENT|phosphorus|phosphorus supplement
214396135|NCT02560740|DIETARY_SUPPLEMENT|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
214396136|NCT02560740|DIETARY_SUPPLEMENT|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
214396137|NCT03335891|PROCEDURE|Core Stabilization Exercises|Volunteers received an asthma education program and trained for diaphragmatic, pursed lip breathing exercises as well as participated in the core stabilization exercises program.
214396138|NCT03335891|PROCEDURE|Control|Volunteers received an asthma education program and trained for diaphragmatic andpursed lip breathing exercises
214396139|NCT04668664|DEVICE|EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™)|Measuring the portal pressure gradient in patients with cirrhosis who are referred for an esophagogastroduodenoscopy (EGD) and/or endoscopic ultrasound (EUS).
214396140|NCT03753607|OTHER|No intervention|No intervention
214396141|NCT05043311|BIOLOGICAL|SCTV01C|intramuscular injection
214396142|NCT05043311|OTHER|Placebo|intramuscular injetion
214396143|NCT01058863|DRUG|Albuterol Spiromax®|Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
214396144|NCT01058863|DRUG|ProAir® HFA|ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
214396145|NCT01058863|OTHER|Placebo Inhaler|Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
214396146|NCT00681187|DRUG|lanreotide (Autogel formulation)|90 mg or 120 mg once every 28th day
214396147|NCT02254850|PROCEDURE|Flow Mediated Dilation|"Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel."
215001348|NCT06552195|OTHER|learning with traditional methods|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a presentation to introduce the study session.~* Study session: The study session consists of the learning resources most used by students: specific sections from four different neuroanatomy books, access to two websites, two 3D videos, and two online learning programs. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test at the end of the study and after three months.~* Final questionnaire: At the end of the study session participants will be given a questionnaire to assess adverse health symptoms and user experience"
215001349|NCT03819127|DRUG|Vildagliptin 50 MG Oral Tablet|
215001350|NCT03819127|DRUG|Metformin Pill|
215001351|NCT03380741|DIAGNOSTIC_TEST|Tumour markers detection|Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab
215001352|NCT01001104|DRUG|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
215094974|NCT02834286|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
214396148|NCT02254850|DRUG|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
214396149|NCT02254850|DRUG|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
214396150|NCT02254850|DRUG|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
215001353|NCT01001104|DRUG|Placebo|Administered by SC injection, QW for 12 weeks.
215001354|NCT00087412|DRUG|erlotinib hydrochloride|Given orally
215001355|NCT00087412|OTHER|laboratory biomarker analysis|Correlative studies
215094975|NCT02834286|DRUG|Eltrombopag|Eltrombopag 50 mg PO days 1-28
215094976|NCT02834286|DRUG|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
215094977|NCT06110000|OTHER|pragmatic set of interventipons|"The pragmatic set included 6 interventions as follows.~1. Pragmatic posterior capsular stretch (PPCS)~2. Serratus anterior stretch (SAS)~3. Rotator cuff facilitation (RCF)~4. Acromioclavicular joint mobilization.~5. Pectoralis minor stretch~6. Thoracic manipulation Five to ten sweeps per minute are administered three to four times. The applied force is combined with deep breathing. The subject is asked to report discomfort and the applied force is adjusted."
214396151|NCT02254850|DRUG|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
214396152|NCT03508102|DRUG|remifentanil|the effects of remifentanil on the average value of BIS at the time period of before induction , induction , intubation , skin incision, peritoneum incision, uterine incision, and delivery
214396153|NCT03653416|DEVICE|Ipack|IPACK block - local anesthesia injected safely under ultrasound guidance in the interspace between the popliteal artery and capsule of the knee.
214396154|NCT03653416|DRUG|Bupivacaine|20 cc of bupivacaine(o.25%) injection
214396155|NCT03653416|PROCEDURE|Peri Articular Infiltration|Adductor Canal Catheter and Peri Articular Infiltration
214396156|NCT02712112|DRUG|Imatinib Mesylate|
214396157|NCT00086086|DRUG|Darbepoetin Alfa|
214396158|NCT06309095|DEVICE|use of VDW Silver Endodontic motor|All patients will be subjected to local anesthesia with articaine hydrochloride (Maxicaine, Istanbul) containing 1:100,000 adrenaline. After the entrance cavities of the teeth are opened, a rubber dam will be applied to the relevant teeth for isolation from the oral environment. After the entrance cavity is opened, the working length of the canals will be determined with the help of a No. 10 K-file (Dentsply Maillefer, Ballaigues, Switzerland) canal file and an electronic apex finder (Woodpex III, Woodpecker Medical Instrument Co, Guilin, China). In both groups, it was planned to use the NiTi rotary instrument system using V Taper Gold (Fanta Dental Material, Shanghai, China) files with the help of VDW.Silver endomotor (VDW, München, Germany). The endodontic motor will be used to adjust different speed and torque values during root canal treatment. Post-operative pain caused by different speed and torque values will be compared.
214396159|NCT02210962|DIETARY_SUPPLEMENT|essential fatty acids|Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)
214396160|NCT02210962|DIETARY_SUPPLEMENT|olive oil|Yellow capsules containing olive oil (placebo)
214396161|NCT03557489|DEVICE|Mepilex Border Sacrum|Patients use gel pad(in usual) in addition to use Mepilex Border Sacrum foam pad during surgery.
214396162|NCT03867708|RADIATION|ASD device closure|transcatheter secundum ASD device closure
214396163|NCT04893070|OTHER|Questionnaires COVID+|"* 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms~* 1 questionnaire on quality of life 18 months after COVID-19 first symptoms"
214396164|NCT04893070|OTHER|Questionnaires COVID-|"* 1 questionnaire on quality of life at enrollment~* 1 questionnaire on quality of life 6 months after enrollment"
214396165|NCT02839135|DRUG|Reformulated scopolamine patch|Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours
214503137|NCT05763953|DRUG|Etripamil NS|"Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A."
214503138|NCT05064306|DRUG|131I-omburtamab|50 mCi 131I-omburtamab
214503139|NCT03295227|BIOLOGICAL|Pembrolizumab|Given IV
214503140|NCT05018624|BEHAVIORAL|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
214503141|NCT05018624|BEHAVIORAL|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
214503142|NCT05018624|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
215001356|NCT02092428|OTHER|Image Quality|"The following procedures may be conducted as part of this study:~* Coronary MRI scan with no contrast~* Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~* MRI scan with an oral beta blocker (metoprolol)~* Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions."
215001357|NCT02092428|OTHER|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
215001358|NCT02560766|DRUG|HORIZANT 300 mg|HORIZANT 300 mg once daily
215001359|NCT02560766|DRUG|HORIZANT 600 mg|HORIZANT 600 mg once daily
215001360|NCT02560766|DRUG|Placebo|Placebo once daily
215001361|NCT03235414|DEVICE|MRI|Will receive a one time research MRI (MR elastography)
215001362|NCT03235414|DIAGNOSTIC_TEST|Blood draw|Will receive a one time blood draw to confirm healthy liver status
215001363|NCT02397837|DRUG|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
214396166|NCT02839135|DRUG|Marketed scopolamine patch|Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
215001364|NCT02397837|DRUG|Placebo|placebo match study drug
215001365|NCT05592691|PROCEDURE|Fascial block|The end of the drug infusion will be considered the time zero (T0); subsequently blood samples (4ml) will be taken at pre-established time intervals (after 5, 15, 30, 60, 120 and 180 minutes). Blood samples will be collected in test tubes and centrifuged within 1 hour of collection; subsequently they will be stored at a low temperature and transported to the reference analysis laboratory.
215094978|NCT06110000|OTHER|scapular strengthening exercise.|• Subjects in Group B receive strengthening exercises (exercise will perform with 15 repetitions for each set- 3sets/day, 3 days /week for 6 weeks. In Scapular strengthening exercises, treatment protocol will involve the individualized for focus muscle Serratus anterior (Dynamic hug, Scaption with external rotation, Diagonal PNF (shoulder flexion horizontal flexion, external rotation),Trapezius - Upper trapezius (unilateral shoulder shrug, rowing, forward shoulder flexion, shoulder abduction in scapular plane above 120 degrees, Middle trapezius (prone shoulder horizontal abduction, scaption, horizontal abduction with external rotation), Lower trapezius (Unilateral scapular retraction, prone bilateral shoulder external rotation at 90 degrees of abduction, prone shoulder abduction), Levator Scapulae (horizontal abduction with shrug, horizontal abduction with ER, prone shoulder extension, Rhomboids (ER at 90° of abduction, ER at 0° of abduction, Horizontal abduction, Shoulder extension)
214396167|NCT04230980|DRUG|Gabapentin|Gabapentin 600mg tablet
214396168|NCT04230980|DRUG|Placebo|Placebo tablet
214396169|NCT03647839|DRUG|Nivolumab 10 MG/ML|Nivolumab will be supplied free of charge by Bristol-Myers Squibb (BMS) as sterile liquid in 10mL glass vials.
214396170|NCT03647839|DRUG|BNC 105|BNC105 will be provided free of charge by Bionomics, as a sterile solution of BNC105P. BNC105P is a clear, colorless to yellow liquid presented in a clear glass vial and is intended to be diluted with commercially available sterile 0.9% saline prior to IV administration.
214396171|NCT03647839|DRUG|BBI608|BBI-608 will be supplied free of charge by Boston Biomedical as capsules.
214396172|NCT02157415|DEVICE|Uro-Tainer Polihexanide 0.02%|Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
214396173|NCT00549822|DRUG|Letrozole|Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
215001366|NCT05016336|OTHER|Social interaction combined with cognitive training based on mnemonic strategies.|In the first six sessions, participants in the experimental group learned and practiced six different mnemonic strategies: Story-Formation strategy, Face-Name strategy, Peg-Word strategy, Chunking strategy, Key-Word strategy and the Method of Loci. In the following six sessions, in order to assimilate the strategies they learned, participants practiced the same tasks.
214396174|NCT04019119|BEHAVIORAL|Digital intervention|The information group will receive through a mobile application tips to reduce sedentary lifestyle and promote healthy living habits.
214396175|NCT00416923|BIOLOGICAL|rituximab|
214396176|NCT00743522|DEVICE|ICD/ CRT-D|Cardiac device
214396177|NCT05047562|OTHER|Pilates Group|16 Pilates exercise sessions twice a week for 2 months.
214396178|NCT05047562|OTHER|Segmental Stabilization group|16 sessions of segmental stabilization exercises, 2 times a week for 2 months.
214396179|NCT02788006|DRUG|Regorafenib 160 mg|
214396180|NCT05521594|PROCEDURE|Fine Needle Aspiration Cytology|Comparison between FNAC and post operative specimen after thyroid surgery
214396181|NCT04948879|PROCEDURE|Vascular resection/reconstruction|The resection of a major blood vessel with or without reconstruction
214396182|NCT02951299|DRUG|Pentoxifylline 400Mg Tablet|Investigators with AKI will received oral pentoxifylline (400 mg) three times a day for 14 days or no pentoxifylline according to their decision.
214396183|NCT03859336|DEVICE|Transdermal Neuromodulation Stimulation|The TEN device administers a tuned high frequency electrical stimulation delivered to the cervical plexus (C2-C4) on the back of the neck for 20 minutes. This stimulation will activate common trigeminovagal pathways modulating noradrenergic signaling to attenuate sympathetic activity. This stimulation can subsequently regulate the activity of several deep-brain nuclei within the ascending reticular activating system (RAS). Nuclei in the RAS regulate powerful neuromodulators like norepinephrine (NE), acetylcholine (ACh), and serotonin (5-HT). The investigators will examine whether this modulation from TENS will decrease anxiety and improve sleep quality in the study participants.
214396184|NCT04141579|DRUG|Evolocumab 140 MG/ML [Repatha]|Evolocumab (also known as Repatha, formerly referred to as AMG 145) is a human monoclonal immunoglobulin G2 (IgG2) that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) preventing its interaction with the low-density lipoprotein receptor (LDLR). The inhibition of PCSK9 by evolocumab leads to increased LDLR expression and subsequent decreased circulating concentrations of low-density lipoprotein cholesterol (LDL-C).
214396185|NCT04141579|DRUG|Placebo|Matching placebo
214396186|NCT05375136|OTHER|Non-interventional|No intervention will be administered.
214396187|NCT03927872|OTHER|blood biomarkers|assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome
214396188|NCT04696848|DRUG|CKD-516 plus Durvalumab|"Stage 1 : dose escalation durvalumab (1500 mg Q4W) in combination with CKD-516 at 1 of 3 planned dose levels (9, 11, or 13 mg/m2 twice a week for 3 weeks in each cycle, Q4W).~Stage 2 : durvalumab (1500 mg Q4W) in combination with CKD-516 at recommended phase 2 dose (twice a week for 3 weeks in each cycle, Q4W)."
214396189|NCT02145481|BEHAVIORAL|Decision Aid|Decision aid describing treatment choices for patients with coronary artery disease.
214396190|NCT02145481|BEHAVIORAL|CAD Education|Education for patients with coronary artery disease
214396191|NCT00570258|DRUG|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
214396192|NCT00570258|DRUG|erlotinib|150 mg PO QD
214396193|NCT00570258|DRUG|Fulvestrant|250 mg IM Q 4 weeks
214396194|NCT00570258|DRUG|Placebo|Placebo 150 mg PO QD
214396195|NCT01925261|DRUG|TPX-100 50mg|
214396196|NCT01925261|DRUG|TPX-100 100mg|
214396197|NCT01925261|DRUG|TPX-100 200mg|
214396198|NCT01925261|DRUG|TPX-100 20mg|
214396199|NCT01925261|DRUG|Placebo|
214396200|NCT02694614|BEHAVIORAL|smartphone-assisted dietary coaching|
214396201|NCT05540691|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
214396202|NCT06309030|DRUG|Bushen quhan zhiwang decoction|Treatment with 100ml of Bushen quhan zhiwang decoction twice a day for 3 months.
214396203|NCT06309030|DRUG|Bushen quhan zhiwang decoction placebo|Treatment with 100ml of Bushen quhan zhiwang decoction placebo twice a day for 3 months.
214396204|NCT03050398|DRUG|Ribociclib|ribociclib + letrozole
214396205|NCT03050398|DRUG|letrozole|ribociclib + letrozole
214396206|NCT00598481|GENETIC|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
214396207|NCT00598481|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
214396208|NCT00457613|DRUG|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
214396209|NCT01723553|DRUG|C-11 PiB|One time intravenous administration of \~740 megabecquerel (MBq) of \[N-methyl-C-11\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
214396210|NCT04455334|OTHER|Error-augmented treadmill training|walk on split-belt treadmill
214396211|NCT04455334|OTHER|active control group|walk on tie-belt treadmill
214396212|NCT04455334|OTHER|Error-augmented concept combined physical therapy group|Error-augmented concept combined physical therapy
214396213|NCT04455334|OTHER|conventional physical therapy group|conventional physical therapy
214396214|NCT04455334|OTHER|NO INTERVENTION|NO INTERVENTION
215094979|NCT00747409|DRUG|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
215094980|NCT00747409|DRUG|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
214396215|NCT00673634|PROCEDURE|Standard preoxygenation|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.
214396216|NCT00673634|PROCEDURE|BiPAP assisted preoxygenation|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
214396217|NCT04387539|DRUG|SOF/SMV/DCV/RBV|SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.
214396218|NCT02778282|OTHER|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
214396219|NCT04726475|BEHAVIORAL|Interoceptive Aversive Memory Reactivation|In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
214396220|NCT04726475|DIETARY_SUPPLEMENT|Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil|300mg CBD-rich hemp-derived formulation in MCT coconut oil.
214396221|NCT04726475|DIETARY_SUPPLEMENT|Placebo Oil|3ml oral dose of MCT coconut oil.
215001367|NCT05016336|OTHER|Social interaction group|In the control group, each session also began with a conversation between the participants. The sessions then dealt with the content of interpersonal communication and the acquisition of tools for creating interpersonal relationships. Participants were asked to share the way they used the tools they acquired between sessions and received feedback from the other participants
215001368|NCT00599313|DRUG|Sunitinib|50 mg/day orally each of Days 1-28 of each 6 week cycle
215001369|NCT00078494|DRUG|EBV-LMP-2|
215001370|NCT00258661|PROCEDURE|Osteopathic Manipulative Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
215001371|NCT00258661|PROCEDURE|Light-touch Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
215001372|NCT02536794|BIOLOGICAL|Anti-B7H1 Monoclonal Antibody MEDI4736|Given IV
215001373|NCT02536794|OTHER|Laboratory Biomarker Analysis|Correlative studies
215001374|NCT02536794|OTHER|Pharmacological Study|Correlative studies
215001375|NCT02536794|BIOLOGICAL|Tremelimumab|Given IV
215001376|NCT03745781|DRUG|Placebos|placebo pills
215001377|NCT04033913|OTHER|Self questionnaire|Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
215001378|NCT01011296|DRUG|PF-04427429|Single 0.2mg dose of intravenous infusion
215094981|NCT03153488|RADIATION|MRI|All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
214396222|NCT03288389|DIETARY_SUPPLEMENT|NTFactor Lipids®|Membrane Lipid Replacement with NTFactor Lipids wafers
214396223|NCT03288389|DIETARY_SUPPLEMENT|Placebo|Placebo wafers
214396224|NCT04479098|OTHER|Resistance exercise training|The exercise training program will last 12 weeks, with a frequency of three sessions per week, held on Mondays, Wednesdays, and Fridays. Each session will last approximately 50 minutes. Whenever the maximum number of pre-established repetitions is successfully performed, the intensity will be increased by 5 to 10%. All sessions will be supervised by trained professionals.
214396225|NCT04479098|OTHER|Exercise detraining|The exercise detraining will last 12 weeks without exercise.
214396226|NCT01071889|DRUG|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
214396227|NCT01071889|DRUG|Placebo|Placebo - only excipients with no API
214396228|NCT05538299|BEHAVIORAL|questionnaire, KAP|Diagnostic studies including questionaire, CXR, spirometry, clinical assesment, occupational safety training
214396229|NCT02838225|DRUG|Docetaxel, Doxorubicin|
214396230|NCT02838225|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|
214396231|NCT03523871|DRUG|Mavyret|Patients will be on 8 weeks of Mavyret
214396232|NCT01397929|DRUG|BAL101553|Intravenous administration
215001379|NCT01011296|DRUG|PF-04427429|Single 1mg dose of intravenous infusion
215001380|NCT01011296|DRUG|PF-04427429|Single 3 mg dose of intravenous infusion
215001381|NCT00926120|DIETARY_SUPPLEMENT|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
215001382|NCT01926639|BIOLOGICAL|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
215001383|NCT01191385|DRUG|Any treatment for unresectable HCC as chosen by the physician|Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
215001384|NCT00169260|BEHAVIORAL|motivational counseling|behavioral motivational counselling
215001385|NCT00169260|BEHAVIORAL|placebo|
215001386|NCT01406912|OTHER|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
215094982|NCT02288988|PROCEDURE|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
215094983|NCT00003719|DRUG|irinotecan hydrochloride|
214396233|NCT05758155|OTHER|mental health literacy training supported by creative drama|nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.
214396234|NCT05758155|OTHER|mental health literacy training supported by classroom instruction|nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
214396235|NCT05740475|DRUG|9MW3811 injection|Single dose intravenously infused on day 1
214396236|NCT05740475|DRUG|Placebo|Single dose of matching placebo intravenously infused on day 1
214396237|NCT03416504|BEHAVIORAL|Gradual Exposure (EXP-G)|In EXP-G, exposure proceeded hierarchically from mildly, to moderately, to highly intense stimuli so that exposure intensity gradually built between (but not within) sessions.
214396238|NCT03416504|BEHAVIORAL|Variable Exposure (EXP-V)|In EXP-V, exposure stimuli were chosen at random (i.e., pieces of paper with exposure stimuli written on them were pulled randomly from an opaque container) so that mild, moderate, and high intensity exposures could occur in any order during any of the sessions (the participant was not informed which level was coming next). This aimed to maximize (a) uncertainty, (b) variability in exposure intensity, and (c) variability in corresponding physiological arousal.
214396239|NCT04456582|PROCEDURE|Shear wave elastography|The elastographic technique by ultrasound (USE), shear waves or shear wave elastography (SWE), quantitatively evaluates tissue stiffness by mapping the propagation of acoustic waves (shear waves), in a non-invasive manner and without emission of ionizing radiation. Their speeds are tracked by the ultrasound equipment after tissue deformation occurs, generated by pulses of acoustic radiation (ARFI) of the transducer itself. Assuming the correlation between tissue stiffness and increased acoustic propagation speeds, it is possible to describe mathematically the elasticity of tissues by measuring specific acoustic waves.
214396240|NCT02552849|OTHER|No intervention|
214396241|NCT00558324|PROCEDURE|LASIK|Mechanical microkeratome Hansatome 160 microns
214396242|NCT00558324|PROCEDURE|LASIK|Mechanical microkeratome K 3000 130 microns
214396243|NCT00558324|PROCEDURE|LASIK|Femtoseconds laser 100 microns
214396244|NCT05472220|DRUG|Alpelisib|Given orally
214396245|NCT05472220|DRUG|Carboplatin|Given IV during imaging
214396246|NCT05472220|DRUG|Hyperpolarized Carbon-13 (13C) Pyruvate|Given IV
214396247|NCT05472220|DEVICE|Continuous Glucose Monitor (CGM)|Self-applied devices that sit partially beneath the skin
214396248|NCT00126685|BIOLOGICAL|autologous tumor cell vaccine|
214396249|NCT00126685|BIOLOGICAL|therapeutic autologous dendritic cells|
214396250|NCT05461560|DIETARY_SUPPLEMENT|Sucrose solution|50 g of sucrose dissolved in 500 ml of tap water
214396251|NCT05461560|DIETARY_SUPPLEMENT|Seaweed extract in sucrose solution|1 g of seaweed extract in solution of 50 g of sucrose in 500 ml of tap water
214503143|NCT05018624|BEHAVIORAL|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
214503144|NCT05018624|BEHAVIORAL|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
214503145|NCT06449378|DEVICE|Transorb™ Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for repair of open ventral hernia.
214503146|NCT06230783|OTHER|TalkTracker|Participants will be asked to complete the speech collection procedures remotely/at home once per week for 8 weeks. The 8-week period of weekly remote speech collection will take place yearly for a total of 3 years. At the end of each 8-week study period for years 1-3, participants will complete a survey that asks questions about how easy/difficult the application was to use, how frustrated they felt using the application, and other usability questions.
214396252|NCT02306395|PROCEDURE|Endometrial local injury|The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
214396253|NCT04515563|BEHAVIORAL|Stretching exercise|Control Group
214396254|NCT04515563|BEHAVIORAL|Low-frequency, moderate-intensity walking group|once-a-week walking exercise at moderate intensity
214396255|NCT04515563|BEHAVIORAL|High-frequency, moderate-intensity walking group|thrice-a-week walking exercise at moderate intensity
214396256|NCT04515563|BEHAVIORAL|Low-frequency, vigorous-intensity walking group|once-a-week walking exercise at vigorous intensity
214396257|NCT04515563|BEHAVIORAL|High-frequency, vigorous-intensity walking group|thrice-a-week walking exercise at vigorous intensity
214396258|NCT01274130|DRUG|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
214396259|NCT01994720|DRUG|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
214396260|NCT01994720|DRUG|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
214396261|NCT06423586|DIETARY_SUPPLEMENT|Curcuma longa and Boswellia serrata extracts|Participants received 500 mg of Curcuma longa and 150 mg of Boswellia serrata extracts (Meriva™ and Casperome™) twice daily for 30 days.
214396262|NCT03949751|DRUG|Acne Crème Plus|The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
214396263|NCT00801424|DEVICE|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher\&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
215001387|NCT01406912|OTHER|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
215001388|NCT02887599|PROCEDURE|Blood collection|1ml of blood specimen collection
215001389|NCT04424602|DRUG|cyclo phosphamide|500mg vial
214396264|NCT06380595|PROCEDURE|Complex endovascular aortic repair (cEVAR)|Complex endovascular aortic repair (cEVAR) collectively refers to the use of fenestrated/branched EVAR (f/bEVAR) or other EVAR variations allowing alternative visceral incorporation approaches, such as laser or radiofrequency (RF) fenestration or parallel endografts (snorkel, periscope, chimney or sandwich EVAR) to enable repair of perivisceral AAA (pvAAA), thoracoabdominal aortic aneurysms (TAAA), and aortic arch aneurysms.
215001390|NCT04424602|DRUG|mycophenolate|500mg film-coated tablets.
215001391|NCT00458835|DRUG|Ciclesonide|
215001392|NCT00005795|DRUG|arsenic trioxide|
215001393|NCT05470998|DRUG|L-Arginine|L-Arginine 1000 mg free form, rapid release capsules
214396265|NCT03073629|DIAGNOSTIC_TEST|Clinical Pathway|Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
214396266|NCT05552690|PROCEDURE|blood draw|10 ml of blood will be draw to genetic analysis (sequencing)
214396267|NCT04305899|DRUG|BMS-986165 Tablet formulation 1|Specified dose on specified days
214396268|NCT04305899|DRUG|BMS-986165 Tablet formulation 2|Specified dose on specified days
214396269|NCT05468671|DRUG|Remimazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil.
214396270|NCT05468671|DRUG|Propofol|Propofol is used to put you to sleep and keep you asleep during general anesthesia for surgery or other medical procedures.
214396271|NCT05468671|DRUG|Rocuronium|Rocuronium is a non-depolarizing neuromuscular blocker
214503147|NCT06484751|DEVICE|SelfBack|The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
214503148|NCT04907617|OTHER|FAW|After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.
215094984|NCT03639142|OTHER|Prunus domestica|Patients will receive prunes at dose 3,5 g/kg/d (max.100mg/day) in three portions a day, for 4 weeks (amount of prescribed prunes will be calibrated with the weight that child ought to have on WHO growth charts at 50th percentile). Prunes should be introduced every day in three meals. Prunes can be chopped or grinded before eating them. They can be eaten alone or child may eat them as a part of bigger meal (which is preferred version). Prunes can be introduced with yogurt, cereals, nuts and seeds as a morning meal.
214396272|NCT05468671|DRUG|Remifentanil|Remifentanil is an esterase-metabolized opioid
214396273|NCT05468671|DRUG|oxycodone|Oxycodone is an opiate painkiller.
214396274|NCT05468671|DRUG|Sugammadex Sodium|Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery
214396275|NCT05468671|DRUG|Flumazenil|Flumazenil is used to reverse the effects of a benzodiazepine
214396276|NCT05474443|OTHER|Myofascial gun with conventional therapy|"MYofascial gun was applied for the duration of 5 minutes over upper trapezius muscle. every week, on first two sessions frequency was set to 1-2 then for next two 3-4 and so on conventional therapy Hot Pack applied at the beginning of session for 10 minutes Muscle stretching of Upper Trapezius, Levator Scapulae and Pectoralis Major applied with holding time 20 seconds and 4 repetitions.~Cold pack was applied at the end of the session for few minutes"
214396277|NCT05474443|OTHER|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool was applied over upper trapezius muscle from its origin to insertion kept at the angle of 45 Conventional Therapy Hot pack 10mins Upper Trapezius, Levator scapule and Pectoralis major muscle stretching(20s hold and 4 reps) Cold pack for few minutes
215001394|NCT05397418|BEHAVIORAL|Supervised resistance exercise program|12 week supervised low impact resistance training program
215001395|NCT05397418|BEHAVIORAL|Unsupervised resistance exercise program|12 week unsupervised low impact resistance training program
215001396|NCT06096948|DEVICE|NEXPOWDER-ENDOHS|Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
215001397|NCT00152230|DRUG|UFT (uracil, tegafur)|to receive oral uracil-tegafur 400 mg square meter for one year
215001398|NCT00152230|PROCEDURE|Surgery alone|Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
215001399|NCT01496456|DEVICE|Resin infiltration|Split-mouth design (at least two lesions per patient): Treatment of one caries lesion with resin infiltration therapy
215001400|NCT01496456|BEHAVIORAL|Caries management|Split-mouth design (at least two lesions per patient). Baseline preventative caries management: dietary and behavioral modification, and over-the-counter fluoride supplements
215001401|NCT02199496|BIOLOGICAL|Stelara (ustekinumab)|"* In the single-phase part of the study, subjects receive a single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit.~* In the multi-phase part of the study, subjects receive single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit with follow up dose of Stelara (ustekinumab) 90 mg subcutaneously at Week 8, Week 16, Week 24, Week 32 and Week 40"
215001402|NCT02971904|OTHER|human milk collection|
215001403|NCT01287247|BIOLOGICAL|Xeomin®|Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.
215001404|NCT04171076|PROCEDURE|Transcutaneous spinal cord stimulation|Theta burst stimulation at thoracic level (T5) over 2 minutes
215094985|NCT03639142|DRUG|Polyethylene Glycol 4000|Patients will receive PEG at dose 0,5 g/kg/d once daily orally, for 4 weeks.
214396278|NCT03709875|DEVICE|TR Treatment|A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech (mainly lexical based) and cognitive (attention focused) exercises will be delivered from the two Research Institutes to the patient's home. During the treatment at home, the patients will use wearable monitoring devices to monitor their status (speed, heart rate, respiratory rate, training load and single-lead ECG in real-time) and to provide real-time feedback during exercises.
214396279|NCT01991197|DRUG|Sitagliptin|"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
214396280|NCT01991197|DRUG|Gliclazide|"Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
214396281|NCT01991197|DRUG|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
214396282|NCT01991197|DRUG|Gliclazide matched placebo capsule|"Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
214396283|NCT03054974|OTHER|Modern rehabilitation treatment|PT 1 hour per day and OT 30min per day
214396284|NCT03054974|OTHER|Modern rehabilitation &TCM|Traditional Chinese Medicine, including massage and medicated bath
214396285|NCT03054974|OTHER|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment with Baimai Ruangao and massage
214396286|NCT03054974|OTHER|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine(medicated bath with wuweiganlu and rub with baimairuangao)
214396287|NCT06071975|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
214396288|NCT06071975|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
214396289|NCT05580640|PROCEDURE|OMT|For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system
214396290|NCT00792428|DEVICE|Real Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
214396291|NCT00792428|DEVICE|Sham Transcranial Direct Current Stimulation|A sham current runs between two electrode positions and might affect the underlying brain tissue.
214396292|NCT05814757|DRUG|OTX-DED|0.3mg dexamethasone ophthalmic insert
214396293|NCT05814757|DRUG|Controlled Insertion|Collagen Punctal Plug 0.2mm (Controlled Insertion)
214396294|NCT05814757|DRUG|Collagen Punctal Plug|Collagen Punctal Plug 0.2mm (Full Insertion)
214396295|NCT02216422|DRUG|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
214396296|NCT02216422|DRUG|Dasabuvir|Tablet
214396297|NCT02216422|DRUG|Ribavirin (RBV)|Tablet
214396298|NCT02909361|DRUG|Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
214396299|NCT03654586|BEHAVIORAL|Sugary drink warning labels|The description of each intervention appears in the descriptions of the experimental arms.
214396300|NCT00004189|BIOLOGICAL|filgrastim|
214396301|NCT00004189|DRUG|becatecarin|
214396302|NCT00004189|DRUG|cisplatin|
214396303|NCT04745858|OTHER|Bowen's Technique|In Bowen's Technique, sequence of short gentle moves are applied over Hamstrings. Skin slack is taken to the lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are given for 4 weeks. The treatment time for each session is 20 minutes.
214396304|NCT04745858|OTHER|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
214503149|NCT04907617|OTHER|Warmed fluids|In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
215001405|NCT05404659|OTHER|Oscillatory Mobilization|conventional physical therapy treatment, postural correction and maitland's oscillatory mobilizitions.
214396305|NCT02677103|DEVICE|radial extracorporeal shock wave therapy|he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.
214396306|NCT02677103|PROCEDURE|ultrasound-guided needle puncture|After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.
214396307|NCT02677103|PROCEDURE|RSWT and USNP|each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
214396308|NCT04285229|DRUG|Ixekizumab|Administered SC
214396309|NCT04285229|DRUG|Placebo|Administered SC
214396310|NCT03870503|DRUG|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
214396311|NCT03870503|DRUG|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol
214396312|NCT03870503|DRUG|Carbetocin|The patient received Carbetocin 100 mic gm
214396313|NCT02674243|DRUG|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
214396314|NCT02674243|DRUG|Talc|In this group, Talc will be used as pleurodesis substance
214396315|NCT02059317|OTHER|Flexion-extension in the sagittal plane|The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
214396316|NCT02059317|OTHER|Rotation in a transverse plane|The movement required of the subject is a rotational movement where the subject alternately touches with his/her left and right hands two targets. The latter are positioned horizontally on either side of the subject at shoulder height and at arm's length. The movement is repeated 30 times at a frequency of 0.28 Hz.
214396317|NCT02059317|OTHER|Complex movement in three dimensions|The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
214396318|NCT00391456|BEHAVIORAL|Animal-assisted Therapy|
214396319|NCT01759875|DRUG|Ritonavir-boosted Atazanavir|Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
214396320|NCT01759875|DRUG|Ritonavir-boosted Atazanavir plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
214396321|NCT01759875|DRUG|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
214396322|NCT02628847|DRUG|sildenafil citrate|
214396323|NCT02628847|DRUG|Placebo|
214396324|NCT00003175|DRUG|fluorouracil|
214396325|NCT03706729|DEVICE|Spraino|"Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch developed with the purpose of minimizing lateral shoe-surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the study sponsor, Spraino® ApS. The participants will receive four pairs of Spraino® upon their enrollment to the study."
214396326|NCT00746317|DRUG|GC33|IV administration at 4 escalating dose levels.
214396327|NCT00372333|DRUG|IDEA-033|
214396328|NCT06285617|DRUG|1-week predisone+1-week celecoxib|20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib (a type of nonsteroidal anti-inflammatory drug) on day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
214396329|NCT06285617|DRUG|6-weeks predisone|20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
214396330|NCT00649480|DRUG|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
214396331|NCT00649480|DRUG|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
214396332|NCT00231894|DRUG|Pioglitazone|pioglitazone 30-45 mg/day
215001406|NCT05404659|OTHER|Mckenzie Retraction Exercises|conventional physical therapy treatment, postural correction and Mckenzie retraction exercises.
214396333|NCT00231894|BEHAVIORAL|Life style diet group|life style diet education group 1x/week
214396334|NCT00231894|OTHER|Placebo|placebo comparator capsules
214396335|NCT00747981|PROCEDURE|Thoracic CT Scan|Perform a CT Scan and an endoscopy
214396336|NCT04447443|DIETARY_SUPPLEMENT|Prebiotic Fiber Supplement + loperamide hydrochloride capsule|"2-week sequential supplementation with prebiotic fiber supplement (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
214396337|NCT04447443|DIETARY_SUPPLEMENT|Maltodextrin + loperamide hydrochloride capsule|"2-week sequential supplementation with placebo of of maltodextrin (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
214396338|NCT04239365|DIAGNOSTIC_TEST|WLE followed by NBI or NBI followed by WLE (crossover design)|EMR scar is inspected using WLE followed by NBI or vice versa
214396339|NCT02153294|PROCEDURE|low tidal volume|Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
214396340|NCT02153294|PROCEDURE|high tidal volume|Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
214396341|NCT02025205|DEVICE|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
214396342|NCT03753217|DEVICE|qCON Monitor|supervision by qCON monitor of the depth of anesthesia
214396343|NCT04110873|DRUG|Antroquinonol Capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
214396344|NCT04110873|DRUG|Antroquinonol Capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
214396345|NCT04110873|DRUG|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
214396346|NCT03508128|OTHER|surgical procedure|Surgical procedure
214396347|NCT00111254|PROCEDURE|Microdermabrasion|Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).
215001407|NCT01056575|DRUG|OC000459|OC000459 100mg tablet, twice daily
215001408|NCT04548128|DEVICE|HeartMate 3 Left Ventricular Assist System (HM3 LVAS)|This clinical trial investigates implant of the HM3 LVAS by techniques other than full median sternotomy.
215001409|NCT02957825|DEVICE|Continuous wireless monitoring|Continuous wireless monitoring of vital signs
215001410|NCT00738088|DRUG|gliclazide|Gliclazide 80mg bd for 6 weeks
215001411|NCT02153281|OTHER|phenelzine treatment|Subjects will have a PET and MRI scan before and after treatment with phenelzine.
215001412|NCT01792466|PROCEDURE|Transpancreatic sphincterotomy|A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
215001413|NCT04529460|DIAGNOSTIC_TEST|COVID-19 antibody point of care test kit|A disponible point of care test that identifies the presence of antibodies to COVID-19
214396348|NCT00962663|DRUG|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
214396349|NCT00962663|DRUG|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
214396350|NCT00962663|DRUG|Placebo|"Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4."
214396351|NCT04575675|DRUG|Dapagliflozin|Dapagliflozin 10mg once daily
214396352|NCT04575675|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan, maximal tolerated dosage
214396353|NCT04575675|DRUG|Beta blocker|Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
214396354|NCT04575675|DRUG|Mineralocorticoid Receptor Antagonist|Mineralocorticoid receptor antagonist, including spironolactone or eplerenone
214396355|NCT04575675|DEVICE|Cardiac resynchronization therapy and/or implantable cardioverter defibrillator|CRT-P, CRT-D or ICD if clinically indicated
214396356|NCT00743743|DIETARY_SUPPLEMENT|Longevinex brand resveratrol supplement|1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient
214396357|NCT00743743|DIETARY_SUPPLEMENT|placebo|1 capsule of placebo daily for 52 weeks
214396358|NCT00309920|BIOLOGICAL|darbepoetin alfa|
214396359|NCT00309920|DRUG|cyclophosphamide|
214396360|NCT00309920|DRUG|docetaxel|
214396361|NCT00309920|DRUG|doxorubicin hydrochloride|
214396362|NCT00309920|DRUG|epirubicin hydrochloride|
214396363|NCT00309920|DRUG|fluorouracil|
214396364|NCT05040490|DRUG|sugammadex as reversal drugs|use sugammadex to reverse neuromuscular blockade
214396365|NCT02166086|PROCEDURE|Endoscopy|Endoscopy involving advanced imaging techniques
214396366|NCT00747773|DEVICE|CryoSpray Ablation System|"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"
214396367|NCT01767129|DRUG|AVP-923-45|One capsule twice daily for 14 days
215001414|NCT05316987|RADIATION|Narrow band ultraviolet B|48 sessions of narrow band ultraviolet
215001415|NCT01695746|DRUG|C.E.R.A.|Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
215001416|NCT06520059|COMBINATION_PRODUCT|Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration|"Group 1 will receive two intraosseous injections of PRP and a subsequent/synchronous intra-articular injection of PRP on the same day.~Group 2 will only receive two intra-articular injections of PRP, separated by one week."
215001417|NCT02145858|DEVICE|Blood drainage post cardiac surgery using PleuraFlow System|
215001418|NCT05569941|DRUG|ABI-4334 Tablet|ABI-4334 Tablet
214396368|NCT01767129|DRUG|Placebo|One capsule twice daily for 14 days
214396369|NCT04165161|DIAGNOSTIC_TEST|search for a patent foramen ovale|Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;
214396370|NCT03308903|DIAGNOSTIC_TEST|DEXA scan|The participant will undergo a whole-body DEXA (DEXA; GE Medical Systems, Chalfont St Giles, UK) scan, lasting approximately 5 minutes. This scan will produce body composition data, including estimates of lean body mass (LBM), appendicular lean mass (aLM) and body fat percentage (BF%).
214396371|NCT00197912|BIOLOGICAL|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with p53, survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate pulsed dendritic cells. 50 mg cyclophosphamide (Sendoxan®, Baxter A/S) is administered p.o. twice a day bi-weekly and 200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day. From the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
214396372|NCT03389893|DRUG|Dupilumab|Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
214396373|NCT03389893|DRUG|Placebo|Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
214396374|NCT02702934|OTHER|Test meal|Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.
214396375|NCT00804869|DEVICE|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
214396376|NCT00804869|DEVICE|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
214396377|NCT01471067|DRUG|Melphalan|140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
214396378|NCT01471067|DRUG|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
214396379|NCT01471067|DRUG|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
214396380|NCT01471067|DRUG|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
214396381|NCT01471067|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
214396382|NCT01471067|DRUG|Rituximab|375 mg/m\^2 by vein on Day -10 for B cell malignancy.
214396383|NCT01471067|DRUG|ATG|"1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3."
214396384|NCT01471067|DRUG|Busulfan|Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
214396385|NCT01471067|DRUG|Clofarabine|30 mg/m\^2 IV Day -7 to Day -4;
214396386|NCT01471067|RADIATION|Total Body Irradiation (TBI)|2 Gy in AM of Day -3.
214396387|NCT01146808|DRUG|Adefovir dipivoxil and hepatitis B vaccination|Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
214396388|NCT05424861|BEHAVIORAL|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4 and SP6 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
214396389|NCT05424861|OTHER|Control group|No application will be made. The mothers in this group will fill in the visual analog scale, which evaluates postpartum uterine pain 3 times between 6-24 hours after birth.
214396390|NCT01833117|OTHER|FID 119515A|topical ocular drops
214396391|NCT01833117|OTHER|Blink® Tears|topical ocular drops
214396392|NCT00636714|BEHAVIORAL|Nursing judgement|Based on the nursing judgement, titrate insulin infusion and determine glucose check frequency to achieve a target glucose of 5-8 mmol/L
214396393|NCT00636714|BEHAVIORAL|Nomogram|A preprinted order outlining a nomogram with instructions for how insulin infusion should be changed based on measured glucose values and how frequent the glucose checks should be
214396394|NCT00569361|PROCEDURE|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
214396395|NCT00004074|BIOLOGICAL|recombinant interleukin-12|Given IV
214396396|NCT00004074|BIOLOGICAL|ABI-007/carboplatin/trastuzumab|Given IV
214396397|NCT01232556|DRUG|Inotuzumab ozogamicin|1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
214396398|NCT01232556|DRUG|Rituximab|375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
214396399|NCT01232556|DRUG|rituximab + gemcitabine|rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
214503150|NCT04907617|OTHER|Combination|"After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet."
215001419|NCT05569941|DRUG|ABI-4334 Placebo|Placebo to ABI-4334 Tablet
214396400|NCT01232556|DRUG|rituximab +bendamustine|rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
214396401|NCT04237480|DIAGNOSTIC_TEST|serum value 1,25(OH)2 vitamin D|statistical evaluation of the serum values
214396402|NCT02225275|DRUG|Lenalidomide|Given PO
214396403|NCT02225275|BIOLOGICAL|Obinutuzumab|Given IV
214396404|NCT02200393|DEVICE|Abdominal FES|"Stimulation intensity was adjusted on a channel by channel basis until a strong visible contraction of the abdominal muscles is observed. During the session, manual adjustment of both the stimulation intensity (to compensate for fatigue) and the duty cycle is possible.~Four pairs of surface electrodes were placed on the participant's abdomen. One pair will be placed on both the right and left side of the rectus abdominis around the naval. One pair of electrodes will also be placed on both the right and left side of the external oblique muscles with one electrode being placed just below the participant's bottom rib and the other below this with a separation of around 3cm."
214396405|NCT04622020|PROCEDURE|Cervical Plexus Block with Local Anaesthesia|Ultrasound guided intermediate cervical plexus block
214396406|NCT04622020|PROCEDURE|Cervical Plexus Block with Depot Steroids|Ultrasound guided intermediate cervical plexus block
214396407|NCT00369811|DRUG|Oxycodone, fentanyl|
214396408|NCT03713814|OTHER|Exercise|"8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.~The researcher will explain, demonstrate and supervise the participants. It will start with 10 minutes of warming-up using a ergometer bicycle, followed by the mat exercises. Some of these will require motor control with mobility, others will require isometry, or concentric and eccentric phases with progression of eccentric phase timing."
215001420|NCT03175939|RADIATION|Radiotherapy|External beam radiotherapy with curative intent, at least 66 Gy
215001421|NCT03175939|DRUG|Cisplatin|cisplatin IV injection over 3 hours
215001422|NCT03175939|DRUG|5-FU|5-FU IV 24 hours continuous infusion
215001423|NCT00120718|DRUG|fasudil|
215001424|NCT01144806|BEHAVIORAL|Nutrition education|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
214396409|NCT01473420|BIOLOGICAL|Epoetin Hospira|Variable dose
214396410|NCT01473420|BIOLOGICAL|Epogen Amgen|Variable dose
214396411|NCT00955903|BEHAVIORAL|Exercise|Participants will participate in supervised exercise sessions
214396412|NCT00955903|BEHAVIORAL|Reduced Calorie Diet|Participants will follow a reduced calorie diet
214396413|NCT00955903|BEHAVIORAL|Weight Maintenance Diet|Participants will follow a weight maintenance diet
214396414|NCT01811017|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
214396415|NCT02308501|DRUG|Lastacaft ®|
214396416|NCT02308501|DRUG|Tears Naturale ® (Placebo)|
214396417|NCT00712855|BIOLOGICAL|mapatumumab|3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
214396418|NCT00712855|DRUG|sorafenib|400 mg orally, twice a day continuously in each cycle
214396419|NCT01190033|DEVICE|Neurotome OFF|In this intervention the neurotome will be unconnected.
214396420|NCT01190033|PROCEDURE|neurolysis|In this procedure the neurotome will be connected
214396421|NCT02492217|DRUG|Adalimumab|
214396422|NCT03020095|DRUG|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
214396423|NCT03020095|DRUG|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
214396424|NCT03020095|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
214396425|NCT03020095|DRUG|Ribavirin|Ribavirin(RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)administered orally
214396426|NCT00134524|PROCEDURE|MME procedure|
214396427|NCT03862482|DEVICE|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Brånemark® implant placed at sites 2 (left medial) and 5 (right distal), Swede-Vent® implant placed at sites 1 (left distal) and 4 (right medial), Screw-Vent® implant placed at site 3 (para symphysis)
214396428|NCT03862482|DEVICE|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Brånemark® implant placed at site 3 (para symphysis), Swede-Vent® implant placed at sites 2 (left medial) and 5 (right distal), Screw-Vent® implant placed at sites 1 (left distal) and 4 (right medial)
214396429|NCT03862482|DEVICE|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Brånemark® implant placed at sites 1 (left distal) and 4 (right medial), Swede-Vent® implant placed at site 3 (para symphysis), Screw-Vent® implant placed at sites 2 (left medial) and 5 (right distal)
214396430|NCT01121640|PROCEDURE|CA125 assay on Abbott Architect i1000SR platform|Bead-based sandwich ELISA style assay
214396431|NCT01121640|PROCEDURE|HE4 assay on Architect i1000SR platform|Bead-based sandwich ELISA style assay
214396432|NCT01121640|PROCEDURE|Transvaginal Ultrasound|Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
214396433|NCT04101864|PROCEDURE|Electromagnetic navigation|Acetabular component placement in total hip arthroplasty will be performed wit the help of electromagnetic image-less navigation system.
214396434|NCT04101864|PROCEDURE|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
214396435|NCT01474408|BEHAVIORAL|interval training day 1|
214396436|NCT01474408|BEHAVIORAL|Moderate exercise day 2|
214396437|NCT01474408|BEHAVIORAL|Control day 3|
214396438|NCT06363955|DEVICE|Carbamide Peroxide Mouthwash|The experinmental mouthwah is a solution containing 4.3% w/v hydrogen carbamide, which breaks down to 1.51% w/v hydrogen peroxide, serving as the active ingredient. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine. It is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.
214396439|NCT06363955|DEVICE|Placebo mouthwash|Placebo mouthwash is a similar (look-and-taste-alike) solution to the experinmental mouthwash made by the same manufacturer, without active ingredients. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine.
214396440|NCT04840953|DEVICE|Vçac|VAC THERAPY vs SURGICAL DREINAGE
214396441|NCT03667235|OTHER|Treatment of human pericardium with glutaraldehyde in OZAKI procedure|10 versus 20 minutes treatment of human pericardium with 0.6% glutaraldehyde in OZAKI procedure
214396442|NCT03667235|OTHER|Treatment of human aortic valve tissue with glutaraldehyde|10 versus 20 minutes treatment of human aortic valve tissue with 0.6%glutaraldehyde
214396443|NCT05401682|OTHER|Cox chiropractic care|Manual distraction of spine in a prone position using specially assisted table
214396444|NCT00388362|DRUG|Sirolimus|Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
214396445|NCT00388362|DRUG|Prednisone|Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
214396446|NCT00178243|PROCEDURE|3D Conformal Radiation Therapy and Radiosurgery|
214396447|NCT04457622|OTHER|Auditory perception tasks in healthy participants|"The participants complete auditory perception tasks while EEG, and MEG record brain signals (primary outcome measure). The tasks acquire behavioral responses with button presses (secondary outcome measure).~All analyses are intra-subject (no analyses are between-subject)."
214503151|NCT04907617|OTHER|Control|The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
214503152|NCT02873897|DIETARY_SUPPLEMENT|Session A: Experimental products (selected enriched products)|
214503153|NCT02873897|DIETARY_SUPPLEMENT|Experimental session: to select enriched products|
214503154|NCT02873897|DIETARY_SUPPLEMENT|Session B: Control (standard products without enrichment)|
214503155|NCT02873897|DIETARY_SUPPLEMENT|Control session|
215001425|NCT01144806|DIETARY_SUPPLEMENT|RUTF|Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
214396448|NCT05608941|OTHER|Respiratory muscle training|The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.
214396449|NCT05608941|OTHER|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
214396450|NCT01916317|DRUG|0.5% lignocaine 60mM|
214396451|NCT01874093|DEVICE|The Ischemic Stroke System|SPG stimulation and standard of care
214396452|NCT01874093|DEVICE|Sham control|Sham stimulation and standard of care
214396453|NCT00435903|DEVICE|Palm Pilot|
214396454|NCT04648891|DRUG|Lidocaine|Subcutaneous injection 0.5cc 2% in 1:100,000 epinephrine
214396455|NCT04648891|DEVICE|Vibrating wand|a vibrating instrument held adjacent to the cricothyroid space
214396456|NCT02595229|PROCEDURE|Pronator quadratus repair|Suturing of the pronator quadratus muscle
214396457|NCT05822297|DEVICE|Neuromuscular electrical stimulation|NMES will consist of a 12 week electrical stimulation program, three times a week. Electrical stimulation will be done on the quadriceps muscles of both legs simultaneously. For each leg, one electrode is placed on the proximal side and one on the distal side of the quadriceps muscle. Electrical stimulation sessions will take 30min, at a stimulation frequency of 50Hz, an intensity where we can at least see a visible or palpable contraction with a maximum intensity of 100mA (we will choose the highest intensity that is easily supported by the participant without inducing discomfort) and a pulse width of 400μs. The activation within the activation-rest cycle consists of a 1s ramp-up, 7s full activation and 1s ramp-down, followed by 18s rest. Every 4 weeks the rest period will be diminished with 3s until a total of 9s.
214396458|NCT02890056|BEHAVIORAL|H2GO!|
214396459|NCT03259373|BEHAVIORAL|Early Patient-Level and Provider-Level Educational Intervention|"Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.~Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation."
214396460|NCT03259373|BEHAVIORAL|Delayed Provider-Level Educational Intervention|Delayed intervention letters to patients' providers, where they may be identified, that explain this project, the nature of the problem, and identify a list of their patients who are flagged as at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation.
214396461|NCT05576259|OTHER|oVRcome phone app with headset|The intervention oVRcome is self-help VRET for social anxiety, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
214396462|NCT04919434|OTHER|IRECO|During 5 days, women included in the study will have to only use personal care product distributed by the research team.
214396463|NCT04798378|DEVICE|Neurosleeve|Myoelectric devices for restoration of independent arm function
214396464|NCT06634056|DRUG|Pentoxifylline|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
214396465|NCT06634056|OTHER|Placebo|One placebo orally three times a day and another placebo orally two times a day on day one of radiotherapy and continue treatment for 6 months.
214396466|NCT06634056|OTHER|α-Tocopherol|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
214396467|NCT04474223|DRUG|Dexamethasone|"In mother in whom 2° AVB or AV interval \>170 ms has been diagnosed in the fetus:~Dexamethasone 8 mg po/day for 10 days. Then dexamethasone 4 mg po/ day through 28 weeks 6 days gestational age (GA); then 3 mg/day from 29 wks 0 days to 29 wks 6 days GA; then 2 mg/day until delivery"
214396468|NCT04474223|DRUG|IVIG|"In a mother in whom 2° AVB has been diagnosed in the fetus:~One dose of IVIG \[1g/kg of maternal weight (max dose 70 g)\] at diagnosis of 2° AVB (within 12 hours of detection by mother via home monitoring and within 6 hours of confirmation by echocardiogram). A fetal AV interval \> 170 ms will not be treated with maternal IVIG, only dexamethasone."
214396469|NCT03466151|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
214396470|NCT03466151|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
214396471|NCT06096974|DRUG|YL-17231|YL-17231 will be administered orally once daily in a continuous regimen
215001426|NCT00837460|OTHER|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
214396472|NCT05837975|DEVICE|FREE Walk Exoskeleton|Using a robotic exoskeleton to help with lower limb activities that are difficult due to neurological diseases. Used at home for individual patient training.
214396473|NCT05837975|OTHER|Traditional Rehabilitation|Traditional rehabilitation refers to the use of conventional therapeutic methods.
215001427|NCT06287229|DRUG|Blinatumomab|Given by Infusion
215001428|NCT06287229|DRUG|Inotuzumab Ozogamicin|Given by IV
215001429|NCT06287229|DRUG|Hyper-CVAD|Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.
214396474|NCT05216666|PROCEDURE|Lateral approach|Total hip arthroplasty performed through a lateral surgical approach (Gammer)
214396475|NCT05216666|PROCEDURE|Posterior approach|Total hip arthroplasty performed through a posterior surgical approach (Moore)
214396476|NCT01997502|DEVICE|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.~Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.~No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
214396477|NCT01997502|OTHER|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
214396478|NCT06041763|PROCEDURE|Meniscal Repair Procedure|All meniscal repairs will be performed by the surgeons who are listed as investigators for the study. Meniscal repair consists of arthroscopic suturing of torn fragments. This takes approximately 20 minutes. In the interventional group, the BEAR implant will be inserted through preexistent arthroscopic portals after repair is complete. This will take an additional 2 minutes.
214396479|NCT06041763|DEVICE|BEAR Implant|The BEAR Implant (22 mm in diameter and 45mm in length) is cylindrical in shape and comprised of collagen and extracellular matrix derived from bovine connective tissue, which has been cleaned, disinfected and processed by a proprietary manufacturing method. The implant has been terminally sterilized by electron-beam inadiation and is intended to be used with up to 10 ml of autologous blood drawn during the surgical implantation procedure. The BEAR Implant is resorbed within 8 weeks and replaced with a fibrovascular repair tissue.
214396480|NCT04619368|OTHER|Follow up calls|The follow-up will consist in phone call with an intensive care doctor. These visits would be the opportunity to screen the complications after intensive-care with, find solutions to cure them or decrease their impact on patient's life to improve quality of life and prevent the post-traumatic syndrome disorder PTSD. A review would be sent to the patients' General Practitioners at the end of each visit.
214396481|NCT04925700|DIETARY_SUPPLEMENT|ProDentis Lozenge|1-2 ProDentis Lozenges per day
214396482|NCT04925700|OTHER|Placebo Lozenge|1-2 Placebo Lozenges per day
214396483|NCT05742230|DRUG|Henagliflozin 10 mg|Participants will receive 10 mg single oral tablets orally once daily.
214396484|NCT05742230|DRUG|blank control|standard treatment
214396485|NCT01540396|BEHAVIORAL|Dietary modification and medications|Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
214396486|NCT01227408|DRUG|doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate|doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
214396487|NCT02172456|DRUG|99mTc-radiolabelled tiotropium|
214396488|NCT02172456|DRUG|non-radiolabelled tiotropium|
214396489|NCT06343337|DIAGNOSTIC_TEST|Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman|Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).
214396490|NCT04451343|OTHER|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
214396491|NCT05095129|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
215001430|NCT06287229|DRUG|Mini-hyper-CVD|Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD
214396492|NCT03329430|OTHER|Foot orthoses|Customized foot orthoses
215001431|NCT01021189|DRUG|AZD1446|Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
215001432|NCT01021189|DRUG|Placebo|Oral solution Dose single and followed by 7-day multiple dosing.
215001433|NCT04487236|DRUG|ZN-A-1041 50mg BID|Orally 21days for one cycle
215001434|NCT04487236|DRUG|ZN-A-1041 100mg BID|Orally 21days for one cycle
215001435|NCT04487236|DRUG|ZN-A-1041 200mg BID|Orally 21days for one cycle
215094986|NCT01906112|PROCEDURE|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
215094987|NCT01177969|BEHAVIORAL|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
214396493|NCT05408923|DRUG|saline 0.9%|Control group will get normal saline for irrigation throughout the case.
215001436|NCT04487236|DRUG|ZN-A-1041 400mg BID|Orally 21days for one cycle
215001437|NCT04487236|DRUG|ZN-A-1041 600mg BID|Orally 21days for one cycle
215001438|NCT04487236|DRUG|ZN-A-1041 800mg BID|Orally 21days for one cycle
215001439|NCT04487236|DRUG|ZN-A-1041 1000mg BID|Orally 21days for one cycle
215001440|NCT04487236|DRUG|ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
215001441|NCT04487236|DRUG|ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
215001442|NCT04487236|DRUG|ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
215001443|NCT04487236|DRUG|ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle|Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
215001444|NCT00990886|DRUG|Placebo|Once daily for 12 weeks
215001445|NCT00990886|DRUG|Oxybutynin chloride|15 mg once daily for 12 weeks
214396494|NCT05408923|DRUG|(0.05% chlorhexidine gluconate (CHG) in sterile water)|Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
214396495|NCT05763992|DIETARY_SUPPLEMENT|Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)|Each FLA cycle will consist of 5 consecutive days of a specific FLA scheme, which will be repeated with a three-week interval. The FLA will consist of a plant-based, low-calorie (about 600 Kcal on day 1; about 300 Kcal on day 2 to 5), low-protein, low-carbohydrate diet. The first FLA cycle will start two days prior to the day of first chemo-immunotherapy cycle administration and will continue for two more days after chemotherapy. In the absence of significant contraindications or severe adverse events, subsequent FLA cycles will recur with three-week intervals and will maintain the same timing with respect to chemo-immunotherapy administration.
214396496|NCT04669912|OTHER|glucose control and sensor usage|Data related to glucose control and sensor usage collected from the Libreview platform
214396497|NCT05957757|DRUG|RC48|"RC48 was scheduled to be administered at a dose of 2.0mg/kg every 2 weeks, with the first dose on day 1 of the first cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
214396498|NCT05957757|DRUG|Tislelizumab|"Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
214396499|NCT00284765|PROCEDURE|flector|
214396500|NCT05966376|DEVICE|Hemostatic device for distal radial approach.|Hemostasis after distal radial approach is done with one of two devices, one of them is designed specifically for the distal radial approach; the other is not but a modified technique with the last one could be helpful.
214396501|NCT06489093|DRUG|NSF|Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of NSF using a microapplicator on the carious lesion for 1 minute. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
214396502|NCT06489093|DRUG|SDF+KI|Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of 38% silver diamine fluoride (Riva star 38%, SDI) using a microapplicator on the carious lesion. Immediately afterwards, potassium iodide is applied as a reducing agent. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
214396503|NCT06489093|OTHER|Control group|Subjects will receive oral hygiene instructioins to apply fluoridated toothpaste to a toothbrush and brush teeth thoroughly for at least 2 minutes, then expectorate and rinse.
214396504|NCT02329600|DRUG|green tea tablets (Green tea extract 5:1) 200 mg|Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
214396505|NCT02329600|DRUG|Triamcinolone Acetonide|topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
214396506|NCT00115375|DRUG|Clopidogrel (SR25990)|
215094988|NCT01177969|BEHAVIORAL|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
214396507|NCT02304328|OTHER|Clinical assessment|Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
214396508|NCT03587350|DEVICE|Shimmer monitoring|The shimmer monitor, monitors movement and the range of movement.
214396509|NCT01977001|DEVICE|MigraineBoxTM|
214396510|NCT05681403|DRUG|Improved BEAM regimen|Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.
214396511|NCT06379230|OTHER|This study is purely descriptive study.|This study is purely descriptive study.
214396512|NCT02868437|DEVICE|intrauterine self-cross-linked hyaluronic acid gel|intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
214396513|NCT06029530|DRUG|Atropine Ophthalmic|eye drops to be administered once daily
214396514|NCT00850720|OTHER|Blood draws|Samples of blood to be drawn before surgery, and nine hours after surgery.
214396515|NCT02950935|DRUG|Progesterone|subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
214396516|NCT02950935|DRUG|Placebo|subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
214396517|NCT04374500|DRUG|Leptin infusion plus vasodilators in healthy men|This applies only to protocol 2 with two arms (leptin or saline) where four vasodilatators (bradykinin, acetylcholine, sodium nitroprusside and verapamil) were infused concomitantly
214396518|NCT04374500|DRUG|Leptin infusion in healthy men|This applies only to protocol 1 when only leptin was given
214503156|NCT03008785|OTHER|exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
214503157|NCT03008785|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
215094989|NCT02093910|DRUG|Monosialotetrahexosylganglioside|
215094990|NCT04474041|DEVICE|EyeQue Insight|The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
215094991|NCT03629912|BEHAVIORAL|Socially-Based Exercise Intervention for Older Adults|A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
215094992|NCT05807984|RADIATION|Carbon ion radiation therapy DT: 74Gy/20 fractions|patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation
214503158|NCT03008785|OTHER|Placebo|Daily supplementation in 1 capsule per day containing starch of corn.
214503159|NCT06369714|DRUG|Concerta|Methylphenidate Hydrochloride Extended-Release Tablets with the following specifications: 18mg dosage, oral administration, once a day for a duration of 8 weeks.
214396519|NCT04374500|DRUG|Vasodilators in CAD patients|This applies only to protocol 3
214396520|NCT04963062|DEVICE|Holmium laser with Moses lasers|The holmium laser with Moses is FDA approved. It emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed. The goal is to increase stone ablative volume and decrease retropulsion of the stone.
214396521|NCT04963062|DEVICE|Holmium laser with thulium lasers|The holmium laser with thulium laser is FDA approved. It has a different wavelength then the holmium laser with Moses and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns
214396522|NCT01482949|DRUG|AGS-003|Autologous Dendritic Cell Immunotherapy
214396523|NCT01857323|DRUG|Albuterol Spiromax®|Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
214396524|NCT05128292|DIETARY_SUPPLEMENT|CoQ10 plus Selenium|400 mg/day CoQ10 soft gel capsula (Bio-Quinone active 100 mg b.i.d) plus 200 microgram organic selenium yeast tablet (SelenoPrecise 100 microgram b.i.d.) over 8 weeks
214396525|NCT03873246|DRUG|OC-01 0.1% 0.6 mg/ml|OC-01 (varenicline) nasal spray: 0.1 % (0.6 mg/ml)
214396526|NCT03873246|DRUG|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
214396527|NCT03873246|OTHER|placebo comparator|vehicle control
214396528|NCT06529211|DIETARY_SUPPLEMENT|Low caloric diet|Low caloric diet: the participants will receive low caloric diet program (1500 Kcal/ day) for 6 weeks as follows: 45% carbohydrate, 20% fat and 35% proteins of total calorie intake.
214396529|NCT06529211|DEVICE|Ultrasound cavitation|"Ultrasound cavitation + Low caloric diet Low caloric diet program (1500 Kcal/ day): for 6 weeks.~Ultrasound cavitation: It will be on abdomen for 30 minutes/session, 2 sessions/week for 6 weeks as follows:~* The participants will be in supine lying position and the abdomen is divided into two sides right and left from the midline.~* The Ultrasound pulsed waves will be set with power input (AC100/ 240V), frequency (40 KHz), and Power output (45W). This will be for 15 minutes on each abdominal side."
214396530|NCT06529211|DEVICE|Whole body vibration|"Whole body vibration + Low caloric diet Low caloric diet program (1500 Kcal/ day) for 6 weeks.~Whole body vibration: for 30 minutes/session, 2 sessions/week for 6 weeks as follows:~* The participants will begin with a brief warm-up for 5 minutes by doing deep breathing exercises.~* Then they will stand with feet shoulder-width apart on the platform while holding handrails to maintain balance and stability. They will be instructed to relax and allow the vibrations to pass through her body. This will be applied for 20 minutes per session.~* The vibration will be started with lower settings and gradually will be increased till the desired frequency and amplitude (45 HZ) will be reached.~* After the session will be completed, the participant will be instructed to cool down gradually by doing deep breathing for 5 minutes to help their body to return to a resting state. They will be advised to drink plenty of water to be hydrated and recovered after the WBV session."
214396531|NCT03752736|BEHAVIORAL|"I wear sunscreen everyday song-based video"|"All four classes (arms) will be shown (sitting on carpet, not participating) a 2-3 minute song-based video titled I wear sunscreen everyday in which they observe elementary age children applying sunscreen in a systematic fashion. Following the viewing, classes will be administered this video guided, song- based intervention while their teacher documents their independent participation using our classroom map data collection sheet."
214396532|NCT03262701|DRUG|Hydrogen Peroxide Gel, 13 weeks|13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
214396533|NCT03262701|DRUG|Hydrogen Peroxide Gel, 26 weeks|26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
215001446|NCT04560842|DEVICE|A high flow oxygen device.|The HFNC group use high flow oxygen device for 48 hours
214396534|NCT03262701|OTHER|Scaling and Root planing group|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without custom tray application of 1.7% peroxide gel
214396535|NCT03423459|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
214396536|NCT02031744|DRUG|erlotinib [Tarceva]|150 mg oral administration once daily
214396537|NCT02031744|DRUG|Placebo|15 mg/kg intravenous administration every 3 weeks
214396538|NCT02031744|DRUG|Onartuzumab [MetMAb]|15 mg/kg intravenous administration every 3 weeks
214396539|NCT03868319|PROCEDURE|lung protective ventilation strategy|low tidal volumes and positive end-expiratory pressure mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
215001447|NCT04560842|DEVICE|Conventional oxygen therapy|Conventional oxygen device
215001448|NCT05130437|BIOLOGICAL|mRNA-3927|mRNA-3927 dispersion for IV infusion
215001449|NCT02239289|OTHER|Biofeedback|Idem as described in the arm section (above)
215001450|NCT03010501|OTHER|Food Energy Density|Food Energy density manipulated
214396540|NCT03868319|PROCEDURE|nonprotective ventilation|large tidal volume and zero PEEP mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
214396541|NCT01368211|BIOLOGICAL|2-4-day-old Mirasol-treated Platelets Transfusion|"2-4-day-old Mirasol-treated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL"
214396542|NCT01368211|BIOLOGICAL|2-4-day-old Untreated Platelets Transfusion|"2-4-day-old Untreated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL"
214396543|NCT03749460|BIOLOGICAL|Nivolumab|Given IV
214396544|NCT03749460|BIOLOGICAL|Ipilimumab|Given IV
215001451|NCT01453231|PROCEDURE|thighplasty|Plastic surgery of thigh
214396545|NCT03749460|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
214396546|NCT03315819|PROCEDURE|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique.
214396547|NCT03315819|PROCEDURE|Immobilization interne rotation|Immobilisation in rotation Internal (Dujarrier) 3 weeks then rehabilitation
214396548|NCT03883958|PROCEDURE|Erector Spinae Plane Block|ESPB will be performed in sitting or lateral decubitus position. The target vertebral level will be correspond to the approximate mid-point of the extent of fractured ribs. The tip of the transverse process of the target vertebra will be identified using the high-frequency linear placed in cephalocaudal orientation about 3 cm to the spinous process. The skin and subcutaneous tissue will be infiltrated with 2-3 ml of 2% lignocaine. With the transducer fixed over the targeted TP, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be advanced in-plane to the ultrasound beam in a cephalo-caudal direction to contact the TP. Correct needle tip position will be confirmed by doing alternating aspiration to confirm lack of inadvertent vascular puncture with injection of 1-2 ml of saline and visualizing linear fluid spread deep to erector spinae muscle, separating it from the TP. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
214396549|NCT03883958|PROCEDURE|Paravertebral Block|TPVB will be performed at a spinal level midway between the uppermost and the lowest fractured rib with the patient in sitting or lateral decubitus position (with patients lying on their unaffected side). The ultrasound-guided technique will be used. A high-frequency linear transducer will be used to confirm the levels of the fractured ribs. The most cephalad and most caudad fractured ribs will be identified first. The fractured rib in the middle will be then identified, and the rib will be then traced back medially. After skin and subcutaneous tissue infiltration with 2-3 ml of 2% lignocaine, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be inserted in a lateral-to-medial direction until the needle tip entered the paravertebral space. 1-2 ml of Saline will be injected into the paravertebral space while observing the pleura being moved deeply. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
214396550|NCT03930134|PROCEDURE|sparse uterine suture|The slowly absorbed Vicryl 1 suture with a large round needle is introduced intramyometrially right above the endometrium. The suture starts in one corner and proceeds along the lower then the upper edge returning back to the incision point. Subserous layer is closed upon using the same thread in order to cover the purse suture and to complete the haemostasis while increasing the wound thickness.
214396551|NCT03930134|PROCEDURE|one layer uterine closure|one layer classical continious uterine closure using slowly absorbed Vicryl 1
214396552|NCT02806284|BIOLOGICAL|PPSV23, Act-HIB|"described in Arm description"
214396553|NCT01987830|DEVICE|MRI-PET|"* \[11C\] temozolomide for PET scan and a contrast dye for the MRI scan~* Drawing blood to assess the radioactivity of \[11C\] temozolomide"
214396554|NCT01987830|DEVICE|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of \[11C\] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
214396555|NCT02406209|DRUG|NS2|NS2 ophthalmic drops (0.5%)
214396556|NCT02406209|DRUG|Prednisolone acetate ophthalmic suspension (1%)|
214396557|NCT02283437|BEHAVIORAL|Problem-solving Based Bibliotherapy Program|The PSBPF will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.
215094993|NCT06380010|OTHER|Mediterranean diet group|Females who met the inclusion and exclusion criteria were allocated in groups of one to either the Control group or the Intervention (MD) group using a random assignment method applied by an independent statistician. During the trial, every participant in both groups had two individual sessions with the assigned researchers. These sessions took place at the beginning of the trial and three months later, and involved anthropometry measurements, evaluation of dietary habits, assessment of psychological well-being, and collection of blood samples. Treatment allocation was not revealed to the appointed statistician until the end of the study and release of the final outcomes.
215121402|NCT03726489|DEVICE|Daavlin 7 series 3 panel narrow band phototherapy home units|"Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors"
214396558|NCT02283437|BEHAVIORAL|Behavioral Management and Education Program|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the behavioral management and education group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) family management programs for schizophrenia.
214396559|NCT06353659|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU
214396560|NCT01349660|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks
214396561|NCT01349660|DRUG|BKM120|BKM120 orally (PO) once daily
214396562|NCT04193748|DRUG|Topical pomegranate seeds and peel extracts|Topical pomegranate seeds and peel extracts in the form of gel
214396563|NCT02099435|DEVICE|Hemospray|The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
214396564|NCT03746756|BEHAVIORAL|SBIRT|"As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study."
214503160|NCT06369714|DEVICE|Digital therapeutics|30 sessions of digital therapeutics, each lasting 30 minutes, will be conducted with a frequency of once every 1-2 days over an 8-week period.
214503161|NCT06364280|DEVICE|BVM|Bag-Valve-Mask Ventilation
214503162|NCT06364280|DEVICE|SGA|Supraglottic Airway
214503163|NCT06364280|DEVICE|ETI|Endotracheal Intubation
214396565|NCT03746756|BEHAVIORAL|SBIRT+RMC-PC|In addition to SBIRT, those randomly assigned to the experimental condition will also receive Recovery Management Checkups for Primary Care (RMC-PC) at the time of referral/study enrollment and quarterly for 12 months. RMC-PC involves a linkage manager reviewing the assessment data and using motivational interviewing to encourage the person to go to treatment and identify barriers to entering or staying in treatment. It also involves problem solving on how to address common issues (e.g., transportation, scheduling), staying in regular contact for the first two weeks to make sure they stay in treatment, and checking in on continuing care compliance at later checkups.
214396566|NCT05764239|DRUG|SYNB1934v1|SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.
214396567|NCT05764239|DRUG|Placebo|Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
214396568|NCT00518141|DRUG|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
214396569|NCT05200637|DEVICE|Orsiro stent|Orsiro stent
214396570|NCT05200637|DEVICE|Xience stent|Xience stent
214396571|NCT05200637|DEVICE|Any drug-eluting stent|Any drug-eluting stent
214503164|NCT06794138|PROCEDURE|dental implant placement|The fit of the surgical guide was checked and a flapless procedure was performed under local anesthesia. However, in cases where the width of keratinized mucosa was insufficient a limited full-thickness flap was elevated. The surgical template was fixed on the remaining dentition and mucosa using template fixation pins. Fully guided implant bed preparation was performed. Osteotomies were carried out with external cooling at a drill rotation speed of 800 rpm. Implant placement was performed using a manual torque wrench Dental implants were placed non-submerged. In cases of flap elevation, wound margins were stabilized with single interrupted sutures. Sutures were removed at 7 days postop.
214503165|NCT05915026|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
214396572|NCT00028314|DRUG|Abacavir sulfate|
214396573|NCT00028314|DRUG|Atazanavir/Ritonavir|
214396574|NCT00028314|DRUG|Lopinavir/Ritonavir|
214396575|NCT00028314|DRUG|Nevirapine|
214396576|NCT05353543|DRUG|SSRIs|In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
214396577|NCT05353543|PROCEDURE|acupuncture (strong reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Strong reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
214396578|NCT05353543|PROCEDURE|acupuncture (weak reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Weak reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
214503166|NCT06239012|DEVICE|Position measurement with BePow|14 measurements taken with the device
214503167|NCT06239012|OTHER|Position measurement with MCPAA scale|MCPAA : measurement of seated postural control in adults in French 12 measurements taken with the goniometer
214503168|NCT02610439|OTHER|Laboratory Biomarker Analysis|Correlative studies
215001452|NCT03796663|BEHAVIORAL|Mindful Parenting Program|"The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines."
215001453|NCT03796663|BEHAVIORAL|MATCH BPT Program|The MATCH BPT Program consists of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 60 minute individually-implemented sessions.The sessions will consist of the coach obtaining and reviewing weekly assignments completed by the parent, followed by activities and discussions that focus on a particular parenting skill (i.e. praise, active ignoring, giving effective instructions). The discussions will emphasize benefits and possible problems that the parent may encounter throughout the week while implementing the new skill. The coach will assign to the parent a practice assignment to further encourage use of the concept.
214396579|NCT05353543|PROCEDURE|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to strong reaction acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
214396580|NCT00057811|DRUG|doxorubicin hydrochloride|Given IV, IT, or orally
214396581|NCT00057811|DRUG|cyclophosphamide|Given IV
214396582|NCT00057811|DRUG|methotrexate|Given IV or IT
214396583|NCT00057811|DRUG|rasburicase|Given IV
214396584|NCT00057811|DRUG|leucovorin calcium|Given IV or orally
214396585|NCT00057811|DRUG|prednisone|Given IV or orally
214396586|NCT00057811|DRUG|methylprednisolone|Given IV or orally
214396587|NCT00057811|BIOLOGICAL|filgrastim|Given subcutaneously
214396588|NCT00057811|BIOLOGICAL|rituximab|Given IV
214396589|NCT00057811|DRUG|cytarabine|Given IT
214396590|NCT00057811|DRUG|etoposide|Given IV
214396591|NCT00057811|DRUG|vincristine sulfate|Given IV
214396592|NCT00057811|DRUG|hydrocortisone sodium succinate|Given IT
214396593|NCT00057811|OTHER|laboratory biomarker analysis|Correlative studies
214503169|NCT03702777|DRUG|ASP8302|Oral Capsule
214503170|NCT03702777|DRUG|Placebo|Oral Capsule
214503171|NCT02357654|DRUG|GnRH|single shot of GnRH agonist
214503172|NCT02357654|DRUG|placebo|placebo
214503173|NCT03009344|DRUG|Tazemetostat|Tazemetostat tablets.
214503174|NCT04329598|OTHER|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
214503175|NCT04329598|OTHER|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
214503176|NCT00378898|DEVICE|BRAVO capsule|
214503177|NCT00378898|PROCEDURE|Fluoroscopy|"one time xray to determine evacuation of bravo"
214503178|NCT00378898|OTHER|sham BRAVO capsule placement|
214503179|NCT02794428|DRUG|Eflornithine|Eflornithine\*, 2 tablets, Oral, Daily for 18 months
214396594|NCT06004596|DIAGNOSTIC_TEST|13C-Spirulina Gastric Emptying Breath Test (GEBT)|Diagnostic test
214396595|NCT06004596|DIAGNOSTIC_TEST|13C-Spirulina Gastric Emptying Breath Test (GEBT) - repeat|Diagnostic test - repeat for biological variability deterination
214503180|NCT02794428|OTHER|Eflornithine placebo|Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
214503181|NCT02534233|DEVICE|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
214396596|NCT03764423|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
214396597|NCT03764423|DIETARY_SUPPLEMENT|Microcrystalline cellulose|Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.
214396598|NCT06327763|PROCEDURE|ilioinguinal nerve section|patients operated on by open inguinal hernioplasty with ilioinguinal neurectomy
214396599|NCT02337712|RADIATION|q.d. RT|65 Gy in 26 fractions
214503182|NCT00551421|BIOLOGICAL|pertuzumab|Given IV
214503183|NCT00551421|BIOLOGICAL|cetuximab|Given IV
214503184|NCT00551421|DRUG|irinotecan hydrochloride|Given IV
214503185|NCT00551421|OTHER|immunohistochemistry staining method|Correlative study
215001454|NCT00640289|DRUG|Fibrogammin P|Prophylaxis treatment
215001455|NCT06480630|DRUG|Basiliximab|Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)
214396600|NCT02337712|RADIATION|b.i.d.RT|45 Gy in 30 fractions
214396601|NCT02337712|DRUG|etoposide and cisplatin|etoposide and cisplatin concurrent with radiotherapy
214396602|NCT03161119|DEVICE|Ultrasound guided embryotransfer with Cook K-Jets-551910-S|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
214396603|NCT03161119|DEVICE|Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
214396604|NCT02089815|BEHAVIORAL|Home based exercise|modified Otago exercise program to simple designed home based exercise program
214396605|NCT02089815|OTHER|fall prevention education and counseling|
214503186|NCT00551421|OTHER|fluorescence in situ hybridization|Correlative study
214503187|NCT00551421|OTHER|gene expression analysis|Correlative study
214503188|NCT00551421|OTHER|mutation analysis|Correlative study
214503189|NCT00551421|OTHER|polymerase chain reaction|Correlative study
214503190|NCT00551421|OTHER|laboratory biomarker analysis|Correlative study
214503191|NCT05867381|DEVICE|HEPA filtration|HEPA filters with the capacity to reduce PM2.5 levels
214503192|NCT05867381|DEVICE|Sham filtration|Sham filtration use the same appearance of air purifier but with HEPA filter removed.
214503193|NCT00369460|OTHER|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
214503194|NCT03393559|PROCEDURE|leg elevation|Patients' leg will be raised by a pillow under both legs and the hip and knee joints will be flexed 45 degrees to position both knees at the heart level.
214503195|NCT05905549|PROCEDURE|extended pancreatic transection during laparoscopic pancreaticoduodenectomy|the pancreatic transection was performed at the pancreatic neck beyond the left side of the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy
214503196|NCT02271906|DRUG|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
214503197|NCT05421572|DIAGNOSTIC_TEST|Fibrotouch|Fibrotouch will be performed showing the stiffness and fat content of liver
214503198|NCT00978718|DIETARY_SUPPLEMENT|high-selenium baker's yeast|Given orally
215001456|NCT00886457|DRUG|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
214396606|NCT06204328|OTHER|Benson relaxation technique and mHealth psychoeducation|"Benson relaxation technique \& mHealth psychoeducation (combined intervention) will receive: 6 months.~Benson relaxation technique: Definition, benefits, and instruction about the Benson relaxation technique will be provided through recorded video, and a nurse will guide individuals face-to-face after receiving training from a physiotherapist.~mHealth psychoeducation: There will be six sessions in a total of six months of intervention, and every session will be conducted at the beginning of each month. During each session, recorded videos based on the self-determination theory (symptom management, maintaining and enhancing relationships, problem-solving, stress and coping, self-care, and effective communication) will be provided face-to-face to the intervention group via smartphones, tablets, or handheld computers. As well as phone calls and SMS reminders will continue every week for follow-up and question and answer sessions."
214396607|NCT00429260|DRUG|Saredutant|
214396608|NCT05264493|DRUG|NaxRedy ™|5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
214396609|NCT05264493|DRUG|Naloxone Hydrochloride Injection, USP|2 mg IM (2mg/2 mL) injection into gluteal muscle
214396610|NCT05264493|DRUG|Naloxone Hydrochloride Injection, USP|2 mg bolus IV (2mg/2 mL)
214396611|NCT04228328|DIAGNOSTIC_TEST|The 6-minutes Walk Test|To walk for 6 minutes
214396612|NCT04174235|DEVICE|Ultrasound scan|A full history taking was obtained according European surveillance of congenital anomalies EURO-CAT core data. All women underwent abdominal and transvaginal US (Toshiba Xario 200 unit)
214396613|NCT01475786|BIOLOGICAL|Low Dose: 16 mg Engensis (VM202)|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
214396614|NCT01475786|BIOLOGICAL|High Dose: 32 mg Engensis (VM202)|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
214396615|NCT01475786|OTHER|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
214396616|NCT00528190|DRUG|Itraconazole|Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
214503199|NCT00978718|DIETARY_SUPPLEMENT|selenium|Given orally
215001457|NCT01202591|DRUG|AZD4547|Tablet oral twice daily
215094994|NCT02388542|BEHAVIORAL|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
215001458|NCT01202591|DRUG|Exemestane|Tablet oral once daily
215001459|NCT01202591|DRUG|Placebo|Tablet oral twice daily
214503200|NCT00978718|OTHER|placebo|Given orally
214503201|NCT03136159|DEVICE|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
215001460|NCT01202591|DRUG|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
215001461|NCT05699681|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography|"After induction of anaesthesia and stabilization of hemodynamics, transthoracic echocardiography will be done on a GE Vivid e9 workstation (GE Vingmed, Horton, Norway) with MS5 transthoracic probe with synchronized ECG.~From TTE the following views and measurements will be acquired :~* Apical four chamber (A4C) view~* Apical two chamber view (A2C) view~* Right ventricle (RV) focused A4C view~* Right ventricular systolic pressure (RVSP)~* Pulmonary arterial acceleration time (PAAT),~* Tricuspid annular plane systolic excursion (TAPSE),~* Tricuspid annular plane systolic velocity (s'),~* Right ventricular fractional area change (RV FAC)~* RV free wall strain,~* RV myocardial performance index (MPI),~* RV isovolumic relaxation time (IVRT),~* RV isovolumic acceleration time (IVA)~Invasive PA pressure measurement will be done after surgical exposure with a fine needle and a zeroed transducer by the Surgeon."
215094995|NCT00389675|DRUG|Darusentan|Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
215094996|NCT00389675|DRUG|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
215094997|NCT00117689|BIOLOGICAL|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
215094998|NCT00117689|DRUG|Corticosteroid|For a minimum of 3 months
214396618|NCT01870817|DIETARY_SUPPLEMENT|Home jejunostomy feeding|
214396619|NCT06330818|DIAGNOSTIC_TEST|MRI|Patients will get special MRI sequences (CO2-triggered BOLD MRI, Vessel-wall imaging, resting state BOLD MRI) to identify cerebral vasoreactivity and disease activity.
214396620|NCT06330818|DIAGNOSTIC_TEST|H2 15O PET/CT|Patients will get H2 15O PET/CT with acetazolamide challenge to define the cerebral vasoreserve for comparison with fMRI Images
214396621|NCT06330818|OTHER|Biosampling|Patients do get a venous puncture for blood analysis on circulating endothelial cells and virus PCR analysis
214396622|NCT04129580|DEVICE|reSET-O app|The reSET-O app, owned by Pear Therapeutics, Inc., is designed to work as cognitive behavioral therapy, adjunctive to medication assisted treatment, for opioid use disorder. The app provides psychoeducation related to opioid use and dependence, coping skills, and skills to avoid relapse,
214396623|NCT06788236|DRUG|AVTR101|three times daily
214396624|NCT06788236|DRUG|Placebo|three times daily
214503202|NCT01039610|DRUG|GSK945237|Dose detailed in Arm description
214503203|NCT01039610|DRUG|Placebo|matching placebo tablet
214503204|NCT01039610|DRUG|Linezolid|600 mg BID, 14 Days
214503205|NCT01039610|DRUG|Moxifloxacin|40 mg single dose
214503206|NCT00916110|DRUG|ATN-103|1.5 mg solution, single subcutaneous injection
214503207|NCT00916110|DRUG|ATN-103|4 mg solution, single subcutaneous injection
214503208|NCT00916110|DRUG|ATN-103|10 mg solution, single subcutaneous injection
214396625|NCT03757169|OTHER|Hand grip isometric contraction|The patients at the Hand Grip group will perform 12 weeks of hand grip exercises, three times/week for 16 minutes with time to rest.
214396626|NCT03757169|OTHER|Control|The patients will receive verbal orientations about the OSA and the arterial hypertension.
214396627|NCT00394875|PROCEDURE|Treated and educated by nurses specialized in diabetes.|
214396628|NCT01766518|DRUG|Mycophenolate mofetil|MY-REPT capsule 500\~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation
214396629|NCT03248570|DRUG|Pembrolizumab|All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.
214396630|NCT03248570|DRUG|Chemotherapy|At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
214396631|NCT03620071|OTHER|GoalKeeper|Mobile-health communication tool for parents of children with medical complexity
214396632|NCT03620071|OTHER|Standard Care|Standard Clinical Care
214396633|NCT01332240|PROCEDURE|Endoscopic ultrasonography|in order to stage the mediastinum
214396634|NCT02875678|DRUG|ABX-1431|Single-dose ABX-1431
214396635|NCT02875678|DRUG|Placebo|Single-dose matching placebo
214396636|NCT00387192|DRUG|Optivate|Plasma-derived Factor VIII
214396637|NCT05488379|OTHER|Group well child care|Beginning with the 1-month well child care visit, mother-infant dyads will participate in well child care together, with subsequent visits occurring at the American Academy of Pediatrics recommended intervals (2, 4, 6, 9, 12, 15, and 18 months of age).
214396638|NCT02018861|DRUG|Parsaclisib|
214396639|NCT02018861|DRUG|Itacitinib|
214396640|NCT02018861|DRUG|Rituximab|
214396641|NCT02018861|DRUG|Ifosfamide|
214396642|NCT02018861|DRUG|Carboplatin|
214396643|NCT02018861|DRUG|Etoposide|
214396644|NCT05210140|DRUG|Escitalopram|"Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is commercially known as ELORYQA®, Elicea®, Escital®,PRAMES® or Lata® in Serbia. The recommended dose for Major depressive disorder is 10mg/day. Based on the individual response, dose can be adjusted and the maximum dose is 20 mg/day; 5 mg/day dose is also available. Escitalopram is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia) and Panic disorder (with or without agoraphobia) by Medicines and Medical Devices Agency of Serbia.~In known CYP2C19 poor metabolizers, initial dose should be 5mg/day during first 2 weeks, and based on the individual response it can be increased up to maximum of 10 mg of escitalopram per day, according to the guidelines of Medicines and Medical Devices Agency of Serbia."
214396645|NCT02500511|BIOLOGICAL|NmVac4-A/C/Y/W-135-DT™|no intervention in this study, received test vaccine in trial JN-NM-002
214396646|NCT00483821|OTHER|medical chart review|medical chart review
214396647|NCT02629445|DEVICE|Cardiac Resynchronisation Defibrillator|Defibrillation testing of cardiac defibrilator
214396648|NCT03739385|OTHER|Exercise Intervention|The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.
214396649|NCT05187598|OTHER|Effective communication training in perinatal patient safety|Students will be given theoretical training, group discussion will be made over sample videos, and students will participate in the standard participant practice and a post-analysis session will be held.
214396650|NCT02606747|OTHER||routine blood sugar control
214396651|NCT02079207|BIOLOGICAL|NBP606|13-valent peumococcal conjugate vaccine(13vPnC)
214396652|NCT02079207|BIOLOGICAL|Prodiax-23|23-valent peumococcal polysaccharide vaccine(23vPS)
214396653|NCT06258239|OTHER|Communication between nursing staff and participants|The analgesic treatment that will be given are part of clinical routine - the participants will get the same exact treatment regardless if they entered the study and to which study arm they entered. The effect that we are interested to capture is the potential added value of communication between the nursing staff and participants while administrating analgesics.
214396654|NCT03833011|PROCEDURE|Osteopathic Manipulation|Osteopathic manipulation
214396655|NCT00827944|DEVICE|Parietex Progrip|"Surgical technique:~Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation."
214396656|NCT00827944|DEVICE|Low weight polypropylene mesh|"Surgical technique:~Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures"
214396657|NCT00709891|DEVICE|cobas® 4800 HPV Test|
214396658|NCT02968940|BIOLOGICAL|Avelumab|Avelumab 10 mg/kg intravenously (IV) every 2 weeks
214396659|NCT02968940|RADIATION|Hypofractionated radiation therapy (HFRT)|Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions
214396660|NCT02938728|OTHER|Biopsies|
214396661|NCT05835492|DEVICE|myCOPD|myCOPD is a digital self-management application (app), that supports all elements of managing COPD by creating a supported self-help environment, and in turn reduce medical visits, and hospital admissions and re-admissions. myCOPD allows for key aspects of disease management, such as PR, to be provided remotely, based on a person's self-assessment. Furthermore, it can help people with COPD manage their condition at home, or anywhere away from a clinical setting. Successful implementation of myCOPD provides an opportunity to build capacity in primary and secondary care, and community teams where a blended approach with traditional PR and myCOPD is used. Studies have shown myCOPD is able to deliver similar improvements in symptoms and exercise tolerance compared to PR exercise-classes and helps patients admitted to hospital recover more quickly at home(5)(6). myCOPD is widely deployed across the NHS and is being used by patients in different areas of the UK.
215001462|NCT00306488|DRUG|OT-551 antioxidant eye drop|0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
215094999|NCT00117689|DRUG|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
215095000|NCT00117689|DRUG|Mycophenolate Mofetil|for at least 1 month posttransplant
215121403|NCT03726489|DEVICE|narrow band phototherapy clinic units|Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
214396662|NCT05881083|BEHAVIORAL|1-week nicotine replacement therapy sampling|Participants will be given an 1-week sample of nicotine replacement therapy (patch or gum) with brief instructions on how to use the product
214396663|NCT05881083|BEHAVIORAL|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
214396664|NCT02353117|BEHAVIORAL|Congenital Syphilis Intervention Group|
214396665|NCT05854940|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|Intelligent diagnostic system based on Raman spectrum of serum
215001463|NCT03785821|DIETARY_SUPPLEMENT|BMSO|BMSO was extracted from Hualien No. 4 cultivate of bitter melon seed. BMSO were incorporated into capsules containing 0.5 g of oil. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily, resulting in daily consumption of 2.3 g alpha-ESA in the BMSO group.
214396666|NCT03644134|BEHAVIORAL|Assessment of physiological stress and sleep pattern|The personalized intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
215001464|NCT03785821|DIETARY_SUPPLEMENT|OO|Olive oil (extra virgin grade) was purchased from La Espanola (Acesur, Spain). OO were incorporated into capsules containing 0.5 g of oil, identical appearance to BMSO. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily.
215001465|NCT04298853|DRUG|Morphine PRN|Dose given every 3 hours as-needed for severe NAS, defined by a threshold Finnegan score.
215001466|NCT04298853|DRUG|Morphine scheduled|Dose given every 3 hours on a scheduled basis and slowly weaned once stabilized.
215001467|NCT04050605|DEVICE|somofilcon A toric contact lens|Contact Lens
215001468|NCT04050605|DEVICE|fanfilcon A toric contact lens|Contact Lens
215001469|NCT04546698|OTHER|blood sampling|Analyse of expression modulation of 5-HT7 receptor in correlation with the immunological context, in 3 differents groups : 2 with multiple sclerosis patients, one healthy volunteers group
215001470|NCT02830087|PROCEDURE|Tourniquet Cuff Pressure|Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
215001471|NCT07104617|DRUG|TY-302|Take the specified dose (75mg or 100mg) orally once a day. Take it on an empty stomach in the morning with about 200 mL of warm water.
214396667|NCT01474512|DRUG|80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Administered SC
214396668|NCT01474512|DRUG|Placebo|Administered SC
214396669|NCT03888885|BEHAVIORAL|Sport Education Model|A total number of 25 lecturers participated in the 12-hour CPD workshop on Sport Education curriculum on June 2018. The content of the workshop focused on the development of a Sport Education season, the changing roles of teachers and students, the assessment of personal and social responsibility, and the application of sport education season and related pedagogies on handball, badminton, swimming and physical conditioning. The Sport Education courseware and class materials were then designed by the eligible lecturers. The intervention was lasted for 10-lesson, 1-day per week and the duration for each lesson was around 90 minutes. The specific five phases in Sport Education model of team selection, teacher-directed, pre-season, formal competition and cumulating event were included. The eligible lecturers led the lessons according to the designated course wares and lesson plans for each sport.
214396670|NCT02187211|DRUG|Minocycline|
214396671|NCT02187211|DRUG|Placebo (for Minocycline)|
214396672|NCT02724072|DEVICE|Thoraflex™ Hybrid Device|Single-use medical device sterilized by ethylene oxide which is pre-loaded into a delivery system. The device comprises a gelatin sealed vascular graft combined with a stented graft.
214396673|NCT03040219|DRUG|Folic Acid|Tablets
214396674|NCT02060253|DRUG|ganetespib|Given IV
214396675|NCT02060253|DRUG|paclitaxel|Given IV
214396676|NCT02060253|BIOLOGICAL|trastuzumab|Given IV
214396677|NCT02060253|BIOLOGICAL|pertuzumab|Given IV
214396678|NCT04908163|BEHAVIORAL|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
214503209|NCT00916110|DRUG|ATN-103|25 mg solution, single subcutaneous injection
214503210|NCT00916110|DRUG|ATN-103|25 mg solution, single intravenous injection
214503211|NCT00916110|DRUG|ATN-103|50 mg solution, single subcutaneous injection
214503212|NCT00916110|DRUG|ATN-103|100 mg solution, single subcutaneous injection
214503213|NCT00916110|DRUG|ATN-103|200 mg solution, single subcutaneous injection
215001472|NCT07104617|DRUG|Abiraptor|Take orally, 1000mg each time, once a day. Take it on an empty stomach in the morning with warm water, or take it orally at least two hours after fasting.
215001473|NCT07102719|DRUG|HD-P023|Single dose administration of HD-P023
215001474|NCT07102719|DRUG|Teneligliptin and Empagliflozin|Single does administration of Teneligliptin and Empagliflozin High
215001475|NCT07104058|DIAGNOSTIC_TEST|68Ga-FAPI PET / CT|IgG4-RD patients with clinical complete remission after hormone and immunosuppressive therapy and 18F-FDG PET / CT negative were included. After enrollment, 68Ga-FAPI PET / CT screening was performed.
215001476|NCT07103018|DRUG|KTX-2001|Participants will receive escalating doses of KTX-2001 monotherapy
215121404|NCT02655029|DRUG|Perindopril/Indapamide/Amlodipine fixed dose combination|Dose selection is based on investigators management.
215121405|NCT03744949|DRUG|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
215121406|NCT03744949|DRUG|Remifentanil dose 1 ug/kg|Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
215121407|NCT03744949|DRUG|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
215001477|NCT07103018|DRUG|KTX-2001 + Darolutamide (NUBEQA®)|Participants will receive escalating doses of KTX-2001, in combination with the oral androgen receptor (AR) pathway inhibitor (ARPI), darolutamide (NUBEQA®)
214396679|NCT04908163|BEHAVIORAL|Mediterranean diet-based culinary intervention|The culinary intervention will be developed integrating eight culinary and nutritional workshops that will be given every week, twice per week, during one-month intervention. The duration of each culinary and nutritional workshop will be 1 hour, thus, the program will provide a total of hours of nutritional education and a total of 8 hours of nutritional and cooking training. The courses will take place in a well-equipped kitchen from the Basque Culinary Center and participants will be connected online in order to be able to cook and practice at the same time. All cooking classes will begin with a theoretical introductory part that aim to explain the main take-home messages from the workshop. Subsequently, every class will be characterized by a hands-on part that will include the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients.
214396680|NCT05338983|DRUG|Topical anesthetic|20% Benzocaine gel will be applied on the area of infiltration
214396681|NCT05338983|DEVICE|Avent baby bottle warmer|Warming device
214396682|NCT05338983|DRUG|Sodium bicarbonate|0.1ml of 8.4% of sodium bicarbonate will be removed from the 50ml vial by one ml insulin syringe , directly injected into the local anesthetic cartridge and will be shacked 5 times to mix the solution.
214396683|NCT05338983|DEVICE|Buzzy device|"Bee-shaped apparatus consisting of two parts: the main vibrating body of a bee and detachable ice wings.~External application of Buzzy device during administration of dental anesthetic."
214396684|NCT05338983|DRUG|Mepivacaine Hydrochloride|Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration
214396685|NCT00900289|GENETIC|DNA methylation analysis|
214503214|NCT00916110|DRUG|ATN-103|200 mg solution, single intravenous injection
214503215|NCT03377049|DRUG|Acetazolamide|1 g acetazolamide through a peripheral IV line
214503216|NCT04918719|DRUG|Acetylcysteine|The dosing of Acetylcysteine will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours. (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
214503217|NCT04918719|DRUG|Dextrose in Water|The placebo will consist of a 5% Dextrose in Water instead of NAC (dosage and timigs are the same as the NAC arm). (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
214503218|NCT03770715|DEVICE|Respiratory polygraphy|The respiratory polygraphy consisted of continuous polygraphical recordings for a whole night from 22:00 h to 07:00 h with standardised equipment
214503219|NCT03888807|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
215001478|NCT07115303|PROCEDURE|Laparoscopic Appendectomy with application of clips for stump closure|in patients who will undergo Laparoscopic Appendectomy, appendicular stump will be closed by application of clips
214396686|NCT00900289|GENETIC|microarray analysis|
214503220|NCT03888807|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
215001479|NCT07115303|PROCEDURE|Laparoscopic Appendectomy with ligature for stump closure|in patients who will undergo Laparoscopic Appendectomy, appendicular stump will be closed by ligation
215001480|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT A|A 3 km solo hike at a leisurely walking pace on a path that is easy to walk and has very little elevation gain. Located in Pontevedra Province.
215001481|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT B|A 3 km solo hike at a leisurely pace on an easy walking trail with very little elevation gain. Located in the province of Pontevedra.
215001482|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT C|3 km solo hike at a leisurely pace on an easy trail with little elevation gain. Located in the province of Pontevedra.
215001483|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT D|Individual 3 km treadmill walk in a closed room facing a wall without pictures or windows at a leisurely walking pace with no gradient. This room will be located on the Pontevedra University Campus.
215001484|NCT07115238|DRUG|XTR006|all patients will receive one injection of \[18F\]XTR006, a PET radiopharmaceutical selective for NFTs. For the injection, subjects will receive a target dose of 4-6 mCi IV as a bolus injection. \[18F\]XTR006 injection will be followed by a 10 ml saline flush.
215121408|NCT03744949|DRUG|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
215121409|NCT01466608|DRUG|Rosuvastatin|Oral administration of rosuvastatin 20 mg once daily for 21 days.
214396687|NCT00900289|GENETIC|polymerase chain reaction|
214396688|NCT00900289|OTHER|immunohistochemistry staining method|
214396689|NCT00900289|OTHER|laboratory biomarker analysis|
214396690|NCT01890967|DRUG|LY3015014|Administered SC
214396691|NCT01890967|DRUG|Placebo|Administered SC
214396692|NCT01890967|DRUG|Statin|Administered orally
214396693|NCT01890967|DRUG|Ezetimibe|Administered orally
214396694|NCT01861301|OTHER|Laboratory Biomarker Analysis|Correlative studies
214396695|NCT01861301|DRUG|Tivantinib|Given PO
214396696|NCT02089451|DRUG|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
214396697|NCT03453632|DRUG|Botulinic toxin|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of botulinic toxin (200 UI) on right or left foot"
214396698|NCT03453632|DRUG|Placebo|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of physiological serum (200 UI) on right or left foot"
214396699|NCT04524182|OTHER|control group|"There was no intervention in the control group during study.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
214396700|NCT04524182|OTHER|mobilization group|"Lumbosacral mobilization for 10 minutes in the study group (pelvis forward and backward distraction, passive rotation of the lower body, short lever rotation, long lever rotation, lumbar central posterior-anterior, lumbar unilateral posterior-anterior, anterior rotation-posterior superior iliac spine- down, posterior rotation-posterior superior iliac spine-up were applied.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
214503221|NCT06301048|PROCEDURE|Stent Placement in Pancreatic and Bile Ducts|Post-resection, endoscopic retrograde cholangiopancreatography (ERCP) was performed for stent placement in pancreatic or bile ducts as needed, with X-ray confirmation of stent positioning.
214503222|NCT01732757|DRUG|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
214503223|NCT01732757|DRUG|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
214503224|NCT01732757|DRUG|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
214396701|NCT01556841|BIOLOGICAL|TroVax®|"Pre-amendment 10:~Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.~Post-amendment 10:~Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity."
214396702|NCT01556841|BIOLOGICAL|Placebo|"Pre-amendment 10:~Matched placebo will be administered as above.~Post-amendment 10:~TRI-70 onwards received TroVax only."
214396703|NCT04559399|PROCEDURE|smiley face shape rod|For treatment of isthmic spondylolithesis a transpedical screws for the same level and rod revolve around spinal process to stabilization of pars interarticularis of the same segment after removes bone at the margine of defects pars till reach to healthy bleed margine then put bone graft at the defect then stablizing pars and bone graft by rods.
214396704|NCT06187181|PROCEDURE|implant overdenture|. Videofluoroscopy swallowing evaluation was done using 10 ml of thin liquid bolus at three different oral conditions: Without dentures (WOD), with the conventional complete denture (CDs) and with mandibular implant retained overdenture (IODs).
214396705|NCT06187181|RADIATION|videofluroscopy|videofluroscopy evaluation of swallowing function
214396706|NCT02341911|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
214396707|NCT02341911|DRUG|Gemcitabine,carboplatin|Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
214503225|NCT06086548|OTHER|metabolomic on plasma sample|metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling
214503226|NCT05983939|DRUG|PIPE-791|Single and multiple ascending oral doses of PIPE-791 tablets.
214503227|NCT05983939|DRUG|Placebo|Single and multiple ascending oral doses of matching placebo tablets.
215001485|NCT07117123|DEVICE|Transcutaneous electrical acupoint stimulation|The doctor will stick special electrodes on your wrist (Lieque point) and the inside of your ankle (Zhaohai point), and connect the electrical stimulation device (Han's Pain Treatment Device, Nanjing Jisheng Medical Technology Co., Ltd., which has been clinically used and provided by this project team). The current intensity will gradually increase from a small amount to the maximum level you can tolerate (starting from 1mA, not exceeding the maximum safety range of 10mA). The entire transcutaneous acupoint electrical stimulation lasts for 30 minutes. This electrical stimulation is non-traumatic and painless. Most people only feel slight numbness, swelling, and heat.
214396708|NCT01395771|BEHAVIORAL|Phone call intervention, no phone call intervention|Biweekly phone call intervention +routine service will be assigned to intervention group of new cases and old cases. Only routine service will be assigned to the control group of abovementioned two kind of cases.
214396709|NCT03503994|DRUG|Inhaled Beclomethasone Dipropionate Monohydrate|"Beclomethasone Dipropionate (HFA-BDP, QVAR\*) in the following doses will be evaluated:~1. 200 mcg bid~2. 400 mcg bid~3. 600 mcg bid~4. 800 mcg bid"
214503228|NCT01858649|PROCEDURE|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
214503229|NCT01858649|DRUG|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
214503230|NCT01858649|DRUG|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
214503231|NCT01858649|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
214503232|NCT01858649|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
215001486|NCT07117123|OTHER|No electrical stimulation|The doctor will attach special electrodes to your wrist (Lieque point) and the inside of your ankle (Zhaohai point), and connect them to an electrical stimulation device (Han's pain treatment device, Nanjing Jisheng Medical Technology Co., Ltd., which has been clinically used and is provided by this project team). No electricity (i.e. no stimulation)
214503233|NCT02400060|BEHAVIORAL|Telephone-Based Intervention|Receive text messaging
214503234|NCT02400060|OTHER|Survey Administration|Ancillary studies
214503235|NCT02400060|OTHER|Laboratory Biomarker Analysis|Correlative studies
214503236|NCT05453435|DRUG|Entecavir|All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 6 months after completing CD20 monoclonal antibody therapy.
214396710|NCT04966156|BEHAVIORAL|CaRE-4-alloBMT plus usual care group|CaRE-4-alloBMT uses emerging eHealth technologies to reduce barriers to accessing and providing cancer rehabilitation which includes: 1) Individualized progressive exercise prescriptions that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials; 2) Individualized nutrition plans and stepped stratified care such as education, counselling, intervention based on nutritional status and delivered by registered dietitians; 3) On-line e-modules provide interactive education to promote self-management skills for stress management, nutrition, managing common symptoms, etc.; 4) Remote monitoring using FitbitTM devices to monitor patients physical activity, caloric intake, and sleep for duration of the program. CRS and alloBMT clinicians will have access to real-time Fitbit data through our clinical dashboard; 5) Remote clinical support: check-ins and health coaching sessions with a member of the CRS team (phone or MS Teams video).
214396711|NCT04708821|DRUG|Dexamethasone ophthalmic insert 0.4Mg|Dextenza 0.4Mg Ophthalmic Insert
214396712|NCT04708821|DRUG|0.2% loteprednol etabonate ophthalmic suspension|0.2% loteprednol etabonate ophthalmic suspension
214396713|NCT04708821|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%|olopatadine hydrochloride ophthalmic solution 0.7%
214396714|NCT04027569|OTHER|Patient Specific Functional Scale|A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
214396715|NCT04027569|OTHER|PROMIS PF|A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
214396716|NCT05348330|PROCEDURE|Thoracic intervertebral foramen block|Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
214396717|NCT05348330|PROCEDURE|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
214396718|NCT05361746|DEVICE|Scotchbond Universal Plus Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU+ treatment group will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive using total-etch mode and Filtek Universal Restorative material.
214396719|NCT05361746|DEVICE|Scotchbond Universal Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU Control group will undergo restoration(s) using Scotchbond Universal Plus (SBU) Adhesive using total-etch mode and Filtek Universal Restorative material.
214396720|NCT02733133|DRUG|Testagen® TDS Testosterone 5% HypoSpray®|Topically applied Testosterone Hormone Replacement Lotion
214396721|NCT06040645|OTHER|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
214396722|NCT06040645|OTHER|E-consult|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
214396723|NCT06518499|PROCEDURE|Pilonidal sinus surgery|Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure
214396724|NCT05584657|DRUG|Sulopenem etzadroxil/probenecid|Oral sulopenem twice daily for 5 days
214396725|NCT05584657|DRUG|Amoxicillin/clavulanate|Oral Augmentin twice daily for 5 days
214503237|NCT06569836|OTHER|12-week intervention|"Rehabilitation Exercise Plan Week 1-4 For No Symptom Group: Therapeutic home exercise prescription(2 sessions, 60 minutes per session) For Mild \& Moderate Group: Rehabilitation Plan provided by Physiotherapist (4 sessions, 60 minutes per session)~Enhancement of Self-Management Capacity Week 5-8 For No Symptom Group: Educational Workshops provided by Physiotherapist (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Self-management group provided by Social Worker (4 sessions, 60 minutes per session)~Exercise Maintenance Week 9-12 For No Symptom Group: Mobilized Intervention (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Exercise Maintenance provided by Exercise Mentor (4 sessions, 60 minutes per session)"
214503238|NCT06569836|OTHER|12-week attention control|The attention and waitlist control group will have weekly educational and virtual workshops for 12 weeks. Three topics will be covered, including online exercise class, cognitive training, leisure and recreational activities. Each session will be 30-45 minutes and each topic last for four weeks. Participants could access the virtual sessions by their electronic devices.
214503239|NCT05616039|PROCEDURE|Standard Liver Surgery|Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours
214396726|NCT05070650|DRUG|Acetylcysteine|200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
214396727|NCT05070650|DRUG|Paracetamol|500 mg/10 mg granules for oral solution: one sachet three times per day
214396728|NCT05070650|DRUG|Phenylephrine|500 mg/10 mg granules for oral solution
214396729|NCT03585114|DRUG|[F-18] DCFPyL|\[18F\]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of \[18F\]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
214396730|NCT03585114|PROCEDURE|PET/CT imaging|As per standard of care, acquisition will be performed on PET/CT scanner (Siemens, Germany) operating in 3D emission mode with CT-derived attenuation correction.
214396731|NCT02702349|OTHER|penicillin test|children are tested for penicillin allergy and then challenged with penicillin P.O.
214396732|NCT02268318|OTHER|1-Fermented Dairy Product with Phytosterols (test)|1- 1 bottle of test product/day
214396733|NCT02268318|OTHER|2-Fermented dairy Product with No Phytosterols (control)|2-1 bottle of control product/day
214396734|NCT00684268|DRUG|Silibinin|"comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion"
214396735|NCT00684268|DRUG|Silibinin|20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
214396736|NCT06385210|OTHER|Semi structured interviews|Participants will be interviewed concerning perceived barriers to routine surgical video recording
214396737|NCT05730218|DRUG|ONL1204 Ophthalmic Solution|ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
214396738|NCT05730218|DRUG|Sham treatment|Sham injection is performed by touching the eye surface with a syringe without a needle
214396739|NCT02922673|DRUG|Aspirin|
214396740|NCT02922673|DRUG|Placebo|
214396741|NCT00061360|DRUG|ATG+Rapamune+cyclosporine|ATG+Rapamune+cyclosporine
214396742|NCT00061360|DRUG|ATG+cyclosporine|ATG+cyclosporine
214396743|NCT02151019|RADIATION|IMRT|IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
214396744|NCT00886470|BIOLOGICAL|ST266|ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
214396745|NCT02807246|BIOLOGICAL|Maflor®, Mamsel Pharmaceuticals, Turkey|"Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey)~Other Name: Maflor®"
214396746|NCT02807246|OTHER|drops of saline|Dietary Supplement: Breast milk +drops of saline
214396747|NCT00245596|DRUG|sildenafil|
214503240|NCT05616039|DIAGNOSTIC_TEST|Indocyanine Fluorescent Image Guided Surgery (I-FIGS)|Use of I-FIGS in accurate identification of tumours and their margins
214503241|NCT05779631|DIAGNOSTIC_TEST|mpMRI plus a same-day cystoscopic bladder biopsy|mpMRI plus a same-day cystoscopic bladder biopsy
214503242|NCT05779631|PROCEDURE|TURBT|Transurethral resection of the bladder tumor
214503243|NCT05893966|RADIATION|Whole breast irradiation +/- tumor bed boost|Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)
215001487|NCT07118644|DRUG|MEOPA|Induced sputum with be performed by trained physiotherapist using hypertonic saline aerosol and salbutamol. MEOPA will be used for nebulization. MEOPA is a gas with analgesic, amnesic and anxiolytic properties.
215001488|NCT07118644|OTHER|Standard induced sputum|Induced sputum with be performed by trained physiotherapist using hypertonic saline aerosol and salbutamol. Oxygen will be used for nebulization.
215001489|NCT07116720|OTHER|Unloading maneuvers|Participants will perform unloading maneuvers four times with 15 min of spinal flexion protocol in between. The intervention will include self traction on a box (5 s) and sustained standing trunk extension (8 s). Both maneuvers will be repeated twice at each timepoint.
214396748|NCT05188391|DIAGNOSTIC_TEST|Deltoid Gap Sign|At first deltoid sign test will be performed and the result of the test will be noted for the patients who are already scheduled open medial ankle surgery due to diagnosed as ankle fracture. During the open surgery, the test results will be evaluated.
214396749|NCT00065416|PROCEDURE|massage|
214396750|NCT04128033|OTHER|Puncture of the RP6 point|"Puncture of RP6 San Yin Jiao point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus."
214396751|NCT04128033|OTHER|Puncture of the placebo point|"Puncture of a placebo point outside the meridian, with no effect"
214396752|NCT04763083|DRUG|NVG-111|Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles
214396753|NCT06413550|BIOLOGICAL|Hibiscus Sabdariffa|The fresh red Roselle plant was obtained; the red calyxes of Hibiscus Sabdariffa were separated from the plant and dried for a week at 25°C. The dried calyxes were ground to powder, kept in a sealed container, and stored in a refrigerator (4°C) until used. Aqueous Roselle calyx extract was prepared by adding 10 gm of the previously prepared powder to 100 ml of boiling water and then heated on a hot stirrer plate for 30 min. To remove the remnants, the mixture was filtered via Whatman No 1 filter paper (Whatman products, Springfield Paper Mill, Maidstone, UK). The water content of the filtered solution was evaporated using an air recirculation oven and then kept at 4°C in the dark until used to determine antibacterial effectiveness \[20\].
214396754|NCT05961813|BEHAVIORAL|Intensive intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation and will complete 6 visits (2 before surgical intervention, 4 visits within the following 12 months), as well as follow up phone calls for progressi monitorization.
215001490|NCT07117565|DRUG|Intervention 1: Intrathecal Dexmedetomidine with Bupivacaine|"Intervention 1: Intrathecal Dexmedetomidine with Bupivacaine~Detailed Description:~This intervention consists of a single intrathecal injection of 10 micrograms of dexmedetomidine combined with 15 mg (3 mL) of 0.5% hyperbaric bupivacaine, administered during spinal anaesthesia for lower limb surgery. The total volume administered is 3.5 mL. Dexmedetomidine is an alpha-2 non-opioid adjuvant used as a spinal adjuvant for enhancing analgesia"
214396755|NCT05961813|BEHAVIORAL|Brief intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation 4 weeks before surgery, as well as follow up phone calls for progressi monitorization.
214396756|NCT04006366|BEHAVIORAL|Time restricted feeding|We propose a pilot and feasibility trial of a 10 hour time restricted eating intervention among post-bariatric surgery patients.
214396757|NCT03479060|PROCEDURE|Wet Cupping|cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Bloodletting and secondary suction and Removing and dressing
215001491|NCT07117565|DRUG|Intervention 2: Intrathecal Fentanyl with Bupivacaine|This intervention consists of a single intrathecal injection of 25 micrograms of fentanyl combined with 15 mg (3 mL) of 0.5% hyperbaric bupivacaine, administered during spinal anesthesia for lower limb surgery. The total volume administered is 3.5 mL. Fentanyl is a lipophilic opioid commonly used as a spinal adjuvant for enhancing analgesia. This arm is being compared with dexmedetomidine to evaluate differences in POUR incidence, analgesic effectiveness, and side effect profiles.
215001492|NCT07117318|DRUG|NSAIDs|All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure
215001493|NCT07117318|DEVICE|NSAIDs plus PDS|All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure. When eligibility is met, PDS placement will be performed by ERCP colonoscopists.
215001494|NCT07118618|DRUG|Probenecid Oral Tablet|2gr daily
215001495|NCT07118618|DRUG|Placebo Oral Tablet|Inactive compound
215095001|NCT04570189|DEVICE|Auscul-X|The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
214396758|NCT05843630|DIAGNOSTIC_TEST|without|without
214396759|NCT04936490|DRUG|Crocin|15 mg/d
214396760|NCT04936490|DRUG|Placebo|15 mg/d
214396761|NCT01080196|BEHAVIORAL|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
214396762|NCT05721027|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg PO every 8 hours as needed for 7 days
214396763|NCT05721027|DRUG|Dexamethasone Oral|Dexamethasone 16 mg PO during ED visit and next day
214396764|NCT05721027|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
215095002|NCT05018741|PROCEDURE|liver transplantation|liver transplantation for chronic liver disease or acute liver failure
215095003|NCT02739516|DRUG|Human chorionic gonadotropin|In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
214396765|NCT06395077|DIAGNOSTIC_TEST|CBCT low-dose protocol|The patient underwent two CBCT examinations (Accuitomo 170; J Morita Corp., Kyoto, Japan): one examination followed the clinical standard-dose protocol (exposure settings: 90 kV, 5 mA, and 9.4 s), and one, the low-dose protocol (90 kV, 2 mA, 9.4 s).
214396766|NCT02260089|DRUG|Low dose of telmisartan|
214396767|NCT02260089|DRUG|High dose of telmisartan|
214396768|NCT02260089|DRUG|Placebo|
214396769|NCT03908281|BEHAVIORAL|Fasted Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
214396770|NCT03908281|BEHAVIORAL|Postprandial Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
214503244|NCT04456413|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
214396771|NCT01151982|BEHAVIORAL|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
214396772|NCT03767478|DEVICE|Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 12 weeks at suprathreshold (2 x motor threshold).
214396773|NCT03767478|DEVICE|Sham Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 12 weeks at suprathreshold (2 x motor threshold).
214396774|NCT03215121|PROCEDURE|One handed mask airway, switch to two hands|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand mask airway with switch to two hand for Group 1 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group one, the mask holding will switch to two hands for 20 seconds."
214396775|NCT03215121|PROCEDURE|Two handed mask airway + jaw thrust|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group two patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. In Group 2 patient's mask will be held with two hands first for 40 seconds."
214396776|NCT03215121|PROCEDURE|Two handed mask airway, switch to one hand|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group 3 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group 3, the mask holding will switch to one hand for 20 seconds."
214396777|NCT03887104|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
214396778|NCT05674968|BEHAVIORAL|Managing Challenging Behaviors in ADHD; Psychosocial program|MCB-ADHD is a brief Behavioral Parent Training (BPT) program delivered to caregivers and children together. THe researchers have specially designed this program to be flexible so that it can be delivered over telehealth and/or in-person. All sessions are guided by web-based tool to provide parent support materials and direct the work to be completed in session. MCB-ADHD combines brief BPT skills modules adapted from an established evidence-based BPT called Helping the Noncompliant Child (HNC; McMahon \& Forehand, 2003) with high quality psychoeducation and advocacy training that were developed by the investigators specifically for use in this project. Families receive 4 sessions adapted from HNC focused on behavior management and 2 sessions focused on education and empowerment.
214396779|NCT01440049|OTHER|Prospective Observational|this is an observational study non interventional
214396780|NCT05226845|OTHER|prescribed exercise|the therapist chooses the five exercises to do
214396781|NCT05226845|OTHER|chosen exercise|the patient chooses the five exercises to perform among fifteen possibilities
214396782|NCT04266990|OTHER|Planned Sweat collection|Four times a day at fixed time points (9:30, 11:30, 13:30, 15:30), a researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher.
214396783|NCT04266990|OTHER|Spontaneous Sweat collection|As the patient will be under continuous monitoring, sweat and saliva samples will be also collected during and/or right after a seizure occurs if the volunteer is not holding a gauze at that time. The sweat samples will be collected by the researcher by applying a sterile gauze to the patients hands, either during or immediately following a seizure during 10 minutes.
214396784|NCT04266990|OTHER|Healthy volunteers sweat collection|A researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher. The healthy samples will be collected on the same floor of Ghent University Hospital and as close as possible to where patients reside
214396785|NCT02728518|DRUG|Nebulized Amikacin|400mg twice daily nebulized amikacin
214396786|NCT02728518|DRUG|Intravenous Amikacin|20mg/kg once daily intravenous amikacin
215001496|NCT07121621|DRUG|PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity.|"The pharmacological intervention, which will be the same for all patients in the study, will consist in administering MPH at CIC 1415 (URHC of Tours) in the form of Prolonged Release at the patient's usual dosage, in the early morning.~Pharmacokinetic study with repeated measurements at T0 (just before MPH administration) then T30 minutes, T1 hour, T2h, T3h, T4h, T6h, T8h (8 measurements) after MPH administration, in 15 patients with ADHD and obesity (BMI≥30 kg/m2) and in 15 patients with ADHD but without obesity (BMI\<30 kg/m2)."
215001497|NCT07121764|DRUG|Bupivacaine %0.25 (isobaric)|1 ml/kg of 0.25% Bupivacaine will be used for caudal block.
215001498|NCT07121764|DRUG|Dexmedetomidine & Bupivacaine.|1 ml/kg of 0.25% Bupivacaine PLUS 1 μg/kg Dexmedetomidine in 1 ml Normal Saline will be used for caudal block.
215001499|NCT07120802|BEHAVIORAL|BETTER4U Mobile App and Wearable Use (End-User Group)|"Participants from the general population (end-users) will use a smartwatch and the BETTER4U mobile app for 21 days. The app passively collects data (physical activity, sleep, eating behaviors, environment), while participants may self-report certain behaviors. The goal is to assess the usability, feasibility, and acceptability of the tools and to collect real-world behavioral data for refining AI models."
214396787|NCT00540605|DRUG|Tenofovir 1% vaginal gel|topical gel containing 1% tenofovir
214396788|NCT04121221|DRUG|GA Depot|Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
214396789|NCT04121221|OTHER|Placebo|IM injection once every 4 weeks
214396790|NCT00000836|DRUG|Sevirumab|
214396791|NCT02375763|OTHER|Software instruction|
214396792|NCT04314128|DIAGNOSTIC_TEST|TOS and TCD|TOS: Transorbital sonography TCD: Transcranial Doppler
214396793|NCT00146211|DRUG|Ethyl-EPA (Miraxion™)|
214396794|NCT00056290|BIOLOGICAL|VEGF|3 sets of injections, at 2 week intervals
214396795|NCT00056290|BIOLOGICAL|VEGF|3 sets of injections, at 2 week intervals
214503245|NCT04456413|OTHER|Best Supportive Care|Patients will receive best supportive care. Patients randomized to this arm may receive plasma should they require hospitalization for progression of COVID-19 disease.
214503246|NCT03774849|DEVICE|PicoWay™ 532nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
214503247|NCT03774849|DEVICE|PicoWay™ 730nm wavelength|PicoWay™ Laser System is picosecond 532/1064/785 laser
215095004|NCT02739516|DRUG|FSH co-trigger|In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
214396796|NCT01386840|OTHER|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
214396797|NCT00997243|BIOLOGICAL|lintuzumab|Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
214396798|NCT00997243|DRUG|5-azacytidine|75mg/m2 IV/SC daily on days 1-7.
214396799|NCT02261415|DRUG|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
214396800|NCT02261415|DRUG|Normal saline|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
214503248|NCT03774849|DEVICE|PicoWay™ 1064nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
214503249|NCT01742494|PROCEDURE|Water-jet POEM|Water-jet assisted POEM procedure was performed
215095005|NCT02739516|DRUG|Letrozole|Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
215095006|NCT03624088|BEHAVIORAL|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
214396801|NCT02602457|BEHAVIORAL|moderate-intensity continuous exercise training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
214396802|NCT02602457|BEHAVIORAL|high-intensity interval training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
214503250|NCT01742494|PROCEDURE|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
214503251|NCT03543059|DRUG|GnRH analogue|gonadotrophin releasing hormone analogue
214503252|NCT02395497|BIOLOGICAL|Monoclonal Antibody (Humanized Anti-CD52)|
214503253|NCT02395497|DRUG|Tacrolimus|
214396803|NCT02273011|PROCEDURE|caesarean section|elective caesarean section under regional anesthesia
214396804|NCT02602249|BIOLOGICAL|MUC1-gene-DC-CTL|MUC1-gene-DC-CTL will be used against tumor cells.
214396805|NCT02602249|BIOLOGICAL|MUC1-peptide-DC-CTL|MUC1-peptide-DC-CTL will be used against tumor cells.
214396806|NCT03795805|PROCEDURE|total knee arthroplasty|Total knee arhroplasty
214503254|NCT02395497|PROCEDURE|Penile Allotransplantation|
214503255|NCT00089609|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.
214503256|NCT00089609|DRUG|Thalidomide|Thalidomide 200 mg by mouth daily throughout the cycle.
214503257|NCT00089609|DRUG|Prednisone|Prednisone 10 mg by mouth daily throughout the cycle.
214503258|NCT00089609|BIOLOGICAL|bevacizumab|Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
214503259|NCT00089609|GENETIC|polymorphism analysis|Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.
215095007|NCT00687609|DRUG|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
215001500|NCT07120802|BEHAVIORAL|BETTER4U Intervention Platform Testing (Implementer Group)|Healthcare professionals and other potential implementers will test the BETTER4U Intervention Platform and mobile app for 7 days. They will assess system usability, complete synthetic case simulations, and provide daily feedback via Google Forms. They also wear the smartwatch and use the app for data validation purposes. The goal is to evaluate platform usability and collect ground-truth data for validating AI algorithm outputs.
215001501|NCT07120321|DRUG|Mineral Trioxide Aggregate (MTA)|Used as the capping agent after coronal pulp removal in primary molars.
215001502|NCT07120321|DRUG|Biodentine|Used as a bioactive pulpotomy agent following coronal pulp amputation.
215001503|NCT07120321|DRUG|Ferric Sulfate|15.5% Ferric Sulfate applied to pulp stumps for 15 seconds during pulpotomy procedure.
214503260|NCT00089609|OTHER|immunoenzyme technique|The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.
214396807|NCT03795805|PROCEDURE|Tourniquet limb cuff|Tourniquet limb cuff and regular anesthesia
214396808|NCT03795805|DRUG|Intaarticular lidocain|20 ml of 2% lidocain application intraarticular before surgery (intraarticular lidocain)
214396809|NCT02900781|DEVICE|Steprite™|Steprite™ Device shoe insert monitoring device
214396810|NCT02900781|OTHER|Standard of care|No Device. Standard of care physical therapy
214396811|NCT02453087|DRUG|DCDS0780A|Participants will receive escalating doses of DCDS0780A as intravenous infusion.
214396812|NCT02453087|DRUG|Rituximab|Participants will receive rituximab at a dose of 375 mg/m\^2 of body surface area as intravenous infusion.
214396813|NCT02453087|DRUG|Obinutuzumab|Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
214396814|NCT02862704|BIOLOGICAL|MG7-CART|Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
214396815|NCT01897857|DEVICE|duplex Doppler ultrasonography|
214396816|NCT02460471|RADIATION|palliative radiation therapy|thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
214396817|NCT06363435|DEVICE|AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans|Tumour burden will be automatically calculated and stored in a database. The result of the AI-based measurements will not involve the handling of the patients
214396818|NCT05543421|DEVICE|TMS|rTMS (30sessions) or iTBS (40sessions)
214396819|NCT02949518|OTHER|Enhanced Recovery Pathway (ERP) for Spine|The study team emphasizes that all components of the ERP are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERP will receive these standard of care components.
214396820|NCT04273503|BEHAVIORAL|Mentoring/educational session|12 mentoring/educational sessions focused on physical activity and healthy nutrition by Mayo Clinic experts.
214396821|NCT00906503|DRUG|dexamethasone|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
214503261|NCT00089609|OTHER|laboratory biomarker analysis|Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.
214503262|NCT00089609|OTHER|pharmacological study|Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
214503263|NCT03455868|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
214503264|NCT04376788|BIOLOGICAL|exchange blood transfusion from normal donor|IV method
214503265|NCT04376788|BIOLOGICAL|plasma from convalescent patients with COVID-19|IV method
214503266|NCT04376788|DRUG|Methylene Blue 5 MG/ML|IV method
215001504|NCT07120321|DRUG|Sodium hypochlorite gel application|5% NaOCl gel applied to pulp tissue during pulpotomy for its hemostatic and disinfectant effects.
215001505|NCT07114042|DIAGNOSTIC_TEST|Upper endoscopy|Prediction of upper gastrointestinal r\_bleeding and mortality
214396822|NCT00906503|PROCEDURE|PET/Computed Tomography (CT)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
215001506|NCT07120139|PROCEDURE|episodic use of the desensitizing toothpaste|subjects assigned to episodic treatment will use the assigned toothpaste with the same previous instructions for two 8-week treatment periods, followed by an 8-week phase in which they will use the conventional fluoride dentifrice (Signal Complete 8 Original, Unilever, Egypt), which has no documented desensitizing efficacy
215001507|NCT07120139|PROCEDURE|continuous use of the conventional desensitizing toothpaste|The patients will be instructed to use 1 inch amount of the assigned desensitizing toothpaste and soft bristle toothbrushes with the same brushing technique they will be taught in the intervention visit for 2 minutes twice a day (morning and last thing at night ) without further rinsing, only spitting of the excess material every day along the whole study period for the continuous treatment group.
214396823|NCT00906503|RADIATION|fludeoxyglucose (18F)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
214396824|NCT04439487|DIAGNOSTIC_TEST|Anthropometric measurements during routine preoperative visit|During routine preoperative anaesthetic visit and physical examination the following predictive test measurements are obtained by a research team member not involved in the further assessment of laryngoscopy: score in modified Mallampati test, Thyromental height, Sternomental distance, Thyromental distance, Neck circumference, Mouth opening distance
214396825|NCT04439487|OTHER|Assesment of intubation parameters during induction of general anaesthesia|During induction of general anaesthesia and intubation research team member not involved in obtaining anthropometric measurements notes Number of intubation attempts, Intubation time, Subjective intubation difficulty, Use of bougie and Need of technique modification.
214396826|NCT03142217|OTHER|Study of dysarthria in patients with Huntington's disease|Study of dysarthria in patients with Huntington's disease
214396827|NCT00479037|DRUG|Full Length Parathyroid Hormone, PTH(1-84)|Once daily subcutaneous injection in the abdomen by self administration
214396828|NCT00479037|DRUG|Strontium Ranelate|The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
214396829|NCT05655481|OTHER|Aerobic and Resistance training with rehabilitation|Effects of home telerehabilitation program improve functional capacity variables
215001508|NCT07120620|DEVICE|TTFields before and during radiotherapy|Administration of TTFields before and during radiation therapy in patients with primary glioblastoma (Arm A)
215001509|NCT07120620|DEVICE|TTFields before and during radiotherapy|Administration of TTFields before and during radiation therapy in patients with primary glioblastoma (Arm B)
215001510|NCT07121413|DRUG|SV001|SV001 ： Multiple-dose
215001511|NCT07121413|DRUG|Placebo|Placebo ： Multiple-dose
215001512|NCT07121088|DRUG|(Intensive treatment) Chuanzhi Tongluo Capsules|4 capsules each time, orally, 3 times a day; administration from day 1 to day 14 of the disease.
215001513|NCT07121088|OTHER|Standard Treatment (Guideline-Based)|Combination therapy including: 1. Antiplatelet: aspirin 100 mg/day + clopidogrel 75 mg/day. 2. Lipid-lowering: atorvastatin 20 mg/day. 3. Antidiabetic: metformin 500 mg bid (max 2000 mg/day). \*Doses may be adjusted per local guidelines or patient tolerance.
215001514|NCT07121088|DRUG|(Sequential treatment) Chuanzhi Tongluo Capsules|2 capsules each time, orally, 3 times a day; administration from day 15 to day 365.
215001515|NCT07121088|DRUG|TCM Syndrome Differentiation Decoction|Individualized herbal decoction based on TCM diagnosis (four diagnostic methods), administered for 14 days during intensive phase.
215001516|NCT07122362|DEVICE|Elastic Lower Extremity Orthosis|Participants in the intervention group receive conventional neurodevelopmental therapy combined with an elastic lower extremity orthosis designed to correct internal rotation deformities and improve gait and balance in children with spastic cerebral palsy. The orthosis applies elastic tension around the femoral region and tibia to target rotational problems.
215001517|NCT07122362|BEHAVIORAL|Neurodevelopmental Therapy|Participants receive conventional neurodevelopmental therapy only.
215001518|NCT07123844|DIETARY_SUPPLEMENT|low cholesterol diet|low cholesterol diet
215001519|NCT07123792|DRUG|Calcium Hydroxide (20%)|A 20% calcium hydroxide paste will be placed as an intracanal medicament following root canal instrumentation. Applied using a Lentulo spiral, excess is removed, and the tooth is sealed with a glass ionomer temporary restoration.
215095008|NCT03255564|OTHER|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
214396830|NCT05655481|OTHER|Health education|Telehealth and guidelines for the practice of physical activity and health education
214396831|NCT00280293|DRUG|Lamotrigine|Lamotrigine
214396832|NCT00280293|DRUG|Placebo|Placebo
215001520|NCT07123792|DRUG|Chlorhexidine Gel (2%)|A 2% chlorhexidine gel will be used as an intracanal medicament following canal preparation. It will be delivered with a Lentulo spiral, cleaned from the chamber, and the tooth sealed.
215001521|NCT07123792|DRUG|Modified Triple Antibiotic Paste|A modified triple antibiotic paste consisting of ciprofloxacin, metronidazole, and clindamycin (1:1:1 by weight) will be placed in the canal using a Lentulo spiral. The excess paste will be removed, and the cavity will be sealed with temporary restorative material.
215001522|NCT07124520|DEVICE|Iowa Oral Performance Instrument (IOPI)|The Iowa Oral Performance Instrument/IOPI is an instrument that objectively measures tongue strength using a standard-sized air-filled bulb. An individual presses the bulb against the roof of the mouth with the tongue to generate a pressure measurement in kilopascals (kPa). Maximum tongue strength can be determined using a measure of pressure.
215001523|NCT07124065|DIAGNOSTIC_TEST|Diffuse reflectance spectroscopy|Spectral data collection with diffuse reflectance spectroscopy
215001524|NCT07126002|BEHAVIORAL|Yoga|: Participants in this arm received a structured yoga course intervention for a period of 4 months. Sessions were held twice weekly, with each lasting 60 minutes. The curriculum was specifically designed to be gentle, slow-paced, and low-impact, making it suitable for older adults while emphasizing body awareness, mind-body integration, and psychological regulation. The course content included: breathing exercises (e.g., basic abdominal breathing combined with simple movements), asana (posture) practice (e.g., seated chair exercises, standing poses, prone poses, supine poses, and side-lying poses, emphasizing muscle activation, joint flexibility, bodybalance training, and coordination of breath with movement), and meditation and relaxation (e.g.supine rest, moon breath training, and OM chanting). All classes were instructed by experienced yoga teachers certified by the Yoga Alliance.
215001525|NCT07124884|DRUG|Administration of experimental treatment association (sotorasib, panitumumab 5FU)|Panitumumab is administered at a dose of 6 mg/kg via intravenous infusion over one hour during the first cycle, and over 30 minutes from the second cycle onward. The LV5FU2 regimen includes folinic acid (400 mg/m², or 200 mg/m² if levo-leucovorin is used) as a two-hour IV infusion, followed by a 5-FU bolus (400 mg/m² over 10 minutes), and a continuous 5-FU infusion (2400 mg/m² over 46 hours). Sotorasib is given orally at a dose of 960 mg once daily on a continuous basis.
215001526|NCT07124143|OTHER|PRP|venous blood will be drawn postoperatively and sent to Erciyes University Medical Faculty laboratories for PRP preparation. PRP will be centrifuged according to the manufacturer's specifications, transferred to sterile eye drop bottles, and given to the patients for application. Since PRP maintains its efficacy for seven days, a second blood draw and PRP preparation will be conducted during the first-week follow-up.
214396833|NCT00178022|BEHAVIORAL|Case management and problem solving therapy|
214396834|NCT02981485|DEVICE|Fat Grafting|Treatment of breast cancer related lymphedema by fat grafting
214396835|NCT06478875|COMBINATION_PRODUCT|[68Ga]Ga-PentixaFor PET imaging|PET imaging of adrenal glands
215095009|NCT00908037|DRUG|eltrombopag|thrombopoietin receptor agonist
215095010|NCT00908037|DRUG|Placebo|placebo for comparison
215095011|NCT03300778|BEHAVIORAL|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
214396836|NCT06504576|DRUG|Cilostazol 50 MG Oral Tablet|Two consecutive weeks of Cilostazol (50mg BID) two days after admission
214396837|NCT06504576|PROCEDURE|Conventional internal medicine treatment|Receives only conventional internal medicine treatment
214396838|NCT00004767|DRUG|Sodium Benzoate|
215001527|NCT07124143|OTHER|Placebo|Patients will be provided with sterile eye drop bottles containing physiological saline and instructed to apply 3-4 drops to the wound site four times a day for 14 days.
215001528|NCT07125690|OTHER|local heat application|The newborns included in this group received local dry heat application 5 minutes before the heel prick procedure, with the newborn in the supine position. Local dry heat was applied using a thermometer heated with water between 40 and 45˚C. The temperature of the water inside the thermometer was measured before application. The thermometer was applied to the sole of the newborn's right foot. Contact with bare skin was prevented, and the thermometer was used in a protective cover.
215001529|NCT07125690|OTHER|oral sucrose|In accordance with the Neonatal Pain and Treatment Guidelines, a total of 1 ml of sucrose at a 24% concentration recommended for full-term infants was prepared in a syringe. It was administered to the anterior tongue 2 minutes before the heel prick
215001530|NCT07125690|OTHER|mixed group|Newborns included in the combined intervention group received local dry heat with a thermometer heated with water at 40-45˚C 5 minutes before blood collection, with the infant in the supine position. At the third minute of the local heating, 1 ml of 24% sucrose was applied to the anterior tongue over 1 minute. A stopwatch was used to monitor the procedure times.
215001531|NCT07124819|DRUG|Sodium enoxaparin|"Subgroup 2A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive Clexane® subcutaneously administered 12±1 hours before surgery starting 6-10 hours after surgery everyday for 35±2 days.~Subgroup 2B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive Clexane® subcutaneously administered 12±1 hours before surgery everyday for 14±1 days."
215001532|NCT07124819|DRUG|Dimolegin|"Subgroup 1A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive Dimolegin® starting 6-10 hours after surgery everyday for 35±2 days.~Subgroup 1B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive Dimolegin® starting 6-10 hours after surgery everyday for 14±1 days."
215001533|NCT07124819|DRUG|Dimolegin placebo|Subgroup 2A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive placebo Dimolegin® starting 6-10 hours after surgery everyday for 35±2 days. Subgroup 2B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive placebo Dimolegin® starting 6-10 hours after surgery everyday for 14±1 days.
215001534|NCT07124819|DRUG|Sodium enoxaparine placebo|"Subgroup 1A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive palcebo Clexane® subcutaneously administered 12±1 hours before surgery starting 6-10 hours after surgery everyday for 35±2 days.~Subgroup 2B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive placebo Clexane® subcutaneously administered 12±1 hours before surgery everyday for 14±1 days."
215001535|NCT07125287|BEHAVIORAL|Exposure based CBT|This intervention is an exposure-based CBT program developed for children with blood-injection-injury (BII) phobia and a co-occurring somatic illness. The treatment includes a structured home training kit with medical materials (e.g., syringes, swabs) related to the child's fear, enabling frequent and realistic exposure exercises at home between sessions, guided by parents. This allows for higher treatment intensity and continuity. The intervention is tailored to children who require regular medical procedures and whose phobia interferes with essential care. Unlike previous studies, this model integrates both clinical sessions and structured home practice to increase adherence and reduce fear in medical settings.
215001536|NCT07124533|DRUG|Toothpaste Tablet|Denttabs toothpaste tablets
215001537|NCT07124533|DRUG|Conventional Toothpaste|Colgate Cavity Protection toothpaste
215001538|NCT07125352|OTHER|neutrophil lymphocyte ratio in COPD patients|Neutrophil lymphocyte ratio in determining severity and prognosis in exacerbation of COPD patients
215001539|NCT07125170|DEVICE|Kinesix XR on Meta Quest 3|Participants receive cognitive rehabilitation using immersive virtual reality through the Meta Quest 3 headset and the Kinesix XR application. Each session lasts one hour, with the first 30 minutes involving VR-based tasks guided by an occupational therapist. The intervention consists of a total of ten sessions, delivered two to three times per week. The VR component is integrated into the standard outpatient cognitive rehabilitation program. The study aims to evaluate the feasibility, safety, and acceptability of using this device during therapy.
215001540|NCT07124000|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan monotherapy
215001541|NCT07124156|BIOLOGICAL|SUM-101|Once randomised to either the SUM-101 or the rabies control vaccine, the participant will always receive the same dose of the same compound (150 µg MSP1 protein dissolved in 0.9% NaCl with 250 µl (5µg) of adjuvant GLA-SE and there are no dose adjustments foreseen. The three vaccine doses will be applied in 4-week intervals on day 0, day 28 and day 56.
215001542|NCT07124156|OTHER|CHMI|"Experimental intervention: The participants will receive a target dose of 2,800 viable intraerythrocytic P. falciparum 3D7 parasites, in a volume of 2 mL injectable saline. The erythrocytes will be thawed, resuspended and viability will be calculated. The total erythrocyte number will be between \~3.9×106 and \~5.2×108 (average: \~4.55×108) per dose with ≥80% (\~3.64×108) P. falciparum ring-stage parasites and around 34% (\~1.24×108) viability. This number of viable P. falciparum ring-stage parasites will be diluted to establish 2800 per syringe that will be administered. Challenge dose will be administered to all volunteers as an intravenous injection at the clinical site following instructions in an established SOP. The parasites injected in each volunteer will be quantified retrospectively using qPCR analysis.~The parasites injected in each volunteer will be quantified retrospectively using qPCR analysis. No dose adjustments are foreseen. As described in the protocol"
214396839|NCT00004767|DRUG|Sodium Phenylacetate|
214396840|NCT00004767|DRUG|Sodium Phenylbutyrate|
214396841|NCT00004767|BEHAVIORAL|Dietary Intervention|
214396842|NCT04934319|BEHAVIORAL|Balance and Proprioceptive Training|"* Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* Four weeks"
214396843|NCT01375712|DIETARY_SUPPLEMENT|Fermented milk containing Lactobacillus casei strain Shirota|A fermented milk containing Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10\^9 colony-forming units of Lactobacillus casei strain Shirota.
215001543|NCT07124156|BIOLOGICAL|Verorab®|Once randomised the participant will receive the or Verorab® and there are no dose adjustments foreseen. The three vaccine doses will be applied in 4-week intervals on day 0, day 28 and day 56.
214396844|NCT01375712|DIETARY_SUPPLEMENT|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; and 0.9 g of protein.
214396845|NCT03757611|DIETARY_SUPPLEMENT|Tabetri capsule|1,000 mg/capsule (Taheebo extract 600 mg/day)
214396846|NCT03757611|DIETARY_SUPPLEMENT|Placebo capsule|1,000 mg/capsule
214396847|NCT01684488|BEHAVIORAL|YRI|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 10 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
214396848|NCT01684488|OTHER|EducAid educational programming|EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
215001544|NCT02583269|DIAGNOSTIC_TEST|Laboratory Biomarker Analysis|Correlative studies
215001545|NCT02583269|DRUG|Muscadine Grape Skin Extract|Given PO
214396849|NCT06302790|OTHER|Molli Suit Apply|Exopulse Mollii Suit is a neuromodulation application that has been extensively evaluated and is a reliable technique in patients with spasticity. Unlike many neurostimulation techniques that focus only on symptomatic muscles, Suit relieves spasticity and associated pain by stimulating the weakened antagonist of the spastic muscle. Its wearable structure is designed to manage spasticity and associated pain in both upper and lower extremities.
214396850|NCT03012217|OTHER|Observational Study|
214396851|NCT05611619|RADIATION|Tyre noise - continuous flow|Tyre noise from continuous traffic, throughout the night
214396852|NCT05611619|RADIATION|Tyre noise - discrete events|Tyre noise from few, discrete traffic events, occurring throughout the night
214396853|NCT05611619|RADIATION|High noise level|Tyre noise corresponding up to 65 dB LAEq,24h
214396854|NCT05611619|RADIATION|Moderate noise level|Tyre noise corresponding up to 60 dB LAEq,24h
215001546|NCT02583269|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
215001547|NCT01253486|BEHAVIORAL|Disease-related Expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
215001548|NCT01253486|BEHAVIORAL|Active Comparator: Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
214396855|NCT05611619|RADIATION|Low noise level|Tyre noise corresponding up to 55 dB LAEq,24h
214396856|NCT05611619|RADIATION|Air-filled tyres|Tyre noise from traditional, air-filled tyres
214396857|NCT05611619|RADIATION|Composite tyres|Tyre noise from newly designed, airless composite tyres
215001549|NCT01253486|BEHAVIORAL|Sham Comparator: Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
214396858|NCT04450433|DIAGNOSTIC_TEST|aortic dissection and healthy people|Differential expression of metabolites in patients with aortic dissection and healthy people
214396859|NCT02834715|DIETARY_SUPPLEMENT|Stevia rebaudiana liquid extract|Sweetener made of liquid stevia self administered daily for 30 days
214396860|NCT01041508|DRUG|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry (30, 40 or 52 mg/m2).
214396861|NCT01041508|RADIATION|Total Body Irradiation|"Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines."
215001550|NCT01267032|BEHAVIORAL|Integrated Care|A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
215001551|NCT01267032|BEHAVIORAL|Cognitive-Behavioral Treatment for Insomnia|A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
215001552|NCT01267032|BEHAVIORAL|Desensitization Treatment for Insomnia|A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
215001553|NCT05662618|PROCEDURE|Percutaneous selective arteriography of peripheral arteries|Treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery with rapamycin coated balloon catheter.
215001554|NCT05662618|PROCEDURE|Percutaneous selective arteriography of peripheral arteries|Paclitaxel coated balloon catheter for the treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery.
215001555|NCT04503005|OTHER|Time Restricted Eating|Effect of 16, 14 or 12 hours of daily fasting
215001556|NCT02812043|DEVICE|1,064nm Long-pulsed Nd:YAG|Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails
215001557|NCT02812043|DRUG|Amorolfine|Amorolfine nail lacquer will be applied by the patient once a week on the infected nails
215001558|NCT02172547|DRUG|Spiriva|
215001559|NCT02402751|PROCEDURE|acquisition of normative database with ultra high field MRI|characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart
215001560|NCT02402751|DEVICE|MRI|
214396862|NCT01041508|OTHER|Stem Cell Transplantation|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
214396863|NCT01041508|DRUG|Cyclosporine|"Cyclosporine is given IV based on body weight at:~* Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs).~* Age \> 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)~Cyclosporine should be started on day -1 after completion of Clofarabine. Levels should be maintained between 300-400 ng/ml."
214396864|NCT01041508|DRUG|Mycophenolate Mofetil|MMF will be at 15 mg/kg, based on adjusted body weight, q 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant. Oral doses will be rounded to the nearest 250 mg (capsules are 250 mg). MMF is also available in oral suspension form. MMF will be given until day +40 post transplant and then tapered by 10% per week to be discontinued by day +90.
214396865|NCT03252678|OTHER|a book and videos about ACP|A book and three videos about advanced care planning are provided for self-education
214396866|NCT03252678|OTHER|a book and videos about pain control|A book and three videos about pain control for cancer patients are provided for self-education
215001561|NCT02677389|OTHER|Educational Intervention|Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
215001562|NCT02677389|OTHER|Internet-Based Intervention|Receive email and technical or how-to support from study coordinator
215001563|NCT02677389|DEVICE|Monitoring Device|Wear a Fitbit web-integrated physical activity tracker
215001564|NCT02677389|OTHER|Quality-of-Life Assessment|Ancillary studies
215001565|NCT02677389|OTHER|Questionnaire Administration|Ancillary studies
215001566|NCT04910464|DRUG|Tranexamic acid|administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.
215095012|NCT03300778|BEHAVIORAL|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
214396867|NCT04600622|BEHAVIORAL|Rural Diabetes One-Day Education and Care program (R-D1D)|One time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
214396868|NCT04600622|BEHAVIORAL|Diabetes Education Materials|Diabetes Education Materials
214396869|NCT06479993|DIETARY_SUPPLEMENT|Chlorella supplementation|Supplementation with chlorella (6g/day for 3-weeks)
214396870|NCT06479993|DIETARY_SUPPLEMENT|Placebo supplementation|Supplementation with placebo - microcrystalline cellulose (6g/day for 3-weeks)
214396871|NCT03100695|OTHER|Concentrated autologous PRP-BMA|Injection of autologous, concentrated platelet-rich plasma and bone marrow aspirate at the site of fixation.
214396872|NCT04690296|DEVICE|cathetherization approach|real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization
214396873|NCT01273649|DEVICE|cryotherapy|cryotherapy is given with other physical training
214396874|NCT05981729|OTHER|Technology enriched stroke rehabilitation|In order to increase time spent in rehabilitation activity, participants will be prescribed and supported to use (by NHS staff) commercially available technology, such as robotics, adapted treadmills, virtual reality, and mobile digital devices such as smartphones, tablets, and wearable sensors.
214503267|NCT06549725|DEVICE|software Lipidica|"The investigational in vitro diagnostic medical device-software (IVDSW) Lipidica processes and analyses data inputs from the analysis of lipid profile in human plasma using an in-house in vitro diagnostic medical device."
214503268|NCT06549725|PROCEDURE|endoscopic ultrasonography|Endoscopic ultrasonography - maximum frequency: 3 times during the participation
214503269|NCT06549725|PROCEDURE|magnetic resonance|Magnetic resonance - maximum frequency: 3 times during the participation
214503270|NCT06549725|DIAGNOSTIC_TEST|laboratory examination|Lipidomic analysis, CA 19-9, CEA, HbA1c and hCG levels assessment (hCG only in women of childbearing potential in Arm 2)
214503271|NCT06549725|PROCEDURE|computed tomography|computed tomography - maximum frequency: 3 times during the participation
215001567|NCT04910464|OTHER|0.9% saline|administer the same volume (100ml normal saline) and same duration (first three days).
215095013|NCT03976284|BEHAVIORAL|Garden-fresh produce and exercise|The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
215095014|NCT01727791|DRUG|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
215001568|NCT06982508|DRUG|Obicetrapib 10mg|Active Drug
215001569|NCT06982508|DRUG|Placebo|Placebo Control
215001570|NCT05926596|DEVICE|Wearable Robotic Exoskeleton|"* Participant preparation, placement of wearable sensors and monitoring, and wearable device fitting.~* Lower-limb joint rotations and leg stretching protocol (40-60 minutes). The wearable exoskeleton and its control algorithm are evaluated to rotate leg joints and apply stretching similarly to the forces applied by nurses and caregivers when providing manual forces. Joint rotation and limb stretching is conducted while participants sit down (e.g., in a wheelchair, on a chair, on one side of a bed, or on a clinical mat) or lay down on a bed/mat. The protocol involves ankle plantarflexion and dorsiflexion, knee extension, hip flexion with the knee flexed, and toe flexion and extension (bilaterally) assisted by the exoskeleton, and each movement is repeated at a low-to-moderate rate of 10-30 cycles/minute.~* Treadmilll and Overground Walking (60-90 minutes including rest periods)~* Cool down (5-10 minutes)"
215001571|NCT06396416|DRUG|Semaglutide|Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
215001572|NCT06396416|BEHAVIORAL|Virtual Weight Management Coaching|Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.
215001573|NCT06989814|DIAGNOSTIC_TEST|Blood Product|An (extra) blood test will be done on participants. This will be analyzed for circulating tumor DNA (ctDNA) via a multi-omics approach.
215001574|NCT00514254|OTHER|questionnaire administration|
215001575|NCT00514254|OTHER|study of socioeconomic and demographic variables|
215001576|NCT00514254|PROCEDURE|evaluation of cancer risk factors|
215001577|NCT06993363|OTHER|Quadriceps Strengthening|"Static Quad Pull the toes up towards your shin, push your knee into the bed to tighten the quad muscles. This should cause your heel to slightly lift off the bed. Hold for 7 seconds. Repeat on affected leg.~Straight leg raising~* Lie on back with hips square and legs laid out comfortably on the floor~* Bend the knee of non-injured leg at a 90-degree angle, planting the foot flatly on the floor.~* Stabilize the muscles on your straight leg by contracting your quadriceps (the group of muscles on the front of your thigh).~* Inhaling slowly, lift the straight leg six inches off the ground.~* Hold for three seconds.~* Exhaling slowly, lower the leg to the floor with control~* Relax and repeat 10 times more."
215001578|NCT06993363|OTHER|Hamstring and calf stretching exercise|"Hamstring stretching exercise will be done in the long sitting position. The patient will be instructed to keep his affected knee always extended while folding the other leg to the side then he will bend his trunk forward as much as he could in order to touch his toes by his fingers.~Calf muscle stretching: The patient will be positioned in the long-sitting with the knees extended. The patient will be instructed to pull his foot into dorsiflexion as much as he could with the assistance of a rolled towel holding this position for 30 seconds (Fig14). The patient will then be instructed to go back to starting position and relax for 30 seconds. This exercise will be done 5 times per session."
215001579|NCT06993363|OTHER|Kinesotaping application|"1 full 25cm strip of KT Tape cut in half. Apply one hour before beginning activity. Clean dirt, oils and lotions from area. After application rub tape vigorously to activate adhesive. Bend the knee at a 90 degree angle Anchor the middle of a half strip of tape diagonally over the point of pain with 80% stretch. Apply ends of tape without stretch.~Anchor the middle of a second half strip across the first strip to form an X pattern over the point of pain with 80% stretch."
215001580|NCT04960566|OTHER|Cognitive Behavioral Therapy|The CBT intervention is based on the theoretical framework that under stress (reflux symptoms) a person makes a rapid cognitive appraisal of the potential threat (automatic thoughts), leading to both emotional and physical responses in the body, thereby reacting behaviorally (avoidance, increased HCU) in an attempt to mitigate unpleasantness. CBT is a collaborative, present-focused treatment that utilizes a skills-based approach with home practice exercises. CBT targets automatic thoughts and appraisals of threat via education, self-monitoring of stressors and symptoms, and strategies to reframe problematic thinking patterns to more adaptive ones. Resonance frequency breathing (RFB) is achieved when a person breathes at a pace, typically 4 to 6 breaths per minute, that engages the body's baroreflex to modulate arousal. Prior research demonstrates 4 to 6 weeks of RFB training is sufficient to significantly increase baseline HRV with enduring effects for up to 6 months.
214396875|NCT01458249|DRUG|eribulin mesylate|Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
215001581|NCT04960566|OTHER|Sham-SOC Lifestyle Coaching|Sham-SOC Lifestyle Coaching
215001582|NCT06672185|DRUG|ARC101|ARC101 will be administered according to an assigned dose schedule.
214396876|NCT05625841|OTHER|Honey product|Bee products intervention from the first day of radiation to the end of radiation therapy duration 8-12 weeks.
214396877|NCT05625841|OTHER|propolis|propolis
214396878|NCT05625841|OTHER|Usual care|Usual care
215001583|NCT06280677|OTHER|AURORA-Donor|Explorative study of cumulus cells gene expression in relation to the oocyte competence for good quality blastocyst formation and predictive for clinical pregnancy.
215095015|NCT02099201|DRUG|ACT-389949 40 mg|
215095016|NCT02099201|DRUG|ACT-389949 200 mg|Predicted dose
215095017|NCT02099201|DRUG|ACT-389949 800 mg|Predicted dose
214396879|NCT01824082|DRUG|Perineural infusion [continuous peripheral nerve block(s)]|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
214396880|NCT02116140|OTHER|[C11]Acetate and HED PET|
214396881|NCT00503828|DRUG|Derris scandens Benth extracts|Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
214396882|NCT00503828|DRUG|naproxen|Naproxen 500 mg/day for 4 weeks
214396883|NCT05993871|DIAGNOSTIC_TEST|Clinical Evaluation/Questionnaires|Anthropometric measures, somatosensory assessment (NPS, UENS, TCNS), autonomic assessment (COMPASS-31, Ewing battery), and severity and quality of life evaluation (NPS, TCNS, COMPASS-31, and EuroQOL-5D-5L index score)
214396884|NCT05993871|DIAGNOSTIC_TEST|Nerve Conduction Study|Routine Nerve Conduction Study.
214396885|NCT05993871|DIAGNOSTIC_TEST|Small fiber electrodiagnostic tests|R-R interval analysis, Cutaneous Silent Period and Sympathetic Skin Response.
214396886|NCT05993871|DIAGNOSTIC_TEST|Nerve Ultrasound|Bilateral vagal, left median, right ulnar, left tibial and right sural nerves ultrasound.
214396887|NCT05993871|DIAGNOSTIC_TEST|Skin Biopsy|distal leg 3mm punch skin biopsy
214396888|NCT02056119|DEVICE|Vibrating Mesh Nebulizer Arm|"* Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~* Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~* Aerosol treatment delivered per physician order.~* Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
214396889|NCT02056119|DEVICE|Jet Nebulizer Arm|"* Physician order received for subject, randomization to jet nebulizer occurred.~* Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~* Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~* Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
214396890|NCT01285219|DRUG|pegylated filgrastim and ﬁlgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
214396891|NCT01285219|DRUG|ﬁlgrastim and pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
214396892|NCT01348854|DEVICE|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
214396893|NCT05089110|PROCEDURE|blood sample|5 cm blood sample from COVID-19 patients
215001584|NCT06673979|DIAGNOSTIC_TEST|Numeric Rating Scale|The patients are asked to rate their pain according to the Numeric Rating Scale (0=no pain; 10=worse possible pain).
215001585|NCT06669351|DRUG|ZX-7101A|On day1: Take two tablets of ZX-7101A orally once (specification: 10mg/ tablet) with appropriate amount of warm water
215001586|NCT06669351|OTHER|Placebo for ZX-7101A tablet|"Placebo for ZX-7101A tablet:~The appearance and properties of placebo tablets were identical to those of the trial drug ZX-7101A tablets. On Day 1, two placebo for ZX-7101A tablets were taken orally with appropriate warm water."
215001587|NCT06669351|DRUG|Oseltamivir phosphate dry suspension|"Drug: Oseltamivir phosphate dry suspension:~From Day1 to Day 5 : Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label."
215001588|NCT06669351|OTHER|Placebo for Oseltamivir phosphate dry suspension:|"Drug: Placebo for Oseltamivir phosphate dry suspension:~From Day1 to Day 5 : Placebo for Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label."
214396894|NCT02395705|DRUG|cisplatin and paclitaxel|"1. Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~2. Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~3. Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles."
214503272|NCT00663611|DRUG|Norditropin|Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.
215001589|NCT04620915|BEHAVIORAL|High-level construal|"In the high-level construal condition, participants will be sent messages asking them to consider why they are quitting (What are your main reasons for quitting?) and to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014). The corpus for this condition is 100 messages composed by a large independent sample of mTurk workers who are smokers and validated by a team of RAs trained to 0.8 reliability on ratings of high-level construal. To meet criteria for inclusion, a message must be rated as significantly closer to high-level (vs. low-level) on a rating scale of construal level.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
215095018|NCT02099201|DRUG|ACT-389949 (Group C1 dose to be selected)|
215095019|NCT02099201|DRUG|ACT-389949 (Group C2 dose to be selected)|
215095020|NCT02099201|DRUG|Placebo|
215095021|NCT02310997|OTHER|Umbilical Cord Blood Transplant|
215095022|NCT02310997|DRUG|Cyclophosphamide|
215095023|NCT02310997|RADIATION|Total body irradiation|
215095024|NCT02310997|DRUG|Busulfan|
215095025|NCT02310997|DRUG|Melphalan|
215095026|NCT02310997|DRUG|Fludarabine|
215095027|NCT00869401|DRUG|dasatinib|Given orally
214396895|NCT04583319|DIAGNOSTIC_TEST|EasyCov POC|Saliva samples will be collected according to the sampling protocol defined each for EASYCOV test. The EasyCoV test will be performed at the beginning of the study before obtaining the routine RT- PCR test results. The operators performing this test will be blinded from the routine RT-PCR results.
214396896|NCT03220737|BIOLOGICAL|VAXCHORA (Cholera Vaccine, Live, Oral)|VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.
214396897|NCT03220737|OTHER|Placebo|Placebo control for this study is normal (0.9%) saline.
214396898|NCT01345461|DEVICE|transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)|two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
215001590|NCT04620915|BEHAVIORAL|Down-regulation of craving for cigarettes|"In the down-regulation of craving condition, participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences). The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability on ratings of plausibility AND effortful cognitive inhibition or control.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
215001591|NCT04620915|BEHAVIORAL|Up-regulation of goal energization|"In the up-regulation of goal energization condition, participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking. These messages will name a specific core value that the participant rated in the top three (of 19) during the baseline session, and will draw a connection between quitting and the core value. For example, a message for a person who nominated family as one of her top three core values might read, Quitting will help you model a healthy lifestyle for your family. This intervention is grounded in robust theory and evidence supporting Self-Affirmation Theory. The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability in correctly identifying to which core value the message is tied.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics."
215001592|NCT04882709|DEVICE|Recording with hearing aid|Each participant will listen to sound samples via headphones. Sound samples have been recorded with a hearing aid that was set to each participant's individual hearing loss and different amplification strategies, and an unaided reference. Participants will be asked to rate different aspects of sound quality while listening to the different sound samples.
215001593|NCT07001384|DRUG|Alectinib|All patients will receive a lead-in cycle (28 days) of alectinib.
215001594|NCT07001384|DRUG|Duvelisib|After the lead-in cycle of alectinib, in the absence of progressive disease as assessed by PET/CT scan, all patients will then receive two 28-day cycles of alectinib plus duvelisib.
215001595|NCT07009288|OTHER|Children's Oncology Group Heart Health Link|Educational materials on healthy lifestyle behaviors.
214396899|NCT04280328|DRUG|Ciforadenant|100 mg orally twice daily for 28-day cycles
214396900|NCT04280328|DRUG|daratumumab|"16 mg/kg administered intravenously as follows based on 28-day cycles:~* Cycles 1 - 2: Days 1, 8, 15, and 22~* Cycles 3 - 6: Days 1 and 15~* Cycles 7 - 24: Day 1"
214396901|NCT06460012|BEHAVIORAL|STELLA-R Curriculum|The STELLA-R curriculum is presented utilizing the ABC analytic approach to address care recipient's distressing behaviors. Using the scaffold of the ABC pyramid, they will receive video instructions on how to fully define the Behaviors they want to address by observing, describing, and writing about them. The care partners will learn to identify the Activators, the triggers for the behaviors. Next, care partners will learn to consider what happens after the behaviors, the Consequences. This is an 8-week self-directed, online weekly curriculum.
214396902|NCT06460012|BEHAVIORAL|Unrestricted Access|Following the STELLA-R curriculum, care partners will receive 8 weeks of unrestricted access to all lessons and resources.
214503273|NCT00663611|DRUG|Placebo|0.9% normal saline
214503274|NCT05989542|DRUG|PLB1001|200mg BID Oral
215001596|NCT07009288|OTHER|Monthly weights|Weight (kg): measured remotely via Withings Body + scale, Height, weight, waist circumference, BP, and % body fat
215001597|NCT07009288|OTHER|Fasting|(14-hour fast x 2 weeks; 15-hour fast x- 1 week; 16-hour fast for the remainder of the active intervention)
215001598|NCT07009288|OTHER|Calls|Month 1-3: Bi-weekly call using motivational interviewing Months 4-6: Monthly call using motivational interviewing Support via SMS text
215001599|NCT07009288|OTHER|Participant Questionnaires|Questions on worry, perceived self-efficacy, health beliefs and knowledge of late effects (adapted from EQUAL study), Behavioral Risk Factor Surveillance System, Physical Activity Questionnaire, Link to Automated Self-Administered 24-Hour (ASA24) Dietary Assessment Tool with accompanying sleep module
215095028|NCT00869401|DRUG|temozolomide|Given orally
215095029|NCT00869401|OTHER|placebo|Given orally
215095030|NCT00869401|RADIATION|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
215095031|NCT01992562|DRUG|Ziconotide|
215095032|NCT01992562|DRUG|placebo|
214396903|NCT06460012|BEHAVIORAL|Limited Access|Experimental and Waitlist Control group will experience 8 consecutive weeks of limited access to the STELLA-R website and resources. Waitlist Control will experience this from Week 1 to Week 8 while the Experimental Group will reach this phase from Week 17 to Week 24.
214503275|NCT03116464|BEHAVIORAL|Telemental Health Family Intervention|"Approximately 12-16 session family intervention that will include the following specific strategies, the implementation of which will be tailored by clinicians to the specific interpersonal deficits identified in an assessment: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs"
214396904|NCT04798105|BEHAVIORAL|Effects of tDCS of dlPFC on Probabilistic Selection Task|Predictors of Probabilistic Selection Task Performance including anodal tDCS of dlPFC, eye blink rate, extraversion and impulsiveness
214396905|NCT02064725|DRUG|Sodium cridanimod|Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
214396906|NCT01720797|DEVICE|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
214396907|NCT01720797|DRUG|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
214396908|NCT01720797|OTHER|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
214396909|NCT00178620|DRUG|Reteplase 10 Units (U) plus a second dose of reteplase 10 U|Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose
214396910|NCT00178620|DRUG|Reteplase 10 U|Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose
214396911|NCT00178620|PROCEDURE|Urgent Percutaneous Coronary Intervention (PCI)|
214396912|NCT00178620|PROCEDURE|Primary Percutaneous Coronary Intervention (PCI)|
214396913|NCT00684983|DRUG|Capecitabine|Given PO
214396914|NCT00684983|BIOLOGICAL|Cixutumumab|Given IV
214396915|NCT00684983|DRUG|Lapatinib Ditosylate|Given PO
214396916|NCT00684983|OTHER|Quality-of-Life Assessment|Ancillary studies
214396917|NCT03366883|COMBINATION_PRODUCT|Paclitaxel, Cisplatin Plus 5-FU (TCF)|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)
214396918|NCT03366883|RADIATION|radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)
214396919|NCT03807193|BEHAVIORAL|Self-selected treatment|The participants will select their own treatment material with the help of a written manual. The interventions possible to choose are all interventions used in standard cognitive behavior therapy for anxiety and depression.
214396920|NCT03807193|BEHAVIORAL|Predetermined treatment|The participants will be given a treatment program designed to address worry and generalized anxiety disorder. The program are based on newer forms of cognitive behavior therapy and include mindfulness and acceptance.
214396921|NCT03807193|BEHAVIORAL|Weekly support|The participants will have scheduled weekly support, once a week, during the treatment. The support till be delivered by students in clinical psychology.
214396922|NCT03807193|BEHAVIORAL|Support on demand|The participants will have support if and when they ask for it by themselves. If asked for the support will be delivered by students in clinical psychology.
214396923|NCT02243072|BEHAVIORAL|Fit Families plus Standard Medical Care|Adolescents will receive the Fit Families plus Standard Medical Care which consists of twice weekly home-based, family psychotherapy from a CHW for 6 months
214396924|NCT00675961|BEHAVIORAL|Brief Counseling Intervention (BCI)|Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
214396925|NCT00675961|DRUG|Naltrexone|Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
214396926|NCT00675961|OTHER|BCI + Naltrexone|Combination of the two previous interventions
214396927|NCT00675961|BEHAVIORAL|Treatment as Usual|Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
214396928|NCT02973126|PROCEDURE|FFRct and SPECT|enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
214396929|NCT04011384|BEHAVIORAL|Behavioral economic intervention of online purchasing at a food pantry|This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
214396930|NCT00050401|DRUG|MERREM I.V. 2g as a 3 hour infusion every 8 hours|
214396931|NCT00050401|DRUG|vancomycin I.V. 1 g every 12 hours|
214396932|NCT00050401|DRUG|tobramycin I.V. 5 mg/kg every 24 hours|
214396933|NCT00050401|DRUG|MERREM I.V. 1g as a 30 minute infusion every 8 hours|
214396934|NCT00050401|DRUG|MERREM I.V. 500 mg as a 3 hour infusion every 8 hours|
214396935|NCT01094171|BIOLOGICAL|Poliorix TM|Intramuscular administration, 3 doses
215095033|NCT00508612|BEHAVIORAL|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
214396936|NCT01094171|BIOLOGICAL|Infanrix TM|Intramuscular administration, 3 doses
214396937|NCT00594932|DRUG|mycophenolate mofetil|First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
214503276|NCT03324724|BEHAVIORAL|Integrative cognitive-affective therapy for adolescents (ICAT-A)|Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
214503277|NCT03464955|BEHAVIORAL|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
214503278|NCT05912374|BEHAVIORAL|standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.
214396938|NCT00594932|OTHER|placebo|"oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant). During the fourth month mycophenolate mofetil will be given in ascending doses to 3 gms/day (or less if tolerance issues arise) and continues until the end of the study at 6 months."
214396939|NCT06641219|DRUG|One single intravenous injection of [177Lu]Lu-BQ7876|One single intravenous injection of 600-800 MBq \[177Lu\]Lu-BQ7876 in prostate cancer patients.
215095034|NCT00508612|BEHAVIORAL|High school classes|The control group will attend regular high school classes.
215001600|NCT07009288|OTHER|Dried blood spot|Glucose, insulin, hemoglobin A1c, lipids. Measured remotely in the fasting state via dried blood spots in the participant's home.
215001601|NCT06615570|DRUG|VX-973|Suspension for oral administration.
215001602|NCT06615570|DRUG|Placebo|Suspension for oral administration.
215001603|NCT06072183|DRUG|Ritlecitinib|100mg Capsule
215095035|NCT00299247|DRUG|sulfadoxine/pyrimethamine|
215095036|NCT03046524|OTHER|Chart Review|Data between the years of 1/1/2002 and 12/31/2013 analyzed.
215001604|NCT06072183|DRUG|Ritlecitinib|50mg Capsule
214396940|NCT04047004|DRUG|Doxorubicin|Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
214396941|NCT04047004|DRUG|Cisplatin|Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
215095037|NCT03511469|OTHER|Control Group|Control Group: Standart rehabilitation
214396942|NCT04539379|DRUG|Magnesium sulfate|intravenous infusion
214396943|NCT04539379|DRUG|Labetolol|intravenous infusion
214396944|NCT01250249|BIOLOGICAL|BCG Vaccine IP - Serum Institute of India|0.1 ml for adults and children aged 1 month and over 0.05 ml for infants under 1 month of age
214396945|NCT04056728|BIOLOGICAL|Eupenta Inj.|fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA \[recombinant-deoxyribonucleic acid\])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
215095038|NCT03511469|OTHER|Isokinetic Group|Concentric group: Standart rehabilitation + isokinetic training
215095039|NCT05287048|DIAGNOSTIC_TEST|MCM5 ELISA|ADXGYNAE is a non-invasive ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the detection of endometrial cancer in women with postmenopausal bleeding who are suspected of having endometrial cancer. Participants will be asked to provide a urine specimen, which will be centrifuged before the sediment is lysed. The lysed sample will then be tested with the MCM5 ELISA.
215095040|NCT01147900|BIOLOGICAL|Boostrix™|Intramuscular, single dose
215095041|NCT01147900|BIOLOGICAL|Boostrix™-US formulation|Intramuscular, single dose
215095042|NCT04170387|OTHER|Relaxometer|Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
214396946|NCT00303082|DRUG|Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14|
214396947|NCT00274911|DRUG|cisplatin|
214396948|NCT00274911|DRUG|lomustine|
214396949|NCT00274911|DRUG|vincristine sulfate|
214396950|NCT00274911|PROCEDURE|adjuvant therapy|
214396951|NCT00274911|RADIATION|radiation therapy|
214396952|NCT02826564|DRUG|pembrolizumab|
215001605|NCT06072183|DRUG|Placebo|Matching capsule
215001606|NCT06622109|BIOLOGICAL|20-valent Pneumococcal Conjugate Vaccine|Injection in the muscle or subcutaneous , 1 dose 0.5mL
215001607|NCT07008482|OTHER|Music intervention|patient enrolment, administration of the APAIS and NRS scales (T0), administration of the standard music therapy/assistance intervention (20 minutes duration), re-evaluation with re-administration of the APAIS and NRS scales (T1) and completion of the CRF. The administration will take place at the patient's bedside, respecting the privacy and confidentiality of the subjects involved, guaranteeing absolute tranquillity, also with the help of dividers to avoid distractions and interruptions.
215001608|NCT06987318|BIOLOGICAL|VRC07-523LS|Administered by Intravenous (IV) infusion at Week 0 and 12 weeks later
215001609|NCT06987318|BIOLOGICAL|PGT121.414.LS|Administered by IV infusion at Week 0
215001610|NCT06880445|PROCEDURE|Povidone-Iodine (PVP-I)|The experimental group will use povidone-iodine for disinfection.
215001611|NCT06880445|PROCEDURE|Water|The control group will undergo perineal preparation using clean water
215095043|NCT00368121|DRUG|Cetuximab +/- Dexamethasone|"Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally"
214396953|NCT00918749|DRUG|150 mg|150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.
214396954|NCT00918749|DRUG|75 mg|75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
214396955|NCT00918749|DRUG|100 mg|100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
214396956|NCT01951092|OTHER|Text messaging|
214396957|NCT01712789|DRUG|Pomalidomide|Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
214396958|NCT01712789|DRUG|Dexamethasone|Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
214396959|NCT00072163|DRUG|temozolomide|Given orally
215001612|NCT06674824|DEVICE|massimo|measure plethysmography variability index in patients on spontaneous trial planning for extubation and evaluate its sensitivity in relation to transthoracic echocardiographic velocity time integral in early detecting weaning induced pulmonary edema
214396960|NCT00072163|DRUG|thalidomide|Given orally
214396961|NCT03587987|DEVICE|Neopff|manual ventilation
214396962|NCT03587987|DEVICE|rPap|Manual ventilation
214396963|NCT04592133|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography Examination
214396964|NCT03729349|BIOLOGICAL|Golimumab|Participants will receive golimumab as a part of clinical practice.
214396965|NCT04049721|PROCEDURE|HBO|2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks.
214396966|NCT04049721|OTHER|Standard of Care|20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
214396967|NCT01610973|PROCEDURE|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
214396968|NCT01610973|PROCEDURE|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
214396969|NCT01708187|BIOLOGICAL|Clarix™1k graft|"Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.~Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue."
214396970|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
214396971|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment~If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle"
214396972|NCT00788255|DRUG|Final exogenous oxytocin concentration=22.5 μU/mL|Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
214396973|NCT00788255|DRUG|Final exogenous oxytocin concentration=30.1μU/mL|Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
214396974|NCT00788255|DRUG|Final exogenous oxytocin concentration=32.9μU/mL|Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
214396975|NCT03584685|DEVICE|Mask|All participants will initially be treated without the mask. In the next appointment, half will be treated with the mask.
214396976|NCT03584685|PROCEDURE|Routine wound treatment|All participants will initially be treated for their wounds without the mask. In the next appointment, half will again be treated for their wounds without the mask.
214396977|NCT02053779|DRUG|Triptorelin 0.1mg|Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
214396978|NCT02309606|OTHER|PET scan with 5-HT receptor ligands|Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.
214396979|NCT00917228|DEVICE|recordings with device equipped|
214396980|NCT00917228|DEVICE|Control|Recording without device equipped
214503279|NCT05912374|BEHAVIORAL|enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
214503280|NCT00597376|OTHER|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
215001613|NCT07009847|OTHER|Case control study of clinical malaria|Case control study of clinical malaria
214503281|NCT00597376|OTHER|Cerefolin NAC placebo|Placebo tablet once a day
215001614|NCT07009847|OTHER|Case control study of severe malaria|Case control study of severe malaria
215001615|NCT07009847|OTHER|Case control study of death (all cause)|Case control study of death (all cause)
215001616|NCT05635370|DRUG|Pentoxifylline|Pentoxifylline claim is used as the exposure group.
215001617|NCT05635370|DRUG|Cilostazol|Cilostazol claim is used as the reference group.
215001618|NCT06678022|DEVICE|No Drone delivery|Usual ART delivery to landing sites
215001619|NCT06678022|DEVICE|Fixed Wing drones|Last Mile fixed wing drone delivery
214396981|NCT03509922|DRUG|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
214396982|NCT03509922|DRUG|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
214396983|NCT03055832|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
214396984|NCT03055832|DEVICE|LipiFlow Pulsation System|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
214396985|NCT00655070|DEVICE|Timi3 Transthoracic ultrasound|Low frequency ultrasound over the chest using Timi3 ultrasound device
215001620|NCT06426498|DEVICE|Brainsonix Bx Pulsar machine tFUS|This is a tFUS device, delivering ultrasound at a dose within the FDA safety guidelines.
215001621|NCT06685640|OTHER|prefabricated stainless steel crowns|Full coverage restoration after pulpal treatment in multi-surface deep caries of primary mandibular second molars requiring pulpotomy
214396986|NCT00904228|OTHER|placement of plastic cap during delivery room stabilization|placement of plastic cap during delivery room stabilization
214396987|NCT00904228|OTHER|placement of routine cap during delivery room stabilization|
214396988|NCT00232843|DEVICE|stent|Cordis SMART™ nitinol self-expanding stent.
214396989|NCT00232843|DEVICE|angioplasty|balloon angioplasty
214396990|NCT00897728|OTHER|laboratory biomarker analysis|
214396991|NCT00006085|DRUG|CP-609,754|
214396992|NCT01152554|DRUG|TC-5214|Tablet, oral, twice daily for 52 weeks
214396993|NCT01152554|DRUG|Placebo|Tablet, oral, twice daily for 52 weeks
214396994|NCT06355908|BIOLOGICAL|IL13Rα2 CAR-T|The IL13Rα2 CAR-T cells will be administered via intraventricular infusion every 2 weekly via an Ommaya reservoir.
214396995|NCT00029627|DRUG|Yohimbine|
214396996|NCT01854333|OTHER|ADOS module 1-4 or ADI-R|
214396997|NCT00801593|PROCEDURE|Steroid injection into the TMJs.|In case of otherwise noncontrollable TMJ involvement steroids are injected into arthritic TMJs under MRI guidance.
214396998|NCT03108287|DRUG|RAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily
214396999|NCT03108287|DRUG|RBAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
214397000|NCT00443469|DEVICE|magnetic stimulation|SMS was delivered with a repetitive magnetic stimulator connected to a figure of eight coil capable of delivering a maximum output of 2 Tesla per pulse. The coil measured 90 mm in each wing and was centered over the surface landmark corresponding to the cauda equina region. SMS was performed with the patient lying comfortably in the prone position and a soft pillow supported the lower abdomen. The coil was placed flat over the back with the handle pointing cranially. Each patient on active treatment received 200 trains of 5 pulses delivered at 10 Hz, at an interval of 5 s between each train. As this was a pilot study, each only received 1000 pulses in a single session.
214397001|NCT00443469|DEVICE|Magnetic Stimulation with tilted coil|The placebo arm consisted of 'sham' SMS delivered with the coil angled vertically and one of the wing edges in contact with the stimulation point. As this coil type allows maximum magnetic flux at the center of the intersection, we believe minimum or no stimulation was effected at the edge of the coil in contact with the patient. Stimulation parameters and duration were unchanged in this arm.
215001622|NCT06685640|OTHER|prefabricated zirconia crowns|Full coverage restoration after pulpal treatment in multi-surface deep caries of primary mandibular second molars requiring pulpotomy
215001623|NCT07016295|BEHAVIORAL|Biomechanical analysis of arm movement|Marker based kinematic analysis
215001624|NCT07016295|BEHAVIORAL|Pose estimation of arm movement|Marker free kinematic analysis
214397002|NCT01071265|PROCEDURE|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
215001625|NCT07014345|PROCEDURE|DLT placement performed in lateral position|In the lateral position group, patients were positioned laterally (as required for surgery) before anesthesia induction. After anesthesia induction, Double lumen tube placement was performed while the patient remained in the lateral position.
214397003|NCT01071265|PROCEDURE|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
214397004|NCT03217734|BIOLOGICAL|Adalimumab|Subcutaneous Injection
214397005|NCT03217734|DRUG|Methotrexate|Oral Tablet
214397006|NCT03217734|DRUG|Placebo|Oral Tablet
214397007|NCT00268229|DRUG|cytarabine|300 mg/m2/day
214397008|NCT00268229|DRUG|daunorubicin hydrochloride|45 mg/m2/day
214397009|NCT00268229|DRUG|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
214397010|NCT04783324|BEHAVIORAL|E-Mobile Health Application|The e-mobile health application prepared by the researcher will be used. E-mobile health application include information about postpartum care.
214397011|NCT01620736|DRUG|Raltegravir|Raltegravir 400 mg po bid
214397012|NCT04212481|PROCEDURE|uniport video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using single port or two ports or three ports
214397013|NCT04212481|PROCEDURE|two ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using two ports
214397014|NCT04212481|PROCEDURE|three ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using three ports
214397015|NCT00002354|DRUG|Indinavir sulfate|
214397016|NCT00002354|DRUG|Stavudine|
214397017|NCT03450421|DEVICE|Actamax™Adhesion Barrier|Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.
214397018|NCT00312975|DRUG|CP-675,206|Given intravenously every 3 months
214397019|NCT00312975|DRUG|best supportive care|As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
214397020|NCT02967211|DRUG|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214397021|NCT02967211|DRUG|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214397022|NCT02967211|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214397023|NCT02967211|DRUG|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214397024|NCT02967211|DRUG|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214397025|NCT01693939|DEVICE|FS200 Femtosecond Laser|
214397026|NCT05459220|DRUG|SHR0410 Injection|SHR0410 Injection（Low Dose）
214397027|NCT05459220|DRUG|SHR0410 Injection|SHR0410 Injection（High Dose）
214397028|NCT05459220|DRUG|Placebo|Placebo for SHR0410 Injection.
214397029|NCT02117544|DEVICE|Lotrafilcon B multifocal contact lenses (new)|
214397030|NCT02117544|DEVICE|Lotrafilcon B multifocal contact lenses|
214397031|NCT03354988|OTHER|Physical exercise group|For the exercise group, systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital
214397032|NCT03354988|OTHER|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
214397033|NCT02718352|OTHER|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
214503282|NCT06543797|DEVICE|wearable rTMS|Application of inhibitory low-frequency rTMS on unaffected primary motor cortex by wearable rTMS
215001626|NCT07015515|OTHER|Sham blood flow restriction exercise|"a BFR cuff will be placed on the upper extremity in the same location as in the real BFR group. During the application, the participant will be led to believe that the cuff is being inflated, although no actual pressure will be applied. The participant will see the cuff being wrapped and apparently inflated, but there will be no physical pressure restricting circulation during the exercise. This aims to control the psychological effects (e.g., the belief that something is being applied) on performance"
215001627|NCT07015515|OTHER|Control group|Participants perform push-up exercises without any cuff application. The same repetition and rest protocol is followed
215001628|NCT07015515|OTHER|Blood flow restriction exercise group|Participants will perform push-up exercises with 50% arterial occlusion pressure applied to their dominant arm. The cuff is inflated before the exercise and maintained throughout 3 sets of 5 repetitions. There is a 2-minute rest between sets.
215001629|NCT03890887|DRUG|BI 1291583|Tablet
215001630|NCT03890887|DRUG|Itraconazole|Oral solution
215001631|NCT04836546|DEVICE|Blood glucose meter|First phase: SMBG for 6 months
215001632|NCT04836546|DEVICE|Eversense CGM System|Second phase: CGM for 6 months
214397034|NCT00059254|DIETARY_SUPPLEMENT|Oleic acid (OA)|OA-enriched (HI OA; fat, 40%; PA, 1.7%; OA, 31.4%)
214397035|NCT00059254|DIETARY_SUPPLEMENT|Palmitic Acid (PA)|PA-enriched (HI PA; fat, 40% of energy; PA, 16.8%; OA, 16.4%)
214397036|NCT01850966|DRUG|Iguratimod|The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
214397037|NCT04957940|DRUG|SMOFlipid|Intravenous fish-oil-based lipid (SMOF lipid 20%) (Fresenius Kabi, Bad Homburg, Germany) emulsion supplementation to standard enteral nutrition in a dose of 100 ml/day at a rate of 12.5 ml/h over 8 h daily for 5 days.
214397038|NCT04957940|OTHER|0.9% saline|Receive standard enteral nutrition plus 100 ml/day 0.9% normal saline at a rate 12.5 ml/h over 8 h for 5 days
214397039|NCT01171365|DRUG|Ciclesonide|Inhaled ciclesonide 320mcg twice daily
214397040|NCT01171365|DRUG|Placebo|Matched placebo inhaler two inhalations twice daily
214397041|NCT00283465|DRUG|Epoetin alfa|
214397042|NCT03640689|DEVICE|Endovenous ablation + iliac US +/- iliac stenting|Concomitant Ablation of the GSV with endovenous therapy with associated iliac vein interrogation and stenting if required
214397043|NCT03640689|DEVICE|Endovenous ablation of Great Saphenous Vein|Ablation of the Great Saphenous Vein and subsequent Graduated Compression
214397044|NCT03863899|PROCEDURE|Nerve block|drug mixture: 10-15 ml 0.5% ropivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline
214397045|NCT03863899|PROCEDURE|Local infiltration|15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)
214397046|NCT03863899|PROCEDURE|TAVI|Insertion of an aortic valve prothesis through the aorta accessed through femoral artery
214397047|NCT03863899|DRUG|Additional intraoperative analgesia|Administration of any analgesics during the operation
214397048|NCT03863899|DRUG|Additional postoperative analgesia|Administration of any analgesics within first 24 hours after the operation
214397049|NCT03938948|DEVICE|low-level laser/light therapy|Participants will wear light therapy devices for 14 weeks
214397050|NCT05535686|OTHER|Rheumatoid Arthritis|Rheumatoid Arthritis Disease (R.A)
214397051|NCT00605371|DRUG|Lamotrigine tablet|Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
214397052|NCT00605371|DRUG|Lamotrigine caplet|Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
214397053|NCT02212938|DRUG|BI 14332 CL|
214397054|NCT02212938|OTHER|high fat breakfast|
214397055|NCT00941278|DRUG|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
214397056|NCT05905471|OTHER|Interview|Interview study
214397057|NCT01439711|DRUG|letrozole|
214397058|NCT01439711|PROCEDURE|MRI|
214397059|NCT01439711|PROCEDURE|conventional surgery|
214397060|NCT02769611|DRUG|Ruboxistaurin|Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.
214397061|NCT03527693|DEVICE|Lipogems injection|Micro-fragmented adipose tissue (10 cc) was injected intra-articular after the arthroscopic procedure (shaving or shaving + meniscectomy).
214397062|NCT05212493|DRUG|Cannabis oil|Cannabis oil 20:1 CBD:THC ratio
214397063|NCT02025348|DRUG|IntelliCap|Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
214397064|NCT01164163|DRUG|ruxolitinib phosphate|
214503283|NCT01030237|OTHER|FID 114657|1 drop both eyes four times a day for 6 weeks
215001633|NCT06688734|PROCEDURE|Inital water seal|After chest tube placement, the chest tube will be placed to 20cm H2O of suction for 1 minute to evacuate all pneumothorax. After this, the chest tube will be placed to water seal, defined as the water seal chamber on the chest tube drainage system being filled up to the 2cm line and not on suction. All other management decisions related to the chest tube will be left to the providers.
215001634|NCT06688734|PROCEDURE|Initial suction|After chest tube placement, the suction group will have their chest tube placed to 20cm H2O of suction delivered by the chest tube drainage suction. All other management decisions related to the chest tube will be left to the providers.
215001635|NCT05823727|DIETARY_SUPPLEMENT|SOLUGEL|Bovine collagen peptide supplement
215001636|NCT05823727|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
215001637|NCT05308654|DRUG|ABBV-453|Oral; Tablet
215001638|NCT05308654|DRUG|Dexamethasone|Oral Tablet
215001639|NCT05308654|DRUG|Daratumumab|Subcutaneous Injection
215001640|NCT05308654|DRUG|Lenalidomide|Oral Capsule
215001641|NCT07011992|DRUG|Rosuvastatin|Oral tablet
215001642|NCT07011992|DRUG|BPN14770|Oral capsule
215001643|NCT06682559|OTHER|Prefabricated healing abutment with scan peg|12 participants will receive single posterior implants by fully guided implant protocol followed by placement of prefabricated healing abutment with scan peg having convex emergence profile
215001644|NCT06682559|OTHER|Customized healing abutment|12 participants will receive single posterior implants by fully guided implant protocol followed by placement of custom healing abutment having concave emergence profile
215001645|NCT07024134|OTHER|Shoulder flossing application|Select a floss band, typically made of latex, which is about 1-2 inches wide. Ensure the area to be wrapped is clean and dry to prevent slipping. Begin wrapping the floss band around the upper arm, just below the shoulder joint. Start at the deltoid's base. Leave about 2 inches of the band free at the start to tuck in the end when you finish wrapping. Wrap the band tightly but not to the point of causing discomfort or cutting off circulation, the band should be snug but not so tight that it causes numbness or tingling. Aim for about a 50% stretch of the band as you wrap. Continue wrapping down the arm, covering the entire upper arm and ending just above the elbow Overlap each layer by about 50% to ensure even coverage and compression. Once you reach the desired coverage area, tuck the end of the band under the last loop to secure it. Check the tightness to ensure it is snug but not overly constrictive.
215001646|NCT07024134|OTHER|Nerve glide application|With the band in place, perform slow and controlled arm movements. Start with shoulder abduction (lifting the arm sideways) and progress to external rotation (turning the arm outward) this is for axillary nerve glide, (extending your arm and fingers while tilting your head away from the affected side) this for median nerve glide and (Extend your arm out to the side at shoulder height-Rotate the arm so the palm faces upwards-Flex the wrist and fingers back gently-Tilt your head away from the extended arm to increase the stretch) this for radial nerve glide. Ensure movements are within a pain-free range. Stop if any discomfort occurs. Keep the floss band in place for 1-2 minutes while performing nerve glides. Remove the band after the exercise, allowing the skin to recover from compression.
215001647|NCT07024134|OTHER|Shoulder flossing with Nerve Glide|Procedures of Shoulder flossing application adding to Procedures of Nerve glide application.
215001648|NCT03611946|BIOLOGICAL|Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml)|Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection
215001649|NCT03611946|BIOLOGICAL|Single dose of placebo via subcutaneous injection (0.5ml).|Administered by subcutaneous injection.
215001650|NCT03611946|BIOLOGICAL|Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)|Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.
215001651|NCT07120750|DRUG|Intervention for Group 1|Participants will receive standard NAs therapy, which may include entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF). NAs are antiviral medications used to suppress HBV replication and manage chronic hepatitis B infection.
215001652|NCT07120750|DRUG|Intervention for Group 2|Participants will receive Peg-IFNα-2b in addition to NAs therapy. Peg-IFNα-2b is an antiviral medication that works by boosting the immune system and has additional antiviral, antifibrotic, and anti-tumor effects. It is used to treat chronic hepatitis B and may help reduce the recurrence of liver cancer.
215001653|NCT07122375|DIAGNOSTIC_TEST|Angle Specific Torque Profile Analysis|All assessment data will be obtained from the archival records of young healthy adults, and no new assessments will be conducted. Raw data from wrist flexion and extension evaluations performed using an isokinetic dynamometer will be utilized.
215001654|NCT07123454|DRUG|AZD4512|AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion
215001655|NCT07123038|OTHER|Long Term Safety Monitoring Procedures|In accordance with the schedule of assessments, participants will complete the long term safety and health questionnaire and will undergo routine physical examinations. A review will be conducted on selected adverse events, medical history, and concomitant medication use. Collection of biospecimens (blood and tissue) will be taken as appropriate at scheduled visits to monitor for delayed adverse events related to prior cell therapy.
215001656|NCT06892002|DRUG|Teplizumab|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
215001657|NCT07047638|DEVICE|Restylane Skinboosters Vital Lidocaine|Restylane Skinboosters Vital Lidocaine is an injectable, sterile, transparent, biodegradable gel of non-animal crosslinked sodium hyaluronate. Restylane Skinboosters Vital Lidocaine has the addition of lidocaine hydrochloride. They are supplied in a glass syringe.
215001658|NCT06889831|BEHAVIORAL|WORTH Paths Digital Intervention|Participants in this arm will receive the WORTH Paths digital intervention, a culturally tailored program designed for women involved in the criminal legal system with substance use disorders and unmet contraceptive needs. The intervention consists of three facilitated group sessions over videoconference with digital interactive activities to support behavior change.
215001659|NCT06889831|BEHAVIORAL|WORTH Paths Wellness Group|A wellness-focused intervention consisting of three facilitated group sessions over videoconference with digital interactive activities. Sessions cover general health, stress reduction, and navigating health services, including education about substance use and sexual/reproductive health risks, guided meditation, stress management techniques, and an overview of available health services. Participants also receive digital wellness resources, including recorded mindfulness exercises and links to online health service platforms.
215001660|NCT00230516|DRUG|Nexium|
215001661|NCT00230516|DRUG|Prevacid|
214397065|NCT01164163|OTHER|laboratory biomarker analysis|
214397066|NCT01164163|OTHER|pharmacological study|
214397067|NCT04471883|PROCEDURE|Percutaneous coronary interventions|Percutaneous coronary interventions in coronary bifurcation lesions
214397068|NCT02362113|OTHER|GI/GL|GI and GL would be categorized as tertile. due to cross-sectional design of this study, intervention would not be applicable.
214397069|NCT05994599|COMBINATION_PRODUCT|EVE119 vaginal ring|EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
214397070|NCT05994599|COMBINATION_PRODUCT|Nuvaring vaginal ring|Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
214397071|NCT01012973|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
214397072|NCT01012973|OTHER|Sham treatment|Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
214397073|NCT01773668|DEVICE|Integrated sensor and infusion set.|
214503284|NCT01030237|OTHER|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
214397074|NCT06175117|DRUG|compound E Jiao Jiang(cEJJ)|compound E Jiao Jiang(cEJJ)：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
214397075|NCT06175117|DRUG|compound E Jiao Jiang(cEJJ) placebo|"compound E Jiao Jiang(cEJJ) placebo：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.~ferrous succinate tablet：1 tablet at a time, 2 times a day, should be taken in the morning, after dinner or during meals."
214397076|NCT02501759|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
214397077|NCT02501759|RADIATION|Gadodiamide|Given IV
214397078|NCT02501759|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
214397079|NCT02501759|PROCEDURE|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
214397080|NCT02501759|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
214397081|NCT04026282|PROCEDURE|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
214397082|NCT04026282|PROCEDURE|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
214503285|NCT03353285|PROCEDURE|intracytoplasmic sperm injection (ICSI)|All eggs will be fertilized by ICSI
214503286|NCT03559205|OTHER|MSK-Tracker|"The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~* Pre-clinic preparation.~* Clinic dashboard.~* Summary action plan.~* Personal goal setting.~* Follow-up and monitoring."
214503287|NCT01065532|DEVICE|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
214397083|NCT02448719|DRUG|TAK-792 30 mg|TAK-792 30 mg was administered in the morning after a fast.
214397084|NCT02448719|DRUG|TAK-792 30 mg placebo|TAK-792 30 mg placebo was administered in the morning after a fast.
214397085|NCT02448719|DRUG|TAK-792 100 mg|TAK-792 100 mg was administered in the morning after a fast.
214397086|NCT02448719|DRUG|TAK-792 100 mg placebo|TAK-792 100 mg placebo was administered in the morning after a fast.
214397087|NCT02448719|DRUG|TAK-792 250 mg|TAK-792 250 mg was administered in the morning after a fast.
214397088|NCT02448719|DRUG|TAK-792 250 mg placebo|TAK-792 250 mg placebo was administered in the morning after a fast.
214397089|NCT02448719|DRUG|TAK-792 500 mg|TAK-792 500 mg was administered in the morning after a fast or after breakfast.
214503288|NCT01065532|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
215001662|NCT05465408|BEHAVIORAL|Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention|One-to-One virtual (videoconference) behavioral intervention.
215001663|NCT07073404|DRUG|Omalizumab Injection|Treatment with omalizumab in monotherapy for 16 weeks in patients allergic to vegetables due to sensitization to lipid transfer proteins (LTPs) and profilin.
215001664|NCT06241287|BEHAVIORAL|Better Living with Non-memory led Dementia programme|an 8-week duration 6-module educational programme covering the following topics: 1) Welcome to the programme and what to expect from it; 2) Understanding the disease; 3) How to provide better support for the person with dementia; 4) How to look after the caregiver's own mental health; 5) Where to find additional sources of support, and 6) An introduction to the value of support groups. At the end of modules 2, 3, and 4, participants will be asked to complete a real-life task to put in practice skills learned in the specific module (e.g., approaching a friend and explaining the disease in lay terms). The first session (onboarding) will be facilitated via Zoom by one of the members of the research team. Up to 3 total interactions between facilitators and participants will be offered to support participants' engagement with the programme. All course modules will be printable using the pdf download button on the programme's page.
215001665|NCT06241287|OTHER|Waiting list|Signposting individuals to the publicly available Rare Dementia Support website. The control group will further receive access to the Better Living with Non-memory led Dementia programme after completing the collection of measures at 6 months.
215001666|NCT04743466|OTHER|Electronic Health Record Review|Biobank records are reviewed
214688172|NCT06926764|PROCEDURE|Sham Block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany). ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 25 ml placebo is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume study drug.
214397090|NCT02448719|DRUG|TAK-792 500 mg placebo|TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
214397091|NCT02448719|DRUG|TAK-792 750 mg|TAK-792 750 mg was administered in the morning after a fast.
214397092|NCT02448719|DRUG|TAK-792 750 mg placebo|TAK-792 750 mg placebo was administered in the morning after a fast.
214397093|NCT02448719|DRUG|TAK-792 1250 mg|TAK-792 1250 mg was administered in the morning after a fast.
214397094|NCT02448719|DRUG|TAK-792 1250 mg placebo|TAK-792 1250 mg placebo was administered in the morning after a fast.
214397095|NCT01153256|DRUG|magnesium sulphate|The patients of group M receive 50 mg/kg of magnesium sulphate in 100 ml of isotonic saline over 10 min immediately before anaesthesia induction. After induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg), rocuronium 0.6 mg/kg is given over 5 s in a running infusion.
214397096|NCT01153256|DRUG|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
214397097|NCT01153256|DRUG|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
214397098|NCT05962840|DRUG|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
214397099|NCT05962840|OTHER|Placebo of Telitacicept|Patient will be treated with placebo of Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
214397100|NCT06276413|DEVICE|GORE TAG Thoracic Branch Endoprosthesis|deployment of the GORE TAG Thoracic Branch Endoprosthesis fro thoraci aorta pathologies
214397101|NCT06285526|PROCEDURE|Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy|Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy
214397102|NCT06285526|PROCEDURE|Cephalic DuodenoPancreatectomy|Cephalic DuodenoPancreatectomy
214397103|NCT00915070|DRUG|BQ-123|60 mcg/min, infusion period: 60 min
214397104|NCT00915070|DRUG|Physiological saline solution|infusion period 60 minutes
214397105|NCT00915070|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
214397106|NCT00915070|DEVICE|Goldmann Applanation Tonometer|intraocular pressure measurements
214397107|NCT00915070|OTHER|squatting|subjects will perform squatting for 6 minutes while blood flow measurements
214397108|NCT05123716|DRUG|MDMA|Participants will be given 100 mg of MDMA
214397109|NCT05123716|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
214397110|NCT02548195|DRUG|oxaliplatin and gemcitabine|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.
214397111|NCT02548195|DRUG|capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
214397112|NCT05167526|DRUG|ASP8731|Oral
214397113|NCT05167526|DRUG|ASP8731 Matching Placebo|Oral
214397114|NCT02617420|DEVICE|Propeller Health Monitoring Device|
214397115|NCT00401921|DRUG|Minocycline|100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
214397116|NCT00401921|DRUG|Placebo oral capsule|1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
214397117|NCT00002087|DRUG|Alvircept sudotox|
214397118|NCT04920461|DEVICE|Additional MRI sequences|Additional MRI sequences (3D T2 SPACE sequence, 4/5 minutes approximatively)
214397119|NCT04920461|OTHER|Neuropsychological assessment|Neurovisual function assessed with neuropsychological tests
214397120|NCT01448837|DRUG|Bimatoprost/Timolol, 24-hour intraocular pressure monitoring|Administered once in the evening
214397121|NCT01448837|DRUG|Latanoprost, 24-hour intraocular pressure monitoring|assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
214397122|NCT00209027|OTHER|fMRI|fMRI scanning during behavioral reward task
214397123|NCT00209027|DRUG|Aripiprazole|30 mg by mouth once daily
214397124|NCT02181205|DRUG|bupivacaine|
214397125|NCT02181205|DRUG|placebo|
214397126|NCT05158257|DEVICE|balloon and Stent|balloon dilatation combined stent angioplasty
214397127|NCT05158257|DEVICE|endovascular debulking and DCB|endovascular debulking combined drug-coated balloon
214397128|NCT01932996|DRUG|nicotine patch plus nicotine gum/lozenge|12-week treatment with nicotine patch plus nicotine gum/lozenge
214397129|NCT01932996|BEHAVIORAL|Intensive Alcohol Intervention|Intensive alcohol abstinence counseling using CBT will include weekly individual sessions for 3 months followed by monthly booster group sessions for 3 months
214397130|NCT05616949|BEHAVIORAL|Treatment as Usual (TAU) (Arm 1)|Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
214688173|NCT06926764|DRUG|Levobupivacaine 0.25%|Drug used for intertransverse process block (intervention group)
214688174|NCT06926764|DRUG|Sodium Chloride (NaCl) 0.9 %|As placebo for sham block group
214397131|NCT05616949|BEHAVIORAL|Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)|Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
214397132|NCT00338715|DEVICE|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
214503289|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety normal nebulizer and mask+ distraction|Children in group 2 will receive their inhaler treatment with a normal nebulizer and mask, while at the same time one of the distraction techniques of their choice (drawing a picture, reading a story or watching an age-appropriate cartoon) will be applied.
214503290|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety a toy nebulizer and a toy mask|Children in Group 3 will receive their inhaler treatment using a toy nebulizer and a toy mask.
214397133|NCT05210842|OTHER|Endoscopy|The procedures are performed using a flexible therapeutic linear array echoendoscope.
214397134|NCT02806336|BEHAVIORAL|Multi Modal Balance Training (MMBI)|Group balance class, obstacle course, strengthening exercises
214397135|NCT02806336|BEHAVIORAL|Weight Loss (WL)|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
214503291|NCT04620252|DRUG|Inactive supplement|Chewable candy (negative control), chewed for 30 seconds.
214503292|NCT04620252|DRUG|Tricalcium phosphate supplement|Chewable tricalcium phosphate supplement, chewed for 30 seconds.
214503293|NCT04620252|DRUG|Calcium carbonate supplement|Chewable calcium carbonate supplement, chewed for 30 seconds.
214503294|NCT04620252|DRUG|Calcium citrate supplement|Chewable calcium citrate supplement, chewed for 30 seconds.
214503295|NCT04620252|DRUG|Inactive supplement and fluoride mouthwash|A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
214503296|NCT04620252|DRUG|Calcium carbonate supplement and fluoride mouthwash|A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
214503297|NCT04620252|DRUG|Calcium citrate supplement and fluoride mouthwash|A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
214503298|NCT04926259|DRUG|18F-T807|Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
214503299|NCT01703598|DEVICE|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
214503300|NCT01703598|PROCEDURE|DBS surgery|Placement of DBS electrodes
214503301|NCT00786344|BEHAVIORAL|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
214397136|NCT01929005|OTHER|Comprehensive Care|Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
214503302|NCT01231178|DIETARY_SUPPLEMENT|Alginate beverage|The dosage is 3x500ml daily
214503303|NCT01231178|DIETARY_SUPPLEMENT|Control beverage|The dosage is 3x500ml daily
214503304|NCT04186377|OTHER|Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers|Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing
214503305|NCT04186377|DRUG|S26E|Daily application of S26E extract on wound site
214503306|NCT05771857|DEVICE|Obesity|the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19
214503307|NCT00355745|DEVICE|Ultrasound breast scanning|breast scanning
214503308|NCT00540956|DRUG|cytarabine|
214503309|NCT00540956|OTHER|laboratory biomarker analysis|
214503310|NCT00239967|DRUG|Rimonabant (SR141716)|
214503311|NCT00239967|DRUG|Placebo|
214503312|NCT04241640|DRUG|Nefopam 20 MG/ML|Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative
214503313|NCT04241640|DRUG|Placebo|Placebo
214503314|NCT06835985|OTHER|Chatbot Intervention|Participants screened for suicidality during the ETUDES Center Primary Care Study and who disclose experiencing online victimization will be onboarded by a research clinician on how to use SMILEY, the web-based intervention that delivers psychoeducation, basic concepts of social media self-efficiency, and guidance on how to respond to and cope with online victimization. The chatbot and/or research clinician will send out periodic reminders to users to remind them to engage with the chatbot over four weeks. Technical troubleshooting concerns will be carried out by research clinician and chatbot developer team.
215001667|NCT06594991|DRUG|Fianlimab|Fianlimab IV given every three weeks
215001668|NCT06594991|DRUG|Cemiplimab|Cemiplimab IV given every three weeks
215001669|NCT06594991|DRUG|Ipilimumab|Ipilimumab will be give every 6 weeks continuously
215001670|NCT05222620|OTHER|Questionnaire Administration|Ancillary studies
214397137|NCT06222554|DEVICE|MoveMend Health|Software-based therapeutic tool that offers gamified exercises and activities. The device is designed for deployment on tablets. The core purpose of the device is to augment patient engagement and participation in their own rehabilitation by providing additional therapeutic interventions between formal occupational therapy sessions.
214397138|NCT04225949|OTHER|survey 1|survey with one version of depiction
214503315|NCT06835985|OTHER|Brief Psychoeducation|When youth onboard the study, a research clinician will deliver psychoeducation for youth and caregivers supported by web-based resources. Content will introduce basic concepts of social media self-efficacy (screen time guidance, technological coping skills, and encouragement of positive online interactions) and guidance on how to respond to and cope with online victimization.
215001671|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo single fraction SRS
215001672|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo fractionated SRS
215001673|NCT05222620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215001674|NCT06494657|OTHER|Corticosteroid injection|Corticosteroid injection for frozen shoulder
214397139|NCT04225949|OTHER|survey 2|survey with one version of depiction
214397140|NCT05879120|DRUG|Pembrolizumab|Given by IV (vein)
214397141|NCT05879120|DEVICE|Exablate MRgFUS + neoadjuvant pembolizumab|Given by IV (vein)
214397142|NCT03936309|OTHER|Scar Deactivation Surface Release Technique protocol|▪ Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
214397143|NCT03936309|OTHER|Scar Infiltration with 0.25-1% Lidocaine|▪ Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
214503316|NCT02489357|PROCEDURE|Cryosurgery|Undergo whole gland cryoablation
215001675|NCT05805501|DRUG|Tobemstomig|Participants will receive IV tobemstomig Q3W.
215001676|NCT05805501|DRUG|Tiragolumab|Participants will receive IV tiragolumab Q3W.
215001677|NCT05805501|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W.
215001678|NCT05805501|DRUG|Axitinib|Participants will receive axitinib PO BID.
214397144|NCT03936309|OTHER|Physical therapy|▪ Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
214397145|NCT02387905|PROCEDURE|Management of Therapy Complications|Undergo vertebral body cement augmentation
214397146|NCT02387905|OTHER|Quality-of-Life Assessment|Ancillary studies
214397147|NCT02387905|OTHER|Questionnaire Administration|Ancillary studies
214397148|NCT02387905|RADIATION|Stereotactic Radiosurgery|Undergo standard stereotactic spinal radiosurgery
214503317|NCT02489357|DRUG|Degarelix|Given SC
214503318|NCT02489357|OTHER|Laboratory Biomarker Analysis|Correlative studies
214503319|NCT02489357|BIOLOGICAL|Pembrolizumab|Given IV
214503320|NCT05703659|DIETARY_SUPPLEMENT|B. longum subsp. infantis|Infants will receive 1 dose of a B. infantis probiotic daily for 4 weeks
214503321|NCT05703659|DIETARY_SUPPLEMENT|L. reuteri probiotic|Infants will receive 1 dose of an L. reuteri probiotic daily for 4 weeks
215001679|NCT06846008|BEHAVIORAL|Ahead of the Game|"Evidence-based injury prevention training programs and exercises will be send weekly to participants in the intervention arm.~Additionally, participants in the intervention arm will be encouraged to access a study specific online platform containing information, inspiration, pep-talks and posters on injury prevention training."
215001680|NCT06846008|OTHER|Usual Practice|Usual training
215001681|NCT01294332|OTHER|Aerobic Exercise Training|supervised exercise on the treadmill at target heart rate range for 12 weeks, 3 times a week for 30 minutes.
215001682|NCT06813053|OTHER|Decision Aid (DA)|Tools designed to foster shared decision-making by contextualizing the risks and benefits of treatment options around the patient's personal values, thereby allowing them to weigh personal preferences when making treatment decisions. The study team has developed a prototype DA incorporating longitudinal institutional QoL data among patients who have undergone breast cancer surgery .
215001683|NCT06813053|OTHER|Standard of Care (SOC)|Electronic copy of an alternative educational pamphlet discussing surgical options for breast cancer.
215001684|NCT07114874|DRUG|NBI-1117568|NBI-1117568 will be administered per schedule specified in the arm description.
215001685|NCT07118995|OTHER|Analysis of preoperative CTA|A review of preoperative contrast-enhanced CTA from patients with thoracoabdominal aneurysms, included in Braile's database, who were indicated for endovascular treatment with Braile's custom-made multi-branched endograft between 2022 and 2024
215001686|NCT07124871|BIOLOGICAL|PRP-derived exosomes injection|"All subjects will receive three sessions of PRP-derived exosomes injection with 21± 3 days treatment interval.The patient will be positioned supine.~A ¼-inch Penrose drain will be used as a tourniquet by placing it at the base of the penis and maintaining it in place under tension by a sterile clamp. We will obtain 10 mL of PRP per patient, but one of them will be used for platelet cell count analysis. A total 9 mL of the PRP-derived exosomes will be infused steadily over a 2 minutes period - 4.5 mL each into the right and left corpus cavernosum. The infusion will be performed at this slow speed - each side over 2 minutes of infusion - to minimize injury to the exosomes and cells. Following administration, compression of the penis will be achieved with a clenched fist for 20 minutes. At 20 minutes, the tourniquet will be removed, and a compressive dressing will be placed around the penile shaft. The patient will be instructed to remove the compression bandage in 4 hours"
215001687|NCT07118137|DEVICE|7T MRI|Resting and activity-based MRI. Dring activity based MRI, the participant will complete tasks testing semantic memory.
215001688|NCT07118137|DEVICE|EEG|Resting-state EEG
215001689|NCT07118137|BIOLOGICAL|Blood samples|Blood samples taken for analysis of central blood biomarkers.
215001690|NCT07118137|BIOLOGICAL|Stool samples|Stool samples collected to identify distinct gut-microbiota compositions between the groups.
215001691|NCT07118137|DIAGNOSTIC_TEST|Neuropsychologic test (MoCA)|Map cognition with clinically well-established neuropsychology test
214397149|NCT02196961|DRUG|Nivolumab|adjuvant treatment of completely resected Merkel cell carcinoma
214397150|NCT05960604|DIAGNOSTIC_TEST|Passive leg raising|"All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes."
214397151|NCT03587844|DRUG|brentuximab vedotin|MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.
214397152|NCT03587844|DRUG|brentuximab vedotin|LyP Brentuximab vedotin 0.9 mg/kg2
214397153|NCT03587844|DRUG|brentuximab vedotin|MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
214397154|NCT02409303|BEHAVIORAL|Screen-Refer-Treat Intervention|This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
214397155|NCT04657523|DEVICE|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
214397156|NCT00895843|DRUG|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
214397157|NCT00895843|DRUG|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
214397158|NCT00895843|DRUG|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
214397159|NCT04717063|DRUG|Peroxyl Oral Product|mouth wash
215001692|NCT07124897|BEHAVIORAL|VR-Supported Psychosocial Nursing Care Based on Swanson's Theory of Caring|This intervention involves psychosocial nursing care based on Swanson's Theory of Caring, supported by VR technology. It is applied to women experiencing perinatal loss, aiming to reduce grief, anxiety, depression, and stress, postpartum depression, and to enhance psychosocial well-being. The care is delivered face-to-face during hospitalization and includes emotional support, active listening, presence, and empathy, aligned with the core concepts of Swanson's theory. The VR component consists of immersive, calming 360-degree visual environments that are integrated into the care sessions to promote emotional regulation. The intervention continues with structured psychosocial support via telephone on day 7 and day 30 after discharge.
215001693|NCT07124897|BEHAVIORAL|Psychosocial Nursing Care Based on Swanson's Theory of Caring|This intervention involves psychosocial nursing care based on Swanson's Theory of Caring, without the use of VR. It is delivered to women who have experienced perinatal loss, aiming to support emotional healing and reduce psychological symptoms such as grief, anxiety, depression, stress, and postpartum depression. The intervention is provided face-to-face during hospitalization and focuses on presence, listening, empathy, and emotional support in alignment with Swanson's caring processes. Follow-up support is also provided via telephone calls on day 7 and day 30 after discharge, continuing the psychosocial care process without any technological enhancement.
215001694|NCT07125924|DEVICE|Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.)|Bladder instillation of Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.) will be administered aseptically once weekly for a total of five times following each session of radiotherapy.
215001695|NCT07125924|OTHER|Normal Saline (NS)|Normal saline will be instilled into the bladder following the same schedule as the intervention group, i.e., five times after each radiotherapy session.
215001696|NCT07123493|BIOLOGICAL|Anti ALPP CAR-T cells treatment|Biological: anti ALPP CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide
215001697|NCT07123506|DRUG|Beta-blocker treatment group|After PFO closure, the beta-blocker treatment group will receive an extended-release beta-blocker, either bisoprolol or nebivolol, at a dose of 1.25 mg QD for 30 days.
215001698|NCT07123506|DRUG|Non-treatment group|After PFO closure, the non-treatment group will not receive a beta-blocker.
215001699|NCT07124546|BEHAVIORAL|Acceptance and Commitment Therapy|Attend ACT-HBC telehealth group sessions
215001700|NCT07124546|OTHER|Questionnaire Administration|Ancillary studies
215001701|NCT07124546|OTHER|Telemedicine|Attend ACT-HBC telehealth group sessions
214397160|NCT04717063|DRUG|Placebo|placebo mouth wash
214397161|NCT03989791|DIETARY_SUPPLEMENT|absolute diet|Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
214397162|NCT03989791|DIETARY_SUPPLEMENT|normal diet|Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
214397163|NCT05106985|DEVICE|ApplTree reminder app|The reminder app will be introduced to participants to support adherence to chosen goal-related tasks. Reminder app will be introduced following a baseline phase of 10, 16 or 22 days. The duration of the baseline phase will be randomly assigned using an online random number generator.
214397164|NCT02637050|OTHER|Standard of care|At the discretion of the attending physician.
214397165|NCT01260857|DRUG|Aldazide|Aldazide 25 mg OD
214397166|NCT04063579|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization|Imaging, blood tests, LV pressure measurement
214397167|NCT04063579|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)|Imaging and Blood tests
214397168|NCT03250598|DRUG|AG-348|50 mg single-dose
214397169|NCT03250598|DRUG|AG-348|5 mg single-dose
215001702|NCT07122596|DRUG|Meropenem Infusion|"Inclusion Criteria:~* 1 month to 16 years old~* Bacterial Infection (suspected or known) Admitted to PICU with suspected or known bacterial infection~* Prescribed intravenous meropenem~* Informed consent obtained from parent/guardian~Exclusion Criteria:~* Known allergy to carbapenems~* Severe renal impairment (eGFR \< 30 mL/min/1.73 m²)~* Use of other investigational antibiotics at the same time~* Prematurely Terminating the Treatment or Early Discharge Against Medical Advice Age Range: 1 month to 16 years old Gender: BOTH Sample Size (Number of participants): 150"
215001703|NCT07125586|DIAGNOSTIC_TEST|High-Sensitivity Spectroscopy with Autofluorescence for eCRSwNP Diagnosis|This intervention employs a non-invasive diagnostic procedure using a high-sensitivity spectroscopy system with autofluorescence to identify eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP). A specialized thin probe, guided by an endoscopic light source, contacts nasal polyp tissue to emit a proprietary wavelength laser light, exciting fluorescent substances (primarily flavin adenine dinucleotide, FAD). The probe captures autofluorescence signals at a specific emission wavelength, and signal intensity analysis distinguishes eosinophilic from non-eosinophilic polyps in real-time. Unlike invasive histopathological diagnosis via biopsy or surgery, this method enables rapid preoperative typing. Conducted once at the initial visit, results are validated against post-biopsy/surgical histopathology (gold standard) to assess diagnostic accuracy (sensitivity ≥90%, specificity ≥85%). Safety is monitored for adverse events like mucosal irritation or bleeding within 24 hours.
215001704|NCT07122206|PROCEDURE|Blood Draws|Research-related blood draws will be used to ascertain FGF19 levels.
215001705|NCT07125300|DIAGNOSTIC_TEST|Artificial Intelligence-Assisted Colonoscopy|"The intervention involves the use of an artificial intelligence tool during screening colonoscopy. This system includes two integrated functions:~* CADe (Computer-Aided Detection): Highlights suspected lesions in real time on the endoscopic video to assist in identifying polyps.~* CADx (Computer-Aided Diagnosis): Provides real-time optical histology predictions to help distinguish between hyperplastic and adenomatous polyps.~The AI system operates autonomously during the procedure and displays visual cues on the monitor to support the endoscopist in detecting and characterizing colorectal lesions."
215001706|NCT04524611|DRUG|Risankizumab|Intravenous (IV) Infusion
215001707|NCT04524611|DRUG|Risankizumab|Subcutaneous (SC) Injection
214397170|NCT03250598|DRUG|AG-348|200 mg single-dose
214397171|NCT02120989|BEHAVIORAL|Partner-Assisted Cognitive Behavioral Therapy for Insomnia|Study treatment includes partner-assisted Cognitive Behavioral Therapy for Insomnia (CBT-I) and consists of 7-8 weekly group therapy sessions of 2 hours each. Partner-assisted CBT-I focuses on altering patients' sleep schedules and changing their behaviors and patterns around sleeping in order to help them sleep in a single block of time overnight. As part of this treatment, participants will be asked to change, possibly reduce, the amount of time spent in bed and to maintain a specific bed time and wake time, as well as other potential changes depending on his/her specific insomnia pattern. This treatment has been shown to be safe and efficacious for a wide range of patients.
214397172|NCT00541957|BEHAVIORAL|behavior therapy|10 sessions over 4 months
214397173|NCT00541957|DRUG|Medication prescribed by PCP|Can include any antidepressant medication
214397174|NCT05357807|PROCEDURE|Standard RYGB|Roux-en-Y Gastric bypass
214503322|NCT02166632|PROCEDURE|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
214503323|NCT02166632|PROCEDURE|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
214503324|NCT04514653|BIOLOGICAL|Ranibizumab|Ranibizumab (anti-VEGF agent)
214503325|NCT04514653|GENETIC|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
214503326|NCT04514653|GENETIC|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
214503327|NCT04514653|GENETIC|RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
214503328|NCT04514653|DRUG|Local Steroid|Local steroid
215001708|NCT04524611|DRUG|Ustekinumab|Intravenous (IV) infusion
215001709|NCT04524611|DRUG|Ustekinumab|Subcutaneous (SC) injection
214397175|NCT05357807|PROCEDURE|Extended Pouch RYGB|Roux-en-Y gastric bypass with an extended pouch
214503329|NCT04514653|DRUG|Topical Steroid|Topical steroid
214503330|NCT04693637|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion
214397176|NCT05357807|PROCEDURE|Banded extended pouch RYGB|Roux-en-Y gastric bypass with a banded extended pouch
214397177|NCT03922828|DIAGNOSTIC_TEST|CT scans|CT surveillance, Lung biopsy, Lung resection
214397178|NCT01140022|OTHER|CT Screening|Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
214397179|NCT00404482|DRUG|Cyclosporine A|
214397180|NCT06291077|DRUG|Belatacept|Changing of anticalcineurins by Belatacept
214503331|NCT04237792|DRUG|dexmedetomidine|dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
214503332|NCT04237792|DRUG|propofol|propofol IV administration will be given if needed to maintain sedation
214503333|NCT02322489|DEVICE|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
214503334|NCT02322489|DEVICE|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
214503335|NCT00807079|DRUG|carboplatin|
214503336|NCT00807079|DRUG|topotecan hydrochloride|
215001710|NCT07092267|DEVICE|ArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries.|ArtiFix® is a synthetic surgical dural sealant graft intended to close dural defects following cranial and spine surgeries. ArtiFix® adheres to the dura, so that sutures are not required to prevent cerebrospinal fluid (CSF) leakage.
215001711|NCT06907953|OTHER|Observational - no intervention|Pilot, observational study - no intervention
214397181|NCT06291077|DRUG|anticalcineurins|Keeping of anticalcineurins
214397182|NCT03854240|OTHER|Classic block (Group C) and modified block (Group M) groups|Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position by using ultrasound device
214397183|NCT04678869|DRUG|Ciprofloxacin|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
214397184|NCT04678869|DRUG|Antibiotic|Standard of care antibiotic as per local policy
214397185|NCT05697432|DIAGNOSTIC_TEST|Oral Examination|A complete examination of oral and dental hygiene any health problems will be registered
214397186|NCT05697432|DIAGNOSTIC_TEST|PUFA index|An assessment of the presence of oral conditions resulting from untreated caries. P=Pulpal involvement, U=ulceration, F=fistula, A=abscess index
214397187|NCT05697432|DIAGNOSTIC_TEST|Plaque index|An assessment of the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth. The index varies between 0-4.
214397188|NCT05697432|DIAGNOSTIC_TEST|Streptococcus mutans screening|A strip test for specific bacteria named streptococcus mutans, which plays an important role in caries formation, from patients' collected saliva
214397189|NCT05697432|BEHAVIORAL|Education|Education on correct toothbrushing technique, oral hygiene, dietary education on foods detrimental for dental hygiene.
214397190|NCT04436081|DRUG|THC-free CBD Oil|Hemp-based CBD oil Gelcaps
214397191|NCT04436081|DRUG|Placebo|Placebo Gelcaps
214397192|NCT03888508|OTHER|SIT|"sensory integration therapy along with standard therapy.~Primary care giver will be trained to perform sensory integration therapy at home.~. Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home~Daily sessions of approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 days in a week will be done."
214397193|NCT05379140|BEHAVIORAL|Three Weekly Therapeutic Chinese Massage Sessions|Participants in the therapeutic Chinese massage group received three weekly 25-minute therapeutic Chinese massage sessions. The intervention included acupressure to points along the distal lower extremity acupuncture points of the Gall Bladder Channel (GB 40 and then 34). Further Chinese Massage incorporates kneading, rolling, movement of the ankle, rotating, pulling, and scrubbing to the lower extremity.
214397194|NCT05379140|BEHAVIORAL|Three Weekly Placebo Massage Sessions|The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
214503337|NCT05051826|OTHER|Resistance training that combines water and land|"Device: Swimmers in the experimental group received resistance training in water for 12 weeks, and the resistance training in the experimental group was divided into 3 categories:Resistance palm and resistance umbrella, resistance suit.~Device: The swimmers in the experimental group underwent core strength training on land for 12 weeks, and the resistance training in the experimental group was divided into 4 types of resistance zones: Swiss ball, medicine ball and drive zone.The combination of two resistance training methods can improve teenagers' swimming performance."
215001712|NCT06825702|DRUG|KIO-104|KIO-104 is an ophthalmic formulation for IVT injection of the active pharmaceutical ingredient (API) KIO-100, a novel, non-steroidal, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
214503338|NCT06640842|DIAGNOSTIC_TEST|A combination of various test and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy in brain health in midlife.|Participants will be asked to complete a blood draw, 5-lead ECG, MRI, a series of cognitive assessments, dietary assessments, monitor sleep and physical activity and DXA scan.
215001713|NCT07103122|OTHER|Experimental Group|A Personalized Adaptive Mirror Therapy for Upper-Limb Post-Stroke Rehabilitation using Virtual Reality and Myoelectric Control for 24 sesion in 8 weeks in add on to standard therapy.
215001714|NCT07103122|OTHER|Control Group|Conventional Therapy
215001715|NCT07103603|DRUG|Menopausal hormone therapy|Menopausal hormone therapy including oral or transdermal estrogen, with or without progestin, administered based on clinical indications.
214688175|NCT06926764|DEVICE|Ultrasound guided injection with local anaestethic|Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany)
215001716|NCT06589934|DIAGNOSTIC_TEST|Precise Image|Image reconstruction software
214397195|NCT03658811|DEVICE|intense pulsed light|Use of 6 mm SapphireCool light guide to treat upper lid margins from tragus to tragus including the nose
214397196|NCT00184613|DEVICE|pump|
214397197|NCT00184613|DRUG|insulin glargine|
214397198|NCT00184613|DRUG|insulin aspart|
214397199|NCT02739243|BEHAVIORAL|Tailored group intervention (PREPARE)|
214397200|NCT02739243|BEHAVIORAL|Individual treatment as usual|
214397201|NCT04381702|PROCEDURE|Pancreatoduodenectomy|Open or laparoscopic pancreato-duodenectomy with pancreatojejunal anastomosis
214397202|NCT02093143|DRUG|Remifentanil|Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
214397203|NCT05165875|DRUG|Hydrocortisone-Lidocaine|"Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
214503339|NCT04272385|OTHER|Observational|Observational
215001717|NCT07109492|OTHER|Mandala|Mandala Painting
214397204|NCT05165875|OTHER|Splint|"Intervention will be done on the same day based on the randomization. For the splint group, a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks. Subsequently, the splint will be weaned and passive range of motion exercises taught.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
214397205|NCT00988585|DIETARY_SUPPLEMENT|EPA 600|EPA 600 mg/day for 6 weeks
214397206|NCT00988585|DIETARY_SUPPLEMENT|EPA 1800|1800 mg/day for 6 weeks
214397207|NCT00988585|DIETARY_SUPPLEMENT|Olive Oil|600 mg/day for 6 weeks
214397208|NCT00988585|DIETARY_SUPPLEMENT|DHA|600 mg/day for 6 weeks
214397209|NCT01920776|OTHER|ultrasound examination|
214397210|NCT01920776|OTHER|Ultrasound group|Ultrasound group will receive ultrasound examination at least once a day, the results will be noted to the attending who is in charge of the treatment.
214397211|NCT00946647|DRUG|Panobinostat (LBH589)|Panobinostat was supplied by Novartis as immediate-release hard gelatin capsules in strengths of 5 mg, 10 mg, and 20 mg packaged in high density polyethylene bottles.
214397212|NCT00946647|DRUG|5-Azacytidine|
214397213|NCT05991050|DIETARY_SUPPLEMENT|energy-restricted diet|Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E.
214397214|NCT05991050|DEVICE|Whole body vibration|"For 8 weeks, WBV participants completed 3 supervised training sessions a week. The exercises were consisted of dynamic squats starting from upright position into the assigned degree of knee ﬂexion squats with 90° knee angle, semi-squats with 120° knee angle and heel elevation (calf-raise), each exercise was performed for 3 sets and each set consisted of 5 repetitions."
214397215|NCT05770596|DRUG|vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
214397216|NCT05770596|OTHER|placebo group|patients in this group will receive placebo tablets with the same manner; orally 1 hour before surgery and for 50 days starting from the 2nd postoperative day.
214397217|NCT05553132|COMBINATION_PRODUCT|Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier|Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip. There are not enough cartilage cells to fill the defect so cartilage cells need to be mixed with MSCs. MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair. MSCs can be found in bone marrow and in the fatty tissues (i.e., area under the skin of the belly or breast) of patients. Fibrin glue is a product made from the naturally occurring compounds in blood which cause clotting. This glue hardens into a gel-like substance into which cells such as cartilage cells (chondrons) and AMSCs can be placed.
214688176|NCT06821555|BEHAVIORAL|Nutrition and Physical Activity Education with Mindful Eating Intervention|Mindful Eating Intervention applied to Obesity treatment for Adolescent alongside with Nutrition and Physical Activity Education from Nutritionist and Psychologist
215001718|NCT07108361|PROCEDURE|Osseodensification|Septum width will be directly measured post molar extraction confirming the premeasure of the CBCT. Measurement will be recorded at the narrowest width of the septum. Implant site preparation starts with a pilot drill, in clockwise motion, in the center of the septum, until 1 mm deeper than the planned implant length. Densah® Burs (Versah, LLC, Jackson, MI, USA) were then sequentially used in OD mode (counterclockwise, drilling speed 800-1500 rpm, with copious irrigation) in small increments to gradually expand the osteotomy, until reaching the desired width for the planned implant diameter, Osteotomy diameter as a reflection of septum width expansion will then be directly measured and recorded after site instrumentation. Implants of adequate diameter (4, 4.5, or 5mm) and length (selected using preoperative CBCT) will be inserted in the prepared osteotomies to engage the bone apical to the socket, insertion torque will be measured using the torque wrench and ISQ values
215095044|NCT05768815|BEHAVIORAL|Breaking the Cycle Program|BTC is a prevention and early intervention program in Toronto, Canada, serving substance-using pregnant and/or parenting women with children under six years of age. Established by the Canadian Mothercraft Society in 1995, BTC is funded by the Community Action Program for Children and the Canadian Prenatal Nutrition Program through the Public Health Agency of Canada. BTC provides three program components that act synergistically: a) individualized services for mothers, b) individualized services for children, and c) relational interventions that enhance the mother-child relationship and promote infant mental health. Coordinated supports are offered through formal partnerships across service sectors. In 2004, BTC was recognized by the United Nations as an exemplary program serving pregnant and parenting women with substance use problems, and their young children.
214397218|NCT05763732|BEHAVIORAL|Rhythmic Auditory Stimulation (RAS)|"Rhythmic auditory stimulus (RAS) is a Neurologic Music Therapy (NMT) technique that utilizes an auditory rhythmic cue to entrain gait to a specific rhythm.~RAS, as an anticipatory time cue, can be used as both an immediate entrainment stimulus, providing rhythmic cues during movement, and as a facilitating stimulus for planning and executing a movement to achieve more functional gait patterns. Cadence, gait velocity, and stride length are the commonly used parameters to monitor changes in a patient's gait."
214397219|NCT05989321|PROCEDURE|PVI alone|pulmonary vein isolation
214397220|NCT05989321|PROCEDURE|PVI + SPs ablation|pulmonary vein isolation + SPs ablation
214397221|NCT05884190|OTHER|Remote Medical Model (RMM)|Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive
214397222|NCT05884190|OTHER|Community Health Model (CHM)|Utilization of community health workers trained in a strength-based trauma informed dyadic evidence-based approach.
214397223|NCT05884190|OTHER|SoC|SoC for Postpartum Hypertension
214397224|NCT05138484|DRUG|experimental group 10% mouthwash of M. sylvestris extract|To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
214397225|NCT02169037|PROCEDURE|FIRM Ablation|Substrate ablation for AF, via ablation of rotors and focal sources alone.
214397226|NCT02169037|PROCEDURE|Conventional AF ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
214397227|NCT01674257|OTHER|USPIO (ferumoxytol)-enhanced MRI scan|Two separate MRI scans will form this intervention. A baseline scan followed by an infusion of USPIO (ferumoxytol), followed by another MRI scan.
214397228|NCT01674257|RADIATION|18f-Fluoride PET/CT scan|
214397229|NCT01674257|RADIATION|18F-Flurodeoxyglucose PET/CT scan|
214397230|NCT03990363|DRUG|Verinurad|"Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9"
214397231|NCT03990363|DRUG|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol
214397232|NCT03990363|DRUG|Placebo for Verinurad|Matching Capsule
214397233|NCT03990363|DRUG|Placebo for Allopurinol|Matching tablet
214397234|NCT02171182|DRUG|Qutenza|capsaicin patch
214397235|NCT00566358|PROCEDURE|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
214397236|NCT04299802|DRUG|Leukocyte-Rich Platelet-Rich Plasma|LR-PRP will be a concentration of PRP with the addition of leukocytes. Studies have shown that LR-PRP is more effective in treating tendinopathy than leukocyte-poor platelet-rich plasma.
214397237|NCT04299802|PROCEDURE|Percutaneous Ultrasonic Tenotomy|Discussed in Percutaneous Ultrasonic Tenotomy Arm section
214397238|NCT01079624|OTHER|Glucose-insulinotropic peptide, Glucagon-like peptide-1|GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
214397239|NCT02092818|DRUG|Riociguat (Adempas, BAY63-2521)|The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
215001719|NCT07108361|PROCEDURE|conventional drilling|Septum width will be directly measured post molar extraction confirming the premeasure of the CBCT. Measurement will be recorded at the narrowest width of the septum. The initial (pointed) drill will be used to make a hole (starting point) in the interradicular bone to avoid slippage of the subsequent the drills in the socket of the remaining roots. The drills of increasing diameters will be used to complete the implant osteotomy according to manufacturer instructions. In case of limited interradicular bone volume, drilling will be made at the socket of mesial or distal roots. Osteotomy diameter as a reflection of septum width expansion will then be directly measured and recorded after site instrumentation. Implants of adequate diameter (4, 4.5, or 5mm) and length (selected using preoperative CBCT) will be inserted in the prepared osteotomies to engage the bone apical to the socket insertion torque will be measured using the torque wrench and ISQ values
215001720|NCT07102771|PROCEDURE|Ultrasound guided erector spinae plane block|ESP block is most often performed using an in-plane ultrasound-guided technique. It is a paraspinal fascial plane block in which the needle placement is between the erector spinae muscle and the thoracic transverse processes, and a local anesthetic is administered, blocking the dorsal and ventral rami of the thoracic and abdominal spinal nerves
215001721|NCT07104812|DRUG|Osilodrostat 1 MG|Osilodrostat 1 mg administered between noon and 6 pm daily, for 4 weeks
215001722|NCT07115290|DEVICE|Glass ionomer-based fissure sealant|A high-viscosity, self-curing glass ionomer sealant used for the occlusal surfaces of newly erupted permanent molars. This material releases fluoride and is moisture-tolerant during application. The product used in this study was Fuji Triage™ Capsule (GC Corporation, Japan).
215001723|NCT07115290|DEVICE|Resin-based fissure sealant|A moisture-tolerant, light-cured resin-based fissure sealant designed for application to occlusal surfaces in partially erupted permanent molars. The material exhibits strong adhesion in moist conditions and forms a durable barrier against caries. The product used in this study was UltraSeal XT® Hydro (Ultradent Products Inc., USA).
215001724|NCT07116512|DRUG|Finerenone (BAY94-8862): intervention A|Study intervention A: one tablet of dose strength 1 one tablet of dose strength 1 = two tablets of dose strength 2
215001725|NCT07116512|DRUG|Finerenone (BAY94-8862): intervention B|Study intervention B: two tablets of dose strength 2 two tablets of dose strength 2 = one tablet of dose strength 1
214397240|NCT05266651|DRUG|Tadalafil 5mg|oral tablets for one month duration
214397241|NCT05266651|DRUG|Placebo|oral tablets for one month duration
214397242|NCT02334527|DRUG|Palbociclib|125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
214397243|NCT05216224|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
214397244|NCT05216224|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
214397245|NCT00488215|DRUG|prucalopride|The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
214397246|NCT00488215|OTHER|Placebo|During the placebo session, the number of placebo tablets will be consecutively escalated in an identical way as described for prucalopride. This means 1 tablet more every day, up to 10 tablets.
214397247|NCT03281278|OTHER|standard treatment|standard medical treatment
214397248|NCT02797223|BEHAVIORAL|Semi-structured interviews|Qualitative phenomenological study. Data collection will be done through semi-structured interviews. Each interview will last between 60 and 90 minutes. It will be the same researcher who interviewed and analyze them.
214397249|NCT02535559|BEHAVIORAL|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
214397250|NCT02826304|PROCEDURE|Vaginal hysterectomy|"All the cases were performed by the same surgical team~1. Incision is made at the anterior cervical lip below the bladder reflection~2. Anterior peritoneal entry .~3. Douglas pouch entry.~4. The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~5. Uterine artery clamping division and ligation~6. After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~7. Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~8. Hemostasis~9. The vaginal vault is closed after insertion of intraperitoneal drain and"
214397251|NCT02826304|PROCEDURE|Laparoscopic assisted vaginal hysterectomy|"1. Uterine manipulator was inserted through the cervix to mobilize the uterus~2. Veress needle was inserted through the base of the umbilicus~3. creation of pneumoperitoneum~4. Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~5. The round and the utero-ovarian ligament are coagulated and divided.~6. Dissection through the vesico-uterine space to displace bladder away from the cervix.~7. Uterine artery was coagulated and divided laparoscopically~8. anterior colpotomy over the cup of the uterine elevator.~9. Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis."
214397252|NCT00556374|DRUG|Placebo|
214397253|NCT00556374|BIOLOGICAL|Denosumab|Administered as a subcutaneous injection
214397254|NCT00556374|DRUG|Non-steroidal aromatase inhibitor therapy|An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
214397255|NCT00556374|DRUG|Zoledronic Acid|5 mg zoledronic acid administered at a constant infusion rate
214397256|NCT00556374|OTHER|Standard of Care|Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
214397257|NCT06183515|PROCEDURE|CPAP group: postoperative CPAP support, non-CPAP group: oxygen 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a trash|The effect of CPAP was prevent atelectasis after apnoeic ventilation during the procedure and to reduce post-procedural airway problems.
214397258|NCT04039880|DRUG|Olorofim|single oral dose (120 mg, 3.7 MBq)
214503340|NCT02625025|PROCEDURE|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
214503341|NCT02625025|PROCEDURE|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
214503342|NCT02625025|PROCEDURE|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
214503343|NCT03177707|OTHER|Mindfulness-based Therapy Group for Couples|"Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital."
214503344|NCT05155046|DRUG|18F-DCFPyL|18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.
214503345|NCT00330499|DRUG|Cisplatin|Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
214503346|NCT00330499|RADIATION|External beam radiation treatment|64Gy reference dose in 32 fractions over 6.5 weeks
214503347|NCT05243056|OTHER|Best Practice|Receive enhanced usual care
214503348|NCT05243056|OTHER|Educational Intervention|Receive Y-AMBIENT
214503349|NCT05243056|OTHER|Quality-of-Life Assessment|Ancillary studies
215001726|NCT07115433|BEHAVIORAL|School-Based Oral Health Promotion Program|Arm Description: The oral health promotion intervention will be implemented through weekly interactive sessions lasting 30-40 minutes over a period of six months. These sessions, conducted by trained dental educators and teachers, will use animations, storytelling, demonstrations, and role-plays to teach proper toothbrushing, the importance of fluoride toothpaste, healthy eating habits, and the need for regular dental visits. Children will participate in supervised toothbrushing once a week, supported by peer ambassadors who reinforce daily practices. Educational leaflets and videos will engage parents, while posters in classrooms serve as reminders. Follow-up assessments, including questionnaires and clinical indices, will be conducted at six months.
214503350|NCT05243056|OTHER|Questionnaire Administration|Ancillary studies
214503351|NCT00456339|DRUG|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
214503352|NCT04091347|BEHAVIORAL|DAPPER|The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
214503353|NCT04468737|BEHAVIORAL|Bowel preparation|Observe patients who undergo bowel preparation by enema or irrigation
214503354|NCT05371483|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring|Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.
214397259|NCT05666102|BEHAVIORAL|Transgender men's perspectives on HIV risk and HIV prevention interventions|Investigators will enroll 30 TMSM in 5 focus groups where they will examine the unique contexts in which risk for HIV acquisition occurs for TMSM, and explore participant preferences for HIV prevention services. Focus group questions will focus on five areas: 1) Gathering information related to partner selection and sorting among TMSM; 2) assessing TMSM's perceptions of HIV risk in their lived experiences; 3) exploring the various types of sexual behavior TMSM are engaging in; 4) understanding the various HIV prevention strategies currently being deployed by TMSM; and 5) examine the preferences TMSM have for receiving information related to sexual health and HIV prevention information.
214503355|NCT05371483|DIAGNOSTIC_TEST|Oculo-Cognitive Addition Test (OCAT)|Tracks users' eye movements as they complete a simple mental addition test.
214503356|NCT05357820|DRUG|AB-106, Itraconazole|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17
214503357|NCT05357820|DRUG|AB-106, Rifampicin|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21
214503358|NCT05716100|DRUG|XEN1101|XEN1101 Capsules
214503359|NCT05716100|DRUG|Placebo|Placebo Capsules
214503360|NCT06462963|RADIATION|single-fraction SBRT|Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.
214503361|NCT06462963|RADIATION|multiple-fraction SBRT|Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.
214503362|NCT03205566|DRUG|Raltegravir 400Mg Tab|bd for 7 days
214503363|NCT03205566|DRUG|Lamivudine 150Mg Tablet|\+ Raltegravir 400Mg tablet bd for 7 days
214503364|NCT06180070|DRUG|Ibuprofen/ Paracetamol tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
215001727|NCT07115771|OTHER|Postoperative analgesia management|After determining the L5-S1 level with ultrasound guidance, an 80 mm block needle (Stimuplex Ultra®, Braun, Melsungen, Germany) will be advanced in a cranio-caudal direction. Following hydrodissection, 30 ml of 0.25% bupivacaine local anesthetic solution containing 7.5 mcg of epinephrine (1:200,000) will be administered.
215001728|NCT07115771|OTHER|Postoperative analgesia management|After identifying the adductor canal with a high-frequency linear US probe (GE ML6-15-D Matrix Linear), 30 ml of 0.25% bupivacaine local anesthetic solution containing 7.5 mcg of epinephrine (1:200,000) will be administered into the adductor canal using an 80 mm block needle (Stimuplex Ultra®, Braun, Melsungen, Germany).
215001729|NCT07115511|PROCEDURE|Surgery|Recombined recanalization surgery
215001730|NCT07114731|OTHER|Synchronous Action Observation Therapy|Real-time observation and execution of motor tasks through structured video modules designed based on participants' GMFCS level and extremity involvement.
214397260|NCT05906303|DRUG|Caffeine and Sodium Benzoate Injection|Provide caffeine to shorten second stage of labor and augment pushing efforts
214397261|NCT05906303|DRUG|Normal Saline|Provide normal saline to serve as a placebo
214397262|NCT04925596|BEHAVIORAL|ePrimaPrescribe online educational program|online training program aiming to change general practitioners' benzodiazepine prescription
214397263|NCT04925596|BEHAVIORAL|ComunicaSaudeMental online educational program|online training program aiming to improve general practitioners' communication with mentally ill patients
214503365|NCT06180070|DRUG|Nuromol® tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
214503366|NCT05860504|DIAGNOSTIC_TEST|Echocardiography|All patients in the study will be examined with echocardiography
214503367|NCT05860504|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
214503368|NCT05860504|DIAGNOSTIC_TEST|Coronary CT|Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
214503369|NCT02732990|BEHAVIORAL|Exercise training|All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)
214503370|NCT00255372|DRUG|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
214503371|NCT00255372|DRUG|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
214503372|NCT04458779|DEVICE|CPAP|CPAP will be given after obstructive sleep apnea being diagnosed in the acute stage of stroke.
214503373|NCT01793779|PROCEDURE|cold water immersion|
214397264|NCT03240341|BEHAVIORAL|Patient Activation Measure Questionnaire|Measure the level of patient engagement in cancer care pathway
214503374|NCT01793779|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
214503375|NCT01793779|DIETARY_SUPPLEMENT|Placebo|
214503376|NCT02438007|DRUG|Galeterone|2550 mg galeterone tablets once daily PO
214503377|NCT02438007|DRUG|Enzalutamide|160 mg enzalutamide capsules once daily PO
214503378|NCT04255225|BEHAVIORAL|Walking for 10 minutes|Participants will walk on a treadmill for 10 minutes at a moderate intensity.
214503379|NCT04255225|BEHAVIORAL|Walking for 20 minutes|Participants will walk on a treadmill for 20 minutes at a moderate intensity.
214503380|NCT04255225|BEHAVIORAL|Walking for 30 minutes|Participants will walk on a treadmill for 30 minutes at a moderate intensity.
214503381|NCT06343727|DIETARY_SUPPLEMENT|Egg white protein pudding|Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks
214503382|NCT06343727|DIETARY_SUPPLEMENT|: Ensure Plus|Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks
215001731|NCT07114731|OTHER|Asynchronous Action Observation Therapy|Observation of structured motor task videos followed by delayed execution, adapted to individual GMFCS levels and extremity involvement patterns.
214397265|NCT04088318|DRUG|OQL011|OQL011 is an ointment containing active ingredient.
214397266|NCT04088318|DRUG|Vehicle Ointment|Vehicle ointment is an ointment containing no active ingredient.
214397267|NCT00425217|DRUG|Rituximab|
214397268|NCT00663962|DRUG|Pregabalin|"PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op."
214397269|NCT00663962|DRUG|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
214397270|NCT03509792|BEHAVIORAL|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
214397271|NCT03509792|BEHAVIORAL|Attention placebo|Smartphone activity for same amount of time.
214397272|NCT03760471|OTHER|Evidenced-based symptom management and coping intervention|The intervention visits will focus on coping and the following symptoms prevalent during CRT: (1) pain and mucositis, (2) nausea, (3) constipation, (4) fatigue, (5) sleep disturbances, (6) xerostomia, (7) thick mucus, and (8) depression
214397273|NCT04436796|DEVICE|interoperable Artificial Pancreas System (iAPS)|Use of the iAPS at home for 13 weeks, with weekly adaptation of insulin delivery settings occurring automatically in the iAPS.
214397274|NCT04436796|OTHER|Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)|Use of personal pump with study CGM \& glucometer at home for 13 weeks.
214397275|NCT03136835|DRUG|Maternal Hyperoxygenation|Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
214397276|NCT05211375|PROCEDURE|Duodenojejunal bypass|Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.
214397277|NCT05211375|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.
214397278|NCT02398162|PROCEDURE|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
215001732|NCT07114562|DEVICE|Epicare|All participants will receive treatment with the Epicare fractional nano-thulium (Tm:YAP, 1938 nm) laser device for the reduction of periorbital wrinkles.
214397279|NCT02398162|PROCEDURE|Single Blood Collection|On the enrollment day
214397280|NCT04681430|BIOLOGICAL|Convalescent plasma|transfusion of convalescent plasma (CP) with neutralizing antibodies against anti-SARS-CoV-2 ((titer of at least 1:160)
214397281|NCT04681430|DRUG|Camostat Mesilate|Tablets over 7 days, daily dose of 600 mg split into 3 doses
214397282|NCT04681430|DRUG|Placebo for Camostat Mesilate|Placebo Tablets over 7 days, split into 3 doses
214503383|NCT03411382|OTHER|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
214503384|NCT03411382|OTHER|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
214503385|NCT03411382|OTHER|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
215001733|NCT07114315|DRUG|AK112|Following a predefined dose and date.
215001734|NCT07114315|DRUG|AK130|Following a predefined dose and date.
214397283|NCT04681430|OTHER|Standard of Care (SoC)|Control Arm for convalescent plasma (CP)
214397284|NCT01438671|PROCEDURE|Nintendo Wii Fit|The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
214397285|NCT01438671|PROCEDURE|Traditional balance training|This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
214397286|NCT00462644|DRUG|RSI sedation with etomidate/succinylcholine|etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
214397287|NCT00462644|DRUG|RSI sedation with fentanyl/midazolam/succinylcholine|100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
215001735|NCT07110896|DIETARY_SUPPLEMENT|Humiome Post LB (Postbiotic)|Heat-inactivated lactobacilli with fermented medium (a postbiotic) in 340mg powder format
215001736|NCT07110896|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose, 340mg powder format
215001737|NCT07113691|DRUG|Iadademstat|Iadademstat is administered orally (PO) on an empty stomach (two hours after eating or one hour prior to food ingestion). After drinking the entire solution, the participant will be asked to refill the bottle with water and drink it again. Then they will drink another glass of water to wash their mouth and esophagus. Time of administration of the drug should be the same every day, preferentially in the mornings, and the time should be registered using the Dosing Instructions and Participant Drug Diary. If a dose is missed, the dose should be administered as soon as possible within 24 hours of the missed dose time. If more than 24 hours have passed, or a dose is vomited, the participant should call their medical team for instructions.
214503386|NCT03411382|OTHER|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
214503387|NCT00023400|DRUG|Nelfinavir|
214503388|NCT00023400|DRUG|Rifabutin|
214503389|NCT01279707|BIOLOGICAL|humanised monoclonal antibody, veltuzumab|Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
214503390|NCT01279707|BIOLOGICAL|humanised monoclonal antibody epratuzumab|Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
214503391|NCT01279707|BIOLOGICAL|humanised monoclonal antibodies veltuzumab and epratuzumab|Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
214503392|NCT05538572|DRUG|PRT3645|PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
214503393|NCT03133299|DRUG|Glucocorticoids|Oral prednisolone for four months
214503394|NCT03133299|DRUG|Vitamin D|Oral vitamin D for two months
214503395|NCT04419207|DIAGNOSTIC_TEST|Breath test|Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).
214503396|NCT04017104|DIAGNOSTIC_TEST|18F-FDG PET/CT|"For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
214397288|NCT03407261|PROCEDURE|micro-osteoperforations|Three vertical micro-osteoperforations, using Excellerator, in the buccal extracted site were executed following the aseptic procedure and local anesthesia
214397289|NCT02964715|DRUG|Empagliflozin|25 mg daily for 6 months
214397290|NCT02846558|OTHER|Frequent Patient Interaction|Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.
214397291|NCT02846558|BEHAVIORAL|Timing Restriction|Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.
214503397|NCT04017104|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
214688177|NCT06821555|BEHAVIORAL|Nutrition and Physical Activity Education|Nutrition and physical activity education from Nutritionist applied as Obesity treatment for Adolescent
215001738|NCT07113691|DRUG|Atezolizumab|"Atezolizumab will be administered by IV infusion at a fixed dose of 1680mg on Day 1 (+/-3 days) of each 28-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the treating investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.~Administration of atezolizumab will be performed in a monitored setting where there is immediate access to trained personnel and adequate equipment and medicine to manage potentially serious reactions."
215001739|NCT07113691|RADIATION|SBRT|The first fraction of SBRT should be delivered after the initiation of iadademstat and atezolizumab, ideally between Cycle 1, Day 8, and Cycle 1, Day 15. Initiation of SBRT may be delayed up to 14 days beyond Cycle 1, Day 15 if iadademstat dose adjustment is required for toxicity
215001740|NCT06921603|OTHER|Furosemide (Standard Diuretic) Treatment|Participants in this group will receive intravenous furosemide as part of their routine care, based on clinical assessments including symptoms, physical examination. Daily POCUS imaging will be performed for research purposes; however, the findings will not be shared with the treating clinical team. Fluid management decisions and discharge planning will follow usual care protocols, without additional imaging-based guidance.
215001741|NCT06921603|OTHER|POCUS-Assessed Diuretic Management|POCUS will be used to provide objective, non-invasive assessments of fluid status by measuring right internal jugular vein (RIJV) cross-sectional area (CSA) and calculating the Distensibility Index (DI). This information will be shared with the treating clinical team as an additional tool for fluid management. However, all final decisions regarding diuretic therapy will be made at the discretion of the treating physicians.
214397292|NCT02846558|DEVICE|LoseIt! Smartphone Application|Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
214397293|NCT03241264|DRUG|ND-L02-s0201|Specified dose on specified day
214397294|NCT00872014|DRUG|AMG 386|Two doses of AMG 386 (15 mg/kg) IV QW will be studied
214397295|NCT00872014|DRUG|AMG 386|Two doses of AMG 386 (10 mg/kg) IV QW will be studied
214397296|NCT00872014|DRUG|Sorafenib|Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort \& 10mg/kg cohort
215001742|NCT07115914|RADIATION|PSMA PET/CT scan|A PSMA PET scan, or prostate-specific membrane antigen positron emission tomography scan, is an imaging test that scans and takes pictures of the prostate. PSMA scans use a specialized radioactive imaging dye that sticks to the proteins that are typically found in prostate cancer cells. This imaging dye helps locate areas of prostate cancer anywhere in the body, both inside and outside prostate.
214397297|NCT01728805|BIOLOGICAL|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
214397298|NCT01728805|DRUG|Vorinostat|
215001743|NCT07113886|PROCEDURE|Mixture of Autogenous and Xenograft Particulates|This group will receive guided bone regeneration using a 1:1 mixture of autogenous bone harvested from the mandibular ramus and xenograft bone substitute (e.g., Bio-Oss). The graft material will be covered with a titanium meshes. Standard flap design, fixation, and suturing techniques will be used
215001744|NCT07113886|PROCEDURE|Patient-Specific Sticky Bone|This group will receive guided bone regeneration using patient-specific sticky bone, created by mixing autogenous bone and xenograft with autologous fibrin glue (PRF). The sticky bone graft will be molded and applied directly to the defect site, covered with a titanium meshes, and stabilized using standard surgical protocol.
214397299|NCT00744081|DRUG|Glivec|
215001745|NCT07115563|DIETARY_SUPPLEMENT|Targeted Amino Acid Supplement|Blend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD).
215001746|NCT07115563|DIETARY_SUPPLEMENT|Control (placebo)|The inert amino acid (alanine) will serve as an isonitrogenous control.
215001747|NCT07116473|DRUG|Acoramidis (AG10)|TTR stabilizer administered orally twice daily (BID)
215001748|NCT07114744|OTHER|Take home tests|"These tests will test the discriminability of sounds that vary systematically along the frequency and temporal dimensions of sound. Over the course of the 3 months post-activation, subjects will self-complete take-home tests at location of their choosing. Each test session will include the entire test-battery will be repeated frequency as often as every day and then reducing frequency of testing corresponding to the rate of speech perception improvement."
215001749|NCT07116668|DEVICE|Colovac Anastomosis Protection Device placement following low anterior resection of colon cancer|Subjects in the Investigational cohort (SAFE-3CV) will undergo an LAR procedure followed by Colovac placement. Colovac retrieval will then occur at \~10 days post LAR procedure.
215001750|NCT07116057|BIOLOGICAL|MOv19-BBz CAR T cells|Autologous T cells engineered to express an extracellular single chain variable fragment (scFv) with FRa specificity.
215001751|NCT07116057|DRUG|Cyclophosphamide/Fludarabine|Cytotoxic chemotherapy agents used for lymphodepletion prior to MOv19-BBz CAR T cell administration.
215001752|NCT07116057|DEVICE|FRa Expression Testing|Laboratory Developed Test used to determine subject eligibility
215001753|NCT07114406|DRUG|PBK_M2502 1-Day|Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
215001754|NCT07114406|DRUG|PBK_M2502 2-Day|Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
215001755|NCT07114666|BIOLOGICAL|XH001|mRNA neoantigen cancer vaccine
215001756|NCT07114666|DRUG|Chemotherapy|Gemcitabine+Capecitabine or Oxaliplatin+lrinotecan+Calcium folinate+5-FU
215001757|NCT07116031|DRUG|Belumosudil|Pharmaceutical form:Oral suspension -Route of administration:Oral or nasogastric tube
215001758|NCT07116031|DRUG|Belumosudil|Pharmaceutical form:Tablet formulation-Route of administration:Oral
215001759|NCT07115836|PROCEDURE|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
214397300|NCT00744081|DRUG|Mitoxantrone|
214397301|NCT00744081|DRUG|Topotecan|
214397302|NCT00744081|DRUG|AraC|
214397303|NCT04366570|OTHER|clinical assessment of the shoulder and the cervical spine includes stress guideline tests|As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol
214397304|NCT02610712|DRUG|Ketamine|
214397305|NCT06236581|BEHAVIORAL|GEM Intervention|Lifestyle coaching
214397306|NCT06109415|DRUG|HTX-011|400 mg
214397307|NCT06109415|DRUG|Bupivacaine Hydrochloride|100 mg
214397308|NCT06109415|DRUG|Ibuprofen|400 mg
214397309|NCT06109415|DRUG|Acetaminophen|1 g
215001760|NCT07115836|PROCEDURE|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
215001761|NCT07115758|PROCEDURE|control GBR|will have a full thickness papilla preservation FLAP, followed by an immediate implant placement using a surgical guide. Then a guided bone regeneration will be achieved by bone graft (autogenous bone chips and xenograft particles and a membrane barrier 1 mm thickness will be applied. The membrane shield then will be stabilized to the apical bone using 2 membrane tacks, customized healing abutment will be connected , then, the elevated flap will be sutured to its original position.
215001762|NCT07115758|PROCEDURE|VST|"Pre extraction procedure:~Prior to tooth extraction, cone beam computed tomography (CBCT) images will be taken to inspect the overall socket condition.~All patients will be scanned pre-operatively using an intra-oral scanner (IOS).~Extraction protocol:~incisal extraction technique, where atraumatic tooth extraction to the hopeless tooth will be performed using periotomes followed by conventional forceps."
214397310|NCT06109415|DEVICE|Luer lock applicator|Applicator for instillation
214397311|NCT01899495|OTHER|High sodium diet and low sodium diet|Isocaloric diet with 60 mEq of potassium and 1gm protein/kg body weight with high sodium 300mEq; low sodium 10 mEq.
214397312|NCT03799679|DRUG|Chemotherapeutic Agent|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV"
214397313|NCT00810641|PROCEDURE|Gufoni maneuver|For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
214397314|NCT00810641|PROCEDURE|Head-shaking maneuver|For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
214397315|NCT00810641|PROCEDURE|sham maneuver|For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
214397316|NCT01843075|DRUG|Liraglutide|Daily subcutaneous injection
214397317|NCT01843075|DRUG|Placebo|Daily subcutaneous injection
214397318|NCT00205231|DRUG|etanercept|
214397319|NCT03703206|DRUG|ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)|nerve block for posterior knee pain after a TKA.
214397320|NCT00761917|DEVICE|Tear Film Analyzer|tear film images
214397321|NCT05790564|OTHER|Almond|Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks
214397322|NCT05790564|OTHER|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)
214503398|NCT04017104|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
215001763|NCT07115342|DRUG|Standard Allergic Rhinitis Treatment|Participants will receive standard-of-care treatment for allergic rhinitis, including oral antihistamines and/or intranasal corticosteroids, according to current clinical guidelines. No additional supplementation will be provided in the control group. This arm serves as the comparator for evaluating the effects of probiotic and vitamin D supplementation
215001764|NCT07115342|DIETARY_SUPPLEMENT|Combined Vitamin D and Probiotics Supplementation|Participants in this group will receive a combination therapy of Vitamin D3 plus a daily oral probiotic capsule containing a standardized blend of Lactobacillus and Bifidobacterium species. Both supplements will be administered once daily for 12 weeks. This intervention aims to assess the synergistic effect of vitamin D and probiotics on immune response and symptom relief in allergic rhinitis.
215001765|NCT07114224|DIAGNOSTIC_TEST|AV45/AV-1、AV1451 PET|"Use PET equipment to collect multimodal imaging data. Sixty to ninety minutes after intravenous injection of 3.7 MBq/kg of 18F-AV45 or 18F-AV1, perform PET imaging in list mode to simultaneously collect structural and functional information under the same pathophysiological conditions.~The next day, perform 18F-AV1451 PET imaging to obtain tau protein distribution information."
215001766|NCT07114445|OTHER|Diabetes Treatment|Training with virtual reality glasses
215121410|NCT06458790|BEHAVIORAL|AARC|This intervention will adapt an already-existing evidence-based Centering Parenting program addressing topics that are specific to African American families. There will be 7 90 min sessions via zoom. Group education topics include (parenting goals, infant feeding and sleep, self-care). Participants will complete surveys and interviews at various times to evaluate the program. The survey topics will include: parent stress, parent confidence and thoughts about the intervention. Surveys will be completed independently by participants online via redcap at a time that is convenient to them; if requested, the coordinator may complete the survey with the participant directly by phone /zoom. Interviews will be completed with a coordinator via zoom/phone.
214397323|NCT06307340|BEHAVIORAL|Skills Training in Affective and Interpersonal Regulation with Narrative Therapy (STAIR-NT)|Adapted version of evidence-based behavioral PTSD intervention.
214397324|NCT06307340|BEHAVIORAL|Treatment as Usual|Treatment as usual.
214397325|NCT00000561|DEVICE|pacemaker, artificial|
214397326|NCT05728593|OTHER|parent-based occupational therapy|Parent-based occupational therapy intervention While the therapist, parent and child were in the therapy area in the first session, the child received the same standard occupational intervention as the control group, and during this process, the parents recorded the therapy with a video recorder. In the second 20 minutes, three activities (such as eating, dressing or mobility activities), which had been decided and planned by the parent and the therapist before the session, were performed by the child and helped by the parent and video-recorded by the occupational therapist.
214397327|NCT05728593|OTHER|Standard occupational therapy intervention|"The sessions in this intervention included the creation of a client-based programme to increase each child's individual skills, functions and social participation. Each session lasted 45 minutes and took place twice a week until 10 sessions had been completed.~Various materials such as toys, blocks, paper and pencils were used to increase the child's participation in daily living, leisure and play activities."
214397328|NCT02684903|BEHAVIORAL|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
214397329|NCT01222221|BIOLOGICAL|glioblastoma multiforme multipeptide vaccine IMA950|
214503399|NCT01953679|DRUG|Ulipristal Acetate|
214503400|NCT03183804|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.
214397330|NCT01222221|BIOLOGICAL|sargramostim|
214397331|NCT01222221|DRUG|temozolomide|
214397332|NCT01222221|OTHER|laboratory biomarker analysis|
214397333|NCT01222221|OTHER|pharmacological study|
215001767|NCT07113977|BIOLOGICAL|CAR-T(CD70)|In this clinical study, participants with advanced renal cell carcinoma will receive a novel humanized CD70-targeted CAR-T-cell product that incorporates the TLR2 co-stimulatory domain. Peripheral blood mononuclear cells will be collected from each subject, genetically modified to express the CAR construct, and expanded ex vivo; after passing multiple quality-control assays, the CAR-T cells will be administered intratumorally under CT guidance at the pre-specified dose. Following treatment, the efficacy and safety of CD70-directed CAR-T-cell therapy will be comprehensively assessed through clinical symptom evaluations, quality-of-life questionnaires, biomarker analyses, laboratory tests, imaging studies, adverse-event monitoring, and long-term follow-up.
214397334|NCT01222221|PROCEDURE|adjuvant therapy|
214397335|NCT01222221|RADIATION|radiation therapy|
214503401|NCT03183804|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
214503402|NCT04482413|DRUG|AstroStem|Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.
214503403|NCT04482413|DRUG|Placebo|Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
214503404|NCT02604693|OTHER|Nothing|No interventions will be administered.
214503405|NCT06174948|DEVICE|CUE1 non-invasive device|This is a 9-week feasibility study which will involve wearing the CUE1 device on a daily basis at participants' homes while they continue their usual activities of daily living (ADL). The CUE1 is a non-invasive medical device which delivers low frequency metronomes like tactile cueing and high frequency focused vibrotactile stimulation. All participants will be using the same pre-programmed settings for the CUE1 device which are: vibration strength delivered at 80%, pulse length 800 milliseconds (ms), and rest length 800ms as set at baseline and will not change. The CUE1 device is attached to the skin via an adhesive patch which has been dermatologically tested and approved. Participants will be provided with the adhesive patches and shown how to use them and the CUE1 device by the research team.
214503406|NCT06174948|DEVICE|CUE1+ device active vs sham CUE1+ device|30-40 participants with idiopathic Parkinson's disease only will be randomly allocated to one of two interventions groups: one group will use the active CUE1+ device while the other group will use the CUE1+ at silent settings (e.g., sham device). All participants will use their device in the same way which is starting the usage from the morning, within an hour once they took their medications for Parkinson's (if any) and continue using the device for 8 hours, once a day, every day for 12 weeks
214503407|NCT02022670|DRUG|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
214397336|NCT03776994|BIOLOGICAL|Vaccinations on Day 0, Day 28, and Day 140|The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)
214397337|NCT00216762|DRUG|Rituximab|Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
214503408|NCT02022670|DRUG|Sodium Nitrite|80 mg/d or 160 mg/d
214503409|NCT02113449|DRUG|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
214503410|NCT01263522|OTHER|different training programs|two different endurance programs and one strength endurance program
215001768|NCT07117604|OTHER|Virtual Reality|Standard virtual reality applications rely on computer-generated animation environments and avatars; however, in the present study, the content created by actors/actresses with theater training by using cameras and audio recording devices suitable for creating virtual reality content included images of real environments and people.
215121411|NCT03654690|DIAGNOSTIC_TEST|HIV self-test|Home delivery of HIV self-test kits (OraSure OraQuick Rapid HIV test)
215121412|NCT03654690|BEHAVIORAL|Counseling|Post-Test HIV Risk ReductionCounseling
214503411|NCT01263522|OTHER|control condition|unchanged lifestyle
214503412|NCT02590198|OTHER|ANAES algorithm|care as recommended by ANAES, with ANAES algorithm
214503413|NCT02590198|OTHER|PCT algorithm|care based on PCT algorithm
214503414|NCT01031056|PROCEDURE|Blood Draw|
214397338|NCT06603961|DEVICE|CPG-EB group|Customized-pressure guided elastic bandage group
214397339|NCT06858436|DRUG|Canagliflozin 100mg|receiving Canagliflozin 100mg QD
214397340|NCT03726021|DRUG|Irinotecan,Oxaliplatin, and S1|"Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.~Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells~Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells"
214397341|NCT05064111|DIAGNOSTIC_TEST|TRUS biopsy|The biopsy procedure will be completed using an FDA-approved ultrasound machine with the addition of an investigational (non-FDA approved) image fusion software.
214397342|NCT05443100|OTHER|Whole-body cryostimulation (WBC)|Multidisciplinary rehabilitation program consisting of 10 WBC sessions.
214397343|NCT05443100|OTHER|Rehabilitation program|Multidisciplinary rehabilitation program consisting of diet and physical exercise.
214397344|NCT06918691|BEHAVIORAL|technology addiction prevention program|technology addiction prevention program
214397345|NCT05204550|DRUG|unfractionated heparin|intranasal
214397346|NCT05204550|DRUG|0.9%sodium chloride|intranasal
214397347|NCT06625853|OTHER|Mtwo R files with Xp-Endo finisher file|"XP-endo Finisher file will be inserted without rotation into the root canals filled with 2.5% NaOCl and will be activated (800 rpm; torque of 1 N.cm) for~1 min in each canal using slow and gentle 7-8 mm lengthwise movements."
214503415|NCT01031056|PROCEDURE|Frozen Tumor Specimens|
214503416|NCT04409392|OTHER|Prothestic joint infection due to Staphylococcus lugdunensis|description of prosthetic joint infection with Staphylococcus lugdunensis
214503417|NCT04008953|DEVICE|ultrasonography|Intravascular volume assessment using ultrasonography, CVP and echocardiography
214503418|NCT05749120|PROCEDURE|Recipient vessel selected for microanastomosis|Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
214503419|NCT04374981|DRUG|Celecoxib 100mg|Tablets
214397348|NCT06625853|OTHER|Mtwo R files|obturation material will be removed using Mtwo R (VDW, Munich, Germany)files attached to an endodontic motor (Ecube, seachin, Korea) with a constant speed of 280 rpm, as suggested by the manufacturer. Mtwo R 25/0.05 will be used to empty the coronal and middle thirds of the root. Mtwo R 15/0.05 will be used to reach the working length.
214503420|NCT04374981|DRUG|Montelukast 10mg|Tablets
214503421|NCT03441009|OTHER|Physio-/occupational therapy|Physio-/occupational therapy, ADL
215001769|NCT07117604|OTHER|Control group|While the participants in the intervention group received training on virtual reality, those in the control group took the standard curriculum course. Students in the control group received no training. The students in the control group were told that the program would be implemented to those who volunteered after the study was completed.
215001770|NCT07117292|DEVICE|Xsens DOT|Wearable inertial sensor used to capture cervical range of motion in three planes.
214503422|NCT04964037|OTHER|No intervention|No intervention
214503423|NCT02400931|PROCEDURE|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
214503424|NCT02400931|PROCEDURE|no mask ventilation|
214503425|NCT02400931|DRUG|Rocuronium|
214503426|NCT06303869|DEVICE|Deep Brain Stimulation (DBS) of the Motor Thalamus|All participants enrolled in this group will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days.
215001771|NCT07117292|DEVICE|Trigno Avanti Sensors|Wearable inertial sensor used to capture cervical range of motion in three planes.
215001772|NCT07117292|DEVICE|Universal Goniometer|Standard clinical tool used to measure cervical spine motion angles manually.
215001773|NCT07118410|DEVICE|Application of a vascular restriction device during resistance training|"In the BFR-RT group, sessions will consist of 30 repetitions, followed by 3 sets of 15 repetitions at 40% 1-MR (maximal repetition), interspersed with 60 sec of recovery. An arterial occlusion pressure of 50% of systolic pressure will be maintained constant using a digital tourniquet. The cuff will be deflated during the recovery phases.~In the control group (RT group) it will be the same intervention with same intensities but without using BFR."
215001774|NCT07117331|BEHAVIORAL|Technology-Enhanced Continuous Nursing System|A multi-faceted behavioral and educational intervention lasting 6 months post-discharge. It utilized a smartphone app, WeChat, tele-monitoring (phone/video calls), and community health partnerships to provide structured education, personalized rehabilitation plans, and continuous professional nursing support.
215001775|NCT07117331|BEHAVIORAL|Routine Postoperative Care|Standard institutional care including standard discharge instructions and routine outpatient follow-up appointments.
215001776|NCT07117019|OTHER|Self-care and lifestyle intervention advice|All females in both groups will follow self-care and lifestyle advice for 4 weeks.
215095045|NCT05768815|BEHAVIORAL|Maxxine Wright Program|Founded in 2005 and located in Surrey, British Columbia, the Maxxine Wright Community Health Centre (MWCHC) supports women who are pregnant and/or have young children and are impacted by substance use and/or violence. Women do not need to have children in their care to receive services. The program is funded and operated by the Fraser Health Authority, with additional in-kind support from the BC Ministry for Children and Family Development and the BC Ministry of Social Development and Poverty Reduction. MW addresses maternal substance use and exposure to violence through women-centered, trauma-informed, culturally grounded, and interdisciplinary approaches. Primary services offered include addiction counselling, primary health care, and group therapy to address interpersonal violence. Within MW, child-focused services are limited to primary health (e.g., well baby checks, childcare).
215095046|NCT01756859|PROCEDURE|MRI Scan|
215095047|NCT04578561|PROCEDURE|Prophylactic mesh use|After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
215095048|NCT03850002|OTHER|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
215095049|NCT01848847|PROCEDURE|Hysteroscopy|
215095050|NCT02705274|DRUG|Bevacizumab|"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
215095051|NCT02705274|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
215095052|NCT01691976|DRUG|Oestrogen Patches|
214397349|NCT06626217|OTHER|Resting conditions|The volunteers hand is at rest and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch
214397350|NCT06626217|OTHER|Movement artifacts|The volunteer periodically spreads his/her fingers and clenches them into a fist, and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch.
214503427|NCT06454721|DRUG|[89Zr]Zr-DFO-BIIB080|Administered as specified in the treatment arm.
214503428|NCT06454721|DRUG|BIIB080|Administered as specified in the treatment arm.
214503429|NCT01784744|OTHER|Hydroworx Pool at 98 degrees Fahrenheit|
214503430|NCT01784744|OTHER|Hydroworx Pool at 102 degrees Fahrenheit|
214503431|NCT00087022|BIOLOGICAL|girentuximab|Given IV
214503432|NCT00087022|OTHER|placebo|Given IV
214503433|NCT05212272|PROCEDURE|PET-MRI Brain Scan|Before starting radiation, participants will have a PET scan and MRI scan of the brain. After 2 to 3 weeks of radiation treatments, participants will have a repeat PET scan. Then 1 month after radiation participants will have another PET scan
214503434|NCT05212272|DIAGNOSTIC_TEST|Blood draw|Blood draws will be taken at baseline, one month after radiation treatment and 3 to 4 months after radiation treatment.
215095053|NCT01691976|DRUG|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
214397351|NCT06626217|OTHER|Circulation constriction|The volunteers arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize. The measurement is repeated three times.
214397352|NCT06626217|OTHER|Physical exercise|The volunteer is seated on the exercise bike, rests his forearms on the handlebars and is instructed not to move his arms. The volunteer\&#39;s heart rate is controlled to increase to 120 beats per minute. For five minutes, the perfusion index is recorded from a pulse oximeter and smartwatch.
214397353|NCT06863662|DRUG|Etoricoxib + Tizanidine fixed dose|One sachet with 120 mg / 4 mg, dissolved in 100 mL of water
214397354|NCT06863662|DRUG|Etoricoxib fixed dose|One sachet with 120 mg, dissolved in 100 mL of water
214397355|NCT06624852|OTHER|Screening for coronary artery revascularization based on TMT-ECG|Screening for coronary artery revascularization based on TMT-ECG with and without the assistance of PROPECG-TMT
214397356|NCT05314556|BEHAVIORAL|Group psychotherapy|Additional group psychotherapy for patients with narcolepsy type 1 with standard medication
214397357|NCT04147767|DIETARY_SUPPLEMENT|Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|"Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)\*\*\*, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~\*\*\* Equivalent to 2% Free Plant Sterols"
214397358|NCT04147767|DIETARY_SUPPLEMENT|Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)|Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
214397359|NCT01803841|PROCEDURE|Transradial coronary angiography and intervention|
214397360|NCT01803841|PROCEDURE|Transfemoral coronary angiography and intervention|
214397361|NCT06002906|DRUG|Indocyanine green|Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.
214397362|NCT06002906|DEVICE|Stryker 1688 AIM system|The Stryker 1688 AIM system used during laparoscopic surgery which is sensitive in the visible and infrared spectrum. ICG (SPY AGENT™ GREEN) is used with the SPY mode in the Stryker 1688 AIM fluorescence imaging system to perform intraoperative fluorescence angiography.
214397363|NCT03239405|DEVICE|Suction callibrated system|One-step suction callibrated SG system
214397364|NCT05902533|RADIATION|Radiation (reduced elective nodal dose (30.6 Gy)|28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.
214397365|NCT05902533|DRUG|Capecitabine|825 mg/m2 BID (Oral Twice daily on days with RT)
214397366|NCT05902533|DRUG|Mitomycin c|10 mg/m2 slow IV push Day 1 and 29
214503435|NCT05212272|BEHAVIORAL|Memory testing|3 sessions with simple tests to evaluate how the brain is working. These tests primarily check things like memory, attention, and thought process. The whole set of tests will take 1 hour each time.
214503436|NCT05212272|PROCEDURE|Optional lumbar puncture for cerebrospinal fluid collection|Participants that consent for cerebrospinal fluid collection will have 6 and 20 ml of cerebrospinal collected at baseline.
214503437|NCT03475264|DIAGNOSTIC_TEST|Lung MRI|Participants will be undergoing hyperpolarized xenon and proton lung MRI
214503438|NCT04207424|PROCEDURE|Emblization of the gastro-epiploic arcade|Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
214503439|NCT01280513|DIETARY_SUPPLEMENT|High protein intake|30% of energy intake coming from proteins
214503440|NCT01280513|DIETARY_SUPPLEMENT|Low Protein intake|9% of energy intake coming from proteins
214503441|NCT04543812|DRUG|Ferric citrate|Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
214503442|NCT04543812|DRUG|Placebo|Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
214503443|NCT03885245|DRUG|L-ctirulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
214397367|NCT02841267|DRUG|PF 06252616|
214503444|NCT03885245|DRUG|Matching Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
214503445|NCT06803342|BIOLOGICAL|cAD3-Sudan Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-Sudan) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
214503446|NCT06803342|BIOLOGICAL|Placebo|0.9% NaCl solution for injection.
214503447|NCT04527874|BEHAVIORAL|VITAL model|"The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening."
214503448|NCT03665532|BEHAVIORAL|Youth Engagement in Services|Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
214503449|NCT00035100|DRUG|epothilone b|
214503450|NCT01291212|DRUG|Testosterone and FSHr-LHr|75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
214397368|NCT05771974|DEVICE|Compression therapy using surgical gloves|Intervention group wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
214397369|NCT06692452|DRUG|Tazemetostat|EZH2 inhibitor, 200 mg tablet, taken orally per protocol.
214397370|NCT06692452|DRUG|Doxorubicin|Anthracycline antibiotic, 10, 20, 50, 100, and 200 mg vials, via intravenous (into the vein) infusion per institutional standard of care.
214397371|NCT06692452|DRUG|Vincristine|Vinca Alkaloid, 1, 2, and 5mL vials, via intravenous (into the vein) infusion per institutional standard of care.
214397372|NCT06692452|DRUG|Prednisone|Corticosteroid, 1, 2.5, 5, 10, 20, 25, and 50 mg tablets, taken orally per institutional standard of care.
214397373|NCT06692452|DRUG|Cytoxan|Alkylating agent, 100mg, 200 mg, and 500mg vials, and 1 and 2 gram vials, via intravenous (into the vein) infusion per institutional standard of care.
214397374|NCT06692452|DRUG|Carmustine|Alkylating agent, 100 mg single dose vials, via intravenous (into the vein) infusion per institutional standard of care.
214397375|NCT06692452|DRUG|Etoposide|Topoisomerase II inhibitor, 100mg single dose vial, via intravenous (into the vein) infusion per institutional standard of care.
214397376|NCT06692452|DRUG|Cytarabine|Antineoplastic, 20mg single dose vial, via intravenous, intrathecal, or subcutaneous injection per institutional standard of care
214397377|NCT06692452|DRUG|Melphalan|Alkylating agent, 90 mg multi-dose vial, via parenteral infusion per institutional standard of care.
214397378|NCT06695195|DRUG|Cannabidiol (CBD)|25 mg capsule twice daily
214397379|NCT06695195|DRUG|Placebo|25 mg capsule twice daily
214397380|NCT06686303|OTHER|High frequency Segmental Vibrator|Segmental vibrations of high frequency was used on each flexor and extensor interspersed with a 1 minute break.
214397381|NCT06686303|OTHER|Combined effects of high frequency segmental vibrator and neuromuscular electrical stimulation.|Segmental vibrations of high frequency with Neuromuscular Electrical Stimulation was given on each flexor and extensor.
214397382|NCT03873636|OTHER|Stimulation via noninvasive brain stimulation systems|Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, \& Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
214397383|NCT06710379|DRUG|ADRX-0405|Antibody Drug Conjugate targeting STEAP1
214397384|NCT06698809|DEVICE|Active tPBM|tPBM is a neuromodulatory treatment that uses red and/or near infrared light to penetrate the cortex and can alter both cerebral metabolism and blood flow. Subjects will receive treatment for approximately 12 minutes per treatment.
214397385|NCT06894043|OTHER|Adapted Physical Activity (APA)|The APA intervention will consist of a 2-week running-in period, followed by a period of adapted physical activity (APA) for 8 weeks.
214397386|NCT06894043|BEHAVIORAL|Compensatory Nutrition (NC)|The Compensatory Nutrition (NC) intervention will consist of a 2-week running-in period, followed by a period of compensated nutrition (NC) for 8 weeks.
214397387|NCT04894578|PROCEDURE|reverse distal metatarsal minimal-invasive osteotomy|minimal-invasive oblique osteotomy of the two or three metatarsal bones using a straight burr
214397388|NCT04894578|PROCEDURE|tarsometatarsal fusion|open procedure with fusion and screw and plate fixation of two to three tarsometatarsal joints
214397389|NCT04321993|DRUG|Baricitinib (janus kinase inhibitor)|Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.
214397390|NCT04321993|DRUG|Remdesivir (antiviral) + barictinib (janus kinase inhibitor)|"Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).~Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner."
214503451|NCT01291212|DRUG|testosterone and FSHr alone|FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
214503452|NCT00332319|DRUG|GW679769|
214397391|NCT04321993|DRUG|Remdesivir (antiviral)|Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).
214397392|NCT04321993|DRUG|Tocilizumab (interleukin 6 inhibitor)|Tocilizumab will be administered as a single IV infusion over one hour. Dosage will be 8 mg/kg total bodyweight up to a maximum of 800 mg.
214397393|NCT02635087|DEVICE|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
214397394|NCT06842927|OTHER|data collection|"An additional collection of peritoneal dialysate and spot urine samples will be collected.~Participants randomized to the training/validation arm will have their data used for model development, including the training and validation phases."
214397395|NCT06842927|OTHER|data report|An additional collection of peritoneal dialysate and spot urine samples will be collected. Participants randomized to the test arm will have their data isolated and reserved exclusively for evaluating the performance of the final AI model
214503453|NCT03232398|DRUG|Apixaban Oral Tablet [Eliquis]|Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
214503454|NCT03232398|DRUG|Warfarin|Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
214503455|NCT03141918|DIETARY_SUPPLEMENT|Curcumin|The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
214503456|NCT03141918|OTHER|Placebo of Curcumin|"The intervention will consist of the placebo administration curcumin for 30 days.~The Curcumin placebo will be given in 2 doses of 500mg per day."
214503457|NCT00894894|DRUG|MP-470|escalating daily doses of amuvatinib
214503458|NCT00894894|DRUG|amuvatinib (MP-470)|escalating doses of daily amuvatinib
214503459|NCT01957163|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
214397396|NCT06744933|COMBINATION_PRODUCT|Self-administered auricular acupressure integrated with a smartphone application|"6 to 8 Vaccariae Semen ear patches will be affixed on one ear of the patient. The patient will be required to press on the ear patches 3 times a day, and 30 minutes before a meal. Every 3 to 4 days, the patient will visit the clinic to change a new set of ear patches on the same auricular acupoints of the opposite ear alternately. The whole course of intervention will be 8 weeks. The smartphone app will send scheduled pop-up notifications to remind patients to press on the ear patches. The patient will be required to enter the number of times pressing and of defaecation every day on the smartphone application. The smartphone application will send more notifications to the patient if he/ she has a low compliance. When the participants record the number of times pressing on the auricular acupoints, positive reinforcement messages will pop-up, such as Excellent job! for those with good compliance while You are almost there! Keep going! for those with poor compliance."
214397397|NCT06902402|DIETARY_SUPPLEMENT|Supportan® Drink, flavour Tropical Fruits|flavour Tropical Fruits
214397398|NCT06902402|DIETARY_SUPPLEMENT|Supportan® Drink, flavour Cappuccino|flavour Cappuccino
214397399|NCT06902402|DIETARY_SUPPLEMENT|Supportan® Drink, flavour Pineapple-Coconut|flavour Pineapple-Coconut
214397402|NCT06909708|PROCEDURE|SIRT|Y-90 administered
214397403|NCT06909708|PROCEDURE|cTACE|cTACE administered
214397404|NCT05971823|OTHER|Tobacco product administration and assessment|Subjective measures 1 is followed by product sampling that includes 5 self-directed ECIG/own brand cigarette puffs over 10 minutes. After sampling is complete participants complete subjective measures 2. Ten minutes after their sampling has been completed, they complete subjective measures 3 and the behavioral economic task(s). These activities are preceded and followed by cardiovascular response assessment.
214397405|NCT05940298|DRUG|Intravenous injection of [99mTc]Tc-DB8|One single intravenous injection of \[99mTc\]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
214397406|NCT06910969|BEHAVIORAL|HORIZONS Intervention|Therapist-delivered multidisciplinary group-based telehealth intervention comprised of 8 sessions
214397407|NCT06910969|BEHAVIORAL|Minimally enhanced usual care|Receiving a standardized booklet with evidence-based information on chronic GHVD management and HST survivorship recommendations
214397408|NCT06912308|OTHER|Active Physiotherapy|Involves patient-driven exercises such as verticalization, sitting on the edge of the bed, and active breathing exercises.
214397409|NCT06912308|OTHER|Passive Physiotherapy|Employs methods like passive movements and electrostimulation of the diaphragm, providing therapeutic benefits without requiring active patient engagement.
214503460|NCT01957163|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
214503461|NCT01957163|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
214503462|NCT01957163|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
214503463|NCT02498145|OTHER|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
214503464|NCT02498145|OTHER|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
214503465|NCT04863365|DRUG|Placebo ophthalmic solution|A matching placebo ophthalmic solution, 3 drops daily, 28 days
214503466|NCT04863365|DRUG|PHP-201 ophthalmic solution|PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
214503467|NCT02131922|PROCEDURE|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
215095054|NCT03888118|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
215095055|NCT02024126|OTHER|Exercise therapy|Exercise therapy
215095056|NCT00580762|PROCEDURE|Roux-en-y gastric bypass (RYGB)|
215095057|NCT00366327|DRUG|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
214397410|NCT06583122|PROCEDURE|Ultrasound Guided Approach|All enrolled patients will receive the new ultrasound-guided approach to occipital nerve radiofrequency ablation
214397411|NCT07102628|DRUG|Placebo|The participants will receive placebo subcutaneous at randomization (Day 1, Baseline visit) and Day 90
214397412|NCT07102628|DRUG|Inclisiran|The participants will receive Inclisiran sodium 300 mg subcutaneous at randomization (Day 1, Baseline visit) and Day 90
214397413|NCT06914960|PROCEDURE|2-point Radiofrequency Ablation|"For the radiofrequency ablation (RFA) procedure, a 10 cm long, 22 gauge RF cannula with a 10 mm active tip (Model SC-K, Top Neuropole, MPS Medical Product Service GmbH, Germany) will be used.~In order to increase the accuracy of the location determined by ultrasound, sensory stimulation will be applied at a frequency of 50 Hz and with a threshold value lower than 0.6 volts. In order to prevent the motor nerves from being affected, the absence of lower extremity muscle fasciculations in the relevant area will be confirmed with 2 volt stimulation at 2 Hz frequency. Patients in 2 nerve groups (SM and IM) will undergo 2-point RFA at 42°C using a 120-second pulse RFA generator (TOP Lesion Generator TLG-20, MPS Medical Product Service GmbH, Germany).~To address any discomfort that may occur after the procedure, a total of 2 cc of betamethasone (5 mg+2 mg/1 cc) and %2 lidocaine (1 cc) will be injected into the points where RFA is applied, after aspiration."
214397414|NCT06914960|PROCEDURE|3-point Radiofrequency Ablation|Description: For the radiofrequency ablation (RFA) procedure, a 10 cm long, 22 gauge RF cannula with a 10 mm active tip (Model SC-K, Top Neuropole, MPS Medical Product Service GmbH, Germany) will be used. In order to increase the accuracy of the location determined by ultrasound, sensory stimulation will be applied at a frequency of 50 Hz and with a threshold value lower than 0.6 volts. In order to prevent the motor nerves from being affected, the absence of lower extremity muscle fasciculations in the relevant area will be confirmed with 2 volt stimulation at 2 Hz frequency. 3-point RFA will be applied to patients in 3 nerve groups (SM, SL and IM) using a generator (TOP Lesion Generator TLG-20, MPS Medical Product Service GmbH, Germany) in the form of 120-second pulse RFA at 42°C. To address any discomfort that may occur after the procedure, a total of 2 cc of betamethasone (5 mg+2 mg/1 cc) and %2 lidocaine (1cc) will be injected into the points where RFA is applied, after aspiration.
214503468|NCT02131922|PROCEDURE|Dental Hygienization Treatment|
214397415|NCT06914960|PROCEDURE|5-point Radiofrequency Ablation|Description: For the radiofrequency ablation (RFA) procedure, a 10 cm long, 22 gauge RF cannula with a 10 mm active tip (Model SC-K, Top Neuropole, MPS Medical Product Service GmbH, Germany) will be used. In order to increase the accuracy of the location determined by ultrasound, sensory stimulation will be applied at a frequency of 50 Hz and with a threshold value lower than 0.6 volts. In order to prevent the motor nerves from being affected, the absence of lower extremity muscle fasciculations in the relevant area will be confirmed with 2 volt stimulation at 2 Hz frequency. 5-point RFA will be applied to patients in 5 nerve groups (SM, SL and IM, recurrent fibular nerve-RFN, infrapatellar branch of saphenous nerve-IPBSN) via same generator in the form of 120-second pulse RFA at 42°C. To address any discomfort that may occur after the procedure, a total of 2cc of betamethasone (5mg+2mg/1cc) and %2 lidocaine (1cc) will be injected into the points where RFA is applied, after aspiration.
214397416|NCT07102602|DEVICE|high intensity laser therapy|The high-intensity laser used in this study is approved by the Ministry of Health and Welfare, Taiwan (No. 032670). It operates at a wavelength of 940 nm. For the active treatment (HILT), the laser delivers 900 joules to the quadriceps at a power output of 3 W for 5 minutes and is applied along the length of the quadriceps muscle
214397417|NCT07102602|DEVICE|Sham laser therapy|In the sham condition (SHAM), the output is set to 0 W for 5 minutes, resulting in no energy delivery.
214397418|NCT06919913|DIETARY_SUPPLEMENT|Culturelle Digestive Daily Probiotic Capsule|Each capsule contains 10 billion colony-forming units (CFU) of Lactobacillus rhamnosus GG. Subjects will self-administer 1 oral capsule daily for 6 weeks post operatively.
214397419|NCT06918717|PROCEDURE|Direct Laryngoscopy-to-VideoLaryngoscopy sequence|Participants will proceed with a double intubation technique sequence, first performing an initial direct laryngoscopy without looking at the video screen until they reached the epiglottis, then performing an indirect lryngoscopy for intubation.
214397420|NCT06918717|PROCEDURE|Free use of videolaryngoscopy|Participants are free to use of the videolaryngoscope as they intended
214397421|NCT06919900|BEHAVIORAL|Perturbation Training|Unexpected slips blended with trips and unperturbed walking trials on a treadmill. A safety harness will be worn at all times.
214397422|NCT06919900|BEHAVIORAL|Treadmill Walking|Treadmill walking for the same amount of time as the training group without perturbation. A safety harness will be worn at all times.
214397423|NCT06918470|OTHER|Standard monitoring techniques|（3）atients were given the same anesthesia regimen. Standard monitoring techniques include electrocardiogram, pulse oximeter, heart rate and blood pressure monitoring, continuous monitoring of bispecific index of electroencephalography, and the use of remifentanil (0.3 mg/kg) Rapid sequence induction was performed using sufentanil (0.3 μ g/kg), propofol (2.5mg/kg), and rocuronium bromide (0.6 mg/kg). Anesthesia was maintained using remifentanil (0.1-0.2 μ g/0kg/min), inhaled sevoflurane (1%), and intravenous propofol (1-4 mg/kg/h) to maintain BIS 40-60, with heart rate and blood pressure within 20% of baseline values.
214397424|NCT06918470|OTHER|noise cancelling headphones|The treatment group started wearing noise cancelling headphones until the end of the surgery in the general anesthesia induction group to isolate intraoperative environmental noise,patients were given the same anesthesia regimen. Standard monitoring techniques include electrocardiogram, pulse oximeter, heart rate and blood pressure monitoring, continuous monitoring of bispecific index of electroencephalography, and the use of remifentanil (0.3 mg/kg) Rapid sequence induction was performed using sufentanil (0.3 μ g/kg), propofol (2.5mg/kg), and rocuronium bromide (0.6 mg/kg). Anesthesia was maintained using remifentanil (0.1-0.2 μ g/0kg/min), inhaled sevoflurane (1%), and intravenous propofol (1-4 mg/kg/h) to maintain BIS 40-60, with heart rate and blood pressure within 20% of baseline values.
214503469|NCT02131922|DRUG|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
214503470|NCT01939509|DRUG|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
214503471|NCT01939509|DRUG|Bisoprolol|
214503472|NCT03735381|DEVICE|Pedometer watch 'Xiomi mi band2'|"1. They receive information on the use of the pedometer.~2. Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~3. Prescription of benefits of walking in pregnancy:~   * Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~  * Receive information on the adequacy of walking with moderate intensity.~4. They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group)."
214503473|NCT05014607|BIOLOGICAL|Personalized multi-peptide vaccine|"Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 1-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen.~Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned.~Treatment schedule:~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses."
214503474|NCT06566690|DEVICE|Addition of ORi monitoring to SpO2 monitoring|Integration of Oxygen Reserve Index (ORi) monitoring into standard SpO2 monitoring
214503475|NCT04333485|OTHER|Home-based Active Case Finding (HACF)|Existing healthcare workers at the participating NTEP TB units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer a standardized TB symptom screen questionnaire to treated TB cases and their household contacts (HHC). All those who screen positive will have a spot sputum taken at the home for microbiological testing at the TB unit.
215001777|NCT07117019|OTHER|Myofascial release|Females in the experimental group will receive intravaginal myofascial release in lithotomic position. After ensuring empty bladder/bowel, therapist uses sterile gloves and lubricant to insert fingers 2-3cm into vagina, pressing vaginal walls bilaterally for 2 minutes. Perineal massage follows, targeting scar tissue and tender points with friction at right angles. Treatment duration starts at 5 minutes (due to pain tolerance) and gradually increases to 20 minutes. Hot pack or ultrasound may be used pre-treatment for pain relief. Therapist performs gentle U-shaped reciprocating massage movements up and down towards rectum for 20 minutes total. Sterile technique maintained throughout with hand washing and glove changes between procedures.
214397425|NCT06918197|PROCEDURE|PAS Technique|"PAS Technique Protocol:~The following steps outline the PAS Technique. While the example below uses 6 injection sites, the approach can be adapted for different pain management procedures with a different number of needle injection sites as needed.~Timer: Begin stopwatch for entire procedure from start to medication insertion. Positioning: The patient is placed in a prone position on the fluoroscopic table. Time out was performed.~Skin Preparation: Clean the injection site with an antiseptic solution and drape it to maintain sterility.~Anesthesia: Administer intravenous sedation Identification of Anatomical Landmark:The spinous process was located and marked as the reference point (SP), which was then used as a guide for the following steps.~Marking Target Points: Using the spinous process (SP) as the anatomical landmark and X-ray guided fluoroscopy, Target Point 1 (TP1) was identified and its position verified. The X value (the horizontal distance from the SP to TP1) was measured."
214397426|NCT06918197|PROCEDURE|Standard Technique|"In the Standard or Traditional technique, the spinal needles are used to localize the anatomical objective using fluoroscopic guidance for each needle placement. Traditionally, each needle is placed individually with a spot radiological view before placement and after placement of each needle to confirm the localization."
215095058|NCT00581360|DRUG|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
215095059|NCT02280447|BIOLOGICAL|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
214397427|NCT06917807|PROCEDURE|Pericapsuler nerve group block|A single shot pericapsular nerve group block preformed under ultrasound guidance with a local anesthetic agent ( Marcaine )
214397428|NCT06917807|PROCEDURE|Quadratus lumborum block|A single shot Quadratus lumborum block preformed under ultrasound guidance with a local anesthetic agent ( Marcaine )
214397429|NCT06918171|PROCEDURE|Clinical Efficacy of Open Reduction and Anchor Suture Bridge Fixation|Under general anesthesia, patients were positioned prone, and a midline posterior incision was made at the level of the popliteal fossa. After incising the fascia, careful dissection was undertaken to expose the posterior joint capsule and fracture fragment, with particular attention to safeguarding the neurovascular structures. Once the fracture site was fully exposed, hematoma and any interposing soft tissue were meticulously cleared to prepare for reduction. The avulsed bone fragment, located at the PCL insertion site, was identified and prepared for fixation. A suture anchor (Johnson \& Johnson, USA) was carefully implanted into the prepared osseous bed. The suture threads were passed anteriorly around the PCL and configured in a figure-of-eight pattern to achieve precise anatomical reduction of the fracture fragment. To enhance fixation stability, two extracortical anchors (Johnson \& Johnson, USA) were additionally positioned approximately 2 cm distal to the fracture site, securing
214397430|NCT06919328|DIETARY_SUPPLEMENT|Niagen®|nicotinamide riboside
214397431|NCT06919328|OTHER|NAD+|Nicotinamide adenine dinucleotide
214397432|NCT06919328|OTHER|Placebo|bacteriostatic water
214397433|NCT00583505|DEVICE|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
214397434|NCT06919575|COMBINATION_PRODUCT|Multicomponent frailty intervention|"First, the underlying causes of the patient's frailty should be analyzed. Individualized goals should be established using Goal Attainment Scaling (GAS), followed by implementation of tailored measures. For patients presenting with malnutrition or mood-related disorders, comprehensive nutritional and psychological assessments must be conducted, with subsequent nutritional support or pharmacological treatment initiated when clinically indicated.~The patients of the intervention group with poor physical function would receive exercise prescription tailored to the subjects' physical ability from a trained specialist. For Participants requiring exercise-based interventions, a moderate and gradually increasing intensity exercise regimen home-basethree times a week, over a 12-week duration will be administer under telehealth-based monitoring."
214397435|NCT04627103|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.
214397436|NCT00035958|DRUG|Prednisone|
214397437|NCT00035958|DRUG|Methotrexate|
214397438|NCT00035958|DRUG|Etanercept|
214397439|NCT03133143|BEHAVIORAL|Cognifit|CogniFit is an Internet browser-based digital brain training program, to improve cognitive abilities based on a personalised brain training regimen. Participants are instructed to play all games assigned by cognifit from three categories (memory, spatial perception, and mental planning) during each training session. After playing the games in these three categories, they are free to choose which exercises they wish to play.
215095060|NCT02280447|BIOLOGICAL|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
215095061|NCT02280447|BIOLOGICAL|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
215095062|NCT02280447|BIOLOGICAL|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
215095063|NCT02399514|OTHER|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
215095064|NCT04405245|DRUG|Latanoprost ophthalmic solution|Latanoprost opthalmic solution to be dosed once daily
215095065|NCT04405245|DRUG|AKB-9778 4%|Razuprotafib opthalmic solution
215095066|NCT04405245|DRUG|Placebo|placebo for razuprotafib opthalmic solution
215095067|NCT05674110|BEHAVIORAL|DSMES Intervention|This study will provide participants with on-line education, plus weekly text messaging that will contain messages of support or encouragement sent to participants in the individual's preferred language (English or Spanish). Participants will be encouraged to attend monthly group support meetings to review the content and address any questions. Group meetings will occur at 3-time intervals (end of months: 1, 2, and 3). Group support meetings will be held in-person at a food pantry and moderated by peer mentors, nursing students, registered dietitian nutritionist (RDN), and/or a diabetes care and education specialist (DCES). Group support meetings will be held in Spanish and/or English, with no more than 10 participants in a group at one time, and will last approximately 50 minutes. For the duration of the study, participants will continue to receive monthly food items from the food pantry.
214397440|NCT03133143|BEHAVIORAL|SIMS 4 (Maxis, Inc)|The Sims 4 is a life simulation PC game. It is purely an entertainment game without known cognitive or health-related outcomes. Does not iclude high-intensity action and competition. This specific game and non-competitive games like it in general do not improve attention, working memory, or other cognitive abilities despite being engaging and fun.
214397441|NCT00895973|OTHER|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
214397442|NCT02654067|PROCEDURE|photograph|photograph of airway
214397443|NCT03159650|DEVICE|intravascular ultrasonography|intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
214397444|NCT06268353|OTHER|blood sampling|Measure CAPGDF15 in plasma of 3 pregnant and 3 non-pregnant women
214397445|NCT04351490|DIETARY_SUPPLEMENT|Zinc gluconate|Zinc gluconate capsule 15 mg x 2 per day during 2 months
214397446|NCT04351490|DIETARY_SUPPLEMENT|25-OH cholecalciferol|25-OH cholecalciferol drinkable solution 10 drops (2000 IU) per day during 2 months
214397447|NCT02435511|OTHER|HealtheRx|The HealtheRx is an informational intervention. The HealtheRx is generated and administered at the point of care. It includes a list of community resources, tailored to a patient's needs based on diagnoses, that are located near the patient's home. A health care provider and/or administrative staff administers and reviews the HealtheRx with the patient.
214397448|NCT00309335|DRUG|Phentolamine Mesylate (NV-101)|
214397449|NCT00862875|DRUG|Detemir or Glargine|Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
214397450|NCT06082128|BEHAVIORAL|FOCUSau|"FOCUSau is a self-administered web-based intervention and completed autonomously via the internet by the dyad. Delivery encompasses the completion of four prescribed consecutive FOCUSau sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and family carer, together at a computer. The intervention sessions can be completed at any time within the 12-week timeframe. Participants receive tailored individual and dyadic messages according to the information provided at study enrollment and their responses to questions within the sessions. Dyads are also provided with an online personal workbook containing the results of interactive exercises completed during the internet sessions. Any information sheets that the dyad indicated as 'of interest to them' during the internet sessions are included as a hyperlink in their personal workbook which also contains evidence-based local advanced cancer related resources."
214397451|NCT04404257|RADIATION|ControlRad System|Cardiac Catheterization or electrophysiology implant procedures with Control Rad system device installed in the cath lab room #5.
215095068|NCT06331689|OTHER|Mortality ratio|Mortality rates at 30-day, 90-day and 1-year intervals
214503476|NCT04333485|OTHER|Telephonic Active Case Finding (TACF)|Existing healthcare workers at the participating NTEP TB Units will administer a standardized TB symptom screen questionnaire to the index patient via telephone calls at 6 and 12 months post-treatment completion. The index patient will also be asked about any TB symptoms among household contacts (HHCs). If TB is suspected among any HH members, a home visit will be conducted and spot sputum specimens will be collected for microbiological testing at the TB unit.
215095069|NCT01950091|BEHAVIORAL|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
215095070|NCT01950091|OTHER|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
214397452|NCT04404257|RADIATION|Without ControlRad System|Cardiac Catheterization or electrophysiology implant procedures in cath lab room 5 without the ControlRad system device.
214397453|NCT04212169|DRUG|MEDI3506|multiple doses
214397454|NCT04212169|DRUG|Placebo|multiple doses
214397455|NCT02176928|DEVICE|AutoPAP|"PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.~AutoPAP treatment 7 nights a week for four months (16 weeks)."
214397456|NCT02176928|DEVICE|Sham PAP|"Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.~Sham PAP treatment 7 nights a week for four months (16 weeks)./"
214397457|NCT05148624|PROCEDURE|embryo transfer|immediate ambulation after embryo transfer
214397458|NCT02078310|DRUG|ITI-007|ITI-007 for Part 1
214503477|NCT05843552|OTHER|no intervention|no intervention, this is an observational study
214503478|NCT06040294|OTHER|DDS program|dementia virtual reality and disability simulation of activity design for seniors
214503479|NCT06040294|OTHER|dementia course with no DDS|Regular dementia course and group discussions of activity design for seniors with no DDS
215095071|NCT01771445|DRUG|IL-1Ra|100mg, s.c, once only
215095072|NCT01771445|DRUG|Placebo|100mg, s.c., once only
214397459|NCT02078310|DRUG|Placebo|ITI-007 for Part 1
214397460|NCT02078310|DRUG|ITI-007|ITI-007 for Part 2
214397461|NCT02078310|DRUG|Placebo|Placebo for Part 2
215095073|NCT03088553|DRUG|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
215095074|NCT01789216|DRUG|NSAID|
215095075|NCT01789216|DRUG|Gabapentinoids|
215095076|NCT01789216|DRUG|placebo|
215001778|NCT07117019|OTHER|Acupressure|"Each female in the experimental group will receive acupressure on BL 23 as follows: Acupressure is also another branch of acupuncture. In this method, fingers press the key points on the skin to stimulate and induce the body's natural self-healing capabilities. In the present study, the BL23 point located 1.5 cm lateral to the lower border of the spinous process of the second lumbar vertebra was employed.~The therapist will apply pressure on BL 23 points with the thumb for 5 minutes in the counterclockwise direction. In the second 5 minutes, pressure was applied in the opposite direction for 5 minutes. Similarly, the pressure was continued for 20 minutes."
215001779|NCT07117357|BEHAVIORAL|Neuroathletic Training Protocol|This intervention involves a 20-minute neuroathletic training session using the Z-Health® kit. It includes visual reset exercises (eye massage, palming), star chart eye muscle training, saccade training with letter cards, convergence-divergence drills using Brock string, vestibular activation through lunges, spinal and hip extension exercises, slap tap coordination drills, and use of pinhole glasses. The aim is to stimulate sensory pathways and enhance neuromotor readiness acutely.
215001780|NCT07117357|BEHAVIORAL|Standard Warm-Up Protocol|This 20-minute warm-up consists of two components: 10 minutes of light walking at a moderate pace and 10 minutes of dynamic stretching (leg swings, hip flexor stretches, knee hugs, high knees, butt kicks, arm circles, and trunk rotations). It is intended to mimic standard pre-activity routines and serves as the comparator condition.
215001781|NCT07118787|OTHER|Active Release Technique|A manual therapy technique applied to release soft tissue tension in the hamstrings.
214397462|NCT04911114|BEHAVIORAL|Be-Balanced|The BE-BALANCED program will run for 12-weeks, with participants attending group-based virtual supervised exercise sessions twice weekly. Participants will complete an individual in-person assessment at baseline and again at end of intervention to collect physical outcome measures and will complete questionnaires electronically using REDCap, (or mailed version). Follow-up assessments will be administered electronically to each participant using REDCap at 3-months after program completion (24 weeks post-baseline).
214397463|NCT00224133|DRUG|Silodosin|8 mg daily
214397464|NCT00000764|DRUG|Isotretinoin|
214397465|NCT00000764|DRUG|Interferon alfa-2a|
214397466|NCT02372175|BIOLOGICAL|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
215001782|NCT07118787|OTHER|Proprioceptive Neuromuscular Facilitation|A stretching technique involving passive stretching and isometric contractions of the hamstrings.
215001783|NCT07116941|BEHAVIORAL|Cognitive Exercises|Participants perform a 30-minute session of cognitive tasks during the sitting phase of early ICU mobilization. Activities include word games, attention exercises, and simple problem-solving tasks designed to engage memory and executive function.
215001784|NCT07116941|BEHAVIORAL|Auditory Stimulation|Participants listen to calming music or nature sounds through headphones for 30 minutes during early mobilization in the ICU. The auditory content is selected to reduce anxiety and promote relaxation.
215001785|NCT07116941|BEHAVIORAL|Multisensory Stimulation|Participants receive 30 minutes of combined sensory stimulation during the sitting phase in the ICU. This includes tactile stimulation using hand therapy balls and olfactory stimulation with lavender or mint-scented materials to enhance relaxation and sensory engagement.
215001786|NCT07117487|BIOLOGICAL|mRNA-1345|Suspension for injection
215001787|NCT07117630|DRUG|L-Ornithine L-Aspartate|3g orally three times daily
214397467|NCT00151008|DRUG|Bexarotene/NBUVB vs placebo NBUVB|
214397468|NCT01639261|DRUG|Interferon gamma 1b|Initial dose: 50µg s.c. three times/week, without fever \>38,5 dose increase: 50µg/m² BSA three times/week
214397469|NCT04896905|OTHER|Rehabilitation|Rehabilitative procedures in isolation ward
214397470|NCT02718417|DRUG|carboplatin|Given Q3W during chemotherapy phase
214397471|NCT02718417|DRUG|paclitaxel|Investigator choice of weekly or Q3W during chemotherapy phase
214397472|NCT02718417|DRUG|Avelumab|Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
214397473|NCT02718417|DRUG|Avelumab|Given as single agent in maintenance portion Q2W
214397474|NCT00042393|DRUG|Adefovir Dipivoxil|
214397475|NCT05799924|DEVICE|Transcutaneous electrical acupoint stimulation|The transcutaneous electrical acupoint stimulator applied alternating current (including sine wave, pulse wave and modulation wave) with frequency of 2 \~ 100Hz and intensity of 10-20mA to stimulate corresponding acupoints through skin electrodes. The stimulated acupoints include Hegu acupoints, Luogong acupoints, Neiguan acupoints and Waiguan acupoints.
214397476|NCT05799924|DRUG|non steroidal anti inflammatory drugs|Hormonal contraception can suppress ovulation, NSAIDS can ease pain
214397477|NCT02451930|DRUG|Necitumumab|Administered IV
214503480|NCT05508464|RADIATION|Arm 2: SABR|SABR to all tumors 6 Gy x 5 over three weeks
215001788|NCT07117630|DRUG|Dalpiciclib|150mg orally once daily (3 weeks on/1 week off per 28-day cycle)
215001789|NCT07117630|DRUG|Fulvestrant|500mg IM on Days 1 \& 15 of Cycle 1, then Day 1 of subsequent cycles
215121413|NCT00203229|DRUG|lamotrigine|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
215121414|NCT00203229|DRUG|Placebo|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
215121415|NCT04229628|OTHER|No special intervention|No special intervention
215121416|NCT06284850|DRUG|Empagliflozin10Mg Tab|TB JARDIANCE 10MG
214397478|NCT02451930|DRUG|Pembrolizumab|Administered IV
214397479|NCT05616208|BIOLOGICAL|Bioengineered Internal Anal Sphincter|Autologous Bioengineered Internal Anal Sphincter
214397480|NCT05156801|DEVICE|ArchSinus stent|Post FESS unilateral placement of the ArchSinus stent into the randomized ethmoid sinus cavity.
214397481|NCT00835874|DRUG|Probiotics|Lactobacillus acidophilus, b.lactis capsule. Once daily.2X 10 by the power of 10 bacteria per dose.
214503481|NCT05508464|RADIATION|Arm 1: Standard of Care|Standard of care palliative radiotherapy
214503482|NCT06463340|DRUG|SGR-3515|SGR-3515 will be administered orally with an intermittent schedule.
214503483|NCT04799301|BEHAVIORAL|Diet with no soda|Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane
214397482|NCT03681340|OTHER|Hydroxyapatite toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
214397483|NCT03681340|OTHER|Fluoridated toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
215001790|NCT07118969|OTHER|Breast Cancer Awareness Training|A structured breast cancer education program consisting of five sessions, each lasting 90 minutes. The program covers breast cancer risk factors, early detection methods including breast self-examination (BSE), clinical breast examination, mammography, and health-promoting behaviors. The sessions are conducted in group settings within university faculties. The education aims to increase participants' knowledge and awareness of breast cancer and encourage early detection practices.
215001791|NCT07119125|DRUG|MRT-8102|Oral capsules
215001792|NCT07119125|DRUG|Placebo|Oral capsules
215001793|NCT07116746|DRUG|AR882 75 mg|Solid Oral Capsule
215001794|NCT07116746|DRUG|XOI Low Dose|Solid Oral Tablet
215001795|NCT07116746|DRUG|XOI High Dose|Solid Oral Tablet
215001796|NCT07118930|DRUG|Sivelestat Sodium injection 2 h after OPCABG for 72 h|Sivelestat Sodium injection 2 h after OPCABG for 72 h
215001797|NCT07118930|DRUG|Saline (0.9% NaCl)|Saline (0.9% NaCl) instead of Sivelestat
215001798|NCT07117916|BEHAVIORAL|Supervised nutritional guidance, physical exercise, cognitive training, social engagement, and management of vascular and metabolic risk factors.|In addition to health advice, participants in the intervention group will receive a structured, multidomain lifestyle program comprising nutritional guidance, physical exercise, cognitive training and social engagement, and monitoring and management of vascular and metabolic risk factors. The STRONGER 60+ intervention is based on the FINGER protocol and has been specifically adapted for primary care to enhance feasibility and scalability. Key adaptations include 1) delivering physical exercise sessions at external gym facilities rather than at primary care centers, and 2) shortening the intervention duration from two years to six months.
215001799|NCT07117812|PROCEDURE|Laparoscopic purse-string forceps and multifunctional sealing ring|Performing totally laparoscopic radical total gastrectomy with R0 resection, completing esophagojejunostomy using purse-string forceps and multifunctional sealing ring.
215001800|NCT07118293|BEHAVIORAL|MSE-PEACE|"The MSE-PEACE (Multi-Sensory Environment-Parent Empowerment and Child Engagement) intervention is a family-centered, therapist-guided sensory integration program specifically developed for children with developmental disabilities and their caregivers. Unlike traditional child-only sensory therapies, this intervention actively involves parents in all stages-assessment, goal setting, activity participation, and follow-up.~Each participant dyad (parent and child) attends 10 biweekly sessions (60 minutes each) in a structured sensory therapy space equipped with adjustable lighting, tactile materials, auditory inputs, and other multisensory tools. The intervention is tailored to each child's sensory processing profile and emotional regulation needs, while promoting parent-child co-regulation, bonding, and collaborative engagement.~Occupational therapists facilitate the sessions using individualized strategies to support child-led participation and empower parents with real-time coaching,"
215121417|NCT06105840|PROCEDURE|Acupressure and Standardized Curcuminoid from Turmeric Extract|capsules containing curcuminoid from Tumeric Extract three times a day for 3 weeks and acupressure massage at points provide comfort for knee pain twice a week for 3 weeks
214397484|NCT00000286|DRUG|Nefazodone|
215121418|NCT06105840|PROCEDURE|Sham Acupressure and Placebo|capsules containing starch three times a day for 3 weeks and acupressure massage at points that are not to provide comfort for knee pain twice a week for 3 weeks
214397485|NCT03406429|DEVICE|Active rTMS|All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
214397486|NCT03406429|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
214397487|NCT05483842|OTHER|Reiki|"Consisting of the words rei meaning spirit and ki meaning universal life force, Reiki means spiritually directed life force energy. Reiki practice has an important place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, is safe, effective and economical.~In the Reiki method, which is one of the complementary and alternative methods, energy is transferred through the hands. Its basis is based on the principle that when there is a blockage in an energy center, disease occurs and the energy transferred by touching, strengthens and heals the body's self-healing ability by opening the blockages. Reiki practitioners who have received training and initiation perform the practice by holding their hands in certain positions on the recipient's body."
214503484|NCT04799301|BEHAVIORAL|Diet with 50% of carb intake from soda|Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
214503485|NCT04799301|BEHAVIORAL|Diet with 20% of carb intake from soda|Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
214503486|NCT06461234|BEHAVIORAL|Pelvic floor muscle training|A therapist will instruct the patient to contract the anus, perineum as well as the urethra, until the patient masters the correct method.
214503487|NCT06461234|OTHER|Biofeedback electrical stimulation|The therapist will place the electrodes of the instrument into the vagina, adjust the current value until the woman feels obvious contraction of the pelvic floor muscles but no pain, and instructs the patient to refer to the biofeedback mode for vaginal and anal contraction and relaxation.
214503488|NCT06461234|OTHER|Magnetic Stimulation|The therapist will use the magnetic stimulator to intermittently stimulate the and adjust the stimulation intensity at any time according to the patient\&amp;amp;amp;#39;s condition, adjusting it until there is a clear sense of contraction and feel comfortable.
214397488|NCT05483842|OTHER|Sham Reiki|Sham means to pretend; therefore, in this study, the sham Reiki placebo provider pretended to perform a Reiki session by moving her hands on the patient's body in a specific order for a 30-minute period following strictly operationalized measures.
215001801|NCT07117383|DEVICE|ASP-001.1|Bottle/pump containing ASP-001.1 suspension
214397489|NCT03704311|PROCEDURE|Muscle biopsy|Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
214397490|NCT02991287|PROCEDURE|Inguinal hernia repair|
214397491|NCT02991287|PROCEDURE|Abdominal hysterectomy|
214397492|NCT02991287|PROCEDURE|Vaginal hysterectomy|
214397493|NCT02991287|PROCEDURE|Thoracotomy|
214397494|NCT04344834|DIAGNOSTIC_TEST|A questionnaire or scales|A questionnaire or scale to assess the participants mental health.
214397495|NCT03655496|DEVICE|Home-based tool|The tool consists of a tablet computer and a Bluetooth connected weight scale. The patient is encouraged to use the tool daily. The weight is titrates the dose of diuretics and a short tip about how to improve living with heart failure, this is presented on the screen. Every five days the patient assess their self-perceived symptoms on the tablet computer. If the weight increases by 2kg or more in 3 days or less, the high dose is recommended for two days, after which the effect on the weight is assessed. If the weight increased was reverted, the dose is returned to normal and if it is still elevated, an alert on the table computer. If the self-assessed symptoms deteriorate, the same type of alert will appear on screen, urging the patient to contact the health care provider.
214397496|NCT03826563|DRUG|oral melatonin tablets (NatureMade brand)|melatonin tablets
214397497|NCT03826563|OTHER|Placebo|pill placebo
214397498|NCT01387256|DRUG|medical abortion|pregnancy termination with drugs
214397499|NCT06279429|DIETARY_SUPPLEMENT|Sideral® Sucrosomial Iron|Sucrosomial Iron 30mg
214397500|NCT06279429|DIETARY_SUPPLEMENT|Iron chewable tablet|Iron chewable tablet 100mg
214397501|NCT00788424|DRUG|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
214397502|NCT06036394|DIAGNOSTIC_TEST|The images (CT, MRI, PET) used for RT planning, mid-treatment imaging as part of IGRT or disease evaluation, and response assessment/ surveillance post-RT|The radiation plans and dose-volume histogram will be obtained from TPS. All the images and radiation-related data will be downloaded from the PACS and TPS, applying anonymization filters. Clinical features (patient, disease, treatment-related characteristics, and outcomes) will be extracted by review of electronic medical records. Imaging pre-processing will be done, which will include skull stripping and registration across different modalities (e.g., MRI and CT) or different sequences(e.g., T1C, T2W, ADC) will be done using rigid or deformable algorithms as suited best for the modality
214397503|NCT00980109|DRUG|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
215001802|NCT07117383|DRUG|ASP-001|Oral liquid suspension of sildenafil
214397504|NCT00980109|DRUG|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
214397505|NCT00980109|DRUG|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
214397506|NCT00980109|DRUG|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
214397507|NCT06446843|COMBINATION_PRODUCT|(Arthrocentesis followed by i-PRF +HA)|Intra-articular I-PRF with HA will be injected in the joint,1 ml of I-PRF will be injected inside the joint, Then from 25mg/ml of HA , 1ml will be injected into the superior joint space
214397508|NCT02698280|DRUG|Bevacizumab|Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
214397509|NCT02698280|DRUG|Nimustine|Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.
214397510|NCT01700504|DRUG|Axillary lavage with gentamicin solution|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
214397511|NCT04403061|DIAGNOSTIC_TEST|Cytokines measurement|Quantification of plasma cytokine levels of human GM-CSF, IFN-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNF-α using multiplex technol-ogy (quantitative measure).
215121419|NCT05876507|BEHAVIORAL|Progressive relaxation exercise|Progressive relaxation exercises will take 25-30 minutes of patients daily.
214397512|NCT04403061|DIAGNOSTIC_TEST|Cellular response|SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).
214397513|NCT04403061|DIAGNOSTIC_TEST|TLRs activation measurement|After specific cell activation through TLR7/8 receptors, such as resiquimod, ORN R-0002, ORN R-0006, ORN R-1263, ORN R-2336, and controls as Poly (I:C), the release of IFNa, IFNg, TNFa, IL12, and IL6 will be analyzed (quantitative measure).
214503489|NCT06461234|OTHER|Magnetic stimulation combined with biofeedback electrical stimulation|Pelvic floor magnetic stimulation for 30 minutes followed by biofeedback electrical stimulation.
214503490|NCT03697603|DRUG|Brexpiprazole|Tablets, Oral, once daily, 14 weeks
214503491|NCT03697603|DRUG|Placebo|Tablets, Oral, once daily, 14 weeks
214503492|NCT00828126|PROCEDURE|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
215001803|NCT07117383|DRUG|Commercial Sildenafil and Sildenafil/Tadalafil Products|A selection of marketed sildenafil or sildenafil + tadalafil products used as comparators. Includes tablets and chewables such as Viagra®, Galotam, BlueChew, Aristo Sildaristo, Lemonaid Viagra, Ro Sparks, Hims Hard Mints, and Hello Cake ED Cake Meds.
215001804|NCT07118345|PROCEDURE|Early prophylactic decompressive hemicraniectomy|Early prophylactic decompressive hemicraniectomy (decompressive hemicraniectomy is required to initiate within 6 hours after completion of mechanical thrombectomy and within 4 hours after randomization).
215121420|NCT00390767|BIOLOGICAL|MultiGeneAngio|Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
214397514|NCT04403061|DIAGNOSTIC_TEST|KIR phenotype evaluation|Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.
214397515|NCT03950219|OTHER|Group course|Education and support
214397516|NCT02268552|DRUG|branaplam|
214397517|NCT03433092|OTHER|serum carotenoids|In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography
214397518|NCT00671541|DRUG|Merogel Nasal Stent and Nasopore Stent|Merogel Nasal Stent and Nasopore Stent
214397519|NCT00671541|DRUG|Nasopore Stent and either Gentamycin or Bacitracin|Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
214397520|NCT05126446|DEVICE|the Aorta Arch Stent Graft System combined with the Endovascular Needle System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with device
214397521|NCT04329052|BEHAVIORAL|Adventure-based training with health educational talk|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
214397522|NCT01476579|DEVICE|Cardiac Computer Tomography|Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
214397523|NCT02537353|DEVICE|Metal clips|The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
214397524|NCT02537353|DRUG|Hemospray|The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
214397525|NCT02537353|PROCEDURE|Endoscopy Exam|All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
214397526|NCT02537353|DRUG|Adrenaline|The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
214397527|NCT02184897|DRUG|lenograstim 10 microgram/kg/day|
214397528|NCT03617874|OTHER|PC4PrEP- Intervention Clinics|PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.
214397529|NCT03617874|OTHER|Standard of Care Clinics|The standard of care model is the model approved by the health system for their health care clinics.
214397530|NCT01587729|DRUG|Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants|TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.
214397531|NCT01999660|DEVICE|SpaceOAR™ implantation|
214397532|NCT02472314|DRUG|1.3% Liposomal Bupivacaine|local tissue infiltration of Liposomal Bupivacaine during surgery
214397533|NCT02472314|DRUG|0.125% Bupivacaine|Continues nerve block with Bupivacaine during surgery and postoperatively
214397534|NCT03149211|DRUG|UB-421|Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).
214397535|NCT03149211|DRUG|current standard HAART treatment|Subjects will receive current standard HAART treatment as the active control group.
214397536|NCT03756779|OTHER|Dietary intervention|Dietary intervention with dietary modification of fat intake.
214503493|NCT06971861|BEHAVIORAL|Acceptance and Commitment Therapy|The current program is based on ACT and consists of four one-hour sessions covering the six core components of psychological flexibility. The four sessions respectively focus on Cognitive Defusion, Being Present and Acceptance, Self-as-Context and Values, and Committed Action. All sessions involve experiential learning activities and reflective discussions. Each participant also receives a workbook to facilitate post-session home practice.
215121421|NCT04039958|DRUG|Soviredia|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
215121422|NCT04039958|DRUG|Harvoni (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
215121423|NCT04039958|DRUG|Harvoni (Second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
215121424|NCT03647657|DRUG|177Lu-PP-F11N|Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient
215121425|NCT03647657|DRUG|Sacuitril|Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N
214397537|NCT00321477|DRUG|GW679769 oral tablets|
214397538|NCT06417905|OTHER|Supervised exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
214397539|NCT06417905|OTHER|video based exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
214397540|NCT03631147|DRUG|Rifaximin|400mg bid for 8 weeks
214397541|NCT03391713|BEHAVIORAL|Poster|The poster includes the FAST symptoms but translated to the Malay language (Ce.P.A.T) Cakap tak jelas (slurred speech - Speech slurring) Perubahan muka (face changes - Face drooping) Anggota lemah (weak limbs - Arm weakness) Terus ke Hospital (straight to the hospital - Time to call 911
214397542|NCT00090272|DRUG|MK0826, ertapenem sodium|
214397543|NCT00090272|DRUG|Comparator: cefotetan|
214397544|NCT03415022|BEHAVIORAL|computer-based treatment|30 minute sessions of free viewing of faces and listening to music
214397545|NCT04466618|BIOLOGICAL|Saline|Saline infused during the study
214397546|NCT04466618|BIOLOGICAL|Exendin-9,39|Exendin-9,39 infused during the study
214397547|NCT04466618|BIOLOGICAL|Saline + Intralipid/Heparin|Saline infused during acute insulin resistance
214397548|NCT04466618|BIOLOGICAL|Exendin-9,39 + Intralipid/Heparin|Exendin-9,39 infused during acute insulin resistance
214397549|NCT01702389|DRUG|Remifentanil|
214397550|NCT04730934|OTHER|Perceived stress scale|Perceived stress scale (PSS) : The PSS is a validated 10-item self-report questionnaire which asks individuals to indicate how often they have found their lives unpredictable, uncontrollable, and overloaded in the last month. The higher scores indicating greater perceived stress.
214503494|NCT06647498|DRUG|Remternetug|Administered subcutaneously every 12 weeks
214503495|NCT06647498|DRUG|Matching Placebo (Remternetug)|Administered as subcutaneous injection of placebo every 12 weeks
214503496|NCT01800305|DRUG|Pegylated rhEPO|
214503497|NCT01800305|DRUG|EPIAO®|
214503498|NCT06965348|DEVICE|Application of kinesio tape|"The facilitating taping technique for the quadriceps and hamstring muscle group described by Kase et al. will be applied to the kinesio tape group. The tape will be applied from the muscle origin to the insertion (proximal to distal) for facilitation.~The application for the hamstring muscle group will be applied from the proximal to the distal of the muscle up to the lateral and medial heads of the gastrocnemius muscle. The tape will be applied to the quadriceps muscle from the proximal to the distal of the muscle, ending on the undersurface of the patella.~The physiotherapist places the tape base without tension in the first 5 centimeters of the starting point of the hamstring muscles and quadriceps muscle. Light to moderate tension (25-50%) is applied for facilitation. The tail parts of the tape are placed on the skin without tension at a distance of 2 to 5."
215001805|NCT07117149|BEHAVIORAL|multicomponent, tiered intervention|"Kindergarten: Train teachers and integrate healthy weight management into kindergarten health policies; deliver health education sessions for children; monitor extra dietary intake and physical activity; conduct monthly height and weight measurements.~Family: Provide multi-format health education (lectures, short videos, articles) to communicate core intervention messages; set health behavior goals and deliver personalized feedback; conduct motivational interviewing in offline parent meetings or by phone.~Hospital: Offer professional health guidance and medical services. PKU-SMART online platform: Health Education Module; Growth Monitoring Module; Health Behavior Module; Home-Kindergarden Partnership Module."
215001806|NCT06918704|BEHAVIORAL|Coherence|Coherence is a music-based rhythm training app.
215001807|NCT06918704|BEHAVIORAL|Worder|Worder is a word search app.
215001808|NCT07116434|BEHAVIORAL|Discovery Prgoram|"The Discovery Program is a novel, hybrid intervention specifically designed to address the psychosocial barriers faced by adolescents and young adults with T1D. This intervention integrates three key components:~1. Patient-Reported Measures~2. In-Clinic Collaborative Goal Setting~3. Personalized Mobile Health Communications~The Discovery Program will be delivered over a 3-month intervention period, followed by a 6-month follow-up to assess outcomes. This approach not only aims to improve glycemic control but also seeks to enhance diabetes self-management behaviors, reduce diabetes distress, and build problem-solving skills among participants. The integration of clinical informatics, personalized support, and mobile health technology distinguishes this intervention from traditional diabetes care practices, which often overlook psychosocial factors affecting health outcomes."
215001809|NCT07116213|RADIATION|Moderately Hypofractionated Adaptive Radiotherapy|Moderately Hypofractionated Adaptive Postoperative Radiotherapy
215095077|NCT03961412|BEHAVIORAL|family-based intervention|The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
215095078|NCT03961412|BEHAVIORAL|Participant only intervention|Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
215095079|NCT03150277|BEHAVIORAL|Plyometric exercise|2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
215095080|NCT03150277|BEHAVIORAL|Heavy resistance exercise|10 single repetitions of back half squats at 90% of 1 repetition maximum
215095081|NCT05993962|DIETARY_SUPPLEMENT|Fortified yoghurt|Food-grade vitamin B12 in the form of methylcobalamin (purity: 99%) was used for fortification. Yoghurts were Greek-style and locally produced by a yoghurt company in British Columbia, Canada. The pre-measured vitamin B12 was added into yoghurt vats in amounts that corresponded to the chosen dosage (50 µg of B12 per 150 g). The yoghurt was packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
214397551|NCT04730934|OTHER|Fibromyalgia impact questionnaire|Fibromyalgia impact questionnaire (FIQ): The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
214397552|NCT04730934|OTHER|The drugs used before and during the pandemic, the patient's job status, physical activity conditions, pain status|"Drug using: Antidepressant, SNRI, gabapentin, SSRI, myorelaxan, nsaid, paracetamol, pregabalin, tramadol, food supplement.~Job status: Participants were questioned about their occupational status before and during the pandemic as I am a housewife, I quit my job, I worked from home, I worked part-time and there was no change in my job.~Physical activity: I do not have physical activity, I do my daily work at home, I do daily walks, I exercise regularly.~Pain status: Participants were questioned that their pain conditions before and during the pandemic were much worse, worse, a little bad, no change, a little good,  better, It was questioned as much better."
214397553|NCT04947969|DEVICE|laser acupuncture|This study will use German-made low-level laser pen (Al-Ga-As diode laser, 810nm, NIR, Physiolaser Olympic Basic, RJ laser). The parameters are power of 100mW, frequency of Bahr, apply on acupoint. Well will irradiate each point for 2 J. Each patient will receive this treatment six times for one week.
214397554|NCT01433653|BEHAVIORAL|Cognitive Behavioral Therapy for Complicated Grief|Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
214397555|NCT00514072|BIOLOGICAL|BCG vaccine|given intradermally
214397556|NCT00514072|BIOLOGICAL|prostate cancer vaccine ONY-P1|given intradermally
214397557|NCT00514072|OTHER|placebo|given intradermally
214397558|NCT03781960|DRUG|Abemaciclib|Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.
214397559|NCT03781960|DRUG|Nivolumab|Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
214397560|NCT03093090|DIETARY_SUPPLEMENT|Water|6 oz
214397561|NCT03093090|DIETARY_SUPPLEMENT|Parmalat™ Whole Milk|6 oz
214397562|NCT03093090|DIETARY_SUPPLEMENT|Similac Pro-Advance™|6 oz
214397563|NCT03093090|DIETARY_SUPPLEMENT|Ensure Plus™|6 oz
214397564|NCT03093090|DRUG|Furosemide 20 MG|Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.
214397565|NCT05565222|DRUG|Piperacillin/tazobactam or temocillin|"Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)"
214397566|NCT05565222|DRUG|Meropenem|2 g every 8 hours by intravenous route (adjusted in case of renal failure)
214397567|NCT00249093|DRUG|oxygen|
214397568|NCT05813925|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
214397569|NCT05813925|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
214397570|NCT05813925|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide
214397571|NCT00730301|PROCEDURE|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
214397572|NCT01676220|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
214503499|NCT06965348|OTHER|Placebo Group|The application for the hamstring muscle group will be applied from the proximal to the distal of the muscle up to the lateral and medial heads of the gastrocnemius muscle. The tape will also be applied to the quadriceps muscle from the proximal to the distal of the muscle, ending at the lower surface of the patella.The placebo group will have tape applied to the quadriceps and hamstring muscle groups without any tension.
214503500|NCT03749187|DRUG|PARP Inhibitor BGB-290|Given PO
214503501|NCT03749187|DRUG|Temozolomide (TMZ)|Given PO
214503502|NCT02686658|DRUG|Avacincaptad Pegol|Avacincaptad Pegol 20 mg/mL solution for intravitreal (IVT) injection
214503503|NCT02686658|OTHER|Sham|The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
214503504|NCT03981588|OTHER|Imaging studies|Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity
214503505|NCT04448652|DRUG|NSAID|no other intervention than described in the groups.
215001810|NCT07116330|OTHER|Vascuar risk factor screening (blood pressure, medical history, BMI, laboratory tests)|"The vascular risk assessment is outlined below, there may be slight variations according to local routines. Overall, the screening should include:~Family history of vascular disease~Tests/examinations (order or obtain from medical records \[past 3 months\]) Weight Height Waist circumference 12-lead ECG Resting and standing blood pressure Total cholesterol HDL cholesterol LDL cholesterol HbA1c High sensitivity CRP Serum creatinine Urine albumin-to-creatinine ratio~Medical history Atherosclerotic cardiovascular disease Atrial fibrillation Congestive heart failure Diabetes mellitus Hypertension Kidney disease Life-style risk factors (smoking, exercis"
215095082|NCT05993962|OTHER|Control yoghurt|Yoghurts were locally produced by a yoghurt company in British Columbia, Canada. Yoghurts produced were Greek-style and packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
215095083|NCT01380704|DRUG|ABT-436|QD Days 1-7
214503506|NCT00869934|OTHER|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
214397573|NCT01676220|DRUG|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
214397574|NCT03511079|BEHAVIORAL|Music|Music will be delivered through Pandora Plus radio via patient's computer or smartphone. The patient will choose a favorite song to create a playlist which will be used for the duration of the entire study. The subgenre of the initial song will be recorded.
214397575|NCT01994733|DRUG|Calcium carbonate ( Intensive phosphate control)|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of \< 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice
214397576|NCT01994733|DRUG|Calcium carbonate (Liberalized phosphate control)|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
214397577|NCT05345093|DEVICE|Ialuxid gel|"Ialuxid® Gel is intended for topical external use. It is formulated with the appearance of white to pale yellow coloured consistent gel.~Ialuxid® Gel will be used for 8 weeks, 2-3 times a day."
214397578|NCT01719640|DRUG|infusion of MSCs|infusion of MSCs
214397579|NCT01719640|DRUG|infusion MCs|infusion of MCs
214397580|NCT01719640|DRUG|insulin|intensive insulin care
214397581|NCT04496167|DRUG|EN3835|Collagenase clostridium histolyticum
214397582|NCT04496167|DRUG|Placebo|Placebo comparator
214503507|NCT00869934|OTHER|Behavior Therapy|Sleep restriction and stimulus control
214503508|NCT00869934|OTHER|Cognitive Therapy|Cognitive restructuring therapy
214397583|NCT00113698|DRUG|Enalapril|Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
214503509|NCT00467272|DRUG|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
214503510|NCT05364697|DEVICE|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloy-based stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
214503511|NCT06476015|OTHER|Therapeutic exercise|Duration: 30 minutes. Frequency: Once a week. Type of excercise: Cardiovascular, strengthening and balance. Supervised by a health professional.
214503512|NCT05094011|BIOLOGICAL|Aadipose-Derived Mesenchymal Stem Cells|Stereotactic intrastriatal implantation of 3×10\^7 per hemisphere (total 6×10\^7 cells) or 1×10\^8 per hemisphere (total 2×10\^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).
214503513|NCT04275167|DEVICE|Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope|Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.
214503514|NCT03018067|DRUG|RDX227675|
214503515|NCT03018067|DRUG|Placebo|
214503516|NCT04198467|BIOLOGICAL|Platelet rich plasma|Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular
214503517|NCT04198467|DRUG|Hyaluronic Acid|Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
214503518|NCT01572805|DRUG|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
214503519|NCT01572805|DRUG|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
214503520|NCT01572805|DRUG|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
214503521|NCT01841515|DRUG|Desmopressin administration|
214503522|NCT00570505|DEVICE|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
214503523|NCT01695291|DRUG|Minocycline|Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.
214503524|NCT01695291|OTHER|Placebo|A placebo pill will be administered twice a day (BID) for 12 weeks.
214503525|NCT03051568|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
214503526|NCT02045498|DEVICE|capnography feedback|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
214503527|NCT00614614|BIOLOGICAL|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
214503528|NCT00614614|BIOLOGICAL|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
214503529|NCT00614614|BIOLOGICAL|Infanrix®|One dose as intramuscular injection
214503530|NCT00614614|BIOLOGICAL|ActHIB®|Three doses in the priming phase as intramuscular injection
214503531|NCT00614614|BIOLOGICAL|Pediarix®|Three doses in the priming phase as intramuscular injection
214503532|NCT04990856|PROCEDURE|Exercise|Tumor blood flow after acute exercise
214503533|NCT03988283|BIOLOGICAL|Personalized neoantigen DNA vaccine|At each vaccination time point, patients will receive one injection of the neoantigen DNA vaccine, one injection into the vastus lateralis.
214503534|NCT03988283|DEVICE|Papivax Biotech TDS-IM v2.0|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM v2.0 device - Papivax Biotech).
215095084|NCT01380704|DRUG|Matching Placebo|QD Days 1-7
215095085|NCT00026377|DRUG|bicalutamide|50 mg daily for 1 month
214397584|NCT00113698|OTHER|Placebo|Placebo An inert preparation with similar appearance and taste to the drug
215095086|NCT00026377|DRUG|flutamide|250 mg 3 times daily for 1 month
215095087|NCT00026377|DRUG|goserelin acetate|3.6 mg once a month for 4 months
215095088|NCT00026377|DRUG|leuprolide acetate|7.5 mg once a month for 4 months
215095089|NCT00026377|DRUG|SU5416|IV infusion at assigned dose
215095090|NCT00026377|RADIATION|radiation therapy|daily for 5 days each week
215095091|NCT02832336|DRUG|Vivarin|Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
215095092|NCT02832336|DRUG|Fiber|Fiber will be used as placebo.
214397585|NCT00026637|DRUG|sertraline|Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.
215095093|NCT04018742|OTHER|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
214397586|NCT00026637|BEHAVIORAL|cognitive behavior therapy|CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
215001811|NCT07116122|DEVICE|Tracking/finding system|Persons living with Alzheimer's Disease or Related dementias will wear the Care Companion smartwatch for approximately one month (stage I) or 6 months (stage 2). The Caretakers will utilize the smart phone application (app) to monitor the person wearing the watch and be alerted to elopements. The system will notify a caregiver if the person with dementia leaves a defined area (e.g., the home) via the application. In the tether mode (e.g., outside of the home), the system monitors the distance between the smartwatch and the caregiver's smartphone. When a separation distance exceeds a set threshold, the application will alert the caregiver and start tracking the location of the person with dementia by displaying the person's position on the caregiver's smartphone.
215001812|NCT07118579|DRUG|Remimazolam|remimazolam induction (0.3-0.5 mg/kg) + maintenance (1-3 mg/kg/h)
214503535|NCT03988283|PROCEDURE|Peripheral blood draw|-After trial enrollment and up to 7 days after the first vaccine dose (baseline); no more than 2 weeks after the 3rd vaccine dose; no more than 2 weeks after the 6th vaccine dose; two weeks after the last dose; time of progression or discontinuation (optional)
214503536|NCT06354985|DRUG|Modafinil 200mg|Modafinil 200mg daily for 8 weeks.
215001813|NCT07118579|DRUG|Propofol|Anesthesia induction (2-3 mg/kg) + Anesthesia maintenance (6-10 mg/kg/h)
214397587|NCT06312527|DEVICE|Silicone dressing|"Participant will apply silicone dressing at 2 weeks after TKA on one side of knee.~Silicone dressing will change every week until 12 week postoperative."
214397588|NCT06344611|OTHER|Other|It is an observational study. Subjects will receive the treatment as per institute protocol.
214503537|NCT06354985|DRUG|Placebo|Placebo daily for 8 weeks.
214397589|NCT02339701|RADIATION|IMRT|
214397590|NCT02339701|RADIATION|SBRT|
214397591|NCT00182663|DRUG|clarithromycin|Given PO
214397592|NCT00182663|DRUG|thalidomide|Given PO
214397593|NCT00182663|DRUG|dexamethasone|Given PO
214503538|NCT06354985|BEHAVIORAL|Exercise|Exercise three times per week for 8 weeks.
214503539|NCT05212285|DEVICE|Inbody 570|Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up
214503540|NCT05212285|DEVICE|JAMAR Dynamometer|Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up
214503541|NCT05212285|RADIATION|CT scan|Chest and abdominal CT scan during each follow-up
214503542|NCT06346886|BEHAVIORAL|FAITH! HTN app|Participants will remain in the intervention for 11 weeks. The app-based intervention is a tailored program to promote HTN self-management and knowledge through an 11-module educational video series with a focus on HTN. Participants will also be provided with at home Blood Pressure (BP) monitoring system to allow for self-tracking of BP measurements(automatically synchronized with the app). The app will include pre-post module quizzes, a tracking component for participants to input self-monitored measures (medication adherence, diet, physical activity, etc.). The app sharing board will be a moderated discussion platform and feed for participant interaction by posting healthy lifestyle practices through text, photographs and video to foster discussion on HTN management barriers/facilitators. The project team will post weekly to the sharing board on HTN-related topics to generate discussion among patients.
214688178|NCT07083830|DEVICE|ECP-DL treated mononuclear cell infusion|Participants in this study will undergo the infusion of donor white blood cells treated with ECP one week before their living donor kidney transplant, combined with standard of care antirejection medications. You will also then have ECP treatments using your own blood on two consecutive days once per month for 6 months. This combination is intended to cause your immune system to create a state called tolerance to the donor kidney. The ECP procedure has not been approved to prevent rejection after kidney transplant and the use of ECP to prevent rejection of transplanted organs is experimental, and is not a part of standard treatment which is based on the long term use of anti-rejection drugs such as tacrolimus (Prograf), everolimus, and prednisone.
215001814|NCT07118579|DRUG|Ciprofol|Anesthesia induction (0.4-0.5 mg/kg) + Anesthesia maintenance (0.8-1.2 mg/kg/h)
215095094|NCT03775564|OTHER|REMEDRUGBY PROGRAM|"* 1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~* 2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~* 5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~* 8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~* 10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~* 12th General Debriefing session Including : - 3 tournaments~* 8 hours of Touch Rugby"
215095095|NCT03775564|OTHER|TOUCH RUGBY PROGRAM|Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
215095096|NCT03775564|OTHER|TAU|Treatment as usual
214397594|NCT02550275|BEHAVIORAL|neuropsychological test|
214397595|NCT02550275|RADIATION|MRI|
214397596|NCT00982982|DRUG|THC and Iomazenil|"* Iomazenil: 3.7 μg/kg intravenously over 10 minutes~* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes."
214397597|NCT00982982|DRUG|Placebo (control)|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
214397598|NCT00422396|DRUG|Fenofibrate (drug)|
214397599|NCT02269943|DRUG|CC-486|
214397600|NCT03541642|BEHAVIORAL|Enhanced Intervention|Targeted PrEP counseling; targeted written/visual materials; follow up supportive text messages; distribution of PrEP at the syringe exchange
215001815|NCT07114068|OTHER|Self mobilization of Obturator Internus Muscle using wand|Participants will be randomly assigned to the internal or external Obturator Internus mobilization groups. The internal mobilization group will access the Obturator Internus muscle via the vagina, which is common practice in Pelvic Health Physical Therapy. The external mobilization group will be accessing the Obturator Internus muscle with the same pelvic wand, but externally. Pelvic wands will be provided for each participant at no cost and will be used for only that participant. Prior to intervention with a pelvic wand, each participant will be provided education regarding the anatomy of the pelvic floor and hip and a protocol review of the intervention.
215001816|NCT07113730|OTHER|immune reconstitution|Detection of immune reconstitution in peripheral blood of patients by flow cytometry at 30-day intervals for 180 days post-transplantation.
215001817|NCT07119008|DEVICE|Virtual reality|Patients will perform 12 virtual reality sessions at a rate of 2 sessions per week for 6 weeks. The patient will be offered to properly store food groceries by differentiating perishable or non-perishable foods from non-food items, or to prepare cooking recipes.
214503543|NCT05987774|DEVICE|AI Modules for Improving Social Conversation|"The application if the modules will be delivered using software. These modules have been developed to provide feedback on specific areas following voice or text input (user preference will be recorded in case this effects the results).~The investigators currently have developed AI modules for common social communication challenges exhibited by individuals with ASD. Examples include:~Empathy (general and in the work setting), Asking Relevant Questions, Listen and Respond, Talking the right amount, giving the right amount of personal information, Tactful Responses, Giving compliments, and Staying on topic during Conversation. These are all areas that can be challenging for individuals diagnosed with autism spectrum disorder.~AI modules consist of thousands of total training examples. Participants may access the modules on their phones or computers."
214503544|NCT00900341|GENETIC|DNA analysis|
214503545|NCT00900341|GENETIC|gene expression analysis|
214503546|NCT00900341|GENETIC|protein expression analysis|
214503547|NCT00900341|GENETIC|reverse transcriptase-polymerase chain reaction|
215095097|NCT00439881|DRUG|SB-681323|
215095098|NCT02391961|DRUG|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
215095099|NCT02391961|DRUG|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
214397601|NCT03541642|BEHAVIORAL|Basic Intervention|General messaging from medical personnel; reminder text messages; distribution of PrEP at the syringe exchange
214397602|NCT02255630|OTHER|Cycling Exercise|
214503548|NCT00900341|GENETIC|western blotting|
215095100|NCT01348555|DRUG|Bronchodilatator|
215095101|NCT01348555|DRUG|Bronchodilatator|
215095102|NCT04560894|DRUG|SCT-I10A|Participants receive SCT-I10A intravenously，200mg，d1，Q3w
214397603|NCT00002750|DRUG|melphalan|
214503549|NCT00900341|OTHER|immunohistochemistry staining method|
214503550|NCT00900341|OTHER|laboratory biomarker analysis|
214503551|NCT06190132|DRUG|Omega 3 fatty acid, gabapentin|To study the effect of omega 3 fatty acids on uremic pruritus in prevalent hemodialysis patients versus the effect of gabapentin
214503552|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
215095103|NCT04560894|DRUG|SCT510|Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
214397604|NCT03436121|DRUG|Ketamine|"Ketamine is a medication approved by the US Food and Drug Administration (FDA) for anesthesia, sedation, and post-surgical pain treatment. It is not approved for emergency patients complaining of pain but is often used off-label. Ketamine may be useful for acute pain management and in treatment of depressed mood. The purpose of this study is to determine whether a single low dose of ketamine can relieve pain and reduce negative mood for 2 weeks after emergency department (ED) treatment."
214397605|NCT03436121|DRUG|Midazolam|In this study, all patients will also receive midazolam. Midazolam is a sedative that typically makes people feel relaxed and is intended to increase comfort with ketamine and reduce anxiety.
214503553|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
214503554|NCT01584752|PROCEDURE|Gore-BioA Fistula Plug|Gore-BioA Fistula Plug
214503555|NCT02627391|OTHER|Early surgical aortic valve replacement|
214503556|NCT02627391|OTHER|Delayed Surgical aortic valve replacement|
214503557|NCT00219466|OTHER|Zinc Oxide Diaper Rash Ointment|Desitin Original at diaper change
214503558|NCT00219466|OTHER|Aloe Vera/Tocopherol/Zinc Oxide Cream|Desitin Creamy at diaper change
214503559|NCT03665792|DEVICE|nociception index qNOX|non-invasive, real time, monitoring for nociception stimulation
214688179|NCT06930131|BEHAVIORAL|Semantic rehabilitation|Semantic rehabilitation, consisting of validated lexico-phonological training exercises
215001818|NCT07118202|DEVICE|TheraBionic P1|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening
215001819|NCT07117435|DRUG|paclitaxel cationic liposome for injection|Paclitaxel cationic liposome was administered through hepatic arterial catheter infusion, in a gradual increment dose range from 33 mg/m\^2 to 55 mg/m\^2
215001820|NCT07117435|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 i.v. on D1
215001821|NCT07117435|DRUG|Capecitabine|Capecitabine 1000 mg/m2 p.o. Bid on Day 1-14
215001822|NCT07117435|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg i.v. on D1
215001823|NCT07118722|BEHAVIORAL|Quiet Focus|Mindfulness-based cognitive therapy adapted for older adults at-risk for chronic pain and depression
215001824|NCT07118722|BEHAVIORAL|Health Enhancement Program|Time- and dose-matched control for Quiet Focus.
215001825|NCT07118696|DRUG|Extra 600mg of Rifampicin|Intervention group participants will receive standard treatment (RHZE), plus an optimised regimen consisting of RIfampicin at 20 mg/kg (additional 600mg rifampicin in each weight band) during a shortened treatment period of 16 weeks.
214503560|NCT00476905|DEVICE|Spectral Diagnosis Probe|The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
214397606|NCT03436121|DRUG|Placebo|In this study, patients in the active comparator group will receive midazolam first, then placebo. A placebo is an inactive solution that looks like the study drug, but contains no active ingredients.
214397607|NCT05015673|DRUG|SEP363856|
214397608|NCT05015673|DRUG|Placebo|
214397609|NCT02498743|PROCEDURE|echocardiography|TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.
214397610|NCT02498743|BEHAVIORAL|Watching Animated cartoons|
214397611|NCT02682563|DRUG|Dapagliflozin 10mg QD|Dapagliflozin 10mg once daily for 12 weeks
214397612|NCT02682563|DRUG|Gliclazide 30mg QD|Gliclazide30mg once daily for 12 weeks
214397613|NCT05898737|DEVICE|NOL-Index|NOL Index monitoring with the PMD100™ (Medasense Biometrics Ltd.)
214397614|NCT02136485|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|8 sessions of MBSR
214397615|NCT02136485|OTHER|waiting list control|
214397616|NCT03088137|DRUG|Follitropin alfa (Gonal-f)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
214503561|NCT03951259|DRUG|SM934|In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
214503562|NCT03951259|DRUG|Placebos|The placebo pills are made identical to the investigating SM934 in appearance.
214503563|NCT01548703|DRUG|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
214503564|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
215001826|NCT07118696|DRUG|Placebo|The standard treatment regimen for DS-TB (rifampicin at 10 mg/kg and isoniazid for 6 months, plus pyrazinamide and ethambutol for the first 2 months; 2RHZE/4RH), with additional placebo for the first 4 months (16 weeks).
215001827|NCT07116993|DEVICE|theraputic ultrasound|Ultrasound is a mechanical sound wave with frequencies above human hearing, requiring a medium like air or tissue to travel, commonly used in imaging.
215001828|NCT07116993|DEVICE|infrared radiation|Infrared, in contrast, is electromagnetic radiation associated with heat, doesn't need a medium, and is used in applications like thermal imaging and remote controls.
215001829|NCT07118605|PROCEDURE|Minimally Invasive Sagittal Split Ramus Osteotomy|This procedure involves a limited mucosal incision and tunnel dissection technique combined with low and short osteotomy and minimal soft tissue manipulation. The goal is to reduce surgical trauma, edema, blood loss, and operative time while maintaining clinical effectiveness.
214503565|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
215001830|NCT07118605|PROCEDURE|Conventional Sagittal Split Ramus Osteotomy|This procedure follows the traditional wide exposure technique with full-thickness mucoperiosteal flap elevation. This method is widely accepted and serves as the control for comparison.
215001831|NCT07117305|DRUG|CD7 CAR-T combined with autologous hematopoietic stem cell transplantation|"Phase I adopts a standard 3+3 dose-escalation design (with exploratory doses of 1×10⁶, 2×10⁶, and 2.5×10⁶ CAR⁺ cells/kg) to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Phase II expands at the RP2D to further assess efficacy.~During screening, eligible patients will be identified and consented. In the collection phase, patients undergo two separate apheresis procedures: G-CSF-mobilized peripheral blood stem cell collection for ASCT and PBMC collection for CAR-T manufacturing. Bridging therapy and gut preparation may be performed. The pretreatment phase(recommended: BEAM therapy) starts from Day -8. Investigators may adjust the pretreatment regimen based on the patient's performance. On Day 0, autologous stem cells are infused. CD7 CAR-T cells are infused on Days 2-7 post-transplant. Follow-up visits occur on Days 10, 14, 21, 28, and Months 2, 3, 6, and 12."
215001832|NCT07116824|DRUG|HB1801|HB1801 is administered by intravenous infusion.
215001833|NCT07116824|DRUG|Trastuzumab|Trastuzumab is administered by intravenous infusion, 8mg/kg loading dose and then 6mg/kg per cycle, Q3W.
214397617|NCT03088137|DRUG|Follitropin alfa (Primapur)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
214397618|NCT02433093|DRUG|Basimglurant|Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
214397619|NCT02433093|DRUG|Placebo|Participants will receive 22 days of once-daily oral matching placebo capsules.
214397620|NCT06126419|DRUG|High-Dose Insulin Therapy|A baseline blood glucose value will be obtained. Two units of insulin will be administered IV if the blood glucose is \> mmol/L. An insulin infusion of 0.12 units/kg/hr will be started. Ten minutes after starting the insulin, and when the blood glucose is \< 6 mmol/L, dextrose 20% supplemented with phosphate (30 mmol/L) will be infused. Blood glucose levels will be measured every 15 minutes, and the dextrose infusion rate adjusted to maintain glycemic levels between 4 and 6 mmol/L for a duration of 6 hours. At the end of the 6 hour period, the insulin will be stopped and the dextrose will be weaned off.
214397621|NCT01026675|PROCEDURE|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
214503566|NCT06426966|DIETARY_SUPPLEMENT|Berberine|Berberine is an alkaloid derived from plants native to China called Rhizoma coptidis, Cortex phellodendrine and Hydrastis canadensis. These plants are used in the treatment of infectious diarrhea, inflammation, DM2, non-alcoholic fatty liver disease, dyslipidemias, cardiovascular diseases, and obesity. They have been shown to improve insulin sensitivity and stimulate glucose uptake through the activation of AMP-activated protein kinase (AMPK)
214397622|NCT03699046|PROCEDURE|Subchondroplasty and Knee Arthroscopy|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The bone marrow lesion(s) will be located using pre-operative MRI combined with fluoroscopy (intra-operative X-ray) and a small, drillable AccuPort® Delivery Cannula will be placed in the appropriate position. The cannula will then be drilled into the bone marrow lesion(s) and a flowable, synthetic, calcium phosphate bone substitute (AccuFill® Bone Substitute Material, Zimmer Biomet) will be injected into the lesion(s). The calcium phosphate bone substitute will then harden, improve the structural integrity of the damaged subchondral bone, and will gradually be resorbed and replaced with new bone.
214397623|NCT03699046|PROCEDURE|Knee Arthroscopy Alone|Knee arthroscopy is a surgical procedure that involves the orthopaedic surgeon making small incisions in the knee and then inserting a small camera into the joint. Following the insertion of the camera, multiple procedures can be completed to treat a number of different conditions such as repair or partial/complete removal of the meniscus, debridement, lavage, removal of a loose body among others.
214397624|NCT03699046|BIOLOGICAL|Subchondroplasty|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The specific biological component of the procedure involves the injection of the AccuFill® Bone Substitute Material (Zimmer Biomet), which is a a flowable, synthetic, calcium phosphate bone substitute, into the bone marrow lesion(s).
214397625|NCT06341257|RADIATION|Stereotactic Central/Core Ablative Radiation Therapy (SCART)|The patient will receive a dose of 21 Gy in 3 fractions, with the dose maintained at 5 Gy per fraction for the entire tumor GTV boundary.
214397626|NCT03070314|DRUG|Echinaforce junior|Echinacea Purpurea Extract Pill, sweetened and with orange flavour
214397627|NCT05629442|OTHER|ctDNA|initial research biopsy, quality of life assessments and ctDNA collection
214397628|NCT03198260|OTHER|Fascial manipulation|Deep frictional massage
214397629|NCT03870087|DEVICE|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
214397630|NCT04612049|DEVICE|Immersive virtual reality visuo-motor skill assessment|Visuo-motor skill assessment in an immersive 3D virtual environment using a head-mounted display.
214397631|NCT05058586|OTHER|The Effects of Aerobic Exercise Training on Cardiorespiratory Fitness, Functional Capacity, Balance and Ventricular Repolarization Indices in Stroke Patients|Seventy patients with history of stroke admitted to our center between July 2017 and January 2018. Subjects participated in the study were randomly assigned to anti-gravity treadmill training, underwater walking therapy and control group. We examined aerobic capacity of participants by using 6-minute walk test and cycle ergometer testing before starting the treatment along with one month follow up. Patient's balance examined by using the Berg Balance Scale (BBS).
214397632|NCT04698889|DIETARY_SUPPLEMENT|natural cow|
214397633|NCT04698889|DIETARY_SUPPLEMENT|high protein cow milk|
215001834|NCT07116824|DRUG|Pertuzumab|Pertuzumab is administered by intravenous infusion, 840mg loading dose and then 420mg per cycle, Q3W.
215001835|NCT07116824|DRUG|Docetaxel|Docetaxel is administered by intravenous infusion, 75mg/m\^2, Q3W.
214397634|NCT04698889|DIETARY_SUPPLEMENT|natural human|
214397635|NCT04698889|DIETARY_SUPPLEMENT|low protein cow milk|
214397636|NCT04786470|DRUG|Ropivacaine|Ropivacaine infusion via transversus abdominis plane catheter.
214397637|NCT04786470|DRUG|Saline|Saline infusion via transversus abdominis plane catheter.
214397638|NCT00101569|DRUG|Aripiprazole|Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
214397639|NCT00101569|DRUG|Aripiprazole|Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
214397640|NCT00873093|DRUG|L-asparaginase|Given IM 6000 IU/m2/dose Days 2 and 9
214397641|NCT00873093|DRUG|doxorubicin hydrochloride|Given IV 60 mg/m2/dose on Day 1
214397642|NCT00873093|DRUG|therapeutic hydrocortisone|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
214397643|NCT00873093|DRUG|vincristine sulfate|Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22
214397644|NCT00873093|DRUG|cytarabine|Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9
214397645|NCT00873093|DRUG|prednisone|Given PO or IV 40 mg/m2/day on Days 1-28
214397646|NCT00873093|DRUG|bortezomib|Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8
214397647|NCT00873093|DRUG|pegaspargase|Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22
215001836|NCT05390541|BEHAVIORAL|Empowered to Test Yourself|There will be 5 sessions of the intervention, all of which will follow the same format. Participants will be sent push notifications for each session. Each session will begin with using relevant constructs from sIMB (i.e., information and behavioral skills). Next, participants will choose positive outcomes resulting from the behavior, barriers to performing the behavior (mental contrasting), select situational cues and action plans to overcome selected barriers (implementation intentions), and practice typing in implementation intentions and positive outcomes from memory (memory practice). To ensure participants retain the implementation intentions, the investigators will use memory practice. Participants will be asked to self-code if the participant is correct or incorrect. Lastly, participants will learn behavioral skills to engage in each of the 5 actions to increase self-efficacy.
215095104|NCT04560894|DRUG|Sorafenib 200mg|Participants receive sorafenib orally，400mg bid
214397648|NCT00873093|DRUG|methotrexate|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
214397649|NCT00873093|DRUG|etoposide phosphate|Given IV 100 mg/m2/dose on Days 1-5
214397650|NCT00873093|DRUG|cyclophosphamide|Given IV 440 mg/m2/dose on Days 1-5
214397651|NCT00873093|BIOLOGICAL|filgrastim|Given IV or SC 5 micrograms/kg/dose Only on Day 6
214397652|NCT00873093|DRUG|leucovorin calcium|Given PO or IV 15mg/m2/dose q6h x 3 doses
214397653|NCT00873093|OTHER|laboratory biomarker analysis|Correlative studies
214397654|NCT00873093|DRUG|High Dose MTX|IV 5000 mg/m2/dose Block 2: Day 22
214397655|NCT06529562|RADIATION|Surgery combined with Target-reduction intensity-modulated radiotherapy|in control arm
214397656|NCT06529562|RADIATION|Surgery combined with Dose-reduction intensity-modulated radiotherapy|in experimental arm
214397657|NCT00459511|PROCEDURE|Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin|
214397658|NCT00734890|BIOLOGICAL|bevacizumab|
214397659|NCT00734890|DRUG|vandetanib|
214397660|NCT00734890|OTHER|laboratory biomarker analysis|
214397661|NCT00734890|OTHER|pharmacological study|
214397662|NCT05586074|DRUG|Clifutinib|tablet, oral
214397663|NCT05586074|DRUG|LoDAC|subcutaneous (SC) or intravenous (IV) injection
214397664|NCT05586074|DRUG|Azacitidine|SC or IV
214397665|NCT05586074|DRUG|Decitabine|IV
214397666|NCT05586074|DRUG|Ara-C±IDA|SC and IV
214397667|NCT05586074|DRUG|FLAG-IDA|SC and IV
214397668|NCT06304311|PROCEDURE|Routine Obstetrics care & Lamaze breathing techniques and backside massage|"Lamaze breathing techniques Five breathing patterns were introduced namely- cleansing breathing for relaxation, slow-paced breathing, modified-paced breathing and patterned- paced breathing. These patterns were used during and following contractions. Gentle pushing, and breath-hold during pushing were instructed during the second stage of labor which encouraged descent of the baby.~Backside massage during 2nd stage of labor by the trained massage therapist."
214397669|NCT05307900|OTHER|Confirmation of feeding tube placement in critically ill patients|Confirmation of feeding tube placement using ultrasonography
214397670|NCT00136916|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
214397671|NCT00136916|DRUG|Subcutaneous insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
214397672|NCT01585922|PROCEDURE|noninvasive positive pressure ventilation (NPPV)|Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.
214397673|NCT01585922|PROCEDURE|invasive mechanical ventilation|Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
214397674|NCT03505411|DIETARY_SUPPLEMENT|melatonin supplementation|
214397675|NCT05331820|OTHER|weekly mobile reminder|a weekly reminder will be sent to participants in the intervention group via mobile internet applications
214397676|NCT00620165|DRUG|levetiracetam|Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
214397677|NCT00620165|DRUG|placebo|Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
214397678|NCT02938741|DRUG|Anti-human Thymoglobulin|r-ATG 2.5MG/KG\*4days were used in the conditioning
214397679|NCT02938741|DRUG|Placebo|r-ATG 2.5MG/KG\*4days were not used in the conditioning
214397680|NCT03553940|BIOLOGICAL|Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine|Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.
214397681|NCT03553940|OTHER|Placebo|H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.
214397682|NCT03553940|BIOLOGICAL|Quadrivalent MDCK Inactivated Influenza Vaccine|A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
214397683|NCT02366585|DRUG|Ciclosporin|Ciclosporin gel applied to two periodontal pockets
214397684|NCT04242875|DIAGNOSTIC_TEST|Angle Kappa|Angle kappa will be measured using the OPD III scan.
214503567|NCT06426966|DIETARY_SUPPLEMENT|Gymnema sylvestre|"Gymnema sylvestre also known as meshashringi, is a plant from central and southern India. The leaf extract has been used as a laxative, diuretic, and cough suppressant; Likewise, it has antimicrobial, antihypercholesterolemic, and hepatoprotective activities. It is associated with antioxidant properties . Its adjuvant effect has been reported in the therapy of type 2 diabetes, revealing how its active compounds can influence glucose regulation and improve insulin sensitivity."
214503568|NCT06179875|DRUG|Intervention/Treatment|VRDN-001 10 mg/kg (5 infusions of VRDN-001 10 mg/kg)
214503569|NCT03975400|BEHAVIORAL|search engine advertisement campaign|This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
214503570|NCT05851495|PROCEDURE|physiotherapist-led groups, home-based follow up groups|The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Home-based follow up groups, after the exercise training was given to the patients with a physiotherapist, daily text messages (SMS) were sent to the patients and the patients were reminded to do the exercises
214397685|NCT04242875|OTHER|Visual disturbance questionnaire.|Questionnaire evaluating visual disturbances.
214397686|NCT03913728|OTHER|Drug level blood tests|All information included previously.
214397687|NCT03913728|OTHER|Telephone Interview|All information included previously.
214397688|NCT03289546|BEHAVIORAL|Mindfulness training|"The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'."
214503571|NCT03454256|DEVICE|Virtual Reality|Virtual Reality Rehabilitation System
214503572|NCT02433444|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP's performed at Cedars-Sinai Medical Center.
214397689|NCT03289546|BEHAVIORAL|Aerobic training|Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.
214397690|NCT01449214|PROCEDURE|Ultrasound|Ultrasound-guided technique
214397691|NCT01449214|PROCEDURE|Landmarking|Landmark-guided technique
214397692|NCT04437771|OTHER|Safety and efficacy assessments|Long term disease and gene therapy specific safety evaluations and efficacy assessments
214503573|NCT03924869|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT will be administered once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray \[Gy\] total) over approximately 2 weeks.
214503574|NCT03924869|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
214503575|NCT03924869|DRUG|Placebo|Placebo (normal saline solution) will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
214397693|NCT05825729|DIAGNOSTIC_TEST|Dry suction technique (A)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~\- Dry suction puncture: Once the lesion is located and punctured, the stylet will be completely removed, and a 10 mL syringe with a vacuum of 10 mL will be attached. In each pass, the needle will be advanced and retracted 20-30 times according to the standard technique. The suction will then be closed, and the needle will be removed. The fanning technique will be performed whenever possible."
214503576|NCT02401503|DRUG|Bendamustine|Debulking: Cycles 1-2, d1 \& 2: 70mg/m² i.v.
214503577|NCT02401503|DRUG|GA101|Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg
214503578|NCT02401503|DRUG|ABT-199|Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
214503579|NCT05131685|PROCEDURE|Reduction|closed reduction under conscious sedation followed by casting
214503580|NCT05131685|PROCEDURE|Immobilization|immobilization in cast without reduction
214503581|NCT02542943|DEVICE|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
214503582|NCT02542943|DEVICE|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
214503583|NCT02542943|OTHER|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
214503584|NCT02542943|DRUG|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
214503585|NCT03126604|DIAGNOSTIC_TEST|female sexual function index|evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
215001837|NCT05390541|OTHER|Educational Control|Participants will receive the HIV/STI home testing kit, instructions to mail in the kit, notification when results are ready to check online, treatment from a provider at Kind Clinic for positive results, and referral to Kind Clinic for PrEP. Each session and assessment will occur every 3 days. Session 1: Basic information about STIs. Session 2: HIV and stigma, basic information about HIV, and HIV transmission facts and myths. Session 3: Four stories about different people who are HIV-positive, how HIV was contracted, and one story about a woman who contracted herpes and how to all cope and live healthy lives. Session 4: How to disclose positive STI status. Session 5: Basic information about PrEP, and information on how to correctly use a male condom, female condom, and dental dam.
215001838|NCT07117825|OTHER|AORTIC DISSECTION CT SCAN ANALYSIS|Patients with type A or type B acute aortic dissection, treated either with medical therapy or with endovascular/open surgery in the study period and who underwent subsequent radiological follow-up.
215001839|NCT07118475|BIOLOGICAL|Autologous islet transplantation|"1. EUS-FNB or surgical procurement of pancreatic tissue~2. In vitro culture of adult pancreatic progenitor~3. In vitroinduction of islets~4. islet transplantation beneath the anterior rectus sheath~5. Post-transplant follow-up"
215001840|NCT07116707|BEHAVIORAL|Short Mental Health Literacy Program (SMHLP)|A single 45-minute behavioral health education lesson delivered by homeroom teachers. The session included a slide-based introduction to mental health, a 10-minute animated video about a student experiencing psychological stress, and a worksheet-based reflection activity. Teachers prepared using self-guided materials.
215001841|NCT07118709|DRUG|KC1086|"Part 1: Dose-escalation phase , five dose groups are included: 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg.~Part 2: Dose-expansion phase, 2 to 3 dose levels will be selected for expansion based on the results of the dose escalation phase."
214397694|NCT05825729|DIAGNOSTIC_TEST|Slow-pull technique (B)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms."
214503586|NCT05527808|DRUG|Tislelizumab|200 mg ,intravenous injection ,Q3W 2-4 cycles
214503587|NCT05527808|DRUG|pemetrexed|500 mg/m2,intravenous injection ,Q3W 2-4 cycles
214503588|NCT05527808|DRUG|cis-platemum|60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
214503589|NCT05527808|DRUG|or carboplatin|AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
214503590|NCT02734355|DRUG|Telmisartan 80 mg and amlodipine 5 mg|
214503591|NCT02734355|DRUG|Placebo (for telmisartan and amlodipine)|Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
214503592|NCT03315299|DRUG|ASP2215|Subject will take ASP2215 by mouth daily for 28 day cycles
214503593|NCT04976764|OTHER||
214503594|NCT05097105|DEVICE|MRI|MRI sequences: TI. T2 and diffusion weighted
214503595|NCT06153745|DEVICE|Tecnis Eyhance ICB00 intraocular lens (Johnson&Johnson Vision, Santa Ana, California USA)|pediatric cataract surgery
214503596|NCT04814108|DRUG|ZN-c3|ZN-c3 is an investigational drug.
214397695|NCT05825729|DIAGNOSTIC_TEST|Wet suction technique (C)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~\- Wet suction technique: Prior to puncture, the stylet should be removed and the needle should be flushed with 1-2 ml of physiological saline and a 10 ml vacuum syringe with 3-5 ml of saline should be attached. In each pass, the needle should be moved forward and backward 20-30 times. Aspiration should be opened as the needle advances and closed as it is withdrawn. Afterwards, the aspiration should be closed and the needle should be removed. The fanning technique should be performed whenever possible."
214397696|NCT04172987|DRUG|Tirzepatide|Administered SC
214397697|NCT04172987|DRUG|EE/NGM|Combination oral contraceptive administered orally
214397698|NCT04179461|DRUG|Cholecalciferol|Oral administration
214397699|NCT04179461|DRUG|antihistamine|Oral administration
214397700|NCT04179461|DRUG|Azithromycin|Oral administration
214397701|NCT04179461|DRUG|emollient cream|Topical
214397702|NCT04179461|DRUG|Fluticasone Propionate|Nasal spray
214397703|NCT04179461|DRUG|Asthma Controller Medication|Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
214397704|NCT05676073|DRUG|SHEN26 dose 1|Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
214397705|NCT05676073|DRUG|SHEN26 dose 2|Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
215001842|NCT07118059|DIETARY_SUPPLEMENT|Omega-3 (EPA+DHA)|In this study omega-3 will be the real thing mega omega supreme capsule, it will be used as an adjunct therapy with TB treatment in the intensive phase of treatment. Participant will receive x3, 1g capsules which will provide approximately 2g of EPA and DHA
214397706|NCT05676073|DRUG|SHEN26 placebo|Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
214397707|NCT01944943|DRUG|Vismodegib|150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
214503597|NCT05731440|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.
214503598|NCT03848143|DRUG|onabotulinum toxin A|Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
214503599|NCT06242535|BIOLOGICAL|GLY-LOW|This supplement is available for over-the-counter purchase. Each capsule is a combination of vitamins and natural products: Vitamin B1 (100mg); Vitamin B6 (50mg); Niacin (200mg); Alpha Lipoic Acid (150mg); and Piperine (15mg). The supplement, GLY-LOW, is FDA approved for use as a dietary supplement (IND 162006)
214503600|NCT06227130|BEHAVIORAL|MindYou|A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work.
214503601|NCT04190550|DRUG|Cytarabine|Given IV
214503602|NCT04190550|DRUG|Idarubicin Hydrochloride|Given IV
214503603|NCT04190550|DRUG|Navtemadlin|Given PO
214503604|NCT06666543|OTHER|Questionary|"The questionnaire will address the following topics for each child who is not infected with HIV and was born to an infected mother at the time of birth:~* Pregnancy progression~* Immediate postpartum course~* Medical development of the child from 0 to 3 years~* Medical development of the child from 3 to a maximum of 15 years"
215001843|NCT07118059|DIETARY_SUPPLEMENT|Placebo|This group will receive the placebo, which will be 3 x 1g capsules of high linoleic sunflower oil, the sunflower capsules have been encapsulated to match the dimension of the omega 3 supplement. The capsules will also be given as and adjunct to TB treatment of the intensive phase of TB treatment
214503605|NCT02223923|DRUG|AZD6738|
214503606|NCT02223923|RADIATION|Palliative radiotherapy|
214503607|NCT05728840|OTHER|Immersive virtual reality gamified cognitive activities|This intervention will include 20 sessions of training with the experimental rehabilitation program using immersive VR cognitive gamified activities, in addition to the standard of care.
215001844|NCT05006508|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
214503608|NCT05728840|OTHER|Double neuropsychological standard activities|This intervention will include 20 sessions of training using a standard neuropsychological rehabilitation program, in addition to the standard of care.
214503609|NCT00266448|DRUG|Chlorhexidine solution 4%|
214397708|NCT02509351|DRUG|misoprostol|400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section
214503610|NCT00644514|BIOLOGICAL|Endotoxin - lipopolysaccharide (LPS)|Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
214397709|NCT02509351|DRUG|placeboo|women will recive 2 identical tablets as placeboo
214397710|NCT02011308|DEVICE|Green light Laser|Laser vs TURP
214397711|NCT02011308|DEVICE|Transurethral Resection of the Prostate (TURP)|Laser vs TURP
214397712|NCT01627847|DRUG|Ropinirole|
214397713|NCT01198925|DRUG|piperacillin continuous infusion|piperacillin continuous infusion
214397714|NCT01198925|DRUG|piperacillin extended infusion|piperacillin extended infusion
214397715|NCT06247085|DRUG|Pegtibatinase|Full Target Dose of pegtibatinase BIW
214397716|NCT06247085|OTHER|Placebo|volume-matched saline SC BIW
214397717|NCT01013220|OTHER|Depression Product Detailing|"1. two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits~2. technical assistance in purchasing high quality depression management products"
214397718|NCT01013220|OTHER|Depression HEDIS detailing|"1. academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition~2. technical assistance"
214397719|NCT03750773|DRUG|Gabapentin 600mg|Subject is given Gabapentin 600mg every 8 hours x 48 hours postoperatively for pain control.
214397720|NCT03750773|DRUG|Placebo oral capsule|Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
214397721|NCT00632528|DRUG|MEOPA|Administration of MEOPA gaz during postoperative physical therapy
214397722|NCT00632528|DRUG|Medicinal air|Administration of medical air during postoperative physical therapy
214397723|NCT01019356|DRUG|Rosiglitazone|4 mg twice daily for 8 weeks orally
214397724|NCT01019356|DRUG|Acarbose|100 mg three times daily for 8 weeks orally
214397725|NCT04598880|DRUG|Polyethylene glycol + ascorbate|Pleinvue® is administered orally in 2 doses (3 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose is administered at 9 pm on the day before intervention (sachet 1: MACROGOL 3350 100 g + SODIUM SULFATE ANHYDROUS 9 g + SODIUM CHLORIDE 2 g + POTASSIUM CHLORIDE 1 g). Second dose is administered 5 hours before intervention and it is composed by 2 sachets (sachet A: MACROGOL 3350 40 g + SODIUM CHLORIDE 3,2 g + POTASSIUM CHLORIDE 1,2 g; sachet B: SODIUM ASCORBATE 48,11 g + ASCORBIC ACID 7,54 g).
214397726|NCT04598880|DRUG|Sodium picosulfate + magnesium citrate|Citrafleet® is administered orally in 2 doses (2 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose (sachet 1) is administered at 9 pm on the day before intervention. Second dose (sachet 2) is administered 5 hours before intervention. Sachets 1 and 2 have the same composition: SODIUM PICOSULFATE 10 mg + MAGNESIUM OXIDE 3,5 g + CITRIC ACID 10,97 g.
214397727|NCT02420275|OTHER|placebo|THIS GROUP WILL RECEIVE NO BRIGHT LIGHT
214397728|NCT02420275|DEVICE|"Luminette,Lucimed Belgium"|THIS GROUP WILL RECEIVE BLEU LIGHT ENRICHIDED IN WITHE BRIGHT LIGHT
214397729|NCT03613779|COMBINATION_PRODUCT|LUS-guided therapy|Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment. If no congestion (less than 3 B-lines), low dose (0-40mg PO/day furosemide) will be prescribed until next follow up re-assessment
214397730|NCT03613779|OTHER|Standard of Care|Standard of care will be provided.
214397731|NCT00615082|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
214397732|NCT00615082|BEHAVIORAL|Caregiver Education & Social Support|An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
214397733|NCT00892268|PROCEDURE|acupuncture therapy|Undergo acupuncture
214397734|NCT00892268|PROCEDURE|pain therapy|Receive standard care
214397735|NCT00043095|DRUG|gemcitabine hydrochloride|
214397736|NCT00043095|DRUG|ixabepilone|
214397737|NCT00487786|DRUG|OGX-427|OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn
214503611|NCT05510310|PROCEDURE|Breast stimulation|By breast pump
214503612|NCT05510310|BIOLOGICAL|Oxytocin|Oxytocin will be administered intravenously and titrated
214503613|NCT06236802|DEVICE|ProVee device|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
214503614|NCT03685071|OTHER|role of CBC as prognostic tool in sepsis.|"Our study will be conducted on children who admitted to PICU in Assuit University Hospital .CBC parameters as TLC , platelet count , and Hb will be evaluated at time of admission , another CBC will be done at 5th day and another one at day of discharge or last one before death.~* patients will be classified into three groups according to the outcome(discharge, mortality and has morbidity sequel.)~* correlation between the outcome and CBC will be done."
215001845|NCT06923423|BEHAVIORAL|Group Cognitive Processing Therapy (CPT)|Participants in CPT group therapy will learn about trauma and how to change upsetting thoughts related to it. Participants will attend up to a total of 12 sessions held 1-2x/week for 90 minutes. No more than 10 participants will be in a group. In this study, CPT provided is a version that was adapted for prisons.
214397738|NCT00487786|DRUG|Docetaxel|injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 \& 7 only, together with appropriate dose of OGX-427 until withdrawn from study
214397739|NCT06413849|OTHER|Telephone coached graphic narrative bibliotherapy|Eight weekly sessions of telephone coached graphic narrative bibliotherapy
214397740|NCT06413849|OTHER|Control group|Reading educational booklet
214397741|NCT02894320|BEHAVIORAL|Behavioral observation|
214397742|NCT01770990|BEHAVIORAL|Tel-PT including mail|Patients receive telephone-based psychotherapy and one letter after each telephone session.
214397743|NCT01770990|BEHAVIORAL|Tel-PT without mail|Patients receive telephone-based psychotherapy without additional letters.
214397744|NCT02836327|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging
214397745|NCT02076685|DRUG|isoniazid|dose adjustment according to the pharmacogenomic results
214503615|NCT00910832|DRUG|Eductyl suppository|one suppository every morning during 21 days
214503616|NCT00910832|DRUG|Placebo suppository|placebo suppository every morning during 21 days
214397746|NCT05409196|BIOLOGICAL|ShigETEC live, attenuated, oral vaccine|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
214397747|NCT05409196|DRUG|Placebo|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
214397748|NCT01226628|BIOLOGICAL|CNTO 2476|
214397749|NCT01226628|PROCEDURE|iTrack Model 275 micro catheter|CNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula.
214503617|NCT06521619|PROCEDURE|Femoral and sciatic nerve blocks|Patients receiving Adductor canal block and infiltration of posterior capsule of knee
214503618|NCT02335554|BEHAVIORAL|MoodHacker|Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
214503619|NCT02335554|BEHAVIORAL|Alternative Care|Online information about depression from government and other trusted sources to educate users about depression.
214397750|NCT01435057|PROCEDURE|exercise training|comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
214397751|NCT01354275|OTHER|To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle|150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
214397752|NCT01354275|OTHER|GnRH Antagonist|GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
214397753|NCT06316505|BEHAVIORAL|Oral hygiene motivation with individual oral photograps|Oral photograps was taken at control sessions.
214397754|NCT05229172|DEVICE|Volume Targeted Ventilation|There is no study specific intervention planned. Procedures will be conducted according to standard of care of each participating hospital and the instructions for use of the study device.
214397755|NCT02425475|DEVICE|LIMES|All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
214397756|NCT01469793|DRUG|DMOT4039A|DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.
214397757|NCT00579540|DIETARY_SUPPLEMENT|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
214397758|NCT00579540|DIETARY_SUPPLEMENT|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
214397759|NCT00579540|DIETARY_SUPPLEMENT|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
214397760|NCT05748782|OTHER|Baska Mask|The Baska mask (Logikal Health Products PTY Ltd., Morisset, NSW, Australia) is a supraglottic airway device introduced in 2012 with many innovations that might be expected to overcome these derangements.
214503620|NCT04840433|DEVICE|MACE|Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
214503621|NCT00893555|DRUG|voriconazole|TDM (through level of 2-5mg/L).
214503622|NCT00893555|DRUG|voriconazole (dosing according to the SPC)|No serum concentrations are determined
214397761|NCT05748782|DEVICE|Endotracheal tube|BASKA Mask
214397762|NCT05683522|OTHER|Sub-omohyoidal Plane Block|The ultrasound guided sub-omohyoidal plane block will be performed. Patients in this group will be given 15 mL of local anesthetic into the interfascial plane under the omohyoid muscle. This block will be performed preoperatively.
214397763|NCT05683522|OTHER|Cervical Plexus Block|A cervical plexus block will be applied by applying 10 mL of local anesthetic under ultrasound guidance. This block will be done before the surgery.
214397764|NCT05683522|OTHER|Costoclavicular Block|Costoclavicular brachial plexus block will be applied by administering 20 mL of local anesthetic under ultrasound guidance. This block will be performed preoperatively.
214397765|NCT04827290|BEHAVIORAL|Low-AGE diet|Low-AGE diet during 24 months
214397766|NCT04827290|BEHAVIORAL|High-AGE diet|High-AGE diet during 24 months
214503623|NCT05753176|BEHAVIORAL|Online 1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained facilitators (i.e., psychotherapists, social workers, nurses, and/or a psychiatrist) consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. Participants are also given a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
215001846|NCT06923423|BEHAVIORAL|Control Group Individual trauma focused self-help via workbook|The self-help therapy is a therapy that people do on their own using a workbook. By reading and doing practice assignments in the workbook, people can learn skills to recover from trauma.
215001847|NCT07103668|DRUG|CAR T cells|better PFS/OS data comparing to the other studies.
215001848|NCT07103668|DRUG|Control|Chemo therapy by PI options.
215001849|NCT06231511|DEVICE|Hip flexion soft exosuit|Participants will utilize a Wyss designed hip flexion soft exosuit. This device has a small rope winch at the front of the hip connected to a functional textile waistband and thigh band. It applies an assistive torque in response to wearable sensor measurements.
214397767|NCT00491725|DRUG|repaglinide|
214397768|NCT00491725|DRUG|metformin|
214397769|NCT04600401|OTHER|Mentis Plus+ (Experimental Group)|"Each factor can be considered a module, so it is a modular program. So, each module has 3 sessions to be carried out in full. It is a systematic program, so the order of the sessions is regulated by the letters A, B and C for each module. The modules to be worked on correspond to the low-level or languising factors identified after the application of the positive mental health questionnaire (PMHQ). After the application of the PMHQ, people are grouped with the same module to work."
214397770|NCT05441358|PROCEDURE|Open Heart Surgery|Blood collection at 4 timepoints (prior to anesthesia induction, immediately post-protamine, 1-2 hours post protamine, and up to 48 hours post-surgical completion) to assess platelet function.
214397771|NCT02654795|RADIATION|computed tomography|CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
214503624|NCT04491292|OTHER|Questionnaire Administration|Complete questionnaires
214397772|NCT05810675|BEHAVIORAL|Telehealth Early Intervention Program (TEIP)|The Telehealth Early Intervention Program (TEIP) that will be carried out by parents at home when interact with their children; and to train parents in delivering developmental and behavioral techniques to their children. The participating families will be randomized in parallel to treatment and comparison groups for teaching the knowledge and techniques: (1) Treatment group: providing the training of TEIP for parents via telehealth modalities as they learn critical skills with their child with the goal of increasing multidimensional child developments. Intervention provider will provide the training for parent-child dyad interaction to work with parents to implement these strategies at home environment.
214397773|NCT06058143|PROCEDURE|CLIF-LP|CLIF-LP surgery method was applied
214397774|NCT06058143|PROCEDURE|TLIF|TLIF surgery method was applied
214397775|NCT02658292|DRUG|Naftifine hydrochloride foam, 3%|Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
214397776|NCT02658292|DRUG|Vehicle|Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
214397777|NCT05270382|OTHER|cetylpyridinium chloride|The mouthwash is used to see the effects on wound healing and the oral microbiome.
215001850|NCT06231511|DEVICE|ReWalk ReStore soft exosuit|Participants will utilize the ReWalk ReStore ankle soft exosuit. This device provides dynamic plantarflexion and dorsiflexion during walking intended to restore paretic limb function resulting in improved gait symmetry, reduced energy cost of walking and improved stability. The exosuits consists of a body-worn actuation unit containing motors, gears, and pulleys that when powered generate forces that are transmitted via Bowden cables to functional textiles anchored proximal and distal to a joint. This actuation occurs in response to signals from embedded wearable sensors.
215001851|NCT06231511|OTHER|Conventional physical therapy|Participants will complete conventional physical therapy without use of exosuits during the course of their inpatient rehabilitation stay.
215001852|NCT07119866|OTHER|OXYGEN RESERVE INDEX|Noted for each patient.
215001853|NCT07120126|DEVICE|EDDY Sonic Activation|Sonic activation was performed using the EDDY device with 2.5% NaOCl and 17% EDTA solutions during final irrigation, following root canal preparation.
214397778|NCT03334760|OTHER|Danish National Birth Cohort|DNBC is a nationwide cohort study of pregnant women and their offspring. The women were enrolled early during pregnancy between 1996 and 2002. They provided information on exposures during and after pregnancy by means of four computer-assisted telephone interviews in gestational weeks 12 and 30 and post-partum when the child was 6 and 18 months old.
214397779|NCT03734159|DRUG|Ropivacaine|Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
214397780|NCT03734159|DRUG|sodium chloride 0.9%|Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
214397781|NCT05353738|BIOLOGICAL|Blood sample for research of anti-xoprs netralizing anti spike|"The evaluation of the ex vivo efficacy of the Moderna vaccine by the search for anti Spike AcN at 6,24, 40 and 52 or 64 weeks after the second injection of the vaccine.~The effectiveness of vaccination of CANNEMUSS patients will be evaluated by comparing the antibodies anti-S neutralizers from patients in the CANNEMUSS study to those from patients whose sample was carried out before the pandemic (negative control group) and those of patients infected with the omicron virus (positive control group)."
214397782|NCT05353738|OTHER|Questionnaire|Evaluation of vaccine efficacy in real life by filling out questionnaires
214397783|NCT04055285|PROCEDURE|Sympathetic Renal Denervation|Catheter-based sympathetic renal denervation (RDN) using radiofrequency, ultrasound, or perivascular injection of neurotoxic agents such as alcohol has been introduced as a minimally invasive alternative treatment option for patients with resistant hypertension. RDN consists of endovascular catalysis of the kidney sympathetic nerves running in the wall of the renal arteries.
214397784|NCT04055285|DEVICE|Implantable Loop Recorder|Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
215001854|NCT07120126|PROCEDURE|Conventional Syringe Irrigation|Final irrigation was performed using syringe irrigation with 2.5% NaOCl and 17% EDTA solutions, without any activation.
215001855|NCT07119918|DRUG|Recaticimab|Recaticimab 300mg subcutaneous Q8W for 1 year.
215001856|NCT07119918|DRUG|Placebo|Matched placebo subcutaneous Q8W for 1 year.
214397785|NCT02168920|DRUG|2 mg/day|Once daily for 10 weeks
215001857|NCT07120984|BIOLOGICAL|L19TNF|1 cycle of TNF before resection and 6 cycles after surgery
215001858|NCT07120984|BIOLOGICAL|L19TNF and TMZ|6 cycles of 28 days with L19TNF and TMZ
215095105|NCT03584555|PROCEDURE|SMILE using 120μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
214397786|NCT02168920|DRUG|3 mg/day|Once daily for 10 weeks
214397787|NCT02168920|DRUG|6 mg/day|Once daily for 10 weeks
214397788|NCT02168920|DRUG|Placebo (0 mg/day)|Once daily for 10 weeks
214397789|NCT06139263|DEVICE|a percussion massage gun (Compex Fix 2.0)|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the trapezius, levator scapula and cervical paravertebral muscles with a percussion massage gun (Compex Fix 2.0) along the origo-insersio line for 3 minutes for each muscle group. Vibration application will be made with the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
214503625|NCT06979323|BIOLOGICAL|Depemokimab|Depemokimab will be administered.
215001859|NCT07120984|BIOLOGICAL|L19TNF and CCNU|6 cycles of 6 weeks of L19TNF and CCNU every 6 weeks
215001860|NCT07120984|BIOLOGICAL|L19TNF monotherapy|6 cycles of 6 weeks with L19TNF
215001861|NCT07120984|BIOLOGICAL|L19TNF and TMZ in recurrent astrocytoma|6 cycles of 28 days with L19TNF (D1, D3, D5) and temozolomide chemotherapy TMZ (D1-5).
214397790|NCT06139263|OTHER|conventional treatment program|In the conventional treatment program, heat will be applied to the neck area for 20 minutes and TENS (100 Hz) will be applied to the painful area. Additionally, patients will be given joint range of motion (ROM) exercises under the supervision of a physiotherapist. Patients will be asked to perform ROM exercises in 2 sets of 10 repetitions, holding for 2 seconds at the end point in all directions. As a strengthening exercise, isometric exercises will be given in the flexion extension, right and left lateral flexion directions by waiting for 6 seconds at the end point. Isometric exercises will be performed in 2 sets of 10 repetitions with 1 minute rest between sets.
214397791|NCT00129675|DRUG|[123I]ß CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
214397792|NCT04333173|PROCEDURE|endovascular procedure|Endovascular therapies for erectile dysfunction
214397793|NCT05515029|COMBINATION_PRODUCT|GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor|Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28
214397794|NCT03285711|DRUG|Filgotinib|200 mg tablet administered orally once daily
215001862|NCT07120984|BIOLOGICAL|L19TNF and CCNU in recurrent astrocytoma|6 cycles of 6 weeks of L19TNF (D1, D3, D5, D22, D24 and D26) and CCNU (D1) every 6 weeks
215001863|NCT07120984|BIOLOGICAL|L19TNF monothery in recurrent oligodendroglioma|6 cycles of 6 weeks with L19TNF
215001864|NCT07119814|DEVICE|Conventional Separators placement|Safe T separators and conventional elastomeric separators will be placed in patients of fixed orthodontic treatment.
215001865|NCT07119814|DEVICE|Safe T separator|Safe T separators will be placed in patients of fixed orthodontic treatment
215001866|NCT07119450|DRUG|GZR18 injection、[14C]GZR18 injection|Participants will get a single dose of \[14C\]GZR18 injection
215001867|NCT07121738|BEHAVIORAL|Healthy Eating Active Lifestyle (HEAL): Gyn Cancer Program|Evidence-based lifestyle medicine program for cancer survivors
215001868|NCT07120308|DRUG|ZKY001 eye drops|Administer to eyes
215001869|NCT07120308|DRUG|Vehicle (placebo)|Administer to eyes
215001870|NCT07120646|OTHER|Questionnaire, actigraphy measurement and sleep diary|Baseline questionnaires (measuring socio-demographic and health-related information, as well as most outcome measures), followed by 2 weeks of actigraphy measurement and daily sleep diary.
215001871|NCT07121699|DRUG|Inotrope|Hypotensive attacks with MAP below 55 mmHg or prolonged duration (2 minutes or more) will be treated with ephedrine 0.1 mg/kg.
215001872|NCT07120815|DRUG|Metformin 1500 mg daily|metformin 500mg tablets, 3 times per day
215001873|NCT07120815|DRUG|Metformin 2250 mg daily|Metformin 750mg, 3 times daily
215001874|NCT07117929|DEVICE|Active PEMF|PEMF: 1.5mT, 10Hz, 10 minutes
214397795|NCT03285711|DRUG|Lanraplenib|30 mg tablet administered orally once daily
214397796|NCT03285711|DRUG|Filgotinib placebo|Tablet administered orally once daily
214397797|NCT03285711|DRUG|Lanraplenib placebo|Tablet administered orally once daily
214397798|NCT00865644|DRUG|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
214397799|NCT00085059|DRUG|boronophenylalanine-fructose complex|
214397800|NCT02935855|DRUG|Dabigatran|
214397801|NCT02935855|DRUG|Apixaban|
214397802|NCT02935855|DRUG|Rivaroxaban|
214397803|NCT02935855|DRUG|Edoxaban|
214397804|NCT02935855|DRUG|Warfarin|
214397805|NCT02935855|DRUG|Acenocumarole|
214397806|NCT02053194|BEHAVIORAL|Pharmacist-led educational intervention|1\) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
214397807|NCT00122161|BEHAVIORAL|ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers|
214397808|NCT00122161|BEHAVIORAL|Profiling performance|
214397809|NCT01607411|DRUG|Fluoride|Fluoride Toothpaste
215001875|NCT07117929|DEVICE|Sham PEMF|PEMF 0mT, 0Hz, 10 minutes
215001876|NCT07117929|OTHER|Exercise|Standardised home exercise protocol
215095106|NCT03584555|PROCEDURE|SMILE using 140μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
214397810|NCT01607411|DRUG|Placebo|Fluoride free toothpaste
214397811|NCT02431533|DIETARY_SUPPLEMENT|PX0612|PX0612 is a probiotic contained in a veggie capsule.
214397812|NCT02431533|DIETARY_SUPPLEMENT|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
215001877|NCT07120932|BEHAVIORAL|Effects of Emotional Freedom Techniques (EFT)|Effects of Emotional Freedom Techniques (EFT)
215001878|NCT07116408|DRUG|Lidocaine (drug)|Tx 360/lidocaine
215001879|NCT07116408|DEVICE|Tx 360|Tx 360 device
215001880|NCT07121400|PROCEDURE|Interactive e-learning-group|The Interactive-E-learning group had full access to a pedagogical internet platform with online documents; national experts' recommendations on the management of diabetic patients in anesthesia, slide presentation lectures on the topic by local university teachers, and, the possibility to contact a virtual mentor (anaesthesiologist of our department) by email for interactive discussion or questions about the topic.
215001881|NCT07122908|DEVICE|repetitive transcranial magnetic stimulation|10Hz stimulation group will receive 1600 pulses of stimulation in a single session
215001882|NCT07122310|DEVICE|1064-nm Fractional Picosecond Laser (PicoWay)|Intervention Name: 1064-nm Fractional Picosecond Laser (PicoWay) Participants in this group received full-face treatments using a PicoWay® laser system (Candela, Wayland, MA, USA) equipped with a 1064-nm RESOLVE fractional handpiece. Treatment parameters included a 6 mm spot size, 6 Hz repetition rate, 450 ps pulse duration, and energy settings ranging from 1.5 to 2.3 mJ per microbeam. Each session consisted of 2-3 passes (approximately 2000-4000 pulses), adjusted based on individual response. Three sessions were delivered at 4-6-week intervals. Cold compresses were applied for 20 minutes immediately post-treatment.
215001883|NCT07122310|DEVICE|Intense Pulsed Light Therapy (M22 IPL System)|"Intervention Name: Intense Pulsed Light Therapy (M22 IPL System)~Intervention Description:~Participants in this group underwent full-face treatments using an M22® IPL system (Lumenis, Yokneam, Israel) with a 560 nm cutoff filter. Treatment parameters included a pulse duration of 3.5-4 ms, pulse delay of 25-30 ms, and fluence of 12-18 J/cm², adjusted based on individual response. Each treatment involved approximately 40-60 pulses. Three sessions were performed at 4-6-week intervals. A layer of medical ultrasound gel was applied before treatment and maintained for 15-20 minutes post-treatment."
215001884|NCT07120191|DEVICE|post op communication software|MyConnect Post Op is a communication tool that utilizes Technology Assisted Conversation to aid in the recovery of total knee and hip replacement patients
215001885|NCT07120282|DRUG|Tislelizumab 400 mg iv, q6w, for up to 1 year for pts in intervention group|Tislelizumab 400 mg iv, q6w, for up to 1 year; patients are permitted to receive concurrent adjuvant platinum-based doublet chemotherapy (q3w, up to 4 cycles) starting from the first dose of tislelizumab; during concurrent chemotherapy, a tislelizumab dosage of 200 mg iv, q3w is allowed.
214503626|NCT06977828|DRUG|tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy|After receiving 4 cycles of tislelizumab combined with anlotinib and platinum-based doublet chemotherapy, the subjects will be evaluated by a multidisciplinary team (MDT) to determine whether to proceed with radical surgical resection. The surgery will be performed within 3 to 7 weeks after the last neoadjuvant treatment. Postoperatively, patients will be divided into two subgroups based on the pathological results: For patients with postoperative pathological pCR, tislelizumab monotherapy will be used for maintenance treatment; For patients with postoperative pathological non-pCR, tislelizumab combined with anlotinib will be used for maintenance treatment. Both groups will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor therapy, death, or other situations specified in the protocol that require treatment cessation, whichever occurs first. The maximum treatment duration is 12 months
214503627|NCT05250206|OTHER|Myopia control lens|Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.
214503628|NCT04267588|OTHER|Navio Mobile App|Participants will use the Navio Mobile App to track participants' pain and pain treatment
214503629|NCT04986475|OTHER|Music Therapy|Music therapy was performed by listening to the ney sound during the non-stress test procedure.
215001886|NCT07119827|DIAGNOSTIC_TEST|Motor, cognitive and psychological assessment|Participants evaluated at T0 (Initial assessment upon admission to the rehabilitation facility), T1 (at discharge from the inpatient rehabilitation program, as long as at least 30 days have passed since the initial assessment (T0), T2 (at 12 months from the event for patients with stroke, and at 18 months from the event for patients with sABI).
215001889|NCT07122544|BEHAVIORAL|Therapeutic stay in subterranean sanatorium chambers (microclimate therapy)|"Characteristics of the underground environment in the Wieliczka sanatorium chambers:~Stable climatic conditions: relative humidity ranging from 60-75%, temperature between 12.9-14.5°C; High chemical and biological air purity; Mineral content in the air: 2.7-8.1 mg/m³, consisting mainly of chloride, sodium, potassium, calcium, and fluoride ions; Air ionization: 1,200-4,700 aeroions/cm³ of air. Elevated atmospheric pressure: increased by approximately 16-20 mmHg compared to surface conditions."
215001890|NCT07122544|BEHAVIORAL|Breathing exercises|30 minutes daily. Breathing exercises will include active respiratory exercises, drainage and effective coughing techniques, resistance training of the respiratory muscles, chest mobilization and relaxation exercises, breathing through pursed lips, as well as short and prolonged exhalation exercises.
215001891|NCT07122544|BEHAVIORAL|General fitness exercises|30 minutes daily. General conditioning exercises will incorporate components aimed at improving overall aerobic capacity (e.g., walking-based activities, dance routines, step exercises), flexibility and coordination (e.g., stretching and balance exercises), and strength (e.g., exercises using resistance bands or dumbbells). The training will be conducted in interval, circuit, and free-form formats. Resistance levels will be individually adjusted to the patient's capacity.
215001892|NCT07122544|BEHAVIORAL|Relaxation training|30 minutes, once during the entire cycle. Relaxation training will include rest in a seated position, with dimmed lighting and calming music.
215001893|NCT07122544|BEHAVIORAL|Health education|"Educational materials in printed form for distribution covering the following topics:~COPD - information about the disease;~Breathing exercises and bronchial hygiene;~Benefits of physical activity, including examples of exercises that can be performed at home."
215001894|NCT07123974|BEHAVIORAL|Dialectical Behaviour Therapy for Post-Traumatic Stress Disorder (DBT-PTSD)|DBT-PTSD is 45-week individual psychotherapy (DBT-PTSD) designed to treat adults presenting with both borderline personality disorder (BPD) and complex post-traumatic stress disorder (C-PTSD). The intervention integrates dialectical behavior therapy (DBT) skills, trauma-focused exposure-based interventions, and strategies from compassion-focused therapy and acceptance and commitment therapy. All participants will receive the full sequence of the therapy in outpatient settings, following the structured treatment protocol.
215001895|NCT07122492|BEHAVIORAL|FoRtitude 2.0|A website and an interactive text-messaging feature
215001896|NCT07122492|BEHAVIORAL|Attention Control|Access to the non-interactive study intervention website that lists links to help you access websites that provide information to read and resources for breast cancer survivors.
215095107|NCT04596085|DIETARY_SUPPLEMENT|Investigational Product - ViraCide|Viracide
215095108|NCT04596085|OTHER|Placebo - Starch Powder Soft gels|Starch Powder Soft gels
215095109|NCT02940483|DRUG|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
215095110|NCT06459882|BEHAVIORAL|progressive relaxation exercises|Patients in the intervention group received 30-minute progressive relaxation exercises for 6 weeks
214503630|NCT06854640|DRUG|BAY3389934|Solution for IV infusion
214503631|NCT05519852|BEHAVIORAL|Pilates training|the pilates group (20 patients) will be trained 30 minutes of pilates exercise (before it there will be warm up period and after it there will be cooldown period , each will be 5 minutes). the pilates will be repeated five sessions per the week for 3 months
214503632|NCT06587919|DEVICE|Neurofeedback|EEG-based neurofeedback, administered with the Neuroguide software.
214503633|NCT04644575|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:Solution for Injection Route of administration: Intravenous
214503634|NCT06585865|BEHAVIORAL|Resistance training|After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.
214503635|NCT06585865|DIETARY_SUPPLEMENT|Resveratrol 500 mg oral once daily.|Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
214503636|NCT06585865|DIETARY_SUPPLEMENT|Placebo|Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
214503637|NCT06592794|BIOLOGICAL|mRNA-1403|Intramuscular (IM) injection.
215001897|NCT07121920|DEVICE|Confocal Laser Endomicroscopy|"Patients will undergo Esophagogastroduodenoscopy (EGD) and/or Ileocolonoscopy (IC) EGD with CLE as per standard of care. Each participant will have 3-4 mucosal biopsies taken from the terminal ileum, rectosigmoid and cecum, ideally from the most affected areas of accessible segment.~Ex vivo staining of biopsied tissue will be expanded to include FITC-labeled antibodies to cytokines IL12 and IL12/IL23 and to cytokine receptors IL12R and IL23R and possibly other cytokines, receptors and adhesion molecules. All biopsies tested for membrane bound antibodies will be done using CLE technology with artificial intelligence (AI). The cellular landscape will be characterized by surveying surface markers using bar-coded antibodies and performing gene expression profiling on every cell within inflamed tissue of patients with IBD.~We will develop algorithm using AI to predict responders versus non-responders and to further subclassify IBD patients using phenotype data."
215001898|NCT07122414|DRUG|FL115|FL115 single agent dose escalation,
215001899|NCT07122414|DRUG|FL115+BCG|FL115 in combination with BCG
215001900|NCT07123701|DRUG|Tanshinone capsules|Tanshinone capsules were used in this intervention for COVID-19 patients
215001901|NCT07121790|DEVICE|Implant Mg-based RemeOs™ drillpins|"This is a first-in-human clinical feasibility study of a novel absorbable magnesium-zinc-calcium alloy DrillPin (RemeOs™) for internal fixation during surgical correction of hammertoe deformities in adult patients. The implant is investigational, not CE-marked, and represents an alternative to conventional stainless steel or titanium K-wires commonly used in toe correction surgery.~The RemeOs™ DrillPin is designed to provide mechanical stability during osteotomy healing and gradually resorbs over 2-3 years, potentially eliminating the need for secondary implant removal.~The study focuses on evaluating safety, performance, and implant resorption using standardized clinical and radiographic assessments. The DrillPin is made from the same magnesium alloy (ZX00) as the CE-marked RemeOs™ Screw, which has demonstrated clinical safety and performance in prior applications."
215001902|NCT07123779|BIOLOGICAL|HS235|Subcutaneous Injection
215095111|NCT01146964|PROCEDURE|MSSICS|Manual super small incision cataract surgery
215095112|NCT01146964|PROCEDURE|Phacoemulsification|cataract surgery with Phacoemulsification
214397813|NCT06520033|DEVICE|humanoid robot|"The humanoid robot will execute an educational hydration plan that will be integrated into the usual dynamics of the residence. In order to increase the fluid intake of the residents, stimulation activities will be proposed that will be carried out by the robot such as reminders, interactive activities and positive reinforcement. It will also allow the daily recording fluid intake of each residents.~This intervention will last two months."
214397814|NCT06520033|OTHER|Usual care|The center's usual hydration plan
214397815|NCT03208309|DRUG|Diacerein|
214397816|NCT03208309|DRUG|Placebo|
214397817|NCT00281944|DRUG|oxaliplatin|Given IV
214503638|NCT06592794|BIOLOGICAL|Placebo|0.9% sodium chloride solution by IM injection.
215001903|NCT07123779|OTHER|Placebo|Subcutaneous Injection
215095113|NCT05340803|RADIATION|Ultrasonograghic optic nerve sheath diameter US-ONSD|To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD
215095114|NCT05340803|DRUG|midazolam|midazolam
215095115|NCT05340803|DRUG|dexmedetomidine|dexmedetomidine
215001904|NCT07123935|DEVICE|RenalGuard® Therapy|RenalGuard Therapy®
215001905|NCT07123935|OTHER|Standard of Care (SOC)|Standard of care
215001906|NCT07123376|DRUG|HRS-9231|HRS-9231 was administered intravenously;
214397818|NCT00281944|DRUG|fluorouracil|Given IV
214397819|NCT00281944|DRUG|leucovorin calcium|Given IV
214397820|NCT00281944|OTHER|pharmacological study|Correlative studies
214397821|NCT00281944|PROCEDURE|positron emission tomography|Undergo PET scan
214397822|NCT00281944|PROCEDURE|computed tomography|Undergo PET/CT scan
214397823|NCT02107443|BEHAVIORAL|Geriatric Assessment Summary|Complete summary of results from the Geriatric Assessment
214397824|NCT02107443|BEHAVIORAL|Geriatric Assessment Targeted Recommendations|"Recommendations are made based on areas patients were impaired in on the Geriatric Assessment. They include referrals, tests, medication review, instructions, and support services. The choice of which recommendation to implement is left to the discretion of the physician.~Treatment modifications"
215001907|NCT07123376|DRUG|Placebo|Placebo was administered intravenously.
215001908|NCT07122674|DRUG|18F-Pentixafor|Patients with hematological malignancies receive 55 MBq/kg of 18F-Pentixafor intravenously followed by PET/CT or PET/MR after 60min of injection.
215001909|NCT07122557|DRUG|Biktarvy|this study applies secondary use of data collected from medical health records
215001910|NCT07123415|DRUG|APX-343A|Oral administration twice daily
215001911|NCT07123415|DRUG|Pembrolizumab|intravenous \[IV\]
215001912|NCT07122024|DRUG|Keverprazan 10 days|"Keverprazan dual therapy for 10 days (K10 group):~Keverprazan 20 mg per dose, twice daily (bid) + Amoxicillin 1 g per dose, three times (tid) daily, for 10 days."
215001913|NCT07122024|DRUG|Keverprazan 14 days|Keverprazan dual therapy for 14 days (K14 group): Keverprazan 20 mg, bid + Amoxicillin 1 g, tid, for 14 days.
215001914|NCT07122024|DRUG|Rabeprazole|Rabeprazole quadruple therapy for 14 days (R14 group): Rabeprazole sodium 10 mg + Amoxicillin 1 g + Clarithromycin 500 mg + Colloidal pectin bismuth 200 mg, bid, for 14 days.
215001915|NCT07122947|DEVICE|Apple Watch: AFib History|The Apple Watch AFib History feature uses PPG pulse rhythm data to detect and quantify the burden of atrial fibrillation.
215001916|NCT07122947|DEVICE|Zio Patch|The 14-day Zio Patch monitoring device (iRhythm Technologies, Inc., San Francisco, CA) uses continuous ambulatory ECG monitoring to quantify the burden of atrial fibrillation.
215001917|NCT07125573|DRUG|Saline Solution (NaCl 0,9%)|Administer 0.5 ug/kg of dexmedetomidine 10 minutes before surgery, and maintain at 0.4 ug/kg/h after intubation until 30 minutes before the end of surgery,Administer saline solution one minute after induction of anesthesia and continue until 30 minutes before the end of surgery.
215001918|NCT07125573|DRUG|Low-dose esketamine infusion|Administer 0.5 ug/kg of dexmedetomidine 10 minutes before surgery, and maintain at 0.4 ug/kg/h after intubation until 30 minutes before the end of surgery, administer esketamine 0.2 mg/kg 1 minute after induction of anesthesia, maintain at 2 μg/kg/min after intubation until 30 minutes before the end of surgery.
215001919|NCT07125573|DRUG|High-dose esketamine infusion|Administer 0.5 ug/kg of dexmedetomidine 10 minutes before surgery, and maintain at 0.4 ug/kg/h after intubation until 30 minutes before the end of surgery, Administer 0.2 mg/kg of esketamine 1 minute after induction of anesthesia, and maintain at 4 μg/kg/min after intubation until 30 minutes before the end of surgery.
215001920|NCT07125222|DRUG|Gocovri (extended-release amantidine)|Gocovri is extended release formulation of amantidine. Starting on Day 1, patients will start Gocovri 137mg daily. If there is no dose-limited event after 28 days, the dose will be increased to 274mg daily which will become the new standard dose for the remaining 20 weeks of the patient's participation in the study.
215001921|NCT07125326|PROCEDURE|Intermittent catheterization|intermittent bladder catheterization every four hours, or shorter intervals if volume exceeds 500mL per expert recommendation
215001922|NCT07125326|PROCEDURE|Continuous catheterization|One catheter is placed in the bladder until pushing
215001923|NCT07125950|DRUG|SHR2554|SHR2554
215001924|NCT07125950|DRUG|HRS-8080|HRS-8080
214397825|NCT02107443|BEHAVIORAL|Geriatric Assessment (GA)|A GA measures the issues important to older patients, including function, psychological status, cognitive abilities, social support, and the impact of medical problems on quality of life.
215001925|NCT07125950|DRUG|HRS-1358|HRS-1358
215001926|NCT07125508|DRUG|Tranexamic Acid (TXA) treatment|Patients randomized to the interventional arm will take oral tranexamic acid 650 mg three times per day for 3 months. They will have blood work drawn every month for the 3 month trial period.
215001927|NCT07125508|DRUG|Placebo|Placebo intervention
214397826|NCT01839643|DRUG|Meloxicam 2.4 g|2.4 g in Vaginal Ring
214397827|NCT01839643|DRUG|Meloxicam 3.0 g|3.0 g in Vaginal Ring
214397828|NCT02528955|RADIATION|A: De-Intensification RT primary tumor region|"A:~* Reduction of radiation dose in the primary tumor region to 56 Gy,~* Elective Radiotherapy of both neck sides"
214397829|NCT02528955|RADIATION|B: De-Intensification RT contralateral lymph nodes|"B:~* No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
215001928|NCT07125755|DRUG|Cisplatin|Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
215001929|NCT07124390|DEVICE|Name: Electroacupuncture (EA) Type: Device-based acupuncture therapy|Description: Insertion of acupuncture needles at specific points with electrical stimulation (2 Hz) for 30 minutes per session.
215095116|NCT05340803|DRUG|magnesium sulfate|magnesium sulfate
215095117|NCT02219503|DRUG|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
215095118|NCT02219503|DRUG|Dasabuvir|Tablet
215095119|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)|programmed intermittent bolus 5ml each one hour.
214397830|NCT02528955|RADIATION|C. De-Intensification RT primary tumor region AND contralateral lymph nodes|"C:~* Reduction of radiation dose in the primary tumor region to 56 Gy, AND~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
214397831|NCT03615209|DEVICE|Transauricular vagus nerve stimulation|Stimulation will be performed for 150 minutes (throughout the entire OGTT).
214397832|NCT03615209|DEVICE|Transauricular sham stimulation|Sham stimulation will be performed for 150 minutes (throughout the entire OGTT)
214397833|NCT03724461|BEHAVIORAL|High Intensity resistance training (12 weeks)|High intensity resistance training (80% of 1 repetition maximum), 2 d/wk (Longitudinal)
214397834|NCT03724461|BEHAVIORAL|Light-moderate intensity resistance training (12 weeks)|Light-moderate intensity resistance training (40% of 1 repetition maximum), 2 d/wk (Longitudinal)
214397835|NCT03724461|BEHAVIORAL|Control (12 weeks)|No resistance training during the intervention period.
214397836|NCT03724461|BEHAVIORAL|One High Intensity resistance training session|High intensity resistance training, 1 training session
214397837|NCT03724461|BEHAVIORAL|One Light-moderate intensity resistance training session|Light-moderate intensity resistance training, 1 training session
214397838|NCT02589925|DEVICE|Vercise deep brain stimulation|implantation of a Vercise neurostimulation system
214397839|NCT02589925|PROCEDURE|subthalamic nucleus (STN) stimulation|bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
214397840|NCT02589925|PROCEDURE|NBM stimulation|bilateral low-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
214397841|NCT02589925|PROCEDURE|sham stimulation|ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
214397842|NCT04769882|DEVICE|Er:YAG Laser|"Selected Er:YAG settings: enamel removal program for adult, with normal modality (frequency: 20 Hz, energy: 400 mJ, power: 8.0 W, air: 80%, water: 60%) and dentin removal program for adult, with normal modality (frequency: 20 Hz, energy: 200 mJ, power: 4.0 W, air: 90%, water: 30%)"
214397843|NCT03862443|BEHAVIORAL|Fixed Incentive|The Fixed Incentive intervention is a fixed reward, in which participants are eligible for fixed weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
214503639|NCT06605053|BEHAVIORAL|Co-produced intervention to optimize PMTCT care engagement|While the specific interventions package will developed earlier in the project, it may include evidence-based approaches such as peer mentor mothers, male partner involvement, flexible hours for girls/young women and mobile phone reminders. Overall, the interventions should be brief and easy to integrate into standard care, aiming to 'nudge' or motivate participants (towards improved engagement, retention, and outcomes) as well as health care providers or community stakeholders to better understand and support girls/young women\&#39;s specific needs. A focal team of 2-3 persons will be trained and engaged to drive the implementation of the interventions at randomized faciltiies. The focal team will orient and engage other staff and stakeholders to deliver the interventions, identify and address gaps, and monitor implementation fidelity and quality using standard operating procedures.
214503640|NCT06586398|DEVICE|rTMS|Participants will be randomized to 15 sessions of double-blind multi-target rTMS treatment (active vs sham) and then will receive only open-label active stimulation for another 15 sessions. Each session will include rTMS to the left dorsolateral prefrontal cortex (DLPFC), followed by rTMS to left primary motor cortex (M1).
214503641|NCT02581137|OTHER|Laboratory Biomarker Analysis|Correlative studies
214503642|NCT02581137|DRUG|Metformin Hydrochloride|Given PO
214503643|NCT04463446|BEHAVIORAL|Use of the CHD app|Use of the CHD app
214503644|NCT04463446|BEHAVIORAL|Nurse-led intervention|Teaching session with clinic nurse
214503645|NCT06819020|DEVICE|Percept RC|Using the Percept RC pulse generator, patients receive clinically-optimized open loop stimulation to the pallidum/subthalmaic nucleus.
214503646|NCT06819020|DEVICE|Percept RC|Using the Percept RC pulse generator, patients receive increased adaptive stimulation to the pallidum/subthalmaic nucleus.
214503647|NCT06819020|DEVICE|Percept RC|Using the Percept RC pulse generator, patients receive decreased adaptive stimulation to the pallidum/subthalmaic nucleus.
214503648|NCT03476798|DRUG|Rucaparib|Rucaparib 600mg PO BID daily
214503649|NCT03476798|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV on day 1 of each cycle
214397844|NCT03862443|BEHAVIORAL|Drawing Incentive|The Drawing Incentive intervention is a drawing reward, in which participants are eligible for weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
214503650|NCT06816927|DRUG|Nivolumab|For Neoadjuvant treatment, on both Arms 1 and 2, all 92 patients will receive single dose of 480 mg by IV infusion on Day 1 followed by surgery. Post-resection, in Part 1 Adjuvant treatment, all patients will receive two doses of 480 mg of nivolumab by IV infusion on Days 1 and 29. In Part 2 Adjuvant Treatment of Nivolumab dosing will continue for up to 12 cycles. Each cycle is 28 Days long.
214503651|NCT06816927|DRUG|Relatlimab|For Neoadjuvant treatment, only on Arm 2, 69 patients will receive a single dose of 480 mg of nivolumab and 480 mg of relatimab by IV infusions on Day 1 followed by surgery. Post resection in Part 1 Adjuvant treatment, all patients will receive two doses of 480 mg of nivolumab and relatlimab by IV infusion on Days 1 and 29. In Part 2 Adjuvant Treatment of Relatimab dosing will continue for up to 12 cycles. Each cycle is 28 Days long.
215001930|NCT07124390|DEVICE|Neuromodulation therapy|"Type: Neuromodulation therapy~Description: Insertion of a needle electrode near the medial malleolus with low-voltage electrical stimulation (20 Hz) applied for 30 minutes per session."
214397845|NCT06312631|DEVICE|Putting on the gripping glove|taking measurements and putting the gripping glove on the patient
214397846|NCT06312631|OTHER|ULPA questionnaire|"The evaluation of the effectiveness of the gripping glove on the performance of the upper limb in daily life will be evaluated using the ULPA score.~The investigator asks the patient to perform a task and the ULPA collects the total number of errors made by the patient (inability/omission, imprecision, repetition, time to complete the task)"
214397847|NCT06312631|OTHER|Motor Activity Log (MAL) Questionnaire|"The MAL is a self-assessment of the integration of the upper limb into daily life. This measurement allows a quantified evaluation of the perceived performance of the use of the upper limb in the actions of daily life.~The patient will answer 30 questions about daily life and for each item, rate the quantity from 0 to 5: 0 = never uses the hemiplegic arm and 5 = uses as much as before the accident"
214397848|NCT06312631|OTHER|Fugl-Meyer Assessment Upper Extremity (FMA-UE) questionnaire|This questionnaire assesses the motor selectivity of the upper limb. Several questions are asked about the movements that the patient can perform and to each question, the patient can answer either 0 (minimum) and 2 (maximum).
215001931|NCT07124390|DEVICE|Sham Acupuncture|"Type: Placebo~Description: Non-invasive, non-penetrating placebo needles placed at the same points as in the EA group, without electrical stimulation, for 30 minutes per session."
215001932|NCT07124338|OTHER|Exercise, supervised|nital nutrition plan by a trained dietician, based on Nutritional risk, identifying of nutrion impact symtomes, daily nutritional intake regristration and adjustments to the nutrion plan
215001933|NCT07124299|DRUG|Experimental: Alpha-blocker group|Participants in the experimental arm will receive an oral alpha-blocker (tamsulosin 0.4 mg) once daily for 7 consecutive days before undergoing flexible ureterorenolithotripsy. The medication is intended to relax ureteral smooth muscle fibers, potentially facilitating the insertion of the ureteral access sheath and reducing the need for a secondary procedure. The dose, route, and timing are standardized for all participants in this arm.
215001934|NCT07124299|DRUG|No intervention (observational study)|Participants in this arm will undergo flexible ureterorenolithotripsy without receiving any alpha-blocker prior to surgery. All other perioperative care and surgical procedures will follow the same protocol as the experimental group.
215001935|NCT07125547|DRUG|PD-1 inhibitior|Tislelizumab 200mg iv will be administered on Day 1 every 3 weeks for 2-3 cycles.
215001936|NCT07125547|DRUG|Nab-paclitaxel|Nab-Paclitaxel 125mg/m2 IV will be administered on Day 1 every 3 weeks for 2-3 cycles
215001937|NCT07125547|PROCEDURE|distal ureterectomy|Distal ureterectomy (Distal ureterectomy + Partial cystectomy +Psoas hitch procedure + Ureteral reimplantation into the bladder + Ipsilateral pelvic lymph node dissection) will be conducted after neoadjuvant treatment.
215001938|NCT07125040|OTHER|Cardiac MRI|On a subset of adult patients
214397849|NCT06312631|OTHER|Score Action Arm Research Test|"This questionnaire evaluates 4 different actions: Grasping an object (6 different objects to grasp), holding an object (4 different objects), pinching an object (6 different objects) and the overall movements made by the patient (3 different overall movements).~For each item, each object or each movement evaluated, the patient must rate the task on a scale of 0 to 3 (0=cannot perform any part of the test and 3=performs the test normally)"
214397850|NCT06312631|OTHER|EuroQol five-level (EQ-5D-5L) questionnaire|This questionnaire assesses the patient's state of health. 5 items are proposed (mobility, autonomy, current activity, pain, anxiety) and for each the patient must check one of the 5 propositions (no problem, mild problems, moderate problems, severe problems, incapable). The patient must also rate their state of health on a scale of 0 to 100.
214397851|NCT06312631|OTHER|Quebec User Evaluation of Satisfaction with Assistive Technology|This questionnaire assesses satisfaction with the technical aid (here the gripping glove) and the related services. The technique and related services will be evaluated by items provided to the patient and he will have to rate for each of them a score between 1 and 5 (1 = not satisfied at all and 5 = very satisfied)
214397852|NCT06312631|OTHER|Psychosocial Impact of Assistive Devices Scale (PIADS)|This questionnaire measures the effect of technical aids on the psychosocial level. 26 sentences or words are offered to the patient concerning his psychological state and the patient must evaluate them between -3 and 3 (-3 = decreased and +3: increased)
214397853|NCT06312631|OTHER|Goal Attainment Scale (GAS)|Carrying out an activity in the patient's real context is assessed using the Goal Attainment Scale (GAS). The doctor gives the patient objectives to achieve and the patient must give the quotation for each objective between initial state (-2), expected result (0) and best possible result (2)
214397854|NCT06312631|OTHER|installation and collection of accelerometers|The accelerometer quantitatively reports the spontaneous use of the upper limb in daily life. It counts the number of voluntary movements of the upper limbs. The amount of movement of the paretic upper limb will be expressed as a percentage of the movements of the non-paretic limb.
215095120|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)|continuous infusion 6ml/h
214397855|NCT03318211|DRUG|Magnesium Sulfate|Intravenous ampules of MgSo4 was given to only to control group after delivery
214397856|NCT04222309|PROCEDURE|Laparoscopically harvested omental free flap|Laparoscopically harvested omental free flap into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
214397857|NCT04430296|PROCEDURE|Cyclophotocoagulation|"High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU): parameters: 21 MHz frequency, 2.45 W acoustic power, with the activation of each transducer lasting 6 seconds MicroPulse cyclophotocoagulation (MP-CPC):Laser settings of 2 Watts (W) will be applied for a 90 seconds treatment time for each 180 degrees, with a duty cycle of 31.3%, which consists of 0.5ms on time and 1.1 ms off-time and delivering a total of 112,7 Joules Continuous Wave cyclophotocoagulation (CW-CPC): The laser settings used will be 1.250 W, 4s exposure time per burn, 22-24 burns per eye."
214397858|NCT01638468|DEVICE|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
214397859|NCT05672004|OTHER|PUMP-fit strategy (implementation toolbox)|"Healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting (during the control period).~Healthcare professionals will be informed about the platform and toolbox. Healthcare professionals receive a personal log-in for the online platform. Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible on the platform Within the separate environment of the online platform, healthcare professionals can access their implementation toolbox. The toolbox is tailored to their personal context based on the results of the 'Readinesstool'."
215001939|NCT07124091|BEHAVIORAL|Positive Event Writing Intervention|Mothers in the intervention group will be asked to write down three positive events each day for four weeks as part of a positive psychology journaling activity..
215001940|NCT07125144|BEHAVIORAL|Black Youth Suicide Prevention in Chicago|The Culturally Adapted intervention uses intervention video content that specifically addresses topics that shape Black youth's psychological wellbeing and development. The goal of this intervention is to share suicide prevention information in ways that are culturally responsive and attentive to the specific needs of Black adolescents.
215095121|NCT04934436|OTHER|sleeping glasses and earplug|In this study, the effect of the chronotype-appropriate nursing care on the intervention group will be examined.
215095122|NCT00491608|BIOLOGICAL|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
215095123|NCT05992194|OTHER|multimodal oculomotor measurements|"* Visual assessment to ensure that the subject meets the inclusion and non-inclusion criteria, including anamnesis and the following visual tests: Lang stereotest, H-test ocular motility, convergence, masking and accommodative rock.~* Evaluation by experimenter A (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR headset~* Evaluation by experimenter B (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR helmet The sequence of experimenters A-B or B-A will be randomized."
215095124|NCT00211952|DRUG|celecoxib|
215095125|NCT00025155|DRUG|ixabepilone|Given IV
215095126|NCT03572790|DRUG|Prucalopride|1mg prucalopride capsule, once daily for seven days
215095127|NCT03572790|OTHER|Placebo|Lactose placebo capsule, once daily for seven days
215095128|NCT04485260|DRUG|KRT-232|administered by mouth
215095129|NCT04485260|DRUG|Ruxolitinib|administered by mouth
215095130|NCT02238015|PROCEDURE|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
215095131|NCT03559894|DIAGNOSTIC_TEST|Trans-thoracic echocardiography|Trans-thoracic echocardiography
215095132|NCT02367404|DRUG|Duloxetine|Duloxetine 60mg OD for 3 months
215095133|NCT02367404|BEHAVIORAL|Pelvic Floor Muscle Training|PMFT weekly for 3 months
215001941|NCT07125144|BEHAVIORAL|Signs of Suicide: Standard/Existing|Students attending schools assigned to the Standard/Existing Intervention condition will receive the Signs of Suicide curriculum.
215001942|NCT07125092|DEVICE|compression group|"All patients enrolled in the study will be instructed to wear the compression garment for 8 weeks, as long as possible during the day. In parallel, all patients will receive the same advice about routine care: physical exercises, nutrition aspect that are part of the centre's current practice.~3 study visits are planned: the inclusion visit (V0) includes patient information and consent signature, measurements for custom-made compression stockings. The initial visit (V1) includes devices collection and fitting, patient questionnaires, physician assessment (medical and lipedema history, BMI, WHtR, blood sample collection, pain description, lipedema associated symptoms, leg perimeter measurements, Moisture Meter, pressure under the garment). The follow-up visit (V2) after 8 weeks includes: patient questionnaires and physician assessment.~After 8 weeks, another compression garment will be given to the patient with a new satisfaction e-questionnaire at 10 weeks of follow-up."
215001943|NCT07125846|DEVICE|Bioactive Glass Bone Graft (UNIGRAFT)|A bioactive glass bone graft material (UNIGRAFT, Biomed Inc., USA) used for maxillary sinus floor augmentation via open sinus lift technique.
215001944|NCT07125846|DEVICE|Xenograft Bone Graft (Bio-Oss)|A commercially available bovine-derived xenograft material (Bio-Oss, Geistlich Pharma) used for maxillary sinus floor augmentation via open sinus lift technique.
214503652|NCT06816927|DRUG|TMZ|All patients in safety lead-in, Arm 1 and Arm 2 post resection in Part 1 Adjuvant Treatment setting will receive 75 mg/m2 TMZ from Day 1 to Day 42 orally. In Part 2 Adjuvant Treatment of TMZ dosing with TMZ will continue for up to 6 cycles with 150 mg/m2 for cycle 3 and escalating to 200 mg/m2 for cycles 4 to 8 day 1 to 5 for these 6 cycles.
215001945|NCT07124858|DRUG|Fruquintinib|Fruquintinib will be administered according to the summary of product characteristics (SmPC) : 5 mg, 21 days of treatment followed by a 7-day break until progression, unacceptable toxicity, death, or patient refusal.
215001946|NCT07124767|OTHER|6 weeks of diet with low insulin index diet|6 weeks diet period for the low insulin index group. this group has a diet programme assigned by the conductor dietitian.
215001947|NCT07124767|OTHER|6 weeks of dieting according to TÜBER nutrition recommendations|6 weeks of diet according to the TÜBER recomendations were applied to this group. Diets were assigned by the conductor dietitian.
215001948|NCT07119788|DIETARY_SUPPLEMENT|Placebo|6g serving of a calorie-matched powder, artificially coloured and flavoured to resemble berry powder
215095134|NCT00413374|DRUG|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
215095135|NCT01431885|PROCEDURE|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
215095136|NCT01431885|PROCEDURE|Cervical change|Diagnosis will be made by digital examination of cervical change
215095137|NCT02391493|DEVICE|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
215095138|NCT01092793|DIETARY_SUPPLEMENT|Krill|Encapsulated oil from the antarctic crustacean Krill
215095139|NCT01092793|DIETARY_SUPPLEMENT|Fish oil|Encapsulated, raffined cod-oil
214503653|NCT06816927|RADIATION|Radiation Therapy|All patients in safety lead-in, Arm 1 and Arm 2 post resection in Part 1 Adjuvant Treatment will receive External Beam Radiation 2 Gy/day (60 Gy in total) Once daily, 5 days per week, for 6 weeks Starting on Day 1
214503654|NCT06061978|PROCEDURE|left bundle branch of His pacing|left bundle branch of His pacing
215001949|NCT07119788|DIETARY_SUPPLEMENT|Pure haskap berry powder|6g serving of a pure, freeze-dried haskap berry powder
215001950|NCT07119788|DIETARY_SUPPLEMENT|Vitamin-and mineral-enhanced haskap berry powder|6g serving of a vitamin- and mineral-enhanced haskap berry powder (fortified with potassium iodide, zinc bisglycinate, vitamin B5, and vitamin B12
215001951|NCT07102953|BEHAVIORAL|Focused-attention meditation|This is a type of mindfulenss meditation, which instructes participants to keep focusing on own breathing with a sitting and rest posture.
215001952|NCT07102953|BEHAVIORAL|Open-monitoring meditation|This is a type of mindfulenss meditation, which instructs participants to stay aware of their vision with a sitting and rest posture.
215001953|NCT07102953|BEHAVIORAL|Audio-listening control|Participants listen to stories about creativity with a sitting and rest posture.
215001954|NCT07120451|DRUG|Senaparib|100mg qd
215001955|NCT07120451|DRUG|Bevacizumab|7.5mg/kg q3w
215001956|NCT07117617|BEHAVIORAL|Dynamic Stability Training with Inertial load of water|A 10-week training program using AquaBag to enhance lower limb joint stability and neuromuscular coordination. Exercises included dynamic stepping, lunging, and landing tasks under water load-induced perturbations.
215001957|NCT07120087|BEHAVIORAL|Intervention|Virual Webinar and online personalised clinical visit
215001958|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 5mg/kg/day in two divided doses will be given for three days to two subjects
215001959|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 10mg/kg/day in two divided doses will be given for three days to two subjects.
215001960|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 20mg/kg/day in two divided doses will be given for seven days to three subjects.
215001961|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 25mg/kg/day in two divided doses will be given for 14 days to three subjects.
215001962|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 15mg/kg/day in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, the next Cohort will increase to 25mg/kg/day (Cohort 2) or decrease to 10mg/kg/day (Cohort 3)
215001963|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 25mg/kg/day in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, either 25mg/kg/day or 15mg/kg/day will be dose selected for the next Cohort (Cohort 4)
215001964|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 10mg/kg/day in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, either 10mg/kg/day dose selected for the next Cohort (Cohort 4) or the study will be stopped due to excessive toxicity.
214397860|NCT05672004|OTHER|Implementation as usual|"First, healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting.~At the end of the training healthcare professionals are informed about the mandatory conditions to implement ProMuscle (champion, material, approval of management).~Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible. Results contain a graph of possible barriers for implementation in their practice.~Hereafter they will be instructed to start with implementation as usual."
214397861|NCT06290167|DEVICE|360° media|sessions with head mounted display in hospital and sessions with tablet at home
214397862|NCT06290167|OTHER|Treatment As Usual (TAU)|sessions of TAU rehabilitation in hospital and sessions TAU rehabilitation at home
214397863|NCT06290167|OTHER|In hospital sessions|sessions will be carried out under the supervision of a therapist
214397864|NCT06290167|OTHER|at home sessions|sessions will be carried out without the supervision of a therapist
214397865|NCT06290167|OTHER|Mild Cognitive Impairment|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
214397866|NCT06290167|OTHER|Subjective Memory Complain|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
214397867|NCT05895058|DEVICE|Gastric bypass surgery with 2D 4K laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
214397868|NCT05895058|DEVICE|Gastric bypass surgery with 3D HD laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
214397869|NCT04341155|DRUG|Dexamethasone|Patients in experimental arms will receive i.v. dexamethasone 20 mg (4 ampules = 20mL) for 7 days
214397870|NCT04341155|DRUG|Placebo|Patients in placebo arms will receive 20 mL normal saline intravenously for 7 days
214397871|NCT00161096|DRUG|pantoprazole 20 mg (drug)|
214397872|NCT00063674|BEHAVIORAL|Nutrition Education|
214397873|NCT00063674|BEHAVIORAL|After-school dance class|
214397874|NCT01513967|DRUG|RPh201, botanical drug product|SC administration at varying doses
214397875|NCT01513967|DRUG|Placebo|SC administration at varying doses
214397876|NCT06004752|DRUG|Ciclosporin|Cyclosporine was taken orally at 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml
214397877|NCT06004752|DRUG|Avatrombopag|Avatrombopag was administrated at 40 mg/d and increased by 20 mg/d during the biweekly follow-up if platelet was not 20 × 109/L higher than baseline. AVA dose was gradually reduced if PLT ≥ 150 × 109/L. The maximum dose was 60 mg/d, while the minimum was 20 mg/week.
215001965|NCT07120971|DRUG|Metformin (open-label)|The dose for this cohort will be selected from either Cohort 2 or 3 based on tolerance. Enteric metformin 10-25mg/kg/day in a single daily dose will be given for seven days to 6 subjects.
214397878|NCT03400904|OTHER|Patients with brain injury and mechanical ventilation exposed to extubation/tracheostomy|Extubation and/or tracheostomy if applicable
214397879|NCT05012254|DRUG|Ipilimumab|"Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion."
214397880|NCT05012254|DRUG|Nivolumab|"Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion."
214397881|NCT05012254|DRUG|Carboplatin|"Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
214397882|NCT05012254|DRUG|Cisplatin|"Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center."
215001966|NCT07120971|DRUG|Metformin (open-label)|The dose for this cohort will be the same as Cohort 4. Enteric metformin 10-25mg/kg/day in a single daily dose will be given for 14 days to 6 subjects.
215001967|NCT07121205|OTHER|This study is a retrospective study, and all data have been collected in advance with no active intervention required.|This study is a retrospective study, and all data have been collected in advance with no active intervention required.
215001968|NCT07120828|DRUG|Empagliflozin (oral)|Empagliflozin 10 mg oral tablet administered once daily for 6 months.
215001969|NCT07120828|DRUG|Dapagliflozin (DAPA)|Dapagliflozin 10 mg oral tablet administered once daily for 6 months
215001970|NCT07120828|DRUG|Metfomin|metformin 500-1000 mg/day administered as part of standard care, based on clinical indication.
215001971|NCT07123584|DIETARY_SUPPLEMENT|Eye Empower|A multi-ingredient oral supplement formulated to support eye health. Daily dose (3 capsules).
215001972|NCT07123584|DIETARY_SUPPLEMENT|Placebo|Identical gelatin capsules filled with inert rice flour, administered in the same dosage (3 capsules daily).
214397883|NCT05012254|DRUG|Paclitaxel|"Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
214397884|NCT05012254|DRUG|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol \[2,3 d\]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
214397885|NCT02906202|GENETIC|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
214397886|NCT00630214|DIETARY_SUPPLEMENT|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
215001973|NCT06925542|BIOLOGICAL|CTX112|CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
215001974|NCT03327467|BIOLOGICAL|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling, autologous, or unrelated donor)
214397887|NCT00630214|DIETARY_SUPPLEMENT|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
215001975|NCT06072651|BEHAVIORAL|Relative Reinforcing Value of Food|Researcher gives child opportunity to press a button to earn three types of rewards: a high-reward food, a low-reward food, and a non-food reward.
215001976|NCT05630794|PROCEDURE|Biopsy Procedure|Undergo biopsy
215001977|NCT05630794|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215001978|NCT05630794|PROCEDURE|Colonoscopy|Undergo colonoscopy
215001979|NCT05630794|DRUG|Dordaviprone|Given PO
215001980|NCT05630794|OTHER|Questionnaire Administration|Ancillary studies
214397888|NCT01791634|PROCEDURE|proximal chevron osteotomy|
214397889|NCT01791634|PROCEDURE|proximal open wedge osteotomy with LPS system|
214397890|NCT01305928|OTHER|Warm Hand-off|"Warm Hand-Off~Staff brief intervention and warm hand-off (5 min):~* Assess withdrawal, need for medication change~* Describe warm hand-off process~* Provide 2-page flyer~* Perform call, leave room~* Notify patients' nurse patient is talking to quitline~Quitline session (20 min):~* Collect minimum data set~* Explore thoughts/feelings toward quitting~* Provide medication education~* Build plan to stay quit~* Schedule next call~Staff check-back (5 min):~* Ask patient how session went~* Ask if patient requests cessation medication script on discharge"
214503655|NCT06061978|PROCEDURE|right ventricular pacing|right ventricular pacing
214503656|NCT03532477|DRUG|Venlafaxine|Patients are tested for their normal prescription metaprolol medication
215001981|NCT05630794|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
215001982|NCT05623488|DRUG|huCART-meso cells|Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains
215001983|NCT05623488|DEVICE|Mesothelin Expression Testing|Laboratory Developed Test
215001984|NCT05178862|DRUG|SCY-078|Oral ibrexafungerp (SCY-078) as step-down therapy.
215001985|NCT05178862|DRUG|Fluconazole|Oral fluconazole (SCY-078) as step-down therapy.
215001986|NCT05178862|DRUG|Echinocandin|Intravenous echinocandin
215001987|NCT06939283|DRUG|WTX-330|Investigational Product
215001988|NCT06937346|DEVICE|The Rehand Robotic Glove|"The exoskeleton hand system provides recovery and training for paralyzed fingers using an innovative method that mirrors the movements of a healthy hand. The system uses a sensor glove to read movements and transfer them to a rehabilitation glove. This forces the injured hand to repeat the same movements as the healthy hand, helping to restore motor skills.~The system combines flexible robotics with neuroscience to help patients retrain their muscles. It reduces muscle tension and swelling, relieves stiffness, improves blood circulation, and restores muscle performance after atrophy. It also reduces hypertension and joint pain, and activates neuroplasticity through passive and active techniques.~All patients received standard rehabilitation treatments in accordance with clinical protocol No. 94 for the third stage of medical rehabilitation, approved by the Joint Commission on Quality of Medical Services from the Ministry of Health of Kazakhstan on 14 May 2020."
215001989|NCT06937346|OTHER|Standard Rehabilitation|All patients received standard rehabilitation treatments in accordance with clinical protocol No. 94 for the third stage of medical rehabilitation, approved by the Joint Commission on Quality of Medical Services from the Ministry of Health of Kazakhstan on 14 May 2020.
215001990|NCT03580928|DRUG|Venetoclax|Venetoclax is an oral drug that blocks the function of a protein called BCL-2. CLL cancer cells are thought to depend on the BCL-2 protein for their survival. By blocking BCL-2, venetoclax may kill cancer cells or stop them from growing.
215001991|NCT03580928|DRUG|Obinutuzumab|Obinutuzumab is a type of drug called a monoclonal antibody. It targets a protein CD20 on the surface of the CLL cell, causing it to die
215001992|NCT03580928|DRUG|Acalabrutinib|Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps CLL cells live and grow
214397891|NCT01305928|OTHER|Fax|"Fax~Staff standard in-patient session: (30 minutes):~* Assess withdrawal, need for medication change~* Conduct assessment of smoking history, interest in quitting~* Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting~* Provide 2-page flyer~* Provide medication education~* Build plan to stay quit~* Describe fax-referral process~* Ask if patient requests cessation medication script on discharge"
215001993|NCT06939426|BEHAVIORAL|Music therapy intervention|"The intervention protocol is based on four main themes, which are addressed over the course of eight sessions:~* Self-care~* Self-recognition and expression of emotions~* Empathy~* Teamwork~Each theme is related to factors from the HUMAS (affection, self-efficacy, emotional understanding, dispositional optimism, and sociability) and/or ProQOL (compassion satisfaction, burnout, and compassion fatigue). A variety of techniques related to the four main methods of music therapy will be used in the sessions: receptive, re-creative, composition, and improvisation."
215001994|NCT06936930|OTHER|Sex hormone monitoring|Sex hormone monitoring includes the concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P), prolactin (PRL), and testosterone (T).
214397892|NCT01758874|PROCEDURE|phlebotomy|repeated phlebotomy for 4 weeks
214397893|NCT02085343|BEHAVIORAL|EXP|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
214397894|NCT02085343|BEHAVIORAL|EXP + SBF|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
215001995|NCT06380569|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 10 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
215001996|NCT07115940|DEVICE|Endovascular Thrombectomy|EVT will be provided in addition to medical management and is a procedure to remove a thrombus in one of the brain arteries that is obstructing the blood flow and is responsible for the occurrence of stroke. Removing this occlusion results in restoration of blood flow to ischemic brain tissue and the parts that are still viable and salvageable may survive, which is expected to improve functional outcomes. Endovascular thrombectomy procedure will be provided by the means of stent retrievers, aspiration devices or combination approach at the discretion of the treating physician, using devices approved by the local regulatory authority. For patients treated in the United States of America, only US Food and Drug Administration approved neurothrombectomy devices can be used.
215001997|NCT07115940|OTHER|Medical Management|Medical management comprises various measures to prevent further deterioration, enhance patients' outcomes and prevent occurrence of a secondary stroke in short and long term. This includes 1) evidence-based practices for blood pressure management 2) Neurocritical care monitoring with appropriate osmotic therapy and neurosurgical interventions such as hemicraniectomy for management of cerebral edema that occurs due to infracted brain tissue based on local institutional protocol, 3) stroke etiology identification by requisite neurology , cardiology, immunology evaluations and 4) short and long-term strategies for secondary stroke prevention, including anticoagulation, antiplatelet therapy, medical optimization and modification of stroke risk factors such as hypertension, hyperlipidemia, diabetes and other potential comorbidities.
215001998|NCT07103083|DIETARY_SUPPLEMENT|Beverage 1|Fruit juice with zero sugar
215001999|NCT07103083|DIETARY_SUPPLEMENT|Beverage 2|Fruit juice with low sugar - formulation 1
215002000|NCT07103083|DIETARY_SUPPLEMENT|Beverage 3|Fruit juice with low sugar - formulation 2
215002001|NCT07103083|DIETARY_SUPPLEMENT|Beverage 4|Fruit juice with full sugar
214397895|NCT02085343|BEHAVIORAL|EXP + SBF + AA|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided explaining the rationale for eliminating safety behaviors, and how engagement in anti-phobic actions may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment, and will instruct participants to enact a series of progressively challenging anti-phobic actions which oppose the prototypical fear response.
214397896|NCT01248520|OTHER|influenza and general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.
214397897|NCT01248520|OTHER|general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
214397898|NCT04802226|OTHER|self exclusion procedure|self exclusion procedure( responsible gambling tool)
214397899|NCT05039034|OTHER|Advice according to primary prevention guidelines on stroke of China|
214397900|NCT02601586|DRUG|PR Oxycodone|PR Oxycodone
214397901|NCT02601586|DRUG|Levodopa|Levodopa
214397902|NCT02601586|DRUG|Oxycodone Placebo|Placebo of PR Oxycodone
214397903|NCT02601586|DRUG|Levodopa placebo|
215002002|NCT07103083|DIETARY_SUPPLEMENT|Beverage 5|Fruit juice with full sugar
215002003|NCT07103083|DIETARY_SUPPLEMENT|Beverage 6|Glucose control beverage
214397904|NCT02766998|PROCEDURE|Preserved umbilical vein as shunt/conduit|All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.
214397905|NCT02313896|BEHAVIORAL|Phone calls|Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
214397906|NCT03881033|OTHER|Peep 5cmH2O|Face mask ventilation with peak inspiratory pressure according to the group P7+5 means face mask ventilation with peak inspiratory pressure 7cmH2O plus PEEP 5 cmH2O.
214397907|NCT03881033|OTHER|Peak inspiratory pressure|Face mask ventilation with peak inspiratory pressure according to the group P12 means face mask ventilation with peak inspiratory pressure 12cmH2O without PEEP.
214397908|NCT02476097|DRUG|Esomeprazole: Nexium® 20mg, Astra Zeneca|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
215002004|NCT06943014|DEVICE|Actimetry Protocol|Our goal is to develop an actimetry protocol using both accelerometers and pressure insoles to quantify physical activity, involving the upper and/or lower limbs, as well as sedentary behavior in post-stroke individuals. Recent studies have explored the use of validated accelerometer configurations designed for healthy individuals, applied to the post-stroke population to monitor their physical activity and sedentary behavior. However, although these protocols have been validated for healthy individuals, they need to be adapted for post-stroke patients, who exhibit slower, asymmetric, and lower-amplitude movements compared to healthy subjects. This protocol could be valuable in both clinical practice and research, helping to optimize stroke rehabilitation and promote a healthy, active lifestyle.
214397909|NCT02476097|OTHER|CYP2C19 phenotypical analysis|All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.
215002005|NCT06805656|DRUG|Maraviroc|antiretroviral intensification
215002006|NCT06805656|DRUG|Dolutegravir|antiretroviral intensification
215002007|NCT06805656|BIOLOGICAL|Dendritic Cell Vaccine|therapeutic vaccination
215002008|NCT06805656|DRUG|Auranofin|purging
215002009|NCT06805656|DRUG|Sirtuin Histone deacetylase inhibitor|latency disruption
215002010|NCT06936891|COMBINATION_PRODUCT|Virtual Ward|Hospital-level care at home using remote vital sign monitoring, digital anamnesis via the Digizorg app, and integration with the Electronic Medical Record (HiX), managed by Virtual Ward staff following predefined care pathways.
215002011|NCT06945276|DRUG|ALG-097558|A selective, reversible, and potent inhibitor of the SARS-CoV-2 3CLpro with pan-coronavirus activity
215002012|NCT06945276|DRUG|Dabigatran|A direct thrombin inhibitor approved for the treatment and prevention of blood clots to reduce the risk of stroke
215002013|NCT06945276|DRUG|Itraconazole|A substrate and strong dual inhibitor of CYP3A4/P-glycoprotein (P-gp)
215002014|NCT06945276|OTHER|Placebo|Placebo
215002015|NCT06945237|DRUG|Flupentixol-Melitracen + Lansoprazole|Flupentixol-Melitracen and Lansoprazole for the treatment of GERD
215002016|NCT06945237|DRUG|Lansoprazole and placebo|Placebo and Lansoprazole for GERD
215002017|NCT06940830|DRUG|Efanesoctocog alfa|Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the Sponsor.
215002018|NCT06943066|OTHER|Reformer Pilates|Reformer Pilates
215002019|NCT06943066|OTHER|Pilates control|Pilates control
215002020|NCT06943066|OTHER|online pilates|online pilates
214503657|NCT05950672|BEHAVIORAL|CAT Intervention Group|The experimental group will take part in the CAT intervention after baseline assessments. All cat-training methods will be positive reinforcement based, using owner-approved food, toys and social reinforcers (e.g. petting).
214503658|NCT00592345|RADIATION|Proton Beam Radiation|Administered over a period of 12 weeks.
214503659|NCT00592345|RADIATION|Photon Beam Radiation|Administered over a period of 12 weeks.
215002021|NCT06942247|DEVICE|Active Comparator: Fracture Fixation (Inion Freedom Screws)|Device: Absorbable screw for internal fixation of fracture. Patients were divided into the Inion Freedom Screws group and the Biological Hollow Bone Screws group according to the type of the screws they used.
215002022|NCT06942247|DEVICE|Experimental: Fracture Fixation (Biological Hollow Bone Screws)|Device: Absorbable screw for internal fixation of fracture. Patients were divided into the Inion Freedom Screws group and the Biological Hollow Bone Screws group according to the type of the screws they used.
215002023|NCT05389215|DRUG|DWN12088|DWN12088 Xmg Tablet (BID)
215002024|NCT05389215|DRUG|Placebo|Placebo 0mg Tablet (BID)
214503660|NCT00592345|RADIATION|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
214503661|NCT06981078|DRUG|Verekitug|Verekitug (UPB-101) formulated solution
214503662|NCT06981078|OTHER|Placebo|Matching Placebo to Verekitug (UPB-101)
214503663|NCT06855745|DRUG|zabalafin|Active IP
214397910|NCT02476097|DRUG|Placebo|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
214397911|NCT04478227|DRUG|Romiplostim|Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
214503664|NCT06594445|DRUG|GTB-360|"GTB-3650 is administered by a continuous infusion (CI). A patient's dose of GTB-3650 is calculated using their assigned Dose Level and their actual body weight (ABW) obtained within 5 days prior to or on Cycle 1, Day 1.~Dose Level 1: 1.25 ug/kg/day Dose Level 2: 2.5 ug/kg/day Dose Level 3: 5 ug/kg/day Dose Level 4: 10 ug/kg/day Dose Level 5: 25 ug/kg/day Dose Level 6: 50 ug/kg/day Dose Level 7: 100 ug/kg/day"
214503665|NCT06386744|DRUG|Dusquetide|1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks
214503666|NCT06841172|RADIATION|radiotherapy|Radiotherapy (Biologically Equivalent Dose \[BED\]≥60Gy)
214503667|NCT06841172|DRUG|Systemic therapy (Continuation of current first-line systemic therapy)|Continuation of current first-line systemic therapy, which may include, but is not limited to, combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at the discretion of the treating physician.
215002025|NCT06834906|DIAGNOSTIC_TEST|EasyEyeFM-AutoML-AI-platform test|AI platforms using
215002026|NCT06834906|DIAGNOSTIC_TEST|AutoML-EasyEyeFM-AI-platform test|AI-platform using
214397912|NCT01799772|BEHAVIORAL|Comprehensive Behavioral Intervention|"1. Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.~2. Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.~3. Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.~4. Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c."
215002027|NCT06947538|BEHAVIORAL|webSTAIR|WebSTAIR consists of 10 online modules that provide psychoeducation on trauma and emotions and teach skills to improve coping with emotions and strengthen interpersonal relationships. Modules are completed at the participants' own pace and utilize interactive exercises, and audio and video components to aid in delivery.
215002028|NCT06947538|BEHAVIORAL|WebSTAIR plus coaching|WebSTAIR with up to five 30-min coaching sessions with a CHW will focus on guiding participants through the program, discussing exercises that are valuable or problematic, and reviewing module content.
215002029|NCT06947538|BEHAVIORAL|Clinician administered Brief STAIR|Brief STAIR is a brief, low intensity, therapy that utilizes psychoeducation, coping skills training, and does not include recounting of the trauma memory, making it highly tolerable. It will be delivered by mental health clinicians in five to six 30-minute individual sessions.
215002030|NCT06947538|BEHAVIORAL|Clinician administered WET|WET is a brief, high intensity, exposure-based treatment delivered by mental health clinicians consisting of six 30-minute individual sessions that cover treatment rationale, psychoeducation about PTSD, and directing participants to write in session about their traumatic experience using scripted instructions.
215002031|NCT05800145|BEHAVIORAL|Resource information Supplemental Nutrition Assistance Program (SNAP)|Participants randomized to the resource referral arm will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address FI (e.g. SNAP).
215002032|NCT05800145|BEHAVIORAL|community health worker (CHW)|Participants randomized to the CHW intervention will have an initial baseline visit scheduled at a mutually convenient location.
215002033|NCT05800145|BEHAVIORAL|medically tailored meals|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
215002034|NCT07114081|DIAGNOSTIC_TEST|Diagnostic laparoscopy|Minimal access surgery to determine the presence of characteristic endometriosis lesions on visual inspection of the pelvis
215002035|NCT07105280|DEVICE|Conventional DBS|Treatment for a minimum of 2 to a maximum of 7 days with the patient's original conventional DBS (cDBS) settings.
215002036|NCT07105280|DEVICE|Optimized conventional DBS|Treatment for a minimum of 2 to a maximum of 7 days with a previously optimized version of the patient's original conventional DBS (O-cDBS) settings.
215002037|NCT07105280|DEVICE|Optimized adaptive DBS|Treatment for a minimum of 2 to a maximum of 7 days with previously optimized adaptive DBS (O-aDBS) settings.
215002038|NCT07115472|DRUG|Fluoxetine|Refractory SMAS patients with SSD received oral fluoxetine treatment, initiated at 20 mg/day and increased to a maximum of 60 mg/day based on therapeutic response.
214397913|NCT01799772|OTHER|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
215002039|NCT07103044|BEHAVIORAL|Early Achievements - Shaping Early Language and Literacy Skills|EA-SHELLS is a professional development program that includes a 6-hour workshop and about 14 in-person coaching sessions using Practice-Based Coaching. Teachers will implement the EA-SHELLS instructional approach in their classrooms during whole-group book sharing activities to target vocabulary, syntax, story grammar, and listening comprehension. Teachers will also lead story retelling activities using pictures cards and 3D props to further target all four skills. Teachers will be provided with commercially available children's books augmented with supplemental text to explicitly define vocabulary and cue teachers' elicitation of children's verbal engagement for targeted vocabulary, syntactically elaborated sentences, and story grammar elements. Instructional strategies include naturalistic developmental behavioral intervention and language facilitating (e.g., focused stimulation) strategies. Teachers will read each provided book about four times over one to two weeks.
215002040|NCT06947304|DRUG|Miricorilant|100 mg administered orally, once daily
215002041|NCT06952478|BIOLOGICAL|CT-P44(Daratumumab)|CT-P44 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 26, whichever occurs first.
215002042|NCT06952478|BIOLOGICAL|Darzalex Faspro(Daratumumab)|Darzalex Faspro 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 13, whichever occurs first.
215002043|NCT06955871|OTHER|Toothpaste containing 1.05% Chitosan|Toothpaste containing 1.05% Chitosan
215002044|NCT06955871|OTHER|Silica-based NaF Toothpaste|Silica-based NaF Toothpaste
215095140|NCT05580068|DEVICE|Hypertension therapy through iATROS medical device|"The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension.~In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better."
215095141|NCT00096330|DIETARY_SUPPLEMENT|dietary intervention|oral folic acid supplementation once daily on days 57-84
215095142|NCT00096330|DIETARY_SUPPLEMENT|folic acid|oral folic acid supplementation once daily on days 1-56.
215095143|NCT00552760|DRUG|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
215095144|NCT00552760|DRUG|Placebo|one tablet at bedtime for up to 6 months
215002045|NCT06955871|OTHER|Toothpaste with 67% bicarbonate|Toothpaste containing 67% Bicarbonate
215002046|NCT07123649|BEHAVIORAL|Shared Decision-Making Toolkit|The SDM toolkit is designed to support discussions on the continuation of surveillance mammography. It provides evidence-based guidelines, communication strategies, and education materials to aid in personalized decision-making.
215002047|NCT07124611|OTHER|Interview|Ancillary studies
214397914|NCT01133860|DRUG|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
215002048|NCT07124611|PROCEDURE|Nutritional Therapy|Attend nutritional appointments
215002049|NCT07124611|PROCEDURE|Physical Therapy|Attend physical therapy appointments
215002050|NCT07124611|BEHAVIORAL|Psychosocial Care|Receive psychosocial care
215002051|NCT07124611|OTHER|Questionnaire Administration|Ancillary studies
215095145|NCT04863690|BEHAVIORAL|Meditation|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations, as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks. If they also wish to use the Muse system more frequently (day or night), they will be encouraged to do so and will be able to choose between several styles of available meditation (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations). Participants will be asked to also wear their Muse device while they sleep, as often as they like in order to track their sleep.
215095146|NCT04863690|BEHAVIORAL|Digital Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
214397915|NCT03195920|DEVICE|Enhanced Lithotripsy System|The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
215002052|NCT07119554|BEHAVIORAL|HBM-Based Postpartum Contraceptive Counselling|This intervention involves providing a structured, individual contraceptive counseling session based on the Health Belief Model (HBM) to women in the postpartum period.The session is delivered face-to-face, lasts approximately 30 to 45 minutes, and is structured around the core components of the HBM: perceived susceptibility, perceived severity, perceived benefits, perceived barriers, self-efficacy, and cues to action. The aim of the intervention is to improve attitudes toward family planning and increase the intention to use contraceptive methods.
215002053|NCT02850406|DRUG|Voxelotor|"* Part A: Voxelotor will be administered as oral capsules or tablets~* Part B: Voxelotor will be administered as oral capsules or tablets~* Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~* Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension"
215002054|NCT07120061|DIAGNOSTIC_TEST|First MWT|MWT during the first visit of the protocol
215002055|NCT07120061|DIAGNOSTIC_TEST|second MWT|MWT during the second visit of the protocol
215002056|NCT07120061|DEVICE|actimetry|In order to monitor compliance with the guidelines prior to each MWT, namely good sleep hygiene in the 14 days preceding the MWT, and in accordance with the recommendations of the AASM, an actimeter will be worn by the participant.
215002057|NCT07120997|DIETARY_SUPPLEMENT|Prunes|Participants randomized to the 50g prune group will consume 6 prunes per day for the duration of the 18-month intervention.
215002058|NCT07120997|DIETARY_SUPPLEMENT|Calcium supplement|All participants will consume calcium supplements daily for a baseline period and for the duration of the 18-month intervention.
215002059|NCT07120997|DIETARY_SUPPLEMENT|Vitamin D Supplement|All participants will consume Vitamin D supplements daily for a baseline period and for the duration of the 18-month intervention.
215002060|NCT06460961|BIOLOGICAL|MK-6837|IV Infusion
215002061|NCT06460961|BIOLOGICAL|Pembrolizumab|IV Infusion
215002062|NCT06460961|DRUG|Rescue Medications|Antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) administered per product label prior to MK-6837.
215002063|NCT07117890|DRUG|Sunvozertinib|sunvozertinib 300mg QD
215002064|NCT07113782|DRUG|1. Magnesium Sulphate 2. Tramadol|"Magnesium Sulphate (Group M): 50 mg magnesium sulphate added to 12.5 mg of 0.5% hyperbaric bupivacaine, administered intrathecally.~Tramadol (Group T): 25 mg tramadol added to 12.5 mg of 0.5% hyperbaric bupivacaine, administered intrathecally."
215002065|NCT06545695|DRUG|Erlotinib|Part B will be the dose escalation component, in which the subject will initiate 50 mg erlotinib,8 weeks later escalate to 75 mg, and then 8 weeks later to 100 mg erlotinib pending tolerance after each 8-week period.
215002066|NCT07121777|DRUG|Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis|A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）
215002067|NCT07121751|DRUG|use of combination of recombinant FSH and recombinant LH|in this arm the patients will use the combination of recFSH:recLH in the same dose as in her prior cycle
215002068|NCT07121751|DRUG|higher dose recFSH|in this arm the patient will use an additional 75 IU/day recFSH compared to her previous drug dose
215002069|NCT07121751|DRUG|unchanged dose|in this groups the patient will receive the same recFSH dose as in her prior cycle
214397916|NCT05322135|DRUG|18F-FSPG|Given by vein (IV)
214397917|NCT05322135|DRUG|11C-Glutamine|Given by vein (IV)
214397918|NCT01622712|DEVICE|Rebound HRD Mesh|Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
214397919|NCT03677063|OTHER|No dressing|Then, care is the same and exit-site remains covered with an occlusive dressing to promote tunnel epithelialization and healing. The shower is forbidden during this period.
214397920|NCT00099216|DRUG|Rivastigmine|
215002070|NCT07114120|DRUG|Bailing Capsules in combination Guben Kechuan Granules|Bailing Capsules (four capsules each time, three times a day) in combination Guben Kechuan Granules (1 bag each time，three times a day,)
214397921|NCT05470413|DRUG|SHR0302|SHR0302 4 mg
214397922|NCT05470413|DRUG|SHR0302|SHR0302 8 mg
214397923|NCT05470413|DRUG|Placebo|Placebo
214397924|NCT01706965|DRUG|Kuvan|20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
214397925|NCT01706965|DRUG|Multivitamin|Multi-vitamin will be used as an active control in this study. Will be dosed daily
215002071|NCT07120035|DIETARY_SUPPLEMENT|Lycopene-rich juice|We sought to deliver 8400 µg of lycopene per day, and so participants were asked to drink approximately 4 fluid ounces per day of the tomato-based, lycopene-rich juice.
214397926|NCT03944980|DRUG|Docetaxel|Docetaxel injection
214397927|NCT03944980|BIOLOGICAL|PD1-T cells|PD1-T cells injection
214397928|NCT00884520|DRUG|[F-18] VM4-037|"The individual doses of \[F-18\]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
215002072|NCT07113613|RADIATION|Exemption from additional radiotherapy on the tumor bed after surgery|For patients who met the inclusion criteria and were enrolled, postoperative tumor bed boost radiotherapy was waived, and only whole breast and/or regional lymph node irradiation was administered.
215002073|NCT07120581|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy at increasing pressure to 2.8 ATA for 2 hours sessions. Breaks of 5 every 20 minutes from the oxygen to air to avoid hyperoxia. Continued for the duration of the hospitalization in the ICU on a daily basis.
215002074|NCT07120074|OTHER|Exercise|A low-activity exercise group, and highly active dual-task exercise group determined based on physical performance level, was subjected to 6 weeks of dual-task exercises aimed at improving balance and cognitive function. Dual-task refers to performing two different tasks simultaneously. In the first week, tasks included generating 3- and 4-letter words while standing in a tandem position, reciting the months and seasons in order while shifting weight forward and backward on a balance board, and performing addition and subtraction tasks while walking. The difficulty level of the tasks was increased each week.
214397929|NCT05925738|DIAGNOSTIC_TEST|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting the Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
214397930|NCT02506621|DEVICE|R test|
215002075|NCT07118488|PROCEDURE|Multitarget PFA Ablation|"* Informed consent gave by the patient.~* Implantable loop recorder procedure~* Clinical procedure starts~* Electrophysiologycal study~* Non-invasive map is obtained.~* Electroanatomical map of both atria is generated.~* Intracavitary electrogram (EGM) driver assessment~* Pulmonary vein isolation~* Extra pulmonary drivers ablation based on EGM findings (rotational and high frequency sites).~* Non-invasive map is obtained to assess ablation impact on driver distribution.~* Remap and extra pulmonary lesions are carried out until activity. At drivers sites disappears or decreases in at least 2 hertz or up to physician criteria.~* Patient follow up"
215002076|NCT07120490|OTHER|FMT (fecal microbiota transplantation)|This intervention consists of a two-phase treatment for Clostridioides difficile infection in high-risk adults. First, participants receive a short-course (5 days) of oral vancomycin to reduce C. difficile bacterial load. Following antibiotic pretreatment, fecal microbiota transplantation (FMT) is administered to restore healthy gut microbiota. FMT is delivered primarily via encapsulated microbiota capsules, with alternative routes including colonoscopy, gastroscopy, nasojejunal tube, or rectal enema if capsules are contraindicated. A second FMT dose is given 7 days after the first, either as daily capsules over six days or as a single endoscopic administration. This approach aims to reduce CDI recurrence by combining targeted antibiotic reduction of pathogens with microbiome restoration.
215002077|NCT07120490|DRUG|Fidaxomicin|Participants receive a 10-day course of fidaxomicin administered orally at a dose of 200 mg twice daily. Fidaxomicin is a narrow-spectrum macrocyclic antibiotic specifically targeting Clostridioides difficile with minimal impact on the normal gut microbiota. This monotherapy aims to eradicate C. difficile infection while preserving the intestinal microbiome, thereby reducing the risk of recurrence. No additional interventions are provided during the treatment period. Biological samples are collected before and after treatment to evaluate clinical response, safety, and microbiome changes.
215002078|NCT07120490|DRUG|Vancomycin (VAN) treatment|Participants receive a 10-day course of oral vancomycin at a dose of 125 mg four times daily. Vancomycin is a broad-spectrum glycopeptide antibiotic commonly used as standard-of-care therapy for Clostridioides difficile infection. This monotherapy aims to eradicate C. difficile by reducing bacterial load in the colon. No additional interventions are applied during the treatment period. Biological samples are collected before and after treatment to monitor clinical outcomes, safety, and changes in the gut microbiome.
215095147|NCT04863690|BEHAVIORAL|Digital Coaching plus Human Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation. All participants will also be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account.
214397931|NCT02506621|DEVICE|Nuubo|
214397932|NCT02506621|DEVICE|TECHNOMED pocket ECG|
214503668|NCT06841172|DRUG|Systemic therapy (Early switch to second-line systemic therapy)|For patients who received sorafenib as FLST, regorafenib will be the preferred second-line option. For patients who received other FLST regimens, the SLST selection will be determined through an MDT discussion led by the treating physician based on the patient's overall condition, prior therapies, drug indications, and potential adverse effects, ensuring an individualized treatment approach. The specific dosing regimen, administration frequency, and dose adjustments will strictly follow the same prescribing information for each drug.
214397933|NCT02506621|DEVICE|ZIO xt patch|
214397934|NCT02506621|DEVICE|MoMe|
215002079|NCT07115589|OTHER|Muscle Your Heart home-based program|2 one-hour sessions of adapted physical activity per week - HIIT and free adapted physical activity - 1 one-hour monthly therapeutic patient education session - A dedicated platform - Adapted physical activity educators - Dedicated education therapeutic nurses
215002080|NCT07121296|BEHAVIORAL|Contingency management for substance use|Participants receive escalating incentives for each consecutive negative weekly urine drug screen.
215002081|NCT07121296|BEHAVIORAL|Contingency management for attendance|Participants receive escalating incentives for each consecutive counseling session they attended.
215002082|NCT07121296|BEHAVIORAL|Group-based Matrix counseling|Group-based Matrix counseling
214397935|NCT04287192|OTHER|Digital Bridge:Tool Intervention|Our Digital Bridge is an integration of the Care Connector and ePRO technologies that will support care transitions by: 1) inviting PCPs to access Care Connector while the patient is in hospital, allowing for asynchronous communication via the messaging feature for proactive discharge planning, 2) facilitating the inclusion of inter-professional recommendations in the discharge module (e.g. diet and mobility) typically missing from traditional physician generated discharge summaries, 3) electronic generation of PODS for use in patient-centred discharge teaching, 4) providing patients electronic access to PODS post discharge to facilitate use of information at home, 5) adoption of digital enabled goal-oriented process to engage patients and families in discharge process, and 6) providing ongoing self-management support for patients using ePRO for the vulnerable period 6 months post discharge.
214397936|NCT02814110|DRUG|Granulocyte colony-stimulating factor (Filgrastim)|Drug administration
215002083|NCT07121296|BEHAVIORAL|Individual-based Matrix counseling|Individual-based Matrix counseling
214397937|NCT05551429|BEHAVIORAL|Invitation to the CR|"1. Oral and written information emphasise the benefits of cardiac rehabilitation in terms of treatment of heart diseases, increasing functional capacity, reducing morbidity and mortality, and enhancing secondary prevention.~2. Introducing the scope and method of administration of CR to patients.~3. Setting up the appointment for the initial CR session four weeks later."
215002084|NCT07119710|BEHAVIORAL|Cognitive Behavioral Therapy|Individual tele-therapy 12-16 weeks
215002085|NCT07119710|BEHAVIORAL|Cognitive Behavioral therapy with 2 check in calls|Cognitive Behavioral therapy with 2 calls a week
215095148|NCT01065311|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
214397938|NCT05502224|OTHER|Ergospirometry|Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ
214397939|NCT06083311|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 3x10\^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
215095149|NCT01065311|BEHAVIORAL|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
215095150|NCT01065311|BIOLOGICAL|Standard psychiatric care|"Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
215095151|NCT04079881|DRUG|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
215095152|NCT01688908|PROCEDURE|Endoscopic Screening|"1. Upper G.I. endoscopic examination with Lugols Iodine in esophagus~2. Biopsy at the visually abnormal sites~3. Pathologic examination of all biopsy tissue specimens~4. Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~5. Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
215095153|NCT04547361|DRUG|E2511|E2511 tablets.
214397940|NCT06083311|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for 28 days
215095154|NCT04547361|DRUG|E2511 Matched Placebo|Placebo tablets matching E2511 tablets.
214397941|NCT01563978|DRUG|fostamatinib|fostamatinib 100 mg twice daily
214397942|NCT01563978|DRUG|placebo|placebo
214397943|NCT00729690|DRUG|Pregabalin|"Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.~Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.~Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2."
214397944|NCT00729690|DRUG|Pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
214397945|NCT00729690|DRUG|Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
215002086|NCT07121361|DEVICE|Mouthwash Product|DNA mouthwash
214397946|NCT00003639|BIOLOGICAL|recombinant interferon alfa|
214397947|NCT00003639|DRUG|chlorambucil|
214397948|NCT00003639|DRUG|dexamethasone|
214397949|NCT00003639|DRUG|idarubicin|
214397950|NCT00324012|DRUG|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
214397951|NCT03314649|OTHER|Observational study|Lavage of the Peritoneal Cavity
215002087|NCT07121361|DEVICE|Control|Placebo mouthwash
215002088|NCT07120256|OTHER|locator attachment|mandibular single implant overdenture retained by locator attachment
215002089|NCT07120256|OTHER|ball and socket attachment|mandibular single implant overdenture retained by ball and socket attachment
215002090|NCT07116811|DRUG|Steroids therapy|Methylprednisolone sodium succinate 80 mg powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed by 20 mg of prednisone acetate (oral intake, once daily) from day 4 to day 10.
215002091|NCT07116811|DRUG|Placebo|Methylprednisolone sodium succinate placebo powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed by prednisone acetate placebo (oral intake, once daily) from day 4 to day 10.
215002092|NCT03817398|PROCEDURE|Biospecimen Collection|Undergo blood collection
215002093|NCT03817398|OTHER|Drug Withdrawn|Stop taking TKI medication
215002094|NCT03817398|OTHER|Quality-of-Life Assessment|Ancillary studies
214397952|NCT01621282|OTHER|Education|A 6-month interactive course on critical appraisal
214397953|NCT01621282|OTHER|Conventional|Conventional method/no intervention
214397954|NCT02999893|DRUG|APR-246|APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
214397955|NCT01591161|DRUG|Mapracorat|1 drop of study medication into the study eye QID for 14 days
214397956|NCT01591161|DRUG|Placebo|1 drop of vehicle into the study eye QID for 14 days.
214503669|NCT05678231|DEVICE|Zero Degree Knee Positioner|The Zero Degree Knee (ZDK) positioning device is a knee extension pillow designed to simplify knee extension exercise following TKA surgery.
214397957|NCT04860843|DRUG|Thoracic paravertebral block|Participants will receive a thoracic paravertebral with local anesthetic infiltrate (30ml of 0.35% ropivacaine with 1:400K epinephrine).
214503670|NCT06988059|DRUG|CAR-T cells Infusion chimeric antigen receptor T cells|CAR-T cells Infusion
215002095|NCT03817398|OTHER|Questionnaire Administration|Ancillary studies
214397958|NCT04860843|DRUG|Pecs block|Participants will receive a pecs block with local anesthetic infiltrate (30ml of 0.25% ropivacaine with 1:400K epinephrine).
215002096|NCT03817398|DRUG|Tyrosine Kinase Inhibitor|Re-start TKI medication
214503671|NCT05462821|DEVICE|Eye Patch|adhesive patch to cover eye
214397959|NCT04860843|DRUG|Sham Pecs block|Participants will receive a and a pecs block with saline infiltrate (30ml normal saline; 0.9% NaCl).
214397960|NCT04239456|DEVICE|RehaCom (software)|RehaCom software has gamified, interactive modules that will help participants practice the application of various memory strategies at custom, increasingly more difficult levels. Instructor will also use the software to teach and demonstrate the use of memory strategies with the domains targeted (i.e., list learning, remembering written/verbal information, and memory for names/faces).
214503672|NCT06857968|BEHAVIORAL|Mobile Mindfulness Training|Participants will be instructed to complete a mobile application-based mindfulness training daily for 30 days.
214503673|NCT05824559|DRUG|ME-344|ME-344 will be administered intravenously (IV)
214503674|NCT05824559|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV)
214503675|NCT06196840|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
214503676|NCT06196840|BIOLOGICAL|Aflibercept intravitreal injection|Commercially available Active Comparator
214503677|NCT06612840|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
214503678|NCT05282706|DRUG|Lavender Oil|A hydrogel lavender oil infused aromatherapy patch
214503679|NCT05282706|DRUG|Mandarin Oil|A hydrogel mandarin oil infused aromatherapy patch
214503680|NCT05282706|DRUG|Peppermint oil|A hydrogel peppermint oil infused aromatherapy patch
215002097|NCT07119775|DRUG|Tideglusib|
214503681|NCT05282706|OTHER|Placebo|A placebo patch containing no aromatherapy oil
214503682|NCT06993415|OTHER|data collection|"The ORACLE program is a prospective, deep phenotyping, study based on multimodal information and artificial intelligence computation. We will prospectively collect in-hospital and out-of-hospital data of a large cohort of patients presenting with MI, including data from wearable devices recording continuous ECG, interstitial-fluids, non-invasive blood pressure and mobility, behavioural patterns from a dedicated mobile application, blood and urine biomarkers and non-invasive imaging. We will leverage on AI, using statistical learning methods and neural networks, to explore patterns and higher order interactions within the data to provide novel computational biomarkers of ischemic and bleeding risk."
214503683|NCT06994975|DRUG|0.25mg/kg TNK|Patients in the tenecteplase group were administered a 0.25mg/kg dose as a bolus over 5-10 seconds, followed by a 2 mL saline flush.
215002098|NCT05339126|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
215002099|NCT04804150|DEVICE|Vacuum suspension system active or inactive|The device will be plugged in, or won't be plugged in, depending of the randomization. The patient and the investigator will not know whether the device is plugged in or not, and if the medical device is active or not
215002100|NCT06480357|PROCEDURE|laparoscopic adrenalectomy|laparoscopic transabdominal approach.
215002101|NCT03477981|OTHER|Alginate bread|White bread with 4% alginate (wet weight of dough) included into the bread.
215002102|NCT06037915|DEVICE|low flow oxygen with nasopharyngeal tube|low flow oxygen with nasopharyngeal tube
215002103|NCT06037915|DEVICE|high flow oxygen with OptiflowTM Nasal High Flow|high flow oxygen with OptiflowTM Nasal High Flow
215002104|NCT01379209|DRUG|RGI-2001|A single administration of RGI-2001 on Day 0 post AHSCT.
215002105|NCT01379209|DRUG|Calcineurin Inhibitors|GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
215002106|NCT01379209|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|According to institutional guidelines.
215002107|NCT01379209|DRUG|Conditioning Regimen|Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
215002108|NCT01379209|PROCEDURE|Allogeneic Bone Marrow Transplantation|According to institutional guidelines
215002109|NCT01379209|DRUG|Methotrexate|
215002110|NCT01379209|DRUG|Mofetil Mycophenolate|
214503684|NCT06994975|DRUG|Standard medical treatment|Patients in the standard medical treatment group will receive the standard treatment selected by local doctors, including antithrombotic agents, lipid-lowering agents, antihypertensive drugs, and hypoglycemic agents. Patients would be ineligible if bridging endovascular treatment is planned at the time of randomization.
215002111|NCT01379209|DRUG|sirolimus|Administered for GVHD prophylaxis as per institutional guidelines
215002112|NCT04167670|DRUG|Vonoprazan|Over-encapsulated tablets administered orally.
214397961|NCT02117336|DRUG|P1446A-05|"The study have dose escalation phase, followed by a dose extension phase.~* Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~* Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death."
214397962|NCT02672163|PROCEDURE|CABG surgery|Elective CABG surgery
214397963|NCT02672163|PROCEDURE|AADC therapy|Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
214397964|NCT06227325|DRUG|RC48 combined with Sintilimab and XELOX|RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1；Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks
214397965|NCT03857711|PROCEDURE|Conventional CABG|Coronary artery bypass grafting
214503685|NCT05346224|DRUG|HLX11|Neoadjuvant(q3w/cycle，total 4cycle): HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
214503686|NCT05346224|DRUG|EU-Perjeta®|Neoadjuvant(q3w/cycle，total 4cycle): Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11 or Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
214503687|NCT02823028|DRUG|NRT|8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
214503688|NCT02823028|BEHAVIORAL|Web Guide|"A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules."
215095155|NCT00868036|PROCEDURE|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
214397966|NCT03857711|PROCEDURE|CABG+ PVI|CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins
215002113|NCT04167670|DRUG|Amoxicillin|Capsules administered orally.
215002114|NCT04167670|DRUG|Clarithromycin|Tablets administered orally.
214397967|NCT03857711|PROCEDURE|CABG+ PVI+amiodarone|CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)
214397968|NCT03857711|PROCEDURE|CABG+amiodarone|
214503689|NCT02823028|BEHAVIORAL|Tweet2Quit|"A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group."
214503690|NCT03765567|DRUG|Vancomycin|2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
214503691|NCT06536504|OTHER|Steinway Spirio M recording/player piano|Patients will be equally randomized into one of the three arms (simulated live music, recorded music, or no music) applying the random permutated block. Randomization will be conducted via an approved institutional database with the randomization list generated by the study statistician.
215002115|NCT04167670|DRUG|Lansoprazole|Over-encapsulated capsules administered orally.
215002116|NCT00962598|DRUG|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
215002117|NCT00962598|DIETARY_SUPPLEMENT|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
215002118|NCT05011435|DEVICE|web-application for burnout|Use of burnout advisor web-application for detection of professional burnout
215002119|NCT01892852|PROCEDURE|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
215002120|NCT06451744|OTHER|Blood samples collection|50 mL blood sample
215095156|NCT03681613|OTHER|NEMEX program combined with a CNS-focused protocol|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training."
215095157|NCT03681613|OTHER|NEMEX program|The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
215095158|NCT04507971|BIOLOGICAL|MET-3|Human microbiome supplementation derived from bacterial strains isolated from fecal matter and grown in a laboratory environment
215095159|NCT06505538|DEVICE|NL-Mapp|Mobile applicaiton
214397969|NCT05075655|DEVICE|Endobronchial ultrasound guided miniforceps biopsy and transbronchial needle aspiration|"Mediastinal node is sampled using three path of classic ultrasound guided transbronchial needle aspiration (EBUS-TBNA).~A reduce size forceps is then inserted inside the mediastinal node via the duc EBUS-TBNA made and biopsies (EBUS-MFB) are made using real time ultrasound guidance."
214397970|NCT00290082|DRUG|loxapine, midazolam|agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
214397971|NCT00290082|BIOLOGICAL|blood sample|was evaluated in patients sedated, alcohol level, blood sugar
214397972|NCT00290082|OTHER|patient monitoring|Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
214397973|NCT00290082|DRUG|Loxapine|Loxapine 1 mL / 10 kg
214397974|NCT00290082|DRUG|Midazolam|Midazolam 1 mL / 10 Kg
214397975|NCT03390361|DEVICE|Femtosecond Laser-assisted|Laser cataract surgery will be performed in one eye
214397976|NCT03390361|PROCEDURE|Manual Cataract Surgery|Manual cataract surgery will be performed in contralateral eye
214397977|NCT03816592|PROCEDURE|Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
214397978|NCT03816592|PROCEDURE|Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
214397979|NCT05721339|BEHAVIORAL|Acceptance and Commitment Therapy|"ACT will be applied through 8 sessions by the psychological flexibility processes, which were grouped into three response styles: open, aware, and active. Openness is reflected by acceptance, which means the conscious embrace of psychological events without unnecessary attempts to change their frequency. Defusion means untangling unhelpful thoughts and responding to mental experiences as experiences rather than guides to action. The awareness set, which is reflected by applying self-as-context, which means a continuous and secure I from which events are experienced but distinct from those events. A present moment means ongoing, nonjudgmental contact with internal and external events as they occur in the present moment. The active set, which was reflected by making the intern nurses embrace their desired and chosen life values directions, and commit action to selected values."
214397980|NCT06307483|BEHAVIORAL|Taichi group|Participants in the Tai chi group were regular Tai chi practitioners who had practiced Tai chi for at least 3 months, at least three times a week for at least 30 minutes each time.
214397981|NCT06307483|BEHAVIORAL|Exercise group|The subjects in the exercise group had regular exercise habits, and insisted on non-Tai chi exercise for at least 3 months, at least three times a week, at least 30 minutes each time.
214397982|NCT04562779|DRUG|Naltrexone 380 MG|XR naltrexone to be given once prior to hospital discharge
214397983|NCT04562779|DRUG|Ketamine Hydrochloride|IV ketamine infusion to be given once prior to hospital discharge
214397984|NCT04562779|BEHAVIORAL|Enhanced linkage|Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up
214397985|NCT05332951|OTHER|Interpersonal Reactivity Index|Questionnaire to be completed by the patient
214397986|NCT00333138|DRUG|FTY720|FTY720 capsule was taken orally once a day
214397987|NCT00333138|DRUG|Placebo|Placebo 1.25 mg capsule was given once daily
214397988|NCT05103254|DRUG|Bempedoic Acid|Bempedoic Acid 180 MG
214397989|NCT05103254|DRUG|Bempedoic Acid / Ezetimibe|Bempedoic Acid 180 MG / Ezetimibe 10 MG
214397990|NCT04581239|OTHER|Active neural mobilization|"Active neural mobilization Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization.~Active oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set"
214397991|NCT04581239|OTHER|passive neural mobilization|"Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization~Passive neural mobilization This oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set. Both groups received total 18 session 3 session per week for consecutive 6 weeks"
214397992|NCT02541539|DIETARY_SUPPLEMENT|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
214503692|NCT06863051|PROCEDURE|Immediate Implant Placement and Alb-PRF|Immediate Implant Placement in lower molar region, Grafted with Xenograft and Albumin PRF Gel
215002121|NCT06451744|OTHER|Skin or mucous membrane brushing|brushing on skin or mucous membrane lesions
215002122|NCT06451744|OTHER|Skin or mucous membrane biopsy|6 mm biopsy
215002123|NCT03850587|DRUG|Celecoxib 200mg|comparator medication
215002124|NCT03850587|DRUG|Tramadol 37.5Mg+ Celecoxib 200mg|experimental medication
215002125|NCT03850587|DRUG|Tramadol 75mg+ Celecoxib 200mg|experimental medication
215002126|NCT03850587|DRUG|Tramadol 150mg+ Celecoxib 200mg|experimental medication
215002127|NCT00297934|DEVICE|Pro-adjuster mechanical spinal manipulative device|
215002128|NCT00470613|GENETIC|SGT-53|For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
215002129|NCT01092923|DRUG|sevoflurane on air/O2|sevoflurane on air/O2
215095160|NCT00924404|DRUG|Xylitol|5% solution for sinus rinse
215002130|NCT01092923|DRUG|sevoflurane in N2O/O2|sevoflurane in N2O/O2
215002131|NCT00330096|DRUG|Hesperidin|
215002132|NCT00330096|OTHER|Placebo|
215002133|NCT00587457|DRUG|CAT-8015 5 mcg/kg|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
215002134|NCT00587457|DRUG|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
215002135|NCT00587457|DRUG|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
215002136|NCT03392857|OTHER|Assessment by caregivers of the quality of the end of life in intensive care units|Quality of the end of life in intensive care units perception will be explore from the side of the caregivers, trough the CAESAR scale.
214397993|NCT02541539|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
214397994|NCT03839121|DEVICE|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of CRT patients
214397995|NCT05190068|DRUG|HMPL-760|HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
214397996|NCT05654272|DIAGNOSTIC_TEST|MRI|Cardiac MRI
214397997|NCT06373588|BEHAVIORAL|Patient Navigator|The patient navigator will meet the following requirements: a bachelor's degree in health or social sciences, or equivalent experiences; strong knowledge of the local health and social services system; trauma-informed care and cultural safety; strong interpersonal skills, ability to problem-solve, and autonomy; have prior experiences with migrant communities (including lived experiences) and working in healthcare setting. The navigator will be trained on topics related to their role, through case discussions, and role playing, as done in other navigator trials. Topics will include Indigenous cultural safety as applied to migrant health, systems navigation, care coordination, family-centred care, social determinants of health (health insurance, income supplements, etc.) and inequities, advanced communication and helping skills (e.g., motivational interviewing), ethics, privacy, and confidentiality, and others as determined through our co-design process.
214503693|NCT06863051|PROCEDURE|Immediate Implant Placement and L-PRF|Immediate Implant Placement in lower molar region, Grafted with Xenograft and L-PRF
215002137|NCT02314884|DRUG|Cafusertib Hydrochloride|
215002138|NCT00876395|DRUG|Everolimus|Everolimus was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
215002139|NCT00876395|DRUG|Placebo|Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
215002140|NCT00876395|DRUG|Trastuzumab|Trastuzumab, 2 mg/kg weekly was used intravenously.
215002141|NCT00876395|DRUG|Paclitaxel|Paclitaxel, 80 mg/m2 weekly was used intravenously.
215002142|NCT03168724|BEHAVIORAL|GMT intervention|
215002143|NCT06031129|DRUG|Butorphanol|The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery
215002144|NCT06031129|DRUG|normal saline|normal saline contain 0.9% NaCl sodium.
215002145|NCT01850329|OTHER|computed-assisted information program|
215002146|NCT06505148|DRUG|Acetaminophen|administered alternatively with other drug
215002147|NCT06505148|DRUG|Ibuprofen|administered alternatively with other drug
215095161|NCT00924404|DRUG|Saline|saline for sinus rinse
215095162|NCT06000605|OTHER|Fed|Participants will eat a light meal prior to testing and be fed a light meal during testing.
215095163|NCT06000605|OTHER|Fasted|Participants will completely abstain from calories for 72 hours prior to testing and not receive any calories during testing.
215095164|NCT02725190|BEHAVIORAL|Sleepless night|Each subject will undergo 28 hours of sleep deprivation.
215095165|NCT02725190|BEHAVIORAL|Normal sleep night|Normal sleep at home before trial.
215095166|NCT00145691|DRUG|Oxcarbazepine|
215095167|NCT01932775|DEVICE|GlucoTab System|
215095168|NCT06506539|DRUG|Placental Extract|add placental extract gel as a local delivery drug in periodontal pocket
214397998|NCT03502603|DIAGNOSTIC_TEST|Railroad Test|This is a test designed to evaluate visual perception capacities and requires the participant to match photographs with railroads as a central theme. The participant is presented with a photograph image at the top of the screen and is asked to match it to one of the two, three or four choices in the lower portion of the display.
214397999|NCT03502603|DIAGNOSTIC_TEST|Swamp Test|This is a test of immediate visual memory/attention for photographs with swamp wetlands as a central theme. The participant is briefly presented with a photograph which is replaced by two, three or four choices, one of which the participant is asked to select as the initially presented image.
215002148|NCT03588520|DIAGNOSTIC_TEST|Home Blood Pressure Monitoring|Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
214398000|NCT03502603|DIAGNOSTIC_TEST|Presidents Recognition Test|This is a test of history knowledge and facial recognition using pictures of US presidents and non-president distractors. The participant is presented with two photographs and is asked to identify which is the picture of a US president
214398001|NCT03502603|DIAGNOSTIC_TEST|Judgment of Line Orientation|This test requires participants to visually match the orientation of line segments. This is a test of visual perception and was included as a relative equivalent of the Railroad Test.
214398002|NCT03502603|DIAGNOSTIC_TEST|Symbol Span subtest of the Wechsler Memory Scale-IV|This test requires participants to immediately recall a sequence of designs after a brief presentation. This is a test of immediate visual memory/attention and was included as a relative equivalent of the Swamp Test
214398003|NCT03502603|DIAGNOSTIC_TEST|Information subtest of the Wechsler Adult Intelligence Scale-IV:|This test requires participants to answer factual knowledge questions. This is a test of fund of knowledge and was included as a verbal equivalent for the non-verbal Presidents Recognition Test.
214398004|NCT03502603|DIAGNOSTIC_TEST|Digit Span subtest of the Wechsler Adult Intelligence Scale-I|This test requires the participant to repeat sets of digits forward, backward, and to sequence digits in ascending order. This is a test of immediate memory/attention and was included to investigate possible attentional correlates of the Swamp Test. This test includes a performance validity indicator that will permit analyses of validity indicators included with the experimental tests
214398005|NCT03502603|DIAGNOSTIC_TEST|Reading subtest of the Wide Range Achievement Test|This test requires participants to read words printed on a card. This is a test of word knowledge/academic achievement and was included to investigate the academic achievement concomitants of the Presidents Recognition Test.
214398006|NCT03502603|DIAGNOSTIC_TEST|Symbol Digit Modalities Test:|This test requires participants to visually match abstract symbols with numbers within a certain time period. The participant either verbalizes or writes the response on an answer sheet. This is a test of speed of information processing and was included to assess speed of response factors pertaining to all of the experimental tests as reflecting speed of information processing.
215002149|NCT00482144|PROCEDURE|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
215002150|NCT00482144|PROCEDURE|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
215002151|NCT03807843|BIOLOGICAL|V184|Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.
215002152|NCT03807843|OTHER|Placebo|Sterile physiological saline for IM injection
215002153|NCT01312129|DRUG|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
214398007|NCT03502603|DIAGNOSTIC_TEST|Dot Counting Test|This test requires participants to count arrays of dots presented on a card while being timed. This is a performance validity test and was included to ascertain validity factors pertaining to each of the experimental tests.
214398008|NCT05289934|BEHAVIORAL|Music Stimuli|Nine-minute-long Mozart K.448 (1st movement) and instrumental age-appropriate songs will be played via single-use earbuds with 10 minutes wash-out in between music stimuli.
214503694|NCT06857981|OTHER|Clinical data collection|Patient's data will be collected, including: date of birth, age, gender/sex, pathology for admission, comorbidities, treatment received, and proposed interventions based on initial assessment.
214503695|NCT05355428|OTHER|offering of breast milk feed 3 hours prior to planned surgery start|parents will be asked to offer a breast milk feed (from breast or expressed in bottle) at a given time 3 hours prior to planned induction time
215002154|NCT01312129|DRUG|Placebo|Placebo capsule x 3 doses 12 hours apart
215002155|NCT05053828|DRUG|Antiplatelet Drug|Antiplatelet drugs and agents
215002156|NCT03975634|DEVICE|Transcutaneous Spinal Stimulation|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
215002157|NCT00104234|DRUG|N-acetylgalactosamine 4-sulfatase|
215002158|NCT00104234|DRUG|Placebo/rhASB|
215002159|NCT04674527|DRUG|Elemene|Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.
215002160|NCT04674527|DRUG|Temozolomide|Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
215002161|NCT00236431|DRUG|Galantamine hydrobromide|
215095169|NCT03463668|DEVICE|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
215095170|NCT06507670|DIAGNOSTIC_TEST|Point of care ultrasound|"Point of care medical ultrasound machines will be used to sonographically visualize the esophagus and following sonographic data will be collected:~* Presence/absence of suspected foreign body~* Sonographic esophageal measurements (diameters, area)~* Other relevant secondary sonographic findings"
215095171|NCT00111904|DRUG|paclitaxel-loaded polymeric micelle|
214503696|NCT06020274|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF. Upon logging on to the iCF-PWR, the viewer will see two paths (i.e., child with CF or sibling) and will be encouraged by program narrator to choose the appropriate path. Each pathway (i.e., child with CF or sibling) is comprised of five text/voice-delivered, animated, interactive modules: (1) CF education, (2) CF health, (3) emotions and CF, (4) cognitive behaviour model of emotions, and (5) coping strategies. Each module takes 15-20 minutes to complete.
214398009|NCT03841708|DEVICE|Pleth variability index|The utility of a early goal directed therapy will be evaluate by the pleth variability index (PVI). If above\>13% in a well sedated patients perfectly synchronized with the ventilator providing at least 6ml/kg of ideal body weight, a fluid challeng with 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
215002162|NCT02113566|DRUG|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
215002163|NCT00924651|BEHAVIORAL|exercise|home based walking and progressive resistance training exercise
215002164|NCT03318419|DRUG|Cladribine|5mg/㎡ d1-5
215002165|NCT03318419|DRUG|G-CSF|300ug d0-14
214503697|NCT04411199|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
215002166|NCT03318419|DRUG|Cytarabine|10mg/㎡ q12h SC d1-14
215002167|NCT03318419|DRUG|Pegaspargase|2500U/m2 im d1
215002168|NCT05301699|OTHER|data analysis; validating the nomogram|Not Applicable. Our study did not involve intervention
214503698|NCT04411199|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
214503699|NCT06156410|DRUG|Cabozantinib|Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles. If still on study therapy the participants will continue with cabozantinib monotherapy for up to 12 total cycles.
215095172|NCT01843270|DEVICE|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
215095173|NCT01843270|DEVICE|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
215095174|NCT06508879|COMBINATION_PRODUCT|Aquacel Ag Surgical®|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
214503700|NCT06995625|DRUG|SNE-101|Experimental: Cohort 1 - SNE-101 4.8 × 10e10 particles (n=3 to 6) Experimental: Cohort 2 - SNE-101 9.6 × 10e10 particles (n=3 to 6) Experimental: Cohort 3 - SNE-101 19.2 × 10e10 particles (n=3 to 6)
214503701|NCT03615352|PROCEDURE|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
214503702|NCT03615352|PROCEDURE|ovarian cyst aspiration and coagulation|laparoscopic ovarian cyst aspiration and coagulation in endometrioma
215002169|NCT00729586|OTHER|Laboratory Biomarker Analysis|Correlative studies
215002170|NCT00729586|DRUG|Megestrol Acetate|Given PO
215002171|NCT00729586|DRUG|Tamoxifen Citrate|Given PO
215002172|NCT00729586|DRUG|Temsirolimus|Given IV
215002173|NCT02663986|BEHAVIORAL|Organizational Skills Training (OST) Intervention|
215002174|NCT03090906|PROCEDURE|Soft tissue augmentation palate|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Palate (CG) The double incision was made approximately 2 to 3 mm apical to the gingival margins of premolars. The donor tissue was removed and cross-mattress sutures were used to approximate the wound on the palate.~In both groups the epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
215002175|NCT03090906|PROCEDURE|Soft tissue augmentation tuberosity|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Tuberosity (TG) The double incision was made from the distal of the terminal tooth. A second incision was made perpendicular to the linear incision at a distal point, which joined the two linear incisions. The graft was removed and a crossed horizontal suspension suture was used.~Epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
215002176|NCT03090906|DEVICE|Intraoral optical scan|Intraoral optical scan was performed at both groups at baseline, 3 months, 4 months and 12 months to be able to compare volumetric changes.
215095175|NCT06508879|OTHER|Standard Care (sterile gauze and adhesive tape)|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
215095176|NCT00369694|DRUG|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
215095177|NCT00369694|DRUG|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
215095178|NCT03851419|DIAGNOSTIC_TEST|Diagnosis of (Neuro)cysticercosis|"* Serological tests for cysticercosis~* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~* Stool testing for T. solium"
215095179|NCT04117763|DRUG|Empagliflozin 25 MG|Empagliflozin once daily, for three months
215002177|NCT00214435|DRUG|once daily minimum 3-drug regimen of anti-retroviral medications|
215002178|NCT01665027|PROCEDURE|vacuum|"Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).~Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections."
215002179|NCT01665027|PROCEDURE|routine manual maneuvers for fetal head extraction|fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
215002180|NCT06532942|DRUG|(Part A) MKND-201|Participants will receive single ascending doses (Target Dose, High Dose, and Very High Dose) of MKND-201 or placebo administered via oral inhalation on Day 1
215002181|NCT06532942|DRUG|Placebo|Participants will receive matching placebo across Part A and Part B of the study.
215002182|NCT06532942|DRUG|(Part B) MKND-201|Participants will receive multiple ascending doses (Target Dose and High Dose) of MKND-201 or placebo administered via oral inhalation, twice daily, from Day 1 to Day 7
215002183|NCT01865851|DEVICE|Classic Face Mask and NuMask|
215002184|NCT04134871|BEHAVIORAL|Group walk and one to one coaching|Participants will be invited to attend a group education session, weekly group walks and fortnightly coaching sessions
215002185|NCT00563173|DRUG|CHRONVAC-C®|DNA vaccine, solution for injection, i.m. administration in combination with electroporation
214398010|NCT03841708|DEVICE|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG. If deemed necessary by the treating physician a fluid challenge of 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
214398011|NCT01717183|DEVICE|Urgo 310 3113|URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
214398012|NCT01717183|DEVICE|Placebo URGO 310 3113 dressing|
214398013|NCT03027687|DEVICE|tDCS|tDCS is an electrical brain stimulation method
214398014|NCT02862041|DEVICE|Echogenic needle - Pajunk sonoplex echogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
214398015|NCT02862041|DEVICE|Non Echogenic needle - Stimuplex Braun Nonechogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
214398016|NCT05593211|DEVICE|Kronos Electrocautery Device|The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition
214398017|NCT04343222|DRUG|Bromfenac|An NSAID used to treat eye pain and swelling
214398018|NCT04343222|DRUG|Artificial tears|eye drops to lubricate the eye and maintain moisture
214503703|NCT06677203|DRUG|ASN51|Oral capsules
214503704|NCT06677203|DRUG|Placebo|Oral capsules
215002186|NCT05502172|DIETARY_SUPPLEMENT|fish oil|healthy individuals will be taking the composition of fish-deraivd oils BioMarine®Medical Immuno \& Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.
215002187|NCT05408988|DIAGNOSTIC_TEST|hs-TnT (high-sensitive cardiac troponin T) plasma concentration|hs-TnT plasma concentration measured once every 12 hours
214398019|NCT00859092|DIETARY_SUPPLEMENT|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
214398020|NCT03077620|DRUG|Suvorexant|Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
214398021|NCT03077620|DRUG|Placebo|Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
214398022|NCT00454428|PROCEDURE|pulsatile intra-aortic balloon pump|
214398023|NCT05092425|OTHER|no intervention|no intervention
214398024|NCT03225846|DRUG|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide (ASO)
214398025|NCT03225846|DRUG|Placebo|0.9% Sodium Chloride
214398026|NCT00253539|DRUG|arzoxifene hydrochloride|Given orally
214398027|NCT00253539|DRUG|tamoxifen citrate|Given orally
214398028|NCT00253539|OTHER|placebo|Given orally
214503705|NCT07002593|OTHER|Myofascial release (MFR)|A 10-minute manual myofascial release (MFR) technique targeting active upper trapezius trigger points (MTrPs), applying sustained pressure until tissue release was achieved.
214503706|NCT07002593|OTHER|Muscle Stretching|Three 30-second static muscle stretches were performed for the upper trapezius by placing neck side flexion with contralateral rotation.
215002188|NCT05408988|DIAGNOSTIC_TEST|CK-MB (creatine kinase myocardial band) plasma concentration|CK-MB plasma concentration measured every 12 hours
215002189|NCT05408988|DIAGNOSTIC_TEST|CPK (creatine phosphokinase) plasma concentration|CPK plasma concentration measured every 12 hours
215002190|NCT05408988|DIAGNOSTIC_TEST|NT-proBNP (N-terminal prohormone of brain natriuretic peptide) plasma concentration|NT-proBNP plasma concentration measured every 12 hours
215002191|NCT05408988|DIAGNOSTIC_TEST|Metanephrine concentration in urine|Metanephrine concentration measured in 12-hour urine collection using spectrophotometry.
215002192|NCT01609972|DEVICE|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
215002193|NCT04621084|BEHAVIORAL|Eating habits|Questionnary online
215002194|NCT03382093|BEHAVIORAL|Personalized Feedback Intervention|Personalized Feedback Intervention for smoking and anxiety.
215002195|NCT03382093|BEHAVIORAL|Smoking Information Control|Smoking Information with no personalized feedback.
215002196|NCT00974870|PROCEDURE|needling treatment|Needling treatment applied to half of the face at each study visit
215002197|NCT04464772|DEVICE|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
214398029|NCT01157143|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form : solution~Route of administration : intramuscular"
214398030|NCT02231372|DRUG|Berodual® Respimat® solution for inhalation|
215002198|NCT02126332|OTHER|ropivacaine and sufentanil|Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.
215002199|NCT02126332|OTHER|acetaminophen, nefopam, tramadol, opidoids|Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
214398031|NCT03722719|OTHER|the Knack|The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.
215002200|NCT03201107|OTHER|Pilates|"Training based on a basic level Pilates exercise program will be as follows:~A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty."
215002201|NCT00576615|DRUG|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
214398032|NCT03722719|OTHER|PFMT|The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.
214398033|NCT03722719|OTHER|The Knack + PFMT|These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
214398034|NCT01028521|DRUG|CM3.1-AC100|Solution for sc injection, single ascending doses
214398035|NCT01028521|DRUG|Placebo|Solution for sc injection
214398036|NCT00026520|BIOLOGICAL|recombinant interferon alfa|
214398037|NCT00026520|DRUG|thalidomide|
214398038|NCT06013332|DEVICE|PBF PLLA microsphere (injectable poly-L-lactic acid)|Poly-L-lactic acid (PLLA) is a collagen stimulator, helps restore the deep, underlying structure of the skin to diminish facial wrinkles. PLLA microparticles are absorbable for human body, and it works with human body within the deep dermis to help revitalize collagen production and help restore human skin's inner structure and volume. PLLA can rebuilt collagen strands begin gradually helping to restore facial volume and the look of fullness to wrinkles and folds.
214398039|NCT06013332|DEVICE|Sculptra®|Sculptra®
214398040|NCT05427513|DRUG|Tranexamic acid injection|will inject tranexamic acid in limb salvage surgery of sarcoma patient to check its efficacy in preventing blood loss
214398041|NCT05427513|OTHER|normal saline|normal saline will be injected to ensure placebo
214398042|NCT03434613|DRUG|Rosuvastatin|Rosuvastatin 5mg 1T daily for 6 months
214398043|NCT03434613|DRUG|Rosuvastatin/ezetimibe combination|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
214398044|NCT02934516|PROCEDURE|Cesarean section|"Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally"
214398045|NCT05559437|DRUG|Levo-bupivacaine 0.25|The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
214503707|NCT07002593|OTHER|High-powered pulsed therapeutic ultrasound (HPPT-US)|A 5-minute high-powered pulsed therapeutic ultrasound (HPPT) was delivered subcutaneously with specific parameters of 1.5 W/cm², 1 MHz, and pulsed mode.
214503708|NCT01836445|BEHAVIORAL|Keep It Up!|
214503709|NCT01836445|BEHAVIORAL|HIV Knowledge Control|
215095180|NCT02613169|DRUG|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
215095181|NCT00343382|DRUG|pilocarpine hydrochloride|Given orally
215095182|NCT00343382|OTHER|placebo|Given orally
215095183|NCT02601547|DEVICE|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
215095184|NCT02762747|PROCEDURE|preperitoneal suction drainage|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
215095185|NCT00933894|DRUG|Telaprevir; Escitalopram|
215002202|NCT00576615|DRUG|propofol|"On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.~Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks."
215002203|NCT01949987|OTHER|two hours|
214398046|NCT05768516|OTHER|Implementation of best practice for low back pain in primary care|"1. Stratified care: GPs will use a simple algorithm based on the risk of chronicity to determine the management plan. The risk level bas will be based on the Start Back Tool (SBT) and other variables that have been shown to improve the classification, such as work capacity.~2. Healthcare professional education: GPs will receive education to improve their knowledge about low back pain guidelines, diagnostic triage, patient education, stratified care and best practice.~3. Patient education: An education booklet Understanding My Low Back Pain will be used by GPs during their consultations. Second, GPs, PTs and OTs will provide similar reassuring messages and direct patients to the website www.infomaldedos.ch.~4. Interprofessional collaboration: A structured assessment form and a facilitated contact will be implemented between healthcare providers."
214398047|NCT06195124|DRUG|RGL-193（low-dose）|Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10\^11 VG and a bilateral dose of 3.0×10\^11 VG.
214398048|NCT06195124|DRUG|RGL-193（high-dose）|Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10\^11 VG and a bilateral dose of 1.0×10\^12 VG.
214398049|NCT00238420|DRUG|Paclitaxel|Given IV
214398050|NCT00238420|RADIATION|Radiation Therapy|Undergo radiation therapy
215002204|NCT01949987|OTHER|one hour|
215002205|NCT06324591|OTHER|Collection biological sample and analysis|collection of a stool sample collected at clinical practice check-ups during the first year after diagnosis of Crohn's disease. This is followed by the evaluation of clinical, laboratory and instrumental data at the time of diagnosis
215002206|NCT05415657|DRUG|Denosumab|Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
214398051|NCT00238420|BIOLOGICAL|Trastuzumab|Given IV
214398052|NCT00338793|DRUG|prednisolone|
214398053|NCT00108121|DRUG|PEP005|
214398054|NCT03666910|DIAGNOSTIC_TEST|Audiometer|detection of hearing problems
214398055|NCT02450019|PROCEDURE|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.
214398056|NCT02450019|PROCEDURE|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
214398057|NCT05364619|DRUG|Qingre Huashi Granules combined the modified dual therapy|Qingre Huashi Granules combined the modified dual therapy for 14 days
214398058|NCT05364619|DRUG|Bismuth containing quadruple therapy|Bismuth containing quadruple therapy for 14 days
214398059|NCT02754414|PROCEDURE|Apheresis platelet collection|A single apheresis platelet unit will be collected from a healthy adult volunteer subject using the Trima Accel® Automated Blood Collection System. Concurrent plasma will be collected.
214398060|NCT02754414|OTHER|Refrigerated storage of apheresis platelets in PAS/plasma|The apheresis platelet unit will be stored, without agitation, at 4°C, for up to 20 days.
214398061|NCT02754414|RADIATION|Infusion of aliquot of autologous radiolabeled platelets|Fresh and stored aliquots will be labeled with Indium-111. We are administering ≤30 microcuries in both infusions for a total dose of 0.8 mSv.
214398062|NCT02754414|OTHER|In vitro tests|Tests to evaluate platelet function will be performed on the platelet unit on day of collection and end of storage
214398063|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 1, once daily
214398064|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 2, once daily
214398065|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 3, once daily
214398066|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 4, once daily
214398067|NCT01119339|DRUG|LAS 41004|LAS 41004 , dosage 5, once daily
214398068|NCT01119339|DRUG|LAS 41004 dosage 6|LAS 41004, dosage 6, once daily
214398069|NCT01119339|DRUG|Placebo|Placebo, once daily
214398070|NCT01119339|DRUG|Reference|Reference, once daily
214398071|NCT05343117|DRUG|Palbociclib based-therapy as initial endocrine therapy|Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)
214398072|NCT05343117|DRUG|Palbociclib based-therapy after chemotherapy|Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)
214398073|NCT01053637|DRUG|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
215002207|NCT05415657|DRUG|Placebo|Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
215002208|NCT00662259|DRUG|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
215002209|NCT00662259|DRUG|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
215002210|NCT02537496|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.
215002211|NCT02537496|PROCEDURE|Repetitive Transcranial Magnetic Stimulation - Sham|Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects
214398074|NCT01053637|DRUG|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
215002212|NCT02323438|OTHER|Usual Brand Cigarette|Combustible cigarette brand style smoked most frequently by subject
215002213|NCT02323438|OTHER|Electronic Cigarette #1|Electronic cigarette
214398075|NCT04499417|DEVICE|Electromyostimulation Whole-Body-Workout|Electromyostimulation - intensity 5 (muscle stimulation)
214398076|NCT04499417|DEVICE|Electromyostimulation Sham Whole-Body-Workout|Electromyostimulation - intensity 0 (no muscle stimulation)
214398077|NCT02102464|DEVICE|LipiFlow treatment|The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
214398078|NCT02933190|PROCEDURE|transvaginal surgery；UAE and D&C|For cesarean scar pregnancy treatment
215002214|NCT02323438|OTHER|Electronic Cigarette #2|Electronic cigarette
214398079|NCT03580460|BEHAVIORAL|Computer delivered smoking cessation counseling|15 to 20 minute computer-delivered interactive smoking cessation counseling
214398080|NCT05709691|OTHER|Oculomotor therapy|Visual exercise to improve oculomotor behavior.
214398081|NCT05709691|OTHER|Adapted yoga|Muscular Stretching Therapy, postural control, respiratory physiotherapy.
214398082|NCT04140890|BEHAVIORAL|Habit Formation|Treatment sessions consist of 12 weekly health coaching sessions at participants' home. During the intervention period, an occupational therapist will help the participant to commit to developing new simple habits (dietary habits or physical activity habits) in each 60-minute session.
214398083|NCT04140890|BEHAVIORAL|Education|In the education group, participants will receive newsletters containing general healthy aging materials over 12 weeks. A trained research assistant will call participants to verify receipt of the newsletter, and answer their questions about the materials. Each phone call will last \~15 minutes.
214398084|NCT03713255|PROCEDURE|PVB group|Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
214398085|NCT03713255|PROCEDURE|MTP block group|Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
215002215|NCT02323438|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
215002216|NCT03558724|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure
215002217|NCT03558724|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.
214398086|NCT03713255|PROCEDURE|Control Group|Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
214398087|NCT03530046|COMBINATION_PRODUCT|High SID fluid|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
214398088|NCT03530046|COMBINATION_PRODUCT|Hartmann's solution|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
214398089|NCT02722317|BEHAVIORAL|psychological support|psychological support was given to men by the service, the researcher didn't interfered in the intervention, just ask questions about it.
214398090|NCT00822315|DRUG|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
214398091|NCT00822315|DRUG|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
214398092|NCT00822315|DRUG|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
214503710|NCT03559413|BIOLOGICAL|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod|Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
215002218|NCT01750346|DRUG|Topical acetyl hexapeptide-8|
215002219|NCT01750346|DRUG|Placebo|
215002220|NCT05390554|BEHAVIORAL|Buteyko Breathing Technique|"* The child was instructed to sit and take a relaxed posture in a vertical chair, relax his shoulders and lean his lower back against the back of the chair.~* Until conducting CP, the child was told to avoid alternate breathing, the child was asked to take a small breath in (two seconds), a small breath out (three seconds) and clutch the nose with empty lungs but not too clear on the 'out-breath. To prevent air from escaping through the airways, clutching the nose is necessary.~* The researcher estimates how many seconds the child can continue safely before the need to breathe in again,~* The child was told to hold their breath until the first need to breathe in was felt. Release the nose then and naturally breathe through it smoothly.~* The first intake of breath after the CP should be no higher than the breath before taking the measurement; the child should not hold the breath for too long as this could lead the child to take a major breath after measuring the CP."
215002221|NCT03248895|DEVICE|Mobile Direct Observation of Therapy (MDOT)|Patients who are enrolled in the study will be randomised into two groups (I-med or D-med) to receive Mobile Direct Observation of Therapy (MDOT). Participants or parents/guardians of participants will be asked to capture a DOT video twice daily (morning and evening) on their mobile devices of ICS use by the patient. In the I-med group, participants will be asked to upload daily video recordings via the internet to a repository for a 6 week period at the start of the study. Participants in the D-med group will be free from DOT for the first 6 weeks of the study and will be asked to carry out their usual therapy management. After that, DOT as described above will be applied for the next 6 weeks.
215002222|NCT00598403|DRUG|cefditoren pivoxil|400 mg, oral, single dose during 3 days
215002223|NCT00598403|DRUG|Ciprofloxacin|250 mg, oral, twice a day for 3 days
215002224|NCT00109369|OTHER|Information and decision support for providers and patients|Laboratory-based decision support, reminders, and population report cards.
215002225|NCT03888690|DEVICE|Virtual Reality Headset|Standardized procedures, with or without Virtual Reality Headset.
214398093|NCT04201496|COMBINATION_PRODUCT|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks.
214398094|NCT04201496|COMBINATION_PRODUCT|Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks.
214398095|NCT04201496|DEVICE|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Empaglizflozin will not be provided to this group.
214398096|NCT04201496|DEVICE|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Empaglizflozin will not be provided to this group.
215002226|NCT02034591|DRUG|Apixaban|
215002227|NCT02034591|DIETARY_SUPPLEMENT|Boost Plus|
215002228|NCT00597675|BIOLOGICAL|Peanut OIT|Defatted peanut flour ingested daily as oral mucosal immunotherapy
215002229|NCT00597675|BIOLOGICAL|Placebo|Oat flour matched by weight and consistency that is ingested daily as a placebo
215002230|NCT04893031|DRUG|Tocilizumab|400mg or 800 mg IV tocilizumab treatment according to patient clinical severity
215002231|NCT02174172|DRUG|Atezolizumab|Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.
214398097|NCT05222438|DRUG|loncastuximab tesirine|loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
214503711|NCT07001423|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy within 2 weeks after endoscopic removal of common bile duct stone
214503712|NCT04580745|DRUG|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
214503713|NCT04580745|DRUG|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
214503714|NCT07003906|DEVICE|Negative pressure wound therapy|"Avance Solo Negative Pressure Wound Therapy (NPWT) System is a portable battery powered single use negative pressure system, suitable for use in closed incision and chronic wound indications.~The system consists of Avance Solo Pump, Avance Solo Canister 50 mL, Avance Solo Border Dressing and Avance Solo Foam."
214503715|NCT07003906|DEVICE|Standard postoperative dressing|Mepilex Border Post-Op is a self-adhesive absorbent surgical dressing designed for exuding wounds. It is intended for acute wounds, such as surgical wounds, cuts and abrasions.
215002232|NCT02174172|DRUG|Bevacizumab|Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.
215002233|NCT02174172|DRUG|Interferon alfa-2b|Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.
215002234|NCT02174172|DRUG|Ipilimumab|Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).
215002235|NCT02174172|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).
215002236|NCT02174172|DRUG|PEG-interferon alfa-2a|Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).
215002237|NCT02503930|DEVICE|Active tDCS|In this group subjects will receive 20 min of treatment.
215002238|NCT02503930|DEVICE|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
215002239|NCT04697706|DIETARY_SUPPLEMENT|Moonstone|"Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
215002240|NCT04697706|OTHER|Water|"Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
215002241|NCT00229528|DRUG|Paxil-CR|
215095186|NCT00186277|DRUG|Oxaliplatin|Calculated per patient
215095187|NCT00186277|DRUG|Taxotere|Calculated per patient
215095188|NCT01073007|DRUG|Simvastatin|Simvastatin 40 mgrs daily for three months.
215095189|NCT00945932|DRUG|GW870086X|Investigational product
215095190|NCT00945932|DRUG|Placebo|Placebo control
215095191|NCT05687513|DRUG|Yisui granule|Yisui granule
215002242|NCT05074147|DRUG|Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks|"Drugs :~* Rifampin (IP an PO) : 10mg/Kg/12h~* Ofloxacin (PO) : 200Mg/8h~* Levofloxacin (PO) : 500mg ot 1g/ twice a day~* Ciprofloxacin : IV : 400mg/8h if Pseud spp ; 400mg/12h for others Gram-negative bacilli strains; PO : 1gr/12h if Pseud spp ; 750mg/12h for others Gram-negative bacilli strains~* Clindamycin : 600-900mg/8h~* Fusidic Acid : 500mg/8h~* Teicoplanin : 10mg/kg/12h for 5 dosis in combination, then in monotherapy.~* Ceftasidim : 2g/8h if Pseud spp ; 2g/12h for others Gram-negative bacilli strains~* Trimethoprim-sulfamethoxazole (800mg/160mg) : once per day if patient \< 80Kg ; one and a half per day if patient \> 80Kg.~* Doxycyclin : 200mg/day~* Minocyclin : 100mg/8h to 12h~* Ceftriaxon : 1g to 2g/day in IV, IM or SC~* Cefotaxim : 1g to 2g/day in IV~* Pristinamycin : 1g thrice a day"
214503716|NCT04602728|BEHAVIORAL|Back2Life|The Back2Life intervention uses an adaptive treatment approach with module-based treatment sessions selected on the basis of baseline assessment (rather than a fixed treatment approach) to allow flexibility in tailoring treatment components to meet individual family needs. All youth participants will receive the standard 6-session pain coping skills training program, consisting of learning ways to cope with and manage chronic sickle cell pain. The standard program includes topics that were identified by young people with chronic sickle cell pain and their parents as important skills for all youth with chronic pain and sickle cell disease. In addition to the standard 6-session program, youth participants may receive an additional 1 to 4 sessions that may help with specific problems and/or co-morbidities related to pain. At least one parent or guardian is required to attend the sessions with their child.
214503717|NCT07004634|PROCEDURE|Chest mediastinal tube|Transthoracic mediastinal drainage was performed for postoperative management of the patient.
214503718|NCT07004634|PROCEDURE|Abdominal mediastinal tube|Transperitoneal mediastinal drainage was performed for postoperative management of the patient.
215002243|NCT03464838|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
215002244|NCT03464838|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
214398098|NCT01346670|DRUG|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
214503719|NCT07004634|PROCEDURE|Chest tube + chest mediastinal tube|Chest tube insertion combined with transthoracic mediastinal drainage was performed for postoperative management of the patient.
214503720|NCT06674889|OTHER|Rehabilitation-based intervention|Assessment of the subject by a specialty consultation and exercise program development.
214503721|NCT07002502|DRUG|PRaG-1(cordycepin tablet)|"The PRaG-1 cordycepin tablet involved in this clinical study is produced by Shengmingyuan Company, a subsidiary of the National Biochemical Engineering Research Center at Nanjing Tech University. It is an oral tablet, with each tablet containing 200 mg of cordycepin. The product has obtained a national food production license, and the production license number is SC11332019200201."
214503722|NCT07000851|DIAGNOSTIC_TEST|C-11 ER176 Radiotracer|PET scan looking for inflammation
214503723|NCT07000851|DIAGNOSTIC_TEST|C-11 PiB|PET scan looking for amyloid protein
214503724|NCT07000851|DIAGNOSTIC_TEST|AV1451 Tau|Pet scan looking for Tau protein
214503725|NCT06092970|DRUG|RBT-1|Intravenous administration
214503726|NCT06092970|DRUG|Placebo|Intravenous administration
215002245|NCT04307394|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge.
215002246|NCT04298385|OTHER|Traction orthosis|Traction applied to a finger using elastic thread and sports tape and attached to an orthosis
215002247|NCT00440024|DRUG|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
215002248|NCT00440024|DRUG|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
215002249|NCT00440024|DRUG|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
215002250|NCT02375503|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Daily, calcium and vitamin D fortified snack bar
215002251|NCT02375503|DIETARY_SUPPLEMENT|Placebo|
215002252|NCT03847077|BEHAVIORAL|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application.
215002253|NCT03847077|BEHAVIORAL|Standard Counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
215002254|NCT01175720|PROCEDURE|Periodontal surgery to gingival recessions|Test and control technique to treat gingival recessions.
215002255|NCT02254824|DRUG|Xuezhikang|Xuezhikang
215002256|NCT02254824|DRUG|Atorvastatin|Atorvastatin
214503727|NCT02037126|DRUG|Psilocybin|this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
214398099|NCT04814875|DRUG|ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)|"Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design."
214398100|NCT02181972|DRUG|Gingko biloba|
214398101|NCT02181972|DRUG|Placebo|
214398102|NCT03427086|DRUG|Biotin|High dose biotin
214398103|NCT03427086|DRUG|Placebo Oral Tablet|Placebo tablet similar in shape and size to the biotin tablet
214503728|NCT02037126|DRUG|Diphenhydramine|This drug will be used as the control. Diphenhydramine is a histamine blocker.
215002257|NCT02254824|BEHAVIORAL|Lifestyle modification|Lifestyle modification
215002258|NCT05619419|BEHAVIORAL|Mindfulness-enhanced positive affect induction|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the MPAI via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the MPAI to manage pain during the cold pressor test.
215002259|NCT05619419|BEHAVIORAL|Breathing Meditation|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the BM via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the BM to manage pain during the cold pressor test.
215002260|NCT03942731|OTHER|Behavioral allergy testing protocol|skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months
215002261|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
215002262|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
215002263|NCT00679198|BEHAVIORAL|nurse-patient communication|"We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting."
215002264|NCT05834153|DEVICE|kinesiotaping|"This group underwent a KT application on rectus abdominis muscle (RAM), oblique abdominal muscles (OAM) and cesarean incision twice a week for a period of 4 weeks. First, the scar technique will apply using I band with a tension of 50 % on cesarean incision when the patient will be in supine position. Then, tape will apply on RAM using muscle technique from origin to insertion of the muscle with a tension between 15 and 25 %.~Band will start on symphysis pubis with no tension, and then the patient was asked to stretch the abdominal region by deep abdominal respiration, and it will ended on xiphoid process.~Finally, it will perform on the right and left external oblique muscles. The procedure will start with no tension from the bottom end of the 6-12th ribs and then the hip will placed in flexion and rotation to the opposite direction and the band will taped on pubic bone with a tension between 15 and 25 %"
215002265|NCT05834153|DEVICE|electrical muscle stimulation|"It consists of 24 patients who will receive NMES and core stabilization exercises.~The subjects will explain to relax their abdominal muscles while application Stimulation will apply by four large rectangular electrodes placed over the origin (pubic crest) and insertion (xiphoid process) of the rectus abdominis muscles bilaterally. Straps will used to fix the electrodes in place. A frequency of 80 pulses/min and with a pulse width of 0.1-0.5ms, will the parameter settings apply in this study. The total time for the application of stimulation will 30mins and until a good enough observable muscle contraction will achieve a gradual increase in intensity will perform"
215002266|NCT04964232|DEVICE|Infrared Camera|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
215002267|NCT04964232|DEVICE|Esophageal Temperature Probe|In patients undergoing general anesthesia, the Esophageal temeperature parameters are measured using an Esophageal probe.
215002268|NCT04964232|DEVICE|Skin temperature probe|In patients undergoing general anesthesia, the skin spot temeperature parameters are measured using an skin adhesive probe.
215002269|NCT00416949|DEVICE|Patient-specific dosimetry|Patient-specific 3D-RD dosimetry was applied to the data collected
215002270|NCT02782468|DRUG|Pevonedistat 25 mg/m^2|Pevonedistat 25 mg/m\^2 intravenous infusion.
215002271|NCT02782468|DRUG|Pevonedistat 44 mg/m^2|Pevonedistat 44 mg/m\^2 intravenous infusion.
215095192|NCT05687513|DRUG|Placebo|placebo
215095193|NCT02976103|DEVICE|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
215002272|NCT02782468|DRUG|Pevonedistat 10 mg/m^2|Pevonedistat 10 mg/m\^2 intravenous infusion.
215002273|NCT02782468|DRUG|Pevonedistat 20 mg/m^2|Pevonedistat 20 mg/m\^2 intravenous infusion.
215002274|NCT02782468|DRUG|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
215002275|NCT01722799|DEVICE|Drug elluting Balloon (DEB)|Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.
215002276|NCT01722799|DEVICE|Drug elluting coronary stent (DES)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
215002277|NCT06091384|OTHER|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths per day at 75% of maximal inspiratory pressure, six days a week, during 6 weeks.
215095194|NCT02976103|OTHER|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
215095195|NCT01985360|PROCEDURE|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
215095196|NCT01985360|PROCEDURE|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
215002278|NCT04114370|DRUG|18F-fluciclovine|Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.
215002279|NCT03342859|DRUG|Vilaprisan, BAY1002670|Daily single oral doses of 2 mg vilaprisan over 8-12 weeks
215002280|NCT03342859|DRUG|Ulipristal|Daily single oral doses of 5 mg ulipristal over 8-12 weeks
215002281|NCT00074191|DRUG|cytarabine|
215002282|NCT00074191|DRUG|dexamethasone|
215002283|NCT00074191|DRUG|lomustine|
215002284|NCT00074191|DRUG|methotrexate|
215002285|NCT00074191|DRUG|procarbazine hydrochloride|
214398104|NCT01270763|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
215002286|NCT00607594|DRUG|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
215002287|NCT02591303|OTHER|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
214398105|NCT01270763|BEHAVIORAL|Diabetes support and education|Behavioral intervention focused on diabetes support and education
214398106|NCT03655873|DRUG|HEC30654AcOH capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.~Multiple ascending-dose study:~15-、30-、60mgHEC30654AcOH capsule in day1-day7，2 times everyday."
214398107|NCT03655873|DRUG|Placebo capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.~Multiple ascending-dose study:~15-、30-、60mg placebo capsule in day1-day7，2 times everyday."
214398108|NCT05552274|DRUG|ECC4703|ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.
214398109|NCT05552274|DRUG|Placebo|Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
214398110|NCT04729283|PROCEDURE|Sigmoidectomy|The sigmoid resection surgery, realized by laparoscopy or laparotomy, with anastomosis.
214398111|NCT05433896|DRUG|Dasatinib ASD|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation
215002288|NCT01410604|DRUG|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
215002289|NCT01410604|DRUG|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
215002290|NCT04003571|BEHAVIORAL|Augmented Reality with Functional Electrical Stimulation group|Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.
214398112|NCT05433896|DRUG|Omeprazole 40 MG|Omeprazole Delayed Release Capsules, USP 40 mg
214398113|NCT01715623|BIOLOGICAL|a blood sample|Dosage of Ig
214398114|NCT01209338|BEHAVIORAL|Health education|Health education about HPV infection, HPV vaccine and cervix cancer.
214398115|NCT03958630|DRUG|11C-ER176|PET biomarker for inflammation
214398116|NCT03958630|DRUG|11C-PIB|PET biomarker for amyloid
214398117|NCT03958630|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Scan|Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB
214398118|NCT00670696|DRUG|Rapydan|Topical anaesthetic plaster
214398119|NCT00670696|DRUG|tetracaine gel|Topical tetracaine gel
214398120|NCT01941004|DRUG|fingolimod|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
214398121|NCT01941004|DRUG|Placebo (6mos) + open label fingolimod (6 mos)|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
214398122|NCT03676036|DRUG|DS107E|
214398123|NCT03676036|DRUG|Vehicle|
214398124|NCT04370743|OTHER|No intervention|
214398125|NCT03796013|DRUG|Entrectinib Form A|Participants will receive a single oral dose of entrectinib form A under fasted conditions.
214398126|NCT03796013|DRUG|Entrectinib Form C|Participants will receive a single oral dose of entrectinib form C under fasted conditions.
214398127|NCT04250961|OTHER|postoperative early shower|The shower group showered in 48-72 hours after median sternotomy with tap water.
214398128|NCT01628380|PROCEDURE|Cytoreductive Surgery and HIPEC|"CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).~HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C."
214398129|NCT01628380|PROCEDURE|CRS alone|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
214398130|NCT05409274|OTHER|No Intervention|No Intervention
215002291|NCT04003571|BEHAVIORAL|Traditional physiotherapy|Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
215002292|NCT05189002|DRUG|Dimolegin 40 mg|Dimolegin - DD217 - 40 mg
215002293|NCT05189002|DRUG|Dimolegin 60 mg|Dimolegin - DD217 - 60 mg
215002294|NCT05189002|DRUG|Fragmin|Fragmin 5000 IU in 0.2 ML Prefilled Syringe
215002295|NCT05753475|OTHER|renal transplantation|patients undergoing renal transplantation
215002296|NCT04784975|OTHER|No intervention|No intervention
215002297|NCT04856566|DRUG|Low Marijuana, Hash, THC, or Grass|Cannabis with low amount of THC
215002298|NCT04856566|DRUG|High Marijuana, Hash, THC, or Grass|Cannabis with high amount of THC
215002299|NCT04856566|DRUG|Placebo|Placebo drug with no THC
214398131|NCT04956263|DRUG|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China."
214398132|NCT04956263|DRUG|Dapagliflozin|Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
215002300|NCT04856566|DRUG|0.05 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.05
214398133|NCT05181813|PROCEDURE|Ginge-Cal|Fill the infected root canal of of primary teeth with Gingerols extract and Calcium Hydroxide (Ginge-Cal)
214398134|NCT05181813|PROCEDURE|Metapex|Fill the infected root canal of of primary teeth with Metapex
214398135|NCT04939311|DRUG|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
214398136|NCT04939311|DRUG|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
214398137|NCT04969744|DEVICE|ICE|Intermittent Cooling Exposure using cooling garment for 1-2 hours
214398138|NCT01695122|DRUG|Valproic Acid|
214398139|NCT01147211|DRUG|MK2206|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
214398140|NCT03694457|PROCEDURE|Reversed total shoulder arthroplasty|Replacement of the proximal humeral head by a reversed prosthesis through an anterior approach
214398141|NCT03694457|PROCEDURE|lateral approach|Replacement of the proximal humeral head by a reversed prosthesis through a lateral approach
214398142|NCT02912429|DEVICE|Patellofemoral Arthroplasty|
214398143|NCT01282320|BEHAVIORAL|Physical activity intervention program|Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
214398144|NCT00245011|BIOLOGICAL|filgrastim|Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.
214398145|NCT00245011|DRUG|ifosfamide|Ifosfamide administered IV.
214398146|NCT00245011|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
214398147|NCT00245011|RADIATION|Sm-EDTMP (low dose)|Sm-EDTMP (low dose) administered after autologous stem cell collection
214398148|NCT00245011|RADIATION|sm-EDTMP (higher dose)|Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
214398149|NCT02427555|OTHER|Barley kernel bread|3 days intervention with barley kernel bread
214398150|NCT02427555|OTHER|white wheat bread|3 days intervention with white wheat bread
214398151|NCT04005729|DRUG|Cangrelor 50 MG|30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
214398152|NCT05724524|OTHER|Stool sample collection|50mg stool sample taken for protein extraction
214398153|NCT05724524|OTHER|Blood sample collection|Venous blood sample taken for analysis of serum and plasma
214398154|NCT01740011|PROCEDURE|Laparoscopic surgery|
214398155|NCT06336499|OTHER|Multi-parametric MRI and image analysis by deep learning or machine learning algorithms|Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.
214398156|NCT00438867|GENETIC|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
214398157|NCT00438867|GENETIC|Placebo|Control group
214398158|NCT03040687|BIOLOGICAL|Anti CS6 BSIgG product (Lot PD1601105CS)|
214398159|NCT03040687|BIOLOGICAL|Anti B7A BSIgG product (Lot PD1601132ET)|
214398160|NCT03040687|BIOLOGICAL|Bovine Immunoglobin Negative Control (Lot PD161071NC)|
214398161|NCT03040687|BIOLOGICAL|B7A- CS6-expressing ETEC challenge strain|
214398162|NCT00003384|OTHER|Cervical Papanicolaou Test|Undergo Pap smear
214398163|NCT00003384|PROCEDURE|Conization|Undergo cone biopsy
214398164|NCT00003384|OTHER|Laboratory Biomarker Analysis|Correlative studies
214398165|NCT05050370|BEHAVIORAL|Brief messaging and personalized support|Patients will receive (i) a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise (including breathing, balance, aerobic, strength, stretching exercises), cancer-related care information and support.
215002301|NCT04856566|DRUG|0.08 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.08
215095197|NCT01985360|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
215095198|NCT01985360|BEHAVIORAL|Lifestyle|Diet, physical activity, smoking cessation
215095199|NCT01985360|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
214398166|NCT01635361|OTHER|New Medicine Service|The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
215002302|NCT00744835|PROCEDURE|Ablation procedure and/or cardioversion|Ablation Frontiers Cardiac Ablation System
215002303|NCT00356590|BIOLOGICAL|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
215002304|NCT05505890|OTHER|suprainguinal fascia iliaca block|Suprainguinal fascia iliaca block will be performed after the end of surgery for postoperative analgesia.
215002305|NCT02979288|DRUG|Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Probiotic vaginal tablets vith active probiotic strains
215002306|NCT02979288|OTHER|NO Intervention|NO Intervention
215002307|NCT06283030|DEVICE|Hypoglossal nerve stimulation|Device-mediated stimulation of the hypoglossal nerve
215002308|NCT05678114|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol (4g/die)
215002309|NCT01201863|DRUG|Androgel (Testosterone Gel)|2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
215002310|NCT01201863|OTHER|Placebo gel|2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.
215002311|NCT01149785|DRUG|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
215002312|NCT01149785|DRUG|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
215002313|NCT01149785|DRUG|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
214398167|NCT04408001|OTHER|Clinical interview|At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.
214398168|NCT04408001|BIOLOGICAL|Blood collection|"At each study visit,~* 1 EDTA tube for complete blood count~* 3 dry tubes with gel for serology, serum neutralisation test and serum library~* 1 cell preparation tube for the separation of immune cells within the circulating blood will be collected."
214398169|NCT04408001|BIOLOGICAL|Saliva collection|At each study visit, a saliva sample will be collected for the determination of IgA antibodies.
214503729|NCT05865392|BEHAVIORAL|Move physical activity support program|The Move program includes four intervention components: 1) 3, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) access to an online fitness membership, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week. They will receive an online fitness center membership during this entire 12-week program.
215002314|NCT02124226|DRUG|Methotrexate|7.5 mg/week + folic acid the day after
215002315|NCT02124226|DRUG|Placebo|matched placebo
215002316|NCT02199574|DRUG|EXPAREL|133 mg EXPAREL in 10 mL.
215002317|NCT01264471|PROCEDURE|Skin biopsy|A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
214398170|NCT05967104|OTHER|Education based on the PLISSIT model|Training to the intervention group was carried out in 3 sessions of 45 minutes each week, organized by the first author (AD). In each session, training was organized based on the PLISSIT framework.
214398171|NCT03066570|BEHAVIORAL|Graded Exposure|Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity.
214398172|NCT01473511|BEHAVIORAL|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focussed on skill learning for parents
214398173|NCT02018315|DRUG|Triheptanoin|Triheptanoin is a 7-carbon medium chain triglyceride
215002318|NCT01264471|PROCEDURE|Blood Collection|Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
215002319|NCT03605056|DRUG|chidamide|20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle
215002320|NCT03605056|DRUG|lenalidomide|25 mg/d, will be administered orally on Days 1-14 each 21 day cycle
215002321|NCT03605056|DRUG|dexamethasone|40mg weekly, will be administered orally or intravenously
215002322|NCT00448357|BIOLOGICAL|rabbit anti-thymocyte globulin (ATG)|.5 mg/kg on day -3 and 2.5 mg/kg on day -2
215002323|NCT00448357|BIOLOGICAL|therapeutic allogeneic lymphocytes|minimum total cluster of differentiation (CD34+) cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
215002324|NCT00448357|DRUG|busulfan|PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
215002325|NCT00448357|DRUG|fludarabine phosphate|30 mg/m\^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3
215002326|NCT00448357|DRUG|tacrolimus|The suggested starting dose is 0.03 mg/kg po bid starting on day -1
215002327|NCT00448357|PROCEDURE|allogeneic hematopoietic stem cell transplantation|A minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and maximum of 8 x 10\^6 cells/kg will be infused on day 0
215002328|NCT00448357|PROCEDURE|peripheral blood stem cell transplantation|minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
215002329|NCT00448357|DRUG|methotrexate|5 mg/m\^2 on days +1, +3 and +6
215002330|NCT00828256|PROCEDURE|arthroscopy of shoulder|arthroscopic repair of chronic rotator cuff tears
215002331|NCT01491516|DEVICE|TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System|The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
215002332|NCT02714738|PROCEDURE|Ultrasound guided peripheral nerve block|Ultrasound guided peripheral nerve block
215002333|NCT03470766|DEVICE|Nevro Senza System (HF10 Therapy)|Nevro 10kHz High Frequency Spinal Cord Stimulation
215002334|NCT04221971|DRUG|chemotherapy combined with NK cells infusion|chemotherapy combined with NK cells infusion
215002335|NCT01464762|DRUG|TMC207|400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
215002336|NCT02413762|OTHER|No intervention|No intervention
215002337|NCT04215770|DRUG|inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day|Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
215002338|NCT02500355|PROCEDURE|Carpal Tunnel Release via limited approaches|Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
215002339|NCT02500355|PROCEDURE|Carpal Tunnel Release via standard approach|Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
214398174|NCT06250166|BEHAVIORAL|iPLANT diet plan and diet counselling|A diet plan which mainly consists of plant-based food will be designed based on participants' energy and protein needs. The counselling covers (1) guidance to achieve energy and protein requirement (2) advice on food to be included in iPLANT diet plan (Mediterranean diet: increase intake of fish and legumes; moderate intake of eggs, dairy, nuts, poultry; limit intake of red meat).
214398175|NCT06250166|BEHAVIORAL|Usual diet counselling|General dietary advices on how to improve oral intake and maintain healthy weight will be provided.
214398176|NCT04998695|OTHER|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
214398177|NCT04998695|OTHER|Sunflower oil|Volunteers consumed during 4 weeks 45 g/d of sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
214398178|NCT00107744|DIETARY_SUPPLEMENT|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
214398179|NCT00107744|DIETARY_SUPPLEMENT|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
214398180|NCT00107744|DIETARY_SUPPLEMENT|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
214398181|NCT00564590|DRUG|Melatonin|4 mg of Melatonin once a day for 3 months
214398182|NCT00564590|OTHER|omeprazole|omeprazole 20 mg once a day
214398183|NCT00564590|DRUG|Placebo|Placebo once a day
214398184|NCT02769299|RADIATION|Radiation Therapy|less than 1 Gy with protons to 4-8 Gy with photons
214398185|NCT02359383|OTHER|Chest physiotherapy|Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
214398186|NCT00721331|DRUG|nortriptyline HCl + loratadine|Topical
215002340|NCT02500355|PROCEDURE|Endoscopic Carpal Tunnel Release|Carpal tunnel release under endoscope.
215002341|NCT02500355|DEVICE|endoscope or an arthroscopic device|
215002342|NCT00898807|DRUG|citalopram|target dose 30mg daily for 9 weeks
215002343|NCT00898807|DRUG|placebo|daily for 9 weeks
215002344|NCT03469973|PROCEDURE|Partial adenoidectomy|"The procedure will be completely visualized with a 45 degrees, 4- mm nasal endoscope; the upper part of the adenoid will be removed using the microdebrider, while the lower part will be preserves to maintain the velopharyngeal competence.~• Adenoid enlargement causing Obstructive Sleep-Disordered Breathing (OSDB) with velopharyngeal insufficiency (proved or suspected)."
215002345|NCT04804488|PROCEDURE|nasal polyp surgery|A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out.
215002346|NCT02885675|OTHER|blood sampling|sample no more than 3ml
215002347|NCT02103842|DRUG|Omega-3 fatty acids|
215002348|NCT00942643|DEVICE|CPAP machine|a machine delivers positive airway pressure into the upper airway via a nasal mask
214398187|NCT00721331|DRUG|nortriptyline HCl + loratadine|Topical
214398188|NCT00721331|DRUG|nortriptyline HCl|Topical
214398189|NCT00721331|DRUG|mometasone furoate|Topical
214398190|NCT00721331|DRUG|Active ingredient free vehicle cream of CRx-197|Topical
214398191|NCT01875861|OTHER|Evidence-Based Quality Improvement Plus Facilitation|The intervention involves researchers partnering with clinical stakeholders, offering tailoring in local implementation strategies to address barriers to metabolic side-effect monitoring and management. External facilitation to support, problem-solve and refine implementation will be provided for a six-month implementation phase.
214398192|NCT01835561|DRUG|Pomalidomide|Single oral dose of 4-mg capsule
214398193|NCT01835561|DRUG|Pomalidomide|4-mg capsule
214398194|NCT04425993|DRUG|Isosorbide Dinitrate 5 MG|All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
214398195|NCT04425993|DRUG|Indomethacin 100 MG|All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
214398196|NCT04425993|DRUG|Sublingual Placebo|All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
214398197|NCT04425993|DRUG|Rectal placebo|All patients without contraindications should receive rectal placebo within 30 min before ERCP.
214398198|NCT03292042|BEHAVIORAL|Physical health promotion program|"The program has 24 sessions. Each session has two parts:~* first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.~* Second part: 1 hour of physical activity (walk)"
214398199|NCT02635282|DRUG|intranasal ketamine|
214398200|NCT02635282|DRUG|intranasal fentanyl|
214398201|NCT02635282|DRUG|intranasal midazolam|
214398202|NCT02325713|DRUG|Oral dispersible tablet of praziquantel (ODT-PZQ)|Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
214398203|NCT02325713|DRUG|Cysticide|Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
214398204|NCT02325713|DRUG|ODT-PZQ|Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
214398205|NCT02325713|DRUG|ODT-PZQ|Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
215002349|NCT00105378|BEHAVIORAL|Dutch EASYcare Study Geriatric Intermediate Care Programme|
215002350|NCT01800760|DIETARY_SUPPLEMENT|Probiotics|Probiotics once a day for three weeks.
215002351|NCT00795574|DRUG|infliximab|Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
215002352|NCT00795574|DRUG|Placebo Comparator|5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
214398206|NCT02325713|DRUG|ODT-PZQ|Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
214398207|NCT02325713|DRUG|Cysticide|Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
214398208|NCT02150265|BEHAVIORAL|SMART manual cognitive behavioral therapy|
214398209|NCT02398682|OTHER|Rapid diagnosis of AKI cause|"The Outreach team will advise on an evidence-based package of care:~1\) Rapidly establish a credible diagnosis of the cause of AKI including:~1. Improved assessment of volume status~2. Standardised use of urine dipstick .~3. Appropriate sepsis investigations.~4. Urgent ultrasound with suspected obstruction."
215002353|NCT04444869|DRUG|Cisplatin injection|Standard dose cisplatin given concurrently with radiation therapy
215002354|NCT00513448|OTHER|Group wellness intervention|
215002355|NCT00513448|OTHER|Individualized physical rehabilitation|
215002356|NCT06091514|DEVICE|CS Medical Watch|The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF).
215002357|NCT06091514|OTHER|Specific questionnaire|Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF)
215095200|NCT02914561|DRUG|Filgotinib|Filgotinib tablets administered orally once daily.
215095201|NCT02914561|OTHER|Placebo|Placebo administered orally once daily.
214398210|NCT02398682|OTHER|Rapid treatment of AKI cause|Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
214398211|NCT02398682|OTHER|Stopping 'nephrotoxic' drugs|Cessation of all potentially nephrotoxic drugs.
214398212|NCT02398682|OTHER|Early nephrology followup for stage 3 AKI|A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
214398213|NCT02398682|OTHER|Preventing recurrent AKI|Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
215002358|NCT04919161|DEVICE|Body weight support system control group|The BWSS control group interventions consisted of various balance activities, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. The BWSS control group also practiced various gait tasks, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.
214398214|NCT02398682|OTHER|Good standard care|Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
214398215|NCT04912622|DIAGNOSTIC_TEST|Clinical Trial|Retinal image acquisition with Cellularis version 2.0
214398216|NCT04493918|COMBINATION_PRODUCT|Mesenchymal Stem cell + Nacl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit
214398217|NCT04493918|COMBINATION_PRODUCT|NaCl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml
215002359|NCT04919161|DEVICE|Body weight support system with balance perturbations|"The BWSS with balance perturbations group conducted the same balance and gait activities as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.In addition, this arm will receive eight balance perturbations, two in each direction (lateral, anterior, and posterior) each session. BWSS-P participants will start at perturbation level one and progress up to level ten as appropriate. Each session, the perturbation level will be set based on the participant's progress."
215002360|NCT03686111|DIAGNOSTIC_TEST|oocytes collect|After stimulation, an echo-guided oocyte puncture is performed under anesthesia
215002361|NCT03808857|BIOLOGICAL|GB226|GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml\~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.
215002362|NCT00712920|DRUG|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
215002363|NCT00712920|DRUG|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
215002364|NCT00712920|DRUG|Placebo|Placebo
215002365|NCT06348043|DEVICE|Jarvik 2015 LVAD|Medical device used to treat children awaiting heart transplant who fail optimal medical therapy.
215095202|NCT05611814|OTHER|Osteopathic Manipulative Treatment|Targeted anatomical structures are Scalene Muscles (Anterior/Middle/Posterior), Sternocleidomastoid Muscles (SCM), Suboccipital region, Cervical Paraspinal Muscles, Levator Scapulae Muscles, Upper Thoracic Paraspinal Muscles, Upper Trapezius Muscles, Atlanto-occipital (OA), Atlanto-axial (AA), C2-C7 vertebrae, T1-T4 vertebrae, Rib 1 bilaterally. Techniques include Suboccipital Myofascial Release, Soft tissue inhibition, kneading stretching, Facilitated Positional Release, and muscle energy technique.
215095203|NCT05611814|OTHER|Sham treatment|"Targeted anatomical structures are Thoracic Paraspinal Muscles, Lumbar Paraspinal Muscles, Lower Trapezius Muscles, Sacrum, Supraspinatus, T5-T12, and Rib 2-12. Techniques include Soft tissue inhibition, Stretching, Kneading, counterstrain, Facilitated Positional Release, and muscle energy technique.~L1-L5"
215095204|NCT02237482|DEVICE|Trilogy cup|
215095205|NCT02237482|DEVICE|Trabecular metal cup (TM)|
215095206|NCT02237482|DEVICE|ZCA cup|
215095207|NCT04300803|BIOLOGICAL|Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression|Expanded Access Program, Non-Interventional Study
215095208|NCT01362452|GENETIC|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
215095209|NCT01362452|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0.
215002366|NCT02826096|BEHAVIORAL|Biofeedback therapy|The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
215002367|NCT02004171|OTHER|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
215002368|NCT02004171|DRUG|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
215002369|NCT04863534|DEVICE|Ultrasound|Muscular grayscale ultrasound
215002370|NCT05259293|OTHER|No intervention - retrospective study|This is a retrospective study. No intervention.
215002371|NCT04926493|BIOLOGICAL|microbiological characterization|microbiological characterization of endotracheal tube biofilm
215095210|NCT03294629|DEVICE|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
215095211|NCT06107660|DRUG|Liposomal bupivacaine|Patients will receive either liposomal bupivacaine as part of the ESPB .
215095212|NCT06107660|DRUG|Bupivacaine|This is the control group comparator as this is standard of care at the investigator's institution.
214398218|NCT06812221|DRUG|Sublingual administration|Participants will receive a sublingual dose of 5-MeO-DMT or placebo, once a week for four consecutive weeks.
214398219|NCT06812221|PROCEDURE|Electroencephalography|Conducting baseline electroencephalography and during the consumption of the corresponding dose.
214398220|NCT06812221|DIAGNOSTIC_TEST|Biochemical mesurements|Biochemical determinations will be performed to assess hematological, renal, hepatic, cardiac, and cellular lysis functions. The biochemical markers that will be measured include red blood cells, hematocrit, hemoglobin, glycated hemoglobin, white blood cells, microalbuminuria (urine albumin/creatinine ratio), and various serum markers such as cortisol, glucose, urea, serum creatinine, total cholesterol, HDL, LDL, triglycerides, AST, ALT, lactate dehydrogenase (LDH), creatine kinase (CK), CK-MB, and C-reactive protein.
214398221|NCT06812221|DIAGNOSTIC_TEST|Acute Subjective Ratings of Psychedelic Effects|To determine the intensity of the acute effects experienced by subjects, retrospective ratings will be collected 1 hour after 5-MeO-DMT or placebo exposure. Subjective ratings will include the Peak Experience Scale (PES), the Ego Dissolution Inventory (EDI), and the Mystical Experiences Questionnaire (MEQ).
214398222|NCT06812221|DIAGNOSTIC_TEST|Vital signs|Vital signs, including blood pressure, heart rate, oxygen saturation, respiration rate, body temperature, and electrocardiograms (ECGs), will be monitored over the six weeks of the treatment.
214398223|NCT06812221|DIAGNOSTIC_TEST|Cognitive Assessments|Cognitive assessments will evaluate the effects of sublingual 5-MeO-DMT on cognitive functions. Participants will complete the Phonological Verbal Fluency Test (FAS) to assess executive function, the Paced Auditory Serial Addition Test (PASAT) to evaluate processing speed, and the Digit Span Scale (DSS) to measure attention span and working memory. These tests will be administered at baseline, during treatment, and post-treatment to monitor any cognitive changes in response to either a 6 mg dose of 5-MeO-DMT or placebo. This will help determine how the intervention may affect cognitive processing, memory, and attention.
214398224|NCT06812221|DIAGNOSTIC_TEST|Psychiatric Assessments|Psychiatric evaluations will be conducted to assess the emotional and psychological effects of sublingual 5-MeO-DMT. Participants will complete the Beck Depression Inventory II (BDI II) to measure mood and depressive symptoms, the State-Trait Anxiety Inventory (STAI) to evaluate state anxiety, and the Depression, Anxiety, and Stress Scale (DASS-21) to assess stress levels. Additionally, the Suicidal Ideation Scale (SSI) will be used to monitor any changes in suicidal ideation throughout the study. These psychiatric assessments will be administered at multiple time points during the study to evaluate the potential therapeutic effects of 5-MeO-DMT in improving mood, anxiety, and overall psychological well-being.
214398225|NCT05694975|DRUG|Vitamin C|The total dosage of vitamin C for the treatment group is 24 g per day.
214398226|NCT05694975|DRUG|Placebo|The total dosage of placebo(5% glucose) for the control group is 24 g per day.
214398227|NCT02353832|DEVICE|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
214503730|NCT06397937|BEHAVIORAL|SHIFT team intervention|The SHIFT team, comprising a community health worker (CHW), community social worker (CHW), and community nurse (CN) will visit the participant starting within 72 hours of hospital discharge and provide social service referrals related to food insecurity, housing, immigration, and employment, and assist with medical appointment preparation (CHW), deliver individualized counseling focused on coping skills, reducing caregiver strain, and the psychological distress associated with experiences of racism and SDOH (CSW), and address health literacy and review of treatment goals and medications (CN).
214503731|NCT07007052|DRUG|Venetoclax|Single interventional arm
215002372|NCT05920265|PROCEDURE|Quadratus Lumborum plain Block|ultrasound guided Quadratus Lumborum plain Block using 0.5 ml/kg bupivacaine 0.25% .
215002373|NCT05920265|PROCEDURE|fascia iliaca block|ultrasound guided fascia iliaca block using 0.5 ml/kg bupivacaine 0.25%
215002374|NCT05920265|DIAGNOSTIC_TEST|control group|no intervention
215002375|NCT02078037|DEVICE|Arctic Sun cooling device|The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.
215002376|NCT02078037|OTHER|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
215002377|NCT05017636|DEVICE|shock wave therapy|The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.
215002378|NCT00817102|PROCEDURE|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
215002379|NCT04501575|OTHER|Osteopathic Consultation|A consultation including case history taking, physical assessment, osteopathic manual treatment, exercise prescription, and postural advice.
215002380|NCT04501575|OTHER|Sham Osteopathic Consultation|A sham treatment using light touch on bony structures, no diagnosis, advise or prescriptions
215002381|NCT05144282|PROCEDURE|intravitreal injection of anti VEGF|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF).
215002382|NCT05144282|PROCEDURE|laser photocoagulation|The treatment for ROP was either primary laser photocoagulation.
215002383|NCT02887586|OTHER|auricular needling|Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
215002384|NCT01010620|BEHAVIORAL|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
215002385|NCT00215956|DRUG|topotecan|Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
214398228|NCT06555133|COMBINATION_PRODUCT|yttrium-90 radioembolization|yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
215002386|NCT00215956|PROCEDURE|radiation|Preoperative radiation
215002387|NCT00215956|PROCEDURE|surgery|surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
215002388|NCT04493177|BEHAVIORAL|Educational intervention|Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.
215002389|NCT04493177|OTHER|Conventional treatment Guia de Practica Clinica IMSS-029-08|Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.
215002390|NCT00169312|BEHAVIORAL|behavioral dietary intervention|
215002391|NCT00169312|DIETARY_SUPPLEMENT|dietary intervention|
214398229|NCT03617159|DEVICE|Magnetic Resonance Imaging|Diagnostic Modality
215002392|NCT00169312|OTHER|educational intervention|
215002393|NCT00169312|OTHER|internet-based intervention|
215002394|NCT00169312|OTHER|preventative dietary intervention|
215002395|NCT00169312|PROCEDURE|evaluation of cancer risk factors|
215002396|NCT00005769|DRUG|Hormone Replacement Therapy|
215002397|NCT04428489|OTHER|Observation and necessary supportive care|For patients with ICUS and CCUS, necessary supportive care could be given. No addtitional treatment is administrated.
215002398|NCT01098695|OTHER|Ecological Family Intervention and Treatment (EcoFIT)|Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
215002399|NCT05523739|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
215002400|NCT05323851|BEHAVIORAL|COVID-surg-SPIGC questionnaire|The questionnaire aimed to evaluate how the COVID-19 pandemic determined a shift in daily practice through a multidimensional assessment of surgical clinical care in three different time frames.
215002401|NCT00002940|DRUG|hydroxyurea|
215002402|NCT04822909|DRUG|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study"
215002403|NCT02115386|DRUG|Nilotinib|supplied in 150 mg capsules to be taken orally
215002404|NCT05496010|OTHER|Dry Needling and Ischemic Compression Technique|"For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups."
215002405|NCT00530166|DRUG|JNJ-18054478|3(100 mg) tablets once daily for 12 weeks
215002406|NCT00530166|DRUG|sham comparator|3(100 mg) tablets once daily for 12 weeks
215002407|NCT02493855|DRUG|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
215002408|NCT02493855|DRUG|Dasabuvir|Dasabuvir tablets
215002409|NCT02493855|DRUG|Ribavirin (RBV)|Ribavirin tablets
214398230|NCT06824246|BEHAVIORAL|Water conservation education|The programme of training for participants will be based on the Health Belief Model, and will consist of two sessions on individuals' water footprints and water consumption habits. Support for the sessions will be provided by brochures and videos that have been prepared for this purpose. Women will be given brochures and a list of things to do to save water. They will also be informed that their monthly water bill will be monitored during the process.
214398231|NCT06824246|BEHAVIORAL|Monitoring water bill|Participants in the control group will be informed that their water bills will be monitored for water savings.
214398232|NCT00250172|DRUG|[C-11](R)-rolipram|
214398233|NCT03194074|DRUG|Propofol|In propofol/remifentanil group, propofol at a rate 75\~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
214398234|NCT03194074|DRUG|Desflurane|In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7\~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
215002410|NCT05104346|PROCEDURE|appendectomy|open or laparoscopic appendectomy
215002411|NCT00620919|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
215002412|NCT02453048|BIOLOGICAL|BPZE1|Intranasal live, attenuated vaccine
215002413|NCT02453048|OTHER|Placebo|Diluent
215002414|NCT01484002|DEVICE|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
215002415|NCT00656526|DRUG|Lidocaine, perineural injection, intraoperatively|0.5 cc lidocaine, one single injection over the dorsal root.
215002416|NCT00656526|DRUG|Lidocaine|0.5 cc %2 lidocaine,single injection
215002417|NCT06193629|DRUG|Lang Qingata|Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
215002418|NCT06193629|DRUG|placebo|Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use
215002419|NCT03268863|DEVICE|Virtual Reality|Google Cardboard virtual reality headset
215002420|NCT03268863|OTHER|Cold Pressor|A cold ice water bath for use in pain/discomfort simulation
215002421|NCT02136589|DRUG|dicrofenac and travoprost|dicrofenac drop 3 times a day travoprost 0.005% once daily
215002422|NCT03512886|OTHER|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
215002423|NCT03512886|OTHER|Single task training|An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
215002424|NCT04600037|DRUG|Pregabalin 150mg|"Patients in group I received pregabalin at a dose of 75 mg twice daily during the first week that was increased to 150 mg twice daily thereafter and maintained at that level for 12 weeks.~Patients in two groups received exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months"
214398235|NCT06609473|BEHAVIORAL|CHEF Intervention Program|Poverty-targeted intervention utilizing direct resource provision of healthy meal kits and groceries, as well as assisted referral and enrollment in government nutrition assistance benefits, SNAP (Supplement Nutrition Assistance Program) and/or WIC (Woman, Infants, and Children Program). Meal kits will be delivered by a commercial meal kit vendor. Grocery gift cards will be delivered via email, mail, or in-person. Kitchen equipment will be delivered to caregiver residence.
214398236|NCT05591469|DEVICE|IR Camera|the respiration parameters are measured using an IR camera.
214398237|NCT05591469|DEVICE|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
214398238|NCT01813032|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
214398239|NCT01813032|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
215002425|NCT01482221|DRUG|AZD6765 iv|50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
215002426|NCT01482221|DRUG|AZD6765 iv|100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
215002427|NCT01482221|DRUG|Placebo|0.9 sodium chloride \[normal saline\] solution for injection by iv infusion
214398240|NCT01421485|BEHAVIORAL|Integrated treatment program|CBT, psychopharmacological treatment, family treatment, HIV prevention, case management
214398241|NCT01421485|BEHAVIORAL|Treatment as Usual|Treatment in community, case management
214398242|NCT06991283|DEVICE|transcutaneous vagus nerve stimulation|The stimulation times are fixed between 07:00-09:00 in the morning and 19:00-21:00 in the evening, with an interval of 12 hours between the two sessions. The device is set with a pulse width of 200 microseconds and a pulse frequency of 20 hertz. The stimulation intensity is individually adjusted to above the perception threshold and below the discomfort level of 1 milliampere.
215002428|NCT01574404|PROCEDURE|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
215002429|NCT06373510|BIOLOGICAL|Blood collection|Collection of blood before and after a non mandatory vaccination
215002430|NCT00589368|BEHAVIORAL|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
215002431|NCT05827744|OTHER|Isokinetic evaluations|Peak torque and total amount of work of hip flexors and extensors will be determined by the Cybex 6000 model computer-aided isokinetic system.
215002432|NCT05827744|OTHER|Ultrasonographic evaluations|Ultrasonographic evaluations will be performed with a 5-12 MHz linear probe (Logic e portable; GE Healthcare, China). The thicknesses of the hip flexor (psoas major) and extensor (gluteus maximus) muscles will be measured while the patient is in the prone position, in accordance with the literature.
215002433|NCT03646578|OTHER|State of anxiety|"Patient anxiety assessment by STAI-Y-A self-assessment questionnaire provided before and after pediatric interview.~The assessment is given to patients upon arrival in the hospitalization service of pregnancies and again after the pediatric interview. This pediatric interview should take place between 1 and 7 days after admission to the hospital ward.The second part includes a 6-week inclusion period with assessment of patients' state of anxiety by a STAI-Y-A self-assessment questionnaire given before and after pediatric interview associated with the delivery of a written document. on prematurity."
215002434|NCT04399005|OTHER|after-each-case room disinfection|After-each-case room disinfection was defined as after completing each case.
214398243|NCT06991283|DEVICE|Sham (no implant)|Vagus nerve stimulation is delivered through a transcutaneous electrical nerve stimulation device by attaching an ear clip to the tragus. But no stimulation will be delivered. The sham stimulation will be performed twice daily, each session lasting for half an hour. The stimulation times are fixed between 07:00-09:00 in the morning and 19:00-21:00 in the evening, with an interval of 12 hours between the two sessions.
214398244|NCT06991231|PROCEDURE|Total knee arthroplasty (TKA)|Administered as part of patient standard of care.
214398245|NCT06991231|DEVICE|Cryoablation|Cryoablation will be administered on the leg of the knee indicated for surgery.
214398246|NCT06991218|PROCEDURE|cardiac surgery|Adult patients (age ≥18 years) who underwent cardiac surgery with cardiopulmonary bypass were included.
214398247|NCT05259553|OTHER|Blood samples|"Peripheral blood sampling will be performed at different time points of the study, for a total volume of 20-40 mL:~* Sampling before MM treatment,~* Sampling during MM treatment (at 3 months post-initiation if no autograft or before autograft),~* Only for Patients treated with Apixaban or Eliquis®, 2 additional samplings during MM treatment for pharmacokinetics analysis."
214398248|NCT05218980|DIETARY_SUPPLEMENT|Olives|Organic olives (provided by Sakellaropoulos Organic Farms; Sparta, Greece)
214503732|NCT07007052|DRUG|Tagraxofusp|Single interventional arm
214503733|NCT07003061|PROCEDURE|Standard Anesthesia Management|All patients will receive standard anesthesia care as per institutional protocols. No experimental intervention will be applied.
214503734|NCT06871228|DEVICE|PPG/ECG dual mode based smartwatch|The intervention initiates anticoagulation when AF is detected as either a single episode ≥1 hour or cumulative ≥2 hours/24h (adjusted for monitoring compliance), triggering a 30-day NOAC therapy cycle that restarts if AF recurs during treatment. Participants are required to wear the device ≥12 hours daily, supported by automated reminders (vibration/SMS/phone alerts) and a reward system to reinforce adherence.
214503735|NCT06871228|DRUG|Continuous DOAC therapy|Continuous standard-dose DOAC therapy with dose adjustments per the drug labels.
215002435|NCT04399005|OTHER|daily room disinfection|Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
215002436|NCT03086343|DRUG|Abatacept|IV infusion
215002437|NCT03086343|DRUG|Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)|IV infusion
215002438|NCT03086343|DRUG|Upadacitinib|15 mg extended release tablet
215002439|NCT03086343|DRUG|Placebo for upadacitinib|Film-coated tablet
215002440|NCT04549441|PROCEDURE|Distal radius fracture plating surgery|We performed open reduction and plating surgery for the distal radius fracture.
215002441|NCT01667614|DRUG|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
215002442|NCT05457543|DIAGNOSTIC_TEST|Adult|Investigational use of a novel liver function diagnostic test that involves a paper-based test device and a smartphone application.
215002443|NCT01159847|DRUG|sitagliptin|sitagliptin tablet,100 mg p.o. qd,2 year
215002444|NCT01159847|DRUG|Insulin|
215002445|NCT03723824|DRUG|grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
215002446|NCT03940092|OTHER|MRI|"This is a prospective, non-randomised, exploratory study on healthy female volunteers (\>18 years), and female patients (\>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery."
215002447|NCT03940092|OTHER|PET/MRI|Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI
215002448|NCT03607084|BEHAVIORAL|School Health Worker Program|The intervention trains selected teachers to deliver health lessons to students, perform basic first aid, recognize common illnesses, refer student to skilled medical attention when needed. The intervention provides schools with basic medical supplies including pain relief medication, thermometers, bandages, antiseptics, and oral rehydration solution. Vitamin A supplementation and presumptive deworming medication are administered to students during biannual health screenings.
215002449|NCT04857710|DEVICE|Wide-pulse neuromuscular electrostimulation (WP NMES)|The WP NMES program consists of electrical stimulation trains of 1000 symmetrical biphasic pulses (1 ms, 100 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s. A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé).
215002450|NCT04857710|DEVICE|Conventional neuromuscular electrostimulation (CONV NMES)|"The CONV NMES program consists of electrical stimulation trains of 500 symmetrical biphasic pulses (0.2 ms, 50 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s (duty cycle: 1/3). A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.~During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé)."
215002451|NCT04857710|DEVICE|Control (CONT) modality|Control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations.
215002452|NCT00580281|OTHER|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
215002453|NCT01047501|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
215002454|NCT01047501|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
215002455|NCT01047501|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks
215002456|NCT00219271|DRUG|Zoledronic acid|
215002457|NCT00741611|DEVICE|HD Mesh Ablation System|Ablation using the HD Mesh Ablation System
214398249|NCT06674265|BIOLOGICAL|Allogenic NK cells infusion|Natural Killer (NK) cells are extracted from a healthy donor through apheresis and processed in a clean room using the CLINIMACS device. After quality assessment, these cells are stored at -198°C until needed. When required, the cells are thawed, washed, and evaluated for viability and sterility before being administered to the patient at a dosage of 5 × 10\^6 cells per kilogram of body weight. Two further injections may be considered based on the patient's response and confirmed improvement via MRI MIBG. Injections are scheduled seven to ten days after each chemotherapy course according to the standard treatment protocol.
215002458|NCT00741611|DRUG|Anti-arrhythmic drugs|5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
215002459|NCT02049762|DRUG|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
215002460|NCT04558827|OTHER|Low Carbohydrate Diet|Dietary choices are counseled to come primarily from lean meats, eggs, nuts, seeds, vegetables and berries.
215002461|NCT04558827|OTHER|Time Restricted Feeding|Participants will be asked to have 2 meals within an 8 hour period, preferably before 2pm.
214398250|NCT06746506|BEHAVIORAL|Amigurumi toy|A toy prepared using anti-allergic yarn to suit children's developmental stages.
214398251|NCT06918054|DIETARY_SUPPLEMENT|Dietary modification|Patients will follow Mediterranean Diet (MD), this diet is characterized by a high intake of vegetables, fruit, whole cereals, legumes, nuts, and fish and a low intake of red meat and homemade desserts. The main added fat was extra virgin olive oil, with 35-40% kcal from fat (\<10% from saturated fat), 40-44% kcal from carbohydrate, and 20% kcal from protein
214398252|NCT06918054|DIETARY_SUPPLEMENT|Supplementation of omega 3 fatty acids|Supplementation of omega 3 fatty acids ( dose based on weight: \<40 kg-450 mg/day, 40-60 kg-900 mg/day, \>60 kg-1300 mg/day)
214398253|NCT06916585|DRUG|AS1501 for injection|Single administration, after 20 days of elution, enter continuous administration, once a week for 4 consecutive weeks
214398254|NCT06544096|BEHAVIORAL|intervention group (WeChat platform + healthcare)|The study will implement the WeChat-based Neonatal Home Skin Care Management System, designed based on neonatal skin characteristics and evidence-based care guidelines. The intervention materials included a WeChat platform functional module (comprising a newborn information registration interface, online consultation, and questionnaire features) along with standard educational brochures used in the control group. During hospitalization, study group healthcare providers will deliver standard health education (identical to the control group) while additionally guiding mothers through platform registration and data entry, with demonstrations of system functionality. Post-discharge, the system automatically will deliver stage-appropriate skin care recommendations based on neonatal age with read reminders prompting parental engagement. Parents can access educational materials or submit queries at any time, while researchers utilize the platform for survey distribution.
214522596|NCT01509040|DEVICE|Low Volume Hemofiltration|"Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required."
215002462|NCT04407520|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
215002463|NCT03355027|DRUG|Alirocumab 150 MG/ML|Dosing to be performed by subcutaneous injection in clinic
215002464|NCT03355027|DRUG|Ezetimibe 10Mg Tablet|Patients will be instructed to take once daily at night.
215002465|NCT03355027|DRUG|Atorvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
215002466|NCT03355027|DRUG|Atorvastatin 80Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
215002467|NCT03355027|DRUG|Rosuvastatin 20Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
215002468|NCT03355027|DRUG|Rosuvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
215002469|NCT03355027|DRUG|Simvastatin 80mg|Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
215002470|NCT00762905|DEVICE|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
215095213|NCT03989323|OTHER|Estimation of the incidence of the irAE|Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
215002471|NCT00762905|DEVICE|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
215002472|NCT00731198|DRUG|Drotaverine hydrochloride|Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
215002473|NCT00731198|DRUG|Hyoscine-N-butylbromide|Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
214398255|NCT06544096|BEHAVIORAL|control group (routine health education)|When the parturient is discharged from the hospital, the medical staff of the control unit will give the parturient health education about the discharge of the newborn. The contents of the education include neonatal jaundice, umbilical care, vaccination, 42-day follow-up, breastfeeding and so on, which are not included in the system.
214398256|NCT02800486|DRUG|Intra-arterial Cetuximab|
215002474|NCT03787160|DIAGNOSTIC_TEST|initial VOC|Difference in VOC profile between patients with CDH and healthy controls (2 samples per patient will be obtained after obtaining informed consent).
215002475|NCT03787160|DIAGNOSTIC_TEST|initial fecal microbiome|Difference of alpha and beta diversity and relative fecal bacterial abundance between patients with CDH and healthy controls (1 stool sample will be taken per patient after obtaining informed consent)
214398257|NCT02800486|DRUG|Intra-arterial Mannitol|
214503736|NCT06069297|OTHER|Multimodal Prehabilitation|Preoperative multimodal intervention including exercise training, nutritional therapy and psychosocial counseling, aimed at preventing or attenuating surgery-driven functional decline. A personalized intervention program will be prescribed based on specific physical, nutritional and psychological conditions recognized during the multimodal assessment. Patients will follow a 2 to 3-day per week exercise program for 4-6 weeks including endurance, resistance, and inspiratory muscle training, tailored to individual preferences and clinical conditions. Based on dietary habits and nutritional status, a certified nutritionist will provide a comprehensive diet management program. A food-based intervention with a balanced macronutrient composition coupled with oral nutritional supplements will be prescribed to achieve the estimated daily energy and protein requirements. Patients will meet with a psychologist to explore their emotional and psychosocial needs related to their current situation.
215002476|NCT03787160|DIAGNOSTIC_TEST|initial pulmonary microbiome|Difference of alpha and beta diversity and relative pulmonary bacterial abundance between patients with CDH and healthy controls (1 deep induced sputum sample will be taken per patient after obtaining informed consent)
215002477|NCT03787160|DIAGNOSTIC_TEST|Maximum oxygen uptake|Comparison of the maximum oxygen uptake (corrected for body weight and gender) as determined by bicycle spiroergometry between patients with CDH and healthy controls
215002478|NCT03787160|DIAGNOSTIC_TEST|Functional residual capacity|FRC will be determined by spirometry, bodyplethysmography and N2-breath wash out method. FRC will be compared between patients after CDH and healthy controls.
215002479|NCT03787160|DIETARY_SUPPLEMENT|Probiotic treatment|CDH patients will receive OmniBiotic 6(R) (Allergosan, Graz, Austria) probiotic supplementation 1 sachet daily for 3 months.
215002480|NCT03787160|DIAGNOSTIC_TEST|VOC probiotic|Determination of the VOC profile 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
215002481|NCT03787160|DIAGNOSTIC_TEST|Fecal microbiome probiotic|Determination of the fecal microbiome from 1 sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
215002482|NCT03787160|DIAGNOSTIC_TEST|Pulmonary microbiome probiotic|Determination of the fecal microbiome from 1 deep induced sputum sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
215002483|NCT04942873|OTHER|adherence|PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
215002484|NCT02242344|DRUG|Telmisartan|
214398258|NCT02800486|RADIATION|Hypofractionated re-irradiation|
214398259|NCT02902029|DRUG|Vemurafenib|960 mg vemurafenib BID until progression or unacceptable toxicity develops
214503737|NCT06870630|DEVICE|Per oral endoscopy myotomy|Poem procedure is meant for cutting of circular and longitudinal muscle fibers in esophagus to reduce the symptoms of dysphagia, regurgitation and chestpain, weight loss.
215002485|NCT02242344|DRUG|Placebo|
215002486|NCT06403722|DIAGNOSTIC_TEST|Standard of care|No intervention. Clinical evolution was recorded, looking for perinatal complications.
215002487|NCT00536835|DRUG|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
215002488|NCT02940379|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
215002489|NCT02940379|DRUG|midazolam|"Pharmaceutical form: HCl syrup~Route of administration: oral"
215002490|NCT02940379|DRUG|metoprolol|"Pharmaceutical form: tablet~Route of administration: oral"
215002491|NCT00675350|DRUG|Omacetaxine|1.25 mg/m2 subcutaneous twice daily for 14 days
215002492|NCT05876494|DIAGNOSTIC_TEST|serum lactate|assessment of serum lactate and mean platelets volume
215002493|NCT03578913|OTHER|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.
215002494|NCT03578913|OTHER|PFM Crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
215002495|NCT00378859|BEHAVIORAL|Skim milk|
214398260|NCT02902029|DRUG|Cobimetinib|60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
214398261|NCT02902029|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
214398262|NCT04031430|DEVICE|Telemonitoring|Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.
214398263|NCT04031430|OTHER|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
214398264|NCT04031430|OTHER|CV profiling before and after the start/switch of antihypertensive medication|CV profiling before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
214398265|NCT02344394|DEVICE|Medtronic Cryoballoon|For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
214398266|NCT02344394|DEVICE|Thermocool Catheter|For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
214398267|NCT02344394|DEVICE|nContact|For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
214398268|NCT06624501|OTHER|Observational cohort study|
215002496|NCT00378859|BEHAVIORAL|Lean meat|
215002497|NCT02715557|BEHAVIORAL|Relapse prevention program|The relapse prevention program is an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
215002498|NCT04757584|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
215002499|NCT00429299|DRUG|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
215002500|NCT00429299|BIOLOGICAL|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
215002501|NCT00429299|DRUG|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
215002502|NCT00429299|DRUG|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
215002503|NCT00429299|DRUG|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
215095214|NCT03871660|DEVICE|FreeStyle Libre Pro|Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
214398269|NCT06625580|PROCEDURE|transverse thoracic muscle plane and serratus anterior plane block|ultrasound guided transverse thoracic muscle plane block and serratus anterior plane block will be performed with 0.25% bupivacaine
214398270|NCT06625580|PROCEDURE|erector spinae plane block|ultrasound guided erector spinae plane block will be performed with 0.25% bupivacaine
214398271|NCT06625866|BEHAVIORAL|Feedback and information|"The healthcare professionals in the intervention arm will be exposed to feedback and information behavioral strategies. Namely, interns, residents, obstetricians/gynecologists, and nurses will receive written feedback about the episiotomy rates in the hospital each month during the study period. Moreover, at least two academic sessions will be designed to outline the indications, surgical technique, complications, and surgical ethics for the procedure (i.e., episiotomy). Likewise, each session will also include a patient testimonial about their experience during delivery and their follow-up when an episiotomy was performed.~The feedback intervention will be provided for 2 months, and the feedback intervention + the information intervention will be provided for 2 additional months."
214398272|NCT03824535|DIAGNOSTIC_TEST|Computed Tomography|Undergo PET/CT
214398273|NCT03824535|DRUG|Fludeoxyglucose F-18|Given IV
214398274|NCT03824535|DRUG|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
215095215|NCT05769166|OTHER|thired domain of nordic orofcial test-screen|its a questionnaire which the parent will answer
214503738|NCT06683105|OTHER|MyIBDDiet app|Participants in the Standard of Care arm will be administered the intervention (using the app) for 30 days, and participants in the MYIBDDiet arm will use the app for 60 days.
214503739|NCT06390267|DEVICE|Sparrow Hawk (Active)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of active (prophylactic or acute) therapy according to the participant's randomization group.
215002504|NCT00429299|DRUG|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
215002505|NCT02992379|DEVICE|pivot splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
215095216|NCT06038994|OTHER|No intervention|This is an obvertional study, and there is no intervention.
215002506|NCT02992379|DEVICE|stabilizing splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
215002507|NCT00306072|DRUG|nutritional herbal extract from Salacia oblonga|
214398275|NCT03824535|DIAGNOSTIC_TEST|Positron Emission Tomography (PET/CT)|Undergo PET/CT
215002508|NCT01510756|DRUG|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
215002509|NCT05181384|OTHER|isolated pelvic floor muscles training|isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.
215002510|NCT05181384|OTHER|comprehensive stabilization exercise program|incorporated the contraction of PFMs with other spinal or extremity muscles
214398276|NCT06625450|DRUG|Tofacitinib|Tofacitinib alone will be continued at a dose of 11 mg once a day
214398277|NCT06625450|DRUG|Tofacitinib plus mesalamine|Both tofacitinib 11 mg once a day and mesalamine will be continued
214398278|NCT06625879|PROCEDURE|Serratus Anterior Plane Block (SAPB)|"Group I: (Serratus Anterior Plane Block (SAPB) Group) (n=15):~The patient will lay on her side with arm brought forward, the linear US transducer probe (10-12 MHz) will be placed in the midaxillary line and then moved caudal from second rib until the sixth intercostal space. At this point, the subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction. In-plane technique will be used until the tip of the needle placed between the serratus anterior muscle and the external intercostal muscle (deep SABP) . A volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection."
214398279|NCT06625879|PROCEDURE|Midpoint transverse process to pleura (MTP) block|In the lateral postion, the T4 spine will be counted by ultrasound, and high frequency linear US transducer probe (10-12 MHz) will be placed longitudinally, approximately 2.5 cm lateral to the midline the needle will be advanced in plane from cranial to caudal direction. The desired end point for the needle tip will be the midpoint of the line between the posterior border of the transverse process of T4 and the pleura(injection will be deep (anterior) to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligment),the needle tip dose not enter the paravertebral space , a volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection,pleural displacement and bowing of erector spinae will be observed at the side of injection .
214398280|NCT06624332|BEHAVIORAL|e-SBI main session|Single 20-minute e-SBI session that includes screening followed by brief motivational intervention.
215002511|NCT05181384|OTHER|education of pelvic girdle|educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
215002512|NCT03315364|DRUG|Oral paclitaxel|Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
215002513|NCT03315364|DRUG|Paclitaxel injection|Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
215002514|NCT00118794|DRUG|Chlorproguanil-dapsone (Lapdap)|
215002515|NCT00118794|DRUG|Lumefantrine-artemether (Coartemether )|
215002516|NCT04871113|BIOLOGICAL|GSK3810109A|GSK3810109A available as sterile aqueous solution.
215002517|NCT04871113|BIOLOGICAL|Dolutegravir+lamivudine SOC regimen|Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines
215002518|NCT03848078|DEVICE|Optical Coherence Tomography|"OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. In such ways, microscopic details of lesions and tissues can be visualized. This information can be used to identify a lesion as BCC, and to specify the subtype. Therefore, we assume that the use of the OCT might reduce the number of biopsies and the accompanying morbidity.~The investigator scans 6mm of skin with the OCT (30 seconds) and decides whether the lesion is a BCC or not."
214503740|NCT06390267|DEVICE|Sparrow Hawk (Sham)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of sham (prophylactic or acute) therapy according to the participant's randomization group.
214398281|NCT06624332|BEHAVIORAL|e-SBI Booster Session|A 20-minute booster e-SBI session that reinforces content from the main e-SBI session.
214398282|NCT06624332|BEHAVIORAL|Text messaging|4 weeks of daily automated text messages that reinforce content from the e-SBI main session.
214503741|NCT06664879|DRUG|MBG-453 + Azacitidine|Given intravenously (by vein)
214503742|NCT06873204|DIETARY_SUPPLEMENT|Soluble Arabinoxylan|10 grams of soluble arabinoxylan diluted in 200 mL of water, twice daily for 3 consecutive weeks.
215002519|NCT04613869|DRUG|High-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
215002520|NCT04613869|DRUG|Low-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
215002521|NCT04613869|DRUG|Hydromorphone|No esketamine added
215002522|NCT00933127|GENETIC|DNA analysis|
215002523|NCT00933127|GENETIC|polymerase chain reaction|
215002524|NCT00933127|GENETIC|polymorphism analysis|
215002525|NCT00933127|OTHER|laboratory biomarker analysis|
215002526|NCT02253498|DEVICE|deep brain stimulation (DBS)|
215002527|NCT00315822|OTHER|80% oxygen|Supplemental oxygen will be administered during surgery
215002528|NCT00315822|OTHER|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
214398283|NCT06625125|BEHAVIORAL|Mindfulness-based intervention|"The mindful mediators are asked to act as neutral observers who quietly attend to, notice, and let go of internal and external stimuli (present experiences) such as thoughts, feelings, physical sensations, and sounds without reactions, evaluation, and judgments. (Smith, 2005).~The subjects in the mindfulness-based intervention (MBI) group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks (Alhawatmeh et al., 2022; Thomas et al., 2017). Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's MBI protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
214503743|NCT06873204|DIETARY_SUPPLEMENT|Rice Bran|10 grams of rice bran fiber diluted in 200 mL of water, twice daily for 3 consecutive weeks.
214503744|NCT06873204|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|10 grams of maltodextrin diluted in 200 mL of water, twice daily for 3 consecutive weeks.
214503745|NCT06867705|DEVICE|Resilience PRO|The patient will use Resilience PRO remote symptoms monitoring.
214503746|NCT07014280|DRUG|Bevacizumab|anti-VEGF
215002529|NCT01522547|DRUG|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
215002530|NCT01257542|DRUG|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
215002531|NCT01257542|DRUG|Placebo|A single 10 mL dose of matching placebo syrup
215002532|NCT04705571|DEVICE|MorpheusV Applicator|1 treatment with the MorpheusV Applicator
215002533|NCT02912377|BIOLOGICAL|Neulasta, B12019|GCSF, Growth Colony Stimulating Factor
215002534|NCT01566162|DRUG|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
215002535|NCT04187521|OTHER|Meal A|A breakfast meal with a specific macronutrient proportions.
215002536|NCT04187521|OTHER|Meal B|A breakfast meal with a specific macronutrient proportions.
215002537|NCT02038842|BIOLOGICAL|LIPO-5|LIPO-5: 1mL IntraMuscular, 2 shots;
215002538|NCT02038842|BIOLOGICAL|MVA HIV-B (MVATG17401)|MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;
215002539|NCT02038842|BIOLOGICAL|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
215002540|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
215002541|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
215002542|NCT02197637|DRUG|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
215002543|NCT02413268|DRUG|Nitroglycerin|
215002544|NCT04693728|BEHAVIORAL|Resilient Intrinsic Self-Regulation Strategies in Extremes|The manualized intervention covered resilience strategies organized into four modules: (1) engagement, (2) social relatedness, (3) transformation of pain and (4) building a good life. The modules were delivered in 8 weekly sessions of 90 minutes each.
214503747|NCT07014280|DRUG|Triamcinolone Acetonide|corticosteroid
214503748|NCT07011966|DEVICE|ASV therapy|Adaptive servo ventilation (ASV) therapy using ResMed AirCurve 11 device will be used to target potential upper airway resistance and respiratory related arousals in patients with insomnia. The ASV device is approved for the treatment of obstructive sleep apnea, and this will be designated as the investigational device for this study with appropriate labelling.
214503749|NCT07012330|DRUG|Capecitabine (Xeloda)|Capecitabine (1650 mg/m2/day) was administered for two weeks from the start of each PRRT cycle.
214503750|NCT07012330|DRUG|177Lu-DOTATATE|Patients with advanced somatostatin receptor positive GEP NET or bronchopulmonary NET were included to receive four cycles of 7.4 GBq 177Lu-Dotatate.
214503751|NCT07012317|OTHER|High Fiber Bar with Inulin|Bar with Inulin - high fiber
214503752|NCT07012317|OTHER|High Fiber bar with Fiber Blend|Bar with a fiber blend of psyllium husk and bran fibers - high fiber
215002545|NCT02585167|PROCEDURE|operation|the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
215002546|NCT02585167|DEVICE|VAAFT|Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
215002547|NCT05340595|OTHER|Orthodontic retainer bonding|Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.
215002548|NCT01721239|OTHER|Standardized Followup program|Standardized written information, patient photos and three followup consultations.
215002549|NCT00000678|DRUG|Zidovudine|
215002550|NCT00000678|DRUG|Zalcitabine|
215002551|NCT00712049|DRUG|simvastatin|simvastatin 40 mg
215002552|NCT00712049|DRUG|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
215002553|NCT06190119|OTHER|none intervention|This study has no intervention
215002554|NCT01723943|OTHER|educational intervention|"Receive the What's Happening to the Woman I Love? booklet"
214398284|NCT06625125|BEHAVIORAL|Progressive muscle relaxation|"he progressive muscle relaxation (PMR) group will receive the ABC version of PMR (Smith, 2005). This abbreviated version of PMR involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot.~As the MBI group, the subjects in the PMR group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks. Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's PMR protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
214503753|NCT07012317|OTHER|High Fiber Bar with Resistant Starch type 4|Bar with Resistant Starch type 4 - High Fiber
214503754|NCT07012317|OTHER|Low Fiber Bar|Snack Bar - Low Fiber
215002555|NCT01723943|OTHER|counseling intervention|Undergo Helping Her Heal educational counseling program
215002556|NCT01723943|OTHER|educational intervention|Undergo Helping Her Heal educational counseling program
215002557|NCT01723943|OTHER|psychosocial support for caregiver|Undergo Helping Her Heal educational counseling program
215002558|NCT02243826|DRUG|50:50 mixture of nitrous oxide/oxygen|
215002559|NCT04167800|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
215002560|NCT03177850|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
215002561|NCT03177850|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
215002562|NCT03562507|DRUG|ESK981|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
215002563|NCT03562507|DRUG|Nivolumab|480 mg/dose IV, Day 1 of each 28-day cycle
215002564|NCT04764253|BEHAVIORAL|Modified Sodium Watcher Program + Digital Self-Monitoring|Participants randomized to the experimental group will be asked to follow the modified Sodium Watchers Program intervention along with goal setting for low salt foods. Each participant will be registered to assign a unique ID in the Connected Health Platform developed by the Center on Smart and Connected Health Technologies at UT Health Science Center San Antonio and each account from the individuals' wireless and wearable devices (Fitbit and BP monitor) will be connected to his or her unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor. Through the Connected Health Platform, the Fitbit app and BP monitor will transmit the data of the intervention group to the research team.
215095217|NCT04152213|BEHAVIORAL|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
215095218|NCT01455220|DRUG|Tysabri ® (Natalizumab)|IV, monthly
214398285|NCT06874413|BEHAVIORAL|Prehabilitation|Physical prehabilitation or exercise conducted through the YMCA's Silver Sneaker's program prior to receiving surgery that will be assessed through the use of wearable activity monitors.
214503755|NCT07012655|DEVICE|Colour Doppler Ultrasound|All study participants will undergo abdominal Ultrasound and Colour doppler ultrasound study of the superior and inferior mesenteric arteries and the resistance index and peak systolic velocity (cm/s) of radial and ulnar arteries measured by ultrasonography color Doppler with spectral wave analysis.
214503756|NCT07014150|DRUG|Lenvatinib|daily,8mg/ day for less than 60kg, 12mg/ day for more than 60kg, for 9 weeks
215002565|NCT04764253|BEHAVIORAL|Usual care + Digital Self-Monitoring|Participants randomized to the control group will be asked to follow usual care which is based on their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium-restricted diet and take medications as prescribed. The participants will receive wireless and wearable devices (Fitbit wristband, BP monitor). Each participant will be registered to assign a unique ID in the Connected Health Platform at the baseline and each account from the individual's wireless and wearable devices (Fitbit and BP monitor) will be connected to their unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
215002566|NCT01108159|PROCEDURE|Blood Draw|
215002567|NCT01108159|PROCEDURE|Skin Biopsy|
215002568|NCT00792480|BEHAVIORAL|Dietary and lifestyle counseling|"The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise."
215002569|NCT02132468|DRUG|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
215095219|NCT04543240|DEVICE|Integra™ dermal regeneration template|Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
215095220|NCT03974672|PROCEDURE|Re-laparotomy|
215095221|NCT06175013|DEVICE|Sérum PURIFIANT|Application of Sérum PURIFIANT only, twice daily during 112 days
214503757|NCT07014150|DRUG|Iparomlimab and Tuvonralimab|7.5mg/kg, every 3 weeks, for 3cycles.
214398286|NCT06874413|OTHER|Standard of Care (SOC)|Patients will receive standard of care preoperative instructions.
214398287|NCT05650307|DIAGNOSTIC_TEST|MRI|The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.
214398288|NCT06883006|BEHAVIORAL|Sleep Extension|A 1.5-hour nap opportunity compared to a neutral 1.5 hour waking activity (e.g., puzzle completion) prior to task. Participants will either nap or not prior to the emotion regulation task. These two conditions will be counter-balanced within gender and participants will complete them 1 week apart. If they are in the nap condition, they will nap for 1.5 hours with PSG in a dark, soundproofed room with optional fan, white noise, or music. If they are in the no nap condition, they will work on puzzles for 1.5 hours in the same room but with the lights on.
214398289|NCT06918821|BEHAVIORAL|Healthy Toddler Parent Group (HTPG)|Parent education class
214398290|NCT06918821|BEHAVIORAL|Families Understanding Nutrition and Physically Active Lifestyles (FUNPALs) Playgroup|Family playgroup
214398291|NCT06500611|OTHER|Sensory Integration and Vestibular Exercise with Routine Physical Therapy|"1. Stand with feet hip-width apart 5 rep~2. Sit in chair without backrest 5 rep~1.Stand with feet hip -width apart 5 rep~2.Sit to stand sit on chair without backrest and perform sit to stand repeatedly 5 rep~1.Tandem Walk one foot directly in front of the other.2 sets 5 steps forward and backward~2.Patientwalk forward cross an obstacle, continue walk. Walk Lateral Walk Backward 2 sets~1. Stand and slowly move head side to side and up down 10 repetition~2. Fix gaze and move head side to side or up and down 10 repetitions~1\. Stand on one leg for 10 seconds hold on. Repeat 5 times on each leg.~2\. Stand and rotate body to right and left 10 rotations~1. Walk on straight line , zigzag pattern, walk while looking your shoulder 5 rep~2. Sit and swing your legs back and forth 5rep~3. Play catch in standing. 2 sets 5-8 catches.~Static stretching 30 sec hold 5 times"
214398292|NCT06500611|OTHER|Vestibular Exercise with Routine Physical Therapy|"Vestibular exercise~1\. Stand with feet hip -width apart and slowly move head side to side and up down.10 repetitions for each direction.~2 .Fix your gaze on object while moving your head side to side or up and down. 10 repetitions for each movement.~1.Patient will stand on one leg for 10 second. Hold onto a stable support if needed. 5 times on each leg.~2\. Stand with feet hip-width apart and rotate body to the right and left. 10 rotations in each direction.~1. Walk on a straight line or in a zigzag pattern or walk while looking over your shoulder. (5 rep)~2. Sit on a stable chair and swing your legs back and forth, similar to a pendulum. (5rep)~3. Catch and Throw play catch with a partner while standing. 2 sets of 5-8 catches.~Routine Physical Therapu Static stretching exercises for 30 sec hold with 30 sec rest. 5 times for each muscle group"
214398293|NCT06739590|BEHAVIORAL|Learning with CT scans|The average performance improvement in this group will serve as the baseline for learning achievable through conventional CT and MR imaging alone.
214398294|NCT06739590|BEHAVIORAL|Learning with 3D visualization models|Learning anatomical structures using three-dimensional visualization models displayed on a computer.
214398295|NCT06739590|RADIATION|Learning with 3D-MR visualization models|Viewing and manipulating 3D visualization models to learn anatomical structures using the MR headset.
214398296|NCT06744127|DRUG|BR1015|One tablet administered alone
214503758|NCT07012850|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|To reduce radiation exposure while simultaneously allowing for the visualization of soft tissues, newer imaging methods, including magnetic resonance imaging (MRI), as well as Black Bone and CT-like MRI protocols (ZTE, UTE), are being explored. These MRI techniques offer high-resolution, non-ionizing alternatives, showing promise for diagnosing soft tissue injuries and fractures without radiation risks.
214503759|NCT07012486|DRUG|Oral DHA + Topical minoxidil 5%|DHA 20mg tid po plus daily topical minoxidil 5% for 180 days
214503760|NCT07012486|DRUG|Topical Minoxidil 5%|Topical minoxidil 5% daily for 180 days
215002570|NCT00693303|BEHAVIORAL|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
215002571|NCT03459651|BEHAVIORAL|ANS training|In-home computer-based ANS training
215002572|NCT01484366|PROCEDURE|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
215002573|NCT01484366|PROCEDURE|plating|Surgical plating of both bonforearm fractures
215002574|NCT05702151|PROCEDURE|ESP Block|After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.
215002575|NCT05702151|DRUG|Morphine injection|Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
215095222|NCT06175013|DEVICE|Sérum PURIFIANT in association Sérum BOOSTER|Application of Sérum PURIFIANT twice daily during 112 days AND Application of Sérum BOOSTER before the Serum PURIFIANT, twice weekly
215095223|NCT06055660|GENETIC|Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma|Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
215095224|NCT04881747|DRUG|Lasmiditan|Administered orally.
215095225|NCT01573156|DRUG|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 \& 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
215002576|NCT01133106|BEHAVIORAL|Brief pleasurable events/behavioral therapy|"Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients."
215002577|NCT01133106|OTHER|Standard care|The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
215002578|NCT04985656|DRUG|Pevonedistat|Pevonedistat IV infusion
215002579|NCT04985656|DRUG|Decitabine|Decitabine tablets
215002580|NCT04985656|DRUG|Cedazuridine|Cedazuridine tablets
215095226|NCT02132273|OTHER|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
215095227|NCT03579173|DIAGNOSTIC_TEST|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
215095228|NCT03579173|DIAGNOSTIC_TEST|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
215002581|NCT03600428|BIOLOGICAL|Live Attenuated Influenza Vaccine (LAIV)|1 dose, 0.2 mL, intranasal administration
215002582|NCT03600428|BIOLOGICAL|Inactivated Influenza Vaccine (IIV)|1 dose, 0.5 mL, intramuscular administration
215002583|NCT01295892|DRUG|Estrogen|transdermal 17-β-estradiol 1mg/day during three months
215002584|NCT05188794|PROCEDURE|lateral tap block|In the axial plane on the midaxillary line between the subcostal margin and the iliac crest with a linear probe using a 12 cm insulated nerve block needle is advanced in planely from skin, external, and internal oblique muscles to the target of fascial plane between the internal oblique and the transversus abdominis muscles.
215002585|NCT05188794|PROCEDURE|posterior tap block|In the axial plane on the midaxillary line a linear probe using a 12 cm insulated nerve block needle is advanced posteriorly to the most posterior limit of the TAP between the internal oblique and transversus abdominis muscles.
215095229|NCT03579173|DIAGNOSTIC_TEST|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
215095230|NCT01629472|BEHAVIORAL|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
215002586|NCT00446784|DRUG|CE-224,535|
215002587|NCT00446784|DRUG|Methotrexate|
215095231|NCT02067494|OTHER|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
215095232|NCT02067494|OTHER|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
215095233|NCT00214929|BEHAVIORAL|treatment at home|
215095234|NCT05776628|DEVICE|Plenum® Tissue ortho membrane (polydioxanone membrane)|Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
215095235|NCT02315508|DRUG|AUT00063|800 mg orally, once a day, for 4 weeks
215095236|NCT02315508|DRUG|Placebo|orally, once a day, for 4 weeks
215095237|NCT05104541|OTHER|Weight loss|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
215095238|NCT01878669|DRUG|N-acetyl cysteine|
215095239|NCT01878669|DRUG|Saline|
215095240|NCT04598269|DRUG|ATI-1777|ATI-1777 topical solution 2.0% w/w
215095241|NCT04598269|DRUG|Vehicle|Vehicle topical solution containing no ATI-1777
215095242|NCT03436823|OTHER|nurse semi-structured interview|The first session of rTMS is D1. From the first meeting to D14 semi -structured interviews are set up
215095243|NCT03436823|OTHER|Music & Relaxation with eyes closed|The first session of rTMS is D1. From the first meeting to D14 music \& relaxation with eyes closed sessions are set up
215095244|NCT05473286|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
215095245|NCT05910333|OTHER|observation|To compare the effect of the mandibular implant retained OVD using quadrilateral distribution (QD) versus linear distribution (LD) on posterior mandibular ridge resorption (PMandRR), anterior maxillary ridge resorption (AMaxRR), and changes to the crestal bone level around implants after 10 years of function.
215095246|NCT02387489|BEHAVIORAL|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
215095247|NCT02387489|BEHAVIORAL|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
215002588|NCT02368236|BEHAVIORAL|Tailored Printout|The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
215002589|NCT02617290|DRUG|Ticagrelor|Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.
215002590|NCT02617290|DRUG|Clopidogrel|Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
214398297|NCT06744127|DRUG|BR1015-1|One tablet administered alone
215002591|NCT03251599|DRUG|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
215002592|NCT03251599|DRUG|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
215002593|NCT03611127|OTHER|pulmonary rehabilitation|pulmonary rehabilitation standardized program
214398298|NCT06744127|DRUG|BR1015-2|One tablet administered alone
214398299|NCT06744062|DRUG|BR1015|One tablet administered alone
214398300|NCT06744062|DRUG|BR1015-1|One tablet administered alone
214503761|NCT03365622|DRUG|acetaminophen|Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.
214503762|NCT03365622|DRUG|Acetaminophen|500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
215002594|NCT04482790|PROCEDURE|Conventional celluloid matrix technique in management of black triangle|conventional restorative technique in management of black triangle
215002595|NCT04482790|PROCEDURE|Bioclear cervical matrix with injection molding technique|New restorative technique in management of black triangle restorative papilla regeneration
214503763|NCT03365622|DRUG|Placebos|Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.
215002596|NCT04398134|DRUG|ABI-H2158|3 X 100 mg tablets for oral administration
214503764|NCT03365622|DRUG|Placebo Oral Tablet|Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
214503765|NCT07012746|DRUG|TJ0113 capsules|Oral intake on an empty stomach in the morning, 200 mg each time, fasting within half an hour after taking. It is recommended to keep the drug at the same time (± 1 h ) of a day .
215002597|NCT04398134|DRUG|Placebo|Sugar pill manufactured to mimic the ABI-H2158 tablets
215002598|NCT04398134|DRUG|Entecavir (ETV)|0.5 mg tablet for oral administration
215002599|NCT04925323|BIOLOGICAL|BLOOD SAMPLES|BLOOD SAMPLES
215002600|NCT04925323|BIOLOGICAL|surgical tissue samples|unused surgical tissue removed during plastic surgeries
215002601|NCT03802110|DEVICE|commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.|The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
215095248|NCT00721539|DEVICE|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
215095249|NCT00721539|PROCEDURE|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
215095250|NCT06943404|DRUG|BXCL501 (dexmedetomidine HCl)|BXCL501 (dexmedetomidine HCl) taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.
215095251|NCT06943404|DRUG|Placebo|Placebo taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.
215095252|NCT00225784|DRUG|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
214398301|NCT06744062|DRUG|BR1015-2|One tablet administered alone
214503766|NCT07012746|DRUG|Placebo capsules|Oral intake on an empty stomach in the morning, 200 mg each time, fasting within half an hour after taking. It is recommended to keep the drug at the same time (± 1 h ) of a day .
214398302|NCT06887517|DRUG|Antimalarial with or without oral glucocorticosteroid|"Intervention one: Antimalarial and Oral Glucocorticosteroid, Prednisone or equivalent dose of glucocorticoid tapering: 0.5\~0.6mg/kg/d(week 0\~2), 0.3\~0.4mg/kg/d(week 3\~4), 15 mg/d(week 5\~6), 10 mg/d(week 7\~8), 7.5 mg /d(week 9\~10), 5 mg/d(week 11\~12), 2.5 mg/d(week 13\~24), \<2.5 mg/d(after week 24)；Hydroxychloroquin 6.5mg/kg/d but no more than 400mg/d for initial therapy, and reduce to 4\~5mg/kg/d for maintenance therapy~Intervention two: Antimalarial only. Hydroxychloroquin 6.5mg/kg/d but no more than 400mg/d for initial therapy, and reduce to 4\~5mg/kg/d for maintenance therapy"
214398303|NCT06920173|PROCEDURE|Experiemental: Peripheral Venous Catheter|Patients older than 18 years of age who present with shock requiring vasopressors at the following minimum doses: norepinephrine 5 mcg/min, phenylephrine 50 mcg/min, epinephrine 5 mc/min, dobutamine 5 mcg/kg/min. Vasopressors are infused through a peripheral venous catheter (18 gauge or larger); however, patients are crossed over to the central venous catheter group if the maximum vasopressor dose is reached or more than two vasopressors.
214398304|NCT06915051|DIAGNOSTIC_TEST|Determining the relationship between the coiling number and fetal echocardiography findings.|Fetal echocardiography findings to be performed simultaneously with the determination of the coiling number.
215002602|NCT06268119|OTHER|training nurses and caring for patients to prevent, diagnose, and intervene in postoperative delirium.|The intervention group received care in line with the postoperative delirium prevention, diagnosis and intervention protocol after the delirium training given by the researcher to intensive care unit nurses.
215002603|NCT04135651|PROCEDURE|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
215095253|NCT00225784|PROCEDURE|Radiotherapy|Daily radiotherapy for 28 days
215002604|NCT04135651|PROCEDURE|Cricoid pressure|To apply cricoid pressure, the crocoid cartilage was compressed with a single-handed three-finger maneuvre towards the vertebral bodies.
215095254|NCT04054999|DRUG|Hydroxocobalamin|Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
215095255|NCT04054999|DRUG|Methylene Blue|Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
215002605|NCT03664258|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor|The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).
215002606|NCT02792634|PROCEDURE|Sleeve-Gastrectomy, Roux en Y gastric bypass|
215002607|NCT02565472|OTHER|White grape juice|
215002608|NCT02565472|OTHER|Apple juice|
215002609|NCT01442636|DEVICE|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
215002610|NCT04601285|DRUG|JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)|"Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.~Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose."
215002611|NCT04002271|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be titrated to produce a BIS value of between 40-60. For induction, remifentanil 1mcg/kg and rocuronium 0.6 mg/kg will be given intravenously prior to intubation. Sevoflurane will not be given. Air and oxygen will be given, and FiO2 will be kept at between 35-50%. Similarly, to the GAS group, remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min and titrated according to the haemodynamic parameters stated for the GAS group. Morphine sulphate will be given at a dose of 0.1mg/kg before skin incision. TCI propofol and remifentanil will be switched off at the end of the procedure. Reversal of muscle relaxation will be achieved as for the GAS group.
215002612|NCT04002271|DRUG|Sevoflurane|Patients in the GAS group will be induced with intravenous bolus propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6mg/kg for induction of general anaesthesia and intubation of patient. General anesthesia monitoring will be used. Maintenance of general anesthesia to be provided using sevoflurane, together with air and oxygen. FiO2 will be maintained between 35-50%. Bispectral (BIS) monitoring will be applied and level of anaesthesia will be maintained at a BIS value of 40-60. Remifentanil infusion will be given at between 0.1-0.2mcg/kg/min, to be titrated to maintain mean arterial blood pressure within 20% of baseline (blood pressure in ward before surgery as baseline) and heart rate between 45 to 100 bpm. Morphine sulphate to be given at a dose of 0.1mg/kg before skin incision. Sevoflurane and remifentanil infusion will be switched off at the end. Reversal of muscle relaxation to be achieved using intravenous neostigmine 50mcg/kg and atropine 20mcg/kg after the operation.
215002613|NCT04002271|PROCEDURE|Spinal anaesthesia|Patients in the SA group will receive intrathecal (L4-5, or L3-4 if failed at L4-5) administration of 2.2-2.4ml 0.5% heavy bupivicaine using a 25G Whitacare needle. No intrathecal opioid will be given during the procedure. Light sedation will be given during surgery with target-controlled infusion of propofol using the Marsh effect site model (0.3 -1 mcg/ml). Supplemental oxygen 2L/min will be given via the nasal cannula.
215002614|NCT00153920|DRUG|bortezomib|
215002615|NCT01029821|DRUG|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
215002616|NCT05667129|DRUG|XEN-101|Capsule formulation
215002617|NCT05667129|DRUG|Placebo|capsule formulation
215095256|NCT03869333|BIOLOGICAL|Invaplex[AR-DETOX]|Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine
215095257|NCT03869333|OTHER|Placebo|Saline
214398305|NCT06915155|DEVICE|Swing-Mesh™|A lightweight, macroporous, three-dimensional polypropylene mesh implant developed by THT BioScience™ and distributed by B. Braun™, used in laparoscopic-endoscopic inguinal hernia repair without fixation. The mesh is designed to conform to the anatomical shape of the myopectineal orifice and is available in two sizes (15×11 cm or 16×12 cm).
215002618|NCT04797728|DRUG|Elacestrant|Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)
215002619|NCT03637829|OTHER|Control|Water
215002620|NCT03637829|OTHER|White chocolate|Experimental snack treatment
215002621|NCT03637829|OTHER|Dark chocolate 1|Experimental snack treatment
215002622|NCT03637829|OTHER|Dark chocolate 2|Experimental snack treatment
215095258|NCT05086055|BEHAVIORAL|Kinematic movement analysis|moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.
215095259|NCT03286179|OTHER|modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)|Provision of estimated risk for major cardiac events at 60 days based on the modified HEART and/or EDACS, using KPNC specific estimates derived from an internal validation study
215095260|NCT03155308|DEVICE|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
214398306|NCT05956834|DEVICE|PAMSys|Wearable accelerometer and gyroscope for measuring movement
214398307|NCT05956834|DEVICE|LEGSys|Wearable accelerometer and gyroscope for measuring movement
214398308|NCT05041634|BEHAVIORAL|IHOPE|Integrating Healthy Habits Optimized by Community Participation and Engagled Learning
215002623|NCT03517215|BEHAVIORAL|Enhanced CB-ASP|The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.
215095261|NCT00438152|DRUG|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
215002624|NCT03517215|BEHAVIORAL|Standard CB-ASP|A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
215002625|NCT00538538|DRUG|vitrectomy with subretinal lucentis|A gas bubble will be placed in the eye after the gel has been removed.
214398309|NCT04068727|OTHER|Clinical Pharmacist Intervention|After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.
215095262|NCT00438152|DRUG|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
215095263|NCT03612050|BEHAVIORAL|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
215095264|NCT02054793|DRUG|Itraconazole|100 mg 200 mg 300 mg
215095265|NCT02054793|DRUG|Orteronel|300 mg
214398310|NCT03038074|DEVICE|Pulse Oximeter with respiration rate sensor|
215002626|NCT00538538|DRUG|vitrectomy with subretinal lucentis|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
215002627|NCT03807635|DEVICE|ergoLance safety lancet|The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
215002628|NCT03807635|DEVICE|Acti-Lance safety lancet|The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.
215095266|NCT02598128|DEVICE|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
215095267|NCT02598128|DEVICE|Placebo|Sham device
215095268|NCT01804569|OTHER|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
215095269|NCT02177513|DRUG|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
215095270|NCT02177513|DRUG|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
215095271|NCT02177513|DRUG|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
215095272|NCT02177513|DRUG|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
215095273|NCT02177513|DRUG|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
215095274|NCT00319241|BEHAVIORAL|Parenting Intervention|
214398311|NCT01361815|DEVICE|H-Coil Deep TMS in combination with SSRIs|The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
214398312|NCT05923268|DRUG|[99mTc]Tc-G3-(G3S)3C|One single injection of \[99mTc\]Tc-G3-(G3S)3C, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours
214503767|NCT07013565|DRUG|Vinblastine (Velban)|Low risk cohort patients will receive 2 cycles of Induction therapy with single-drug vinBLAStine (VBL), then undergo disease assessment. If complete remission (CR) and MRD -, LR patients will continue single-drug VBL for a total of 24 months (if absent disease progression or unacceptable toxicity).
214503768|NCT07013565|DRUG|Brentuximab vedotin (Adcetris)|HR cohort patients with no previous exposure to BV will receive 2 cycles of Induction therapy with BV and NIVO \[BV + NIVO\] one every 21 days, then undergo disease assessment. Patients in CR will proceed with consolidation with RTC allogeneic SCT (SCT)\*. If patient has any response other than CR and MRD-, they will receive 2 cycles of BV, VBL, and NIVO \[BV + VBL + NIVO\] once every 21 days
215002629|NCT00063622|DRUG|Pioglitazone|30 mg daily
215002630|NCT00063622|DIETARY_SUPPLEMENT|Vitamin E|800 IU daily
215002631|NCT00063622|DRUG|Matching placebo|Daily
215002632|NCT01878266|RADIATION|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
215002633|NCT01878266|RADIATION|Hypofractionated Arm (2)|The total dose to 4500 cGy in 15 fractions in 3 weeks
215002634|NCT01878266|RADIATION|Conventional Arm (3)|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
215095275|NCT02831790|OTHER|Fontan Education Videos|"The intervention will consist of three brief (\~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~1. Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~2. Anticoagulation~3. Prolonged pleural drainage"
215095276|NCT00137189|PROCEDURE|Resource-oriented music therapy|
215095277|NCT00137189|PROCEDURE|Standard care|
215002635|NCT02551146|DEVICE|A Locator with retention elements|Insertion of GC Pilier locator abutments with retention elements
215002636|NCT02551146|DEVICE|B Locator without retention elements|Insertion of GC Pilier locator abutments without retention elements
215002637|NCT00259636|DRUG|zonisamide|zonisamide 100 mg -300 mg daily vs placebo
215002638|NCT00006180|DRUG|Alendronate|
215002639|NCT00205166|PROCEDURE|Cardiac SPECT imaging Rest and Stress|adenosine perfusion scintigraphy
215002640|NCT00205166|DRUG|Caffeine|Caffeine 400 mg po
215002641|NCT00205166|DRUG|Caffeine|Caffeine 200 mg po
215002642|NCT03170310|DRUG|Apatinib|Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
215002643|NCT05224323|OTHER|Airway pressure, flow, esophageal pressure, ventilation distribution|After informed consent, baseline characteristics of patients will be collected. Airway pressure, flow and esophageal pressure will be recorded using high sampling rate and ventilation distribution using electrical impedance tomography will be recorded during the study. The ventilator will be set at a positive end-expiratory pressure of 15 cmH2O during 10 minutes. Then, respiratory rate will be decreased to 8 breaths/min, and positive end-expiratory pressure will be decreased to 5 cmH2O over one breath to measure the recruited volume. Then, three low-flow inflation and deflation pressure-volume curves will be performed before resuming clinical ventilator settings. Patients will be followed until Day 28 after inclusion or ICU discharge. Maneuvers performed are part of the usual care of patients with acute respiratory distress syndrome in our unit.
215002644|NCT05735470|DEVICE|antibacterial bone traction needles|Whether to use bone traction needles containing antibacterial coatings
215002645|NCT02246894|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
215002646|NCT04229901|DRUG|HepaStem|HepaStem will be administered as an intravenous (IV) infusion
215002647|NCT04229901|DRUG|Placebo|Placebo will be administered as an intravenous (IV) infusion
215002648|NCT01706627|DRUG|10 mg Melatonin|Active Comparator: Drug: Melatonin 10 mg
215002649|NCT01706627|DRUG|20 mg Melatonin|Active Comparator: Drug: Melatonin 20 mg
215002650|NCT01706627|DRUG|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
215002651|NCT02747160|BEHAVIORAL|Managing Anxiety from Cancer (MAC)|The intervention consists of six telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques (patient only), problem-solving strategies (caregiver only), and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
215002652|NCT02038426|BIOLOGICAL|BLOOD SAMPLES|
215002653|NCT02038426|DEVICE|Radiographs of the sacroiliac joints|
215002654|NCT02038426|DEVICE|Radiographs of heels|
215002655|NCT02038426|DEVICE|SCAN|
215095278|NCT00861016|DRUG|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
215002656|NCT04502524|BEHAVIORAL|Smoking Cessation Intervention (New website)|Complete the new website smoking cessation program
215002657|NCT04502524|BEHAVIORAL|Smoking Cessation Intervention (Standard of care website)|Complete the standard of care website smoking cessation intervention
215002658|NCT04502524|BEHAVIORAL|Health Education|Receive information about the cost of smoking, benefits of quitting, ways to prepare for quitting, ways to handle triggers and withdrawal symptoms, and available medications to help with quitting. And will receive additional resources available at the VA handout via email at the end of the study.
215002659|NCT04502524|OTHER|Health Promotion and Education|Receive motivational and reminder text messages
215002660|NCT04502524|OTHER|Questionnaire Administration|Ancillary studies
215002661|NCT05026918|OTHER|MCPT|Postural Drainagewith percussion and vibration
215002662|NCT05026918|OTHER|ACBT|ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique
215002663|NCT01523197|DEVICE|BiPAP ventilation, auto-trilevel ventilation|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
215002664|NCT02060162|OTHER|Standard of care|routine standard of care per Ministry of Health protocol including blood draws and examinations.
215002665|NCT01600859|DRUG|E2609|"E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg~E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg~According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo"
215002666|NCT01600859|DRUG|Placebo for E2609|"Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo"
215002667|NCT06196359|PROCEDURE|Combined Femoral and Popliteal nerve block|Patients who receive a combined femoral and popliteal nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
215095279|NCT00739466|DRUG|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
215002668|NCT00832806|BEHAVIORAL|Extended IVR (integrated voice response technology)|See detailed description
215002669|NCT00832806|DRUG|Varenicline (Champix)|See detailed description
215002670|NCT00832806|BEHAVIORAL|IVR treatment|See detailed description
215002671|NCT02800252|DRUG|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
215002672|NCT02800252|DRUG|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
215002673|NCT02800252|DRUG|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
215002674|NCT02896023|DRUG|human menopausal gonadotropin|Induction of ovulation followed by ICSI
215002675|NCT03947723|DEVICE|Radiofrequency ablation|The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
215002676|NCT00634387|DIETARY_SUPPLEMENT|Anthocyans|Anthocyans
215002677|NCT00634387|OTHER|placebo|
214398313|NCT01710293|BEHAVIORAL|Communication of Patients Lost to Follow-up to Providers|"The investigators will query the VA's database weekly to identify possible lost to follow-up events for a random sample of about half of the providers at our study sites. The queries will use the trigger criteria developed in our previous work for colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, and bladder cancer. The list of trigger positive patients will be transmitted to a facility-level recipient who will either disseminate the information to existing facility individual cancer care coordinators/trackers or will review the charts of the triggered patients in order to determine whether these patients have been truly lost to follow-up or not. If patients are found to be lost to follow-up, the Facility Recipient or cancer care coordinator/tracker will communicate the need for follow-up to the PACT or primary care provider, using secure emails, phone calls, or in person, depending on which method of communication they deem most appropriate and effective."
214398314|NCT02643771|PROCEDURE|Full Mouth Scaling and Root Planing|This procedure was performed as described by Quirynen et al. 2005 with some modifications
214398315|NCT00322868|DRUG|pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.
214398316|NCT03565861|DRUG|Placebo|Intravenous vehicle
214398317|NCT03565861|DRUG|NP10679|NP10679
214398318|NCT03290469|OTHER|clinical whole genome sequencing (cWGS)|Clinical Whole Genome Sequencing (cWGS) consists of the sequencing, analysis and interpretation of subjects samples and a return of the result to the ordering physician.
215002678|NCT00634387|DIETARY_SUPPLEMENT|Anthocyans|
215002679|NCT01586182|RADIATION|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
215002680|NCT04185727|OTHER|Supervised strength training|12 weeks supervised strength training exposure. The study will allocate patients to groups consisting of 4 members who receive strength training for 12 weeks. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session.
215002681|NCT04700605|BEHAVIORAL|Dual task balance test|Participants will be conducting two dual task tests; an 8m gait test and a Wii Balance Board test with simultaneous various cognitive tests.
215002682|NCT02151201|BEHAVIORAL|Influenza vaccination video education|Influenza vaccination video education
215002683|NCT02151201|BEHAVIORAL|Hand washing video education|Hand washing video education
215002684|NCT03804307|RADIATION|standard treatment|3000 cGy in 10 daily fractions
215002685|NCT03804307|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
215002686|NCT02703025|DIETARY_SUPPLEMENT|GCB-70|green coffee bean extract
215002687|NCT02632214|OTHER|fMRI measure|
215002688|NCT06956547|DRUG|nogapendekin-alfa inbakicept|1.0mg nogapendekin-alfa inbakicept (NAI) administered by subcutaneous injection no less than every 3 weeks and no more frequently than every 2 weeks between doses in combination with the standard of care schedule of chemotherapy, immunotherapy, and/or radiation therapy. Patients who are known HIV+ will be dosed with NAI at 0.5 mg
215002689|NCT06831565|DIAGNOSTIC_TEST|ROTEM|ROTEM Tests
215002690|NCT01756703|DRUG|MT-3995 Low|MT-3995 Low dose for 8 weeks
215002691|NCT01756703|DRUG|MT-3995 High|MT-3995 High dose for 8 weeks
215002692|NCT01756703|DRUG|Placebo|Placebo for 8 weeks
215095280|NCT00739466|DRUG|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
214398319|NCT04125511|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of IgG4-RD by PET/CT.
215002693|NCT04858711|DRUG|ketamine-lidocaine-dexmedetomidine|In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.
215002694|NCT04858711|DRUG|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
215002695|NCT03053011|OTHER|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
215002696|NCT03791372|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
215002697|NCT03791372|BIOLOGICAL|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Cerebral Palsy for safety and effect evaluation.
215002698|NCT02472093|OTHER|Physical exercises treatment|Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.
215002699|NCT02472093|OTHER|Perceptive Rehabilitation Treatment|therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
215002700|NCT02472093|OTHER|Control group|The control group did brief educational sessions.
215002701|NCT01666652|BIOLOGICAL|4 µg TDENV-PIV with Alum adjuvant|
215002702|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS03B1 adjuvant|
215002703|NCT01666652|OTHER|Phosphate buffered saline|
215002704|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with Alum adjuvant|
215002705|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS01E1 adjuvant|
215002706|NCT02716090|DRUG|Adapalene and Benzoyl peroxide Dalap Duo®|
215002707|NCT02716090|DRUG|Adapalene and Benzoyl peroxide Epiduo®|
215002708|NCT01018979|DRUG|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
215002709|NCT01018979|DRUG|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
215002710|NCT04841265|DIETARY_SUPPLEMENT|Vitamin D3|The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.
215002711|NCT00113139|BEHAVIORAL|Telephone-based coping skills/stress management|Telephone-based coping skills/stress management: 12 weekly sessions.
214398320|NCT04646447|DIETARY_SUPPLEMENT|L-serine|"L-Serine Arm L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320.~All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.~The L-Serine will be manufactured, packaged, labeled and/or distributed by NUTRICIA or delegated contractors. It will be presented in a powdered form of 100 gr of the amino acid L-serine. For oral use.~Sufficient L-serine will be dispensed at home considering the dose according the weight of the patient."
214398321|NCT01917734|OTHER|Therapeutic feeding for children with SAM|Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
214398322|NCT04223154|DEVICE|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
214503769|NCT07013565|DRUG|Nivolumab (Opdivo)|High risk cohort patients with previous exposure to Brentuximab vedotin (BV) will receive 2 cycles of Induction therapy with VBL and NIVO \[VBL + NIVO\] on day 1 and 15, then undergo disease assessment. If response is not CR, or patient has PR/SD/PD, patient will receive \[BV+VBL+NIVO\] and subsequent therapy as defined for the HR2 cohort.
214503770|NCT07013058|DIETARY_SUPPLEMENT|Nigella sativa extract (Nisatol®)|Participants will take 2 softgel capsules daily of Nigella sativa oil standardized to 10% thymoquinone (Nisatol®), one capsule with lunch and one with dinner, for 4 months.
215002712|NCT00113139|OTHER|Usual Care|Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
215002713|NCT04770974|OTHER|Biomarkers and proteomics|Biomolecular, proteomic, metabolomic and spectroscopy characterization of urothelial bladder neoplasia, on a 3D culture model (organoid) obtained from bladder tumor tissue
215002714|NCT02909426|DEVICE|Ultrasonography|Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
215002715|NCT02909426|DEVICE|Digital mammography|Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
215002716|NCT04093999|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve branch of the 11th-12th intercostal nerve was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
215002717|NCT04790383|OTHER|Advanced Self-Adhesive resin composite hybrid restorations (Surefil one (Dentsply Sirona)).|Hybrid resin composite that doesn't need bonding system and releases calcium and flouride.
215002718|NCT04790383|OTHER|Conventional resin composite restoration. (Sphere Tec, (Dentsply Sirona|Conventional Nanohybrid resin composite
215002719|NCT03570424|DIETARY_SUPPLEMENT|Nutrient support to HIIT|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).
215002720|NCT03570424|DIETARY_SUPPLEMENT|Placebo|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Fed Whey protein 45 minutes prior to exercise; iii) Fed Whey protein hydrolysate 45 minutes prior to exercise).
215002721|NCT02287519|BEHAVIORAL|Group Session|
215002722|NCT02287519|BEHAVIORAL|Telephone Coaching Session|
215002723|NCT02287519|BEHAVIORAL|Webinar|
215002724|NCT02317549|DRUG|LB1148|
215002725|NCT02317549|DRUG|Placebo|
215002726|NCT05841576|OTHER|COMET monitoring device|Cellular Oxygen METabolism (COMET) mitochondrial oxygen tension monitoring device
215002727|NCT04354571|PROCEDURE|Erector spinae plane block|An ultrasound-guided Erector spinae plane block was performed with the patient lying on the his side and the surgical side on the top. After skin disinfection, sterile draping was be placed and the ultrasound probe was sheathed. The level of the block was the transverse process of L2. The block was performed using a 9-12 MHz linear probe (LOGIQe, GE Healthcare, USA), which was placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) was identified, and a 22 G, 50 mm insulated needle (Sonoplex Stim, Pajunk, Germany) was inserted cranio-caudally in plane between the transverse process and the fascia of the ESM. After negative aspiration, 0.3 ml/kg of 0.25% bupivacaine was injected to confirm the correct position by visualizing the solution lifting the ESM off the transverse process.
215002728|NCT04354571|PROCEDURE|caudal block|caudal block was performed using anatomical landmarks and ultrasound guided and confirmed with a concentration of bupivacaine of 0.25%.
215002729|NCT01371682|DRUG|Ropinirole XL|Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
215002730|NCT02279251|BEHAVIORAL|VÅG|Low-intensity CBT intervention
215002731|NCT02279251|BEHAVIORAL|CHILLED|Standard length CBT intervention
215095281|NCT00739466|DRUG|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
215002732|NCT01802671|OTHER|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
215002733|NCT01802671|BEHAVIORAL|cognitive behavioural therapy (CBT)|"Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~* Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~* Cognitive restructuring techniques~* Behavioural therapy and activity pacing~* Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions."
215002734|NCT01802671|BEHAVIORAL|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
215002735|NCT04087590|DRUG|Formoterol-glycopyrronium co suspension (PT003)|Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
215002736|NCT04005339|DRUG|Nanoliposomal Irinotecan|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days
215002737|NCT04005339|DRUG|Leucovorin|Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
214398323|NCT04223154|DEVICE|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
214398324|NCT00900536|GENETIC|mutation analysis|
214398325|NCT00900536|GENETIC|polymorphism analysis|
214398326|NCT00900536|GENETIC|protein expression analysis|
214398327|NCT00900536|OTHER|immunohistochemistry staining method|
214398328|NCT00900536|OTHER|laboratory biomarker analysis|
214398329|NCT05151861|OTHER|Complete removal of pharmacological treatment|Removal of treatment
214398330|NCT05151861|DRUG|Control|Maintenance of pharmacological treatment
214503771|NCT07013058|BEHAVIORAL|Mediterranean Diet|Participants will follow a Mediterranean diet for 4 months under dietary guidance, without receiving any Nigella sativa supplementation.
215002738|NCT04005339|DRUG|Fluorouracil|Fluorouracil 2,400 mg/m IV over 46 hours.
214398331|NCT00739583|DRUG|CHG 2% w/v and IPA 70% v/v|Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds
214398332|NCT00739583|DRUG|Iodophor 0.7% and IPA 74% w/w|Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
215002739|NCT06405581|OTHER|Edmonton frailty scale calculation|"The frailty status of the patients will be assessed using the Edmonton frailty scale.~According to the Edmonton frailty scale;~* (0-5): not frail~* (6-7): sensitive~* (8-9): slightly fragile~* (10-11): moderately fragile,~* (12-17): extremely fragile"
215095282|NCT02713516|OTHER|Virtual Reality|Use of virtual reality to deliver exposure therapy
214398333|NCT00973947|OTHER|questionnaire administration|
214398334|NCT00973947|RADIATION|3-dimensional conformal radiation therapy|
214398335|NCT00973947|RADIATION|radiation therapy treatment planning/simulation|
214398336|NCT01668485|PROCEDURE|Hypoglycemic and euglycemic glucose clamp|Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
214398337|NCT04227925|BIOLOGICAL|Trichuris trichiura|Infective eggs from human whipworm, Trichuris trichiura
214398338|NCT02468505|BEHAVIORAL|STEPS|time-limited behavioral counseling, online materials, training
214398339|NCT03869710|DEVICE|Ultrasound-guided Dry-Needling Therapy|The needle will be insert under ultrasound guidance to elicit the myofascial response on the neck of the patients
214398340|NCT01220674|OTHER|cognitive testing|computer-based cognitive assessment
214398341|NCT06029218|RADIATION|Proteus ONE one daily beam|A single daily beam is used, doubling the dose delivered for this treatment incidence.
214398342|NCT06029218|RADIATION|Proteus ONE two daily beam|two daily beams are used, in accordance with the initial treatment plan and the patient's standard of care
214398343|NCT01938664|DRUG|Candesartan with CBT|8 mg, po (by mouth)
214398344|NCT01938664|OTHER|Placebo with CBT|
214398345|NCT05894759|BEHAVIORAL|Psychological stress relief techniques|Psychological stress relief techniques
214398346|NCT02486705|BEHAVIORAL|PTSD Family Coach Full|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information, support resources, tools for coping with caregiver-related stress, and tools for self-monitoring stress symptoms.
214398347|NCT02486705|BEHAVIORAL|PTSD Family Coach Basic|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information and support resources,
214398348|NCT06501300|BEHAVIORAL|Emotion-focused: Tuning in to Kids in School|The aim of the TIKiS is to improve emotion coaching and reduce emotion dismissing in elementary school teachers through six x 90-minute group sessions.
214398349|NCT00386711|BEHAVIORAL|training on identification of suicide risk and depression|
215002740|NCT01772862|BEHAVIORAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
215002741|NCT02229604|OTHER|EA|For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.
215002742|NCT02229604|DRUG|HRT, DHEA and herb|HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
215002743|NCT05694585|DRUG|Esmolol|Esmolol 50μg/kg /min is intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, esmolol 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
215002744|NCT05694585|DRUG|saline|Saline 50μg/kg /min were iv administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, saline 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
215002745|NCT01470534|DIETARY_SUPPLEMENT|carbohydrate drink|carbohydrate drink
215002746|NCT01470534|PROCEDURE|Muscle biopsy|Open muscle biopsy
215002747|NCT01470534|PROCEDURE|Blood sampling|Venopuncture
215002748|NCT01470534|DIETARY_SUPPLEMENT|Placebo|
215002749|NCT05743972|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.
215002750|NCT05743972|DIAGNOSTIC_TEST|Conventional ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
215002751|NCT02259322|BEHAVIORAL|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
215002752|NCT02259322|BEHAVIORAL|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
215002753|NCT02259322|BEHAVIORAL|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
215002754|NCT01320566|DEVICE|AeriSeal System|Not applicable. Follow-Up study only.
215002755|NCT02439619|OTHER|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
215002756|NCT00852878|BEHAVIORAL|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
215002757|NCT00852878|BEHAVIORAL|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
215002758|NCT05600959|DIAGNOSTIC_TEST|cytokine|Peripheral blood samples were collected at diagnosis, 2 weeks after the first cycle of chemotherapy and 2 weeks after the second cycle of chemotherapy to monitor cytokine level changes.
215002759|NCT05758454|BEHAVIORAL|Caries and Obesity Prevention|A culturally adapted oral health education intervention to prevent development of ECC and to improve parental oral health related knowledge and attitudes.
215002760|NCT02629458|PROCEDURE|Treatment by Surgical resection|
215002761|NCT02629458|PROCEDURE|Stereotactic Ablative Radiotherapy (SABR)|
215095283|NCT03867682|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
215095284|NCT03867682|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
215095285|NCT03867682|DRUG|Spironolactone|25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
215002762|NCT03251417|DRUG|Irinotecan|Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
215002763|NCT03251417|DRUG|Apatinib|Apatinib 500 mg oral take, daily
215002764|NCT06518226|RADIATION|Ultrahypofractionated MRgRT in 2 fractions|2x12 Gy with boost to GTV up to 13.5 Gy
215095286|NCT04552327|DEVICE|Solcera|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
215002765|NCT06518226|RADIATION|Standard of care: MRgRT in 5 fractions|5x7.25 Gy
215002766|NCT04341090|DRUG|Apatinib Mesylate|Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
215002767|NCT06068959|DEVICE|Photobiomodulation using LED|Photobiomodulation Using a Cluster of LEDs in the Red and Infrared Wavelengths in the Cervical Spine Region and Over the Masticatory Muscles
215002768|NCT06068959|DEVICE|Placebo|Photobiomodulation Placebo
215002769|NCT00864318|DRUG|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
215002770|NCT00864318|DRUG|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
215002771|NCT00864318|DRUG|Carboplatine|"From cycle 3 to cycle 5 :~Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient"
215095287|NCT04552327|DEVICE|Placebo|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
215095288|NCT04552327|DRUG|Solaraze|Twice daily application for a duration of 60 days
215095289|NCT00994994|DRUG|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
215095290|NCT02495688|PROCEDURE|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
214398350|NCT03985098|BEHAVIORAL|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
214398351|NCT00790829|DRUG|transdermal nicotine patch|Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
214398352|NCT01668875|OTHER|Head down 30 degree postural drainage position|supine head down 30 degree on tilt table (intervention period in the treatment condition)
214398353|NCT01668875|OTHER|Horizontal supine lying|horizontal supine lying on tilt table (intervention period in the sham condition)
214398354|NCT04270513|OTHER|Endovascular treatment by Flying Intervention Team|After telemedicine-assisted decision for endovascular treatment, the Flying Intervention Team is transferred via helicopter to the primary stroke center and performs endovascular treatment in the local angiography suite.
214398355|NCT00004645|PROCEDURE|Plasma exchange|
214398356|NCT01962064|BEHAVIORAL|Cognitive assessment|
214398357|NCT01962064|OTHER|Brain imaging examination MRI|
214398358|NCT03685747|DRUG|Vancomycin|Vancomycin one-time 20 mg/kg intraperitoneal dose.
214398359|NCT00795132|DRUG|Busulfan|This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
214398360|NCT00795132|DRUG|Anti-Thymocyte Globulin|"Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of~1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion."
214398361|NCT00795132|DRUG|Fludarabine|Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
214503772|NCT07014163|DEVICE|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|0.1 mL or 0.15 mL of a 10 mg/mL deoxycholic acid solution will be injected into every 1\*1 cm2 of the lipoma using an insulin syringe with a 1cm needle attached (the max volume of injection is 2 cc in each treatment session).
215002772|NCT00864318|DRUG|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
215002773|NCT00864318|PROCEDURE|cytapheresis + transfusion of autologous peripheral blood stem cells|"Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.~At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end"
215095291|NCT02495688|PROCEDURE|General anesthesia|Standard procedure.
215095292|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
215002774|NCT02103075|DEVICE|Neuromuscular electrical stimulation|All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.
215002775|NCT02257151|DRUG|BMS-986142|
215002776|NCT02257151|DRUG|Placebo|
215002777|NCT00544882|DRUG|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
215002778|NCT00544882|DRUG|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
215095293|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
215095294|NCT04454736|BEHAVIORAL|"Amateur Group Singing"|45-minute singing session led by a professional choirmaster without a therapeutic background once a week
215002779|NCT00544882|DRUG|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
215002780|NCT07115329|DRUG|Zelquistinel|Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
215002781|NCT07116044|DIAGNOSTIC_TEST|virological tests diagnostic tests|"The parameters collected will include blood sugar, HbA1c, complete blood count, lipid profile (total cholesterol, LDL, HDL, triglycerides), liver profile (ALT, AST, total and fractionated bilirubin, alkaline phosphatase, GGT) and renal profile (creatinine, azotemia), electrophoretic protein picture. Additionally, specific data for HDV and HBV infection will be collected, including HBsAg, anti-HBs, anti-HBc, HBV-DNA, and HDV-RNA. The glomerular filtration rate shall be calculated using the formula CKD-EPI.~• Instrumental Tests: Results of abdominal ultrasounds, Fibroscan®/CAP for the evaluation of liver fibrosis"
215002782|NCT07117955|OTHER|Autologous Platelet Rich Plasma|6 mL PRP intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
214398362|NCT00795132|DRUG|Cyclosporine|"Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G~1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference."
214398363|NCT00795132|DRUG|Mycophenolate mofetil|MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
214398364|NCT00002956|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
215002783|NCT07117955|OTHER|Saline solution|6 mL saline solution intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
215002784|NCT07118150|OTHER|Assessment of Pre-Hospital Neglect and Abuse in Elderly Trauma Surgery Patients|"This study is an observational research that does not involve any direct intervention (treatment, application, etc.). After obtaining informed consent from the patients or their legal representatives, data will be collected through hospital records, face-to-face interviews with the patients and/or their relatives, and standardized questionnaires.~Pre-hospital living conditions, care status, and signs of neglect and abuse will be assessed.~The relationship between clinical data, trauma severity, and the presence of neglect or abuse will be examined."
215002785|NCT07118423|OTHER|Exercise|The intervention group performed twice per week, nonconsecutive, resistance training over 12 weeks. The sessions consisted of 1-3 sets of eight exercises at 50-70% of the estimated one-repetition maximum.
215002786|NCT07120763|DRUG|Ketamine + Lidocaine|Including comparisons between patients randomized for treatment with full ketamine sedation in setting of distal radius fracture reduction, hematoma block/minimal ketamine pain control (. 0.25mg/kg) for distal radius fracture reduction, or intranasal fentanyl and hematoma block, utilized in the setting of distal radius fractures in pediatric patients requiring reduction
215002787|NCT07120763|DRUG|Ketamine group|Including comparisons between patients randomized for treatment with full ketamine sedation in setting of distal radius fracture reduction, hematoma block/minimal ketamine pain control (. 0.25mg/kg) for distal radius fracture reduction, or intranasal fentanyl and hematoma block, utilized in the setting of distal radius fractures in pediatric patients requiring reduction
215002788|NCT07120763|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|Including comparisons between patients randomized for treatment with full ketamine sedation in setting of distal radius fracture reduction, hematoma block/minimal ketamine pain control (. 0.25mg/kg) for distal radius fracture reduction, or intranasal fentanyl and hematoma block, utilized in the setting of distal radius fractures in pediatric patients requiring reduction
215002789|NCT06927076|DRUG|N,N-Dimethyltryptamine|administration of a 2mg/min DMT perfusion over 20 min
215002790|NCT06927076|DRUG|Placebo|administration of a placebo perfusion over 20 min
215002791|NCT06927076|PROCEDURE|Propofol|30 min propofol sedation
214398365|NCT03082300|DRUG|naquotinib|Oral
214398366|NCT04307602|OTHER|Exercise - High Intensity Interval Training (HIIT)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children
214398367|NCT04307602|OTHER|Exercise - Submaximal Steady State Training (SST)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled
214398368|NCT02883322|OTHER|Cross cultural adaptation of patient reported outcomes (PRO)|Process used to adapt a questionnaire from one cultural setting to another
215095295|NCT04454736|BEHAVIORAL|"Professional Group Singing"|120-minute singing session led by a professional choirmaster without a therapeutic background three times a week. Assessments take place twice a week.
215095296|NCT03323671|DRUG|preemptive mefenamic acid|preemptive analgesia before menstrual pain
215095297|NCT03323671|DRUG|mefenamic acid|mefenamic acid given only during menstruation
215095298|NCT02887547|PROCEDURE|micro-osteoperforation|
215095299|NCT03751514|BIOLOGICAL|Bordetella Pertussis B1917|"The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally."
215095300|NCT03751514|DRUG|Azithromycin 500 mg|To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
215095301|NCT03751514|OTHER|Sterile Saline|To compare against B. pertussis, some volunteers will be enrolled onto the Sham arm. These volunteers will not receive B. pertussis but instead be given sterile saline
214398369|NCT01536262|DRUG|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
215002792|NCT06927076|PROCEDURE|no sedation|no sedation
215095302|NCT00431119|DRUG|Azathioprine or Mycophenolate mofetil|
215095303|NCT02504931|DRUG|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
214398370|NCT01536262|DEVICE|Respimat|Respimat inhaler
214398371|NCT01536262|DRUG|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
214398372|NCT01536262|DRUG|Olodaterol|Olodaterol once daily inhalation
214398373|NCT01536262|DEVICE|Respimat|Respimat inhaler
214398374|NCT01536262|DEVICE|Respimat|Respimat inhaler
214398375|NCT01547104|DRUG|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
214398376|NCT01547104|DRUG|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
214398377|NCT00412516|BIOLOGICAL|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
214398378|NCT05523622|DEVICE|Tono-Vera tonometer|The tonometer measures intraocular pressure with a small rebound probe, similar to those used with other tonometers currently on the market, such as the iCare.
214398379|NCT05523622|DEVICE|Goldman Applanation Tonometry|This is the current gold standard for measuring eye pressure.
214398380|NCT04464941|BEHAVIORAL|a composite intervention with both group and individual components for oral health promotion program|"The group intervention consisted of:~1\. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:~1\. Instruction in the Bass tooth-brushing method, 2. Individual behavioral modification method"
214398381|NCT01355120|DRUG|Ipilimumab|Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
214398382|NCT02580825|BEHAVIORAL|Biofeedback gait retraining|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
214398383|NCT02580825|BEHAVIORAL|Exercise|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section).
214398384|NCT01781611|DRUG|extended release dipyridamole 200mg/aspirin 25mg|one tablet twice daily for 24 weeks
214398385|NCT01781611|DRUG|81mg aspirin|half a tablet twice daily for 24 weeks
214398386|NCT03639675|DRUG|Aflibercept (EYLEA, BAY86-5321)|2 mg (0.05 mL), Intravitreal injection (IVT), single dose.
214398387|NCT03639675|DRUG|Topical IOP-lowering drugs|A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
214398388|NCT01760655|DRUG|Fludarabine phosphate|Given IV
214398389|NCT01760655|DRUG|Busulfan|Given IV
215002793|NCT07125482|OTHER|bed exercise group|"In the first interview, demographic data and other patient information will be collected from the patient record file between 07-08 in the morning before starting bed exercise and nutrition, and the Patient Information Form and Comfort Behavior Checklist, Wong-Baker Face Pain Scale, 'Enteral Nutrition Monitoring Form' will be filled in by the researcher before the intervention and nutrition (1st Interview).~* In the first interview, bed exercises will be applied by the researcher for approximately 15 minutes before nutrition between 07-08 in the morning (1st Interview).~* In the second interview, bed exercises will be repeated for approximately 15 minutes after filling out the 'Enteral Nutrition Monitoring Form' before bed exercise and nutrition between 07-08 in the morning (2nd Interview).~* In the third interview, bed exercises will be repeated for approximately 15 minutes after filling out the 'Enteral Nutrition Monitoring Form' before bed exercise and nutrition between 07-08 in"
215095304|NCT02504931|DRUG|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
215095305|NCT03134183|DRUG|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D\&E
214398390|NCT01760655|RADIATION|Total-Body Irradiation|Undergo TBI
214398391|NCT01760655|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Undergo DLI
214398392|NCT01760655|DRUG|Cyclophosphamide|Given IV
214398393|NCT01760655|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
214398394|NCT01760655|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
214398395|NCT01760655|DRUG|Tacrolimus|Given IV
214398396|NCT01760655|DRUG|Mycophenolate Mofetil|Given IV
214398397|NCT01760655|OTHER|Laboratory Biomarker Analysis|Correlative studies
214398398|NCT04078100|PROCEDURE|Transseptal approach.|surgical approach to the mitral valve through the Fossa Ovalis by way of the right atrium.
214398399|NCT05389358|BEHAVIORAL|Asiphephe health worker training|Lay health workers are already employed by the Department of Health and are trained in-service (30 hours) and receive monthly supervision (total of approximately 6 one-on-one hours; 15 group hours).
214398400|NCT05389358|BEHAVIORAL|Asiphephe therapeutic sessions|Asiphephe sessions are manualized using illustrated job aids, a participant workbook, session checklists, and an intervention manual. The model is informed by problem-solving therapy (Lund, 2018), trauma-informed coping (Sikkema, 2018) and safety planning (Garcia-Moreno, forthcoming) and was piloted with 12 health workers with input from 3 global mental health experts.
214398401|NCT05389358|OTHER|IPV assessment|IPV intensity as measured by WHO Multicountry Study Instrument at a cut-off of any past-year physical/sexual/psychological violence exposure vs. none
214398402|NCT05389358|OTHER|Referral for IPV or Mental Health|Study staff are trained to recognize signs or symptoms of distress and to make appropriate referrals to appropriate community-based services, if necessary. Experienced mental health professionals on the investigative can be consulted or referred to should a participant exhibit severe symptom of mental distress.
214398403|NCT00677456|PROCEDURE|R-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
215002794|NCT07125482|OTHER|abdominal massage|"* In the first interview, between 07-08 in the morning, demographic data and other information about the patients will be collected from the patient record file before the intervention and feeding by the researcher using the Patient Information Form and Comfort Behavior Checklist, Wong-Baker Facial Pain Scale, 'Enteral Feeding Monitoring Form' (Interview 1).~* In the first interview, between 07-08 in the morning, abdominal massage will be applied to the patient by the researcher for approximately 15 minutes before feeding (Interview 1).~* In the second interview, between 07-08 in the morning, abdominal massage will be repeated for approximately 15 minutes by filling out the 'Enteral Feeding Monitoring Form' before feeding and abdominal massage will be repeated (Interview 2).~* In the third interview, between 07-08 in the morning, the 'Enteral Nutrition Monitoring Form' will be filled out before abdominal massage and feeding, and the abdominal massage will be repeated for approxim"
215002795|NCT07125482|OTHER|control group|"In the first interview, between 07-08 am, demographic data and other patient information will be collected from the patient record file before feeding, using the Patient Information Form and the Comfort Behavior Checklist, Wong-Baker Facial Pain Scale, 'Enteral Feeding Monitoring Form', before the intervention and feeding (Interview 1).~* In the second interview, between 07-08 am, the 'Enteral Feeding Monitoring Form' will be filled out before feeding (Interview 2).~* In the third interview, between 07-08 am, the 'Enteral Feeding Monitoring Form' will be filled out before feeding (Interview 3).~* In the fourth interview, between 07-08 in the morning, data will be collected with the Comfort Behavior Checklist, Wong-Baker Facial Pain Scale and 'Enteral Feeding Monitoring Form' before feeding (Interview 4)."
215002796|NCT07124169|OTHER|Kinesiotape + home exercise|Kinesiotaping will be applied to the knee once weekly for 6 weeks. In addition, participants will perform a structured home exercise program three times per week, including strengthening, stretching, and balance exercises.
215002797|NCT07124169|OTHER|Home exercise|In addition, participants will perform a structured home exercise program three times per week, including strengthening, stretching, and balance exercises.
215002798|NCT05872126|PROCEDURE|VATS-Surgical pleurodesis|VATS drainage and surgical abrasion.
215002799|NCT05872126|PROCEDURE|Tube Drainage|Tube drainage for malignant pleural effusion
215002800|NCT03768375|BIOLOGICAL|conventional chemotherapy(FORFIRINOX) combined with target agents|Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib
215095306|NCT03134183|DRUG|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D\&E
215095307|NCT00724906|DRUG|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
215095308|NCT02925169|DEVICE|CT Scan|CT imaging
214398404|NCT00677456|PROCEDURE|P-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
215095309|NCT03323866|DRUG|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
215095310|NCT03323866|DRUG|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
215095311|NCT05808010|BIOLOGICAL|Mononuclear cells|2 times gastric submucosal injection of mononuclear cells (10\^8) at 1 month interval
215095312|NCT05808010|DRUG|Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|Orally delivered tablets for 7 months. Take it according to the instructions.
215095313|NCT01416623|DRUG|henatinib|Henatinib Maleate Tablets
215095314|NCT00845065|DRUG|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
215095315|NCT00845065|OTHER|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
215095316|NCT00845065|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
215095317|NCT00845065|DRUG|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~* \<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~* \>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
215095318|NCT03645109|DIETARY_SUPPLEMENT|Vitamin D3|Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
215095319|NCT03645109|OTHER|Capsules with placebo (talcum food grade)|Capsules with placebo (talcum food grade)
215095320|NCT02182765|DRUG|Nevirapine|
215095321|NCT02182765|DRUG|Amprenavir|
215095322|NCT02182765|DRUG|Abacavir|
215095323|NCT00162266|DRUG|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
215095324|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
215095325|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
215095326|NCT00162266|DRUG|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
215095327|NCT01198509|DRUG|doxycycline|doxycycline - 100 mg twice per day, for 2 months
215095328|NCT01198509|DRUG|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
215095329|NCT00499746|DRUG|tramadol|oral dose, once per day
215095330|NCT00499746|DRUG|placebo|oral dose, once per day
215095331|NCT00499746|DRUG|Hydromorphone|oral dose, once per day
215095332|NCT00499746|DRUG|Methylphenidate|oral dose, once per day
215095333|NCT00120328|DRUG|SPP301|
215095334|NCT04515329|DRUG|Cyclosporine|Eye drops taken twice daily.
215095335|NCT04515329|DRUG|Artificial tear|Preservative-free artificial tear drops 4 times a day.
215095336|NCT01410708|DRUG|Dasatinib|
215095337|NCT02858557|BEHAVIORAL|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
215095338|NCT02858557|BEHAVIORAL|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
215095339|NCT01102894|DEVICE|SmartPill|SmartPill
215002801|NCT03768375|BIOLOGICAL|conventional chemotherapy(FORFIRINOX)|conventional chemotherapy(FORFIRINOX)
215002802|NCT07123857|DIAGNOSTIC_TEST|re-triage|Patients in the test group will be re-triaged into the orange MTS category.
215095340|NCT00846716|DRUG|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
215095341|NCT00846716|DRUG|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
215095342|NCT04378296|OTHER|Teledermatology|The experimental group will be made up of dermatological patients monitored asynchronously.
215095343|NCT04346121|OTHER|GPs reports of potential patient safety incidents, non-COVID-19 related|GPs reports of potential patient safety incidents, non-COVID-19 related
215095344|NCT02264080|DRUG|WAL2014|
215095345|NCT02264080|DRUG|Placebo|
215095346|NCT00003709|DRUG|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
215095347|NCT02584920|DRUG|HLX01|
215095348|NCT02584920|DRUG|Rituximab|
215095349|NCT03898076|DEVICE|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
215095350|NCT03898076|OTHER|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
215095351|NCT03898076|OTHER|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
215095352|NCT01238965|DRUG|panobinostat|Given orally
215095353|NCT01238965|DRUG|fluorouracil|Given IV
215095354|NCT01238965|DRUG|leucovorin calcium|Given IV
215095355|NCT01238965|PROCEDURE|biopsy|Correlative studies
215095356|NCT01238965|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
215095357|NCT01238965|GENETIC|western blotting|Correlative studies
215095358|NCT01238965|OTHER|laboratory biomarker analysis|Correlative studies
215095359|NCT01238965|GENETIC|gene expression analysis|Correlative studies
215095360|NCT01238965|GENETIC|RNA analysis|Correlative studies
215095361|NCT01238965|GENETIC|polymorphism analysis|Correlative studies
215095362|NCT03480009|DRUG|Dextromethorphan Hydrobromide|Dextromethorphan capsule
214398405|NCT00677456|PROCEDURE|Pouch reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
215002803|NCT07085702|BIOLOGICAL|Low dose Strep A Alum|Low dose Strep A Alum vaccine will be administered intramuscularly (IM)
215002804|NCT07085702|BIOLOGICAL|Medium dose Strep A Alum|Medium dose Strep A Alum vaccine will be administered IM
215002805|NCT07085702|BIOLOGICAL|High dose Strep A Alum|High dose Strep A Alum vaccine will be administered IM
215095363|NCT03480009|DRUG|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding|Placebo capsule
215095364|NCT03480009|DRUG|Oxycodone|Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
215002806|NCT07085702|BIOLOGICAL|Low dose Strep A AS37|Low dose Strep A AS37 vaccine will be administered IM
215002807|NCT07085702|BIOLOGICAL|Medium dose Strep A AS37|Medium dose Strep A AS37 vaccine will be administered IM
215002808|NCT07085702|BIOLOGICAL|High dose Strep A AS37|High dose Strep A AS37 vaccine will be administered IM
215002809|NCT07085702|DRUG|Strep A Alum Placebo|Strep A Alum Placebo will be administered IM
215002810|NCT07081139|OTHER|observational study, no interventional|no interventions
215002811|NCT06905067|OTHER|questionnaire and dental clinical examination|Assessment of the DMFT index
215095365|NCT01954316|DRUG|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
215095366|NCT05403229|DRUG|Topiramate|The topiramate arm receives additional oral topiramate for 6 weeks. The dose of topiramate is started from 25mg orally daily with the weekly escalation of 25mg to a maximum of 100mg.
215095367|NCT05403229|DRUG|Systemic Steroids|Both groups receive a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
215095368|NCT06156501|PROCEDURE|ACL Reconstruction|Reconstruction of the anterior cruciate ligament
215095369|NCT04186507|COMBINATION_PRODUCT|Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)|"To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat."
215095370|NCT01424280|DRUG|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
215095371|NCT01424280|DRUG|Placebo|Single dose of matching placebo tablets
215095372|NCT00696969|DRUG|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
215095373|NCT00696969|DRUG|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
215095374|NCT00696969|DRUG|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
215002815|NCT03043573|BEHAVIORAL|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
215002816|NCT03043573|BEHAVIORAL|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
215002817|NCT07084233|BEHAVIORAL|Mindfulness based, trauma informed, self-regulation skills training|"The study intervention, MMFT, consists of 7.5 hours of live, online courses, in three sessions, over three weeks. The entire intervention group (n=100) will participate in each session simultaneously, with four trainers and two translators.~Session 1 (3 hours): This session will introduce three mind fitness exercises. Session 2 (3 hours): This session will begin with mind fitness practice and discussion about participants' experience with the exercises during the previous two weeks.~Session 3 (1.5 hours): This session is for participants to integrate course content at an experiential level-no new content will be offered. The session will include some guided practice, but mostly focus on answering questions from participants and/or providing guidance to participants for how to navigate challenges with practice.~During the three weeks participants are in the course, they will be asked to practice the MMFT techniques for 5-60 minutes per day."
215002818|NCT05291975|DEVICE|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
215002819|NCT05291975|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
215002820|NCT06387667|DIAGNOSTIC_TEST|Complete blood count|blood sample
215002821|NCT06387667|DIAGNOSTIC_TEST|C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT)|serum sample
215002822|NCT06387667|RADIATION|CT chest|Computed tomography of the chest
215002823|NCT06387667|DIAGNOSTIC_TEST|Microscopic examination|sputum and bronchoalveolar lavage (BAL)
215002824|NCT06387667|DIAGNOSTIC_TEST|culture and sensitivity|for bacterial and fungal
215002825|NCT07091578|BEHAVIORAL|Supervised toothbrushing|In supervised toothbrushing intervention, dental hygienists trained school staff, obtained consent forms, distributed the oral hygiene kits, and provided support and advice if needed. Teachers' training included guidelines for infection prevention and control, and toothbrushing in dry areas adapted from the Public Health England (PHD) toothbrushing programme toolkit. A dry toothbrushing model was employed. Toothbrushing sessions took place daily during regular school hours for one academic year. Each session lasted for approximately 10 minutes and occured after break time at 9:20 am. Oral hygiene kits that include soft toothbrushes and 1450ppm fluoridated toothpaste were disseminated every three months. Teachers and dental hygienists provided monthly oral health educational sessions to students during regular school time.
215002826|NCT07091578|BEHAVIORAL|Oral Health Education|In oral health education intervention, dental hygienists and school staff collaborated to educate students about oral health. Dental hygienists trained school staff to deliver this programme effectively and offer continued support and guidance to school staff during the programme implementation. An oral health education toolkit partly adapted from the PHE toothbrushing programme toolkit was provided to the school before the start of the programme. Educational materials including lectures, leaflets, and activities were dispensed monthly. Oral health education was conducted once a month during regular school hours in the classroom, and each session lasted for one hour. Students were provided with comprehensive knowledge about oral health, such as proper toothbrushing techniques, the importance of routine dental check-ups, and healthy nutrition. Moreover, toothbrushing kits that include soft toothbrushes and 1450ppm fluoridated toothpaste were distributed every three months.
215002827|NCT05751668|DRUG|Paclitaxel|Given IV
215002828|NCT05751668|DRUG|Monosialotetrahexosylganglioside|Given IV
215002829|NCT05751668|OTHER|Questionnaire Administration|Ancillary Studies
215002830|NCT05751668|OTHER|Quality-of-life assessment|Ancillary Studies
215002831|NCT05751668|DRUG|Placebo Administration|Given IV
215002832|NCT07090863|DEVICE|AM manufacturing method|additively manufactured implant-supported prostheses
215002833|NCT07090863|DEVICE|SM manufacturing method|subtractively manufactured implant-supported prostheses
215002834|NCT06909110|BIOLOGICAL|Adenovirus Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
215002835|NCT06909110|BIOLOGICAL|Cytomegalovirus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
215002836|NCT06909110|BIOLOGICAL|Epstein-Barr Virus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Epstein-Barr viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
215095375|NCT00696969|DRUG|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
215095376|NCT00226070|PROCEDURE|interview and advising|
215002837|NCT06901687|DEVICE|Active tDCS|tDCS is a noninvasive brain stimulation technique that delivers a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp. For Active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
215002838|NCT06901687|DEVICE|Sham tDCS|tDCS is a noninvasive brain stimulation technique that delivers a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp. For Sham tDCS (or placebo) the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30-s) and down (for 30-s) at the end.
215002839|NCT06332560|BEHAVIORAL|Anti-inflammatory diet (DI)|12-week personalized dietary advice based on the Dutch Dietary Guidelines under the guidance of a dietician.
215002840|NCT06332560|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Seven individual sessions led by a psychotherapist. The content of the CBT will be psycho-education regarding pain mechanisms and DI.
215002841|NCT07097584|DEVICE|Selecting the size of a Left Double-lumen endobronchialtube one size smaller than the traditional method|During tracheal intubation，choose a Left Double-lumen Endobronchial Tubethat is one size smaller than the traditional method.In this study, all patients planned to be enrolled are female. In experimental group the relationship between height and size is roughly as follows: For patients with a height between 152 - 165 cm, a 32Fr (French) tube is often selected. For patients with a height between 165 - 177 cm, a 35Fr tube is often selected. For patients with a height of more than 177 cm, a 37Fr tube is often selected.
215002842|NCT07097584|DEVICE|Selecting the size of a Left Double-lumen endobronchialtube according to traditional methods|"During tracheal intubation，choose the regular Left Double-lumen endobronchial tube according to the traditional method. The selection of double-lumen tube sizes using traditional methods relies on two factors: height and gender. In this study, all patients planned to be enrolled are female, so the traditional corresponding relationship is roughly as follows:~For patients with a height of less than 152 cm, a 32Fr (French) tube is often selected.~For patients with a height between 152 - 165 cm, a 35Fr tube is often selected. For patients with a height between 165 - 177 cm, a 37Fr tube is often selected. For patients with a height of more than 177 cm, a 39Fr tube is often selected."
215002843|NCT07090759|DRUG|GST-HG141|GST-HG141 50 mg BID
215002844|NCT07090759|DRUG|GST-HG141 Placebo|GST-HG141 Placebo BID
214398406|NCT00677456|PROCEDURE|P-I reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
214398407|NCT02459587|BEHAVIORAL|Crisis Line Facilitation (CLF)|This single session therapist-delivered intervention addresses Veterans' perceived barriers and facilitators of crisis line use during periods of suicidal crisis. The CLF session culminates with the Veteran calling the Crisis Line with the therapist in the room as a way for the Veteran to practice the logistics of making the call and to have direct experiences that may counter any negative beliefs about Crisis Line use.
215002845|NCT07096830|DRUG|Topical Tetrachlorodecaoxide (TCDO/Oxoferin)|Topical Tetrachlorodecaoxide (TCDO), a solution with antimicrobial and oxygen-releasing properties, will be applied once daily to the wound bed for 21 consecutive days or until satisfactory healing.
215002846|NCT07096830|OTHER|Standard Wound Care|Standard wound care includes saline irrigation, wound debridement, antibiotic administration as necessary, and sterile dressing. Provided to all participants.
215002847|NCT07090811|DEVICE|Aortic valve repair/replacement|TAVR or valvuloplasty using the Fusion System for delivery of the treatment system and for temporary rapid pacing
215002848|NCT07093008|DRUG|AQ280 Capsule|AQ280 administered orally in capsule formulation.
215002849|NCT07093008|DRUG|AQ280 Tablet for Oral Suspension|AQ280 administered orally in tablet for oral suspension formulation.
215002850|NCT07093008|DRUG|Placebo Capsule|Placebo administered orally in capsule formulation.
215002851|NCT07093008|DRUG|Placebo Tablet for Oral Suspension|Placebo administered orally in tablet for oral suspension formulation.
215002852|NCT06864273|BEHAVIORAL|Pharmacy Technician Educational Training|Pharmacy Technicians will participate in a stepped-wedge educational training program. The first step will be a control condition where they will receive no training, the second step will include viewing online modules, the third step will include online discussions, and the fourth step will include practical experiences with adults with bilateral hearing loss. Pre-training quizzes and surveys will be completed before and after each step.
215002853|NCT07094425|DIAGNOSTIC_TEST|transthoracic echocardiography|"Transthoracic echocardiography (TTE) is a non-invasive method for assessing cardiac morphology and function. As part of the study protocol, TTE will be performed at the time of study inclusion (within the first 24 hours after ICU admission), on day 3, day 7, and day 14, followed by weekly assessments (until discharge from the ICU), as well as on the day of planned ICU or hospital discharge.~To verify skeletal muscle mass in relation to myocardial mass and its changes over the course of the ICU stay, bioelectrical impedance analysis (BIA) will be performed at the time points mentioned above."
215095377|NCT00226070|BEHAVIORAL|3 follow up interviews and personal advising|
215095378|NCT00226070|PROCEDURE|interview SF-36 self rated health|
215095379|NCT04107441|DRUG|AX-8 Part 1|5, 10, 20, and 40 mg AX-8 orally disintegrating tablets (ODTs), up to 80 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue while the subject is in a sitting position. The subjects will be instructed not to suck, chew or swallow the tablet, i.e. to allow it to dissolve on the back of the tongue without any further intervention.
215095380|NCT04107441|DRUG|AX-8 Part 2|5 and 40 mg AX-8 orally disintegrating tablets (ODTs), 45 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved in the mouth while the subject is in a sitting position. The subjects will be instructed to actively move the tablet around in their mouth (i.e. active oral manipulation of the tablet) until it is fully dissolved.
215095381|NCT02966470|DEVICE|Obtain grip strength from a standardized gripometer|Obtain grip strength from a standardized gripometer, 3 times on each hand
215095382|NCT02532985|OTHER|Negative Control|No added fiber beverage
215095383|NCT02532985|OTHER|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
215002854|NCT06909565|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter
215002855|NCT06909565|DRUG|Normal Saline (Placebo)|Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter
214398408|NCT02459587|BEHAVIORAL|Enhanced Usual Care (EUC)|Those in the EUC condition received the same promotional items and information about the Veterans Crisis Line (VCL) as the CLF condition. Participants were encouraged to seek help via a provider or the VCL if they felt suicidal in the future. Research staff briefly explained key information about the VCL to those in the EUC condition (e.g., the links between the VCL and the VA, the 24/7/365 availability, etc.).
215002856|NCT07095452|DRUG|Etentamig|Intravenous (IV) Infusion
215002857|NCT07095452|DRUG|Lenalidomide|Oral Capsule
215002858|NCT07095452|DRUG|Daratumumab|Subcutaneous Injection
215002859|NCT07095452|DRUG|Dexamethasone|Oral Tablet
215002860|NCT07095452|DRUG|Dexamethasone|IV Injection
214398409|NCT06011967|OTHER|Intubation using C-MAC D blade videolariyngoscope|all patients were intubated using the C-MAC D-Blade videolaryngoscope but for each group the intubation tubes were angled in different degrees. First group was intubated using the stylet of 60 degrees, second group was intubated using the stylet of 80 degrees and the third group was intubated using the stylet of 90 degrees.
214398410|NCT04171726|DRUG|Edoxaban|A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.
214398411|NCT05609019|DRUG|SYHX2005|Tablets. Take orally.
214398412|NCT01212263|DRUG|Step-up HP u FSH|HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
214398413|NCT01212263|DRUG|Clomiphine citrate plus low dose uFSH|Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
214398414|NCT00938899|DRUG|TMC435350; Placebo|
214398415|NCT00507611|PROCEDURE|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
214398416|NCT02696720|DRUG|Lidocaine|
214398417|NCT02696720|OTHER|Sham|
214398418|NCT02264574|DRUG|Ibrutinib|Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
214398419|NCT02264574|DRUG|Obinutuzumab|Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
214398420|NCT02264574|DRUG|Chlorambucil|Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
215002861|NCT07100366|BEHAVIORAL|ChatGPT|Phase 3:In Experimental Group 1, participants will be invited to use the ICT app, which they are encouraged to engage with for at least 15 minutes daily. This app is designed to actively monitor the users' emotional status and automatically notify both the research team and family members if any negative mood is detected.
215002862|NCT07100366|BEHAVIORAL|community social|Phase 3:In Experimental Group 2, participants will be encouraged to increase their social participation through community-based activities, while the Control Group will continue with their routine lifestyle.
215002863|NCT07100158|OTHER|Ultrasonographic Measurement of Optic Nerve Sheath Diameter (ONSD)|Non-invasive ultrasonographic measurement of optic nerve sheath diameter (ONSD) using a 7.5 MHz linear probe at predefined time points: preoperative and postoperative 6, 12, 24, 36, and 48 hours.
215002864|NCT07104240|OTHER|Best Practice|Offer standard of care adolescent vaccination promotion practices
215002865|NCT07104240|OTHER|Educational Intervention|Receive vaccination information
215002866|NCT07104240|OTHER|Health Promotion and Education|Receive all TweenVax components and trainings for the practice, providers and staff, parents and adolescents
215002867|NCT07104240|OTHER|Health Promotion and Education|Receive components and trainings for the practice and provider levels
215002868|NCT07104240|OTHER|Internet-Based Intervention|Receive access to TweenVax application
215002869|NCT07102940|DRUG|Eftilagimod Alfa (Efti)|Eftilagimod Alfa (Efti) will be administered subcutaneously at a dose of 30 mg beginning of week 1 of the trial for a total of 3 doses (week 1, 2 and 3). After 3 weeks, efti will be administered starting with week 4, every 2 weeks and combined with either TC or AC
215002870|NCT07102940|DRUG|Docetaxel-cyclophosphamide (TC) intravenous (i.v)|"TC will be administered at docetaxel 75mg/m2 IV and cyclophosphamide 600mg/m2 IV every 3 weeks for a total of 4 administrations starting on week 4 of the trial (weeks 4, 7,10, and 13).~Docetaxel is administered over 60min (dilute in 250 mL NS or D5W to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes).~Cyclophosphamide is administered over 30-60min (dilute in 250 to 500 mL NS or D5W and administer over 30 to 60 minutes after docetaxel).~G-CSF support for TC is per institutional SOC guidelines. Efti is to be given always ≥ 30 minutes after TC is finished if both regimens are administered the same day."
214398421|NCT03454932|OTHER|Blood sampling|
214398422|NCT02224014|DRUG|Lendormin D tablets|
214398423|NCT02794961|BIOLOGICAL|CD22 CAR-T|Autologous CAR-T cells with average 1\*10\^6 cells/kg body weight
214398424|NCT01697137|BEHAVIORAL|Participant Video and Provider Cueing|Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
214398425|NCT01587833|DRUG|Benzodiazepine (BZD) use, defined by ATC codes|BZD prescription during the study period between January 1, 2001 and December 31, 2009
214398426|NCT00311792|BEHAVIORAL|LapSimGyn training until expert proficiency level is reached|Two consecutive simulations reaching predefined expert level
215095384|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
215095385|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
215095386|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
215002871|NCT07102940|DRUG|Dose dense Adriamycin-cyclophosphamide (AC) i.v|"AC will be administered at doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 IV every 2 weeks for a total of 4 administrations starting week 4 of the trial (weeks 4, 6, 8 and 10):~Doxorubicin is administered over 5 min (Dilute with NS to a final concentration of 2 mg/mL and administered as an IV bolus over three to five minutes into a free flowing IV infusion of NS or D5W).~Cyclophosphamide is administered over 30-60min (Dilute in 250 to 500 mL NS or D5W and administer over 30 to 60 minutes).~G-CSF support is per SOC/institutional guidelines.~Paclitaxel is given weekly for a period of 12 weeks (weeks 12 to 23) at 80mg/m2 (Dilute with 250 to 500 mL NS or D5W (final concentration of 0.3 to 1.2 mg/mL) and administered per institutional guidelines). Alternatively nab-paclitaxel weekly can be used (if paclitaxel cannot be used due to allergic reaction).~Efti is to be given always ≥ 30 minutes after AC or paclitaxel is finished if both regimens are administered the same day."
215002872|NCT07104084|DEVICE|lavage chlorhexidine|Patient will receive a chlorhexidine lavage for 3 minutes following total hip component placement followed by saline lavage.
215002873|NCT07104084|DEVICE|lavage povidone-iodine|Patient will receive povidone-iodine lavage for 3 minutes following total hip component placement followed by saline lavage.
215002874|NCT07105384|COMBINATION_PRODUCT|Radiotracer|Patients will receive a brain tau radiotracer
215002875|NCT07104981|PROCEDURE|Mesenchymal Stem Cell Transplantation|intraoperative infiltration of micronized adipose tissue obtained using the Matrigen system.
215002876|NCT07103408|DRUG|Immuno-chemotherapy|Immuno-chemotherapy regimen included etoposide, cisplatin, iparomlimab and tuvonralimab, and thymosin alpha 1.
215002877|NCT07103408|RADIATION|Radiotherapy|"Definitive dose of thoracic radiotherapy was delivered no later than the three cycle of immuno-chemotherapy.~Prophylactic cranial irradiation (PCI) was delivered with a total dose of 25Gy in 10 fractions. PCI was recommended for patients who achieved complete response or partial response after thoracic chemoradiotherapy."
215002878|NCT07103408|DRUG|Consolidative therapy|Consolidation therapy regimen included iparomlimab and tuvonralimab, and thymosin alpha 1, with a duration of one year.
215002879|NCT07103200|BEHAVIORAL|COGED|The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).
215002880|NCT07103200|BEHAVIORAL|Restless Bandit|"Participants are presented with three targets (decks of cards) on the screen, which they select with a mouse movement. Each of the three targets is associated with a hidden probability of reward, which drifts unpredictably and independently across trials. This encourages participants to exploit good options when they are available, but also occasionally to explore other targets, which could become better at any time. Eye Tracking is done at each visit while the participant completes the Restless Bandit tasks."
215002881|NCT07103642|DRUG|BGF|BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
215002882|NCT07105189|DEVICE|Wireless monitoring|"Patients included in the study will be continuous monitored by CPC12S is a wearable sensor that is worn on the chest using electrodes measuring electrocardiography single lead (ECG), Heart rate, respiratory rate, SpO2, blood pressure and temperature.~The system calculates the heart rate by analysing R-peaks of QRS-complexes in the raw ECG data.~Respiratory rate is recorded using impedance pneumography. SpO2 is determined by analysing the photoplethysmogram (PPG) wave. Blood pressure is derived by calculating the pulse transit time (PTT) using R-peaks from the QRS complexes, peaks in the photoplethysmogram (PPG) pulse waves, and timing of the second heart-tone corresponding to the dicrotic notch, measured by a stethoscope in the device.~Temperature is measured by a thermistor placed in the axilla. Vital signs are updated every 20 seconds and measurements are transmitted via Bluetooth to an Android cell phone that is uploading the data via WIFI to a secured server."
215002883|NCT07104227|BEHAVIORAL|body mechanics training|"Randomization: The Demographic and Health Data Form will be applied to the participants by the researcher responsible for randomization, and the information obtained will be kept in consecutively numbered, closed, opaque envelopes. The block randomization method will be used when dividing the participants into intervention and control groups. In order to ensure balance in important demographic and health-related variables, the participants will be randomized by stratifying them according to age. The person responsible for collecting the study data will be unaware of the randomization process until the researcher responsible for randomization reports the results. Intervention group: After the initial data collection, the breastfeeding behaviors of the mothers in the intervention group will be observed. Then, the mothers will be given training on ergonomic breastfeeding, correct breastfeeding positions and body mechanics to strengthen the musculoskeletal system during the breas"
215095387|NCT03246659|DRUG|111In-CP04|Radiopharmaceutical preparation
215095388|NCT03246659|DRUG|111In-CP04 with co-administration of gelofusine/gelaspan|Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
215095389|NCT01120990|OTHER|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
214398427|NCT00311792|BEHAVIORAL|Traditional clinical education|
214398428|NCT02948946|PROCEDURE|NETest|5 mL of blood will be drawn from participants for testing.
214398429|NCT03090217|BEHAVIORAL|Pelvic Physiotherapy|1\) daily pelvic floor muscle training (PFMT).
214398430|NCT03090217|BEHAVIORAL|Standard care (SC)|1\) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
214398431|NCT00110201|DRUG|Nesiritide|
214398432|NCT04572542|DRUG|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg
214398433|NCT04572542|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday
214398434|NCT04572542|DRUG|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2
214398435|NCT00412867|DRUG|Alteplase|0.6 mg/kg of Alteplase is intravenously administered
214398436|NCT00641953|DRUG|IMX-150|(0.3%) 0.5g topically BID to each foot for 4 weeks
214398437|NCT00641953|DRUG|IMX-150|(0.6%) 0.5g topically BID to each foot for 4 weeks
214398438|NCT00641953|DRUG|Placebo|0.5 g topically BID to each foot for 4 weeks
214398439|NCT03219437|DRUG|risankizumab|subcutaneous (SC) injection
214398440|NCT03219437|DRUG|methotrexate|capsule
214398441|NCT03291275|OTHER|Follow-up for death and recurrence|All patients are followed up to determine definite date of diagnosis, recurrence and death.
214398442|NCT02889042|OTHER|MRI and biological assessment|performing a MRI and a biological assessment
214398443|NCT06357364|BEHAVIORAL|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
214398444|NCT06357364|BEHAVIORAL|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
214398445|NCT06357364|BEHAVIORAL|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
214398446|NCT01356030|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
214398447|NCT01356030|PROCEDURE|EUS FNA|Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
214398448|NCT03403569|DRUG|Triptolide Wilfordii|In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.
214398449|NCT03403569|DRUG|Placebo Oral Tablet|In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
214398450|NCT01477749|BIOLOGICAL|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
214398451|NCT04271592|DRUG|ABI-H3733 Liquid Oral Dosage Form|ABI-H3733 liquid oral dosage form
214398452|NCT04271592|DRUG|ABI-H3733 Solid Oral Dosage Form|ABI-H3733 solid oral dosage form
214398453|NCT04271592|DRUG|Placebo to ABI-H3733 Liquid Oral Dosage Form|Placebo to ABI-H3733 liquid oral dosage form
214398454|NCT04271592|DRUG|Placebo to ABI-H3733 Solid Oral Dosage Form|Placebo to ABI-H3733 solid oral dosage form
214398455|NCT06358742|OTHER|ZCT toothpaste|
214398456|NCT06358742|OTHER|Control toothpaste|
214398457|NCT03372486|DRUG|Bupivacaine plus naloxone|Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)
214398458|NCT03372486|DRUG|Bupivacaine|Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline
214398459|NCT03383185|DEVICE|Intrauterine device|Use of Intrauterine device during the follow-up period
214398460|NCT03383185|DRUG|Combined Oral Contraceptive|Use of combined oral contraceptive during the follow-up period
214398461|NCT03383185|DRUG|Progestin-only pills|Use of progestin-only pills during the follow-up period
214398462|NCT03383185|DRUG|Depot-Medroxyprogestereone Acetate|Use of depot-medroxyprogesterone acetato during the follow-up period
214398463|NCT04499040|BIOLOGICAL|Blood sample|Blood samples to assess biological parameters such as:
214398464|NCT04499040|OTHER|Fecal samples|Microbiota analysis
215002884|NCT07104227|OTHER|to inform|Kontrol grubundaki anneler, hastanenin rutin bakım hizmetleri kapsamında emzirme danışmanı ebe tarafından verilen bilgilendirme ve destek hizmetlerinden yararlanacaklardır. Ayrıca bu anneler için emzirme döneminde doğru duruş ve emzirme pozisyonlarında dikkat edilmesi gereken durumlar konusunda bir broşür hazırlanacak ve kendilerine verilecektir. Kontrol grubunun izlem verilerinin telefon görüşmesi yöntemi ile toplanacağı belirtilerek bir görüşme-izlem planı anne ile birlikte oluşturulacaktır. Kontrol grubundaki anneler müdahale grubu ile eşzamanlı olarak doğum sonu 6. Hafta ve 3.aylarda aranarak sırt ve boyun ağrıları değerlendirilecektir.
215095390|NCT01638559|DRUG|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
214398465|NCT04499040|BEHAVIORAL|Neuropsychological|Neuropsychological assessment
214398466|NCT05528887|BIOLOGICAL|Autologous CAR-T cells|D0: CAR-T cells will be infused intravenously.
214398467|NCT05528887|DRUG|Fludarabine|D-5 to D-3: Fludarabine (30 mg/m\^2/day) will be administered intravenously for 3 days.
214398468|NCT05528887|DRUG|Cyclophosphamide|D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.
214398469|NCT00107185|BIOLOGICAL|therapeutic autologous dendritic cells|
214398470|NCT04897087|OTHER|patient safety event|This study will explore the perceptions of patients, carers and relatives who have experienced a patient safety event. Telephone interviews will be undertaken lasting up to 60 minutes This study involves NHS patients, their carers or relatives. We will ask participants about their experience of being involved a patient safety event and the barriers and enablers to participation in the review. We will ask what 'good' patient involvement in patient safety reviews should look like from those with lived experience. This is because we wish to understand from their perspective what matters to them when things go wrong and how best to involve them.
214398471|NCT02096081|DRUG|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
215002885|NCT07102927|DEVICE|Virtual reality-based training for the treatment of neglect syndrom in stroke|"An occupational therapist provided 1:1 assistance with fitting and removing the virtual reality headset (HMD), operating the software and explaining the procedures, as well as offering physical support and movement assistance when necessary to enable participants to engage in the virtual reality-based training program for neglect syndrome.~Following measurement of each participant's interpupillary distance, the headset (HTC VIVE PRO) was adjusted and fitted while the participant was seated. The lens distance was fine-tuned using adjustment knobs to match the individual's eyes.~The training for neglect was performed with participants seated and wearing the headset. The NEGTREA program provided a virtual environment along with visual fixation training."
215095391|NCT03299361|OTHER|Magnetic resonance image (MRI)|Diffusion tensor magnetic resonance imaging (DTI) of MRI reveals tissue microstructure based on random movements of water molecules. Here we monitored, by means of DTI, median nerve integrity in CTS patients before and after corticosteroid injection. This information may help to explain the hypothesis regarding the effect of corticosteroid to the median nerve, to identify which anatomic location of median nerve relevant to the symptom relief of CTS after corticosteroid injection, and be useful for the clinical follow-up of patients with nerve entrapments following conservative treatment.
215095392|NCT02539511|DRUG|CI-581a|
215095393|NCT02539511|DRUG|CI-581b|
215095394|NCT02539511|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
215095395|NCT05369481|DRUG|Sildenafil 2%|Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
214398472|NCT02096081|DRUG|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
215095396|NCT05369481|DRUG|Minoxidil 5 %|Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
215095397|NCT04343118|PROCEDURE|Hardware Removal|elective removal of plate osteosynthesis at the clavicle
215095398|NCT02858921|DRUG|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
215095399|NCT02858921|DRUG|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
215095400|NCT02858921|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
214398473|NCT02716597|DRUG|25% Albumin|
214398474|NCT02716597|DRUG|Placebo|
214398475|NCT03548545|DEVICE|tDCS|subjects will receive a total of 8-structured CBT sessions administered by a certified therapist(according to the NICE guidelines).In the first two weeks, participants will undergo 6-sessions of CBT every other day(3 CBT sessions per week) and 10 daily sessions of either active or sham tDCS(2 mA, 30 minutes).They will undergo additional booster sessions of the same intervention(active or sham tDCS followed by CBT) by week 4 and 6.
214398476|NCT04770597|DEVICE|Aranet4 Home CO2 monitor|The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.
215002886|NCT07102927|BEHAVIORAL|Conventional occupational therapy|"An occupational therapist conducted conventional neglect therapy in a 1:1 setting for 30 minutes per session. The therapy comprised therapist-supervised, table-top tasks carefully designed to parallel the virtual reality exercises as closely as possible.~These table-top tasks primarily focused on promoting visual scanning and sustained attention toward the neglected hemifield through practical, goal-oriented activities such as object search and manipulation. The therapist utilized a variety of tools to facilitate and optimize patient engagement in these training."
215002887|NCT07105228|DRUG|aflibercept 2mg|No study-specific interventions administered in this observational study
215002888|NCT07104487|DRUG|[18F]AlF-OC|Participants received a single intravenous (IV) bolus injection of 4 MBq/kg \[¹⁸F\]AlF-OC (Al¹⁸F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide), followed by a flush with 0.9% NaCl.
215002889|NCT07098273|DEVICE|TMS and FES- based rehabilitation|"Each subject will receive 15 individual sessions (45 minutes each, 3 times per week for 5 weeks) of task-based hand and arm exercises.~Before movement execution, the hand area of the primary motor cortex will be stimulated using active rTMS. The rTMS protocol will use intermittent theta burst stimulation (iTBS), which delivers bursts of 3 pulses at 50 Hz every 200 ms (5 Hz) for 2 seconds, followed by 8 seconds of rest, totaling 600 pulses in \~3 minutes. The hand area will be identified as the optimal site for eliciting a motor evoked potential (MEP) in the abductor digiti minimi (ADM) muscle, contralateral to the dominant limb, with the lowest possible stimulation intensity.~Subsequently, FES will be applied to assist the subject's voluntary movements during the task-oriented activities. The stimulation will be triggered based on the achievement of the electromyographic (EMG) threshold of the selected muscles."
215002890|NCT07098273|DEVICE|FES-based rehabilitation|"Each subject will receive 15 individual sessions (45 minutes each, 3 times per week for 5 weeks) of task-based hand and arm exercises.~Before movement execution, the TMS coil will be positioned over the hand areas of the primary motor cortex, but tilted away from the scalp so as to produce a sound similar to the real intervention, but at a low intensity, without inducing current in the cortex.~FES will then be applied to assist the patient's voluntary movements during the task-oriented activities. The stimulation will be triggered based on the achievement of the electromyographic (EMG) threshold of the selected muscles."
215002891|NCT07104786|DRUG|Obeticholic Acid 10 MG|10mg OCA was given once daily for 6 months
215002892|NCT07104786|DIETARY_SUPPLEMENT|Vitamin E 400mg|Vitamin E 400mg was given twice daily for 6 months
215002893|NCT07104357|DEVICE|Inspiratory muscle training|Participants will perform 20 sessions of respiratory muscle strengthening (20 minutes at 30-60% of MIP), using the Threshold Inspiratory Muscle Training device
215002894|NCT07104565|DRUG|INCA000585|Tafasitamab will be administered intravenously at protocol defined timepoints.
215095401|NCT00094432|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
214398477|NCT02886728|DRUG|Filgotinib|Tablet(s) administered orally once daily
214398478|NCT02886728|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
215002895|NCT07104474|OTHER|RESTORE|RESTORE is a process intervention that combines systems analysis and human-centered design (HCD) approaches to directly engage hospital nursing staff in ongoing organizational redesign to address burnout. Specifically, RESTORE is comprised of multiple in-person sessions with hospital unit design teams. In these sessions, hospital nurses are guided through using a well-known systems analysis model to understand their unit, including what factors act as drivers of burnout, what can be modified, and/or what constraints might be in place regarding system changes. Then, using HCD, nursing staff design, develop, and implement a system redesign solution to address the unique drivers of burnout in their unit that works within their constraints.
215002896|NCT01251861|DRUG|Akt Inhibitor MK2206|Given PO
215002897|NCT01251861|DRUG|Bicalutamide|Given PO
215002898|NCT01251861|OTHER|Clinical Observation|Undergo clinical observation
215002899|NCT01251861|OTHER|Laboratory Biomarker Analysis|Correlative studies
215002900|NCT07106034|DRUG|Ongericimab + Toripalimab + Bevacizumab + FOLFOX|Ongericimab, Toripalimab, Bevacizumab, Oxaliplatin, Calcium folinate, 5-FU, Q2W
215002901|NCT07106034|DRUG|Ongericimab + Toripalimab + Bevacizumab + FOLFIRI|Ongericimab, Toripalimab, Bevacizumab, Irinotecan, Calcium folinate, 5-FU, Q2W
215002902|NCT07105917|DRUG|SGLT-2 inhibitors|"Any of the following SGLT2 inhibitors (SGLT2i) can be selected for treatment:~Dapagliflozin 10 mg once daily (QD) or Empagliflozin 10 mg once daily (QD) If the patient has concurrent diabetes, the use of other antidiabetic drugs is not restricted.~The treatment should last for at least 14 days."
215002903|NCT07105917|OTHER|Standard medical treatment|According to the guideline-recommended standard treatment, if the patient has diabetes, there is no restriction on the use of other antidiabetic drugs (except SGLT-2 inhibitors).
215002904|NCT07106398|DEVICE|repetitive transcranial magnetic stimulation|"Six sessions of rTMS using the EXOMIND™ device, administered once or twice a week.~Each session will deliver 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total duration of 24 minutes and 30 seconds.~The target site would be left dorsolateral prefrontal cortex (DLPFC), determined by the most common used 5-cm rule. The procedure would be conducted in the research centre with medical staff supported."
215002905|NCT06826599|DEVICE|Investigational Biometer|Investigational non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and measurement of anterior segment and biometric parameters
215002906|NCT06826599|DEVICE|IOLMaster 700 Biometer|Commercially available non-contact instrument used to capture optical biometry measurements
215002907|NCT07100821|DIAGNOSTIC_TEST|Hemodynamic parameters was measured by using electric cardiometry (ICON)|Hemodynamic parameters was measured daily at 10 a.m by using ICON non-invasive cardiometer model C3 made in Germany by OSYPKA medical (figure 5) by placing the four sensors on the neck and left side of the thorax allow for the continuous measurement of the changes of electrical conductivity within the thorax parameters such as CO, TFC, SVV and FTC were calculated 3 times with 5-min intervals and stored on the device automatically.
214398479|NCT02886728|DRUG|MTX|Capsule(s) administered orally once weekly
214398480|NCT02886728|DRUG|Placebo to match MTX|Capsule(s) administered orally once weekly
214398481|NCT00884286|DRUG|Aplidin®|Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
214398482|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions
214398483|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
214398484|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
215002908|NCT07107802|DRUG|ATX101|Single intravenous dose
215002909|NCT07107802|DRUG|Placebo|Single intravenous dose
215002910|NCT06911177|DIETARY_SUPPLEMENT|Yeast mannan|Yeast cell wall fraction of manno-oligosaccharides and mannoproteins supplemented at 12 g/day.
215002911|NCT06911177|DIETARY_SUPPLEMENT|Control (placebo)|A supplement containing yeast protein, yeast extract, and maltodextrin, provided at 12 g/day.
215002912|NCT07105137|BEHAVIORAL|AI-GNW|This is a three-day writing intervention. Each session lasts 20 minutes. On the first day, participants in both GNW conditions will recount a negative experience and reflect on their thoughts and feelings; on the second day, they will focus exclusively on the negative aspects of that experience; and on the third day, they will explore its positive dimensions. AI-GNW participants would receive AI-generated feedback.
215002913|NCT07105137|BEHAVIORAL|NF-GNW|guided narrative writing without feedbacks
214398485|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
214398486|NCT03650738|DRUG|Apatinib|Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
215002914|NCT07105137|BEHAVIORAL|NWG|In contrast, NWG participants will objectively document their previous day's daily routine.
215002915|NCT07104682|BIOLOGICAL|GCAR1|GCAR1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting GPNMB. The CAR comprises a single-chain variable fragment (scFv) binding domain derived from a fully human GPNMB-specific monoclonal antibody (CDX-011), a CD8 hinge and transmembrane domain, a myc sequence for product identification, and the CD137 (4-1BB) and CD3 zeta chain intracellular signaling domains. After infusion, the autologous GPNMB CAR T-cells expressing the genetically engineered anti-GPNMB CAR enable the specific targeting of GPNMB-expressing cells. Upon binding to GPNMB-expressing cells, the CAR transmits T cell activation signals that promote the elimination of target cells through CAR T cell degranulation and the release of cytotoxic molecules. The cellular signal also facilitates CAR T cell proliferation and persistence that may enable prolonged disease control through immunosurveillance
215002916|NCT07113327|DIAGNOSTIC_TEST|Artificial Intelligence-Assisted Staging and Grading for Diagnosis of Periodontitis|A deep learning diagnostic model (using DenseNet and VGG16 architectures) was applied to panoramic radiographs of 47 patients to classify the stage and grade of periodontitis. The model was trained on an external dataset and validated against expert-labeled outcomes. The purpose was to assess the accuracy of AI in replicating clinician-level diagnosis based on the 2017 classification system of periodontitis.
215095402|NCT00094432|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
215002917|NCT07103187|PROCEDURE|Zygomatico-Orbital reconstruction|Zygomatico-Orbital reconstruction was done by ORIF for the zygomatic complex fractures at multiple suture lines by mini plates and screws. Orbital floor reconstruction was done mainly by using a prebent titanium mesh on a 3D printed model.
215002918|NCT06780800|OTHER|The Back Belief Questionnaire Tr (BBQ) and Backs-tr|200 people will be administered The Back Belief Questionnaire Tr (BBQ) and Backs-tr.
215002919|NCT06780800|OTHER|Backs-tr retest|100 people will fill in the Backs-tr again after 1 week.
214398487|NCT03430128|DIETARY_SUPPLEMENT|IMPACT immunotherapy|Powdered formula that is pre-packaged in individual packets which the patients will be instructed to mix with water before consumption.
215002920|NCT07121543|RADIATION|Brachytherapy|Brachytherapy is a cancer treatment where radioactive sources are placed inside or near the tumor.
215002921|NCT07121595|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215002922|NCT07121595|DRUG|Carboplatin|Given IV
215002923|NCT07121595|DRUG|Cisplatin|Given IV
215002924|NCT07121595|PROCEDURE|Computed Tomography|Undergo CT and/or SPECT-CT
215002925|NCT07121595|PROCEDURE|Modified Barium Swallow|Undergo video fluoroscopic swallow study
215002926|NCT07121595|DRUG|Paclitaxel|Given IV
215002927|NCT07121595|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
215002928|NCT07121595|OTHER|Questionnaire Administration|Ancillary studies
214398488|NCT03430128|DIETARY_SUPPLEMENT|ENSURE|Liquid milk formula available over the counter
214398489|NCT03518736|BEHAVIORAL|Supporting Play Exploration and Developmental Intervention (SPEEDI)|Physical Therapy intervention
215002929|NCT07121595|RADIATION|Radiation Therapy|Undergo RT
215002930|NCT07121595|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLNB
215002931|NCT07121595|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT
215002932|NCT07121595|RADIATION|Technetium Tc 99m-labeled Tilmanocept|Given via injection
215002933|NCT07121595|OTHER|Technetium Tc-99m Sulfur Colloid|Given via injection
215002934|NCT06865391|BEHAVIORAL|Delayed cord clamping|
215002935|NCT07121023|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 2 tablets and Placebo 4 tablets for the first time ，TRD205 1 tablets and Placebo 2 tablets each for the other three times.
214398490|NCT00264043|DEVICE|emboli capturing guidewire device combined with stent|AngioGuard™ device and Bx Velocity™ stent
214398491|NCT02029703|DEVICE|Synvisc-One Injection|
215002936|NCT07121023|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 4 tablets and Placebo 2 tablets for the first time ，TRD205 2 tablets and Placebo 1 tablets each for the other three times.
215002937|NCT07121023|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 6 tablets and Placebo 0 tablets for the first time ，TRD205 3 tablets and Placebo 0 tablets each for the other three times.
215002938|NCT07121023|DRUG|Placebo|Administered orally every 12 hours for a total of four times；Take Placebo 6 tablets for the first time ，Placebo 3 tablets each for the other three times.
215002939|NCT07119242|DRUG|68Ga-DOTATATE Injection|The eligible subjects who participate in 68Ga study will be intravenously injected with 68Ga-DOTATATE Injection on Day1，and undergo PET/CT examination within 60 minutes after injection. Corresponding safety examination is performed before administration of 68Ga-DOTATATE Injection, 3h±1.0h after administration, and Day2. Telephone safety visit is conducted at Day7 after administration.
215002940|NCT07119632|OTHER|RFE therapy|
215002941|NCT07121647|PROCEDURE|renal replacement therapy.|veno-venous hemodiafiltration for emergency indications (CVVHDF).
215002942|NCT07121647|PROCEDURE|early isolated CVVHDF.|early isolated CVVHDF.
215002943|NCT07121647|PROCEDURE|combined extracorporeal blood purification therapy|Patients received early combined extracorporeal blood purification therapy (EBPT) (SPF and CVVHDF).
215002944|NCT07118462|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
214398492|NCT02029703|OTHER|Sham Injection|
214398493|NCT05527470|DRUG|Gemcitabine,Cisplatin|Induction chemotherapy: Patients receive 1000 mg/m2 gemcitabine intravenously on day 1and day 8， 80mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
214398494|NCT05527470|RADIATION|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
214398495|NCT05527470|DRUG|Cisplatin|Concurrent chemotherapy: Patients received 100mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
214398496|NCT06073964|BEHAVIORAL|Trauma Resilience & Understanding Self-help Therapy|A self-help psychosocial therapeutic intervention requiring one to undergo a basic training in its community-based utilization.
214398497|NCT03645486|GENETIC|Infusion of lentiviral TYF-CGD-modified autologous stem cells|Infusion of lentiviral TYF-modified autologous stem cells at 1\~10x10\^6 gene-modified cells per kg body weight
214398498|NCT00074243|DRUG|CC-8490|
215002945|NCT07118462|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
215002946|NCT07118553|OTHER|classic facial massage|Powder was used as an intermediate product in facial massage application. Before the application, the participants were made to lie in the supine position on the patient's bed. The researchers performed the facial massage by standing at the participants' bedside. During the massage application, three stroking movements were applied to the chin, mouth, nose, eyes and forehead areas, respectively. Kneading motion was then applied to the same areas three times each. Then, stroking was applied to these five areas again and the facial massage application was terminated at the end of approximately 20-30 minutes. Friction movement was applied to the temporal region in each stroking and kneading application
215002947|NCT03762447|DRUG|INCB086550|INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
215002948|NCT07119905|GENETIC|genotyping assay by polymerase chain reaction|"Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube.~Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction"
215002949|NCT07119697|OTHER|Shacklock Neural Mobilization|In the SNM group, participants lay supine with hips neutral and knees flexed to 45 degrees. Therapists applied the remote slider technique by extending the knee near end-range and dorsiflexing the ankle to 15 degrees, performed in 3 sets of 15 reps with 30-second rests. Each session lasted 20 minutes including setup. Progression was made by increasing hip flexion in 5 degrees increments when a VAS pain reduction of ≥2 cm was observed. This technique, based on neurodynamic principles, was designed to reduce neural mechanosensitivity and improve mobility in patients with lumbar radiculopathy.
215002950|NCT07119697|OTHER|McKenzie Extension Principle|MEP group was treated with MEP in a prone position, starting with 10 repetitions of active trunk extension, holding end-range for 3 seconds. If no symptom centralization occurred, therapists progressed from patient-applied overpressure (EIL-POP) to clinician-applied grade III mobilizations (3 oscillations/second), following McKenzie's force progression model. Each session included 3 sets of 10 repetitions with 1-minute rest between sets, totaling 15 minutes of active intervention. For unilateral symptoms, the approach advanced to hips-off-center techniques involving a 15 degree lateral shift. This graded sequence aimed to reduce nerve root compression and promote symptom centralization.
215002951|NCT07119697|OTHER|Hydrocollator hot packs|Both groups received standardized thermotherapy using hydrocollator-heated moist hot packs (40 degrees centigrade, wrapped in 6-8 towel layers) applied to the lumbar region for 15-20 minutes to improve tissue compliance and reduce pain. Participants were positioned prone or side-lying based on comfort and symptom severity; semi-prone positions with pillow support were used for those with heightened sensitivity to maintain spinal neutrality. Thermotherapy was administered five times in week 1 and three times weekly during weeks 2-3. Skin condition and comfort were monitored. This pre-treatment method promoted transient pain relief and muscle relaxation, enhancing tolerance to subsequent therapeutic interventions.
215002952|NCT06393452|DRUG|PP405 0.05% Topical Gel|PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC)
215002953|NCT06393452|DRUG|PP405 Topical Vehicle Gel|PP405 Vehicle = placebo
214398499|NCT01785641|DRUG|ceftazidime+ciprofloxacin|2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
215002954|NCT06262113|OTHER|Letters about NF1 Care (Content Type 1)|Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
215002955|NCT06262113|OTHER|Letters about NF1 Care (Content Type 2)|Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
215002956|NCT06955845|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|Patients in this arm will receive weekly EMDR sessions for 6 weeks
214398500|NCT01785641|DRUG|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
215002957|NCT06955845|DRUG|Selective serotonin reuptake inhibitors|The patients will receive an SSRI medication daily for 6 weeks. The dose will be titrated by the clinician.
215002958|NCT04239664|OTHER|Acceptance Based Telephone Support (ABS+UC)|Support based on Acceptance and Committment Therapy (Hayes, 1999)
215002959|NCT04270955|PROCEDURE|Embolization of the Middle Meningeal Artery|Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
215002960|NCT04270955|PROCEDURE|Standard of care including possible surgical evacuation of subdural hematoma|Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
215002961|NCT04604782|DRUG|Regadenoson|Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
215002962|NCT05937568|DRUG|Imetelstat|Participants will receive imetelstat, intravenously (IV) by infusion every 4 weeks.
215002963|NCT06148883|PROCEDURE|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation is the implantation of a biological aortic valve percutaneously
214398501|NCT01785641|DRUG|cefazolin+gentamicin|cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
214398502|NCT01785641|DRUG|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
214398503|NCT03033121|DRUG|Growth Hormone|
215002964|NCT06478095|BEHAVIORAL|Visual aids|Diagrams, models, and videos
215002965|NCT00479232|DRUG|vorinostat|
215002966|NCT00479232|DRUG|decitabine|
215002967|NCT01373229|DRUG|Lenalidomide + Plerixafor (+ Rituximab)|"1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) \<100.0 x 109 / L.~4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~   * Cohort 1: 0.24 mg/kg~  * Cohort 2: 0.32 mg/kg~  * Cohort 3: 0.42 mg/kg~  * Cohort 4: 0.54 mg/kg~5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~6. Subjects will then continue single agent lenalidomide until disease progression."
215002968|NCT05855759|OTHER|Acellular Dermal Matrix|Patinets will be treated with acellular dermal matrix with standard arthroscopic technique performed as per normal clinical practice. For the tendon repair the acellular dermal matrix patch will be placed over the repaired tendon with dedicated sutures and anchors.
215002969|NCT05855759|OTHER|Acellular Dermal Matrix with autologous orthobiologics|Patinets will be treated with acellular dermal matrix enriched with autologous humeral bone marrow concentrate and subacromial bursa with standard arthroscopic technique. Humeral bone marrow concentrate will be harvested from the proximal humeral head inthe operating room and concentrated by an automatic close system.
215002970|NCT01388426|DEVICE|7eye( Panoptx)™ moisture chamber glasses|moisture chamber glasses
215002971|NCT03881787|DRUG|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
215002972|NCT03881787|DRUG|Cetuximab injection|Cetuximab injection
215002973|NCT01051284|RADIATION|Cyberknife radiation and gemcitabine|25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
215002974|NCT03219580|DRUG|5-Fluorouracil|50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
215002975|NCT03219580|DRUG|Normal Saline Flush, 0.9% Injectable Solution|0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
215002976|NCT02520973|OTHER|Sputum sample|
215002977|NCT05804903|DEVICE|(ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Plus Transcatheter Heart Valve in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
215002978|NCT03991767|OTHER|"POP-UP electronic alert"|"Implementation of the POP-UP electronic alert for all patients with eligibility criteria"
215002979|NCT03991767|DIAGNOSTIC_TEST|Serology HIV|Realization of HIV serology for included patients.
215002980|NCT04200924|OTHER|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
215002981|NCT04200924|OTHER|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
215002982|NCT01178931|DRUG|Oral dydrogesterone|oral-2x10mg
215002983|NCT01178931|DRUG|Crinone 8% gel|vaginal-1x90mg
215002984|NCT05246748|OTHER|Human Caring Theory based Education|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
215095403|NCT00483002|DRUG|varenicline|As prescribed by physician in usual clinical practice.
215095404|NCT01744314|DRUG|Indomethacin and Pantoprazole|
215095405|NCT01744314|DRUG|microcrystalline cellulose powder tablets|
215095406|NCT01462890|BIOLOGICAL|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
214398504|NCT04934553|BEHAVIORAL|Amplification of Positivity Training|12 90-minute, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
214398505|NCT04934553|BEHAVIORAL|Cognitive-behavioral Therapy|12 90-minute, clinician-administered treatment sessions focused on strategies to alter cognitions and behavior related to alcohol use.
214398506|NCT02424331|OTHER|Pursed Lips Breathing|Pursed Lips Breathing for six minutes.
214398507|NCT02424331|OTHER|Quiet Breathing|
214398508|NCT03839563|BEHAVIORAL|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
214398509|NCT01015183|DRUG|Zinc Sulfate|Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
214398510|NCT01015183|DRUG|Placebo|Placebo: as the same of intervention group
214398511|NCT04814485|DRUG|SHR-1020+albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
215002985|NCT05246748|OTHER|Standard Education|The control group received solely standard education program for one sessions in prenatal period.
215002986|NCT01405573|OTHER|Best Supportive Care|Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.
215095407|NCT01462890|DRUG|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
215095408|NCT01462890|DRUG|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
214398512|NCT01013480|DRUG|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
214398513|NCT05103774|DIAGNOSTIC_TEST|T3-T4-TSH|thyroid function tests
214398514|NCT06304844|DIAGNOSTIC_TEST|transient elastography (Fibroscan)|conduct fibroscan for patients with (MAFLD by abdominal ultrasonography)
214398515|NCT05866250|DIAGNOSTIC_TEST|Doppler-based renal resistive index|The kidney's interlobular or arcuate artery was preferentially selected and measured by pulse-wave Doppler.
214398516|NCT00878358|OTHER|Hydrotherapy|
214398517|NCT00878358|OTHER|Physiotherapy|
214398518|NCT06255847|DRUG|Pomalidomide, cyclophosphamide combined with dexametha|The starting dose of pomalidomide was 2 mg in all cases，the starting dose of cyclophosphamide was 50 mg/day.If the adverse event is attributable to a specific study drug, the dose is reduced accordingly for that drug; if the adverse event is associated with multiple drugs, the dose is reduced appropriately for one of the predominantly associated drugs at the discretion of the investigator; and if multiple adverse events occur concurrently, the dose should be adjusted according to the guidelines for the most severe toxicity.
214503773|NCT07013604|DEVICE|Neuromuscular Electrical Stimulation (NMES) Group,Resistance + BFR Group|"NMES Group: Receives neuromuscular electrical stimulation to the thigh muscles for 30 minutes, three times per week, over 8 weeks.~Resistance + BFR Group: Performs low-load resistance exercises with blood flow restriction applied to the thighs, also for 30 minutes per session, three times per week, over 8 weeks.~Control Group: Receives placebo treatment using a turned-off stimulation device with no active intervention during the 8-week period."
215002987|NCT01405573|DRUG|sorafenib|400 mg twice a day
215002988|NCT02666599|RADIATION|18F-FDG PET/CT|"A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically."
215002989|NCT00386698|BIOLOGICAL|Fluarix|
215002990|NCT00386698|BIOLOGICAL|adjuvanted influenza vaccine|
215002991|NCT02961725|BIOLOGICAL|UCMSC|UCMSC: umbilical cord mesenchymal stem cells 3-5\*10\^7/5 ml
215002992|NCT03685513|OTHER|BioHPP PEEK-based single posterior crowns|BioHPP PEEK is 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymer for extreme durability especially for frameworks for fixed and removable dental prostheses. It has many advantages as low density, light weight, shock absorber, biocompatible and venerable with composite resin.
215002993|NCT03685513|OTHER|Metal ceramic single posterior crowns|Standard metal coping veneered with glass ceramics
215002994|NCT00496457|DRUG|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
215095409|NCT01462890|OTHER|specialized pathology review (Germany only)|before randomization
214398519|NCT00678990|PROCEDURE|Transplantation of islets with heparin coating|Transplantation of islets with heparin coating
215002995|NCT00496457|DRUG|Placebo comparator|4 Capsules of PBO per day before noon meal
215002996|NCT06798298|GENETIC|Non-interventional|No study drug administered. Long-term follow-up only.
215002997|NCT02315820|PROCEDURE|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
215002998|NCT01233830|DRUG|AZD2423|oral solution
214398520|NCT05125120|OTHER|COGNİTİVE ORİENTATİTON DAİLY OCCUPATİONAL PERFORMANCE APPROACH|Polatajko et al. (2001) developed the CO-OP approach, which is an occupation-oriented problem-solving approach that combines cognitive strategies to help children acquire motor abilities throughout daily tasks (9, 29). The CO-OP approach of therapy focuses on the goal or task at hand rather than the acquisition of functions in occupational performance. CO-OP is a 'deductive' or 'occupational performance-oriented' approach that focuses on the activity target selected throughout the therapy, as opposed to 'inductive' or 'impairment-focused' alternatives (13). As a verbal approach, CO-OP focuses on skill acquisition at the activity level and strives to provide children with global problem-solving skills. Necessary performance strategies specific to the child and the activity are determined with a customised programme (12, 30). Skill acquisition, cognitive strategy development, and adapting and transferring these acquired skills to daily life are the three key goals of the approach.
214503774|NCT07012369|OTHER|Experimental group: sanitary pads with messages about family planning on them|"Sanitary pads with messages about family planning on them.~Signing the Informed Consent Form, Filling in the first section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, Obtaining contact information, Giving 2 packages of sanitary pads (14 in each package, 28 in total) with messages about family planning methods, Notifying that contact will be made three months after the end of the first menstrual bleeding, Filling in the second section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, three months after the sanitary pads are given, Expressing gratitude for participating in the study and saying goodbye."
214503775|NCT07012369|OTHER|Control group: not be given any materials|"Not be given any materials~Signing the Informed Consent Form, Filling in the first section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, Obtaining contact information, Notifying that contact will be established three months after the end of the first menstrual bleeding, Filling in the second section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, three months after the sanitary pads are given, Expressing gratitude for participation in the study and saying goodbye,"
214503776|NCT07012941|DEVICE|Superpulse Thulium Fiber laser (SPTFL) ureteroscopy for treatment of upper urinary tract stone or renal stone|RIRS procedure for upper ureteral or renal stone lithotripsy with Superpulsed Thulium Laser
214503777|NCT07012941|DEVICE|Holmium: YAG laser ureteroscopy for treatment of upper urinary tract stone or renal stone|RIRS procedure for upper ureteral or renal stone lithotripsy with Holmium: YAG Laser
215002999|NCT01233830|DRUG|Placebo|oral solution
215003000|NCT05885958|OTHER|Time|Patients will be given up to 30 minutes to void.
215003001|NCT05885958|OTHER|Time|Patients will be given up to 60 minutes to void.
215003002|NCT02080130|DIETARY_SUPPLEMENT|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
215003003|NCT02080130|DIETARY_SUPPLEMENT|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
215003004|NCT02080130|OTHER|Placebo|Placebo
215003005|NCT05686941|OTHER|Trans-cutaneous Laryngeal ultrasound (TLUS)|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords
215003006|NCT05686941|OTHER|TLUS and simultaneous laryngoscopy|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords with simultaneous video laryngoscopy (usual care)
215003007|NCT02078466|OTHER|Assessment of functional ability and follow-up at home|Assessment of functional ability and follow-up at home
215003008|NCT06224049|BIOLOGICAL|hNeo-T|After subject screening, peripheral blood mononuclear cell （PBMC） donors matching half or more of the subject's HLA matching will undergo blood collection to prepare hNeo-T. hNeo-T preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning, and the investigators will decide whether to use it. Chemotherapy preconditioning will be performed before hNeo-T transfusion. If the absolute value of lymphocyte (LYM) before pretreatment is \<0.8×10\^9/L and the subject meets the criteria for cell transfusion, the chemotherapy preconditioning will not be performed and subsequent cell transfusion can be performed directly.
215003009|NCT06224049|DRUG|Cyclophosphamide|Chemotherapy preconditioning will be performed before hNeo-T transfusion.
215003010|NCT06224049|DRUG|Fludarabine|Chemotherapy preconditioning will be performed before hNeo-T transfusion
215003011|NCT05709080|OTHER|family-professional collaboration practice model|Online instructional sessions will be conducted in two sessions for six hours (3 hours per session) for the physical therapists in the experimental group. The instructional session focus on explaining the specific strategies and process to implement the Family-professional Collaboration (four step process) Model as ( Step 1: Mutually agreed-upon goals, Step 2: Shared planning, Step 3: Shared implementation and Step 4: Shared evaluation of child and family outcomes.
215003012|NCT03445429|OTHER|3D-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 3D-display system means that the training-set up is performed first with 3D-display system an after that with the 4K-display system.
214398521|NCT00939796|DEVICE|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
214398522|NCT05983471|DRUG|ME-015 (Suplatast Tosilate)|Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)
214398523|NCT05983471|OTHER|Identical placebo|Without active component
214398524|NCT02118714|DRUG|Atrasentan|Atrasentan
214398525|NCT01310868|DRUG|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
214398526|NCT01310868|DRUG|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
214398527|NCT01310868|RADIATION|Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
214398528|NCT01310868|DRUG|Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
214398529|NCT01310868|DRUG|Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
214398530|NCT00109551|DRUG|zinc sulphate dietary supplement|
214398531|NCT00109551|DRUG|iron sulphate-folic acid dietary supplement|
214398532|NCT05602337|OTHER|Observational Study Only|Non-invasive Skin Sampling
214398533|NCT05170035|PROCEDURE|MMS + Autologous patch|A patch of consisting of platelets, leucocytes and fibrin, formed by the patients own blood sample.
214398534|NCT05170035|PROCEDURE|MMS and secondary intention healing|Mohs micrographic surgery (standard of care) (wounds will heal by secondary intention healing)
214398535|NCT05539690|BEHAVIORAL|Balance training|"* Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* 4 weeks"
214398536|NCT02544737|DRUG|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
214398537|NCT02411591|DRUG|Necitumumab|Administered IV.
214398538|NCT02411591|DRUG|Abemaciclib|Administered orally.
214398539|NCT00000736|DRUG|Zidovudine|
214398540|NCT04227340|DEVICE|Photobiomodulation Therapy (PBM)|The PBM will be delivered through application of the LED Cluster Probe externally to the right external buccal, left external buccal, mid face with mouth open and submandibular and left/right cervical. Patients who develop an oral lesion, intra-oral directed therapy will be administered with the dental light probe. For patients that can tolerate, an intraoral probe will deliver light directly onto the oral mucosa, this will then replace the mid face application with mouth open. Each laser application will be timed at 60 seconds.
214503778|NCT07013526|PROCEDURE|Ropivacaine|Administration of ropivacaine in a Suprazygomatic maxillary nerve block
214503779|NCT07011823|RADIATION|Partial breast-irradiation|"First, 8Gy partial breast irradiation will be delivered in immune-cold triple-negative breast cancer (TNBC) confirmed by PD-L1 and TILs.~Sequentially, standard neoadjuvant chemotherapy for triple-negative breast cancer including pembrolizumab, paclitaxel, carboplatin, doxorubicin, and cyclophosphamide (KeyNote-522 regimen) will be administered, followed by surgical treatment."
214503780|NCT07014059|DRUG|Autologous Serum 20%|The collection of autologous serum in a closed blood processing system for ocular use
214398541|NCT04227340|OTHER|Pain and Oral Function Assessment|After the 6-minute laser/ treatment session the child and parent will complete the mucositis evaluation scale on paper or ipad which includes self-report oral function specific to ability to swallow, eat and drink, as well as the patient's self-reported need for medication specific to mouth pain.
214398542|NCT04227340|OTHER|Parent-Reported Satisfaction Survey|A parent-reported satisfaction survey will be administered via paper questionnaire after the initial LLLT treatment. Parent satisfaction will be reported by parents on a 5-point Likert scale to questions adapted from a parent satisfaction survey used in a study regarding child life services in pediatric imaging.
214398543|NCT03529903|BEHAVIORAL|Health Coaching|Our trained health coaches will use the Way To Health platform to track patient health behaviors, and will communicate with patients via both SMS text messaging (up to four messages per week) and biweekly phone calls (up to one hour). During these interactions, health coaches will connect the patient to helpful resources and to help them reflect on previous goals and to set realistic, achievable goals for the upcoming weeks.
214398544|NCT03537053|BEHAVIORAL|A plan to Move a Little and Often|"The intervention content is reported using the behaviour change technique (BCT) Taxonomy v1 (Michie, et al. 2013). The video will contain the BCT: information about health consequences. The booklet will consist of BCTs: self-monitoring of behaviour, goal setting behaviour, action planning, commitment, social support (practical), self-talk, and mental rehearsal of successful performance. Lastly, usage of the Facebook group will include BCTs: commitment, and social support unspecified, practical and emotional.~Mental rehearsal, goal setting behaviour and action planning will be delivered through mental simulation exercises (Taylor, et al. 1998). BCTs self-monitoring of behaviour, goal setting behaviour, and commitment will be delivered using implementation intentions (Gollwitzer 1993)."
214398545|NCT01628874|DEVICE|J-Tip|Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
214398546|NCT01628874|DRUG|EMLA|In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
214398547|NCT01628874|DRUG|Lidocaine|5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
214398548|NCT01899248|DRUG|Sevoflurane|
214398549|NCT01899248|DRUG|Desflurane|
214398550|NCT01200719|DEVICE|transcranial alternating current stimulation (tACS)|Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: \< 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity \~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
215095410|NCT03984656|DRUG|lidocaine treatment|The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
214398551|NCT05081375|DRUG|Enoxaparin Injectable Product|Not holding prophylaxis dose prior to surgical procedure
214398552|NCT05081375|DRUG|Sodium chloride|Holding prophylaxis dose of Enoxaparin replacing with placebo
214398553|NCT01987375|DRUG|Cetuximab-IRDye800|a single dose of the study drug following a single loading dose of unlabeled cetuximab
214398554|NCT03093311|OTHER|NIRS based protocol|Each desaturation episode will be managed according to a standardized protocol - correction of extreme head position will be followed by optimisation of mean arterial pressure (MAP), arterial hemoglobin oxygen saturation, end tidal carbon dioxide concentration and a level of hemoglobine concentration.
214398555|NCT06022874|OTHER|Phoilex Releaf Gel|"Patients will be given the Releaf Gel to apply to the affected areas daily. They will be examined at the following time points: Immediately after application, 1 week, 2 weeks, and 4 weeks.~The instructions given to the patient shall be to apply one pump per every affected area, wash hands before applying to affected area, apply twice a day (morning, and evening), apply on clean skin, and application after showering is advised.~The number of pumps of Phoilex Releaf gel will be documented within a chart provided to the patient. It is suggested that not more than 25 lesions compassing an area greater than 50 cm² in total be treated during the course of this study.~The maximum dose would be 240 mL of Phoilex Releaf gel in 30 days. The minimum dose would be 0.5 mL (one pump) of the Phoilex Releaf gel in 30 days. The maximum daily dose of CBD per day 46 mg per application, equivalent to 92 mg per day."
214398556|NCT00000242|DRUG|Carbamazepine|
214398557|NCT03265379|OTHER|FACT-B and Brief Pain Inventory|Quality of Life Questionnaires
214398558|NCT00876122|DRUG|GDC-0941|Escalating oral dose
214398559|NCT02522546|OTHER|nasopharyngeal swab|nasopharyngeal swab
214398560|NCT04199715|BIOLOGICAL|Heplisav-B|This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.
214398561|NCT01615861|PROCEDURE|IOL implantation|Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.
214398562|NCT01615861|DEVICE|IOL Implantation|Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
214398563|NCT02600858|BEHAVIORAL|Upper limb feeding training|"Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days."
214398564|NCT01226173|DEVICE|Bio-Rad Platelia Dengue NS1 Ag test|The purpose of the study is to screen blood donors for the presence of dengue NS1 antigen at the ARC in Puerto Rico region using the Bio-Rad Platelia Dengue NS1 Ag test.
214398565|NCT04584606|DIAGNOSTIC_TEST|Lab workup (on admission and regularly during follow up).|"Complete blood count with differential leucocytic count. Absolute lymphocytic and neutrophilic count. Liver functions: Aspartate transaminase and Alanine transaminase . Renal functions: Blood urea nitrogen, serum Creatinine. HbA1C. C-reactive protein (quantitative). Serum ferritin level. D - dimer level (quantitative). Coagulation profile (Prothrombin time/ Partial thromboplastin time/ International normalized ratio).~Troponin level. Arterial blood gases when needed."
214398566|NCT05553574|BEHAVIORAL|Stop signal food task|The participants need to classify pictures of food and not food. They were asked to hold their response if they see a white frame around the picture.
214398567|NCT03018106|DRUG|Ospemifene|Ospemifene is a selective estrogen receptor modulator (SERM), and it is the only SERM approved in the United States to treat moderate to severe dyspareunia associated with VVA. It is an oral medication that is taken as a 60mg tablet once daily. Food intake increases its absorption by 2 to 3-fold, and this is not impacted by the fat or calorie content of the food. It is metabolized primarily in the liver, and is excreted in feces.
214503781|NCT07014293|OTHER|Enhanced Usual Care|Participants will receive a singleevaluation with a site social worker along with a list of mental health, social or community resources . This most closely resembles the real-world care available to survivors on an outpatient basis, however, we call this enhanced usual care since proactive identification and referral of posttreatment survivors is not routinely done.
215003013|NCT03445429|OTHER|4K-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 4K-display system means that the training-set up is performed first with 4K-display system and after that with the 3D-display system.
215003014|NCT01991314|DRUG|Ferrous sulphate|200mg tablets.
215003015|NCT02190058|DRUG|DS-1971a|suspension
215003016|NCT02190058|DRUG|placebo|placebo matching DS-1971a
215003017|NCT00209482|DRUG|glucophage XR|
215003018|NCT03834012|DRUG|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 µg HFA per day
215003019|NCT03834012|DRUG|Placebo|Intervention: Drug: placebo
215003020|NCT03834012|DRUG|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg HFA per day
215003021|NCT03834012|DRUG|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day
215003022|NCT05311865|OTHER|Club event|Participate in a club event without a mask, indoors, with vaccinated people.
215003023|NCT06215495|RADIATION|reduced target volume|"Delineate residual tumor(GTVp) and tumor bed(GTVtb) on enhanced contrast CT-MRI(T2 fluid attenuated inversion recovery, T2 FLAIR) fusion images. GTVtb and GTVp are expanded by 1cm to CTV\_6000.~The clinical target volume\_6000 cGy (CTV\_6000) is partially reduced beyond the skull and midline. According to the CT-MRI(T2 FLAIR) fusion images, the edema area that cannot be seen on contrast-enhanced CT and only can be seen on MRI should be included.~If CTV\_6000 includes thalamus, basal ganglia, brainstem or motor cortex, dose of these areas will be limited no more than 54Gy"
215003024|NCT06215495|RADIATION|EORTC (European organisation for research and treatment of cancer) target volume|delineate according to EORTC guideline
215003025|NCT01718496|DRUG|Morphine|patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
214398568|NCT03018106|DRUG|Vaginal conjugated estrogens|Conjugated estrogens are a mixture of several different estrogen salts derived from natural sources and blended to approximate the composition of estrogens in the urine of pregnant horses. The main components are sodium estrone sulphate and sodium equilin sulfate. Vaginal estrogen is considered the medication of choice for treating vulvovaginal atrophy (VVA).
215003026|NCT01718496|DRUG|Placebo|patients with advanced COPD on the other study arm will randomly receive Placebo
214398569|NCT05249296|OTHER|Nature based solution for stress reduction|participation in nature activities: daily 30 min walking in nature
214398570|NCT01898975|OTHER|500ml fluid loading|Fluid loading to evaluate fluid responsiveness
214503782|NCT07014293|OTHER|SMART3RP-Lymphoma|The intervention components include: 1. Eliciting the relaxation response (RR) involves sustained mental focus with an attitude of open receptive awareness. 2. CBT to improve stress management involves increasing awareness and identification of the components of one's stress response (negative thoughts, emotions, physical reactions, behaviors, and relational) and learning skills at each session to alter these components (e.g., cognitive restructuring). 3. Positive psychology strategies to achieve growth enhancement focus on utilizing techniques and skills to promote positive growth. Skills focus on increasing social support, positive affect, and compassion.
214503783|NCT07012993|DRUG|18F-Florbetapir or 18F-Flutemetamol|Participants will be injected with 18F-Florbetapir or 18F-Flutemetamol and imaged for up to 3 hours on a PET scanner
214503784|NCT07012447|DRUG|Venetoclax|Orally by mouth
214503785|NCT07012447|DRUG|Azacitidine|Subcutaneous injection
215003027|NCT02650752|DRUG|Lapatinib in Tandem With Capecitabine|
215003028|NCT01936155|DEVICE|Custom-built, two-channel stimulator|Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
215003029|NCT00879359|DRUG|carboplatin, paclitaxel, and bevacizumab|All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
215003030|NCT05314725|DRUG|SGLT2 inhibitor|10 days of SGLT2 inhibitor after surgery
215003031|NCT05314725|DRUG|Placebo|10 days of placebo after surgery
215003032|NCT01539200|DIETARY_SUPPLEMENT|ONS+JDR|Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
215003033|NCT01539200|DIETARY_SUPPLEMENT|JDR|Jacques-Delacroze Eurythmic training with placebo ONS
215003034|NCT00864071|DRUG|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
215003035|NCT00864071|DRUG|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
215003036|NCT00970944|DRUG|Amantadine Hydrochloride|184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
214398571|NCT05034510|DEVICE|Deep Brain Stimulation|modification in stimulation parameters
214398572|NCT01529190|DRUG|Pregabalin|Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
214398573|NCT01529190|DRUG|Placebo|placebo
214398574|NCT04739683|DEVICE|Foley bulb placement|A 16 F Foley catheter with a 30-mL balloon and stylet is inserted into the endocervical canal under direct visualization by sterile speculum exam or by digital palpation. The Foley catheter is advanced to or past the internal os, and the balloon is filled with 30-40 mL of sterile water. The catheter is then placed on genital traction by taping the end of the catheter to the medial portion of the thigh.
214503786|NCT07012447|DRUG|Cytarabine|Intravenous infusion
214503787|NCT07012759|OTHER|biomarkers|pleural effusion biomarkers in lung adenocarcinoma
214503788|NCT07014215|DRUG|Sintilimab combined with Bevacizumab and tafolecimab|Patients who met the inclusion criteria were treated with sintilimab(200mg Q3W) combined with Bevacizumab(7.5mg/kg Q3W) and tafolecimab(600mg Q6W) until disease progression or intolerable adverse reactions or death(up to 24 months)
215003037|NCT00970944|DRUG|Placebo|Placebo administered twice daily.
215003038|NCT06306703|OTHER|group1, group2, group 3|to teaching with verbal instruction to teaching with digital vaginal palpation to teaching with perineometer
215003039|NCT05913947|DRUG|Lithium|The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
215003040|NCT05913947|DRUG|Cariprazine|The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
215003041|NCT03022175|DRUG|SPR741|"SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days."
215003042|NCT03022175|DRUG|Placebo|0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
215003043|NCT00972738|DRUG|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
215003044|NCT00972738|DRUG|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
214398575|NCT04739683|DEVICE|DILAPAN-S® placement|A bivalve speculum will be used to visualize and prepare the cervix with an antiseptic solution. The DILAPAN-S® (4 x 65 mm) will be inserted in the cervical canal until it traverses the internal os. As many dilators as needed to achieve the desired effect should be inserted. Specific number of pieces always depends on decision and clinical judgement of physician and indications. A gauze pad moistened with sterile water or saline may be inserted into the vagina to help keep the DILAPAN-S® in place, if needed
214398576|NCT03619174|DEVICE|Viveve Treatment|The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
214398577|NCT03779451|DRUG|17-OHPC|received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery.
214398578|NCT03779451|DRUG|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
215003045|NCT00972738|DRUG|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
215003046|NCT03366753|PROCEDURE|acute normovolemic hemodilution|acute normovolemic hemodilution (ANH) is performed by using 5 ml/kg of blood salvage and intravenously administering 5 ml/kg of balanced hydroxyethystarch 130/0.42 (Tetraspan™) for 15 min
215095411|NCT03984656|DRUG|serratus plane block treatment|"The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block."
215095412|NCT06004570|DIETARY_SUPPLEMENT|Complex product|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica, rutin, vitamin B6, vitamin B12, folic acid Single oral dose - 2 capsules
215095413|NCT06004570|DIETARY_SUPPLEMENT|Polyphenol-rich extracts|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica Single oral dose - 2 capsules
215003047|NCT03366753|PROCEDURE|In-vitro hemodilution|Blood sample after ANH 5 ml/kg undergoes further 30% in-vitro dilution by adding 1-1.5 ml hydroxyethystarch 130/0.42
215095414|NCT06004570|OTHER|Placebo|Single oral dose - 2 capsules
215003048|NCT03499132|PROCEDURE|anesthesia|Different anesthetic procedures
215003049|NCT00697164|DRUG|Placebo|Saline Admission, day 1, day 2 3 days
215003050|NCT00697164|DRUG|Erythropoietin|Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
215003051|NCT00033644|BIOLOGICAL|sargramostim|
215095415|NCT00004874|RADIATION|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
214398579|NCT03682822|PROCEDURE|Early Artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
214398580|NCT03682822|PROCEDURE|Delayed Artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
214503789|NCT07012200|OTHER|Immersive Interactive Nursing Instruction|360-degree introduction to the environment of the cardiac catheterization laboratory, cardiac catheterization procedures (including preoperative, intraoperative, and postoperative), wound care, and precautions for home care (including diet, medication, and exercise)
215003052|NCT00033644|DRUG|cisplatin|
215003053|NCT00033644|DRUG|dacarbazine|
215003054|NCT00033644|DRUG|doxorubicin hydrochloride|
215003055|NCT00033644|DRUG|mitomycin C|
215003056|NCT05578547|OTHER|combined Kendell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"• The combined exercise will be done as follow:~1\) slowly pull the subject's neck to the head, thereby attaching the chin to the neck.~(2) the subject's eyes should be looking directly forward. (3) hold both hands on the back of the subject's head. (4) ask the subject to push his/her head backwards against the hands. (5) ask for the hands to be spread as wide as possible in order to stretch the pectoralis major.~Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
215095416|NCT02254395|DEVICE|Deep Brain Stimulation|
215095417|NCT02517671|DEVICE|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
215095418|NCT00119964|BEHAVIORAL|internet based weight management tools|
215003057|NCT05578547|OTHER|ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
215095419|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
215095420|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
215095421|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
215095422|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
215095423|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
215095424|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
215095425|NCT01893736|OTHER|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
214398581|NCT05608733|DRUG|Epidural catheter|Bony landmarks and the space between the lower lumbar vertebrae are identified. Subsequently, infiltration of the skin and subcutaneous cellular tissue with local anesthetic (Lidocaine 2% without epinephrine) is performed at the site to be punctured. A 17G Tuohy needle is inserted 2-4 cm through the skin, then the mandrel is removed, the low-resistance syringe is connected, and the loss of resistance is checked using the air or liquid technique, depending on the preference of the anesthesiologist. . Appreciating the loss of resistance in the embolus, the mandrel is then withdrawn and the epidural catheter is advanced to leave it an additional 5 cm inside the epidural space.
215095426|NCT01893736|OTHER|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
215095427|NCT05727800|DRUG|VX-668|Suspension for oral administration.
215095428|NCT05727800|DRUG|Placebo|Suspension for oral administration.
215095429|NCT04706000|GENETIC|Beclin 1 gene|The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.
215095430|NCT01381536|DRUG|GSK1550188 1mg/kg or 10mg/kg|IV one shot
215095431|NCT06497296|DRUG|Lidocaine|Lidocaine spray in both group with same puff number, but the timing before EGD insertion is different
215095432|NCT01379300|DRUG|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
215095433|NCT01379300|DRUG|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
215095434|NCT01624090|DRUG|Mithramycin|30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
215095435|NCT00752726|DRUG|Orlistat|Weight loss treatment
215095436|NCT00752726|DRUG|Placebo|Inactive
215095437|NCT01403116|DRUG|Oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
215095438|NCT01403116|DRUG|topical testosterone gel|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
215095439|NCT03888209|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
215095440|NCT01954563|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
214503790|NCT07012200|OTHER|Routine Nursing Instructions|Health education by talking and leaflets and key explanations, and providing talks and consultations
215095441|NCT01895309|DRUG|Enbrel (etanercept)|
215095442|NCT01895309|DRUG|SB4 (proposed biosimilar to etanercept)|
215095443|NCT02741037|BEHAVIORAL|Dyadic lifestyle intervention|Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
215095444|NCT02741037|BEHAVIORAL|Individual lifestyle intervention|Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
215095445|NCT02741037|OTHER|Usual Care|Usual Care: Mother and daughter participants will receive Usual Care.
215095446|NCT00042666|DRUG|LY317615|500 mg, oral, QD, up to six 28 day cycles
215095447|NCT00805064|DRUG|triamcinolone and bevacizumab|
215095448|NCT03504748|DEVICE|deep rTMS|
215095449|NCT03504748|DEVICE|placebo deep rTMS|
215003058|NCT02661724|BEHAVIORAL|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
215003059|NCT05855187|DRUG|Bravamax 200 mg (Modafinil)|Test drug
215003060|NCT05855187|DRUG|Vigil 200 mg (Modafinil)|Reference drug
214398582|NCT05608733|DRUG|Continuous sciatic nerve block|The patient is placed in the prone or supine position with the limb to be blocked flexed at 90°. Using a high-frequency linear transducer and using sterile technique, the popliteal sciatic nerve is identified in an axial axis. A 17G Tuohy needle is inserted plane and medial. Saline solution (5 ml) is applied to open the perineural space. Adequate hydrodissection and donut sign in the nerve are observed..A perineural catheter is then advanced 5 cm beyond the tip of the needle. The catheter is fixed with stitches and a transparent sterile dressing is placed.
214398583|NCT04763538|OTHER|Standard of care|Patients are treated according to the standard of care for each individual disease.
215003061|NCT03915067|DRUG|BOTOX® purified neurotoxin complex|BOTOX® superficial intramuscular injections.
215003062|NCT03915067|DRUG|Placebo|Placebo injections.
215003063|NCT01033942|DRUG|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
215003064|NCT01033942|DRUG|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
215003065|NCT01033942|BEHAVIORAL|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
215003066|NCT04011072|RADIATION|Far infrared radiation|The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
214398584|NCT03963882|DRUG|Two cycles of neoadjuvant chemotherapy|Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
214398585|NCT03963882|DIAGNOSTIC_TEST|First imaging evaluation|First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)
214398586|NCT03963882|DIAGNOSTIC_TEST|Second imaging evaluation|Second imaging evaluation consists of pelvic magnetic resonance imaging
214398587|NCT03963882|DRUG|The third cycles of neoadjuvant chemotherapy|The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
214398588|NCT03963882|PROCEDURE|RH|Radical hysterectomy
214398589|NCT03963882|RADIATION|Radiochemotherapy|Concurrent radiochemotherapy
215003067|NCT02693418|DRUG|Acidform 5 g|Effect of 5 g vaginally administered Acidform on pH over 7 days
215003068|NCT02693418|DRUG|Placebo 4 g|Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
215003069|NCT02693418|DRUG|Acidform 4 g|Effect of 4 g vaginally administered Acidform on pH over 7 days
215003070|NCT02693418|DRUG|Acidform 3 g|Effect of 3 g vaginally administered Acidform on pH over 7 days
215003071|NCT00934882|DRUG|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
215003072|NCT03071744|DRUG|Lazanda|Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
215095450|NCT02189681|PROCEDURE|Conventional landmark guided midline spinal anaesthesia|Spinal anaesthesia was administered based on conventional landmark based midline approach.
214398590|NCT03963882|DIAGNOSTIC_TEST|Pathologic evaluation|Pathologic evaluation for RH patients
214398591|NCT03486899|DRUG|BMS-986036|Specified dose on specified days.
214398592|NCT03486899|OTHER|Placebo|Specified dose on specified days.
214398593|NCT00949962|DRUG|antiandrogen therapy|Given systemically
215003073|NCT01199614|DRUG|open-label PTH(1-84)|open label PTH(1-84) at either 25mcg every other day, 25mcg every day, 50mcg daily, 75mcg daily, or 100mcg daily
215003074|NCT02811107|OTHER|Questionnaires|Completion of questionnaires on tablet computers in the preoperative area by 6 nurse anesthetists, 1 hospital physician and 1 resident physician.
215003075|NCT04256408|DEVICE|Bronchoscopic transparenchymal interlobar fissure closure using Aeriseal|Transbronchial or transparenchymal injection of AeriSeal into the interlobar collateral ventilation channels region to convert CV-positive lobes into CV-negative lobes.
215095451|NCT02189681|PROCEDURE|pre-procedure ultrasound guided L5S1 paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
214398594|NCT00949962|DRUG|leuprolide acetate|Given subcutaneously
214398595|NCT00949962|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
214398596|NCT01010217|DRUG|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
214398597|NCT01010217|DRUG|Fludarabine|40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.
215095452|NCT02189681|DEVICE|spinal anaesthesia|Spinal anaesthesia is administered with appropriate spinal needle
215095453|NCT04246957|BEHAVIORAL|general quality of life questionary|Every patient will have to fill out a general quality of life questionary : DLQI (Dermatology Life Quality Index)
215095454|NCT04246957|BEHAVIORAL|specific quality of life questionary|Every patient will have to fill out a specific quality of life questionary : Hair Specific Skindex 29.
215095455|NCT03674879|OTHER|Text Message|Patient contact attempted with text message.
215003076|NCT06553469|DEVICE|sacral neuromodulation|After screening according to the inclusion and exclusion criteria, the subjects were enrolled in the study. The sacral nerve regulation treatment was divided into two phases. Phase I was the testing phase, during which the sacral nerve stimulation electrode component was implanted. After the electrode was implanted, it was tested for 2-4 weeks. According to the urine diary and scale scores, if the symptoms improved by ≥ 50%, or if the patient requested to continue with Phase II and was evaluated by the researcher as suitable for implantation, Phase II (permanent implantation phase) treatment was performed, during which the sacral nerve stimulation pulse generator component was implanted
215003077|NCT06045260|DRUG|177Lu-DOTATOC|Administration of 4 cycles of therapy with 7.4 Gbq Dose for No risk factors Arm and 5.5 Gbq Dose for Risk Factor Arm. Both through slow intravenous infusion in 30 minutes with a dedicated pump system.
215003078|NCT01143792|BEHAVIORAL|Community Reinforcement Approach (CRA) + HIV prevention|12 sessions of the CRA and 2 sessions of HIV prevention.
215003079|NCT01143792|BEHAVIORAL|Case Management + HIV Prevention|12 sessions of case management and 2 sessions of HIV prevention.
215003080|NCT01143792|BEHAVIORAL|Motivational Enhancement Therapy (MET) + HIV prevention|2 sessions of MET and 2 sessions of HIV prevention.
215003081|NCT02548182|DEVICE|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults \[REF\]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
215003082|NCT02548182|OTHER|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
215003083|NCT02260986|DRUG|Dupilumab|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
215003084|NCT02260986|DRUG|Placebo (for Dupilumab)|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
215003085|NCT02260986|OTHER|Topical Corticosteroid (TCS)|All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
215003086|NCT02194491|OTHER|[11C]AS2471907|intravenous radiotracer
215003087|NCT02194491|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
215003088|NCT02194491|DRUG|ASP3662|oral
215003089|NCT03137368|DRUG|Exemestane Tablets|drug therapy
215003090|NCT03137368|OTHER|ovarian function suppression/ablation|Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
215003091|NCT03137368|GENETIC|CYP2D6*10 gene test|CYP2D6\*10 gene test
215003092|NCT03137368|DRUG|Tamoxifen|drug therapy
215003093|NCT01860508|DRUG|pemetrexed /carboplatin|
215003094|NCT02841735|DEVICE|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
215003095|NCT02841735|DEVICE|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
215003096|NCT02841735|DEVICE|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
215003097|NCT03657953|OTHER|surgical approach|
215003098|NCT00202150|BEHAVIORAL|Application of a management action plan|
215003099|NCT06430060|DRUG|zinc containing toothpaste|Toothpaste
215003100|NCT06430060|DRUG|MFP Fluoride toothpaste|toothpaste
215003101|NCT04764604|DEVICE|Acapella Choice|3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.
215003102|NCT04764604|DEVICE|Tube-in-water|3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.
215003103|NCT00574652|DRUG|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
215003104|NCT02310308|DIETARY_SUPPLEMENT|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
215095456|NCT00435084|DRUG|APO866|
215095457|NCT04232215|DEVICE|HeraBEAT™|A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy
215095458|NCT04232215|DEVICE|Doppler fetal heart rate monitor|A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.
215003105|NCT02341469|OTHER|integrated ediagnostic approach (IeDA)|"IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:~* REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.~* The training of nurses on IMCI and REC.~* A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.~* A supervision system conducted implemented by district managers to provide support and guidance to health centres.~* A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres."
214398598|NCT01010217|DRUG|Melphalan|140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
214398599|NCT01010217|DRUG|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
214398600|NCT01010217|DRUG|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
214398601|NCT01010217|PROCEDURE|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
214398602|NCT01010217|DRUG|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
214398603|NCT01010217|DRUG|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
214398604|NCT01010217|DRUG|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
214398605|NCT01010217|DRUG|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.
214398606|NCT00082290|OTHER|massage therapy|
214398607|NCT00082290|OTHER|visit with a volunteer|
214398608|NCT00082290|OTHER|period of quiet time|
214398609|NCT00082290|BEHAVIORAL|questionaire about pain|
214398610|NCT04431687|DRUG|CKD 501|QD, PO
214398611|NCT04431687|DRUG|D759, D150|QD, PO
214398612|NCT04431687|DRUG|CKD-501, D759, D150|QD, PO
215003106|NCT02274428|DRUG|pneumostem|human umbilical cord blood derived mesenchymal stem cells
214398613|NCT05914428|OTHER|ALDH2 rs671 mutation|We selected blood samples from sepsis patients from the biological bank of Qilu hospital and tested their genotypes. The intervention group was ALDH2 rs671 mutation patients
214398614|NCT01046461|DRUG|Ramosetron, Aprepitant, Dexamethasone|"Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning"
215003107|NCT02866448|DRUG|Vehicle control|Described in arm
215003108|NCT02866448|DRUG|Isoquercetin|Described in arm
215003109|NCT02866448|DRUG|Aspirin|Described in arm
215003110|NCT02866448|DRUG|Isoquercetin plus Aspirin|Described in arm
215003111|NCT05752409|DRUG|The median dose of esketamine|1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.
215003112|NCT05752409|DRUG|The high dose of esketamine|1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.
215003113|NCT05752409|DRUG|Propofol|2mg•kg-1propofol for general anesthesia induction.
214398615|NCT03504865|DRUG|Liposomal bupivacaine|Given at the end of the operation.
215003114|NCT01793935|DRUG|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
214398616|NCT03504865|DRUG|Standard bupivacaine|Given at the end of the operation.
214398617|NCT03504865|OTHER|Placebo|Saline will be administered as the placebo and will be given at the end of the operation.
214398618|NCT03911375|OTHER|Mindfulness Based Stress Reduction (MBSR)|"Psycho-educational program of stress reduction based on mindfulness. Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.~Each week the theoretical contents necessary to understand the attention development practices proposed in mindfulness-based interventions will be covered. In addition, basic concepts of the psychobiology and psychology of stress and pain are explained. The subjects will have a homework load of approximately 45 minutes per day during the duration of the intervention."
214398619|NCT00479596|DRUG|Botox|
214398620|NCT04323319|DEVICE|ESWT, Graston Technique|"The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week."
214398621|NCT02321085|PROCEDURE|Sinus Rhythm control|
214398622|NCT02321085|PROCEDURE|Pulse Rate control|
214398623|NCT04729140|DRUG|Ivermectin Tablets|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
214398624|NCT04729140|DRUG|Doxycycline Tablets|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
214398625|NCT04729140|DRUG|Placebo|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
214398626|NCT02887560|PROCEDURE|transoesophageal echocardiography|
214398627|NCT03190083|DEVICE|2-dimensional mammogram|This is standard of care for breast cancer diagnosis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
214398628|NCT03190083|DEVICE|digital breast tomosynthesis (DBT)|The radiation dose from this/these procedure(s) will be no more than 0.4mSv for a bi-lateral breast tomosynthesis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
214398629|NCT03066388|OTHER|Pulse pressure variations|Stroke volume and, pulse pressure variations obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin.
214398630|NCT05856474|OTHER|pancreatectomy|pancreaserving surgery, using end to side or end to end, pancreaticojejunostomy
215003115|NCT01793935|DRUG|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
215003116|NCT02087592|BEHAVIORAL|Structured exercise training plus mediterranean diet|
215003117|NCT01635647|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 1 x 10\^8 pfu heterologous prime-boost immunisation
214398631|NCT05620017|DRUG|BAT8008 for Injection|Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.
215003118|NCT01635647|BIOLOGICAL|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
214398632|NCT00394511|PROCEDURE|low-LET photon therapy|
214398633|NCT06234137|DRUG|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
214398634|NCT06234137|DRUG|Carboplatin|AUC=6 min/mL iv 3-weekly
214398635|NCT06234137|DRUG|Inetetamab|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
214398636|NCT06234137|DRUG|Pyrotinib|400mg orally daily
215003119|NCT01453647|OTHER|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
215003120|NCT04772547|DRUG|Vigabatrin Only Product|enteral medication administration, serial blood draws, and outcome assessment
215003121|NCT01771913|GENETIC|centrifuged fat graft|fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
215003122|NCT01771913|GENETIC|ADSCs enriched fat graft|fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
215003123|NCT03909503|DEVICE|Porcine-derived collagen wound dressing|Patients who meet the inclusion criteria will be treated with porcine-derived collagen dressings. The dressing will be used in accordance with its label. After cleansing the wound, the dressing will be placed on the wound. Appropriate primary and secondary dressings will be placed over the intervention product. Patients will visit the clinic once per week to have their dressings re-applied. Wound evaluations will take place once per week with the intervention lasting up to twelve weeks. Concomitant standard of care such as compression for venous ulcers will be provided according to individual patient needs.
214398637|NCT01236027|OTHER|no intervention|not applicable-no intervention
214398638|NCT03781011|BEHAVIORAL|Vegetarian diet intervention|Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.
214398639|NCT01782326|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
214398640|NCT01782326|DRUG|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
214398641|NCT02278575|DRUG|Atenativ|intravenous transfusion
214398642|NCT03685279|BEHAVIORAL|Nurtured Heart Approach|Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.
215003124|NCT00447681|DRUG|ILV-094|
215095459|NCT02454153|DEVICE|REMStar Positive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
214398643|NCT02445885|PROCEDURE|PCI|Guideline directed Percutaneous Coronary Intervention
214398644|NCT03725943|DIAGNOSTIC_TEST|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG.
214688180|NCT06929715|OTHER|Intervention for Teaching the First Link in the Chain of Survival to 7- and 8-Year-Old Children|Unlike traditional CPR training programs designed primarily for older children or adults, this intervention is uniquely tailored for 7- and 8-year-old schoolchildren. It employs a narrative-based, age-appropriate educational approach that incorporates storytelling, interactive activities, and practical simulation exercises aligned with the cognitive and motor development of young learners. Delivered by school nurses in a classroom setting, the program not only focuses on teaching the first link in the chain of survival but also ensures that its content and methods are rigorously validated by experts. Moreover, the intervention includes a follow-up evaluation at three months to assess the retention of knowledge and skills, distinguishing it from other clinical studies that lack such long-term assessment.
215003125|NCT06161090|BIOLOGICAL|CM310|CM310 injection
215095460|NCT02454153|BEHAVIORAL|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
214398645|NCT00399178|DRUG|Transdermal delivery system|
214398646|NCT05390892|DRUG|SGLT2 inhibitor|Empagliflozin, dapagliflozin, or canagliflozin
214398647|NCT05390892|DRUG|GLP-1 receptor agonist|Dulaglutide, liraglutide, semaglutide
214398648|NCT01843452|RADIATION|RADIOTHERAPY|"External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.~* Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).~* Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV."
214398649|NCT01843452|BIOLOGICAL|PANITUMUMAB|6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
215003126|NCT06161090|DRUG|Placebo|subcutaneous injection
215003127|NCT04403282|DRUG|Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
215003128|NCT04403282|DRUG|Placebo Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
214398650|NCT01843452|DRUG|MITOMYCIN|10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
214398651|NCT01843452|DRUG|CAPECITABINE|825mg/m2 orally twice daily on study days 1 through 45.
215003129|NCT04656119|OTHER|there is no intervention in our study|there is no intervention in our study
215003130|NCT01111370|DEVICE|DexCom™ G4 Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
215003131|NCT04038125|DRUG|Ozurdex Drug Implant Product|Intravitreal Ozurdex injection
215003132|NCT01149252|OTHER|Psoralait|Cream to be used as instructed.
214398652|NCT00503568|BIOLOGICAL|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient
214398653|NCT04239287|DIAGNOSTIC_TEST|Lung function + exercise tests|Lung function + exercise tests
214398654|NCT00030654|DRUG|bicalutamide|
214398655|NCT00030654|DRUG|docetaxel|
214398656|NCT00030654|DRUG|doxorubicin hydrochloride|
214398657|NCT00030654|DRUG|estramustine phosphate sodium|
214398658|NCT00030654|DRUG|flutamide|
214398659|NCT00030654|DRUG|ketoconazole|
214398660|NCT00030654|DRUG|paclitaxel|
214398661|NCT00030654|DRUG|releasing hormone agonist therapy|
214398662|NCT00030654|DRUG|vinblastine sulfate|
214398663|NCT06386224|BEHAVIORAL|Internet-delivered pain self-management (CBT Condition)|Participants will login to the website for 15-20 minutes per week, and complete 5 modules focused on different skills delivered over 8 weeks (e.g., symptom identification, changing negative thoughts, activity pacing)
214398664|NCT06386224|BEHAVIORAL|Education Program|Participants will login to the website for 15-20 minutes per week, and complete 5 modules focusing on pancreatitis pain topics, including: an introduction to pancreatitis, treatment options, specific therapies, surgical procedures.
214398665|NCT00107874|DRUG|misoprostol|
214398666|NCT00349102|RADIATION|Free breathing|Free breathing during conformal radiation
215003133|NCT01149252|OTHER|Placebo cream.|Cream to be used as instructed
214398667|NCT00349102|RADIATION|Breath holding|Breath holding during conformal radiation
214398668|NCT01788020|DRUG|Dexamethasone, Rituximab, Cyclophosphamide|
214398669|NCT01788020|DRUG|Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib|
214398670|NCT06047873|DEVICE|Endoscopy|clinical and endoscopic pattern in patients with upper and lower gastrointestinal bleeding
214398671|NCT05946382|BEHAVIORAL|RNT-ACT Protocol|Swedish Translation of the 2\*60 minute Acceptance and Commitment Protocol for Repetitive Negative Thinking.
214398672|NCT05946382|BEHAVIORAL|iCBT Treatment|Internet-based Cognitive Behavioral Therapy as mandatory routine care in Swedish Primary care and therefore considered Treatment as usual.
215003134|NCT04136301|OTHER|Informative Video group|Informative Video group before labor in nulliparous women
215003135|NCT00313170|DRUG|Fulvestrant|intramuscular injection 250 mg \& 500 mg
215003136|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml + 1% lidocaine|Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain
215003137|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml+ 0.9% saline|Response to intra-articular injection of steroid only as a placebo
215003138|NCT05302232|OTHER|painDETECT questionnaire|painDETECT questionnaire
215003139|NCT04949295|DEVICE|ocular surface analyzer|Using ocular surface analyzer for Inspection
215095461|NCT03514901|OTHER|Experimental combination beyond Focal Progression|"Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy)."
214398673|NCT04207684|DRUG|Testosterone injection|250 mg of testosterone cypionate (equivalent to 174,8 mg of testosterone) administered via intramuscular injection in a single dose (2 mL)
214398674|NCT05315219|PROCEDURE|Endoscopic Thyroidectomy Bilateral Areola Approach|The endoscopic thyroidectomy achieves better cosmetic effects than open thyroidectomy, and is one of the most widely applied approach in China, meanwhile its safety and effectiveness has been broadly discussed since being introduced.
214398675|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 3 mg administered SC
214398676|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 6 mg administered SC
214398677|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 12 mg administered SC
214398678|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 24 mg administered SC
214398679|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.1 mg/kg administered IV
214398680|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.2 mg/kg administered IV
214398681|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.4 mg/kg administered IV
214398682|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.8 mg/kg administered IV
214398683|NCT04183192|BIOLOGICAL|Placebo|Placebo (administered either IV or SC)
214398684|NCT03291600|BEHAVIORAL|Virtual Psychiatric Care|Virtual psychiatric care for perinatal depression will be offered to participants, in addition to care as usual, for a 12-week period by their treating perinatal psychiatrist. Virtual care will be delivered by video-based visits through the Ontario Telemedicine Network (OTN). The treating psychiatrist may request that an intervention group participant present for in-person care at any visit, and this may include need for behavioural activation, or another health-related indication at the discretion of the treating psychiatrist.
215003140|NCT05680701|OTHER|real tACS|The participant will receive one session of 10 Hz tACS for 20-minutes
215003141|NCT05680701|OTHER|sham tACS|The participant will receive one session of active-sham tACS for 20-minutes
214398685|NCT06483412|BEHAVIORAL|Healthy Futures: Alternative-to-Suspension Curriculum|Healthy Futures: Alternative-to-Suspension Curriculum uses a trauma-informed and restorative practice lens and uses principles of motivational interviewing (MI) and cognitive-behavioral therapy (CBT) to help students understand the harms of nicotine, reduce stress, increase positive coping, and provide resources to quit.
215003142|NCT05419440|PROCEDURE|laparoscopic drainage of appendicular abscess|access to caecum and remove any adhesions with surrounding by sharp \& blunt dissection , then access to appendicular abscess by sharp and blunt dissection after complete separation of the appendix from surrounding \& complete drainage of pus \& removal of all necrotic tissue , removal of the remnant appendix , in cases with healthy base of appendix ,we closed the stump with endo-loop , in case with unhealthy base , we closed the stump by suturing by ethibond 2/0 in two layers in case with little edema \& inflammation of caecum ( sutures not cut through ) , in cases with marked edema and inflammation of caecum , we close the site of base by omental patch fixed by taking full thickness sutures in wall of caecum and pass through omental patch , we examine any leak by pressing on caecum and observe any fecal matter comes \& air leak test , in all cases we put large drain at pelvis
214398686|NCT04895787|BEHAVIORAL|Gait + aerobic exercise|Following skill-based gait training, the participants in the AEX group will engage in 20 minutes of moderate to high intensity aerobic exercise on a recumbent bicycle. The participants will first perform a brief warm-up, followed by 20 minutes of moderate to high intensity aerobic exercise pedaling at 60-80 rpm with a target heart rate range between 60-70% of heart rate reserve (HRR). Given the potential of having autonomic dysfunction in this population, it has been suggested that a RPE scale between 14-17 is appropriate.
214398687|NCT04895787|BEHAVIORAL|Gait + resistance exercises|Following skill-based gait training, the participants in the REX group will engage in resistance training, which will target major muscle groups important for daily activities. The resistance training will be provided with free weights or therabands at an intensity of 8-12 repetition maximum (RM). Each muscle group should be trained with 8-12 repetitions ranging from 1 to 3 sets with resting intervals provided between each set. The target RPE scale will be set between 14-17, and the training load will be progressively increased as the participants improved.
215003143|NCT05531097|DRUG|HSK31679|Single or multiple oral doses of HSK31679
215003144|NCT05531097|DRUG|Placebo|Matching placebo
215003145|NCT00198120|DRUG|D-cycloserine|D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg
215003146|NCT00198120|DRUG|Placebo|Placebo: same dosing schedule and capsule strength
215003147|NCT04900272|BEHAVIORAL|VIPA and companion booklet|Participants will be asked to use the VIPA and accompanying second iteration of the instructional booklet focused on social-isolation. These participants will be surveyed over the phone for 16 weeks (baseline, 2 weeks, 4 weeks, 8 weeks, and 16 weeks) with outcomes measured at each time point.
215003148|NCT00226213|PROCEDURE|Peripherally Inserted Central Catheter Placement|
215003149|NCT01975441|DRUG|Diethylcarbamazine|Diethylcarbamazine 6mg/kg
215003150|NCT01975441|DRUG|Albendazole|Albendazole 400mg
214398688|NCT04895787|BEHAVIORAL|Gait + conventional physical therapy|Following skill-based gait training, the participants in the CPT group will receive conventional physical therapy, which may include stretching exercise, balance training, or practice over-ground walking based on the participant's need.
214398689|NCT04895787|BEHAVIORAL|Gait + rest|Following skill-based gait training, the participants will sit and rest on a chair.
215003151|NCT01975441|DRUG|Ivermectin|Ivermectin 200 mcg/kg
215003152|NCT01716195|RADIATION|Induction Chemotherapy followed by Response Adapted Chemoradiation|All patients receive induction chemotherapy with 2 cycles of paclitaxel and carboplatin followed by response adapted, de-escalated chemoradiation. Patients with a complete or partial response will receive 54 Gy with concurrent paclitaxel and patients with stable disease will receive 60 Gy with concurrent paclitaxel.
215003153|NCT01804907|BEHAVIORAL|Cognitive Behavioral Therapy|
215003154|NCT01804907|BEHAVIORAL|Behavioral Modification|
215003155|NCT01852903|DIETARY_SUPPLEMENT|calcium ascorbate|
215003156|NCT01852903|DIETARY_SUPPLEMENT|ascorbic acid|
215003157|NCT01852903|OTHER|placebo|
215003158|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
215003159|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
215003160|NCT03962816|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
215095462|NCT03514901|DRUG|Pembrolizumab or Nivolumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
215095463|NCT06228859|PROCEDURE|overdentures with different attachments|different types of overdenture attachments in relation to retention, bite force, and periimplant tissue health.
215095464|NCT05494372|OTHER|safety precautions|Nursing safety precautions on CPB
215095465|NCT04806360|PROCEDURE|ACRF surgery|A new surgical procedure that previously proposed by our team.
215095466|NCT04806360|PROCEDURE|conventional anterior surgery|Anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
215003161|NCT04051801|DRUG|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
215003162|NCT04051801|DRUG|Dose Escalation of Placebo|dose levels of the cohorts will be increased step wise
215003163|NCT01458977|DRUG|Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)|TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months
215003164|NCT01458977|DRUG|Placebo|Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
215095467|NCT04806360|PROCEDURE|conventional posterior surgery|Laminectomy and fusion surgery or laminoplasty surgery.
215095468|NCT02048371|DRUG|Regorafenib|Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
215095469|NCT02048371|DRUG|Placebo|21 days on and 7 days off
215095470|NCT03416075|DEVICE|Mechanical ventilation|Noninvasive and/or invasive mechanical ventilation were performed when patients had respiratory failure.
214398690|NCT06458387|DIETARY_SUPPLEMENT|Active protein supplementation|The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day. NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active protein supplementation arm were protein supplementation at over 1.5 g/kg/day during first 3 days after ICU admission. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%.
215003165|NCT00406380|DRUG|Bevacizumab|
215003166|NCT00406380|PROCEDURE|Intravitreal injection of Bevacizumab|
215003167|NCT05720247|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is a safe and effective test using ultrasound to measure liver elasticity and can detect early signs of liver disease even before a patient shows symptoms.
215003168|NCT05720247|BEHAVIORAL|Brief Intervention|Short counselling session to discuss drinking behavior, risks to health and available sources of treatment and support.
215003169|NCT04163380|BEHAVIORAL|Resistance Training|Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
215003170|NCT00063037|BEHAVIORAL|Behavioral modification - nutrition education|
215003171|NCT02903654|OTHER|observational|
215003172|NCT04491487|OTHER|pre-operative counselling|pre-operative Speech-Language Pathology (SLP) counselling before Total Laryngectomy
215003173|NCT04061629|DEVICE|Cuffed ETT|Cuffed endotracheal tube.
215003174|NCT04623151|BEHAVIORAL|Online leaflet about foot care|Short text-based leaflet about foot care, presented online
215003175|NCT04172272|DRUG|Systemic multimodal analgesia administered intravenously|"Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
215003176|NCT04172272|PROCEDURE|Transversus abdominis plane block (TAP block)|"The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacin in 40 ml bilaterally. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
215003177|NCT04172272|OTHER|Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously|TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
215003178|NCT03027934|DRUG|Ticagrelor|Ticagrelor, 90mg twice daily
215003179|NCT03027934|DRUG|Prasugrel|Prasurgrel, 10mg once daily
215003180|NCT03940534|DEVICE|TAD|TAD is a device used to aid medication adherence.
215003181|NCT05607043|DEVICE|Testing for SARS CoV2 RNA|Device: Testing for SARS CoV2 RNA- lab-based RNA RT-PCR testing
215003182|NCT01785316|PROCEDURE|IHP|
215003183|NCT03061643|DRUG|Docetaxel|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
215003184|NCT03061643|OTHER|Androgen-Deprivation Therapy (ADT)|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
215003185|NCT02811978|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.
215003186|NCT02811978|DRUG|Dexamethasone|Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
215003187|NCT03613870|DEVICE|PermeaDerm|Wound treatment with PermeaDerm
215003188|NCT03613870|DEVICE|Mepilex Ag|Wound treatment with Mepilex Ag
215003189|NCT02353741|DRUG|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
215003190|NCT02353741|RADIATION|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
215003191|NCT04903977|DIAGNOSTIC_TEST|Laboratory tests: blood and faeces tests|To be performed at V2
215003192|NCT04903977|DIAGNOSTIC_TEST|Gynaecological and proctological examinations|To be performed at V1 (Examination with a gynaecological speculum, Bimanual examination, Rectal examination, and Anoscopy)
215003193|NCT04903977|DIAGNOSTIC_TEST|3-D Endoanal Ultrasound|To be performed at V1 (as a reference and for group assignment)
215003194|NCT04903977|DEVICE|ONIRY measurement|To be performed at V2 (the electrical impedance of anal sphincter muscles will be measured)
215003195|NCT04903977|DIAGNOSTIC_TEST|High-resolution anorectal manometry|To be performed at V3
215003196|NCT04903977|DIAGNOSTIC_TEST|ECG|To be performed at V1 and V2 (for safety reasons)
215003197|NCT00505583|DRUG|MOA-728|
215003198|NCT04648176|DEVICE|Moses technology|Using Holmium laser with Moses technology or conventional one
215003199|NCT00478036|DRUG|Acular LS|Details covered in arm description
215003200|NCT00478036|DRUG|Pred Forte|Details covered in arm description
215003201|NCT00478036|OTHER|Refresh Tears|Placebo
215003202|NCT05924932|DEVICE|Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6|type of hybrid close loop insulin delivery system
215003203|NCT05924932|DEVICE|MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4|type of hybrid close loop insulin delivery system
215003204|NCT03669679|PROCEDURE|Breast reduction|breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique
215003205|NCT02004795|RADIATION|BNCT + IG-IMRT|Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
215003206|NCT00756301|OTHER|Lidocaine local anesthesia- Alternative|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
215003207|NCT03787407|BEHAVIORAL|stress management and meditation|mindfulness training using mobile application
214398691|NCT06458387|DIETARY_SUPPLEMENT|Conventional protein supplementation|The participants in conventional protein supplementation arm received conservative nutritional management without specific protein targets.
215003208|NCT06115980|DEVICE|lead extraction (Xtrac O.S. system)|"This is an open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.~The decision upon lead extraction will be based upon the applicable Heart Rhythm Society guidelines or European Heart Rhythm Association (EHRA).~Each enrolled patient will undergo a pre procedural evaluation to enable planning of the extraction procedure. The evaluation includes an assessment of the CIED components to be removed, dwell time, anatomic course on radiography and patient characteristics that may require management prior to extraction.~A multidisciplinary team evaluation involving cardiac surgery, electrophysiologist, and cardiac anesthesiology should allow for a rapid and successful response to major complications"
215003209|NCT01116531|DRUG|Tramadol|Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.
215003210|NCT01116531|DRUG|Duloxetine|The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.
215003211|NCT01116531|DRUG|Pregabalin|The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
215003212|NCT03357055|DRUG|Ketamine|IV infusion of 0.25mg/kg of ketamine over 10 minutes before pneumatic tourniquet inflation. Throughout procedure patient will receive 0.25mg/kg of ketamine infusion.
215003213|NCT03357055|DRUG|Normal saline|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
215003214|NCT03917888|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound will be performed daily in mechanically ventilated patients after 48 hours of ventilation to screen for ventilator associated pneumonia
215003215|NCT03647007|OTHER|FIFA 11 for health|The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
215003216|NCT05084326|PROCEDURE|Engagement of fetal head as a predictor of a successful vaginal delivery|"In addition to the fetal lie, presentation, and position, the level or station of the presenting part in the maternal pelvis is an important factors in the labor process.~In primigravida, Delayed engagement of fetal head has been theorized that it is more likely in women with a possible cephalo-pelvic disproportion, so far they are associated with higher risk of cervical dystocia, which led to increased rate of caesarean section."
215003217|NCT03823625|DRUG|Nivolumab plus Ipilimumab|Nivolumab will be administered at the standard dose of 360 mg every 3 weeks. Ipilimumab will be administered at the dose of 1 mg/kg every 6 weeks.
215003218|NCT03823625|DRUG|Platinum-based chemotherapy plus Nivolumab|"Nivolumab will be administered at the standard dose of 360 mg every 3 weeks.~Platinum-based chemotherapy will be chosen by the investigator among the following regimens:~* Cisplatin 80 mg/mq iv day 1 and Gemcitabine 1250 mg/mq iv days 1 and 8 every 21 days;~* Carboplatin AUC 5 iv day 1 and Gemcitabine 1000 mg/mq iv days 1 and 8 iv every 21 days;~* Carboplatin AUC 6 iv day 1 and paclitaxel 200 mg/mq iv day 1 every 21 days."
215095471|NCT02108691|DIETARY_SUPPLEMENT|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
215095472|NCT02108691|DIETARY_SUPPLEMENT|Placebo|Placebo (2.5g/day)
214398692|NCT00030875|DRUG|bortezomib|
214398693|NCT04033991|DRUG|Sunitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
214398694|NCT04033991|DRUG|Axitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
215003219|NCT04695678|DIAGNOSTIC_TEST|COVID-19 nasal/pharyngeal swab|each study participant receives a nasal/pharyngeal swab
215003220|NCT00420836|DRUG|Tobramycin|
215003221|NCT02875600|OTHER|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
215003222|NCT00265278|DRUG|Modafinil|
215003223|NCT00800540|DRUG|Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Fixed combination ophthalmic suspension
215003224|NCT00800540|DRUG|Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution|Fixed combination ophthalmic solution
215095473|NCT05296993|DIETARY_SUPPLEMENT|Extracts found in the Extended Longevity supplements|Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.
215095474|NCT03135977|DRUG|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
215095475|NCT04518033|DEVICE|Various commercially available face coverings|Various commercially available face coverings
215095476|NCT03337464|OTHER|cycling exercise|5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
215095477|NCT02628548|BEHAVIORAL|Cognitive training program|8 week cognitive training program
215003225|NCT01385644|OTHER|Placental MSC|MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
215003226|NCT00078520|BIOLOGICAL|Dose Level 1|IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 0
215003227|NCT00078520|BIOLOGICAL|Dose Level 2|IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^6
215003228|NCT00078520|BIOLOGICAL|Dose Level 2- Fixed Dose|IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^7
215003229|NCT04687722|OTHER|High Intensity Aerobic Training.|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of high intensity aerobic training at 80-90% of heart rate maximum increased gradually on treadmill and elliptical trainer and then 2-5 minutes of low to moderate intensity cool down exercises.
215003230|NCT04687722|OTHER|Low intensity Aerobic Training|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of low intensity aerobic training at 40-60% of heart rate maximum increased gradually on elliptical trainer and jogging and then 2-5 minutes of low to moderate intensity cool down exercises.
215003231|NCT05909423|DRUG|Influenza vaccine|Intratumoral influenza vaccine treatment, administered via endoscopic procedure
215003232|NCT05909423|DRUG|Pembrolizumab|Single dose pembrolizumab treatment
215003233|NCT01805050|PROCEDURE|Arthroscopically repair of the anterior shoulder instability|Arthroscopically repair of the anterior shoulder instability
215003234|NCT02142543|DRUG|2-DeNT powder|powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
215003235|NCT02142543|DRUG|Placebo Comparator|
215003236|NCT03457597|DRUG|Midazolam hydrochloride|Midazolam hydrochloride 2.5 mg
215003237|NCT03457597|DRUG|Metoprolol tartrate|Metoprolol tartrate 100 mg
215003238|NCT03457597|DRUG|Pioglitazone hydrochloride|Pioglitazone hydrochloride 15 mg
215003239|NCT03457597|DRUG|Tolbutamide|Tolbutamide 500 mg
215003240|NCT03457597|DRUG|Omeprazole|Omeprazole 20 mg
215003241|NCT03457597|DRUG|Relacorilant|Relacorilant 350mg
215003242|NCT05125497|PROCEDURE|In Vitro Fertilisation (IVF)|Natural Cycle In Vitro Fertilisation (IVF): without hormonal stimulation Conventional In Vitro Fertilisation (IVF): conventional hormonal stimulation Minimal Stimulation In Vitro Fertilisation (IVF): low dose of hormonal stimulation will be applied
215003243|NCT04604860|BEHAVIORAL|Fitness intervention|Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).
215003244|NCT05371704|DIETARY_SUPPLEMENT|Multivitamin Supplementation|Participants will supplement daily with an over-the-counter oral multivitamin pill
215003245|NCT05371704|OTHER|Dietary Replication|Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
215003246|NCT03261258|OTHER|Questionnaire|
215003247|NCT04781465|DEVICE|Immersive Virtual Reality|"Dedicated virtual reality sessions.~* Duration 20 minutes per session.~* The virtual reality session will be supervised by a health professional trained in this tool after 1.5 hours of training by the team responsible for the equipment (use of the equipment, and use of the 20 minutes of VR). This supervising professional may be a doctor, an occupational therapist, a caregiver or any other health professional trained in the tool under this protocol.~* The exercises proposed will be standardized virtual reality exercises with the same exercises for all, but adapted to the level and abilities of each patient."
215003248|NCT00860925|DRUG|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
215003249|NCT00860925|DRUG|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
215003250|NCT00860925|DRUG|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
215003251|NCT00860925|DRUG|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
215003252|NCT05141994|DRUG|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
215003253|NCT05141994|DRUG|4mg of BAT5906|Specification: 4mg of BAT5906
215095478|NCT00370838|DRUG|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
215003254|NCT00850577|DRUG|Paclitaxel|Solution, IV, 200 mg/m2, Q21days, 6 cycles
215003255|NCT00850577|DRUG|Carboplatin|Solution, IV, AUC=6, Q21days, 6 cycles
215003256|NCT00850577|DRUG|CT-322|Solution, IV, 2 mg/kg, Q7days, Until PD
215003257|NCT00850577|DRUG|Bevacizumab|Solution, IV, 15 mg/kg, Q21days, Until PD
215003258|NCT00850577|DRUG|Bevacizumab placebo (ie saline solution)|Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
215003259|NCT04874779|OTHER|non|follow up investigations
215003260|NCT02140827|OTHER|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
215003261|NCT02447029|DRUG|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
215003262|NCT02447029|DRUG|standard lidocaine paracervical block|1% lidocaine paracervical injection
215003263|NCT01601795|DRUG|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
215003264|NCT01601795|DRUG|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
214398695|NCT05447247|OTHER|Acupuncturing Ba Liao point under ultrasound guidance|Acupuncturing Ba Liao point under ultrasound guidance
214398696|NCT02410161|DIETARY_SUPPLEMENT|alpha-linolenic acid-rich supplement|each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
214398697|NCT05607966|DEVICE|ORIGIN® CR devices|It is planned to include consecutive eligible subjects which will be treated with the ORIGIN® CR devices.
214398698|NCT00738530|DRUG|Bevacizumab [Avastin]|10 mg/kg IV every 2 weeks
215003265|NCT00075374|DRUG|docetaxel|"Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every 2 courses during study treatment, and then at study completion.~Patients are followed at 1 month and then every 2-3 months thereafter."
215003266|NCT04332120|PROCEDURE|tubal sterilization|
215003267|NCT00000599|DRUG|colestipol|
215003268|NCT00000599|DRUG|niacin|
215003269|NCT00000599|BEHAVIORAL|diet, fat-restricted|
214398699|NCT00738530|DRUG|Interferon alfa 2a [Roferon]|9 MIU SC 3 times/week
214398700|NCT00738530|DRUG|Placebo|IV every 2 weeks
214398701|NCT01224561|BEHAVIORAL|Lipid overnutrition|During 4 months, the daily caloric intake will be increased by about 70 g fat as butter 20 grams, 100 grams of cheese (Emmental) and 40 grams of almonds. This overnutrition corresponds to an excess of 760 kcal / day or 21,280 calories for the period and then taken to a theoretical 2.4 kg of fat (1 kg fat = 9000 kcal).
214398702|NCT00200421|DRUG|Nebivolol and Atenolol|
214398703|NCT05503680|BEHAVIORAL|Yoga|In this study, the researcher will provide participants with two month of Hatha yoga as an experimental intervention for managing stress. All participants who belong to the intervention group will be required to complete 120 minutes per week of home-based, online streaming yoga for eight weeks with our certified yoga instructor. The intervention will be conducted online by Zoom video; participants will be sent a link to join a scheduled live online yoga session twice every week. The data collection will be undertaken in three times: baseline (before the intervention begins), posttest one ( after two month intervention), and posttest two (one month after yoga intervention finish) to evaluate the lasting effect of yoga.
214398704|NCT01628510|DEVICE|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
214398705|NCT01628510|OTHER|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
215003270|NCT00549328|DRUG|Pazopanib (GW786034)|Pazopanib monotherapy
215003271|NCT00770484|DRUG|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
215095479|NCT00370838|DRUG|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
215095480|NCT03196531|DRUG|Loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
214398706|NCT05685680|PROCEDURE|total mesorectal excision in rectal carcinoma|total mesorectal excision laparoscopic versus open technique in management of rectal carcinoma
214398707|NCT04501458|OTHER|Training of youth, community health assistants and community health workers.|Training of youth, community health assistants, and community health workers in the screening, detection, contact tracing, prevention, and management of COVID-19 with concurrent maintenance of essential health services.
214398708|NCT04501458|OTHER|Training clinicians in basic critical care and the management of severe COVID-19 cases|Training clinicians in basic critical care and the management of severe COVID-19 cases with concurrent maintenance of essential health services.
214398709|NCT06445920|OTHER|No Intervention|No Intervention
214398710|NCT01653847|DRUG|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
215003272|NCT00770484|DRUG|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
215003273|NCT00535834|PROCEDURE|diagnostic procedure|
215003274|NCT00535834|PROCEDURE|molecular diagnostic method|
214398711|NCT01653847|DRUG|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is \< 3 ng/mL, or reduced if the trough level is \> 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
214398712|NCT01889160|DRUG|AZD4721 Solution|1-9 mg/mL liquid solution
214398713|NCT01889160|DRUG|AZD4721 Placebo|Liquid solution
215003275|NCT00535834|PROCEDURE|protein expression analysis|
215003276|NCT00523380|DRUG|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
215003277|NCT00523380|DRUG|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
215003278|NCT03963830|BEHAVIORAL|MOVE UP|Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
215003279|NCT02162433|DRUG|Normal Saline|to arms 2,4. Serves as the placebo.
215003280|NCT02162433|DRUG|Dexmedetomidine|to arms 1,3
215003281|NCT05616897|BEHAVIORAL|Physiological responses during sustained CPR|
215003282|NCT02189447|PROCEDURE|Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus|Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
215003283|NCT05183620|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and the outer thigh of the test subject to measure skin temperature during erection
215003284|NCT05463770|DRUG|SEP-363856|SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
215095481|NCT03196531|DRUG|Loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
214398714|NCT01889160|DRUG|AZD4721 Suspension|9 mg/g liquid suspension
214398715|NCT00136903|DRUG|Prochymal® - 2 Million cells/kg|2 million hMSCs/kg actual body weight, IV on study Days 1 and 4
214398716|NCT00136903|DRUG|Prochymal®- 8 Million cells/kg|8 million hMSCs/kg actual body weight IV on study Days 1 and 4
214398717|NCT00136903|DRUG|Methylprednisolone|Methylprednisolone 2 mg/kg administered intravenously.
214398718|NCT00136903|DRUG|Prednisone|Prednisone 2.5 mg/kg administered orally.
214398719|NCT00136903|DRUG|Cyclosporine|Administered as prescribed by the caregiver.
214398720|NCT00136903|DRUG|Tacrolimus|Administered as prescribed by the caregiver.
214398721|NCT00136903|DRUG|Mycophenolate Mofetil|Administered as prescribed by the caregiver.
214398722|NCT04400708|PROCEDURE|adductor canal block|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of 0.5% ropivacaine 15ml is given.
214398723|NCT04400708|PROCEDURE|control group|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of normal saline15ml is given.
214398724|NCT04716595|DRUG|K-877 ER 0.2 mg/day morning administration (once daily)|K-877 ER 0.2 mg tablet
214398725|NCT04716595|DRUG|K-877 ER 0.2 mg/day evening administration (once daily)|K-877 ER 0.2 mg tablet
214398726|NCT02471508|DEVICE|Body-mapping Tank-top Embedded with Biofeedback System|In this study, the eligible subjects will be given tailor-made tank-top embedded with biofeedback system to wear it 8 hours daily. Monitor, observation and additional posture training sessions will be provided during the 6 months wearing period. The effectiveness of the biofeedback tank-top will be evaluated by pre-and post- treatment ultrasonic imaging device (measuring the angle of the spine) and electromyography muscle signal
214398727|NCT00169741|OTHER|Renogram|Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).
214398728|NCT00669747|DRUG|Carboplatin i.d. Days 1 & 15|Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 \& 15
214398729|NCT00669747|DRUG|Carboplatin i.d. Day 1; Normal Saline i.d. Day 15|Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
214398730|NCT00669747|DRUG|Normal Saline|Normal Saline, 10 ml, i.d. on Days 1 and 15
214398731|NCT02264392|PROCEDURE|Ultrasound Guided Incision and Drainage|Ultrasound guidance of the abscess drainage
214398732|NCT02264392|PROCEDURE|Blind Incision and Drainage|Incision and drainage of abscess guided by physical exam alone
214398733|NCT04707391|COMBINATION_PRODUCT|MenABCWY vaccine|2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.
214398734|NCT04707391|COMBINATION_PRODUCT|Placebo|1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group
214398735|NCT04707391|BIOLOGICAL|MenACWY vaccine|1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group
214398736|NCT04707391|COMBINATION_PRODUCT|MenB vaccine|2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.
214503791|NCT07014254|DRUG|177Lu-CTR-FAPI nuclide-targeted therapy|Fasting, special diets, or other specific preparations are not required on the day of 177Lu-CTR-FAPI administration. Patients were given 4 mg ondansetron 30 minutes before treatment to prevent nausea and vomiting. The radiopharmaceutical 177Lu-CTR-FAPI (200 ± 10% mCi) was diluted with 100 mL of 0.9% saline and given slowly by intravenous infusion over 20-30 minutes (flow rate 200 ml/h). Symptoms and vital signs were monitored before and after treatment. The treatment regimen was planned for a maximum of 3 courses of treatment, with 4-8 weeks between each cycle
214503792|NCT07015619|OTHER|Task Specific Balance Training|Group A participants will undergo Task Specific Balance Training. It is a rehabilitation approach that focus on improving balance by practicing specific balance related tasks.
215003285|NCT04680143|DRUG|Systemic erythropoietin injection|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
215003286|NCT01332201|DRUG|Advagraf|oral
215003287|NCT01332201|DRUG|Prograf|oral
215003288|NCT03097315|DRUG|4 mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints
214503793|NCT07015619|OTHER|Task-oriented Basketball Training|Group B participants will undergo Task-oriented Basketball Training. It is a rehabilitation approach that focuses on balance, coordination and gross motor skills through specific basketball related tasks.
215003289|NCT01946802|DEVICE|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
215003290|NCT03890939|DEVICE|BiPAP AutoSV Advanced System One|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
214398737|NCT06175663|DRUG|Antihypertensive medication withdrawal|To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs are known to interfere with this ratio, patients often have to discontinue drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine). Drugs have to be stopped for at least four weeks (for mineralocorticoid receptor antagonists) or two weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly and blood pressure levels drop again.
214398738|NCT03059836|DIETARY_SUPPLEMENT|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
214398739|NCT03059836|DIETARY_SUPPLEMENT|Placebo|Organic Sunflower Oil 5000mg per day
214398740|NCT00000926|DRUG|Nonoxynol-9|
214398741|NCT03246672|BEHAVIORAL|maintenance intervention|Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
214398742|NCT02062411|BEHAVIORAL|CBT only|Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.
214398743|NCT02062411|BEHAVIORAL|CBT with booster sessions|Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.
214398744|NCT04635787|DEVICE|ANNE One|Wireless vital sign monitoring device
214398745|NCT01913964|DRUG|Acetylcarnitine|
214398746|NCT01913964|DRUG|Placebo|(sugar pill)
215003291|NCT03890939|DEVICE|Dreamstation BiPaP AutoSV|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
215003292|NCT03890939|DEVICE|ResMed S7 VPAP Adapt Device|A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
214398747|NCT06261944|DEVICE|Near-infrared (NIR)|Near-infrared assessment of glycated keratin in middle fingernail
214398748|NCT03666065|DRUG|Aspart insulin|Standard insulin
214398749|NCT02430636|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.
214503794|NCT07012564|DIETARY_SUPPLEMENT|Vitamin C|1000 mg oral vitamin C tablet taken daily from one day before surgery to postoperative day 7.
214503795|NCT07012564|OTHER|Placebo|Identical-appearing oral tablet taken on the same schedule as the vitamin C group.
214503796|NCT03816163|DRUG|zolbetuximab|Administered as an intravenous infusion.
214503797|NCT03816163|DRUG|nab-paclitaxel|Administered as an intravenous infusion
214398750|NCT02430636|DEVICE|NanoKnife|
214398751|NCT06340529|OTHER|Clinical Simulation|Carrying out a total of 9 clinical simulation in three days, one day every two weeks, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
214398752|NCT05725343|DRUG|Canakinumab|Canakinumabwill be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
214398753|NCT05725343|DRUG|Placebo|placebo will be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
214398754|NCT01347645|DRUG|FOLFIRI|Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
214398755|NCT01347645|DRUG|E7820|"Test product: dose and mode of administration:~E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study.~The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle)."
214503798|NCT03816163|DRUG|gemcitabine|Administered as an intravenous infusion
215003293|NCT00811109|DEVICE|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
215003294|NCT00811109|DEVICE|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
215003295|NCT00811109|DEVICE|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
215003296|NCT05372939|DRUG|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
215003297|NCT05372939|OTHER|Placebo (oral)|Orally administered placebo comparator taken once daily
215003298|NCT05372939|COMBINATION_PRODUCT|Humira (adalimumab)|Humira comparator is administered subcutaneously, on Humira frequency schedule.
215003299|NCT02112591|PROCEDURE|transobturator subtrigonal tape S-TOT|Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.
215003300|NCT02112591|PROCEDURE|Transobturator suburethral tape (TOT)|Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
214398756|NCT06845683|OTHER|Group A|Progressive wall squat exercises will commence with a knee flexion angle of 135°, instructed to hold this position for 20 seconds, exercise progresses, the knee joint angle will be decreased by 10° until reaching the 95° stage or until participants can no longer maintain the knee joint angle within 5° of the target value due to volitional fatigue. Cognitive tasks during the intervention, including the recall of words and counting forward (1, 4, 7, 10...) and backward (...10, 7, 4, 1) by adding 3 to the digits. Sustained stretching (with a hold time of 10 seconds per stretch, totaling 10 repetitions per session) and active range of motion exercises (10 repetitions per session) targeting both the upper and lower extremities in routine rehabilitation.
215003301|NCT06380608|PROCEDURE|Local anesthesia|Patients who will undergo a dental surgery under local anesthesia
214398757|NCT06845683|OTHER|Group B|Progressive wall squat exercises will commence with a knee flexion angle of 135°, instructed to hold this position for 20 seconds, exercise progresses, the knee joint angle will be decreased by 10° until reaching the 95° stage or until participants can no longer maintain the knee joint angle within 5° of the target value due to volitional fatigue. Sustained stretching (with a hold time of 10 seconds per stretch, totaling 10 repetitions per session) and active range of motion exercises (10 repetitions per session) targeting both the upper and lower extremities in routine rehabilitation.
214398758|NCT01438229|DEVICE|St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)|Catheter-based RF ablation in renal artery
214398759|NCT05186844|BEHAVIORAL|survey application|Scales and questionnaires were applied to children and their parents according to age groups.
214398760|NCT06441019|DRUG|HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab|The patient will receive combined treatment with HAIC, TQB2868, and Ramucirumab. After enrollment, the patient will undergo routine hepatic artery angiography via femoral artery catheterization and placement of a hepatic artery catheter，they will then receive 150ml of 5% sodium bicarbonate + Oxaliplatin (85mg/m2) for 4-6 hours + Raltitrexed (2mg/m2) for 2-4 hours . This will be done every 3-4 weeks for at least 2 cycles. Systemic treatment will be administered every 21 days, with TQB2868 injection given on the first day of each cycle (1-7 days after HAIC). The fixed dose of TQB2868 will be 300mg, and Ramucirumab will be given at a dose of 500mg (initial intravenous infusion for 60 minutes, followed by 30 minutes if tolerated).
215003302|NCT06380608|PROCEDURE|General anesthesia|Patients who will undergo a dental surgery under general anesthesia
215003303|NCT06426407|DRUG|Vasopressin|Fixed dosage vasopressin ordered as an adjunctive vasopressor to norepinephrine
215003304|NCT01567514|PROCEDURE|Glass ionomer cement lining|Resin-modified glass ionomer lining
215003305|NCT06303817|OTHER|Double knots facia closure method during cesarean section|In Group I (double knots group), the edge of the fascia was identified with a Kocher clamp. A synthetic absorbable multifilament suture was used to close the fascia in a continuous fashion, starting from the opposite side up to the Kocher clamp. The knots were tied with the same single suture. I
215003306|NCT06303817|OTHER|Triple knots facia closure method during cesarean section|n Group II (triple knots group), the edge of the fascia was fixed with the same suture material instead of the Kocher clamp. The fascia was closed similarly, starting from the opposite corner via the second loop. The loops from the first suture were tied to the second suture.
215003307|NCT02019251|DRUG|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time with the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
215003308|NCT02019251|DEVICE|MRI|
215003309|NCT04067245|DEVICE|Tetrasodium EDTA catheter lock solution|Home parenteral nutrition patients who meets inclusion criteria is to receive tetrasodium edta catheter lock solution. Patient will receive standard catheter lock solution of heparin/saline for 1 month, followed by tetrasodium EDTA catheter lock solution using withdrawal method for 1 month and followed by tetrasodium EDTA catheter lock solution using flush method for 1 month. In total, patient will stay in the study for 3 months. A phone call will be conducted before the start of the study to give instruction to patient regarding the use of catheter lock solution. Time taken to connect and disconnect TPN will be recorded by patients, twice a month on first and last mondays of the month for 3 months. A survey regarding the ease of use of catheter lock solution will be conducted at the end of each month via phone by nurse coodinator.
215003310|NCT03841292|DRUG|Varenicline|Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
215003311|NCT03841292|DEVICE|Active tDCS|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session
215003312|NCT03841292|DEVICE|Sham tDCS|Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.
215003313|NCT04658589|PROCEDURE|Laparoscopic versus open distal gastrectomy|Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
214398761|NCT01539434|BEHAVIORAL|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
215003314|NCT00993889|BEHAVIORAL|VR during Physical Therapy|Virtual Reality will be performed during a painful physical therapy procedure.
214398762|NCT01539434|BEHAVIORAL|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
214398763|NCT03377075|DEVICE|AL measurement|IOL Master 500 (Carl Zeiss AG, Germany)
214398764|NCT03377075|DEVICE|OCT|Choroidal and retinal thickness measurement (DRI OCT-1 Model Triton (plus), Topcon, Tokyo, Japan)
214398765|NCT02459340|OTHER|therapeutic treatment (inpatient and outpatient setting)|
214398766|NCT05359159|OTHER|Data collection|Data collection
214398767|NCT01163149|DRUG|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
214398768|NCT01163149|DRUG|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
214398769|NCT02758678|BIOLOGICAL|A single 2 ml heparinised peripheral blood sample|A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
214398770|NCT01968161|DRUG|Asenapine|
214398771|NCT01517022|DRUG|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
214398772|NCT04685473|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) Capsule
214398773|NCT06088420|PROCEDURE|Intrathcal Morphine Group|intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs(10-12 mg 0.5% hyperbaric bupivacaine)
214398774|NCT06088420|PROCEDURE|Quadratus Lumborum nerve block(QL) group|intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral QL block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
214398775|NCT06088420|PROCEDURE|Erector Spinae nerve block (ESP)group|intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral ESP block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
214398776|NCT04221477|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
214398777|NCT04221477|DRUG|MMF|MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
214398778|NCT04221477|DRUG|Prednisone|Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
214398779|NCT04221477|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
214398780|NCT04221477|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
214398781|NCT04221477|DRUG|Acetaminophen|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
214398782|NCT04221477|DRUG|Diphenhydramine|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
215003315|NCT00993889|BEHAVIORAL|VR Background Pain|Virtual Reality is used at anytime during the day for the background pain, not during physical therapy.
215003316|NCT00993889|BEHAVIORAL|NO VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
215003317|NCT02080078|DRUG|Theophylline|
215003318|NCT02080078|DRUG|Erlotinib|
215003319|NCT03687697|BIOLOGICAL|Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media|A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
214398783|NCT06074653|OTHER|Mulligan Bent Leg Raise technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given.Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
214398784|NCT06074653|OTHER|PNF Contract Relax technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given. Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
214398785|NCT03983993|DRUG|Niraparib|Given PO
214398786|NCT03983993|BIOLOGICAL|Panitumumab|Given IV
214398787|NCT03867474|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The intervention group will be delivered in a group-based format, for one three-hour session per week for an 8-week period. Each session will consist of mindfulness practice (e.g. lying down body scan, sitting meditation, mindful eating, mindful movements such as walking and light hatha yoga movements) along with an inquiry about the practice. Strategies on stress reactivity, responding to stress, and some basic content on cognitive behaviour therapy principles will also be taught. Participants will be placed in dyads during the group. Homework practice will be given to complete on a daily basis for approximately 30-45 minutes. During week six participants will attend an all-day silent meditation retreat on a Saturday (Total of 10 sessions = 8 sessions, 1 orientation, and 1 all-day retreat).
214398788|NCT01107730|DRUG|Vitamin C|VitC intravenously (2g/day \[500mgX4\] for 2 days prior to surgery, and postoperatively for 4 days
214398789|NCT01107730|DRUG|L-Carnitine|L-Carnitine intravenously (2 gr/day \[1grX2\] for 2 days prior to surgery, and postoperatively for 4 days
214398790|NCT01107730|DRUG|Placebo|Placebo
214398791|NCT01504451|DEVICE|ILR insertion|Insertion of implantable loop recorder
214398792|NCT01504451|PROCEDURE|AF ablation|AF ablation
214398793|NCT02774213|OTHER|Questionnaires completion|
214398794|NCT02774213|OTHER|Clinical Pain Assessments|
215095482|NCT06171646|BEHAVIORAL|breathing exercise|The patients in the intervention group will first be informed by the researcher about pursed lips and diaphragmatic breathing exercises through a face-to-face interview technique, and then the breathing exercises will be taught practically to each patient for approximately 30 minutes, and the first session will be held. Each session takes place once a day in the morning, lasts 10-15 minutes and is applied every day; Sessions other than the first session will consist of 10 pursed lip breathing exercises, relaxation (2 minutes) and 10 diaphragmatic breathing exercises; Three days a week, the researcher will be reminded via online video call once a day in the morning, and on the other days, the patients will be reminded by phone call that they will be asked to do themselves, and breathing exercises will be performed for a total of four weeks.
214398795|NCT02999971|OTHER|circuit class therapy in water|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
214398796|NCT02999971|OTHER|circuit class therapy on land|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
214398797|NCT02543593|DEVICE|Active tDCS or Sham tDCS|tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
214398798|NCT03795779|BIOLOGICAL|CLL1-CD33 cCAR T cells|CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.
214398799|NCT05495061|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 3 months
214398800|NCT05495061|DRUG|Latanoprost ophthalmic solution 0.005%|1 drop Latanoprost ophthalmic solution 0.005% once daily for 3 months
214398801|NCT02638064|PROCEDURE|Surgiflo injection|Curettage of sinus cavity then injection of surgiflo material
215003320|NCT06473818|DEVICE|Non-invasive monitoring|Non-invasive cardiac output monitoring
215003321|NCT06473818|DEVICE|Invasive monitoring|Invasive cardiac output monitoring
215003322|NCT04327271|BEHAVIORAL|Text-based VMMC follow-up|2wT clients will receive automated daily texts from days 1-13. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts or return for any visit by day 14, they will be traced by SMS, phone or home visit. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 21, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
215003323|NCT01251679|BEHAVIORAL|Hand washing|hand washing education and material
215003324|NCT01251679|DEVICE|Hand washing and surgical mask|hand washing education and material and paper surgical face masks
215003325|NCT04645706|OTHER|Characteristics of innate T cells|functional and phenotypic characteristics of innate T cells
215003326|NCT01972828|DRUG|FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
215095483|NCT04046250|DRUG|TK-112690|TK112690 treatment pre-methotrexate treatment
214503799|NCT07009782|PROCEDURE|QIP block|The Quadroiliac Plane (QIP) block is a novel ultrasound-guided fascial plane block. In this study, it will be performed postoperatively under spinal anesthesia in the prone position. A low-frequency convex transducer will be used to visualize the quadratus lumborum muscle at its attachment to the inner iliac crest. Using an in-plane technique with a 22G x 100 mm needle, 40 mL of 0.25% bupivacaine will be injected into the fascial plane beneath the quadratus lumborum muscle. The block will be performed unilaterally on the surgical side. The aim is to provide postoperative analgesia in patients undergoing femur fracture surgery.
214503800|NCT07012382|PROCEDURE|Inferior Alveolar Nerve Block|Administration of standard IANB with 2% lidocaine containing 1:80,000 epinephrine
215095484|NCT04046250|DRUG|Placebo TK-112690|Placebo
215095485|NCT00709878|PROCEDURE|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
214398802|NCT02554435|DEVICE|EAM|The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.
214398803|NCT02554435|BEHAVIORAL|5 A's counseling|Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.
214398804|NCT02554435|DEVICE|Pedometer|The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
214398805|NCT04807829|DRUG|Nabilone|Nabilone is a synthetic endocannabinoid and CB1 agonist.
214398806|NCT04807829|DRUG|Placebo|Inactive placebo comparator
214398807|NCT06428253|DEVICE|HMM1-022|intradermal injection
214398808|NCT06647043|DIETARY_SUPPLEMENT|SMT04 Pro|Consists of a blend of food-grade Bifidobacterium as active probiotics
214398809|NCT05951296|DRUG|Leramistat|Drug: Leramistat
214398810|NCT05951296|DRUG|Placebo|Placebo comparator
214398811|NCT03184662|OTHER|HIPA|"inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months"
214398812|NCT03184662|OTHER|Counseling PA|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
214398813|NCT06084429|OTHER|pre and post test (health educational intervention)|"The health education will be provided the following sessions.~Introduction to Global and Bangladesh Health, Health Information access (Validity), Critical Values (Vital signs, BMI, RBS etc.), Emergency Management (burn, chocking, knife cut, fainting etc.), Food (classification, healthy food, unhealthy, food label, salt intake) (NCDs from unhealthy diet), Smoking and Alcohol (NCD related, substance abuse, secondhand smoking), Physical activity (Benefits, sedentary lifestyle, NCD related), Women's health (menstruation, menstrual cycle, hygiene, STD, contraception), Hygiene (water, food, brushing, bath, toileting, healthy habits), Environmental Sanitation and Communicable disease (clean, effects on health), and Women's health and societal contribution"
214398814|NCT06509464|DEVICE|High intensity interval training|High intensity interval training on treadmill
214398815|NCT06509464|DIETARY_SUPPLEMENT|Caloric restricted diet|Caloric restricted diet
214398816|NCT05814861|DIAGNOSTIC_TEST|culture and PCR|"Stool samples will be cultured inTwo media :~A-Locke egg serum medium (LE) B- Jones' medium Then Molecular identification of Blastocystis hominis using polymerase chain reaction (PCR)."
214398817|NCT03213002|DRUG|Capecitabine|Capecitabine at 1500 mg/m2
214398818|NCT03213002|DRUG|Temozolomide|Temozolomide at 150 mg/m2 - 200 mg/m2
214398819|NCT05687071|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 52 weeks
214398820|NCT05421650|OTHER|CCRT|CCRT
214398821|NCT05421650|PROCEDURE|Surgical debulking of lymph nodes + CCRT|Surgical debulking of lymph nodes + CCRT
214398822|NCT05407311|DRUG|64Cu-SAR-BBN|64Cu-SAR-BBN
214398823|NCT05995431|PROCEDURE|scaling and root planing|All the participants will undergo scaling and root planing
214398824|NCT05995431|PROCEDURE|Subgingival instrumentation|All the participants will undergo subgingival instrumentation
214503801|NCT07012382|PROCEDURE|Inferior-Alveolar-Nerve-Block|Administration of IANB with 2% lidocaine containing 1:80,000 epinephrine
215003327|NCT01972828|DRUG|STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
214398825|NCT04259775|DEVICE|Automated Insulin Dose Adjustment|The system originally developed at Boston Children's Hospital, obtains CGM, insulin delivery, and activity data, from the cloud each day at approximately 8:00 PM using an Application Program Interface (API) calls to commercial companies (primarily Glooko and Tidepool) that aggregate data from different devices used to manage glucose levels in individuals. A detailed statistical and control analysis (see preliminary data study 1 for algorithm details) of the data are then conducted to determine if a change in therapy is required. If the analysis indicates a change in therapy is required, the patient or parent is notified by text or email directing then to a web portal detailing the change. The patient or parent can accept or modify the recommended change. If a change is made, the AIDA system confirms that the change is correctly implemented into the patient's pump or Bluetooth enabled pen when the patient next uploads the device data to the cloud.
214398826|NCT04259775|DEVICE|Control|Standard Care - change in therapy settings effected at regularly scheduled patient visits
214398827|NCT01614574|BIOLOGICAL|velaglucerase alfa|60 U/kg every other week intravenous infusion
214398828|NCT03786484|DRUG|PBF-999|Phosphodiesterase 10 inhibitor (PDE10i)
214398829|NCT00492934|DRUG|human menopausal gonadotrophins|Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation
214398830|NCT01792362|OTHER|Weight loss diet|Control the patients diet to make them loosing weight
214398831|NCT04780217|BIOLOGICAL|T3011|T3011 will be administered through IV drip or pumping.
214398832|NCT04029558|DIETARY_SUPPLEMENT|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
214398833|NCT04029558|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
214398834|NCT00211601|BEHAVIORAL|Disease Management Assessment|
214398835|NCT01923428|DRUG|AZD1722|
214398836|NCT01923428|DRUG|Placebo|
215095486|NCT00334711|DRUG|Sulfonylurea|
215095487|NCT03417934|PROCEDURE|Hip Arthroscopy Procedure|The purpose of this pilot study is to evaluate the effects of hip distraction without a perineal post on the lower extremity during hip arthroscopic procedures by peri-operative monitoring of various prognostic markers for venous, nerve and tissue injury.
215003328|NCT06404528|OTHER|Blood glucose stress combined with low-dose chemotherapy|By controlling the patient's blood sugar, low-dose chemotherapy is used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, produce very strong anticancer effects, and have no cytotoxic reactions to chemotherapy.
214398837|NCT00469781|DRUG|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
214398838|NCT00469781|DRUG|1. Pred Forte|"Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks."
214398839|NCT03997058|OTHER|Auricular point pressure therapy|Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
214398840|NCT03997058|DRUG|Oral estazolam medication|The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
214398841|NCT03230422|DEVICE|normal airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
214398842|NCT03230422|DEVICE|difficult airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
214398843|NCT02550873|BIOLOGICAL|PRM-151|PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
214398844|NCT02550873|OTHER|placebo|Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
214398845|NCT01822353|DIETARY_SUPPLEMENT|Dietary supplement|Milk, egg or nut oral immunotherapy
215003329|NCT03976700|DRUG|Bufei Jianpi granule|Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
215003330|NCT03976700|DRUG|Placebo Bufei Jianpi granule|Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
215003331|NCT04007900|BEHAVIORAL|Positive Affect Treatment|PAT was designed as a 15-week intervention delivered in 3 modules. Module 1 (Pleasant Events Scheduling) uses behavioral activation methods to enhance positive experiencing before, during, and after rewarding events. Module 2 (Attending to the Positive) applies cognitive training techniques to promote shifting attention towards rewarding aspects of daily situations and to learn behavior mood associations. Module 3 (Cultivating the Positive) uses mindfulness approaches to foster reward experiencing. Treatment length has been expanded to 20 sessions to enhance the suitability of the intervention for AN and target the reward mechanisms that characterize AN. Additional adaptations include: 1) An emphasis on a mindful balance between reward and inhibition; 2) Additional module on shifting attention away from AN-specific rewards; 3) Addition of exercises to work towards long-term life goals and enhance healthy experiences; and 4) Further focus on navigating social rewards.
215003332|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
215003333|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
215003334|NCT01554813|BIOLOGICAL|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
215003335|NCT03637374|DEVICE|Visceral Manifold and Thoracic Bifurcation|Endovascular stent graft system
215003336|NCT03637374|DEVICE|Unitary Manifold|Endovascular stent graft system
215003337|NCT03637374|DEVICE|TAAA Debranching Stent Graft System|Endovascular stent graft system
215003338|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6
214398846|NCT05323214|DRUG|Control Analgesic regimen|testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia
214398847|NCT05323214|DRUG|Fentanyl Analgesic regimen|testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia
214398848|NCT05323214|DRUG|Dexmedetomidine Analgesic regimen|testing the efficiency of Dexmedetomidine as an adjuvant drug to bupivacaine in epidural analgesia
214398849|NCT05625919|DRUG|Sirolimus for Injection (Albumin Bound)|Sirolimus for injection (Albumin-bound), intravenously, once a week, 21 days per cycle (two weeks-on and one week-off)
214398850|NCT03003546|OTHER|Laboratory Biomarker Analysis|Correlative studies
215003339|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at the maximum tolerated dose or the maximum administered dose of 2 mcg/kg/day on days 1-5 of cycles 1-6
215003340|NCT03759184|BIOLOGICAL|Obinutuzumab|Intravenous (IV) Obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1: then 1,000 mg on day 4 of each subsequent cycle
215003341|NCT00708669|DEVICE|TAXUS stent|Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
215003342|NCT00708669|DEVICE|Cypher stent|CYPHER stent, approved for commercialization in Japan(March 25, 2004)
215003343|NCT01356810|OTHER|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
215003344|NCT01356810|OTHER|Standard Care|Delirium management by the attending physician's preferences.
215003345|NCT03469804|DRUG|Pembrolizumab|Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
215003346|NCT02662920|OTHER|No Intervention|
214398851|NCT03003546|DRUG|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Given IV
215003347|NCT02504203|BIOLOGICAL|BCG-Denmark 1331 (Statens Serum Institute)|See above
215003348|NCT01479530|DRUG|Placebo|Once daily; tablet; orally; 16 weeks
215003349|NCT01479530|DRUG|Azilect®|1 mg daily; tablet; orally; 16 weeks
215003350|NCT00312611|DEVICE|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
215003351|NCT01995435|DEVICE|Telemedicine refraction|
215003352|NCT01995435|DEVICE|Traditional refraction|
215003353|NCT02905864|DRUG|Liraglutide 3 mg (Saxenda)|
215003354|NCT02905864|DRUG|Liraglutide 3 mg placebo|
215003355|NCT01223677|BEHAVIORAL|Rumination Focused CBT|see arms
215003356|NCT00292994|BEHAVIORAL|Exercise|
215003357|NCT00292994|BEHAVIORAL|Weight Loss|
215003358|NCT04986969|BEHAVIORAL|Online cognitive behavioral therapy|online cognitive behavioral therapy delivered using one of two active methods
215003359|NCT04918628|DRUG|Sintilimab|A humanized anti-PD-1 monoclonal antibody
215003360|NCT02216162|OTHER|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
215003361|NCT02216162|OTHER|No intervention|Usual clinical follow-up
215003362|NCT00608738|OTHER|informational intervention|
215003363|NCT00608738|OTHER|medical chart review|
215003364|NCT00608738|OTHER|questionnaire administration|
215003365|NCT00608738|PROCEDURE|assessment of therapy complications|
215003366|NCT00608738|PROCEDURE|management of therapy complications|
215003367|NCT01457027|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
214398852|NCT03003546|OTHER|Pharmacological Study|Correlative studies
214398853|NCT04268953|DRUG|Tricaprilin|Tricaprilin formulated as AC-SD-03 mixed in 300mL water
215003368|NCT00231192|DRUG|Repaglinide and Insulin|
215003369|NCT00303628|DRUG|oxaliplatin|Given IV
215003370|NCT00303628|DRUG|fluorouracil|Given IV
215003371|NCT00303628|DRUG|leucovorin calcium|Given IV
214398854|NCT04320615|DRUG|Tocilizumab (TCZ)|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.
214398855|NCT04320615|DRUG|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
214398856|NCT04653298|OTHER|Evaluation of quality of life, comorbidities and return to work status|Quality of life will be evaluated thanks to several methods: Short Form 36, EQ 5D 5L and return to work status Questionnaires will be evaluated through postal and phone call at least 12 months after ECMO.
214398857|NCT06206980|OTHER|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about pneumonia pathophysiology, healthy-lifestyle habits, benefits of being physically active, and any questions patients may have would be answered.~Additionally, an exercise program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
215003372|NCT00303628|DRUG|bevacizumab|Given IV
215003373|NCT01899703|DRUG|GSK2330672|GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
215003374|NCT01899703|DRUG|Placebo|Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
215003375|NCT01899703|DRUG|Ursodeoxycholic acid|UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
215003376|NCT00376506|DEVICE|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
215003377|NCT00376506|DEVICE|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
215003378|NCT02040064|DRUG|Gefitinib|Oral tablet
215003379|NCT02040064|DRUG|Tremelimumab|IV
215003380|NCT02962466|OTHER|CC-Test|classification of the oocyte based on the expression pattern observed in the cumulus cells
215003381|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 10|One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
215095488|NCT00922714|DRUG|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
215003382|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 20|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
215003383|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 40|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg
215003384|NCT05007509|BIOLOGICAL|Commercial COVID-19 vaccine|One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
215003385|NCT00032760|BEHAVIORAL|Meditation|
215003386|NCT00689988|BEHAVIORAL|speech-language therapy with AAC intervention|speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
215003387|NCT02819388|BEHAVIORAL|Contraceptive counseling|A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
215003388|NCT04626778|DRUG|Peroxyl Mouthwash|Mouthwash
215003389|NCT04626778|DRUG|Placebo Mouthwash|Mouthwash
215003390|NCT03073057|DRUG|Budesonide/formoterol|2 inhalations as a single dose
215003391|NCT03073057|OTHER|Charcoal|
215003392|NCT03073057|DRUG|Symbicort Turbuhaler|2 inhalations as a single dose
215003393|NCT02211742|DRUG|Dapagliflozin|euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
215003394|NCT04516200|DEVICE|transcranial direct current stimulation and traditional physical therapy program|Transcranial stimulation will be applied only for the study group.
215003395|NCT04516200|OTHER|designed physical therapy program|sensory training and balance training
215003396|NCT05196139|OTHER|retrospective study|vitrectomy performed in case of submacular bleeding
215003397|NCT04787458|DEVICE|abdomen binder (Sejung Korea, Seoul, Republic of Korea)|abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea)
215003398|NCT01430884|OTHER|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
215003399|NCT02843607|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
215003400|NCT02843607|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
215003401|NCT02306785|DRUG|TP05 Coating D|One radio-labelled tablet given to subjects
215003402|NCT02306785|DRUG|TP05 Coating E|One radio-labelled tablet given to subjects
215003403|NCT02306785|DRUG|TP05 Coating H|One radio-labelled tablet given to subjects
215003404|NCT04675281|OTHER|2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks|All specimens are fixed with 4% neutral formaldehyde and embedded in paraffin wax in the department of pathology of each participating centre. Afterwards, all samples are sent for analysis to the department of pathology of Nantes university hospital. All biopsies are independently analysed by a group of pathologists who are experts in lung tissue and blinded to clinical information. All biopsies will be analysed using a predetermined semi-quantitative histological scoring grid. The pathologists are asked to assess the degree of: edema, cell necrosis, hyaline membrane formation, proliferation of alveolar type 2 cells, fibrosis, capillary congestion, alveolar edema, neutrophilic infiltration, and microscopic thrombosis. Finally, the following patterns are recorded: exudative diffuse alveolar damage (DAD), proliferative DAD, fibrosis, intra-alveolar haemorrhage, lymphocytic pneumonia, organizing pneumonia, acute fibrinous organizing pneumonia (AFOP), thrombotic microangiopathy.
215003405|NCT03780387|BIOLOGICAL|Felis Catus|Inhalation of Felis Catus allergen in subjects allergic to Felis Catus
215003406|NCT00002390|DRUG|Abacavir sulfate|
215003407|NCT00776997|DEVICE|Magnetic Sphincter Augmentation|The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
215003408|NCT03803696|BEHAVIORAL|Enhanced Standard Care|"* Baseline data collection, registration and randomization~* Inform primary transplant clinician of sexual dysfunction causing distress~* Receive American Cancer Society sexual educational material"
215003409|NCT03803696|BEHAVIORAL|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~\- 3 Monthly visits with trained study nurse practitioners~* Referral to specialist if~* Psychological etiology~* Sexual Trauma~* Relationship Discord~* Concern for Malignancy or anatomic scarring requiring surgery"
215003410|NCT02948400|BEHAVIORAL|pedestrian safety training in pedestrian virtual environment|pedestrian safety training
215003411|NCT02403271|DRUG|Ibrutinib|BTK Inhibitor
215003412|NCT02403271|DRUG|Durvalumab|Anti PDL-1
215003413|NCT02292225|DRUG|IPI-145 (duvelisib)|25mg and/or 5mg oral capsule
215003414|NCT02292225|DRUG|Obinutuzumab|1000mg/40mL single-use vials
215003415|NCT02450136|DRUG|pazopanib|
215095489|NCT00922714|DRUG|saline (placebo)|NaCl 0.9 g/L
215095490|NCT02166827|DEVICE|NeuroAD|Synchronized TMS and cognitive stimulation to 6 brain areas.
215095491|NCT02166827|DEVICE|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
215095492|NCT00934908|DIETARY_SUPPLEMENT|Green Tea|Green tea capsules taken twice a day.
215095493|NCT00934908|OTHER|Placebo|"Non-active sugar pill."
215095494|NCT04576897|DIAGNOSTIC_TEST|Velacur|Ultrasound elasticity imaging
214503802|NCT07013331|OTHER|[18F]MPPF PET-MRI|"Patients will be seen during an first inclusion visit during which a review of eligibility criteria, medical history and a clinical examination will be done. Participants will be scheduled for a PET-MRI scan within 2 to 8 weeks. For all women of childbearing age a urine pregnancy test will be performed before the PET-MRI.~Anatomical MR imaging will be first acquired for anatomical co-registration and morphometry analyses (Neuromelanin sensitive images and 3D anatomical T1-weighted covering the whole brain volume with 1mm3 cubic voxels) After i.v. injection of a bolus of 180 MBq ± 10%, with a maximum of 198 MBq MBq, of \[18F\]-MPPF, a dynamic emission scan consisting of 35 frames of increasing duration (20s to 5min) will be acquired over 90-min post-injection"
215003416|NCT02193893|OTHER|Biological: Cell-based therapeutics|Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
215003417|NCT02193893|OTHER|Symptomatic treatment of ALS|Symptomatic neurological treatment of ALS
215003418|NCT01193985|DEVICE|TIGR Matrix Surgical Mesh|Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
215003419|NCT05463393|BIOLOGICAL|Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/|The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
215003420|NCT05749185|DEVICE|radiofrequency high voltage|nvolved a high voltage PRF technique, where the voltage started at 65 V and could be adjusted up to 80 V based on patient tolerance. Both protocols involved two cycles of PRF application, with each cycle lasting 240 seconds and comprising alternating periods of current application and deactivation. The pulse rate frequency was set at 2 Hertz (Hz), resulting in two active phases/second (20 milliseconds (ms) of current application followed by 480 ms without stimulation)
215003421|NCT05749185|PROCEDURE|standard RF|A standard voltage PRF technique, administering PRF at a fixed voltage of 45 volts (V)
215003422|NCT05783050|DEVICE|Wei Nasal Jet Tube|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
215003423|NCT05783050|DEVICE|Nasal Cannula Oxygen Support|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
215003424|NCT04092153|DEVICE|Total knee arthroplasy|Surgical implantation of prosthetic knee using robotic-arm assist
214503803|NCT07012902|DRUG|Etomidate|Group A was induced with etomidate, the initial dose was 0.120mg/kg, and the ratio of adjacent doses was 1:0.6
214503804|NCT07012902|DRUG|Remimazolam|Group B was induced with remimazolam, the initial dose was 0.20mg/kg, and the ratio of adjacent doses was 1:0.8
215003425|NCT06511102|BEHAVIORAL|GPT Support|The computer interface used for the essay writing task follows a split-screen design. The writing instructions and text input field are administered on a survey platform, placed on the left half of the screen. ChatGPT is placed on the right half of the screen for technology assistance.
215003426|NCT05650697|BIOLOGICAL|Group 1 cannabidiol (CBD) with silicone ointment|"Vantage Hemp CBD Isolate + Silicone patch The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
215003427|NCT05650697|BIOLOGICAL|Group 2 silicone patch|"Silicone patch Standard of care silicone patch will be used as the control part of the split scar study. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
215003428|NCT06959888|DRUG|ALG-055009|"Single PO dose of 0.7 mg ALG-055009 softgel capsule (formulation 1)~Single PO dose of 0.7 mg ALG-055009 softgel capsule (formulation 2)"
215003429|NCT03487445|DRUG|Selatogrel 8 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
215003430|NCT03487445|DRUG|Selatogrel 16 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
214398858|NCT06206980|OTHER|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional
214398859|NCT01427335|DRUG|calcium|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
214398860|NCT01427335|DRUG|0.9 % saline|0.9 % saline intravenous infusion
214398861|NCT00306904|DRUG|bevasiranib|
214398862|NCT03269448|DIAGNOSTIC_TEST|Peripheral venous blood sampling|Blood collected from peripheral venous (extremities) and central venous (central catheter) for blood gas analyses
214503805|NCT07012902|DRUG|Remimazolam-etomidate|In group C, 0.25ED50 remimazolam +0.75ED50 etomidate was used as the initial measurement In group D, 0.5ED50 remimazolam +0.5ED50 etomidate was used as the initial measurement In group E, 0.75ED50 of remimazolam +0.25ED50 of etomidate was used as the initial measurement
214503806|NCT07013084|BEHAVIORAL|3D VR smoking cessation program|Participants in the experimental group engaged with the VR system using a head-mounted display, allowing for full immersion in the virtual environment.
214503807|NCT07014553|BEHAVIORAL|web based nursing navigator programme|health education guidance surveillance case management
215003431|NCT00474513|DRUG|GSK239512|
215003432|NCT05821478|DRUG|ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy|a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
215003433|NCT05821478|DRUG|Lymecyclin and corresponding placebos of the experimental arm|12-week course of oral lymecycline.
215003434|NCT02252263|DRUG|Elotuzumab|
215003435|NCT02252263|DRUG|Lirilumab|
215003436|NCT02252263|DRUG|Urelumab|
215003437|NCT06415331|PROCEDURE|Pulsed radiofrequency|Individualized dose of pulsed radiofrequency is given for 6 minutes.
215003438|NCT06415331|OTHER|Conventional therapy|"Conventional therapy for HNP consisting of:~* Acetaminophen~* NSAID: Etoricoxib, celecoxib, meloxicam, diclofenac, ibuprofen~* Muscle relaxant: eperisone, diazepam~* Opioid: codein, tramadol~* Adjuvant analgesics: Amitriptyline, pregabalin, gabapentin~* Physiotherapy: Short wave diathermy, ultrasound diathermy, transcutaneous electrical nerve stimulation, and exercise"
215003439|NCT05191784|DRUG|GX-I7|Administered by intramuscular (IM) injection
215003440|NCT05191784|DRUG|Bevacizumab|Administered by intravenous (IV) injection
215003441|NCT00221104|DRUG|Pravastatin|
215003442|NCT00733798|DRUG|131I-TM601|After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
215003443|NCT05803317|OTHER|usual care : Evaluation of walking on a baropodometric platform|Pure observationnal study
214398863|NCT03684005|OTHER|MyPatientPal smartphone app|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
215003444|NCT05969691|DIAGNOSTIC_TEST|Validation of IDH1 mutations from the radiomics model|During surgery, clinicians will select several typical target sites for puncture based on the preoperative model outputs. After surgery, the acquired tumour tissues will be subjected to histological diagnosis and pathological diagnosis by professional pathologists, and the results will be compared with the model output to verify its accuracy.
215003445|NCT03918200|OTHER|Serum amyloid A level|For determination of SAA level, a 5-ml sample of venous blood will be taken from each participant under aseptic conditions, and centrifuged at 2500 g for 15 minutes at 4°C c. separated into serum aliquots,and stored frozen at -80°C until analysis of SAA ,which will be done by a double-antibody sandwich Enzyme Linked Immunosorbent Assay (ELISA) kits supplied by cusabio,USA according to manufacturers instruction .Each sample was tested in duplicate and the average will be taken. A cut off level of 30 mg/L SAA level will be chosen to reflect a real increase in its level
215003446|NCT05011032|DIAGNOSTIC_TEST|Homocysteine|It is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues
215003447|NCT03301714|BEHAVIORAL|Oral Health Education|Group-based oral health education vs Individual-based oral health education using motivational interviewing
215003448|NCT06322498|DIAGNOSTIC_TEST|Uterine lavage|Infusion of 2ml 0.9%NACL into the uterine cavity and aspiration of the fluid
215003449|NCT01194310|PROCEDURE|phaco|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone
215003450|NCT01194310|PROCEDURE|phaco-ELT|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus excimer laser trabeculotomy (ELT)
215003451|NCT01194310|PROCEDURE|phaco-Trabectome|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus Trabectome
215003452|NCT03415269|DRUG|Ambroxol Hydrochloride|single lozenge of 20mg ambroxol
215003453|NCT04055519|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
215003454|NCT04055519|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
215003455|NCT04055519|DEVICE|Multi-purpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
215003456|NCT01709344|BEHAVIORAL|PS-OT|
215003457|NCT01709344|OTHER|Usual care|Supportive and rehabilitation services available at DHMC
215003458|NCT05733299|DEVICE|aflo™ digital respiratory management platform|medical device, user app, clinician portal, data analytics hub
215003459|NCT05733299|OTHER|Standard care|Health service standard care will be continued
215003460|NCT01418898|OTHER|Dietary Intervention|Nutrient fortified oat beverage
215003461|NCT01669850|DEVICE|Clipped anastomosis|The vascular clip devise will be used to complete the anastomosis during fistula creation.
214398864|NCT04702100|OTHER|instrument assisted soft tissue mobilization|the patients will receive instrument-assisted soft tissue mobilization:The subject was seated in a relaxed sitting position. M2T blade was used to find specific areas of restriction on RT upper trapezius. Then treatment plane 1 - 2 and 3 were used.The lubricant (Vaseline) was applied to the skin around the neck area prior to treatment and the tool was cleaned with an alcohol preparation pad. Then by using M2T blade with angle 45, we were giving long slow strokes without causing any discomfort or pain over muscle starting from its insertion up to its origin approximately for 2 to 3 min repeated two times.
215003462|NCT01669850|PROCEDURE|Handsewn anastomosis|a handsewn anastomosis technique will be used during fistula creation.
215003463|NCT01326221|DRUG|tenofovir + emtricitabine|tenofovir 300mg + emtricitabine 200mg x one dose
215003464|NCT04984408|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"* The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~* Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
215003465|NCT04984408|BIOLOGICAL|influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)|"* The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~* Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
215003466|NCT01403584|DEVICE|AutoVPAP with addition of AutoEPAP|Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.
214398865|NCT04702100|OTHER|integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition technique: from supine lying position.we the patients will perform ischemic compression at trigger points then positional release technique and finally muscle energy technique.
214398866|NCT04702100|OTHER|conventional therapy|the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches
215003467|NCT01403584|DEVICE|AutoVPAP with EPAP manually selected|Conventionally applied Expiratory Positive Airway Pressure (EPAP)
214398867|NCT01023880|DRUG|CEP-18770|CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
215003468|NCT02635035|DRUG|Lisdexamfetamine|Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.
215003469|NCT02635035|DRUG|Placebo|Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
215003470|NCT04913636|DEVICE|Treatment Gel|In the evening subjects will perform their regular denture cleaning routine. They will be instructed to sleep without dentures. Subjects will rinse out their mouth with water (if subjects brush their oral mucosa with brush, they will be allowed to continue doing so) and apply the gel to their mucosa where they normally wear upper or lower denture.
215003471|NCT04913636|OTHER|Sham Control|Subjects will perform their regular denture cleaning routine.
215003472|NCT04464447|BEHAVIORAL|Acceptance and Commitment Therapy|"The treatment ACT for Health in Adolescents (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module. Six to eight patients participate in each treatment Group. An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module."
214398868|NCT03356860|DRUG|Paclitaxel|80mg/m2 IV weekly from week 1 to week12
214398869|NCT03356860|DRUG|Epirubicin|90 mg/m2 IV Q 2 weeks from week 14 to week 20
214503808|NCT07017192|PROCEDURE|SIFI Block|Infiltration of local anesthetics in the suprainguinal iliac fascia (Ropivacaine 0.375 40 mls)
214398870|NCT03356860|DRUG|Cyclophosphamide|600 mg/m2 IV Q 2 weeks from week 14 to week 20
214693845|NCT04745793|OTHER|Hyperspectral and Fluobeam acquisition|"Once enough exposure of the operative site is achieved, an RGB (Red Green Blue) picture will be taken and the surgeon will depict the parathyroid glands on it, this picture will act as ground truth. At this point, without changing the surgical exposure, a second surgeon involved in the study will attempt once to detect the parathyroid glands intraoperatively using the HSI system and the Fluobeam® alternatively. The number and the position of the parathyroid glands visualized with each tool will be compared to the number and position of the glands previously visualized by the operating surgeon. The procedure will be repeated every time the surgeon attempts to visualize the parathyroid glands. The order of the detection tools randomized for each case will be preserved in case of repeated visualizations."
215003473|NCT03543774|DRUG|Simvastatin 40mg|Simvastatin mono-therapy at the dose of 40 mg/day for 12 months
214398871|NCT03356860|DRUG|Durvalumab|Durvalumab 1500 mg IV at week 14 and 18
215003474|NCT03543774|DRUG|Ezetimibe/simvastatin 10/20 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months
215003475|NCT03543774|DRUG|Ezetimibe/simvastatin 10/40 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
214398872|NCT03752762|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study will not include sugar.
214398873|NCT03752762|BEHAVIORAL|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits and group sessions.
215003476|NCT01460771|DEVICE|TDCS (Transcranial Direct-current Stimulation)|active TDCS
214398874|NCT01449721|DRUG|Intravenous fluid|0.9% Sodium chloride intravenous fluid
215003477|NCT01460771|DEVICE|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
215003478|NCT02247856|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
215095495|NCT04487561|DEVICE|hemopatch|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
215095496|NCT04487561|PROCEDURE|Aspirative drainage|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
215095497|NCT01961648|DEVICE|Rebreathing bag|
215095498|NCT01961648|DEVICE|Sham rebreathing|
214503809|NCT07017192|PROCEDURE|ESP block|Infiltration of local anesthetics in the fascial plane underneath the erector spoinae mulscle at lumbar level (Ropivacaine 0.375 40 mls)
214503810|NCT07017829|BIOLOGICAL|Anti-CFH Monoclonal Antibody GT103|Given IV
214503811|NCT07017829|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214503812|NCT07017829|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214503813|NCT07017829|PROCEDURE|Computed Tomography|Undergo CT
214503814|NCT07017829|PROCEDURE|Echocardiography Test|Undergo ECHO
214503815|NCT07017829|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215003479|NCT02247856|DEVICE|Jet Nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min"
214398877|NCT01907412|BEHAVIORAL|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
215003480|NCT02247856|DEVICE|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
215003481|NCT04419259|DRUG|AMG 334|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
215003482|NCT04131192|DRUG|Z650|250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
214398878|NCT03490903|DEVICE|Virtual Reality|Subjects undergoing the Virtual Reality Intervention will be fitted with a VR headset and headphones, and undergo an immersive meditation experience provided by AppliedVR, Inc. The headphones will not be noise-cancelling, and the subject will be able to communicate with the physician or circulating nurse if needed.
215003483|NCT04131192|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
215003484|NCT05138757|DRUG|Prebiotic|A prebiotic is a purified fiber of plant origin that has digestive health benefits by fostering the growth of beneficial microbes.
215003485|NCT05138757|DRUG|Placebo|A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.
215003486|NCT05822466|BEHAVIORAL|Virtual tai ji quan: moving for better balance intervention (V-TJQMBB)|This intervention involves a tai ji quan exercise program, named tai ji quan: moving for better balance
215003487|NCT05822466|BEHAVIORAL|Virtual multimodal exercise intervention (V-Multimodal)|This intervention involves a multimodal exercise program that consists of balance, strength, light walking, and stretching exercises
214398879|NCT03490903|DRUG|Fentanyl Injection|Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
215003488|NCT04840719|DEVICE|RECO|
215003489|NCT05324371|DEVICE|Watchman FLX Device|Left atrial appendage closure using the Watchman FLX device
215003490|NCT05838599|DRUG|Imiquimod|5% cream applied topically 5 days/week for 6 weeks
215003491|NCT05838599|RADIATION|Radiation Therapy|2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.
215003492|NCT01166334|BEHAVIORAL|WebQuit study group|Description withheld to protect integrity of study
215003493|NCT01166334|BEHAVIORAL|WebQuit control group|Identity and description withheld to protect integrity of study
215003494|NCT01770964|DRUG|Pregabalin|
215003495|NCT01770964|DRUG|placebo|
215003496|NCT01770964|BEHAVIORAL|Training Type A|
215003497|NCT01770964|BEHAVIORAL|Training Type B|
214503816|NCT07017829|BIOLOGICAL|Pembrolizumab|Given IV
214503817|NCT07011836|BEHAVIORAL|mNav Interactive Video + Navigator|A personalized, video-based tool paired with navigator support to address individual screening barriers.
215003498|NCT02719795|DRUG|Ropivacaine|Local injection of local anesthetic into the fascial spaces
215003499|NCT02719795|DRUG|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
215003500|NCT06099483|OTHER|Action observation and motor imagery|EEG recording was taken while watching a 10-minute video recording of specified breathing exercises and imagining the exercises.
215003501|NCT06099483|OTHER|Active breathing exercise|EEG recording was taken while the physiotherapist performed active breathing exercises for 10 minutes.
215003502|NCT06099483|OTHER|Control group|EEG recording was taken while resting with eyes closed for 10 minutes.
215003503|NCT02883556|DRUG|Pembrolizumab|200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
214398880|NCT03490903|DRUG|Midazolam injection|Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.
214503818|NCT07011836|BEHAVIORAL|Educational Video|A culturally tailored cervical cancer education video without additional support or tailoring.
214503819|NCT07012070|BEHAVIORAL|supervised exercise therapy (SET)|Supervised exercise therapy (SET) is a structured program of exercise designed for individuals with peripheral artery disease (PAD) and intermittent claudication (IC). It consists of 12 weeks of intermittent treadmill walking to moderate to severe claudication pain at a speed of ≈2 mph and at a grade equal to 40% of the highest workload achieved during the baseline maximal treadmill test, with intermittent period of rest, for at least 3 times per week with a minimum of 30-45 minutes per session
215003504|NCT00923312|BIOLOGICAL|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
215003505|NCT03205631|OTHER|Natural Frequency Patch|Participants will receive in randomized order the differing patches to wear during three nights separated by a washout period of 3-4 nights
215003506|NCT02013427|DRUG|Naproxen|Take one 500mg naproxen capsule twice a day.
215003507|NCT02013427|DRUG|Placebo|Take one placebo capsule twice a day.
215003508|NCT02013427|DRUG|Omeprazole|Take one 20mg omeprazole capsule twice a day.
215095499|NCT01961648|DEVICE|Mask|
215003509|NCT02453022|DRUG|Danirixin HBr 50 mg IR Tablet|Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
215003510|NCT02453022|DRUG|Danirixin FB 50 mg IR Tablet|Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
215003511|NCT02453022|DRUG|Prilosec (omeprazole) 40mg Delayed-Release capsule|Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
214398881|NCT03822624|DIETARY_SUPPLEMENT|Probiotic|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.
215003512|NCT03906994|OTHER|Video game Mario Kart Wii|Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior
215003513|NCT00008177|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
215003514|NCT00008177|RADIATION|total-body irradiation|Undergo total-body irradiation
215003515|NCT00008177|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
214522597|NCT01509040|DEVICE|High Volume Hemofiltration|"Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required."
214522598|NCT01580735|DRUG|ARQ 197|"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd"
215003516|NCT00008177|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
215003517|NCT00008177|DRUG|fludarabine phosphate|Given IV
215003518|NCT00008177|DRUG|cyclosporine|Given orally or IV
215003519|NCT00008177|DRUG|mycophenolate mofetil|Given orally or IV
215003520|NCT00008177|OTHER|laboratory biomarker analysis|Correlative studies
215003521|NCT00430365|DRUG|lenalidomide|oral drug
215003522|NCT00430365|DRUG|placebo|oral placebo
215003523|NCT02177357|DRUG|Pramipexole|
215003524|NCT02177357|DRUG|Placebo|
214398882|NCT03822624|OTHER|Placebo|Placebo comparator with maltodextrin as a carrier.
214398883|NCT03171558|PROCEDURE|Gastric Pull Up|Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.
214398884|NCT03171558|PROCEDURE|Free Flap Surgery|Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
215003525|NCT04801082|DRUG|Alcohol injection|Chemical ablation is performed by injection of 10 mL of 0.25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol using a 22G FNA needle (Cook and Olympus)
215003526|NCT04801082|DEVICE|Radiofrequency Ablation|coeliac plexus is identified and punctured with 19G EUSRA RFA needle with 10W-30W of energy for 10-50s bilaterally or unilaterally depends on individual anatomical characteristics.
215003527|NCT05779644|DRUG|Liraglutide|Liraglutide is injected once a day.
215003528|NCT05779644|DRUG|Semaglutide|Semaglutide is injected once a week.
215003529|NCT05779644|DRUG|Metformin|Metformin is taken orally daily.
215003530|NCT00331487|DRUG|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
215003531|NCT00331487|DRUG|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
215003532|NCT03411551|PROCEDURE|regional anesthesia|The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
215003533|NCT02797730|BEHAVIORAL|art-therapy sessions|
215003534|NCT01653886|OTHER|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
214398885|NCT04159961|DRUG|DWJ211|Inject the Drug into submental fat and abdominal fat via subcutaneous
214398886|NCT01216982|DRUG|Lovaza, omega-3 fatty acid ethyl ester|Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
214398887|NCT01216982|DRUG|Placebo, visually identical to Lovaza|Three 1g corn oil capsules/day for three months
214398888|NCT02793635|DEVICE|Indego Powered Exoskeleton|Subjects who have Spinal Cord Injury will wear the Indego device which will include being trained and evaluated for fifteen (15) sessions.
214398889|NCT01672450|DRUG|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
215003535|NCT01653886|OTHER|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
215003536|NCT01653886|OTHER|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
215003537|NCT07115355|PROCEDURE|Removable Uterine Compression Suture (RUCS)|Removable Uterine Compression Suture (RUCS) is a uterus-preserving surgical technique used to control postpartum hemorrhage (PPH) when medical management fails. The suture is placed in a way that allows for its removal after hemostasis is achieved, potentially reducing the risk of complications such as intrauterine synechiae. In this study, RUCS was applied to 11 patients following delivery-related hemorrhage.
214398890|NCT00885495|DRUG|darunavir, ritonavir, rosuvastatin|darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
214398891|NCT00885495|DRUG|rosuvastatin, darunavir, ritonavir|rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
214398892|NCT01400893|DEVICE|SCD|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
214398893|NCT05806099|DRUG|MBS303|"Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg \~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7.~Phase Ⅱ: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7"
214398894|NCT06129695|PROCEDURE|Zygomatic implants|the ideal way to support implant-based restorative procedures for full and partially edentulous patients who are missing bone in the upper posterior maxilla.
215003538|NCT07115784|DRUG|Chlorhexidine Varnish|A 40% chlorhexidine varnish formulation (40% chlorhexidine, 36% sandarac, 24% ethanol) applied topically to the buccal surfaces of teeth in the selected upper quadrant. The varnish is applied using a blunt needle syringe before bonding and at monthly follow-up visits for three months. Teeth are dried before application, and patients are instructed not to eat or drink for 3 hours and to avoid brushing until the next day.
215003539|NCT07115784|DRUG|Placebo Varnish|A placebo varnish composed of 60% sandarac and 40% ethanol applied topically in the same manner and frequency as the chlorhexidine varnish. Used on the opposite quadrant of the same patient in a split-mouth design. Participants are blinded to whether chlorhexidine or placebo was applied.
215003540|NCT07114835|PROCEDURE|Cycling with Blood Flow Restriction (15 min at 40% VO₂max with 60-80% LOP)|This intervention involves low-intensity cycling exercise at 40% of VO₂max performed on an electronically braked Astrand cycle ergometer for 15 minutes per session. During each session, pneumatic cuffs (10 cm wide, manually adjustable) are applied to the upper thighs to restrict blood flow. Individualized limb occlusion pressure (LOP) is determined via Doppler ultrasound and set progressively at 60% (weeks 1-4), 70% (weeks 5-7), and 80% (weeks 8-9). Sessions are conducted three times per week over a 9-week period. The aim is to simulate the physiological effects of high-intensity training using a low-intensity protocol.
215003541|NCT07114835|PROCEDURE|Cycling Exercise (40 min at 40% VO₂max)|This intervention involves standard low-intensity cycling exercise at 40% of the participant's VO₂max, performed for 40 minutes per session on an electronically braked Astrand cycle ergometer. Sessions are conducted three times per week for a total duration of 9 weeks. This group does not receive any blood flow restriction or external loading. The aim is to observe the effects of traditional low-intensity, long-duration aerobic exercise on VO₂max, muscle strength, and muscle thickness.
215003542|NCT07114835|PROCEDURE|Short-Duration Cycling Control (15 min at 40% VO₂max)|This intervention involves low-intensity cycling exercise at 40% of VO₂max performed for 15 minutes per session, using an electronically braked Astrand cycle ergometer. Participants exercise three times per week for 9 weeks. No blood flow restriction is applied. The aim of this control condition is to match the duration of the BFR intervention while omitting the occlusion component, to isolate the effect of BFR.
215003543|NCT07116421|DRUG|2-phenylethanol rose scent|"Name: 2-phenylethanol (rose scent). Dose: 3 drops, diffused into room air over 24 hours. Frequency: Once over 24 hours. Route of administration: Essential oil diffuser. Manufactured by: The Essential Oil Company in Portland, OR. Manufacturing details: The rose scent is purified by hydrodistillation, shelf-stable, and in terms of verification of quality has been previously used in a peer-reviewed and IRB-approved study by Woo et al (2023) published in Frontiers in Neuroscience. Preparation: The Key Personnel listed in the study's IRB will prepare the rose essential oil scent by squeezing 3 drops of the product from the manufactured bottle into the essential oil compartment of the Aroma Ace™ MINI Diffuser essential oil diffuser, corresponding with both the rose essential oil and diffuser manufacturers' instructions for each product respectively."
215003544|NCT07114302|BEHAVIORAL|Interactive E-book BBTI Group|Researchers will guide you on how to use the interactive e-book and help install it on your smartphone. Over the next four weeks, you will be asked to record your sleep diary daily. You will use the e-book to perform sleep stimulus control, sleep restriction, and relaxation techniques to promote better sleep. Researchers will contact you via LINE during the second and fourth weeks, and may call you if necessary.
215095500|NCT06431230|BEHAVIORAL|standard high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. It is based on the standard physical exercises: squats, push-ups, sit-ups, toe-touches, mountain climber, jumping jacks, standing abs twist and squat to side.
214398895|NCT04387162|BEHAVIORAL|Prism Adaptation Treatment|Spatial retraining treatment
214398896|NCT03227484|DRUG|Empagliflozin 25mg|Once daily over 8 weeks
214398897|NCT03227484|DRUG|Placebo Oral Tablet|Once daily over 8 weeks
215003545|NCT07114302|BEHAVIORAL|BBTI-APP Group|Researchers will assist you in creating an account for the mobile application and will explain the interface and how to operate it. Over the next four weeks, you will be asked to record your sleep diary daily. You will use the mobile app to carry out sleep stimulus control, sleep restriction, and relaxation techniques to improve sleep. Researchers will contact you via LINE during the second and fourth weeks, and may call you if necessary.
214398898|NCT03171168|DEVICE|AposTherapy|AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).
214398899|NCT03171168|OTHER|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
214398900|NCT03786094|DRUG|Eribulin|Eribulin alone
214398901|NCT03786094|DRUG|Balixafortide|Balixafortide + Eribulin
214398902|NCT00670982|DRUG|bevacizumab|Given intravenously every 2 weeks
214398903|NCT00670982|DRUG|vinorelbine|Given intravenously once a week
214398904|NCT00670982|DRUG|trastuzumab|Given intravenously once a week
214398905|NCT03954496|DEVICE|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
214398906|NCT03954496|BEHAVIORAL|Intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills the participant wants to regain.
214398907|NCT00277589|DRUG|Levothyroxin-Na|1 tablet 30 minutes before breakfast
214398908|NCT00277589|DRUG|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
214398909|NCT00277589|DRUG|Iodide|1 tablet 30 minutes before breakfast
214398910|NCT00277589|DRUG|Placebo|1 tablet 30 minutes before breakfast
214398911|NCT03396536|OTHER|Evaluation of KM|"KM will be evaluated. The alveolar mucosa will be stained with Lugol's solution, by means of a cotton swab. A cotton roll will be soaked in the solution and gently applied on the mucosa around the implant. Since Lugol's solution is selective to the glycogen present in AM, the muco-gingival junction as the borderline between the blue-stained alveolar mucosa and KM can be easily identified.~A manual periodontal probe with 1 mm markings will measure the distance from the peri-implant margin and the muco-gingival junction.~Mucosal thickness (MT) will be measured after topical application of the anesthetics. MT will be evaluated inserting a 27G needle with a rubber stop 1 mm below the peri-implant mucosal margin at the mid-buccal aspect, until the abutment is engaged. The needle will be removed and the distance between the rubber stop and the point of the needle will be measured with a manual periodontal probe."
214398912|NCT02600182|DEVICE|Bilevel Positive Airway Pressure|Bilevel positive airway pressure twice per day during the hospital stay.
214398913|NCT02788136|DRUG|human chorionic gonadotropin|At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
214398914|NCT04628416|DEVICE|PICO dressing|Use of a portative miniature negative pressure dressing system named PICO® on the split-thickness skin graft of fibula free flap donor sites
214398915|NCT04628416|DEVICE|Conventional dressing|use of a conventional dressing (parrafin gauze) on the split-thickness skin graft of fibula free flap donor sites
214503820|NCT07012070|DEVICE|Wearable activities monitor (WAM)|The WAM use in this study is the FitBit Inspire 3 Advanced Activity Tracker (FitBit Inc. San Francisco, CA, USA), which is a commercially available tri-axis accelerometer and heart rate monitor capable of continuous monitoring of heart rate using LED sensor, and activities including daily steps count and derived daily activity level, detection of arrythmia and measuring peripheral capillary oxygen saturation. Fitbit devices connect with HOBBIT-PAD platform which was developed specifically for patients with PAD based on user-centred design. It contains patient education information, instruction for exercise, activity record, and embedded messaging function between the patient and the research team about any technical and clinical issue. Important and thorough customizations will be made to tailor this mobile health platform for this study, which includes the addition of patient education materials on PAD and its management, tips on health eating and lifestyle, and tips on exercise.
214503821|NCT07012070|BEHAVIORAL|enhanced HBET|Instructions for HBET are programmed according to the AHA recommendation on the exercise programs for patients with PAD and are automatically generated by the mobile apps. Patients will be prompted to use the exercise function on the mobile apps at least 3 times per week. Once the exercise function is activated, it will extract the steps counts and the walking pace from the WAM during exercise. Patients will be instructed to walk to maximal claudication symptom before stopping, at which point they will press pause on the WAM which will mark the claudication onset time. After the claudication subside, they can resume walking and resume recording on their WAM. Each exercise session will last for 45 minutes excluding rest periods, but the subject can terminate the exercise before the session ends.
215121426|NCT06042634|BEHAVIORAL|Online psychoeducation|Online psychoeducation aimed to enhance the knowledge and skill of family caregivers of people with dementia, who could not physically attend in-person class. Knowledge covering dementia caregiving including disease nature, communication skill, stress and coping, daily care, management of behavioral and psychological symptoms of dementia, and future planning. The intervention provided opportunities to practice through simulation and weekly home assignment. There was a total of 6 sessions and provided weekly. Each session lasted for 2 hours. Participants had discussion with peers and coached by a facilitator. Online psychoeducation wad delivered via Zoom videoconferencing.
214398916|NCT02344836|BEHAVIORAL|Podcast + mobile diet app|Use of a mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
214398917|NCT02344836|BEHAVIORAL|Podcast + theory-based mobile diet app|Use of a theory-based mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
214398918|NCT02654379|BIOLOGICAL|Rituximab|Rituximab use in non-oncology indications
214398919|NCT02320721|DRUG|Insulin Glargine (HOE901 - U300)|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
214398920|NCT02320721|DRUG|Insulin Glargine (HOE901 - U100)|Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
214398921|NCT02320721|DRUG|Background therapy|Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
214398922|NCT04630756|DRUG|AZD4573|AZD4573 will be administered as an absolute (flat) dose, 2-hour (± 15 minutes) IV infusion once weekly (as monotherapy for Module 2 only) and in combination with orally administered acalabrutinib twice daily continuously. For both Part A and Part B of this study, Cycle 1 consists of 5 weeks, with a dose ramp-up. Subsequent cycles are 21 days (3 weeks) with once weekly dosing of AZD4573 in combination with acalabrutinib twice daily continuously (in Module 1 and Module 2, period 2).
214398923|NCT04630756|DRUG|Acalabrutinib|Oral Acalabrutinib capsule will be administered twice daily continuously from Day 1 of Cycle 1 Week 1 in combination with AZD4573.
214398924|NCT05965167|DRUG|EBP05|Oral tablets
214398925|NCT05965167|DRUG|Forteo 20 mg|Subcutaneous injection
214503822|NCT07012070|BEHAVIORAL|Mobile application|The mobile apps and mobile platform are adopted from the HOBBIT-PAD platform prototype that was developed specifically for patients with PAD based on user-centred design. This platform contains patient education information, instruction for exercise, activity record, and embedded messaging function between the patient and the research team about any technical and clinical issue. The source code for this platform is publicly available. Important customization will be made to tailor this mobile health platform for this study, which includes addition of patient education materials on PAD and its management, tips on health eating and lifestyle, and tips on exercise. These materials are adopted from the patient education materials available on the Hospital Authority and the AHA website. This information will be periodically sent to the subject's mobile device as a push notification to help them better understand their disease and to promote independent self-care and healthy lifestyle.
214503823|NCT07015437|DEVICE|INTERCEPT Blood System for RBCs|RBCs treated with the INTERCEPT Blood System for RBCs
214503824|NCT07015437|OTHER|Infusion of autologous radiolabeled RBCs|Subject will receive a single intravenous infusion of approximately 10 to 30 mL of autologous Day 35 51Cr radiolabeled RBCs and fresh 99mTc RBCs.
215003546|NCT07116980|DEVICE|'Transcranial Direct Current Stimulation - tDCS|"Participants will receive by trained personnel, transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex (DLPFC). According to the international 10-20 EEG system, the anodal electrode will be placed over the left F3 position and the cathodal electrode over the right F4 position. Active stimulation will be delivered using a constant current of 2 milliamperes (mA) for 20 minutes per session. The intervention will consist of twelve consecutive daily sessions (Monday to Friday), totaling four week of treatment. A certified tDCS device will be used, programmed to deliver a ramp-up and ramp-down period of 30 seconds.~In the sham condition, the same electrode montage will be used; however, the device will automatically ramp down the current after 30 seconds, mimicking the initial tingling sensation without producing lasting neuromodulatory effects. This sham protocol is commonly used to ensure participant blinding in tDCS studies."
215003547|NCT07114640|DRUG|Mirabegron 25mg|Taking 25 mg mirabegron in the nighttime
215003548|NCT07114640|DRUG|Solifenacin 5 mg|Taking 5 mg solifenacin in the nighttime
215003549|NCT07114640|DRUG|Tolterodine 4 mg|Taking 5 mg tolterodine in the nighttime
215003550|NCT07114640|DRUG|Oxybutynin ER 5 mg|Taking 5 mg oxybutynin ER in the nighttime
215003551|NCT07118826|BEHAVIORAL|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
215003552|NCT07118826|BEHAVIORAL|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
215003553|NCT07116850|DEVICE|Intermittent Theta-Burst Stimulation (iTBS)|Stimulation delivered using a Magstim RAPID2 stimulator. The target was the left DLPFC (F3 position). The protocol consisted of 20 sessions (5 days/week for 4 weeks) at 100% of the individual's motor threshold (MT), with each session delivering 2400 pulses.
215003554|NCT07116850|DRUG|Risperidone|Oral risperidone (Jiangsu Enhua Pharmaceutical Co., Ltd.) initiated at 1 mg/day and flexibly titrated based on efficacy and tolerability to a maximum of 6 mg/day.
215003555|NCT07116850|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Manualized CBT administered twice weekly for 12 weeks. The therapy comprised an initial individual phase (4 weeks) focusing on psychoeducation and a subsequent group phase (8 weeks) targeting social and emotional skills.
215003556|NCT07118735|DIETARY_SUPPLEMENT|A standardized extract of cultured Lentinula edodes mycelia (AHCC®)|3 grams of AHCC® taken orally once daily for 6 months or until disease progression or intolerance
215003557|NCT07118735|DIETARY_SUPPLEMENT|Placebo|3 grams of dextrin (placebo) taken orally once daily for 6 months or until disease progression or intolerance
215003558|NCT07119138|BEHAVIORAL|Emotional Freedom Technique|"Emotional Freedom Technique (EFT) is used as an effective method for managing various adverse conditions, including the reduction of exam anxiety. Although there are several studies in the literature on this topic, research conducted specifically with nursing students remains limited. In particular, the Surgical Nursing course is a fundamental subject offered in the second year of nursing education, encompassing both theoretical and clinical components. Academic success in this course is an important indicator of the quality of nursing education. Therefore, as a surgical nursing instructor, it is believed that reducing exam anxiety can positively influence student performance.~This study also aims to improve student success through anxiety management. To date, no studies addressing this issue with nursing students have been found in the literature."
214398926|NCT05965167|DRUG|EBP11|Oral tablets
214398927|NCT05965167|DRUG|EBP22|Oral tablets
214398928|NCT01412814|DEVICE|AposTherapy Biomechanical System|The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
214398929|NCT01412814|OTHER|Physical Therapy Program|Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
214398930|NCT04464837|DEVICE|Cold Snare Polypectomy of intermediate sized polyps (10-15 mm)|If an eligible polyp (10-15mm) is found, cold snare polypectomy is performed with the Olympus SnareMaster® Plus Snare
214398931|NCT00996580|DRUG|DR-103|"One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE."
215003559|NCT07116902|DEVICE|phone application|Participants in the digital twin arm will receive information on their disease progression which will be based on projected change in HbA1C in alternative realities and specific recommendations on medication dosing and lifestyle changes based on this data. The digital twin information will be presented on an iPad in a game- like manner. The alternate realities will include scenarios of change in medication adherence, physical activity metrics, dietary changes etc.
215003560|NCT07116902|OTHER|Standard of Care (SOC)|Participants in the control arm will receive standard of care which is medication change recommendations based on HbA1C and blood glucose values every 3 months and standard lifestyle education.
215003561|NCT07119502|OTHER|Minimal-equipment progressive resistance training|The intervention consists of resistance training exercises that target major upper and lower body muscle groups with the use of portable equipment such as resistance bands and wrist/ankle weights. The exercise dosage will be progressively increased across the 16 weeks to achieve training adaptations. The exercise programme will be conducted three times per week, with each session lasting approximately 30 to 45 minutes.
215003562|NCT07121270|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is delivered via 6 weekly 60-min sessions via telemedicine. CBT-I is a multisession treatment approach that focuses on sleep-specific behaviors and thoughts through various methods.
214398932|NCT03072758|BEHAVIORAL|Men's Club|"Interactive session: This will be a one-day five-hour session that will take place at the church, and will be facilitated by trained lactation nurses. This will involve a maximum of 10 male participants and will occur during the female partner's 3rd trimester. Male partners will (a) complete a structured questionnaire to determine baseline knowledge, attitudes and beliefs about breastfeeding practices, and (b) actively engage in educational information on the benefit of exclusive breastfeeding. At the end of the session, the participants will receive educational pamphlets on breastfeeding to reinforce all the information that had been provided.~Phone call reminders: Participants will receive weekly robocalls during the first six weeks following the birth of the infant to reinforce the benefits of exclusive breastfeeding. This will be an automated service that will deliver the calls at a specific time of the day the participants have indicated on their questionnaire."
214398933|NCT00553020|DRUG|Insulin glargine|"Lantus (commercial formulation, Reference):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)~NPH-insulin (Protaphan) (Test):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"
214398934|NCT03084939|BIOLOGICAL|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
214398935|NCT03084939|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
214398936|NCT03084939|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
214398937|NCT00696163|DRUG|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
214398938|NCT04013490|DIETARY_SUPPLEMENT|Cassava dietary fiber capsule|Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
214398939|NCT02036515|DRUG|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
214398940|NCT02036515|DRUG|Ertugliflozin 15 mg|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
215121427|NCT06042634|BEHAVIORAL|Face-to-face psychoeducation|Face-to-face psychoeducation has the same content and flow of presentation as online psychoeducation.
215121428|NCT00091091|OTHER|medical chart review|
215121429|NCT00091091|OTHER|questionnaire administration|
215121430|NCT00091091|PROCEDURE|management of therapy complications|
215121431|NCT01751100|BEHAVIORAL|HIV Test Offer|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
215121432|NCT01751100|BEHAVIORAL|General Health Screen Offer|A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
215121433|NCT03285269|DIAGNOSTIC_TEST|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
214398941|NCT02036515|DRUG|Placebo for ertugliflozin 5 mg|Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
214398942|NCT02036515|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
214398943|NCT02036515|DRUG|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
214522599|NCT02725359|DRUG|Placebo|Group Placebo: will receive a placebo pill 1 hour before surgery
215121434|NCT03285269|DEVICE|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
215003563|NCT07121270|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia and Nightmares|Cognitive Behavioral Therapy for Insomnia and Nightmares (CBT-I\&N) is a combination of CBT for Insomnia (CBT-I) and Exposure, Relaxation, and Rescripting Therapy used for the treatment of nightmares (ERRT). CBT-I\&N is delivered via 6 weekly 60-min sessions via telemedicine and includes the modification of sleep habits, exposure, and progressive muscle relaxation.
215003564|NCT07121270|BEHAVIORAL|Sleep Education|Sleep education is delivered via telemedicine via 6 weekly 60-min sessions. These sessions will be focused on psychoeducation on sleep after trauma, including common sleep disturbances that may emerge and sleep hygiene guidelines to minimize these disruptions (e.g., wind-down routine, avoid caffeine).
215003565|NCT07121270|BEHAVIORAL|Sleep Education enhanced with Nightmare Education|Sleep education enhanced with nightmare education will include all the components of normal sleep education, as described above, in addition to normalizing the experience of nightmares after trauma and providing psychoeducation on nightmares. The treatment is provided over 6 weekly 60-min sessions via telemedicine.
215003566|NCT07121075|DEVICE|Dynamic arm support|The participant will receive a new dynamic arm support.
215003567|NCT07118566|PROCEDURE|Hyperthermia|Each session of hyperthermia should be spaced at least 24 hours apart, with at least one session administered prior to ICI (immune checkpoint inhibitor) treatment. Five times q3w.
215003568|NCT07118566|DRUG|Immunotherapy|iv，d1，q3w
215003569|NCT07119463|DRUG|Human Serum Albumin Infusion for LAT Group|Participants in this group will receive human serum albumin infusion when their serum albumin level falls below 25 g/L. The infusion is goal-oriented, with the aim of maintaining albumin levels above 25 g/L during the postoperative period. The dose is calculated based on the albumin deficit and patient weight to ensure optimal therapeutic effect.
215003570|NCT07119463|DRUG|Human Serum Albumin Infusion for HAT Group|Participants in this group will receive human serum albumin infusion when their serum albumin level falls below 30 g/L. The intervention aims to maintain albumin levels above 30 g/L during the postoperative period. The dose is similarly calculated based on the albumin deficit and patient weight.
215003571|NCT07121829|DRUG|Tovorafenib|Tovorafenib tablet for oral use.
215003572|NCT07121829|DRUG|Tovorafenib Drug: Pimasertib|Tovorafenib tablet for oral use. Pimasertib capsule for oral use
215003573|NCT07123766|DEVICE|PoliaValve (Aortic)|Aortic Valve Replacement
215003574|NCT07124026|OTHER|No Intervention: Observational Cohort|No intervention
215003575|NCT07125313|BEHAVIORAL|YOGA|The participants randomized to the yoga group will perform 16 weeks of yoga training, three times/week for 60 minutes.
215003576|NCT07125313|BEHAVIORAL|Control|Usual care
215003577|NCT07124416|OTHER|No intervention|No intervention: observational case-control study
215003578|NCT06748547|PROCEDURE|scalp nerve block|scalp nerve block is performed bilaterally by an anesthesiologist after induction of anesthesia and 5 minutes before head immobilization, according to the technique described by Pinosky et al. Prepare a syringe (20 mL) for scalp blocks. It is performed using 0.35% bupivacaine and 5 mcg epinephrine (1:2,000,000) using a 23-gauge needle inserted at a 45° angle to the skin and penetrating deeply into the outer edge of the scalp.
215003579|NCT00851487|DRUG|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
215003580|NCT00851487|DRUG|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
215003581|NCT04377295|DRUG|Ranibizumab 0.5Mg/0.05Ml Oph Inj|All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography
215003582|NCT01173172|RADIATION|Boron Neutron Capture Therapy|Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
215003583|NCT04792892|OTHER|Questionnaires|Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months
215003584|NCT06514131|PROCEDURE|Pre-moistened wipes|Patients receiving the experimental treatment will have perineal hygiene performed with the pre-moistened wipes without water
215003585|NCT01741870|DIETARY_SUPPLEMENT|Nutritional supplement|Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
214398944|NCT02036515|DRUG|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
214398945|NCT02036515|BIOLOGICAL|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
214398946|NCT02036515|DRUG|Placebo for ertugliflozin 10 mg|Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
214398947|NCT03621982|DRUG|ADCT-301|intravenous infusion
214398948|NCT03621982|BIOLOGICAL|Pembrolizumab|intravenous infusion
214398949|NCT04547426|OTHER|Wine with or without alcohol and snuff with or without nicotine|Two by two factorial of wine and snuff with meals
214398950|NCT05733819|DEVICE|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
214398951|NCT05733819|BEHAVIORAL|Active Walking|Walking without RAS cueing
214398952|NCT00859131|DRUG|Rabbit Antithymocyte globulin|1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4
214398953|NCT00859131|DRUG|Daclizumab|1.0 mg/kg pre-op and 1.0 mg/kg on Day 7
214398954|NCT03781713|OTHER|KDIGO|Interventions to prevent renal replacement therapy
214398955|NCT03781713|OTHER|Delta SOFA|interventions to improve SOFA score
215003586|NCT01741870|OTHER|Treatment as usual|routine care
215003587|NCT00112164|DRUG|Xigris|
215003588|NCT07115615|DEVICE|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
215121435|NCT03285269|PROCEDURE|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
215121436|NCT02335307|GENETIC|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
215003589|NCT07115615|DEVICE|Sham tDCS|To demonstrate the same stimulation sensation as under real conditions, only 40 seconds of real stimulation (2mA) are given at the beginning of the treatment. In the remaining 20 minutes, only about 15ms of short current pulses of 110uA occur every 550ms.
215003590|NCT07117032|OTHER|Simulation-free workflow|Pre-existing diagnostic images (CTs, PET/CTs, or MRIs) will be imported into the online treatment planning system called Ethos. The Ethos platform and online adaptive radiation therapy (ART) will be utilized at the time of treatment planning and delivery.
214398956|NCT03781713|COMBINATION_PRODUCT|Hypoglycemia|Interventions to prevent new episodes of hypoglycemia in the next 24 hours
215003591|NCT07117032|RADIATION|Celiac plexus SBRT|Participants will receive SBRT per standard of care. This treatment visit will take up to 1.5 hours.
215003592|NCT07124572|OTHER|Imaging and ocular examinations|"2D and 3D Facial photography, blinking videos, orbital CT and MRI images, fundus images and images of nine gaze positions are taken.~Clinical information is recorded. Quality of life is assessed. Ocular examinations, such as visual acuity, levator function, exophthalmos measurement, strabismus test, visual field examination, axial length measurement, OCT, OCTA are made."
215003593|NCT07125196|OTHER|Data collection and self-administered questionnaire|Exhaustive collection of data in a health data warehouse: collection of clinical, radiological examinations (standard of care), and self-administered questionnaire: a questionnaire concerning the psychological state of the patients (questionnaire according to DSM V) and a questionnaire on nutritional status.
215003594|NCT07122739|BEHAVIORAL|Active Real-time fMRI Neurofeedback|Active neurofeedback to target a functional connection associated with increased memory control ability
215003595|NCT07122739|BEHAVIORAL|Sham Real-time fMRI neurofeedback|Sham neurofeedback
215003596|NCT06928597|PROCEDURE|Global Postural Reeducation|"Global Postural Reeducation, better known as GPR, was developed by Philippe Souchard in the 1980s and involves a sequence of postures or treatment positions, including the main ones: frog on the ground with arms open; frog on the ground with arms closed; frog in the air with arms open; frog in the air with arms closed; standing against the wall; standing at the center; anterior tilt sitting; anterior tilt standing.~GPR is based on the concept of proprioception and inhibition. Souchard (2016) describes RPG as a proprioceptive method of inhibition, where proprioception refers to the body's ability to perceive its position in space, and inhibition refers to the muscle relaxation induced after intense contraction. This principle is applied through the postures and techniques used in treatment, aiming to correct postural deviations, promote one bigger conscious body, and relieve pain."
215003597|NCT06928597|PROCEDURE|Global Postural Reeducation Sham|Global Postural Reeducation Sham is the comparator group.
215003598|NCT07118007|OTHER|adapted physical activity|adapted physical activity for 30 to 45 minutes twice per week
215003599|NCT07104669|OTHER|diet|diet adherence
215003600|NCT07104669|OTHER|Physical activity|Physical activity level
215003601|NCT07104669|OTHER|body composition|body composition assessment
215003602|NCT07104669|OTHER|hydration status|hydration status assessment
215003603|NCT07104669|OTHER|health status|perception of health status
215003604|NCT07120555|DEVICE|atherectomy|Conventional balloon angioplasty remains a first-line endovascular treatment but is limited by high restenosis and vessel recoil rates. Atherectomy, a plaque debulking technique, aims to improve luminal gain and vessel compliance prior to angioplasty, potentially enhancing outcomes in heavily calcified lesions. The combination of atherectomy and balloon angioplasty has shown promise in reducing dissection rates and improving technical success, yet its superiority over conventional angioplasty alone remains controversial.
214503825|NCT07013721|PROCEDURE|Transversus Abdominis Plane Block, TAPB|The procedure was performed by anesthesiologists with extensive expertise in nerve blockade techniques. For upper abdominal surgical incisions, a subcostal approach transversus abdominis plane block (TAPB) was implemented under ultrasound guidance to identify the transversus abdominis plane. A total of 20 mL of 0.33% ropivacaine hydrochloride injection (Naropin®) was incrementally administered, followed by contralateral application using identical techniques, with ultrasonographic confirmation of fusiform drug distribution within the transversus abdominis plane to achieve upper abdominal incision analgesia. For lower abdominal incisions, a lateral approach was employed, with the same dosage of local anesthetic injected at the target site and bilateral blocks performed after confirming fluid dispersion patterns under real-time ultrasound visualization.
214503826|NCT07013279|BIOLOGICAL|DWP712 inj.|Clostridium botulinum Toxin
215003605|NCT07120555|DEVICE|Percutaneous transluminal angioplasty of infra-popliteal arteries lesions with primary long|Percutaneous transluminal angioplasty of infra-popliteal arteries lesions with primary long
215003606|NCT07120503|DRUG|WIN378|WIN378 is a fully human, long-acting monoclonal antibody that binds to thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving asthma control over an extended dosing interval.
215003607|NCT07120503|DRUG|Placebo|A sham injection consisting of placebo to mask WIN378.
215003608|NCT07119385|OTHER|Multicomponent non-pharmacological interventions|Multicomponent non-pharmacological interventions to prevent delirium in frail patients
215003609|NCT07119385|OTHER|Usual care|Usual care
215003610|NCT07119359|OTHER|Home-based HIV self-testing|Integration of HIV self-testing into TB household contact investigation
214398957|NCT03781713|DRUG|Drug interaction risk D or X|Intervention in the therapeutic plan in order to avoid adverse drug reactions.
214398958|NCT03781713|DRUG|Antimicrobial stewardship|Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
215003611|NCT07119359|OTHER|Home-based initiation of PrEP|Integration of PrEP initation into TB household contact investigation
215003612|NCT07120542|DEVICE|Dermoscopy|dermoscopic assessment of skin aging signs
215121437|NCT02335307|OTHER|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
214398959|NCT01117597|RADIATION|low RF exposure level|Exposure with 1.5 W/kg
214398960|NCT01117597|RADIATION|sham exposure|intervention with sham RF exposure
214398961|NCT01117597|RADIATION|high RF exposure|intervention with high RF exposure
214398962|NCT02834572|BEHAVIORAL|All About Me|Assessment and algorithm to determine recommended HIV testing approach
214398963|NCT02834572|BEHAVIORAL|Control|HIV testing information
214398964|NCT01132196|DRUG|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
214398965|NCT01954524|DRUG|IV bolus injection of Sildenafil|"Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil."
214398966|NCT04069221|DRUG|Single oral dose of 800 mg OZ439|Single oral dose of 800 mg OZ439
214398967|NCT04069221|DRUG|Single oral dose of 400 mg OZ439|Single oral dose of 400 mg OZ439
214398968|NCT04069221|DRUG|Single oral dose of cobicistat|Single oral dose of 150 mg cobicistat
214398969|NCT04069221|DRUG|iv infusion of [14C]-OZ439|15-minute 10-mL iv infusion of 100 μg \[14C\]-OZ439
214503827|NCT07013279|BIOLOGICAL|Botox® 100 Units|Clostridium botulinum Toxin
214503828|NCT07012629|DRUG|acetylsalicyclic acid (ASA)|Daily dose 75 mg to 100 mg p.o.
214503829|NCT07012629|DRUG|Clopidogrel|Daily dose 75 mg p.o.
214503830|NCT07012629|DRUG|Rosuvastatin|"Daily dose 20 mg p.o. (10 mg once daily for the first 4 weeks, then 20 mg once daily for the remainder of the study period if tolerated).~If Rosuvastatin 20 mg is not tolerated, a dose reduction to 10 mg is allowed."
214503831|NCT07012629|DRUG|Atorvastatin|Daily dose 40 mg p.o. If Atorvastatin 40 mg is not tolerated, a dose reduction to 20 mg is allowed.
214503832|NCT07012798|DRUG|Durvalumab|1120mg, iv, q3w
214503833|NCT07012798|DRUG|Bevacizumab|15mg/kg, iv, q3w
215003613|NCT07121452|BEHAVIORAL|Sleep Navigator|Sleep Navigator will provide education, troubleshooting, motivation, and support pertaining to any additional questions or concerns regarding OSA. They will consult closely with the board-certified sleep medicine physician to ensure that participant care needs are met.
215003614|NCT07121036|DRUG|high - dose vitamin C|Different dose of high - dose vitamin C in arm1, 2 and 3
215003615|NCT07114679|DEVICE|Molecular Breast Imaging|MBI is a molecular imaging (nuclear medicine) technique using a low dose i.v. radiopharmaceutical injection and solid-state gamma cameras to image the breast, where cancer mitochondria avidly take up the radiopharmaceutical.
215003616|NCT07114679|DEVICE|MBI-guided biopsy|Two stereotactic MBI views of the breast produce a precise 3D location for each lesion targeted for biopsy. A vacuum-assisted core biopsy needle is guided to the lesion position.
215003617|NCT07117084|DIAGNOSTIC_TEST|CCTA-derived Plaque Quantification|Quantitative analysis of coronary plaque features based on coronary CT angiography using semi-automated software.
215003618|NCT07120854|OTHER|Decision aid with decision analysis model|Women will use the web version of the decision aid tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by their central research team via e-mail. Each woman is expected to use the web tool and select her preferences (utilities) regarding different health conditions (e.g. hip fracture). The results of the exercises will be received automatically at the central level (by institutional e-mail to the researcher responsible for the data a PDF file will be sent from the web). The research team at the central level will apply the decision analysis model, using information on the baseline fracture risk and preferences of each participant entered into the tool. The results of the decision analysis model will be delivered to the women directly by e-mail in plain language, so that they can make the final decision together with their general practitioner in a second visit.
215095501|NCT06431230|BEHAVIORAL|plyometric high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. However, there is a difference, comparing to the St-HIIT, related to different exercises used in protocol. This kind of HIIT programme will be based on plyometric exercises: jumping jacks, skip A, skip C, jumps back into a push-up position and returns to the squat position, throwing the legs out of support and jumping out, jumping out of a squat.
215095502|NCT03389178|DIAGNOSTIC_TEST|Cohen Perceived Stress Scale-10 (PSS-10)|Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score \< 19 will be entered into Phase II as control
215095503|NCT03417986|DRUG|TEP|"For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening."
215095504|NCT01896245|DRUG|sevoflurane 1,0|anesthesia induction with propofol, remifentanil, and sevoflurane 1,0 MAC; afterwards tracheal intubation
214503834|NCT07012798|DRUG|HAIC of FOLFOX|"HAIC (FOLFOX): oxaliplatin 100mg/m2, 4h, day 1 + leucovorin 300mg/m2, 2h, day~1 + fluorouracil 500mg/m2, 20min, day 1 + fluorouracil 1500mg/m2, 20h, q3w"
214503835|NCT07020390|PROCEDURE|Anesthesia method|Patients will be divided into subgroups according to different anesthesia methods (general, spinal, and combined spinal-epidural anesthesia) and compared in terms of recovery quality (QoR-40) and other parameters.
214503836|NCT07016399|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214503837|NCT07016399|PROCEDURE|Breast Biopsy Procedure|Undergo breast biopsies
214503838|NCT07016399|DRUG|Carboplatin|Given IV
214503839|NCT07016399|DRUG|Cyclophosphamide|Given IV
214503840|NCT07016399|DRUG|Darolutamide|Given PO
214503841|NCT07016399|DRUG|Doxorubicin|Given IV
214503842|NCT07016399|DRUG|Epirubicin|Given IV
214503843|NCT07016399|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214503844|NCT07016399|DRUG|Paclitaxel|Given IV
214503845|NCT07016399|BIOLOGICAL|Pembrolizumab|Given IV
214503846|NCT07016399|PROCEDURE|Surgical Procedure|Undergo breast surgery
214503847|NCT07016399|PROCEDURE|Ultrasound Imaging|Undergo US
214522600|NCT02725359|DRUG|Tizanidine|Group T: 6 mg tizanidine1 hour before surgery
214398970|NCT01518114|BEHAVIORAL|Exercise Training|Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
214398971|NCT03993405|OTHER|Ultrasonographic evaluation|Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
215003619|NCT07120854|OTHER|Decision aid alone|Participants will use the web tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by the central research team via e-mail. Each woman is expected to navigate through the different functions of the web tool, at home or at a time other than the medical visit, and select her preferences (utilities) with respect to different health conditions (e.g. hip fracture). The women in this group would decide whether or not to take the pharmacological treatment based on the information provided by the tool but without the results of the decision analysis model described for the intervention group. Subsequently, those who wished to do so would make a final decision together with their physician at a second visit.
215003620|NCT07120854|OTHER|Usual Care|Women in this group will receive standard clinical practice, without the use of the shared decision support tool or the decision analysis model or any other support. At the end of the visit, their physician will provide them with a link to access the assessment questionnaires.
215003621|NCT07120633|OTHER|AntiCD19 CAR-T combined with BTKi in the treatment of newly diagnosed high-risk CLL/SLL patients|After chemotherapy, the tumors of the patients in the experimental group were re-graded to determine the basic burden status of the tumors. It should include imaging diagnosis, physical examination, laboratory tests of blood, assessment of bone marrow MRD and evaluation of the toxic and side effects of chemotherapy, etc
215003622|NCT07118449|DRUG|XC001|22 injections will be administered at the end of the CABG procedure as a one time treatment.
215003623|NCT07118449|DRUG|A195/placebo|22 injections of A195/placebo will be administered at the end of the CABG procedure.
214398972|NCT02202694|BEHAVIORAL|Culturally Adapted Cognitive behavior therapy|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
214398973|NCT03377673|DIAGNOSTIC_TEST|CMR|CMR is performed using a 1,5T whole-body system (Siemens Aera, Siemens Medical Solutions; Erlangen, Germany)
215003624|NCT07118956|OTHER|Active RAVANS|Real RAVANS was performed on the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve according to the Participant's respiratory rhythm. Stimulation parameters: frequency = 100 Hz; pulse width = 200 us, once a day, 30 minutes each time, one second of stimulation occurs during exhalation.
215003625|NCT07118956|OTHER|Sham RAVANS|Sham RAVANS was performed on on the cymba conchae of left ear according to the Participant's respiratory rhythm. Stimulation parameters: frequency = 100 Hz; pulse width = 200 us, once a day, 30 minutes each time, one second of stimulation occurs during exhalation and the interval between stimulus is 29 seconds.
215003626|NCT07119021|DRUG|Intravenous thrombolysis + edaravone|The patient underwent intravenous t-PA thrombolysis and sublingual administration of edaravone tablets in the prehospital ambulance. Intravenous t-PA thrombolysis was performed in accordance with international guidelines: t-PA dose was calculated according to 0.9mg/kg; 10% of the total dose was injected intravenously, and the remaining 90% was administered intravenously at a uniform rate within one hour.
215003627|NCT07119021|DRUG|IV thrombolysis + placebo (control group)|Patients underwent intravenous t-PA thrombolysis + placebo sublingual administration. The method of intravenous t-PA thrombolysis is in accordance with the international guideline standards: t-PA dose is calculated according to 0.9mg/kg; 10% of the total dose is injected intravenously, and the remaining 90% is administered intravenously at a constant rate within 1 hour.
215003628|NCT07117500|BEHAVIORAL|Routine|"Inpatient Care: Continuously monitor vital signs (BP, HR, SpO₂), neurological status, and limb function; administer prescribed antihypertensives with thorough medication education and efficacy tracking. Strictly prohibit Valsalva maneuvers . Assess pain levels, wounds, and psychological state; deliver scheduled analgesics and emotional counseling to maintain stable mood. Implement lifestyle optimization: 7+hr sleep/night, portion-controlled nutrition, and gradual postoperative mobilization.~Discharge \& Follow-up: Enforce BP control through medication adherence. Ban vigorous activities (mountaineering/swimming/competitive sports); allow low-stress aerobics . Distribute Exercise Diaries (Appx 6) mandating daily logs with critical warnings: STOP immediately if nausea, chest pressure, dizziness, dyspnea, or arrhythmia occur and urgent revisit. Require complete tobacco cessation and secondhand smoke avoidance."
215095505|NCT01896245|DRUG|sevoflurane 1,2|anesthesia induction with propofol, remifentanil, and sevoflurane 1,2 MAC; afterwards tracheal intubation
215095506|NCT01896245|DRUG|sevoflurane 1,4|anesthesia induction with propofol, remifentanil, and sevoflurane 1,4 MAC; afterwards tracheal intubation
215095507|NCT02085330|DEVICE|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
215095508|NCT03878303|DRUG|AC0058TA|25 mg capsules
215095509|NCT03878303|DRUG|Placebo AC0058TA|equivalent dose of investigational product
215095510|NCT00527332|DRUG|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
215095511|NCT00527332|DRUG|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
215095512|NCT00527332|DRUG|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
214398974|NCT05744882|PROCEDURE|coronectony|root canal treatment
214398975|NCT05744882|PROCEDURE|root canal treatment|root canal treatment
214398976|NCT03050437|DRUG|Cisplatin|cisplatin is added to Pem/cis arm
214398977|NCT03050437|DRUG|Pemetrexed|Pem is applied to both arms
214398978|NCT04877574|PROCEDURE|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI.
214398979|NCT04877574|PROCEDURE|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
214398980|NCT05429359|OTHER|CPET: CardioPulmonary Exercise Test for CSII users|"* Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* CSII users: 100% basal"
215003629|NCT07117500|BEHAVIORAL|BCW|"1.1 Assessment of physical fitness and formulation of individualized exercise rehabilitation plans 1.2 Inpatient Phase (Postoperative Day 1 - Week 1): Monitor via ICU Mobility Scale (IMS) before each session:▪ Score 0 : Passive range of motion (PROM) exercises▪ Scores 1-3 : Active bed-based joint mobility training▪ Scores 4-6 : Standing balance training▪ Scores 7-10 : Ambulatory walking training 1.3 Early Outpatient Phase (Weeks 2-4): Initiate when IMS=10:▪ Perform 6-Minute Walk Test (6MWT) ▪ If distance \>450m: Prescribe low-intensity aerobic walking  Speed: 3 km/h Progression: Start at 10 min/day (≈500 steps), increase by 10 min every other day up to 40 min/day 1.4 Intermediate Rehabilitation (Weeks 5-12): Moderate-intensity aerobic walking + Resistance training :▪ Walking: 4-6 km/h, 30 min/session, 3 sessions/week▪ Resistance training: Seated elastic band exercises, 20 min/session, 2 sessions/week"
215003630|NCT07118774|BEHAVIORAL|Behavioral: mindfulness and compassion training|Parallel randomized controlled trial
214398981|NCT05429359|OTHER|AEX1: Aerobic Exercise Test 1 for CSII users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -2h target 150 mg/dL"
215003631|NCT07118774|BEHAVIORAL|Behavioral: caregiver skills training|Parallel randomized controlled trial
215003632|NCT07118774|BEHAVIORAL|Behavioral: Communication skills training|Parallel randomized controlled trial
215003633|NCT07117786|OTHER|CT Contrast|Participants will undergo a CT-based radiomics assessment as part of the intervention. This approach involves the extraction of high-dimensional quantitative imaging features from preoperative contrast-enhanced CT scans, which are then analyzed using machine learning algorithms to identify patterns predictive of early postoperative renal function decline. Unlike conventional radiologic evaluations that rely on visual inspection and basic metrics (e.g., tumor size or enhancement), this radiomics-based intervention captures subtle heterogeneity within renal tumors and surrounding parenchyma. The integration of these features with clinical variables distinguishes this study from other imaging or predictive model studies, enabling the development of a personalized nomogram for patients with localized RCC undergoing partial nephrectomy.
214398982|NCT05429359|OTHER|AEX2: Aerobic Exercise Test 2 for CSII users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -1h target 150 mg/dL"
214398983|NCT05429359|OTHER|CPET: CardioPulmonary Exercise Test for MDI users|"* Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* MDI users: 100% basal"
214398984|NCT05429359|OTHER|AEX1: Aerobic Exercise Test 1 for MDI users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 50% basal"
214398985|NCT05429359|OTHER|AEX2: Aerobic Exercise Test 2 for MDI users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 80% basal"
214398986|NCT02429921|DIETARY_SUPPLEMENT|high-selenium lentils|lentils grown on naturally selenium-rich soils in the Canadian Prairies
214398987|NCT02429921|DIETARY_SUPPLEMENT|Low-Se lentils|lentils grown on selenium-deficient soils in Idaho, USA.
215003634|NCT07117786|OTHER|Computed Tomography|Participants will undergo a CT-based radiomics assessment as part of the intervention. This approach involves the extraction of high-dimensional quantitative imaging features from preoperative contrast-enhanced CT scans, which are then analyzed using machine learning algorithms to identify patterns predictive of early postoperative renal function decline. Unlike conventional radiologic evaluations that rely on visual inspection and basic metrics (e.g., tumor size or enhancement), this radiomics-based intervention captures subtle heterogeneity within renal tumors and surrounding parenchyma. The integration of these features with clinical variables distinguishes this study from other imaging or predictive model studies, enabling the development of a personalized nomogram for patients with localized RCC undergoing partial nephrectomy.
215095513|NCT00527332|DRUG|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
215095514|NCT00527332|DRUG|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
215095515|NCT00527332|DRUG|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
215095516|NCT00527332|DRUG|Morphine|5 mg is given IV (intravenously) before end of surgery
215095517|NCT03959787|OTHER|Educational|Educational pamphlet will be given to intervention group.
215095518|NCT02666105|DRUG|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
215095519|NCT01078168|DRUG|Acitretin|30mg per day from Day 1 to Day 28
214398988|NCT03461250|DIAGNOSTIC_TEST|HCV serology|Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
214398989|NCT02708602|GENETIC|β2AR polymorphism|
214398990|NCT01372358|DRUG|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
214522601|NCT02725359|DRUG|Bupivacaine|Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
215095520|NCT01078168|DRUG|Placebo|Placebo
215095521|NCT02138357|DRUG|buprenorphine transdermal delivery system (BTDS)|
215095522|NCT02138357|DRUG|Placebo for BTDS patch|A placebo patch will be manufactured to mimic the BTDS patch.
214522602|NCT02725359|DRUG|Saline|USG guided SCPB with saline bilaterally 10 ml each side
214693846|NCT00568958|BEHAVIORAL|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
215095523|NCT00302757|DRUG|Radioimmunotherapy|
215095524|NCT00302757|PROCEDURE|allogeneic hematopoietic cell transplantation|
215095525|NCT02868658|BIOLOGICAL|Blood sampling|
215095526|NCT02868658|OTHER|Nasal swab|
215095527|NCT04216355|DRUG|Azacitidine|Low-dose AZA
215095528|NCT04216355|DRUG|CAG Protocol|Short term CAG derived regimen
215095529|NCT00867906|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
215095530|NCT00867906|BIOLOGICAL|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
215095531|NCT02147769|DEVICE|NIRS monitoring|All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
215095532|NCT02635997|DRUG|antiresorptive therapy|
215003635|NCT07116785|DEVICE|BrainsWay Deep TMS HAC/H7-Coil|Rotational field TMS (rfTMS) is a novel technology where two orthogonal coils are operated with a 90 phase shift between them. The combined electric field vector of rfTMS from both coils rotates up to a complete cycle during the TMS pulse. This method overcomes the inherent limitation of conventional unidirectional TMS by influencing neurons in various orientations (Roth et al., 2020b). This unique advance bears enormous potential for therapeutic applications in various neuropsychiatric disorders. The coil Array includes the H7 coil as the lower coil, and an upper coil perpendicular to it. Hence, the HAC/H7 coil Array induces similar electric field distribution and affects the same brain structures as the H7 coil, but stimulates neurons in various orientations within these regions.
215003636|NCT07116785|DEVICE|BrainsWay Deep TMS Sham Coil|Participants assigned to this intervention will receive sham stimulation using a BrainsWay Deep TMS sham coil that mimics the sensation and acoustic properties of active stimulation but does not deliver effective magnetic pulses to the brain. This condition is used as a placebo control to blind participants and investigators.
215003637|NCT07118176|PROCEDURE|Computed Tomography|Undergo PET/CT
215003638|NCT07118176|OTHER|Fludeoxyglucose F-18|Given IV
215003639|NCT07118176|RADIATION|Gallium Ga 68 FAPi-46|Given IV
215003640|NCT07118176|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215003641|NCT07117474|DRUG|HRS-9563, placebo|A single subcutaneous injection of HRS-9563 injection or placebo was administered
215003642|NCT07118085|DRUG|experimental Arm IMC-003|"Part 1: Single Dose Dose Escalation (SAD):~Dose and frequency: 0.03mg/kg, 0.1mg/kg, 0.3mg/kg, 0.7mg/kg, 1.0mg/kg for single administration, with the test drug or placebo administered respectively.~Part 2: Multiple Dose Dose Escalation (MAD):~Dose and frequency: Tentatively set at 0.3mg/kg, 0.5mg/kg, 0.7mg/kg. Administer once every 3 weeks for 5 consecutive times (unless the subject cannot tolerate, withdraw prematurely, or is lost to follow-up, etc.), with the test drug or placebo administered respectively."
215003643|NCT07118085|DRUG|The placebo Arm: The placebo of IMC-003|Part 1(SAD) subject will receive IMC-003 once ; Part 2 (MAD) subject will receive the placebo of IMC-003 for 5 times, with an interval of 21 days between each administration.
214398991|NCT06119906|DEVICE|Hyper-Spectral Endoscopy|We have developed a custom hyperspectral endoscopy approach based around a commercially available endoscopy system. An Olympus gastroscope (GIF-H260) and video processor and display are used with a modified light source that incorporates a laser with tunable wavelength for illuminating the scene through the endoscope. A live video feed from the gastroscope is displayed on the endoscopy monitors and can be acquired and saved in the native video acquisition system. The spectral imaging data is also saved within this video feed, where imaging wavelength corresponds to a given timestamp in the video.
214398992|NCT02812212|DEVICE|ultrasonography|bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
214398993|NCT02812212|DEVICE|diuretic renography|diuretic renography to measure the cortical transit time.
214398994|NCT01369173|OTHER|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
214398995|NCT05107778|DRUG|ASC42 10mg|ASC42 10mg orally once daily;
214398996|NCT05107778|DRUG|ASC42 15mg|ASC42 15mg orally once daily.
214398997|NCT05107778|DRUG|ih PEG-IFN α-2a|ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
214398998|NCT05107778|DRUG|Entecavir|Entecavir 0.5 mg orally once daily.
214398999|NCT05107778|DRUG|Placebo|Placebo orally once daily.
214399000|NCT05631990|DRUG|AD-209|PO, Once daily(QD), 8weeks
214399001|NCT05631990|DRUG|AD-209-1A|PO, Once daily(QD), 8weeks
214399002|NCT05631990|DRUG|AD-209-1B|PO, Once daily(QD), 8weeks
214399003|NCT05631990|DRUG|AD-209-1C|PO, Once daily(QD), 8weeks
214399004|NCT05631990|DRUG|AD-209 placebo|PO, Once daily(QD), 8weeks
214399005|NCT05631990|DRUG|AD-209-1 placebo|PO, Once daily(QD), 8weeks
214399006|NCT03317379|BEHAVIORAL|Peer mentorship|Weekly meetings with a recovered peer mentor once per week. Dyads discuss eating disorder symptoms and how to overcome them.
214399007|NCT03317379|BEHAVIORAL|Social support mentorship|Weekly meetings with a social support mentor who has not personally struggled with an eating disorder, once per week. Dyads engage in activities unrelated to the eating disorder (e.g., a movie, a community event, volunteer work).
214399008|NCT03317379|BEHAVIORAL|Recovery Record use with mentor|Recovery Record is a smart phone or web-based application designed to provide recovery support to eating disorder patients. Includes a number of features aimed to promote recovery, such as a meal tracking, prompts for completing meals/snacks, tracking for additional symptoms such as stress and mood, motivational messages, information about coping strategies, and capacity to share logged data with clinicians and mentors.
214693847|NCT00568958|DRUG|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
215003644|NCT07116876|OTHER|Graft Application|Place the graft on the debrided DFU and secure. Follow with conventional care wound management (dressings and off-loading). Product may be applied weekly.
215003645|NCT07116876|OTHER|Wound Dressing Material|The wound will be debrided and undergo a moist-wound therapy and will be covered with a gauze that is appropriate for the type of wound (moist or dry). Dressings will cover each wound wound for at least 5 days, but no more than 9 days, (7 days +/- 2 days) until the next study visit. Off-loading of the wound is required.
215003646|NCT07119047|BEHAVIORAL|"A Brazilian adaptation of the Irish intervention iHELP Stroke"|The intervention comprises a set of interactive experiential learning activities. A physiotherapist will serve as the coordinator, and other healthcare professionals will be invited to participate as guest speakers. The educational session aims to provide knowledge about stroke (what stroke and recurrent stroke are, their signs and symptoms, and lifestyle-related risk factors). The individual session aims: (1) to identify the current self-reported health status after stroke; (2) to recognize and raise awareness of risk factors associated with lifestyle-related behaviors, including the setting of behavior change goals, which are structured using the SMART Goals method; and (3) to identify the individual's preferences and ability to participate in the intervention program. Each group session comprises six components covered across the six sessions: education, goal setting, physical activity participation, emotional self-regulation, skill training, and peer learning.
215003647|NCT07116928|DRUG|ganagliflozin|50 mg Once daily, 120 weeks
215003648|NCT07116928|DRUG|Placebo|50 mg Once daily, 120 weeks
215003649|NCT07119957|OTHER|Blood, urine and stool biocollection|Collection of blood, urine and stool sampling in order to build up a biocollection
215003650|NCT07119151|DEVICE|Dental Implant|Dental Implant placement and loading.
215003652|NCT07120685|OTHER|maintaining mechanical load|"The method for maintaining mechanical load (artificially reproducing the stabilization of initial body weight) will involve the use of a weighted vest.~Participants will be asked to wear the weighted vest for at least eight hours a day over a four-week period without changing their lifestyle. Patients will also be contacted by phone every week after surgery to confirm that they are using the vest in accordance with the protocol and to collect information on any potential adverse events. During these calls, weight adjustments-based on body weight changes-will be discussed with the patient and regularly recorded to stay as close as possible to the initial body weight, with a tolerance of ±1 kg. However, the maximum weight of the vest will not exceed 15% of the patient's initial weight (weight at the time of surgery).~Between the 4th and 12th week, patients will be asked to wear the weighted vest loaded with the weight lost calculated at week 4 for at least four hours per day."
215003653|NCT07120893|BEHAVIORAL|brief culturally adapted behavioral activation|The brief culturally adapted behavioral intervention in this study is a three individual-session intervention, delivered in primary health care center by primary care psychologist. Each session will last 30-45 minutes in face-to-face. During each session, participants will learn about behavioral techniques to reduce depression and enhance well-being, and practice it in their daily life through homework activities.
215003654|NCT07120594|DRUG|Unbuffered lidocaine 2% with epinephrine 1:80,000|Standard local anesthetic solution without pH modification. Used for maxillary extraction of infected primary molars in pediatric patients.
215003655|NCT07120594|DRUG|Buffered lidocaine 2% with epinephrine 1:80,000|Local anesthetic solution mixed with sodium bicarbonate to increase pH before injection. Used for maxillary extraction of infected primary molars in pediatric patients.
215003656|NCT07122531|OTHER|Medium chain triglyceride oil|Supplementation with 15 g of medium chain triglyceride oil, a food product commercially available over-the-counter in regular grocery stores, emulsified in beverage of choice, twice daily (morning and evening) for 12 weeks.
215003657|NCT07123831|OTHER|virtual reality supported privacy education|The experimental group was shown a video with virtual reality application for 15 minutes in an empty classroom environment determined in the primary school at a time and in a way that would not disrupt the lessons. Then, verbal expression, question-answer and feedback were given for 10 minutes. After this training session, the experimental group was repeated twice with virtual reality goggles at two-week intervals and their questions were answered. No intervention was made to the students in the control group. At the end of the sixth week, the researcher administered post-tests to each student in the experimental and control groups.
215003658|NCT07119931|DRUG|lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab|Iparomlimab and Tuvonralimab Injection（Q1706）: 7.5 mg/kg, q3w, given on Day 1 (±7 days) of each 21-day cycle; Bevacizumab: 7.5 mg/kg, q3w, administered on Day 1 (±7 days) of each 21-day cycle; HAIC:Oxaliplatin 85 mg/m² via arterial infusion over 2-3 hours, Levoleucovorin 200 mg/m² via arterial infusion over 1-2 hours, 5-Fluorouracil 400 mg/m² via arterial bolus injection, followed by continuous arterial infusion of 2400 mg/m² over 23 hours, q3w, with the treatment interval not exceeding 4 weeks.
214399009|NCT04308538|PROCEDURE|Standard Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using standard tables
214399010|NCT04308538|PROCEDURE|Reduced Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using reduced numbers
214399011|NCT03079505|DRUG|Dasatinib 100 MG [Sprycel]|Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
214399012|NCT03079505|DRUG|Nilotinib 150mg oral capsule [Tasigna]|Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
214503848|NCT00504322|GENETIC|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10\^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
215003659|NCT07122791|OTHER|Home Exercise Group|In addition to the exercise program, Group 2 will receive motor imagery training. This will be carried out using the telerehabilitation method, under the supervision of a physiotherapist, and will be delivered twice a week for six weeks. A text containing posture exercises will be prepared by the physiotherapist for motor imagery training. The motor imagery text will be updated as the home exercise program is completed. The content of the motor imagery program will consist of 5 minutes of relaxation and 15 minutes of imagery training. Relaxation training will include relaxation and breathing exercises. After relaxation training, the patient will be asked to stand up with his eyes closed in a safe environment where he feels comfortable, and then a text containing posture exercises prepared by the physiotherapist for motor imagery will be read. The patient will be asked to perform the exercise by imagining it in his mind without moving his body.
215003660|NCT07123896|DEVICE|Normal treatment with catheter ablation or medicine|Routine clinical care with catheter ablation and/or medicine; real-world clinical cases
215003661|NCT07123896|DRUG|Drug Treatment|Routine clinical care with medicine; real-world clinical cases
215003662|NCT07122804|OTHER|Assessment|Within the scope of the study, without any intervention, data regarding the participants' hyperventilation symptoms and physical capacities will be evaluated.
215003663|NCT07123610|BEHAVIORAL|Mediterranean Diet Education Program|"The intervention consists of a 4-week Mediterranean Diet Education Program designed specifically for nurses working rotating shifts.~The program included four weekly group sessions, each lasting approximately 60 minutes, delivered in-person by a registered dietitian with training in behavioral change and clinical nutrition. Sessions are interactive and supported by visual and printed educational materials.~Participants receive a printed handbook including a food pyramid graphic, portion guides, weekly shopping lists, and sample menus tailored to shift work schedules. They also gain access to a moderated online discussion group and receive weekly motivational text messages to reinforce key messages.~No food is provided directly."
215003664|NCT07122284|DIAGNOSTIC_TEST|13C-Urea Breath Test|Participants underwent the 13C-urea breath test following a standardized protocol to detect active Helicobacter pylori (H. pylori) infection. After an overnight fast (≥8 hours), baseline breath samples were collected by exhaling gently through a straw. Participants then ingested 75 mg of 13C-labeled urea dissolved in 50 mL of citric acid solution to delay gastric emptying and maximize urease exposure. A second breath sample was collected 30 minutes post-ingestion using identical procedures.
215003665|NCT07122284|DIAGNOSTIC_TEST|Hydrogen-Methane Breath Test|Participants underwent a standardized hydrogen-methane breath test to evaluate for small intestinal bacterial overgrowth (SIBO) or carbohydrate malabsorption. After a 12-hour overnight fast, baseline breath samples were collected via controlled end-expiratory exhalation. Participants then ingested a substrate solution.
215003666|NCT07123181|OTHER|Control (Standard treatment)|Patients receive standard medical treatment.
215003667|NCT07123181|OTHER|Higher polyphenol intake by consumption of oregano and basil|Patients consume 4-5 grams of dried oregano and 4-5 grams of dried basil leaves daily for two months in addition to their usual medical treatment.
215003668|NCT07122830|OTHER|Family Education and Parental Involvement|Parents will be oriented to the programme, tools provided for their own learning (pamphlets, information handouts, audio-visual resources), and a checklist of infant care topics to be completed. The primary caregiver will be asked to commit to spending one to two hours per day to attend education sessions on the topic(s) of their choice. Parents will be encouraged to provide progressively more daily care for their infants as they complete more education sessions. After each education session, parents will check off for each completed topic on their skills checklist.
214399013|NCT04445155|BEHAVIORAL|Modified DECIDE Parent and Provider Intervention|The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.
214399014|NCT00550173|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
214399015|NCT00550173|DRUG|erlotinib|150 mg, orally, once daily until progression or unacceptable toxicity develops
215095533|NCT01392612|DRUG|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
215095534|NCT01681524|DRUG|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
215095535|NCT02012049|DRUG|Risperdal OD Tab. 2mg|1 tablet Risperdal OD 2 mg administered orally.
215095536|NCT02012049|DRUG|Risperdal Quicklet Tab. 2mg|1 tablet Risperdal Quicklet Tab. 2mg administered orally.
215095537|NCT01264419|DEVICE|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
215095538|NCT01735942|DRUG|Ingenol mebutate|
215095539|NCT01735942|PROCEDURE|cryotherapy|
215095540|NCT01962870|DRUG|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
215095541|NCT01962870|DRUG|Placebo|
215095542|NCT03869307|OTHER|Exercise|The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
214503849|NCT00504322|GENETIC|Placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
214399016|NCT00366262|DRUG|PLA-695|
214399017|NCT00366262|DRUG|Naproxen|
214399018|NCT00366262|DRUG|Placebo|
214693848|NCT00568958|DRUG|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
215003669|NCT07122726|PROCEDURE|Otago and PNF exercise|"Otago Exercise:~This 6-week protocol focuses on strengthening and balance exercises. It starts with supported exercises and progresses to unsupported ones. Exercises include knee flexors, extensors, and hip abductors with ankle weights, ankle plantar and dorsiflexors, knee bends, backward stepping, walking and turning, sideways walking, tandem stance, and one-leg stance. Repetitions increase over time, from 10-20 reps with support to 30 reps without support.~PNF Exercise The PNF protocol consists of 6 levels, progressing from simple to complex exercises. Level 1 involves D1/D2 patterns for ankle and hip with light resistance, while Level 2 focuses on seated D1/D2 patterns for the lower limb. Levels 3-6 introduce more dynamic exercises, including arm reaches while standing, PNF walking, dynamic step-ups, walking on unequal terrain, and obstacle navigation. The protocol emphasizes approximation, stabilization, resistance, and dynamic reversals to improve proprioception \& balance."
215003670|NCT07122726|PROCEDURE|Otago Exercise|Knee Flexors, Knee Extensors, Hip-abductors- 10 reps of each Exercise with ankle weights to provide muscle resistance. For ankle planter flexors and dorsi flexors starting from 20 repetitions at week 1 with hold support and ending at 30 repetitions without any support on 6th week. For knee bends starting with 10 reps at week 1 and ending at 30 reps without support at 6th week. Backward stepping 10 times 2 steps backward at week 1 progressing to 10 times x 4 Steps x No Support at week 6 gradually. Walking and Turning Around- (make a figure of 8), twice, first with support and then without support. Sideways Walking- 10 steps, 4 times x first with support and then without support over the time of 6 weeks. Tandem Stance- 10 seconds first with support and then without support. Tandem Walk/ 20 reps first with support and then without support over the period of 6 weeks.
215003671|NCT07122648|BIOLOGICAL|placebo|Participants will receive a single IV dose of 300 µg of placebo
215003672|NCT07122648|BIOLOGICAL|PN-101|Participants will receive a single IV dose of 300 µg of PN-101
214399019|NCT03067103|DRUG|Tramadol|Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
215003673|NCT07122648|BIOLOGICAL|PN-101|Participants will receive a single IV dose of 600 µg of PN-101.
215003674|NCT07123948|DIAGNOSTIC_TEST|Wechsler Intelligence Test, performed by educated psychologists|"At the age of six, parents of children who meet the inclusion criteria will receive a notification about the study from the responsible paediatrician. If they agree to participate, they will sign an informed consent form. They will then be invited to the clinic for a neurological and neurodevelopmental assessment. The neurological examination will be conducted by the principal investigator or collaborators who are paediatric specialists. The neurodevelopmental evaluation will be performed by a qualified psychologist using the Wechsler Intelligence Test.~The Wechsler Intelligence Test for Children - Fourth Edition is a clinical tool for measuring the intelligence of children aged 6 to 16 years and 11 months. It assists in identifying specific learning difficulties, hyperactivity disorder, speech and language challenges, and intellectual impairments. The test comprises 15 subtests."
215003675|NCT07122518|DEVICE|PALMAZ MULLINS XD™ Pulmonary Stent|The PALMAZ MULLINS XD™ Pulmonary Stent is indicated for the non-emergency treatment of pulmonary artery stenosis in pediatric patients who are at least 10kg in weight with two ventricle anatomy. The PALMAZ MULLINS XD™ Pulmonary Stent is a balloon-expandable, laser cut stent made from 316L stainless steel tubing. The stent is supplied unmounted and in five (5) nominal unexpanded lengths: 19 mm, 25 mm, 29 mm, 39 mm, and 59 mm.
215003676|NCT07122713|RADIATION|Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor|Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions
215003677|NCT07122713|RADIATION|Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes|Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions
215003678|NCT07122128|DIAGNOSTIC_TEST|saliva a a diagnostic tool for early detection of oral cancer|Three groups will be compared on the basis of cytology, genes and biochemical analysis
215003679|NCT07123909|DEVICE|Patients will undergo a combined hemodialysis and hemosorption procedure. The study cartridge for hemosorption by Jafron HA130 contains the original adsorbing material.|The test cartridge will be used in addition to the ongoing program hemodialysis three times a week in the first month, twice a week in the next month, once a week in the third month
215003680|NCT07123688|DEVICE|Tc-99mMDP bone scan|5 mCi of Tc-99mMDP is used for dynamic renography followed by 15 mCi for post 3-hr whole body imaging.
215003681|NCT07123207|DIETARY_SUPPLEMENT|Bacillus subtilis Capsules|"Bacillus subtilis is a type of probiotic. Studies have found that supplementation with Bacillus subtilis can effectively maintain the remission of inflammatory bowel disease by protecting intestinal integrity, regulating epithelial proliferation, and reshaping the structure and function of the microbiota.~Bacillus subtilis capsules are a Bacillus supplement containing 3×10⁹ CFU of Bacillus subtilis per capsule. Patients in the Bacillus subtilis supplementation group take Bacillus subtilis capsules orally once a day, one capsule each time, for 12 weeks."
215003682|NCT07122245|BEHAVIORAL|Demographics and risk factors of lung cancer|A retrospective cohort study will be conducted on bronchogenic carcinoma patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU).
215121438|NCT02335307|OTHER|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
215121439|NCT00117299|DRUG|PTK787/ZK222584|PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
214399020|NCT03067103|DRUG|Ketamine|Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
214399021|NCT03067103|DRUG|Placebos|Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
214399022|NCT01103986|BEHAVIORAL|Motivational/health literacy education (Test group)|"Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick."
214399023|NCT04131283|DRUG|Epinephrine|Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
214399024|NCT02522975|DRUG|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
215003683|NCT07124273|PROCEDURE|Standardized Mandibular Anesthesia Protocol|Participants receive an inferior alveolar nerve block (IANB) using 1.8 ml 4% articaine with 1:100,000 epinephrine (Ultracaine DS Forte) via a 27-gauge dental needle, followed by buccal and lingual infiltration anesthesia after 5 minutes. Topical 10% lidocaine spray is applied prior to injection. All procedures are performed by the same clinician between 09:00-12:00. Salivary cortisol, pulse oximetry, and pain assessments are conducted before and after the anesthesia.
214399025|NCT02522975|DRUG|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
215003684|NCT07125274|DIAGNOSTIC_TEST|Biomarker-guided diagnostic tests|mRNA-Signature from blood; immunophenotyping from blood; MBLA from sputum, PATHFAST-LAM and EclLAM from sputum, stool, urine; CRISPR-Cas from blood; stool PCR; QuantiFERON(R)-TB Gold Plus.
215003685|NCT07125066|DRUG|Sodium phenylbutyrate|open-label design with doses of sodium phenylbutyrate
215003686|NCT07124104|BEHAVIORAL|Positive Psychotherapy-Based Self-Compassion Training|Participants in the experimental group will receive Positive Psychotherapy-Based Self-Compassion Training, while participants in the control group will not receive any intervention.
215003687|NCT07125989|DEVICE|non-invasive ventilation|During the patient's first three respiratory rehabilitation sessions, each test on the cycle ergometer will be performed at 70% of maximum power (defined during the initial oxygen consumption (VO2) test) with ventilatory assistance at a different intensity (Low, moderate or high intensity).
215003688|NCT07124325|DEVICE|Pregnabit Pro device and PregnaOne platform|Remote CTG device and online dashboard for remote pregnancy care
214399026|NCT00488241|DEVICE|Zarzenda|Topically applied daily for 2 weeks
214399027|NCT01725997|PROCEDURE|hook plate|Surgery with hook plate followed by physiotherapy
214399028|NCT01725997|OTHER|Physiotherapy|Patients will be following a program specific for AC joint dislocations
214399029|NCT05934097|DRUG|FT596|Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously
214399030|NCT05934097|DRUG|Cyclophosphamide|750 mg/m\^2 intravenously
214399031|NCT05934097|DRUG|Doxorubicin|50 mg/m\^2 intravenously
214399032|NCT05934097|DRUG|Vincristine|1.4 mg/m\^2 (maximum dose 2 mg) intravenously
214503850|NCT07011953|DRUG|Antipsychotics plus Levothyroxine Sodium|Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks. Manufacturer: Merck Serono Ltd. Levothyroxine Sodium Tablets should be administered as a single daily dose on an empty stomach, 30 minutes before breakfast, with sufficient liquid (e.g., half a glass of water).
215003689|NCT07125001|OTHER|Ataulfo mango|4 weeks of Ataulfo mango intake
215003690|NCT07125430|OTHER|strengthening exercise|a strengthening exercise program will be carried out for three weeks
215003691|NCT07125430|OTHER|shock wave|3 sessions of shock wave therapy, frequency of one session per week
215003692|NCT07125807|OTHER|upper extremity plyometric exercises|upper extremity plyometric exercises in neuro rehabilitation
215003693|NCT07125807|OTHER|upper extremity resistance exercises|upper extremity resistance exercises in neuro rehabilitation
215003694|NCT07123662|BIOLOGICAL|Gamma-Delta T cell injection|Experimental group: Peripheral intravenous infusion of γδ T cells
215003695|NCT07123662|OTHER|Standard prophylactic treatment|Standard prophylactic treatment
215003696|NCT07124780|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support is an evidence-based model of supported employment for individuals with mental illness. In IPS, participants will meet with an IPS specialist weekly who will help the study participant create resumes, conduct job searches online or in the community, complete job applications, role-play interviews, and, if requested, accompany them when visiting prospective employers.
214399033|NCT05934097|DRUG|Prednisone|100 mg orally
214399034|NCT05934097|DRUG|Rituximab|375 mg/m\^2 intravenously
214399035|NCT05934097|DRUG|Bendamustine|90 mg/m\^2 IV infusion
214503851|NCT07011953|DRUG|Antipsychotics plus Placebo|"All participants maintain pre-study antipsychotic medication at stable doses. ADDITIONALLY, they receive a visually identical placebo tablet.~Placebo characteristics \& Blinding guaranteet: Matches levothyroxine in appearance (size/color/coating), taste, and packaging.~Active ingredien : starch tablet with no biological activity. Administration: Once daily in the morning under identical fasting conditions."
215095543|NCT03048604|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
215095544|NCT05023278|DRUG|Venlafaxine 37.5 MG|venlafaxine 37.5mg daily for 7 consecutive days.
215095545|NCT05023278|DRUG|Placebo|placebo filled pill daily for 7 consecutive days.
214399036|NCT02385617|DRUG|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
214399037|NCT02385617|DRUG|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
214399038|NCT03911193|DRUG|Cabozantinib|Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.
214399039|NCT05532020|DRUG|DCCR (diazoxide choline) extended-release tablets|All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.
214399040|NCT06198660|OTHER|positional release technique|positional release techniques in addition to conventional therapy two sessions per week for 6 weeks
214399041|NCT06198660|OTHER|cognitive behavioral therapy|cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks
214399042|NCT06198660|OTHER|conventional therapy only|conventional therapy two sessions for 6 weeks
214399043|NCT02062190|DRUG|resveratrol|"100mg 2x/day~1 month"
214399044|NCT00000582|DRUG|factor ix|
215095546|NCT05230485|OTHER|CPAP level|The level of continuous distending pressure (or positive end-expiratory pressure) chosen on CPAP
215121440|NCT00047515|DRUG|Alcon Investigational Agent|
215003697|NCT07124780|BEHAVIORAL|Standard Vocational Services|In Standard Vocational Services, participants will meet with a representative from the American Jobs Center (AJC) who will help them find a job by identifying their interests, assess their skills and abilities, and advise them on in-demand jobs and potential training opportunities.
215003698|NCT07123805|DEVICE|Acupuncture group|In the Acu group, acupuncture and auriculotherapy will be added to the standard treatment: patients will undergo three/four sessions of manual acupuncture lasting 20 minutes, the first in the immediate pre-operative period and the subsequent ones at a distance of 24, 48, 72 hours from surgery. The treatment includes manual acupuncture applied to specific points: LI4, LV3 and ST36 bilaterally and monolaterally SP6 and GB34, ipsilateral to the knee to be prostheticized. Furthermore, auricolar needles will be positioned, before surgery, for self-stimulation of the auriculotherapy points corresponding to Shen Men bilaterally and the knee point ipsilateral to the surgical side.
215003699|NCT07122505|BEHAVIORAL|Orofacial myofunctional therapy|Orofacial myofunctional therapy consists of a set of oropharyngeal exercises to correct abnormal orofacial functions such as mouth breathing and a caudal tongue position, and strengthen upper airway muscles (e.g., muscles of the tongue and soft palate) that are involved in maintaining airway patency.
215003700|NCT07121907|DEVICE|TAVR using a guidance software|TAVR procedure with TAVIPILOT augmented reality guidance software operating during the procedure, enabling clinicians to assess the live analysis and recommendations provided by the software.
214399045|NCT03160911|DEVICE|Over-the-scope clip (OTSC)|The device provides a robust and strong tissue apposition. The system was developed to close perforations and treat bleeding in the gastrointestinal tract. In chronic ulcers, an anchor device can be used to pull the ulcer base toward the aspiration cap to facilitate accurate clip application. Endoscopic haemostasis would be achieved with the use of this device and/or injection of adrenaline
214399046|NCT03160911|DEVICE|Conventional Endoscopic Haemostasis|This includes the use of heater probe, endoscopic clipping and injection of adrenaline for endoscopic haemostasis
214399047|NCT01556243|PROCEDURE|therapeutic conventional surgery|
214399048|NCT01556243|RADIATION|whole breast irradiation|
214399049|NCT01388543|DRUG|Atazanavir|Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
214399050|NCT06476340|OTHER|No intervention|None, questionnaires/CBCT/3D photography/physical examination
214399051|NCT03540979|PROCEDURE|endometrial preparation for frozen blastocyst transfer|medical endometrial preparation for frozen blastocyte transfer
214399052|NCT03540979|DRUG|Letrozole|Aromatase inhibitor - 2.5mg/d for 5 days
214399053|NCT03540979|DRUG|Ovidrel|recommbinant hCG 250 mcg- single sc injection to induce ovulation
214399054|NCT03540979|DRUG|Estrofem|Estrofem 2mg\*3/d for endometrial preparation
214399055|NCT03540979|DRUG|Endometrin 100Mg Vaginal Insert|vaginal tab for lutheal support
214399056|NCT05919667|DIETARY_SUPPLEMENT|Dairy and plant-based dairy beverages and solids|Crossover design: participants received all treatment arms in a randomized order
214503852|NCT05366751|DRUG|SAGE-324|SAGE-324 oral tablets
215003701|NCT07119398|COMBINATION_PRODUCT|Oxytocin plus Foley Catheter|Intravenous oxytocin and a transcervical Foley catheter
215003702|NCT07119398|DRUG|Oxytocin|Intravenous oxytocin
215003703|NCT06934252|DRUG|TRB-061|Single subcutaneous injection of TRB-061 at escalating doses
214399057|NCT03491124|OTHER|Auricular Acupuncture|Up to five small ASP needles placed in each ear until pain is reduced to 1/10.
214399058|NCT03491124|OTHER|Sham Treatment|Laser pointer pointed at the ear, but not turned on.
214399059|NCT00408161|BEHAVIORAL|Contingency Management|prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake
214399060|NCT00408161|BEHAVIORAL|standard case management treatment|6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
214399061|NCT02948543|BIOLOGICAL|Bacillus of Calmette-Guerin (BCG)|A strain of tubercle bacillus which modifies biologic response.
214399062|NCT02948543|DRUG|Mitomycin (MM)|An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
214399063|NCT03492996|DRUG|LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose|To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a \[14C\]-LCB01-0371-tracer dose to healthy subjects
214399064|NCT05397808|OTHER|Pilates Training|The group that received pilates training.
214399065|NCT05397808|OTHER|breathing and relaxation exercises|The group who received breathing and relaxation exercises with a home program.
214399066|NCT04532437|OTHER|artificial intelligence-based skin aging simulation|Photographs of the volunteers' facial skin will be taken in the Department of Dermatology at baseline using a modern skin analysis photo system (VISIA®, Canfield Scientific, Parsippany, NJ, USA) and afterwards a simulation of the participants' facial skin aging will be performed with the VISIA® photo analysis System.
214399067|NCT04532437|OTHER|electronic questionnaire 1|Electronic questionnaire about current sun-related knowledge and protective behaviours via link with smartphone before and after the skin aging simulation.
214399068|NCT04532437|OTHER|electronic questionnaire 2|Participants report their perception of the interventions and their motivation for improved sun protection by completing an electronic questionnaire after the skin aging simulation.
214399069|NCT05967676|DIAGNOSTIC_TEST|Turkish adaptation, validity and reliability|"This study was conducted as test-retest design and the psychometric properties of PRIA-RS were examined in injured athletes"
214399070|NCT01656928|BEHAVIORAL|preschool-based nutritional intervention|6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
214399071|NCT01947595|BEHAVIORAL|intensified lifestyle intervention|"* physical activity 6 hours per week, 50% guided activity~  * recorded by an accelerometer (Aipermotion 440)~* 16 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
214503853|NCT00179933|BEHAVIORAL|Newborn Individualized Assessment Program|
215003704|NCT06934252|DRUG|TRB-061|Subcutaneous TRB-061 administered every 4 weeks for a total of 4 doses
215003705|NCT06934252|DRUG|TRB-061|Subcutaneous TRB-061 administered every 4 weeks for 3 doses
215121441|NCT00249509|DRUG|Nefazodone|
215003706|NCT06934252|DRUG|Placebo|Single and multiple Subcutaneous doses of placebo matching TRB-061 in patients.
214399072|NCT01947595|BEHAVIORAL|normal lifestyle intervention|"* physical activity 3 hours per week~  * recorded by an accelerometer (Aipermotion 440)~* 8 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
215003707|NCT03599713|DRUG|Retifanlimab|INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks
215003708|NCT06507917|DIAGNOSTIC_TEST|anal swabbing|anal swabbing
215003709|NCT06937619|DRUG|Risankizumab|Subcutaneous Injection
215003710|NCT06938529|DRUG|VCT220|Small molecule GLP-1RA tablet, film coated
215003711|NCT06938529|DRUG|Placebo|VCT220 Placebo tablet
215003712|NCT03452787|OTHER|None, cohort studies|this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.
215003713|NCT04358159|DEVICE|Ventralex|Repair of the hernia by a Ventralex patch in sublay position
215003714|NCT04358159|DEVICE|Progrip|Repair of the hernia by a Progrip mesh in onlay position
215095547|NCT00595816|OTHER|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
215095548|NCT03753139|DEVICE|Heart rhythm monitoring with portable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~4. Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel."
214399073|NCT01947595|BEHAVIORAL|Single lifestyle advice|"\- Single Health care advice and lifestyle advice (30 minutes) at the beginning~* recommend the individual target weight (5% less, if BMI 25\> kg/m²)"
214399074|NCT04278430|DEVICE|transcranial direct current stimulation|"The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge."
214503854|NCT07014072|PROCEDURE|intensive toe pressure evaluation|This measurement is non-invasive, painless and is also carried out as part of the care in the follow-up of critical limb ischemia. It takes place like a blood pressure measurement except that it is carried out at the level of a toe.
214503855|NCT07014072|OTHER|data collection|retrospective data
214503856|NCT07013357|BEHAVIORAL|Virtual Community Intervention|Modules of community building, civic participation, and achieving personal goals
215003715|NCT03383575|DRUG|Azacitidine|Given IV or SC
215003716|NCT03383575|DRUG|Enasidenib|Given PO
215003717|NCT03383575|OTHER|Quality-of-Life Assessment|Ancillary studies
215003718|NCT03537963|OTHER|mHealth Stepped-care Intervention|Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
215003719|NCT03537963|OTHER|Educational Control Condition|General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.
215003720|NCT03537963|OTHER|Questionnaire|After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
215003721|NCT03537963|OTHER|Interview|Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
215003722|NCT03537963|OTHER|Qualitative Interviews|To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.
215003723|NCT03537963|OTHER|Virtual Reality|The intervention will comprise six 360º videos of relaxing natural landscapes from which patients can choose (i.e., beaches, tropical scenes, calm thunderstorms, snowfall). Participants will also choose an audio accompaniment: a progressive muscle relaxation script, a deep breathing exercise script, a mindfulness meditation script, or scene-relevant audio (e.g., waves crashing for the beach scene).
215003724|NCT06948565|OTHER|observational study|This observational study aims to describe the clinical practices and the outcome of patients admitted in ICU.
215003725|NCT06950593|OTHER|Task Specific Training (TST)|Task specific training activities are types of activities that may be used in standard of care for stroke rehabilitation. Tasks will be completed in sitting or standing. As is usual in studies for upper limb hemiparesis, study participants will be picking up objects with their affected hands. They will work on grasp, grasp-lift of objects, release of objects, reaching and grasping, and reaching without grasping.
215003726|NCT06950593|OTHER|Transcutaneous electrical spinal cord stimulation (TESS)|The Digitimer DS8R Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation. The stimulus intensity used during the intervention will be determined based on individual maximum tolerance. We expect this current amplitude to be between 10mA and 100mA. Stimulation time will be standardized to a 30min duration during which the participant will perform task specific training tasks.
215095549|NCT01908439|OTHER|whole-body vibration|High amplitude whole-body vibration
215095550|NCT03465787|DRUG|Lurasidone HCL 160 mg|Lurasidone HCL 2 80mg tablets, QD
215095551|NCT03465787|DRUG|Quetiapine XR 600 mg|Quetiapine XR 2 300 mg tablets, QD
215095552|NCT00006056|DRUG|anti-thymocyte globulin|
215095553|NCT00006056|DRUG|busulfan|
215095554|NCT00006056|DRUG|cyclophosphamide|
215095555|NCT00006056|DRUG|cyclosporine|
215095556|NCT00006056|DRUG|etoposide|
215095557|NCT00006056|DRUG|filgrastim|
215003727|NCT06950593|OTHER|Sham transcutaneous electrical spinal cord stimulation (Sham TESS)|The Sham TESS intervention will utilize the same device and setup as the true TESS intervention. However, after turning on the stimulation and reaching the appropriate intensity, the stimulation will be ramped down and turned off for the remainder of the treatment session. The participant will be told that the stimulation was brought down to a sub-threshold level in order to maintain treatment group blinding.
215003728|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 0.3 mg
215003729|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 1 mg
215003730|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 3 mg
215003731|NCT01420744|DRUG|BT086|"BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.~Infusion rate:~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period."
214399075|NCT04278430|DEVICE|Sham tDCS|Five children with LSIH were randomly allocated to this group. All participants received sham tDCS for 3 weeks on alternate days and completed 10 treatment sessions. The sham tDCS followed preparatory procedures similar to that used for the experimental group, except that the device was disconnected after the initial increase of the current. Children usually started the activity without noticing that the device was disconnected. The children were assessed at baseline, during the 5th and 10th sessions, and during a follow-up that was scheduled for 4 months later.
214399076|NCT00099450|DRUG|INS50589 Intravenous Infusion|
214399077|NCT01337830|OTHER|Ariva® Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
214503857|NCT07013357|BEHAVIORAL|Control|Civic participation websites and educational information on civic and social connection provided to participants
214503858|NCT06691113|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
214503859|NCT06691113|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
214503860|NCT06691113|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
214503861|NCT04894591|DRUG|Zepzelca|Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.
215003732|NCT01420744|DRUG|1% Human Albumin infusion|"1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)"
215003733|NCT06551558|OTHER|global warming|A systematic pre- and post-operative warming associated with the optimization of per-operative warming.
215003734|NCT06551558|OTHER|per operative warming|"per-operative warming only thanks to the Optimized Forced air blanket with a prewarming of 10 minutes performed in the operating room."
214399078|NCT01337830|OTHER|Silver Wintergreen|Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
215003735|NCT04652310|DEVICE|TFNA extended-short nail (235 mm)|The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)
215003736|NCT04652310|DEVICE|TFNA long nail (260-480mm)|The long version of the TFN-advanced proximal femoral nailing system (TFNA)
215003737|NCT00347490|DRUG|Enoxaparine|
214399079|NCT04927039|DRUG|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
214503862|NCT06699784|BEHAVIORAL|Progressive lenses intervention|Progressive lenses intervention group will receive 1-month progressive lens correction in daily life.
214503863|NCT06699784|BEHAVIORAL|Single-vision lenses intervention|Single-vision lenses intervention group will use near-vision spectacles during near work and use their original habitual distant glasses for distance tasks for 1 month.
214503864|NCT07030842|PROCEDURE|liver resection|"This is a retrospective observational study analyzing existing clinical data; no experimental interventions were administered. The study evaluates the predictive performance of two deep learning models (preoperative and postoperative) using standard-of-care medical data collected during routine clinical practice, including:~Preoperative contrast-enhanced MRI scans Postoperative hematoxylin and eosin (H\&E)-stained whole slide images Clinical variables (laboratory results, pathology reports, and demographic data)~All data were collected as part of standard diagnostic and treatment protocols for hepatocellular carcinoma (HCC) patients undergoing liver resection. No additional interventions or modifications to clinical care were implemented for study purposes. The artificial intelligence models were applied to previously acquired, de-identified data to predict aggressive recurrence patterns"
214503865|NCT05502523|PROCEDURE|Pulmonary Artery-First Surgical Technique|Undergo pulmonary artery first surgical technique
215003738|NCT03537430|PROCEDURE|TNT uniportal VATS mediastinal tumor resection|TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.
215003739|NCT03537430|PROCEDURE|Traditional uniportal VATS mediastinal tumor resection|The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
215003740|NCT01127061|BEHAVIORAL|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
215003741|NCT04827446|OTHER|Wearable Sensor|Patient is given a wearable device to wear for 12 weeks.
215003742|NCT04827446|OTHER|Blue-blocking glasses|Patient is given blue-blocking glasses to wear at instructed times.
215003743|NCT04827446|OTHER|Clear glasses|Patient is given glasses that block no visible light.
215003744|NCT04827446|OTHER|Full SYNC app|Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.
215003745|NCT04827446|OTHER|"Dummy SYNC app"|Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.
215003746|NCT03719547|PROCEDURE|Abdominal radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
215003747|NCT03719547|PROCEDURE|Robot-assisted radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
215003748|NCT03719547|DIAGNOSTIC_TEST|Sentinel lymph node biopsy|Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
215003749|NCT06532916|OTHER|Experimental: Group1: Estelite Sigma Quick|Preheated conventional composite (Estelite Sigma Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Sigma Quick is a resin composite with the following composition (Silica-zirconiasupra-nano, monodispersingc spherica, Bis-GMA, UDMA, TEGDMA).
215003750|NCT06532916|OTHER|Experimental: Group 2: Estelite Flow Quick|Second group: Injectable flowable (Estelite Flow Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Flow Quick is a resin composite with the following composition (Silica-zirconia, supra-nano monodispersing spherical, Bis-GMA, UDMA,TEGDMA).
214399080|NCT04927039|DRUG|20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline|After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
215003751|NCT06558799|DEVICE|NovoTTF-200T|The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields exert electric forces intended to disrupt cancer cell division and induce immunogenic cell death.
215003752|NCT06558799|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
215003753|NCT05310552|OTHER|No interventions - observational study|No interventions - observational study
215003754|NCT02955394|DRUG|Enzalutamide|160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
214399081|NCT02359019|BIOLOGICAL|Pembrolizumab|Given IV
214399082|NCT02359019|OTHER|Laboratory Biomarker Analysis|Correlative studies
214399083|NCT00012181|DRUG|alvocidib|Given IV
214399084|NCT00012181|OTHER|pharmacological study|Correlative studies
215003755|NCT02955394|DRUG|Fulvestrant|500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
215095558|NCT00006056|DRUG|methotrexate|
215095559|NCT00006056|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214503866|NCT05502523|PROCEDURE|Biospecimen Collection|Correlative studies
214503867|NCT07032584|OTHER|Telerehabilitation Intervention|TheTelerehabilitation Intervention (TR) group utilizes a touchscreen tablet equipped with a computer-guided rehabilitation program that provides ongoing support and feedback for home-based rehabilitation.
215003756|NCT02729168|BIOLOGICAL|Human rabies vaccine|
215003757|NCT05846581|DEVICE|GORE® ACUSEAL Vascular Graft|"The device placement will be performed according to each participating site's standard practice. No specific procedures are required by the protocol.~At the time of the GORE® ACUSEAL Vascular Grafts implantation, procedural and adverse event information will be collected."
215003758|NCT05957107|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection|The drug was administered once every 4 weeks.
215003759|NCT06367114|BIOLOGICAL|ssCART-19|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
215003760|NCT06367114|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
215095560|NCT02291926|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
215121442|NCT00249509|DRUG|Bupropion|
215121443|NCT00742183|DEVICE|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
215121444|NCT00742183|DEVICE|Silvadene|Silvadene - dressing changes every day, more frequently if needed
215121445|NCT04057807|DRUG|LPS|LPS (0.4 ng/kg)
215121446|NCT04526626|DEVICE|Radiofrequency ablation for treatment of lower limb varicose veins (ClosureFast, Medtronic)|Thermal injury to long saphenous vein
214399085|NCT06488768|OTHER|Radial nerve block|Ultrasound-guided Radial nerve block. Conducted with 10 mL of Lidocaine 2%. Ultrasound image are stored for documentation.
214399086|NCT05774028|DRUG|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen|P-GEMD regimen (Every 3 weeks as a cycle, a total of 6 cycles) : Pegaspargase 3750 IU, d2; Gemcitabine 1000mg/m2, d1; Etoposide 65mg/m2, d2-d4; Mitoxantrone hydrochloride liposome 12mg/m2, d1; Dexamethasone 40mg/d, d1- d4.
215003761|NCT06367114|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
214399087|NCT01213173|DRUG|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
214399088|NCT01213173|DRUG|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
214399089|NCT06050291|DRUG|Fixed-Dose Combination (FDC) Tablet|Obicetrapib/Ezetimibe FDC tablet
215003762|NCT05872399|OTHER|Attitudes Towards Psychiatry - 30|The participants will answer their beliefs in 30 statements about psychiatry and mental health.
215003763|NCT03172000|DIAGNOSTIC_TEST|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
214399090|NCT02870946|PROCEDURE|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
214399091|NCT02870946|PROCEDURE|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
214399092|NCT06652737|BIOLOGICAL|PfSPZ-LARC2 Vaccine|The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)
214399093|NCT06652737|BIOLOGICAL|Normal Saline (Placebo)|Normal Saline Placebo
215003764|NCT01168180|OTHER|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
214399094|NCT06331299|DRUG|UGN-103|UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-103 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
214399095|NCT00001125|BIOLOGICAL|Varicella Virus Vaccine (Live)|
214399096|NCT06655012|DRUG|Salmeterol|Participants are administered 200 µg salmeterol (8 puffs) from a MDI device
214399097|NCT06655012|DRUG|Placebo|Participants are administered placebo (8 puffs) from a MDI device
214399098|NCT06654986|DRUG|Salmeterol + amino acid availability|The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device and 40 g amino acid availability (clear whey in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
214399099|NCT06654986|DRUG|Salmeterol + placebo|The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
214399100|NCT06654986|DRUG|Placebo + placebo|The participants will be administered placebo (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
214399101|NCT05727033|BEHAVIORAL|Participatory teaching group|"The intervention will be called FEDE-ITS® methodology. This methodology is self-designed and self-developed and draws on previous work in equivalent populations. It is based on teaching in a participatory way knowledge and healthy attitudes related to the five most prevalent STIs in the province of Barcelona and Lleida, the methods to avoid contagion, and the health resources that can be consulted in case of infection, contact with an infected person or concerns. In addition, a gender perspective is incorporated to contribute to freer and more egalitarian relationships and reduce the likelihood of violence against women which develops in adolescence.~The cross-cutting themes of the training are: health, pleasure, self-esteem, knowledge-based freedom of choice, equality between people and respect for sexual freedom. Therefore, the ultimate goal is to prevent abusive power relations and macho violence."
214399102|NCT05727033|BEHAVIORAL|Sham control group|"The Health and School program was implemented to promote health in schools, and for this reason the program's nurse attends annually to address problems related to sexual affective health within the curricular itinerary of each school, but not specifically on sexually transmitted infections or gender perspective."
214399103|NCT05538481|OTHER|Semi-structured interview|A collection of individual cultural values and palliative care preferences within the focus group meetings
214399104|NCT05538481|OTHER|Developed survey completion|A collection of individual responses to a survey created after focus group completion and analysis
214399105|NCT05538481|OTHER|Systems of Belief Inventory (SBI-15R)|A 15-item questionnaire designed to measure religious and spiritual beliefs and practices and the social support derived from a community sharing those beliefs.
214399106|NCT00852137|DRUG|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
214503868|NCT07035470|OTHER|PhenoAge-Based Biological Age Assessment|Biological age was retrospectively calculated using the PhenoAge algorithm, based on nine routine laboratory parameters and chronological age. This model estimates phenotypic aging and was used to predict short-term outcomes including mortality, functional status, comorbidity burden, and hospital length of stay. No new intervention was administered; all data were collected from existing medical records.
214503869|NCT07039214|OTHER|Observation of low-back pain symptoms|No intervention was applied.
214399107|NCT00852137|DRUG|Vehicle Gel|Vehicle Gel once daily for 2 consecutive days
214399108|NCT03253770|DEVICE|SIMMAX2|Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
214399109|NCT04880161|BIOLOGICAL|Ampion|Inhaled Ampion
215003765|NCT01168180|OTHER|Ultrasound therapy and hot pack|
215003766|NCT00133211|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation
215003767|NCT04373057|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.
215003768|NCT04373057|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
215003769|NCT01576965|DRUG|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
215003770|NCT01610388|DRUG|500mg IV GSK1322322/placebo|500mg IV
215003771|NCT01610388|DRUG|1000mg oral GSK1322322/placebo|1000mg oral
215003772|NCT01610388|DRUG|1000mg IV GSK1322322/placebo|1000mg IV
215003773|NCT01610388|DRUG|1500mg oral GSK1322322/placebo dose|1500mg oral
215003774|NCT01610388|DRUG|1500mg IV GSK1322322/placebo|1500mg IV
214399110|NCT04880161|OTHER|Placebo|Inhaled Placebo
214399111|NCT01244139|DRUG|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
214399112|NCT01244139|DRUG|Placebo|IV infusion dummy drug
214399113|NCT04788030|OTHER|Nerve reconstruction|Nerve bridging with muscle-in-vein conduits
214503870|NCT07039214|OTHER|Observation of healthy comparators|No intervention was applied.
214503871|NCT07035171|OTHER|Multimodal prehabilitation intervention|"Multimodal prehabilitation interventions (CABGpreHAB):~* Home-based exercise intervention delivered by a skilled physiotherapist via a web-based application.~* Nutritional intervention~* Psycho-educative intervention~* Smoking cessation~* Alcohol cessation"
214503872|NCT07035171|OTHER|Control (Standard treatment)|This includes standard information about CABG surgery, pre- and postoperative care, and postoperative physical activity advice. Patients are either admitted days before or on the day before surgery. They receive written materials and links to animated videos about preparing for surgery. This preparation includes counseling with a multidisciplinary team, including a department nurse, a physiotherapist, a cardiac anesthesiologist, and a surgeon.
214503873|NCT07036224|DEVICE|Exergaming Training using Kinect sensor device|A 6-week standardized training program was carried out with the use of the game rehabilitation platform with Kinect sensor device. The subjects exercised under the supervision of an instructor for at least 30 minutes twice a week.
214503874|NCT07043829|DIETARY_SUPPLEMENT|SAEP (Solution of Cimarrón Bean Extrudate in Water)|A single oral dose of 10 grams of Cimarrón bean (Phaseolus vulgaris, variety Cimarrón) extrudate dissolved in 500 mL of water, consumed once under fasting conditions. Used to evaluate acute effects on platelet function and postprandial glycemia.
214503875|NCT07044284|DEVICE|Fractal mindfulness recombination|Immersive virtual reality using fractal mindfulness software
214503876|NCT07044076|OTHER|Quality of life|The four questionnaires (MQOL, EQ-5D, Karnofsky, and FACT-Br) will be sent to patients online using the secure online platform Redcap.
214503877|NCT07043179|DEVICE|Nighttime Splinting|Nighttime splinting for 6 weeks.
214503878|NCT07043179|DRUG|Corticosteroid Injection|Local corticosteroid injection (triamcinolone acetonide 40mg). A single injection of triamcinolone acetonide 40mg mixed with an equal volume of 1% lidocaine is administered. The injection is performed under ultrasound guidance and anatomical landmarks to target the proximal carpal tunnel. With the wrist extended, the needle is typically inserted on the ulnar side of the palmaris longus tendon, approximately 1 cm proximal to the wrist crease. If blood is aspirated or the patient reports paresthesia (which usually indicates nerve irritation), the injection site should be adjusted.
214503879|NCT07043179|OTHER|Evaluation and Dynamic Adjustment|6 weeks later, all patients will undergo evaluation of their initial treatment. Further therapeutic decisions will be made based on physician assessment, including: continuing nighttime splinting, administering corticosteroid injections to patients who initially received only the splint, adding nighttime splinting for patients initially received only corticosteroid injections, and transitioning from nighttime splint use to continuous wear. Subsequently, evaluations will be conducted every 6 weeks, with dynamic adjustments to the treatment plan. Corticosteroid injections will be administered at least 24 weeks apart, and the second injection dosage may be adjusted based on the patient's condition, with a maximum dose of 80mg. Throughout the study period, physicians will perform electrophysiological examinations according to changes in patients' clinical status.
215003775|NCT01610388|DRUG|2000mg IV GSK1322322J/placebo|2000mg IV
215003776|NCT01610388|DRUG|3000mg IV GSK1322322J/placebo|3000mg IV
214399114|NCT05151042|PROCEDURE|wafer-less approach|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position. CAD/CAM generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment. Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts.~Removal of guide, then BSSO is performed. The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
214503880|NCT07044219|PROCEDURE|Third molar surgery|During the operation, after local anaesthetics (LIDOCAIN-ADRENALIN 20 mg/0,01 mg/ml) the same mucoperiosteal (sulcular flap without vertical incision) is raised. Bone removal happens with physio-dispenser driven surgical handpiece (60ml/min irrigation; 8.000-16.000 rpm) and tungsten carbide round drills. Tooth section is made where indicated. After tooth removal wound is rinsed with 10-20ml physiologic salt, the wound is closed with 4.0 monofil non-resorbable suture material and then gel test or placebo is injected with syringe and applicator tip into the wound and on the surface of the wound. Patient bites a gauze for 20 minutes.
214503881|NCT07043218|DRUG|Chimeric Antigen Receptor T Cells (CAR-T)|chimeric antigen receptor T cells
214522603|NCT05422859|OTHER|MobiDig|"The application will contain the following modules:~1. information and knowledge about heart failure;~2. vital sign diary, which can be sent to the certified HFU~3. pedometer (individualized step-goal), cardiac home training videos~4. frequently asked questions and connection to a certified HFU provider by a heart failure hotline"
215003777|NCT01610388|DRUG|1000mg IV GSK1322322J/placebo|1000mg IV
215003778|NCT04375215|PROCEDURE|Selective caries removal|After caries removal restoration of tooth will be performed
215003779|NCT04375215|PROCEDURE|Stepwise caries removal|After caries removal restoration of tooth will be performed
215003780|NCT00003456|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
215003781|NCT06078293|BEHAVIORAL|Home-based Exercise Program|12-week home-based exercise program that involves individualized exercise prescription and motivational health coaching calls.
215003782|NCT05136664|DRUG|Patiromer Powder for Oral Suspension (Part A)|"Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
215003783|NCT05136664|DRUG|Placebo (Part B)|Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.
214399115|NCT05151042|PROCEDURE|Computer Guided orthognathic surgery using occlusal wafers|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position.~dental casts will be scanned dental casts are superimposed to the CT cuts into the virtual software environment to produce final wafer CAD/CAM repositioning guide. the generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment.~Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts. Removal of guide, then BSSO is performed.~The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
214399116|NCT06662695|DIETARY_SUPPLEMENT|Ginger-based supplement|Ginger-based supplement in a dosage of 1500 mg
214399117|NCT06662695|DIETARY_SUPPLEMENT|Placebo|Capsules containing corn flour
214503882|NCT07043530|BEHAVIORAL|In-person sleep hygiene-based intervention|The in-person sleep hygiene-based intervention will be delivered in 8 sessions by an sleep expert using digital resources, previously designed and expert validated. During the intervention, the following topics will be covered: (1) sleep hygiene generalities, (2) sleep and environment, (3) sleep and technology, (4) sleep and diet, (5) sleep and excercise, (6) sleep and stimulus control, (7) breathing techniques, (8) mindfulness. The sessions will be delivered twice a week with an approximated duration of 45 minutes each, until completed.
215003784|NCT05136664|DRUG|Patiromer Powder for Orals Suspension (Part B)|"Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
214399118|NCT04419532|DRUG|DS-1055a|"Administered as an intravenous infusion on Day 1 of every 21-day cycle following low dose administration(s) in priming dose period.~Infusion duration: 180 minutes for the first infusion, and if no infusion-related reaction, 120 minutes for subsequent infusions"
214399119|NCT00723333|PROCEDURE|Reduced Intensity Conditioning (RIC) Allogenic Transplant|Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
214399120|NCT01354106|DEVICE|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
214399121|NCT06918951|RADIATION|Stereotactic ablative radiotherapy (SABR)|SABR is a safe and effective modality for metastasis-directed therapy, delivering a high dose of radiotherapy to a small target using conformal techniques. Emerging evidence suggests that SABR for oligoprogressive cancer may extend the duration of systemic therapy, and result in improvements in Progression Free Survival (PFS) and Overall Survival (OS) compared to historic controls.
214399122|NCT06918951|RADIATION|Palliative radiotherapy|"Radiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression.~Participants will continue their current systemic therapy (if already on systemic therapy at the time of oligoprogression event) or continue off systemic therapy (if the participant was not on systemic therapy at the time of the oligorecurrence event)."
214399123|NCT06875895|OTHER|Traditional Physiotherapy|Hotpack, Tens and Ultrasound application
214399124|NCT06875895|OTHER|Motor Imagery Training|Kinesthetic and visual motor imagery will be applied.
214399125|NCT06703580|DRUG|Hyperbaric prilocaine 2% 40 mg|this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in a dose of 40 mg.
214399126|NCT06703580|DRUG|hyperbaric prilocaine 2% 50 mg|comparison of 3 different doses of prilocaine
214399127|NCT06703580|DRUG|hyperbaric prilocaine 2% 60 mg|this study compare 3 different doses of prilocaine
214503883|NCT07043530|BEHAVIORAL|Online sleep hygiene-based intervention|The online sleep hygiene-based intervention will be delivered in 8 sessions through a self-paced educational platform; the content will be the same as in the in-person intervention, but tailored for use in digital learning platforms. The suggest completion time for each session will be 45 minutes. Although its self-paced nature, participants are required to complete it within one month, following the same timeline as the face-to-face arm.
214399128|NCT06920446|BIOLOGICAL|UCAR T-cell group|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
214503884|NCT07044271|DRUG|Olomorasib|Single dose
215003785|NCT06957223|DRUG|Dextromethorphan-Bupropion|Participants will receive a fixed-dose combination of dextromethorphan-bupropion, dosed according to approved guidelines for major depressive disorder, administered orally for 6 weeks.
215003786|NCT06957223|DRUG|SSRIs|Participants will receive an SSRI at standard therapeutic doses, administered orally for 6 weeks.
215003787|NCT03794856|OTHER|Functional and Structural Magnetic Resonance Imaging (research grade)|Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.
215003788|NCT03794856|OTHER|Cognitive Function Testing (non-diagnostic)|Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.
215003789|NCT03794856|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Participants will fill out asthma and psychological questionnaires (non-diagnostic)
215003790|NCT02689622|OTHER|research of disease-related factors|included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
214399129|NCT06908278|BEHAVIORAL|Suture Simulation Training for Episiotomy Repair|"This intervention involves training participants to perform episiotomy repairs using a suture simulator. Participants will practice suturing techniques in a controlled, safe environment to improve their self-efficacy in performing the procedure. The training includes both theoretical learning and hands-on practice. The goal is to enhance the participants' confidence and competence in performing episiotomies.~(This description outlines the nature of the intervention and the learning objectives.)"
215003791|NCT02689622|OTHER|research of comorbidities|HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G
215003792|NCT02689622|OTHER|physical performance|Activities of Daily Living and physical performance
215003793|NCT03945136|BEHAVIORAL|Dynamic Interpersonal Therapy|Dynamic Interpersonal Therapy is a time-limited, manualized, interpersonal and affect-focused psychodynamic treatment that is frequently used to target depression and anxiety.
215003794|NCT05399771|DEVICE|Laser Doppler|Study team will use a PeriScan PIM 3 System Laser Doppler to scan for blood perfusion before and after the Thermofield treatment. The PeriScan PIM 3 System is for non-invasive two-dimensional imaging of peripheral tissue.
214399130|NCT06919874|BEHAVIORAL|Thinking out Loud Session|Participants will complete one thinking out loud session (approx. 60 minutes). The session will be led by a yoga therapist (see below) either in person at the hospital or via Zoom. Individual patients, caregivers or patient-caregiver dyads will attend the session. Each participant will need to either bring their own device or will use an institutional loaner device if no personal device is available. During the session, participants will be asked to download the app from the device appropriate app store and open the app. Then, we will implement the thinking out loud methods asking participants to continuously think out loud, meaning verbalizing their thoughts as they move through the user interface of the app. The sessions will be audio recorded with permission obtained during the consent process. Specific feedback will be requested using a semi-structured interview approach
215003795|NCT05399771|DEVICE|Radiofrequency Heating System|The radiofrequency will be set to achieve 42°C/107.6°F) and maintain this temperature consistently during the application time. This temperature is mild and may feel like a drugstore heating pad. The device will be turned on on one leg and will remain off on the other. The time for the heating will be 36 minutes, during which participants will remain in a reclined position, with their legs elevated. The device takes approximately 6 minutes to achieve a tissue temperature of 42°C, and the treatment time with consistent temperature application will be 30 minutes.
214399131|NCT06918418|DRUG|Salbutamol (Ventolin®)|Children were given 0.5% salbutamol aerosol solution (0.15 mg/kg weight, up to a maximum of 5 mg) in 5mL of normal saline solution for 7 min every 20 min for 2 h, and then every 30 min for two more hours. Aerosol were generated by nebulizer powered by compressed-air (5 L/min) with Y-connection with oxygen (3 L/min) and delivered via a face mask.
215003796|NCT05399771|DEVICE|Thermal Imaging|Study team will take thermal imaging photographs of the treatment area following each treatment.
215003797|NCT05399771|OTHER|Healthcare Questionnaire & Measurement|"A survey tool created to collect info from participants including:~1. Name~2. Age~3. Weight/ height~4. Pregnant or nursing?~5. History of blood clots?~6. Any wound healing problems?~7. Any active open wounds on the legs?~8. Any autoimmune disorders?~9. Phone number~10. Email address~A measurement of the participants calf will be taken as well using a measuring tape."
215003798|NCT05879913|DEVICE|Coronary CT Angiography (CCTA)|Coronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
215003799|NCT05253508|DRUG|Lidocaine 2% Injectable Solution|A digital nerve block by injections to the base of the finger
215003800|NCT03112252|OTHER|no specifications. Depending on the patients|patients with allergic rhinitis
214399132|NCT06918418|DRUG|salbutamol + ipratropium bromide nebules|In addition to Salbutamol nebulization, children received ipratropium bromide nebulization. Ipratropium bromide solution (250 mcg in children \<20 kg weight or 500 mcg in children \>=20 kg) every 20 min for the first 2 hours then every 30 min for 2 hours more will be given in between the salbutamol nebulization. Aerosol were generated by nebulizer powered by compressed-air (5 L/min) with Y-connection with oxygen (3 L/min) and delivered via a face mask.
214399133|NCT06917924|DIAGNOSTIC_TEST|lumbar puncture|Standard of care of LP
215003801|NCT02562885|DEVICE|Acoustic pulses|"Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB."
215003802|NCT00520000|DRUG|Carboplatin|standard dose of area under the curve (AUC) AUC of 6 in all arms
215003803|NCT00520000|DRUG|Abraxane|75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
215003804|NCT00520000|DRUG|Abraxane|180mg/m2 - 340mg/m2, repeated every 21 days
214399134|NCT06919523|DRUG|Dapagliflozin 5mg|Dapagliflozin 5m orally once daily for 3 months plus standard care (diuretics and Large volume paracentesis)
214399135|NCT06919523|DRUG|Standard care treatment|Diuretics and Large volume paracentesis as indicated
215003805|NCT00520000|DRUG|Abraxane|100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
215003806|NCT06962579|BEHAVIORAL|Exercise intervention|"* 30-minute face-to-face session with physiotherapist outlining the state of the science on the importance and benefits of physical activity during and after cancer treatment and advising patients to engage in regular physical activity according to the general guidelines~* 12-week individually tailored exercise program~  * Home-based aerobic exercise, 3 times per week at moderate intensity~ * Supervised resistance and sensorimotor exercises, 2 times per week"
215003807|NCT03542799|BIOLOGICAL|EGFR IL12 CART|EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
215003808|NCT05579340|OTHER|Exercise|6 months of combined aerobic and resistance exercise
215003809|NCT03284099|DRUG|ACEi, ARB|To take the ACEis or ARBs before bedtime instead of in the morning
215003810|NCT01713517|OTHER|Indoor residual insecticide spraying (IRS)|Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
215003811|NCT01713517|DEVICE|Long Lasting Insecticidal Nets (LLIN)|Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
215003812|NCT02849886|DRUG|T lymphocytes iCASP9 ΔCD19|Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene
214399136|NCT06917911|PROCEDURE|Biospecimen Collection|Undergo optional buccal cell collection and/or blood sample collection
215003813|NCT02849886|DRUG|Dimerizer drug AP1903|"AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~* Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~* Grade ≥3 toxicity attributable to GMC."
214399137|NCT06917911|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214399138|NCT06917911|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214399139|NCT06917911|DRUG|Cytarabine|Given IV
214399140|NCT06917911|DRUG|Daunorubicin Hydrochloride|Given IV
214399141|NCT06917911|PROCEDURE|Echocardiography Test|Undergo echocardiography
214399142|NCT06917911|DRUG|Gemtuzumab Ozogamicin|Given IV
214399143|NCT06917911|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214399144|NCT06917911|DRUG|Venetoclax|Given PO
214399145|NCT01686594|DRUG|8-methoxypsoralen|8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
214503885|NCT06745362|OTHER|self-monitoring of breath acetone|Participants perform self-monitoring of braeth acetone in order to get information about their ketosis state.
215003814|NCT05751863|OTHER|Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects|"The Intervention is using a sedation strategy for MV trauma that initially targets pain by intermittent boluses followed by an IV drip only if required. Sedatives are limited to agitation management and for a limited duration as needed. This analgo-sedation approach differs from the approach of using IV drips of analgesics and sedatives simultaneously and discontinuing both once daily to assess subjects."
215003815|NCT05751863|OTHER|Protocol Directed Sedation and Daily Sedation Interruption|The active comparator in this study is using a sedation strategy for MV trauma that uses IV drips of analgesics and sedatives simultaneously and discontinues both once daily to assess subjects.
215003816|NCT00957710|BEHAVIORAL|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
215003817|NCT02906618|DRUG|LY3039478|Administered orally
215003818|NCT02906618|DRUG|13C 15N 2H-LY3039478 IV|Administered IV
215003819|NCT02467816|BEHAVIORAL|SmartMeal application|The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
215003820|NCT02467816|BEHAVIORAL|Distributed points of sale|To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
215003821|NCT02467816|BEHAVIORAL|Staff wellness curriculum|A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
215003822|NCT04254211|OTHER|NLR|neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
215003823|NCT02787291|DEVICE|Ellipse VR ICD and Durata/Optisure lead|Non-diagnostic MRI Scan sequence of head and chest
214399146|NCT05455463|BEHAVIORAL|Online aphasia-adapted physical activity class|Online 50-minute physical activity sessions, two to three times weekly for 10-11 weeks. The activity instructions will be modified to be aphasia-friendly (simplified language, multimodality support).
214399147|NCT02283099|BIOLOGICAL|rVSVΔ-ZEBOV-GP|single dose of rVSVΔ-ZEBOV-GP (3x10\^6 pfu, 2x10\^7 pfu or 3x10\^5)
214399148|NCT03575442|BEHAVIORAL|"3 session program of art therapy"|With this program, we expect to offer socio-emotional well-being in the psychiatric context, and creative self-expression through painting. In addition, we hope to provide contributions towards the creation of quality standards of the professional practice of nurses, within the context of implementing psychosocial programs in mental health.
214399149|NCT00542945|DEVICE|ICD|Implantation of an ICD
214399150|NCT00542945|OTHER|Optimal medical treatment|ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
214399151|NCT03312985|PROCEDURE|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
214399152|NCT03312985|PROCEDURE|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
214399153|NCT00283309|DRUG|Memantine|
214503886|NCT06745362|OTHER|lifestyle-intervention via LIM-App|Participants are offered a lifestyle intervention via LIM-App.
214503887|NCT06812507|PROCEDURE|intact umbilical milking|"Umbilical cord milking will be performed by holding the newborn at or~∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team."
215003824|NCT04320667|DIAGNOSTIC_TEST|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
215003825|NCT01730196|BEHAVIORAL|Fit Body and Soul|
215003826|NCT01730196|BEHAVIORAL|Wellness Education|
214399154|NCT00283309|DRUG|Riluzole|
214399155|NCT04339218|DEVICE|Cryoablation|"Cryoablation will be performed by a specialized radiologist, percutaneously, ie through the skin. The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold.~The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly."
215003827|NCT02874898|BEHAVIORAL|Brief Imaginal Exposure|Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
215003828|NCT04213131|OTHER|Stem cell transplantation|The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.
215003829|NCT00143507|DRUG|Ivabradine|
215003830|NCT00143507|DRUG|Placebo|
215003831|NCT04095013|DRUG|Bupivacaine, fentanyl|Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,
215003832|NCT04095013|DRUG|Bupivacaine, dexmedetomidine|Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
214399156|NCT04339218|DRUG|Pembrolizumab|Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
215003833|NCT04136678|OTHER|walking training|15 minutes of conventional walking training 15 minutes of treadmill backward walking training 15 minutes of treadmil forward walking training
215003834|NCT06256276|DIETARY_SUPPLEMENT|Whey protein powder and L-carnitine|Dietary supplement intervention for 16 weeks
214399157|NCT04339218|DRUG|Pemetrexed|Pemetrexed will be prescribed and administered at the dose recommended by market authorization.
214399158|NCT04339218|DRUG|Carboplatin|Carboplatin will be prescribed and administered at the dose recommended by market authorization.
214399159|NCT00731042|DRUG|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
215003835|NCT06256276|DIETARY_SUPPLEMENT|Maltodextrin placebo powder and Psyllium Husk capsules|Maltodextrin placebo powder and Psyllium Husk capsules
215003836|NCT01268735|DRUG|Lubricating eyedrops containing hydroxypropyl-guar|Eyedrops BID
215003837|NCT00484159|PROCEDURE|Radiofrequency denervation of medial branches|Radiofrequency of medial branches that innervate the lumbar facet joints
215003838|NCT00484159|DRUG|0.5% bupivacaine|Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
215003839|NCT00484159|DRUG|2% lidocaine|Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
215003840|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic block
215003841|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
215003842|NCT00484159|PROCEDURE|Radiofrequency denervation|Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
215003843|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic facet block.
215003844|NCT00446875|OTHER|Administration of oral Sucrose|Participants received oral sucrose 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
215003845|NCT00446875|OTHER|Administration of oral Placebo|Participants received Placebo 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
215003846|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (Z-Drug-mono cohort)|"1. Pretreatment phase: Continue pre-registration treatment (Z-drug monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for Z-Drug. Increasing LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment from the first treatment phase. Changing LEM dose is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
215003847|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (SUV-mono cohort)|"1. Pretreatment phase: Continue pre-registration treatment (SUV monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed."
215003848|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (SUV-combination cohort)|"1. Pretreatment phase: Continue pre-registration treatment (SUV and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
215003849|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (RMT-combination cohort)|"1. Pretreatment phase: Continue pre-registration treatment (RMT and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for RMT and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
215095561|NCT05805644|DEVICE|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial or full assistance for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
215095562|NCT02506023|DRUG|Desmopressin|Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
214399160|NCT00731042|DRUG|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
214399161|NCT03104569|PROCEDURE|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
214399162|NCT00149721|PROCEDURE|Ventriculo-peritonal shunting|
214399163|NCT05365074|DRUG|Chloroprocaine Injection|Spinal anesthesia with 50 mg of 1% Chloroprocaine
214399164|NCT00906295|OTHER|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
214503888|NCT06812507|PROCEDURE|cut umbilical milking|Another technique, used more often in Asia, involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM
214503889|NCT06812507|PROCEDURE|Delayed cord clamping|Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60-second before clamping the cord.
215003850|NCT05206539|DRUG|Self-assembling peptide (P11-4)|"Prior to application, teeth are isolated by cotton rolls and gently air dried. The surface of the lesion is conditioned with a 2% sodium hypochlorite solution for 20 s and then rinse with water. Application of 35% phosphoric acid etching gel for 20 sec followed by rinsing with water-air spray for 30 sec. Drying the surface with compressed oil-free air for 60 sec. Curodont Repair is dissolve in 0.05 ml of distilled water and applied to the surface and allowed to work for about 5 min.~Participants will receive oral hygiene instructions."
215003851|NCT05206539|DRUG|CPP-ACFP|"Prior to application, teeth are isolated by cotton rolls and gently air dried. Application of fluoride varnish with a brush applicator on the surface of the teeth for 5 minutes. Patients is advising not to brush their teeth or chew food for at least 4 h after treatment.~Participants will receive oral hygiene instructions"
215003852|NCT05206539|DRUG|Resin infiltration|The validated ICON Vestibular (DMG) infiltration lesion infiltration protocol is applied. Icon Etch (DMG) etching gel containing 15% hydrochloric acid is applied for 120 seconds using an applicator. It is then removed by rinsing thoroughly with water-air spray for 30 seconds. Then follows application of pure alcohol - Icon Dry (DMG) for 30 seconds for complete drying of the lesion and additional drying compressed oil-free air for 40 sec. Application of Icon Infiltrant (DMG) using a microapplicator allows it to penetrate for 3 minutes, during which, if necessary, it is reapplied several times. Excess material is removed with dry microbrushes and followed by light curing for 40 seconds. Re-applying of the infiltrate for 1 minute, removal of excess material, light curing for 40 seconds. Participants will receive oral hygiene instructions
214399165|NCT00906295|OTHER|Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L|Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
214399166|NCT01419301|BEHAVIORAL|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is program based on daily meditation practice that guides an individual towards increased awareness and self-regulation of thoughts and actions. MBSR is easier to implement and may be shown to be more effective than cognitive-behavioral stress reduction, and is more applicable to patients with chronic illness.
214503890|NCT06876194|OTHER|Music intervention|A previously defined list of songs will be administered to these patients during the procedure.
215095563|NCT00358436|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
214399167|NCT02692235|DIETARY_SUPPLEMENT|carnitine|1500 mg/d l-carnitine-l-tartrate
214399168|NCT02692235|DIETARY_SUPPLEMENT|placebo|isonitrogenous
215003853|NCT05206539|OTHER|Control Group, No Treatment|Everyday oral hygiene instructions Subjects will receive non-prescription fluoride toothpaste (1400 ppm Fluoride, Elmex junior) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate and rinse.
215003854|NCT02971826|DEVICE|REVIVETM SE thrombectomy|Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion
214399169|NCT00802841|DRUG|nilotinib|Supplied as 200 mg tablets
214399170|NCT00802841|DRUG|imatinib|Supplied as 100 mg and 400 mg tablets
214399171|NCT01219465|BIOLOGICAL|umbilical cord mesenchymal stem cells|Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
214399172|NCT04312828|PROCEDURE|Orthopedic management of the Z-foot|Orthopedic treatment with femoropedic plasters and slotted splints in 1st intention
215003855|NCT04569344|OTHER|Laboratory test positive for SARS-CoV-2 virus|Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2
215095564|NCT00358436|DRUG|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
215095565|NCT00416325|DIETARY_SUPPLEMENT|lycopene|
214399173|NCT05498974|OTHER|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
215095566|NCT00416325|OTHER|laboratory biomarker analysis|
215095567|NCT05101798|DRUG|5-Aminolevulinic acid Hydrochloride|The closure consists of colorless glass vial (Type II, Ph Eur) and bromobutyl-rubber stopper ø 20 mm (Type I, Ph Eur) and flip cap. The powder for oral solution is intended for single (partial) use. To prepare the ready-to-use solution the content of one vial is dissolved in 50 ml of water or apple juice. The concentration of the reconstituted solution is 3%. Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW). The reconstituted solution may be prepared up to 24 hours prior to use if protected from light. It should be given 3 hours (range 3-5 hours) prior to planned induction of anesthesia for surgery, although its effect is present for up to 8-12 hours. This step is critical for an optimal visualization of tumor tissue due to pharmacokinetic properties of Gleolan®.
214399174|NCT05090982|OTHER|Audio recordings during the consultations|50 patients with audio recordings of the consultation
214399175|NCT05090982|OTHER|Audio recordings during the consultations and test of the shared medical decision-making tool for modification|50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification
214399176|NCT05090982|OTHER|Audio recordings during the consultations and test of the shared medical decision-making tool for validation|50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.
214399177|NCT02391220|OTHER|LCA symbiotic fermented milk|LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
215003856|NCT00171288|DRUG|fluvastatin, ezetimibe|
215003857|NCT02194075|DRUG|Fluvoxamine+Methylphenidate hydrochloride|
215003858|NCT02194075|DRUG|Fluvoxamine+sugar pill|
215003859|NCT00432432|DRUG|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
215095568|NCT05936528|DRUG|Lactoferrin|antioxidant, immunomodulatory, anti-inflammatory, antimicrobial effect
215003860|NCT03234881|BEHAVIORAL|MOVE!|Participants randomized to the MOVE!(or TeleMOVE!) arm only. MOVE! is 16 weeks of 60-minute weekly groups that are led by a physical therapist, dietician, and/or clinical health psychologist. Clinicians utilize materials available online and encourage the use, but do not require or provide food diaries. TeleMOVE! is a 90-day program utilizing technology to provide home-based messaging focusing on health education and as needed clinician contact. \*TeleMOVE! was added as an option since many in-person MOVE! programs were on pause due to the pandemic.
215003861|NCT03234881|BEHAVIORAL|MOVE!+CBT|Participants randomized to the MOVE!+CBT arm will attend the 16 weeks of 60-minute weekly MOVE! or 90-days of the TeleMOVE! Treatment groups, along with up to 10 clinician-led individual sessions over a 3-month period. Participants will also be given a patient treatment manual to read at home, food diaries that will be expected to be completed on a daily basis, and gradually increase daily physical activity.
215003862|NCT05057208|BIOLOGICAL|COVID|COVID vaccination
215003863|NCT02071160|DRUG|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
214399178|NCT02391220|OTHER|heat-treated fermented milk|heat-treated fermented milk without probiotic cultures and dietary fibres
214399179|NCT02174198|DEVICE|BioOss Collagen at the time of implant placement|Experimental: placement of BioOss Collagen No intervention: no BioOss Collagen
214399180|NCT06410443|DRUG|Dexamethasone|Retention enema with 10mg dexamethasone, once a day, the total course of treatment for 1 week.
214399181|NCT06410443|DRUG|Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation|Treatment according to guideline of radiation-induced intestinal injury.
214399182|NCT06423261|DRUG|GB002 Recombinant Peptide Inhalation Solution|Inhalation administration
214399183|NCT06423261|DRUG|Placebo|Inhalation administration
214399184|NCT02720887|PROCEDURE|Nanoparticles load|Pregnant women will have a sampling of amniotic fluid to measure load and composition of nanoparticles.
214399185|NCT02711995|DRUG|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
214399186|NCT02711995|DRUG|Botulinum Toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
215003864|NCT03011853|PROCEDURE|Non-invasive and/or invasive mechanical ventilation|Use of Non-invasive and invasive mechanical ventilation, focussing particularly on the first respiratory support mode in ICU
215003865|NCT02329288|DRUG|Triamcinolone Acetonide|
215003866|NCT02329288|DRUG|placebo|
215003867|NCT01181882|DIETARY_SUPPLEMENT|Fish Oil and Aspirin|4 grams of fish oil each day for 28 days and 81 mg aspirin
215095569|NCT05936528|DRUG|Antioxidant therapies|Acetyl cysteine 600 mg / 12 hr
215095570|NCT05936528|DRUG|Dexamethasone|dexamethasone I.V 8 mg / day
215095571|NCT05936528|DRUG|Antibacterial therapies|Antibacterial drugs in their approved doses
215095572|NCT04508153|DEVICE|Leva Pelvic Digital Health System|Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
215095573|NCT04508153|OTHER|Kegel exercises|"Pelvic floor muscle training (PFMT), commonly referred to as Kegel exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI)."
214399187|NCT00377741|DRUG|valganciclovir [Valcyte]|900mg po
214399188|NCT06314191|OTHER|blood sampling|blood sampling with analyses
214399189|NCT06314191|OTHER|knee radiography|radiography of both knees in Schuss
214399190|NCT00940134|BIOLOGICAL|PYY 3-36|0.8 pmol/kg/min x 3 hours
214399191|NCT00940134|BIOLOGICAL|GLP-1|1.0 pmol/kg/min x 3 hours
214399192|NCT00940134|BIOLOGICAL|saline infusion|saline infusion x 3 hours
214399193|NCT04006795|OTHER|Serum|Participants will be topically applied adhesive patch containing developmental serum
214399194|NCT04006795|OTHER|Lotion|Participants will be topically applied adhesive patch containing developmental lotion
214399195|NCT04006795|OTHER|Cream|Participants will be topically applied adhesive patch containing developmental cream
214399196|NCT04006795|OTHER|Normal Saline|Participants will be topically applied adhesive patch containing normal saline
214399197|NCT04192942|OTHER|protocol of management of major burn in intensive care unit|primary assessment first aid management laboratory investigation radiological investigation surgical intervention
215003868|NCT05668247|OTHER|FOOT BATH|In general, foot bath is a type of relaxation and care performed by putting feet in water. Feet, as the organs carrying the whole body weight are the body parts where fatigue is felt most. In this study, a specially designed foot bath bucket was used in order to apply foot bath for the patients in the experimental group.
215003869|NCT03530228|DRUG|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment A
215003870|NCT03530228|DRUG|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment B
215003871|NCT03530228|DRUG|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
215003872|NCT03530228|DRUG|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 1
215003873|NCT03530228|DRUG|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 2
215003874|NCT03530228|DRUG|Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days. Group 3
215003875|NCT03530228|DRUG|Tegoprazan (C3)|Tegoprazan QD, oral administration
215003876|NCT04641637|PROCEDURE|TACE|Through a 7 French sheath placed through a single femoral arterial puncture, a guide catheter (Cobra 1 Guide Catheter, Mach 1, Boston Scientific Corporation, Marlborough, USA) is placed at the coeliac axis. From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders. The therapeutic agent was delivered under fluoroscopic control until the vasculature of the whole tumors is entirely filled, which was assessed with DSA and non-contrast CT performed at the completion of the procedure.
215095574|NCT04467034|BEHAVIORAL|Stanford Tobacco Prevention Toolkit curriculum|Stanford Toolkit curriculum delivered as a 5-session course in a school classroom setting.
214399198|NCT02703961|DRUG|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
214399199|NCT02703961|DRUG|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
214399200|NCT02703961|RADIATION|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
214399201|NCT02703961|RADIATION|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
214399202|NCT02703961|DRUG|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
214399203|NCT02752152|BEHAVIORAL|Computer-assisted counseling|The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.
214399204|NCT02752152|BEHAVIORAL|On-demand counseling|The counselor only invites the participants to ask questions about HIV and other STIs.
214399205|NCT02752152|BEHAVIORAL|Standard counseling|The counselor gives face-to-face general information/education
214399206|NCT02752152|BEHAVIORAL|Appointment + reminder|Has an appointment and receive reminders for further testing
214399207|NCT02752152|BEHAVIORAL|Reminder|Only receive reminders for further testing
215003877|NCT00410488|DRUG|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
215003878|NCT00410488|DRUG|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
214399208|NCT02752152|BEHAVIORAL|No appointment and no reminder|No appointment and no reminders for further testing
214399209|NCT00107380|BIOLOGICAL|rituximab|
214399210|NCT00107380|DRUG|cyclophosphamide|
214399211|NCT00107380|DRUG|doxorubicin hydrochloride|
214399212|NCT00107380|DRUG|prednisone|
214399213|NCT00107380|DRUG|vincristine sulfate|
214399214|NCT00107380|RADIATION|tositumomab and iodine I 131 tositumomab|
214399215|NCT03673098|BEHAVIORAL|Adapted 3RP|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The adapted 3RP intervention consists of 10, 90-minute weekly group sessions. Content specific to older women living with HIV, including self-compassion exercises, was added to the intervention in the first phase of this study (open pilot).
214399216|NCT04058210|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
214399217|NCT04058210|DRUG|IVA|150-mg tablet for oral administration.
214399218|NCT02162693|BIOLOGICAL|Mesenchymal progenitor cells|Administrated for intra-articular injection
214399219|NCT02162693|BIOLOGICAL|Sodium Hyaluronate|
214399220|NCT03114995|DRUG|Tirofiban|
214399221|NCT00987792|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Hospitalized patients receiving Avelox according to local drug information
215003879|NCT00410488|DRUG|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
214399222|NCT01454336|BIOLOGICAL|Cell injection|MSCs introduced into portal vein
214399223|NCT02249481|PROCEDURE|Adductor Canal catheter delivering 0.0625% L- Bupivacaine|Adductor canal catheter: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
215003880|NCT00410488|DRUG|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
215095575|NCT05162313|DEVICE|confirmation of endotracheal tube positioning|After performing the tube insertion by direct laryngoscopy, videolaringoscopy or fiberoptic technique, the attending neonatologist will connect both the colorimetric capnometer and the proximal flow-sensor to the tracheal tube. If the flow sensor is not proximal but incorporated into the mechanical ventilator, the care provider will connect the capnometer only. During the procedure, the information given by the capnometer will be evaluated by the care provider performing the intubation, while the flow sensor information will be monitored only by a study investigator, who will not reveal any details to the care provider. In particular, the yellow color change by the capnometer and the presence of exhalation flow curves on the ventilator screen will be considered as confirmation of correct tracheal tube positioning, respectively.
214399224|NCT02249481|PROCEDURE|Femoral nerve catheter delivering 0.0625% L- Bupivacaine|Femoral nerve catheter: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
214399225|NCT02662244|DEVICE|Nd:YAG laser|Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
214399226|NCT05645913|DRUG|Oral anticoagulant|Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)
214399227|NCT03138083|DRUG|OMO-1|OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
214399228|NCT06431802|OTHER|Conventional intervention|A nursing specialist with extensive clinical and teaching experience will provide on-site course training. The training will cover topics related to pain and pain assessment, such as: pain definition, types, physiological mechanisms, performance, pain assessment tools, and frequency of pain assessment. Interventions will be provided once a week for 4 weeks.
214399229|NCT06431802|BEHAVIORAL|Platform intervention|Using a pre-assigned account to log in to the platform, read the guidance instructions and enter the platform to start training. Basic knowledge of pain and pain assessment can be learnt through the Learning Resources module on the platform, and pain assessment training can be conducted through the Pain Assessment Exercise module. During pain assessment training the platform provides instant feedback based on the participant's exercises. Interventions will be completed in 4 weeks.
214399230|NCT02110927|DEVICE|Transcutaneous microcurrent|Microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25 Hz to 10 Hz.
214399231|NCT02110927|DEVICE|Aerobic exercise|50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
214399232|NCT04699448|OTHER|Nutritional intervention.|Diets designed for body weight loss, based on different macronutrient content.
214399233|NCT00029809|BEHAVIORAL|Chinese exercise modalities|
214399234|NCT02135393|DIETARY_SUPPLEMENT|13C5-folic acid or 13C5-6S-5-FormylTHF|Subjects with an insitu transjugular intrahepatic porto systemic stent shunt assigned to receive either a physiological 500 nmol (220 µg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-FormylTHF at the time of routine shunt venography to check patency followed by portal venous sampling at pre defined time points for 85 minutes and then given 13C5-6S-5-FormylTHF ator 13C5-folic acid at their next annual venography patency check with portal venous sampling at pre defined time points for 85 minutes
214399235|NCT03531905|DRUG|Bempedoic acid + Ezetimibe FDC Oral Tablet|Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
214399236|NCT03531905|DRUG|Ezetimibe 10 mg Oral Tablet|Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
214399237|NCT03531905|DRUG|Placebo Oral Tablet|Placebo tablet, matched for the FDC product for blinding purposes
214399238|NCT03531905|DRUG|Placebo oral capsule|Placebo over-encapsulated for blinding purposes
215003881|NCT00410488|DRUG|Zinecard|750 mg/m2 as an IV bolus.
215003882|NCT00410488|DRUG|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
215003883|NCT00410488|DRUG|Vincristine|"2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only."
215003884|NCT00410488|DRUG|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
215003885|NCT00296595|BEHAVIORAL|Nutrition|
215003886|NCT02513199|RADIATION|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
215003887|NCT02513199|DRUG|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
215003890|NCT00095966|DRUG|sorafenib tosylate|Given orally
215003891|NCT00095966|DRUG|gemcitabine hydrochloride|Given IV
215003892|NCT03247244|DRUG|Cannabis|THC 10%, CBD \<0.5%
215003893|NCT03247244|DRUG|Cannabis|THC 8.6%, CBD 8.6%
215003894|NCT03247244|DRUG|Cannabis|THC 0.6%, CBD 14%
215003895|NCT06334900|OTHER|GAD patients|Describe the clinical and demographic characteristics of patients with anti-GAD65 antibody associated cerebellar ataxia.
215003896|NCT03639389|DRUG|Bupivacaine|Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
215003897|NCT03639389|DRUG|Analgesics|Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
214399239|NCT02477943|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
214399240|NCT02477943|DEVICE|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
215003898|NCT05875480|PROCEDURE|synchronized telerehabilitation|In the synchronized telerehabilitation group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. after 2 weeks, they were treated 2 days a week until the 6th week by meeting with the physiotherapist in real time via the Albert Health Assistant application. In the remaining days, they were asked to follow the exercise videos uploaded to the Albert system, it will be checked whether they have done the daily exercises, and a daily reminder message will be sent through the system.
215003899|NCT05875480|PROCEDURE|asynchronized telerehabilitation|The exercise program for the asynchronized telerehabilitation group will be uploaded to the Albert Health Assistant in the form of 2-week programs in video form from the first Day. Whether the patients apply these videos on a daily basis will be checked through the system, a message reminding the daily routine exercise program will be sent through the system.
215003900|NCT05875480|PROCEDURE|supervised (face to face) rehabilitation|In the supervised physiotherapy group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. After 2 weeks, they attended the rehabilitation program in the physical therapy department of the hospital accompanied by a physiotherapist, starting from the 14th postoperative day, 2 days a week until the 6th week. The ROM, pain, functional and general health evaluations of the patients in this group were carried out on the online platform. In addition, on the days when they did not come to treatment, their daily routine exercises were followed through the Albert system.
215003901|NCT02216409|DRUG|Hu5F9-G4|
215003902|NCT00223431|DEVICE|all-ceramic fixed partial denture|
215003903|NCT04808453|DRUG|CPI-300|CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
215003904|NCT02204462|DRUG|FBnTP|A PET imaging radiotracer
214399241|NCT01549691|DRUG|Zopiclone|7.5 mg before sleep, the evening before surgery
215003905|NCT03545841|OTHER|HIT|Participants completed 6 weeks of HIT
215003906|NCT03545841|OTHER|MICT|Participants completed 6 weeks of MICT
215003907|NCT04527250|DRUG|ASC41|ASC41,1mg/table;5mg/table
215003908|NCT04527250|DRUG|ASC41 placebo|ASC41 placebo,1mg/table;5mg/table
214399242|NCT01549691|DRUG|Alprazolam|0.5 mg at awakening, the day of surgery
215003909|NCT01381510|DRUG|5-alpha Reductase Inhibitor (5ARI)|A 5ARI: Either dutasteride or finisteride
215003910|NCT02321904|PROCEDURE|Corneal Confocal Microscopy|Close-up pictures of the front part of the eye (the cornea)
215003911|NCT02321904|PROCEDURE|Nerve Conduction Studies|The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
215003912|NCT02321904|PROCEDURE|Quantitative sensory testing|Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
215003913|NCT02321904|PROCEDURE|Neuropathy Symptom Score|A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
215003914|NCT02321904|PROCEDURE|Clinical nerve examination|Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
214399243|NCT01549691|DRUG|placebo|given night before surgery and at awakening, the day of surgery
215003915|NCT03223194|GENETIC|AT342|AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
215003916|NCT05143775|PROCEDURE|Awake craniotomy|Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
215003917|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level -1|(1 x 10\^3 T cells/Kg)
215003918|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 1|(1 x 10\^4 T cells/Kg)
215003919|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 2|(1 x 10\^5 T cells/Kg)
215003920|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 3|(1 x 10\^6 T cells/Kg)
214399244|NCT01155726|DEVICE|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
214399245|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
214399246|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
215003921|NCT00586547|BIOLOGICAL|T-Cell Infusion- Dose Level 4|(5 x 10\^6 T cells/Kg)
214399247|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
214399248|NCT01155726|DEVICE|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
214399249|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
214399250|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
214399251|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
214399252|NCT06696612|DIAGNOSTIC_TEST|Dermoscopy|Dermoscopic examination of the nails
214399253|NCT06696950|OTHER|Mutimodal gait training includes unilateral step training, inclined treadmill training, over ground training with rhythmic auditory stimulation|Unilateral step training, inclined treadmill training, over ground training, repetitive isochronous pulses via metronome
214399254|NCT06696950|OTHER|Multimodal gait training|Unilateral step training, inclined treadmill training, over ground training,
214399255|NCT06242509|DIAGNOSTIC_TEST|Biological samples|"Plasma sampling ans stool sampling~* at inclusion~* at 1 month~* at 3 months~* at progression within the 3 months"
214399256|NCT01540435|DRUG|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
214399257|NCT05417997|DIETARY_SUPPLEMENT|Kunamin®|Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)
214399258|NCT05417997|DRUG|Favipiravir|Antiviral medication used to treat influenza
214399259|NCT05417997|DRUG|Enoxaparin|Anticoagulant medication
214399260|NCT05417997|DRUG|Lansoprazole|Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
215003922|NCT00009893|DRUG|fluorouracil|
215003923|NCT00009893|DRUG|gemcitabine hydrochloride|
215003924|NCT00009893|DRUG|leucovorin calcium|
215095576|NCT04976361|OTHER|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
214399261|NCT05417997|DRUG|Paracetamol|Analgesic to treat minor aches and pains, and fever reducer.
214399262|NCT05417997|DRUG|Ceftriaxone/ Clarithromycin|Inhibits the production of pneumolysin
214399263|NCT05417997|DRUG|Methylprednisolone|Treat inflammation, severe allergies, flares of chronic illnesses
215003925|NCT02756520|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
215003926|NCT01764581|PROCEDURE|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
215003927|NCT04338997|DRUG|IZD174|Small molecule inhibitor of NLRP3
215003928|NCT06457932|BEHAVIORAL|Heart rate variability biofeedback training|An 8-week intervention based on daily 10-minute HRV biofeedback training at rest using the Pulse HRV smartphone application.
215003929|NCT06457932|BEHAVIORAL|Guided meditation|An 8-week intervention based on daily 10-minute guided meditation sessions led by an instructor with over 20 years of experience in teaching meditation.
215003930|NCT05442931|DRUG|Pregabalin 150mg|The oral tablet half an hour preoperative 150 milligrams
215003931|NCT05442931|DRUG|Magnesium Sulfate|Intravenous administration half an hour preoperative 2 grams
215095577|NCT00304655|DRUG|Aripiprazole|
215095578|NCT01267942|DRUG|Enhancin|"Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm."
215095579|NCT05409066|DRUG|Epcoritamab|Subcutaneous Injection
215095580|NCT05409066|DRUG|Rituximab|Intravenous Infusion
215095581|NCT05409066|DRUG|Lenalidomide|Oral Capsules
214399264|NCT02333851|DRUG|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
214399265|NCT02333851|DRUG|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
214399266|NCT04737590|DEVICE|Bioactive glass|Comparison of bioactive glass to allogenic bone in pediatric bone cysts
214399267|NCT02106767|DRUG|Rosuvastatin|Rosuvastatin 20mg po x1
214399268|NCT02106767|DRUG|Rosuvastatin plus rifampin|Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
214399269|NCT04953104|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214399270|NCT04953104|BIOLOGICAL|Nivolumab|Given IV
214399271|NCT04953104|DRUG|Relatlimab|Given IV
214399272|NCT03673202|DIAGNOSTIC_TEST|Cx bladder Monitor test|Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
214399273|NCT00157586|DRUG|Delapril, Delapril-Manidipine Fixed combination|
214399274|NCT02883504|PROCEDURE|Echo-Doppler examination and left heart catheterization|
214399275|NCT02593175|DRUG|Carboplatin|Given IV
214399276|NCT02593175|DRUG|Paclitaxel|Given IV
215003932|NCT05442931|DRUG|Nitroglycerin|measure total dose of nitroglycerine in milligrams using a syringe pump
215095582|NCT05858710|DRUG|DPPG2-TSL-DOX|DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.
215095583|NCT05858710|DRUG|Dexrazoxane|For cardioprotection of participants.
215095584|NCT02905006|DRUG|Bimekizumab|Subjects will be randomized to receive a combination of injections of Bimekizumab.
215095585|NCT02905006|OTHER|Placebo|Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
215095586|NCT03090672|DRUG|Normal Saline|Normal Saline IV delivery
215095587|NCT03090672|PROCEDURE|Tissue Stromal Vascular Fraction|tSVF
215095588|NCT03090672|BIOLOGICAL|Platelet Rich Plasma|PRP
215095589|NCT03090672|PROCEDURE|Cellular Stromal Vascular Fraction|cSVF
215095590|NCT01365858|OTHER|Rehabilitation|"The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy)."
215095591|NCT00421135|DRUG|ZIO-201|ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
215095592|NCT01387464|DRUG|ISV-303|0.075% bromfenac in DuraSite dosed QD
214399277|NCT02593175|BIOLOGICAL|Panitumumab|Given IV
215003933|NCT05442931|OTHER|surgeon satisfaction|surgeon satisfaction measured according to Likert's scale
215003934|NCT06154473|PROCEDURE|Open heart surgery group.|Patients undergoing open heart surgery.
215095593|NCT01387464|DRUG|Bromday™|0.09% bromfenac dosed QD
215095594|NCT05513794|DEVICE|MRI Imaging|Neuromelanin sequence imaging
215095595|NCT04091048|DEVICE|Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)|Aortic valve replacement
215095596|NCT03088943|OTHER|TTE Apical 4 Chamber View|We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction
215095597|NCT03088943|OTHER|TEE dTG View|We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
215095598|NCT03088943|OTHER|TEE ME 4C View|We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
215095599|NCT00763841|DEVICE|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
215095600|NCT00763841|DEVICE|Sham|
214399278|NCT03259347|BEHAVIORAL|Group-based Therapy|Young women with body dissatisfaction will be randomized to one of two conditions: 1) an educational-support group condition; or 2) a counter-attitudinal therapy condition. We will test if a brief dissonance-based eating disorder prevention program produces intervention effects when delivered to participants with sub-threshold and threshold eating disorders.
214503891|NCT04033224|DEVICE|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
215003935|NCT06154473|PROCEDURE|Percutaneous cardiovascular surgery group.|Patients undergoing percutaneous cardiovascular surgery.
215003936|NCT06104293|OTHER|Grass Pollen Allergen Exposure|"After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations."
215003937|NCT00330018|DRUG|Valganciclovir|Valganciclovir
215003938|NCT00330018|DRUG|Acyclovir|Acyclovir
215003939|NCT00580398|BEHAVIORAL|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
215003940|NCT00580398|DRUG|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
215003941|NCT03291015|DEVICE|radiographic|using plain x ray to determind the treatment plan
215003942|NCT03291015|DEVICE|arthroscopy|using wrist arthroscopy to determind the treatment plan
215003943|NCT05452512|OTHER|Self monitoring|Self monitoring using smart clinical trial application
215003944|NCT05452512|OTHER|Smart watch assisted monitoring|Smart watch-assisted adherence monitoring
215095601|NCT01932502|DRUG|clobazam (Onfi)|"Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated"
215095602|NCT01932502|DRUG|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
215095603|NCT01932502|DRUG|Conversion schedule - Week 1|"The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg."
215095604|NCT01932502|DRUG|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
215095605|NCT01932502|DRUG|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
215095606|NCT05814640|DRUG|Fluoxetine|Commonly used oral antipsychotics intervention therapy.
215095607|NCT05814640|DRUG|Sertraline|Commonly used oral antipsychotics intervention therapy.
215095608|NCT05814640|DRUG|Vortioxetine|Commonly used oral antipsychotics intervention therapy.
215095609|NCT05814640|DRUG|Duloxetine|Commonly used oral antipsychotics intervention therapy.
215095610|NCT05814640|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
215003945|NCT05452512|DRUG|Vitamin D|Vitamin D self-administration for 3 months
215003946|NCT04119336|DRUG|Nivolumab|Given intravenously once per cycle
215003947|NCT04119336|DRUG|Ixazomib|Given orally on days 1, 8, 15.
215003948|NCT04119336|DRUG|Dexamethasone|Given orally on days 1, 8, 15, 22
214399279|NCT02354248|PROCEDURE|Triple stimulation technique|Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
215003949|NCT04119336|DRUG|Cyclophosphamide|Given intravenously on days 1, 8, 15.
215003950|NCT03243890|DIETARY_SUPPLEMENT|Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).|Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
215003951|NCT03243890|DIETARY_SUPPLEMENT|Placebo|Half of the patients are randomized to placebo treatment (no active treatment).
215003952|NCT00164866|DRUG|Omeprazole|
214399280|NCT05460130|BEHAVIORAL|Simplified Hepatitis C Virus (HCV) Treatment Protocol|A simplified, low-barrier, locally contextualized, HCV treatment protocol delivered by trained front-line health care providers (primary care physicians and mid-level providers) serving hard-to-reach-populations.
215003953|NCT01784185|PROCEDURE|virtual bronchoscopy guided transbronchial needle aspiration|
215003954|NCT01784185|PROCEDURE|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
215003955|NCT05390606|COMBINATION_PRODUCT|Flourish HEC and BioGenesis|Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.
215003956|NCT05467137|DEVICE|MSOT|MSOT imaging (after ICG injection)
215095611|NCT05814640|DRUG|Lithium Carbonate|Commonly used oral antipsychotics intervention therapy.
215095612|NCT05814640|DRUG|Olanzapine|Commonly used oral antipsychotics intervention therapy.
214399281|NCT02658721|DRUG|Lidocaine|
214399282|NCT02658721|DRUG|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
214399283|NCT02658721|DRUG|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
215003957|NCT01733888|DEVICE|Office Bleaching|Teeth will be cleaned with pumice first, followed by placing cheek retractors and covering of the lip surface with petroleum gel. Thereafter, teeth will be dried and gingival barrier will be applied to both arches - slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds. This is followed by homogeneous mixing of the powder and liquid in a powder pot the application of a thick layer of the resulting gel to all teeth undergoing treatment (35 % Hydrogen Peroxide, Pola Office, SDI, Australia). The gel will be left in place for 8 minutes and subsequently removed using a surgical aspirator tip.
215003958|NCT01733888|DEVICE|Resin Infiltration|Fluorosed teeth will be isolated using a rubber dam and the resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. In short, tooth surface will be dried using cotton rolls and air syringe. This is followed by an etching (Icon Etch) and drying step (Icon-Dry) to open the lesion surface. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds and subsequent cleaning of the surface with pumice and rubber polishing cup as well as rinsing with water for 30 sec.
215095613|NCT05814640|BEHAVIORAL|GCBT|Commonly used intervention therapy of psychotherapy.
215095614|NCT05529654|DEVICE|Impella 5.5 with SmartAssist|For subjects enrolled in the Trial, the Impella 5.5 will be placed intra-operatively during the index cardiac surgical procedure
215095615|NCT03976180|DEVICE|Stadard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
215095616|NCT03976180|DEVICE|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
215003959|NCT01733888|DEVICE|Resin Infiltration twice|"The intervention will be done similar to the Resin infiltration arm, which the exception that the icon infiltration step will be done twice."
215003960|NCT01733888|DEVICE|Bleaching + Resin Infiltration|"In this arm, the fluorosed teeth of the patients will first be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) as explained in the intervention arm Office bleaching; followed by wash over period of 20 days. After these 20 days, patients will be recalled and the fluorosed teeth will treated according to the description in the Resin infiltrant intervention arm using the resin infiltrant (Icon, DMG, Hamburg, Germany) as per manufactures' instructions."
214399284|NCT02658721|DRUG|Fentanyl|If the patient had a VAS score of \>4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
214399285|NCT02658721|DRUG|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.~In case of bradycardia (HR \<50/min), 0.5 mg intravenous atropine was administered."
215003961|NCT03281720|PROCEDURE|TAD|the same intervention as listed in the arm description
214399286|NCT02658721|DRUG|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
214399287|NCT02658721|DRUG|Diclofenac sodium|The patients with a VAS score of \>4 were administered with 75 mg diclofenac sodium via intramuscular route.
214399288|NCT02658721|DRUG|Ephedrine|In the event of hypotension (systolic arterial pressure \<90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
214399289|NCT02658721|DRUG|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
214399290|NCT05368506|DRUG|Wee1 Inhibitor ZN-c3|Given PO
214399291|NCT00552474|DEVICE|Libra Deep Brain Stimulation System|Active DBS Therapy
214399292|NCT00552474|DEVICE|Libra Deep Brain Stimulation System|Implanted system but no stimulation
214399293|NCT03501238|OTHER|Chocolate Milk|Chocolate bovine milk will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
214399294|NCT03501238|OTHER|Chocolate milk substitute|Chocolate milk substitute will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
214399295|NCT03501238|OTHER|Chocolate milk substitute with gelatin|Chocolate milk substitute with gelatin added will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
214399296|NCT04436003|BEHAVIORAL|Muscle and articulation chains GDS method|"A physiotherapy method adapting treatment to patient's terrain, or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement."
214399297|NCT02690402|BEHAVIORAL|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
215003962|NCT05376306|BEHAVIORAL|Stress Reduction: MBSR|Four activities, one each week - raising body awareness, sitting meditation, mindful yoga, expanding awareness meditation.
215003963|NCT05376306|BEHAVIORAL|Stress Reduction : PMR|Progressively tensing and releasing each muscle group from head to toe in a specific order.
214503892|NCT06898073|BEHAVIORAL|cognitive dual-task group|Cognitive tasks as the second task in addition to walking
214399298|NCT04551703|DRUG|Adrenaline saline irrigation|The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
214503893|NCT06898073|BEHAVIORAL|Single-task group|walking without performing a second task during the walking training
215003964|NCT03715647|OTHER|Sepsis|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
215003965|NCT03715647|OTHER|HELLP Syndrome|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
215003966|NCT03715647|OTHER|Respiratory Distress Syndrome Adult|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
215003967|NCT05403073|PROCEDURE|Ultrasound guided Suprainguinal Iliac Fascia Nerve Block.|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
214399299|NCT06063369|DRUG|Palmitoylethanolamide|"Dose: PEA 1200 mg given in 400 mg capsules (3 capsules per day) or Placebo Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA and placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
215003968|NCT03928327|DRUG|TAK-788|TAK-788 Capsules
215003969|NCT03928327|DRUG|Itraconazole|Itraconazole Oral solution
215003970|NCT03928327|DRUG|Rifampin|Rifampin Capsules
215003971|NCT00174395|DRUG|eletriptan|
215003972|NCT00407511|DRUG|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
215003973|NCT00529035|DRUG|Interleukin-2|Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
215003974|NCT05470803|BIOLOGICAL|AstraZeneca/Fiocruz|4th dose of SARS-CoV-2 vaccine
215003975|NCT05470803|BIOLOGICAL|Pfizer/Wyeth|4th dose of SARS-CoV-2 vaccine
215003976|NCT05470803|BIOLOGICAL|Clover SCB-2019|4th dose of SARS-CoV-2 vaccine
215003977|NCT02026349|DRUG|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
215003978|NCT02026349|DRUG|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
214503894|NCT06750653|OTHER|CeraVe Moisturizing Cream|CeraVe is a formulation of Purified Water, Glycerin, Cetareth-20 and Cetearyl Alcohol, Caprylic/Capric Triglyceride, Behentrimonium Methosulfate and Cetearyl Alcohol, Cetyl Alcohol, Petrolatum, Dimethicone, Hyaluronic Acid, Ceramide 1, Ceramide 3, Ceramide 6-II, Cholesterol, Phytosphingosine, Potassium Phosphate, Dipotassium phosphate, Phenoxyethanol, Methylparaben, Propylparaben, Disodium EDTA, Sodium Lauroyl Lactylate, Carbomer, Xanthan Gum, manufactured by L'Oréal, for topical skin use.
215003979|NCT05400330|BIOLOGICAL|LX1001|Gene therapy
214399300|NCT02915380|BIOLOGICAL|Evaluation of pituitary endocrine function|"The basal thyroid hormone and test to perform will be: TSH, fT4, fT3.~When available, the following hormones will be tested:~FSH, LH, estradiol (in women), testosterone (in men), sex hormone-binding globulin (SHBG), ACTH, cortisol, prolactin, Na, K; serum levels of GH and IGF-1; and serum and urine osmolality.~Adrenal function will be evaluated through ACTH-stimulation testing . Adrenal or GH insufficiency will be evaluated by insulin tolerance testing (ITT)"
214399301|NCT02915380|BEHAVIORAL|Evaluation of clinical outcome|Patients' outcome will be assessed as modified Rankin Scale (mRS) at discharge from the hospital, at 3, 6 and 12 months.
214399302|NCT02915380|BEHAVIORAL|Evaluation of neuropsychological function|Neuropsychological examination will be conducted focusing on verbal comprehension (Token Test) and visual neglect. Verbal and visual short term and working memory visuospatial construction and figural memory will be performed through Rey Osterrieth Complex figure test, and psychomotor speed attention and concentration through Trail Making Test.
214399303|NCT04027920|DRUG|Shenghua Decoction|Three days' shenghua decoction treatment
214399304|NCT00311428|BIOLOGICAL|Influenza|
214399305|NCT01969162|PROCEDURE|Tear Sample Collection|Tear sample collection as per protocol. No investigational drug is administered in this study.
214399306|NCT04105985|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
214399307|NCT04105985|DRUG|Articaine Injection|Local anesthetic
214399308|NCT05059574|BEHAVIORAL|Breast Crawling|The mother's first breast-feeding of her baby is not routine biological breast-feeding, but as a cradle to the breast.
214399309|NCT01084122|DRUG|Iron sucrose|Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
214503895|NCT06750653|DRUG|Vaseline|Vaseline is a formulation of active ingredient white petrolatum, USP (100%), manufactured by Unilever, for topical skin use.
214503896|NCT07099625|DEVICE|Adaptive Indoor Rowing Seat|Light weight adjustable indoor rowing seat for Veterans with limited trunk stability.
215003980|NCT05619341|DIETARY_SUPPLEMENT|psyllium|psyllium 20g
214503897|NCT07099625|DEVICE|Paddle Sport adaptive seating system|On market comparator (discontinued) adaptive indoor rowing seat for individuals with limited trunk stability.
214503898|NCT06910956|OTHER|CXR-LC|Alert to provider to discuss lung cancer screening CT eligibility, for patients considered at high risk of lung cancer based on CXR-LC AI tool.
214503899|NCT05479929|OTHER|Canadian Triage Assessment Scale (CTAS)|The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
215003981|NCT05619341|DIETARY_SUPPLEMENT|inulin|long chain fructan
215003982|NCT05036460|PROCEDURE|Ultrasonography|"The transducer will be placed over the anterior neck just above the suprasternal notch, in the transverse orientation. The position of the transducer could be adjusted to visualize both the esophagus and trachea. It will be considered as esophageal intubation if esophageal dilation or double-tract sign are noted."
214399310|NCT04841044|DIETARY_SUPPLEMENT|Cetoleic acid|Very long monounsaturated fatty acid ( C22:1n-11)
214399311|NCT04841044|DIETARY_SUPPLEMENT|Control Oil|Control oil consisting of: mix of anchovy oil, olive oil, high-oleic sunflower oil and rapeseed oil
214399312|NCT04157764|DEVICE|HomeChoice Claria APD machine with SHARESOURCE|HomeChoice Claria APD machine with SHARESOURCE software. SHARESOURCE is a software can telemonitor patients' compliance
214399313|NCT00409240|OTHER|MEDIC|Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
214399314|NCT02620189|DRUG|Anti-TNF Biologics Therapy|
215003983|NCT05036460|PROCEDURE|Direct visualization|While performing the intubation, the intubator will report ETI if visualizing the tracheal tube passing through the glottis. Otherwise, it will be regarded as esophageal intubation.
215003984|NCT04935515|DRUG|Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
215003985|NCT04935515|DRUG|Oral low dose steroid|Low dose oral methyl prednisolone was added.
215003986|NCT04935515|DRUG|Intravenous Antibiotics with Low dose steroid.|Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
214503900|NCT04937504|BEHAVIORAL|STAIR-PC Group|Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) is a face-to-face, individual, brief (5 session) therapy adapted from the STAIR program. STAIR-PC is an appropriate treatment for individuals who have experienced traumatic stressors, and addresses symptom targets by teaching skills to improve coping with emotions and strengthen interpersonal relationships.
214503901|NCT04937504|BEHAVIORAL|WebSTAIR Group|WebSTAIR is a web-based self-help program adapted from the STAIR program for individuals who have experienced traumatic stressors. WebSTAIR contains 10 self-guided interactive modules that teach skills to improve coping with emotions and strengthen interpersonal relationships.
214503902|NCT02881554|PROCEDURE|Computed Tomography|Undergo SC SPECT/CT
215003987|NCT04935515|DRUG|Oral anti-coagulant|Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
214399315|NCT04655313|DRUG|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
214399316|NCT02724020|DRUG|Everolimus|Everolimus capsules.
214399317|NCT02724020|DRUG|MLN0128|MLN0128 capsules.
214399318|NCT02724020|DRUG|MLN1117|MLN1117 capsules.
214399319|NCT00425503|DRUG|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
214399320|NCT00479947|DRUG|Probiotics (Natural product)|
214399321|NCT00479947|DRUG|Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)|
214399322|NCT00647413|BEHAVIORAL|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
214399323|NCT01060566|DRUG|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
214503903|NCT02881554|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SC SPECT/CT
214503904|NCT02881554|DRUG|Technetium Tc-99m Sulfur Colloid|Given IV
214503905|NCT06330610|OTHER|Intermittent enteral nutrition|Patients will receive intermittent enteral nutrition, defined as 3 60-minute administrations every 8 hours.
215003988|NCT03439514|DRUG|ARRY-371797 (PF-07265803)|400 mg twice daily (BID)
215003989|NCT03439514|OTHER|Placebo|BID
214399324|NCT01060566|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
214399325|NCT00591747|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
214399326|NCT00591747|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
214399327|NCT06339047|OTHER|Projector Kaleidoscope|Children in the projector kaleidoscope group will be watched for approximately 5 minutes before induction in the operating room.
214399328|NCT06339047|OTHER|Cartoon|Children in the cartoon group will be asked which cartoon they want to watch from the cartoon pool and will be shown the cartoon they want. The cartoon duration is approximately 5 minutes.
214399329|NCT03794349|BIOLOGICAL|Dinutuximab|Given IV
214399330|NCT03794349|DRUG|Eflornithine Hydrochloride|Given PO or via NG or G tube
214399331|NCT03794349|DRUG|Irinotecan Hydrochloride|Given IV
214399332|NCT03794349|BIOLOGICAL|Sargramostim|Given SC or IV
214503906|NCT02337985|DRUG|Prednisone|Given PO
214503907|NCT02337985|BIOLOGICAL|Rituximab|Given IV
215003990|NCT04966429|DRUG|Maraviroc|Tablets
215003991|NCT04987970|DRUG|CKD-386(2)|QD, PO
215003992|NCT04987970|DRUG|D013, D326, D337|QD, PO
215003993|NCT05786300|DEVICE|NMES+|"The Treatment Group will follow the rehabilitation protocol with the addition of the NMES+.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz."
215003994|NCT05786300|PROCEDURE|Rehab|"The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
215003995|NCT01776203|DRUG|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
215003996|NCT00747513|BEHAVIORAL|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
215095617|NCT03976180|DEVICE|HFNO with intermediate FiO2 (50%)|In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
215003997|NCT00465868|PROCEDURE|PCI (percutaneous coronary intervention)|Outcome of PCI following AMI
214399333|NCT03794349|DRUG|Temozolomide|Given PO or via NG or G tube
214399334|NCT04704401|OTHER|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
215003998|NCT01521364|DRUG|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
214399335|NCT03821701|DRUG|Entresto|Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study
214399336|NCT03821701|DRUG|ACEI/ARB|Choose one of ACEI/ARB according to the clinical condition among the whole study.
214399337|NCT04028115|DRUG|Ixazomib|Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
214399338|NCT00060463|BEHAVIORAL|Increased access to emergency contraceptive pills|
214399339|NCT00192621|DRUG|Combivir (zidovudine [AZT] / lamivudine [3TC])|
214399340|NCT00192621|DRUG|Kaletra (lopinavir [LPVr])|
214399341|NCT00688259|BEHAVIORAL|Supportive Therapy (ST)|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
214399342|NCT00688259|BEHAVIORAL|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
214399343|NCT05403359|DRUG|Steroids|"Description of the intervention in each of the work packages:~* WP1A admission: Steroid dose \>6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~* WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (\> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~* WP2 ICU admission: High-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~* WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) or no steroids up to day 28."
214399344|NCT01220141|DRUG|activated recombinant human factor VII|Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
214399345|NCT00023439|OTHER|Nucleic Acid Amplification Methods for diagnosis|no intervention
214399346|NCT02496494|DRUG|Tacrolimus|Tacrolimus for maintenance immunosupression in kidney transplant recipients
215095618|NCT03976180|DEVICE|HFNO with high FiO2 (100%)|In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
214399347|NCT00963703|DRUG|Rituximab|Rituximab 1000 mg Intravenously day 1 and day 15
214399348|NCT02131714|BEHAVIORAL|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
214399349|NCT02131714|BEHAVIORAL|lifestyle counseling|
214399350|NCT03994575|OTHER|Guideline recommended feedback|The ACS Reflective III Pilot program is a quality assurance program where the decision to follow the recommendations and all treatment decisions related to patient care are left to the physician's discretion and feedback to the physician with their aggregate and individual patient data is intended as a quality assurance undertaking
214399351|NCT00280475|DEVICE|Whole brain radiation therapy arm|Whole brain radiation therapy arm
214399352|NCT00280475|DEVICE|Salvage stereotactic radiosurgery arm|Salvage stereotactic radiosurgery arm
214399353|NCT02954575|DRUG|Wilate|
214399354|NCT00229619|DRUG|Rituximab|Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.
214399355|NCT02491892|DRUG|Pertuzumab|Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
214399356|NCT05466903|DIETARY_SUPPLEMENT|Early diet opening|Effects of early dietary recovery after colon polypectomy and colonoscopic mucosal resection on postoperative hemorrhage in patients
214399357|NCT04681677|RADIATION|Radiation: Intra-operative Radiation Therapy - IORT|Single fraction, Intra-operative Radiation Therapy at the time of surgical resection of recurrent GBM followed by Bevacizumab 28-56 days after surgery.
214399358|NCT04681677|DRUG|Bevacizumab|Bevacizumab
214503908|NCT02337985|DRUG|Etoposide|Given IV
215003999|NCT05129202|DRUG|immune therapy|The patient receives immunotherapy
215004000|NCT03454958|OTHER|Measurements of body composition|Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer \& skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.
215004001|NCT02175758|DRUG|SOF|SOF administered orally once daily
215004002|NCT02175758|DRUG|RBV|RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
215004003|NCT01026597|DRUG|REGN727|5 IV cohorts (dose 1, 2, 3, 4, and 5)
215004004|NCT01026597|DRUG|Placebo|5 IV cohorts (dose 1, 2, 3, 4, and 5)
215004005|NCT04213911|RADIATION|low-dose chest CT scan|The low-dose chest CT scan is now commonly used as a quick, painless, and non-invasive approach to screen for lung cancer. The radiation exposure from one low-dose CT scan of the chest (1.5 mSv) is comparable to 6 months of natural background radiation for a person living in the US.
215095619|NCT06437470|OTHER|blood flow restriction technique|"All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising.~All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff."
215095620|NCT03033251|DEVICE|Non Invasive Ventilation|Patients will receive non invasive ventilation as a standard of care.
214399359|NCT03337880|OTHER|instrumental delivery|the birth was assisted with an extractor.
215004006|NCT04213911|DEVICE|insertion of esophageal balloon|The esophageal catheter is a flexible thin plastic tube with an air-filled balloon at the distal end. The tube will be placed through the nasopharynx after local anesthesia.
215004007|NCT05080270|BIOLOGICAL|Tolerogenic Fibroblasts|administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
215004008|NCT00508508|BEHAVIORAL|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
215095621|NCT03033251|DEVICE|High Flow Oxygen Cannula 50|Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
214399360|NCT03943303|RADIATION|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
214399361|NCT03943303|RADIATION|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
214399362|NCT02488694|DRUG|Afatinib|40 mg/d
214399363|NCT02488694|DRUG|Pemetrexed|500 mg/m² i.v. on d1 of each 21-day cycle
215004009|NCT00508508|BEHAVIORAL|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
215004010|NCT02636283|DRUG|Entresto|Oral pills
215004011|NCT02636283|DRUG|Placebo group|The placebo pills
214399364|NCT01154803|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|1 sachet/day, 500 kcal and multi micronutrients (fortified high quality food(RUTF),for 2 weeks after an illness (malaria, diarrhoea, pneumonia)
214399365|NCT01154803|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP)|2 sachets / day for 14 days after an illness (diarrheoea, malaria, pneumonia)
214399366|NCT06027775|DRUG|Targeted agent|The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
214399367|NCT01066156|DRUG|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
214399368|NCT01018823|DRUG|Ertugliflozin|Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
214399369|NCT01018823|DRUG|Placebo to Ertugliflozin|Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
214399370|NCT02809274|OTHER|questionnaires|• Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form
214399371|NCT01820533|OTHER|Cell Phone Survey|Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
214399372|NCT00658671|DRUG|ENMD-2076|Capsules, daily dosing in 28 day cycles
214503909|NCT02337985|DRUG|Doxorubicin Hydrochloride|Given IV
214503910|NCT02337985|DRUG|Vincristine Sulfate|Given IV
214503911|NCT02337985|DRUG|Cyclophosphamide|Given IV
214503912|NCT02337985|BIOLOGICAL|Filgrastim|Given SC
214503913|NCT02337985|BIOLOGICAL|Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells|Given IV
214503914|NCT05414955|DEVICE|Neuromodulation|Neuromodulation
215004012|NCT04408079|DRUG|TQB3558|TQB3558 is a kinase inhibitor of the TRK protein family.
215004013|NCT00652652|DRUG|nesiritide, furosemide|
215004014|NCT04791852|DIAGNOSTIC_TEST|Donor-derived Cell Free DNA|We will compare ddcfDNA with coronary angiogram determined CAV grading, according to ISHTL2010 classification
215004015|NCT02307500|DRUG|Regorafenib|oral therapy
215095622|NCT03033251|DEVICE|High Flow Oxygen Cannula 30|Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
215095623|NCT04864847|DIAGNOSTIC_TEST|RENISCHEM L-FABP POC Test|Point-of-care test cassette with quantitative reader used for the measurement of L-type fatty acid binding protein (L-FABP) in human urine specimens.
215095624|NCT05851430|DEVICE|PEF ablation|Pulsed Electric Field (PEF) Ablation per institutional standard of care
215095625|NCT04201093|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5mg tablet once daily orally for 27 weeks.
215095626|NCT04201093|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
215095627|NCT04201093|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 15mg tablet once daily orally for 27 weeks.
214399373|NCT05925959|OTHER|Preoperative Weight Management Program|The medical obesity intervention is comprised of monthly visits with an obesity medicine (OM) provider +/- a registered dietitian (in person or virtual). Lifestyle modifications (nutrition, physical activity, stress, sleep), appetite control, and medication side effects will be addressed in all visits. At initial visit, patients will evaluated in person by an OM provider +/- registered dietitian. An individualized intense lifestyle intervention will be implemented with the addition of an anti-obesity medication (phentermine, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, etc). Medication use will be based on disease risk, patient preference, severity of obesity, contraindications, potential drug interactions and insurance coverage. A diet recommendation will be tailored to the patient's medical and food allergy history. Weight and vital signs will be monitored at each visit. Participants will have a total of 5 follow-up monthly encounters, every 30 +/- 7 days.
214399374|NCT03904342|BEHAVIORAL|Sophie CBT System|The Sophie CBT system is a tablet-based system that delivers self-paced cognitive behavioral therapy educational curriculum in the format of 6 discrete modules.
214399375|NCT03904342|BEHAVIORAL|iHope CBT|Licensed therapists will use the iHope HIPAA-compliant telemedicine platform to deliver cognitive behavioral therapy to patients via telephone, videoconferencing, and/or text chat.
214399376|NCT01700673|DRUG|Azacitidine|Azacitidine will be administered days 1-5 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
214399377|NCT01700673|BIOLOGICAL|Sargramostim|Sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
214399378|NCT01734382|DRUG|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.
214399379|NCT04729049|PROCEDURE|Erector Spinae plane Block|Ultrasound-guided interfascial technique, aiming to block the anterior and posterior branches of the spinal nerves for multi-dermatomal analgesia. Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve a craniocaudal distribution along several vertebral levels.
214399380|NCT04729049|DRUG|Patient controlled analgesia with intravenous morphine|Patient-controlled intermittent boluses of morphine 1 mg (maximum once every 15 minutes).
214399381|NCT00305682|BIOLOGICAL|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
214399382|NCT00305682|DRUG|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
214399383|NCT00305682|DRUG|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
214399384|NCT00305682|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
214399385|NCT00305682|PROCEDURE|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
214399386|NCT00305682|RADIATION|total body irradiation|Administered Day -1, 200 cGy
214399387|NCT00305682|DRUG|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
214399388|NCT04543370|DRUG|Edasalonexent 2000 mg TID|CAT-1004 capsules
214399389|NCT04543370|DRUG|Midazolam 2 MG/ML|2 mg/ml syrup
214399390|NCT04543370|DRUG|Deflazacort 36Mg Tab|36 mg tablets
214399391|NCT01112150|DEVICE|NormaTec Pump|Normatec Pump
214399392|NCT04562506|DEVICE|rTMS with H-coil|Deep repetitive transcranial manetic stimulation or sham stimulation with H-coil
214399393|NCT04562506|DEVICE|Sham rTMS stimulation with H-coil|Sham rTMS stimulation
214399394|NCT01932138|OTHER|Enhanced CHW intervention|"The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention."
214399395|NCT01932138|OTHER|Standard of care|The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
214399396|NCT04945343|PROCEDURE|Growing Rods|Growing Rods(GR), are implants used to correct pediatric scoliosis deformity. They attempt to allow the growth of the spine and thorax while controlling curve progression to preserve normal lung volume.
214399397|NCT00661258|BEHAVIORAL|Electronic drug monitoring feedback data|All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
215004016|NCT06355921|PROCEDURE|radiofrequency ablation|"Anesthesia: Local (Novocaine, Lidocaine, Bupivacaine) Access: transcutaneous Navigation under CT control Cannulas are used: 22G 100 and 150 mm, the size of the electrode corresponds to the size of the cannula The starting power is 20W followed by steps of 10W every 2 minutes until the maximum power is reached, the maximum power is 60W.~In order to prevent infectious complications, two-day antibiotic prophylaxis of Cefazolin (1g) is carried out 3 times a day In order to prevent skin burns with superficially located DFS, the skin is cooled during the procedure."
215004017|NCT03974490|OTHER|Rhythmic auditory stimulation|Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
215004018|NCT04153656|OTHER|Reading and studying Spiritual Flow|The Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey. Two months after the first survey, the Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey.
214399398|NCT04895020|BIOLOGICAL|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
214399399|NCT03890120|DRUG|Cilofexor|100 mg tablet administered orally once daily
214399400|NCT03890120|DRUG|Placebo|Tablet administered orally once daily
214399401|NCT01259336|DRUG|Itraconazole|Tablet 200 mg twice daily for 6 months
214399402|NCT01259336|DRUG|treatment in cavitary pulmonary aspergillosis|Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
214503915|NCT06951035|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"The repeated stimulations will be carried out using an eight-part probe detected by the infrared camera (eight shaped tracked coil), connected to a Rapid 2 stimulator (Magstim Company, Whitland, UK). The stimulation will be performed manually or with robotic assistance using TMS-Robot (Axilum Robotics, SCHILTIGHEIM, France)"
215004019|NCT02409901|BEHAVIORAL|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
215004020|NCT03372421|OTHER|Social Story|A short story written in the third person about what it's like to attend an assessment for ASD.
215004021|NCT03372421|OTHER|Standard Information|Information the host site currently sends out to patients informing them about what to expect from the assessment
215004022|NCT05880030|DRUG|Cholecalciferol|cholecalciferol 10000 UI
215004023|NCT05880030|OTHER|placebo|sunflower oil
215004024|NCT06109688|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Orally intake 1 sachet per day for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
215004025|NCT06109688|DIETARY_SUPPLEMENT|placebo|Orally intake 1 sachet per day for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
215004026|NCT01576393|BEHAVIORAL|Home-based Family Therapy|12 home-based family therapy sessions
215004027|NCT01576393|BEHAVIORAL|office-based family therapy|12 office-based family therapy sessions
215004028|NCT01576393|BEHAVIORAL|WHE|12 Women's Health Education Sessions
215004029|NCT03295448|OTHER|Low carbohydrate diet|Diet low in carbohydrates (38%E), but higher in total and saturated fat.
215004030|NCT03295448|OTHER|High carbohydrate, high sugar diet|Diet high in carbohydrates (53%E) and sugars, but low in wholegrain, rye and wheat fibre.
214399403|NCT03496415|DEVICE|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
214399404|NCT03496415|DEVICE|sham remote ischemic conditioning|sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
214399405|NCT02622971|OTHER|PBMT|Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.
214399406|NCT02622971|OTHER|Cryotherapy|Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
214399407|NCT00248443|PROCEDURE|Fiberoptic bronchoscopy and bronchoalveolar lavage|
214399408|NCT02696278|OTHER|Lesson about vegetables|During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
214399409|NCT02696278|OTHER|Vegetables|During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
214522604|NCT04021927|DEVICE|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
214522605|NCT01799785|BEHAVIORAL|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
215004031|NCT03295448|OTHER|High carbohydrate, low sugar diet|Diet high in carbohydrates (53%E), wholegrain, rye and wheat fibre, but low in sugars.
215004032|NCT06125418|PROCEDURE|customized healing abutment|patients will undergoes one-stage implant placement with customized healing abutments with different macrogeometry and emergence angle made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
215004033|NCT06125418|PROCEDURE|standard healing abutment|patients will undergoes one-stage implant placement with standard titanium healing abutment made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
215004034|NCT02184117|DRUG|Adenosine|Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
215004035|NCT02184117|DRUG|Contrast Media|"Intracoronary injection of contrast medium to induce hyperemia for contrast FFR"
215004036|NCT02184117|DRUG|Resting conditions|Baseline measurement of aortic and coronary pressures
215004037|NCT03055078|BIOLOGICAL|mesenchymal stem cells|Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
215004038|NCT01537796|BEHAVIORAL|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
215095628|NCT01956370|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
215004039|NCT01537796|BEHAVIORAL|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
215004040|NCT01537796|BEHAVIORAL|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
215004041|NCT00157625|BEHAVIORAL|Automatic stop order|
215004042|NCT01244282|PROCEDURE|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
215004043|NCT02643784|DRUG|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
214399410|NCT02696278|OTHER|Hummus|During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
215004044|NCT02643784|OTHER|Control|"Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
215004045|NCT01594268|DRUG|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
215095629|NCT01956370|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
214399411|NCT01080963|DRUG|Daptomycin|one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
214399412|NCT01080963|DRUG|Cefuroxime|1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
214399413|NCT00545142|DRUG|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
214399414|NCT00545142|DRUG|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
214399415|NCT02796443|PROCEDURE|Laparoscopic cholecystectomy (LC)|Removal of the gallbladder via a minimally invasive approach
214399416|NCT03952455|PROCEDURE|Bilateral surgical implantation of DBS system to Nucleus Accumbens|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
214399417|NCT03722212|DIAGNOSTIC_TEST|METAglut1|A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.
214399418|NCT01253382|BIOLOGICAL|ecallantide|10 - 30mg subcutaneous injection.
214399419|NCT00683449|DRUG|Dose Group 1|IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
214399420|NCT00683449|DRUG|MN-221 placebo|i.v. infusion of placebo for 15 minutes
214399421|NCT00683449|DRUG|Dose Group 2|i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
214399422|NCT00683449|DRUG|Dose Group 3|i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
215095630|NCT02135978|OTHER|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
215095631|NCT04046172|PROCEDURE|supra/sub gingival root surface debridement|The test group will undergo Intensive periodontal treatment (IPT)
214399423|NCT05414721|DRUG|Low flow desflurane anesthesia (Group D)|When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air). Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
214522606|NCT01799785|OTHER|Usual Care|
215004046|NCT03927157|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
215004047|NCT03927157|OTHER|Placebo|Placebo subcutaneous injection
215004048|NCT04954144|DEVICE|Leap Motion Sensor|As a virtual reality treatment method, leap motion sensor was integrated with laptop computer and participants played object capture, firefly, bee-batting games to improve performance based hand skills.
215004049|NCT04954144|OTHER|Neurodevelopmental Treatment Approach|It is a method that tries to control sensorimotor components of muscle tone, reflexes, abnormal movement patterns, postural control, sensory-perception and memory problems with special techniques.
215004050|NCT00361153|DRUG|Colesevelam hydrochloride|Welchol tablet 625mg
215004051|NCT00361153|DRUG|placebo|placebo
215095632|NCT04046172|PROCEDURE|supra-gingival scaling and polishing|Control group will receive the Control periodontal treatment (CPT).
214399424|NCT03753971|OTHER|Sound stimulation|Short sound stimulations will be emitted through a head band during sleep apneas
215004052|NCT05249751|DIAGNOSTIC_TEST|Assessement of serum copeptin by ELISA technique|Assessement of serum copeptin by ELISA technique
215095633|NCT00881504|DRUG|"Bevacizumab in combination with modified FOLFOX6."|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks
215095634|NCT06133296|OTHER|Conventional fixed treatment|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment
215095635|NCT06133296|OTHER|Clear aligner treatment|After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
215095636|NCT06506929|OTHER|Task specific physical therapy|Physical Therapy based specifically on tasks that the participant os having difficulty with
215095637|NCT00007020|DRUG|Cholic Acids|10-15 mg/kg body weight/day taken orally.
214399425|NCT01866241|DRUG|Misoprostol|Is a prostaglandin
215004053|NCT01830686|OTHER|Sugarcane bagasse|One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
214399426|NCT04831762|BEHAVIORAL|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
214399427|NCT04831762|BEHAVIORAL|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
214399428|NCT04831762|BEHAVIORAL|Laby 5-12|Test of motor planning using labyrinths
214399429|NCT04831762|BEHAVIORAL|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
214399430|NCT04831762|BEHAVIORAL|Stroop animals|Stroop test for preK children using animals instead of words
214399431|NCT01991717|DEVICE|Victus|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
215004054|NCT01830686|OTHER|Non-caloric, non-fermentable fiber|One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
215004055|NCT01830686|OTHER|Minimal fiber|One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
215004056|NCT06054425|DRUG|Risankizumab|Infusion; intravenous
215004057|NCT05549245|DEVICE|high-flow nasal cannula oxygen therapy,|Patients were treated with high-flow nasal cannula oxygen therapy for three nights
215004058|NCT05549245|DEVICE|CPAP|Patients were treated with CPAP for three nights
215004059|NCT04082520|RADIATION|Gallium Ga 68-DOTATATE|Given IV
215004060|NCT04082520|DRUG|Lutetium Lu 177 Dotatate|Given IV
215004061|NCT04082520|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
215004062|NCT04082520|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
215004063|NCT04082520|OTHER|Questionnaire Administration|Ancillary studies
215004064|NCT04082520|PROCEDURE|Computed Tomography|Undergo PET/CT and/or SPECT/CT
215004065|NCT04082520|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215004066|NCT04082520|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
215004067|NCT05341245|PROCEDURE|Graphene oxide and open flap debridement|Using Graphene oxide with open flap debridement in management of periodontal intrabony defects in dogs
215004068|NCT05341245|PROCEDURE|Open flap debridement|Using Open flap debridement in management of periodontal intrabony defects in dogs
215004069|NCT04472741|DEVICE|difference between colonoscopes|patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff
215004070|NCT00093938|DRUG|Cranberry juice|
215004071|NCT06506955|DRUG|futibatinib|TAS-120 futibatinib monotherapy
215095638|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
215095639|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
215095640|NCT01276223|DRUG|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
215095641|NCT01276223|OTHER|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
215095642|NCT02744989|DEVICE|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental tDCS group will receive the ACTIVE stimulation with the following parameters: oscillatory Direct Current with high frequency random noise stimulation (hf-tRNS - 100 to 500 Hz), Intensity = 2 mA, offset = + 1 mA, seance duration = 20 minutes ramp up/ramp down 30 seconds. Total number of sessions = 10 (sessions twice daily for 5 days separated by at least 2 hours for 5 consecutive weekdays).
215095643|NCT02744989|DEVICE|Sham tDCS|The control group will receive the SHAM stimulation (placebo) following the same regimen (i.e., twice daily sessions separated by at least 2 hours for 5 consecutive weekdays). Sham stimulation consists of a 20 minutes session including 40 seconds of active stimulation (same parameters as in the ACTIVE arm) at the beginning of the sessions, whatever the stimulator
215095644|NCT02516319|DRUG|ICG Dye|
214399432|NCT01991717|DEVICE|Conventional Phaco|The capsulotomy as well as the lens fragmentation is performed manually.
214399433|NCT00007930|PROCEDURE|conventional surgery|
214399434|NCT00007930|PROCEDURE|laparoscopic surgery|
215004072|NCT06506955|DRUG|futibatinib, fulvestrant|TAS-120 futibatinib combination therapy with fulvestrant
214399435|NCT00156338|PROCEDURE|fluid management|volume and sodium restriction
214399436|NCT00156338|PROCEDURE|fluid management|volume restriction
214399437|NCT00156338|PROCEDURE|fluid management|liberal fluid management
214399438|NCT01600950|DRUG|LY2963016|Single 0.3 U/kg dose administered subcutaneously
214399439|NCT01600950|DRUG|Lantus|Single 0.3 U/kg dose administered subcutaneously
214399440|NCT00451815|DRUG|active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.|
214399441|NCT00451815|DRUG|placebo|
214399442|NCT02711722|DEVICE|Neurally adjusted ventilatory assist|"Ventilation supported by NAVA~* Blood gas analysis~* Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured."
214399443|NCT02711722|DEVICE|PScli1|Pressure support set by clinicians prior to inclusion
214399444|NCT02711722|DEVICE|PScli2|Pressure support at the same level as prior to the study
214399445|NCT06264934|DEVICE|Breast scan using the Z-scanner|Four repeated scans of both breasts using the Z-scanner.
214399446|NCT06264934|DEVICE|Breast scan using the Z-scanner|A scan of both breasts using the Z-scanner.
214399447|NCT02818608|DEVICE|Functional Electrical Stimulation (FES)|Functional Electrical Stimulation (FES) + Sham Transcranial direct brain stimulation (tDCS)
214399448|NCT02818608|DEVICE|Combination of Transcranial direct brain stimulation (tDCS) and FES|Real Functional Electrical Stimulation (FES) + Real Transcranial direct brain stimulation (tDCS)
214399449|NCT05180812|DEVICE|ExoNet Tuned to Gravity Support|This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
214399450|NCT03729206|DIAGNOSTIC_TEST|intravital microscopy|intravital microscopy with sidestream dark-field imaging
214399451|NCT01761786|GENETIC|CYP2C19 genotyping|CYP2C19 genotyping will be performed in the intervention group. In patients with \*1/\*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (\*2 or \*3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
214399452|NCT04081298|BEHAVIORAL|Health Education|Attend nutrition and PA classes, and cooking sessions
214399453|NCT04081298|OTHER|Physical Activity|Participate in physical activities
215004073|NCT03570593|PROCEDURE|REMOVAL OF URINARY CATHETER AFTER RADICAL SURGERY|Removal of urinary catheter on the first day after radical surgery
214399454|NCT04081298|OTHER|Health Promotion and Education: Text Messages|Receive motivational text messages
214399455|NCT04081298|OTHER|Health Promotion and Education: Web Site|Given access to nutrition website
214399456|NCT04081298|OTHER|Quality-of-Life Assessment|Ancillary studies
214399457|NCT04081298|OTHER|Questionnaire Administration|Ancillary studies
214399458|NCT02724787|BEHAVIORAL|Manage Emotions to Reduce Aggression (MERA)|MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
215004074|NCT00726557|BIOLOGICAL|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
215004075|NCT00726557|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
215004076|NCT01239745|DRUG|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
215004077|NCT02011334|DRUG|tocilizumab [RoActemra/Actemra]|162 mg will be administered once weekly by subcutaneous injection.
214399459|NCT03285451|DIAGNOSTIC_TEST|submental ultrasonography|Submental ultrasound, the noninvasive and convenient tool, has been widely applied to measure the tongue base thickness in patients with obstructive sleep apnea, so as to predict the severity and relationship with upper airway collapse.
214399460|NCT01242943|DRUG|131I-L19SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.~Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167."
214399461|NCT01305057|OTHER|Pyridoxine tri-isopalmitate|2% dosage, oil-in-water emulsion, twice a day, 28 days
214399462|NCT02787538|BEHAVIORAL|US-ANSWER-2 decision aid|US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
214399463|NCT02787538|BEHAVIORAL|Control group (Online medication guide)|Standard online medication guide.
214399464|NCT01150851|OTHER|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
215004078|NCT00159809|DRUG|Viagra (Sildenafil citrate)|
215004079|NCT00396669|DRUG|Bupropion|We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
215004080|NCT00396669|DRUG|Bupropion|Brain imaging after treatment with Bupropion
214399465|NCT01150851|OTHER|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
214399466|NCT02145793|BEHAVIORAL|ADHD Group Curriculum|Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
214399467|NCT00282321|BEHAVIORAL|High Protein diet|
214399468|NCT00282321|BEHAVIORAL|High carbohydrate diet|
214399469|NCT03497182|DEVICE|Breath sample collection|Subject exhales into breath collection container.
214399470|NCT00479674|DRUG|Abraxane|100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
214399471|NCT00479674|DRUG|Bevacizumab|10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
214399472|NCT00479674|DRUG|Carboplatin|area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
214399473|NCT00643500|DRUG|Levetiracetam|
214399474|NCT04232748|DRUG|first line systemic treatment for colorectal cancer|systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.
214399475|NCT05471193|DIAGNOSTIC_TEST|Machine Learning Prediction|Machine Learning Prediction
214399476|NCT01138319|GENETIC|DNA analysis|
214399477|NCT01138319|GENETIC|mutation analysis|
215004081|NCT01229553|DRUG|decolonization|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
215004082|NCT01837303|PROCEDURE|Pap smear|"A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.~These slides will be processed so that they may be reviewed by a single board certified pathologist.~There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo."
214399478|NCT01138319|GENETIC|polymerase chain reaction|
214399479|NCT01138319|OTHER|laboratory biomarker analysis|
214399480|NCT01980979|DRUG|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
214399481|NCT04555629|OTHER|Advanced Cognitive Stimulation Therapy Hong Kong|A modified version of Cognitive Stimulation Therapy for people with moderate to severe dementia translated and culturally adapted for the Hong Kong Chinese population.
214399482|NCT04018443|DIAGNOSTIC_TEST|common carotid artery diameter measurement|measurement of common carotid artery diameter will be carried out two times: the initial measurement (pre-infusion) which is followed by infusion of crystalloid solution (Ringer lactate) 30 ml/min till reaching a total infusion volume of 7 ml/kg body weight then another ultrasound measurement will be taken (prost-infusion). Between these sequential measurements, the patient position will not be changed. The percentage increase in CCA diameter will be calculated using the formula: \[(dia-mpost/dia-mpre) × 100\] - 100 \[11\].
214399483|NCT00060021|PROCEDURE|acupuncture therapy|
214399484|NCT00060021|PROCEDURE|management of therapy complications|
214399485|NCT00060021|PROCEDURE|pain therapy|
214399486|NCT00146640|DRUG|MR Prednisone|Participants will receive tablets containing MR prednisone (to achieve the appropriate dose of 3-10 milligrams \[mg\] prednisone per day) at bed time.
214399487|NCT00146640|DRUG|IR Prednisone|Participants will receive tablets containing IR prednisone (to achieve the appropriate dose of 3-10 mg prednisone per day) in the morning.
214399488|NCT00146640|DRUG|Placebo - MR Prednisone|Participants will receive placebo matching to MR prednisone tablet at bed time.
214399489|NCT00146640|DRUG|Placebo - IR Prednisone|Participants will receive placebo matching to IR prednisone tablet in the morning.
214399490|NCT02071095|DRUG|Arm A: Poly-ICLC|Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
214399491|NCT02071095|DRUG|Arm B: Normal Saline|Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
214399492|NCT03983902|PROCEDURE|Delayed cord clamping|Delayed cord clamping will occur for up to 2 minutes.
214399493|NCT03983902|PROCEDURE|Umbilical cord milking|Umbilical cord milking will occur milking of the 30 cm of the cord from placental site to baby, at a speed of 5 cm/second, 3 times in preterm newborns, 4 times in term newborns.
214399494|NCT03983902|PROCEDURE|Immediate cord clamping|Immediate cord clamping will occur in 20 seconds after birth.
214399495|NCT02059161|DRUG|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
215095645|NCT02618551|PROCEDURE|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
215095646|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)|Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.
215095647|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)|These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
215095648|NCT03094065|OTHER|News items with spin|Interpretation of news items with spin
215095649|NCT03094065|OTHER|News items without spin|Interpretation of news items without spin
215095650|NCT02488460|BEHAVIORAL|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
215095651|NCT06210555|PROCEDURE|Renal transplantation|Operative procedure - receipt of a kidney
214399496|NCT02059161|DRUG|Lantus™|Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
214399497|NCT02059161|DRUG|Prandial Insulin|Participants will continue their prandial insulin during the study.
214399498|NCT00905060|BIOLOGICAL|HSPPC-96|Autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.
214399499|NCT00905060|DRUG|Temozolomide|Maintenance temozolomide treatment is given 2 weeks after administration of the fourth vaccine at an initial dose of 150 mg per square meter (mg/m2) for 5 consecutive days in a 28-day cycle. The dose was increased to 200 mg/m2 for 5 days in subsequent cycles.
214399500|NCT00905060|PROCEDURE|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
214399501|NCT01306708|DRUG|amitriptyline|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
214399502|NCT03790293|DRUG|Rituximab|Patient was enrolled into the RITUXIMAB 3 study in the arm Rituximab in association with low corticosteroids'therapy
214399503|NCT03790293|DRUG|corticosteroids'therapy|Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
214399504|NCT01364961|DIETARY_SUPPLEMENT|Resveratrol capsules|2 x 75 mg resveratrol each day, for 4 weeks
214399505|NCT01325987|DIETARY_SUPPLEMENT|Vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D \<20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
214399506|NCT01325987|OTHER|Sugar pill|"1. group: vitamin D2 50000 IU weekly once for 8 weeks~2. nd group: placebo weekly once for 8 weeks"
214399507|NCT01228383|BIOLOGICAL|Rabies virus-specific monoclonal antibodies|CL184 20 IU/kg intramuscularly on Day 0.
214399508|NCT01228383|BIOLOGICAL|human polyclonal rabies immune globulin (HRIG)|HRIG 20 IU/kg intramuscularly on Day 0.
215095652|NCT06210555|PROCEDURE|Living kidney donation|Operative procedure - donation of a kidney
215095653|NCT02136147|DRUG|methylphenidate medication|
215095654|NCT02136147|DRUG|atomoxetine medication|
215095655|NCT02136147|DRUG|lisdexamphetamine medication|
215095656|NCT02136147|DRUG|guanfacine medication|
215095657|NCT04772508|PROCEDURE|Scaling and root planing|15 sites with periodontal pockets ≥ 5mm received only SRP
215095658|NCT04772508|BIOLOGICAL|Amnion membrane|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
214399509|NCT01228383|BIOLOGICAL|Placebo|Placebo intramuscularly on Day 0.
214399510|NCT01228383|BIOLOGICAL|Human diploid cell vaccine (HDCV)|Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
214399511|NCT01228383|BIOLOGICAL|Purified verocell rabies vaccine (PVRV)|Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
214399512|NCT02821390|DRUG|Nepafenac Eye Drops|One drop instilled to the eye's cul de sac prior to the intravitreal injection.
214399513|NCT02821390|DRUG|Placebo (Artificial Tears)|One drop instilled to the eye's cul de sac prior to the intravitreal injection
214522607|NCT00763087|BEHAVIORAL|weightbearing exercise|All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
215095659|NCT04772508|DRUG|Taurine|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
215095660|NCT02881619|DRUG|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
215095661|NCT02881619|DRUG|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
214399514|NCT05050487|PROCEDURE|PENG block|"The PENG block is performed under US guid¬ance, . The pa¬tient is placed in the supine position a curvilinear low-fre¬quency ultrasound probe (2-5 MHz) is initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe approximately 30-45 degrees . .~The needle, usually a 22-G80-mm echogenic device, is inserted from lateral to medial with an in-plane approach to place the tip in the plane between the psoas tendon anteriorly and the pu¬bic ramus posteriorly .~After needle insertion and following negative aspiration, the local anesthetic is injected . The volume used of 20 ml of(L-bupivacaine; concentration 0,25% ) . This fascial plane appeared to continue in the hip pericapsular plane."
214399515|NCT05050487|PROCEDURE|lumbar erector spinae plane block|"The lumbar erector spinae block is performed under US guid¬ance, after adequate skin disinfection The patient is placed in the lateral decubitus position according to the selected site of surgical intervention.~The 4th lumbar vertebral level will determined The convex USG transducer was placed at the mid-vertebral line in the sagittal plane. The transducer was shifted from the midline, 3.5-4 cm laterally to the side of the surgery to visualize the erector spinae muscle and transverse process . 0.5-1 ml of the prepared LA solution (20 ml bupivacaine 0.25%). All LA was administered to this location between the transverse process and the erector spinae muscle."
214399516|NCT03127592|DRUG|Fixed Dose Combination|Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg
214399517|NCT03127592|DRUG|Etodolac|Individual drug
214399518|NCT03127592|DRUG|Cyclobenzaprine|Individual drug
214399519|NCT01840761|DRUG|herbal drug|
214399520|NCT01840761|DRUG|placebo|
214399521|NCT02633319|BEHAVIORAL|Skilful Parenting|Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.
214399522|NCT02633319|OTHER|Agrics|Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.
214399523|NCT02958228|BEHAVIORAL|Positive Mental Imagery Training (PMIT)|
214399524|NCT02958228|BEHAVIORAL|Cognitive Control Training (CCT)|
215095662|NCT04480255|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
215095663|NCT04480255|OTHER|Group 2: NICU2HOME+ app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
215095664|NCT05325476|OTHER|JomPrEP App|The JomPreP app will be ideally designed to optimize HIV prevention cascade by providing a virtual platform to access to HIV prevention (e.g., HIV testing and PrEP) and other support services (e.g., mental health). The JomPrEP app will be available on the Apple Store and the Google Play Store for the users to download. However, access to the app will be restricted to the research participant using a unique registration code.
215095665|NCT05325476|OTHER|Inactivated JomPrEP app|Participants will have access to the JomPrEP app with major intervention features inactivated. Information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The RA will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
215095666|NCT02984540|OTHER|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
214399525|NCT02958228|OTHER|Treatment as Usual|
214399526|NCT02511561|DRUG|OTO-201 (ciprofloxacin)|
214399527|NCT03511183|DRUG|XELIRI + bevacizumab|Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
214399528|NCT03511183|DRUG|XELOX + bevacizumab|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
214399529|NCT02086799|DRUG|IV thyroxin|Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.
214399530|NCT02086799|DRUG|Placebo|Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
214399531|NCT01798082|OTHER|Pelvic organ prolapse decision aid|
214399532|NCT02460744|RADIATION|Hypofractionation|Radiation dose of 34Gy in 10 fractions over 2 weeks.
214522608|NCT00763087|BEHAVIORAL|nonweightbearing exercise|All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
214522609|NCT00763087|BEHAVIORAL|nonexercising control|All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
214522610|NCT00108407|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|
215095667|NCT02984540|OTHER|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to \<40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
214399533|NCT03405181|OTHER|Training with additional weight|The infants will be positioned in a reclined position. A bracelet with an additional weight (20% of the total mass of the upper limb) will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches it. After reaching, the object will be carefully removed and resubmitted in order to elicit a new movement. The interval between each presentation will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
214399534|NCT03405181|OTHER|Training without additional weight|The infants will be positioned in a reclined position. A bracelet without the additional weight will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches the object. After reaching, the object will be carefully removed (or picked up) and resubmitted in order to elicit a new movement. The interval between each presentation of the object will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
214399535|NCT02447679|DRUG|thalidomine|thalidomine (400mg/day) for 1 year to prevent HCC recurrence
214399536|NCT02447679|DRUG|tegafur-uracil|tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
214399537|NCT00170235|OTHER|Prehabilitation|Exercise class pre-surgery
214399538|NCT00170235|OTHER|Usual care|Exercise booklet, physiotherapy if needed
214399539|NCT03023332|BEHAVIORAL|Resourcefulness Training|A cognitive-behavioral intervention delivered through iPad technology that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
214399540|NCT03023332|BEHAVIORAL|Biofeedback training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and continue to influence behavior."
214399541|NCT03023332|BEHAVIORAL|Bipolar Education|An educational program designed to teach family caregivers of about the types, causes, symptoms, episodes, warning signs, and treatments for individuals with bipolar disorder, as well as available resources for assisting a family member with bipolar disorder. The content to be presented within an audiovisual format using iPad technology follows the recommendations and guidelines developed through research and by the Depression and Bipolar Support Alliance and the National Institute of Mental Health.
214399542|NCT01818700|DRUG|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
214399543|NCT00739193|DRUG|amiodarone|
214399544|NCT00000390|DRUG|Imipramine hydrochloride|
214399545|NCT05281393|BEHAVIORAL|PrEPresent|PrEP2Prevent is being done in several phases (parts) to develop and pilot test a PrEP activation, navigation and support intervention for young men who have sex with men (YMSM), trans youth and non-binary youth in Los Angeles. It targets an intervention for these young people where they need it most - on PrEP uptake. PrEP stands for pre-exposure prophylaxis.
214399546|NCT03295006|DEVICE|TheraSphere|Patients who had received TheraSphere
214399547|NCT01852955|DRUG|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure
214399548|NCT01852955|DRUG|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
214399549|NCT04974320|BIOLOGICAL|blood biomarkers|All patients were obtained blood biomarkers: troponin, ST2, copeptin
214399550|NCT04751175|DRUG|Ketamine|Ketamine, being a non-competitive antagonist of NMDA receptors, could represent a good option as an opioid treatment enhancer for acute postoperative pain and avoid chronic pain, by reducing the '' wind-up '' phenomenon of central sensitization
214522611|NCT00108407|BEHAVIORAL|Twelve Step Facilitation Therapy|
214522612|NCT02854657|BEHAVIORAL|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
214522613|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in plasma|
214522614|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in human albumin|
214522615|NCT02001207|OTHER|Salivary cortisol test|
215004083|NCT01328119|OTHER|4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF|Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
215095668|NCT05849376|BEHAVIORAL|Emergent Multi-Class Imitation Training|Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments. A maximum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 15-20 min to conduct. Novel probe trials will be embedded throughout all sessions to continuously assess for the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.
215095669|NCT05881252|PROCEDURE|Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP \>= 160 mmHg.
215095670|NCT05881252|PROCEDURE|Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP \>= 180 mmHg.
215095671|NCT06634134|BEHAVIORAL|Adjusting training advice|Based on discomfort related to the menstrual cycle the female cyclist can choose to adjust the suggested training.
214399551|NCT04751175|DRUG|Dexamethasone|"A meta-analysis published in September 2011 affirms that the administration of dexamethasone at a dose of 0.1 mg / kg is an effective complement to multimodal analgesia strategies to reduce postoperative pain and opioid consumption after surgery.~Preoperative administration of the drug produces a more consistent analgesic effect than intraoperative administration"
215095672|NCT03950492|DEVICE|Deep Brain Simulator|This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.
214399552|NCT04751175|DRUG|Physiologic saline|placebo
214399553|NCT01729897|DRUG|Etomidate|
214399554|NCT01729897|DRUG|Fentanyl|
214399555|NCT01729897|DRUG|Propofol|
214399556|NCT05715450|PROCEDURE|Falciformopexy for Treatment Perforated Peptic Ulcer|use the falciform ligament on perforated peptic ulcer
215004084|NCT00081458|DRUG|Placebo|placebo injectable subcutaneously daily into thigh or abdomen
215004085|NCT00081458|DRUG|Teduglutide 0.05 mg/kg/d|Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
215004086|NCT00081458|DRUG|Teduglutide 0.1 mg/kg/d|Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
215095673|NCT04281979|DRUG|Study Agent|The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
215095674|NCT04281979|DRUG|Placebo|In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
215095675|NCT02870088|BEHAVIORAL|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
215095676|NCT02870088|BEHAVIORAL|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
215095677|NCT02455076|DRUG|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
215095678|NCT02455076|DRUG|Glargine|"Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.~1. FBG \>180 mg/dL, no hypoglycemia; glargine increased by 4 IU.~2. FBG \>140 mg/dL, no hypoglycemia; glargine increased by 2 IU.~3. FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.~4. FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.~5. FBG or RBG \< 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.~6. FBG or RBG \< 40 mg/dl, decrease dose of glargine by 30%."
215095679|NCT02455076|DRUG|Rapid-acting insulin analogs|"If the BG levels are \>140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG\> 400 mg/dL, the insulin will be 8,12 or 16 units."
214399557|NCT01043536|RADIATION|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
214399558|NCT01043536|DRUG|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
214399559|NCT03550729|BEHAVIORAL|Endurance training|Endurance training 3 times per week during 3 months using interval training above 70% of load peak reached in the incremental exercise test. The duration of the sessions will be adapted individually to each patient (approximately 60 minutes).
214399560|NCT00004108|DRUG|exatecan mesylate|
214399561|NCT02408549|DRUG|Lacosamide Tablet|"* Active substance: Lacosamide~* Pharmaceutical form: Tablet~* Concentration: 50 mg and 100 mg~* Route of Administration: Oral administration"
215095680|NCT06543680|OTHER|Dental restoration|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
215095681|NCT05788133|OTHER|treatment and screening by neuropsychological tests on humanoid robot|treatment and screening by neuropsychological tests on humanoid robot
215095682|NCT01474070|DEVICE|Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT
214522616|NCT05274906|OTHER|Randomized, cross-over controlled feeding trial testing a Healthy Eating Index 2015 (HEI-2015) diet with and without red and processed meat|Healthy Eating Index-2015 (HEI-2015) with or without red/processed meat (HEI-2015-M)
215095683|NCT03071289|RADIATION|Radiation Method B|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.
215095684|NCT03071289|DRUG|Cisplatin|The regimen of chemotherapy is cisplatin 30mg/m2 every week.
215095685|NCT03071289|RADIATION|Radiation Method A|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
214399562|NCT02408549|DRUG|Lacosamide Oral Solution|"* Active substance: Lacosamide~* Pharmaceutical form: Oral solution~* Concentration: 10 mg/ml~* Route of Administration: Oral administration"
214399563|NCT03062150|DRUG|Placebo|Placebo
214399564|NCT03062150|DRUG|Fludrocortisone|Fludrocortisone
214399565|NCT03062150|DRUG|D-Cycloserine|D-Cycloserine
214399566|NCT05542017|PROCEDURE|Surgical Ablation for Atrial Fibrillation|Surgical ablation in combination with other cardiac procedures through a median sternotomy or thoracotomy. Main procedures were valve surgery (i.e. repair, replacement) and/or coronary artery bypass grafting (CABG). Surgical ablation procedures for atrial fibrillation were divided into three different groups according to Heart Rhythm Society (HRS) expert consensus 2017: (1) Pulmonary vein isolation alone; (2) Pulmonary vein isolation combined with left atrial lesion sets; (3) and biatrial procedure.
214399567|NCT01047943|DRUG|Topical application of STA-21 ointment for treatment of psoriasis|
214399568|NCT02742909|DRUG|rhBNP|rhBNP was administered as a continuous infusion for 24 hours before or after placebo
214399569|NCT02742909|DRUG|placebo|normal saline as a placebo was administered as a continuous infusion for 24 hours
214399570|NCT01656759|DRUG|Evicel Fibrin Spray|10cc syringe dose, once at the end of TKA
214522617|NCT01526486|PROCEDURE|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
214522618|NCT01526486|PROCEDURE|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
215095686|NCT05373693|DEVICE|Single vision lens|Wear single vision lens
214399571|NCT02687919|OTHER|Modified Paleo diet|Nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
214399572|NCT00217100|DIETARY_SUPPLEMENT|Multivitamin|1 tablet a day
215004087|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Left Side|Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
215004088|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Right Side|Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
215004089|NCT06252337|OTHER|bioceramic sealer group|epoxy resin based + carrier based technique group. The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
214399573|NCT00217100|DIETARY_SUPPLEMENT|Placebo|1 tablet a day
214399574|NCT01192295|DRUG|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
214399575|NCT03460717|OTHER|Peripheral Nerve Field Stimulation by Thermal Micro-Cautery|The most painful points over the knee received an intense heat by a metal rod for 0.5 seconds.
214399576|NCT00190346|DEVICE|Humidification devices: HH vs HME|
214399577|NCT04682574|DRUG|Vitamin C|mega dose is given to the selected critically ill patients
214399578|NCT01444976|DRUG|local anesthesia|patients will receive only topical anesthesia with 1% lidocaine
215004090|NCT04190095|DEVICE|Motion Tracking in VR|Participant will wear motion sensors and VR devices
214399579|NCT01444976|BEHAVIORAL|hypnosis|Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
214399580|NCT01444976|DRUG|Midazolam|Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
214399581|NCT02859597|DEVICE|High flow nasal cannula|High flow nasal cannula at 50 liters per minute and 50% oxygen will initially be used for oxygenation.
214399582|NCT02859597|DEVICE|Nasal Cannula|Control group will receive oxygen via standard flow nasal cannula at 5 liters per minute (approximately an FiO2 of 0.35)
214399583|NCT02605499|OTHER|UV-C light disinfection|UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
214399584|NCT00461448|DIETARY_SUPPLEMENT|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
214399585|NCT06417645|DRUG|fixed propofol infusion 15 mg/kg/h until 1% BSR (burst suppression ratio)|after a slow induction with propofol to loss of consiousness (LOC), we proceed to give remifentanil TCI and rocuronium and intubate the patient. After 5 min we infuse 15 mg/kg/h until 1%BSR observe in the BIS monitor. Then we reduce the TCI LOC predicted concentration.
215004091|NCT04190095|BEHAVIORAL|VR Interaction|Participant will perform VR interaction task
215004092|NCT04135001|BEHAVIORAL|HBM Training|A computer-based training to reduce hostile bias and interpersonal conflict as a mechanism to improve trust and cohesion within an operational military unit across the deployment cycle. The computer training is based on the Go/No-Go task (Fillmore et al., 2006) and Lexical Decision Task (Lepore \& Brown, 2002). The training reduces HAB by affecting two cognitive mechanisms: prime seeking non-hostile concepts when presented with ambiguous cues and conditioning inhibition in response to hostile cues. Thus, the training induces a non-hostile attribution bias while simultaneously training the inhibition of hostile attribution bias and aggressive behavior in response to ambiguous cues.
215004093|NCT04135001|OTHER|Placebo Training|Volunteers in the placebo condition will be told to complete the fragments with the first word that comes to mind. This placebo still exposes volunteers to the training stimuli and computer task, but does not train inhibition or selectively prime non-hostility, which are the hypothesized mechanisms of the training.
215095687|NCT05373693|DEVICE|+2D PDL|Wear Peripheral defocus lense with +2D
215095688|NCT05373693|DEVICE|+3D PDL|Wear Peripheral defocus lense with +3D
215095689|NCT05373693|DEVICE|+4D PDL|Wear Peripheral defocus lense with +4D
215095690|NCT06447701|DRUG|Tocilizumab|Single dose intravenous application
215095691|NCT06447701|DRUG|NaCl 0.9% 100ml|Single dose intravenous application
215095692|NCT05848297|DEVICE|Transcranial Doppler ultrasonography (TCD)|Portable, bedside, non-invasive diagnostic tool used for real-time assessment of cerebral hemodynamics
215095693|NCT06573242|OTHER|Home-based cardiac rehabilitation for people living with Heart Failure and their caregivers|Intervention DK:REACH-HF is a home-based 12-week CR program for people living with HF and their caregivers.
215095694|NCT04051827|DRUG|Midazolam|Midazolam Oral Solution and Midazolam Intravenous Infusion.
215095695|NCT04051827|DRUG|TAK-788|TAK-788 Oral Capsules.
215095696|NCT01921686|OTHER|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
215095697|NCT06500442|DRUG|NEU-111|Oral Doses
215095698|NCT06500442|DRUG|Placebo|Oral Doses
215095699|NCT02573753|BEHAVIORAL|Sleep restriction|
215095700|NCT02573753|DIETARY_SUPPLEMENT|Weight gain|
215095701|NCT06979518|DRUG|GSK3862995B|GSK3862995B will be administered.
215095702|NCT06979518|DRUG|Placebo|Matching placebo will be administered.
215095703|NCT06601192|DRUG|zelicapavir (therapeutic dose)|Subjects will receive zelicapavir (TD) once per treatment period.
215095704|NCT06601192|DRUG|zelicapavir (supratherapeutic dose)|Subjects will receive zelicapavir (SD) once per treatment period.
215095705|NCT06601192|DRUG|Placebo|Subjects will receive zelicapavir matching placebo once per treatment period.
215095706|NCT06601192|DRUG|moxifloxacin|Subjects will receive moxifloxin once per treatment period.
214503916|NCT06951958|BEHAVIORAL|Cardiac Rehabilitation Program Based on Health Action Process Approach Model|The intervention program will start in the hospital setting and continue at home. A work schedule will be created with each individual in intervention group 1 by determining the times when they are available separately. Individuals are planned to receive 60-minute home visits once a week. In the following weeks, care interventions such as home visits, training, counseling and monitoring will be organized according to the specific needs and requirements of each individual. In the face-to-face preparation phase, the patient's health needs will be identified, health status will be assessed, daily activities will be reviewed, incompatibility between activity levels and recommended exercise guidelines will be examined, and individualized exercise goals and a behavior-specific exercise program will be created for behavioral changes. In the intervention phase, the parts that the patient lacks will be determined and the trainings needed will be given.
214503917|NCT06953206|PROCEDURE|Transcatheter aortic valve (S3UR) replacement (TAVR)|Elective transfemoral TAVi procedure with S3UR valve.
214503918|NCT06951139|DIAGNOSTIC_TEST|Ultrasound and Shear Wave Elastography|Non-invasive diagnostic imaging techniques used to assess the stomatognathic system. Ultrasound was performed to measure the thickness of the masseter, temporalis, and sternocleidomastoid muscles, as well as the articular disc of the temporomandibular joint. Shear Wave Elastography was used to evaluate the elasticity (stiffness) of the same muscles and joint structures in kilopascals. All evaluations were conducted at rest, using standardized positioning, and by the same experienced operator.
214503919|NCT05429632|DRUG|mocravimod|S1PR modulator
214503920|NCT06953986|DRUG|Vonoprazan|Vonaprazon is potassium competitive acid blockers
214503921|NCT06953986|DRUG|Esomeprazole 40mg|esomeprazole is a proton pump inhibitor as it prevents excess of gastric acid secretion in the stomach
214503922|NCT06947434|OTHER|Laughter Yoga|Laughter yoga is a behavioral intervention that combines intentional laughter exercises with yogic breathing techniques. In this study, the intervention consisted of 10 sessions delivered over five weeks (two sessions per week), each lasting approximately 40 minutes. Sessions were conducted live via Zoom and included components such as rhythmic clapping, deep breathing (pranayama), playful movements, and guided laughter exercises. The aim was to promote relaxation, reduce stress, and enhance psychological well-being in individuals with multiple sclerosis.
214503923|NCT06950242|DEVICE|Balloon dilation treatment for intracranial arterial stenosis in order to improve intracranial blood supply.|Balloon dilation treatment for intracranial arterial stenosis in order to improve intracranial blood supply.
214503924|NCT06950242|DEVICE|Boston Scientific Corporation|Balloon dilation treatment for intracranial arterial stenosis in order to improve intracranial blood supply.
214503925|NCT04118894|DEVICE|Foot and Ankle Devices|Wright devices used in foot and ankle procedures
215004094|NCT00422435|DEVICE|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
214399586|NCT00393627|BEHAVIORAL|Sleep Education Program|The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
215004095|NCT02999321|OTHER|aspartame|will be given 5mg aspartame or 15 mg aspartame
214399587|NCT00630162|GENETIC|amoeba|
214399588|NCT04127344|BEHAVIORAL|Music Therapy Intervention|Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
215004096|NCT02999321|OTHER|water|control group
215004097|NCT05665842|OTHER|Music Application|The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
215095707|NCT07087886|BEHAVIORAL|Combined Resilience Intervention|"A two-phase behavioral intervention aimed at improving psychological resilience among socioeconomically disadvantaged adolescents. The intervention includes:~1. a 5-day structured summer camp led by trained university student volunteers, featuring psychoeducational group sessions, emotional expression activities, and life skills training, based on SEL, CBT, and positive psychology frameworks; and~2. a 10-month pen-pal letter-writing component, where each child is matched with a trained university volunteer to receive monthly supportive letters. This stage reinforces the gains from the summer camp through sustained emotional support, skill reminders, and positive guidance.~The intervention is designed to be low-cost, scalable, and ethically safe, and has been standardized through manuals and training protocols."
214399589|NCT03746444|OTHER|General Anesthesia|The patients in general anesthesia group will undergo general anesthesia
214399590|NCT03746444|OTHER|Regional Anesthesia|The patients in Group R will be given combined spinoepidural anesthesia
214399591|NCT05049525|DRUG|Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.|Itraconazole capsules of 100 mg, antifungal agent. Terbinafine tablets 250 mg (as terbinafine hydrochloride), antifungal agent.
214399592|NCT05049525|DRUG|Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.|Matching placebo of itraconazole capsules of 100 mg, antifungal agent. Matching placebo of terbinafine tablets 250 mg, antifungal agent.
215095708|NCT06922097|DRUG|Giving atropine at heart rates below 60 beats per minute|In patients assigned to the atropine therapy at heart rates below 60 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 60 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 60 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.
215095709|NCT06922097|DRUG|Giving atropine at heart rates below 30 beats per minute|In patients assigned to atropine therapy at heart rates below 30 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 30 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 30 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.
215095710|NCT04969536|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Supplementation with 8 g Nutrex Research Amino Acid Drive BCAA in 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
215004098|NCT05665842|OTHER|Sleep Hygiene Training|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal \& Nunes, 2014; Dinis \& Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
215004099|NCT04881721|PROCEDURE|Urethropexy|Suture based (Mesh-free) surgery to stabilize the urethra for the treatment of stress urinary incontinence
215004100|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
214399593|NCT04389255|OTHER|Star Excursion Balance Test|The Star Excursion Balance Test (SEBT) is a dynamic test that requires strength, flexibility, and proprioception. It is a measure of dynamic balance that provides a significant challenge to athletes and physically active individuals. The test can be used to assess physical performance, but can also be used to screen deficits in dynamic postural control due to musculoskeletal injuries (e.g. chronic ankle instability), to identify athletes at greater risk for lower extremity injury, as well as during the rehabilitation of orthopeadic injuries in healthy active adults.\[
215004101|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
215004102|NCT01805336|OTHER|Assessment of attentional functions by traditional tests|For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
214503926|NCT03685305|BEHAVIORAL|Hypocaloric diet with hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. Counseling will include specific instructions on a dietary manipulation which may reduce hunger, in order to facilitate dietary adherence.This will include tracking of the strategy. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
215004103|NCT01805336|OTHER|Assessment of attentional functions by virtual reality tests|For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
215004104|NCT01805336|OTHER|Assessment of executive functions by traditional tests|For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
215095711|NCT04969536|OTHER|Placebo|Supplementation with 2.0 milliliters of a sucralose-based drink mix with 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
215095712|NCT00459472|BEHAVIORAL|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
214503927|NCT03685305|BEHAVIORAL|Hypocaloric diet without hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
215004105|NCT01805336|OTHER|Assessment of executive functions by virtual reality test|For assessment of executive functions, virtual reality test include : VAP-S.
215004106|NCT01805336|OTHER|Evaluation of cognitive complaint, fatigue, anxiety and depression|The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
215004107|NCT05309889|OTHER|no intervention|no intervention
215004108|NCT00247793|DRUG|Oral Impact (preoperative enteral nutritional supplement)|
215095713|NCT04394715|OTHER|Electronic Alert|"Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events. This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit. The alert consists of a pop up that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy. It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits."
215095714|NCT01441700|PROCEDURE|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
215095715|NCT07040839|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg orally twice daily for 14 days
215095716|NCT07040839|DRUG|Amoxicillin 1 g|Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
215095717|NCT07040839|DRUG|Omeprazole 40 mg|Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
215095718|NCT07040839|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg orally twice daily for 14 days
215095719|NCT07040839|DRUG|Amoxicillin 1 g|Amoxicillin 1 g orally twice daily for 14 days
215004109|NCT00277563|DEVICE|reduction of pain scores by magnetic energy|
215004110|NCT04328285|DRUG|Hydroxychloroquine|Hydroxychloroquine Oral Tablets
215004111|NCT04328285|DRUG|Placebo of Hydroxychloroquine|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets
215004112|NCT04328285|DRUG|Lopinavir and ritonavir|LPV/r Oral Tablets
215095720|NCT07040839|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg orally twice daily for 14 days, then 20 mg once daily for 4 weeks
215095721|NCT07040839|DRUG|Levofloxacin 500 mg|Levofloxacin 500 mg orally once daily for 14 days
215095722|NCT07040839|DRUG|Amoxicillin 1 g|Amoxicillin 1 g orally twice daily for 14 days
215095723|NCT07040839|DRUG|Omeprazole 40 mg|Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
215004113|NCT04328285|DRUG|Placebo of LPV/r Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
215004114|NCT06468917|BEHAVIORAL|1st day removal of abdominal drain|once POPF is excluded in middle-low risk pancreatic resection, abdominal drains can be removed
215004115|NCT03166176|DRUG|Vistusertib(AZD2014)|vistusertib(AZD2014) is selective inhibitor of mTOR kinases and inhibits signalling of both mTOR complexes, mTORC1 and mTORC2.
215095724|NCT07040839|DRUG|Levofloxacin 500 mg|Levofloxacin 500 mg orally once daily for 14 days
215095725|NCT07040839|DRUG|Amoxicillin 1 g|Amoxicillin 1 g orally twice daily for 14 days
215095726|NCT07040839|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg orally twice daily for 14 days, then 20 mg once daily for 4 weeks
215095727|NCT07041775|OTHER|myoelectric interface for neurorehabilitation (MINT) conditioning|Myoelectric interface for neurorehabilitation (MINT) conditioning involves training to reduce abnormal co-activation of limb muscles to improve movement.
215095728|NCT07041775|OTHER|One muscle myoelectric feedback|Training to control muscle activity in one muscle only.
215004116|NCT04772430|RADIATION|snow globe|"Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure."
215004117|NCT03880409|DRUG|2% lidocaine with 1:000,000 epinephrine|2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
215004118|NCT03880409|DRUG|4% articaine with 1:000,000 epinephrine|4% articaine with 1:000,000 epinephrine is dental local anesthesia
215004119|NCT05842707|DRUG|dualCAR-NK19/70 cell|Given by IV (vein)
215004120|NCT04279678|PROCEDURE|Mitral valve repair|surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
215004121|NCT03996460|DRUG|Placebo|"Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food."
215004122|NCT03996460|DRUG|192 mg powder of K0706|Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
215004123|NCT03996460|DRUG|384 mg powder of K0706|Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
215095729|NCT06885229|DEVICE|FloMask - reuseable face mask|Reuseable, elastomeric face mask with replaceable filters
214399594|NCT04389255|DEVICE|Balance Master device|The Balance Master (Neurocom International, Inc Clackamas,) device is a computerized posturography device. The device consists of a fixed support surface consisting of a force table and individuals, a variety of ground elements and a computer screen that will provide visual feedback and conduct test protocols. Posturography tests a person's ability to integrate visual, vestibular and somatosensory inputs and suppress inappropriate sensory information. Thus, it can quantitatively score the person's balance and examine balance problems in detail with the tests it contains. There are various protocols that evaluate balance differently in Balance Master (BMc). Limits of Stability Test (LOS) and Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) were used in the BMc.
214399595|NCT00147654|DRUG|Tolterodine ER 4 mg QD|
214399596|NCT00147654|DRUG|Tamsulosin 0.4 mg QD|
214399597|NCT04044079|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
214399598|NCT04044079|DRUG|Misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
214399599|NCT04044079|DRUG|Placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
214399600|NCT02923895|OTHER|Stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride
214399601|NCT02923895|OTHER|Sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
214399602|NCT02463162|OTHER|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
214503928|NCT06325280|DIAGNOSTIC_TEST|Exercise cardiac MRI Assessment|Participants will undergo a standard cardiac MRI to assess resting ventricular structure and function then complete an exercise cardiac MRI assessment using an MRI-compatible stepping ergometer.
215004124|NCT00726427|DRUG|AZD1656|Dose escalation to achieve maximum tolerated dose
215004125|NCT00726427|DRUG|AZD1656|Oral single dose
215029358|NCT04832659|BEHAVIORAL|CEASE + BIO|Children randomized to the CEASE + BIO group will have leftover blood from an already collected blood sample that was taken for a clinically indicated blood draw analyzed for cotinine. Parents of children in the CEASE +BIO group will receive a report of biomarker results followed by proactive outreach from a BIO counselor. The BIO counselor will explain the laboratory results and refer all parents in the household who smoke to tobacco treatment through the parent's primary care provider and/or the state quitline. The BIO counselor will troubleshoot any barriers to obtaining nicotine replacement therapy that may have been prescribed as part of the CEASE protocol and will promote strict smoke-free and vape-free home and car policies. BIO counselors will conduct a maximum of 6 calls per enrolled smoker.
215095730|NCT06454877|DEVICE|active heating|"Preheating will be performed for 15 minutes 30 minutes before surgery with a hot air blowing device in accordance with the normothermia care package so that the body temperature is 36-37 C°.~Active heating during surgery will be done with a heating bed placed on the operating table.~Patients taken to the postoperative care unit will continue to be heated with a hot air blower and the device will be turned off when the body temperature reaches 37 C°."
214399603|NCT04187534|OTHER|Albumin Fluid Resuscitation Optimization Intervention|Multi-faceted quality improvement intervention to optimize appropriateness of albumin use for fluid resuscitation
214399604|NCT04187534|OTHER|Usual Practice|Albumin fluid resuscitation according to usual practice
214399605|NCT06184477|OTHER|PEDIATRIC TONSILLECTOMY; SURGICAL EXPERIENCE AND PROLONGED HOSPITALIZATION|we aim to compare hospitalization times of pediatric patients that operated by expert surgeon or young surgeon
214399606|NCT02883543|DRUG|icotinib|Icotinib is orally administered three times per day.
214522619|NCT02416297|PROCEDURE|Micro-osteoperforation|Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
214522620|NCT04816435|DIAGNOSTIC_TEST|Ultrasound test|Ultrasound evaluation of airway
214399607|NCT02883543|DRUG|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
215004126|NCT06328231|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
215004127|NCT02892708|PROCEDURE|Surgery|partial or complete resection followed by radiotherapy
215004128|NCT02892708|RADIATION|radiotherapy|radiotherapy after a brain biopsy
215004129|NCT02352142|OTHER|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
215004130|NCT02352142|BEHAVIORAL|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
215004131|NCT04900857|OTHER|Dry needle|Local twitch responses (LTRs) were obtained by multiple rapid insertions of the needle in and out of the point, similar to Hong's rapid-entry and rapid exit technique. Hong 1994). The needle was not removed from that site for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
215004132|NCT04900857|DEVICE|Localize vibration|the vibration was applied with 110 Hz and 5.57 mm amplitude.
215004133|NCT03573765|PROCEDURE|Shoulder arthroplasty|Any form of joint replacement of the glenohumeral joint including prosthetic and excision.
215004134|NCT03573765|PROCEDURE|Elbow arthroplasty|Any form of joint replacement of the elbow joint including prosthetic and excision.
215004135|NCT03573765|PROCEDURE|Hand and wrist arthroplasty|Any form of joint replacement of joints of the hand and wrist including prosthetic and excision.
215004136|NCT03573765|PROCEDURE|Nerve decompression|Open or endoscopic release of peripheral nerve entrapment - subdivided by anatomical site of compression. Specific subgroups will include carpal tunnel and cubital tunnel release.
215004137|NCT03573765|PROCEDURE|Tendon repair|Open or arthroscopic repair or reconstruction of tendons of the shoulder, hand and upper limb in general.
215095731|NCT06454877|BEHAVIORAL|pasive heating|"In accordance with the normothermia care package, the reflective blanket will be covered to cover the whole body 30 minutes before surgery.~During the operation, the body will be covered with a reflective blanket in accordance with the surgical intervention.~Patients taken to the postoperative care unit will continue to be warmed with reflective blankets."
215095732|NCT06045910|DRUG|ALETA-001|ALETA-001 will be administered intravenously (IV) every two weeks.
214399608|NCT02883543|RADIATION|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
214399609|NCT01627236|DRUG|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
214399610|NCT03589482|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
215095733|NCT04528056|DRUG|Sulfasalazine|Sulfasalazine is an anti-inflammatory and immunosuppressive drug
214399611|NCT03589482|OTHER|ExPRESS-derived PEEP level|The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.
215095734|NCT04528056|DRUG|Ambrisentan|Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
215004138|NCT03573765|PROCEDURE|Joint stabilisation|Any procedure designed to increase stability of a joint, including soft tissue and bony blocking procedures.
215004139|NCT03573765|PROCEDURE|Excision/division/release of palmar fascia|Any procedure performed for treatment of Dupuytren's contracture.
215004140|NCT03573765|PROCEDURE|Surgical fixation of fractures|Any internal or external fixation of upper limb fractures - analysed by anatomical site.
215095735|NCT04528056|DRUG|Sulfasalazine's placebo|Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
215095736|NCT04528056|DRUG|Ambrisentan's placebo|Ambrisentan's placebo is similar to Ambrisentan in form and dosage
215095737|NCT06809517|DRUG|AK112|Intrathecal injection of PD-1/VEGF bispecific antibody was administered every two weeks for six weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
215095738|NCT06809517|DRUG|Pemetrexed (Alimta)|Pemetrexed was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
215095739|NCT04971252|DIAGNOSTIC_TEST|Hematologic tests for patients with diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among diabetic patients with chronic kidney disease
215095740|NCT07088107|DEVICE|fNIRS-triggered TMS|The firing of TMS will be triggered according to fNIRS signal intensity.
214399612|NCT06063317|BIOLOGICAL|CF33-CD19 IT Monotherapy|Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.
214399613|NCT06063317|BIOLOGICAL|CF33-CD19 IV Monotherapy|Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.
215004141|NCT03573765|PROCEDURE|Soft tissue release/debridement/excision|Any removal or release of soft tissue for treatment of stiffness, functional impairment or pain. Specific subgroups will include trigger finger release, subacromial surgery and surgery for frozen shoulder.
215004142|NCT03573765|PROCEDURE|Intra-articular injection|Any intra-articular injection
215004143|NCT03868566|DRUG|SNP-612 dose1|Subjects will take dose1 once a day orally for 12 weeks
215004144|NCT03868566|DRUG|SNP-612 dose2|Subjects will take dose2 once a day orally for 12 weeks
215095741|NCT07088367|BEHAVIORAL|Virtual reality meditation|"This intervention involves immersive virtual reality (VR)-based guided meditation sessions using MediboothVR, the first Turkish-language supported virtual reality meditation application developed in Türkiye. It is distinct from other VR interventions in the following ways:~Cultural and language adaptation: MediboothVR is fully available in Turkish, providing culturally relevant audio-guided content. This makes it more accessible and emotionally resonant for Turkish-speaking participants, unlike many VR applications designed in other languages.~Duration and consistency: The intervention is delivered over three consecutive days, with a different video used each day, each lasting approximately 10 minutes.~Technical delivery: The application is used exclusively via VR headsets, creating a fully immersive experience that eliminates visual and auditory distractions from the hospital environment."
214399614|NCT06063317|BIOLOGICAL|CF33-CD19 IT Combination|Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28 day cycle.
214399615|NCT06063317|BIOLOGICAL|CF33-CD19 IV Combination|Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28 day cycle.
214399616|NCT06063317|DRUG|Blinatumomab|Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.
214399617|NCT06063317|DRUG|Hydroxyurea|Hydroxyurea will be orally administered daily.
214399618|NCT04245033|DRUG|Dihydroartemisinin-Piperaquine (DP)|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment of malaria in school children (IPTsc).
214399619|NCT06094933|BEHAVIORAL|Mobile Anger Reduction Intervention (MARI)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will download the MARI app and be instructed to complete at least 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
214399620|NCT06094933|BEHAVIORAL|Health Education Condition (HED)|This is a mobile application that delivers videos with psychoeducation about healthy habits and selfcare for general wellness. Participants will download the HED app and be instructed to use it at least 5 times a week for a period of 4 weeks.
214399621|NCT05526235|BEHAVIORAL|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, has been adapted for use on a smartphone or other device with internet access. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
214399622|NCT05526235|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
214399623|NCT05526235|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a brief intervention consisting of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.
214399624|NCT05377086|OTHER|Schroth 3-Dimensional scoliosis exercise|Schroth 3-Dimensional scoliosis exercises
214399625|NCT05377086|OTHER|conventional scoliosis exercise|conventional scoliosis exercise
214522621|NCT02720978|DRUG|Intravenous oxytocin|"Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
215004145|NCT04508413|OTHER|KB295|KB295 is a novel glycan
215004146|NCT00701194|BEHAVIORAL|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
215004147|NCT01300520|DEVICE|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
214399626|NCT03175991|DIAGNOSTIC_TEST|ultrasonography|"A morphologic evaluation will be performed according to International Ovarian Tumor Analysis Group recommendations for the following parameters:~Bilaterality , wall thickness, septations , papillary projections, solid areas, and echogenicity. The presence of ascites also will be recorded. Pattern recognition analysis will be used for ovarian masses highly suggestive of some diseases , then color Doppler will be activated to identify vascular color signals within the lesion."
214399627|NCT00813111|DRUG|SKY0402|600mg SKY0402 instilled into breast pocket during surgery
214399628|NCT00813111|DRUG|Bupivacaine HCl|200mg Bupivacaine HCl instilled into breast pocket during surgery
214399629|NCT06013488|BEHAVIORAL|Character Strengths Based Coaching Support|Residential (five day) workshop and remote (weekly) telephonic support for 8 to 10 weeks
214399630|NCT06013488|BEHAVIORAL|Routine Supervision|Weekly face-to-face supervision by supervisor in groups of \~20 (1 supervisor for \~20 health workers)
214399631|NCT04776447|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02"
214399632|NCT04776447|DRUG|Placlitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
214399633|NCT04776447|DRUG|Atezolizumab|"Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions."
214399634|NCT04634357|DRUG|ET140203 T Cells|"Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct"
214399635|NCT03552978|BEHAVIORAL|Tech-Facilitated IC Intervention|The Integrated Care (IC) treatment protocol for smoking cessation is a PTSD-informed intervention that has been adapted to be delivered over video or telephone and to incorporate technological components, including the Stay Quit Coach (SQC) smart phone application (app) which is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation. and the coVita Bedfont® Scientific Ltd iCO® Smokerlyzer® device and app which is a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The coVita mobile app is compatible with iOS \&Android and used with the iCO® Smokerlyzer® to display CO readings. Content of sessions is consistent with that delivered in the IC treatment protocol for veteran smokers with post-traumatic stress disorder (PTSD).
214399636|NCT03552978|BEHAVIORAL|VA Quitline|The SFVAMC's standard of care referral service, known as the VA Quitline which involves weekly telephone sessions through the VA's proactive telephone Quitline, available to all veterans for up to 8 weeks.
214399637|NCT05601232|RADIATION|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
214399638|NCT05087095|BEHAVIORAL|CALM Intervention|"The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~* Within one week before initiating the CALM intervention therapy~* Within one week after its completion,~* 3 months after the CALM intervention is complete~  * After each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components"
214399639|NCT03998462|BEHAVIORAL|Mindfulness Based Stress Reduction|MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
215004148|NCT01289535|PROCEDURE|Blood sample|Blood sample of 7 ml
214399640|NCT03998462|BEHAVIORAL|Creative Education Care|Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
214399641|NCT03892785|DRUG|Prednisone treatment|tapering prednisone regimen
214399642|NCT03892785|DRUG|Tocilizumab treatment|Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)
214399643|NCT03892785|DRUG|Methotrexate treatment|"Methotrexate subcutaneous from W0 to W51 (52 administrations).~* W0: 7.5 mg/week~* W1: 0.2 mg/Kg/week~* W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51"
215004149|NCT02403037|DEVICE|True auricular acupressure|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
215004150|NCT02403037|DEVICE|Sham auricular acupressure|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
214399644|NCT03892785|OTHER|Questionnaires|HAQ, SF-36, FACIT-fatigue
214399645|NCT03892785|BIOLOGICAL|Blood samples|Additionnal blood samples for immunomonitoring
214399646|NCT06668285|BEHAVIORAL|parental presence|parental presence in PICU
215004151|NCT02403037|DRUG|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
215004152|NCT04796467|DRUG|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
215004153|NCT04796467|DRUG|68Ga-P16-093|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
215004154|NCT00909974|DIETARY_SUPPLEMENT|UNIMMAP - multiple micronutrients|"Daily supplementation of one UNIMMAP tablet~multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
215004155|NCT00909974|DIETARY_SUPPLEMENT|Food supplement enriched with multiple micronutrients|"One dose of 72g per day during whole pregnancy~Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
215004156|NCT03862885|DRUG|Avapritinib|Avapritinib will be administered orally (PO) at a dose of 300 mg once daily (QD) in continuous 28-day cycles.
215004157|NCT02407015|OTHER|Nintendo 3DS gameplay|
215029359|NCT02988908|DRUG|Donepezil|"Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
214399647|NCT01670500|DRUG|Cisplatin|administered intravenously every 3 weeks for 4 doses
214399648|NCT01670500|DRUG|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
214399649|NCT01670500|DRUG|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
214399650|NCT05940844|DRUG|OB-002|The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
214399651|NCT03588026|DRUG|rVA576|6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
214399652|NCT03588026|OTHER|Standard of care (SOC)|6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
214399653|NCT06368687|OTHER|Anorexia nervosa plus autism|In the inpatient care the treatment model takes into account the patient's perception disorders, meaning e.g. an adapted mealtime situation where the patient can eat separately or wear hearing protection if necessary. The patients have an adapted meal plan regarding difficulties with specific textures or foods. To meet their need for continuity, they have the same contact persons throughout the entire period of care. The healthcare staff receive training in working with the specific subgroup and have regular exchanges of experience regarding the patient group, 15 minutes every or every two weeks.
214503929|NCT06325280|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|Cardiopulmonary exercise testing will be performed using a cycle ergometer. Consistent with standard guidelines, workload will progressively increase (10W ramp protocol) such that peak oxygen consumption (VO2peak) is achieved within 8-12 minutes. VO2peak, VO2 at anaerobic threshold, peak power output (PPO), ventilation/carbon dioxide production (VE/VCO2) slope, peak heart rate (HR), and HR recovery at 1- and 3-minutes will be recorded. VO2peak will be converted to age-, weight, and sex-specific norms and a %predicted value.
215029360|NCT02988908|DRUG|Placebos|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
215029361|NCT02972645|DRUG|LY3305677|Administered SC
215029362|NCT02972645|DRUG|Placebo|Administered SC
214399654|NCT04702022|DIAGNOSTIC_TEST|18FDG PET / CT|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.
214399655|NCT06318663|OTHER|Survivor Mom Companion|Weekly intervention sessions will follow the survivor Moms' Companion manualized modules. One module each week. The module centers on reinforcement of information introduced in each previous module, then emotional support, and referrals to additional services or specialists as needed. Participants in each session will practice applying knowledge and skills using the module's vignettes. Process guides prompt inquiry about in vivo management of post-traumatic stress disorder reactions and emotional and interpersonal responses to events since the last session. Each module may require 45 minutes of self-study before each session and 45 minutes of in-session time spent with the interventionist.
214399656|NCT06443697|OTHER|No intervention|This is a secondary analysis and no intervention is implemented.
214399657|NCT06136312|DEVICE|Multi4|TURBT procedure performed with the Multi4 instrument in local anesthesia
214503930|NCT02872532|PROCEDURE|Testicular tissue cryopreservation|Testicular tissue will be removed
214503931|NCT03715946|DRUG|Nivolumab Injection|A fully human anti-programmed death 1 (PD-1) monoclonal antibody
214503932|NCT03715946|RADIATION|Radiotherapy (RT)|45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
215029363|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 21 mg administered SC
215029364|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 35 mg administered SC
215029365|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 70 mg administered SC
215029366|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 140 mg administered SC
215029367|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 15 mg administered SC
215029368|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 25 mg administered SC
215029369|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 50 mg administered SC
215029370|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 100 mg administered SC
215029371|NCT04189484|BIOLOGICAL|Placebo|Placebo administered SC
215029372|NCT03242434|OTHER|Lactulose and Mannitol solution|Participants will receive 100 milliliter (mL) oral solution of Lactulose \[5 grams (g)\]/ Mannitol (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
214399658|NCT06110117|DEVICE|Sterimar Stop & Protect Irritation & Dryness|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for seven days.
215004158|NCT03313193|OTHER|Acupressure for Children in Treatment for a Childhood Cancer|This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for \~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
214399659|NCT03175575|BEHAVIORAL|Access to a community garden in deprived neighborhoods|
214399660|NCT03473756|DRUG|Rogaratinib (BAY1163877)|Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.
214399661|NCT03473756|DRUG|Atezolizumab|Part A: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.
214399662|NCT04489693|BEHAVIORAL|Ambulatory Care Coordinator Team (ACCT)|See arm description
214399663|NCT04489693|BEHAVIORAL|Comprehensive Care Physician Program (CCP)|see arm description
214399664|NCT04489693|BEHAVIORAL|Comprehensive Care Community & Culture Program (C4P)|see arm description
214399665|NCT02120885|BEHAVIORAL|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
214399666|NCT03675243|DIAGNOSTIC_TEST|sphincterometry|Sphincterometry is a method of the spincter function examination, which allows to assess the state of the anal sphincter muscle and its function
214399667|NCT03514264|PROCEDURE|Gutta Percha and AHPLUS cement (group A)|"First intervention: endodontic instrumentation and introduction of intact medication that will remain inside the tooth for 4 weeks.~Second intervention: removal of intracanal medication and canal filling with cement AHPLUS and guttapercha"
214399668|NCT03514264|PROCEDURE|PBS CIMMO cement (group B)|Single intervention: endodontic instrumentation and obturation with cement PBS CIMMO
214399669|NCT02915718|PROCEDURE|protein A immunoadsorption|protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
215004159|NCT05103592|DIAGNOSTIC_TEST|Tartrate- resistant Acid Phosphatase marker|marker could be diagnostic for osteoporosis
214399670|NCT02148718|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
214399671|NCT00003509|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
214399672|NCT03964025|DEVICE|Wearing Cardioskin™ for 14 days|The current standard of care for diagnosing AF is through the use of a 24 hour Holter device. In this study, in addition to wearing the 3-lead Holter recorder for 24 hours, the subject will be wearing the Cardioskin™ for a period of 24 hours as well, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
214399673|NCT04129632|BEHAVIORAL|IEPF Wellness Tool|A daily 5 minute mindfulness exercise over 28 days
214399674|NCT05183009|DEVICE|eXciteOSA|eXciteOSA
214399675|NCT05398263|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
214399676|NCT05398263|OTHER|Placebo|Placebo subcutaneous injection
214399677|NCT06827496|DRUG|Oral antibiotic treatment|"Initial antibiotics:~Below 5 years: High-dose amoxicillin-clavulanate (8:1 ratio; 100/12.5 mg/kg/day in 3 doses) until clinical improvement and decrease in CRP, followed by dose reduction (4:1 ratio) to 50/12.5 mg/kg/day in 3 doses).~5 years and above: High-dose anti-staphylococcal penicillin (200 mg/kg/day in 4 doses) until clinical improvement and decrease in CRP, with dose reduction (100 mg/kg/day in 4 doses) after clinical improvement~Treatment duration of follow-up therapy (after initial high-dose antibiotics): One week for uncomplicated joint infections, three weeks for bone infections, and four weeks for spondylodiscitis"
214399678|NCT00389090|DRUG|Temozolomide and O6-Benzylguanine|O6BG + Temozolomide
214399679|NCT02175160|OTHER|Braking and functionality|
214399680|NCT00519987|DRUG|intranasal ketamine|intranasal ketamine
214399681|NCT04752540|DRUG|Olorofim|single oral dose
214399682|NCT01548859|DRUG|Midazolam|0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
214399683|NCT01548859|DRUG|Sevoflurane|end tidal concentration of % 0,5-8
214399684|NCT02711826|BIOLOGICAL|Polyclonal Regulatory T Cells|Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10\^6 polyTregs.
214399685|NCT02711826|DRUG|Everolimus|
214399686|NCT02711826|DRUG|Tacrolimus|
215029373|NCT03242434|OTHER|Sucralose|Participants will receive 3 capsules of Sucralose (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
215029374|NCT02714348|OTHER|Effect of helminth infection on vaccine immunogenicity|Observational; immunology
215029375|NCT04477616|DRUG|Day 7 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
215004160|NCT05099406|DEVICE|Transcranial electrical stimulation|"By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session."
215004161|NCT04273789|DEVICE|Far infrared reflecting sleepwear|100% microlyocell sleepwear (shorts + shirt) with a ceramic print that reflects far infrared light (FIR, 5.6-1000 µm) emitted by the human body. Since FIR active garments are not powered, but reflect recycle light energy emitted by the body of the wearer, they have irradiances between 0.1-5 mW/cm\^2.
215095742|NCT07088367|BEHAVIORAL|Virtual Reality Videos|"This intervention involves the use of a virtual reality headset to present immersive 360-degree calming nature videos to participants. It is distinct from other video- or relaxation-based interventions in several key ways:~Delivery via VR headset: Unlike standard video-based relaxation interventions presented on screens or tablets, this method delivers video content in a fully immersive virtual reality environment, which blocks out external visual and auditory stimuli from the unit.~Non-guided and passive exposure: The video group receives no audio-guided instruction or meditation scripting, making it a purely visual and passive exposure intervention.~Cultural relevance and visual neutrality: The nature videos are non-verbal, visually neutral, and free of religious, symbolic, or emotionally provocative imagery, allowing them to be suitable for a diverse patient population."
215095743|NCT07087808|BEHAVIORAL|Digital Wellness Nurse - FIT Families|Participants in this arm will receive a digital adaptation of FIT families, an evidenced based treatment for adolescent obesity. The social support condition will add one additional participant to the treatment group (i.e., caregiver, youth, community health worker, and social support person). The social support person's role is to review the daily engagement reports and completion of weekly goals and provide encouragement via peer-to-peer messaging in the DWN app. The social support person does not communicate with the CHW or participate in any treatment sessions. This person is selected by the family at the beginning of the study and provides reinforcement to the family through encouraging messages.
214399687|NCT02711826|DRUG|Mycophenolate mofetil|All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
214399688|NCT02711826|DRUG|Mycophenolic acid|All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
214399689|NCT02711826|DRUG|Acetaminophen|650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
214399690|NCT02711826|DRUG|Diphenhydramine|25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
214399691|NCT02711826|PROCEDURE|Biopsy, Kidney|
214399692|NCT02711826|PROCEDURE|Blood Draw|
214399693|NCT02711826|PROCEDURE|Leukapheresis|
214399694|NCT02711826|PROCEDURE|IS regimen conversion|Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
214399695|NCT02710994|DRUG|CDFR0209|Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
214399696|NCT02710994|DRUG|Losec|Losec 40 mg
214399697|NCT05942079|OTHER|REİKİ|Reiki is applied as an alternative and complementary treatment method.
214399698|NCT01433393|DRUG|TAK-875|
214399699|NCT01433393|DRUG|TAK-875|
214503933|NCT06520462|PROCEDURE|Pharmacopuncture|The physicians will decide the specific methods of pharmacopuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
214503934|NCT06520462|PROCEDURE|Acupuncture|The physicians will decide the specific methods of acupuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
215095744|NCT07089199|DRUG|neoadjuvant therapy|tislelizumab （200mg，iv, q3w） + Anlotinib （10mg, orally, D1-14, q3w）+nab-paclitaxel（260mg/m2，q3w）3-4cycle
215095745|NCT07089199|PROCEDURE|Surgery|Surgery should be performed 4 to 6 weeks after the last neoadjuvant therapy (at least 4 weeks after the end of anlotinib treatment).
215095746|NCT07089199|DRUG|Adjuvant therapy|Tislelizumab: 200mg, iv, Q3W, 1year at most(including preoperative treatment medication, a total of 17 cycles).
214503935|NCT03261466|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|
214503936|NCT03261466|DRUG|Placebos|
214399700|NCT01433393|DRUG|Placebo|
214399701|NCT01521325|DRUG|Amatuximab|Subjects will receive one infusion of radiolabeled amatuximab.
214399702|NCT04968028|PROCEDURE|ACAF|(1)A standard right-side Smith-Robinson approach is performed. (2) The involved disc tissues are removed. The posterior longitudinal ligament is cut down at the levels cephalic and caudal to OPLL. (3) The anterior portion of the middle vertebral bodies is removed according to the thickness of ossification. Suitable cages are placed into each intervertebral space. (4) On the left side of the vertebra, a 2-mm-wide groove is created at the medial border of the transverse foramina. After that, an curved plated is fixed with screws. (5) On the right side of the vertebrae, a similar groove was also created. (6) Finally, tightening the screws to achieve a gradual evaluation of the vertebrae with OPLL.
214399703|NCT04968028|PROCEDURE|Laminoplasty|(1) In the prone position, the skin and nuchal ligament were cut through the posterior median incision, and the paravertebral muscles were stripped layer by layer to expose the bilateral vertebral lamina, lateral mass and articular process.（2) Part of spinous process were removed with bone biting forceps. The side with more severe symptoms was selected as the open side, bone groove was performed at 2-3 mm of the medial edge of bilateral facet joints with the medial cortex was reserved at the shaft side.（3) Slowly lift the lamina and maintained.（4)Determining the opening width of each segment by trial, and selecting the appropriate size Arch miniplate, and fixed with screws.
214503937|NCT03605082|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
214503938|NCT03605082|OTHER|Placebo|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
215004162|NCT04273789|DEVICE|Placebo sleepwear|100% microlyocell sleepwear (shorts + shirt)
215004163|NCT00417729|DRUG|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
215095747|NCT07089472|BEHAVIORAL|Dry Needling Therapy|Dry needling will be applied along the lateral femoral cutaneous nerve (LFCN) pathway, targeting muscles such as piriformis, iliacus, tensor fascia latae, vastus lateralis, and sartorius. Sterile solid filiform needles (0.25x30mm and 0.30x50mm) will be inserted for 90 seconds to 2 minutes using a cone technique and retained in situ for 15 minutes. Sessions will occur twice weekly for 8 weeks, with standard physiotherapy (hot pack, EMS, and guided stretches) administered alongside.
215095748|NCT07089472|BEHAVIORAL|Cyriax Technique|"The Cyriax technique involves deep friction massage and mobilization of the lateral femoral cutaneous nerve (LFCN) near the anterior superior iliac spine (ASIS). Using the pinch and roll and deep pressure technique, therapists will apply sustained pressure along the nerve path in 3-5 repetitions per session, holding each for 10-15 seconds. Sessions will occur twice weekly for 8 weeks, alongside standard physiotherapy modalities and exercises."
215095749|NCT06087263|DRUG|Regorafenib|Given by PO
215095750|NCT07088094|PROCEDURE|bone-patellar tendon-bone or meniscus allograft transplantation techniques|This clinical study follows an interventional design, focusing on the evaluation of bone-patellar tendon-bone and quasi-anatomical meniscus allograft transplantation techniques。
215095751|NCT07088094|PROCEDURE|Quasi-anatomical meniscus allograft transplantation|Quasi-anatomical meniscus allograft transplantation
215095752|NCT05930145|DEVICE|Double stentriever|Double stentriever technique
215095753|NCT05930145|DEVICE|Single stentriever|Single stentriever technique
215095754|NCT04450628|PROCEDURE|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
215095755|NCT04450628|DEVICE|EndoFLIP 1.0 System EF-100|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
214693849|NCT01709136|DRUG|Sirolimus|Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
215004164|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.
215004165|NCT03384966|DRUG|Placebo|Matching placebo for subcutaneous administration.
215004166|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
215004167|NCT06330376|OTHER|Usual care of traditional treatment|Usual care of traditional treatment which is PT and/or OT when indicated Followed by Pulmonary rehabilitation when indicated
215004168|NCT06330376|OTHER|Specific DB program/Diaphragmatic manipulation program|12 weeks of 2 sessions/week: one session will be remote and one in-person
214399704|NCT01194882|DRUG|HUMAN INSULIN (BIOSYNTHETIC)|Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml
215004169|NCT03697356|DRUG|Lenalidomide, Bortezomib, Rituximab, Dexamethasone|"step 1; R-VRD induction : rituximab, bortezomib, lenalidomide, and dexamethasone induction~* Rituximab 375 mg/m2 intravenous on day 1~* Bortezomib 1.3mg/m2 subcutaneous on day 1, 8, 15~* Lenalidomide 15mg p.o on day 1-21~* Dexamethasone 20 mg/m2 intravenous or p.o on day 1-4~Step 2 ; Maintenance Beginning 8 weeks after completion of induction therapy, patients receive lenalidomide 10mg once day 1-21 for 4 weeks. Treatment repeats every 1 months for 24 months."
215004170|NCT02202616|DRUG|Glycopyrronium /Indacaterol maleate|Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
215004171|NCT00696566|DRUG|Clopidogrel and Rifampicin|"Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days"
215004172|NCT06407440|OTHER|control|There will be no interference ergonomics training
215004173|NCT06407440|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
215004174|NCT05925634|BEHAVIORAL|RPE (usual care)|Patients in the active comparator group will follow standard exercise prescription protocols in cardiac rehabilitation.
215004175|NCT05925634|BEHAVIORAL|GXT+THHR (intervention)|Patients in the personalized care group will perform a graded exercise test and the peak heart rate from the test will allow the researcher to calculate a target heart rate range (THRR). Then, the patients will receive psychoeducational feedback (PF) about their test results and exercise performance. After PF, their THRR will be reviewed and how it will be used to guide exercise intensity in CR will be discussed.
215004176|NCT01334515|BIOLOGICAL|hu14.18-IL2 fusion protein|Given IV
215004177|NCT01334515|DRUG|isotretinoin|Given PO
214399705|NCT01194882|DRUG|Insuplant|"Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:"
214399706|NCT06199947|OTHER|Biopsies and Blood collection|Each participant will have 2 additionnal biopsies during his/her diagnostic endoscopy plus two blood test during his/her inclusion
214399707|NCT04453059|DRUG|Iopamidol|Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)
214399708|NCT06392685|OTHER|Silane coupling agent|Silane coupling agent (Porcelain primer) will be applied following the acid etch rinsing and drying step, for 30 seconds and then it will be thoroughly dried using air syringe then universal adhesive with regular silane will be actively applied for 20 seconds and then it will be light cured for 20 seconds and final restoration will be done
214399709|NCT06392685|OTHER|Adhesive containing silane.(Intervention 1 )|Universal adhesive with regular silane will be applied for 20 seconds, air thinned for 10 seconds and then it will be light cured for 20 seconds and final restoration will be done using same resin composite material
214399710|NCT06392685|OTHER|Acid resistance silane containing adhesive.(Intervention 2)|Acid resistance silane containing adhesive will be applied for 20 seconds, dry with gentle air for 3 seconds, then with stronger air and light cured for 10 seconds and final restoration will be done
214399711|NCT04672356|BIOLOGICAL|IBI939|IBI939 injection
214399712|NCT04672356|BIOLOGICAL|Sintilimab|Sintilimab injection
214399713|NCT00008047|DRUG|fluorouracil|
214399714|NCT00008047|DRUG|hydroxyurea|
214399715|NCT00008047|DRUG|paclitaxel|
215004178|NCT01334515|BIOLOGICAL|sargramostim|Given SC
215004179|NCT01334515|OTHER|laboratory biomarker analysis|Correlative studies
215004180|NCT04649983|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
215004181|NCT02029547|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
215004182|NCT02158598|DRUG|Vitamin D chewable tablet supplementation|
215004183|NCT02158598|DRUG|Vitamin D pill supplementation|
215095756|NCT07088172|PROCEDURE|free gingival grafts during the second stage of implant surgery|Free gingival graft surgery performed simultaneously with implant stage II, followed by upper restoration 6-8 weeks later.
215095757|NCT07088172|PROCEDURE|free gingival grafts prior to the implantaion|Free gingival graft surgery performed 6-8 weeks before implant placement
215095758|NCT07089589|DRUG|Preoperative Statin Use|Administration of any statin medication prior to liver transplantation. Statin therapy was previously prescribed by the treating physician before the transplant procedure, not assigned by the study protocol.
215095759|NCT07089615|DEVICE|Capsule swallow|Participant will swallow the investigational device
214399716|NCT00008047|PROCEDURE|conventional surgery|
214399717|NCT00008047|RADIATION|radiation therapy|
214399718|NCT00043888|DRUG|fosamprenavir|
214399719|NCT00043888|DRUG|COMBIVIR|
214399720|NCT00043888|DRUG|ritonavir|
214399721|NCT00043888|DRUG|TRIZIVIR|
214399722|NCT00428064|DRUG|Sirolimus|
214399723|NCT00428064|DRUG|cyclosporine|
214399724|NCT03017144|OTHER|Pit crew model education|A pit crew model for resuscitation is educated to all resuscitation team members.
214399725|NCT01500746|PROCEDURE|Pulse lavage treatment|A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).
214399726|NCT01500746|OTHER|Dressing changes|Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
214399727|NCT04052230|OTHER|ultrasound measure|Admission to the intensive care unit, and setting up an ECMO Daily monitoring from D1 to D7, follow up at D60
214399728|NCT02431728|DIETARY_SUPPLEMENT|Melatonin|5 mg capsule p.o. at bedtime daily
214399729|NCT02431728|DIETARY_SUPPLEMENT|Matched Placebo|5 mg capsule p.o. at bedtime daily
215004184|NCT01248975|DRUG|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
215004185|NCT01248975|DRUG|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
215004186|NCT01248975|DRUG|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
215004187|NCT01248975|DRUG|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
215004188|NCT01248975|DRUG|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
215004189|NCT01248975|DRUG|Placebo capsule (PM)|Placebo capsule (PM)
215004190|NCT04517539|DRUG|rhGM-CSF，Peginterferon alfa-b2，radiation|"Radiation:~If there are two measurable lesions totally, One lesion received radiotherapy for 30 Gy in 5 fractions and rested for one week; If there are three measurable lesions totally, two lesion received radiotherapy for 30 Gy in 5 fractions separately.~drug: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy. Peginterferon alfa-b2 90 ug in d8 in each cycle.~And the 1 month after the end of all radiotherapy courses, 4 weeks as a course of treatment, once per course of treatment, each dose is 90μg until desease progress."
215004191|NCT03156140|OTHER|Motion|Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
215004192|NCT00363168|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
215004193|NCT00363168|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
215004194|NCT05303285|DRUG|Secukinumab 300mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks
215095760|NCT07088003|BEHAVIORAL|Yoga as Mindful Movement|YMM is an 8-week hybrid (in-person and virtual) school-based mindful yoga program (modified from its original 10-week, in-person design due to complications of COVID-19) informed by the teachings of Radiant Child Yoga. It was designed to teach students about self regulation through the integration of movement, breath, and present-moment awareness. It was delivered in the form of three, 30-minute YMM sessions each week by the same instructor-an individual with training and experience as an occupational therapist and yoga teacher through the Yoga Alliance and Radiant Child Yoga.
215095761|NCT07088003|BEHAVIORAL|Adapted Physical Education|Adapted PE took place daily (Monday-Friday) for one hour and consisted of lessons on movement skills such as catching, throwing, aiming, running, jumping, skating, and dancing through various activities and games.
214399730|NCT02451813|PROCEDURE|Apposition of needle bevel against femoral nerve|Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure during the controlled injection of 1 ml of dextrose (D5W) solution
214399731|NCT06161103|PROCEDURE|3D Printed Prefabricated Composite Resin Crown Group|3D Crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
214399732|NCT06161103|PROCEDURE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
214399733|NCT02908854|OTHER|Adding spices and herbs to school lunch vegetables|Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
214399734|NCT05800119|BEHAVIORAL|Brain-level condition|Participants will receive a brief reading passage about the neurobiological effects of psychotherapy.
214399735|NCT05800119|OTHER|Mind-level condition|Participants will receive an active control consisting of a brief reading passage about the effectiveness of psychotherapy.
214399736|NCT03832725|OTHER|High Protein (HP) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HP diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
214399737|NCT03832725|OTHER|High carbohydrate (HC) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HC diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
214399738|NCT02465333|PROCEDURE|Heel Fat Grafting|"Fat grafting is widely used by plastic surgeons and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested with a small liposuction cannula. The fat is then centrifuged, cleaned, and loaded into 1cc syringes and injected into the heel fat pad using specialized cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
214399739|NCT00168051|DRUG|ReFacto|
214399740|NCT00168051|DRUG|Advante|
214399741|NCT06016374|OTHER|telerehabilitation|"During this study, the patient will be asked to use the TeleRé programme at least 5 times a week for 30 minutes for one month. Through the programme, they will have access to exercises in video format and thus self-rehabilitation as well as serious therapeutic games. The self-education games and videos target the functional and motor recovery of the upper limb. In addition, cognitive functions (attention, memory, etc.) will also be stimulated via the programme. Therapeutic education modules and PROMS assessments will also be available."
214693850|NCT00651404|DRUG|Ezetimibe|oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
215004195|NCT05303285|DRUG|Secukinumab 150mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
215004196|NCT01365611|DRUG|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
214693851|NCT00651404|DRUG|Placebo|oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
214693852|NCT02572258|OTHER|Nutritional cookie|
214693853|NCT02929849|DIETARY_SUPPLEMENT|300 mg SC|Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
214693854|NCT02929849|DIETARY_SUPPLEMENT|500 mg SC|Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
214693855|NCT02929849|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given with breakfast (mixed meal tolerance test)
215004197|NCT01365611|DRUG|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
215004198|NCT03459586|OTHER|9zest app facilitated exercise|The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease
215004199|NCT06397638|PROCEDURE|Rescue carotid stenting|Rescue carotid stenting in tandem occlusions
214399742|NCT03358212|DRUG|Denosumab|Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment
215004200|NCT04632719|DEVICE|The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19|Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
215004201|NCT04256499|PROCEDURE|Acute water load test|The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.
215004202|NCT04416542|DIAGNOSTIC_TEST|Home Sleep Testing|"Two-night Home Sleep Tests (HSTs) will be conducted using commercially available Home Sleep Test equipment. The HST will be ordered by the clinical center through a HIPAA compliant HST service that has been selected by the study sponsor.~The HSTs will be scored and interpreted according to AASM Guidelines by board certified sleep physicians affiliated with the HST service. The HST will be scored using the 4% oxygen desaturation rule."
215121447|NCT03953833|BIOLOGICAL|Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.|"Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage.~Infusion time：90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle."
214399743|NCT02492061|BEHAVIORAL|Demand creation for couples' HCT|The demand creation for couples' HCT intervention aims at improving uptake of couples' HCT among married couples in Rakai, southwestern Uganda
214399744|NCT05760430|COMBINATION_PRODUCT|PVE+cTACE+Camrelizumab+Apatinib|After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
214399745|NCT05760430|COMBINATION_PRODUCT|cTACE+Atirizumab+Bevacizumab|After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
214399746|NCT01048203|DRUG|ABR-215050|1 mg ABR-215050
214503939|NCT03845699|DEVICE|Diagnostic algorithms that detects/predicts hypoventilation|Produce mild and moderate respiratory depression (hypoventilation) using a controlled intravenous infusion of fentanyl while measuring/recording respiratory rate, tidal volume, body activity, and body position.
214503940|NCT05819294|PROCEDURE|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
214503941|NCT04468191|DEVICE|Experimental expiratory muscle strength training (EMST)|The experimental EMST will involve blowing into a device with a spring-loaded valve set to 50% of the patient with ALS' maximum expiratory pressure.
214503942|NCT04468191|DEVICE|Sham expiratory muscle strength training (EMST)|The sham EMST will involve blowing into a device without a spring-loaded valve (0% resistance).
214503943|NCT00846222|PROCEDURE|Hypothermia|Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
214503944|NCT02640703|BIOLOGICAL|Infanrix + Prevenar 13|Different time of application
214503945|NCT01748864|DRUG|Etarfolatide (EC20)|
214503946|NCT05033327|BEHAVIORAL|Nutrition and Exercise app|Personalized, home-based, interactive therapy app
214399747|NCT03356873|DRUG|Vitamin D|Vitamin D supplementation
214399748|NCT03356873|OTHER|Placebo|Placebo
214399749|NCT05085743|DIAGNOSTIC_TEST|Deep convolutional neural networks analysis|using Deep convolutional neural networks to analyze pre-intubation chest radiographs along with patients' data to predict the proper depth of ETT fixation
214503947|NCT02304614|OTHER|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
214503948|NCT02304614|OTHER|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
214503949|NCT02304614|OTHER|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
214503950|NCT02304614|OTHER|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
215004203|NCT03039725|OTHER|Observational|Retrospective chart review on vaccine compliance
215004204|NCT02836769|BEHAVIORAL|Rehabilitation Consult (RC)|The RC was designed to foster key contributors to self management in the participants. The RC is administered by a rehabilitation professional and consists of an initial one-hour face-to-face consult and follow-up appointment(s) 2-12 weeks later, either telephone or face-to-face. The initial consult consists of orientation, consultation, goal-setting, teaching cognitive strategies, introduction to online resources/action planning/planning coping responses, review/implementation intentions/scheduling follow-up. The follow-up consists of a reminder, reorientation, checking of progress on goals and plans, re-planning as necessary, and discharge or scheduling of further follow-up as necessary.
215004205|NCT02285972|DRUG|saline|before the anesthesia induction, 2mL saline iv injection
214503951|NCT00686257|DEVICE|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
214503952|NCT00686257|DEVICE|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
214503953|NCT03066921|DIETARY_SUPPLEMENT|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
214503954|NCT03066921|DIETARY_SUPPLEMENT|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
215004206|NCT02285972|DRUG|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
214399750|NCT05278923|DEVICE|SALAD simulation device|An airway CPR manikin was modified to simulate regurgitation during CPR . A manual pump was fixed on the bottom of the torso to simulate the stomach. A clear vinyl tube was connected the manikin's oesophagus and the outflow port of the pump. A water container outside the manikin was filled with simulated gastric content and connected to the inflow port of the pump through another vinyl tube. The manikin's left main bronchus was occluded using a red cap provided by the manufacturer. The lung was simulated by an anaesthesia breathing bag placed outside the manikin and connected to the manikin's right main bronchus via a breathing circuit. A compression pad was attached to the bottom of the manikin's compression plate. During chest compression, the compression pad squeezed the pump to regurgitate gastric contents into the oropharynx
214399751|NCT03524274|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
214399752|NCT03524274|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
214399753|NCT02169219|DRUG|Glucocorticoids|"Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~* 60mg for 2 weeks~* 40mg for 2 weeks~* 30mg for 1 week~* 20mg for 1 week~* 10mg for 1 week~* 5mg for 1 week"
214399754|NCT02169219|DRUG|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
214503955|NCT05732727|DRUG|Antihypertensive algorithm|Antihypertensive algorithm based on diuretics agents
214503956|NCT05732727|DRUG|Standard of care|standard of care management for antihypertensive therapy intensification
214503957|NCT01579799|DRUG|L-lysine|Dose finding study for L-lysine
214503958|NCT04320914|OTHER|High Intensity LASER Therapy|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J Duration of the treatment will be 8 minutes in one session/knee joint for each day for 3 days/week for 8 weeks."
215004207|NCT02285972|DRUG|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
215004208|NCT00514527|DRUG|oritavancin|Oritavancin as a single, infrequent or daily dose.
215004209|NCT02580071|DIETARY_SUPPLEMENT|Sheng-Yu-Tang|"Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)"
215004210|NCT01119222|DRUG|Gabapentin|Capsule, single 1200mg dose
215004211|NCT01119222|DRUG|Diphenhydramine|Tablet, single 50mg dose
215004212|NCT01119222|DRUG|Morphine|IV, single 10mg dose
215004213|NCT01119222|DRUG|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
215004214|NCT04288791|OTHER|Equia Forte Fil|Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.
214399755|NCT05733806|OTHER|chemotherapy, surgery|this is an observational prospective study, therefore no intervention is planned. Patients perform medical and surgical treatment as per standard of case.
215004215|NCT04288791|OTHER|Zirconomer Improved|Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
215004216|NCT04626336|PROCEDURE|Cystectomy|Cystectomy
215004217|NCT04452006|DRUG|ACT-541478 10 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
215004218|NCT04452006|DRUG|ACT-541478 30 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
214503959|NCT04320914|OTHER|Ibuprofen gel phonophoresis|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. Each treatment session will last for 8 min with one session each day for 3 days/week for 8 weeks.
214503960|NCT02634307|DRUG|ALKS 8700|Administered as specified in the treatment arm.
214503961|NCT02698475|DRUG|Ustekinumab 0.75 mg/kg|Participants weighing less than (\<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
214503962|NCT02698475|DRUG|Ustekinumab 45 mg|Participants weighing greater than or equal to (\>=) 60 kg to less than or equal to (\<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
215004219|NCT04452006|DRUG|ACT-541478 100 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 50 mg.
215004220|NCT04452006|DRUG|ACT-541478 300 mg|ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 50 mg and 250 mg.
214503963|NCT02698475|DRUG|Ustekinumab 90 mg|Participants weighing \>100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
215004221|NCT04452006|DRUG|ACT-541478 1000 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 250 mg.
215004222|NCT04452006|DRUG|ACT-541478 high or low dose (or placebo)|Cross-over design: ACT-541478 will be provided in HPMC capsules for oral administration at high or low dose strengths (to be defined after completion of Part A).
215004223|NCT04452006|DRUG|ACT-541478 dose E1|E1 is a dose level that has been investigated and well tolerated in the adult dose level groups C1 to C3. ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 10, 50, and 250 mg.
215004224|NCT04452006|DRUG|Matching placebo|Matching placebo will be provided in HPMC capsules for oral administration.
215004225|NCT02861976|OTHER|Opioid risk screen development & implementation|Development of a screening tool for the risk of opioid misuse in patients with traumatic injury.
215004226|NCT05658991|DIAGNOSTIC_TEST|Retinal electrophysiology|Retinal electrophysiology to assess retinal function before and with fasting during ramadan in both groups.
215004227|NCT00585650|BIOLOGICAL|Etanercept|Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.
215004228|NCT00585650|OTHER|Placebo injections|Placebo injections twice weekly for 12 weeks.
215004229|NCT05967559|OTHER|Online Flipped Learning Group|The experimental group is the group that receives online flipped learning training.
214399756|NCT00255567|DRUG|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
214399757|NCT00255567|DRUG|Paromomycin sulphate|Paromomycin sulphate
214399758|NCT00255567|DRUG|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
214399759|NCT03881540|OTHER|tDNA-MI group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements and motivational interviewing counseling. .
214399760|NCT03881540|OTHER|tDNA-CC group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements+ 150 min/week of moderate intensity exercise + and conventional counselling.
214399761|NCT03881540|OTHER|UC group|Meal plan of 1200-1500 kcal/day using conventional foods + 150 min/week of moderate intensity exercise + and conventional counselling
214399762|NCT02688920|PROCEDURE|EUS and OCT imaging|Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
214399763|NCT03524313|DIAGNOSTIC_TEST|End tidal carbon monoxide|"* Evaluation of cardiac output estimated by transthoracic echocardiography and end tidal carbon monoxide~* Evaluation of cardiac output estimated by transthoracic echocardiography and portal veinous velocity~* Evaluation of femoral veinous velocity"
214399764|NCT04019561|DRUG|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
214399765|NCT04019561|DRUG|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
214399766|NCT04019561|DRUG|MEDI0382 low dose|MEDI0382 low dose administered subcutaneously
214399767|NCT04019561|DRUG|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
214399768|NCT00518505|OTHER|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
214399769|NCT01034761|BEHAVIORAL|Pop-up alert|Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
214399770|NCT04842279|OTHER|FACE-Q scale|"FACE-Q is a recently developed and validated patient reported outcome measure (PROM) tool that allows clinicians to assess patient perspectives after skin cancer surgery of the face.The PROM is used to assess the perspective and impact of skin cancer as well as its treatment on the patient's quality of life (QoL). Patients with skin cancer may have increased anxiety, social isolation, and cosmetic concerns after surgery. The FACE-Q utilizes five scales to measure the psychometric, QoL, patient experience, and cosmetic outcomes. Raw scores are transformed to a 0-100 scale with a higher score indicating a better outcome.~Any studies using FACE-Q for facial surgery reconstruction at our center may be eligible for inclusion in the database"
214399771|NCT02044419|DRUG|lomitapide|
214399772|NCT04946448|OTHER|FIT diet|Dietary intervention as add-on therapy to biologicals
214399773|NCT02886936|DEVICE|iFIT Transtibial Prosthesis|Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
214399774|NCT02886936|DEVICE|iFIT Transfemoral Prosthesis|Transfemoral amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
214399775|NCT06396962|OTHER|WANG DAORONG|surgery
214399776|NCT01933347|DRUG|Gefitinib|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
214399777|NCT03713645|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant|Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients
214399778|NCT00510796|BEHAVIORAL|Interview|Interview regarding perception of pain and the benefits and barriers to the combined screening.
214399779|NCT03826433|BIOLOGICAL|Peripheral iv|6\*10\^7 cells
214503964|NCT03263611|DRUG|Placebo|single intradiscal injection
214503965|NCT03263611|DRUG|AMG0103|single intradiscal injection
214522622|NCT02720978|DRUG|vaginal prostaglandin|"Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
215004230|NCT05967559|OTHER|Traditional learning Group|The control group is the group that received traditional learning training.
214522623|NCT03508830|DRUG|Liposomal bupivacaine|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
215004231|NCT01573377|DRUG|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
215004232|NCT01573377|DRUG|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
215004233|NCT01197898|BIOLOGICAL|Collagenase Santyl Ointment|Topical daily application
215004234|NCT01197898|OTHER|Placebo Comparator|Topical daily application
215004235|NCT03786575|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) detection|The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
215004236|NCT06007443|OTHER|pain related variables assessment|Pressure pain threshold, conditioned pain modulation, temporal summation, and two-point discrimination will be evaluated on the upper trapezius muscle. Average pain intensity will be asked.
214399780|NCT02514564|BEHAVIORAL|Exercise|Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
214399781|NCT05557383|BEHAVIORAL|use peanut ball|The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
214399782|NCT03439371|OTHER|HLA-mismatched micro-transplantation after induction chemotherapy|HLA-mismatched micro-transplantation after induction chemotherapy
215004237|NCT01354535|PROCEDURE|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
215004238|NCT01354535|PROCEDURE|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
215004239|NCT04558242|DEVICE|Genix|Low Level Light (LEDs)
214399783|NCT02721199|OTHER|Neural Respiratory Drive Automated EMGpara assessment|Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
214399784|NCT00110682|DRUG|Imiquimod used as an adjunct to cryotherapy|
214399785|NCT05824221|DEVICE|rTMS|Non invasive brain stimulation in Cocaine Use Disorder
214399786|NCT05004064|DRUG|Acalabrutinib|Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.
214399787|NCT05004064|DRUG|Rituximab|Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
214399788|NCT05893563|OTHER|Standard Post-Operative Clinic Visit|In clinic, the joint will be assessed (ROM, stability testing), standard X-rays will be taken of the joint, and patient reported outcomes (questionnaires) will be completed by patient (WOMAC, UCLA, VR12, EQ5D, Oxford Hip).
214399789|NCT05893563|OTHER|Study-Specific Outcomes|Patients will complete additional questionnaires (SF12 and HHS), will undergo RSA and CT imaging for implant stability analysis, and will provide a stool sample for gut microbiome analysis.
214503966|NCT03876184|OTHER|Aesthetic archwires|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
214522624|NCT03508830|DRUG|Bupivacaine Injection|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
215004240|NCT04558242|DEVICE|Sham|Incandescent Bulbs Colored Red
215004241|NCT05540275|DRUG|Tislelizumab plus Bevacizumab|200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks
215004242|NCT02372084|DRUG|osilodrostat|
215004243|NCT00653757|DRUG|goserelin acetate|
215095762|NCT05546671|DIAGNOSTIC_TEST|Hand grip strength measurement|"Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI \>28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI \>29: hand grip strength ≤21 kg"
215004244|NCT00653757|DRUG|leuprolide acetate|
215004245|NCT00653757|RADIATION|image-guided radiation therapy|
215004246|NCT00653757|RADIATION|intensity-modulated radiation therapy|
215004247|NCT00983970|BEHAVIORAL|Interactive video game cycling|"Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session."
215004248|NCT00983970|BEHAVIORAL|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
215004249|NCT06217146|DRUG|Medical Cannabis|MediCane's medical cannabis oil
214399790|NCT04131907|DEVICE|Optilume BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
214399791|NCT04131907|DEVICE|Optilume Sham Device|21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)
215004250|NCT06217146|DRUG|Placebo Oil|Placebo Oil
215004251|NCT04311580|COMBINATION_PRODUCT|intravesical electromotive administration of mitomycin|
215004252|NCT05903443|DIAGNOSTIC_TEST|ancillary tests|electroencephalogram, short latency somatosensory evoked potential, transcranial Doppler
215004253|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 3 Secs|3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
215004254|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 2 Secs|3 attempts of 28 inhalations, 2 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
214399792|NCT06219486|DIAGNOSTIC_TEST|D-dimer|The investigators will measure a D-dimer test on participants and randomize on informing the physician on the value.
214399793|NCT04533776|BEHAVIORAL|Celiac Disease Definition, Symptoms and Treatment|"* Adolescents share their knowledge about the disease~* Emphasizing the definition and symptoms of celiac disease~* Discussion of the treatment of celıac disease Expression Question-Answer Discussion Summarizing"
214399794|NCT04533776|BEHAVIORAL|Difficulties Due to Celiac Disease|"* Determining what experience living with celiac is fot the patient (What do I think about the disease, how do I feel about the disease,how do I perceive the disease, how does the disease affect me)~* Determining the difficulties encountered in Daily life due to illness (How do I deal with difficulties)~* Determining how the disease affects life Expression Question-Answer Discussion Summarizing"
215095763|NCT07088809|PROCEDURE|Nanocrystalline hydroxyapatite loaded in PRF+ coronally advanced flap|"Two horizontal incisions were made at right angles to the adjacent interdental papillae at the CEJ level without interfering with the gingival margin of the neighbouring teeth. To mobilize the flap, two oblique vertical releasing incisions were extended beyond the mucogingival junction. A full thick¬ness trapezoidal flap was then elevated up to the mucogingival junction, and follow¬ing penetration of the periosteum, a par¬tial thickness flap was dissected further apically. The papillae mesial and distal to the recession defects were deepithelialized.~Following conditioning, the root surface was rinsed with sterile saline for 1 minute. Following conditioning, the root surface the PRF membrane loaded by nanocrystale hydroxyapatite was positioned to cover the recession up to CEJ. The flap was then coronally advanced to cover the membrane, and flap was closed using simple interrupted sutures. A periodontal dressing was placed over the recipient site for 10 days to protect the wounds."
215121448|NCT03166241|DIAGNOSTIC_TEST|serum interleukin 21|it is cytokine used as a marker to detect it's level in patients with adverse drug reactions
215121449|NCT03166241|DIAGNOSTIC_TEST|Complete Blood Picture|It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study
215004255|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 4 Secs|3 attempts of 14 inhalations, 4 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
215004256|NCT03144635|DRUG|Grazoprevir plus Elbasvir|An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
215004257|NCT05074537|DIAGNOSTIC_TEST|MRI exam|Participants who are receiving standard of care or investigational MRI exams at the Wright Center will be eligible for enrollment in this data bank.
215121450|NCT03166241|DIAGNOSTIC_TEST|Liver function test|It is a blood sample will taken from patients to detect any associated liver disease at the start of the study
214399795|NCT04533776|BEHAVIORAL|Gluten Free Diet in Celiac Disease|"* Evaluating dietary information~* Identifying the difficulties in diet therapy Expression Question-Answer Discussion Summarizing Case Study Presentation (Transfer of life experience of an individual who is 22 years old with celiac disease)"
214399796|NCT04533776|BEHAVIORAL|Difficulties Related to Disease in School and Social Life|"* Assessment of difficulties encountered in school and social life~* Evaluation of the solution suggestions fort he difficulties encountered Expression Question-Answer Discussion Summarizing Örnek Olay Sunumu (Transfer of life of experience of a 23 years old dietician with celiac disease)"
214399797|NCT04533776|BEHAVIORAL|Celiac Disease and Its Effects on Acamdemic Success Peer Relations|"* Evaluation of the effects of the disease on academic success~* Evaluation of the effects of the disease on peer relationships in the school enviroment~* Difficulties experienced in peer relations and evaluation of relationships (exclusion) Expression Question-Answer Discussion Summarizing"
215004258|NCT05074537|DIAGNOSTIC_TEST|PET/CT imaging exam|Participants who are receiving standard of care or investigational PET/CT exams at the Wright Center will be eligible for enrollment in this data bank.
215004259|NCT05074537|DIAGNOSTIC_TEST|CT imaging exam|Participants who are receiving standard of care or investigational CT exams at the Wright Center will be eligible for enrollment in this data bank.
215004260|NCT01759914|DRUG|Potent topical steroid|
215004261|NCT01759914|DRUG|Superpotent topical steroid|
215004262|NCT00766818|DRUG|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
215004263|NCT02989389|DRUG|LY3323795|Administered orally
215004264|NCT02989389|DRUG|Itraconazole|Administered orally
215004265|NCT02989389|DRUG|Placebo|Administered orally
214503967|NCT03876184|OTHER|Control group|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
215004266|NCT04857177|DRUG|CKD-701|CKD-701 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
214399798|NCT04533776|BEHAVIORAL|Celiac Diseae anf Future Goals|"* General summary of all sessions so far~* Summarizing the topics discussed in the previous session~* Evaluating the future goals of the participants Expression Question-Answer Discussion Summarizing"
215004267|NCT04857177|DRUG|Lucentis®|Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
214399799|NCT04533776|OTHER|No Intervention: routine health care- control group|Peer interactive group support was not provided to the control group. After all the sessions of the peer interactive group support of the study were completed, a separate training meeting was held for the control group.
214399800|NCT01297530|DRUG|BAY87-2243|Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
214399801|NCT01874327|BEHAVIORAL|Baby JASPER|Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
215004268|NCT01837342|PROCEDURE|Surgical reserction|
215004269|NCT01837342|OTHER|Radiological percutaneous drainage and washing drainage|
215004270|NCT00374868|DRUG|pemetrexed|"Phase 1: 300 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m\^2, 400 mg/m\^2, and 500 mg/m\^2)~Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
215004271|NCT00374868|DRUG|cisplatin|"Phase 1: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles~Phase 2: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
215004272|NCT04470427|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
214399802|NCT01874327|BEHAVIORAL|Standard Baby Classroom|Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
214399803|NCT03655522|DRUG|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.
215004273|NCT04470427|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
215004274|NCT03815305|DRUG|Centella Asiatica Extract|centlla asiatica oral drug at 1100 mg dose
215004275|NCT03815305|DRUG|Topical CA|1% centella asiatica ointment
215004276|NCT03815305|DRUG|Petroleum jelly|vaseline album
214399804|NCT03655522|DRUG|Placebo|There were two Placebos per group.
215004277|NCT01179516|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
215004278|NCT01179516|DRUG|Placebo|Vortioxetine placebo-matching capsules
214399805|NCT01730014|DRUG|148-0287-A-4.2mM-cartridge|In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
214399806|NCT01730014|DRUG|placebo|In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
214399807|NCT01730014|DRUG|148-0287-A-4.2mM-cartridge|In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
214399808|NCT01730014|DRUG|placebo|In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
214503968|NCT06360276|BEHAVIORAL|Seated Exercises|A quasi-experimental research was conducted in the main University Hospital, Alexandria, Egypt. women practiced seated exercises
214503969|NCT06360276|BEHAVIORAL|Psychoeducational Rehabilitation|Women received Psycho-educational Rehabilitation, including mindfulness breathing, problem-solving training, cognitive re-framing technique, and thought stopping.
215004279|NCT00164723|PROCEDURE|Capsule endoscopy|Capsule endoscopy and colonoscopy
215004280|NCT03869021|OTHER|3D printed surgical guide constructed|A printed surgical guide ( to direct through the surgery and make results predictable), the guide is designed by Mimics 19.0, Materialise NV,Belgium and printed with self cure resin
215004281|NCT03869021|OTHER|free hand surgery|A control group in which patients are randomly assigned and surgeries are planned without surgical guides and performed free handed
215004282|NCT02661477|DRUG|pegylated interferon alfa 2|
215121451|NCT03166241|DIAGNOSTIC_TEST|Random Blood Sugar|measure blood sugar in patients included in the study at the start of the study
215004283|NCT02661477|OTHER|Placebo|0,9% natrium chlorine solution
215004284|NCT03682640|DRUG|Azithromycin Monohydrate|Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
215004285|NCT03682640|DRUG|Insulin Lispro|Solution for intravenous or subcutaneous use
215121452|NCT03166241|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate|blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study
215004286|NCT03682640|BEHAVIORAL|Dietician support|Dietary advice
215004287|NCT02525978|BEHAVIORAL|Video Task|Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.
215004288|NCT02525978|OTHER|Imaginal Task|Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
215004289|NCT04285411|DEVICE|Accuracy of the VitalDetect™ pulse oximetry system|The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
215095764|NCT07088809|PROCEDURE|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF+ coronally advanced flap|"Two horizontal incisions were made at right angles to the adjacent interdental papillae at the CEJ level without interfering with the gingival margin of the neighbouring teeth. To mobilize the flap, two oblique vertical releasing incisions were extended beyond the mucogingival junction. A full thick¬ness trapezoidal flap was then elevated up to the mucogingival junction, and follow¬ing penetration of the periosteum, a par¬tial thickness flap was dissected further apically. The papillae mesial and distal to the recession defects were deepithelialized.~Following conditioning, the root surface was rinsed with sterile saline for 1 minute. Following conditioning, the root surface the PRF membrane loaded by Nanocrystalline tricalcium was positioned to cover the recession up to CEJ. The flap was then coronally advanced to cover the membrane, and flap was closed using simple interrupted sutures. A periodontal dressing was placed over the recipient site for 10 days to protect the wounds."
215095765|NCT02907749|DRUG|Spironolactone and carvedilol|Patients are treated with carvedilol in combination with spironolactone.
214399809|NCT01730014|DRUG|insulin glargine|In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
214399810|NCT01730014|DRUG|sodium chloride 0.9% w/v|In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
214399811|NCT06332950|DRUG|Adebrelimab, Irinotecan Liposome (II)|"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Escalating doses to determine recommended phase 2 dose (RP2D) of Irinotecan Liposome (II).~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II)."
214399812|NCT06332950|DRUG|Adebrelimab, Irinotecan Liposome (II), Famitinib|"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD~Escalating doses to determine recommended phase 2 dose (RP2D) of Famitinib.~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II) and Famitinib."
214399813|NCT00354367|DRUG|Certolizumab pegol|
214399814|NCT04756011|OTHER|Health related quality of life|Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL
214399815|NCT01670227|BEHAVIORAL|PARENTCORPS|ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.
214399816|NCT02023216|DEVICE|Pacifier|The effect of NNS on GER features will be evaluated in preterm infants suffering from GER symptoms, for which a 24-hour pH-MII monitoring has been scheduled. During the monitoring period each infant will receive 8 meals: 4 meals will be followed by NNS, applied by pacifier, while the other 4 not. The sequence of NNS application will be consecutively alternated in study participants. At least 2 hours of NNS are required for the validity of each post-prandial evaluation; measures to fix the pacifier will be strictly forbidden. In the subgroup of babies with recurrent desaturations a simultaneous non-invasive 6-hour PSG monitoring comprehensive of 2 meals (one followed by NNS, the other not), will be performed to evaluate the effect of NNS on apneas, bradycardias and hypoxic episodes.
214399817|NCT01082146|DRUG|Lurasidone|40 mg suspension, PO, for 7 days
214399818|NCT02718534|BEHAVIORAL|stroke rehabilitation|Physical rehabilitation exercise between 24 and 48 hours and after 48 hours
214399819|NCT00871793|OTHER|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
214399820|NCT02980796|BEHAVIORAL|Exercise|Each experimental day participants will complete an acute bout of exercise on a recumbent bike.
214399821|NCT02980796|BEHAVIORAL|Practice|Each experimental day participants will complete a session of skilled motor practice.
214399822|NCT03975387|DRUG|ASTX295|ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
214399823|NCT04248465|DRUG|Placebo|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
214399824|NCT04248465|BIOLOGICAL|Ravulizumab|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
215004290|NCT01766284|DEVICE|NIRIS 1300e|Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
214399825|NCT05708846|OTHER|Telemonitoring|"All patients will be telemonitored in order to create a labeled and diverse dataset that will include the following data:~Physiological parameters (measured periodically), socio-demographic data, risk factors, medication tracking, symptomatology questionnaire for patients, NYHA-class, clinical interventions, health questionnaire answers, classified alarms with their respective timestamp and annotation by the MD, and measurement ranges for each personalized alarm and their changes"
214399826|NCT03276663|OTHER|Formula feeding regimen|The feeding regimen consists of an existing commercial starter formula followed by a new follow-up formula
214399827|NCT01831414|OTHER|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
214399828|NCT01831414|OTHER|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
214399829|NCT04178200|DRUG|Lidocaine 2% Injectable Solution 0.75 ml|0.75 ml of Lidocaine will be added to the anesthetic solution.
214399830|NCT04178200|DRUG|Bupivacaine Hcl 0.5% Inj 0.75 ml|0.75 ml of Bupivacaine will be added to the anesthetic solution.
214399831|NCT04178200|DRUG|Lidocaine 2% Injectable Solution 1.5 ml|1.5 ml of Lidocaine will be added to the anesthetic solution.
214399832|NCT04178200|DRUG|Bupivacaine Hcl 0.5% Inj 1.5 ml|1.5 ml of Bupivacaine will be added to the anesthetic solution.
214399833|NCT04912141|DRUG|conestat alfa or placebo|"Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line."
214399834|NCT02166151|DRUG|Omalizimab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
214503970|NCT06360276|BEHAVIORAL|Routine Care|Women received routine health education in the unit, where nurses provided general instructions about the postoperative activities for women with breast cancer.
214503971|NCT02315014|OTHER|whey protein|whey protein.
214503972|NCT02315014|OTHER|placebo|placebo.
214503973|NCT03528915|OTHER|Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
214503974|NCT03528915|OTHER|whithout Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
214503975|NCT03528213|DRUG|Sodium Lactate light dose|bolus 2.5ml/kg then 0.25ml/kg/h
215004291|NCT04490707|DRUG|Azacitidine|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine
215004292|NCT04490707|DRUG|Lenalidomide|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
215004293|NCT04041518|PROCEDURE|Autotransplantation|Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
215004294|NCT00694746|DRUG|Omega-3-acid ethyl esters|Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
215004295|NCT00694746|DRUG|Placebo|Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
215095766|NCT02907749|DRUG|Carvedilol|Patients are treated with carvedilol only.
214503976|NCT03528213|DRUG|Sodium Lactate high dose|bolus 2.5ml/kg then 0.5ml/kg/h
214503977|NCT03528213|DRUG|Normal saline|normal saline at physician discretion
214503978|NCT02042703|DEVICE|anterior segment OCT|
214503979|NCT01158248|BIOLOGICAL|panitumumab|
214503980|NCT01158248|DRUG|cisplatin|
214503981|NCT01158248|RADIATION|brachytherapy|
214503982|NCT01158248|RADIATION|external beam radiation therapy|
214503983|NCT04580004|OTHER|Med Optimization Arm|An evidence-based medication recommendation website that is provided to the patients.
214503984|NCT05440240|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
214503985|NCT05440240|DRUG|Corticosteroid injection|Depo-Medrol
214503986|NCT05440240|OTHER|Saline injection|Isotonic saline
214503987|NCT02132949|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m\^2 IV on Day 1 of each cycle q3w.
214503988|NCT02132949|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.
215095767|NCT00336635|BIOLOGICAL|cell-culture derived smallpox vaccine|
215121453|NCT03166241|DIAGNOSTIC_TEST|Kidney function tests|blood sample will be taken from patients to detect any kidney disease before the start of the study
214399835|NCT02641951|OTHER|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
214399836|NCT02641951|OTHER|Pecs II block|Ultrasound guided Pecs II block
214503989|NCT02132949|DRUG|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m\^2 IV for the first cycle and the dose may be escalated to 100 mg/m\^2 for subsequent cycles q3w.
214503990|NCT02132949|DRUG|Doxorubicin|Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.
214503991|NCT02132949|DRUG|Epirubicin|Participants will receive epirubicin 100 mg/m\^2 IV on Day 1 of each cycle q3w.
214503992|NCT02132949|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV given weekly.
214503993|NCT02132949|DRUG|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
214503994|NCT02132949|DRUG|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
214503995|NCT00549666|DRUG|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
214503996|NCT00549666|DRUG|Placebo 40 mg|Placebo 40 mg once daily during treatment period
214503997|NCT00549666|DRUG|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
214503998|NCT05033522|BIOLOGICAL|AlloStim® immunotherapy|3 cycles of intradermal and intravenous administrations
215004296|NCT03349515|DRUG|Provodine-Iodine Solution|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes.
215004297|NCT03349515|DRUG|Group B will receive three drops in each eye of ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes
215004298|NCT01855906|PROCEDURE|Gap balanced surgical technique|Gap balanced surgical technique
215004299|NCT01855906|PROCEDURE|Measured resection|Measured resection surgical technique
215004300|NCT02842021|DRUG|S2G6T-1|Twice a day topical cream
215004301|NCT02842021|DRUG|S2G6T-2|Twice a day topical cream
215095768|NCT05027984|DEVICE|Optical coherence tomography|OCT images will be acquired by means of the FD C7 XR system or the OPTIS system (both St. Jude Medical, St. Paul, MN, USA) with a non-occlusive technique.(33) The acquired OCT coronary images will be analyzed on-line using a proprietary OCT console (St Jude Medical, Inc., USA). Definitions and cut-offs for OCT vulnerability parameters derived from available consensus documents and from main IVUS/OCT studies.
214399837|NCT01049061|DRUG|MORAb-003|MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
214503999|NCT05033522|DRUG|FOLFOX regimen|Comparative arm: Physician Choice of FOLFOX4 chemotherapy
214504000|NCT05033522|DRUG|Sorafenib|Comparative arm: Physician Choice of Sorafenib
215004302|NCT02842021|DRUG|S2G6T-3|Twice a day topical cream
215004303|NCT02842021|DRUG|S2G6T-4|Twice a day topical cream
215004304|NCT00745160|OTHER|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
215004305|NCT00872157|DRUG|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
215004306|NCT04512872|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
215004307|NCT04512872|BIOLOGICAL|EU-approved Prolia|60 mg/mL single dose, Solution for injection in PFS
215004308|NCT06165874|RADIATION|[68Ga]Ga-NOTA-RW102 PET Imaging|Intravenous injection of 1.8 MBq\[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RW102 in a single dose.
215004309|NCT01526382|DEVICE|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
215004310|NCT01526382|PROCEDURE|central venous catheter|patients in this arm can receive central venous catheter
215095769|NCT05027984|DEVICE|iFR/FFR/RFR|The iFR and FFR measurements will be obtained using a coronary-pressure guidewire (Pressure Wire / Certus or Aeris for FFR assessment and PressureWire™ X Guidewire/QUANTIEM™ for the RFR assessment by Abbott Vascular, Abbott Park, Illinois, U.S.A; Comet by Boston Scientific, Marlborough, MA, USA), OptoWire by Opsens, Quebec, Canada, or Verrata by Philips, San Diego, CA, USA.).
215095770|NCT02182271|DRUG|BI 201335 ZW - single rising dose|
214399838|NCT05217823|DEVICE|Er:YAG laser|
214504001|NCT05033522|DRUG|Lenvatinib|Comparative Arm: Physician's Choice of Levantinib
214399839|NCT05217823|OTHER|hand instruments|
214399840|NCT06487767|OTHER|Surgery|Surgery for operable cervical cancer
214504002|NCT01823224|DRUG|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
214399841|NCT03877263|DIAGNOSTIC_TEST|Endocervical swab for detection of STI|After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.
215004311|NCT02763995|BEHAVIORAL|Pharmaceutical care|This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
215004312|NCT00474565|PROCEDURE|Placement of an aortic root pigtail catheter.|Seldinger technique for placement of catheter.
215004313|NCT03718260|DIAGNOSTIC_TEST|[18F]-DCFPyL PET/ CT scan (PSMA PET)|Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).
215004314|NCT00318864|BEHAVIORAL|Cognitive behavioral therapy|
215004315|NCT04627584|COMBINATION_PRODUCT|MW33 injection|a recombinant fully human antibody to coronavirus
215004316|NCT04627584|COMBINATION_PRODUCT|MW33 injection placebo|Placebo
214399842|NCT03877263|DIAGNOSTIC_TEST|Vaginal swab for detection of STI|"After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.~We will then compare the results from a vaginal vs. endocervical specimens within and between the groups"
214399843|NCT04772690|OTHER|A resource-oriented intervention|The intervention is delivered by an interdisciplinary team of occupational therapist, physiotherapist, nurse, psychologist, physician and social worker. It consists of a five-day residential stay at REHPA and a two-day follow-up stay after seven weeks at home. The residential stays include both workshops and engagement in physical and creative activities.
214399844|NCT00442286|DEVICE|Rheos® Baroreflex Hypertension System|Electrical activation of the Carotid Baroreflex
214399845|NCT06077669|DRUG|Methylphenidate|Single oral dose of methylphenidate (5mg or 10 mg)
214399846|NCT06077669|DRUG|Placebo|oral placebo
214399847|NCT03331627|DRUG|STR001-IT and STR001-ER|STR001-IT intrataympanic injection and STR001-ER tablet
214399848|NCT03428815|DEVICE|Prosthesis suspension liner|Liners out of phase change material will be fitted
214399849|NCT03532893|OTHER|No intervention|This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.
215004317|NCT04259489|BEHAVIORAL|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
215004318|NCT03408145|DEVICE|Hyaluronic Acid|Injection of 3x 2.5ml of Hyaluronic Acid
215004319|NCT03408145|DEVICE|Amniotic Tissue Allograft|Injection of 1x 1ml of Amniotic Tissue Allograft
215004320|NCT03408145|DRUG|Saline|Injection of Saline
214399850|NCT01700348|DEVICE|Airflosser|Use of Philips Airflosser
215004321|NCT03412890|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
214399851|NCT01700348|DEVICE|Manual Floss|Active Comparator
215004322|NCT03412890|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1 mg) and NETA (0.5 mg) administered orally once daily
215004323|NCT05320588|DRUG|BIO-106|BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
215004324|NCT05320588|DRUG|Pembrolizumab|Programmed death receptor-1 (PD 1)-blocking antibody
215004325|NCT02342951|OTHER|Lung clearance index determination|Lung clearance index determination
215004326|NCT05389839|DEVICE|Wechat program|The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
215004327|NCT00515593|DRUG|Parathyroid hormone (PTH) (Preotact)|Patients with severe postmenopausal osteoporosis
214399852|NCT03691285|PROCEDURE|Mandibular Overdenture|Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
214399853|NCT02378818|BEHAVIORAL|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
214399854|NCT02357680|OTHER|Diary|"The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU."
214399855|NCT06210763|BEHAVIORAL|Threshold IMT and traditional physical therapy program|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). this Group will receive 3-set IMT (two sessions daily via threshold IMT, the set contain 10 repetitions) 5 times weekly. The study duration will be 1 month.
215004328|NCT05582603|BEHAVIORAL|CCT Long COVID|A 15-day training protocol in which every 48 hours participants' complete a series of different cognitive tasks in the form of games selected among a pool of 12 games from CogniFit (CogniFit Inc., San Francisco, USA) whose difficulty level is tailored to each individual by the a patented Individualized Training System™ (ITS) software that automatically chooses the activities and difficulty levels for each person in every session.
215004329|NCT01642160|BEHAVIORAL|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
215004330|NCT01642160|BEHAVIORAL|Standard of care|participants will receive education from staff nurses as needed.
215004331|NCT02941952|DEVICE|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
215004332|NCT05756478|OTHER|Medication review|This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria)
215004333|NCT04450875|DIETARY_SUPPLEMENT|Experimental group (with diet)|Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.
215095771|NCT02182271|DRUG|Placebo|
215004334|NCT02450474|DEVICE|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
215004335|NCT02450474|DEVICE|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
215004336|NCT06464159|BIOLOGICAL|Biological collection|A collection of maternal plasma, serum and urine
215004337|NCT05271487|OTHER|Multi-Step Botanical Skin Care Regimen|"The intervention includes 7 different topical products:~1. Cleanser~2. Toner~3. Oil Control Cream~4. Exfoliating Facial Scrub~5. Clay Mask~6. Acne Spot Treatment~7. Body Scrub"
215004338|NCT01522053|PROCEDURE|Catheter-over-needle|Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
215004339|NCT01522053|PROCEDURE|Catheter-through-needle|Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
215004340|NCT05055596|BEHAVIORAL|Tai Chi|Qigong/Tai Chi Easy is a manualized intervention with formal training for instructors through the Institute of Integral Qigong and Tai Chi (IIQTC). The protocol can be modified based on participant needs and physical abilities. Qigong/Tai Chi Easy uses a series of repeated and simple-to-learn movements (rather than long forms with complicated choreography).
215004341|NCT05055596|BEHAVIORAL|Health Coaching|The Health Education group will be adapted from a previously developed time and attention control condition used in HIV research. Additional health education material will be based on information learned in the qualitative interviews conducted prior to the start of this study. Examples of session material include the following: sleep hygiene, healthy diet, sun safety, and healthy homes.
215095772|NCT06187168|PROCEDURE|exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.|This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
215095773|NCT01011972|DRUG|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
215095774|NCT04221191|DRUG|Dimethyl Fumarate|DMF as prescribed as standard of care.
215095775|NCT04221191|OTHER|PSP|PSPs is to support patient care.
215095776|NCT04262713|OTHER|Radiographs|Radiographs of the implanted hip with Meije duo size1 or 2 are performed in eligible patients ( Weigh\>60, Long neck stem, Varus; DEVANE score ≥ 4)
214399856|NCT06210763|BEHAVIORAL|traditional physiotherapy program|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly).
214399857|NCT01778062|DRUG|Indacaterol|Indacaterol 150µg once daily oral inhalation
214399858|NCT01778062|DRUG|Control|Placebo once daily oral inhalation
214399859|NCT05471258|OTHER|Experimental: monopolar dielectric diathermy|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar muscles by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. 3 weekly sessions will be performed for 3 weeks, a total of 9 treatment sessions.
214399860|NCT05471258|OTHER|Control: Placebo|"The 30 participants in the control group will receive a placebo treatment, consisting of the same execution protocol as the EG, but with a non-emitting device whose software and hardware will be exactly the same as that used in the EG. The intervention will be simulated for 20 minutes.~3 weekly sessions will be held for 3 weeks, a total of 9 treatment sessions."
214504003|NCT01823224|DRUG|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
215004342|NCT05460247|DIETARY_SUPPLEMENT|Protein|Participants will receive a diet supplemented by the above protein
215004343|NCT00397241|DRUG|Drug: dorzolamide/timolol|
215004344|NCT00397241|DRUG|Drug: latanoprost/timolol|
215095777|NCT04334213|DRUG|CKD-501|QD, PO
214399861|NCT06159296|DEVICE|Hydroxy gas|Hydroxy gas is a combination of hydrogen and oxygen together.
214504004|NCT00156507|BEHAVIORAL|Asthma education for parents of very low birth weight infants|Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
214504005|NCT01898585|DRUG|Zelboraf|Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
215004345|NCT00397241|DRUG|dorzolamide/timolol and latanoprost|
215004346|NCT00397241|DRUG|placebo (artificial tears)|
215004347|NCT02092935|DRUG|SMT19969|
215095778|NCT04334213|DRUG|D745, D150|QD, PO
215095779|NCT04334213|DRUG|CKD-501, D745, D150|QD, PO
215095780|NCT00964847|BEHAVIORAL|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
215095781|NCT00964847|BEHAVIORAL|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
215004348|NCT02092935|DRUG|Vancomycin|
215004349|NCT02315625|DRUG|Sunitinib|37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
215004350|NCT02315625|DRUG|Everolimus|10 mg daily will continue until progression or unacceptable treatment-related toxicity
215095782|NCT03883334|DRUG|Metisoprinol|Immunodulator
215095783|NCT00467675|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
215004351|NCT02960906|DRUG|Nivolumab|"For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
215004352|NCT02960906|DRUG|Ipilimumab|"For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol."
215004353|NCT02960906|DRUG|Pazopanib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
215004354|NCT02960906|DRUG|Sunitinib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
214399862|NCT01632358|DRUG|TAP311 capsules|
214399863|NCT01632358|DRUG|Placebo|
214399864|NCT05667259|OTHER|Surgical resection for cancer rectum|Curative resection for cancer recum
214399865|NCT01824472|DEVICE|CPAP|Treatment for sleep apnea
214399866|NCT01824472|BEHAVIORAL|CBT|Treatment for insomnia
214399867|NCT01824472|DEVICE|sham CPAP|Placebo for sleep apnea
214399868|NCT01824472|BEHAVIORAL|CC|Placebo (sham) for insomnia
214399869|NCT03758924|DRUG|ANAVEX2-73|Liquid oral solution
214399870|NCT03758924|DRUG|Placebo|Liquid oral solution
214399871|NCT01736358|DRUG|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
215004355|NCT01415674|DRUG|Afatinib|Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
215004356|NCT03778372|DRUG|Methadone|see desc above
215004357|NCT00021255|DRUG|Doxorubicin|
215004358|NCT00021255|DRUG|Cyclophosphamide|
215004359|NCT00021255|DRUG|Docetaxel|
215004360|NCT00021255|DRUG|Herceptin|
214399872|NCT01736358|DRUG|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
215004361|NCT00021255|DRUG|Carboplatin|
214399873|NCT00799071|DRUG|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
214399874|NCT06328920|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
214399875|NCT06328920|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
214399876|NCT04323644|PROCEDURE|Surgery|Emergency or elective surgery
214399877|NCT04421937|BEHAVIORAL|Procedure: Traditional Dysphagia Therapy (TDT)|"Traditional dysphagia therapy includes diet modification training, teaching postural compensatory methods, training of oral motor control exercises and tongue root exercises, training of swallowing maneuvers, and practice of chin-resistance exercise, which is the exercise of opening the upper esophageal sphincter.~Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks."
214399878|NCT04421937|DEVICE|Procedure: Neuromuscular Electrical Stimulation with TDT|The skin to be treated will be cleaned and dried. NMES will be implemented with signals received from two channels. In the first channel, the upper electrodes will be placed horizontally just above the hyoid bone. This is the place where the cupping is felt when the finger is pressed right under the chin. In the second channel, the lower electrodes will be placed horizontally, just above the thyrohyoid muscle. This is the place where you can feel a cupping when pressed with your finger, on both sides of the apple in the larynx. The device will be set to start at the lowest power, with very short pulses of approximately 700 microseconds, at intervals of 1 second. The power will be gradually increased according to the device and the power that the patient feels vibration will be stopped. The power to be applied will not exceed 25 milliamps. NMES application and Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks.
214399879|NCT03418896|DRUG|human chorionic gonadotropin|a single injection of a standard dose
214399880|NCT01815736|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
214399881|NCT01815736|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
214399882|NCT01815736|DRUG|EFV/FTC/TDF|600/200/300 mg FDC tablet administered orally once daily
214399883|NCT01815736|DRUG|RTV|100 mg tablet administered orally once daily
214399884|NCT01815736|DRUG|ATV|300 mg capsule administered orally once daily
214399885|NCT01815736|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
215004362|NCT04223037|BIOLOGICAL|Japanese Encephalitis Vaccine produced by IMBCAMS|Dosage form: 0.5mL/vial
215004363|NCT04223037|BIOLOGICAL|Japanese Encephalitis Vaccine produced by Liaoning Chenda|Dosage form: 0.5mL/vial
215004364|NCT01163656|DEVICE|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
215004365|NCT01163656|DEVICE|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
215004366|NCT00420264|DEVICE|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
215004367|NCT01182961|OTHER|gait training|subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
215095784|NCT03675516|OTHER|No specific intervention|Usual care
214399886|NCT01815736|DRUG|COBI|150 mg tablet administered orally once daily
214504006|NCT04909333|DRUG|Exenatide|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously."
215004368|NCT01182961|OTHER|gait training 2|subjects will walk on a treadmill under a progressive intensive gait protocol
215004369|NCT01182961|OTHER|exercise group|standard of care exercise group to improve strength and balance
215004370|NCT01801254|OTHER|STRIDES|Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
215004371|NCT01801254|OTHER|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
215004372|NCT04490655|BEHAVIORAL|Active somatosensory training|Patients in the experimental group will be required to move the robotic handle using their paretic arm from the start position to a visual target shown on screen. However, patients' paretic arm will be occluded from vision throughout the training session. They will make the reaching movement by depending on their proprioception of the arm position in space, without relying too much on the vision of their arm. Haptic guidance will be provided as somatosensory cues while participants are actively moving. Positive reinforcement will also be given for each successful movement that reaches the target in the form of a pleasant audio tone, visual feedback, and a running score. Assessment will be performed before and after the completion of the whole 15 training sessions.
215004373|NCT04490655|BEHAVIORAL|Motor-based training|Patients in the control group will also be required to propel the robotic handle using their paretic arm to a target location. This training covers the same centre-out reaching movements but without any emphasis on proprioception, where the view of the paretic arm will not be occluded. However, no haptic guidance will be provided during the reaching movement. Positive reinforcement will still be given to inform the participants of their trial outcomes. Assessment will be performed before and after the completion of the whole 15 training sessions.
215004374|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
215004375|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
215004376|NCT06055179|DRUG|Xiao Chai Hu Tang (XCHT)|XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
215004377|NCT06055179|DRUG|Placebo|Placebo 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
215004378|NCT06055179|DRUG|Irinotecan regimen|"Patients will receive 3 cycles of irinotecan chemotherapy. FOLFIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Folinic acid (400 mg/m2) IV over 2 hours on Day 1. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours. Every 2 weeks.~mXELIRI regimen:irinotecan (200 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (800 mg/m²) PO bid on day 1-14. Every 3 weeks.~CapIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (1000 mg/m²) PO bid on day 1-14. Every 3 weeks.~FOLFOXIRI regimen:irinotecan (165 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Oxaliplatin (85 mg/m2) intravenous (IV) for over 2 hours on Day 1.Folinic acid (400 mg/m2) IV over 2 hours on Day 1, followed by 5-FU (2400 - 3200 mg/m2) IV continuously for 48 hours. Every 2 weeks."
215004379|NCT06055179|OTHER|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing, on Day 3 (the day before chemotherapy), for 3 cycles of chemotherapy.
215004380|NCT02705157|PROCEDURE|Stabilisation of (impending) pathological fracture|Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
215004381|NCT02705157|RADIATION|Radiotherapy of bone metastasis|Radiotherapy of bone metastasis, single or multi-fractionated
214399887|NCT05389969|OTHER|digital arch scanning|"Scanning of the maxillary and mandibular dental arch will be performed for the same group of patients twice. The first time is before bracket positioning using two different scanners and the three different techniques. The second time is after brackets positioning using the same two different scanners and the same three different scanning techniques.~Then these scans will be compared to by superimposition techniques and linear measurement techniques."
214399888|NCT03656393|DRUG|Gefitinib|Gefitinib (250 mg, orally, every day) for 56 days
214399889|NCT03656393|DRUG|Vinorelbine|Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
214399890|NCT03656393|DRUG|Carboplatin|Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
214399891|NCT05299879|DIAGNOSTIC_TEST|Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization|Screening for advanced HF with modified criteria from the Heart Failure Association of the European Society of Cardiology
214399892|NCT06398028|DRUG|Indocyanine green|Indocyanine green has a sharply defined spectral peak absorption of near-infrared light at 800 nm in blood plasma or blood. This is the same wavelength at which the optical density of oxygenated hemoglobin in blood approximately equals that of reduced hemoglobin. Therefore, this coincidental light absorption makes it possible to measure indocyanine green concentrations in blood, plasma and serum in terms of its optical density at 800 nm, independent of variations in oxygen saturation level
214504007|NCT04909333|DRUG|0.9% saline solution|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously."
215004382|NCT04225650|OTHER|Pulmonology consultation|In case of functional respiratory signs, a consultation with a pulmonologist will be booked. At the end of this consultation, if the doctor deems it necessary, other investigations will be proposed and/or regular follow-up will be organised.
215004383|NCT05278091|OTHER|None, pure observationnal study|None, pure observationnal study
215004384|NCT00048659|DRUG|YM598|
215004385|NCT04124796|OTHER|Semi-structured interviews|Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
215004386|NCT00728923|DRUG|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
215004387|NCT00731003|DRUG|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
214399893|NCT06529601|DEVICE|CAD/CAM mandibular fixed retainer|Keeppy is a Class IIa custom-made medical device manufactured by Digital Service Leone s.r.l. - via Pratese 160/b, Florence, Italy. The Keeppy is an individualized fixed retainer, made of a Nickel-free Chrome Cobalt alloy, produced with a CAD-CAM procedure starting from a digital impression made with an intraoral optical scanner (3 Shape), which allows a perfect adaptation to the lingual surfaces of the 6 lower anterior teeth on which it is bonded. The device is characterized by the presence of applicators that can be placed temporarily on the buccal surface of the canines, which facilitate the clinician in the precise application of the device and which are removed as soon as the bonding phase of the retainer is complete. Bonding is performed using classic composite resins following a preparation phase of the lingual surface of the tooth consisting of the application of etchant (37% orthophosphoric acid) for 30 seconds and adhesive (primer-bonding).
214399894|NCT06529601|DEVICE|Conventional mandibular fixed retainer|The standard control device, which is among the most commonly used in routine clinical practice, consists of a steel braided wire. The device selected for the Class IIa investigation is the Ortho Flex Tech manufactured by Reliance Orthodontic Products, Inc. 1540 West Thorndale Ave. Itasca, IL 60143 USA. The Ortho Flex Tech steel braided wire is manually shaped by the clinician and cut with a wire cutter so that it has the proper length to extend over the 6 dental elements. Once the correct length has been defined, it is then held in place on the lingual surface of the teeth by the use of 2 interdental wires passing doubly through the interdental area (between the lateral incisor and canine on one side and the other). This allows the device to be bonded using composite resin after etching the lingual surfaces of the lower anterior teeth.
214399895|NCT02413684|BEHAVIORAL|Patient engagement toolkit|"Pack Health LLC and Duke will develop a patient engagement toolkit known as Packs to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care"
214399896|NCT03387514|DRUG|PSMA-based 18F-DCFPyL PET tracer for PET/CT exams|"18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~* PET2A - Post-surgery and prior to start of standard of care systemic therapy~* PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~* PET3A - Prior to start of additional anti-angiogenesis therapy~* PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy"
214399897|NCT01159535|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
215004388|NCT00731003|OTHER|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
215004389|NCT00731003|OTHER|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
214399898|NCT01159535|BEHAVIORAL|Relapse Prevention|intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
214399899|NCT01159535|BEHAVIORAL|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
214399900|NCT00118144|DRUG|bortezomib|Given IV
214399901|NCT05028010|BEHAVIORAL|Capacity building|Four days of training on the promotion of maternal and child nutrition will be given. The training will be based on Pender's health promotion model. Supportive supervision will be conducted.
214399902|NCT04701593|DRUG|Triamcinolone Acetonide 40mg/mL|Sub-tenon irrigation 1cc
215004390|NCT00731003|DRUG|Placebo capsule|Placebo for 5-HTP
215004391|NCT02641834|OTHER|Vegetarian diet|7-days dietary profile with an isocaloric Vegetarian diet for 3 months
215004392|NCT02641834|OTHER|Mediterranean diet|7-days dietary profile with an isocaloric Mediterranean diet for 3 months
215004393|NCT05232721|DIAGNOSTIC_TEST|The new instrument and colonoscopy with pathological examination|Detect hemoglobin in stool by the point-of-care testing instrument before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
215004394|NCT03556306|PROCEDURE|Bariatric surgery|"The gastric bypass (simplified technique) was performed in an antecolic fashion, with a calibrated 2 cm gastro-jejunal anastomosis (linear stapler); biliary and alimentary limbs measured 70 and 150 cm respectively \[17\] . Mesenteric defects were closed and the omentum divided. The sleeve gastrectomy was performed at 5-6 cm from the pylorus over a 36 Fr. bougie, with oversuture of the staple line (2-0 polypropylene). Methylene blue test and the use of drains were done routinely."
215004395|NCT06410183|OTHER|no intervention|no intervention
215004396|NCT01949896|OTHER|NPO|Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
215004397|NCT01949896|OTHER|Control group: continue feedings|Feedings will be continued in this group.
215004398|NCT03447795|PROCEDURE|Alveolar ridge preservation|grafting procedure using autogenous tooth.
215004399|NCT04324840|DRUG|CC-90010|Specified dose on specified days
215004400|NCT04324840|DRUG|Temozolomide|Specified dose on specified days
215095785|NCT05148416|RADIATION|High intensity laser treatment|20 patients received high power laser therapy . Zimmer High power laser applied by laser probe perpendicular to and in slight contact with the skin around knee joint , the total energy was delivered to the patient during one session was 1060 j in 3 phases of treatment.
214399903|NCT00075803|DRUG|Fluconazole|Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients \> 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients \< 12 years, intravenous doses will be prepared.
214399904|NCT00075803|DRUG|Voriconazole|Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients \> 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients \> 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age \< 12 years.
215004401|NCT04324840|RADIATION|Radiotherapy|Specified dose on specified days
215004402|NCT04547751|OTHER|targeted high-resolution mass spectrometry|"difference between the number of new substances identified using targeted analysis by liquid chromatography coupled with high-resolution mass spectrometry versus using targeted analysis. narcotics-new substance by liquid chromatography coupled with tandem mass spectrometry"
215004403|NCT03094728|DIAGNOSTIC_TEST|HLA cross matching|"HLA Typing and Mismatch~Cross matching (total and autocross):~Cross match involves placing recipient serum onto donor lymphocytes and a cytotoxic reaction (deemed 'positive') suggests the presence of preformed donor specific antibodies (DSAs),Second, the original crossmatch should be repeated with the addition of the agent Dithiothreitol (DTT). DTT reduces the disulfide bonds in IgM thereby preventing IgM antibodies from generating a positive result."
215004404|NCT02691338|OTHER|EEG|EEG analysis
215095786|NCT05148416|DEVICE|sham HILT.|"20 patients received placebo laser  sham laser . The same treatment protocol of HILT was given to the sham group, but the laser instrument was switched off during applications. All laser applications were performed by the same physiotherapist."
215095787|NCT05148416|OTHER|knee osteoarthritis conventional exercises program|"knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
215095788|NCT00004751|PROCEDURE|Surgery|
214399905|NCT03496025|DEVICE|Electrical muscle stimulation|The intervention consists of activating paralyzed facial muscles with electrical stimulation.
215004405|NCT02691338|OTHER|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
215004406|NCT02991521|PROCEDURE|Fast exam|Positional change before Fast exam
215095789|NCT00004751|PROCEDURE|Physical therapy|
215095790|NCT01301105|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
215095791|NCT01301105|BEHAVIORAL|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
215095792|NCT03743064|DRUG|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
215095793|NCT03743064|DRUG|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
215004407|NCT01474187|DRUG|Irinotecan|initial from 50mg/m2/week and increased by 15mg/m2/week
215004408|NCT01474187|DRUG|Capecitabine|625mg/m2,bid,d1-5,qw
214399906|NCT00650494|DRUG|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
214399907|NCT00650494|DRUG|Valtrex® 1000 mg|1000mg, single dose fed
214399908|NCT02218021|DRUG|Samidorphan|
214399909|NCT02218021|DRUG|Placebo|
214399910|NCT02218021|DRUG|Oxycodone|
214399911|NCT01910558|DIETARY_SUPPLEMENT|Alpha-cyclodextrin and digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch
214399912|NCT01910558|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin
214399913|NCT01910558|DIETARY_SUPPLEMENT|Digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
214399914|NCT01443975|PROCEDURE|x-pander|Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
214399915|NCT03740074|BEHAVIORAL|PAI|"Consenting subjects will be given a Mio Slice, along with instructions on how to utilize the device.~They will register on line with PAI Health, and will be asked to sync their device at least once every 7 days. They will be encouraged to look at the device app on their smart phone at least once daily.~After 1 week of obtaining baseline data, subjects will be encouraged to try to obtain a PAI score of at least 30 initially. Once they obtain a score of 30 consistently, they will be encouraged to increase the score toward 50. If they consistently obtain 50, they can increase their goal sequentially toward a maximum goal of 100. The duration of the study will be 12 weeks."
214399916|NCT04261361|BEHAVIORAL|CBCBT intervention|8 group CBT sessions and 4 weekly follow-up calls
215004409|NCT01474187|RADIATION|Radiotherapy|50Gy for whole pelvis
215004410|NCT05112133|DIETARY_SUPPLEMENT|Mulberry leaf extract|Oral administration
215095794|NCT02326766|DIETARY_SUPPLEMENT|KRG|5g Korea red ginseng (KRG)
215095795|NCT02326766|DIETARY_SUPPLEMENT|Placebo|5g placebo
214399917|NCT04261361|BEHAVIORAL|Adherence counseling|All participants in both CBCBT and ETAU groups will have one session of Life-Steps, a stand-alone CBCBT intervention designed to improve adherence to medical recommendations and individualized DM self-management goals.
214399918|NCT04261361|BEHAVIORAL|Psycho-education package|Printed materials of a DM self-management education program will be delivered to both the CBCBT and ETAU groups.
214399919|NCT01625039|BEHAVIORAL|Employee wellness programme|The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.
214399920|NCT01625039|BEHAVIORAL|Comparator (Once off educational session and educational materials)|Once off educational session and educational materials
214399921|NCT03044496|DRUG|Supraclavicular nerve block|Supraclavicular nerve block using ultrasound and 10ml ropivacaine 0.5% with 20ml mepivacaine 1%
214399922|NCT01287793|DRUG|tigecycline|intravenous, 200 mg, single dose
214399923|NCT01287793|DRUG|tigecycline|intravenous, 50 mg, single dose
214399924|NCT01287793|DRUG|moxifloxacin|oral tablet, 400 mg, single dose
214399925|NCT01287793|DRUG|100 mL 0.9% Sodium Chloride intravenous|intravenous fluid, 100 mL, single dose
214399926|NCT01287793|DRUG|placebo|0.9% Sodium Chloride intravenous 100mL, single dose
214399927|NCT02868580|DRUG|Triumeq|Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
214399928|NCT02661854|BIOLOGICAL|MM09 Mannosylated 5.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
214399929|NCT02661854|BIOLOGICAL|MM09 Mannosylated 10.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
214399930|NCT02661854|BIOLOGICAL|MM09 Mannosylated 30.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
214399931|NCT02661854|BIOLOGICAL|MM09 Mannosylated 50.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
214399932|NCT02661854|BIOLOGICAL|MM09 Mannosylated 5.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
214399933|NCT02661854|BIOLOGICAL|MM09 Mannosylated 10.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
215004411|NCT05112133|DIETARY_SUPPLEMENT|Water|Oral administration
215004412|NCT01060371|GENETIC|All Participants|If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
215004413|NCT05927415|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
215004414|NCT03038139|OTHER|Cervical exercises|Cervical correction program consist of 3 strengthening and 2 stretching exercises for neck and scapula Lumbosacral correction program consist of strengthening and stretching exercises for lumbar and sacral regions
215004415|NCT03038139|OTHER|Lumosacral exercises|Cervical and Lumbosacral correction program Lumbosacral program consist of 2 strengthening and 4 stretching exercises
215004416|NCT01836822|PROCEDURE|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
215004417|NCT01836822|PROCEDURE|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
215004418|NCT01836822|PROCEDURE|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
215004419|NCT01836822|PROCEDURE|Bronchoalveolar lavage (BAL)|
215004420|NCT01836822|PROCEDURE|Endobronchial forceps biopsy|
215095796|NCT02073851|DEVICE|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
215095797|NCT03696901|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
215095798|NCT00036101|DRUG|aripiprazole|
215095799|NCT00248716|DRUG|Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
214399934|NCT02661854|BIOLOGICAL|MM09 Mannosylated 30.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
215004421|NCT02338830|DRUG|Progesterone|Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
215004422|NCT02949934|DRUG|Tolcapone|
215004423|NCT02949934|DRUG|Placebo|
215004424|NCT05331924|PROCEDURE|IPL therapy|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
215004425|NCT05331924|PROCEDURE|Punctal plugs|Silicone punctal plugs are small pieces of silicone designed to block tear drainage through occluding the lacrimal punctum.
215004426|NCT02546141|OTHER|skimmed milk (UHT)|
215004427|NCT02546141|OTHER|skimmed milk (pasteurized)|
215004428|NCT02546141|OTHER|skimmed yoghurt|
215095800|NCT01498016|DRUG|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
215095801|NCT03580824|BIOLOGICAL|R21 in Matrix- M adjuvant vaccine|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
215095802|NCT05504551|PROCEDURE|ultrasound guided superficial cervical plexus block|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
214399935|NCT02661854|BIOLOGICAL|MM09 Mannosylated 50.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
214399936|NCT02661854|BIOLOGICAL|Subcutaneous placebo|Comparison between placebo and active group
214399937|NCT02661854|BIOLOGICAL|Sublingual placebo|Comparison between placebo and active group
214399938|NCT05690022|PROCEDURE|sleeve gastrectomy|Patients will be recruited for a sleeve gastrectomy according to the guidelines of the National Institute of Health.
214504008|NCT06488794|DRUG|colistimethate sodium|100 000 IU/kg of colistimethate sodium (equivalent to 0.96 mg/kg of colistin base) ,maximum 750000 IU, will be nebulized daily, divided into two doses for a maximum of 7 days for eligible ventilated children starting from day 3 of mechanical ventilation.
214504009|NCT06488794|DRUG|0.9% Saline|Nebulization of 3 ml of 0.9% saline twice a day for a maximum of 7 days from day 3 of invasive mechanical ventilation for eligibile ventilated children
214504010|NCT05741450|DEVICE|Lens 1 (monthly replacement)|Monthly replacement spherical silicone hydrogel contact lens for 15 minutes
215004429|NCT02546141|OTHER|full-fat milk (UHT)|
215004430|NCT02546141|OTHER|non-homogenized full-fat milk (pasteurized)|
215004431|NCT02546141|OTHER|full-fat cheese (semi-matured)|
214399939|NCT05261750|BIOLOGICAL|Auto-Dendritic Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.
215004432|NCT02546141|OTHER|whey protein|
215004433|NCT02546141|OTHER|micellar casein|
215004434|NCT05639595|DEVICE|Web interface for health center staff and mobile application on smart phones for village health volunteers|The designated health center staff will receive a web interface that will allow them to offer job aid for supervision, including real-time information about VHSGs' performance in the form of process indicators and coverage of MCH services. The tool will also support health center staff in their daily tasks, such as high-risk patient tracking, low-supply-inventory alerts, supply chain management, electronic health records, vital events tracking, and automatic calculation of performance-based incentives and motivation for VHSGs. The mobile application will be offered to two female VHSGs from each of the 200 villages connected to their respective health centers in the intervention arm. The mobile application will provide job aid to VHSGs for scheduling home visit tasks, including ANC, home-based newborn care, reporting outcomes of pregnancies, and follow-up visits of complicated cases.
215004435|NCT06023797|DRUG|Neoadjuvant immunochemotherapy|Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
215004436|NCT01684592|BEHAVIORAL|Phone-based postpartum continuing care|PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.
215004437|NCT01684592|BEHAVIORAL|Standard care|All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by American College of Obstetricians and Gynecologists (ACOG) for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
214399940|NCT05261750|BIOLOGICAL|Allo-Dendritic-Secretome Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
214399941|NCT04789200|DRUG|NX9 Oral Contrast Agent|Distension and marking of the bowel lumen will be compared between the 1st and 2nd scan. Ability to see IV contrast enhancement will be assessed on the 3rd scan in relationship to the 2nd scan.
214399942|NCT05125692|PROCEDURE|vaginal surgical repair of isthmocele|after preoperative identification of the borders of the isthmocele using transvaginal ultrasound measurements, the isthmocele is repaired via vaginal approach
214399943|NCT03162965|OTHER|Oraquick HIV Self Test|This is an oral swab in home HIV test.
214399944|NCT03162965|OTHER|Clinic Based HIV Counseling and Testing (HCT)|Receiving Counseling and Testing for HIV at the clinic.
214399945|NCT01186861|DRUG|OSI-906|Tablet administered with food and with up to 200 mL of water
214399946|NCT01186861|DRUG|erlotinib|Tablet administered at least 2 hours after food with up to 200 mL of water
214399947|NCT01186861|DRUG|placebo|Tablet administered at least 2 hours after food with up to 200 mL of water
214399948|NCT02881190|DRUG|RC48-ADC|
214399949|NCT05151562|BEHAVIORAL|Virtual Music Therapy|Each study participant will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be delivered by a board-certified music therapist (using Zoom as a primary platform). These individualized therapeutic encounters will use music that is personally meaningful and familiar to the participant and the participant's loved ones to facilitate reminiscence. Decision-making processes made by the music therapist will reflect a flexible session structure and series of intervention choices contingent on each participant's cultural identity, expressive and receptive communication, fine and gross motor ability, affect, orientation to time and place, and personal preferences on any given day.
214399950|NCT06918639|PROCEDURE|Pulpotomy|VPT: Partial pulpotomy: 2 mm of pulp tissue is removed with a high speed 014 diamond round bur different from the one used to remove carious tissue. In those cases in which access to the pulp tissue induces a painful sensation due to failure of the anaesthetic technique, intrapulpal anaesthesia shall be used, and this parameter shall be recorded.Cotton wool impregnated with 2.5% stabilised sodium hypochlorite shall be held over the pulp exposure to achieve haemostasis. If it is not possible to control bleeding, proceed to a complete pulpotomy procedure. If in this case it is impossible to achieve haemostasis, the possibility of performing a TPV is ruled out and the RCT is excluded from the study. Once haemostasis has been achieved, BiodentineXp is applied according to the manufacturer's instructions and a material thickness of 2-3 mm is ensured. Full pulpotomy: The same anterior procedure .Complete removal of the tissue from the pulp chamber. Maximum haemostasis time: 10 minutes
215004438|NCT04088253|PROCEDURE|umbilical herneal repair|reduction of the herneal content an repair of the defect with IPOM
215004439|NCT01052415|BEHAVIORAL|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
215004440|NCT02980653|DRUG|Megestrol acetate (MA) 400 mg/day|Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
214445436|NCT05554198|BEHAVIORAL|Attend Behavior Parent Training|Attend Behavior is a Parent Training intervention available in application form for smartphones or online. Attend Behavior consists of 12 instructional modules and it is recommended that parents complete one module a week in addition to practicing the techniques taught in that course. Each learning module typically around 30 minutes to complete and includes an introductory video to give parents an overview of the different features of the application. At the start of the intervention, parents will take an assessment that will provide information for the program to create individualized goals, plans, reinforcement agents, and even daily schedules. A HIPPA compliant clinician portal within the application allows the clinician to have real time access to monitor the parent learning progress, tracked behaviors, parental notes, and message with the parent.
215004441|NCT01122953|DRUG|Phenytoin|Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
215004442|NCT01122953|DRUG|Epamin|Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
215004443|NCT03734094|DEVICE|Ceramic barrier|The use of a ceramic barrier to induce bone formation during GBR
215004444|NCT03734094|DEVICE|Titanium Mesh|The use of a titanium mesh to induce bone formation during GBR
215004445|NCT04831112|DRUG|Honey|Dressing of necrotizing fascitis wounds with honey.
215004446|NCT04831112|COMBINATION_PRODUCT|EUSOL|Dressing of necrotizing fascitis wounds with EUSOL.
215004447|NCT02615353|BEHAVIORAL|Intensive Lifestyle Intervention|6-months of lifestyle education
215004448|NCT02615353|OTHER|Usual Care Control|Medical visit and dietary counseling
215004449|NCT02448108|BEHAVIORAL|i-IPSRT|"internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.~CH will have participated in a two day training about Bipolar Disorder and IPSRT."
215004450|NCT02448108|OTHER|Written Psychoeducation|Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
215004451|NCT00848432|DRUG|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
215004452|NCT05015023|BEHAVIORAL|Behavioral intervention|A cluster-randomized controlled trial will be conducted.
215004453|NCT00118287|DRUG|azacitidine|Given SC or IV
215004454|NCT00118287|BIOLOGICAL|etanercept|Given SC
214399951|NCT06625281|PROCEDURE|Epleys Maneuver|"* The patient begins in an upright sitting posture, with the legs fully extended and the head rotated 45 degrees towards the affected side.~* The patient is then quickly and passively forced down backwards by the therapist performing the treatment into a supine position with the head held approximately in a 30-degree neck extension~* The therapist observes the patient's eyes for primary stage nystagmus. The patient remains in this position for 1-2 minutes.~* The patient's head is then turned 90 degrees to the opposite direction so that the unaffected ear faces the ground, for 1-2 minutes.~* Keeping the head and neck in a fixed position relative to the body, the individual rolls onto their shoulder, rotating the head another 90 degrees in the direction they are facing. The patient is now looking downwards at a 45-degree angle.~* The eyes should be immediately observed by the therapist for secondary stage nystagmus. The patient remains in this position for 1-2 minutes."
214399952|NCT06625281|PROCEDURE|Semont-plus maneuver|"* The Semont-plus maneuver includes the upright position with turning of the head by 45° toward the non-affected side.~* Then movement of the body by 150° toward the affected side, which moves the otoconia further in the direction in which they should move and since the clot is beyond the vertex, the movement of body by 240° moves the clot into the direction of the vestibulum."
214399953|NCT06625281|PROCEDURE|Brandt-Daroff exercises|"* Patient sits on the edge of bed. and lies down onto the side that causes dizziness to increase. Look towards the ceiling. Stay in this position for 2 minutes.~* Sits upright and then wait for 30 seconds.~* Moves rapidly to the opposite side for 2 minutes."
214399954|NCT05902403|OTHER|invasive mechanical ventilation|Invasive mechanical ventilation for patients admitted to the ICU
214399955|NCT03179540|PROCEDURE|Non-operative management|Patients who are eligible and provide informed consent to participate in the trial will undergo non-operative management (i.e., active surveillance for 24 months) according to the schedule outlined in the study protocol.
215004455|NCT03837275|PROCEDURE|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique) and implant placement
215004456|NCT03837275|PROCEDURE|closed maxillary sinus lift|transdcrestal sinus lift and immediate implant placment
215004457|NCT05201417|OTHER|adapted physical activity|The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants We will account for 24 APA sessions. We will leverage the Step Tracker phone app and pedometer to get the number of steps done, number of calories spent, Workout duration and distance walked per participant per APA session; this data will be collected weekly (after every two sessions)
215004458|NCT00627978|DRUG|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
215004459|NCT05411978|DRUG|Idebenone+ placebo|Participants will receive Idebenone 30 mg+ placebo 60 mg for 12 weeks.
215004460|NCT05411978|DRUG|Idebenone|Participants will receive Idebenone 90 mg for 12 weeks.
215004461|NCT05411978|DRUG|Placebo|Participants will receive Placebo 90 mg for 12 weeks
215095803|NCT03805516|BEHAVIORAL|SCOPP-CW|The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
215004462|NCT03442569|DRUG|Panitumumab|6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
215004463|NCT03442569|DRUG|Nivolumab|240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
215004464|NCT03442569|DRUG|Ipilimumab|1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
215004465|NCT06106997|RADIATION|brain radiotherapy|brain radiotherapy planned on synthetic CTs
215004466|NCT04549428|DRUG|Atezolizumab|Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.
215004467|NCT06027437|DRUG|Danicamtiv|Specified dose on specified days.
215004468|NCT01529996|PROCEDURE|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
215004469|NCT03611660|BEHAVIORAL|Traditional Healthy Lifestyle Program|Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
215004470|NCT03611660|BEHAVIORAL|Mindfulness Meditation Instruction|Participants receive six mindfulness sessions.
215095804|NCT03805516|BEHAVIORAL|Control|This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
215095805|NCT02603848|DRUG|Ibuprofen|(10mg/kg; maximum 600 mg) every six hours as needed
215095806|NCT02603848|DRUG|Morphine|0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
214399956|NCT00394095|DRUG|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
214399957|NCT00394095|DRUG|Placebo|Matched placebo to Experimental arm
214399958|NCT02990221|DRUG|Ingenol mebutate|150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive
214399959|NCT02990221|PROCEDURE|cryotherapy|application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp
214399960|NCT03147092|DRUG|Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,|Treatment of hypertensive subjects
214399961|NCT03147092|DRUG|Atenolol|Treatment of hypertensive subjects
214399962|NCT03147092|DRUG|Losartan potassium 50mg|Treatment of hypertensive subjects
214399963|NCT03147092|DRUG|Clonidine|Treatment of hypertensive subjects
214399964|NCT03805360|DRUG|Ropivacaine|Ropivacaine is a local anesthetic that is expected to provide numbness to the chest wall when injected into the erector spinae plane.
214399965|NCT03805360|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
214399966|NCT02516579|DRUG|Siklos|
214399967|NCT00624104|DIETARY_SUPPLEMENT|Food (fat free meal)|Fat free meal (40% of REE)
214399968|NCT02343614|DRUG|Celecoxib|
215004471|NCT06277375|BEHAVIORAL|Massage|The application starts from the neck with small circular strokes with the thumbs. Surface strokes are performed with the palm of the hand from the base of the skull towards the sacral region. Then rhythmic strokes are repeated from the sacrum along the entire spine towards the skull.The application to the experimental group will be done 3 days a week for 10 minutes for a total of 30 minutes.
215004472|NCT02756442|OTHER|Respiratory disorder assessment during sleep|
214399969|NCT05151133|BIOLOGICAL|Low dose UCMSCs|Receive one course of treatment with a single injection : 0.5×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;
214399970|NCT05151133|BIOLOGICAL|Moderate dose UCMSCs|Receive one course of treatment with a single injection : 1.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;
214399971|NCT05151133|BIOLOGICAL|High dose UCMSCs|Receive one course of treatment with a single injection : 2.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;
214504011|NCT05741450|DEVICE|Lens 2 (daily disposable)|Daily disposable spherical silicone hydrogel contact lens for 15 minutes
215004473|NCT01590875|DRUG|Adenosine arm|In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
215004474|NCT01819662|OTHER|Enhanced standard management|Echocardiogram followed by letter to GP about results.
215004475|NCT01819662|OTHER|Optimised heart failure management|Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction
215004476|NCT01819662|OTHER|Standard management|Usual care
215004477|NCT03509090|PROCEDURE|erector spinae block|erector spinae block will be performed in this group as postoperative analgesia treatment.
215004478|NCT03509090|PROCEDURE|Control group|patients will receive only multimodal analgesic treatment including patient-controlled analgesia
215004479|NCT00323219|DRUG|Cefazolin and Moxifloxacin|See Detailed Description.
215004480|NCT01214720|DRUG|bevacizumab [Avastin]|Intervenous repeating dose
215004481|NCT02482844|OTHER|pacemaker implantation|
215004482|NCT02482844|OTHER|holter implantation|
215004483|NCT05534672|OTHER|Rapamycin|Rapamycin in liquid administered orally
215004484|NCT05534672|OTHER|Placebo|Placebo in liquid administered orally
215004485|NCT02347787|BEHAVIORAL|IMPaCT|"The IMPaCT intervention has three stages:~1. Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~2. Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~3. Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group."
215004486|NCT02347787|OTHER|Usual care|
215004487|NCT06524518|DRUG|Chemotherapy combined with immunization|MRD positive patients receive chemotherapy ± immune for 4 cycles before adaptive therapy
215004488|NCT02416141|DRUG|fast release oro dispersible tramadol 50 mg|idem arm 1
215095807|NCT03594812|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45º. The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis.
215095808|NCT03594812|DEVICE|Radiofrequency without power|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45ºC (Celsius degrees). The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis. In this group, the radiofrequency device was switched off.
214399972|NCT06490094|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|"The 8-week IBSR program is a clinical intervention based on The Work method, developed by Byron Katie and run in the US and Europe for 35 years. The IBSR intervention will involve weekly group meetings (3 hours/meeting) throughout 8 weeks. Home practice between sessions will be supported by facilitator assistants (1-hour session per week). All sessions will be standardized according to the IBSR certification program guidelines and will be assessed to maintain consistency in the program, as in previous studies. ."
214399973|NCT03348826|DRUG|Sodium Bicarbonate 8.4% Solution for Injection|3 mL injection into line with up to 2 injections administered
214399974|NCT03348826|DRUG|Alteplase Injectable Solution|2 mL injection into line with up to 2 injections administered
214399975|NCT03905811|DRUG|Terazosin 5 MG|5 milligrams by mouth daily at bedtime
214399976|NCT03905811|DRUG|Placebo oral capsule|1 capsule by mouth daily at bedtime
214399977|NCT04975789|OTHER|InfoViz|The pain InfoViz tool is a two-page paper tool that consists of an explanation of how to use the tool in both Hmong and English, a culturally-appropriate Faces pain severity scale, pain body diagram, and 13 pain qualities in the form of icons representing each pain quality metaphor. The interpreter explains the instructions in Hmong, then marks the body areas corresponding to the location of pain reported by the participant, and marks the pain qualities expressed by the metaphors selected by the Hmong patient. In the clinic appointment, the interpreter communicates to the physician, in English, the pain location and qualities identified by the participant, using the medical terms identified on the InfoViz tool.
214399978|NCT01646320|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
214504012|NCT04415775|OTHER|Game based treadmill Program|Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.
215004489|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
215004490|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
215004491|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
215095809|NCT03594812|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
215095810|NCT05676216|DRUG|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
215095811|NCT05676216|DRUG|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
214399979|NCT01646320|DRUG|Placebo matching with Dapagliflozin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
214399980|NCT01646320|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
214399981|NCT01646320|DRUG|Metformin immediate release (IR)|Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks
214399982|NCT06449235|DRUG|Omarigliptin|"Chemical name: MK-3102 Class: Dipeptidyl peptidase-4 (DPP-4) inhibitor~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Once-weekly oral dosing."
214399983|NCT06449235|DRUG|Sulphonylureas|"Chemical Name: Sulphonylureas Class: Sulphonylureas~Mechanism of Action:~Stimulates insulin release from pancreatic beta cells. Enhances the sensitivity of beta cells to glucose. Reduces hepatic glucose production. Increases peripheral glucose uptake and utilization. Administration: Typically administered once or twice daily, depending on the specific medication and patient needs."
214399984|NCT06449235|DRUG|Metformin|"Chemical Name: Metformin Class: Biguanide~Mechanism of Action:~Decreases hepatic glucose production. Improves insulin sensitivity in peripheral tissues. Enhances peripheral glucose uptake and utilization. Reduces intestinal absorption of glucose. Administration: Administered orally, usually once or twice daily with meals."
214399985|NCT06449235|DRUG|Other DPP4-i|"Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Typically administered orally once daily. Dosage may vary depending on the specific medication and patient needs."
215004492|NCT01456117|DRUG|Placebo|Pioglitazone matching placebo once daily for up to 14 days.
215004493|NCT01170650|DRUG|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
215004494|NCT01170650|DRUG|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
215095812|NCT05676216|DRUG|Diphenhydramine + Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push when vertigo patients visit Emergency Department
215095813|NCT06256471|OTHER|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months for detection of impact of parasitic infection on these diseases courses
215095814|NCT04122131|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical analysis of biomarker in post-surgical sample
215095815|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)|vaccination
215095816|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)|vaccination
215095817|NCT01447303|OTHER|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
215095818|NCT00071448|DRUG|insulin human|
215095819|NCT00071448|DRUG|insulin lispro|
214399986|NCT06449235|DRUG|Thiazolidinediones|"Chemical Name: Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) Class: Thiazolidinediones (TZDs)~Mechanism of Action:~Activates peroxisome proliferator-activated receptor-gamma (PPAR-γ) in adipose tissue, muscle, and liver.~Increases insulin sensitivity in peripheral tissues. Enhances glucose uptake and utilization in muscle and adipose tissue. Reduces hepatic glucose production. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response."
214399987|NCT06449235|DRUG|Alpha-Glucosidase Inhibitor|"Chemical Name: Alpha-Glucosidase Inhibitors (e.g., Acarbose, Miglitol) Class: Alpha-Glucosidase Inhibitors~Mechanism of Action:~Inhibits alpha-glucosidase enzymes in the small intestine. Delays the breakdown and absorption of complex carbohydrates. Reduces postprandial blood glucose levels. Administration: Administered orally, typically taken with the first bite of each main meal. Dosage may vary based on the specific medication and patient response."
214522625|NCT02522299|DRUG|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
214522626|NCT02522299|DRUG|Placebo|Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
215004495|NCT01170650|DRUG|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
215004496|NCT01170650|DRUG|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
215004497|NCT02049632|PROCEDURE|Omission of axillary clearance|
215004498|NCT07117643|OTHER|Ischemic Preconditioning|"The ischemic procedure will be carried out before the start of the WanT and eccentric exercises procedures and muscle damage in accordance with the detailed description of the RIPC procedure. Four-fold filling of the flotation flange will be performed by 5 minutes to the value of 200 mm Hg with 5 minutes' rest interval near the attachment of the initial straight thigh muscle. All performed procedures will be carried out under the Doppler USG control to perform full arterial blood flow restriction.~The whole research will be carried out in the Laboratory in morning hours. Each participant will be in a hydrated state and before the first meal."
215095820|NCT00071448|DRUG|insulin aspart|
215095821|NCT02616770|DRUG|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
215004499|NCT07117110|DIETARY_SUPPLEMENT|Supplement|Group will take 40 mg lycopene (2,5 pills of food supplement Vitabiotics Ultra Lycopene 15mg, potent extract).
214399988|NCT06449235|DRUG|Glucagon-Like Peptide-1|"Chemical Name: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: GLP-1 Receptor Agonists~Mechanism of Action:~Mimics the action of endogenous GLP-1. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication."
215095822|NCT02616770|DRUG|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
215004500|NCT07117110|OTHER|Tomato soup|Group will take 250 ml of tomato soup (matching with 40 mg lycopene) with 20 ml olive oil.
214399989|NCT06449235|DRUG|Receptor Agonists (GLP1RA)|"Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists~Mechanism of Action:~Activates GLP-1 receptors. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication."
215004501|NCT07117864|COMBINATION_PRODUCT|T-DXd concurrent brain radiotherapy|T-DXd：5.4mg/kg ivgtt Q3w SRT/WBRT
215095823|NCT02616770|DRUG|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
215004502|NCT07117695|OTHER|Referral to the Duke Cardiometabolic Prevention Clinic|Patients who are referred to the cardiometabolic prevention clinic within the intervention arm will be evaluated first by a cardiology provider (as each patient has a history of ASCVD). On this initial visit, the cardiology provider will assess the patient's risk factor profile - to identify the presence of co-morbid conditions or uncontrolled risk factors. The need for additional referrals to other clinicians within the cardiometabolic clinic will specifically outlined criteria. These referrals will be offered to the patient and facilitated after the first visit. Preventive care will follow routine, evidence-based care. Clinicians within the cardiometabolic prevention clinic will meet bi-weekly to discuss enrolled patients, thus every individual in the intervention arm will receive coordinated, multi-specialty care.
215004503|NCT07120048|DEVICE|Edwards INSPIRIS RESILIA Aortic Valve|Surgical replacement of the aortic valve with the Edwards INSPIRIS RESILIA Aortic Valve
215004504|NCT07120165|OTHER|Demographic data collection|Demographic data collection: age, gender, level of education/study, time spent in near vision, sports practice, medical history
215004505|NCT07120165|OTHER|Ophthalmological history|Ophthalmological history: age of myopia discovery, parental refraction, previous refractions, presence of a braking treatment
215004506|NCT07120165|OTHER|Ophthalmological data at each examination|Ophthalmological data at each examination: visual acuity, subjective refraction, cycloplegia with SKIACOL, axial length.
215004507|NCT07120165|OTHER|Potential adverse events|Potential adverse events: halos, photophobia, stinging, infections, etc.
215095824|NCT02616770|DRUG|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
215095825|NCT02616770|DRUG|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
215095826|NCT02616770|DRUG|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
215095827|NCT01862367|DRUG|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
215095828|NCT00313859|DRUG|simvastatin|
215095829|NCT02771626|DRUG|CB-839|Glutaminase inhibitor
215004508|NCT07120360|OTHER|Gender-Based Microaggression Awareness and Prevention Psychoeducation Program|The psychoeducation program consisted of six modules aiming to increase awareness of microaggressions, develop coping and assertiveness skills, enhance critical thinking regarding gender roles, and reduce gender role stress. The program included theoretical knowledge, experiential learning, assertiveness training, and stress management strategies.
215004509|NCT05213130|OTHER|Information|A reminder to inform donors that their blood has saved patient's life in a questionnaire.
215004510|NCT00031993|DRUG|erlotinib hydrochloride|Given PO
215004511|NCT00031993|OTHER|laboratory biomarker analysis|Correlative studies
215004512|NCT00295685|DRUG|Antacids|
215004513|NCT05955833|DIAGNOSTIC_TEST|89Zr-DFO*-trastuzumab PET scan|Patients will be administered 37 MBq 89Zr-DFO\*-trastuzumab and undergo 3 PET scans on the total body PET scanner at day 1, day 2 and day 4 post-injection (p.i.). The first 3 patients will undergo an additional PET 1-2 h p.i. for dosimetry purposes. Three scans are needed for PK modelling and day 4 p.i. is chosen because it is the same time point as in historical controls. Blood samples for (radioactive) PK analysis will be taken at 10 min, 30 min, 1 h and 2 h p.i., and at every PET scan.
215004514|NCT02366416|BEHAVIORAL|Exercise training|Physical activity
215004515|NCT07123558|DIAGNOSTIC_TEST|High resolution anoscopy|to study biomarkers for anal cancer screening
215004516|NCT07046338|GENETIC|Lentiviral TYF-ARSA correction of patient's autologous HSCs|Infusion of lentiviral TYF-ARSA modified autologous HSCs at 1\~10x10\^6 gene-modified cells per kg body weight.
215095830|NCT02771626|DRUG|Nivolumab|PD-1 inhibitor
215095831|NCT02414620|DEVICE|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
215095832|NCT00399100|PROCEDURE|HBO - hyperbaric oxygen treatment|
214399990|NCT06449235|DRUG|SGLT2 inhibitors|"Chemical Name: Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) Class: SGLT2 Inhibitors~Mechanism of Action:~Inhibits SGLT2 in the proximal renal tubules. Reduces reabsorption of filtered glucose from the renal tubules. Increases urinary glucose excretion. Lowers blood glucose levels independently of insulin. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response."
214399991|NCT01489020|BIOLOGICAL|subcutaneous immunotherapy with DPT extract|Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
214399992|NCT01489020|BIOLOGICAL|Subcutaneous depot placebo|Increasing doses of subcutaneous depot placebo in three different scales
214399993|NCT04610424|BEHAVIORAL|"Cooperative Parent Mediated Therapy (CPMT)"|CMPT usually last 6 months, for a total amount of 15 sessions of 90 min; twelve core sessions (one session per week) are delivered in the first 3 months, followed by 3 monthly booster sessions. Each weekly core session had a specific focus and specific intervention strategies based on active parent coaching during parent-child interaction, and included the parent-child dyad with the parent being actively coached by a trained therapist. Live active coaching increases parents' competence in implementing strategies to enhance child development, and at the same time increases their confidence. This intervention has demonstrated evidence of effectiveness in socio-communicational improvement as measured by ADOS-G (Valeri, 2019) in a randomized controlled trial (RCT).
214399994|NCT04610424|BEHAVIORAL|As usual|Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
214399995|NCT05935280|OTHER|Room temperature|Room temperature injection
214399996|NCT05935280|OTHER|Cold temperature|Cold temperature injection
214399997|NCT05935280|DRUG|Lidocain|Unspecific sodium channel blocker
214399998|NCT05935280|DRUG|PF-05105679|Specific antagonist of the TRPM8 ion channel
214399999|NCT05935280|DRUG|A967079|Specific antagonist of the TRPA1 ion channel
214400000|NCT05935280|DRUG|PF-05089771|Specific antagonist of the Nav1.7 sodium channel
214400001|NCT05935280|DRUG|PF-06305591|Specific antagonist of the Nav1.8 sodium channel
214400002|NCT00258713|DRUG|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg BID
214400003|NCT00375856|DEVICE|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
214400004|NCT04460443|DRUG|sofosbuvir|Sofosbuvir once daily
214400005|NCT04460443|DRUG|Sofosbuvir ledipsavir|Sofosbuvir ledipsavir once daily
214400006|NCT04460443|DRUG|Daclatasvir|Daklatasuvir tablets
214400007|NCT06696846|BIOLOGICAL|CD70 CAR-NK|"CAR - NK cells constructed by using genetic engineering technology retain the original extensive tumor - killing ability of NK cells. By using their unique target cell recognition mechanism, the target is accurately locked on specific antigen proteins, thereby enhancing the anti - tumor effect. Cord blood-derived CAR - NK cell products shorten the treatment time and are inexpensive. Multiple studies have confirmed the feasibility of CAR - NK cells in treating hematological tumors.~Blocking the CD70/CD27 signaling pathway plays an important role in inhibiting CD70 - positive tumors, such as refractory/relapsed T - cell lymphoma and acute myeloid leukemia. Pre - clinical studies in our laboratory have proved that CD70 CAR - NK can effectively inhibit the in - vivo and in - vitro proliferation of T - cell lymphoma and prolong survival."
214400008|NCT05980221|DIAGNOSTIC_TEST|Metabolomics|Plasma samples taken for the investigation of the metabolome
214400009|NCT05980221|DIAGNOSTIC_TEST|13C MTGT|sequential breath samples taken for investigation of PEI (reference test)
215004517|NCT07045545|PROCEDURE|- Group A: Platelet-rich fibrin membrane prepared intraoperatively and applied over neourethra|In this arm, a platelet-rich fibrin membrane will be prepared intraoperatively from the patient's blood using centrifugation. The prepared PRF membrane will then be applied directly over the neourethra following urethroplasty to promote healing and tissue regeneration.
214400010|NCT06712498|PROCEDURE|External Oblique Intercostal Plane Block|After endotracheal intubation, a 22-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
214400011|NCT06712498|DRUG|control group|No intervention
214400012|NCT01732575|BEHAVIORAL|Enrichment with meaning-generating activities|Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
214400013|NCT00549497|DRUG|GW870086X|
214400014|NCT06390553|DEVICE|Task-Oriented Virtual Reality Application with Crowd Simulation|Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
214400015|NCT06390553|PROCEDURE|Conventional Parkinson Rehabilitation|Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
214400016|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
214400017|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
214400018|NCT04103047|OTHER|SAD|The patients who have an SAD inserted as part of their normal Anaesthetic plan will be consented prior to their Anaesthetic and then have a questionnaire to fill out post operatively.
215004518|NCT07045545|PROCEDURE|Group B: Ventral dartos flap rotated over neourethra|Participants in this arm will undergo hypospadias repair with the application of a ventral dartos fascia flap. The procedure involves elevating a vascularized flap of ventral dartos fascia from the penile shaft, rotating it over the neourethra to provide additional tissue coverage and promote healing. This flap helps in reducing the risk of fistula formation and enhances vascular support to the neourethra. The surgical steps include dissecting the dartos fascia carefully, rotating it over the neourethral reconstruction, and securing it in place, followed by standard postoperative care and follow-up.
215004519|NCT07125911|DRUG|Ibuprofen 400 mg (if necessary)|Single oral dose of 400 mg ibuprofen administered in a blinded capsule. Prior to dosing, baseline pulpal sensibility tests (cold test with Endo-Ice and Electric Pulp Test) and pain rating (VAS) will be recorded on a contralateral healthy tooth and the target tooth with symptomatic irreversible pulpitis. The drug is given orally and tests are repeated 30 minutes after ingestion. Participants are monitored for adverse effects. Participants who cannot take NSAIDs are excluded
215004520|NCT07125911|DRUG|Paracetamol 500 mg|A single oral dose of 500 mg paracetamol administered in a blinded capsule. Baseline pulpal sensibility testing (cold test with Endo-Ice and Electric Pulp Test) and pain level assessment using a Visual Analogue Scale (VAS) will be performed on both the tooth with symptomatic irreversible pulpitis and a contralateral healthy tooth prior to administration. The same tests will be repeated 30 minutes after ingestion to evaluate any masking effect on test results.
214400019|NCT04027361|DRUG|Amphetamine Extended Release (ER) Tablet 20 mg|A single 20 mg dose of amphetamine ER Tablet, orally administered
214400020|NCT00069719|DRUG|Glaucoma therapy|
214400021|NCT00099918|DRUG|vildagliptin|
214400022|NCT02814760|OTHER|training of emergency professionals to acute stroke management|"The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~* Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~* Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization)."
214400023|NCT02424344|DRUG|Aclidinium/Formoterol|Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
214400024|NCT02424344|DRUG|Placebo|Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
214400025|NCT04252937|DRUG|Adrecizumab|HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).
214400026|NCT03128203|DRUG|Oxytocin|Oxytocin, intranasally administrated
215004521|NCT07118917|OTHER|Prehabilitation|Patients with COVID-19 history postponed for the surgery according to multidisciplinary decision.
215095833|NCT06380894|DEVICE|Virtual Reality Cognitive Training|"Participants who were assigned to the VRCT intervention group underwent 60 minutes of weekly VRCT sessions over a 10-week intervention period. The program consisted of two components: (1) psychoeducation on cognitive functioning and ways to maintain cognitive health, (2) VR multi-domain cognitive training tasks that target cognitive domains of attention, memory, and executive functioning.~The VR experiences were administered through a head-mounted Oculus Go Screen V7. The VR system runs on a software developed by Dancing Mind Pte Ltd. The software specifications and service provided by Dancing Mind Pte Ltd include: MindGym System Functions: System Setup (Processor Setup, Password Changing etc) and Data Centre (Memory Care Therapy Data Analytics Report Querying and Printing Functions). The MindGym cognitive training content was developed based on the Singaporean culture, with visual stimuli reflecting familiar local environments."
214400027|NCT03128203|DRUG|Placebos|Saline, intranasally administrated
214400028|NCT01411280|DRUG|methylphenidate|Ritalin 10mg, Ritalin 20mg
214400029|NCT00414414|DRUG|Prednisone|
214400030|NCT00414414|DRUG|placebo|placebo
214400031|NCT00083564|DRUG|STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)|
214400032|NCT01174550|PROCEDURE|Coronary Angiography|Use of standard equipment for usual-care testing
214400033|NCT01174550|PROCEDURE|Stress Echocardiogram|Use of standard equipment for usual-care testing
214400034|NCT01174550|PROCEDURE|Nuclear Stress Test|Use of standard equipment for usual-care testing
214400035|NCT01174550|PROCEDURE|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
214400036|NCT04609540|DRUG|Trastuzumab|Dual anti-HER2 therapy
214400037|NCT04509284|OTHER|Training|The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period. The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions. Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed. A 3-5min rest period is provided throughout the program.
214400038|NCT04509284|OTHER|Control|The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet. However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
215004522|NCT07118917|OTHER|No postponement|Patients who were COVID negative proceeded for surgery
215004523|NCT07123051|DEVICE|right colectomy|Robotic-assisted right colectomy with the DEXTER robotic surgery system
215004524|NCT07124377|OTHER|A complete physical examination of all body systems, including height and body weight|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
214400039|NCT06268925|OTHER|Exercises|number of exercises will be guided to do through zoom
214400040|NCT00846209|OTHER|Enhanced drug labeling|use of clear concise text and icons on drug warning labels
214400041|NCT03115775|DIETARY_SUPPLEMENT|Conjugated linoleic acid|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.
214400042|NCT03115775|DIETARY_SUPPLEMENT|Vitamin D|Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.
214400043|NCT03115775|DIETARY_SUPPLEMENT|Conjugated linoleic acid and Vitamin D|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.
214400044|NCT03115775|OTHER|Corn oil (placebo)|Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
214400045|NCT02821312|DRUG|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
214400046|NCT02821312|DRUG|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
214400047|NCT03572413|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
214400048|NCT03572413|DRUG|Rocuronium bromide|Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
214400049|NCT05080595|OTHER|Transportation assistance (Lyft rides)|Lyft rides will be provided to patients for any transplant-related medical visits
214400050|NCT06783673|PROCEDURE|Upper GIT endoscopy|upper GIT endoscopy of suspected cases and multiple biopsies will be taken for histopathological examination
215004525|NCT07124377|OTHER|Neurological examination includes motor strength testing; sensory testing with pinprick, light touch, temperature, and proprioception; deep tendon reflexes; and gait assessment.|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
215004526|NCT07124377|DIAGNOSTIC_TEST|Electrocardiogram (12-lead ECG)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
215004527|NCT07124377|DIAGNOSTIC_TEST|24-Hour Holter Monitoring|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
215004528|NCT07124377|DIAGNOSTIC_TEST|"Color Doppler echocardiography with two-dimensional strain (longitudinal strain)"|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
215004529|NCT07124377|OTHER|The Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
215004530|NCT07124377|OTHER|questionnaire, the NIS-LL (Neuropathy Impairment Score in the Lower Limbs)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
214400051|NCT05036694|DEVICE|FUJILAM KIT|Urine based test to detect LAM
214504013|NCT04415775|OTHER|Conventional Gait Rehabilitation|Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
214504014|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
214504015|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
214504016|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
214504017|NCT00628706|DRUG|Delta9-tetrahydrocannabinol (THC)|inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
214504018|NCT05136794|OTHER|Data collection|complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay
214504019|NCT01096472|DRUG|LAS41003|Once daily
215004531|NCT07124377|OTHER|COMPASS-31 (Composite Autonomic Symptom Score-31)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
214400052|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
214400053|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
214504020|NCT01096472|DRUG|LAS189961|Once daily
214504021|NCT01096472|DRUG|LAS189962|Once daily
214504022|NCT00745875|DRUG|ZD4054|10mg oral tablet, once daily
214504023|NCT00745875|DRUG|Pemetrexed|500mg2/m IV infusion
214504024|NCT00745875|DRUG|Placebo|10mg oral tablet, once daily
215004532|NCT07124377|DIAGNOSTIC_TEST|Electromyogram (EMG)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
214400054|NCT05835050|DIAGNOSTIC_TEST|serum interleukin 10 level|b. Serum levels of IL-10 were measured using a quantitative enzyme-linked immunosorbent assay (ELISA)
214400055|NCT04061161|DRUG|Tiotropium Bromide|Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
214504025|NCT01602913|DRUG|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
214504026|NCT01602913|DRUG|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
214522627|NCT02522299|DEVICE|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
215004533|NCT07124377|DIAGNOSTIC_TEST|[99mTc]Tc-DPD scintigraphy|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
215004534|NCT07124377|DIAGNOSTIC_TEST|Laboratory assessments|Laboratory assessments include blood and urine sample collection for serum chemistry, hematology, and urinalysis, with specific biomarker analyses (troponin T, NT-proBNP, Kappa, and Lambda light chains
215004535|NCT07086651|DRUG|Enzalutamide|As provided in real-world setting
215004536|NCT07086651|DRUG|Apalutamide|As provided in real-world setting
214400056|NCT00000568|BEHAVIORAL|smoking cessation|
215004537|NCT07086183|OTHER|Observation|Observation of intraoperative and postoperative outcomes
215004538|NCT07083843|BEHAVIORAL|Exercise|Intervention, will receive home based exercise multi times per week for 6 months
215004539|NCT07083843|OTHER|Standard medical treatment|Control group will receive the usual standard care.
215004540|NCT07113210|DRUG|pilocarpine HCL ophthalmic solution|Qlosi will be given to participants and quality of life will be determined.
214400057|NCT00000568|DRUG|ipratropium|
214400058|NCT05588882|PROCEDURE|Wavefront-guided LASIK|Topography-guided utilizes topography mapping to perform the ablation
214400059|NCT05588882|PROCEDURE|Wavefront-guided|Wavefront-guided utilizes aberrometry to perform the ablation
214400060|NCT03504605|OTHER|Online self-compassion intervention|Parents are asked to write in an online text box about a parenting event in which they felt shame. They are then given a validated set of instructions asking them to reflect on the event and write self-compassionate responses.
215004541|NCT07117201|BEHAVIORAL|Culturally Tailored Cooking Classes|Cooking skills session will be offered by the Delicious Legacy Program. The Delicious Legacy program is a culturally tailored, community-based nutrition and wellness intervention designed to promote health equity. Rooted in the intergenerational transmission of knowledge, the program emphasizes family socialization practices related to food, health beliefs, and caregiving. It integrates evidence-based nutritional education with ancestral foodways to address diet-related chronic illnesses while fostering cultural pride and resilience. Through interactive workshops, individuals engage in hands-on learning that reinforces traditional roles in food preparation and shared meals as sites of emotional support and identity formation. Dr. Haynes will lead the cooking sessions and create cardiometabolic-appropriate recipes.
215004542|NCT07117201|BEHAVIORAL|Prescription Produce Plan|The standard PPP includes three major parts. 1) Screening and personalized referrals/support for social needs including food, housing, health insurance and transportation by a community health worker. 2) Bi-weekly wellness visits with an MHWP team of interprofessional healthcare students, supervised by a clinical faculty, and guided by the participants' health and social needs and interests. They include education and SMART-EST goals around nutrition, physical activities, chronic disease management, care coordination, and/or recipes. 3) Delivery of a bag of fresh fruits and vegetables as well as heart healthy food items every two weeks over a period of 12 months. The produce bags will be made by the Underground Kitchen, a local non-profit organization creating curated bags of healthy food items and recipes to support the prevention and management of chronic diseases.
215004543|NCT07119736|DEVICE|VR relaxation|Relaxation with a VR glass and 360° video's of nature
215004544|NCT07119736|OTHER|Standard relaxation|Relaxation with music, reading a book, playing computer game
214400061|NCT02087033|DIETARY_SUPPLEMENT|ritmonutra|2 tablets a day by mouth for 4 weeks
214400062|NCT02087033|DIETARY_SUPPLEMENT|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
214504027|NCT01602913|DRUG|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
214504028|NCT05302076|DEVICE|Low-intensity electrical current (LIEC)|Each patient in the electrical group will be asked to wear a removable device containing a small electrical circuit that will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
214504029|NCT05302076|DEVICE|Traditional fixed orthodontic appliance|"The maxillary arch will be levelled and aligned. The rectangular stainless steel archwires (0.019 × 0.025) with anterior 8mm height soldered hooks distal to the canines will be inserted. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction."
214522628|NCT02522299|DEVICE|ELLIPTA|It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
215004545|NCT07119606|DIAGNOSTIC_TEST|SHANK3 mutation|blood sampling for diagnostic test
215004546|NCT07119970|BIOLOGICAL|Additional blood sampling|At inclusion (T0) and at 12 months (T1), venous blood will be drawn for plasma markers of NETosis
215004547|NCT07120737|DEVICE|H.A.L.T. MAX spectacles|The Essilor® Stellest® 2.0 lens features a 2 times larger signal area, significantly enhancing the effect of slowing down myopia progression
215004548|NCT07116889|BIOLOGICAL|GB-0895 (SC)|Single subcutaneous dose of GB-0895
214400063|NCT05257837|BEHAVIORAL|Gun handling behavior|Children will play in an observed room for 20 minutes. Aside from a selection of toys, two real handguns will be placed in a drawer. The handguns have been modified so they cannot fire. Inside the magazine, the handgun contains no bullets. Instead, it contains a sensor that counts the number of times the trigger is pulled with sufficient force to discharge the gun. This allows us to distinguish reliably the children who pull the trigger from those who handle the gun but do not pull the trigger
214400064|NCT05257837|OTHER|Debriefing|Children and their parents will be debriefed on the actual purpose of the study, including the role of the safety video and how the movie clips were edited.
214400065|NCT00164593|BEHAVIORAL|Youth Empowerment Solutions for Peaceful Communities|YES is a multi-faceted program that (1) engages 7th and 8th graders in a youth development program, (2) enhances neighborhood organizations' ability to include youth in their activities, and (3) connects the youth participants and adults in neighborhood organizations (e.g., crime watches, block groups, neighborhood associations) to carry out neighborhood improvement activities (e.g., community gardens, parks cleanup).
214400066|NCT06437405|DIETARY_SUPPLEMENT|Vinegar liquid|one pill daily
214400067|NCT06437405|DIETARY_SUPPLEMENT|vinegar pill|One pill daily
215004549|NCT07116889|BIOLOGICAL|GB-0895 (SC)|Multiple subcutaneous doses of GB-0895
215004550|NCT07116889|DRUG|Placebo (SC)|Single subcutaneous dose of placebo
215004551|NCT07116889|DRUG|Placebo (SC)|Multiple subcutaneous doses of placebo
215004552|NCT07120347|OTHER|Remote Ambient Sensor System|Remote sensors (motion, door contact) deployed in participants' home connected through raspberry pi and mobile hotspot
215004553|NCT07117422|DRUG|VEN + DEC|"Induction regimen~Venetoclax (VEN): Day1-10~Decitabine (DEC):20mg/m²/day, Day 2-4~20mg/m² every 8 hours, Day 5-6~FLT3 Inhibitors (for FLT3/ITD+ patients only):~Sorafenib or Gilteritinib, Day 8-14~Post-Remission Treatment~Venetoclax (VEN): 400 mg/day, Day 1-7~Decitabine (DEC): 20 mg/m² every 8 hours, Day 2-3 (Regimen repeated every 4-6 weeks)~FLT3 Inhibitors (for FLT3/ITD+ patients only):~Sorafenib or Gilteritinib, Day 8-14"
215004554|NCT07119073|DRUG|Dexmethylphenidate|Subjects will be randomized to one of two sequences. Subjects will be dosed with 50 mg dose of Cox-1301 during each sequence. Subjects will serve as their own control.
215004555|NCT07119086|BIOLOGICAL|Biological samples|Blood and urine samples
215004556|NCT07119086|OTHER|Questionnaires|Quality of life questionnaires
215004557|NCT07116798|OTHER|Exercise|Strengthening Exercises Based on Proprioceptive Neuromuscular Facilitation Patterns
215004558|NCT07116798|OTHER|Exercise|Plyometric Exercises
215004559|NCT07120672|OTHER|patients were monitored for reentubation for 48 hours.|patients were monitored for reentubation for 48 hours.
215004560|NCT07120672|OTHER|weaning group|patients were monitored for reentubation for 48 hours.
215004561|NCT06310629|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula
215004562|NCT06310629|DEVICE|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"
215004563|NCT03720847|DRUG|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
214400068|NCT01625338|DRUG|SOF|SOF 400 mg tablet administered orally once daily
214400069|NCT01625338|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
214400070|NCT01625338|DRUG|Peg-IFN|Peg-IFN 180 μg administered once weekly by subcutaneous injection
214400071|NCT04565314|DIETARY_SUPPLEMENT|Plumpy'Mum|Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
215004564|NCT03720847|DRUG|Oral Micronized Progesterone|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation
215004565|NCT03720847|DRUG|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
215004566|NCT03720847|DRUG|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
214400072|NCT05767164|PROCEDURE|cervical single open-door surgery|The patients were operated by the cervical single open-door surgery, which were used with the Centerpiece titanium plate to internal fixation.
214400073|NCT00318825|DRUG|Nitrous oxide|
214400074|NCT03701425|DIETARY_SUPPLEMENT|Mediterranean diet and exercise plan|"Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%"
214400075|NCT05599633|DIETARY_SUPPLEMENT|Sago starch drink|Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
214400076|NCT05599633|DIETARY_SUPPLEMENT|Corn starch drink|Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
214400077|NCT02719951|DRUG|[18F]FPEB PET imaging|PET exam
214400078|NCT02719951|OTHER|Biological samples|blood sample and urine sample
214400079|NCT02719951|OTHER|MRI|MRI exam
214400080|NCT02485353|DRUG|Vosaroxin and Cytarabine|
214400081|NCT06109259|DRUG|DWJ1567|One tablet of DWJ1567
214400082|NCT06109259|DRUG|DWC202312|One tablet of DWC202312
214400083|NCT01837043|DRUG|Belatacept|
214522629|NCT06037109|DEVICE|Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test|Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
215004567|NCT00272090|DRUG|Insulin glargine|
215004568|NCT00129896|DRUG|Myocet|Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
215004569|NCT00129896|DRUG|Taxotere|Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
215004570|NCT00129896|DRUG|Herceptin|Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles
215004571|NCT05548556|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
215004572|NCT05548556|DRUG|RO7204239|Participants will receive SC RO7204239 Q4W
215004573|NCT01710085|DEVICE|Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011|Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
215004574|NCT04621201|OTHER|observation and biopsy|biopsy
215004575|NCT04257617|DRUG|ZL-1201|Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.
215004576|NCT00653562|DRUG|zolpidem|Oral
215004577|NCT05222815|OTHER|CGM|Continuous glucose monitor (CGM)-based glucose monitoring
215004578|NCT05222815|OTHER|SMBG|Self-monitoring of blood glucose (SMBG)-based glucose monitoring
215004579|NCT01239680|DRUG|Glutamine|Intravenous 25 grams once over 6 hours
215004580|NCT01239680|DRUG|Ringer's Lactate|Intravenous 1 liter once over 6 hours
215004581|NCT01239680|DRUG|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
215004582|NCT03033901|DEVICE|Polysomnography - Level 1 and Level 3|Participants will undergo simultaneous administration of Level 1 and 3 polysomnography on the rehabilitation unit with study funded sleep technologist present to meet Level 1 standards.
215004583|NCT03033901|DEVICE|Actigraphy monitoring|Participants will undergo actigraphy monitoring to assess habitual sleep duration to determine readiness for polysomnography and examine trajectory and duration of sleep.
214400084|NCT01837043|DRUG|Calcineurin Inhibitor|
215004584|NCT03033901|OTHER|Sleep Apnea Screening|Participants and their family member or proxy, and clinical staff will be asked to answer questions in order to complete the three standardized sleep apnea screening measures.
215004585|NCT03096353|OTHER|Placebo|saline
215004586|NCT03096353|DRUG|Naloxone|We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
215004587|NCT05293470|OTHER|Piqray|There is no treatment allocation. Patients administered Piqray by prescription will be enrolled.
215004588|NCT06182995|BEHAVIORAL|Usual Care post-Intensive Care Unit (ICU)|routine clinic visits
214400085|NCT05564182|DEVICE|High intensity laser therapy|HILT will be applied to the patients five times a week for a period of three weeks and one session per day for a total of 15 sessions by a physical therapy technician who is experienced in using a laser device (BTL-6000 high intensity laser 12 W, Stevenage, Hertfordshire, England). It will be used in the rotator cuff muscles area in two stages, Phase I and Phase II. For analgesic effect in phase I. Phase II will also be applied for the biostimulation effect.
214400086|NCT05564182|OTHER|Therapeutic Exercise|Therapeutic Exercise As therapeutic exercise program; A multidisciplinary stroke rehabilitation program will be implemented in the presence of a specialist physiotherapist. In addition, a therapeutic exercise program including passive, actively supported and active ROM exercises, stretching, strengthening and mobilization exercises will be applied to all patients by physiotherapists according to the level of pain and limitation.It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes.
215004589|NCT06182995|BEHAVIORAL|Anticipating Decline and Providing Therapy (ADAPT)|routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge
215004590|NCT03832452|DRUG|Lucerastat (Treatment A)|2000 and 4000 mg; hard capsules for oral administration
215004591|NCT03832452|OTHER|Placebo|hard capsules for oral administration
215004592|NCT03832452|DRUG|Moxifloxacin|400 mg; film-coated tablets for oral administration
215004593|NCT03832452|DRUG|Lucerastat (Treatment B)|1000 mg; hard capsules for oral administration
214400087|NCT03930186|DRUG|Apremilast|Tablets for oral administration
214400088|NCT03930186|DRUG|Topical Therapy|Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
214400089|NCT02022514|OTHER|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
214400090|NCT02022514|DRUG|Conventional medical treatment|
214400091|NCT06343961|PROCEDURE|Intraoperative Fluorescein Angiography|Targeted laser photocoagulation under the guidance of intraoperative fluoroscopy
214522630|NCT02342275|DRUG|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
215004594|NCT03832452|DRUG|Lucerastat (Treatment C)|4000 mg; hard capsules for oral administration
215004595|NCT04716309|PROCEDURE|Open reduction and volar locking plate and closed reduction and K-wires.|DVR Anatomic Plate, K-wires
215004596|NCT03799367|DEVICE|Drug delivery during breastfeeding|This study aims to give a vitamin B12 supplement to babies during breastfeeding. 30 mother-infant pairs will be recruited. The supplement will be placed into a nipple shield, both of which are commercially available, and the mother will breastfeed her baby as usual. Before and after the feed, we will 1) collect a small blood sample from the baby to see whether the vitamin levels in the infant have increased, 2) ask the mother to participate in two short interviews about her expectations and experiences using the Therapeutic Nipple Shield.
215004597|NCT05801978|BIOLOGICAL|Live Attenuated Yellow Fever 17D Vaccine|The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.
215004598|NCT05801978|BIOLOGICAL|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
215004599|NCT06838013|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be delivered by a constant-current electrical stimulator (DC-stimulator; Eldith, Ilmenau, Germany). Rectangular electrodes covered with a saline-soaked sponge will be used for the anode and cathode. The anode will be placed over the leg area of the motor cortex, on the lesioned side, with the medial border of the electrode placed laterally to Cz on the international electroencephalogram 10-20 system. The cathode will be placed above the contralateral orbit. The stimulation intensity will be set at 2 mA for 30 minutes.
215004600|NCT06838013|DEVICE|Sham transcranial direct current stimulation (Sham-tDCS)|Sham tDCS will be delivered by a constant-current electrical stimulator (DC-stimulator; Eldith, Ilmenau, Germany). Rectangular electrodes covered with a saline-soaked sponge will be used for the anode and cathode. The anode will be placed over the leg area of the motor cortex, on the lesioned side, with the medial border of the electrode placed laterally to Cz on the international electroencephalogram 10-20 system. The cathode will be placed above the contralateral orbit. The stimulation intensity will The stimulator will only be applied for the first and last 30 seconds.
214400092|NCT05471921|BEHAVIORAL|SBIRT|SBIRT is an evidence-based treatment for unhealthy alcohol and other drugs (AOD) use in non-humanitarian settings and can efficiently provide individuals with an appropriate level of care based on their symptoms. Participants randomized to SBIRT will receive an on-the-spot alcohol brief intervention (CETA-BI) and be categorized as low or moderate/high severity using the AUDIT scale. Participants who are moderate/high severity will be connected to a counselor and will begin full CETA treatment. CETA is a transdiagnostic approach that combines motivational interviewing with cognitive behavioral therapy to assist clients in considering changing their rates of AOD use. The intervention lasts 30-40 minutes and consists of 6 components including 1) screening; 2) identifying the impacts of unhealthy AOD use; 3) talking about change/goal-setting; 4) understanding the primary reason for drinking; 5) skill-building; and 6) referral for services.
214400093|NCT05471921|BEHAVIORAL|Treatment as usual|Mantapala health workers and supervisors were trained in mental health gap action program-humanitarian intervention guide (mhGAP-HIG), which is a mental health service provision guide for use in humanitarian settings; this training was led by staff from United Nations High Commissioner for Refugees. This training did not include evidence-based psychological interventions (e.g., CETA). Participants randomized to TAU will be referred to the existing services that exist in the health clinic located in Mantapala refugee settlement. More specialized services are referred to the District Hospital in Nchelenge.
214400094|NCT06273189|DEVICE|Conventional|In conventional group, contralateral side mandibular osteotomies were performed with Lindeman and round bur (Karl Storz, Tuttlingen, Germany)
214400095|NCT06273189|DEVICE|Bone Scalpel|In ultrasonic device group, osteotomies one side of the mandible were performed unilaterally using an ultrasonic bone scalpel (BoneScalpel; Misonix, Farmingdale, NY) with a serrated standard blade
215004601|NCT06838013|DEVICE|Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)|TENS will be delivered to the common peroneal nerve of both intact and paretic leg for 30 minutes using a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching.
215004602|NCT06838013|DEVICE|Placebo transcutaneous electrical nerve stimulation (Placebo-TENS)|Placebo-TENS will be applied to identical-looking TENS devices, with the electrical circuit disconnected inside the devices. Placebo-TENS will be delivered to the common peroneal nerve of both intact and paretic leg for 30 minutes that set at 100 Hz, with 0.2 ms square pulses.
215004603|NCT06838013|BEHAVIORAL|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 5 exercises for 30 minutes, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, gait re-education and transition training.
215004604|NCT02748993|DRUG|PAC-14028 Cream 0.1%|Topical application
215004605|NCT02748993|DRUG|PAC-14028 Cream 0.3%|Topical application
215004606|NCT02748993|DRUG|PAC-14028 Cream 1.0%|Topical application
215004607|NCT02748993|DRUG|PAC-14028 Cream Vehicle|Topical application
215004608|NCT03300765|DRUG|Apatinib|Apatinib will be used as induction therapy in experimental arm.
215004609|NCT03300765|RADIATION|Intensity modulated radiation therapy|Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.
215004610|NCT03885063|BEHAVIORAL|Benjamin Rose Institute Care Consultation (BRI-CC)|The BRI-CC is a telephone-based intervention designed for adults with chronic conditions and has been used in persons with dementia and their caregiver (CG). This assessment is guided by the use of assessment tools with domains that trigger specific and pertinent needs of the dyad such as relationship strain, depression, financial concerns, memory problems, and difficult behaviors. To address unmet needs, the care consultant and dyad develop action plans with specific action steps pertinent to the dyad. The intervention involves maintenance and support where the care consultant (CC) continues the relationship with the dyad through regular telephone contact, email and mail. CC use a web-based reporting system, to maintain and track dyad information, assessments, action plans, completed tasks, and ongoing contacts. At a minimum, the care consultant will contact the dyad by telephone once per month over the duration of the study period (i.e. 6 months).
215004611|NCT01464138|DRUG|Fosmidomycin and Clindamycin co-administration|Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
215004612|NCT06093711|DIAGNOSTIC_TEST|Description|All patients were briefed about the research purpose and procedure. They were also informed about the following points: (1) participation is voluntary, (2) they can withdraw from the study at any stage without explanation, (3) the data will be used only for scientific purposes and will not be shared with third parties, and (4) they will remain anonymous throughout the research. Informed consent was obtained from those who agreed to participate. It took each participant 20-25 minutes to fill out the data collection tools.
215004613|NCT02734667|DEVICE|CGM at diagnosis of T1D|Initiation of non-adjunctive CGM use at diagnosis of T1D
215004614|NCT01803386|DEVICE|EIM Measurements|EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
215004615|NCT03528031|OTHER|Intervention Daily Avocado|Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.
214400096|NCT02037061|DRUG|Bupivacaine|Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
214400097|NCT02037061|OTHER|Normal Saline|
215004616|NCT01870596|DRUG|Cytarabine|Given IV
215004617|NCT01870596|DRUG|CHK1 Inhibitor SCH 900776|Given IV
215004618|NCT01870596|OTHER|Laboratory Biomarker Analysis|Correlative studies
215004619|NCT06355973|DEVICE|Using tablets and workbooks cognitive function.|Cognitive training programs corresponding to memory, attention, time and space, and orientation are conducted for 35 to 60 minutes.
215004620|NCT06355973|DEVICE|self-programming of physical function training.|The fitness program consisting of stretching, muscle strength, coordination, and aerobic exercise lasts 20 to 30 minutes, and additional 3-4 times/mainly 30 to 40 minutes of aerobic exercise.
214400098|NCT00557505|DRUG|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
214400099|NCT01639274|OTHER|COPD prevalence|Determine prevalence of COPD
214400100|NCT04873713|DEVICE|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension over low back
214400101|NCT04873713|DEVICE|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
214400102|NCT02782429|DRUG|Ketamine|
214400103|NCT02782429|OTHER|Saline|
214400104|NCT02033993|DRUG|Nab-Paclitaxel|
214400105|NCT02033993|DRUG|Paclitaxel|
214400106|NCT02332317|BEHAVIORAL|Palliative rehabilitation|12-week individually customized, specialized palliative rehabilitation program
214400107|NCT06352190|DRUG|[14C] SY-5007|Carbon-14 labeled SY-5007
214400108|NCT03457194|BIOLOGICAL|Quadrivalent Influenza Vaccine|Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.
214400109|NCT03457194|BIOLOGICAL|DTP Vaccine (Multiple Actives)|Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.
215004621|NCT04461392|DIAGNOSTIC_TEST|Cardiorespiratory exercise test|"* Cardiorespiratory exercise test to evaluate the exercise tolerance~* Cardiac imaging for the assessment of the left atrium anatomy and function."
215004622|NCT06387316|OTHER|No Oral Stimulation|No oral stimulation
215004623|NCT06387316|OTHER|Oral water stimulation|Oral water stimulation
214400110|NCT03914339|PROCEDURE|Periodontal and orthodontic treatment|Eighteen periodontally compromised patients who give be given both periodontal and orthodontic treatment
214400111|NCT03914339|PROCEDURE|periodontal treatment|Eighteen periodontally compromised patients who give be given periodontal treatment alone.
214400112|NCT04710693|DIAGNOSTIC_TEST|CAD polyp-detection system|Software will be used during the procedure to aid the detection of polyps during the procedure.
214400113|NCT06270511|DRUG|S-337395|Administered as an oral suspension.
214400114|NCT06270511|DRUG|Placebo|Administered as an oral suspension.
214400115|NCT02046642|BEHAVIORAL|Maternal rest in left lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their left sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
214400116|NCT02046642|BEHAVIORAL|Maternal rest in right lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their right sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
214400117|NCT03244137|OTHER|Pulmonary rehabilitation|See group description.
214400118|NCT05420987|DIETARY_SUPPLEMENT|Jing Si herbal tea liquid packet|Jing Si herbal tea includes eight Taiwan native-grown herbs: such as mugwort leaves, fish needle grass, Ophiopogon japonicus, platycodon, perilla leaves, chrysanthemum, and licorice
214400119|NCT01241578|BEHAVIORAL|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
214400120|NCT02548793|OTHER|Education: CPR Training via Mobile App|Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
214400121|NCT02548793|OTHER|Education: CPR Training using the CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
214400122|NCT00099424|BEHAVIORAL|High-intensity exercise training|
215004624|NCT06387316|OTHER|Oral Salt Stimulation|Oral Salt Stimulation
215004625|NCT06387316|OTHER|Oral Sucralose Stimulation|Oral Sucralose Stimulation
215004626|NCT06387316|OTHER|Oral Sucrose stimulation|Oral Sucrose stimulation
215004627|NCT03945890|OTHER||
215004628|NCT00499213|PROCEDURE|Home Care Assisted Peritoneal Dialysis|
215004629|NCT01996995|DEVICE|Nd:YAG laser pulse therapy|
215004630|NCT01996995|DEVICE|Sham procedure|Sham procedure
215004631|NCT02166879|BEHAVIORAL|Questionnaire|Participants complete anesthesia questionnaire before elective surgical procedure.
214400123|NCT05353569|DIAGNOSTIC_TEST|OCT Device(s)|Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).
214400124|NCT02744274|OTHER|Verum acupuncture|"Patients will lay supine. The acupuncture physicians will disinfect the selected acupuncture points with alcohol and then needle them (30 gauze, 1.5-inch, Yuguang, Taiwan) with a plastic device is fixed needle body, so that the patient achieves a de qi sensation, which is often described as a pressure or achiness feeling. The acupuncture point will be bilateral Quchi, Waiguan, hegu, baxie, Zusanli, Yanglingquan, Sanyinjiao, Taichong, bafeng. Acupuncture needles will be left in place for approximately 30 minutes, and every 10 minutes twisting stainless steel needle to get a de qi."
214400125|NCT05173493|DRUG|Amoxicillin,Furazolidone|Amoxicillin-Furazolidone-containing quadruple group
214400126|NCT05173493|DRUG|Amoxicillin,Levofloxacin|Amoxicillin-Levofloxacin-containing quadruple group
215004632|NCT05177094|DRUG|LY3526318|Administered orally
215004633|NCT05177094|DRUG|Placebo|Administered orally
215004634|NCT01988415|DEVICE|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).
215004635|NCT03852576|DRUG|KSP/QRH dimer|KSP-QRH-E3-IRDye800 (Peptide 919288G)
214400127|NCT05173493|DRUG|Tetracycline,Furazolidone|Tetracycline-Furazolidone-containing quadruple group
214400128|NCT01971307|OTHER|SGE-PsyScan|
214400129|NCT01214564|DRUG|PEP005 (ingenol mebutate) Gel|0.05%
214400130|NCT05874999|OTHER|Supramaximal High-Intensity Interval Training at 60% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 60% of maximum mean power output for 6 seconds (MPO6) with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of maximum aerobic power (MAP) obtained during maximal incremental cardiopulmonary exercise test (CPET) on a stationary bicycle."
214400131|NCT05874999|OTHER|Moderate-Intensity Continuous Training|"MICT is performed against a load of 60% of MAP obtained during a maximal incremental CPET on a stationary bicycle.~Duration MICT: 20 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
214400132|NCT05874999|OTHER|Supramaximal High-Intensity Interval Training at 80% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 80% of MPO6 with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
214400133|NCT03569969|PROCEDURE|device: Tympanoplasty with Membrane Amniotic|amniotic membrane Tympanoplasty
214400134|NCT03569969|PROCEDURE|Tympanoplasty With Autologous Fascia|Autologous Temporalis fascia Tympanoplasty
214400135|NCT05004779|PROCEDURE|human stem cell conditioned media was applied after non-ablative laser therapy|After laser treatment on hypertrophic scars, human stem cell media was applied to one side
214400136|NCT05004779|PROCEDURE|normal saline was applied after non ablative laser therapy|physiological saline was applied to the other side.
214400137|NCT02647918|DRUG|Sotagliflozin|Single dose
214400138|NCT02647918|DRUG|Sotagliflozin|2 single doses
214400139|NCT04089176|DRUG|Carbetocin|carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
214400140|NCT04089176|DRUG|oxytocin|oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
214400141|NCT00125983|DRUG|Lopinavir/ritonavir|
214400142|NCT00125983|DRUG|Ortho Novum 1/35|
214504030|NCT05691842|OTHER|HIIT intervention|Patients will perform a muscle strength training circuit interspersed with resistance training circuit. The strength training circuit will consist of 10 strength exercises and resistance training circuit will consist of walking, jogging and running exercises. Each exercise will be performed for one minute, trying to reach maximum intensities adapted to each individual's condition.
214400143|NCT00125983|DRUG|Ortho Evra|
214400144|NCT03835520|DRUG|Immunotherapeutic Agent|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
214400145|NCT03835520|DRUG|Molecular Target|Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
214400146|NCT05878743|BEHAVIORAL|Safety Planning a recovery-orientated mental health risk management intervention|Developing the skills to manage risks associated with mental health difficulties in ways which increase personal recovery for individuals.
214400147|NCT04816682|DRUG|Silymarin|Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
214400148|NCT02162940|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
214504031|NCT05691842|OTHER|Dual task intervention|Dual task training will consist of the progressive and specific assignment of primary motor tasks and secondary motor or cognitive tasks focused on: i) Primary tasks: static, dynamic balance and gait exercises; ii) Secondary tasks (motor or cognitive): verbal fluency, mathematical calculation, memory, visual-spatial planning, auditory discrimination, fine motor task, motor transport task.
214504032|NCT02955199|BEHAVIORAL|Mothering From the Inside Out (MIO)|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
214504033|NCT02955199|BEHAVIORAL|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
214504034|NCT05603182|DRUG|PRA052|PRA052
214504035|NCT05603182|OTHER|Placebo|Placebo
214400149|NCT02162940|OTHER|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
214400150|NCT04135495|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)
214400151|NCT04135495|DRUG|Ivacaftor|CFTR potentiator
214400152|NCT06021990|DRUG|Clopidogrel Bisulfate 75Mg Tab|Severe COPD patients who meet eligibility criteria will be given Clopidogrel Bisulfate 75 mg Tablet daily, along with standard of care treatment till the completion of the study duration or any side effects that warrants stoppage of the drug
214400153|NCT00440674|DEVICE|CoStar Paclitaxel-eluting coronary stent system|
214400154|NCT00238199|DIETARY_SUPPLEMENT|calcitriol|
214400155|NCT00238199|DRUG|docetaxel|
214400156|NCT01207934|DIETARY_SUPPLEMENT|placebo|saline placebo
214400157|NCT01207934|DRUG|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
214400158|NCT01207934|DRUG|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
214400159|NCT03522428|DIETARY_SUPPLEMENT|vitamin b12|Vitamin B12 has been added to the experimental group of pregnant women, at a dose of 5 μg / 100 days
214400160|NCT00457080|DEVICE|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
214400161|NCT03044093|DRUG|Mifepristone|The group that will get in addition to Misoprostol also Mifepristone
214400162|NCT03044093|DRUG|Placebo|The group that will only get Misoprostol
214400163|NCT03044093|DRUG|Misoprostol|Both groups will get think drug
215004636|NCT01507727|DRUG|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
215095834|NCT06380894|BEHAVIORAL|Active Control|Participants who were assigned to the active control group were provided treatment-as-usual, which included: (1) psychoeducation on MCI, cognitive functioning, and compensatory strategies, and (2) brain training cognitive stimulation booklet which consisted of weekly homework activities focusing on attention, memory, and executive functioning. Control participants were reviewed for 3 sessions monthly to follow up on their progress on the cognitive stimulation activity booklet.
215095835|NCT04787185|RADIATION|Valutation of toxicity|"Observation of toxicity~All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy"
215095836|NCT04860622|DIAGNOSTIC_TEST|Serum thyroid function tests|At the first hospital visit, the blood tests will be made for TSH, FT4, FT3, and beta HCG concentration measurement
215095837|NCT01852383|DRUG|Duloxetine|"Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.~Adverse events: All adverse events and serious adverse events were documented.~The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.~Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial."
215095838|NCT05389189|BEHAVIORAL|Intervention Arm|"The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour)."
214400164|NCT03076658|RADIATION|EOS imaging|The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
214400165|NCT05915871|DRUG|Tegoprazan|Tablet for oral administration
215004637|NCT01507727|DRUG|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
215004638|NCT05804968|OTHER|Digital HIV Self Disclosure Intervention|This project will develop a digital HIV disclosure intervention, drawing from the HEADSUP manual (Evangeli et al., 2020), which consists of four modules, including a HIV disclosure planning component. A SCED will be used to explore HIV disclosure intention, amongst other variables throughout baseline, intervention and follow up phases. Participants will further be asked to complete a participant experiences questionnaire to explore how they found the digital intervention and assess acceptability. This project will recruit a diverse sample of Sub-Saharan Africa adults living with HIV and residing in the U.K.
215095839|NCT00635089|DRUG|reslizumab|
214400166|NCT05915871|DRUG|Bismuth|Capsule for oral administration
214400167|NCT05915871|DRUG|Amoxicilli|Capsule for oral administration
214400168|NCT05915871|DRUG|Clarithromycin|Tablet for oral administration
214400169|NCT00421694|DRUG|Bicalutamide|
214400170|NCT05724212|DIAGNOSTIC_TEST|Interferon gamma release assay (IGRA)|in vitro test
214400171|NCT03897166|DEVICE|Trimodality|Positron Emission Tomography coupled with Computed tomography and immediately followed by Magnetic Resonance Imaging
214400172|NCT05804864|DRUG|KM501|1a: The program evaluated six dose levels, i.e., 0.1, 0.3, 0.6, 1.2, 1.8, 2.4 mg/kg, An accelerated titration was performed in the 0.1 and 0.3 mg/kg dose groups, and then a Bayesian optimal interval design was used to determine MTDS for four subsequent dose levels. Ib: The antitumor activity of KM501 monotherapy in subjects with specific types of tumors that are HER2-positive or express, amplify, or mutate will be evaluated at the RP2D dose level
214400173|NCT01521949|DRUG|Acai Juice Product|2 ounces of Acai Juice Product twice daily.
214400174|NCT00422721|PROCEDURE|realization of a family tree|
214400175|NCT00422721|PROCEDURE|refractometry|
214400176|NCT00422721|PROCEDURE|evaluation of the presence of a nystagmus|
214400177|NCT00422721|PROCEDURE|ocular behavior|
214400178|NCT00422721|PROCEDURE|test of baby vision|
214400179|NCT00422721|PROCEDURE|test of keenness|
214400180|NCT00422721|PROCEDURE|reading test|
214400181|NCT00422721|PROCEDURE|visual field|
214400182|NCT00422721|PROCEDURE|color vision|
214400183|NCT00422721|PROCEDURE|electroretinographical activity|
214400184|NCT00422721|PROCEDURE|biomicroscopical test|
214400185|NCT00422721|PROCEDURE|retinal imaging|
214400186|NCT00422721|PROCEDURE|retinal autofluorescence|
214400187|NCT00422721|PROCEDURE|genotyping|
214400188|NCT06169761|OTHER|Assessment of motor skills of the tongue and others muscles, see below) and risk for sleep apnea|"The following items will be assessed:~1. Risk for sleep apnea, through the STOP-BANG Questionnaire.~2. Anthropometric data: Height, weight, neck circumference, maximal mouth opening and maximal mouth opening with tongue to palate (with the Quick Tongue-Tie Assessment tool).~3. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb in kPa) during 3 sec. of tongue protrusion and elevation.~4. Tongue endurance (i.e., the time to task failure in maintaining a pressure equal to a fixed percentage of Pmax against the IOPI bulb) during tongue protrusion and elevation~5. Tongue mobility restriction measured with the Quick Tongue-Tie Assessment Tool~6. Maximum inspiratory and expiratory pressures measured with MicroRPM in cmH2O~7. Handgrip strength (measured with a JAMAR dynamometer in kg)~Tongue skills measurements will be repeated 2 to 4 weeks after baseline to assess the reliability of these measurements."
215004639|NCT03234452|DIETARY_SUPPLEMENT|Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
215004640|NCT03234452|DIETARY_SUPPLEMENT|Placebo Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
215004641|NCT02565251|DEVICE|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
215004642|NCT02565251|DEVICE|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
215004643|NCT02565251|DEVICE|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
215004644|NCT02773628|DEVICE|Acar'up system|
215095840|NCT03997643|RADIATION|Radiotherapy to all dissected areas|Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
215095841|NCT03997643|RADIATION|Omit radiation to pN0 neck|post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
215095842|NCT01476631|BEHAVIORAL|Walking|"* 7 days prior to baseline participants must wear a blinded pedometer~* At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale."
215095843|NCT02602665|PROCEDURE|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
215095844|NCT02602665|PROCEDURE|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
214400189|NCT03819569|PROCEDURE|Small Renal Mass Biopsy|Subjects will receive a small renal mass biopsy prior to making a treatment decision
214400190|NCT03819569|OTHER|No Small Renal Mass Biopsy|Subjects will not receive a small renal mass biopsy prior to making a treatment decision
214400191|NCT01429961|DRUG|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1\~14
214504036|NCT01532648|DRUG|Budesonide MMX®|Oral tablet taken daily in the morning after breakfast.
214504037|NCT01532648|DRUG|Placebo|Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
214504038|NCT01532648|DRUG|5-ASA|"Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g"
214504039|NCT02929420|DRUG|Xiaoru Sanjie capsules|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
214504040|NCT02929420|DRUG|Xiao Yao pills|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
215004645|NCT02773628|DEVICE|Acar'up placebo system|
215004646|NCT00609505|OTHER|Telemedicine|Telemedicine genetic counseling
215004647|NCT00609505|OTHER|Face-to-Face|Face-to-face genetic counseling
215004648|NCT02375997|OTHER|Palliative care|Early nutrition intervention and psychological intervention
215004649|NCT02617862|PROCEDURE|Examination under anaesthetic (EUA)|The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.
215004650|NCT02617862|DEVICE|RetCam|The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.
215004651|NCT02617862|DEVICE|COSMOS|The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
215004652|NCT01794975|DRUG|Ketamine|
215004653|NCT01794975|DRUG|Atomoxetine|
215004654|NCT01794975|OTHER|Cold pressor test|
214400192|NCT04525274|DRUG|normal saline|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of 40 ml bupivacaine 0.25% + 5 ml normal saline will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
214504041|NCT03637036|OTHER|Communication intervention|The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
214504042|NCT00479375|PROCEDURE|Adding Human Papillomavirus testing to organised cervical screening|
215004655|NCT01794975|DRUG|Placebo|
215004656|NCT02952677|BEHAVIORAL|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
215004657|NCT02952677|BEHAVIORAL|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
215004658|NCT02952677|OTHER|Control|Participants received usual care
215095845|NCT02175914|DRUG|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
215095846|NCT03525132|PROCEDURE|Laser Doppler Velocimetry + Optic Adaptative Camera|Fluxometry measure while subject is sitting in front of the optic adaptative camera
215095847|NCT02472613|DEVICE|acupuncture|"Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
215004659|NCT01565551|OTHER|N/A (Observational Study)|No Interventions: Observational Study
215004660|NCT04987905|OTHER|Mindfulness|"In the study, for 60 minutes once a week for 8 weeks MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice)."
215004661|NCT05527522|COMBINATION_PRODUCT|nutritional and educational intervention|individualized diet plus educational intervention with/without nutritional supplements
215004662|NCT05527522|OTHER|standard practice|The patients received the usual treatment and clinical practice
215004663|NCT01118923|DIETARY_SUPPLEMENT|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
215004664|NCT01118923|DIETARY_SUPPLEMENT|Placebo|3 placebo-tablets daily for 12 weeks
215004665|NCT03033043|DEVICE|Relay Pro Stent-Graft|Endovascular treatment of an aortic dissection
215095848|NCT02472613|DRUG|placebo|Placebo was given for 12 consecutive weeks.
215095849|NCT02472613|DEVICE|sham-acupoint acupuncture|"Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
215095850|NCT02472613|DRUG|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
215004666|NCT02057991|OTHER|educational intervention|Watch an educational video
215004667|NCT02057991|PROCEDURE|CAM exercise therapy|Watch a mindfulness exercise video
215004668|NCT02057991|OTHER|caregiver-related intervention or procedure|Watch mindfulness exercise video and/or educational video
215095851|NCT03704610|DRUG|Infliximab|An initial period with 2 injections with infliximab allowing the determination of the primary criteria Then an extension with infliximab with 3 supplementary perfusions
215095852|NCT03704610|DRUG|Placebo|An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions
215095853|NCT00444067|DEVICE|Spinal Sealant|Spinal Sealant System
214400193|NCT04525274|DRUG|dexmedetomidine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
215004669|NCT02057991|OTHER|questionnaire administration|Ancillary studies
215095854|NCT00444067|OTHER|Standard of Care|Standard of Care
215095855|NCT06050798|DIAGNOSTIC_TEST|Von willebrand antigen|Von willebrand antigen change and hematological disorder in patients with angiodysplasia
214504043|NCT03983759|DRUG|sintilimab maintenance|the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
215004670|NCT02057991|OTHER|laboratory biomarker analysis|Correlative studies
214504044|NCT02132039|OTHER|12-step sitting Tai Chi Chuan|The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
215004671|NCT04379180|DRUG|Bosentan Tablets|2mg/kg, bid
215004672|NCT04379180|DRUG|Sildenafil Tablet|1mg/kg, q6h/q8h
215004673|NCT04379180|DRUG|Tadalafil Tablets|1mg/kg, qd
215004674|NCT01620346|PROCEDURE|Intracytoplasmic sperm injection (ICSI)|ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
215004675|NCT01620346|PROCEDURE|Intracytoplasmic morphologically selected sperm injection|IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
215095856|NCT01152177|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
215095857|NCT05135962|DEVICE|orthodontic - rapid maxillary expansion|Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.
215004676|NCT01422447|OTHER|regular intervention|the subjects in the control group live in the used model
215004677|NCT01422447|OTHER|community intervention|in addition to regular intervention, those subjects in the intervention group will be given education intervention.
215004678|NCT05679310|DIETARY_SUPPLEMENT|Hydroxytyrosol/Essential oils|A dietary supplement containing 10 mg of hydroxytyrosol, synthesised using genetically modified Escherichia coli strains and equal amounts (8.33 μL) of essential oils from oregano vulgaris, sage officinalis and crithmum maritimum.
215004679|NCT00924482|DEVICE|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery|Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
215004680|NCT02821559|DRUG|TOMOX|
215004681|NCT02821559|DRUG|Bevacizumab|Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.
215004682|NCT01508897|DRUG|liraglutide|Single dose administered as subcutaneous injection
215004683|NCT01508897|DRUG|liraglutide|Single dose administered as subcutaneous injection
215004684|NCT00226733|BEHAVIORAL|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
215004685|NCT00226733|BEHAVIORAL|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
215004686|NCT04508985|OTHER|Temporarily holding the RAAS inhibitor [intervention]|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
215004687|NCT04508985|OTHER|RAAS inhibitor [continued standard of care]|No intervention, Continuation RAAS inhibitor \[continued standard of care\].
215004688|NCT00515190|DRUG|S-1,oxaliplatin|"Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles."
215004689|NCT02874131|BEHAVIORAL|Behavioral Activation|Behavioral activation
214400194|NCT04525274|DRUG|Ketamine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
214400195|NCT03084952|DRUG|18-Methoxycoronaridine|Drug under evaluation for leishmaniasis treatment
214400196|NCT03084952|DRUG|Glucantime|Leishmaniasis standard drug in Brazil
214400197|NCT02958761|BIOLOGICAL|intraarticular injections of platelet lysate|
215004690|NCT02874131|BEHAVIORAL|Cognitive Processing Therapy|Cognitive processing therapy
214400198|NCT02958761|DRUG|hyaluronic acid|intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
214400199|NCT05645042|BEHAVIORAL|Transcendental Meditation (TM)|During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.
214400200|NCT05645042|BEHAVIORAL|Present Centered Therapy (PCT)|PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.
214400201|NCT00933062|DRUG|SRT2104|2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
214400202|NCT00933062|DRUG|Placebo|Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
215004691|NCT06478628|BEHAVIORAL|Inpatient rehabilitation|Inpatient multimodal rehabilitation in specialist health care
215004692|NCT06478628|BEHAVIORAL|Outpatient day rehabilitation|Multimodal rehabilitation in specialist health care with program lasting whole work days
215004693|NCT02785705|BIOLOGICAL|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
215004694|NCT00243061|DRUG|cediranib maleate|Given orally
215004695|NCT00875667|DRUG|Lenalidomide|"For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but \< 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity."
215004696|NCT00875667|DRUG|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
215004697|NCT00915187|DRUG|CCS/C|Adjuvant to influenza vaccine
215004698|NCT00915187|BIOLOGICAL|Influenza Vaccine|Influenza vaccine
215004699|NCT00756834|DEVICE|Screening|The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
215004700|NCT02471742|PROCEDURE|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
215004701|NCT02471742|PROCEDURE|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
215004702|NCT00005790|OTHER|laboratory biomarker analysis|
214400203|NCT03566589|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
214400204|NCT00180687|DRUG|Nebulised Bupivacaine intraperitoneally|Nebulised Marcaine (Bupivacaine)
214400205|NCT00180687|DRUG|Normal Saline|Nebulised Normal Saline
214400206|NCT00180687|DRUG|Injected Bupivacaine intraperitoneally|Injected Marcaine directly into the peritoneal cavity
214400207|NCT00180687|OTHER|No Intraperitoneal Therapeutics|No Intraperitoneal Therapeutics given
214400208|NCT00538408|PROCEDURE|Whole body magnetic resonance angiography (dotarem)|
214400209|NCT00538408|DEVICE|Whole body magnetic resonance angiography (vasovist)|
214504045|NCT02132039|OTHER|Control|The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
215004703|NCT00005790|PROCEDURE|biopsy|
215004704|NCT00005790|PROCEDURE|magnetic resonance imaging|
215004705|NCT00005790|RADIATION|gadopentetate dimeglumine|
215004706|NCT05455866|DEVICE|central venous catheter|collection and descriptionof central venous catheter-related complications
214400210|NCT02270073|BEHAVIORAL|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 25 sessions, while on average every fourth is supervized by an CBT expert therapist.
214400211|NCT04394819|OTHER|electromyography-triggered electrical stimulation|All treatments were planned as 2 sessions per week, for a total of 10 sessions for 5 weeks. For EMG-trigger-ES application, dual-channel Nu-Tek® brand, Maxi plus 2 Model EMG-trigger-BF-ES Device in our clinic was planned to be used. With EMG-triggered-ES application, while the patient is in a sitting position, shoulder adduction, and the elbow is 90 degrees of flexion and pronation, the patient will extend to the ball of 5 cm in diameter, which is placed as far as the distance between the acromion and the 3rd toe, and then the finger-wrist active extension will be stimulated and then It was planned to apply the ball to be grasped. One of the two 5x5 cm superficial square electrodes of the device was planned to be placed on the extensor carpi radialis and extensor digitorum Communis and the other 2 cm distal.
214504046|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
214400212|NCT03847168|DRUG|KN026|Patient will be intravenously administrated with one dose of KN026 every week or every other week.
214400213|NCT02055911|DRUG|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
214400214|NCT04990440|DRUG|Bermekimab|Participants will receive bermekimab IV.
214400215|NCT04990440|DRUG|Placebo|Participants will receive placebo IV.
215004707|NCT02196545|BEHAVIORAL|Exercise|
215004708|NCT04241523|DRUG|Lenvatinib 4 mg Oral|"Planned doses of 8 mg of lenvatinib per day for patients with body weight \<60 kg, and 12 mg for those with body weight ≥60 kg.~In case of treatment-related adverse effects, interruption or reduction is allowed."
214504047|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
214504048|NCT02753998|PROCEDURE|Conventional angioplasty|
215004709|NCT00894647|DRUG|imiquimod cream|Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
214504049|NCT00031720|DIETARY_SUPPLEMENT|soy protein|Given orally
214504050|NCT00031720|DIETARY_SUPPLEMENT|isoflavones|Given orally
214504051|NCT00031720|DRUG|Tamoxifen|
214504052|NCT00031720|OTHER|Placebo|Oral
214504053|NCT05532501|DRUG|Oral Oxytocin|Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
214504054|NCT05532501|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
214504055|NCT05532501|DRUG|Oral placebo|Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
214504056|NCT05532501|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
214504057|NCT05566249|DEVICE|ArtiSential|Articulating laparoscopic instrument
214504058|NCT01990508|BEHAVIORAL|Targeted beverage education and financial incentives|
214504059|NCT01990508|BEHAVIORAL|Traffic-light labeling of all beverages in store|All beverages in the supermarket will be labeled as red, yellow, or green
214504060|NCT00047125|RADIATION|radiation therapy|
214504061|NCT00729794|DRUG|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
214504062|NCT00729794|DRUG|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
215004710|NCT00894647|DRUG|placebo cream|cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
215004711|NCT03687255|DRUG|cefepime/AAI101 combination|cefepime 2 g / AAI101 500 mg
215004712|NCT03687255|DRUG|Piperacillin/tazobactam|piperacillin 4 GM / tazobactam 500 MG
215004713|NCT00412451|DRUG|ocriplasmin|Intravitreal injection, single administration
215004714|NCT00412451|OTHER|Sham injection|Sham intravitreal injection
215004715|NCT02985281|DRUG|Sofosbuvir Oral Product|direct acting antiviral drug for HCV infection
215004716|NCT02985281|DRUG|Ribavirin|antiviral drug for HCV infection
215004717|NCT05985551|OTHER|SLND or TAD by the magnetic technique (SPIO)|All patients will receive Radioisotope according to standard of care. They will also receive SPIO in a timeframe of clinical convenience, depending on whether primary response is planned by means of MRI. For patients that are ycN0, SLND or TAD will be performed. For those that convert from cN1 to ycN0, the index lymph node will be marked with a paramagnetic marker. Axillary surgery will be undertaken with the magnetic technique and each retrieved lymph node will be controlled for radiation. Upon the completion of the procedure, a background control will be performed with the radioactive signal as guide, to ensure standard of care best practice. Any palpable lymph nodes that are not sentinels with either tracer may be removed at surgeon discretion but will be reported seperately.
215004718|NCT03308643|DRUG|Oxytocin|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
215004719|NCT03308643|OTHER|saline|Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
215004720|NCT04285684|DRUG|ketamine in lactation|2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals
215004721|NCT05804500|BEHAVIORAL|Cardiac Telerehabilitation (CTR) via the RecoveryPlus platform|RecoveryPlus has developed an innovative CTR platform for patients with CVD that leverages: (1) video conferencing functionality (Zoom) for synchronous telehealth sessions of CR instruction for patients and licensed exercise physiologists (EPs), (2) a patient-facing mobile application delivering asynchronous exercise videos, and (3) a health care provider web portal for clinicians and EPs. The RecoveryPlus platform includes the ability for EPs and clinicians to monitor patient clinical data (e.g., heart rate) and input (e.g., rating of difficulty for individual exercises) and tailor individual patient regimens regularly for increased safety and optimal outcomes.
215004722|NCT01139372|OTHER|FID 115958D (Lubricant Eye Drop)|1 drop in each eye at least twice daily
215004723|NCT04389138|OTHER|Physiotherapy Intervention|Physiotherapy intervention will include an assessment to identify individual areas that physiotherapy should target. Intervention will be based on the core areas recommended by the European Physiotherapy Guideline for Parkinson's Disease: physical capacity (muscle power, tone, joint range of movement, exercise tolerance and pain), transfers, manual dexterity, balance and gait. Posture is incorporated as part of these 5 core areas. The intervention will be delivered over 4 visits.
215004724|NCT03873688|OTHER|expiratory muscle training|The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
215004725|NCT00748930|OTHER|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
215004726|NCT04834115|DRUG|Ivermectin Tablets|Oral ivermectin at a one time dose
215004727|NCT04834115|OTHER|Placebo|Oral placebo at a one time dose
214693856|NCT06317233|BEHAVIORAL|Chronic Pelvic Pain Treatment Guide|The treatment guide includes mobile and web-based resources and applications specifically chosen to empower patients with information and to promote self-efficacy. The treatment guide is designed to be easily understood, visually appealing, and largely translatable from institution to institution. Patients using the treatment guide will be followed with a clearly defined follow up schedule, which includes touch points between appointments to aid with resource navigation.
215004728|NCT02365129|OTHER|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
215004729|NCT06444100|PROCEDURE|Impact of structural training on child abuse|"A focus group discussion to delve into teachers' perceptions of child abuse. Based on the findings, the training module will be modified as need-based.~Phase II: Randomly selected samples will be invited, with the researcher explaining the study procedures and obtaining verbal and written consent from teachers and assent from children. A dedicated room will be arranged for data collection, and participants will be instructed on how to respond to child abuse questions on tablets.~Phase-III A pretest will be conducted to assess the existing knowledge level and attitude of the teachers toward child abuse. A 5-hour training session, led by an expert team, will follow the pretest questionnaire administration to all participants. Teachers will also be educated on how to report instances of child abuse. A post-test will be administered using the same questionnaires two weeks after the training."
215004730|NCT04034680|OTHER|TIME|The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
215004731|NCT04034680|OTHER|Education-only intervention|Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
215004732|NCT04145934|BEHAVIORAL|ADSTEP|ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.
215004733|NCT05423262|BIOLOGICAL|TRK-950|5 or 10 mg/kg administered intravenously over 60 minutes (weekly)
215004734|NCT05423262|BIOLOGICAL|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
215004735|NCT05423262|BIOLOGICAL|TRK-950|20 mg/kg administered intravenously over 60 minutes (bi-weekly)
215004736|NCT05423262|DRUG|Nivolumab|240 mg administered intravenously over 30 minutes (bi-weekly)
215004737|NCT00823888|DEVICE|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
215004738|NCT00195429|DRUG|Tacrolimus|
215004739|NCT00195429|DRUG|Sirolimus|
214693857|NCT06553677|PROCEDURE|Tunneled coronal advanced flap with connective tissue graft|Tunneled coronal advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites.
214400216|NCT03352050|DIETARY_SUPPLEMENT|mushroom|
215004740|NCT00195429|DRUG|prednisone|
214400217|NCT03352050|OTHER|ground beef|
214400218|NCT04537351|BIOLOGICAL|CYP-001|The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.
214400219|NCT03712098|DRUG|Liraglutide|Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
214400220|NCT03712098|DRUG|Placebo|The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
214400221|NCT03712098|BEHAVIORAL|Smoking Cessation Counseling|All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
214400222|NCT02724761|DRUG|Racemic Epinephrine|1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery
214400223|NCT02724761|DRUG|Placebo (for racemic epinephrine)|0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
214400224|NCT00498277|PROCEDURE|Magnetic Resonance Imaging|One MRI sequence done to look for relative fat, and a second extra MRI sequence done to look for the diffusion.
214400225|NCT04524104|BEHAVIORAL|Lumen Treatment|the virtual AI agent, Lumen, via an iPad-based application. Each participant will receive a locked, encrypted study iPad installed with Lumen. They will complete 8 problem solving therapy (PST) sessions beginning with 4 weekly and then 4 biweekly intervals over 12 weeks on their assigned iPad.
214400226|NCT02790762|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
214400227|NCT02303340|RADIATION|Dual Energy X-ray Absorptiometry|
214400228|NCT00994136|DRUG|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
214400229|NCT05284188|PROCEDURE|Open or arthroscopic Modified Broström operation|Patients with CLAI and GJL were randomly allocated to accept the open or arthroscopic Modified Broström operation.
214400230|NCT01612364|PROCEDURE|thoracic sympathetic block|Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
214688181|NCT06929715|OTHER|Placebo Intervention - First Aid (Excluding Basic CPR)|In the control arm, participants receive a structured first aid educational program that intentionally excludes any training on the first link in the chain of survival. This intervention focuses on general first aid skills-such as wound care, management of minor injuries, and other non-cardiac emergency procedures-ensuring that no content related to recognizing a cardiac emergency or activating the emergency response system is provided. Delivered in a classroom setting by qualified personnel, the program is designed to mirror the overall structure, duration, and engagement level of the CPR intervention without overlapping its core content. Expert validation has been obtained to confirm that the curriculum remains neutral and strictly adheres to general first aid, thereby serving as a robust comparator to isolate the specific effects of CPR training in young schoolchildren.
214688182|NCT04902703|DRUG|Sargramostim|Sargramostim is a granulocyte macrophage colony stimulating factor that will be administered at a dose of 250 mcg/m2 per day subcutaneously, 5 days/week, for 24 weeks
215004741|NCT03713788|OTHER|Cold pressor test|Participants placed their non-dominant hand into cold water for 2 minutes
214400231|NCT00724061|BIOLOGICAL|Pegylated interferon α-2b|PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
214400232|NCT00724061|OTHER|Psoralens with ultraviolet light A|Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
214400233|NCT00724061|OTHER|Narrowband-ultraviolet light B|The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
214400234|NCT01342653|OTHER|Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC|see Design
214400235|NCT00513903|BEHAVIORAL|Minimal intervention|Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
214400236|NCT00513903|BEHAVIORAL|Enhanced Intervention|Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
215004742|NCT01535066|PROCEDURE|acupuncture therapy|Receive acupuncture
215004743|NCT01535066|PROCEDURE|sham acupuncture|Receive sham acupuncture
215004744|NCT05016050|DEVICE|HPDT-DA-013|Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).
215004745|NCT00559715|DRUG|bevacizumab|1.25 mg intravitreally monthly/on demand
215004746|NCT00559715|DRUG|ranibizumab|0.5 mg intravitreally monthly/on demand
215004747|NCT00477217|DRUG|Zoledronic acid|
215004748|NCT00373711|DRUG|Iodine-124|2 mCi, oral
215004749|NCT00373711|DRUG|Iodine-123|2 mCi, oral
215004750|NCT00373711|DRUG|F-18 FDG|10-15 mCi, iv
215004751|NCT00351104|DRUG|Ketoprofen Topical Patch 20%|
214400237|NCT02310490|DEVICE|DA-13-007 right with left side Sculptra left side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
214400238|NCT02310490|DEVICE|DA-13-007 left with left side Sculptra right side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
215004752|NCT03313765|BEHAVIORAL|Motivational interviewing (MI)|Brief MI intervention
215004753|NCT03313765|OTHER|Standard-of-care|Standard-of-care education and counseling
215004754|NCT01495728|PROCEDURE|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
215004755|NCT01495728|PROCEDURE|Sham Manipulation|Mid and Upper Thoracic Spine
215004756|NCT04775134|DIAGNOSTIC_TEST|Lung biopsy|Biopsy of residuary material from a medically indicated pulmonary resection
215004757|NCT00156130|RADIATION|Conventional radiotherapy schedule|50 Gy in 25 fractions over 35 days
214400239|NCT02783482|BIOLOGICAL|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
214400240|NCT01536782|PROCEDURE|Bolus|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
214400241|NCT01536782|PROCEDURE|Gravity|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
214400242|NCT01536782|DEVICE|Pump|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
214400243|NCT02539758|OTHER|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
214400244|NCT02539758|DEVICE|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
214400245|NCT02539758|DEVICE|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
215004758|NCT00156130|RADIATION|Accelarated radiotherapy schedule|42.5 Gy in 16 fractions over 22 days
215004759|NCT05219344|PROCEDURE|Tissue flossing|After the standardized warm-up, participants will be instructed to stand still with their legs shoulder-width apart. The floss band (1.3 mm thick, 50 mm wide, 2 meters long, and strength level 3), consisting of a thick elastic latex band (COMPRE Floss, Sanctband), will be applied bilaterally around the distal third of the thigh. The applied pressure will be individualized by thigh circumferences, whereas low target pressure was chosen for this study, showing potential to elicit the most beneficial outcomes following flossing. The pressure will be monitored by the PicoPress device, which was placed at the middle distance of the application of the floss band to ensure that the entire surface of the pressure sensors was always completely covered. The flossing will be applied for 2 minutes with 2 minutes rest between sets. During flossing application subjects will be instructed to conduct 10 deep squats followed by 15 repetitions of knee extensions without added weight.
215004760|NCT02965131|PROCEDURE|Temporary portocaval shunt|The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
215004761|NCT04956965|RADIATION|Cardiac electro-mapping|Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
215004762|NCT05811975|DRUG|KSX01-TCRT injection|individualization TCR-T cell injection
215004763|NCT02541903|DRUG|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
215004764|NCT04795323|DEVICE|TARA v3.1, only non-pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
215029376|NCT04477616|DRUG|Day 3 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
215029377|NCT01907282|BEHAVIORAL|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
215095858|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with leaf expander|Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.
215095859|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with self leaf expander|Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
215095860|NCT00196053|DEVICE|Archimedes Constant Flow Implantable Pump|
215095861|NCT00025623|DRUG|carboplatin|
215095862|NCT00025623|DRUG|cyclophosphamide|
215095863|NCT00025623|DRUG|doxorubicin hydrochloride|
215095864|NCT00025623|DRUG|etoposide|
215095865|NCT00025623|DRUG|vincristine sulfate|
215095866|NCT00025623|PROCEDURE|conventional surgery|
215095867|NCT05428813|BEHAVIORAL|art therapy techniques|Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
215095868|NCT01300455|DRUG|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
215095869|NCT01300455|DRUG|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
215095870|NCT05052593|OTHER|compressive myofascial release|Patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. With pressure directed from distal to proximal.
215095871|NCT05052593|OTHER|conventional treatment group|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
215095872|NCT01420666|DRUG|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
215095873|NCT01420666|DRUG|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
215095874|NCT01420666|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
215095875|NCT01420666|DRUG|Placebo|placebo, three tablets four times a day, orally, with food
215095876|NCT05986903|DRUG|Tumor necrosis factor (TNF)-alpha inhibitors|"Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and \> 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml."
215095877|NCT05771961|DIAGNOSTIC_TEST|coronary pressure/temperature sensor-tipped guidewire|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire will be first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
215095878|NCT05771961|DIAGNOSTIC_TEST|Angiography-derived index of microcirculatory resistance (IMRangio)|Angiography-derived index of microcirculatory resistance (IMRangio) will be calculated by an anticipated software
215095879|NCT00262990|DRUG|EPO906 (Patupilone)|
215095880|NCT00262990|DRUG|doxorubicin|
215004765|NCT04795323|DEVICE|TARA v3.2, both non-pharmacological and pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
215004766|NCT05807503|DRUG|Cerebrolysin|Cerebrolysin administration in short period of time after TBI
215004767|NCT06447896|DEVICE|Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000)|"Cardiovascular autonomic reflex tests (CARTs) and heart rate variability analysis (HRV) are conducted with Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000). CARTs include five standardized tests, which are heart rate response to lying-to-standing, Valsalva maneuver, deep breathing, and blood pressure response to lying-to-standing and sustained isometric handgrip. These series of movements act as standardized stimuli to trigger hemodynamic changes in the body, altering vagal and sympathetic activity through mechanisms such as the baroreflex, thereby producing changes in heart rate and blood pressure. The sensor-monitoring interactive design of the device ensures the standardization of these maneuvers."
214400246|NCT06204523|DIAGNOSTIC_TEST|investigated biomarkers regarding the efficacy of first-line chemotherapy|The present study was designed to generate solid evidence on the predictivity of the investigated biomarkers regarding the efficacy of first-line chemotherapy in patients with GC
215004768|NCT06447896|DIAGNOSTIC_TEST|Conventional method of CARTs|Conventional method are conduced using blood pressure kit with manual sphygmomanometer and ECG machine. Conventional method and the investigated device are used simultaneously to record electrocardiograms. Conventional blood pressure taking are carried out in sequence with the investigated device. CARTs results from the conventional method are used as control.
215004769|NCT06447896|DEVICE|Ambulatory holter station Model i12 plus|Model i12 plus (manufactured by RENCARE) is an ambulatory holter station, which was approved by the Center for Medical Device Evaluation (CMDE), China National Medical Products Association (NMPA). It can analyze electrocardiogram and generate HRV indices, which include SDNN, RMSSD, NN50, pNN50, triangular index, average RR, deceleration capacity (DC), deceleration runs (DRs), VLF, LF, HF, LF/HF, and total power. Model i12 plus is used to analyzed the same ECG signals as the investigated device.
215004770|NCT04783948|OTHER|Brace Treatment|Compliance to brace compression used for the correction of pectus carinatum will be evaluated.
215004771|NCT03003689|PROCEDURE|Scaling and Root Planing|Standard of care scaling and root planing using hand instruments and ultrasonic scaler
215004772|NCT03003689|DEVICE|Er:YAG Laser|Er:YAG laser as an adjunct therapy to standard of care scaling and root planing using hand instruments and ultrasonic
215004773|NCT02271802|DIETARY_SUPPLEMENT|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
215004774|NCT02271802|DIETARY_SUPPLEMENT|NaCl|
215004775|NCT02079870|DRUG|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
215004776|NCT02079870|DRUG|placebo|Solution for subcutaneous (s.c. - under the skin) injection
215004777|NCT00380523|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
215004778|NCT01815619|OTHER|on-site specimen evaluation|The specimen will be evaluated on-site by a cytopathologist during the procedure to render a diagnosis
214400247|NCT02537444|DRUG|Acalabrutinib|
214400248|NCT02537444|DRUG|acalabrutinib and pembrolizumab combination|
215004779|NCT01815619|OTHER|off-site specimen evaluation|The specimen will be evaluated off-site by a cytopathologist
215004780|NCT01186406|DRUG|Gliadel|Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
215004781|NCT01186406|RADIATION|Radiation Therapy|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.
215004782|NCT01186406|DRUG|Avastin|"Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.~Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days."
215004783|NCT01186406|DRUG|Temodar|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
215004784|NCT04077606|OTHER|ceramo-metallic crown prepartion|tooth will be prepared to receive ceramo-metallic crowns
214400249|NCT01686269|PROCEDURE|blood collecting|
214400250|NCT04798703|DRUG|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase) followed by maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months in patients who achieved a complete response (CR) after the 12 weekly instillations.
214400251|NCT05168644|DRUG|Niclosamide Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 0.25 mg or 1 mg of Niclosamide Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
214504063|NCT01475266|DRUG|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
214400252|NCT05168644|DRUG|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
214400253|NCT04808869|OTHER|Exercise|Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
214400254|NCT03434535|DEVICE|Technology Intervention|A combination of existing technology and a new app developed by InHealth Measurement Corp to (1) remotely monitor a participant's activity level and weight and (2) remotely provide updates to the participants regarding their progress towards the goals established in the Prostate Cancer Foundation Health and Wellness guidelines.
214400255|NCT04802863|DRUG|XNW4107, Imipenem/Cilastatin|Five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin
214504064|NCT01475266|DRUG|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
214400256|NCT03553862|BEHAVIORAL|collaborative care|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.nurses and dietitians as well as a pharmacist.
215004785|NCT04077606|OTHER|full anatomical monolithic zirconia crown|tooth will be prepared to receive monolithic zirconia crowns
215004786|NCT04116047|DRUG|Cisplatin|
215004787|NCT04116047|DRUG|Durvalumab|
214400257|NCT00444717|DRUG|pitavastatin|Pitavastatin (2mg/day) was administered for 12 weeks
215004788|NCT04116047|PROCEDURE|Radiotherapy|
214400258|NCT00792129|DEVICE|The Atavi System|"The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used."
214400259|NCT03904082|PROCEDURE|Erector Spinae Plane block ( Group ı)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
214400260|NCT03904082|PROCEDURE|Serratus Anterior Plane block ( Group ıı)|SAP Block will perform preoperative to all patients in SAP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
215004789|NCT02357433|DEVICE|High Doses CPFA|
215004790|NCT02723422|PROCEDURE|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
215004791|NCT02723422|PROCEDURE|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
215004792|NCT00741949|DRUG|Propofol|Sedation in TCI with propofol
215004793|NCT00741949|DRUG|Placebo|Isotonic saline solution infusion
214400261|NCT03904082|PROCEDURE|Control Group (GROUPIII)|Control group will receive no intervetion. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
214400262|NCT06392516|DRUG|Ketoacid|250 ml ketoacid two hours before the hemodialysis session ended
214400263|NCT01537354|DRUG|Curosurf®|Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
215004794|NCT02451319|PROCEDURE|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
215004795|NCT01275027|DIETARY_SUPPLEMENT|Nutralin|7 capsules taken 15 minutes before each of the three main meals of the day
215004796|NCT01344200|DRUG|Celecoxib|In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
215004797|NCT01344200|DRUG|Placebo|In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
215004798|NCT01687933|DEVICE|three-dimensional glasses(manufactor Vuzix,wrap 920)|The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.
214400264|NCT01537354|DRUG|Survanta®|Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
214400265|NCT04368195|PROCEDURE|Erector spinae block|Erector Spinae Plane Block (ESPB) - first recently described for the treatment of thoracic neuropathic pain, is a peri-paravertebral regional anesthesia technique that has since been reported as an effective technique for prevention of postoperative pain in various surgeries (10-12). In ESPB, local anesthetic is reported to be administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces.
214400266|NCT03150680|GENETIC|SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins|Genotyping will be carried out by Next-Generation Sequencing (NGS)
214400267|NCT00980707|DRUG|Inhaled corticosteroid (fluticasone)|inhaled fluticasone 220 ug/bid
214400268|NCT00324532|DRUG|ProBactrix|
215004799|NCT01687933|OTHER|usual care|Women in Control group did not use the glasses.
215004800|NCT04307563|BEHAVIORAL|Mindfulness session|1.5 hour weekly session with health educator
215004801|NCT03033836|DRUG|ARV treatment|Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
215004802|NCT03821532|OTHER|Constipation Action Plan|Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
215004803|NCT02691663|DIETARY_SUPPLEMENT|Oral bicarbonate supplementation|
215004804|NCT02691663|DIETARY_SUPPLEMENT|Placebo|
215004805|NCT06363500|OTHER|non applicable|Only blood sample collection
215004806|NCT00111332|BEHAVIORAL|Progressive resistance and aerobic training|
215004807|NCT02960685|PROCEDURE|Echocardiography|
214400269|NCT04816994|DRUG|Single-dose of cannabis oil|Single-dose of cannabis oil in order to treat acute radicular pain
214400270|NCT04816994|DRUG|Control|Giving a sub-linguistic olive oil that is similar in appearance and taste to cannabis oil
214400271|NCT01237678|DRUG|IMGN901|Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
215004808|NCT05886023|DIETARY_SUPPLEMENT|High nitrate vegetables|Vegetable burger containing high nitrate vegetables
214400272|NCT01237678|DRUG|Carboplatin and Etoposide|Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
215004809|NCT05886023|DIETARY_SUPPLEMENT|Low nitrate vegetables|Vegetable burger containing to low nitrate vegetables
215004810|NCT03142750|DEVICE|Gastrostomy tube dressing|Two types of dressings to secure gastrostomy tube in children
215004811|NCT04925934|DRUG|VIB7734|VIB7734
214400273|NCT05728983|OTHER|Sleep levels|Sleep levels are what the experimenter prescribes to participants in the study.
214400274|NCT03040193|DRUG|Lignocaine Nebulization|4% Lignocaine delivered via Nebulization
214400275|NCT03040193|DRUG|Saline Nebulization|Normal Saline Delivered via Nebulization
214400276|NCT03404869|DRUG|ORL-1M - D-mannose|Oral ORL-1M
215004812|NCT04925934|OTHER|Placebo|Placebo
215004813|NCT04094389|OTHER|Orthotic continuous wear group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
215004814|NCT04094389|OTHER|Orthotic wear during waking hours only group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
214400277|NCT01723826|DRUG|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
215004815|NCT04094389|OTHER|Orthotic wear only while sleeping group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~In the night-wear group, participants will be told to wear their orthosis only at night. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated"
214400278|NCT05455944|DRUG|Pregabalin 150mg|Two capsules of pregabalin is administered orally to patients
214400279|NCT05455944|DRUG|Placebo|Two identical placebo capsules is administered orally to patients
214400280|NCT04184024|OTHER|Massage|"Soft tissue massage known as Swedish massage technique was applied to the neck area for 20 minutes. This massage was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist."
214400281|NCT04184024|OTHER|Kinesio tape|Patients were taped according to the Kenzo Kase's Kinesio Taping Method by an experienced physical therapist. The application was carried out in a relaxed sitting position. Y banding with extensor muscles on the back of the neck with muscle technique, I banding with the upper trapezius with muscle technique and I banding with ligament technique to the middle region of the neck were performed.
214400282|NCT04184024|OTHER|Neck stabilization exercise|Neck stabilization exercise was performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program started with postural training and then the cervical bracing technique with the activation of deep neck flexors for NSE was performed. The patients were asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises were increased weekly. It was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.
214400283|NCT05018962|DEVICE|Cutting balloon followed by paclitaxel coated balloon|Cutting balloon followed by paclitaxel coated balloon
214400284|NCT02567474|BEHAVIORAL|5 A model|self management program based on 5A model
214400285|NCT03939221|BEHAVIORAL|Infrared Lamp and Acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6 and ST36 for one minutes) for our patient for the cold limbs, pain control and constipation problems.
214400286|NCT02237378|RADIATION|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
214400287|NCT04919681|OTHER|Stretch exercises|The intervention comprises of six weeks daily bi-lateral static stretching of the knee flexors. Stretches are performed seated on the ground. The participant sits upright on the floor with one leg straight. The sole of the other foot should be placed on the inside of the outstretched leg. The participant leans slightly forward, trying to touch their toes while maintaining full knee extension. Stretching is performed to the point of discomfort, and each stretch is held for 30-seconds for three repetitions.
214400288|NCT04962893|BIOLOGICAL|SARS-CoV-2 VLP Vaccine-Wuhan|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
214400289|NCT04962893|BIOLOGICAL|SARS-CoV-2 VLP Vaccine-Alpha (British) variant|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
214400290|NCT04962893|BIOLOGICAL|SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants
214400291|NCT04994574|DRUG|tiotropium/olodaterol|From Visit 2(Baseline), test subjects will be use tiotropium/olodaterol inhaler once a day for 4 weeks. After that, visit the hospital at 4 weeks to receive examination and terminate participation.
214400292|NCT05531903|DEVICE|Description of Slow pathway signals to facilitate ablation|3D endocardial mapping in order to identify slow pathway signals and abolish or modificate them after radiofrequency ablation
215004816|NCT03158688|DRUG|Dexamethasone|Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
214400293|NCT03369288|DIAGNOSTIC_TEST|PET MRI|18F-fluoride PET-MRI
214400294|NCT00191048|DRUG|Atomoxetine|
215004817|NCT03158688|DRUG|Daratumumab|Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
214400295|NCT05968521|BEHAVIORAL|Cardiac Rehabilitation (CR): Experimental|CR will consist of six sessions lasting 90 minutes of a structured exercise programme, educational and lifestyle modules, and a psychological component. Sessions include group discussions, experiential learning and homework tasks that participants are asked to complete between sessions. Participants in this treatment arm will also receive routine clinical outpatient management alongside CR.
214400296|NCT05968521|BEHAVIORAL|Treatment as usual: Control|Treatment as usual will include routine clinical outpatient management.
214400297|NCT01699893|OTHER|unique arm|blood, nasal swab, skin biopsy, stool samples
214400298|NCT01272011|OTHER|Intermittent Hypoxia|Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
214400299|NCT01272011|OTHER|Locomotor Training|Individuals received 10 days of locomotor training, intense walking training on a treadmill with body weight support. Manual assistance was provided at the legs to optimize stepping patterns.
214400300|NCT01627340|BIOLOGICAL|Engerix™-B vaccine|3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
214400301|NCT03513211|DRUG|SUBA-itraconazole|150mg PO BD
214400302|NCT03513211|DRUG|Hydroxychloroquine|Escalating doses in Rolling 6 Phase I
215004818|NCT03158688|DRUG|Carfilzomib|"Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.~Dose could be modified based on a \>20% change in body weight or toxicity."
215004819|NCT06264622|DIETARY_SUPPLEMENT|Low dose|2 tablets per day during the morning for 12 weeks.
215004820|NCT06264622|DIETARY_SUPPLEMENT|High dose|2 tablets per day during the morning for 12 weeks.
215004821|NCT06264622|DIETARY_SUPPLEMENT|Placebo|2 tablets per day during the morning for 12 weeks.
215004822|NCT05635864|PROCEDURE|Catheter ablation|Catheter ablation of atrial tachyarrhythmia (atrial fibrillation, atrial flutter)
215004823|NCT05312060|DEVICE|PC Pneumatic compression|Pneumatic compression of the operated limb
215004824|NCT05312060|OTHER|AE Antithromboembolic exercises|Exercises for the edema
215004825|NCT06296849|BEHAVIORAL|Financial Incentive Treatment (FIT)|In the present study, the investigators will provide financial incentives of $200 for biochemically verified abstinence at each of three time points (1 month, 3 month, and 6 month) following baseline. Additionally, the investigators will provide a bonus of $200 for participants who demonstrate abstinence at each of the time points. This incentive value is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.
214400303|NCT02013687|BIOLOGICAL|Pfs25 VLP- FhCMB|
214400304|NCT05752578|OTHER|Neuropsychological testing|During the session the patient will be administered the Memory for Intentions Screening Test (MIST; Raskin et al., 2010) with the purpose of investigating prospective memory ability. Then during the same meeting the following tests will be offered to the patient: Montreal Cognitive Assessment (MOCA; Nasreddine. Translation Pirani et al 2006) investigating global cognitive performance; - Interpersonal Reactivity Index (IRI; Davis, 1980;1983- Italian version edited by Bonino et al, 1998) with the purpose of assessing cognitive and affective empathy (Hot cognition); Modified Five Point Test (Ruffi et al 1987) aimed at assessing figurative fluency (Cold cognition).
214504065|NCT00457119|DRUG|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
214504066|NCT00352131|DRUG|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
214504067|NCT01160588|DRUG|Sertraline|Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
214504068|NCT02310581|DRUG|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
215004826|NCT05545787|PROCEDURE|Cold snare endoscopic mucosal resection|During CS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The polyp and 1-2mm of surrounding mucosa will then be closely snared and transected mechanically.
215004827|NCT05545787|PROCEDURE|Hot snare endoscopic mucosal resection|During HS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The snare will be placed around the lesion, and then cautery will be applied using the electrosurgical generator.
215029378|NCT01907282|BEHAVIORAL|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
214400305|NCT04859049|PROCEDURE|infromedial single injection|"Group 1: We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin."
214504069|NCT02310581|DRUG|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
214504070|NCT01737021|OTHER|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
214504071|NCT00794807|DRUG|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
215029379|NCT03629704|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
215004828|NCT01115010|DEVICE|Colonoscope stiffening device|"Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The standard stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the firm wire replaces the standard wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
215004829|NCT01115010|DEVICE|Colonoscope stiffening device|"Standard stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the standard wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
215004830|NCT01115010|DEVICE|Colonoscope stiffening device|"Firm stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the standard wire and so on until cecal intubation is achieved or the procedure is abandoned."
215004831|NCT04928586|DRUG|Pirfenidone|CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose
214400306|NCT04859049|PROCEDURE|medial canthus injection|": We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid classical medial canthal injection"
214400307|NCT04123873|DRUG|Paracetamol|1g x 4 p.o.
215004832|NCT04928586|DRUG|DMARDs|CTD-ILD patients treated with DMARDs according to the condition of the disease
215004833|NCT05210946|DRUG|Pemigatinib|"Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0."
215004834|NCT00001857|DRUG|BG9588|
215095881|NCT05941260|DIAGNOSTIC_TEST|Computational fluid dynamics (CFD)|"\- Video recording starts in an antegrade manner starting from the bladder neck through the prostatic urethra and ends after the verumontanum at the external sphincter. Videos were taken with a very slow movement of the endoscope to ensure the sharpness of the data and to prevent complications in post-processing.~The focal length and zoom of the endoscope camera were set at the beginning and maintained throughout the capturing, while the angle of the lens changes to capture the widest field possible for each targeted area.~* Computational fluid dynamics (CFD) can then be used to numerically model the behavior of the flow inside the urethra by solving the governing equations of the flow using the finite volume method.~* Through which we can develop a urodynamic computer model to simulate the bladder-urethral passage and predict the success of the resection undertaken by the surgeon. No extra intervention will be provided to our patients apart from their routine surgery."
215095882|NCT05957029|DEVICE|NuEra Tight RF system|monopolar radiofrequency device
214400308|NCT04123873|DRUG|Ibuprofen|400mg x 4 p.o.
214400309|NCT04123873|DRUG|Dexamethasone|24mg IV x 1 after induction om anaesthesia
214504072|NCT00650169|DRUG|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fed
214504073|NCT00650169|DRUG|Plavix® Tablets 75 mg|75mg, single dose fed
215004835|NCT05916287|BIOLOGICAL|Blood and urine samples|Blood and urine samples
215004836|NCT05916287|GENETIC|Blood samples|Blood samples
215095883|NCT05715515|DIAGNOSTIC_TEST|Panbio™|"The Panbio™ COVID-19/Flu A\&B Rapid Panel Professional use device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in nasopharyngeal swabs, collected by a trained health worker.~The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users"
214504074|NCT05377918|OTHER|Diary|spiritual diary group and diary gruop will write a diary
214504075|NCT03183349|PROCEDURE|deprotienized bovine bone (tutogen)|
214504076|NCT03183349|PROCEDURE|platelet rich fibrin|
214504077|NCT04843449|DRUG|ASC40|Oral tablets
214400310|NCT04123873|DRUG|Placebo oral capsules|p.o. x 4
214400311|NCT04123873|DRUG|Placebo IV|IV x 1
214400312|NCT01657032|DIETARY_SUPPLEMENT|Smectite|Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
214400313|NCT01657032|DIETARY_SUPPLEMENT|Placebo|Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
214504078|NCT04843449|DRUG|Itraconazole|Oral capsules
214504079|NCT04843449|DRUG|rifampicin|Oral capsules
214504080|NCT00010049|DRUG|imatinib mesylate|
214504081|NCT04652869|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
214504082|NCT04652869|BEHAVIORAL|Mindfulness|Mindfulness is a type of meditation in which you focus on being intensely aware of what you're sensing and feeling in the moment, without interpretation or judgment.
214504083|NCT04301206|BEHAVIORAL|Intervention Group|Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
214504084|NCT05964426|OTHER|Turkey Health Literacy Scale (TSOY-32)|A survey will be conducted.
215004837|NCT05916287|OTHER|Cardiovascular assessment|Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
215004838|NCT05916287|BEHAVIORAL|Dietary intake|Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
215004839|NCT05916287|OTHER|Anthropometric parameters|Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
215004840|NCT05916287|OTHER|Hemodynamic parameters|Systolic pressure index measurement
215004841|NCT05916287|OTHER|Hemodynamic parameters|Heart rate measurements, blood pressure measurements, orthostatic BP measurements
215004842|NCT05916287|OTHER|Hemodynamic parameters|"Blood pressure measurements by unattended BP monitor over 5 min"
215004843|NCT05916287|OTHER|Hemodynamic parameters|Electrocardiogram
215004844|NCT05916287|BEHAVIORAL|Assessment of compliance with antihypertensive treatments for treated participants|EVALOBS scale and compliance questionnaire
215004845|NCT05916287|OTHER|Ambulatory 24 hours measurment of blood pressure|For the first 100 patients willing to participate
215004846|NCT05916287|BIOLOGICAL|24 hours urinary collection|For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
215004847|NCT05916287|OTHER|General questionnaires|Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
215004848|NCT05916287|OTHER|Women specific questionnaire|Women specific questionnaire
215004849|NCT05916287|BEHAVIORAL|Women specific questionnaire|Women specific questionnaire
215004850|NCT05916287|DIAGNOSTIC_TEST|NYHA dyspnea questionnaire|Determination of NYHA class.
215004851|NCT05916287|BEHAVIORAL|Anxiety questionnaire|Assessment of anxiety
215004852|NCT05916287|BEHAVIORAL|Epworth Sleepiness Scale|sleep quality assessment
215004853|NCT05916287|OTHER|"A questionnaire on the perception of the management of cardiovascular risk factors"|Patient's evaluation of cardiovascular risk factors by the health system
215004854|NCT05916287|BEHAVIORAL|A questionnaire on eating behaviors|Assessment of eating behaviors
215004855|NCT05916287|BEHAVIORAL|A questionnaire on eating habits to determine consumer profiles|Assessement of eating habit to create a consumer profile
215004856|NCT05916287|DIETARY_SUPPLEMENT|A questionnaire on food supplements use|Evaluation od food supplements intake
215004857|NCT05916287|OTHER|SARS-CoV-2 Infection Questionnaire|SARS-CoV-2 Infection Questionnaire
215004858|NCT05916287|OTHER|Instantaneous expired air analysis|Carbon monoxyde analysis in expired air
215004859|NCT05916287|BIOLOGICAL|Capillary sampling|Capillary sampling for pollutant analysis (Optional)
215004860|NCT05145491|PROCEDURE|Immediate Vitrectomy|Surgery to remove epiretinal membrane (ERM). Vitrectomy will be performed on eyes within 1 month of randomization
215004861|NCT05145491|PROCEDURE|Deferred Vitrectomy|"Vitrectomy may be performed only if at least one of the following criteria is met:~1. Decrease in visual acuity ≥10 letters from baseline at a single visit presumed to be from ERM~2. Decrease in visual acuity ≥5 letters from baseline at two consecutive visits presumed to be from ERM~   a. Visits must be at least one month apart~3. Participant actively requests surgery due to worsening symptoms~4. Complication requires prompt surgical intervention (e.g., macular hole, retinal detachment, non-clearing vitreous hemorrhage)"
215004862|NCT06005155|DRUG|Lithium|Sustained long-term exposure
215004863|NCT05842980|OTHER|sepsis|collect 5ml blood from patient
215004864|NCT04887038|DRUG|SRT-015|Each study part (A,B and C) will be completed sequentially, but with partial overlapping. The first cohort of Part B (Cohort B1) may be initiated after safety, tolerability and available PK data are assessed and deemed suitable to continue for a single dose on Part A that is equal to or greater than the total exposure of cohort B1. Part C (Cohort C1 \& C2) may be initiated after safety, tolerability and PK data are assessed and deemed suitable to continue for a single dose in part A that is at least double the specified dose from part C.
215004865|NCT04887038|OTHER|Matching Placebo for SRT-015|Matching Placebo
215004866|NCT00006457|DRUG|oltipraz|
214400314|NCT01657032|DIETARY_SUPPLEMENT|Lactobacillus GG|All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
214400315|NCT01694875|DEVICE|APTIMA HPV Assay|In Vitro Diagnostics Assay
214688183|NCT04902703|DRUG|Saline - placebo comparator|Saline will be administered subcutaneously, 5 days/week, for 24 weeks
215004867|NCT05753969|DEVICE|MT1 Device|Pre-and post-evaluation in MT1 device following stimulant treatment or placebo control
215004868|NCT05722795|DRUG|Imatinib 400 MG Oral Tablet|One tablet daily 10 days before surgery.
215004869|NCT01104298|DRUG|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
215004870|NCT01104298|DRUG|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
215004871|NCT00565864|DRUG|L-thyroxine (L-T4)|L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
215004872|NCT05076786|DRUG|Chidamide|20mg, administered orally. Week 1/2: twice a week (d0, d4, d7, d11); Week 3: stop. Repeat every 3 weeks for 4-6 cycles.
215004873|NCT05076786|DRUG|Etoposide + Cisplatin/Carboplatin|"Etoposide (100mg/m2; intravenous infusion; d1-3) + Cisplatin (75mg/m2; intravenous infusion; d1). Repeat every 3 weeks for 4-6 cycles.~OR Etoposide (100mg/m2; intravenous infusion; d1-3) + Cisplatin (25mg/m2; intravenous infusion; d1-3). Repeat every 3 weeks for 4-6 cycles.~OR Etoposide (100mg/m2; intravenous infusion; d1-3) + Carboplatin (AUC=5; intravenous infusion; d1). Repeat every 3 weeks for 4-6 cycles."
214504085|NCT03900585|BEHAVIORAL|Interval walking|Interval walking administered by an app on the patient's telephone. Interval walking for 150 minutes/week for 10 weeks.
215004874|NCT04715035|OTHER|Physical therapy interventions|mobilization, stretch, education, eccentric exercises
215004875|NCT02788227|BIOLOGICAL|rVSV-Zebov GP vaccine|primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.
215004876|NCT05266469|OTHER|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
215004877|NCT05266469|OTHER|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription will be enrolled.
215004878|NCT05229913|DRUG|Esketamine is not added|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg
215004879|NCT05229913|DRUG|Esketamine 0.2mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
215004880|NCT05229913|DRUG|Esketamine 0.4mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.
215004881|NCT05229913|DRUG|Esketamine 0.6mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
214504086|NCT02291406|PROCEDURE|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
214504087|NCT02291406|PROCEDURE|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
214504088|NCT00135018|DRUG|celecoxib and chemotherapy|
214504089|NCT02323776|OTHER|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
214504090|NCT00987324|DEVICE|Taxus stent|Implantation of paclitaxel-eluting stent
214504091|NCT00987324|DEVICE|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
214504092|NCT00987324|DEVICE|Conventional Balloon Catheter|Ryuijin, Trek
215004882|NCT05229913|DRUG|Esketamine 0.8mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
215004883|NCT05765734|DRUG|TAS3351 oral administration|TAS3351 will be administered orally
215004884|NCT01140139|BIOLOGICAL|HIV DNA Vaccine|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
215004885|NCT04837521|BEHAVIORAL|Unified Protocol|Five session psychotherapy
215004886|NCT06397781|DRUG|Skin Cleanser Combination No.1|"1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily~2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed.~3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults. Dosing for pediatric patients will be calculated to 5 to 6 mg/kg trimethoprim also given twice daily."
215004887|NCT06129760|DEVICE|Apple Watch|The wearable sensor device is the Apple Watch Series 6 or newer
215004888|NCT06482996|OTHER|Intraocular pressure (IOP) was measured|The Frail Scale was used to assess the frailty of the patients.Intraocular pressure (IOP) was measured before anesthesia, 5 minutes after induction of anesthesia and 1 hour postoperatively. IOP was measured using a Tono-pen tonometer (AccuPen). The normal range of IOP is 11-21 mmHg (mean 16 mmHg) and values above 24 mmHg are pathologic.
215004889|NCT02611024|DRUG|Lurbinectedin|lurbinectedin (PM01183) 4 mg vials
215004890|NCT02611024|DRUG|Irinotecan|irinotecan 40 mg, 100 mg or 300 mg vials
215004891|NCT06223516|DRUG|Subcutaneous (SC) ABBV-383|SC Injection
215004892|NCT06223516|DRUG|Intravenous (IV) ABBV-383|IV Infusion
215004893|NCT05955378|DEVICE|DSR Ankle|This is the experimental ankle component used in the overall prosthetic intervention.
215004894|NCT05955378|DEVICE|Predicate Ankle|This is the participant's prescribed ankle/foot complex used in the overall prosthetic intervention.
214400316|NCT01333761|DEVICE|Cardiox FDS|The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
214400317|NCT03178305|BEHAVIORAL|Do CHANGE|"Besides the behavior change programme (Do Something Different)~1. All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~2. patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~3. Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
214400318|NCT03633903|BEHAVIORAL|Mindfulness|Mindfulness based stress reduction adapted for teens is a mindfulness intervention designed to aid adolescents in understanding stress, better coping with stress, and promoting resilience
214400319|NCT06337539|DRUG|SSRI|"Outpatients with a diagnosis of major depression in the Psychiatry Outpatient Clinics will be evaluated for recruitment.~* Recruitment visit: It will be carried out by one of the psychiatrists participating in the study. The patient will be informed about the study and written consent will be requested. Subsequently, the inclusion and exclusion criteria will be reviewed, and all demographic and clinical variables will be collected.~* Baseline visit: One of the psychiatrists will interview the patient and apply the semi-structured clinical interview and the psychopathological evaluation questionnaires. In addition, a blood draw will be performed for serum collection, spectral cytometric analysis of lymphocyte subpopulations and obtaining peripheral blood mononuclear cells (PBMCs).~* Follow-up visit after 3 months of treatment: Clinical variables will be collected and the same procedures will be performed as during the baseline visit. Not in the control group."
214400320|NCT05968482|DRUG|Diclofenac Sodium Gel|Topical application on both knees
214400321|NCT03908242|DRUG|salvianolic acid A|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
214504093|NCT01933100|OTHER|Experimental Diet|Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
215004895|NCT02922036|DEVICE|WiSE System|The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
215004896|NCT03290950|DRUG|daratumumab|Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.
215004897|NCT03290950|DRUG|carfilzomib|Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
215004898|NCT03290950|DRUG|lenalidomide|Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
215004899|NCT03290950|DRUG|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, 16 and 22; Cycles 3-4: Dexamethasone 20mg/dose, days 1,2,8,9,15 and 16, Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16
215004900|NCT03290950|DRUG|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 1, 2, 22; 40 mg/dose days 8 and 15, Cycles 2: Dexamethasone 40mg/dose, days 1, 8, 15; 20 mg/dose day 22, Cycles 3-4: Dexamethasone 40mg/dose, Days 1, 8 15, Cycles 5-8: Dexamethasone 20mg/dose, Days 1, 8, 15
215095884|NCT02528357|DRUG|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
215095885|NCT02528357|DRUG|Pembrolizumab|Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
214400322|NCT03908242|DRUG|Placebo|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
214400323|NCT04186169|PROCEDURE|Catheter ablation|Catheter ablation
214504094|NCT01945372|OTHER|EEG NeuroFeedback|
215004901|NCT06055556|PROCEDURE|Partial Heart Transplantation|"Partial heart transplantation involves surgical replacement of the semilunar heart valve with a fresh donor graft. The surgical procedure (homograft valve replacement) is common and standard of care. The investigational aspect of this is using a freshly procured valve rather than a cryopreserved, cadaveric one and also the use of limited immunosuppression to help maintain the freshly procured valve as living tissue."
215004902|NCT06055556|OTHER|Freshly procured valve|Fresh donor graft semilunar heart valve.
215004903|NCT04865276|BEHAVIORAL|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
215004904|NCT05250037|PROCEDURE|Home spirometry|Undergo spirometry measurements
215004905|NCT05250037|PROCEDURE|Biospecimen Collection|Undergo nasal and/or oral swabs, and blood collection
214400324|NCT01720017|OTHER|Preclinical Manikin Training|During the preclinical manikin training, each subject will perform 10 intubations in a manikin with a difficult airway simulated by swelling the manikin tongue and placing it in a cervical collar.
215004906|NCT05250037|OTHER|Questionnaire Administration|Complete questionnaires
215004907|NCT06266507|BEHAVIORAL|Ergotherapy Based Parent Coaching|Occupational Therapy Based Parent Coaching intervention will last 10 sessions and will be carried out on the online platform. Sessions are planned to last between 45-60 minutes. The interviews to be held during the sessions are considered as the basic principles of parent coaching; It will be carried out in line with the principles of joint planning, observation, implementation, reflection and feedback. This intervention aims to educate mothers on proper feeding strategies for their children and to enable them to carry out these practices independently.
215004908|NCT06266507|OTHER|Informative Brochure Distribution|No active intervention will be applied to mothers in the target group, and an informative brochure about nutritional problems will be distributed.
215004909|NCT06850727|DRUG|OD-07656|Experimental intervention
215004910|NCT06850727|DRUG|Vedolizumab|Active standard of care comparator
214400325|NCT01720017|OTHER|Inservice Training|Inservice training will include review of a product information handout and a video demonstration.
215004911|NCT06848400|DEVICE|AI-integrated Capsule Gastroscopy (ACG) examination|Product name: Gastric Capsule Endoscope System Specification model: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd.
215004912|NCT06848400|DEVICE|Electronic gastroduodenoscopy (EGD) examination|"EGD was the reference standard against which ACG was compared, and it was performed within 24 hours post-ACG ingestion time.~Product name: Electronic gastrointestinal endoscope (EGD) Specifications and models: GIF-290 series Manufacturer: Olympus, Tokyo, Japan"
215004913|NCT06077604|OTHER|Assessment of exposure to air pollution|For each patient, exposure to air pollution will be assessed over a period immediately prior to any flare-up and over four periods at a distance from the flare-up.
214400326|NCT01398761|OTHER|Signout tool|Electronic signout tool
215004914|NCT06094491|BEHAVIORAL|Virtual Group Visit|Group visits must have these core components: diabetes education, group social support and goal setting.
215004915|NCT04225871|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
215004916|NCT01944774|DRUG|Nemonoxacin 500 mg|IV Infusion, once daily for 7\~14 days
214400327|NCT06128317|OTHER|no intervention is intended.|no intervention is intended.
214400328|NCT02559817|DRUG|Linaclotide Dose A|
214400329|NCT02559817|DRUG|Linaclotide Dose B|
214400330|NCT02559817|DRUG|Linaclotide Dose C|
214400331|NCT02559817|DRUG|Linaclotide Approved Adult Dose|
214400332|NCT02559817|DRUG|Matching Placebo|
214400333|NCT00189280|DRUG|Imiquimod|cream 5%, 5 days out of seven, for 6 weeks
214400334|NCT02046538|DRUG|Leucovorin|400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
214400335|NCT02046538|DRUG|Oxaliplatin|85 mg/m2 IV over two hours
214400336|NCT02046538|DRUG|5-FU|400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
214400337|NCT02046538|DRUG|Irinotecan|180 mg/m2 IV over 90 minutes
214400338|NCT06278389|DRUG|ACC017 tablets|ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo
214400339|NCT06278389|DRUG|Emtricitabine and Tenofovir Alafenamide Fumarate Tablets|Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.
214400340|NCT05653180|DRUG|IBI310|2mg/kg IV,3 weeks later, 1mg/kg IV Q6W
214400341|NCT05653180|DRUG|sintilimab|200mg IV Q3W
215004917|NCT01944774|DRUG|Nemonoxacin 650 mg|IV Infusion, once daily for 7\~14 days
215004918|NCT01944774|DRUG|Moxifloxacin 400 mg|IV Infusion, once daily for 7\~14 days
215004919|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 14
215004920|NCT06847464|DRUG|Itraconazole|Subjects will receive itraconazole QD Days 5-18
215004921|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 23
215004922|NCT06847464|DRUG|carbamazepine|Subjects will receive carbamazepine on Days 5 - 27
215004923|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 8
215004924|NCT06847464|DRUG|Quinidine|Subjects will receive quinidine on Days 5-12
215004925|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 14
215004926|NCT06847464|DRUG|fluconazole|Subjects will receive fluconazole on Days 5-18
215004927|NCT03022825|DRUG|N-803 and BCG|BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
215004928|NCT03022825|DRUG|N-803|N-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
215004929|NCT06390436|DIAGNOSTIC_TEST|Blood sample|A blood sample will be taken, in addition to blood samples taken for the usual follow-up, with 4 dry tubes for the determination of ADA and anti-ADA antibodies and for bio-collection.
215004930|NCT06390436|DRUG|Adalimumab Injection|Adalimumab Injection
215004931|NCT04763291|DIETARY_SUPPLEMENT|Juice Plus+ Fruit, Vegetable and Berry blends|Encapsulated juice powder concentrate derived from 36 dried fruits, vegetables and berries.
214400342|NCT03302533|PROCEDURE|Total elbow arthroplasty|Implantation of a total elbow arthroplasty after distal humerus fracture
214400343|NCT01018043|OTHER|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
214400344|NCT02848235|OTHER|Standard of Care + EMMA|Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
214400345|NCT01739556|DRUG|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
214400346|NCT00003840|BIOLOGICAL|DTGM fusion protein|
214400347|NCT04887961|DRUG|PLD and Trabectedin rechallenge|Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments
214400348|NCT05312619|OTHER|Cross sectional survey|A cross-sectional descriptive survey of the Burden of Lyme disease for individual with a history of Lyme disease who contract COVID-19 or are vaccinated against COVID-19
214400349|NCT02685592|DRUG|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
215095886|NCT00412074|DRUG|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
214400350|NCT03374345|DRUG|Sipjeondaebo-tang Granule|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
214400351|NCT03374345|DRUG|Placebo|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
214400352|NCT03328052|DEVICE|MYnd Analytics PEER Online directed antidepressant therapy|"PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm."
214400353|NCT03328052|OTHER|Conventional antidepressant therapy|Anti-depressant therapy chosen based on physician best judgement.
214400354|NCT02314455|OTHER|D-xylose|There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
215095887|NCT00412074|DRUG|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
215095888|NCT00412074|DRUG|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
214400355|NCT00004643|DRUG|cytarabine|
215004932|NCT04763291|DIETARY_SUPPLEMENT|Juice Plus+ Omega blend|Encapsulated plant-based fatty acid supplement.
215004933|NCT03204123|DRUG|Ga-HBED-iPSMA PET|Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
215004934|NCT03204123|DIAGNOSTIC_TEST|PET/CT|PET/CT will be acquired using a GE 710 or 690 time-of-flight PET/CT scanner. Following a waiting period of 60-90 minutes post 68Ga-HBED-iPSMA administration, patients will be scanned from top of the skull to mid-thigh. Images will be acquired with patients in a supine position with their arms raised above their head. If patients cannot raise their arms above the head, the arms will be comfortably positioned and secured by the side of the patient. The PET may be combined with a CT scan as a PET/CT or a MRI scan as PET/MR.
215004935|NCT03204123|DIAGNOSTIC_TEST|MRI|Patients may undergo a diagnostic MRI of the prostate, other body parts or a whole-body MRI at the same imaging session as clinically indicated.
215004936|NCT04095637|DEVICE|Medial knee arthroplasty|Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
215095889|NCT04439994|OTHER|hypertonic saline|The participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution
215095890|NCT04439994|OTHER|Saline injection|The participant will be given i.d. in 0.1 mL volumes of a saline solution
215095891|NCT04439994|PROCEDURE|Blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
215095892|NCT01399268|DRUG|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
215095893|NCT01399268|DRUG|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
215004937|NCT05431608|BIOLOGICAL|MCARH125|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
215004938|NCT05431608|BIOLOGICAL|MCARH109|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
215004939|NCT06961838|OTHER|Inspiratory muscle training programme|In addition to their standard treatment, individuals in the inspiratory muscle training group will participate in inspiratory muscle training for a total of 30 minutes with a threshold loading device (POWERbreathe®) for 15 minutes twice a day, 5 days a week for 4 weeks under the supervision of a physiotherapist.
214400356|NCT02839083|OTHER|Thoracic Paravertebral group|Thoracic paravertebral block is performed using bupivacaine 0.25% in a total volume of 30 ml
214400357|NCT02839083|OTHER|Pecs II group|Ultrasound guided ipsilateral Pecs II block is performed using bupivacaine 0.25% in a total volume of 30 ml
214400358|NCT03059160|DRUG|Tridecanoic Acid|3 times daily oral doze of the drug for 20 weeks with 4 weeks of baseline and 4 weeks of washout
214400359|NCT05188365|OTHER|true acupuncture|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
214400360|NCT05188365|OTHER|sham acupuncture|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days
214400361|NCT04086173|DIETARY_SUPPLEMENT|Probiotics|Probiotics will be administered at night and will consist of 4 capsules
215004940|NCT06961838|OTHER|control group|Individuals in the control group will continue their standard treatment. No changes will be made in the medical treatments (type, dosage and frequency) of the individuals in both groups (the inspiratory muscle training group and the control group) during the study.
215004941|NCT02714647|BEHAVIORAL|Attentional prime|
215004942|NCT02714647|BEHAVIORAL|Sham prime|
215004943|NCT00355719|DRUG|Atazanavir (Reyataz)|Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
215004944|NCT00355719|DRUG|Ritonavir (Norvir)|Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
215004945|NCT00355719|DRUG|Nevirapine (Viramune)|Nevirapine (Viramune): tablets 200 mg (1 tablet/12h\*)
215004946|NCT00254085|DRUG|Insulin Aspart|
215004947|NCT02460731|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma \[young (\<30 years of age) healthy male donors\] Solution for intravenous infusion
215004948|NCT03557944|OTHER|Medication reduction|Systematic approach to reduction in polypharmacy.
215004949|NCT00112333|PROCEDURE|fMRI|A liquid meal (Ensure 1Kcal/cc) will be infused into the stomach via a nasogastric tube at a rate of 60cc/min till the subject reaches maximal satiety. The amount of liquid meal will differ per subject.
215004950|NCT03188185|DRUG|ALKS 5461|Samidorphan + buprenorphine, administered sublingually
215004951|NCT03188185|DRUG|ALKS 5461 Placebo|Placebo tablet, administered sublingually
215004952|NCT03325439|DRUG|Brivaracetam (BRV) intravenous (iv)|"Exploratory Cohort:~Subjects will be dosed with BRV (0.5 mg/kg twice daily (bid)) according to the sites standard procedures. Treatment with 1 or more of the following antiepileptic drugs (AEDs): phenobarbital (PB), midazolam (MDZ), phenytoin (PHT), levetiracetam (LEV), or lidocaine (LDC) (first-line, second-line, or subsequent treatment) will continue in parallel with BRV treatment.~Confirmatory Cohort:~For subjects who enter the Confirmatory Cohorts, for the strength of BRV 1 mg/kg bid (2 mg/kg/day) has been determined based on the Pharmacokinetic (PK) findings of the Exploratory Cohort. Based on further monitoring of PK and safety findings dosing may be adjusted as new data are available. Administration of BRV is proposed as approximately 15-minute intravenous (iv) infusions. Treatment with previous antiepileptic drugs is permitted to continue if the subject is on a stable dose from 1 hour prior to initiation of the BRV treatment."
215004953|NCT03325439|DRUG|Brivaracetam (BRV) oral|Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period
214400362|NCT04086173|OTHER|Placebo|Placebo
214400363|NCT04305236|DRUG|Abemaciclib|Given PO
214400364|NCT04305236|DRUG|Fulvestrant|Given Intramuscularly
214400365|NCT00597870|DEVICE|Endoluminal treament of thoracic lesions|Endoluminal treament of thoracic lesions with a thoracic stent-graft
215004954|NCT05624541|DIAGNOSTIC_TEST|Measurements|All infants at high risk of cp will be assessed by Specific Test of Early Infant Motor Performance (STEP) Version 3.0 at term age and at corrected age 3 months, by Hammersmith Infant Neurological Examination (HINE) a corrected age 3 and 6 months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at corrected 6 months.
215004955|NCT00369759|OTHER|Emergency Dept. Subjects with LRI or Apnea|No intervention; Epidemiological Study
215004956|NCT03297697|PROCEDURE|Tumor biopsy|Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
214400366|NCT01882894|DEVICE|Custom PFO|PFO made out of thermoplastic material molded to the patient's foot
214400367|NCT01882894|OTHER|Faux orthosis|Foam cut out
214400368|NCT01806415|DRUG|Fenobam|Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)
214400369|NCT01806415|DRUG|Placebo|Oral administration of placebo or lactose 150 mg
214400370|NCT05711329|OTHER|Accuracy|We will validate the accuracy of the method proposed by the SFAR to detect OSA patients via videoconference (in comparison with the results of the PSG).
214400371|NCT05911074|DIAGNOSTIC_TEST|The Abbott Panbio™ COVID-19 Ag Rapid Test|This is the intervention or medical device(s) intended to be used with a study participant according to the study protocol.
214400372|NCT01056211|PROCEDURE|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
214400373|NCT01056211|PROCEDURE|treatment without laser|Starlux 300 Lux 1540nm Fractional laser hand piece
215004957|NCT03297697|PROCEDURE|Peripheral blood draw|-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
215004958|NCT03297697|PROCEDURE|Lymphotrack TCR clonality assay|-Assay with high sensitivity that can be performed with peripheral blood
215004959|NCT02281877|PROCEDURE|Neuromuscular electrical stimulation (NMES)|5x/week, 2x/day, for 45 minutes/session
215004960|NCT02281877|BEHAVIORAL|Standard Rehabilitation Protocol|Standard physical therapy after TKA
215004961|NCT03965650|OTHER|Video coaching exercises|Patients will perform physical exercises following a specifical video coaching program during 6 months.
215004962|NCT03965650|OTHER|Routine exercises|"Routine method by advising and encouraging patients to perform exercises according to the WHO recommendations during the first 3 months of the study.~Thereafter, patients will have access to the video coaching program of physical activities during the following 3 months."
215004963|NCT05219890|DIETARY_SUPPLEMENT|Fish oil|They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
215004964|NCT05862701|DRUG|Permethrin|5% permethrin cream
215004965|NCT05862701|DRUG|Sulphur|10% Sulfur ointment
215004966|NCT03754543|OTHER|Labeled iron salt Fe54|Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
215004967|NCT03754543|OTHER|Labeled iron salt Fe57|Ferrous fumarate enriched with Fe 57 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
214400374|NCT01056211|PROCEDURE|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
214400375|NCT00725582|DRUG|IMA-026|
215004968|NCT03754543|OTHER|Labeled iron salt Fe58|Ferrous bisglycinate enriched with Fe 58 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
215004969|NCT05546528|DEVICE|Photobiomodulation|G1 will receive the photobiomodulation application with the Laser Therapy XT device, (DMC, São Paulo, Brazil). The laser will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
215004970|NCT05546528|DEVICE|Photobiomodulation- Sham|G2 will receive the photobiomodulation application with the Laser Therapy XT device off. The laser off will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
215004971|NCT01460472|BIOLOGICAL|Racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
215004972|NCT01460472|OTHER|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
214400376|NCT00725582|OTHER|Placebo|
214400377|NCT00070629|DRUG|CPG 7909|CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle.
214400378|NCT00070629|DRUG|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
214400379|NCT00070629|DRUG|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
214400380|NCT01773538|DRUG|Lactulose and rifaximin|3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
214400381|NCT01773538|DIETARY_SUPPLEMENT|Branched Chain amino acids|30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
214400382|NCT01773538|OTHER|Placebo|Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
214400383|NCT00005864|DRUG|chloroquinoxaline sulfonamide|
215004973|NCT00634972|DRUG|ACULAR|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
215004974|NCT00634972|DRUG|REFRESH TEARS|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
215004975|NCT00634972|DRUG|placebo|
214400384|NCT04422821|DEVICE|Flash Glucose Monitoring|Flash Glucose Monitoring FreeStyle Libre™ (Abbott Diabetes Care, Alameda, CA) sensor placed subcutaneously that will be applied for 14 days, then removed and changed for the second sensor for the next 14 days.
214522631|NCT02342275|DRUG|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
215004976|NCT04415905|DRUG|Propofol|The participants in the group P are anesthetized with propofol
215004977|NCT04415905|DRUG|Sevoflurane|The participants in the group S are anesthetized with sevoflurane.
215004978|NCT02036723|DRUG|Bevacizumab|Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
215004979|NCT02036723|DRUG|Ranibizumab|Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
215004980|NCT04045171|DRUG|Tacrolimus|Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months
214400385|NCT04422821|DEVICE|Self-Monitoring of Blood Glucose|Self-Monitoring of Blood Glucose with a standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) performed through a skin-puncturing 4 times a day for 28 days.
214400386|NCT01634711|DEVICE|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
215004981|NCT02522845|DEVICE|Class II Compression Stockings (no specific device used)|This study will be looking at the effect of compression therapy in patients having endothermal treatment for truncal incompetence of their varicose veins
215004982|NCT06101446|OTHER|Lavander Aromatherapy|Aromatherapy is one of the potential non-pharmacological methods. Lavender oil has been known to have calming properties and is one of the most effective aromatherapy oils. It reduces blood pressure and anxiety by stimulating the parasympathetic system
215004983|NCT00774748|DEVICE|Insuflon|Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
215004984|NCT04976972|DEVICE|NAVIO/CORI Surgical System|Total knee replacement with robotic assistance
215004985|NCT04976972|PROCEDURE|Non-robotic conventional instrumentation|Total knee replacement with non-robotic conventional instrumentation
215004986|NCT06151938|DRUG|Standardised allergen extract from house dust mites|Drug: Allergen immunotherapy \[ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet\] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.
214400387|NCT02916472|BEHAVIORAL|CyberCycling|All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Participants in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the participants' tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.
214400388|NCT02916472|BEHAVIORAL|Stretching|Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Participants will be provided with two different colored resistance bands (lighter colored - easier resistance; darker colored - harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participant by the exercise physiologist before the 12 week program begins.
214400389|NCT02916472|BEHAVIORAL|Resistance Bands|"Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks.~The resistance band program will include upper body and lower body exercises and will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participants by the exercise physiologist before the 12 week program begins."
214400390|NCT03082209|DRUG|ABBV-621|Intravenous (IV)
214400391|NCT03082209|DRUG|Venetoclax|tablet, oral
214400392|NCT03082209|DRUG|Bevacizumab|IV infusion
214400393|NCT03082209|DRUG|FOLFIRI|IV infusion
214400394|NCT02186938|DEVICE|FloTrac|
214400395|NCT03888703|DEVICE|Fractional ablative CO2 laser|Three treatments with a fractional ablative CO2 laser 8 weeks apart
215004987|NCT06544590|DEVICE|taVNS|TaVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms \[18,28\]. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. In the taVNS group received 12 weeks of treatment (30 min each time, once daily, 5 times per week).
215004988|NCT06544590|DRUG|Betahistine Mesylate tablet|Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
215004989|NCT03125733|PROCEDURE|Submucosal tunneling endoscopic septum division|"STESD includes 4 steps:~1. Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.~2. Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.~3. Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.~4. Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips."
214400396|NCT06009783|OTHER|ChatGPT Language Model|ChatGPT Language Model - ability to converse with the model and ask questions regarding vasectomies
215004990|NCT05518552|OTHER|Manual lumbar traction|Patient in the group were treated with manual traction
215004991|NCT05518552|OTHER|Prone traction|Patient in the group were placed on prone traction
215004992|NCT01676662|DEVICE|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
215004993|NCT01676662|DEVICE|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
214400397|NCT05539404|PROCEDURE|Endovascular treatment in addition of best medical treatment.|Endovascular treatment (EVT) of acute ischemic stroke (AIS) related to an anterior large cerebral vessel occlusion (LVO)
214400398|NCT00761774|DRUG|Brivaracetam|Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
214400399|NCT03165383|DRUG|Bupivacaine (Transversus Abdominis Plane Block)|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
214504095|NCT05451589|BEHAVIORAL|RESET|RESET consists of 7 weekly group phone sessions led by Community Health Workers, along with an accompanying podcast series.Topics will include positive psychology, physical activity, social connection, eating well, relaxation, and more. There will be one individual session with the Community Health Worker to screen for unmet social needs and to offer connections to resources as needed. In the group sessions, participants will set goals incorporating positive activities and strategies to improve daily functioning. Up-to-date information related to COVID-19 prevention and treatment will be provided.
214504096|NCT05451589|BEHAVIORAL|Wellness Check Control|"After completing the baseline survey, control group participants will be mailed an educational packet consisting of information about COVID-19 prevention and treatment, as well as essential community resources. Control group participants will also be invited to take part in a wellness check telephone session with a Community Health Worker, about a half-hour long, at which a social needs screener will be administered, and any needed referrals will be made. After completing the 8-month follow up, they will have the opportunity to participate in the full intervention."
214504097|NCT04996225|OTHER|Aerobics exercises, Balance exercises|Aerobic exercise, or endurance exercise, is a subdivision of physical exercise that improves cardiovascular and respiratory health. Additionally, it is generally assumed to increase well-being and reduce negative mood states such as anxiety and depression.
214504098|NCT00075998|DRUG|"Interferon gamma-1b (Actimmune)"|200 mcg, SQ, 3x per week
214504099|NCT02978066|OTHER|Spinal anaesthesia|
214504100|NCT01232166|OTHER|Auscultation|
214504101|NCT01232166|OTHER|Observation of symmetric chest movements|
214504102|NCT01232166|OTHER|Tube depth|
214504103|NCT01232166|OTHER|All three|
215004994|NCT03933033|DEVICE|Fractional Erbium Yağ Laser|Multiple sessions of Fractional Erbium Yağ Laser
215004995|NCT03933033|PROCEDURE|Platelet Rich Plasma|Multiple injections of Platelet Rich Plasma
215004996|NCT04151732|BEHAVIORAL|Physical activity, alcohol, tobacco|Physical activity, alcohol, tobacco - selfreported in the 1990's
215004997|NCT04151732|OTHER|Hormonal factors|Hormonal factors - selfreported in the 1990's
215004998|NCT04151732|OTHER|Cardiovascular disease|Cardiovascular disease - selfreported in the 1990's
214400400|NCT03165383|DRUG|Intravenous Patient Controlled Analgesia (PCA) Morphine|PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
214400401|NCT01403844|OTHER|Carotenoid Depletion|Depletion of carotenoids using a restricted food list
214400402|NCT01403844|OTHER|Carotenoid Repletion|Carotenoid repletion with provided diet based on dietary guidelines.
214400403|NCT01403844|OTHER|Carotenoid Depletion|Carotenoid depletion using a restricted food list.
214400404|NCT01403844|OTHER|Natural Repletion|Resumption of usual personal diet regimen. No restrictions.
214504104|NCT00284466|PROCEDURE|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
214504105|NCT01583868|DEVICE|B&L RD2135-01 lens C|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
214504106|NCT01583868|DEVICE|B&L RD2135-01 lens D|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
214504107|NCT01583868|DEVICE|PureVision2|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
214693858|NCT06553677|PROCEDURE|Coronally advanced flap with connective tissue graft|Coronally advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites
215004999|NCT04151732|OTHER|Anthropometric measures|Height, length, BMI
214400405|NCT05530954|OTHER|Mineral trioxide aggregate (MTA)|Materials for Vital Pulp Capping
214400406|NCT05530954|OTHER|Hard setting Calcium Hydroxide (Dycal)|Materials for Vital Pulp Capping
214400407|NCT01925170|DEVICE|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
215005000|NCT02503865|DRUG|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
215005001|NCT02503865|DIETARY_SUPPLEMENT|"Analimentary detoxication"|Vegetable and salt diet
215005002|NCT01356056|DEVICE|Kinesia HomeView|Quantifies motor symptom severity in the home
214400408|NCT01925170|DEVICE|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
214400409|NCT01925170|DRUG|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
215005003|NCT05431855|BEHAVIORAL|eWrapper-Engagement strategies to facilitate alcohol biosensor wearing|We will conduct a 30-day micro-randomized trial (MRT)--a clinical trial design for developing and optimizing mHealth interventions to test which engagement strategy works better, for who, and under what condition. A subset of the participants will be micro-randomized in the morning and in the evening, to either a prompt delivering non-contingent small reward (reciprocity); or a prompt containing feedback on self-monitoring progress based on dynamic self-regulation theories (personalized feedback); or no prompt.
214400410|NCT04900883|OTHER|survey|anonymous survey
214400411|NCT01077024|OTHER|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
214400412|NCT03042442|DIAGNOSTIC_TEST|Point-of care biomarkers|Point-of care biomarkers(Activin,Midkine) assessed by WB and IHC
214400413|NCT03042442|OTHER|Clinical, venous blood samples, pancreatic tissue|Clinical evaluation, venous blood samples and pancreatic tissue needed for determining point-of-care biomarkers.
214400414|NCT03042442|OTHER|Follow-up|Participants will be assessed (by telephone) over a period of 2 years
214400415|NCT01238029|DRUG|Lapatinib and Capecitabine and Vinorelbine|Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
214400416|NCT01603121|DRUG|Lisofylline|Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
214400417|NCT01340833|DRUG|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) \[14C\]GSK2118436, starting 1.75 hours after the oral dose
214504108|NCT01583868|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
214504109|NCT00362219|OTHER|Placebo|Gel with no active ingredient.
215005004|NCT03704207|OTHER|nNO testing|Collection of already performed clinical data and nNO testing
215005005|NCT06350071|BEHAVIORAL|Kangaroo Care|Kangaroo care will be applied so that the infant and mother will have skin-to-skin contact, and heel blood will be taken.
215005006|NCT06350071|BEHAVIORAL|Swaddling|Heel blood will be taken while the infant was swaddled in the maternal holding.
215005007|NCT05999968|DRUG|Abemaciclib|Administered orally.
215005008|NCT05999968|DRUG|Darolutamide|Administered orally.
215005009|NCT05999968|DRUG|LHRH agonist/antagonist|Physician's choice. Administered in accordance with the prescribing information.
215005010|NCT06199492|DEVICE|tVisio-1|Standard of Care Biopsy
214400418|NCT00577720|DRUG|risedronate|35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks
214400419|NCT00577720|DRUG|risedronate|35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
214400420|NCT00577720|DRUG|risedronate|50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
214400421|NCT00577720|DRUG|risedronate|50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks
214400422|NCT02932111|PROCEDURE|osteopathic session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
214400423|NCT02932111|PROCEDURE|Placebo manipulative session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
214400424|NCT02682017|OTHER|Pork meat from pigs feed with a standard feed.|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.
214504110|NCT00362219|DRUG|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
214504111|NCT00362219|DRUG|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
214504112|NCT00362219|DRUG|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
214504113|NCT00474799|DRUG|MNS075|MNS075 7.5mg q1h MNS075 15mg q3h
214504114|NCT00797550|BIOLOGICAL|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
214504115|NCT00797550|PROCEDURE|Autologous bone graft|
214522632|NCT04975386|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram will be performed before the operation and at certain time intervals during the operation.
214522633|NCT04908800|DRUG|KRP-A218|KRP-A218 tablet
214522634|NCT04908800|DRUG|Placebo|Placebo tablet
214522635|NCT04908800|DRUG|itraconazole|10 mg/mL oral solution
214522636|NCT03639792|PROCEDURE|gastric cancer surgery|Gastric cancer surgery
214522637|NCT03148353|PROCEDURE|Subacromial injection|"1. Modified ultrasound guided corticosteroid subacromial injection~2. Standardized ultrasound guided corticosteroid subacromial injection"
214522638|NCT01256814|BEHAVIORAL|SystemCHANGE-HIV|SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
214522639|NCT01979822|OTHER|PH patients with LenusPro pump|Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
214400425|NCT02682017|OTHER|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
215005011|NCT04557761|DEVICE|microMend®|microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.
215005012|NCT04557761|DEVICE|Closure with Sutures|The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
215005013|NCT05482191|BEHAVIORAL|Lifestyle intervention|"This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the treatment group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses~* Diet and exercise instruction by professional nutritionist using internet applet~* Take part in sports activities that are organized by the sports health teacher during school hours."
215005014|NCT04777760|DRUG|one dose of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
215005015|NCT04777760|DRUG|two and more doses of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
215005016|NCT02685930|BEHAVIORAL|Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy|ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
215095894|NCT02438813|DRUG|Deoxycholic acid|Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
215095895|NCT02438813|PROCEDURE|Surgical Procedures|Surgical procedures for treatment of SMF as per standard of care in clinical practice.
215095896|NCT02438813|PROCEDURE|Laser Liposuction|Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
215095897|NCT02438813|DEVICE|Energy Devices|Energy Devices for the treatment of SMF as per standard of care in clinical practice.
215095898|NCT02438813|OTHER|Other Treatments|Other treatments for SMF as per standard of care in clinical practice.
215095899|NCT05833178|BEHAVIORAL|Drawn Blood Volume|Hemoglobine Changes
215095900|NCT04809350|DIETARY_SUPPLEMENT|Adjustable Human Milk Fortification|"BUN and sodium concentrations will be measured every week in infants on full enteral feeds with fortified human milk.~Liquid protein will be added based on serum urea."
215095901|NCT04809350|DIETARY_SUPPLEMENT|Targeted Human Milk Fortification|"Human milk will be analyzed twice weekly. Before the day of analysis, each mother will store fresh milk pumped from 10:00 AM until 8:00 AM of the previous day in a refrigerator and bring it to the hospital.~Protein, fat, and sodium supplementation will be added to the human milk to meet the recommended daily intakes."
215095902|NCT02795312|BEHAVIORAL|Smoking Cessation Program|Participants will take part in a 9-week Smoking Cessation Program
215095903|NCT00046553|DRUG|RU-486 (Mifepristone)|
215095904|NCT01357460|DEVICE|Implantation of intrabronchial valves (IBV) (Spiration IBV)|"In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of new air during inspiration."
215095905|NCT04702113|DIAGNOSTIC_TEST|Cipherome Lighthouse Pilot|Preemptive pharmacogenomic testing
215095906|NCT00556413|BIOLOGICAL|cetuximab|
215095907|NCT00556413|DRUG|fluorouracil|
215095908|NCT00556413|DRUG|irinotecan hydrochloride|
215095909|NCT00556413|DRUG|leucovorin calcium|
214400426|NCT04344990|PROCEDURE|Epidural analgesia - Group E|Postoperative analgesia with continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
214400427|NCT04344990|PROCEDURE|Femoral blockade - Group F|Postoperative analgesia with continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min) .
214400428|NCT04344990|PROCEDURE|Intraarticular infusion - Group I|Postoperative analgesia with continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
214400429|NCT00628628|DRUG|As Needed Rasburicase|.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
214400430|NCT00628628|DRUG|Fixed Dose Rasburicase|.15 mg/kg IV Over 30 Minutes Daily
214400431|NCT05170542|DRUG|Camrelizumab+S-1|Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.
215095910|NCT00556413|DRUG|oxaliplatin|
214400432|NCT01218685|BIOLOGICAL|Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS|1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.
214400433|NCT01989715|OTHER|analyzing the position of the body, muscle activity|
214400434|NCT02839681|DRUG|Anetumab Ravtansine|Administered intravenously (IV) every 3 weeks
214400435|NCT02839681|DEVICE|Blood test|Research blood test for eligibility
214688184|NCT06746259|DIAGNOSTIC_TEST|Rapid point of care test to detect host immune response in ARI|FebriDx is a rapid lateral flow immunoassay for the visual, qualitative, in vitro detection of elevated levels of host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), directly from fingerstick blood to aid in the differentiation of bacterial from non-bacterial acute respiratory infections.
215095911|NCT00756951|DRUG|Placebo|Placebo
215005017|NCT01053832|DEVICE|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
215005018|NCT02642900|PROCEDURE|Photodynamic Therapy|evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.
215005019|NCT02642900|DRUG|Nystatin 100.000 units|Control group treated with nystatin
214400436|NCT01539941|BEHAVIORAL|Medication integration protocol|MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
214400437|NCT00125775|BIOLOGICAL|Engerix-B|Engerix-B at 0, 1, 6 months
214400438|NCT00419003|DRUG|Lamotrigine|anticonvulsant medication
215005020|NCT02585765|DRUG|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
215005021|NCT02585765|DRUG|Placebo|8 weeks of daily placebo capsules.
215005022|NCT00087802|DRUG|gemcitabine/Eloxatin (GEMOX)|GEMOX \[gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle\] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days \[3-week cycle\]
215005023|NCT00087802|DRUG|carboplatin/paclitaxel (CP)|"CP \[carboplatin/paclitaxel - 21 day cycle\]~o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days \[3-week cycle\]"
215005024|NCT00962962|BEHAVIORAL|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
214400439|NCT00419003|DRUG|Ketamine|subanesthetic dose of NMDAR antagonist
214400440|NCT00419003|DRUG|Riluzole|glutamate release inhibitor
214400441|NCT05250479|BEHAVIORAL|Mindfulness education|44 primiparous pregnant women will receive mindfulness education
215005025|NCT00962962|BEHAVIORAL|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
215005026|NCT00962962|BEHAVIORAL|Aerobic Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
215005027|NCT00962962|BEHAVIORAL|Exercise and Diet|"* Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~* Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
215005028|NCT00218959|BEHAVIORAL|Narrative Exposure Therapy|Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos \& Monelli).
215005029|NCT00218959|BEHAVIORAL|treatment as usual|
215005030|NCT01290328|DRUG|Epoetin Alfa|150 units/kg/weekly
214400442|NCT03848312|BEHAVIORAL|Cognitive Training|Participants will be completing a total of 45 computerized sessions.
214400443|NCT03848312|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will be completing a total of 45 computerized cognitive stimulation sessions.
214400444|NCT02531438|DRUG|Omadacycline|Injection for IV; Oral tablets
214400445|NCT02531438|DRUG|Moxifloxacin|IV solution; Oral tablets
214400446|NCT01000870|DRUG|MNI-513-01|Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
214400447|NCT03259698|DRUG|nPEP|Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.
214400448|NCT03259698|BEHAVIORAL|Text Messaging Support|"Text messaging support service ('WelTel'): community-based counselors will provides standardized weekly 'check-in' messages during the participants 12-week course of nPEP follow-up. Participants in the text-message arm will also have the option of receiving generic non-specific automated text reminders of their upcoming appointments in the form of Don't forget about tomorrow."
214400449|NCT03259698|OTHER|Nurse-Led nPEP|nPEP follow-up is provided by nurse-led care at a local sexual health clinic instead of a hospital-based ID physician.
214400450|NCT03327675|OTHER|68Ga-PSMA (HBED-CC) PET|68Ga-PSMA PET/MR
214400451|NCT06425705|DRUG|Silymarin|140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.
214400452|NCT06425705|DRUG|Placebo|placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
214400453|NCT02667691|DIETARY_SUPPLEMENT|SODB Dimpless|Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
214400454|NCT02667691|DIETARY_SUPPLEMENT|Placebo|Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
214400455|NCT02667691|OTHER|caloric restriction|Caloric recommendation reduced by 20%
214400456|NCT03730298|DIETARY_SUPPLEMENT|American Ginseng|cpr
214400457|NCT03730298|OTHER|Placebo|cpr
214400458|NCT00772928|BIOLOGICAL|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
214400459|NCT00772928|BIOLOGICAL|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
214400460|NCT05099887|BIOLOGICAL|Procenta conformable barrier|Wound care dressing biologic allograft
214400461|NCT04917692|DRUG|Empagliflozin|2.5 mg daily
214400462|NCT05463211|DEVICE|Trexo Plus Pediatric Exoskeleton|Wearable pediatric robotic walker for the lower extremities
215005031|NCT04240873|BIOLOGICAL|Catholic MASTER cell|Injection of CATHOLIC MASTER cells 1 x 10\^8 cells/DMEM 5cc into knee of patents with osteoarthritis
214400463|NCT05040061|BEHAVIORAL|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
214400464|NCT05040061|BEHAVIORAL|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI prompted participants to notice and write current thoughts and feelings, plan the day's major activities, remember and write about their daily events, and anticipate upcoming important events.
214400466|NCT01693146|DEVICE|Nasal oxygen insufflation with a TNI® 20 oxy device|Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
214400467|NCT01693146|DEVICE|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
214400468|NCT02843022|BEHAVIORAL|standardized electronic messages|supportive and educational short messages
215005032|NCT04240873|OTHER|Saline|Injection of saline 5cc into knee of patents with osteoarthritis
215005033|NCT05290675|DIAGNOSTIC_TEST|Quantra QPlus System|Whole blood coagulation testing system
215005034|NCT00692016|DRUG|Naproxen sodium|Administered under fasting condition
215005035|NCT00692016|DRUG|Naproxen sodium|Administered under fed condition
215005036|NCT03117270|DRUG|filgotinib|one filgotinib oral tablet q.d.
214400469|NCT02843022|BEHAVIORAL|nurse phone call if requested|"If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response"
214400470|NCT02843022|BEHAVIORAL|Staff nurse phone follow-up|Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
214400471|NCT02165124|DEVICE|Artificial Embolization Device|Embosphere Microspheres
214400472|NCT01488110|DEVICE|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an active nasal probe.
214400473|NCT01488110|DEVICE|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an inactive nasal probe.
215005037|NCT03117270|DRUG|Placebo Oral Tablet|one placebo oral tablet q.d.
214693859|NCT02939924|DEVICE|Kanshas DCB|The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length. The balloons is sized to ensure the full length of the lesion is treated. The initial inflation of the study device should be approximately 1 minute for optimal drug release. In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
214693860|NCT00455130|DRUG|Inhaled mannitol|
215005038|NCT03181555|OTHER|Exploratory|
215005039|NCT00120744|DRUG|Ondansetron Oral Disintegrating Tablet|
215005040|NCT00807872|BIOLOGICAL|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
215005041|NCT04764890|OTHER|Electroacupuncture|Electroacupuncture in several point
215005042|NCT04764890|OTHER|Manual therapy|Manual therapy in the lower spine.
215005043|NCT05942222|BIOLOGICAL|dupilumab|Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.
215005044|NCT05942222|BIOLOGICAL|mepolizumab|Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.
214400474|NCT00325559|PROCEDURE|Normoinsulinemic eu- or hyperglycemic clamp|
215005045|NCT00247286|BEHAVIORAL|weighted vaginal cones|
215005046|NCT00247286|BEHAVIORAL|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
215005047|NCT00303953|DRUG|belinostat|Given IV
215005048|NCT03502109|OTHER|Medication review with follow-up|Medication review with follow-up: trained pharmacists will conduct consecutive medication reviews by detecting and resolving drug related problems, educational interventions and applying pharmacotherapy changes made in collaboration with physicians.
215005049|NCT05598268|BIOLOGICAL|T3011|T3011 will be administered through IV drip
214400475|NCT03100838|DRUG|Nifedipine 60 MG Extended Release Oral Tablet|Reference Drug (Brand)
214400476|NCT03100838|DRUG|Nifedipine 60 MG Extended Release Oral Tablet|Test Drug (Generic)
214400477|NCT03100838|DRUG|omeprazole/sodium bicarbonate|Proton Pump Inhibitor/Antacid for drug-drug interaction
214400478|NCT03100838|DEVICE|SmartPill (TM)|Gastric pH measurement using SmartPill (TM) Technology
214400479|NCT06021210|DRUG|Letermovir Pill|Letermovir is the world's first and only new drug approved for the prevention of CMV infection. In 2017, it was approved by the U.S. Food and Drug Administration (FDA) for the prevention of CMV infection and disease in CMV-seropositive adult recipients (R+) of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It was approved in China on December 31, 2021.
214400480|NCT04288466|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin solution 450ml
214400481|NCT01233102|DRUG|Conserved Therapy|Conserved Therapy
215005050|NCT05643508|DRUG|(D) DWC202206|Drug of DWC202206 A mg
215005051|NCT05643508|DRUG|(D) DWC202207|Drug of DWC202207 B/C mg
215005052|NCT05643508|DRUG|(P) DWC202206|Placebo of DWC202206 A mg
215005053|NCT05643508|DRUG|(P) DWC202207|Placebo of DWC202207 B/C mg
215005054|NCT02649933|DEVICE|Watch PAT 200|screening of OSA with Watch PAT 200
215005055|NCT02522741|BEHAVIORAL|Parenting STAIR|Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
215005056|NCT00717080|PROCEDURE|IOL surgery|IOL surgery using capsular tension ring (AURORING)
215005057|NCT00717080|PROCEDURE|IOL surgery|IOL surgery without CTR
215005058|NCT02122276|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch exercise on ankle.
215095912|NCT00756951|DRUG|SCV-07|0.02 mg/kg
215095913|NCT00756951|DRUG|SCV-07|0.10 mg/kg
214400482|NCT01233102|PROCEDURE|Hepatic artery infusion or Intravenous infusion|Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.
214400483|NCT05678153|DIAGNOSTIC_TEST|Nordic Orofacial Test-Screen (NOT-S)|screening tool to detect orofacial dysfunction
214400484|NCT00803140|PROCEDURE|Cautery vs Active Control Arm (Scalpel)|"Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.~A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.~The closure will be standardized."
214400485|NCT00305890|BEHAVIORAL|Lifestyle Behavioral Weight Management Program|The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
214400486|NCT00305890|BEHAVIORAL|Pain-Coping Skills Training|The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
215005059|NCT01777724|BEHAVIORAL|Combination of Triple P Discussion Groups and Stress Control|The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
215005060|NCT05759910|DIETARY_SUPPLEMENT|Brainphyt high dose|Participants will take BrainPhyt capsules during 3 months
215005061|NCT05759910|DIETARY_SUPPLEMENT|Placebo|Participants will take placebo capsules during 3 months
215005062|NCT00085579|BIOLOGICAL|aldesleukin|
215005063|NCT00085579|BIOLOGICAL|sargramostim|
215005064|NCT00085579|PROCEDURE|adjuvant therapy|
215005065|NCT02280954|DRUG|Indocyanine Green (ICG)|
215005066|NCT00056264|DRUG|Infliximab|
215005067|NCT03692962|BEHAVIORAL|Sleep restriction|Time in bed will be restricted to 5 hours per night for 7 nights.
215005068|NCT03692962|OTHER|Acoustic stimulation|Brief tones will be presented time-locked to ongoing slow waves during deep sleep.
215005069|NCT03052673|DRUG|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
215005070|NCT03052673|DRUG|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
215005071|NCT01486433|DRUG|Simvastatin|40 mg (1 tablet) simvastatin once a day
215005072|NCT01486433|DRUG|acetylsalicylic acid (ASA)|81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
215005073|NCT01486433|DRUG|omefas|4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
214400487|NCT00305890|OTHER|Standard Care|Standard care will include routine medical care.
214400488|NCT02781064|DRUG|Atorvastatin 20mg|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
214400489|NCT02781064|DRUG|Placebo|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
214400490|NCT00801242|DRUG|Degarelix 240 mg / 80 mg|For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.
215005074|NCT00594737|DRUG|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
215005075|NCT02612675|OTHER|ONS|
215005076|NCT00464464|BEHAVIORAL|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
215005077|NCT05710822|DEVICE|pulmonary vein isolation|pulmonary vein isolation utilizing the QDOT Micro ablation catheter
215005078|NCT03015701|DRUG|Mifepristone|a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
215005079|NCT03015701|OTHER|Placebo|placebo matching mifepristone
215005080|NCT01651598|DRUG|Placebo to BI 144807|multiple dose (bid)
215005081|NCT01651598|DRUG|BI 144807|multiple dose (bid, low to high dose)
215005082|NCT00019123|DRUG|thalidomide|
215005083|NCT01779661|OTHER|Infant Aquatics|Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
214693861|NCT01313806|DEVICE|Resonator|Treatment group vs. Placebo group
215005084|NCT01779661|OTHER|Infant Massage|Infant Massage
215005085|NCT05788198|OTHER|Integrated care|"The intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are:~1. empowering and engaging people and communities;~2. strengthening governance and accountability;~3. reorienting the model of care;~4. coordinating services within and across sectors;~5. creating an enabling environment."
215005086|NCT01377506|BEHAVIORAL|lifestyle counseling|21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
215005087|NCT01377506|BEHAVIORAL|Cognitive Training|21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
214400491|NCT01182922|BEHAVIORAL|Invitation letter|Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
214400492|NCT06171048|BIOLOGICAL|CM310|CM310 injection
214504116|NCT00307216|BEHAVIORAL|Graduated Recovery Intervention Program (GRIP)|GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.
214504117|NCT00307216|BEHAVIORAL|Treatment as usual (TAU)|Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
214504118|NCT03866824|DRUG|injection of Platelet Enhanced Plasma(PRP)|intra-articular injection
214504119|NCT03866824|DRUG|injection of corticosteroids|intra-articular injection
214504120|NCT03866824|DEVICE|RMI|A CONTROL RMI at 1 year follow-up.
214504121|NCT01776320|DRUG|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
214504122|NCT03642834|DRUG|ICP-105|25mg, 100mg capsule
214504123|NCT06269029|OTHER|Chest mobility exercises|exercises were repeated 6 times on each side with rest of period for 30 seconds in between. The intervention will be carried out for one week with total of 7 sessions. Each Exercise will be accompanied by breathing pattern. In neutral position of exercises, subjects will be asked to exhale during flexion, turning or extension subject will be asked to do inhale.
214693862|NCT01313806|DEVICE|Placebo|Inactive Resonator Device
215005088|NCT04678102|DRUG|PHI-101 administration|Escalated doses of PHI-101 will be administered to each cohort.
215005089|NCT04170933|PROCEDURE|Magnetic recanalization|"1. Establish a percutaneous transhepatic cholangio drainage (PTCD) fistula.~2. Perform endoscopic sphincterotomy (EST).~3. Place one magnet above the stricture through the PTCD fistula.~4. Introduce another magnet below the stricture through the common bile duct with ERCP.~5. Place the magnets at the appropriate point to attract each other.~6. The patient will be strictly followed, and the magnets will be taken out out of the mouth by the thread connected with the magnets.~7. A plastic stent will be placed in the bile duct for lasting support."
215005090|NCT01895998|DRUG|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
215005091|NCT05737147|DEVICE|Zero Heat Flux Thermometer|Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
215005092|NCT01132755|PROCEDURE|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
215005093|NCT02183974|PROCEDURE|Peptest|
215005094|NCT02232698|DEVICE|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
214504124|NCT06269029|OTHER|proprioceptive neuromuscular facilitation|The technique used in this study Proprioceptive neuromuscular facilitation technique of hold and relax stretching for isolated clavicular head of the pectoralis major muscle. The subjects sitting on a chair with back support to keep spine in a neutral position and both their arms are extended and hands are placed behind the occipital region. His both arms will be positioned in glenohumeral horizontal extension, and glenohumeral abduction and external rotation with elbow bent to perform stretch position of pectoral muscle. Then ask him to contract the pectoral muscles .This isometric contraction is held for 6 seconds. The patient then relaxed and passive stretch in the opposite direction . and it was repeated 6 times with rest period 30 seconds. The session will be given every day for one week
214504125|NCT06959771|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|The study cell product is base edited autologous HSPCs which will be administered as a one-time infusion following myeloid conditioning.
214504126|NCT06959771|DRUG|Alemtuzumab|Serotherapy agent, 10 mg/m\^2 on days -21, -20 and -19
215095914|NCT05471180|OTHER|protective spray film|Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.
215095915|NCT05471180|DEVICE|photobiomodulation therapy|application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days.
215095916|NCT04337008|OTHER|blood draw|20 mL blood draw will be performed at J1 et J7
215095917|NCT06941571|OTHER|Irrigation Solution|In this group, the effects of washing burn wounds with different irrigation solutions will be investigated.
215095918|NCT01027260|DRUG|Itopride HCI 50 mg|Variable dosing
215095919|NCT01027260|DRUG|Itopride HCI 100 mg|Variable dosing
214400493|NCT01845636|DRUG|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
214400494|NCT01845636|DRUG|Atropine|A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
214400495|NCT04734041|BEHAVIORAL|Anti-inflammatory (Mediterranean-style) diet|Prescription of an anti-inflammatory diet, which encourages increasing whole fruits, vegetables, and grains, as well as balancing macronutrients (proteins, carbohydrates, and fat) for every meal.
215095920|NCT01027260|DRUG|Placebo|Variable dosing
214400496|NCT04734041|BEHAVIORAL|Behavioral and psychosocial support|Capture a complete and detailed medical history and background. Discuss familial and social support, provide psychosocial support, assess the patient's current self-management strategies for self-care, and assess the patient's current self-management strategies for mental health. Recommendations will be made in accordance with the needs of the participant.
214400497|NCT02093585|DRUG|abacavir (600 mg QD)|
214400498|NCT02093585|DRUG|tenofovir (245 mg QD)|
214400499|NCT02053311|DRUG|Orteronel|300mg orteronel
214400500|NCT02053311|DRUG|Placebo|Placebo
214400501|NCT03092544|DRUG|dimethyl fumarate|Active drug
215005095|NCT02232698|DEVICE|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
215005096|NCT02076841|DEVICE|interferon beta-1a|Administered as specified in the treatment arm
215005097|NCT05817604|RADIATION|SBRT|"Tumors ≤ 4cm: Single SBRT 26Gy dose or Multifraction SBRT dose 14Gyx3 fraction-squeme.~Tumors ≥ 4cm: Multifraction SBRT dose 14Gyx3 or 9Gyx5 fraction-squeme."
215005098|NCT05711147|PROCEDURE|Abutment removal|4 times healing abutment removal during prosthesis making (impressions, metal try-in, ceramic try-in, prosthesis loading)
215005099|NCT05711147|PROCEDURE|Placement of definitive abutment|Placement of the final prosthetic abutment at the moment of implantation
215005100|NCT01997931|DEVICE|Bispectral Index Sedation monitor|
215005101|NCT00387127|DRUG|Lapatinib oral tablets|Lapatinib is administered orally once daily.
215005102|NCT00387127|DRUG|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
215005103|NCT00387127|DRUG|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
215005104|NCT05381870|BEHAVIORAL|Test Preparation-Reference preparation|Under fasting conditions, subjects randomly divided into TR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period.
214400502|NCT02554513|DEVICE|EPG Tx|behavioral intervention that incorporates a device that provides visual biofeedback
214400503|NCT02554513|BEHAVIORAL|SPT|A treatment hierarchy involving integral stimulation
215005105|NCT05381870|BEHAVIORAL|Reference preparation-Test Preparation|Under fasting conditions, subjects randomly divided into RT group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period.
215005106|NCT02393755|DRUG|Capecitabine|Given PO
215005107|NCT02393755|OTHER|Laboratory Biomarker Analysis|Correlative studies
215005108|NCT02393755|DRUG|Nintedanib|Given PO
215005109|NCT02393755|OTHER|Pharmacological Study|Correlative studies
215005110|NCT04058301|OTHER|Text message information|Geographically proximate resources delivered by text message
214400504|NCT05702203|OTHER|Creative Music Therapy|Creative Music Therapy 3x20 minutes per week during admission, at least 10 session during admission, after discharge once every other week until 6 months of age.
214400505|NCT06086002|DEVICE|Microwave ablation|Microwave ablation will be performed by using single antenna (Emprint, Medtronic) with overlapping ablation or two antennas (Starwave, STARmed) with simultaneous ablation.
215005111|NCT04396275|OTHER|Food-1|Cooked whole navy beans (300 kcal)
214400506|NCT05565755|OTHER|Motivational interview|Motivational interview Training
214400507|NCT04055480|DEVICE|Closed-loop using standard rapid-acting insulin|Closed-loop using standard rapid-acting insulin
214400508|NCT04055480|DEVICE|Closed-loop using faster insulin aspart|Closed-loop using faster insulin aspart
214400509|NCT06337643|BIOLOGICAL|MVX01|Pneumococcal Vaccine Candidate
214400510|NCT06337643|BIOLOGICAL|MVX01 Placebo|Placebo
214400511|NCT02295982|PROCEDURE|Hand assisted laparoscopic nephrectomy|patients with renal cancer will undergo hans assisted laparoscopic nephrectomy
214400512|NCT03985722|DRUG|Olaratumab and Trabectedin|"Dose escalation levels:~LEVEL -1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 0.9 mg/m2 D1 This is a security level in case level 0 causes DLT.~LEVEL 0\*: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.1 mg/m2 D1. \* Dose starting level is 0.~LEVEL 1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.3 mg/m2 D1.~LEVEL 2: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.5 mg/m2 D1.~LEVEL 3\*\*: Olaratumab 20 mg/kg C1D1 and C1D8 (induction) + Trabectedin 1.5 mg/m2 D1 and Olaratumab 15 mg/kg D1 and D8 (maintenance) + Trabectedin 1.5 mg/m2 D1~\*\*In LEVEL 3, Olaratumab dose of 20 mg/kg will be considered only for the first 2 doses (as induction doses, cycle 1 days 1 and 8). Then, the maintenance dose will be 15 mg/m2 for the rest of cycles."
214400513|NCT04992442|DRUG|TAK-935 Oral Tablet|TAK-935 tablet
214400514|NCT04992442|DRUG|[14C]TAK-935 IV Infusion|\[14C\]TAK-935 IV infusion
214400515|NCT04992442|DRUG|[14C]TAK-935 Oral Solution|\[14C\]TAK-935 oral solution
214400516|NCT02114827|BEHAVIORAL|Video|23-minute video
214400517|NCT02114827|BEHAVIORAL|FAQ Sheet|
215005112|NCT04396275|OTHER|Food-2|Cooked whole yellow split peas (300 kcal)
215005113|NCT04396275|OTHER|Food-3|Cooked rice considered as control (300 kcal)
215005114|NCT03590002|DEVICE|Electronic ICU Medical Transfer Tool|Patient transfers of care from the ICU to inpatient wards prepared using the electronic ICU medical transfer tool within the health zone's clinical information system, Sunrise Clinical Manager.
215005115|NCT04023253|DRUG|Mirabegron|Mirabegron 25 mg
215005116|NCT04023253|DRUG|Solifenacin|Solifenacin 5 mg
215005117|NCT03737019|BEHAVIORAL|Education with Acceptance and Commitment Therapy|Group education with Acceptance and Commitment Therapy of the personnel at each center.
215005118|NCT03737019|OTHER|Control, no intervention|Control, no interventions.
214400518|NCT04858620|DRUG|Xlear Nasal Spray|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nostrils, every 6 hours
214400519|NCT04858620|DRUG|Placebo|Saline nasal spray, 2 puffs per nostrils, every 6 hours
214400520|NCT01386216|DEVICE|Magellan®|Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
214400521|NCT01029600|PROCEDURE|Arthroscopic capsular release|Surgical division of thickened capsule in the shoulder
214504127|NCT06959771|DRUG|Sirolimus|Immunophilin drug, will start on day -1, targeting a trough level between 4-12 ng/mL.
214504128|NCT06959771|DRUG|Palifermin|Mucositis prophylaxis agent, will be administered at 60 mcg/kg/day for 3 days before initiation of busulfan (days -6 to -4), as well as for the 3 days following study agent administration (days 1 to 3).
214504129|NCT06959771|DRUG|Busulfan|Myeloid conditioning agent, administered once daily (3 mg/kg) x 2 days, targeting a daily AUC of 4500 micromol\*min/L or a cumulative AUC of 9000 micromol\*min/L for the 2 days of therapy, if levels are available
214504130|NCT06959771|BIOLOGICAL|Base-edited T lymphocyte cells|The secondary study cell product is base edited autologous which will be administered as a one-time infusion two weeks following the infusion of the base-edited autologous HSPCs.
214504131|NCT01883193|DIETARY_SUPPLEMENT|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
214504132|NCT02840045|DEVICE|high-density electroencephalography|Musical stimulation during electroencephalography recording
214504133|NCT01289600|DEVICE|Mechanical ventilation|The mechanical ventilator is set to different ventilation modes as described in the individual arms.
214504134|NCT06488742|OTHER|3% kanuka oil|To assess the efficacy in patients with mild atopic dermatitis, 3% kanuka oil will be applied twice a day for 28 days. 3% kanuka oil is a naturally occurring extract from the kanuka tree and is considered an over-the-counter agent.
215005119|NCT05954689|OTHER|Femoral artery block|Injection on the antero-medial side of the femoral artery of 10mL 0.5% ropivacaine with ultrasound guidance.
215005120|NCT03485456|DRUG|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
215005121|NCT01786109|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
215005122|NCT01786109|DRUG|Placebo|Placebo will match study drug; taken as one dose orally with water.
215005123|NCT06410131|DRUG|FTL008.16|IV infusion every 2 weeks
215005124|NCT05993104|DIAGNOSTIC_TEST|Intrachamber ultrasound|Ultrasound left atrial geometry collecting using AcQMap.
215005125|NCT05993104|OTHER|Statistical shape analysis|Statistical shape analysis tools used to investigate left atrial geometry
215005126|NCT04145817|GENETIC|BRIDGES gene panel testing|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
214400522|NCT01029600|PROCEDURE|Distention with steroid|Intraarticular distention with steroid, saline, contrast and local anaesthetic
214504135|NCT06259032|OTHER|Mechanical alignment|Goal alignment in TKA with mechanical alignment, resection bone in perpendicular to mechanical axis of femur and tibia.
214504136|NCT06259032|OTHER|Functional alignment|Goal alignment in TKA with functional alignment, resection of bone base on native joint line obliquity.
214504137|NCT06071052|PROCEDURE|TACE and HAIC Combined With Regorafenib|TACE and HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer who failed the second line treatment regimens
215005127|NCT04145817|GENETIC|Breast cancer risk polygenic risk score (PRS)|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
215005128|NCT04145817|BEHAVIORAL|Questionnaires|Self-administered questionnaires for counselees to evaluate Psychosocial Aspects of Hereditary Cancer (PAHC), Breast Cancer risk perception adequacy, risk communication within the family and cancer risk management choice,
215005129|NCT00781950|DIETARY_SUPPLEMENT|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
215005130|NCT00781950|DIETARY_SUPPLEMENT|Placebo|Wheat and Mixed Dietary Oils
215005131|NCT00780832|BEHAVIORAL|Dietary Caffeine reduction|Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.
215005132|NCT00780832|DRUG|Anticholinergic medication|Detrol LA 4mg. orally, once daily for 30 days
215005133|NCT03826615|DRUG|Gabapentin|Patients receive gabapentin 100mg orally for 3 times a day during the period of first and second cataract operations
215005134|NCT05362084|PROCEDURE|lumbar medial branch block|lumbar medial branch block
214400523|NCT02703285|OTHER|Sound|task of the participants in the study to determine the chest sound based on specific sounds: Vesicular - Diminished; Expiratory Wheeze; Bronchovesicular; pneumonia; pulmonary Oedema; Stridor; Agonal respiration
214400524|NCT01944982|BIOLOGICAL|Expanded haploidentical natural killer cells (NKAEs)|
214400525|NCT02129569|OTHER|Psychoeducational intervention|Receive information about strategies for cognitive self-management of distress
214400526|NCT02129569|BEHAVIORAL|behavioral intervention|Receive individualized walking prescription and wear pedometer
214400527|NCT02129569|OTHER|counseling intervention|Receive supplemental counseling support over the phone
214400528|NCT02129569|OTHER|educational intervention|Receive NCI educational booklets and a link to the ACS website
214504138|NCT04270032|DIAGNOSTIC_TEST|ABUS and HHUS|Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images
214504139|NCT00486304|OTHER|ADD|The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
215005135|NCT03006679|DRUG|Meropenem-Vaborbactam|meropenem 2 g and vaborbactam 2 g
214400529|NCT02129569|OTHER|telephone-based intervention|Receive calls that are primarily social in nature
214400530|NCT02129569|OTHER|questionnaire administration|Ancillary studies
214400531|NCT02129569|OTHER|quality-of-life assessment|Ancillary studies
214400532|NCT00184028|DRUG|Taxotere|Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
214400533|NCT00184028|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
214400534|NCT05145556|DEVICE|Videolarygoscopy|In a randomised order we evaluate the first pass success rate of the tracheal tube into the trachea.
214400535|NCT05145556|DEVICE|conventional laryngoscopy|In a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
214400536|NCT04019821|DRUG|Insulin Glulisine|A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
214400537|NCT04019821|DRUG|Insulin Aspart|A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
214400538|NCT04019821|DRUG|Insulin Lispro|A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
215005136|NCT03006679|DRUG|Piperacillin/Tazobactam|piperacillin 4 g and tazobactam 0.5 g
215095921|NCT04361890|DIAGNOSTIC_TEST|perineal ultrasound|all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
214400539|NCT00191685|DRUG|duloxetine|
214400540|NCT02760862|DRUG|hydrocortisone 100mg.|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
214400541|NCT02760862|DRUG|mannitol 20% intravenous fluid|group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
214504140|NCT00486304|OTHER|Placebo|Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
214504141|NCT06369532|DEVICE|Active tDCS|During the whole therapy period, active tDCS group will receive active tDCS after CBT. They also receive active home-based tDCS.
214400542|NCT01791426|DEVICE|Artelac Rebalance|Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
214400543|NCT01791426|DEVICE|Vismed|Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
214400544|NCT00812630|DRUG|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
214400545|NCT00908856|BIOLOGICAL|autologous bone marrow mononuclear cell transfusion|a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
214400546|NCT00908856|BIOLOGICAL|marrow stromal cells|a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)
214400547|NCT00908856|DRUG|placebo|a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
214400548|NCT03110679|BIOLOGICAL|injection of autologous bone marrow concentrate|
214400549|NCT03110679|BIOLOGICAL|injection of hyaluronic acid.|
214400550|NCT02179645|DRUG|GRC 27864|
214400551|NCT02179645|DRUG|Celecoxib|
214400552|NCT02179645|DRUG|Placebo|
214400553|NCT01803932|BEHAVIORAL|Male-focused group violence prevention intervention|
214400554|NCT00256139|DRUG|Raptiva|
214400555|NCT00162942|DEVICE|Adacolumn|"Ten apheresis sessions:~One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9)."
214400556|NCT00162942|DEVICE|Sham|Sham, ten apheresis sessions within 9 weeks
214400557|NCT04569214|DRUG|PAZ320|Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
214400558|NCT04569214|OTHER|Placebo|Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
214504142|NCT06369532|DEVICE|Sham tDCS|The sham tDCS group will receive sham tDCS after CBT. They also receive sham home-based tDCS.
214504143|NCT01271244|DRUG|Escitalopram|10-20mg daily for 12 weeks
215005137|NCT03915457|OTHER|Dry immersion Control Group|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
215005138|NCT03915457|OTHER|Thigh cuffs intervention|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water. During the 5 days of dry immersion, the subjects will wear the thigh cuffs daily for 10 hours during the day (8 am to 6 pm). Thigh cuffs are strips of fabric with inserts of elastic fabric. Different sizes exist to adapt to different thighs. Each cuff has five tightening positions (from 1 to 5) and they will be tightened at the upper third of the thighs to create an occlusion pressure of about 30 mmHg.
215005139|NCT02993900|DEVICE|Image-Guided Brachytherapy|Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
215005140|NCT05926531|DEVICE|CBTI online programe|20 MIN VR RELAX PROGRAME
215005141|NCT03673358|BEHAVIORAL|Cognitive Behavioural Therapy|"Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT"
215005142|NCT03491917|DEVICE|DBT plus S-View|DBT plus S-View images
215005143|NCT03491917|DEVICE|FFDM alone|FFDM alone images
215005144|NCT00250003|BEHAVIORAL|Preventive home visits|
215005145|NCT02395770|OTHER|Rehabilitation program|"Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.~Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.~Stretching \& Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.~Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports"
215005146|NCT00069745|DRUG|Satraplatin|
214400559|NCT06252389|PROCEDURE|Achilles Tendon Repair augmented with Bioinductive Collagen Patch|Standard Achilles Tendon Repair augmented with Bioinductive Collagen Patch. Standard Rehabilitation Protocol.
214400560|NCT01513356|DRUG|BKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
214400561|NCT00037700|DRUG|anakinra|
214400562|NCT00037700|DRUG|pegsunercept|
214504144|NCT02234999|DRUG|CC-122|3mg \[14C\]-CC-122 will be administered as a single dose
214504145|NCT05532553|DEVICE|Carotid Doppler U/S|Measurement of carotid intima media thickness by carotid doppler ultrasound
214504146|NCT04313699|DRUG|Antiretroviral treatment|The cohort will recruit HIV infected participants who are on antiretroviral treatment
214504147|NCT00615368|DRUG|Epoetin alfa|1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
214504148|NCT00615368|DRUG|Isotonic NaCl (Placebo)|1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
214504149|NCT05469165|DRUG|Cyproheptadine 4 Mg Oral Tablet|Cyproheptadine treatment for 3 months
215005147|NCT00069745|DRUG|Prednisone|
215005148|NCT03040531|DIETARY_SUPPLEMENT|Genistein aglycone|27mg bid in tablets
215005149|NCT03040531|DRUG|Alendronate Oral Tablet|70 mg/week in tablets
215005150|NCT03040531|DIETARY_SUPPLEMENT|Calcium + vitamin D3 tablet|500mg Calcium + 200 IU Vitamin D3 bid in tablets
215005151|NCT03896620|DEVICE|Preoperative RT|Radiation delivered before surgery.
215005152|NCT03896620|DEVICE|Postoperative RT|Radiation delivered after surgery.
215005153|NCT03896620|DRUG|Chemotherapy|Physician's choice of chemotherapy.
215005154|NCT03896620|OTHER|Surgery|Surgical excision of tumor.
214400563|NCT04879355|DEVICE|Spinal needle (25G)|Fine needle aspiration from thyroid nodules using a 25G spinal needle.
214400564|NCT04879355|DEVICE|Conventional fine needle (25G)|Fine needle aspiration from thyroid nodules using a conventional 25G fine needle
214504150|NCT05469165|OTHER|Placebo|Placebo administration for 3months
214504151|NCT02697968|DEVICE|Electroacupuncture|
214504152|NCT04658784|DEVICE|2-0 dioxanone, glycolide and trimethylene carbonate|delayed absorbable, monofilament barbed suture
214504153|NCT04658784|DEVICE|2-0 polydioxanone|delayed absorbable, monofilament non-barbed suture
214504154|NCT04574206|BEHAVIORAL|Elaborative Reminiscence (ER)|Parents will be trained to use elaborative communication techniques in conversations with their child.
215005155|NCT00657605|DRUG|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
215005156|NCT06047327|DIAGNOSTIC_TEST|EUS guided liver biopsy|Procedure will be performed by 19G Franseen needle.
215005157|NCT06047327|DIAGNOSTIC_TEST|Percutaneous Liver Biopsy|procedure will be done by 18G BioPince Needle
215005158|NCT04776772|DIETARY_SUPPLEMENT|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
215005159|NCT04776772|DIETARY_SUPPLEMENT|Placebo|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo)."
215005160|NCT00395382|DRUG|Alendronate|70mg weekly orally
215005161|NCT00395382|DRUG|Placebo|weekly orally
215005162|NCT04288037|DIAGNOSTIC_TEST|fetal heart rate variability|observational study. no intervention
215005163|NCT00945620|DRUG|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
215005164|NCT00945620|DRUG|placebo|Placebo
215005165|NCT04069520|OTHER|aNMT Biofeedback|"aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention. The aNMT biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks."
215005166|NCT04069520|OTHER|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases. The sham biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks.
214400565|NCT03691584|DRUG|TP-6076|The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).
214400566|NCT03691584|PROCEDURE|Bronchoalveolar lavage|Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.
214400567|NCT01354938|DRUG|Clarithromycin modified release 500 mg|Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
215005167|NCT01068912|DRUG|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
215005168|NCT01068912|DRUG|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
215005169|NCT01068912|DRUG|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
215005170|NCT03678662|OTHER|Hypoalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information."
215005171|NCT03678662|OTHER|Hyperalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information."
214400568|NCT06488729|OTHER|Foot massage|Foot massage
214400569|NCT04424485|PROCEDURE|Total thyroidectomy (TT)|Standard TT procedure for thyroid carcinoma, for both groups
214400570|NCT04424485|PROCEDURE|Central lymph node dissection (CLND)|Standard CLND for thyroid carcinoma, for both groups
214400571|NCT04424485|DIAGNOSTIC_TEST|Sentinel lymph node (SLN) bopsy|Intrathyroidal injection of ICG for SL biopsy, for only experimental group
214400572|NCT04424485|DIAGNOSTIC_TEST|Identification of parathyroid glands (PGs)|Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
214400573|NCT01133509|DRUG|Gardasil|0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
214400574|NCT03496961|BEHAVIORAL|Yan Nian Jiu Zhuan Fa|Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
214400575|NCT00080002|DRUG|Pegamotecan|
214400576|NCT04785183|DIETARY_SUPPLEMENT|Melatonin drops|Melatonin oral administration
214400577|NCT04785183|OTHER|Placebo|Oral 5% glucose
214400578|NCT05843175|OTHER|Exercise and meal testing (acute stimuli)|"Pre-meal exercise: 1º milkshake intake + 2º exercise test~Post-meal exercise: 1º exercise test + 2º milkshake intake~Non-exercise meal: Only milkshake intake"
214400579|NCT03186937|DIETARY_SUPPLEMENT|hominex-2|Hominex-2 is a methionine-free amino acid modified medical supplement
214400580|NCT02424461|DRUG|Ceftriaxone|1 injection 1 g per day for 2 days
214400581|NCT02424461|DRUG|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for seven days
214400582|NCT02424461|DRUG|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
214400583|NCT02424461|DRUG|Placebo of ofloxacine|Placebo of ofloxacine for 7 days
214400584|NCT01253200|DEVICE|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
214400585|NCT01253200|DEVICE|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
214400586|NCT04047069|BEHAVIORAL|Awareness Training and Person-Centered Occupational Therapy Intervention|Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.
214400587|NCT04047069|BEHAVIORAL|Awareness Training|"Exp.~* General information about HD~* Approaches to Coping with HD Symptoms~* Self care skills (eg hygiene)"
214400588|NCT03112278|PROCEDURE|Ceramic ultrathin occlusal veneers|Severely eroded teeth will be restored with ultrathin occlusal veneers made of ceramic (e.max CAD/Ivoclar Vivadent) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
214400589|NCT03112278|PROCEDURE|Composite resin ultrathin occlusal veneers|Severely eroded teeth will be restored ultrathin occlusal veneers made of composite resin (Lava Ultimate/3M Espe) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
214400590|NCT06116643|DIETARY_SUPPLEMENT|Soluble protein hydrolysate (SPHi)|Participants that are already on stable maintenance therapy for ulcerative colitis will continue with their therapy regimen and the addition of 10g of SPHi in 100ml of water every day for 12 weeks.
214504155|NCT04574206|BEHAVIORAL|Present Tense Talk (PTT)|Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
215005172|NCT03678662|OTHER|Neutral|"Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles."
215005173|NCT03634150|BIOLOGICAL|Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.|Once weekly treatment, with IV doses of Nerofe (96mg\\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
215005174|NCT05414773|OTHER|measurement of axial length and keratometry by sonographers with a topographic module|measurement of axial length and keratometry by sonographers with a topographic module
215005175|NCT04777903|OTHER|collect date about all participants|a standardized and structured questionnaire that included information on age, residence, education, pregnancy history, disease history, height, and conception method, after obtaining the consent of all participants.
215005176|NCT00857051|OTHER|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
215005177|NCT00857051|OTHER|Film|A DVD addressing common stressors in the early postpartum.
215005178|NCT00680173|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
215005179|NCT00512863|DRUG|Humira (adalimumab)|
214400591|NCT05987150|RADIATION|Variation in anisotropy of the Spinal Cord using diffusion tensor imaging|All examinations were performed on a 3.0-T MRI machine with a 12-channel spine special coil (Ingenia CX, Philips Healthcare, Best, the Netherlands). The multi-sequence MRI protocol included conventional T1-weighted (sag \& tra), T2-weighted (sag \& tra), and DTI sequence.
214400592|NCT01016990|DRUG|valproic acid|
215005180|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
214400593|NCT01016990|GENETIC|western blotting|
214400594|NCT01016990|OTHER|laboratory biomarker analysis|
214504156|NCT05227898|DEVICE|Device: Attune™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
214504157|NCT05227898|DEVICE|Device: Cerena™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
214504158|NCT03624283|DRUG|Betahistine|Betahistine is used in the treatment of and vertigo.
214504159|NCT03624283|BEHAVIORAL|Exercise-based vestibular rehabilitation|Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
214504160|NCT01189552|BEHAVIORAL|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
214504161|NCT01189552|BEHAVIORAL|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
215005181|NCT04573946|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
215005182|NCT04573946|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
215005183|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3|"Vitamin D3 (cholecalciferol), 2000 IU per day.~Other Names: cholecalciferol"
215005184|NCT01868451|DRUG|Brentuximab vedotin (SGN-35)|
215005185|NCT01868451|DRUG|Doxorubicin HCL|
215005186|NCT01868451|DRUG|Vinblastine Sulfate|
214400595|NCT01016990|OTHER|pharmacological study|
215005187|NCT01868451|DRUG|Dacarbazine|
215005188|NCT01868451|RADIATION|Involved-Site Radiation Therapy (ISRT)|
215005189|NCT01868451|PROCEDURE|Interim PET|
215005190|NCT01868451|RADIATION|consolidation volume RT (CVRT)|
215005191|NCT05705271|DRUG|Finerenone (Kerendia, BAY94-8862)|Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
215005192|NCT03485417|DRUG|Aripiprazole|for oral or depot preparation
215005193|NCT03485417|DRUG|Paliperidone|for oral or depot
215005194|NCT03485417|OTHER|Treatment as Usual|to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone
215005195|NCT05621980|BEHAVIORAL|Actuated Virtual Keyboard (AVK) system|"The participant controls an avatar hand by the movement of their own digits. Each avatar digit corresponds to a given virtual key. Sufficient digit flexion results in playing of that key, with visual and auditory feedback of key strike. Participants will wear a soft exoskeleton, the PneuGlove, with embedded bend sensors to provide real-time measurement of digit flexion. Pneumatic resistance to flexion can be applied to each digit independently, along with extension assistance, through air chambers running through the glove. The FES is intended to assist finger flexion by activating extrinsic finger flexor muscles. A high-density 2×8 stimulation electrode grid will be placed over the median and ulnar nerves at the medial side of the upper arm. The stimulator can deliver electrical stimulation to any pair of electrodes. At the beginning of each session, the investigators will identify the electrode pairs which best produce flexion of each digit with minimal discomfort."
215005196|NCT05621980|BEHAVIORAL|Occupational Therapy (OT)|Traditional occupational therapy training sessions.
215005197|NCT05919056|OTHER|Frequent and automatic cardiovascular risk assessment|The 10-year cardiovascular risk scores using the 2019 World Health Organization (WHO) laboratory-based risk charts will be automatically calculated using the latest health information on an EHR-based system per month.
215005198|NCT05919056|OTHER|Dynamic risk monitoring|High-risk individuals will be reassessed by the Dynamic Risk-based Early wArning and Monitoring (DREAM) system to obtain the short-term risk. The DREAM system will send a text message about advice to the high-risk individual every month. The text message includes information on the health status (e.g., current cardiovascular risk, level of blood pressure and lipid) and real-time warning messages (e.g., high short-term risk).
215005199|NCT05919056|OTHER|Regular GP visits|"The general practitioners will communicate with the participants based on the information automatically generated from the DREAM system every three months: each participant's cardiovascular risk score, health status (e.g., diabetes mellitus and/or hypertension), and Chinese guidelines-based recommendations (e.g., for the management of dyslipidemia, to provide clear treatment targets for high-risk participants)."
215005200|NCT04423874|BEHAVIORAL|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance.~Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min.~The procedure is safe because the hand is removed before adverse effects can occur.~The participant will be given a break of 5 min in between trials, and will interchange hands between trials.~During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand. Each participant will complete no more than three trials (conditions) in a randomised order."
215005201|NCT04423874|DIAGNOSTIC_TEST|index NOL|Measurement of the index NOL™: Four sensors, placed non-invasively on one of the four participants' fingers, will make it possible to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
215005202|NCT04423874|BEHAVIORAL|Playback Experiments|During the experience, participants are led to listen, via headphones, to aversive non-verbal vocalizations (baby crying). The sound levels used to broadcast the non-verbal vocalisations will be scrupulously measured using approved and certified equipment during the preparation of the experiments. These sound volumes will be chosen so as not to inconvenience participants.
215005203|NCT04423874|DIAGNOSTIC_TEST|Video-pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
215005204|NCT04822194|BEHAVIORAL|Cognitive Emotion Regulation Training|Cognitive emotion regulation training via cognitive reappraisal involves the ability to modify the trajectory of an emotional response by thinking about and appraising emotional information in an alternative, more adaptive way. Reappraisal to down-regulate negative emotion can be operationalized via two tactics: psychological distancing and reinterpretation. The current study will randomly assign participants to receive a brief course of reappraisal training using either psychological distancing or reinterpretation.
215005205|NCT06853145|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe129-MRI: Patients will undergo hyperpolarized Xe129-MRI at the University of Virginia Radiology Imaging Core (Charlottesville, VA, USA). The entire procedure visit takes approximately 3 hours based on our team's experience.
215005206|NCT04611815|PROCEDURE|Total knee arthroplasty|Participant will undergo robotic-assisted or conventional total knee arthroplasty
214400596|NCT06492538|PROCEDURE|various types of angle interventions|procedures include laser peripheral iridotomy (LPI) to relieve pupillary tissue and deepen peripheral anterior chamber depth, Argon laser peripheral iridoplasty (ALPIp) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositor. Ab interno goniotomy using instruments like retina hooks, trabeculectomy hooks, or cannulas are used to incise trabecular meshwork and Schlemm's canal walls to enhance aqueous humor outflow.
214400597|NCT02217995|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual (automatic) dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams \& Teasdale, 2002)."
214400598|NCT00705640|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously and intradermally
214400599|NCT00705640|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given subcutaneously and intradermally
214400600|NCT00705640|BIOLOGICAL|tetanus toxoid helper peptide|Given subcutaneously and intradermally
215005207|NCT04611815|DIAGNOSTIC_TEST|Computer tomography scan|CT scans of the affected knee joint before and after the surgical procedure
215005208|NCT04611815|DIAGNOSTIC_TEST|biomechanical assesment|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
215005209|NCT01346306|DEVICE|Eldith Company - direct current stimulator|Direct current stimulation montage 1.
215005210|NCT01346306|DEVICE|Eldith Company - direct current stimulator|Direct current stimulation montage 2.
215005211|NCT04701996|BIOLOGICAL|serological surveillance|serological surveillance, detection of antibodies (Total Ig and IgM) developed against SARS-CoV-2 in a population living in a rural area (Kimpese, DRC)
215005212|NCT04057768|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.
214400601|NCT00705640|PROCEDURE|biopsy|Patients undergo surgical biopsy at replicate vaccine site
215005213|NCT01452256|DRUG|Desflurane|4-6 Vol %
215005214|NCT01452256|DRUG|Propofol|TIVA to achieve BIS value of 40-60
215005215|NCT02745730|OTHER|Glucose|
215005216|NCT02745730|OTHER|Fructose|
215005217|NCT02745730|OTHER|Sucralose|
214400602|NCT01096095|DRUG|Placebo|Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
214400603|NCT01096095|DRUG|Sodium Phenylbutyrate|Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
214400604|NCT02335268|DRUG|N-Plate / romiplostim|medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
214400605|NCT05465694|PROCEDURE|2-minute-time interval of per oral 24% sucrose|Experiment began with a five-minute observation period of all outcome measures while infant was resting in an incubator. Later, attendant nurse gave 1 ml of 24% sucrose solution on neonate's tongue. In the 2-two minute-time interval prior to heel lance intervention, following two minutes of waiting period, heel lance procedure was applied to infant's foot. In no time interval of sucrose given immediately prior to heel lance intervention, attendant nurse performed heel lance procedure immediately after giving 1 ml of 24% sucrose solution sucrose on tongue. Infant's facial actions and heart rate, and oxygen saturation were recorded by using two video cameras. Recording was carried out by a nurse during whole procedure. After collecting data, researcher watched videos separately and scored them by using PIPP-R. Measurement of study outcome relied on data collection strategies: Neonatal close-up video recording of infant facial actions, pulse oximeter, observation for adverse events.
215005218|NCT02745730|OTHER|Allulose|
215005219|NCT03060681|DRUG|Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block|After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
215005220|NCT04078308|BIOLOGICAL|Intravenous Injection of autologous mesenchymal stem cells|Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 \& 3
215005221|NCT04078308|OTHER|Intravenous injection of placebo|Intravenous injection of normal saline (sodium chloride 0.9%)
214400606|NCT05465694|PROCEDURE|no time interval of per oral 24% sucrose|no time interval of per oral 24% sucrose
214400607|NCT00625274|DRUG|Esomeprazole|40mg Oral
214400608|NCT00625274|DRUG|Lansoprazole|30mg Oral
214400609|NCT00625274|DRUG|Pantoprazole|40mg Oral
214400610|NCT00000195|DRUG|Naltrexone|
214400611|NCT02706626|DRUG|brigatinib|Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer
214504162|NCT04192357|BEHAVIORAL|WLM3P|18 months behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 month and 5 months, respectively; and a third phase of weight maintenance, during 12 months).
214504163|NCT04192357|BEHAVIORAL|Low-carb diet|18 months behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance during 12 months).
214504164|NCT04751981|PROCEDURE|Patient Specific Guide|For lumbar fusion pedicle screws will be placed with the aid of patient specific guides.
215005222|NCT02178332|OTHER|Yhteispeli, whole school programme|
215005223|NCT02178332|OTHER|Two theoretical lectures|
215005224|NCT05574985|BIOLOGICAL|Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)|Injected one dose of research vaccine
215005225|NCT05574985|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero Cell)|Injected one dose of control vaccine
215005226|NCT03594552|DRUG|Arbaclofen_15|Single oral dose (15mg)
215005227|NCT03594552|DRUG|Arbaclofen_30|Single oral dose (30mg)
214504165|NCT04751981|PROCEDURE|Navigation|Conventional navigation will be used to place pedicle screws.
215005228|NCT03594552|DRUG|Placebo|Single oral dose placebo (oral tablet)
215005229|NCT01947933|BIOLOGICAL|Mirikizumab- IV|Administered IV
214504166|NCT05722626|PROCEDURE|PRP|2 ml of platelet rich plasma intraarticular injection twice in one week interval
215005230|NCT01947933|BIOLOGICAL|Mirikizumab - SC|Administered SC
215005231|NCT01947933|BIOLOGICAL|Placebo - IV|Administered IV
215005232|NCT00130364|DRUG|Pimecrolimus|Pimecrolimus 1 % cream
215005233|NCT00130364|DRUG|Placebo|Pimecrolimus vehicle cream (placebo)
215005234|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
215005235|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
215005236|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
215005237|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
215005238|NCT03195556|DEVICE|Ultrasound|Ultrasound exposure of Definity microbubbles infused over 10 min. Ultrasound administered at 1.3 MHz, mechanical index of 1.3, and pulsing interval of 10 s.
215005239|NCT03407456|OTHER|Gastroesophageal reflux symptoms questionnaire|Reflux Symptom Questionnaire, 7-day recall (RESQ-7).
214400612|NCT03065790|DIAGNOSTIC_TEST|2-Deoxy-2-[18F]fluoro-D-glucose (FDG)|2-Deoxy-2-\[18F\]fluoro-D-glucose (FDG)
214400613|NCT00843362|DRUG|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
214400614|NCT00843362|DRUG|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
214504167|NCT05722626|OTHER|Normal Saline|NaCl 0.9%
214504168|NCT05018156|BEHAVIORAL|Default Genetics Referral Process|Patients and their oncology providers will be notified of their eligibility for a cancer genetics referral, with an option to opt out if they are not interested in proceeding. Everyone else will be automatically referred to their local hospital's cancer genetics program for contact and scheduling. Standard genetic counseling, testing, and results disclosure will take place, including usual methods of payment and insurance coverage for testing.
214504169|NCT03260998|DIAGNOSTIC_TEST|electrocardiogram|measurment of QT dispersion and corrected QT and other electrocardiogram changes
215005240|NCT04571034|PROCEDURE|Sham Therapeutic Ultrasound|A standard ultrasound machine (Vectratm by Chattanooga Group, Inc.) with inactive probe will be used to deliver sham massage.
215005241|NCT04571034|PROCEDURE|Medium-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (25 newtons of force directed perpendicular to the surface of the thigh).
215005242|NCT04571034|PROCEDURE|High-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (45 newtons of force directed perpendicular to the surface of the thigh).
215005243|NCT02260271|OTHER|Database Entry/Biospecimen Collection|blood, urine, buccal samples and medical data collected
215005244|NCT05309772|DIAGNOSTIC_TEST|Basophil activation test (BAT)|"Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT:~• BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c.~MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils."
215005245|NCT05309772|DIAGNOSTIC_TEST|Oral food challenge (OFC)|Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.
215005246|NCT03509155|OTHER|National portion & IYCF counseling|Eight or twelve pieces of Biscuits supplementation per day as serving size recommendation based on the requirement from Ministry of Health, accompanied by IYCF Counseling emphasizing on local food optimization. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
215095922|NCT05703594|DIAGNOSTIC_TEST|performance based balance test|Performance based balance test; 360° Turn Test, Alternative Step Test, Pen Pickup Test,5 Repetitive Stand Up and Sit Test, 10 Meter Walk Test Lower extremity strengthening exercises; Quadriceps femoris strengthening exercise Hamstring strengthening exercise Gluteus medius muscle strengthening exercise Strengthening exercise for hip adductor muscles Balance exercises; Standing tandem walk Standing side walks Standing cross walks Standing back walking
215095923|NCT01927055|DRUG|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
215095924|NCT01927055|DRUG|Placebo|Placebo to match droxidopa capsules and strength designations
214400615|NCT01879878|DIETARY_SUPPLEMENT|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
214400616|NCT01879878|DIETARY_SUPPLEMENT|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
215005247|NCT03509155|OTHER|Adjusted portion & local food counseling|four pieces of Biscuits supplementation per day as serving size recommendation, accompanied by IYCF Counseling. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
215005248|NCT04032223|PROCEDURE|Implant placemet in the mandibular canine regions|Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
214400617|NCT03670745|BEHAVIORAL|An electronic self-administered pre-visit planning tool.|An electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit.
214400618|NCT03670745|BEHAVIORAL|Control group|No planning tool
214400619|NCT04462913|OTHER|no intervention|This is an observation study, with no intervention
214400620|NCT04700319|DRUG|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T,Infusion,iv,0.2×10\^6-5×10\^6γδT /kg,once
214400621|NCT00547664|DRUG|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
214400622|NCT00547664|OTHER|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
214400623|NCT02938390|PROCEDURE|Ultrasound for localizing intercostal perforating vessels|Use of an Intra-operative ultrasound during nipple sparing mastectomy to localize intercostal perforating vessels.
215005249|NCT03588468|OTHER|Electrophysiological biomarkers|Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
215005250|NCT03588468|OTHER|MRI biomarkers|T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
215005251|NCT02700256|BEHAVIORAL|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
215005252|NCT00350285|BEHAVIORAL|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
215005253|NCT00350285|BEHAVIORAL|Marijuana education|Information about health and behavioral effects of marijuana use.
215005254|NCT00248547|DRUG|aprepitant|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
215005255|NCT00248547|DRUG|dexamethasone|For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
215005256|NCT00248547|DRUG|ondansetron|For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
215005257|NCT00248547|DRUG|placebo|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
214504170|NCT05030415|DRUG|Ixekizumab Auto-Injector|160 mg week 0 followed by 80 mg every two weeks
215005258|NCT04021797|DEVICE|transcutaneous vagal nerve stimulation|The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.
215005259|NCT00294398|OTHER|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
215005260|NCT00294398|OTHER|Standard Asthma ED Discharge Therapy|Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
214400624|NCT04889885|DEVICE|High-intensity laser therapy (HILT)|"HILT was done by Multiwave Locked System (MLS) laser therapy combining 2 laser wavelengths (808 and 905 nm) in order to strengthen the effects of HILT. The laser was applied on medial, lateral and posterior parts around the knee joint. The total energy per session was 562.5 Joules (J) which was done 2-3 times a week for a total of 10 sessions.~Additionally, the participants received conservative treatment for knee OA such as education about the disease, proper activities, and exercise."
214400625|NCT04889885|DEVICE|Sham laser|The control group received a sham laser (2-3 times a week for a total of 10 sessions) plus conservative treatment as in the intervention group. The laser machine was the same as in the intervention group; however, the laser was applied without releasing laser energy to the knee joint.
214504171|NCT01833598|PROCEDURE|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
214504172|NCT01833598|PROCEDURE|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
215005261|NCT03620279|BEHAVIORAL|Magic camp intervention|Hand-arm bimanual motor skills training
215005262|NCT02965833|DEVICE|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix|For cleaning, disinfection and overnight storage of contact lenses
215005263|NCT02965833|DEVICE|Habitual Multi-Purpose Contact Lens Solution|
215005264|NCT02965833|DEVICE|Habitual Contact Lenses|Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
215005265|NCT01769365|DRUG|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
214400626|NCT03207425|DRUG|EDP 305|Each subject will receive a single dose of EDP 305 on Day 1.
215005266|NCT01769365|DRUG|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
215005267|NCT01769365|DRUG|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
215005268|NCT03860480|PROCEDURE|ESP with Bupivacaine 0.5%|Regional anesthesia procedure with Bupivacaïne 0.5%
215005269|NCT03860480|PROCEDURE|ESP with Saline 0.9%|Regional anesthesia procedure with Normal Saline
215005270|NCT05726136|DRUG|acetated Ringers|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
214400627|NCT03943186|DEVICE|Ectoin Lozenges Honey Lemon|application of Ectoin Lozenges (EHT02) in accordance with the instructions for use
214400628|NCT03943186|DEVICE|Hyaluronic Acid/Icelandic moss Lozenges|application of the lozenges in accordance with the instructions for use
214400629|NCT03423901|OTHER|Blood sampling|Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)
214400630|NCT03785340|DRUG|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
214400631|NCT03785340|DRUG|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
214504173|NCT02930317|DRUG|Recombinant Factor VIII (50 IU/kg)|
214504174|NCT02930317|DRUG|Recombinant Factor VIII (On-demand treatment)|
214504175|NCT01083706|DRUG|azacitidine|Given SC or IV
215005271|NCT05726136|DRUG|albumin 5%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
214504176|NCT01083706|OTHER|laboratory biomarker analysis|Correlative studies
214504177|NCT02269852|BIOLOGICAL|trivalent seasonal influenza vaccine|"* Infants: 0.25 ml/ dose;~* Adults: 0.5 ml/ dose;~* Seniors: 0.5 ml/ dose;"
214504178|NCT02224469|DEVICE|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
214504179|NCT04634851|BEHAVIORAL|Virtual home visits|These participants will have a tailored evaluation of dietary choices based on their home dietary environment (refrigerator, pantry, etc). This will be conducted over video exchange.
215005272|NCT05726136|DRUG|albumin 20%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
215005273|NCT00408954|DRUG|UK-369,003|100 mg MR tablet once daily for 2 weeks
215005274|NCT00408954|DRUG|UK-369,003|UK-369,003-100 mg MR formulation for 2 weeks
215005275|NCT05708651|DEVICE|Investigational device [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep steady-state sedation \[I-II\] or procedural sedation according to SOC \[III-IV\].
215005276|NCT05708651|DEVICE|Comparator [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock \[I-II\] or no device \[II-IV\]) in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep levels of steady-state sedation \[I-II\], and during procedural sedation according to SOC for scheduled colonoscopy \[III\] or ureteral catheterization \[IV\].
214400632|NCT02519179|BEHAVIORAL|Opaque, weighted bottle|This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.
214400633|NCT02519179|BEHAVIORAL|Clear, conventional bottle|This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
214400634|NCT03281564|OTHER|Quality of life after Essure® removal|Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device
214400635|NCT01253980|DRUG|Amoxicillin|Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
214400636|NCT01253980|DRUG|Placebo|"Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days"
214400637|NCT01700530|DRUG|Statin|Statins (40mg/day)for 12 weeks
214400638|NCT01700530|OTHER|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
214504180|NCT03210324|DRUG|Mifepristone tablets|Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
214504181|NCT03387826|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg twice daily
214504182|NCT03387826|DRUG|Prasugrel 5mg|Prasugrel 5 mg once daily
214504183|NCT03466983|DRUG|Iron Isomaltoside|administered IV
214504184|NCT03466983|DRUG|Ferric Carboxymaltose|administered IV
214504185|NCT02223728|BEHAVIORAL|Lifestyle|
215005277|NCT06286943|DIETARY_SUPPLEMENT|Short Chain Fatty Acids (SCFAs).|Colon-delivery capsules of SCFAs.
215005278|NCT06286943|DIETARY_SUPPLEMENT|Placebo|Microcrystaline cellulose placebo capsules.
215005279|NCT06286943|OTHER|Maastricht Acute Stress Task|The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.
215005280|NCT06286943|OTHER|No-stress control task|The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
215005281|NCT02606539|PROCEDURE|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
214504186|NCT02223728|BEHAVIORAL|Health Education|
215005282|NCT02606539|DRUG|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
215095925|NCT04577079|DEVICE|Evaluation of the need of emergency medical services|The main aim of this study is to validate the use of IPFM in a hospital setting by evaluating the association of IPFM output with 1) clinical urgency and severity of the conditions (using Emergency Severity Index \[ESI\], an international triaging protocol for emergency units, and an assessment by triage nurse); and 2) actual diagnoses made by the hospital doctors. The objective is also to assess the correlation of IPFM output with redirection or referral to various specialties
215095926|NCT03829956|DEVICE|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
215095927|NCT02126072|DIETARY_SUPPLEMENT|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
214400639|NCT01700530|OTHER|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
214504187|NCT05210309|PROCEDURE|Stem Cell Therapy|Application of Darvadstrocel locally, after fistula tract curettage and internal opening closure.
214504188|NCT05493488|BIOLOGICAL|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with tinea pedis
214504189|NCT05493488|BIOLOGICAL|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with tinea pedis
214400640|NCT02250144|DEVICE|Foot orthoses|
214400641|NCT06086808|OTHER|Resistance Training|A resistance training program will be used as a progressive, high-intensity protocol. The training stimulus will be provided using free weights. The exercises will consist of bench presses, biceps curls, triceps extensions, Latissimus Dorsi pull-down exercises, hamstring curls, and calf raises. The intensity of the training stimulus will be at a working range of 6 to 8 repetitions (2 sets). The training stimulus will subsequently be increased using the 7-RM (repetition maximum) method when 2 sets of 6 to 8 repetitions are completed with proper form and without discomfort. Other key strength exercises will include mini-squats, mini-lunges, and lunge walks. The number of sets completed and the load lifted for each exercise will be recorded for each participant in every class.
214504190|NCT05493488|BIOLOGICAL|Aqueous Gel|Topical application of Aqueous gel on foot/feet affected with tinea pedis
214504191|NCT02095145|OTHER|Laboratory Biomarker Analysis|Correlative studies
214504192|NCT02095145|OTHER|Pharmacological Study|Correlative studies
214504193|NCT02095145|OTHER|Placebo|Given PO
214504194|NCT02095145|DRUG|Pomegranate-Extract Pill|Given PO
214504195|NCT03492853|GENETIC|DNA extraction and sequencing|DNA extraction from peripheral blood and KASP sequencing
214504196|NCT02916576|DEVICE|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
214400642|NCT06086808|OTHER|General Fitness and Toning|The general fitness and toning program will consist of stretching exercises, range-of-motion exercises, basic core-strengthening exercises, balance exercises, and relaxation techniques. Key balance exercises will include tandem stand, tandem walking, and single leg stance (eyes opened and closed). No additional loading (e.g., hand weights or resistance bands) will be applied to any of the exercises. This group will serve to control for confounding variables such as physical training received by traveling to the training centers, social interaction, and changes in life style secondary to study participation.
215005283|NCT03017664|OTHER|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
215005284|NCT03017664|OTHER|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
214400643|NCT05300880|OTHER|Training program|A multi-component intervention based on health coaching. The strategies of this program consisted in five 16-hour sessions using case studies to find out whether nurses were able to empower chronic cardiac patients and debriefing and a 4-hour booster session seven months later.
214400644|NCT00737308|OTHER|ceramic crown|Zirconia
214400645|NCT02420587|DRUG|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
214400646|NCT02420587|BEHAVIORAL|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
214400647|NCT04253821|OTHER|muscle tonus, stiffness and elasticity,six-minute walk test, Pulmonary function tests, The neck disability index|The muscle tonus, stiffness and elasticity of upper trapezius (UT), semispinalis capistis (SSC), pectoral muscles (PM) and sternocleidomastoideus muscles (SCM) were measured by using MyotonPro® device. Functional capacity was measured with six-minute walk test. Pulmonary function tests was evaluated with spirometer. The neck disability index (NDT) was applied. The forward head posture was determined by measurements of craniovertebral angle (CVA). Physical activity levels of participants were evaluated by Physical Activity Index (FIT).
214400648|NCT02452229|OTHER|Review of the Literature for Human Herpes Virus infections|"Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used."
214400649|NCT01023178|DRUG|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
215095928|NCT02126072|DIETARY_SUPPLEMENT|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
215095929|NCT00499408|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
215095930|NCT00499408|DIETARY_SUPPLEMENT|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
215095931|NCT03792152|DRUG|Rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).
214504197|NCT02630186|DRUG|Rociletinib|A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
214504198|NCT02630186|DRUG|MPDL3280A|A human IgG1 monoclonal antibody administered intravenously (IV)
215005285|NCT03478995|DRUG|GX-I7|GX-I7 25mg/ml/vial
215095932|NCT03792152|DRUG|Warfarin|After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
215095933|NCT04065594|PROCEDURE|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
215095934|NCT04065594|PROCEDURE|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
214400650|NCT01023178|DRUG|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
214504199|NCT01542255|DRUG|vinblastine|1 mg/m2 vinblastine given three times per week administered intravenously.
214504200|NCT01542255|DRUG|Cyclophosphamide|60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
215005286|NCT02639533|DRUG|Pregabalin|Pregabalin 150 mg PO, single dose.
215005287|NCT02639533|OTHER|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
215005288|NCT00120484|DRUG|Vitamin B12|
215005289|NCT02537470|DRUG|Biphasic Remogliflozin Etabonate|Experimental Drug
215005290|NCT02537470|OTHER|Placebo|Placebo Comparator
215005291|NCT03942055|DEVICE|Sonosite Edge II Ultrasound|Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound
214400651|NCT01023178|DRUG|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
214504201|NCT01542255|DRUG|dacarbazine|15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
214504202|NCT03677167|OTHER|walking on a treadmill|Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
215005292|NCT03407482|DRUG|GDC-0853|Participants received GDC-0853 at a dose of 200mg, as per the dosing schedule described above.
215095935|NCT04826016|DRUG|POL6326|POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
215095936|NCT04826016|DRUG|Eribulin|Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
215095937|NCT04826016|DRUG|Nab paclitaxel|Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
215095938|NCT06232551|OTHER|EHR (electronic health record) alert|Pop-up alert that informs the discharging clinician that the patient meets criteria to be considered for extended duration thromboprophylaxis
215095939|NCT06232551|OTHER|No EHR (electronic health record) alert|During the baseline phase while risk is assessed and stored, no alerting occurs
214400652|NCT01023178|DRUG|Progesterone, micronized|Given starting at 18 months
214400653|NCT06206044|DRUG|Intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg preservative-free morphine|Patients will receive standard intrathecal medications for urgent and scheduled cesarean delivery at the study site. All study subjects will receive bupivacaine, fentanyl, and morphine.
214400654|NCT03708068|OTHER|Early exclusive enteral nutrition|Infants will be fed at least 80% of reference daily fluid intake from day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards to meet reference daily fluid intake until infant reaches full enteral feed.
215005293|NCT00533988|DEVICE|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
215005294|NCT02741778|PROCEDURE|Minimally invasive group|In this group, all manipulations are finished by laparoscopy and thoracoscopy.
214400655|NCT01126021|BEHAVIORAL|Financial incentives|Participants are eligible for incentives if they participate in at least 30 games per day.
214400656|NCT01126021|BEHAVIORAL|No incentives|Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
214400657|NCT05727059|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
214400658|NCT03838159|DRUG|Paclitaxel|"Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected."
214400659|NCT03838159|DRUG|Carboplatin|Carboplatin must be administered at the end of the Paclitaxel infusion
214400660|NCT03838159|DRUG|Nivolumab|"Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~The administration of nivolumab infusion must be completed within 24 hours of preparation."
214400661|NCT05115955|DRUG|DS group|In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
214400662|NCT05115955|DRUG|Control group|In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
215005295|NCT02741778|PROCEDURE|Open group|Right lateral position, Traditional thoracotomy through the 7th intercostal incision.
215005296|NCT00162734|DRUG|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
215005297|NCT05143502|DRUG|Montelukast|"Montelukast is a leukotrienes antagonist which has proven efficacious in chronic inflammatory conditions of the airways, including allergic rhinitis, asthma, and aspirin-exacerbated respiratory disease (AERD), all diseases that often coexist with CRSwNP.~We will use oral Montelukast (montelukast 10 mg, once a day) for 3 monthes"
214400663|NCT05370768|BEHAVIORAL|Parenting Mindfully Intervention|Includes meditation and using meditation and mindfulness in everyday life and in parenting interactions.
214400664|NCT04952987|DRUG|Diquafosol|Diquafosol (Diquas) is a P2Y2 receptor agonist which improves mucin and tear secretion
214400665|NCT05832580|DRUG|Etidronate|Etidronate in capsules of 200 mg or 400 mg.
214400666|NCT05832580|DRUG|Placebo|Placebo in similar capsules
214504203|NCT03447912|BEHAVIORAL|Intervention Condition|The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in public indoor and and outdoor spaces.
215005298|NCT05143502|DRUG|Prednisolone|Oral Prednisolone 40 mg/day for two weeks.
215005299|NCT05143502|DRUG|Fluticasone Furoate|fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily
215005300|NCT03967327|DRUG|Buprenorphine transdermal patches|It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
215005301|NCT03967327|DRUG|Morphine Sulfate Sustained-Release Tablet|It will be administered orally twice (q12h) daily.
215005302|NCT00446277|PROCEDURE|cataract surgery|
215005303|NCT02285192|RADIATION|18F-Fluorodeoxyglucose (18F-FDG)|
214400667|NCT02498379|DRUG|Cu[64]-25%CANF-Comb|Intravenous injection of 4-8 mCi of Cu\[64\]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
214400668|NCT00461214|OTHER|Participation in laparoscopic training curriculum|General Surgery Training Outcome
214400669|NCT03276702|PROCEDURE|Re-biopsy|For those participants who agree, a biopsy of their tumor to obtain tissue for genetic analysis will be done at the time of relapse or disease progression.
215005304|NCT02285192|DEVICE|PET/CT imaging|
215005305|NCT02285192|DEVICE|PET/MRI imaging|
214400670|NCT03276702|OTHER|Questionnaire|Parents or patients will be asked to complete a questionnaire to assess the impact and perception of an optional/research only biopsy. A second questionnaire will be administered approximately 4-8 weeks after biopsy to assess decisional regret.
214400671|NCT04354311|DEVICE|ANI|Under steady state total intravenous anaesthesia with propofol and remifentanil at constant dosage, tetanus stimulation of the ulnar nerve was performed followed by orotracheal intubation. The variation of ANI and hemodynamic parameters as well as the somatic response associated with both maneuvers were collected.
215005306|NCT05413551|DRUG|Low-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 5 mg/kg oral tablet (maximum 300 mg)
215005307|NCT05413551|DRUG|Standard dose of isoniazid|15 mg/kg oral tablet (up to 900 mg)
215005308|NCT05413551|DRUG|High-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 25 mg/kg oral tablet (maximum 1500 mg)
215005309|NCT06417411|DRUG|Aspirin 100mg|Daily use of low dose aspirin.
215005310|NCT02193425|DRUG|F-18FDG|18F-Fluorodeoxyglucose (FDG)-PET session to assess the association between functional connectivity (FC) and glucose metabolism in the human brain.
215005311|NCT02193425|DEVICE|MRI|Two MRI/MRS sessions to evaluate test-retest reliability of functional connectivity (FC) at rest as well as during task performance.
215095940|NCT01930552|DRUG|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
215095941|NCT01930552|DRUG|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
215095942|NCT01930552|DRUG|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
214400672|NCT05560516|DRUG|Qutenza|Capsaicine patch: Qutenza 8% patch will be applied to the skin according to the instruction of the manufacturer. After application of local anesthetics on the skin, a Qutenza 8% patch will be placed. 1-4 patches will be placed and can be adjusted to the right size, depending on the surface of the CIPN. The patch(es) will be removed after 30-60 minutes. The effect will last about 12 weeks.
214400673|NCT05560516|DRUG|Duloxetine|Duloxetine tablets: In week 1 patients will receive 30 mg duloxetine one time per day. In week 2 the dose will be increased to 60 mg one time per day. In case of inacceptable adverse events the patient is allowed to reduce the dose to 30 mg one time per day after consultation with the researcher or physician.
214400674|NCT02351895|OTHER|Copper impregnated linen|Copper impregnated linen was used in place of regular linen on one ward (out of two) for each period of the study. Each study period lasted for 23 weeks. After the washout period (3 weeks) the wards were switched.
214400675|NCT01577732|BIOLOGICAL|Infanrix-IPV+Hib™|Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.
214400676|NCT03289455|BIOLOGICAL|AUTO3 (CD19/22 CAR T cells|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
214400677|NCT03956576|OTHER|[Pyr]apelin-13|Peptide \[Pyr\]apelin-13 infusion
214400678|NCT00471263|DRUG|Casigold|
215095943|NCT01930552|DRUG|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
215095944|NCT00228865|PROCEDURE|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
214400679|NCT00471263|DRUG|Casimax|
214400680|NCT00471263|DRUG|Placebo|
214504204|NCT05271045|DIETARY_SUPPLEMENT|fortified canola oil with vitamins A and D and γ-oryzanol|30 g fortified canola oil with vitamins A and D and γ-oryzanol
214504205|NCT05271045|DIETARY_SUPPLEMENT|Active comparator|30 g fortified canola oil with vitamins A and D
214504206|NCT05271045|DIETARY_SUPPLEMENT|Placebo|30 g fortified sunflower oil with vitamins A and D
214504207|NCT04022421|DRUG|Hydroxychloroquine|the drug will be taken by one group of the patients daily at a dose of 400mg
215005312|NCT04376229|OTHER|Registry|Registry of cancer patients who receive proton radiation therapy
214504208|NCT00221065|DEVICE|Nasal Continuous positive airway pressure - Tyco 420G|CPAP at determined pressure nightly for 1 month
214504209|NCT03843606|OTHER|Modified ketogenic diets|Different diet composition
215005313|NCT06485336|DRUG|Atorvastatin 40mg|Each tablet will be taken once daily for 84 days.
215005314|NCT06485336|DRUG|Placebo|Each tablet will be taken once daily for 84 days.
215005315|NCT03678753|DRUG|Cenobamate|12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
215005316|NCT03678753|DRUG|Placebo|Matching Placebo
215005317|NCT02347618|RADIATION|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
215005318|NCT06430489|DRUG|Nitrous oxide|inhaled nitrous oxide (1 hour at 50% concentration)
215005319|NCT06430489|DRUG|Medical air|inhaled medical air (1 hour)
215095945|NCT00228865|PROCEDURE|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
215095946|NCT00710242|DRUG|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
215095947|NCT00710242|DRUG|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
215095948|NCT00346645|DRUG|Bortezomid (VELCADE®)|
215095949|NCT03002454|DRUG|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
215095950|NCT04506515|DIAGNOSTIC_TEST|Psychological stress and adaptation at work score (PSAS)|completing a survey based on PSAS
215005320|NCT07044570|BEHAVIORAL|Physical Activity Goals mHealth Intervention|On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
215005321|NCT07044570|BEHAVIORAL|TYPE/CONTEXT enhancement|TYPE/CONTEXT augments intervention effects by providing tailored recommendations for activity types and contexts that satisfy personally-important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk will be used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm will then recommend the corresponding activity type or context while accounting for reported constraints (e.g., ability, access). These details will be incorporated into a tailored recommendation provided to participants each Sunday as they make activity plans for the upcoming week. Specifically, the program will randomly select either type or context (i.e., location, audio, social) recommendations and will rotate every two weeks. For TYPE, participants' top 3 activity types are recommended; for CONTEXT, participants' top 3 activity contexts are recommended.
215005322|NCT07044570|BEHAVIORAL|SAVOR enhancement|SAVOR implements a brief savoring exercise on the smartphone that takes place either after the planned physical activity session or during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer three open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty. Savoring prompts will rotate daily and have a day lag built in every week (i.e., Week 1 Monday Savoring Prompts are Week 2 Tuesday Savoring Prompts).
215005323|NCT07118033|PROCEDURE|Specific Manual Therapy|Participants in this group receive a standardized physiotherapy program (exercise and education) plus 5 minutes of targeted lumbar postero anterior mobilizations. These mobilizations are selected using the Algo K decision algorithm, which guides the therapist to choose the most appropriate technique based on the patient's pain response during preliminary movement tests.
215005324|NCT07118033|PROCEDURE|Non specific Manual Therapy|Participants in this group receive the same physiotherapy program, but the additional 5 minutes of mobilization are applied to the upper thoracic spine (T4-T7), away from the symptomatic lumbar region. This sham mobilization mimics the manual therapy without targeting the affected area or following the algorithm's logic.
215005325|NCT07121426|OTHER|Lower limb Intensive Functional Training|LIFT will help the child in motor learning, skill progression and resistance training to target the strength, proprioception and coordination impairments of the lower extremities. Motor learning will be based on Strength domain (Cycling) . Balance and Coordination domain involves activities such as (ball kicking with alternate legs and Static standing) Proprioception domain (Vertical jumping, sit to stand and cursing) while applying knee-immobilizers if needed.
215095951|NCT00619489|DRUG|vedolizumab|Vedolizumab for intravenous (IV) infusion
215095952|NCT02966015|DEVICE|Coloplast test catheter|This is a newly developed catheter
214400681|NCT05763459|DRUG|ABBV-CLS-7262|Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin
214400682|NCT04298684|DRUG|METFORMIN|"After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control. In case of intolerance, the tolerated and effective dose will be taken back provided an effective glycemic control.~A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced."
214400683|NCT04298684|DRUG|Sitagliptin|"After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced."
214400684|NCT04751864|DEVICE|Cranial Electrotherapy Stimulator (CES) Device|Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device
214400685|NCT06310122|DEVICE|Extracorporeal shockwave therapy|"Devices used to improve foot function pain and gait pattern~Patients will be placed in prone position, therapist locate the point of maximum tenderness. treatment area will be prepared with coupling gel to minimize the loss of shockwave therapy at the interface between applicator tip and skin. Each patient will receive 2000 impulses ,3 bar energy,15mm depth applicator at frequency (10 HZ) per session / week for 4 weeks"
215095953|NCT01699711|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
215095954|NCT00000480|PROCEDURE|electrophysiology|
214400686|NCT06310122|DEVICE|ultrasound|"Devices used to improve foot function pain and gait pattern~Participants in the study group will be treated with 5 minutes of therapeutic ultrasound at a frequency of 1 MHz and continuous current at a pulse intensity of 1.8 W/cm2 (when the sensitivity level was too high and the procedure hurt the patient, the therapist reduced the intensity . 3 sessions /week for 4 weeks"
214400687|NCT03656016|DEVICE|Magnetic Resonance Imaging|Phase contrast magnetic resonance imaging technique
214400688|NCT00333788|BIOLOGICAL|Certolizumab pegol (CDP870)|400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
215005326|NCT07121426|OTHER|Conventional physical therapy|Stretching followed by Strengthening program and traditional gait training at clinical setting. Stretching muscles were hip flexors, hip adductors, hamstrings and calf and stretching applied for 30 sec with 30 sec rest for 3-5 times for each muscle group with in pain limit followed by strengthening exercise for week muscle which includes the strengthening of anti-gravity muscles of lower limb they are: Quadriceps, Gluteus maximus and soleus performed in 3 groups. Each group contain 10 rep for each week muscle group.
215005327|NCT07121465|BEHAVIORAL|Education group|"First stage: Pregnant women will be administered a Personal Information Form, the Prenatal Breastfeeding-Self-Efficacy Scale, the Prenatal Hygiene Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale. Second stage: In this stage, pregnant women will be given a 60-minute breastfeeding education session.~Third stage: This stage will take place one week after the second stage, and pregnant women will receive baby care training. The training will be conducted face-to-face in the training room of the hospital where the study will be conducted, using the training manual prepared by the researchers according to Mercer's theory as a guide.~Fourth stage: In this stage, pregnant women will again be administered the Prenatal Breastfeeding-Self-Efficacy Scale, the Prenatal Hygiene Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale."
215005328|NCT07121465|BEHAVIORAL|Control group|"First stage: In this stage, pregnant women will be informed about the study and their voluntary written consent will be obtained. They will then complete a Personal Information Form, the Prenatal Breastfeeding Self-Efficacy Scale, the Prenatal Hygienic Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale.~Second stage: Pregnant women will be administered the Prenatal Breastfeeding Self-Efficacy Scale, the Prenatal Hygienic Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale."
215005329|NCT07119684|BEHAVIORAL|Short-Duration Walking Exercise|articipants performed three 10-minute walking sessions per day, 5 days per week for 6 weeks, at 60% of their maximum heart rate on a treadmill.
215005330|NCT07119684|BEHAVIORAL|Long-Duration Walking Exercise|Participants performed one continuous 30-minute walking session per day, 5 days per week for 6 weeks, at 60% of their maximum heart rate on a treadmill.
215005331|NCT07119255|PROCEDURE|PRP Pharmacopuncture|Participants in the PRP pharmacopuncture arm will receive a single administration of platelet-rich plasma (PRP) via intramuscular injection at acupuncture points corresponding to chronic neck pain in cervical myofascial syndrome in the upper trapezius muscle.
215005332|NCT07119255|PROCEDURE|Placebo Pharmacopuncture|Participants in the placebo pharmacopuncture arm will receive a single administration of normal saline via intramuscular injection at acupuncture points corresponding to chronic neck pain in cervical myofascial syndrome in the upper trapezius muscle.
215005333|NCT07120607|BIOLOGICAL|CD7 CAR-γδT cell（QH106）|Allogenic CD7 CAR-γδT cell，Intravenous on day0; dose escalation (3+3) : dose 1 (1 × 10\^8 CAR+ cells) , dose 2 (3 × 10\^8CAR+ cells/kg，dose 3 (6× 10\^8 CAR+ cells）;
215005334|NCT07120607|DRUG|Fludarabine (FLU)|Intravenous fludarabine 30\~50 mg/m\^2/day on days-5, -4, and -3；
215005335|NCT07120607|DRUG|Cyclophosphamide (CTX)|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
214504210|NCT02110914|BEHAVIORAL|Coaching|"Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months."
214504211|NCT06346652|OTHER|Routine Physical Therapy|Routine physical therapy involving muscle strengthening exercises, range of motion exercises and stretching exercises up to patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks.
215005336|NCT07121283|DEVICE|True AI|True output from bone age AI
215005337|NCT07121283|DEVICE|Fake AI|Randomized output from bone age AI
215005338|NCT07119515|BEHAVIORAL|Third-Wave CBT via Teletherapy|Twelve weekly 40-minute remote sessions via video conferencing, including mindfulness, behavioral activation, and exposure therapy.
215005339|NCT07119515|BEHAVIORAL|Third-Wave CBT In-Person|Twelve weekly 40-minute face-to-face sessions with identical third-wave CBT content.
215005340|NCT07122778|DIETARY_SUPPLEMENT|Controlled energy-deficit diet|Participants receive a prepared diet providing approximately 50% of their estimated daily energy expenditure to induce a sustained energy deficit
215005341|NCT07122778|DIETARY_SUPPLEMENT|Habitual diet with surplus snacks|Participants continue their normal diet with the addition of high-calorie snack items to achieve an approximate daily energy surplus
215005342|NCT07122388|DIAGNOSTIC_TEST|Questionnaires about autism spectrum disorders and sleep and PSG.|Recruitment of subjects with autism spectrum disorder at all developmental ages and of all severity levels.
215005343|NCT07122388|DIAGNOSTIC_TEST|ADOS-2, ADI-R, SRS-2, PSG|Recruitment of subjects with autism spectrum disorder at all developmental ages and all severity levels.
214504212|NCT06346652|OTHER|Routine Physical Therapy+ PNF and Core Stregthening|Routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in lower extremity in D1 flexion pattern and D1 extension pattern up to patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks.
214504213|NCT01355809|DRUG|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
214504214|NCT01355809|DRUG|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
214504215|NCT01355809|DRUG|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
214504216|NCT02782000|OTHER|lessons,long-term supervision and message|
214504217|NCT02782000|OTHER|lessons,short-term supervision and message|
214504218|NCT04263714|BEHAVIORAL|Exercise|Aerobic exercise and resistance exercise
215005344|NCT07123428|DRUG|TRD205|TRD205 tablet
215005345|NCT07123428|DRUG|Placebo|TRD205 placebo tablet
215095955|NCT00000480|DRUG|anti-arrhythmia agents|
215095956|NCT00000480|DEVICE|defibrillators, implantable|
215005346|NCT07122934|DIAGNOSTIC_TEST|Assessment of cervico-cerebral arterial occlusion pattern|Assessment of cervico-cerebral arterial occlusion pattern for the development of a radiological score
215005347|NCT07121842|DIAGNOSTIC_TEST|Extended MRI|The MRI protocol for every clinical follow-up MRI scan is extended with 15 minutes to add the APTw-CEST scan.
215005348|NCT07123116|DRUG|Shenbai Granules|Dosage: bag 10g per , administered twice daily continuously for 180 days.
215005349|NCT07123116|DRUG|Placebo|Dosage: 10g per bag, administered twice daily continuously for 180 days.
215005350|NCT07118332|DRUG|Psilocybin (drug)|25mg of Psilocybin will be given to all subject
215095957|NCT04276155|DRUG|non-systematic prescription of anticoagulant therapy|the prescription of anticoagulant is managed by an implantable device follow up
215005351|NCT07123870|DRUG|Sevofluorane|In this group of patients, \<0.5 MAC sevoflurane will be used in combination with TIVA. (TIVA method described above)
215005352|NCT07123870|DRUG|Desflurane|In this group of patients, \<0.5 MAC Desflurane will be used in combination with TIVA.
215005353|NCT07123870|DRUG|Total Intravenous Anesthesia(TIVA)|In this group, TIVA will be applied with the combination of BIS-guided propofol + remifentanil.
215005354|NCT07121816|DEVICE|ECG watch|ECG watch in palpitation assessment
215005355|NCT07122453|DRUG|CNTX-3001|non-opioid analgesic
215005356|NCT07122453|DRUG|Placebo|Placebo product
215005357|NCT07125131|OTHER|Gamification-Enhanced Problem-Based Learning|An educational intervention combines principles of problem-based learning (PBL) with game design elements including scores, leaderboards, digital badges, challenges, immersive experiences, feedback and rewards into problem-based learning.
215005358|NCT07125131|OTHER|Conventional didactic lecture (usual practice)|A didactic teaching approach in which course content is delivered to nursing students primarily through PowerPoint presentation by lecturer.
215005359|NCT07124182|OTHER|shewing gum|Chewing gum is a cost-effective practice that can provide comfort to women. A Pap smear is an important test. Women experiencing pain, anxiety, or other symptoms may discourage testing. Chewing gum can reduce these sensitivities.
215005360|NCT07125872|BIOLOGICAL|CD19 t-haNK- IV Administration|"N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered subcutaneously. It is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells without stimulating regulatory T cells. N-803 SQ differs from other cytokine therapies due to its improved pharmacokinetic profile, enhanced in vivo activity, and reduced toxicity.~CD19-Directed Therapies: CD19-targeted therapies, are biologic agents specifically designed to recognize and eliminate CD19-expressing B-cell malignancies. These therapies differ from traditional chemotherapy or small molecule inhibitors by leveraging the patient's immune system to achieve targeted cytotoxicity. Their mechanism of action involves direct binding to the CD19 antigen on malignant B cells, leading to immune-mediated cell death."
215005361|NCT07125443|DRUG|"Prospective iNO Administration (After Group)"|Adult patients undergoing liver transplantation after the implementation of the iNO protocol, with prospective intervention involving intraoperative administration of iNO and prospective data collection. Inhaled nitric oxide will be administered via the anesthesia machine, under the supervision of the attending Anesthesiologist, at a concentration of 20 parts per million (ppm) starting at induction of anesthesia. At the onset of the anhepatic phase (i.e., after explantation of the native liver), the concentration will be increased to 80 ppm. Administration will be continued until the end of the surgical procedure, at which point iNO will be discontinued.
215005362|NCT07125443|OTHER|"No Intervention Retrospective Before Group"|Adult liver transplant recipients identified retrospectively from the institutional transplant database, including all patients who underwent orthotopic liver transplantation since the implementation of the OneChart electronic medical record (EMR) system between the time period of January 1, 2020 - May 31, 2025.
215005363|NCT07125391|DRUG|Cohort A|received propranolol hydrochloride (20mg, BID, QD), paclitaxel/paclitaxel liposome (135-175mg/m2, d1, Q3W), carboplatin (AUC=4-5, d1, Q3W) for 3-4 cycles of neoadjuvant therapy. Subsequently, interval debulking surgery (IDS) was performed. Propranolol hydrochloride was taken one week before neoadjuvant therapy
215005364|NCT07124962|PROCEDURE|Root Canal Therapy|Regenerative endodontic procedure using autologous platelet-rich plasma injected into the root canal space to promote pulp-dentin regeneration, followed by placement of MTA and composite restoration.
215095958|NCT05571956|OTHER|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|Pancreatic masses were sampled using a 22-gauge FNB needle. If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs
214400689|NCT01067495|BEHAVIORAL|Cardiac rehabilitation|Participants will participate in a 6-month cardiac rehabilitation exercise program. This program will include aerobic and resistance training, and education sessions on risk factor management.
214400690|NCT04931173|OTHER|IVA+OA versus IVA+MBP+OA|Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery
215005365|NCT07124962|PROCEDURE|Platelet-Rich Plasma (PRP) Revascularization|Regenerative endodontic procedure using autologous platelet-rich plasma injected into the root canal space to promote pulp-dentin regeneration, followed by placement of MTA and composite restoration.
215005366|NCT04517838|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor tissue samples
215005367|NCT00049595|BIOLOGICAL|bleomycin sulfate|
215005368|NCT00049595|BIOLOGICAL|filgrastim|
215005369|NCT00049595|BIOLOGICAL|pegfilgrastim|
215005370|NCT00049595|DRUG|ABVD regimen|
215005371|NCT00049595|DRUG|BEACOPP regimen|
215005372|NCT00049595|DRUG|cyclophosphamide|
215005373|NCT00049595|DRUG|dacarbazine|
215005374|NCT00049595|DRUG|doxorubicin hydrochloride|
215005375|NCT00049595|DRUG|etoposide|
215005376|NCT00049595|DRUG|prednisone|
215005377|NCT00049595|DRUG|procarbazine hydrochloride|
215005378|NCT00049595|DRUG|vinblastine sulfate|
215005379|NCT00049595|DRUG|vincristine sulfate|
215005380|NCT05429840|DRUG|MT1980|single dose
215005381|NCT05429840|DRUG|Placebo|single dose
215095959|NCT00552409|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU by mouth daily for one year
215095960|NCT00552409|DIETARY_SUPPLEMENT|Placebo|One softgel daily for one year
215005382|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 12.5 mg (titration only)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg
215095961|NCT03445390|DRUG|Acetaminophen|Acetaminophen 1 g intravenous given at the beginning and end of surgery.
214504219|NCT05227092|DEVICE|3D OPTIMIZED WMN MPRAGE|"* At the cervical level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 2D Sagittal PSIR / 3D MPRAGE and the 3D OPTIMIZED MPRAGE WMN data set with sagittal and axial acquisition.~* At the thoracic level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 3D MPRAGE and the 3D Sagittal OPTIMIZED MPRAGE WMN data set."
214688185|NCT07091591|BEHAVIORAL|Changing (version: pandemic)|The application explains that, faced with a complex situation such as a pandemic, decision-makers have to navigate through uncertainty, often without knowing exactly how the situation will evolve. Scientific research guides their choices, but early studies can sometimes prove inaccurate and require adjustments. For example, during the COVID-19 pandemic, some initial studies showed that certain drugs could help, but more rigorous research showed that they were not effective. Over time, accumulated knowledge enables us to better understand the situation and make informed decisions. Lessons learned from past crises help to better prepare for future complex situations.
215005383|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
215005384|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg
215005385|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg, then week 3 to 37.5 mg
215005386|NCT05286762|DRUG|Placebo|Subjects will be randomized at Visit 2 to Placebo
215005387|NCT06344572|DEVICE|SAT-001|Device: SAT-001(a Software as Medical Device) Using SAT-001 application for 48 weeks and wearing single vision spectacles
215005388|NCT06344572|OTHER|Single vision spectacles|Wearing single vision spectacles
215005389|NCT06950190|BEHAVIORAL|Low-Intensity Walking Intervention|Participants in the experimental group will be asked to take part in a home-based, walking program. Each participant will receive a pedometer and will be instructed to increase their baseline daily step count by 100%. For example, if a participant typically walks 3,000 steps per day, they will be asked to increase their activity to 6,000 steps per day. Step counts will be regularly monitored, and participants will receive encouragement and support from study staff to help maintain adherence to the walking goals. In addition to the exercise intervention, participants in this group will undergo cognitive testing using the Montreal Cognitive Assessment (MoCA) at four timepoints: baseline, 6 months, 9 months, and 12 months. They will also complete self-reported questionnaires related to cognitive function at these same intervals. This group is designed to evaluate whether increased physical activity can improve or preserve cognitive function in patients undergoing chemotherapy.
215005390|NCT06950190|BEHAVIORAL|Control Group Intervention|Participants in the control group will receive standard care and will not be given any specific exercise instructions. They will be provided with pedometers to track their daily steps, but they will not be asked to increase or change their usual level of physical activity. These participants will continue with their routine activities and cancer care as directed by their treating physicians. Like the intervention group, they will complete the Montreal Cognitive Assessment (MoCA) at baseline, 6 months, 9 months, and 12 months, as well as self-reported questionnaires about cognitive function at each timepoint. This group will serve as a comparator to determine the impact of the walking intervention on cognitive outcomes.
215005391|NCT07125014|PROCEDURE|Observational study|This is an observational study with no experimental or therapeutic interventions administered to participants. All data were collected retrospectively from existing hospital records for patients who underwent ERCP between January 2023 and December 2023 at Lady Reading Hospital, Peshawar. No drugs, devices, or procedures were assigned to participants as part of this research.
215095962|NCT03445390|DRUG|Placebo|Placebo to match acetaminophen given at the beginning and end of surgery.
215005392|NCT07117903|DIETARY_SUPPLEMENT|Normal diet + vehicle|Participants in the control group were instructed to maintain their usual diet for the duration of the study. While they were free to choose their food, they were required to provide a detailed dietary record. After diet intervention, whole blood will be drawn and incubated with vehicle drug.
215005393|NCT07117903|DIETARY_SUPPLEMENT|Normal diet + aspirin|Participants in the control group were instructed to maintain their usual diet for the duration of the study. While they were free to choose their food, they were required to provide a detailed dietary record. After diet intervention, whole blood will be drawn and incubated with aspirin.
215005394|NCT07117903|DIETARY_SUPPLEMENT|Ketogenic diet + vehicle|The calorie-restricted KD intervention consisted of a very-low-carbohydrate, high-fat diet (5% of calories from carbohydrates, 30% from protein, and 65% from fat, with an energy deficit of 600 kcal/day, 3 meals distributed over 24 h: breakfast, lunch, and dinner). This intervention was performed without schedule restrictions and supported by commercial replacement meals only for the first meal (100 kcal, 15 g of protein, 3 g of fat, of which 1 g was saturated fat, and 50 mg of docosahexaenoic acid, 2 g of carbohydrates, of which \< 1 g was simple sugars). After diet intervention, whole blood will be drawn and incubated with vehicle drug.
215095963|NCT06423560|RADIATION|Computed tomography|Follow-up computed tomography at 3-6 months and 12 months
215095964|NCT00584129|OTHER|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
215095965|NCT00584129|OTHER|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
214504220|NCT00074646|DRUG|CC-8490|
215095966|NCT03214731|DRUG|Artesunate|Artesunate was produced by pharmaceutical factory for research specifically
215095967|NCT03214731|OTHER|placebo|placebo was produced by pharmaceutical factory for research specifically
215095968|NCT00509171|DEVICE|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
215095969|NCT00240604|DRUG|Rosiglitazone|4 mg rosiglitazone per day
215095970|NCT00119496|DRUG|rosiglitazone|oral tablet, 4mg bd for 4 weeks
215095971|NCT00119496|DRUG|theophylline|Oral theophylline, 200mg bd
215095972|NCT00119496|DRUG|beclomethasone|inhaled beclomethasone, 200mcg bd
215095973|NCT00119496|DRUG|inhaled beclomethasone and oral theophylline|inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
215095974|NCT00054028|DRUG|suramin|Given IV
214400691|NCT04951479|DEVICE|Gel-Bead embolization|OptiSphere is FDA approved for the embolization of hypervascular tumors. The product is crosslinked with glutaraldehyde, which improves the mechanical strength of the spheres and provides controlled degradation after implant. The spherical shape provides smooth embolic delivery and even, predictable distribution. In this study the Optispheres will be used for Geniculate artery embolization (GAE) which is a minimally-invasive procedure that has historically been performed for treatment of patients with recurrent knee hemarthrosis. Embolization is a procedure in which material is used to block small blood vessels. Angiogenesis, or growth of new vessels, has been implicated in the initiation and maintenance of joint inflammation. GAE has been applied to patients with moderate osteoarthritis-related pain refractory to maximal medical management with preliminary studies demonstrating a reduction in patient pain.
215005395|NCT07117903|DIETARY_SUPPLEMENT|Ketogenic diet + aspirin|The calorie-restricted KD intervention consisted of a very-low-carbohydrate, high-fat diet (5% of calories from carbohydrates, 30% from protein, and 65% from fat, with an energy deficit of 600 kcal/day, 3 meals distributed over 24 h: breakfast, lunch, and dinner). This intervention was performed without schedule restrictions and supported by commercial replacement meals only for the first meal (100 kcal, 15 g of protein, 3 g of fat, of which 1 g was saturated fat, and 50 mg of docosahexaenoic acid, 2 g of carbohydrates, of which \< 1 g was simple sugars). After diet intervention, whole blood will be drawn and incubated with aspirin.
215005396|NCT07125105|BEHAVIORAL|Adapted Physical Activity Only|This intervention consists of 10 individual Adapted Physical Activity (APA) sessions over five weeks, each lasting 45 to 60 minutes. Sessions are delivered by a trained APA instructor and focus on muscle strengthening, endurance, and body awareness. Exercises are tailored to the functional capacities and fatigability of patients living with Myasthenia Gravis. The delivery format includes a mix of in-person and remote sessions, with individualized adaptation based on patient needs.
215005397|NCT07125105|BEHAVIORAL|Adapted Physical Activity + Art Therapy|This intervention includes 10 individualized sessions of APA integrated with movement-based Art Therapy, delivered over five weeks (45-60 minutes each). The program incorporates creative and expressive methods (e.g., role play, improvisation, dramatized movement, dramatherapy) within a therapeutic physical activity framework. It is designed to support both physical functioning and psychosocial well-being. The artistic dimension is adapted to the patients' preferences and capacities, as identified during the baseline anamnesis interview.
214400692|NCT05012423|DRUG|Placebo|Matching Placebo will be administered as oral capsules.
214400693|NCT05012423|DRUG|ECC0509|ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.
214400694|NCT05012423|DRUG|Placebo|Matching Placebo will be given orally during each dosing day.
214400695|NCT05012423|DRUG|ECC0509|ECC0509 1 mg and 10 mg capsules
214400696|NCT01090037|DRUG|TRK-100STP high dose|
214400697|NCT01090037|DRUG|TRK-100STP low dose|
214400698|NCT01090037|DRUG|Placebo|
215005398|NCT05672459|DRUG|Single Injection of IVS-3001- Anti - HLA-G CAR-T cells|Given by IV (vein)
215005399|NCT05672459|DRUG|Fludarabine phosphate|Given by IV (vein)
215005400|NCT05672459|DRUG|Cyclophosphamide|Given by IV (vein)
214400699|NCT04367194|BEHAVIORAL|Neurorehabilitation|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
214400700|NCT06625359|DRUG|Thiotepa in conditioning before transplantation|"For patients with ECOG PS 0 or 1 For patients with ECOG PS 0 or 1 and age \&lt; 60 years old, conditioning regimen before autologous stem cell transplantation consists of thiotepa, bulsulfan, and cyclophosphamide from day -9. Beginning on day -9 and through day -7, each patient was treated with thiotepa (200mg/m m2 IV per day). On days -6 to -4, patients received bulsulfan (2.7mg/kg IV over 3 hours per day every). Bulsulfan-related seizure prophylaxis was given with levetriacetam (1500mg loading on day -6, 500mg twice daily on days -5 to -3). On days -3 and -2, cyclophosphamide (60mg/kg IV per day) was given given.~Patients with ECOG PS 2 or age ≥ 60 years old received bulsulfan (3.2mg/kg IV over 3 hours per day for 2 days) resulting in 8 days regimen."
215005401|NCT05672459|PROCEDURE|leukapheresis|Given by IV (vein)
214400701|NCT06624813|PROCEDURE|Robot-assisted partial prostatectomy|Focal therapy with surgery for single lobe prostate cancer, partial robot-assisted partial prostatectomy
214400702|NCT03008720|DEVICE|Transcranial direct current stimulation (tDCS)|
214400703|NCT03008720|DEVICE|Functional electrical stimulation (FES)|
214400704|NCT03008720|DEVICE|Sham stimulation|
215005402|NCT04338204|DRUG|tofacitinib|Observational study
215005403|NCT05020275|DIAGNOSTIC_TEST|Blood Samples|"* Samples for ctDNA blood concentration and osimertinib plasma concentration~* Sample for genetic polymorphisms"
215005404|NCT04792073|DRUG|Avelumab|Avelumab 800 mg given intravenously over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days)
215005405|NCT04792073|RADIATION|Comprehensive Ablative Radiation Therapy|Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
215005406|NCT02626611|DRUG|Omalizumab|Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
214400705|NCT06687681|BIOLOGICAL|NK cell therapy|Active NK cell injection through lumbar puncture in patient with Astrocytoma IDH-mutant, Oligodendroglioma IDHmutant, Glioblastoma IDH-wild type, Diffuse midline glioma, Diffuse hemispheric glioma, Diffuse pediatrictype high-grade glioma IDH-wild type
214400706|NCT06624826|DEVICE|Emmetropic modality|PureSee IOL, emmetropic modality
214400707|NCT06624826|DEVICE|Monovision modality|PureSee IOL, monovision modality
214400708|NCT06697990|DRUG|Iruplinalib|60 mg of Iruplinalib, once daily for 7 days, followed by 180 mg of Iruplinalib, once daily in a 28-days cycle.
214400709|NCT06897215|DEVICE|Hyaluronic acid hydrogel|Assigned to the Experimental Cohort once OM grade 2.0 presents, Gelclair is a hyaluronic acid hydrogel that acts as a protective film in the management of OM. This product is used internationally and has been recently approved by Health Canada as a Class 2 Medical Device with an indication to manage the symptoms of OM caused by radiotherapy and chemotherapy.
215095975|NCT00054028|DRUG|paclitaxel|Given IV
215095976|NCT00054028|OTHER|pharmacological study|Correlative studies
215095977|NCT04054466|BEHAVIORAL|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
215095978|NCT04054466|BEHAVIORAL|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
215095979|NCT03274804|BIOLOGICAL|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
215005407|NCT02626611|DRUG|Food Flour Buildup|Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
215095980|NCT03274804|DRUG|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
215095981|NCT02583321|DEVICE|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
215005408|NCT04568109|BEHAVIORAL|Cognitive-behavior therapy|The manualized protocol (Gloster et al., 2011) comprise of 12 weekly sessions of CBT focusing on therapist-guided interoceptive and in-situ exposure exercises.
215005409|NCT05643794|DRUG|rozanolixizumab|Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
215095982|NCT02583321|DEVICE|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
215095983|NCT00214084|DRUG|Allopurinol|
215095984|NCT01183468|BIOLOGICAL|Aralast NP 45 mg dose|\- 45 mg/kg/week
215095985|NCT01183468|BIOLOGICAL|Aralast NP 90 mg dose|\- 90 mg/kg/week
214400710|NCT05182892|OTHER|Change of stimulation amplitudes in dopaminergic OFF drug state|Change of stimulation amplitudes during experiment in dopaminergic OFF drug state.
214400711|NCT05091684|DRUG|Fibrinogen Concentrate Human|Refractory transfused patients who present grade ≥ 2 hemorrhagic symptoms will receive a single injection of fibrinogen concentrate (1.5g) followed by platelet transfusion within 2 hours. Blood sampling will be done at different time points to measure clot viscoelasticity: at baseline, after fibrinogen injection, after platelet transfusion and the day after transfusion or before the next platelet transfusion if \< 24 hours.
215005410|NCT05643794|OTHER|Placebo|Study participants will receive Placebo during the dosing periods as pre-defined.
215095986|NCT01183468|BIOLOGICAL|Aralast NP 180 mg dose|\- 180 mg/kg/week
215095987|NCT02231268|DRUG|Gladem|
215095988|NCT00437255|DRUG|Clobetasol Propionate, 0.05%|Topical, twice daily for 4 weeks
215005411|NCT02813447|DRUG|Sertraline|
215005412|NCT02813447|DRUG|Placebo|
215005413|NCT05607459|OTHER|Dry Needling|"Dry needling consists of a skilled intervention which uses a thin filiform needle (as those used in acupuncture) to penetrate the skin and stimulate underlying myofascial trigger points (defined as a hyperirritable spot in skeletal muscle that is associated with a hypersensitive palpable nodule in a taut band which is painful on manual compression and can give rise to characteristic referred pain, referred tenderness, motor dysfunction and autonomic phenomena.)~This intervention will be performed targeting the upper trapezius and cervical multifidus muscles"
215005414|NCT05607459|BEHAVIORAL|Therapeutic Exercise|Patients will include a supervised therapeutic exercise program in their daily life, based on strengthening exercises for neck muscles.
215095989|NCT00437255|DRUG|Calcipotriene and betamethasone dipropionate ointment|Topical, once daily
215095990|NCT06455748|DRUG|Daratumumab/daratumumab and hyaluronidase-fihj|Daratumumab/daratumumab and hyaluronidase-fihj: Dara SC 1800mg subcutaneous (IH) or Dara 16mg/kg intravenously (IV) administered weekly (qwk) x 4 every 2 weeks X 3 doses per month starting C7.
215095991|NCT06455748|DRUG|Pomalidomide|Pomalidomide: pom 2-4mg PO day (D) 1-21/28 (adjust dose for renal function).
215095992|NCT06455748|DRUG|Dexamethasone|Dexamethasone: dex C1: 20mg IV D1/8, 20mg PO D2/9 and 40mg PO C1D15 weekly up to C6, then 20mg IV monthly starting C7D1 and 20mg PO D8, 15, 22.
215095993|NCT01172574|OTHER|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
215095994|NCT00181610|DRUG|Recombinant Human Prolactin|60 mcg/kg every 12 hours
215095995|NCT00181610|BIOLOGICAL|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
215095996|NCT00181610|BIOLOGICAL|Normal Saline|twice per day
215095997|NCT01994993|DRUG|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
215095998|NCT01994993|DRUG|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
214400712|NCT06910514|COMBINATION_PRODUCT|Mucopolysaccharide saline solution 0.9%|Injectable solution designed for submucosal elevation in endoscopic mucosal resection. Administered via submucosal injection prior to polyp resection, adding 1% indigo carmine before administration.
215005415|NCT05607459|OTHER|Manual Therapy|Patients will receive a manual compression (30 seconds) over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus muscle.
215005416|NCT05607459|OTHER|Sham Dry Needling|"For the sham DN intervention, a similar approach will be used, but the skin will be not pierced since the material used will be a telescopic Park's sham device.~The guide tube will be pressed against the skin mark and the sham needle will be allowed to drop. The handle will be tapped briskly, but the (blunted) needle tip will not not break the skin."
214400713|NCT06910514|COMBINATION_PRODUCT|Saline solution 0.9%|Control injectable solution composed of saline 0.9 %. Administered via submucosal injection prior to polyp resection, adding 1% indigo carmine before administration.
214400714|NCT06911515|OTHER|peripheral venous blood samples, these will be performed in order to measure the biological markers in the serum|peripheral venous blood samples, these will be performed in order to measure the biological markers in the serum
214400715|NCT06919120|DRUG|Simethicone is mixed into the final packet of compound polyethylene glycol electrolyte powder|The patients added one bottle of simethicone when taking the final packet of compound polyethylene glycol electrolyte powder.
214400716|NCT06919120|DRUG|Take simethicone separately|Take one bottle of simethicone orally after finishing the last sip of compound polyethylene glycol electrolyte solution.
214400717|NCT06917820|PROCEDURE|Interscalene brachial plexus block|Ultrasound-guided peripheral nerve block that includes injection of local anesthetics between the C5 and C6 nerve roots and between C6 and C7 nerve roots.
214400718|NCT06917820|PROCEDURE|Clavipectoral fascia plane block|Ultrasound-guided peripheral nerve block that includes injection of local anesthetics between the periosteum of clavicle and the surrounding clavipectoral fascia.
214400719|NCT06918535|OTHER|Progressive Muscle Relaxation Technique|Progressive Muscle Relaxation (PMR) is a relaxation technique that involves systematically tensing and then relaxing different muscle groups in the body to reduce physical tension and stress. Developed by Edmund Jacobson in the 1930s, PMR aims to promote deep relaxation by increasing awareness of muscle tension and learning to release it. The technique is typically performed in a quiet environment, starting from the feet and progressing upward or vice versa. It is commonly used for stress management, pain relief, anxiety reduction, and improving overall well-being.
214400720|NCT06918535|OTHER|Muscle Energy Technique|Muscle Energy Technique (MET) is a manual therapy approach that uses the patient's voluntary muscle contractions against a controlled resistance provided by the therapist to improve musculoskeletal function. It is commonly used to lengthen shortened muscles, improve joint mobility, and reduce pain. MET works by engaging the target muscles in an isometric or isotonic contraction, followed by a relaxation phase, allowing for a greater stretch or repositioning of the joint. It is frequently used in physiotherapy for conditions such as muscle tightness, joint restrictions, and postural imbalances.
214400721|NCT06918028|OTHER|With fundus diseases|With fundus diseases
215005417|NCT01192698|DRUG|IV interferon|IV interferon 5MU during anhepatic phase
215005418|NCT05850689|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
215005419|NCT05850689|DRUG|Placebo|Matching capsules administered orally, once daily
215005420|NCT06260748|DRUG|Chenodeoxycholic acid|250mg capsules
215005421|NCT06260748|DRUG|Chenodeoxycholic acid Placebo|Placebo to match
215005422|NCT06495554|DIAGNOSTIC_TEST|Measurement of circulating tumor-DNA|Liquid biopsies will be collected at baseline and prospectively during follow-up to measure circulating tumor-DNA.
215095999|NCT01994993|DRUG|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
215096000|NCT01994993|DRUG|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
214400722|NCT06918028|OTHER|Without fundus diseases|Without fundus diseases
214400723|NCT06378762|BEHAVIORAL|Endurance Exercise|30 minutes of running at an intensity corresponding to the heavy-domain (between the first and second ventilatory thresholds)
214400724|NCT06378762|BEHAVIORAL|Strength Exercise|Combination of strength and power exercises Weeks 1-5 focus on building maximal strength Weeks 6-11 focus on maintaining maximal strength and improve muscle power
214400725|NCT06378762|BEHAVIORAL|Concurrent Exercise|Combining both strength and endurance training programs, with strength preceding endurance, incorporating a 20-min rest period between each modality
214400726|NCT04939207|DIAGNOSTIC_TEST|CT-FFR|CT-images will be processed by an algorithm to calculate FFR-values of the full coronary tree
214400727|NCT04939207|DIAGNOSTIC_TEST|Angiography-derived FFR|FFR-values are calculated during coronary angiography based on the acquired images of the coronary arteries
215005423|NCT06495554|OTHER|Collection of patient-reported outcomes|Patient-reported outcomes will be collected at baseline and prospectively during follow-up.
215005424|NCT06495554|OTHER|Algorithmically determined telephone interview with a nurse|Dependent on the patient's responses on the patient-reported outcome measures.
215005425|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 2-dose regimen|Investigators will randomly assign patients into a 2-dose regimen.
215005426|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 3-dose regimen|Investigators will randomly assign patients into a 3-dose regimen.
215096001|NCT01994993|DRUG|metronidazole, clindamycin, or piperacillin-tazobactam|IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
214400728|NCT04939207|DIAGNOSTIC_TEST|Angiography with invasive FFR-measurements|during coronary angiography, a specialized pressure wire is passed through the coronary stenosis to calculate FFR based on the difference between the actual pressure and the expected pressure in the hypothetical healthy coronary artery.
215005427|NCT01334047|BIOLOGICAL|DC-006 vaccine|Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
215005428|NCT06198413|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
215005429|NCT04667169|PROCEDURE|Haemorrhoidal Artery Ligation|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
215005430|NCT04667169|PROCEDURE|Laser Haemorrhoidoplasty|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
215005431|NCT04041310|BIOLOGICAL|GAd-209-FSP low dose|GAd20-209-FSP IP, low dose
215005432|NCT04041310|BIOLOGICAL|MVA-209-FSP low dose|MVA-209-FSP IP, low dose
215005433|NCT04041310|BIOLOGICAL|GAd-209-FSP high dose|GAd20-209-FSP IP, high dose
215096002|NCT02228096|BIOLOGICAL|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10\^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10\^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg).
215096003|NCT04569812|PROCEDURE|Cardiopulmonary Resuscitation|flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
215096004|NCT03079856|BEHAVIORAL|Brief Intervention|"Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a \~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment."
215096005|NCT02412059|DRUG|Prednisolone acetate|
215096006|NCT02999152|OTHER|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
214400729|NCT05696730|OTHER|Communication intervention about sexuality in people with COPD|"COSY is a communication intervention which consists of one face to face counselling (75 min) and two 30-min telephone call counselling.~Patients assigned to the intervention group will get the COSY communication intervention with a special focus on the positive impact of sexuality on wellbeing plus specific motivation for physical activity. Together with the patient, a personalized re-enforcement instrument, the COSY-Compass, is elaborated to set individual goals and motivation for physical activity over the whole intervention period (3 months).~Participants will learn to understand the positive effect of regular physical activity on physical, mental, and cognitive wellbeing and a more fulfilling sex life as well as get inspiration about the spectrum and possible expressions and manifestations of caring and intimacy with oneself."
214400730|NCT04267146|DRUG|Nivolumab|"Solution for intravenous injection 10 mg/ml. Initial dose : 3 mg/kg Nivolumab will be given at 3 mg/kg/injection every two weeks from the first day of radiotherapy to the last day of chemotherapy.~One de-escalation dose : 1 mg/kg"
214400731|NCT04267146|DRUG|Temozolomide|Capsules: 5, 20, 100, 140, 180 and 250 mg orally. Temozolomide will be given at 75mg/m2/day from the day of start of radiotherapy to the last day of radiotherapy, then, after one month rest at 200mg/m2/day for five consecutive days for 12 cycles (28 days cycle).
215096007|NCT01070108|DRUG|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
215096008|NCT01070108|DRUG|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
214400732|NCT04267146|RADIATION|Radiotherapy|Total dose of 54 Gray(Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation period.
214400733|NCT03923673|PROCEDURE|Pericardiotomy|The minimally invasive procedure that creates a small opening in the sac that surrounds the heart.
214400734|NCT02408419|DRUG|Bupivacaine|Bupivacaine is injected proximally to anesthetize the obturator nerve
214400735|NCT02408419|DRUG|Saline|Saline is injected as a placebo
214400736|NCT00252681|PROCEDURE|laparotomy|
214400737|NCT00252681|PROCEDURE|primary peritoneal drainage|
214400738|NCT05339906|DEVICE|ZOV.ai digital therapy candidate|ZOV.ai is a novel auditory neuro modulating technology that leverages euphonic music tracks with broad-spectrum binaural beats to induce selective EEG spectral power changes to improve stuttering symptoms
214400739|NCT03735810|DRUG|LBS-008|LBS-008 oral capsules
214400740|NCT03735810|DRUG|Placebos|Oral capsules
215005434|NCT04041310|BIOLOGICAL|MVA-209-FSP high dose|MVA-209-FSP IP, high dose
215005435|NCT04041310|BIOLOGICAL|GAd20-209-FSP, RP2D|GAd20-209-FSP IP, RP2D
215005436|NCT04041310|BIOLOGICAL|MVA-209-FSP, RP2D|MVA-209-FSP IP, RP2D
215005437|NCT04041310|DRUG|KEYTRUDA®|anti-PD-1 checkpoint inhibitor (200 mg; Q3W)
215005438|NCT04372615|DRUG|Inebilizumab|"RCP: Blinded treatment on Day 1, Day 15,~* Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~* Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care)."
215005439|NCT04372615|DRUG|Placebo|The placebo group will receive IV matching placebo on Day 1 and Day 15,
215005440|NCT05277259|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
215005441|NCT05277259|OTHER|Kinesiotaping|Elastic band to be used to stretch the upper trapezius muscle in the desired direction.
215005442|NCT05277259|OTHER|Conventional Physical Therapy|Conventional physical therapy will be consisted of hotpack, therapeutic ultrasound and tens applications.
215005443|NCT05326100|OTHER|Conventional Therapy (CPT)|The exercises may include traditional vestibulo-ocular reflex (VOR) exercises, cervical musculoskeletal exercises, somatosensory exercises, habituation, gait exercises, and aerobic conditioning. The treating PT will modify specific exercises as appropriate based on the participant's symptoms.
215005444|NCT05326100|DEVICE|CAREN Therapy|The CAREN, an FDA-registered exempted Class I device, is a VR-based system which includes a six degree-of-freedom motion platform with an embedded, instrumented treadmill surrounded by an immersive 180-degree screen. The CAREN can display a variety of virtual environments (VEs), where the difficulty level and task requirements can be easily modified by the treating clinician to target patient-specific needs.
215005445|NCT05326100|DEVICE|Augmented Reality (AR) Therapy|AR head-mounted displays are designed to provide immersive virtual environments similar to the CAREN, but with the portability to be used in most outpatient clinical settings and potentially for at-home therapy as well as significantly reduced cost compared to the CAREN. AR devices have integrated eye-tracking and inertial measurement units (IMUs) which can be used to objectively quantify characteristics of eye, head and body movement.
215005446|NCT03846232|OTHER|No intervention|No intervention
215005447|NCT00517062|DRUG|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
215005448|NCT00517062|DRUG|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
215005449|NCT03400553|DIAGNOSTIC_TEST|Blood analysis|The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
215005450|NCT03698916|DRUG|Celecoxib cream 8%|transdermal delivery of 8% Celecoxib
215005451|NCT01363076|DRUG|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing \<50 kg.
214400741|NCT05196633|OTHER|radial extracorporeal shock wave therapy|rESWT (Endopuls 811; Enraf Nonius B.V. Va-reseweg 127, 3047 AT Rotterdam MedTech, Wessling, Germany) will be applied on the myotendinous junction of both the gastrocnemius and the soleus muscles in post-stroke spasticity patients. 2000 shots will be applied on the gastrocnemius and soleus myotendinous junction with a frequency of 10 Hz and energy density of 60 mJ (1 bar) within tolerable pain limits.
214400742|NCT05196633|OTHER|sham radial extracorporeal shock wave therapy|The control group will receive sound over the myotendinous junction of gastrocnemius and soleus with transducer-like contact.
214400743|NCT04305678|DRUG|Mepolizumab|Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
214400744|NCT04635878|OTHER|Blood collection|Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes
214400745|NCT03325621|BIOLOGICAL|PRS-080#022-DP|Biological/Vaccine: PRS-080#022-DP Hepcidin antagonism to mobilize iron and to treat anemia
214400746|NCT03325621|BIOLOGICAL|PRS-080-Placebo#001|Placebo Comparator
214400747|NCT05820074|DIAGNOSTIC_TEST|Neural Activity Recording|Neural Activity is measured using EEG in all groups. Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.
214400748|NCT05820074|DIAGNOSTIC_TEST|Movement Parameter Recording|Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.
214400749|NCT05820074|OTHER|Neuromodulation|Neural signals are recorded with the electrodes of the deep brain stimulation device. Parkinson's patients are asked to modulate their neural activity by observing the streamed neural activity and applying mental strategies.
214400750|NCT01682538|DRUG|Nitisinone, capsule|
214400751|NCT01682538|DRUG|Nitisinone, suspension|
214400752|NCT04660968|BEHAVIORAL|Dyadic health behaviour change intervention|The dyadic behaviour change intervention adopts a dyadic coping perspective wherein appraisal of shared responsibility, agreement on tasks, and collaboration are fostered throughout the intervention. The intervention will target four behaviour goals: reducing overall caloric intake, substituting empty calorie foods with healthier alternatives, reducing sedentary behaviour, and increasing physical activity. The specific behavioural change strategies will include motivational interviewing, self-monitoring, goal setting, stimulus control, problem solving, and relapse prevention. Each session will also include a short education component on healthy eating to improve participants' adherence to the updated Canada's Food Guide. Participants will have access to web-based exercise training sessions. Intervention sessions will be delivered online.
215005452|NCT01363076|DRUG|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
215005453|NCT01769872|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
215005454|NCT05220995|GENETIC|protocol|ovarian stimulation protocols on euploid rates were compared.
215005455|NCT04220281|DRUG|Propofol|propofol infusion during surgery
215005456|NCT04220281|DRUG|Nitroglycerin|nitroglycerin infusion during surgery
215096009|NCT01070108|DRUG|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
215096010|NCT02989129|BEHAVIORAL|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
215096011|NCT02989129|DRUG|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
215096012|NCT00558272|DRUG|AZD0530|Daily oral dose
215096013|NCT00558272|DRUG|Zoledronic Acid|
215005457|NCT04706403|BEHAVIORAL|Communication from a physician about the COVID-19 Vaccine|Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.
215005458|NCT04989738|BEHAVIORAL|THRIVE intervention|Parents learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
215005459|NCT04989738|BEHAVIORAL|Active Control|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
215005460|NCT04781985|PROCEDURE|cystoscopy|extraction of the bladder stone via suprapubic incision
215005461|NCT04858529|DRUG|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
215005462|NCT04858529|DRUG|investigator-selected taxane/trastuzumab/pertuzumab (THP)|investigator-selected taxane/trastuzumab/pertuzumab (THP)
215005463|NCT03475563|PROCEDURE|Coronary angioplasty with stent implantation|Coronary angioplasty with BiOSS LIM C stent implantation
215005464|NCT05998499|OTHER|Description|This study aimed to understand the situation of Latin American HIV-positive migrants seeking asylum in Spain and identify the challenges they encounter in getting HIV treatment. The main result measured was the proportion of participants with an HIV-1 RNA level of 50 copies/mL or higher at their first clinic visit
215005465|NCT00182637|DRUG|bortezomib|
214400753|NCT04660968|BEHAVIORAL|Dyadic nutrition counselling intervention|The couples-based education nutrition intervention will provide extensive information on healthy eating. However, it will not include any behavioural change principles. Topics will be based on Dietitians of Canada's Practice-based Evidence in Nutrition (PEN) discussions in the database that focus on healthy eating for older adults. The topics covered will include increasing fruits and vegetables, hidden (empty) calories, how to read food labels, portion control, reducing salt and saturated fat, plant-based proteins, and eating for healthy bones. Participants in this group will also be told to increase their levels of physical activity to 150 minutes of moderate to vigorous physical activity per week, as per the Canadian Guidelines. Participants will have access to web-based exercise training sessions. However, physical activity will not be discussed explicitly during the intervention. Intervention sessions will be delivered online.
214400754|NCT03606135|OTHER|The Pneumonia Group|
214400755|NCT03606135|OTHER|The Control Group|
214400756|NCT00413608|DRUG|Clopidogrel|Clopidogrel
214400757|NCT04049201|PROCEDURE|elective surgery|investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
214400758|NCT04049201|DRUG|Midazolam|Oral Midazolam
214400759|NCT04049201|DEVICE|Interactive Tablet|interactive Tablet containing many cartoon's videos
214400760|NCT02114281|OTHER|Care|
214400761|NCT02114281|OTHER|Not care|
214400762|NCT01907399|OTHER|Blood samples|
214400763|NCT04106687|PROCEDURE|Ultrasound Guided Caudal Block|Postoperative pain procedure
214400764|NCT04106687|PROCEDURE|Sacral Erector Spinae Block|Postoperative pain procedure
215005466|NCT01050842|DRUG|bicalutamide|Given orally
215005467|NCT01050842|DRUG|raloxifene|Given orally
215005468|NCT01050842|PROCEDURE|quality-of-life assessment|Ancillary study
215005469|NCT03118271|DEVICE|lumbar traction|
215005470|NCT03118271|PROCEDURE|spinal manipulation|
215005471|NCT03118271|PROCEDURE|surgery|
215005472|NCT03850301|DRUG|XBD173|7 days treatment
215005473|NCT03850301|DRUG|Etifoxine|7 days treatment
215005474|NCT06963983|DEVICE|Rehabilitation using virtual reality|During the four physiotherapy (PT) sessions (60 min for each session), a set of exercises from the conventional PT is replaced by multiple short sessions of 30 minutes each, where the patient will be equipped by a set of motion trackers mounted on a belt and on a set of straps to be worn around both arms and both forearms. The patient will also hold a controller in each hand and wear a commercial VR headset on his head. Then, thanks to the headset, the patient will be able to experience a set of VR environments, where he or she will be guided through a set of exergames. His/her movements in the real world will be used to move his/her avatar's body in the virtual world, and the exergames will be designed to push him/her to perform the motions required by the therapy in order to go through the games. Various strategies, including a virtual coach will also appear to prevent the patient from doing potentially hazardous movements.
215005475|NCT05229601|DRUG|HFB301001|"Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation."
215005476|NCT06964711|DRUG|GW117 ODT|Sublingual route ， 0.5mg/1mg/2mg/4mg，QD
215005477|NCT06964711|DRUG|Placebo|GW117 Placebo matching for Sublingual route ，QD
215005478|NCT04896021|DIAGNOSTIC_TEST|Cardiovascular disease risk assessment|Intervention in which the addition of guideline-recommended absolute cardiovascular disease risk assessment is embedded into point-of-care blood collection services for cholesterol measurement and results (including risk score) are reported to referring doctors.
215005479|NCT04896021|DIAGNOSTIC_TEST|Usual care assessment|Usual care in which blood cholesterol results are reported to referring doctors
215005480|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine tumor DNA test|Urine sample DNA is analyzed using a targeted sequencing panel encompassing the coding regions of 21 genes that are recurrently mutated in urothelial cancer
215005481|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine cytology (comparator)|Urine cytology sample
215005482|NCT05203679|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor IX (hFIX) transgene in liver.
215005483|NCT05402085|DIETARY_SUPPLEMENT|High Protein Diet|Subjects will be provided with high protein diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
215005484|NCT05402085|DIETARY_SUPPLEMENT|High Fat Diet|Subjects will be provided with high fat diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
215005485|NCT05402085|DIETARY_SUPPLEMENT|High Carbohydrate-Low Glycemic Index Diet|Subjects will be provided with high carbohydrate-low glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
215096014|NCT02880995|DEVICE|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
215096015|NCT02880995|BEHAVIORAL|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
215096016|NCT02880995|DRUG|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
215096017|NCT00625638|BEHAVIORAL|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
214400765|NCT02929290|DRUG|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
214400766|NCT02187822|DRUG|TPI 287|TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m\^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).
214400767|NCT02187822|PROCEDURE|Fractionated Stereotactic Radiotherapy (FSRT)|The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
214400768|NCT01941914|DRUG|Calcium chloride|
214400769|NCT04288973|DIAGNOSTIC_TEST|Microsoft Kinect Detection during mother child interaction|methodology based on RGB-D sensors applied to the setting of free parent-infant interaction
215005486|NCT05402085|DIETARY_SUPPLEMENT|High Carbohydrate-High Glycemic Index Diet|Subjects will be provided with high carbohydrate-high glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
215005487|NCT05628389|BEHAVIORAL|Educational materials|Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.
215005488|NCT05628389|BEHAVIORAL|Phone counseling|Cessation counseling to address insufficient patient self-efficacy and motivation.
214400770|NCT01759992|DEVICE|Threshold® Inspiratory Muscle Trainer (treatment).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
215005489|NCT05628389|DRUG|Nicotine Replacement Therapy|Nicotine patches to address nicotine withdrawal symptoms in patients.
215005490|NCT05628389|BEHAVIORAL|Provider training|Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.
214400771|NCT06224595|DRUG|CS32582 capsule|Participants receive CS32582 orally single or multiple doses
214400772|NCT06224595|DRUG|Placebo capsule|Participants receive placebo matching CS32582 orally single or multiple doses
214400773|NCT05786586|DEVICE|650 nm low-level red-light|650 nm low-level red-light is a kind of laser, concentrated into a beam, to repeatedly irradiate the retina
214400774|NCT03564938|DRUG|Regorafenib (Stivarga, BAY73-4506)|The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
214400775|NCT06244147|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha Root Extract|Participants will take KSM-66 Ashwagandha root extract 300mg twice a day for the duration of the study.
215005491|NCT05628389|BEHAVIORAL|Electronic reminders|Electronic reminders to address the lack of integration of AAA/AAC into practice.
215005492|NCT05199272|DRUG|23ME-00610|23ME-00610 given by IV infusion
215005493|NCT05419011|BIOLOGICAL|Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5|Given SC
215005494|NCT05419011|PROCEDURE|Biopsy Procedure|Undergo biopsy
215005495|NCT05419011|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215005496|NCT05419011|PROCEDURE|Colonoscopy|Undergo SOC colonoscopy
214400776|NCT01982071|DRUG|Micafungin|Intravenous (IV)
214400777|NCT06440174|PROCEDURE|endoscopic ultrasound|EUS is an invasive procedure combining upper gastrointestinal endoscopy with ultrasonography. An ultrasound probe located at the end of the endoscope allows direct visualisation of the oesophageal wall layers and adjacent tissues providing local assessment of the depth of tumour invasion and lymph nodes. This assessment informs local tumour (T-) and node (N-) staging which are important prognostic indicators of survival. Patients undergoing EUS require sedation and there are risks of complication. EUS is a specialist investigation requiring many years of dedicated training to perform competently.
215005497|NCT05419011|DRUG|Nogapendekin Alfa|Given nogapendekin alfa inbakicept (N-803) SC
214400778|NCT06542705|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
214400779|NCT06542705|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace. ACLR technique will be standardized to standard anteromedial (AM) portal femoral drilling to ensure consistency between surgeons.
214400780|NCT01277237|DRUG|Omacor|Active comparator: omacor 4g/day
214400781|NCT01277237|DRUG|lactose tablet|placebo: lactose tablet 4g/day
214400782|NCT03878082|DRUG|Propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
214400783|NCT03878082|DRUG|Propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
214400784|NCT03878082|DRUG|IVPCA|pain control with IVPCA
215005498|NCT05419011|DRUG|Placebo Administration|Given SC
215005499|NCT05419011|OTHER|Questionnaire Administration|Ancillary studies
214400785|NCT01034475|DRUG|CPI-613|"This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient \& traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is \>Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme."
214400786|NCT05501132|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days
214400787|NCT02466126|BEHAVIORAL|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
214400788|NCT00315627|DRUG|Islet transplantation|Islet transplantation
214400789|NCT00915850|DRUG|DCF|docetaxel, Cisplatin and 5-FU
214400790|NCT04428970|PROCEDURE|Invasive ICP monitoring|Insertion of a parenchymal pressure measuring probe
214400791|NCT00548275|BEHAVIORAL|Enhanced Sexual Risk Management|management of sexual risk
214400792|NCT00548275|BEHAVIORAL|Standard Sexual Risk Management|management of sexual risk
214400793|NCT00244361|DRUG|rituximab|
214400794|NCT01268059|DRUG|Carboplatin|Carboplatin (carboplatin area under the plasma concentration-time curve \[AUC\] of 6 milligram per milliliter into minute \[mg/mL\*min\] administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
214400795|NCT01268059|DRUG|Paclitaxel|Paclitaxel 200 milligram per square meter (mg/m\^2) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
215005504|NCT06318715|PROCEDURE|modified deep extubation (mDE)|The proposed study is to compare a modified DE technique, which is regularly used for low-risk patients by staff anesthesiologists at our institution, to a standard awake extubation.
215005505|NCT06318715|PROCEDURE|standard awake extubation|awake extubation (AE) is still considered the standard practice.
215005506|NCT05623085|OTHER|Aerobic exercise|Individuals in this group will be given 8-week individualized exercise according to the Karvonen protocol (heart rate reserve percentage-% HR). Exercise training will be 30 minutes at 50% of HR between weeks 0-2, 45 minutes at 50% of HR between weeks 2-4, 45 minutes at 60% of HR between weeks 4-6 and 6-8 weeks It will be done on the treadmill 3 days a week, for 60 minutes at 60% of HR between weeks. The treadmill speed will be adjusted during exercise to maintain the set target heart rate level.
215005507|NCT05623085|OTHER|Yoga exercise|Individuals in this group will be given 8-week individualized yoga exercise including stretching, relaxing, strength training. Exercise training will be done 3 days a week. The duration of the exercise will be adjusted to be the same as the aerobic exercise group.
215096018|NCT00625638|OTHER|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
214400796|NCT01268059|DRUG|MEDI-575|MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
214400797|NCT02819479|DRUG|25% Mannitol|"Route of administration:~In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery."
214400798|NCT02819479|DRUG|Low-dose Intra-arterial Bevacizumab|"Route of administration:~In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery."
214400799|NCT03114943|BIOLOGICAL|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
214400800|NCT03114943|BIOLOGICAL|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
214400801|NCT02174679|DRUG|68Ga DOTATATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
214400802|NCT00196911|PROCEDURE|Implantation of stimulation electrodes in the STN|
214400803|NCT05310084|BIOLOGICAL|BNT162b2|Intramuscular injection
215005508|NCT04241718|DEVICE|Aquadex FlexFlow System and BVA-100|Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100
215096019|NCT03084354|OTHER|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
215096020|NCT00031564|BIOLOGICAL|Interleukin-2|
215096021|NCT00031564|BIOLOGICAL|B7-1|
215096022|NCT04084821|OTHER|none - observation only|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
214400804|NCT05310084|OTHER|Placebo|Saline intramuscular injection
214400805|NCT05310084|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV intramuscular injection
214400806|NCT01097980|DRUG|Trazodone|50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained
214400807|NCT01097980|DRUG|Placebo|Placebo
214400808|NCT02578602|DRUG|Gadoxetate Disodium|Given IV
214400809|NCT02578602|DEVICE|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
214400810|NCT02294162|DRUG|Ketamine i.v|
214400811|NCT05899049|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
214400812|NCT05899049|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
214400813|NCT05899049|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
214400814|NCT05899049|DRUG|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
214400815|NCT01120574|OTHER|Home mechanical ventilation|Home mechanical ventilation will be performed with a bilevel pressure ventilator.
214400816|NCT02941146|DEVICE|The ZELTIQ System|The CoolSculpting System will be used to perform the treatments with the CoolAdvantage family of applicators.
214400817|NCT05732948|DRUG|autologous T cells & cyclophosphamide|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T administered one day after pretreatment with cyclophosphamide.
214400818|NCT06292702|PROCEDURE|Traditional Burch colposuspension|Peforming two stitches between the anterior vaginal wall and Cooper's ligament.
214400819|NCT06292702|PROCEDURE|Modified Burch colposuspension|Performing lateral tension for the anterior vaginal wall towards the intersection point of the arcus tendineus and the lower edge of the pubic bone then performing two stitches between the anterior vaginal wall and Cooper's ligament.
214400820|NCT01142999|DRUG|Sunflower oil|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
214400821|NCT01142999|DRUG|Control group|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
214400822|NCT01142999|DRUG|Aquaphor ointment|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
214400823|NCT01142999|DRUG|Cetaphil cream|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
214400824|NCT01021332|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|oral
214400825|NCT01021332|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|oral
214400826|NCT01746394|BEHAVIORAL|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
214400827|NCT01746394|BEHAVIORAL|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
214400828|NCT01358916|OTHER|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
214400829|NCT06297096|DRUG|Tocilizumab|Tocilizumab 162 mg s.c./week
214400830|NCT06297096|DRUG|Nintedanib|Nintedanib - established doses of nintedanib for adults in the treatment of ILD, also SSc-ILD: 2 x 150 mg daily, in the event of e.g. increased liver enzyme levels, poorer treatment tolerance (e.g. diarrhea), the dose can be reduced to 2 x 100 mg
214400831|NCT06297096|DRUG|Standard therapy|mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
215005509|NCT05463055|RADIATION|Proton Therapy System (ProBeam)|All of subjects (tumor patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors) will be treated with Proton radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months ( for this trial). Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.
214400832|NCT04489784|DEVICE|Infrared Laser|An aluminum gallium arsenide (AlGaAs) diode laser device (Twin laser, MMOptics, São Carlos, SP, Brazil) was used. The irradiation parameters were as follows: infrared laser (808 nm wavelength) with a spot area of 0.04 cm2, and an average optical power of 100 mW operated in a continuous mode during 1 minute per point, leading to an irradiance of 2,500 mW/cm2, energy of 6 J and fluence of 125 J/cm2 per point. The laser was applied on ballerina's feet twice a week during three months.
214400833|NCT05845073|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules twice daily, for the duration of antibiotic therapy, and 14 days thereafter.
214400834|NCT05845073|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for for the duration of antibiotic therapy, and 14 day thereafter.
214400835|NCT05249998|OTHER|Program combing APA, Nutrition, and Therapeutic Education|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
214504221|NCT03516877|BEHAVIORAL|Enhanced Stress Resilience Training for Faculty Physicians|Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
214504222|NCT05738434|DRUG|Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib|camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investigator' choice： paclitaxel 135\~150 mg/m2, i.v. d1,q3w; paclitaxel-albumin 150\~180 mg/m2, i.v. d1,q3w. up to 4 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w
214504223|NCT05738434|DRUG|Camrelizumab+Chemotherapy→Camrelizumab|camrelizumab 200 mg, i.v. d1,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investgator' choice： paclitaxel 175 mg/m2, i.v. d1,q3w; paclitaxel-albumin 200 mg/m2, i.v. d1,q3w up to 6 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w;
214504224|NCT02797743|OTHER|Whole blood|"* Adults ≥18 yrs of age: up to 50 mL (5 tubes)~* Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)~* Children 0-11 yrs of age: single tube (1 tube, 10 mL)"
214504225|NCT02331485|DEVICE|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
214504226|NCT05636111|DRUG|Paclitaxel|Given by (IV) vein
214504227|NCT05636111|DRUG|Bevacizumab|Given by (IV) vein
214504228|NCT05636111|DRUG|Lurbinectedin|Given by (IV) vein
214504229|NCT05660473|DRUG|Vincristine|Anti-tumor alkaloids
214504230|NCT05660473|DRUG|Daunorubicin|Anthracycline
214504231|NCT05660473|DRUG|Cyclophosphamide|Alkylating agent
214504232|NCT05660473|DRUG|Pegaspargase|Polyethylene glycol (PEG) conjugated to L-asparaginase
214504233|NCT05660473|DRUG|Prednisone|Glucocorticoids
214504234|NCT05660473|DRUG|Cytarabine|Pyrimidine antimetabolites
214504235|NCT05660473|DRUG|6-mercaptopurine|Cell cycle-specific antitumor drug
215096023|NCT05755802|PROCEDURE|PENG block|"A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
214400836|NCT04744662|DRUG|ONL1204 Ophthalmic solution|Liquid formulation administered by intravitreal (IVT) injection
214400837|NCT04744662|PROCEDURE|sham injection|sham injection is done by touching the eye surface with a syringe without a needle
214400838|NCT00234559|DEVICE|VAC® Therapy System|
214504236|NCT05660473|DRUG|Dexamethasone|Glucocorticoids
214504237|NCT05660473|DRUG|Methotrexate|Antifolate antineoplastic drug
215005510|NCT03819205|OTHER|kinesiotaping|The participants will receive kinesiotaping treatment on the affected side for the hemiplegic CP's and for diplegic, tetraplegic CP's the side of upper extremity which children have been used to but have obstacles in daily life for 1 week at least 2-3 hours a day, renewing if it's necessary. The participants will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day. In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion
215005511|NCT04581746|OTHER|questionnaire|bi-monthly questionnaire and then one visit with questionnaire and covid-19 test
215005512|NCT04766333|BEHAVIORAL|Healthcare Worker Focused Outreach|This a focused outreach intervention strategy specifically designed for healthcare workers.
215005513|NCT04766333|BEHAVIORAL|Community Organization Led Outreach|This is a standard community engaged outreach approach that has traditionally been used in previous research. Analogous to the standard of care for outreach.
214400839|NCT05636436|BIOLOGICAL|Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
214400840|NCT05636436|BIOLOGICAL|High Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
214400841|NCT05636436|BIOLOGICAL|Low dose adjuvant|0.5 mL per dose, containing low dose MA105 adjuvant.
215096024|NCT05755802|PROCEDURE|Shoulder block|The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it Will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. A 50 mm nerve block needle will be used in the long axis view for the block. After confirming extravascular placement of the needle, injectate will be given below the supraspinatus fascia and then during axillary nerve block,The posterior surface of the humerus will be visualised in the short axis view. So, the circumflex artery will be visualised longitudinally. After confirming extra-vascular placement of the needle, injectate will be given into space.
214400842|NCT05636436|BIOLOGICAL|High dose adjuvant|0.5 mL per dose, containing high dose MA105 adjuvant.
214400843|NCT05636436|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
214400844|NCT05636436|BIOLOGICAL|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
214400845|NCT04731714|DEVICE|Rhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
214400846|NCT04731714|DEVICE|Arrhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
214400847|NCT03487666|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
214400848|NCT03487666|DRUG|Capecitabine|Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
214400849|NCT06434051|OTHER|Traditional Chinese cervical manipulation|The CMP will first palpate the transverse processes of C1 and C2. The transverse process with apparent tenderness will be regarded as the pain side. The right side will be the painful side for the following example). During the manipulation, the CMP will use his left hand to support the lower jaw and passively rotate the neck to the left side by 70-75 degrees (or to the maximum angle without discomfort). The physician's right-hand fingers will support the left-side transverse processes of C1 and C2, and the thumb and thenar muscle will be placed on the spinous process and occipital area. While maintaining a passive left neck rotation, the physician will increase the rotation angle by 5-10 degrees with both hands under a sudden pulling force. The above procedure will be repeated on the right side (pain side).
214400850|NCT06434051|OTHER|Sham manipulation|The posture and position of the participant and the practitioner and the procedure are the same as the CCM technique. The right side will be regarded as the pain side once again. When performing the sham technique, the CMP uses the left hand to support the lower jaw position and passively rotates the neck to the left side by 70-75 degrees or to the maximum angle. The right hand presses the upper inner corner of the right scapula. While maintaining the passive left rotation of the neck, the right hand slowly exerts force downwards and outwards on the inner side of the scapula. The left hand only maintains the left rotation of the neck without any pulling force. After completion, repeat the above actions on the right side. After the technique is completed, participants can get up after resting for 5-10 minutes.
215005514|NCT03583346|DRUG|M6495|Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
215005515|NCT03583346|DRUG|Placebo|Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
215005516|NCT05124184|DEVICE|GORE® PROPATEN® Vascular Graft|Patients that have had treatment with GORE® PROPATEN® Vascular Graft
214400854|NCT04758403|RADIATION|Navigation Bronchoscopy|Navigation Bronchoscopy procedure will be performed per product instructions and the institution's standard practice.
214400855|NCT04758403|RADIATION|Cone beam computed tomography (CBCT)|Per Protocol
215005517|NCT05124184|DEVICE|GORE-TEX® Vascular Grafts|Patients that have had treatment with GORE-TEX® Vascular Grafts
214400856|NCT04545593|BEHAVIORAL|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) was designed to provide a single, integrated program that could address the dual challenges of mental health and disability among minority elders. PMSB-E seeks to improve mood symptoms, identify and correct negative distortions or cognitions, promote behavioral activation through engaging the participant in pleasant activities, and encourage developing supportive relationships. All sessions are tailored to the participant's needs using a collaborative approach.
214400857|NCT04545593|BEHAVIORAL|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. Research staff will call the participant 4 times over the course of 6 months to administer mental health items, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group.
214400858|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
214400859|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
214400860|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
214504238|NCT05660473|DRUG|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
215005518|NCT06784765|PROCEDURE|Intervention Group|Preventive pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin (10 mg/m2) and doxorubicin (2.1 mg/m2) + perioperative chemotherapy (FLOT regimen) +gastrectomy with D2 lymphadenectomy
215005519|NCT06784765|PROCEDURE|Control Group|Retrospective cohort receiving standard perioperative chemotherapy (FLOT regimen) + gastrectomy with D2 lymphadenectomy
214400861|NCT05493722|OTHER|PS and OS stimulation order 1|PS, OS, OS
215005520|NCT00298194|DRUG|Z-338|
215005521|NCT00639379|DEVICE|senofilcon A toric|silicone hydrogel toric lens, 2 wk replacement, daily wear
215005522|NCT00639379|DEVICE|alphafilcon A toric|hydrogel toric lens, 2 wk replacement, daily wear
215005523|NCT02090595|BEHAVIORAL|MBCT-C|A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.
215005524|NCT02090595|BEHAVIORAL|Waitlist Control|Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
215005525|NCT01452087|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
215005526|NCT04268524|COMBINATION_PRODUCT|drug: miltefosine with thermotherapy|see previous
215005527|NCT00263536|PROCEDURE|Interpersonal Psychotherapy|
215005528|NCT06486779|OTHER|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
215005529|NCT01886157|PROCEDURE|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
214400862|NCT05493722|OTHER|PS and OS stimulation order 2|OS, PS, OS
214400863|NCT05493722|OTHER|PS and OS stimulation order 3|OS, OS, PS
214400864|NCT05343455|DRUG|DFD-29|DFD-29 (40 mg) extended release capsules
214400865|NCT05343455|DRUG|Doxycycline|Doxycycline 40 mg capsules
214400866|NCT05343455|DRUG|Placebo|Placebo capsules
214400867|NCT05929807|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
214504239|NCT01477177|DEVICE|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
214504240|NCT01505166|BIOLOGICAL|Vigil™ Vaccine|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
214688186|NCT07091591|BEHAVIORAL|Changing (version: nutrition)|The intervention discusses the evolving nature of scientific research on diet and health. It explains how initial studies can suggest one thing, only for later studies to offer new insights or clarify previous findings. For example, while early research linked high fat intake with heart disease, more recent studies have shown that some fats, like those in nuts, avocados, and oily fish, are actually beneficial. It emphasizes that science often advances gradually, and rigorous, long-term studies help understanding. It also points out that health recommendations are influenced by multiple factors, and over time, accumulated knowledge enables us to better understand the situation and make informed decisions.
215005530|NCT01886157|PROCEDURE|Corticosteroid injection|Standard trigger finger corticosteroid injection.
215005531|NCT03979989|DRUG|Tapentadol IR capsule|Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.
215005532|NCT03979989|DRUG|Omeprazole capsule|Omeprazole capsule containing 40 mg omeprazole.
214400868|NCT04600180|PROCEDURE|sigmoidoscopies and and venous blood sampling|Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.
214400869|NCT04411940|DRUG|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
214400870|NCT04411940|DRUG|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
214504241|NCT01505166|DRUG|Placebo|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
214504242|NCT06020352|DRUG|KN046 plus Axitinib|KN046 combined with axitinib as a neoadjuvant treatment regimen
214504243|NCT01428206|OTHER|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
215005533|NCT06288178|DIETARY_SUPPLEMENT|Bread consumption|There were four groups: whole wheat (WWB), buckwheat (BWB), corn bread (CB) and reference bread.
215005534|NCT00723944|DEVICE|Osseotite Certain Prevail|Root form titanium dental implant
215005535|NCT00723944|DEVICE|Osseotite Certain|Dental implant without the lateralized design
215005536|NCT04947722|BEHAVIORAL|PREVENT Program|A standardized PREVENT educational program will be offered to each intervention LTC home and health-care staff. The curricula includes video modules with fracture-prevention care recommendations and an orientation to the Fracture Prevention Toolkit. Using the Fracture Risk Scale (i.e., a clinical decision support tool embedded in the RAI-MDS 2.0), the LTC team will identify residents at high-risk for fracture and will implement the fracture prevention recommendations into care plans on an individual resident basis.
215005537|NCT03274258|BIOLOGICAL|Ipilimumab|Given IV
215005538|NCT03274258|BIOLOGICAL|Nivolumab|Given IV
215005539|NCT03754647|DIETARY_SUPPLEMENT|Vitamin C|One tablet of Vitamin C (500 mg) twice daily with SSRIs for 8 weeks
215005540|NCT03994432|BEHAVIORAL|intervention group|"follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model."
215005541|NCT03546959|OTHER|Lycra sleeve|custom-fitted lycra sleeve extending from axilla to wrist
215005542|NCT03546959|OTHER|Rehabilitation|Passive, active and active assistive range of motion and stretching exercises for shoulder, elbow, wrist, facilitation and inhibition techniques, neuromuscular electrical stimulation for wrist extensors, strengthening exercises for affected upper extremity, occupational therapy
214400871|NCT05061771|DRUG|nomacopan (rVA576)|Nomacopan an inhibitor of complement C5 and LTB4
215005543|NCT03546959|DRUG|Botulinum Toxin|Botulinum toxin injection for upper limb spasticity after stroke
215005544|NCT01620099|DRUG|Extrafine treatment (Clenilexx(R) or Foster(R))|Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
214400872|NCT05061771|OTHER|Placebo|Placebo
214400873|NCT06121791|OTHER|Normal values of abdominal level muscle areas of Turkish children|age, sex, L3-L4 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area, L4-L5 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area
214400874|NCT05138796|DRUG|TP-05 (lotilaner oral capsules)|TP-05 (lotilaner oral capsules)
214400875|NCT05138796|DRUG|Placebo|Placebo to match TP-05 (lotilaner oral capsules)
214504244|NCT00031941|DRUG|lenalidomide|
215005545|NCT06553820|BEHAVIORAL|Intervention group I, Yoga 20 minutes x2 pr week|App-based MediYoga exercises, 20 minutes per session, twice a week for a total of 10 weeks.
215005546|NCT06553820|BEHAVIORAL|Intervention Group II, Yoga 40 minutes x2 pr week|App-based MediYoga exercises, 40 minutes per session, twice a week for a total of 10 weeks.
215005547|NCT06553820|OTHER|Control Group, No intervention|standard of care only
215005548|NCT06848218|OTHER|Music Therapy|"This procedure is carried out using headphones installed in the child's ears. The music will be activated if the child is in the Music group, and will not be activated but present if the child is not in the Music group.~NIV implementation will begin after 10 min of listening. The listening period will continue until the nadir period (when the music is slowest, for maximum relaxation), until 10 min after the start of the NIV."
215005549|NCT06848218|PROCEDURE|Setting Up NIV|Non invasive ventilation is set up in several stages, with the help of at least two caregivers. The patient will be placed in a half-seated position or seated. Installation begins with the placement of the non invasive ventilation mask harness around the child's head, followed by the application of the mask to the face, held by a caregiver. Once the mask has been applied, ventilation is started by connecting the non invasive ventilation circuit to the mask. The harness is then tightened by the second caregiver.
215005550|NCT02400736|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is the evidenced based model of supported employment.
215005551|NCT02400736|OTHER|Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)|Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
214504245|NCT02973594|DRUG|Ivabradine|
214504246|NCT02973594|DRUG|Placebo|
214504247|NCT01744808|DRUG|EB-1020 IR|Immediate release
214504248|NCT01744808|DRUG|EB-1020 SR1|sustained release
214400876|NCT00002896|DRUG|chemotherapy|
214400877|NCT00002896|DRUG|fluorouracil|
214504249|NCT01744808|DRUG|EB-1020 SR2|Sustained release
214504250|NCT01744808|DRUG|EB-1020 SR3|Sustained release
214504251|NCT01744808|OTHER|Placebo|Placebo formulation
214504252|NCT05623033|OTHER|The study is an observational study without intervention|The study is an observational study without intervention
214688187|NCT04633239|DRUG|Abemaciclib|Given PO
215005552|NCT00552903|BEHAVIORAL|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
215005553|NCT04137315|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
215005554|NCT06169085|DRUG|Leritrelvir|Oral
215005555|NCT03228914|DRUG|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
215005556|NCT03228914|DRUG|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
215005557|NCT01326936|BEHAVIORAL|Online education|A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
215005558|NCT00801268|DRUG|tripterygium wilfordii|TW，60mg/d
215005559|NCT00801268|DRUG|Emodin|100mg/d
215005560|NCT00894725|PROCEDURE|laparoscopic left colonic resection|laparoscopic colonic resection
215005561|NCT00894725|PROCEDURE|open left colonic resection|conventional open colonic resection
215005562|NCT05858229|DRUG|RP1|Recombinant Herpes Simplex Virus Type 1 - hGM CSF/GALV-GP-R-
215005563|NCT04841876|OTHER|rugby matches|standard rugby-7s match
215005564|NCT03165903|BEHAVIORAL|Cue and Implementation Intention-Based Intervention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
215005565|NCT03165903|BEHAVIORAL|Control arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
214400878|NCT00002896|DRUG|leucovorin calcium|
214400879|NCT00002896|PROCEDURE|conventional surgery|
214400880|NCT00002896|RADIATION|low-LET cobalt-60 gamma ray therapy|
215005566|NCT04286958|DRUG|Camrelizumab|Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)
215005567|NCT01960478|BIOLOGICAL|(for each intervention)|
215005568|NCT01960478|OTHER|Blood test|
214400881|NCT00002896|RADIATION|low-LET photon therapy|
214400882|NCT03498040|OTHER|Study of the occurrence of Carcinoid Heart Disease|"Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, …) biological parameters (urinary 5HIAA, NT-ProBNP …) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease."
214400883|NCT04864496|DRUG|Prescribe N-acetylcysteine tablets|N-acetylcysteine tablets ,1200 mg two times daily
214400884|NCT04864496|DRUG|Prescribe placebo tablets|manufactured by Daroo Salamat Pharmed, two times daily
215005569|NCT03346512|PROCEDURE|Cardiac surgery|Cardiac surgery
215005570|NCT02383173|OTHER|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
214400885|NCT04761419|BEHAVIORAL|Parents' longer presence beside their infant|They are not intervention. We will collect data about these items.
214400886|NCT00635843|DEVICE|MAVERICK™ Disc|The MAVERICK™ disc is a spinal arthroplasty system and is intended to replace a damaged disc in the lumbar spine. It is a permanent implant used to maintain motion at the treated level and is inserted using an anterior surgical approach.
214400887|NCT00635843|DEVICE|LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft|The control is the treatment with LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft. It is commercially available for anterior lumbar spine interbody fusion procedures.
214504253|NCT05340231|DRUG|TACE protocol|"Transarterial infusion chemotherapy: Oxaliplatin(85mg/m\^2)+Raltitrexed(3mg) Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)，The endpoint for embolization was defined as stagnation of blood flow of the posterior mesenteric artery.~Intervention cycle：4W; Treatment times: 2. followed by mFOLFOX6"
215005571|NCT02383173|OTHER|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
215005572|NCT04498507|DIAGNOSTIC_TEST|HADS questionnaire|Patients will be asked to answer to 3 questionnaires about anxiety and depression, post-traumatic stress disorder and health-related quality of life
215096025|NCT04659694|OTHER|Wellness programme provided by Oomph! Wellness company|The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
215005573|NCT01801332|DIETARY_SUPPLEMENT|intensive nutrition|"Patients randomized in  intensive enteral nutrition  arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde."
214400888|NCT03554187|DEVICE|Ultrasonic periodontal Debridement, with appropriate device|Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.
214400889|NCT03554187|BIOLOGICAL|Analyzes of periodontopathogenic bacteria|Collection of plaque, to analyze the bacteria in the pocket
214400890|NCT03554187|GENETIC|IL1B test|susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)
214400891|NCT03554187|BIOLOGICAL|Salivary Sampling|Salivette to chew. To analyse salivary microbiota
214400892|NCT03554187|DEVICE|Halitosis measure|With appropriate device : halimeter
214400893|NCT02722941|DRUG|Panobinostat|Maintenance therapy dosing as outlined in Cohorts A and B.
214400894|NCT04223596|DRUG|Brigatinib|Brigatinib 90 mg for the first 7 days (D1-7 at cycle 1) and then 180 mg daily thereafter for QW4 cycles of duration (28 days+-3 days)
214400895|NCT00027768|PROCEDURE|adjuvant therapy|
214400896|NCT00027768|RADIATION|iodine I 131 ethiodized oil|
214400897|NCT06486935|DEVICE|IoT sensors|The proposed assistive Activities of Daily Living (ADL) monitoring system consists of ambient infrared sensors embedded seamlessly into the living environment, and a visualization app. Multimodality sensors with wireless data transmission capability will be installed at different locations (e.g. bedroom, kitchen, toilet, bathroom, living room, etc.) to monitor and detect the activities performed by individual elderly, such as cooking, sleeping, going to the bathroom, going out of the apartment or potential wandering, bathroom falls, etc. In addition, a micro-bend fiber optic pressure sensor mat will be placed unobtrusively below the bed mattress to measure the elderly's heart and respiratory rates during sleep. This mat helps provide information on the quality of sleep and sleep-wake rhythms of the elderly with sleep disorders. The collected data will then be transferred through a secured gateway with Raspberry Pi to a dedicated server for data processing and analysis.
214400898|NCT06486935|OTHER|Traditional/Manual elderly monitoring|Traditional elderly care without the use of IoT sensors.
214400899|NCT00003928|DRUG|cisplatin|Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214400900|NCT00003928|DRUG|gemcitabine hydrochloride|Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
214400901|NCT02510066|DEVICE|Acupuncture|Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.
214400902|NCT02510066|DEVICE|Placebo acupuncture|Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
214400903|NCT02451904|OTHER|Observation|
214400904|NCT06526208|DRUG|MB-IMP|MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.
214504254|NCT05340231|DRUG|Neoadjuvant Chemotherapy|mFOLFOX6, Q2W
214688188|NCT04633239|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214400905|NCT06526208|OTHER|Placebo|Does not contain CBD or THC
214400906|NCT02688036|RADIATION|hypofractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.
214400907|NCT02688036|RADIATION|conventionally fractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
214400908|NCT02318225|DRUG|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
214504255|NCT05123079|DRUG|Darigabat|Tablets
214504256|NCT04701372|BEHAVIORAL|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.
214504257|NCT04378894|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
214688189|NCT04633239|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214688190|NCT04633239|DRUG|Olaparib|Given PO
214688191|NCT05128162|DRUG|Psilocybin|Two oral doses of psilocybin in a capsule formulation taken approximately 2 weeks apart.
215005574|NCT01801332|DIETARY_SUPPLEMENT|usual meals|"Patients randomized in  classical oral nutrition  arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily."
214400909|NCT02318225|DRUG|Placebo|"Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
214504258|NCT06014372|DRUG|Envafolimab|Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
215005575|NCT01297244|DRUG|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
214400910|NCT05441475|DRUG|ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w|All subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w).
214400911|NCT05149079|DIETARY_SUPPLEMENT|Cod protein hydrolysate|Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM is treated wth enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption.
214400912|NCT05149079|DIETARY_SUPPLEMENT|Placebo|Whey protein powder, commercially available
214400913|NCT02748512|DRUG|FAI Insert administered using the Mk II inserter|
214400914|NCT02748512|DRUG|FAI Insert administered using the Mk I inserter|
214400915|NCT02977975|OTHER|Raw sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
214400916|NCT02977975|OTHER|Pasteurized sauerkraut|Sauerkraut without live bacteria.
214400917|NCT03826212|DIETARY_SUPPLEMENT|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
214400918|NCT03826212|DIETARY_SUPPLEMENT|Placebo|Placebo 1,600 mg/day for 12 weeks.
214400919|NCT03589924|PROCEDURE|Immediate IBBR+TiLoop®Bra|Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra
214400920|NCT03589924|PROCEDURE|Immediate-delayed IBBR+TiLoop®Bra|Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra
214400921|NCT03681821|BEHAVIORAL|Transtheoretical Model (TTM)-based Intervention|Patients in the intervention group had access to conventional care, in addition to receiving the follow-up TTM-based intervention sessions. The intervention was provided by trained nurses, including one researcher and one ET nurse. Sessions were held in the meeting room in the unit four times: at baseline (T0), 2 days before discharge (T1), and at 1-month (T2) and 3-months (T3) after discharge, according to the assessment of their current stage of change delivered by filling the Stages of Change Subscale. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
214400922|NCT03344614|DRUG|raltitrexed combined with apatinib|raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles
214400923|NCT06438393|DIAGNOSTIC_TEST|CT coronary angiography and non-contrast CT|"A CTCA is an X-ray computed tomography of the coronary arteries that allows visualization of coronary plaques with high temporal and spatial resolution, however, it implies the use of iodine contrast and exposition to clinically significant ionizing radiation.~Non-contrast ECG-gated CT (calcium score - CCS image). A non-contrast cardiac CT for CCS can be performed very quickly with significantly lower radiation (\~6 times lower) than CTCA and without the need for contrast."
214504259|NCT06014372|DRUG|CAPEOX|The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
214504260|NCT01034306|DRUG|CF101|orally q12h
214504261|NCT01034306|DRUG|Placebo control|orally q12 hours
214688192|NCT05128162|BEHAVIORAL|Psychotherapy|1\. Pre-dose preparatory sessions; 2. Dosing day monitoring; and, 3. Post-dose integration sessions.
215005576|NCT03677401|DRUG|5mg Serlopitant Tablets|Serlopitant Tablets
215005577|NCT03677401|DRUG|Placebo Tablets|Placebo Tablets
215005578|NCT05234333|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccination
215005579|NCT01953276|DEVICE|Serial Electrocardiograms|All participants will have serial electrocardiograms performed.
214504262|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Standard product (SP)|2 capsules - 200 mg total CoQ10
214504263|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP1)|2 softgels - 200 mg total CoQ10
214504264|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP2)|2 softgels - 200 mg total CoQ10
214504265|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP3)|2 softgels - 200 mg total CoQ10
214504266|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP4)|2 capsules - 200 mg total CoQ10
215096026|NCT01569386|BEHAVIORAL|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
215005580|NCT05935020|OTHER|Usual care - Municipal exercise-based rehabilitation|"The patients in this group follow prescribed (by the orthopedic surgeon) usual care municipal exercise-based rehabilitation. The content of the rehabilitation is planned in collaboration between the patient and the physical therapist, based on the offered municipal treatment options (which varies between municipalities) and patient preferences (i.e., home-based exercise, outpatient exercise, group-based exercise, or a combination thereof). The contents of the municipal services offered will be described in detail in the trial report.~A prescribed therapeutic rehabilitation exercise plan could for instance be a 6-week combined home-exercise (1-2 times/week) and group-exercise (1 time/week) intervention, followed by encouragement to continue self-administered home exercise after the 6 weeks."
214504267|NCT00836498|BIOLOGICAL|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
214504268|NCT00836498|BIOLOGICAL|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
214504269|NCT00836498|BIOLOGICAL|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
214504270|NCT02821299|OTHER|Laryngeal transplantation|Laryngeal transplantation
214504271|NCT02082652|DRUG|Etonogestrel|Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
214688193|NCT06910124|BIOLOGICAL|Linvoseltamab|"Participants will receive Linvoseltamab intravenously (IV) according to the following schedule and regimen, for up to 24 cycles, each cycle lasting 28 days:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 25mg~* Cycle 1 Days 15, 22: 100mg~* Cycles 2 and 3, Days 1, 8, 15, 22: 100mg~* Cycles 3 and 6, Days 1 and 15: 100mg~* Cycles 7 through 24: 100mg"
215005581|NCT05935020|OTHER|Return to Everyday life|"The patients in this group return to their desired pre-surgical activities, at their own speed, when they feel that they are ready for it. They are not prescribed any exercise-based rehabilitation (usual care) by their orthopedic surgeon.~This effectively means they will not receive a therapeutic progressive exercise plan; designed and prescribed to restore previous function or reducing pain or disability caused by injury, disease, or surgery - typically referred to as exercise therapy or therapeutic exercise."
214400924|NCT02990728|DRUG|Metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
214400925|NCT02990728|DEVICE|Mirena®|
214400926|NCT00787943|DRUG|Topical benzoyl peroxide 10.0% cream - Formulation 1|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
214400927|NCT00787943|DRUG|Topical benzoyl peroxide 10.0% cream - Formulation 2|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
214400928|NCT05969106|DEVICE|Tandem Control-IQ|AID-system
214400929|NCT04012320|OTHER|No intervention, observational study|No intervention, observational study
214504272|NCT02923479|DEVICE|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
214504273|NCT02923479|OTHER|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
214504274|NCT02923479|OTHER|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
214504275|NCT02923479|DEVICE|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
214504276|NCT02923479|DEVICE|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
214504277|NCT01939249|DEVICE|Abbott Laboratories Xience|
214504278|NCT01939249|DEVICE|Biotronik Orsiro|
214504279|NCT02195856|DIETARY_SUPPLEMENT|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
214504280|NCT02195856|DIETARY_SUPPLEMENT|Placebo|
214504281|NCT01619059|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
214504282|NCT01619059|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
214504283|NCT01619059|DRUG|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
214504284|NCT01619059|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
214504285|NCT00649857|DRUG|Cetirizine HCl Tablets 10 mg|10mg, single dose fed
214504286|NCT00649857|DRUG|Zyrtec® 10 mg|10mg, single dose fed
214504287|NCT02381132|DRUG|Norco 7.5mg/325|
215005582|NCT05935020|BEHAVIORAL|Symptom guide and encouragement to follow DHA/WHO recommendations for physical activity|"Participants in both groups receive a recovery-guide pamphlet at discharge, containing the following information: 1) Recommendations to follow DHA/WHO guidelines for physical activity, 2) Figures and tables describing common post-operative symptoms (symptom guide), and when to react (when the symptoms may require attention from a health-professional), 3) What to expect from the post-surgical period in relation to activities of daily living, 4) Common short- and long-term complications to total knee arthroplasty and 5) Trial-participant and ethics-committee information documents. Parts 2-4 are usual clinical practice, with slight variations in descriptions between sites.~After surgery, participants in both groups are encouraged to resume their desired pre-surgical activities when they feel they are able (within the limits given from the orthopedic wards)."
215005583|NCT04664114|BEHAVIORAL|Virtual Reality|Ultrasound images of the fetus in the 28th week of pregnancy of the women in the intervention group were recorded. These images were shown to the woman through virtual reality glasses during the labor. Routine practices in the hospital were made to the women in the control group. VAS (Visual Analog Scale) was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale (POBS) and Perinatal Anxiety Screening Scale (PASS) were administered.
215005584|NCT06322303|OTHER|Placebo (CBD 0%)|Participants are required to vaporize placebo at 0% CBD concentration
215096027|NCT01569386|BEHAVIORAL|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
215096028|NCT03358940|OTHER|urine collection|For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
214400930|NCT04003311|DEVICE|Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
214400931|NCT04003311|DEVICE|Comprehensive Anatomic Versa-Dial Titanium Humeral Head|Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.
214504288|NCT02381132|DRUG|MNK155|
214400932|NCT05830461|BEHAVIORAL|Online psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be online and self-applied. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
214400933|NCT05830461|BEHAVIORAL|Psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be delivered through printed materials. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
214400934|NCT01314092|BIOLOGICAL|Autologous cultured adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
214504289|NCT02024217|RADIATION|S1，oxaliplatin，radiation|Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
214400935|NCT01314092|BIOLOGICAL|Autologous cultured adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
214400936|NCT05034575|OTHER|Eye Tracking Technology Sensor|Eye tracking will be performed using Tobii Pro eye tracking technology sensor (Tobii Pro Fusion, Stockholm, Sweden), providing binocular eye tracking up to 250 Hz. The sensor, positioned on the inferior aspect of the computer monitor, reflects infrared (IR) light beams off of each cornea and are subsequently captured.
214504290|NCT03080805|DRUG|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/ m\^2 BID)
214504291|NCT03080805|DRUG|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
214504292|NCT01431118|OTHER|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
214504293|NCT01431118|OTHER|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
214504294|NCT03500523|DIAGNOSTIC_TEST|corneal biomechanical properties|We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
214504295|NCT01595269|OTHER|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
214504296|NCT02108704|DRUG|Helicobacter pylori eradication therapy|
214504297|NCT02108704|DRUG|Placebo|
215005585|NCT06322303|OTHER|CBD 15%|Participants are required to vaporize CBD at a concentration of 15%.
215005586|NCT06322303|OTHER|CBD 30%|Participants are required to vaporize CBD at a concentration of 30%.
215005587|NCT02421211|DRUG|Simeprevir (SMV)|Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
215096029|NCT01029444|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
214400937|NCT00765362|DEVICE|Encore Mobile-Bearing Knee|Used for primary total knee replacement
214400938|NCT00298935|PROCEDURE|Osteopathic manipulative treatment (OMT)|
214400939|NCT00950209|DIETARY_SUPPLEMENT|saline infusion|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48"
214400940|NCT00950209|OTHER|euglycaemic hyperinsulinic clamp|an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l
214400941|NCT00950209|DIETARY_SUPPLEMENT|infusion of Endolipide and heparin|an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids
215005588|NCT02421211|DRUG|Ledipasvir (LDV)|Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
214400942|NCT00950209|OTHER|hyperglycaemic hyperinsulinic clamp|a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.
214400943|NCT02585310|OTHER|Packed red blood cell transfusion|Record number of PRBC transfusion during perioperative period.
214400944|NCT06367062|OTHER|MRI|MRI is used to assess of brain development.
215096030|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel \[200 milligram/square meter (mg/m\^2)\] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram\*minute/milliliter (mg\*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
215096031|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
214400945|NCT04415593|DIETARY_SUPPLEMENT|High dose of peanuts|Patients will receive a high dose of ground peanuts (300 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
214400946|NCT04415593|DIETARY_SUPPLEMENT|Low dose of peanuts|Patients will receive a low dose of ground peanuts (150 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
214400947|NCT03337347|DEVICE|CTC/DTC count|The presence of CTCs/DTCs in the peripheral blood and/or bone marrow may identify colorectal cancer patients with high risk of disease recurrence who may benefit from adjuvant therapy.
214400948|NCT04066543|DEVICE|TACE|The modified Seldinger puncture was used to puncture the cutaneous-femoral artery, insert the catheter and perform hepatic artery angiography. The location, morphology and blood supply of liver tissue lesions were comprehensively understood. The use of chemotherapeutic drugs and the dosage of iodized oil as the embolic agent were determined according to the general situation. The catheter was injected into the supply vessel of the tumor, and 5-FU and adriamycin were injected according to the situation. The embolic agent was injected with iodized oil as carrier, mixed with chemotherapeutic drugs at the same time, and then assisted with gelatin sponge for embolization. Antiemetic drugs were given before treatment and hepatoprotective drugs were given after operation. Until the disease progresses.
214504298|NCT02944123|DRUG|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
215005589|NCT02421211|DRUG|Sofosbuvir (SOF)|Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
214504299|NCT02944123|DRUG|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
215005590|NCT04000256|BEHAVIORAL|Activity based rehabilitation|Activity based rehabilitation for the upper extremity involves various gross and fine movements, reach and object transportation, and object manipulation. The rehabilitation equipment used during training will include gaming and instrumented training equipment, conventional table-top tasks, and exercise aids.
215005591|NCT05935488|OTHER|EVOCs emulsion|Continuous breath sampling directly into SIFT-MS equipment. The instrument is equipped with a mouthpiece connected to the SIFT inlet where the subject blows in and the breath is analyzed in real-time
215005592|NCT01196611|BEHAVIORAL|Voice Amplification|Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.
215005593|NCT01196611|BEHAVIORAL|Function Voice Exercises|Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
215005594|NCT01177410|DRUG|Placebo|placebo capsules once daily for 12 weeks
215005595|NCT01177410|DRUG|Mesalamine Granules 750 mg|750 mg mesalamine granules once daily for 12 weeks
214504300|NCT02944123|DRUG|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
214504301|NCT03627637|DIETARY_SUPPLEMENT|Soy nuts|Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.
215005596|NCT01177410|DRUG|Mesalamine Granules 1500 mg|1500 mg mesalamine granules once daily for 12 weeks
215005597|NCT02000271|PROCEDURE|Vaginal packing|
215005598|NCT02000271|PROCEDURE|No vaginal packing|
215005599|NCT02901860|OTHER|Sleep, Dietary and Cardio-metabolic Measurements|"At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken."
215096032|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
214400949|NCT04066543|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
214400950|NCT04525300|DRUG|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
214400951|NCT04525300|DRUG|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
214504302|NCT06134193|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
214504303|NCT06134193|DRUG|Surufatinib|250mg PO d1, Q3W
214504304|NCT06134193|DRUG|Tislelizumab|200mg IV d1, Q3W
215005600|NCT05643690|DIAGNOSTIC_TEST|UriFind Bladder Cancer Assay|The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
215005601|NCT05382728|DRUG|TY-9591|"The dose of TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
215005602|NCT05382728|DRUG|placebo Osimertinib|"The dose of placebo Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
215096033|NCT00454649|DRUG|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m\^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
214400952|NCT03046303|PROCEDURE|ERAS|optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
214400953|NCT06580834|DEVICE|Cergenx Wave|Short EEG recording using EEG amplifier with cloud based algorithm to assess brain injury.
214504305|NCT03418545|DEVICE|JUVÉDERM VOLBELLA® XC injectable gel|JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area.
214504306|NCT03074032|DRUG|ONC1-0013B|ONC1-0013B per os daily
214504307|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
214504308|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day placebo capsule|Once per day, 12 weeks
214504309|NCT05268991|OTHER|Geriatric Assessments and Frailty Indices|Eligible and consented subjects will undergo a baseline assessment prior to chemotherapy initiation inclusive of geriatric/frailty assessments, patient reported outcomes and blood samples for biomarkers of aging. Assessment measures and blood samples will be repeated post cycle 1 and 2 of chemotherapy. Toxicity will be recorded from the medical record
214504310|NCT03333824|DRUG|CYP1A2 (caffeine)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
214504311|NCT03333824|DRUG|CYP2C19 (omeprazole)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
214504312|NCT03333824|DRUG|CYP3A (midazolam)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
214504313|NCT03333824|DRUG|Kytril (granisetron)|Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.
215005603|NCT05382728|DRUG|Osimertinib|"The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
215005604|NCT05382728|DRUG|placebo TY-9591|"The dose of placebo TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
215005605|NCT04208711|OTHER|biological sample|whole blood sample
214400954|NCT04576195|OTHER|Real PENS|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~TENS Frequency 2 Hz TENS Pulse width - 250 microseconds Duration - 30 minutes. TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~Administration - One single session."
214400955|NCT04576195|OTHER|Sham PENS|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The electrical current will not be working, and the needles will be placed during 30 minutes:~\- Administration - One single session"
215005606|NCT02890888|OTHER|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
215005607|NCT04874168|DEVICE|TAP block|bilateral ultrasound-guided TAP block was performed using a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used
215005608|NCT00442156|PROCEDURE|Laser photocoagulation|modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
215005609|NCT01834794|BEHAVIORAL|MET/CBT/CM plus NRT|Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
215005610|NCT04400747|DRUG|Vitamin D3|one group will take weekly oral 50000 IU Vitamin D3, other group will take daily oral 6000 IU Vitamin D3.
214400956|NCT03941938|PROCEDURE|Cyanoacrylate reinforcement|Anastomosis Reinforcement with with nebulization of 1cc of glue on the anastomosis line
215005611|NCT00315315|PROCEDURE|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
215005612|NCT00315315|PROCEDURE|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
214400957|NCT03941938|PROCEDURE|No reinforcement|Nothing applied on the anastomosis line
214504314|NCT03333824|DRUG|Wee-1 kinase inhibitor AZD1775|Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
215005613|NCT00315315|PROCEDURE|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
215005614|NCT00012246|BIOLOGICAL|carcinoembryonic antigen peptide 1-6D|
215005615|NCT00012246|BIOLOGICAL|incomplete Freund's adjuvant|
215005616|NCT00012246|BIOLOGICAL|sargramostim|
215005617|NCT03791021|DIAGNOSTIC_TEST|draw a person (DAP)|the subjects will be given a blank sheet of white paper and a pencil, and will be asked to draw themselves with no other additional instructions.
215005618|NCT03791021|DIAGNOSTIC_TEST|Edinburgh Postnatal Depression Scale (EPDS)|measure of postpartum depression symptoms.
215005619|NCT03791021|DIAGNOSTIC_TEST|Beck Depression Inventory- II (BDI-II)|BDI-II is based on clinical observations of behaviors associated with depression, and it retains the somatic items in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria related to loss of energy. ansd sleep disturbances.
215005620|NCT03791021|DIAGNOSTIC_TEST|Traumatic Events Questionnaire (TEQ)|The TEQ assesses experiences with nine specific types of traumatic events (e.g., accidents, crime, adult abusive experiences) reported in the empirical literature as having the potential to elicit PTSD symptoms.
215005621|NCT01909102|BEHAVIORAL|ACT-based intervention|
215005622|NCT01909102|BEHAVIORAL|usual care|
215005623|NCT05363904|OTHER|Observation|Questionnaires, Clinical Scores, Biomaterial Sampling
215005624|NCT03494179|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
215005625|NCT04510168|DRUG|11C-ER176|PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)
215005626|NCT04510168|DRUG|[F-18]MK-6240|PET imaging to measure tau; target imaging dose of 4 to 5 mCi
215005627|NCT04510168|DRUG|Florbetaben|PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi
215005628|NCT04510168|OTHER|Magnetic Resonance Imaging|Brain MRI
215005629|NCT00357162|DRUG|belinostat|Given IV
215005630|NCT02852044|BEHAVIORAL|Rest|Allowed to watch television or read for one hour prior to oral glucose tolerance test
215005631|NCT02852044|BEHAVIORAL|Exercise|One hour of cycling at 50% of maximal power output
215005632|NCT02852044|OTHER|Dorsal Hand Vein Cannulation (heated hand technique)|
215005633|NCT02852044|OTHER|Venous Cannulation|
215005634|NCT02738515|DRUG|0.75 % Boric Acid|After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
215005635|NCT02738515|DRUG|placebo|After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
215005636|NCT00986141|PROCEDURE|Surgery|Selective Laser Trabeculoplasty for glaucoma
214400958|NCT04187911|BEHAVIORAL|Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. The role of the therapist during sessions is to maintain an attuned relationship with both child and parent - modelling and encouraging development of a similarly attuned relationship between the child and parent. Therapists are trained to use Playfulness, Acceptance, Curiosity and Empathy (PACE). Our research suggests that key mechanisms of action in DDP might include the active participation of the parents and increased carer empathy and emotional warmth for the child. DDP experts believe this helps build parental capacity for attuned dialogue with the child, co-creation of the meanings underlying child behaviour, and co-regulation of experienced emotions aiming to address four main problem areas: 1. child emotional regulation 2. parental stress 3. the parent-child relationship 4. child mental health.
214400959|NCT04187911|BEHAVIORAL|Services as Usual (SAU)|"SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise. At the time of our UK mapping and modelling work, these services were usually CAMHS based. This may have changed, at least for adoptive families, with the advent of the Adoption Support Fund, which, since May 2015, has allowed local authorities / adoption agencies to apply for funding for essential therapeutic services. A wide range of interventions, many with a scant evidence base, have been purchased - sometimes from private practitioners - since 2015. In addition, relevant NICE guidelines, particularly those on Looked After and Accommodated Children, Attachment and Child Abuse and Neglect, have been published or updated.Our detailed qualitative and quantitative process evaluation throughout all study Phases will be crucial to carefully characterise SAU in all study sites."
215005637|NCT00986141|PROCEDURE|Selective Laser Trabeculoplasty|Glaucoma Treatment
215005638|NCT04241731|DRUG|Raltitrexed|Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
215005639|NCT04241731|DRUG|Cetuximab|Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
215005640|NCT02960789|OTHER|Formalized clinical assessment of hydration status|Undertake and record a standard formalized clinical hydration assessment
215005641|NCT02960789|OTHER|Take a measurement of body weight on calibrated scales|Standard body weight measurements conducted on calibrated scales
214400960|NCT03019458|DIETARY_SUPPLEMENT|MINGO|6 20oz sachets will be taken daily by intervention group
214400961|NCT00379249|DRUG|Rosuvastatin|
214400962|NCT05608720|BEHAVIORAL|Information Booklet|Information Booklet prior to the dental visit
214400963|NCT04099953|DIAGNOSTIC_TEST|Hand grip, joint range of motion , functional level of the upper extremity, physical activity levels|Hand grip force with Jamar Hand Dynamometer, joint range of motion with Baseline Digital Goniometer, functional level of the upper extremity with the Shoulder-Arm and Hand Problems Questionnaire(DASH), physical activity levels with International Physical Activity Questionnaire Short Form(IPAQ-short form) and physical functions with Human Activity Profile (HAP) were evaluated.
214400964|NCT03140293|DRUG|Lidocaine injection|Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.
214400965|NCT03140293|DRUG|Gebauer Ethyl Chloride Spray|Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
214400966|NCT04302090|OTHER|Regulated expiratory method|This method was originally a postpartum abdomino-perineal rehabilitation technique. It allows a functional abdominal rehabilitation by combining a regulated breath in a specific mouthpiece and an abdominal stimulation triggered by this same breath. The use of this method was extended to labor and childbirth. In fact, the application of the method during labor is based on the use of a flow regulating device (Winner Flow + URO-MG®). By regulating the flow of breath during a uterine contraction, it allows better pain management.
214400967|NCT02945202|DEVICE|Biometry|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
214400968|NCT02945202|DEVICE|Refraction|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
214688194|NCT06910124|DRUG|Lenalidomide|Participants will take 10mg of Lenalidomide maintenance therapy standard of care by mouth daily from days 1 through 21 of each 28 day cycle of Linvoseltamab therapy. Lenalidomide therapy will begin on Cycle 2 Day 1 of Linvoseltamab therapy.
214688195|NCT04902443|DRUG|Pomalidomide|Pomalidomide will be administered as an oral planned starting dose of 3 mg daily (dose escalation) or at an MTD of 4 mg (dose expansion). Pomalidomide will be given from day 1 to day 21 of each cycle.
215005642|NCT02960789|DEVICE|"RF wristband hydration status measurement"|"Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device"
215005643|NCT02960789|OTHER|Measure capillary refill time with manual stopwatch|A standard visual assessment of capillary refill time, aided by the use of a stopwatch
215005644|NCT02960789|DEVICE|"CRT device hydration status measurement"|"Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time"
215005645|NCT05852288|DIAGNOSTIC_TEST|Inflammatory markers|Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.
215005646|NCT04443829|BIOLOGICAL|CD19CAR T-cells|Infusion with: CD19CAR T-cells
215005647|NCT00357604|DRUG|Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)|Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
215005648|NCT00357604|DRUG|Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days|Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
215005649|NCT00694343|DRUG|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
215005650|NCT00694343|DRUG|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
214400969|NCT02945202|DEVICE|Corneal Topography|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
214400970|NCT06459362|DIAGNOSTIC_TEST|Serum cystatin C|Diagnostic test for detection of acute kidney injury
214400971|NCT05675774|DIAGNOSTIC_TEST|Dual Energy CT|Patients with acute stroke who receive intervention will undergo dual-energy CT in lieu of single-energy CT at 24 hours post-intervention.
214400972|NCT01800409|DEVICE|AFES|During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
214400973|NCT01330121|OTHER|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic \& non-glycemic goal levels Explaining the importance of compliance with medications \& appointments Educating on the basics of nutrition and physical activity"
214400974|NCT05148767|DRUG|Neoadjuvant chemoradiotherapy based on irinotecan|"Patients with locally advanced rectal cancer treated with irinotecan-based chemoradiotherapy were enrolled in this study. The dose of irinotecan is determined by the genotype of UGT1A1.Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2 (UGT1A1\*28 and \*6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1\*28 and \*6 ：7/7+GG or 6/6+AA or 6/7+GA）."
214400975|NCT00375128|BIOLOGICAL|FP9-PP (FP9 polyprotein)|
214400976|NCT00375128|BIOLOGICAL|MVA-PP (Modified Virus Ankara polyprotein)|
214504315|NCT04781868|DRUG|Multi-nutrient supplement|Multi-nutrient supplement containing a combination of vitamins, minerals and antioxidants
214504316|NCT04781868|DRUG|Placebo|Placebo
215005651|NCT06139640|OTHER|Damask Rose Essential Oil|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
215005652|NCT03608085|BEHAVIORAL|Pharmacist Heart failure MTM training|"The MTM training for pharmacists will consist of:~1. Online material for home self-study (10 contact hours);~2. Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~3. 1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~4. Monthly coaching conference calls/webinars with URI and Brown Faculty;"
215005653|NCT03608085|BEHAVIORAL|Patient Heart failure MTM intervention|"The baseline visit will take place \>= 7 but \<= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers."
214400977|NCT01418092|DRUG|ALKS 37|Capsules for oral administration
214400978|NCT01418092|DRUG|Placebo|Capsules for oral administration
214400979|NCT00518752|PROCEDURE|Standard Oral Care|Patients in this arm will receive standard oral care with manual brushes and routine oral hygiene products twice a day
214400980|NCT00518752|PROCEDURE|Comprehensive Oral Care|Patients will receive a comprehensive oral care protocol using mechanical brushes and oral care products formulated for patients with a dry mouth twice a day
214400981|NCT00031447|DRUG|Acyclovir|Oral suspension 300 mg/m\^2/dose, 3 times per day (TID), for 6 months.
214400982|NCT00031447|DRUG|Placebo|Placebo identical to oral acyclovir suspension in appearance and taste.
214400983|NCT05665309|PROCEDURE|3D anatomical model of aneurysm|Surgery prepared with 3D anatomical model of aneurysm
214400984|NCT01636362|DEVICE|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
214400985|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant D
214400986|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant E
214400987|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant F
214400988|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant G
214400989|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant H
214400990|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Spiriva 18 µg/capsule inhaled via Handihaler
214400991|NCT04850144|DRUG|Tiotropium Easyhaler with oral activated charcoal|The charcoal suspension will be administered orally with Tiotropium Easyhaler 10 µg/dose Product variant F
214400992|NCT02786979|DRUG|Beraprost|Oral
214400993|NCT02786979|DRUG|Aspirin|Oral
214400994|NCT01244763|DRUG|Roxadustat|Oral capsule
214400995|NCT06090435|BEHAVIORAL|Therapeutic exercise plus motor imagery|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a motor imagery intervention (which consists of imagining the same movements but not performing them for real).
214504317|NCT01249638|DRUG|Capecitabine|Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
214504318|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1 q day 21
214504319|NCT01249638|DRUG|Capecitabine|Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
214504320|NCT01249638|DRUG|Irinotecan|Irinotecan: 200 mg/m2 day 1 , q day 21
214504321|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1, q day 21
214504322|NCT04273672|DIAGNOSTIC_TEST|Cognitive Battery|Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
214504323|NCT04273672|BEHAVIORAL|Voice, Speech and Language Analysis|Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
214504324|NCT04273672|BEHAVIORAL|Questionnaires and Clinical Assessments|Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
214400996|NCT06090435|BEHAVIORAL|Therapeutic exercise plus action observation|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added an action observation intervention (which consists of observing the same movements but not performing them for real).
214504325|NCT04273672|GENETIC|DNA Analysis|Participants will have their blood drawn for DNA analysis.
214504326|NCT04945538|OTHER|Scatter radiation exposure measurement|Scatter radiation exposure of the operator and sterile assistant is recorded with digital live dosimeters at 3 locations of the operator (frontal head at eye level, left lateral head, below the left shoulder) and at 2 locations of the sterile assistant (left neck and below the left shoulder)
214504327|NCT05486494|OTHER|Treatment (non- surgical/surgical)|Treatment Outcome based on different aspects
214504328|NCT02333318|DRUG|VVZ-149 injection|Colorless, transparent liquid in water for injection
214688196|NCT04902443|DRUG|Nivolumab|Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days
215005654|NCT01124474|OTHER|goal directed therapy|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV\>12%.
215005655|NCT04656665|DRUG|Aspirin|For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy
215005656|NCT05003999|DEVICE|HPC - SpeediCath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter
215005657|NCT05003999|DEVICE|Non-HPC - Self-Cath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
215005658|NCT01948778|DEVICE|oXiris™ filter|
214400997|NCT06090435|BEHAVIORAL|Therapeutic exercise|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a sham action observation intervention (which consists of observing planets in space).
215005659|NCT01948778|DEVICE|Toraymyxin Filter|
215005660|NCT01948778|DEVICE|Standard of Care|
215005661|NCT05205395|DIAGNOSTIC_TEST|Transperineal ultrasound|Ultrasonography was used with curved linear-array transducer placed between the major labia and underneath the external urethral orifice. The measurement was done on the midsagittal plane to obtain the image of pubic symphysis, urethra, and bladder in a view. Ultrasonic measurement of the overall rest-stress distance was define as the linear distance of bladder neck position change from resting status to maximal strain.
214400998|NCT00926965|DRUG|amisulpride|amisulpride tablet 100-1200mg/day for 24 months
214400999|NCT00926965|DRUG|Olanzapine|Olanzapine tablet 2.5 to 30 mg/day for 24 months
215005662|NCT03751787|OTHER|cranial osteopathy|two sessions at three weeks intervals
215005663|NCT03751787|OTHER|comfort massage|manipulation, comfort massage, standardized and not affecting the skull
215005664|NCT02950584|OTHER|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
215005665|NCT02950584|OTHER|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
214401000|NCT00926965|DRUG|Conventional antipsychotics|the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
214401001|NCT00003431|BIOLOGICAL|recombinant flt3 ligand|
214504329|NCT02333318|OTHER|Placebo|water for injection
214504330|NCT00545311|DRUG|NVA237|
214504331|NCT00545311|DRUG|NVA237|
214504332|NCT00545311|DRUG|NVA237|
214504333|NCT00545311|DRUG|NVA237|
214504334|NCT00545311|DRUG|Placebo|
214504335|NCT04007705|BEHAVIORAL|Anti-inflammatory and low FODMAPs diet|Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
214504336|NCT04007705|BEHAVIORAL|General healthy eating|Healthy eating counseling according to the World Health Organization
214504337|NCT05522309|DRUG|ET0111|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0111 administered, once daily (QD).
214504338|NCT05380115|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|weekly one on one video or telephone interviews with a study coach
214504339|NCT00850915|OTHER|community IPT|"In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB."
214504340|NCT00001930|DRUG|Amantadine|
214688197|NCT07091734|DRUG|Tirzepatide|"Participants will receive study drug (Tirzepatide) according to the dose titration plan described in the FDA-approved Prescribing Information (starting with 2.5 mg/wk and increasing the dose every 4 weeks by increments of 2.5 mg.~Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial."
215005666|NCT05898373|DRUG|vedicitumomab (Edisil, RC48）|intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
215005667|NCT05898373|DRUG|vedicitumomab in combination with pyrrolizidine|vedicitumomab in combination with pyrrolizidine
215005668|NCT05898373|DRUG|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 in combination with a platinum-based chemotherapeutic agent
215005669|NCT05898373|DRUG|RC48 in combination with teraplizumab|RC48 in combination with teraplizumab
215005670|NCT05874297|OTHER|Best Practice|Receive standard of care
215005671|NCT05874297|BEHAVIORAL|Internet-Based Intervention|Access to enhanced Cook for your life website
215005672|NCT05874297|OTHER|Questionnaire Administration|Ancillary studies
215005673|NCT00977873|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
215005674|NCT00977873|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
215005675|NCT01302171|DRUG|granulocyte colony stimulating factor (GCSF)|10mcg/kg per day 5 days
215005676|NCT01302171|PROCEDURE|bone marrow mononuclear cells|intra coronary injection of stem cells or placebo
215005677|NCT03509597|BEHAVIORAL|Aerobic Exercise|Physical exercise training consisting of aerobic exercise and strength/resistance training.
215005678|NCT03509597|BEHAVIORAL|Cognitive Training|Cognitive remediation program using REHACOP rehabilitation program.
215005679|NCT03509597|BEHAVIORAL|Treatment as usual|Standard care for schizophrenia + Leisure and free time activities.
215005680|NCT03509597|BEHAVIORAL|Occupational Activities|Engagement in activities aimed to keep patients actively involved in demanding tasks.
215005681|NCT02327247|DRUG|Felodipine|Extended Release Tablets, 10mg
215005682|NCT02327247|DRUG|PLENDIL®|Extended Release Tablets, 10mg
214688198|NCT07091734|DRUG|Usual care medications|"Participant's will continue on participant's regular diabetic and hypertriglyceridemia medications that were used during the run-in period for 24 weeks. This will be either Phase 1 or Phase 2 based on randomization.~Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial."
215005683|NCT06049277|OTHER|Mulligan techniques with manual traction|group A will be treated with Mulligan techniques with manual traction.16 patients in group A will be treated with Mulligan Techniques SNAGS in sitting, standing and prone position by applying Antero cranial glide in the direction of treatment plane over the spinous or transverse process and Spinal mobilization with leg movement at 6 to 8 repetitions per sessions and spinal mobilization with leg movement will be performed in side lying, patient facing the physiotherapist while the leg movement may assisted by another person (Physiotherapist/assistant). Sustained transverse glide is given on the desired spinous process with 10 repetitions of offending movement in first session while 10 reps in each of 3 sets in further sessions.
215005684|NCT06049277|OTHER|McKenzie extension exercises with manual traction|group B will be treated McKenzie extension exercises with manual traction.16 patients in group B will be treated with McKenzie active EEP in prone position with repeated movements along with standard protocols. McKenzie Extension Exercises performed actively in prone position. Extension exercises performed in three stages, initially patient instructed to be just lift the neck and look on front at the eye level, then progressed next and weight bearing on the elbow by lifting up the shoulder and then moved on third and final steps in which complete trunk extension is performed and weight bearing is on the hands.
215005685|NCT03132259|DRUG|high dose dexmedethomidine|Dexmedethomidine continuous drip 0.5 mcg/kg/hr a
215005686|NCT03132259|DRUG|low dose dexmedethomidine|Dexmedethomidine continuous drip 0.2 mcg/kg/hr
215005687|NCT01033370|DRUG|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes \& titrated to the desired BP lowering effect to SBP goal of \< 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
215005688|NCT05140980|OTHER|Data collection|evaluation of women's knowledge concerning sexuality
215005689|NCT00738517|DEVICE|Immunoadsorption / Immunoglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
215005690|NCT00050427|DRUG|ET743|580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
215005691|NCT00050427|DRUG|ET743|1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
215005692|NCT02143778|DEVICE|Methacetin Breath Test|13C labelled methacetin solution for breath test monitoring
215005693|NCT05719597|OTHER|PEP (Positive Expiratory Pressure)|Group A containing 12 participants, will perform Positive expiratory pressure (PEP) technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
215005694|NCT05719597|OTHER|IS (Incentive spirometry)|Group B containing 12 participants, will perform Incentive spirometry technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
215005695|NCT05706402|DRUG|N-acetylcysteine|Patients will be randomized to receive oral N-acetylcysteine at 600 mg twice daily for 1 week. The randomization will be done via computer software with half of the patients randomized to receive NAC. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
215005696|NCT05706402|DRUG|Placebo|Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
215005697|NCT04517058|OTHER|psychology therapy|If the symptoms are mild, patients will get the psychology therapy. If it's necessary according to patients' willings, patients will be given SSRIs antidepressant therapy.
215005698|NCT04938674|DEVICE|ultrasonic guidance|Standard process for blood collection using Ultrasonic Guided puncture
215005699|NCT03623490|OTHER|managment of oral therapy|Initial consultation with a trio oncologist / pharmacist / nurse
215005700|NCT06632860|DRUG|68Ga-TATE-RGD|Intravenous injection of 68Ga-TATE-RGD with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses will be used to image lesions of by dual-targeted postive cancers PET/CT.
215005701|NCT06632860|DRUG|18-FDG|Intravenous injection of 18F-FDG with the dosage of 1.8-2.2 MBq(0.12-0.15mCi/kg). Tracer doses will be used to lesions therapy of dual-targeted postive cancers by SPECT/CT.
215005702|NCT00625378|DRUG|Sorafenib (Nexavar, BAY43-9006)|At the same dose and schedule as in the participants' original clinical trials
215005703|NCT03270241|DEVICE|Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet|This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for Vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with Vitiligo and normal skin in healthy participants.
215005704|NCT05339061|DEVICE|Endovascular Treatment of Complex abdominal or Thorocoabdominal aneurysms (TAAA).|"Modification~* Deploy the graft on the sterile, surgical table~* Mark out on the graft the locations of the fenestrations on the graft adjusting as necessary~* Using handheld electrocautery, fashion the fenestration in the appropriate location on the moistened graft material in order to prevent inadvertent progression of the fenestration size~* If the fenestration is going to remain as such, then a snare is used to fashion the marker on the fenestration with 5-0 stitch~* If the fenestration is going to be made into a branch, then an appropriately sized, self-expanding stent is beveled and fashioned to be 15 mm long and sewn to the fenestration in addition to a snare with the 5-0 stitch~* Two orientation markers are placed at the proximal edge and distal edge of the graft consisting of portions of the snare sewn to the anterior portion of the graft in a J fashion with a 5-0 stitch"
215005705|NCT03391323|DEVICE|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
214401002|NCT04990687|DEVICE|gammaCore™|"Implantable VNS (iVNS), the electrical stimulation of the nervous system to modulate or modify function, has been FDA approved in the United States since the late 1990s. Implantable VNS therapy has been approved for use in epilepsy and depression.~When treating major depression with implanted VNS, the widely held belief is that chronic stimulation is required for therapeutic effect. In trials of implantable VNS in major depression, more patients respond at 12 months than at 3 months. Once depressed patients respond to VNS, the effects have been demonstrated to continue for up to five years with continued stimulation. This finding suggests that VNS gradually changes brain function through neuroplasticity."
214401003|NCT04457271|BEHAVIORAL|Goal Management Training (GMT)|GMT is a structured, short-term cognitive remediation program with an emphasis on mindfulness and practice in planning and completion of goal-oriented behaviours. The main objective of GMT is to help participants regain executive control in order to better define goals and monitor performance in achieving them. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Mindfulness meditation is also incorporated for the purpose of developing the skill of bringing one's mind to the present to monitor ongoing behaviour, goal states, and the relationship between them, and for the development of attentional control. The program incorporates real-life examples to illustrate goal attainment failures and successes, as well as in-session practice of complex tasks that mimic real-life tasks - typically a challenge for individuals with executive function deficits (e.g., planning and set-shifting tasks).
214401004|NCT02947711|DRUG|E2027|2 x 50 mg capsules, once daily on Day 1 and Day 12
214401005|NCT02947711|DRUG|Diltiazem ER|1 x 300 mg capsule, once daily on Days 7 through 24
214401006|NCT05466708|DRUG|Esketamine combined with dexmedetomidine|"Esketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature.~Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature."
214401007|NCT05466708|DRUG|Dexmedetomidine|Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
214401008|NCT02181959|DRUG|Pharmaton® with DMAE|
214401009|NCT02181959|DRUG|Pharmaton® without DMAE|
215005706|NCT03391323|DEVICE|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
214401010|NCT02181959|DRUG|Placebo|
214401011|NCT02044198|BIOLOGICAL|FMP2.1/AS01B|50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
214401012|NCT00021398|DRUG|fluorouracil|
214401013|NCT00021398|DRUG|leucovorin calcium|
214401014|NCT00021398|PROCEDURE|conventional surgery|
215005707|NCT04386148|PROCEDURE|Obsidian ASG®|As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.
215005708|NCT05787509|DRUG|Progesterone Sustained-release vaginal gel|the treatment time of vaginal progesterone
215005709|NCT02639559|DRUG|BL-8040|
215005710|NCT02639559|PROCEDURE|Leukapheresis|
215005711|NCT02639559|PROCEDURE|Hematopoietic cell transplant|
215005712|NCT03880565|DEVICE|Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation|Early use of ECMO
215005713|NCT03880565|DEVICE|Standard Advanced Cardiac Life Support (ACLS) Resuscitation|Standard life support resuscitation
215005714|NCT01692756|DRUG|Kenalog or placebo|
215005715|NCT01692756|DRUG|Kenalog then Placebo|
215005716|NCT01692756|DRUG|Kenalog|
215005717|NCT01692756|DRUG|Placebo|
215005718|NCT02969018|DRUG|PF-06700841|
215005719|NCT02969018|OTHER|Placebo|
215005720|NCT02292251|BEHAVIORAL|Device-assisted therapy|
214401015|NCT00021398|RADIATION|radiation therapy|
214401016|NCT02622425|DIETARY_SUPPLEMENT|Placebo|maltodextrin
214401017|NCT02622425|DIETARY_SUPPLEMENT|PD01|Carotenoid-producing Bacillus strain PD01
214401018|NCT04621071|DIETARY_SUPPLEMENT|Probiotics (2 strains 10x10^9 UFC)|Probiotic vs Placebo (1:1)
215005721|NCT02292251|BEHAVIORAL|Therapy-based occupational therapy|
215005722|NCT01723605|PROCEDURE|insitu repair|closure of the uterine incision while the uterus initu
215005723|NCT01723605|PROCEDURE|exteriorisation of the uterus|uterine closure while the uterus is exteriorised
215005724|NCT00367458|DRUG|Atorvastatin|80 mg atorvastatin oral daily
215005725|NCT00367458|DRUG|Placebo|patients will be administered placebo
215005726|NCT01731496|OTHER|Telephone reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a telephone reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
215005727|NCT01731496|OTHER|Text Message reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a text message reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
215005728|NCT01616927|DRUG|Lanreotide|Lanreotide will be administered once every 4 weeks as a subcutaneous injection
215005729|NCT02556788|DRUG|CD5789 (trifarotene) 50µg/g Cream|CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
214401019|NCT04621071|DIETARY_SUPPLEMENT|Placebo (potato starch and magnesium stearate)|Probiotic vs Placebo (1:1)
214401020|NCT02521259|DEVICE|BIS|BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
214401021|NCT04082455|RADIATION|carbon ion radiotherapy|carbon ion radiotherapy
214401022|NCT04313387|DIAGNOSTIC_TEST|Corneal tomography multivariate index derived from a support vector machine (CTMVI).|MATHEMATICAL ALGORITHM: To build the equation extracted from SVM, 58 variables were used, some of them were extracted from the spreadsheet.. After the construction of these 58 feature vectors (FV), an SVM-derived index was created, which was called the corneal tomography multivariate index derived from a support vector machine (CTMVI). Considering that each patient represents a point on a cartesian plane with 58 dimensions (each coordinate representing one of the 58 FV), the role of SVM is to find the hyperplane that best separates the CG, KCG, and VAE-NT G subjects. A hyperplane is algebraically described by a linear equation; in this case, there are 59 coefficients, 58 of which are related to the FV and one independent coefficient representing the bias (which is a possible parallel dislocation of a given hyperplane).
214401023|NCT03969602|BEHAVIORAL|Cognitive-behavioral Therapy|The biopsychosocial approach of CBT focuses on the complex interaction between psychological, social and biological factors. The biopsychosocial model assumes that health problems are hardly ever limited to just one domain of human experience but by multiple domains of human experience. CBT helps patients understand thoughts and feelings that influence behaviors. It consists of a cognitive aspect and a behavioral aspect. The cognitive aspect is based on Becks cognitive model: the way that individuals perceive a situation is more closely connected to their reaction than the situation itself. A person's cognition has impact on their mood and emotions, their bodily reactions and their behavior. The second part of cognitive behavior therapy focuses on the actual behaviors that are contributing to the problem. The goal of CBT is to identify maladaptive thoughts and change them into more realistic and constructive thoughts to modify feelings and behavior and thereby the experience of pain.
214401024|NCT03969602|OTHER|Biomedical and surgery-specific education|Biomedical and surgery-specific education preoperatively and an exercise manual postoperatively.
214401025|NCT01561079|DRUG|Buprenorphine|Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.
214401026|NCT01244009|DRUG|MK-4827|MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
215005730|NCT02556788|DRUG|Placebo Cream|Placebo cream applied once daily during 12 weeks.
215005731|NCT04664309|OTHER|No intervention|No intervention
215005732|NCT02217033|OTHER|'R' (Electro-kinetically altered beverage)|
215005733|NCT02217033|OTHER|Placebo (water)|
215005734|NCT01381640|DRUG|Marketed paracetamol|marketed formulation
215005735|NCT01381640|DRUG|Experimental paracetamol formulation|Experimental formulation
215005736|NCT06095531|DEVICE|Tetranite for Cranial Flap Fixation (TN-CFF)|Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
215005737|NCT02334189|BEHAVIORAL|Letter|Patients receive an information letter following an avoidable visit to the Emergency Department.
215005738|NCT03943082|BEHAVIORAL|Cancer Educational Materials|Receive FRP brochure
214401027|NCT04561414|DEVICE|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope.
215005739|NCT03943082|OTHER|Follow-Up Care|Receive follow-up phone call
215005740|NCT03943082|BEHAVIORAL|Questionnaire|Ancillary studies
215005741|NCT06229834|PROCEDURE|Chiropractic Care|The chiropractic care protocol can be personalized to the patient's clinical needs and follows the scope of chiropractic care practice in the Commonwealth of Massachusetts and the State of Connecticut. Components of the chiropractic intervention include: posture correction / spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation (i.e. chiropractic adjustment) / mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports.
215005742|NCT06229834|BEHAVIORAL|Headache Health Education|"Participants randomized to the HHE arm will receive 14 interactive 15-minute education sessions delivered via video conference.~To partially control for attention and expectation associated with chiropractic care, participants randomized to the control group will receive a modified version of a headache education intervention we employed in our pilot study. Participants randomized to HHE will receive 14 interactive 15-minute education sessions delivered via VA or MGB Teams. Material to be covered will focus on pre-defined migraine-specific topics, compared with the control for our pilot study, in addition to greater contact time, HHE will be delivered in a more interactive manner utilizing active learning principles known to support adult learning. We will also utilize publicly available short videos (e.g., from the American Headache Society) followed by scripted discussions with the participant. Example topics include the physiology of migraine or the contribution of life."
215005743|NCT05553912|BEHAVIORAL|QBSafe|an intervention comprised of (a) a set of conversation cards (QBSafe ASK) designed to enable patients to identify aspects of life with diabetes important to them and to share them with their clinician to obtain their input; and (b) materials that help clinicians respond to patient concerns.
214401028|NCT04561414|DEVICE|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use Ureteral stent (Cook Ireland Ltd.).
215005744|NCT03521596|OTHER|MRD and clonal evolution|Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques
215005745|NCT01857518|OTHER|-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI|"* Visit V1: Diagnostic and clinical assessments~* Visit V2: psycho-behavioral assessment and neuroimaging~* Visit V3: Diagnostic and clinical assessments~* Visit V4: psycho-behavioral assessment and neuroimaging"
214401029|NCT05719636|OTHER|Conventional treatment|Conventional protocol that involves simple active and passive range of motion exercises of lower limb with positioning for assistive devices was provided
214401030|NCT05719636|OTHER|Progressive resistance exercise|The protocol that was applied on the members of (experimental group) are progressive resistance exercises. These passive resistance exercises included Flexion, Extension, Abduction, Adduction of hip; Flexion, Extension of knee; with minimum time in start and minimum quantity of loads, with Thera bands and sandbags,.
214401031|NCT01212705|DEVICE|Adaptive servoventilation|Background expiratory positive airway pressure with some inspiratory pressure support when needed
214401032|NCT02781155|OTHER|Moxibustion|Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy
214401033|NCT02900911|OTHER|Early rehabilitation|"Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy~Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.~All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months."
214401034|NCT02900911|OTHER|Late rehabilitation|Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
214401035|NCT05408650|OTHER|Aromatherapy Massage|"The PI will dilute pure lavender essential oil (Lavandula angustifolia) with almond oil at a dilution rate of 2.5% and apply it to the hands and feet of the patient.~* The massage technique including effleurage, petrissage, friction and lymphatic drainage on hands and feet will be adapted from Salvo, (2015) and Youssef and Hassan, (2017).~* The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position."
214401036|NCT06429566|DRUG|GB001 recombinant peptide spray low dose group、high dose group|Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.
214401037|NCT06429566|DRUG|GB001 recombinant peptide spray placebo|Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times
214401038|NCT05315804|OTHER|MINSD and amelogenins|After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, amelogenins in gel will be applied to the intraosseous periodontal pockets using a sterile syringe with plasticized needle.
214401039|NCT05315804|OTHER|MINSD|Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
214401040|NCT00765661|DRUG|Tacrolimus (Tacro™)|"The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release"
214522640|NCT05153161|DEVICE|Memesto|Edgewater plans to develop the next generation Memesto, a wearable device able to sense increasing agitation in ADRD sufferers and automatically deliver agitation-reducing personalized voice messages and music most effective at calming the individual based on past interventions. This innovative product will be the first wearable ADRD device to track agitation via body-worn sensors and automatically deploy agitation-reducing voice and music therapy without any caregiver interaction. The new system will use analytics to track the effectiveness of the various media and update the calming 'play list' over time.
215005746|NCT01017497|RADIATION|Stereotactic Radiosurgery|PTV Diameter \< 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
215005747|NCT00471120|OTHER|P2x7 assay|compare P2X7 assay to biopsy
215005748|NCT04655872|DRUG|[14C]TPN171H|A single 10 mg oral dose of \[14C\]TPN171H containing approximately 100 microcurie of \[14C\]-TPN171H.
215096034|NCT00454649|DRUG|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m\^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
215005749|NCT02473601|DRUG|Mivacurium Chloride|"Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%\~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 \~ 60. PetCO2 was 30 \~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane."
215005750|NCT02518269|PROCEDURE|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
215005751|NCT04088955|OTHER|DigiMeds|Digitized Capecitabine
215096035|NCT00454649|DRUG|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m\^2) 60-minute infusion on Day 1 of each cycle.
215096036|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
215096037|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
215096038|NCT00454649|DRUG|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m\^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m\^2) infusion on Day 1 of each cycle.
214401041|NCT00765661|DRUG|Prograf|"Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
214401042|NCT03394664|BEHAVIORAL|Feeding Study|Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
214401043|NCT02623556|BIOLOGICAL|ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
214504341|NCT03690804|DEVICE|Evaluation of Autonomic nervous system indices|The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
215096039|NCT00454649|DRUG|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m\^2) 10-minute infusion followed by cisplatin (75 mg/m\^2) infusion on Day 1 of each cycle.
215096040|NCT00272116|DRUG|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
214401044|NCT02623556|BIOLOGICAL|ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
215096041|NCT00272116|DRUG|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
215096042|NCT03943849|OTHER|Particulate bone graft|Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
215096043|NCT03943849|OTHER|Autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket.
215096044|NCT03943849|OTHER|Resorbable collagen membrane|After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured.
215096045|NCT03943849|OTHER|Suture|Resorbable or non-resorbable suture material
215096046|NCT02082106|OTHER|Alpine skiing|
215096047|NCT02082106|OTHER|cross country skiing|
215096048|NCT02082106|OTHER|Indoor training (cycling)|
215096049|NCT05327764|OTHER|Work to rest cycles of 40:20 minutes|Walking in a hot environment for 2 hours with repeated 40 minutes of work and 20 minutes of rest
215096050|NCT05327764|OTHER|Work to rest cycles of 20:10 minutes|Walking in a hot environment for 2 hours with repeated 20 minutes of work and 10 minutes of rest
215096051|NCT05948046|BEHAVIORAL|Visual training in hospital|Completion of 1 session of standardized visual training
215096052|NCT00871962|OTHER|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2\<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
215096053|NCT02745535|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|
214401045|NCT00058851|PROCEDURE|Manual lymph drainage|
214401046|NCT00058851|PROCEDURE|Combined physiotherapy|
214401047|NCT00058851|PROCEDURE|Compression bandaging|
214401048|NCT05722171|BIOLOGICAL|gdT cell injection targeting B7-H3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1E8, 2E8 and 4E8 CAR-gdT groups in order of sequence. And the subjects will be administered once.
215005752|NCT05606016|BEHAVIORAL|Facilitated Self-Sampling Intervention (FSSI)|CHWs will consent and enroll participants to the FSSI from the randomized PBGs. FSSI will consist of Community Health Worker (CHW) delivered education intervention about COVID-19 testing at a home visit. In addition, the participant will receive a batch of 4 rapid antigen tests which can be shared with people in the household or other close contacts if needed. The CHWs will provide low-literacy instructions for administering the tests, including print and video. The CHWs will also provide guidance if they tested positive (e.g. quarantine, notify contacts, wearing a mask). The CHWs will also be available by phone to the participants for any follow-up questions. CHW will follow-up via text and phone with the participants during the two months post intervention. In addition to the intervention, the participants will be asked to complete the pre and post test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
215005753|NCT05606016|BEHAVIORAL|Testing Navigation Intervention (TNI).|CHWs will consent and enroll participants to the TNI from the randomized PBGs. The TNI will consist of CHW-led intervention at a home visit where they will provide low health literacy materials about how and when to conduct a COVID 19 test (including antigen and PCR) using a decision tree model and provide navigation to nearby PCR testing sites, locations to purchase antigen tests and support in accessing federal government antigen tests if not already obtained by the participant. In addition to the intervention, the participants will be asked to complete the pre and post-test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
215005754|NCT05606016|BEHAVIORAL|Control|Participants in the Control arm will receive CDC-designed COVID-19 testing brochures, and pre and post surveys only.
215005755|NCT02650557|PROCEDURE|angiography|angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
214401049|NCT06556030|DRUG|Botulinum Toxin A|Botulinum Toxin
214401050|NCT06556030|OTHER|CONTROL|Saline Solution
215005756|NCT05762679|DIAGNOSTIC_TEST|Imaging|Phase 1 is an imaging biomarker study.
215005757|NCT02842099|DRUG|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
215005758|NCT02842099|DRUG|X|Capecitabine
214401051|NCT04521205|DRUG|fecal microbiota capsule|a capsule full of fecal microbiota extracting from the health
214401052|NCT03748264|OTHER|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant but will continuously be available to site staff personnel.
214401053|NCT03748264|DEVICE|DreamMapper Application|The DreamMapper application condition will receive the site's therapy initiation standard of care and will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously.
215005759|NCT04560218|DRUG|sublingual Misoprostol|apply drug by Anesthesiologist
215005760|NCT04560218|DRUG|Intrauterine Misoprostol|apply drug by surgeon at uterine cornu
215005761|NCT03670628|DEVICE|Shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
215005762|NCT03670628|OTHER|Sham shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver sham shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
215005763|NCT01899885|PROCEDURE|AHA (Acute Highrisk Abdominalsurgery): Optimized Course|"optimized course: Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~1. standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~2. GDT-LiDCO fluid management pre-, per- and postoperative~3. Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~4. Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
215005764|NCT01748682|OTHER|A very low calorie diet of two different consistencies|Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
215005765|NCT05327738|BIOLOGICAL|Atezolizumab|Given IV
215005766|NCT05327738|PROCEDURE|Biopsy|Undergo biopsy
214401054|NCT03748264|DEVICE|DreamMapper Application with Therapist Assist|The DreamMapper with Therapist Assist will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, their Philips Respironics mask and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously.
214401055|NCT00664521|BIOLOGICAL|Rituximab|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
215005767|NCT05327738|DRUG|Cabozantinib S-malate|Given PO
215005768|NCT05327738|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
215005769|NCT00057070|PROCEDURE|Smoking cessation information, collection, and dissemination|
215005770|NCT02614014|BEHAVIORAL|Cognitive-behavior interventional program|
215096054|NCT02342262|DIETARY_SUPPLEMENT|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
215096055|NCT02342262|OTHER|Placebo|similar appearance as the probiotic product, but without bacteria
215096056|NCT05035589|DRUG|Tocilizumab|Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
215005771|NCT04995107|DEVICE|Electro Press needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
215096057|NCT01789606|DRUG|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
215096058|NCT04714021|OTHER|CO2|to insufflate CO2 into the stomach instead of air during the PEG
215096059|NCT04714021|OTHER|air|to insufflate air into the stomach instead of CO2 during the PEG
215096060|NCT01291277|DEVICE|Endoscopic Variceal Ligation|Ligation of esophageal varices
215096061|NCT03492931|DRUG|Ticagrelor|Patients will receive a single dose of ticagrelor
215096062|NCT03208439|DEVICE|lower-limb cycling system|patients will receive 30-minute cycling exercise
215096063|NCT02116998|BIOLOGICAL|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~* GB104: ABC transporter, substrate-binding protein~* GB144: Maltose/maltodextrin binding protein, ABC transporter~* GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
215096064|NCT02116998|BIOLOGICAL|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
214401056|NCT00664521|DRUG|Atacicept|Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
214401057|NCT00664521|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
214401058|NCT03818997|DRUG|DKN-01|Patient will receive DKN-01 300 mg IV every 2 weeks
214401059|NCT03818997|DRUG|Atezolizumab|Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD
214401060|NCT03818997|DRUG|Paclitaxel|Patient will receive Paclitaxel 80 mg/m2 IV on day 1, 8 and 15 of a 28 day cycle until PD
214401061|NCT05362526|DEVICE|HFOT using AIRVO2|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases. The subjects in this group will receive HFOT at a flow rate of 60-30L liters per minute, maximum concentration of 40%, which will be titrated by bedside nurse to maintain an oxygen saturation of 92% or greater (unless there is a history of COPD and then the clinician can recommend \>88%)
215005772|NCT05227235|OTHER|3D Telemedicine|Clinical consultation with patient performed with 3D Telemedicine
215005773|NCT05227235|OTHER|2D Telemedicine|Clinical consultation with patient performed with 2D Telemedicine as standard of care
215005774|NCT05698212|DIAGNOSTIC_TEST|MetriDx|Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
215096065|NCT02116998|BIOLOGICAL|Streptococcus pneumoniae inoculation|Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
215096066|NCT00849108|DRUG|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
215096067|NCT00716742|DRUG|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
215096068|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a neurological examination is taken~* a saliva sample is taken"
215096069|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a saliva sample is taken"
215096070|NCT01654809|BIOLOGICAL|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
215096071|NCT01654809|BIOLOGICAL|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
215096072|NCT01654809|BIOLOGICAL|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
215096073|NCT04014127|DIAGNOSTIC_TEST|Coronary flow reserve assessment|Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
215096074|NCT04014127|DIAGNOSTIC_TEST|Sphygmocor|Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
214401062|NCT05362526|DEVICE|COT|Subjects will be placed on aerosolized trach mask with cool humidification, and titrated to keep oxygen saturation \>92% (unless there is a history of COPD and then the clinician can recommend \>88%)
215005775|NCT02271542|DRUG|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
214401063|NCT03667326|DRUG|Aspirin tablet|Low dose aspirin, 81mg tablets, PO
214401064|NCT03667326|DRUG|Placebo oral capsule|Placebo oral capsule, PO
215005776|NCT05790681|DRUG|Insulin icodec|Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.
215096075|NCT04014127|DIAGNOSTIC_TEST|Electrocardiogram|An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease
215096076|NCT04014127|OTHER|Blood test|Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury
215096077|NCT04014127|OTHER|Urinary albumin/creatinine ratio|Urine will be analysed for albumin/creatinine ratio
215096078|NCT02411370|BEHAVIORAL|phonetic tests|
215096079|NCT03197909|OTHER|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
215096080|NCT03051594|DEVICE|fluorescent camera|used too detect residual caries depending on the bacterial byproducts.
215096081|NCT03051594|OTHER|caries detector dye|dye used to detect the residual caries.
215096082|NCT03051594|DIAGNOSTIC_TEST|visual tactile assessment|method usually used to detect the residual caries.
215005777|NCT03986268|DRUG|Vit D|The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
215005778|NCT01164605|DRUG|Raltegravir|60 tablets (30-day supply)
215005779|NCT01420978|PROCEDURE|CSF Diversion|CSF drainage
215005780|NCT01334775|PROCEDURE|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
214401065|NCT02459964|DRUG|Fentanyl Nasal Spray|Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
215005781|NCT05331833|RADIATION|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.|
215005782|NCT02942407|DRUG|apixaban|oral anticoagulant
215005783|NCT02942407|DRUG|warfarin|oral anticoagulant
215005784|NCT03324958|DEVICE|Virtual reality Helmet|The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
215005785|NCT03324958|OTHER|No Virtual Reality Helmet|The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
215005786|NCT05424198|PROCEDURE|Cervical Medial Branch Radiofrequency Ablation|The skin and superficial tissues will be anesthetized at each site with 1-2 mL of lidocaine. Prior to the ablation up to 2 mL of lidocaine may be used at each site to ensure adequate pain control during the ablation. Once in position, a radiofrequency ablation lesion will be made using a 30 second ramp-up time to a maximum temperature of 80 °C, followed by an additional 90 seconds at maximum temperature.
215005787|NCT02750423|PROCEDURE|DHCA+RCP|During deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP) the participant is placed on cardiopulmonary bypass (heart-lung machine) and their body temperature is lowered to a range of 14-18 °C. Once the goal temperature has been achieved, the circulation is stopped and aortic arch replacement is performed in a bloodless surgical field. Blood will be pushed to the brain through arterial vessels, much like the natural blood flow pattern. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
215005788|NCT02750423|PROCEDURE|MHCA + SACP|During moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA + SACP) the participant is placed on cardiopulmonary bypass (heart-lung machine0 and the native blood flow to the brain is temporarily suspended. The body is cooled to temperatures of ≤28°C and blood is administered to the brain via an artery in the neck during the period of arch reconstruction. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
215005789|NCT06069609|DEVICE|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
215005790|NCT06069609|DEVICE|Acuvue Oasys 1-Day for Astigmatism|Acuvue Oasys 1-Day for Astigmatism
215005791|NCT00891397|DRUG|Pregabalin|Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
215005792|NCT00891397|OTHER|Placebo|Sugar pill
215005793|NCT02371005|RADIATION|Cone Beam Computed Tomography (CBCT)|
215096083|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (UV treated)|"Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
215096084|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (untreated)|"commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
215096085|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
215096086|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
214401066|NCT02459964|DRUG|Hydromorphone Hydrochloride|Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
214401067|NCT02459964|BEHAVIORAL|Phone Call|Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
214401068|NCT02383550|OTHER|Observational Cognitive assessments|Observational
214401069|NCT01409226|DEVICE|3.0-T MRI|Participants undergo MRI prior to biopsy.
214401070|NCT01409226|PROCEDURE|biopsy|Participants undergo breast biopsy after 3.0-T MRI.
215005794|NCT03892733|BEHAVIORAL|calorie health education knowledge and skills|45 minute intervention done by health educator to give participants skills to use calorie information posted in fast-food restaurants
215005795|NCT01666977|DRUG|AMG 386|15mg/kg
215005796|NCT01666977|DRUG|AMG 386|30 mg/kg
215005797|NCT01666977|DRUG|AMG 386 Placebo|AMG 386 Placebo
215005798|NCT01666977|DRUG|Pemetrexed|Pemetrexed 500 mg/m2
215005799|NCT01666977|DRUG|Carboplatin|Carboplatin AUC 6
215005800|NCT00528151|DRUG|curcumin|curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
215005801|NCT06398587|DRUG|Onvansertib|Given PO
215005802|NCT06398587|DRUG|Gemcitabine|Given IV
215005803|NCT06398587|DRUG|Nab-paclitaxel|Given IV
215005804|NCT06398587|PROCEDURE|Electrocardiography|Undergo electrocardiography
215005805|NCT06398587|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215005806|NCT06398587|PROCEDURE|Positron Emission Tomography|Undergo PET
215005807|NCT06398587|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214401071|NCT04559308|DRUG|Metformin|first-line anti-diabetic drug
214401072|NCT04559308|DRUG|Chemotherapy|First line neoadjuvant chemotherapy protocol
214401073|NCT00367237|DRUG|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
214401074|NCT00367237|DRUG|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
215096087|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
215005808|NCT06398587|PROCEDURE|Biospecimen Collection|Undergo tumor biopsy
215005809|NCT06398587|PROCEDURE|Computed Tomography|Undergo CT
215005810|NCT03060928|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
215005811|NCT03060928|PROCEDURE|Micro-perforations|Biological stimulation with micro-perforations
215005812|NCT03060928|PROCEDURE|Artelon®|Biological stimulation with Artelon® Tissue Reinforcement
215005813|NCT05467202|DRUG|CLL1 CAR-T|A single infusion of autologous CLL1 CAR-T cells administered intravenously
215005814|NCT00186511|BEHAVIORAL|workbook/journal on coping with breast cancer|
215005815|NCT00186511|BEHAVIORAL|supportive expressive group therapy using videoconferencing|
214401075|NCT02785055|PROCEDURE|Thoracic Epidural Placement|Thoracic Epidural Placement
214401076|NCT02785055|DRUG|Bupivacaine 0.05%|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
215005816|NCT05480371|DEVICE|Conventional tracheal suctioning|"Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations."
214401077|NCT02785055|DRUG|Hydromorphone 0.01mg/mL|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
214401078|NCT02274246|DRUG|gadobutrol|Gadobutrol administration in healthy volunteers
215096088|NCT01563172|OTHER|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
215096089|NCT02986815|OTHER|[11C]Acetate Brain Imaging|Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the \[11C\]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
215096090|NCT05097352|BEHAVIORAL|High Intensity Interval Training (HIIT)|Twenty minutes of HIIT will be completed three days a week for six weeks.
214401079|NCT05972616|BIOLOGICAL|Natural Matrix Protein (NMP)|human bone allograft
214401080|NCT06493084|DRUG|LAE102 intravenous administration|A single dose of LAE102 administered intravenously
214401081|NCT06493084|DRUG|placebo intravenous administration|A single dose of placebo administered intravenously
214401082|NCT06493084|DRUG|LAE102 subcutaneous administration|Single dose of LAE102 administered subcutaneously
215096091|NCT05097352|OTHER|Waitlist|Waitlist participants will be tested on the outcomes at the same time points as the treatment group.
214401083|NCT06493084|DRUG|placebo subcutaneous administration|single dose of placebo administered subcutaneously
214401084|NCT06493084|DRUG|LAE102 multiple subcutaneous administration|Multiple dose of LAE102 administered subcutaneously
215005817|NCT05480371|DEVICE|Mechanical insufflation/exsufflation|Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
215005818|NCT05115253|BEHAVIORAL|HAPA behavioural counselling + SMS text message boosters|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) paired with daily personalized HAPA guided SMS text message boosters to reduce consecutive workplace sedentary behaviour.
215005819|NCT05115253|DEVICE|JITAI|EMA monitoring mobile phone application that uses a phone's on-board accelerometer to monitor a participant's sedentary behaviour and deliver a push notification once a set condition has been met. This intervention will be utilized to reduce consecutive workplace sedentary behaviour.
215005820|NCT01092156|BEHAVIORAL|Education|Education on Infant-led latching
215005821|NCT00768677|DRUG|topiramate|
214401085|NCT06493084|DRUG|Placebo multiple subcutaneous administration|Multiple dose of placebo administered subcutaneously
214401086|NCT05318014|DIETARY_SUPPLEMENT|Intervention group|dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks
215005822|NCT02177292|RADIATION|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
214401087|NCT05318014|OTHER|Regular nutrition education|dietitian regular nutrition educataion which was following a low protein diet
215005823|NCT03611270|DEVICE|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
214401088|NCT06131073|OTHER|speed endurance production (SEP) training along with conventional training.|this include speed endurance training for 3 days in a week for 8 weeks.
214401089|NCT06131073|OTHER|conventional training|this include conventional training for 3 days in a week for 8 weeks.
214401090|NCT04010175|BEHAVIORAL|Control - Cognitive training in a practitioner's office one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office during 4 months (16 weeks of training = 16 hours of training). This training will include 10 short tasks of increasing difficulty. Performance of these tasks involve cognitive functions such as: executive functions, reasoning, auditive, visual and visuo-spatial memory, speed of processing, short-term memory and working memory. Thus the training aims to exercise all these cognitive functions.
214401091|NCT04010175|BEHAVIORAL|Experimental group 1 - Cognitive training in a practitioner's office one time per week and cognitive distance training one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and one time per week cognitive distance training in her/his place of residence, during 4 months (16 weeks of training = 32 hours of training).
214401092|NCT04010175|BEHAVIORAL|Experimental group 2 - Cognitive training in a practitioner's office one time per week and cognitive distance training four times per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and four times per week cognitive distance training in her/his place of residence during 4 months (16 weeks of training = 80 hours of training).
214401093|NCT03826602|DRUG|Tucatinib|150mg administered orally twice daily
214401094|NCT03826602|DRUG|Metformin|850mg administered orally
214401095|NCT03826602|DRUG|Iohexol|1500 mg administered intravenously (IV)
214401096|NCT00221130|PROCEDURE|surgical operation of cell transplantation|
214401097|NCT02718443|DRUG|VXM01|Oral immunotherapy targeting VEGFR2
214401098|NCT00415155|DRUG|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
214401099|NCT04975581|BIOLOGICAL|Allograft Patch|Rotator Cuff repair with Allograft Patch (Graftjacket Now)
214401100|NCT05571800|OTHER|Mango|120g of fresh Mango
214401101|NCT05571800|OTHER|Placebo|200g isocaloric Granola Bar
214401102|NCT06475599|DRUG|Anlotinib hydrochloride capsule + TQB2450 injection|"Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time.~TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response."
215005824|NCT00899275|OTHER|Cytology Specimen Collection Procedure|Correlative studies
215005825|NCT03281915|PROCEDURE|High inguinal Varicocelectomy|Semen parameters after high inguinal varicocelectomy will be collected
215005826|NCT03281915|PROCEDURE|Subinguinal varicocelectomy|Semen parameters after subinguinal Varicocelectomy will be collected
215005827|NCT01716156|DRUG|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
215096092|NCT05019768|OTHER|accelerated custom-fast CXL|The accelerated custom fast CXL (aCFXL) has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin consumption rate and the corneal thickness at its thinnest point. By knowing both values, the mathematical model allows to objectively calculate both the exact UVA irradiation value (intensity), expressed in mW/cm2, and the irradiation time
214401103|NCT06475599|DRUG|Chemotherapy drug|Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
214401104|NCT00866216|DRUG|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
214401105|NCT00866216|DRUG|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
214401106|NCT05256043|DIAGNOSTIC_TEST|Diabetes Diagnosis|HbA1c \> 6.5%
214401107|NCT01966536|PROCEDURE|CD133+ cells transplantation into ovarian artery of one ovary|
214401108|NCT01960205|DRUG|Saxagliptin|5mg a day for 6 months
214401109|NCT01960205|DRUG|saxagliptin|2.5 mg a day for 6 months
214401110|NCT01960205|DRUG|metformin|500mg three times a day for 6 months
214401111|NCT01960205|OTHER|lifestyle intervention|lifestyle intervention for 6 months
214401112|NCT04961216|BEHAVIORAL|OPTIMISE|Self-regulation intervention
214401113|NCT00707863|DRUG|Escitalopram|10 mg of Escitalopram by mouth once a day for 8 weeks
214401114|NCT05255263|OTHER|PIEB|Programmed Intermittent Epidural Bolus with Patient-Controlled Epidural Analgesia
214401115|NCT05255263|OTHER|CEI|Continuous Epidural Infusion with Patient-Controlled Epidural Analgesia
214401116|NCT04902170|PROCEDURE|25 gauge pars plana vitrectomy|25 gauge pars plana vitrectomy
214401117|NCT04027335|DEVICE|leva|Vaginal device used for pelvic floor muscle exercises
214401118|NCT02800928|DRUG|CERC-501|CERC-501
214401119|NCT02800928|DRUG|Placebo|Placebo
215005828|NCT01716156|DRUG|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
215005829|NCT03616587|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
215005830|NCT03616587|DRUG|AZD9833|Part B: AZD9833 monotherapy expansion.
215005831|NCT03616587|DRUG|AZD9833 with palbociclib|Part C: AZD9833 in combination with palbociclib dose escalation
215005832|NCT03616587|DRUG|AZD9833 with palbociclib|Part D: AZD9833 in combination with palbociclib expansion
215005833|NCT03616587|DRUG|AZD9833 with everolimus|Part E: AZD9833 in combination with everolimus dose escalation
215005834|NCT03616587|DRUG|AZD9833 with everolimus|Part F: AZD9833 in combination with everolimus dose expansion
215005835|NCT03616587|DRUG|AZD9833 with abemaciclib|Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation
215005836|NCT03616587|DRUG|AZD9833 with abemaciclib|Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion
215005837|NCT03616587|DRUG|AZD9833 with capivasertib|Part I: AZD9833 in combination with capivasertib dose escalation
215005838|NCT03616587|DRUG|AZD9833 with capivasertib|Part J: AZD9833 in combination with capivasertib dose expansion
215005839|NCT03616587|DRUG|AZD9833 with ribociclib|Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation
215005840|NCT03616587|DRUG|AZD9833 with ribociclib|Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion
215005841|NCT03616587|DRUG|AZD9833 with anastrozole|Part M: AZD9833 in combination with anastrozole dose escalation
215096093|NCT05019768|OTHER|Standard CXL|The standard CXL procedure has been carried on following the Dresden protocol
215096094|NCT05408026|DRUG|Daratumumab|"Daratumumab (and hyaluronidase) will be given over 3-5 minutes subcutaneously (under the skin) in the clinic at alternating left/right abdominal sites. Patient will take dexamethasone orally (by mouth) either before coming to clinic or in clinic, before other medications.~Only for the first cycle, patient will receive on Day 1 daratumumab (which is mixed with a compound called hyaluronidase) and dexamethasone, 1 day before patient start the other 2 medications."
214401120|NCT01853163|PROCEDURE|Gadolinium analysis in bone and tissue samples|Gadolinium analysis in bone and tissue samples from patients undergoing an orthopaedic surgical procedure who had received GBCAs in the past.
214401121|NCT03231449|OTHER|observation of current care|The study FEVRIER (survey of hospitalizations in cardiology units in sub-Saharan Africa) aims to establish a description of sub-Saharan standard of care, in order to get a cross sectional analysis (globally and per country) and a longitudinal analysis (evolution during 5 years).
214401122|NCT03560141|DEVICE|LID011121 contact lens|Investigational silicone hydrogel contact lens
214401123|NCT03560141|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
214401124|NCT00861978|DRUG|St. John's Wort extract|Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
214401125|NCT00861978|DRUG|Placebo|Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
215005842|NCT03616587|DRUG|AZD9833 with anastrozole|Part N: AZD9833 in combination with anastrozole dose expansion
215005843|NCT03925220|BEHAVIORAL|The SUPPER Project|Substance Use Promoted by Eating family meals Regularly
215005844|NCT03925220|BEHAVIORAL|Improving nutrition and physical activity among youth|A brief intervention focused on improving nutrition and physical activity among youth
215005845|NCT03814356|DRUG|Methylphenidate|IV MPH
215005846|NCT03220646|DRUG|abemaciclib|abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
215005847|NCT03220646|DRUG|abemaciclib|200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
215005848|NCT05221866|BEHAVIORAL|Empowering Patient to Steer Their Pain Management After Surgery|Participants will be randomized to receive the consumer health informatics app (UControlPain) versus an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or participants.
215005849|NCT05221866|BEHAVIORAL|Provider-facing Prescription Aid|Providers will be given information to inform a participant-centered post-discharge pain management plan. This tool will be activated once half the subjects are enrolled. Participants will be masked when the provider-facing tool is turned on.
215096095|NCT05408026|DRUG|Pomalidomide|On day 2 of cycle 1, patient will start the other medications and will therefore receive bortezomib administered subcutaneously (SC) over 3-5 minutes and dexamethasone given orally (by mouth), either before coming to clinic or in clinic, before bortezomib. Patient will also start pomalidomide on the same day, which patient will take that evening at home and every evening for 21 days.
214401126|NCT06303830|DIETARY_SUPPLEMENT|Sodium nitrate|Sodium Nitrate
214401127|NCT05677867|DRUG|Formulation A (PF-07081532 20 mg plus 60 mg)|Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet
214401128|NCT05677867|DRUG|Formulation B (PF-07081532 80 mg)|Formulation B: administered as a 80 mg immediate release tablet
214401129|NCT02628522|OTHER|ADRCs therapy|Patients with chronic anal fissures will receive one treatment of local injections of fat enriched with adipose derived regenerative cells starting from December 2014.
214401130|NCT02628522|DEVICE|Celution|Adipose derived regenerative cell isolation
214401131|NCT02628522|DEVICE|Tulip cannulas|Lipoaspiration
214401132|NCT02628522|OTHER|20mL Lidocaine 2% and Epinephrine 1:100 000|Infiltration prior to liposuction
214401133|NCT00576602|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
214401134|NCT00576602|DRUG|Supportive treatment|As prescribed
214401135|NCT04289285|DRUG|IBI306 450mg SC Q4W|Subjects will receive IBI306 450mg every 4 weeks subcutaneously.
214401136|NCT04289285|DRUG|Placebo SC Q4W|Subjects will receive placebo every 4 weeks subcutaneously.
215005850|NCT05561140|DRUG|Voxelotor Oral Tablet|Synthetic small molecule supplied as 500 mg tablets, administered Orally
215005851|NCT05561140|OTHER|Placebo|Placebo
215005852|NCT06538402|PROCEDURE|10 cm pouch|A 10 cm pouch will be constructed
215005853|NCT06538402|PROCEDURE|15 cm pouch|A 15 cm pouch will be constructed
215005854|NCT05658731|RADIATION|substructure informed planning|Radiation Therapy with substructure informed planning determined by the PI.
215005855|NCT05658731|OTHER|Neurocognitive Testing|California Verbal Learning Test (CVLT) and other cognition assessments.
214401137|NCT04289285|DRUG|IBI306 600mg SC Q6W|Subjects will receive IBI306 600mg every 6 weeks subcutaneously.
214401138|NCT04289285|OTHER|Placebo SC Q6W|Subjects will receive placebo every 6 weeks subcutaneously.
214401139|NCT03114046|BEHAVIORAL|Lower extremity Constraint-induced movement therapy(LE-CIMT)|"Both phases (A and B) will last 10 weekdays, and during baseline and treatment phases, the data will be collected on 5 different odd days. Considering the long period of data collection. During the baseline phase, no assessment will be administered on even days. The treatment will be delivered daily, along 10 weekdays, 3.5 hours per day. The motor training will be delivered during 3 hours and 30 minutes will be allocated to the administration of the TP.~Both caregivers and participants will be individually interviewed before and after treatment."
214401140|NCT03505359|OTHER|partial knee immobilization protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength with a 0-60 degrees articulated knee brace in the first 6 weeks in the experimental group.
214401141|NCT03505359|OTHER|standard ACL reconstruction rehabilitation protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength.
214401142|NCT04237454|DEVICE|Thermal Imaging Camera|To develop a non-ionising radiation-based method of excluding fractures in children with suspected physical abuse
214401143|NCT06014567|PROCEDURE|Magnetic Resonance Imaging|"1. A single (≤45 minutes) brain MRI will include T1w and T2w imaging to assess the morphology and structure of the brain, as well as inflammatory processes. Diffusion-weighted imaging will be used to gain information about internal brain connectivity related to brain functions. MRI, MR angiography (MRA) and fMRI pulse sequences will also be acquired to detect vascular pathologies and brain lesions. T2w morphological images of the whole spine will also be obtained.~2. A single (≤45 minutes) MR imaging investigation to include cardiovascular, abdominal, and musculoskeletal regions. MRI will be performed to assess the structure and function of these body regions and organs, including functional imaging of the heart. These investigations will include T1w and T2w imaging to assess morphology and structure, mapping studies of T1, T2 and T2\*, perfusion imaging and cine imaging to assess the heart dynamically."
214401144|NCT00799461|OTHER|internet-based intervention|Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
214401145|NCT00799461|OTHER|questionnaire administration|Completion of questions in an online format
214401146|NCT00799461|PROCEDURE|psychosocial assessment and care|Assessment and care of psychosocial aspects
215096096|NCT01949519|DRUG|Lycopene and Docetaxel|During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
214401147|NCT00799461|PROCEDURE|assessment of therapy complications|Evaluation of complications of treatment
215005856|NCT05658731|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) using whole brain diffusion tensor imaging (DTI) and resting state functional MRI (rsfMRI).
215005857|NCT06216873|OTHER|multiple trauma|Review the medical record to gather the physical parameters, blood examination result and radiologic examination results
215005858|NCT05568706|DRUG|EDP-938|Subjects will take EDP-938 once daily for 5 days
214401148|NCT00799461|PROCEDURE|management of therapy complications|Managing therapy complications
215005859|NCT05568706|DRUG|Placebo|Subjects will take matching placebo, once daily for 5 days
214401149|NCT00799461|PROCEDURE|fatigue assessment and management|Assessing and managing fatigue
214401150|NCT00799461|OTHER|counseling intervention|Counseling provided via telephone
214401151|NCT03172793|DRUG|Telavancin Injection|Receive 3 doses of telavancin as described in arm/groups, followed by collection of blood for pharmacokinetic analyses.
214401152|NCT04792983|OTHER|No intervention|This is an observational study with no interventions.
215005860|NCT06377488|DEVICE|JJVC Investigational Multifocal Toric Contact Lens manufactured in Senofilcon A (C3) material with UV blocker / HEV filter|Test Lens
215005861|NCT04385992|DRUG|177Lu-Dotatate|Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE
214401153|NCT01336335|DEVICE|CPAP|CPAP
214401154|NCT01203241|PROCEDURE|Pulmonary vein encircling|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
214401155|NCT01203241|PROCEDURE|Pulmonary vein encircling plus roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
214401156|NCT01817543|DEVICE|AutoloGel|Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
215005862|NCT00866320|DRUG|sorafenib tosylate|Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
215005863|NCT04072471|DRUG|Zurampic®|non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
215005864|NCT04072471|DRUG|Control group: xanthine oxidase inhibitor monotherapy|non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
214401157|NCT02106221|OTHER|Intervention|Will receive payments based on achievement in meeting goals based on specified high value elements as well as effort.
214401158|NCT02106221|OTHER|Control|Will receive payments based on achievement in meeting goals.
215005865|NCT06462612|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
215096097|NCT01105377|DRUG|entinostat|Given orally
215096098|NCT01105377|DRUG|azacitidine|Given SC
215096099|NCT01105377|OTHER|laboratory biomarker analysis|Correlative studies
215096100|NCT02934737|OTHER|Progression of diabetes|
215005866|NCT06462612|DRUG|Placebo|Matching capsules administered orally, once daily
215005867|NCT06478186|DRUG|triamcinolone acetonide extended-release injectable suspension; TCA-ER|Mode of Administration: IA Knee Injection Nominal 32 mg TCA, intra-articular (IA) injection, administered as a 5 mL injection
215005868|NCT06478186|DRUG|Triamcinolone Acetonide- Immediate Release;TCA-IR|Mode of Administration: IA Knee Injection Triamcinolone Acetonide- Immediate Release (TCA-IR)
215005869|NCT06372561|DRUG|Mineral trioxide aggregate (dressing material)|MTA (Angulus Industrial de productus Odontologists S/a, Brazil) that applied on dental pulp for tissue regeneration
215005870|NCT06372561|DRUG|Melatonin (dressing material)|melatonin powder 250mg (sigma, Aldrich)- white powder mixing with saline and applied on dental pulp
215005871|NCT02422758|DEVICE|3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket|3M™ Bair Hugger™Preoperative \& Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.
215005872|NCT02422758|OTHER|Passive Prewarming|
215096101|NCT04198675|BEHAVIORAL|Supervised EMG Biofeedback Exercise Training Group|Posture training and ergonomic arrangements in the workplace. EMG biofeedback training will be carried out with electromyography-controlled video game combined with PNF exercises. Each game sessions comprising the work-rest cycle covers performing the upper trapezius muscle contraction simultaneously the upper extremity PNF patterns.
215005873|NCT00619463|BEHAVIORAL|Exercise|Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
215096102|NCT04198675|BEHAVIORAL|Home-Based Exercise Training Group|Posture training and ergonomic arrangements in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program. Exercise diary and weekly calls will be use to maintain the exercise adherence
215096103|NCT04198675|BEHAVIORAL|Posture Training/Ergonomic Regulations Group|Posture training and ergonomic arrangements in the workplace.
215096104|NCT02495454|DRUG|Ga101|
215096105|NCT01531751|DEVICE|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
215096106|NCT01531751|DRUG|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
214401159|NCT05439265|OTHER|Electronic medical record order panel and resident involvement|Prior to 2014, there was no formal process for evaluation of patients with HIT. In November of 2014, an EMR tool was created in an effort to improve heparin allergy documentation and HIT management. This EMR tool prompts the medical team to perform the 4T score, displays the appropriate HIT labs, alternative anticoagulation strategies, instructs the nurse to apply an allergy bracelet, and notifies the pharmacy resident through the order verification queue. The pharmacy resident then performs an independent 4T score, discontinues all heparin products, documents the heparin allergy in the medical record, and assesses the need for alternative anticoagulation.
214401160|NCT04943835|OTHER|Observational - No intervention|
215005874|NCT00619463|BEHAVIORAL|Exercise|Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
215005875|NCT05073315|DRUG|Adalimumab|Participants will receive subcutaneous (SC) injection of adalimumab
215096107|NCT00745797|RADIATION|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
214401161|NCT03941782|DRUG|Alpelisib|As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication.
214401162|NCT05265988|DRUG|Cabozantinib|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
215096108|NCT05945303|PROCEDURE|Coronary Artery Bypass Grafting surgery|Assessing the reliability of predicting fluid responsiveness in adults undergoing coronary artery bypass graft surgery using ultrasonography of the internal jugular vein for assessment of vessel distensibilty in relation to stroke volume variation (SVV) measured by electrical cardiometry.
214401163|NCT00839982|DRUG|clofarabine|Given PO
214401164|NCT00839982|DRUG|cytarabine|Given SC
215005876|NCT05073315|DRUG|ABP 501|Participants will receive SC injection of ABP 501
215005877|NCT02660099|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
215005878|NCT01610843|OTHER|Survey|Longitudinal surveys
215096109|NCT06393881|DRUG|UI059|take UI059 once a day for 7 days
215096110|NCT06393881|DRUG|UIC202201|take UIC202201 once a day for 7 days
215096111|NCT03950310|DEVICE|Excimer laser catheter|The excimer laser catheter is equipped with multiple optical fibers on the periphery of the guide wire lumen corresponding to 0.014 inch, which is used for the purpose of reperfusion of barrier site of coronary artery. The connector on the front side is connected with the CVX-300 laser generator, and the tip at the top contact directly with the lesion. The laser catheter consisting of multiple optical fibers transmits the energy in the ultraviolet region from the CVX300 laser generator to the blockage in the blood vessel. The ultraviolet energy is transmitted from the tip of laser catheter, transpires the fibrous, calcified and arteriosclerotic lesion by light, and enables reperfusion in the lesion. The laser catheter has appropriate hydrophilic coating and easily follows the inside of coronary artery.
215096112|NCT04115982|DRUG|Cholecalciferol|One vial every 15 days during 2 months
215096113|NCT04115982|DRUG|Placebos|One vial every 15 days during 2 months
215096114|NCT00474461|BIOLOGICAL|Treatment group|Intracoronary injection of cardiac stem cells
215096115|NCT00712582|DRUG|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
215005879|NCT04724057|DEVICE|AutocathFFR|The MedHub Autocath FFR device is a software only medical device. The FFR is computed from several standard DICOM format 2D angiography images retrieved from the C-arm imaging system, which display the structure of the vessels. The MedHub AutocathFFR device software analyzes these images and automatically (without the need for user selection or markings) and computes and displays the FFR on the viewed blood vessel.
215005880|NCT01014676|DIETARY_SUPPLEMENT|Probiotic|
215096116|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
215005881|NCT01014676|OTHER|Placebo|
214401165|NCT05010382|PROCEDURE|Implant placement surgery|Under local anaesthesia, full-thickness mucoperiosteal flaps were elevated, the alveolar ridge measured, and a proper implant dimension (3.75 mm and 4.25 mm diameter; 8 mm, 10 mm and 11.5 mm length) and position selected. After site preparation, each patient was randomly allocated to the test or the control group. Patients in the test group received a modified implant design with the coronal third presenting a machined surface (hybrid surface (HS) group), while in the control group the same implant design with a titanium rough surface up to the implant shoulder was used (rough surface (RS) group). Implants were placed 1 mm sub-crestally. In the case of dehiscence or fenestrations around the implant, the patient was excluded from the study. Once inserted, healing abutments (ranging between 3 -5 mm) were placed, and flaps sutured around the abutments to allow for a transmucosal healing.
214401166|NCT04252703|PROCEDURE|Percutaneous coronary intervention (PCI)|Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.
215096117|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
215005882|NCT05763316|OTHER|CRIB II|Calculate Clinical Risk Index for Babies II score
214401167|NCT02075983|BIOLOGICAL|GTU®-multiHIV B clade|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
214401168|NCT03048110|DRUG|BAY1841788 (ODM-201)|In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5, In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8.
215096118|NCT00491374|DRUG|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
215005883|NCT05763316|OTHER|SNAP-II|Calculate Score for Neonatal Acute Physiology II
215096119|NCT00491374|DRUG|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
215096120|NCT04041245|DEVICE|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~   They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
215096121|NCT03334383|DEVICE|Sponge|Compressed cellulose sponge for use in laparoscopic surgery to retract the intestines from the surgical field.
215005884|NCT05763316|OTHER|SNAPPE-II|Calculate Score for Neonatal Acute Physiology Perinatal Extension II
215005885|NCT05763316|OTHER|STOPS|Calculate Sensorium, temperature, oxygenation, perfusion, skin color, and blood sugar score
215005886|NCT05763316|OTHER|MSNS|Calculate Modified Sick neonatal Score
215005887|NCT05763316|OTHER|nSOFA|Calculate neonatal sequential organ failure assessment
215005888|NCT01370915|DRUG|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
215005889|NCT01370915|DRUG|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
215005890|NCT01642966|DRUG|Prasugrel|Prasugrel 10mg/day for 15 days
215005891|NCT01642966|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
215005892|NCT02095860|DRUG|DCV 3DAA FDC|Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
215005893|NCT06296693|DEVICE|Pocket-size lung ultrasound for etiological definition of pneumonia and surveillance of complications in children hospitalized|The investigators will study the diagnostic accuracy of a pocket-size POCUS device vs. CXR for the etiological diagnosis of CAP, in paediatric age. During 1 year, all children aged \>12 months and \<18 years admitted to the Paediatric Department with the diagnosis of CAP on admission will be included. At least 76 participants will be required. Two investigators will perform, independently, a POCUS at admission, daily during hospitalization, 15 days and 1 month after discharge. All children will also undergo a CXR upon admission and whenever necessary. A third investigator will classify the CXR independently. It will be used the General Electrics Vscan AirTM®, with Bluetooth connection to smartphone/tablet. It will be collected the systematized description of POCUS and CXR, sociodemographic, clinical and therapeutic variables.
215005894|NCT02581423|DRUG|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
215005895|NCT02263690|PROCEDURE|Group Drops|The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%
215005896|NCT02263690|PROCEDURE|Group SC|The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.
215005897|NCT02263690|PROCEDURE|Group gel|For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
215005898|NCT05599932|DRUG|Siremadlin|HDM201 capsule
215005899|NCT06350084|BEHAVIORAL|Mother's Touch|Heel blood will be taken while the infant was Mother's Touch. Mother's touch will be applied to the infants before, during and after the procedure.
215096122|NCT02622646|DRUG|Recombinant VIII factor|"Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence)."
215096123|NCT02014584|DRUG|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
215096124|NCT02014584|DRUG|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
215096125|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
215096126|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
214401169|NCT03048110|DRUG|Itraconazole|200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1, 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7.
214401170|NCT03048110|DRUG|Rifampicin|600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10.
214401171|NCT03605017|BEHAVIORAL|Virtual Reality Executive Function Training (VREFT)|
214401172|NCT01609153|DRUG|Olanzapine|Coated tablet 5-20 mg milligram(s) per day for 16 weeks
214688199|NCT06911905|DIETARY_SUPPLEMENT|Nutritional supplements|The nutritional supplements, including Vitamin B1, Vitamin B2, folic acid, Mecobalamin, Vitamin D3, Choline, and Coenzyme Q10, will be administered for a period of three months.
215005900|NCT06350084|BEHAVIORAL|Nurse's Therapeutic Touch|Heel blood will be taken while the infant was Nurse's Therapeutic Touch.Therapeutic Touch will be applied to the infants before, during and after the procedure.
215005901|NCT06375889|OTHER|blood test|During the routine blood test of the patient, 5 more tubes of 2.7 milliliters (mL) will be collected to make Platelet Activation Analysis
215005902|NCT04606719|PROCEDURE|Advanced Platelet Rich fibrin|Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
215005903|NCT00588224|OTHER|3D ultrasound|measurement of stomach volume by 3D ultrasound
215005904|NCT01449487|DRUG|PPC-5650|Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
215005905|NCT01449487|DRUG|Placebo|Solution for administration in the rectum Identical tp active solution but without active drug
215005906|NCT04761991|DIAGNOSTIC_TEST|CMR and CTCA with CT-FFR|multi-parametric CMR assessment and CT coronary angiography with FFR assessment
215005907|NCT04498104|OTHER|Psychological assessment|Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.
215005908|NCT02096913|DRUG|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period."
214401173|NCT01609153|DRUG|Amisulpride|200-800 mg milligram(s)per day for 16 weeks
214401174|NCT01609153|DRUG|Olanzapine and Amisulpride|"Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks"
214401175|NCT00043940|DRUG|bivalirudin|Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours.
214504342|NCT03316690|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2"
214504343|NCT03316690|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2"
214504344|NCT03316690|BEHAVIORAL|Physical training|Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
214504345|NCT01824849|PROCEDURE|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
214504346|NCT01824849|PROCEDURE|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
215005909|NCT02096913|DRUG|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment."
215005910|NCT05141799|DEVICE|high intensity laser therapy|Laser treatment is noninvasive and painless and can be easily administered in therapy units for a wide range of conditions. High-intensity laser therapy (HILT) has gained importance for the treatment of different kinds of sports injuries such as tendon injuries, contusions, and muscle spasms.
214401176|NCT05382455|OTHER|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in Ai in healthcare.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the AI reporting standards in systematic reviews and objectively identify critical aspects of reporting methodology and results.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
214401177|NCT03738579|DEVICE|Next Science Group|TorrentX Wound Wash will be used for irrigation and then BlastX Wound Gel will be applied to the wound after debridement/irrigation during in-clinic visits. BlastX Wound Gel will be re-applied again during mid-week dressing change. Dressing used will be plain foam dressing from control group arm.
214401178|NCT03738579|DEVICE|Control Group|Foam Dressing will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
214401179|NCT03738579|DEVICE|Antibacterial Control Group|Foam Dressing AG will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
214401180|NCT04267653|DRUG|Lactoferrin Bovine|treatment for 30 days
214401181|NCT04267653|DRUG|Ferrous Sulfate|treatment for 30 days
214401182|NCT05000775|DIETARY_SUPPLEMENT|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
214401183|NCT05000775|DIETARY_SUPPLEMENT|Placebo|Placebo
214401184|NCT00000816|DRUG|Sulfamethoxazole-Trimethoprim|
214401185|NCT04032457|DEVICE|Phase A - olifilcon B with Tangible Coatings|Daily disposable silicone hydrogel contact lens
214401186|NCT04032457|DEVICE|Phase B - etafilcon A with Tangible Coatings|Daily disposable hydrogel contact lens
214401187|NCT03291795|OTHER|Exercise Intervention|Study patients will undergo a program of prehabilitation exercise for 6 days per week prescribed for them by an exercise physiologist, for up to 4 weeks prior to surgery.
214401188|NCT02328456|OTHER|SMS and free eye drops|The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
214401189|NCT02034084|PROCEDURE|left radial approach|Coronary diagnostic procedures performed through left radial approach
214401190|NCT02034084|PROCEDURE|Right radial approach|coronary diagnostic procedures performed through right radial approach
214504347|NCT03096470|PROCEDURE|anesthesia|no anesthesia
215005911|NCT05252975|OTHER|Setup and Imaging for at CT radiation planning|Patients will undergo an additional CT scan acquisition at CT radiotherapy planning in order that all participating patients have a prone and supine CT scan available to compare radiation therapy plans.
215005912|NCT02286830|DRUG|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
215005913|NCT04099420|BEHAVIORAL|Lifestyle counseling|An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students
215005914|NCT00714480|DRUG|anti-thymocyte globulin|Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
215005915|NCT00714480|DRUG|anti-thymocyte globulin|anti-thymocyte globulin post-operative days -2, 0, 2 and 4
215005916|NCT00714480|DRUG|anti-thymocyte globulin|Post-operative days 0, 2, 4 and 6
215005917|NCT02475837|DRUG|Vorapaxar sulfate|The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
215005918|NCT02475837|DRUG|Placebo|The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
215005919|NCT01505335|DEVICE|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
215005920|NCT06159036|DEVICE|Inertial Strength training|Low speed strength training with classic movements, derived from Olympic lifting and jumping
215005921|NCT00679601|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
215005922|NCT02663505|PROCEDURE|Patients receiving the surgery planned for them|"For each patient the following potential influence (risk) factors are documented:~sex, urgency of the operation, BMI, age, ASA classification, preconditions, physical fitness, Hb value.~In phase 2 only selected influence factors will be recorded.~No intervention will be performed apart from the surgery planned for each patient."
215005923|NCT04645056|OTHER|Stretching and Mobility exercises for neck and shoulder|9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
215005924|NCT02049879|DRUG|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
214401191|NCT01601743|BEHAVIORAL|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
214401192|NCT01601743|BEHAVIORAL|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
214401193|NCT01601743|BEHAVIORAL|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
214401194|NCT05648955|DIETARY_SUPPLEMENT|an enriched high protein and high energy oral nutrition supplement (ONS)|NA (see intervention name)
214401195|NCT05374083|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by hydrochloric acid (HCL) acid and inserted as demineralized dentin block graft in the socket
214401196|NCT05374083|PROCEDURE|Alveolar ridge preservation using particulate deproteinized bovine bone graft|Atraumatic extraction of non restorable tooth, then the socket will be packed by particulate deproteinized bovine bone
214401197|NCT05847764|DRUG|RC48+Tislelizumab+carboplatin|RC48+PD-1/PD-L1 inhibitor+chemo in treatment-naive patients harboring HER2 alterations
214401198|NCT05847764|DRUG|RC48+Furmonertinib, 1L|RC48+Furmonertinib in treatment-naive patients harboring EGFR mutations as well as HER2 alterations
214401199|NCT05847764|DRUG|RC48+Furmonertinib, 2L+|RC48+Furmonertinib in patients who failed at least one line of standard treatment and harboring HER2 alterations
214401200|NCT00953160|DEVICE|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
214401201|NCT05121870|BIOLOGICAL|UC-MSCs|3 does of UC-MSCs(6.0×10E7cells per time) intravenously at week 0, week 4, week 8.
214401202|NCT05121870|BIOLOGICAL|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo intravenously at week 0, week 4, week 8.
214401203|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pattern.
214401204|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine tongue diagnosis.
214401205|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine pulse diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pulse diagnosis.
214504348|NCT00516399|DRUG|povidone-iodine 1.25% ophthalmic solution|
214504349|NCT00516399|DRUG|natamycin ophthalmic suspension, USP 5%|
214504350|NCT02336802|BEHAVIORAL|Avoidance experiment|Participants complete an avoidance task
214504351|NCT00003654|DRUG|patent blue V dye|
214504352|NCT00003654|PROCEDURE|lymphangiography|
214504353|NCT00003654|PROCEDURE|radionuclide imaging|
214504354|NCT00003654|PROCEDURE|sentinel lymph node biopsy|
214504355|NCT00003654|RADIATION|technetium Tc 99m sulfur colloid|
214504356|NCT02134626|DRUG|Simvastatin|40mg / pill, one pill orally once a day for three months
214688200|NCT06911905|BEHAVIORAL|Treatment as usual (TAU)|Participants will undergo treatment as usual, such as behavioral interventions
215005925|NCT02387918|DRUG|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
215005926|NCT02387918|DEVICE|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
215005927|NCT05194488|DEVICE|Low level laser therapy|Patients will receive low-level laser therapy on the temporomandibular joint disc
215005928|NCT05194488|DRUG|Botulinum toxin type A|Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.
215005929|NCT05194488|DEVICE|Anterior repositioning appliance|Patients will receive hard maxillary anterior repositioning appliance.
215005930|NCT05089357|BIOLOGICAL|AbobotulinumtoxinA|Participants received a total dose of AbobotulinumtoxinA (Dysport®), 50 U (0.25 mL total; 10 U \[0.05 mL per injection site\] of study drug into 5 injection sites intramuscularly.
215005931|NCT06803654|DRUG|BTOS-HA|Brimonidine tartrate ophthalmic solution 0.025% with sodium hyaluronate (BTOS-HA) administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart
215005932|NCT06803654|DRUG|Lumify®|Brimonidine tartrate ophthalmic solution 0.025%, administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart
215005933|NCT04844775|BIOLOGICAL|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"1. Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
215005934|NCT04844775|BIOLOGICAL|DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)|"1. Drep-HIV-PT1 1mg (see above)~2. Drep-HIV-PT1 1mg (see above)"
215005935|NCT04844775|BIOLOGICAL|DNA-HIV-PT123 4mg and CN54gp140/MPLA-L|"1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef~2. CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
215005936|NCT03734185|OTHER|Learning and Coping|'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
214504357|NCT02134626|DRUG|Placebo pill|
214688201|NCT07098403|DRUG|SHR-1905 Injection|SHR-1905 injection.
214688202|NCT07098403|DRUG|SHR-1905 Placebo Injection|SHR-1905 placebo Injection.
215005937|NCT06971354|BEHAVIORAL|Biofeedback|Three sessions of biofeedback before and after a standardized meal.
215005938|NCT06971354|DIETARY_SUPPLEMENT|Placebo|Three sessions of placebo followed by standardized meal.
215005939|NCT04240704|DRUG|JBH492|Anti-CCR7 antibody-drug conjugate (ADC)
215005940|NCT05325008|DRUG|Immunosuppression reduction/modification + intravenous immunoglobulin|Participants will receive intravenous immunoglobulin along with immunosuppression reduction/modification.
215005941|NCT05325008|OTHER|Immunosuppression reduction/modification|Participants will receive immunosuppression reduction/modification.
215005942|NCT06059846|DRUG|TBP-PI-HBr|TBP-PI-HBr film-coated immediate-release tablets.
215005943|NCT06059846|DRUG|Imipenem-cilastatin|Sterile powder for reconstitution administered as IV.
215005944|NCT06059846|DRUG|Dummy Infusion|0.9% sodium chloride administered as IV infusion.
215005945|NCT06059846|DRUG|Dummy Tablets|TBP-PI-HBr matching dummy tablets.
215005946|NCT05537571|DRUG|SLN360|SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
215005947|NCT05537571|DRUG|Placebo|Sodium chloride, solution for injection
215005948|NCT05542056|OTHER|Data and biosample collection|Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation)
215005949|NCT05651919|BIOLOGICAL|Blood test|During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.
215005950|NCT05651919|BEHAVIORAL|quality of life Questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~* Level 1 is coded as a '1' (indicating no problem)~* Level 2 is coded as a '2' (indicating some problems)~* Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems."
215005951|NCT05651919|BEHAVIORAL|Diet habits questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients."
215005952|NCT06975748|DRUG|STSP-0902 ophthalmic solution|Eye drop, 3 times daily for 8 weeks
215005953|NCT06975748|DRUG|STSP-0902 ophthalmic solution|Eye drop, 6 times daily for 8 weeks
215005954|NCT06975748|DRUG|STSP-0902 Placebo|Eye drop, 3 or 6 times daily for 8 weeks
215096127|NCT04943120|PROCEDURE|"Snow-plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
215096128|NCT04943120|PROCEDURE|Bulk fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
215005955|NCT06559189|BIOLOGICAL|CD19x22 CAR T|The CD19 CAR contains an FMC63 binding domain, a CD28 hinge/transmembrane/endodomain, and a CD3 zeta endodomain. The CD22 CAR contains the binding domain (m971), a CD8alpha hinge and transmembrane domain, a 41BB endodomain, and a CD3 zeta endodomain.
215005956|NCT05211986|DRUG|IMM01-STEM|IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
215005957|NCT06198010|OTHER|Best Practice|Receive enhanced usual care
215005958|NCT06198010|OTHER|Educational Intervention|Receive ASCENT guide
215096129|NCT03963102|DRUG|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
215096130|NCT03005808|DRUG|Ropivacaine|Surgery for appendicitis
214401206|NCT03937271|DIAGNOSTIC_TEST|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
215005959|NCT06198010|OTHER|Questionnaire Administration|Ancillary studies
215005960|NCT06198010|OTHER|Electronic Health Record Review|Ancillary studies
215005961|NCT06198010|PROCEDURE|Health Telemonitoring|Attend video or phone calls with a CHW and/or PCM
215005962|NCT06198010|BEHAVIORAL|Cancer Pain Management|Receive personalized pain management plan
215096131|NCT01493856|DRUG|Cresto|tablet, rosuvastatin 20mg
215096132|NCT01493856|DRUG|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
215096133|NCT01493856|DRUG|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
215096134|NCT03605290|DIAGNOSTIC_TEST|REHAGAIT ANYLIZER|Gait analysis instrumentation
215096135|NCT00859742|PROCEDURE|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
215005963|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program. Specifically reducing interaural frequency mismatch in experienced SSD-CI recipients.|We will modify the CI speech processor program to reduce interaural frequency mismatch between the CI ear and the contralateral ear in experienced CI recipients with SSD.
215005964|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program to reduced interaural frequency mismatch in newly implanted SSD-CI recipients.|We will modify the CI speech processor program to reduce interaural frequency mismatch between the CI ear and the contralateral ear in newly implanted CI recipients with SSD.
215005965|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program to reduced interaural loudness mismatch in experienced SSD-CI recipients.|We will modify the CI speech processor program to reduce interaural loudness mismatch between the CI ear and the contralateral ear in experienced CI recipients with SSD.
215005966|NCT02099734|BEHAVIORAL|Questionnaires|
215005967|NCT02099734|OTHER|sample of blood or saliva|A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
215005968|NCT05167721|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells administered intrathecally
215005969|NCT05167721|OTHER|Placebo|Placebo administered intrathecally
215005970|NCT00871013|DRUG|Melphalan|"Given by vein, Day 3~First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2~Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days~Years 2 \& 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days"
215005971|NCT00871013|DRUG|Velcade|Given by vein, Days 1, 5, 8, 11
214401207|NCT03937271|DIAGNOSTIC_TEST|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
215005972|NCT00871013|DRUG|Thalidomide|Given by mouth at bedtime, Days 5-8
215005973|NCT00871013|DRUG|Dexamethasone|Given by mouth, once per day Days 5-8
215005974|NCT00871013|DRUG|Cisplatin|Given by vein, Days 5-8 continuous infusion
215005975|NCT00871013|DRUG|Adriamycin|Given by vein, days 5-8 continuous infusion
215005976|NCT00871013|DRUG|Cyclophosphamide|Given by vein days 5-8 continuous infusion
215005977|NCT00871013|DRUG|Etoposide|Given by vein days 5-8 continuous infusion
215005978|NCT04910568|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment after Cycle 13. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
215005979|NCT04910568|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
215005980|NCT04910568|DRUG|Pomalidomide|Pomalidomide will be administered orally (PO) on a 28-day cycle.
215005981|NCT04910568|DRUG|Daratumumab|Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
215005982|NCT04910568|DRUG|Dexamethasone|"Arm A: Dexamethasone will be administered as a premedication.~Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product."
215005983|NCT06091241|PROCEDURE|Pre-operative Erector Spinae Plane block prior to DIEP surgery|After obtaining informed consent to participate in the study, patients will be randomized by a computer 50/50 to either the Erector Spinae Plane group or the Transversus Abdominus Plane group at the time of their surgical clinic visit prior to their scheduled surgery. Then on the morning of surgery, the Erector Spinae Plane group will receive a bilateral ultrasound-guided Erector Spinae Plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected below the fascia of the erector spinae muscle group.
215005984|NCT06091241|PROCEDURE|Pre-operative Transversus Abdominus Plane blocks prior to DIEP surgery|On the morning of surgery, the patients in the TAPs group will receive a bilateral ultrasound-guided Transversus Abdominus plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected into the transversus abdominus plane above the transversus abdominus muscle.
215005985|NCT05752487|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|Participants will undergo catheter ablation with the PF /RF ablation system consisting of the TRUPULSE Generator (delivers RF or PF energy through the study catheter) and the THERMOCOOL SMARTTOUCH SF (STSF) Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a Generator, for cardiac ablation).
215005986|NCT02457091|BEHAVIORAL|Resistance exercise|strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
215005987|NCT02457091|BEHAVIORAL|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
215005988|NCT02748772|DRUG|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
215096136|NCT01295970|PROCEDURE|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
215096137|NCT01295970|PROCEDURE|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
215005989|NCT02748772|DRUG|Pure chemotherapy（Xelox）|"CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops."
215005990|NCT03356093|OTHER|complete questionnaire|Patients were asked to complete a questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of radiotherapy.
215005991|NCT03238131|DRUG|Ivermectin|Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
215005992|NCT03238131|DRUG|Albendazole|Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
215005993|NCT04976725|OTHER|Osteopathic Manipulative Therapy|"75 individuals will be included in our study, including 3 groups: control group (N= 25), osteopathic manipulative technique (n= 25), myofascial relaxation group (n=25). Which group of individuals will be determined by randomizing them with closed envelope method.~Osteopathic Manipulative Therapy and myofascial relaxation treatment applications will be applied 2 days a week, for periods of 30 min for 4 weeks."
214401208|NCT03656900|DEVICE|rTMS BA9/BA46|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.
215096138|NCT06304779|DRUG|Lidocaine|"Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine."
215096139|NCT06304779|DRUG|Placebo|atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
215096140|NCT01411384|PROCEDURE|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
214401209|NCT03656900|DEVICE|rTMS BA46/BA9|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.
215005994|NCT03091439|DRUG|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
215005995|NCT03091439|DRUG|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
215005996|NCT01243281|DRUG|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
214401210|NCT03656900|RADIATION|brain MRI|T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
214401211|NCT03656900|OTHER|Medical evaluation|complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
214401212|NCT03656900|OTHER|Psychological assessment|Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
214401213|NCT01341080|DRUG|Varenicline|Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.
214401214|NCT01341080|DRUG|Sugar pill|1mg twice daily for eight weeks after a one week dose escalation phase.
214401215|NCT01637558|DRUG|8 hourly LPV/r during TB treatment|8 hourly LPV/r during TB treatment
214401216|NCT01637558|DRUG|Nevirapine|
214401217|NCT01637558|DRUG|Lopinavir/Ritonavir|
214504358|NCT04440540|BEHAVIORAL|Dietitian led life style modification intervention|lifestyle changes supervised by dietitians
215005997|NCT01922583|DRUG|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
215005998|NCT03922685|COMBINATION_PRODUCT|Dietary manipulation (25% carbohydrate diet) and behavioral (exercise)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. Exercise was walking 1 hour on level treadmill at 50% of maximal effort starting 40 minutes after the beginning of the meal
215005999|NCT03922685|COMBINATION_PRODUCT|Dietary manipulation (25% carbohydrate diet) and behavioral (sedentary)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. There was no exercise during this trial.
215006000|NCT05598736|DEVICE|FlowOx 2.0|-40mmHg intermittent negative pressure for 60 minutes per day
215006001|NCT00482092|DRUG|Prochymal®|Prochymal® IV infusion
215006002|NCT00482092|DRUG|Placebo|Prochymal® Placebo-matching IV infusion
215096141|NCT01411384|DEVICE|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
214401218|NCT03022266|BEHAVIORAL|Financial Incentive and Mobile Phone App|Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
214401219|NCT00766857|DRUG|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
214401220|NCT00766857|DRUG|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
214401221|NCT04145336|DEVICE|5cm 5-Fr PDS|High-risk patients receive 5cm 5-Fr PDS
214401222|NCT04145336|DEVICE|7cm 5-Fr PDS|High-risk patients receive 7cm 5-Fr PDS
214401223|NCT04145336|DRUG|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
214401224|NCT02476643|OTHER|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
214401225|NCT04830514|OTHER|Recommended Dietary Allowance of Protein|0.8 g/kg/day protein intake
214401226|NCT04830514|OTHER|Habitual protein intake|1.0 g/kg/day protein intake
214401227|NCT04830514|OTHER|Optimal Protein Intake|1.5 g/kg/day protein intake
214401228|NCT01275053|DRUG|leptin|0.01mg/kg
214401229|NCT03393910|DIAGNOSTIC_TEST|Experimental Pelvic Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the standard group. In the Experimental group the pelvic exam will be done with external xam, bimanual exam then speculum exam."
214401230|NCT01924481|DIETARY_SUPPLEMENT|High Caffeine|
214401231|NCT01924481|DIETARY_SUPPLEMENT|Low caffeine|
214401232|NCT01924481|DIETARY_SUPPLEMENT|High theobromine|
214401233|NCT01924481|DIETARY_SUPPLEMENT|low theobromine|
214401234|NCT01924481|DIETARY_SUPPLEMENT|No theobromine|
214401235|NCT00201253|OTHER|Bronchoalveolar lavages and venipunctures only|
214401236|NCT05510401|OTHER|SECURIDRAP® SELFIA®|Use of SECURIDRAP® SELFIA® for 15 night
214401237|NCT00570661|DRUG|ITF2357|ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.
214401238|NCT06048796|OTHER|Early cessation of sedation and TTM|Early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate
214401239|NCT00131560|GENETIC|VRX496-Modified Autologous T cells|Genetic: Anti-HIV antisense
214401240|NCT04664335|OTHER|questionnaire|if no Reply to questionnaire, telephone interview
214401241|NCT01823120|OTHER|Supportive and interactive text messages|
214401242|NCT02500927|DRUG|ASP8273 Capsules|oral
214401243|NCT02500927|DRUG|ASP8273 Capsules A|oral
214401244|NCT01663675|GENETIC|karyotype|
214401245|NCT04672746|BEHAVIORAL|Brief MI interaction via instant communication|Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
214401246|NCT04672746|BEHAVIORAL|General health information|"Telephone peer counselling+referral to treatment if required+general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
214401247|NCT06201013|BEHAVIORAL|urotherapy|Participants were asked to undergo a 30-min session every 6 weeks at follow-up, including (1) education about the disease to dispel doubts about it and to understand the benefits of curing the dysfunction in order for the child to have a better therapeutic outcome, (2) urination at regular intervals and the establishment of good urination habits, (3) dietary instructions to avoid constipation, (4) accurate recording of symptoms of OAB, and (5) communication with the research team every 2 weeks.
214401248|NCT06201013|DRUG|Solifenacin Succinate|In addition to urotherapy, take Solifenacin succinate 5mg once daily, maximum dose 10 mg/day
214401249|NCT06201013|DRUG|Vitamin D3|In addition to urologic therapy, vitamin D drops containing 400 IU of vitamin D3 per capsule, 1,200 iu per oral dose, twice daily, for a total of 2,400 iu/d; serum vitamin D levels need to be rechecked at every 6-week follow-up visit
214401250|NCT05079880|DRUG|300 mg of caffeine citrate infusion|At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
214504359|NCT04440540|BEHAVIORAL|Conventional care (control)|receive routine care
215006003|NCT05324696|DEVICE|autoinflation device|The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.
215006004|NCT00776256|DIETARY_SUPPLEMENT|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
215006005|NCT06328088|DIETARY_SUPPLEMENT|Non vegetarian|Non vegetarian diet plus supportive treatment including lactulose and/or rifaximin
215006006|NCT00822471|BEHAVIORAL|Diabetes Self-Management Education|"DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor."
215006007|NCT04075149|DRUG|Spironolactone|Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if \> 60 kg, 100 mg twice daily.
215006008|NCT02698293|DRUG|Gliolan|orally, 40 mg/kg 4-6 hours prior to light application
215096142|NCT06544759|BEHAVIORAL|Aa educational Documentry|"The Gift of Life: Become an Organ Donor, Transform the Future! is an informative and captivating documentary that delves into the world of organ transplantation and the powerful implications of organ donation. This documentary aims to dispel common misconceptions about organ donation and shares a heartwarming real-life story that highlights the life-saving potential of organ transplants. Through its comprehensive exploration of the subject and engaging storytelling, the documentary not only educates but also inspires profoundly. The documentary challenges preconceptions and aims to cultivate a culture of empathy, generosity, and life-saving commitment through its meticulous examination of the topic. The documentary serves as a powerful tool to raise awareness about the importance of organ donation and its potential to make a positive change in the world."
215096143|NCT06303856|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
215096144|NCT04691908|BIOLOGICAL|QazCovid-in®-vaccine against COVID-19|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
215096145|NCT04691908|OTHER|Placebo|Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)
215096146|NCT05781646|DIAGNOSTIC_TEST|Xpert MTB/RIF|CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
215096147|NCT03914677|DRUG|Mecamylamine Oral Tablet|nicotinic antagonist (ganglionic blocker)
215096148|NCT04566146|OTHER|scapular muscle training, serratus anterior strength, scapular stabilization exercises|patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
215096149|NCT02383771|DRUG|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
215006009|NCT02698293|DRUG|Vitamin D3 cholecalciferol)|Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
215006010|NCT02698293|OTHER|Photodynamic Therpay|"Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter."
215006011|NCT02198352|DRUG|BIBN 4096 BS - in single rising doses|
215006012|NCT02198352|DRUG|Placebo|
215096150|NCT02383771|DRUG|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
215096151|NCT02383771|DRUG|Control|No Anti-platelet Therapy
215096152|NCT02383771|DRUG|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
215096153|NCT01601210|DRUG|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
215096154|NCT03664583|BEHAVIORAL|ACHRU-Community Partnership Program (CPP)|The intervention is a 6-month community navigation and self-management program for patients with diabetes and at least one additional chronic condition, and their caregivers, to improve health outcomes. The intervention will be provided by an interprofessional team of providers and consists of six core components.
215096155|NCT00381030|DRUG|carvedilol plus nurse management|
215096156|NCT02160444|BEHAVIORAL|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
215096157|NCT00651365|DRUG|JNJ-38877605|
215006013|NCT03808766|OTHER|embolization|Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.
214401251|NCT05079880|DRUG|Placebo|At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
214401252|NCT00925028|DRUG|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
214401253|NCT00925028|DRUG|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
214401254|NCT03248440|DRUG|SUN-131 1.5% TDS|SUN-131 1.5% TDS will be worn for 14 days
214401255|NCT03248440|DRUG|Placebo TDS|No active substance; Placebo TDS will be worn each day for 14 days
214401256|NCT04737174|DRUG|ES-481|28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
214401257|NCT01052662|DRUG|Memantine|30mg/day Memantine orally everyday for 12 weeks
214401258|NCT01052662|DRUG|Memantine|15 mg/day Memantine orally everyday for 12 weeks
214401259|NCT01052662|DRUG|Placebo|Placebo orally everyday for 12 weeks
214401260|NCT04558099|BEHAVIORAL|MBSR|Described previously
214401261|NCT00816140|DRUG|Cravit based triple therapy|"Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days"
214401262|NCT00816140|DRUG|Klaricid based triple therapy|"Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days"
214401263|NCT01148043|DRUG|Hydroxychloroquine|200 mg capsule, 2 capsules QD for 24 weeks.
214401264|NCT01148043|DRUG|cellulose|capsule, 2 capsules QD for 24 weeks
214401265|NCT00401817|DRUG|Bevacizumab|15 mg/kg on day 1 of each of 6 cycles
214401266|NCT00401817|DRUG|Rituximab|"Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.~The dose to be administered is:~Rituximab: 375 mg/m2"
214401267|NCT00401817|DRUG|CHOP|Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7
214401268|NCT02015663|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
214401269|NCT01113463|DRUG|TPI 287|Starting dose of 160 mg/m\^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
215006014|NCT03391895|OTHER|Home based exercise program|Program will include deep diaphragmatic breathing exercises, local expansion exercise on the collapsed areas in scoliosis concave sides with elastic exercise bands, dynamic lumber stabilization exercises for core stabilisation, strengthening of interscapular muscles with elastic bands and stretching exercises for lumbar extensor, hip flexor and hamstring muscles. Exercises will be applied 2 sets of 10 repetitions and once a day.
214401270|NCT00533247|DRUG|Celecoxib|
214401271|NCT01054911|DRUG|Sunitinib|All patients will receive sunitinib 37.5 mg p.o. daily for up to 12 weeks to be taken orally.
214401272|NCT01054911|PROCEDURE|Surgery|Following sunitinib therapy, patients will be evaluated for surgery. It is anticipated that the quality of response will allow for complete resection of residual tumor. Surgical resection, if eligible, will occur around week 14-16.
214401273|NCT00436787|DRUG|Fondaparinux Sodium|
215006015|NCT03391895|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure after assessment of respiratory muscle strength for each patient every week.
215006016|NCT01860989|DRUG|KAE609|KAE609 75mg single dose
215006017|NCT01860989|DRUG|KAE609|KAE609 150mg single dose
215006018|NCT01860989|DRUG|KAE609|KAE609 225mg single dose
214401274|NCT04531683|OTHER|electroacupuncture|same as described in experimental arm.
214401275|NCT04531683|OTHER|sham electroacupuncture|same as described in sham comparator.
214401276|NCT04531683|BEHAVIORAL|life style counselling|life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
214401277|NCT05562843|BIOLOGICAL|Autologous Cellular Therapy with PRP-PC|In this study, cells will be harvested from the patient from the peripheral blood, isolated and concentrated using centrifugation, then returned to the patient same day via the peripheral circulation.
214504360|NCT03672032|DEVICE|Fork-tip Needle|Fork-tip Needle will be used to obtain biopsy
214504361|NCT03672032|DEVICE|Franseen Needle|Franseen Needle will be used to obtain biopsy
215006019|NCT01860989|DRUG|KAE609|KAE609 300mg single dose
215006020|NCT00941343|DRUG|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
215006021|NCT02425085|PROCEDURE|multi-endodiathermy retinectomy|patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
215006022|NCT02425085|PROCEDURE|relaxing retinectomy|patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
215006023|NCT01512888|GENETIC|CL20-i4-EF1α-hγc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
215006024|NCT01512888|DRUG|Busulfan|Given intravenously (IV).
215006025|NCT01512888|DEVICE|CliniMacs|Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
215006026|NCT04023708|DRUG|CYD-TDV Dengue Vaccine|Pharmaceutical form:Solution Route of administration: Intramuscular
215006027|NCT04812158|OTHER|standard ankle physiotherapy or rehabilitation for chronic ankle instability|6 weeks of combined interventions of video aided mindful deep breathing and standard ankle physiotherapy in rehabilitating the chronic ankle instability for participants with chronic ankle instability
215006028|NCT02943213|DRUG|Chlorpromazine Hydrochloride|Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.
215006029|NCT03028441|OTHER|Placebo|Placebo
215096158|NCT02797496|OTHER|Asymmetric Motor Strengthening|"In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks."
215096159|NCT02797496|OTHER|Conventional therapy|Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
215096160|NCT03946085|DIETARY_SUPPLEMENT|Lumega-Z|A specially-formulated carotenoid supplement formula that utilizes a micronized, lipid-based liquid form of delivery.
215096161|NCT03946085|DIETARY_SUPPLEMENT|AREDS2|A commercially-available multivitamin soft gel formula.
215096162|NCT05658380|DRUG|atropine|patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
215096163|NCT05658380|DRUG|Isotonic saline|patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
215096164|NCT05161689|BEHAVIORAL|HUG-M+|A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
215096165|NCT05277428|DIETARY_SUPPLEMENT|GTB1|2 capsule/day
215096166|NCT05277428|DIETARY_SUPPLEMENT|Placebo|2 capsule/day
215096167|NCT00006455|DRUG|cyclophosphamide|
215096168|NCT00006455|DRUG|cytarabine|
214504362|NCT01080404|PROCEDURE|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
215096169|NCT00006455|DRUG|dexamethasone|
215096170|NCT00006455|DRUG|doxorubicin hydrochloride|
214504363|NCT01080404|DEVICE|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
214504364|NCT03170050|DEVICE|YYD701-2|HA Filler
214504365|NCT03170050|DEVICE|Restylane Perlane Lidocaine|HA Filler
214504366|NCT06285812|DEVICE|OtoSight Middle Ear Scope|Subjects will be evaluated with the OtoSight Middle Ear Scope
214504367|NCT00462072|DRUG|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
215006030|NCT03028441|BIOLOGICAL|VRC-CHKVLP059-00-VP|Measles-vectored Chikungunya vaccine
215006031|NCT00080262|DRUG|Ixabepilone|Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
215006032|NCT01762787|DRUG|Cantharidin solution|5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
215006033|NCT01762787|DRUG|Aspirin|300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
215006034|NCT01762787|DRUG|Prednisolone|30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
215006035|NCT01762787|DRUG|Placebo to aspirin|0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
215006036|NCT01762787|DRUG|Placebo to prednisolone|0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
215006037|NCT01481493|BIOLOGICAL|BT061|subcutaneous administration of the monoclonal antibody BT061
215006038|NCT01481493|BIOLOGICAL|Placebo|subcutaneous injection of placebo
215006039|NCT00003723|DRUG|gemcitabine hydrochloride|Gemcitabine 1000 mg/m\^2 days 1, 8 15 (q 28 days)
215006040|NCT04784689|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine
215006041|NCT04507321|DRUG|GSK3640254 Oral tablet|GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.
215096171|NCT00006455|DRUG|etoposide|
215096172|NCT00006455|DRUG|ifosfamide|
215096173|NCT00006455|DRUG|leucovorin calcium|
215096174|NCT00006455|DRUG|methotrexate|
215096175|NCT00006455|DRUG|therapeutic hydrocortisone|
215096176|NCT00006455|DRUG|vinblastine sulfate|
215096177|NCT05124171|BIOLOGICAL|BNT162b2|"ARM 1 receiving Pfizer-BioNTech vaccine~* Group 1.A: 18-64 years old~* Group 1.B: 65 years and older"
215096178|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|"ARM 2 receiving SP/GSK subunit D614 vaccine~* Group 2.A: 18-64 years old~* Group 2.B: 65 years and older"
215096179|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|"ARM 3 receiving SP/GSK subunit B.1.351 vaccine~* Group 3.A: 18-64 years old~* Group 3.B: 65 years and older"
215096180|NCT03649009|OTHER|Normal Saline|Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.
215006042|NCT04507321|DRUG|[14C]-GSK3640254 intravenous infusion|\[14C\]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.
215006043|NCT04507321|DRUG|[14C]-GSK3640254 powder|\[14C\]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.
215006044|NCT03561207|DIAGNOSTIC_TEST|EV3D Assay|The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.
215006045|NCT01685437|BIOLOGICAL|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
215006046|NCT03579537|OTHER|Intradyalisis without exercise programe|patients on hemodialysis are evaluated with all the variables at first (T1) and without intervening in the treatment for 3 months they are evaluated again (T2).
215006047|NCT03579537|OTHER|Intradyalisis with exercise programe|After 3 first month without intervention and also during the time of hemodialysis, the patients star the exercise programe, the first part of the session, an exercise was carried out for cardiovascular work (pedaling on ergometer) and muscle toning, with special attention to the muscular development of the lower limbs (exercises with elastic bands and / or weighted ankles). The session increased in duration and intensity as the physical action program progressed throughout the duration of the permitted period (3 months) and always attending to the individual needs of each subject. In addition, each of the participants will be given a series of recommendations of exercise practice to be carried out during non-hemodialysis days, in order to complement the work done during the sessions.3 month later the investigator evaluated all the variable again (T3)
215006048|NCT00523575|DIETARY_SUPPLEMENT|Cubitan|400 ml/d
215006049|NCT03965364|DEVICE|INCRAFT|Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
215096181|NCT03649009|DRUG|Thiamine|IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
215096182|NCT03649009|DRUG|Hydrocortisone|If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
215006050|NCT03399084|DRUG|Ferric carboxymaltose|750 mg/15 mL
215006051|NCT04581512|DRUG|EP0042|EP0042 Oral 20 mg 50 mg capsules
215096183|NCT03649009|OTHER|Metoclopramide|If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
215096184|NCT01702506|DRUG|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
215096185|NCT01702506|DRUG|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
215096186|NCT01702506|DRUG|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
215006052|NCT06121505|RADIATION|low-dose radiation therapy and stereotactic body radiation therapy|Patients will receive radiation therapy.
215096187|NCT03164330|BEHAVIORAL|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
215096188|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
214504368|NCT05199506|DEVICE|RAP|Treatment of cellulite with RAP device
214504369|NCT04190485|OTHER|Placebo|Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.
214504370|NCT04190485|OTHER|GMNL-143 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-143 probiotic toothpastes toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
215006053|NCT06121505|DRUG|chemotherapy|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
215006054|NCT06121505|DRUG|Sintilimab|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
214401278|NCT02319447|BEHAVIORAL|Additional education|"Our Intervention includes a 60-90 minute educational seminar, entitled Destination: Transplant, featuring live speakers, delivered to small groups of Black kidney transplant candidates and their family and friends. Topics include: 1) basic facts about Chronic Kidney Disease (CKD), transplant, and the waiting list; 2) the experience of receiving a LDKT transplant (by a Black LDKT recipient); 3) the experience of serving as a living kidney donor (by a Black living kidney donor); and 4) strategies to increase the chances of getting a transplant sooner. Participants receive monthly mailed, written information for 9 months and a follow-up phone call from a transplant educator, 3 months after attending the seminar."
214401279|NCT00280449|BEHAVIORAL|strengths-based case managed proactive service model|
214401280|NCT01356238|OTHER|MRC media|Culture media
214401281|NCT01356238|OTHER|Sydney IVF media|Culture media
214401282|NCT03293485|DRUG|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
215006055|NCT00174668|DRUG|Insulin Glulisine|insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
215006056|NCT00174668|DRUG|Insulin Therapy|NPH (70%) plus regular insulin or insulin aspart (30%)
215006057|NCT00174668|DRUG|Insulin Glargine|1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
215006058|NCT02957643|DRUG|Iron|oral treatment
215006059|NCT02399020|BEHAVIORAL|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
215006060|NCT04501692|PROCEDURE|VivaSight|see above
215006061|NCT04501692|PROCEDURE|Videolaryngoscopy|see above
215006062|NCT00709670|PROCEDURE|MSCT and stress echocardiography|tests MSCT and stress echocardiography
215006063|NCT01059851|DRUG|Suvorexant|single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast
215006064|NCT04992533|PROCEDURE|Long-duration tourniquet|Tourniquet is used in arthroscopic exploration and high tibial osteotomy
215006065|NCT04992533|PROCEDURE|Short-duration tourniquet|Tourniquet is only used for arthroscopic exploration
215006066|NCT03972228|COMBINATION_PRODUCT|Microdevice loaded with 19 chemotherapeutic agents|The microdevice containing 19 FDA-approved chemotherapeutic agents will be placed in the suspected tumor tissue at the time of surgical resection. Multiple chemotherapeutic agents will passively diffuse into local, confined regions (several microns) of the surrounding microenvironment. The agents are released at approximately one millionth of a systemic dose. The device(s) will be removed for analysis at the time of resection, which will be performed for clinical indications independent of enrollment in this study.
215006067|NCT04245163|BEHAVIORAL|Educational program|The intervention program will include 3 phases. At phase 1 a presentation on Microsoft PowerPoint in order to increase the general knowledge about glaucoma. At phase 2 a video and a one on one teaching to develop skills of administering the eye drops in a correct and systematic way. At phase 3, a discussion in order to identify cues to action that can easily be adopted by the patient in his/her daily routine, (such as, how to remember to put in drops) will take place.
215006068|NCT04142827|DEVICE|High Flow Humidification|myAirvo2 gives at home for long therapy treatment
215006069|NCT06476249|OTHER|without|without
215006070|NCT04483037|DRUG|Bowklean|assigned intervention
215006071|NCT01886560|DRUG|Doxycycline|Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
214401283|NCT01451060|DRUG|Metaraminol|It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
214401284|NCT01451060|DRUG|Ephedrine|It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
214401285|NCT06413615|DRUG|FDA022-BB05|Monoclonal antibody-drug conjugate for injection
214504371|NCT04190485|OTHER|GMNL-464 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-464 probiotic toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
214504372|NCT05847452|DRUG|Benralizumab|30mcg ever month for 3 months
214401286|NCT03789903|DIAGNOSTIC_TEST|amniotic fluid lactate|AF lactate
214401287|NCT03180411|BEHAVIORAL|Interview|"Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes."
215006072|NCT01886560|DRUG|Placebo|Tablets placebo one PO per day for 12 weeks
215006073|NCT04093076|DRUG|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
215006074|NCT04093076|DEVICE|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.
215006075|NCT04093076|DRUG|Placebo|Placebo will be administered ID on Day 0 and Week 4.
215006076|NCT05370482|DEVICE|Focal laser ablation|MRI-guided focal laser ablation for prostate cancer
215096189|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, \& waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); \& (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
214401288|NCT03180411|BEHAVIORAL|Questionnaire|Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
214401289|NCT04889781|DRUG|Dexamethasone injection|Compare the effect of dexamethasone injection on reducing post-op pain after impacted third molar Surgery
215096190|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
215096191|NCT03164330|BEHAVIORAL|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
214401290|NCT04889781|PROCEDURE|Piezosurgery|Compare the effect of Piezosurgery device use on reducing post-op pain after impacted third molar Surgery
214401291|NCT04889781|PROCEDURE|Conventional Rotatory instruments|Surgical extraction using conventional rotatory instruments to perform osteotomy
214401292|NCT05767138|BEHAVIORAL|HPV Vaccine Acceptance Survey|
215096192|NCT03164330|BEHAVIORAL|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
214401293|NCT02202590|DEVICE|SECM Capsule|Imaging of the esophagus using the SECM capsule and system
214401294|NCT05269511|DRUG|Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.|Oral administration, twice per day.
214401295|NCT04542447|DRUG|Nuvastatic|Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
214401296|NCT00813007|BEHAVIORAL|Questionnaires|5 Questionnaires at differing times before and after surgery.
214401297|NCT04724174|PROCEDURE|pancreaticogastrostomy|Pancreaticogastrostomy technique was performed according to the precise description of Addeo et al.
214401298|NCT04724174|PROCEDURE|pancreaticojejunostomy|Pancreaticojejunostomy technique was performed using the 5/0 polypropylene interrupted monofilament suture in a one-layered duct-to-mucosa end-to-side anastomosis (Cattell-Warren anastomosis).
214401299|NCT02885532|OTHER|University of California, San Diego Brief Assessment of Capacity to Consent Tool|Non-pregnant, English speaking patients older than 18 with evidence of acute alcohol intoxication were considered eligible for participation. Patients were asked to complete the 10 question tool on arrival to the emergency department. Patie
214401300|NCT00680693|BEHAVIORAL|Mindfulness training|8 weekly 2-hour classes
214401301|NCT00680693|BEHAVIORAL|Psycho-educational support group for women with IBS|8 weekly 2-hour meetings
214401302|NCT03894943|DIAGNOSTIC_TEST|PET/CT scan|Patient receive a PET/CT scan of their cerebrum and lumbar spine prior to surgery, 4-6 weeks after surgery and 6 months after surgery
214504373|NCT02384382|DRUG|Enzalutamide|
214504374|NCT03695549|PROCEDURE|CAF + (A-PRF)|advanced platelet rich fibrin prepared by low speed centrfugation concept(LSCC) together with coronally advanced flap .
214401303|NCT03894943|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Patients undergo a battery of quantitative sensory tests prior to surgery, 4-6 weeks after surgery and 6 months after surgery
214401304|NCT04273685|BEHAVIORAL|Cognitive remediation training, social recovery therapy|10 weeks cognitive remediation training plus social recovery therapy. One hour face to face contact time with intervention therapist per week. At-home cognitive remediation training completion.
214504375|NCT03695549|PROCEDURE|CAF+SCTG|cornally advanced flap plus subepithilial connective tissue graft harvested from the palate
214504376|NCT05036434|DRUG|Pembrolizumab / Lenvatinib|Pembrolizumab Plus Lenvatinib administration.
214401305|NCT04273685|OTHER|treatment as usual|10 weeks Treatment as usual non directive counselling One hour face to face contact time with intervention therapist per week.
214401306|NCT01580527|PROCEDURE|Total parenteral nutrition|Total parenteral nutrition in postoperative of pancreaticoduodenectomy
214401307|NCT01580527|PROCEDURE|Enteral nutrition|Early enteral nutrition in postoperative of pancreaticoduodenectomy
215006077|NCT06147154|OTHER|16S rRNA amplicon sequencing and untargeted metabolomics|"16S rRNA sequencing is a method for large-scale identification of community composition, expression abundance, and phylogenetic analysis by polymerase chain reaction (PCR) amplification of specific variable regions of 16S rRNA, combined with high-throughput sequencing and bioinformatics analysis. It also enables large-scale identification of the entire flora in a given habitat to study microbial diversity.~Untargeted metabolomics refers to the use of Liquid Chromatograph Mass Spectrometer (LC-MS), Gas Chromatograph Mass Spectrometer (GC-MS), and nuclear magnetic resonance (NMR) technology. The dynamic changes of small molecular metabolites in cells, tissues, organs or organisms before and after stimulation or disturbance were detected without bias. The differential metabolites were screened by bioinformatics analysis, and the pathway analysis of differential metabolites was performed to reveal the physiological mechanism of their changes."
215006078|NCT06177353|OTHER|Sampling|Blood sampling Skin biopsy Collection of soiled bandages
215006079|NCT03770455|DRUG|Avelumab|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
214401308|NCT04849728|DRUG|IVA337|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
215006080|NCT03770455|DRUG|2nd generation ADT (abiraterone or enzalutamide)|2nd generation ADT (abiraterone or enzalutamide)
215096193|NCT03853564|BEHAVIORAL|Video-Feedback Intervention|Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
215096194|NCT03853564|OTHER|Phone-Call Intervention|Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
215096195|NCT01555125|DRUG|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
215096196|NCT01555125|DRUG|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
215096197|NCT01555125|DRUG|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
215096198|NCT01067365|DRUG|Androxal|12.5 mg once daily
215096199|NCT01067365|DRUG|Androxal|25 mg once daily
215096200|NCT03346967|COMBINATION_PRODUCT|adipose-derived mesenchymal stem cells|Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
214401309|NCT04849728|DRUG|Placebo|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
214401310|NCT03905382|OTHER|Qualitative|Focus group and 1:1 telephone interviews
214401311|NCT00087490|DRUG|linezolid|
214401312|NCT00087490|DRUG|vancomycin|
214401313|NCT02034435|OTHER|Low Salt diet plus Placebo tablet|
214401314|NCT02034435|OTHER|Low Sodium diet plus Salt tablet|
214401315|NCT02034435|DRUG|Epleronone|50mg daily
214401316|NCT02034435|DRUG|Amlodipine|5mg daily
214401317|NCT03379233|COMBINATION_PRODUCT|Concept2 inhaler|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler
214401318|NCT03379233|COMBINATION_PRODUCT|Concept2 inhaler with patient application|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler with application used for monitoring
214522641|NCT06646068|OTHER|Philips 66 with CBL|Each team is given six minutes to brainstorm ideas or solutions to specific clinical cases. This technique is applied during case-based learning sessions to enhance clinical judgment and critical thinking skills among nursing students.
215006081|NCT02955082|DRUG|Carboplatin|Intravenous carboplatin infusion every 3 weeks.
214401319|NCT05495451|BEHAVIORAL|Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting|Multidisciplinary program will provide the teaching and supervision necessary to integrate the new knowledge and commitment to these lifestyle changes.
214401320|NCT03208556|BIOLOGICAL|iPD1 CD19 eCAR T cells|"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.~CAR T cell dose escalation: 1×10\^5 /kg，1×10\^6 /kg，3×10\^6 /kg，and 6×10\^6 CAR T cells/kg"
214401321|NCT03208556|DRUG|Fludarabine and cyclophosphamide|Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
215096201|NCT02651220|DRUG|Epiduo® Forte Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
215096202|NCT02651220|DRUG|Adapalene and Benzoyl Peroxide Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
215096203|NCT02651220|DRUG|placebo gel|vehicle used as placebo
215096204|NCT00909740|DRUG|MEGF0444A|Intravenous escalating dose
215096205|NCT00774982|DRUG|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
214401322|NCT04500743|DRUG|Dienogest|Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF
214401323|NCT04500743|DRUG|leuprorelin acetate|Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
214401324|NCT04651231|PROCEDURE|releasable sutures in punch trabeculectomy|punch trabeculectomy,scleral flap suturing
214401327|NCT04755868|DRUG|Talazoparib|The Arm A (Experimental arm) Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
214401328|NCT04755868|DRUG|Placebo|The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
215006082|NCT03735342|OTHER|Audio Recording|All participants will be provided with a re-playable audio recording of the discharge discussion on a portable electronic device. In addition, participants will have the option to record the discharge discussion on a personally-owned smartphone or receive access to the recording online, via the Open Recording Automated Logging System (ORALS).
215006083|NCT02475447|DRUG|Asimadoline|kappa-opioid receptor agonist
215006084|NCT02475447|DRUG|Placebo|placebo-matched control
215006085|NCT00645931|BEHAVIORAL|protein and calorie controlled diet and self-hypnotic relaxation|daily
215006086|NCT04510753|DEVICE|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform and blood pressure values.
215006087|NCT04510753|DEVICE|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
215006088|NCT04510753|DEVICE|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
215006089|NCT04880317|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|All enrolled patients will undergo a contrast-enhanced CMR examination for the assessment of extracellular volume
215006090|NCT04880317|DIAGNOSTIC_TEST|Additional CT acquisition|All enrolled patients will undergo an additional CT scan at 5 minutes post-contrast injection to evaluate myocardial relative enhancement
215006091|NCT04880317|DIAGNOSTIC_TEST|Blood tests|Patients will undergo blood tests to review hematocrit, Sars-CoV-2 antibody status and cardiac fibrosis biomarkers
215006092|NCT00223821|DRUG|Oxybutynin chloride, extended-release, individually-titrated|Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
215096206|NCT00774982|DRUG|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
215096207|NCT00800410|BEHAVIORAL|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
215096208|NCT04936347|PROCEDURE|cold knife|Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
215096209|NCT04936347|PROCEDURE|hot knife|Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
215096210|NCT05381285|OTHER|No intervention|Non-interventional study
215096211|NCT02795091|OTHER|manual cleaning|manual clean the rag and floor towel
215096212|NCT02795091|DEVICE|machine clean|machine clean the rag and floor towel
215096213|NCT03880344|DEVICE|Vibration Therapy|Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
215096214|NCT03880344|COMBINATION_PRODUCT|Physiotherapy|Physiotherapy as post-operative rehabilitation programme for 6 months.
215096215|NCT01530607|DRUG|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
215096216|NCT01530607|DRUG|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
214401329|NCT03131141|DRUG|BC-3781|Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
214401330|NCT02300311|DRUG|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
214401331|NCT02300311|DRUG|placebo matching nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
214401332|NCT02874846|DRUG|Netarsudil ophthalmic solution 0.02%|Once daily in both eyes (OU) in the evening (PM) for 7 days
214401333|NCT02874846|OTHER|Netarsudil Ophthalmic Solution Vehicle|Once daily in both eyes (OU) in the evening (PM) for 7 days
214401334|NCT00768599|DRUG|Econazole Nitrate Cream 1%|Topical cream, applied once daily for 4 weeks.
214401335|NCT00768599|DRUG|Econazole Nitrate Foam 1%|Topical foam, applied once daily for 4 weeks.
215006093|NCT00223821|BEHAVIORAL|Behavior Training|Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
215006094|NCT02629302|OTHER|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
215006095|NCT02629302|OTHER|standard therapy|standard physiotherapy, speech therapy and occupational therapy
215006096|NCT05414188|BEHAVIORAL|Pulmonary rehabilitation|Pulmonary rehabilitation runs for 60 minutes per session. The pulmonary rehabilitation program is based on a comprehensive approach, not simply providing regular exercise. And it includes patient education, active encouragement, and psychological support by investigators. Exercise is performed more than twice a week. Each session is performed for 60 minutes and includes breathing exercises, low to medium-intensity aerobic exercises, and muscle exercises under the guidance of a investigator. After radiation therapy is completed, investigators will recommend that patients perform pulmonary rehabilitation at home more than twice a week and for 60 minutes or more. The patients will record whether and when exercise is performed every day in the diary for pulmonary rehabilitation.
215096217|NCT03755908|DEVICE|Forced oscillation technique (FOT)|FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
215006097|NCT01801540|DIETARY_SUPPLEMENT|L-arabinose - effect on glucose metabolism|L-arabinose is mixed into the dough of the buns and cup cakes
215006098|NCT01578265|DRUG|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
215096218|NCT02420548|BEHAVIORAL|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
214401336|NCT00768599|DRUG|Vehicle Foam|Topical foam, applied once daily for 4 weeks.
214401337|NCT04042662|OTHER|no intervention|no intervention
214401338|NCT02381899|DRUG|Bendamustine and Rituximab|Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
214401339|NCT06012838|BEHAVIORAL|Cause classification of OHCA protocol|training program with cause classification of OHCA protocol
214401340|NCT03233165|PROCEDURE|Er:YAG laser|"Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.~Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute."
214401341|NCT03233165|PROCEDURE|Er,Cr:YSGG laser|Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
214401342|NCT02015195|OTHER|Acetic Acid (5%)|
214401343|NCT02015195|OTHER|Sodium Bicarbonate Slurry (50%)|
215006099|NCT01578265|DRUG|Ondansetron Hydrochloride|8 mg tablet once a day
215096219|NCT02420548|BEHAVIORAL|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
215096220|NCT01704703|DRUG|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
215096221|NCT01704703|DRUG|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
215096222|NCT02575703|DRUG|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi \[¹⁴C\]-LY3023414
215096223|NCT00158951|DEVICE|CONTAK RENEWAL 2/4/4HE CRT-D|
214401344|NCT02015195|OTHER|Papain Slurry (70%)|
214401345|NCT02015195|OTHER|Ammonia (10%)|
214401346|NCT02015195|DRUG|Lidocaine (4%)|
214401347|NCT02015195|OTHER|Isopropyl Alcohol (70%)|
214401348|NCT02015195|OTHER|Hot Tap Water (40 degrees Celsius)|
214401349|NCT02015195|OTHER|No treatment|
214401350|NCT04322487|DIAGNOSTIC_TEST|Lung ultrasound|A proposal of a standardized approach in order to optimize the use of lung ultrasound in COVID-19 patients. We focus on equipment, procedure, classification and data-sharing.
214401351|NCT03660072|OTHER|Non-Interventional|Non-Interventional
214401352|NCT01318811|DRUG|Dilute unfractionated heparin|Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
214401353|NCT01318811|DRUG|Standard concentration unfractionated heparin|Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
214401354|NCT05122754|DRUG|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.
214522642|NCT03452735|OTHER|Questionnaire about fertility|Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
215006100|NCT00193908|DRUG|Cavilon (TM) Durable Barrier Cream|Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
215006101|NCT00193908|DRUG|Sorbolene|Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
215006102|NCT00193908|RADIATION|Radiotherapy|Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
215006103|NCT02790177|DRUG|Hyaluronic Acid|
215006104|NCT02790177|DRUG|NORMAL SALINE|
215006105|NCT05486273|OTHER|interviews with coachs, semi-structured interviews and questionnaires|You will be offered 6 coaching sessions at a rate of one session per month and the first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12. Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
215006106|NCT05486273|OTHER|semi-structured interviews and questionnaires|The first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12.Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
215006107|NCT03065660|DRUG|Mifepristone, Oral, 200 Mg|The Investigational Medicinal Product (IMP) is a single dose of 200mg mifepristone to be taken orally after confirmation of missed miscarriage by pelvic ultrasound scan.
215006108|NCT03065660|DRUG|Placebo Oral Tablet|The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
215006109|NCT02602327|DRUG|Tas-102|Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
215096224|NCT00158951|DEVICE|EASYTRAK 2 Lead|
215096225|NCT04374058|OTHER|less-frequency hemodialysis|Patients of treatment group would be evaluated quarterly
215006110|NCT02602327|DEVICE|SIR-Sphere|20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
215006111|NCT03676829|DEVICE|Arterial Embolization of the Shoulder|Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
215006112|NCT04705584|DRUG|Prednisolone (as Acetate)|Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.
214401355|NCT05122754|DRUG|TDF-based triple ART regimen switching to B/F/TAF|Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.
214401356|NCT00209729|DRUG|Taxotere|X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
215006113|NCT04705584|DRUG|CycloSPORINE Ophthalmic Suspension|This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.
215096226|NCT00896441|DRUG|Citalopram|"Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI."
215096227|NCT01304589|DRUG|Milnacipran|6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose) for 12 weeks - total treatment period is 18 weeks
215096228|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
215006114|NCT04705584|DRUG|LTacrolimus Topical|This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.
215006115|NCT01753063|BEHAVIORAL|Patient Expectations|Baseline Expectations survey (parent/guardian and adolescents 12 and older)
215096229|NCT01633177|DRUG|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
215096230|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
215096231|NCT01633177|DRUG|Fish oil placebo|Fish oil placebo
215096232|NCT00244634|DRUG|candsartan cilexetil|
215096233|NCT01769820|DRUG|Dexamethasone|studies 1\&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
214401357|NCT00209729|DRUG|TS-1|Day 1-14, P.O. everyday
215006116|NCT01753063|BEHAVIORAL|Patient Expectations|3 month follow up survey (parent/guardian and adolescents 12 and older)
214401358|NCT03618303|DIAGNOSTIC_TEST|PET-MRI scan|Patients will undergo combined Positron Emission Tomography and Magnetic Resonance Imaging prior to a planned invasive angiogram (performed as standard of care). During the angiogram procedure, an additional imaging test (optical coherence tomography) will be performed.
214401359|NCT00811187|DRUG|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
214401360|NCT00811187|DRUG|Normal Saline|5cc Normal Saline injection in each paracervical region
214401361|NCT00131911|DRUG|sorafenib tosylate|400 mg given orally
214401362|NCT00329303|DRUG|Certolizumab Pegol (Cimzia®)|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use~* Dose and Administration details :~  2 x 1 mL Certolizumab Pegol at Week 0, followed by~* 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10~* 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10"
215006117|NCT04663516|OTHER|Exergaming|games provided by the console requiring the movement of upper body, lower body and trunk.
215006118|NCT03844737|DEVICE|VisuXL®|Treatment of discomfort forms of the ocular surface, in professional water-polo athletes exposed to pool water for prolonged periods.
215006119|NCT02777788|DRUG|JinFuKang|treated with chemotherapy
215006120|NCT02777788|DRUG|XingZaoRuanJian|treated with chemotherapy
215006121|NCT02777788|DRUG|pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin|
215006122|NCT02895737|DEVICE|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra|
215006123|NCT02895737|DEVICE|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems|
215006124|NCT02895737|DEVICE|TAVI: CoreValve® Evolut R™, CoreValve Medtronic|
215006125|NCT02895737|DEVICE|TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems|
215006126|NCT00207688|DRUG|Infliximab 5 mg/kg|Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
215006127|NCT00207688|DRUG|Infliximab 10 mg/kg|Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
215006128|NCT00207688|DRUG|Placebo|Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
215006129|NCT03463447|DEVICE|Electronic Dynamometer|Mensuration of the handgrip strength of each volunteer using an electronic dynamometer.
215006130|NCT03463447|DEVICE|Hydraulic dynamometer|Mensuration of the handgrip strength of each volunteer using a hydraulic dynamometer.
215006131|NCT04302597|PROCEDURE|Staples|Skin closure using surgical stapler.
215006132|NCT04302597|PROCEDURE|Tissue adhesive|Skin closure using 2-octylcyanoacrylate tissue adhesive.
215006133|NCT04146883|DRUG|Antibiotics|Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
215006134|NCT06298149|BEHAVIORAL|Turtle Island Tales|All participating families will receive a monthly lesson targeting a healthy behavior (increase fruit/vegetable intake, decrease added sugar intake, increase physical activity, decrease sedentary/screen time, promote healthy sleep, and promote emotional regulation) over the course of one year.
214401363|NCT02877953|BEHAVIORAL|the prevention of complications post-TIPS|Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.
215006135|NCT00562341|OTHER|Bariatric Surgery|one time lapb-band gastric bypass surgery
215006136|NCT02150005|PROCEDURE|Periodontal treatment|
215006137|NCT01039675|DRUG|500mcg/25mcg once daily|GSK573719/GW642444
215006138|NCT01039675|DRUG|Placebo once daily|Inactive, excipients only
215006139|NCT00153842|DRUG|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg"
215006140|NCT00153842|DRUG|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg"
215006141|NCT01990781|DRUG|LD: Lidocaine and dexamethasone|LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
215006142|NCT01990781|DRUG|L:Lidocaine|Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
215006143|NCT01990781|DRUG|D: Dexamethasone|D:intravenous dexamethasone 8 mg before induction of anesthesia
214401364|NCT00747279|OTHER|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
214401365|NCT00747279|DRUG|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
214401366|NCT04326985|BIOLOGICAL|Autologous Mesenchymal Stem Cells Treatment (MSCs)|The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.
214401367|NCT04326985|DRUG|Hyaluronic acid (HA)|The HA group patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.)
214401368|NCT05585762|OTHER|Ketone ester|75 mL chocolate flavored beverage containing 25 g of ketone ester. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
214504377|NCT04284085|OTHER|Psychoeducational intervention|Psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
214504378|NCT02447666|DRUG|Azacitidine|
215006144|NCT01990781|DRUG|N: Normal saline (placebo)|Normal saline: 2ml
215096234|NCT01769820|DRUG|placebo|
215006145|NCT03555929|DRUG|Dexamethasone|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
215006146|NCT03555929|DRUG|Normal saline|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
215006147|NCT05695391|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|LR769
215006148|NCT06389461|OTHER|4th Ventricular Compression Technique|"The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator joins hands in a cupping position, with the pads of the 1st fingers forming a triangle. The pads of the 1st fingers make contact with the spinous processes of the 2nd and 3rd cervical vertebrae. The thenar eminences make contact with the occipital squama, avoiding contact with the occipito-mastoid sutures during 5 minutes.~A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique."
215006149|NCT06389461|OTHER|"Sham Therapy"|"The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator places hands on the patient's shoulders during 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique."
215006150|NCT06867003|OTHER|physical therapy with bracing|"Strengthens the upper back muscles and reduces tension:~1. Stand or sit with an upright posture and shoulders pulled back~2. Squeeze your shoulder blades together as tightly as you can and hold for five to ten seconds"
215096235|NCT03189836|BIOLOGICAL|ACTR707|autologous T cell product
215096236|NCT03189836|BIOLOGICAL|rituximab|CD20-directed cytolytic antibody
215096237|NCT04858282|OTHER|mobile application (BC-SDM)|"The mobile application (BC-SDM)includes four functions to support SDM activity: Understanding breast cancer, Surgical approach, Choose the right breast cancer knowledge, and Let's make a decision for myself. Patients first read the information in Understanding breast cancer and Surgical approach to receive a tailored education in breast cancer"
214401369|NCT05585762|OTHER|Non-ketone placebo|75 mL chocolate flavored beverage containing 25 g of non-ketogenic fat. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
214401370|NCT01367587|DRUG|IV Methylnaltrexone|
214401371|NCT00526305|DRUG|Vincristine|1,5 mg/m2 i.v., days 1 and 8
214401372|NCT00526305|DRUG|Daunorubicin|60 mg/m2, i.v., days 1 and 8
215006151|NCT06867003|OTHER|physical therapy without bracing|"Strengthens the upper back muscles and reduces tension:~1. Stand or sit with an upright posture and shoulders pulled back~2. Squeeze your shoulder blades together as tightly as you can and hold for five to ten seconds"
215006152|NCT02845427|DEVICE|closed suction drain|using closed suction drain system postoperative
215006153|NCT02845427|PROCEDURE|no suction drain|the surgical wound will be closed with no suction drain
215006154|NCT06261242|DEVICE|Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)|The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
215006155|NCT06977633|BEHAVIORAL|Temporary Insulin Suspension|Participants will suspend insulin delivery from their personal insulin pumps for up to 3 hours. Insulin suspension is temporary and participant-driven under supervision.
215006156|NCT06977633|DEVICE|Glucose and ketone sensor|The participants wear a prototype continuous glucose-ketone monitoring (CGM-CKM) device using painless hydrogel microneedles for 4 hours.
215006157|NCT01171599|BEHAVIORAL|Fit4Life|As previously described, the purpose of this study is to develop a web and text message based weight loss intervention for childhood acute lymphoblastic leukemia survivors (ALL) survivor. The web and text message based intervention that is being developed will be evaluated in a separate ACS (American Cancer Society) funded trial randomized control trial. The web and text message based intervention (there are other intervention features that do not relate to the web \& text based platforms that were developed as part of this NIH funded study) is a 16-week program that includes:
215006158|NCT07037680|DRUG|Anlotinib|"For patients treated with conventional Intensity-Modulated Radiation Therapy (IMRT), the median prescribed dose was 60 Gy/30 fractions (range: 50.0-70.0 Gy, in 25-35 fractions) (median BED10 72 Gy, range: 60-84 Gy) to the planning target volume (PTV). As for patients with IMRT-based simultaneously integrated boost (SIB), the median prescribed dose was 59.92 Gy/28 fractions (range: 50.0-70.0 Gy, in 25-33 fractions) (median BED10 72.74 Gy, range: 60-84 Gy) to the planning gross tumor volume (PGTV), and 50.4 Gy/28 fractions (range: 45-59.4 Gy, in 25-33 fractions) (median BED10 59.47 Gy, range: 53.1-70.1 Gy) to the PTV. It should be noted that the PTV in the SIB group contains the PGTV.~Anlotinib was administered orally concurrently with the first day of radiotherapy, at a dose of 12 mg for a maximum of three cycles. Each cycle was defined as 2 weeks on-treatment followed by 1 week off-treatment. If intolerance occurs, the dose may be reduced to 8-10 mg/day or stopped."
215006159|NCT07043686|DRUG|Cerebrolysin treatment|The patients will receive Cerebrolysin treatment, 10 days consecutively, 30 ml/day, intravenous infusion diluted up to 100 ml of 0.9% saline in 15 minutes.
215006160|NCT07043686|OTHER|Standard treatment (including neurorehabilitation) of acute ischemic stroke|"Standard treatment entails acute ischemic stroke reperfusion treatment according to international guidelines and local policies, instituting secondary preventive treatment, a proper management of stroke risk factors and neurorehabilitation according to patient's needs: locomotor physiotherapy, occupation therapy, speech therapy, and neuropsychological assessment."
215006161|NCT07044830|DEVICE|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP)
215006162|NCT07046325|DRUG|dexametedomidine|1\. Group DB: are administered Ultrasound guided STB with bupivacaine and dexametidomedine.
215006163|NCT07046325|DRUG|Bupivacain|2\. Group B: are administered Ultrasound guided STB with bupivacaine.
215006164|NCT06728488|OTHER|PENG Block|The patients in the PENG block group will provide their consent. Standard monitoring will be applied. The patients will be positioned supine. After antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The linear ultrasound probe will be placed in the transverse plane over the AIIS. The position of the ultrasound probe will be verified by visualizing the iliopectineal eminence, iliopsoas muscle and tendon, femoral artery, and pectineus muscle. Using a Stimuplex® A 100 mm 20 gauge needle (Braun Melsungen AG, Melsungen, Germany) with the in-plane technique, the needle will be inserted laterally to medially into the space between the psoas tendon and the pubic ramus. Negative aspiration will be performed to ensure no blood is aspirated, and then 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be injected to perform the PENG block. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.
215006165|NCT06728488|OTHER|PENG block and pulse radiofrequency ablation|After obtaining consent, the patients in the PENG block and pulse radiofrequency ablation group will be brought into the operating room. Standard monitoring will be applied (ECG, SpO2, NIBP). The patients will be positioned supine. After performing the necessary aseptic and antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The Boston Scientific unified echogenic 10cmx10mmx20G (0.9mm) radiofrequency cannula will be advanced until it makes contact with the superior ramus near the iliopectineal eminence. Pulse radiofrequency ablation will be performed with two cycles of 90 seconds each, and after each cycle, the needle will be moved 2 mm medially. After pulse radiofrequency ablation, 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be applied. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.
215006166|NCT07051928|DIAGNOSTIC_TEST|c-FLIP expression on MDSC|Longitudinal c-FLIP expression on circulating MDSC
215006167|NCT06733376|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is a first-line intervention for the treatment of PTSD that focuses on changing unhelpful patterns of thinking.
215006168|NCT06733376|BEHAVIORAL|Prolonged Exposure|Prolonged Exposure is an evidence-based treatment for PTSD that helps to reduce the intensity of distress by gradually exposing participants to trauma-related memories, feelings, and situations in real life.
215006169|NCT06733376|BEHAVIORAL|Skills Training for Affective and Interpersonal Regulation|Skills Training for Affective and Interpersonal Regulation (STAIR) is a evidence-based treatment geared towards helping regulate emotional and interpersonal needs of those with PTSD.
214401373|NCT00526305|DRUG|Prednisone|60 mg/m2 day, i.v. or oral, days 1 to 14
214401374|NCT00526305|DRUG|L-Asparaginase|10.000 UI/m2, i.v., days 5-7 and 11-13. Total: 6 doses.
214401375|NCT00526305|DRUG|Mitoxantrone|12 mg/m2 i.v days 15, 16 and 17
214401376|NCT00526305|DRUG|Cytosine Arabinoside|1.500 mg/m2 /12 hours, days 16, 17 and 18 (total: 6 doses) If slow response to treatment: 3.000 mg/m2/12 hours, days 18, 19, 20 and 21 (8 doses)
214401377|NCT00526305|DRUG|Hydrocortisone|10 mg ,15 mg or 20 mg depending of age
214401378|NCT00526305|DRUG|Mercaptopurine|50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
215006170|NCT03033706|PROCEDURE|Pulse pressure variation guided fluid therapy|Pulse pressure variation obtained from invasive blood pressure waveform
214401379|NCT00526305|DRUG|Cyclophosphamide|600 mg/m2 day, i.v., days 1 to 15 in consolidation
214401380|NCT00526305|DRUG|Dexamethasone|10 mg/m2 day, oral or i.v. days 1-14 5 mg/m2 day, oral. or i.v., days 15-21
214401381|NCT05706662|PROCEDURE|inguinal hernia repair with mesh|inguinal hernia repair with mesh
214401382|NCT05415059|DEVICE|Covatech Stoma bag material|Strips of Covatech Stoma bag used to asses adhesion of 3M material to be used in LEAFix device
215096238|NCT03000036|DRUG|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
215096239|NCT03000036|DEVICE|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
215006171|NCT03033706|PROCEDURE|Traditional fluid therapy|4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
215006172|NCT03033706|PROCEDURE|Brain tumor excision|Brain tumor excision under general anesthesia
215006173|NCT01039441|PROCEDURE|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
215006174|NCT01039441|PROCEDURE|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
215006175|NCT01039441|PROCEDURE|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
215006176|NCT01039441|OTHER|normal saline|
215006177|NCT03157791|DRUG|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
215006178|NCT03780192|DEVICE|Inspiron Sirolimus Eluting Stent|Bifurcation treatment using provisional stent technique
215006179|NCT07125625|DIETARY_SUPPLEMENT|Experimental arm: probiotic|a dietary supplement containing L. Rhamnosus GG 1x1010 CFU plus L. Plantarum 299V. 1x1010 CFU
215006180|NCT07125625|DIETARY_SUPPLEMENT|Placebo|Placebo (maltodextrine)
215006181|NCT07125794|PROCEDURE|Original Denis Browne splint|Patients who were managed with the original Denis Browne splint.
215006182|NCT07125794|PROCEDURE|Modified Denis Browne splint|Patients who were managed with the modified Denis Browne splint.
215006183|NCT07124507|DIETARY_SUPPLEMENT|PICOZYME ET|The investigational product is a dietary supplement containing aldehyde dehydrogenase (ALDH), administered orally twice daily (one packet in the morning and one in the evening) for 3 months before meals.
215006184|NCT07122297|PROCEDURE|Retraction cord|"A thin cord (type 00) was soaked in 15% ferric sulfate ferric sulfate hemostatic solution and carefully packed into the gingival sulcus. After 3 minutes, the cord was removed and the sulcus was rinsed. This is a traditional mechanical gingival displacement method."
215006185|NCT07122297|PROCEDURE|Retraction paste in capsule form|A retraction paste was applied using a capsule tip placed around the gingival margin. The paste remained in place for 3 minutes and was then rinsed off with air-water spray. This is a non-traumatic chemical displacement technique.
215006186|NCT07122297|PROCEDURE|Retraction paste in injector form|Retractrion paste in injector form with compression cap (15% aluminum chloride) was injected into the sulcus, and a cotton compression cap was placed over the tooth. Patients gently bit on the cap for 3 minutes to apply pressure. Afterward, the paste and cap were removed and the area was rinsed. This method combines chemical and slight mechanical displacement.
215006187|NCT07122297|PROCEDURE|Diode Laser|A 810-nm diode laser with a 400-micron fiber optic tip was used in contact mode to ablate the sulcular epithelium. The laser was operated at 1.0 W with pulsed settings. The procedure was completed by wiping the area with saline to remove residues. This technique enables precise, bloodless gingival retraction with minimal trauma.
215006188|NCT07126041|OTHER|Prescription for Action (SPHERES Model)|"A system-level intervention consisting of:~* a digital dashboard displaying local health services, outcome indicators, and operational data in a secure Public Health Data Theater;~* structured monthly prescription guides targeting service improvements across three priority program areas;~* monthly performance monitoring with district health leaders. The intervention is applied at the PHC level, all supported by digital capacity building, district-level deployment of implementation teams, and intersectoral secure health data exchange."
214401383|NCT04179994|OTHER|Miswak extract-containing toothpaste|Miswak extract-containing toothpaste will be applied to the tooth diagnosed with DH
214401384|NCT04179994|OTHER|Potassium nitrates-containing toothpaste|Potassium nitrates-containing toothpaste will be applied to the tooth diagnosed with DH
214401385|NCT04179994|OTHER|Placebo|A toothpaste containing the same ingredients of the test toothpaste except for the active ingredient
214401386|NCT05549024|DRUG|68Ga-RM26-RGD|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
214401387|NCT05549024|DRUG|18F-FDG|18F-FDG injection
214401388|NCT05549024|DRUG|68Ga-RM26|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
214401389|NCT05549024|DRUG|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
214504379|NCT01030263|OTHER|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
214504380|NCT01030263|OTHER|Random four-quadrant biopsies.|Random four-quadrant biopsies.
214504381|NCT03338166|OTHER|LDH serum level|Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
214504382|NCT00630500|DRUG|Memantine|Tablets, 5 or 10 mg, twice daily
214401390|NCT02651402|BEHAVIORAL|FRIENDS for Life|Friends for Life (FRIENDS): FRIENDS, a GCBT program, is an effective program for the prevention and treatment of anxiety disorders in children evidenced by a meta-analysis on school-based interventions for at-risk and clinically anxious youth. FRIENDS was developed based on the view that anxiety is a tripartite construct involving physiological, cognitive, and behavioral components. Core Intervention components: Experts in CBT for childhood anxiety disorders have identified 5 essential components: psychoeducation, somatic management skills training, cognitive restructuring, exposure methods, and contingency management. The FRIENDS protocol consists of 10 weekly sessions and two booster sessions. We included the booster sessions in the regular protocol for a total of 12 sessions.
214401391|NCT02651402|BEHAVIORAL|Adapted FRIENDS|Adapted Friends (aFRIENDS): We conducted planned adaptations to the FRIENDS protocol based on our collective experience with the protocol and qualitative data (focus group and interviews). We followed procedures developed by Lee and colleagues, including surveying service providers and trainers regarding the appropriateness of FRIENDS for the target population. Changes were made to the language (idioms, metaphors, words), cultural fit (cultural values), methods (session length, number of sessions), activities (in-session practices), which resulted in additions and substitutions in these areas while maintaining the 5 essential components of the treatment. aFRIENDS is a briefer (8-session) and more engaging and culturally-sensitive protocol than FRIENDS.
214401392|NCT02651402|BEHAVIORAL|Train-the-Trainer|Train the Trainer (TT): agency supervisors are trained to conduct effective supervision (one initial training and 2 booster sessions), and then go on to train intervention therapists.
214401393|NCT02651402|BEHAVIORAL|Train-the-Trainer Plus|Train the Trainer Plus (TT+): a modified train-the-trainer approach by which supervisors receive training plus extended on-going consultation on conducting effective supervision with intervention therapists.
214401394|NCT06277128|DRUG|WS016 3g|Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.
214401395|NCT06277128|DRUG|WS016 6g|Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.
214401396|NCT06277128|DRUG|WS016 12g|Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.
215006189|NCT07124910|COMBINATION_PRODUCT|Epi-ON corneal cross-linking|"Corneal cross-linking involves the following steps:~* applying riboflavin (Vitamin B2 eye drops) to the eye, then~* exposing the eye to ultraviolet (UV-A) light"
215006190|NCT06400914|DEVICE|Lens A (ocufilcon D)|15 minutes of daily wear.
215006191|NCT06400914|DEVICE|Lens B (fanfilcon A)|15 minutes of daily wear.
215006192|NCT06941818|DRUG|HS-IT101 Injection|Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
215006193|NCT02591368|PROCEDURE|Ligament reconstruction tendon interposition|In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
215006194|NCT02591368|PROCEDURE|Suspensionplasty with one-suture construct|In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
215006195|NCT02591368|PROCEDURE|Suspensionplasty with two-suture construct|In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
215096240|NCT03000036|DRUG|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
215096241|NCT01447121|DEVICE|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
215096242|NCT01976143|DRUG|NKTR-102|
214401397|NCT06277128|DRUG|Matching Placebo|Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.
214401398|NCT04142125|DRUG|Rivaroxaban 2.5 Mg Oral Tablet bid|Pts will receive rivaroxaban + aspirin
214401399|NCT04142125|DRUG|Acetylsalicyclic acid 81 mg tablet qd|Pts will receive ASA
214401400|NCT01359410|DEVICE|Mesh reinforced staple line (SEAMGUARD)|Reinforce the pancreatic transaction with SEAMGUARD®
215096243|NCT00346229|BIOLOGICAL|filgrastim|
215096244|NCT00346229|BIOLOGICAL|pegfilgrastim|
215096245|NCT00346229|DRUG|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
215096246|NCT00346229|PROCEDURE|hyperthermia treatment|
215096247|NCT01922843|DRUG|DP001 softgel capsules|
215096248|NCT01922843|DRUG|Placebo|
215096249|NCT01257022|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
214401401|NCT01359410|DEVICE|Stapled without mesh reinforcement (PER-STRIPS DRY)|Stapled without mesh reinforcement (PERI-STRIPS DRY®)
214401402|NCT00374621|DRUG|Misoprostol with or without isosorbide mononitrate|Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
214504383|NCT00630500|DRUG|Placebo|Tablets corresponding to 5 or 10 mg, twice daily, 6 months
215096250|NCT04256252|DRUG|Rituximab|A scheduled therapeutic regimen with low-dose rituximab was performed.
215096251|NCT02545244|DIETARY_SUPPLEMENT|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
215096252|NCT02545244|DIETARY_SUPPLEMENT|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
214401403|NCT01697787|DRUG|Amodiaquine-Artesunate|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
214401404|NCT01697787|DRUG|Artemether-lumefantrine|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
214401405|NCT05590910|OTHER|Music|Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
214401406|NCT02848495|GENETIC|Non-Interventional|
215006196|NCT06947720|PROCEDURE|stenting|All individuals are anesthetized, with local or general anesthesia depending on the patient's level of cooperation. During the surgery, heparin must be injected intravenously to control the activated clotting time between 250-300 seconds. The surgery is performed via the femoral artery, and the choice of stent type and size, as well as any required equipment, are determined by the intervention personnel themselves.
215006197|NCT06954831|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
215006198|NCT06954831|RADIATION|Hypofractionated External Beam Radiation Therapy|Undergo UF-WBI with CB
215006199|NCT06954831|OTHER|Questionnaire Administration|Ancillary studies
215006200|NCT06954831|RADIATION|Radiation Boost|Undergo UF-WBI with CB
215006201|NCT06954831|RADIATION|Whole Breast Irradiation|Undergo UF-WBI with CB
215006206|NCT02831777|DEVICE|non-invasive blood pressure monitor|Equivalence of CareTaker blood pressure to classical sphygmomanometry
215006207|NCT01211171|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
215006208|NCT06933472|DRUG|AP301|Three times a day, administered orally with three meals at a daily dose level from 2.7g to 9.0g
214401407|NCT04427722|DEVICE|MPS-Flex Total Knee Joint Prostheses|Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.
214401408|NCT03232190|OTHER|Web Application|Parents receive a web application that offers information and support until the age of 2.
214401409|NCT04317170|OTHER|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia during their routine standard of care dermatologic procedure
214401410|NCT00994279|BEHAVIORAL|Yoga|Yoga sessions
214401411|NCT00994279|BEHAVIORAL|Education|Educational Wellness Group
214401412|NCT01649102|DEVICE|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:~* Palindroom~* Hemoglide Bard"
215006209|NCT06933472|DRUG|AP301 Low Dose|Three times a day, administered orally with three meals at a daily dose level from 0.075g to 0.25g
215006210|NCT06946966|OTHER|Reformer Pilates|Reformer Pilates
215006211|NCT06946966|OTHER|Pilates control|Pilates control
215006212|NCT06946966|OTHER|pilates online pilates|pilates online pilates
215006213|NCT07124559|DRUG|Rifapentine|Dispersible Tablet administered orally
215006214|NCT07124559|DRUG|Isoniazid|Dispersible Tablet administered orally
215006215|NCT07124559|DRUG|Dolutegravir|Tablets and Tablets for oral suspension administered orally
215006216|NCT07125560|BEHAVIORAL|MyBRUSH module|oral health education module that comprises of booklet for educational material, oral health talk, toothbrushing demonstration and return demonstration, and small group discussion
215006217|NCT07125560|BEHAVIORAL|BEGIN program|BEGIN program that comprise of toothbrushing demonstration and return demonstration
215006218|NCT07124247|DEVICE|Activity registration for one week with an activity monitor (MOX1)|"The participants will be equipped with the MOX activity monitor, which will be attached to the thigh. The device is waterproof, allowing participants to shower and swim, and does not require recharging during the study period.~The MOX will be attached on the same day as the BBS and Handgrip strength measurements, which will take place on a Friday. The following Monday, the 10mWT will be conducted, thus within the same week that the MOX is attached.~The MOX monitor will be worn for one week."
215006219|NCT06168812|DRUG|Glipizide|The therapeutic intervention in this study involves the sulfonylurea glipizide in ER formulation.
215006220|NCT07124845|OTHER|Focusing on the mind|8 times of multimedia cases videos and focused conversation
215006221|NCT07124754|DIAGNOSTIC_TEST|Multimodal Artificial Intelligence Diagnostic Model for Lymph Node Metastasis in T1 Gastric Cancer|"This intervention involves the use of a custom-built artificial intelligence (AI) diagnostic model that integrates multimodal data-including clinical variables, histopathological features, and imaging data-to predict lymph node metastasis in patients with T1-stage gastric cancer.~The model provides risk probability scores and classification outputs that assist physicians in diagnostic decision-making.~The AI system will be compared with physician performance at different levels of experience (resident, attending, senior) to assess its impact on diagnostic accuracy and clinical decision support."
215006222|NCT05642325|DRUG|Vamikibart|Participants will receive vamikibart IVT injection
215006223|NCT05642325|OTHER|Sham|Participants will receive a sham procedure that mimics an IVT injection.
215006224|NCT06519097|DRUG|Vitamin E Delta Tocotrienol|"Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration.~400 mg orally, twice daily"
215006225|NCT06519097|OTHER|Placebo|"Placebo contains no active ingredients.~465 mg pure olive oil orally, twice daily"
215006226|NCT06544694|DRUG|0.003% AR-15512|Ophthalmic solution administered via topical ocular instillation
214401413|NCT04121273|BIOLOGICAL|CAR-T cell immunotherapy|"Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows:~Dose 1: 1x10\^7/m2~Dose 2: 3x10\^7/m2~Dose 3: 1x10\^8/m2~The cell numbers are calculated according to CAR-positive T cells."
214401414|NCT05168969|OTHER|Questionnaire|The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
214401415|NCT01506921|DRUG|Racemic ketamine|0.6 mg/kg
214401416|NCT01506921|DRUG|S-ketamine|0.3 mg/kg
215006227|NCT06544694|OTHER|Artificial Tears|Commercially available, preservative-free lubricant eye drops
215096253|NCT02545244|DRUG|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
214401417|NCT05868499|BIOLOGICAL|EXG34217|Single infusion
214401418|NCT01616719|DEVICE|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
214401419|NCT01899209|PROCEDURE|STARR|
214401420|NCT01899209|PROCEDURE|Laparoscopic Ventral Rectopexy|
214401421|NCT00430378|PROCEDURE|Acupuncture|Acupuncture for 20 minutes before the radiation therapy session, 3 days a week for 7 weeks.
214401422|NCT00430378|OTHER|Standard Care|No Acupuncture.
214401423|NCT06193330|PROCEDURE|antibiotic-coated plate|A plate for fixing long bone fractures is coated with antibiotics cement prepared in theatre
214401424|NCT06193330|PROCEDURE|external fixator|external fixators are applied to participants with severe long bone fractures
215006228|NCT05155033|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV over approximately 30 minutes on Day 1 of cycles 1 and 2 during Courses 1 and 2.
215006229|NCT05155033|DRUG|Aldesleukin|Aldesleukin (IL-2) administration \[600,000 IU/kg IV bolus every 8 hours continuing for up to 4 days (maximum 10 doses)\] starting on Day 1 of cycles 1 and 2 during Course 1.
215006230|NCT03496636|PROCEDURE|Ovarian tissue transplant|Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
215006231|NCT04886791|PROCEDURE|Vaginal NOTES hysterectomy|Vaginal assited NOTES hysterectomy
215006232|NCT04886791|PROCEDURE|Vaginal hysterectomy|Vaginal hysterectomy
215006233|NCT03651609|PROCEDURE|Simple decompression of the ulnar nerve|Surgical release 2-3 cm distal to medial epicondyle with minimal-incision technique .
215006234|NCT03651609|BEHAVIORAL|Conservative treatment|Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
215006235|NCT04020263|DRUG|Levosimendan 2.5 MG/ML Injectable Solution|Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
215006236|NCT04020263|DRUG|Placebo|Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
215006237|NCT06164704|DRUG|Verekitug (UPB-101)|Verekitug (UPB-101) 0.5 mL of formulated solution (100 mg verekitug \[UPB-101\])
215006238|NCT06164704|DRUG|Placebo|Verekitug (UPB-101) matching placebo
215006239|NCT05508256|DEVICE|CE-marked Catheter Ablation|Once patients have been randomized to the catheter ablation (CA) group, the ablation procedure must be performed within 4 weeks. CA will initially aim at pulmonary vein isolation.
215006240|NCT06398691|DEVICE|Nazal CPAP|
215006241|NCT06398691|DEVICE|Heated humidified high-flow air support with nasal cannula|
215006242|NCT02896842|DRUG|Posology dose modification|
215006243|NCT02896842|OTHER|active comparator|
215006244|NCT05492240|OTHER|i-STRONGER|An 8RM is the dose necessary for most effective strength gains in community-dwelling older adults, and is equivalent to 80% of a one repetition max, which is the maximal load needed to voluntarily complete one repetition of a given exercise with proper form. Clinicians will tailor the intervention for each activity, so the patient achieves 8 repetitions with failure on the 9th repetition. Failure is the inability to complete a repetition through the full, available range of motion without significant compensation. Further, high-intensity dosing requires continuous, volitional effort from the patient; therefore, incorporation of motivational interviewing strategies across sessions will maximize patient effort and self-efficacy.
215006245|NCT05492240|OTHER|Usual Care|Usual Care SNFs will continue with routine collection and documentation of physical performance outcomes (gait speed, SPPB, Modified Barthel ADL Index) as standard practice. Furthermore, a combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Importantly, the Usual Care SNF including the facility, rehabilitation clinicians, and patients will not have access to i-STRONGER materials.
215006246|NCT05206331|DEVICE|contrast enhanced mammography|Dual-energy contrast images; low-energy CEM images will be obtained with a kilovoltage below 35 kVp while the high-energy images will be obtained with 45-49 kVp.The average glandular dose of the CEM procedure is approximately 2.44 mGy per view
215006247|NCT05206331|DRUG|Iodinated Contrast Media (ICM)|standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
215096254|NCT04294914|OTHER|Cold Pressor Test|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
215096255|NCT04294914|OTHER|Cold Pressor Test + Virtual Reality|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
214401425|NCT01716832|BEHAVIORAL|Mindfulness Walking|Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
214401426|NCT04833855|BIOLOGICAL|Tezepelumab Dose 1|Subcutaneous injection.
215096256|NCT03582696|BEHAVIORAL|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
214401427|NCT04833855|BIOLOGICAL|Tezepelumab Dose 2|Subcutaneous injection.
214401428|NCT04833855|BIOLOGICAL|Omalizumab|Subcutaneous injection.
215006248|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|2,5 mg twice daily (5 mg total daily dose)
215006249|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|5 mg twice daily (10 mg total daily dose)
215006250|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily (20 mg total daily dose)
215006251|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg twice daily (40 mg total daily dose)
215006252|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|30 mg twice daily (60 mg total daily dose)
214401429|NCT04833855|BIOLOGICAL|Placebo|Subcutaneous injection.
215006253|NCT00398905|DRUG|Enoxaparin|40 mg once daily (40 mg total daily dose)
214401430|NCT03852615|DIAGNOSTIC_TEST|Pre operation Blood sample for AMH|Blood sample for Anti Mullarian Hormone (AMH) analysis will be taken during preparation for surgery, while inserting vein line and taking the customary blood samples.
215006254|NCT04720833|DIETARY_SUPPLEMENT|dried plum|Dried plum
215006255|NCT04720833|DIETARY_SUPPLEMENT|Calcium and vitamin D|Calcium and vitamin D supplement
215096257|NCT05286216|BEHAVIORAL|effectiveness of education|"The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools."
214401431|NCT03852615|DIAGNOSTIC_TEST|3 month post operation blood sample for AMH|Additional blood sampling that will include a single tube containing 3 cc of blood for analysis of AMH will be taken three month from operation.
214401432|NCT03008122|OTHER|Placebo|Placebo
214401433|NCT03008122|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
214401434|NCT05953753|BEHAVIORAL|Food system and demand generation|The project is focused on improving egg consumption through enhanced availability, accessibility, and improved demand. To achieve this goal, the project intervention mix will work through three pathways: access, enabling environment, and demand. The access pathway aims to sustain availability and consumption of eggs by school children (age 6-9 years) from BoP households through interventions targeted at the Poultry Association of Nigeria (PAN) and state lead egg aggregators for the HGSFP. The enabling environment pathway focuses on the broader institutional, governance, and political factors to support accessibility, availability, improved consumption, and increased consumer demand for eggs. The demand pathway will be addressed by mass media and interpersonal communication to increase the willingness and motivation of parents/caregivers in BoP households to support and sustain egg consumption by pre-school children in Kaduna State.
214401435|NCT04338529|DRUG|Binosto 70Mg Effervescent Tablet|As discussed in group descriptions
214401436|NCT05569005|OTHER|THS use|Subjects who are not willing to quit smoking during the study duration will switch from cigarettes to using THS
214401437|NCT05569005|OTHER|Cigarette|Subjects who are not willing to quit smoking during the study duration will continue smoking their own preferred brand of commercially available cigarettes.
214401438|NCT05569005|OTHER|Smoking Abstinence|Subjects who are willing to quit smoking may be prescribed an NRT to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
214401439|NCT02065011|DRUG|Blood draw for the laboratory assessment|
214401440|NCT06493929|OTHER|Chest ultrasound|to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT.
214504384|NCT01455948|DEVICE|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
214504385|NCT01455948|PROCEDURE|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
214504386|NCT06263673|DRUG|Sitagliptin|100 mg once daily, oral
215006256|NCT04762589|DRUG|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
215006257|NCT04762589|DRUG|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
215006258|NCT01010100|DRUG|Acarbose (Glucobay, BAYG5421)|50 mg TID
215006259|NCT01010100|DRUG|Placebo|50 mg TID
215006260|NCT02466542|DRUG|Placebo group|Patients will receive regular general anesthesia
215006261|NCT02466542|DRUG|Esmolol group|Patients will receive regular general anesthesia plus esmolol infusion
215006262|NCT04664088|PROCEDURE|Acupuncture|"Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary."
215006263|NCT04664088|DRUG|Venlafaxine|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
215006264|NCT03128086|PROCEDURE|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
214401441|NCT06493929|OTHER|Calculation of Mechanical Power on the first day of intubation and before First trial of weaning:|"Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP)."
214401442|NCT05877560|DEVICE|Anodal-Transcranial Direct Current Stimulation|Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
214401443|NCT05877560|BEHAVIORAL|Office-Based Vergence/Accommodative Therapy|Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.
214401444|NCT05877560|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 20 minutes.
214401445|NCT06774248|BEHAVIORAL|Youth Opioid Recovery Support (YORS)|"The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to medication adherence in this vulnerable young adult population. The YORS intervention primary components are (as detailed below):~1. Low barrier access to MOUD, including home delivery, ride-share app transportation and mobile van delivery and low barrier access to MOUD in general~2. Engagement of families in collaborative treatment planning and monitoring with a focus on medication adherence~3. Assertive continuing care: actively tracking and communicating with youth and families by text and social media to promote engagement and adherence~4. Contingency management: to provide incentives for medication adherence"
214401446|NCT06494072|DRUG|Ampicillin for Injection|Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
214401447|NCT06494072|DRUG|Ceftriaxone for Injection|Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
214401448|NCT06494072|DRUG|Amoxicillin|Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
214401449|NCT06494072|DRUG|Ampicillin / Sulbactam Injection|Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
214401450|NCT06494072|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
214401451|NCT06494072|DRUG|Clindamycin|Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
214401452|NCT06494072|DRUG|Cefprozil|Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
214401453|NCT06494072|DRUG|Levofloxacin|Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
214401454|NCT05913778|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
214401455|NCT04883346|DRUG|Liraglutide|Liraglutide by subcutaneous injection administered daily. Dose will be initiated at 0.6mg per day and increased to a maximum of 3.0 mg per day as tolerated.
214401456|NCT04707716|OTHER|conometric concept Acuris system|implant crown retention type using friction only
215006265|NCT05420740|DEVICE|Aerobika OPEP|Subjects given Aerobika OEP to assess changes in small airway disease parameter , CAT Score , 6 minute walking test and exacerbation
214401457|NCT04707716|OTHER|screw retention|screw retained implant crown
215006266|NCT03310515|BEHAVIORAL|Risk reduction counseling|Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.
215006267|NCT03310515|OTHER|Social harm interview|Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.
215006268|NCT03310515|OTHER|Computer-Assisted Self Interviewing technique|Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.
215006269|NCT00780039|DRUG|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
215006270|NCT00780039|DRUG|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
215006271|NCT00134719|BIOLOGICAL|MenHibrix (Hib-MenCY-TT)|One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
215006272|NCT00134719|BIOLOGICAL|Infanrix® Penta|One intramuscular dose at 2, 4 and 6 months of age
215006273|NCT00134719|BIOLOGICAL|Prevenar®|One intramuscular dose at 2, 4 and 6 months of age
215006274|NCT00134719|BIOLOGICAL|ActHIB®|One intramuscular dose at 2, 4 and 6 months of age
215006275|NCT00134719|BIOLOGICAL|Meningitec®|One intramuscular dose at 2, 4 and 6 months of age
215006276|NCT00134719|BIOLOGICAL|M-M-R®II|One subcutaneous dose at 12-15 months of age
215006277|NCT00134719|BIOLOGICAL|Varivax®|One subcutaneous dose at 12 to 15 months of age
215006278|NCT00134719|BIOLOGICAL|PedvaxHIB®|One intramuscular dose at 12 to 15 months of age
215006279|NCT01765491|OTHER|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
214401458|NCT04707716|OTHER|cementation|cement retained implant crown
215006280|NCT01765491|OTHER|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
214401459|NCT05190549|PROCEDURE|CAV regimen bridging to HSCT|The enrolled patients will be firstly given CAV bridging regimen (cladribine 5mg/m2/ day for 5 days, cytarabine 20mg q12h for 10 days, and began at 100 mg on day 1 and increased stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, and 400 mg) on days 1-21. Conditioning regimen for allo-HSCT may be administrated after completion of the CAV regimen, with or without consolidation therapy.
214401460|NCT04712565|DEVICE|Astra Tech Implant System Profile EV|dental implant with a sloped neck configuration
214401461|NCT04712565|DEVICE|Astra Tech Implant System EV|dental implant with a conventional neck configuration
214401462|NCT04002479|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
215006281|NCT02214082|OTHER|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
215006282|NCT01331902|OTHER|Maximal Hyperemia with Adenosine Followed by Nicorandil|Firstly FFR was measured with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
215006283|NCT01331902|OTHER|Maximal Hyperemia with Nicorandil Followed by Adenosine|Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
215006284|NCT04866108|DRUG|fruquintinib plus capecitabine|oral fruquintinib plus capecitabine
215006285|NCT01203371|DRUG|Naftopidil|0,25 mg (2weeks) and 0,50 mg (10 weeks)
215006286|NCT01203371|DRUG|Tamsulosin|0,4 mg/day
215006287|NCT03439839|DRUG|iptacopan|iptacopan bid orally administered
215006288|NCT03439839|COMBINATION_PRODUCT|Standard of Care|Standard of Care (SoC) is defined as an antibody with anti C5 activity. At the time of study start, eculizumab was the only available SoC; eculizumab will be hereafter referred to as SoC.
215006289|NCT02355834|OTHER|IBD nurse intervention|Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
215006290|NCT06552026|DEVICE|repeated transcranial magnetic stimulation|repetitive transcranial magnetic stimulation by use of high-frequency (10 Hz) left-side DLPFC stimulation is currently widely used in the treatment of depression17.Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered with shorter duration of stimulation sessions and apparent efficacy at lower stimulation intensities18. Both 10 Hz and intermittent theta burst stimulation pulses have an excitatory effect on cortical excitability
214401463|NCT04529538|BIOLOGICAL|Novel Oral Polio Vaccine Type 1 (nOPV1)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
214401464|NCT04529538|BIOLOGICAL|Novel Oral Polio Vaccine Type 3 (nOPV3)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
214401465|NCT04529538|BIOLOGICAL|Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)|The Sabin mOPV1 control vaccine contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
214401466|NCT04529538|BIOLOGICAL|Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)|the Sabin mOPV3 control vaccine contains ≥ 10\^5.8 CCID50 per 0.1 mL (2 drops) dose.
214401467|NCT05317143|OTHER|Evaluation of prostate cancer margins|Evaluation of prostate cancer margins
214401468|NCT04599478|DRUG|Naltrexone and Bupropion medication|NB medication will be taken daily in pill form.
214401469|NCT04599478|BEHAVIORAL|Behavioral Weight Loss|Behavioral Weight Loss (BWL) counseling includes weekly sessions.
214401470|NCT04599478|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
214401471|NCT00204035|BEHAVIORAL|Evaluation (behavior)|TEACH is a precollege enrichment program for highschool students to encourage and promote these students towards careers in clinical research. To accomplish this, instruments designed to evaluate the knowledge, attitudes, and behaviors are administered during their participation in the TEACH program.
214401472|NCT05257590|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
214401473|NCT05257590|DRUG|CVM-1118|CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
214504387|NCT06263673|DRUG|Dapagliflozin|10 mg once daily, oral
215006291|NCT00461968|DRUG|Ezetimibe and Simvastatin|
215006292|NCT03247114|OTHER|Water|Water, 300 ml at room temperature
215006293|NCT03247114|OTHER|Glucose|Glucose, 50 grams in 300 ml water at room temperature
215006294|NCT03247114|OTHER|Fructose|Fructose, 50 grams in 300 ml water at room temperature
215006295|NCT03247114|OTHER|Sucrose|Sucrose, 50 grams in 300 ml water at room temperature
215006296|NCT03247114|OTHER|Sucralose|Sucralose, 0.33 grams in 300 ml water at room temperature
215006297|NCT00990288|DRUG|Hemostatic Matrix|FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
214401474|NCT05930756|PROCEDURE|Radiofrequency ablation|Genicular radiofrequency ablation uses thermal energy to percutaneously create lesions in neural tissues of the genicular nerves that innervate the anterior knee capsule and disrupt the conduction of pain signals.
215006298|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with contegra|Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.
215006299|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with pulmonary homograft|cryopreserved pulmonary homografts
215006300|NCT05037383|OTHER|Video recordings|The surgery of the patient will be recorded by cameras placed on the top of the displays used by the operating staff. The recordings will be only carried out while the patient is draped for the surgery, thus completely covered.
215096258|NCT01569230|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
215096259|NCT01569230|PROCEDURE|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
215006301|NCT05134818|OTHER|observer tool|comparison of the efficacy of an observer tool to enhance learning of technical skills of CVC insertion in anesthesiology residents The resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
215006302|NCT04663672|OTHER|Experimental Scent|Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
214401475|NCT06379893|DRUG|Voltaren Gel 1% (diclofenac sodium) (US only)|Participants in the US will use Volatren Gel containing 1% diclofenac sodium.
214401476|NCT06379893|DRUG|Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only)|Participants in the EU will use Volatren Gel containing 1.16% diclofenac diethylammonium.
214401477|NCT06379893|DRUG|Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only)|Participants in the EU will use Volatren Gel containing 2.32% diclofenac diethylammonium.
215096260|NCT01569230|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
215096261|NCT01569230|OTHER|Waiting|No interventions were applied to the patients in this group.
215096262|NCT02001337|OTHER|medical chart review|baseline, quarterly follow-up for 24 months
215096263|NCT02001337|OTHER|survey administration|baseline
215096264|NCT02001337|OTHER|Specimen collection|baseline
215006303|NCT04663672|OTHER|Control Scent|Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
215006304|NCT04663672|OTHER|No-Scent Control|Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
215006305|NCT04663672|BEHAVIORAL|In-Vivo Exposure|Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
215006306|NCT01000714|DRUG|Psirelax|
214504388|NCT06263673|DRUG|Placebo|Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.
215006307|NCT04529980|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (LGG) Probiotic|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
215006308|NCT04529980|DIETARY_SUPPLEMENT|Placebo|Placebo
215006309|NCT00611156|DIETARY_SUPPLEMENT|ginger|added to a brunch meal
215006310|NCT00611156|DIETARY_SUPPLEMENT|black pepper|Added to a brunch meal
215006311|NCT00611156|DIETARY_SUPPLEMENT|horseradish|Added to a brunch meal
215096265|NCT03256435|BEHAVIORAL|RAMP PrEP initiation, adherence, and retention intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
214401478|NCT00924989|DRUG|OSI-906|Administered orally
214401479|NCT00924989|OTHER|Placebo|Matching placebo administered orally
214401480|NCT06391034|DRUG|hyperpolarized pyruvate +/-urea (13C/15N)|Given IV
214504389|NCT00407888|DRUG|doxorubicin hydrochloride|Given IV
214504390|NCT00407888|DRUG|cyclophosphamide|Given orally
214504391|NCT00407888|BIOLOGICAL|filgrastim|Given SC
214504392|NCT00407888|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
214504393|NCT00407888|BIOLOGICAL|trastuzumab|Given IV
214504394|NCT00407888|OTHER|laboratory biomarker analysis|Correlative studies
214504395|NCT00407888|PROCEDURE|quality-of-life assessment|Ancillary studies
214504396|NCT02941692|DRUG|Oxytocin|
214504397|NCT02941692|DRUG|Placebo|Placebo for Oxytocin
214504398|NCT03187548|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste|Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
214504399|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2.5 grams
215006312|NCT00611156|DIETARY_SUPPLEMENT|mustard|Added to a brunch meal
214504400|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
215006313|NCT00611156|DIETARY_SUPPLEMENT|placebo|Added to a bruch meal
215006314|NCT00778414|DRUG|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|
215006315|NCT03712852|PROCEDURE|PRF+CAF treated patients|Patients will be treated by coronally advanced flap with addition of PRF membrane
215096266|NCT06089512|PROCEDURE|paravertebral block group|Paravertebral block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
215096267|NCT06089512|PROCEDURE|Mid point transverse process block group|Mid point transverse process block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
215006316|NCT03712852|PROCEDURE|SCTG+ CAF treated patients|Patients will be treated by coronally advanced flap with addition of SCTG graft
214401481|NCT06391034|RADIATION|Non-investigational Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy given outside of this study
214401482|NCT06391034|PROCEDURE|Radiotherapy (RT)|Radiation therapy given outside of this study
214401483|NCT06391034|PROCEDURE|Multi-parametric magnetic resonance imaging (mpMRI)|Imaging scan
214401484|NCT06391034|BIOLOGICAL|Non-interventional hormone therapy|Therapy given outside of this study as part of standard of care
214401485|NCT06391034|PROCEDURE|Prostate Biopsy|Biopsies may be taken from Trans-rectal ultrasound (TRUS) -visible lesion at the urologist's discretion
214401486|NCT05653310|DRUG|Tradipitant|Tradipitant Capsule
214401487|NCT05653310|DRUG|Placebo|Placebo Capsule
215006317|NCT03712852|PROCEDURE|CAF treated patients|Patients will be treated by coronally advanced flap
215006318|NCT04894188|RADIATION|radiation therapy|Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
215006319|NCT04894188|DRUG|Goserelin 3.6 MG|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
214401488|NCT05138536|PROCEDURE|Pan-Computer Tomography|trauma centers use the pan-computed tomography (CT) scan (head, neck, chest, and abdomen/pelvis) for the evaluation of blunt trauma.
214401489|NCT06301399|DRUG|Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy|Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.
214401490|NCT05649332|DEVICE|Argogen (silver zeolite powder)|The medical device will be self-administered by each patient twice daily without interruption for the duration of the study (4 weeks) or until complete healing. Application is carried out by spraying at short intervals, lightly pressing the dispenser button and directing the spray onto the area to be treated.
214401491|NCT05349136|OTHER|Synchronous telerehabilitation group|This group will receive Action Observation Treatment with a synchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under the supervision of a physiotherapist via videoconferencing.
214401492|NCT05349136|OTHER|Asynchronous telerehabilitation group|This group will receive Action Observation Treatment with an asynchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under parental supervision.
214401493|NCT05604235|OTHER|Therapeutic upper limb strength exercise treatment|A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. It will take approximately 30 minutes.
214401494|NCT05604235|OTHER|Treatment with passive and active mobilization of the upper limb.|A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulo-humeral complex and neurodynamics, where mobilizations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
214401495|NCT00995358|BIOLOGICAL|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
214401496|NCT02322775|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
214401497|NCT02322775|BIOLOGICAL|Placebo|Placebo administered subcutaneously every 4 weeks
214401498|NCT05711238|OTHER|Robotic rehabilitation|In robot-assisted therapy, the therapist selects different programs with personalized environments to train patients to strengthen limb muscles that have previously had difficulty with movements or are relatively weak. Active (individual finger movement, memory, motility, apple tree, target board, recycling bins, balloons, firefighter), auxiliary, and passive (cpm, cpm plus) treatment options are available in the system.
214401499|NCT05711238|OTHER|Conventional rehabilitation|Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.
215096268|NCT06089512|PROCEDURE|Control group|Only general anesthesia was applied to the patients.
215096269|NCT01132586|DRUG|Lenalidomide|Given PO
215096270|NCT01132586|DRUG|Cytarabine|Given IV
215096271|NCT01132586|DRUG|Idarubicin|Given IV
214504401|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
215006320|NCT04894188|PROCEDURE|radical prostatectomy|Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
215006321|NCT05225363|BIOLOGICAL|Chimeric Antigen Receptor T-cells|Receive TAG72-CAR T cells IP
215006322|NCT05225363|DRUG|Cyclophosphamide|Given IV
215006323|NCT05225363|DRUG|Fludarabine|Given IV
215096272|NCT01132586|OTHER|Pharmacological Study|Correlative studies
215096273|NCT01132586|OTHER|Laboratory Biomarker Analysis|Correlative studies
215096274|NCT00371982|DRUG|Fish oil (Maxepa)|
215096275|NCT06147583|OTHER|Simulation of an insulin pump failure|The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
215096276|NCT02243891|PROCEDURE|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
215096277|NCT02243891|PROCEDURE|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
214401500|NCT05413564|OTHER|optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months|optimized self-exclusion procedure A
214401501|NCT04725968|PROCEDURE|Urgent major general surgery|All geriatric patients (75 years and over) going under urgent major general surgery during 2018 in our centre
214401502|NCT01273532|DRUG|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
215006324|NCT05404061|OTHER|Gut hormones|"Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~1. 0.9% saline,~2. GLP-1"
215006325|NCT03549260|BIOLOGICAL|LIB003|LIB003 or placebo
214401503|NCT01273532|DRUG|tapentadol (CG5503) ER 50-mg TRF|100 mg TRF single oral dose
214401504|NCT01402258|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
214401505|NCT03656458|OTHER|Warm Up|10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise
214401506|NCT03656458|OTHER|Conventional Balance Training|"Internal Protuberances:~1. Looking up/Looking down/looking over the shoulder (Rt. /Lt.) 10 Reps Each~2. Looking behind over the shoulder (Rt. /Lt.)10 Reps~3. Looking Up with overhead Upper Limb Flexion. 5 Reps~4. Reaching out of Base of support (Rt. /Lt. / midline Cross) 10 Reps Each~5. Side to Side weight Shifting 10 Reps~6. Standing on toes/Heels 10 Reps each~External Protuberance:~1. Tuck forward/ Backward/ Sideways(Rt. /Lt.) 10 reps Each~2. Bosu Ball Training"
214401507|NCT03656458|OTHER|Biodex Balance Training|Biodex Balance Training Using Biodex Balance System SD
214401508|NCT02076867|BEHAVIORAL|Intensive Short-Term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
214401509|NCT02076867|BEHAVIORAL|Medical Care As Usual (MCAU)|This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
214401510|NCT05553158|DEVICE|Compression pants|Similar to compression stockings for the legs which are designed to apply pressure to improve venous return in the legs, compression pants have been designed to apply pressure to pelvic veins to improve the symptoms of Pelvic Congestion Syndrome.
214401511|NCT05553158|DEVICE|Embolization coils|Embolization coils are used to block the veins they are positioned in. This is a standard treatment offered to patients at The Whiteley Clinic.
214401512|NCT00135746|DRUG|nicotine transdermal system|
214401513|NCT00870025|BIOLOGICAL|human chorionic gonadotropin|200 IU, sc, every 5 days, 4 doses
214401514|NCT00870025|BIOLOGICAL|placebo|diluent, every 5 days, s.c., 4 doses
214401515|NCT05581797|OTHER|Psilocybin-assisted psychotherapy|8 sessions of interpersonal therapy and 2 doses of psilocybin
214401516|NCT05802550|OTHER|Ocular Surface Disease Index|Questionnaire on ocular surface disorders
214401517|NCT05802550|OTHER|Interferometry|Non-contact examination measuring NIBUT (non-invasive break-up time), meibography and tear meniscus measurement
215006326|NCT02636452|OTHER|cardiopulmonary exercise test|
214401518|NCT05802550|OTHER|Oxford score|Investigation and quantification of superficial corneal punctate keratitis using the Oxford score
214401519|NCT05802550|OTHER|Conjunctival collection|Two conjunctival prints: one for metabolomic and one for lipidomic
214401520|NCT05802550|OTHER|Aqueous humor collection|Collection of 0.1 mL of aqueous humor immediately after making the accessory corneal incision at the beginning of the cataract surgery.
214401521|NCT05802550|OTHER|Quantification of Tyndall and flare|Quantification of Tyndall and flare (from 1 to 4 crosses) in anterior chamber
214401522|NCT00796536|BEHAVIORAL|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
214504402|NCT00490789|DRUG|sirolimus|daily oral sirolimus with dosage individualised by trough blood levels
215006327|NCT02582632|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet
215006328|NCT02582632|DRUG|dasabuvir|Tablet
215006329|NCT03298061|DRUG|Mepolizumab|Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
215006330|NCT03298061|DRUG|Prednisolone|Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
214401523|NCT00796536|BEHAVIORAL|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
214401524|NCT02818075|OTHER|Mobile Phone Based Peer Support|Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
214401525|NCT02818075|OTHER|Usual Care|Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
214401526|NCT06145022|BEHAVIORAL|lifestyle modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and mind / body medicine. In this project, this program will be adapted to the specific needs of irritable bowel syndrome patients.
214401527|NCT06145022|BEHAVIORAL|waitlist control group|Participants in this group receive a one-time education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
214401528|NCT00971516|PROCEDURE|Implant placement|dental implant placement
214401529|NCT00971516|PROCEDURE|Implants surgery|dental implant surgery
214401530|NCT00831246|OTHER|chewing gum - Extra Winterfresh|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
214401531|NCT00831246|OTHER|Standard Post-Op Care|Patients are given standard post-op care with clear liquid diet as tolerated.
215006331|NCT00344825|DRUG|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
215006332|NCT05702268|DRUG|ICP-332|Tablet, 40 mg
215006333|NCT05702268|DRUG|ICP-332 Placebo|Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332.
215006334|NCT04488185|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg administered s.c. (2 single-use prefilled syringes of 150 mg/mL), on Days 1, 8, 15, 22, 29, 57, 85.
215006335|NCT04488185|OTHER|Placebo|Placebo administered s.c. (2 single-use prefilled 1 mL syringes) on Days 1, 8, 15, 22, 29, 57, 85.
215006336|NCT00899457|GENETIC|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
215006337|NCT00899457|OTHER|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
215006338|NCT00899457|OTHER|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
215006339|NCT00899457|PROCEDURE|bronchoscopy|Collection of breath condensate.
215006340|NCT02242006|OTHER|serial serum sampling for quantification of drug concentration|
214401532|NCT05185700|BEHAVIORAL|post covid 19 symtoms|observation
214401533|NCT00052559|BIOLOGICAL|bevacizumab|Given IV
214401534|NCT00052559|DRUG|fluorouracil|Given IV
214401535|NCT00052559|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
214522643|NCT02650661|BEHAVIORAL|Online health management program|"Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior."
215006341|NCT00705822|DRUG|Docetaxel + Estramustine + Hydrocortisone|"Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks"
214401536|NCT00052559|PROCEDURE|therapeutic conventional surgery|Undergo surgery
215006342|NCT00705822|DRUG|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
215006343|NCT04665232|DRUG|aqueous subcutaneous progesterone|25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.
215006344|NCT01956942|DEVICE|Micropulse Laser Trabeculoplasty|
215006345|NCT01956942|DEVICE|Selective Laser Trabeculoplasty|
215006346|NCT00209820|BEHAVIORAL|Supervised Nordic Walking|
215006347|NCT00209820|BEHAVIORAL|Unsupervised Nordic Walking|
215006348|NCT00209820|BEHAVIORAL|Advice to stay active|
215006349|NCT01407419|OTHER|Treatment Acceleration|"Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.~Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)"
215006350|NCT01407419|OTHER|Monthly Assessment|Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
215006351|NCT00992836|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
215006352|NCT00138294|BIOLOGICAL|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
215006353|NCT01724190|DRUG|Vitamin D|
215006354|NCT01724190|DRUG|Placebo|
214401537|NCT00052559|OTHER|laboratory biomarker analysis|Correlative studies
215096278|NCT02733965|OTHER|Pharmaceutical Consultations|"The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.~Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).~These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T"
214401538|NCT02663258|DRUG|Pembrolizumab|
214401539|NCT05823779|OTHER|Blood draw|We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR
214401540|NCT06089876|BEHAVIORAL|STRAVA mobile application|The adolescents in the intervention group will use the STRAVA mobile application for a period of 10 weeks. To do so, they will follow the instructions provided by the researchers on the frequency of use, the distance to be covered and how to record it.
215096279|NCT02733965|OTHER|No Pharmaceutical Consultations|
215006355|NCT02463877|PROCEDURE|Minimally-Invasive Procedure|Laparoscopy
215096280|NCT01870648|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
214401541|NCT01641861|DEVICE|Papacarie®|Papacarie® is chemo-mechanical method for caries removal
214401542|NCT01641861|PROCEDURE|Conventional method|caries removal by using rotary instrument.
214401543|NCT04858789|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This transdiagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase well-being by targeting cognitive and behavioral changes.
214401544|NCT03174964|DRUG|IVIg|Patients will take a dose of 400mg/kg of IVIg 2 days before ET.
214401545|NCT06031662|DEVICE|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting MT
214401546|NCT06031662|DEVICE|Sham Intermittent Theta-Burst Stimulation|Magventure Active/Placebo B70 coil specifically designed for randomized clinical trials with TMS. This system uses electrodes placed on the scalp to provide stimulation mimicking the active treatment condition
215006356|NCT01864694|BEHAVIORAL|TLC-Diet|Participants receive diet intervention through an automated telephone system
215006357|NCT01864694|BEHAVIORAL|WEB-Diet|Participants receive diet intervention through a web-based system
215006358|NCT01864694|OTHER|Assessment-only control|Assessment-only control
215006359|NCT05639868|OTHER|Video-assisted CPR|Participants in V-CPR group get video-based (vocal and visual) instructions from the dispatcher.
215006360|NCT05639868|OTHER|Telephone-assisted CPR|Participants in T-CPR group get voice-based (vocal) instructions from the dispatcher.
215006361|NCT05830630|DRUG|Bupivacaine methylene blue|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
215006362|NCT05830630|DRUG|bupivacaine saline|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
215096281|NCT01870648|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
215096282|NCT06464419|DEVICE|ultrasound|Measurement of optic nerve sheath diameter by ultrasound
214401547|NCT04125017|DEVICE|ICSI with laser pulse|Using laser pulse before ICSI
214401548|NCT04125017|DEVICE|ICSI with micro needle technique|Using micro needle technique before ICSI
214401549|NCT04248075|DEVICE|Electroencephalogram|Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.
214401550|NCT02914106|OTHER|Observational Study|Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
215006363|NCT04694638|OTHER|Body position change|combined use of prone positioning and high-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) can reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.
214401551|NCT05162768|DRUG|Elamipretide|60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks
214401552|NCT05162768|DRUG|Placebo|Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks
214401553|NCT05002361|DRUG|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
214401554|NCT05002361|DRUG|Isotonic saline|6 ml of isotonic saline
214401555|NCT03230929|DEVICE|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and adheres the neuromuscular monitoring device on the medial side of the wrist and the ipsilateral thumb to continuously monitor the state of consciousness and muscle relaxation before, during and after surgery. Reversal of muscle relaxant could be performed by intravenous injection of sugammadex 4 mg/ kg in the case of deep neuromuscular relaxation, and 2 mg / kg in the case of shallow muscle relaxation degree under neuromuscular monitoring. After then, they monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring in 1 minute increments for 5 minutes.
214401556|NCT05168865|DRUG|Letrozole 2.5mg|Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
214401557|NCT02173353|DEVICE|Ultrasound|Ultrasound to be done just before standard radiation therapy treatment
214401558|NCT06697470|DEVICE|Ultrasound and Bioelectrical Impedance Analysis for Muscle Thickness and Fluid Balance Assessment Translation|This intervention involves the use of ultrasound and bioelectrical impedance analysis (BIA) to monitor changes in muscle thickness and assess fluid balance in critically ill patients. Measurements will be taken daily during the patients' ICU stay, with a focus on rectus femoris, tibialis anterior, and biceps brachii muscles, as well as total body fluid compartments. The study aims to explore correlations between muscle thickness variations, fluid balance, and patient outcomes.
214401559|NCT06919549|PROCEDURE|mini anchor|arthroscopic repair of triangular fibrocartilage complex tears using mini anchor
215006364|NCT01643187|DIETARY_SUPPLEMENT|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
215006365|NCT01643187|DIETARY_SUPPLEMENT|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
214401560|NCT06918769|DIAGNOSTIC_TEST|Sysmex UF-5000 system|Provide real time bacterial count in urine samples and Gram-staining results. High bacterial count suggests likelihood of active UTI and indicated for antibiotics treatment; while low bacterial count suggests UTI not likely.
214401561|NCT06918769|DRUG|Empirical antibiotics|Empirical antibiotics per local guideline/ investigator's discretion for urinary tract infection
214401562|NCT06919978|BEHAVIORAL|The Position to Prevent Pleural Irritation (PPPI)|The Position to Prevent Pleural Irritation (PPPI) was administered once before sleep on the first night of the day the participant arrived at the clinic.
214401563|NCT02239653|BEHAVIORAL|Physician communication|
214401564|NCT05904106|DRUG|Venetoclax plus Azacitidine|"Induction cycle 1:~100 mg venetoclax p.o. on day 1; 200 mg venetoclax p.o. on day 2; 400 mg venetoclax p.o. on days 3-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Induction cycles 2-3:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Postremission cycles 1-9:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7"
215006366|NCT02557789|DRUG|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
215096283|NCT02342080|OTHER|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
215096284|NCT02342080|DEVICE|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
214401565|NCT05904106|DRUG|standard of care chemotherapy plus gemtuzumab ozogamicin|"Induction cycle 1:~200 mg/m\^2 cytarabine cont inf i.v. on days 1-7; 60 mg/m\^2 daunorubicin i.v. on days 3-5; 3 mg/m\^2 (max 1 vial) gemtuzumab ozogamicin i.v. on days 1+4+7~Induction cycle 2 (patients not in remission, moderate or non-responders):~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3; 10 mg/m\^2 mitoxantrone i.v. on days 3-5~Postremission cycles 1-3:~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3"
214401566|NCT05567952|DRUG|nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
214401567|NCT05567952|DRUG|ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
214401568|NCT05567952|DRUG|placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
214401569|NCT03299374|OTHER|Pilates Intervention|Intervention based on Pilates principles
214401570|NCT03299374|OTHER|Fall prevention intervention|Intervention based on principles to prevent falls
215006367|NCT05474209|OTHER|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes"|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months"
214401571|NCT00777803|DRUG|NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))|NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
214401572|NCT00777803|DRUG|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
214401573|NCT04680910|DRUG|Propofol|Targeted propofol infusion in TRD patients will induce sedation with maximal expression of EEG slow waves and minimal burst suppression.
214401574|NCT04680910|DIAGNOSTIC_TEST|Electroencephalography (EEG)|EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
214401575|NCT04680910|DIAGNOSTIC_TEST|Slow-Wave Activity|Duration of slow waves during sedation will be evaluated using automated approaches. SWA during sedation will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes. SWA during N2/N3 sleep will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes in the N2 and N3 sleep stages. Delta sleep ratio will be computed from the SWA measured during the first and second N2/N3 cycles.
214401576|NCT04707794|DRUG|Sevoflurane|Sevoflurane delivery will will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
214401577|NCT04707794|DRUG|Desflurane|Desflurane delivery will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
215096285|NCT03068208|PROCEDURE|Methylene blue-mediated photodynamic therapy|The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
214504403|NCT05654285|OTHER|Cola beverage with aspartame and acesulfame K|"Before starting the study: Subjects were asked to avoid non-nutritive sweetener consumption for 48 hours prior to the study sessions. A standardized menu of 346 Kcal was prescribed for dinner and fasting for at least 8 hours prior to each study session. A 7-day washout period was left between each study session.~Session 1: Weight, height, and waist circumference were measured, the BMI was calculated, and sociodemographic data of the participants and information on the habitual consumption of soft drinks were collected.~In each session: The beverages were offered at approximately 4°C, in standardized disposable cups, and the participants were asked to drink them in a maximum time of 10 minutes. Heart rate, respiratory rate, and blood pressure were measured before the intervention and every 30 minutes during the observation period. The subjects who manifested adverse sensations were referred to receive medical attention and withdrawn from the session."
215006368|NCT02786667|DRUG|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
215006369|NCT02786667|DRUG|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
215006370|NCT05552131|DEVICE|T-wave coronary lithotripsy catheter system|Subjects who plan to receive possible interventional therapy meet all admission criteria and do not meet any exclusion criteria, and enter the screening stage of this clinical trial after signing informed consent. All subjects who sign the informed consent will be provided with a unique subject screening number. All subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled and lumen pretreated with a coronary shock catheter system followed by the implantation of drug-eluting stents.
215006371|NCT00739570|DEVICE|AAI signature IV AMCT|Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
215096286|NCT00279812|DIETARY_SUPPLEMENT|50ug selenium enriched yeast|Selenomethionine supplement (50ug/d Se) for 12 weeks
215096287|NCT00279812|DIETARY_SUPPLEMENT|100ug selenium enriched yeast|Selenomethionine supplement (100ug/d Se) for 12 weeks
215096288|NCT00279812|DIETARY_SUPPLEMENT|200ug selenium enriched yeast|Selenomethionine supplement (200ug/d Se) for 12 weeks
215006372|NCT01617967|DRUG|Patisiran|Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks \[Q3W\]: Day 0 and Day 21) and an alternative premedication regimen.
215006373|NCT05703776|BEHAVIORAL|Nordic Walking|Nordic Walking (NW) is an aerobic physical activity where regular walking is enhanced by the addition of the active use of specifically designed NW poles. The physical strain is distributed in a balanced way to various muscle groups of the whole body.
215096289|NCT00279812|DIETARY_SUPPLEMENT|Control onion|3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
215096290|NCT00279812|DIETARY_SUPPLEMENT|Enriched onion|3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
215096291|NCT00279812|OTHER|Placebo|Placebo supplement for 12 weeks
215096292|NCT05856097|OTHER|kinesio taping with diaphragmatic breathing|.kinesio tape was applied on1st day of intervention with the 20 minutes session of diaphragmatic breathing 3 sessions were given
215096293|NCT05856097|OTHER|kinesio taping without diaphragmatic breathing|kinesio tape was applied day 1st of intervention. 3 sessions were given
215096294|NCT03100110|DEVICE|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
215096295|NCT01274429|DRUG|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
215096296|NCT05350189|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|At discretion of attending physician
214401578|NCT06287450|BIOLOGICAL|Bivalent RSV Vaccine (IN006)|Formulation for injection
214401579|NCT06287450|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214401580|NCT05139160|DIETARY_SUPPLEMENT|Protein quality|the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
214401581|NCT06158347|DEVICE|hyperbaric oxygen chamber|Hyperbaric oxygen therapy allows patients to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied by gradually increasing the barometric pressure from normal pressure to 1.5 atmospheres absolute (ATA).
214401582|NCT03549806|DIAGNOSTIC_TEST|No Intervention. Test is computer algorithm.|Diagnostic algorithms (test) will be run on already acquired clinical data. No study intervention in operator-prescribed clinical ablation. Predictive accuracy of test for study outcome will then be determined in follow-up
214401583|NCT03282019|DEVICE|High-flow nasal cannula therapy|Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
214401584|NCT03282019|DEVICE|Home oxygen therapy (HOT)|All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
214401585|NCT05468567|DIAGNOSTIC_TEST|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHEAR protocol).
214401586|NCT05468567|DIAGNOSTIC_TEST|French Matrix Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
214401587|NCT05468567|BEHAVIORAL|SSQ15 questionnaire of life : (The Speech, Spatial and Other Qualities of Hearing Scale)|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
214401588|NCT06042127|PROCEDURE|POEM-F|POEM-F would be performed as described in the arms section
214401589|NCT06042127|PROCEDURE|Conventional POEM|Anterior POEM performed as described in the arms section
214401590|NCT04230694|DEVICE|Dexcom Generation 6 CGM (Dexcom Gen6) device|Standing orders for blood sugars less than 100 will allow for administration of glucose replacement in the intervention group based on Dexcom Gen6 readings.
214401591|NCT03381794|PROCEDURE|Corneal transplantation|PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
214401592|NCT06320366|DEVICE|Sham TMS|The TMS Cool-B65 A/P coil on its placebo side delivers electrical stimulation to the scalp (e.g., mimicking sensations associated with real stimulation) but does not provide magnetic stimulation to the targeted cortical structure.
215006374|NCT04764539|BEHAVIORAL|Video Assisted Speech Therapy (VAST)|Six children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the VR-integrated and the tablet-based VAST application. Three subjects received a 3D VR-integrated, bone conduction VAST prototype, while the remaining group of three received a tablet with a 2D version of the software. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).
215006375|NCT00005585|DRUG|cyclophosphamide|Given IV
215006376|NCT00005585|DRUG|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
214401593|NCT06320366|DEVICE|Active TMS|The TMS Cool-B65 A/P coil delivers magnetic stimulation to targeted cortical structure.
214401594|NCT02697799|BEHAVIORAL|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
214401595|NCT02697799|BEHAVIORAL|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
214504404|NCT05654285|OTHER|Cola beverage with sucrose and stevia|
215006377|NCT00005585|DRUG|daunorubicin hydrochloride|Given IV
215006378|NCT00005585|DRUG|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
214504405|NCT03049332|BEHAVIORAL|self- and family-management intervention sessions|The self- and family management intervention will have six elements: (a) biofeedback for relaxation; (b) family support; (c) coping skills; (d) anxiety, stress, and depression management; (e) cognitive-behavioral management skills; and (f) psycho-educational classes.
214504406|NCT05939505|OTHER|Su Jok therapy|Sujok therapy will be applied with Mexican bean seeds 14 times with an interval of one day.
214504407|NCT05939505|OTHER|placebo|Instead of the Mexican bean seed applied in sujok therapy, plastic beans will be applied 14 times with an interval of one day.
214504408|NCT05939505|OTHER|routine interventions|routine applications in the hemodialysis unit
214504409|NCT02865785|DRUG|Intralipid 20%|intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
214504410|NCT02865785|DRUG|Placebo|saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
214504411|NCT01607320|DRUG|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
215006379|NCT00005585|DRUG|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
215006380|NCT00005585|DRUG|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
215006381|NCT00005585|DRUG|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
215006382|NCT00005585|DRUG|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
215006383|NCT00005585|DRUG|thioguanine|Given orally
215006384|NCT00005585|DRUG|vincristine sulfate|Given IV
215006385|NCT00977184|PROCEDURE|50 HZ Repetitive TMS|
214401596|NCT05931198|OTHER|Modified illusion of the rubber (syncrhone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis at the same time (synchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
215006386|NCT00977184|PROCEDURE|Sham rTMS|
215006387|NCT05434676|DEVICE|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 & S4|To assess the safety and effectiveness of IVL treatment used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries
215096297|NCT00005834|BIOLOGICAL|filgrastim|Arms 1 and 2: 300 mcg (pts \</= 60 kg) or 480 mcg (pts \> 60 kg), SC beginning day 5
215096298|NCT00005834|DRUG|cisplatin|Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
215096299|NCT00005834|DRUG|cyclophosphamide|Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
215096300|NCT00005834|DRUG|dexamethasone|Arms 1 and 2: 40 mg/d PO days 1-4
215096301|NCT00005834|DRUG|etoposide|Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
214401597|NCT05931198|OTHER|Modified illusion of the rubber (asynchrone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis not at the same time (asynchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
214401598|NCT05474664|DRUG|Camostat mesylate|"1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day~2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day"
214401599|NCT04569708|OTHER|Auditory stimulation|Quiet auditory stimulation timed with sleep physiology
215096302|NCT00005834|DRUG|thalidomide|Arm 2: 800 mg/d (max dose) PO daily
214401600|NCT05610410|OTHER|Laser speckle contrast analysis|Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
214401601|NCT06068738|OTHER|Biological sample collection|Collection of ascites, blood and fresh tumour tissues (if available)
214401602|NCT05417204|BEHAVIORAL|Abdominothoracic biofeedback|A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.
214504412|NCT01607320|DRUG|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
214504413|NCT02792738|BEHAVIORAL|hypnosis|
214504414|NCT03784898|OTHER|Blood draw for future biomarker analysis|Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
215006388|NCT04763720|BEHAVIORAL|Dyadic Developmental Psychotherapy|DDP involves approximately twenty sessions with the family, conducted by a trained DDP therapist. DDP is developed to treat trauma-related and attachment difficulties. DDP is not a manualized treatment but involves using a set of core communication techniques (termed PACE; Playfulness, Acceptance, Curiosity and Empathy).
215096303|NCT06136130|DEVICE|Tortoise Positioning Material Group|Preterm infants were placed in the nest with positioning material and placed in lateral and prone positions The positioning material and hand-face maneuver were applied together to the preterm infants in the Positioning Material Group 2, and they were given lateral and prone positions in this way
215096304|NCT05464264|DRUG|Ketamine|Participants suffering from TRD will receive their ketamine treatment intravenously twice weekly for two weeks (4 treatments in total). A dose of 0.5 mg/kg is infused over 40 minutes, with dose adjustments made at the psychiatrist's discretion.
215006389|NCT06125782|DRUG|Omega 3 fatty acid|Omega 3 fatty acid 1 gm softgel capsule- 1 for children at or below 25 kg and two for above 25 kg.
215096305|NCT02423980|DRUG|Glucagon|
215096306|NCT00076349|DRUG|bendamustine and rituximab|Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
215006390|NCT06125782|DRUG|Placebo of Omega-3 fatty acid softgel capsule|Placebo of Omega-3 fatty acid softgel capsule- colour and shape almost similar to the original drug- 1 for children at or below 25 kg and 2 for above 25 kg.
215096307|NCT03312205|BIOLOGICAL|Autologous CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
215096308|NCT05359601|PROCEDURE|Infusion set replacement intervals|24-hour or 96-hour infusion set replacement intervals
215096309|NCT02517320|DRUG|MT-3995 Low|
215096310|NCT02517320|DRUG|MT-3995 Middle|
215096311|NCT02517320|DRUG|MT-3995 High|
215096312|NCT02517320|DRUG|Placebo|
215096313|NCT00857974|OTHER|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
215096314|NCT00598325|BIOLOGICAL|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
215096315|NCT01729494|DRUG|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
214401603|NCT04213846|BEHAVIORAL|Experimental: Mobile Alcohol Expectancy Intervention|Participants randomized to the intervention condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
215006391|NCT05276804|DRUG|Sugammadex|The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
215006392|NCT02827708|DRUG|semaglutide|Oral administration once daily.
214401604|NCT04423393|BIOLOGICAL|VIR-3434|VIR-3434 given by subcutaneous injection or intravenous infusion.
214401605|NCT04423393|OTHER|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
214401606|NCT02867839|DRUG|Oxaliplatin plus S-1|8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
214401607|NCT02867839|DRUG|S-1 only|16 cycles of adjuvant chemotherapy with S-1 only
214401608|NCT02193633|DRUG|AZD2014 3 on/4 off & weekly paclitaxel|AZD2014 3 days on, 4 days off + weekly paclitaxel
214401609|NCT02193633|DRUG|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 2 days on, 5 Days off + weekly paclitaxel
214401610|NCT03337503|DRUG|THC and CDB in a 1 to 1 ratio|capsule containing cannabis oil
214401611|NCT03337503|DRUG|Experimental: THC and CBD in a 1 to 2 ratio|capsule containing cannabis oil
214401612|NCT03337503|DRUG|High CBD with trace THC oil|capsule containing cannabis oil
214401613|NCT03337503|OTHER|placebo|carrier oil capsule
215006393|NCT02827708|DRUG|placebo|Oral administration once daily.
214401614|NCT01005771|DRUG|GF-001001-00|GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
214401615|NCT01005771|DRUG|Placebo|Matching placebo
214688203|NCT07099560|PROCEDURE|Ultrasound-guided sacral erector spinae plane block (sESPB)|After induction of general anesthesia, bilateral sESPB is performed under ultrasound guidance. Needle advanced to the sacral interfascial plane near the median sacral crest; after negative aspiration, bupivacaine 0.25% at 0.5-1 mL/kg (max total 20 mL) is injected. Standardized perioperative care; rescue pethidine 0.5 mg/kg if FLACC ≥4.
215006394|NCT04100187|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
215006395|NCT01783782|BEHAVIORAL|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
215006396|NCT01783782|DRUG|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
215006397|NCT01783782|DRUG|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
215006398|NCT02087683|OTHER|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
215006399|NCT02087683|OTHER|Control group (Placebo)|Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
215006400|NCT00474032|DRUG|Botulinum Toxin (Type A) injection (10 U/Kg)|See Detailed Description.
215006401|NCT04329741|BEHAVIORAL|6-week basic dog obedience training course|The class focused on teaching owners how to better communicate with their dog and covered basic commands (e.g., sit, down, watch), loose leash walking, and polite greetings, among other skills. The importance of dog walking was implied, but not specifically emphasized. Classes were held once per week for 45 minutes, with 5-8 students per class.
215006402|NCT02063269|DRUG|Rivastigmine|9-18mg/rivastigmine for 52 weeks
215006403|NCT06013085|BEHAVIORAL|cognitive behavioral therapy|6 weeks cognitive behavioral therapy
215006404|NCT06088446|PROCEDURE|Supplementary anesthetic injections|Supplementary anesthetic injections after failed primary nerve block
215006405|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
215006406|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
215096316|NCT01729494|DRUG|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
214401616|NCT02459509|DRUG|Dexmedetomidine|Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
214401617|NCT04494321|DRUG|Budesonide|Inhaled corticosteroid
214401618|NCT04494321|DRUG|Formoterol|Long Acting Beta Agonist (LABA)
215006407|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
215006408|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
215006409|NCT01266928|DRUG|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
215006410|NCT04259242|PROCEDURE|SRP|scaling and root planing with ultrasonic scaler and manual instruments
215006411|NCT00361244|DRUG|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
215006412|NCT00361244|DRUG|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
215006413|NCT00361244|DRUG|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
215006414|NCT05176574|BEHAVIORAL|Questionnaire|A questionnaire will be developed via the Delphi method, will be pilot tested and implemented to assess physicians' perceptions and behaviors on physical activity and exercise in chronic, non-communicable diseases.
215006415|NCT03081078|BEHAVIORAL|Volunteer support|Each participant will be matched with a pair of trained volunteers (under pre-determined safety measures), who will initiate caring contact via telephone or text messages at least twice a month for two months. Participants will be free to respond or not.
215006416|NCT03081078|OTHER|Mobile app|Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.
215096317|NCT01729494|DRUG|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
215096318|NCT01729494|DRUG|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
215096319|NCT01729494|DRUG|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
215096320|NCT01729494|DRUG|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
215096321|NCT05556538|PROCEDURE|Transforaminal Epidural Steroid Injection|Patients are placed in the prone position, with a pillow under their abdomen (to reduce lumbar lordosis) and taken to the operating table. The procedure area is cleaned 3 times with povidone-iodine antiseptic and covered with a sterile cover. In order to view the foramen to be processed, the fluoroscopy arm is evaluated at AP-oblique / cranial or caudal angles to obtain an optimal image. Local anesthetic (3 cc 2% prilocaine) is injected into the skin and subcutaneous tissue. The spinal Quincke 21-gauge 90 mm needle is advanced by targeting the relevant foramen under the guidance of fluoroscopy image. Needle position is confirmed by taking a lateral view. Needle aspiration is checked for blood. 1-2 ml of contrast material is injected to confirm that there is no vascular distribution and that it is in the epidural space. When distribution without vascular invasion is observed, an injection of a mixture of 10 mg dexamethasone, 1 cc saline and 1 cc (0.5%) bupivacaine is performed.
215096322|NCT04313491|OTHER|Yoga|Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
215096323|NCT01399008|DRUG|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
215096324|NCT01399008|DRUG|Allopurinol|Allopurinol 300 mg as active comparator
215006417|NCT05866328|OTHER|Cognitive Rehabilitation and Individual Placement and Support|Cognitive Rehabilitation and Individual Placement and Support
215006418|NCT05364255|DRUG|[14C]AZD9833 Oral Solution, 75 mg|Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
215096325|NCT01399008|DRUG|Colchicine|0.6 mg colchicine daily as flare prophylaxis
215096326|NCT01399008|DRUG|Placebo|Placebo
215096327|NCT02709876|BIOLOGICAL|Stem Cell Transplantation|Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
214401619|NCT03685188|DRUG|Oxycodone Hydrochloride|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
214401620|NCT03685188|DRUG|Sufentanil Citrate|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
215096328|NCT04957056|PROCEDURE|Hospitalization|Hospitalization
215096329|NCT00076232|DRUG|Acyclovir|400 mg tablet taken orally twice daily
214401621|NCT03302065|DRUG|Tiotropium|
214504415|NCT02320097|OTHER|Foot pressure measurement|"Description of the foot pressure measurement:~The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
215006419|NCT04358562|DRUG|Gefitinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
215006420|NCT04358562|DRUG|Anlotinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
215006421|NCT03079583|DIETARY_SUPPLEMENT|Intervention-group|Biofortified Rice is grown by foliar Zn application
215006422|NCT03079583|DIETARY_SUPPLEMENT|Control-group|Control Rice with normal zinc levels
215006423|NCT03918343|OTHER|Blood sample|blood samples (4 times; 14ml per visit)
215006424|NCT01137812|DRUG|Sitagliptin 100 mg|One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
215006425|NCT01137812|DRUG|Canagliflozin 300 mg|One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
215006426|NCT01137812|DRUG|Metformin|Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
215006427|NCT01137812|DRUG|Sulphonylurea|Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
215006428|NCT00086125|DRUG|ridaforolimus|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
215006429|NCT00753142|DRUG|Intralipid 20%|Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
215006430|NCT00753142|DRUG|Glucose infusion|Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.
215006431|NCT01168440|DRUG|Sunitinib|Sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of treatment followed by 2 weeks of rest).
214401622|NCT04769024|DEVICE|LUMEEN Virtual Reality sessions|"It will consist in carrying out 12 virtual reality sessions in groups of 6 participants, at a rate of 2 per week for approximately 6 weeks, using the LUMEEN EVASION module. Each session lasts approximately 45 minutes. This module allows the simultaneous broadcasting in virtual reality headsets of 360° videos accompanied by music about different themes: nature, animals, travel, art and live performance.~The course of an EVASION session is as follows:~1. The participants are seated in armchairs in an open environment and sufficiently spaced so that they can move their arms without bumping into each other.~2. The facilitator announces the immersion theme of the session~3. Participants are equipped with virtual reality head-mounted displays.~4. Participants watch the content.~5. The head-mounted displays are removed.~6. A group discussion encouraging participants to share their feelings and what they have learned from the immersion is conducted by the facilitator."
214401623|NCT04769024|BEHAVIORAL|Control/non-digital stimulation sessions|It will consist in non-digital stimulation (sensory, social, cognitive, creative) group sessions offering various typical pen-and-paper activities for this public which mainly stimulate language, immediate memory, semantic memory, and visual recognition (e.g., definitions, games of 7 differences, reconstruction of proverbs, quizzes…). A set of activities with instructions will be provided to the investigating centres but the choice of activities in each session will be left to the facilitator's decision in order to adapt the sessions to the participants' desires and abilities, as is usually done in such stimulation groups. The sessions will last 45 minutes and will be offered twice a week for 6 weeks by a facilitator or a caregiver with group care training. The sessions will be organized in groups of 6 participants to match the group size of the intervention groups.
214504416|NCT01198314|PROCEDURE|immunosuppression withdrawal|tapering off immunosuppressant
214504417|NCT01198314|PROCEDURE|continue of taking immunosuppressant|maintain immunosuppression
214504418|NCT04870788|BEHAVIORAL|Mindfulness Relaxation|Participate in mindfulness program
215006432|NCT00042978|BIOLOGICAL|oblimersen sodium|Given IV
215006433|NCT00042978|DRUG|carboplatin|Given IV
215006434|NCT00042978|DRUG|etoposide|Given IV
215006435|NCT02537925|DRUG|Celecoxib|Celecoxib 200mg bid po, to the end of concurrent radiotherapy
215006436|NCT02537925|DRUG|Nedaplatin|40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
215006437|NCT02537925|RADIATION|Concurrent Radiotherapy|The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
215006438|NCT04393428|OTHER|[TIMP-2]*[IGFBP-7]|\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
215096330|NCT00076232|DRUG|Acyclovir placebo|Oral tablet taken twice daily
214504419|NCT04870788|OTHER|Quality-of-Life Assessment|Ancillary studies
214504420|NCT04870788|OTHER|Questionnaire Administration|Ancillary studies
215006439|NCT04621760|BEHAVIORAL|HIV Prevention Decision Support Tool (DST)|The tool is founded on principles of decision-science and developed in a systematic manner including pilot testing. The tool will present HIV prevention information through a tablet in the clinical setting. The decision support tool will address barriers to PrEP delivery, including 1) limited client knowledge about PrEP, 2) limited time to educate patients in busy clinics, 3) women's lack of knowledge of their own HIV vulnerability, and 4) hesitancy of women to initiate discussions about PrEP with providers due to judgmental attitudes and stigma. Also, the tool emphasizes the highly variable and individual nature of baseline risk.
215006440|NCT04621760|BEHAVIORAL|Standard Counseling|Participants in this arm will receive usual care.
215006441|NCT05951842|DRUG|anesthetic method|Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
215006442|NCT05595954|OTHER|Preoperative data collection|Preoperatively, patients will be assessed with Montreal Cognitive Assessment (MoCA), Geriatric Depression Scale (GDS), Clinical Frailty Scale, 3-minute Diagnostic interview for Confusion Assessment Method-defined delirium (3D-CAM, incl. severity score), modified National Institutes of Health Stroke Scale (mNIHSS), and hand grip strength measurement (using a hand dynamometer) to establish a baseline measurement of the physical, cognitive and mental status.
215006443|NCT05595954|DIAGNOSTIC_TEST|Intraoperative NIRS|Intraoperatively, NIRS data will be collected and recorded in real-time.
215006444|NCT05595954|DIAGNOSTIC_TEST|Intraoperative TCD|Intraoperatively, TCD data will be collected and recorded in real-time.
215006445|NCT05595954|DIAGNOSTIC_TEST|Intraoperative invasive MAP|Intraoperatively, invasive arterial blood pressure data will be collected and recorded in real-time.
215006446|NCT05595954|DIAGNOSTIC_TEST|Postoperative NIRS|Postoperatively, NIRS monitoring will be continued in the ICU after the surgery until (i) endotracheal extubation, or (ii) for the first 24 hours or (iii) until emergency re-operation, whichever occurs first.
215096331|NCT06368908|DEVICE|Transcutaneous Functional Magnetic Muscle Stimulation|Peripheral neuromuscular system stimulation will be conducted for the quadriceps femoris muscle using a magnetic stimulator (Tesla stym, Iskra Medical, Otoče, SLO). For magnetic stimulation, we will use pulse trains (20-50 Hz) with intensities ranging from 0.5 to 2.5 Tesla. The stimulation trains will be up to 3-6 seconds long, and the duty cycle will be varied from 1:1 to 1:10. Muscles will be stimulated with a magnetic field intensity that triggers visible contraction. The stimulation will last for 55 minutes per selected limb and will be performed 5 days a week.
215006447|NCT05595954|OTHER|Postoperative data collection|Postoperatively patients will be evaluated for POD with 3D-CAM or CAM-ICU and for clinical stroke with mNIHSS. Postoperative neurocognitive disorders will be assessed using MoCA.
214401624|NCT03869034|COMBINATION_PRODUCT|HAIC+PD1|Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.
215006448|NCT05595954|DIAGNOSTIC_TEST|Collection of serum biomarker panel|The serum biomarker panel will consist of four markers of neurological injury glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), t-tau and ubiquitin-C-terminal-hydrolase-L1 (UCH-L1). Blood samples will be obtained preoperatively, after ICU admission, on postoperative day 1, 2, 6 (or hospital discharge, whichever occurs first) and between 6 and 12 weeks after surgery.
215006449|NCT05595954|DIAGNOSTIC_TEST|Collection of blood sample for genetic study|A blood sample for the genetic study will be obtained preoperatively.
215006450|NCT05796817|DEVICE|Ventilator modification|The ventilator modification will be fitted to a ResMed Lumis 150, Breas® Nippy 4+ or Vivo 1, 2 or 3 ventilator. The participants oxygen level will be measured with and without the modification in place at their baseline ventilation, and with 1, 2 and 3 litres oxygen extra to their baseline. the researcher will then leave the modification on and slowly reduce the oxygen going into the ventilator, maintaining the participants SP02 at an acceptable level (\>95%)
215006451|NCT04576546|DIETARY_SUPPLEMENT|D-chiro-inositol|Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration
215006452|NCT04576546|DIETARY_SUPPLEMENT|Myo-inositol|Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration
215006453|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
215006454|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
215006455|NCT04602000|BIOLOGICAL|Placebo|Placebo (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
215006456|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
215006457|NCT04602000|BIOLOGICAL|Placebo|Placebo (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
215096332|NCT02385435|DRUG|Bupivacaine|Caudal Bupivacaine 2 mg/kg single shot
215096333|NCT02385435|DRUG|dexmedetomidine 1μg.kg-1|Caudal dexmedetomidine 1μg.kg-1, single shot
215006458|NCT03729440|BEHAVIORAL|development of complications or not|assessment of development of complications
215006459|NCT04697901|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|"Active simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
215006460|NCT04697901|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|"Sham simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Sham stimulation will consist of active stimulation for 120s, including the ramping up to 2 mA and down to no stimulation. Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
215006461|NCT06118320|DRUG|Potassium sodium hydrogen citrate|"Medication: Potassium sodium hydrogen citrate granules (MADAUS GMBH, Germany, 2.5g/package).~Method: Preprandial urine pH was monitored to maintain an effective range of 6.2 to 6.8. One package should be taken after breakfast, one after lunch, and two after dinner. If the pH falls below 6.2, a half-package dose should be added; if it exceeds 6.8, a half-package dose should be reduced accordingly. Oral medication will be administered for a duration of three months.~Medication requirements: Abstain from alcohol and smoking during treatment period and avoid using any probiotics or drugs that lower uric acid levels."
215096334|NCT02385435|DRUG|dexmedetomidine 2μg.kg-1|Caudal dexmedetomidine 2μg.kg-1, single shot
215096335|NCT02619721|DEVICE|PINS SNS|
215096336|NCT05104970|DRUG|SunnyD insta ampoule|Cholecalciferol 200000 IU insta ampoule
215096337|NCT05104970|DIETARY_SUPPLEMENT|SunnyD STAT softgel capsule|Cholecalciferol 200000 IU softgel capsule
215096338|NCT05104970|DRUG|Placebo SunnyD insta ampoule|Olive oil
215006462|NCT02967887|DRUG|cisplatin and 5-fluorouracil|Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
214401625|NCT03869034|DRUG|HAIC|FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
214401626|NCT03613584|DRUG|Von Willebrand Factor|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
215006463|NCT02323815|DIETARY_SUPPLEMENT|Small-Quantity Lipid-based nutrient supplement|A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
215006464|NCT02323815|BEHAVIORAL|Child's health and nutrition topics|Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
215006465|NCT01324180|DRUG|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
215006466|NCT01324180|DRUG|Vincristine|1.5 mg/m\^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
215006467|NCT01324180|DRUG|Dexamethasone|"* 10 mg/m\^2/day divided BID~* Take dexamethasone by mouth days 2-15"
215006468|NCT01324180|DRUG|PEG-asparaginase|"* 2500 IU's/m\^2/day~* Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~* If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~* Patients will receive Erwinase® 25,000 IU/m\^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
215006469|NCT01324180|DRUG|Doxorubicin|60 mg/m\^2/day IV over 15 minutes on day 2
215006470|NCT01324180|DRUG|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
214401627|NCT03613584|DRUG|Saline Solution|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
215006471|NCT06091033|DIETARY_SUPPLEMENT|Fermented rice|1,000 mg of black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks
215006472|NCT06091033|DIETARY_SUPPLEMENT|placebo|1,000 mg of a placebo for 8 weeks
215006473|NCT01846871|DRUG|Tivozanib|
215006474|NCT02092103|PROCEDURE|Cord Milking|See description in cord milking arm.
215006475|NCT01230008|RADIATION|no drugs|Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
215006476|NCT01025050|PROCEDURE|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
215006477|NCT00471354|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
215006478|NCT02794311|OTHER|Alcoolpredict|psychological (personality), neuropsychological (executive functions, memory), genetic (snp polymorphisms) and neuro-anatomical (fMRI)
215006479|NCT03522168|DRUG|Risperidone|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
215006480|NCT03522168|DRUG|Aripiprazole|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
215006481|NCT00211094|DRUG|Dapoxetine|
215006482|NCT04856618|BIOLOGICAL|Massive Transfusion of Allogeneic Blood|Massive Transfusion of Allogeneic Blood, \> pRBCs
215006483|NCT00265291|DRUG|fluoxetine or desipramine|fluoxetine 5-40 mg/day desipramine 50-150 mg/day
215006484|NCT01875237|DRUG|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
215006485|NCT01875237|DRUG|Melphalan|140 mg/m2 by vein on Day -2.
215006486|NCT01875237|DRUG|Alemtuzumab|50 mg by vein on Day -1.
215006487|NCT01875237|PROCEDURE|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 10\^6 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
215006488|NCT01875237|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
215006489|NCT01875237|DRUG|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
215006490|NCT01875237|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
215006491|NCT01875237|PROCEDURE|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10\^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
215096339|NCT05104970|DIETARY_SUPPLEMENT|Placebo SunnyD STAT softgel capsule|Olive oil
214401628|NCT03374072|BEHAVIORAL|Siblings FORWARD program|Siblings will participate in a program developed by the researchers designed to engage adults with their autistic sibling and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with autistic adults. The program will involve a series individual and joint sessions with siblings and autistic adults using Zoom.
214401629|NCT03374072|BEHAVIORAL|Information Only Condition|Siblings will be provided with online information about services for adults with ASD and future planning.
215006492|NCT01875237|DRUG|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade \> 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
215006493|NCT01875237|DRUG|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
215096340|NCT00542061|DEVICE|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
215096341|NCT02858752|OTHER|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
215096342|NCT02858752|OTHER|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, …). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
215096343|NCT02858752|OTHER|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
215096344|NCT02858752|OTHER|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
215096345|NCT02858752|OTHER|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
215096346|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
215096347|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
215096348|NCT00658307|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
215096349|NCT00115661|DRUG|Rosiglitazone|
215096350|NCT05749393|DRUG|Heparin sodium|Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
215096351|NCT05327361|DRUG|Liftactiv B3|Participants will apply a dime size amount of the serum to 1 side of the face.
215096352|NCT05327361|OTHER|Sunscreen|Participants will apply a dime size amount of sunscreen to cover the other half of the face.
215096353|NCT01776723|DRUG|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
214401630|NCT00421421|DRUG|Dutasteride|
215096354|NCT04672850|DIETARY_SUPPLEMENT|Probiotic|The participants will consume 2 capsules daily for three months
214401631|NCT05202236|DRUG|pemigatinib|The patients will receive 13.5 mg (1 pill/time) of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen, with 21 days as a cycle. They should take pemigatinib at regular times of the day to avoid the effects of inconsistent timing on plasma concentrations.
215006494|NCT01875237|BEHAVIORAL|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
215096355|NCT04672850|DIETARY_SUPPLEMENT|Placebo|The participants will consume 2 capsules daily for three months
215096356|NCT05477914|OTHER|questionnaire|questionnare about nutritional knowledge of pregnant women
215096357|NCT04485884|DRUG|IN-C005 dose A|One time dose of IN-C005 dose A taken orally.
215096358|NCT04485884|DRUG|IN-C005 dose B|One time dose of IN-C005 dose B taken orally.
215096359|NCT04485884|DRUG|IN-C005 dose C|One time dose of IN-C005 dose C taken orally.
215096360|NCT04485884|DRUG|IN-C005 dose D|Oral administration of IN-C005 dose D once daily for 7 days.
215006495|NCT06309758|OTHER|Breinzorg|"The BreinZorg multidomain lifestyle website comprises 16 domains, namely (1) physical activity, (2) healthy diet, (3) smoking, (4) alcohol, (5) sleep, (6) cognitive activity (7) social activity, (8) diabetes, (9) blood pressure, (10) cholesterol, (11) heart- and vascular diseases, (12) kidney diseases, (13) hearing damage, (14) obesity, (15) anxiety, and (16) depression. These 16 modules are separated into three big themes: mood, lifestyle, and body.~Each module consists of the following:~1. General information on the risk factor;~2. Tips on how to improve and decrease the risk;~3. Quiz questions about the risk factor, giving extra knowledge/ in a playful and interactive manner;~4. Examples of SMART goals fitting the risk factor (goal examples are given in a Specific, Measurable, Achievable, Relevant, and Time-Bound manner)."
215096361|NCT04485884|DRUG|IN-C005 dose E|Oral administration of IN-C005 dose E once daily for 7 days.
214401632|NCT03768661|PROCEDURE|Single-incision Laparoscopic cholecystectomy|laparoscopic cholecystectomy performed through a single device located at a unique umbilical incision
214401633|NCT03768661|PROCEDURE|Laparoscopic Cholecystectomy|laparoscopic cholecystectomy performed using three-trocars standard technique
214401634|NCT05247879|DIETARY_SUPPLEMENT|Glucose containing Oral Rehydration Solution (ORS)|Oral rehydration solution
214401635|NCT05247879|DIETARY_SUPPLEMENT|Sugar free - amino acid and electrolyte ORS|Glucose free oral rehydration solution
214401636|NCT06532552|DRUG|VACl|Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.
214401637|NCT06532552|DRUG|VACh|Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days
214401638|NCT06532552|DRUG|VACl Alternating With VACh|"VACl:~Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.~VACh:~Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days"
214401639|NCT06532552|DRUG|VA|Azacitidine: 75mg/m2 Subcutaneous (SC) daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28).
214401640|NCT03410485|DEVICE|BIS index/NoL index|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a NoL index between 10-20.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then adapted to the BIS between 45-55."
214401641|NCT03410485|DEVICE|Variation of baseline mean arterial pressure|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a baseline mean arterial pressure between 10% of variation.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then ajusted to 0.8 MAC."
214401642|NCT01968005|DRUG|Etoreat®(Etodolac-Lidocaine Topical Patch)|
214401643|NCT01968005|DRUG|Placebo|
214401644|NCT05829941|BEHAVIORAL|Smartwatch app to deliver binge-eating CBT strategies|Participants will receive a smartwatch with a pre-loaded app that will alert the participant to relevant binge-eating strategies based on their previous detected behavior.
214401645|NCT05829941|BEHAVIORAL|Reminder control condition|Participants will receive a smartwatch that vibrates randomly, and will be instructed the vibration is a cue not to binge eat.
214401646|NCT00611637|BIOLOGICAL|CMV pp65 Specific T Cells|Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
214401647|NCT00432159|DEVICE|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
214401648|NCT00432159|DEVICE|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
214401649|NCT00002374|DRUG|Ritonavir|
214401650|NCT00002374|DRUG|Nelfinavir mesylate|
214401651|NCT00002374|DRUG|Saquinavir|
214401652|NCT00002374|DRUG|Stavudine|
214401653|NCT02522052|OTHER|Blue mussel diet|5 meals a week containing blue mussels
214401654|NCT02522052|OTHER|Meat/Control diet|5 meals a week containing meat
214401655|NCT03516149|OTHER|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets
214401656|NCT06242496|OTHER|Retrospective follow-up|Data collection
214401657|NCT01939860|OTHER|Written and verbal patient education on hypertension and its treatment|
214401658|NCT03303274|PROCEDURE|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
214401659|NCT03437434|OTHER|Visual Acuity|Ocular Examination
215006496|NCT05202431|BEHAVIORAL|Treatment adherence|The patients were reminded to take drug by patient training, telephone follow-up, and daily sms. It was determined that the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence.
215096362|NCT04485884|DRUG|IN-C005 dose F|Oral administration of IN-C005 dose F once daily for 7 days.
214401661|NCT05516342|BEHAVIORAL|LEAD IT! Programming|LEAD IT! is an intervention that enables persons with dementia to lead activities for their peers. The activities take place on tablets.
214401662|NCT03094897|DRUG|18F-Al-NOTA-MATBBN PET/CT|18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
215096363|NCT01269502|DEVICE|"Temp Touch Diabetica Solutions inc."|Daily measurement of skin temperature on feet for one year
215096364|NCT01269502|OTHER|Inspection|Inspection of feet daily for one year
215096365|NCT01439373|DRUG|GSK2336805|Active Investigational Drug
215096366|NCT01439373|DRUG|Pegylated interferon alfa-2a|Standard of Care drug
215096367|NCT01439373|DRUG|Ribavirin|Standard of Care drug
215096368|NCT01439373|DRUG|GSK2336805 Matching Placebo|Placebo of Investigational Drug
215096369|NCT02086422|DRUG|ivabradine|
215096370|NCT02086422|DRUG|Placebo|
215096371|NCT02086422|OTHER|Exercise|
214401663|NCT03094897|DEVICE|PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT.
215096372|NCT05784298|DEVICE|low-intensity rTMS|40 hz, 150 gauss, 1 session that lasts 45 minutes.
215096373|NCT00366912|DEVICE|non-invasive ventilation|
215096374|NCT02945644|DRUG|Trazodone|take at bedtime for 14 days
215096375|NCT02945644|DRUG|Placebo|take at bedtime for 14 days
215096376|NCT00801021|DRUG|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
215096377|NCT01731093|DRUG|AT-001|
214401664|NCT01329120|PROCEDURE|Minimally invasive repair of pectus excavatum|Minimally invasive surgical technique basically consisting of inserting one or more convex steel bars under the sternum through small bilateral incisions in the thoracic wall
214401665|NCT01329120|PROCEDURE|Open surgical repair of pectus carinatum|Open surgical removal the affected cartilages bilaterally and the excess cartilage over the sternum
214401666|NCT04643743|DEVICE|Endarterectomy|Endarterectomy is a surgical procedure to remove the atheromatous plaque material, or blockage, in the lining of an artery constricted by the buildup of deposits. It is carried out by separating the plaque from the arterial wall.
214401667|NCT05370989|OTHER|Technology-Based Parent School Program|The program will be continued for 10 weeks in the intervention group and will be included five web-based modules, five online group interactions after each module, and consultation throughout the program and the follow-up period.
214401668|NCT05370989|OTHER|ongoing treatment|Health service of the control group will ongoing.
214401669|NCT03064503|BIOLOGICAL|Blood sampling|Blood sampling will be performed at inclusion to investigate some biological eligibility criteria, and the day of MRI in order to analyse fibrosis biomarkers and collagen synthesis biomarkers
214401670|NCT03064503|DEVICE|MRI|MRI will be performed to measure interstitial fibrosis
214401671|NCT03064503|BIOLOGICAL|Skin auto-fluorescence|Skin auto-fluorescence measures will be performed to measure advanced glycation end-products (AGE) produced by collagen degradation
214401672|NCT03224338|DRUG|Dolutegravir 50 mg|Dolutegravir will be used in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs used in combination with DTG will be abacavir (ABC) plus lamivudine (3TC) or tenofovir (TDF) plus emtricitabine (FTC), which is in line with the current standard of care. The combination ABC/3TC/DTG will be preferential except in case of hepatitis B co-infection or in case the subject has a positive HLA-B\*5701 allele screening assessment.
214401673|NCT02991885|BIOLOGICAL|HAL-MPE1|Weekly subcutaneous administrations of HAL-MPE1
214401674|NCT02991885|DRUG|HAL-MPE1 placebo|Weekly subcutaneous administrations of HAL-MPE1 placebo
214401675|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
215006497|NCT04855812|DEVICE|MyoMo|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
215006498|NCT04855812|OTHER|Myo-SB|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
215006499|NCT04855812|OTHER|Control|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
215006500|NCT03010865|DRUG|Sodium Butyrate|Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
215006501|NCT03010865|DRUG|Placebo Oral Capsule|Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
215006502|NCT02949453|BEHAVIORAL|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:~* first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~* second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
215006503|NCT03050489|PROCEDURE|On-Pump CABG.|Standard On-Pump CABG.
215006504|NCT03050489|PROCEDURE|Off-Pump CABG.|Standard Off-Pump CABG.
215096378|NCT01731093|DRUG|Placebo|
215096379|NCT03281304|DRUG|CP-690,500 5 mg|CP-690,550 5 mg tablet BID
215096380|NCT03281304|DRUG|CP-690,550 10 mg|CP-690,550 10 mg tablet BID
215096381|NCT00491881|BEHAVIORAL|no added salt diet|
215096382|NCT00734721|BEHAVIORAL|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
215096383|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
215096384|NCT04611802|OTHER|Placebo (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
215096385|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21
215096386|NCT04611802|OTHER|Placebo (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21
215096387|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
215096388|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)|In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
215096389|NCT00626405|BIOLOGICAL|bevacizumab|Given IV over 30-90 minutes
215096390|NCT00626405|DRUG|carboplatin|Given IV over 30 minutes
215096391|NCT00626405|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
215096392|NCT00626405|DRUG|temozolomide|Oral temozolomide on days 1-5
215096393|NCT02438345|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCr5
215006505|NCT03050489|PROCEDURE|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
214401676|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
214401677|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
214401678|NCT06349486|DRUG|vonoprazan, amoxicillin, tripotassium dicitrate bismuthate|bismuth-amoxicillin-vonoprazan triple therapy
214401679|NCT06349486|DRUG|vonoprazan, amoxicillin|vonoprazan-amoxicillin dual therapy
214401680|NCT06349486|DRUG|rabeprazole, amoxicillin, clarithromycin|proton pump inhibitor-based standard triple therapy
214401681|NCT05229510|DRUG|50 mg/mL Virazole Inhalant Product|50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
214401682|NCT05229510|DRUG|100 mg/mL Virazole Inhalant Product|100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
215006506|NCT01913470|DRUG|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
215006507|NCT02573467|DRUG|Bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
215006508|NCT02573467|DRUG|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
215006509|NCT02328274|PROCEDURE|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
215006510|NCT04361045|BEHAVIORAL|StriveWeekly|"The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program brand name versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displayed user progress. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity.~Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning."
215006511|NCT02269449|DEVICE|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
215006512|NCT02269449|DEVICE|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
215006513|NCT02269449|PROCEDURE|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
214401683|NCT05229510|DRUG|Placebo|Placebo (10 or 20 ml total volume) aerosolized and administered until solution depleted
214401684|NCT01115998|OTHER|Power wheelchair|Children used power wheelchairs for one year. They continued to receive their usual early intervention services.
215006514|NCT02269449|PROCEDURE|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
215006515|NCT00923702|BIOLOGICAL|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.
215096394|NCT02500446|DRUG|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
214401685|NCT01115998|OTHER|No power wheelchairs|Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
214401686|NCT06270290|OTHER|Exposure to contact sports or history of concussions|History of contact sports practices or of concussions
214401687|NCT01214447|OTHER|No intervention|Observational study - no intervention
214401688|NCT02783105|OTHER|Musical intervention|
214401689|NCT02783105|OTHER|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
214401690|NCT03081208|DRUG|Nolasiban 900mg|Nolasiban dispersible tablets for single oral administration
214401691|NCT03081208|DRUG|Placebo|Placebo dispersible tablets for single oral administration
214401692|NCT03850444|BIOLOGICAL|pembrolizumab|
214401693|NCT03850444|DRUG|carboplatin|
214401694|NCT03850444|DRUG|paclitaxel|
214401695|NCT03850444|DRUG|pemetrexed|
214401696|NCT03329833|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.
214401697|NCT03329833|BEHAVIORAL|Web-based application|Web-based application participants will be asked to log activity at least on a daily basis.
215006516|NCT02153827|OTHER|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
214401698|NCT05154344|DRUG|Capmatinib|Available through expanded access
214401699|NCT06216028|BIOLOGICAL|Autologous Bone Marrow Aspirate Concentrate|Range of between 18.7 X 104 cells/mL and 21.8 X 106 cells/mL total nucleated cells (TNC)
214504421|NCT04870788|OTHER|Group II (mindfulness waitlist)|Patients and their partners participate in mindfulness program together or separately, depending on their preference, as in Group I beginning 12 weeks after starting the study and completing the third study visit.
214504422|NCT00868894|DRUG|DE-104 medium concentration|Topical ocular application
215006517|NCT02153827|OTHER|General Shoulder exercise|general exercise consisting of active shoulder movements
215096395|NCT02500446|OTHER|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
215096396|NCT03834220|DRUG|Debio 1347|Debio 1347 oral tablets.
215096397|NCT01521377|DRUG|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
215096398|NCT01521377|DRUG|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
215006518|NCT00991432|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
214401700|NCT04096365|DEVICE|Subcostal Temporary Extracardiac Pacing Lead|The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.
214401701|NCT04019522|OTHER|Acute Intermittent Hypoxia (AIH)|An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered to the subject. Inspired fraction of oxygen (FiO2) of the gas mixture will be individually adjusted using the valve settings to reach the targeted SpO2. The gas mixtures administered during the four sessions will be 21% O2 (target SpO2 = 95%), 17% O2 (target SpO2 = 92%), 13% O2 (target SpO2 = 87%) and 9% O2 (target SpO2 = 82%).
214401702|NCT01452672|RADIATION|Radiotherapy|RT 40 Gy in 15 fractions
214401703|NCT01452672|RADIATION|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
214401704|NCT04577820|DRUG|garetosmab|Repeated doses administered intravenously (IV) every four weeks (Q4W)
215006519|NCT00862901|DEVICE|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
214401705|NCT00839202|OTHER|FVIII immuno-assay|There is no intervention. This is a study of the differences in assays.
214401706|NCT04921995|DRUG|Tislelizumab|"1. Chemotherapy (including but not limited to following):~   GP regimen: gemcitabine 1000mg/m2 d1, d8 + cisplatin 25 mg/m2 d1-3, every 3 weeks for 4-6 cycles; GX regimen: gemcitabine 800mg/m2 d1 + capecitabine 750 mg/m2 d1-14, every 3 weeks for 4-6 cycles.~   Capecitabine: 750 mg/m2 d1-14, every 3 weeks until unacceptable toxicities or patient's withdraw.~2. anti-PD-1 antibody: Tislelizumab concurrently with chemotherapy: 200mg, every 3 weeks for 12 weeks. Tislelizumab in maintenance period: 200mg every 3 weeks or 400mg every 6 weeks, until one year or disease progression, or in the case of intolerable toxicities."
215006520|NCT03426488|BEHAVIORAL|VIP - Västerbotten Intervention Programme|Intervention on CVD (cardiovascular disease) and diabetes
214401707|NCT05406986|OTHER|care bundle application|The patients in the experimental group will be given care according to the current care bundle for 14 days
214401708|NCT04727710|BEHAVIORAL|Mindfulness-based Intervention|A self-directed, web-based mindfulness training. Investigators recommend one module a week for 6 weeks. Each module is approximately 1 hour long and consists of didactic components as well as meditation and mindfulness exercises.
214401709|NCT04727710|BEHAVIORAL|Usual Care|Standard pre-operative survivorship seminar, offered monthly to all patients at Michigan Medicine about to undergo prostatectomy and their partners is aimed at promoting realistic expectations of prostatectomy outcomes, typical side effects, rehabilitation and emotional adjustment.
214401710|NCT05373901|DRUG|Dinutuximab Beta|Dinutuximab beta was administered intravenously at a dosage of 10 milligrams/ meters squared (mg/m2) per day for 10 consecutive days
214401711|NCT05373901|DRUG|13-cis-Retinoic Acid|13-cis-Retinoic Acid was administered orally at a daily total dose of 160 mg/m2, divided into approximately two equal doses given twice daily for 14 days following the conclusion of dinutuximab beta infusion.
214401712|NCT04440228|BEHAVIORAL|TeamSTEPPS|"TeamSTEPPS is an evidence-based approach for teams that can be adapted for school mental health.~Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS), has been widely disseminated in health care settings with promising outcomes. TeamSTEPPS is designed to build competencies in the areas of leadership, situation monitoring, mutual support, and communication and has been associated with improvements in teamwork and communication as well as patient outcomes, such as decreased seclusion in psychiatric hospitals."
214401713|NCT05628662|DEVICE|Automated Insulin Delivery System (SAFE-AP)|Each subject will undergo a 32-hour in-hospital study, including 4 meals (60 grams of carbohydrates each, except 50 grams for breakfast), one overnight period and 2 unannounced aerobic exercise sessions. Each exercise session consists of three 15-minute sets on a cycle ergometer at 70% of maximum heart rate with 5 minutes of rest between sets.
214401714|NCT01598987|DRUG|Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.|Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m\^2/dose in combination wit Cyclosporine A or 2.0 mg/m\^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
214401715|NCT00006221|DRUG|ixabepilone|
215006521|NCT02583009|DRUG|PAC-14028 cream 0.1%|Topical application
215006522|NCT02583009|DRUG|PAC-14028 cream 0.3%|Topical application
215006523|NCT02583009|DRUG|PAC-14028 cream 1.0%|Topical application
215096399|NCT01521377|DRUG|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
215006524|NCT02583009|DRUG|PAC-14028 cream vehicle|Topical application
215006525|NCT01243125|DRUG|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
215006526|NCT01243125|DRUG|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
215096400|NCT01521377|DRUG|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
215096401|NCT01521377|DRUG|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
215096402|NCT01521377|DRUG|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
215006527|NCT05560321|OTHER|Sani24|Disinfectant
215006528|NCT05560321|OTHER|Routine Disinfection|Routine disinfection at the study hospital
215006529|NCT03524144|OTHER|gastroscopy|Two endoscopists performed upper gastrointestinal endoscopy and biopsy on all patients; and histological review was performed by two pathologists. From each patient, 10 specimens were taken from 6 areas in the upper gastrointestinal tract and basic informations was collected.
215006530|NCT03361345|DRUG|Tranexamic Acid|Topical tranexamic acid in cream form applied to dark spots on right side of face.
215006531|NCT03361345|DRUG|Vehicle|The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
215096403|NCT06262217|DEVICE|Mobile MRI scanner|Use of mobile MRI scanner in patients with suspected or confirmed acute stroke (including Transient Ischaemic attacks)
215096404|NCT02593318|DRUG|Oxaloacetate (OAA) 1g|Pills to be taken orally in 500mg dose two times per day
215096405|NCT02593318|DRUG|Oxaloacetate (OAA) 2g|Pills to be taken orally in 1000mg dose two times per day.
215096406|NCT02020408|DRUG|[11C]raclopride|1.\[11C\]raclopride -The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
215006532|NCT04790201|BEHAVIORAL|Friendship Bench Delivered by Professional Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a professional counselor.
215006533|NCT04790201|BEHAVIORAL|Friendship Bench Delivered by Lay Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a trained lay counselor.
215006534|NCT04790201|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care (EUC) will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care. Information will be collected in follow-up interviews to characterize the care that patients receive. These activities will occur in all three arms, but they are the only activities in the EUC arm.
215006535|NCT06510582|DRUG|Bevacizumab 2 mg/kg|Single 2mg/kg dose of bevacizumab to treat unilateral cSDH
215006536|NCT06510582|DRUG|Bevacizumab 4 mg/kg|Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH
215096407|NCT02020408|DRUG|[11C]DASB|BPND of \[11C\]DASB.
215096408|NCT02020408|DRUG|amphetamine|The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
215096409|NCT03996317|OTHER|Room air|Avoidance of hyperoxygenation
215096410|NCT03207802|DEVICE|Discontinuation of using device|Subject will be instructed to discontinuation of use of device
215096411|NCT00371904|DRUG|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
214401716|NCT01144117|DRUG|Erythropoietin|Erythropoietin 48000 IU given I.V. in 17 courses
215006537|NCT00144885|BEHAVIORAL|Modification of therapy|Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
215096412|NCT00371904|DRUG|Standard Care|Standard care
215096413|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
215096414|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
215096415|NCT03693781|DRUG|Placebo Oral Tablet|Corresponding tablets for 30 weeks
215096416|NCT00552604|DRUG|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
215096417|NCT00552604|DRUG|Placebo|Matching placebo capsules, twice daily
215096418|NCT00156871|BEHAVIORAL|exercise|
215096419|NCT03688568|DRUG|Imatinib Mesylate|Imatinib given orally as dose escalation treatment.
215006538|NCT02228122|DEVICE|Aquacel® Ag+ Extra|Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
215096420|NCT05498467|DRUG|Anakinra|100 mg Anakinra injections s.c.
215006539|NCT01431846|BEHAVIORAL|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
215006540|NCT01651884|DEVICE|HD-tDCS (Soterix)|Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
215096421|NCT05498467|DRUG|Sodium Chloride 9mg/ml Injection|9 mg Sodium Chloride injections s.c.
215096422|NCT02789592|DRUG|Melatonin PR|For experimental treatment of RBD
215096423|NCT02789592|DRUG|Clonazepam|For experimental treatment of RBD
214401717|NCT04497311|DIAGNOSTIC_TEST|Thoraxic computed tomography|Diagnostic lung CT.
214401718|NCT02107274|DRUG|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
214401719|NCT02107274|DRUG|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
214401720|NCT02293707|BIOLOGICAL|GX301|"GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG."
214401721|NCT05878353|PROCEDURE|Decontamination of the pocket with local doxycycline|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage. Local doxycycline was administered according to the manufacturer's instruction. Briefly, the plastic needle of the syringe will be inserted into the sulcus and the product will be progressively released in the periodontal pocket up to the gingival margin. The syringe will be then removed and a cotton pellet used to compact the gel into the sulcus. Patients will be then instructed not to floss or use interdental brushes in that area for the following 10 days.
214401722|NCT05878353|PROCEDURE|Decontamination of the pocket with mechanical instrumentation|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage.
214401723|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
214688204|NCT07099560|PROCEDURE|Ultrasound-guided caudal epidural block|After induction of general anesthesia, caudal epidural injection via sacral hiatus under ultrasound guidance; after negative aspiration, bupivacaine 0.25% at 0.5-1 mL/kg (max total 20 mL) is injected. Standardized perioperative care; rescue pethidine if FLACC ≥4.
214688205|NCT06929104|OTHER|No intervention|No intervention
215006541|NCT01651884|DEVICE|Transcranial Direct Current Stimulation (Neuroconn)|
214401724|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
214401725|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
214401726|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
214401727|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
214401728|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
214401729|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
214504423|NCT00868894|DRUG|DE-104 high concentration|Topical ocular application
215006542|NCT04339972|DEVICE|LIFUP|Low Intensity Focused Ultrasound Pulsation (LIFUP) is an interesting new form of brain stimulation that may be possible to stimulate non-invasively, safely, deep in the brain with focal precision.
215006543|NCT04339972|DEVICE|Sham LIFUP|The same as LIFUP but the device is not turned on and the subject does not receive any ultrasound.
215006544|NCT03745469|DEVICE|Smartphone|A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
215096424|NCT02789592|DRUG|Melatonin PR placebo|Placebo pill manufactured to mask melatonin PR 2mg tablet
215096425|NCT02789592|DRUG|Clonazepam placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
215096426|NCT02343705|DEVICE|Latella Knee Implant System|
214504424|NCT00868894|DRUG|Placebo|Topical ocular application
214504425|NCT00868894|DRUG|0.005% latanoprost|Topical ocular application
215096427|NCT00199823|GENETIC|Intracoronary aotologous stem cell transplantation|
215096428|NCT03994198|DIETARY_SUPPLEMENT|Alpha-lactalbumin|A protein fraction of whey protein, higher in tryptophan
214504426|NCT04931966|PROCEDURE|block|Adductor canal block
214504427|NCT04931966|PROCEDURE|adductor canal block|adductor canal block bupivacain
214504428|NCT04931966|PROCEDURE|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using bupivacaine
214504429|NCT04931966|PROCEDURE|adductor Canal Block plus PAI Block|Adductor Canal Block plus PAI Block using bupivacaine
214504430|NCT02042092|DEVICE|Ultrasound|
215006545|NCT05565547|DEVICE|META|The META device is used for a comprehensive ophthalmic examination.
215006546|NCT05565547|DEVICE|Commercial devices|Commercial devices (including near and far eye charts, refractometer, optical biometry, slit lamp microscopy, fundus camera and OCT) are used for a comprehensive ophthalmic examination.
215096429|NCT03994198|DIETARY_SUPPLEMENT|Collagen peptides|Collagen peptides from bovine sources
215006547|NCT04790799|OTHER|Treatment at the skin department at Gentofte Hospital|Treatment in a hospital setting at Gentofte Hospital skin department
215006548|NCT05491889|BIOLOGICAL|trans arterial chemoembolization|trans arterial chemoembolization in patient with partial portal vein thrombosis
214401730|NCT01178242|PROCEDURE|Salivary Gland and Labial Mucous Membrane Transplantation|"Minor salivary glands (SG) will be obtain en block from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures"
214401731|NCT03940469|DRUG|Saline|2 ml normal saline
214401732|NCT03940469|DRUG|Dexamethasone Injection|8 mg dexamethasone
214401733|NCT03940469|DRUG|Dexmedetomidine Hydrochloride|100 microgram dexmedetomidine
214401734|NCT02298374|OTHER|Homecare reablement|
214401735|NCT02298374|OTHER|usual care|
214401736|NCT03412838|PROCEDURE|graft surgery|A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants
214401737|NCT02763098|DRUG|Remi 0.1|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
214504431|NCT02042092|DEVICE|MRA|
214504432|NCT03917186|DRUG|Sevoflurane|administration of sevoflurane
215006549|NCT00127010|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
215006550|NCT01116843|DRUG|PF-00299804|PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
215006551|NCT03240380|BEHAVIORAL|joint crisis plan|"Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare."
215006552|NCT03240380|BEHAVIORAL|crisis card|"Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office."
215006553|NCT03683901|DEVICE|TENS|Electrical Stimulation
215006554|NCT03683901|DEVICE|t-NMES|Electrical Stimulation
215006555|NCT03683901|OTHER|No stimulation|No stimulation
215006556|NCT05485558|DRUG|N-acetyl cysteine|10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
215006557|NCT05485558|DRUG|Placebo|15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
215006558|NCT05485558|DRUG|NAc|40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
215006559|NCT04074512|DRUG|copper histidinate|copper histidinate for subcutaneous injection
215006560|NCT06248671|DRUG|Atorvastatin 40mg|Each tablet will be taken once daily for 84 days.
215006561|NCT06248671|DRUG|Placebo|Each tablet will be taken once daily for 84 days
215006562|NCT06248671|DRUG|Atorvastatin 20mg|Each tablet will be taken once daily for 84 days.
215006563|NCT03522259|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
215006564|NCT02921022|DRUG|Gemcitabine|
215006565|NCT02921022|DRUG|Nab-paclitaxel|
215006566|NCT02921022|DRUG|PEGPH20|
215006567|NCT05098483|PROCEDURE|Regeneration in primary molars by using MTA|Regenerative endodontic procedure in nonvital primary molars using MTA capping material
215006568|NCT05098483|PROCEDURE|Regeneration in primary molars by using biodentine|Regenerative endodontic treatment in primary molars with biodentine as capping material
215006569|NCT05098483|PROCEDURE|Conventional Root canal treatment in primary molars|Removal of pulp tissue from the canals of primary molars
215006570|NCT05199480|DRUG|Tobacco flavored liquid type 1|A commercially available cartridge-based device with tobacco flavored liquid.
215006571|NCT05199480|DRUG|Tobacco flavored liquid type 2|A commercially available cartridge-based device with tobacco flavored liquid.
215006572|NCT06961058|OTHER|referral to telehealth treatment|the intervention tested will be referral to get outpatient treatment via telehealth. Participants in the telehealth arm will receive the intervention.
215006573|NCT06961058|OTHER|referral to in person treatment|participants in the in person arm will be referred to in person OUD treatment after they leave the ED
215006574|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|MIV-818 - oral capsules; pembrolizumab - IV
215006575|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|MIV-818 - oral capsules; lenvatinib - oral capsules
215006576|NCT05536297|DRUG|avacincaptad pegol|Intravitreal Injection
215006577|NCT06836128|DRUG|N-acetyl cysteine|N-Acetyl Cysteine (NAC) has antioxidant properties and is essential for the body's production of glutathione, and both glutathione and NAC are potent antioxidants.
215006578|NCT06836128|DRUG|Metfomin|metformin is commonly used for managing polycystic ovary syndrome (PCOS) due to its benefits in addressing several underlying features of the condition. While it is not officially approved by regulatory agencies like the FDA for PCOS, it is widely recognized and recommended in clinical practice guidelines as an off-label treatment for PCOS, particularly in women with insulin resistance and metabolic dysfunction.
215006579|NCT01188447|PROCEDURE|Canadian C-Spine Rule|Paramedics will apply a validated decision rule (the Canadian C-spine Rule) to determine whether or not immobilization is required for trauma patients being transported to the emergency department.
215006580|NCT02941497|BEHAVIORAL|Social marketing and health promotion campaign|Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
214401738|NCT02763098|DRUG|Remi 0.2|.Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
215096430|NCT02687516|BEHAVIORAL|Family-based behavioral social facilitation therapy|"Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities."
214401739|NCT02763098|DRUG|Remi 0.3|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
214401740|NCT00767715|DRUG|olanzapine|physician determined dose, oral, daily, 5 months
215096431|NCT02687516|BEHAVIORAL|TAU - Treatment as usual|"This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic."
214401741|NCT00767715|DRUG|haloperidol|physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
214401742|NCT00767715|DRUG|zuclopentixol|physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
214401743|NCT05838612|OTHER|Heat acclimation|Participants will complete a 7-day passive heat acclimation protocol consisting of immersion in warm water (\~40°C) for 1 hour over 7 consecutive days.
214401744|NCT01660295|DRUG|Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU subcutaneous injection once daily
214401745|NCT01660295|DRUG|Certoparin 3,000 IU Twice a Day|Certoparin 3,000 IU subcutaneous injection twice a day
214401746|NCT01660295|DRUG|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU subcutaneous injection once daily
214401747|NCT01660295|DRUG|Certoparin 8,000 IU Twice a Day|Certoparin 8,000 IU subcutaneous injection twice a day
214504433|NCT03917186|DRUG|Desflurane|administration of Desflurane
214504434|NCT04826211|DIAGNOSTIC_TEST|PET/MRI|All included patients will undergo PET/MRI both prior to PST and prior to surgery. In order to analyze results the population will be divided into two groups: women with positive axillary lymph nodes after PST (Group 1) and women with negative axillary lymph nodes after PST (Group 2).
215006581|NCT06641310|PROCEDURE|Endurance Exercise Therapy|"* Exercise: Endurance exercise therapy comprising treadmill walking administered by exercise physiologists via a study-kit which includes a smart-watch (activity tracker), heart rate monitor, blood pressure cuff, body composition scale, and etablet)~* Exercise escalation trial testing 3 exercise levels (150, 225, and 300 minutes per week), with one de-escalation exercise of 90 minutes per week, if required.~* The phase 1b trial will evaluate the highest feasible exercise level and one exercise below identified in the phase 1a study."
215006582|NCT05830279|GENETIC|Pharmacogenetic testing|Genotyping for CYP2D6 and CYP2C19
215006583|NCT05830279|OTHER|Drug-Drug interaction analysis|Evaluating potential drug interactions with CYP2D6, CYP2C9 and CYP3A4 inhibitors and inducers using the Medical Letter.
215096432|NCT04171232|OTHER|Balance It|Each patient in group 1 i.e. Balance It group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to balance the objects falling from above on the imaginary bar (and an actual bar at later stages) held with their both hands, and not let those objects fall by opening their arms wide open and by staying or moving according to the target spot for the set time. This session would be repeated three times a week for two months (total 12 sessions/month).
215096433|NCT04171232|OTHER|Bubble Pop|Each patient in group II i.e. Bubble Pop group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to reach for the balloons coming from random directions and pop them by moving their upper limbs and even their whole body if required. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
215096434|NCT04171232|OTHER|Scoop'd|Each patient in group III i.e. Scoop'd group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to hold an imaginary ice cream cone (and an actual basket designed similar to an ice cream cone in later stages) with their both hands and move to catch the ice cream scoops falling at random spots from above, one spot at a time. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
214401748|NCT01972087|BEHAVIORAL|Telephone simulation training|The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
214401749|NCT02394886|BIOLOGICAL|ALLO-ASC-DFU|
215096435|NCT04675996|DRUG|INT-1B3|60-min i.v. infusions twice per week in 21-day cycles
215096436|NCT01311440|OTHER|Modified Atkins diet treatment|Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
215096437|NCT04889482|OTHER|No intervention|No intervention
215096438|NCT03764930|OTHER|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
214401750|NCT03281265|OTHER|standard treatment|
214401751|NCT02180711|DRUG|acalabrutinib|
214401752|NCT02180711|DRUG|rituximab (IV)|
214401753|NCT02180711|DRUG|Lenalidomide|
214401754|NCT01036087|DRUG|Panitumumab|2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.
214401755|NCT01036087|DRUG|Nab-paclitaxel|100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.
214401756|NCT01036087|DRUG|Carboplatin|AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.
214401757|NCT01036087|DRUG|5-Fluorouracil|500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
214401758|NCT01036087|DRUG|Epirubicin|100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
214401759|NCT01036087|DRUG|Cyclophosphamide|500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
214401760|NCT00134810|BIOLOGICAL|Botulinum toxin type A|
214401761|NCT00406809|DRUG|ABT-263|"Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~\- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose."
214401762|NCT02595307|BEHAVIORAL|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
214401763|NCT00512408|DRUG|testosterone|
215006584|NCT06290713|DRUG|Tadalafil|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
215006585|NCT06290713|DRUG|Placebo|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
214401764|NCT04376476|BIOLOGICAL|Blood sample|blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0
214401765|NCT04376476|BIOLOGICAL|Low or upper respiratory tract sample|"Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0"
214401766|NCT04376476|BIOLOGICAL|Stool collection or fecal swab|"The stool collection or fecal swab will be collected in order to take virology measurements:~Group E1: / Group E2: At day 0, day 7, day 14 Group E3: At day 0"
214401767|NCT04376476|OTHER|phone call|phone calls will be performed to collect data regarding patients' symptoms at: Group E1: Day 14 Group E3: Day 14
214401768|NCT06356181|DEVICE|Respiratory Maximus Training Device|Those in the intervention group will wear the respiratory training device for 3 days per week of high-intensity functional training over 6-weeks.
215096439|NCT05889078|BEHAVIORAL|A 4-week walking intervention|Participants will walk along a predetermined route 3 times per week for a period of 4 weeks, answering a pre- and post-intervention questionnaire as well as weekly questionnaires measuring their affect and other variables related to wellbeing. Participants will be randomly assigned to one of two conditions (nature vs urban setting), determining whether the predetermined route they will walk is in a nature or urban setting.
215006586|NCT06290713|OTHER|Exercise Training|The home-based cycling exercise training program is designed to improve muscle strength and endurance. Participants will engage in individualized exercise sessions up to four times per week, lasting up to 40 minutes each. Live video and heart rate monitoring will ensure proper exercise performance and allow for adjustments to the program throughout the study. The participants will receive the exercise equipment for use at home.
215006587|NCT00117819|DRUG|[123I]ß CIT and SPECT imaging|To assess \[123I\]ß CIT and SPECT imaging
215006588|NCT06030882|OTHER|Biologic Care Pathway|Receiving care administered through a biologic care pathway.The central biologic intake nurse will touch base with the IBD program nurse navigator at preselected time points as per the pathway in order to coordinate the baseline pre- biologic work-up, clinical and biomarker assessments, and clinical assessments. Clinical management decisions will be informed by a combination of data points including clinical risk factors, TDM, fecal calprotectin concentrations, endoscopic and clinical disease activity indices as well as drug tolerance and adverse events. Within the care pathway, time- bound clinical and biomarker data will be provided to the treating clinician to help inform their clinical decisions.
215006589|NCT06575452|DIAGNOSTIC_TEST|Blood, urine and tumoral tissue samples|Blood, urine and tumoral tissue samples
215006590|NCT06575452|DIAGNOSTIC_TEST|Tumoral tissue samples|tumoral tissue samples
215096440|NCT02654665|BEHAVIORAL|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
215096441|NCT02654665|DRUG|Liraglutide|GLP-1 agonist
215096442|NCT01662323|BEHAVIORAL|GP's treating HF according the dutch guidelines|
215096443|NCT02476786|BEHAVIORAL|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
215096444|NCT02476786|DRUG|Goserelin|
215096445|NCT02476786|DRUG|Anastrozole|
215096446|NCT02476786|DRUG|Exemestane|
215096447|NCT02476786|DRUG|Fulvestrant|
215096448|NCT02476786|DRUG|Tamoxifen|
215096449|NCT02476786|OTHER|Archived tissue collection|
215096450|NCT01390922|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
215096451|NCT03545074|BEHAVIORAL|Mindful Awareness Practices- English|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in English)
215096452|NCT03545074|BEHAVIORAL|Mindful Awareness Practices- Spanish|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in Spanish)
214401769|NCT06356181|DEVICE|No Respiratory Training Device|Those in the control group will train for 3 days per week of high-intensity functional training over 6-weeks.
215096453|NCT03545074|BEHAVIORAL|Health Education - English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in English)
215096454|NCT03545074|BEHAVIORAL|Health Education - Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in Spanish)
214401770|NCT03961256|DRUG|Exenatide SR|Exenatide SR 2 mg subcutaneous (SQ) weekly
214522644|NCT02650661|BEHAVIORAL|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
215006591|NCT00002835|BIOLOGICAL|Bleomycin Sulfate (BLM)|
215006592|NCT00002835|BIOLOGICAL|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
215006593|NCT00002835|BIOLOGICAL|Recombinant Interferon Alfa|
215006594|NCT00002835|DRUG|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
215006595|NCT00002835|DRUG|Cisplatin (CDDP)|
215006596|NCT00002835|DRUG|Cyclophosphamide|
215006597|NCT00002835|DRUG|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
215006598|NCT00002835|DRUG|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
215006599|NCT00002835|DRUG|Idarubicin|
215006600|NCT00002835|DRUG|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
215006601|NCT00002835|DRUG|Leucovorin Calcium|
215006602|NCT00002835|DRUG|Melphalan|
215006603|NCT00002835|DRUG|Methotrexate|
215006604|NCT00002835|DRUG|Methylprednisolone|
215006605|NCT00002835|DRUG|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
215006606|NCT00002835|DRUG|Vincristine Sulfate|
215096455|NCT05549791|DRUG|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
215096456|NCT02146794|DEVICE|Renal denervation|Renal denervation
215096457|NCT06170918|DRUG|Remimazolam|remimazolam is given intravenously
215096458|NCT02416596|PROCEDURE|Hysteroscopy|"Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection."
215096459|NCT02416596|DEVICE|Hysteroscope|"The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
215096460|NCT00079092|DRUG|procarbazine hydrochloride|
215096461|NCT00079092|DRUG|thalidomide|
215096462|NCT01233063|BEHAVIORAL|Physical Activity and Diet Intervention via Alive2|Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.
215006607|NCT00002835|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
215006608|NCT00002835|RADIATION|Radiation Therapy|
215006609|NCT02496429|DEVICE|BrownieForSymphony use|Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
215006610|NCT05166096|DRUG|Rho-11|Subjects will be administered 325 mg aspirin by rapid IV push
215006611|NCT05166096|DRUG|aspirin 325mg|Subjects will be administered 325 mg aspirin orally
215096463|NCT02391181|DRUG|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
215096464|NCT02391181|DRUG|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
215096465|NCT04457063|PROCEDURE|PKP|"1. The horizontal axis was marked with a pointed marker at the slit lamp immediately before surgery.~2. TICL loading into the STAAR injector cartridge~3. Temporal clear corneal 3 mm incision \& 2-side ports then viscoelastic injection into the AC~4. Implantation of the TICL using the injector, then rotation according to the implantation diagram guided with Mendez protractor, and lastly placement of the haptics under the iris.~5. Pupil constriction with A.Ch.~6. Washing the viscoelastic \&Wound hydration.~7. Topical antibiotic steroids (Vigamox and Tobradex) 4 times /day for 3weeks"
215006612|NCT01529268|DRUG|DR cysteamine bitartrate capsule|"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
215096466|NCT05440214|BEHAVIORAL|Dialectical Behavior Therapy Skills Training|Dialectical Behavior Therapy Skills Training (DBT-ST) is a group-based intervention focused on teaching skills for improving emotion regulation. The sessions will be offered in-person or via approved telehealth services.
215096467|NCT03576859|OTHER|blood sample|Peripheral venous blood is collected before liver transplantation and after restoration of liver function
215096468|NCT04055779|OTHER|estimation method for arterial occlusion pressure|The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=\[SBP+10\]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
215096469|NCT04055779|OTHER|the limb occlusion pressure|: using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
215096470|NCT03130036|OTHER|[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan|A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study
215096471|NCT04361240|RADIATION|Proton vs Photon Radiation|Assignment to proton vs photon by randomization on RadComp parent study.
215096472|NCT01445197|BIOLOGICAL|Biostate|200 IU/kg administered daily
215096473|NCT02720692|DRUG|N1539|
215096474|NCT02720692|DRUG|Intravenous Placebo|
215096475|NCT05011513|DRUG|PF-07321332|PF-07321332 (tablet)
215096476|NCT05011513|DRUG|Ritonavir|Ritonavir (capsule)
215096477|NCT05011513|DRUG|Placebo|Placebo (tablet)
214401771|NCT05310721|BEHAVIORAL|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
215096478|NCT05011513|DRUG|Placebo|Placebo (capsule)
215096479|NCT00582777|BEHAVIORAL|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
215096480|NCT00582777|BEHAVIORAL|HS DOSING|Take your usual BP meds at bed time
215096481|NCT00582777|DRUG|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
215096482|NCT02636023|DEVICE|SPhENo-Cardiograph|SPhENo-Cardiograph
214401772|NCT05310721|BEHAVIORAL|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
215006613|NCT01529268|OTHER|DR cysteamine bitartrate placebo|"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
215006614|NCT05361837|PROCEDURE|Single level serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third rib
215006615|NCT05361837|PROCEDURE|Single level serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib
215006616|NCT05361837|PROCEDURE|Bilevel serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third and fifth rib
214688206|NCT06929169|DRUG|iSGLT2|"Participants randomized to the experimental arm will receive a once-daily dose of a sodium-glucose cotransporter 2 inhibitor (SGLT2i), administered orally, in addition to their standard hemodialysis care. The specific agent (e.g., dapagliflozin or empagliflozin) and dose will be selected based on safety data and clinical guidelines applicable to patients with end-stage renal disease (ESRD) on dialysis. The intervention will be maintained for 12 months. Dosing will be monitored by the research team to ensure tolerability and adherence. All patients in the experimental group will undergo comprehensive cardiovascular assessment, including serial cardiac MRI, echocardiography, and measurement of fibrosis-related biomarkers.~This intervention differs from standard care by introducing a pharmacologic agent not routinely administered in the dialysis population, targeting cardiac remodeling, fibrosis, and intradialytic complications."
214401773|NCT05310721|BEHAVIORAL|Self-selected time-restricted eating|Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
215096483|NCT01455896|DRUG|ITCA 650|ITCA 650
215096484|NCT01455896|OTHER|ITCA placebo|ITCA placebo
215006617|NCT05361837|PROCEDURE|Bilevel serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib
214401774|NCT02708641|DRUG|pembrolizumab|200 mg IV given every three weeks
214401775|NCT04591184|BIOLOGICAL|Covigenix VAX-001 placebo|Placebo vaccine
214688207|NCT04359446|PROCEDURE|NC ( Non- Compliant) Balloon dilatation|NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
215006618|NCT03755466|DRUG|"Baricitinib, olumiant®"|To examine the effects of baricitinib in RA patients
215006619|NCT03755466|DRUG|"Biologics"|To examine the effects of biologics in RA patients
215006620|NCT03755466|DRUG|Tofacitinib 5 MG [Xeljanz]|To examine the effects of tofacitinib in RA patients
215006621|NCT02529332|DIETARY_SUPPLEMENT|Omega-3|Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
215096485|NCT02412046|PROCEDURE|Muscle biopsy|
214401776|NCT04591184|BIOLOGICAL|Covigenix VAX-001|Active Covigenix VAX-001
214401777|NCT02347449|OTHER|Questionnaires, Oncotype Dx Assay|"1. Physician pre-assay questionnaire~2. Patient pre-assay questionnaire~3. Oncotype DX® Assay~4. Physician post- assay questionnaire~5. Patient post-assay questionnaire"
214401778|NCT01021878|OTHER|icodextrin|glucose sparing dialysis solution
214401779|NCT01021878|OTHER|Dianeal|glucose based dialysis solution
214401780|NCT03251144|DRUG|Switch to E/C/FTC/TAF daily|"If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)\] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months.~b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
214401781|NCT02213679|DIETARY_SUPPLEMENT|Guanidinoacetic acid|Dietary supplement
214401782|NCT02213679|OTHER|Placebo|Placebo
214688208|NCT04359446|PROCEDURE|Laser Excimer + NC Balloon|Laser Excimer + NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
214688209|NCT04094961|DRUG|Ixazomib|Oral, administered four times per cycle
214688210|NCT04094961|DRUG|Pomalidomide|Oral, administered 14 times per cycle
215006622|NCT06530693|OTHER|OPUS-i algorithm|A novel pre-hospital algorithm.
215006623|NCT02661971|DRUG|Docetaxel|Docetaxel 50 mg/m², d1
215006624|NCT02661971|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m², d1
215006625|NCT02661971|DRUG|Calciumfolinat|Leucovorin 200 mg/m², d1
215006626|NCT02661971|DRUG|5-Fluorouracil|5-FU 2600 mg/m², d1
215006627|NCT02661971|BIOLOGICAL|Ramucirumab|Ramucirumab 8mg/kg, d1
215006628|NCT03651492|BEHAVIORAL|questionnaire administration|All the patients will be administered the Pittsburgh Questionnaire after completion of ABPM.
215006629|NCT01909271|BEHAVIORAL|Stroke Education Film Viewing|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
215006630|NCT01909271|OTHER|Stroke Education Pamphlet Exposure|"Usual Care: Stroke Education pamphlet and brochure distribution."
215006631|NCT01713127|DRUG|remifentanil infusion|
215006632|NCT01713127|DRUG|Placebo|
215006633|NCT05789342|DRUG|GP681|GP681, tablet, oral
215006634|NCT05789342|DRUG|Rosuvastatin|Rosuvastatin, tablet, oral
215006635|NCT05789342|DRUG|Digoxin|Digoxin, tablet, oral
215006636|NCT05789342|DRUG|Itraconazole|Itraconazole, capsule, oral
215006637|NCT05789342|DRUG|Oseltamivir|Oseltamivir, capsule, oral
215006638|NCT02891330|BEHAVIORAL|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
215006639|NCT02369250|DRUG|Rosuvastatin|Rosuvastatin, is a statin group of drug.
215006640|NCT02369250|BIOLOGICAL|platelet rich fibrin|AUTOLOGUS PLATELET GROWTH FACTOR
215096486|NCT01989247|BEHAVIORAL|Self-management programme|Seven weekly group-based sessions for people with anxiety and depressive symptoms
215096487|NCT03878758|DEVICE|BD Nano™ PRO|Insulin Pen needle
215096488|NCT03878758|DEVICE|33G Artsana Insupen Extr3me|Insulin Pen Needle
215096489|NCT03878758|DEVICE|34G Artsana Insupen Extr3me|Insulin Pen Needle
215096490|NCT03878758|DEVICE|Simple Diagnostics Comfort EZ™|Insulin Pen Needle
215096491|NCT02138968|OTHER|Multidisciplinary intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
215096492|NCT01996124|DRUG|Indacaterol Fumarate|150 mcg inhalation powder, hard capsules, once daily
215096493|NCT01996124|DRUG|Placebo|Fructose, dry inhalation powder, hard capsules via breezhaler
215006641|NCT05719688|DEVICE|Mechanical thrombectomy|Treatment of ischemic stroke patients with Mechanical thrombectomy
214401783|NCT02651103|DEVICE|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
215006642|NCT00191880|DRUG|atomoxetine|
214401784|NCT05175443|OTHER|Exercise|Participants will be trained, by a physical therapist, to perform a set of four daily exercises requiring 1 sets of 2 minutes for each exercise totaling 8 minutes of targeted exercise per day for 8 weeks of the intervention. These exercises will be progressed or modified every 2-4 weeks to assure the participant is receiving maximal benefit for their exercise intervention.
214688211|NCT04094961|DRUG|Dexamethasone|Oral, fixed dose administered 8 times per cycle
215006643|NCT02974504|DRUG|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
215006644|NCT02974504|DRUG|Linagliptin|linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg
215006645|NCT01741662|OTHER|neuropsychological evaluation|
215006646|NCT04433312|OTHER|Questionnaire|The questionnaire is developed based on a literature review and clinical experience. Initial testing of the questionnaire will be performed with 20 patients to assess the reliability and inter-rater variations. After initial testing, the final questionnaire will be formulated. The first sector of the questionnaire includes patient demographics and baseline characteristics; the second sector is regarding patient clinical condition, diagnosis, and scheduled surgery. The following sector examines the process of delivering the cancellation to the patient and requirements for re-scheduling. Patients will be classified into satisfied or dissatisfied according to the responses in this sector. The following sector addresses the course of care after cancellation and whether the patient conducted the surgery elsewhere or not. The last sector explores the impact of cancellation on patient health, career, and financial aspects.
215006647|NCT01615718|PROCEDURE|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
215006648|NCT01615718|PROCEDURE|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
215006649|NCT05478746|DEVICE|BioNourish, a component of the Flourish HEC kit|BioNourish is a vaginal moisturizing gel which obtained FDA 510k clearance in 2020. It is one component of the full system being tested. The main intervention is to use this kit to improve the vaginal microbiome.
215096494|NCT03841435|RADIATION|Hypofractionated Radiotherapy|Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.
215096495|NCT02315560|DEVICE|TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS|electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
214401785|NCT00345462|BIOLOGICAL|Trivalent virosomal influenza vaccine|
214401786|NCT05737563|DRUG|PD-1 Inhibitors|Teripulimab 240mg, injection or Carrelizumab 200mg, injection, every 3 weeks.
215006650|NCT05478746|OTHER|Control - no intervention|No intervention; participants only receive routine care.
215006651|NCT02096224|DRUG|Sevoflurane|Sevoflurane will be used.
215006652|NCT02096224|DRUG|Desflurane|Desflurane will be used
215006653|NCT03324009|DIAGNOSTIC_TEST|2-stage screen|Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
214401787|NCT05737563|DRUG|Irinotecan|Irinotecan: 200mg/m2, injection (For patients who are confirmed to be homozygous for UGT1A1\*6 or UGT1A1\*28 or UGT1A1\*6 and UGT1A1\*28 at the same time, the starting dose of CPT-11 is 150 mg/m2).
214401788|NCT05737563|DRUG|Capecitabine tablets|Capecitabine: 1600 mg/m2/d, oral, 2 weeks on and 1 week off.
214401789|NCT01049750|OTHER|type 2 diabetic patients|males; type 2 diabetic patients
215006654|NCT03073447|OTHER|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
215006655|NCT00200824|DRUG|Soy Isoflavone Nutritional Supplements|
215006656|NCT00834938|OTHER|No intervention|No intervention
214401790|NCT05305040|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
214401791|NCT05305040|BIOLOGICAL|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
214688212|NCT06076928|DEVICE|Brain Computer Interface integrated HandyRehab platform (BCI-HR)|To test the usability, safety and efficacy of an experimental prototype of a wearable hand robotic glove integrated with brain computer interface system being developed and researched.
214688213|NCT06076928|DEVICE|HandyRehab (HR)|A wearable hand robotic glove approved by Health Sciences Authority, class I commercial device
214688214|NCT06076928|OTHER|Standard Treatment of Care|Standard Conventional Occupational Therapy
215096496|NCT06480149|OTHER|SMALC|Classical shoulder massage was applied to both shoulders of the patient for 10-15 minutes each.
215096497|NCT06480149|OTHER|no application|In the control group, there was no massage application and only pain and sleep quality were evaluated.
215096498|NCT06238206|OTHER|Focus group discussion|The participant will be asked to take part in three separate focus group discussions implementing the co-design principle. Following the co-design principle the participants will actively contribute towards the primary outcomes. Open questions will be asked to guide the discussion. Interaction between participants will be encouraged.
214401792|NCT01532050|DEVICE|Mandibular Advancement Device ( MAD)|
214401793|NCT00184561|DRUG|biphasic insulin aspart|
214401794|NCT03700255|PROCEDURE|PickUpSimTM simulation training program|"The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians."
214401795|NCT04442672|PROCEDURE|acute compartment syndrome model of health volunteer|the acute compartment syndrome model of health volunteer is induced by pressurizing the calves by the cuff, and the cuff is inflated and pressurized to a pressure value of 20, 30, 40, 50, 60, 70, 80 mmHg. the pressure inside the cuff was up to 10 s during pressurization and maintained stable for 1 min, measured and the above indicators were recorded within 3 min.
214401796|NCT04442672|PROCEDURE|sham|surrounding the cuff but not inflate it.
214401797|NCT03356743|DEVICE|Spectrum Analysis|The ultrasound probe will be placed on the lung surface in several different directions to obtain the cross section with maximum diameter. Three spectral parameters including midband-fit (dB), intercept (dB), and slope (dB/MHz) will be calculated and compared between the tumor and the lung.
214401798|NCT00868205|DIETARY_SUPPLEMENT|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
214401799|NCT02008058|BEHAVIORAL|Survey|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
214401800|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing adherence markers|The supplement will be provided once daily for 10 days
214401801|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing or not containing adherence markers|The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.
214401802|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement not containing adherence markers|The supplement will be provided once daily for 10 days
214401803|NCT02488772|DEVICE|Sleep mask|
214401804|NCT02488772|OTHER|Standard of care|Standard of care as decided by treating emergency physician
214401805|NCT02488772|DEVICE|Ear Plugs|
214401806|NCT05661526|OTHER|Bloodpoly board game|Blood transfusion training given by Bloodpoly board game
214401807|NCT05661526|OTHER|Text-to-speech group|Blood transfusion training given by text-to-speech
214401808|NCT01421043|DRUG|triazolam liquid oral drops|0.25 mg single dose oral drops
214401809|NCT01421043|DRUG|triazolam tablets|0.25 mg single oral dose
214401810|NCT02400190|OTHER|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
214401811|NCT05372003|DRUG|Dupilumab|dupilumab injections will be prescribed and managed by dermatology as standard of care
214401812|NCT05372003|OTHER|Photo therapy|light therapy will be prescribed and managed by dermatology as standard of care
214401813|NCT00593164|DEVICE|Cooling with ThermoSuit with Magnesium Sulfate Infusion|Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
214688215|NCT07100847|PROCEDURE|Periprostatic neurolysis with dehydrated alcohol (ethanol)|Pre-operative ultrasound guided periprostatic neurolysis by injection of dehydrated alcohol
214688216|NCT07101705|DRUG|OriV508 Injection|OriV508 injection is one kind of non-replicative self-inactivating lentivirus vector which carries an effective BCMA/CD19 dual-target CAR. OriV508 can be administered intravenously and produce BCMA/CD19 CAR-T in vivo.
215006657|NCT06370975|DRUG|3% hypertonic Saline|"the patients received 3% HS at the rate of 4 mL/kg for 30 minutes. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
214401814|NCT00593164|DEVICE|Cooling with ThermoSuit with Normal Saline Infusion|Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
214688217|NCT03321552|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
214688218|NCT03321552|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
214688219|NCT06063967|DRUG|Risankizumab SC|subcutaneous (SC) injection
214688220|NCT06063967|DRUG|Placebo for risankizumab|subcutaneous (SC) injection
215006658|NCT06370975|DRUG|Ringer's lactated solution|"the patients received ringer's lactated solution at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
214401815|NCT02920398|DRUG|turoctocog alfa pegol|Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
215006659|NCT06370975|DRUG|0.9% Normal saline|"the patients received 0.9% Ns at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
215006660|NCT00291915|DRUG|Adalimumab|
215006661|NCT00291915|DRUG|Methotrexate|
214401816|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
214401817|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
215006662|NCT05484167|DRUG|Natesto Nasal Product|Nasal Gel used for 90 days then crossed over to placebo gel
214401818|NCT00003802|DRUG|pyrazoloacridine|
214401819|NCT04721509|DEVICE|Experimental : Smartphone-based telemedicine with the app 'Songaree diabetes'|Experimental group: outpatient clinic and offline education every 12 weeks plus telemedicine and education with smartphone app 'Songaree diabetes' every 2 weeks for 24 weeks
215006663|NCT05484167|DRUG|Placebo|A nasal gel with no active ingredients
215006664|NCT06302283|OTHER|Survey|Survey (online or paper) on caregiving burden and bereavement
215006665|NCT03838874|DRUG|Low-Dose Bupivacaine|10 mg (2 mL of 0.5%) administered as an isobaric spinal anesthetic
215006666|NCT03838874|DRUG|Mepivacaine|70 mg (3.5 mL of 2%) administered as an isobaric spinal anesthetic
215006667|NCT03476512|OTHER|Adherence Education|Patients were given adherence education to resolve the identified deficits
215006668|NCT05378321|DIAGNOSTIC_TEST|Non-invasive diagnostic testing|Non-invasive diagnostic testing consists of the use of the FibroScan device and the calculation of non-invasive blood-based scores for the diagnosis of NAFLD
215006669|NCT05293834|BEHAVIORAL|Virtual Reality Aggression Prevention Training (VRAPT)|"VRAPT consists of sixteen 45- to 60-minute sessions that take place once or twice per week (total duration of the intervention = 8 to 16 weeks). Session time and intensity will be adapted to the individual participant and the sessions will be delivered by specially trained VRAPT therapists in individual settings. The immersive and interactive three-dimensional virtual environment will be presented via headphones and head-mounted displays, using software developed by CleVR. In the virtual environment, participants will interact with virtual characters that are controlled by the psychotherapist and practice new skills . The therapy program is targeted at factors and processes related to aggression and the underlying theoretical framework is based on cognitive behavioural therapy and the General Aggression Model (GAM).~The VRAPT consists of 4 phases:~1. Introduction (Session 1)~2. Inventory phase (Sessions 2-6)~3. Skills-training (Sessions 6-15)~4. Evaluation (Session 16)"
214401820|NCT06450184|DRUG|Pimavanserin 34 mg|1 capsule of Pimavanserin Capsule 34mg
214401821|NCT06450184|DRUG|NUPLAZID 34 MG Oral Capsule|1 capsule of Pimavanserin Capsule 34mg
214401822|NCT06395363|PROCEDURE|fixation method|The fixation methods were either involved trans-articular fixation through the acromioclavicular joint, supplemented with an additional cerclage wire tension band for enhanced stability. Or, creating a tunnel in the sub-acromial space posterior to the acromioclavicular joint and inserting the hook into this tunnel.
214401823|NCT00335543|DRUG|cisplatin|
214401824|NCT00335543|DRUG|gemcitabine hydrochloride|
214401825|NCT00335543|PROCEDURE|adjuvant therapy|
214401826|NCT00335543|PROCEDURE|conventional surgery|
214401827|NCT00335543|PROCEDURE|neoadjuvant therapy|
214401828|NCT00335543|RADIATION|radiation therapy|
214401829|NCT02442414|DRUG|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
214401830|NCT05037656|BEHAVIORAL|School-based curriculum|Participants will be randomized, at the school level, to receive either the e-cigarette/tobacco/areca nut use prevention curriculum or the standard of care (i.e., control). The curriculum will be implemented using 5 intensive in-class lessons over the span of 6 weeks. All sessions of the curriculum follow the same basic format: a) an introduction and/or review of the past lesson, b) a cultural wall activity, c) a video, d) 1-2 interactive activities, and e) a wrap-up activity. Lessons are designed such as to help improve knowledge about drugs and correct cognitive misperceptions and to train on skills to resist normative social influence. Participants will complete identical survey questionnaires for assessments at 3 time-points: pretest (baseline, before implementing the intervention), immediate posttest (following the end of the intervention), and six-month follow-up. The surveys will be administered in the classroom, during regular school hours.
214401831|NCT06439953|DEVICE|Chlorhexidine gluconate solution|Evaluating the prophylactic use of Irrisept irrigation alone
214401832|NCT06439953|DRUG|Vancomycin|Evaluating the use of versus vancomycin-saline irrigation with or without topical vancomycin
214401833|NCT06755710|BEHAVIORAL|Introductory PTSD module|The Introductory PTSD module consist of four session focusing on motivation
214401834|NCT06755710|BEHAVIORAL|Shared Decision Making|A patient-centred shared decision making session where one of four standardised treatments can be chosen
214401835|NCT06755710|BEHAVIORAL|Treatment as Usual|Treatment as usual
215006670|NCT05100342|DIAGNOSTIC_TEST|Point score prediction tool for 30-day survival|"This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days"
214401836|NCT06755710|BEHAVIORAL|Standardised treatments|One of four treatments Treatment as ususal Sessions with psychologists Sessions with nurses Sessions with medical doctors
215006671|NCT04359888|OTHER|Multi-Modality Balance Intervention|Three one-hour training sessions 2-3x per week for six weeks in Multi-Modality Balance Intervention (MMBI). (See Study Design)
215006672|NCT04359888|OTHER|Balanced Reach Training (BRT)|One-hour training sessions 2-3x per week for six weeks in the Balanced Reach Training Protocol (BRTP) (See Study Design).
215006673|NCT05709132|BEHAVIORAL|iPeer2Peer Program|Behavioral: iPeer2Peer Support Mentorship Program is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
215006674|NCT06034392|DEVICE|CHAMP App|CHAMP® App is a downloadable software mobile Application with a Software Platform. CHAMP® App is an electronic version of data entry for children with conditions that require close monitoring from their homes. The primary Intended Use is to relay monitoring information from homes to the health care team. This monitoring includes data options that can facilitate the collection of monitoring data of children in the home setting to improve communications between parents at home and remote caregivers. The CHAMP® App itself does not do home monitoring of the child's medical condition. It is not designed to alert parents if data entered has reached a red flag (problem) level. Users of the CHAMP App are advised in writing and in the informed consent process that urgent medical conditions should not be managed through the CHAMP App, and that appropriate emergency care should be obtained directly rather than through the CHAMP App.
214401837|NCT06522373|DRUG|MT-0169|Given by Vein (IV)
214401838|NCT03596424|DRUG|Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
214401839|NCT03596424|DRUG|Dexmedetomidine Hydrochloride|Intraoperative bolus and infusion (see arm description)
215006675|NCT05029063|DRUG|Rivaroxaban 10 MG|Identical comparator drug
215006676|NCT06508827|DRUG|Iron dextran 1000 mg IV|Iron dextran 1000 mg IV will be administered once, about 7 days prior to standard of care treatment.
215006677|NCT06495489|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
215006678|NCT05893823|DIAGNOSTIC_TEST|Pelvis CT scan|Post-THA hip pelvis CT scan execution for pain, noise or THA planning for the controlateral hip, with identification of acetabular cup protrusion. Comparation of cases and controls to identify radiological factors that could potentially lead to symptomatic psoas impingement prediction.
215006679|NCT06964737|BIOLOGICAL|Anti-GARP Chimeric Antigen Receptor-T Cells|Given intracavitary
215006680|NCT06964737|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood samples
215006681|NCT06964737|PROCEDURE|Chest Radiography|Undergo chest x-ray
215006682|NCT06964737|PROCEDURE|Echocardiography Test|Undergo ECHO
215006683|NCT06964737|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215006684|NCT06964737|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215006685|NCT06964737|PROCEDURE|Pheresis|Undergo apheresis
215006686|NCT06964737|PROCEDURE|Surgical Procedure|Undergo surgery and placement of CSF reservoir
215006687|NCT05575011|DRUG|BIIB115|Administered as specified in the treatment arm
215006688|NCT05575011|DRUG|BIIB115-Matching Placebo|Administered as specified in the treatment arm
215006689|NCT04912817|OTHER|Off the Shelf VR|"Operates using Oculus quest VR HMD and uses auditory and visual stimuli during the pain rehabilitation treatment. The Off-the-shelf VR program for Oculus Quest VR features a suite of off-the shelf applications that can be tailored by the PT and used with participants including. PR-VR sessions will be 30 minutes in total with approximately 20 minutes in the virtual experience and 10 minutes for set-up, screening, instructions, and rest breaks. The Off-the-shelf VR intervention group will also receive 30 minutes of usual care, and Standard Virtual Physiotherapy Treatment (SVPT) during the same appointment, for a total 1-hour usual care session length."
215006690|NCT04912817|OTHER|Custom VR|Operates using Oculus Quest VR HMD with PR-VR software developed with two gaming options: Fruity Feet and Space Burgers 2. Game settings are manipulated by the physiotherapist in session to target specific limb movements and intensity and also motivates participants to cycle using a leg ergometer. Motion sensors on the ergometer track the participants revolutions per minute. For participants in this study arm, a leg ergometer (DeskCycle) will be provided to them during the study phase alongside the Actigraph and Oculus Quest HMD. During the 30min VR portion of the session, 20 minutes will be dedicated to gaming and exercise, and 10 minutes dedicated for set up, tear down, and rest breaks. During the 20 minutes gaming time, a minimum of 15 minutes will be dedicated to Custom VR, with 5 minutes for 'free play' where the participant can opt to try an off-the-shelf VR game.
215006691|NCT05920005|DRUG|candesartan cilexetil + chlorthalidone + amlodipine|Antihypertensive drugs in a single tablet (association candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg)
215006692|NCT05920005|DRUG|Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)|Antihypertensive drugs in a single tablet (association valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
214401840|NCT03596424|COMBINATION_PRODUCT|dexmedetomidine Hydrochloride and Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
215006693|NCT04412889|BIOLOGICAL|BCMA/CD19 dual-target CAR-T cell immunotherapy|The intervention is a CAR-T cell immunotherapy targeted CD19 and BCMA. The dosage ranges from 2×10\^5 to 1×10\^6 CAR+T/Kg.
215006694|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 1）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
214401841|NCT04430517|DRUG|Nicotinamide riboside|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
215096499|NCT03090555|PROCEDURE|Translational manipulation|After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.
215096500|NCT03090555|PROCEDURE|Manual therapy|The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
214401842|NCT05663892|DRUG|Biktarvy 50/200/25 Tab|As the HIV ART, the combination of B/F/TAF, known as Biktarvy®, which is a widely available Single Tablet Regimen (STR) approved by Health Canada is the drug under investigation. Participants in groups 1 and 2 will either have to already be taking B/F/TAF or will be required to switch to it at baseline and they will self-administer B/F/TAF once daily in the morning, with or without food. Participants taking their dosage at night will be required to switch to a morning dose at the screening visit.
214401843|NCT05663892|DRUG|Estradiol Tablets|"Oral 17(beta)-estradiol as the estrogen and an anti-androgen (pharmaceutical \[e.g., spironolactone, cyproterone, finasteride, leuprolide, bicalutamide, dutasteride\] and/or surgical \[orchiectomy\] and/or medical \[hypogonadism\]).Doses of estradiol range from 1 mg to a maximum of 6 mg per day.~Participants must take 2 mg until the Month 2 Visit. Trans women participants in both groups 1 and 3 must divide their dose to twice a day (BID) if they are taking \> 2 mg per day and take 2 mg in the morning and the rest of the dosing in the evening. Participants who are only taking 2mg of estradiol once daily at night must switch their dosing to the morning. Participants who either crush or take the oral estradiol sublingually must switch to swallowing the tablet orally from the day after the screening visit until the Month 2 visit, otherwise the estradiol concentrations will be markedly higher."
214401844|NCT05992233|DEVICE|Dual wavelength low level laser|Application of double wavelength low level laser to the related area after tooth extraction.
214401845|NCT05992233|DEVICE|Placebo|Only red light applied.
214401846|NCT05406791|OTHER|VIRA App|Support from coach and using the VIRA app
214401847|NCT05406791|OTHER|Mood Education App|Support from mood education app
214401848|NCT04018781|OTHER|medication reconciliation|"During hospitalization, the hospital pharmacist will carry out a pharmaceutical analysis for all patients included in the study, each time the prescription is changed and within a maximum of 24 hours (working days).~If necessary, in consultation with the doctor in charge of the patient, the pharmacist may also propose a pharmaceutical interview to the patient at any time during his hospitalisation (e.g. proposal for the de-prescription of benzodiazepines, Proton Pump Inhibitors, etc., according to the recommendations in force)."
214401849|NCT03674593|PROCEDURE|Mitral valve chordae prosthesis|"The method consists of five stages:~1. Measure the required length of the chords~2. Forming loops~3. Fixation of the loop group to the papillary muscles~4. Fixation of chordal loops to the free edge of the valve~5. Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse"
214401850|NCT03674593|PROCEDURE|Mitral valve chordae translocation|"The method consists essentially of three stages:~1. Selection of the secondary chord.~2. Fixation of secondary chords to the free edge of the valve.~3. Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
214401851|NCT05144386|BIOLOGICAL|EBT-101|EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration
214401852|NCT03947957|DIAGNOSTIC_TEST|collection of expectoration, stools and blood|collection of expectoration, stools and blood
214401853|NCT06796049|BEHAVIORAL|Information pamphlet + social norm driver|"The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 Colorectal cancer (CRC) screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.~The information pamphlet will also contain a social norm driver that displays the sub-par screening rate the clinic compared to a collective New York State screening rate and a national screening rate goal set by the CDC."
214401854|NCT06796049|BEHAVIORAL|Information pamphlet|The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 CRC screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.
214401855|NCT03844516|OTHER|Peak oxygen uptake test with pacing|Peak oxygen uptake test with paced heart rate
215006695|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 2）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
215006696|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 3）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
215006697|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 4）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
215096501|NCT02253485|DRUG|telbivudine|"in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.~in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV."
214401856|NCT03844516|OTHER|Peak oxygen uptake test without pacing|Peak oxygen uptake test without paced heart rate
214401857|NCT04359056|OTHER|Clinical pharmacy activities along the care pathways|"PICC line implantation: Optimize the logistics circuit of the PICC line by rationalizing orders through the evaluation of potential losses.~Ensure the due traceability of the implanted medical device. Discharge order : Analysis, optimization and pharmaceutical interventions if necessary Discharge Pharmaceutical Interview : Discussion with the patient, Information about the PICC line maintenance and associated therapies, Information about the prescribed drugs.~Call to the community pharmacist to transfer the patient's prescription. Follow-up calls for 3 months after discharge~* Patients: Two calls the first week after implantation, then one call per month for a maximum of 3 months, Clinical data collection :Pharmaceutical advices if necessary~* Liberal nurses: same frequency, Clinical data collection, Pharmaceutical advices if necessary~* Community pharmacist: one call per month, information relevant to the patient's follow-up will be collected."
215006698|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 5）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
215006699|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 6）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
215006700|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 7）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
215096502|NCT03615339|DIETARY_SUPPLEMENT|Molkosan|Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
215096503|NCT06434467|DRUG|Nelarabine injection|Nelarabine is a prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). Nelarabine undergoes catalytic transformation by adenosine deaminase (ADA), resulting in the removal of its methoxy group and conversion into ARA-G, Subsequently, ARA-G undergoes sequential monophosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase, yielding the active compound 5'-Guanosine triphosphate (GTP), ARA-GTP. This active compound accumulates within leukemic blast cells and binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death.
214401858|NCT03927365|DEVICE|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
214401859|NCT01426620|DIETARY_SUPPLEMENT|Blueberry powder|The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
214401860|NCT05836662|OTHER|CrashCourse Concussion Education in Virtual Reality|The TeachAids concussion education, including CrashCourse and Brain Fly-Through, will be shown in 3D (via a Virtual Reality headset). These educations are the exact same content as the 2D versions viewed on a laptop, but the modality (via a VR headset) is different.
214401861|NCT01462201|DEVICE|Non Invasive Ultrasound|Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
214401862|NCT05942404|PROCEDURE|mechanical bowel preparation|mechanical bowel preparation before surgery
214401863|NCT01414530|DRUG|oral contraceptive|ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
214401864|NCT01414530|DRUG|NSAID|ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
215006701|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 8）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
215096504|NCT04416906|DRUG|Biktarvy|Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit
215096505|NCT01105273|BIOLOGICAL|anti-thymocyte globulin|On days -3 to -1
215096506|NCT01105273|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
215096507|NCT01105273|DRUG|Fludarabine|30mg/M2 once daily IV on days -6 to -2
215096508|NCT01105273|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
215096509|NCT01105273|PROCEDURE|CD3±CD19 depleted hematopoietic stem cell transplantation|Immunogenetic depletion on CliniMACS
215096510|NCT01831674|DRUG|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
215096511|NCT01831674|DRUG|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
215096512|NCT00853138|BEHAVIORAL|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week."
215096513|NCT01969435|DRUG|Carmustine|
215096514|NCT01969435|DRUG|Etoposide phosphate|
215096515|NCT01969435|DRUG|Cytarabine|
215096516|NCT01969435|DRUG|Melphalan HCl (propylene glycol-free)|
215096517|NCT04139850|DRUG|Discontinuation of antiviral treatment in chronic hepatitis B cohort patients|For the selective patients in the cohort with long-term antiviral therapy and with conditions such as HBeAg negative or loss more than one year, antiviral therapy is able to be discontinued with an intensive inspection who agreed to the process. If there are need of this intervention, another multicenter IRB approval will be taken.
214401865|NCT02751099|OTHER|transplanted patients|bone biopsy, echocardiogram, blood samples
214522645|NCT02650661|BEHAVIORAL|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
214401866|NCT05169021|DRUG|Amlodipine folic acid 5.8mg+intensive antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
214401867|NCT05169021|DRUG|Amlodipine folic acid 5.8mg+standard antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
215006702|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 9）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
215006703|NCT02490579|BEHAVIORAL|Responses to Brief Video Messages (Facebook)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.
215006704|NCT02490579|BEHAVIORAL|Response to Brief Video Messages (Clinic)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.
215006705|NCT02490579|BEHAVIORAL|Response to Brief Video Messages (Social Network)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
215006706|NCT04808037|DRUG|Belantamab mafodotin|Belantamab mafodotin in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed Multiple Myeloma transplant-ineligible
215006707|NCT02265653|DRUG|BIIL 284 BS tablet C|
215006708|NCT02265653|DRUG|BIIL 284 BS tablet D|
215006709|NCT02265653|DRUG|BIIL 284 BS WIF tablet|
215006710|NCT02768181|BEHAVIORAL|Nutrition-specific Behaviour change communication (BCC)|Door-to-door counseling on nutrition during pregnancy and exclusive breastfeeding from enrolment into study till birth; exclusive breastfeeding and nutrition of lactating mothers during post-natal 6 months; timely and appropriate complementary feeding with continued breastfeeding until 2 years of child's age, and nutrition of lactating mothers during post-natal 6-24 months; all counseling would be supplemented with associated issues including hygiene and sanitation, mother's sleep and rest, maternal and child healthcare seeking etc.
215096518|NCT02610946|BEHAVIORAL|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
214401868|NCT05169021|DRUG|Amlodipine+intensive antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
215096519|NCT02610946|BEHAVIORAL|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
215096520|NCT04616222|DRUG|CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
215096521|NCT04616222|DRUG|Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
215096522|NCT03620084|DEVICE|Expiratory Muscle Strength Training (EMST)|The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).
215096523|NCT04243733|OTHER|CEM and MTA|Pulpotomy agent
215096524|NCT04243733|OTHER|MTA and CEM|Pulpotomy agent
215096525|NCT02369419|OTHER|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as \<14/17 points using the ONCODAGE score
215096526|NCT04039737|DRUG|Qingpeng Ointment|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
215096527|NCT06156748|PROCEDURE|postoperative adjuvant transarterial chemoembolization|HCC patients received hepatectomy and PA-TACE.
214401869|NCT05169021|DRUG|Amlodipine+standard antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
214401870|NCT01102478|DRUG|losartan potassium / hydrochlorothiazide|100 mg / 25 mg tablet
215096528|NCT05147298|OTHER|eHealth phone program|The automated eHealth phone program uses text to speech technology to deliver educational content to increase awareness, confidence, and motivation for physical activity.
215096529|NCT05147298|OTHER|Environment program|The environment surrounding the PHDs will be changed to make it more amenable to walking by creating walking trails and walking maps and using Healthy Living Advocates (HLA)-led walking groups within the community. Also advocating for changes to the built environment.
215096530|NCT04906746|DRUG|Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.|There will be intra-patient dose escalation of ruxolitinib in every patient enrolled on study.
215096531|NCT05614037|DRUG|Felodipine sustained release tablets (trade name: plendil®)|Reference preparation (R) : Felodipine sustained release tablets (trade name: plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer: AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
214401871|NCT05337969|DRUG|Metformin and Vildagliptin 850/50 mg|50 mg Vildagliptin + 850 mg Metformin as single-dose per study period
214401872|NCT03861728|DEVICE|0.01% Hypochlorous acid|Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
215096532|NCT05614037|DRUG|Felodipine Controlled Release Tablets|Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10\~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
215006711|NCT02768181|DIETARY_SUPPLEMENT|Nutrient supplement to pregnant women (PNS)|"A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.~Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA \~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
214401873|NCT03861728|OTHER|Placebo|Placebo to be used four times a day to the affected eye for 2 weeks
215006712|NCT02768181|DIETARY_SUPPLEMENT|Nutrienr supplement to children 6m to 2 years|"A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets \~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
214401874|NCT03344289|DIAGNOSTIC_TEST|Colonoscopy|Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
214401875|NCT05578924|OTHER|" women group "|women aged more than 18 years old
214401876|NCT04656002|DRUG|Vactosertib|Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
215006713|NCT04474106|DEVICE|Shock waves|The shockwave generator orthogold 100® generates high-energy acoustic waves that behave much like other sound waves except that they have much greater pressure and energy. As with sound waves, Spark Waves® can easily travel great distance as long as the acoustic impedance stays the same.
215006714|NCT04474106|DEVICE|dummy head|The shockwave generator orthogold 100® will be used in combination with a dummy head, to Refrain shock waves
215006715|NCT02691572|PROCEDURE|Spinal anesthesia|Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
215006716|NCT02691572|DRUG|Intrathecal bupivacaine|Bupivacaine 12.5 mg will be administered in the subarachnoid space.
215006717|NCT02691572|DRUG|Intrathecal fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space.
215006718|NCT02691572|PROCEDURE|Cesarean delivery|Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
214401877|NCT00004225|BIOLOGICAL|Ad5CMV-p53 gene|
214401878|NCT00004225|RADIATION|radiation therapy|
214401879|NCT00203138|DRUG|rasagiline mesylate|
214401880|NCT02297503|DRUG|Azzalure|Glabellar lines
214401881|NCT02297503|DEVICE|Restylane/Emervel filler|Facial tissue augmentation
214401882|NCT02297503|DEVICE|Restylane Skinbooster|Facial skin rejuvenation
214401883|NCT00809432|DEVICE|Face mask (Dust Respirator)|Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
214401884|NCT00809432|OTHER|No Face mask|Subjects will not wear a face mask to reduce their personal exposure to air pollution
214401885|NCT00351221|DRUG|rhIGF-1/rhIGFBP-3|
214401886|NCT00950053|PROCEDURE|Achilles decompression & debridement|Surgical intervention
214401887|NCT00950053|PROCEDURE|Achilles decompression and debridement with FHL transfer|surgical intervention
214401888|NCT03904628|DRUG|TG02 capsules oral administration, BIW in every 28d|TG02 capsules150mg oral administration, BIW in every 28d
214401889|NCT03904628|DRUG|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 200mg oral administration, BIW in every 28d
214401890|NCT03904628|DRUG|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 250mg oral administration, BIW in every 28d
214401891|NCT04609150|OTHER|Bone marrow fat quantification by MRI|Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty
215006719|NCT02691572|PROCEDURE|Wound infiltration|30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.
214401892|NCT02021461|DRUG|ESL Banana taste|oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
214401893|NCT02021461|DRUG|ESL Grape taste|oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
215006720|NCT02691572|PROCEDURE|Sham procedure|Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients' abdomen.
215006721|NCT02691572|PROCEDURE|Transversus abdominis plane block|Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.
215006722|NCT02691572|DRUG|Ketorolac|IV ketorolac 30 mg/8 h starting at the end of surgery.
215006723|NCT02691572|DRUG|Paracetamol|Oral paracetamol 1 gm/8 h starting 4 h after surgery.
215006724|NCT02691572|PROCEDURE|Fentanyl patient-controlled analgesia|Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
215096533|NCT03893162|DIETARY_SUPPLEMENT|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains:~Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.~Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram."
215096534|NCT03893162|OTHER|Placebo|Visually identical capsules in identical packaging containing no active bacteria.
215096535|NCT02100969|DRUG|HIZENTRA ®|Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
214401894|NCT02021461|DRUG|ESL Tutti-Frutti taste|oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
214401895|NCT03273803|DIAGNOSTIC_TEST|Heart sound recording using smartphone application|Heart sound recording and analysis using android smartphones (Samsung Galaxy S5, Galaxy S6, and LG G3)
214401896|NCT04974502|PROCEDURE|Nonsurgical periodontal treatment|Oral hygiene instructions, scaling and root planning.
214401897|NCT05701943|BEHAVIORAL|Home-Based|During the home-based intervention, aerobic training was performed using body weight exercises such as jumping jacks, standing box, side shift with floor touch, high knees, half burpee, and hook box (Borrega-Mouquinho et al., 2021).
214401898|NCT05701943|BEHAVIORAL|Gym-Based|During the gym-based intervention, aerobic training was performed on cycle ergometers (Star Trac Spinner Blade ION 7220, Vancouver, WA).
214401899|NCT00671593|BIOLOGICAL|House Dust Mite|"Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,~1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml"
214401900|NCT00671593|BIOLOGICAL|Diluent|Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
214401901|NCT03351361|DRUG|Nivolumab + Ipilimumab|Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
214401902|NCT03351361|DRUG|Chemotherapy|Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
214401903|NCT04365413|DEVICE|MSOT Device|The MSOT Device will be used to take images of the tumor and/or lymph nodes of patients with solid tumors before and after surgery to measure the margins of the tumor and/or positive lymph node.
214401904|NCT04365413|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
214401905|NCT00426374|PROCEDURE|echocardiography and blood test|
214401906|NCT05731375|DIAGNOSTIC_TEST|31-MRS at 7 Tesla (T)|31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.
215006725|NCT00699751|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.
215006726|NCT00699751|DRUG|Placebo|Isotonic saline 6 IV administrations separated by 4 weeks intervals.
215006727|NCT00699751|DRUG|Best standard of care (BSoC)|Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
215006728|NCT01148732|PROCEDURE|ultrasonography|a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
215006729|NCT00649688|DRUG|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fasting
215006730|NCT00649688|DRUG|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fasting
215006731|NCT01148485|OTHER|Nasal, throat, inguinal and skin lesions swab samples will be performed|Nasal, throat, inguinal and skin lesions swab samples will be performed
215006732|NCT03206138|BIOLOGICAL|GX-188E, GX-I7|Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.
215006733|NCT03206138|BIOLOGICAL|GX-188E, Imiquimod|1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.
215096536|NCT01318148|DRUG|caspofungin|Intermittent intravenous application of caspofungin
215096537|NCT01629953|OTHER|Group vocational intervention|Group based manualized vocational rehabilitation
215096538|NCT01629953|OTHER|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
215006734|NCT02313714|DEVICE|stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),|All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
215006735|NCT02313714|DEVICE|Sham|very low electric muscular stimulation
215006736|NCT01142921|DEVICE|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
215006737|NCT01142921|DEVICE|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
215006738|NCT01422902|OTHER|Plasticity-based Cognitive Training|
215006739|NCT01422902|OTHER|Non-plasticity-based Training|Computer games
215006740|NCT06441799|DEVICE|Home radiofrequency skin treatment instrument|Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
215006741|NCT06441799|OTHER|Ultrasonic coupler for medical purposes|In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
215006742|NCT03575156|BIOLOGICAL|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
215006743|NCT03575156|BIOLOGICAL|urine sample|6 ml
215006744|NCT02327481|PROCEDURE|3D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
215006745|NCT02327481|PROCEDURE|2D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
215006746|NCT03148340|DIAGNOSTIC_TEST|VIPS Monitoring|Bioimpedance asymmetry
215096539|NCT02189512|OTHER|blood sampling|cases - blood sampling controles - blood sampling
214401907|NCT00862511|DEVICE|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
214401908|NCT00862511|DEVICE|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
215006747|NCT01257438|DEVICE|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
215006748|NCT01257438|DEVICE|Percutaneous Transluminal Angioplasty only|Treatment of in-stent restenosis
215006749|NCT04520100|BEHAVIORAL|Clinical Hypnosis performed by the PI|The patient will receive clinical hypnosis by the PI prior to examination and listen to recorded session during their MRI.
215006750|NCT04520100|BEHAVIORAL|Care by technician trained in empathic communication|The patient will be taken care of by an MRI technician who has been previously trained in empathic communication.
215006751|NCT02085551|DEVICE|Mechanical Thrombectomy by the Indigo System|
215006752|NCT01370889|DRUG|resveratrol|Given PO
215006753|NCT01370889|OTHER|laboratory biomarker analysis|Correlative studies
215006754|NCT00377481|DRUG|darbepoetin alfa|30 micrograms sc weekly (2 doses)
215006755|NCT00377481|DRUG|epoetin beta [NeoRecormon]|6000 IU sc weekly (2 doses)
215006756|NCT01054248|DRUG|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
215006757|NCT01054248|DRUG|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
215006758|NCT01054248|DRUG|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
215006759|NCT05713448|OTHER|No intervention|No intervention
215006760|NCT03370302|DRUG|TAK-228|TAK-228 Capsules.
215006761|NCT02411136|DRUG|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
215006762|NCT02411136|DRUG|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
215006763|NCT01011725|DRUG|MK 0773|25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
215006764|NCT01011725|DRUG|Placebo|Placebo oral tablet b.i.d for 12 weeks
215006765|NCT00807404|PROCEDURE|histopathologic examination|
215006766|NCT00807404|PROCEDURE|optical coherence tomography|
215006767|NCT00452257|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
215006768|NCT05729191|BIOLOGICAL|Anti Covid 19 vaccination campaign for pregnat women|Assessment of vaccine hesitancy and Covid-19 disease knowledge
215006769|NCT03893214|BEHAVIORAL|virtual reality exposure for acrophobia|"The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase."
215006770|NCT03893214|BEHAVIORAL|movie|Participants will watch a movie without height content for the same amount of time as the virtual reality exposure will need.
215096540|NCT03034330|OTHER|Two-Tier Stroke Family Empowerment|The family-based care management intervention will be implemented in two tiers. The first tier is the Family Care Management that a care manager is responsible for empowering family caregivers to support their stroke survivors through reorganizing family roles, enhancing family functioning, and maximizing their family and community resources. The second tier is led by trained volunteers who are responsible for increasing the capacity of caregivers for the mastery of stroke care by providing psychoeducation, skill-training, and social support. Each caregiver participant will be assigned a care manager and a volunteer. All care managers who are social workers from the participating centres have undergone 4-day training to improve their knowledge of stroke and skills required for the intervention. Similarly, volunteers have undergone 6.5-day training to equip them with the knowledge and skills to conduct the intervention.
214401909|NCT01446029|DEVICE|Video Telemonitoring Device with Clinical Care Modules|Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
214401910|NCT05267015|PROCEDURE|Gingival coverage using coronally advanced flap and a connective tissue graft|A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using a subepithelial connective tissue graft
214401911|NCT05267015|PROCEDURE|Gingival coverage using coronally advanced flap and platelet rich fibrin membranes|A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using platelet rich fibrin membranes
215006771|NCT04071886|BEHAVIORAL|Mindfulness-Based Training|Mindfulness-Based Training comprises of mindful walking, body scanning and raisin meditation exercise. Participants will receive a guided session of mindfulness meditation, and will be asked to finish at least 30 minutes of Mindfulness-Based Training every day as homework as well as keep a diary describing their experiences and reflections. An expert in mindfulness practice will offer feedback and answer any questions online.
215006772|NCT04071886|BEHAVIORAL|Relaxation Training|Participants will listen to a 15-minute Relaxation Training tape twice a day.
215006773|NCT00985790|BIOLOGICAL|Influenza vaccine GSK2321138A|Intramuscular injection
215006774|NCT00985790|BIOLOGICAL|Fluarix™|Intramuscular injection
215006775|NCT05594238|BEHAVIORAL|Telephone Engagement|Brief phone session with a study counselor.
215006776|NCT05594238|BEHAVIORAL|Portal Engagement|Access to a virtual portal where participant messages with study counselors.
215006777|NCT05594238|BEHAVIORAL|MI-CBT|8 one-on-one sessions done over the phone or video chat with a study counselor
215006778|NCT01648959|OTHER|EEG Recording|
215006779|NCT04143048|OTHER|DNA extraction of tumer tissue samples and high-throughput sequencing of small panels|DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed
215006780|NCT04143048|OTHER|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
215096541|NCT03034330|OTHER|Volunteer Support Psychoeducation|The active control group will receive a standard, non-family-based psychoeducation intervention provided by the trained volunteers under the supervision of care managers. It will provide 4 in-home visits and 2 telephone follow-up interviews about psychoeducation for caregivers of stroke survivors.
215096542|NCT06359080|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 10 weeks.
215096543|NCT03558490|DEVICE|ZEMY software|"The ZEMY software medical device integrates specific algorithms based on international and validated guidelines. It provides individually customized information and defines for the patient an adapted action to follow for each of the following reported symptoms or anti-cancer treatment-related toxicities: diarrhea, fatigue, nausea, vomiting, cutaneous and mucosal toxicities, pain, fever/febrile neutropenia, high blood pressure, anxiety and depression.~During the 3-month study period, participants will be asked to enter their symptoms among the 10 symptoms listed in ZEMY on their smartphone dedicated to the study. Consequently, ZEMY software will provide to the participants adapted real-time information to advise them on the management of the experienced symptom and recommend hygienic-dietetic advice and symptomatic treatments."
215096544|NCT03558490|DRUG|Investigator's choice of anti-cancer treatment (except immunotherapy)|All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
214504435|NCT05951036|PROCEDURE|Low-load Blood Flow Restriction training|Physical therapist will apply the BFR cuffs with 70% of arterial occlusion pressure on the both legs of participants. Then, participants will be asked to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 30% of repetition maximum.
214504436|NCT05951036|PROCEDURE|Sham Low-load Blood Flow Restriction training|Physical therapist will apply the BFR cuffs with 10% of arterial occlusion pressure on the both legs of participants. Then, participants will be asked to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 30% of repetition maximum.
215096545|NCT02591485|BEHAVIORAL|Attention Control Training|In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
214688221|NCT06232772|DIAGNOSTIC_TEST|α- Synuclein Ultrafine Fluorescence Detection Method|This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.
215006781|NCT04143048|OTHER|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
215096546|NCT06413472|PROCEDURE|Mechanical ventilator adjustment for PCV|In pressure control ventilation (PCV) mode, patients will be ventilated for 5 minutes at a Tslope of 5% and another 5 minutes at 15% for both 1:1 and 1:2 I:E ratios. After each adjustment, screenshots of the mechanical ventilator (P-V loop screenshots) will be obtained . A total of 20 P-V loop screenshots will be captured over a 20-minute period (10 for the 1:2 ratio and 10 for the 1:1 ratio), which will be stored in the ventilators memory. The stored data will then be transferred from the ventilators memory to a computer via a flash drive.
215096547|NCT06413472|PROCEDURE|Mechanical ventilator adjustment for VCV|In volume control ventilation (VCV) mode, patients will be ventilated for 5 minutes at a Tslope of 5% and another 5 minutes at 15% for both 1:1 and 1:2 I:E ratios. After each adjustment, screenshots of the mechanical ventilator (P-V loop screenshots) will be obtained . A total of 20 P-V loop screenshots will be captured over a 20-minute period (10 for the 1:2 ratio and 10 for the 1:1 ratio), which will be stored in the ventilators memory. The stored data will then be transferred from the ventilators memory to a computer via a flash drive.
215096548|NCT03654066|DRUG|Botulinum toxin type A|Botox injection in the LES
215006782|NCT03884764|PROCEDURE|pulsed radiofrequency|patients with chronic pelvic pain due to chronic prostatitis will receive pulsed radiofrequency on sacral root number 3 and ganglion impar denervation and the patients will be followed for 6 months to assess pain severity radiofrequency procedure: patients will positioned prone on the operating table and under x-ray guidence sacral foramen number 3 will be identified and through it radiofrequency needle will be advanced to target the sacral root ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
215006783|NCT03884764|PROCEDURE|ganglion impar denervation|patients with chronic pelvic pain due to chronic prostatitis will receive ganglion impar denervationand and the patients will be followed for 6 months to assess pain severity ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
215006784|NCT04759547|DEVICE|handheld ultrasound-assisted technique|Ultrasound with 3D navigation function is used to determine the needle insertion point and the insertion angle.
215006785|NCT04759547|OTHER|conventional palpation-guided technique|The interspinous space is detected by palpation
215006786|NCT04120779|DEVICE|The EMPOWER-SUSTAIN e-Health Self-Management Intervention|Multifaceted chronic disease management strategies involving web-based self-management intervention mobile apps based on chronic care model and persuasive technology theory to improve patient activation and self-management behaviours among patients with metabolic syndrome.
215006787|NCT01495247|DRUG|BEZ235|Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
215006788|NCT01495247|DRUG|Paclitaxel|"The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.~BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts."
215006789|NCT05015634|OTHER|Active Arm|Patient develops possible cardiac symptoms, takes an ECG, BP and oxygen saturation as per their training. Patient will receive a phone call by the trial cardiologist who will have access to a high-quality ECG trace, as well as blood pressure and oxygen saturations, and coupled with the clinical history, can decide on the most appropriate course of further management. With remote follow up over the phone at 3, 6 and 9 months.
215006790|NCT05015634|OTHER|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
215006791|NCT05792488|BEHAVIORAL|Coach|Coaching to a healthy lifestyle
215006792|NCT05792488|BEHAVIORAL|App|The app will coach people to a healthy lifestyle
215006793|NCT05792488|OTHER|Standard of care|Patients will receive standardized lifestyle advice by their specialist
215006794|NCT06058156|DRUG|SAR444656 (KT-474)|Oral Tablet
215006795|NCT06058156|DRUG|Placebo|Oral Tablet
215006796|NCT04023552|DRUG|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
215006797|NCT04023552|DRUG|Placebo|Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
215006798|NCT06434883|BEHAVIORAL|Anxiety/Depression Program|Participants will complete the Headspace Anxiety/Depression Program, which is a 21 day program based on CBT, combined with mindfulness. The program is trans-diagnostic in nature (i.e. addresses both anxiety and depression symptoms).
215006799|NCT06434883|OTHER|Waitlist|Participants will continue their regular routines for an 21 day period and will not be assigned to an intervention.
215096549|NCT03654066|DEVICE|Endoscope balloon dilator|Distal esophageal dilation
215096550|NCT03654066|OTHER|Patient reported outcomes|Subjects will complete two patient reported outcome measures (Eckardt and MADS).
215096551|NCT03654066|DIAGNOSTIC_TEST|Barium esophagram|Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
215096552|NCT06584435|DRUG|Tremelimumab|Tremelimumab is administered intravenously at a fixed dose of 240 mg every 3 weeks for 1 treatment cycle until tumor recurrence or intolerable toxic effects.
215096553|NCT00306527|BIOLOGICAL|Cell culture derived influenza vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
214504437|NCT05951036|PROCEDURE|High-load Eccentric training|Physical therapist will ask participants to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 70% of repetition maximum.
214522646|NCT02650661|BEHAVIORAL|Standard health educational booklet|"Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment."
215006800|NCT06971939|COMBINATION_PRODUCT|NT-501/revakinagene taroretcel-lwey|NT-501 is surgically implanted into the vitreous cavity to continuously release recombinant human ciliary neurotrophic factor (CNTF).
215096554|NCT00306527|BIOLOGICAL|egg-derived influenza subunit vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
215096555|NCT06534359|OTHER|Transpyloric tube feeding|Tube feeding into the small bowel
215096556|NCT06534359|OTHER|Gastric tube feeding|Tube feeding into the stomach
215006801|NCT06965309|DRUG|HN2301 injection|Description: Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.
215006802|NCT04180696|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled
215006803|NCT04180696|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
215006804|NCT06638385|PROCEDURE|DCE + SPACE SHIELD|Patients receive a DCE with implantation of a space-expanding shield.
215006805|NCT06638385|PROCEDURE|DCE + CP|Patients in the control group receive a DCE similar to the intervention group, but without implantation of a space-expanding shield. Cranioplasty (CP) is performed after \~ 90 days in the customary manner.
215006806|NCT03406663|BEHAVIORAL|Group 1|"Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change, \< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
215006807|NCT03406663|BEHAVIORAL|Group 2|"Fasting SMPG (median of the last 3 days including current day) in the range of~* 7.8 mmol/L, increase 6 units of Gla-300 dose, \> 5.6 and \< 7.8 mmol/L, increase 3 units of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change,~* 3.3 and \< 4.4 mmol/L, reduce 3 units of Gla-300 dose, \< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
215006808|NCT02759458|DEVICE|Smith & Nephew Healicoil Anchor|
215006809|NCT02759458|DEVICE|Smith & Nephew Twinfix Anchor|
215006810|NCT02179619|DEVICE|Dermalax(Deep)|Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
215006811|NCT02179619|DEVICE|Restylane|Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
215006812|NCT02593864|DEVICE|Variable-Stiffness Shoe|A load-modifying variable-stiffness shoe previously shown to reduce joint loading
215096557|NCT04037254|BIOLOGICAL|Gonadotrophin Releasing Hormone|Receive standard of care GnRH agonist androgen suppression therapy
215096558|NCT04037254|RADIATION|Intensity-Modulated Radiation Therapy|Undergo standard of care IMRT
214522647|NCT05055999|DRUG|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day
214522648|NCT00346242|DRUG|Zoledronic Acid|
215006813|NCT00699127|BEHAVIORAL|Lecture|Lecture of information regarding prematurity, NICU hospitalization, etc.
215006814|NCT04739709|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
215006815|NCT04739709|DRUG|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
215006816|NCT01282788|DIETARY_SUPPLEMENT|Caterpillar Cereal|Infants will receive once-daily servings of caterpillar cereal (30 g from 6-12 months of ages and 45 g from 12-18 months of ages). Study food will be delivered to homes weekly by Community Coordinators, who will also observe feedings of the cereal during the home visit. Feedings will be observed 3x/week for the first 3 weeks after enrollment, then 1x/week until 18 months of age. Parents and other care providers will receive specific instructions about cereal preparation and general education about feeding practices, food preparation and hygiene. This information will be reinforced during weekly visits.
215006817|NCT01697046|DRUG|Truvada and Isentress|"Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.~Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days."
215096559|NCT04037254|DRUG|Niraparib|tablet
215096560|NCT05663840|BEHAVIORAL|Progressive resistance exercise|Patients with predominant symptoms of cervical dystonia will receive exercise training. Patients will receive progressive resistance exercise focused cervical and shoulder training (PERFECT) plus standard-of-care (SOC) therapy. Resistance training will consist of mainly muscle-strengthening exercises for the neck, shoulder and arms and a few upper trunk muscles. Resistance training will be guided by physical therapists at twice a week schedule for 6 months. These participants will also receive SOC therapy.
215096561|NCT05663840|BEHAVIORAL|Standard of care|Subjects will receive SOC therapy only
215096562|NCT01586455|DRUG|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
215096563|NCT00711789|DRUG|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
214401912|NCT00519779|DIETARY_SUPPLEMENT|omega-3 supplementation|2.5 g/day omega-3
214401913|NCT00519779|DIETARY_SUPPLEMENT|Oral omega-3 fish oil placebo|to match experimental dosage
214401914|NCT00376480|BIOLOGICAL|anti-thymocyte globulin|
214401915|NCT00376480|BIOLOGICAL|peripheral blood lymphocyte therapy|
214401916|NCT00376480|DRUG|fludarabine phosphate|
214401917|NCT00376480|DRUG|methylprednisolone|
214401918|NCT00376480|DRUG|thiotepa|
214401919|NCT00376480|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214401920|NCT00376480|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214401921|NCT00376480|RADIATION|total-body irradiation|
214401922|NCT05908448|DEVICE|13 CGM (continuous glucose monitor)|The I3 CGM consists of three main components: a Sensor Pack (Applicator-Sensor assembly), a Transmitter Pack (with Bluetooth Low Energy (BLE)) and a mobile application (I3 CGM App). The user can view their glucose data on the I3 CGM App running on a compatible mobile device.
215006818|NCT02111044|DRUG|Octreotide|octreotide 100 mcg sc t.i.d. for 4 weeks
215096564|NCT00711789|DRUG|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
215096565|NCT04654078|DRUG|IN-C004 with water|One time dose of IN-C004 taken with water
215096566|NCT04654078|DRUG|IN-C004 without water|One time dose of IN-C004 taken without water
215096567|NCT04654078|DRUG|K-CAB tab. with water|One time dose of K-CAB tab. taken with water
215096568|NCT01321957|DRUG|Oxaliplatin, 5FU/LV, Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
215096569|NCT01321957|DRUG|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
215096570|NCT02319135|DRUG|Azacitadine|
215096571|NCT02319135|DRUG|Fludarabine|
214401923|NCT06113029|DIAGNOSTIC_TEST|The Hamilton Rating Scale for Anxiety|The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety).
214401924|NCT06113029|DIAGNOSTIC_TEST|The Beck Depression inventory|one of the most widely used instruments for measuring the severity of depression
214401925|NCT06113029|DIAGNOSTIC_TEST|Rand SF-36 Questionnaire|The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). Component analyses showed that there are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS). All scales do contribute in different proportions to the scoring of both PCS and MCS measures
214401926|NCT03330119|DRUG|Alternate Management|With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.
214401927|NCT03330119|DRUG|Control|The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
214401928|NCT03215225|PROCEDURE|Root canal orthograde treatment|
214401929|NCT05284422|PROCEDURE|Traditional Peripheral venous catheter insertion|Insertion of a short catheter in a peripheral vein with the help of visualization palpation
214401930|NCT05284422|PROCEDURE|Ultrasound-guided insertion of a peripheral venous catheter|Insertion of a short catheter in a peripheral vein with the help of an ultrasound device
214522649|NCT03778606|DIETARY_SUPPLEMENT|Potato starch|Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
214522650|NCT03421600|DEVICE|blue laser imaging|blue laser imaging
215006819|NCT02111044|DRUG|ITF2984 500 mcg|ITF2984 500 mcg sc b.i.d for 4 weeks
215006820|NCT02111044|DRUG|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
215006821|NCT02111044|DRUG|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
215006822|NCT02839317|BIOLOGICAL|Biological|comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
215006823|NCT00867880|DRUG|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
215006824|NCT02640209|BIOLOGICAL|CART 19|The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
215096572|NCT02319135|DRUG|Cytarabine|
215096573|NCT02319135|DRUG|Lenograstim|
215096574|NCT02319135|DRUG|Filgastrim|
215096575|NCT01023672|DRUG|Armodafinil|150-250 mg armodafinil by mouth daily
215096576|NCT05899972|OTHER|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The contact is made with the hands on the shoulder blades of the volunteer for 6 minutes.
215096577|NCT05899972|OTHER|Suboccipital inhibition technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator starts by placing both hands under the patient's head in the occipital region. After palpating the suboccipital muscles, the investigator uses the second, third and fourth fingers of both hands flexed against the muscle belly and remains in this position.
214401931|NCT01930617|PROCEDURE|Burr hole surgery with various drainage techniques|"Surgical technique~1. Continuous irrigation and drainage~2. Passive subdural drain~3. Active subgaleal drain"
214401932|NCT00917189|BEHAVIORAL|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
214401933|NCT01349855|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
214401934|NCT00227747|DRUG|capecitabine|
214401935|NCT00227747|DRUG|oxaliplatin|
214401936|NCT00227747|PROCEDURE|conventional surgery|
214401937|NCT00227747|PROCEDURE|neoadjuvant therapy|
214401938|NCT00227747|RADIATION|radiation therapy|
214401939|NCT04860700|DRUG|anlotinib hydrochloride|Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
214401940|NCT01819415|DIETARY_SUPPLEMENT|Anti-VEGF plus AREDS-2|Omega-3 metabolites supplementation
214401941|NCT01819415|DIETARY_SUPPLEMENT|Anti-VEGF plus AREDS-1|Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
214401942|NCT04069390|DEVICE|CARDIOSKIN - Short record|A short record (max 2H15) is performed with Cardioskin
214401943|NCT04069390|DEVICE|Cardioskin - long record|A long record (max 8H) is performed with Cardioskin
215006825|NCT01614223|PROCEDURE|ACP|Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
215006826|NCT01614223|DRUG|Corticosteroid (celestone) injection|Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
215006827|NCT01449084|PROCEDURE|immediate stent removal|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE"
215006828|NCT01449084|OTHER|Leaving the stent in place|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE"
215006829|NCT02213783|DRUG|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
215006830|NCT02213783|DRUG|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
214401944|NCT04069390|DEVICE|Neuronaute - long record|A long record (max 8H) is performed with Neuronaute
214401945|NCT04069390|DEVICE|Neuronaute -short record|A short record (max 2H15) is performed with Neuronaute
214401946|NCT00268411|DRUG|gemcitabine hydrochloride|
214401947|NCT00268411|DRUG|oxaliplatin|
214401948|NCT03765697|DRUG|Lidocaine 5% medicated plaster|Topical application at the site of skin affected by painful PHN for up to 12 hours per day (plaster-free interval at least 12 hours).
214401949|NCT02644538|DRUG|PegIFN alfa-2a|chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA \<1000copies/ml, and HBsAg\<3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks
214401950|NCT06297980|OTHER|Personalized modifications to treatment to address menstrual cycle effects on glycemia|The study physician will examine glucose patterns measured using continuous glucose monitoring over a 3 month observational period to identify hypo- or hyperglycemia related to menstrual cycle phase or exercise, and will provide changes to insulin basal or bolus rates, carbohydrate ratios, post-exercise food intake or use of sleep mode on automated insulin delivery systems.
214401951|NCT05708820|BEHAVIORAL|Online education programme|Online group will follow the education programme through videos that they can view at any time and a live session to answer questions.
214401952|NCT05708820|BEHAVIORAL|Standard education programme|Face-to-face educacion programme in a group session
214401953|NCT03659487|PROCEDURE|Nissen|Laparoscopic total (Nissen) fundoplication
214401954|NCT03659487|PROCEDURE|Toupét|Laparoscopic posterior 270 degrees partial fundoplication
214401955|NCT06296251|OTHER|Placebo treatment|Microcrystaline cellulose (MCC)
214522651|NCT03421600|DEVICE|White light imaging|White light imaging
215006831|NCT03393572|DRUG|Bupivacaine 0.25%|Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%
215096578|NCT05899972|OTHER|Frontal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions the tips of both index fingers on either side of the metopic suture while the third finger remains resting on the frontal bone so that the tips of the fourth fingers contact the zygomatic processes bilaterally. A slight pressure is applied with the index fingers and an anterior pressure is performed.
215096579|NCT05899972|OTHER|Parietal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator places the palms on the lateral edges of the parietal bones and the thumbs crossed at the sagittal suture. First, a medial pressure is administered with the second, third and fourth fingers and then a cephalic traction is performed.
215006832|NCT03393572|DRUG|Magnesium sulphate.|Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.
214401956|NCT06296251|DIETARY_SUPPLEMENT|Plant derived phenolics|Dietary supplement containing plant derived phenolics
214401957|NCT04056156|BEHAVIORAL|HIV-screening advice|To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail
214401958|NCT04056156|BEHAVIORAL|HIV-testing advice plus group-level training|To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
214401959|NCT01605331|DRUG|sustained-release recombinant human GH (SR-rhGH)|
214401960|NCT04982380|DRUG|Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
214401961|NCT04982380|DRUG|Siliankang simulating tablets|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
214401962|NCT05205941|DRUG|MMV688533|Not exceeding 200mg
214504438|NCT04180683|OTHER|Battery of screening tests with semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria and an ID will be assigned to the participants that meet the criteria. Posteriorly, a clinical psychologist will administer the GDS-30, GDS-15, GDS-10 and GDS-5, the BDI-II and a semi-structured interview about depressive disorders according to the DSM-5 criteria. Participants with even ID's from each institution will be answer the instruments according to the order GDS-30, GDS-10, BDI-II, GDS-5 e GDS-15 and participants with odd ID's will answer the battery in the reverse order. The assessment session will take place in a single moment in time. After the assessment, the clinical psychologist will answer a questionnaire about which version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
215006833|NCT03393572|DRUG|nalbuphine|Patients will receive intraperitoneal 5 mg nalbuphine
215006834|NCT04012645|PROCEDURE|application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used to evaluate the anastomotic flood perfusion during the operation; The operator may decide whether to change the surgical programme based on the outcome of the evaluation.
215006835|NCT04012645|PROCEDURE|Non-application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
215006836|NCT05769101|DIETARY_SUPPLEMENT|Ingestion of a Post-Workout Supplement|The Post-Workout Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
215006837|NCT05769101|DIETARY_SUPPLEMENT|Ingestion of a Maltodextrin Supplement|The Maltodextrin Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
215006838|NCT04359212|DRUG|thromboprophylaxis with low-molecular-weight heparin or fondaparinux|thromboprophylaxis with low-molecular-weight heparin or fondaparinux
215006839|NCT02969278|PROCEDURE|18FDG-PET/TC|Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes
215096580|NCT05899972|OTHER|IV ventricle technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions his hands in a shell and thumbs together at the level of the spinous apophyses of the patient's second or third cervical vertebra.
215096581|NCT02767661|DRUG|Capecitabine|Capecitabine, 500mg, orally three times daily (continuously)
215096582|NCT02767661|DRUG|Aromatase Inhibitor|Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
215096583|NCT00020878|DRUG|celecoxib|Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
215096584|NCT00006773|DRUG|bortezomib|Given IV
214401963|NCT04637464|OTHER|Early termination of empirical antibiotics|Termination of empirical antibiotics for febrile neutropenia based on clinical parameters, regardless of neutrophile count.
214401964|NCT05248360|DEVICE|Hydrogen-oxygen mixed gas(H2-O2) inhalation|H2-O2 inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)
214401965|NCT05248360|DEVICE|Air inhalation|Air inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)
214401966|NCT01813955|DRUG|Papaverine or placebo|Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
214401967|NCT03665506|DRUG|Trifluridin/Tipiracil|QoL assessment
214401968|NCT04138628|DRUG|Atezolizumab|The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
214401969|NCT03454243|DRUG|RXDX-106|Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
214401970|NCT05113589|DEVICE|PBM TREATMENT|Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed. For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear). Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions
214401971|NCT05113589|DEVICE|PLACEBO PBM|The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment. There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
215006840|NCT02969278|PROCEDURE|Sentinel node biopsy|Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
215006841|NCT00019071|DRUG|chemotherapy|
214401972|NCT00039208|DRUG|fluorouracil|
214401973|NCT00039208|DRUG|irinotecan hydrochloride|
214401974|NCT00039208|DRUG|leucovorin calcium|
214401975|NCT00039208|DRUG|oxaliplatin|
214401976|NCT03318744|DRUG|Aspirin|Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.
214401977|NCT03318744|DRUG|Placebo Oral Tablet|Placebo resembling aspirin tablet will be be given to participants in control arm.
215006842|NCT00019071|DRUG|cladribine|
215006843|NCT00019071|RADIATION|radiation therapy|
215006844|NCT04124965|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
214401978|NCT04979390|DRUG|SHR-1316|SHR-1316 administrated intravenously (IV) at protocol defined dose levels
214401979|NCT05506644|OTHER|HRV-Biofeedback/Mind-Body Therapy|A 7-week protocol using real-time feedback on heart rate variability
214401980|NCT01269398|DEVICE|GO-LIF and SpineAssist SYSTEMS|
214401981|NCT03558113|DIAGNOSTIC_TEST|light induced fluorescence intraoral camera|intraoral oral light induced fluorescence diagnostic camera
215006845|NCT02705703|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
215006846|NCT04486144|OTHER|Proprietary extract of Nerium oleander|This is a proprietary extract of Nerium oleander that is 6.25 ug per 0.5 ml of suspension. It is administered sublingually every six hours for 5 days. The daily dose is 25 ug and the 5 day dose is 125 ug.
215006847|NCT04754295|OTHER|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
215006848|NCT04754295|OTHER|STANDARD|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
214401982|NCT02725203|BEHAVIORAL|Activate|The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
214401983|NCT01960361|DEVICE|ICE dental implant|ICE- Implant Classical Esthetic implant
214401984|NCT05883579|PROCEDURE|percutaneous coronary intervention|doing percutaneous revascularization of chronic coronary total occlusion.
214401985|NCT00423644|DRUG|Darinaparson|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
214401986|NCT03809884|BEHAVIORAL|Dietary Counselling|Individually tailored strategy to increase potassium in the diet.
214688222|NCT06916728|DEVICE|Marketed Product - MP01|Marketed Product - MP01 was implanted via a mini-arthrotomy or arthrotomy approach, using the designated surgical tools and surgical technique.
215006849|NCT03665324|OTHER|Evaluation of the relationship between atrial remodeling evaluated by ECG and ETT with the occurrence of supraventricular arrhythmias|"Subjects will be retrospectively retrieved from the Sport Medicine Service of Rennes University Hospital database.~Medical data will then be collected from the athletes' medical records. The ECG present in the medical file will be reinterpreted to obtain the resting heart rate, the amplitude of the P wave, the morphology of the P wave and the duration of the PR space.~The data from the stress test will be found from reports in the medical records: resting heart rate, maximum heart rate, sustained peak load, arrhythmia during the test.~ETTs will be retrieved from the local server. They will be reinterpreted to collect anatomical and functional cardiac data necessary for the study."
215006850|NCT02184156|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
215006851|NCT02184156|DRUG|4 mL injection of Placebo|
215006852|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using HAP-containing toothpaste)|Toothbrushing using standardised technique and pear-sized amount of HAP-containing toothpaste twice daily for 1 month.
215006853|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using Zn Mg HAP-containing)|Toothbrushing using standardised technique and pear-sized amount of Zn Mg HAP-containing toothpaste twice daily for 1 month.
215006854|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using FAP-containing toothpaste)|Toothbrushing using standardised technique and pear-sized amount of FAP-containing toothpaste twice daily for 1 month.
215006855|NCT03789006|DRUG|Antithymocyte Immunoglobulin (Rabbit)|Induction agent for living donor kidney transplantation
215006856|NCT03789006|DRUG|Interleukin 2 Receptor Antagonist|Induction agent for living donor kidney transplantation
215006857|NCT05324202|DEVICE|Cynosure Cynergy Nd:YAG Laser 1064nm|The Nd:YAG Laser 1064nm is intended to be used as a treatment option in individuals suffering from low-risk basal cell carcinoma(s).
215006858|NCT00874133|PROCEDURE|Acupuncture|Acupuncture treatment for 12 weeks.
215006859|NCT00874133|DRUG|Motilium|20 mg motilium thrice daily
214401987|NCT03809884|DRUG|Potassium Citrate|Dosing of 50 to 100 mmol of potassium citrate per day (as 25 to 50 ml of the liquid solution).
214401988|NCT01444066|PROCEDURE|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
215006860|NCT02115477|PROCEDURE|Lymphadenectomy|Pelvic and/or paraaortic lymphadenectomy
215006861|NCT04351971|OTHER|Intervention Group|The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.
215006862|NCT04351971|OTHER|Placebo group|The technique consists of placing the patient in the supine position, one hand is located in the arches of the atlas, the other hand is located in the occipital. The therapist's shoulder is located in the anterior region. This position is maintained for 5 minutes without exerting pressure.
215006863|NCT00002874|DRUG|bicalutamide|One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
215006864|NCT00002874|RADIATION|radiation therapy|64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
215006865|NCT00002874|DRUG|placebo|One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
215006866|NCT01732900|OTHER|Morphology|Embryos selected for transfer will be based upon morphology alone.
215006867|NCT01732900|OTHER|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
215006868|NCT03602781|DRUG|Placebo|Placebo at a dose setting of 75 mcg/kg IBW/hr
215006869|NCT03602781|DRUG|iNO|iNO at a dose setting of 75 mcg/kg IBW/hr
215006870|NCT00387842|PROCEDURE|Laparoscopic surgery|
215096585|NCT05348239|DRUG|Sodium Copper Chlorophyllin|Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
215096586|NCT06385054|DIETARY_SUPPLEMENT|Probiotic|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
215096587|NCT06385054|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
215096588|NCT05014685|DRUG|Rabeprazole|20mg bid
215096589|NCT05014685|DRUG|Bismuth potassium citrate|0.6g bid
215096590|NCT05014685|DRUG|Metronidazole|0.4g tid
215096591|NCT05014685|DRUG|Amoxicillin|1g tid
215096592|NCT05050656|DRUG|Duloxetine 60mg|Duloxetine is a selective SNRI prescribed in depression, anxiety, and chronic pain like diabetic neuropathy and fibromyalgia, it acts through central and peripheral pain modulation
215096593|NCT05050656|DRUG|Placebo|placebo tablets identical to duloxetine tablets
215006871|NCT00387842|PROCEDURE|Conventional surgery|
215096594|NCT01058629|DEVICE|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
215096595|NCT06208111|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy would be used as intervention strategy for women facing partner violence to Clear about actual problems, re-educate about the issue of domestic problems and mental health, Logical expectations, Identify negative automatic thoughts,Thinking errors, and Improve understanding to identify which stressors trigger negative emotions. Moreover, this intervention will help to Prepare women how to deal with stress and overcome the reaction.
215096596|NCT06043908|DRUG|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
214401989|NCT03664661|DRUG|BCMA nanobody CAR-T cells|"step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
214401990|NCT02697721|BEHAVIORAL|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
214401991|NCT02697721|OTHER|Control with delayed intervention|Control with delayed intervention
215006872|NCT04558528|DIAGNOSTIC_TEST|Novel in vitro diagnostics and medical applications|Novel in vitro diagnostics and medical applications
215006873|NCT05926492|DRUG|Surufatinib plus chemotherapy|"Surufatinib: (1) for patients aged \> 21 years old and ≤70 years old, surufatinib 200 mg, qd, oral, continuous administration; (2) For patients aged ≥2 years and ≤21 years, starting from the low dose of patient BSA (body surface area), Stevenson's formula developed according to the Chinese population was used: BSA = 0.0061H+0.0128W-0.1529 (H: BSA = 0.0061H+0.0128W-0.1529). Height /cm; W: body weight /kg); Chemotherapy : 1) Doxorubicin 60 mg/m2, or liposome doxorubicin 45mg/ m2, day 17; 2) Cisplatin: 100 mg/m2, day 15; 3) Ifosfamide; 2.5g/m2, day 8-12;~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
215096597|NCT06043908|DRUG|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
215006874|NCT05926492|DRUG|Chemotherapy|"1\) High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
215006875|NCT03275922|DRUG|Placebo ZNS|Placebo Zolmitriptan Nasal Spray
215006876|NCT03275922|DRUG|ZNS|Zolmitriptan Nasal Spray
215006877|NCT00583544|DRUG|TC-2216|Multiple ascending dose groups will be explored.
215006878|NCT00690651|PROCEDURE|Early mobilization|pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
215006879|NCT00690651|PROCEDURE|Standard mobilization|this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
215006880|NCT03251105|DEVICE|supraglottic airway intubation|
215006881|NCT04393012|OTHER|Provide alternative nurse call and communication device|Evaluate impact of providing access to the nurse call system and a speech generating device.
215006882|NCT01626313|BEHAVIORAL|FOCUS Individualized Family Resiliency Training|Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
215006883|NCT03875417|PROCEDURE|liver resection|resection of one or more HCC nodules within the liver
215006884|NCT03875417|PROCEDURE|Thermic ablation|ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves
215006885|NCT03875417|PROCEDURE|Transcatheter arterial chemoembolization|embolization of HCC nodule via drug-eluted microbeads.
215006886|NCT03876353|OTHER|Floss|All participants will have half of their mouth flossed. Each participant will act as their own control.
215006887|NCT03837938|DRUG|Levopront® syrup 30 mg/5 ml|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).
215096598|NCT02787915|BIOLOGICAL|DC1-CTL|Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
215096599|NCT04766008|DRUG|Metformin|Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
215096600|NCT03720288|DRUG|Acetazolamide|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
215096601|NCT03720288|DRUG|Placebo|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
215096602|NCT02504580|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) by injection.
214504439|NCT04180683|OTHER|Battery of screening tests without semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria an ID will be assigned to the participants that meet the criteria. Posteriorly, a psychologist will administer the GDS-30, GDS-15 and the BDI-II. Participants with even ID's from each institution will answer the instruments according to the order GDS-30, BDI-II and GDS-15 and participants with odd ID's the administration order will answer the battery in the reverse order. The assessment session will take place in a single moment in time.
214504440|NCT00951132|DRUG|rosuvastatin|10mg tablets, once daily in three months
214504441|NCT00951132|DRUG|Placebo|tablet, once daily, three months
215006888|NCT03837938|DRUG|Libexin®|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.
215006889|NCT01789775|DRUG|Drug: CD07805/47 gel|
215006890|NCT01789775|DRUG|CD07805/47 gel Placebo|
215006891|NCT03743818|DEVICE|dry needling|dry needling on the trigger point of the vastus medialis of the quadriceps
215006892|NCT03743818|OTHER|ultrasound|aply ultrasound on the knee
215006893|NCT03743818|DEVICE|hyauluronic acid|aply hyaluronic acid on the knee
215006894|NCT01481025|DRUG|Cimicifuga + Hiperico|"1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months"
215006895|NCT01481025|DRUG|Cimicifuga Herbarium|"2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months"
215006896|NCT01481025|DRUG|Aplause®|4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
215006897|NCT04737694|DIETARY_SUPPLEMENT|Ketone ester|Oral ketone ester + glucose supplement
215006898|NCT04737694|DIETARY_SUPPLEMENT|Glucose|Glucose supplement
215006899|NCT03828383|DEVICE|In-home technology|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using a trusted circle of friends and family who are encouraged to stay in contact and share photos and videos with the caregiver and person with dementia via the digital display.
215096603|NCT02504580|DRUG|Placebo|Saline placebo by injection.
215096604|NCT02504580|DRUG|HTX-002|HTX-002, by injection or instillation (pooled).
215096605|NCT02504580|DRUG|Bupivacaine HCI (Marcaine)|Bupivacaine HCI (Marcaine) by injection.
215096606|NCT02504580|DRUG|HTX-011A|HTX-011A (bupivacaine/meloxicam) by injection.
215096607|NCT02504580|DRUG|HTX-011B|HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
215096608|NCT02504580|DRUG|HTX-009|HTX-009 by injection and instillation (combination).
215096609|NCT00448747|DRUG|AEZS-130 (formerly ARD-07)|A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
214401992|NCT00550732|DRUG|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
214401993|NCT03455413|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device and NeoSensor Belts will be used to assess lung aeration, ventilation distribution and strech during invasive ventilation in perioperative care.
214401994|NCT00112723|DRUG|alvocidib|Given IV
214401995|NCT05326373|DRUG|Stannous fluoride|brush twice daily with stannous fluoride toothpaste for 8 weeks
214401996|NCT00183573|BEHAVIORAL|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
214401997|NCT00183573|BEHAVIORAL|Brief Informational Intervention|15 minute informational DVD on safer sex
214401998|NCT00183573|BEHAVIORAL|Intensive Informational Intervention|4-hour, information-only intensive group workshop
215006900|NCT03828383|DEVICE|Limited in-home technology|Intelligent bot monitors the in-home water leak sensor and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome conditions occur.
214401999|NCT00183573|BEHAVIORAL|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
214402000|NCT00320866|DEVICE|syringe driver|
214402001|NCT05121155|DEVICE|ICP wave morphology comparison between a non-invasive (Brain4care) and a invasive method|We prospectively collected data of adults admitted to an intensive care unit (ICU) with subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) or ischemic stroke (IS) in whom invasive ICP monitoring placed. Measures had been simultaneously collected from the following non-invasive indices: optic nerve sheath diameter (ONSD), pulsatility index (PI) using transcranial Doppler (TCD), a 5-point visual scale designed for Computed Tomography (CT) and two parameters (time-to-peak \[TTP\] and P2/P1 ratio) of a non-invasive ICP wave morphology monitor (Brain4care\[B4c\]). Intracranial hypertension was defined as an invasively measured ICP \> 20 mmHg for at least five minutes
214402002|NCT06055907|DIAGNOSTIC_TEST|Serum anti-Xa activity|4 hours after third dose of dalteparin, serum anti-Xa activity is measured
215006901|NCT02858258|DRUG|R-CHOP/R-DHAP|Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
215006902|NCT02858258|DRUG|Ibrutinib (Induction)|Ibrutinib: only in cycle 1,3,5 on Day 1-19
215006903|NCT02858258|DRUG|ASCT conditioning|"ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)"
215006904|NCT02858258|DRUG|Ibrutinib (Maintenance)|Ibrutinib (Maintenance), daily 560 mg for 2 years;
215006905|NCT00540267|OTHER|No Intervention|No Intervention
215006906|NCT00504309|DRUG|4/day of 4g P-OM3 capsules|4/day of 4g P-OM3 capsules for 8 weeks
215006907|NCT00504309|DRUG|4/day of 1g P-OM3 capsules|4/day of 1g P-OM3 capsules for 8 weeks
215006908|NCT00504309|DRUG|Corn Oil Placebo, 4 capsules/day for 8 weeks|4 capsules per day of corn oil placebo for 8 weeks
215096610|NCT00448747|DRUG|L-ARG+GHRH|A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
215006909|NCT05122715|DEVICE|Additional PET/CT Scan|The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.
215006910|NCT04713995|OTHER|Dietary recommendations|Dietary recommendations based on microbiome analysis of samples will be given and expected to receive and report in \~3 months survey after following recommendations.
215006911|NCT02301091|PROCEDURE|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
215006912|NCT02301091|PROCEDURE|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
215096611|NCT00777361|DRUG|AZD3480|Iv single dose, 4-hour infusion of 25 mg
215096612|NCT00777361|DRUG|AZD3480|Oral solution single dose of 50 mg
215096613|NCT00590343|DRUG|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
214402003|NCT04689698|DIAGNOSTIC_TEST|Thomayer test|Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
214402004|NCT02205879|DRUG|Pregabalin|
214402005|NCT02205879|DRUG|Placebo|
214402006|NCT03074981|DEVICE|Combined TopClosure & Vcare Alpha|"Combined TopClosure \& Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
214402007|NCT00060827|DEVICE|Head Impact Recording Technology (HIRT)|
214504442|NCT02035046|PROCEDURE|Samplings of blood|
214504443|NCT02035046|PROCEDURE|Sampling of urine|
215006913|NCT02301091|DRUG|pirarubicin,mitomycin and lobaplatin|They were cytotoxic drugs used in the TACE procedure.
215006914|NCT06413329|BEHAVIORAL|preoperative physical activity level within 3 months|The exercise compliance criteria are moderate exercise of at least 150 minutes per week or high-intensity exercise of at least 75 minutes per week.
215006915|NCT02997670|OTHER|Algorithmic Cardiac Resynchronisation Therapy Optimisation|Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
215006916|NCT00321412|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
214402008|NCT00305760|DRUG|Cetuximab|Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
214402009|NCT00305760|BIOLOGICAL|Pancreatic tumor vaccine|Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
214402010|NCT00305760|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
214402011|NCT03302910|OTHER|Short Stay Unit|Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.
214402012|NCT03302910|OTHER|Standard of Care|Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
214402013|NCT04004208|DRUG|Eylea (Aflibercept, BAY86-5321)|Solution in a sterile glass vial, Dose A, IVT injection.
214402014|NCT04004208|PROCEDURE|Laser photocoagulation|Transpupillary conventional laser ablative therapy
215006917|NCT01957800|BEHAVIORAL|Website|Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.
215006918|NCT01957800|BEHAVIORAL|Usual Care|Participants will record their weight and complete surveys online.
214402015|NCT04463615|DRUG|Leflunomide|Given PO
214402016|NCT03793855|BEHAVIORAL|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
215006919|NCT06060886|DRUG|Aripiprazole|Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
215006920|NCT06060886|DRUG|Paliperidone|Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
215006921|NCT05838170|DRUG|Lotilaner Gel, 2.0%|Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).
215006922|NCT05838170|OTHER|Vehicle control gel|Aqueous gel
215006923|NCT05539287|DRUG|Lactobacillus-Based Capsule|25 patients will receive Lactobacillus species 5 billion colonies forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
215006924|NCT03694652|BEHAVIORAL|PACE|Patient-centered Assessment and Counseling for Exercise \[PACE\] program
215006925|NCT03694652|BEHAVIORAL|Diet|Motivating healthy dietary habits
215006926|NCT03694652|OTHER|App|Using an app to deliver communication to the participant.
215006927|NCT03694652|OTHER|Face-to-face|Using in person meetings and/or phone communication with the participant.
215006928|NCT03158311|DRUG|QVM149|Indacaterol acetate / glycopyrronium bromide / mometasone furoate
215006929|NCT03158311|DRUG|Salmeterol/fluticasone plus tiotropium|Free triple arm of salmeterol / fluticasone plus tiotropium
215006930|NCT01849809|PROCEDURE|Gamma Ventral Capsulotomy|
215096614|NCT00742729|BEHAVIORAL|Arm 1|Educational small group session with free FOBT kit
215096615|NCT00742729|BEHAVIORAL|Arm 2|Educational small group session with no FOBT kit
214402017|NCT03793855|BEHAVIORAL|Dietary Prescription|Dietary prescription according to guidelines.
214402018|NCT06164353|BIOLOGICAL|Partially demineralized dentin graft covered with a collagen membrane|The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
214402019|NCT05720000|DEVICE|Photobiomodulation|Patient will receive the application of the low-power 660 nm Newskin MMO red LED in the immediate postoperative period. The application will be made punctually over the entire length of the wire, which measures 5 cm, totaling 10 application points with 1 cm of distance between them. The LED application will be repeated twice a week, with a minimum interval of 48 hours, totaling 9 laser applications over 30 days.
214504444|NCT02035046|PROCEDURE|Measure of the blood pressure|
214504445|NCT02035046|PROCEDURE|glycemia test|
214504446|NCT03700554|DEVICE|Pleuralvent™|Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)
214504447|NCT03700554|PROCEDURE|Chest tube|Chest tube insertion
215006931|NCT02102737|DRUG|6-DIG|injection of 6-DIG
215006932|NCT02102737|PROCEDURE|clamp|hyperinsulinemic euglycemic clamp
215006933|NCT04216004|BEHAVIORAL|Controlled-Feeding Intervention|All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
215006934|NCT04216004|DIETARY_SUPPLEMENT|Non-dairy beverage|Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.
215006935|NCT04216004|OTHER|Full-fat milk|3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
215006936|NCT04216004|OTHER|Fat-free milk|3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.
215006937|NCT01018953|DRUG|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
215006938|NCT03927716|DRUG|SB206 12%|Topically once daily
215006939|NCT03927716|DRUG|Placebo|Topically once daily
215006940|NCT02633657|DRUG|HORIZANT 300 mg|HORIZANT 300 mg once daily
215006941|NCT05785715|DRUG|NX-13 250mg|NX-13 250mg tablet, plus 2 placebo tablets
215006942|NCT05785715|DRUG|NX-13 750mg|NX-13 250mg tablets times 3 to equal 750mg
215006943|NCT05785715|DRUG|NX-13 Placebo|NX-13 Placebo tablets times 3 for blinding purposes
215006944|NCT03033433|DRUG|DCB-DM101|determination of optimal dose for Stage 2
215096616|NCT00742729|BEHAVIORAL|Arm 3|Educational small group session, exercise
215096617|NCT01575314|DEVICE|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
215096618|NCT01052506|DRUG|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
215096619|NCT01052506|DRUG|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
214402020|NCT05720000|PROCEDURE|PDO thread|The participant's face will be cleaned with a 0.2% chlorhexidine solution. 0.1 ml of injectable anesthetic (2% lidocaine hydrochloride without vasoconstrictor, XYlestesin) will be administered in the skin layer at the point of incision in the glabellar region with a 30-gauge needle. A subincision will be made with a 21-gauge cannula in the glabellar ridge and then an injectable thread will be applied in the deep dermal layer below the glabellar ridge in the same direction as it.
214402021|NCT04387890|DIAGNOSTIC_TEST|Serologic SARS-CoV-2 screening|Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up
214402022|NCT05198453|BIOLOGICAL|vaccination|patients who received COVID-19 vaccine
214402023|NCT02926300|BIOLOGICAL|stem cells|IV infusion
215006945|NCT04565223|BEHAVIORAL|Cognitive behavioral therapy for insomnia|is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed
215006946|NCT01922414|DEVICE|Laser|Patients will undergo laser lithotripsy durin PNL
215006947|NCT01922414|DEVICE|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
215006948|NCT05907759|DRUG|Daratumumab SC|Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)
215006949|NCT06232083|RADIATION|PLDR+Cardunizumab|Application of PLDR external irradiation combined with Cardunizumab in recurrent lung cancer, esophageal cancer and cervical cancer.
215006950|NCT06126978|DEVICE|Vibration Therapy (Galileo Dela Interface)|Vibration Therapy uses vibration as a physical tool during the treatment. It can be applied with different devices that transmit mechanical vibration throughout the whole or a part of the body. Focal Muscle Vibration (FMV) is a safe, well-tolerated and non-invasive technique, which may be an efficient intervention in reducing the upper extremity spasticity, whereas Whole Body Vibration (WBV) can provide proper somatosensory stimulation, and improve muscle strength and postural control in stroke patients (Oliveira et al., 2018).
215006951|NCT06126978|DEVICE|Mirror Therapy ( Mirror Box)|Mirror Therapy is a structured, inexpensive, simple and patient-directed treatment. The principle of Mirror Therapy is the use of a mirror to create a reflective illusion of an affected limb, in order to trick the brain into thinking the movement has occurred without pain. It has shown to improve movements of the affected upper limb and the ability to carry out daily activities, in addition to reducing pain (Dhami et al., 2019).
215096620|NCT04423081|OTHER|EXIT scale|completion of EXIT scale translated in french
214402024|NCT05067959|BIOLOGICAL|Covid-19 vaccine|blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine
214402025|NCT03016013|BIOLOGICAL|Placebo plus MTX|The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
214402026|NCT03016013|BIOLOGICAL|RC18 160 mg plus MTX|The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
214402027|NCT04864561|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide 2 vaccinations 28 days apart
214402028|NCT04864561|BIOLOGICAL|AZD1222|2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein.
214402029|NCT04864561|BIOLOGICAL|VLA2001 - adolescent part|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later.
214402030|NCT04864561|BIOLOGICAL|Placebo|2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium )
214504448|NCT02520219|DRUG|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.
215096621|NCT05541445|DRUG|Pembrolizumab|The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
215096622|NCT06514313|DRUG|Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine|Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion , 4 cycles.
215096623|NCT06514313|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 4 cycles
215096624|NCT03592485|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
214504449|NCT02520219|BIOLOGICAL|Endostar|"Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days."
214504450|NCT02161354|DRUG|NTC-510 capsules|Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
214402031|NCT05215652|OTHER|adherence monitoring package (AMoPac)|"AMoPac is a tool that consists of~* an electronic monitoring device,~* data management and data analysis,~* feedback on patient's performance,~* clinical-pharmaceutical evaluation of medication adherence,~* transmission of an adherence report."
214402032|NCT03743012|OTHER|Integrated cardiac rehabilitation|Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
214402033|NCT03743012|OTHER|Usual Care|Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
214402034|NCT02785601|DRUG|Trazodone Hydrochloride prolonged-release tablets|strength 75mg, 150 mg. Oral administration with 200ml water
214402035|NCT02945293|OTHER|Oxycodone|This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed
214402036|NCT04404140|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 mg, as per the dosing schedule described above.
214402037|NCT04404140|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg, as per the dosing schedule described above.
214402038|NCT04404140|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m\^2, as per the dosing schedule described above.
214402039|NCT00795418|BIOLOGICAL|Placebo|Placebo comparator
214402040|NCT00795418|BIOLOGICAL|CAD106|
214402041|NCT02400307|DRUG|Bictegravir|75 mg tablet administered orally
214402042|NCT00519363|DRUG|atorvastatin|atorvastatin 40mg, given orally daily for 3 months.
215006952|NCT01218178|DRUG|Sodium bicarbonate plus NAC|154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
215006953|NCT01218178|DRUG|Saline hydration plus NAC|0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
215006954|NCT00931424|PROCEDURE|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
215006955|NCT04393948|RADIATION|Phase 1|Dose Level 1 - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
215006956|NCT04393948|RADIATION|Phase 1|Dose Level 2 - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
215006957|NCT04393948|RADIATION|Phase 2|Arm A - No irradiation
215006958|NCT04393948|RADIATION|Phase 2|Arm B - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
214402043|NCT03688542|OTHER|Quality Circle Deprescribing Module|The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..
215006959|NCT04393948|RADIATION|Phase 2|Arm C - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
215006960|NCT04325347|OTHER|Virtual Reality application|Virtual Reality application with a VR goggle
215096625|NCT03592485|PROCEDURE|Pectoral Fascia block|Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
215096626|NCT03592485|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
215096627|NCT03592485|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
215096628|NCT03592485|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
215096629|NCT03155438|DIAGNOSTIC_TEST|Oxidative stress-related gene expression (RNA expression)|Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
215096630|NCT03155438|DIAGNOSTIC_TEST|oocyte competence biomarkers|Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
214402044|NCT00033956|DRUG|M40403|
214504451|NCT02161354|DRUG|Placebo Capsules|Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
215006961|NCT00004897|BIOLOGICAL|recombinant interferon alfa|
214504452|NCT02161354|DRUG|NTC-510A Capsules|Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
214504453|NCT01989793|DRUG|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
214504454|NCT01989793|DRUG|Placebo|Placebo will be given to those in placebo arm
214504455|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.
215006962|NCT00004897|DRUG|cisplatin|
215006963|NCT00004897|DRUG|fluorouracil|
215006964|NCT00004897|DRUG|hydroxyurea|
215006965|NCT00004897|DRUG|leucovorin calcium|
215006966|NCT00004897|PROCEDURE|conventional surgery|
215006967|NCT00004897|RADIATION|radiation therapy|
215006968|NCT02622685|DRUG|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
215006969|NCT02622685|DRUG|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
215006970|NCT02622685|DRUG|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
215006971|NCT02622685|DRUG|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
215096631|NCT04780412|DRUG|Misoprostol|Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.
215096632|NCT04780412|DRUG|Placebo|Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
215096633|NCT00067379|PROCEDURE|interceptive orthodontic treatments|orthodontic procedures
215096634|NCT05604742|DRUG|Belimumab (Benlysta)|Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
214402045|NCT01455740|BEHAVIORAL|Provider Visit Incentive (PVI)|"All participants received the standard of care (SOC), which included not only medical care but also a wide range of social services. In addition, participants in the PVI arm received financial incentives designed to motivate health-improving behaviors. After the initial study enrollment visit, participants in the PVI arm received a $30 payment each time they showed up as scheduled for one of their next four HIV primary care visits.~Participants in the PVI arm were also asked to return for a sixth, unanticipated study visit approximately three months after the last of the four study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the fifth and sixth study visits."
214402046|NCT01455740|BEHAVIORAL|Incentive Choice (IC)|"All participants received the SOC. In addition, participants in the IC arm received financial incentives designed to motivate health-improving behaviors. At the initial study enrollment visit, participants in the IC arm chose between either the incentive scheme assigned to the PVI arm or an incentive scheme that tied payments to clinic attendance and ART medication adherence. Participants who selected the 2nd option received a $30 payment at each of their next 4 HIV primary care visits if the (i) showed up as scheduled and (ii) presented a dose-recording pill bottle cap indicating that they correctly took at least 90% of doses of a sentinal medication since the previous study visit.~Participants in the IC arm were also asked to return for a 6th, unanticipated study visit approximately three months after the last of the 4 study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the 5th and 6th study visits."
214402047|NCT01289405|DEVICE|Continuous Positive Airway Pressure (CPAP)|mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
214402048|NCT06450535|PROCEDURE|Autogenous onlay bone block harvesting from retromolar bone in anterior maxilla|"Surgical protocol ( retromolar bone harvesting) After injecting local anesthesia a crestal incision is done, from a point on the occlusal surface along the external oblique ridge and extending anteriorly and inferiorly through the buccal mucosa, parallel to the gingival margin of the mandibular molars.~The subperiosteal dissection extend to expose the ascending ramus and the retromolar region With the aid of surgical carbide burs, two proximal vertical cuts penetrating the cortex of the external oblique ridge.~The depth of penetration of the posterior cut did not exceed 2.5 mm to avoid injury to the inferior alveolar nerve.~By using microsaw , an inferior cut of 3.2 mm in depth joining the anterior and posterior vertical cuts was done.~Small perforations of 3-4 mm in depth were performed on the superior aspect of the external oblique ridge using 1 mm drill bur.~Finally, the block was sheared off using a chisel."
214504456|NCT00361907|PROCEDURE|Effect of Pulsatile IV Insulin on blood markers|Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
214504457|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
215006972|NCT02452411|BEHAVIORAL|Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.|The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
215006973|NCT04029597|BEHAVIORAL|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the RPMS. The RPMS was developed in collaboration with the University of Mississippi Medical Center (UMMC) Center of Telehealth. Patients enrolled in this open trial of the RPMS will interact with the RPMS system on a daily basis and with UMMC's Center for Telehealth nurse care coordinators and research and clinical staff on an as needed basis. The RPMS will provide patients with include an electronic tablet (i.e., iPad) and the ability to receive data from the patient's weight scale and pedometer. Patients will be asked to wear the pedometer daily to track engagement in physical activity and weigh themselves weekly to track weight during the 3 month period. Educational information specific to pediatric obesity and healthy eating and engagement in physical activity will be presented daily through brief presentations and video clips.
215096635|NCT04573686|DRUG|Erythropoietin|Erythropoietin will be given subcutenous to all patients
215006974|NCT04970108|DRUG|Egito|EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
215096636|NCT02286635|DRUG|Deflazacort and rifampin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
215096637|NCT02286635|DRUG|Deflazacort and Clarithromycin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
215096638|NCT01085435|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
215096639|NCT00133224|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
215096640|NCT00133224|DRUG|Chemotherapy (docetaxel and prednisone)|Chemotherapy (docetaxel and prednisone)
215096641|NCT04936009|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
215096642|NCT06651528|BEHAVIORAL|TBRI|The adapted TBRI WRA (Prison Only Component) will consist of an individual introductory module (1 hour) and a series of group modules (a minimum of 4 sessions, approximately 1-2 hours in length, delivered over the course of 3 months, with the final number and frequency to be determined in R61) focused on the core components of TBRI. The original TBRI approach includes a focus on group skills training; similarly, it is anticipated that R61 phase adaptations will meet the need for tailored skills training reflected by anticipated differences in the target population of women - including how their early attachment and trauma histories influence their current self-image and behavior (which likely has a tremendous impact on their relational attachments as adults). Group sessions will provide opportunities to build skills for regulating emotions and building healthy connections.
215096643|NCT06651528|BEHAVIORAL|TAU + TBRI + Re-entry Recovery Support|This condition includes the proposed adapted TBRI as well as on-going re-entry recovery support with the Safe Support Person (SPP). The SSP will be identified by the study participant as someone who will provide prosocial support during re-entry (e.g., support towards abstinence, establishing healthy recovery support relationships, rebuilding relationships with family and children) and in most cases will involve a close family member (mother, grandmother) or friend at the woman's identified home placement. This individual will be identified by the study participant as someone who is not involved in active substance use nor has a current legal system status (e.g., on probation).
215096644|NCT06651528|OTHER|Treatment as Usual (TAU)|Women in the TAU condition will not receive TBRI intervention services, but will receive traditional in-prison SUD treatment over 6 months as usual in the four targeted prison sites. The programs are separate units with the prisons and emphasize participation by all program members in the overall goal of addressing substance use and criminal thinking. Although trauma and violence are addressed as part of the holistic group process approach in these programs, these topics are not addressed from an on-going systematic or relational perspective and are not specifically addressed as part of re-entry planning.
215096645|NCT00700583|DRUG|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
215096646|NCT02785614|DRUG|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
214402049|NCT06450535|PROCEDURE|Autogenous cortical shell technique from retromolar bone in anterior maxilla|"The harvested cortical plate was then split longitudinally in two parts using a microsaw, and thinned with the bone scraper to achieve a plate of 1 mm thickness.~The plate was fixed at a distance from the residual ridge with 2 screws. Autogenous bone particles, collected with the bone scraper, were tightly packed into the gap between the plate and the recipient site."
214402050|NCT04987710|DEVICE|intracranial rescue stenting|use of intracranial rescue stenting as re-perfusion technique after failed thrombectomy
214402051|NCT05101109|DRUG|ABL501|ABL501 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
214402052|NCT00003650|DRUG|asparaginase|
214402053|NCT00003650|DRUG|cyclophosphamide|
214402054|NCT00003650|DRUG|cytarabine|
214402055|NCT00003650|DRUG|daunorubicin hydrochloride|
214402056|NCT00003650|DRUG|dexamethasone|
214402057|NCT00003650|DRUG|etoposide|
214504458|NCT04352517|OTHER|Online Survey|Online survey completion through google app.
215096647|NCT02785614|DRUG|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
215096648|NCT05792917|DRUG|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
215096649|NCT05792917|DRUG|tafolecimab (a original manufacturing process)|450mg，SC，single dose
215096650|NCT02114255|OTHER|Placebo|Administration of 0.9% NaCl.
215096651|NCT02114255|BIOLOGICAL|BCG|Vaccination with the live attenuated BCG vaccine.
214402058|NCT00003650|DRUG|mercaptopurine|
214402059|NCT00003650|DRUG|methotrexate|
214402060|NCT00003650|DRUG|methylprednisolone|
214402061|NCT00003650|DRUG|mitoxantrone hydrochloride|
214402062|NCT00003650|DRUG|prednisone|
214402063|NCT00003650|DRUG|vincristine sulfate|
214402064|NCT00003650|RADIATION|radiation therapy|
214402065|NCT02058342|BEHAVIORAL|Active Play at Home|The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
214402066|NCT02553941|DRUG|Azacitidine|Given intravenous or subcutaneous
214402067|NCT02553941|DRUG|Ibrutinib|Given by mouth once daily
214504459|NCT00817154|BEHAVIORAL|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
214504460|NCT05422846|OTHER|standard treatment|The control group will be provided with the necessary approaches for diabetic foot ulcer care and diaphragmatic breathing exercises.
214504461|NCT05422846|OTHER|aerobic exercise|The aerobic exercise group will be provided with the necessary approaches for diabetic foot ulcer care and in addition to diaphragmatic breathing exercises, they will be provided with aerobic exercise twice a week with a physiotherapist.
215006975|NCT04970108|DRUG|Empagliflozin + telmisartan|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
215006976|NCT04115228|DEVICE|Implantation and neuromodulation therapy|The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.
215006977|NCT02131688|DRUG|Mitoxantrone Hydrochloride Liposome|
215006978|NCT05072951|DIAGNOSTIC_TEST|Urine Biomarker for Kidney Transplant Rejection|Biomarker for active kidney transplant rejection.
215006979|NCT01922297|OTHER|Day Treatment MDFT-HIV|MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.
215006980|NCT01922297|OTHER|Day Treatment SAU|Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall \& Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
215006981|NCT03812328|DRUG|SelK2|I.V., single-dose
215006982|NCT03812328|BIOLOGICAL|Enoxaparin|SC, QD for up to 10 ± 2 days
215006983|NCT06021496|BEHAVIORAL|face to face health education|Face-to-face health education with home visit
215006984|NCT06021496|BEHAVIORAL|online health education|online health education with video call
215006985|NCT00415259|DEVICE|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
215006986|NCT00415259|DEVICE|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
215006987|NCT03693677|DRUG|Irinotecan Liposomal Injection|Nal-IRI at 80 mg/m2 IV over 90 minutes
215006988|NCT03693677|DRUG|5-FU/LV|5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
215006989|NCT03693677|DRUG|Nab-Paclitaxel|Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.
215006990|NCT03693677|DRUG|Gemcitabine|1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.
215006991|NCT06980337|OTHER|Conventional treatment program|"Ultrasound, hot packs, cervical postural stretching and strengthening exercise will be done for all groups.~Stretching Exercises Posture correction exercises training will include stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles and, sternocleidomastoid.~Strengthening Exercises Exercises will include Chin Tucks exercise and Neck isometric exercises"
215006992|NCT06980337|OTHER|Scapulothoracic exercises|Scapulothoracic exercises It is a strengthening exercises of the serratus anterior muscle, as well as the middle and inferior fibres of the trapezius muscle
215006993|NCT06980337|OTHER|Kendall exercises|"The exercise techniques used by Kendell were as follows:~1\. Stretching of the Cervical Extensors: By sitting with the head down and putting both hands across the occipital area, the cervical extensors can be stretched by adopting a flex neck position 2- Strengthening of the Deep Cervical Flexors Positioning supine with the chin tucked in and lifting the head for 2 to 8 s 3- Strengthening the Shoulder Retraction Maintaining an upright posture, keep the resistance band circling with strong support and stretching it with the upper limbs of both sides so that there is full retraction of the scapula 4-Stretching the Pectorals muscle Assigning both hands on the occipital area and pulling the elbows back up (bilateral) and performance arm abduction and external rotation (unilateral)."
215006994|NCT01928771|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
215006995|NCT01928771|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
215096652|NCT03007095|BEHAVIORAL|Evaluation of the children's social cognitive development|standardized neuropsychological tests
215096653|NCT04840329|BEHAVIORAL|Education|One-time educational session about menstrual health and endometriosis
215096654|NCT05270239|BEHAVIORAL|N-back Cognitive Training|N-back task mainly trains working memory and information processing speed. This training lasts 10 days (1 hour per day).
215096655|NCT05270239|BEHAVIORAL|Virtual Reality Motor and Cognitive Training|"Virtual Reality Ball Task mainly trains inhibitory control, attention, working memory and motor functions. This training lasts 10 days (30 minutes per day)"
215096656|NCT04079712|DRUG|Cabozantinib S-malate|Given PO
214504462|NCT05422846|OTHER|exercise protocol|The protocol exercise group will be provided with the necessary approaches for diabetic foot ulcer care and exercises suitable for the physical condition of the wound and the patient, in addition to diaphragmatic breathing exercises. This group will also work with a physiotherapist twice a week.
215096657|NCT04079712|BIOLOGICAL|Ipilimumab|Given IV
215096658|NCT04079712|BIOLOGICAL|Nivolumab|Given IV
215096659|NCT03034824|PROCEDURE|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
214504463|NCT00973505|DRUG|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
214504464|NCT03385031|OTHER|CBCT imaging|CBCT imaging at first and last fraction of radiotherapy treatment
214504465|NCT03567616|DRUG|Venetoclax|Tablet; oral
214504466|NCT03567616|DRUG|Pomalidomide|Capsule; oral
214504467|NCT03567616|DRUG|Dexamethasone|Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]
214402068|NCT04890665|BEHAVIORAL|Online psychological intervention for healthcare workers|"The intervention is based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, Acceptance and Commitment Therapy and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of anxiety, depression, burnout, fatigue compassion, posttraumatic stress disorder, and affectations in sleep quality and perception of life quality in healthcare workers.~And 3 complementary modules that according to the scientific literature could affect the mental health of healthcare workers related to how to deliver bad health news, Psychological first aid and how beliefs could influence physical and emotional self-care in the face of the COVID-19 pandemic."
215006996|NCT06811415|PROCEDURE|virtual temporomandibular joint reconstruction with costochondral graft|All patients were placed in preoperative occlusion in CASS. The planned rib was harvested in the standard manner through an inframammary incision. The length of the rib was equal to the prefabricated template as calculated in the cranial-maxillofacial 3D reconstruction, and comprised at most 5 mm of cartilage. The cartilage was trimmed and contoured to facilitate the setting of the cartilage side properly into the center of the TMJ fossa. A 4-hole titanium plate was fixed with four bicortical screws as previously planned
215006997|NCT03932331|DRUG|Acalabrutinib|Acalabrutinib 100 mg orally twice daily
215006998|NCT04518059|PROCEDURE|punch skin biopsy|An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.
215006999|NCT06981715|OTHER|Conservative treatment|"Night Splint Resting splint fixing the ankle in neutral position~Worn every night before going to bed, used for 6-8 hours~Objective: To reduce the pressure on the median nerve~Exercise Programme:~Applied 1-2 times a day~Each exercise 10 repetitions, 2 sets~Content:~Nerve mobilisation exercises (median nerve sliding and stretching)~Wrist stretching and flexor-extensor tendon sliding exercises~Finger opening-closing, fist making exercises"
215096660|NCT03034824|PROCEDURE|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
215096661|NCT03034824|PROCEDURE|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
214504468|NCT01253213|DRUG|BR55|One to two bolus (2nd bolus optional) of BR55 per patient
214504469|NCT04675684|BEHAVIORAL|Recovery-group|The complex intervention are instructions in ruminations-therapy and mindfulness, advice in healthy diets, physical - and social activities and sleep hygiene, and support in smoking cessation, alcohol counseling and medication adherence.
214504470|NCT04613713|OTHER|Somatocognitive physiotherapy|"The main intervention areas include:~1. education about the PVD, healthy vulvo-vaginal and sexual behaviors, nature of chronic pain and factors influencing pain intensity~2. bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension and respiration pattern in different situations~3. techniques to cope with emotions and thoughts related to bodily experiences and to PVD~4. structured homework assignments promoting application of the learned techniques in daily situations and gradual exposure of the patient to activities associated with pain.~Participants will be offered maximally 15 treatment sessions. No minimal number of sessions is set. Treatment will be conducted by female physiotherapists experienced in treating long-standing pain conditions."
214504471|NCT04613713|OTHER|Treatment as usual|The participants will follow the current treatment advice as recommended by the Vulva Clinic at OUH, a tertiary health care center specialized in treatment of vulvar disorders. Advice include guidance about the management of PVD as a condition, use of medication, physiotherapy, sexologist and psychological counseling, usage of internet resources (vulva.no) and others. Participants will be free to pursue treatment options of their choice. The type of treatment, number of treatments and medication usage will be monitored by bi-weekly electronic forms during the whole study period.
214504472|NCT06218758|OTHER|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
214504473|NCT05075421|PROCEDURE|Gastrectomy|Any type of gastrectomy for gastric cancer
214504474|NCT00004805|BEHAVIORAL|CPR instruction|
214504475|NCT01296230|PROCEDURE|Hormone and semen measurements before varicocelectomy|Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
214504476|NCT03960957|BIOLOGICAL|AbobotulinumtoxinA|Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
214504477|NCT03960957|OTHER|Placebo|Treatment of glabellar facial lines with placebo
214504478|NCT01264172|PROCEDURE|PCCP|PCCP: an minimal-invasive surgery technique, in wich a special plate is pushed in position and fixed through 2 small approaches only (about 2 cm long)
214504479|NCT01264172|PROCEDURE|DHS|Conventional surgical treatment of proximal femur fracture including one longer approach from lateral
214504480|NCT01264172|PROCEDURE|Osteosynthesis with nails|Osteosynthesis with nails is a minimal-invasive surgery technique for proximal femur fractures.
215007000|NCT06981715|OTHER|ESWT|"ESWT Protocol:~Device Radial ESWT device Area of application Wrist volar surface (carpal tunnel area) Parameters Frequency: 5 Hz 4 Bar Number of beats 2000 pulses/session Application time 5-10 minutes per session"
215096662|NCT04724967|DRUG|CeraVe Hydrating Cleanser|topical cleanser applied twice a day for 28 days
215096663|NCT04724967|DRUG|CeraVe Moisturizing Cream|topical cream applied twice a day for 28 days
215096664|NCT05586776|DRUG|4% Chlorhexidine Gluconate|Used for daily showering/bathing for 30 days after hospital discharge.
215096665|NCT05586776|DRUG|2% Mupirocin|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
215096666|NCT05586776|DRUG|Soap Without Antiseptic Properties (Placebo)|Used for daily showering/bathing for 30 days after hospital discharge.
215096667|NCT05586776|DRUG|Placebo Nasal Ointment|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
215096668|NCT04494295|DEVICE|Aurora Surgiscope System|MIS evacuation of hematoma using the Aurora Surgiscope System
215096669|NCT02429791|DRUG|DTG 50 mg|Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
215096670|NCT02429791|DRUG|RPV 25 mg|Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
215096671|NCT02429791|DRUG|CAR|CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
214402069|NCT02034721|DIETARY_SUPPLEMENT|Protein supplement|24 g protein before, 12 g during, and 24 g after eccentric exercise
214402070|NCT02034721|DIETARY_SUPPLEMENT|Placebo|Placebo
214402071|NCT00431743|DRUG|Hydroxyethylstarch 130/0,4|
214402072|NCT00431743|DRUG|Lactated Ringer's solution|
214402073|NCT03007342|DRUG|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|
215007001|NCT06981715|OTHER|Kinesiotaping|Kinesio taping was performed with the Button hole technique described by Dr Kenzo Kase. In this technique, a kinesio tape was measured and cut from the medial and lateral epicondyle level on the palmar side of the forearm, from the base of the proximal phalanges to the epicondyles of the humerus on the dorsal side of the forearm. The tape was folded and the midpoint was found, 2 short incisions were made and 2 button holes were obtained through which the 3rd and 4th finger would pass. The paper behind the band was torn and the 3rd and 4th fingers were passed through the holes. The patient's wrist was brought to extension and radial deviation and the tape was glued with a slight (15-25%) tension towards the medial epicondyle on the palmar side of the forearm. Then the wrist was flexed and ulnar deviated and the tape was glued with a slight (15-25%) tension towards the lateral epicondyle.
215007002|NCT05722236|BEHAVIORAL|IBD Strong Peer2Peer|Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.
215007003|NCT05722236|OTHER|Waitlist control|Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
215007004|NCT01455519|DRUG|Hydromorphone ER|Total target dose of 32 mg/day. All subjects will have a lead in for 2 weeks; then begin a 'forced' 2-week up-titration schedule as follows: 8mg/d (1 pill, 5 days), 16mg mg/d (2 pills, 5 days), and 24mg/d (3 pills, 5 days) then finally 32 mg/d (4 pills a day) for the 'stable dose' phase of the study, or identical placebo pills. If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 8 mg/day (or one pill a day), at the discretion of the PI. Subjects unable to tolerate 8 mg/day will be discontinued from the study. A 2-week down-titration will be used.
215007005|NCT01455519|DRUG|Sugar pill|Sugar pill
215007006|NCT04979013|OTHER|Smoking Abstinence|Smokers will be switched to smoking abstinence for 14 days
215007007|NCT01271855|DRUG|Belladonna and opioid suppository|Belladonna and opioid suppository 16.2mg/30mg per rectum every 8 hours for 24 hours following delivery
215007008|NCT01271855|DRUG|Glycerin Suppository|A vegetable oil suppository (placebo) per rectum every 8 hours for the first 24 hours following delivery.
215007009|NCT06179940|OTHER|Pairwise food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The experimental group will conduct the protocol activity in pairs.
215007010|NCT06179940|OTHER|Individual food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The control group will conduct the activity individually.
215007011|NCT02528227|OTHER|Know Your Baby Language Curriculum|Early language activities that parents can do with their infants
215007012|NCT02528227|OTHER|Reading Aloud Language Curriculum|Early language activity that parents can do with their infants
215007013|NCT02528227|OTHER|Sing A Long Language Curriculum|Early language activity that parents can do with their infants
215007014|NCT02528227|OTHER|Mimicking First Sounds Language Curriculum|Early language activity that parents can do with their infants
215007015|NCT02528227|OTHER|Language Games and Narrating Your Day Language Curriculum|Early language activity that parents can do with their infants
215007016|NCT02528227|OTHER|Feeding Safety|Part of Health and Safety Curriculum
214402074|NCT03007342|DRUG|Placebo|
214402075|NCT04377997|DRUG|Enoxaparin|Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
214402076|NCT00942240|DRUG|ACU-4429|administered orally once a day for 14 days
214402077|NCT00942240|DRUG|matching placebo tablet|administered orally once a day for 14 days
214402078|NCT06215729|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
214402079|NCT06215729|BEHAVIORAL|conventional cognitive training|including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
215096672|NCT05607667|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
214402080|NCT06215729|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
214402081|NCT05482568|DRUG|SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316|"Drug: SHR-A1811 \& Pyrotinib~SHR-A1811： intravenous Pyrotinib：oral~Drug: SHR-A1811 \& SHR-1316~SHR-A1811： intravenous SHR-1316： intravenous"
214402082|NCT00083174|DRUG|exemestane|one 25 mg tablet daily in am
214402083|NCT00056368|DRUG|Anidulafungin|
214402084|NCT00056368|DRUG|Fluconazole|
214402085|NCT03582137|DRUG|Cannabidiol|Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
214402086|NCT03582137|OTHER|Placebo|Subjects randomized to this arm will receive Placebo
214504481|NCT01307254|PROCEDURE|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
215007017|NCT02528227|OTHER|Car Seat Safety|Part of Health and Safety Curriculum
215007018|NCT02528227|OTHER|Bath Safety|Part of Health and Safety Curriculum
215007019|NCT02528227|OTHER|Back to Sleep/SIDS prevention|Part of Health and Safety Curriculum
215007020|NCT02528227|OTHER|Taking a Temperature and Signs of Infection|Part of Health and Safety Curriculum
214504482|NCT01982994|BEHAVIORAL|Education/Daily Planning|"In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)"
215007021|NCT02528227|OTHER|Infection Control Measures and Vaccine Information|Part of Health and Safety Curriculum
215007022|NCT00932711|BEHAVIORAL|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
215007023|NCT01617109|DIETARY_SUPPLEMENT|Ca/Vit D|800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars
215007024|NCT01617109|OTHER|Placebo|administered as 5 pills daily or as 2 snack bars
215007025|NCT03910946|DRUG|Tuberculin, Purified Protein 5Unt/0.1 mL Solution|Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
214402087|NCT05569655|DRUG|Tolvaptan|Within 12 hours of admission, subjects were randomly assigned to two groups using the central randomization method. For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide:20-40mg/d). The treatment lasts for a total of seven days to assess the efficacy and safety of tolvaptan in the treatment of PAH-induced right heart failure.
214402088|NCT05569655|DRUG|Furosemide|Within 12 hours of admission, traditional standard therapy (furosemide:20-40mg/d) is used for all subjects in our clinical trial. The treatment lasts for a total of seven days.
214402089|NCT02726555|DRUG|Red yeast rice and atorvastatin|Participants will receive 2 capsules of 300mg red yeast rice and 2 capsules of 10mg atorvastatin for 24 weeks.
215007026|NCT01607008|OTHER|MRI imaging|"3 total MRI imaging studies:~1. pre standard radiation treatment~2. during standard radiation treatment~3. post standard radiation treatment"
215007027|NCT06381843|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
215007028|NCT06381843|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
214402090|NCT02726555|DRUG|Atorvastatin alone|Participants will receive 2 capsules of placebo and 2 capsules of 10mg atorvastatin for 24 weeks.
214402091|NCT04554498|DEVICE|1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up|"1. the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~2. the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~3. the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands)."
214402092|NCT03230487|DRUG|BI 1015550|Part 1 - single rising dose. Part 2 multiple rising dose
214402093|NCT03230487|DRUG|Placebo|Part 1 - single rising dose. Part 2 multiple rising dose
215007029|NCT06569355|DRUG|VCT220|A small molecule GLP-1R agonist tablet, orally administration, once daily
215007030|NCT06569355|DRUG|Placebo|Placebo tablet
215096673|NCT01591356|DRUG|EphA2-targeting DOPC-encapsulated siRNA|Given IV
215096674|NCT01591356|OTHER|Laboratory Biomarker Analysis|Correlative studies
215096675|NCT01591356|OTHER|Pharmacological Study|Correlative studies
215096676|NCT03567473|DRUG|Oral dexamethasone|Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later
215096677|NCT03567473|DRUG|Nebulized Epinephrine|Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
214402094|NCT02453529|DRUG|WCK 4873|Oral tablets
214402095|NCT02485795|OTHER|Observational|This study will evaluate the impact of genetic testing information on medical regimen plans and whether this information results in benefits to patient care.
214402096|NCT00162539|OTHER|echography|Correlation of neonatal thyroid volume with maternal iodine deficiency
214402097|NCT02303574|DRUG|AZD7986, oral solution, 1 to 50 mg/mL|Starting dose in single ascending dose part: 5 mg
214402098|NCT02303574|DRUG|Placebo, oral solution|Matching placebo
214402099|NCT03695289|BEHAVIORAL|iOTA SMI|Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.
214402100|NCT03695289|BEHAVIORAL|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.
214402101|NCT04875260|OTHER|Critical Care|Critical care in the intensive care units
214402102|NCT01873677|DRUG|M518101|
214402103|NCT01873677|DRUG|Vehicle|
214402104|NCT01606189|DRUG|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
214402105|NCT01606189|DRUG|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
214402106|NCT01606189|DRUG|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
214402107|NCT05635266|DIAGNOSTIC_TEST|Specimen sample|The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.
214402108|NCT03753087|DRUG|Empagliflozin|10 mg tablet
214402109|NCT03753087|OTHER|Standard care|Standard care with no SGLT-2 inhibitors
214402110|NCT00220103|DRUG|epirubicin, capecitabine, cisplatin|
214402111|NCT00220103|PROCEDURE|Surgical resection|
214402112|NCT02162732|DEVICE|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
214402113|NCT04730180|DEVICE|Transcranial Magnetic Simulation|Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.
214402114|NCT04730180|DEVICE|Mixed reality neuronavigation|Targeting of the dorsolateral prefrontal cortex will be performed with the help of a mixed reality neuronavigation system.
214402115|NCT00287638|DEVICE|CPAP|Continuous positive pressure device with a time clock
214402116|NCT00287638|DEVICE|placebo|no CPAP
215007031|NCT06811844|DRUG|Two-cycle induction chemotherapy + immunotherapy|Two cycles of nab-paclitaxel at 260 mg/m2 on day 1, cisplatin at 25 mg/m2 from days 1 to 3, and oral S1 twice daily from days 1 to 14 (40 mg twice daily on patients with a body surface area \[BSA\] less than 1.25 m2, 50 mg twice daily for patients with a BSA between 1.25 and 1.5 m2, and 60 mg twice daily for patients with a BSA \>1.5 m2). Camrelizumab was administered intravenously at a dose of 200 mg on the first day of each cycle.
215007032|NCT06811844|DRUG|Three-cycle induction chemotherapy + immunotherapy|Three cycles of nab-paclitaxel at 260 mg/m2 on day 1, cisplatin at 25 mg/m2 from days 1 to 3, and oral S1 twice daily from days 1 to 14 (40 mg twice daily on patients with a body surface area \[BSA\] less than 1.25 m2, 50 mg twice daily for patients with a BSA between 1.25 and 1.5 m2, and 60 mg twice daily for patients with a BSA \>1.5 m2). Camrelizumab was administered intravenously at a dose of 200 mg on the first day of each cycle.
215007033|NCT06654999|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|"DERM variants + and DS"
215096678|NCT03567473|DRUG|Oral placebo|Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.
215096679|NCT03567473|DRUG|Nebulized normal saline|Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
215096680|NCT03567473|DRUG|MDI Epinephrine|Two doses of Epinephrine given by MDI plus spacer at 625 mcg (5 actuations of 125mcg) 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
214402117|NCT01167023|DRUG|Prasugrel|Administered orally, once daily for 30 days.
214402118|NCT01167023|DRUG|Placebo|Administered orally, once daily for 30 days.
214402119|NCT00410384|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
214402120|NCT00410384|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
214402121|NCT00410384|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
214402122|NCT00429702|DRUG|Decadron®|Given IV
214402123|NCT00429702|DRUG|Benadryl®|Given IV
214402124|NCT00429702|DRUG|Ativan®|Given IV
214402125|NCT00429702|DRUG|ondansetron hydrochloride|Given IV
214402126|NCT00108784|BEHAVIORAL|Reduced-energy-density diet|
214402127|NCT01111890|DRUG|Azarga (brinzolamide 1% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
214402128|NCT01111890|DRUG|Cosopt (dorzolamide 2% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
214402129|NCT04502927|PROCEDURE|Passive extension mobilization of the hand and wrist joints|"The physiotherapist will proceed with the passive mobilization of the spastic hand of the stroke patient or the dominant hand for healthy volunteers.~Two mobilizations will be performed for each participant, i.e. one for each type of medial or lateral grip. The order of mobilization will be determined by randomization."
214402130|NCT05651880|DRUG|Baricitinib 4 MG|4 mg per day for 6 months (For patients with creatinine clearance between 30 and 60 mL/min at baseline or during the study, the dosage of baricitinib will be 2 mg daily)
214402131|NCT04392258|DIAGNOSTIC_TEST|TSH determination|Determination of serum concentration of thyrotropin (TSH)
214402132|NCT04392258|DIAGNOSTIC_TEST|FT4 determination|Determination of serum free thyroxine (FT4) concentration
215007034|NCT06821737|DEVICE|Diagnostic ultrasound|A portable wireless ultrasound system (Vscan Air, General Electric Healthcare) with dual probes-linear array (3-12 MHz) for neck scanning and curved array (2-5 MHz) for subxiphoid scanning-will be used. The linear probe is placed transversely on the anterior neck, slid left at the thyroid level to focus on the esophagus, then rotated for longitudinal views. The curved probe is applied subxiphoid, using the liver as a landmark, and tilted left to image the stomach. A positive result is confirmed by visualizing the NGT shadow in the esophagus and stomach, followed by dynamic upsurge fogging after injecting 50cc of air. Ultrasonography and X-ray results will be compared.
215007035|NCT06821737|DEVICE|Diagnostic X-ray|This study will employ chest radiography as the reference standard for verification of correct nasogastric tube placement. Radiographic imaging will be conducted following NGT insertion and interpreted by physicians to verify positional accuracy.
215007041|NCT05382962|BEHAVIORAL|iCanCope Post Op Application|The iCanCope program is designed to enhance pain self-management and self-efficacy, defined as perception of one's ability to successfully produce a desired effect in a task or behavior affecting their life. The intervention will be delivered on the iOS or Android smartphone platform depending on the participant's device. Usage of app features will be centrally tracked by the research team using Analytics Platform to Evaluate Effective Engagement (APEEE), developed at the Centre for Global eHealth Innovation. Participants will receive alerts through iCanCope to complete a pain diary check-in once per week preoperatively, twice per day over the initial 2-week postoperative period, and once per day for the subsequent 2-week period.
215007042|NCT04211896|DRUG|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
215007043|NCT04211896|DRUG|Nivolumab|Nivolumab will be given at a dose of 240 mg every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
215007044|NCT04705753|DIETARY_SUPPLEMENT|Cretan IAMA|Cretan IAMA (CAPeo) soft gels, 1 ml/day of a 1.5% essential oil combination from three aromatic plants (Thymbra 59 capitata (L.) Cav., Origanum dictamnus L., Salvia fruticosa Mill.) in extra virgin olive oil
215007045|NCT00469729|DRUG|StemEx®|The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
215007046|NCT00097968|DRUG|everolimus|
215007047|NCT05877105|OTHER|Ventilator-associated pneumonia prevention Evidence-based practices (VAPPEBP) which consists of ten items bundle|VAP prevention EBP which consists of ten items bundle; hand hygiene, head-of-bed elevation, oral care with cetylpyridinium chloride, avoidance of oversedation, proper breathing circuit management, appropriate maintenance of endotracheal tube cuff pressure, closed system and subglottic suctioning, daily assessment for extubation, early ambulation and rehabilitation, and peptic ulcer and deep vein thrombosis (DVT) prophylaxis.
215007048|NCT04692818|DIAGNOSTIC_TEST|GE Logiq E10 clinical ultrasound scanner|2D B-mode, Doppler, and shear wave elastography images of the lesion
215007049|NCT04692818|DIAGNOSTIC_TEST|Verasonics research scanner|3D B-mode imaging, microvessel imaging, and shear wave elastography
215007050|NCT03658967|DRUG|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
215007051|NCT03658967|DRUG|Placebo|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
215007052|NCT06988488|DRUG|Elranatamab|Specified dose on specified days
214402133|NCT04392258|DIAGNOSTIC_TEST|FT3 determination|Determination of serum free triiodothyronine (FT3) concentration
214402134|NCT04392258|DIAGNOSTIC_TEST|SPINA-GT|Calculation of thyroid's secretory capacity (SPINA-GT)
214402135|NCT04392258|DIAGNOSTIC_TEST|SPINA-GD|Calculation of total deiodinase activity (SPINA-GD)
214402136|NCT06221774|DRUG|TT-00420 + Toripalimab|TT-00420 tablets in combination with Toripalimab injection
214402137|NCT02049437|DRUG|tocilizumab|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
214504483|NCT01920126|DRUG|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
214504484|NCT01920126|DRUG|Saline|
215007053|NCT06988488|DRUG|Mezigdomide|Specified dose on specified days
215007054|NCT06988488|DRUG|Dexamethasone|Specified dose on specified days
215007055|NCT01952951|DRUG|Capecitabine Oxaliplatin|after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
215007056|NCT01952951|RADIATION|pelvic radiation capecitabine 5-fluorouracil|50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
214402138|NCT02049437|DRUG|Placebo|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
214402139|NCT00740519|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
214402140|NCT04121208|DRUG|JNJ-40346527|Active study drug
215096681|NCT03567473|DRUG|MDI placebo|Two doses of inhaled placebo given by MDI plus spacer, 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
215096682|NCT00097890|DRUG|Replagal (Agalsidase Alfa)|
215096683|NCT00097890|DRUG|Replagal|
214402141|NCT04121208|OTHER|Placebo|Non-active study drug
214402142|NCT02235610|PROCEDURE|EVLP Group|"EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.~Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice."
214402143|NCT01649726|PROCEDURE|Apnea test - control|
214402144|NCT01649726|PROCEDURE|Apnea test - CPAP|
214402145|NCT03918018|DEVICE|BORA Band SpO2 Validation Study|"Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. Reference sensor(s) will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk.~Simultaneous data collection will be set up for device under test and the control pulse oximeter. The data from the test device will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.~The investigational device will only be placed on the wrist. The control pulse oximeter may be alternated through fingers between subjects."
214402146|NCT04970238|DRUG|Levosimendan|Test drug: drug preparation method: 5ml (12.5mg) levosimendan injection was mixed with 500ml 5% glucose injection, the initial loading dose was 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg/ kg / min for 24 hours.
214402147|NCT04970238|OTHER|placebo|Control drug: 5% glucose injection, intravenous injection method is the same as the experimental group pump dose, the initial load dose of treatment is 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg / kg / min for 24 hours.
215007057|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
214402148|NCT01505075|RADIATION|Hypofractionated radiation|40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
214402149|NCT03950908|OTHER|Single bite biopsy technique|During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.
214402150|NCT03950908|OTHER|Double bite biopsy technique|During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
214402151|NCT00910884|OTHER|laboratory biomarker analysis|No supplements are given
214402152|NCT00910884|PROCEDURE|therapeutic dietary intervention|Given orally daily for 12 months
215007058|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity. During the first week of the study, participants will be introduced to the program, and the Noom app.
215007059|NCT04377568|BIOLOGICAL|Convalescent plasma (CP)|Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL
215007060|NCT04863521|OTHER|MHP|MyHealthyPregnancy app (MHP 3.0) is a mHealth app specifically focused on detection and referral for depression and IPV (Intimate Partner Violence) risk, in addition to its other pregnancy risk detection and support features.
215007061|NCT01452347|DRUG|warfarin 1mg|comparator warfarin
215007062|NCT01452347|DRUG|dabigatran etexilate intermediate dose|active treatment (medium)
215007063|NCT01452347|DRUG|dabigatran etexilate low dose|active treatment (low)
215007064|NCT01452347|DRUG|warfarin 5mg|comparator warfarin
215007065|NCT01452347|DRUG|dabigatran etexilate high dose|active treatment (high)
215007066|NCT01452347|DRUG|warfarin 3mg|comparator warfarin
215007067|NCT06998199|OTHER|Dual Task Balance Exercise|"The content of the DT training is summarized below with 30 minutes of routine PT. Participants will receive total of 16 sessions, 2 sessions per week for 8 weeks.~1. Walking 3 m on hard/soft ground while performing a motor task (carrying an empty box) and then combined with a cognitive task (saying the names of some fruits and vegetables),~2. Sitting on a Pilates ball for 1 min with eyes open/closed while performing a motor task (arms flexed to 90 degrees) and then combined with a cognitive task (saying the names of friends)~3)2-feet Jumping forward with both feet for 3 m while performing a motor task (carrying an empty box) then with a cognitive task (naming the colors in the room)~4)Standing on one leg for 30 s while arms abducted to 90 degrees and then combined with a cognitive task (saying the names of relatives)~5)Sit-to-stand using a stool 15 repetitions with a motor task (carrying an empty box) and then with a cognitive task (saying the names vegetables etc)"
214402153|NCT05880693|DRUG|Dexmedetomidine|Group 1 received dexmedetomidine
214402154|NCT05880693|DRUG|Magnesium sulfate|the group 2 received magnesium sulfate
214402155|NCT01575145|BEHAVIORAL|Quitline facilitation intervention|brief quitline facilitation intervention
214402156|NCT01575145|BEHAVIORAL|Brief stop-smoking intervention|brief review of tips to help maintain smoking abstinence, using brochure
214402157|NCT03459495|DEVICE|therapeutic ultrasound|Patients in the ultrasound group will be administered to the posterior neck region for 5 minutes in pulsed mode (pulse rate 1: 1) at 1 MHz, 1.5 W / cm2. The treatment will be done 5 days a week for a total of 10 days
215007068|NCT06998199|OTHER|Vestibular Stimulation|The child will place in sitting position on the swing and his hands grasping the ropes at the sides then the therapist stand behind him and begin pushing the platform in fast and jerky movement in back and front, side to side and in spinning directions with the child trying to maintain his balance in all different directions. The subject will receive pushing for each direction for five minutes; the total mechanical vestibular session duration was 15 minutes with 30 minutes of routine physical therapy. Participants will receive total of 16 sessions, 2 sessions per week for 8 weeks.
214402158|NCT03459495|DEVICE|placebo ultrasound|When the ultrasonic device is in the closed position, the ultrasonic probe will be applied for 5 minutes in the posterior neck region of the patients. The treatment will be done 5 days a week for a total of 10 days.
214402159|NCT04135924|OTHER|Rehabilitation|physical exercise and respiratory muscle training
214402160|NCT00626600|DRUG|Oxycodone Hydrochloride|
214402161|NCT06394336|OTHER|Muscle strengthening|Strengthening exercises for the intrinsic muscles of the foot and hips
214402162|NCT06394336|DRUG|Standard treatment (oral analgesic/anti-inflammatory drug)|oral analgesic/anti-inflammatory drug. Education.
214402163|NCT00602901|OTHER|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
214402164|NCT00602901|OTHER|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
214402165|NCT00602901|DRUG|Usual medical care|Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
214402166|NCT05630339|DIETARY_SUPPLEMENT|Magnesium chloride|Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.
214402167|NCT05630339|DIETARY_SUPPLEMENT|Vitamin D|Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.
214402168|NCT05630339|DIETARY_SUPPLEMENT|Inert placebo|Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.
214402169|NCT01632865|DEVICE|stenting|Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
214402170|NCT04541225|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
214402171|NCT00630539|DRUG|Placebo|1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
214402172|NCT00630539|DRUG|Ospemifene 5 mg|1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
214402173|NCT00630539|DRUG|Ospemifene 15 mg|1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
214402174|NCT00630539|DRUG|Ospemifene 30 mg|1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
215007069|NCT07008638|DRUG|Bortezomib|Bortezomib at assigned study dose in mg/m2 will be given subcutaneously on days 1, 4, 8, and 11
215007070|NCT07008638|DRUG|CPX-351|CPX-351 given intravenously on day 1, 3, and 5
215007071|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The patient's back was prepared for surgery. They were positioned on their side, with the operative side facing upward. The L3-4 spinal interspace was identified, and numbed, and a thin spinal needle was inserted. After confirming Cerebrospinal Fluid (CSF), 12.5 mg of isobaric bupivacaine 0.5% was injected into the spinal canal.
215007072|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The L3-4 spinal interspace was identified, numbed, and a thicker needle (Tuohy needle) was inserted. After confirming Cerebrospinal Fluid (CSF), a thin catheter was inserted into the spinal canal and secured. An initial dose of 1 ml isobaric bupivacaine 0.5% was injected, followed by additional doses as needed to maintain the block height.
215007073|NCT06625606|DRUG|Isoflurane Inhalant Product|General anesthesia was initiated with propofol and rocuronium. Anesthesia was maintained with isoflurane, with additional rocuronium and fentanyl as needed. Breathing was controlled by the ventilator, and muscle relaxation was reversed at the end of surgery.
214402175|NCT06488066|OTHER|Data collection|Collection of clinical data from groups of patients already implanted with the light adjustable lens (LAL) and have completed light treatments.
214402176|NCT02482909|PROCEDURE|Hepatic resection|Anatomical surgical resection of the liver including the tumor
214402177|NCT02482909|PROCEDURE|Radiofrequency ablation|Percutaneous ablation using radiofrequency under the imaging guidance
214402178|NCT00315965|DRUG|Nitric oxide, Carbon monoxide, Helium|
214402179|NCT06102785|DRUG|Fruquintinib, TAS102|Fruquintinib combined with TAS102
214402180|NCT02007447|DRUG|OCYTOCINA - SPRAY NASAL|The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
214402181|NCT02135783|PROCEDURE|Decompressive Craniectomy|A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
214402182|NCT02135783|PROCEDURE|non-Decompressive Craniectomy|a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
214402183|NCT00000989|DRUG|Zidovudine|
214402184|NCT00000989|DRUG|Sargramostim|
214402185|NCT00000989|DRUG|Ganciclovir|
214402186|NCT01783457|OTHER|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
214402187|NCT01783457|OTHER|Individual psychoeducation|"Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request."
214402188|NCT01687192|BIOLOGICAL|HPV prophylactic vaccine Gardasil|3 injections: at Inclusion visit then 2 and 6 months after.
214402189|NCT00696293|DRUG|Duloxetine|Duloxetine up to 120 mg/day + Clinical Management
214402190|NCT02953548|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
215007074|NCT07012343|RADIATION|Photodynamic Therapy with Conventional Methylene Blue|Methylene Blue mediated photodynamic therapy
215007075|NCT07012343|DRUG|urea 40% cream|40% Urea cream with occlusion
215007076|NCT03119974|DRUG|Tpo-RA discontinuation|a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (\> 2 months) complete response (platelets counts \> 100 x 109/L) period on Tpo-RA treatment.
215007077|NCT07044869|PROCEDURE|FACILITATED POSITIONAL RELEASE TECHNIQUE|Participants in experimental group A receive FPRT as a main intervention along with piriformis stretches. 30 minutes' session starts with application of 10 minutes hot pack, followed by FPRT and stretches respectively. For FPRT, the patient position was prone with the hip flexion approximately (60°-90°) and abduction. The therapist was seated on the side that was affected, and the treated leg was hanging off the table with the knee bent resting on the therapist thigh. The painful tender area was felt in the piriformis muscle's belly around midway between the greater trochanter and the inferior lateral angle of sacrum. At the point when tender area was palpated, therapist applied ischemic pressure over the area with finger pads. Pressure hold for 1 minute and two repetitions were performed (2 minutes' pressure for whole was given). After that piriformis stretches were performed with 5reps\*5 sec hold\*1set.
215007078|NCT07044869|PROCEDURE|MANUAL MYOFASCIAL RELEASE TECHNIQUE|Experimental Group B participants received MFRT as a main intervention along with application of hot pack and piriformis stretches. They also received 30 min session started with application of hot pack for 10 minutes followed by MFRT and piriformis stretches. For application of MFRT patient was in prone lying position. The therapist was standing at the affected/unaffected side of the patient. Myofascial release was provided, using the therapist's palm, finger pads or elbow directly on the piriformis muscle, pressure was provided on the tender area directly and held for a while (60 seconds approx.) and 3 repetitions were performed. Back and forth little kneading motions were applied in accordance with the muscle fiber's direction. After MFRT piriformis stretches were performed with frequency of 5 repetitions \*5 second hold\* 1 set.
215007079|NCT07044895|OTHER|Diode laser and Immediate implant|patients with non-restorable teeth in the maxillary esthetic zone will be included in this prospective single-arm study. The non-restorable tooth will be atraumatically extracted and immediate implant placement will be placed. The extraction socket will be sealed with diode laser photocoagulation and customized healing abutments fabrication.
215007080|NCT07049133|OTHER|T-DXd toxicity marker identification|to find potential predictive markers associated with T-DXd-related toxicities
214402191|NCT00696904|DRUG|ABT-333|Capsule, see arms for intervention description
214402192|NCT00696904|DRUG|Placebo|Capsule, see arms for intervention description
214402193|NCT04569279|DRUG|Rivaroxaban|Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.
214402194|NCT04569279|DRUG|Warfarin|Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
214402195|NCT00651677|PROCEDURE|HAL proctectomy|Hand-assisted laparoscopic proctectomy
214402196|NCT00651677|PROCEDURE|"straight laparoscopic proctectomy"|"straight laparoscopic proctectomy"
215007081|NCT07046052|OTHER|continuous infusion of levobupivacaine|Participants in this arm will receive a continuous infusion of levobupivacaine via a regional anaesthesia catheter placed in the PENG fascial space. The total dose over 24 hours will be equivalent in both arms of the study.
214402197|NCT00651677|PROCEDURE|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
214402198|NCT00651677|PROCEDURE|SL Proctectomy|Straight laparoscopic proctectomy
214402199|NCT00586274|PROCEDURE|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
214402200|NCT00586274|DRUG|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m\^2
214402201|NCT00586274|BIOLOGICAL|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are \> 1000/ul.~Dose level -1 (1 x 10\^3 T cells/Kg); Dose level 1 (1 x 10\^4 T cells/Kg); Dose level 2 (1 x 10\^5 T cells/Kg); Dose level 3 (1 x 10\^6 T cells/Kg); Dose level 4 (5 x 10\^6 T cells/Kg)"
214402202|NCT00586274|BIOLOGICAL|Campath 1h|10 mg iv over 4 hours day-8 through day-6
214402203|NCT00586274|BIOLOGICAL|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
214402204|NCT02133274|BEHAVIORAL|Brief Psychosocial Intervention|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy designed specifically for the present study.
214402205|NCT02133274|OTHER|Early Palliative Care|Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.
215007082|NCT07046052|OTHER|Programmed Intermittent Bolus of Levobupivacaine|Participants in this arm will receive a timed pre-set bolus dose of levobupivacaine via a regional anaesthesia catheter placed in the PENG fascial space. The total dose over 24 hours will be equivalent in both groups.
215007083|NCT07046546|PROCEDURE|Thyroid artery embolization|A minimally invasive procedure where one or more thyroid arteries are occluded to shrink the thyroid gland or thyroid nodules
215007084|NCT07045610|DIAGNOSTIC_TEST|re-biopsy tumor with primary ALK tKI resistance for NGS|Lung cancer patients who initially use ALK TKI as first-line treatment will be invited to enroll and sign the consent form. Only those who meet the criteria for primary resistance or rapid progression will proceed with tumor sample collection for genetic analysis. Alternatively, patients who develop primary resistance or rapid progression after using ALK TKI and are about to undergo tumor re-biopsy can also sign the subject consent form to be included in this study.
215007085|NCT07045272|BEHAVIORAL|Experimental|The intervention team provides lifestyle guidance to the subjects according to the behavioural intervention programme, and the subjects record information on diet, exercise and weight on the platform on a daily basis. Subjects are required to learn relevant health education knowledge on the platform by themselves, and they can also exchange experience in the group and receive motivational counselling from the instructors.
215007086|NCT07044505|PROCEDURE|Uterine Lavage|Saline is introduced into the uterine cavity and retrieved during surgery to collect cells and fluid for downstream molecular and cellular analyses.
215007087|NCT07049731|DIETARY_SUPPLEMENT|Protein powder intervention|On the basis of a balanced diet, 2 sachets of Aiben Leap Protein Nutritional Powder (each sachet containing 6g of milk protein) were supplemented daily.
215007088|NCT07049731|BEHAVIORAL|Resistance exercise intervention|Low-intensity resistance training was conducted 3 times a week.
215007089|NCT07049731|DIETARY_SUPPLEMENT|Placebo control|placebo was given and an individualized balanced dietary plan based on the Dietary Guidelines for Chinese Residents was provided.
215007090|NCT07048184|DEVICE|Negative Pressure Wound Therapy (NPWT) Dressings|During wound closure, skin glue is not permitted as this interferes with the NPWT suction mechanism. The NPWT is a mesh-based dressing that will be applied following the transparent occlusive dressing as per the manufacturer's instructions. Patients assigned to NPWT will have their dressing connected to a suction device (ActiV.A.C.®, KCI) providing a constant negative pressure of 125mmHg and left in situ for between 5 and 7 days. The dressings and suction device are all CE-marked medical devices that are being used within their intended usage.
215007091|NCT07048184|DEVICE|Standard Absorbent Dressings|The wound will be closed as per the standard surgical technique and the operating surgeon's preference. Following wound closure of sarcoma tumour resection, standard absorbent dressing will be applied as per local protocols and the pre-op plan
215007092|NCT07049809|COMBINATION_PRODUCT|Focal Muscle Vibration|"The focal vibration machine will be used. The device has 6 muted transducers that generate power between 30-300 Hz, but for this study we will use between 100-150 Hz for 30 minutes.~The application of the 6 transducers or heads is at the level of the lower extremities, since those muscle groups present the most clinical correlation with functional parameters such as gait and balance. 3 transducers will be placed on one leg (vastus medialis, vastus lateralis and rector anterior) and the other 3 transducers on the other leg, on the same muscles. To speed up the intervention program and cover more participants, 4 focal vibration machines will be used. Each participant wil use 1 machine and 6 transducers, so during the 30 minutes that the intervention lasted, the groups will be of 4 participants with t"
215007093|NCT07049809|OTHER|Multicomponent Exercise|The program consists of a multi-component approach, integrating aerobics, resistance, and balance training. The weekly schedule include three intervention days: one day focused on aerobic exercise, one day dedicated to resistance training and one day centered on balance training. The combined program is individualized based on the intrinsic capabilities of each individual.
215007094|NCT07052526|OTHER|Prevention|Conventional Hydrophobic Sealant (Helioseal F - Control) will be used as a positive control; applied to partially erupted molars with and without bonding in a split-mouth design.
214402206|NCT00310362|BEHAVIORAL|Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures|Interactive voice response system (IVR) calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
214402207|NCT00555347|DRUG|Armodafinil|Dosage 150-250 mg
214402208|NCT00555347|DRUG|Placebo|Placebo
214402209|NCT01759121|RADIATION|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
215007095|NCT07052526|OTHER|Prevention of caries|Embrace WetBond sealant will be applied to partially erupted first permanent molars using a split-mouth design with and without bonding agent.
214402210|NCT01759121|RADIATION|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
214402211|NCT02374502|BEHAVIORAL|Brief Intervention|'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
214402212|NCT00565318|DRUG|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
214402213|NCT00565318|DRUG|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
214402214|NCT00318513|DRUG|Bevacizumab|
214402215|NCT00647140|OTHER|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
214402216|NCT00715286|OTHER|timing of surgery|Surgery is followed by chemotherapy
214402217|NCT00715286|OTHER|timing of surgery|Chemotherapy is followed by surgery
214402218|NCT05365867|BEHAVIORAL|iCAN Group|See description in iCAN study arm.
214402219|NCT03453385|BEHAVIORAL|Electronic Cigarette|An e-cigarette and four weeks of e-liquid provided to participants.
215007096|NCT07052526|OTHER|Prevention therapy|DENU Seal applied using a split-mouth design to evaluate bonding and non-bonding application outcomes from retention and caries prevention
215007097|NCT07055646|DIAGNOSTIC_TEST|Traditional Assistive Technology|Participants in Group 1 utilize traditional, non-digital assistive devices designed to enhance mobility and spatial orientation
215007098|NCT07055646|DIAGNOSTIC_TEST|Digital Assistive Technology|Participants in Group 2 use modern, digital assistive technologies specifically designed to improve navigation, orientation, and real-time decision-making for visually impaired individuals
215007099|NCT07055646|COMBINATION_PRODUCT|Combined Technology Users|Participants in Group 3 use a combination of traditional tools (e.g., cane, magnifiers) alongside modern digital aids (e.g., smart canes, GPS apps). This group is important to examine how integrated usage of both types of technologies
215007100|NCT07057440|OTHER|High-dose Nicotine Pouch|"A High Dose Nicotine Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions.~After 20 minutes pouches are removed from the oral cavity and disposed."
215007101|NCT07057440|OTHER|Low Dose Nicotine Pouch|A Low Dose Nicotine Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions. After 20 minutes pouches are removed from the oral cavity and disposed.
215007102|NCT07057440|OTHER|Placebo Pouch|A Placebo Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions. After 20 minutes pouches are removed from the oral cavity and disposed.
215007103|NCT07057375|DEVICE|Pulsed electromagnetic fields Thearpy|Pulsed electromagnetic fields (PEMF) is a non-invasive and non-thermal treatment used to stimulate muscle regeneration, resulting in increased muscle mass and strength.
215007104|NCT07057375|DEVICE|Sham Therapy|Sham Therapy
214402220|NCT04308616|OTHER|Blood samples|Blood samples
214402221|NCT00419068|DRUG|Cholecalciferol|
215007105|NCT07056075|DEVICE|Nasal PAP Ventilation System|medical devices that provide nasal positive airway pressure ventilation during endoscopy
215007106|NCT07056075|DEVICE|Low Flow Oxygen|low flow oxygen though nasal cannula
215007107|NCT07056075|DEVICE|Capnometry|capnometry measurement
215007108|NCT07056088|DRUG|Insulin Drip Therapy|"Simple randomization will be used for randomization. The participants will be randomized into two groups based on methods of insulin delivery.~* Group A: Insulin drip will be administered at a starting rate of 2 units/hour and titrated to maintain blood glucose levels between 80-180 mg/dL.~* Group B: Insulin boluses will be administered every 30 minutes to maintain blood glucose levels between 80-180 mg/dL.~Insulin boluses will be considered as a control group."
214402222|NCT00419068|DRUG|Migliol Placebo Oil|
214402223|NCT02055859|RADIATION|Radiosurgery|
214402224|NCT03912103|OTHER|Interdisciplinary Deprescribing and Medication Optimization Intervention|as current
214402225|NCT05561855|BEHAVIORAL|lifestyle intervention|"During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of Weight Loss and Glucose Control.They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data."
215007109|NCT07056088|DRUG|Insulin boluses|"Insulin boluses will be administered every 30 minutes to maintain blood glucose levels between 80-180 mg/dL.~Insulin boluses will be considered as a control group"
214402226|NCT04284748|OTHER|Plyometric exercise with blood flow restriction|"Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)"
214402227|NCT04284748|OTHER|Plyometric exercise|Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
214402228|NCT04284748|OTHER|Routine physiotherapy program|Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
214402229|NCT06336746|DEVICE|Esophageal Doppler|Esophageal Doppler: measuring cardiac performance. INVOS: measuring regional saturation of the brain.
214402230|NCT02117115|RADIATION|Dynamic contrast-enhanced computed tomography|CT scan performed between Day +7 and Day +14.
214402231|NCT02117115|DRUG|Ioversol|To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
214402232|NCT04863105|DRUG|Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)|"Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
214402233|NCT04455724|DEVICE|Negative pressure incisional wound therapy|A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues.
214402234|NCT04455724|DEVICE|Standard sterile dressing|A standard, sterile island dressing
215007110|NCT06544655|DRUG|BMS-986484|Specified dose on specified days
215007111|NCT06544655|BIOLOGICAL|Nivolumab|Specified dose on specified days
215007112|NCT06544655|DRUG|Oxaliplatin|Specified dose on specified days
215007113|NCT06544655|DRUG|Capecitabine|Specified dose on specified days
215007114|NCT06544655|DRUG|Fluorouracil|Specified dose on specified days
215007115|NCT06544655|DRUG|Calcium folinate|Specified dose on specified days
215096684|NCT03771950|BEHAVIORAL|Early team based neuro-rehabilitation|A structured interview will be made by OT about activity level, and an examination of the patients bodily and neurological symptoms will be made by PT. Based on this result a rehabilitation plan is established consisting of the patient's goals, and the purpose that the patient shall be as active as possible without triggering symptoms. An individual exercise program is prescribed. Between each appointment the patient will have personal tasks to accomplish with the purpose of being active based on symptoms and the adaptation to the current level of energy. The perceived symptoms will be logged. A week-schedule will be created in the purpose of helping the patient to a balanced activity level in relation to their current capacity. The PT assesses physical activity level and reactions to physical strain. Adaptations are made to the exercise program and advice is given on physical activity and exercises. When appropriate OT advices about returning to work and adaptations concerning work.
215007116|NCT05534984|DRUG|Tecovirimat Oral Capsule|"Drug: Tecovirimat Oral capsules~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
215007117|NCT05534984|DRUG|Placebo|"Drug: Placebo Oral capsules~* Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days"
215007118|NCT05534984|DRUG|Tecovirimat Oral Capsule (Open Label)|"* Participants weighing \<3kg - Tecovirimat 533.3mg every 12 hours for 14 days~* Participants weighing 3 kg to less than 6kg- Tecovirimat 50 mg every 12 hours for 14 days~* Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~* Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
215007119|NCT06152081|DEVICE|LumiCare rinse|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. Lumicare rinse will be applied onto the test areas for 30 seconds and the excess removed using a saliva ejector. The sites will then be rinsed with plain water for 10 seconds and excess will be removed using high volume suction. A blue curing light will then be held 1-2 inches from the test surfaces while the examiner assesses the surfaces for the presence or absence of fluorescent illumination.
215007120|NCT06152081|DEVICE|QLF Inspektor Pro Imaging|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. The QLF device will be positioned over the tooth surface to be tested and an image will be taken. The images will be stored automatically and assessed by the examiners for the presence of green fluorescence using the QA2 program (Version 1.25, Inspektor Research systems BV, Amsterdam, The Netherlands) . The trend in green fluorescence will also be calculated using this software algorithm.
215007121|NCT06040762|OTHER|Best Practice|Receive SOC educational materials
215007122|NCT06040762|OTHER|Exercise Intervention|Receive (P)REHAB exercise program
215007123|NCT06040762|OTHER|App-Based Intervention|Use ExerciseRx app
215007124|NCT06040762|OTHER|App-Based Intervention|Use FitBit app
215007125|NCT06040762|OTHER|Interview|Ancillary studies
215007126|NCT06040762|OTHER|Wearable Activity Tracker|Wear FitBit
215007127|NCT06040762|OTHER|Physical Performance Testing|Ancillary studies
215007128|NCT06040762|OTHER|Questionnaire Administration|Ancillary studies
214402235|NCT06422026|DIETARY_SUPPLEMENT|APCP I|Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 3 g.
215007129|NCT02642679|DEVICE|Opticell Ag|Opticell Ag+ applied to STSG donor site
214402236|NCT06422026|DIETARY_SUPPLEMENT|APCP II|Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 4 g.
214402237|NCT06422026|DIETARY_SUPPLEMENT|Placebo|Each subject takes one active bottle per day for 24 weeks.
214504485|NCT02317172|OTHER|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
215007130|NCT02763748|PROCEDURE|Laparoscopic endoscopy combined surgery|
215007131|NCT02763748|PROCEDURE|laparoscopic and endoscopic cooperative surgery|
215007132|NCT02763748|PROCEDURE|Single-arch laparoscopic and endoscopic cooperative surgery|
215007133|NCT04411095|OTHER|Measuring thoracic rotation mobility|Measuring the thoracic rotation mobility with a goniometer, from a standardized position
215096685|NCT04195555|DRUG|Ivosidenib|Given PO
215096686|NCT02166463|BIOLOGICAL|Bleomycin Sulfate|Given IV or SC
215096687|NCT02166463|DRUG|Brentuximab Vedotin|Given IV
215096688|NCT02166463|DRUG|Cyclophosphamide|Given IV
214402238|NCT06224075|BEHAVIORAL|Task-specific training|"Participants in the intervention group will receive the treatment established for the control group and nursing care based on task-specific training. The intervention was designed with the aim of improving inhaler management in COPD patients. The content of the tasks will be adapted to the different types of devices present in the patient's therapeutic regimen, mainly pressurized cartridge and dry powder devices.~In order to carry out the intervention, several tasks related to education, assessment and/or training will be established with the aim of improving the ability to use the prescribed inhalers. The tasks have been classified into 3 blocks: technique execution, device cleaning and medication administration."
214402239|NCT06224075|OTHER|Usual care|All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
215007134|NCT02148770|DEVICE|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
215007135|NCT06440759|DEVICE|oXiris filter|"Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris.~The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared."
214402240|NCT02656940|DIETARY_SUPPLEMENT|Group 1 - diet rich in n-3 and n-6 PUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
214402241|NCT02656940|DIETARY_SUPPLEMENT|Group 2 - diet rich in MUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
214402242|NCT02656940|DIETARY_SUPPLEMENT|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
215007136|NCT06440759|DEVICE|M100 filter|Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.
215007137|NCT01454557|OTHER|Auditory Stimuli|Auditory Stimuli during rest and during physical activity
215007138|NCT00371631|BIOLOGICAL|Insertion of urinary catheters coated with E. coli 83972|All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
215007139|NCT03930108|OTHER|SOFA score|Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.
215007140|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
215007141|NCT01112267|DRUG|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
215007142|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
215007143|NCT01112267|DRUG|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
215007144|NCT02731859|DEVICE|Insertion of EndoBarrier for approximately one year|Insertion of EndoBarrier for approximately one year then explantation and follow-up
215096689|NCT02166463|DRUG|Doxorubicin Hydrochloride|Given IV
214402243|NCT04654351|DRUG|TAK-667|TAK-667 single SC administration
214402244|NCT03364816|PROCEDURE|TDR|total artificial disc replacement
215007145|NCT05378542|BEHAVIORAL|Mobile application usage|The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
215007146|NCT03889795|DRUG|Metformin|Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
215096690|NCT02166463|DRUG|Etoposide|Given IV
215096691|NCT02166463|OTHER|Laboratory Biomarker Analysis|Correlative studies
215096692|NCT02166463|DRUG|Methylprednisolone|Given IV
215096693|NCT02166463|OTHER|Pharmacological Study|Correlative studies
214402245|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
214402246|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
214402247|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
214402248|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
215007147|NCT03889795|DRUG|Simvastatin|Simvastatin oral pill will be taken daily in the evening.
215096694|NCT02166463|DRUG|Prednisone|Given PO
215096695|NCT02166463|OTHER|Quality-of-Life Assessment|Ancillary studies
215096696|NCT02166463|OTHER|Questionnaire Administration|Ancillary studies
215096697|NCT02166463|DRUG|Vincristine Sulfate|Given IV
215096698|NCT05074277|BEHAVIORAL|Simulated short term night shift work schedule|Participant sleep schedules (in the experimental arm) will be modified to simulate short-term (3 consecutive nights) night shift work schedule (kept awake at night and offered sleep opportunities during the day instead) in each of two inpatient stays.
215096699|NCT05856227|DRUG|Ceftobiprole medocaril|Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
214402249|NCT05073081|OTHER|Prehab for LSS|The 8-week prehabilitation program will be delivered online by physiotherapists, chiropractors, and kinesiologists through synchronous and asynchronous exercise sessions, along with online educational sessions.
214402250|NCT05073081|OTHER|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice.
214402251|NCT03306615|DRUG|Hyaluronidase|HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
214402252|NCT03306615|DRUG|Placebo|0.9% Sodium Chloride Injection
214402253|NCT03682536|DRUG|Luspatercept|Specified dose on specified days
214402254|NCT03682536|DRUG|Epoetin alfa|Specified dose on specified days
214402255|NCT04385342|DRUG|FSH|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
214402256|NCT04385342|DRUG|HP-hMG|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
214402257|NCT05786313|PROCEDURE|Centerpiece titanium plate|All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.
214402258|NCT01269853|DRUG|Bevacizumab|"Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
214402259|NCT01269853|DRUG|Bevacizumab|"ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle"
214402260|NCT06629025|DIAGNOSTIC_TEST|High-resolution impedance manometry|High-resolution impedance manometry (HRIM) can calculate the bolus motion parameters and the ratio of complete esophageal transit
214402261|NCT05144802|PROCEDURE|acute hypoxia|Participants will be exposed to a 3-hour acute hypoxia
214402262|NCT02057380|DRUG|linsitinib|oral
214402263|NCT02057380|DRUG|erlotinib|oral
214402264|NCT02057380|DRUG|paclitaxel|Intravenous (IV) infusion
214402265|NCT02057380|DRUG|Bortezomib|Subcutaneous or IV
214402266|NCT02057380|DRUG|Dexamethasone|IV, Oral
214402267|NCT06345872|BEHAVIORAL|CBT-I|Includes 8 weekly sessions of CBT-I and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
214402268|NCT06345872|BEHAVIORAL|Treatment as usual|Includes 8 weekly sessions of standard treatment and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
214402269|NCT06345872|OTHER|Tapered Withdrawal|Individualized gradual tapered withdrawal following CDC guidelines, additional check-ins and motivational interviewing with a therapist.
214402270|NCT03909139|BIOLOGICAL|BMAC|A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone marrow is aspirated then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers) is removed. The buffy coat layer contains mesenchymal stromal cells. This is called BMAC or Bone Marrow Aspirate Concentrate. The BMAC will be injected into the intra-articular space.
214402271|NCT04940546|DRUG|Sintilimab|Mode of administration: Intravenously
214402272|NCT04940546|DRUG|Oxaliplatin|Mode of administration: Intravenously
214402273|NCT04940546|DRUG|Capecitabine|Mode of administration: Orally
214402274|NCT04940546|DRUG|Bevacizumab|Mode of administration: Intravenously
215007148|NCT03889795|DRUG|Digoxin|Digoxin oral pill will be taken once daily.
215007149|NCT04103606|DEVICE|GGBI: Positive Body Image (Mobile App)|Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features
215007150|NCT04566731|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.
215007151|NCT04566731|DEVICE|Sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
215007152|NCT04566731|BEHAVIORAL|Modified Contraint-Induced Language Therapy (mCILT)|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
215007153|NCT04928339|DRUG|Bupivacaine Injection|10mL of 0.25% bupivacaine
215007154|NCT04928339|DRUG|Liposomal bupivacaine|15mL of 133mg liposomal bupivacaine
215007155|NCT04928339|OTHER|Saline|25mL saline control
215007156|NCT05638737|DRUG|AZD4831|AZD4831
215007157|NCT05638737|OTHER|Placebo|Placebo
215007158|NCT03990844|DIETARY_SUPPLEMENT|Okra seed|Noodle enriched with 10% and 20% Okra seed flour.
215007159|NCT05743374|OTHER|Normal diet|These patients will be given advice about a normal healthy diet.
215007160|NCT05743374|DIETARY_SUPPLEMENT|E400 elimination|Patients in the intervention group will be given advice how to eliminate E440 additives with regard to carragenan, CMC and polysorbates.
215007161|NCT00142597|DEVICE|Acupuncture|"Involves the insertion and manual stimulation of thin acupuncture needles into specific points in the body.~Fibromyalgia participants will be randomized to receive 9 acupuncture treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
215007162|NCT00142597|OTHER|Sham treatment|"Fibromyalgia participants will be randomized to receive 9 sham treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
215007163|NCT01482728|DRUG|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
215007164|NCT01482728|DRUG|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
214402275|NCT03431805|DRUG|Tranexamic Acid Injectable Solution|After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.
214402276|NCT03431805|DRUG|Sodium Chloride 0.9%|After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.
215007165|NCT04633447|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
215007166|NCT04633447|DRUG|Placebo|Matching placebo will be administered subcutaneously.
215007167|NCT06438471|DRUG|EC5026 oral tablet|"There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose regimens consecutively, for a total duration of 14 days.~Oral doses of EC5026 tested in each Treatment Period:~Treatment Period 1: 6 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 Treatment Period 2: 8 mg loading dose on Day 8 / 4 mg Maintenance dose on Days 9-14"
215007168|NCT06438471|DRUG|Placebo oral tablet|Participants will be administered a matching oral placebo for 14 consecutive days.
215007169|NCT05793125|DEVICE|Ultrasonography|"A full obstetrics ultrasound scan will be performed within 24 hours before delivery to document fetal biometry, estimated fetal weight and correlate it to fetal growth charts to exclude IUGR, amniotic fluid index and umbilical artery Doppler studies.~Fetal echocardiography will be done.Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time (At/Et) ratio will be measured in the main pulmonary artery."
215007170|NCT06173843|OTHER|PFAS / heavy metal testing, exposures|PFAS / heavy metal concentrations, exposure survey
215007171|NCT03641924|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
215007172|NCT04098081|DRUG|galeterone|Therapeutic
215007173|NCT04098081|DRUG|Gemcitabine|Therapeutic
215007174|NCT04333498|BEHAVIORAL|Feedback on DBS Concentrations|The study team will examine the feasibility and acceptability of a feedback system based on DBS concentration amounts.
215007175|NCT01565694|DRUG|Solifenacin succinate|Oral suspension administered once a day via syringe.
215007176|NCT05862584|OTHER|Questionnaires|Distribution of questionnaires to patients to be completed on a weekly basis.
215007177|NCT06964490|DEVICE|determination of working length|Compare the effect of WL determination using different apex locator devices (ProPex Pixi, Root ZX, and Raypex 6) on the incidence and intensity of postoperative pain following endodontic retreatment in single-rooted teeth
215007178|NCT00652132|DRUG|cisplatin|
215007179|NCT00652132|DRUG|sodium thiosulfate|
215007180|NCT06118073|OTHER|Headspace|Headspace is a smartphone-based application that guides individuals through various mindfulness sessions and has been shown to reduce symptoms of depression, anxiety, and pain. Participants will be required to answer questions regarding anxiety levels and pain for 6 weeks after surgery.
215007181|NCT06118073|PROCEDURE|Total Knee Replacement|Participant will have total knee replacement surgery
215007182|NCT05017155|DRUG|Mexiletine|Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.
215007183|NCT05017155|DRUG|Lamotrigine 25Mg Oral Tablet, Extended Release|Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.
215007184|NCT06963450|DIAGNOSTIC_TEST|Taking photos of a baby's eye|Taking photos of a baby's eye and using the color of the sclera to estimate the bilirubin level, which determines if the baby is significantly jaundiced.
215007185|NCT06963398|DRUG|HS-10529|Participants in all subjucts will receive HS-10529
215007186|NCT06963320|DRUG|H001 Capsule 200mg-qd|H001 Capsule, 50 mg/capsule, 200 mg orally once daily for 10-14 days.
215096700|NCT06007378|OTHER|Bupivacaine and ketamine|Bilateral erector spinae plane block (bupivacaine and ketamine)
215096701|NCT06007378|OTHER|Bupivacaine and transdermal fentanyl patch|Bilateral erector spinae plane block (bupivacaine) and transdermal fentanyl patch
214402277|NCT06410911|PROCEDURE|Subcostal Transversus Abdominis Plane block in patients undergoing open cholecystectomy surgery.|"Subcostal Transversus Abdominis Plain block will be performed under ultrasound guidance using a 5-10 MHz linear transducer. The needle will be inserted perpendicular to the skin 2 fingers below the costal~margin, just lateral to the rectus abdominis muscle. After confirming the needle tip's location within the TAP, 20 mL of 0.25% bupivacaine will be injected on both sides in patients undergoing open cholicystectomy surgery."
214402278|NCT06410911|PROCEDURE|Erector Spinae Block in patients undergoing open cholecystectomy|Ultrasound-guided Erector Spinae block using 20 mL of 0.25% bupivacaine will be injected bilaterally at the T7- T8 vertebral level in patients undergoing open cholecystectomy The probe will be advanced 3 cm to the right lateral direction and rotated 90 degrees, and the transverse processes will be determined . Next, 5 mL of 2% lidocaine will be administered to the predicted needle entry point. A 22-gauge, peripheral nerve block needle will cephalocaudally advanced by the in-plane technique. The needle tip will be continuously advanced toward the transverse process to 1-2 mm before contact with the transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine will be injected with intermittent negative aspirations into the fascia of the erector spinae muscle.
214504486|NCT04528914|OTHER|Low-FODMAP diet|The low-FODMAP diet will contain the amount of FODMAPs that will not exceed the cut-offs for each FODMAP sugar per serving of food per sitting. Diets will be individually tailored by dietitian and delivered by a catering company (five meals each day).
214504487|NCT03776760|DEVICE|Fingerstick GeneXpert HCV RNA quantitative assay|All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
214504488|NCT03776760|DRUG|sofosbuvir/velpatesvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
214504489|NCT03776760|DRUG|glecaprevir/pibrentasvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
214504490|NCT04730726|DEVICE|MSOT Acuity Echo|Hybrid optoacoustic and ultrasonography imaging
215007187|NCT06963320|DRUG|Enoxaparin Sodium Injection|Enoxaparin Sodium Injection,0.4 mL: 4000 AXaIU, 40 mg subcutaneously once daily for 10-14 days
215007188|NCT06963320|DRUG|H001 Capsule 300mg-qd|H001 Capsule, 50 mg/capsule, 300 mg orally once daily for 10-14 days.
215007189|NCT06963320|DRUG|H001 Capsule 200mg-bid|H001 Capsule, 50 mg/capsule, 200 mg orally twice daily for 10-14 days.
215007190|NCT06963931|BEHAVIORAL|Change4Better (C4B) mobile app|The content of the C4B app is designed to teach key CBT strategies to address gambling behaviors. The content targets concerns that people with gambling problems often experience (gambling debts, cognitive distortions related to gambling - for example, how unrelated events might be related to gambling outcomes). We have designed the content such that people using the app can see the pattern of progress, identify mistakes and setbacks, and learn from common experiences of people with gambling disorder
215007191|NCT06963502|DRUG|HS-10370|Participants will receive HS-10370 dose 1 administered orally
215007192|NCT06963502|DRUG|HS-20117|Participants will receive HS-20117 given as dose 3 intravenous infusion(IV) once every 14-day cycle.
215007193|NCT06963502|DRUG|Adebrelimab|Participants will receive Adebrelimab intravenous infusion(IV) once every 21-day cycle
215007194|NCT06963502|DRUG|Capecitabine|Participants will receive Capecitabine administered orally
215096702|NCT06007378|OTHER|Bupivacain|Bilateral erector spinae plane block (bupivacaine)
215096703|NCT04705766|OTHER|Urine Collection|A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.
215096704|NCT05006599|DRUG|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
215096705|NCT05006599|DRUG|Placebo|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
215096706|NCT05006599|DEVICE|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
215096707|NCT05651126|DRUG|Psilocybin 5 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
215096708|NCT05651126|DRUG|Psilocybin 2 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
215096709|NCT05651126|DRUG|Placebo|Inactive placebo
215096710|NCT06465693|DEVICE|Unblinded CGM plus nutrition therapy|"will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.~will receive Dexcom G6 Pro CGMs to wear throughout the study. The CGM will be unblinded so that the glucose data will be available in real time to the participant and investigators. The dietitian and participant will review CGM data together"
215096711|NCT06465693|BEHAVIORAL|Nutrition therapy only|will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.
215096712|NCT05210283|DEVICE|MRD|ctDNA MRD test
215096713|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 25 mg
215096714|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 50 mg
215096715|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 75 mg
215007195|NCT06963502|DRUG|Oxaliplatin|Participants will receive Oxaliplatin intravenous infusion(IV) once every 21-day cycle.
215007196|NCT06963502|DRUG|Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan|Participants will receive Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan intravenous infusion(IV) once every 14-day cycle.
215007197|NCT06963502|DRUG|HS-20093|Participants will receive HS-20093 intravenous infusion(IV) once every 21-day cycle
215007198|NCT06963502|DRUG|platinum (cisplatin or carboplatin)|Participants will receive platinum (cisplatin or carboplatin) administered IV in 21-day cycles.
214402279|NCT06410911|DRUG|Sbcostal transversus Abdominis block and erector spinae block for both groups|Each patients group will recieve a type of block by injecting 20 ml of 0.25% bupivacaine on each side in patients undergoing open cholecystectomy
214402280|NCT04293809|DRUG|Exparel Injectable Product|bupivacaine liposome injectable suspension
214402281|NCT04293809|DRUG|Bupivacaine Hydrochloride|1.3%, 13.3 mg/mL
214402282|NCT02789163|DEVICE|Ultrasound|breast ultrasound; hand held and automated volume breast scanner
214402283|NCT03513198|DIAGNOSTIC_TEST|Endoscopic ultrasound (including fine needle aspiration)|"EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.~* Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.~* Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~* EUS-FNA will be performed in all pancreatic masses with at least four passes."
215007199|NCT06963879|DEVICE|Bgaze Therapy|BGaze Therapy is a digital intervention by Braingaze designed to enhance attention and memory in individuals with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). It uses an interactive video game controlled through eye-tracking, allowing users to play using only their gaze. The therapy is based on research linking eye vergence and pupil responses to cognitive processing-physiological markers that may indicate neurodegeneration. During gameplay, these responses are modulated, potentially inducing gamma brain oscillations associated with reduced AD pathology. Patients play at care-center for 5-10 minutes daily over two months. Equipment is provided, and both in-person and remote support ensure usability. The game adapts difficulty in real time and provides feedback to keep users engaged and stimulate cognitive function.
215007200|NCT06963879|DIAGNOSTIC_TEST|Bgaze Attention Task|For the validation of diagnosis of AD with vergence method the Attention Test (B-Gaze) will be used. This is an odd ball paradigm where visual target has to be detected among blue distractors. The test consist of 100 trials of 1 second and last about 3 minutes. The task uses remote eye infra-red tracking to measure eye vergence. Subjects merely have to fixate at the computer screen during the task.
215007201|NCT02727803|BIOLOGICAL|Allogeneic Natural Killer Cell Line NK-92|Given IV
215007202|NCT02727803|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
215007203|NCT02727803|DRUG|Busulfan|Given IV
215007204|NCT02727803|DRUG|Clofarabine|Given IV
215007205|NCT02727803|DRUG|Cyclophosphamide|Given IV
215007206|NCT02727803|DRUG|Fludarabine Phosphate|Given IV
215007207|NCT02727803|OTHER|Laboratory Biomarker Analysis|Correlative studies
215007208|NCT02727803|DRUG|Melphalan|Given IV
215007209|NCT02727803|BIOLOGICAL|Rituximab|Given IV
215007210|NCT02727803|RADIATION|Total-Body Irradiation|Undergo total body irradiation
215007211|NCT02727803|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplantation
215096716|NCT06777901|DEVICE|Auryon Atherectomy System|Auryon Atherectomy System is composed of a laser and catheter
214402284|NCT03513198|OTHER|Contrast-enhanced endoscopic ultrasound (CE-EUS)|"CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.~* The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).~* The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.~* All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box"
214504491|NCT06428656|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule of postbiotics supplement per day
214504492|NCT06428656|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule of placebo per day
215007212|NCT05416203|BEHAVIORAL|Brief Enhanced Anxiety Sensitivity Treatment|BEAST is a CBT-based intervention that includes psychoeducation, identifying and challenging maladaptive thoughts, and interoceptive exposure. The intervention is delivered through a single virtual face-to-face session supplemented with a mobile app for two weeks after the face to face session.
215096717|NCT06777901|DEVICE|Balloon Angioplasty|Balloon Angioplasty alone
215096718|NCT05134948|DRUG|BMS-986213|Specified dose on specified days
215096719|NCT05796921|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain|Patients allocated to the probiotic arm will take the dietary supplement, containing 10 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days.
215096720|NCT05796921|DIETARY_SUPPLEMENT|placebo|Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days.
215096721|NCT00771615|BIOLOGICAL|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
215007213|NCT05035693|DEVICE|MOVE®-C|Momo- or bisegmental implantation of MOVE®-C cervical prothesis.
215007214|NCT06059066|PROCEDURE|Standard number of injection sites|200 units or 300 units BTX-A reconstituted in 20 mL normal saline, injected into the bladder detrusor in 20 separate injections of 1 mL including the trigone.
215007215|NCT06059066|PROCEDURE|Reduced number of injection sites|200 units or 300 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder detrusor in 5 separate injections of 1 mL including the trigone.
215096722|NCT06583486|BIOLOGICAL|Rcombinant botulinum neurotoxin type A for injection (YY001)|Five sites will be injected at 0.05 mL each, 2 sites in corrugator muscle of each side and 1 site in the procerus muscle, for a total dose of 20U.
215007216|NCT01787903|DEVICE|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
215096723|NCT02478164|DRUG|Ponatinib|
215096724|NCT06481735|BIOLOGICAL|TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2 : dose of RP2D.
215096725|NCT06481735|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
215096726|NCT06481735|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
215096727|NCT00596141|DEVICE|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
214402285|NCT03513198|OTHER|Endoscopic ultrasound elastography (EG-EUS)|"EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD~* The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided~* The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.~* SR and SH will be measured; with three measurements made and recorded on the embedded HDD."
215007217|NCT06149013|DEVICE|MindAhead Active|MindAhead's Active app focuses on increasing meaningful and enjoyable cognitive, physical, and social activities specifically adapted to patients with early cognitive decline (MCI or mild dementia). These techniques include psychoeducation (explaining the rationale, the components of behavioral activation, and protective activities), action planning (selecting activities, goal setting, activity scheduling, graded task assignment, written schedules, and step-by-step sequencing) and action/self-monitoring (assessing execution of and enjoyment in activities, monitor mood and cognitive problems), as well as value-based activation (understanding most important values, selecting activities according to these values). This process aims to enable the users to understand which activities are enjoyable and meaningful to them and how to implement these activities into their daily lives. MindAhead's Active app consists of one to five sessions per week.
215007218|NCT06149013|OTHER|Treatment-as-usual|Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.
215007219|NCT05718518|DRUG|ASC11 tablets|"Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)"
215007220|NCT05718518|DRUG|Placebo|Part 1 and 2: Subjects will be randomized to receive placebo.
215007221|NCT05718518|DRUG|RTV tablets|"Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)"
215007222|NCT00409760|DRUG|valsartan+amlodipine combination, valsartan, amlodipine|
215007223|NCT02188732|BEHAVIORAL|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
215007224|NCT02188732|BEHAVIORAL|CBHH+SMT|Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
215007225|NCT02188732|BEHAVIORAL|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
215007226|NCT06519175|OTHER|Conservative treatment|Patients are provided with physiotherapy support and the provision of prostheses with the goal of ensuring as much walking functionality as possible.
215007227|NCT06519175|PROCEDURE|Single or multi-stage surgery|Correction of the deformity is pursued by one or more surgical procedures with the timing and the techniques (growth modulation, acute correction, gradual correction, soft tissues procedures, combined techniques) chosen according to the surgeon's preference to achieve the maximum possible walking functionality without orthopedic aids.
215007228|NCT06519175|PROCEDURE|Amputation|Limb surgery, whether or not associated with realignment or soft-tissue surgery, is performed, aimed at providing the maximum possible walking function through a prosthesis.
215007229|NCT05417113|DRUG|Liposomal bupivacaine|liposomal bupivacaine
215007230|NCT05417113|DRUG|Bupivacaine|bupivacaine 0.25% in ESP blocks
215096728|NCT04588389|DRUG|Ropivacaine injection Location 1|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1
215096729|NCT04588389|DRUG|Ropivacaine injection Location 2|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2
214504493|NCT06453590|PROCEDURE|Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
214504494|NCT06453590|PROCEDURE|Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
215096730|NCT04588389|DRUG|Multimodal Pharmacological Management|standard of care multimodal pharmacological management
215096731|NCT00230958|DRUG|Viramidine|
215096732|NCT00230958|DRUG|Ribavirin|
215096733|NCT00230958|DRUG|pegylated interferon alfa-2b|
215096734|NCT04390724|DEVICE|Y90 radioembolization|Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
215096735|NCT06112938|DRUG|Antibiotic|We aim to examine differences in clinical outcomes and failure rates between standard and alternative treatment strategies such as minocycline (or moxifloxacin, ciprofloxacin, ceftazidime) alone or in combination with TMP-SMX, alternative TMP-SMX dosing regimens, or variations in durations of therapy for the treatment of S. maltophilia infections within Methodist Health System (MHS).
214402286|NCT03513198|DIAGNOSTIC_TEST|Contrast-enhanced computed tomography (CT)|"* Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.~* A template will be used to report the imaging results.~* The template includes morphologic, arterial, venous, and extrapancreatic evaluations.~* Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)."
215007231|NCT01022580|DRUG|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
215007232|NCT01022580|DRUG|Sham (No Treatment)|Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
215007233|NCT00541229|DRUG|sitagliptin phosphate|sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
214402287|NCT01739387|DEVICE|Flutiform® pMDI and Breath Actuated Inhaler (BAI)|Both devices contain placebo
214402288|NCT01164787|DRUG|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
215096736|NCT06259136|PROCEDURE|A transitional palliative care intervention|The Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient. The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan. Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter.
215096737|NCT02963064|BIOLOGICAL|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
215096738|NCT06299891|DRUG|Phentermine / Topiramate Extended Release Oral Capsule [Qsymia]|To assess safety and maximum tolerated dose as well as efficacy on weight loss of Phentermine/Topiramate in individuals with hypothalamic obesity.
215007234|NCT00541229|DRUG|sitagliptin phosphate|sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
215096739|NCT06299891|OTHER|Placebo|To assess safety and maximum tolerated dose as well as efficacy on weight loss of placebo treatment in individuals with hypothalamic obesity.
215096740|NCT06054178|DRUG|Fluorescein Sodium|Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
214504495|NCT06453590|PROCEDURE|Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
215007235|NCT00541229|DRUG|Comparator: Placebo|sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
215007236|NCT00637182|DRUG|Anastrozole|
215007237|NCT05539508|BEHAVIORAL|Psychophysical evaluation|All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. They will have to perform various tasks on these images using the keys on the keyboard.
215007238|NCT06145074|DRUG|Propranolol|Oral administration.
215096741|NCT06115291|OTHER|Smell Test|Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
215096742|NCT05076682|DRUG|Choline|Choline 300mg tid or 500mg bid, p.o
215096743|NCT05076682|DRUG|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
215096744|NCT05076682|DRUG|Sodium Cromoglicate|Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
215096745|NCT05076682|DRUG|Efavirenz|Efavirenz 600mg qd, p.o
215096746|NCT05076682|DRUG|SHR-A1811|4.8mg/kg q3w
215096747|NCT05076682|DRUG|SHR-A2102|6mg/kg q3w
215096748|NCT05076682|DRUG|SHR-1316|1200mg q3w
215096749|NCT05076682|DRUG|Mecapegfilgrastim|Mecapegfilgrastim, 6mg, d3, q3w, s.c.
214504496|NCT03055559|DIETARY_SUPPLEMENT|Globifer Forte|
215096750|NCT05076682|DRUG|AK131|AK131, 40mg/kg i.v., q2w
215096751|NCT06818097|DRUG|TKI|Lenvatinib
215096752|NCT06818097|DRUG|anti PD-1|Sintilimab or Camrelizumab or Tislelizumab
215096753|NCT06818097|DRUG|XELOX chemotherapy|Capecitabine and Oxaliplatin
214402289|NCT01164787|DRUG|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
214504497|NCT04496388|BEHAVIORAL|exercise|different type of exercise
214504498|NCT04496388|BEHAVIORAL|No exercise intervention|No exercise intervention
214504499|NCT04069416|PROCEDURE|living donor liver transplantation|liver graft from a living donor
215007239|NCT06145074|DRUG|Placebo|Oral administration.
215007240|NCT01807520|BIOLOGICAL|Secukinumab|Study treatment was provided in pre-filled 1 mL syringes.
215007241|NCT01807520|BIOLOGICAL|Placebo|Placebo was provided in pre-filled 1 mL syringes.
215007242|NCT03600129|PROCEDURE|Qadratus Lumborum Block|Bilateral, ultrasound - guided Quadratus Lumborum Block
215007243|NCT03600129|DRUG|30 milliliters of 0.375% Ropivacaine|30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block
215007244|NCT03600129|DRUG|30 milliliters of 0.9% NaCl|30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
215007245|NCT01500096|DRUG|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
215096754|NCT06981351|BEHAVIORAL|Attention to Context (ATC) training|ATC training focuses on learning to attend to and integrate contextual cues present in the environment. Three tasks, Reversal Learning, Divided Visual Field, and Affective Gaze, require ATC functioning and provide individuals with practice noticing changes in contextual information, such as rule changes and using emotion information to modulate behavior.
215096755|NCT06981351|BEHAVIORAL|Affective Cognitive Control (ACC) training|ACC training focuses on providing individuals with practice inhibiting behavior, particularly within motivational or affective contexts. Three tasks, Shapes, Numbers, and Lottery, tap ACC functioning and place demands on the basic employment of cognitive control, such as task switching, as well as on the concurrent engagement of cognitive control and affective processing.
214402290|NCT05445687|BEHAVIORAL|Narrative language intervention program|"Narrative language targets improving narrative macrostructure and microstructure.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.~Each story will reflect specific content with several target vocabulary words and complex morphosyntax. Each story will be followed by comprehension questions to facilitate understanding and answering question about stories.~The following procedure will be implemented with each story: Modeling, answering comprehension questions, retelling with icons and colored illustrations, retelling with icons only, and retelling without icons. This procedure is adapted from story champs intervention program"
214402291|NCT05445687|BEHAVIORAL|Conventional language intervention|Language rehabilitation targets improving semantics, syntax, pragmatics and phonology.
214402292|NCT00330213|BEHAVIORAL|red wine and cognac consumption|
214402293|NCT03888365|DRUG|Treprostinil|Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
214402294|NCT03888365|DRUG|Non-Treprostinil PAH Medications|Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
214402295|NCT03577145|DIETARY_SUPPLEMENT|Tomato, onion & lovage soup with inulin|Source of polyphenols and non digestible carbohydrate
214402296|NCT03577145|DIETARY_SUPPLEMENT|Tomato, onion & lovage soup|Source of polyphenols
214402297|NCT03577145|DIETARY_SUPPLEMENT|Inulin|Source of non digestible carbohydrate
214402298|NCT06498674|DIAGNOSTIC_TEST|Supplementary Pathological Examination|For the same thyroid nodule, if there is discordance between the interpretations of AI-assisted ultrasound and traditional two-dimensional ultrasound, supplementary fine needle aspiration biopsy or intraoperative biopsy will be performed to clarify the nature of the nodule.
214402299|NCT06498674|OTHER|No Need for Supplementary Pathological Examination|For the same thyroid nodule, if there is discordance between the interpretations of AI-assisted ultrasound and traditional two-dimensional ultrasound, there is no need for supplementary fine needle aspiration biopsy or intraoperative biopsy.
214402300|NCT06229886|OTHER|Application of positive-end-expiratory pressure|Application of PEEP on mechanically ventilated pediatric patients. Point-of-care-ultrasound performed after each PEEP application.
214402301|NCT03298815|BIOLOGICAL|Amniotic Fluid Eye Drops (AFED)|One drop (0.25 mL) in one eye twice daily for up to 3 months
215007246|NCT01500096|DIETARY_SUPPLEMENT|Placebo for American ginseng|"Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day"
215007247|NCT04649554|DEVICE|Exablate treatment|Ablation
215007248|NCT04651088|DRUG|Potassium citrate|Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
215007249|NCT04651088|DRUG|Sodium bicarbonate|650mg tabs. Take 3 tabs twice daily.
215007250|NCT04651088|DIETARY_SUPPLEMENT|Litholyte|One packet is taken with 170ml of water. Two packets daily.
215007251|NCT04651088|DIETARY_SUPPLEMENT|Crystal Lite|The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
215007252|NCT04651088|DRUG|Potassium Bicarbonate|20 mEq tablets, one tablet twice daily
215007253|NCT03706352|PROCEDURE|tunneling epidural catheter|The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.
214402302|NCT03298815|OTHER|Saline Solution|One drop (0.25 mL) in the other eye twice daily for up to 3 months
215007254|NCT00229216|DRUG|Tinidazole|
215007255|NCT01797185|DRUG|SPARC1104 modified dose regimen I|Subjects who exited study CLR\_09\_21
215007256|NCT01797185|DRUG|SPARC1104 modified dose regimen II|Subjects who received prior treatment regimen I
215007257|NCT01797185|DRUG|SPARC1104 modified dose regimen III|Subjects who received no prior treatment regimen
215007258|NCT03879109|DRUG|Chemotherapy FOLFIRINOX, 6 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)"
215096756|NCT05943119|RADIATION|Radiotherapy in painting dose on histoscannographic mapping|"The target volumes to be delineated are as follows:~* High-risk CTV (Clinical Target Volume), corresponding to all initially invaded areas, as identified by comparison between the operative report and the anatomo-pathological report (ideally with histo-surgical mapping).~* Low-risk CTV, corresponding to naso-sinusal structures not initially invaded but at risk of recurrence, and located close to the high-risk target volume, including at least 5 mm around the high-risk volume and excluding non-risk areas (muscle, bone)."
215007259|NCT03879109|RADIATION|Radiochemotherapy|Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
215096757|NCT05943119|RADIATION|Standard pan-sinusal Radiotherapy|"The target volumes to be delineated are as follows:~* High-risk CTV, including the entire post-operative cavity,~* Low-risk CTV, adapted from the recommendations described by Lapeyre (Cancer/Radiotherapy 2005), and including at least 5 mm around the high-risk volume, excluding non-risk areas (muscle, bone)."
215096758|NCT04494113|PROCEDURE|Biopsy Procedure|Undergo biopsy
215096759|NCT04494113|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
215096760|NCT04494113|PROCEDURE|Resection|Undergo surgical resection
215096761|NCT04494113|DRUG|Triapine|Given IV
214402303|NCT03083743|BIOLOGICAL|Recombinant human Apo-2 ligand for Injection|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
214402304|NCT03083743|BIOLOGICAL|Placebo|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
214402305|NCT02538679|OTHER|Placebo|The usual intraoperative and postoperative pain control; NO TAP block performed
214402306|NCT02538679|DRUG|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
215007260|NCT03879109|PROCEDURE|Surgery|"Surgery will be performed at:~* Arm A: 8 weeks (±1) after the end of treatment~* Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~* Total mesorectal excision (TME)~* Extended-TEM (e-TME)~* Pelvic exenteration (PE)"
215096762|NCT03441698|DEVICE|Genuine acupuncture (A)|A) Acupuncture is administered bilaterally to the acupuncture point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpii radialis. Sharp acupuncture needles were inserted into a depth of a half body-inch. The needles are manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
215096763|NCT03441698|DEVICE|Sham acupuncture (B)|B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6. The telescopic Park Sham Device was used. The needle looks identical to a real needle, but is blunt and glides upward into its handle instead of penetrating. The marking tubes holds the needle in place. The therapist give an illusion of manipulating the needle by turning it three times until it touched the skin, but no deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
215096764|NCT03441698|OTHER|Rest|C) Rest means resting for 30 minutes, either sitting or lying down. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
214402307|NCT02538679|DRUG|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
214402308|NCT06161649|BEHAVIORAL|accepting the operation process of automated intelligent education software system|"1. Execute registration and qualification review~2. Automated smart education interaction"
215096765|NCT05251038|DRUG|Sotorasib|Intervention instruction outlined in protocol
215096766|NCT05251038|DRUG|Liposomal Irinotecan (nal-IRI)|Intervention instruction outlined in protocol
215096767|NCT05251038|DRUG|5 Fluorouracil (5FU)|Per standard of care
214402309|NCT04361630|DRUG|FGF 2|Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.
214402310|NCT02451423|DRUG|Atezolizumab|1200 mg Given IV
215096768|NCT05251038|DRUG|Leucovorin (LV)|Per standard of care
215096769|NCT05251038|DRUG|Gemcitabine (GEM)|Per standard of care
215096770|NCT05251038|DRUG|Nab paclitaxel|Per standard of care
215096771|NCT03445559|BEHAVIORAL|Clinical Order Check|A Clinical Order Check is an evidence-based, systems-level method to affect significant behavior change. It addresses the intervention functions of education, enablement and incentivization which are effective methods to change behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. All VA facilities currently use locally adapted clinical reminders. This strategy is technologically simple, straightforward, and is considered to be a best practice within the VA IT community. The reminder will be self-explanatory and non-intrusive to workflow.
214402311|NCT00881010|BEHAVIORAL|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
214402312|NCT00881010|BEHAVIORAL|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
214402313|NCT05157204|PROCEDURE|measurment of interleukin-6 at exhaled condensate|the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants
215007261|NCT03012945|DRUG|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia. General anesthesia is performed as that in the general anesthesia group. Epidural anesthesia is performed with ropivacaine. Epidural analgesia is performed with a mixture of ropivacaine and sufentanil.
214402314|NCT00899002|GENETIC|comparative genomic hybridization|
214402315|NCT00899002|GENETIC|molecular genetic technique|
214402316|NCT00899002|GENETIC|mutation analysis|
214402317|NCT00899002|GENETIC|polymerase chain reaction|Not noted
214402318|NCT00899002|GENETIC|proteomic profiling|
214402319|NCT00899002|OTHER|immunohistochemistry staining method|not noted
214402320|NCT00899002|OTHER|laboratory biomarker analysis|not noted
214402321|NCT00899002|OTHER|mass spectrometry|not noted
214402322|NCT00899002|OTHER|medical chart review|not noted
214402323|NCT01373853|PROCEDURE|Lens Fragmentation by means of a femtosecondlaser|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
214402324|NCT01373853|PROCEDURE|Manual Phacoemulsification|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
214402325|NCT05976594|DIAGNOSTIC_TEST|serology and virology detection of hepatitis E virus|Serum will be tested for HEV serology and virology, including HEV-IgM, HEV-IgG, HEV-antigen, and HEV-RNA for HEV species A (HEV-A) and HEV species C (HEV-C)，and further HEV genotyping for those positive for HEV-RNA.
214402326|NCT01140659|PROCEDURE|Video-assisted sympathectomy|All participants were randomized into two groups of 20 patients (G3 and G4) and underwent video-assisted sympathectomy, being followed for 12 months. During this period, the subjects completed a questionnaire about quality of life and carried out the measurements of sweat by VapoMeter.
214402327|NCT02507219|DRUG|Ibuprofen|On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
214402328|NCT03050294|BEHAVIORAL|Phone calls|Phone calls twice daily
214402329|NCT03050294|DRUG|Desoximetasone 0.25% spray|Desoximetasone 0.25% spray applied twice daily
214402330|NCT04843319|DRUG|VERU-100|GnRH antagonist
214402331|NCT06561230|OTHER|Chart review|Patients eligible for prescreening will be identified using structured criteria (e.g., anyone with an appointment in the upcoming 2 months with a relevant provider). All individual charts will be de-identified. De-identified EHRs will then be transferred to Mendel's secure data abstraction platform, where trial eligibility criteria will be abstracted. Patients will be rank-ordered by number of eligibility criteria met, with patients meeting the most eligibility criteria at the top of the queue. The study team will then review eligibility criteria and flag eligible patients.
214522652|NCT03521076|DEVICE|Virtual Reality|Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
215007262|NCT03012945|DRUG|General anesthesia|General anesthesia and postoperative intravenous analgesia. General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance. Intravenous analgesia is performed with morphine.
215007263|NCT03451032|OTHER|Non Interventional Study|Non Interventional Study
215007264|NCT01371760|PROCEDURE|Venous PTA|PTA of the internal jugular and/or azygous vein
215007265|NCT01371760|OTHER|Catheter Venography|The patients will undergo catheter venography but not PTA
215007266|NCT02619656|PROCEDURE|CO2 insufflation|Patients were randomized to insufflation with CO2.
215007267|NCT02619656|PROCEDURE|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
215007268|NCT02347007|DIETARY_SUPPLEMENT|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
215007269|NCT02347007|DIETARY_SUPPLEMENT|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
215007270|NCT02126202|PROCEDURE|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
215007271|NCT05345587|OTHER|THESS monitoring|Consultation with the pharmacist to look for possible medication interactions between the oral therapy and the patient's usual treatments and to inform the patient about his treatment to improve QOL and compliance. Consultation and follow-up by a nurse. Weekly notification by THESS Application of the symptoms experienced by the patient over the last 7 days
215007272|NCT03520569|DRUG|Octreotide|we are using it to block insulin secretion from the pancreas
215007273|NCT03520569|DRUG|Insulin|we are using to replace basal insulin and in two protocols to raise insulin concentrations during the insulin clamp
215007274|NCT03520569|DRUG|Dextrose 20% solution|We are using dextrose to maintain glycemia level
215007275|NCT00882765|DIETARY_SUPPLEMENT|genistein|Given orally
214402332|NCT01156415|DRUG|AGO178|
214402333|NCT01156415|DRUG|AGO178|
214402334|NCT00333515|DRUG|Human Butyrylcholinesterase (HuBChE) derived from human plasma|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
214402335|NCT00333515|DRUG|Placebo: Normal saline|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
214402336|NCT05395143|DRUG|Zinc sulfate|Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
214402337|NCT05395143|DRUG|Placebo|Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
215007276|NCT05130697|OTHER|eMPowEr App|A mobile app to support participants in the management of malignant pleural effusions at home
215007277|NCT01952678|OTHER|DaTscan™ - Non-Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
214402338|NCT03982940|DEVICE|BGP+ Stent Graft System as bridging stent|BGP+ Stent Graft System as bridging stent
214504500|NCT03948438|PROCEDURE|Endoscopic septotomy|Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)
215007278|NCT01952678|OTHER|DaTscan™ - Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
215007279|NCT05911386|OTHER|study of biological samples and echocardiographic data and link with need of hemodynamic support|observational study : there is no intervention
215007280|NCT04939389|DIAGNOSTIC_TEST|Orthelligent Pro|The sensor is attached to the knee of the participant and eight different movement exercises are performed
215007281|NCT03418675|DRUG|Rexulti|Atypical antipsychotic
215007282|NCT03418675|DRUG|Placebo|Pill that contains no medicine
215096772|NCT03445559|BEHAVIORAL|Academic Detailing|Academic detailing is an individual and facility-level intervention consistently shown to improve provider behavior. This strategy addresses the intervention functions of persuasion, coercion, modeling, and education which are effective methods for affecting behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. During the meeting, the detailer will follow a script explaining that the visit is part of an experimental program to provide physicians with up-to-date, unbiased information about imaging to stage prostate cancer.
215096773|NCT03445559|BEHAVIORAL|Audit and Feedback|Audit and feedback is an effective, individual-level intervention for changing healthcare provider behavior, resulting in small but potentially clinically important benefits. Audit and feedback addresses the intervention functions of education, persuasion and incentivization, all of which are important for addressing beliefs about capabilities and consequences, knowledge, and social influence.
215096774|NCT06587165|OTHER|N15-thymidine|50mg/kg (oral administration)
215007283|NCT05827120|DEVICE|Mechanical / pharmacomechanical thrombectomy plus local catheter directed thrombolysis|"* Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;~* Mechanical thrombectomy: mechanical aspiration of fresh thrombus;~* Pharmacomechanical thrombectomy (PMT): combination of mechanical disruption of the thrombus, and its aspiration, with simultaneous application of alteplase via dedicated catheter - instilation of acute/subacute thrombus with its subsequent aspiration;"
215007284|NCT05827120|DEVICE|Local catheter directed thrombolysis alone|\- Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;
215007285|NCT03422718|BEHAVIORAL|Healthy Behavior Texts|Participants receive motivational health behavior texts
215096775|NCT05432024|DEVICE|Catheter ablation|An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.
215096776|NCT06085664|DRUG|REGN5678|Given by IV (vein)
215096777|NCT06085664|DRUG|Piflufolastat F18|Given by IV (vein)
214402339|NCT06218134|BIOLOGICAL|human Wharton's jelly-derived mesenchymal stem cells|human Wharton's jelly-derived mesenchymal stem cells(product name: EN001)
214522653|NCT03075111|DIAGNOSTIC_TEST|ImmunoXpert|Host based immune response test distinguishing viral versus bacterial infection
214402340|NCT02710058|BEHAVIORAL|one-time qualitative assessment|The study involves a one-time qualitative assessment to explore key cultural influences on AMBER breast cancer survivors' health behavior. We will focus on self-efficacy in healthcare, coping with breast cancer, social networks of support, and culturally-sensitive support groups. The study investigator will administer questions from the structured interview guide, estimated to take 90 minutes.
214522654|NCT02433392|PROCEDURE|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
214522655|NCT02267746|DRUG|Tazarotene (Fabior™)|
215007286|NCT03422718|BEHAVIORAL|No healthy behavior texts|Participants do not receive healthy behavior texts
215007287|NCT03422718|BEHAVIORAL|BP Monitoring Daily Via Text Messaging|Daily text messages will prompt participants for BP by home cuff
215007288|NCT03422718|BEHAVIORAL|BP Monitoring Weekly Via Text Messaging|Weekly text messages will prompt participants for BP by home cuff
215007289|NCT03422718|BEHAVIORAL|Physician appointment and transportation scheduling|Participants receive assistance scheduling physician appointment and transportation to those appointments
215007290|NCT03422718|BEHAVIORAL|No physician appointment and transportation scheduling|Participants do not receive assistance scheduling physician appointment or transportation
215007291|NCT00143351|DRUG|Ziprasidone|
215007292|NCT04248569|DRUG|DNAJB1-PRKACA peptide vaccine|"1. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and on Day 1 of cycle 2, 3 and 4 (priming phase). Boost vaccinations: every 3 cycles beginning C5D1.~2. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5mg Poly-ICLC"
215007293|NCT04248569|DRUG|Nivolumab|"1. Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5.~2. Drug: 3mg/kg and 480mg IV"
215007294|NCT04248569|DRUG|Ipilimumab|"1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 1, 2, 3 and 4 of the study, every 3 weeks of the priming phase.~2. Drug: 1mg/kg IV"
215096778|NCT06609590|PROCEDURE|Glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block|Ultrasound guided anterior glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block
215096779|NCT06609590|PROCEDURE|Interscalene brachial plexus block|Ultrasound guided interscalene brachial plexus block
215096780|NCT06610825|DRUG|Enhertu|This is an open label, multi-center, single arm, phase II study designed to investigate the anti-tumor activity, efficacy and safety of Enhertu in HER2-positive metastatic castrate-resistant prostate cancer patients who progressed on androgen deprivation therapy and novel hormonal agents (such as Abiraterone and Enzalutamide), who also progressed, refused, or were not candidates to receive taxane-based chemotherapy.
215096781|NCT01761773|DRUG|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
214402341|NCT05922163|DEVICE|Evidence-based VR simulation|Evidence-based VR simulation videos on BTs for nursing students were developed, including 1) animated blood formation physiology and side effects of BT and 2) 360° BT nursing practice.
214402342|NCT00593320|RADIATION|Stereotactic Radiosurgery|
214402343|NCT01342887|DRUG|cyclosporine|Given IV
214402344|NCT01342887|DRUG|pravastatin sodium|Given PO
214402345|NCT01342887|DRUG|mitoxantrone hydrochloride|Given IV
214402346|NCT01342887|DRUG|etoposide|Given IV
214402347|NCT01342887|PROCEDURE|bone marrow aspiration|Correlative studies
214402348|NCT01015014|DRUG|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
214402349|NCT01015014|DRUG|Placebo|0.9% sodium chloride for injection
215007295|NCT03295916|RADIATION|Stereotactic Body Radiotherapy|Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
215007296|NCT03555344|OTHER|Mantra Chikitsa|Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
215096786|NCT07012122|OTHER|visual spatial memory task|The child will be asked to put numbers in an imagined matrices and memorize the position very well then will be asked to remember the position of these numbers.
215096787|NCT07012122|OTHER|nonspatial verbal memory task|The child is presented with a series of sentences that are similar in structure and content, with only slight variations in elements such as the verb, subject, or object. The child's task is to remember and accurately recall these sentences. For example: The dog is running in the park, The cat is running in the park, The dog is playing in the park, The dog is running in the yard.
215096788|NCT07012122|OTHER|visuomotor tracking task|Then the rest will be introduced in the form of computer screen in front of the child with a dot moving under the control of a computer mouse and asking the child to track the dot while maintaining his balance as much as he can.
215096789|NCT05952960|OTHER|Placebo|Open Label Placebo + Rationale
215096790|NCT02484950|BIOLOGICAL|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
215096791|NCT02484950|PROCEDURE|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
214402350|NCT02221323|DRUG|Insulin LISPRO|
214402351|NCT02100618|PROCEDURE|Blood sampling|Blood samples will be collected from all subjects at Year 6.5
214402352|NCT03470285|PROCEDURE|Multiparametric MR imaging (mpMRI)|The main objective of the study is to assess the diagnostic accuracy of mpMRI in small renal tumors. The study characteristics will comply with recommended methods (Quadas, Stard). The population to be included will be representative of patients who would benefit from mpMRI if it is demonstrated to be accurate. In this project, the MR protocol will used the conventional MR sequences either on 1.5 or 3T systems and do not require development. Each center may use their own protocol as long as it includes the mandatory sequences.
214402353|NCT00209274|DEVICE|Percutaneous mitral valve repair using MitraClip implant|MitraClip Implant
214402354|NCT00209274|PROCEDURE|Mitral valve repair or replacement surgery|Repair or replacement of mitral valve
214522656|NCT02267746|DRUG|Tazarotene (Actavis)|
214522657|NCT02267746|DRUG|Vehicle foam|
214522658|NCT06336707|DRUG|HS-20089|Intravenous infusion
214522659|NCT06336707|DRUG|Adebrelimab|Intravenous infusion
214522660|NCT06336707|DRUG|Bevacizumab|Intravenous infusion
214522661|NCT06336707|DRUG|Cisplatin / carboplatin|Intravenous infusion
214522662|NCT03720717|DRUG|Baclofen 10mg|Baclofen administration pre-operatively
214522663|NCT03720717|OTHER|Placebo|Placebo administration
214522664|NCT06370572|OTHER|PAINAD EHR Prompt|Implementation of PAINAD EHR prompt in the ED workflow for PLWD presenting to the ED with hip pain
215007297|NCT01178411|DRUG|Tivantinib|Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.
215007298|NCT01178411|DRUG|Anti-Cancer Combination Therapy|Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
215096792|NCT05147662|BIOLOGICAL|Damoctocog alfa pegol (Jivi, BAY94-9027)|"Part A: 40 IU/kg (up to 60 IU/kg at the investigator's discretion), two times per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, participants will continue their treatment as home treatment. Dose may be increased up to 60 IU/kg if needed at any time during the study at the investigator's discretion.~Part B: Each participant may continue on prophylaxis dose regimen as prescribed in part A (40 - 60 IU/kg, 2x per week) or adjustments to prophylaxis dose / dose frequency can be made at the investigator's discretion (based on the bleeding events and individual needs): Dose frequency may be decreased to every 5 days with a prophylaxis dose of 60 IU/kg."
214402355|NCT05827822|DEVICE|Sober Time ACT|Mental health assessment (regular assessment and reporting feedback), daily clock-in (reporting alcohol use and providing encouragement and reinforcement), mental knowledge base (Tips for the Day based on cognitive behavioral techniques, popular alcohol withdrawal courses, alcohol health education manuals) and self-assistance tools (mindfulness meditation training and emergency help buttons)
214402356|NCT02753530|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
214402357|NCT02753530|OTHER|Placebo|2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime
214402358|NCT05229874|DRUG|carbon nanoparticles|Endoscopic injection
214402359|NCT05229874|DRUG|Indocyanine green|Endoscopic injection
214402360|NCT01797796|DRUG|PF-06305591|150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
215007299|NCT04387214|OTHER|survey|online survey
215007300|NCT02305459|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
215007301|NCT02305459|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
215007302|NCT06494813|DIAGNOSTIC_TEST|conventional pcr|conventional pcr to study matrix metalloproteinase -9 gene polymorphismin rheumatoid arthritis
215096793|NCT07081425|DEVICE|VRG Group|Care was taken to ensure that patients did not receive analgesia for at least 4 hours before the procedure. Before drain removal, the patient's NRPS level was assessed, and the STAI-I questionnaire was filled out. The experimental group was given a video to watch before the procedure began, and the use of glasses was explained. VRG was put on the patient, and the drain was removed in the 3rd minute while the video was being watched. After the procedure, the patients' pain perception during the procedure was assessed with the NRPS form. The STAI-I questionnaire was filled out again.
215096794|NCT07081347|DEVICE|MINT Minimally Invasive Nasal Trabeculostomy|The MINT® system is a powered surgical device for ab-interno nasal trabeculostomy. It creates \~100-micron trabeculostomy openings from the anterior chamber into Schlemm's canal by removing trabecular meshwork (TM) segments. The system includes a sterile stainless-steel Surgical Device with a micro trephine, driven by a motorized Activation Device that controls rotation and movement. The procedure facilitates aqueous outflow to lower IOP, with minimal collateral tissue damage.
214402361|NCT01797796|OTHER|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
214402362|NCT01797796|DRUG|Placebo|Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
215007303|NCT02216877|DRUG|Mablet 360 mg|
215007304|NCT02216877|DRUG|Placebo|
215007305|NCT00771602|DRUG|Rituximab|375 mg/m\^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
215007306|NCT00771602|DRUG|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
215096795|NCT07082257|OTHER|Functional Assessment|Undergo chair-to-table assessment
215096796|NCT07082257|BEHAVIORAL|Timed Get Up and Go Test|"Undergo Get Up and Go assessment"
215096797|NCT07083024|BEHAVIORAL|infection control education|This intervention includes a lecture, hands on practice and identifying IPAC practices in videos
215096798|NCT05929612|RADIATION|Ultra Low Dose 4 Gy Radiation|4 Gy in 2 fractions
215096799|NCT04320888|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and/or CT/MRI
214402363|NCT01797796|OTHER|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
214402364|NCT00816660|BIOLOGICAL|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
214402365|NCT00816660|BIOLOGICAL|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
214402366|NCT05794282|PROCEDURE|the robot assisted total hip arthroplasty|the robot assisted total hip arthroplasty
214402367|NCT05794282|PROCEDURE|the conventional total hip arthroplasty|the conventional total hip arthroplasty
214402368|NCT06376318|DRUG|Inotrope|Vasopressors: Norepinephrine, vasopressin Inotropes: Epinephrine, Dobutamine, Milrinone
215007307|NCT01629862|DEVICE|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
214402369|NCT06376318|DEVICE|Mechanical circulatory support|Intra-aortic balloon pump Extracorporeal membrane oxygenation (ECMO)
214402370|NCT06376318|DRUG|anti-bodies|Anti-Dipeptidyl peptidase 3 (DPP3), Anti-Bioactive adrenomedullin (bio-ADM)
214402371|NCT01493830|GENETIC|fluorescence in situ hybridization|
214402372|NCT01493830|GENETIC|gene expression analysis|
215007308|NCT01629862|DEVICE|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
215007309|NCT05932030|OTHER|Survey|Submission of a survey to solid organ transplant patients and health professionals working in transplantation to assess their knowledge and perception of the use of artificial intelligence in transplantation
215007310|NCT03590470|OTHER|Implementation of a nurse-led model of care|A nurse-model of care consisting of a specifically trained geriatric nurse expert, communication and quality improvement tools will be implemented in 11 nursing homes in the German speaking part of Switzerland
214402373|NCT01493830|GENETIC|microarray analysis|
215096800|NCT04320888|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
215096801|NCT04320888|PROCEDURE|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
215096802|NCT04320888|PROCEDURE|Radionuclide Imaging|Undergo scintigraphy
215096803|NCT04320888|DRUG|Selpercatinib|Given PO
215096804|NCT04320888|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
215096805|NCT07089329|DRUG|Striatin|Daily administration of Striatin extract will be carried out for 14 days. The dose is 1 sachet/day (5 g of Striatin) which dissolved in 10 mll of syrup.
215096806|NCT07089329|DRUG|Placebo|Daily administration of 1 sachet of placebo will be carried out for 14 days.
215096807|NCT07089264|OTHER|Physical rehabilitation|Physical Rehabilitation in 36 sessions
215096808|NCT07089095|OTHER|questionnaire|This is a Relation Research. Use the patient decision aids for acute stroke rehabilitation, then data are collected with patients' characteristics, National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), Modified Rankin Scale (mRS), and factors and preferences in the patient selection of rehabilitation care questionnaire.
215096809|NCT07088887|OTHER|control group|The control group included patients aged 18-65 who were systemically healthy, had no clinical or self-reported signs of bruxism, and were eligible for implant treatment. Data collected included demographic characteristics (age, gender), systemic and periodontal health status, and clinical examination findings confirming the absence of bruxism. These patients also completed the Fonseca Anamnestic Index (FAI) to assess temporomandibular disorder (TMD) symptoms and the Perceived Stress Scale-14 (PSS-14) to evaluate emotional stress levels. A bruxism awareness questionnaire was also applied to determine baseline knowledge in individuals without bruxism. All assessments were conducted before implant surgery using standardized diagnostic tools.
214402374|NCT01493830|GENETIC|mutation analysis|
214402375|NCT01493830|GENETIC|protein analysis|
214402376|NCT01493830|OTHER|immunohistochemistry staining method|
214402377|NCT01493830|OTHER|laboratory biomarker analysis|
214402378|NCT01493830|OTHER|microscopy|
214402379|NCT04845438|DIAGNOSTIC_TEST|fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index|fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
214402380|NCT06083675|DRUG|Semaglutide|Administered as oral tablets.
215007311|NCT01147835|DIETARY_SUPPLEMENT|Chinese Licorice Root|Chinese Licorice Root lollipops are given to the subjects in the study group to ingest twice daily for 10 days. Then the subjects must wait 3 months, and then again ingest the lollipops twice daily for 10 days.
215007312|NCT06469268|DEVICE|Epro software|EPRO software：patients with symptoms will fill in report forms via the software, when the data upload to the terminal, the doctor according to the results of the upload ePRO corresponding medical assessment,and give advises.
215007313|NCT03278145|GENETIC|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
215096810|NCT07088354|DIAGNOSTIC_TEST|The high-throughput extraction of large amounts of quantitative image features from medical images|The high-throughput extraction of large amounts of quantitative image features from medical images
215096811|NCT07088133|DRUG|NA(s)+HT-102+FD-001|Nucleos(t)ide analogues will be administrated throughout the entire treatment course; Patients will be injected with HT-102 once in Day1 (Week1), Day8 (Week2), Day15 (Week3), Day22 (Week4); Patients will be injected with FD-001 once in Day29 (Week5), Day57 (Week9), Day85 (Week13), Day113 (Week17), Day141 (Week21), Day169 (Week25) after confirmed reduction of serum HBsAg to below 10 IU/mL.
214402381|NCT06083675|DRUG|Empagliflozin|Administered as oral tablets.
214402382|NCT06083675|DRUG|Metformin|Administered as oral tablets.
214402383|NCT03754738|DEVICE|Balloon guide catheter|Use a balloon guide catheter in the mechanical thrombectomy
214402384|NCT03754738|DEVICE|Non-balloon guide catheter|Use a non-balloon guide catheter in the mechanical thrombectomy
214402385|NCT03672760|DEVICE|CardioBreathApp|Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
214402386|NCT03672760|DEVICE|IMT PowerBreath|Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
214402387|NCT03672760|DEVICE|IMT PowerBreath Placebo|Inspiratory Muscle Training (IMT) without load
214402388|NCT03425136|OTHER|Systems Analysis and Improvement Approach (SAIA)|Five-step systems analysis and iterative improvement cycles applied by district maternal and child health supervisors to subordinate health facilities providing prevention of mother-to-child HIV transmission services at the facility level.
214402389|NCT01672983|DRUG|ABT-450/ritonavir, ABT-267|ABT-450 (tablet) dosed with ritonavir (capsule), and ABT-267 (tablet)
214402390|NCT01901549|PROCEDURE|Renal denervation|The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
215007314|NCT01992471|BEHAVIORAL|Pre-test Assessment|Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
215007315|NCT01992471|BEHAVIORAL|Pre test Counseling|Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
215007316|NCT01992471|OTHER|Blood draw|After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
215007317|NCT01992471|BEHAVIORAL|Post-test counseling, and post-test assessment|When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
215007318|NCT01992471|BEHAVIORAL|Follow-up assessments (6 and 12 months)|At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
215007319|NCT01973400|DIETARY_SUPPLEMENT|Tocotrienol|Palm-Oil derived Vitamin E, tocotrienol
215007320|NCT01973400|DIETARY_SUPPLEMENT|Placebo|Placebo
215007321|NCT02985710|DEVICE|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
215007322|NCT02985710|PROCEDURE|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
215007323|NCT02985710|PROCEDURE|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
214402391|NCT01901549|DRUG|Metoprolol|Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
214402392|NCT01901549|DRUG|Lisinopril|ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
214402393|NCT03610217|OTHER|Interstitial lung disease induction algorithm|Patients failing first line mycophenolic acid (MFA) will be randomized to MFA plus rituximab or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.
214402394|NCT03610217|OTHER|Pulmonary arterial hypertension algorithm|Patients diagnosed with pulmonary arterial hypertension secondary to systemic sclerosis will be randomized to receive anticoagulation (warfarin, rivaroxaban or apixaban)
214402395|NCT03610217|OTHER|Raynaud's phenomenon algorithm|"Patients with mild Raynaud's phenomenon not responding to the first line treatment (nifedipine), will be randomized to receive losartan or nifedipine plus atorvastatin or nifedipine plus losartan. If they fail the second line they will be crossed over to the other options randomly.~Patients with severe Raynaud's phenomenon not responding to the first line treatment (nifedipine) or failing the previous mild Raynaud's algorithm, will be randomized to receive nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option."
214522665|NCT05078450|BEHAVIORAL|Mood Lifters|Participants will need to attend 12 hour long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
215007324|NCT00799669|BEHAVIORAL|smoking cessation intervention|Standard quit-smoking counseling to help decrease their risk of cancer.
215007325|NCT00799669|OTHER|counseling intervention|Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
215007326|NCT00799669|OTHER|preventive intervention|
215007327|NCT00799669|OTHER|questionnaire administration|
215007328|NCT04954443|PROCEDURE|Removing urinary catheter|Removing urinary catheter after vaginal surgery of pelvic organ prolapse
215007329|NCT01037465|DRUG|N-acetylcysteine|N-acetylcysteine
215007330|NCT01037465|DRUG|Placebo|Placebo
215007331|NCT06337409|DRUG|Generic empagliflozin 25 mg film-coated tablets|Empagliflozin 25 mg film-coated tablets
215007332|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule approximately 30 mcg daily 21 days
215007333|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule 300 mcg daily 21 days
215007334|NCT03097159|PROCEDURE|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
215007335|NCT03168087|OTHER|Plasmalyte-148|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.
215007336|NCT03215615|PROCEDURE|Periodontal surgery|Coronally advanced flap for root coverage
215007337|NCT03215615|PROCEDURE|Total Etch adhesive|Total-etch adhesive system (two step)
215007338|NCT03215615|PROCEDURE|Universal Adhesive|One-step self-etching adhesive system
215007339|NCT03215615|PROCEDURE|Nanofilled Composite|Partial nanofilled-resin composite restoration
215007340|NCT03215615|PROCEDURE|Micro-Hybrid Composite|Partial micro-hybrid composite restoration
215007341|NCT04293965|DRUG|Single ascending dose of X842|A total of 7 dose groups will be set for the ascending dose: 5.6 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg. In the 5.6 mg dose group, 4 subjects will receive X842; in the 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg dose groups, 8 subjects in each group will receive X842. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
215007342|NCT04293965|DRUG|Multiple ascending dose of X842|Two dose groups will be set, including the groups receiving the recommended phase II dose and a higher dose; Eight subjects will be enrolled in each group, with half male and half female, who will receive X842 once daily for 5 consecutive days. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
215007343|NCT04293965|OTHER|Food Effect|Twelve subjects (appropriate ratio of male to female) screened for eligibility will be randomized into Group A and B. The 6 subjects in Group A will take the study drug (X842) in fasted condition and subject in Group B will take the study drug in fed condition in the 1st cycle. In the 2nd Cycle, subjects in Group A will take the study drug in fed condition, and subjects in Group B will take the study drug in fasted condition. The interval between the two cycles is at least 7 days.
215007344|NCT04783727|DIAGNOSTIC_TEST|Individualised treatment duration based on RNA transcriptomic model|Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.
215007345|NCT02575625|DEVICE|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
215007346|NCT02575625|BIOLOGICAL|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
215007347|NCT02575625|DEVICE|MRI|Liver MRI
215007348|NCT04201210|OTHER|TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|Haploidentical 5+/10 HSCT from a relative, α/β T-depleted
215007349|NCT04201210|OTHER|Matched sibling donor transplantation|10/10 HSCT - matched family donor
215007350|NCT01149967|DRUG|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
215007351|NCT02869139|OTHER|Mentholated lip moisturizer and ice popsicle|Mentholated package of measures
215007352|NCT02869139|OTHER|Non-mentholated lip moisturizer and ice popsicle|Non-mentholated package of measures
215007353|NCT04447248|DEVICE|QDSP Protocol|Computerized expert system for fetal monitoring, based on cardiotocogrpaphy
215007354|NCT01713738|DRUG|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
215007355|NCT00167271|BEHAVIORAL|Cognitive Behavior Therapy|Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
215007356|NCT02832999|DRUG|sub cutaneous liraglutide|Liraglutide 1.2mg/day
215007357|NCT02832999|DRUG|Oral Vildagliptin|Vildagliptin 50mg/day
215007358|NCT03423472|BEHAVIORAL|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake|Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children \< 2y; especially diet diversity and vitamin A intake.
215007359|NCT03423472|BEHAVIORAL|Healthy Baby Toolkit|The toolkit consists of a demarcated bowl, a slotted spoon, and a counseling card. The demarcations on the bowl guide caregivers on age-specific meal volume and frequency. The slotted spoon promotes thicker food consistency - and therefore nutrient density - by cuing caregivers when food drips through the slots. The counseling card relies on images rather than text to reinforce messages of the previous two instruments, promote dietary diversity, and promote hygienic food preparation.
215007360|NCT03423472|BEHAVIORAL|Standart of care|Government standard of care for nutrition education through the Health Development Army
215007361|NCT03779607|OTHER|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
215007362|NCT05575427|DRUG|Minocycline|The patients will receive minocycline oral between 7-28 days
214688223|NCT06916728|PROCEDURE|Surgical Standard of Care|"As no single, current therapy could be used as a single comparator for the treatment of the knee lesions treated in the pivotal study which included focal cartilage lesions on the one hand and moderate knee osteoarthritis on the other, current general practice (e.g., SSOC: Deb and MFx) was used.~Deb (SSOC) is a common orthopedic surgical procedure that removes damaged cartilage and tissue from the knee. MFx (SSOC) is another common orthopedic surgical procedure that treats knee cartilage defects by creating small holes in the bone beneath the damaged cartilage."
214688224|NCT07112222|DRUG|LM-350 for injection|Q3W,Intravenous Drip
215007363|NCT05575427|DRUG|Levofloxacin or Cotrimoxazole|The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
215007364|NCT05575427|DRUG|Placebo|Capsule without active compound
215007365|NCT01168479|RADIATION|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
215007366|NCT01168479|RADIATION|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
214688225|NCT06923137|DRUG|BNT162b2|BNT162b2
214402396|NCT03610217|OTHER|Digital ulcer algorithm|"Patients with active digital ulcers not healing after 3 months or developing new ones with nifedipine will be randomized to nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.~Patients who develop new digital ulcers under treatment with nifedipine will be randomized to nifedipine plus atorvastatin plus standard of care or nifedipine plus standard of care. If they fail the second line they will be crossed over to the other option."
214402397|NCT03610217|OTHER|Inflammatory arthritis algorithm|Patients with inflammatory arthritis failing methotrexate and/or prednisone and/or hydroxychloroquine and/or sulfasalazine will be randomized to receive intravenous rituximab or subcutaneous tocilizumab. If they fail the second line they will be crossed over to the other option.
214402398|NCT03610217|OTHER|Gastroesophageal reflux algorithm|Patients with gastroesophageal reflux failing standard doses of proton pump inhibitors (PPI) will be randomized to receive double doses of PPI or standard dose of PPI plus ranitidine or double doses of PPI plus domperidone or double doses of PPI plus prucalopride/erythromycin. If they fail the second line they will be crossed over to the other options randomly.
214402399|NCT03610217|OTHER|Bacterial overgrowth algorithm|Patients with bacterial overgrowth will be randomized to receive erythromycin or metronidazole or amoxicillin. If they fail the second line they will be crossed over to the other options randomly.
214402400|NCT03610217|OTHER|Constipation algorithm|Patients with constipation will be randomized to receive bisacodyl or magnesium sulphate or polyethylene glycol or senna.If they fail the second line they will be crossed over to the other options randomly.
214402401|NCT03610217|OTHER|Skin involvement algorithm|"Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option.~Patients with skin involvement and modified Rodnan skin score \>32 will be randomized to receive methotrexate plus mycophenolic acid or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option."
214402402|NCT03610217|OTHER|Pain algorithm|Patients with pain failing first line treatment with acetaminophen or celecoxib or ibuprofen will be randomized to receive pregabalin or duloxetine. Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. In case they fail the second line they will be treated with medical marijuana.
214402403|NCT05160025|OTHER|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
214402404|NCT01445639|DRUG|Dexmedetomidine|Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
215007367|NCT01069640|BIOLOGICAL|HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
215096812|NCT07089537|OTHER|progressive muscle relaxaiton|Participants will undergo approximately 30 minutes of Progressive Muscle Relaxation (PMR). Prior to the session, a brief introduction to the basic concepts of PMR will be provided. Participants will be instructed to close their eyes and focus on the sensations in their muscles. Following verbal instructions, they will sequentially contract and relax 14 major muscle groups from top to bottom. For each muscle group, participants will be asked to contract the muscles as strongly as possible for 7 seconds, followed by a 45-second relaxation period. This process will be repeated twice for each muscle group.
214402405|NCT01445639|DRUG|Normal saline|as placebo
214402406|NCT00378872|DRUG|IV Tranexamic acid 10mg/kg pt body weight|
214402407|NCT00378872|DRUG|Quixil topical sealant|
214402408|NCT06036030|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
214402409|NCT06036030|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
214402410|NCT06036030|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
214402411|NCT06036030|OTHER|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
214402412|NCT05976490|BEHAVIORAL|Information and Support Intervention|Information guide and four one-on-one coaching sessions
214402413|NCT05976490|OTHER|Usual supportive care|Referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician
214402414|NCT02944903|OTHER|Audit|Questionnair
215007368|NCT00421733|DRUG|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
215007369|NCT00421733|DRUG|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
215007370|NCT00421733|DRUG|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
215007371|NCT06194669|OTHER|Blood and urine sample collection|One whole blood sample per individual (3 ml) will be collected. Up to 5 urine samples per individual will be collected
215096813|NCT07089537|OTHER|Rest|Rest in a semi-recumbent position with eyes closed for 30 minutes, without any additional intervention.
215096814|NCT07088575|PROCEDURE|major gastrointestinal or hepatobiliary surgery under general anesthesia|major gastrointestinal or hepatobiliary surgery under general anesthesia
215096815|NCT07088159|DRUG|SPG302|300 mg SPG302 will taken by mouth once daily.
214402415|NCT00262444|PROCEDURE|Different turning frequencies|
214402416|NCT05879640|BEHAVIORAL|Sleep education|Participants receive a handout about age appropriate sleep goals and tips for improving sleep. The handout also contains links to educational videos about sleep hygiene and the importance of sleep to healing after illness. The handout is reviewed with a clinician at bedside prior to hospital discharge.
214402417|NCT00465361|PROCEDURE|performance feedback with an educational module|individual performance feedback with an educational module
214402418|NCT05476822|DIAGNOSTIC_TEST|Obtain antibody titers|Obtain blood samples for antibody titers at the time of enrollment, at three months, six months and nine months post vaccine booster (+/- ten days).
214402419|NCT04351750|OTHER|general exercise|The participants will receive training sessions twice a week for 8 weeks. General exercise includes aerobic exercise (stationary bike) and resistance training (thera-band, sandbags, dumbbell and swiss ball), and the intensity and progression of both aerobic and resistance exercises will be provided as recommended by the ACSM, and the exercise will individualized based on participant's HRR, 1 RM weight and Borg Scale of Perceived Exertion Scale (Borg RPE scale). An oximeter will be utilized to monitor the heart rate and SPO2 of the participants to ensure safety during the training session.
215007372|NCT03429205|OTHER|No external heating used during surgery|Deviation from external heating for all surgery standard
215007373|NCT03429205|OTHER|External heating blanket used during surgery|Standard external heating plan used in all surgery types
215007374|NCT06413394|OTHER|environmental education|environmental education
215007375|NCT06485180|PROCEDURE|Active comparator|"Participants from conservative group were selected as uterine curettage (D\&C) cohort , hysteroscopy cohort, Uterine Artery Embolization (UAE) in Combination with D\&C, without MTX cohort, UAE in Combination D\&C with MTX cohort and UAE+ D\&C+hysteroscopy.~Participants from CSP excision plus hysterotomy closure group were selected as transvaginal CSP excision cohort, hysteroscopy-assisted laparoscopic CSP excision cohort and abdominal CSP excision cohort."
215007376|NCT02265744|DRUG|BMS-931699|
215007377|NCT02265744|DRUG|Placebo matching BMS-931699|
215007378|NCT04505917|DRUG|dinoprostol|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
215007379|NCT04505917|DRUG|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
214402420|NCT04351750|OTHER|pelvic floor muscle training|Participants will do pelvic floor muscle training in different positions. Each session includes three sets of eight to twelve maximum voluntary contractions of pelvic floor muscle, with holding the contraction for 6 to 8 seconds, and if possible, to do three fast contractions at the end of each set.
214402421|NCT03623412|DIAGNOSTIC_TEST|75g oral glucose tolerance test|Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM
215007380|NCT04505917|DRUG|placebo|2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion
215007381|NCT04181645|DRUG|Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection
215007382|NCT05098990|DRUG|Jinfukang oral liquid|Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
215007383|NCT05098990|DRUG|Platinum-based doublet chemotherapy|Platinum-based doublet chemotherapy as first line therapy has been shown to be efficacious against non-small cell lung cancer.
215007384|NCT04698486|OTHER|Hyperinsulinemic euglycaemic clamp|"Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention."
215007385|NCT06403501|DRUG|Clascoterone|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
215007386|NCT06403501|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
215007387|NCT00299221|DRUG|Tacrolimus|tacrolimus
214402422|NCT03623412|DIAGNOSTIC_TEST|75g GTT|post-partum GTT
214402423|NCT03701100|DEVICE|tDCS|tDCS
215007388|NCT00299221|DRUG|combination therapy|MMF
215007389|NCT00720200|BEHAVIORAL|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
215007390|NCT00720200|BEHAVIORAL|Usual Care|Family Members receiving usual care/clinical interaction
215007391|NCT04086459|DEVICE|Repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
215007392|NCT01666600|DRUG|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
214402424|NCT01289704|OTHER|TreSPE|"1. treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~2. Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~3. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~4. Proprioceptive and postural kinesitherapy according to the Perfetti method.~5. Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls."
215007393|NCT01666600|RADIATION|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
215007394|NCT01297790|OTHER|Cough Challenge Tests|Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
215007395|NCT01297790|OTHER|ambulatory cough recording|Cough recording with a portable device to capture cough sounds
215007396|NCT01297790|OTHER|Cough questionnaires|Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
215007397|NCT05161936|DRUG|Lumasiran|Lumasiran will be administered by SC injection.
215007398|NCT05161936|DRUG|Placebo|Placebo will be administered by SC injection.
215007399|NCT01086475|DRUG|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
215007400|NCT01086475|DRUG|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
215007401|NCT05371197|DRUG|Neoadjuvant therapy with PD-L1 inhibitor|Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab), 300mg, Q3W for 4 cycles
214402425|NCT01289704|OTHER|SPE|"1. Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.~2. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.~3. Proprioceptive and postural kinesitherapy according to the neurocognitive method.~4. Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls."
214402426|NCT01333943|PROCEDURE|Study Group: Experimental|The study group will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivicaine. The study group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
214402427|NCT01333943|PROCEDURE|Control Group|The control group will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivicaine. The control group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
214402428|NCT01189253|DRUG|doxorubicin hydrochloride|
214402429|NCT01189253|DRUG|trabectedin|
214402430|NCT01189253|OTHER|laboratory biomarker analysis|
214402431|NCT01189253|PROCEDURE|quality-of-life assessment|
214402432|NCT03626974|BIOLOGICAL|Venipuncture|Venipuncture for blood collection
214402433|NCT03626974|DEVICE|Diffuser spreading odor|Diffuser will place under a Hood with an air-flow
214402434|NCT01353235|DRUG|Prednisolone|Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
214402435|NCT01353235|DRUG|usual care|no drug administered
214402436|NCT04502719|DIAGNOSTIC_TEST|Nutritional screening.|Nutritional screening with the RFH-NPT and LDUST questionnaires.
214402437|NCT03109717|DRUG|Monoamine Oxidase Inhibitor (MAOI)|Monoamine Oxidase Inhibitor
214402438|NCT04502667|DRUG|Cholecalciferol|1000U or 2000U every 24 hours orally
214402439|NCT05178394|DEVICE|Weightlifting belts and wrist straps|"The participants wore a weightlifting belt (Heavywear Nylon Contour Belt H9, North Carolina, USA) for the with weightlifting belt conditions and/or put on a pair of wrist straps (Versa Gripps Professional Series, Versa Gripps, Maine, USA) for the with wrist strap conditions. The steps involved in completing a conventional deadlift have been detailed in Holmes."
214402440|NCT05247840|DIAGNOSTIC_TEST|uroflowmetry|Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.
214402441|NCT05247840|DIAGNOSTIC_TEST|Cardiovascular autonomic dysfunction test proposed by Ewing et al.|CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.
214402442|NCT05247840|DIAGNOSTIC_TEST|peripheral nerve conduction test|Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.
214402443|NCT02144324|DEVICE|Tandem Appliance|We are going to use a modified version of the Tandem Appliance
214402444|NCT01421771|DRUG|Antihypertensive Agents|"Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator"
215007402|NCT00326040|DEVICE|Glaucoma Surgery|
215007403|NCT00505362|PROCEDURE|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
215007404|NCT03246854|DRUG|DBPR112|DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
215007405|NCT01004393|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
215007406|NCT01691807|DRUG|ofatumumab|treatment for NHL
215007407|NCT01691807|DRUG|bendamustine|treatment for NHL
215007408|NCT01691742|DRUG|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
215007409|NCT01691742|DRUG|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
215007410|NCT01691742|DRUG|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
215096816|NCT07089407|DEVICE|Dental implant placement|Implant site prepared through a consecutive drilling procedure in the maxilla or the mandible, implant placed.
215096817|NCT07089849|OTHER|Rapid HIV testing|At the designated sites for RHT, providers will offer RHT to patients as part of their dental routine care.
215096818|NCT07089849|OTHER|Referral for HIV testing|At the designated sites for HIV testing referral, providers will offer an HIV test referral to the affiliated CHC laboratory to patients as part of their dental routine care.
214402445|NCT01421771|OTHER|Dry weight Challenge|Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal
214402446|NCT01421771|DIETARY_SUPPLEMENT|Extend dialysis treatment time and re-challenge estimated dry weight|Extend dialysis treatment time and re-challenge estimated dry weight
214402447|NCT01561690|DRUG|ARRY-502, CRTh2 antagonist; oral|multiple dose, single schedule
214402448|NCT01561690|DRUG|Placebo; oral|matching placebo
214402449|NCT02091063|DRUG|ACY-1215|All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
214402450|NCT06629129|DRUG|Latanoprost (0.005%)|MEAN OCULAR PERFUSION PRESSURE WAS MEASURED AND CORRELATED TO THE IOP AND OPTIC NERVE PERFUSION IN RESPONSE TO LATANOPROST TREATMENT
214402451|NCT02863159|DEVICE|Tecnis Multifocal 1-Piece IOL|+2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
214402452|NCT03367364|BEHAVIORAL|Patient education bundle (PEB),|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
214402453|NCT03367364|BEHAVIORAL|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
214402454|NCT03259971|DIETARY_SUPPLEMENT|Probiotic-Lactobacillus plantarum PS128|Probiotic supplement of Lactobacillus plantarum PS128 , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
214402455|NCT03259971|DIETARY_SUPPLEMENT|Placebo|placebo , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
214402456|NCT03232177|DRUG|Anagre Cap.|from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
214402457|NCT04751513|OTHER|auricular acupressure|Pressure on auricular point of Shenmen (TF4), Sympathesis (AH6a), Subcortex (AT4), Endocrine (CO18), finger (SF1), and toe (AH2) of the ear.
214402458|NCT04953156|DRUG|Nitroglycerin|data will be retrieved from intraoperative medical records for the period from May 2020 to May 2021 for patients meeting the eligibility criteria who developed uncontrolled elevation of their blood pressure and received nitroglycerine infusion
214402459|NCT04953156|DRUG|Dexmedetomidine|All patients who develop uncontrolled elevation of their blood pressure and meeting the eligibility criteria from July 2021 to July 2022 will receive dexmedetomidine bolus of 1mic/kg over 20 minutes and then continuous infusion of 0.2-0.7 mic/kg/hour adjusted according to each patient hemodynamic response.
214402460|NCT00252785|DRUG|Budesonide/Formoterol|
215007411|NCT04000711|OTHER|Outpatient oral treatment.|Participants allocated in oral outpatient group were discharged home with oral antibiotic to continue management. Participants were given Cefixime oral suspension (100 mg/5 mL). Antibiotic was given to the caretakers with written instructions about dosage and time of administration. Dosage indicated was 8 mg/kg/day to be given orally as a single dose (max dose 400 mg/day). Oral antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
215007412|NCT04000711|OTHER|Inpatient intravenous treatment.|Participants allocated in the intravenous inpatient group continued receiving Cefepime 150 mg/kg/day every 8 hours (max dose 2 grams per dose or 6 grams per day) according to local standard of care guidelines. Intravenous antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
215007413|NCT03519607|BEHAVIORAL|FertiStrong App|The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
214402461|NCT00252785|DRUG|Budesonide|
214402462|NCT00252785|DRUG|Theophylline|
214402463|NCT06103461|PROCEDURE|Autologous fat grafting|Autologous fat grafted at contour defects with pigmentary changes
214402464|NCT01391156|DRUG|3%Minoxidil lotion|3% Minoxidil lotion apply two times a day
214402465|NCT01391156|DRUG|3% Minoxidil with 0.1% Finasteride lotion|3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
214402466|NCT05557019|DEVICE|Booster Balloon Catheter|The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
214402467|NCT05186090|BEHAVIORAL|24-week resistance exercise program|This group will perform a 24-week resistance exercise program. Participants will engage in 180 minutes/week of resistance exercise (3 supervised sessions peer week, 60 min/session). The training will consist of a combination of upper and lower body exercises using elastic bands and participants' body weight as the primary resistance. Exercise load and intensity will be based on the number of repetitions (i.e.,10-12 repetitions), resistance of the elastic bands, in ascending order with seven intensities, and also on the exercises' difficulty (i.e., three levels). The prescribed targeted intensity will reach 70-80% of the participants' maximum rating perceived exertion (i.e., 7-8 RPE).The progression (horizontal) will be standardized according to the execution time and RPE, and individualized according to execution speed and band resistance. Heart rate will be monitored in all sessions. Further, intrinsic motivation before and after session and sleep quality will be registered.
214402468|NCT02408562|OTHER|i.c.v. infusion of sNN0031 by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
215096819|NCT07088549|DEVICE|Continuous glucose monitoring|Intravenous insulin therapy will be guided by interstitial glucose measurements using DexcomG7 continuous glucose monitor. Confirmatory blood glucose tests will be performed daily. In extreme clinical conditions (post-resuscitation, pH \< 7.20, severe hypoxia, severe haemodynamic compromise), confirmatory blood tests will be performed in 2 hour intervals until clinical improvement.
215096820|NCT07088549|DIAGNOSTIC_TEST|Control Arm - standard of care|Intravenous insulin dosing will be guided according to blood glucose measurements using RadiometerABL800 (standard of care). DexcomG7 continuous glucose monitor will be applied in blinded mode for interstitial glucose monitoring for later CGM metrics and comparison analysis.
215096821|NCT07089069|DEVICE|3 mA transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The stimulation intensity will be set at 3 mA. The stimulation will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
215096822|NCT07089069|DEVICE|2 mA transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The stimulation intensity will be set at 2 mA. The stimulation will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
215096823|NCT07089069|DEVICE|1 mA transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The stimulation intensity will be set at 1 mA. The stimulation will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
215096824|NCT07089069|DEVICE|sham transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The intervention will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation，but there is not current in between. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
215096825|NCT07089420|DEVICE|ALPCO Calprotectin CLIA|Measurement of calprotectin in feces
215007414|NCT02105142|BEHAVIORAL|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
215007415|NCT02105142|BEHAVIORAL|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
215007416|NCT02105142|BEHAVIORAL|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
215007417|NCT01279187|DRUG|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
215007418|NCT01279187|DRUG|Placebo|20ug per day, self administered injection, for 7 weeks
215007419|NCT06262373|DIAGNOSTIC_TEST|Ultrasound|Ultrasound based observational study
215007420|NCT05476718|OTHER|Kinesio taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th- 5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
215007421|NCT05476718|OTHER|placebo taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th-5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
215007422|NCT00848315|BEHAVIORAL|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
214402469|NCT02408562|OTHER|i.c.v. infusion of aCSF by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
214402470|NCT03350321|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
214402471|NCT03350321|DRUG|Darbepoetin alfa|Starting dose of darbepoetin alfa once every 2 weeks will be titrated based on the subject's Hb (Hemoglobin) response
215007423|NCT02746731|OTHER|Cardiorespiratory and resistance training.|"A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.~Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training."
215007424|NCT02746731|OTHER|Reference|No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
215007425|NCT03723239|DEVICE|TricValve® System|The TricValve® Delivery System is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is unsheathed at the implantation site and positions itself as per the anatomy - self expanding frame.
215007426|NCT02420574|DRUG|albendazole BENDEX|randomized clinical trial with 2 parallel arms
215007427|NCT02420574|DRUG|albendazole OVIS|
215007428|NCT04553094|OTHER|Endurance training|Aerobic circuit training
215007429|NCT04553094|OTHER|Muscle building training|Muscle strengthening circuit training
215007430|NCT04999020|DRUG|Ravulizumab|Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
215007431|NCT04999020|DRUG|Placebo|Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
215007432|NCT01865773|PROCEDURE|HFR dialysis|HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
215007433|NCT04664296|OTHER|Review of medical patient file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
215007434|NCT04664296|OTHER|Phone call interview|less than 15 minutes phone call
215007435|NCT01635140|RADIATION|Hypofractionated radiotherapy|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
215007436|NCT01635140|RADIATION|Conventional arm|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
215007437|NCT04530123|DRUG|Placebo|TAK-101 placebo-matching intravenous infusion
215007438|NCT04530123|DRUG|TAK-101|TAK 101 intravenous infusion
215007439|NCT04530123|DIETARY_SUPPLEMENT|Gluten|Powder form (vital wheat gluten)
215007440|NCT03608969|OTHER|NOT-S|Participants are assessed for the orofacial function using the Nordic Orofacial test- screening (NOT-S), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) and Communication Function Scale (CFS). Oral health related quality of life is assessed using the Parental- Caregiver Perceptions Questionnaire (P-CPQ). Caries experience was measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft). Gingival index and type of occlusion will be recorded.
215007441|NCT03279315|DIETARY_SUPPLEMENT|iodized table salt, non-iodized table salt|During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
215007442|NCT03359083|OTHER|Correlation|Correlation between assesment parameters
215007443|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
215007444|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
215007445|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
215007446|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
215007447|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
215007448|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
214402472|NCT05515094|BEHAVIORAL|Empowerment Counseling Intervention|The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
214402473|NCT03234621|OTHER|ventilator setting during one-lung ventilation|providing various tidal volumes according to the groups with constant PEEP
215007449|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
215007450|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
215007451|NCT04640402|BIOLOGICAL|Low-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
215007452|NCT04640402|BIOLOGICAL|Low-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
215007453|NCT04640402|BIOLOGICAL|High-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
214402474|NCT05640921|BEHAVIORAL|Gi-CBT|Gi-CBT designed to cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience.
214402475|NCT05640921|OTHER|Media Orientation|The MO sessions will embed media content to create awareness of the government's approaches to reintegration.
214402476|NCT02652130|BIOLOGICAL|Remestemcel-L|No intervention was given in Study MSB-GVHD002 (NCT02652130). It was a safety follow-up trial of remestemcel-L-treated participants from Study MSB-GVHD001.
214402477|NCT02711982|PROCEDURE|Optic canal and optic nerve sheath decompression|within 5 days from trauma
214402478|NCT02711982|DRUG|methylprednisolone|within 5 days from trauma
214402479|NCT02028884|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
214402480|NCT02028884|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
214402481|NCT02028884|DRUG|Baseline Treatment|As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
214402482|NCT03810482|DEVICE|Pedometer|A pedometer will be worn by the patient at home for days 1 to 14 and 60 to 74.
214402483|NCT03810482|OTHER|6 minute walking test|Performed according to current recommendations during routine visits (baseline and \~90 days for the purposes of this study).
215007454|NCT04640402|BIOLOGICAL|High-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
215007455|NCT04640402|BIOLOGICAL|Low-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
215007456|NCT04640402|BIOLOGICAL|Low-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
215007457|NCT04640402|BIOLOGICAL|High-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
215007458|NCT04640402|BIOLOGICAL|High-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
215007459|NCT05309005|BEHAVIORAL|VR TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT. The stimulus material in the Virtual Reality version is perceived through a head mounted display. This allows the test person to watch the scenes in three dimensions and a 360 degree angle, increasing the sense of social presence.
215007460|NCT05309005|BEHAVIORAL|DT TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT, with identical content as the VR TASIT. The stimulus material in the desktop version is perceived on a two dimensional desktop computer screen.
215007461|NCT02495675|DEVICE|High flow nasal cannulas|Comparison of different flow levels
215007462|NCT02495675|DEVICE|Conventional flow via nasal prongs|Low flow of air delivered through conventional nasal prongs
215007463|NCT02448043|DRUG|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
215007464|NCT02448043|OTHER|Placebo: saline|Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days
215007465|NCT04341051|OTHER|Case|Mesure with NIRS regional saturation in patients undergoing popliteal block during vascular surgery for chronic obliterating arteriopathy (IIa to III Fontaine Classification)
214402484|NCT00354029|DRUG|S (+) Ketamine|0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
214402485|NCT00354029|DRUG|Placebo|isotonic saline
214402486|NCT04577248|DEVICE|edge-to-edge valve repair|edge-to-edge valve repair
214402487|NCT03279198|BEHAVIORAL|TIWeb|Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
214402488|NCT03279198|BEHAVIORAL|CSC|Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
214402489|NCT03279198|BEHAVIORAL|UC|Intervention: The usual care group received usual care that varies dependent upon the practice setting.
214402490|NCT03279198|BEHAVIORAL|TIWeb+CSC|Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
214402491|NCT03434743|OTHER|Rehabilitative|Non-nutritive sucking on emptied breast
214402492|NCT03434743|OTHER|Active Comparator|Non-nutritive sucking on pacifier
215007466|NCT00046943|DRUG|atrasentan hydrochloride|
215007467|NCT02320292|OTHER|Quality-of-Life Assessment|Ancillary studies
215007468|NCT02320292|BIOLOGICAL|Rituximab|Given IV
215007469|NCT02320292|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
215096828|NCT07088744|DIAGNOSTIC_TEST|Probe-based Confocal Laser Endomicroscopy|Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. All patients scheduled for endoscopic submucosal dissection (ESD) of gastric lesions must undergo probe-based confocal laser endomicroscopy (pCLE) prior to the ESD procedure.
215096829|NCT07088744|DIAGNOSTIC_TEST|Pathological biopsy|A pathological biopsy is a medical procedure that involves the removal of a small sample of tissue or cells from the body for microscopic examination. It is a crucial diagnostic tool used to identify diseases, particularly cancer, infections, inflammatory conditions, and other abnormalities.
214402493|NCT02693626|BEHAVIORAL|intensive cessation message|Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
214402494|NCT02693626|BEHAVIORAL|Not intensive cessation message|Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
214402495|NCT00185484|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
214402496|NCT04931680|OTHER|Data collection|During the follow-up consultation, six weeks after inclusion (S6), data will be collected using a standardized digital questionnaire, including clinical features, economic, social and cultural characteristics, housing conditions and therapeutic details (type of environmental decontamination and treatment received). Data will then be compared between patients with therapeutic success or failure. A urine test strip will also be used during the S6 consultation to screen for proteinuria. The prevalence of post-streptococcal glomerulonephritis will be extrapolated from that of proteinuria.
214402497|NCT02547805|DRUG|ALLN-177|ALLN-177 7,500 units (5 capsules) PO TID with meals
214402498|NCT02547805|DRUG|Placebo|Placebo 5 capsules PO TID with meals
215007470|NCT05621473|DEVICE|PICC|Tunnel PICC puncture technology is a perfect combination of ultrasound-guided puncture, ECG lead technology, PICC and subcutaneous tunnel. The valve conduction PICC is equipped with an integrated ECG lead Doppler ultrasound machine. Before the catheter is placed, in the yellow area, in the ultrasound mode, evaluate the blood vessel condition, measure the blood flow velocity, and correctly select the puncture site. When the catheter is pushed close to the superior vena cava, the electrocardiograph mode is switched to complete the precise positioning of the catheter according to the principle of ECG positioning technology. A subcutaneous tunnel was prepared in the green area, and the PICC at the puncture site in the yellow area was introduced to the green area and carefully bandaged. Whole-process integrated operation, simple and efficient operation.
215007471|NCT04542564|DEVICE|telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
215007472|NCT04542564|OTHER|usual care|These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments
215007473|NCT05745298|DEVICE|Xcite Clinical Station|The abdominal functional electrical stimulation (AFES) will be conducted using the Xcite system. This is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education. The electrical stimulation will be applied to the abdominal and back muscles. In addition, participants will receive two specific respiratory muscle training exercises performed 3 days per week.
215007474|NCT03595891|OTHER|Non-Interventional|Non-Interventional
215007475|NCT03983005|PROCEDURE|EUS-B-FNA|Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
215007476|NCT02219204|PROCEDURE|Acupuncture|
215007477|NCT02219204|OTHER|Herbal treatment|
215007478|NCT01251458|DRUG|Torisel|Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
215007479|NCT06545864|DRUG|Streptokinase Injection|250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours
215007480|NCT06545864|DEVICE|Penumbra System|"which comprised of several devices:~* RED Reperfusion Catheters~* Penumbra JET Reperfusion Catheters~* ACE Reperfusion Catheters~* MAX Reperfusion Catheters~* 3D Revascularization Device~* Penumbra ENGINE Aspiration Source~* Penumbra ENGINE Canister~* Aspiration Tubing"
215007481|NCT04806425|DRUG|Intralipid|intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia
215007482|NCT04806425|DRUG|Placebo|normal saline is given in same volume to normal saline group over the same duration
215007483|NCT04947787|BEHAVIORAL|Physical activity referral scheme (PARS)|Participants of the intervention group will receive brief physician advice and be referred to an exercise professional (e.g., physiotherapist, sports therapist) for a more intensive counseling intervention. The counseling intervention consists of an initial assessment, individual physical activity counseling (360'), a final assessment after 12 weeks, and a follow-up assessment after 24 weeks.
214402499|NCT01071694|DRUG|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
214402500|NCT05557422|DIAGNOSTIC_TEST|BD OneFlow LST, and B-CLPD T1 to T4 Assays|a panel of fluorochrome-conjugated antibodies for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations on the BD FACSLyric™ flow cytometer with BD FACSuite™ Clinical application.
214402501|NCT03737669|BIOLOGICAL|Mirasol-treated Fresh Whole Blood|Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
214402502|NCT03737669|BIOLOGICAL|Standard Fresh Whole Blood|Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
214402503|NCT03783455|PROCEDURE|Non arthroscopic joint lavage|Instillation of 4 litters of cold physiological serum
215096830|NCT07089212|BEHAVIORAL|Phased Rehabilitation Training|"Rehabilitation is divided into three postoperative phases:~Early Phase (Weeks 1-2): Focus on edema control, quadriceps activation, and passive/active-assisted range of motion (ROM) exercises.~Intermediate Phase (Weeks 3-6): Progress to strength training, endurance exercises, and early proprioception drills.~Late Phase (Weeks 7-12): Advance to functional training , dynamic proprioception, and full ROM restoration."
215007484|NCT04947787|BEHAVIORAL|Physical activity advice (PAA)|Participants of the control group will only receive brief physician advice regarding the promotion of physical activity and as an information sheet with tips on how to adopt a more physically active lifestyle.
215007485|NCT00932802|DRUG|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
215007486|NCT01967953|PROCEDURE|EVLP Group|"EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.~Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy"
215007487|NCT04938947|DEVICE|Blood Flow Restriction Cuffs|This intervention consists of inflatable cuffs that are designed to partially occlude veinous blood return from the lower extremities during resistance training.
215007488|NCT04938947|OTHER|Low-Intensity Resistance Training|This intervention consists of performing low-intensity bilateral (both legs at the same time) leg extensions using 30% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
215007489|NCT04938947|OTHER|High-Intensity Resistance Training|This intervention consists of performing high-intensity bilateral (both legs at the same time) leg extensions using 80% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
215096831|NCT07089212|DEVICE|Cyclic Compression Cryotherapy|"Initiation: Begin within 24 hours postoperatively. Each session lasts 20-30 minutes, administered 2-3 times daily.~Procedure: Apply a cryotherapy wrap circumferentially around the knee using a pneumatic compression device, with precise control of pressure and temperature.~Pressure Settings: Start at Level I-II (low-to-moderate) and adjust incrementally based on patient tolerance.~Temperature Control: Maintain at 10-12°C."
214402504|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus corticosteroid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of triamcinolone
214402505|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus hyaluronic acid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of hyaluronic acid
214402506|NCT03783455|PROCEDURE|Intraarticular injection of corticosteroid|Intraarticular injection containing 40 mg of triamcinolone acetonide.
214402507|NCT03783455|PROCEDURE|Intraarticular injection of hyaluronic acid|Intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
215007490|NCT06033664|BEHAVIORAL|Fresh Funds|Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.
215096832|NCT07089212|BEHAVIORAL|Conventional rehabilitation treatment.|The control group underwent a 12-week conventional rehabilitation program, which primarily included muscle strength training, endurance training, proprioception training, and joint range of motion (ROM) exercises. Assessments were conducted at baseline (before treatment), as well as at 2 weeks, 6 weeks, and 12 weeks post-treatment. The evaluated outcomes included knee joint ROM, muscle strength, knee function, pain levels, and activities of daily living (ADL).
215096833|NCT07089290|BEHAVIORAL|Nurse-led Telehealth Intervention|"Control group: Patients will receive standard care as per Nepal government guidelines. This includes lifestyle counseling (salt reduction, physical activity, avoiding tobacco/alcohol), antihypertensive medications based on BP and risk profile, and follow-up every 1-3 months. BP will be recorded at 3 and 6 months by research nurses.~Intervention group: Nurse-led telehealth care will be delivered over six months using the Intervention Mapping approach. Participants will receive initial orientation, a BP diary, and instructions to check BP at least twice weekly at nearby centers. Nurses will train local staff, and conduct teleconsultations via Viber/WhatsApp every 15 days (months 1-2) and monthly (months 3-6) covering BP review, adherence, and lifestyle advice. If \<75% of BP readings meet target, nurses will consult physicians for medication adjustments. Emergency protocols will be in place. Data will be collected at baseline, 3, and 6 months."
215096834|NCT07089381|DIETARY_SUPPLEMENT|Resveratrol 1 gm.|59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix, Egypt) (given as one 1000 mg tablets once daily) for 3 months.
214402508|NCT00723294|PROCEDURE|cryosurgery|
214402509|NCT00723294|PROCEDURE|therapeutic conventional surgery|
214402510|NCT02403674|DRUG|Doravirine, Tenofovir, Lamivudine|One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
214402511|NCT02403674|DRUG|ATRIPLA™|One ATRIPLA™ tablet taken q.d. by mouth
214402512|NCT02403674|DRUG|Placebo|Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
214402513|NCT01530009|DRUG|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
215007491|NCT03970512|DEVICE|Apioc-A and Apioc-S Contact Lenses|Appropriately fit, document and dispense a new spherical and toric contact lens design worn for up to 35 days.
214402514|NCT01530009|OTHER|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
214402515|NCT06191536|OTHER|Pilates|
215007492|NCT01305629|BEHAVIORAL|Spiritual Self-Schema Therapy|"The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life."
215007493|NCT04924790|BEHAVIORAL|COVID-19 Pandemic|Comparison of the intervention preferences of patients diagnosed with obstructive urinary stones in the urology clinic and recommended for intervention during and before COVID-19
215007494|NCT03967314|OTHER|TLIP block group (group T)|In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).
215007495|NCT03967314|OTHER|Wound infiltration group (group W)|In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
215007496|NCT02120079|DRUG|Lotemax|Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
215007497|NCT02120079|DRUG|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
215007498|NCT02120079|DIAGNOSTIC_TEST|In Vivo Confocal Microscopy (IVCM)|In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
215007499|NCT04184908|DRUG|gel xerostomia|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
215007500|NCT04184908|OTHER|gel placebo|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
215007501|NCT02242110|BEHAVIORAL|ERRT-Bipolar Disorder|The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
215007502|NCT02817204|BEHAVIORAL|Aerobic Exercise|Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
215007503|NCT02817204|BEHAVIORAL|Health Education|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
215096835|NCT07089381|DRUG|Methotrexate|59 patients will receive the standard treatment for management of RA for 3 months
215096836|NCT07089810|DEVICE|Digital intervention has a high blood pressure in the high-risk population of stroke Study on the effect of stress on self-management behavior of patients|"Intervention group (n = 60) : Interventions were developed for five behavioral problems, as follows:~1. Lack of knowledge about hypertension~   \- Measures: APP push knowledge (risk factors, medication, lifestyle, etc.), blood pressure monitoring teaching, monthly online lectures, regular feedback and encouragement of blood pressure data.~2. Poor medication compliance~   \- Measures: Medication reminders were set by the APP, and repeated and recorded when no medication was taken.~3. Obesity/overweight Targets: BMI 18.5-23.9, waist circumference \<90cm in men and \<85cm in women Interventions: promoting knowledge about the dangers of obesity, daily exercise reminders, setting weight loss goals and encouraging weight loss.~4. A high-sodium diet Target: \<6g salt per day~   \- Measures: Release of low-salt dietary guidelines (graphic and text) and distribution of salt-limiting spoons (1-2 grams).~5. Drinking too much Target: ≤25g alcohol per day for men and ≤15g for women; Weekly male ≤140g, female ≤80"
215096837|NCT07088926|BIOLOGICAL|AZD0292|AZD0292 high-dose or low-dose administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
215096838|NCT07088926|OTHER|Placebo|Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
215096839|NCT07087977|DEVICE|HoYAG laser|Patients will be randomly assigned (1:1) to HoYAG laser or TFL laser group for miniPCNL surgery according to standard of care.
214402516|NCT06191536|OTHER|Pelvic floor exercises|
215096840|NCT07087977|DEVICE|TFL laser platform|Patients will be randomly assigned (1:1) to HoYAG or TFL laser group for MiniPCNL surgery according to standard of care.
215096841|NCT07088445|DRUG|Faricimab|Intravitreal injection of 6mg famotizumab into the vitreous cavity of patients with non primary wet age-related macular degeneration
215096842|NCT07088198|PROCEDURE|Joshi's step|Patients will undergo dorsal onlay buccal mucosal graft urethroplasty with Joshi's step
214402517|NCT05708417|BEHAVIORAL|Lifestyle Intervention|"The intervention in SDOI has the predominantly focus on each individual reflection and realisation and is built upon ACT' six core processes: 1) Acceptance, 2) Cognitive defusion 3) Being present, 4) Self as context, 5) Values, and 6) Committed action.~The program is based on up to 13 times attendance within the 12 months intervention period."
214402518|NCT05708417|OTHER|Placebo|No lifestyle intervention within the study, only test/datacollection
214402519|NCT00826280|DRUG|regadenoson|IV
214402520|NCT00826280|DRUG|overencapsulated caffeine|oral
214402521|NCT00826280|RADIATION|technetium|IV
214402522|NCT00826280|DRUG|placebo|oral
214402523|NCT03831438|DRUG|AVID200|Intravenous infusion of AVID200 Q2 weeks for 3 doses
215007504|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
215007505|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
215007506|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
215007507|NCT02111356|DEVICE|Phinhole glasses|Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
215007508|NCT02786511|DRUG|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
215007509|NCT00236678|DRUG|Epoetin alfa|
215007510|NCT04941911|DRUG|Octreotide Acetate|Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.
215007511|NCT04941911|OTHER|Placebo|Sodium chloride 0.9% w/v
215007512|NCT04591132|DEVICE|kinematic analysis|motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
215007513|NCT02282033|DEVICE|The Moderato System|The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
215007514|NCT00933166|DEVICE|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
215007515|NCT01558570|PROCEDURE|Blood Draw|One time blood draw
215096843|NCT07088965|OTHER|16 / 5.000 survey application|Participants will be administered a self-administered questionnaire containing basic demographic information, questions on job profile and lifestyle practices, as well as the Standardized Nordic Questionnaire (SNA).
215007516|NCT05409638|BEHAVIORAL|Cognitive Behavioral Therapy to manage cancer-related fatigue|Participation will consist of attending 90-minute virtual groups for 4 consecutive weeks on cancer-related fatigue. During the 4 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework.
215007517|NCT04242134|DEVICE|Drug-coating balloon|Provisional stenting technique with DCB
214402524|NCT03789552|DRUG|T89 capsule|T89 capsules (75mg)
214402525|NCT03789552|DRUG|Placebo capsule|Placebo capsules (0mg)
214402526|NCT04135144|OTHER|Group 1 (printed materials)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
214402527|NCT04135144|OTHER|Group 2 (video phone reminder)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
214402528|NCT02360345|DRUG|ONX-0801|
214402529|NCT03201757|DRUG|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
214402530|NCT04778371|OTHER|Almonds|64 g total dry roasted, unsalted almonds per day for a total of 12 weeks
214402531|NCT04778371|OTHER|Placebo|200 g total calorie matched granola bar per day for total of 12 weeks
214402532|NCT05974826|BEHAVIORAL|the SI! Program for Secondary Schools (NCT03504059)|The SI! Program is implemented from 1st to 4th grade of Secondary Schools. A total of 12 hours of classroom intervention per academic year, organized through three educational units, and with active and participative methodologies, and complementary intervention in the family setting, at school and on teachers.
214504501|NCT05254392|DEVICE|Digital BP monitor (Chidalex®)|Interventions were provided in groups of 4 - 10 participants after data collection at baseline while reinforcing individualized interventions were provided during subsequent visits to the research clinic for follow-up at 6 months and 12 months. Medication reminder text messages were delivered to each participant biweekly.
215007518|NCT05683496|DRUG|lonigutamab|subcutaneous injection
215007519|NCT05683496|DRUG|Placebo|subcutaneous injection
215007520|NCT05334979|OTHER|Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic|"Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks."
215096844|NCT04676867|DRUG|Dalcetrapib|Dalcetrapib 300 mg Film-Coated Tablets
215096845|NCT04676867|OTHER|Placebo|Placebo Tablets
215096848|NCT07087756|PROCEDURE|laparoscopic ovarian suspension|Suspension of the ovary during laparoscopy for endometriosis
215096849|NCT07088952|PROCEDURE|Trigger at smaller folicular size|Trigger indicated at folicular diameter smaller than standard clinical practice, from 13mm to 16.9mm
214402533|NCT05974826|BEHAVIORAL|the Fifty-Fifty Program (NCT02367963)|"1. Training stage: the focus is on improving individual health, through workshops (given in person by experts), and on the challenges of changing habits supervised and supported by the SHE Foundation~2. Peer-to-peer support group sessions: It is designed to make the subjects participate actively in their healthcare. Along the sessions subjects propose assumable health goals. Participants will be able to view videos with key messages from the workshops to continue the sustainability of the changes made, and the development of new ones. Peer-to-peer support group sessions have two phases: a) leaders will receive support from the Foundation; b) participants will become agents of change with the people around them, and also in their municipality with specific actions to promote health. The role of Foundation's will only be to monitor and resolve possible doubts."
214402534|NCT06534463|OTHER|All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.|The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
214402535|NCT05098600|OTHER|Exposure of interest|Common autoimmune and atopic conditions consist of atopic dermatitis, allergic rhinitis, asthma, Crohn's disease, ulcerative colitis, Celiac disease, Pernicious anaemia, Type 1 diabetes, Autoimmune thyroiditis (Hashimoto's thyroiditis, Grave's disease, atrophic, unspecified), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Systemic lupus erythematosus, Sjogren syndrome, psoriasis, vitiligo, Multiple sclerosis
214402536|NCT06022809|BEHAVIORAL|Dada Kwa Dada (individual-level)|Dada Kwa Dada (DKD) intervention is an adapted version of Sister to Sister (S2S) intervention (a brief, health profession-led, individual-level intervention proven to increase condom use and decrease STIs among African American women). Intervention is a 1hr to 1.5hrs session and offered in English or French.
214402537|NCT06022809|BEHAVIORAL|DADA (group-level)|DADA intervention is an adapted version of Sisters Informing Sisters about Topics on AIDS (SISTA) intervention (a peer-led, group-level intervention proven to increase condom use and decrease STIs among African American women). This is a 6hrs intervention implemented in two three-hour sessions and offered in English or French.
214402538|NCT01551589|RADIATION|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV（primary tumor）：66-70Gy/33\~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33\~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33\~35F，once a day, 5 times per week.
214402539|NCT01551589|DRUG|docetaxel and cisplatin|Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
214402540|NCT01551589|RADIATION|Elective Nodal Irradiation (ENI)|The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
214402541|NCT06540287|OTHER|Observational|No intervention
214402542|NCT03327506|DRUG|Alprazolam 0.5 mg|alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
214402543|NCT01424163|DRUG|Single dose reduced|Treatment 1 (Part A)
214402544|NCT01424163|DRUG|Single dose standard|Treatment 2 (Part A)
214402545|NCT01424163|DRUG|Multiple Dose|Treatment 3 (Part A)
214402546|NCT01424163|DRUG|Multiple Dose|Part B
214402547|NCT01254305|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
214402548|NCT01254305|DRUG|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
214402549|NCT01254305|DRUG|Placebo|Matching placebo capsules, oral administration, once daily dosing
214504502|NCT01012063|DRUG|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
214504503|NCT01012063|DRUG|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
214504504|NCT03543631|OTHER|Survey|Online survey
214504505|NCT03707899|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
214504506|NCT03707899|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
215007521|NCT06406296|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
215007522|NCT06246955|BEHAVIORAL|Behavioral Intervention: Group Therapy Session|Attend virtual group therapy sessions
215096850|NCT07088328|DRUG|Pentoxifylline|Intravenous administration for 3 days
215007523|NCT06246955|OTHER|Survey Administration|Ancillary study
215007524|NCT03912519|PROCEDURE|Parallel placement of 16 gauge electrodes|Parallel technique
215007525|NCT03912519|PROCEDURE|Perpendicular placement with 22 gauge electrodes|Perpendicular technique
215096851|NCT07088328|OTHER|placebo distilled water|Intravenous administration for 3 days
215096852|NCT01628003|DEVICE|Brain MRI|Brain MRI
215096853|NCT01628003|DEVICE|MRI|Physical examination Neuropsychological testing Questionnaires
215096854|NCT04378231|DRUG|Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension|dry suspension of amoxicillin clavulanate potassium
214402550|NCT06418373|BEHAVIORAL|Get Ready with My Heart Program|"In the intervention group, adolescent CHD patients undergo a comprehensive assessment by cardiology and cardiothoracic experts to determine their suitability for transitional care management. Based on the Get Ready with My Heart Program, a personalized transition plan is developed, offering courses and resources that enhance self-management skills such as medication management, symptom monitoring, and health record maintenance. Throughout the transition period, regular support and follow-ups are provided to ensure that both patients and their families are adequately supported. The program includes regular assessments of transition readiness and quality of life changes to understand the intervention's impact and make necessary adjustments. Additionally, feedback is actively collected from patients and their families to continuously improve and refine the program."
214402551|NCT06418373|BEHAVIORAL|Conventional intervention|Adolescent CHD patients and their caregivers receive comprehensive health education and medical management. Upon admission, a detailed assessment of each patient's medical history and physical examination is conducted. A treatment and perioperative care plan is then tailored, including medication management with anticoagulants and antiarrhythmics, and surgery-related health guidance. Regular cardiac monitoring and follow-up assessments ensure treatment effectiveness and health status updates. Post-discharge, patients receive lifestyle management advice through remote consultations, focusing on diet and physical activity. Additionally, training on recognizing and managing emergencies is provided, equipping patients and caregivers to handle potential crises effectively. This holistic approach aims to improve both immediate and long-term health outcomes for adolescent CHD patients.
214402552|NCT05329389|DEVICE|StoneMD|StoneMD - is an app from App Store (for iOS) or Google Play (for Android).
214402553|NCT05329389|BEHAVIORAL|Schools of Patients|"The Schools for Patients with Urolithiasis is an online course for patients with urinary stone disease."
214402554|NCT05329389|BEHAVIORAL|Standard recommendation|Only fluid balance recommendations given at the day of discharge.
214402555|NCT01511536|DRUG|Cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: injection
214402556|NCT01511536|DRUG|Abiraterone acetate|Pharmaceutical form:tablets Route of administration: oral
214402557|NCT01511536|DRUG|Prednisone 5 mg|Route of administration: oral
214402558|NCT01800344|DEVICE|LMA|
214402559|NCT01800344|DEVICE|Ultra|Ultra
214402560|NCT02272465|OTHER|No intervention|Observational study
214402561|NCT00928460|PROCEDURE|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
214402562|NCT02357758|DRUG|Antibiotic Prophylaxis|Approved clinical dosage or antibiotics
214402563|NCT00688506|DEVICE|combined sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
214402564|NCT00688506|DEVICE|placebo therapy (Placebo Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
214504507|NCT02736422|OTHER|Hyperpolarised Xenon|Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
214504508|NCT03470805|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
215007526|NCT02787369|DRUG|ACY-1215|
215007527|NCT02787369|DRUG|Ibrutinib|
215007528|NCT02787369|DRUG|Idelalisib|
215007529|NCT05459532|DRUG|Molnupiravir 200 mg|The drug is orally bioavailable (and is indicated for treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. The recommended dose is 800 mg (four 200 mg capsules) taken orally 12-hourly for five days, and should be administered as soon as possible after diagnosis of COVID-19 has been made and within five days of symptom onset.
215007530|NCT03914703|PROCEDURE|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
215007531|NCT06183567|PROCEDURE|Sedoanalgesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under sedoanalgesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
215007532|NCT06183567|PROCEDURE|general anesthesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under general anesthesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
215007533|NCT05641363|DRUG|Ketorolac Tromethamine|ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.
215007534|NCT05844124|OTHER|Exercise for Knee Osteoarthritis Recommendations (Control group)|Patients in this group will receive available exercise recommendations of 150 minutes of moderate intensity exercise per week (30 minutes per day).
215007535|NCT05844124|OTHER|Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking)|Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise
215007536|NCT05844124|OTHER|Exercise for Knee Osteoarthritis - (Aquatic Walking)|Aquatic Walking exercise
215007537|NCT05621798|OTHER|Hearing Aid Manufacturer's Software|"When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software."
215007538|NCT05621798|OTHER|REM (Real Ear Measurements)|Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.
214402565|NCT01062984|PROCEDURE|Continuous Venovenous Hemofiltration (CVVH)|The NxStage system will be used for CVVH using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid will be delivered pre-filter for CVVH; the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
214402566|NCT01062984|PROCEDURE|Continuous Venovenous Hemodialysis (CVVHD)|The NxStage system will be used for CVVH and CVVHD using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid dialysate will be infused countercurrent to blood flow the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
214402567|NCT03696979|OTHER|Myofascial induction therapy|Myofascial induction therapy is a therapy concept focused on optimizing function and balance within the fascial system. The approach aims at global recovery, local correction and painless body use.
214402568|NCT03696979|OTHER|Therapeutic pain education|Therapeutic pain education is a training intervention that aims to reduce pain and disability by helping patients better understand the biological processes that support pain states. The neurobiology of pain and pain processed by the nervous system is explained to the patient in detail. Changes the patient's olab viewpoint to pain. For example, the patient believes that the cause of pain is caused by tissue damage. The patient who receives pain training understands that the cause of pain is the hypersensitive central nervous system. As a result, the patient's fear avoidance behavior decreases and he starts to move more easily. Because the sensitivity of the central nervous system will be alleviated, the perceived pain will decrease.
214402569|NCT03205020|DIAGNOSTIC_TEST|serum amyloid a test|"* Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.~* Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.~* The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University"
214402570|NCT04786886|OTHER|VIrtual Reality Visual Field Exam|Virtual reality visual field exam will be administered using the virtual reality headset. Exams can take up to 20 minutes.
214402571|NCT00353054|DRUG|Caltrate® 600 + D|
214402572|NCT00353054|BEHAVIORAL|Weight loss intervention|
214402573|NCT00105885|PROCEDURE|telephone care|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
214402574|NCT00740662|PROCEDURE|Distal gastric bypass|Distal gastric bypass
215096855|NCT04874090|OTHER|Acupuncture|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program
214402575|NCT02703532|BEHAVIORAL|CARE-CITE Education Program|"CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.~If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.~Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.~Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete."
215007539|NCT03034928|DEVICE|Contact lens with investigational coating 1|Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
215007540|NCT03034928|DEVICE|Balafilcon A contact lens|Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS
215007541|NCT03034928|DEVICE|OPTI-FREE® RepleniSH® MPDS|Multipurpose contact lens solution
215007542|NCT03034928|DEVICE|Contact lens with investigational coating 2|Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS
215007543|NCT02818803|OTHER|Propolis|
215096856|NCT04874090|OTHER|Exercises|Patient will perform neck exercises
215007544|NCT02818803|DRUG|Miconazole|
215007545|NCT01835756|DEVICE|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
215007546|NCT01835756|DEVICE|Placebo Laser|The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
215096857|NCT00549770|DRUG|LCZ696|
215096858|NCT00549770|DRUG|Valsartan|
215096859|NCT00549770|DRUG|AHU377|
215096860|NCT00549770|DRUG|Placebo|
215096861|NCT01916850|DRUG|LX4211 400 mg|
215096862|NCT01916850|DRUG|LX4211 800 mg|
215096863|NCT01916850|DRUG|LX4211 Placebo|
215096864|NCT04761484|PROCEDURE|Vascular access on admission|PIVC insertion
215096865|NCT02742311|PROCEDURE|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
214402576|NCT02703532|BEHAVIORAL|Traditional Education|Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
214402577|NCT02703532|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|"Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.~Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete."
214402578|NCT04547803|OTHER|Standard of Care|Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice
214402579|NCT04547803|OTHER|Video Visit|15-20 minute Video visit with an advanced practice provider (nurse practitioner or physician assistant) approximately 2-5 days after discharge.
214402580|NCT06148259|OTHER|International prostate symptom score|Questionnaire of 8 questions to be administered to all patients about prostate symptoms
214402581|NCT06148259|DIAGNOSTIC_TEST|Assessment of prostate volume|Measurements using ultrasound
214402582|NCT06148259|OTHER|Pittsburgh sleep quality Index|Questionnaire to assess quality of sleep
215007547|NCT05283447|OTHER|Osteopathic Medicine|The clinical protocol subject to analysis for the intervention group consists of manual approach techniques for the myofascial and viscerofascial structures of the anterior face of the neck, maneuvers for the mediastinal region, techniques for normalizing the tone of the thoracic diaphragm and its pillars, on the peritoneal ligaments, and caudal traction of the stomach for manual correction of hiatal hernia.
215007548|NCT05283447|OTHER|Control|The physiotherapeutic treatment on the control group consists of an approach to the lumbopelvic joint restrictions and a massage on the inframesocolic abdominal region with minimal pressure, which does not affect the activity and position of the stomach.
215007549|NCT06814054|DIAGNOSTIC_TEST|Carotid Artery Corrected Flow Time measurement|"* The cFT is defined as the time between the onset of systolic flow until closure of the aortic valve corrected for the HR and has been found to correlate with the intravascular volume.~* carotid ultrasound imaging will be performed 10 minutes before induction of general anesthesia in the preoperative holding area.~* Ultrasound measurements will be performed under a vascular setting with a 6.0 to 13.0MHz linear array transducer~* The right common carotid artery cFT will be measured in supine position with their heads tilted 30° to the left~* After that, a pulse wave Doppler will be chosen, and the sampling frame will be positioned at an angle of less than 60° in the region of the carotid artery with the best color flow to acquire the blood flow spectrum."
215007550|NCT06814054|DIAGNOSTIC_TEST|Inferior vena cava collapsibility index|"* The IVC will be examined while the patient has been spontaneously, quietly breathing and lying in the supine position for at least 5 min before assessment.~* A two-dimensional image of the IVC as it entered the right atrium will be obtained through the paramedian long-axis view via a subcostal approach using a curvilinear phased array probe (2-5 MHz)~* Then, using M-mode imaging produced at a medium sweep speed, changes in IVC diameter with breathing will be evaluated 2 to 3 cm distal to the right atrium.~* During the same respiratory cycle, measurements will be made of the IVC's greatest expiratory diameter (dIVC expiration) and lowest inspiratory diameter (dIVC inspiration). The formula IVCCI = (dIVC expiration - dIVC inspiration) × 100/dIVC expiration will be used to determine IVCCI as a percentage. (12)~* IVCCI will be assessed by the same trained anesthesiologist who was blinded to postin duction hemodynamic measurements."
215007551|NCT06495944|DRUG|Dazucorilant|75 mg soft gelatin capsules formulation for oral administration
215007552|NCT06495944|DRUG|Itraconazole|100 mg capsules for oral administration
215007553|NCT04095845|DEVICE|CO THA|Replacement of arthritic hip with artificial implant using CT-based navigation and conventional technique
215007554|NCT04095845|DEVICE|Mako THA|Replacement of arthritic hip with artificial implant using mako robotic-arm assist
215007555|NCT04242745|BEHAVIORAL|Intervention group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.~A Beyid wristwatch was used. This spoke the time in Turkish, every hour on the hour. In this way, the old people were reminded to drink a glass of liquid each hour. The watch had an alarm capability, and could be taken on to sleep mode at night in order not to wake the old people."
215007556|NCT04242745|BEHAVIORAL|Control group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes."
215007557|NCT04620538|DIAGNOSTIC_TEST|Breath Analysis|Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.
215007558|NCT02112552|DRUG|Paclitaxel|Given IV
215007559|NCT02112552|DRUG|Carboplatin|Given IP
215007560|NCT02112552|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
215007561|NCT02112552|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
215096866|NCT01940393|DRUG|Cetirizine|Drug administration
215096867|NCT01940393|DRUG|Desloratadine|Drug Administration
215096868|NCT01940393|DRUG|Fexofenadine|Drug administration
214402583|NCT06148259|DIAGNOSTIC_TEST|Glycated hemoglobin|Measures control of diabetes
215007562|NCT02112552|OTHER|Quality-of-Life Assessment|Ancillary studies
215007563|NCT02112552|OTHER|Laboratory Biomarker Analysis|Correlative studies
215007564|NCT00016172|DRUG|pegylated liposomal doxorubicin hydrochloride|
215096869|NCT01940393|DRUG|Ebastine|Drug administration
215096870|NCT01940393|DRUG|Bilastine|Drug administration
214402584|NCT03654989|DRUG|Treprostinil iontophoresis|We will administer treprostinil at increasing doses by a iontophoresis.
214402585|NCT03654989|DEVICE|Remodulin® placebo iontophoresis|"Placebo iontophoresis will be performed using Remodulin® placebo (United Therapeutics) delivered with Axion GmbH electrodes connected to a PeriIont generator (Perimed).~* Part 1: 1 administration/day, on separate days, with 72h between two doses. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~* Part 2: 1 administration/day for 10 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
215007565|NCT00016172|DRUG|picoplatin|
215007566|NCT00837447|DEVICE|Total knee replacement with NexGen CR knee prosthesis|comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis
215007567|NCT00837447|DEVICE|Total knee replacement(TKR) with Nexgen CR-flex|TKR using Nexgen CR-flex implant
215007568|NCT04384874|OTHER|Exercise therapy|A 12 week multi-stage exercise rehabilitation program
215007569|NCT05992038|PROCEDURE|Osteotomy with putty|Synthetic ceramic putty
215007570|NCT05992038|PROCEDURE|Conventional osteotomy|conventional osteotomy
215007571|NCT04021355|OTHER|Oral sodium supplementation|Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.
215007572|NCT06493942|OTHER|BioCoat® by Premier®|BioCoat is a 56% filled resin formula that provides added strength and excellent long-term resistance to wear ؤomparable to flowable composites.
215007573|NCT06493942|OTHER|UltraSeal XT™ plus by Ultradent|UltraSeal XT plus is a 58%-filled resin fluoride-releasing sealant. It is strong and has high wear resistant
215007574|NCT06169397|DRUG|XTMAB-16|XTMAB-16 infusion
215007575|NCT06312930|DEVICE|Transcranial pulse stimulation|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency)
215007576|NCT04752462|BEHAVIORAL|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
215007577|NCT05311969|OTHER|cognitive evaluations and non cognitive evaluations|"Cognitive evaluations with executive functions evaluations :~* Mini Mental State Examination~* Stroop Victoria Test~* Hayling test~* Frontal Assessment Battery test mental flexibility:~* Trial Making Test (TMT) A and B~* Connection test~* Alphaflex test~* Verbal and visuospatial working memory~* Wechsler Adult Intelligence Scale (WAIS) span~* Visuo-spatial span~* Visuo-spatial span simplified version~* Month Of the Year Backwards (MOTYB) Planning~* Tinker Toy test~* Clock Test~Non-cognitive evaluations:~The Katz Autonomy Scale Neuropsychiatric Inventory version Care team Geriatric Depression Scale 15-item version Apathy inventory"
215007578|NCT04465955|BIOLOGICAL|NGM621|NGM621 Dose 1
215007579|NCT04465955|BIOLOGICAL|NGM621|NGM621 Dose 2
215096871|NCT04578925|BEHAVIORAL|Happy, Healthy, Loved|A text message based, mobile-device delivered intervention that provides educational information to primiparous mothers and their partners about breast-feeding and coping with stress.
215096872|NCT02207257|DRUG|PER977|Reversal of edoxaban-induced anticoagulation
215096873|NCT02207257|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
215096874|NCT02207257|DRUG|Edoxaban|
215096875|NCT00348647|BEHAVIORAL|physical training program to prevent injuries|
214402586|NCT03941301|DEVICE|Light therapy|Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
214402587|NCT05470062|DEVICE|arch support insoles (FootDisc)|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
215007580|NCT04465955|OTHER|Sham Comparator|Sham Comparator
215007581|NCT01587404|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter (including Surround Flow)|Variable contact force as measured at the catheter tip within the left atrium
215007582|NCT05354947|DEVICE|Ultrasound Delivery|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.
215007583|NCT00410527|DRUG|Merrem|
215007584|NCT03959319|OTHER|Movement Pattern Training|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
215007585|NCT03959319|OTHER|Manual Therapy|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
215007586|NCT01102283|DEVICE|Evolution(R) Colonic Stent|Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
215007587|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) and dentin (15sec) etching with phosphoric acid~4. Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~5. Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~6. Finishing and polishing"
215007588|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~4. Composite-resin application using a transparent cervical matrix and curing for 40sec~5. Finishing and polishing"
215096876|NCT03001687|DIETARY_SUPPLEMENT|enteral supplementation with vitamin D|"Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)"
215096877|NCT03001687|OTHER|blood collection 3mL|all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
214402588|NCT05481034|DEVICE|SMA bolus option|SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.
214402589|NCT05481034|DEVICE|Exactly estimated carbohydrate content bolus option|The carbohydrate content of meals is estimated in grams of carbohydrates prior to a meal bolus
214402590|NCT03980756|DRUG|AD-206 20mg|1 tablet administered before the breakfast during 7 days
214402591|NCT03980756|DRUG|Esomeprazole 20mg|1 tablet administered before the breakfast during 7 days
214402592|NCT03980756|DRUG|AD-206 40mg|1 tablet administered before the breakfast during 7 days
214402593|NCT03980756|DRUG|Esomeprazole 40mg|1 tablet administered before the breakfast during 7 days
214402594|NCT01426815|DRUG|Placebo|The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
214402595|NCT01426815|DRUG|Golimumab|The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
214402596|NCT03239210|DRUG|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
214402597|NCT03239210|DRUG|Placebo|placebo equivalent
214402598|NCT02664220|DRUG|Povidone-iodine irrigation|"Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister."
214402599|NCT02664220|PROCEDURE|No irrigation|Patients allocated to the control group will not undergo intra-abdominal irrigation.
214402600|NCT01841840|OTHER|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
214402601|NCT01841840|OTHER|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
214402602|NCT06502015|DIAGNOSTIC_TEST|biomaker levels|this study will discover and validate novel biomarkers (including blood, feces, bone marrow and lymph nodes etc al) of various neurological autoimmune diseases
214402603|NCT06192706|DEVICE|Foldax Tria Aortic Valve|Aortic Valve Replacement
214402604|NCT06200038|OTHER|Mulligan Reverse Natural Apophysial Glide Technique (RNAGS)|"Mulligan mobilization techniques was applied to the upper thoracic segments with the RNAGS technique. The application was performed with one hand (thumb in extension, other fingers flexed) that was used to perform the pushing maneuver on the transverse processes, while the other arm was used to gently grasp the head of the patient and recline the neck against the body for stabilization.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist."
214402605|NCT06200038|OTHER|Conventional physical therapy and sham manual therapy|"A sham Mulligan RNAGS technique with low pressure compression was applied to thoracic region.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist."
214402606|NCT06200038|OTHER|Conventional physical therapy|Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist
215096878|NCT00028886|BIOLOGICAL|filgrastim|
215096879|NCT00028886|BIOLOGICAL|recombinant interferon alfa|
215096880|NCT00028886|DRUG|cyclophosphamide|
214402607|NCT06085196|BEHAVIORAL|Mindful walking activity|Participate in 24 sessions of outdoor mindful walking on a local walking trail over three months
214402608|NCT05692843|DRUG|Cyclosporin A|"Once the patient is included in the clinical trial their therapeutic management will be carried out according to usual clinical practice, but additional procedures will be performed:~1. The frequency of follow-up visits will be increased in order to collect data related to clinical efficacy, safety and quality of life;~2. Biological samples will be obtained (blood and urine) for biochemical, kinetic, pharmacogenetic and immunological biomarker analysis to identify variables associated to CsA treatment."
214402609|NCT05692843|OTHER|Follow-up of Cyclospoin treatment already started|"If the patient is receiving cyclosporine therapy, a blood sample for pharmacogenetic analysis will be obtained at screening; also, at discretion of the treating physician, biological samples will be obtained (blood and urine) in this visit and in the follow-up visits to assess biochemical and kinetic variables. Clinical data (scales) will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.~If the patient received cyclosporine previously but is no longer under CsA therapy, a blood sample will be extracted at screening for pharmacogenetic analysis. Clinical data (scales) will be collected from clinical records."
214402610|NCT05764317|DRUG|Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
215096881|NCT00028886|DRUG|dexamethasone|
215096882|NCT00028886|DRUG|doxorubicin hydrochloride|
215096883|NCT00028886|DRUG|melphalan|
215096884|NCT00028886|DRUG|thalidomide|
215096885|NCT00028886|DRUG|vincristine sulfate|
215096886|NCT00028886|PROCEDURE|bone marrow ablation with stem cell support|
215096887|NCT00028886|PROCEDURE|peripheral blood stem cell transplantation|
215096888|NCT01209221|DRUG|Placebo - MAD|Once or twice daily doses of matching placebo to RO5271983 for 14 days
215096889|NCT01209221|DRUG|Placebo - SAD|Single dose of matching placebo to RO5271983 for up to 3 periods
215096890|NCT01209221|DRUG|RO5271983 - MAD|Once or twice daily doses of RO5271983 for 14 days
215096891|NCT01209221|DRUG|RO5271983 - SAD|Single dose of RO5271983 at each period (for up to 3 periods)
214402611|NCT05764317|DRUG|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
215007589|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) etching with phosphoric acid~4. Application of AdheSE One and curing for 10sec~5. Composite-resin application using a transparent cervical matrix and curing for 40sec~6. Finishing and polishing"
215007590|NCT06473129|BEHAVIORAL|Food for Life Culinary Workshops|Whole food, plant based 2hr workshop, which includes background information on diabetes, how to shop for food, etc and then a culinary demonstration and tasting of whole food, plant based dishes.
215007591|NCT02286674|OTHER|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
215007592|NCT03090269|DRUG|Methylphenidate Pill|3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
215007593|NCT05399355|DEVICE|Active Pulsed Shortwave Treatment with BioElectronics Model 088|Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
215007594|NCT05399355|DEVICE|Sham Treatment|Application of 7-30 days of a nonfunctional sham device(s)
215007595|NCT00849329|DRUG|lapatinib|1250mg lapatinib
215007596|NCT00849329|DRUG|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
215007597|NCT05573282|OTHER|Regorafenib combine with ICIs|Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W
215007598|NCT05442632|DRUG|Hetrombopag|The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day
215007599|NCT05442632|DRUG|Placebo|The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
215007600|NCT01015196|DRUG|Zavedos|
215007601|NCT01015196|DRUG|Cerubidine|
215096892|NCT01656694|DEVICE|DePuy Sigma HP Partial Knee|
214402612|NCT05764317|DRUG|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
215096893|NCT01105156|BEHAVIORAL|VEW Questionnaire|Patient Self reported questionnaire filled in.
215096894|NCT01079936|DRUG|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
214402613|NCT05095155|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
214402614|NCT06629623|OTHER|No intervention|No intervention
214402615|NCT01363947|DRUG|DNIB0600A|Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
214402616|NCT00355667|DRUG|furosemide|Patients with chronic heart failure receive furosemide and other standard treatment/
215096895|NCT01079936|DRUG|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
215096896|NCT01079936|PROCEDURE|Stem Cell Infusion|Stem cell infusion on Day 0.
214402617|NCT00355667|DRUG|azosemide|Patients with chronic heart failure receive azosemide and other standard treatment.
214402618|NCT02677246|DRUG|Denosumab|"Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils \> 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab"
215007602|NCT03501277|DRUG|Alogliptin|Alogliptin tablets.
215007603|NCT03501277|DRUG|Pioglitazone|Pioglitazone tablets.
215007604|NCT03501277|DRUG|SYR-322-4833 BL|SYR-322-4833 BL FDC tablets.
215007605|NCT03608332|DEVICE|diaphragmatic ultrasound|Diaphragmatic excursion; Diaphragmatic movement will be measured with a 3.5-MHz US probe (Mindray machine, DC-N6).
215007606|NCT06210295|COMBINATION_PRODUCT|Laboratory investigtions|To study causes of anemia in SLE in our environment and causes of refractory type and its relation to bone marrow affection and different drugs used in SLE
215007607|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
215096897|NCT05215158|DRUG|Dexmedetomidine|to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
215096898|NCT00665236|OTHER|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
215096899|NCT00665236|PROCEDURE|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
215096900|NCT00358839|DRUG|CGRP|
215096901|NCT06047496|BEHAVIORAL|Time restricted eating|Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period.
215096902|NCT05061628|DRUG|JS006 as Monotherapy|"1. JS006 as Monotherapy dose-escalation: JS006, 18/ 60/ 180/ 600/ 1800mg, IV infusion, every 3 weeks (q3w).~2. JS006 as Monotherapy dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w)."
215096903|NCT05061628|DRUG|JS006 in combination with Toripalimab|"1. JS006 in combination with Toripalimab dose-escalation: JS006, 2 or 3 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~2. JS006 in combination with Toripalimab dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~3. JS006 in combination with Toripalimab indications expansion: JS006, RP2D, IV infusion, every 3 weeks(q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w)."
214402619|NCT01403987|BEHAVIORAL|Residency Program Teaching|The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.
214402620|NCT01403987|BEHAVIORAL|Lecture|During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.
215007608|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
215007609|NCT01419925|BIOLOGICAL|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
215007610|NCT01419925|BIOLOGICAL|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
215096904|NCT05954429|DRUG|serplulimab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10"
215096905|NCT05954429|DRUG|Fruquintinib|5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
215096906|NCT00898391|OTHER|laboratory biomarker analysis|Correlative studies
215007611|NCT01419925|BIOLOGICAL|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
215007612|NCT01419925|BIOLOGICAL|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
215096907|NCT00898391|GENETIC|polymerase chain reaction|Correlative studies
215096908|NCT00898391|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
215096909|NCT00898391|GENETIC|DNA analysis|Correlative studies
215096910|NCT04556422|OTHER|Aerobic exercise|15 minutes of aerobic exercise using stationary bicycle
215096911|NCT04556422|OTHER|Sauna bathing|Passive heat exposure
215096912|NCT04293302|OTHER|No intervention|No intervention
215096913|NCT03446417|DRUG|ZN-e4|Oral dose, tablet, daily dosing
215096914|NCT03936647|PROCEDURE|surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
215096915|NCT03936647|DEVICE|WEB embolization device|WEB embolization device
215096916|NCT00002020|DRUG|Zidovudine|
215096917|NCT05308771|DEVICE|VPC syringe|Use of the visual pressure control syringe for epidural space detection
215096918|NCT02667782|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
215096919|NCT02667782|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
215096920|NCT04946617|DRUG|undefined|Rinsing with mouthwashes
215096921|NCT04989647|RADIATION|No adjuvant therapy|Patients will not receive any type of adjuvant therapy.
215096922|NCT04989647|RADIATION|Adjuvant radiotherapy|Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
215096923|NCT00548717|DRUG|Sirolimus|
215096924|NCT00548717|DRUG|Mycophenolate mofetil|
215096925|NCT00548717|DRUG|Bortezomib|
215096926|NCT04151277|DRUG|FOLFOX-A|Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
215096927|NCT04151277|DRUG|Gemcitabe and Abraxane|Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4
215096928|NCT04151277|DRUG|G-CSF|Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
215096929|NCT01407796|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|
215096930|NCT01407796|DRUG|[18F](+/-)NOS|
215096931|NCT03587753|OTHER|Dietary fatty acid partitioning|There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
215096932|NCT02759224|DRUG|BRI-1501|
215096933|NCT02759224|DRUG|Lafutidine|
215096934|NCT02759224|DRUG|Irsogladine maleate|
215096935|NCT01430676|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
215096936|NCT00821912|DRUG|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
215096937|NCT00821912|DRUG|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
214402621|NCT01403987|OTHER|Pocket Card Reference|A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.
214402622|NCT01403987|BEHAVIORAL|Pager|"The intensive education arm will be given a pager number at their initial meeting that they can use to call for personal assistance with performing paracentesis. Since a paracentesis is frequently referred to by housestaff as a tap, the pager number will correlate with the letters, TAPS, or #8277. The goal of the pager is to provide supervision and individual teaching so that the care provider can become proficient in the procedure."
215096938|NCT06216314|OTHER|Heart rate (HR)|Runners ran according to speeds and HR associated with ventilatory thresholds. Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold.
215096939|NCT06216314|OTHER|Race pace based approach (RP)|"Runners ran respecting three intensity zones.~The average speed achieved in the 7-km was calculated. From this, three intensity zones were calculated, adhering to the % of the race pace of the 7-km test.~Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace"
214402623|NCT04937075|OTHER|No intervention|No intervention
215007613|NCT01327703|DRUG|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
215007614|NCT01327703|DRUG|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
215007615|NCT01131585|PROCEDURE|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
215007616|NCT01131585|DRUG|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
215007617|NCT01131585|DRUG|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
215007618|NCT05914285|DRUG|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
215007619|NCT05914285|DRUG|2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline|After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
215007620|NCT03833258|BEHAVIORAL|Rehabilitation with no precautions|Patients will recover from total hip replacement surgery being guided by pain only and not by the precautions imposed upon them by clinicians.
215007621|NCT00812097|DEVICE|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
215007622|NCT00927082|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
215007623|NCT00004785|DRUG|dexamethasone|
215007624|NCT00004785|DRUG|methylprednisolone|
215007625|NCT00317369|DRUG|OPC-6535(Tetomilast)|
215007626|NCT06319196|DRUG|Opdualag|Opdualag vial IV every 4 weeks (Q4W)
215007627|NCT06319196|DRUG|Nivolumab|Nivolumab 480mg IV Q4W
215007628|NCT03516981|BIOLOGICAL|Pembrolizumab|200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
215007629|NCT03516981|BIOLOGICAL|Favezelimab|200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
215007630|NCT03516981|DRUG|Lenvatinib|20 mg lenvatinib capsules administered orally once daily
215007631|NCT03516981|DRUG|Quavonlimab|Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
215007632|NCT06549543|OTHER|High Intensity Laser Therapy|HILT is applied per session, with a maximum of 10.0 W, a mean of 5.7 W, a dose of 99 J/cm², and a total energy flux of 2079 J were applied over 6 minutes and 5 seconds on a 21 cm² field on the medial aspect of the knee joint.
215007633|NCT06549543|OTHER|Transcutaneous Electrical Nerve Stimulation|TENS is an analgesic modality of physical therapy
215007634|NCT06549543|OTHER|Hotpacks|Hotpacks is a thermoanalgesia modality of physical therapy
215007635|NCT06549543|OTHER|SHAM - High Intensity Laser Therapy|for control group, sham HILT was applied, with lights on but no laser beam
215007636|NCT03108690|DRUG|Continuous infusion of beta-lactam antibiotics .|Beta-lactam antibiotic will be administered as continous infusion.
215007637|NCT03108690|OTHER|Therapeutic drug monitoring of beta-lactam antibiotics.|Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.
215007638|NCT03062839|DRUG|Melatonin 5 mg|Melatonin 5 mg taken 30 minutes before bed time
215096940|NCT06216314|OTHER|Heart rate + heart rate variability (HRV)|Runners completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. High-intensity training was performed only under optimal HRV conditions, thus only when each participant had HRV values in their reference range. If HRV was not optimal, low-intensity training was prescribed. If HRV was not optimal for two days consecutively, rest was prescribed.
215096941|NCT01968577|DRUG|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
215096942|NCT02496923|DEVICE|High flow nasal oxygen therapy (Optiflow™)|
215096943|NCT02496923|DEVICE|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
215096944|NCT01723540|PROCEDURE|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
215096945|NCT03459053|BEHAVIORAL|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
215007639|NCT01656746|PROCEDURE|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
215007640|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
215007641|NCT01704859|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
215007642|NCT01704859|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
215096946|NCT00275977|PROCEDURE|Coronary catherization and stem cell infusion|
215007643|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
215007644|NCT00890318|DRUG|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
215007645|NCT00890318|OTHER|ketoconazole|Tablet, see Arm Description for intervention information.
215007646|NCT00890318|DRUG|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
215007647|NCT02154659|DEVICE|24hr pH monitoring|
215096947|NCT01302054|DRUG|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
215096948|NCT01302054|DRUG|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
215096949|NCT01945684|DRUG|Botulinum toxin type A|Maximum dose 360 U
215096950|NCT02463864|OTHER|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
215096951|NCT02463864|OTHER|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
215096952|NCT00847015|DRUG|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
215096953|NCT00847015|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m\^2
215096954|NCT00847015|DRUG|cisplatin|cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.
215007648|NCT05331898|BEHAVIORAL|Education|the education given increased the rational drug use of the parents.
215007649|NCT00819195|DRUG|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
215007650|NCT05133570|DEVICE|vista care|Prospective, open-label, multi-centre study evaluating the performance of the VistaCare® wound healing device in routine practice.
215007651|NCT03432429|OTHER|REIMS iKnife|Use of REIMS iKnife in breast conserving surgery
215007652|NCT00849472|DRUG|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
215007653|NCT00849472|DRUG|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
215007654|NCT00849472|PROCEDURE|surgery|neoadjuvant surgery for breast cancer
215007655|NCT00849472|DRUG|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
215007656|NCT02173951|DRUG|Deferiprone|"in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat \> 90 % and or LPI \> 0.6 will start deferiprone 75 mg/kg/d"
215007657|NCT06465901|OTHER|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
215007658|NCT06465901|OTHER|Intraoperative wound wash (e.g. Granudacyn)|Intraoperative wound wash (e.g. Granudacyn)
215096955|NCT02809053|BIOLOGICAL|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
215096956|NCT02809053|BIOLOGICAL|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
215096957|NCT03323606|BEHAVIORAL|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
214402624|NCT00825474|OTHER|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
214402625|NCT00180440|DEVICE|ICD|all models of Guidant/Bsc ICD's
214402626|NCT00310713|BIOLOGICAL|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
214402627|NCT00237367|DRUG|rabeprazole and pantoprazole|
214688226|NCT06929520|BEHAVIORAL|ENDS Prevention Intervention (TBD)|The ENDS Prevention Intervention will consist of (1) a modular classroom curriculum with ENDS-focused lessons and lessons covering alcohol, tobacco, and other drug use; (2) social media content that is related to the classroom curriculum and video content, and (3) a print media campaign across school campuses on Hawaii Island.
215007659|NCT06465901|OTHER|DACC surgical wound dressing (e.g. Leukomed Sorbact)|DACC surgical wound dressing (e.g. Leukomed Sorbact)
215007660|NCT02918799|BEHAVIORAL|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
215007661|NCT06141681|OTHER|photoplethysmography|Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.
215096958|NCT03323606|BEHAVIORAL|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
215096959|NCT01872442|DRUG|Dasatinib|"Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes \> 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
215096960|NCT01872442|DRUG|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
214402628|NCT00751790|DRUG|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
214402629|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
214402630|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST & FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~3. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
214522666|NCT05095506|OTHER|eHealth Intervention|The intervention platform is interactive, and uses multimedia-assisted components. The system uses three SCI-QOL computer-adaptive tests (CATs) to assess depression, anxiety, and resilience; cut scores are used to tailor multi-media content that specifically addresses users' emotional health concerns.
214522667|NCT05095506|OTHER|Active Control Condition|The active control condition is a static site that displays symptom assessments followed by one educational video each week. These videos, which play in a predetermined order, provide education about managing physical health in individuals with SCI.
214522668|NCT03441750|DRUG|metformin|Metformin tablets will be administrated in the experimental arm.
214522669|NCT03441750|OTHER|Standard lifestyle intervention|"Standard lifestyle advice will be united for all subjects by providing special booklet.~* All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.~* The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.~* Moderate intensity physical activity (150 minutes per week) is recommended.~* Smoking cessation is encouraged for the smoker.~* Excessive alcohol intake is encouraged to avoid."
214522670|NCT06329011|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
214402631|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
214402632|NCT01614756|BIOLOGICAL|BMS-981164|
214402633|NCT01614756|BIOLOGICAL|Placebo matching with BMS-981164|
214402634|NCT00917254|DRUG|YM150|oral
214402635|NCT00917254|DRUG|Placebo|oral
214402636|NCT00917254|DRUG|Enoxaparin|injection
214402637|NCT01276535|DEVICE|Erchonia MLS + Erchonia THL|"The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.~The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.~Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.~The intent is to evaluate the effectiveness of Erchonia MLS \& Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL"
214402638|NCT04215744|BEHAVIORAL|Ice water immersion|Ice water immersion of the left hands
214402639|NCT00482105|OTHER|EGIR Tape|Tape stripping is a non-invasive method that allows the recovery of cells
214402640|NCT04871087|DEVICE|Green Light|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~It is not an implant It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
215007662|NCT00902967|DRUG|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
214402641|NCT01591395|PROCEDURE|laparoscopic total extraperitoneal hernia repair (single port vs. multiport)|comparison of single port laparoscopic TEP and multiport laparoscopic TEP repair for adult inguinal hernia
214402642|NCT02988375|BEHAVIORAL|dCBTI|
214402643|NCT02988375|BEHAVIORAL|Sleep Education|
214402644|NCT01147549|DRUG|[C14]AZD9668|Oral Solution 60 mg Single Dose
215007663|NCT00902967|DRUG|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
215007664|NCT00825175|BEHAVIORAL|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
215007665|NCT00825175|DEVICE|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
215007666|NCT03544164|OTHER|Manual Ventilation|Manual ventilation via endotracheal tube using adult manual resuscitation device
215096961|NCT05115747|OTHER|weight off-loading aerobic exercise training.|"Mild to moderate intensity weight off-loading aerobic exercise training on the anti-gravity Alter-G treadmill. (speed 8-12 mph, 50%-70% heart rate reserve HRR, 12-16 score on the Borg's scale)"
215096962|NCT06143033|OTHER|DIME Beauty Luminosity Eye Serum|Test product contains: Water/Aqua, Organic Aloe Vera Juice, Lycium Barbarum (Goji Berry) Fruit Extract, Vitis Vinifera (Grape Seed) Extract, Cucumis Sativus (Cucumber) Extract, Glycerin, Niacinamide, Squalane, Camellia Seed Oil, DL-Panthenol (Vitamin B5), Carbomer, Sodium Hyaluronate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Phenoxyethenol, Caprylyl Glycol, Acacia Senegal Gum, Caffeine, Helianthus Annuus (Sunflower) Seed Oil, Malus Domestica (Apple) Fruit Stem Cell Extract, Argania Spinosa (Argan) Sprout Stem Cell Extract, Tetrahexyldecyl Ascorbate (Vitamin C), Acetyl Tetrapeptide, Acetyl Hexapeptide-8, Vitamin E Mixed Tocopherols, Sodium Hydroxide.
215096963|NCT03958708|DRUG|Rifaximin 550 MG|Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
214402645|NCT00537862|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
214402646|NCT06275880|OTHER|Intra-articular infiltration of PVP Collagen|Intra-articular collagen injection plus physiotherapy program
214402647|NCT06275880|OTHER|Rehabilitation|Patients who received conservative treatment through rehabilitation with a home program for one month
215007667|NCT05132946|PROCEDURE|Nerve block|unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
215007668|NCT04424680|BEHAVIORAL|Advanced Care Planning program of health decisions|Application of an Advanced Care Planning program program for decision-making in patients with advanced Heart Failure, in comparison to usual follow up and care.
215007669|NCT05433350|DRUG|Acoziborole|"Two different mode of administration will be used during the study depending on the body weight and on the step of the study:~whole tablets of 320 mg dose for paediatric patients weighing 30 to 40 kg in step 1 whole or crushed tablets for paediatric patients weighing 10 to 40 kg in step 2"
215007670|NCT04373525|OTHER|Genome analysis|Venous blood will be obtained for later genome analysis
215007671|NCT06436924|DEVICE|Left Atrial Appendage Device Implant|The Watchman Device is implanted into the left atrial appendage and is designed to close it off and keep blood clots from escaping that area.
215007672|NCT01767415|DRUG|Indigo carmine|During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
215007673|NCT00564239|BEHAVIORAL|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
215007674|NCT00564239|BEHAVIORAL|Cognitive Behavioral Group Therapy|12 children group sessions
214402648|NCT04514042|PROCEDURE|Peroral endoscopic myotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as peroral endoscopic myotomy. All the procedures will be documented with photographs or videorecordings.
214402649|NCT04514042|PROCEDURE|Flexible endoscopic septotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as flexible endoscopy septotomy. All the procedures will be documented with photographs or videorecordings.
215007675|NCT00338078|DEVICE|nocturnal oxygen treatment from oxygen concentrators|
215007676|NCT04530851|PROCEDURE|ERAS|"* Counseling~* H2- antagonist and metroclopramide for prevent aspiration~* Drink clear liquid until 2 hour before surgery~* First generation cephalosporin in 60 minute before surgery~* Clorhexidine for skin cleansing and Povidine for vaginal cleansing~* Regional anesthesia~* Keep warming~* Blunt expansion of uterine incision~* Do not peritoneal suture and subcuticular suture if less than 2 cm~* Local wound anesthesia.~* Paracetamol and NSAIDs for for pain control~* Early remove catheter and ambulation~* 5-HT3 antagonist for prevent nausea"
214402650|NCT01822158|OTHER|Vaginal Delivery Debrief Checklist|Participating team members will utilize Vaginal Delivery Debrief checklist
214402651|NCT00568347|DRUG|fluticasone 100mcg/ salmeterol 50mcg|inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
214402652|NCT00568347|DRUG|fluticasone 250/salmeterol 50|inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
215096964|NCT00938522|DRUG|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
214402653|NCT00568347|DRUG|salmeterol|salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
214402654|NCT00568347|DRUG|Salmeterol|salmeterol 50mcg bid X 3months
214402655|NCT00568347|DRUG|salmeterol and fluticasone propionate|salmeterol 50mcg/fluticasone 250mcg by DPI bid
214402656|NCT05971641|OTHER|progressive relaxation exercise|Patients who undergo total knee replacement surgery in the experimental group will be taught progressive relaxation exercises. The exercise will last for 30 minutes and will be applied twice a day. Patients will wear a smart wristband. Patient Information Form, Numeric Rating Scale, Richard Campbell Sleep Quality Survey, and Postoperative Recovery Index Scale will be administered. The scales will be filled out for 5 days and will take approximately 10-15 minutes.
214402657|NCT02377219|OTHER|hormonal and blood analysis|
214402658|NCT03676556|DRUG|Lidocaine|Two sterile gauzes will be dampen with the content of the syringe (20ml lidocaine 0.5%) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
214402659|NCT03676556|DRUG|Saline Solution|Two sterile gauzes will be dampen with the content of the syringe (20ml saline serum) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
215007677|NCT06963671|BEHAVIORAL|Blood Flow Restriction|The treatment group will receive standard rehabilitation as a home program plus low-load resistance training with BFR application while at the hand therapy clinic for their appointments
215007678|NCT05933460|DIETARY_SUPPLEMENT|dietary supplement with probiotics, prebiotics, magnesium and saffron extract|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Saffron extract 28mg was administered 3 times per day
215007679|NCT05933460|DIETARY_SUPPLEMENT|dietary supplement with probiotics, prebiotics, magnesium|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg was administered 3 times per day
215007680|NCT06183190|OTHER|No intervention|No intervention
215007681|NCT04892277|BIOLOGICAL|Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563|Given IV
215007682|NCT04892277|DRUG|Bendamustine|Given IV
215096965|NCT00938522|DRUG|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
215096966|NCT00084149|DRUG|Abacavir sulfate, Lamivudine, and Zidovudine|antiretroviral therapy
215096967|NCT00084149|DRUG|Lopinavir/Ritonavir|antiretroviral therapy
215007683|NCT04892277|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
215007684|NCT04892277|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215096968|NCT01856621|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
215096969|NCT01856621|DRUG|Seretide Diskus|2 inhalations as a single dose
215096970|NCT01856621|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
215007685|NCT04892277|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214402660|NCT00502281|DRUG|highly purified urinary FSH|
214402661|NCT00502281|BEHAVIORAL|timed intercourses, intrauterine insemination|
214402662|NCT05864768|DIETARY_SUPPLEMENT|Vegan/vegetarian diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
214688227|NCT06930001|OTHER|Etamine Application Group /Intervention|Before the intervention, students in the intervention group will complete the Informed Consent Form, Personal Information Form, Perceived Stress Scale, and Attitudes Towards Learning Scale (pre-test). In the first week, a 45-minute etamine training (history, tools, basic techniques) will be given individually by the scholarship holder (Şeyma Demir). Techniques such as threading, knotting, and cross-stitching will be taught, and students will apply a simple pattern, correcting mistakes. Room conditions (21℃) and student comfort will be ensured, with restricted access. One week later, students will practice weekly for 3 weeks (45 minutes each) using the Etamine starter set. In week five, the project manager will provide 2 hours of theory and 4 hours of practical episiotomy training. Students will then be assessed with the Episiotomy Repair Skill Form (post-test). Final evaluations will include the Perceived Stress Scale and Attitudes Towards Learning Scale (post-test).
214688228|NCT06933381|DEVICE|Vapocoolant spray|Pain Ease will be used per manufacturer instruction, applying the spray for 5 seconds or until the skin turns white, whichever occurs first.
215007686|NCT04892277|PROCEDURE|Computed Tomography|Undergo CT
214688229|NCT06933381|OTHER|Placebo|Nature's Tears will be applied to the arm as a placebo spray
215007687|NCT04892277|DRUG|Cyclophosphamide|Given IV
215007688|NCT04892277|DRUG|Fludarabine|Given IV
215007689|NCT04892277|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215007690|NCT04892277|PROCEDURE|Positron Emission Tomography|Undergo CT/PET
215007691|NCT00572481|PROCEDURE|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
215007692|NCT05853887|BEHAVIORAL|iNUDGE|Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.
215007693|NCT00661440|DRUG|Neramexane mesylate|2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
215007694|NCT05890820|OTHER|Preoperative nutritional assessment|Preoperative nutritional assessment and postoperative pulmonary complications
215007695|NCT05503069|BEHAVIORAL|Interventions with social and cultural components|"Intervention Components~* Enrollment: We are expecting an enrollment rate of 20 participants per week, and completing enrollment in 6 weeks (n=120 participants)~* Baseline Data Collection~* Distribution of Educational Materials~* Lactation Training~* Dietary Literacy Training~* Follow Up Data collection: Infant's information on growth and development and Medical History of Infections, GI problems (diarrhea, constipation, colic, vomits, reflux) will be collected at 3, 6 and 12 months.~* Follow UP Surveys: Mothers will complete a short survey at 3, 6, and 12 months exploring their breastfeeding behaviors and challenges.~* Exit survey: Mothers will be asked to complete an exit survey on month 12 post-enrollment to explore their perception on the participation in the study."
215007696|NCT04217356|BIOLOGICAL|Hematopoietic stem cell transplant|Intravenous infusion of hematopoietic stem cells from a donor.
215007697|NCT04217356|DRUG|Ruxolitinib|Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).
215007698|NCT04217356|DRUG|Hydroxyurea|Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).
215007699|NCT02916329|OTHER|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
215007700|NCT02474706|DRUG|Cefoxitin|
215007701|NCT02474706|DRUG|imipenem|
215007702|NCT01428128|DRUG|Arsenic Trioxide|IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
215007703|NCT06025370|OTHER|Prone Position|"All healthy volunteers will be positioned in prone position, on a bed equipped with a mapping pressure system.~The volunteers will spend 5 minutes in each of the positions corresponding to the study groups."
215007704|NCT04508075|BIOLOGICAL|SARS-CoV-2 vaccine (inactivated)|SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac
215007705|NCT04508075|BIOLOGICAL|Placebo|Placebo manufactured by PT. Bio Farma
215007706|NCT02710747|GENETIC|CYP2C9;VKORC1|
215007707|NCT06523790|BEHAVIORAL|Yoga|Participants in the yoga group will attend 90-minute yoga sessions, 3 times per week, for 8 months. The sessions will include a combination of asanas (postures), pranayama (breathing exercises), and meditation.
215007708|NCT06523790|BEHAVIORAL|Brisk walking|Participants in the brisk walking group will engage in one-hour fast-paced walking sessions, 6 times per week, for 8 months. The walking regimen is designed to improve cardiovascular fitness, endurance, and support weight loss.
215007709|NCT00918450|DRUG|ABT-263|"Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed"
214688230|NCT06439719|PROCEDURE|Blood sample collection|Collection of blood sample
214688231|NCT01922427|DRUG|RNS60|
215007710|NCT03185507|DEVICE|CryoHelmet|Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
214402663|NCT05864768|DIETARY_SUPPLEMENT|Omnivorous diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
214402664|NCT03990025|DIAGNOSTIC_TEST|Linked Color Imaging|Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.
214402665|NCT03990025|DIAGNOSTIC_TEST|White Light Imaging|White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
214402666|NCT00145262|PROCEDURE|Autologous Bone Marrow Mononuclear Cell Implantation|
214402667|NCT05592652|OTHER|Survey|Survey including demographic, clinical and psychopathological questions
214402668|NCT03318120|BEHAVIORAL|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
214402669|NCT03035240|BEHAVIORAL|Financial Education|Participants randomized to financial education will undergo a year long financial education. This involves 9 weeks of weekly classes followed by one on one coaching for a year.
214402670|NCT01663337|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
214402671|NCT01663337|BEHAVIORAL|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
214402672|NCT03486743|BEHAVIORAL|Educational video on LARC|Participants will watch a short educational video on long acting reversible contraceptive or LARC
215007711|NCT01888588|DRUG|Risk of symptomatic peptic ulcer|Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
214402673|NCT02527850|DEVICE|B-cure laser|
214688232|NCT07162831|BEHAVIORAL|Mio-Training|The Mio-Training aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and coordinative skills to strenghten cognitive development in children and adolescents with ADHD.
215007712|NCT04846257|OTHER|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is the acquisition of sequential images during the passage of a contrast agent within a tissue of interest.
215007713|NCT06255743|DIAGNOSTIC_TEST|Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies|determine Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) and its relation to the degree of Depression and Anxiety in Systemic Lupus Erythematosus Patients
215007714|NCT03895489|DEVICE|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
215007715|NCT03895489|DEVICE|Stryker|Stryker Triathlon Total Knee prosthesis
215007716|NCT03895489|DEVICE|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
215007717|NCT05954728|BEHAVIORAL|Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|CBT-AR is a four-stage modular treatment for ARFID delivered by a mental health clinician. The four stages include: 1) Psychoeducation and early change; 2) Treatment planning; 3) Addressing maintaining mechanisms; and 4) Relapse prevention. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
214402674|NCT01445756|DRUG|Lidocaine|During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
214402675|NCT01445756|DRUG|Placebo|Placebo; no topical lidocaine administered
215007718|NCT05954728|BEHAVIORAL|Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder|Nutrition counseling will be provided by skilled registered dietitians at the MGH Translational and Clinical Research Center (TCRC). Sessions focus on the foods necessary for a healthy diet, how to meet nutritional needs, how to incorporate healthy exercise, and support for making these changes. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
215007719|NCT05135169|DRUG|Definity Suspension for Injection|Administration of Definity
215007720|NCT00424008|DRUG|Mometasone furoate/formoterol (MF/F) MDI|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.
215007721|NCT00424008|DRUG|Fluticasone propionate/salmeterol (F/SC) DPI|Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
215007722|NCT00963508|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
215007723|NCT00963508|DRUG|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
215007724|NCT03104023|PROCEDURE|Staple line inversion|A staple line inversion will be performed with a running suture of Polypropylene 2/0
215096971|NCT01856621|DRUG|SF Easyhaler|2 inhalations as a single dose
215096972|NCT02565810|DRUG|Adalimumab PFS and Pen|
215096973|NCT02981966|DRUG|Dapagliflozin|dapagliflozin, 10mg tablet
215096974|NCT02981966|DRUG|Placebo|Placebo for dapagliflozin
215096975|NCT05241925|OTHER|Rehabilitation, exercise|"Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~\- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
215096976|NCT03530670|OTHER|oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction
214402676|NCT01378897|DEVICE|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
215007725|NCT03104023|COMBINATION_PRODUCT|Staple line buttressing|The gastric section will be performed with a stapler with preloaded buttress material
215096977|NCT03530670|OTHER|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|"Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction."
215096978|NCT03530670|OTHER|Playing smartphone game|Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
215007726|NCT02664493|DRUG|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
215007727|NCT03565289|DIAGNOSTIC_TEST|Blood sample collection|During a routine blood draw an additional tube of blood will be taken for the study.
215007728|NCT05662995|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed with the patient in supine position (with or without left uterine displacement, depending on clinical circumstances). A phased-array transducer will be used for lung ultrasound and will be used for the assessment of B-lines, which arise from the pleural line and extend to the bottom of the screen and move with the sliding lung
215096979|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
215096980|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
215096981|NCT04527627|BEHAVIORAL|Nursing Empowerment Intervention|"Nursing empowerment intervention The intervention will be carried out during the ICU discharge planning. A Patient Information Guide for Intensive Care Unit patients will be developed.~The guide will be based on the findings obtained in a previous qualitative study and on previous studies on patient empowerment and education. Its structure will take into account the dimensions of empowerment: bio-physiological, functional, social, experience, ethics and the financial aspect. The guide will be reviewed by experts in the development of information guides for patients and family members and will be evaluated by the participating ICUs before use.~EG patients will receive the intervention verbally and in booklet format from the study nurses at each ICU."
215096982|NCT03724656|DEVICE|acupuncture treatment|"TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
215096983|NCT03724656|DEVICE|sham acupuncture treatment|"Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
215096984|NCT01402648|DIETARY_SUPPLEMENT|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
215096985|NCT01402648|DIETARY_SUPPLEMENT|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
215096986|NCT05329207|BEHAVIORAL|Experimental group|Web Based Adolescent Health Promotion Education Program
215096987|NCT02185989|OTHER|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
215096988|NCT02816463|DEVICE|Ambu AuraGain|
215096989|NCT02816463|DEVICE|LMA Supreme|
215096990|NCT03171818|DRUG|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
215096991|NCT03171818|DRUG|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
214402677|NCT04036240|OTHER|Finger feeding|After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
215007729|NCT05522530|OTHER|Assessment scale|Evaluation scale to carry out its cross-cultural adaptation and study its validity
215007730|NCT06805097|OTHER|Self-assessment of bleeding events|After each transfusion, the patient completes a daily bleeding event self-assessment (adapted from the WHO bleeding event scale) until the next transfusion or over a period of 10 days.
215007731|NCT02331420|PROCEDURE|Gastric bypass|A subcardial gastric pouch with a 30±10 ml capacity will be created by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastro-enterostomy.
214402678|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 150mg|leaves of the mango food plant
214402679|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 300mg|leaves of the mango food plant
214402680|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 600mg|leaves of the mango food plant
214402681|NCT05580146|DIETARY_SUPPLEMENT|Placebo|Sunflower oil matched for appearance
214402682|NCT01571921|DIETARY_SUPPLEMENT|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
214402683|NCT02485743|OTHER|Active Diet Products|A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
214402684|NCT02485743|OTHER|Placebo Diet Products|A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
214402685|NCT04268563|DRUG|placebo|Oral rehydration solution
214402686|NCT04268563|DRUG|metformin|metformin tablet
215007732|NCT02331420|BEHAVIORAL|Medical therapy|"* Assessment and treatment by a multidisciplinary team (diabetologist, dietitian, nurse);~* Planned visits at baseline and at 1, 3, 6, 9, 12, and 24 months after study entry;~* Oral hypoglycemic agents and insulin doses optimized on an individual basis with the aim of reaching a glycated hemoglobin level of less than 7%;~* Programs for diet and lifestyle modification, including reduced overall energy and fat intake (\<30% total fat, \<10% saturated fat, and high fiber content) and increased physical exercise (≥30 minutes of brisk walking every day, possibly associated with moderate-intensity aerobic activity twice a week);~* low-calorie diet (every day: 50% carbohydrate, 30% protein and 20% lipids)."
214402687|NCT04268563|DRUG|Sitagliptin|Sitagliptin tablet
214402688|NCT04268563|DRUG|Sitagliptin/metformin|Sitagliptin/metformin tablet
215096992|NCT03139617|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|"The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration."
215007733|NCT01181479|DRUG|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel
215007734|NCT01181479|DRUG|Lessina crossover to AG200-15|Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen for 6 cycles followed by AG200-15 for 6 cycles.
215007735|NCT02978807|PROCEDURE|Point of care and venous screening|
215007736|NCT06515782|OTHER|Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.|"In one group investigators will look at the Med diet alone for 6 months. Then investigators will have the patients add on 3 rounds of FMD.~In the other group, patients will do Med diet and FMD for 6 months followed by Med diet alone for 6 months. This will allow investigators to look for a diminution in effect of the Med diet 6 months after the last FMD."
214402689|NCT00239161|DRUG|Levofloxacin|
214402690|NCT02783157|DEVICE|Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)|Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
215007737|NCT01045200|OTHER|Comparison of follow-up|Comparison of follow-up by nurse or surgeon after rectal cancer surgery
214402691|NCT02783157|DEVICE|Sham LLVNS|A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
214402692|NCT01575470|BIOLOGICAL|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
215007738|NCT02272101|DIETARY_SUPPLEMENT|Vitamin D versus placebo|Cross-over design
215007739|NCT00759096|DEVICE|RESTOR IOL Model SA60D3|Implanted into the study eye following cataract extraction surgery
214402693|NCT01065272|DRUG|Dexamethasone|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days"
214402694|NCT01065272|DRUG|Placebo|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days"
214402695|NCT03317353|DEVICE|Vestibular rehabil.: CDP|Vestibular rehabilitation, ten sessions
214402696|NCT03317353|DEVICE|Vestibular rehabil.: optokinetic stimuli|Vestibular rehabilitation, ten sessions
214402697|NCT03317353|OTHER|Vestibular rehabil.: home exercises|Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
215096993|NCT03139617|PROCEDURE|3 in 1 femoral block (FNB)|"The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood ."
215096994|NCT01066962|DRUG|darunavir/ritonavir QD + raltegravir BID|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)"
215096995|NCT01066962|DRUG|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)"
215096996|NCT01443663|BIOLOGICAL|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
215096997|NCT01435837|DRUG|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
215096998|NCT01435837|DRUG|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
215096999|NCT01435837|DRUG|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
214402698|NCT02873676|BEHAVIORAL|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
215007740|NCT01276652|BEHAVIORAL|Environmental modification|Environmental modification consists of nursing-related efforts to optimize daytime light exposure, to minimize nighttime light and noise exposure, and to batch nursing care at night.
215007741|NCT05462678|BEHAVIORAL|Cognitive Rehabilitation|Each patient performed two weekly sessions of 45 minutes each, for 12 weeks
215007742|NCT05462678|BEHAVIORAL|Combined Rehabilitation|Each patient performed one session per week (45 minutes) of CR and one session per week of traditional MR training for 12 weeks.
214402699|NCT02873676|BEHAVIORAL|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
214402700|NCT02873676|BEHAVIORAL|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
214402701|NCT02873676|BEHAVIORAL|control|The intervention involve dietary pattern modification and protein intake standardization
214402702|NCT05930899|OTHER|Genetics|TOmAS is a biobank and all patients will be genotyped
214402703|NCT04617600|DRUG|MTA|Survival rate using MTA in cariously exposed vital primary molars
214402704|NCT04617600|DRUG|TheraCal PT|Survival rate using TheraCal PT in cariously exposed vital primary molars
214402705|NCT02179918|DRUG|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
215007743|NCT05462678|BEHAVIORAL|Motor Rehabilitation|Each patient performed two weekly sessions45 minutes each, for a total of 12 weeks.
215007744|NCT05359068|DRUG|SPH3127 tablet|1 tablet
215007745|NCT05359068|DRUG|SPH3127 tablet|2 tablets
215007746|NCT05359068|DRUG|SPH3127 tablet|4 tablets
215007747|NCT05359068|DRUG|Valsartan|1 valsartan capsule
215007748|NCT05359068|DRUG|SPH3127 tablet|2 tablets
215007749|NCT05359068|DRUG|Valsartan|1 valsartan capsule
215007750|NCT00334919|BEHAVIORAL|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
215007751|NCT02226900|PROCEDURE|Hybrid Revascularization|Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
215007752|NCT02226900|PROCEDURE|Conventional Coronary Artery Bypass Surgery|On pump coronary artery by-pass surgery
215007753|NCT05151614|DRUG|Colchicine 0.5 MG|Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).
215007754|NCT06241443|OTHER|hybrid simulation|"During the hybrid simulation, a student and a standardized patient participated. The patient wore a wearable pregnancy model. Before the start of the Natural Birth Approach Scenario, a pre-briefing session was conducted. The student's performance during the simulation was recorded on video, and each simulation lasted approximately 30 minutes. After the simulation, a debriefing session was held with the student, and feedback was given. Scales were used to evaluate the implementation of the practices."
215097000|NCT01435837|DRUG|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
215097001|NCT05407961|DRUG|LY3532226|Administered SC.
215097002|NCT05407961|DRUG|Placebo|Administered SC.
215097003|NCT05407961|DRUG|Dulaglutide|Administered SC.
215097004|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
215097005|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 alone
215097006|NCT03437707|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
215097007|NCT03437707|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
215097008|NCT03437707|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
214402706|NCT02179918|DRUG|MK-3475|2 mg/kg q3wks, IV
215007755|NCT06241443|OTHER|video-modeling|"The students in the group had the opportunity to learn through an educational video that followed the Natural Birth Approach Scenario. Afterward, they put their knowledge into practice and were evaluated using the Birth Approach Clinical Skills Guide. A feedback session followed the practice session. Finally, they were assessed using scales to measure their performance."
214402707|NCT03429387|DIAGNOSTIC_TEST|FDG-PET/CT|FDG-PET performed with low dose CT
214402708|NCT03429387|DIAGNOSTIC_TEST|Conventional CT|HRCT and CT of sinuses +/- other regions as per clinician's discretion
214688233|NCT07163130|DEVICE|Transcutaneous auricular vagus nerve stimulation|"Transcutaneous auricular vagus nerve stimulation (tVNS) is an emerging therapeutic modality in cardiovascular diseases. tVNS has been shown to exert antiadrenergic and anti-inflammatory effects in humans. Recently, tVNS has been tested in experimental and human POTS, leading to improved autonomic function, reduction of anti-autonomic autoantibodies and inflammatory cytokines.~Parasym device; Parasym Health, London, United Kingdom Frequency: 20Hz, pulse width: 200μs, amplitude will be individually titrated to 1 mA below the level that caused mild discomfort."
215007756|NCT03237754|DEVICE|tDCS device from neuroConn|weak electrical direct current stimulation
215007757|NCT02373072|DRUG|PF-06649751|Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
215007758|NCT02373072|DRUG|Trimethobenzamide Hydrochloride|300mg TID, Capsules. Optional in both Cohorts.
215007759|NCT02373072|DRUG|Placebo|Subjects completing all three treatment periods will be receiving placebo once.
215007760|NCT02680275|DRUG|Dead Sea Peloid Gel|intravaginally
215007761|NCT04249778|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
215007762|NCT04249778|DRUG|Placebo|Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
215007763|NCT03233217|BIOLOGICAL|QIV-HD by IM|IM, injected into the upper arm (deltoid area)
215007764|NCT03233217|BIOLOGICAL|QIV-SD by SC|SC, injected into the upper arm (posterior region)
215007765|NCT03233217|BIOLOGICAL|QIV-HD by SC|SC, injection into the upper arm (posterior region)
215007766|NCT05920226|DEVICE|pacemakers implantation and assessment of cardiac function and cardiac fibrosis|"150 patients will be implanted with pacemakers. In addition to the echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers, the tests described above will be repeated at 1 (V1), 12 (V2), 24 (V3) months after inclusion. Echocardiography and peripheral venous blood sampling for myocardial fibrosis markers detection will be repeated to all patients before pacemakers implantation and after 6,12 and 24 months of observation period. Contrast-enhanced cardiac magnetic resonance imaging (MRI) will be performed before pacemaker implantation and 6 months after surgery.~In addition, pacemakers programming data will be evaluated after 1, 12, 24 months after inclusion in the study (atrioventricular delay, percentage of ventricular stimulation, episodes of high atrial frequency, fibrillation/atrial flutter, ventricular tachycardia)."
215007767|NCT05920226|DIAGNOSTIC_TEST|assessment of cardiac function and cardiac fibrosis|The patients who do not require a pacemaker placement will undergo diagnostic testing such as echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers.
215007768|NCT02530242|DEVICE|End-tidal Carbon Monoxide Subjects|ETCO monitor will be used to measure CO levels in subjects and controls.
215007769|NCT02530242|DEVICE|End-tidal Carbon Monoxide Controls|ETCO monitor will be used to measure CO levels in subjects and controls.
215007770|NCT03436927|OTHER|Nintendo Wii Fit Balance exercises|Nintendo Wii Fit' training protocol consisted of 'Penguin Slide', 'Table Tilt', 'Ski Slalom', 'Heading' and 'Balance Bubble' games that selected from the Wii Fit Plus balance games section
215097009|NCT03544307|BEHAVIORAL|Taekwondo training|Exercise group
215097010|NCT01732913|DRUG|Placebo|Tablets administered orally twice daily
215097011|NCT01732913|DRUG|Rituximab|375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
215097012|NCT01732913|DRUG|Idelalisib|150 mg tablets administered orally twice daily
215097013|NCT05512013|DRUG|Ibuprofen 800 mg|Ibuprofen taken orally 2 hours prior to exercise
215097014|NCT05512013|DRUG|Celecoxib 200mg|Celebrex taken orally 2 hours prior to exercise
215097015|NCT05512013|DRUG|Flurbiprofen 100 mg|Flurbiprofen taken orally 2 hours prior to exercise
215097016|NCT05512013|DRUG|Placebo|Inert placebo taken orally 2 hours prior to exercise
214402709|NCT04814940|OTHER|MENOPUR Cohort|"Non-interventional~All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study take place."
214402710|NCT05602116|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The Investigational Product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark).~C2C\_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C\_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C\_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The excipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
214402711|NCT02774252|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - Y49-103)
214402712|NCT04118699|DRUG|Rifaximin oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks
214688234|NCT07163234|DEVICE|Cardiac surgery|cardiac surgery
214402713|NCT04118699|DRUG|Placebo oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks
215007771|NCT03436927|OTHER|Balance Trainer Balance Exercises|Balance Trainer' training protocol consisted of 'Collect Apples', 'Outline', 'Paddle War' and 'Evaluation of Movement' games which were included in the device software and allowed the patients to done balance exercises in different directions.
215007772|NCT00283959|DRUG|migalastat HCl|
215007773|NCT05993143|DRUG|Ivermectin|Round and white tablets
215007774|NCT05993143|DRUG|Placebo|Round and white tablets
215007775|NCT05225831|BIOLOGICAL|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|A single infusion of CD19 and CD22 CAR-T cells.
215007776|NCT05225831|DRUG|Cyclophosphamide,Fludarabine|Given
215007777|NCT05591755|DRUG|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
215007778|NCT05591755|DRUG|Ketotifen fumarate ophthalmic solution 0.035%|Ketotifen fumarate ophthalmic solution 0.035%
215007779|NCT05591755|DRUG|Brimonidine tartrate ophthalmic solution 0.025%|Brimonidine tartrate ophthalmic solution 0.025%
215007780|NCT05591755|DRUG|Experimental: Vehicle ophthalmic solution|Experimental: Vehicle ophthalmic solution
215007781|NCT04441398|DRUG|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
215007782|NCT04441398|DRUG|Placebo|Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
215007783|NCT03535688|DRUG|D-cycloserine|200 mg twice daily
214402714|NCT06563531|PROCEDURE|Pharmacological thromboprophylaxis and elastic compression|Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis and elastic restraint after total hip or knee arthroplasty.
214402715|NCT06563531|PROCEDURE|Pharmacological thromboprophylaxis without elastic compression|Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis only after total hip or knee arthroplasty.
214402716|NCT00276250|DRUG|Efalizumab|Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.
214402717|NCT00276250|DRUG|Abatacept|Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
214504509|NCT02795884|DRUG|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
215007784|NCT03535688|DRUG|Placebo|twice daily
215007785|NCT01922193|DRUG|Highly Purified Urofollitropin|for injection
215007786|NCT01922193|DRUG|Recombinant Human Follitropin Alfa|for injection
215007787|NCT05175365|BEHAVIORAL|Dance|Each session consists of a 60-minute dance class taught by a professional dancer. Dance classes begin with a seated warm-up with various coordination, rhythm, range of motion, memorization and coordination exercises. The level of difficulty of the exercises increases as the sessions progress. Balance is also an important part of training as well as the feeling of being part of a group, of interacting with each other. The hour ends with stretching in a sitting position.
215007788|NCT00433290|DRUG|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
215007789|NCT00433290|DRUG|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
215007790|NCT01060956|OTHER|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
215007791|NCT01060956|OTHER|"reporting mixed growth on urine culture"|"reporting mixed growth on urine culture"
215007792|NCT00308347|DRUG|MK0954, losartan / Duration of Treatment: mean 3.4 years|
215007793|NCT00308347|DRUG|Placebo / Duration of Treatment: mean 3.4 years|
215007794|NCT03217097|DRUG|Oxaliplatin-based chemotherapy|"The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
215007795|NCT03217097|DRUG|Alkylating-based chemotherapy|"The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
215007796|NCT00554723|DRUG|NeuroAid|4 capsules 3 times daily, for three months
215097017|NCT02350504|BEHAVIORAL|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
215097018|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
215007797|NCT00554723|DRUG|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
215007798|NCT00004055|BIOLOGICAL|filgrastim|
215007799|NCT00004055|DRUG|paclitaxel|
215007800|NCT00004055|DRUG|topotecan hydrochloride|
215097019|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
214402718|NCT00276250|DRUG|Belatacept|Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
215007801|NCT01483651|DRUG|Glucagon|The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
215007802|NCT01483651|DRUG|Insulin|Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
215007803|NCT04248179|DRUG|Ropivacaine injection|Ropivacaine 5mg/ml
215007804|NCT04248179|DRUG|Saline 0.9%|Saline 0.9%
215007805|NCT04248179|DRUG|Sufentanil and PONV prophylaxis|30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV prophylaxis) will be administered.
215097020|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
215007806|NCT00571090|PROCEDURE|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
215007807|NCT00335075|DRUG|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
215007808|NCT00335075|DRUG|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
215007809|NCT00315575|PROCEDURE|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
215007810|NCT00500890|DRUG|Carboplatin|350 mg/m\^2 by vein, Over 2 Hours x 2 Days
215097021|NCT00064402|DRUG|Salmeterol|Salmeterol MDI 42 mcg BID
215097022|NCT00064402|DRUG|Placebo|Placebo BID
215097023|NCT02831322|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
215097024|NCT00479479|DRUG|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
215097025|NCT05674253|DRUG|Dexmedetomidine + Hydrocortisone|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
215097026|NCT03726931|DIAGNOSTIC_TEST|18F-Fluorestradiol PET/CT scan|\[18F\]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.
215097027|NCT05245214|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Muscle analysis by Magnetic Resonance Imaging
215097028|NCT01828411|DEVICE|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
215097029|NCT01828411|DEVICE|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
215097030|NCT05946005|DRUG|honey|Tresno Joyo honey applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: MD252109001219
214402719|NCT03189134|DRUG|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
214402720|NCT03189134|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
214402721|NCT06023550|OTHER|Treatment with surgery and/or conservative measures|Patients will be treated according to established clinical practice with surgery and/or conservative measures.
214402722|NCT02678052|DRUG|Vedolizumab|Vedolizumab exposure
214402723|NCT02678052|BIOLOGICAL|Other Biological Agent|Other Biological Agent exposure
214402724|NCT04337489|DEVICE|SensiumVitals wearable sensor|A waterproof, light, wearable sensor measuring vital signs (heart rate, respiratory rate, temperature) continuously.
215007811|NCT00500890|DRUG|Cyclophosphamide|1 g/m\^2 by vein, Over 1 Hour x 2 Days
215007812|NCT00500890|DRUG|Etoposide|100 mg/m\^2 by vein, Over 1 Hour x 5 Days
215007813|NCT00500890|DRUG|Vincristine|1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5
215007814|NCT00500890|RADIATION|Radiation Therapy|Radiation treatment over a period of about 6 weeks.
215007815|NCT01989273|DEVICE|Ultrasound of inferior vena cava|
215007816|NCT00064454|DRUG|OPC-6535 Tablets (drug)|
215007817|NCT06188546|DRUG|Propofol|trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
215007818|NCT00005850|DRUG|cisplatin|80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
215007819|NCT00005850|DRUG|fluoxetine|10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
215007820|NCT00005850|DRUG|gemcitabine hydrochloride|1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
215007821|NCT02596672|BEHAVIORAL|The friendly walking group|A 12 week peer led walking group for adults and older adults (\> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
215007822|NCT05360446|DRUG|Inclisiran sodium 300 mg|Subcutaneously administered on Days 1, Month 3 (Day 90), and every 6 months thereafter.
215007823|NCT05360446|DRUG|Placebo|Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
214402725|NCT01615627|DRUG|HypotonicTreprostinil Solution|Hypotonic Treprostinil Solution
214402726|NCT01615627|DRUG|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
214402727|NCT06339112|OTHER|Playing with toy nebulizer|The child who needs to take inhaler medication is taken to the observation room. Before starting the procedure, the toy nebulizer is introduced to the child. The toy nebulizer is shown to the child as an example and allowed to play, thus reducing the level of fear. Inhaler medication is given through a mask for 10 minutes. Vital signs (pulse) before and after the application. , blood pressure, SPo2, respiration), the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
214402728|NCT06339112|OTHER|Cartoon|"Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. 2-3 minutes before starting drug treatment, the child will be allowed to watch cartoons according to his age group and will be encouraged to do so throughout the procedure.~Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher."
214402729|NCT03711838|DIETARY_SUPPLEMENT|N-Acetylcysteine|N-Acetylcysteine in a powder form diluted in a 250 ml drink containing 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
215007824|NCT06011226|OTHER|focus groups|A dozen patients with Chiari malformation and syringomyelia (n = 4) or isolated Chiari malformation (n = 4) or isolated syringomyelia (n = 4) will be brought together in at least two focus groups. Each focus group will include 5 to 8 patients and will last approximately 1 to 2 hours. The focus groups will be recorded (audio only, no personal data will be collected during these sessions) and will be conducted in the presence of a neurosurgeon and a psychologist, who will moderate the session.
215007825|NCT06011226|OTHER|questionnaire|developed questionnaire will be proposed to the patients in phase 2 and 3
215007826|NCT01917773|DRUG|Octreotide|Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
215007827|NCT01917773|DRUG|Bisacodyl|
215007828|NCT02260622|DRUG|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
215007829|NCT02260622|DRUG|clopidogrel plus aspirin|Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
215007830|NCT04867148|DEVICE|Inertial measurement unit sensor-based gait analysis system|Gait analysis was performed on 20-m long corridor to collect gait data on more than 23 strides. The gait protocol was performed with an IMU sensor-based gait analysis system (DynaStab™, JEIOS, South Korea) consisting of a shoe-type data logger (Smart Balance1 SB-1, JEIOS, South Korea) and a data acquisition system (DynaStab-Spotfire1, Tibco Spotfire 7.10). The shoe-type data logger included an IMU sensor (IMU-3000™, InvenSense, USA) that measured tri-axial acceleration (up to ± 6 g) and tri-axial angular 136 velocity (up to ± 500˚ s-1) along three orthogonal axes.12,16 The IMU sensors were installed in both shoe outsoles, and the data were transmitted wirelessly to a data acquisition system via Bluetooth®. Shoe sizes were adapted to each participant, with available sizes ranging from 225 mm to 280 mm. The local coordinate system for the IMU sensors included the 140 anteroposterior, mediolateral, and vertical directions.
215007831|NCT00800514|DRUG|amantadine|amantadine twice daily
215007832|NCT00800514|DRUG|amantadine|amantadine 100 mg twice daily
215007833|NCT00308685|DRUG|Albuterol|Albuterol 90mcg
215007834|NCT00308685|DRUG|Placebo|Placebo
215007835|NCT03345095|DRUG|Marizomib|Intravenous administration of Marizomib
215007836|NCT03345095|DRUG|Temozolomide|Oral Administration of Temozolomide
215007837|NCT03345095|RADIATION|radiotherapy|60 Gy in 30 fractions over 6 weeks
215007838|NCT01121575|DRUG|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
215007839|NCT01121575|DRUG|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
215007840|NCT01121575|DRUG|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
215007841|NCT01121575|DRUG|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
215007842|NCT01799278|DRUG|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
215007843|NCT04375592|DIETARY_SUPPLEMENT|Phenylalanine-free protein substitute in tablet form (XPhe minis)|Intervention is a Phenylalanine-free protein substitute in tablet form. Subjects who currently take a concentrated second stage phenylalanine-free protein substitute will be recruited. Subjects will take the study product for 7 days and daily questionnaires will be completed. Subjects will replace some or all of their usual protein substitute with the new product. The amount of study product prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Daily acceptability and tolerance questionnaires will record information on ease of preparation and administration; how it is taken; and any problems or gastrointestinal effects. Additional questions at the beginning and end of the study will record information on taste, appearance, smell, presentation and packaging of the product. Routine weekly finger prick blood spots will be collected and analysed for phenylalanine and tyrosine as usual.
215007844|NCT02665455|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (pre-meals and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
214402730|NCT03711838|DIETARY_SUPPLEMENT|Placebo|Placebo consisted of 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
215007845|NCT03331588|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
215007846|NCT03331588|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
215007847|NCT00724503|DEVICE|SIR-Spheres yttrium-90 microspheres|"SIR-Spheres microspheres (yttrium-90 \[Y-90\] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
215007848|NCT00724503|DRUG|Systemic chemotherapy (FOLFOX)|"mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
215007849|NCT05814497|OTHER|Multisensory Task|Reversing checkerboard, tones, and finger opposition.
215007850|NCT05814497|OTHER|Graphesthesia|Trace numbers on skin.
215007851|NCT05814497|OTHER|Divided attention|Divide attention between two noxious stimuli.
215097031|NCT05946005|DRUG|lidocaine|Dolones cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: DKL0922246629AI
215097032|NCT05946005|DRUG|povidone-iodine|Betadine cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: PKD20501710037
214504510|NCT02795884|DRUG|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
214504511|NCT02093169|DRUG|Part A: Lu AF35700|One 30 mg single dose for one day; orally
215007852|NCT06810531|DRUG|Ondanesterone plus dexamethasone combination|"Group D: Ondanesterone 4mg plus dexamethasone 8mg All the drugs will be prepared and diluted by normal saline in 10 ml syringe by an anesthesiologist who is not included in the study.~The drugs will be slowly injected intravenous 15 minute from spinal anesthesia."
215007853|NCT06810531|DRUG|ondanesterone plus metoclopramide combination|"Group M: ondanesterone 4mg plus metoclopramide 10 mg All the drugs will be prepared and diluted by normal saline in 10 ml syringe by an anesthesiologist who is not included in the study.~The drugs will be slowly injected intravenous 15 minute from spinal anesthesia."
215097033|NCT05946005|OTHER|control groups|no intervention is given
215097034|NCT01409369|DRUG|RO4995819|single oral dose
215097035|NCT01409369|DRUG|activated charcoal|orally 3 times daily, Days 1-7
215097036|NCT03046979|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
215097037|NCT06407102|OTHER|Collection of nasal cells during programme surgery|During programmed surgery (meatotomy, septoplasty or turbinoplasty for example, or other programmed surgeries), the surgeon will take an atraumatic sample from the nasal cavity using a dedicated device (brush) from the healthy nasal mucosa.
215097038|NCT03392870|OTHER|Integrative interventional programme|The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.
214402731|NCT06042985|DRUG|The absorption effect between calcium citrate and calcium carbonate|Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.
214402732|NCT02817490|OTHER|patient education program|"The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session."
214504512|NCT02093169|DRUG|Part B: Lu AF35700|Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
214504513|NCT03590899|DEVICE|Optical coherence tomography angiography (Zeiss Cirrus HD OCT 5000 AngioPlex)|Non-invasive, non-contact optical coherence tomography angiography scans of the retina are done per built-in device protocol using the Zeiss Cirrus HD OCT 5000 AngioPlex machine.
214504514|NCT04486703|OTHER|Exercise with music|physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.
215097039|NCT03392870|OTHER|As usual|The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.
215097040|NCT02678884|DRUG|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
215097041|NCT01869413|DRUG|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
215097042|NCT01869413|DRUG|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
215097043|NCT00148785|DRUG|Indinavir/Ritonavir/Fosamprenavir|
214402733|NCT06510517|OTHER|Calculation of Mechanical Power.|"Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP)."
214402734|NCT06510517|OTHER|Measurement Diaphragmatic Excursion after first SBT|Chest ultrasound to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT. The DE at 0 min, 5 min, and 30 min of SBT was respectively named as DE0, DE5, and DE30. The variation of right DE between each time point was named as ΔDE30-5 and ΔDE30-0. (7)
215097044|NCT02925741|OTHER|Silk-Like Linens|Synthetic moisture-wicking fabric
215097045|NCT02901652|DEVICE|noninvasive respiratory support devices|
215097046|NCT05086510|PROCEDURE|Radiofrequency ablation|Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.
215097047|NCT02983994|DEVICE|TURBUHALER®|
215097048|NCT02983994|DEVICE|SPIROMAX®|
215097049|NCT03022981|DRUG|SOF/VEL|SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
215097050|NCT03022981|DRUG|SOF/VEL|SOF/VEL FDC 200/50 mg oral granules
214402735|NCT05465421|OTHER|bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation|"Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later"
214402736|NCT01719146|OTHER|Specimen collection|At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
215097051|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 60 mg|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
215097052|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 90 mg|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.
215097053|NCT03537196|DRUG|Ribavirin|"In case of cirrhosis:~* Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight \< 75 kg) will receive 500 mg x 2/day.~* In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks."
215097054|NCT03537196|DRUG|Sofosbuvir and Daclatasvir for 24 weeks|In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
215097055|NCT00870298|DRUG|Trimethoprim/Sulfamethoxazole and Warfarin|
215097056|NCT01577472|DRUG|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
215097057|NCT01577472|DRUG|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
215097058|NCT01577472|DRUG|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
215097059|NCT01577472|DRUG|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
214402737|NCT00974103|OTHER|exercise advise|Exercises
214402738|NCT00974103|OTHER|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
215007854|NCT05788926|DRUG|TG6050|Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose.
215097060|NCT06507124|OTHER|This is observational with no intervention|This is observational with no intervention
215097061|NCT01119677|DRUG|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
215097062|NCT00295932|BIOLOGICAL|rituximab|Given IV
215007855|NCT00627107|DEVICE|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device.
215007856|NCT01186419|DRUG|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
215007857|NCT02756468|OTHER|pts operated for pancreatic cancer|measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
215007858|NCT03982654|DEVICE|Bloomlife|Women use the Bloomlife sensor to collect data throughout their pregnancy. The collected data is stored locally in the device, but it is not used to provide any feedback to the patients or to the clinical team. Therefore the use of the device doesn't have an impact on clinical decision making and patients' care.
215007859|NCT04253860|DEVICE|Transcutaneous electrical neurostimulation|Sessions of 30 minutes of TENS will be applied three times a week during 90 days
215007860|NCT00411541|DRUG|vincristine|
215007861|NCT00411541|DRUG|dexamethasone|
215007862|NCT01937117|PROCEDURE|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
215007863|NCT01937117|DRUG|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
215007864|NCT01937117|DRUG|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
215097063|NCT00295932|DRUG|bortezomib|Given IV
215097064|NCT00295932|DRUG|cyclophosphamide|Given IV
215097065|NCT00295932|DRUG|prednisone|Given orally
215097066|NCT06508242|DRUG|Cholecalciferol|cholecalciferol
215007865|NCT04374552|DRUG|Hydroxychloroquine sulfate &Azithromycin|Drug - Hydroxychloroquine sulfate \&Azithromycin
215007866|NCT04374552|DRUG|Placebo|Drug - placebo
215097067|NCT06508242|OTHER|Placebo|placebo
214402739|NCT00972543|BIOLOGICAL|Efalizumab (Raptiva)|"Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks."
215007867|NCT03827798|DRUG|CFZ533|s.c.
215007868|NCT03827798|DRUG|Placebo to CFZ533|s.c.
215007869|NCT03827798|DRUG|LYS006|p.o.
215097068|NCT01888419|OTHER|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
214402740|NCT00972543|BIOLOGICAL|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
215007870|NCT03827798|DRUG|Placebo to LYS006|p.o.
215007871|NCT03827798|DRUG|MAS825|s.c.
215007872|NCT03827798|DRUG|Placebo to MAS825|s.c.
215007873|NCT03827798|DRUG|LOU064 25mg|p.o.
215007874|NCT03827798|DRUG|LOU064 100mg|p.o.
215007875|NCT03827798|DRUG|Placebo to LOU064|p.o.
215007876|NCT03827798|DRUG|VAY736|s.c.
215007877|NCT03827798|DRUG|Placebo to VAY736|s.c.
215007878|NCT06856759|GENETIC|Intrathecal injection of AAV-MECP2 for the treatment of Rett syndrome|"For Dose 1, the first 5 subjects will be enrolled in the trial in sequence, with one patient completing the administration and no significant dose limiting toxicity (DLT) observed during a one month follow-up. The latter subject will be enrolled in the trial medication.~Once the fifth subject in Dose 1 completes the administration and no significant DLT is observed after a follow-up period of at least two weeks, the study dose can be escalated to a higher level.~For Dose 2, the 3 subjects will be enrolled in the trial in sequence, with one patient completing the administration and no significant DLT observed during a one month follow-up. The latter subject will be enrolled in the trial medication.~DLT definition: see Study Description."
215007879|NCT06659991|DRUG|alcohol condition|Ethanol
215007880|NCT06659991|OTHER|control condition|sparkling water
215097069|NCT00044889|DRUG|clofarabine (IV formulation)|
215097070|NCT00841932|PROCEDURE|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
215097071|NCT02560298|DRUG|Capecitabine|
215097072|NCT02560298|DRUG|Carboplatin|Given IV
215097073|NCT02560298|DRUG|Cisplatin|Given IV
215097074|NCT02560298|DRUG|Fluorouracil|Given IV
215097075|NCT02560298|OTHER|Laboratory Biomarker Analysis|Correlative studies
215097076|NCT02560298|DRUG|Paclitaxel|Given IV
215097077|NCT02560298|OTHER|Quality-of-Life Assessment|Ancillary studies
215097078|NCT05569694|OTHER|Movement-based pelvic health education|A single virtual education session led by a physical therapist trained in pelvic health. The virtual course was approximately one hour and included movement-based education through various positions, exercises, and movements with explanations for each pose as it relates to pelvic health.
215097079|NCT03493789|DRUG|Fludeoxyglucose F-18|Given IV
215097080|NCT03493789|PROCEDURE|Positron Emission Tomography (PET)|Undergo FDG-PET
215097081|NCT03493789|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
215097082|NCT01009190|DRUG|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
215097083|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
215097084|NCT01009190|DRUG|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
215007881|NCT05164263|DRUG|Empagliflozin|Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
215007882|NCT01426646|DRUG|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
215007883|NCT01426646|DRUG|S-1 plus cisplatin|"S-1 plus cisplatin every 3 weeks, a total of eight cycles~* S-1: 40mg/m2 orally twice daily (days 1-14)~* Cisplatin: 60mg/m2 IV on day 1"
215007884|NCT03092232|DRUG|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.
215007885|NCT03092232|DRUG|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.
215097085|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
215007886|NCT03092232|DRUG|PF-06865571|Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.
215097086|NCT03364413|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
215097087|NCT00002447|DRUG|Ritonavir|
215007887|NCT03092232|DRUG|Placebo|Matching Placebo for PF-06865571 for each cohort.
215007888|NCT02265835|OTHER|no intervention|no intervention
215097088|NCT00002447|DRUG|Efavirenz|
214504515|NCT03298295|DEVICE|Continous Subcutaneous Insulin Infusion Catheter|Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
214504516|NCT06461286|DRUG|PYC-001|Single Group Assignment
214504517|NCT05699174|DRUG|Standard of Care PO (oral) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to PO (oral) antibiotics for up to 6 weeks post hospitalization. The exact type of oral antibiotic will be depended on the patient's infection diagnosis.
214504518|NCT05699174|DRUG|Standard of Care Intravenous (IV) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to intravenous (IV) antibiotics for up to 6 weeks post hospitalization. The exact type of IV antibiotic will be depended on the patient's infection diagnosis.
214504519|NCT03395080|DRUG|Paclitaxel|Administered by IV infusion
214504520|NCT03395080|DRUG|300mg DKN-01|Administered by IV infusion
215007889|NCT06862960|DRUG|Ozanimod|A sphingosine-1-phosphate receptor regulator
215007890|NCT06862960|DRUG|Conventional medication|Conventional medications for moderate AD
214504521|NCT03395080|DRUG|600mg DKN-01|Administered by IV infusion
215097089|NCT00002447|DRUG|Saquinavir|
215097090|NCT03885050|OTHER|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
215097091|NCT04370379|DRUG|IBI302 (the first dose level)|q4week (3 injections) followed by PRN dosing
215097092|NCT04370379|DRUG|IBI302 (the second dose level)|q4week (3 injections) followed by PRN dosing
215097093|NCT04370379|DRUG|Aflibercept|2mg, q4week (3 injections) followed by q8week
215097094|NCT02599623|PROCEDURE|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
215097095|NCT02599623|PROCEDURE|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
215097096|NCT06429189|BEHAVIORAL|Home-based combined exercise program with self-selected intensity|Before the beginning of the exercise program, participants will receive an education session on how to use Borg's Perceived Rate of Exertion Scale (RPE) to monitor their effort during aerobic and resistance training and tips on when they may increase the exercise intensity. During the training sessions, participants in the intervention group will be asked to choose their preferred load to execute each exercise in the resistance component, told to perform the aerobic exercises at their preferred speed, and informed that they can stop exercising whenever they need to rest. The exercise professional may suggest increasing loads in specific exercises, but these increases will not be imposed on the participants. Attendance to the sessions in the intervention and control groups will be registered. Additionally, women in this group will be encouraged to perform brisk walking at their preferred intensity and receive a pedometer to increase walking motivation.
215097097|NCT04891107|DEVICE|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Participants will walk using the music-based, rhythm-modulating wearable sensor system (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 5 times a week for 4 weeks.
215097098|NCT04629027|DRUG|Immune checkpoint inhibitor|the patients receive necessary treatment without special intervention
215097099|NCT01571453|DRUG|Vortioxetine (Lu AA21004)|10 mg/day
215097100|NCT01571453|DRUG|Venlafaxine extended release|150 mg/day
215007891|NCT05965895|PROCEDURE|Ultrasound-guided continuous serratus anterior plane block|Patients will receive US-guided SAP block with a bolus of 2 mg/kg levobupivacaine made up to a volume of 40 ml followed by an infusion of 0.125% levobupivacaine will be commenced at rate of 8 ml/hr for 48 hr.
215007892|NCT05965895|DRUG|intravenous dexmedetomidine infusion|Patients will receive initial loading dose of dexmedetomidine of 1 µg/kg over 30 min followed by a continuous infusion at a rate of 0.5 µg/kg/hr for 48 hr.
214402741|NCT03413605|BEHAVIORAL|A Multilevel CBPR Intervention|The intervention will be implemented through a group-based education workshop. The education session is a curriculum-based group education; each group will be having about 15-20 participants. All group education sessions will take place at collaborating Viet community partners sites, and delivered in Vietnamese language, with offering of refreshment. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics--- (a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion.
215007893|NCT06675708|DIETARY_SUPPLEMENT|Creatine|From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. One experimental group will receive creatine supplementation, and the other group will receive a placebo through dextrose administration. In both cases, the doses will be administered in the same manner to both groups
214402742|NCT01888562|DRUG|Ponatinib|Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
214402743|NCT02981225|DIETARY_SUPPLEMENT|Phytostandard® Rhodiola-Saffron|
214402744|NCT06140667|DEVICE|LarysealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr.
214504522|NCT05824871|DRUG|Sudapyridine|Sudapyridine (WX-081) will be administered as a loading dose for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days) and a maintenance dose (150 mg once daily) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for bedaquiline.
214504523|NCT05824871|DRUG|Bedaquiline|Bedaquiline will be administered as a loading dose for 2 weeks (400 mg once daily) and a maintenance dose (200 mg three times per week, with at least 48 hours between doses) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for Sudapyridine.
214504524|NCT03396107|DRUG|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
214504525|NCT03396107|DRUG|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
214504526|NCT05683990|DRUG|Diamyd|4 μg (0.1 mL) of Diamyd administered 1 month apart.
215097101|NCT06303895|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
215007894|NCT06675708|DIETARY_SUPPLEMENT|Dextrose|From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. Dextrose group will be administered in the same manner as creatine to the experimental group. The doses will be prepared in the same way for both groups.
215007895|NCT07006467|DEVICE|Implantation of RFS|Percutaneous transluminal implantation of the RFS in the infrapopliteal lesion
215097102|NCT06303895|BEHAVIORAL|Swallowing rehabilitation training|"Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced."
215097103|NCT06303895|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
215097104|NCT05243303|DEVICE|Active taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated. Subjects self-administer the stimulation on a daily basis for 3 months.
214504527|NCT07042958|PROCEDURE|zirconia membrane|Patients with atrophic maxilla will undergo a direct sinus lift procedure, utilizing a customized zirconia membrane for tenting, along with simultaneous implant placement.
214504528|NCT07042958|PROCEDURE|control group|Patients with atrophic maxilla will undergo a direct sinus lift procedure, using tenting with simultaneous implant placement.
215007896|NCT07009860|DRUG|Pemvidutide|Pemvidutide 2.4 mg
215007897|NCT07009860|OTHER|Placebo|Subcutaneous injection
215007898|NCT07012694|DEVICE|22G Franseen Needle Group|Fine-needle-biopsy (22G Franseen, Boston Scientific, Winston-Salem, USA)
215007899|NCT07012694|DEVICE|22G Adapt Needle Group|Fine-needle-biopsy (22G Adapt, Micro.Tech Endoscopy, Nanjing, China)
214402745|NCT06140667|DEVICE|Ambu Aura Gain|The AuraGain is Ambu ꞌs 3rd generation disposable laryngeal mask, satisfying 3 fundamental airway management needs by integrating gastric access channel for managing gastric content and intubation capability using standard ET-tubes in an anatomically curved single-use device that facilitates rapid establishment of a safe airway through integrated bite absorption area that could prevent airway occlusion. Other characters include pilot balloon that identifies mask size and provides tactile indication of degree of inflation, navigation marks for guiding flexible scope and is made of phthalate-free material. Its thin and soft cuff is designed to deliver high seal pressure up to 40 cmH2O. It was presented in the clinical market in sizes 3, 4, 5 and 6 (according to the body weight; size 3: 30-50 kg, size 4: 50-70 kg, size 5: 70-100 kg, and size 6: \>100 kg) with maximum suction catheter size of 16 Fr.
214402746|NCT04533217|PROCEDURE|Vertebroplasty|Injection of cement into vertebral lesion(s)
214402747|NCT04537949|BIOLOGICAL|BNT162b3|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost (P/B) regimen).
214402748|NCT03381014|DRUG|Chemotherapy, Cancer, Anthracyclines|follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin
214402749|NCT01882062|DRUG|Triheptanoin 1g/kg/day|
214504529|NCT07042659|DEVICE|Photobiomodulation|Accelerated photobiomodulation therapy using EmoLED™, a portable blue LED device (415 nm, 120 mW/cm², 7.2 J/cm²). The device delivers continuous blue light at 4 cm from the wound surface, 60 seconds per 25 cm² sub-area (120 seconds for diabetic wounds), administered twice weekly for 4 consecutive weeks. The protocol is combined with standard wound care (cleansing, dressings, compression as indicated). The intervention is designed to promote wound healing in hard-to-heal wounds by modulating inflammation, enhancing angiogenesis, fibroblast activation, and re-epithelialization. This accelerated protocol (twice weekly vs. standard weekly regimens) aims to optimize clinical outcomes in a nurse-led outpatient setting and distinguishes this intervention from lower-frequency or red/infrared-based photobiomodulation approaches.
215007900|NCT06873334|DRUG|SKY-0515|"Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months~Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements."
215007901|NCT06873334|DRUG|SKY-0515 Placebo|"Route of Administration: Oral Dosage~Frequency: Once daily~Blinded Treatment Duration: 12 months~Use: Experimental~Sourcing: SKY-0515 placebo will be provided centrally by the Sponsor or subsidiary, or designee~Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements"
215007902|NCT07015671|DRUG|10 mg Torsemide tablet|Single dose 10 mg Torsemide tablet
215097105|NCT05243303|DEVICE|Sham taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted. Subjects self-administer the sham taVNS on a daily basis for 3 months.
215097106|NCT03502174|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
215097107|NCT03468322|DRUG|AC-203|The investigational product is formulated as 1% topical ointment
215097108|NCT03468322|DRUG|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
215097109|NCT05772910|BEHAVIORAL|EDUcation|The education intervention will consist of an individualized educative program based on intrinsic capacity optimization through lifestyle changes. To develop the program, the program creation team will be multidisciplinary (psychologists, medical doctor, dietitian…) and will discuss goal setting, the education strategy, and retention of motivation. The experts are required to create the education program such that the participants can manage their health by themselves. The goal will be self-management of dietary habits and increases in physical activity levels for each individual case. The education program will be in Spanish or in English; as it will consist in personal counselling, even with a low level of the language the communication will be possible. The nutritional education program will be conducted every 2 weeks for 10 consecutive weeks, with 20-min counselling sessions by an expert.
214402750|NCT02710006|PROCEDURE|Sonohysterography|Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
214402751|NCT04296942|BIOLOGICAL|Brachyury-TRICOM|Every three weeks, until cycle 9, then every 12 weeks: \*Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD): 4 injections of vaccines with 1 given subcutaneous (SC) in each extremity on Day 1 of Cycles 1 and 2. Each injection of MVA-BN-Brachyury consists of 2.0 x 10\^8 infectious units (Inf.U). \*Recombinant fowlpox virus (FPV)-BN-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond. Each injection of FPV-BN-Brachyury consists of 1.0 x 10\^9 Inf.U.
214402752|NCT04296942|DRUG|Entinostat|5mg by mouth weekly (RP2D) administered by patient on Days 1, 8 and 15 of each cycle.
214402753|NCT04296942|BIOLOGICAL|M7824|1800mg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
214402754|NCT04296942|BIOLOGICAL|Ado-trastuzumab emtansine|3.6mg/kg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
215097110|NCT05772910|OTHER|EXERcise|The intervention period will have 10 weeks, in which the EXER group will carry out 2-3 sessions a week (total of 20-30 sessions). In this concurrent program, exercises of the lower extremities (leg press, abduction and plantar flexion) will be performed mainly on weight training machines. Intensity in each exercise will be individualized for each participant through a test to determine muscle power. In addition, in the last part of each session the participants will perform an endurance training type high insensitive interval training on a cycle ergometer (60-80 rpm). The intensity will be individualized to each patient through an incremental stress test until volitional exhaustion, and the subjects will alternate intervals of 30 seconds at 90% of the maximum workload, with intervals of 90 seconds at 40% of the maximum. Each session is estimated to have a total duration of 30-50 minutes.
215097111|NCT05772910|OTHER|EDU-EXER|This group will carry out the same two previous interventions together.
215097112|NCT05772910|OTHER|CONtrol|CONtrol group will continue the usual clinical treatment and their normal life
215097113|NCT03098745|DEVICE|Omafilcon A|contact lens
214402755|NCT01680120|PROCEDURE|Continuous spinal anaesthesia|"Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.~Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.~Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12)."
214402756|NCT02920593|DRUG|Vitamin D3|Vitamin D prophylaxis
214402757|NCT05913323|DEVICE|Rapid Expiratory Occlusion Monitor (REOM)|Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.
214402758|NCT05913323|DIAGNOSTIC_TEST|Standard oscillometry|tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada
214402759|NCT05913323|DIAGNOSTIC_TEST|Standard pulmonary function test|Standard-of-care respiratory test.
214504530|NCT07043699|OTHER|Phonophoresis|Each woman in the first group received phonophoresis treatment. The procedure was performed using diclofenac sodium gel. Treatment was administered three times per week over a period of eight weeks. Ultrasound was applied at an intensity of 1 W/cm² for 8 minutes using a pulsed mode at a frequency of 1 MHz.
214688235|NCT07162272|DRUG|Melatonin Patches|Group 1 (n=26): Participants in the intervention group will receive two melatonin patches on their forearm (each containing 1mg of melatonin, AVEELA, USA) attached to the skin of their forearm 30 minutes prior to their invasive dental treatment. Pulse Rate, Blood Pressure, and Modified Child Dental Anxiety Scale will be measured before melatonin patches application, after 30minutes of patches application, then after local anesthesia injection, and finally after completing the invasive dental treatment.
215097114|NCT03098745|DEVICE|Somofilcon A|contact lens
215097115|NCT03098745|DEVICE|Omafilcon A - Proclear (PC)|contact lens
215097116|NCT00205816|DRUG|Tigecycline|
215097117|NCT00905203|OTHER|exercise|exercise training
215007903|NCT07015671|DRUG|25 mg Aldactone (Spironolactone) tablet|Single dose 25 mg Aldactone® (Spironolactone) tablet
214402760|NCT04164160|OTHER|integrated-care-model benefiting group|Patients will be called for the ﬁrst interview of the study by the healthcare professional. Their data will be automatically entered in the Salut + Social app, they will be asked to respond to the study questionnaires (ad hoc questionnaire for sociodemographic data, EuroQol-5D, Zarit questionnaire and Morisky-Green test) and will take part in the future actions to be planned for them. Patients will receive an appointment to attend their PCC at 6, 9, and 12 months after their incorporation into the program. In those follow-up, the same questionnaires will be provided together with the IEXPAC questionnaire, which evaluates the experience of the chronic patient with the new care model.
215007904|NCT07015671|DRUG|FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet|Single dose FDC (12 mg ER Torsemide + 15 mg Spironolactone) tablet
215007905|NCT04356924|BEHAVIORAL|Psychological treatment|The treatment is an adjusted (to the cognitively impaired individual) combination of CBT, ACT, validation strategies, and psychoeducation. One focus is to increase motivation to lifestyle changes, and to a larger degree live life in correspondence with internal goals.
214402761|NCT06421974|PROCEDURE|DaVinci si or xi system|In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
214402762|NCT06421974|PROCEDURE|laparoscopic radical resection|In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
215097118|NCT04248023|BEHAVIORAL|Practice Facilitation|A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
215097119|NCT03403023|DEVICE|Tear Film Imager|The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).
214402763|NCT04038099|DRUG|Water-Based Vaginal Lubricant|5cc water based jelly applied intraurethral
214402764|NCT04038099|DRUG|lidocaine topical|5cc 2% lidocaine jelly applied intraurethral
214402765|NCT00166660|BEHAVIORAL|NIDCAP (Newborn Individualized Developmental Care)|The NIDCAP model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account the infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists formally observed each infant's behavior weekly throughout the hospitalization, starting with the phase of the infant's initial stabilization, and then every seven days throughout hospital discharge and to 2wCA.
214402766|NCT03992911|DRUG|Simmtecan, 5-FU and l-LV|Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.
214402767|NCT03992911|DRUG|Toripalimab|Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.
215007906|NCT04356924|BEHAVIORAL|Cognitive training|Computer based training tasks implemented with adaptive intensity. The cognitive training method that will be used is mainly related to executive control (i.e., ability to coordinate thoughts and actions in accordance with internal goals).
215007907|NCT04174261|DRUG|Ticagrelor|Preprocedural ticagrelor loading and standard dose thereafter
215007908|NCT04174261|PROCEDURE|Remote Ischemic Preconditioning|Preprocedural remote ischemic preconditioning on the non-dominant arm
215097120|NCT03403023|DRUG|Restasis|Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
215097121|NCT05160818|RADIATION|Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiotherapy radiosurgery (SRS)|intervention description see above
215097122|NCT04839445|PROCEDURE|General anesthesia + TAP block|Post induction TAP block for intra and postoperative analgesia.
215097123|NCT04839445|PROCEDURE|General anesthesia + ESP block|Pre induction ESP block for intra and postoperative analgesia.
214402768|NCT03992911|DRUG|Etoposide, Cisplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.
214402769|NCT03992911|DRUG|Etoposide, Carboplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
215007909|NCT04174261|DRUG|Clopidogrel|Preprocedural clopidogrel loading and standard dose thereafter
215007910|NCT07046182|BIOLOGICAL|CEP + Dasatinib + Azacitidine|CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma
215007911|NCT07046442|OTHER|Pulmonary Rehabilitation|The Active Cycle of Breathing Technique (ACBT), is a structured method aimed at restoring normal breathing patterns, improving respiratory muscle efficiency, and reducing airway irritation.
215007912|NCT07045701|COMBINATION_PRODUCT|Epinephrine 4mg nasal powder spray|Epinephrine nasal powder spray in a unidose nasal applicator device. Will be administered together with a placebo saline IM injection
215007913|NCT07045701|COMBINATION_PRODUCT|Adrenalin 0.5mg Injectable Product|Epinephrine 0.5mg for IM injection. Will be administered together with a placebo nasal powder spray.
215097124|NCT01008085|DEVICE|Stentys coronary stent|Self-expanding Nitinol stent
215097125|NCT01008085|DEVICE|Balloon-expandable stent|VISION/Driver
215097126|NCT00037154|DRUG|Saw Palmetto|
215097127|NCT00000802|DRUG|Atovaquone|
215097128|NCT00000802|DRUG|Dapsone|
214402770|NCT03264196|PROCEDURE|Open Reduction and Internal Fixation|Surgical treatment of fracture
214402771|NCT01349751|DRUG|isobaric levobupivacaine|0.42% either isobaric levobupivacaine 3 ml spinal injection once
215007914|NCT06734897|OTHER|music therapy after Cochlear Implantation|The music therapy is specially designed for the rehabilitation of CI-patients. It focuses on learning to distinguish different sound sources, especially when they occur at the same time. Training involves familiarization with different aspects of music such as rhythm, melody, and pitch while at the same time also getting to know the sound of different musical instruments, including singing. The training is also aimed at learning to concentrate on spoken instructions while the music is going on. This latter aim is fundamental to the goal of this study and plays a central role in the therapy.
214402772|NCT01349751|DRUG|hyperbaric levobupivacaine|0.42% hyperbaric levobupivacaine 3 ml spinal injection once
214402773|NCT02478359|BEHAVIORAL|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
214402774|NCT05489861|BEHAVIORAL|M-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
214402775|NCT05489861|BEHAVIORAL|F-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
214402776|NCT00996086|DEVICE|CRT device implant|CRT device-recipients
214402777|NCT03891680|DRUG|Botox Injectable Product|Intra articular Botox injection
215007915|NCT06734897|OTHER|no music therapy after Cochlear Implantation|Group C consists of persons who do not receive any music therapy after Cochlear Implantation.
215007916|NCT07052071|PROCEDURE|TAVI|Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive method for replacing the aortic valve in patients with severe aortic stenosis. The procedure involves the placement of a bioprosthetic valve within the patient's degenerated aortic valve via a catheter.
215007917|NCT07052201|DRUG|Dexamethasone|"DART regimen group (cumulative dose 0.89 mg/kg over 10 days): intravenous dexamethasone administered as follows:~0.075 mg/kg/dose every 12 hours for 3 days 0.05 mg/kg/dose every 12 hours for 3 days 0.025 mg/kg/dose every 12 hours for 2 days 0.01 mg/kg/dose every 12 hours for 2 days, then discontinue.~If extubation is not successful within one week after completing the treatment, the regimen may be repeated."
215007918|NCT07052201|DRUG|Dexamethasone|"Low-dose tapering regimen group (cumulative dose 0.45 mg/kg over 3 days): intravenous dexamethasone administered as follows:~0.1 mg/kg/dose every 12 hours on Day 1 0.075 mg/kg/dose every 12 hours on Day 2 0.05 mg/kg/dose every 12 hours on Day 3 If extubation is not successful within one week after completing the treatment, the regimen may be repeated."
215007919|NCT07052201|DRUG|Dexametasone|"Medium-dose tapering regimen group (cumulative dose 2.35 mg/kg over 7 days): intravenous dexamethasone administered as follows:~0.5 mg/kg/dose once daily for 3 days 0.25 mg/kg/dose once daily for 3 days 0.1 mg/kg/dose once daily for 1 day If extubation is not successful within one week after completing the treatment, the regimen may be repeated."
215007920|NCT07052409|DIETARY_SUPPLEMENT|Inkomazi|Pasteurized fermented milk
215007921|NCT07056491|OTHER|mRNA level of REST4 in serum;|"1. mRNA level of REST4 in serum The mRNA expression level of REST4 was measured in serum-derived exosomes using RT-qPCR at the time of patient enrollment.~2. Computed tomography angiography (CTA) Baseline maximum internal diameter of the abdominal aortic aneurysm (AAA) was determined by CTA at enrollment. During follow-up, CTA was performed to assess the increase in maximum AAA diameter."
215007922|NCT07056582|DRUG|Dexmedetomidine|patients in this group will receive nebulized Dexmedetomidine before onset of surgery
215007923|NCT07056582|DRUG|Ketamine|patients in this group will receive nebulized ketamine before onset of surgery
215007924|NCT07056582|DRUG|0.9%sodium chloride|patients in this group will receive nebulized 0.9% normal saline before onset of surgery
215007925|NCT07055776|COMBINATION_PRODUCT|non-invasive vagus nerve stimulation (nVNS)|Group 1 will receive non-invasive vagus nerve stimulation (nVNS) targeting the auricular branch of the vagus nerve (ABVN) using a TENS device with specialized ear clip electrodes. The electrodes will be placed on the cymba conchae or tragus region of the ear, where the ABVN is accessible. The stimulation parameters will be set to a frequency of 1 Hz (significantly reduced migraine headache), pulse width of 200-300 µs, and intensity adjusted to a strong but comfortable level without causing pain, applied for 15-30 minutes per session, 5 days a week for 12 weeks, based on protocols supported by evidence from studies such as Badran et al. (2018) and Yakunina et al. (2017), which demonstrated positive neuromodulatory effects through auricular stimulation. Baseline conventional physiotherapy for both groups will include: thermotherapy (e.g., moist hot packs for 15 minutes), range of motion (ROM) exercises, stretching of involved muscles, and strengthening exercises.
215097129|NCT05950620|OTHER|Medical obesity management.|Dietician visits, education, anti-obesity medications, and/or referral for metabolic-bariatric surgery as indicated by American Academy of Pediatrics guidelines for obesity management.
215097130|NCT01014468|DRUG|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
215097131|NCT01014468|DRUG|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
214402778|NCT03891680|DEVICE|Radiofrequancy|Genicular nerves radiofrequancy
214402779|NCT01800149|PROCEDURE|Ridge Augmentation|After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
214402780|NCT04315038|PROCEDURE|spinal anesthesia|Plan to enroll 200 health volunteers and 40 neurodegenerative diseases patients with received spinal anesthesia. Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
214402781|NCT05513521|OTHER|High-velocity interval training|For the velocity training protocol, the 11 exercises will be completed at 40% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
215097132|NCT01309685|DRUG|Varenicline|
214402782|NCT05513521|OTHER|Resistance training|For the load training protocol, the 11 exercises will be completed at 79% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
215097133|NCT00738218|OTHER|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
215097134|NCT05751148|DRUG|Hyperbaric bupivacaïne|Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution
215007926|NCT07055776|COMBINATION_PRODUCT|non-invasive transcutaneous electrical nerve stimulation (TENS)|Group 2 will receive non-invasive transcutaneous electrical nerve stimulation (TENS) applied to the other areas to target other nerves stimulation (e.g., neck, upper trapezius, or occipital area). Surface electrodes will be placed paravertebrally, using a conventional TENS protocol: frequency of 20-25 Hz, pulse width of 200-300 µs, and intensity set to produce a strong but comfortable tingling sensation without muscle contraction. Each session will last 20-30 minutes, administered 5 days a week for 12 weeks. Baseline conventional physiotherapy for both groups will include: thermotherapy (e.g., moist hot packs for 15 minutes), range of motion (ROM) exercises, stretching of involved muscles, and strengthening exercises.
214402783|NCT05808647|BEHAVIORAL|5-day controlled metabolic dietary intake|Over 5-days, all food will be provided from the metabolic kitchen and participants will be instructed to eat all of the food provided each day and only the food provided each day.
214402784|NCT02830789|DIETARY_SUPPLEMENT|Calcium Carbonate|
214402785|NCT02830789|DIETARY_SUPPLEMENT|Calcium Citrate|
215007927|NCT07056231|DIETARY_SUPPLEMENT|Caffeine|A single oral dose of 3 mg of caffeine per kilogram of body weight form approximately 60 minutes before performance testing. Supplied by Oxford Vitality, ISO-certified.
215007928|NCT07056231|DIETARY_SUPPLEMENT|Placebo|polydextrose used as Placebo
215097135|NCT05751148|DRUG|Hyperbaric prilocaïne|Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
215097136|NCT00448305|DRUG|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
215097137|NCT00448305|DRUG|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
215097138|NCT00448305|DRUG|Paclitaxel|Paclitaxel 90 mg/m² weekly
214402786|NCT02830789|DIETARY_SUPPLEMENT|Placebo|Tablet manufactured to mimic a calcium carbonate tablet
214402787|NCT02830789|PROCEDURE|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
214402788|NCT02184884|DEVICE|MACE after OPCAB|
214402789|NCT02184884|DEVICE|without MACE after OPCAB|
214402790|NCT02069587|DIETARY_SUPPLEMENT|pomegranate|
214402791|NCT05146011|PROCEDURE|Gatsric balloon insertion|Insertion of Gastric balloon prior to laparoscopic gastric bypass surgery
214402792|NCT05397015|OTHER|No intervention will be done|No intervention will be done
214402793|NCT06479473|RADIATION|Radiotherapy to all residual lesions|Patients assigned to chemoimmunotherapy with radiotherapy group would first receive PET-CT and cranial contrasted MRI to ascertain residual lesions. All residual lesions would be irradiated in a hypofractionated manner.
214402794|NCT06479473|DRUG|Chemoimmunotherapy|atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy
214402795|NCT03513861|OTHER|FASTER Assessment tool|The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.
215097139|NCT03266913|DRUG|Probiotic|Probiotics drop
215097140|NCT04420260|DIETARY_SUPPLEMENT|Group A: oropharygeal spray and immunostimulant emulsion|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of 3 natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.~Intervention 2. Preparation in an emulsion functional food presentation for oral administration, that contains the 8 bioactive compounds that have demonstrated antiviral activity and modulation of the inflammatory response recognized at the moment in the immune activation against the virus."
214402796|NCT04124991|DRUG|Durvalumab|Radioembolization with Yttrium-90 Microspheres
214402797|NCT04124991|RADIATION|Radioembolization|Radioembolization with Yttrium-90 Microspheres
214402798|NCT04626921|DRUG|CNM-Au8|30 mg of CNM-Au8
214402799|NCT01220440|DRUG|Methylphenidate|Methylphenidate:10mg x 3 for one week
214402800|NCT01220440|DRUG|Placebo|Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
214402801|NCT01220440|DRUG|Dextroamphetamine|Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
214402802|NCT05078021|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopy will be performed in all groups with endobronchial biopsies, brushings and bronchial washing performed.
214402803|NCT04560582|PROCEDURE|Blood Draw|Participants will have blood drawn for analysis at baseline and every 4 weeks for a total of 7 blood draws over 24 weeks.
214402804|NCT02809638|OTHER|ultrasound elastography|
214402805|NCT04448327|DEVICE|active tVNS|non-painful electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
214402806|NCT04448327|DEVICE|Sham tVNS|Sham stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
214402807|NCT01235429|BEHAVIORAL|Partners in Care|Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
215007929|NCT07057011|DRUG|Paroxetine 20 Mg Oral Tablet|to compare the safety and efficacy of paroxetine alone versus the combination of paroxetine and sildenafil in Premature Ejaculation Patients with genetic polymorphism in the serotonin transporter gene-linked polymorphic region.
215007930|NCT07057206|DEVICE|PFM-guided cortical stimulation|Abbott Eterna IPG and Lamitrode 44 paddles with accessory extensions and clinical programmers
215007931|NCT07057349|DRUG|[18F]CSB-321|\[18F\]CSB-321 is a PET imaging agent that is bound to released granzyme B from T-cells
215007932|NCT07056699|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin (10 mg/day)
215007933|NCT07056699|DRUG|Pioglitazone 15 MG and 30mg|Pioglitazone (15 mg/day for 2 weeks, then 30 mg/day for 14 weeks)
215097141|NCT04420260|DIETARY_SUPPLEMENT|Group D:Placebo oropharyngeal spray + Placebo taken PO|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.~Intervention 2. Preparation in an emulsion presentation for oral administration that contains the Placebo compounds"
214402808|NCT01235429|BEHAVIORAL|Partners in Care|Diabetes self-management education
214402809|NCT06059053|DEVICE|Semibranch CMD branched aortic stentgraft|bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design
214402810|NCT00562965|DRUG|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
214402811|NCT00562965|DRUG|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
214504531|NCT07043699|OTHER|Iontophoresis|Each woman in the second group received iontophoresis treatment using a diclofenac sodium solution (Voltaren ampoules). The solution was applied under the cathode (drug delivery electrode). The iontophoresis leads were connected, and the current intensity was adjusted based on individual tolerance, ranging between 1 and 4 mA, for a duration of 20 minutes. The negative electrode was placed on the medial side of the calcaneal tubercle (origin), while the positive electrode was positioned on the forefoot. Treatment was administered three times per week over a period of eight weeks.
215007934|NCT07056699|OTHER|Placebo|Inert placebo for Pioglitazone
215007935|NCT07056374|DEVICE|C-REX RectoAid Cath|Adaptive anastomotis
215007936|NCT07056569|DEVICE|047_TD Dermatitis cream twice a day for 28 days|047\_TD Dermatitis cream will be applied twice a day for 28 days on the affected skin zone in sufficient amount of cream and let it dry.
215007937|NCT07055672|COMBINATION_PRODUCT|Modified WalkFlex DB Splint (Intervention Arm)|"Application of the Modified WalkFlex Denis Browne (DB) Splint~Children with corrected idiopathic clubfoot will use the Modified WalkFlex DB Splint for maintenance. This splint allows knee and some hip movement and includes a detachable bar for walking. It will be used after Ponseti casting, and patients will be followed at 1 and 3 months to check splint tolerance, maintenance of correction (using Pirani score), and any signs of relapse"
215007938|NCT07055880|BIOLOGICAL|Rabies Vaccine (Serum-free Vero Cell), Freeze-dried|"Receiving five doses of rabies vaccine manufactured by Sinovac using the Essen PEP schedule"
215007939|NCT07055880|BIOLOGICAL|Verorab®|"Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the Essen PEP schedule"
215097142|NCT06782997|DEVICE|Electroretinogram|Electroretinogram (RETevalTM devices, LKC Technologies) performed and interpreted by an advanced practice nurse compared to the gold standard (retinography) interpreted by an ophthalmologist
215097143|NCT05710276|OTHER|abdominal infrared radiation|In a specific room (controlled temperature and humidity) with a patient lying on his back, we will determine the abdominal infrared radiation with a FLIR® thermal camera (without contact) and quantify the thermal signal by spectral analysis (in degrees Celsius).
215097144|NCT00520260|DRUG|bromfenac|0.09%, BID, 6 weeks
215097145|NCT00520260|DRUG|ketorolac|0.4%, BID, 6 weeks
214402812|NCT00562965|DRUG|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
214402813|NCT00562965|DRUG|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
214402814|NCT00562965|DRUG|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
214402815|NCT00562965|DRUG|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
214402816|NCT00562965|DRUG|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
215097146|NCT00084487|DRUG|becatecarin|Given IV
214402817|NCT00562965|DRUG|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
214402818|NCT00562965|DRUG|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
214402819|NCT05275270|OTHER|oxytocin gel|The active oxytocin gel (A) consisted of oxytocin dissolved in a gel-based on hypromellose with a pH of 3.8. 1 ml of gel contained 600 IU of oxytocin
214402820|NCT05275270|OTHER|placebo gel|The placebo gel (B) consisted of the gel alone
214402821|NCT00525057|DRUG|Dalteparin|Given SC
214402822|NCT02402179|OTHER|Tryptophan|Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
215007940|NCT07055893|BIOLOGICAL|Rabies vaccine|"Receiving five doses of rabies vaccine manufactured by Sinovac using the Essen PEP schedule"
215007941|NCT07055893|BIOLOGICAL|Verorab®|"Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the Essen PEP schedule"
215007942|NCT07057427|DRUG|Nab paclitaxel|Nab-paclitaxel (on days 1 and 8 of a 21-day cycle)
215007943|NCT07057427|DRUG|Docetaxel and Carboplatin|Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1)
215007944|NCT07057427|DRUG|Trastuzumab + Pertuzumab|Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and pertuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
215007945|NCT07055737|COMBINATION_PRODUCT|supervised aerobic activities|Participants performed supervised aerobic activities including warm-up (15 min), brisk walking, jogging, or cycling (30 min), squats on exercise ball (10 min), and cool down (5 min). Sessions were conducted three times a week
214504532|NCT07044206|DEVICE|Use of bone substitute during intervertebral fusion surgery|Participants randomized will receive bone substitute during intervertebral fusion surgery. Routine postoperative follow-up procedure (identical for both groups) with two postoperative visits at 3 months and 12 months.
215007946|NCT07055737|COMBINATION_PRODUCT|Barre group performed light warm-up|Barre group performed light warm-up (15 min), lower abdominal crunches, leg raises, wall push-ups, and planks (3 sets each), followed by cool-down stretches (5 min). Sessions were conducted three times a week.
215007947|NCT00677222|BIOLOGICAL|AMI MultiStem®|AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
215007948|NCT07055568|DRUG|iNKT|iNKT: Intravenous infusion, 0.5×10\^8cell-3.0×10\^8 cell
215007949|NCT07057401|DEVICE|CAD-CAM Manufactured Crowns|Single crowns produced using computer-aided design and milling technology applied to permanent molars.
215007950|NCT07057401|DEVICE|3D Printed Crowns|Single crowns produced using 3D printing technology applied to permanent molars.
215007951|NCT06756308|DRUG|Enasidenib|Enasidenib 100 mg daily on 28-day cycles.
215007952|NCT06756308|DRUG|Rituximab|IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter on 28-day cycles, for a total of four months of rituximab.
215007953|NCT07056322|DIETARY_SUPPLEMENT|200 ml dairy|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
215007954|NCT07056322|DIETARY_SUPPLEMENT|100 ml milk|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
215007955|NCT07056322|DIETARY_SUPPLEMENT|100 g banana|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
215097147|NCT06259682|BEHAVIORAL|Paradoxical Intention|Paradoxical intention (PI). PI is described as instructing patients with sleep onset insomnia to try to remain awake for as long as possible rather than to focus on trying to fall asleep
215097148|NCT04197388|DEVICE|Inspiratory muscle training device|Inspiratory muscle training, 6 cycles of 30 breaths for 12 weeks.
215097149|NCT00001136|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
215097150|NCT02517372|DRUG|CRD007|
215097151|NCT00003691|BIOLOGICAL|filgrastim|
215097152|NCT00003691|DRUG|cisplatin|
215097153|NCT00003691|DRUG|doxorubicin hydrochloride|
214504533|NCT07042906|DEVICE|anesthesia depth monitorizing, awareness|Investigation of BIS and PSI Monitoring Methods for Anesthetic Depth and the Factors Affecting These Methods in Open-Heart Surgery
215007956|NCT07056322|DIETARY_SUPPLEMENT|100 ml dairy and fibers|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
215007957|NCT07056322|OTHER|Fasting (control)|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
215007958|NCT07056322|DIETARY_SUPPLEMENT|100 ml dairy|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
215007959|NCT07057479|DRUG|Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione|Oral fixed-dose combination tablet containing an SGLT2 inhibitor and a thiazolidinedione, administered once daily. Participants also receive matching placebos for both comparator drugs to maintain blinding. All participants continue background metformin therapy (≥1000mg/day).
215007960|NCT07057479|DRUG|Control Group 1 Intervention - SGLT2 inhibitor monotherapy|Oral tablet containing an SGLT2 inhibitor, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the thiazolidinedione comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.
215007961|NCT07057479|DRUG|Control Group 2 Intervention - Thiazolidinedione monotherapy|Oral tablet containing a thiazolidinedione, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the SGLT2 inhibitor comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.
215007962|NCT07057479|DRUG|Background Therapy (All Groups) - Metformin|Extended-release metformin tablets (≥1000mg daily) continued as background therapy for all participants throughout the study duration.
215007963|NCT01179399|DRUG|TAK-960|TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
215007964|NCT03018730|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
215097154|NCT00003691|DRUG|paclitaxel|
215097155|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -3-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, phone check-ins, crisis management and individual initial assessment.
215097156|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -6-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, individual psychotherapy, coaching calls and treatment-team consultation.
215097157|NCT05701891|COMBINATION_PRODUCT|Physiotherapy with integrated Virtual Reality|A 12-week personalised, VR-integrated physiotherapy intervention.
215097158|NCT05701891|OTHER|Physiotherapy (usual care)|A 12-week usual physiotherapy care intervention.
215097159|NCT01848366|DEVICE|Biowave Treatment|Twelve weekly treatments
215097160|NCT02068872|PROCEDURE|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of \> 40 or \> 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
215097161|NCT04588090|PROCEDURE|The concurrent 3 weeks TP regimen|paclitaxel + cisplatin regimen (TP-TAX: 150mg/m\^2, DDP: 70mg/m\^2 (35mg/m\^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
215097162|NCT04588090|PROCEDURE|The concurrent weekly TP regimen|paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m\^2, DDP: 25mg/m\^2) 6 cycles of chemotherapy
215007965|NCT03739554|DRUG|CYC065|intravenous infusion
215007966|NCT03739554|DRUG|Venetoclax|oral capsule
215007967|NCT01939457|DRUG|Misoprostol|
215007968|NCT05947006|OTHER|Standard care|Patients in this arm will receive the standard care stablished in the emergency room after a febrile seizure, consisting of a medical assessment of the child, followed by 6 hours of supervision of the child and his parent in the waiting room, a reassessment of the child by the doctor, and finally they can return home
215007969|NCT05947006|OTHER|CONSULFE consultation|In addition to the standard care, patients in this arm will receive a consultation managed by the pediatric nurse (CONSULFE) during the 6 hour supervision time in the waiting room
215007970|NCT01009697|DRUG|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
215007971|NCT06478563|DRUG|NNC0487-0111 (formulation D)|Participants will receive NNC0487-0111 (formulation D) tablet once daily.
215007972|NCT06478563|DRUG|NNC0487-0111 (formulation C)|Participants will receive NNC0487-0111 (formulation C) tablet once daily.
215007973|NCT03921541|DRUG|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
215007974|NCT03921541|DRUG|Placebo|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
215007975|NCT06808854|PROCEDURE|Dental implant treatment (variable-thread implants)|Replacement of a missing tooth with a dental implant with variable-thread implants
215007976|NCT06808854|PROCEDURE|Dental implant treatment (standard implants)|Replacement of a missing tooth with a dental implant with standard implants
215007977|NCT04975919|DRUG|Decitabine and Cedazuridine|Given PO
215097163|NCT04588090|RADIATION|External radiation plus intraluminal after-loading irradiation|External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
215097164|NCT00988481|DRUG|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
215097165|NCT01501123|DRUG|Haloperidol|5mg IM
215097166|NCT01501123|DRUG|Midazolam|IM midazolam
215097167|NCT03040986|OTHER|Laboratory Biomarker Analysis|Correlative studies
215097168|NCT03040986|DRUG|Selumetinib Sulfate|Given by mouth (PO)
215097169|NCT04421209|DRUG|Propranolol Hcl 40mg Tab|40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.
215097170|NCT04421209|DRUG|Placebo oral tablet|Placebo tablets administered with the same schedule of Propranolol tablets
215097171|NCT02228447|BEHAVIORAL|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
215097172|NCT00235950|DRUG|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
215097173|NCT00288327|BEHAVIORAL|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
215097174|NCT00288327|BEHAVIORAL|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
215007978|NCT04975919|DRUG|Venetoclax|Given PO
215007979|NCT01712464|DRUG|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
215097175|NCT04100941|DIAGNOSTIC_TEST|standard suction|After the needle is inserted in the mass, removing the stylet before performing EUS-FNA. Then attach a 10mL syringe to the end of needle. 20 times of for-backward Suction was applied after the lesion was punctured.
215097176|NCT04100941|DIAGNOSTIC_TEST|slow pull|After the needle is inserted in the mass, slowly pull the stylet out while performing EUS-FNA with 20 times for-backward.
215007980|NCT04597112|OTHER|Myofascial Release Technique|Myofascial release focuses on reducing pain by easing the tension and tightness in the trigger points. Therapist will gently massage the myofascia and feel for stiff or tightened areas. Normal myofascia should feel pliable and elastic. The therapist will begin massaging and stretching the areas that feel rigid with light manual pressure. The therapist then aids the tissue and supportive sheath in releasing pressure and tightness. The process is repeated multiple times on the same trigger point and on other trigger points until the therapist feels the tension is fully released.
215007981|NCT04597112|OTHER|Exercise|"Exercise is recommended by physical therapists for most cervical radiculopathy patients.~In this study, a customized exercise program will be applied for patients with cervical radiculopathy."
215007982|NCT01653262|DRUG|Brivaracetam|
215007983|NCT02975453|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
215007984|NCT02182700|DRUG|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
215007985|NCT02616952|DIETARY_SUPPLEMENT|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
215097177|NCT04100941|DIAGNOSTIC_TEST|wet suction|After removing the stylet, the needle was flushed with 5mL of saline solution to replace the column of air with saline. A 10mL syringe was attached to the end of the needle. 20 times of for-backward Suction was applied after the lesion was punctured.
215097178|NCT00578630|OTHER|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
215007986|NCT02616952|BEHAVIORAL|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
214504534|NCT07042568|BEHAVIORAL|Nursing education aimed at preventing oral mucositis|The intervention group was trained on the use of the Oral Mucositis Prevention Patient Education Handbook, which was prepared by the researchers based on literature information and expert opinions. Participants in the intervention group received telephone consultations on days 7 and 14. The control group continued to receive routine nursing care. The second interview was completed on day 21, when both the intervention and control group patients returned for their next treatment cycle, using the WHO Oral Toxicity Criteria, ADR, and EORTC QLQ-C30 Version 3.0 Quality of Life Scale.
215007987|NCT02046187|DIETARY_SUPPLEMENT|Ketogenic Diet|Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
215007988|NCT02046187|RADIATION|Radiation therapy|Patients receive standard dose (60Gy/30 fractions) external beam radiation
215007989|NCT02046187|DRUG|Temozolomide|patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
215007990|NCT02030639|DRUG|rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib (\[14C\]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
215007991|NCT02798952|BIOLOGICAL|Engerix-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
215007992|NCT04745988|DRUG|Lenvatinib 20mg|Lenvatinib will be administered at a dose of 20mg as oral dose, once a day.
215007993|NCT04745988|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
215007994|NCT04745988|DRUG|Lenvatinib 8mg|Lenvatinib will be administered at a dose of 8mg as oral dose, once a day.
215007995|NCT04745988|DRUG|Docetaxel|Docetaxel will be administered at a dose of 50mg/m\^2 as a IV infusion, Q2W.
215007996|NCT04745988|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85mg/m\^2 as a IV infusion, Q2W.
215007997|NCT04745988|DRUG|Levofolinate|Levofolinate will be administered at a dose of 200mg/m\^2 as a IV infusion, Q2W.
215097179|NCT02547051|OTHER|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
215097180|NCT05283590|DIAGNOSTIC_TEST|Automated echocardiographic inferior vena cava measurement|Patients will be place in supine position. view: subcostal view, importantly supine is standard position for IVC measurement, the IVC is larger in the right lateral decubitus position and vice versa, alternatively directly through a transhepatic approach. Measures will be performed in the two dimensional mode close to the hepatic vein (1 - 3cm from the IVC connection to the right atrium). The IVC will be measured by MM-Mode manually and with the automated mode (both measures will be recorded. In the manual mode this measure requires concurrent utilization of M-Mode and two dimensional mode
215007998|NCT04745988|DRUG|Fluorouracil|Levofolinate will be administered at a dose of 2600mg/m\^2 as a IV infusion, Q2W.
215007999|NCT00420407|DRUG|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
215008000|NCT00420407|DRUG|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
215008001|NCT02424786|OTHER|STOPP/START criteria|Evaluation of medication lists
215008002|NCT05044611|DRUG|Anhydrous Amiloride Hydrochloride|"Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI.~Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase"
215008003|NCT05044611|DRUG|Placebo|Route of administration : oral the control arm will receive a placebo twice daily during 2 months
215008004|NCT04536103|DIAGNOSTIC_TEST|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in healthy patients and patients with ACL injury.
215097181|NCT02273960|DRUG|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
215097182|NCT02273960|DRUG|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
215097183|NCT02273960|DRUG|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
215097184|NCT02273960|DRUG|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
214688236|NCT07162272|OTHER|Placebo Group|Group 2 (n=26): Participants in the intervention group will receive two placebo patches on their forearm attached to the skin of their forearm 30 minutes prior to their invasive dental treatment. Pulse Rate, Blood Pressure, and Modified Child Dental Anxiety Scale will be measured before placebo patches application, after 30minutes of patches application, then after local anesthesia injection, and finally after completing the invasive dental treatment.
215097185|NCT04086992|OTHER|Remote monitoring|Caregivers will be able to monitor blood pressure from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
214402823|NCT06036979|PROCEDURE|Paravertebral plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the transverse processes clearly visualized . Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique toward the paravertebral space, immediately above the pleura and below the superior costotransverse ligament. The position of the needle is confirmed by the descent of the pleura when injecting 2 to 3 ml of saline solution for hydrolocalization. Then 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
215008005|NCT06425081|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri AMBV339|Limosilactobacillus reuteri AMBV339 is a probiotic strain
215097186|NCT00265031|DRUG|Cyclophosphamide|
215008006|NCT06425081|DIETARY_SUPPLEMENT|Humiome B2|Colon-delivered Riboflavin
215008007|NCT06425081|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri AMBV339 + Humiome B2|Combination of supplements used in arm 1 and 2
215097187|NCT00265031|DRUG|Adriamycin|
215097188|NCT00265031|DRUG|Etoposide|
215097189|NCT00265031|DRUG|Procarbazine|
215097190|NCT00265031|DRUG|Prednisone|
214402824|NCT06036979|PROCEDURE|Erector spinae plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the tips of the transverse processes clearly visualized . The following muscles seen from superficial to deep layer are trapezius, rhomboid major and erector spinae muscles. Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique to reach the interfascial plane between the transverse process and the erector spinae muscle. Following confirmation of the accurate position of the needle tip with 3-5 ml normal saline solution, 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
214402825|NCT06036979|DRUG|Intravenous morphine, ketorlac and paracetamol|• In the control group only we add 10mg intravenous morphine, 30 mg intravenous ketorlac and 1 gm intravenous paracetamol for analgesia.
215008008|NCT06425081|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose
215008009|NCT04630886|DRUG|Tranexamic acid injection|subcutaneous injection of 50mg/ml TXA
215008010|NCT04630886|DRUG|Lidocaine Epinephrine|subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
215008011|NCT05417776|DRUG|[68Ga]CBP8|An injection of up to 350 MBq of \[68Ga\]CBP8 will be administered intravenously followed by PET-MRI.
215008012|NCT05417776|DRUG|Dotarem|Dotarem will be administered during MRI portion of study.
215008013|NCT06957847|DEVICE|Blood pressure measurement|The patient will be measured alternatively with a reference mercury sphygmomanometer (four times) and the device under study (3 times)
215008014|NCT06957210|BEHAVIORAL|EMDR|Participants will receive structured EMDR therapy sessions conducted by trained therapists following standard EMDR protocols. Sessions will occur weekly over a 6 week period.
215008015|NCT06957210|DRUG|SSRIs|Participants will receive pharmacotherapy with an SSRI prescribed according to standard clinical guidelines for PTSD, monitored by a psychiatrist over a 6-week period.
215008016|NCT04636307|OTHER|Biomarkers|To identify biomarkers obtained using non-invasive procedures that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in NPDR.
215008017|NCT06829160|BEHAVIORAL|Communication with exercise therapist|A personalized exercise program will be designed. The assigned therapist will identify potential barriers to this plan and develop mitigation strategies. The assigned therapist will then make phone contact with participants weekly for the duration of the study. Exercise recommendations will be titrated during calls based on review of activity data.
215097191|NCT00265031|DRUG|Vincristine|
215097192|NCT00265031|DRUG|Bleomycin|
215097193|NCT00265031|PROCEDURE|radiation therapy|
215008018|NCT06829160|BEHAVIORAL|mHealth-CR|mHealth-CR software (currently, from Corrie Health) will permit 1) participant data entry about exercise; 2) viewing of educational material pertinent to the condition.
215097194|NCT03161574|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
215097195|NCT05538546|DIAGNOSTIC_TEST|Complete blood count|Complete blood count will be conducted at 12th month and 24th month from baseline.
215097196|NCT05538546|DIAGNOSTIC_TEST|Transient elastrography|Transient elastrography, and endoscopy will be conducted at 12th month and 24th month from baseline.
215097197|NCT05538546|DIAGNOSTIC_TEST|Endoscopy|Endoscopy will be conducted at 12th month and 24th month from baseline.
215097198|NCT00455208|DRUG|Cura-100|
215097199|NCT00300352|DRUG|Folic Acid|
215097200|NCT00569088|DRUG|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
215097201|NCT00569088|DRUG|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
215097202|NCT04166760|DIETARY_SUPPLEMENT|speWHE|25 gram of a specific whey fraction (confidential)
215097203|NCT04166760|DIETARY_SUPPLEMENT|WHE|25 gram protein of a regular whey compound
215097204|NCT02193113|DRUG|KVD001 Injection|A novel plasma kallikrein inhibitor
215097205|NCT01608841|DRUG|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
215097206|NCT06947642|DRUG|Pectoral nerve block (PECS)|Patients will receive pectoral nerve block (PECS).
215097207|NCT06947642|DRUG|Erector spinae plane block (ESP)|Patients will receive erector spinae plane block (ESP).
215097208|NCT06947642|DRUG|Serratus anterior plane block (SAP)|Patients will receive serratus anterior plane block (SAP).
215008019|NCT06829160|BEHAVIORAL|Wearable activity monitoring device|Participants will be offered the Fitbit Charge 5. This commercially available product measures physical activity.
215008020|NCT05713630|DRUG|Tranexamic acid (TXA)|Marcan-Tranexamic Acid 500 mg oral tablet over-encapsulated to match the placebo. Sandoz-Tranexamic Acid 100 mg/mL solution for injection via intravenous (IV) added to a 100mL infusion bag of NaCl 0.9% and infused by slow intravenous injection over 20 minutes.
215008021|NCT05713630|DRUG|Placebo|Placebo 500 mg consisting of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed. Placebo 100 mg/mL solution for injection via intravenous (IV) consisting of 0.9% sodium chloride (saline).
215008022|NCT05994183|DRUG|Dexamethasone Oral|Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)
215008023|NCT05896124|DRUG|2mg CS0159|Oral QD
215008024|NCT05896124|DRUG|Placebo|Oral QD
215008025|NCT04851015|DRUG|trimethoprim-sulfamethoxazole|10mg/kg/day of TMP component
215008026|NCT04851015|DRUG|trimethoprim-sulfamethoxazole|15mg/kg/day of TMP component
215008027|NCT03594838|OTHER|HCV viremia testing approaches|Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
215008028|NCT03690544|DRUG|Apremilast 30mg|Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
215008029|NCT06963723|OTHER|Financial Hardship Screening|Financial Hardship Screening and Financial Needs Assessment
215097209|NCT05517694|OTHER|Pelvic floor exercises and behavioral therapy|Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.
215097210|NCT05517694|OTHER|Respiratory exercises|"Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.~Respiratory exercises will be given 6 breaths/minute with expiration and inspiration times of 7 seconds and 3 seconds, respectively. At least 10 diaphragmatic breaths will be given in each session, 2 times a day, 7 days a week, 8 weeks."
215097211|NCT00278811|PROCEDURE|mobile crisis team|
214402826|NCT01911221|BIOLOGICAL|rMenB+OMV NZ|Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
214402827|NCT05071573|OTHER|Optimised electronic patient records|Viral load champions trained in the monitoring of patient on antiretroviral therapy to aid prompt identification of virological failure and institution of appropriate clinical management
215097212|NCT01780753|DRUG|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
215097213|NCT02619032|DRUG|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
214402828|NCT05556005|DRUG|Trimetazidine Dihydrochloride|Trimetazidine Dihydrochloride 35 mg modified release tablet used twice daily
214402829|NCT05556005|DRUG|Placebo|Starch tablets used twice daily
214402830|NCT02298543|OTHER|coronary spasm|
215008030|NCT06963723|OTHER|Enhanced Usual Care|Enhanced Usual Care
214402831|NCT00563654|DRUG|Alfuzosin GITS (Xatral XL)|
214402832|NCT04795141|DRUG|ABY-035|ABY-035 Solution for injection
214402833|NCT04795141|DRUG|Placebo|Normal Saline for injection
214688237|NCT07162155|BEHAVIORAL|School-based Hybrid Intervention to Prevent Vaping and Prescription Drug Misuse|Psychosocial school-based hybrid intervention which includes traditional classroom sessions and online e-learning modules to reduce risk of vaping and prescription drug misuse among upper elementary school students.
215008031|NCT05208047|DRUG|CGT9486 plus sunitinib|Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.
215008032|NCT05208047|DRUG|CGT9486|Participants will receive CGT9486 until steady state then both CGT9486 and sunitinib orally until study stopping rules are met.
215008033|NCT05208047|DRUG|Sunitinib|Participants will receive sunitinib until steady state then both sunitinib and CGT9486 orally until study stopping rules are met.
214688238|NCT07163572|DRUG|Intravenous brivaracetam|Patients received intravenous brivaracetam as a loading dose of 2 mg/kg (maximum 100 mg) diluted in 100 ml of normal saline infused over 10 minutes.
214688239|NCT07163572|DRUG|Intravenous levetiracetam|Patients received intravenous levetiracetam as a loading dose of 40 mg/kg (maximum 3000 mg) diluted in 100 ml of normal saline infused over 10 minutes.
215008034|NCT05208047|DRUG|Sunitinib|Participants will receive sunitinib orally until study stopping rules are met.
215008035|NCT05208047|DRUG|Midazolam|Participants will receive a single-dose of midazolam on Day 1 and Day 16
215008036|NCT05208047|DRUG|CGT9486 plus sunitinib|Patients will receive CGT9486 orally starting on Day 2 and sunitinib starting on Day 16 until study stopping rules are met.
215008037|NCT06964451|PROCEDURE|Extraction tooth|Extraction of MIH Grade 4 molar
215008038|NCT02724644|BIOLOGICAL|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Injectable intervention
215008039|NCT02724644|BIOLOGICAL|Placebo Comparator|
215097214|NCT02619032|DRUG|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
215097215|NCT03150732|DRUG|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
215097216|NCT03150732|DRUG|Local nalbuphine|Patients will receive local nalbuphine 10 mg
215097217|NCT03464149|DIAGNOSTIC_TEST|One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)|Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)
215097218|NCT04454944|BEHAVIORAL|LPG subsidy|Different subsidy rates, ranging between 0% and 100% (listed below) will be written on cards. Individuals will randomly select a card to display the subsidy rate for each household. The card will be concealed with a scratch-off sticker, with a higher likelihood of drawing a high price (low subsidy) than a low price (high subsidy) given that take up will be higher in the latter group.
215097219|NCT04454944|BEHAVIORAL|Distance allocation|We will set up fuel supply depots to increase the convenience and lower costs and hassle associated with traveling to an established filling station. The supply depots will mirror a recirculation model of LPG distribution currently being piloted by the National Petroleum Authority of Ghana. Households will be randomly assigned to one of the supply depots in advance or to continue refilling their cylinder at the filling station.
215097220|NCT01873651|DEVICE|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
215097221|NCT00554762|DRUG|GW842166X|Administer
215097222|NCT04453176|OTHER|Patient Satisfaction|Patient satisfaction evaluated with EVAN G questionnaire
215097223|NCT02098889|DRUG|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
214402834|NCT03505645|PROCEDURE|Periarticular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~Treatment group 1: Periarticular infiltration~Intra-operatively after bone cuts have been made and prior to implant cementation, the multimodal injection will be infiltrated around the knee at 6 specific sites:~1. Medial femoral condyle periosteum~2. Medial gutter~3. Lateral femoral condyle periosteum~4. Lateral gutter~5. Posteromedial capsule~6. Posterolateral capsule"
214688240|NCT07162883|DRUG|QL2107|IV infusion.
214688241|NCT07162883|DRUG|Keytruda®|IV infusion.
214688242|NCT07163975|PROCEDURE|complete pulpotomy|the exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 5 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 5 minutes. After hemostasis, MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using a carrier. This will be followed by application of a layer of light-cure RMGIC and light-curing for 20 sec. The tooth then will be restored using composite resin following etch and rinse technique.
215097224|NCT02098889|DRUG|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
215097225|NCT05345028|DIETARY_SUPPLEMENT|lecithin-based delivery form of Boswellia serrata|250 mg for 5 days
215097226|NCT05345028|COMBINATION_PRODUCT|Placebo|250 mg for 5 days
215097227|NCT01608451|DRUG|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
215097228|NCT01608451|DRUG|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
215097229|NCT03475329|OTHER|adenotonsillectomy|adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
215097230|NCT03023163|OTHER|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
215008040|NCT01734928|DRUG|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
215008041|NCT01734928|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
215097231|NCT03672786|DIETARY_SUPPLEMENT|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
215097232|NCT02530736|OTHER|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
215097233|NCT04272333|DRUG|Motolimod|Intratumoral microdose injection by the CIVO device.
215097234|NCT04272333|BIOLOGICAL|Nivolumab|Intratumoral microdose injection by the CIVO device.
215097235|NCT04272333|COMBINATION_PRODUCT|Motolimod + Nivolumab|Intratumoral microdose injection by the CIVO device.
215097236|NCT01158209|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
215008042|NCT01734928|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
215008043|NCT01765621|OTHER|DDI+ System and Pharmacogenetic Data|
215008044|NCT01778985|DRUG|Premarin|
215008045|NCT01778985|OTHER|Placebo|
215008046|NCT06166641|PROCEDURE|Surgical procedure at operating room|A surgical procedure in an operating room is a medical intervention that involves making incisions or using minimally invasive techniques to treat a specific condition or perform a diagnostic procedure. The operating room, also known as the operating theater or surgical suite, is a sterile environment specifically designed to minimize the risk of infection and ensure the safety of both the patient and the surgical team.
215008047|NCT05966597|BEHAVIORAL|Written persuasive leaflet|Additional written behavioural persuasive technique leaflet and a standard referral leaflet provided at the end of the home-based health screening.
215008048|NCT05966597|BEHAVIORAL|Standard referral leaflet|Standard referral leaflet provided at the end of the home-based health screening.
215008049|NCT06793722|PROCEDURE|Technological device in circumcision|Circumcision is performed by watching a video/playing a game during the procedure in children who are circumcised.
215008050|NCT06797466|PROCEDURE|3D imaging technique on the PCNL|Establishing a percutaneous access route for the stone is the first and most important step in PCNL surgery. Choosing the perfect route, position and direction largely depends on surgical experience and the ability to understand renal/peri-renal anatomy. In general, a good CT scan of the abdomen and pelvis and an experienced surgeon are sufficient, but this requires significant time in the learning curve. The aim of our study is to investigate the effect of 3D imaging technique on the PCNL learning curve in specialist training.
215008051|NCT03761914|BIOLOGICAL|galinpepimut-S|"* Induction phase: the first two GPS + Montanide injections are administered Q3W on Week 0 and Week 3. Thereafter, GPS + Montanide is co-administered with pembrolizumab Q3W (Weeks 6, 9, 12, 15, 18).~* Early immune booster phase: A single administration of pembrolizumab (Week 21), and then GPS + Montanide resumes Q3W for six additional doses (Weeks 24, 27, 30, 33, 36, 39).~* Following the early immune booster, there is a 12-week interval of pembrolizumab administration (Weeks 42, 45, 48, 51), and then GPS is resumed every 12 weeks for an additional four doses.~* After 84 weeks, participants who had not progressed will continue in the study and be treated with pembrolizumab alone."
215008052|NCT03761914|BIOLOGICAL|pembrolizumab|Pembrolizumab is administered at a dose of 200 mg intravenously every 3 weeks on Day 1 of each cycle (3-week cycles) starting on Study Week 6 and continuing for up to 2 years thereafter (Study Week 108). Pembrolizumab is to be administered no earlier than 30 minutes after the administration of GPS on Day 1 of each cycle.
215008053|NCT03761914|OTHER|Montanide|Adjuvant
215008054|NCT03761914|BIOLOGICAL|GM-CSF|Participants receive 70 μg GM-CSF SC on Day -2 and on Day 1 before each GPS injection. The GM-CSF injections occur at the same anatomical site of the next planned study treatment injection.
215097237|NCT02127177|DEVICE|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
214693863|NCT06433518|DRUG|recombinant hCG|"Experimental Group: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.~Control Group: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.~All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.~The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.~Primary and secondary outcomes will be compared between the two groups."
214693864|NCT03009201|DRUG|Doxorubicin Hydrochloride|Given IV
215008055|NCT06550453|DRUG|Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)|"Pabolizumab is an lgG4 subclass monoclonal antibody humanized against PD-l molecules thatblocks the immune escape mechanism of cancer cells by inhibiting the PD-l receptor oflymphocytes, thereby allowing the immune system to destroy them.~In the single-arm study, all enrolled patients received a combination of chemotherapy and immunotherapy, as outlined below:~Pembrolizumab:~Day 1：Pembrolizumab injection 200mg was administered once and repeated every 21 days, expected to last 2-4 cycles. Two vials (200 mg) of pembrolizumab injection should be diluted into 100-200 mL of saline, and the infusion time should be more than 30 minutes.~Chemotherapy (CapeOX regimen):~Day 2: Bevacizumab (7.5 mg/kg) + Oxaliplatin (135 mg/m2) + Capecitabine (1 g/m2, did, d1-d14). Treatment repeated every 3 weeks (q3w) until disease progression or intolerable toxicity."
215008056|NCT05930938|DRUG|Xevinapant|Xevinapant is a multi-IAP antagonist that blocks the activity of several IAPs including X-linked IAP (XIAP), cellular inhibitor of apoptosis proteins (cIAP) 1, cIAP2 and ML-IAP
215008057|NCT05930938|DRUG|Placebo|Xevinapant without active substance
215008058|NCT05930938|DRUG|cetuximab|cetuximab
215008059|NCT05930938|RADIATION|IMRT|IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction)
215008060|NCT02885753|DRUG|Oxaliplatin intravenous|85 mg/m² in intravenous. 1 cycle each 15 days
215008061|NCT02885753|DRUG|5 FU bolus|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
215008062|NCT02885753|DRUG|Folinic acid|400 mg/m² in intravenous
215008063|NCT02885753|DRUG|Oxaliplatin intra-arteriel|85 mg/m² in intra-arterial. 1 cycle each 15 days
215008064|NCT02885753|DRUG|Panitumumab|Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
215097238|NCT02520739|DIETARY_SUPPLEMENT|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
215097239|NCT02520739|DIETARY_SUPPLEMENT|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
215008065|NCT02885753|DRUG|Bevacizumab|5 mg/kg at each cycle in intravenous
215008066|NCT02885753|DRUG|5 FU continuous|2400 mg/m² intravenously over 46 hours
215008067|NCT02885753|DRUG|Irinotecan|150 mg/m² intravenous
215008068|NCT06959420|OTHER|Questionnaire|Anonymous self-administered questionnaire on the Limesurvey platform.
215008069|NCT02394834|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
215008070|NCT02394834|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
215008071|NCT05107934|BIOLOGICAL|RPH-104|solution for subcutaneous injection, 40 mg/mL
215008072|NCT05107934|DRUG|Placebo|0.9% Sodium Chloride solution for Injection
215008073|NCT05803499|BEHAVIORAL|Targeted Cognitive Behavior Therapy for Insomnia|This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.
215008074|NCT05803499|OTHER|Information-Only Control|The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.
215008075|NCT06958861|DRUG|Low-dose H057+standard-of-care|Subjects are administered low-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
215008076|NCT06958861|DRUG|High-dose H057+standard-of-care|Subjects are administered high-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
215008077|NCT06958861|DRUG|H057 placebo+standard-of-care|Subjects are administered inhaled H057 placebo, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
215008078|NCT04214782|DIAGNOSTIC_TEST|Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm|AI Enabled Transvaginal Ultrasound diagnosis for ovarian cancer
215008079|NCT03053323|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
215008082|NCT06630338|OTHER|Non-Interventional Study|Non-interventional study
215008083|NCT04926584|DRUG|induction therapy|induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy
215097240|NCT02520739|DIETARY_SUPPLEMENT|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
214402835|NCT03505645|PROCEDURE|Intra-articular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~After implant cementation and watertight joint capsular closure, the multimodal injection will be injected intra-articularly through the closed capsule."
214693865|NCT03009201|OTHER|Laboratory Biomarker Analysis|Correlative studies
215008084|NCT04783662|DEVICE|Intraoperative frontal electroencephalogram|Intra operative frontal electroencephalogram registration with 1 age adjusted Minimum Anesthetic Concentration of Sevoflurane
215097241|NCT05635474|DIETARY_SUPPLEMENT|Bacillus Coagulans|Bacillus coagulans is a Gram-positive bacterium belonging to the genus Bacillus and does not exist in the intestinal microbiota, because it has the characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains.
215097242|NCT05635474|DIETARY_SUPPLEMENT|Placebo|The placebo was also administered in the form of capsules consisting of maltodextrin, silicon dioxide, and magnesium stearate.
215097243|NCT03553082|DRUG|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
215097244|NCT03553082|DRUG|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
215097245|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
215097246|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
215097247|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
215097248|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
215097249|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
215097250|NCT01237782|DRUG|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
215097251|NCT01237782|DRUG|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
215008085|NCT03079492|DEVICE|Magnetic resonance imaging|Magnetic resonance imaging will be used to estimate brain temperature and cerebral blood flow
215008086|NCT01631188|PROCEDURE|Minimally Invasive Aortic Valve|Patients having minimally invasive aortic valve surgery will have a pacing wire placed through the endovent catheter. The anesthesiologist will attempt to pace the ventricle with this wire if needed to wean from bypass.
215097252|NCT03695965|PROCEDURE|magnetic resonance imaging.|1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
215097253|NCT01725243|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
215097254|NCT05678452|PROCEDURE|HOLEP for treating BPH|HoLEP will be performed using 100W Versapulse, Luminis Inc., with 2J/25Hz for LP-HoLEP and 2J/50Hz for HP-HoLEP.
215097255|NCT06386705|DRUG|TSN084|TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
215097256|NCT00825721|DRUG|LiquiTears|4 drops applied daily for 360 days
215097257|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
215097258|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
215097259|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
215097260|NCT01313962|DRUG|Flufirvitide-3 0.05 mg single dose|Nasal Spray
215097261|NCT01313962|DRUG|Flufirvitide-3, 0.1 mg single dose|Nasal spray
215097262|NCT01313962|DRUG|Flufirvitide-3, 0.2 mg single dose|nasal spray
215097263|NCT01313962|DRUG|Flufirvitide-3, 0.4 mg single dose|Nasal spray
215008087|NCT01631188|PROCEDURE|Minimally Invasive Aortic Valve Surgery|The Anesthesiologist will advance a pacing wire through the Endovent Catheter under TEE in order to pace the heart when the subject is coming off the Cardiopulmonary bypass machine
215008088|NCT01631188|DEVICE|Manipulation in OR surgical technique|Endovent and pacing wire when coming off cardiopulmonary bypass
215097264|NCT01313962|OTHER|Placebo|Nasal spray
215097265|NCT03189901|DRUG|Regular management+Levosimendan|Patients are treated with regular management recommended in guidelines and levosimendan.
215097266|NCT01191346|OTHER|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
215097267|NCT05172674|DIAGNOSTIC_TEST|ultrasound according routine antenatal care|ultrasound examinations at 11-14, 19-22 and 33-35 weeks
215097268|NCT01042652|DRUG|Raltegravir|Raltegarvir 400mg bid
215097269|NCT01872013|DRUG|ASP7991|oral
215097270|NCT01872013|DRUG|Placebo|oral
215097271|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccinations (high dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
215097272|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccination (low dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
215097273|NCT04033068|BIOLOGICAL|One MV-ZIKA-RSP vaccination (high dose) and one placebo|"In this arm of the study, 12 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
215097274|NCT04033068|OTHER|Two placebo injection|"In this arm of the study, 8 participants will receive:~1. V1= day 0; placebo treatment~2. V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
215097275|NCT03233035|DRUG|Ketamine|25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
215097276|NCT03233035|DRUG|Placebo|0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
215097277|NCT04303299|DRUG|Oral|Anti virus treatment
214402836|NCT01894958|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
214402837|NCT01894958|DRUG|Placebo|Strawberry flavored solution
214402838|NCT01026415|DRUG|brentuximab vedotin|1.8 mg/kg IV every 21 days
214402839|NCT01026415|DRUG|rifampin|600 mg/day PO
214402840|NCT01026415|DRUG|midazolam|1 mg IV
214402841|NCT01026415|DRUG|ketoconazole|400 mg/day PO
214402842|NCT01026415|DRUG|brentuximab vedotin|1.2 mg/kg IV every 21 days
214402843|NCT04701502|DIETARY_SUPPLEMENT|Viusid|"Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days"
214402844|NCT04701502|DIETARY_SUPPLEMENT|Asbrip|"Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days"
214402845|NCT04701502|DRUG|Standard Care|Standard care for COVID-19
214402846|NCT02288715|OTHER|no interventions|
214402847|NCT03637595|PROCEDURE|Acupuncture|3 sessions of acupuncture will be the reference therapy against which the energy medicine intervention is being compared.
215008089|NCT03600350|BIOLOGICAL|pTVG-HP|Plasmid DNA vaccine encoding Prostatic Acid Phosphatase (PAP)
215008090|NCT03600350|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
215008091|NCT03600350|DRUG|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
215008092|NCT03643991|OTHER|Weighted Blanket|Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.
215008093|NCT00001270|DRUG|interleukin-1|
215008094|NCT02131883|BEHAVIORAL|Group-Cognitive Behavioral Therapy|psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention
215008095|NCT02131883|OTHER|Wait-List with treatment as usual|Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
215008096|NCT01051167|DRUG|Cetuximab|500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
215008097|NCT04599218|OTHER|Prostate Biopsy|Standard of care
215097278|NCT03220386|OTHER|Decolonization by nasal Octinidin treatment and skin washings|Patients receive nasal Octinidin treatment and skin washings for five consecutive days
215097279|NCT03911024|BEHAVIORAL|HIV|At the completion of each EMA, participants in the intervention group (n=50) will receive messages that address:1) unsafe sexual behaviors, 2) alcohol/drug use, 3) PrEP interest, and 4) HIV testing. In addition, participants will have access to a button in the app that will link them to resources when/if they are the victim of sexual assault. Finally, intervention arm youth will be asked to set a behavioral goal related to HIV prevention during this session. Those goals will include increasing condom use, PrEP use, non-occupational post-exposure prophylaxis (nPEP) use, reducing number of sexual partners, not having sex with using drugs or drinking alcohol, avoiding IV drug use, getting testing for HIV, and testing and treating sexually transmitted infections (STIs) as needed
214402848|NCT03637595|PROCEDURE|Enery Medicine Intervention|3 sessions performed by Energy Medicine practitioner, who will perform an assessment followed by the intervention.
214402849|NCT03637595|PROCEDURE|Sham Energy Medicine|a non-energy trained confederate to be determined from the clinical research coordinators and non traditional volunteers enrolled administering assessments and providing therapeutic company.
214402850|NCT03782948|DEVICE|Standard gait training on BART without pelvic perturbations|The Balance Assisted Robot on Treadmill (BART) enables various types of gait training on treadmill with visual feedback. It interfaces to the pelvis of the walking subject in an actuated and admittance-controlled manner, thus providing transparent haptic interaction with negligible power transfer.
214402851|NCT03782948|DEVICE|Robotised gait training with BART with pelvic perturbations|In addition to the standard gait training, the BART will deliver perturbations in the forward/backward and left/right direction.
214402852|NCT00965484|DEVICE|New Genotropin Pen|Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
214402853|NCT00315211|DRUG|Intravenous Topotecan|Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
215008098|NCT04599218|OTHER|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy (Arm 1) or a Transperineal Ultrasound guided fusion prostate biopsy (Arm 2). All patients will under go a standard ultrasound guided biopsy at the time of their targeted (fusion) biopsy.
215008099|NCT04599218|DEVICE|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
215008100|NCT03480074|PROCEDURE|Staple Ligation|Using a stapler that staples the DVC and then cuts it.
215008101|NCT03480074|PROCEDURE|Selective Suture Ligation|Suture the DVC, suspend it to the pubic bone, and then cut.
215008102|NCT03480074|PROCEDURE|Single Suture Ligation|Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.
215008103|NCT05412420|OTHER|Patient Self-Reporting of Symptoms|"At baseline, clinical research staff will:~* verify the possibility of an internet connection at the patient's home~* help the patient to fill in the 1st questionnaire (baseline questionnaire - frailty)~Every two weeks for 3 months:~* patients complete questionnaires via app (toxicity; quality of life, medication adherence)~* responses are verified by clinical research staff~* In case of severe symptoms, the clinician contacts the patient and arranges for management.~At the end of the study :~\- patients answer a satisfaction questionnaire"
215008104|NCT04895280|DRUG|Ketorolac|Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
214693866|NCT03009201|OTHER|Pharmacological Study|Correlative studies
215008105|NCT04895280|DRUG|Marcaine|Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine
214402854|NCT00315211|DRUG|Intravenous Docetaxel|Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 \& 8 of a 21 day cycle
214402855|NCT00848211|OTHER|Placebo|Subcutaneous injection on Day 0, Day 28, and Day 84
214402856|NCT00848211|BIOLOGICAL|TUTI-16 (0.03mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
215097280|NCT03911024|BEHAVIORAL|General health|Participants in the attention control condition (n=50) will answer the same EMA items as the Intervention group. However, the intervention messages will contain content related to nutrition, physical activity, sleep hygiene, and tobacco use. Finally, control arm youth will be asked to set a behavioral goal related to general health during this session.Those goals will include getting 7+ hours of sleep, eating \>= 5 servings of fruits or vegetables, not using tobacco products, exercising at least 60 minutes.
215008106|NCT04895280|DRUG|Kenalog|Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.
215008107|NCT01217450|DRUG|selumetinib|Given orally
215097281|NCT02039856|OTHER|Multilevel stakeholder engagement|Structured, in-person stakeholder panel meeting of VA network, VA medical center, and primary care and women's health leaders using modified Delphi panel techniques to come to consensus on a quality improvement (QI) roadmap within each participating VA network, followed by intermittent progress reporting and post-24 months in-person capstone stakeholder panel meetings
215097282|NCT02039856|OTHER|Quality improvement (QI) education/training|Initial in-person and ongoing virtual team training in QI principles, methods, and project proposal development and refinement
215097283|NCT02039856|OTHER|Technical support|Research team provided technical review of and feedback on local QI project proposals, helped develop and/or recommend process/outcome measures, identified and shared relevant published literature (e.g., measures, interventions), and provided general technical support (e.g., how to analyze local data, how to conduct a local focus group)
215097284|NCT02039856|OTHER|Formative feedback|Research team provided aggregated all-site and local data from baseline patient and provider/staff surveys, 12-month patient surveys, and other data and findings to local teams for ongoing and new QI project idea development
215097285|NCT02039856|OTHER|External practice facilitation|Within and across site calls with local teams to review progress, identify needs, help solve problems, discuss current and new projects, as well as potential for spread
215097286|NCT02039856|OTHER|National policy guidance|VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
215097287|NCT06502938|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
214402857|NCT00848211|BIOLOGICAL|TUTI-16 (0.1mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
214402858|NCT00848211|BIOLOGICAL|TUTI-16 (0.6mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
214402859|NCT00646867|DEVICE|Tetrix|Twice daily topical application
215097288|NCT06502938|PROCEDURE|Traditional artificial percutaneous coronary intervention|Doctors perform traditional percutaneous coronary intervention
215097289|NCT01912534|DRUG|Valsartan|40, 80 and 160 mg tablets of Valsartan
215097290|NCT01912534|DRUG|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
214402860|NCT00646867|DEVICE|Placebo|Twice daily topical application
214402861|NCT01124617|DRUG|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
214402862|NCT01124617|DRUG|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
214504535|NCT07042646|BEHAVIORAL|Sexual and Reproductive Health Training program|'The Sexual and Reproductive Health education program was prepared by researchers who are experts in the field of public health and public health nursing. The program was implemented once a week for 3 weeks (why 3 weeks) in 50-60 minute sessions (Table 1). The content and duration of the application were prepared in accordance with the Ministry of Health Sexual and Reproductive Health: National Strategic Action Plan for the Health Sector (2005-2015) and the Turkey Reproductive Health Program Sexual and Reproductive Health Service Standards (2007). Each program session was two education sessions, and all the questions of the disabled woman were answered .
215008108|NCT01217450|BIOLOGICAL|cetuximab|Given IV
215008109|NCT01217450|OTHER|laboratory biomarker analysis|Correlative studies
215008110|NCT01217450|OTHER|pharmacological study|Correlative studies
215008111|NCT06780943|OTHER|Biomechanics|"Amputees and controls will be equipped with measurement sensors to record spatio-temporal, kinetic, kinematic, pressure, electromyographic and physiological parameters of gait in the movement analysis laboratory (GRAIL System).~16 Anatolog FSR sensors will be installed in the amputee population (transtibial, transfemoral on the medial, lateral, anterior and posterior parts of the stump, 4 per side, aligned in the proximal/distal axis. The Anatolog sensors have a sampling frequency of 100Hz. Electromyographic data recording is performed by setting up a number of EMGs depending on the healthy population or the level of amputation. Surface electromyography (sEMG) signals will be recorded from 10 muscles on each lower limb for control subjects and transtibial amputees"
215097291|NCT04892108|PROCEDURE|STARR (Stapled Trans Anal Rectal Resection)|Patients randomly assigned to surgical intervention of STARR (Stapled Trans Anal Rectal Resection)
214402863|NCT00945477|DRUG|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
214402864|NCT00669695|DRUG|Atorvastatin treatment|Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.
214402865|NCT00669695|OTHER|CPAP device|This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
214402866|NCT00669695|OTHER|sham CPAP treatment|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
215097292|NCT04892108|PROCEDURE|LVR (Laparoscopic Ventral Rectopexy)|Patients randomly assigned to surgical intervention of LVR (Laparoscopic Ventral Rectopexy)
215097293|NCT03675984|BEHAVIORAL|asymmetrical stabilization exercise|Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
215008112|NCT06780943|OTHER|Physiological|Energy consumption (VO2), will be performed using the VO2 Master Pro (VO2 Master Health Sensors Inc., Vernon, British Columbia, CA). Each participant will wear a face mask connected to the VO2 Master, which will measure oxygen consumption in real time during the assessment. The mask will be adjusted to prevent air leakage and ensure accurate measurements.
215008113|NCT06780943|OTHER|Proprioceptive|For amputees, the joint above the amputation will be measured due to the presence of the proximal insertions of the bi-articular muscles and the absence of their distal insertion (i.e., knee joint for transtibial amputees and hip joint for transfemoral amputees).
215008114|NCT03269006|DEVICE|Inesfly Paint|"Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin"
215008115|NCT03269006|DEVICE|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
215008116|NCT03269006|DEVICE|ITN (KO-Tab 123)|Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
215008117|NCT03269006|DEVICE|IRS (Delthamethrin)|Indoor residual spraying with Delthamethrin in the living rooms
215008118|NCT04981054|PROCEDURE|Cystocele repair|Repair of endopelvic fascia and anterior colporrhaphy
215008119|NCT01850940|DRUG|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
215008120|NCT01850940|OTHER|conventional thearpy|conventional therapy with salt limitation ,et al
215008121|NCT03684057|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
215008122|NCT04937530|DRUG|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
215008123|NCT04937530|DRUG|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
214402867|NCT04108338|OTHER|Trial setting|Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.
215008124|NCT03474835|DIAGNOSTIC_TEST|ISCHEMIC HEART DISEASE diagnostic|ISCHEMIC HEART DISEASE diagnostic
215008125|NCT05979597|PROCEDURE|Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
215008126|NCT05979597|PROCEDURE|Suprainguinal fascia iliaca block+dexamethasone|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic+dexamethasone injection will be made between the fascia and the muscle.
215097294|NCT04839120|DRUG|MDPK67b|Two subgroups (Panels A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
215097295|NCT04839120|DRUG|Placebo|Two subgroups (Panel A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
215097296|NCT06342596|DRUG|[14C]-LY3473329|Administered orally
214402868|NCT01192087|DRUG|Cetuximab|cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface cetuximab weekly doses (from RT treatment start throughout radiation treatment): 250 mg/m² body surface
214402869|NCT00619151|DEVICE|Top Hat|Implant of CarboMedics Top Hat mechanical valve.
214402870|NCT00619151|DEVICE|Regent|Implant of the St. Jude Medical Regent mechanical valve
215097297|NCT06342596|DRUG|[14C]-LY3473329|Administered IV
215097298|NCT06342596|DRUG|LY3473329|Administered orally
214693867|NCT03009201|DRUG|Ribociclib|Given PO
214693868|NCT01062620|DRUG|AXL1717|Phase I study with increasing dosage and treatment duration
214693869|NCT02437058|OTHER|preidictive model|
215008127|NCT03343574|OTHER|Abdominal Strengthening Exercise|Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
215008128|NCT01105130|OTHER|Placebo|Given orally
215008129|NCT01105130|DRUG|Oral L-Arginine|Given orally 3 capsules ArginMax and 3 Placebo capsules
215008130|NCT01105130|DRUG|Oral L-Arginine|Patients will take 6 capsules of ArginMax twice daily
215008131|NCT05308693|OTHER|Education material - Patient Compatible Stoma Educational Material|It is an educational material made of rubber, similar to a stoma, that can be placed on the patient.
215008132|NCT06423027|BEHAVIORAL|Nature-Oriented Chatbots|Nature-oriented chatbots are an intervention with nature-based video delivered by self-developed chatbots
215008133|NCT00729001|BIOLOGICAL|Human Rotavirus Vaccine - two different formulations|Two oral doses
215008134|NCT00729001|BIOLOGICAL|Prevnar|Three-dose intramuscular injection (US subjects only)
215008135|NCT00729001|BIOLOGICAL|IPOL|Two-dose intramuscular injection (US subjects only)
215008136|NCT00729001|BIOLOGICAL|Infanrix|Three-dose intramuscular injection (US subjects only)
215008137|NCT00729001|BIOLOGICAL|OmniHIB|Three-dose intramuscular injection (US subjects only)
215008138|NCT00729001|BIOLOGICAL|Pentacel|Three-dose intramuscular injection (Canada only)
215008139|NCT03664141|DRUG|Cannabis oil|Treatment with cannabis oil
215008140|NCT03664141|DRUG|Placebo/ Regular Oil|Treatment with placebo (Regular Oil)
215008141|NCT05061355|PROCEDURE|Heart valve surgery|Heart valve surgery will be performed as soon as possible and preferably within 48 hours
215008142|NCT03404167|DRUG|AZD0914|Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
215008143|NCT00943904|DEVICE|Interstim implant for SNS|stimulates third sacral nerve root
215008144|NCT02971189|DEVICE|Librata Endometrial Ablation|The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
215008145|NCT01328626|DRUG|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
215008146|NCT01305343|PROCEDURE|Routinely performed surgical correction of spinal deformity|Routinely performed surgical correction of spinal deformity
215008147|NCT01363440|DRUG|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
215008148|NCT01363440|PROCEDURE|Macular Laser Photocoagulation|Laser therapy
215008149|NCT04426162|OTHER|Multi-domain Intervention|Intervention includes neurofeedback, heart rate variability biofeedback, memory and cognitive training, and one-on-one coaching to encourage behavior change in diet, sleep, physical fitness, and stress reduction.
215008150|NCT00126217|BIOLOGICAL|Bacille Calmette Guerin (BCG)|0,1 ml, revaccination at 19 months of age
215008151|NCT02323334|DRUG|LY3202626|administered orally
215008152|NCT02323334|DRUG|Placebo (Part A, B, C)|administered orally
215008153|NCT02323334|DRUG|Itraconazole|administered orally
215008154|NCT02513082|PROCEDURE|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
215097299|NCT02409342|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
214693870|NCT01021072|DRUG|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
215097300|NCT02409342|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
214693871|NCT03285074|OTHER|No intervention|No intervention
215097301|NCT02409342|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m\^2) every 21 days for 4 or 6 cycles as per local standard of care.
215097302|NCT02409342|DRUG|Gemcitabine|Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m\^2 (in combination with cisplatin) or 1000 mg/m\^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
215097303|NCT02409342|DRUG|Pemetrexed|Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
214402871|NCT04358471|BIOLOGICAL|Intravitreal AAVCAGsCD59|AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye
214402872|NCT04358471|OTHER|Intravitreal Sham Injection|Sham injection mimics a real injection in the enrolled eye
214402873|NCT02825043|DEVICE|High-Flow Nasal Cannula|This is a humidified oxygen delivery system.
215097304|NCT02212158|BEHAVIORAL|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
215097305|NCT02486250|OTHER|Validation Study|
215097306|NCT06297473|BEHAVIORAL|Telephone-/video follow-up|"The yearly routine review of patients takes place by using a telephone or video interview rather than in-person interview in the endocrine outpatient department.~All other assessments, e.g. biochemical, MRI, is conducted as usual."
215097307|NCT06297473|BEHAVIORAL|In-person follow-up|The yearly routine review on patients takes place at the endocrine outpatient department
215097308|NCT03908970|DRUG|1% OPA-15406|Twice daily
215097309|NCT03908970|DRUG|Placebos|Twice daily
215097310|NCT04671992|DEVICE|Out of-Plane Technique and In-Plane on|A comparison of out of-plane technique and in-plane
215097311|NCT04457492|OTHER|Application of FES to the Face|Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.
215097312|NCT03678168|OTHER|Throat Pack|Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
215097313|NCT03678168|OTHER|Pharyngeal Tampons|Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
215097314|NCT02380898|DRUG|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
215097315|NCT02380898|DRUG|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
214402874|NCT00592748|RADIATION|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
214693872|NCT02024191|DIETARY_SUPPLEMENT|Glutamine|
215097316|NCT01605721|DEVICE|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"
215097317|NCT03262467|PROCEDURE|Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)|In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
215097318|NCT03883087|DRUG|HQP1351|40 mg tablet, taken orally once every other day of a 28-day cycle
215097319|NCT05069753|PROCEDURE|Immediate sequential bilateral cataract surgery (ISBCS)|Surgery on both eyes will be performed on the same day as separate procedures: Once surgery on the first eye is completed, a new sterile procedure on the second eye will commence.
215097320|NCT05069753|PROCEDURE|Delayed sequential bilateral cataract surgery (DSBCS)|The group will undergo bilateral cataract surgery on two separate days with a time period of one week between the two procedures.
215097321|NCT05735249|DRUG|ARN-75039 oral capsules|SAD: Up to 5 single escalating doses MAD: Up to 3 escalating doses Food-effect: Selected single dose
215097322|NCT05735249|DRUG|Placebo|Given at frequency and amounts matching ARN- 75039 dosing regimen
215097323|NCT00002077|DRUG|Fluconazole|
215097324|NCT00854815|PROCEDURE|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
214693873|NCT01354353|DRUG|LY2140023|Administered orally
214693874|NCT01354353|DRUG|Aripiprazole|Administered orally
215097325|NCT00854815|PROCEDURE|No Irrigation|Suction only using suction/irrigator
215097326|NCT06409247|BEHAVIORAL|iExposure|There will be 4 treatment sessions, covering the iExposure intervention. The intervention and assessment process is entirely self-guided. Each session will last approximately 60 minutes. Participants will complete 10 mock-interaction trials for each session.
215097327|NCT06409247|BEHAVIORAL|iExposure plus attention guidance|The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.
215097328|NCT06409247|BEHAVIORAL|iExposure plus attention control|The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.
215097329|NCT05044013|OTHER|Full access to JomPrEP app|All participants will receive the JomPrEP app with access to all of its features which include: customizable page (using avatars and pseudonyms); visual dashboard (track and visualize progress); HIV testing plan (create plan for HIV testing, order self-testing kits, testing site locator); PrEP Care Plan (PrEPxpress, automated reminders for follow-up care, labs, delivery); chat function and discussion forum; tailored messages and reminders; assessment center (weekly assessment on adherence to PrEP, HIV risk, mood); knowledge center (resources on HIV testing and PrEP); Mental health support (screen for P/SUD, counseling feedback, referral to support services); Integration of provider locator (provides users with a GPS enabled map for PrEP and mental health support providers in Malaysia) and Gamification (offers extrinsic motivation by rewarding points/milestones for doing activities within the app). Participants can also contact the RA using the chat function for support.
215097330|NCT05044013|OTHER|inactivated JomPrEP app|Only information and resources for PrEP services will be available along with access to risk assessment tools.
215097331|NCT01814124|OTHER|Manual therapy plus exercise|
215097332|NCT01814124|OTHER|Advice and home exercise|
215097333|NCT03442218|DRUG|Clorhexidine|Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
214402875|NCT05805540|PROCEDURE|Cold-water immersion|Subjects were immersed, in a sitting position where legs were always covered, in cold water at 11ºC in periods of 2 minutes submerged and 2 minutes out of the water at room temperature (25ºC), repeating this process 5 times
214402876|NCT05805540|PROCEDURE|Protein-carbohydrates supplementation|Subjects consumed a mixed carbohydrate and protein beverage, composed of 0.3gr/kg of maltodextrin and 0.2gr/kg of neutral whey protein in 0.5 litres of water. Subject sat for 25 minutes until all recovery methods were completed.
214402877|NCT05805540|PROCEDURE|Active recovery|Subjects was carried out using a bicycle ergometer. The subjects pedaled for 25 minutes at 50% of the maximum heart rate (HRmax)
214402878|NCT05805540|PROCEDURE|Placebo|Subjects drank a water-based drink and sweetener. Subject sat for 25 minutes until all recovery methods were completed.
214402879|NCT02444143|DRUG|tacrolimus extended release|
214402880|NCT00938561|DRUG|Inulin|
215097334|NCT03442218|DRUG|Saline solution|Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
215097335|NCT01280695|DRUG|Placebo|Placebo Capsules
215097336|NCT01280695|DRUG|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
215097337|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
215097338|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
215097339|NCT01280695|DRUG|Pioglitazone|Pioglitazone 45 mg Capsules
215097340|NCT05456971|DEVICE|Art Filler Volume|Midface correction with injectable hyaluronic acid based-filler
215097341|NCT05456971|DEVICE|Art Filler Lips|Lipscorrection with injectable hyaluronic acid based-filler
214402881|NCT05391204|OTHER|Functional Tests|Various physical exercices of inferior members
214402882|NCT02402764|DRUG|Selinexor|Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m\^2).
214402883|NCT01982760|DRUG|DDAVP|Patients Receiving DDAVP prior to operation
214402884|NCT01166087|DRUG|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
214693875|NCT03583372|DRUG|Vibegron|single daily dose 75 mg
214693876|NCT03583372|DRUG|placebos|placebo to match vibegron (experimental drug) and tolterodine (active comparator)
215097342|NCT05231239|DEVICE|tDCS : Transcranial direct current stimulation|Transcranial direct current stimulation
215097343|NCT00246701|DRUG|Simvastatin|Simvastatin
215097344|NCT00246701|DRUG|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
215097345|NCT01012544|DRUG|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
215097346|NCT02462161|DRUG|Insulin aspart|Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
215097347|NCT02462161|DRUG|Placebo|Participants will administer placebo two times per day with an intranasal delivery device.
215097348|NCT04584255|DRUG|Niraparib|Predetermined dosage PO Daily
214504538|NCT07043491|DIAGNOSTIC_TEST|Endoscopy|We first observed the residual esophagus to evaluate the mucosal color. We then reached the top of the anastomosis to obtain a full view of the anastomosis to exclude obvious leakage around that site. We next conducted a more detailed endoscopic examination at a close focal distance, circumferentially around the anastomosis. During this process, we utilized saline solution to meticulously remove white fibrin coverings and bloodstains to the greatest extent possible to ensure a thorough evaluation of anastomotic integrity. Finally, we inspected the staple line of the tubularized stomach to exclude gastric fistula and assessed the perfusion of the gastric graft. Endoscopic findings were assessed by an additional endoscopist and 3 esophageal surgeons during the examination, as well as by reviewing captured images or videos after endoscopy.
214693877|NCT03583372|DRUG|Tolterodine Tartrate ER|single daily dose of 4 mg
214693878|NCT02685891|OTHER|Playing tones during deep sleep|Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)
215008155|NCT05380596|BEHAVIORAL|Telepharmaceutical Care|The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3). In the opportunities, aspects related to pharmacotherapy and health status, non-pharmacological approaches, treatment adherence and evaluation of problems related to pharmacotherapy (PRM) will be discussed.
215008156|NCT05921500|DRUG|sodium peborate|Internal bleaching of discolored primary anterior teeth by using sodium peborate
215008157|NCT06103682|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
215008158|NCT03057327|BEHAVIORAL|Improve awareness of checking moles|"Intervention:~1. Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~2. Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant."
215097349|NCT04584255|DRUG|Dostarlimab|Predetermined Dosage, IV,q3 weeks
215097350|NCT04062305|BEHAVIORAL|Hand Function Test|Complete tasks that test grip strength, pinch strength, and ability to use and feel with hands
215097351|NCT04062305|PROCEDURE|Navigated Transcranial Magnetic Stimulation|Undergo nTMS
215008159|NCT03057327|OTHER|Comparator|Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
215008160|NCT04715100|OTHER|Observational group|The study dependent variables will be: pain (vas scale), joint status (Hemophilia Joint Health Score), perception of quality of life (SF-36 questionnaire), list of roles (Oakley questionnaire), performance of basic activities of daily life (Barthel index) and the performance of instrumental activities of daily living (Lawton and Brody scale).
215008161|NCT04234542|OTHER|Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be increased along with intensity as the stages progress.
215097352|NCT04062305|OTHER|Quality-of-Life Assessment|Ancillary studies
215097353|NCT04062305|OTHER|Questionnaire Administration|Ancillary studies
215097354|NCT05364502|DEVICE|Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter|The Embrace Hydrogel Embolic System (HES) is indicated for embolization of peripheral arterial bleeds in vessels ≤6mm
215097355|NCT01107223|OTHER|Experimental: Training to antibiotic prescription|GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.
215097356|NCT01107223|OTHER|No education on antibiotic prescription rules.|GPs assigned to control group received no specific recommendations on antibiotic prescription.
215097357|NCT05333549|DRUG|Istradefylline medication|2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
215097358|NCT00125021|DRUG|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
215097359|NCT00125021|DRUG|OSI-774|Given once daily
215097360|NCT02078388|DRUG|Doxorubicin|
215097361|NCT03204422|OTHER|No intervention|no any other intervention
215097362|NCT03502902|DRUG|HEC 68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
215097363|NCT03502902|DRUG|Placebo|Placebo
215097364|NCT01364740|DEVICE|PMP-300E|Data collected from Level 3 device
215097365|NCT01364740|DEVICE|In-lab PSG|Data collected from Type I In-Lab Polysomnography
215097366|NCT05532891|OTHER|COVID-19 pandemic|Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
215097367|NCT00417963|DEVICE|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
215097368|NCT05390658|OTHER|Not application|Not application
215008162|NCT04234542|OTHER|Sham Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be progressed, but power will always be set to 1%..
215008163|NCT01263379|BIOLOGICAL|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
215008164|NCT00295776|DRUG|Lamictal in the treatment of Post-Herpetic Neuralgia|
215008165|NCT02233153|OTHER|Elder-Friendly Surgical Unit|
215008166|NCT01726686|DRUG|Ropivacaine|100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
215008167|NCT01726686|DRUG|Placebo|
215008168|NCT01701648|OTHER|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
215008169|NCT03521336|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
215008170|NCT03521336|DRUG|Placebo|Saline，Sham operation
215008171|NCT04383015|OTHER|Exercise strategies|Strategies for exercise in type 1 diabetes to maintain glucose control
215008172|NCT03604627|OTHER|Coronal calcium score measurement|"A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research."
215008173|NCT01129284|DRUG|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
214402885|NCT03791177|OTHER|Music Therapy|"Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy"
214402886|NCT00377598|DRUG|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
214402887|NCT00377598|DRUG|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
214402888|NCT00377598|DRUG|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
214402889|NCT00377598|DRUG|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
214402890|NCT00377598|DRUG|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
215008174|NCT02201082|PROCEDURE|Airway clearance technique|
215008175|NCT02201082|DRUG|Amikacin nebulization|
215008176|NCT02510482|OTHER|No intervention|
215008177|NCT00298857|DRUG|Valproic acid|
215008178|NCT03990688|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
215008179|NCT03990688|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
215008180|NCT02345343|DRUG|Apixaban|
215008181|NCT04725643|DEVICE|Track bleeding patterns before and after implant|Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart. Participants will also complete weekly surveys regarding their satisfaction with their bleeding. We will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.
214402891|NCT03766828|PROCEDURE|inside-out-access technique with inside-out access device (Surfacer (R))|inside-out-access technique with (Surfacer (R)) with a new CE certified device (Surfacer (R), Bluegrass Vascular)
214402892|NCT03766828|PROCEDURE|access technique including Sharp recanalization|access technique with Sharp recanalization via interventional radiology
214402893|NCT05789355|DIETARY_SUPPLEMENT|NUV001|Daily supplementation with NUV001 at 1000 mg (4 tablets of 250 mg each) for 90 days with a prolonged follow-up of 1 month (30 days) after stopping the supplementation
214402894|NCT04007809|OTHER|Glucagon|Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).
214402895|NCT05084300|OTHER|Pain Neuroscience Education|A total of 10 PNE sessions (Neuroscience pain education) will be carried out, two each week in addition medical treatment similar to control group (Usual care). The NPE sessions will be conducted by an experienced NPE certified physical therapist in 35 minute face-to-face group sessions. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
214693879|NCT02685891|OTHER|sham condition|in the sham condition, no tones will be played
214402896|NCT05084300|OTHER|Usual care|The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.
215008182|NCT04871438|DEVICE|Flash glucose monitoring|Group A will use FreeStyle Libre for two weeks of FGM-based titration of medications at two time-points: 1) At recruitment and 2) At 6 weeks. Outside of these time points, they will use SMBG (standard care) for monitoring of blood glucose.
215008183|NCT02859012|DRUG|Axitinib|Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
214402897|NCT01607970|DRUG|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
214402898|NCT00918190|DRUG|Placebo|Saline
215008184|NCT02859012|OTHER|Observation|this group is observational ones.
215008185|NCT02927314|DRUG|CF102|orally q12h
215008186|NCT02927314|DRUG|Placebo|orally q12h
215008187|NCT01625182|DRUG|Fingolimod|Fingolimod 0.5 mg capsules
215008188|NCT01625182|DRUG|Placebo Comparator|Matching placebo capsules
214402899|NCT00918190|DRUG|Ondansetron, Dexamethasone|Use of ondansetron and dexamethasone as combined antiemetics
214402900|NCT00918190|DRUG|Midazolam, dexamethasone|use of midazolam and dexamethasone as combined antiemetic
214402901|NCT05943587|OTHER|culture-sensitive PNE4kids|Culturally adapted PNE4kids used by physiotherapists worldwide in chronic pain rehabilitation.
214402902|NCT05943587|OTHER|standard education|Standard education used by physiotherapists worldwide in chronic pain rehabilitation.
215008189|NCT03380572|DEVICE|Senhance Assisted Cholecystectomy|Cholecystectomy performed using Senhance surgical robotic system
215008190|NCT03380572|PROCEDURE|Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy
215008191|NCT01433874|PROCEDURE|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
215008192|NCT01433874|PROCEDURE|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
215008193|NCT01433874|PROCEDURE|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
215008194|NCT01433874|PROCEDURE|Control group|Co2 was removed by passive exsufflation through the port site.
215008195|NCT02920554|PROCEDURE|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
215008196|NCT02920554|PROCEDURE|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
215008197|NCT01235819|DRUG|Insulin|Exenatide Sitagliptin
215008198|NCT01235819|DRUG|Sitagliptin|Sitagliptin 100 mg per day oral
215008199|NCT01235819|DRUG|Exenatide|Exenatide 10 micrograms daily twice
215008200|NCT05737498|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
215008201|NCT00354211|DEVICE|minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)|
215008202|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
215008203|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
214402903|NCT05212948|DRUG|S-268019-b|Solution for IM injection
214402904|NCT05212948|DRUG|Placebo|Saline solution for IM injection
214402905|NCT04002089|DRUG|Exparel Injectable Product|bupivacaine liposome injectable suspension
214402906|NCT04002089|DRUG|Bupivacaine|1.3%, 13.3 mg/mL
214402907|NCT00859014|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
214402908|NCT05030376|DIETARY_SUPPLEMENT|intraileal infusion|intraileal glucose or intraileal saline infusion
214402909|NCT02731404|PROCEDURE|HFJV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
215008204|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
215008205|NCT02585492|OTHER|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
215008206|NCT02585492|OTHER|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
215008207|NCT04428905|OTHER|Quality-of-Life Assessment|Ancillary studies
215008208|NCT04428905|OTHER|Questionnaire Administration|Ancillary studies
215008209|NCT04428905|OTHER|Survivorship Care Plan|Receive personalized care plan/resource manual
215008210|NCT04428905|OTHER|Telemedicine|Participate in telehealth sessions
214402910|NCT02731404|PROCEDURE|IPPV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
214402911|NCT01863966|OTHER|hot water drinking therapy|Drink 200ml hot water 3min before and after a meal. Swallow food with hot water and drink 200ml hot water before sleep
214402912|NCT01863966|PROCEDURE|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation under endoscope
214402913|NCT03697226|DRUG|Topical ABI-1968|Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
214402914|NCT04796935|DEVICE|Tactile Imaging (VerTouch)|VerTouch device used to identify and mark, or begin placement of a needle at an insertion site. After the device is taken off the back, the procedure will continue in the usual manner.
214402915|NCT04796935|OTHER|Control (palpation)|Control, palpation used to identify and mark an insertion site.
214402916|NCT03431519|PROCEDURE|VP|Percutaneous Injection of Strontium Containing Hydroxyapatite versus Polymethacrylate plus Short Segment Pedicle Screw Fixation
214402917|NCT00599677|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
214402918|NCT00599677|DRUG|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
214402919|NCT02888795|DRUG|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
214402920|NCT00783718|DRUG|vedolizumab|Vedolizumab for intravenous infusion
214402921|NCT00783718|OTHER|Placebo|Placebo intravenous infusion
215008211|NCT05007444|DRUG|P2Et (Caesalpinia spinosa extract)|Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
215008212|NCT05007444|DRUG|Placebo|After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
215008213|NCT00447278|DRUG|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
215008214|NCT00447278|DRUG|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
215097369|NCT04909658|BEHAVIORAL|ACT Matrix|"The ACT protocol group performs exercises to improve the psychological well-being of parents. The matrix is an ACT protocol that is usually presented visually to patients and consists of two intersecting lines that make up four quadrants, which provide a point of view on one's psychological actions and experiences. The vertical line is the line of experience, the upper part corresponds to the experience of life linked to the five senses - sight, hearing, taste, smell and touch - (experience of the five senses), the lower part refers to the experiences internal as thoughts and feelings (internal/mental experience). The horizontal line is the behavior line, the left side concerns the actions that perform the function of moving us away from experiences, emotions, unwanted thoughts (experiential avoid-ance), the right side indicates the actions we take to get closer and go towards our values (committed action)."
215097370|NCT04909658|BEHAVIORAL|PT Protocol|The PT protocol group received behavioral tasks related to child management. Parent training interventions carried out in groups can be a good solution to modify parent behavior by providing social support and new coping strategies. The intervention includes 24 weekly meetings lasting 90 minutes each. The total intervention is six months.
215097371|NCT03603106|DRUG|P03277|"Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s."
214402922|NCT03903835|DRUG|Enzalutamide Oral Capsule|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
214402923|NCT03903835|DRUG|Abiraterone Oral Tablet|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
214402924|NCT03903835|DRUG|Carboplatin|Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].
214693880|NCT05175937|DEVICE|smartphone APP based remote monitoring|smartphone APP to monitor remotely patients implanted with ICD
214693881|NCT05175937|DEVICE|bedside transmitter based remote monitoring|bedside transmitter to monitor remotely patients implanted with ICD
214402925|NCT03903835|DRUG|Cabazitaxel 60 mg Solution for Injection|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
214402926|NCT03903835|DRUG|Docetaxel Injectable Solution|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
214402927|NCT03903835|DRUG|Radium Chloride Ra-223|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
214402928|NCT03903835|DRUG|Niraparib plus Abiraterone acetate plus Prednisone|Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.
215097372|NCT03603106|DRUG|Placebo|"Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s."
215097373|NCT04878692|DRUG|Application of Onco-Rash cream|"The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
215097374|NCT04878692|DRUG|Application of Onco-Neutre cream|"The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
215097375|NCT00477152|DRUG|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
215097376|NCT04706156|BIOLOGICAL|COVID-19 Vaccine|Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine
215097377|NCT01910467|DEVICE|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases \>5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
215097378|NCT01910467|DEVICE|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
214402929|NCT03903835|DRUG|Capivasertib plus Docetaxel|Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.
214402930|NCT03903835|DRUG|Apalutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
214402931|NCT03903835|DRUG|Darolutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
214402932|NCT05877547|DRUG|Efinopegdutide|Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg
214402933|NCT05877547|DRUG|Semaglutide|SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg
215097379|NCT04274556|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
215097380|NCT00385749|DEVICE|RV apical vs RV septal defibrillation threshold testing|
215097381|NCT01966224|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose."
215097382|NCT05332652|DEVICE|trancranial magnetic stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
214402934|NCT05877547|DRUG|Placebo|SC injection of matching placebo
214402935|NCT06511934|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into arm-hand motor-related cortex.
214402936|NCT01912326|DEVICE|Pacemaker Implantation|Implantation of a dual chamber pacemaker
214402937|NCT04607252|DRUG|Metformin plus Megestrol acetate|metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
214402938|NCT04607252|DRUG|Megestrol Acetate|megestrol acetate 160mg per day, oral
214402939|NCT04536025|OTHER|Qualitative focus group interviews|Prosthetists and/or expert working group members will participate in qualitative focus group interviews up to 120 minutes in length.
214402940|NCT04536025|OTHER|Qualitative semi-structured interviews|People with lower limb amputation and/or expert working group members will participate in qualitative individual, semi-structured interviews approximately 60 minutes in length.
214402941|NCT04159896|DRUG|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Given PO
214402942|NCT04159896|BIOLOGICAL|Nivolumab|Given IV
214402943|NCT02156791|BIOLOGICAL|gpASIT+TM|
214402944|NCT03050281|OTHER|Simulation/Cadaver lab|The primary focus of this study is to determine whether the use of a comprehensive, combined, and simplified approach of using cadavers and simulation laboratories to train third-year medical students will have a beneficial effect on student performance in the OB-GYN and surgical clerkships.
214402945|NCT03050281|OTHER|Lectures|Standard Anatomy lectures were offered.
214402946|NCT03862521|OTHER|Low carbohydrate diet|Low carbohydrate diet
214402947|NCT03862521|OTHER|Very low carbohydrate diet|Very low carbohydrate diet
214402948|NCT04872062|DEVICE|NIV cards|Reading the data available on the NIV cards
214402949|NCT04872062|OTHER|Medical file|Using the data available in the medical file including clinical data, blood gas results, nocturnal oximetry results
214402950|NCT05297123|DRUG|All-trans retinoic acid|All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.
214402951|NCT05297123|DRUG|Arsenic Trioxide|ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)
214402952|NCT05297123|DRUG|Realgar-Indigo naturalis formula|60 mg/kg/d for 8 weeks
215008215|NCT05791084|OTHER|mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.|The DIBH-App consists of 1) a mobile application that patients download to their own smart mobile phone, and 2) associated stretch-sensors that are attached around the chest and connected to the mobile phone via Bluetooth. Visually, the graphics is similar to the software used for DIBH in the RT department. Coaching takes place through instructional videos, text, and audio recordings (Image 2). The following information will be recorded and stored: date and time of practice, outcome of each session (including sensor data and calibration parameters), and user behavior within the application (such as screen visits, FAQ sections viewed, and key button presses).
214402953|NCT02338609|DRUG|Everolimus|At the discretion of the investigator, pediatric patients could be treated with commercially available everolimus, as per local product information / standard of care. Treatment duration and dose modifications were at the investigator's discretion, as per the local product information.
214402954|NCT02977156|BIOLOGICAL|Pexa-Vec|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
214402955|NCT02977156|DRUG|Ipilimumab|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
214402956|NCT02116387|OTHER|Routine Physical Therapy|Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
214402957|NCT02116387|DEVICE|I-Moove Physical Therapy|Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
215008216|NCT02072044|DRUG|Anlotinib|Anlotinib p.o. qd
215008217|NCT00886236|DRUG|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
215008218|NCT00886236|DRUG|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
215008219|NCT00886236|DRUG|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
215008220|NCT04767516|OTHER|no intervention|no intervention
215008221|NCT01770730|DEVICE|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
215097383|NCT02219373|DRUG|Gabapentin|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
215097384|NCT02219373|DRUG|Oxcarbazepine|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
214402958|NCT02519556|DRUG|Probiatop|Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
214402959|NCT02519556|DRUG|Placebo|1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
214504539|NCT07043114|OTHER|BFR-Walking|The training consists of the patients walking on a treadmill twice a week for a total of six weeks until their pain becomes too severe and they have to take a break. After a one-minute break, this is increased again until the pain reaches its maximum. This is done a total of three times per appointment. Additionally, patients will receive a individual BFR intervention bilaterally with a exercise pressure corresponding to 60% of their LOP.
214504540|NCT07043465|DIAGNOSTIC_TEST|14 days ambulatory rhythm monitoring|14 days ambulatory rhythm monitoring using Byteflies
214504541|NCT07044167|DIETARY_SUPPLEMENT|Polyphenol-enriched functional product|Polyphenol-enriched functional product
214504542|NCT07044167|DIETARY_SUPPLEMENT|Control without active polyphenols|Product with identical characteristics to the experimental product, but without active polyphenols.
214402960|NCT03547505|PROCEDURE|R-Pilot®|Glide path preparation using R-Pilot® in reciprocating manner.
214402961|NCT03547505|PROCEDURE|ProGlider®|Glide path preparation using ProGlider® in a rotating manner.
214402962|NCT03547505|PROCEDURE|Manual preparation|Glide path preparation using manual K-files numbered from 08 to 15.
214504543|NCT07043101|OTHER|Extended Reality based Gait Rehabilitation|XR headset augmenting traditional Vector based gait rehabilitation.
214504544|NCT07043660|BEHAVIORAL|AdoptMindful2Care|AdoptMindful2Care is a mindful parenting post-adoption intervention with eight weekly group sessions (approximately 90 minutes each), delivered in person by trained psychologists, plus one follow-up session held two months after completion. The intervention integrates psychoeducation, mindfulness-based exercises, mindful parenting and self-compassion practices, as well as strategies informed by Cognitive Behavioral Therapy (CBT). The program is designed to help adoptive parents reduce parenting stress and promote positive parenting practices.
214693882|NCT01151046|DRUG|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
214693883|NCT01151046|DRUG|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
214693884|NCT01151046|DRUG|Exemestane|Exemestane (25 mg) administered orally once per day
214693885|NCT05078099|DEVICE|CureSight|Binocular eye-tracking-based passive home treatment system delivering personalized amblyopia therapy
214402963|NCT02655653|DRUG|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
214402964|NCT02655653|DRUG|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
214402965|NCT04460079|DRUG|Peg-filgrastim|PegaGen® was injected as a single subcutaneous dose after completion of cytotoxic chemotherapy
214402966|NCT03985579|OTHER|Kinesiology taping application|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
214402967|NCT01799954|BIOLOGICAL|DNA-HIV-PT123|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
214402968|NCT01799954|BIOLOGICAL|NYVAC-HIV-PT1|(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
214402969|NCT01799954|BIOLOGICAL|NYVAC-HIV-PT4|(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
214402970|NCT01799954|BIOLOGICAL|AIDSVAX® B/E|300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
214402971|NCT01799954|BIOLOGICAL|Placebo for DNA/NYVAC|Sodium Chloride for injection, 0.9% administered IM
214402972|NCT01799954|BIOLOGICAL|Placebo for AIDSVAX(R) B/E|600 mcg of aluminum hydroxide adjuvant, administered IM
214693886|NCT03270553|DRUG|plazomicin|single intravenous dose
215008222|NCT04165902|DRUG|compare the effects of steroid plus hyaluronic acid and destrose plus hyaluronic acid on knee osteroarthritis|compare the immediate effect (one week after 3 times of injections), short-term effects (one month and three months after 3 times of injections), and midterm effect (6 months after 3 times of injections).
215008223|NCT02714959|DRUG|Proleukin|
215008224|NCT03309111|BIOLOGICAL|ISB 1342|ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)
215008225|NCT05427916|DEVICE|Avance Solo|Avance® Solo will include the collective description for a complete device capable of delivering negative pressure to the incision site and managing exudate generated by the incision.
215008226|NCT05427916|OTHER|Optifoam|Optifoam is a silicone backed foam that is conformable, with a border that is waterproof, flexible and breathable for increased comfort, with a wear time of up to seven days. It is a standard of care product that is given to patients for surgical wounds.
215008227|NCT01374789|DRUG|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
215008228|NCT01374789|DRUG|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
215008229|NCT00979511|OTHER|milk and exercise|"* milk fortified with 1000mg calcium or low-calcium milk~* weight-bearing exercise or passive exercise"
215008230|NCT03558672|DEVICE|Flexitouch system with Head and Neck Garments|Flexitouch system or Flexitouch Plus Head and Neck Treatment, as prescribed
215008231|NCT00743262|DEVICE|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
215008232|NCT02898441|DEVICE|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
215008233|NCT02810327|GENETIC|Genetic Sequencing|Sequencing of the SERPINA1 gene
215008234|NCT04368910|DRUG|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
215008235|NCT04368910|DRUG|Chloroquine|Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
215008236|NCT04565288|DRUG|Atomoxetine|Participants randomized to receive the study medication, atomoxetine (brand name: Straterra) for 6-weeks (40 mg/day for 3 days then 80 mg/day thereafter). A comparator group will receive placebo (sugar pills).
215008237|NCT04565288|DRUG|Placebo|Matching placebo (sugar pill)
215008238|NCT04983732|DRUG|FL-101-Intravenous|150 mg administered via the IV route
215008239|NCT04983732|DRUG|FL-101-Subcutaneous|150 mg administered via the SC route
215008240|NCT00999011|PROCEDURE|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
215008241|NCT00999011|PROCEDURE|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
215008242|NCT01158404|DRUG|LY900009 - Dose Escalation Phase (Part A)|"2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
215008243|NCT01158404|DRUG|LY900009 - Dose Confirmation Phase (Part B)|"30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
214402973|NCT05209399|PROCEDURE|Ultrasound guided injection|All intraarticular hip injections will be performed under real-time ultrasound guidance using a GE LOGIQ P9 ultrasound machine with a C1-5-RS 1-5 MHz curvilinear transducer (GE Healthcare, Chicago, IL, USA). For the procedure, patients will be placed in a supine position. The curvilinear transducer and ultrasound machine will be used to visualize the anterior aspect of the hip joint in a sagittal oblique plane. Sterile technique will be used to perform the procedure.
214693887|NCT03270553|DRUG|metformin|single oral dose
214402974|NCT05860543|DIAGNOSTIC_TEST|C2i-WGS-MRD Test|The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD) in patients diagnosed with muscle-invasive bladder cancer (MIBC) and histopathologically classified as stage II-IIIA
215008244|NCT03949231|DRUG|PD1/PDL1 inhibitor|Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
215008245|NCT04763408|DRUG|Lenvatinib|Oral capsules.
215008246|NCT04763408|DRUG|Sorafenib|Oral tablets.
215008247|NCT03360487|RADIATION|Photobiomodulation in the sublingual region|In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.
215008248|NCT03360487|RADIATION|Photobiomodulation in the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
215008249|NCT03360487|RADIATION|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
215008250|NCT03971526|OTHER|MRI images review|MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.
215008251|NCT02454582|DEVICE|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
215097385|NCT02219373|OTHER|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
214402975|NCT05675696|OTHER|Esophageal Catheter|Newly designed external monitor that will capture esophageal pressure from a proprietary nasogastric tube combined with simultaneous pressure, flow, and volume measurements from the ventilator tubing.
214402976|NCT02633943|OTHER|Safety and efficacy assessments|"Genetic: No interventional drug product utilized in this follow-up study~Participants received a single IV infusion of LentiGlobin BB305 Drug Product in the parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term effects of autologous transplant are conducted in this study."
214402977|NCT06458543|DRUG|Longidaza|Bovhyaluronidase azoximer, vaginal suppositories 3000 IU, 1 suppository vaginally every other day, course of 10 days
214402978|NCT06458543|DRUG|Metronidazole 500 mg|Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days
214402979|NCT03921905|DIAGNOSTIC_TEST|ABI measurement|ABI measurement wil be done with an automatic device to diagnose PAD in patients with CAD
214402980|NCT06624189|OTHER|Auto-pended bot liver ultrasound order|This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.
214402981|NCT02223182|BIOLOGICAL|Viaskin Milk 150 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
214402982|NCT02223182|BIOLOGICAL|Viaskin Milk 300 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
214402983|NCT02223182|BIOLOGICAL|Viaskin Milk 500 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
214402984|NCT02223182|BIOLOGICAL|Viaskin Placebo|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
214402985|NCT06648096|DRUG|Afatinib|Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)
214402986|NCT05039450|DRUG|EFX|Investigational drug, Efruxifermin
214402987|NCT05039450|DRUG|Placebo|Placebo
214402988|NCT00180947|DRUG|Vinorelbine, cyclofosfamide|
214402989|NCT03886181|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214402990|NCT06499207|DIAGNOSTIC_TEST|Photon-counting detector computed tomography (PCD-CT)|Patients undergoing follow-up coronary angiography with IVI after percutaneous coronary intervention (PCI) as part of routine clinical practice will additionally receive coronary computed tomography angiography (CCTA) with PCD as part of this study.
215008252|NCT01123525|DRUG|Adenosine|1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
215008253|NCT02289378|DRUG|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
215008254|NCT02839460|PROCEDURE|Outpatient Muscle Biopsy|Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
215008255|NCT02384460|DRUG|SD-101-6.0 cream|applied topically once a day for 90 days
215008256|NCT02384460|DRUG|Placebo (SD-101-0.0) cream|applied topically once a day for 90 days
215008257|NCT02277860|BEHAVIORAL|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
215097386|NCT04241471|PROCEDURE|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
215097387|NCT04241471|DEVICE|traditional incision and drainage (I&D)|traditional incision and drainage (I\&D)
215097388|NCT05937789|DIETARY_SUPPLEMENT|Vitamin D3|Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
215097389|NCT05937789|DIETARY_SUPPLEMENT|Medium Chain Triglycerides (MCT)|Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
215097390|NCT03670368|BEHAVIORAL|Mentoring|The intervention will include one-on-one mentoring sessions held after school, focusing on coping, social relationships, and healthy lifestyles.
215097391|NCT03670368|BEHAVIORAL|Comparison group - written materials|Written materials from the mentoring sessions will be provided to those in the comparison group
214402991|NCT05970731|DRUG|Beclomethasone|84 mcg of Beclomethasone administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
214402992|NCT05970731|OTHER|Placebo|Placebo (0.9% sodium chloride) administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
214402993|NCT05970731|DEVICE|Microsponge|Drug delivery using chitosan-based biocompatible microsponge
214402994|NCT03069469|DRUG|Vimseltinib|Colony-stimulating factor 1 receptor (CSF1R) inhibitor
214402995|NCT06119087|DEVICE|Mechanical insufflation|"Mechanical insufflation (MI) is a chest physiotherapy exercise that will be performed using a type of mechanical insufflator-exsufflator (MI-E) known as the BiWaze Cough device. The device connects to a tube that can interface with a patient using either a facemask or mouthpiece.~Mechanical insufflation is a chest physiotherapy exercise that passively inflates the chest with positive pressure that is delivered in coordination with the patient's own inspiratory timing until maximal inflation capacity (MIC), determined by the patient or maximal chest rise on visual inspection. At MIC, the patient passively exhales, which completes one cycle. Prior literature has used a dose of 5 sets of 5 cycles once or twice daily. The maneuver is usually performed with assistance of a caregiver to hold the mask or mouthpiece in place."
214402996|NCT06397885|DEVICE|Milli Vaginal Dilator|Patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion
214402997|NCT06442189|DIETARY_SUPPLEMENT|Mediterranean Diet|The aim was to evaluate the effects of the application of a Mediterranean diet on the reproductive and metabolic parameters in the 3rd month of patients with a body mass index of 25 and more who were treated in our clinic due to a diagnosis of PCOS.
214693888|NCT05626517|DIAGNOSTIC_TEST|Ocular Imaging|The retinal photography will be acquired from macula-centre and an optic-disc centre for both left and right eye after their cardiac assessment. Patient will be required to focus at a target inside the machine for approximately 5 to 10 seconds, with a flash followed at the end when eye image is captured. Based on patients' eye conditions, additional or less images may be taken. This allows a snapshot of both retinal and coronary vessels at a single point in time, no mydriatic drops will be used. Participants will be given the option to undergo mydriatic photographs of the retina at SNEC/SERI depending on participant eye condition. For mydriatic photograph, images will be obtained after pupil dilation and graded for presence and severity of diabetic retinopathy according to the modified ETDRS system and other retinal abnormalities by trained graders.
215008258|NCT00532857|DRUG|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
215008259|NCT04105660|OTHER|Training for EEG monitoring|Training for reading EEG curves during anaesthesia
215008260|NCT04105660|OTHER|Standard monitoring|Standard monitoring including clinical parameters and BIS index
215008261|NCT05824676|DEVICE|Variable Angle LCP Patella Plating System|FDA approved device, 510K number of, K210408. The Variable Angle LCP Patella Plating System is a device that can be formed to a patients specific need with various anchoring points to best fix what is needed for fixation.
215008262|NCT05824676|DEVICE|Traditional Fixation|Traditional fixation methods for patellar fracture (screws, suture fixation, wire fixation, other plates).
215008263|NCT01060111|DRUG|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
215008264|NCT01060111|DRUG|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
215008265|NCT01060111|DRUG|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
215008266|NCT05409612|BIOLOGICAL|Supemtek®|"Quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
215008267|NCT05409612|BIOLOGICAL|Vaxigriptetra®|Quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
215008268|NCT01277068|PROCEDURE|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
215008269|NCT03281538|DRUG|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
214402998|NCT05804396|DEVICE|Relivion®|Active stimulation device
214403000|NCT03714022|DRUG|Abatacept|Participants will receive abatacept at a single dose 750 mg as IV infusion.
215008270|NCT02116062|DEVICE|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
214403001|NCT04685733|DEVICE|Non-invasive hemodynamic measurements|Non-invasive hemodynamic measurements
215008271|NCT02116062|DEVICE|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
215008272|NCT02116062|DEVICE|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
214403002|NCT06352268|PROCEDURE|Pallidal, subthalamic or thalamic lesioning|Radiofrequency, ultrasound guided or other lesioning procedures of the Globus pallidus interna, subthalamic nucleus or Vim nucleus of the thalamus for the management of Movement disorders
214403003|NCT00367393|DRUG|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
214403004|NCT02005003|BEHAVIORAL|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
214403005|NCT02005003|PROCEDURE|Blood samples|Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
215008273|NCT03319121|DRUG|Empirical therapy group|Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
215008274|NCT03319121|DRUG|Guided therapy group|Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
215008275|NCT05012969|DEVICE|Hipstop bandage|12 weeks use of a bandage to prevent hip dislocations in patients with previous dislocations
215008276|NCT03049800|DEVICE|Magnetic Resonance Imaging|Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.
215008277|NCT00583804|DEVICE|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
215008278|NCT05213351|OTHER|Graded Motor Imagery|"Graded Motor Imagery program will be performed two times a week for six consecutive weeks and will include the following three steps: laterality training, imagined movements, and mirror therapy.~1. Right-left discrimination training (lateralization training)~2. Imagination of hand movements (motor imagery):~3. Mirror therapy Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc."
215008279|NCT05213351|OTHER|Exercise|Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc.
215008280|NCT04031768|OTHER|Timing of rest prior to blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
215008281|NCT03921437|RADIATION|decision support intervention|CKD Guardian is the decision-maker and uses the e-book software to develop medical decision-assist tools, and applies this tool and decision-directed mode to introduce and select. The implementation steps include team discussion, option discussion and decision-making. The group is introduced with traditional care instructions for routine care.
215008282|NCT02558569|DRUG|Levobupivacaine|L form of bupivacaine with less cardiotoxicity.
215008283|NCT02558569|OTHER|NSS|Clear intravenous fluid looks alike local anesthetic.
215008284|NCT00997126|DRUG|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
215008285|NCT00997126|DRUG|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
215008286|NCT03536962|OTHER|no intervention|no intervention
215008287|NCT03152890|DRUG|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
215008288|NCT00731536|OTHER|No intervention|This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
215008289|NCT03597555|DRUG|Sodium Oxybate Oral Solution 500 MG/ML|"First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
215008290|NCT03597555|DRUG|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
215008291|NCT05516095|DEVICE|Transcranial magnet stimulation|Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.
214403006|NCT02005003|BIOLOGICAL|Feces collection|Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
214403007|NCT02005003|PROCEDURE|Caloric preload|A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
215008292|NCT05516095|DEVICE|Sham Transcranial magnet stimulation|Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
215008293|NCT06156267|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
214693889|NCT05626517|OTHER|Questionnaires|3 to 4 questionnaires will be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire) to investigate the correlation between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and outcomes.Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function (IIEF) questionnaire. Participants have the option to not complete the whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
215008294|NCT06156267|DRUG|mRNA tumor vaccines|neoantigen personalized mRNA vaccines
215008295|NCT05831046|OTHER|ED management software|Patients utilize software after being screened, but prior to being re-evaluated by physician
215008296|NCT03278782|BIOLOGICAL|Pembrolizumab|Given IV
215008297|NCT03278782|DRUG|Romidepsin|Given IV
214403008|NCT02005003|BEHAVIORAL|Food selection task|Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
214403009|NCT02005003|BEHAVIORAL|Memory task|Participants perform short memory tasks on each visit
215008298|NCT04402957|DRUG|LSALT peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
215008299|NCT04402957|DRUG|Placebo|0.9% saline solution
215008300|NCT04246476|BEHAVIORAL|Mentally singing|All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
215008301|NCT04246476|BEHAVIORAL|Listening to music|All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
215008302|NCT04195347|DRUG|CM4620|IV
215008303|NCT02122952|BIOLOGICAL|AVXS-101|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
215008304|NCT01527981|BEHAVIORAL|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
215008305|NCT00940459|DEVICE|Senofilcon A contact lens (Acuvue Oasys)|Silicone hydrogel contact lens CE-marked for the intended usage.
215008306|NCT00940459|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens CE-marked for the intended usage.
215008307|NCT00940459|DEVICE|Lotrafilcon B contact lens (Air Optix)|Silicone hydrogel contact lens CE-marked for the intended usage.
215097392|NCT02783092|DRUG|Cannabidiol|Oral solution of cannabidiol 200 mg / mL dissolved in corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
215097393|NCT02783092|DRUG|Placebo|The placebo will be an oral solution of corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
215008308|NCT00940459|DEVICE|Balafilcon A contact lens (PureVision)|Silicone hydrogel contact lens CE-marked for the intended usage.
215008309|NCT00940459|DEVICE|Etafilcon A contact lens (Acuvue 2)|Hydrogel contact lens CE-marked for the intended usage.
215008310|NCT00940459|DEVICE|Contact lens care system (EasySept)|Contact lens care system CE-marked for the intended usage.
215008311|NCT05087303|OTHER|Types of Telemedicine Delivery Models|Each arm delivers standard sickle cell care using a different model based on patient location.
215008312|NCT01857154|DIETARY_SUPPLEMENT|Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate."
215097394|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
215008313|NCT01857154|DIETARY_SUPPLEMENT|Non-Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate."
215008314|NCT01857154|DIETARY_SUPPLEMENT|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
215008315|NCT00896233|PROCEDURE|MRE|"Part 1: Participants will have a screening visit, followed \~1 month later by two imaging visits over \~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed \~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans."
215008316|NCT04700462|BEHAVIORAL|Sm-EMA|Self-monitoring ecological momentary assessment behavior change tool to promote adherence to a desired behavior (i.e. COVID-19 preventative behaviors).
215008317|NCT04280562|DEVICE|Sana Pain Reliever|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's normal settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
215097395|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
215097396|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
215097397|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
215097398|NCT02479815|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP)|Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
215097399|NCT03944408|PROCEDURE|stent implantation|stent implantation
214403010|NCT02005003|BEHAVIORAL|Food consumption task|Participants are given a selection of food items to consume on each visit
214693890|NCT05480293|DRUG|Ranibizumab|ranibizumab，0.5mg,IVT
214693891|NCT05480293|DRUG|SCT510A|SCT510A，1.25mg,IVT
214693892|NCT02054143|PROCEDURE|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
214403011|NCT05121675|BEHAVIORAL|Neuroflow app: Mental health and wellbeing resources for adults|"The NeuroFlow app delivers resources on resilience training, mindfulness-based strategies and cognitive behavioral therapy to adults looking to support their mental health and wellbeing. The specific journey (i.e., content such as activities, videos, trackers, and journaling) is tailored to individuals based on depression and anxiety screeners administered upon signing up to the app."
214403012|NCT04616118|OTHER|Phone Visit|Participants randomized to this arm will receive usual care via telephone only
214403013|NCT04616118|OTHER|Video Visit|Participants randomized to this arm will receive usual care via video call
214403014|NCT01907152|OTHER|Protein enriched yoghurt drink and bread|
214403015|NCT00165867|DRUG|E7070|
214403016|NCT04625478|OTHER|Patients having had an osteo-articular infection with Stahylococcus|Immunostaining targeting staphylococci and components will be performed on tissue samples collected from patients with osteo-articular infection
214403017|NCT03157102|DEVICE|HFNC|"Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher \& Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 \>92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). ."
214403018|NCT03157102|DEVICE|Standard Oxygen Treatment|"Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion."
214403019|NCT00197301|BIOLOGICAL|Vaccination|
215008318|NCT04280562|DEVICE|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
215008319|NCT04714580|OTHER|Animal Fun Program|This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
215008320|NCT05311163|PROCEDURE|MitraClip|Transcatheter Mitral Edge-To-Edge Repair
215008321|NCT01220063|RADIATION|Radiation|10 Gy for 4 times (total 40 Gy)
215008322|NCT01220063|DRUG|Irinotecan|40 mg/m² : Day 1 and day 8
215008323|NCT00104715|DRUG|antiandrogen therapy|
215008324|NCT00104715|DRUG|docetaxel|
215008325|NCT00104715|DRUG|goserelin acetate|
215008326|NCT00104715|PROCEDURE|orchiectomy|
215008327|NCT00393146|DRUG|GW856553|Study drug
215008328|NCT05716022|DIAGNOSTIC_TEST|Blood Collection|Prior to subject's surgical procedure, blood (about 3 tablespoons (44 mL)) will be collected through a needle in vein for research purposes. The UVA researchers will analyze the biomarkers that are expressed in subject's blood.
215008329|NCT05716022|DIAGNOSTIC_TEST|Bronchoscopy|Following blood collection, the subject will undergo the bronchoscopy for research purposes. While in the operating room, a bronchoscope will be inserted through the breathing tube that is already been placed for the surgery. Subject's airways will be examined with the bronchoscope in both lungs. Ten tablespoons (150 mL) of saline solution will be injected into one of subject airways. The fluid will be re-collected by suctioning it back up with the bronchoscope. The fluid will be collected from the bronchscope.
215008330|NCT02965456|DRUG|IDP 121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
215008331|NCT02965456|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
215008332|NCT02583477|DRUG|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
215008333|NCT02583477|DRUG|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
215008334|NCT00002308|DRUG|Stavudine|
215008335|NCT03943485|DEVICE|The uterine manipulator which is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We adopted this device in abdominal hysterectomy.|The uterine manipulator is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We hypothesized that adoption of a uterine manipulator would help the surgeon to better identify the colpotomy site by moving the uterus cranially and thus providing better visualization of the colpotomy site.
214403020|NCT06157775|DIAGNOSTIC_TEST|Shear-wave elastography|Shear-wave elastography using a manual ultrasound with a 9L-Probe in B-mode.
214403021|NCT00859417|PROCEDURE|Traditional surgery|Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).
214403022|NCT00859417|DEVICE|Perigee® prosthesis|Surgical method with Perigee® prosthesis
214403023|NCT03864133|DRUG|Omidria|Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.
214403024|NCT00927628|PROCEDURE|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were \>40-years-of-age.
214403025|NCT02668432|DRUG|Amiodarone|Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO equivalents (accounting for 50% bioavailability of PO vs IV amiodarone). Randomization may be overridden by the attending or fellow physician if the patient's severity of illness warrants. Discontinuation of amiodarone in the full-load group will be at the discretion of the physician/pharmacists, after the pre-determined randomization loading dose has been provided.
214403026|NCT04391075|PROCEDURE|Pudendal nerve block|Pudendal nerve block provided during last fase of delivery
214403027|NCT04447820|DRUG|K-877-ER (Dose A)|Dose A Oral Administration
214403028|NCT04447820|DRUG|K-877-ER (Dose B)|Dose B Oral Administration
215008336|NCT06144801|DEVICE|CoolSense Group|Patients in the CoolSense group received a CoolSense device that had been pre-chilled in the freezer for a minimum of one hour. The cover of the CoolSense device was removed, and the arteriovenous fistula, whose metal tip had been cleaned with batikon, was brought into contact with the area where the arteriovenous fistula cannulation would occur. This contact was maintained for 5 seconds, involving circular movements, and the fistula cannulation took place promptly.
215008337|NCT04607759|DIETARY_SUPPLEMENT|nutraceutical|Subjects will consume two capsules for eight weeks
215008338|NCT02273453|DRUG|Songha® Night|
215008339|NCT02273453|DRUG|Oxazepam|
215008340|NCT02273453|DRUG|Placebo|
215008341|NCT05930470|OTHER|Magnetic Mitohormesis Therapy|The MMT device that will be used in the trial will be the QuantumTx BIXEPS Fitness and Wellness. The apparatus will provide pulsed electromagnetic fields at flux densities 1.5 mT. During the treatment period, participants will receive PEMF therapy during two ten-minute sessions each week for a total of 12 weeks. The treatment period will be preceded or followed by 12 weeks of twice-weekly sham treatments depending on randomization.
215097400|NCT06271395|DRUG|Injectable Type A Botulinum Toxin|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
215097401|NCT01737853|DRUG|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
214403029|NCT04447820|DRUG|K-877-IR|K-877-IR Oral Administration
214403030|NCT04850742|PROCEDURE|Cryopreserved aorta|After resection of the tracheal or bronchial lesion with standard surgical techniques, the airway gap is reconstructed with a segment of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis. An Ultraflex covered tracheobronchial stent is inserted to prevent collapse for the aortic graft.
214403031|NCT00159510|DRUG|Methylene blue|Injection bolus of 2 mg/kg PBW and infusion of 0.2 mg/kg/hr
214403032|NCT00159510|DRUG|Nitric oxide|An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
214403033|NCT00159510|DRUG|Methylene blue & nitric oxide|See the dosage in the previous arms
214403034|NCT00250419|BIOLOGICAL|V930|
214403035|NCT02303743|DEVICE|Smart Phone Application|Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
214403036|NCT02303743|DEVICE|Written instructions with visual aids|written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
214403037|NCT01766583|DRUG|CC-292 + lenalidomide|CC-292 + lenalidomide
214403038|NCT02899598|BIOLOGICAL|Extra blood draw samples|NEVER STARTED
214403039|NCT02899598|BIOLOGICAL|extra amniotic fluid samples|NEVER STARTED
214403040|NCT03753880|DEVICE|HEMOPATCH Sealing Hemostat|Hemopatch sealing hemostat used after LR to cover the resection surface
214403041|NCT02838004|DEVICE|IOL MINI WELL READY|IOL MINI WELL READY
215008342|NCT02198131|PROCEDURE|laser therapy|Undergo pulsed dye laser
215008343|NCT02198131|OTHER|questionnaire administration|Ancillary studies
215008344|NCT04235075|DEVICE|ECG/PCG and ultrasound signal acquisition|"The ECG - PCG signals are acquired over a 20-minute monitoring phase with passive non invasive sensors (abdominal and thoracic). The volunteer's abdomen is photographed when the electrodes and sensors are installed. An ultrasonography is also performed for 10 minutes.~The session is filmed for 5 volunteers accepting the video. Any distinctive elements will be removed from photos and videos to prevent the identification of participants."
215097402|NCT01737853|DRUG|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
215097403|NCT06098248|DIAGNOSTIC_TEST|cCeLL - Ex vivo|Neoplastic brain tissue biopsied from participant will be visualized, and images will be captured using cCeLL - Ex vivo.
215097404|NCT00568126|DRUG|Maca Root|3g/day of Maca Root for 12 weeks.
214403042|NCT00183924|DRUG|Estramustine|
215008345|NCT05298839|DIAGNOSTIC_TEST|Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test|"Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test."
215008346|NCT06153238|DRUG|GME751|400 mg Q6W, i.v. infusion, over 24 weeks period
215008347|NCT06153238|DRUG|Keytruda - EU|400 mg Q6W, i.v. infusion, over 24 weeks period
215008348|NCT06153238|DRUG|Keytruda - US|400 mg Q6W, i.v. infusion, over 24 weeks period
215008349|NCT00729807|DRUG|pentamidine|
214403043|NCT00183924|DRUG|Docetaxel|
215008350|NCT06075290|BEHAVIORAL|internet plus model|Intelligent transcutaneous bilirubin meter and Internet plus model for neonatal jaundice monitoring at home and remote follow-up
215008351|NCT06075290|BEHAVIORAL|control|follow-up by conventional methods; hospital or community follow-up depending on arrangement
215008352|NCT06646848|DEVICE|Vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the infants's extremity and routine heel blood collection procedure was performed.
215008353|NCT06646848|DEVICE|Heel Warming|The heel warning group will warm the heel of the infants using a hot thermal bag 3-5 minutes before the application. Then, the thermal bag will be removed and the nurse will take the heel blood.
215008354|NCT06646848|DEVICE|Shotblocker|The protruding surface of the Shotblocker was placed on the heel lance procedure site. While applying pressure on the skin through the Shotblocker, the nurse performed heel lancing with the needle through the opening in the center of the Shotblocker. During the 10-second waiting phase, the Shotblocker was kept at the procedure site with the same pressure. Then Shotblocker was removed from the skin and routine capillary heel collection procedure was performed.
215008355|NCT06099600|PROCEDURE|Reconstructive surgery of the anterior cruciate ligament|surgical reconstruction after rupture of the anterior cruciate ligament is widely proposed as first-line treatment, with the aim of restoring knee joint stability and facilitating functional recovery
215008356|NCT01008787|BEHAVIORAL|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
215008357|NCT01008787|BEHAVIORAL|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
215008358|NCT01008787|BEHAVIORAL|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
215008359|NCT01008787|BEHAVIORAL|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
215008360|NCT04056468|DRUG|Mobocertinib|Mobocertinib capsule.
215008361|NCT03299309|DRUG|PEP-CMV|Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.
215008362|NCT05445336|BEHAVIORAL|PREVENT Program|PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
215097405|NCT00568126|DRUG|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
215097406|NCT06161480|DEVICE|Weighted Blanket|Weighted Blanket is an occupational therapy modality which has been associated with significant increases in grounding, orientation to reality, soothing, and quality of life.
214403044|NCT00183924|DRUG|Carboplatin|
214403045|NCT02355405|DEVICE|lung ultrasound|lung ultrasound investigations were performed right before and after the surgical procedure.
214403046|NCT02355405|RADIATION|thoracic computed tomography|thoracic CT were performed within one hour after the LUS investigation
214403047|NCT05080621|DRUG|Ripretinib|50 mg tablets
214403048|NCT05080621|DRUG|binimetinib|15 mg tablets
214693893|NCT02054143|DRUG|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
215008363|NCT01860404|DRUG|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
215008364|NCT01860404|DRUG|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
215008365|NCT00009555|DRUG|Testosterone|
215008366|NCT05906004|DEVICE|Pitch-Patch|Pitch-Patch device used for rotator cuff augmentation/ reinforcement.
215008367|NCT06633289|OTHER|Experimental formula|New hydrolyzed rice protein-based formula
215008368|NCT06633289|OTHER|Control formula|Commercially available amino acid-based formula.
215008369|NCT01761344|OTHER|Intraoperative cortisol measurement.|Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
215008370|NCT04668963|DEVICE|MIRROR THERAPY|patients were seated on a chair, with the mirror positioned between the upper limbs perpendicular to the subject's midline and with the unaffected upper limb facing the reflective surface. Following the physiotherapist indications, the patients observed the reflection of their unaffected limb while performing the following movements with the both arms, the affected one as good as possible: flexion and extension of the shoulder, elbow, wrist and finger, prone supination of the forearm.
215097407|NCT03873935|OTHER|Evaluation of periodontal status|Clinical examination
215097408|NCT00369642|BEHAVIORAL|Cognitive-behavioral therapy|
214403049|NCT02234310|BIOLOGICAL|rFIXFc|Adjustments to the dose and interval of rFIXFc was made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There was an option to start study dosing as episodic treatment (on-demand).
214403050|NCT00884819|DRUG|Fenofibrate|fenofibrate 200 mg daily for 6-months
214403051|NCT00884819|OTHER|Placebo|Placebo match for 6 months
214403052|NCT02810808|PROCEDURE|1+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the injection of the same does at the first month.
215008371|NCT00401115|DRUG|MS-R001 (rapamycin)|Subconjunctival injection in various dosages
215008372|NCT00401115|DRUG|MS-R001 (rapamycin)|Intraocular injection in various dosages
215008373|NCT03084484|DIETARY_SUPPLEMENT|Kiwifruit addition to the diet|Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
215008374|NCT03084484|PROCEDURE|Non Surgical periodontal treatment|Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
215008375|NCT01721902|DEVICE|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
215008376|NCT01721902|OTHER|Carrier Solution|Intra-myocardial injection of carrier solution
215008377|NCT05652842|BEHAVIORAL|Work-type|Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.
215008378|NCT05638984|DRUG|Decitabine Injection|Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion
215008379|NCT05638984|DRUG|tirelizumab|10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
215008380|NCT02823561|DIETARY_SUPPLEMENT|Garcinia mangostana|
215008381|NCT02823561|BEHAVIORAL|Control group|
215097409|NCT06582927|BEHAVIORAL|Mindfulness-Based Attention Training (MBAT)|"MBAT is an evidence-based 8-hour mindfulness program that comprises 4 central topics and associated practices. The concentration topic introduces participants to mindfulness basics, including discussion of focused attention and mind wandering. The body awareness theme involves the cultivation of greater self-awareness, and the development of equanimity. The open monitoring theme emphasizes awareness of and receptivity to changing experiences and moments of uncertainty. The theme of connection addresses leadership and group cohesion, and the cultivation of kindness and connection with others.~The course content and materials in the present study will entail the foundational MBAT curriculum and other related content delivered virtually over Zoom but will consist of 8, 1-hour sessions delivered across 8 consecutive weeks."
215097410|NCT05035836|DRUG|Zanidatamab|Given IV
215097411|NCT05035836|DRUG|Letrozole|Given by PO
215097412|NCT05035836|DRUG|Tamoxifen|Given by PO
215097413|NCT01474720|DRUG|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
214403053|NCT02810808|PROCEDURE|3+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the first three monthly intravitreal injections of the same does.
214403054|NCT02810808|DRUG|Ranibizumab|Ranibizumab - a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration
214403055|NCT00235495|BIOLOGICAL|Albumin|human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset
214403056|NCT00235495|DRUG|Saline|equivalent volume of isotonic saline control
214403057|NCT00248521|DRUG|alvespimycin hydrochloride|
214403058|NCT05211830|DRUG|SXR1096 cream|Skin cream to be applied twice a day to a predefined area of the skin
215008382|NCT05375799|OTHER|Clinical Observation|"This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects )."
215008383|NCT05225168|PROCEDURE|laparoscopic burch colposuspension operation|By pushing the urethra medially, two sutures are placed on the bladder at trigon level and midurethral and suspended on the bilateral iliopectineal ligament and colposuspension is supplied.
215008384|NCT05225168|PROCEDURE|minisling suburethral sling|A vertical vaginal incision is made 1 cm below the external urethral meatus. It is followed by minimal vaginal dissection from the inferior portion of the ascending ramus of the ischiopubic bone to the obturator muscle. The arms of the mesh are fixed on both sides of the obturator internus muscle with the help of a trocar. After leaving a 1-2 mm gap between the mesh and the urethra, the vaginal wall is closed by suturing.
215008385|NCT03270488|OTHER|Laser|Laser (power of 3.0w).
215008386|NCT03270488|OTHER|Placebo|Laser (power 0,0w)
215008387|NCT04836130|PROCEDURE|patient specific guide|patient specific guide reduction
215008388|NCT04836130|PROCEDURE|conventional technique|conventional anatomical reduction
215008389|NCT06480955|DEVICE|Cryoablation system|Any cryoablation system from Boston Scientific that has received CE Mark and/or FDA clearance for the ablation of bone malignancies.
215008390|NCT03468127|OTHER|Soy foods|Isolated soy protein, soy protein, soybean products, soy milk
214403059|NCT05211830|DRUG|Placebo cream|Skin cream to be applied twice a day to a predefined area of the skin
214403060|NCT02242461|DRUG|Rhodiola placebo capsules|Corn starch
214403061|NCT02242461|DRUG|Rhodiola Crenulata|Rhodiola Crenulata
215008391|NCT02762604|BEHAVIORAL|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
215008392|NCT02762604|BEHAVIORAL|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
215008393|NCT04755478|PROCEDURE|Thoracotomy|Participants will undergo lobectomy via open thoracotomy at the discretion of the surgical team.
215008394|NCT04755478|PROCEDURE|VATS|Participants will undergo lobectomy via VATS at the discretion of the surgical team.
215008395|NCT05823857|OTHER|Aquatic Therapy|Participants in this experimental intervention group will perform trunk stabilization, which will be based on a variety of aquatic exercises in different positions, intended to activate the multifidus and transverse abdominis in a co-contraction. Additionally, hip exercises will be completed to promote the strengthening of the gluteus maximus, gluteus medius, and gluteus minimus muscles. The aim of these exercises is to enhance the strength and dynamic stability of the spine and its surrounding musculature in a functional and yet non-weight-bearing way. Each exercise will be performed 10 times while sustaining the muscles co-contraction for 5-10 seconds and will be progressed gradually. Each training session (60 minutes) will be supervised by a Certified Athletic Therapist and take place in the PERFORM AT Clinic/Swim Ex pool.
215008396|NCT05823857|OTHER|Standard Care|Participants in this experimental intervention group will receive the standard LBP treatment in the PERFORM Athletic Therapy clinic.Two Certified Athletic Therapists (AT) will be conducting the sessions. The ATs will complete a thorough assessment of the eligible participants with chronic LBP and administer a range of interventions including stretching, strengthening and stabilization exercise, aerobic conditioning, and manual mobilization techniques. Other modalities could include application of ice and heat, ultrasound, and transcutaneous electrical nerve stimulation (TENS).
215008397|NCT04266977|DRUG|Dexamethasone|restrictive use of DEX, based on standardized clinical and radiological criteria.
214403062|NCT05350995|OTHER|No intervention|No intervention
214403063|NCT01226264|PROCEDURE|Diffusion weighted MRI (DW- MRI)|"An MRI examination (including diffusion-weighted sequences) belongs to the standard protocol for patients with cervical uterine cancer. The additional burden is therefore restricted to an extra MRI scan during and/or early after therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous and vaginal contrast medium will be administered. In most cases, patients do not experience any discomfort and the use of these contrast agents is part of the clinical routine."
214403064|NCT00374387|DRUG|Nuvaring|
214403065|NCT00374387|DRUG|low-dose combination pill|
214403066|NCT00374387|DRUG|minipill|
214403067|NCT06077825|OTHER|postoperative rehabilitation|30 patients took postoperative rehabilitation after total hip arthroplasty surgery, 3 times a week, for 6 weeks. They took conventional rehabilitation (hip range of motion exercises, progressive strengthening exercises for hip and knee muscles, balance and proprioceptive exercises and gait training).
214403068|NCT01305824|DRUG|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
215008398|NCT06038643|BEHAVIORAL|Motivational behavioural intervention and daily activities monitoring|Social motivation manipulation, self-transcendence daily messaging, and daily activities monitoring through accelerometry. Participants in this arm will have a study partner who receives daily feedback on the main participant's daily step count.
215008399|NCT06038643|BEHAVIORAL|Active Control|Daily activities monitored through accelerometry.
215008400|NCT05048472|DIAGNOSTIC_TEST|Abbott HIV-1/2 VL Point of care Device|Point of care viral load monitoring
215008401|NCT02741817|DRUG|Aspirin|The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
214403069|NCT01305824|DRUG|Placebo|Placebo administered at the time of AVF creation.
214403070|NCT01305824|DRUG|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
214403071|NCT06492941|DRUG|Docetaxel for Injection (Albumin bound)|Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.
214403072|NCT06492941|DRUG|Placebo|Placebo was human blood albumin without the active ingredient docetaxel
214403073|NCT06492941|DRUG|Best supportive care|Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.
214403074|NCT05756842|DIETARY_SUPPLEMENT|Honey-based gel supplementation|70 g/day of a honey-based gel divided into 2 equal doses of 35 gr (in the morning and evening) for a total duration of 14 days
214403075|NCT05623969|DIAGNOSTIC_TEST|Holter ,Echo , Speckle tracking echocardiography|A 24-h ambulatory Holter Echocardiography Speckle tracking echocardiography (STE)
214693894|NCT02935699|DRUG|Test Drug (JDP-205)|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
215008402|NCT03783806|DIAGNOSTIC_TEST|Posturography measurements|Determination of functional status, Posturography measurements, postural tests
215008403|NCT02944266|OTHER|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
215097414|NCT04267081|DRUG|Venetoclax|Ex vivo venetoclax sensitivity testing is used for patient selection.
215097415|NCT06480695|DIETARY_SUPPLEMENT|Nitrate-Rich Beetroot Juice|subjects will consume 1 bottle of nitrate-rich beetroot juice (\~400mg of nitrate each) 2x a day
215097416|NCT06480695|BEHAVIORAL|High Intensity Exercise|exercise at an intensity midway between the lactate threshold and VO2peak, from the screening test at an RPE of \~ 15-17
215097417|NCT06480695|BEHAVIORAL|Moderate Intensity Exercise|exercise at the RPE at LT associated an \~ RPE of 10-12
215008404|NCT04519398|GENETIC|Complete thrombophilic profile testing by multiplex PCR|"Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~* Factor V Leiden~* Factor V 4070 A\>G (Hr2)~* Factor II G20210A~* Methylenetetrahydrofolate reductase (MTHFR) C677T~* MTHFR A1298C~* Cystathionine β-synthase (CBS) 844ins68~* PAI-1 4G/5G~* Glycoprotein IIIa T1565C (HPA-1a/b)~* ACE-DEL/INS~* Apolipoprotein E (ApoE)~* AGT M235T~* Angiotensin II type 1 receptor (ATR-1) A1166C~* Fibrinogen - 455 G\>A~* Factor XIII Val34Leu"
214403076|NCT04216160|OTHER|ACN cream (YUN)|Application of the facial cream ACN (YUN) twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
214403077|NCT04216160|OTHER|Placebo cream (YUN)|Application of the facial placebo cream twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
214403078|NCT05051787|BIOLOGICAL|Blood and milk samples|"2 types of samples will be taken over the same time slots in breastfeeding mothers treated with amoxicillin for at least 2 days:~* 3 breast milk collections of about 20 ml each made using an electric breast pump provided to the participant.~* 3 blood samples of approximately 5 ml each."
215008405|NCT02990377|BEHAVIORAL|RL-supported IVR intervention|Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
215008406|NCT02825459|BEHAVIORAL|Abstinence from e-cigarettes|Abrupt cessation for 6 days
215008407|NCT05297838|OTHER|Stationary Bike|Stationary Bike while hand is submerged in ice bath
215008408|NCT05297838|OTHER|Virtual Reality (VR) Headset|VR headset containing gameplay
215008409|NCT05297838|OTHER|Ice Bath|Pain was elicited via a cold pressor test, which is an established method of producing controlled and repeatable painful stimuli in an experimental setting
215008410|NCT00762177|DRUG|Fluoride|Brush twice a day for 14 days
215008411|NCT00762177|DRUG|Fluoride, Triclosan|Brush twice daily for 14 days
215008412|NCT00762177|DRUG|Stannous Fluoride|Brush twice daily for 14 days
215097418|NCT06480695|DIETARY_SUPPLEMENT|Nitrate-Depleted Placebo Beetroot Juice|Subjects will consume 1 bottle of nitrate-depleted beetroot juice 2x a day
215097419|NCT01019850|DRUG|Vorinostat|Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
215097420|NCT01019850|RADIATION|131- I Metaiodobenzylguanidine|Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
215097421|NCT01019850|PROCEDURE|Peripheral Blood Stem Cell Infusion|Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
214403079|NCT02490384|PROCEDURE|Physical exam indicated cerclage|Cervical cerclage
214403080|NCT06433466|OTHER|Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities|Young adults were randomly shown 10 videos, featuring influencers promoting e-cigarettes alongside healthy lifestyle activities (experimental group), or a healthy lifestyle activity alone (control).
215008413|NCT05876312|DRUG|ADX-038|siRNA duplex oligonucleotide
215008414|NCT05876312|DRUG|Placebo|Saline
215008415|NCT05111964|DEVICE|High Intensity Focused Ultrasound Ablation|"The focused ultrasound exposure will be performed using the Haifu® Model-JC200 Focused Ultrasound Tumour Therapeutic System at the Churchill Hospital site, CE-approved for tumour therapy (or subsequent CE-approved device upgrades by Haifu®). The participant will be positioned over the therapeutic device and water bath used to transmit the focused ultrasound to the target tumour. No anaesthesia or any combination of local anaesthesia, nerve block, epidural, conscious sedation or general anaesthetic may be used, depending on anatomical location, size of tumour, preference of HIFU team, patient and anaesthetist and other patient factors.~In therapy mode, the tumour volume is treated with focused ultrasound to ablate the tumour tissues to high temperatures (in excess of 60ºC) using focused ultrasound targeted from outside the body.~Patients are typically discharged with 24 hours."
215008416|NCT05111964|DIAGNOSTIC_TEST|Tumour Biopsy and Venous Blood Tests|"Where appropriate, participants are also encouraged to undergo a pre-HIFU (and in the case of unresectable STS, post-HIFU) ultrasound biopsy of the target tumour and additional blood tests to inform the immunological aspects of the study. Having the biopsy does not mandate enrolment on the trial, and patients will be free to leave the trial at any stage. The pre-HIFU (and post-HIFU) biopsies are altruistically encouraged but not absolutely essential to enrolment on the trial.~Biopsies will be performed under ultrasound guidance by an experienced radiologist using local anaesthetic."
215008417|NCT04136366|DRUG|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
215008418|NCT04136366|OTHER|Standard surgical care procedure|Standard surgical care performed upon completion of pars plana vitrectomy
215008419|NCT03052036|PROCEDURE|Coronary Angiography|Coronary angiography to determine location of blocked or narrowed arteries.
215097422|NCT01019850|DRUG|Filgrastim|All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
215097423|NCT06106763|OTHER|Mandala coloring|Mandala coloring page
215008420|NCT03052036|PROCEDURE|Coronary revascularisation|PCI or CABG will be performed following coronary angiography at the discretion of the treating cardiologist.
215097424|NCT00006094|DRUG|oxaliplatin|Given IV
215097425|NCT00006094|DRUG|fluorouracil|Given IV
215097426|NCT00006094|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
215097427|NCT04039152|OTHER|locally adapted neonatal sepsis treatment protocol|the neonatal sepsis treatment protocol was modified according to the local antibiotics susceptibility patterns
215097428|NCT05354687|OTHER|Small-group Teaching|The Small-group Teaching will include theoretical lectures and laboratory practice. Theoretical training will be given in 2 hours and will last 2 week. After the theoretical training, laboratory practice will be made with mannequins, pressure injury models and photographs in the nursing skills laboratory. Laboratory practices will be done in groups of about 10 students. Laboratory application will take 1 week.
215097429|NCT05354687|OTHER|Self-directed Learning|The training will be given in two stages. The first stage of the training will be given via the mobile application for 2 weeks. Students will be able to access the training individually, wherever and whenever they want, via the mobile application. In the second stage, students will individually conduct laboratory practice. Students who start using the mobile application will make laboratory applications individually, whenever they want when the laboratory is available. Models and materials that students will need will be available in the laboratory. They will be able to get help from the trainer when they need it. Individual laboratory application will take 1 week.
215097430|NCT06130111|PROCEDURE|Mastectomy|Mastectomy as a surgical procedure for breast cancer (regardless of perioperative treatment).
215097431|NCT06386991|OTHER|Using ethylenediaminetetraacetic acid (EDTA), citric acid ((MONO/ANH) and etidronic acid (HEBP) to clean root canals during regenerative endodontic treatments|Regenerative endodontic treatment using different irrigation solutions
214403081|NCT05194007|DRUG|Frondanol|Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
214693895|NCT02935699|DRUG|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
215097432|NCT00369499|DEVICE|PFO Closure|
215097433|NCT04965662|DRUG|Maraviroc|Maraviroc 300 mg, TWO tablets once daily.
215097434|NCT04965662|DRUG|Truvada|Truvada one tablet once daily
215097435|NCT06835699|DRUG|Psilocybin 25 mgs|All participants will be administered 25 mg psilocybin and undergo TMS
215097436|NCT06835699|DEVICE|TMS|All participants will be administered 25 mg psilocybin and undergo TMS
215097437|NCT05014867|PROCEDURE|Embryo transfer method|"1. Sequential embryo transfer on day 3 and day 5 in a frozen cycle~2. Sequential embryo transfer on day 3 and day 5 in a fresh cycle~3. Sequential embryo transfer on day 3 and day 5 after performing PGS~4. Conventional Day 5 frozen embryo transfer"
215097438|NCT06446089|BEHAVIORAL|THP: cognitive behavior therapy and behavioral activation|The adapted THP takes into account cultural and linguistic characteristics of the participants. Participants will be invited to complete three modules on an Android based app on their mobile, populated with information and activities from the adapted THP.
215097439|NCT04504942|DRUG|Leronlimab|Drug: Leronlimab 525mg
215097440|NCT01272869|DEVICE|SenSura|The ostomy bag filter will be tested for a period of 14 days
215097441|NCT01272869|DEVICE|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
215097442|NCT00859937|DRUG|Dasatinib|Given PO
215097443|NCT00859937|OTHER|Laboratory Biomarker Analysis|Correlative studies
215097444|NCT03385278|OTHER|rTMS|20HZ Repetitive Transcranial Magnetic Stimulation
214403082|NCT05194007|DRUG|Placebo|Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
214403083|NCT02219594|DEVICE|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
214403084|NCT06162819|DRUG|Amitriptyline|Amitriptyline will be used for prophylaxis of migraine, also used as antidepressant
214403085|NCT06162819|DRUG|Flunarizine 5mg|Flunarizine will be used for prophylaxis of migraine,
214403086|NCT02192359|BIOLOGICAL|Carboxylesterase-expressing Allogeneic Neural Stem Cells|Given intracranially
214403087|NCT02192359|DRUG|Irinotecan|Given IV
214403088|NCT02192359|DRUG|Irinotecan Hydrochloride|Given IV
214693896|NCT05439460|DRUG|Phenylephrine|5 subjects will get Phenylephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
215008421|NCT03052036|OTHER|Optimal Medical Therapy|Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.
215008422|NCT00191750|DRUG|Pemetrexed|
215008423|NCT06432439|PROCEDURE|microneedling followed by CAF procedures|microneedling will be done on gingiva of RT1 recession tooth in 4 sessions followed by CAF 2months later for root coverage
215008424|NCT06432439|PROCEDURE|CAF procedure|RT1 gingival recession coverage by CAF procedures alone.
215008425|NCT00892255|DEVICE|Microwave Ablation|Tumor tissue from the liver is inter-operatively treated with the microwave ablation device to measure the destruction of tissue.
215097445|NCT01043588|PROCEDURE|TURP|TransUrethral Resection of the Prostate
215097446|NCT01043588|PROCEDURE|PVP|Photo selective Vaporization of the Prostate
215097447|NCT00773890|DRUG|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
215097448|NCT00773890|DRUG|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
215097449|NCT05242952|BEHAVIORAL|Gaming in a virtual environment|To address the primary outcomes of feasibility and acceptability of the VE, we will capture process data using a computer-based virtual environment and self-report measures using an online survey.
214403089|NCT02192359|OTHER|Laboratory Biomarker Analysis|Correlative studies
214403090|NCT02192359|OTHER|Pharmacological Study|Correlative studies
214403091|NCT06094140|DRUG|Durvalumab|"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."
214403092|NCT06094140|DRUG|Oxaliplatin|85mg/m2 intravenously on day 1
214403093|NCT06094140|DRUG|Irinotecan|150mg/m2 intravenously on day 1
215008426|NCT06188806|OTHER|ADDUKTOR CANAL BLOCK|All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.
215008427|NCT06188806|OTHER|CONTROL GROUP|No nerve block procedure is applied to patients.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia) tramadol 50 mg at 10 mg / hour basal rate after loading (20 mg bolus dose + 30 minutes lock time) and paracetamol 10 mg / kg iv (8 hours apart) will be given.
215008428|NCT01470807|DEVICE|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
215008429|NCT01246323|PROCEDURE|Spinal anesthesia with Fentanyl+ Morphine|Fentanyl 15 microgram Morphine 0.1-0.5 mg
215008430|NCT06527703|OTHER|no intervention|"Patients have to answer a questionnaire. The following data will be recorded:~Patient Number:~Informed Consent: ☐ yes ☐ no~Screening for eligibility Age \>/= 18 years: ☐ yes ☐ no Gender: ☐ M ☐ F Patient undergoing elective procedure: ☐ yes ☐ no~Time of arrival in the operating room \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~Procedure:~General surgery ☐ Orthopaedic surgery ☐ Neurosurgery ☐ Cardiac surgery ☐ Vascular ☐ Urology ☐ ENT/ dental/ maxillo-facial ☐ Obstetrics and Gynaecology surgery ☐ Ophthalmic surgery ☐ Non-operating room anaesthesia ☐ Endoscopy ☐ Other \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~Type of Anaesthesia (choose 1):~GA ☐ Sedation ☐ Regional ☐~Date and Time at which clear fluids were last consumed:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_"
215008431|NCT05935449|DEVICE|Formaderm Lidocaine|Dermal filler injection to facial areas
215008432|NCT05935449|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
215008433|NCT04873583|DRUG|Methylprednisolone|At the time of inclusion, intravenous Methylprednisolone for 3 days. Dose: 30 mg/kg/day (max. 1000 mg/dose)
215097450|NCT06186700|DRUG|Pentoxifylline 400mg plus chemotherapy|The patient will take 400 mg tablets of Pentoxifylline, 3 tablets per day, starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the cycles of neoadjuvant chemotherapy comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel, dose-dense paclitaxel or docetaxel.
215097451|NCT06186700|DRUG|Chemotherapy|The patient will take chemotherapy cycle comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous Cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel, dose-dense paclitaxel or docetaxel..
214403094|NCT06094140|DRUG|Calcium folinate (leucovorin)|50mg as an intravenous bolus
214403095|NCT06094140|DRUG|Fluorouracil|2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1
214403096|NCT06094140|DRUG|Pegylated G-CSF|6mg by subcutaneous injection to be given on day 3 of each cycle.
214693897|NCT05439460|DRUG|Epinephrine|5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
214403097|NCT00315224|BEHAVIORAL|heart-rate controlled 12 week exercise program|
214403098|NCT03157011|OTHER|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.
214403099|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
214403100|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
214403101|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
214403102|NCT04069910|OTHER|Quality-of-Life Assessment|Ancillary studies
214403103|NCT04069910|OTHER|Questionnaire Administration|Ancillary studies
214403104|NCT04069910|RADIATION|Stereotactic Radiosurgery|Undergo SRS/SRT
214403105|NCT04069910|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
214403106|NCT05256303|OTHER|Home Hospital care|Patients receive hospital-level care in their home
214403107|NCT05256303|OTHER|Traditional Hospital care|Patients receive hospital-level care in the hospital.
214693898|NCT05439460|DRUG|Arginine Vasopressin|5 subjects will get Arginine Vasopressin during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
214693899|NCT02066753|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature between 32-34°C.
214403108|NCT00114959|DRUG|Homoharringtonine|"Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m\^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles.~Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m\^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule."
214403109|NCT00114959|DRUG|Imatinib Mesylate|Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML. For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
214403110|NCT03251378|DRUG|Fruquintinib (HMPL-013)|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
214403111|NCT03572764|DRUG|CPX-351|-CPX-351 will be provided by Jazz Pharmaceuticals
214403112|NCT03572764|PROCEDURE|Research skin biopsy|"-And/or buccal swab~* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)"
214403113|NCT03572764|PROCEDURE|Research blood draw|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
214403114|NCT03572764|PROCEDURE|Research bone marrow aspirate|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
215008434|NCT04873583|DRUG|Prednisolone|"Intravenous treatment will be immediately followed by oral tapering with Prednisolone.~Oral Prednisolone, 2 weeks (week 1 and 2) Dose: 1 mg/kg/day (max 40 mg/day) Oral Prednisolone, 2 weeks (week 3 and 4) Dose: 0.5 mg/kg/day (max 20 mg/day)"
215008435|NCT04514458|OTHER|Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
215008436|NCT05721742|OTHER|virtually administered dietitian consults for IBS patients.|Participants will receive virtual one on one consults with a dietitian who has training in the dietary management of IBS.
214403115|NCT05051540|DEVICE|Sigvaris Compreflex Inelastic Compression Wrap|Compreflex compression system using wraps to apply compression of 30-40 mmHg.
215008437|NCT05721742|OTHER|IBS Group Online Session|IBS online group session run by Happy Bellies Nutrition
215008438|NCT05259033|DRUG|IcoSema|"IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month."
215008439|NCT05259033|DRUG|Semaglutide 1 mg|Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.
215008440|NCT06471569|BEHAVIORAL|Low/Mod|Aerobic exercise at 50% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial
215008441|NCT06471569|BEHAVIORAL|High/Mod|Aerobic exercise at 50% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial
215008442|NCT06471569|BEHAVIORAL|High/Vig|Aerobic exercise at 75% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial
215008443|NCT04210375|DRUG|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
215008444|NCT04210375|DRUG|Matching Placebo|Vehicle control
215008445|NCT03414866|BEHAVIORAL|EQ-5D-5L QOL questionnaire|Written questionnaire
215008446|NCT05502783|DRUG|fostamatinib|Participants will receive fostamatinib 100 mg BID for 4 weeks. On the 4-week evaluation, a) if cytopenia improves (hemoglobin =10 g/dL, platelets = 50 x 109/L), patients will continue the same dose for a total of 12 weeks, b) if refractory cytopenias persist (hemoglobin \< 10 g/dL, platelets \< 50 x 109/L), the dose will be increased to 150 mg BID. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response after week 5 can increase their dose to 150 mg BID until at end of the study on week 12.
215097452|NCT06362928|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
215008447|NCT05813977|DEVICE|tritube|The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
215008448|NCT00008424|DRUG|irinotecan hydrochloride|
215008449|NCT04199520|COMBINATION_PRODUCT|surgery combined with systemic therapy|surgery combined with systemic therapy
215008450|NCT04199520|OTHER|systemic therapy|systemic therapy
215008451|NCT01405911|DRUG|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
215008452|NCT01405911|DRUG|Placebo for Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
215008453|NCT01405911|DRUG|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
215008454|NCT01405911|DRUG|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
215008455|NCT01650376|DRUG|Olaparib|Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
214403116|NCT05765110|OTHER|Dopaminergic OFF drug state|Experiment will be performed without dopaminergic medication
214403117|NCT05765110|OTHER|DBS OFF state|Turning off the stimulation during experiment
215008456|NCT01650376|DRUG|Carboplatin|AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
214403118|NCT05765110|OTHER|Dopaminergic ON drug state|Experiment will be performed with dopaminergic medication
214403119|NCT05765110|OTHER|DBS ON state|Experiment will be performed with stimulation (ON condition)
214403120|NCT00081029|PROCEDURE|management of therapy complications|
214403121|NCT00081029|RADIATION|radiation therapy|
214403122|NCT06851156|DEVICE|tTIS|CM-pf tTIS
214403123|NCT04289987|BIOLOGICAL|CVI-HBV-002|Investigational Product
214403124|NCT04289987|BIOLOGICAL|Normal Saline(placebo)|Investigational Product
214403125|NCT04996069|DEVICE|Crest Whitening Emulsions|Subjects with Xerostomia will be asked to apply the study intervention product to their teeth up to 4 times per day for 1 week to investigate if the study intervention product increases saliva production in this dry mouth populaiton.
214403126|NCT06160921|OTHER|Standard therapy|Individualized blood pressure reduction program
214403127|NCT05115656|BEHAVIORAL|Online group 1|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
214403128|NCT05115656|BEHAVIORAL|Online group 2|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
214403129|NCT05355597|DRUG|Exparel Injectable Product|Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
214403130|NCT05355597|DRUG|Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)|Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
214403131|NCT04060680|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
214403132|NCT06662448|DEVICE|SAVIR Alpha Synch mobile (SASm)|The SAVIR Alpha Synch mobile is a device first used in office and then intended to be used for the home therapy of the visual system with non-invasive electrical stimulation.
214403133|NCT00935792|DRUG|alemtuzumab|Given subcutaneously
214403134|NCT00935792|DRUG|everolimus|Given orally
214403135|NCT02719197|DRUG|AC-083|Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
215008457|NCT01650376|DRUG|Paclitaxel|60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
214403136|NCT02719197|DRUG|Placebo|Placebo capsules matching AC-083 capsules
214403137|NCT03931005|OTHER|Collaboration Decision Support Guide|Electronic toolkit intended to help organizational leaders select partners and negotiate partnerships for implementation. This will contain: 1) a brief summary of collaboration approaches associated with implementation, 2) detailed descriptions of collaboration strategies, 3) a decision analysis tool that guides the selection of collaborative strategies given the community context, and 4) sample contract or agreement language that specifies the nature of the partnership and expectations.
214403138|NCT06306430|DEVICE|STANDARDTM F TB LAM FIA|STANDARDTM F TB LAM Ag FIA is a fluorescent immunoassay for the qualitative detection of specific antigen from mycobacterial lipoarabinomannan (LAM) in urine specimen. STANDARDTM F TB LAM Ag FIA should be used with the STANDARD F Analyzers manufactured by SD BIOSENSOR.
214403139|NCT04739423|DRUG|clenbuterol (CST-103), nadolol (CST-107), matching placebo|clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules
214403140|NCT02006303|PROCEDURE|Green light PVP|The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
214403141|NCT02006303|PROCEDURE|Prostatic artery embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
214403142|NCT01691443|PROCEDURE|pressure sensor and wrist shaker, not marked CE, developped by Texisense|
214403143|NCT02556723|DRUG|Intravitreal injections of ziv-aflibercept|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
215008458|NCT02779296|OTHER|2-Octyl Cyanoacrylate Glue|topical
215008459|NCT05410067|OTHER|Cervicothoracic Junction Mobilization Technique|It is a part of manual therapy technique. Patient would be in prone position with his forehead in the palm of the therapist. Maitland mobilization to the C7- T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions unilateral PA glide) is given. For central PA glide, a central pressure angled towards the participant's head was given with overlapping thumbs of the therapist placed on the spinous process of C7. The therapist's thumbs were placed on the posterior surface of the articular process to be mobilized (C7 on the side of restriction), and anteriorly directed oscillatory pressure was applied for unilateral PA mobilization.
214403144|NCT00866710|OTHER|Exercise-based behavioral therapy|Participants will be taught pelvic floor muscle exercises as well as urge suppression strategies to overcome the urge to void. In the first 20 participants, computer-assisted biofeedback will also be utilized to help participants identify the pelvic floor muscles and contract and relax these muscles while keeping the abdominal muscles relaxed
214403145|NCT04770818|DEVICE|Modified Brostrum procedure with Internal Brace Augmentation|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability with InternalBrace augmentation.
215097453|NCT04802720|OTHER|Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)|"The sessions are outlined as follow:~1. psychoeducation, goal-setting, and describing the rationale for CBT (Session 1);~2. coping effectiveness training (Session 2);~3. identifying unhelpful cognitions and dysfunctional beliefs (Session 3);~4. challenging and restructuring unhelpful cognitions (Session 4);~5. behavioral activation within the limitations of the caregiving context (Session 5);~6. problem-solving (Session 6);~7. communication strategies and assertiveness training (Session 7);~8. consolidating gains, maintenance, and relapse prevention (Session 8)."
215097454|NCT04802720|OTHER|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|"The sessions are outlined as follow:~1. psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);~2. attention regulation skills training (Sessions 1-2);~3. training in metacognitive skills (Sessions 3-4);~4. exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);~5. consolidating gains, taking larger proactive steps, and relapse prevention (Session 8)."
215097455|NCT05240001|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
215008460|NCT05410067|OTHER|Eccentric Muscle Energy Technique|Eccentric muscle energy technique would be applied to the patient's cervical spine. The cervical spine would be brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then patient would be asked to push their heads into the direction opposite that of the barrier.
215008461|NCT05401851|DEVICE|Left Bundel Area Pacing|RV Lead will be placed deep in the interventricular septum
215008462|NCT00093028|DRUG|CC-5013 (Revlimid™)|N/A Study Complete
214403146|NCT04770818|DEVICE|Modified Brostrum procedure|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability
214403147|NCT04130906|DEVICE|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
214403148|NCT04130906|DEVICE|Sham Intermittent Theta Burst Stimulation|Sham stimulation will be delivered left dorsolateral prefrontal cortex (DLPFC) using the same parameters as real iTBS however, a sham coil will be used. The sham coil makes the same noise and creates a similar sensation on the scalp as the real coil but does not produce a magnetic field.
215008463|NCT00093028|DRUG|bortezomib|N/A Study Complete
215008464|NCT00864981|DRUG|Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.|
215008465|NCT00864981|DRUG|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|
215008466|NCT01182363|BEHAVIORAL|Project Solve Education|Problem solving education (PSE), a brief skills-building psychotherapeutic intervention that focuses on specific daily problems, and applies to these problems a structured approach to finding and evaluating solutions, is one such problem solving approach. Problem solving education differs from other problem solving interventions in that it can be conducted by a variety of health providers, who do not have specific training as mental health clinicians. Sessions are fairly brief (approximately 30 minutes in length) and positive, sustained effects have been achieved in 6-8 sessions. Problem solving education's success is based on premise that strong problem solving abilities promote a sense of control and self-efficacy and buffer the negative effects of life stressors.
215008467|NCT01843231|DEVICE|g-CathTM EZ Suture Anchor Delivery Catheter|Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
215008468|NCT01843231|OTHER|Diet and Exercise Control Group|Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
215008469|NCT05307107|BEHAVIORAL|SHINE|Intervention group will use a 8-workweeks the digital Smart Break SHINE program with workplace support (encouragement and time-support) including daily 3 minutes break exercises twice a day; 1) physical exercise - break and 2) body/mind breathing exercise - break earning stars for exercise completed. The program includes weekly self-reflective task of individual well-being during working hours with weekly changing theme (avoiding sitting time, nature benefits, relaxation exercises, increasing physical activity in workplace etc.) earning diamonds for every weekly task completed. Participants self-monitors their weekly individual resources levels asked in every Thursday (1-5, 1= very poor. 5= very good). Program includes e-mail remainders set by participant themselves for suitable time frame These individual well-being actions takes approximately 15 minutes/workday. Control group will receive this program after this study (waitlist protocol).
214403149|NCT01007552|DRUG|Gemcitabine, Capecitabine and Bevacizumab|Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
214403150|NCT00102193|DEVICE|Adacolumn Apheresis System|
215008470|NCT02479282|PROCEDURE|natural cesarean section|
215008471|NCT02479282|PROCEDURE|traditional cesarean section|
215008472|NCT03179267|DEVICE|SNAP40|SNAP40 ambulatory monitoring device
215008473|NCT02319382|RADIATION|PET with the tracer 18F-DPA-714|
215008474|NCT02319382|RADIATION|PET with the tracer 11C-PE2I|
215008475|NCT02319382|OTHER|MRI|Magnetic field
215008476|NCT04387968|DIAGNOSTIC_TEST|Covid-19 presto test|Use an auto-test in 15 minutes get the results about covid-19 anticorps
215008477|NCT02967575|DEVICE|cTDR|"The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:~* Implantation through a standard anterior cervical approach~* Midline identification~* Routine discectomy with endplate preparation and decompression~* Implant sizing and trial implantation~* Keel preparation~* Implant preparation and loading of the appropriate Triadyme-C implant~* Triadyme-C insertion, positioned as close to the midline as possible"
215008478|NCT04516876|OTHER|Camp-based bimanual intensive training(BIT)|The day-camp BIT model will be delivered in a group-based design. In day-camp model, each child is assigned to a trained therapist to maintain at least a 1:1 to 1:2 ratios of therapy and child. The therapist will monitor and modify the activities to fit each individual's ability and need to make sure the intervention quality is equivalence to the individualized treatment method. The chosen tasks of each intervention session have to be considering the child's preference, age-appropriated, and at the right level of difficulty. Target movements are embedded in the functional activities, whereby the environment is manipulated to vary task requirement and the difficulty is graded to match the child's capacity.
214403151|NCT01448174|DRUG|Atorvastatin|"Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:~* atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or~* placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks."
214403152|NCT00236028|DRUG|Infliximab|
214403153|NCT05781490|DRUG|Lumentin® 44 Powder for oral foam|Lumentin® 44 is a foam for oral use.
214403154|NCT01521143|BIOLOGICAL|Cvac|Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.
214403155|NCT01521143|BIOLOGICAL|Placebo|"Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.~Placebo consisted of the Cvac formulation buffer (5% HSA, 10% DMSO) with 0.9% simethicone provided in 1 mL vials that had been cryopreserved and stored at the manufacturing facility."
215008479|NCT02430233|DRUG|micronized progesterone 400 mg (Utrogestan)|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
215008480|NCT03343028|OTHER|Psychotherapy|
215008481|NCT01660542|DRUG|Neoadjuvant Chemotherapy with Docetaxel|Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -\> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
215008482|NCT06520280|OTHER|polyamide and 3D printed complete denture|pts. receive 2 sets of complete dentures made from polyamide and 3d printed to use
215008483|NCT00238290|DRUG|Trastuzumab + Letrozole|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
215008484|NCT04092764|DEVICE|Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks. The acupoints will be stimulated by the electroacupuncture machine with alternating frequencies in order to induce endorphins at different points in the nervous system. Frequencies between 2 Hz and 100 Hz will be utilized. Sterile single-use needles will be placed at Ba Feng, four points on the dorsum of each foot between the digits. KI2 (Rang Gu), a point located at the soles of the feet and SP-4 (Gongsun) will also be needled per recommendation of our acupuncturist. A total of 12 needles will be used per participant.
215008485|NCT04092764|DEVICE|NeuroMetrix|The NeuroMetrix is a point-of-care conduction device that will be used to measure peripheral neuropathy
215008486|NCT04092764|DEVICE|Rydel-Seiffer tuning fork|The level of periphal neuropathy will be measured by vibration detection using a Rydel-Seiffer graduated tuning fork placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated weights at the ends, and as the amplitude decreases, the intersection of the triangles moves upward on the weight. This test will be performed three times and a mean of the scores calculated. Vibration sensation is lost sooner in CIPN, which means that lower scores are associated with increased CIPN
215008487|NCT01935804|DRUG|Pioglitazone|30 mg/daily for 12 months
215008488|NCT01935804|DRUG|Metformin|850 mg/daily for 12 months
215008489|NCT00189670|PROCEDURE|6 TEC q 3 weeks|
214403156|NCT01593735|DRUG|MK-2748|MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
215008490|NCT00189670|PROCEDURE|4 EC q 2 weeks followed by 4 TXT q 2 weeks|
215008491|NCT00189670|PROCEDURE|4 TXT q 2 weeks followed by 4 EC q 2 weeks|
215008492|NCT02213575|DRUG|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and 26 week follow-up MRI and PET scans for changes in the paraventricular nucleus.
215008493|NCT06214390|PROCEDURE|Single strategy|In the single strategy, RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use
215097456|NCT05240001|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
214403157|NCT01593735|DRUG|Placebo|Placebo tablets, orally, once daily for 7 days
214403158|NCT00649129|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
214403159|NCT00649129|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
215097457|NCT00558298|DRUG|risperidone|
215097458|NCT02911142|DRUG|Lenalidomide|Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.
214688243|NCT07163975|PROCEDURE|Root canal treatment|"RCT will be performed in single visit. Root canal orifices will be explored using a DG 16 probe. A size 10 or 15 K-file will be passively inserted into the coronal two- thirds of the canal to verify a smooth glide path.~Coronal enlargement will be done using Gates-Glidden drills. Working length will be determined with the help of electronic apex locator and will be confirmed radiographically. Canals will be prepared using the crown down technique with NiTi rotary instruments. The master apical file (MAF) size for each canal will be selected to be three sizes larger than the initial apical binding file at the WL. 5ml of 5.25% sodium hypochlorite using a 30-gauge side-vented needle will be used for optimal irrigation after each instrument.~After completion of canal instrumentation, the canals will be irrigated with 5.0 ml of 17% ethylene-diamine-tetra acetic acid for 1 minute followed by a final irrigation with 5.0 ml of 5.25% sodium hypochlorite. Canals will be dried with"
214688244|NCT07161791|DRUG|Camrelizumab Combined With Pirfenidone and Chemotherapy|"Treatment Regimen:~Camrelizumab: 200 mg intravenous (IV) every 3 weeks (q3w). Pirfenidone: 200 mg three times daily (tid), escalated to 600 mg tid based on tolerability.~Chemotherapy: Investigator's choice of standard regimens (e.g., paclitaxel 175 mg/m² IV q3w or capecitabine 1000 mg/m² orally bid on days 1-14 of a 21-day cycle)."
215008494|NCT06214390|PROCEDURE|Combined strategy|In the combined strategy, when urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine \> 5.2mmol/day \[5\] and 3) urinary urea \> 1.35mmol/kg/day (using the patient's body weight at ICU admission) \[6\], RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume.
215008495|NCT03603704|DRUG|LY3209590|Administered SC
215008496|NCT03603704|DRUG|Placebo|Administered SC
215008497|NCT05984459|DIETARY_SUPPLEMENT|VLCKD|The analysis will focus on the observation of the evolution of anthropometric and clinical parameters,such as the improvement or normalization of HbA1c, as well as on the evolution of the hypoglycemic medication between patients who accept VLCKD method
215008498|NCT06071988|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
215008499|NCT06071988|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
215008500|NCT02679105|DRUG|ALK Alutard birch or 5-grasses|3 injections with 4-5 weeks interval.
215008501|NCT02679105|DRUG|ALK diluent|0,3% human albumin
215008502|NCT03731143|PROCEDURE|insertion of self retaining bicanalicular stent|"The pigtail probe was passed through the canalicular system from the normal punctum to the occluded aspect. When the tip of the pigtail probe was positioned near the occluded punctal area, the surgeon pushed the area to be tented with the pigtail probe. After they advanced the pigtail probe back and forth several times until they could locate the correct position of the occluded punctum, the authors incised the tented area with a scalpel No. 11 to make a new punctal opening.~To ensure punctal and canalicular patency, syringing was repeated through the perforated punctum. To prevent re-occlusion of punctal opening, a self retaining bicanalicular tube (FCI®; Paris, France) was inserted through the normal and perforated puncti"
215008503|NCT06098547|PROCEDURE|Liver transplantation|"Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver).~Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis."
215008504|NCT03868371|DIETARY_SUPPLEMENT|High phosphorous containing meal|A meal with a high phosphorous content
215008505|NCT03868371|DIETARY_SUPPLEMENT|Low phosphorous containing meal|A meal with a low phosphorous content
215008506|NCT03514797|DRUG|Bleaching Agents|In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.
215008507|NCT03514797|DRUG|Bleaching Agents|At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
215008508|NCT00589264|DIETARY_SUPPLEMENT|zinc|10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
215008509|NCT00589264|DIETARY_SUPPLEMENT|iron + copper|10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
215008510|NCT03569462|BEHAVIORAL|"Mobile WeChat intervention"|Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
215008511|NCT03569462|BEHAVIORAL|Control condition|Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
215008512|NCT03033628|DEVICE|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
215008513|NCT03033628|DEVICE|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
215008514|NCT01980888|DRUG|Idelalisib|150 mg tablet administered orally twice daily
215008515|NCT01980888|DRUG|Bendamustine|Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
215008516|NCT01980888|DRUG|Rituximab|Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
215008517|NCT01980888|DRUG|Placebo|Placebo to match idelalisib administered orally twice daily
215008518|NCT02761538|BEHAVIORAL|AVIITAM|"The purpose of the project is to test the medico economic impact related to the utilization of the Aviitam online platform in primary care.~.~."
215008519|NCT02193152|DRUG|Pazopanib|
215008520|NCT03990753|DIAGNOSTIC_TEST|esophagogastroduodenoscopy|standard esophagogastroduodenoscopy
215008521|NCT02990962|DRUG|5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
215008522|NCT02990962|DRUG|1cc 2% Xylocaine+4cc Triamcinolone (40mg)|Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
215008523|NCT00665639|DRUG|micafungin|IV
215008524|NCT00665639|DRUG|caspofungin|IV
215008525|NCT04569370|PROCEDURE|Laparoscopic Cholecystectomy|Surgical removal of Gall bladder using laparoscopy
214403160|NCT02517333|OTHER|EPIC Club|Weekly exercise gym sessions (1-2 times weekly) for 45-60 mins each session. Participants will start with a warm-up of 30 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. Gym sessions aim to involve bursts of high-intensity and monitoring of heart rate (potentially with wrist activity monitors with heart rate monitoring and accelerometers) to identify level of physical activity intensity. Participants will also have the opportunity to engage in 'Have a go' sports days run by the Oxfordshire Sports Partnership.
214688245|NCT07161726|COMBINATION_PRODUCT|(-)-Epicatechin-rich cocoa supplementation combined with exercise training|12 weeks of daily cocoa (2 capsules/d containing 450 mg cocoa flavanols/d, including 80 mg of (-)-epicatechin) combined with aerobic (30min of moderate-intensity walking) and resistance (30 min of whole-body workout) exercise training 3 times a week
214403162|NCT05459818|DEVICE|Viabahn implanted|An individual patient data analysis obtained from databases used in prospective studies that published results of patients treated with the latest generation heparin-bonded Viabahn in the femoropopliteal artery.
214403163|NCT00324714|DRUG|risedronate sodium|
214403164|NCT00324714|OTHER|diagnostic laboratory biomarker analysis|
214403165|NCT06663579|OTHER|Fathers who practicing kangaroo care|The study group (n=28) It consists of fathers of babies practicing Kangaroo Care with both their mothers and fathers in the neonatal intensive care unit.
214403166|NCT05230550|DRUG|Somapacitan|Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
214403167|NCT06613659|DRUG|traditional Chinese medicine (TCM)|Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
214403168|NCT06613659|DRUG|non traditional Chinese medicine (non-TCM)|Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
214403169|NCT00901485|DEVICE|AutoVPAP|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.
214403170|NCT00901485|DEVICE|VPAPIIIST-A|Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.
214403171|NCT06918262|DIAGNOSTIC_TEST|local treatment|Tumour somatic mutations were identified by 1021 panel sequencing of tumour tissues from cancer patients, and up to 20 mutations were selected as follow-up monitoring loci based on the tumour somatic variants of the patients, and a personalised panel was designed and customised.Post-operative blood from patients was analysed for recurrence risk stratification and drug indications using a combination of personalised panel and a cancer-specific core panel (\~5 kb) stacked on top of each other. The postoperative blood of patients was subjected to cfDNA targeted capture and ultra-high depth NGS sequencing (\&gt;100,000×) to analyse the status of the surveillance loci in the peripheral blood for recurrence risk stratification and medication advice.
215008526|NCT03878459|DRUG|Pioglitazone 45 mg|patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
215008527|NCT03878459|DRUG|Placebo|PATIENTS WILL RECEIVE PLACEBO
215097459|NCT02911142|DRUG|Rituximab|During cycle 1, rituximab will be administered on day 4 prior to the start of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH). During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.
214403172|NCT06691971|DEVICE|AeviceMD|The AeviceMD device will be placed on the patient to detect the presence of wheeze and perform auscultation.
214403173|NCT06696196|DEVICE|smart watches(wearable devices)|Participants will be asked to wear two smart watches simultaneously. The first smart watch is a dedicated prototype for validating algorithm developed by MediaTek. The second smart watch is Basis Peak. These watches are going to acquire PPG, body movements, skin temperature, and skin conductance.
214403174|NCT06744439|DRUG|BR1015|One tablet administered alone
214403175|NCT06744439|DRUG|BR1015-2|One tablet administered alone
214688246|NCT07161726|COMBINATION_PRODUCT|Placebo combined with exercise training|12 weeks of placebo (alike-looking cellulose-based capsules) combined with aerobic (30min of moderate-intensity walking) and resistance (30 min of whole-body workout) exercise training 3 times a week
215008528|NCT01550185|DRUG|eltrombopag olamine|Given PO
215008529|NCT01550185|PROCEDURE|standard follow-up care|Receive standard care
215008530|NCT01003626|PROCEDURE|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
215008531|NCT01003626|DEVICE|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
215008532|NCT03537677|BEHAVIORAL|Reduction in Sedentary Behavior|This 12-week intervention targets a reduction in prolonged sitting and includes provision of a wrist-worn activity prompter and in-person group sessions with behavioral counseling.
215097460|NCT02911142|DRUG|Prednisone|During cycle 1, Prednisone 60 mg/m\^2 /day by mouth (PO) days 6 to 10. During cycles 2-6, Prednisone 60 mg/m\^2 /day PO days 1-5.
214403176|NCT06744439|DRUG|BR1015-3|One tablet administered alone
214403177|NCT06748911|DEVICE|NaviCam Detachable String Capsule|Subjects will swallow the NaviCam capsule with 20 ml water while positioned in the upright position. Once the capsule reaches the gastric cardia, the string will slowly be pulled up to systematically inspect the Z-line and upper, middle, and lower thirds of the esophagus guided by real-time viewing and by moving the capsule solely with the tether. Images will be captured at a rate of 2 frames per second.
214403178|NCT06919822|DEVICE|Personalized SCAN Electrical Stimulation|"* Stage 1: iTBS Intervention (14 days) and Washout Period (3-6 months)~  * All enrolled participants undergo:~    * Baseline clinical assessments~   * Structural and functional MRI with pBFS mapping~   * Resting motor threshold determination~ * Daily iTBS sessions targeting individualized SCAN coordinates:~    * Treatment duration: 14 consecutive days~   * Post-intervention evaluation at Day 14-21~ * Mandatory observation window:~    * No neuromodulation therapies permitted~   * Stable PD medication regimen maintained~   * Monthly safety monitoring~* Stage 2: Surgical Intervention and Follow-up (12 months)~  * Surgical Procedure:~    * Epidural electrode implantation~   * 7-day externalized stimulation testing~   * Pulse generator internalization~ * Chronic Stimulation Stage:~    * Parameter optimization visits~   * Scheduled follow-ups at Months 1, 3, 6, 9, 12"
214688247|NCT07162298|OTHER|Dragon Boat Training|"The total training duration is 12 weeks, divided into cycles of 4 weeks each, with distinct training contents and goals for every cycle. Training sessions are held 3 times a week, and all participants train together on the same day. Each training session lasts approximately 60 minutes.~In the first 4 weeks, participants spend half an hour training on land and the subsequent half an hour training on dragon boats.~Then, from week 4 to week 8, they train for 20 minutes on land and 40 minutes on dragon boats.~Finally, from week 8 to week 12, they only conduct 10-15 minutes of land training (as warm-up) followed by nearly an hour of on-boat training.~This progressive training plan is designed to ensure that each participant can tolerate the training intensity as much as possible, preventing injuries caused by training."
214693900|NCT05277688|DRUG|adjuvant concurrent chemoradiotherapy|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
215008533|NCT06470724|BEHAVIORAL|Structural visual approach|"The intervention comprised seven behavior approaches in this research defined as follows:~A successive approach: An approach to familiarization with the unfamiliar environment of the simulated dental office.~Tell-Feel-Show-Do (T-F-S-D): A dental approach explained to the patient's treatment by telling the patient what would happen, what he felt or did, and what had been done.~Visual pedagogy: Introduced dentistry to autistic children through visual media, such as pictures and photographs.~Audiovisual modeling: A learning process through audiovisual media, such as video and animation.~In-vivo modeling: Learning new activities by watching them in front of the model.~Behavioral trials: A learning strategy conducted through practicing the recent activity by him/herself.~Auto-modeling: A learning process following the activity of editing pictures during the prior visit of the patient."
215008534|NCT00222274|BEHAVIORAL|RSA Biofeedback|RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J\&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
214403179|NCT06918587|DEVICE|TPI-120 with On body injector|6mg Subcutaneous injection
214403180|NCT06918587|DRUG|Fylntera|6mg subcutaneous
215008535|NCT00222274|BEHAVIORAL|EEG Biofeedback Condition|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J\&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
215008536|NCT05571488|OTHER|Electronic surveys|Online questionnaires will be used to collect data, at recruitment and follow-up once a year
215008537|NCT05571488|OTHER|Qualitative Interviews|Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
215008538|NCT02469909|OTHER|Overnight observation|patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.
215008539|NCT02469909|OTHER|Pre-discharge evaluation|After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
215008540|NCT02469909|OTHER|outpatient clinic follow ups|all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation
215008541|NCT02469909|PROCEDURE|immediate decannulation|the tracheostomy tube is removed at once
215008542|NCT02469909|PROCEDURE|Gradual tracheostomy tube decrease|The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
215008543|NCT06596486|OTHER|CoolStick|Assessment of block using CoolStick.
215008544|NCT06596486|OTHER|Ethyl Chloride|Assessment of block using ethyl chloride spray
215008545|NCT06596486|OTHER|Question|Participant will be asked if they felt pain or not.
215008546|NCT01801605|PROCEDURE|rTMS|Active session with stimulation and placebo session with fictive stimulation
215008547|NCT06985875|DEVICE|Multidose mosturizing solution DROP 0.4%|Ophthalmic mosturizing solution to be administered 1-4 times per day in both eyes
215008548|NCT06985875|DEVICE|Multidose mosturizing solution Avizor Eye Drops 0.2% Preserved|Ophthalmic mosturizing solution to be administered 1-4 times per day in both eyes
214403181|NCT02861495|DEVICE|Humeral Compression/Distraction (CD) Nail|Surgical fixation of humeral shaft fractures with Humeral Compression/Distraction (CD) Nail implant
214403182|NCT04722224|OTHER|Home-based pulmonary rehabilitation|The reabilitAR program includes the self-management educational program Living Well with COPD. The exercise training will include endurance, resistance/strength, flexibility and balance training.
215008549|NCT06990854|DEVICE|Electroacupuncture (Hans-100A, Nanjing Jisheng Medical Technology, China)|"Acupoint prescription: The therapeutic protocol utilized Ashi points (localized to herpetic lesion areas) and Jiaji points (EX-B2, ipsilateral to affected dermatomes).~Acupuncture procedure: For Ashi points, sterile disposable needles (0.25 mm diameter, 40 mm length) were inserted at a 15° angle to a depth of 15-20 mm, without deqi sensation or manual manipulation. For Jiaji points (EX-B2), needles (0.30 mm diameter, 50 mm length) were inserted perpendicularly to a depth of 40-45 mm, with twisting manipulation (90° rotation at 90 cycles/min) until patients felt soreness, numbness, or distension. Electroacupuncture was applied using the Hans-100A device, with dense-disperse wave mode (2/100 Hz) and intensity adjusted to patient tolerance, for 30 minutes."
215008550|NCT06990854|DRUG|Pharmacotherapy：① Pregabalin ( Lyrica™ ，Pfizer Inc. America) ② Methylcobalamin ( Mecobalamin tablets， Weicai (China) Pharmaceutical Co., Ltd， China）|Patients received protocol-guided therapy consisting of: ① Pregabalin: Initial dose 75 mg twice daily. Dose may be titrated upward to 150 mg twice daily within one week based on therapeutic response and tolerability. Gradual discontinuation is recommended when clinically appropriate, tapered by 100 mg decrements every 3-7 days. ② Methylcobalamin: 5 mg three times daily.
215008551|NCT06990854|PROCEDURE|Streitberger Placebo Needle Set ( Asiamed )|The Streitberger needle, a widely reported placebo needle device in acupuncture RCTs, was applied for sham intervention. This telescoping blunt-tip needle achieves non-penetrating placebo stimulation through its retractable design. Its key advantage lies in evoking a skin-penetrating sensation akin to true needling through tissue compression, while avoiding actual dermal perforation to minimize specific therapeutic effects. Following the perception of needle insertion reported by patients, the device is retracted by approximately 1 mm and connected to electroacupuncture apparatus without electrical stimulation activation.
215008552|NCT05909904|DRUG|Tislelizumab|Administered intravenously
215008553|NCT05909904|DRUG|BGB-A425|Administered intravenously
215008554|NCT05909904|DRUG|LBL-007|Administered intravenously
215008555|NCT02429440|BIOLOGICAL|peptide vaccine|subcutaneous
215008556|NCT02429440|DRUG|Granulocyte Macrophage Colony Stimulating Factor|intradermal
215008557|NCT02429440|DRUG|Montanide ISA-51|subcutaneous
215008558|NCT06989099|PROCEDURE|Immediate Lymphatic Reconstruction (ILR)/|Given by Procedure
215008559|NCT06989099|PROCEDURE|Prophylactic Lymphovenous Bypass (pLVB)|Given by Procedure
215008560|NCT00995878|PROCEDURE|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
215008561|NCT00995878|PROCEDURE|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
215008562|NCT04978779|DRUG|VIP152|Weekly IV infusion for 28 day cycles.
215008563|NCT04978779|DRUG|BTKi|Taken per local prescribing information
215008564|NCT03691532|BEHAVIORAL|Seated control (CON)|Seated rest
214403183|NCT03511989|DEVICE|Bone borne distractor|Bone borne distraction device
214403184|NCT03511989|DEVICE|Tooth borne distractor|Tooth borne distraction device
215008565|NCT03691532|BEHAVIORAL|Arm cycle exercise (ACE)|Arm cycling at a continuous power output
215008566|NCT03691532|BEHAVIORAL|Liquid meal|Liquid meal of 0.5 L volume containing 20 kcal/kg fat free mass (FFM) and 5 mg/kg FFM of uniformly 13-carbon labeled palmitate (\[U-13C\]palmitate) at a macronutrient distribution of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
215008567|NCT05339438|RADIATION|functional MRI|Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)
215008568|NCT03928431|OTHER|Maternal microbiota|See arm descriptions
215008569|NCT06676722|DRUG|SBRT combined with Nimotuzumab followed by Tislelizumab|BRT combined with 3 cycles of Nimotuzumab 400mg qw followed by maintain Tislelizumab for 2 years or until disease progression
215008570|NCT07000955|DRUG|Tirzepatide|Tirzepatide administered subcutaneously (SC) once a week.
215008571|NCT07000955|DRUG|Placebo|Placebo administered subcutaneously (SC) once a week.
215008572|NCT07000955|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
215008573|NCT05762744|DRUG|Exenatide Injection (before the first FSIGT)|"Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting the first frequently sampled intravenous glucose tolerance test.~In this crossover study, participants will also be crossed over to receive saline rather than exenatide: Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test."
215008574|NCT05762744|DRUG|Exenatide injection before the second FSIGT)|Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting the second frequently sampled intravenous glucose tolerance test.
215008575|NCT00789165|DRUG|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
215008576|NCT00789165|DRUG|no therapy|No therapy; this is not a placebo-controlled trial
215008577|NCT04817072|OTHER|Blood sample|Blood sample (20mL) for pro-inflammatory cytokines assay
215097461|NCT02911142|DRUG|Etoposide|During cycle 1, Etoposide 50 mg/m\^2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m\^2/day continuous intravenous infusion days 1 to 4.
214403185|NCT03511989|PROCEDURE|Segmental LF1 Osteotomy group 1|
214403186|NCT03511989|PROCEDURE|Segmental LF1 Osteotomy group 2|
214403187|NCT03511989|PROCEDURE|Segmental LF1 Osteotomy group 3|
214403188|NCT06360601|DRUG|Labetalol Injection|Labetalol intravenous infusion 20ml/hr
214403189|NCT06360601|DRUG|HydrALAZINE Injection|Hydralazine intravenous infusion 5mg/hr
214403190|NCT02993029|DRUG|99Tc-MDP|99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
214403191|NCT02993029|DRUG|Celecoxib|Celecoxib capsule 200mg qd by mouth.
214403192|NCT06120751|BIOLOGICAL|TTVA|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
214403193|NCT06120751|BIOLOGICAL|TT|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
214403194|NCT03177564|PROCEDURE|Protective ventilation 1|Low tidal volume, high inspired oygen fraction (FiO2) and recruitment maneuver.
214403195|NCT03177564|PROCEDURE|Protective ventilation 2|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
215008578|NCT07011368|BEHAVIORAL|Intervention Group|"Healthy Lifestyle Recommender Solution (HLRS) will be developed as intervention tool for the trials. It integrates tools (mostly digital): a meal recommender to propose balanced and individually adapted meal plans, physical activity and sleep pattern measures and recommendations, assessment of behavioural/psychological aspects, and motivational features for sustained engagement and adherence.~Within our multi-disciplinary portfolio approach, a set of predominantly eHealth solutions applied during the intervention trials for overweight/obesity prevention, developed in a participatory design approach with relevant stakeholders. This will include the HLRS, thus combining motivational features (nudging, gamification), targeted psychological support, dietary and physical activity advice, though also additional recommendations (healthy eating guidelines...) or education materials will be provided.~Intervention trials/studies."
215008579|NCT02988609|DEVICE|fMRI|fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
215008580|NCT07028710|DRUG|hCG|Subcutaneous injection of 250 µg of recombinant hCG (Ovitrelle®)
215008581|NCT01560416|DRUG|Fulvestrant|
215008582|NCT01560416|DRUG|Ganetespib|
215008583|NCT07040150|DEVICE|Spinal bracing|The semi-rigid spinal brace was developed to enhance patient compliance while maintaining effective curve correction. Patients were instructed to wear the brace for 18-20 h daily.
214688248|NCT07162298|OTHER|Home-based Unsupervised Training|"The total training duration is 12 weeks. After a 15-minute warm-up (including walking, exercises, etc.), participants will perform the following 10 movements in sequence: squats, rowing simulation with rubber bands, lateral raises, sit-ups, shoulder presses, alternating bilateral lunges, dumbbell curls (for biceps), sit-ups, and planks.~Each movement lasts 60 seconds, with a 10-second rest allowed midway through the same movement (i.e., 15 seconds of exercise followed by a 10-second rest, then another 15 seconds to complete the movement). A 20-second rest is permitted before moving on to the next movement.~Once participants can complete 30 seconds of the same movement without needing rest or adjustment, the training intensity will be increased-progressing from one round of training (10 minutes) to two rounds (20 minutes) or even three rounds (30 minutes)."
214688249|NCT07162649|DRUG|Dexmedetomidine|30μl
215008584|NCT06724198|DIETARY_SUPPLEMENT|Psyllium husk|3.66 gram Psyllium husk twice daily for 8 weeks
215008585|NCT07044973|PROCEDURE|Transcranial focused ultrasound thalamotomy|Thalamotomy Using Exblate
214403196|NCT03177564|PROCEDURE|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 3 to 10 cmH2O during one-lung ventilation and a FiO2 of 60%
214403197|NCT03049982|DEVICE|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
214403198|NCT06028841|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
214403199|NCT00823589|OTHER|Blood test and clinical test|Blood test and clinical test
214403200|NCT02794116|PROCEDURE|Conventional Sealants|It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
214688250|NCT07162649|DRUG|Placebo|30μl
214688251|NCT07162311|DEVICE|tDCS|Home-Based Transcranial Direct Current Stimulation
214688252|NCT07162480|DRUG|P-Sam|Given by IV
214693901|NCT05277688|RADIATION|radiotherapy|Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
215008586|NCT07044999|OTHER|no intervention|no intervention
215008587|NCT07046013|DIAGNOSTIC_TEST|Lactate dehydrogenase|It's elevation at the time of diagnosis
215008588|NCT07044713|OTHER|Hand Puppet|Children who come to the hospital's blood collection unit and meet the research criteria will be randomly assigned to the hand puppet group. The scales will be filled out by the nurse and the child five minutes before the blood collection. The researcher will benefit from the experiences of the child development specialist and preschool teacher before the research on puppet scenarios. In the interview room outside the blood collection unit, the child's parent will be asked to tell the researcher about the things the child enjoys and likes. The researcher will show the child puppet characters on various themes and the child will be asked to choose the puppet character he/she wants before the blood collection. The puppet scenarios will be improvised in light of the information received from the child's mother and father during the demonstration and will be shaped according to the child's wishes. In this way, the child will turn the scary hospital environment into an entertaining environm
215097462|NCT02911142|DRUG|Doxorubicin|During cycle 1, Doxorubicin 10 mg /m\^2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
215097463|NCT02911142|DRUG|Vincristine|During cycle 1, Vincristine 0.4 mg/m\^2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.
215097464|NCT02911142|DRUG|Cyclophosphamide|During cycle 1, Cyclophosphamide 750 mg/m\^2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m\^2 day 5.
215097465|NCT02911142|DIAGNOSTIC_TEST|CT of neck, chest, abdomen and pelvis|Screening
215097466|NCT02911142|DIAGNOSTIC_TEST|18FDG-PET scan|Baseline
214403201|NCT02794116|PROCEDURE|Resin Sealants|It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
214403202|NCT03952065|DRUG|PD1/PDL1/CTLA4 inhibitors|Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.
214403203|NCT01929993|PROCEDURE|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
214403204|NCT01929993|PROCEDURE|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
214403205|NCT01852162|DRUG|Dabigatran|Dabigatran 150mg
214403206|NCT01852162|DRUG|Placebo|Matching placebo tablets
214403207|NCT00378521|DRUG|MQX-503|
214403208|NCT04071080|DRUG|fluorescein sodium|Fluorescein sodium in 500mL Gatorade
214403209|NCT04071080|DRUG|Placebo|500mL Gatorade
214403210|NCT03679702|DEVICE|Viveve System|Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.
214403211|NCT06507969|OTHER|The Effect of Body Composition on Respiratory Parameters, Functional Capacity and Sleep in Healthy Young Adults|Sociodemographic information of all participants will be obtained within the scope of the evaluations. Body composition parameters will be measured with Tanita DC360 Body Analysis Scale. In pulmonary function test, Forced vital capacity (FVC), Forced expiratory volume in 1st second (FEV1), Tiffeneau ratio (FEV1/FVC), peak expiratory flow rate (PEF) values will be evaluated with COSMED Pony FX (COSMED; Italy) spirometer. Respiratory muscle endurance will be assessed by Maximum Minute Ventilation will be determined. Pittsburg Sleep Quality, a reliable questionnaire that assesses sleep quality The index will be filled in by the participants. 6 Minutes to assess functional capacity A walking test will be performed and the distance travelled by individuals will be recorded
214403212|NCT00347659|DRUG|BLVR System|Treatment is administered in a single treatment session.
214403213|NCT01965080|DRUG|Exemestane|One tablet Exemestane 25 mg daily
214403214|NCT01256476|DRUG|pitavastatin|pitavastatin 4 mg once daily (QD)
215008589|NCT07044713|OTHER|The Visual Viewing and Coloring Book|Children who come to the hospital's blood collection unit and meet the research criteria will be randomly assigned to the coloring group. The scales will be filled out by the nurse and the child five minutes before the blood is drawn. The Visual Viewing and Coloring Book consists of pictures that require coloring. The children will be given a book before the blood is drawn and will be asked to draw or color a picture as they prefer during the procedure. The fear scale will be assessed by the nurse and the child five minutes before, during, and five minutes after the procedure. The pain scale will be assessed by the nurse and the child during and five minutes after the procedure. The child will be shown the facial expressions on both the fear scale and the pain scale and asked which one it is, and the score corresponding to the facial expression he/she indicates will be recorded. Mothers will stay with their children during the treatment proce
215008590|NCT07046156|DRUG|Oxybutynin Cl|Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder
214403215|NCT01256476|DRUG|pravastatin|Pravastatin 40 mg once daily (QD)
214403216|NCT04176614|OTHER|cereal-legume snack|cereal-legume biscuit
214403217|NCT04176614|OTHER|cereal snack|cereal biscuit
214403218|NCT06055777|DRUG|SZEY-2108 for injetion|Part1（Single-dose intravenous infusion dose-escalation trial）:100mg，200mg，500mg, 1000mg, 2000mg，4000mg and the dose of last cohort to be determined. Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：1000mg at Q8h，2000mg at Q8h, and one dose level of 1000mg, 1500mg or 2000mg at Q6h. Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1\~D7 and on the morning of D8.
214403219|NCT06055777|DRUG|Placebo|Part1（Single-dose intravenous infusion dose-escalation trial）:250mL/500mL，Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：250mL,Multiple intravenous doses of placebo at Q8h or Q6h on D1\~D7 and on the morning of D8.
214403220|NCT02153385|OTHER|Yoga|Yoga program was 60 min per session, twice per week for 8 weeks. Led by an experienced yoga instructor.
214403221|NCT04941417|DRUG|PD-1 inhibitor|Two to three cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor will be administered before surgery, followed by another one to two cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor and PD-(L)1 inhibitor monotherapy for up to 1 year.
214403222|NCT01427387|DRUG|ASP0456|oral
214403223|NCT01427387|DRUG|Placebo|oral
214403224|NCT05226481|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|Trauma-focused cognitive-behavioral therapy (TF-CBT) is an evidence-based method for the treatment of posttraumatic stress among youth.
215008591|NCT07046156|DRUG|propiverine|Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder
215008592|NCT07046156|DRUG|Tolterodine|Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder
214403225|NCT00002563|PROCEDURE|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
214403226|NCT00002563|PROCEDURE|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
214403227|NCT03904719|DRUG|CM082 plus JS001|CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
214403228|NCT01866475|DEVICE|EZ-IO|To have an EZ-IO placed up to 48 hours
214403229|NCT04727775|DRUG|Favipiravir|Antiviral drugs
214403230|NCT04727775|DRUG|Remdesivir|Antiviral drugs
214403231|NCT02115854|OTHER|labial biopsy|
214403232|NCT03871933|OTHER|Measurement of lung function, electrocardiography, echocardiography and autonomic function|Measurement of lung function, electrocardiography, echocardiography and autonomic function
214403233|NCT04333836|DEVICE|Removable Clear Aligners|"1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner studio®.~4. Aligners will be fabricated on 3d printed models using vacuum formers.~5. Anchorage reinforcement for posterior segments by using buccal miniscrews.~6. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~7. Patient will receive the following aligner after 2 weeks.~8. Follow up visits every 2 weeks until complete canine retraction."
214403234|NCT05104762|DEVICE|plasmapheresis device|Group 1: 54 patients of Guillian Barrie syndrome undergo plasma exchange (5 sessions)
214403235|NCT05104762|DRUG|Intravenous immunoglobulin|group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.
215097467|NCT02911142|DIAGNOSTIC_TEST|MRI Brain|Screening
215097468|NCT02911142|PROCEDURE|Bone marrow biopsy|Baseline
214403236|NCT00163215|DRUG|Somatropin|Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
214688253|NCT07163403|BIOLOGICAL|Autologous Tolerogenic Dendritic cells|Autologous peripheral blood differentiated and matured adult dendritic cells loaded with Frameshift-derived neopeptides (FSDN) (DC-DELAY). Eligible participants will receive six intradermal immunizations of DC-DELAY at week 0, 2, 4, 6, 8 and 10.
214693902|NCT03446651|DRUG|Lysine Chloride|Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
214693903|NCT03446651|OTHER|Placebo|Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
215008593|NCT07050693|DIETARY_SUPPLEMENT|Vitamin + Zinc + micronutrient mixture|a dietary supplement containing Vitamin D, Zinc, Beta glucan WELLMUNE WGP, 2'Fucosyllactose.
215008594|NCT07050693|DIETARY_SUPPLEMENT|Placebo|Placebo is identical to intervention product
215097469|NCT02911142|DIAGNOSTIC_TEST|EKG|Screening
215097470|NCT02911142|DIAGNOSTIC_TEST|Echocardiogram|Screening
215008595|NCT07050836|COMBINATION_PRODUCT|Definity contrast during ultrasound|Definity contrast injection given just prior to brain tumor surgery. Contrast enhanced ultrasound during brain tumor surgical resection to aid in brain tumor visualization.
215008596|NCT07045064|OTHER|Aerobic exercise without medication|"twenty patients will participate in moderate intensity intradialytic aerobic training for 12 weeks. (3 times per week). Using Horizontal electromagnetically braked cycle ergometer during the first half of the dialysis session.~(1) Frequency: received intradialytic, lower-limb, cycling exercise three times per week on alternative days (2) Intensity: the intensity of exercise will be at 12-14 (moderate-intensity: somewhat hard or reports of feeling a little bit tired but still ok to continue) based on the Borg's Perceived Exertion Rating Scale Appendix III (a rating of 6 perceiving no exertion at all to 20 perceiving a maximal exertion of effort) ,Appropriate speed and grade of resistance were adjusted to achieve the required intensity. (3) Time: the duration of each exercise session consisted of a 5-min warm-up in form of circulatory exercise."
215097471|NCT02911142|DIAGNOSTIC_TEST|Ultrasound|Day 6
215097472|NCT02911142|DIAGNOSTIC_TEST|Bronchoscopy|Baseline
215097473|NCT02911142|DIAGNOSTIC_TEST|Endoscopy|Baseline
215097474|NCT02911142|DIAGNOSTIC_TEST|CXR: PA/lat/decub|Screening
215097475|NCT05589675|OTHER|Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program|The individuals eligible for the colorectal cancer screening program will receive at home an invitation letter to participate to the program along with a FIT test. The follow-up will be similar to the standard of care, i.e. reminder letters at 5 and 10 months if there is no participation, and reminders if no coloscopy after a positive FIT test
215097476|NCT05589675|OTHER|Sending of a prior notification to the new entrants of the national program|Dispatch of a notification, one month prior the dispatch of the screening test along the invitation letter. This intervention is among the new entrants to the national program
215097477|NCT06067737|DRUG|Psilocybin|High-dose psilocybin (30 mg) session will be administered following standard-of-care outpatient buprenorphine induction to evaluate its effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
215097478|NCT06067737|DRUG|Psilocybin|A very low dose (1 mg) psilocybin session following standard-of-care outpatient buprenorphine induction will be used as a comparator arm to the high-dose psilocybin arm in evaluating psilocybin's effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
214403237|NCT02836145|OTHER|Differentiation of hiPSCs to skeletal muscle progenitors|
214403238|NCT00535197|BIOLOGICAL|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
214403239|NCT00115180|OTHER|No intervention|No intervention
214403240|NCT05177081|DEVICE|Preemptive management using home BIA monitoring system|Patients check their body composition and fluid using Home BIA system. Investigators analyze patients' body congestion status and send patient's edema status and direction of extra-diuretics usage to enrolled patients every one week.
214403241|NCT00231179|BEHAVIORAL|Home visiting professional support model|Home visits and telephone calls keyed to well child visits.
215097479|NCT06321965|OTHER|evaluation of muscle function|Myogrip (≥ 6 years): precise dynamometric measurement of gripping force, measuring force in Newton up to 90kg with 0.01kg resolution. It's evaluated at D0, M6, M12, M18, and M24 Myopinch (≥ 6 years) : measure thumb-index force up to 15 kg with a resolution of 0.001 kg using a precision sensor equipped with two steel distance blades. It's evaluated at D0, M6, M12, M18, and M24
214403242|NCT00231179|OTHER|Control|The control group received an information booklet on child/family services upon enrollment and transportation for the follow-up evaluations. They were called every 4 months to maintain contact information
215008597|NCT07045064|OTHER|resistive exercise without medication|"Twenty patients will participate in moderate intensity intradialytic resistive training for 12 weeks. (3 sessions per week) using ankle weights.~During session: The warming up phase for 5-minute in form of circulatory exercises, then the main exercise phase and then cooling down phase for 5 minutes. in form of circulatory exercises.~The training protocol consisted of five lower-body resistance exercises using ankle weights 3 days/week, The intensity of the program will be moderate, starting with two sets of each exercise at 60% of each patient's three repetition max (3-RM) strength, progressing to three sets per session, with additional weight added as tolerated"
215008598|NCT07045064|OTHER|circulatory exercise without medication|this group will include 20 patients will participate in circulatory exercises and will be evaluated at the beginning and at the end of the study.
215008599|NCT07048834|OTHER|lidocaine local anesthetic drug|Lidocaine Nerve Block technique
215008600|NCT07048834|OTHER|articaine local anesthetic drug|Articaine Local Infusion technique
214403243|NCT02522520|BEHAVIORAL|Pedometer intervention|12 weeks physical activity intervention (supervised/non-supervised)
214403244|NCT02522520|BEHAVIORAL|Pedometer + hospital based intervention|12 weeks physical activity intervention (supervised/non-supervised)
214403245|NCT02522520|DEVICE|Omron Walking Style pro. 20|
214403246|NCT04729543|BIOLOGICAL|Adoptive therapy with autologous MC2 TCR T cells|Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP
214403247|NCT01039090|DRUG|Continuous Apomorphine infusion|Continuous Apomorphine infusion during 6 months
214403248|NCT01039090|DRUG|Usual dopaminergic per os treatment|No specific change in the dopaminergic per os treatment
214403249|NCT05192512|DRUG|TQB2928 injection|TQB2928 injection is a CD47 Blocker.
214403250|NCT04650347|PROCEDURE|visualized internal urethrotomy|incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.
214403251|NCT00864565|DRUG|Fentanyl 25 μg/h transdermal system, single application|A: Experimental Subjects received Corium International, Inc formulated products
214403252|NCT00864565|DRUG|Duragesic 25 μg/h transdermal system single application|B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products
214403253|NCT05266196|DRUG|Seclidemstat|Treatment assigned as per parent protocol
215008601|NCT06732388|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
215008602|NCT06732388|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215008603|NCT06732388|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
215008604|NCT06732388|DRUG|Itraconazole|Given PO
215008605|NCT06732388|DRUG|Placebo Administration|Given PO
215008606|NCT06732388|OTHER|Questionnaire Administration|Ancillary studies
215008607|NCT06732388|PROCEDURE|Radiofrequency Ablation|Undergo radiofrequency ablation
215008608|NCT07047157|BEHAVIORAL|Video-Based Virtual Reality Education|Participants receive VR-based video training using a headset. The content includes step-by-step instruction on peripheral venous catheterization.
215008609|NCT07047157|BEHAVIORAL|Traditional Education with Demonstration|Participants receive traditional face-to-face instruction and live demonstration of peripheral venous catheterization (PVC).
215008610|NCT07046416|OTHER|Occupation-Based Exercise Program|"In the occupation-based exercise program, while trying to improve the range of motion and muscle strength of the hand, it is aimed to successfully return to daily life activities. For this reason daily activities are used instead of memorized range movements. In this way, the occupation-based exercise program provides a physical recovery in patients with hand injuries, while providing positive improvements in parameters related to the mind and spirit. Patients' participation, motivation and compliance with the treatment are increased in the hand rehabilitation process, which can be challenging for patients.~In addition to the conventional treatment program, the study/experimental group, will be given occupation-based exercises for a total of 4 weeks between the 6th and 10th weeks postoperatively, 2 days a week with a physiotherapist and the other days with a home program."
215097480|NCT06321965|OTHER|First-line cognitive assessment|"Vineland-II (All patients) : is a scale for assessing adaptive behaviors. will be carried out during the telephone call at M1/V2.~All tests are evaluated at D0, and M18 :~Bayley-4 language part (\< 42 months) PVSE (≥ 4 years) CELF-5 (≥ 5 years) Conners-3 (≥ 6 years) AQ (≥ 4 years), EQ (≥ 11 years)~M-CHAT-R (\< 4 years) :~SRS-2 (≥ 2 years)"
214403254|NCT03645603|DRUG|Dexmedetomidine|intravenous infusion
214403255|NCT03645603|DRUG|Placebo|intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion
214403256|NCT04129762|OTHER|Diet without NCS|"A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS."
214403257|NCT04129762|OTHER|Diet with NCS|"A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS."
214403258|NCT03097211|DRUG|Placebo|Placebo capsules. Orally, with 240 mL of potable water.
214403259|NCT03097211|DRUG|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
214403260|NCT03097211|DRUG|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
214403261|NCT03097211|DRUG|Nebicapone|Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
214693904|NCT05553678|DRUG|Midazolam|Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.
214693905|NCT05553678|DRUG|Normal saline|Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.
215008611|NCT07046416|OTHER|Conventional therapy group|Conventional group treatment will be according the early passive hand rehabilitation program. Conventional group will be followed with a cast-splint made by the surgical team for the first 4 weeks within the scope of the conventional treatment program. From the 4th week onwards, the duration of splint use is gradually reduced and is completely discontinued from the 6th week onwards. At the end of the 4th week, depending on the wound condition, contrast bath, scar massage, retrograde massage, active and passive flexion, active extension and tendon shifting exercises are applied as tolerated. After the 6th week, isolated block exercises and stretching exercises are added if there is contracture. Strengthening exercises are started from the 8th-10th week.
215008612|NCT07044856|BEHAVIORAL|distraction with virtual reality|Before the procedure, the patient's vital signs will be checked and pain and anxiety will be assessed. This group will be shown a video using virtual reality glasses during the lumbar puncture procedure. After the intervention, the patient's vital signs will be checked again and pain and anxiety will be assessed.
215008613|NCT06734104|OTHER|Interactive Video Education|After participants are informed about the study, eligible individuals (based on inclusion and exclusion criteria) will be identified. From the students deemed eligible for the study group, 60 students will be selected using a simple random sampling method by an independent statistician. Informed consent will be obtained from students who agree to participate in the study. Initially, a pre-test will be administered to the 60 selected students. Following the pre-test, the students will be randomly assigned to the experimental and active control groups using a simple randomization method. The researcher will provide the interactive video to the students in the experimental group. After one week of interactive video training for the experimental group, a post-test will be administered to all students.
215008614|NCT06734104|OTHER|Non-Interactive Video Education|After participants are informed about the study, eligible individuals (based on inclusion and exclusion criteria) will be identified. From the students deemed eligible for the study group, 60 students will be selected using a simple random sampling method by an independent statistician. Informed consent will be obtained from the students who agree to participate in the study. Initially, a pre-test will be administered to the 60 selected students. After the pre-test, the 60 students will be randomly assigned to the experimental and active control groups using a simple randomization method. The researcher will provide the non-interactive video to the students in the active control group. After one week of watching the non-interactive video, a post-test will be administered to all students.
215008615|NCT06733493|BEHAVIORAL|integrated psychosocial care|Employment of a psychologist in psychotherapeutic training as a member of the multiprofessional team at the ICU ward for the duration of one year. Tasks: Psychosocial Support for staff, patients and their relatives.
215008616|NCT07055490|PROCEDURE|Interdisciplinary Practice Bundle|interdisciplinary practices were combined in a bundle framework called (5-Ps) to maintain normal process during labor and prevent unnecessary routine interventions, which are (patience, positioning, physiological resuscitation, progress, and preventing urinary harm). These practices implemented from the beginning of the second stage of labor which is started from onset of complete cervical dilatation (10 cm) until delivery with a duration of 2 hours period.
215008617|NCT07056127|OTHER|manual dynamic agitaion|5 mL of 2.5% NaOCl solution will be activated with a well-fitting gutta-percha cone that will be placed to full working length and then will be moved in push-pull strokes of 2 mm amplitude at a frequency of 100 strokes in about 1 min
215008618|NCT07056127|OTHER|ultrasonic activation|5 mL of 5.25% NaOCl solution will be activated with PUI using a #20 endosonic ﬁle that will be driven by an ultrasonic device on medium power setting for 1 minute and inserted 1 mm short of the working length
215008619|NCT07056127|OTHER|xp-endo finisher|5 mL of 5.25% NaOCl solution will be activated with XP-Endo Finisher which will be used in the canal for 1 minute at 800 rpm and 1 Ncm up to the working length and in slow up-and-down movements at 7-8mm length according to the manufacturer's recommendations
214403262|NCT05475223|DIAGNOSTIC_TEST|End Tidal Carbon Monoxide Value|A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
214693906|NCT04317352|PROCEDURE|MVR|Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
214693907|NCT06164145|OTHER|Usual care|The training program used in this study is the stroke rehabilitation program focusing on health education for stroke and a routine exercise program based on the National Strategic Plan for Stroke Rehabilitation in Myanmar.
215008620|NCT07056127|OTHER|laser|First, root canals will be filled with 0.5 mL of 0.05% ICG dye and left in place for 1 minute as preirradiation time. A #20 laser fiber will be inserted into the root canals to the working length. Then infrared diode laser with a wave length of 810 nm will be used to activate the dye for 30 seconds. For activation, circular movements will be performed along with the fiber removal movement . After the first activation, dye will be reintroduced, the laser fiber will be inserted again, and a new activation cycle of 30 seconds will be performed similarly to the previous one
215008621|NCT07056855|DRUG|nano hydroxy apatite varnish Intervention (1)|Fygg's professional strength, Fygg, USA
215008622|NCT07056855|DRUG|Potassium Nitrate Gel|Ultradent UltraEZ Desensitizing Gel, Ultradent Inc., USA
215008623|NCT07056855|DRUG|Varnishes, Fluorid|DentKist Charm Varnish 5% Sodium Fluoride Varnish
215008624|NCT07056673|DEVICE|Active CAP therapy|"The patients in the CAP group will receive six sessions of CAP treatment, administered once weekly for six consecutive weeks. If complete clearance of facial acne is achieved before all six sessions, CAP treatment will be discontinued early.~For device selection, the CAP patch trauma therapy device (CAP-PTTD) will be used for lesions located on relatively flat areas of the face. In cases of lesions on areas with greater anatomical curvature (eg, the mandibular angle or near the tragus), the CAP jet trauma therapy device (CAP-JTTD) will be used in combination."
215008625|NCT07056673|DEVICE|sham CAP therapy|the device will be operated with the plasma-generating field disabled, so that no plasma will be produced. Only environmental cues such as sound will be simulated to ensure blinding.
214403263|NCT01501916|DIETARY_SUPPLEMENT|Vitamin D3|daily dosage of 50 µg Vitamin D3 for 8 weeks
214403264|NCT01501916|DIETARY_SUPPLEMENT|Placebo|daily intake of placebo
214693908|NCT00900172|BIOLOGICAL|bevacizumab|
214693909|NCT00900172|DRUG|carboplatin|
214693910|NCT00900172|DRUG|paclitaxel|
214693911|NCT00900172|GENETIC|gene expression analysis|
214403265|NCT02892409|DRUG|Clarithromycin|Clarithromycin tablets
214403266|NCT02892409|DRUG|Amoxicillin|Amoxicillin capsules
214403267|NCT02892409|DRUG|Tripotassium bismuth dicitrate|Tripotassium bismuth dicitrate tablets
214403268|NCT02892409|DRUG|Lansoprazole|Lansoprazole capsules
215008626|NCT07056673|OTHER|standard care based on the JAAD acne guidelines|the group will receive standard care based on the JAAD acne guidelines
214693912|NCT00900172|GENETIC|polymerase chain reaction|
215008627|NCT07055633|DEVICE|CCT+MBLT|Compensatory Cognitive Training + Morning Bright Light Therapy (Aurora LightPad)
215008628|NCT07055633|DEVICE|CCT+ION|Compensatory Cognitive Training + Negative Ion Generator (SphereOne)
215008629|NCT07055971|BEHAVIORAL|Experimental: Pain Neuoescience Education Group|The experimental group will receive a pain neuroscience education (PNE) intervention delivered through an in-person, didactic educational model in small groups of 5 to 10 patients. PNE sessions will be conducted once per week for 6 weeks, each lasting approximately 45 to 60 minutes, by a physiotherapist with extensive clinical experience and specialized training in PNE. The content of the sessions will be based on models described in previous studies. Patients will receive detailed information on the neurophysiology and neurobiology of chronic pain and its relationship to fibromyalgia (FM). Pre-prepared PowerPoint presentations will be used to deliver the material in an accessible and engaging manner, employing images, metaphors, anecdotes, and stories to facilitate understanding. All variables will be recorded at baseline (prior to the intervention), at 6 weeks (end of the intervention), at 12 weeks and at 18 weeks.
215008630|NCT07055971|BEHAVIORAL|Active Comparator: Biomedical Education Group|The control group will receive two sessions of biomedical education and general guidance on chronic pain and its management, delivered in small groups of 5 to 10 patients with a duration about 45-60 minute. These sessions will also be conducted by the same physiotherapist who delivers the intervention sessions. Both groups will be instructed to continue their usual care and will be encouraged to engage in therapeutic exercise tailored to their physical limitations. All variables will be recorded at baseline (prior to the intervention), at 6 weeks (end of the intervention), at 12 weeks and at 18 weeks
215008631|NCT07056998|PROCEDURE|root canal retreatment|if Retreatment was needed, local anesthesia using 1.8 ml (one cartridge) of 4% articaine with 1:100,000 epinephrine local anesthetic solution, administered with end -loading cartridge aspirating syringe and a 27-gauge long needle. Under rubber dam isolation, All carious tissue and existing coronal restorations were thoroughly removed using a round bur, an endodontic access cavity, canal preparation and removal of existing root canal filling, irrigation with 2.6% NAOCL and saline, determining the working length using apex locator and PA radiograph, to be 0.5 to 1 mm shorter than radiographic apex, Drying the canal with paper point and obturation to achieve a dense, well adapted Monoblock obturation. A post-obturation periapical radiograph was taken to confirm the quality of the fill in terms of length, density, then sealed by a temporary restorative material.
215008632|NCT07056647|DIETARY_SUPPLEMENT|Staircase Nutritional Intervention|"Fourteen days before admission, different nutritional supplements will be provided according to whether the patient has diabetes and their nutritional status. Patients without diabetes who are malnourished should take enteral nutrition powder mixture three times a day, with each dose providing 265 kCal of energy. Patients without diabetes but at risk of malnutrition should take enteral nutrition powder mixture twice a day. Patients with diabetes who are malnourished should take low - sugar whole - protein enteral nutrition powder three times a day, with each dose providing 250 kCal of energy. Patients with diabetes and at risk of malnutrition should take low - sugar whole - protein enteral nutrition powder twice a day.~During the peri - operative period, a strict 6 - hour fasting of solid food and 2 - hour fasting of clear liquid before surgery is implemented. Two hours after surgery, all patients should take multi - dimensional carbohydrates, which provide 115 kCal of energy. Four ho"
215097481|NCT06321965|OTHER|second-line cognitive assessment|"In the event of positive cognitive screening at D0 or M18, a second-line cognitive assessment will be carried out at a subsequent visit. A list of tests is proposed below, but will be adapted according to the tests available at each center.~* EVALO BB (0-2 years) or EVALO (2-6 years) or full CELF-5 (5-18 years) following positive screening in the communication domain of first-line tests (Vineland II communication domain, Bayley 4, CELF-5 pragmatic profile)~* FEE and DSM-5 diagnostic criteria for ADHD (from age 6 only) following positive screening in the attention and executive functions domain of first-line tests (Conners 3, BRIEF)~* M-CHAT-R/F (\< 4 years) or SCQ (≥ 4 years) and ADOS-2 (≥ 12 years) following a positive screening in the area of social cognition and autistic traits on first-line tests (Vineland II, M-CHAT-R, SRS-2, EQ, AQ)."
215097482|NCT06321965|OTHER|Cardiac evaluation|"All tests are evaluated at D0, M12, and M24 :~Electrocardiogram (ECG) : This examination will be carried out in accordance with the 12 leads recording the following parameters: verification of sinus rhythm, P wave, PR interval, QRS complex (interval), ST segment, T wave, QT complex, heart rate.~Cardiac ultrasound: Non-invasive ultrasound will focus on the following parameters measured from 2-dimensional images, to look for cardiomyopathy and/or structural abnormality:~* end-diastolic/end-systolic diameter/left ventricular ejection fraction~* Septal wall thickness / left ventricular posterior wall~* Fractional shortening 24-hour Holter-ECG : This examination consists of a continuous test recording the heart rhythm for 24 hours."
214403269|NCT02892409|DRUG|TAK-438|TAK-438 tablets
214403270|NCT02331940|DRUG|tiotropium|Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
214403271|NCT02331940|DEVICE|Handihaler|Inhalation via the HandiHaler once daily
214403272|NCT02331940|DEVICE|Respimat|Inhalation via the Respimat once daily
214403273|NCT02123966|DRUG|Sirolimus|
214403274|NCT03152565|DRUG|Avelumab|"Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity."
214403275|NCT01747161|DRUG|Botulin toxin|50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
214693913|NCT00900172|GENETIC|polymorphism analysis|
214693914|NCT00900172|OTHER|laboratory biomarker analysis|
214403276|NCT01747161|DRUG|physiological water|3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
214403277|NCT00304811|DRUG|Vancomycin|
214403278|NCT00304811|DRUG|Vancomycin plus Gentamicin|
214403279|NCT00304811|DRUG|Vancomycin plus Rifampin|
214403280|NCT00304811|DRUG|Vancomycin plus Gentamicin plus Rifampin|
214403281|NCT06305988|DEVICE|Transcranial direct current stimulation|The anode patch is placed in Fz, and the cathode patch is placed on right cheek, powered by direct current with a current of 1.5mA. Subjects in the placebo comparator group will receive sham tDCS for 1 week, which mimics the tDCS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs. The anode patch is placed at Fz, and the cathode patch is positioned on the right cheek, to maintain the blinding of the intervention.
214403282|NCT05640817|DRUG|Pentoxifylline 400 mg SR tablets|a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases
215008633|NCT07056647|DIETARY_SUPPLEMENT|Standard ERAS Diet Management Group|Only nutritional education is provided to patients before admission, without any specific nutritional supplements. During the peri - operative period, patients are required to fast from food and water for 8 hours before surgery. Six hours after surgery, patients are allowed to drink water. They can start consuming liquid food after passing gas from the anus. No specific energy - containing nutritional supplements are given during this period. A nutritional guidance manual is distributed to patients upon discharge, and there are no targeted nutritional interventions or follow - up measures related to energy intake subsequently.
215008634|NCT07055711|DIAGNOSTIC_TEST|Peripheral Neuropathic Pain|to find out the association between work-related stress and peripheral neuropathic pain in female breast cancer survivors post-chemotherapy.
214403283|NCT05640817|DRUG|cisplatin with standard hydration with normal saline|chemotherapy
214403284|NCT01460381|DRUG|LY2216684|
214403285|NCT01460381|DRUG|Quinidine|
215008635|NCT07056790|DRUG|68Ga-PSMA-CYC|Each prostate cancer patient underwent a 68Ga-PSMA-CYC (3-4 mCi) PET/CT scan, as well as a 68Ga-PSMA-617 (3-4 mCi) or 68Ga-PSMA-11 (3-4 mCi) PET/CT scan, with the time interval between the two scans not exceeding one week.
215008636|NCT07056790|DRUG|CYC|The dose will be 3-4mCi given intravenously.
215008637|NCT07055906|BEHAVIORAL|Video-feedback Intervention to Promote Racial-Ethnic Socialization CompEtency (VIP-RACE)|VIP-RACE is a brief, strengths-based, video-feedback intervention that targets parental racial-ethnic socialization (RES) motivation and competency in parents of 10-to-14-year-old Latino/a/x/e youth. Intervention sessions include: (1) Youth and parent assessment including videotaped parent-adolescent RES conversations; (2) Parent interview; and (3) Video feedback session during which parents and RES coaches review clips from the RES interaction tasks. Video feedback highlights parents' RES strengths and when sensitively applied, encourages parents to examine missed opportunities for engaging in RES. RES coaches emphasize that through the provision of cultural socialization and preparation for bias messages, parents can help protect their children from the damaging effects of discrimination and support positive racial-ethnic identity development. Parents develop a personalized action plan with goals and have the opportunity to receive up to 3-5 follow-up sessions to strengthen RES skill
215008638|NCT01822743|PROCEDURE|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
215008639|NCT01822743|PROCEDURE|sham comparator|
215008640|NCT07057050|OTHER|The designed physiotherapy program|"* Scapular and thoracic mobilization, active assisted and passive exercises, and positioning such as weight bearing on the affected upper limb.~* Strengthening of the shoulder flexors and elbow and wrist extensors.~* Stretching exercises of the spastic muscles (shoulder extensors, elbow and wrist flexors.)"
215008641|NCT07057050|DRUG|The Botulinum toxin injection|The injection of 1000 units per upper extremity will be done into the biceps brachii muscle at 2 sites, and 150 units into the flexor carpi radialis muscle at 1 site per muscle, using anatomical landmarks similar to routine electromyography.
214403286|NCT03679130|BEHAVIORAL|Structured supervised exercise training|EXE contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
214403287|NCT03679130|BEHAVIORAL|Motivational counseling supported by health technology|MOT contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
214403288|NCT06102343|DEVICE|Alma Harmony|Acne scars treatment using non-ablative ER:Glass 1540 nm laser module.
214403289|NCT03742843|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium
214403290|NCT03738657|OTHER|Olfactory screening|Therefore prior to gustatory testing, patients will be screened and assessed as having either normal or abnormal olfactory function using the Sniffin' Sticks (Burghart; Wedel, Germany). The test consists of 12 odour pens which represent every-day odours (peppermint, fish, coffee, banana, orange, rose, lemon, pineapple, cinnamon, cloves, leather and liquorice). Patients are presented with an odour and select the perceived smell using a multiple-forced-choice method.
214403291|NCT03738657|OTHER|Quantative Gustatory Testing using Taste Strips|"Following screening for olfactory function, whole mouth gustatory function will be assessed using validated taste strips (Burghart; Wedel, Germany). Filter paper test strips are impregnated at one end with 2cm2 of either sweet, sour, salty or bitter taste solutions in four concentrations. In a pseudo-randomised sequence, individual strips will be placed on the tongue and patients will be asked to close their mouth in order to assess whole mouth function. Through a forced-choice procedure patients will be asked to identify the taste stimuli. Scores for individual taste qualities will range from 0-4 and an overall taste score will range from 0-16.~Patients will rinse their mouth with tap water prior the application of each taste strip."
214403292|NCT01824446|DRUG|Radiolabeled SPD602 (FBS0701, SSP-004184)|A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
214403293|NCT05240859|DRUG|Geleli|Adalimumab Biosimilar
214403294|NCT06355817|DEVICE|Vibration|Vibration Assist Device, held to the forehead
214403295|NCT06355817|OTHER|Tapping|Tapping on the forehead
214403296|NCT05400980|DEVICE|Urocross implant|Urocross implant inserted via delivery catheter
214403297|NCT05400980|DIAGNOSTIC_TEST|Sham-control|Cystoscopy
214403298|NCT04822298|DRUG|AMG 160|AMG 160 administered as an intravenous (IV) infusion
214403299|NCT00453089|DRUG|VG101|
214403300|NCT02823743|DRUG|Aspirin|Daily medication
214403301|NCT02823743|DRUG|Placebo|Daily intake
215008642|NCT07057050|OTHER|Task oriented training|The training involves 30 minutes of bilateral functional tasks like carrying a block, grabbing and folding a towel, staking cups upright, holding a glass and drinking water, throwing a ball into a basket, and moving pegs.
215008643|NCT07057050|OTHER|Constrained induced movement therapy|The therapy session focuses on enhancing the affected arm's functional tasks, such as throwing a ball, holding a glass, combing hair, turning on and off a light switch, grasping and releasing blocks, pouring from glass to another, moving cups, and moving pegs. Participants are instructed to wear a restrictive mitt on their non-paretic hand for 6 hours a day for 4 days, 7 weeks, and 12 weeks, with the mitt removed for safety, hygiene, or agreed-on activities.
215008644|NCT07045636|OTHER|PEMF abd Sham (control)|Dental implants receive MED that could (test) or could not (control/SHAM) be activated to emit PEMF
215008645|NCT07045636|DIAGNOSTIC_TEST|Teeth wih gingivits|Comparison with dental implants
214403302|NCT01456663|DRUG|AFQ056|
214403303|NCT04484064|BEHAVIORAL|Adherence program|This program combines adherence evaluation using an electronic monitor (MEMS®) and feedback with repeated medication adherence interviews with the pharmacist.
214403304|NCT05946876|DRUG|XH-S003 (A)|IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
214403305|NCT05946876|OTHER|Placebo (B)|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
214403306|NCT05825820|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~A phone call (or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if you have suicidal thoughts, and (c) discuss participants' plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals give for individuals who present to the ED with suicidal thoughts."
214403307|NCT06527105|DEVICE|Eye masks and ear plugs|Eye masks and ear plugs given during sleeping time in Icu After cardiac surgery
214403308|NCT04506671|PROCEDURE|Renal biopsy|Renal biopsy will be performed prior to the cryoablation on the basis of the center and according to the current protocols
214403309|NCT04506671|PROCEDURE|Cryoablation|Cryoablation under CT guidance will be performed on the basis of the center and according to the current protocols
214403310|NCT04506671|PROCEDURE|Partial nephrectomy|Partial nephrectomy will be performed on the basis of the center and according to the current protocols
214403311|NCT03666429|DEVICE|Bulb suction|Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.
215008646|NCT02387112|DEVICE|Early VAD implantation|Implantation of a left ventricular assist device
215008647|NCT00375297|DRUG|sildenafil|
215008648|NCT06349278|PROCEDURE|Pancreatic resection and non-anatomic liver resections.|Pancreatic resection and non-anatomic liver resections.
215097483|NCT06321965|RADIATION|MRI|"Cerebral MRI : Performed at D0, only for patients with ASI type 1 ≥ 6 years, or younger patients for whom the investigator considers that the examination can be performed without sedation or general anesthesia. It will include sequences:~* 3D T1, gradient echo, 1.1 mm voxel, sagittal acquisition~* axial T2, spin-echo, slice thickness 4 mm~* 3D FLAIR, spin-echo, 1 mm voxel, sagittal acquisition Muscular MRI: performed at V1/J0, and V6/M24. The examination will include water-fat imaging (Dixon) in full-body, 3D mode, with proton density weighting and millimeter resolution."
214403312|NCT03666429|DEVICE|NoseFrida|Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.
214403313|NCT00001061|DRUG|Sevirumab|
214403314|NCT00001061|DRUG|Foscarnet sodium|
214403315|NCT00001061|DRUG|Ganciclovir|
215008649|NCT01631253|PROCEDURE|Laparoscopic ovarian cyst enucleation|
214403316|NCT04920214|DIAGNOSTIC_TEST|SonoVue|CEUS examination was performed and corresponding image information of liver lesions was obtained.
214403317|NCT06298630|OTHER|Assessments|Safety and efficacy assessments
214403318|NCT02208323|DEVICE|Bubble CPAP|Respiratory assistance
214403319|NCT01576510|BEHAVIORAL|Prolonged Exposure (PE)|Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
214403320|NCT00951561|DEVICE|Vipon|The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea.
214403321|NCT00951561|DRUG|Ibuprofen|400 mg daily
214403322|NCT02092987|OTHER|Social work support|All study participants were provided access to social support services at Riverstone Senior Life services
214403323|NCT02092987|OTHER|Educational material|All participants received educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.
215008650|NCT03533933|DEVICE|Collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
215008651|NCT03533933|OTHER|autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
214403324|NCT02092987|BEHAVIORAL|NYU caregiver counseling intervention|"The first component consists of 2 individual and 4 family counseling sessions. These sessions last between 1 and 1.5 hours. The second component of the intervention is participation in a caregiver support group . The third component of the treatment is ad hoc counseling. New psychiatric and behavioral problems of patients, which are generally more stressful than the need for assistance with activities of daily living or physical limitations, often precipitate ad hoc calls from caregivers."
214403325|NCT02092987|BEHAVIORAL|REACH OUT counseling intervention|All aspects of the REACH OUT Intervention involve problem solving techniques and the development of written action plans. The goal of this intervention is to engage the caregiver in joint problem-solving with the objective of creating a written action plan targeting specific caregiving problems. The basic steps of problem solving are: 1.Define the problem. 2. Set goals 3. Brainstorm with caregiver and List possible solutions on a pad of paper, 4. Select solutions, 5. Develop an action plan based on these solutions, 6. Implement the action plan, track progress, and make adjustments as needed
214403326|NCT03432221|DRUG|Desvenlafaxine|Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
215008652|NCT05355220|DEVICE|Silver Spike Point Therapy (SSPT)|Silver Spike Point Therapy (SSPT) means passing an electric current through the skin surface with the triangle spike silver coated metal electrode. SSPT was reported by Hyoto and Kitade in Edinburg, Scotland. 3rd World Congress on Pain in 1981; It has a number of advantages over traditional narcotic medication in pelvic girdle pain management. It does not depress the cardiovascular, respiratory, or the metabolic systems and has no apparent effect on the sensorium
215008653|NCT05355220|OTHER|Conservative Managment|2 sets of 10 repetitions Bridging, Cat \& cow exercises, Back press exercises, stretching of hip external rotators and extensors 20 sec / stretch
215008654|NCT04475510|OTHER|Antiplatelet treatment discontinuation|All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
215008655|NCT02744456|DRUG|Losartan|An angiotensin II receptor antagonist drug used mainly to treat high blood pressure.
215008656|NCT02744456|DRUG|Amlodipine|A calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension.
215008657|NCT02744456|DRUG|Hydrochlorothiazide|A diuretic medication often used to treat high blood pressure and swelling due to fluid build up.
215008658|NCT05370118|BEHAVIORAL|Telerehabilitation physical activity behavioral (TPAB) intervention|The intervention includes the behavior change techniques of self-monitoring of behavior, action planning, graded tasks, restructuring the physical and social environment, problem-solving, and prompts/cues.
214403327|NCT00852475|DIETARY_SUPPLEMENT|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
214403328|NCT00852475|DIETARY_SUPPLEMENT|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
214403329|NCT02538640|OTHER|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
214403330|NCT02538640|OTHER|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
215008659|NCT06750185|BIOLOGICAL|BNT317 DL1|Intravenous infusion
215008660|NCT06750185|BIOLOGICAL|BNT317 DL2|Intravenous infusion
215008661|NCT06750185|BIOLOGICAL|BNT317 DL3|Intravenous infusion
215008662|NCT06750185|BIOLOGICAL|BNT317 DL4|Intravenous infusion
215008663|NCT06750185|BIOLOGICAL|BNT317 DL5 (intermediate)|Intravenous infusion
215008664|NCT06750185|BIOLOGICAL|BNT317 DL6 (intermediate)|Intravenous infusion
215008665|NCT06750185|BIOLOGICAL|BNT317 DL7 (additional)|Intravenous infusion
215008666|NCT01955018|DEVICE|New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.
215008667|NCT03334175|DRUG|Walnuts|1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
215008668|NCT04015063|OTHER|Anti-Aging Skin Care product|Primary Subjects will use P29429-01 as an anti-aging skin care product on full face twice a day for 12-week.
215008669|NCT00566033|BEHAVIORAL|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
215008670|NCT03738215|DRUG|Cariprazine|Cariprazine supplied in capsules
215008671|NCT03738215|DRUG|Placebo|Placebo supplied in capsules
215008672|NCT02290093|DRUG|Standard full-volume PEG|Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
215008673|NCT02290093|DRUG|Split-dose full-volume PEG|Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
215008674|NCT02290093|DRUG|Split-dose low-volume PEG|Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
215008675|NCT03150212|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae CNCM I-3856|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
215097484|NCT06321965|OTHER|Assessment of activity and muscle fatigue|"Syde® : evaluated at D0, M6, M12, M24. Patients aged 2 and over will receive the Syde® wearable device to collect their daily activities.~Muscular endurance tests (≥ 6 years) : evaluated at D0, M12, M24 ( only one of 3 tests based on motor function level) oESNHPT : In this test, patients are asked to walk a 10-meter path. oESBBT : In this test, patients have to move 10 blocks over a partition. oESWT: In this test, patients must repeatedly place and remove 9 sticks in 9 holes.~PedsQL Fatigue (≥ 2 years): evaluated at D0, M12, M24. Scale designed to measure fatigue in patients with acute and chronic conditions, as well as in healthy school and community populations.~Fatigue rating scale (≥ 6 years): evaluated at D0, M12, M24. The fatigue assessment scale has 11 numerical points ranging from 0 to 10. The patient is asked to give a rating that best reflects his or her perception of fatigue at that particular moment."
214403331|NCT05876936|DEVICE|contact lens sensor (CLS) SENSIMED Triggerfish®|contact lens sensor CLS placing and fitting evaluation, 24h recording
214403332|NCT00515086|DRUG|Everolimus|Tablets taken once a day with a full glass of water.
214403333|NCT00515086|PROCEDURE|Surgery|Salvage surgical resection
214403334|NCT00121940|BEHAVIORAL|Guided Care|"Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; best practices for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources."
215008676|NCT03150212|DIETARY_SUPPLEMENT|Placebo|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
215008677|NCT03672825|DRUG|REcycled CartiLage Auto/Allo IMplantation|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
215008678|NCT00667966|DRUG|Vardenafil (Levitra, BAY 38-9456), 10 mg|10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
215008679|NCT00667966|DRUG|Placebo|10/20 mg placebo in sequence in respective arm
215008680|NCT00667966|DRUG|Vardenafil (Levitra, BAY 38-9456), 20 mg|20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
215008681|NCT02302456|DRUG|Tranexamic Acid|Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin
215008682|NCT02302456|DRUG|Placebo|Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
215008683|NCT04925401|BEHAVIORAL|The Information brochure will be created on the basis of information given by the French pediatric network Courlygone and the French National Authority for Health.|An information brochure on fever in children and how to deal with a paediatric febrile episode and usual medical management.
215008684|NCT00302471|DRUG|Comparator: MK0429|"Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease."
215008685|NCT00302471|DRUG|Comparator: MK0429|Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
215008686|NCT00302471|DRUG|Comparator: MK0429|Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
215008687|NCT00302471|DRUG|Comparator: MK0429|Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
215008688|NCT00312416|DRUG|Clonidin|
215008689|NCT00312416|DRUG|Brimonidine|
215008690|NCT05047380|BEHAVIORAL|Owstery Disability Scale for disability Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, VAS for pain, Pittsburgh Sleep Quality Scale for sleep quality|All assessments will be made using questionairres. The Oswestry Disability Index scale will be filled in to assess the severity of disability resulting from pain in the patient. Pain severity will be evaluated with the Visual Analog Scale (VAS). Depression and anxiety assessment will be made with Beck Depression Scale and Beck Anxiety Scale, respectively. Sleep quality will be evaluated with the Pittsburg Sleep Quality Index.
215008691|NCT06392087|DRUG|Methoxyflurane|Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
214403335|NCT02373813|DRUG|etanercept pre-filled syringe subcutaneous injection|etanercept for injection in pre-filled syringes
214403336|NCT02373813|DRUG|Oral methotrexate|"During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules."
214403337|NCT02373813|DRUG|Placebo for etanercept subcutaneous injection|etanercept placebo for injection in pre-filled syringes
214403338|NCT02373813|DRUG|Placebo for methotrexate|methotrexate placebo capsules
214403339|NCT02373813|DIETARY_SUPPLEMENT|Folic acid (non-investigational product)|Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
215008692|NCT06392087|OTHER|Standard Care|Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
214403340|NCT00274989|DRUG|Bendamustine|"First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6"
214403341|NCT00274989|BIOLOGICAL|Rituximab|"First-Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6~2nd to 4th -Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6"
214403342|NCT05153954|OTHER|Quantitative Indocyanine Green Fluorescence Angiography|Quantitative analyse of ICG around the proximal/oral part of the anastomosis pre-formation of the primary anasomosis
215097485|NCT06321965|OTHER|Assessment of bulbar function|"DDD-pNMD (≥ 2 years) : evaluated at D0, M6, M12, M18, and M24, is a list of 9 questions used by doctors to screen for dysphagia and dysarthria.~NdSSS (All Patients) : evaluated at D0, M6, M12, M18, and M24, is an 8-level scale for assessing swallowing.~TOMASS-c : (≥ 4 years of age, in patients able to eat solids safely, after assessment of the risk of a false route by the speech therapist): this is a score designed to assess mastication when eating a cracker. Age-dependent standards exist for different types of cracker.~\- Fluid intake test (\> 110 cm, in patients able to drink a liquid safely, after assessment of the risk of a false route by the speech therapist): swallowing limit."
215097486|NCT06321965|OTHER|Evaluation of body composition and metabolism|"Food survey : The dietary survey questionnaire will be sent to parents at D0 and M18. Parents will be asked to complete it for 3 days before the M6 and M24.~Bioelectrical impedancemetry: Evaluated at M6 and M24. Renal ultrasound: Evaluated at M6, is a non-invasive examination that analyzes the appearance of the kidney and urinary tract.~Dual-energy X-ray absorptiometry (DXA) : Evaluated at M6, it measures body composition using spectral imaging, including fat mass, lean mass and bone mineral density.~Fibroscan : Evaluated at M6 and M24. This examination uses pulse elastography to measure liver elasticity, which provides information on the presence of hepatic fibrosis, and sound attenuation, which provides information on the presence of liver fat overload.~Indirect calorimetry : Evaluated at M6. This device enables precise measurement of Resting Energy Expenditure , Respiratory Quotient and metabolic substrate oxidation."
215097487|NCT06321965|OTHER|Questionnaires|"SMAIS : The questionnaire has been developed specifically for ASI. At D0, M6, M12, M18 and M24.~HUI2 : specializes in preference-based measures of health-related quality of life. At D0, M6, M12, M18 and M24.~Peds QL : is a modular instrument designed to measure health-related quality of life and disease-specific symptoms. At D0, M6, M12, M18 and M24.~Neuromuscular module : 17 disease-related items. It is evaluated at D0, M6, M12, M18 and M24.~Family impact module : It measures parents' reported physical, emotional, social and cognitive functioning, communication and concerns. At D0, M12, and M24.~ASI cost questionnaire: At visit 1 (D0): This questionnaire, completed by the parents, includes information on occupation, parents' working hours and any reduction in them due to the child's pathology, the number of working days missed by the parents or school days missed by the child, and disability-related costs."
215097488|NCT06321965|BIOLOGICAL|Biocollection|"A blood bio collection (optional) will be offered to patients at D0, M6 , M12, M18, M24.~Patients receiving intrathecal injections will also be offered the opportunity to participate in a CSF (cerebrospinal fluid) biocollection (optional)."
215097489|NCT06321965|OTHER|Skinfold measurement|The tricipital point should be marked on the posterior aspect of the arm, on the midline of the tricipital muscle, midway between the acromion and the radius. At D0, M6, M12, M18 and M24
215097490|NCT03871257|DRUG|Carboplatin|Given IV
215097491|NCT03871257|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215097492|NCT03871257|OTHER|Quality-of-Life Assessment|Ancillary studies
215097493|NCT03871257|OTHER|Questionnaire Administration|Ancillary studies
215097494|NCT03871257|DRUG|Selumetinib Sulfate|Given PO
215097495|NCT03871257|DRUG|Vincristine Sulfate|Given IV or IV push
215008693|NCT01695772|DRUG|5-FU based doublet chemotherapy|Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.
215097496|NCT05562778|OTHER|Chatbot|A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.
215097497|NCT04514133|BEHAVIORAL|Participating in Action Civics program|Students in school classrooms participating in Action Civics program
215097498|NCT06211049|DRUG|Vitex agnus-castus BNO 1095 (20 mg)|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
215097499|NCT06211049|DRUG|Placebo|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
214403343|NCT02877199|OTHER|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
214403344|NCT00273455|DRUG|bimatoprost 0.03%|
214403345|NCT00273455|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
214403346|NCT00273455|DRUG|placebo|
214403347|NCT02906306|BEHAVIORAL|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
214403348|NCT02906306|BEHAVIORAL|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
214403349|NCT01974921|DEVICE|ALAIR Catheter. Radiofrequency system.|Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
214403350|NCT05811208|DEVICE|automated pupillometry|Automated pupillometry every 6 hours
214403351|NCT05811208|DIAGNOSTIC_TEST|questionnaire|"CAM ICU questionnaire will be used for delirium screening the incidence of pain will be assessed using 3 valid scales. The Visual Analogue Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Observational Tool (CPOT) will be used.~questionnaires will be done the same time as pupillometry"
215008694|NCT01695772|DRUG|bevacizumab|5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
215008695|NCT03277274|DRUG|TAK-954|TAK-954 intravenous infusion.
215008696|NCT03819699|DRUG|Lu AF20513|Lu AF20513 suspension for injection
215008697|NCT03819699|BIOLOGICAL|booster vaccine|booster vaccine (Cohort 2) - to be administered as per national recommendations
215008698|NCT02492386|DEVICE|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
215008699|NCT05752864|BEHAVIORAL|spine manual therapy|The manual treatment method applied to the sacroiliac joint used high-velocity, low amplitude (HVLA).
215097500|NCT05756569|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215097501|NCT05756569|PROCEDURE|Computed Tomography|Undergo CT
215097502|NCT05756569|DRUG|Enfortumab Vedotin|Given IV
215097503|NCT05756569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215097504|NCT05756569|BIOLOGICAL|Pembrolizumab|Given IV
215097505|NCT05756569|OTHER|Questionnaire Administration|Ancillary studies
215008700|NCT05752864|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
215008701|NCT01424852|DIETARY_SUPPLEMENT|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
215008702|NCT01675700|DRUG|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
215008703|NCT06142552|DRUG|FRSW117|once a week, 50 weeks and as needed
215008704|NCT04439409|DEVICE|Holter electrocardiogram|Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
215008705|NCT05601973|DRUG|Amivantamab|Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is \<80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
215008706|NCT05601973|DRUG|Lazertinib|Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
215008707|NCT05601973|DRUG|Zirabev|Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
215008708|NCT06777979|DRUG|Fludarabine|IV
215008709|NCT06777979|DRUG|Cyclophosphamide|IV
215008710|NCT06777979|DRUG|Mesna|IV
215097506|NCT02883062|DRUG|Atezolizumab|Given IV
215097507|NCT02883062|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215008711|NCT06777979|DEVICE|CD19-CD22 CAR T cell infusion|CAR T cell infusion will be given intravenously, either centrally or peripherally.
215008712|NCT04073407|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
215008713|NCT04073407|DIETARY_SUPPLEMENT|Placebo|placebo
215008714|NCT06755216|BEHAVIORAL|Experimantal group|"In order to identify students who meet the criteria for the study, the PIF and SSSCL will be administered as a pre-test to female students studying in the relevant departments of Karabük University Faculty of Health Sciences.~After providing theoretical information to the students, the cardinal movements of the fetal head within the pelvis during the second stage of labor will be demonstrated in a laboratory setting. Students will be divided into groups of five, and after the demonstration, each student will be asked to perform all stages individually. Approximately 15 minutes will be allocated for each student. Two weeks later, the same students will be brought into the laboratory environment and asked to perform all procedural steps. While performing the steps, a researcher will mark the completed and missing actions on the learner's guide, and any missing steps will be explained to the student and corrected. For the post-test, the Learner's Guide (LG) and SSSCL will be administered"
215008715|NCT06577558|DRUG|SR1375 capsule 3mg+regular treatments|SR1375 capsule 3mg QD orally+CAP regular treatments
215008716|NCT06577558|DRUG|SR1375 capsule 1mg+regular treatments|SR1375 capsule 1mg QD orally+CAP regular treatments
215008717|NCT06577558|DRUG|SR1375 capsule 0.3mg+regular treatments|SR1375 capsule 0.3mg QD orally+CAP regular treatments
215097508|NCT02883062|DRUG|Carboplatin|Given IV
215097509|NCT02883062|PROCEDURE|Lumpectomy|Undergo lumpectomy
215097510|NCT02883062|PROCEDURE|Mastectomy|Undergo mastectomy
215097511|NCT02883062|DRUG|Paclitaxel|Given IV
215097512|NCT02888743|BIOLOGICAL|Durvalumab|Given IV
215097513|NCT02888743|RADIATION|Radiation Therapy|Undergo radiation therapy
215097514|NCT02888743|BIOLOGICAL|Tremelimumab|Given IV
215097515|NCT05863650|DEVICE|Digital based simulation|Algorithms will be created for various musculoskeletal diseases and these algorithms will be controlled by taking the opinions of physiotherapists and physicians who are experts in their fields. After the algorithms are created, a website with patient scenarios containing these algorithms will be established with the support of a software company. In addition to the website, a database will be created and the applications made on the site will be recorded. In this way, the data of users using the website will be collected.
215097516|NCT05863650|OTHER|Face to face education|In the face-to-face education group, one case analyzes will be applied by the students together with the educators themselves in the classroom environment, with the educational content prepared in parallel with the patient scenarios in the simulation-based education group.
215097517|NCT05779007|DRUG|Pirfenidone|Pirfenidone
215097518|NCT05779007|DRUG|Nintedanib|Nintedanib
215097519|NCT04597437|DRUG|Zanamivir|Intravenous zanamivir
215097520|NCT04597437|OTHER|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
215097521|NCT05500807|DRUG|Emicizumab|Subcutaneous injection of emicizumab for prophylaxis
215097522|NCT01424566|DRUG|Nabiximols|
215097523|NCT01424566|DRUG|Placebo (GA-0034)|
215097524|NCT06035458|DIAGNOSTIC_TEST|Diagnostic radiology|Clinical procedures include bone mineral measurement (bone densitometry, dxa) performed according to clinical practice; venipunctures for laboratory assessments (haematology and blood chemistry; bone turnover biomarkers P1NP and CTX).
215097525|NCT04160390|OTHER|Biospecimen Collection-Blood|Undergo collection of blood
215097526|NCT04160390|OTHER|Biospecimen Collection-Stool|Undergo collection of stool
215097527|NCT06679361|BEHAVIORAL|Motor Exercise Program|This program consists of wrist motor exercises focused on active range of motion (including flexion, extension, ulnar and radial deviation, and finger flexion) along with nerve mobilization exercises for the medial, radial, and ulnar nerves. The aim is to enhance motor function in the wrist and hand.
215097528|NCT06679361|BEHAVIORAL|Sensory Exercise Group|Arm Description: This group will engage in sensory exercises designed to enhance sensory awareness in the hand and wrist. Exercises will include interaction with varied textures (such as sand and sensory balls), different fabrics (fur, satin, linen), and multisensory foam gels. The goal is to improve sensory function and tactile discrimination.
215097529|NCT06679361|BEHAVIORAL|Combined Motor and Sensory Exercise Group|Participants in this group will perform both motor and sensory exercises as described for the first two groups. By combining motor and sensory interventions, this group aims to improve both motor skills and sensory awareness in the wrist and hand, potentially enhancing overall hand function more effectively.
215097530|NCT04298424|OTHER|PLSM|The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
215097531|NCT04816721|DRUG|EDP-938|Oral suspension
215097532|NCT04816721|DRUG|Placebo|Placebo oral suspension to match EDP-938
215097533|NCT06854458|DIAGNOSTIC_TEST|Quantitative Myocardial Blood Flow Evaluation|The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.
215097534|NCT06854458|DIAGNOSTIC_TEST|Qualitative Myocardial Blood Flow Evaluation|The perfusion sequence will not produce additional quantitative perfusion maps.
215008718|NCT06577558|DRUG|Placebo capsule+regular treatments|Placebo capsule QD orally+CAP regular treatments
215008719|NCT07056777|DRUG|DR30206|Subjects receive DR30206 intravenously
215008720|NCT07056777|DRUG|Oxaliplatin|Subjects receive Oxaliplatin intravenously
215008721|NCT07056777|DRUG|Capecitabine|Subjects take Capecitabine orally
215008722|NCT07056777|DRUG|Calcium Folinate|Subjects receive Calcium Folinate intravenously
215008723|NCT07056777|DRUG|5-FU|Subjects receive 5-FU by Intravenous Bolus
215008724|NCT07056777|DRUG|Irinotecan (CPT-11)|Subjects receive Irinotecan intravenously
215097535|NCT06854458|DRUG|Gadavist|Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).
215097536|NCT06854458|DRUG|Vasodilator|All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).
215097537|NCT06854458|DIAGNOSTIC_TEST|Blood draw for the laboratory assessment|A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.
215097538|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (800mg). Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
215097539|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice depleted in nitrate|The participant will intake beetroot juice depleted in NO3. Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
215008725|NCT07057453|OTHER|Motivation Engagement for Movement and Interactive Nutrition Development|The intervention includes using of fitness bracelets, a gamified mobile app, a web portal, and regular pediatric check-ups to support healthy habits in overweight children (6-11 years). The bracelets track physical activity, while the mobile app monitors energy balance, encouraging movement and healthy eating through challenges and rewards. The web portal provides family education, and pediatric check-ups track progress and overall health outcomes.
215008726|NCT07056725|OTHER|Manual Therapy and Therapeutic Exercises Programs|A treatment based on the combination of Manual Therapy targeting the orofacial region and a therapeutic exercise program focused on either the cervical or orofacial region
215008727|NCT07056062|DRUG|Calcium carbonate|2,000 mg PO calcium carbonate as a single dose
215008728|NCT06771700|DIAGNOSTIC_TEST|Intraoperative PRAETORIAN Score|The intraoperative PRAETORIAN Score is calculated based on the additional measurements.
215008729|NCT06847165|DEVICE|Trigeminal Nerve Stimulation (TNS)|In TNS, a weak electric current is applied to the child's forehead overnight while sleeping to gently stimulate the brain. TNS treatment is typically administered at home at bedtime by the parent to the child. The TNS device is small (size of a cell phone) and easy to use. Two thin wires go from the device to a pair of small electrodes that tape onto the forehead like a band-aid. The parent presses three keys on the device and it is ready to go.
215008730|NCT06931002|BIOLOGICAL|Rhinovirus A-16 Infection|All participants will be deliberately infected with Rhinovirus A-16
215008731|NCT06906848|DIETARY_SUPPLEMENT|Placebo|Oral
214403352|NCT06572462|DRUG|individualized ATG dosing strategy|Investigators quantified active ATG exposure in 106 haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) recipients, who received a conventional fixed dose of 10 mg/kg ATG during conditioning, the optimal concentration range of active ATG-AUC was determined through the application of machine learning methods, was found to be 100-148.5 × 10\^3 UE·d/L. This concentration range was associated with a reduction in CMV/EBV reactivation, without an increase in acute GVHD or malignant disease relapse. Mathematical function was then exploited to determine the total targeted ATG dose on -3days to -2days based on concentrations of active ATG on -5daysto -4days. Based on this function, investigators established a dosing strategy that aimed to maintain the active ATG-AUC within the optimal range.
214403353|NCT02141347|DRUG|Tremelimumab|Tremelimumab administered intravenously
214403354|NCT02141347|DRUG|MEDI4736|MEDI4736 administered intravenously.
214403355|NCT03043066|PROCEDURE|Scaling and root planing|subjects underwent full mouth supragingival and subgingival scaling
214403356|NCT03043066|DRUG|scaling and root planing along with antibiotic intervention|subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
214403357|NCT02810743|DRUG|ddAC-CP-Olaparib|ddAC-CP-Olaparib
214403358|NCT02810743|DRUG|ddAC-mini CTC|ddAC - mini CTC
214403359|NCT05950906|DRUG|PDM608|PDM608 subcutaneous at single or multiple dose(s) assigned by cohort
214403360|NCT05950906|DRUG|Placebo|Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.
214403361|NCT01725867|OTHER|PT program|manual myofascial release for craniomandibular system for 30\~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
214403362|NCT01725867|DEVICE|oral appliance|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
214403363|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
214403364|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
214403365|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
214403366|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
215008732|NCT06906848|DIETARY_SUPPLEMENT|Cognizin®|Oral
215008733|NCT05571254|OTHER|Data collection|All patients will have a focussed Case Report Form completed collecting routine data describing the prevalence, clinical presentation, assessment, management and ESC risk category of patients, at the time or shortly after the patients ED attendance.
215008734|NCT06505642|DEVICE|needle-based confocal laser endomicroscopy|needle-based confocal laser endomicroscopy at the tip of the TBNA needle for two punctures, combined with confirmatory CBCT spin for tool-in-lesion confirmation
215008735|NCT01281072|OTHER|vaccine|
215008736|NCT04611412|OTHER|Risk Factors|BMI in children and adolescents was compared with percentile charts developed by who for children from 5 to 19 years of age (WHO Growth Reference, 2007). Body mass index was defined as the ratio of body weight (in kg) to body length in the supine position or height in the standing position (m2).
214403367|NCT04669080|BEHAVIORAL|Health care provider cost navigation training|Health care providers and asthma educators in a pediatric asthma clinic will receive an online training about the importance of cost of care conversations, how to start cost of care conversations with families, how to refer families to cost navigation resources, and how to lead asthma specialty care teams in cost navigation.
214403368|NCT05886738|OTHER|Fasting|Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.
214403369|NCT01174992|BIOLOGICAL|Evicel|EVICEL is a human plasma derived fibrin sealant
215008737|NCT00000839|DRUG|Didanosine|
215008738|NCT06426888|OTHER|Experimental interventional group 1(scapular stabilization exercise therapy)|"Ball stabilization exercise: While standing close to the wall, the participant will be asked to position her affected hand on the ball and keep the ball from moving as disturbance will be applied in different directions.~Wall push up: While facing wall patient will be asked to place both hands on wall, shoulder width apart. He will be instruct to breath in, bend his elbows, lean into wall and hold this position for one second then breath out slowly push back until arms are straight again Wall slides~• Patient will be asked to lean his head, upper thorax and butts against the wall, place his hands and arms against the wall in high five position."
214403370|NCT01174992|OTHER|Sutures only|Standard of care
214403371|NCT02511704|DRUG|Nicotine|Multiple dose nicotine
214403372|NCT02511704|DRUG|Nicotine|Multiple dose nicotine
214403373|NCT03738241|BIOLOGICAL|A/H7N9|Monovalent split 2017 A/H7N9 Inactivated Influenza Virus Vaccine containing the Hemagglutinin (HA) and Neuraminidase (NA) from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1). The HA content of the 2017 A/H7N9 vaccine formulations were determined by Single Radial Immunodiffusion (SRID) assay to be approximately two times higher (14.45 mcg of HA per 0.5 mL dose) than the targeted HA content on the label (7.5 mcg of HA per 0.5 mL dose).
214403374|NCT03738241|DRUG|AS03|AS03 oil-in-water emulsion-based adjuvant system containing DL-alpha-tocopherol, squalene, polysorbate 80, and a buffer.
215097540|NCT06815302|BEHAVIORAL|Experimental intervention|Specific participant procedures in experimental and active control interventions are simplified to preserve study blinding.
215097541|NCT06815302|BEHAVIORAL|Active intervention|Specific participant procedures in experimental and active control interventions are simplified to preserve study blinding.
215097542|NCT00026312|BIOLOGICAL|Aldesleukin|Given IV
215097543|NCT00026312|BIOLOGICAL|Dinutuximab|Given IV
215097544|NCT00026312|DRUG|Isotretinoin|Given PO
214403375|NCT03738241|OTHER|Phosphate Buffered Saline (PBS) diluent|0.006M PBS diluent for Influenza Virus Vaccine.
215008739|NCT06426888|OTHER|Experimental :interventional group II (scapular mobilizations)|"Patient lies on unaffected side close to the edge of the treatment bench with hips and knees bent for stability.~Therapist will start by supporting the patient arm on his/her forearm so that shoulder is in maximally loose pack position.~Then he/she will grab on the scapula with both hands. One hand supports the scapula from cranial around the acromion and scapular spine and other hand from the caudal at the inferior angle of scapula.~Then both hands move the scapula cranially over the thorax into elevation and caudally into the depression, upward/downward rotation as well as retraction and protraction."
214403376|NCT06283602|DIAGNOSTIC_TEST|oral health status|the dentists examined the dried teeth with a probe and mount mirror in a dental unit.
214403377|NCT04230161|OTHER|Standard long-lasting insecticidal net|Yahe LN (Yamei Industry) contains a pyrethroid insecticide.
214403378|NCT04230161|OTHER|Chlorfenapyr insecticide treated net|Interceptor G2® (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
214403379|NCT04230161|OTHER|Indoor residual spraying|Fludora Fusion (Bayer Vector Control) is a spray containing two active ingredients: clothianidin, a neonicotinoid insecticide, and deltamethrin, a pyrethroid insecticide.
214403380|NCT01238796|DRUG|telavancin|Intravenous
215097545|NCT00026312|OTHER|Laboratory Biomarker Analysis|Correlative studies
214403381|NCT05032235|DRUG|Fluzoparib|Normal Renal Function:A single oral dose of Fluzoparib will be administered.
215008740|NCT06964399|OTHER|Reminiscence therapy|Reminiscence Therapy can be applied as 1 or 2 sessions per week and the longest is 1.5 hours, so it will be applied for 5 weeks, 3 days a week (Monday, Wednesday, Friday) with 2 sessions per day. Each session is planned to last an average of 1.5 hours according to the answers from the elderly. The elderly individuals in the experimental group will be divided into 3 groups. Each group will consist of 15 people. The sessions will include, respectively, getting to know each other, childhood, places lived, holidays-festivals, foods-cooking, unforgettable historical periods, favorite music, movies specific to the period, family life-values in life-achievements, evaluation and closing topics.
215008741|NCT05291481|BEHAVIORAL|CAPAS-yOUTH|11-week parent training intervention exclusively delivered to parents
215097546|NCT00026312|OTHER|Pharmacological Study|Correlative studies
215097547|NCT00026312|OTHER|Quality-of-Life Assessment|Ancillary studies
214403382|NCT05032235|DRUG|Fluzoparib|Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
214403383|NCT05032235|DRUG|Fluzoparib|Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
214403384|NCT03871881|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging (MRI) of the brain's macro- and microstructures. Furthermore, brain regional interactions and activity is examined with quantitative functional-MRI (fMRI)
214403385|NCT03871881|OTHER|Neuropsychological assessment|A special designed neuropsychological test battery of validated tests to assess function of cognitive domains
214403386|NCT04255875|BIOLOGICAL|Placebo|Participants will receive matching placebo
214403387|NCT04255875|BIOLOGICAL|PF-07209326|Participants will receive SC or IV single ascending doses
214403388|NCT04255875|BIOLOGICAL|PF-07209326|SCD participants will receive a multiple dose of subcutaneous PF-07209326
214403389|NCT00554164|DRUG|(R-)CHOP protocol|Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
214403390|NCT00554164|DRUG|B-ALL protocol|Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).
215008742|NCT04676776|DRUG|Levonorgestrel|All participants receive 1.5 mg levonorgestrel on day 1
215008743|NCT04676776|DRUG|Mifepristone|All participants receive 200 mg mifepristone on day 3
215097548|NCT00026312|BIOLOGICAL|Sargramostim|Given IV or SC
215097549|NCT06987890|OTHER|Practical Geriatric Assessment|The Practical Geriatric Assessment (PGA) is an abridged version of the Comprehensive Geriatric Assessment (CGA). This tool can be completed by any provider within 10-25 minutes while still capturing the key domains of the CGA. This screening tool, which is now recommended by American Society of Clinical Oncology (ASCO), the International Society for Geriatric Oncology (SIOG), and the Cancer \& Aging Research Group (CARG), has the potential capacity to delineate relevant baseline features in geriatric populations without creating undue provider burden.
215097550|NCT06987383|DRUG|Vibegron|A drug in a class of medications called beta-3 adrenergic agonists; approved for use with Overactive Bladder; 75mg tablets will be used in this study
215097551|NCT06987383|DRUG|Placebo|Tablets made of inert substance that looks like the vibegron tablets but has no therapeutic value
215097552|NCT05081219|DRUG|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
215097553|NCT05081219|DRUG|Empagliflozin 10 MG|Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.
215097554|NCT05081219|DEVICE|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
215097555|NCT05081219|DRUG|Placebo (Insulin Diluent)|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
215097556|NCT05081219|DRUG|Placebo (Capsules)|Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
215097557|NCT00424697|DRUG|placebo|
215097558|NCT00424697|DRUG|lorazepam|
215097559|NCT00424697|DRUG|GW876008|
215097560|NCT01638546|OTHER|Laboratory Biomarker Analysis|Correlative studies
215097561|NCT01638546|OTHER|Placebo Administration|Given PO
215097562|NCT01638546|DRUG|Temozolomide|Given PO
215008744|NCT03022630|OTHER|Comprehensive Palliative Care services|Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
215008745|NCT03022630|OTHER|Usual hepatic care|Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
215008746|NCT02760511|DIETARY_SUPPLEMENT|Anthocyanin|Capsules with different anthocyanin content
215008747|NCT02760511|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
215008748|NCT02372032|PROCEDURE|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
215008749|NCT02372032|PROCEDURE|ozone therapy|percutaneous intradiscal ozone injection
215008750|NCT03587116|DRUG|Standard of Care FIX Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
215008751|NCT03587116|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
215008752|NCT05266950|BIOLOGICAL|CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)|Recommended lymphodepletion regimen: cyclophosphamide (250 mg/m2/d, ×3d) and fludarabine (30 mg/m2/d, ×3d). If the patient has a hematological toxicity of grade 3 or higher, the alternative regimen is: cyclophosphamide (125mg/m2/d, ×3d) and fludarabine (15 mg/m2/d, ×3d). During lymphodepletion, physicians can give anti-myeloid drugs such as demethoxydaunorubicin or daunorubicin as appropriate.
215008753|NCT04165980|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
215008754|NCT02379897|OTHER|Diet|
215008755|NCT06514248|DEVICE|V5med Lung AI|"During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed on the left window and the same original without any AI mark with be display on the right window. Deeming a nodule, the radiologist will mark location. These may or may not correspond to the locations of the CADe markers. As in the baseline study, the radiologist will assign a level of suspicious to each mark and provide a Lung-RADS score and the size of longest dimension."
215008756|NCT04197505|BEHAVIORAL|FLIR E95 camera|Video will be recorded during the thermal reading for later computer analysis. The following variables will be analyzed: (1) the difference between the mean temperature between the injured and healthy extremities, (2) the difference between the maximum temperatures of both the injured and healthy extremities (ΔTmax), and (3) the difference between the area covered by each isotherm in both the injured and uninjured extremities (Δpix). FLIR software tools and MATLAB software will be used for the analysis.
215008757|NCT05226689|DEVICE|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert
215008758|NCT00088881|BIOLOGICAL|rituximab|Given IV
215008759|NCT00088881|DRUG|prednisone|Given orally
215008760|NCT00088881|DRUG|cyclophosphamide|Given IV
215008761|NCT00088881|DRUG|doxorubicin|Given IV
215008762|NCT00088881|DRUG|vincristine|Given IV
215008763|NCT00088881|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
215008764|NCT00088881|RADIATION|radiation therapy|Undergo radiotherapy
215008765|NCT00088881|PROCEDURE|positron emission tomography|Undergo PET scans
215008766|NCT04567355|BEHAVIORAL|Migraine Manager|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
215008767|NCT04204642|OTHER|CAA patients data collection|Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
215008768|NCT02127541|OTHER|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|Comparison of different imaging modalities
215008769|NCT05487495|BIOLOGICAL|CD5 CAR T (CT125B)|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
215008770|NCT01561105|OTHER|IMPACT|IMPACT is a collaborative care management program for late-life depression
215008771|NCT03763383|PROCEDURE|Lateral Arm Flap|Its a kind of flap that is harvested from the lateral aspect of the arm to cover defects in different parts of the body
215097563|NCT01638546|DRUG|Veliparib|Given PO
215097564|NCT05432804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215097565|NCT05432804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215097566|NCT05432804|DRUG|Selinexor|Given PO
215097567|NCT05432804|DRUG|Temozolomide|Given PO
215097568|NCT03367741|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
215097569|NCT03367741|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215097570|NCT03367741|DRUG|Cabozantinib S-malate|Given PO
215097571|NCT03367741|PROCEDURE|Computed Tomography|Undergo CT scan
215097572|NCT03367741|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215097573|NCT03367741|BIOLOGICAL|Nivolumab|Given IV
214403391|NCT00554164|DRUG|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
214403392|NCT00554164|DRUG|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
214403393|NCT03625011|DRUG|Gabapentin|This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.
214403394|NCT04155099|BIOLOGICAL|RBX7455|RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.
214403395|NCT04155099|BIOLOGICAL|Placebo|Capsule with cellulose filler
215008772|NCT05524909|GENETIC|Genetic Risk Estimate|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).
214403396|NCT03029338|BIOLOGICAL|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
214403397|NCT02788656|DEVICE|Implantable Hemodynamic Monitor|The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.
214403398|NCT02788656|DRUG|Angiotensin-Converting Enzyme Inhibitor|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
215008773|NCT05524909|DEVICE|Genetic Risk Estimate + Fitbit Functions|"The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate."
215008774|NCT01789021|DEVICE|4 blood glucose monitoring systems|
215008775|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - with Virtual Coach Botley|Bootle Boot Camp exercise sessions offered with movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the no feedback condition for a period of 4 weeks (4 sessions/week). Movement feedback will be guided by skeletal data captured by the 3D motion tracking camera and based on predefined movement acceptability criteria for each exercise. Feedback will take the form of visual markers, text/audio cues and rewards.
215008776|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - without Virtual Coach Botley|Bootle Boot Camp exercise sessions offered without movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the movement tracking feedback condition for a period of 4 weeks (4 sessions/week).
215008777|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
215008778|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label) + placebo dose titration (blinded)
215008779|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label)
215008780|NCT06278805|OTHER|The reliability and validity study of the T-LUNS|To test the reliability and validity of the T-LUNS, 110 chronic stroke survivors fulfilling the inclusion / exclusion criteria at the 3 study sites will be assessed. The assessment of each patient will include recording of the demographic and clinical characteristics and administration of the T-LUNS as well as the Turkish version of the Stroke Impact Scale 3.0 (SIS). For the assessment of test-retest reliability of the T-LUNS, half of the participants (n= 55) will fill in the T-LUNS again, 2 weeks after the first administration.
215008781|NCT03197155|DRUG|Direct Acting Antivirals against hepatitis C virus infection|The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
215008782|NCT00768859|DRUG|paclitaxel, trastuzumab and carboplatin|paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
215008783|NCT03940677|PROCEDURE|Brain MRI|3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI
215008784|NCT03940677|PROCEDURE|TMS-EEG|Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study
215008785|NCT03940677|BEHAVIORAL|Behavioral and cognitive battery|Emotional, attentional and behavioral assessment using predefine scales and measures
215097574|NCT06993350|OTHER|experimental group|eight weeks of targeted weight bearing program
215097575|NCT06409052|BEHAVIORAL|Qualitative interviews|Interviews will be conducted for approximately 45-60 minutes
214403399|NCT02788656|DRUG|Angiotensin II Type 1 Receptor Blocker|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients
214403400|NCT02788656|DRUG|sacubitril/valsartan|Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
214403401|NCT03169361|DRUG|Ixazomib|Ixazomib capsules
214403402|NCT02263885|DEVICE|ExAblate Transcranial System|Transcranial MRgFUS
214403403|NCT02402972|DRUG|FUDR +oxaliplatin|IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein
214403404|NCT02402972|DRUG|oxaliplatin+Leucovorin+5-FU|Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
214403405|NCT05551962|PROCEDURE|Soft tissue augmentation with CTG|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Sampling of free connective tissue graft from the maxilla tuber area~4. Fixation of the graft to the vestibular flap~5. Suturing the wound tightly"
214403406|NCT05551962|PROCEDURE|Soft tissue augmentation with CM|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly"
214403407|NCT02695043|BEHAVIORAL|RRTBIMS|TBI patients discharged from Bellevue inpatient rehabilitation and enrolled in the Rusk Rehabilitation Traumatic Brain Injury Model System (RRTBIMS)
214403408|NCT02695043|BEHAVIORAL|Multimedia Multicultural Educational Program for TBI (MMEPT)|
214403409|NCT03174093|BEHAVIORAL|MATCh AFib application|The application comprehends five steps: (1) An educational video about how AF can cause stroke; (2) A calculator of risk scores (CHA2DS2-VASc, HAS-BLED and SAMe-TT2R2); (3) A screen with pictograms to allow better understanding of the scores by patients and to demonstrate how much each anticoagulant can decrease stroke risk or increase bleeding risk; (4) A summary about types of medications available, and (5) An output formulary in which the physician can register patient's contact to continue receiving information about atrial fibrillation and anticoagulation through SMS. Physicians can save patient's history of INR tests and previous doses of anticoagulation prescribed and also use a calculator to adjust the dose.
214403410|NCT00088465|DRUG|Intramuscular olanzapine depot|45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
214403411|NCT03337750|BEHAVIORAL|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
214403412|NCT03845764|DIAGNOSTIC_TEST|Rapid on-site evaluation|Specimens obtained with endoscopic sampling procedures are stained with a rapid method (i.e., Diff Qui) and submitted to on-site cytologic review
214403413|NCT04768062|DRUG|Viltolarsen|Received during weekly intravenous infusions
214403414|NCT01724203|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|
214403415|NCT01724203|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
215008786|NCT03940677|OTHER|Clinical evaluation and clinical scales|Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS
215008787|NCT00688779|DRUG|AZD8848|Concentrate for nasal spray,solution 60 mg/g
215008788|NCT00688779|DRUG|Placebo|
215097578|NCT06597799|DRUG|MRT-6160|Orally administered tablets or capsules of MRT-6160
215097579|NCT06597799|DRUG|Placebo|Orally administered tablets or capsules of placebo
215097580|NCT07000734|BEHAVIORAL|Risk managment|Behavioral lifestyle changes including an exercise program, healthy eating recommendations, reviewing medical management for cardiometabolic risk conditions, deprescribing review for brain toxic meds, online cognitive training, as well as recommendations to improve sleep quality, or smoking cessation as needed
215097581|NCT07000734|DRUG|Dasatinib|dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial
215097582|NCT07000734|DIETARY_SUPPLEMENT|Quercetin (dietary supplement)|e intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial
214403416|NCT01724203|DIETARY_SUPPLEMENT|Placebo|
214403417|NCT05355922|OTHER|Electrical electrostimulation of the quadriceps muscle|Exercises associated with electrical electrostimulation of the quadriceps muscle of patients with knee osteoarthritis
214403418|NCT05355922|OTHER|Electrical electrostimulation of the quadriceps muscle (placebo)|Exercises associated with electrical electrostimulation (placebo) of the quadriceps muscle of patients with knee osteoarthritis
215008789|NCT04027387|BIOLOGICAL|TMB-365|An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
215097583|NCT07000734|DRUG|Vortioxetine|Participants will be prescribed vortioxetine to take daily, in combination with online cognitive training
215097584|NCT05453513|BEHAVIORAL|MRI Study|fMRI Tasks
215097585|NCT00050674|DRUG|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
215097586|NCT05719714|DRUG|Dapagliflozin 10 MG [Farxiga]|10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
214403419|NCT01491529|DRUG|AFQ056|"AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~* Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~* Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
214403420|NCT01491529|DRUG|Placebo|Placebo for AFQ056 will be supplied as oral tablets.
214403421|NCT02616354|DRUG|Imipenem|Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
214403422|NCT02942901|PROCEDURE|PET-CT|
214403423|NCT02275936|DRUG|N91115|S Nitrosoglutathione Reductase Inhibitor
214688254|NCT07164040|DEVICE|The GLOW800, a non-contact, non-invasive device, allows the surgical microscope ARveo 8 and ARveo 8X to produce excitation light and resolve fluorescence emission from the fluorescent agent ICG|When activating the GLOW800 mode, the white light illumination of the Leica microscope stand is extended to InfraRed (IR), to excite the fluorophore (ICG). The technology provides ergonomic advantages as the user can maintain an upright posture while observing the surgical field. To excite the fluorophore, ICG dye is illuminated with light at its excitation wavelength band around 750 - 800nm. GLOW800 utilizes a 400w xenon illumination light source integrated as a standard component within the compatible Surgical Operating Microscope (SOM) stand. Activation of the GLOW800 mode extends the white light illumination of the SOM to the infrared (IR) spectral range using a suitable filter placed in the compatible SOM's standard filter wheel for the excitation of the ICG. Each patient enrolled in this study will undergo standard of care for the surgical procedure. No deviations to the standard of care will occur in the execution of this study.
214688255|NCT07163260|OTHER|No treatment given|No treatment given
214403424|NCT00821925|PROCEDURE|bone densitometry|All patients do a bone densitometry after the inclusion.
214403425|NCT02728219|PROCEDURE|TACE|In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)
214403426|NCT02728219|PROCEDURE|Hepatectomy|Repeat Hepatectomy after postoperation recurrence
214403427|NCT02474615|PROCEDURE|ENDODONTIC SURGERY|ENDODONTIC SURGERY
214403428|NCT02688621|BEHAVIORAL|Internet Only|18 month behavioral weight loss intervention delivered online
214403429|NCT02688621|BEHAVIORAL|Internet + Incentives|18 month behavioral weight loss intervention delivered online with the possibility of earning incentives for losing weight and performing weight loss behaviors including monitoring food intake, exercising, and daily weighing
214403430|NCT05698940|PROCEDURE|Infundibultomy|Infundibultomy on one side of patient
214688256|NCT07162350|BEHAVIORAL|Food Navigation|"For those randomized to the FAME Intervention, it will begin with a Community Health Worker (CHW) Food Navigator consultation. The role of the Food Navigators is as follows:~1. Identify the top dietary and food needs of the participant and their family. The Food Navigator will perform a needs assessment to define food access, kitchen resources/capacity, and other social determinants of health.~2. Set realistic, participant and family-driven nutrition goals. The Food Navigator will utilize Motivational Interviewing (MI), an evidence-based method of counseling that promotes motivation for change.~3. Provide nutrition resources and referrals.~4. Support children and families for up to 12 months."
215008790|NCT05957341|DEVICE|active rTMS: 20min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 20 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
215008791|NCT05957341|DEVICE|active rTMS: 50min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 50 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
215008792|NCT05957341|DEVICE|sham rTMS: 20min inter-session interval|The parameters in this group are the same as in the active rTMS: 20min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
215008793|NCT05957341|DEVICE|sham rTMS: 50min inter-session interval|The parameters in this group are the same as in the active rTMS: 50min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
215008794|NCT02737059|DRUG|Naloxegol|25mg daily
215008795|NCT02737059|DRUG|Codeine|30mg 4 times daily
215008796|NCT02737059|DRUG|codeine placebo|4 times daily (placebo will be made to match the codeine)
215008797|NCT02737059|DRUG|naloxegol placebo|placebo will match naloxegol, given daily
215008798|NCT01078428|OTHER|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
215008799|NCT01078428|OTHER|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
214403431|NCT03132714|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
214403432|NCT03132714|DRUG|Amoxicillin 500mg|Administration of Amoxicillin 500mg tid for 7 days
214403433|NCT03132714|DRUG|Metronidazole 400mg|Administration of Metronidazole 400mg tid for 7 days.
214403434|NCT03132714|DRUG|Clarithromycin 500mg|Administration of Clarithromycin 500mg bid for 7 days
214403435|NCT03132714|PROCEDURE|Single application of PDT|Single application of photodynamic therapy (PDT) at day 0.
214403436|NCT03132714|PROCEDURE|Repeated application of PDT|Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.
214403437|NCT03311854|DRUG|Emapalumab|Emapalumab was administered at an initial dose of 6 mg/kg by intravenous infusion. Emapalumab treatment continued at a dose of 3 mg/kg, every 3 days until study day 15, and then twice-a-week for an additional 2 weeks, i.e., until study day 28. The emapalumab regimen could be adapted (the frequency between infusions shortened, the dose increased, or the treatment prolonged beyond 4 weeks) upon assessment of a favourable benefit-risk profile. There was a 4-week off-drug follow-up period (up to Week 8).
214403438|NCT05748795|PROCEDURE|bronchoscopy brochoalveolar lavage|"* 2%lidocaine gel will be used to anaesthesize nasal mucosa.6ml lidocaine 2%diluted in 5cc normal saline lidocaine spray solution will be used for anaesthesizing the vocal cords and mucosa of the bronchial tree(13).~* Intravenous midazolam (0.01-0.1mg\\kg) will be given to achieve conscious sedation in selected cases(13).~* Flexible Bronchoscopy will be done under continuous monitoring for O2 saturation, heart rate, blood pressure and respiratory rate.~* The bronchoscope will be introduced into the nasal cavity and advanced to the level of the vocal cords. Lidocaine will be instilled through the bronchoscope to the vocal cords and tracheobronchial tree.~* Using sterile bronchoscope in the lobar bronchus of tumor location,100 mL of sterile normal saline in fractionated doses will be injected and then BAL will be removed by suction to be collected in sterile side-way bottles."
214403439|NCT01896011|BIOLOGICAL|Teriparatide 20 mcg|Teriparatide 20 mcg injection pen
214403440|NCT01896011|OTHER|Placebo|Placebo 20 mcg injection pen
214403441|NCT04838821|BIOLOGICAL|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
214403442|NCT04838821|BIOLOGICAL|placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
214403443|NCT03047603|DIAGNOSTIC_TEST|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
214403444|NCT02083640|DRUG|Palbociclib Formulation Reference|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
214403445|NCT02083640|DRUG|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
215008800|NCT03924297|DEVICE|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
215008801|NCT01546298|OTHER|Patch tests|Patch tests for allergic reaction
214403446|NCT02083640|DRUG|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
215008802|NCT02927145|BIOLOGICAL|RH5.1/ ASO1|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."
215008803|NCT05599425|BEHAVIORAL|Enhanced Healthy Living Education|24-session healthy living education program, with enhanced content about health beliefs and mechanisms of behavior change
215008804|NCT05599425|BEHAVIORAL|Basic Healthy Living Education|24-session healthy living education program
215008805|NCT00133354|DRUG|Arimidex (Anastrozole)|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
215008806|NCT00133354|DRUG|Placebo|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
215008807|NCT00133354|DRUG|Growth Hormone|GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of \~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
215008808|NCT04079725|PROCEDURE|Combined trabeculotomy-trabeculectomy with mitomycin c|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease
215008809|NCT00169403|PROCEDURE|Deep brain stimulation|
215008810|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
215008811|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
215008812|NCT03017261|DEVICE|TSolution One®|Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
215008813|NCT00818272|BIOLOGICAL|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
215008814|NCT01597232|OTHER|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
215008815|NCT01597232|OTHER|Maintenance of hemoglobin level more than 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively
214403447|NCT06391203|PROCEDURE|Long-term Drainage|After drilling or puncture, the drainage catheter is indwelling continuously and keeps to drainage for 7 days. Keep incision sterility, record the daily fluid drainage flow, and perform biochemical and bacterial culture identification tests for CSF regularly. Removing drainage catheter when the allocated time is reached. If there is still unabsorbed effusion after the allocated time is reached, the catheter placement time is extended and the relevant information is recorded.
214403448|NCT06391203|PROCEDURE|Short-term Drainage|After drilling or puncture, the drainage catheter is indwelling continuously and keeps to drainage for 2 days. Keep incision sterility, record the daily fluid drainage flow, and perform biochemical and bacterial culture identification tests for CSF regularly. Removing drainage catheter when the allocated time is reached. If there is still unabsorbed effusion after the allocated time is reached, the catheter placement time is extended and the relevant information is recorded.
215008816|NCT01597232|OTHER|Transfusion trigger based on experience|Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
214403449|NCT02307123|PROCEDURE|Intubation|HEMS physician prehospital intubation
214403450|NCT00220935|DEVICE|Orthotrac Pneumatic Vest|
214688257|NCT07163663|OTHER|Hight intensity functional trainning|"Warm-up phase: Low-intensity walking 30-50% MHR combined with dynamic mobility exercises~High Intensity Functional Training (HIFT)~The raised HIFT intervention proposal is divided into three exercises:~1. Strength exercise of the lower limbs such as Sit to Stand / Stand to sit and elevation of the upper limbs up in a standing position or lateral gait with knee flexion of one limb among many others.~2. Upper limb strength exercises: In a standing position with a medicine ball and in front of the wall, throw the ball against it and catch it o Walk while taking the medicine ball from right to left with smooth rotation of the trunk among many others.~3. Coordination and balance exercises: Go up and down stairs or steps in four steps with arms stretched out in front of you and exercises such as standing, knee flexion and raising the contralateral hand with weights.~Cooling phase: Stretching of upper and lower limb muscle groups and head and neck muscles."
214688258|NCT07161765|DEVICE|Rectal Expulsion Device (RED)|"Enrolled participants will complete surveys prior a standard of care visit at the University of Michigan.~Gastroenterology staff will perform the RED device at the time of a participant's anorectal manometry appointment."
215008817|NCT00327535|DRUG|Darbepoetin alfa|According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)
215008818|NCT00327535|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|6.3 micrograms/kg every 3 weeks
215008819|NCT00327535|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|9 micrograms/kg every 3 weeks
215008820|NCT00327535|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|12 micrograms/kg every 3 weeks
215008821|NCT05019053|BEHAVIORAL|Coping Crew|Coping Crew consists of five 60-minute virtual intervention sessions coinciding with five weeks of EMI. Participants will receive psychoeducation, challenge cognitive biases or mythbust, and participate in behavioral exposure and behavioral experiments. An EMI component of this treatment will be included for the purpose of treatment monitoring and homework tracking. Participation in this EMI component involves the daily report of levels of anxiety, depression, stress, and loneliness. When participants endorse elevated levels on any of these constructs, they will receive a targeted message reminding them of the topics covered in COPING CREW. One month after the intervention session, COPING CREW participants will complete follow-up questionnaires and interview. Participants will also participate in a feedback session 3 months after the intervention.
215008822|NCT04723368|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=5 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 14 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
215008823|NCT04132180|OTHER|Early Mobilization|Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
215008824|NCT04132180|OTHER|Late Mobilization|The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
215008825|NCT02506036|OTHER|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
214688259|NCT07163910|DRUG|homoharringtonine|Intravenous infusion of 1mg homoharringtonine plus 250ml of 5% glucose injection, administered once daily for two consecutive days.
214688260|NCT07163910|PROCEDURE|Radical prostatectomy|All patients will undergo radical prostatectomy within 3 weeks (±7 days) after the completion of treatment.
214688261|NCT07162584|DRUG|Oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
214688262|NCT07162584|DRUG|Placebo|intranasal administration of placebo (24 IU)
215008826|NCT00530075|DRUG|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
215008827|NCT00319891|PROCEDURE|Computer-based Cognitive Training|
215008828|NCT04015687|DRUG|AG-881|Supplied as uncoated tablets.
215008829|NCT04015687|DRUG|Lamotrigine|Supplied as tablets of LAMICTAL® or generic equivalent.
215008830|NCT03426007|PROCEDURE|Uterine lavage|embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
215008831|NCT01160900|PROCEDURE|Coronary angioplasty all lesions|treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
214403453|NCT04571073|PROCEDURE|Fascial Distortion Model|"Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity."
214403454|NCT01278693|DRUG|L-carnitine|500 mg,twice daily, 16 weeks
214403455|NCT01278693|DRUG|placebo|500 mg,twice daily, 16 weeks.
214403456|NCT04962100|OTHER|Analysis of capacitation-associated tyrosine phosphorylation in human sperm by flow cytometry|"After the assessment of the macroscopic and microscopic characteristics of the sample, we will wash the sample and process it using three layers of density gradients.~In the case of samples for diagnostic analysis, the remaining volume will be incubated in at 37ºC, and 0.1-0.2 ml aliquots will be taken from the end of the processing at t0 (just before introducing the sample in the incubator), at t1 (after one hour of incubation) and at t3 (after 3 hours of incubation). Additionally, a sample will be taken after washing, prior to processing the sample with the density gradients. In the case of samples processed for insemination, an additional aliquot will be taken at the exact moment in which the insemination is carried out and the elapsed incubation time will be noted.~The evaluation of the capacitation will be carried out by analyzing the state of phosphorylation of tyrosines by flow cytometry."
214403457|NCT04313348|BEHAVIORAL|eMobilize-Uganda application|"Arm 1 is the Control arm. Participants will receive no SMS reminders nor social supporter notifications. Arm 2, Scheduled SMS arm: Will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda CommCare application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery will be sent to participants. The content of the SMS reminders will be customized at enrolment. Arm 3 social support engagement arm: Will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information through the eMobilize-Uganda CommCare application or messaging + weekly SMS reminders + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for all the study follow-up period."
214403458|NCT00180674|DRUG|Warfarin|
214403459|NCT02194218|DRUG|Nevirapine, low dose|50 mg
214403460|NCT02194218|DRUG|Nevirapine, high dose|100 mg
214403461|NCT05428579|PROCEDURE|Retroperitoneal Liposarcoma resection|Retroperitoneal Liposarcoma resection
214403462|NCT03706963|OTHER|Phone Call|-phone call 7 days (+/- 2 days) into preoperative period
214403463|NCT02536690|DRUG|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
214403464|NCT02536690|DRUG|Remifentanil|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
214403465|NCT02536690|DRUG|Midazolam|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
214403466|NCT01192490|DRUG|Lidocaine|5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena
214403467|NCT01192490|DRUG|Lubricant|KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
214403468|NCT06056154|DEVICE|LIO ASQELIO TM monofocal QLIO130C|Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
214688263|NCT07163325|DRUG|EP102|EP102 will be administered orally
215008832|NCT04073576|DEVICE|AHCL|Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
215008833|NCT04073576|DEVICE|SAP+PLGM|Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
215008834|NCT04370600|DRUG|beta hydroxybutyrate (BHB) ester|Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)
215008835|NCT04370600|DRUG|Placebo|Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
215008836|NCT05018559|BEHAVIORAL|BuG lesson|Participants of the intervention group in nursing care received a co-created setting-specific intervention to promote physical activity called BuG lesson. The BuG lesson comprises a weekly 90-minute lesson for apprentices of nursing care during regular school hours, covering physical activity and health in theory and practice. Previously, the nursing teachers voluntarily underwent a qualification process as physical activity instructors, enabling them to conduct the BuG lessons independently.
214403469|NCT00649662|DRUG|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fasting
214403470|NCT00649662|DRUG|Cipro® XR Tablets 1000 mg|1000mg, single dose fasting
214688264|NCT07162246|RADIATION|Radiation Therapy|Adaptive radiation therapy with GK boost
214688265|NCT07161973|DIETARY_SUPPLEMENT|Beetroot Juice - Active|Nitrate-rich beetroot juice
214688266|NCT07161973|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Without Nitrate|Nitrate-free beetroot juice
214403471|NCT01899560|PROCEDURE|Measure lung and chest wall elastance with esophageal catheter|"Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated \[9\]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.~A low flow pressure/volume curve from 0 to 40 cmH2O will be performed."
214403472|NCT01899560|OTHER|non-invasive method for measuring the lung elastance|by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
214403473|NCT03950401|PROCEDURE|Monocryl|subcuticular Monocryl wound closure
214403474|NCT03950401|PROCEDURE|Nylon|wound closure using nylon suture on the skin
214403475|NCT02438774|BEHAVIORAL|post-harvest intervention package|The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
214403476|NCT02438774|BEHAVIORAL|Routine agriculture extension services|This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
214403477|NCT03089372|DEVICE|ARIES-ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
214403478|NCT01472627|PROCEDURE|Blood draws|Blood draws
215008837|NCT05018559|BEHAVIORAL|Tutoring system|Participants of the intervention group in automotive mechatronics received a co-created setting-specific intervention to promote physical activity called tutoring system. In the tutoring system, automotive mechatronics apprentices act as physical activity promotors for their fellow apprentices. In the sense of a peer-to-peer approach, apprentices voluntarily participate in a workshop to be qualified as tutors. Subsequently, the tutoring system takes place every two weeks for about ten to fifteen minutes during regular working hours, allowing the tutors to discuss the issues of physical activity and health among their peers.
215008838|NCT00758043|DRUG|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
215097587|NCT06624540|BEHAVIORAL|This is a pre- and post- quasi-experimental study.|We will use new equipment and implement EBP (VAP management) for patients by trained nurses (Phase 2) and check the outcome of the patients. We will compare our phase 1 findings for this study as historical data.
214403479|NCT02490930|DRUG|Fingolimod|Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
214403480|NCT04488172|DIETARY_SUPPLEMENT|Multi-vitamin supplementation|Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day
214403481|NCT01831492|DEVICE|zeolite + dolomite|Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
214403482|NCT01831492|DEVICE|cellulose|given for 14 weeks
214403483|NCT03391167|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
214403484|NCT03391167|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
214403485|NCT04428086|DRUG|Apatinib in arm1|Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.
214403486|NCT04428086|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.
214403487|NCT04428086|DRUG|Apatinib in arm2|Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.
214403488|NCT04428086|DRUG|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.
214403489|NCT00618670|BEHAVIORAL|Walking Exercise|Three times per week for 3 months
214688267|NCT07162636|OTHER|NMES+|To treat and rehabilitate sarcopenia, participants will undergo physical therapy sessions, using resistance exercises combined with the use of NMES
214688268|NCT07162636|OTHER|NMES -|To treat and rehabilitate sarcopenia, participants will undergo physical therapy sessions using only resistance exercises.
215008839|NCT00758043|DRUG|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
215008840|NCT00758043|BIOLOGICAL|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
215008841|NCT00442689|DRUG|flutamide|250 mg twice daily
215008842|NCT00442689|DRUG|ethinyl estradiol 35 mcg and drospirenone 3 mg|one active pill per day for three weeks and then 1 sugar pill per day for one week
215008843|NCT00442689|OTHER|placebo|
215008844|NCT00875459|DRUG|VIAject™|Subcutaneous injection 25 IU/mL
215097588|NCT06624540|BEHAVIORAL|Education with EBP|"Phase 2: Nurse's EBP training ( VAP management), 2 hours lecture and 3 hours skill training for total 4 times in 1 month.~Phase 3: Introduce new equipment necessary for EBP implementation for VAP management, and EBP-trained nurses implementation for VAP management."
215097589|NCT06624904|DRUG|Losartan potassium 50mg|Single dose losartan (50 mg), encapsulated identically to placebo.
215097590|NCT06624904|OTHER|Placebo|Single tablet encapsulated identically to placebo.
214403490|NCT00618670|BEHAVIORAL|Control--Resistance Training|Three times per week for 3 months
215008845|NCT05669066|BEHAVIORAL|Mindful meditation|Adding mindful meditation to pre- and post-operative care for patients who are having a TKA
215008846|NCT02027571|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( \> 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
215008847|NCT04869930|OTHER|specimen collection|participants will submit at minimum two of four required samples: fecal, urine, finger/toe-prick blood, and cheek swab, collected at home via commercially available kits
214403491|NCT03415490|OTHER|Folded technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. Then, after the second circuit, the bandage is brought on the cheek and up over the eye to the forehead, where it was passed between the eyebrows but not wrapped around the head. Instead, the bandage is folded and then first passed back on the cheek of the affected side then back to the forehead a total of four times. Finally, the bandage is wrapped completely around the head once
214403492|NCT03415490|OTHER|Classic technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. After the second circuit, the bandage was brought below the ear, up over the eye and around the head of the non-affected side and then wrapped around the head in the same manner four times. The bandage is then brought around the head once.
214403493|NCT03250312|OTHER|The Osteopathic Manipulation|The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping
214403494|NCT00004287|GENETIC|H5.001CBCFTR|
214403495|NCT02223689|PROCEDURE|Skin Affix|
214403496|NCT02219828|DRUG|Anakinra|2mg/Kg daily sc up to 100mgday as maximum dose
214403497|NCT02219828|DRUG|Placebo|Placebo
214403498|NCT04349111|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
214403499|NCT06309303|OTHER|Clinical evaluation|Evaluation of clinical manifestation, laboratory ad imaging testing results, disease course, treatment and outcome
214403500|NCT00455468|PROCEDURE|Day-care treatment vs. hospital care|
214403501|NCT05108389|DIAGNOSTIC_TEST|Viscoelastic haemostasis monitor output|Observational
214403502|NCT03164733|OTHER|incubation|standardized wear particles are co-incubated with isolated patient cells (monocytes)
214403503|NCT04658719|DEVICE|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
214403504|NCT04658719|DEVICE|Standard Care|Uncoated Foley Catheter
215008848|NCT02313597|PROCEDURE|SETON|In seton treatment, initially Hydrogen peroxide will be applied to the external opening with a 10-cc syringe, and the internal opening will be located by direct visualization of the anal canal via proctoscope. A probe will be inserted into the external opening and carefully maneuvered through the internal opening. Silk 1/0 suture will be then tied to the tip of the probe, which will be then squeezed out of the external opening. The suture will be then tied around the sphincter and through fistula tract. Later, the seton will be tightened at four-week intervals under local anesthesia until the suture cut through the sphincter.
215008849|NCT02313597|PROCEDURE|VAAFT|Patients assigned to the VAAFT group will receive the following procedure. The external opening will be widened with a probe, and a fistulascope will be inserted to delineate the primary and secondary tracts and locate the internal opening. The internal opening will be then stitched with Vicryl™ (Polyglactin 910) 2-0 suture through the anal route with the help of a proctoscope. The tract of the fistula will be washed and debrided through the scope and cauterized. Finally, the external opening will be excised and will be sent for biopsy.
215008850|NCT06025461|OTHER|no intervention|no intervention
215008851|NCT05438420|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
215008852|NCT05438420|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
214403505|NCT00238043|DRUG|Biogeneric Epoetin|
214403506|NCT06077019|DRUG|Vilanterol and Fluticasone Furoate|Participants inhale 25 µg vilanterol + fluticasone furoate daily
214403507|NCT06077019|DRUG|Indacaterol and Mometasone Furoate|Participants inhale 125 µg indacaterol + mometasone furoate daily
214403508|NCT06077019|DRUG|Placebo|Participants inhale placebo daily
214403509|NCT00278564|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
214403510|NCT00278564|DRUG|Cyclophosphamide|
214403511|NCT00278564|DRUG|Mesna|
214403512|NCT00278564|DRUG|ATG(rabbit)|
214403513|NCT00278564|DRUG|Methylprednisolone|
214403514|NCT00278564|DRUG|G-CSF|
214403515|NCT00278564|DRUG|Rituxan|
214403516|NCT00181779|DRUG|aripiprazole (Abilify)|
214403517|NCT03997942|OTHER|Effect of exercise|Once the data are available, we hope to have information about which of the exercise practices included in the rehabilitation program of acute upper extremity burn patients is more effective.
214403518|NCT03406234|OTHER|No intervention.|Cross-sectional observation without interventions.
214403519|NCT02147860|DEVICE|Diabetes Assistant (DiAs) with USS Virginia|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
214403520|NCT02147860|OTHER|Sensor Augmented Pump Therapy|Subjects randomized to this placebo group will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
215008853|NCT05713370|DIETARY_SUPPLEMENT|high fat meal|A high fat meal (milkshake) will be administered on the morning after the intervention of no exercise and no SR the night before.
215008854|NCT03516500|DRUG|Iron Sucrose Injection|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) into the segmental bronchus.
215008855|NCT03688737|OTHER|low level laser|LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
215008856|NCT03688737|OTHER|placebo|placebo like device as it like low level laser device shape but with no effect to blind the intervention
215008857|NCT02237274|OTHER|High altitude exposition|High altitude exposition
215008858|NCT06355687|DRUG|Melatonin|Obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.
215008859|NCT06355687|DIETARY_SUPPLEMENT|Vitamin Supplement|Obese patients undergoing laparoscopic cholecystectomy will receive placebo medication (Vitamin Supplement) 45 minutes before general anesthesia.
215008860|NCT05015179|PROCEDURE|mixed reality technology in laparoscopic partial nephrectomy|All patients undergo contrast-enhanced computed tomography before surgery. DICOM files are converted to a 3D model. This model is then sent to HoloLens 2 smart glasses using HLOIA software
215008861|NCT00516854|DRUG|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
215008862|NCT00496327|BIOLOGICAL|Varicella Virus Vaccine Live (Oka-Merck)|VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
215008863|NCT00552058|BIOLOGICAL|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
215008864|NCT00552058|OTHER|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
215008865|NCT02328729|PROCEDURE|mandibular block with Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
215008866|NCT02328729|PROCEDURE|C-CLAD-IL with Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
215008867|NCT02328729|PROCEDURE|Infiltration with Epinephrine|Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
215008868|NCT02328729|PROCEDURE|Mandibular block without Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine
215008869|NCT02328729|PROCEDURE|C-CLAD-IL without Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine
215008870|NCT02328729|PROCEDURE|nfiltration without Epinephrine|Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
215008871|NCT05331937|COMBINATION_PRODUCT|repetitive transcranial magnetic stimulation (rTMS)|rTMS (real versus sham) is used as adjuvant to ERP
215008872|NCT04172064|DIAGNOSTIC_TEST|Myocardial perfusion scintigraphy|
215008873|NCT05649774|PROCEDURE|Therapy|Only Myofascial Release will be provided
215008874|NCT05649774|PROCEDURE|Taping technique|Only Kinesiotaping will be provided
214403521|NCT02985333|DRUG|Paclitaxel|Paclitaxel 170 mg/m(2) IV over 3 h d1
214403522|NCT02985333|DRUG|Cyclophosphamide|Cyclophosphamide 200mgmg/m(2) IV d1,3,5
214403523|NCT02985333|DRUG|Dexamethasone|Dexamethasone 20mg iv d1-4
214403524|NCT03250780|PROCEDURE|indigo-carmine 0.2% using a spray catheter|
214403525|NCT03250780|PROCEDURE|0.03% using a foot pump|
215008875|NCT05649774|PROCEDURE|Therapy with taping|Myofascial release will be provided followed by Kinesiotaping
215008876|NCT05649774|PROCEDURE|SHAM|Placebo Treatment will be given
215008877|NCT06579248|DEVICE|Intraoral Device|Device that circulates cooled water through the oral cavity.
215008878|NCT03693898|OTHER|Observeational|No intervention, observational
215008879|NCT06358989|OTHER|HOMA IR|Homa ir
215008880|NCT04678310|OTHER|Support from the hospital palliative and end of life care volunteer service (developed for this study).|Hospital palliative and end of life care volunteer service: a volunteer service to provide support to patients dying in the hospital and their families. The volunteer service has been designed to provide presence and companionship to dying patients at the end of life, and their families.
215008881|NCT04162483|DEVICE|Neuroform Atlas Stent System|Stenting Assisted coiling procedure
215008882|NCT00325585|BEHAVIORAL|Couples HIV counseling and testing|
215008883|NCT00325585|BEHAVIORAL|Women's relationship-focused HIV counseling and testing|
215008884|NCT03418207|PROCEDURE|trans-perineal template-guided mapping biopsy|new super saturation of prostate biopsy technique
215008885|NCT01559623|PROCEDURE|retrospective data analysis|retrospective data analysis
215008886|NCT01067235|DRUG|BF2.649|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
215008887|NCT01067235|DRUG|BF2.649 add on Modafinil|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
215097591|NCT06328660|DEVICE|Lens 1|Frequent replacement silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
215097592|NCT06328660|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
215097593|NCT06687434|BEHAVIORAL|accurate carb counting|Participants will use precise carb counting to manage their meals
215097594|NCT06687434|BEHAVIORAL|Simplified qualitative meal size estimation|participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment.
215097595|NCT07013799|OTHER|BasketUp Warm-up|BasketUp is a basketball-specific warm-up program designed to meet the sport's physical and physiological demands. Based on the FIFA 11+ structure, it includes three blocks: mobility, strength and plyometrics, and agility with neurocognitive exercises. The program progresses weekly and can be adapted in duration and volume to fit different training needs.
214688269|NCT07162142|PROCEDURE|elastic nailing with pollar K.wire|retrograde elastic nailing of metaphyseal diaphyseal fracture of distal radius in pediatrics
214403526|NCT04317768|BEHAVIORAL|Basic oral health education and motivation|Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
214403527|NCT04317768|BEHAVIORAL|Intensive oral health education and motivation|Subjects will be educated and motivated by an intensive program consisting of verbal instructions, PowerPoint lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
214403528|NCT02143674|OTHER|Muscle stretching and Strength Training|"Each step of stretching on specific muscles was repeated three times by keeping the posture for 30 seconds, (Arnold and Kokkonen, 2007; Toraman A, Yildirim. 2010; Dai, Ware, Giuliani, 2012; Duque et al., 2013; Granacher et al., 2013). The Pectoral, Quadriceps, Paraspinal, Abdominal and Ischial tibial and sural triceps muscles were elongated.~Strength Training Muscle strengthening was performed using weights and dumbbells. The training load individually determined through the test of strength with 10 repetitions maximum. The load was reevaluated four weeks of training. The Abdominal, Paraspinal, Quadriceps and Posterior thigh muscles (hamstrings) were submitted to the intervention protocol."
215008888|NCT04522791|BEHAVIORAL|RFB|The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).
215008889|NCT04522791|BEHAVIORAL|VSOP|The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.
215008890|NCT04522791|BEHAVIORAL|IR|Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.
214688270|NCT07163312|PROCEDURE|Endovenous Ablation for Varicose Veins|Participants will receive standard endovenous treatment for lower limb varicose veins as part of their routine clinical care. The procedure may include radiofrequency ablation (RFA), endovenous laser ablation (EVLA), or other accepted thermal ablation techniques, with or without adjunctive phlebectomy or foam sclerotherapy if clinically indicated. The intervention is performed under tumescent local anesthesia by vascular surgeons according to established guidelines. No experimental techniques or investigational devices are used.
215008891|NCT01290250|OTHER|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
214403529|NCT02143674|OTHER|Educated about physical exercises|
214403530|NCT01779921|DRUG|activated recombinant human factor VII|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
214403531|NCT01779921|DRUG|Fresh frozen plasma (Source unspecified)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
214403532|NCT01779921|DRUG|Plasma-derived FVII (LFB)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
214403533|NCT01779921|DRUG|Prothrombin Complex conc. (PCC)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
214403534|NCT01779921|DRUG|Plasma-derived FVII conc. (pdFVII Baxter)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
214403535|NCT01779921|DRUG|Plasma-derived FVII conc. (pdFVII PFL)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
214403536|NCT01094743|DEVICE|galyfilcon A prototype lens|Silicone hydrogel contact lens
214403537|NCT01094743|DEVICE|lotrafilcon B lens|Silicon Hydrogel contact lens
214403538|NCT06140160|PROCEDURE|Doppler ultrasound|To carry out an additional measurement using Doppler ultrasound (non-invasive examination). Doppler ultrasound measurements of the diameter and length of the perforating artery using a high-frequency Doppler ultrasound probe following a Doppler ultrasound of the supra-aortic trunks.
214403539|NCT02851511|BEHAVIORAL|Cognitive Training|Cognitive Training employs an eight component, PositScience BrainHQ suite via its researcher portal.
214403540|NCT02851511|DEVICE|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
215008892|NCT02102828|DEVICE|extended compression|Home use of extended compression therapy and aspirin
215008893|NCT02102828|OTHER|Aspirin|standard therapy of aspirin
215008894|NCT00629213|DRUG|acarbose|
215008895|NCT00629213|DRUG|placebo|
215008896|NCT01549509|BIOLOGICAL|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection in their upper arm of 1 x 10\^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
215008897|NCT00845182|DRUG|Pioglitazone|Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months
215097596|NCT03194438|BEHAVIORAL|Urban Zen Integrative Therapy (UZIT)|Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
215008898|NCT00845182|DRUG|Exenatide|Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
214403541|NCT02851511|DEVICE|tDCS (sham stimulation)|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
214403542|NCT02851511|BEHAVIORAL|Educational Training|Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.
214403543|NCT03230955|BEHAVIORAL|Psychological and psycho-educational support by phone|The intervention is based on cognitive-behavioural therapy (CBT). The intervention, in order to achieve behavioural changes, will include components based in Bandura's social learning theory and social cognitive theory (Bandura, 1986) and the transtheorical model of change (Prochaska, 1992). It has been shown that expectations and self-efficacy are behavioural predictors and that they are an effective framework for the assistance to quit smoking. This theory allows evaluating patient motivation phase and adapting the interventions according to each phase (Fiore, 2011)
214403544|NCT03230955|OTHER|Brief counselling session|Brief counselling session
214403545|NCT05323929|PROCEDURE|ESD|Endoscopic Submucosal Dissection for early gastric cancer
214403546|NCT04643730|OTHER|Acupressure methods|Acupressure on the KI3 and St36 points applied to the babies in the acupressure group for a total of 7 minutes before the heel prick
214403547|NCT04643730|OTHER|Foot Reflexology Methods|Foot reflexology was applied to the babies in the foot reflexology group for a total of 7 minutes before the heel prick
214403548|NCT04643730|OTHER|Control Grup|No pre-application was made to the babies in the control group as a routine procedure.
214403549|NCT02687386|DRUG|Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)|EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
214403550|NCT05487469|DRUG|Thymosin Alpha1|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead
214403551|NCT05487469|OTHER|Blank Control|the Control group did not receive Thymosin alpha 1 or any placebo.
214403552|NCT00970411|DRUG|KRN951|Orally once daily administration
214403553|NCT04494373|DRUG|HS-20090|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
214403554|NCT04494373|DRUG|Xgeva®|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
214403555|NCT00004136|PROCEDURE|Radiofrequency Ablation|Tumors heated to target temperature by electrodes for maximum of 20 minutes
214403556|NCT05258617|DEVICE|LLLT Photobiomodulation|Treatment with red LED light using UltraSlim device.
214403557|NCT01246648|PROCEDURE|Biopsy|dental extraction and gingival epithelial biopsy
215008899|NCT00845182|DRUG|Pioglitazone and Exenatide|Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months
215008900|NCT05174507|DRUG|empagliflozin|Empagliflozin (Jardiance®; Boehringer Ingelheim (Schweiz) GmbH) is a highly selective, reversible inhibitor of the sodium glucose co-transporter 2 (SGLT2). Treatment consists of a single oral tablet of 25 mg of empagliflozin (Jardiance®) two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
215008901|NCT05174507|DRUG|anakinra|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100 mg/0.67ml solution for SC injection. Treatment consists of a single subcutaneous injection of 100 mg Anakinra (Kineret®) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
215008902|NCT05174507|OTHER|saline subcutaneous (s.c.) (placebo)|Placebo for anakinra is 0.67 ml of sterile 0.9 % saline solution s. c. Treatment consists of a single subcutaneous injection of matched placebo (0.67 ml of 0.9 % saline) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
215008903|NCT05174507|OTHER|tablet per oral (p.o.) (placebo)|Placebo for empagliflozin is Winthrop P® (Zentiva, Frankfurt/Main) lactose tablet. Treatment consists of a single oral tablet of matched placebo two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
215008904|NCT02263313|OTHER|EGO-COMBO group|Assess the safety and effectiveness of Combo stent
214403558|NCT01246648|PROCEDURE|biopsy|dental extraction and gingival epithelial biopsy
214403559|NCT01246648|PROCEDURE|Biopsy|dental extraction and gingival epithelial biopsy
215008905|NCT04689243|PROCEDURE|ALA-PDT|Low concentration ALA-PDT, 3 times a week.
215008906|NCT04689243|PROCEDURE|red light|red light, 3 times a week.
215097597|NCT00740623|DRUG|Carisbamate|800 mg/day for 14 weeks
215097598|NCT00740623|DRUG|placebo|placebo for 14 weeks
215097599|NCT00740623|DRUG|Carisbamate|1,200 mg/day for 14 weeks
215097600|NCT07020780|RADIATION|Adjuvant 5 fractions whole breast irradiation with simultaneous integrated boost to the tumor bed|Experimental arm (arm 1-five fractions WBI) patients will be treated to a total dose (TD) of 26 Gy in 5 fractions to whole breast, and a simultaneous integrated boost (SIB) to a TD of 30 Gy to the tumor bed, while arm 2-fifteen-fractions WBI patients with 40 Gy/15 fractions to PTV, and 48 Gy SIB to the tumor bed.
215097601|NCT05273554|DRUG|Pembrolizumab|Given by IV
215097602|NCT05273554|DRUG|lenvatinib|Given by PO
215097603|NCT03626285|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
215097604|NCT03626285|DEVICE|CliniMACS CD34 Reagent System|CD34 selection ex vivo
215097605|NCT03626285|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Receive CD34-selected peripheral blood stem cells from related or unrelated donors
214403560|NCT03791528|OTHER|Kinesio-taping treatment group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the SIJ, and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire.
214403561|NCT00157053|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
214403562|NCT03836664|DRUG|Timolol|Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
214403563|NCT03836664|DRUG|Placebo|Placebo is normal saline solution that will be supplied in container matched to Timolol container.
214403564|NCT04901728|BEHAVIORAL|Cultural Domain Analysis|80 and up to a maximum of 120 participants
214403565|NCT04901728|BEHAVIORAL|Focus Group Discussion|At least 18 and up to a maximum of 60 participants
214403566|NCT04901728|BEHAVIORAL|In-depth interview|At least 18 and up to a maximum of 36 participants
215008907|NCT05340660|RADIATION|[ 18 F]PSS232|\[ 18 F\]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients
215008908|NCT03376009|DIAGNOSTIC_TEST|Blood sample for serum and plasma biomarkers:|Serum/plasma biomarkers: Approximately 10ml (3 teaspoons) of blood will be extracted to measure pre-specified biomarkers of renal injury including kidney injury molecule-1 (KIM-1), cystatin C and neutrophil gelatinase-associated lipocalin (NGAL). Samples will then be stored to facilitate measurement of additional biomarkers in the future.
215008909|NCT03376009|DIAGNOSTIC_TEST|Urine sample for biomarkers|Urinary biomarkers: A random urine sample will be obtained to measure urinary protein to creatinine ratio (uPCR), KIM-1 and liver-type fatty acid binding protein (L-FABP)
215008910|NCT03376009|DIAGNOSTIC_TEST|Cardiac bio-impedance (Cardioscreen Medis)|Cardiac bio-impedance - a non-invasive assessment of cardiac output, cardiac index and systemic vascular resistance index using the bio-impedence technique (Cardioscreen 1000 Medis) Cardiac bio-impedance is performed by attaching sticky electrodes to the participant's neck and thorax. These electrodes pass a very low, constant and alternating current (1.5 mA, 86 kHz) across the thorax, which is imperceptible to the patient. This provides beat by beat data on cardiac output and haemodynamic measurements.
215008911|NCT03376009|DIAGNOSTIC_TEST|Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor)|"Aortic pulse wave velocity (APWV) a non-invasive measure of arterial function using oscillometric recordings to detail peripheral and central haemodynamics. This will be measured using two different techniques:~TensioMed Arteriograph: After a rest period a blood pressure cuff inflates and deflates twice on the arm. This takes \~3 minutes and should cause only mild, temporary discomfort. The test will routinely be performed in duplicate to ensure accuracy of results.~SphygmoCor: A pressure sensor is held over the radial pulse at the wrist to analyse the pulse wave. Then held over the carotid artery and/or femoral artery to assess the speed of the pulse wave through the body. The probe is similar to an ultrasound probe and should not cause any discomfort."
215008912|NCT03376009|DIAGNOSTIC_TEST|Optical Coherence Tomography (Spectralis OCT)|"OCT is a non-invasive imaging test which uses light waves to take cross sectional images of the back of the eye. Examination of the retinal and retinal nerve fibre layer thickness, macular volume, and choroidal thickness provides an assessment of generalised systemic microvascular injury. A strong correlation between choroidal thickness and renal dysfunction has previously been shown in patients with chronic kidney disease (Balmforth C et al, JCI Insight 2016).~The participant is asked to sit in front of the OCT machine and rest their chin on a support to keep it motionless. The equipment will then scan the eye without touching it. Scanning takes about 5 - 10 minutes."
215097606|NCT06692738|DRUG|Rilvegostomig|Administered intravenously (IV) on Day 1 of each 21-day cycle
215097607|NCT06692738|DRUG|Pembrolizumab|Administered intravenously (IV) on Day 1 of each 21-day cycle
215097608|NCT06692738|DRUG|Carboplatin|Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
215097609|NCT06692738|DRUG|Paclitaxel|Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
214403567|NCT03717545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor~2. conditioning regimen: FLU/CY/anti-CD25 moAb"
214403568|NCT01427907|DRUG|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
214403569|NCT01427907|DRUG|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
215097610|NCT06692738|DRUG|Nab-paclitaxel|Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
214403570|NCT03628079|DRUG|ReposMBZ|Capsules 50mg, 100mg, 200mg
214403571|NCT04361747|BEHAVIORAL|nursing counseling|The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
215097611|NCT00175266|DRUG|alemtuzumab|
215097612|NCT00175266|PROCEDURE|islet transplant|
215097613|NCT00175266|DRUG|infliximab|
215097614|NCT05096949|OTHER|Home visit delivery strategy|A nurse will deliver and administer Cabenuva injection at patient's home
215097615|NCT02075892|DIETARY_SUPPLEMENT|Mushroom Blend|Scivation
215097616|NCT02075892|DIETARY_SUPPLEMENT|Placebo|
214403572|NCT01442168|DRUG|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
214403573|NCT01442168|DRUG|atovaquone/proquanil|malanil according to label
214403574|NCT04994262|OTHER|Menthol Lozenge|"In the study, Oka Menthol, a herbal lozenge produced by Otacı, will be used. Its formula contains: menthol 0.26%, eucalyptol 0.065%, thymol 0.0002%, camphor 0.0002%, anise oil, thyme oil, coltsfoot, marshmallow flower, bovine tail flower extracts, glucose and sucrose.~Medical properties: Otacı Oka Menthol Pastil shows antibacterial and fungicidal properties with eucalyptol in its composition. Menthol is effective against local anesthetic, local antitussive and irritation. It also plays a mild analgesic role with camphor in its content. It has an antibacterial and antifungal effect with thymol, a phenolic antiseptic. Otaco Oka Menthol Pastilles also contain extracts of coltsfoot, cow's tail flower and marshmallow flower which are anti-irritant and expectorant."
214403575|NCT00684502|DRUG|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
214403576|NCT00684502|DRUG|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
214403577|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
214403578|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
214403579|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
214403580|NCT00815321|BIOLOGICAL|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
214403581|NCT02392338|PROCEDURE|Hybrid procedure|Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
214504545|NCT07044128|DEVICE|Digital stethoscope using MEMS sensor and mobile application for cardiac auscultation|The intervention is a digital stethoscope system comprising a handheld device with a micro-electromechanical system (MEMS) sensor and a Bluetooth Low Energy (BLE) connection to a mobile application (Keikku Mobile App) installed on an iOS or Android smartphone. The device captures auscultation sounds from standard precordial locations (mitral, tricuspid, aortic, and pulmonary), transmits them in real time to the mobile application, and stores the recordings on a secure, GDPR-compliant cloud server. The device does not interpret sounds. Each auscultation lasts 15 seconds per site. Physicians use Bluetooth headphones to listen during recording. The application allows for annotation and review of sound data. The intervention is administered once per participant during a single study visit, immediately followed by a comparator auscultation using a conventional analog stethoscope by a second blinded physician.
215008913|NCT03376009|DIAGNOSTIC_TEST|Arterial Spin Labelling Magnetic Resonance Imaging|"Magnetic resonance imaging using arterial spin labelling (ASL-MRI) This promising quantitative technique has the potential to identify dysregulated renal perfusion, stratify risk of AKI in pre-OLT patients, and to monitor alterations in renal haemodynamics in the post transplantation setting.~* We aim to recruit 5 participants with 'normal' renal function (eGFR≥60ml/min/1.73m2) and a further 5 participants with 'abnormal' renal function (eGFR\<60ml/min/1.73m2)~* ASL-MRI will be performed in this subgroup during the week of OLT assessment and then repeated at 6-weeks post transplantation in those participants who undergo OLT during the study period."
215008914|NCT03461809|OTHER|Ocular acupuncture|Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
215008915|NCT03213236|DIAGNOSTIC_TEST|Homemonitoring diagnostic system|"In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram."
215008916|NCT04039269|OTHER|Preoperative video information|
215008917|NCT02412319|DRUG|Anti-HBV placenta transfer factor injection|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
215008918|NCT02412319|OTHER|Placebo|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
215008919|NCT04821011|DEVICE|electronic stethoscope|Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.
215008920|NCT04821011|DEVICE|acoustic listening of mother's heartbeats|Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.
215008921|NCT04821011|DEVICE|Recording of the newborn's heart rate|"Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used."
215008922|NCT01348698|PROCEDURE|Tumor tissue biopsy|Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.
215008923|NCT01348698|PROCEDURE|Surgery|Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
215008924|NCT03943992|DRUG|YYD601 40mg|Patients should take druges 30 minutes before breakfast.
215008925|NCT03943992|DRUG|Nexium 40mg|Patients should take druges 30 minutes before breakfast.
215008926|NCT03943992|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
214403582|NCT05892575|BEHAVIORAL|improving quality of life, coping with urinary incontinence and kegel exercise training|Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months.
214403583|NCT02388555|PROCEDURE|Posterior osteotomy correction|The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
214403584|NCT03690856|OTHER|inflammatory, neuropsychological and neuroimaging assessment|"Acts add by research:~pregnancy test; Centralized: IL1, IL6, TNF~Neuropsychologic tests at M6 and M24:~Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)"
214403585|NCT03813056|DRUG|Glanatec|Rho kinase Inhibitor
214403586|NCT03813056|DRUG|Optive, Ophthalmic Solution|artificial tears (placebo)
215008927|NCT06420583|PROCEDURE|MTA pulpotomy|"1. Application of rubber dam for isolation, then a standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove pulpal tissues to the orifice level, bleeding control in the pulp chamber will be achieved by using 5% sodium hypochlorite.~2. gentle condensation of MTA mix in the pulp chamber will be done by a wet sterile cotton pellet and then the rest of the pulp chamber will be filled with Glass Ionomer restoration.~3. The tooth will be restored with a stainless steel crown."
215008928|NCT06420583|PROCEDURE|Extraction|After complete Anesthetic application in the affected area, non-surgical extraction will be done.
215097617|NCT06695533|BEHAVIORAL|Diabetes self management workbook|The diabetes self-management workbook section used in this pilot study will focus on diet management, specifically carbohydrates, following ADA guidelines. It will include exercises based on the ADA diabetes plate method, aimed at helping subjects understand meal planning, food categories, portion sizes, goal setting, and the impact of foods on blood glucose levels. Activities will include word searches, crosswords, and goal-setting exercises. Subjects will begin the first section during a clinic visit. They can complete the workbook at home over three months, with input from subjects and Certified Diabetes Care and Education Specialists to refine the content.
215097618|NCT06628401|BEHAVIORAL|Educational information (Control)|Information packs will be developed for participants outlining the importance of a control group in research studies to maximise compliance. Participants will receive a £10 gift voucher weekly that they can spend at selected retailers of their choosing.
214403587|NCT03813056|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
214403588|NCT06183918|DRUG|Tranexamic acid|"1. Group: Gauze soaked with 1000 mg TXA-topical~2. Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration."
214403589|NCT06183918|OTHER|Saline|3\. Group: Gauze soaked with 10 cc of saline-topical. The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.
214403590|NCT06018194|DEVICE|ElucidVivo|Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
214403591|NCT05793892|DRUG|Lidocaine tetracaine cream|The test drug and the control drug will be uniformly spread over the treatment area using a tongue platula to form a thin layer of approximately 1 mm,right then left . The drug remained in the treatment area for 30 minutes (± 2 minutes) .
214504546|NCT07043998|OTHER|Self-adhesive resin cement in SELF-CURED mode|PFM crowns veneered with porcelain system cemented using self-adhesive resin cement in SELF-CURED mode
214504547|NCT07043998|OTHER|Self-adhesive resin cement in DUAL-CURED mode|PFM crowns veneered with porcelain system cemented using self-adhesive resin cement in DUAL-CURED mode
214504548|NCT07044245|PROCEDURE|immediate maxillary premolar implant placement with no subsequent laser Biostimulation|Sham laser application
214504549|NCT07044245|PROCEDURE|immediate maxillary premolar implant placement with subsequent laser Biostimulation|low lever biostimulation was performed on two consecutive sessions each of 100 s. First session was carried out immediately on surgery time after implant placement, using a diode laser Photo-biomodulation tip in a continuous wave and non-contact mode
215008929|NCT02595749|DRUG|Oxytocin|
215008930|NCT02595749|DRUG|Placebo|
215008931|NCT05830747|DRUG|Prednisone|Pre-operative drug administration before third molar surgery
215008932|NCT05830747|DRUG|Placebo|Pre-operative Placebo administration before third molar surgery
214504550|NCT07047040|DRUG|Ketorolac Tromethamine 30 MG/ML Prefilled Syringe|a pre-operative dose of ketorolac and gabapentin is given to the patients undergoing unilateral TKA one hour prior to surgery, then a post-operative pain scores will be recorded
215008933|NCT00263562|DRUG|Steroid arm|Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
215008934|NCT00263562|OTHER|Placebo|Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
215008935|NCT02024009|DRUG|nab-paclitaxel|Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state
215008936|NCT02024009|RADIATION|60Gy in 30#|
215008937|NCT02024009|RADIATION|50.4Gy in 28#|
215008938|NCT02024009|DRUG|Nelfinavir|VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
215008939|NCT02024009|DRUG|Capecitabine|Given in combination with gemcitabine, known as GemCap.
215008940|NCT02024009|DRUG|Gemcitabine|Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
215008941|NCT00947466|DRUG|Buprenorphine|Transdermal patch
214403592|NCT04890132|BEHAVIORAL|VOR precision training|Subjects are rotated in yaw using a pseudo-random sum of sines motion (0.5 - 2.0 Hz), view a monitor 1 m away, and are instructed to move their avatar through a maze using a joystick. The size of the maze becomes smaller in real-time when they are successful so that the patient is at the limit of their acuity. This task requires patients to optimize dynamic visual acuity to threshold-level images while rotating. We predict that VOR precision will gradually improve during training and that after training VOR precision will be better than the pre-training data. The sham task is as above but the acuity required to see the maze will set at a much larger level so baseline visual precision will be adequate to perform the task easily.
214403593|NCT04866342|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA). By means of a modified closed-loop algorithm, the devise uses MasimoSET or Nellcor pulse oximetry to target a user-set SpO2 value.~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
214403594|NCT02954718|OTHER|activity training|
214403595|NCT04003974|DRUG|Losmapimod oral tablet|Losmapimod will be administered with food when possible.
214403596|NCT04003974|DRUG|Placebo oral tablet|Placebo will be administered with food when possible
215008942|NCT02314429|DEVICE|Vaginal ring releasing lactic acid (racemic mixture)|
215008943|NCT06432426|BEHAVIORAL|Virtual reality training group|Participants will be given virtual reality games on Nintendo Wii Fit® and its peripheral Balance Board system. This equipment offers safe and engaging training protocols. Additionally, it ensures physical exercise in the three planes of movement (sagittal, frontal, and transverse) and with three difficulty levels, thus providing a linear progressive demand.
214403597|NCT02705326|DEVICE|Opti-Speech|Uses visual feedback of the tongue's motion to guide speech sound production
214403598|NCT02372448|OTHER|ALK analysis on CTCs detected by ISET|
214403599|NCT06305507|OTHER|Focussed laser therapy|"Others: Spot laser therapy~Other names:~Spot laser therapy Low Level Laser Therapy (LLLT) - Local Spot~The intervention involves the precise and focused application of low-power laser on specific areas related to plantar fasciitis. The local point technique is characterized by directing the laser directly to the painful point, seeking optimal stimulation in the affected region. This approach allows for targeted delivery of treatment to the area where pain is experienced, with the goal of maximizing the effectiveness of the therapy in reducing the symptoms associated with plantar fasciitis."
215008944|NCT06432426|BEHAVIORAL|Standard physical exercise group|Participants will be submitted to a standard physical exercise program based on the ACSM guidelines. Resistance training will involve exercises for arms and legs, using bodyweight self-loading and external weights. Balance exercises will include the three planes of movement.
215008945|NCT01286324|DIETARY_SUPPLEMENT|Chamomile High Grade Extract|three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days
215008946|NCT01286324|DRUG|Placebo Tablet|
215008947|NCT02043067|OTHER|Comprehensive TB screening|All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
215008948|NCT04688996|DIAGNOSTIC_TEST|Lateral Flow Assay for Pathogens of the Plague|A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
215008949|NCT00472381|DRUG|Insulin|Insulin
215008950|NCT00055107|DRUG|Nitazoxanide|
215008951|NCT06476821|DRUG|BMS-986435|Specified dose on specified days
215008952|NCT03792997|COMBINATION_PRODUCT|combination therapy for high peripheral NK cells|lipid emulsion \& prednisolone \& LMWH
215008953|NCT03517020|DRUG|Torrent's Nebivolol Tablets|
215008954|NCT03517020|DRUG|Forest Pharmaceuticals Inc's Bystolic Tablets|
215008955|NCT05137613|OTHER|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation
215008956|NCT05137613|OTHER|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
215008957|NCT02276833|OTHER|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
215008958|NCT05474677|PROCEDURE|closure of the abdominal fascia|The abdomen will be closed in intervention group with continuous PDS 2\\0 sutures and size zero in control group.
215008959|NCT02551575|DRUG|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
215008960|NCT02551575|DRUG|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
214504551|NCT07047040|DRUG|Gabapentin|a pre-operative dose of ketorolac and gabapentin is given to the patients undergoing unilateral TKA one hour prior to surgery, then a post-operative pain scores will be recorded
214504552|NCT07047040|DRUG|Empty Medication Capsules|two empty capsules of gabapentin
215008961|NCT02551575|DRUG|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
215008962|NCT03195530|DRUG|Propofol|Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
215008963|NCT00986232|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
214403600|NCT06305507|OTHER|Shower laser therapy|"Laser Therapy Sweeping~The intervention involves constantly moving the low-power laser over the areas affected by plantar fasciitis in a sweeping pattern. The sweeping technique seeks to cover a greater extent of the painful area during each treatment session. This approach differs by providing broader stimulation across the affected area, exploring the possibility of additional benefits compared to the local spot technique."
214403601|NCT00840320|DRUG|1278863|15mg, 25mg, 50mg, 150mg
215008964|NCT00986232|BIOLOGICAL|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
215008965|NCT00986232|BIOLOGICAL|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
215008966|NCT02245373|DRUG|Antidepressants|
215097619|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, excluding fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
214403602|NCT00840320|DRUG|Placebo|matching placebo
214403603|NCT00335153|DRUG|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
214403604|NCT00335153|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
214403605|NCT00335153|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
214403606|NCT00335153|DEVICE|J-tube|jejunal tube
214403607|NCT03794778|DRUG|pegylated liposomal doxorubicin|PLD 30 mg/m2, i.v.,d1; once every 21days
214403608|NCT03794778|DRUG|paclitaxel|paclitaxel 175 mg/m2, i.v.,d1; once every 21days
214403609|NCT03794778|DRUG|Carboplatin|carboplatin AUC 5, i.v.,d1; once every 21days,
214403610|NCT00372528|DRUG|pregabalin (LYRICA)|150 mg up to a maximum of 600 mg per day bid or tid as required
214403611|NCT05122403|PROCEDURE|MRgFUS central lateral thalamotomy|MRgFUS central lateral thalamotomy is a minimally invasive and effective procedure for medication-refractory neuropathic pain patients.
215008967|NCT02245373|OTHER|Active Monitoring|
215008968|NCT06502080|RADIATION|Consolidative radiotherapy|Consolidative radiotherapy: total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
215097620|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake + Juice)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, including fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
215097621|NCT07024524|OTHER|Rehabilitation training|This study constructed a novel multimodal assessment system to evaluate speech perception, music perception, and spatial hearing in congenital deafness patients , and subsequently generated targeted rehabilitation training plan based on the assessment data.
214403612|NCT04487028|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
214504553|NCT07042971|DEVICE|Pre-operative BiPAP Training|Seven consecutive nights (≥ 4 h/night) of BiPAP use at home or on ward, pressure ladder EPAP 6→8 cmH₂O / IPAP 12→16 cmH₂O, recorded on SD card; devices: ResMed AirCurve 10 ST or Philips A40.
214504554|NCT07042971|DEVICE|Post-extubation BiPAP Support|Same BiPAP device started immediately after tracheal extubation; EPAP 8 cmH₂O / IPAP 14 cmH₂O (or patient's final training setting) maintained ≥ 48 h, then weaned when SpO₂ ≥ 94 % off-BiPAP for 24 h.
215008969|NCT06502080|DRUG|Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab|Standard-of-care systemic therapy as decided by the treating medical oncologist: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
215008970|NCT00623376|DRUG|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
215008971|NCT00623376|DRUG|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
215008972|NCT03466372|BEHAVIORAL|biofeedback|treadmill walking with biofeedback regarding propulsion and other gait parameters
215008973|NCT05558410|DRUG|Suzetrigine (SUZ)|Tablets for oral administration.
215008974|NCT05558410|DRUG|HB/APAP|Capsules for oral administration.
215008975|NCT05558410|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
215008976|NCT05558410|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
215008977|NCT05202496|DRUG|Calcitriol 0.25Mcg Cap|After orthodontic levelling and alignment, experimental group subjects are administered one capsule of calcitriol 0.25 mcg on a daily basis during the study period. Also, serum vitamin D levels are monitored at monthly intervals and rate of canine retraction is measured at monthly intervals
215008978|NCT05202496|PROCEDURE|orthodontic treatment|experimental group subjects undergo orthodontic treatment after extraction of premolars
214403613|NCT05960279|DEVICE|MD100|"The MD100 (Medfield Diagnostics, Gothenburg, Sweden) consists of 8 antennas and measurement electronics integrated into a single device; rechargeable ion batteries power the instrument. The radiation transmitted from the device equals approximately 1% of the radiation emitted from a mobile phone. The device is non-invasive and small enough that it can be moved around with ease.~The system transmits microwaves with an output of 0.2 milliWatts (mW) for less than 90 seconds. The power absorbed by the body is 100mW/kg which is a factor of 200 less than what is established by the existing safety standard for microwaves. A mobile phone output, by comparison, can be up to 250mW.~The patient's head is placed in the instrument during measurement while the patient is supine. The procedure takes, on average, 5 minutes to perform."
214403614|NCT02842879|OTHER|Outpatient Foley cervix priming|Outpatient setting for cervix priming with Foley catheter
214403615|NCT02412761|DRUG|Lisinopril|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
214403616|NCT02412761|DRUG|Amlodipine|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
214403617|NCT02412761|DRUG|Hydrochlorothiazide|Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
214403618|NCT05992155|DRUG|TAK-279|TAK-279 capsules.
214403619|NCT03195582|DRUG|Corsodyl|following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant. In the test group, Corsodyl gel 1% CLOROHEXIDINE will be applied on the implant and the healing abutment.
214403620|NCT00347867|DRUG|Viagra administration in IUGR/PET pregnancies|
214403621|NCT06108492|DRUG|SHR-2005|"In dose Escalation: Four dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period.~In indication Expansion: Indications will be selected to evaluate preliminary efficacy."
214403622|NCT06028256|DRUG|Norepinephrine Hydrochloride|"Both arms of patients will receive standard anesthesia and surgical management. Radial artery cannulation and invasive blood pressure monitoring will be perform.~Norepinephrine will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision."
214403623|NCT06028256|DRUG|Placebo|Normal saline will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.
214403624|NCT02240680|DRUG|placebo|placebo matching linagliptin 5 mg
215008979|NCT04049084|BIOLOGICAL|autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)|ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
215008980|NCT03560596|BEHAVIORAL|Adherence Intervention|9 sessions with bilingual health coaches who will utilize a culturally tailored adherence checklist to identify patients specific medication adherence barriers.
215008981|NCT03560596|BEHAVIORAL|Usual Care|standard hypertension treatment recommendations as determined by PCP
215008982|NCT04717180|BEHAVIORAL|aphasia rehabilitation using software program or conventional therapy|Patients were randomized into two groups: group I who received therapy using the software aphasia rehabilitation program and group II who received conventional (traditional) language therapy
215008983|NCT04785885|DIAGNOSTIC_TEST|iStat Handheld Blood Analyzer|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
215008984|NCT04785885|DIAGNOSTIC_TEST|Hemochron|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
215008985|NCT01841853|BEHAVIORAL|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
215008986|NCT05381636|PROCEDURE|Esophageal arterial infusion chemotherapy|Percutaneous femoral artery puncture was performed to search for feeding arterial vessels corresponding to the lesion, and chemotherapeutic drugs were directly injected into the tumor vessels via targeted blood vessels.
215008987|NCT05381636|DRUG|Systemic intravenous chemotherapy|Albumin paclitaxel 125 mg / m2, D1, D8 + cisplatin 75 mg / m2, D1, every 3 weeks for 1 cycle
215008988|NCT03363438|OTHER|no intervention survey|there was no intervention this was a survey
215008989|NCT03161847|OTHER|Non-interventional study|Non-interventional study
215008990|NCT06243159|GENETIC|JY231|Infusion of JY231 Injection by dose of 1-10×10\^6 TU/kg、 1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
214403625|NCT02240680|DRUG|linagliptin|5 mg once a day
214403626|NCT04311073|DRUG|Tranexamic Acid|IV Tranexamic acid in 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
214403627|NCT04311073|DRUG|Placebos|IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
214403628|NCT00977028|DRUG|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
214403629|NCT00977028|PROCEDURE|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
214403630|NCT05700708|DIAGNOSTIC_TEST|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin, midodrine, diuretics and domiciliary albumin
214403631|NCT06429371|OTHER|Quantitative Sensory Testing|Participants will undergo heat pain threshold, cold pain threshold, pressure pain threshold, temporal summation, and conditioned pain modulation to characterize pain sensitivity.
214403632|NCT06429371|OTHER|Pain-Related Psychological Factors|Participants will complete psychological questionnaires to characterize these factors.
215008991|NCT04120675|DIETARY_SUPPLEMENT|Early Harvest Extra Virgin Olive Oil|Participants will take 3 tablespoons on a daily basis
215097622|NCT05901103|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
215097623|NCT06872515|BEHAVIORAL|Exercise and Nutrition|"The exercise and nutrition intervention will last up to 8 weeks and will include:~* 3-5 times per week of resistance training and 3-5 times per week of aerobic training. The prescribed exercise will be personalized based on the participant's baseline functionality.~* IMPACT Advanced Recovery nutrition supplement drinks: 2 per day for 5 consecutive days leading up to surgery."
215097624|NCT06872515|BEHAVIORAL|Usual Care Group|The CONT group will not receive any intervention during study participation and undergo usual medical treatment and surveillance during the duration of the study.
215097625|NCT05968755|DEVICE|A chatbot designed to promote PrEP awareness and uptake for Black MSM|Participants in the intervention group will have access to a theory-informed (Self-Determination Theory) chatbot and receive an automated personalized question message (root-node message) from the chatbot. The root-node messages are questions written into the chatbot algorithms to initiate interactive communication with participants. In each round of the interactive communication, the chatbot will provide automated personalized PrEP-related information, autonomous motivation, and psychological needs based on Self-Determination Theory constructs.
215097626|NCT05968755|OTHER|General educational messages|Participants in the control group will received general education messages from a research assistant including healthy diet, exercise, and COVID-19 prevention. The frequency of contact will be pre-specified by participants in interviews prior to the RCT.
215008992|NCT00062959|BEHAVIORAL|Going Places: School program to prevent problem behavior|
215008993|NCT02528136|DRUG|Carbetocin|
215008994|NCT02528136|DRUG|Oxytocin|
215008995|NCT01603914|DEVICE|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|"Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site."
215008996|NCT03938870|OTHER|L-Leucine 13C6|
215008997|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
215008998|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
215008999|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
215009000|NCT00709800|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
215009001|NCT00709800|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
215009002|NCT02400580|DRUG|IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
215009003|NCT02400580|DRUG|placebo|The patients in the placebo arm will receive normal saline.
215009004|NCT00965094|DRUG|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
215009005|NCT00965094|DRUG|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
215009006|NCT00965094|DRUG|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.
215009007|NCT00965094|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
215009008|NCT00965094|DRUG|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
215009009|NCT04953260|OTHER|APRF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of APRF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of APRF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with APRF film
215009010|NCT04953260|OTHER|CGF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of CGF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of CGF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with CGF film
215009011|NCT03280680|OTHER|Female+male group sessions|Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
214403633|NCT05575843|OTHER|Neurostatus-SMARTCARE|The Neurostatus-EDSS is assessed by HCPs while the examination is video-recorded. HCPs underwent extended training. For details of the examination refer to the second section of the detailed description.
214403634|NCT05575843|OTHER|Standard Neurostatus-EDSS|The Neurostatus-EDSS is assessed by neurologists while the examination is video-recorded. Neurologists underwent standard training.
214403635|NCT03668782|PROCEDURE|Umbilical cord milking|The babies were held at the level of the placenta, while the umbilical cord was milked or cut and clamped.
214403636|NCT01657682|DRUG|Crenolanib besylate|"Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.~Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy."
214403637|NCT06201065|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214403638|NCT06201065|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
214403639|NCT06201065|DRUG|Toripalimab|240 mg iv.drip Q3W
214403640|NCT06201065|DRUG|oxaliplatin , fluorouracil, and leucovorin|FOLFOX-HAIC
214403641|NCT00847093|DRUG|LMX4|One inch every six hours
214403642|NCT00847093|DRUG|LMX4 Placebo|One inch every six hours
214403643|NCT02015533|DRUG|CR8020|CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
214403644|NCT02015533|DRUG|Placebo|Placebo will be administered as a single 2-hour intravenous infusion.
215009012|NCT03280680|OTHER|Female group sessions|Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
214403645|NCT01719861|DRUG|Desipramine HCL|Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
215009013|NCT03280680|OTHER|No group sessions|Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
215009014|NCT02866266|OTHER|Retrospective database review|
215009015|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|Roux-en-Y
215009016|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|double tract reconstruction
215009017|NCT04129801|OTHER|Isokinetic Dynamometer|Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
215009018|NCT04129801|OTHER|Bioimpedance|Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
215009019|NCT01336972|DRUG|Tolvaptan|Tolvaptan was supplied as 15 and 30 mg tablets.
215009020|NCT02313272|RADIATION|Hypofractionated Stereotactic Irradiation (HFSRT)|Radiation therapy treatment (FSRT) which will be given to participants over 5 days.
215009021|NCT02313272|DRUG|Pembrolizumab|"Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.~Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase."
214403646|NCT03923608|DIAGNOSTIC_TEST|Maximal muscle strength Test|1RM test performed in 5 different tools (Elastic Band, Pulley, halter, digital dynamometer and isokinetic dynamometer)
214403647|NCT03923608|DIAGNOSTIC_TEST|Exhaustion test|Test performed until individual exhaustion in 5 different tools (Elastic Band, Pulley, halter and isokinetic dynamometer)
214403648|NCT03464396|OTHER|Bedside Physiology study|A 90-minute recording in conjunction with the respiratory evaluations using standard recording equipment that includes a conventional pulse oximeter, an EEG, an airflow sampling catheter near the nose, and respiratory inductance plethysmography (RIP) bands. Standard clinical bedside monitoring will continue during the respiratory evaluations.
214504555|NCT07042971|OTHER|Standard Peri-operative Care|Routine oxygen, nebulized steroids, airway monitoring; rescue re-intubation or tracheostomy per institutional protocol; no planned BiPAP unless crossover criteria met.
214504556|NCT07042932|OTHER|Exercise|26 weeks online high intensity functional training, performed 1-2 times per week + access to a LIFESTYLE PHYSICAL ACTIVITY WEBSITE including 8 modules; 1) Welcome, information about the intervention and the aims of the study, 2) Living a physically active lifestyle, 3) Sedentary behavior, 4) General exercise recommendations, 5) How to stay motivated, 6) Strength training, 7) flexibility, balance, and coordination, and 8) Healthy eating + weekly motivational counseling
215009022|NCT02313272|DRUG|Bevacizumab|Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a \> 10% change in weight.
214688271|NCT07163013|OTHER|Digital cognitive behavioral therapy(DCBT)|Moca is a mobile application designed to deliver structural CBT for adolescents with mood problems. Moca provides six-twelve guided sessions with an estimated proceeding duration of 25-45min each, developed to be processed weekly. The content of each session includes the introduction of the core concepts and principles of CBT, psychological counseling dialogue, skill exercises, and homework. Content presentation forms include text, animation, audio, comics, etc. At the end of each module, the participants will be asked to submit homework that will ask them to apply their learned skills to nursing or daily life situations that they personally perceive as stressful. Participants can review the completed sessions and record their mood status during the intervention period.
214688272|NCT07163013|OTHER|Regular mental health curriculum|The content of regular mental health curriculum includes mental health education lecture. Few lectures address the knowledge and skills involved in CBT in such education lecture.
215009023|NCT04169412|DIAGNOSTIC_TEST|Blood Collection|Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)
215009024|NCT05469061|DRUG|Tislelizumab|The 1st to 3rd doses were administered concurrently with FP regimen chemotherapy, 200 mg Tislelizumab each, on D1, D22 and D43 by intravenous infusion. In patients with successful conversion, one dose of 200 mg was administered 21 days after surgery in concurrent with the 4th to 6th cycles of 5-Fu, then 6 cycles of 200 mg Tislelizumab as adjuvant therapy; in patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
215009025|NCT05469061|DRUG|5-FU|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. 3 cycles of 5-Fu 850mg/m\^2 d1-4 adjuvant chemotherapy were started at 21 days after surgery in patients with a successful conversion. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
215009026|NCT05469061|DRUG|cis Platinum|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
215009027|NCT01997255|DRUG|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
215009028|NCT03865680|DRUG|CPP-ACP|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
215009029|NCT03865680|DRUG|Duraphat|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
215009030|NCT06391515|DIAGNOSTIC_TEST|Blood sample, CRF, thyroid ultrasound|Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3 and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical examination, thyroid US and blood tests.
215009031|NCT00576394|DRUG|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
215009032|NCT00576394|DRUG|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
215009033|NCT05759455|DIETARY_SUPPLEMENT|vitamin d|Assessment of Vitamin D level in Children with Autism in assiut university children hospital
215009034|NCT01777529|BIOLOGICAL|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
215009035|NCT03446573|DRUG|DTG + 3TC|DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
215009036|NCT03446573|DRUG|TAF based regimen (TBR)|Participants will continue to receive their TBR.
215009037|NCT05525715|DRUG|2mg QY201 tablets or 2mg QY201 placebo,BID|2mg QY201 tablets or 2mg QY201 placebo,BID
215009038|NCT05525715|DRUG|5mg QY201 tablets or 5mg QY201 placebo,BID|5mg QY201 tablets or 5mg QY201 placebo,BID
215009039|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,QD|10mg QY201 tablets or 10mg QY201 placebo,QD
215009040|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,BID|10mg QY201 tablets or 10mg QY201 placebo,BID
215009041|NCT05525715|DRUG|15mg QY201 tablets or 15mg QY201 placebo,BID|15mg QY201 tablets or 15mg QY201 placebo,BID
215009042|NCT05525715|DRUG|20mg QY201 tablets or 20mg QY201 placebo,BID|20mg QY201 tablets or 20mg QY201 placebo,BID
215009043|NCT05525715|DRUG|5mg QY201 tablets，BID|5mg QY201 tablets，BID
215009044|NCT05525715|DRUG|10mg QY201 tablets，BID|10mg QY201 tablets，BID
215009045|NCT05525715|DRUG|20mg QY201 tablets，BID|20mg QY201 tablets，BID
215009046|NCT05525715|DRUG|QY201 placebo，BID|QY201placebo，BID
215009047|NCT04837742|DRUG|ESPB group|ESPB injection at T10 region with Chirocaine 100mg(20 cc)+ Omnipaque 10cc
215009048|NCT04837742|DRUG|Control group|ESPB injection at T10 region with Normal saline 20cc + Omnipaque 10cc
215009049|NCT04784403|DIAGNOSTIC_TEST|SARS-CoV-2 PCR and serology tests|Once the informed consent has been signed, the selected subjects must complete an epidemiological survey and go to a UB sample collection center to perform a PCR and serology test for SARS-CoV-2.
215097627|NCT06701578|OTHER|Safe and Sound Protocol|Listening to specially designed filtered and modulated music that is tailored to enhance the individual's auditory system's ability to process and respond to auditory stimuli for up to five hours.
215097628|NCT06701578|OTHER|Control|Listening to music that is not filtered and modulated for up to five hours.
215097629|NCT02394717|BEHAVIORAL|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
214403649|NCT03464396|OTHER|Carotid Body Function Test|Infants without nasal cannula will have a nasal cannula placed in their nares. After a 15-minute baseline period and during quiet sleep, the infant will then be exposed to 30 seconds of 100% oxygen (O2) by increasing FiO2. This test will be repeated 3 times, with at least 3 minutes between tests to allow for return of oxygen saturation (SpO2) to baseline values. If oxygen saturations increase to 99% for 15 seconds or the infant is apneic for greater than 5 seconds following initiation of 100% oxygen (O2), the test will be stopped and FiO2 brought back to baseline. Infants in the NICU will be monitored continuously with heart rate, respiratory rate, and SpO2% for 12 hours after Carotid Body Function Test according to NICU standards. Infants discharge who return for Carotid Body Function Test at 40 and 52 weeks PMA will be monitored continuously for 1 hour after the test is finished.
214403650|NCT03464396|OTHER|Room Air Challenge|Infants receiving nasal cannula high flow support 3 liters per minute (LPM) or less with or without supplemental O2 at 36 weeks PMA will be eligible. After a 15-minute quiet sleep period, infants' FiO2 will be weaned, in 0.20 decrements for 5 min intervals. Flow then decreased in 10 min intervals, initially in 1 Liter Per Minute (LPM) decrement until nasal cannula flow is 1LPM, and then decreased by 50% decrements to 0.125 LPM then off. If the infant is weaned to room air alone for 15 minutes, not meeting failure criteria, he/she has passed the RAC. Failure of the RAC is defined as occurring when SpO2% falls below 80%, even briefly, or remains less than 90% for 5 consecutive minutes any time during the test, bradycardia (Heart rate \[HR\] \< 80 bpmx 10 sec) or persistent apnea despite stimulation. Infant is returned to the level of support provided before the RAC begun if meets any failure criteria.
214403651|NCT03464396|OTHER|Hypoxia Challenge Test|"A physician investigator will review 30 minutes of continuous recording made 24 hours prior to test scheduled to identify infants that are at high risk for significant oxygen desaturations during Hypoxemia Challenge.~If subject passes the screening test, the hypoxic challenge will be performed. For the hypoxemia test, a nasal cannula will be placed prior to a 15 minute period of quiet sleep recorded to confirm antecedent stability of ventilatory pattern and SpO2%. During the 15 minutes of quiet sleep, the infant is required to maintain a SpO2 of \> 92% in order to undergo the HCT. After the 15-minute baseline recording, HCT will begin using FiO2 = 0.18 for 5 minutes, unless failure criteria is met: SpO2% \< 80% even briefly, or SpO2% 80% to 85% for 15 seconds. If infant does not meet failure criteria, infant will be given FiO2 0.15 for 10 minutes. If an infant meets even a single criterion for failure, Hypoxic mixture will be stopped."
214504557|NCT07043569|OTHER|Resistance Training with Sham-BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
215009050|NCT01793909|OTHER|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
215009051|NCT03096990|DRUG|apremilast|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
215009052|NCT02690740|OTHER|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
215009053|NCT00000665|DRUG|Foscarnet sodium|
215009054|NCT00000665|DRUG|Ganciclovir|
215097630|NCT06200051|DIAGNOSTIC_TEST|Prediction of high risk of cancer|This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.
215009055|NCT00407667|DEVICE|transcranial galvanic stimulation|for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
215009056|NCT04731116|DRUG|Cannabidiol|Oral Cannabidiol 150 mg twice daily during 14 days
215009057|NCT05987540|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device.
215009058|NCT00471107|DEVICE|DC brain polarization|0.08 mA/cm2
215009059|NCT03632330|DRUG|Dexmedetomidine|Dexmedetomidine group
215009060|NCT03632330|DRUG|Midazolam|Midazolam group
215009061|NCT03632330|DRUG|Propofol|Propofol group
215009062|NCT03632330|DRUG|Midazolam/Propofol|Midazolam/Propofol group
215009063|NCT01494974|DEVICE|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
215009064|NCT01494974|DEVICE|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
215009065|NCT05169944|DRUG|Magrolimab|Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis
215097631|NCT06710262|DIAGNOSTIC_TEST|T-TAS PL Assay|The T-TAS PL assay is a flow chamber assay for measuring primary hemostatic function
215097632|NCT07038278|DRUG|5-ALA|5-ALA), also known by its brand name Gleolan, is an intermediate in the heme synthesis pathway that has been studied in tumor resections, especially in intracranial tumor resections. One advantage of intraoperative visualization with 5-ALA is the ability to directly visualize fluorescent tumor in the surgical field using a headset-mounted devices with fluorescence in the visual wavelength in real-time.
215097633|NCT06725810|DRUG|Enarodustat|Patients are administered with enarodustat with dosage adjusted according to hemoglobin levels to achieve and maintain hemoglobin target over 96 weeks.
214403652|NCT03464396|OTHER|Effects of Nasal Cannula Flow|"Infants will have nasal catheter in place (NeoTech Premature RAM Cannula). A 15-minute baseline recording of physiologic study parameters prior to initiation. Tested in three groups of infants.~1. 28 and 32 weeks PMA flow rates increased after a 15-minute baseline period to 3LPM, or by 1LPM to a max of 5LPM for 15 minutes. Infant on Bubble CPAP will be increased 1cm H2O to max 8 cm H2O for 15 minutes.~2. Infant's that fail the RAC or HCT at 36 weeks with periodic breathing, high flow at 3LPM will be started for 2 minutes or until periodic breathing stops. Infants on Bubble CPAP will not undergo the RAC or HCT. Their pressure is increased by 1cm H20 to max of 8 cm H2O for 15 minutes.~3. Infant on RA at 40 and 52 weeks PMA with periodic breathing lasting longer than 1 minute during the 15-minute baseline period, flow at 3LPM will be started for 2 minutes or until periodic breathing stops."
214403653|NCT03464396|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|A non-sedating MRI scan will be performed on 3 subsets of infants at 37-40 weeks Post Menstrual Age (PMA), or when infant is within one week of discharge from the NICU. Standard images as well as research images will be obtained. The research images use the same MRI scanner and collection techniques as standard clinical imaging, but provide a more detailed examination of brain anatomy and injury. Collection of these sequences using our standard non-sedated acquisition practices for infants is well tolerated. Infants will be placed in scanner by registered nurse accompanied by radiology technician to assure infants' comfort during scan. Infant will remain on cardio-respiratory monitor during MRI via a pulse oximetry probe. It will take no longer than one hour to complete MRI scan including transportation to radiology unit.
214403654|NCT03464396|DIAGNOSTIC_TEST|Echocardiogram|An echocardiogram (referred to as an ultrasound of the heart on the consent form) will be performed to assess cardiac structure and function. Echocardiograms are performed routinely in premature newborns in the NICU. The Echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse. The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.
214403655|NCT03464396|OTHER|Blood Sample|Infants that have echocardiograms will have a blood sample collected near the time the echocardiogram is obtained, 3-blood samples total. The blood sample will only be collected with parental permission on an opt-in or out-basis and collected only with routine clinical labs.
214403656|NCT01447355|DRUG|cholecalciferol|Given PO
214403657|NCT04651738|DIAGNOSTIC_TEST|DNA methylation testing|Methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177
214403658|NCT06080217|DEVICE|study group|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, where high frequency electricity was released to the bladder for 20 minutes with a frequency of 1.0 MHz and energy to maximum 410 C. Initialy, maximum energy of 75% and a frequency of 0.8 MHz was applied, which was reduced depending on the heat that was pleasant for the patient. Then, the power was reduced to 50% and increased the frequency to 1.0 MHz, which also meant moderate energy absorption. The procedure with this energy was continued until the end, and the patients absorbed 18-19 kJ of energy in average."
214688276|NCT07162961|DRUG|Nintedanib|Participants will be randomly assigned to one of two groups: the Experimental Group will receive oral nintedanib (100 mg twice daily) plus progesterone therapy for three months; the Control Group will receive progesterone therapy only.
214688277|NCT07162961|DRUG|Progesterone|For control group
215009066|NCT05625971|OTHER|MRD Assessment|MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
215009067|NCT03401294|DRUG|FOLFOXIRI and Bevacizumab|Every 2 week for a total of 12 cycles
215009068|NCT06640647|DRUG|HDM1005 injection or placebo|HDM1005 injection or placebo isubcutaneous injection once
215009069|NCT04996264|DRUG|Varespladib Methyl|Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration. Scaled pediatric doses of varespladib-methyl (LY333013) are supplied as 50 mg IR capsules for oral administration.
215009070|NCT04996264|DRUG|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate."
215009071|NCT04996264|DRUG|Standard of care (SOC)|SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
215009072|NCT02574208|PROCEDURE|HIV testing by ELISA|HIV testing randomized between ELISA or rapid test
215009073|NCT02574208|PROCEDURE|HIV testing by rapid test|HIV testing randomized between ELISA or rapid test
215009074|NCT01926535|PROCEDURE|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
215009075|NCT01926535|DEVICE|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
215009076|NCT04433975|BEHAVIORAL|Psychosocial Pain Management (PPMI)|The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
215009077|NCT04433975|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
214403659|NCT06080217|DEVICE|placebo (sham control)|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, but without any energy transferred through the probe,"
214403660|NCT06039891|DRUG|Nimotuzumab、Tislelizumab|Subjects will receive Nimotuzumab 400 mg/time, intravenous injection, qw; Tislelizumab 200 mg/time, q3w until disease progression, intolerable toxicity, or 24 months of medication
214403661|NCT02013232|DRUG|Aripiprazole|
214403662|NCT02724267|BIOLOGICAL|131I-chTNT-1/B|29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment
215009078|NCT00232154|DRUG|Zithromax&#153; (azithromycin) 500mg tablets|
215009079|NCT00232154|PROCEDURE|Endoscopic Sinus Surgery|
215009080|NCT00232154|PROCEDURE|Blood sampling for hematology|
215009081|NCT00232154|PROCEDURE|Blood sampling for plasma chemistry profile|
215009082|NCT00232154|PROCEDURE|Serum pregnancy test (for women of child-bearing potential)|
215009083|NCT04606771|DRUG|Osimertinib + Savolitinib|"Osimertinib 80 mg oral QD~Savolitinib 300mg oral QD"
215009084|NCT04606771|DRUG|Savolitinib + Placebo|"Savolitinib 300mg Oral QD~Placebo to Osimertinib 80mg oral QD"
215009085|NCT06479720|DRUG|Combined pharmacotherapy with Solifenacin and Mirabegron|Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.
215009086|NCT06479720|DRUG|Solifenacin with vaginal estrogen cream|Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
215009087|NCT06479720|DRUG|Mirabegron with vaginal estrogen cream|Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
215009088|NCT04549207|DRUG|Bone modifying agent|Use of bone modifying agent
215009089|NCT05852210|OTHER|Infrared Imaging|This study will use thermal forward looking infrared (FLIR) imaging to assess the severity of Complex Regional Pain Syndrome in newly diagnosed patients.
215009090|NCT04253964|DRUG|Pembrolizumab|ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.
215009091|NCT04253964|DRUG|Carboplatin|FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
215009092|NCT04253964|DRUG|Paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
215009093|NCT04253964|DRUG|Nab paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.
215009094|NCT04253964|OTHER|Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)|The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
215009095|NCT04253964|OTHER|QLQ-C30 Global Health/Quality of Life Questionnaire|30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures
215009096|NCT04253964|OTHER|COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes|Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)
215009097|NCT04253964|DRUG|Pemetrexed|FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
215009098|NCT03896217|DRUG|Simvastatin|Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
215009099|NCT03440437|DRUG|FS118|Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.
215009100|NCT03440437|DRUG|Paclitaxel|Dosing on Days 1, 8 and 15 of each 28 day cycle in combination with FS118 given on days 1, 8, 15 and 22 of each 28 day cycle.
214403663|NCT03675204|OTHER|No intervention|No intervention
214403664|NCT01210053|DRUG|malate Given orally|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
214403665|NCT06042998|PROCEDURE|Robotic radical gastrectomy|Laparoscopic gastrectomy
214403666|NCT04458389|DRUG|TY101|"Dose escalation: TY101 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg Intravenous Q3W, 2 years depending on response.~Dose expansion: Subjects received TY101 injection for a maximum of 2 years until progressive disease, intolerant toxicity, death, or withdrawal from the study occurred."
214403667|NCT06187870|OTHER|Collection of biological data|Biological samples will be collected from the patient at the time of their access to the Hospital
214403668|NCT02461511|OTHER|Therapeutic Education|participation in a therapeutic education program on diabetes
214403669|NCT05328440|DRUG|Pyrotinib Maleate|once a day, 125mg each time, taking for 3 weeks, stopping for 1 week, 4 weeks as a cycle. It is recommended to take medicine at about the same time every day, take it with warm water, and fast at least 1 hour before and after taking medicine
214403670|NCT05328440|DRUG|Dalpiciclib Isethionate Tablets|400mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 28 days as a cycle
214403671|NCT05328440|DRUG|Inetetamab|the initial dose is 8mg / kg and the subsequent dose is 6mg / kg. It is administered intravenously for 21 days.
215009101|NCT04392635|DEVICE|TauTona Pneumoperitoneum Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle during laparoscopic surgery.
215009102|NCT04392635|PROCEDURE|Standard of Care (SOC)|Standard of Care was used for Veress needle insertion.
215009103|NCT02030418|DEVICE|Leadless Pacemaker|Patients will undergo an attempted leadless pacemaker implant
215009104|NCT05498207|BEHAVIORAL|Maya App|Participants will utilize the Maya App for at least 20 minutes per day, 2 days per week, for 6 weeks. Additionally, participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
214403672|NCT05328440|DRUG|Fulvestrant|fluvestrant is administered intravenously on the 1/15 day of the first cycle, and then on the first day of each cycle, 500mg / time, intravenously
215009105|NCT06284304|RADIATION|De-escalated radiotherapy|5 fraction de-escalated dose SBRT protocol
215009106|NCT04093570|DRUG|ASTX727|ASTX727 film-coated, immediate-release FDC tablets
215009107|NCT03483662|BEHAVIORAL|Multicomponent Intervention|The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
215009108|NCT03483662|BEHAVIORAL|Enhanced Usual Care|The investigators will provide an up-to-date clinical guideline for hypertension management to providers. A webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial will be conducted. Otherwise, the investigators will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients
215009109|NCT06637020|DRUG|HDM1005 injection or placebo|Within each cohort, subjects are randomized in a 4:1 ratio to receive either HDM1005 injection or placebo subcutaneously.
215009110|NCT04915027|OTHER|a usual follow-up with Rehabkompassen®|Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.
215009111|NCT04915027|OTHER|a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®|Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
215009112|NCT05114798|BEHAVIORAL|Time restricted eating|daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
215009113|NCT05114798|BEHAVIORAL|Calorie Restriction|daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
215009114|NCT05169268|DRUG|ARIPiprazole Injection [Abilify]|subject already receiving the combination of Abilify Maintena and Rexulti
215009115|NCT05169268|DRUG|Brexpiprazole|subject already receiving the combination of Abilify Maintena and Rexulti
215009116|NCT05821829|DEVICE|Intravascular litothripsy (IVL)|endovascular treatment of primary common femoral artery atherosclerotic disease with intravascular litothripsy
215009117|NCT05452226|DEVICE|neuromuscular electrical stimulation (NMES)|Electrical stimulation will be applied using two adhesive pads affixed to the front of both of the thighs. The intensity will be progressively increased to a level that provokes a strong contraction. The stimulation intensity will be increased until the stimulation is uncomfortable, but does not hurt. Care will be taken to make sure that the level of stimulation will be adjusted such that the intensity does not cause pain. Contractions will last 10 seconds, with 30 seconds of rest between. NMES will occur 6 days per week for 60 minutes per day. Patients will self-administer NMES 6 days per week after discharge for up to 6 weeks.
215009118|NCT03489525|BIOLOGICAL|Dose Escalation, MEDI2228, ADC (antibody drug conjugate)|Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
215009119|NCT03489525|BIOLOGICAL|Dose Expansion, MEDI2228, ADC (antibody drug conjugate)|Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
215009120|NCT02147080|BEHAVIORAL|UV4me|Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator
215009121|NCT02147080|BEHAVIORAL|Skin Cancer Foundation website|Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
215009122|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
215009123|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
215009124|NCT01104337|DRUG|Placebo|Treatment consisted of two matching placebo tablets three times a day.
215009125|NCT03713580|DRUG|Venetoclax|"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."
215009126|NCT03287063|OTHER|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
215009127|NCT04111783|DEVICE|POU protocol ultrasound|The evaluation method performed a preoperative examination of the patient within 10 minutes by a heart scan and a standard scan of the face, a large vascular scan under the xiphoid, a body cavity scan, and a standard scan of the face and a lung scan. Preparation, providing anesthesia and surgeons with a fast, comprehensive and accurate preoperative judgment with important clinical and social significance.
214403673|NCT06088901|PROCEDURE|Autologous Blood Patch|2 ml/kg of whole blood (max 100 ml) is obtained via venipuncture. This blood is then injected via the chest tube which will then be clamped for 180 minutes, before being returned to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
214403674|NCT03605875|BEHAVIORAL|Web-App|Cambian IT Health solutions from Surrey BC developed the infrastructure
214403675|NCT03605875|BEHAVIORAL|Paper|Contains similar questions to the Web-App tool
214403676|NCT03704298|DRUG|Cyclophosphamide|Administered according to package insert
214403677|NCT03704298|DRUG|Fludarabine|Administered according to package insert
215009128|NCT02492919|DEVICE|Medixair®|Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
215009129|NCT01227811|DRUG|Darifenacin|Single oral dose Darisec(R) 15.0 mg
215009130|NCT01227811|DRUG|Darifenacin|Single oral dose Enablex(R) 15 mg
214403678|NCT03704298|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
214403679|NCT03704298|BIOLOGICAL|Utomilumab|Administered as an IV infusion
214403680|NCT00483262|DRUG|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
214403681|NCT00483262|DRUG|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
214403682|NCT05994235|DRUG|Mosunetuzumab|"Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks."
214403683|NCT05994235|DRUG|Tazemetostat Pill|Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
214403684|NCT06101927|DRUG|Whole body study and SPECT with [99mTc]Tc-BQ0413|One single intravenous injection of \[99mTc\]Tc-BQ0413, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
214403685|NCT02209207|DEVICE|Treadmill|
214403686|NCT02209207|OTHER|walking training|
214403687|NCT04482855|DEVICE|Low-level laser|Low-level laser therapy
215009131|NCT00106561|DRUG|Spironolactone|
215009132|NCT00106561|DRUG|Irbesartan|
215009133|NCT00888849|PROCEDURE|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
215009134|NCT00888849|PROCEDURE|Suturing|Suturing
215009135|NCT01939392|DEVICE|Renal Denervation (OneShot™ Renal Denervation System)|
215009136|NCT02663167|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
215009137|NCT01400633|DRUG|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
215009138|NCT02508207|DRUG|Tezacaftor/Ivacaftor|Tezacaftor/Ivacaftor FDC
215009139|NCT02508207|DRUG|Ivacaftor|
215009140|NCT02508207|DRUG|Tezacaftor/Ivacaftor matching placebo|
215009141|NCT02508207|DRUG|Ivacaftor matching placebo|
215009142|NCT01284764|DRUG|Mosapride|Mosapride 10mg, one dosage, once evening of the day before the endoscopy
215009143|NCT06530095|OTHER|prone positioning|prone positioning
215009144|NCT03997201|PROCEDURE|Ripple Mapping guided ischaemic VT ablation|"Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue."
215009145|NCT00662701|PROCEDURE|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
215009146|NCT00662701|PROCEDURE|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
215009147|NCT03707730|DIETARY_SUPPLEMENT|AGY|oral AGY taken prior to meals
214403688|NCT02851043|DEVICE|pneuRIP (breathing with resistance)|subjects are given a resistance element to breath through
214403689|NCT02851043|DEVICE|Respitrace system (Carefusion) (breathing without resistance)|subjects are asked to breath normally
214403690|NCT01435408|OTHER|Conventional primary PCI|Conventional primary PCI in STEMI with implantation of DES.
214403691|NCT01435408|OTHER|Ischemic postconditioning.|Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.
214403692|NCT01435408|OTHER|Deferred stenting in primary PCI.|In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.
214403693|NCT01714089|DRUG|RNS60 125 ml|
214403694|NCT01714089|DRUG|RNS60 250 ml|
215009148|NCT03707730|OTHER|placebo|oral placebo taken prior to meals
215009149|NCT00104260|DRUG|sapropterin dihydrochloride|
215009150|NCT05687565|DIETARY_SUPPLEMENT|Control group placebo|Dietary suplementation
215009151|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 1 lauric acid|Lauric acid 1.5 grams once daily
215009152|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 2 lauric acid|Lauric acid 3 grams once daily
215009153|NCT01447472|DRUG|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
214403695|NCT01714089|DRUG|Interferon beta 1a|
215009154|NCT01475500|PROCEDURE|Sputum sample|This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
215009155|NCT01475500|PROCEDURE|Pulmonary function tests|A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
215009156|NCT01475500|RADIATION|Computerized tomography (CT) scan of the chest|A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
215009157|NCT01475500|OTHER|Buccal epithelium collection|Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
215009158|NCT01475500|PROCEDURE|Nasal brushings|A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
215009159|NCT01475500|PROCEDURE|Bronchoscopy|A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
215009160|NCT01475500|PROCEDURE|Bronchoalveolar lavage|During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
214403696|NCT05029856|BIOLOGICAL|SII B.1.351|"Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
214403697|NCT05029856|BIOLOGICAL|SII B.1.351|"Intramuscular (deltoid) injections of 5 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
214403698|NCT05029856|BIOLOGICAL|SII Bivalent|Intramuscular (deltoid) injections of 6 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
214403699|NCT05029856|BIOLOGICAL|SII Bivalent|Intramuscular (deltoid) injections of 10 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
215009161|NCT01475500|PROCEDURE|Blood sample collection|A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
215009162|NCT01475500|PROCEDURE|Urine sample|Urine will be collected for routine urine tests at baseline and yearly to year 5.
215009163|NCT01475500|PROCEDURE|Questionnaire-data collection|A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.
215009164|NCT01566825|DRUG|Amitriptyline|amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
215009165|NCT01566825|DRUG|Placebo|placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
215009166|NCT06214715|DEVICE|Philips ultrasonography system|RRI will be measured by renal ultrasonography with a C5-1 convex probe using a Philips ultrasonography model device.
215009167|NCT00179179|DRUG|nutritional supplementation|2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
215009168|NCT00179179|BEHAVIORAL|exercise|resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
215009169|NCT06501937|OTHER|Influencer marketing|Participants watched online survey-imbedded promotional videos featuring influencers
215009170|NCT03423693|OTHER|No any intervention|No any intervention is applied to any groups in this study
215009171|NCT04017468|DRUG|Vancomycin|Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
215009172|NCT05381168|DIETARY_SUPPLEMENT|Calcium from fish bone|Calcium from fish bone contained calcium 312 mg and vitamin D 100 IU per capsule.
215009173|NCT05381168|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate contained calcium 600 mg and vitamin D 200 IU per capsule.
215009174|NCT04225520|DEVICE|Cardiac resynchronization therapy ON|Implantation of a CRT device. Bi-ventricular pacing will be turned ON.
215009175|NCT04225520|DEVICE|Cardiac resynchronization therapy OFF|Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.
215009176|NCT02723331|DRUG|Nab paclitaxel|Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
215009177|NCT02723331|DRUG|Gemcitabine|Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
215009178|NCT06239597|BEHAVIORAL|occupation-based lifestyle intervention|9 week lifestyle course
215009179|NCT06239597|OTHER|Other courses|Other courses in the same university, during the same academic years.
215009180|NCT05962905|OTHER|Blood sample|During the standard of care interventional or diagnostic cardiac catheterization, paired arterial and venous blood samples will be obtained. The venous sample will be obtained from 2 cm superior to the clavicle, which is beyond standard of care during the routine cardiac catheterization
215009181|NCT05962905|DEVICE|INVOS monitoring|During the standard of care interventional or diagnostic cardiac catheterization, INVOS monitoring will be used. INVOS™ regional oxygen saturation (rSO2) values will be compared to the calculated global field saturation of cerebral tissue determined from blood sample co-oximetry.
215009182|NCT04556825|DRUG|PRP|After the arthroscopic operation was completed, a local PRP with 4ml was injected
215009183|NCT04556825|DRUG|normal saline|After the arthroscopic operation was completed, a local normal saline injection with same ml was performed
215009184|NCT05592626|DRUG|STAR0602|solution, intravenous infusion
215009185|NCT02502448|PROCEDURE|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
215009186|NCT02502448|DRUG|hydroxyethyl starch (HES 130/0.6)|
215009187|NCT05574049|DRUG|Tetrahydrocannabivarin|The subjects will take once daily oromucosal strip with intervention drug for 90 days.
215009188|NCT05574049|OTHER|Placebo|The subjects will take once daily oromucosal strip with no drug on it for 90 days
215009189|NCT00739219|DEVICE|Apieron Insight eNO monitor|The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
214403700|NCT05029856|BIOLOGICAL|SII B.1.617.2|"Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
214403701|NCT05395572|DEVICE|Kinesio® Tape|In order to increase the activity of underactive muscles, the tape is applied from origin to insertion with a 15-25% tension. The Kinesio® Tape mechanical muscle correction will be performed with one Y-strip of Kinesio® Tape over the bilateral cervical multifidus and semispinalis cervicis muscles, while also including portions of other cervical extensor muscles (the semispinalis capitis, splenius cervicis, levator scapulae, upper trapezius, longus coli, and splenius capitis).
214403702|NCT03212365|DRUG|Fixed dose|Participants will receive 40 mg enoxaparin twice daily
214403703|NCT03212365|DRUG|Variable dose|Participants will receive 0.5mg/kg enoxaparin twice daily
214504558|NCT07043569|OTHER|Resistance Exercise with BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
215097634|NCT07043959|PROCEDURE|Isometrics Exercise|"Shoulder Squeeze:~The therapist instructed the patient to lift their arms to shoulder height while keeping the elbows bent, then move the arms backward until the shoulder blades come together.~Arm Lift to Front and Side:~The therapist instructed the patient to raise their arm forward and upward while applying gentle resistance for 2-3 seconds to facilitate front arm elevation. Then, the patient was guided to lift the arm sideways, with slight resistance applied for 2-3 seconds to assist in side-arm elevation."
215097635|NCT07043959|PROCEDURE|Range of Motion Exercises|"Wall Climb for Flexion: The therapist instructed the patient to move their fingers upward along the wall until they reach their limit, then repeat the movement.~Arm across Chest for Adduction and Internal Rotation: The therapist instructed the patient to move the affected arm toward the unaffected arm and shoulder.~Wand Exercise for Flexion and Abduction: The patient was instructed to hold a wand with both hands and move it forward and sideways toward the affected side"
215097636|NCT05839730|DEVICE|Pacemaker PLR + TRT ON|RAMware modified implantable pulse generator (IPG) with personalized lower rate (PLR) and tachycardia remodeling therapy (TRT) ON
215097637|NCT05839730|DEVICE|Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.|RAMware modified implantable pulse generator (IPG)
215097638|NCT06720714|DRUG|Rozanolixizumab|Dose formulation: Solution for injection Route of administration: Subcutaneous infusion
215097639|NCT06727578|DEVICE|of intrapleural saline irrigation with CLR irrigator|patients will have a CLRTM port and CLRTM irrigator (CLR Medical, Calverton, MD, USA) added to their chest tube and atrium circuit to facilitate pleural irrigation.
215097640|NCT06727136|DRUG|TBP-PI-HBr|TBP-PI-HBr film-coated immediate-release tablets
215009190|NCT05965934|DRUG|Direct Sodium Removal Infusate 2.0|Direct Sodium Removal via peritoneal ultrafiltration using Infusate 2.0 (30% icodextrin, 10% dextrose). Patients (if not yet on SGLT-2 inhibitors) will receive SGLT-2 inhibitors.
215009191|NCT05635760|BEHAVIORAL|Group-based Parent-implemented Social Communication Training|The intervention will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
214504559|NCT06754956|DEVICE|The patient will receive two intravenous injections of the same gadoterate meglumine contrast agent.|Each patient will undergo two different field strength HR-VWIs with enhancement, and on each occasion the patient will be injected with contrast DOTAREM (gadoterate meglumine) .
215009192|NCT05635760|BEHAVIORAL|Self-learning-based Parent-implemented Social Communication Training|Self-learning families will learn the same materials without the guidance of a therapist.
215009193|NCT00424164|DRUG|lapatinib ditosylate|
215009194|NCT00424164|DRUG|tamoxifen citrate|
215009195|NCT00424164|OTHER|pharmacological study|
215097641|NCT07044635|RADIATION|Radiation Therapy|Reduced dose and Hypofractionated radiation therapy
215097642|NCT06729918|OTHER|Virtual reality|Thoracic lung physical examination will be studied using a virtual reality-based thoracic and lung physical examination learning tool.
215009196|NCT03653078|DEVICE|Three dimensional printed digital guide|A CAD/CAM printed plate with a channel for mini-screw insertion
215009197|NCT03334097|OTHER|Prenatal education|"Education intervention will consist of a total of six sessions one week apart, with two hours of duration each one. The sessions that are exclusively oriented towards preparation for childbirth are session 1 and session 2. The content of each session is:~1. St. Birth: Start of childbirth, Symptoms and Signs, Delivery schedules, Phases of childbirth, Normal childbirth, Other circumstances (Obstetrical pathology / previous pathology, Induction of labor, Instrumental birth, Caesarean section).~2. nd:methods for relieving birth pain: Alternative Methods of Pain Relief, Pharmacological analgesia, Regional analgesia. Local and regional anesthesia, General anesthesia, breathing training and accompaniment during childbirth-~3. rd: Puerperium.~4. rd :Breastfeeding~5. rd : Newborn care~6. rd :Positive parenting."
215009198|NCT03341429|DRUG|Liraglutide Pen Injector [Saxenda]|Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.
215097643|NCT06729918|OTHER|simulated patient|Thoracic lung physical examination will be studied using a simulated patient.
215097644|NCT07040423|PROCEDURE|PENG Block|Preoperative ultrasound giuded PENG block (ropivacaine 0,5% 20mL)
215097645|NCT07040423|PROCEDURE|Magnetic resonance imaging|The patient will undergo a pelvic MRI to assess anesthetic diffusion after PENG block
215097646|NCT05382611|DIAGNOSTIC_TEST|ngs next generation sequencing|the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS
215009199|NCT03341429|DRUG|Placebo|Daily subcutaneous injection
215097647|NCT06728332|OTHER|No study intervention|No visits or examinations, laboratory tests or procedures are mandated or required for this study. Providers in the study recruitment network will recruit eligible patients through an existing visit. After this referral, the study is conducted entirely electronically.
215097648|NCT04195399|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214403704|NCT02036060|DRUG|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
214403705|NCT02036060|DRUG|docetaxel 75 mg/m2 + prednisone 10 mg/d|Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
214403706|NCT06481930|DIAGNOSTIC_TEST|Detection of Cervical Lesions by Fluorescence Photoelectric Image|The enrolled patients underwent fluorescence photoelectric cervical lesion image detection, followed by colposcopy and biopsy to obtain histopathological results. The results of fluorescence photoelectric image detection were compared with histopathological results, and at the same time compared with HPV and TCT results at the time of enrollment.
214403707|NCT02434952|DRUG|Dihydroartemisinin piperaquine (DHA PP)|
214403708|NCT02434952|DRUG|Primaquine|
214403709|NCT04921605|DEVICE|DragonFly transcatheter mitral valve clamping system|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
214403710|NCT05162118|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab|Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.
215009200|NCT06373939|DEVICE|Digital lung auscultation|"Two 30-second recordings will be made using CE-marked Littmann® CORE digital stethoscopes and the Pneumoscope at two bilateral lung positions on the posterior chest wall, focusing on the lower lobes. Spectral comparison and audio quality indices will be assessed between the Pneumoscope and the Littmann® CORE digital stethoscope.~Comparator: The Gold Standard Littmann® CORE picks up sounds, such as heart and lung sounds, from a patient's body. After amplification and filtering, the sounds are sent to the user through a binaural headset. The stethoscope chest piece is designed for use with adult, pediatric, and infant patients."
214403711|NCT02656043|DRUG|XPF-005|Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.
214403712|NCT02656043|DRUG|Placebo|
214403713|NCT01443143|OTHER|Portion-controlled diet|During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.
214403714|NCT01443143|DIETARY_SUPPLEMENT|Usual Diet|"During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to Eat how you would normally eat if you were not in this study."
214403715|NCT03853590|PROCEDURE|Roux-en-Y gastric bypass|Creation of a small pouch from the stomach and connection of the newly created pouch directly to the small intestine so that swallowed food bypasses most of the stomach and the first section of the small intestine.
214403716|NCT03853590|PROCEDURE|Laparoscopic adjustable gastric banding|Placement of a soft silicone ring with an expandable balloon in the center, around the top part of the stomach to create a two-compartment stomach, with a much smaller top part above the band. The subject will eat enough food only to fill the top part of the stomach decreasing caloric consumption.
214504560|NCT04412616|BIOLOGICAL|ZZ06|"The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg."
214504561|NCT05206513|DRUG|Placebo|Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube
215009201|NCT06373939|DEVICE|Pulse oximetry measurement|"Pulse oximetry and heart rate will be measured using the CE-marked Masimo Rad-G® and iHealth® Air oximeters, as well as the Pneumoscope's built-in oximeter. Agreement between the Pneumoscope's oximeter and the reference oximeters will be evaluated. Measurement will take 30 second on the right index finger.~Comparators:~1. The Gold Standard Masimo Rad-G® sensor is indicated for the continuous noninvasive peripheral monitoring of arterial oxygen saturation (SpO2) and pulse rate. Its use consists in positioning the emitting window of the sensor attachment envelope on the top of the finger nail bed, while the detector is placed opposite the emitter on the other side of the same finger.~2. The Gold Standard iHealth® Air works by projecting two beams of light through a clip with a transmitter and a detector that is placed around a finger, nail side down and screen side up."
215009202|NCT06373939|DEVICE|Non invasive body temperature measurement|"Comparison of body temperature measurements between the Pneumoscope's built-in thermometer and Gold Standard thermometers (Terumo® C205 and VisioFocus Pro 06480).~Comparators:~1. The Gold Standard Terumo® C205 is an axillary thermometer. Its use consists in placing the probe in the armpit, then lowering the arm and holding the device firmly until the temperature is stabilised and the temperature is read and displayed on the thermometer screen.~2. The Gold Standard VisioFocus Pro 06480 is an infrared thermometer that detects the infrared radiation naturally emitted by the body and in particular from the human forehead. Its use consists in holding the thermometer close to the forehead but without direct contact with the skin. The temperature reading is then projected on the patient's forehead using a symbol system."
215009203|NCT06512233|DRUG|LMW Heparin 5000 U/ML-Aspirin 75 MG|Arm 1
215009204|NCT06512233|DRUG|LMW Heparin 5000 U/ML|Arm 2
215097649|NCT04195399|PROCEDURE|Computed Tomography|Undergo CT
215097650|NCT04195399|PROCEDURE|Echocardiography Test|Undergo ECHO
214403717|NCT01648218|DRUG|Neutral protamine hagedorn (NPH) insulin|
214403718|NCT01648218|DRUG|Regular human insulin or Insulin Aspart|
214403719|NCT01648218|DRUG|Insulin glargine|
214403720|NCT00005982|DRUG|nelarabine|Given IV
214504562|NCT05206513|DRUG|Valbenazine|Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube
214504563|NCT07066657|DRUG|MRG007|MRG007 will be administrated as specified in the protocol.
214504564|NCT06771115|DRUG|VTX3232 Dose A|VTX3232 Dose A
214504565|NCT06771115|DRUG|Placebo|Placebo
214504566|NCT06771115|DRUG|VTX3232 Dose A in combination with semaglutide|VTX3232 Dose A in combination with semaglutide
214504567|NCT06771115|DRUG|Placebo in combination with semaglutide|Placebo in combination with semaglutide
214403721|NCT00005982|OTHER|pharmacological study|Correlative studies
214403722|NCT04948073|OTHER|Dynamic neuromuscular stabilization approach|The experimental group will follow a DNS exercise protocol based on previous procedure for a whole period of 6 weeks (three 50-min sessions per week) in addition the conventional treatment.
214403723|NCT04948073|OTHER|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (18 treatment sessions, three a week, for 30-40min duration).
214403724|NCT00177879|BEHAVIORAL|website comparison|
214403725|NCT00819234|DRUG|Placebo|placebo pramlintide and placebo metreleptin twice daily
214504568|NCT07063914|BEHAVIORAL|Reframe-IT and CARIBOU|"Reframe-IT+ An individual intervention based on cognitive-behavioral therapy (CBT) focused on developing skills in behavioral activation, cognitive restructuring, emotion regulation, stress tolerance, and problem-solving. It is delivered in the school setting by a trained psychologist from the research team. The program consists of 13 weekly sessions of 45 minutes each: 5 face-to-face sessions and 8 combined digital/in-person sessions where students use a computer under the supervision of a psychologist facilitator.~CARIBOU An individual CBT-based intervention focused on behavioral activation, cognitive restructuring, problem-solving, and communication skills. It is conducted in the school setting by a trained psychologist and consists of 16 weekly sessions of 45 minutes each."
214504569|NCT06773208|DRUG|Azacitidine (AZC)|75 mg/m2 daily, on days 1-7, given IV or SC
215009205|NCT03182712|DIETARY_SUPPLEMENT|n-3 PUFA Group|Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
214504570|NCT06773208|DRUG|Venetoclax|Venetoclax 400 mg orally daily on days 1-28
214504571|NCT06749327|BEHAVIORAL|High UPF, high hPDI diet|High ultra-processed foods (UPFs) and healthy plant based diet
214504572|NCT06749327|BEHAVIORAL|Low UPF, high hPDI diet|Low ultra-processed foods (UPFs) and high healthy plant-based diet
215009206|NCT03182712|DIETARY_SUPPLEMENT|Placebo Group|Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
215097651|NCT04195399|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215097652|NCT04195399|DRUG|Nirogacestat|Given PO
215097653|NCT04195399|OTHER|Quality-of-Life Assessment|Ancillary studies
215097654|NCT04195399|OTHER|Questionnaire Administration|Ancillary studies
215097655|NCT04195399|PROCEDURE|X-Ray Imaging|Undergo x-ray
215097656|NCT06732856|DRUG|zolbetuximab|"1. Neoadjuvant treatment~   : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~   (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks)~2. Surgery~   : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node~3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment."
215097657|NCT06732856|DRUG|Oxaliplatin|1\. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
215009207|NCT04588272|DEVICE|DualGuard|DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.
215009208|NCT00769405|DRUG|fluorouracil|Given IV
214403726|NCT00819234|DRUG|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
214403727|NCT03176745|DIAGNOSTIC_TEST|multiple breath washout|determination of lung clearance index using SF6 multiple breath washout
214403728|NCT05392426|DEVICE|Left Ventricular Global Longitudinal Strain|Left Ventricular Global Longitudinal Strain is collected from Speckle tracking imaging (STI) technique of echocardiography. This index is tested before and after the surgery.
214403729|NCT05392426|DEVICE|EF CO SV EDV ESV|Ejection fraction、cardiac output、stroke volume、end diastolic volume、end systolic volume. These indexes are collected before and after the surgery, using traditional echocardiography.
214403730|NCT05564988|OTHER|Preconditionning|"Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days."
214403731|NCT01498874|DRUG|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
214403732|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
214403733|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
214403734|NCT00232076|DRUG|ciclosporin|
214504573|NCT06827080|DRUG|30 mCi NYMO32|The initial dose is set at 30 mCi.
214504574|NCT06827080|DRUG|50 mCi NYMO32|The dose will be escalated to 50 mCi.
214504575|NCT06827080|DRUG|80 mCi NYMO32|The dose will be escalated to 80 mCi.
214504576|NCT06827080|DRUG|130 mCi NYMO32|The dose will be escalated to 130 mCi.
214504577|NCT06827080|DRUG|200 mCi NYMO32|The maximum dose is set at 200 mCi.
215009209|NCT00769405|DRUG|leucovorin calcium|Given IV
214403735|NCT06251908|OTHER|Rewritalize|"REWR is conceptualised as a hybrid between an art group and a group therapy intervention. It is structured as a progressive participatory art group program led by a conductor-tandem: the primary conductor, a professional writer with extensive teaching experience, is supplemented by a co-conductor with clinical expertise who participates in the group activities together with the other participants. The conductor-tandem secure high artistic standards while also ensuring psychological safety. A close collaboration between the two is necessary and both participate in a 30-hour preparatory course and are supervised during the course of the intervention.~The writing course consists in 15 sessions of 3 hours per session. At each session participants are introduced to literary texts that work as prompts for the writing exercises, which last 5-15 min. After each text is read out loud, the participants engage in a reflective discussion about the text."
214403736|NCT06251908|OTHER|Standard mental health care|"F-ACT is a community-based treatment model that provides multidisciplinary, flexible, and assertive outpatient treatment to patients with severe mental illness. OPUS is a nationally implemented 2-year-long early intervention for people with first-episode psychosis. OPUS is a multidisciplinary assertive community treatment model and offer psychoeducation, social skills training, relapse prevention and family involvement, including possibility for treatment participation in psychoeducational multifamily groups.~In F-ACT and OPUS a primary staff member is in regular contact with the patient and responsible for coordinating the treatment elements. The treatment is individual and contingent upon patients' needs."
214403737|NCT06839274|OTHER|transvaginal Ultrasound|The only additional measure will be the measurement of the follicle volumes on the day of trigger and before oocyte pick up procedure. This will be performed at the same time as the pre Oocyte pick up ultrasound prior to the patient admission to the recovery room for preparation. The ultrasound that will be used already has a pre build program that calculates the follicular volume automatically and hence not extending the ultrasound time.
214504578|NCT06778278|BEHAVIORAL|Transition Health and Resilience through Valued Experiences (THRiVE) Program|Six (6) total weekly, 90-minute, small-group, peer-led sessions delivered virtually
214504579|NCT06899607|OTHER|Fibre arm|Increasing daily fibre intake by 10 grams
214504580|NCT06461962|OTHER|Treatment as Usual|Peer-facilitated referral to a local primary care provider to follow-up their screening results.
215009210|NCT00769405|DRUG|oxaliplatin|Given during surgery
215009211|NCT00769405|PROCEDURE|hyperthermia treatment|Given intraperitoneally during surgery
215009212|NCT03296345|DRUG|Ketamine|The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
215009213|NCT02524678|DRUG|Placebo|
215009214|NCT02524678|DRUG|URC102|
215009215|NCT01613833|PROCEDURE|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
215009216|NCT01613833|PROCEDURE|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
215009217|NCT01613833|PROCEDURE|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
215009218|NCT01613833|PROCEDURE|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
215009219|NCT04149353|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
215009220|NCT04967703|PROCEDURE|Group A|Patients received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes), in addition to a conventional physiotherapy program consisting of calf muscles stretching, plantar fascia stretch, strengthening exercises and manual massage for 3 sessions per week, for 4 weeks
215009221|NCT04967703|PROCEDURE|Group B|Patients received radial shock wave therapy protocol with the following parameters (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz, in addition to the same conventional physiotherapy program given for group A
215009222|NCT04967703|PROCEDURE|Group C|Patients received both ultrasound and radial shock wave therapy, in addition to the same conventional physiotherapy program given for group A
215009223|NCT04041128|DRUG|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
215009224|NCT06468475|DRUG|Magnesium Sulphate infusion|Magnesium sulphate 24 hours apart by intravenous infusion at 250 mg/kg/dose (0.5 mL/kg/dose of injection magnesium sulphate 50% w/v diluted in 5 mL/kg of 5% glucose) over a duration of half an hour by an infusion pump
215009225|NCT03650608|DRUG|Cohort 1: HL217 Ophathalmic Solution QD|Cohort 1 (Once a day)
215009226|NCT03650608|DRUG|Cohort 2: HL217 Ophathalmic Solution BID|Cohort 2 (Twice a day)
215009227|NCT03650608|DRUG|Cohort 3: HL217 Ophthalmic Solution QID|Cohort 3 (Four times a day)
215009228|NCT03650608|DRUG|Placebo Ophthalmic solution|Placebo
215009229|NCT04769401|OTHER|Normal Progesterone group|Progesteron supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) as luteal phase support (referred to as day 0 of progesterone administration).
215009230|NCT04769401|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, 25 mg/d of SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day and the blood sample was taken 2 days later to check serum progesterone levels.
215009231|NCT01106950|BIOLOGICAL|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is \< or = 8 x 10\^7 nucleated cells/kilogram.
215009232|NCT01106950|DRUG|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
215009233|NCT01106950|DRUG|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
215009234|NCT01106950|DRUG|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
214403738|NCT04912557|OTHER|postoperative pain assess|numerical pain scale and Metameric levels of cold insensitivity
214403739|NCT05174065|DRUG|Apremilast|Oral tablets
214403740|NCT05174065|DRUG|Placebo|Oral tablets
214403741|NCT05620472|DRUG|Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1|One single intravenous injection of \[99mTc\]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
214403742|NCT05130138|OTHER|Pharmaceutical intervention|Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.
214403743|NCT04474600|DRUG|Propofol|The induction and maintenance of anesthesia was performed by total intravenous anesthesia using propofol. In both groups, remifentanil is continuously infused throughout the surgery.
215009235|NCT01106950|PROCEDURE|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
215009236|NCT01106950|DRUG|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m\^2 every other day for 6 doses).
215009237|NCT00356421|DRUG|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
215009238|NCT00356421|DRUG|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
215009239|NCT03941886|OTHER|Low-dose aspirin in women with high risk of preeclampsia|Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight \<40 Kg, from \<15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
215009240|NCT02694250|DEVICE|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
214403744|NCT04474600|DRUG|Desflurane|The induction and maintenance of anesthesia was performed by inhalation anesthesia using desflurane. In both groups, remifentanil is continuously infused throughout the surgery.
214403745|NCT06357741|DRUG|Denosumab|Desumumab, 60mg single injection
214403746|NCT00184119|PROCEDURE|Psychiatric Intensive Care Unit|
214403747|NCT00184119|PROCEDURE|Care in whole acute unit|psychiatric acute care as usual
214403748|NCT05314283|DEVICE|DV3395 C1|Participants will be exposed to and swallow DV3395 C1 once. The participants will stay at the clinic research center for up to 6 days .
214403749|NCT00216320|DEVICE|WalkAide|Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
215009241|NCT05504421|OTHER|Sustainability education in nursing to be given with two different teaching methods|Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
215009242|NCT00558883|DRUG|acarbose|oral application
214403750|NCT00216320|DEVICE|AFO|Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
214504581|NCT06461962|OTHER|Telehealth-Cardiology|"Peer-facilitated virtual consultation with cardiovascular specialist, for follow-up of their screening results. Activities may include: referral for a locally performed testing including echocardiogram and additional blood work, and transitional care management facilitated by a remote nurse care manager and the peer~Referral for a locally performed testing including echocardiogram~Transitional care management facilitated by a remote nurse care manager and the peer"
215009243|NCT05950126|OTHER|pain catastrophizing scala|"The PCS, a 13-item self-report inventory used to determine the extent to which individuals catastrophize in response to pain, was developed. Total possible scores range from 0 to 52, with higher scores indicating negative results.~The Turkish version was tested for reliability and validity and the Cronbach alpha coefficient was measured at 0.90. PCS scores of 16 or lower are regarded as normal, and scores of 17 or above as high."
215009244|NCT04449809|BEHAVIORAL|Exercise program|3x per week group monitored group exercise sessions
215009245|NCT06479057|OTHER|Supportive Care Pathway|All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.
215009246|NCT00887588|DRUG|LCZ696|50 mg, 100 mg and 200 mg tablets
215009247|NCT00887588|DRUG|Valsartan|40 mg, 80 mg and 160 mg tablets
215009248|NCT00887588|DRUG|Placebo|matching placebo to LCZ696 and Valsartan
215009249|NCT03468946|OTHER|salty taste perception|"salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk )."
215009250|NCT03468946|OTHER|bitter taste perception|"bitter taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate bitter taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
214403751|NCT00216320|DEVICE|AFO|Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
214403752|NCT00924560|DRUG|91-day Levonorgestrel Oral Contraceptive|"Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.~Take 1 tablet daily"
214403753|NCT00924560|DRUG|28-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
214403754|NCT01307280|BEHAVIORAL|RCT1|the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
214403755|NCT01307280|BEHAVIORAL|RCT2|bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments
214403756|NCT01307280|BEHAVIORAL|RCT3|bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
215009251|NCT03468946|OTHER|sour taste perception|sour taste perception in high caries risk, medium caries risk, low caries risk. The aim of this study was to evaluate sour taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk ).
214403757|NCT03074110|DEVICE|Isocapnic hyperventilation|Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
214403758|NCT04997967|DRUG|Ketamine/Propofol|The level of sedation was assessed at 1-3 min intervals, and the infusion rate was adjusted accordingly to achieve a Ramsay Sedation Scale (RSS) score of 5. Any movement of the patient was treated by increasing infusion rate and the infusion was discontinued at the end of the procedure. The total propofol consumed was calculated and the recovery time was recorded and calculated as the time from discontinuation of infusion of the study drug till achievement of RSS score of 3. Then patients were discharged to post-anesthesia care unit (PACU) after attaining an Aldrete Recovery Scale Score of 9- 10 \[19\]. Time taken to achieve this score was also recorded.
214403759|NCT04997967|DRUG|Propofol|Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
215009252|NCT03468946|OTHER|sweet taste perception|"sweet taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate sweet taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
215009253|NCT02575183|DRUG|Varinecline (Chantix)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
214403760|NCT01114620|BIOLOGICAL|Arepanrix™|Intramuscular administration, one dose
214403761|NCT02249871|DRUG|semaglutide|All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
214403762|NCT02249871|DRUG|Omeprazole|Will be given daily with oral semaglutide.
214403763|NCT04635501|DEVICE|ABS 5.6.7|Patients whose access site will be closed with the ABS 5.6.7
214504582|NCT05711719|DRUG|Vericiguat|Up-titration will be performed as guided by the evaluation of blood pressure and clinical symptoms
214504583|NCT05711719|DRUG|Placebo|Administered the same way
214504584|NCT06864494|PROCEDURE|Endometrial ablation|Performed using a transfer catheter (used for embryo transfers) positioned at the level of the internal cervical orifice in the uterine cavity. Five ml of saline will be injected and collected in a dry tube
215009254|NCT02575183|DRUG|Placebo (for Varenicline)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
215009255|NCT02575183|BEHAVIORAL|Behavioral Therapy|This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
214403764|NCT00734513|BEHAVIORAL|Partner-assisted emotional disclosure|Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
214403765|NCT00734513|BEHAVIORAL|Cancer Education|The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
214504585|NCT06780553|DIAGNOSTIC_TEST|Proteomic profiling|Proteomic profiling as a diagnostic tool in the face of suspected extrahepatic cholangiocarcinoma stenosis
214504586|NCT06803615|DEVICE|Electrocardiographic imaging|Electrocardiographic imaging is an electrophysiological mapping technique which is used to noninvasively map cardiac arrhythmias.
214504587|NCT06056206|RADIATION|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list.
214504588|NCT04278833|DRUG|Triamcinolone or Betamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
214504589|NCT04278833|DRUG|Dexamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
214504590|NCT07077395|DRUG|fezolinetant - reference formulation|fezolinetant 45 mg daily x 12 weeks
214403766|NCT05249764|OTHER|Supervised Home Based Exercise Training|Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.
214403767|NCT05249764|OTHER|Unsupervised stretching and breathing exercises|Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
215009256|NCT02321150|PROCEDURE|Cautery|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Relaxing incisions placed at the corners of the recipient site.~* Graft is slid into place~* Graft / host interface is gently dried with a Qtip~* Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~  * Power setting: 25.~ * Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~* Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~* Cautery is applied at the 4 apices of the graft then in between these points."
215097658|NCT06732856|DRUG|Docetaxel|1\. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
214403768|NCT02941185|DRUG|Devit-3 Oral Drop|
214403769|NCT00000316|DRUG|Cocaine|
214403770|NCT06397287|OTHER|Observation of patients undergoing sugery|All patients undergoing urological surgery or treatment receive standardized questionnaires on quality of life, satisfaction, pain and physical recovery. Indication-specific, individual pathways are set up,
214403771|NCT04477850|DRUG|Luspatercept|Specified dose on specified days
214403772|NCT02696226|DRUG|SAVR Warfarin|Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
214403773|NCT02696226|DRUG|SAVR Aspirin|Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
214403774|NCT02696226|DRUG|TAVR Warfarin and clopidogrel|Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
214403775|NCT02696226|DRUG|TAVR Aspirin and clopidogrel|Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
214403776|NCT03564054|PROCEDURE|Photodynamic Therapy|Participants on this arm will be treated with photodynamic therapy. PDT is a two-stage process. The first stage of PDT is the intravenous injection of porfimer sodium (Photofrin) administered as a single slow intravenous injection over 3 to 5 minutes. The second stage involves the application of laser light to the tumor by bronchoscopy.
214403777|NCT03564054|PROCEDURE|Argon Plasma Coagulation|"Participants on this arm will be treated with argon plasma coagulation. A flexible probe housing a wire delivers high-frequency, high-voltage electric current to a monopolar tungsten electrode present at the tip of the probe. Argon gas flows through the probe, and is charged or ionized to produce plasma as it flows around the tungsten electrode. Electric current flows through the plasma to the nearest tissue, and heat is produced as it passes through the tissue. Increased resistance created by coagulated tissue impairs the flow of electric current, and keeps the ablation depth to 1 to 2 mm."
214403778|NCT00671684|PROCEDURE|Endoscopic Mucosal Resection (EMR)|EMR is a common procedure in gastroenterology. The technique involves placing a band around a piece of mucosa in the GI tract. The band and the tissue are then removed using a cautery snare. The technique can be used to obtain tissue for diagnostic purposes or to remove lesions for therapeutic purposes.
214403779|NCT04223921|OTHER|Comparison of patient's medicines|"Comparison of patient's medicines:~* between patient's discharge from hospital and one month after this discharge (acute geriatric care unit)~* between patient's admission and discharge from hospital (acute geriatric care unit"
214403780|NCT00415740|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
214403781|NCT00530179|PROCEDURE|Autologous Blood Stem Transplantation|2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
214403782|NCT00530179|DRUG|R-CHOP|6 - 21 DAY Cycles of R-CHOP
214504591|NCT07077395|DRUG|placebo|placebo daily x 12 weeks
214504592|NCT03671967|DRUG|Piperacillin/tazobactam|4.5 grams QID
214403783|NCT03658629|BIOLOGICAL|NanoFlu (Quad-NIV)|2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine
214403784|NCT03658629|OTHER|Matrix-M Adjuvant|Adjuvant
214403785|NCT03658629|OTHER|Placebo|Placebo
214403786|NCT03658629|BIOLOGICAL|Fluzone HD|2018-2019 Licensed Trivalent Seasonal Influenza Vaccine
214403787|NCT03658629|BIOLOGICAL|Flublok Quadrivalent|2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine
214403788|NCT03658629|BIOLOGICAL|Influenza Vaccine|2018-19 Licensed Seasonal Influenza Vaccine
214504593|NCT03671967|DRUG|Meropenem|1 gram TID
214504594|NCT04447027|DRUG|Romidepsin|Romidepsin (12mg/ m\^2) will be administered on days 1 and 10 of each cycle through a peripheral or central intravenous catheter for 6 cycles.
214403789|NCT01046747|PROCEDURE|Placement of external fixation pins|The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
214403790|NCT02909101|DEVICE|Active Cognitive Training (ACT)|Cognitive training games
214403791|NCT02909101|DEVICE|Control Training (CON)|Cognitive training games
214403792|NCT00752570|DRUG|AMG 386|AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
215097659|NCT06732856|DRUG|S-1|1\. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
215097660|NCT06743529|PROCEDURE|control group|immediate empiric Antibiotic Therapy (started within 1 hour after randomization) with antibiotic(s) chosen by the bedside physician based on time of ventilator-associated pneumoniaoccurrence, risk of antimicrobial resistance, local ecology, and local protocol. If the respiratory samples are negative, Antibiotic Therapy will be stopped. If ventilator-associated pneumonia is confirmed by positive samples, Antibiotic Therapy active against the recovered bacterial specie(s) will be given for a total of 7 days.
215097661|NCT06743529|PROCEDURE|Conservative strategy|No Antibiotic Therapy until receipt of the respiratory sample culture and/or polymerase chain reaction results. If these results are negative, no Antibiotic Therapy is given. If they are positive (confirmed ventilator-associated pneumonia), Antibiotic Therapy is started as appropriate for the bacterial specie(s) detected by culture and/or polymerase chain reaction, without considering gram-stain results and without waiting for antimicrobial susceptibility testing results, and continued for a total of 7 days of Antibiotic Therapy active against the identified bacterial specie(s).
215097662|NCT05804149|DEVICE|acupuncture|study group take acupuncture Acupuncture was applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.
214403793|NCT00752570|DRUG|AMG 386 Placebo|AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
214504595|NCT04447027|DRUG|Lenalidomide|Lenalidomide will be administered by oral intake in a dose-escalation with a starting dose of 5mg daily, a second dose level of 10mg daily, a third dose level at 15mg daily, and a fourth dose level at 20mg daily on days -7 to day 10 of first cycle. After the second cycle, lenalidomide will be given from day 1 to day 10 in each cycle for up to 6 cycles.
214504596|NCT04447027|DRUG|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.
215009257|NCT02321150|PROCEDURE|Sutures|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures"
215009258|NCT03033212|OTHER|Therapist-Guided Rehabilitation|Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
215009259|NCT03033212|OTHER|Self-Guided Rehabilitation|Rehabilitation consists of self-guided exercises with provided instructions. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
215009260|NCT04773977|DRUG|IBI362 liquid formulation|Administered by subcutaneous injection
215009261|NCT04773977|DRUG|IBI362 lyophilized powder|Administered by subcutaneous injection
215009262|NCT02722135|DRUG|Volasertib|
215009263|NCT02245386|RADIATION|transperineal pelvic floor ultrasound|"Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
215097663|NCT05804149|DRUG|Thyroxine|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine
214403794|NCT00752570|DRUG|FOLFIRI|"Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest."
214403795|NCT01125774|DRUG|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
214403796|NCT01125774|DRUG|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
214403797|NCT03202875|DRUG|SAR341402|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214403798|NCT03202875|DRUG|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214403799|NCT03202875|DRUG|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214403800|NCT06270420|DEVICE|Technological Motor Rehabilitation|Patients will undergo to motor treatment in the HoSmartAI room using one of the technological devices (i.e. OAK, VRRS Evo by Khymeia Group, Padova, Italy; AMADEO, PABLO by Tyromotion GmbH, Gratz, Austria), for the upper limb and lower limb motor recovery, balance and manual dexterity recovery. The duration of the treatment will be 15 sessions, 1 hour each, with daily frequency, 5 days a week, for a total of 3 weeks.
214403801|NCT02005614|PROCEDURE|Gamma Knife Radiosurgery|"Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.~Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours."
214403802|NCT01221181|DRUG|Eculizumab|Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
214504597|NCT04447027|DRUG|Dexamethasone|Dexamethasone, 40mg, by mouth (PO), will be given on days 1 and 10 of each cycle.
214504598|NCT04447027|DIAGNOSTIC_TEST|EKG|Screening
214504599|NCT04447027|PROCEDURE|Bone Marrow Aspiration/Biopsy|Baseline, end of treatment and disease progression, and Day 30 (+7).
214504600|NCT04447027|DIAGNOSTIC_TEST|MRI|Baseline, every 2 cycles, end of treatment and disease progression, and follow-up.
214504601|NCT04447027|PROCEDURE|Lumbar Puncture|Baseline, every 2 cycles, end of treatment and disease progression, and follow-up.
215009264|NCT03587857|OTHER|Mobile Health Application|This mobile health app is a modular, adaptive, and personalized intervention delivered via a mobile phone. It is grounded in the Information Motivation Behavioral Skills (IMB) model. It was created in collaboration with YLWH (18-29 years-old) using a Human-Centered Design approach to help improve engagement in HIV care among this age group.
215009265|NCT06133504|PROCEDURE|Early Multimodal Therapy|Early multimodal therapy is defined as the collection of therapeutic maneuvers performed by the physiotherapy, speech therapy, respiratory therapy, and occupational therapy team at the time of study inclusion.
215009266|NCT06133504|PROCEDURE|Late Multimodal Therapy|Late multimodal therapy is characterized by the same set of maneuvers carried out by the same disciplinary team, but it is initiated once indicated by the attending physician.
215009267|NCT04460235|BIOLOGICAL|Prevenar 13 + Pneumovax 23|Cohort study A before modification of vaccination national guidelines
215009268|NCT04460235|BIOLOGICAL|PREVENAR20|"Health authorities changed guidelines to recommend one injection of PREVENAR20 instead of the 2-vaccine scheme general practitioners are usually in charge of this vaccination.~Cohort study B"
215009269|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.
215009270|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.
215009271|NCT06066528|DRUG|Survodutide|once weekly subcutaneous injection
215009272|NCT06066528|DRUG|Placebo|once weekly subcutaneous injection
215009273|NCT01571986|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation
215009274|NCT06259500|OTHER|observational|Profiling the function of iPSC derived Arcuate neurons and PBMC derived microglia
215009275|NCT05469204|DRUG|Midazolam oral solution|2 mg single-dose before and during estradiol treatment.
215009276|NCT05469204|DRUG|Digoxin Oral Tablet|0.25 mg single-dose before and during estradiol treatment.
215009277|NCT05469204|DRUG|Acetaminophen Oral Tablet|500 mg single-dose before and during estradiol treatment.
215009278|NCT05469204|DRUG|Midazolam Injectable Solution|1 mg intravenous single-dose before and during estradiol treatment.
215009279|NCT05712720|DRUG|Experimental: Group 1 - 50mg RZ402|RZ402 50 mg oral tablet, once daily for 3 months
215009280|NCT05712720|DRUG|Experimental: Group 2 - 200mg RZ402|RZ402 200mg oral tablet, once daily for 3 months
215009281|NCT05712720|DRUG|Experimental: Group 3 - 400mg RZ402|RZ402 400mg oral tablet, once daily for 3 months
215009282|NCT05712720|OTHER|Placebo: Group 4 - Placebo|Placebo oral tablet, once daily for 3 months
215009283|NCT06533904|PROCEDURE|Percutaneous Cryoablation of Intercostal Nerves|Percutaneous Cryoablation of Intercostal Nerves
215009284|NCT06533904|OTHER|Multi-modal pain regimen|Standard rib fracture protocol including cyclooxygenase inhibitors, anti-neuropathic, muscle relaxers, short term anesthesia interventions (percutaneous block, epidural)
215009285|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Hair Growth Supplement|Hair growth supplement for women ages 18 - 44
215097664|NCT05804149|DIETARY_SUPPLEMENT|low caloric diet|Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
215097665|NCT01295424|OTHER|No intervention|Observational study, no interventions
215097666|NCT07056517|DRUG|M107 and Duvie - Cohort 1|Dosage form - Oral tablets Dosage - Duvie 0.415 mg and M107 ODT 0.4 mg Participants will receive each treatment once under fasted conditions in a randomized two-period crossover design.
215097667|NCT07056517|DRUG|M107 - Cohort 2|Dosage form - Orally disintegrating tablet Dosage - 0.8 mg Participants will receive M107 once under fasted conditions and once after a high-fat, high-calorie meal in a two-period crossover design.
215097668|NCT07056517|DRUG|M107 - Cohort 3|Dosage form - Orally disintegrating tablet Dosage - 1.2 mg Participants will receive a single oral dose of M107 under fasted conditions.
215097669|NCT07082959|BEHAVIORAL|Nursing Pillow|Although there are studies investigating the effects of breastfeeding pillow use on breastfeeding success, comfort, and positive outcomes for both mother and baby, no study has been found examining the effect of breastfeeding pillow use on nipple pain and maternal comfort in women who have undergone vaginal delivery. Therefore, the aim of this study is to evaluate the effect of breastfeeding pillow use on nipple pain and comfort during the postpartum period.
215097670|NCT07082894|DRUG|Magnesium|preoperative oral magnesium dose of 120 mg at one hour before surgery will be given.
215097671|NCT07082894|OTHER|Placebo control|preoperative oral lemon juice at one hour before surgery will be given.
215097672|NCT07077915|OTHER|Osseodensification burs|Densah burs are osseodensification burs used to condense bone and prepare dental implant site, unlike conventional technique which cuts and removes the bone
215097673|NCT07077915|OTHER|Conventional burs|Preparation of dental implant site by the Conventional technique using Conventional burs that are subtractive
214504602|NCT04447027|DIAGNOSTIC_TEST|TTE|Screening
215009286|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Balance Hair Growth Supplement|Hair growth supplement for women ages 45 - 70
215009287|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Vegan Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet
215009288|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Postpartum Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
215009289|NCT02802722|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.
215009290|NCT02802722|BIOLOGICAL|Peripheral blood and induced sputum sampling|To attain samples for immunological testing
215009291|NCT02802722|RADIATION|Chest computerised tomography (CT) scans|For volumetric quantification of lung abnormalities
215009292|NCT02802722|OTHER|Symptom questionnaire|Symptom questionnaire for recent symptom history
215097674|NCT07087704|DIETARY_SUPPLEMENT|High-fat diet|The group follows a Chilean diet (adapted from the Mediterranean Diet using Chilean ingredients) supplemented with 30 g/day of Gevuina avellana and providing 40% of total energy value from fat. To promote adherence to the diet, individual motivational interviews and group sessions (with approximately 25 participants) are conducted once per month. Each participant is provided once a month with individually packaged Chilean hazelnuts to reach a daily intake of 30 g.
214504603|NCT02227927|DRUG|Domperidone|10-30mg oral dose, four times daily.
214504604|NCT05292989|OTHER|Frailty Assessment|Personalised (tailored) approach that includes assessment of frailty and structured information provided to the consumer
214504605|NCT05292989|OTHER|Standard Care|Standard care practice
215009293|NCT02802722|OTHER|Placebo|To be dispensed using an electronic dispenser to allow real time logging of adherence.
215009294|NCT01870037|DRUG|Placebo (PBS-20% sucrose)|
215009295|NCT01870037|DRUG|hMaxi-K|Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
215009296|NCT02685865|DEVICE|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
215009297|NCT02685865|DEVICE|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
215009298|NCT03753542|OTHER|Multimedia education, booklet Providence and tele-nursing follow-up|Multimedia education, booklet and weekly tele-nursing follow-up is about chemotherapy and side effects management
214403803|NCT06827912|PROCEDURE|Interscalene Nerve Block|After sterile conditions are provided with the patient in the supine position, the brachial plexus will be identified in the supraclavicular fossa above the clavicle with ultrasonography. The transducer will be directed cephalad and 20 cc 0.5% bupivacaine will be applied to the interscalene space with a 50 mm block needle from the point where the C 5-6-7 nerve roots give the impression of a rosary bead between the anterior and medial scalene muscles.
214403804|NCT06827912|PROCEDURE|Shoulder Anterior Capsule Block|In pericapsular nerve block application, the patient will be placed in a supine position and the arm will be externally rotated and abducted to 45 degrees. After sterile conditions are provided, the humerus head, the tendon of the subscapularis muscle and the deltoid muscle above it will be identified with ultrasonography. 15 cc of 0.5% bupivacaine will be injected into the interfascial space between the deltoid muscle and the subscapularis muscle with a 22gauge 50 mm block needle. Then, the block needle will be directed deep into the subscapularis muscle and another 5 cc of 0.5% bupivacaine will be injected under the subscapularis muscle.
214403805|NCT02344303|DRUG|TRV130|
214403806|NCT02344303|DRUG|Moxifloxacin|
214403807|NCT02344303|DRUG|Placebo|
214403808|NCT04855487|BEHAVIORAL|Nurse-patient dyadic storytelling intervention|During the 5-week online intervention, adolescents/young adults with cancer will create their stories following the guiding questions and online meetings with nursing research staff. The target audience of their stories will be their primary nurses. This online dyadic storytelling intervention is designed to promote in-depth self-reflection and meaningful and therapeutic relationships within bedside nurses. The intervention is designed following the Story Theory and Pennebaker's Expressive Writing paradigm.
215009299|NCT04690647|OTHER|Opioid and non opioid postoperative analgesia.|Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
215009300|NCT04690647|OTHER|Fascia iliaca compartment block|Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.
215009301|NCT04690647|DRUG|Dexamethasone|Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
215009302|NCT05395780|DRUG|MAX-40279|MAX-40279 capsule will be administered orally
215009303|NCT04864067|DRUG|Oxaliplatin|Consolidation Chemotherapy
215009304|NCT04864067|DRUG|5-Fluoracil|Consolidation Chemotherapy
215009305|NCT04864067|DRUG|Leucovorin|Consolidation Chemotherapy
215009306|NCT04864067|DRUG|Capecitabine|Consolidation Chemotherapy
215009307|NCT04864067|RADIATION|5x5 Gy|Neoadjuvant Radiotherapy
215009308|NCT04864067|BEHAVIORAL|Quality of Life Questionnaires|Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)
215009309|NCT04864067|PROCEDURE|DRE/ Endoscopy|Flexible Sigmoidoscopy and Digital Rectal Exam
215009310|NCT03573089|DRUG|Liberal phosphate target|All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
215009311|NCT03573089|DRUG|Intensive phosphate target|This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
215009312|NCT06482983|PROCEDURE|Mechanical Ventilation Mode|after intubation different ventilation mode (VC,PC,PC-VG)
215097675|NCT07087704|DIETARY_SUPPLEMENT|Low-fat diet|The group maintains a low-fat diet (\<30% of total energy value) based on the Chilean Ministry of Health (MINSAL) technical guidelines for dyslipidemia management. To promote adherence to the diet, individual motivational interviews and group sessions (with approximately 25 participants) are conducted once per month.
215097676|NCT07088614|OTHER|Remote respiratory physiotherapy|"Remote respiratory physiotherapy protocol supervised 3 times a week via digital video conferencing, based on Chilean national guidelines for cystic fibrosis.~Each 1-hour session (3×/week for 6 months) includes:~Evaluation: respiratory assessment, teaching and reinforcement of airway clearance techniques, inhaled medication use, physical activity, and adherence to non-physiotherapy care. Six checklists are used to guide and monitor weekly patient activities.~Respiratory physiotherapy: conducted on-screen by the patient or caregiver, guided remotely. Includes: short-acting bronchodilator (if indicated), 7% hypertonic saline nebulization (10 min), 5-min Flutter/Acapella, ELTGOL or ELPr (2×5 min), and assisted coughing.~Re-evaluation: reassessment with the initial checklist, Q\&A, and scheduling the next session.~Participants continue their usual hospital-based care and receive baseline and post-intervention measurements."
214403809|NCT03271619|OTHER|Surface current measurement|Measurement of surface current between electrodes placed on the chest wall during defibrillation
214403810|NCT05698654|BEHAVIORAL|Fasting-mimicking diet (FMD)|"The subjects will be instructed to follow their usual diet plan, except for 5 days when they eat the foods in the FMD box.The fasting-mimicking diet consists of a blend of 100% plant based nutrients generally regarded as safe. The formulation of these products is based on studies carried out at the Longevity Institute of the University of Southern California and his collaborators over several decades of studies.~This food plan provides for the replacement of the normal diet with the organic plant products contained in the fasting-mimicking diet for five consecutive days."
215009313|NCT06415487|DRUG|Cyclophosphamide|Lymphodepleting agent
214504606|NCT06850259|DEVICE|PureWick™ System|The PureWick™ System consists of the PureWick™ Urine Collection System used with the PureWick™ Male External Catheter (MEC), which is intended for non-invasive urine output management in male patients. The PureWick™ MEC is a single-use, non-sterile, commercially available device, which is Class I, 510(K) exempt.
214504607|NCT06850259|DEVICE|UltraFlex™ Self-Adhering Male External Catheter|UltraFlex™ is a self-adhering male external catheter used for the drainage of urine. The catheter is applied by the patient or caregiver. The self-adhering male external catheter is designed for the management of adult male urinary incontinence.
214504608|NCT06809842|DRUG|Vastus lateralis nerve block|Patients received vastus lateralis nerve block with 5 ml of bupivacaine 0.5%.
215009314|NCT06415487|DRUG|Fludarabine|Lymphodepleting agent
215009315|NCT06415487|DRUG|ACE2016|Allogeneic gamma delta T (gdT) cell therapy
215009316|NCT06415487|DRUG|Pembrolizumab|Immune checkpoint anti-PD-1 antibody
215097677|NCT07088588|DRUG|SYN608|Patients will orally receive SYN608
215097678|NCT07087652|OTHER|Onco Move multicomponent face-to-face training program|The Onco Move intervention will include three training sessions per week (each lasting 60 minutes), held in the fitness rooms and the gym at Gdansk University of Physical Education and Sport in Poland for 16 weeks. The intervention will include aerobic and strength exercises but also coordination/balance and flexibility, with warm-up and cool-down elements.
215097679|NCT07088627|PROCEDURE|Intervention 1: UG|Participants perform UG targeting SN and C\&J exercises, varying intensity at 80% of 1RM and volume (5 sets of 5, 4, 3, 2, 1 repetitions) over weeks. Rest between sets: 90 seconds.
215009317|NCT03496675|BEHAVIORAL|Group Music Therapy|The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.
215009318|NCT03496675|BEHAVIORAL|Recreational Choir Singing|RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.
215009319|NCT03496675|OTHER|Standard care|May include pharmacological and non-pharmacological interventions as locally available
215009320|NCT02359253|OTHER|Passive stretching|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.
215009321|NCT02359253|OTHER|Passive movement|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
215009322|NCT02359253|OTHER|IntelliArm|During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
215097680|NCT07088627|PROCEDURE|Intervention 2: SG|Participants perform SG with SN and C\&J at consistent 80% 1RM intensity, 5 sets of 5 repetitions each session. Rest between sets: 90 seconds.
214403811|NCT05698654|BEHAVIORAL|Longevity Diet (LD) + Fasting-mimicking Diet (FMD)|"The subjects will be instructed to follow their longevity diet plan, except for 5 days when they eat the foods in the FMD box, based on the following guidelines:~vegan based diet with the addition of low mercuryfish 2-3 times a week; protein content should be 0.7-0.8 grams per kilogram of ideal weight per day (most of the protein coming from whole cereals,vegetables, legumes and tree nuts only part from fish); monounsaturated and polyunsaturated fats are predominant and very low amounts of saturated and trans-fats are allowed; complex Carbohydrates from vegetables, whole grains and legumes; addition of vitamins, minerals and Omega3 fats; food selected between the traditional food consumed by ancestry; time-restricted feeding: all food must be consumed within 12 hours each day. for those who are overweight or are nearly overweight (BMI \>25 kg/m2), either lunch or dinner will be substituted with a low calorie, low sugar snack (approximately 100 kcal: salad, nuts, fruit, etc.)."
215097681|NCT07088627|PROCEDURE|Intervention 3: MG|Participants engage in MG training focusing on SN and C\&J at 100% 1RM, 5 sets of 1 repetition, with 180 seconds rest between sets.
214403812|NCT04578028|DRUG|ONO-2808|Investigational drug
214403813|NCT04578028|DRUG|Placebo|Placebo drug
214403814|NCT03323151|DRUG|Ixazomib|Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities. Note: Ixazomib dose will not be de-escalated but remain at 3 mg.
214403815|NCT03323151|DRUG|Ixazomib|Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.
214403816|NCT03323151|DRUG|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
215097682|NCT07088341|DIAGNOSTIC_TEST|elisa|enzyme- linked immunesorbent assay ( ELISA ) was used to measure soluble programmed death ligand-1 level
215097683|NCT07089446|DRUG|Hyaluronic Acid (HA)|Hyaluronic Acid
214403817|NCT03323151|DRUG|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.
215009323|NCT02359253|OTHER|Hand robot|During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
215009324|NCT04359615|DRUG|Favipiravir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Favipiravir in COVID-19 patients.
215009325|NCT04359615|DRUG|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
215009326|NCT06100250|BEHAVIORAL|Motivational interviewing and specimen self-collection|Participants will be asked to attend a pre-test live AV conferencing session, collect and return a urine sample, a throat swab, a rectal swab, and a blood sample for bacterial STI testing, and attend a post-test live AV conferencing session.
215009327|NCT03940352|DRUG|HDM201|Capsule
215009328|NCT03940352|BIOLOGICAL|MBG453|LIVI (Liquid in vial) Concentrate for Solution for infusion
215097684|NCT07089446|DRUG|Platelet Rich Plasma|Platelet rich plasma
215097685|NCT07089446|DRUG|Hyaluronic Acid (HA) and Platelet rich plasma|Hyaluronic Acid and Platelet rich plasma
214403818|NCT01134211|DEVICE|nelfilcon A|Commercially marketed, single-vision, soft contact lens for daily disposable wear
214403819|NCT01134211|DEVICE|filcon II 3|Commercially marketed, single-vision, soft contact lens for daily disposable wear
214403820|NCT01055106|DRUG|GW05|vaginal gel once daily regimen A
215009329|NCT03940352|DRUG|Venetoclax|Tablet
214403821|NCT01055106|DRUG|GW05|vaginal gel once daily regimen B
214403822|NCT01055106|DRUG|GW05|vaginal gel once daily regimen C
214403823|NCT01055106|DRUG|Metronidazole|vaginal gel 0.75% once daily for 5 days
214403824|NCT03886675|OTHER|CO2 flushing|As above
214403825|NCT03886675|OTHER|Saline flushing|As above
215009330|NCT02021318|DRUG|Roxadustat|Oral tablet.
215009331|NCT02021318|DRUG|Darbepoetin alfa|Subcutaneous or intravenous injection.
214403826|NCT01258218|DEVICE|Implantation of an Accent MRI device|Implantation of an Accent MRI device
214403827|NCT01807078|DRUG|Ezetimibe|10 mg p.d. of ezetimibe
214403828|NCT01807078|DIETARY_SUPPLEMENT|Nutraceuticals|1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
214688278|NCT07162532|DIAGNOSTIC_TEST|1 Complete blood picture (CBC) with blood film, lymphocytic count 2 and viral hepatitis 3 Immunophenotyping 4 LDH 5 Coomb's tests ,deletion 17p,IGVH mutation,ESR|Complete blood picture (CBC) with blood film, lymphocytic count 2 Routine liver and kidney function and viral hepatitis 3 Immunophenotyping 4 LDH 5 Coomb's tests 6 Erythrocyte sedimentation rate (ESR). 7 C reactive protein (CRP). 8 Cytogenetic profiles: del(17p) 9 molecular study :IGHV mutation status.
215009332|NCT06560320|BEHAVIORAL|Virtual Reality Glasses|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the vaccination procedure.
215009333|NCT05636124|DEVICE|Kaneka i-ED coil|The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
215009334|NCT06973304|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection.
215097686|NCT07088783|BEHAVIORAL|Mobile App Education|A 24-week self-care education delivered via a mobile application based on Orem's Self-Care Model
214403829|NCT02521519|OTHER|Medial branch block in one side|MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
214403830|NCT02521519|OTHER|paravertebral deep intramuscular (PDI) injection|injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
214403831|NCT00002735|DRUG|Induction chemotherapy|Cisplatin and 5-Fluorouracil
214403832|NCT00002735|DRUG|cisplatin|Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
214403833|NCT00002735|DRUG|fluorouracil|5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
214403834|NCT00002735|RADIATION|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, every week for eight weeks
214403835|NCT03580720|OTHER|Inspiratory threshold loading protocol|Subjects will be instrumented with catheters that measure electrical activity of the diaphragm and transdiaphragmatic pressure. Subjects will perform a stepwise inspiratory threshold loading protocol to induce a wide range of diaphragm activity.
214403836|NCT02346487|DRUG|LPV/RTV pellets and AZT/3TC or ABC/3TC|"Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~* Between 3 and 5.9kg: 2 capsules twice a day~* Between 6 and 9.9kg: 3 capsules twice a day~* Between 10 and 13.9kg: 4 capsules twice a day~* Between 14 and 19.9kg: 5 capsules twice a day~* Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~* Between 3 and 5.9kg: 1 tablet twice a day~* Between 6 and 9.9kg: 1.5 tablets twice a day~* Between 10 and 13.9kg: 2 tablets twice a day~* Between 14 and 19.9kg: 2.5 tablets twice a day~* Between 20 and 24.9kg: 3 tablets twice a day"
214403837|NCT00429793|DRUG|temsirolimus|Given IV
215009335|NCT04892303|COMBINATION_PRODUCT|Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)|To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
215009336|NCT05356611|BEHAVIORAL|Engage|Engage is a 9-week, behavioral-based, psychotherapy treatment protocol for late-life depression.
215009337|NCT05253469|PROCEDURE|Cryopreserved Aortic Homograft|CAH is used for aortic root reconstruction and for repair of mitro-aortic curtain (emicommando procedure) and it is inserted as miniroot . In cases of PVE the infected prosthesis is removed with aggressive debridement of all infected and necrotic tissue. (7)The coronary ostia are prepared for reconstruction of aortic root. In complex valve endocarditis involving aortic and mitral valve a double homograft may be used.Mitro-aortic endocarditis intervalvular fibrosa is largely involved.The abscess cavity is precisely bounded and debrided. and a double homograft is used for the reconstruction (commando procedure
215097687|NCT07087561|DIETARY_SUPPLEMENT|Personalized Oral Nutritional Supplementation|Participants receive individualized oral nutritional supplementation based on energy and protein requirements, calculated using the Harris-Benedict equation and body weight (1.2-1.5 g protein/kg/day). The supplement may include complete nutrition powder, whey protein powder, and compound multivitamins. The intervention is prescribed and monitored by a clinical nutrition team and adjusted every 3 days during the 14-day intervention phase. The goal is to ensure both energy and protein intake targets are met. Supplements are administered in addition to standard meals.
214403838|NCT05573919|DEVICE|VivAer Stylus|This device will be used to complete its corresponding procedure, which involves reshaping a patient's nasal sidewall tissue through the delivery of radiofrequency heating.
214403839|NCT00403988|DRUG|Oxaliplatin|
214403840|NCT00403988|DRUG|vinorelbine|
214403841|NCT01620411|OTHER|Comprehensive Medical Management|Standard of care for failed back surgery syndrome sustained while on active duty, primarily focused on physical therapy, medication including: opioid analgesics, muscle relaxants, non-opioid analgesics, etc.
215009338|NCT05253469|PROCEDURE|Stented/Non stented xenograft|The insertion of stented/non stented xenograft may be performed using separate or continuos stich with or without teflon pledget. Biological valves may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic bioroot using bioprosthetic valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
215009339|NCT05253469|PROCEDURE|Mechanical prostheses|The insertion of conventional mechanical valves may be performed using separate or continuos stich with or without teflon pledget. Mechanical prostheses may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic valved conduit with a mechanical valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
215009340|NCT06786234|DRUG|STP938|At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.
215009341|NCT05573035|BIOLOGICAL|LYL845|LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology
215009342|NCT03585543|BEHAVIORAL|Voice Crisis Alert V2|Intervention consists of a mHealth app delivered via smartphone
215009343|NCT00421993|DRUG|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
215097688|NCT07087561|DRUG|Personalized Parenteral Nutritional Supplementation|For participants unable to meet nutritional goals through oral intake, parenteral nutrition is administered intravenously. The formulation includes amino acids, glucose, lipids, electrolytes, trace elements, and vitamins. Dosages are aligned with those of the enteral nutrition group, ensuring a consistent intake of energy and protein (1.2-1.5 g/kg/day protein). Formulation and administration follow standardized hospital protocols and are supervised by the nutrition support team.
215097689|NCT07087561|BEHAVIORAL|Structured Nutrition-Focused Health Education|"Participants receive structured health education focused on nutrition, physical activity, and psychological well-being. The education is delivered over 14 days using a digital Internet Plus platform, featuring weekly videos, interactive Q\&A sessions, and guidance from a multidisciplinary nutrition support team. Educational content covers dietary recommendations, exercise safety, stress management, and post-treatment recovery strategies. Materials are updated weekly, and participants may access them remotely via smartphone or tablet. This intervention aims to improve nutrition knowledge, adherence, and health behavior change."
214403842|NCT01620411|PROCEDURE|Spinal Cord Stimulator|This arm combines comprehensive medical management (as above) with the trial and possible eventual permenant placement of a spinal cord stimulator, a common pain management procedure.
214403843|NCT01339494|DIETARY_SUPPLEMENT|Arginine and citrulline supplementations|Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
214403844|NCT03748537|DRUG|Hydrocortisone|After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP \<65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP \< 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
214403845|NCT05375565|OTHER|weight bearing exercises|"* Standing knee raise 10 rep x 2sets~* Standing knee bend 10 rep x 2sets~* Standing hip extension 10 rep x 2sets~* Shallow squats 5 rep x 2 sets After 4 week gradually restricting the use of assistive device when patient become able to walk and stand for 10 mins then add stair climbing and descending with a step height not higher than 7 inch.~The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
214504609|NCT06809842|DRUG|Lateral femoral cutaneous nerve block|Patients received lateral femoral cutaneous nerve block with 5 ml of bupivacaine 0.5%.
214504610|NCT06745986|DRUG|ultrasound guided fascia iliaca compartment block ( bupivacaine 0.25% )|Fascia iliaca compartment block by bupivacaine 0.25% in a total volume of 40 ml.
214504611|NCT06745986|DRUG|Spinal Anesthesia (bupivacaine)|spinal anesthesia by 2.5 ml bupivacaine 0.5%
214504612|NCT06394323|BEHAVIORAL|Behavioral: My Choice for HIV Prevention (MyChoice)|My Choice for HIV Prevention (MyChoice), is a counselor-delivered shared decision-making approach for pregnant women considering PrEP
214403846|NCT05375565|OTHER|non weight bearing exercises|"* Seated knee flexion 10 rep x 2sets~* Seated knee extension 10 rep x2sets~* Use of stationary bicycle 10 mins~* Side lying leg lift 10 rep x2sets~* Straight leg raise 10 rep x 2sets The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
214403847|NCT01667120|DRUG|Ketorolac|Ketorolac 0.5mg/kg IV q8h x 72h.
214403848|NCT01667120|DRUG|placebo|0.9% normal saline 1ml/kg
215009344|NCT00421993|DRUG|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
215009345|NCT00421993|DRUG|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
215009346|NCT00421993|DRUG|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
215009347|NCT03630601|PROCEDURE|Photoacoustic Imaging|Undergo PAI
215009348|NCT00136474|DRUG|Amifostine|Given 30-60 minutes prior to daily radiation therapy
215009349|NCT00136474|RADIATION|Radiation Therapy|Daily radiation therapy
215009350|NCT04079959|PROCEDURE|endometrial biopsy|. Endometrial samples are obtained using a biopsy catheter as follows: the Pipette is inserted through the cervical os and advanced gently until resistance is felt. The inner piton of the device is then withdrawn to create suction, and the endometrial sample is obtained by moving the pipette up and down approximately 2-3 cm within the uterine cavity. The device is rotated 360° to ensure adequate coverage of the area.
215009351|NCT06323993|PROCEDURE|Piezoelectric osteotomy|The piezoelectric technique, another window preparation procedure that does not use a round bur, was first introduced to LSFE in 2001 for its high accuracy of osteotomy and low rate of membrane perforation. Later studies demonstrated that the operation time, postoperative reactions, and perforation rate of this procedure are considered to be acceptable compared with rotary bur. Moreover, the piezoelectric technique allows for the lateral bone window to be cut and preserved relatively completely.
215009352|NCT03969420|DRUG|Alvocidib (flavopiridol) and cytarabine (Ara-C)|Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
215009353|NCT03969420|DRUG|Alvocidib (flavopiridol)|Administered intravenously
215009354|NCT03723954|DEVICE|ECG Holter SpiderFlash-t|"Record at visit V0 (day without match) and the competition days (Visit V1, V2 et V3) during the matches the heart rate of the golf fans.~SpiderFlash-t™ from MicroPort is a long-lasting event recorder set in walking position by the investigator the day of the record and it is activated by detecting rhythm anomalies. This recorder is a Class IIA medical device (according to European Economic Community Directive 93/42). It benefits from European Economic marking."
215009355|NCT03723954|DEVICE|Actigraph GT3Xp|"Record the study participant's physical activity while we record his heart rate.~The GT3Xp based activity monitors provide objective measurements of human activity and are used in many research and clinical applications. It includes a micro-electro-mechanical system (MEMS) based accelerometer and an ambient light sensor. It benefits from CE marking and FDA agreement (Class II medical device)."
215009356|NCT05835700|OTHER|Gasdermin-d|Maternal serum Gasdermin-D levels in preterm labor and healthy pregnant women.
215009357|NCT05312112|DRUG|Venetoclax|Observational study of venetoclax in AML
215009358|NCT05312112|DRUG|Gilteritinib|Observational study of gilteritinib in AML
215009359|NCT00466219|DRUG|Ribavirin|
215097690|NCT07089433|PROCEDURE|Palatal stent as wound dressing|The palatal wound after graft harvesting will be protected with a flowable composite resin adhesively secured to adjacent teeth
215097691|NCT07089433|PROCEDURE|Conventional suturing|The wound will be covered with a collagen sponge that will be hold in place with sutures
214403849|NCT05027750|BEHAVIORAL|Application of The Theory of Planned Behaviour For Weight Control|The training to be imparted to the participants was applied online in groups of 5-6 people via the Google Meet program. Obesity training consisting of a total of five sessions. Each session lasted for approximately 30 minutes. After the training given to intervention group, the women will be followed-up for 6 months. The women in the intervention group will be given counseling service by the researchers, and their status will be evaluated every month.
214403850|NCT05943483|OTHER|CCMQ questionnaire|Test subjects were required to fill out our modified CCMQ (Constitution in Chinese Medicine Questionnaire) Questionnaire.
214403851|NCT02784652|DRUG|Zoledronic acid|Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
214403852|NCT02784652|RADIATION|Radiotherapy|Radiotherapy: 5 days/ week, 3 Gy \* 10-13 fractions or 4 Gy \* 5 fractions,
215009360|NCT00466219|DRUG|Pegylated interferon alpha2a|
215009361|NCT01197027|BEHAVIORAL|Standard counseling|Standard HIV counseling
215009362|NCT05086692|DRUG|MDNA11|MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
215009363|NCT05086692|DRUG|Pembrolizumab (KEYTRUDA®)|MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
215009364|NCT02015104|BIOLOGICAL|BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
215009365|NCT02015104|BIOLOGICAL|PANVAC|A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).
215009366|NCT05068115|PROCEDURE|Clinical characteristics, diagnosis and treatment, survival status|Describe the clinical characteristics, diagnosis and treatment, survival status and the trends of young breast cancer
214504613|NCT04185363|DRUG|Maralixibat|All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) twice daily
215009367|NCT05363800|DRUG|HRS-3738|HRS-3738 will be administrated per dose level in which the patients are assigned.
215009368|NCT04333459|BIOLOGICAL|Hataan DNA Vaccine/Puumala DNA Vaccine|Vaccine compared in High and Lose Doses.
215009369|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily from the time of randomization until delivery.
215009370|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
215009371|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
215009372|NCT06612203|DRUG|Debio 0123 and Sacituzumab govitecan|Debio 0123 will be administered orally during 6 days of each 21-day cycle in combination with 10 mg/kg of Sacituzumab govitecan administered intravenously on D1 and D8 of each 21-day cycle until documented disease progression, death, unacceptable toxicity, or discontinuation from the study treatment for any other reason, whichever occurs first.
215009373|NCT04661358|DRUG|Fenofibrate|Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
215009374|NCT04661358|OTHER|Placebo|Participants begin with a dose of either 160mg or 54mg placebo, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
215009375|NCT06989762|DEVICE|Conventional Foley Catheter(Medline)|The Conventional Foley Catheter is a standard urinary catheter used in ICU care to monitor urine output. It does not have intra-abdominal pressure (IAP) monitoring capabilities.
215009376|NCT06989762|DEVICE|Accuryn Foley Catheter|The Accuryn Foley Catheter is an FDA-approved urinary catheter with continuous intra-abdominal pressure (IAP) monitoring capability.
215009377|NCT06307080|DEVICE|Multi-mode thermal ablation device|The tumor tissue was rapidly frozen until the ice ball exceeded 5mm of the lesion tissue, kept for 5 minutes, then thawed and warmed. Then, complete ablation was performed according to the radiofrequency temperature control mode of multimodal tumor therapy to ensure that the ablation area included a safe range of 5\~10mm around the tumor.
215009378|NCT06307080|DRUG|Intravenous anti-PD-1 and chemotherapy|intravenous anti-PD-1 and chemotherapy
215009379|NCT06993389|OTHER|Inapplicable|Inapplicable
215009380|NCT06675578|DRUG|Tulsi gel|After scaling and root debridement, 4% of Tulsi gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
215009381|NCT06675578|DRUG|Chlorhexidine gel|After scaling and root debridement, 1% of Chlorhexidine gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
215009382|NCT04851717|DRUG|Remimazolam|Remimazolam for intravenous sedation
215009383|NCT07008534|PROCEDURE|Patients receiving computer-guided immediate implant placement and inferior alveolar nerve (IAN) lateralization only.|Standard procedure without Sticky Bone application.
215009384|NCT07008534|PROCEDURE|IAN lateralization with computer-guided immediate implant placement using Sticky Bone|The same as the control with additional application of Sticky Bone as an insulator for enhanced neurosensory disfunction
215009385|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Pain Intensity 3a|PROMIS Scale v2.0 - Pain Intensity 3a is a 3-question short form in which patients rate their worst, average, and current level of pain during the past 7 days.
215009386|NCT06627582|BEHAVIORAL|PROMIS 29+2|PROMIS 29+2 (PROMIS-Preference, PROPr) is a compilation of item banks to assess pain intensity
215009387|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Nociceptive Pain Quality 5a|5-question short form that identifies patients who have experienced nociceptive pain during the past 7 days
215009388|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Neuropathic Pain Quality 5a|5-question short form that identifies patients who have experienced neuropathic pain during the past 7 days
215009389|NCT05482165|BEHAVIORAL|Multi-faceted health promotion programme|"This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the intervention group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses"
215009390|NCT03630354|BEHAVIORAL|Exercise Intervention (supervised)|Complete supervised exercise
215009391|NCT03630354|BEHAVIORAL|Exercise Intervention (unsupervised)|Complete unsupervised exercise
214688279|NCT07162662|DIETARY_SUPPLEMENT|Oral Sialic acid|This study employs a before-after self-control trial design, recruiting 42 volunteers to take oral sialic acid and collecting fecal samples before and after the intervention.
214688280|NCT07163351|OTHER|CAD/CAM allogenic bone block|CAD/CAM allogenic bone block augmentation with immediate non-functional implant loading
215009392|NCT03630354|OTHER|Informational Intervention|Receive instructional DVD
215009393|NCT03630354|OTHER|Questionnaire Administration|Ancillary studies
214504614|NCT06778538|DIAGNOSTIC_TEST|Immunohistochemistry; WB; PCR|The intervention will specifically focus on evaluating the role of HPGD in patients with clear cell renal cell carcinoma by classifying them into high-low expression groups based on median HPGD expression values by immunohistochemical scores for prognostic analysis. Protein and RNA were extracted from collected ccRCC tissues for expression verification.
214403853|NCT00903773|DRUG|telaprevir|
214403854|NCT00465712|PROCEDURE|transabdominal amnioinfusion|transabdominal amnioinfusion performed 4 to 24 hours before the second trial of external cephalic version
214403855|NCT01355783|DRUG|E7777|Treatment in both arms is for 6 cycles at 21 days/cycle.
214403856|NCT00097370|DRUG|mepolizumab|Study Drug
214403857|NCT02733107|DRUG|Apatinib|Apatinib, 250mg daily, po, continue until disease progression
214403858|NCT02733107|DRUG|Etoposide|Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression
214403859|NCT03013361|DRUG|Bupivacaine|Post operative pain control
214403860|NCT03013361|DRUG|Ropivacaine|Post operative pain control
214403861|NCT03013361|OTHER|Normal Saline|Acts as comparator
214403862|NCT01300793|DRUG|Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide|Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 \& 11 q. 28 days.
214403863|NCT04595695|BEHAVIORAL|Transparent mask|A transparent mask worn by the surgeons in customary fashion will be used.
214403864|NCT04595695|BEHAVIORAL|Typical surgical covered mask|A standard covered surgical mask worn by the surgeons in in customary fashion will be used.
214403865|NCT03354299|DIETARY_SUPPLEMENT|coconut milk|50 cc of coconut milk supplementation plus 25 gram sugar (pudding) was given to cirrhosis patients as late night snack
214403866|NCT01031043|DRUG|Bethanechol|Taking part in this research study is voluntary. Patient may choose not to take part in this research study or may withdraw consent at any time. Their choice will not at any time affect the commitment of the health care providers to administer care. If the patient decides not to participate or withdraw from the study there will be no penalty or loss of benefits to which they are otherwise entitled.
214403867|NCT02337361|BEHAVIORAL|Electronic SBI|"Bilingual (English and Spanish) e-SBI with four key components:~1\) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies."
214403868|NCT02419755|DRUG|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
214403869|NCT02419755|DRUG|Vorinostat|Vorinostat should be taken orally (PO) with food.
214403870|NCT02419755|DRUG|Mitoxantrone|Given by intravenous (IV) injection.
214403871|NCT02419755|DRUG|Cytarabine|Given by intravenous (IV) injection.
214403872|NCT02419755|DRUG|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
214403873|NCT02419755|DRUG|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
214403874|NCT02419755|DRUG|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
214403875|NCT02419755|DRUG|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
214403876|NCT02419755|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
214403877|NCT02419755|DRUG|Mercaptopurine|Given orally (PO).
214403878|NCT02419755|DRUG|Doxorubicin|Given intravenously (IV).
214403879|NCT02203097|PROCEDURE|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
214403880|NCT02203097|DRUG|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
214504615|NCT06771661|OTHER|Workshops|The investigators will conduct workshops with parents to get closer to the main topic.
214403881|NCT03432039|BEHAVIORAL|Psychoeducation|This intervention has three phases occurring the same time as the Psychoeducation intervention. Phase I provides verbal and written information about the paediatric acute care unit services and policies. Phase II consists of: (a) verbal and written information about the general paediatric unit and its policies, and (b) a parent-child activity having ''control'' activities like reading a story not related to hospital stay. Phase III of the control program consists of a telephone call 2-3 days after discharge during which time mothers were informed that they should contact their primary healthcare providers if their children were having any problems or unusual symptoms. They also were asked to comment on their children's hospital stays during this telephone call.
214403882|NCT03432039|BEHAVIORAL|Behavioral|This is an educational-behavioural intervention that educates the parent about the children's likely emotional and behavioural problems that may result from ICU admission. Phase I will be delivered within 6 to 16 hours of admission to the hospital where caregivers are provided with information about the child's likely emotional reactions during admission in hospital. Phase II will be delivered within 2 to 16 hours of transfer to the general ward and will consist of: (a) verbal and written information to reinforce information provided in Phase I and (b) a parent-child skills building activities. Phase III of the COPE intervention program will occur 2 to 3 days after hospital discharge and will consist of a telephone call during which a 5 minute script will be read that reinforces young children's typical post-discharge emotions and behaviours and parenting behaviours which would continue to facilitate positive coping outcomes in their children.
214403883|NCT02472561|OTHER|Fitbit Physical Activity Monitor|Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.
214504616|NCT06771661|OTHER|Focus group interviews|The investigators will conduct focus group interviews with parents on their needs before and during child loss.
214504617|NCT06771661|OTHER|Narrative interviews|The investigators will conduct narrative interviews with parents to gain an in-depth understanding of their lived experience before and during the intrauterine or perinatal child loss.
214504618|NCT06771661|OTHER|Delphi approach|The investigators will carry out a Delphi approach with parents to translate and confirm or revise the findings into treatment recommendations for healthcare professionals.
214504619|NCT04039750|DRUG|antibiotic rinse with suction|antibiotic rinse with suction
215009394|NCT07019051|DIAGNOSTIC_TEST|Transthoracic Echocardiographic Evaluation|Non-invasive transthoracic echocardiography will be performed prior to the initiation of continuous veno-venous hemodiafiltration (CVVHDF) in ICU patients. The evaluation includes measurements of LVOT VTI, MAPSE, TAPSE, S' wave velocity, and E/e' ratio to assess cardiac function and estimate the risk of hemodynamic instability. The procedure will be conducted at the bedside using standard parasternal and apical windows by trained intensive care physicians or cardiologists. No contrast, sedation, or invasive monitoring will be used.
215009395|NCT07021313|DEVICE|Pulmonary vein isolation by percutaneous endocardial catheter ablation using the FARAPULSE pulsed high voltage electrical field system in patients with atrial fibrillation|Standard of care 4 pulsed electrical field applications in basket shape and 4 applications in flower shape
215009396|NCT07021313|DEVICE|Pulmonary vein isolation by percutaneous endocardial catheter ablation using a pentaspline pulsed high voltage electrical field system in patients with atrial fibrillation|Experimental treatment delivering 2 pulsed electrical field applications in olive shape, 4 in basket shape and 6 applications in flower shape
215009397|NCT06687928|BIOLOGICAL|CT-P6 SC|A single fixed dose (600 mg) of CT-P6 subcutaneous
215009398|NCT06687928|BIOLOGICAL|EU-Approved Herceptin SC|A single fixed dose (600 mg) of EU-approved Herceptin subcutaneous
215009399|NCT06870149|OTHER|Dance Rehabilitation Intervention|Cognitive Groove (GERAS DANCE) presents a novel approach to increasing or maintaining independence and quality of life by improving physical performance and mobility using reminiscent music and rhythmic movement in a fun, safe environment. Cognitive Groove was designed to meet the complex needs of older adults with frailty. Our pilot quasi-experimental studies have demonstrated Cognitive Groove results in clinically significant improvements in walking speed by 0.1 m/s with enhanced temporal-spatial walking parameters and improved lower extremity function, including balance and chair stands.
215009400|NCT07020546|PROCEDURE|Ovarian Platelet-rich plasma (PRP) injections|This is a procedure that our patients receive at our clinic. We want to use the AI software to evaluate embryo development before and after treatment to see if there is a difference in embryo quality after PRP treatment within the same patient.
215009401|NCT07022938|DIETARY_SUPPLEMENT|Epineuron|Palmitoylethanolamide (PEA, 300 mg), Superoxide Dismutase (SOD, 70 UI), Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2.5 mg) in one tablet
215009402|NCT07022938|DIETARY_SUPPLEMENT|Placebo Tablets|placebo tablet without active ingredients
215009403|NCT01537367|BEHAVIORAL|Enhanced contact plus behavioral skills|The enhanced contact plus behavioral skills arm is the longer experimental arm.
215009404|NCT01537367|BEHAVIORAL|Enhanced contact only|The enhanced contact only arm is the shorter experimental arm.
215009405|NCT01537367|BEHAVIORAL|Standard of Care|The standard of care arm is the comparison group arm that receives only standard clinical services.
215009406|NCT05604313|DEVICE|Ergonomic chinrest used with low shoulder rest (EC)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC) for two weeks before the test day (crossover study), measuring upper body kinematic and muscle activity. The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
215009407|NCT06453460|DRUG|Letermovir|Subjects will receive 14 weeks of letermovir prophylaxis at standard recommended dose follow by CMV-TCIP-directed extended prophylaxis.
215009408|NCT06453460|DEVICE|CMV T Cell Immunity Panel (CMV-TCIP)|Viracor CMV-TCIP assay to measure how a person's immune system responds to CMV. Viracor CMV-TCIP will be measured monthly, starting at week 14, until positive, then at week 30 and 52.
215009409|NCT06453460|DIAGNOSTIC_TEST|CMV DNA PCR|Plasma level of CMV DNA PCR will be measured at enrollment and at least weekly through week 30, then at least every 2 weeks through week 52 of transplant if no GVHD or CMV reactivation.
215009410|NCT07039734|OTHER|collection of data from medical records|collection of data from medical records
214504620|NCT04039750|PROCEDURE|suction only|no irrigation, suction only
215009411|NCT07040475|OTHER|Inpatient TCIM therapy|This multicenter, prospective, uncontrolled observational study is evaluating the effects and safety of inpatient TCIM therapy (German: naturheilkundliche Komplextherapie) at three German clinics: Immanuel Hospital Berlin, Klinikum Bamberg, and Evangelical Clinics Essen-Mitte. This therapy, reimbursed by statutory health insurance under certain conditions, combines evidence-informed TCIM approaches such as hyperthermia, exercise therapy, phytotherapy, and dietary interventions including fasting i.a.
215009412|NCT07040956|DRUG|Tislelizumab|200mg IV Q3W
215009413|NCT07040956|DRUG|Afatinib|Targeted therapy
215009414|NCT07040956|RADIATION|Low dose radiotherapy|Radiotherapy
215009415|NCT07043361|DRUG|semaglutide|testing the effect of baseline vitamin D on metabolic effects of semaglutide
215097692|NCT07087847|BIOLOGICAL|TCRαβ+/CD45RA+depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT)|Approximately 28 days post-CAR-T therapy, a hematologic assessment will be performed. Eligible patients meeting the inclusion criteria will subsequently undergo TCRαβ+/CD45RA+depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT).Collect peripheral blood stem cells (PBSC) from the haplo-donor.Split the graft into two fractions at a 9:1 ratio, 90% fraction: subject to TCRαβ+ T-cell depletion, 10% fraction: subject to CD45RA+ T-cell depletion. Primary graft (TCRαβ+depleted and partial CD45RA+ depleted): Freshly infused into the recipient. Residual CD45RA-depleted lymphocytes: Cryopreserved for prophylactic donor lymphocyte infusion (DLI) as needed.
215097693|NCT07088185|OTHER|Routine medical care|Routine medical care
214504621|NCT05062980|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, re-establishing pathways that promote cancer cell death and modulating the immune system response against cancer cells.
214504622|NCT05062980|DRUG|pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.
214403884|NCT02472561|OTHER|mHealth Glucometer|Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.
214403885|NCT02472561|OTHER|mHealth Blood Pressure|Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.
214403886|NCT01091285|DEVICE|Foley Catheter|Foley Catheter 16-19 H
214403887|NCT01091285|DEVICE|Double Balloon Catheter|Double Balloon Catheter for 16-19H
214403888|NCT00553111|OTHER|educational video|educational video
214403889|NCT04022642|OTHER|High-Intensity Interval Training|"The program will be applied in the first 10-15 minutes of each PE class, twice a week, including a brief warm-up, ranged from 14 to 20 intervals, adopting a 2:1 work to rest ratio (ie, 30-s work, followed by 30-s rest)~A cut-point of \>=90% of maximal heart rate was used as our criterion for satisfactory compliance to high-intensity exercise~In order to estimate effort, fatigue and training load, a subjective effort scale will be used throughout each session. The heart rate will be monitored throughout the session in real time through Bluetooth technology.~Actigraph accelerometers (wGT3X-BT), randomly distributed by the students in each session, will be used to characterize the intensity of the sessions."
214403890|NCT02427646|DRUG|BoNT-A|A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.
214403891|NCT03608020|DRUG|BMX-001|Manganese butoxyethyl pyridyl porphyrin
215009416|NCT07046728|OTHER|Efficay and Safety of DAROMUN on patient treated by intralesionnal injection: DAROMEL|Observationnal study with clincal data collection to evaluate the efficiency and the tolerability of DAROMUN
214403892|NCT03608020|RADIATION|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy per standard of care.
214403893|NCT01553786|DRUG|Lenalidomide|Lenalidomide
215009417|NCT07040111|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of a 4-step egg ladder (muffin \[1.5 g of hen's egg protein per portion\], pancake, hard-boiled egg, soft-boiled egg)
215009418|NCT07040111|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of a 5-step egg ladder (muffin \[0.75 g of hen's egg protein per portion\], muffin \[1.5 g of hen's egg protein per portion\], pancake, hard-boiled egg, soft-boiled egg)
215009419|NCT07045454|DRUG|MHB118C for Injection|IV administration by Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
215097694|NCT07088185|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine care.
215097695|NCT07087782|OTHER|Fortini formula|Fortini, a commercially available formula providing 30 kcal/oz, is commonly used in older children with failure to thrive or feeding intolerance. It offers the theoretical benefit of providing higher caloric density in a lower volume, which may be advantageous in infants with single ventricle physiology, who often have limited volume tolerance and high metabolic demands.
215097696|NCT07087782|OTHER|Standard Nutritional Care|Standard infant formulas (including hydrolyzed formulas) fortification to 24-30 kcal/oz
214403894|NCT01932944|DEVICE|No treatment|
214403895|NCT04136028|DRUG|Kineret|Kineret at a dose of 8 mg/kg per day subcutaneously daily, every day at the same time
214504623|NCT05062980|DRUG|docetaxel|Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.
215009420|NCT07044661|PROCEDURE|Unilateral ARM|ARM is performed to the dependent lung only. During ARM, mechanical ventilation is set to a pressure-controlled ventilation mode with a driving pressure of 20 cmH₂O and an inspiratory-to-expiratory ratio of 1:1. The positive end-expiratory pressure (PEEP) is increased by 5 cmH₂O every five respiratory cycles, reaching a final PEEP of 20 cmH₂O and a peak airway pressure of 40 cmH₂O, which is then maintained for ten respiratory cycles.
215009421|NCT07044661|PROCEDURE|Bilateral ARM|ARM is performed to both lungs. During ARM, mechanical ventilation is set to a pressure-controlled ventilation mode with a driving pressure of 20 cmH₂O and an inspiratory-to-expiratory ratio of 1:1. The positive end-expiratory pressure (PEEP) is increased by 5 cmH₂O every five respiratory cycles, reaching a final PEEP of 20 cmH₂O and a peak airway pressure of 40 cmH₂O, which is then maintained for ten respiratory cycles.
215009422|NCT07047001|DRUG|Vorolanib Tablets|200mg PO QD
215009423|NCT07047001|DRUG|Vorolanib + Toripalimab|"Vorolanib: 100mg PO QD~Toripalimab: 240mg IV infusion Q3W"
215009424|NCT07047690|DRUG|Nemolizumab|Subcutaneous Injection
215009425|NCT07047690|DRUG|Placebo|Subcutaneous Injection
215009426|NCT07046507|DIAGNOSTIC_TEST|Diagnostic procedures|Diagnostic ability of optical coherence tomography in kayser fleischer rings
215009427|NCT07045090|DEVICE|Transcutaneous electrical acupoint stimulation|Before induction of anaesthesia, electrodes were attached to selected acupoints and energised for 30 min, with the electrical stimulation parameter of dispersed dense wave (2/100 Hz), and the current intensity was based on the maximum current intensity that could be tolerated by the patient.
215097697|NCT07088224|OTHER|Observational studies without intervention|Observational studies without intervention
215097698|NCT07087327|DRUG|EB-1020 (Centanafadine) low dose|low dose, capsule, oral, once daily, for 52 weeks
215097699|NCT07087327|DRUG|EB-1020 (Centanafadine) high dose|high dose, capsule, oral, once daily, for 52 weeks
215097700|NCT07089576|DEVICE|Arcevo™ LSA Hybrid Stent Graft System|The Arcevo LSA Hybrid Stent Graft System is an implantable aortic stent graft with LSA branch which is preloaded onto a delivery system and implanted during an open surgical procedure, or more specifically a total arch replacement procedure. The device is intended for use with a proximal surgical graft (not supplied). If additional coverage is needed, a protocol specified thoracic endovascular aortic repair (TEVAR) device may be used.
214403896|NCT00989170|BEHAVIORAL|Family Program for the Prevention of Weight Gain|The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
214403897|NCT00989170|BEHAVIORAL|Control Group|This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
214403898|NCT02288858|DIETARY_SUPPLEMENT|Viviscal Oral Supplement Tablets|Tablet (512 mg)
214403899|NCT03946657|DRUG|Inhalational anesthetic|Oxygen/air (fraction of inspired oxygen (FiO2) of 0.40), inspiratory fresh gas flow of 2 L/min), sevoflurane (1 minimum alveolar concentration \[MAC\]) and remifentanil IV infusion (0.1-0.25 mcg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
214403900|NCT03946657|DRUG|Intravenous anesthetic|Propofol infusion (4-8 mg/kg of total body weight/h), oxygen/air (FiO2 of 0.40; inspiratory fresh gas flow of 2 L/min) and remifentanil IV infusion (0.1-0.25 μg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
214403901|NCT01040663|OTHER|Dietary intervention|Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
214403902|NCT05263453|DRUG|HL-085|HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle
214403903|NCT05263453|DRUG|Vemurafenib|Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle
214403904|NCT05335135|OTHER|TriageGO-MDW Clinical Decision Support|TriageGO-MDW is non-device clinical decision support that provides patient-level clinical risk estimates based on clinical data derived from the electronic health record
214403905|NCT05335135|OTHER|Usual Care|Clinical care without decision support provided by TriageGo-MDW
214504624|NCT05062980|DRUG|ramucirumab|Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.
214504625|NCT05062980|DRUG|Investigator's Treatment of Choice|Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
214504626|NCT06903052|DEVICE|Nurse parental support using a proactive mobile App|Nurse parental support using a proactive mobile App in symptom management for child with mechanical ventilation
215009428|NCT07045090|DEVICE|Transcutaneous electrical acupoint stimulation combined with auricular vagus nerve stimulation|Before anaesthesia induction, the electrodes were attached to the selected acupoints and energized for 30 min, with the electrical stimulation parameters of dispersed dense wave (2/100Hz), and the current intensity was based on the maximum current intensity that the patient could tolerate. At the same time, the left ear auricular region was stimulated with a fasciculus nerve stimulator, the electrical stimulation parameters were: pulse width of 250 μs, pulse frequency of 20Hz, every 30s on, 30s off, and then 30s on again, the current intensity was based on the maximum current intensity that the patient could tolerate, for 30min.
215009429|NCT07045779|BEHAVIORAL|Orofacial myofunctional therapy - traditional|Behavioral interventions, like orofacial myofunctional therapy (OMT), target brain reorganization and plasticity by establishing new motor patterns or re-establishing old ones. The aim of OMT is to correct pathological function and resting positions based on the equilibrium theory. A service model that is often used in OMT is the model provided by Garliner, which includes a 10 week OMT program with a frequency of one session of 45 minutes per week together with home practice. Treatment sessions will be used to introduce and practice new exercises, to monitor home practice and motivation of the patients. Additionally, the participant will be instructed to perform the same exercises from the treatment session at home daily. This intervention will consist of (1) creating awareness, (2) establishing nasal breathing, (3) labial seal and lip closure exercises, (4) tongue posture exercises, (5) lip and tongue strengthening, (6) practicing a physiological swallowing act.
215009430|NCT07045779|BEHAVIORAL|Orofacial myofunctional therapy - reduced|Behavioral interventions, like orofacial myofunctional therapy (OMT), target brain reorganization and plasticity by establishing new motor patterns or re-establishing old ones. The aim of OMT is to correct pathological function and resting positions based on the equilibrium theory. A service model that is often used in OMT is the model provided by Garliner, which includes a 10 week OMT program with a frequency of one session of 45 minutes per week together with home practice. Treatment sessions will be used to introduce and practice new exercises, to monitor home practice and motivation of the patients. Additionally, the participant will be instructed to perform the same exercises from the treatment session at home daily. This intervention will consist of (1) creating awareness, (2) establishing nasal breathing, (3) labial seal and lip closure exercises, (4) tongue posture exercises.
215009431|NCT07045779|BEHAVIORAL|Vocal warm up|The sham treatment program will include exercises from an evidence-based vocal warm up program, with exclusion of the exercises that include active involvement of the tongue or lips. Exercises that will be included are: open mouth approach, glottal fry, producing ascending and descending tones and the hand-over-mouth technique. These exercises aim to improve the dynamics of the extrinsic and intrinsic laryngeal muscles and therefore are expected not to interfere with the content of the OMT program. Furthermore, exercises regarding body posture (no focus on articulators), relaxation and voice onset will be included. This sham treatment program will be provided by the same speech-language pathologist with comparable motivation techniques as those applied in the real OMT programs.
215009432|NCT07045051|OTHER|Low-Glycemic Breakfast Containing Oats and Mango|Low-glycemic breakfast of 80 grams of oats prepared with 473mL water and sweetened with 146 grams of mango.
215009433|NCT07045051|OTHER|High-Glycemic Breakfast Containing Cereal and Mango|High-glycemic breakfast of 84 grams of corn flakes prepared with 355mL of 2% milk and sweetened with 262 grams of mango.
215009434|NCT07045051|OTHER|Low-Glycemic Breakfast Containing Oats and Table Sugar|Low-glycemic breakfast of 80 grams of oats prepared with 473mL of water and sweetened with 20 grams of table sugar.
215009435|NCT07045051|OTHER|High-Glycemic Breakfast Containing Cereal and Table Sugar|High-glycemic breakfast of 84 grams of corn flakes prepared with 355mL of 2% milk and sweetened with 36 grams of table sugar.
215097701|NCT07087691|DEVICE|OneMark device|"The OneMark device system consists of a tumor marker preloaded in a delivery system, a handheld probe, and a display console.~The OneMark marker is a metal clip with microparticles embedded in gelatin forming a hydrogel pellet. The pellet is implanted with a preloaded injector percutaneously in soft tissues, such as breast or lymph nodes, to mark a biopsy site or tissue intended for surgical removal. It can be used as a fiducial implant post-biopsy for future identification or monitoring of the tissue, and as an intra-operative localization mark. The microparticles of OneMark marker can be detected by Doppler ultrasound, magnetic resonance imaging (MRI), radiography, and OneMark Detector. During surgery, the OneMark marker may be removed with the target tissue. If patients do not require surgery, the OneMark marker can be left in place."
214403906|NCT01101542|BIOLOGICAL|Cervarix.|Subjects will receive three doses of the Cervarix vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in routine clinical practice settings.
214403907|NCT01101542|OTHER|Data collection|All adverse events will be recorded by all subjects or the subject's parents/guardians using diary cards.
214403908|NCT04803084|OTHER|Tempus assay|Blood collection
214403909|NCT04803084|OTHER|Advanced pathology 1|Tissue procurement (from diagnostic biopsy)
214403910|NCT04803084|OTHER|Advanced pathology 2|Tissue procurement (from research biopsy)
215009436|NCT06726876|DIETARY_SUPPLEMENT|Manuka honey oral rinse.|"Name: Manuka Honey Oral Rinse~Description:~Dosage: Patients will use 20 ml of Manuka honey diluted in 100 ml of purified water.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the solution for a specified duration and avoid swallowing it.~Unique Elements:~Active Ingredient: Manuka honey, known for its unique antibacterial properties due to high levels of methylglyoxal (MGO).~Mechanism of Action: MGO and Non-Peroxide Activity (NPA) contribute to antibacterial potency, effective against antibiotic-resistant bacteria, and potential immunomodulatory effects that aid wound healing and tissue regeneration.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.~Supplementary Care: Patients receive motivation and detailed oral hygiene instructions (proper tooth brushing technique, flossing, use of inte"
215009437|NCT06726876|DRUG|Normal saline rinses.|"Dosage: Patients will use 20 ml of normal saline.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the saline solution for a specified duration and avoid swallowing it.~Unique Elements:~Control Comparison: Provides a placebo comparison to evaluate the efficacy of the Manuka honey intervention.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm."
215009438|NCT07047196|DEVICE|HS-20116|Innovative chitosan-based biomaterial intended for intra-articular injection
215009439|NCT07047196|DEVICE|Medical Chitosan (for intra-articular injection)|Medical chitosan for intra-articular injection
215009440|NCT06741670|BEHAVIORAL|Breastfeeding|The routine practice of the Breastfeeding Group is to place the infants in their mother's arms and start breastfeeding 1 minute before the procedure. Then, the nurse will take the heel blood.
215009441|NCT06741670|DEVICE|Vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The infants in the Vibration Group will be placed in their mother's arms and vibration will be applied 30 seconds before the routine application, and vibration will be applied during the 10-second waiting phase while the nurse performs the heel prick blood collection procedure.
215009442|NCT06741670|OTHER|Breastfeeding+Vibration|"The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage.~The routine practice for the Breastfeeding+Vibration Group babies will be started by holding them in their mother's arms and breastfeeding will be started 1 minute before the application. At the same time, vibration will be applied 30 seconds before the application and vibration will be applied in a 10-second waiting phase while the nurse performs the heel prick procedure."
214403911|NCT04606888|DEVICE|Transcutaneous electrical acupoint stimulation|According to the traditional Chinese medicine 15,three acupuncture points were selected as the target points: bilateral Neiguan ,Yintang and bilateral Zusanli.. A transcutaneous electrical stimulator was used to provide an altered frequency 2/100 Hz,disperse-dense waves,and adjusted intensity which was less than 10mA.
214403912|NCT04187703|DRUG|5-azacytidine|5-azacytidine 50 mg/m\^2 Day 1 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
214403913|NCT04187703|DRUG|Decitabine|Decitabine 5 mg/m\^2 Day 4 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
214403914|NCT05823337|DIETARY_SUPPLEMENT|selenium+ diet|Selenium functions as an active site component of an antioxidant enzyme, glutathione peroxidase, and helps scavenge free radicals.
214403915|NCT05823337|DIETARY_SUPPLEMENT|only diet|diet suitable for pregnancy
214403916|NCT06697652|PROCEDURE|adrenalectomy|adrenalectomy
214403917|NCT04207255|DRUG|Opaganib|500mg of Opaganib orally twice a day continuously.
214403918|NCT04207255|DRUG|Abiraterone|IV as directed by SOC
214403919|NCT04207255|DRUG|Enzalutamide|IV as directed by SOC
214403920|NCT04207255|DRUG|Opaganib|250mg of Opaganib orally twice a day continuously.
214403921|NCT06846034|OTHER|Hypoxia administration study group|Acute 2-hour hypoxia (14.5%FiO2 corresponding to 3000m altitude)
214403922|NCT06846034|COMBINATION_PRODUCT|Renal clairance study|"Assessment of renal clearance by measuring Glomerular Filtration Rate (GFR) after two agents infusion:~* Aminohippurate Sodium (or or para-aminohippuric acid \[PAH\]) Inj 20% Diagnostic agent used to measure effective renal plasma flow (ERPF)~* Iohexol Inj 300 MG/ML Diagnostic agent used to measure glomerular filtration rate (GFR)"
214403923|NCT06919406|BEHAVIORAL|Mindfulness Intervention for emotional distress(MIED）|MIED is an eight-week program developed based on MBSR and the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. MIED consists of weekly group sessions with daily interactive materials delivered via a WeChat-based mini-program. The group sessions, conducted online, provide structured content and interactive discussions aligned with the weekly themes, for example including psychoeducation on mindfulness, emotions, and emotional distress. Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks).
214403924|NCT06919679|DRUG|BrECADD|Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone
215009443|NCT07047547|DRUG|Vericiguat|Under the premise of ensuring safety, treat with a stable dose of Vericiguat 2.5mg PO QD for 2 weeks. After 2 weeks, increase the dose to 5mg PO QD. If blood pressure elevation occurs during the operation phase, the researchers suggest titrating or starting additional antihypertensive drugs, with a follow-up of 12 months. If the patient has tolerability issues (symptomatic hypotension or SBP\<90 mmHg), the dose should be reduced or discontinued.
215009444|NCT07045298|DEVICE|Libre 2 rt-CGM|Freestyle Libre 2 consists of a sensor applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin's surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor continuously reads interstitial glucose readings every minute and syncs with the Freestyle View app. The hypoglycemia alarm will be set to \< 80 mg/dl (for prevention of low blood glucose levels). Participants will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm. The hyperglycemia alarm will be set at 300 mg/dl. Participants will call the research team if they experience repeated episodes \> 300 mg/dl (more than 2 episodes in a single day or 2 or more episodes in consecutive days). The research team will instruct the participant to check with their physician for a possible new insulin regimen, but they will be allowed to remain in the study.
215009445|NCT07045298|DIAGNOSTIC_TEST|POC BG + Blinded CGM|Standard of care point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the study participation for up to 3 months.
215009446|NCT07055620|OTHER|Mediterranean diet|The group that will be applied the Mediterranean diet will be prepared with diet lists that include 35-40% carbohydrate, 15-20% protein and 35-45% fat (\>50% Monounsaturated Fatty Acid (MUFA)) of daily energy. The Mediterranean diet pyramid will be explained to the participants who will be applied the Mediterranean diet, and the portions and frequency of olive oil, nuts, olives, fish, yogurt, fruits and vegetables that they should consume will be planned by the dietitian. The Mediterranean diet pyramid recommends the frequency of foods that should be consumed daily, weekly and monthly. It recommends consuming fish and seafood at least twice a week, 2 portions of white meat, 2-4 portions of eggs, less than 2 portions of red meat, 1 portion or less of processed meat and less than 3 portions of dessert. It is recommended to consume 2 portions of dairy products, 1-2 portions of oil seeds and nuts, more spices, herbs, garlic and onions on a daily basis.
215009447|NCT07055620|OTHER|Standard diet|When writing the weight loss diets applied to the individuals in the standard diet group, it will be taken into account that 45-60% of the energy comes from carbohydrates, 10-20% from protein and 20-35% from fat, as specified in the Turkish Nutrition Guide (TUBER). It will be planned that 10% (preferably 7-8%) of the total energy from fat will come from saturated fats (fat found in animal foods, butter, tallow, tail fat), 12-15% from monounsaturated fats (olive oil, hazelnut oil, rapeseed oil) and 7-10% from polyunsaturated fats (corn, soy, sunflower and cottonseed oils containing n-6 fatty acids and fish, fish oil, walnut, flaxseed containing n-3 fatty acids). It will be stated that this ratio is 1 part solid oil, 1 part any vegetable oil and 1.5 or 2 parts olive oil among the oil types.
215009448|NCT07055620|OTHER|standard diet and time-restricted feeding|In time-restricted nutrition, the focus is on when the food is consumed rather than the type of food. However, in medical nutrition treatment of obesity, the content of the meals is also important along with the time (Soran and Öney 2022). As stated in the Turkish Nutrition Guide (TÜBER), it will be taken into account that 45-60% of the energy comes from carbohydrates, 10-20% from protein and 20-35% from fat (Ministry of Health, 2022). A time-restricted nutrition model will be implemented from intermittent fasting diet models. The time restriction will be planned as 8 hours of eating and 16 hours of fasting, suitable for the lifestyle of the individuals. The feeding time for individuals who agree to participate in the study will be determined as 11.00-12.00 and 19.00-20.00. Individuals will be given 2 main meals and the first meal will start with breakfast or lunch according to their wishes.
215009449|NCT07055789|OTHER|Combined respiratory muscle training, incorporating both inspiratory and expiratory muscle training|IMT: Inspiratory Muscle Training EMST: Expiratory Muscle Strength Training RMST: Respiratory Muscle Strength Training In this trial we are combining both IMT and EMST in the intervention group.
214403925|NCT06919211|PROCEDURE|Perfluorocarbon Liquid vs. Posterior Retinotomy during Pars-plana Vitrectomy for The Surgical Repair of Rhegmatogenous Retinal Detachment|This study compares outcomes of perfluorocarbon liquid (PFCL) versus posterior retinotomy (PR) during Pars plana vitrectomy (PPV) for Rhegmatogenous retinal detachment (RRD), focusing on anatomical success, visual acuity, intraocular pressure (IOP), and complications
214403926|NCT06920511|DEVICE|Cognitve rehabilitation with virtual reality and robotic arm|The intervention consists of a cognitive rehabilitation program using the PRoBio platform, a bio-cooperative robotic system integrating virtual reality and real-time multisensory feedback. The PRoBio platform includes a robotic arm (TIAGo), a virtual reality interface (VRRS), and sensors to monitor biomechanical, cognitive, and emotional parameters during training.
214403927|NCT06919367|OTHER|age estimation using orthopantomography|Dental age estimation will be performed with 3 different methods based on orthopantomographic images obtained during routine examinations of patients.
215009450|NCT07056868|PROCEDURE|extraperitoneal colostomy|Patients in this group will undergo extraperitoneal stoma creation using the arcuate line approach. This technique involves creating a stoma through the extraperitoneal space by accessing the posterior sheath at or below the arcuate line, thereby avoiding direct peritoneal entry. The goal is to reduce the risk of parastomal hernia by maintaining abdominal wall integrity and preventing intra-abdominal content herniation around the stoma.
215009451|NCT07056868|PROCEDURE|transperitoneal colostomy|Patients in this group will receive a conventional transperitoneal stoma. In this approach, the stoma is brought out through the abdominal wall via a peritoneal opening, which is the standard method used in colorectal surgery. This technique serves as the control for evaluating whether the arcuate line approach offers improved outcomes, particularly in reducing parastomal hernia incidence.
215097702|NCT07088848|DEVICE|Gamified Digital Balance Assessment|"The GDBA further enhances the digitalized Brief-BESTest experience by incorporating gamification elements tailored to older adults, including points, avatars, real-time performance graphs, and leaderboards. The system provides automated feedback and maintains engagement through periodic avatar demonstrations when user inactivity is detected. Upon meeting task initiation criteria, a countdown triggers data capture.~The interface is designed for accessibility, featuring a high-contrast color scheme (black background with orange/green highlights), voice prompts, and intuitive controls. Upon completion, users receive a comprehensive report including total score, task-level feedback and training recommendations. A leaderboard feature promotes continued engagement, with gamified training modules under development.~At the end of the assessment, the system displays a summary including total balance score, task-specific feedback, a fall risk rating, and personalized training suggestions. Users"
215097703|NCT07088848|DEVICE|Digitalized Brief-BESTest design|"The digitalized Brief-BESTest was designed to digitize and automate the Brief-BESTest. While the traditional clinician-administered Brief-BESTest relies on subjective scoring, the digitalized Brief-BESTest enables self-guided assessments with automated, objective scoring-improving accessibility in community and home settings.~The system employs OpenPose to capture skeletal data via a standard 2D camera, tracking 17 anatomical landmarks (e.g., nose, neck, shoulders, hips, knees). Ten joint angles relevant to static and dynamic postural tasks (e.g., standing, sitting, single-leg stance, and simulated falls) are computed. The torso is defined as a vector from the neck to the midpoint between the hips, serving as a reference for postural alignment.~To convert pixel-based coordinates into metric units, the system uses the user's self-reported height with adjustments based on ISO anthropometric standards (correction factors: 10.77 cm for males, 10.06 cm for females) to approximate true body"
215097704|NCT07087730|BEHAVIORAL|Virtual Training Program|Therapists randomized to this condition will receive the professional development via an asynchronous virtual training course. The Virtual Training will include written material, videos, interactive learning activities, and a text-based discussion forum where therapists and faculty will be able to interact in relation to the given activities. Clinical scenario and simulation-based interactive learning will allow therapists to explore clinical situations, make decisions, and evaluate consequences of their actions in a safe environment. Therapists will complete 6 study-related therapy sessions with 3 new patients. After therapists receive the Virtual Training and after they enroll their first patient, therapists will attend bi-weekly 1-hour online consultation meetings that include up to 6 therapists at a time and led by two of the training faculty. Each therapist will attend 10 of these posttraining consultation sessions.
215097705|NCT07087730|BEHAVIORAL|Training as Usual|Therapists randomized to this condition will receive the professional development training via a 3-day synchronous workshop delivered via video conference covering the same didactic content as the virtual training course. The workshop will include lectures, written material, videos, and live role play activities. Therapists will complete 6 study-related sessions with 3 new patients. After therapists receive the professional development through Training as Usual and after they enroll their first patient, therapists will attend bi-weekly 1-hour online consultation meetings that include up to 6 therapists at a time and led by two of the training faculty. Each therapist will attend 10 of these posttraining consultation sessions.
214403928|NCT06918145|PROCEDURE|Lymphaticovenous Anastomosis|The basic principle of LVA surgery is to anastomose the deep cervical lymphatic vessels of the brain with adjacent small veins, effectively enabling the direct reflow of accumulated Aβ and tau proteins in the brain's lymphatic circulation into the venous system, thereby improving the symptoms of Alzheimer's Disease (AD).
214504627|NCT07084337|BEHAVIORAL|Bodypump Training Program|Participants in this group performed a structured 8-week Bodypump program consisting of three sessions per week (Monday, Wednesday, and Friday), each lasting 45 minutes. The sessions followed the official Les Mills format, incorporating choreographed resistance exercises using barbells, weight plates, and a step platform. All movements were synchronized with music and led by certified instructors. Participants completed high-repetition, low-load exercises (\~20% of 1RM) targeting major muscle groups. Exercises were adapted to individual capabilities to ensure safety and promote adherence.
214504628|NCT06147063|BIOLOGICAL|AZD9838|Intramuscular (IM) injection.
214504629|NCT06147063|BIOLOGICAL|Licensed mRNA vaccine|Intramuscular (IM) injection.
214504630|NCT06147063|BIOLOGICAL|AZD6563|Intramuscular (IM) injection.
214504631|NCT06931028|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
214504632|NCT06931028|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362
214403931|NCT06918405|DRUG|Tirzepatide|"All the included patients in both the diabetic and nondiabetic groups will receive the same intervention of tirzepatide at a dose of 15 mg administered subcutaneously once a week in addition to lifestyle modification.~Initially, tirzepatide will be started with a dose of 2.5 mg once weekly subcutaneous injection for the first 4 weeks. After the stabilization period of the drug, the dose will be increased to 5 mg after 4 weeks, 7.5 mg after 8 weeks, 10 mg after 12 weeks, 12.5 mg after 16 weeks and finally 15 mg after 20 weeks."
214403932|NCT06917898|DRUG|Spinal Anesthesia with Bupivacaine and Fentanyl|25 mcg Fentanyl 12.5 mg Bupivacaine
214403933|NCT06917898|DRUG|Spinal Anesthesia with Bupivacaine and Midazolam|2 Mg Midazolam 12.5 mg Bupivacaine
215009452|NCT07055997|DEVICE|Robotic-assisted needle localization|Robot-assisted needle localization involves the use of a robotic system to assist with the percutaneous localization of pulmonary nodules under CT guidance. The robotic system provides real-time navigation and increased precision during needle placement, reducing the variability in positioning and improving the accuracy of localization. The system offers automatic adjustments to the needle's trajectory, minimizing the need for manual corrections, and potentially reducing the number of CT scans required. This method is designed to enhance the overall localization success rate and reduce complications associated with traditional manual techniques.
215009453|NCT07055997|PROCEDURE|Manual needle localization|Manual needle localization involves the traditional technique of percutaneous localization of pulmonary nodules under CT guidance without the assistance of robotic systems. The procedure is performed by the physician manually guiding the needle based on real-time CT imaging. The physician adjusts the needle position based on visual cues from the CT scan, which may require multiple attempts for accurate localization.
215009454|NCT07055828|DRUG|Ketamine|Patients received IV ketamine 0.25 mg/kg before Spinal anesthesia as a prophylactic drug
215009455|NCT07055828|DRUG|Intranasal ketamine|Patients received nebulized ketamine at a dose of 0.75 mg/kg adjusted to 5 ml by adding normal saline to be inhaled through a breath-actuated nebulizer
215097706|NCT07087730|BEHAVIORAL|No Training|Therapists randomized to this control condition will provide psychotherapy via the study video conference platform to 3 new enrolled patients in their typical manner except that they and their patients will also complete the assessments necessary for the study. After study completion, the investigators will provide therapists in the control condition with access to virtual training.
215097707|NCT07087548|OTHER|Peloid Therapy|Peloid therapy will be applied using medical mud packs at 45°C for 30 minutes per session, 5 sessions per week for 3 consecutive weeks. The therapy will be administered to the lower back region in patients diagnosed with chronic lumbar disc herniation. This intervention aims to reduce pain and improve function through thermomechanical and biochemical effects of natural peloid.
215097708|NCT07087548|OTHER|Hotpack Therapy|The hot pack group applied 20 minutes, 5 days a week, once a day, for 15 sessions on the lumbar region. The boiler temperature of the hot packs used was 90 °C. Two towels were used, with the thickest side of the towels placed on the lumbar area of the individuals. Then, conventional TENS (80 Hz frequency) was applied to the painful area in the lumbar region for 20 minutes
215097709|NCT07087470|BEHAVIORAL|Simulation-based education and classical education|Simulation-based psychosocial care skills training and classical psychosocial care skills training will be prepared for oncology nurses.
214403934|NCT06919484|OTHER|RCexp|patients received different RCexp
214403935|NCT06918301|DIAGNOSTIC_TEST|Measurement of cardiac performance|Measurement of cardiac performance by different devices
214403936|NCT06919029|DEVICE|Advanced Hybrid Closed Loop from onset of type 1 diabetes in children|The objective of this study is to evaluate glycemic control of users of the AHCL system MiniMed 780G with GS4 calibration-free sensor in children and adolescents with newly diagnosed T1D implemented directly upon T1D diagnosis in combination with continuous glucose monitoring system (CGMS) compared with those treated with MDI retrieved from historical data- in a single- arm open-label prospective observational study, assessed at 3 months. After the initial study period there will be a 3month extension phase of the study.
214403937|NCT06914206|DRUG|esketamine group|in addition to receiving the combination of PRF of DRG and standardized drug treatment, patients will also undergo a single intravenous infusion of esketamine.
214403938|NCT06914206|DRUG|PRF group|In the control group, patients will receive PRF+standardized drug treatment. Pulsed radiofrequency (PRF) will be performed on DRG by an designated physician in each participating center. They will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which are carefully inserted until the needle tip reaches the upper edge of the intervertebral foramen. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. The standardized drug treatment will include antiviral therapy, anticonvulsant treatment, three-step analgesic therapy
214403939|NCT06919731|OTHER|whole blood flow cytometry analisys|Evaluation of platelet prothrombotic potential through a flow-cytometry analysis of platelet activation marker expression, including P-selectin, aGPIIbIIIa and TF, as well as platelet-leukocyte aggregate formation.
215009456|NCT07055828|DRUG|Normal Saline|Patients received Intravenous Normal saline
215009457|NCT07055828|DRUG|Saline Inhalants|Patients received nebulized Saline
215097710|NCT07087470|BEHAVIORAL|classical education|classical psychosocial care skills training will be prepared for oncology nurses.
215097711|NCT03472664|OTHER|low carbohydrate/high fat diet|Modified Mediterranean-Ketogenic Diet is a low carbohydrate/high fat diet.
215097712|NCT03472664|OTHER|low fat/high carbohydrate diet|American Heart Association Diet is a low fat/high carbohydrate diet.
215097713|NCT07087678|DEVICE|Prodigy internal pulse generator occipital nerve stimulator|Electrical stimulation of the occipital nerves using an implantable device
215097714|NCT06912360|OTHER|CPAP|Continuous Positive Airway Pressure (CPAP) with Boussignac valve
214403940|NCT06920095|OTHER|Progressive muscle relaxation exercises|A total of 18 sessions of progressive relaxation were performed, 3 days a week for 6 weeks.
215097715|NCT01970059|DRUG|Extended-Release Carvedilol Sulfate|
215097716|NCT01970059|DRUG|Sustained-release Metoprolol Succinate|
214403941|NCT06917833|OTHER|compare infant hypoxic events in both groups|early neonatal resuscitation will be done by the pediatrician according to the guidelines, APGAR score of the baby will be calculated,, any hypoxic events will be traced and any need of respiratory support for the baby or NICU admission, as well as weight of the baby, mode of delivery and any birth traumas will be recorded.all this will be compared between two groups.
214403942|NCT06920355|OTHER|Produce Prescription|Each month, participants will receive a fixed amount of funds on the PRx card. Participants will be able to use these funds to purchase fruits, vegetables, beans, nuts, nut butters, seeds, plant-based oils, seafood, and yogurts from participating grocery stores. These funds will be provided through an electronic PRx benefit card that is activated after the initial baseline in-person visit is completed. The card will be reloaded monthly for a period of 6 months.
214403943|NCT06920355|BEHAVIORAL|Nutrition Education|Participating pharmacies/grocery chains will have Registered Dietitians (RD/RDN) on staff who can provide participants with nutrition education programs, coaching, and/or nudges.
214403944|NCT06934148|BEHAVIORAL|Blocked Trials|Each search task will be presented in a block of trials.
214403945|NCT06934148|BEHAVIORAL|Mixed trials|All tasks will be randomly mixed in a single block of 400 trials
214403946|NCT06934213|BEHAVIORAL|Choice|The observer gets to make a choice about the sequence of trials they see
214403947|NCT06934213|BEHAVIORAL|Mixed trials|The search tasks are either intermixed. Otherwise trials are run in blocks
214403948|NCT00929305|DEVICE|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
215097717|NCT02803996|DRUG|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
214403949|NCT00929305|DEVICE|Placebo laser|Inactive laser light
214403950|NCT06508723|PROCEDURE|Dental implant placement|The same routine implant placement protocol will be applied to both study groups with different surfaces and will be placed in the bone. After local anesthesia, a full-thickness flap will be raised. The implant socket will be created according to the protocol recommended by the company and all implants will be placed in the socket with a torque force of 35 N and the implants will be placed. Once bleeding control is achieved, the flap will be closed primarily. Healing caps will be installed after 3 months. After waiting for wound healing, prosthetic restoration will be performed.
214403951|NCT04827017|OTHER|follow up|follow up population
215009458|NCT06878092|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus is a brief, potentially scalable psychological intervention developed by the World Health Organization and is delivered by non-specialised helpers. In brief, the intervention is based on cognitive behavioural therapy (CBT) techniques and typically consists of five weekly, ninety-minute sessions. Participants are taught the following techniques during the sessions: stress management, problem-solving, behavioural activation, and accessing social support. The effectiveness of both the individual and group formats of the PM+ intervention have been shown in a number of large definitive RCTs. For the purposes of this study, an adapted version of PM+ will be used to match the exposure between the two active intervention arms. There will be six, weekly seventy-five-minute sessions
215097718|NCT02803996|DRUG|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
215097719|NCT00547040|OTHER|no intervention|no intervention
215097720|NCT00652886|DRUG|Oxandrolone|Tablets, 10mg, single-dose
215097721|NCT00652886|DRUG|Oxandrin|tablets, 10mg, single-dose
215097722|NCT03414294|DRUG|K-755 Part A (SAD)|Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
215097723|NCT03414294|DRUG|Placebo Part A (SAD)|Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
215097724|NCT03414294|DRUG|K-755 Part B (MAD)|Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
215097725|NCT03414294|DRUG|Placebo Part B (MAD)|Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
215097726|NCT03414294|DRUG|K-755 Part C (FE)|Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
215097727|NCT03414294|DRUG|K-755 Part D (FE)|Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
215097728|NCT03414294|DRUG|K-755 Part E (MAD)|Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
215097729|NCT03414294|DRUG|Placebo Part E (MAD)|Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
215097730|NCT04690244|OTHER|Tai Chi Chuan trainings|10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
215097731|NCT05207683|OTHER|echocardiography|All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.
214403952|NCT00188409|PROCEDURE|CT scan|
214504633|NCT06192927|DRUG|TenoMiR|Single intralesional injection
214504634|NCT06192927|DRUG|0.9% Sodium Chloride Injection|Single subcutaneous injection
215097732|NCT03610776|DEVICE|Portion control plate|Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
215097733|NCT03610776|DEVICE|Conventional plate|Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
215097734|NCT05241145|DRUG|IVMED-80|Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
215097735|NCT05241145|OTHER|Placebo|This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
215097736|NCT01705678|DIETARY_SUPPLEMENT|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
215097737|NCT01705678|DIETARY_SUPPLEMENT|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
215097738|NCT02700594|OTHER|Joint mobilization|"Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings."
215097739|NCT00438334|DEVICE|Programmable directional/omni-directional hearing aid|
215097740|NCT06911632|DEVICE|ECG-based AI Device - Results Returned to Investigator|An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will be returned to the Investigators.
214403953|NCT03624595|DRUG|Dexmedetomidine|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
215009459|NCT06878092|BEHAVIORAL|Problem Management Plus with Emotional Processing Module (PM+EP)|To more directly address symptoms of traumatic stress, an adapted version of PM+ containing Emotional Processing module will be trialed in this study. The PM+ strategies discussed above are identical across both interventions apart from the additional module. The Emotional Processing module aims to provide a safe environment for participants to engage in the emotional processing of both positive and negative memories. During the additional session, participants will be asked to imagine significant memories as pieces of a jigsaw puzzle; participants will be asked to illicit three memories, two positive/pleasurable and one negative/frightening. Participants will be assisted in processing these memories through discussing the puzzle pieces, the thoughts and emotions that come with the memory, and future perspectives. Participants will be asked to rate the intensity of emotions before and after they talk about their memories each time they are brought up.
215097741|NCT06911632|PROCEDURE|Echocardiogram and Right Heart Catheterization|Echocardiogram- an ultrasound study of the heart and Right Heart Catheterization- a procedure to measure pressures in the heart
215097742|NCT06911632|DEVICE|ECG-based AI Device - Results Not Returned to Investigator|An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will not be returned to the Investigators.
215097743|NCT01032824|BEHAVIORAL|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
215097744|NCT01032824|OTHER|Group Arm|10-session didactic telephone group
214403954|NCT03624595|DRUG|Placebo|Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
214403955|NCT01796665|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%|
214403956|NCT01796665|DRUG|Acanya Gel|
214403957|NCT01796665|DRUG|Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product|
215097745|NCT01032824|OTHER|Book Arm|Book only.
215097746|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
215097747|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB and superficial PIPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
214403958|NCT05603962|BEHAVIORAL|Visual training|Visual training is the main type of management for CI patients clinically; however, the existing training protocol required patients to make several visits to the clinic for visual training, which might increase the burden for patients and result in higher failures in training. Therefore, this study will use a simple training method by utilizing prisms for CI patients to train at home, then compare visual symptoms and binocular vision after the training.
214403959|NCT02268396|DRUG|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler|GFF MDI administered as 2 inhalations BID
215097748|NCT02294734|DRUG|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
215097749|NCT02294734|DRUG|Placebo|Dry powder for inhalation via DISKUS 'device'
215097750|NCT00624754|DRUG|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
215097751|NCT00624754|DRUG|lactose|Lactose 2 puffs b.i.d for 1 month
215097752|NCT05546255|DRUG|Eribulin Mesylate|The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
215097753|NCT05546255|DRUG|Lobaplatin|The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
215097754|NCT00024011|DRUG|bortezomib|Given IV
215097755|NCT00024011|OTHER|laboratory biomarker analysis|Correlative studies
215097756|NCT03657147|BEHAVIORAL|Educational Video and Question Prompt List|A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
215097757|NCT03308149|DRUG|infiltration with triamcinolone and bupivacaine|facet joint infiltration
215028958|NCT02860403|PROCEDURE|motor imagery|Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
214403960|NCT04840147|DEVICE|JointRep®|JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.
214403961|NCT04840147|PROCEDURE|Microfracture|Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
215097758|NCT03442517|BEHAVIORAL|Behavior Lifestyle Intervention|Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.
215097759|NCT03442517|OTHER|Usual prenatal care|Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
215097760|NCT00741702|OTHER|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP \>=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP\>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP\>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP\>=13/80 mm Hg, increase verapamil to 240 mg/d
215097761|NCT01793259|DRUG|methotrexate prefilled pen|
215097762|NCT01793259|DRUG|methotrexate prefilled syringe|
215097763|NCT05003661|BEHAVIORAL|Parents' Voice|the intervention is recording of parents voice of reading children's book.
215097764|NCT02049619|DEVICE|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
215097765|NCT03157583|OTHER|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
215097766|NCT03157583|OTHER|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
215097767|NCT03157583|OTHER|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
215097768|NCT03157583|OTHER|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
214403962|NCT04529057|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
214403963|NCT02342912|BEHAVIORAL|Social Media Treatments|Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
214403964|NCT01620827|OTHER|Hospital Landline Phone Calls|Follow-up phone calls are made from the hospital landline phones in a research office
214403965|NCT01620827|OTHER|Private Cell Phone Calls|Follow-up phone calls are made from the private cell phones of research assistants
214403966|NCT05915130|BEHAVIORAL|Gait training|They will negotiate (natural or virtual) obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
214403967|NCT05202379|DRUG|CC-42344|CC-42344 capsules
214403968|NCT05202379|DRUG|Placebo|Placebo capsules
214403969|NCT02985697|DRUG|Dexmedetomidine|The intervention being tested is intranasal dexmedetomidine
214403970|NCT02985697|DRUG|Midazolam Hydrochloride|Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
214403971|NCT02985697|DRUG|Nitrous Oxide|Nitrous oxide to be administered in conjunction with other interventions, per study design.
215009460|NCT06878092|OTHER|Care as usual|The comparison group will receive care as usual (CAU) only. CAU for forcibly displaced youth (under 18) in Sweden corresponds to primary health care, education, social protection services, and specialized psychological treatment programs. However, adults are only able to access care that cannot be deferred. Once the individual has received their residence permit, they are able to access all healthcare. Upon first arriving in Sweden, refugees are referred to a municipality by the Swedish Board of Migration (Migrationsverket) until they have their residence permit. The municipality is responsible for education and social services while the regions are responsible for health care. In the regions, primary care is responsible for the first line of treatment but can also refer to the child and adolescent mental health services (CAMHS) if needed. Unaccompanied children might either be placed in families or in residential facilities and benefit from the same systems as accompanied children.
214403972|NCT03556826|BEHAVIORAL|Social Value Learning Training|For each child, two faces will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display.
215009461|NCT07057362|OTHER|Intraoperative Hemodynamic Monitoring|Continuous intraoperative monitoring of systolic blood pressure and heart rate following spinal anesthesia. Vasopressor usage and total fluid administration will be recorded.
215009462|NCT07055802|COMBINATION_PRODUCT|Inversion Table|Inversion Table group will receive flexion biased exercises in supine position with 05 repetitions every session and in addition will be given an inversion table therapy as a treatment at the angle of 60' for 5 minutes in every session. Two follow ups in a week were taken for total of 04 weeks. Measurements were taken for NPRS, Oswestry low back disability questionnaire and sit and reach test respectively
215009463|NCT07055802|COMBINATION_PRODUCT|Mulligan flexion biased exercises|experimental group named as Mulligan group will receive flexion biased exercises in supine position with 05 repetitions every session and in addition will be given mulligan technique. It was done at level just below ASIS (at level of L4-L5 spinous process), ten times/session, for 12 sessions three/week every other day for 4 weeks. . Measurements were taken for NPRS, Oswestry low back disability questionnaire and sit and reach test respectively
215009464|NCT07056972|OTHER|Discontinuation of surveillance|The intervention is discontinuation of current surveillance policies which consist of annual imaging with MRI/MRCP and clinical assessment.
215009465|NCT07056257|PROCEDURE|Scaling-root planning (SRP)|Thirteen sites \[scaling-root planning (SRP)\] were used as a control group.
215009466|NCT07056257|PROCEDURE|Scaling-root planning (SRP)+ laser therapy|Thirteen sites \[scaling-root planning (SRP)+ laser therapy with application of methyl cellulose gel at repeated times weekly for one month\].
215009467|NCT07056257|PROCEDURE|Scaling-root planning (SRP)+ omega 3 gel|Thirteen sites \[scaling-root planning (SRP) + omega 3 gel repeated time weekly for one month\].
215009468|NCT07056257|PROCEDURE|Scaling-root planning (SRP)+ laser therapy+ omega 3 gel|Thirteen sites \[combination therapy between scaling-root planning (SRP) + laser + omega 3 gel in repeated time weekly for one month\].
215009469|NCT07057336|DRUG|Conventional Calcium Hydroxide (CH)|Following completion of canal shaping with rotary instrumentation and irrigation using 5 mL of 2.5% sodium hypochlorite (NaOCl), canals were flushed sequentially with 5 mL distilled water, 5 mL of 17% ethylenediaminetetraacetic acid (EDTA), another 5 mL of distilled water, 5 mL of 2.5% NaOCl, and finally 5 mL of distilled water. The cavity was sealed temporarily with a sterile cotton pellet and glass ionomer cement. Conventional calcium hydroxide was retained for 7 days before final obturation.
215009470|NCT07057336|DRUG|Nanocalcium Hydroxide (NCH)|Following completion of canal shaping with rotary instrumentation and irrigation using 5 mL of 2.5% sodium hypochlorite (NaOCl), canals were flushed sequentially with 5 mL distilled water, 5 mL of 17% ethylenediaminetetraacetic acid (EDTA), another 5 mL of distilled water, 5 mL of 2.5% NaOCl, and finally 5 mL of distilled water. The cavity was sealed temporarily with a sterile cotton pellet and glass ionomer cement. Nanocalcium hydroxide was retained for 7 days before final obturation.
215097769|NCT03157583|OTHER|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
215009471|NCT07056660|DEVICE|Active CAP therapy|The CAP group will additionally undergo atmospheric pressure cold plasma (CAP) treatment (plasma-activated gas form, CAP-Activated Gas; patent number: ZL202110209052.X, provided by Xi'an Jiaotong University), once daily for the first five days and every other day thereafter, for a total of 13 sessions. Each session will involve enclosing the target area in a treatment bag sealed with medical adhesive tape; plasma-activated gas rich in ozone (O₃) will be delivered and recirculated for 20 minutes, followed by plasma-activated gas rich in nitric oxide (NO) for an additional 5 minutes, in strict accordance with the standard operating procedures provided by the manufacturer.
215009472|NCT07056660|DEVICE|Sham CAP therapy|In the placebo group, the electric field for plasma generation will remain off, so no plasma will be produced; only operational sounds will be simulated to maintain procedural blinding.
214403973|NCT06401850|OTHER|Education Group|The intervention provided to the training group focuses on improving skills to cope with polycystic ovary syndrome. This intervention includes topics such as encouraging healthy lifestyle habits, raising awareness about nutrition and exercise, teaching stress management techniques, and offering strategies to support hormonal balance. It provides participants with the tools they need to understand and manage symptoms that impact their lives. It also provides a supportive environment, encouraging participants to share their experiences with each other and receive support. This intervention aims to improve individuals' overall quality of life while strengthening their ability to manage their own health and well-being.
214403974|NCT06401850|OTHER|Control Group|No intervention was made to the control group. This group did not receive additional training or support to cope with polycystic ovary syndrome. In this way, the effects of the control group on lifestyle, symptom management and overall quality of life were evaluated in comparison with the training group. This approach focuses on determining the direct effects of the intervention, while allowing to observe the natural course of the control group, and the results help to provide a clear assessment of the effectiveness of the intervention.
214403975|NCT04240119|OTHER|According to current clinical care standards|Enrolled subjects may be treated with medical management or surgically using indirect revascularization surgery.
214403976|NCT06114329|DRUG|AL01211|AL01211 is a novel, proprietary, selective GCS inhibitor with high potency against GCS with limited off target activity.
214403977|NCT04902742|PROCEDURE|Fluoroscopy-guided ganglion impar block|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Being most commonly used technic, transsacrococcygeal technique, a 22-gauge, 1.5-inch spinal needle is advanced through the sacrococcygeal disk and positioned carefully anterior to the sacrococcygeal junction. Injection of contrast results in a classical comma sign. A mixture of steroid and local anesthetic is given.
215009473|NCT07056660|OTHER|standard care|The group will receive standard care according to current clinical guidelines
215009474|NCT07056010|PROCEDURE|curative minimally invasive gastrectomy with D2+PAND lymphadenectomy|Thirty patients with HER2-negative gastric adenocarcinoma or gastroesophageal junction (GEJ) cancer, presenting with PAN metastasis (No. 16 lymph nodes ≥10 mm), will be enrolled. Participants will receive four cycles of conversion immunochemotherapy with a PD-1 inhibitor (Serplulimab) combined with the SOX chemotherapy regimen (oxaliplatin and S-1). After completion of conversion therapy, patients will undergo curative minimally invasive (laparoscopic or robotic) gastrectomy with D2+PAND lymphadenectomy.
215009475|NCT07057284|RADIATION|Orthopantomogram (or a set of Lateral Oblique Radiographs)|A dental assessment will be conducted on eligible participants who still attend annual review appointments in the Oncology Departments at the Royal Manchester Children's Hospital or at The Christie NHS Foundation Trust (approximately 10% of eligible study population). The dental assessment will include the following: a tooth chart, a basic periodontal examination (BPE), a brief orthodontic assessment (incisor, molar and skeletal classification including any asymmetry), caries assessment and an assessment of any dental development disturbances. Clinical photographs of the teeth and face will be taken with a patient's consent. If clinically justified, an OPT will be taken. If cooperation for an OPT proves challenging, lateral obliques as an alternative radiographic image modality will be considered.
215009476|NCT00525356|DEVICE|Medtronic Talent Stent-Graft-System|
215009477|NCT07051239|OTHER|Closed-loop acoustic stimulation|At-home sleep will be monitored using an EEG headband. Non-awakening auditory stimuli will be delivered during non-rapid eye movement sleep (NREM), timed to the ascending phase of slow waves, using either active or control (sham) conditions.
215009478|NCT07055659|DIAGNOSTIC_TEST|Oral hygiene assessment|experimental group will be given a plant to water it during 2-minute brushing habit. number of decayed teeth and and status of gingiva with the amount of plaque will be compared between the groups
215009479|NCT07056218|DEVICE|neck ultrasound|ultrasound scan
215009480|NCT07056218|DIAGNOSTIC_TEST|thyroglobulin|blood test
215009481|NCT07052513|DRUG|Placebo|Intravenous infusion of normal saline.
215009482|NCT07052513|DRUG|M2RLAB 001|Intravenous infusion of M2RLAB 001
214688281|NCT07162623|OTHER|Oziva Bioactive Gluta Fizzy Effervescent Tablets 4.1 g containing Glutathione|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight"
215009483|NCT07056296|DEVICE|3D Maxillary Expansion with 3 expansion screws|In patients requiring maxillary expansion, after randomization and allocation for each to receive which expander, appliance will be cemented. In the 3-way group (A), 3 screw activations will be delivered by the care giver to expand the maxillary arch in 3D manner correcting the collapsed arch anteriorly.
214403978|NCT04902742|PROCEDURE|Fluoroscopy-guided caudal epidural steroid injection|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. An 18-gauge epidural needle (Tuohy) is advanced at an angle of 45° to the skin until a 'give-way' sensation is felt and position of the needle is confirmed by lateral and anteroposterior fluoroscopic images. Then 5 ml of iohexol solution is injected through it to confirm the position. A properly placed needle would produce a classical 'inverted fern tree' appearance in anteroposterior view after dye injection or a 'filling defect'. The needle is introduced up to S3 level for proper spread of the drug. A mixture of steroid and local anesthetics is given.
214403979|NCT01913756|DIETARY_SUPPLEMENT|Gamalost (Norwegian traditional cheese)|
214403980|NCT01913756|DIETARY_SUPPLEMENT|Gouda-type cheese|
214403981|NCT06522672|DIETARY_SUPPLEMENT|My Happy Flo|The intervention aims to alleviate period symptoms including heavy flows, prolonged periods, cramps, mood disturbances, energy levels, cycle regulation, and fatigue. Blood tests for Vitamin D and Iron levels will be conducted at Baseline and after the third menstrual cycle. Participants will complete validated questionnaires assessing period symptoms after each menstrual cycle.
214403982|NCT00003372|DRUG|topotecan hydrochloride|
214403983|NCT04602364|OTHER|Noninterventional|Not applicable; Noninterventional study
214403984|NCT00001538|BIOLOGICAL|APL 400-003|
214403985|NCT03660943|DRUG|Placebo|Receiving Placebo Injection
215009484|NCT07056296|DEVICE|3D Maxillary Expansion using modified Fan expander with springs|For the fan expander with palatal springs (B) , spring activation will be done by the operator after cemenation intraorally, then the care giver too will just activate one fan screw. Also 3D expansion evaluation was done.
215009485|NCT01030900|BIOLOGICAL|Campath|campath plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and rituximab every 3 weeks for up to 6 cycles
215009486|NCT01030900|BIOLOGICAL|Rituximab|rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and campath every 3 weeks for up to 6 cycles
215009487|NCT01030900|DRUG|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles
215009488|NCT07056270|OTHER|static CT scans|Patients with chronic liver disease and liver cancer received static CT scans before hepatectomy to establish a high-definition CT database.
214403986|NCT03660943|DRUG|CNTX-4975-05|Receiving CNTX-4975-05 Injection
215009489|NCT01981252|DEVICE|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
215009490|NCT05497323|DRUG|Combination Cream|The combination cream consists of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA, were applied every morning by group 2 and group 3.
215009491|NCT05497323|DRUG|Adapalene 0,1% cream|Adapalene 0,1 % cream were given to subjects to be applied every night in group 1 and group 3, and intermittently every two nights in group 2.
215009492|NCT02485769|DRUG|PF-06650833|Suspension
215009493|NCT02485769|DRUG|Placebo|Suspension
215009494|NCT02485769|DRUG|PF-06650833|Tablet (Modified Release)
215009495|NCT02485769|DRUG|Placebo|Tablet (Modified Release)
215009496|NCT07056114|OTHER|The patients with active or inactive TED|The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score
215009497|NCT07056348|DEVICE|Deep Brain Stimulation (DBS) of the Motor Thalamus|All participants enrolled will undergo stimulation parameters tuning of deep brain stimulation electrode leads. All subjects will participate in a series of experiments to evaluate the stimulation effects on movement of face and upper extremities, swallowing, and speech abilities.
215009498|NCT07055685|COMBINATION_PRODUCT|Progressive Resistance Training + Core Stability Exercises|"Participants in Group A will engage in a combined program focusing on upper limb strengthening and trunk stabilization. The core stability component aims to improve neuromuscular control and trunk endurance, while the resistance training targets upper limb muscle strength and shoulder stability.~Core Stability Exercises:~Exercise Description Duration/Repetitions Planks Holding a straight-body position on elbows and toes. 30-60 seconds Bird-Dog Extending one arm and opposite leg, maintaining neutral spine. 5-10 sec/rep, 10-12 reps per side Dead Bug Supine position, extending opposite arm and leg. 3-5 sec/rep, 12-15 reps Bridging Lifting hips off ground, maintaining spinal alignment. 10-15 sec/rep, 12-15 reps Swiss Ball Stability Balance in sitting or leg lift positions using a Swiss ball. 20-30 sec/position, 10-12 reps Progression in core exercises will occur by increasing repetitions, duration, or complexity based on individual capability."
215009499|NCT07055685|COMBINATION_PRODUCT|Progressive Resistance Training|will perform only the upper limb progressive resistance training protocol as outlined below. This regimen focuses on strengthening the shoulder complex, upper back, and arm muscles to improve muscular performance, endurance, and control. Progressive Resistance Training
215009500|NCT02859116|PROCEDURE|Collection of digestive tissues|The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
215009501|NCT02803541|BEHAVIORAL|12 day mainstream summer camp experience|see arm description
215009502|NCT05937906|DRUG|Phase I - Mirdametinib - Level 1|Mirdametinib 4 mg twice/day for 7 days per cycle
215009503|NCT05937906|DRUG|Phase II - Mirdametinib|For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm
215009504|NCT05937906|DRUG|Phase I - Mirdametinib - Level 2|Mirdametinib 4 mg twice/day for 14 days per cycle
214403987|NCT04859556|DEVICE|Alcon 25Gauge, 10,000 cuts per minute Ultravit cutter|a proprietary Vitrector from Alcon for the use on the Constellation system
214403988|NCT04859556|DEVICE|Alcon 25Gauge, 5,000 cuts per minute Ultravit cutter|a proprietary Vitrector from Alcon for the use on the Constellation system
214403989|NCT04730336|DEVICE|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
214403990|NCT05484024|DRUG|Sintilimab|PD-1 inhibitor
214403991|NCT05484024|RADIATION|Short-course radiotherapy|Pelvic radiation
214403992|NCT05484024|COMBINATION_PRODUCT|CAPOX/mFOLFOX|chemotherapy regimen
214403993|NCT00003195|BIOLOGICAL|recombinant interferon alfa|
214403994|NCT00003195|DRUG|busulfan|
215097770|NCT03157583|OTHER|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
215097771|NCT03157583|OTHER|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
214403995|NCT00003195|PROCEDURE|allogeneic bone marrow transplantation|
214403996|NCT00003195|PROCEDURE|peripheral blood stem cell transplantation|
215009505|NCT05937906|DRUG|Phase I - Mirdametinib - Level 3|Mirdametinib 6 mg twice/day for 7 days per cycle
215009506|NCT05937906|DRUG|Phase I - Mirdametinib - Level 4|Mirdametinib 6 mg twice/day for 14 days per cycle
215097772|NCT05643586|DRUG|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
215097773|NCT05643586|DRUG|Prasugrel|Patient treated with 60 mg prasugrel 12 hours before the procedure
215009507|NCT05556018|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
215009508|NCT06015100|DRUG|Inetetamab plus pyrotiniband and capecitabine|Inetetamab plus pyrotiniband and capecitabine
215009509|NCT03622840|BEHAVIORAL|Cognitive Remediation|Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks
215009510|NCT06686459|RADIATION|ALL-in-one radiotherapy|ALL-in-one radiotherapy (breast + supraclavicular + internal mammary lymph node drainage area)
215097774|NCT04025177|DRUG|Indomethacin Injection|The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
215097775|NCT01395277|DIETARY_SUPPLEMENT|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
214403997|NCT00003195|RADIATION|radiation therapy|
214403998|NCT02028910|DRUG|Ondansetron|"The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child"
214403999|NCT00408668|BIOLOGICAL|PEV3A|
214404000|NCT00408668|BIOLOGICAL|FP9 ME-TRAP|
214404001|NCT00408668|BIOLOGICAL|MVA ME-TRAP|
214404002|NCT00920374|BIOLOGICAL|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
214404003|NCT02583074|PROCEDURE|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
214404004|NCT02583074|PROCEDURE|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
215009511|NCT06686459|RADIATION|IMRT|IMRT (breast + supraclavicular + internal mammary lymph node drainage area)
215009512|NCT00441896|DRUG|Ganaxolone|
215009513|NCT00441896|OTHER|Placebo|
215009514|NCT03630900|OTHER|Sequential O2 Culture|We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
215009515|NCT01392937|DEVICE|All-in-One Light multipurpose|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
214404005|NCT02491411|DRUG|Dexamethasone|Given PO
214404006|NCT02491411|DRUG|Enzalutamide|Given PO
214404007|NCT02491411|OTHER|Laboratory Biomarker Analysis|Correlative studies
214404008|NCT02491411|OTHER|Quality-of-Life Assessment|Ancillary studies
215009516|NCT01392937|DEVICE|Aquify care|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
215009517|NCT01603160|BEHAVIORAL|Quality Improvement|"There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized."
215097776|NCT01395277|DIETARY_SUPPLEMENT|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
215097777|NCT05375214|DEVICE|Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)|Novel intermittent theta burst stimulation protocol with individualized targets in the brain for stimulation using structural and functional MRI inputs
215097778|NCT04357977|DIAGNOSTIC_TEST|RBA-2|Collection of non-invasive in vivo saliva from confirmed cases of both infected and non-infected COVID-19 patients or site staff at the testing site and compare the test results using the RBA-2 against the standard test results used for diagnosis.
215097779|NCT03550768|OTHER|MDP|evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
214404009|NCT04438811|OTHER|delivery of the spinal anesthetic by a trained medical officer|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
214404010|NCT04438811|OTHER|delivery of spinal anesthetic by a consultant anesthetist|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
214404011|NCT01884974|OTHER|myeloproliferative disease|Echocardiogram, demographic data, St George respiratory questioner
214404012|NCT04034238|DRUG|LMB-100|Arms 1 and 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.
214404013|NCT04034238|DRUG|Tofacitinib|Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.
214404014|NCT04034238|DEVICE|Mesothelin Expression|Test for mesothelin expression in tumor tissues for study eligibility
215009518|NCT01301092|BIOLOGICAL|LY2189265|administered intravenous, subcutaneous or intramuscular
215009519|NCT06305325|BEHAVIORAL|eHealth Antenatal Coparenting Intervention|This intervention focuses on developing conflict management, problem solving, communication, and mutual support to foster positive joint parenting of an infant. A modification in the delivery of this intervention was made in the current study in order to make it deliver online. The eACoP intervention included eight antenatal videos from Feinberg's Family Foundation intervention. A website for the eACoP intervention was developed, and all the videos were uploaded to the website. These videos were 30-40 minutes each. The videos were in English and subtitles in Urdu were added to the videos. These videos were accompanied by an activity-based coparenting workbook. The coparenting workbook includes a worksheet and homework for each video and was also translated into Urdu
215009520|NCT03546543|PROCEDURE|Position change|Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone
215097780|NCT04316364|DRUG|SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Paclitaxel (Albumin Bound) will be administered intravenously on Day 1,8,15 of each 21-day cycle Drug: Carboplatin will be administered intravenously on Day 1 of each 21-day cycle
215009521|NCT01088893|DRUG|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
215097781|NCT04316364|DRUG|SHR-1316、Chemotherapeutic|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
215097782|NCT04316364|DRUG|Placebo、Chemotherapeutic|Drug: Placebo, will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
215097783|NCT01141478|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
215097784|NCT01141478|DRUG|Sorafenib|400 mg po bid
215097785|NCT00563862|PROCEDURE|Conventional RT|
215097786|NCT00563862|PROCEDURE|Accelerated RT|
215097787|NCT00563862|DRUG|Cisplatin|
215097788|NCT00563862|DRUG|5-fluorouracil|
215097789|NCT04180787|DIETARY_SUPPLEMENT|Beverage Consumption|Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
215097790|NCT03096873|BEHAVIORAL|Combined Exercise Training|The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
215097791|NCT05236712|BEHAVIORAL|Mobile app|The app sends reminder 'push' notifications to complete weekly surveys. The survey is a series of questions about foods and drinks participants had in the last week. Once the weekly survey is completed the app generates a personalized weekly report showing foods we encourage participants to eat more of, eat less of, or keep eating the same amount of. The app will also show menu recommendations for breakfast, lunch, dinner, and snacks that will help participants to eat healthier. Finally, the app also has a feature that allows chatting with the research team by sending and receiving in-app texts.
215097792|NCT05852821|OTHER|5STS remote assessment via videoconference|Patients will be asked to perform several times the 5STS test, from their home through videoconference, on 3 occasions (day 1, 24h later and 1month later).
215097793|NCT05013970|OTHER|Clinical assessment|Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire
214404015|NCT03968887|OTHER|plasma oxidized low-density lipoprotein levels|Detection of plasma oxidized low-density lipoprotein levels
214404016|NCT01939158|BIOLOGICAL|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
214404017|NCT01939158|BIOLOGICAL|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
214404018|NCT01182870|DRUG|choleclaciferol|800-6000 IU cholecalciferol per day
214404019|NCT03294265|BEHAVIORAL|Peer support sessions|"Stages of mourning and motivation Patients introduce themselves, share their experience and mention a strategy on moving on to the next stage Reminder of metabolic control goals Leaders write on the board metabolic variables and ask everybody the goal values. Patients share their results and mention plans to improve them Self-care activities Leaders ask who owns a glucometer, how regularly they use it, its importance and consequences of not doing so.~Simplified meal plan Everyone brings a snack. Leaders ask if each snack is appropriate, how everyone carries out their meal plan, barriers and possible strategies Activities to increase physical activity Everyone compares who achieves 10 thousand steps/day and who doesn't, then mention benefits of exercise"
215009522|NCT03827642|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
215009523|NCT03827642|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
214404020|NCT03294265|BEHAVIORAL|Reminders|"Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.~This intervention will be applied to both groups."
214404021|NCT05274789|DRUG|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
215009524|NCT03827642|DRUG|Treatment C: Naloxone HCl Intravenous (IV) Injection|Participants received naloxone HCl IV injection following a 10 hour fast.
215009525|NCT03827642|DRUG|Treatment D: Naloxone HCl Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
215009526|NCT02507284|DRUG|SRX246|
215009527|NCT02507284|DRUG|Placebo|
215009528|NCT05870436|DIAGNOSTIC_TEST|Methacholine Choline Provocation Test|Perform methacholine choline provocation test according to the protocol
215009529|NCT01350973|DRUG|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
215009530|NCT01350973|DRUG|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
215009531|NCT01845857|BEHAVIORAL|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
215009532|NCT01065441|BIOLOGICAL|AlloStim|Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10\^7 cells
215009533|NCT01065441|PROCEDURE|Cryoablation|Percutaneous cryoablation of selected tumor lesion under CT or US guidance
214404022|NCT05274789|OTHER|Saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
214404023|NCT06212921|DIAGNOSTIC_TEST|Sequential blood samples|Sequential blood samples for diagnostic tests is the only intervention in thei study
214404024|NCT02953275|DRUG|vedolizumab|standard of care
215009534|NCT01065441|BIOLOGICAL|AlloStim|intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10\^7 cells
215009535|NCT01065441|BIOLOGICAL|AlloStim|intravenous AlloStim-TM at doses between 1 x 10\^7 to 1 x 10\^9 cells
215009536|NCT01065441|BIOLOGICAL|AlloStim|Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
215009537|NCT01065441|BIOLOGICAL|AlloStim|Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10\^7 cells.
214404025|NCT02953275|DRUG|Pentoxifylline|added to vedolizumab
214404026|NCT02953275|DRUG|placebo|added to vedolizumab
214404027|NCT03296579|DEVICE|BiPAP|The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.
214404028|NCT03296579|DEVICE|CPAP|The patient breathes against a constant pressure delivered by face mask.
215009538|NCT01065441|BIOLOGICAL|AlloStim|Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM
215009539|NCT06516432|PROCEDURE|Parasternal block|In the case-control groups, patients with elevated serum lactate levels above 2 mmol/L and those who remained below this limit will be identified.
215009540|NCT06516432|PROCEDURE|Requirement of total dose regarding fentanyl|In case-control groups, obtain measurement of total postoperative fentanyl requirement.
214404029|NCT03296579|DRUG|Ipratropium|Nebulized q6h
214404030|NCT03296579|DRUG|Magnesium Sulfate|50mg/kg IV, 4 doses q6h
214404031|NCT03296579|DRUG|Aminophylline|6mg/kg IV (if no progress)
215009541|NCT00168532|DRUG|Sulfamethoxazole-Trimethoprim|
215009542|NCT03421457|PROCEDURE|Uterus-preserving laparoscopic lateral suspension with mesh|V-shaped 2cm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3-4 cm superoposterior to the anterosuperior iliac spine.A grasper is introduced retroperitoneally through the sub-peritoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Round ligament is lifted upward and tunnel is practiced horizontally.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba-Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level.
215009543|NCT03421457|PROCEDURE|Uterus-preserving laparoscopic sacrocervicopexy with mesh|The peritoneum over the sacral promontory is incised until the anterior longitudinal ligament is reached and ureters are identified. Peritoneal relaxing incision is made medial to the right ureter, down into the pelvis, posterior to the cervix and rectovaginal fascia, laterally to the rectum. The arm of the mesh is sutured to the posterior cervix by 2.0 prolene and fixated to the sacral promontory by either Tacker (Covidien) and/or 2.0 prolene as tension-free. Complete peritonisation of the mesh is performed.
215009544|NCT04849832|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich
215097794|NCT05013970|OTHER|Radiographic imaging|MRI of the knee
215097795|NCT04082286|OTHER|Yttrium-90 labelled monoclonal antibody against CD66|
214404032|NCT03296579|DRUG|Standard steroid dose, hourly salbutamol, oxygen as needed|Standard common therapies for all three arms.
214404033|NCT03936062|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the exposure
214404034|NCT03936062|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
214404035|NCT00691158|DRUG|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
215097796|NCT02968628|OTHER|Video Electroencephalogram (EEG)|Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.
215097797|NCT02968628|OTHER|Point-of Care Blood Sugar Testing|One-time heel-stick point-of-care blood sugar testing at time of EEG.
215009545|NCT04849832|DIETARY_SUPPLEMENT|SIC + tea|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes
215009546|NCT04849832|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate solution serves as a positive control - and whose absorption is well known.
215009547|NCT04849832|DIETARY_SUPPLEMENT|FeSO4 + tea|Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition
215009548|NCT00744198|PROCEDURE|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
215009549|NCT00744198|PROCEDURE|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
215009550|NCT00744198|PROCEDURE|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
215009551|NCT03795909|DRUG|Ruxolitinib|Ruxolitinib （2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）
215009552|NCT03795909|DRUG|Dexamethasone|Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.
214404036|NCT00691158|DRUG|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
214404037|NCT00691158|DRUG|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
214404038|NCT00691158|DRUG|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
214404039|NCT05972083|DRUG|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
214404040|NCT02705911|OTHER|Isometric handgrip exercise|Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;
214404041|NCT02705911|OTHER|Aerobic endurance training|To perform 150 minutes extra/week at moderate aerobic intensity
214404042|NCT00575978|DRUG|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
214404043|NCT05376605|OTHER|assessment|Evaluations of the patients will be made with scales, questionnaires and physical tests.
214404044|NCT06189716|DEVICE|High flow oxygen through nasal cannula|High flow oxygen through nasal cannula and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions.
214404045|NCT02065245|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion
214404046|NCT02065245|BIOLOGICAL|Placebo|Placebo administered by peripheral intravenous infusion.
214404047|NCT02065245|BIOLOGICAL|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.
214404048|NCT01304706|DRUG|Fluocinolone Acetonide|0.2 μg/day
214404049|NCT05895656|OTHER|7 Tesla MRI|Performing an additional 7 Tesla MRI examination as part of the initial treatment pathway.
214404050|NCT04073355|BEHAVIORAL|Physical Activity|Smartphone-delivered physical activity intervention
214404051|NCT00286689|DRUG|Growth Hormone|
214404052|NCT00286689|PROCEDURE|Whole body Protein turnover|
214404053|NCT00286689|PROCEDURE|DEXA scan|
215009553|NCT05850507|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
215009554|NCT05850507|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells) .
215009555|NCT06767722|BEHAVIORAL|Lifestyle intervention and self-monitoring of blood glucose|The intervention will consist of a lifestyle intervention that comprises advice on diet, exercise, weight management, and self-monitoring of blood glucose (SMBG) with feedback from healthcare professionals on results and insulin treatment if indicated.
215009556|NCT03695588|PROCEDURE|Quadratus lumborum block|Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)
215009557|NCT03695588|PROCEDURE|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
215009558|NCT02557997|OTHER|Blood tube bottom analyses|
215009559|NCT05548855|PROCEDURE|Heart Transplant|Patients who have undergone a heart transplant as standard of care (SOC) procedure
215009560|NCT05548855|DEVICE|Cardiac Assistive Device|Patients who have undergone a placement of a cardiac assistive device
215097798|NCT02968628|OTHER|Medical Record Data Extraction|Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.
215097799|NCT02968628|OTHER|Maternal Questionnaire|One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
215097800|NCT01165970|DRUG|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
215097801|NCT01165970|DEVICE|Saliva natura|Saliva substitute without restriction to be used
215097802|NCT03574428|DRUG|GNbAC1|Monoclonal Antibody infused i.v.
215097803|NCT03574428|OTHER|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
215097804|NCT02636712|DEVICE|ImageReady™ MR Conditional Pacing System|
215009561|NCT01033071|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
215009562|NCT01033071|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
214404054|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
214404055|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and sham repetitive transcranial magnetic stimulation with H-coil over PFC
214404056|NCT04638777|DEVICE|rTMS with H-coil|Sham repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
214404057|NCT03766919|DEVICE|Implant of the INVICTA lead|The implant or the attempt to implant an INVICTA lead
215009563|NCT01033071|DRUG|Olmesartan medoxomil and hydrochlorothiazide|"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
215009564|NCT03208452|DRUG|Magnesium Sulfate|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
215009565|NCT03208452|DRUG|Normal saline|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
215009566|NCT03022448|OTHER|No Intervention|This is a NIS. No intervention.
215009567|NCT00254072|PROCEDURE|3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass|The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
215009568|NCT01824004|DRUG|S-1|
215009569|NCT04094480|DEVICE|polymeric non absorbable clips|a method to secure appendicular stump
215009570|NCT04094480|OTHER|endoloops|a method to secure appendicular stump
215009571|NCT00004859|DRUG|carboplatin|Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
215009572|NCT00004859|DRUG|paclitaxel|Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
215009573|NCT00004859|DRUG|thalidomide|Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
215009574|NCT00004859|RADIATION|radiation therapy|Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
215097805|NCT03930407|PROCEDURE|The Hayman uterine compression suture.|Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
215097806|NCT01088594|DRUG|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
215097807|NCT01088594|DRUG|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
215097808|NCT01088594|DRUG|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
215097809|NCT01088594|DRUG|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
215097810|NCT01088594|DRUG|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
215097811|NCT01088594|DRUG|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
215097812|NCT04916379|DIETARY_SUPPLEMENT|Momordica charantia|Momordica Charantia: 2000 mg per day for 12 weeks
215097813|NCT04916379|OTHER|Placebo|Placebo: 2000 mg per day for 12 weeks
215097814|NCT04607122|DRUG|Landiolol|Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.
215097815|NCT04607122|DRUG|Saline|Continuous infusion of saline solution at the same rate as landiolol infusion.
215097816|NCT06061029|BEHAVIORAL|Brief Yoga- and Mindfulness-Based Psychoeducation Program|A unique mindfulness psychoeducation program incorporating features of Hatha yoga and mindfulness-based cognitive therapy, plus the main concepts of self-compassion
215097817|NCT04460846|DIETARY_SUPPLEMENT|Alkaline water|1.5 liters per day
215009575|NCT06895148|DEVICE|New ventilator|"The new ventilator order (intervention) was developed using economic behavior theory to decrease the cognitive burden on the ordering provider while enhancing the operability of the order itself. The strategy resulted in a new ventilator order that includes the following changes:~1. Automatic calculation of the PBW based on the most recent height~2. If the height is not available, an order to obtain a height will be generated and the choice of tidal volume will be based on cc/kg PBW~3. Simplify ventilator modes to accurately reflect the standard of care~4. Reduce duplicative information in the monitoring and comments portion of the order~5. Cascade ventilator orders based on mode to enhance visualization."
215009576|NCT06895148|DEVICE|control ventilator|Current ventilator order used by control hospitals
215009577|NCT06895447|DRUG|Pre-operative chemotherapy|Patients will undergo pre-operative drug treatment (any chemotherapy drug or immunotherapy drug are accepted).
215009578|NCT06895447|PROCEDURE|Robotic radical gastrectomy after neoadjuvant therapy|"Eligible participants must have stage III resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma based on imaging studies such as ultrasound endoscopy, CT, or MRI.~Patients will receive 3-4 cycles of neoadjuvant therapy, followed by imaging evaluations to assess the treatment response and determine eligibility for radical D2 gastrectomy. Within 2-6 weeks of the final neoadjuvant treatment cycle, eligible patients will undergo robotic radical gastrectomy."
215009579|NCT06912269|OTHER|Exercise|A progressive calf strength training program lasting 12 weeks (twice weekly sessions), with a total of 25 visits to the gym. Specific exercises for ankle flexors: standing unilateral plantar flexion (on the machine) and seated unilateral plantar flexion (adapted on the Smith machine) will be performed. Participants will use progressive load from 55% of one repetition maximum load for the specific plantar flexion exercises.
215097818|NCT04460846|DIETARY_SUPPLEMENT|Reverse osmosis water|1.5 liters per day
215097819|NCT00490620|DRUG|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
215097820|NCT00490620|DRUG|Placebo|placebo BID for 6 months
215097821|NCT01427634|BEHAVIORAL|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
215009580|NCT06912269|OTHER|Exercise|A progressive calf strength training program lasting 12 weeks (twice weekly sessions), with a total of 25 visits to the gym. Specific exercises for ankle flexors: standing unilateral plantar flexion (on the machine) and seated unilateral plantar flexion (adapted on the Smith machine) will be performed. Participants will use progressive load from 70% of one repetition maximum load for the specific plantar flexion exercises.
215009581|NCT04022980|DRUG|Nivolumab|HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
215097822|NCT01427634|OTHER|Usual Care|Receive usual care as provided by the VAD clinical team.
215097823|NCT03853070|DEVICE|ED Coil / Electro-detach Generator v4|The ED Coil is used for vascular embolization with a platinum coil at the target lesion in a patient's blood vessel. The ED Detach Generator is intended to for use solely to detach the platinum coil from the delivery catheter of the ED Coil.
215097824|NCT00901810|DEVICE|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
215097825|NCT00901810|DEVICE|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
214688282|NCT07162623|OTHER|Placebo Effervescent Tablets 4.1 g|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight"
215097826|NCT06171074|BIOLOGICAL|CM310|CM310 injection
215097827|NCT04122170|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
215009582|NCT06932666|OTHER|Diet A group|Diet high in fiber (\> 40g/10MJ), high in resistant starch (\> 10g/10MJ), and containing large food particles. Diet is provided for 3 full days, consists of three meals per day (breakfast, lunch, and dinner) and in-between meals, and covers 100% of the participants' energy requirements.
215009583|NCT06932666|OTHER|Diet B group|Diet low in fiber (\< 10g/10MJ), low in resistant starch (\< 3g/10MJ) and containing small food particles. Diet is provided for 3 full days, consists of three meals per day (breakfast, lunch, and dinner) and in-between meals, and covers 100% of the participants' energy requirements.
215097828|NCT04122170|DRUG|Aspirin (ASA) Oral Tablet - Pre-Treatment|Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
215097829|NCT04122170|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion."
215097830|NCT04122170|DRUG|Placebo (0.9% Sodium chloride) infusion|0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
215009584|NCT05556837|OTHER|Control Cereal|A portion of cereal (25g available carbohydrate), served with 125ml of 2% milk and 250ml water, will be fed to participants and postprandial glucose and insulin will be measured
215097831|NCT05363826|COMBINATION_PRODUCT|photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)|"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"
215097832|NCT00618605|BIOLOGICAL|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
215097833|NCT03222414|DEVICE|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
215097834|NCT03222414|DEVICE|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
215009585|NCT05556837|OTHER|OBG Cereal|A portion of cereal (25g available carbohydrate) containing OBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
215009586|NCT05556837|OTHER|BBG Cereal|A portion of cereal (25g available carbohydrate) containing BBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
215097835|NCT03222414|OTHER|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
214404058|NCT04639154|PROCEDURE|Erector spinea plane block|ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
214404059|NCT02379364|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
214404060|NCT00903045|DRUG|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
214404061|NCT00903045|DRUG|Placebo|Identical placebo twice a day
214404062|NCT05665855|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid ketone monoester supplement.
214404063|NCT05665855|OTHER|Placebo|A liquid placebo that is taste-matched to the ketone monoester supplement.
214404064|NCT04940390|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
214404065|NCT04940390|DRUG|Placebo|Placebo for STS101
214404066|NCT04291521|DRUG|Ketamine|Administering ketamine as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
215097836|NCT05633329|PROCEDURE|single level|injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)
215097837|NCT05633329|PROCEDURE|dual level|injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)
214404067|NCT04291521|DRUG|Etomidate|Administering etomidate as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
215009587|NCT05479045|BIOLOGICAL|NY-ESO-1 Peptide vaccine|300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks.
215009588|NCT05479045|DRUG|Toripalimab-tpzi|240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
215009589|NCT06946927|DRUG|JMKX001899|JMKX001899 tablet administered orally daily.
215009590|NCT06946927|DRUG|IN10018|IN10018 tablet administered orally daily.
215009591|NCT06946927|DRUG|Chemotherapy: Pemetrexed|IV infusion once every 3 weeks
215009592|NCT06946927|DRUG|Carboplatin|IV infusion once every 3 weeks, 4 Cycles
215009593|NCT04210089|DEVICE|Total Contact Soft Cast|"The total contact soft cast will consist of wound dressing of choice to the ulcer and a plantar foot accommodative offloading felt pad for all foot ulcers, with 4x4 gauze pads added to the arch to create a rocker bottom for metarsophalangeal joint (MPJj) and plantar heel ulcers. The next layers will be:~* Unna boot from MPJs to just below the knee,~* Sterile Kerlix from MPJs to just below the knee~* Sterile 4 inch Kling wrap from the MPJs to just below the knee,~* Four inch coban from MPJs to just below the knee, and~* Ace wraps from MPJs to just below the knee"
215009594|NCT04210089|DEVICE|Cam Boot|Removable Diabetic cam boot will be used in patients willing and capable of using it. If patient does not want to use Diabetic cam boot then surgical shoe or regular shoe would be options.
215009595|NCT03495440|BEHAVIORAL|Center Sessions|Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.
215009596|NCT03495440|BEHAVIORAL|At-home|Self-study resources paired with regular contact with study personnel.
215009597|NCT01729091|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
215009598|NCT01729091|BIOLOGICAL|Elotuzumab|Given IV
215009599|NCT01729091|OTHER|Laboratory Biomarker Analysis|Correlative studies
215009600|NCT01729091|DRUG|Lenalidomide|Given PO
215009601|NCT01729091|DRUG|Melphalan|Given IV
215009602|NCT01729091|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
215009603|NCT01729091|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Given IV
215009604|NCT04653064|BEHAVIORAL|Placebo Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.
215009605|NCT04653064|BEHAVIORAL|Control Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect.
215009606|NCT04268511|PROCEDURE|Caudal epidural block group|The linear probe of ultrasound was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone. A 22 Gauge 50 mm echogenic block needle was advanced
215009607|NCT04268511|PROCEDURE|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
215009608|NCT04520906|DEVICE|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
215009609|NCT04423367|DRUG|bortezomib/dexamethasone|Enrolled patients would receive the combination therapy of bortezomib and dexamethasone.
215097838|NCT03774342|PROCEDURE|Coronary Artery Bypass Grafting|Patients undergoing coronary artery bypass grafting
215097839|NCT02250664|OTHER|Very low nicotine content cigarettes|Very low nicotine content cigarettes
215097840|NCT03847909|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
214404068|NCT04291521|DRUG|Propofol|Administering propofol as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
214404069|NCT01345292|DEVICE|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
215009610|NCT05399134|DIETARY_SUPPLEMENT|Modified Functional Foods|"Subjects will be provided with ABREP-fortified bread, microfluidic co-flow noodles, and 5ibrePlus™-fortified white rice served in a mixed meal.~ABREP-fortified bread: Anthocyanins are known to exert anti-diabetic effects through modulating digestion, glucose uptake, insulin secretion and sensitivity. Moreover, inhibitory effects of anthocyanins on various carbohydrases, including a-glucosidase and a-amylase have been widely reported.~Microfluidic co-flow noodles: Microfluidic technology is employed to design noodle-food structures consisting of a mix of soy protein isolate and alginate as gelling agents to offer a type of novel noodles with proteins and negligible carbohydrate content.~5ibrePlus™-fortified white rice: 5ibrePlus™ is a patented novel fibre grain product by Alchemy Foodtech Pte. Ltd (WO 2017/142477) with reduced GI. Its main constituents are insoluble resistant starch and soluble fibre."
215009611|NCT05399134|DIETARY_SUPPLEMENT|Control Functional Foods|Subjects will be provided with control function foods including white bread, beehoon noodles, and jasmine white rice served in a mixed meal.
214504635|NCT06410001|DEVICE|Epidural Spinal Cord Stimulation (eSCS)|"The spinal cord stimulator system (Abbott Eterna system implantable pulse generator (IPG), charger, and TriCentrus lead) will be used for this study which is manufactured by Abbott Laboratories. The The stimulators will be surgically inserted above the dura in the spinal canal and administer an electrical signal from the neurostimulator to specific sections of the spinal cord underlying the electrodes. The duration of implantation will be 10 years (the longevity of the device battery). The device will not be removed unless it causes complications such as malfunction, illness, or other harm.~The device can also be removed electively for any reason."
215009612|NCT00184509|BEHAVIORAL|integrated psychosocial treatment (behavior)|
215009613|NCT06469125|PROCEDURE|Endoscopic Prostate Interventions for Anatomic Enucleation|The intervention in this study involves performing anatomic endoscopic enucleation of the prostate (AEEP) using different energy sources. Following the enucleation, the resected prostate tissue will be morcellated within the bladder using various morcellators to remove the enlarged prostate tissue minimally invasively. The process will also involve evaluating and categorizing any resulting bladder injuries using the BICEP classification system.
215009614|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if \<1500g b.w. or 4.0g/kg/d of enteral protein if \>1500g b.w. until 1 week before discharge
215009615|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
215009616|NCT01773902|DIETARY_SUPPLEMENT|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
215009617|NCT00959452|BEHAVIORAL|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
215009618|NCT04941898|BIOLOGICAL|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
215009619|NCT05850312|DEVICE|Gamified Digital Intervention - Feasibility Analysis on MoM|In first round we aim to clinically analyze the game Militant of the Maze (MoM) as a vehicle for Exposure Theory, including, play, observation, and feedback from five clinicians.
215009620|NCT05850312|DEVICE|Gamified Digital Intervention|In the first phase of round 2 of the study, 5 clinicians will play the game to evaluate the revised game MoMG. In the next phase, 5 carefully-selected non-clinician participants will play the game. under real-time observation of clinicians, to ensure that subjects experience no harm, and that the gameplay is interesting and enjoyable.
215009621|NCT04901052|DIETARY_SUPPLEMENT|n-3 supplementation group|n-3 supplementation group (1.5g of omega 3)
215009622|NCT04901052|DIETARY_SUPPLEMENT|Placebo group|Placebo group (sunflower oil)
215009623|NCT00228852|DRUG|Busulfan, Fludarabine and ATG|
215009624|NCT02073617|RADIATION|Real-time 3-dimensional DynaCT|After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition. Intravenous delivery of contrast as alternative.
215009625|NCT04060745|OTHER|cooling using a water-perfused vest|"BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed"
215009626|NCT04060745|OTHER|thermoneutrality|In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
215028959|NCT05679557|OTHER|Perioperative geriatric assessment and intervention|The intervention will comprise a preoperative, thorough geriatric, multidisciplinary assessment (CGA) and tailored interventions, focused on optimizing health issues of expected importance in further course of surgery. Furthermore, postoperative ward rounds by a geriatric team will be conducted. Thus, the course of treatment for each patient will be a close interdisciplinary collaboration.
215028960|NCT03898973|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV)|Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.
215028961|NCT00191698|DRUG|atomoxetine hydrochloride|
215028962|NCT00191698|DRUG|placebo|
215028963|NCT01442610|DRUG|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
215028964|NCT01442610|DRUG|Placebo|Placebo 1tablet once daily for 8 weeks
215009627|NCT00884949|DRUG|BMN 110|"Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:~* Weeks 1-12: 0.1 mg/kg/week~* Weeks 13-24: 1.0 mg/kg/week~* Weeks 25-36: 2.0 mg/kg/week~Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week."
215009628|NCT04807296|PROCEDURE|TFLEP|"Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.~Fifty (50) patients will undergo TFLEP."
215028965|NCT00006377|DRUG|carboplatin|
215028966|NCT00006377|DRUG|doxorubicin hydrochloride|
215028967|NCT00006377|DRUG|paclitaxel|
215028968|NCT06549231|DRUG|Rituximab|one course of IV rituximab consisting of an infusion of 1000 mg rituximab (diluted in 500 mL of saline 0.9 % sodium chloride) will be given at day 1, day 15 and an infusion of 500 mg rituximab (in 500 mL of saline 0.9 % sodium chloride) at week 24;
214504636|NCT06901648|DRUG|HS-20094|Administrated by subcutaneous injection once a week
215028969|NCT06549231|DRUG|Placebo|one course of intravenous placebo of rituximab consisting of an infusion of 500 mL of saline (0.9% sodium chloride) infusion will be given at day 1, day 15 and week 24;
215028970|NCT03366831|BEHAVIORAL|Thirty Million Words Initiative Newborn Intervention|The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.
215028971|NCT06501976|DRUG|Lurbinectedin|2.6 mg/m2 , Given IV, every 21 days
214688283|NCT07161687|DRUG|Marstacimab|For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcutaneously at a dose of 300 mg as the initial dose, followed by 150 mg once weekly. If the patient weighs 50 kg or more and shows an inadequate response, the dose may be increased to 300 mg once weekly for subcutaneous administration.
214688284|NCT07163377|OTHER|Experimental Group|Participants in the intervention group will undergo art therapy sessions
214688285|NCT07162116|DRUG|XY0206|12.5 mg/table,On the morning of the day of dosing , subjects received XY0206 tablets orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg)；Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg)；Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)
215009629|NCT04807296|PROCEDURE|m-HoLEP|"The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.~Fifty (50) patients will undergo m-HoLEP"
215009630|NCT06783946|BEHAVIORAL|Meditation|The meditation technique will be comprised of breathing techniques, full body relaxation, color meditation, visualization, and positive affirmations. A physician researcher trained in teaching meditation will conduct virtual meditation sessions with patients enrolled in the study. Participants will practice a daily 20-minute meditation for 2-4 weeks before scheduled surgery (whichever is the maximum length of time from enrollment) to 2 weeks post-operatively using the provided audio guided meditation recordings. Participants will also log completion of daily meditation practice electronically.
215009631|NCT03126734|OTHER|Infant Massage course|"Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.~This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually."
215009632|NCT01258855|BIOLOGICAL|Aldesleukin|Given IV
214688286|NCT07162116|DRUG|Moxifloxacin (400 mg)|400mg，On the morning of the day of dosing , subjects received moxifloxacin orally on an empty stomach
215097841|NCT03847909|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
215097842|NCT04302064|DRUG|Eplontersen|Eplontersen administered SC
215097843|NCT04302064|DRUG|Placebo|Eplontersen-matching placebo administered SC
215097844|NCT03514563|DIAGNOSTIC_TEST|MRI imaging|MRI recordings of the craniofacial region
215097845|NCT03514563|DIAGNOSTIC_TEST|Optical scan|Optical intraoral scans
215097846|NCT03514563|DIAGNOSTIC_TEST|3D photography|Facial stereophotogrammetry
215097847|NCT02168985|BEHAVIORAL|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
214404070|NCT01345292|DRUG|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
214404071|NCT01345292|DRUG|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
214404072|NCT00189020|BIOLOGICAL|PCV7|PCV7 at age 2 and 4 months
214404073|NCT00189020|BIOLOGICAL|PCV7|PCV7 at age 2, 4 and 11 months
214404074|NCT05119933|DRUG|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
214404075|NCT04511663|COMBINATION_PRODUCT|Assertive community treatment|The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.
214404076|NCT04511663|COMBINATION_PRODUCT|Basic public health services.|The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
215009633|NCT01258855|OTHER|Laboratory Biomarker Analysis|Correlative studies
215097848|NCT01528748|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
215097849|NCT02882386|OTHER|Strength Training|
215097850|NCT02882386|DIETARY_SUPPLEMENT|Milk 1%|
215009634|NCT01258855|BIOLOGICAL|Ziv-Aflibercept|Given IV
215009635|NCT01958684|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|LNG-IUS once inserted will be effective for 5 years.
215009636|NCT01958684|DEVICE|Copper-IUD|Copper-IUD once inserted will be effective for more than 10 years.
215009637|NCT04330898|DEVICE|Biotronik peacemakers, implantable cardioverter-defibrillators and cardiac resynchronizers|Any of these Biotronik cardiac stimulation devices with the Home Monitoring function activated for the remote control of patients
215009638|NCT01567085|DRUG|Eculizumab|
215009639|NCT04231006|RADIATION|High dose rate brachytherapy|High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
215009640|NCT05719389|DRUG|CT-P13|CT-P13 is a biosimilar of infliximab approved by EMA since 2015, and it is administered intravenously (i.v.) at a standard dose of 5 mg/kg at week 0, 2, 6 and then every 8 weeks, although the scheduled maintenance regimen can be optimized by administering the drug every 4-6 weeks or increasing the dose up to 10 mg/kg2.The safety profile of CT-P13 SC was comparable to that of CT-P13 i.v.; There were also fewer patients with positive anti-drug antibodies with CT-P13 SC than with CT-P13 i.v.3 At the moment, no data are available on the effectiveness, safety and immunogenicity in a real-world population of patients who have been switched from i.v. to s.c. infliximab.
215009641|NCT00449969|DEVICE|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
215009642|NCT00449969|DEVICE|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
215097851|NCT02882386|DIETARY_SUPPLEMENT|Whey protein concentrate 80 (WPC-80)|
215097852|NCT02882386|DIETARY_SUPPLEMENT|Microparticulated whey|
215097853|NCT02882386|DIETARY_SUPPLEMENT|Hydrolyzed whey|
215097854|NCT02882386|DIETARY_SUPPLEMENT|Native whey|
215097855|NCT06027021|DIAGNOSTIC_TEST|18F-Fluoromisonidazole PET|Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.
215009643|NCT06413771|DRUG|Letrozole 2.5mg|Letrozole pretreatment during ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
215009644|NCT06413771|DRUG|Gonadotropin|Ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
215009645|NCT03899493|OTHER|Observation|Patients will be dispositioned to usual obstetric care which may include minimal intervention if spontaneous labor, induction of labor or augmentation of labor as indicated and dictated by the participants obstetrical provider. This study is observational only.
215009646|NCT04762199|DRUG|Flt3/MerTK Inhibitor MRX-2843|Given PO
215009647|NCT04762199|DRUG|Osimertinib|Given PO
215009648|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
215009649|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
215009650|NCT03421080|BEHAVIORAL|MoodGYM|The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.
215097856|NCT05518526|DRUG|Liposomal Annamycin (L-Annamycin)|Study drug consists of L-Annamycin as a lyophilised powder in 50-mL single-use vials containing 45 mg of L-Annamycin must be reconstituted with 45 mL of 0.9% sodium chloride injection between 34 to 42℃, USP, and then diluted 1:1 with 0.9% sodium chloride injection between 34 to 42℃ in non-polyvinyl chloride IV bags before intravenous infusion. The dose of L-Annamycin will be intravenously applied during 2 hours infusion on D1, D8, and D15 of each 28-day cycle (up to Cycle 6th).
215097857|NCT01979939|DRUG|DCV/ASV/BMS-791325|
214404077|NCT03412942|DEVICE|FISH SP|The device will be used to close the femoral artery after angiogram and/or endovascular procedure.
214404078|NCT03397160|BEHAVIORAL|Decision Support Intervention (DSI)|"A question list (QL) that includes areas of patient concern are created by the health coach for use by the patient and the urologist at their first consultation visit where they discuss the extent of their cancer and consider treatment options. The coach uses the Prostate Cancer SCOPED model to complete a Prostate Cancer SCOPED Model Form. The SCOPED model uses concepts such as the situation, choices (treatment), objectives (personal goals and priorities), people (involved in supporting a treatment decision), evaluation and decisions (clarifying which choice is best and next steps)."
214404079|NCT02023944|OTHER|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
214404080|NCT06076759|DRUG|Intrathecal morphine or dexmedetomidine|Intrathecal injection
214404081|NCT05241795|OTHER|Knee then Ankle rehabilitation protocol|"Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction.~Then, Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises"
214404082|NCT05241795|OTHER|Ankle then Knee rehabilitation protocol|"Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises~Then, Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction."
214404083|NCT01033643|DRUG|MK-3614|Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.
215009651|NCT03421080|BEHAVIORAL|Check Your Drinking|Internet intervention designed to assess and provide feedback on hazardous alcohol use. The CYD has been subjected to seven randomized trials from two independent research groups, all of which displayed a significant impact of the CYD to reduce hazardous alcohol consumption compared to controls.
215009652|NCT04597333|DRUG|Dinoprostone|Dinoprostone vaginal insert.
215009653|NCT04597333|DEVICE|Cervical ripening balloon.|Double lumen cervical ripening balloon.
215009654|NCT04331171|DEVICE|Web application users|questionnaire of comorbidity and symptoms completed by the patient on his smartphone
215009655|NCT04348578|OTHER|QMix 2in1|In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
215009656|NCT04029038|BIOLOGICAL|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|Given IV
215009657|NCT04029038|DRUG|Cyclophosphamide|Given IV
215009658|NCT04029038|DRUG|Fludarabine|Given IV
215009659|NCT02360501|DRUG|Docetaxel|75mg/㎡,d1
215009660|NCT02360501|DRUG|Cisplatin|25mg/㎡,d1-3
215009661|NCT02360501|DRUG|Capecitabine|2000mg/㎡,d1-14
215009662|NCT05948982|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion, once every 4 weeks for a total of 3 infusions. All subjects received experimental drugs and conventional treatment during the study period.
214404084|NCT01033643|DRUG|Placebo for MK-3614|Participants were administered dose matched placebo tablets according to randomization.
215009663|NCT03150797|DRUG|Melatonin|Melatonin
215009664|NCT03150797|DRUG|Placebo oral capsule|Placebo
215009665|NCT00652613|RADIATION|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
215009666|NCT00652613|RADIATION|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
215009667|NCT01232907|DRUG|L-Carnitine|L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
215009668|NCT05180656|BEHAVIORAL|Yoga Intervention|The yoga intervention will consist of two 60-minute yoga classes each week, taught by a certified yoga instructor and delivered remotely through videoconferencing. Participants will be asked to participate in the intervention for 8 weeks.
214404085|NCT01430702|DEVICE|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
214504637|NCT06901648|DRUG|Dulaglutide|Administrated by subcutaneous injection once a week
215009669|NCT02887352|OTHER|assessment of problem-solving ability|
215028972|NCT06501976|RADIATION|Radiation Therapy|Thoracic radiotherapy
215009670|NCT00268398|DRUG|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1\&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1\&2) continuous 5FU 600mg/m² (day 1 to 2)
215009671|NCT00268398|DRUG|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
214404086|NCT01893320|DRUG|Vosaroxin|"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."
214404087|NCT01893320|DRUG|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
214404088|NCT06633796|DEVICE|AMADEO|304 / 5.000 The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy, functional occupational therapy and polyarticular mobilization of the fingers with a robotic arm (Amadeo). The sessions will be scheduled 2 times a week for 5 consecutive weeks.
214404089|NCT06633796|PROCEDURE|Standard of care|The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy and occupational therapy for functional purposes. The sessions will be scheduled 2 times a week for 5 consecutive weeks.
214404090|NCT01161160|BIOLOGICAL|GSK Biologicals' GSK2340274A (two different formulations)|Intramuscular injection
214404091|NCT01161160|BIOLOGICAL|GSK Biologicals' - GSK2340272A|Intramuscular injection
214404092|NCT04430374|OTHER|No interverntion|No intervention will be done, registry only
214404093|NCT04222647|DRUG|WO533|Intravaginal application
214404094|NCT04638699|OTHER|OptiScreen training|Special psycho-oncological training for nursing staff to acquire basic knowledge about the experience of mental stress as well as diagnostics of psychosocial stress
215009672|NCT02209909|DRUG|aspirin continuation|Patients are randomized to continue aspirin before OPCAB surgery.
215009673|NCT02209909|DRUG|aspirin discontinuation|Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
215009674|NCT05542537|BEHAVIORAL|Brighter Bites (BB) Produce Distribution|For 16 weeks in the school year, teachers in participating program schools will receive distributions of 8-10 different types of produce items.
215009675|NCT05542537|BEHAVIORAL|Brighter Bites (BB) Nutrition Education|Brighter Bites Nutrition Education will consist of recipes, food preparation and storage ideas, and tips and tools to budget and plan meals. Teachers will be trained in a nutrition education curriculum, which will be implemented in the program schools as part of the BB program.
215009676|NCT05542537|BEHAVIORAL|Create Healthy Futures (CHF) Weekly Wellness Groups|Peer-facilitators will lead virtual weekly group discussions. Penn State Better Kid Care will train the wellness facilitators.
215009677|NCT05542537|BEHAVIORAL|Create Healthy Futures (CHF) Web-Based Module|Create Healthy Futures Web-Based Module is self-paced and focuses on the following topics: 1) Introduction, 2) Challenges of the food environment, 3) Nutrition and your health, 4) Food culture reform, and 5) Providers' role in creating healthy futures. The Create Healthy Futures module utilizes several educational methods to increase interactivity and engagement, including video footage of content experts, reflection activities, downloadable handouts, and action planning. Each chapter takes approximately 30-40 minutes to complete. The program is delivered on the Better Kid Care On Demand platform, an asynchronous learning management system that provides professional development training for teachers in all 50 states and 69 countries.
215009678|NCT02388100|PROCEDURE|Capillary HbA1c collection|
215009679|NCT00504231|BIOLOGICAL|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
214404095|NCT01593878|OTHER|TV|test taken with TV on
214404096|NCT01188122|DEVICE|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
214404097|NCT00670995|BEHAVIORAL|Interactive Tobacco Education|Increase perceived behavioral control (self-efficacy) Decrease willingness to use tobacco Decrease intentions to use tobacco
214404098|NCT04446975|OTHER|BPA|At the time of writing the prescription an automatic notification will appear on the care provider's screen that identifies a suggested post-discharge opioid dose within the electronic prescription pad. If approved by the provider, opioid-only prescriptions will be written as suggested. Final dosing decisions and drug choices will remain at the discretion of the treating provider.
214404099|NCT02271594|BEHAVIORAL|Intensive Training on Best Insulin Injection Technique|The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
214404100|NCT02271594|BEHAVIORAL|Standard education on injection technique|Usual and customary education and training normally provided injecting patients at the center
214504638|NCT06901648|DRUG|Palcebo|Administrated by subcutaneous injection once a week
215009680|NCT06557369|DEVICE|reSEES|"The treatment consists of combining SMPL and PBM light therapies to exploit the full advantage of their action. The combination will result in an additive or synergetic effect.~* Treatment sessions are scheduled for three weeks after enrolment (Loading-Phase).~* Two visits per week are needed.~* At the first visit of every treatment week, two treatment sessions will follow each other; PBM is applied at least 15' after SMPL (treatment pairs).~* Only PBM will be administered during the second visit of every treatment week.~Patients will receive:~* 1x SMPL treatment at days 0, 7, and 14 (3 in total),~* 1x PBM treatment at days 0, 3, 7, 10, 14, and 17 (6 in total)~Nine treatments will be delivered within three weeks. The study will be concluded with three follow-up visits at 18, 24, and 54 weeks."
215097858|NCT00758641|DEVICE|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
215097859|NCT00758641|DRUG|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
215097860|NCT01820312|RADIATION|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
215097861|NCT04218396|DEVICE|Virtual Reality use during painful bedside procedure|Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.
215097862|NCT04218396|DRUG|Standard Treatment during painful bedside procedure|Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
214404101|NCT03464253|DEVICE|Performance of the transcranial Doppler (TCD)|Within 24 hour before the operation, TCD is performed using Siemens Acuson X300 machine with ultrasound frequency is 1 - 5 MHz probe to measure Mean Velocity and Pulsatility Index in the right middle cerebral artery.postoperatively, TCD study is performed twice at 24h and 48h after spinal anesthesia. For 5 days postoperatively, the Patients are assessed clinically for the occurrence of headache. Patients who developed PDPH will be identified and their pre and post puncture measurements will be compared with the corresponding measurements of PDPH free patients.
214404102|NCT02594696|OTHER|Proactive Psychiatry Consultation (PPC)|"* The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.~* The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.~* The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks~* The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).~* Recommendations are documented in the medical record and communicated directly to the oncology team"
214404103|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
215009681|NCT05123105|OTHER|1) cupping therapy|The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.
215009682|NCT05123105|OTHER|2) control test (no intervention)|The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.
215009683|NCT05123105|OTHER|3) ischemic compression|The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
215009684|NCT01382407|DRUG|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
215009685|NCT04836910|OTHER|Dietary recommendations|"Fruit, vegetables, legumes (e.g. lentils and beans), nuts and whole grains (e.g. unprocessed maize, millet, oats, wheat and brown rice).~At least 400 g (i.e. five portions) of fruit and vegetables per day excluding potatoes, sweet potatoes, cassava and other starchy roots.~Less than 10% of total energy intake from free sugars Less than 30% of total energy intake from fats. Unsaturated fats (found in fish, avocado and nuts, and in sunflower, soybean, canola and olive oils) are preferable to saturated fats.~Less than 5 g of salt (equivalent to about one teaspoon) per day."
215009686|NCT04836910|DRUG|Oral contraceptive pills|Hormonal treatment
215009687|NCT04836910|DRUG|Metformin|Insulin resistance treatment
215097863|NCT02554708|DEVICE|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
215097864|NCT00117793|DEVICE|Total Surface Bearing Suction Socket|Current clinical practice
215097865|NCT00117793|DEVICE|Vacuum assisted socket system|Novel socket system
215097866|NCT00000652|DRUG|Zidovudine|
215097867|NCT00000652|DRUG|Didanosine|
215097868|NCT02365571|DRUG|LY3154207|Administered orally
215097869|NCT02365571|DRUG|Placebo|Administered orally
215097870|NCT02365571|DRUG|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
215097871|NCT06754098|DRUG|Doxecitine and Doxribtimine|A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.
215009688|NCT03382171|OTHER|FoodforCare at home|Five small protein rich meals that will be delivered twice a week for 3 weeks.
215097872|NCT06102772|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
215097873|NCT02488642|DRUG|Isosorbide Dinitrate|
215097874|NCT02488642|DRUG|Misoprostol|
215097875|NCT02488642|DRUG|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
214404104|NCT01631903|DRUG|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
214404105|NCT01631903|DRUG|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
214404106|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
214404107|NCT01631903|DRUG|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
215009689|NCT05556187|OTHER|Individualized automated oxygen titration|Automated oxygen titration based on the oxygen saturation during the entire day.
214404108|NCT06104540|OTHER|Experimental I liquid vaseline groups|Patients in the liquid vaseline group will apply liquid vaseline twice a day for 3 months. Depending on the size of the burn area, 5-10 ml of liquid petroleum jelly will be applied to the burn area by massaging for 5 minutes twice a day, and each application will be recorded in the application follow-up form. Patients will be visited on the 15th day, first month, second month, and third month after the application begins.
214404109|NCT06104540|OTHER|Experimental II extra virgin olive oil groups|Patients in the extra virgin olive oil group will apply extra virgin olive oil twice a day for 3 months. Depending on the size of the burn area, 5-10 ml of liquid petroleum jelly will be applied to the burn area by massaging for 5 minutes twice a day, and each application will be recorded in the application follow-up form. Patients will be visited on the 15th day, first month, second month, and third month after the application begins.
214404110|NCT06104540|OTHER|Control Croup|No intervention will be made other than the recommendations of the institution's physicians and nurses.
214404111|NCT04818879|OTHER|Vojta|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
214404112|NCT04818879|OTHER|Control|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg."
214504639|NCT06876623|DRUG|dabigatran etexilate mesylate capsules 150mg|Oral dabigatran etexilate mesylate capsules，150mg Once every seven days，two cycle T drug, two cycles R drug
214504640|NCT06826703|OTHER|Experimental Group|Individuals will receive diabetes education with motivational interviewing technique based on health belief model.
214504641|NCT06476509|DRUG|LV232 40mg|oral
214504642|NCT06476509|DRUG|Escitalopram 20 mg|oral
214504643|NCT06476509|DRUG|LV232 60mg|oral
215009690|NCT05362175|DEVICE|Obstetric ultrasound|ultrasound measurement of the cross sectional area of umbilical cord within 1 cm from the cord insertion in to fetal abdomen and the standard Hadlock's formula
215009691|NCT04290676|DRUG|DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
215009692|NCT00101738|DRUG|Myfortic|
215009693|NCT01793454|OTHER|Fraction of inspired oxygen 40%|
215009694|NCT01793454|OTHER|Fraction of inspired oxygen 80%|
215009695|NCT04557345|DIAGNOSTIC_TEST|Determination of cytokines|Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
215009696|NCT04557345|DIAGNOSTIC_TEST|Two-dimensional transthoracic echocardiogram|With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
215009697|NCT02405208|DEVICE|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
214504644|NCT06476509|DRUG|LV232 20mg|oral
215009699|NCT06169423|OTHER|Educative intervention|"an activity for simulation-based learning First, a theoretical session was carried out in order to acquire theoretical knowledge, skills to provide support for perinatal grief, and improve self-awareness. Prior to this, a pre-questionnaire was carried out in order to previously evaluate these aspects.~Subsequently, a first session was held to make contact with the simulation, teach the scenarios, material, etc. After this, two questionnaires were passed: one related to the acquisition of knowledge, skills to provide support, self-awareness and another on the students' satisfaction with the simulation."
215009700|NCT06959095|DRUG|Depemokimab|Depemokimab as a sterile liquid formulation will be administered.
215097876|NCT05458453|DRUG|Esketamine|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
215097877|NCT02643589|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
214404113|NCT05979194|BEHAVIORAL|Labor Care Guide|Identifying information and labor characteristics at admission, supportive care, care of the baby, care of the woman, labor progress, medication, and shared decision-making
214404114|NCT00495469|DRUG|GSK189075|GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
214404115|NCT00495469|DRUG|Placebo|Available as Placebo matching tablet to GSK189075
214404116|NCT03405298|BEHAVIORAL|Educational Material|Educational material is in the form of a brochure
214404117|NCT03405298|BEHAVIORAL|Supplemental Collaborative Care|Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider
214404118|NCT06476899|DRUG|orelabrutinib|orelabrutinib tablets
214404119|NCT06476899|DRUG|FCR/BR|FCR/BR
214404120|NCT06476899|DRUG|BTK inhibitor|BTK inhibitor choose by physican
215009701|NCT06959095|DRUG|Placebo|Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered.
215009702|NCT05072041|DEVICE|Nexsphere™|Nexsphere™ is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
215009703|NCT03928704|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
215009704|NCT03928704|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
215009705|NCT05411549|BEHAVIORAL|Diet Modification to Adopt Mediterranean Diet|Participants enrolled in group 1 will be counselled by a dietician and asked to adopt a Mediterranean diet for a 12-week period from counselling. Participants will complete a series of Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora.
215009706|NCT06472765|DIAGNOSTIC_TEST|Vaginal Swab Collection|Vaginal Swab Collection
215009707|NCT03597867|OTHER|Placebo|Artificial tears for 3 days preoperatively
215009708|NCT03597867|DRUG|Dicloftil|Dosing of drug 3 days prior to surgery
215009709|NCT03597867|DRUG|Nevanac|Dosing of drug 3 days prior to surgery
215009710|NCT03597867|DRUG|Indom|Dosing of drug 3 days prior to surgery
215009711|NCT03597867|DRUG|Yellox|Dosing of drug 3 days prior to surgery
214404121|NCT02467374|BEHAVIORAL|Behavior Therapy|"BT for OCD focuses primarily on exposure with response prevention (ERP). ERP involves gradual exposure to anxiety-provoking situations (things or situations that frighten or disturb some people), and will help to prevent compulsions (repetitive behaviors)."
214404122|NCT04302675|BEHAVIORAL|Prevention, Maternal Immunization|"This intervention will be focused on behavior change, both through providers gaining context, knowledge, confidence, and skills in talking to pregnant mothers about vaccination during pregnancy, but also with patients having increased knowledge about immunization issues, and decreased anxiety about getting vaccinated.~There is only one intervention arm in this study, and this study is looking at prevention in a pre-post feasibility study."
214404123|NCT00864058|DRUG|Gabapentin 400 mg capsules|A: Experimental Subjects received Actavis formulated products under fasting conditions
214404124|NCT00864058|DRUG|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
214404125|NCT02062905|DRUG|Dexamethasone|
214404126|NCT02062905|OTHER|Placebo Vehicle|
214404127|NCT02303119|DRUG|Rituximab IV|intra-venous, 375 mg/m²
214404128|NCT02303119|DRUG|Rituximab SC|sub-cutaneous, 1400 mg
214404129|NCT04610203|DIETARY_SUPPLEMENT|25 g Nutralys Pea Protein|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose +25g Nutralys S85 Plus
214404130|NCT04610203|DIETARY_SUPPLEMENT|50 g Nutralys S85 Plus.|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose+50 g Nutralys S85 Plus .
214404131|NCT04610203|DIETARY_SUPPLEMENT|50 g Glucose|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose
214404132|NCT00448864|DRUG|Ecallantide|
214404133|NCT00448864|DRUG|Placebo|
215009712|NCT04822415|DRUG|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
215009713|NCT04822415|DRUG|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
215009714|NCT01309880|DEVICE|Test lens|Investigational silicone hydrogel contact lens worn on a daily wear basis
215009715|NCT01309880|DEVICE|Air Optix Aqua|Air Optix Aqua contact lens worn on a daily wear basis
215009716|NCT03149419|DRUG|Paroxetine|
215009717|NCT03149419|DRUG|Placebo oral capsule|
215009718|NCT04415918|DRUG|Bezlotoxumab Injection|A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
215009719|NCT02871362|DIETARY_SUPPLEMENT|IQP-AS-118|Take one a day
215009720|NCT02871362|DIETARY_SUPPLEMENT|Placebo|Take one a day
215009721|NCT04995003|GENETIC|T cells or CAR T cells|"There are 2 dose levels:~Dose Level 1 (1x10\^8 cells/m2) and Dose Level -1 (5x10\^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur."
215009722|NCT04995003|DRUG|Pembrolizumab Injectable Product|2 mg/kg/dose (max 200 mg/dose) every 3 weeks
215009723|NCT04995003|DRUG|Nivolumab Injectable Product|3 mg/kg/dose (\<40kg) or 124 mg (≥40 kg) every 2 weeks
215097878|NCT04268173|OTHER|Community-Based, Client-Centered Prevention Home|Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
215097879|NCT03855852|PROCEDURE|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
215097880|NCT03855852|PROCEDURE|Xenograft and APRF|Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
215097881|NCT00442325|DRUG|Atorvastatin (Lipitor)|
215009724|NCT05129709|BEHAVIORAL|"My Health Priorities Identification Program"|"The web-based My Health Priorities Identification Program may improve values solicitation and operationalization skills in primary care, but has not been optimized for AAs with MCCs and their FCGs. The Program is a facilitator-led evidence- and values-based care communication model for patients, clinicians, and caregivers that has reduced patient-reported treatment burden by aligning value-based priorities with treatment. The web-based program assists patients in identifying their health priorities as they complete t four online modules that help them to identify specific and actionable health goals and preferences. The final result can be printed and brought to the clinic or uploaded to the Electronic Medical Record to inform subsequent healthcare decision making. Unrecognized cultural preferences of AAs, including the important role of R/S beliefs and family-centered values, can interfere with adequate healthcare communication resulting in healthcare disparities and inequities."
214404134|NCT03578562|OTHER|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
215009725|NCT00095771|DRUG|arsenic trioxide|
215009726|NCT00095771|RADIATION|radiation therapy|
215009727|NCT03170440|DEVICE|Transcutaneous nerve stimulation location 1|Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location
215097882|NCT03404856|DRUG|ORL-1G - D-galactose|Oral ORL-1G - D-galactose
214404135|NCT04189328|PROCEDURE|dental implant placement using magnifying loupes and microsurgical instruments|microsurgical dental implant placement employin splt finger technique by Misch
215009728|NCT06252935|DEVICE|FormaAid|FormaAid is mainly composed of pure collagen extracted from bovine tendon, it is fabricated in the form of highly dense collagen matrix without chemical cross-linking to act as a barrier excluding epithelium.
215009729|NCT06252935|DEVICE|Bio-Gide|Bio-Gide is a bilayer collagen membrane made of porcine collagen, permits prompt and homogeneous vascularization and so brings about optimal tissue integration and wound stabilization.
215009730|NCT05413460|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
215009731|NCT02015715|DRUG|RO6864018|A single oral ascending dose of RO6864018 capsules on Day 1.
215009732|NCT02015715|DRUG|Placebo|A single oral dose of placebo matching RO6864018 capsules on Day 1.
215009733|NCT05557682|OTHER|composite restorative treatment|Restorative treatment using dental materials
215009734|NCT04575324|BEHAVIORAL|Telemedicine Linkage Intervention|Participants will be immediately linked to telemedicine care provided by an FQHC provider waivered to prescribe buprenorphine and naltrexone or able to refer patients to methadone treatment. Participants will have their vitals checked and be virtually connected to the provider. The research assistant will share the vitals with the provider, and the provider will provide personalized care during which they discuss treatment options with the participant. If a medication for opioid use disorder is prescribed or if a methadone referral is made, transportation assistance will be provided to the participant as part of the intervention. Transportation to pick up the prescription or complete the first appointment will be provided via a HIPAA compliant ride-share company, and a bus pass will be provided to the participant for the return trip.
215009735|NCT00906581|BEHAVIORAL|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
215009736|NCT03083379|DEVICE|Volumetric Incentive Spirometry|"A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.~* Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.~* Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.~* Incentive Spirometry therapy and monitoring session will last about 15 minutes"
215009737|NCT03083379|DEVICE|EzPAP® POSITIVE AIRWAY PRESSURE|"* A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.~* Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.~* EzPAP® therapy and monitoring sessions will last about 15 minutes"
215009738|NCT06389162|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is a type of non-invasive brain stimulation that involves passing a weak current between two electrodes placed on the scalp.
215097883|NCT00663845|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
215097884|NCT00663845|DRUG|Placebo|Matching placebo
215097885|NCT03158350|OTHER|Instructed Brushing Method|Stationary Bristle Technique
214404136|NCT04189328|PROCEDURE|macrosurgical dental implant placement|macrosurgical placement of single dental implants
214404137|NCT00410995|DRUG|Naproxen|
214404138|NCT01757080|OTHER|Cardiorespiratory performance assessment with ergospirometry test|
214404139|NCT01757080|OTHER|Biochemical analysis|
214404140|NCT04679584|OTHER|Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care
215097886|NCT02128945|OTHER|[18F] - Fludarabine PET/CT|\[18F\] - Fludarabine PET/CT before treatment
215097887|NCT00975143|DRUG|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
214404141|NCT00230451|PROCEDURE|Radiation|
214404142|NCT00230451|DRUG|Paclitaxel|
214404143|NCT00230451|DRUG|Cisplatin|
214404144|NCT00230451|DRUG|5-Fluorouracil|
215097888|NCT00975143|DRUG|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
215097889|NCT01375608|DRUG|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
215009739|NCT01756001|DEVICE|GlowCap|The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
214404145|NCT03312803|PROCEDURE|Mini autogenous skin graft|mini-autogenous skin grafts and skin homograft versus autogenous skin grafts for covering post burn wounds in children.
214404146|NCT00892229|DRUG|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
214404147|NCT00892229|DRUG|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
215097890|NCT05340166|PROCEDURE|Genicular nerve radiofrequency neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
215097891|NCT05340166|PROCEDURE|Genicular nerve chemical neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
215097892|NCT03218579|DIETARY_SUPPLEMENT|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
215009740|NCT01756001|BEHAVIORAL|Daily email, text message, or phone call reminders|
215097893|NCT03218579|BIOLOGICAL|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
214404148|NCT05900999|BEHAVIORAL|Feasibility of idle time exercise|The experiments in this proposal will assess the utility and subjective patient experience performing idle time exercise intervention designed to reduce learned non-use of the hemiparetic arm in the days, and weeks immediately following stroke. Exercise will be cued by wearable technology that provides vibrotactile cues similar to those provided by FitBit devices. Participants will be asked to perform simple exercises after receiving a vibration cue. In the first four sessions they will tap the more-involved wrist; in the second four sessions they will passively move the more-involved elbow through a range of motion; in the final four sessions they will actively move the more-involved elbow through a range of motion. Accelerometers in the wearable devices will monitor motion of the wrist during the exercise sessions. We will interview the participants two months later regarding how well they use the more-involved arm to perform daily activities.
214504645|NCT06825091|RADIATION|SBRT|Standard of care SBRT (36.25 Gy in 5 fractions or 42.7 Gy in 7 fractions) for localized prostate cancer, delivered either via an adaptive or a non-adaptive image-guided treatment. Androgen deprivation therapy use and duration is at the discretion of the treating physician and patient, in accordance with standard practice based on patients' prostate cancer risk group.
214504646|NCT07075705|PROCEDURE|Biopsy of Prostate|Undergo standard of care prostate biopsy
214504647|NCT07075705|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215009741|NCT01756001|BEHAVIORAL|Paid for adherence|
215097894|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
215097895|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 2.4g extended release tablet|SPD476 2.4g administered Once Daily (QD)
215097896|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 4.8g extended release tablet|SPD476 4.8g administered Once Daily (QD)
215097897|NCT00545103|DRUG|Placebo|Placebo administered Once Daily (QD)
215097898|NCT00715858|DRUG|doxycycline|capsule, 100 mg, b.i.d., 12 months
215097899|NCT00715858|DRUG|rifampin|capsule, 300 mg, od, 12 months
215097900|NCT00715858|DRUG|placebo|placebo matched to rifampin; placebo matched to doxycycline
215097901|NCT04235712|OTHER|Harmonized Depression Outcome Measures|This is an observational study where outcome measures will be extracted from patients' medical records and from questionnaires to provide information back to the clinician.
215097902|NCT03959202|BEHAVIORAL|ELDERFITNESS|In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks \& 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps \& minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
215097903|NCT03959202|OTHER|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
215097904|NCT01953913|DRUG|Afatinib|Patient will receive afatinib once daily
214404149|NCT00041262|DRUG|cisplatin|
214404150|NCT00041262|DRUG|epirubicin hydrochloride|
214404151|NCT00041262|DRUG|fluorouracil|
214404152|NCT00041262|PROCEDURE|conventional surgery|
214504648|NCT07075705|PROCEDURE|Micro-ultrasound Imaging|Undergo transperineal micro-ultrasound imaging
214504649|NCT07075705|PROCEDURE|Micro-ultrasound Imaging|Undergo transrectal micro-ultrasound imaging
215009742|NCT05548504|RADIATION|Photon|50-66Gy/ 24 fractions, inhomogeneous dose distribution photon therapy
215009743|NCT05548504|RADIATION|Proton|50-66Gy/ 24 fractions, inhomogeneous dose distribution proton therapy
214404153|NCT00041262|PROCEDURE|neoadjuvant therapy|
214404154|NCT04668183|PROCEDURE|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
214404155|NCT04668183|PROCEDURE|Dorsal penile nerve block group|Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
214404156|NCT05009446|PROCEDURE|endoscopic surgery|endoscopic surgery or endoscope-assisted surgery open surgery
214404157|NCT05009446|RADIATION|intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy|radiotherapy was administrated before surgery
214404158|NCT05009446|DRUG|Chemotherapy drug|Chemotherapy was administrated before surgery. Chemotherapy may also be administrated after surgery in selected cases.
214404159|NCT03881657|BEHAVIORAL|Reverse Colocated Integrated Care|A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.
214404160|NCT03881657|BEHAVIORAL|Usual Care|Behavioral health services without primary care or integrated care services
214404161|NCT01885364|DRUG|Normal saline|intravenous injection with normal saline before injection of propofol
214404162|NCT01885364|DRUG|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
214404163|NCT01885364|DRUG|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
214404164|NCT01885364|DRUG|propofol|intravenous injection after pretreatment
214404165|NCT02107001|PROCEDURE|Lung ultrasound|Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
214404166|NCT01323660|DRUG|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
214404167|NCT01323660|DRUG|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
214404168|NCT01323660|DRUG|GSK573719 125|125mcg QID
214404169|NCT01323660|DRUG|GSK573719 62.5|62.5mcg QID
214404170|NCT01323660|DRUG|GW642444 25|25mcg QID
214404171|NCT01323660|DEVICE|placebo|Comparator QID
214404172|NCT02455687|DRUG|Hi-dose iv MgSO4|
214404173|NCT02455687|DRUG|Nebulized budesonide|
214404174|NCT02455687|DRUG|Std-dose iv MgSO4|
214404175|NCT02455687|DRUG|Nebulized normal saline|
214404176|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
214504650|NCT05511207|DEVICE|RECOM - hBCI training|The RECOM device is a h-BCI system that controls FES of upper limb muscles: the patient is asked to attempt simple upper limb movements (eg extension of fingers); the device recognizes (in correct trials) close-to-normal EEG-EMG activation and initiates FES of extensor muscles in the forearm. RECOM training consists in a set of trial repetition for a total duration per session of approximately 20-30 minutes (excluding set up time and calibration). FES parameters will be set specifically for each patients according to standard guidelines to achieve full movement and so as to avoid any kind of discomfort for the patients. The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
214404177|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
214404178|NCT05287932|BEHAVIORAL|Brief physical activity intervention|See arm/group descriptions
215009744|NCT02847767|PROCEDURE|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution
215009745|NCT02465047|OTHER|Self-help booklet|See Arm/Group Description
215009746|NCT01533220|DRUG|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 03 days
215009747|NCT01533220|DRUG|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 03 days
215009748|NCT02264041|DRUG|Cilobradine, low dose|
215009749|NCT02264041|DRUG|Cilobradine, high dose|
215009750|NCT02264041|DRUG|Itraconazole|
215009751|NCT05904366|DIAGNOSTIC_TEST|MR Spectroscopy (MRS)|MR Spectroscopy (MRS)
215009752|NCT05904366|DIAGNOSTIC_TEST|MR Elastography (MRE)|MR Elastography (MRE) with a device that induces shear waves in the body. This device is placed upon the abdomen of the subject and is hold in place by straps. The device will produce low-frequency vibrations (e.g. 30-60 Hz) which are not painful to the participant. A declaration of conformity and a safety document are provided in the study dossier.
215009753|NCT01838811|BEHAVIORAL|Speed of Process Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself. These training tasks are tailored to each individual's ability by the trainer.
215009754|NCT01002105|DRUG|Baclofen|Baclofen 50mg per day for 12 weeks and psychosocial intervention
215009755|NCT01002105|OTHER|Control group|psychosocial intervention and placebo for 12 weeks
215009756|NCT04894240|DRUG|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
214404179|NCT05379127|OTHER|Patient-empowered follow up|"The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used."
214404180|NCT05379127|OTHER|Standard follow-up|Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
214404181|NCT02891369|OTHER|No intervention. Descriptive study|
214404182|NCT04531540|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.
215097905|NCT01862653|DEVICE|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
215097906|NCT00427882|DRUG|ALFUZOSIN|
214404183|NCT02512146|PROCEDURE|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
215009757|NCT02826499|DEVICE|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
215009758|NCT02826499|OTHER|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
215009759|NCT02035293|OTHER|PEP|
215009760|NCT05431790|DEVICE|Absorbable interface screws manufactured by Natong Biotechnology|Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by Natong Biotechnology.
215009761|NCT05431790|DEVICE|Absorbable interface screws manufactured by INION.|Reconstruction of anterior cruciate ligament using Inion Oy absorbable interface scews from INION, Finland
215009762|NCT04786925|OTHER|Control diet|Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
215097907|NCT02418104|DRUG|CHS-1701|
214404184|NCT00002556|DRUG|vincristine sulfate|Given IV
214404185|NCT00002556|DRUG|carmustine|Given IV
214404186|NCT00002556|DRUG|melphalan|Given PO
214404187|NCT00002556|DRUG|cyclophosphamide|Given IV
214404188|NCT00002556|DRUG|prednisone|Given PO
214404189|NCT00002556|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
214404190|NCT00002556|OTHER|laboratory biomarker analysis|Correlative studies
214404191|NCT06504875|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
214404192|NCT06504875|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
215097908|NCT02418104|DRUG|Pegfilgrastim (Neulasta)|
214404193|NCT06504875|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
215097909|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 1"
215097910|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 2"
215097911|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 3"
215097912|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 4"
215097913|NCT00697281|DRUG|Placebo|"Tablets twice daily for 8 days~Dose level 5"
215097914|NCT00861718|DRUG|AZD7268|Capsule, Oral, QD
215097915|NCT00861718|DRUG|AZD7268|Capsule, Oral, BID
215097916|NCT00861718|DRUG|Placebo|Capsule, Oral BID
215097917|NCT00436592|DEVICE|NeuroFlo™ Catheter|45 minute Treatment
214404194|NCT06504875|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
214404195|NCT00270114|DRUG|epoetin alfa|
214404196|NCT01530074|PROCEDURE|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
214404197|NCT00223054|DRUG|tacrolimus|retrospective analyze of drug levels in comparison to polymorphism
214404198|NCT00223054|DRUG|sirolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
215009763|NCT04786925|OTHER|Nutriprecision diet|Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
215009764|NCT00281801|PROCEDURE|psychosocial assessment and care|psychosocial assessment and care
215097918|NCT04181177|OTHER|Cosmetic product|"Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses)."
214404199|NCT00223054|DRUG|everolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
214404200|NCT00223054|DRUG|cyclosporin A|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
214404201|NCT05634213|DRUG|normal saline|Once the patient is placed on cardiopulmonary bypass, the product will be injected into the left atrial wall using a 27 gauge needle as 4 injections of 200 μL each. Two will be placed in the atrial appendage. The remaining 2 injections will be placed equidistant on the anterior atrial free wall. Each injection will be performed just under the surface of the atrial epicardium over 30 seconds. The needle will stay in place for 10 seconds after the injection to limit back flow from the site of injection.
214404202|NCT05154916|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
215009765|NCT00281801|PROCEDURE|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
215009766|NCT03974009|OTHER|Calcaneal taping|Calcaneal taping will be given in long sitting position foot out of the edge.BSN Medical Leukotape P Sports Tape (3.8cm×137m,1.5inch× 15yds) on focusing the calcaneus with the aim of choosing dorsiflexion with eversion. First strap of tape will be applied below the medial malleolus,stretch towards lateral malleolus on affected side. Second strap of tape will be applied repetitively placing the first strap,another will be applied to fix the small tapes.
215009767|NCT03974009|OTHER|Sham taping|Sham taping will be given to the control group patients.Simple clinical tape will be applied on calcaneus without stretch.It will be applied for 3 days/week for 4 weeks.
215009768|NCT03974009|OTHER|Conventional therapy|Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward \& backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.
215009769|NCT03403517|DRUG|Methylprednisolone|10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery
215009770|NCT03403517|DRUG|Dexamethasone|Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
214404203|NCT00476203|BEHAVIORAL|Yoga|Instructor-led yoga classes 1/time per week + 4 days of home practice
214404204|NCT00476203|OTHER|Delayed yoga classes|Delayed yoga classes (after 6 months) offered \[wait list control group\]
214404205|NCT00108524|BEHAVIORAL|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
215009771|NCT02665936|DRUG|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
215009772|NCT02665936|DRUG|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
215009773|NCT02665936|DRUG|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
215009774|NCT05027282|DEVICE|CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.|CLEAR + BRILLIANT TOUCH(R) diode laser 1440-nm and 1927-nm Combination Wavelength Treatment.
215009775|NCT00932854|PROCEDURE|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
215009776|NCT00167570|DEVICE|Prosthetic socket fabricated using selective laser sintering|
214404206|NCT00108524|DRUG|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
214404207|NCT00108524|BEHAVIORAL|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
214404208|NCT01575860|DRUG|Lenalidomide|Lenalidomide, 10mg, oral tablets, daily
215009777|NCT02981251|BEHAVIORAL|Health education with support by trained female health volunteer|Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
215009778|NCT00456612|PROCEDURE|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
215009779|NCT00266812|DRUG|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
215009780|NCT00266812|PROCEDURE|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
214404209|NCT04166968|DEVICE|Anodal transcranial direct current stimulation (A-tDCS)|Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA
214404210|NCT04166968|DEVICE|Cathodal transcranial direct current stimulation (C-tDCS)|Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA
214404211|NCT04166968|DEVICE|Sham stimulation (sham-tDCS)|placebo stimulation
214404212|NCT04166968|BEHAVIORAL|Neuromotor training|conventional neuromotor treatment
214404213|NCT04648306|DEVICE|Prophylactic Impella support for a non-emergent PCI|Impella percutaneous mechanical circulatory support is placed via the femoral or axillary artery prior to a non-emergent PCI in patients at high risk for periprocedural complications including hemodynamic collapse.
214404214|NCT00020189|DRUG|acetylsalicylic acid|
215009781|NCT03695094|DRUG|Padsevonil|Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed
215009782|NCT03695094|DRUG|Oxcarbazepine|Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
215009783|NCT03695094|DRUG|Levetiracetam|Concomitant administration of levetiracetam (LEV) at therapeutic dosage
215009784|NCT03695094|DRUG|Lamotrigine|Concomitant administration of lamotrigine (LTG) at therapeutic dosage
215009785|NCT03695094|DRUG|Brivaracetam|Concomitant administration of brivaracetam (BRV) at therapeutic dosage
215009786|NCT02470572|OTHER|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
215009787|NCT02470572|OTHER|Conventional light microscope|Conventional light microscope
215009788|NCT04139525|BIOLOGICAL|unfractionated heparin|A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.
215009789|NCT04139525|BIOLOGICAL|8% trisodium citrate|8% trisodium citrate in the dose of 150 ml/h.
215009790|NCT03986541|DIAGNOSTIC_TEST|Immunohistochemistry|Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
215009791|NCT04038398|PROCEDURE|Non-invasive ventilation with different FiO2 settings|CPAP therapy applied with different order of FiO2 settings.
215009792|NCT00205608|DEVICE|Positron Emission Tomography|camera is new
215009793|NCT05000437|OTHER|HIIT|3x/week high intensity interval training for 12 weeks
215009794|NCT01834261|DRUG|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
215009795|NCT01834261|DRUG|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
214404215|NCT00020189|DRUG|alvocidib|
214404216|NCT00020189|DRUG|clopidogrel bisulfate|
215009796|NCT02316613|DRUG|Rituximab|
215009797|NCT04568772|DRUG|Atovaquone / Proguanil 250/100 mg|Atovaquone / Proguanil 250/100 mg tablet
215009798|NCT04568772|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
215009799|NCT04568772|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg tablet
215009800|NCT04568772|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg tablet
215009801|NCT01166945|DRUG|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
215009802|NCT01166945|DRUG|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
215009803|NCT05838872|DEVICE|Minuteful - Kidney Urine Analysis Test System|Urine samples were collected and tested by a lay user, using the Minuteful - Kidney test device. The lay user test results were compared to the results obtained by testing the same urine sample on the comparison device, the URiSCAN Optima.
215009804|NCT02410876|PROCEDURE|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
214404217|NCT05181306|PROCEDURE|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
214404218|NCT05181306|PROCEDURE|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
214404219|NCT03700606|PROCEDURE|High flow nasal cannula|8 liters per minute of blended oxygen through Fisher Paykel Optiflow Jr 2 nasal prongs.
214404220|NCT03700606|PROCEDURE|Nasal CPAP|Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.
214404221|NCT01553162|GENETIC|DNA analysis|
214404222|NCT01553162|GENETIC|RNA analysis|
214404223|NCT01553162|GENETIC|gene expression analysis|
214404224|NCT01553162|OTHER|laboratory biomarker analysis|
214404225|NCT02099032|OTHER|3g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 3g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
214404226|NCT02099032|OTHER|5g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 5 g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
214404227|NCT02099032|OTHER|Unfortified cheese product consumption|Women will have to consume daily 100g of a unfortified cheese product instead of usual cheese products during four weeks
214404228|NCT00914017|DRUG|Atorvastatin|Atorvastatin, 40 mg daily for 1 year
214404229|NCT00914017|DRUG|Placebo|sugar pill daily for 1 year
214404230|NCT02095600|RADIATION|Radiosurgical thalamotomy|
214404231|NCT02797483|OTHER|Test Fat Blue|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
214404232|NCT02797483|OTHER|Test Fat Green|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
215009805|NCT02410876|PROCEDURE|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
215097919|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Unified protocol|"Treatment condition:~The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week."
215009806|NCT01135056|DEVICE|SIR-Spheres|One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
215009807|NCT01135056|DRUG|Sorafenib tosylate|Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
215009808|NCT01192360|PROCEDURE|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
215009809|NCT01192360|PROCEDURE|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
215009810|NCT04398914|DRUG|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
215009811|NCT04398914|DRUG|Trastuzumab|"Trastuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.~Adjuvant treatment: 8 mg/kg loading dose, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab"
215009812|NCT04398914|DRUG|Pertuzumab|"Pertuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.~Adjuvant treatment: 840 mg loading dose, followed by 420mg for remaining cycles till completion of 1 year pertuzumab"
215009813|NCT04398914|DRUG|Nab-paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
214404233|NCT02797483|OTHER|Test Fat Red|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
215009814|NCT04398914|DRUG|EC chemotherapy|Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)
215009815|NCT04398914|DRUG|Physician's choice|Physician decided chemotherapy for 0-4 cycles.
215097920|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Affect phobia treatment|The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
215009816|NCT04398914|DRUG|T-DM1|T-DM1 IV infusion in 3-week cycles. 3.6 mg/kg by intravenous (IV) infusion every 3 weeks for 14 cycles
215009817|NCT04398914|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
215009818|NCT05509374|DRUG|Carfilzomib 56 MG [Kyprolis]|Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)
215097921|NCT05016843|OTHER|Treatment condition: Waitlist control|The waitlist condition is a control condition without any intervention.
215097922|NCT05016843|OTHER|Treatment length: 8 weeks|Participants will partake in their treatment condition for 8 weeks.
215097923|NCT05016843|OTHER|Treatment length: 16 weeks|Participants will partake in their treatment condition for 16 weeks.
215009819|NCT05509374|DRUG|Pomalidomide|Pomalidomide 4 mg per os (Day1-21)
215097924|NCT05016843|OTHER|Access to a moderated forum|During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
215097925|NCT05016843|OTHER|No access to a moderated forum|Participants will not have access to a moderated forum, hence their treatment is self-guided.
215097926|NCT00616694|DRUG|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
215097927|NCT04627935|BEHAVIORAL|The COPD Assessment Test|Used to assess symptoms in COPD patients.
215097928|NCT04627935|DIAGNOSTIC_TEST|Navicular Drop Test|It is the test used to measure the amount of pronation in the foot.
215097929|NCT04627935|BEHAVIORAL|International Physical Activity Questionnaires (IPAQ)|The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.
215097930|NCT04627935|BEHAVIORAL|COPD and Asthma Fatigue Scale (CAFS)|CAFS is a comprehensive, brief, patient-centered questionnaire developed to capture fatigue experienced by patients with asthma or COPD.
215097931|NCT04627935|BEHAVIORAL|Saint George Respiratory Questionnaire|Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
215097932|NCT01571856|DRUG|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
215097933|NCT01571856|OTHER|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
215097934|NCT00082381|DRUG|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
214404234|NCT06272955|DEVICE|Spinal Cord Stimulator (SCS)|"Patients are already implanted with device from the H-49023 study.~The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
215009820|NCT05509374|DRUG|Dexamethasone|Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
215009821|NCT02444377|BEHAVIORAL|Interval training|
215009822|NCT05915169|OTHER|Topical haemoglobin wound care spray|It is a wound care spray used in the care of chronic wounds.
215009823|NCT00000987|DRUG|Bleomycin sulfate|
215009824|NCT00000987|DRUG|Vincristine sulfate|
215009825|NCT00000987|DRUG|Doxorubicin hydrochloride|
215009826|NCT00000987|DRUG|Zidovudine|
215009827|NCT03202550|DRUG|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
215009828|NCT03202550|DRUG|Placebo Comparator|Placebo oral pills
215009829|NCT05343507|DRUG|Ketalar 50 MG/ML Injectable Solution|Intravenous solution (other info already provided)
215009830|NCT05343507|DRUG|Placebo|Saline Solution
215009831|NCT03309605|DRUG|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
215009832|NCT03309605|DRUG|Placebo|Placebo
214404235|NCT04922099|DEVICE|glycemic gap|"Measurements of HbA1c-based adjusted glycemic gap:~The estimated chronic average glucose levels (eAG) over the past 3 months will calculate from the equation AG = 28.7 × HbA1c - 46.7 Glycemic gap was calculated as the ADAG level subtracted from the admission glucose level."
214404236|NCT03606460|DRUG|Ocrelizumab Dose 1|300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.
214404237|NCT03606460|DRUG|Ocrelizumab Dose 2 and Dose 3|600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48
214404238|NCT00309816|DRUG|sildenafil|
214404239|NCT04170023|DRUG|ALXN2050|Oral FD inhibitor
214404240|NCT06401928|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of either 1.5 mA electrical stimulation for 20 minutes each day over 10 consecutive days.
214404241|NCT06401928|DEVICE|transcranial direct current stimulation combined with cognitive training|Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on 10 consecutive days. Each session is followed by 30 minutes cognitive training in which patients conduct several computerized cognitive tests.
214404242|NCT06401928|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of sham (placebo) electrical stimulation for 20 minutes each day over 10 consecutive days.
214404243|NCT02613780|PROCEDURE|Crosslinking|corneal collagen crosslinking with riboflavin
214404244|NCT02613780|PROCEDURE|Photorefractive keratectomy|
214404245|NCT02613780|DEVICE|iDesign® Advanced WaveScan Studio|Used to map wavefront aberration in planning photorefractive keratectomy
215009833|NCT06310109|OTHER|PICU diary|.The PICU diary is a notebook with lined sheets located at the patient's bedside. In this diary parents, other caregivers, family members, healthcare professionals or other visitors can write thoughts, report events related to the child/adolescent's admission, attach drawings or photographs for the patient or related to the PICU admission.
215009834|NCT00784927|BIOLOGICAL|rituximab|
215009835|NCT00784927|DRUG|cyclophosphamide|
215097935|NCT00082381|DRUG|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
214504651|NCT05511207|OTHER|CTRL - upper limb training with FES|An expert physiotherapist will define a set of active exercises focused on upper limb function; the exercises will be combined with FES of forearm muscles. FES parameters will be set specifically for each patients according to standard guidelines to achieve the full required movement and so as to avoid any kind of discomfort for the patients. Session duration will be approximately 20-30 minutes (excluding FES calibration time). The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
214504652|NCT03505905|DRUG|Pregnenolone|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
215009836|NCT00784927|DRUG|dexamethasone|
215009837|NCT00784927|DRUG|lenalidomide|
215097936|NCT02049138|DRUG|Upadacitinib|Tablet taken orally
215097937|NCT02049138|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine (PCV-13)|Administered by intramuscular injection
215097938|NCT03465930|PROCEDURE|Supermicrosurgical lymphatico-venous anastomoses|Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
215097939|NCT00189904|BIOLOGICAL|IMVAMUNE (MVA-BN)|
215097940|NCT05592132|OTHER|Virtual reality headset|Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.
215097941|NCT00154128|DEVICE|occlusal appliance|
215097942|NCT02359227|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
215097943|NCT04635813|PROCEDURE|Thyroidectomy|Thyroidectomy
214404246|NCT03818308|DRUG|Sofosbuvir and Velpatasvir|All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.
214404247|NCT01307852|DEVICE|Plastic Scintillation Detectors|Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
214404248|NCT03963479|COMBINATION_PRODUCT|Magnesium and Vitamin B6|Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months
214504653|NCT03505905|DRUG|Placebo|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
214504654|NCT03999138|DIAGNOSTIC_TEST|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (\~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of \< 3 minutes.
215009838|NCT01779362|DRUG|Metformin|Titrated to 1000 mg BID
215009839|NCT01779362|DRUG|Liraglutide|Titrated to 1.8 mg/day
215009840|NCT01779362|DRUG|Glargine|Titrated to target fasting glucose \<90 mg/dl
215009841|NCT01779362|DRUG|Placebo|Matching to metformin 1000 mg BI
215009842|NCT05649371|OTHER|Prehabilitation|A multiphasic exercise prehabilitation program for alloHSCT candidates across each treatment phase, that includes behaviour change support
215009843|NCT01922661|DRUG|REGN1908-1909|
215009844|NCT01922661|OTHER|placebo|
215009845|NCT00714272|DEVICE|Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1|6 treatments. One per week during the first six consecutive weeks.
215097944|NCT05985096|DIAGNOSTIC_TEST|Virtual reality group|Participants in this group will be expected to meet their physical activity levels using the Oculus Quest 2 VR Goggles platform with Racket, Climb, Acron, Skiing, Cycling games.
215097945|NCT02653716|BEHAVIORAL|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
215097946|NCT02653716|BEHAVIORAL|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
214404249|NCT03951376|BEHAVIORAL|UPRIGHT intervention|The UPRIGHT intervention design consists of two different phases consecutively implemented in two school years: intensive phase and follow-up phase. During the intensive phase, all stakeholders are trained in the UPRIGHT WELL-BEING FOR US programme (18 skills). The follow-up phase (WELL-BEING FOR ALL) intends not only to maintain the effect of the intensive training in youths, but also to boost the positive mental health atmosphere created in the whole school. To do so, different collective activities will be organized at school level such as celebration of thematic days, activities with the community, and outdoor/indoor activities.
214404250|NCT02050789|BEHAVIORAL|flexible duty hours|If a hospital is assigned to the intervention arm, all categorical and preliminary general surgery residents in that general surgery program will switch to the flexible duty hours while at an enrolled hospital.
215009846|NCT00714272|DEVICE|Treatment with a sham device, EXcorLab box 1.2|6 sham treatments. One treatment per week during the first six consecutive weeks.
215009847|NCT05332795|DRUG|Metformin|gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.
215009848|NCT05332795|DRUG|Placebo|gouty patients, will receive placebo tablets once daily for about 3 months.
215009849|NCT02590510|DRUG|methotrexate|The quantity of methotrexate is different in the two groups.
215009850|NCT04568512|DIAGNOSTIC_TEST|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
215009851|NCT04568512|DIAGNOSTIC_TEST|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
215009852|NCT01795937|DRUG|Itraconazole|twice daily
215009853|NCT01795937|DRUG|Atorvastatin|single dose
215009854|NCT01795937|DRUG|Faldaprevir|once daily
215009855|NCT01795937|DRUG|Rosuvastatin|single dose
215009856|NCT01795937|DRUG|Faldaprevir|once daily
214404251|NCT02398838|DRUG|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone.
215097947|NCT03679455|DRUG|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
215009857|NCT04122495|DIETARY_SUPPLEMENT|Probiotic|Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks
215009858|NCT04122495|DIETARY_SUPPLEMENT|Placebo|Oral administration of maltodextrin daily for 4-weeks
215009859|NCT01459159|DRUG|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
215097948|NCT00884832|DRUG|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
215097949|NCT00884832|DRUG|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
215097950|NCT02365415|DRUG|Sirolimus|8 weeks oral sirolimus, following drug levels
215097951|NCT03327064|DRUG|UAB30|9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
215097952|NCT03327064|DRUG|Placebo|This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
215009860|NCT00635180|BEHAVIORAL|isometric exercise|
215009861|NCT00673829|BIOLOGICAL|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
215009862|NCT00673829|BIOLOGICAL|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
214404252|NCT02398838|DRUG|Home or clinic administration of 400 mcg buccal misoprostol|Home or clinic administration of 400 mcg buccal misoprostol
214404253|NCT01153854|DRUG|Racecadotril|oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
214404254|NCT01153854|DRUG|Placebo groups|Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
214404255|NCT01132911|DRUG|Vorinostat (SAHA)|
214404256|NCT01132911|DRUG|Velcade (PS-341, Bortezomib)|
214504655|NCT06037850|DEVICE|Test orthokeratology lens|Randomized to test orthokeratology lens worn during sleep every night
214504656|NCT06037850|DEVICE|Control orthokeratology lens|Randomized to control orthokeratology lens worn during sleep every night
214504657|NCT02831049|BEHAVIORAL|Retrieval-extinction|Memory retrieval-extinction is a novel behavioral procedure for reduction of craving and drinking in problem drinkers.
214504658|NCT02831049|BEHAVIORAL|Alcohol-related cues|Alcohol related cues
215009863|NCT04261595|OTHER|Dates fruit as functional Food|Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment
215009864|NCT04261595|BEHAVIORAL|behavioral modification and stimulation|Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)
215009865|NCT04261595|OTHER|nutritional Guidance|The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
215009866|NCT05634928|OTHER|collection data|collection data
215009867|NCT01028053|DRUG|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
214404257|NCT00972712|DRUG|Bortezomib and Tipifarnib|"Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)"
214688287|NCT07162116|OTHER|XY0206 Placebo|12.5mg/table,On the morning of the day of dosing, subjects received XY0206 placebo orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg)；Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg)；Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)
215009868|NCT04097912|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|75-100mg
215009869|NCT04027946|DRUG|LMB-100|Participants will receive LMB-100 on days 1, 3 and 5 of a 21-day cycle for up to 2 cycles.
215009870|NCT04027946|DRUG|pembrolizumab|Participants will receive pembrolizumab on day 1 of each subsequent 21-day cycle.
215009871|NCT04027946|DIAGNOSTIC_TEST|Mesothelin Expression|Testing for mesothelin expression performed at screening
215009872|NCT04027946|DIAGNOSTIC_TEST|TrueSight Oncology 500|Testing for ROS oncogene 1 (ROS1) gene, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) variations performed at screening.
215009873|NCT03383939|DRUG|Group A|one nebulization with 250mg alpha-1-antitrypsine diluted in 10ml injectable solution once a day during 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
214404258|NCT01468415|DRUG|phenol|1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
214404259|NCT02584790|DEVICE|Laryngoscope with NBI system|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
214404260|NCT02721758|BEHAVIORAL|Brief Motivational Intervention|
214404261|NCT05225454|OTHER||
214404262|NCT04402671|OTHER|non-cross-linked porcine skin collagen membrane|non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.
214404263|NCT04402671|OTHER|glutaraldehyde cross-linked bovine collagen membrane|glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.
214404264|NCT05144815|OTHER|IPC + Exercise protocol|"The intervention consists of two parts: IPC and endurance training protocol.~IPC: participants will be placed in a supine position and a pneumatic compression cuff (Riester Komprimeter, Jungingen Germany) (96 centimetres long x 13 centimetres wide) will be placed on the proximal part of each lower extremity. Occlusion will then be performed by inflating the cuff to 220 mmHg for 5 minutes, followed by reperfusion to 0 mmHg for 5 minutes. Each session will consist of 3 sets of 5 minutes of ischaemia followed by 5 minutes of reperfusion.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks."
214404265|NCT05144815|OTHER|Sham IPC + Exercise protocol|"The intervention consists of two parts: sham IPC and endurance training protocol.~Sham IPC: the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks."
214404266|NCT03770377|DEVICE|Intermittent Perturbation to Continuous Perturbation|Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.
214404267|NCT03770377|DEVICE|Continuous Perturbation to Intermittent Perturbation|Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.
214688288|NCT07163676|BEHAVIORAL|Baduanjin exercise|group I will receive baduanjin exercise for 60 minutes every day ((except fridays) for eight weeks.
215009874|NCT03383939|DRUG|Group B|10ml of 0.9% NaCl saline solution nebulised once daily for 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
215009875|NCT00983957|DRUG|BMS-790052|Tablets, Oral, 60 mg, once daily, 10 days
215009876|NCT00983957|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, once daily, 78 days
215009877|NCT00790933|DRUG|Vedolizumab|Vedolizumab intravenous infusion
215009878|NCT00349076|DRUG|5-FU and oxaliplatin|"Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
215009879|NCT00349076|DRUG|5-FU|"Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
215009880|NCT01155609|PROCEDURE|quality-of-life assessment|Ancillary studies
215009881|NCT01155609|PROCEDURE|management of therapy complications|Discontinue supplement; treat symptomatically
215009882|NCT01155609|DIETARY_SUPPLEMENT|L-lysine|Given PO
215009883|NCT04280861|OTHER|Multicomponent Intervention|Multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
215009884|NCT04080934|BEHAVIORAL|Swimming|Patients will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum.
214404268|NCT05142228|DRUG|Erenumab-Aooe|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
214404269|NCT05142228|OTHER|Placebo|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
214404270|NCT04884698|DEVICE|Stimit Activator|"The Stimit Activator Device is composed of three components.~1. A magnetic stimulator generating current pulses~2. A novel Stimit coil design optimized for phrenic nerve stimulation~3. A coil positioning device for quick, easy and reproducible coil positioning"
214404271|NCT05049629|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
214404272|NCT05049629|DEVICE|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine)
214404273|NCT04878172|DEVICE|TempSure Firm|The TempSure firm will be used on the abdomen for non-invasive lipolysis.
215009885|NCT00076609|DRUG|PHY906|
214404274|NCT04426487|DRUG|Progesterone|Intramusculer progesterone
214404275|NCT04928989|OTHER|convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
214404276|NCT02333773|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
214404277|NCT01902901|GENETIC|Whole Genome Sequencing|Participants will receive Whole Genome Sequencing
214404278|NCT01902901|GENETIC|Carrier status testing|Carrier status testing
214404279|NCT00372567|DRUG|sunitinib malate|37.5 mg daily
214688289|NCT07162259|DRUG|First-line T-DXd followed by SG upon disease progression|Patients will be assigned to Cohort 1 (HER2 IHC 2+) based on different HER2 immunohistochemical expression levels, where they will first receive T-DXd treatment, followed by SG treatment upon disease progression.
215009886|NCT00076609|DRUG|capecitabine|
215009887|NCT03395990|PROCEDURE|Active comparator: chloroprocaine|15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
215009888|NCT03395990|PROCEDURE|Sham comparator: saline|15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
215009889|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
215097953|NCT01972698|OTHER|Self-directed and simulation-assisted training|"All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~* A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~* Participant will have access to an ultrasound simulator.~* Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~\- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm)."
215009890|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
215009891|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
215009892|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
215009893|NCT00245570|DRUG|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
215009894|NCT00245570|DRUG|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
215009895|NCT00245570|DRUG|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
214404280|NCT00372567|DRUG|imatinib mesylate|800mg daily
214404281|NCT00083421|DRUG|ONO-2506PO|
214404282|NCT01079598|DEVICE|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
214404283|NCT06202937|BEHAVIORAL|Mother Baby Yoga|Fragile Baby Perception Syndrome, Maternal Attachment, Depression-Anxiety-Stress Level
214404284|NCT06202937|OTHER|No intervention:control|the control group received the usual care
214504659|NCT02831049|BEHAVIORAL|Soft-drink related cues|Soft drink related cues
214504660|NCT05847257|DRUG|Letrozole tablets|letrozole 2.5mg twice weekly for 3 months
214504661|NCT05847257|DIETARY_SUPPLEMENT|Coenzyme Q10 table|Coenzyme Q10 400 mg per day for 3 months
214504662|NCT06907823|DRUG|propofol|propofol anesthesia
214504663|NCT06907823|DRUG|Sevoflurane|sevoflurane anesthesia
215009896|NCT00245570|DRUG|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
214404285|NCT03261635|DRUG|Ranibizumab Injection|patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
214404286|NCT03261635|DRUG|Indomethacin|patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
215009897|NCT01829165|DEVICE|rTMS Treatment|MRI-compatible TMS stimulator
215009898|NCT01829165|DEVICE|Sham rTMS Treatment|
215009899|NCT05417256|DEVICE|Tappa Endobronchial Blocker|After intubation, the Tappa bronchial blocker will be advanced either through the intubation tube or outside the tube using a fiberoptic broncoscope. Once the position of the blocker is confirmed, the cuff of the blocker will be inflated with 1-3 mL of air. Since Tappa blocker has an autoinflation system, the anaesthetist can both inflate the cuff with one hand and operate the fiberoptic broncoscope at the same time.
215009900|NCT05417256|DEVICE|Arndt Endobronchial Blocker|After intubation, the endobronchial blocker will be passed through a multiport airway adapter that is placed at the proximal end of the tracheal tube.The fiberoptic broncoscope will be passed through the port and then through the guidewire loop at the end of the blocker. The bronchial blocker and the broncoscope will be advanced as a single unit into the target part of a right or left lung. The broncoscope will be withdrawn into the trachea and the blocker cuff will be inflated and the position of the blocker will be confirmed using the fiberoptic broncoscope. The wire loop will be removed after correct placement of the blocker. Once the guide wire is removed, the blocker can't be replaced.
215009901|NCT03290729|PROCEDURE|wedge shape implants insertion|Narrow dental implants inserted in narrow ridges
215009902|NCT01272622|RADIATION|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
215009903|NCT01272622|OTHER|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
215009904|NCT01033227|DRUG|sodium nitrite injection, usp|Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
215009905|NCT01901588|DRUG|Dexmedetomidine|intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
215009906|NCT01901588|OTHER|Placebo|intraoperative dose of intravenous placebo
215009907|NCT05509673|OTHER|Lipofilling (sublesional fat grafting)|
215009908|NCT01881295|DIETARY_SUPPLEMENT|Placebo control|
215009909|NCT01881295|DIETARY_SUPPLEMENT|Low dose potassium gluconate|
215009910|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potassium gluconate|
215009911|NCT01881295|DIETARY_SUPPLEMENT|High dose potassium gluconate|
215009912|NCT01881295|DIETARY_SUPPLEMENT|Low dose potato|
214404287|NCT00303303|BIOLOGICAL|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
214404288|NCT00303303|BIOLOGICAL|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
214404289|NCT00303303|BIOLOGICAL|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
215009913|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potato|
215009914|NCT01881295|DIETARY_SUPPLEMENT|High dose potato|
215009915|NCT01881295|DIETARY_SUPPLEMENT|High dose French fries|
214404290|NCT05675631|OTHER|Suspension training|This group will perform training using suspension devices.
214404291|NCT05675631|OTHER|Strength training|This group will perform training using weights and elastic bands.
215009916|NCT01881295|DIETARY_SUPPLEMENT|Basal diet control|
214404292|NCT02832765|RADIATION|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
215009917|NCT02142621|OTHER|transpyloric feeding|
215009918|NCT02142621|OTHER|gastric feeding|
215009919|NCT02740010|DEVICE|EDOF Mini WELL Ready IOL|implant
215009920|NCT03191201|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
215009921|NCT03191201|DRUG|0.9% sodium chloride solution|250 mL of a commercially available sterile 0.9% sodium chloride solution.
215009922|NCT01805570|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
215009923|NCT01805570|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
215009924|NCT03648970|DRUG|Pravastatin|The participant will be given pravastatin 2 x 20 mg per oral daily
215009925|NCT02548364|DRUG|Calcifediol|calcifediol treatment
215009926|NCT02548364|DRUG|Placebo|placebo control group
215009927|NCT02002208|DRUG|OC000459|Oral CRTH2 antagonist
215009928|NCT03676725|DRUG|Lidocaine gel|Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
215009929|NCT03662971|DRUG|Germinal peptide eye drops|Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
215009930|NCT05696158|DEVICE|MHNA-003|MHNA-003 is a self-guided digital program for people living with tinnitus
215009931|NCT00489268|DEVICE|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
214404293|NCT02832765|RADIATION|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
214404294|NCT02832765|RADIATION|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
214404295|NCT02832765|RADIATION|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases
214404296|NCT01330355|DRUG|Besivance|Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days
214404297|NCT01330355|DRUG|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
214404298|NCT05826548|BEHAVIORAL|Telerehabilitation group|Patients will undergo the experimental intervention for 1 hour/day, for 5 days, for 4 weeks.
214404299|NCT05826548|BEHAVIORAL|Conventioanl treatment group|Patients will undergo the control intervention for 1 hour/day, for 5 days, for 4 weeks.
214404300|NCT01668342|BEHAVIORAL|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
214404301|NCT06530667|DEVICE|broadband collaborative pulse ablation|Via CT guided, patients with malignant pulmonary nodules would be treated by broadband collaborative pulse ablation
214404302|NCT06068166|COMBINATION_PRODUCT|TEA plus GDMT|Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures. Since 1995, Professor Liu Fengqi has pioneered the use of TEA to treat end-stage HFrEF and achieved surprising results. TEA could reduce the enlarged heart cavity, halt and reverse cardiac remodeling, and improve cardiac systolic and diastolic function. Currently, thousands of HFrEF patients have received TEA procedure. All the patients received maximally tolerated guideline-directed medical therapy (GDMT).
214404303|NCT06068166|DRUG|GDMT|All the patients received maximally tolerated guideline-directed medical therapy (GDMT) alone.
214404304|NCT04950543|BEHAVIORAL|Meditation|An online survey will be offered to participants who have enrolled in a 21-day meditation online course. The survey will be conducted using mobile website technology before and after the online course and additionally after 3 and 6 months.
214404305|NCT00582790|DRUG|IL2|Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
214404306|NCT00582790|DRUG|Zoledronic acid|Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
214404307|NCT02699801|DRUG|propofol|propofol for post-sternal closure sedation
215009932|NCT00283582|DRUG|rhTPO|
215009933|NCT02457286|DRUG|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
214404308|NCT02699801|DRUG|Dexmedetomidine|dexmedetomidine for post-sternal closure sedation
214404309|NCT03301922|BEHAVIORAL|Metacognitive therapy and work-focused interventions|Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
214404310|NCT03301922|OTHER|Waiting list|Waiting list
214404311|NCT01941264|OTHER|community based screening and treatment|Already described in intervention arm description.
214404312|NCT00480441|DRUG|Dronabinol|10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
214404313|NCT00480441|BEHAVIORAL|BRENDA therapy|weekly therapy sessions for 6 weeks
214404314|NCT00480441|DRUG|Placebo|4 capsules daily for 2 weeks followed by a 1 week taper
215009934|NCT02457286|BEHAVIORAL|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
215009935|NCT02457286|DEVICE|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
214404315|NCT05039918|BEHAVIORAL|Affective touch|Gentle stroking at CT-optimal speed
214404316|NCT00165360|DRUG|Temozolomide|Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half
214404317|NCT01719120|BEHAVIORAL|Cognitive-Behavioral Therapy|CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
214404318|NCT04560907|PROCEDURE|Aquablation|"By means of a high-pressure saline stream, parenchymal tissue of the prostate is removed endoscopically through a heat-free mechanism called hydrodissection. The intervention is supported by live ultrasound guidance and the required depth as well as the angle of the resection is planned out prior to the resection. The bladder is accessed using a 24-Fr hand-piece, which accommodates the scope. The handpiece is supported by an articulating arm attached to the operation table. Once placed in the optimal position, the system automatically adjusts the alignment as necessary.~Hemostasis is consecutively achieved through diathermy and post procedure, a threeway catheter is inserted and bladder irrigation is initiated."
214404319|NCT04560907|PROCEDURE|HoLEP|This is done endoscopically under general anesthesia the three lobes of the prostate that are cored out intact with the laser are pushed into the bladder before being morcellated by a special instrument inserted through the telescopic camera. A catheter is placed into the bladder to drain the urine while the raw surface heals, then left in place for around 24 hours before being removed on the day of discharge from hospital. Sterile saline fluid is also irrigated into the bladder through the catheter to dilute any blood in the urine and prevent clots from forming.
214404320|NCT04643249|DRUG|KL1333|Tablet
214404321|NCT04643249|DRUG|Flurbiprofen|Tablet
214404322|NCT04643249|DRUG|Dextromethorphan|Syrap
214404323|NCT04643249|DRUG|Bupropion|Tablet
214404324|NCT04643249|DRUG|Midazolam injection|solution for injection
214404325|NCT04643249|DRUG|Omeprazole|Capsule
214404326|NCT04643249|DRUG|Caffeine|Tablet or capsule
214404327|NCT04643249|DRUG|Repaglinide|Tablet
214404328|NCT05407363|PROCEDURE|ABB and ATG with simultaneous implant placement|Ridge augmentation using ABB and ATG as a graft material with simultaneous implant placement
214404329|NCT05407363|PROCEDURE|XBB and ATG with simultaneous implant placement|Ridge augmentation using XBB and ATG as a graft material with simultaneous implant placement
214404330|NCT05407363|PROCEDURE|ABB and ABG with simultaneous implant placement|Ridge augmentation using ABB and ABG as a graft material with simultaneous implant placement
214404331|NCT02865434|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
214404332|NCT02865434|PROCEDURE|SPECT Imaging (60 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.
215009936|NCT05898880|OTHER|Self-acupressure|In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants
215009937|NCT05898880|OTHER|Acupressure by therapists|In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.
215009938|NCT05898880|OTHER|Control group|No intervention will be made in the control group.
215009939|NCT01579305|DEVICE|Juvéderm® Volbella with Lidocaine|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
215009940|NCT01579305|DEVICE|Restylane-L®|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
214404333|NCT02865434|PROCEDURE|SPECT Imaging (180 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.
214404334|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (15 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.
214404335|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (60 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.
214404336|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (180 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.
214404337|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (18-20 Hours post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.
214404338|NCT02865434|PROCEDURE|Blood Collection for PK Testing (15 Mins Before Injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
214404339|NCT02865434|PROCEDURE|Blood Collection for PK Testing (after injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)
214404340|NCT02865434|PROCEDURE|Blood Collection for PK Testing (15 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept
215009941|NCT02227966|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
214404341|NCT02865434|PROCEDURE|Blood Collection for PK Testing (60 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept
214404342|NCT02865434|PROCEDURE|Blood Collection for PK Testing (180 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept
214404343|NCT02865434|PROCEDURE|Blood Collection for PK Testing (18-20 hours post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept
214404344|NCT02865434|PROCEDURE|Planar Image with both Hands in Field of View|Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.
214404345|NCT02689271|OTHER|MRI|VERDICT diffusion-weighted microstructure imaging sequence
214404346|NCT03887962|DEVICE|Virtual Environment Biofeedback|Treadmill walking. Modified available technology for gait capture. Tailored software for virtual environment rendering and immersive qualities
214404347|NCT03887962|DEVICE|Treadmill walking with no Virtual Environment Biofeedback|Treadmill walking. Flat screen / no virtual environment to act as attentional control.
214404348|NCT00508976|DRUG|Injected bupivacaine post-operatively|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
214404349|NCT00508976|DRUG|Streamed bupivacaine versus streamed normal saline|Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
214404350|NCT00508976|DRUG|Aerosolized bupivacaine versus aerosolized saline|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
214404351|NCT00508976|DRUG|Injected lidocaine pre-incision vs saline pre-incision|Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
214404352|NCT03670381|OTHER|Psychiatric diagnosis|
214404353|NCT00067145|BEHAVIORAL|Face-to-face maintenance program|
214404354|NCT00067145|BEHAVIORAL|Internet maintenance program|
214404355|NCT01004263|DRUG|rizatriptan benzoate|Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
214404356|NCT06143020|PROCEDURE|Erector spinae plane block|In the ESPB group, the patients were placed in the lateral decubitus position. The ultrasound probe was located in longitudinal orientation at the level of the T4 spinous process and then placed 3 cm laterally from the midline to the side involved in the surgery. The ultrasound landmarks, T4 transverse process, and the overlying trapezius, rhomboideus, and erector spinae muscles, were identified. Under aseptic conditions, an 80-mm 21-gauge block needle was inserted in-plane at an angle of 30-40° in the cranial-to-caudal direction until the tip contacted the T4 transverse process.After the hydrodissection with 2-3 mL of isotonic saline solution confirmed the correct needle tip position, the intermixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Local anesthetic spread in a fascial longitudinal pattern deep to the erector spinae muscle was visualized using ultrasound guidance.
214404357|NCT02861261|DRUG|1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder|"1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
214404358|NCT02861261|DRUG|1. Berberine placebo tablets ; 2. ProMetS probiotics powder|"1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
214404359|NCT02861261|DRUG|1. Berberine hydrochloride tablets; 2. Probiotics placebo powder|"1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night"
214404360|NCT02861261|DRUG|1. Berberine placebo tablets; 2. Probiotics placebo powder|"1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night"
214404361|NCT04679883|DRUG|5% GLH8NDE|5% GLH8NDE as eye drops
214404362|NCT04679883|DRUG|Placebo|Placebo as eye drops
214404363|NCT06043804|OTHER|Doppler ultrasound measurement of changes in uterine artery blood flow|Doppler ultrasound measurement of changes in uterine artery blood flow
214404364|NCT00936013|DRUG|oseltamivir|75mg p.o Bid for 5 days
215009942|NCT02227966|DEVICE|Sham-Yband (YDT-201N)|tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
214404365|NCT00936013|DRUG|oseltamivir and chinese medicinal herbs|oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days
214404366|NCT05224687|OTHER|Retroactive review of patient data of those receiving a dose of daptomycin|A retrospective analysis will be conducted using patient data of those receiving a dose of daptomycin at MCMC, Methodist Dallas Medical Center, Methodist Richardson Medical Center, or Methodist Mansfield Medical Center.
215009943|NCT05470725|DRUG|CIN-107|A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).
215009944|NCT06237907|OTHER|Patients underwent lymphedema surgery|Patients who have developed lymphedema and undergone lymphedema surgery.
215009945|NCT06237907|OTHER|Patients underwent surgery without LVA|For patients who have not experienced lymphedema but require surgery due to other disease such as cancer, trauma, chronic wounds, skin defects, etc.
215009946|NCT05026385|BEHAVIORAL|Intervention|Targeted nutrition advice, progressive resistance training exercise, and self-management support
215009947|NCT05945758|PROCEDURE|Injectable resin composite technique.|A metal impression tray was filled with transparent vinyl polysiloxane (EXACLEAR, GC) and used to copy the stone model with the wax-up. Then, the replica will be separated from metal tray and a needle-shaped bur will be used to drill holes through the silicone key ending in the middle of the incisal edge. It will be checked whether the holes were large enough to enable the tip of the composite syringe to pass easily and completely. Neighbouring teeth (mesial and distal one) isolated using Teflon tape, as each tooth will individually be restored for establishment of satisfactory contact points. Following etching and rinsing, the tooth dried, and a dental cord (Ultrampak, Ultradent) will be packed into sulcus for mechanical prevention of subgingival composite flow. Then, the transparent silicone index will be placed in the correct intraoral position, and a syringe filled with flowable composite will be inserted through the hole on the incisal edge.
214404367|NCT02444442|DEVICE|Renal Denervation|Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
214404368|NCT02444442|OTHER|Sham control|Arterial access only. No delivery of radio frequency energy to renal arteries.
214404369|NCT05791721|DRUG|Etoricoxib 90 Mg Oral Tablet|Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
214404370|NCT05791721|DRUG|Dexamethasone 4mg|Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
214404371|NCT02336893|BEHAVIORAL|Training|The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
214404372|NCT03500705|DEVICE|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair at a table with a standard mirror placed on the table in the mid-sagittal plane between both arms, with the reflective side of the mirror facing the non-affected arm. The patient is instructed to observe the reflection of the non-affected arm during the sessions. The patient was not given any instruction on the use of the affected arm.
214404373|NCT03500705|OTHER|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected arm of each stroke patient.
214404374|NCT05508516|DRUG|Shugan Dingtong decoction|Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
214404375|NCT05508516|DRUG|Duloxetine Hydrochloride|Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
214404376|NCT00688961|DRUG|Aspirin|generic aspirin
214404377|NCT00688961|DRUG|omega-3 acid ethyl esters|4, 1 g capsules q.d.
214404378|NCT03247062|OTHER|Quality improvement - sleep bundle|implementation of a sleep bundle
214404379|NCT02635061|DRUG|ACY-241|Specified dose on specified days
214404380|NCT02635061|DRUG|Nivolumab|Specified dose on specified days
214404381|NCT04924582|OTHER|Capacity Coaching|Capacity Coaching focuses on developing the capacity within patients to adapt, endure, and function optimally in their lives along with illness and treatment.
214404382|NCT04534855|DRUG|Treprilimab|Treprilimab 240mg Q3W until progression or unacceptable toxicity
214404383|NCT03756194|DEVICE|Socially-assistive Pepper robot with a CARESSES cultural competence solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. The robot will be culturally aware i.e., it will be aware of the participants' cultural background prior to the testing commencing. As such, it will pre-load the appropriate CKB and apply this during its time with the participants. During the next two sessions, the robot will interact and provide culturally-competent assistance, however, it will not learn and adjust to the participants' individual cultural values and preferences.~Week 2. The participants will again utilize the robot for three days, but it now will learn from the responses it receives from them, consequently interacting in a culture-specific personalised way."
214404384|NCT03756194|DEVICE|Socially-assistive control Pepper robot with an alternative CARESSES solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. During the next two sessions, the CARESSES control robot will not be culturally aware: it will pre-load a generic and more limited CKB that is not tailored for anyone's cultural profile. It will also not learn and adjust to the participants' values and preferences.~Week 2. Participants will again utilize the robot for three days, but the CARESSES control robot will now be configured to be able to learn and adapt to the individual's particular profile. This robot's learning will not include propagation: improving its cultural knowledge base in one area will not also automatically lead to knowledge improvements in other related areas. This robot will possess the same full suite of functions as the CARESSES robot although will be less likely to offer these in a culturally appropriate way."
215009948|NCT05945758|PROCEDURE|Conventional layering technique|the palatal surface will be restored by enamel shade; adapted on the index in the spacing area then The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
215009949|NCT04233580|DEVICE|Amnio Excel + weekly|Amnio Excel + weekly
215009950|NCT04233580|DEVICE|Amnio Excel + max every 2 weeks|Amnio Excel + max every 2 weeks
215009951|NCT02746380|DRUG|LBAL|Adalimumab
215009952|NCT02746380|DRUG|Humira®|Adalimumab
215009953|NCT04729426|OTHER|Peanut Ball Position|The group of healthy pregnant women who meet the inclusion criteria will be determined by randomization according to the order of application to the delivery room. A group (intervention group) will be given positions using the peanut ball tool in active phase and transition phase and the positions will be changed every 30 minutes.
215009954|NCT06244251|PROCEDURE|TU-LESS|TU-LESS group will receive TU-LESS for myomectomy; MPLS group will receive MPLS for myomectomy
215009955|NCT06244251|PROCEDURE|MPLS|Patients with uterine who plan to receive MPLS for myomectomy
214404385|NCT05366387|DEVICE|intrapulmonary percussive ventilation|Intrapulmonary percussive ventilation is a non invasive ventilation technique where small boli or air are delivered, at adjustable frequency and pressure, to the upper airways though a mouthpiece. IPV is currently used in the clinic to aid with airway clearance in neuromuscular and airway diseases.
214404386|NCT05366387|RADIATION|delivery of 99mTc-DTPA aerosol|A 99mTc-DTPA aerosol (500 MBq+/-20%, 3 ml volume) is generated with a jet nebuliser (MMAD 4 µm). The aerosol is inhaled by the study subject and lung deposition is imaged by SPECT
214404387|NCT00958009|DEVICE|Rebidose®|The device is a ready to use single use auto injector containing Rebif® 44 mcg in a 0.5 mL prefilled syringe for sc injection
214404388|NCT02947763|DRUG|mixture of metronidazole, ciprofloxacin, and minocycline|placement of intracanal medication
214404389|NCT00755755|DRUG|PGL4001 (ulipristal) and iron|tablets
214404390|NCT00755755|DRUG|PGL4001 matching placebo and iron|tablets
214404391|NCT00755755|DRUG|PGL4001 (ulipristal) and iron|Tablets
214404392|NCT00009958|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given SC
214404393|NCT00009958|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
214404394|NCT00009958|BIOLOGICAL|sargramostim|Given SC
215097954|NCT01972698|OTHER|Traditional apprenticeship training|"All participants will attend an half-day ultrasound introductory course.~* Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~* Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer."
215009956|NCT02929121|DRUG|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
215009957|NCT02929121|DRUG|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
215097955|NCT05484323|OTHER|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
215097956|NCT05484323|OTHER|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
215097957|NCT05484323|DIAGNOSTIC_TEST|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
214404395|NCT00009958|OTHER|laboratory biomarker analysis|Correlative studies
214404396|NCT00353145|DRUG|Gemcitabine (Gemox)|1000 mg/m\^2, infused at 10 mg/m\^2/min on Day 1 repeated every 14 days (one cycle).
214404397|NCT00353145|DRUG|Oxaliplatin|100 mg/m\^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
215009958|NCT01694394|DEVICE|Implantable Cardiac Monitor (Confirm ICM model 2102)|Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
215009959|NCT02781194|DEVICE|3M™ Bair Hugger™|forced-air warming blanket
215009960|NCT02781194|DEVICE|F&P HumiGard™ Surgical Humidification System|warmed, humidified insufflation
215009961|NCT01038895|DRUG|Ramipril|tablet; 10 mg; od; 3 months
215009962|NCT01038895|DRUG|Experimental|tablet; 300 mg; od; 3 months
214404398|NCT00353145|BEHAVIORAL|Questionnaire|Quality of Life Surveys
214404399|NCT04166461|OTHER|Not application, observational study|Not application, observational study
214404400|NCT05420662|PROCEDURE|Manipulation of vagina during abdominal hysterectomy operation|The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point.
214404401|NCT05420662|PROCEDURE|Classical conventional abdominal hysterectomy operation|Classical conventional abdominal hysterectomy operation without any manipulation from the vagina.
214404402|NCT00527085|DRUG|AMG 073|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
214404403|NCT00527085|DRUG|Placebo|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
214404404|NCT03123640|OTHER|Medication reconciliation and medication review|Pharmacist performed medication reconciliation and medication review
215009963|NCT00800150|DRUG|fludarabine phosphate|
215009964|NCT00800150|DRUG|melphalan|
215009965|NCT00800150|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
215009966|NCT00800150|RADIATION|intensity-modulated radiation therapy|
215009967|NCT00800150|RADIATION|tomotherapy|
215009968|NCT00800150|RADIATION|total marrow irradiation|
215009969|NCT00800150|RADIATION|total nodal irradiation|
215009970|NCT01029483|OTHER|Low carbohydrate diet|Ad libitum low carbohydrate diet (\<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
214404405|NCT00558753|DRUG|pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
214404406|NCT00558753|DRUG|Placebo|Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
214404407|NCT04056104|DIAGNOSTIC_TEST|SpO2 and PIx Measurement|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
214404408|NCT05895773|DRUG|Povidone-Iodine|Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.
214404409|NCT05895773|DRUG|Saline spray|Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
214404410|NCT01855308|PROCEDURE|Single site robotic chole|Cholecystectomy
214404411|NCT01855308|DEVICE|da Vinci Si Surgical System|minimally invasive robotic surgical system designed to facilitate complex procedures
214404412|NCT03599115|BEHAVIORAL|Inhibitory Control Training|Computerized go/no-go task where individuals make responses to certain items (go trials) and withhold responses from certain items (no-go trials, in this case, trials surrounded by a black box). Intervention is designed to target and improve inhibitory control cognitive mechanisms in general (generic arm) or towards high-calorie foods specifically (food arm).
214404413|NCT04415840|DIAGNOSTIC_TEST|acetic acid test|using acetic acid to unmask dysplastic lesions on the cervix uteri
214404414|NCT04415840|DIAGNOSTIC_TEST|Lugol's solution test|using Lugol's solution after acetic acid test to unmask dysplastic lesions on the cervix uteri
214404415|NCT05434442|OTHER|simulation model training|"Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator."
214404416|NCT05434442|OTHER|mobile app training|"An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher."
214404417|NCT05434442|OTHER|control group|Clinical routine training will be given to caregivers in this group.
214404418|NCT02854891|OTHER|autorefractometer, A-scan ultrasound|A measurement of refraction will be made by the Autorefractometer. A measurement of the eyes' biometer data will be made by A-scan ultrasound.
214404419|NCT02668835|DEVICE|Non intervention-Monitoring device|Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.
214404420|NCT02668835|GENETIC|Non intervention-Genetic testing|
214404421|NCT05254730|DEVICE|macro-micro tetrodes for intracranial recording|novel design of tetrode micro electrodes within the standard macro intracranial electrodes used clinically for identification of the epileptogenic zone
214404422|NCT06340243|RADIATION|radiotherapy|radiotherapy
214404423|NCT06180798|PROCEDURE|cold snare endoscopic mucosal resection (C-EMR)|"All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used .~submucosal injection of saline mixed with methylene blue will be used (no epinephrine) followed by resection using snare without using electrocautery in C-EMR group.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.~Bleeding will be assessed for 2 mins to decide upon requirement of immediate hemostatic methods in the form of clipping or electrocoagulation."
214404424|NCT06180798|PROCEDURE|Hot snare endoscopic mucosal resection (H-EMR)|"All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.submucosal injection of saline mixed with methylene blue will be used.Using ERBE electrosurgical unit - EndoCut Q mode (effect interval duration) and forced coagulation mode in H-EMR group.~After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps."
215009971|NCT01029483|OTHER|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
214404425|NCT02467153|OTHER|RET|"RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.~The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.~Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months."
214404426|NCT02467153|DIETARY_SUPPLEMENT|Placebo|Placebo given orally as tablets; 1 tablet per day for 6 months.
214404427|NCT02467153|DIETARY_SUPPLEMENT|Vitamin D3|Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
214404428|NCT04668144|DRUG|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.
215009972|NCT01029483|OTHER|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at \~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
214404429|NCT04668144|DRUG|Prasugrel|Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration
214404430|NCT00723320|DRUG|Atorvastatin|atorvastatin 10mg/d
215009973|NCT01492803|DIETARY_SUPPLEMENT|Probiotics|"Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)"
215009974|NCT01492803|DIETARY_SUPPLEMENT|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
215097958|NCT05484323|OTHER|Cookie containing 2.5 g spirulina|TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
214404431|NCT00723320|BEHAVIORAL|Aggressive lifestyle intervention|aggressive lifestyle intervention
214404432|NCT03351829|GENETIC|Gene-modified autologous stem cells|1 infusion for 5x10\^6\~1x10\^7 gene-modified cells; or more infusions depending on the circumstances
214404433|NCT02929108|BEHAVIORAL|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
215009975|NCT02441114|DRUG|HCP0910 and HGP1011|Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
215009976|NCT00593645|DRUG|Clofarabine|
214404434|NCT02929108|BEHAVIORAL|ACCESS|"Intervention will have two components.~1. Participants will be enrolled in a Secret Facebook group for social support and education~2. Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
214404435|NCT01027871|DRUG|LY2605541|subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
214404436|NCT01027871|DRUG|insulin glargine|subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
214404437|NCT01664234|OTHER|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
215009977|NCT00593645|DRUG|Cytarabine|
215009978|NCT00593645|DRUG|Thymoglobulin|
215009979|NCT00593645|PROCEDURE|Stem cell infusion|
215009980|NCT05338580|DRUG|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
215009981|NCT01296113|DRUG|Chemotherapy|"Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~* Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~* Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total"
215009982|NCT02344095|DRUG|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
215009983|NCT02344095|DRUG|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
215009984|NCT02344095|DEVICE|oncothermia|"Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~\- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W."
215009985|NCT03364010|BEHAVIORAL|Evaluation of proprioception|Velocity perception and Position perception
215097959|NCT02096263|BIOLOGICAL|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
215097960|NCT02096263|BIOLOGICAL|Pediarix|3 doses administered intramuscularly in the right thigh
214404438|NCT01664234|OTHER|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
215009986|NCT03364010|BEHAVIORAL|Evaluation of motor learning|Motor accurancy and State Estimation with visual perturbations
215009987|NCT03364010|BEHAVIORAL|Evaluation of written language|Text reading, Identifying words and Phonological awareness: phonemic blending and phonemic elision
215009988|NCT02902315|OTHER|Cryotherapy|The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
215009989|NCT02902315|OTHER|Vitamins C and E|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection.
215097961|NCT02096263|BIOLOGICAL|ActHIB|4 doses administered intramuscularly in the upper left thigh
215097962|NCT02096263|BIOLOGICAL|Pentacel|4 doses administered intramuscularly in the right thigh
214404439|NCT00140881|DRUG|MK0476; montelukast sodium|
214404440|NCT00140881|DRUG|Comparator: placebo|
214404441|NCT06466668|DIAGNOSTIC_TEST|Sleep study|All subjects will undergo a polysomnography at home
214404442|NCT06466668|DIAGNOSTIC_TEST|stress-related biomarkers and microbiome composition will be assessed using saliva samples|stress and stress-related inflammatory biomarkers will be tested using saliva sample
214404443|NCT06466668|DIAGNOSTIC_TEST|Audiological tests|Pure tone audiometry, Uncomfortable Loudness Levels, Distortion-Product Otoacoustic Emissions, tablet test for hyperacusis, tablet test for hearing screening
214404444|NCT01414166|DRUG|ERN/LRPT|ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
214404445|NCT01414166|DRUG|placebo|ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
215097963|NCT02096263|BIOLOGICAL|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
215097964|NCT02096263|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the right thigh
215097965|NCT02096263|BIOLOGICAL|Hiberix|1 dose administered intramuscularly in the left thigh
215097966|NCT02096263|BIOLOGICAL|Prevnar13|3 doses administered intramuscularly in the lower left thigh
215097967|NCT02096263|BIOLOGICAL|Rotarix|2 doses administered orally
215097968|NCT02337725|DRUG|TVP-1012|TVP-1012 1mg Tablets
215097969|NCT02337725|DRUG|Placebo|Placebo tablets
215097970|NCT03322423|DEVICE|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
215097971|NCT03322423|DEVICE|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
214404446|NCT04096313|DIAGNOSTIC_TEST|HbA1c, Lipids, UACR|compare diagnostic tests to reference methods
214404447|NCT05407194|DIETARY_SUPPLEMENT|Collagen + vitamin C|Participants take the supplement (or placebo) every day for 24 weeks. On three days per week they perform tendon loading exercises.
214404448|NCT04268264|PROCEDURE|Incremental haemodialysis|twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
214404449|NCT04268264|PROCEDURE|Conventional haemodialysis|three times weekly 4-hour long haemodialysis sessions from the start
214404450|NCT06356207|DIAGNOSTIC_TEST|Tilt Table Test|The main goal of the study is to evaluate the time elapsed between the T-LOC during Video Tilt Table Testing and the asystole at the ECG using a national registry and to assess its predictive value in patients undergoing invasive treatment. The hypothesis is that a vasodepressive component could lessen the effect of pacing in a patient, leading to cerebral hypoperfusion and syncope despite maintaining a stable rhythm.
214404451|NCT06234397|DRUG|BH3120|BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle
215097972|NCT03322423|DEVICE|Spherical Contact Lens 2|BioTrue ONEDay Spherical
215097973|NCT05691023|DEVICE|Vivistim System|Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
215097974|NCT00446186|DRUG|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
214404452|NCT06234397|DRUG|pembrolizumab|Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle
214404453|NCT05873803|BIOLOGICAL|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
214404454|NCT05873803|BIOLOGICAL|placebo|0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
214404455|NCT02405390|PROCEDURE|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
214404456|NCT02405390|PROCEDURE|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
214404457|NCT02405390|DEVICE|Storz C-Mac® laryngoscope|
214404458|NCT05773898|OTHER|other|The interviewers will collect data from relatives using questionnaires and evaluation grids based on an identification form, a Life Trajectory questionnaire, an anthropological evaluation grid, a retrospective psychiatric diagnosis questionnaire (SCID), a socio-demographic questionnaire, a questionnaire on suicide risks and a questionnaire on emotional state.
214404459|NCT06087692|OTHER|Exercise|-based game therapy applied in addition to aerobic exercise
215009990|NCT02902315|OTHER|Vitamins C and E associated with cryotherapy|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection. The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
215009991|NCT02902315|OTHER|Placebo|The volunteers from placebo exercise session will receive two pills (containing wheat flour) and the remaining procedures were conserved.
215009992|NCT05099211|PROCEDURE|Muscle biopsies|"Optional~In pre-training:~Biopsy performed during the digestive surgery procedure~Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department."
215009993|NCT05099211|OTHER|Muscle Strengthening|3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.
215009994|NCT05099211|BIOLOGICAL|Blood and urine samples|fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
215009995|NCT05099211|OTHER|Aerobic Training|"3 sessions per week for 18 weeks. Duration: 1 hour Training on a classic pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities."
215009996|NCT05099211|OTHER|Evaluation 1 pre-surgery|"Carried out at least 15 days before surgery~1. st visit:~   * Nutritional assessment~  * Body composition~  * Psychometric tests of quality of life + IPAQ Test~  * VO2pic~2. nd visit:~   * Neuromuscular tests~  * Functional tests"
215009997|NCT05099211|OTHER|Evaluation 2 post-surgery|"1. st visit:~   * Body composition~  * Nutritional assessment~  * Psychometric tests of quality of life~2. nd visit:~   * neuromuscular tests~  * Functional tests~  * Familiarization with training equipment if patient participates in re-training"
215009998|NCT05099211|OTHER|Intermediate Evaluation 3|performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6
215009999|NCT05099211|OTHER|Final post-training evaluation 4|Tests identical to evaluation 1 + TM6
215010000|NCT04967170|BIOLOGICAL|Autologous Platelet-Rich Plasma (PRP)|Two intralesional injections of approximately 5-6mL given approximately 6 weeks apart
215010001|NCT04967170|OTHER|Sham Procedure|Intralesional needle insertion without any injectate.
215010002|NCT01371565|DRUG|Mifepristone|mifepristone at doses from 300mg/day up to 1200mg/day
215010003|NCT04765072|BEHAVIORAL|Survivorship Patient Navigation Intervention|Patient navigator assistance for navigating the healthcare system and locating and utilizing beneficial resources
215010004|NCT04765072|BEHAVIORAL|Telehealth Survivorship Visit Intervention|Individualized survivorship care plan
215010005|NCT04120324|OTHER|Eligible for Same Day Discharge|Preoperative Physiotherapy and Anesthesia Criteria met.
215097975|NCT00446186|DRUG|Comparator: placebo / Duration of Treatment: 2 Weeks|
214404460|NCT04869657|BEHAVIORAL|Coaches with Children's Hospital of Philadelphia (CHOP) Research Consultant Support|Coaches employed by the school district will support the implementation of three evidence-based practices, while themselves being remotely supported by CHOP research consultants.
214404461|NCT04869657|BEHAVIORAL|Coaches without CHOP Research Consultant Support|Coaches employed by the school district will support the implementation of three evidence-based practices without any additional support from CHOP research consultants.
214404462|NCT02413788|OTHER|aerobic exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
214404463|NCT02413788|OTHER|combined exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
214404464|NCT02413788|DEVICE|treadmill|
214404465|NCT02877537|DRUG|Salbutamol|bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
214404466|NCT02877537|PROCEDURE|Forced oscillation technique|before and after bronchodilation
214404467|NCT02877537|PROCEDURE|Plethysmography|
214404468|NCT02084082|DRUG|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
214404469|NCT02084082|DRUG|Linagliptin|1x Linagliptin tablet
214404470|NCT02084082|DRUG|Metformin ER|2x Metformin ER tablets
214404471|NCT05055375|OTHER|questionnaire survey|We will conduct a questionnaire survey of outpatients.
214404472|NCT04285502|PROCEDURE|SURGICAL DRAIN|A surgical drain is a tube used to remove blood, abscess and any type of fluid at the site of the place it is inserted
214404473|NCT05266261|DRUG|Ibandronate Oral Tablet|150 mg of ibandronate + 24,000 IU of cholecalciferol
214404474|NCT02887651|RADIATION|Cavity boost radiation|Cavity boost radiation therapy with 10 x 3 Gy for patients suffering from complete resected cerebral metastases
214404475|NCT00522184|PROCEDURE|intra-articular injection of etanercept|
214404476|NCT00522184|PROCEDURE|intra-articular injection of steroid|
215010006|NCT04120324|PROCEDURE|Primary Single Joint Total Hip Arthroplasty|Total Hip Replacement Surgery
215010007|NCT04120324|OTHER|Discharge Same Day|Postoperative criteria for Same Day Discharge met.
215010008|NCT02070991|DRUG|Macitentan|oral tablet, 10 mg once daily
215010009|NCT02070991|DRUG|Placebo|matching placebo
214404477|NCT05705167|DRUG|Plitidepsin|IV infusion over 60-minutes
214404478|NCT06340880|OTHER|Serratus anterior plane block|ultrasound guided SAPB vs anatomical landmark guided SAPB
215010010|NCT00563212|DRUG|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
214404479|NCT04842968|OTHER|Methylene blue injection|Methylene blue solution is injected ex vivo in the main supplying artery trunk of the freshly removed colorectal specimen. (50 mg in 30 ml saline)
215010011|NCT05930951|DRUG|OBT076|OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity
215010012|NCT05930951|DRUG|Balstilimab|Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
215010013|NCT00940173|DEVICE|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
215010014|NCT00940173|DEVICE|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
214404480|NCT03168880|DRUG|Paclitaxel + Carboplatin|Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
214404481|NCT03168880|DRUG|Paclitaxel only|
214404482|NCT05499585|OTHER|Whole Dairy|2 1/2 servings of whole dairy per day
214404483|NCT04736056|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
215010015|NCT00940173|DEVICE|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
215010016|NCT00940173|DEVICE|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
215010017|NCT04225143|PROCEDURE|urostim bilateral|Treatment by bilateral neurostimulation of the tibial nerve
214404484|NCT04348370|BIOLOGICAL|BCG Vaccine|BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.
214404485|NCT04348370|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.
214404486|NCT05806554|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
214404487|NCT04231110|BIOLOGICAL|Fecal microbiota transplantation|Use of fecal microbiota transplantation enemas once weekly in patients who are initiating vedolizumab treatment
214404488|NCT03163511|COMBINATION_PRODUCT|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
214404489|NCT04238455|PROCEDURE|Sham serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
214404490|NCT04238455|PROCEDURE|Serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
215010018|NCT04225143|PROCEDURE|urostim unilateral|Treatment by unilateral neurostimulation of the tibial nerve
215010019|NCT02385357|DIETARY_SUPPLEMENT|Protein-enriched drink|Participants will drink 330 ml of a protein-enriched drink (6 g/ml of protein) after a high intensity exercise that induce muscle damage (30 min running downhill with a slope of -10º)
215010020|NCT03752931|DRUG|Celiprolol|receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
214404491|NCT05002478|OTHER|Prone positioning|Turn patient in prone position after surfactant administration.
215010021|NCT03752931|DRUG|Diltiazem|receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
215010022|NCT00139516|BEHAVIORAL|self-help|
215097976|NCT02029794|PROCEDURE|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
214404492|NCT06099015|DEVICE|Cera™ Vascular Plug System|The Cera™ Vascular Plug System is composed of Cera™ Vascular Plug and its accessory Introducer Kit. The Cera™ Vascular Plug is a self-expandable, cylindrical Ni-Ti wire mesh device.
214404493|NCT03959098|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
215097977|NCT02029794|PROCEDURE|visual inspection with acetic acid (VIA)|
214404494|NCT03959098|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
214404495|NCT03959098|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, hinchang medical co., Korea).
214404496|NCT03959098|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be dministered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
214404497|NCT03959098|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214404498|NCT03959098|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214404499|NCT03959098|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
214404500|NCT03959098|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
214404501|NCT03437668|DRUG|WSE|WSE tablets
214404502|NCT03437668|DRUG|Placebo Oral Tablet|Placebo tablet
214404503|NCT02099539|BIOLOGICAL|N-803|Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
215010023|NCT00139516|DRUG|nicotine replacement therapy|
215097978|NCT02029794|DRUG|3-5% acetic acid|
215097979|NCT04087161|OTHER|Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair
215097980|NCT03703323|OTHER|Rotative thromboelastometry analysis|Obtaining blood sample (one tube of blood)
215097981|NCT00850941|BEHAVIORAL|Questionnaire|Information collection.
214404504|NCT05515874|DRUG|Feraheme|"Ferumoxytol contains iron and is used for the treatment of anemia, so it may affect any iron supplementation prescribed by a physician. Iron is metabolized in the liver, so impaired liver function could interfere with the metabolism of ferumoxytol.~Patients will receive up to a total maximum ferumoxytol dose of 4 mg/kg (71.6 µmol Fe/kg) of body weight, diluted in 200 mL of 0.9% normal saline, at a rate of 10 ml/minute for 20 minutes, The injection rate and maximum dosage are well within the safety thresholds regarding the FDA recommendation of ferumoxytol use."
214404505|NCT05787652|BEHAVIORAL|ARTEMIS mobile app|Access to a self-regulation based mobile application.
214688290|NCT07162259|DRUG|First-line SG followed by T-DXd upon progression|Patients will be assigned to Cohort 2 (HER2 IHC ≤1+) based on different HER2 immunohistochemical expression levels, where they will first receive SG treatment, followed by T-DXd treatment upon disease progression.
215010024|NCT00139516|BEHAVIORAL|smoking cessation|
215010025|NCT00827242|DRUG|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
215010026|NCT00827242|DRUG|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
215010027|NCT04186585|DRUG|BP-C2|Oral daily intake
215097982|NCT02003937|BEHAVIORAL|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
215097983|NCT04545710|DRUG|Abemaciclib|Abemaciclib 150mg BID
215097984|NCT04545710|DRUG|Osimertinib|Osimertinib 80mg daily
214404506|NCT05812794|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Participants will come for 5 sequential days of 2 hour long occupational therapy sessions augmented by tDCS for the first 20 minutes of the session. At arrival, the stimulation safety sheet will be completed by the occupational therapist.The saline soaked electrodes will be placed on the study subjects head and connected to the Soterix 1x1 Limited Total Energy (LTE) enabled tDCS device. Current output through the device will be sham stimulation on day 1 , followed by steady increases to a maximum of 1milliampere (mA) in patients aged 5-12 years old, and 1.5 mA in patients aged 13-19 years old, per the study design flow sheet at the end of this protocol. Blood pressure, pulse rate, and peg-board scores will be recorded as indicated on the stimulation safety sheet during each session.A repeat assessment will be done by the occupational therapist one week post therapy completion.There will be a repeat assessment visit 3 months post intervention."
214404507|NCT05299086|DRUG|Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)|The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.
214404508|NCT01692262|DRUG|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.
214404509|NCT01692262|DRUG|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.
214404510|NCT01692262|DRUG|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.
215097985|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: OPD-Scan|Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
215010028|NCT02919605|DRUG|Single dose of Pentamidine|The patients will come to the hospital to take a single dose of the Pentamidine.
215010029|NCT02919605|DRUG|Two doses of Pentamidine|The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
214404511|NCT02679651|OTHER|Ultrasound of the foot|An ultrasound will be used to determine the thickness of the fat pad
215097986|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: Pentacam|Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
215097987|NCT00328471|BEHAVIORAL|care management|
215097988|NCT06056856|PROCEDURE|Penile skin graft substituttion urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
215097989|NCT06056856|PROCEDURE|Buccal Mucosal Graft substitution urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
215097990|NCT05870683|DRUG|Tegoprazan|Included in dual eradication medication.
215097991|NCT05870683|DRUG|Amoxicillin|Included in dual eradication medication.
215097992|NCT05870683|DRUG|Esomeprazole|Included in dual eradication medication.
215097993|NCT02819401|OTHER|pediatric formula|high-fiber enteral formula
215097994|NCT06033872|COMBINATION_PRODUCT|Focused education, medication adjustment and telemonitoring|"1. Focused diabetes education session for Ramadan fasting~   Participants will be taught to record~  1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~2. Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~3. Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software."
214404512|NCT02679651|OTHER|Pedobarograph Measurements|This non-invasive device measures the force and pressure of the foot while standing and walking.
214404513|NCT02679651|OTHER|Manchester Foot Pain and Disability Index|This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
214404514|NCT04456738|BEHAVIORAL|Parent Training|16 weeks of of parent training led by a trained group facilitator
214404515|NCT02956967|OTHER|Overall satisfaction questionnaires of home use of Nivestim|
215010030|NCT02919605|DRUG|Three doses of Pentamidine|The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
215010031|NCT02845388|DRUG|Sildenafil citrate|
215097995|NCT06485466|COMBINATION_PRODUCT|TACE plus camrelizumab and apatinib|"TACE plus camrelizumab and apatinib group:~Patients who were randomized to this group, TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) and oxaliplatin (50-150mg) are considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol (5-20ml) and other embolic agent( blank microspheres/ PVA/gelatin sponge particles) were determined by diameter and blood supply type of HCC. Within 1 week after first TACE treatment, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
215097996|NCT06485466|COMBINATION_PRODUCT|Camrelizumab and apatinib|"Camrelizumab and apatinib group:~Patients who were randomized to this group, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
215010032|NCT02845388|DRUG|estradiol valerate|
215010033|NCT01192477|OTHER|Ozone|All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
215097997|NCT00119665|DRUG|MF101|
215097998|NCT00514462|DEVICE|diode laser|wavelength at 830nm, 9.7J/cm2 for 10 min
215097999|NCT04083755|DRUG|Ferric Carboxymaltose Injection [Injectafer]|1000mg intravenous
215098000|NCT04083755|OTHER|no treatment or oral iron supplementation|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
215098001|NCT02453555|DRUG|Linagliptin|
214404516|NCT05274776|DEVICE|EOS calculator|For this study the EOS calculator was developed as a mobile application (by everywhereIM), including CE marking. It is concerned a medical device for health care professionals.
214404517|NCT00615433|DRUG|Lurasidone|120mg/day
214404518|NCT00615433|DRUG|Olanzapine|15mg/day
214404519|NCT00615433|DRUG|Placebo comparator|Placebor Comparator
214404520|NCT00615433|DRUG|Lurasidone 40 mg tablets|Lurasidone 40 mg tablets
214404521|NCT00203775|DRUG|risperidone|
214404522|NCT03194776|DRUG|LLG783|LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
215010034|NCT04574700|OTHER|knee joint mobilization and traction|"Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks"
214404523|NCT03194776|DRUG|Placebo|Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
214688291|NCT07162818|DRUG|Nepafenac 0.1% eyedrops|The study eye drops were nepavenac 0.1% eye drops (NEVANAC 0.1%®, Alcon Laboratories, Inc., Fort Worth, Texas). Subjects were instructed to use eye drops on the side of the eye with the ARR, three times daily for five days before and on the day of surgery. Written instructions and a daily checklist to record the eye drop schedule were provided to each subject.
215010035|NCT04574700|OTHER|Post isometric relaxation|"Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks."
215010036|NCT03565653|OTHER|High dietary salt|\~4,000 mg Na+/day
215010037|NCT03565653|OTHER|Placebo|dextrose
215010038|NCT01381588|OTHER|Fracture evaluation|DEXA(Dual-energy X-ray absorptiometry), X-ray
215010039|NCT04688944|OTHER|observation|observation the difference between two groups
215098002|NCT02453555|DRUG|Empagliflozin placebo + linagliptin placebo low dose|Matching placebo empagliflozin + linagliptin
215098003|NCT02453555|DRUG|Empagliflozin + linagliptin low dose|tablet
215098004|NCT02453555|DRUG|Linagliptin placebo|Matching placebo linagliptin
215098005|NCT02453555|DRUG|Empagliflozin + linagliptin high dose|tablet
214404524|NCT00014690|DRUG|plevitrexed|
214404525|NCT00014690|DRUG|topotecan hydrochloride|
214404526|NCT02907697|BEHAVIORAL|Life Steps-Drug Use|
214404527|NCT02907697|BEHAVIORAL|General Health Education|
214404528|NCT00185367|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
214404529|NCT00185367|DRUG|SH D 593 B (Miranova)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
214404530|NCT04360226|OTHER|Non-interventional|Non-interventional, subjects will only have routine testing (blood biomarkers, spirometry, peak inspiratory flow measurements) and be asked to complete questionnaires.
214404531|NCT00894751|DRUG|dexmedetomidine|dexmedetomidine general anesthesia for MRI
215098006|NCT02453555|DRUG|Empa + lina highdose placebo|
214404532|NCT00894751|DRUG|propofol|propofol general anesthesia for MRI
214404533|NCT00958529|DIETARY_SUPPLEMENT|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
214404534|NCT01984125|OTHER|Point-of-Care Prompt|
214404535|NCT00294996|DRUG|Myocet|
214404536|NCT01659138|DRUG|SAR339658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
214404537|NCT01659138|OTHER|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
214404538|NCT01682707|PROCEDURE|laryngoscopy|tracheal intubation with two different techniques, track light and laryngoscopy.
214404539|NCT01682707|PROCEDURE|track light|
214404540|NCT02963597|DEVICE|AirSense™ 10 AutoSet|The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
214404541|NCT02963597|OTHER|Standard Medical Therapy|Standard medical therapy according to current guidelines.
214688292|NCT07162818|DRUG|Control (placebo) group|Cenfresh® eye drops (Cendo pharmaceutical, Indonesia) for the control group. Subjects were instructed to use eye drops on the side of the eye with the ARR, three times daily for five days before and on the day of surgery. Written instructions and a daily checklist to record the eye drop schedule were provided to each subject.
215010040|NCT05970211|DEVICE|Phonak Audeo Lumity Receiver in Canal Hearing Aid|bilateral receiver in canal hearing aids provided as part of a best practices hearing loss intervention including devices, hearing centered counseling, and self management skills training for hearing loss
214404542|NCT01149603|DEVICE|HeartMate II Ventricular Assist Device|The HeartMate II Left Ventricular Assist Device has been approved by the FDA for use in bridge-to-transplant therapy and destination therapy for patients with endstage heart failure.
214404543|NCT00765089|PROCEDURE|Isolation of pulmonary veins with Bipolar radiofrequency ablation|
214404544|NCT01823341|DEVICE|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
214404545|NCT01230034|DRUG|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
215098007|NCT05484284|PROCEDURE|two-stage primary total knee arthroplasty with low-dose antibiotics|Briefly, investigators completely debrided all necrotic soft tissue in the first stage of the operation. The surgical site was flushed twice with hydrogen peroxide, iodine, and saline solutions. Then, the antibiotic-loaded cement spacer was inserted. After surgery, a 10-day course of intravenous organism-specific antibiotics or vancomycin was administered, followed by oral antibiotic therapy. Second-stage reimplantation was performed once there was no sign of infection. The spacer was removed and the new prosthesis was implanted without the use of antibiotic-containing bone cement.
215098008|NCT03779074|DRUG|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
215010041|NCT00899847|PROCEDURE|Autologous peripheral blood stem cells (auto-PBSC) transplantation|"Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective"
215010042|NCT00899847|PROCEDURE|Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
215010043|NCT00899847|DRUG|Filgrastim|"Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection."
215010044|NCT00899847|DRUG|Cyclophosphamide|Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
215010045|NCT00899847|DRUG|Melphalan|Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
215098009|NCT03779074|DRUG|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
215098010|NCT03779074|DRUG|14D high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
214404546|NCT01230034|DRUG|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
215010046|NCT00899847|DRUG|Cyclosporine|Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
215010047|NCT00899847|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
215098011|NCT00500760|DRUG|Cisplatin|Administered intravenously (IV; in a vein)
215098012|NCT00500760|RADIATION|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
215098013|NCT00500760|DRUG|Panitumumab|Administered intravenously
215098014|NCT00141115|DRUG|levetiracetam|Levetiracetam 1500 mg BID
214504664|NCT04434092|DRUG|Crovalimab|"Dosing depends on body weight. Participants will be dosed as follows:~* 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study~* 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study~* 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study~* 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study~* 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study~* 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study."
214504665|NCT04434092|DRUG|Eculizumab|Eculizumab will be administered as specified in the respective arm.
214504666|NCT04224272|DRUG|ZW25 (Zanidatamab)|Administered intravenously
214504667|NCT04224272|DRUG|Palbociclib|Administered orally
214504668|NCT04224272|DRUG|Fulvestrant|Administered as an intramuscular injection
215010048|NCT00899847|BIOLOGICAL|Rabbit anti-thymocyte globulin|ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
215010049|NCT00899847|DRUG|Mycophenolate Mofetil 250mg|MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
215010050|NCT00899847|DRUG|Solumedrol|Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
215010051|NCT00899847|DRUG|Diphenhydramine|Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
215010052|NCT00899847|DRUG|Acetaminophen|Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
215010053|NCT00899847|DRUG|Hydrocortisone|Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
215010054|NCT01176994|DEVICE|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
215098015|NCT01416480|DRUG|Theobromine 300mg|Capsule, b.i.d.
215098016|NCT01416480|DRUG|Levodropropizine 10mg|Syrup, t.i.d.
214404547|NCT04327596|PROCEDURE|RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter|Ablation of AF is standard of care in the management of patients with paroxysmal or persistent AF. The most common triggers initiating AF arise from pulmonary veins (PV) and successful electrical isolation of PV's can significantly reduce the burden of AF. Therefore, the main objective in patients undergoing ablation of AF is to achieve PV isolation.
215010055|NCT02082093|DEVICE|Telemedicine System|
214404548|NCT00217711|DRUG|Capecitabine|capecitabine
214404549|NCT00217711|DRUG|irinotecan hydrochloride|irinotecan hydrochloride
214404550|NCT00217711|DRUG|oxaliplatin|oxaliplatin
214404551|NCT01548391|DRUG|HX-1171|20mg, 200mg, 500mg
214404552|NCT06576908|DEVICE|HyperSight Imaging|Subjects receive both HyperSight imaging and conventional imaging, on their first day of radiation treatment, on their second day of treatment, and on their last day of treatment.
214404553|NCT02027935|BIOLOGICAL|Aldesleukin|Given SC
214404554|NCT02027935|BIOLOGICAL|Autologous CD8+ Melanoma Specific T Cells|Given IV
214404555|NCT02027935|DRUG|Cyclophosphamide|Given IV
214404556|NCT02027935|BIOLOGICAL|Ipilimumab|Given IV
214404557|NCT02027935|OTHER|Laboratory Biomarker Analysis|Correlative studies
214404558|NCT06576193|BEHAVIORAL|Safe Dates for Young Parents (SDYP)|"SDYP is a healthy relationship and intimate partner violence (IPV) prevention program, adapted from Safe Dates (Foshee et al., 1998; Foshee et al., 1996) designed for teens, that focuses on pregnant or parenting females. The program consists of ten group-based sessions (50 minutes each) led by a trained facilitator which include interactive discussions, analysis of scenarios, games, role-plays, brainstorming, and a poster contest and theatrical play."
214404559|NCT05546099|BEHAVIORAL|Self-management of BP medications|Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.
214404560|NCT05546099|BEHAVIORAL|Self-monitoring of home BP|Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.
214404561|NCT05421273|DEVICE|Spinal cord stimulation using passive recharge burst stimulation|Passive recharge burst is marked by a recharge pattern that passively compensates for charge differences.
214404562|NCT05421273|DEVICE|Spinal cord stimulation using active recharge burst stimulation|Active recharge burst is characterized by negative pulses that directly compensate for charge differences.
215010056|NCT02232321|OTHER|PsA MDA|
215010057|NCT02011763|BIOLOGICAL|Avaxim 80U Pediatric: Inactivated Hepatitis A Virus|0.5 mL, Intramuscular (2 injection 6 months apart)
215010058|NCT01769443|DRUG|bortezomib|Bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
215010059|NCT01769443|PROCEDURE|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
215010060|NCT06128226|GENETIC|Blood Sampling|For Tripeptidyl Peptidase 1 enzyme level measurement, blood will be taken from the patient into a 5 mL EDTA tube at Gazi University Faculty of Medicine, Metabolism Laboratory, and for patients with low enzyme activity, the genetic evaluation test will be performed with whole blood at the Gene2Info Laboratory.
215010061|NCT04694885|BEHAVIORAL|Structured Hypnotherapy|"The Intervention includes 10 structured hypnotherapy sessions lasting 45 to 60 minutes. During hypnosis, patients reach a trance-like state comparable to a deep relaxation. The therapist guides the patient verbally and also communicates with the patient.~Patients will be supported to use their own imagination without suggesting any imagery. By repeatedly asking what the patient is perceiving, and by verbally repeating what the patient is saying, the therapist can help the patient to go deeper into trance. In these trance states the patient learns to reduce negative side effects of the chemotherapy and increase the quality of life by activating both physical and mental resources using imagination and focusing on positive memories and feelings."
214404563|NCT04057833|DRUG|E-CEL UVEC|Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site
214404564|NCT06226870|PROCEDURE|root canal tretment|traditional therapy
214404565|NCT06226870|PROCEDURE|biodentin VPT|Alternative therapy
214404566|NCT06226870|PROCEDURE|PRF|Alternative therapy
214404567|NCT00153335|BEHAVIORAL|patient-provider interaction|
214404568|NCT03590743|DRUG|Apixaban|Active anticoagulation with apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily to complete a total of 3 months treatment.
214404569|NCT03590743|OTHER|Placebo|apixaban matching placebo 2 tablets twice daily for 7 days followed by one tablet twice daily to complete a total of 3 months.
214404570|NCT03282175|OTHER|Exercise|Exercise session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
214404571|NCT03282175|OTHER|Training|Each training session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
215010062|NCT05066217|DRUG|Clemizole HCl|Clemizole HCl will be administered as an oral solution.
215010063|NCT05066217|DRUG|Placebo|Placebo will be administered as an oral solution.
215010064|NCT06306183|DIETARY_SUPPLEMENT|Acetaminophen and Vitamin C with Naproxen rescue|"900 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
214404572|NCT03282175|OTHER|Control group|The control group did not receive any treatment.
215010065|NCT06306183|OTHER|Acetaminophen and Placebo with Naproxen rescue|"Placebo taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
215010066|NCT01279200|OTHER|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
215010067|NCT01279200|OTHER|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
215010068|NCT05277766|DRUG|PIPAC with Nal-IRI|Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.
215010069|NCT06467344|DRUG|ACDN-01|ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
215010070|NCT06787144|DRUG|ELVN-001|Orally once or twice daily
215010071|NCT06406595|OTHER|Observation|This study is observational, therefore, there is no intervention included.
215010072|NCT06635161|DEVICE|Trancranial pulse stimulation (without a stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). No stand-off device will be used to target dorsal anteior cingulate cortex.
215010073|NCT06635161|DEVICE|Transcranial pulse stimulation (with Neurology stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A Neurology stand-off device will be used to target the anterior insula cortex.
215010074|NCT06635161|DEVICE|Transcranial pulse stimulation (with a sham stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A sham stand-off device will be used to target vertex.
215010075|NCT04999124|OTHER|Screening and studying characteristics|Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found. Now we want to determine the characteristics of this population.
215010076|NCT05323045|DRUG|BYON3521|BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
215010077|NCT05701085|OTHER|Educational Intervention|The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
215010078|NCT05472909|OTHER|Standardized Relaxation Music|Participants listen to standardized relaxation music during surgery.
215010079|NCT05472909|OTHER|Personal Choice of Music|Participants listen to their preferred music during surgery.
215010080|NCT05455398|PROCEDURE|Surgical treatment of round window niche enlargement via round window for inner ear drug delivery|The round window niche is surgically removed and the hormone is slowly released into the inner ear using a gelatin sponge that has absorbed the hormone in the round window
215010081|NCT05455398|PROCEDURE|Drum chamber drug injection|Injection of drugs into the tympanic chamber through the tympanic membrane
215010082|NCT04046653|DIETARY_SUPPLEMENT|Allin|Dietary supplement
215010083|NCT04046653|DIETARY_SUPPLEMENT|Sulforaphane|Dietary supplement
215010084|NCT04046653|DIETARY_SUPPLEMENT|Placebo|Dietary supplement
215010085|NCT03724344|OTHER|Cross section resaerch|Assessment of cognitive (MoCA), mental behavioral symptoms (NPI） the Self-rating Depression Scale (SDS) and the Self-rating Anxiety Scale (SAS).
214404573|NCT00415974|BEHAVIORAL|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
215010086|NCT01640106|DIETARY_SUPPLEMENT|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
215010087|NCT01640106|DIETARY_SUPPLEMENT|Placebo|Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
215010088|NCT04730375|DRUG|Dexmedetomidine Injection [Precedex]|two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation
215010089|NCT06345820|DEVICE|Evolux|Evolux, enhanced monofocal IOL
215010090|NCT06345820|DEVICE|Tecnis Eyhance|Tecnis Eyhance, enhanced monofocal IOL
215010091|NCT02346422|GENETIC|MYDICAR Phase 1|Single dose of MYDICAR
215010092|NCT02346422|GENETIC|MYDICAR Phase 2|Single dose of MYDICAR
215010093|NCT02346422|GENETIC|Placebo Phase 2 only|Single dose of placebo
215010094|NCT00102167|DRUG|gaboxadol|Duration of Treatment -1 day
215010095|NCT01968317|DRUG|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.
215010096|NCT01968317|DRUG|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.
215010097|NCT03237091|OTHER|bihemispheric transcranial pulsed current stimulation (tPCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
215010098|NCT03237091|OTHER|unihemispheric transcranial pulsed current stimulation (tPCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
214404574|NCT00415974|BEHAVIORAL|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
214404575|NCT00415974|BEHAVIORAL|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
214404576|NCT00415974|BEHAVIORAL|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
214404577|NCT03174795|DRUG|RO7079901|Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
214404578|NCT03174795|DRUG|Meropenem|Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
214404579|NCT00604786|DRUG|omalizumab|Dosing is based on IgE level and weight given every 2 or 4 weeks
214404580|NCT00604786|DRUG|placebo|Dosing is based on IgE level and weight given every 2 or 4 weeks
214404581|NCT00001416|DRUG|CEREDASE™|
214404582|NCT04355676|DRUG|Selinexor|20 mg selinexor oral tablet.
215010099|NCT03237091|OTHER|bihemispheric transcranial direct current stimulation (tDCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
215010100|NCT03237091|OTHER|unihemispheric transcranial direct current stimulation (tDCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
214504669|NCT06906887|DRUG|Induction Chemotherapy (modified FLOT or modified FOLFOX-6)|Subjects are expected to receive 2-4 months of induction chemotherapy; the interval and dosages will be determined and can be modified at the discretion of their medical oncologist. The preferred induction chemotherapies are modified FLOT or FOLFOX-6. Subjects can enroll if they receive less than 2 months of induction chemotherapy as long as they are deemed to be a candidate for concurrent chemoradiation therapy.
214504670|NCT06906887|DRUG|Chemotherapy|The preferred concurrent chemoradiation is carboplatin/paclitaxel weekly.
215010101|NCT03237091|OTHER|sham-control|Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
215010102|NCT02310347|DRUG|dronabinol|
215010103|NCT02310347|DRUG|Placebo|
215010104|NCT04073277|DEVICE|SCF-N-treated needles|The SCF-N-treated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the experimental groups..
215010105|NCT04073277|DEVICE|Untreated needles|he untreated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the control groups.
215010106|NCT04832061|OTHER|Respiratory supports|The respiratory supports used in this patient population included conventional oxygen therapy (COT) via nasal cannula or face mask, non-invasive ventilation (NIV), and invasive mechanical ventilation (IMV). NIV has three different methods, including high-flow nasal cannula (HFNC), bilevel positive airway pressure (BiPAP), and continuous positive airway pressure (CPAP).
215010107|NCT04321499|GENETIC|lung cancer|PCR for SHOX2 and PTGER4
215010108|NCT04595019|RADIATION|SBRT|Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
215010109|NCT05165043|PROCEDURE|position change|The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included,patients changed from the left lateral position to the right lateral position.
215010110|NCT01149538|DRUG|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
215010111|NCT01149538|DIETARY_SUPPLEMENT|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
214688293|NCT07161986|BEHAVIORAL|Mindfullness based Sobriety (MBS)|MBS is combination of Mindfullness , Relapse prevention, motivational interviewing , acceptance and commitment therapy. It helps in dealing underlying depression and anxiety issues among Polysubstance use. it Cover most of underlying problem faced by person with addiction.
214404583|NCT02846662|BEHAVIORAL|CONEMO|The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
214404584|NCT02355704|DRUG|Atorvastatin|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
214404585|NCT02355704|DRUG|Placebo|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
214404586|NCT00158080|PROCEDURE|hemofiltration|
214404587|NCT04884984|BIOLOGICAL|anti-CLL1 CART|Split intravenous infusion of anti-CLL1 CAR T cells \[dose escalating infusion of (5-20)x10\^6 anti-CLL1 CAR T cells/kg\].
214404588|NCT02698436|DEVICE|Acne Mask|The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes
214404589|NCT02698436|DRUG|2.5% Benzoyl Peroxide Treatment|The BPO treatment is applied twice daily, once in the morning and once in the evening
214404590|NCT00253903|DRUG|eplivanserin (SR46349)|oral administration
214404591|NCT00253903|DRUG|placebo|oral administration
214404592|NCT04346303|OTHER|Short-term Interactive Video Games|"1. Collect basic information through a structured questionnaire, which includes basic information, disease status, life style and other related information.~2. Three data collections were performed, namely the baseline period (T0) and the pre-program (T1) two weeks later. Three weeks of intervention activities were provided twice a week, followed by a post-test ( post-program, T2).~3. After a total of six times mentioned above, each 60 minutes of interactive video game intervention, the patient completed the activity feedback form, reflecting the feelings and feedback of participating in the activity."
214404593|NCT02006043|DRUG|Erlotinib 150mg|
214404594|NCT01429714|DEVICE|Individually tailored duration of elastic compression therapy|Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
214404595|NCT01429714|DEVICE|Elastic compression therapy with a standard duration of 24 months|Elastic compression therapy with a standard duration of 24 months
214404596|NCT05597683|PROCEDURE|Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)|"Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs,nefopam, and rescue opioids~Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs, nefopam, and rescue opioids"
214404597|NCT01233635|OTHER|no drug|none, no drug
214404598|NCT01233635|DRUG|start cozaar|start cozaar
214404599|NCT01233635|DRUG|continue cozaar|continue cozaar
214404600|NCT01397487|PROCEDURE|Blastomere biopsy|The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
214404601|NCT03242044|PROCEDURE|Congenital diaphragmatic hernia resuscitation with an intact umbilical cord|10 infants with left or right sided congenital diaphragmatic hernia will be intubated and ventilation initiated while still attached to the placental circulation through the umbilical cord. In addition, at the same time, a nasogastric tube will be placed in the stomach to drain entrained air and secretions. After 5 minutes of resuscitation with the umbilical cord intact, the umbilical cord will be cut, infants separated from the placenta and resuscitation performed per routine neonatal resuscitation protocols. Feasibility, the optimal approach and maternal and infant tolerance to the procedure will be assessed as part of the study.
214404602|NCT04245046|DRUG|Candesartan, Amlodipine, Atorvastatin|compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
214404603|NCT02841722|PROCEDURE|ERIBULIN + G-CSF (Granulocyte-Colony Stimulating Factor)|8 additional blood samples
214404604|NCT06008535|PROCEDURE|Open inguinal hernia repair|Lichtenstein hernioplasty or open inguinal hernia repair with self-gripping mesh
214504671|NCT06906887|RADIATION|Conventional Radiation|For both standard conventional radiation therapy and PLDR radiation therapy, the standard dose (5000cGy/25fx default, 4140-5040 in 23-28 fractions) should be given. Fractions should consist of 180-200 cGy per treatment.
215010112|NCT02747225|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue.
215010113|NCT02216851|DEVICE|Restylane Perlane|Intradermal injection
215010114|NCT01614119|OTHER|Hypoxic exposure|Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture
215010115|NCT01873885|DRUG|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
215010116|NCT01873885|DRUG|Experimental: Single IV Infusion Vasomera (PB1046)|
214404605|NCT03439696|PROCEDURE|Thoracoscopic surgery|Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
214404606|NCT03732586|DIETARY_SUPPLEMENT|Omega 5 fatty acid supplement|Patients will be randomized to receive traditional treatment (prednisone 40 mg per day) plus omega 5 fatty acid ( 2 capsules of 0.64g per day) for 28 days.
214404607|NCT03732586|OTHER|PLACEBO|Patients will be randomized to receive the traditional treatment (prednisone 40 mg per day) plus placebo (2 capsules of placebo with identical appereance and size like omega 5 supplement) for 28 days.
214404608|NCT01020565|DRUG|Entecavir|Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks
215010117|NCT00083109|DRUG|Fluorouracil|Given IV
215010118|NCT00083109|OTHER|Pharmacological Study|Correlative studies
215010119|NCT00083109|DRUG|Suramin|Given IV
215010120|NCT01497093|DRUG|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
215010121|NCT01497093|DRUG|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
215010122|NCT01497093|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
215010123|NCT03139253|DRUG|amoxicillin|amoxicillin 1000 mg bid. for 14 days
215010124|NCT03139253|DRUG|clarithromycin|clarithromycin 500 mg bid. for 14 days.
215010125|NCT03139253|DRUG|tinidazole|tinidazole 500 mg bid. for 14 days.
215010126|NCT03139253|DRUG|levofloxacin|levofloxacin 500 mg qd. for 14 days.
215010127|NCT03139253|DRUG|furazolidone|furazolidone 100 mg bid. for 14 days.
215098017|NCT03148015|OTHER|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
214404609|NCT01862211|OTHER|blood sampling|A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
214404610|NCT04780438|DRUG|Dapagliflozin|Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
214404611|NCT04780438|DRUG|Placebo|Patients rendomized in this arm will receive placebo.
214404612|NCT02851199|DEVICE|Electroencephalography|Electroencephalograph recording following hyperventilation in different participant's body postures
214404613|NCT03980405|DIETARY_SUPPLEMENT|Group 1- Control Diet|Oral 5ASA+ Low Residue Diet for 6 weeks and Oral 5ASA+ Free Diet for 6 more weeks
214504672|NCT06906887|RADIATION|Pulsed Low-Dose-Rate (PLDR) Radiation|"For both standard conventional radiation therapy and PLDR radiation therapy, the standard dose (5000cGy/25fx default, 4140-5040 in 23-28 fractions) should be given. Fractions should consist of 180-200 cGy per treatment.~For PLDR radiation therapy, each fraction will be delivered as a series of 20 cGy (or 0.2 Gy) pulses that are separated by 3-minute time intervals."
214504673|NCT06906887|PROCEDURE|Surgery|Esophagectomy is not required for trial and will be administered per medical judgement of the treating physicians. Surgery will take place at the time directed by the surgeon. This typically will take place approximately 6-13 weeks after chemoradiation therapy.
214688294|NCT07162571|BIOLOGICAL|CD19/22 CAR-T cells|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 150 x 10⁶ CD19/CD22 CAR-T cells
214404614|NCT03980405|DIETARY_SUPPLEMENT|Group 2- UCD Diet|Oral 5ASA+ UC Diet for 6 weeks and Oral 5ASA+ UC Diet Stage 2 for 6 more weeks
214688295|NCT07163598|OTHER|No Intervention: Observational Cohort|This study is a observational cohort study, and we have no intervention.
214404615|NCT01283217|DRUG|DS|Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
214404616|NCT01283217|DRUG|SP|S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
215010128|NCT03139253|DRUG|tetracycline|tetracycline 750 mg bid. for 14 days.
215010129|NCT03139253|DRUG|Ilaprazole|Ilaprazole 5 mg bid. for 14 days.
215010130|NCT01254877|DRUG|ondansetron|ondansetron 0.2 mg bid, oral preparation, 16 weeks
215010131|NCT01254877|DRUG|placebo ondansetron|Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
215010132|NCT01254877|DRUG|Ondansetron|Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
215010133|NCT03406052|BEHAVIORAL|Smartphone-Assisted MB-CBT|Experimental subjects will receive a mindfulness-based CBT online software program workbook (in collaboration with Nex J Systems, Inc.) accessible online. Exposure to and interaction with the online workbook is combined with health coaching (duration of 24 total hours) primarily delivered in phone and software interactions. In addition, each participant will be given a Fitbit-HR Charge, a wearable bracelet that assesses physical steps and 24 hour heart rate in 5 second (averaged) durations (with related access to software that permits daily tracking).
215010134|NCT06281613|DEVICE|AMCOP group|Patients were treated with AMCOP for 18 months.
215010135|NCT06281613|DEVICE|High-pull headgear|Patients were treated with high-pull headgear for 18 months.
214404617|NCT01394991|DRUG|Epoetin alfa 450 IU/kg once a week|450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
214404618|NCT01394991|DRUG|Epoetin alfa 150 IU/kg 3 times a week|150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
215010136|NCT05507450|BIOLOGICAL|V181 High-Potency Level|0.5 mL SC dose of V181 High-Potency vaccine
215010137|NCT05507450|BIOLOGICAL|V181 Mid-Potency Level|0.5 mL SC dose of V181 Mid-Potency vaccine
215010138|NCT05507450|BIOLOGICAL|V181 Low-Potency Level|0.5 mL SC dose of V181 Low-Potency vaccine
215010139|NCT05507450|BIOLOGICAL|Placebo|0.5 mL SC dose of placebo
215010140|NCT01746875|DRUG|Aflibercept|2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
215098018|NCT05435118|OTHER|EMONO + audiovisuals tool|EMONO + use of audiovisuals tool on smartphone or tablet
215098019|NCT02424292|OTHER|Physical activity|Physical activity in a personalised program.
214404619|NCT01394991|DRUG|Epoetin alfa 450 IU/kg once a week (QW)|450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
214404620|NCT01394991|DRUG|Epoetin alfa 150 IU/kg 3 times a week (TIW)|150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
214404621|NCT00001084|DRUG|Indinavir sulfate|
215010141|NCT01746875|DRUG|Verteporfin|given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
215010142|NCT04183478|DRUG|K-001|K-001 is an antitumor active substance (peptidoglycan) which is prepared from the fermentation product of marine microorganism. K-001 is the Chinese first class new drug and get patent licensing in China, America and Japan.
214404622|NCT00001084|DRUG|Lamivudine|
214404623|NCT00001084|DRUG|Stavudine|
214404624|NCT00001084|DRUG|Zidovudine|
214404625|NCT01095718|BEHAVIORAL|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
214404626|NCT01095718|BEHAVIORAL|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
214404627|NCT01095718|BEHAVIORAL|Trial and Error|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
214404628|NCT05886075|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
214404629|NCT03073005|OTHER|Simulation-based Mastery Learning (SBML)|The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
214404630|NCT02621788|BEHAVIORAL|Stress Management and Resiliency Training for Residents (SMART-R)|The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
215010143|NCT04183478|OTHER|placebo|Placebo which looks the same as K-001 in apparence
215098020|NCT00129961|DRUG|sirolimus|
215098021|NCT00129961|DRUG|cyclosporine or tacrolimus|
214404631|NCT04435886|DIETARY_SUPPLEMENT|Probiotic|Probiotic mixture with maltodextrin as a carrier.
214404632|NCT04435886|DIETARY_SUPPLEMENT|Placebo|Placebo comparator with maltodextrin as a carrier.
215010144|NCT02749929|OTHER|Low level laser therapy|The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser
214404633|NCT03024242|DEVICE|Tight vaginoscope|
215098022|NCT05505526|OTHER|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
214404634|NCT02850328|OTHER|examination of muscle function and MVC in weightlessness|"MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~* Rate of force development~* Electromyographic activity~* Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~* Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~* Maximum voluntary activation capacity (%VA): %VA = (1-\[torque superimposed twitch/torque resting twitch\])\*100%."
215010145|NCT02749929|OTHER|Placebo Low Level Laser Therapy|The placebo laser is an identical device to the active laser, made by Irradia Midlaser
215010146|NCT02904356|DEVICE|Repetitive transcranial magnetic stimulation|High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
215010147|NCT01118091|BIOLOGICAL|Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
215010148|NCT01118091|BIOLOGICAL|CD8 enriched Young TIL|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to 2x10\^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10\^8) and the administration of high-dose aldesleukin.
215010149|NCT00034385|DRUG|Valganciclovir|
214404635|NCT01992198|DRUG|cefoperazone + metronidazole|"1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h"
214404636|NCT01992198|PROCEDURE|oral care by chlorhexidine gluconate|oral care by 0.2% chlorhexidine gluconate twice daily
214404637|NCT01992198|PROCEDURE|enteral nutrition|
214404638|NCT01992198|DRUG|Somatostatin|
214404639|NCT01992198|DRUG|Meropenem|"All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.~1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h"
214404640|NCT04279028|BEHAVIORAL|Adapted CBT|"ACBT is derived from traditional CBT principles, but eliminates the text-heavy requirements. Traditional CBT incorporates the use of complex worksheets and a lengthy workbook, whereas ACBT replaces these skill learning activities with simpler, straightforward exercises that are practiced in session along with the therapist. This real world practice eliminates the need for reading and writing as part of CBT while simultaneously recapitulating how the patient would actually implement CBT procedures. In session exercises will mirror that of standard CBT practices. For example, they could include lessons in goal setting, distinguishing situations, moods, and thoughts, and experiments to test underlying assumptions. Participants will be assigned paper-free homework assignments."
214404641|NCT04279028|BEHAVIORAL|Standard CBT|CBT involves the therapist and client working to identify and change negative beliefs and thoughts, replacing them with more accurate and balanced thoughts. CBT for Depression will be conducted according to standard manuals and incorporate the use of a common workbook used within CBT sessions. As per standard practice, participants will be assigned worksheets from their workbook used both in session and as homework assignments.
214404642|NCT02230579|DRUG|MMV390048 5mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
215010150|NCT00514917|DRUG|Docetaxel|75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
214404643|NCT02230579|DRUG|MMV390048 20mg|"Supplied as powder in bottle formulation for reconstitution pre-dose."
214404644|NCT02230579|DRUG|MMV390048 40mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
214404645|NCT02230579|DRUG|MMV390048 80mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
214404646|NCT02230579|DRUG|MMV390048 120mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
214404647|NCT02230579|DRUG|Placebo to match MMV390048|"Supplied as powder in bottle formulation for reconstitution pre-dose"
214404648|NCT04345211|OTHER|Group1, walking group|The walking group includes a weekly walking goal of 75 minutes.
214404649|NCT04345211|OTHER|Group 2, Walking plus manual therapy|Walking plus self-administered thorax manual therapy
214404650|NCT04345211|OTHER|Group 3; Walking plus exercises with Theraband|Walking plus thorax exercises with Theraband
214404651|NCT04374617|DIAGNOSTIC_TEST|Duplex ultrasound and Computed Tomography Angiography|All venous thromboembolisms suspected will diagnosed with ultrasound and CT-angiography
214404652|NCT01081353|DRUG|Acetylsalicylic Acid (Aspirin BAY1019036)|One tablet of new formula Aspirin under fasting conditions
214404653|NCT01081353|DRUG|Alka Seltzer Extra Strength|One effervescent tablet under fasting conditions
214404654|NCT01081353|DRUG|Aspirin Migraine|One effervescent tablet under fasting conditions
214404655|NCT01081353|DRUG|Aspirin Aspro|One effervescent tablet under fasting conditions
214404656|NCT00002915|DRUG|penclomedine|
214404657|NCT04750408|DEVICE|Standard oxygen|COT describes the application of low-flow oxygen in any way (Hudson mask, nasal prongs,...).
214404658|NCT04750408|DEVICE|Nasal high-flow|F is combination of room air supplemented with oxygen can be better patients. This gas mixture will be provided to the patient with a specialized nasal prong.
214404659|NCT04141163|DRUG|Metformin|Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994. It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with other drugs under the names Actoplus Met, Metaglip, Glucovance, Janumet, Kombiglyze XR, and PrandiMet
214404660|NCT04141163|DRUG|Placebo oral tablet|No therapeutic effect
215010151|NCT00514917|DRUG|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
215010152|NCT00514917|DRUG|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
215010153|NCT01877954|DRUG|Extra-fine hydrofluoroalkane beclometasone dipropionate|
215010154|NCT01877954|DRUG|Fluticasone propionate|
214404661|NCT06385470|BEHAVIORAL|Dynamic Temporal and Tactile Cueing treatment|"DTTC is a motor-based treatment designed for children with CAS who may have limited verbal output. It applies the principles of motor learning and focuses on speech movement gestures in the context of functional words and phrases.~The participants will receive two versions of the DTTC treatment (i.e., DTTC in English \[DTTC-E\] and DTTC in Cantonese \[DTTC-C\]), where probe data will be collected before, during, between and after the treatment intervention."
215010155|NCT05319405|DEVICE|Sana Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
215010156|NCT02697422|OTHER|Community-based peer health coach intervention|The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
215010157|NCT00444249|PROCEDURE|White Alcon IOL|Implantation of white Alcon IOL
214688296|NCT07162727|DEVICE|titanium foil in ridge augmentation|Full thickness mucoperiosteal flap was elevated, to expose the alveolar ridge defect. HA graft was placed onto the external defect upon which preformed titanium foil depending on the size and extent of defect was placed. Foil was stabilized with the help of stainless steel screws of diameter 1.5 cm and length varied depending on the depth of the defect. The flaps were approximated and sutured without tension. Periodontal dressing was given.
214404662|NCT02380521|DRUG|Exenatide once weekly (BYDUREON™)|"Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.~Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.~Subjects will follow a fixed dose of 2 mg"
214404663|NCT01324882|DEVICE|Colonoscopy with Olympus Technically Improved Colonoscope|The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
214404664|NCT01324882|DEVICE|Control with standard colonoscope Olympus CF-H180|Standard colonoscopy using the adult scope, Olympus CF-H180.
214404665|NCT06075888|DIAGNOSTIC_TEST|Metagenomic diagnosis (mNGS, DISQVER)|Blood sample taken for metagenomic sequencing at inclusion visit.
214404666|NCT02239185|PROCEDURE|Hernial sac ligation in continuity|Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
214404667|NCT02239185|PROCEDURE|Hernial sac disconnection|Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
214404668|NCT00725010|DRUG|Temozolomide|Temozolomide will be administered orally at 75 mg/m\^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m\^2 to 200 mg/m\^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
214404669|NCT00725010|RADIATION|Radiotherapy|Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
214688297|NCT07162727|DEVICE|collagen membrane|Full thickness mucoperiosteal flap was elevated, to expose the alveolar ridge defect. HA graft was placed onto the external defect upon which preformed collagen membrane depending on the size and extent of defect was placed. The flaps were approximated and sutured without tension. Periodontal dressing was given.
215010158|NCT00444249|PROCEDURE|Yellow Alcon IOL|Implantation of yellow Alcon IOL
215010159|NCT00444249|PROCEDURE|White Hoya IOL|Implantation of white Hoya IOL
215010160|NCT00444249|PROCEDURE|Yellow Hoya IOL|Implantation of yellow Hoya IOL
215010161|NCT00016302|DRUG|prednisone|Given orally
215010162|NCT00016302|DRUG|vincristine sulfate|Given IV
215010163|NCT00016302|DRUG|daunorubicin hydrochloride|Given IV
215010164|NCT00016302|DRUG|asparaginase|Given IM
215010165|NCT00016302|DRUG|methotrexate|Given IT and orally
215098023|NCT05505526|OTHER|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
215098024|NCT00269854|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
215098025|NCT00269854|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
214404670|NCT05391802|DEVICE|Transcatheter mitral valve repair|Transcatheter mitral valve repair (TMVr) is a minimally invasive procedure. Doctors place a thin tube (calleda catheter) into a large vein to reach your heart. A clip is then placed onto the center of your mitral valve. The valve continues to open and close, allowing blood to flow through while reducing MR.
214688298|NCT07163702|DRUG|High-dose Xinglou Chengqi granules|Patients will receive orally high-dose Xinglou Chengqi granules, combined with guidelines-based standard care.
214688299|NCT07163702|DRUG|Low-dose Xinglou Chengqi granules and placebo|Patients will receive orally low-dose Xinglou Chengqi granules, combined with guidelines-based standard care.
215010166|NCT00016302|DRUG|cyclophosphamide|Given IV
215010167|NCT00016302|DRUG|cytarabine|Given IV or SC
215010168|NCT00016302|DRUG|mercaptopurine|Given orally
215010169|NCT00016302|DRUG|leucovorin calcium|Given IV or orally
215010170|NCT00016302|DRUG|dexamethasone|Given orally
215010171|NCT00016302|DRUG|doxorubicin hydrochloride|Given IV
215010172|NCT00016302|DRUG|thioguanine|Given orally
215010173|NCT00016302|RADIATION|radiation therapy|Undergo cranial irradiation
214404671|NCT04757558|DEVICE|C-MAC video-stylet|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
214404672|NCT04757558|DEVICE|Macintosh laryngoscope|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
214404673|NCT06478771|DEVICE|Essix retainer|A clear plastic removable retainer.
214404674|NCT06478771|DEVICE|Lingual retainer|A fixed retainer placed on the lingual side of the teeth.
214404675|NCT02619708|BEHAVIORAL|Immersive Preoperative Experience|The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
215010174|NCT00016302|DRUG|nelarabine|Given IV
215010175|NCT00016302|DRUG|pegaspargase|Given IM
215010176|NCT00016302|RADIATION|radiation therapy|Undergo craniocervical radiotherapy
215010177|NCT00016302|OTHER|pharmacological study|Correlative studies
215010178|NCT00016302|OTHER|laboratory biomarker analysis|Correlative studies
215010179|NCT00235313|PROCEDURE|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
215010180|NCT00235313|DRUG|nicotine patch|normal following with a nicotine patch
215010181|NCT02763358|DEVICE|Bite Counter|This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
215098026|NCT00269854|DRUG|Infliximab 20 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
215098027|NCT00269854|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
214404676|NCT02970747|DRUG|Carfilzomib|In accordance with SmPC.
214404677|NCT06443671|DRUG|CapeOX|"Receiving CapeOX treatment for up to four cycles before surgery:~Capecitabine: 1000mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 130 mg/m2, intravenous drip for 0-2 hours, D1, Q3W."
214404678|NCT06443671|DRUG|Fruquintinib and Tislelizumab combined with mCapeOX|"Receiving Fruquintinib plus Tislelizumab combined with mCapeOX treatment for up to four cycles before surgery:~Fruquintinib: 3mg/d, QD, PO, Use for 2 weeks, stop for 1 week, Q3W; Tislelizumab: 200mg, D1, Intravenous infusion, Q3W; Capecitabine: 825mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 100 mg/m2, intravenous drip for 0-2 hours, D1, Q3W."
214404679|NCT05541419|DRUG|Budesonide Nasal|The patient performed a lavage once daily with 2mg dilute budesonide. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
215098028|NCT06394453|OTHER|enteral feeding with mother milk or human donor breast milk|The experimental group will start enteral feeding with mother milk or human donor breast milk if mother milk is not accesible during the first day of therapeutic hypothermia.
215098029|NCT03178669|DRUG|cobitolimod|Rectal administration
215098030|NCT03178669|DRUG|Placebo|Solution manufactured to mimic cobitolimod
215098031|NCT02626390|OTHER|Frequent instructions/feedback and an Internal Focus of Attention|
215098032|NCT02626390|OTHER|Minimal instructions/feedback and an External Focus of Attention|
214404680|NCT05541419|DRUG|Placebos|Composed of 1% glycerin diluted in water. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
214404681|NCT05104411|OTHER|Rehabilitative intervention|Active rehabilitation programs were done for all patients. Participants were asked to attend exercise program at PT room or bedside. Exercise program was offered once or twice daily on weekdays, by trained kinesiologists. In PT programs, most patients performed strengthening exercise of lower extremities, balance training, sit-up training, sit-to-stand training and gait training for about 30 minutes. Each program was individualized to participants' current physical function. In bedside programs, patients also underwent strengthening exercise and balance training without gait training for about 10 minutes. The duration of exercise program at PT room depends on the patient's condition(upto 1 month).
215010182|NCT01708525|DEVICE|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
215010183|NCT01708525|OTHER|Heavy Water|A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
215010184|NCT02815956|DEVICE|percutaneous tibial nerve stimulation|
215010185|NCT02815956|DEVICE|Placebo|
215010186|NCT04377386|DIETARY_SUPPLEMENT|1000 IU D vitamin|Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
214404682|NCT03116451|BEHAVIORAL|Foot Health Promoting Program|An electronic intervention for 8 weeks consisting of foot self-care guidance targeted to nurses.
215098033|NCT01851785|BEHAVIORAL|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
214404683|NCT05420532|OTHER|Exergaming|A video game-based physical activity training applied using a commercial game console.
214404684|NCT01290094|DRUG|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
214404685|NCT03780205|OTHER|Prescription glasses for bilateral amblyopia|Correction of refractive error with prescription glasses both eyes
214404686|NCT03780205|OTHER|Prescription glasses for unilateral amblyopia|Correction of asymmetric refractive errors with lenses
214404687|NCT05104931|DRUG|Nanoformed Piroxicam IR Tablet|Orally delivered Nanoformed Piroxicam
214404688|NCT05104931|DRUG|Felden (piroxicam) Tablets|orally delivered Felden (reference) tablets
214404689|NCT05104931|DRUG|Brexidol (piroxicam) Tablets|orally delivered Brexidol (reference) tablets
214404690|NCT06021119|DRUG|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors with Iftar meal
214404691|NCT05929456|DRUG|Cetuximab-IRDye800|patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.
214404692|NCT04563052|BEHAVIORAL|Educational Program on Air Pollution as a Health Risk Reduction Strategy|A power point presentation about the health impact of exposure to fine particulate matter (PM2.5) on health. Pm2.5 is found outdoors and indoors. Information will be reviewed about steps to take for the participants to locate the information using a smart phone and steps to take to decrease exposure to prevent illness such as heart disease or strokes.
215098034|NCT00332553|DRUG|Raloxifene|
215098035|NCT00332553|DRUG|medroxyprogesterone acetate|
215098036|NCT00332553|DRUG|estrogen|
215098037|NCT00332553|DRUG|17 beta estradiol|
215098038|NCT04842305|DIAGNOSTIC_TEST|Blood- and saliva tests|Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
214404693|NCT00202826|PROCEDURE|Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage|
214404694|NCT00219401|BIOLOGICAL|Pneumococcal 7 valent conjugate vaccine (Prevenar®)|Accelerated PCV vaccinaton.
215098039|NCT01600092|BIOLOGICAL|RotaTeq™ experimental formulation|
215098040|NCT01600092|BIOLOGICAL|RotaTeq™ existing formulation|
215098041|NCT05492357|OTHER|Liquid platelet-rich fibrin|Liquid platelet-rich fibrin is prepared from the patient's blood and injected into the extraction socket every two weeks (up to 3 months = Just 4 times of application)
215098042|NCT05492357|OTHER|Advanced Platelet-rich fibrin plus|A-PRF+ is placed into the extraction socket immediately after tooth extraction
215098043|NCT03133312|DRUG|Chlorhexidine Gluconate|Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
215098044|NCT03133312|DRUG|Povidone-Iodine Scrub and Paint|Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
215098045|NCT06149377|PROCEDURE|Test cohort|
215098046|NCT03590249|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure. Treatment will last approximately 45 minutes.
215098047|NCT00079677|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
215098048|NCT00079677|DRUG|Placebo|Matching placebo tablets once daily
214404695|NCT02414828|BIOLOGICAL|Placebo|This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area on Study Day 0 for groups 1 and 2 and Study Day 0 and 42 for group 3.
214404696|NCT02414828|BIOLOGICAL|AERAS-402 3 x 10^8 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
214404697|NCT02414828|BIOLOGICAL|AERAS-402 3 x 10^9 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
214404698|NCT02414828|BIOLOGICAL|AERAS-402 3 x 10^10 vp|AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.
214504674|NCT07091981|DEVICE|OneCurve Rotary File|A single-file NiTi system (25/.04) operated at 300 rpm and 2.5 Ncm torque. Applied directly to the MB2 canal without prior hand instrumentation.
215098049|NCT06065592|DRUG|Palbociclib|Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.
215098050|NCT06065592|DRUG|Rivaroxaban|Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.
215098051|NCT06065592|GENETIC|SNP|diagnostics of patients' carriers or not of the risk allele(s)
215098052|NCT02373514|DRUG|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
215098053|NCT02373514|DRUG|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
215098054|NCT06092775|DEVICE|DEXA scan,X_ray|"DEXA scan detect osteoporosis~,X\_ray show subclinical vertebral fractures"
214404699|NCT03766594|DRUG|Sildenafil Citrate|Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period
214504675|NCT07091981|DEVICE|Perfect Minimally Invasive Kit|Two-file system using 10/.06 Shaper for coronal/middle thirds and 25/.04 Finisher for apical third. Operated at 300 rpm and 2.0-2.5 Ncm torque.
215098055|NCT02982083|DRUG|Raloxifene hydrochloride|20 patients consume raloxifene hydrochloride oral tablet daily for one year.
214404700|NCT03766594|DRUG|Folic Acid|Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
214404701|NCT03766594|DRUG|Placebo Oral Tablet|Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
214404702|NCT02669719|BIOLOGICAL|chemotherapy followed dendritic cells|Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
214404703|NCT02669719|DRUG|pemetrexed and carboplatin|Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
214404704|NCT05781529|PROCEDURE|Alveolar ridge augmentation with injectable platelets rich fibrin|Injectable platelets rich fibrin is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
214404705|NCT05781529|PROCEDURE|Alveolar ridge augmentation with hyaluronic acid|Hyaluronic is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
214404706|NCT05781529|PROCEDURE|Alveolar ridge augmentation with xenograft|Xenograft is added alone as a active compatator
214404707|NCT01423357|OTHER|Condom distribution and peer education|Condom distribution and condom demonstrations by youth peer educators at least twice a week
214404708|NCT02729792|DEVICE|rTMS|intermittent theta burst stimulation (iTBS)
214404709|NCT04688021|DRUG|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
214404710|NCT04688021|DRUG|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
214404711|NCT04688021|DRUG|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
214404712|NCT04688021|DRUG|Me-CCNU|250mg/m2 once administered orally on day -3.
214404713|NCT04688021|DRUG|Rabbit antithymocyte globulin|1.5mg/kg/day administered IV day -5 through -2.
214404714|NCT04688021|DRUG|Tocilizumab|8mg/kg administered IV on day -1.
214404715|NCT04688021|PROCEDURE|Allogeneic HSCT|Day 0
215010187|NCT04377386|DIETARY_SUPPLEMENT|200 IU D vitamin|Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
215010188|NCT03170921|OTHER|Angola|The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
215010189|NCT03170921|OTHER|Benguela|The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
215010190|NCT03170921|OTHER|São Bento|The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
215010191|NCT06152354|DEVICE|rotary system|crown down technique using Kedo-SG file rotary system using endodontic motor
215010192|NCT06152354|DEVICE|Manual files|instrumentation were done by step back technique using K- file (Mani ) from size 15 to size 35 in quarter pull turn motion apically
215010193|NCT00143143|DRUG|Pregabalin|
215098056|NCT02982083|DRUG|Placebo Oral Tablet|20 patients consume placebo oral tablets daily for one year.
215098057|NCT03267914|OTHER|Tray|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
215098058|NCT03267914|OTHER|Brush|Patients will brush with the fluoride for 2 minutes each day.
214404716|NCT04688021|DRUG|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
214404717|NCT04688021|DRUG|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
214404718|NCT04688021|DRUG|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
214404719|NCT03635177|PROCEDURE|Remote ischemic conditioning|Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
215010194|NCT01659541|DEVICE|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
215098059|NCT00565136|DEVICE|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
215098060|NCT01900288|BEHAVIORAL|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
214404720|NCT01630499|BEHAVIORAL|Tailored Lifestyle Intervention (TLI)|The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
214404721|NCT01630499|BEHAVIORAL|Commercial Weight Loss Program (CWLP)|This intervention is a generic, widely-available weight management program.
214404722|NCT04680936|DRUG|Dextrose 5% in water|low dose dextrose solution
214404723|NCT04680936|DRUG|Dextrose 15 % in Water|high dose dextrose solution
214404724|NCT04680936|DRUG|Isotonic sodium chloride solution|isotonic saline solution
214404725|NCT03916380|DIETARY_SUPPLEMENT|Grapefruit Juice|Single 8 ounce administration of oral grapefruit juice
214404726|NCT03429309|DRUG|Propofol|Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
214404727|NCT05203731|BEHAVIORAL|Exercise|Moderate intensity exercise (typically a brisk walk or light run) will occur for 20 minutes after the emotional learning procedures on Day 1.
214404728|NCT05203731|BEHAVIORAL|Sitting|Sitting will occur for 20 minutes after the emotional learning procedures on Day 1.
214404729|NCT04949399|DRUG|OnabotulinumtoxinA|Injection
214404730|NCT04949399|DRUG|Placebo|Saline Injection
214404731|NCT00271414|DRUG|Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)|
214404732|NCT00232934|DRUG|Thalidomide|
215010195|NCT01659541|PROCEDURE|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
215010196|NCT03645447|DIAGNOSTIC_TEST|Taste test|A pseudo-randomised series of taste solutions are presented to the participant for identification as sugar or water, in order to establish their taste threshold.
215010197|NCT04825977|OTHER|RISK STRATIFICATION USING AIMS65 SCORE AND RDW|Risk Statification of patients presenting with upper gastrointestinal bleeding to the emergency department using AIMS65 score and Red cell Distribution Width.
214404733|NCT06697535|DRUG|JYP0061|Administered orally with a dose reduction over time as specified in Arm descriptions. Tablets are taken within a specific time frame after meals.
214688300|NCT07163780|BEHAVIORAL|HEP Intervention|"This intervention is administered to the HEP Intervention arm.~The HEP approach, which includes intervention, is a child-centered, family-based early intervention approach based on the principles of enriched environment and plasticity, emphasizing the importance of homeostasis. It is based on theories that argue that development occurs as a result of the dynamic interaction between the environment, time, task, and individual (Ecological Theory, Dynamic Systems Theory, Perception-Action Theory, Neuronal Group Selection Theory, and the Person-Environment-Occupation Model). Hypotheses for intervention are generated based on a comprehensive assessment of these four fundamental factors (environment, time, task, and individual), and 10 core principles derived from environmental enrichment studies are applied with the guidance of ecological models."
215098061|NCT01900288|BEHAVIORAL|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
215010198|NCT01294072|DIETARY_SUPPLEMENT|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
215010199|NCT01294072|DIETARY_SUPPLEMENT|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
215010200|NCT01294072|OTHER|No intervention|no treatment
215010201|NCT01708837|DRUG|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
215010202|NCT00350506|DEVICE|64 Channel VCT|
215010203|NCT01222351|DRUG|BAY 94-9172 (Florbetaben)|Measure of brain amyloid load using BAY 94-9172 PET/CT
215010204|NCT03794063|OTHER|Robson 10 group classification system|WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
215010205|NCT03510702|DIAGNOSTIC_TEST|Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.|"Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers."
215010206|NCT01910532|DRUG|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP \> 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
215010207|NCT04251936|BEHAVIORAL|Exercise training|The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.
215010208|NCT04251936|BEHAVIORAL|Smoking cessation group program|Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
214404734|NCT06697535|DRUG|Intravenous Glucocorticoids|Administered intravenously with a gradually decreasing dose over time, as specified in the Standard Dose Glucocorticoids arm.
214404735|NCT06697535|DRUG|Oral Glucocorticoids|Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.
214404736|NCT04811651|BIOLOGICAL|Umbilical Cord-derived Mesenchymal Stem Cells|umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million.
214404737|NCT04811651|DRUG|Placebo|intravenous placebo solution with the same appearance as the treatment group.
214404738|NCT06711367|BEHAVIORAL|tell show do behavior management technique|tell show do behavior management technique about the the diagnosis and procedures of dental restoration
215010209|NCT05444127|OTHER|Saliva samples|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
214404739|NCT06711367|BEHAVIORAL|a costume-designed storybook|a costume-designed storybook explaining the diagnosis and procedures of dental restoration
214404740|NCT06712472|DRUG|Olaparib (300 mg BID)|Olaparib 300mg Bid during one year.
214404741|NCT06818071|BEHAVIORAL|Points and Leaderboards|"Participants will have the opportunity to gain points if they meet their self-set daily step goal throughout the experiment period.~Participants will also compete with others in their own respective groups on a leaderboard in regards to each day's daily step count."
214404742|NCT06818071|BEHAVIORAL|Social Aspects|Participants will be randomly assigned into groups of three to compete with other groups based on their daily step count. Each day, one participant will be randomly selected to represent the group against their opponent. If they walked more than their randomly selected opponent, the participant's group will receive a positive, encouraging message congratulating them for winning that day. If they did not walk more than their randomly selected opponent, they will receive a motivational message to encourage them to walk more.
214404743|NCT06818071|BEHAVIORAL|Health Messages|Experiment participants will receive messages that encourage healthy behaviors. These include topics such as: nutrition, sleep, physical activity, and decreased consumption/use of unhealthy products (tobacco, alcohol, etc.).
214404744|NCT06818071|BEHAVIORAL|Pikmin Bloom|Participants will play the mobile game Pikmin Bloom, which encourages users to increase their daily step count and allows them to utilize various gamified elements to do so. The game has many gamified elements included, such as personalization and avatar, social aspects, competition, collaboration, progression, and many more.
214404745|NCT06760533|DRUG|Psilocybin 25 mg|Psilocybin 25 mg (active treatment) administered during the psychotherapy treatment session.
214404746|NCT06760533|BEHAVIORAL|Psychotherapy Treatment Session|The psychotherapy treatment sessions will be conducted by two therapists, who will be both present for all the sessions during three phases of treatment: Preparation, Medication Administration, and Integration.
214404747|NCT06760533|DRUG|Niacin 100 mg|Niacin 100 mg (placebo) administered during the psychotherapy treatment session.
214404748|NCT06766981|PROCEDURE|Infiltration with Articain 4%|The experimental group of patients that are diagnosed for tooth extraction of mandibular 1st. molar will undergo extraction using an infiltration technique for local anaesthesia. In contrast to the conventional group that will receive Inferior alveolar nerve block
214404749|NCT06766981|PROCEDURE|Inferior Alveolar Nerve Block|This group will receive a conventional inferior alveolar nerve block (IANB) technique with 2% lidocaine with epinephrine (1:80,000) for tooth extraction.
214404750|NCT06907030|OTHER|No intervention|No intervention
214404751|NCT06913738|BEHAVIORAL|GPM-Extended|GPM-extended is a dimensional adaptation of Good Psychiatric Management (GPM) that retains its core principles-validation, real-life focus, alliance building-while enhancing flexibility and personalization. It emphasizes diagnostic clarity, treatment prioritization, and individualized psychoeducation based on three key personality dilemmas: fear of abandonment, self-esteem dysregulation, and control dependency. These dilemmas guide the focus of therapy and case management. Treatment goals are collaboratively set and regularly reassessed to align with the patient's evolving needs. The intervention includes weekly individual therapy and tailored group programs, with clinical strategies adapted to each dominant dilemma.
214404752|NCT06913738|BEHAVIORAL|Classic GPM|The classic GPM group follows the validated and manualized version of Good Psychiatric Management (GPM) for BPD. It emphasizes symptom stabilization through weekly individual therapy and pragmatic case management every 3 weeks. Unlike GPM-extended, it uses a uniform therapeutic framework rather than tailoring treatment to individual personality dilemmas,.The intervention includes weekly individual therapy and standardized group programs, with clinical strategies applied uniformly across patients, centered on interpersonal hypersensitivity and building stable life roles.
214404753|NCT06913114|DIAGNOSTIC_TEST|Lafayette|The Lafayette handheld dynamometer data correlates with the measurements taken using the 10-Meter Walk Test (10MWT) or not.
215010210|NCT05444127|OTHER|Questionnaire OHIP-14|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
215010211|NCT05444127|OTHER|Thorough dental examination|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
215010212|NCT05343169|BEHAVIORAL|Overdose Education and Naloxone Distribution|"Education on OD risk behaviors and methods for responding to an OD, including naloxone use.~Duration and dose: Single 20-minute training at time of enrollment, provided to all participants in both arms"
215010213|NCT05343169|BEHAVIORAL|Advanced Education in Safer Substance Use, Treatment, and Self-Care|Education about misinformation about OAT, self-care, SEP services, HIV/HCV treatment Duration/dose: 9 mos., monthly \~2 hr. group sessions + ongoing access to video archive of recorded trainings.
214404754|NCT06913114|DIAGNOSTIC_TEST|Lafayette|Lafayette handheld dynamometer.
214404755|NCT06914453|DEVICE|Air Q-3 Supraglottic Airway Device|Oropharyngeal leak pressure and other performance characteristics including time to insertion, first-pass success rate, ease of orogastric tube (OGT) insertion, laryngeal alignment using a fiberoptic scope, and incidence of postoperative sore throat.
214404756|NCT06914453|DEVICE|Ambu AuraGain Supraglottic Airway Device|Oropharyngeal Leak Pressure and other performance characteristics including time to insertion, first-pass success rate, ease of orogastric tube (OGT) insertion, laryngeal alignment using a fiberoptic scope, and incidence of postoperative sore throat.
214404757|NCT06918080|DRUG|Ursodeoxycholic Acid 250 Mg Oral Capsule|Daily doses of Ursodeoxycholic acid (UCD) Ursofalk) in a dose of 20 mg/Kg/day in two divided doses depending on their body weight for 12 weeks will be assigned to arm(1)
214404758|NCT06918080|DIETARY_SUPPLEMENT|Omega -3 fatty acids|Supplementation of omega 3, the dose of omega-3 fatty acids will be determined by baseline weight (\<40 kg-450 mg/day, 40-60 kg-900 mg/day, \>60 kg-1300 mg/day) will be assigned to children in arm (1). Side effect such as gastrointestinal upset and allergy will be monitored, compliance will be monitored by weekly phone call
214404759|NCT06918080|BEHAVIORAL|Physical exercise|Patients assigned to arm (1) will participate in a 12-week exercise program for 30-45 min/day for 3 days/week. in the first two weeks and for 60 min/day for 4-5 days/week in the following weeks
214504676|NCT07091981|DEVICE|VDW Rotate|Three-file NiTi rotary system (15/.04, 20/.05, 25/.04) used sequentially for coronal, middle, and apical thirds. Applied with brushing-pecking motion in 2-3 mm increments under continuous irrigation. Operated at 300 rpm and 1.8 Ncm torque.
214504677|NCT07091981|DEVICE|Perfect Advanced Kit|NiTi rotary file system including 10/.07 Opener, 10/.04, 17/.05, and 25/.04 files. Used in crown-down sequence with rpm and torque settings ranging from 250-300 rpm and 2.0-2.5 Ncm. Brushing-pecking motion and continuous irrigation were applied during instrumentation.
215098062|NCT03973294|DEVICE|EIT-measurement|"The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface."
215098063|NCT04893499|BEHAVIORAL|Chios mastic water|Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
215098064|NCT04893499|BEHAVIORAL|Placebo water|Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
215098065|NCT04893499|BEHAVIORAL|Chios mastic fruit juice|Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
215098066|NCT04893499|BEHAVIORAL|Placebo fruit juice|Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
215010214|NCT05343169|BEHAVIORAL|Social Service and Health Navigation|Help navigate access and barriers to healthcare, motivation and health goals Duration/dose: 9 mos., monthly face-to-face sessions to set goals and schedule appts, phone calls between sessions \> 1x/wk.
214504678|NCT07090252|OTHER|Group I zinc oxide Neem|preperation: 1\\ A standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove coronal pulpal tissues then will remove radicular pulp by barbed broach then will be used K files for chemo mechanical preparation (size 15,20,25) with saline (2%) irrigation to remove necrotic pulp tissues then all the canals will be dried using paper points. 2\\ After complete excavation of all pulp tissue, saline irrigation is done then the canals will be obturated zinc-oxide with Neem ( Zinc oxide powder(Prime Dental Pvt. Ltd.Thane, Maharashtra, India) and 100% Neem oil with mixing ratio of 1:3 will be mixed on a glass slab with a stainless- steel spatula) and then the rest of the pulp chamber will be filled with Zinconol. (reinforced zinc oxide eugenol)3\\ Tooth will be restored with stainless steel crown.
215010215|NCT05343169|BEHAVIORAL|Peer Social Support|Support with social (re)integration, isolation, relationship building Duration/dose: 9 mos., monthly face-to-face events and phone calls/texts between sessions \> 1x/wk.
215098067|NCT06334874|DRUG|Astaxanthin Oral Capsule|12 mg of astaxanthin oral capsule
215098068|NCT06334874|DRUG|Placebo|starch placebo capsule
215098069|NCT06352255|PROCEDURE|Digital block|Frost's H technique
215098070|NCT01073124|PROCEDURE|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
215010216|NCT00222261|DRUG|aspirin|Aspirin 160 mg once daily for two years
215010217|NCT00222261|DRUG|clopidogrel|clopidogrel 75 mg once daily for two years
215010218|NCT01604200|BEHAVIORAL|focus group|key informant review
215010219|NCT03770975|PROCEDURE|delayed implant with immediate provisionaliztion and soft tissue graft|delayed implant placement in the esthetic zone with immediate provisinalization and placement of a connective tissue graft buccal
214404760|NCT06918080|BEHAVIORAL|Mediterrenean diet|"Patients in arm (1) will follow Mediterranean Diet (MD) for 12 weeks, this diet is characterized by a high intake of vegetables, fruit, whole cereals, legumes, nuts, and fish and a low intake of red meat and homemade desserts. The main added fat is extra virgin olive oil, with 35-40% kcal from fat (\<10% from saturated fat), 40-44% kcal from carbohydrate, and 20% kcal from protein.( Plaz et al., 2019) Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age.~Compliance to the MD will be assessed in all patients using the KIDMED index at 4 ,8 and 12 weeks.Those who prove to be non-compliant will be excluded from the study."
214404761|NCT06918080|BEHAVIORAL|Diet according to NASPGHAN guidelines|Patients in arm (2) will receive lifestyle modification according to NASPGHAN Clinical Guidelines for the treatment of NAFLD in Children. Patients will follow healthy and well-balanced diet. Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age, with avoidance of sugar-sweetened beverages, moderate- to high-intensity exercise daily will be encouraged, and screen time will be limited to less than 2 hours.
214404762|NCT06919510|DRUG|lvonescimab|lvonescimab, DS1, D1,q3w, intravenous infusion
215010220|NCT03770975|PROCEDURE|delayed implant placement with immediate provisionalization|delayed implant placement with immediate provisionalization
214404763|NCT06919510|DRUG|CAPOX (oxaliplatin/capecitabine)|Oxaliplatin 130 mg / m2, D1, intravenous infusion, q3w, Capecitabine 1000 mg / m2,twice a day, oral,1-14 days, then rest for 7 days, q3w.
214404764|NCT06919510|RADIATION|radiotherapy|5\* 5Gy, once a day, 5Gy each time, for 5 days
214404765|NCT06919510|PROCEDURE|Surgery or watch&wait|The surgical method is selected by the investigator. Watch and Wait (only for patients with clinical complete response after neoadjuvant therapy)
214404766|NCT06918496|DEVICE|Surgical placement of a prosthetic or biologic graft (patch), or an allograft for cardiac and (cardio)vascular repair.|"Suture line bleeding in cardiac and vascular reconstruction poses significant risks, including morbidity, mortality, and complications related to blood loss and transfusion. Advances in surgical techniques have improved hemostasis but may not suffice, especially in patients on anticoagulant or antiplatelet medications or those using synthetic graft materials.~Surgical adhesives are valuable adjuncts to standard hemostatic techniques, aiming to prevent postoperative bleeding and its associated complications. NE'X Glue R-eco, a novel surgical adhesive, utilizes recombinant human serum albumin (rHSA) and glutaraldehyde (GA) for suture line sealing. It is similar to BioGlue®, which uses bovine serum albumin (BSA) and GA, and has proven safety and benefits.~Distinguishing Features of NE'X Glue R-eco:~Composition: Uses rHSA expressed in plants, offering improved biocompatibility and reduced risk of allergic reactions.~Bonding Strength: Demonstrates high bonding strength in tests, comparab"
214404767|NCT06920264|DRUG|Tranexamic acid|A total of 150 participants will be enrolled and randomized 1:1 to receive either a standard dose of TXA (1000 mg) or an equivalent volume of placebo (normal saline, NS) at the time of surgery. .
214404768|NCT06920264|OTHER|placebo|saline
214404769|NCT06919146|BEHAVIORAL|Physical Activity|EG participated in AGPAP (4:00 pm-5:00 pm) twice a week, every Wednesday and Friday, for a total of 60 minutes, for 12 weeks. EG and CG did not participate in any additional physical activity programs after-school.
214404770|NCT06919263|BEHAVIORAL|Influencer marketing|Participants viewed survey-imbedded promotional images featuring influencers
214688301|NCT07163780|BEHAVIORAL|Traditional Therapy|Participants in this arm will receive conventional pediatric therapy, consisting of 12 weekly sessions of 45 minutes each. Sessions will focus on standard motor and sensory development exercises, delivered by a physical therapist experienced in pediatric rehabilitation.
214404772|NCT06918249|OTHER|No intervention|
214688302|NCT07163533|OTHER|wearble vibrotactile feedback sensor and kendel exercises|Wearable vibrotactile feedback sensor will be applied to the neck for assessment and management and secondly kendel exercises consisting of Strengthening of Deep Cervical Flexors, Stretching the Cervical Extensors, Strengthening Shoulder Retraction, Stretching the Pectoralis Muscle. each exercise will be given 3 days per week for 30 min each.
215010221|NCT03080714|DEVICE|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
215010222|NCT03080714|DEVICE|3D OCT-1 Maestro|The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
215010223|NCT03889262|OTHER|Hippotherapy|Hippotherapy is a therapeutic method in which a mechanical horse is used for therapeutic purposes.
215010224|NCT03889262|OTHER|Neurodevelopmental Therapy|Neurodevelopmental therapy (NDT) is a hands-on treatment approach used by physical therapists, occupational therapists, and speech-language pathologists. NDT was developed to enhance the function of children who have difficulty controlling movement as a result of neurological challenges, such as cerebral palsy and head injury. During treatment interventions, repeated experience in movement ensures that a particular pattern is readily accessible for motor performance. The more a patient performs certain movements, the easier these movements becomes.
215010225|NCT00088101|DRUG|STA-5312|
215010226|NCT01804335|DRUG|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
215010227|NCT01873833|DRUG|capecitabine|Given PO
215010228|NCT01873833|DRUG|cyclophosphamide|Given PO
215010229|NCT01873833|DRUG|lapatinib ditosylate|Given PO
215010230|NCT01873833|BIOLOGICAL|trastuzumab|Given IV
215010231|NCT01873833|OTHER|laboratory biomarker analysis|Correlative studies
215010232|NCT01272856|DRUG|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
215010233|NCT03398109|DEVICE|Customized toric IOL for post-DALK atigmatism|
215010234|NCT03055507|DRUG|Ibuprofen 400 mg|Addition of ibuprofen to standard pain regimen.
215010235|NCT03055507|DRUG|Acetaminophen 650 mg|Standard analgesic provided post-operatively to patients undergoing sinus surgery
215010236|NCT03055507|DRUG|OxyCODONE 5 Mg Oral Tablet|Standard PRN medication offered post-operatively for breakthrough pain
215010237|NCT05219786|BEHAVIORAL|Appendicitis Decision Support Tool|Viewing of a decision support tool.
215010238|NCT05219786|BEHAVIORAL|Control Infographic|Viewing of a standardized infographic
215010239|NCT03545581|OTHER|Experimental diet Fru rich diet|7 days (day 1 to day 7) with fructose enriched drinks 3x/d. Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
214404773|NCT06918106|BEHAVIORAL|Simple advice, Brief-counseling and brochure|"Participants assigned to the intervention group will receive simple advice plus brief counseling and health broacher and then they will be screened for alcohol consumption at 6 months and 12 months of follow-ups."
214404774|NCT06914557|DEVICE|Scrambler Therapy|Scrambler therapy will be administered by the staff of the Supportive Oncology and Palliative Care team who have been trained in Scrambler therapy and have extensive experience providing it to patients with neuropathic cancer-related pain. Patients who meet the study criteria will be treated daily, Monday through Friday, for up to 10 sessions. The treatment may be terminated sooner if a patient experiences complete pain relief or if it is ineffective after five sessions. Patients will be closely monitored during the treatment. The treatment is non-painful and not associated with any significant adverse effects.
215010240|NCT03545581|OTHER|Experimental low Fru diet|7 days (day 1 to day 7) with low-fructose diet (\<10g/d). Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
215010241|NCT04805788|RADIATION|Proton Stereotactic Body Radiation Therapy|Undergo SBPT
215010242|NCT04805788|OTHER|Quality-of-Life Assessment|Ancillary studies
215010243|NCT01467804|DRUG|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
215010244|NCT01467804|DRUG|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
215010245|NCT03983109|DEVICE|EpiFaith loss of resistance detect syringe|An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
215010246|NCT03428204|PROCEDURE|Balloon dilation during 180 seconds|Percutaneous angioplasty with balloon dilation during 180 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
215098071|NCT04190524|OTHER|Application of cricoid pressure|The study first involves recording a baseline image of the neck anatomy using ultrasound, which is a non-invasive, non-irradiating, non-painful imaging modality. Once the baseline anatomy has been imaged, conventional cricoid pressure will be applied with fingers and/or with the ultrasound probe itself and an image will be recorded. The force applied to the cricoid cartilage will be 30 newtons, as determined by a thin force measurement sensor (Tekscan flexiforce sensor) placed in between the patient's skin and the finger (or ultrasound probe).
215098072|NCT04190524|OTHER|Application of Left lateral paratracheal pressure|Next, left lateral paralaryngeal pressure will be applied at the level of the cricoid cartilage with fingers and/or the ultrasound probe itself, and the image will again be recorded. Left lateral paralaryngeal pressure will be 30 newtons, as determined by a thin force measurement sensor placed in between the patient's skin and the finger (or ultrasound probe).
215098073|NCT04891185|DRUG|Indocyanine green|Administration of the IMP: Indocyanine green, 0,25mg/kg of body weight, intravenous bolus injection
214404775|NCT06914557|OTHER|Questionnaire and Physical Exam|15-minute-long questionnaires evaluating Pain and degree of pain.
214404776|NCT06918444|DEVICE|WARIFA app with AI|"Participants will be given access to the WARIFA app on their mobile phones during the study.~This app will collect activity data as well as questionnaires and diaries. Using this data and artificial intelligence, it will provide participants with personalised information and recommendations about their lifestyle and risk of chronic non-communicable diseases."
214404777|NCT06918444|DEVICE|WARIFA app without AI|"Participants will be given access to the WARIFA app on their cell phones during the study.~This app will collect activity data, as well as through questionnaires and diaries. With this data, it will give information and general recommendations to the participants related to their lifestyle habits and risks of chronic non-communicable diseases, following the WHO guidelines. This version will not use artificial intelligence or personalized messages."
214404778|NCT06919848|DRUG|TORIPALIMAB INJECTION(JS001 )|Toripalimab will be administered by IV, 240 mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214404779|NCT06919848|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
214404780|NCT06919848|DRUG|H101|H101 will be percutaneously injected into tumor on day 1 of every 21-day cycle. Lenvatinib plus Toripalizumab will be administered 1-3 days after H101 injection.
214404781|NCT06919848|DRUG|FOLFOX|FOLFOX chemotherapy was administered intravenously every 2 weeks for a maximum of 12 cycles (oxaliplatin 85 mg/m², leucovorin, 400 mg/m2, fluorouracil 400 mg/m² \[bolus\], and fluorouracil 2400 mg/m² as a 46-h continuous intravenous infusion
214404782|NCT06920329|DRUG|Peginterferon α-2b based injection|Peginterferon α-2b injection, 180 μg administered subcutaneously in the abdomen or thigh once weekly, with regular follow-up for HBV recurrence. Patients will be followed up every 12 weeks.
215010247|NCT03428204|PROCEDURE|Balloon dilation during 300 seconds|Percutaneous angioplasty with balloon dilation during 300 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
215010248|NCT00195793|DRUG|fenofibrate|
215010249|NCT00195793|DRUG|ezetimibe|
215010250|NCT00195793|DRUG|atorvastatin|
215010251|NCT03899090|BEHAVIORAL|Float pool|Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
215010252|NCT03899090|BEHAVIORAL|Float chair|Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
215010253|NCT03977688|DEVICE|Cytokin Adsorption|Haemadsorption with Cytokin Adsorber (Cytosorb)
215098074|NCT01106274|RADIATION|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
214404783|NCT06918756|OTHER|Questionnaires|Completion of new questionnaire in addition to other patient reported outcome measures that measure cough severity and cough-related quality of life.
214404784|NCT06918756|OTHER|Focus group interviews|Semi-structured focus group interviews for patients with refractory chronic cough
214404785|NCT06918756|OTHER|Objective cough measures|Cough monitoring and cough sensitivity testing.
214404786|NCT06918600|OTHER|Virtual Reality-Supported Early Mobilization Program|"The intervention involves the use of a virtual reality (VR)-supported mobilization program specifically designed for patients recovering from open-heart surgery. Participants wear a VR headset that delivers guided sessions comprising:~Breathing Exercises: Deep breathing and coughing techniques to support respiratory function and prevent complications.~Lower Limb Exercises: Interactive movements aimed at improving circulation and preventing venous stasis.~Mobilization Strategies: Gradual and guided steps to assist patients in transitioning from bed to ambulation, tailored to their recovery stage.~This intervention is unique because it integrates an immersive and engaging digital environment to promote physical activity, reduce anxiety, and enhance motivation during the critical early postoperative phase. Unlike standard rehabilitation practices, the VR program provides real-time feedback and visual cues to ensure correct execution of movements."
214404787|NCT06917859|DRUG|Methylprednisolone group|In this study patients will be given a single intra-venous dose of methylprednisolone (2 mg/kg) after the induction of anesthesia, and before the initiation of CPB.
214404788|NCT06918652|PROCEDURE|Transmural ultrasound-guided gallbladder drainage|TUGD will be performed using the bi-flanged LAMSs mounted on an electrocautery-enhanced delivery system (Hot-AXIOS™) by an experienced endoscopist defined as \> 10 LAMS positioning per year. The diameter and length of the stent and the modality of placing the stent (under complete EUS view or with endoscopic or fluoroscopic guidance) will be chosen at the discretion of the endoscopist performing the procedure
214404789|NCT06918652|PROCEDURE|Laparoscopic cholecystectomy|LC will be performed by the four-trocar technique with transection of the cystic duct and cystic artery after reaching the critical view of safety. ELC will be performed by a surgeon trained and experienced in laparoscopic surgery defined as \> 5 laparoscopic procedures for ACC on a yearly basis
214404790|NCT06918288|DEVICE|High flow nasal canula|All patients assigned to the HFNC group will receive HFNC immediately after extubation. Researchers will need to choose the suitable size nasal catheter. The initial airflow will be set to 50 L/min and adjusted according to patient tolerance with an absolute humidity setting to 44 mgH2O/L and the temperature setting to 37 °C.The patient's respiratory rate will be maintained below 30 beats/min or the baseline level before extubation with a SpO2 at 88-92%. HFNC failure is defined as escalation to NIV or invasive mechanical ventilation due to respiratory failure.
214404791|NCT06918288|DEVICE|Non-invasive positive pressure mechanical ventilation|All patients assigned to the control group will receive NIV immediately after extubation. Researchers will use a standard oronasal mask to connect the patient to the ventilator. The patients will be on Spontaneous/Timed (S/T) mode, with the initial end-expiratory pressure setting to 4 cmH2O. The pressure level will gradually increase to ensure that the patients can trigger the ventilator with each inhalation. The initial inspiratory pressure will be set at 8 cmH2O and adjusted according to the tidal volume with 6-8 ml/kg and tolerance of patients. The pres- sure level and the fraction of inspiration oxygen will be adjusted in order to maintain the respiratory rate ≤ 30/ min or the baseline level before extubation, a partial pressure of carbon dioxide (PaCO2) at 45-60 mmHg or the last PaCO2 level recorded before extubation, and a pulse oxygen saturation at 88-92%. NIV treatment failure is defined as a return to invasive mechanical ventilation.
214404792|NCT06918678|DEVICE|Tai Chi intervention|The Tai Chi program was delivered virtually via Zoom by a certified Tai Chi instructor for 12 weeks. Tai Chi forms employed in the class was adapted from an evident-based fall prevention program - Tai Ji Quan: Moving for Better Balance. This program is a research-based Tai Chi balance training regimen. The program composed of core adapted Tai Chi movements and various therapeutic movements as well as breathing exercises
214404793|NCT06918678|OTHER|Usual care condiition|In the usual care condition, the investigators requested that participants maintain their regular activities during their time in the usual care condition. The participants were encouraged to refrain from Tai Chi, but not prohibited from engaging in Tai Chi, in the usual care period.
214404794|NCT06036381|DIAGNOSTIC_TEST|Radiomic analysis of imaging - MRI, PET, CT|Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.
214404795|NCT04308551|DRUG|Indobufen|Indobufen Tablets
214404796|NCT04308551|DRUG|Aspirin|Aspirin Tablets
214404797|NCT06914193|DRUG|esketamine+PRF treatment group|In the esketamine group, in addition to receiving PRF treatment+pregabalin, patients will also undergo a single intravenous infusion of esketamine.
214404798|NCT06914193|DRUG|PRF treatment group|In the control group, patients will receive PRF treatment. PRF will be performed on DRG by an designated physician in each participating center. The patients will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which will be carefully inserted until the needle tip reached the upper edge of the intervertebral foramen under the guidance of three-dimensional (3D) CT. PRF treatment (PMG-230, Baylis Medical Inc.) targeting to DRG will be applied for 900 seconds. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. Regarding pregabalin, the dosage is titrated based on patients'pain intensity and tolerance. This process fully accounts for individual patient differences to optimize treatment outcomes.
214404799|NCT06913335|PROCEDURE|laparoscopic ovarian cystectomy using hemostatic sealant|"* A small incision will be made on the ovarian surface using laparoscopic scissors.~* Nontraumatic grasping forceps will be used to dissect the cyst capsule away from the soft tissue of the ovary.~* The cyst will be removed intact to avoid spillage of its contents. If rupture occurs, the peritoneal cavity will be irrigated thoroughly.~* After the removal of the cyst, the ovarian bed should be inspected for bleeding, and if there is minimal bleeding, using of electrocautery should be avoided to minimize thermal damage to the ovary.~* The hemostatic sealant as Surgicel original, Surgicel Fibrillar (ETHICON, USA) which is an absorbable hemostat (oxidized regenerated cellulose) will be applied directly to the bleeding surface 1:5sheets of hemostat will be used."
214404800|NCT06913335|PROCEDURE|laparoscopic ovarian cystectomy using electrosurgical energy|"A small incision will be made on the ovarian surface using laparoscopic scissors.~* Nontraumatic grasping forceps will be used to dissect the cyst capsule away from the soft tissue of the ovary.~* The cyst will be removed intact to avoid spillage of its contents. If rupture occurs, the peritoneal cavity will be irrigated thoroughly.~* After the removal of the cyst, the ovarian bed should be inspected for bleeding, and if there is minimal bleeding, using of electrocautery should be avoided to minimize thermal damage to the ovary In the electrosurgical energy using group the hemostasis method will be different and will be achieved using electrosurgical energy.~* After the cyst removal and cyst bed examination, any bleeding will be carefully coagulated using bipolar electrosurgical energy~* Minimal energy will be applied for short durations to reduce collateral thermal"
214404801|NCT06920563|OTHER|Video|Those in the intervention arm will watch a short educational video.
214404802|NCT06920563|OTHER|Text Reminder|Those in the intervention group will receive regular text message reminders to check their blood pressures
214404803|NCT06920563|OTHER|Blood pressure threshold|Those in the intervention group will have a lower blood pressure threshold to titrate their BP medications towards
214404804|NCT06918314|DEVICE|Blood Flow Restriction Kaatsu Training Device|"The Blood Flow Restriction (BFR) intervention uses a pneumatic cuff to partially restrict arterial and fully restrict venous blood flow, creating a hypoxic environment that enhances muscle activation and strength at low exercise intensities. In this study, BFR will be applied intermittently during low-intensity treadmill walking with controlled pressure adjustments.~The Moxy Muscle Oxygen Monitor is a non-invasive NIRS device that measures muscle oxygen saturation (SmO₂) and total hemoglobin (THb). Placed on the quadriceps femoris muscle, it will track oxygenation changes before, during, and after BFR exercise, helping assess muscle metabolism and performance adaptations."
214404805|NCT06919302|BEHAVIORAL|Digital Heart Health Program|The digital heart health program will include the web-based app, which will deliver the intervention through interactive features (dashboard, goal setting, gamification, nudges, etc.) and will be supported by a 16-session synchronous online behaviour change program and provision of key study foods.
214404806|NCT06224270|BIOLOGICAL|Adjuvanted Recombinant Zoster Vaccine (RZV)|The RZV vaccine is indicated for prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ. Patients with IBD on immunosuppressive therapy are at increased risk for HZ.
214404807|NCT05988489|BEHAVIORAL|Dynamic Deconstructive Psychotherapy (DDP)|DDP treatment with an assigned therapist for up to 12 months
214404808|NCT05988489|BEHAVIORAL|Brief Intervention and Contact (BIC)|BIC treatment with an assigned therapist for up to 12 months
214404809|NCT04666454|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 3 hours.
214504679|NCT07090252|OTHER|Group II zinc oxide eugenol|preperation: 1\\ A standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove coronal pulpal tissues then will remove radicular pulp by barbed broach then will be used K files for chemo mechanical preparation (size 15,20,25) with saline (2%) irrigation to remove necrotic pulp tissues then all the canals will be dried using paper points 2\\ After complete removed of coronal and radicular pulp zinc oxide eugenol will be manipulated in the ratio of 3:1 (powder: liquid) to obtain semisolid mix.This mix will be placed in the canals. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of Zinconol.3\\ Tooth will be restored with stainless steel crown.
214504680|NCT04425473|DRUG|Esketamine|Esketamine will be administrated intravenously when suturing incision, with total dose of 0.2mg/kg and continuous infusion for 40 minutes.
214504681|NCT04425473|DRUG|Normal saline|Equivalent amount of normal saline will be administrated intravenously suturing incision.
215010254|NCT03893708|BEHAVIORAL|Prenatal yoga|The prenatal yoga classes will be offered at Urban Wellness (2024 N. 7th St., Phoenix, AZ 85006). Classes will be offered Tuesdays's from 4:15-5:30 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
215098075|NCT04877769|DRUG|AT-527|administered twice daily (BID) for 2.5 days (5 doses in total)
215098076|NCT01008462|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
215098077|NCT01008462|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
215098078|NCT01008462|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
215098079|NCT01008462|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
215098080|NCT01008462|DRUG|Carmustine|Given IV
214404810|NCT04666454|DRUG|Dipyridamole 200 mg|200 mg b.i.d
214404811|NCT04666454|DRUG|Apixaban 5 mg Oral Tablet|5mg b.i.d
214404812|NCT04666454|OTHER|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome|This treatment will vary depending on local routines and the degree of adherence to the recommendations.
214404813|NCT03621553|DRUG|Ergocalciferol|Vitamin D2 50,000 units
214404814|NCT03621553|DRUG|Placebo|Sugar pill manufactured to mimic ergocalciferol 50,000 units
214404815|NCT03621553|DRUG|Calcium Citrate with Vitamin D2|To meet the recommended minimum daily dietary requirements
214404816|NCT01266044|PROCEDURE|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
214404817|NCT01266044|PROCEDURE|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
214404818|NCT01266044|OTHER|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
215098081|NCT01008462|DRUG|Cyclophosphamide|Given IV
215098082|NCT01008462|DRUG|Cytarabine|Given IV
214404819|NCT01266044|OTHER|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
214404820|NCT05737550|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
214404821|NCT00125151|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|
214404822|NCT04465890|DRUG|ASC22|200mg/1ml/1bottle
214404823|NCT04465890|DRUG|sodium chloride|90mg/10ml/1 bottle
214404824|NCT03395587|BIOLOGICAL|Autologous, tumor lysate-loaded, mature dendritic cells (DC)|Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
214404825|NCT03395587|DRUG|standard therapy|temozolomide, fractionated radiochemotherapy
214404826|NCT04091672|PROCEDURE|Control Intervention (Conventional Autograft)|Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)
214404827|NCT04091672|DEVICE|Investigational Intervention (RECELL + more widely meshed autograft)|More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
214404828|NCT03416218|BEHAVIORAL|Prognosis|Prognosis will be a single-player 2D, digital simulation game and supporting multimedia website. Players are situated as a major official of Hexacago, and tasks them with managing the city's finances, education levels, and health concerns to lower rates of teenage pregnancy and sexually transmitted infections. In the game Prognosis, player dispatches professionals from a variety of fields to different neighborhoods around the city, observing the effects of their resource allocation decisions across multiple systems over many in-game months. The supporting multimedia website will house curriculum and learning tools to support the learning objectives of Prognosis.
214404829|NCT04709731|DRUG|Ponatinib 15mg QD|Ponatinib 15 mg tablet, taken orally once daily
214404830|NCT04709731|DRUG|Ponatinib 30mg QD|Ponatinib 30 mg tablet, taken orally once daily
214404831|NCT06403644|DEVICE|NovoTHOR XL Photobiomodulation Full Body Light Bed|Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of \~30 mW/cm\^2.
214404832|NCT06403644|DEVICE|ARRC LED Photobiomodulation Full Body Light Bed|High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of \~75 mW/cm\^2.
214404833|NCT03037060|OTHER|[11C]-(+)-PHNO PET scan|PET scan
214404834|NCT03037060|OTHER|Alcohol Self-Administration|Session for assessing motivation for consuming alcohol.
214404835|NCT03037060|OTHER|Craving Task|Cue exposure paradigm
214404836|NCT03037060|OTHER|MRI scan|MRI scan scan to analyze the PET data will be administered.
214504682|NCT06482814|BEHAVIORAL|Partial sleep deprivation (sleep restriction)|During the experimental segment the sleep opportunity will be restricted to 5 hours/night. During the acclimation and recovery phases a 9-hour/night sleep opportunity will be provided.
215010255|NCT03893708|BEHAVIORAL|Pregnancy education|Pregnancy education classes will be offered at the Arizona Biomedical Collaborative Building on ASU Phoenix Campus. Classes will be offered on Tuesday's from 5:30-6:45 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
215010256|NCT02867488|OTHER|Soybean oil in salad dressing|
215010257|NCT02322515|OTHER|Intervention taping|A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
215010258|NCT02322515|OTHER|Placebo Taping|A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
214404837|NCT03037060|OTHER|Neuropsychological Assessment|Cognitive questionnaires administered over course of study.
214404838|NCT05296629|DRUG|DFD-29|DFD-29 (40 mg) extended release capsules
214404839|NCT05296629|DRUG|Doxycycline|Doxycycline 40 mg capsules
214404840|NCT05296629|DRUG|Placebo|Placebo capsules
214404841|NCT03720015|BEHAVIORAL|Physical exercise|Physical exercise controlled program supervised by an accredited exercise specialist
214404842|NCT03720015|DIETARY_SUPPLEMENT|Nutritional management|Nutritional management controlled by a PhD clinical and sport nutrition specialist
214504683|NCT06482814|BEHAVIORAL|Normal sleep|During the normal sleep condition a 9-hour/night sleep opportunity will be provided throughout the 10-day inpatient visit.
215010259|NCT04583826|DEVICE|CAVA|CAVA is a medical device containing 5 face-mounted ECG electrodes which are used to record the movement of the eyes.
215010260|NCT00907114|DRUG|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
215010261|NCT00907114|DRUG|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
215098083|NCT01008462|DRUG|Etoposide|Given IV
215098084|NCT01008462|DRUG|Fludarabine Phosphate|Given IV
215098085|NCT01008462|OTHER|Laboratory Biomarker Analysis|Correlative study
215098086|NCT01008462|DRUG|Melphalan|Given IV
215098087|NCT01008462|DRUG|Mycophenolate Mofetil|Given PO
215098088|NCT01008462|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
215098089|NCT01008462|DRUG|Tacrolimus|Given IV or PO
215098090|NCT01008462|RADIATION|Total-Body Irradiation|Undergo TBI
214404843|NCT02272023|BEHAVIORAL|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
214404844|NCT02272023|BEHAVIORAL|Single session of Motivational Interviewing|
214404845|NCT01579656|DIETARY_SUPPLEMENT|Salba|25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
214404846|NCT01579656|DIETARY_SUPPLEMENT|Poppy|25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
214404847|NCT01579656|DIETARY_SUPPLEMENT|Flaxseed|25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
214404848|NCT01579656|DIETARY_SUPPLEMENT|Sesame|25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
214404849|NCT01579656|DIETARY_SUPPLEMENT|Wheat Bran|Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
214404850|NCT04330443|PROCEDURE|Surfactant therapy|To study if lung ultrasound allows an earlier surfactant therapy (within the first 2 hours of life) compare to FiO2 and Chest X Ray
214404851|NCT04925050|DRUG|VB0004|Each study part (A,B and C) will be completed sequentially or with partial overlapping. Safety and PK data through at least day 8 from a subsequent cohort will be reviewed by the SMC prior to dosing the fed period of FE cohort. Safety data will be assessed by SMC after completing each cohorts in MAD healthy volunteers and MAD mild Hypertension patients.
214404852|NCT04925050|OTHER|Matching Placebo for VB0004|Matching Placebo
214404853|NCT03739879|DEVICE|Inspiratory Muscle Trainer Philips Respironics|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
214404854|NCT06256302|PROCEDURE|Transverses Abdominis Plane Block|Transverses abdominis plane block will be provided randomly using prospective double-blinding.
214404855|NCT06256302|PROCEDURE|Local wound infiltration|Local wound infiltration will be provided randomly using prospective double-blinding.
214404856|NCT06477939|DRUG|Administration of L-TC|"Administration of L-TC (300 mg) as an IV perfusion, before each radiotion session~Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~\+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."
214404857|NCT06477939|OTHER|Radiotherapy plus Temozolomide|"Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~\+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."
214404858|NCT06309043|DRUG|recombinant anti-EGFR human/murine chimeric monoclonal antibody injection|a single dose，250 mg/m2
214404859|NCT02600429|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
214404860|NCT02600429|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
214404861|NCT05311475|DRUG|Mometasone|Mometasone furoate nasal spray (50 mcg per actuation)
214404862|NCT05311475|DRUG|Azelastine|Azelastine hydrochloride nasal spray (140 mcg per actuation)
214404863|NCT05311475|DRUG|Placebo|Placebo nasal spray
214404864|NCT05245656|DRUG|RB/RBAC alternating|"Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4"
214404865|NCT05245656|DRUG|RB|"Every 4 weeks for 6 cycles~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2"
214404866|NCT05924893|DRUG|Naltrexone Hydrochloride|naltrexone film
214404867|NCT05924893|DRUG|Carboxy methyl cellulose|Carboxy methyl cellulose drops
214404868|NCT00142064|BEHAVIORAL|observed levels of pain|
214404869|NCT03746275|DRUG|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
214404870|NCT03746275|DRUG|Acetylsalicylic acid|75 - 100 mg once daily according to local label
214404871|NCT05629598|BIOLOGICAL|Recombinant human erythropoietin injection|The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).
214404872|NCT05629598|BIOLOGICAL|Human erythropoietin injection|Refer to the product instructions
214504684|NCT06821451|DEVICE|Bronchoscopic navigation robot|Preoperative CT data creates a 3D image of the lung anatomy to plan the navigation path. The surgeon controls the robotic arm in real-time to reach staining marker points for pulmonary nodule localization. After placing the staining catheter in the working channel, 1 ml of indocyanine green is injected at the site. Then the patient is positioned laterally for video-assisted thoracoscopic surgery for nodule resection, initially focusing on sub-lobar resection. More extensive resection is determined based on intraoperative frozen section results.
214404873|NCT03427229|BIOLOGICAL|Single-infusion FMT|Patients will receive a single fecal infusion by colonoscopy
214688303|NCT07163533|OTHER|kendel exercises|kendel exercises consisting of Strengthening of Deep Cervical Flexors, Stretching the Cervical Extensors, Strengthening Shoulder Retraction, Stretching the Pectoralis Muscle. each exercise will be given 3 days per week for 30 min each.
214404874|NCT03427229|DRUG|Vancomycin (before randomization)|Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
214404875|NCT03427229|BIOLOGICAL|multiple-infusion FMT|Patients will receive multiple fecal infusions by colonoscopy
214404876|NCT02401529|DRUG|IV dexamethasone|0.15 mg/kg
214404877|NCT02401529|DRUG|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
214404878|NCT02401529|DRUG|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
214404879|NCT02401529|DRUG|IV saline|IV saline
214404880|NCT01414036|OTHER|Enhanced Traditional Care control|Educational brochure, list of hospital and community resources
214404881|NCT01414036|BEHAVIORAL|Patient navigation|Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
214404882|NCT02182882|DRUG|GINSANA|
214404883|NCT02182882|DRUG|Placebo|
214404884|NCT00323089|PROCEDURE|microcoil insertion and excision|The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
214404885|NCT03688295|OTHER|No antibiotics|Patients will not receive antiobitherapy post surgery for CAA
214404886|NCT03688295|DRUG|Antibiotics|Patients will receive antiobitherapy post surgery for CAA
214404887|NCT05404113|OTHER|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 minutes/session Type: Mobilization with movement SNAG Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
214404888|NCT05404113|OTHER|deep friction massage|Cyriax deep friction massage+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 20 minutes/session Type: Deep soft tissue massage Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
214404889|NCT05373290|OTHER|there is no intervention in the study|there is no intervention in the study
214404890|NCT03324685|DRUG|BIIB074|BIIB074 is administered as specified in the treatment arm.
214404891|NCT03324685|DRUG|OC (ethinyl estradiol and levonorgestrel)|OC is administered as specified in the treatment arm.
214404892|NCT05219045|OTHER|Ohio RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an active comparator that is not.
214404893|NCT05626283|DRUG|transforaminal epidural injection.|transforaminal epidural steroid injection.
214404894|NCT05626283|OTHER|micro RNA-155 serum level|Estimation of miR-155 expression level:
214404895|NCT01394770|DRUG|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
215010262|NCT02068599|DRUG|TV-45070|TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
214404896|NCT06500949|PROCEDURE|Vagus Nerve Pulmonary Branch Block|Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of 0.375% ropivacaine was administered in close proximity to the targeted vagal branch.
214404897|NCT06500949|PROCEDURE|Vagus Nerve Pulmonary Branch Injection|Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of normal saline was administered in close proximity to the targeted vagal branch.
214404898|NCT00563277|PROCEDURE|combined pterygium and cataract operation|
214404899|NCT00563277|PROCEDURE|pterygium excision followed by cataract operation|
214404900|NCT02201030|BIOLOGICAL|NBP606|A single intramuscular injection into the thigh
214688304|NCT07163585|DRUG|Brivaracetam|Brivaracetam was initiated at a dose of 1-2 mg/kg/day in two divided doses, titrated to a maximum of 5 mg/kg/day based on clinical response and tolerability.
215098091|NCT03377933|OTHER|Compound Lactobacillus acidophilus|Compound Lactobacillus acidophilus Tablet
214404901|NCT02201030|BIOLOGICAL|Prevnar13|A single intramuscular injection into the thigh
214404902|NCT06376890|DIETARY_SUPPLEMENT|Red chili peppers|2.4 grams/day of powdered red chili pepper
214404903|NCT06376890|DIETARY_SUPPLEMENT|Green Chili Pepper|2.4 grams/day of powdered green chili peppers
214404904|NCT06376890|DIETARY_SUPPLEMENT|Placebo|2.4 grams of a metabolically equivalent placebo
214404905|NCT05507697|BIOLOGICAL|HUC-MSCs|5 × 10\^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb
214404906|NCT05507697|BIOLOGICAL|Lipoic Acid|Lipoic Acid Injection，600 mg/d for 15 consecutive days
214404907|NCT00175240|BEHAVIORAL|Evidence summaries endorsed by local opinion leaders|
214404908|NCT01618331|BEHAVIORAL|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
214404909|NCT01618331|DIETARY_SUPPLEMENT|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
214404910|NCT00031291|DRUG|Anthrax Immune Globulin|
214404911|NCT04580654|BIOLOGICAL|CSL312|Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa
214404912|NCT04764019|DIAGNOSTIC_TEST|High resolution intestinal manometry|Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
214404913|NCT00961805|BEHAVIORAL|Dance|Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
214404914|NCT00961805|OTHER|Control Group|The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
214404915|NCT05218603|DRUG|Bortezomib|Maintenance: Administration as per routine clinical practice.
215010263|NCT02068599|DRUG|Placebo|Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
215010264|NCT02282384|DRUG|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
215098092|NCT06308250|OTHER|MIME THERAPY|"Mime therapy consist of:~Self massage: patients will be taught to massage their face and neck daily for about 10 minutes which includes effleurage and kneading of both sides of face.~Breathing exercises: patient will be taught to recognize tension and feel the difference between tension and relaxation in facial musculature for 5 minutes. Expiration exercises will be used to induce relaxation.~Articulation: vowels such as a,e,i,o,u and consonants such as p and b will be used to teach position of the lips for 5 minutes.~Facial expression exercises: forehead wrinkle, smiling, eye closure, frowning, disgust, surprise, anger, sadness will be performed for 10 minutes"
215010265|NCT02282384|OTHER|Placebo|
215010266|NCT00632970|DRUG|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
215010267|NCT00632970|DRUG|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
215010268|NCT00632970|DRUG|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
215010269|NCT02959606|DRUG|Sarpogrelate SR 300mg|
215098093|NCT06308250|OTHER|ACTION OBSERVATION THERAPY|"Function of each of the muscle is observed for 3 minutes and then executed for 2 minutes.~Frontalis (Raising eyebrows and forehead wrinkling). Corrugator Supercili (Moving the eyebrow down and inward toward the nose and inner eye).~Orbicularis oculi (Closing the eyelids). Buccinator (Blowing air in and out of the mouth). Zygomaticus major (Smiling). Orbicularis oris (Lip pursing or puckering)."
215098094|NCT05718960|OTHER|Reassurance-alone|To be informed of the absence of organic disease and provided a diagnostic explanation of functional dyspepsia
215098095|NCT05718960|BEHAVIORAL|Traditional dietary advice|To receive the same information as reassurance-alone group but also recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre
215098096|NCT04133194|DRUG|Mesalazine|1600 mg Asacol \[mesalazine\]
215098097|NCT04133194|DRUG|Mesalazine|800 mg Asacol \[mesalazine\]
215098098|NCT00775333|PROCEDURE|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
215098099|NCT04284774|DRUG|Tipifarnib|Tipifarnib tablets
215098100|NCT01242566|DRUG|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
214404916|NCT05218603|DRUG|Daratumumab|Maintenance: Administration as per routine clinical practice.
214404917|NCT02688972|OTHER|cold water immersion|The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
214404918|NCT02688972|OTHER|Control group|The volunteers stayed in rest about 10 minutes
214504685|NCT06821451|DEVICE|Conventional electromagnetic navigation bronchoscope|Based on preoperative CT data, a three-dimensional image of the virtual bronchi is created to plan the navigation path, and manual registration is completed by selecting registration points using a conventional electromagnetic bronchoscope. After registration, the target position is reached under the guidance of the magnetic navigation positioning system, and when the positioning sensor indicates that it has arrived at the staining marker point, a staining catheter is inserted through the working channel to inject 1 ml of indocyanine green at the marker site, followed by thoracoscopic resection of the pulmonary nodule.
215010270|NCT02959606|DRUG|Clopidogrel|
215010271|NCT01871727|DRUG|E7777 9 mcg/kg|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
215010272|NCT01204372|DRUG|Gemcitabine - Trastuzumab - Erlotinib|"Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~* Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~* Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~* Erlotinib: oral route 100 mg/day from C1D1."
214404919|NCT02824289|BEHAVIORAL|Sun Safe Workplaces Program|The intervention began by sending a Program Announcement Packet and requesting the first face-to-face meeting. At the first meeting, intervention staff covered: 1) Introduction to SSW; 2) Sun Safety Practices in the Workplace; 3) Sun Safety Policy for Outdoor Workers; 4) Sun Safety Policy Adoption; 5) Sun Safety Policy Reinforcement and Maintenance. They presented the SSW Website and a Sun Safety Tool Box. Following the first meeting, the manager scheduled Sun Safety Training by intervention staff with various employee groups. Workplace Sun Safety Materials were sent in four sets (twice a year over two years) for distribution to employees. Research staff made monthly Follow-up Contacts with managers.
214404920|NCT02824289|BEHAVIORAL|Attention Control|Research staff sent printed materials on occupational sun safety to local government organizations twice. These included posters with personal protection messages and skin cancer rates, risk assessment brochures, worksite guides, total skin self-examination CD-Rom, the American Academy of Dermatology SPOT bookmark, and a sun safety tip card from the Occupational Safety and Health Administration (OSHA). Staff made presentations on general sun safety topics (not policy) at state professional conferences.
214404921|NCT02074566|OTHER|Cryoballoon ablation|PVI using cryoballoon
214404922|NCT02746900|PROCEDURE|Cervical cerclage|McDonald cervical cerclage
215010273|NCT01263028|DRUG|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
215010274|NCT00309244|DRUG|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
215010275|NCT00309244|DRUG|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
215010276|NCT03019588|BIOLOGICAL|Pembrolizumab|IV infusion
215010277|NCT03019588|DRUG|Paclitaxel|IV infusion
215010278|NCT04291833|BEHAVIORAL|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
215010279|NCT04291833|BEHAVIORAL|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
215010280|NCT04291833|BEHAVIORAL|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
215010281|NCT00501085|DEVICE|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
215098101|NCT01344720|DRUG|etoricoxib|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die."
214404923|NCT03089346|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
214404924|NCT03089346|DIAGNOSTIC_TEST|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
215010282|NCT03849456|DRUG|GWP42006|Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
215010283|NCT00430859|DRUG|Alkaline Phosphatase|Intravenous over a period of 24 hours
215010284|NCT00430859|DRUG|Placebo|Saline over a period of 24h
215010285|NCT04026516|DEVICE|CAVA Device|The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
215010286|NCT03898609|OTHER|Dietary intervention|3 weeks
215010287|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
215010288|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
215010289|NCT00290420|DRUG|Chloroquine profilaxis|"Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
215010290|NCT01468961|BEHAVIORAL|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
215010291|NCT00366535|DRUG|Placebo|4 tabs b.i.d.
215010292|NCT00366535|DRUG|Neurotropin|4 tabs b.i.d.
215010293|NCT06507865|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Patients presenting with thoracic vascular disease that may benefit from the placement of TBE device. The target registry population is patients who are treated with TBE at participating sites. TBE treatment is qualified as receiving the TBE aortic component, at a minimum.
215010294|NCT00106535|DRUG|tocilizumab [RoActemra/Actemra]|4 mg/kg or 8 mg/kg IV/month every 4 weeks.
215010295|NCT00106535|DRUG|Placebo|IV/month
215010296|NCT00106535|DRUG|Methotrexate|10-25 mg/week
215010297|NCT02958527|DRUG|venlafaxine|The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.
215010298|NCT00004083|DRUG|cisplatin liposomal|
215098102|NCT01344720|DRUG|oxycodone|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy)."
215098103|NCT05622214|DIETARY_SUPPLEMENT|Else nutrition formula|Plant based nutrition from almond and buckwheat
215098104|NCT00224341|DEVICE|Pacemaker Vitatron Selection 9000|
215098105|NCT00224341|DEVICE|Pacemaker Vitatron T70|
214688305|NCT07163585|DRUG|Levetiracetam|Levetiracetam was initiated at a dose of 10-20 mg/kg/day in two divided doses, with gradual escalation up to 60 mg/kg/day if needed.
215098106|NCT01270256|DRUG|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
215098107|NCT01270256|DRUG|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
215098108|NCT00493961|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
215098109|NCT04956588|COMBINATION_PRODUCT|surgical robot|The surgical robot completed the screw placement according to the surgical plan, and the researchers closely monitored the screw placement process.
215098110|NCT04956588|COMBINATION_PRODUCT|controlled approach|The screw placement was performed using a controlled approach according to the surgical plan.
215098111|NCT03408210|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
215098112|NCT03408210|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
215098113|NCT02879578|DRUG|Valbenazine|
215098114|NCT03842072|DEVICE|Cervical collar|cervical collars prescribed will be use immediately following anterior cervical discectomy and fusion surgery.
215098115|NCT06530719|DRUG|Osimertinib mesylate|Osimertinib mesylate , 80mg QD，until the duration of treatment reaches 3 years, the disease progresses, or other treatment termination criteria are met
214688306|NCT07162441|DRUG|treatment A|UIC202502 1 Tab/day for 7 days
214688307|NCT07162441|DRUG|treatment B|UIC202505 1 Tab/day for 7 days
214688308|NCT07162441|DRUG|treatment C|UIC202502+UIC202505 2 Tab/day for 7 days
214688309|NCT07162220|OTHER|The clinic's routine education program|As part of the clinic's routine education program, information about kidney function, CKD, nutrition, exercise, medications, and stress management is provided verbally by a nephrology clinic nurse in approximately 20 minutes.
215098116|NCT00468403|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
215098117|NCT00468403|BIOLOGICAL|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
215010299|NCT02706548|BEHAVIORAL|Integrative Medication Self Management (IMedS) Intervention|Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
215010300|NCT02706548|BEHAVIORAL|Standard Care Educational Intervention|The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association \& American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
215010301|NCT04076215|BEHAVIORAL|Stressogenic stimulus|Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting
214404925|NCT01293461|DRUG|CBX129801|Subcutaneous injection
214404926|NCT01293461|DRUG|Placebo|Subcutaneous injection
215010302|NCT04076215|DEVICE|Biobeat smart watch and adhesive biosensor patches.|Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.
214404927|NCT02949271|OTHER|Programmed Intermittent Epidural Bolus|
214404928|NCT02949271|OTHER|Continuous Epidural Infusion|
214404929|NCT02949271|DRUG|Ropivacaine|
214404930|NCT02949271|DRUG|Fentanyl|
214404931|NCT05448261|BEHAVIORAL|Emotion-centered problem-solving intervention (EPi)|"The EPi is built upon the model of relational/problem-solving model of stress and is aimed at supporting caregivers in (1) revisiting stressful caregiving and associated problem from a psychological distanced perspective; (2) adopting problem orientation toward one's experience in the present moments with curiosity, openness and acceptance; and (3) applying the problem-solving skills learned for the enhancement of their psychosocial wellbeing in the stressful caregiving context. To reduce the incongruence between caregivers and stroke survivors in problem-solving, we will adopt a shared problem, shared action plan approach for the family caregivers and stroke survivors."
214404932|NCT05448261|OTHER|stroke education|Information is related to stroke and recurrent stroke and strategies for assisting stroke survivors in day-to-day activities.
214404933|NCT06500286|DRUG|Marciane|Group A caudal block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
214404934|NCT06500286|DRUG|Marcaine|Dorsal penil block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
214404935|NCT04094012|DRUG|isoniazid and rifapentine|This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
215098118|NCT00468403|BIOLOGICAL|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
215098119|NCT00468403|DRUG|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
214404936|NCT01684046|DEVICE|Opti-Free® PureMoist® MPDS|
214404937|NCT01684046|DEVICE|RevitaLens MPDS|
215010303|NCT03092037|PROCEDURE|Blood draw|The Investigators will collect serum and whole blood from participants.
215010304|NCT04607616|BEHAVIORAL|Baseline sessions TAU|TAU consists of sessions lasting around one/one and a half hour ; the consultant is practicing as usual. The interventions focus on child's behavior, parent infant relationship, with moments of play with the child, advices, informations about child development and Autism.
214404938|NCT01684046|DEVICE|Habitual Contact Lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
214404939|NCT04878042|DEVICE|Hydrogen peroxide|Mouth wash and nasal spray 3 times a day for 3 days
214404940|NCT04878042|DEVICE|Placebo|Mouth wash and nasal spray 3 times a day for 3 days
214404941|NCT03893591|DIAGNOSTIC_TEST|Anti Xa levels|one Blood sample
214404942|NCT04074551|DRUG|HCP1701|HCP1701
214404943|NCT04074551|DRUG|Losartan|Losartan
214404944|NCT04074551|DRUG|Amlodipine|Amlodipine
214404945|NCT04074551|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin and Ezetimibe
214404946|NCT02817633|DRUG|TSR-022|TSR-022 will be administered.
214404947|NCT02817633|DRUG|Nivolumab|Nivolumab will be administered.
214404948|NCT02817633|DRUG|TSR-042|TSR-042 will be administered.
214404949|NCT02817633|DRUG|TSR-033|TSR-033 will be administered.
214404950|NCT02817633|DRUG|Docetaxel|Docetaxel will be administered.
214404951|NCT02817633|DRUG|Pemetrexed|Pemetrexed will be administered.
214404952|NCT02817633|DRUG|Cisplatin|Cisplatin will be administered.
214404953|NCT02817633|DRUG|Carboplatin|Carboplatin will be administered.
214404954|NCT00082485|DRUG|Baclofen|Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)
214404955|NCT00082485|OTHER|Placebo|Placebo
214404956|NCT01131247|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
215010305|NCT04607616|BEHAVIORAL|Interactive guidance therapy|"The objective is to reinforce the identification, deciphering, interpretation, and answer to child's signals by the parent, in order to to promote a synchronous and attuned response to the child's needs.~Sessions last around one/one and a half hour. Parent plays 7-10 minutes with the child, in the presence of the therapist, with toys chosen according to the child's developmental stage. Then therapist proposes an immediate viewing of the play session. The therapist selects short moments of positive interaction. He has determined a  focus , depending on the play, previous sessions, the child's difficulties and parent's interventions. He accompanies, guides and supports the parent to describe the interaction, the alternance in play, joint attention, shared affect, in a co-construction: the parent discovers the child's and his own skills."
214404957|NCT00279474|BEHAVIORAL|cognitive-behavior groups|
215010306|NCT04607616|DIAGNOSTIC_TEST|Developmental and diagnostic assessments|MSEL, CARS, ECAR, CIM10, DMS5, ADOS, ADIR
214404958|NCT03756389|DRUG|BMX-010|Safety and efficacy of BMX-010 in topical treatment of rosacea.
214404959|NCT00984178|OTHER|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
214404960|NCT00984178|OTHER|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
214404961|NCT01359137|BEHAVIORAL|Probation as usual|Routine probation with do deferred jail condition.
214404962|NCT01359137|BEHAVIORAL|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
214404963|NCT01359137|BEHAVIORAL|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
214404964|NCT01386086|DRUG|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
214404965|NCT02161510|DRUG|MK-2248|MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
214404966|NCT06199687|OTHER|Use of Virtual Reality|Use of Virtual Reality after After Thyroid-Parathyroid Surgery
214404967|NCT04358861|PROCEDURE|Nonsurgical Root canal therapy|After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.
215010307|NCT04607616|BEHAVIORAL|Developmental assessment -Parental scales|Vineland II, IFDC, IDE
215010308|NCT04607616|BEHAVIORAL|Qualitative analysis|Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).
215010309|NCT06196827|GENETIC|LX101|Subretinal Administration
215010310|NCT04317846|OTHER|Intravenous administration of vasodilatory drugs|Administration of the vasodilatory drugs in a different pattern than intra-arterially
215010311|NCT00962455|OTHER|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
215010312|NCT00962455|OTHER|usual practice|Usual practice regarding spirometry execution in family practice
215098120|NCT00468403|DRUG|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
215098121|NCT00468403|PROCEDURE|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant\[s\]) will occur intraportally.
215098122|NCT03806075|BEHAVIORAL|Second generation sequencing|Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
215098123|NCT03806075|BEHAVIORAL|16s rRNA gene sequencing|Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
215098124|NCT05856565|OTHER|Photo|Photography intake
214404968|NCT04358861|DEVICE|Dental operating microscope|Dental operating microscope; a high magnification and illumination device was used in experimental group for performing nonsurgical root canal therapy.
214404969|NCT05458102|DRUG|Vesatolimod|Administered orally
214404970|NCT05458102|DRUG|Cobicistat|Administered orally
214404971|NCT05458102|DRUG|Voriconazole|Administered orally
214404972|NCT05458102|DRUG|Rifabutin|Administered orally
214404973|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks.
214404974|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 12 weeks.
214404975|NCT00668174|BEHAVIORAL|Exercise|Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
214404976|NCT05428436|DRUG|BI 1015550 ICF|BI 1015550 intended Commercial Formulation (iCF)
214404977|NCT05428436|DRUG|BI 1015550 TF2|BI 1015550 trial formulation 2 (TF2)
214404978|NCT02828930|DRUG|Idasanutlin|Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
214404979|NCT02828930|DRUG|Placebo|Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
214404980|NCT02828930|DRUG|[13C]-radiolabeled Idasanutlin|\[13C\]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
214404981|NCT02828930|DRUG|[14C]-radiolabeled Idasanutlin|\[14C\]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
214404982|NCT02627625|DRUG|Tiotropium|4 inhalations
215098125|NCT02299284|OTHER|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
215098126|NCT00790478|DRUG|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
215098127|NCT00790478|OTHER|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
215098128|NCT01583816|DRUG|Resiquimod 0.03%|topical application
215098129|NCT01583816|DRUG|Resiquimod 0.01%|topical application
215098130|NCT01583816|DRUG|placebo|topical application
214404983|NCT01785420|DRUG|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
214404984|NCT01785420|DRUG|Placebo|A 90 minute intravenous infusion of saline as placebo
214404985|NCT03014102|DRUG|Recombinant Human Thrombopoietin|Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
214404986|NCT03321760|RADIATION|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
214404987|NCT04616365|PROCEDURE|Semi-Elective Lung Transplantation|When suitable donor lungs become available for a consented recipient, the transplant procedure (anesthesia starting time) will be allowed to begin earliest at 6am with the lungs being preserved at 10°C cold static preservation upon organ arrival to our hospital using a specific incubator, regardless of when donor cross clamp occurs. The maximum time allowed between donor cross clamp and recipient anesthesia initiation will be 12h.
214404988|NCT00515840|OTHER|Physiotherapist|Physiotherapist administered breathing retraining programme
214404989|NCT05709548|DRUG|Indocyanine green|Subjects with a diagnosis of acute cholecystitis who undergo urgent laparoscopic cholecystectomy with the preoperative administration of indocyanine green (between 1-2 hours prior to surgery).
214404990|NCT03837925|DRUG|Atorvastatin 40mg Tablet|Patient participation for 6 weeks of treatment
214404991|NCT03837925|DRUG|Placebo comparator|Patient participation for 6 weeks of treatment
214404992|NCT02562014|OTHER|Glucose|75g glucose
214404993|NCT02562014|OTHER|Inulin|75g glucose plus 24g inulin
215098131|NCT06028360|OTHER|Progressive Muscle Relaxation|Intervention will be applied for 15-20 minutes 3 consecutive days a week for 1 week
214404994|NCT02562014|OTHER|Resistant Starch|75g glucose plus 28.2g resistant starch
214404995|NCT00318968|DRUG|Esomeprazole|
214404996|NCT00049114|DRUG|doxorubicin hydrochloride|
215098132|NCT06028360|DEVICE|Virtual Reality Therapy|Therapy through VR will be given for 8 minutes 3 times a week on consecutively for 1 week
215098133|NCT00233012|DRUG|Topiramate|
214404997|NCT00049114|DRUG|cyclophosphamide|Given IV
214504686|NCT06766838|PROCEDURE|1. Conventional dissection technique (group A) :|In this group, circumcision is performed by the dorsal slit technique. A slit is made dorsally to the level of about 5 mm from the coronal sulcus, and the redundant foreskin and mucosa were excised circumferentially. Hemostasis is secured with ligation , and the cut edges are sutured with absorbable suture. Then, dressing is applied.
215098134|NCT05583149|DRUG|ACALABRUTINIB|Oral, twice daily, timing and dosage per protocol
215098135|NCT05583149|DRUG|LISOCABTAGENE MARALEUCEL|via IV timings and dosage per protocol
215098136|NCT05583149|DRUG|Lymphodepleting chemotherapy|lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.
215098137|NCT00980304|DRUG|Rituximab|
215098138|NCT06946238|RADIATION|Adjuvant single-fraction accelerated partial breast irradiation|Experimental arm (arm 1-single-fraction APBI) patients will be treated to a total dose (TD) of 15.5 Gy to the PTV with a simultaneous integrated boost (SIB) to a TD of 21 Gy to the tumor bed, while arm 2-five-fractions APBI patients with 30 Gy/ 5 fractions to PTV.
214404998|NCT00049114|DRUG|tipifarnib|Given orally
215098139|NCT02641067|DRUG|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
215098140|NCT02782767|OTHER|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
215098141|NCT02782767|OTHER|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
215098142|NCT04231916|DEVICE|Thermal imaging device|
215098143|NCT03066167|OTHER|Validation of different dysphagia scores|
214404999|NCT00049114|BIOLOGICAL|filgrastim|Given subcutaneously
214405000|NCT00049114|PROCEDURE|therapeutic conventional surgery|Undergo complete resection
214405001|NCT00049114|OTHER|laboratory biomarker analysis|Correlative studies
214405002|NCT03521323|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
214405003|NCT03521323|DRUG|Placebos|Placebos: Saline，Sham operation
214405004|NCT05336123|BEHAVIORAL|Hatha Yoga|Weekly hatha yoga classes lasting 10 weeks.
214405005|NCT05336123|BEHAVIORAL|Health Education|Weekly health education classes lasting 10 weeks.
214405006|NCT06063330|COMBINATION_PRODUCT|RQ-001|"Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator. Drug Product RQ-001 has been developed with an Aptar Bidose liquid nasal spray unit device (BDSI V3) capable of intranasally delivering a 200 uL total volume of drug product (specifically, 100 uL per nare, which delivers a 200 uL of total volume). The combination product comprises the drug constituent (RQ-01) and the assembly of commercially available, off-the-shelf device components.~Study staff will be responsible for assembling the drug product RQ-001 and subjects will self-administer under the supervision of study staff in the clinic."
215098144|NCT02672592|DRUG|Anakinra|Anakinra 100mg s.c. bid
215098145|NCT02672592|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
215098146|NCT01608373|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
215098147|NCT01608373|DRUG|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
214405007|NCT06063330|OTHER|Placebo|Matching placebo will be manufactured just as RQ-01 drug substance, with the active ingredient addition step omitted. Placebo will appear similar to RQ-01 drug substance as a clear to hazy, colorless to yellowish liquid. Matching placebo will be administered the same way as RQ-01
214405008|NCT05520827|DRUG|BI 1584862|BI 1584862
215098148|NCT01608373|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
215098149|NCT00140959|DRUG|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
215098150|NCT00140959|DRUG|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
214405009|NCT05520827|DRUG|Placebo|Placebo
214405010|NCT05777057|DIAGNOSTIC_TEST|Diagnodent|using DIAGNDENT depends on the principle that when 655nm wavelength of Diode laser is irradiated on dental surface, intraoral bacteria metabolites will absorb it and then metabolites emit a red fluorescence. The dental surface will reflect this fluorescence and gives number between 0 and 99 on the screen of the DIAGNdent.
214405011|NCT04902586|DEVICE|TTFields|The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
214405012|NCT02111343|OTHER|Computer-based auditory training (CBAT)|"There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.~Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day."
214405013|NCT00421915|DRUG|Enbrel (etanercept)|
215098151|NCT02851823|DEVICE|Periodontal curettes|
215098152|NCT02851823|DEVICE|Er-YAG+Nd-YAG lasers|
214405014|NCT00536666|DRUG|Iron oligosaccharide|
214405015|NCT03371108|BIOLOGICAL|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
214405016|NCT03371108|BIOLOGICAL|Lantus®|Route of administration: subcutaneous injection
214405017|NCT02563600|BEHAVIORAL|Pre-letter telephone call.|A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.
214405018|NCT02563600|BEHAVIORAL|Post-letter telephone call|A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
214405019|NCT04108910|DIAGNOSTIC_TEST|Guidance UTI|
215098153|NCT04780789|PROCEDURE|Transarterial Chemoembolization|A contrast agent (Xenetix350, Guerbet, France) was applied under local anaesthesia via the common femoral artery using a 5F sheath. Selective catheterization of the coeliac trunk and other arteries supplying the liver was then performed under fluoroscopic control. A pathological vascularization pattern was identified and chemoembolization material consisting of DC beads (BTG International Ltd) was injected by the treating angiographist using micro instrumentation. Follow-up CT or MRI was performed after 1-3 TACE sessions according to the extent of the lesion, 3 weeks following the last procedure. Patients with completed treatments were scheduled for an imaging follow-up every 3 months, allowing evaluation of the effect of treatment. In case of a positive response to the treatment another session of TACE was indicated. Chemoembolization sessions were performed as inpatient procedures with the mean hospitalization time of 4 days.
215098154|NCT04679909|BIOLOGICAL|AdCOVID|Administered intranasally
215098155|NCT04679909|OTHER|Placebo|Administered intranasally
215098156|NCT03254550|OTHER|PrEP Promotion Package|A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
214405020|NCT02714829|DEVICE|Inject BMP|Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.
214405021|NCT02714829|DEVICE|ExcelOS-inject|Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
214405022|NCT04416139|BIOLOGICAL|Infusion IV of Mesenchymal Stem cells|Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
214405023|NCT05978609|DRUG|Candonilimab|Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
214405024|NCT05978609|DRUG|Cisplatin|Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
214405025|NCT05978609|DRUG|Gemcitabine|gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
214405026|NCT05190185|BIOLOGICAL|TAA06 injection|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106\~1×108 CAR-T/kg. And the subjects will be administered once.
214405027|NCT00521716|DEVICE|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
215098157|NCT01416428|DRUG|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
215098158|NCT02925728|OTHER|Finger-Food|Finger-Food at lunch and having diner
215098159|NCT02925728|OTHER|Without Finger-Food|Without finger-food
215098160|NCT03468894|BEHAVIORAL|Treadmill desk walking|See intervention arm description
215098161|NCT01096511|DRUG|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
214405028|NCT00521716|DEVICE|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
214405029|NCT05626543|BEHAVIORAL|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs will be used combinedly. CBT will be constructed based on the CBT model of Beck, (2021) and mindfulness practice will be implemented based on the MBSR program developed by Williams et. al. (2011).
214405030|NCT05668091|DRUG|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours.
215010313|NCT05812989|BEHAVIORAL|Social Engage Coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
215010314|NCT05812989|BEHAVIORAL|Connect for Caregivers|Participants will complete an individual session with a coach who will use a digitized prioritization tool to help identify goals and an action plan for social connectedness.
215010315|NCT02177578|DRUG|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
215010316|NCT02177578|RADIATION|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
214405031|NCT05668091|DRUG|Ritonavir|One 100 mg capsule taken by mouth every 12 hours.
214405032|NCT05668091|DRUG|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours.
215098162|NCT05242094|PROCEDURE|Pulmonary Rehabilitation Program|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
215098163|NCT04119102|DRUG|Duobrii|duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
215098164|NCT00135109|DRUG|SPM 927|
215010317|NCT02177578|RADIATION|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
215098165|NCT05383534|DRUG|Propofol Injection|propofol injections were used for the induction of anesthesia according to the body weight of the patients.
215098166|NCT05098509|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
214405033|NCT05805059|DEVICE|Control Contact Lens (stenfilcon A)|one week wear
214405034|NCT05805059|DEVICE|Test Contact Lens (senofilcon A)|one week of wear
214688310|NCT07162220|DEVICE|Mobile game app|The mobile game software developed for patients with chronic renal failure contains information for children on daily life activities such as nutrition, exercise, personal hygiene, etc.
214688311|NCT07163065|PROCEDURE|Inferior Alveolar Nerve Block Anesthesia|Standard inferior alveolar nerve block anesthesia performed with lidocaine and epinephrine for mandibular dental treatment. Success rate and postoperative pain outcomes will be recorded
215098167|NCT05098509|DRUG|Placebo|Matching Placebo for RAD011
214405035|NCT04042467|BEHAVIORAL|Greenlight Plus|Families randomized to the Greenlight Plus arm will receive a HIT intervention starting at the newborn clinic visit. During the newborn visit, these families will receive basic instructions on how to access the Greenlight technology platform, which includes the iOTA text-messaging application and a website (usable on desktop or mobile platform). Families will receive text messages and goal-setting over the first 2 years of the child's life.
214405036|NCT04042467|BEHAVIORAL|Greenlight|All residents and families seen in the participating clinics will receive the basic Greenlight materials.
214405037|NCT06219785|DEVICE|Low-Intensity Shockwave therapy (LiSWT)|Participants will receive once-a-week LiSWT treatments of 0.2 mJ/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.
214405038|NCT05882032|DRUG|LY3502970|Administered orally.
215098168|NCT02874027|OTHER|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
215098169|NCT06102109|PROCEDURE|Pars plana vitrectomy|25gauge pars plana vitrectomy: to remove the vitreous if present
214405039|NCT03892850|BEHAVIORAL|Nurse prescription|Pharmacological nurse prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
214405040|NCT03892850|BEHAVIORAL|Medical prescription|Pharmacological medical prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
214405041|NCT04188288|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
214405042|NCT04188288|DEVICE|Control feedback|Participants provided with control type of feedback (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
214405043|NCT04188288|DEVICE|fMRI|fMRI will be used to assess brain activity
214405044|NCT02790606|DEVICE|Covera(TM) Vascular Covered Stent|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
214405045|NCT02735915|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
214405046|NCT05356403|DRUG|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
214405047|NCT05356403|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
214405048|NCT01789203|DRUG|Ciprofloxacin|Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
214405049|NCT01789203|DRUG|placebo|Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
214405050|NCT04290429|DRUG|Teduglutide|Treatment of patients with SR-GI-GVHD with teduglutide
215010318|NCT06963697|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Neoantigen synthetic long peptide vaccines are composed of synthetic long peptides which are 8-35 amino acids in length and designed to induce immune responses to cancer neoantigens identified by exome sequencing. Neoantigen synthetic long peptide vaccines will be co-administered with poly-ICLC, an innate immune adjuvant capable of activating TLR3 and other pathways.
215098170|NCT06102109|PROCEDURE|IOL explantation|Removing if present a subluxated IOL from the anterior chamber or the vitreous cavity
215098171|NCT06102109|PROCEDURE|Scleral IOL fixation Yamane Technique|Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera using only its haptics, which are externalised 2.5mm behind the blue line. The haptic ends are flanged using a thermo cautery to prevent slipping back in.
215010319|NCT06959303|BEHAVIORAL|Teach Back Education|Discharge training will be given to patients who underwent coronary angiography with the Teach-Back method.
215010320|NCT00840853|GENETIC|CD19CAR/virus specific T cells|CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
215010321|NCT00840853|DRUG|Benadryl and Tylenol|Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
215010322|NCT02821793|OTHER|Consultation, evaluation questionnaire|Consultation, evaluation questionnaire
215010323|NCT02821793|OTHER|Geriatric consultation, evaluation questionnaire|Geriatric consultation, evaluation questionnaire
215010324|NCT02814019|DRUG|Idebenone 150 mg film-coated tablets|
215010325|NCT02814019|DRUG|placebo|
215098172|NCT06102109|PROCEDURE|"Scleral IOL fixation 4-flanged Technique"|Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physical Micropure 123) gets fixated in the sclera using one 6.0 polypropylene suture per 2 haptic loops, which are put trough the loops in a W shape. The suture ends are externalised 2.5mm behind the blue line and its ends are flanged using a thermo cautery to prevent slipping back in.
215098173|NCT02774304|DEVICE|arterial line|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
215098174|NCT02774304|DEVICE|Cheetah®|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
215098175|NCT00083928|DRUG|Å6 subcutaneous injection|
215098176|NCT01840098|DIETARY_SUPPLEMENT|low leucine content drink|
215098177|NCT01840098|DIETARY_SUPPLEMENT|high leucine content drink|
214405051|NCT05835024|DEVICE|Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1|"A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.~A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation."
214405052|NCT05835024|DEVICE|Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2|"A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital."
214405053|NCT02174211|DRUG|Ranibizumab|Intravitreal injection of ranibizumab
214405054|NCT02174211|DRUG|Aflibercept|Intravitreal injection of aflibercept
214405055|NCT03860246|DIAGNOSTIC_TEST|Portable ECG monitor|Recording of ECG rhythm on a portable monitor (Kardia Mobile)
214688312|NCT07162974|DRUG|anhydrous citric acid - 1197.0 mg, potassium bicarbonate - 967.5 mg, sodium citrate anhydrous - 835.5 mg|The dosage was selected individually for each patient, the target pH was considered to be 7.2
215098178|NCT01840098|DIETARY_SUPPLEMENT|low leucine + HMB drink|
215098179|NCT01840098|DIETARY_SUPPLEMENT|Control/carbohydrate|
215098180|NCT01840098|BEHAVIORAL|36 hour fasting|
215098181|NCT05378074|DRUG|Maxipost|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
215098182|NCT05378074|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
215098183|NCT00534833|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, Intramuscular
215098184|NCT00534833|BIOLOGICAL|Tritanrix-HepB/Hib™|0.5 mL, Intramuscular
215098185|NCT00534833|BIOLOGICAL|Oral Polio Vaccine|0.5 mL, Oral
215010326|NCT02836106|OTHER|Butter|Butter with jam and three slices of bread
215098186|NCT00324233|DEVICE|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
214405056|NCT06629974|BEHAVIORAL|Parental empowerment program|"The empowerment program consisted of two parts: the empowerment training program for parents and motivational interviews.~The empowerment training program was prepared to enable parents to carry out the care process more effectively in areas where parents have difficulties caring for their children with autism. Within the scope of the empowerment training program, parents were trained on the importance of play and communication, problems and management in the field of nutrition, sleep problems and management, safety and protection from accidents, and problems and management in the field of self-care.~Ten days after the empowerment training program, two face-to-face motivational interviews were conducted with each participant in the intervention group. Each participant had a one-week break between the first and second motivational interviews. Each motivational interview session lasted approximately 25-30 minutes."
214405057|NCT06629870|DEVICE|virtual reality|patients who received distraction using virtual reality glasses
214405058|NCT06629870|OTHER|control group|no any anxiety-reducing application
214405059|NCT06629870|OTHER|hypnotherapy|patients receiving hypnotherapy
214405060|NCT06629870|OTHER|mindfulness|patients who underwent mindfulness-based meditation
214405061|NCT01979978|OTHER|Healthy Buddies Curriculum|"Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors (Buddies), teaching a 30-minute lesson to their younger students. The Physical activity (i.e.Go Move!) component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary (Go Fuel!) component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image (Go Feel Good!) component, the students are taught to value classmates based on individual traits rather than peer influence."
214405062|NCT00589212|DEVICE|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
214405063|NCT05000450|GENETIC|ALLO-605|ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product
214405064|NCT05000450|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
214405065|NCT05000450|DRUG|Fludarabine|Chemotherapy for lymphodepletion
214405066|NCT05000450|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
214405067|NCT01969890|DRUG|G-CSF administration|Zarzio - 5 microg/kg bis in die for 6 days
214405068|NCT00135967|DRUG|mycophenolate mofetil orally 1000 mg twice a day (BID)|
214405069|NCT00135967|DRUG|prednisone 0,5 mg/kg orally on alternate days|
214405070|NCT00135967|DRUG|intravenous (i.v.) methylprednisolone 1000 mg, total 9|
214405071|NCT02714803|BEHAVIORAL|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
214405072|NCT02714803|BEHAVIORAL|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
214405073|NCT02714803|BEHAVIORAL|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
214405074|NCT06400056|DRUG|Terbinafine|FDA approved
215010327|NCT02836106|OTHER|Cheese|Cheese with jam and three slices of bread
215010328|NCT02836106|OTHER|Whipped cream|Whipped cream with jam and three slices of bread
215010329|NCT02836106|OTHER|Sour cream|Sour cream with jam and three slices of bread
215010330|NCT01486394|OTHER|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
215010331|NCT06235957|OTHER|Cast 3 weeks|patients will be treated either in a cast or a brace, patients in group A are treated by cast immobilization for 3 weeks
215010332|NCT06235957|OTHER|Brace 1 week|patients will be treated either in a cast or a brace, patients in group B are treated in a brace for 1 week
214405075|NCT06281717|DEVICE|Fetal Endotracheal Occlusion (FETO)|The FETO insertion procedure will be performed between gestational age 27 weeks 0 days and 29 weeks and 6 days. The Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus using the Delivery Microcatheter (BALTACCI-BDPE100). The fetal tracheal balloon will be removed between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
214405076|NCT04874610|DRUG|Methylprednisolone|Administration of methylprednisolone Prescribed per Standard of care
214405077|NCT04202575|PROCEDURE|Tube clamping|Clamping of the tube between the additional and standard venous reservoir
215098187|NCT00324233|DEVICE|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
215098188|NCT01274910|DIETARY_SUPPLEMENT|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
215098189|NCT01274910|DIETARY_SUPPLEMENT|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
215098190|NCT03992092|DEVICE|C-MAC VS|C-MAC Video Stylet
215098191|NCT03992092|DEVICE|Flexible Bronchoscopy|Flexible Bronchoscopy
215010333|NCT00250718|DRUG|Vincristine|Vincristine should be administered intravenously through a freely-running IV.
214405078|NCT06492577|OTHER|Pulmonary rehabilitation protocol|In the initial phase (days 1-7), aerobic exercise sessions will be 20-30 minutes, strength training will include 1-2 sets at 50% of 1RM, and breathing exercises will last 10 minutes daily. In the progressive phase (days 8-14), aerobic exercise sessions will increase to 30-40 minutes, strength training to 2-3 sets at 60% of 1RM, and breathing exercises to 10-15 minutes daily. In the advanced phase (days 15-21), aerobic exercise sessions will be 40-45 minutes, strength training will be 2-3 sets at 70% of 1RM, and breathing exercises will continue for 10-15 minutes daily.
214405079|NCT06492577|OTHER|Progressive muscle relaxation protocol|Participants in this arm will undergo a 21-day progressive muscle relaxation (PMR) program aimed at reducing anxiety and improving sleep quality in patients with long-term COVID-19 symptoms. Each daily session lasts 20 minutes and involves systematic muscle tensing and relaxation, starting from the feet and progressing to the head, combined with slow, deep breathing. During the initial phase (days 1-7), the focus is on introducing PMR techniques and targeting different muscle groups. In the progressive phase (days 8-14), full-body PMR sessions enhance relaxation and breathing techniques. The advanced phase (days 15-21) maximizes relaxation and incorporates visualization techniques.
214405080|NCT02256787|DRUG|BILB 1941 ZW - single rising dose part|
214405081|NCT02256787|DRUG|Placebo|
214405082|NCT02256787|DRUG|BILB 1941 ZW - solution|
214405083|NCT02256787|DRUG|BILB 1941 ZW - tablet|
214405084|NCT02256787|OTHER|standardized breakfast|
214405085|NCT03037190|OTHER|withdrawal of gluten from the diet|Gluten free diet the same recommendations as for patients with diabetes and known celiac disease
214405086|NCT06628505|OTHER|Speech in Noise Training|The active controls will receive frequency discrimination training that uses the same visual landscape and basic task of controlling the wisp based on judgments about acoustic cues. The task requires participants to avoid obstacles by swiping upward or downward on the touchscreen to indicate whether a test frequency associated with the obstacle was higher or lower, respectively, than a target sound presented slightly before the test sound.
214405087|NCT06628505|OTHER|Spatial Hearing Training Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are given feedback about how their perceived location related to the actual sound location."
214405088|NCT06628505|OTHER|Spatial Hearing Control Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are NOT given feedback about how their perceived location related to the actual sound location."
214405089|NCT03387917|DRUG|TLD-1|TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.
214405090|NCT03387917|DRUG|Caelyx|Caelyx is a liposomal formulation of the anthracycline doxorubicin
214405091|NCT04950751|BIOLOGICAL|candidate vaccine, SCB-2020S|a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
214405092|NCT05986487|DEVICE|CPAP or usual practice|CPAP (continuous positive airway pressure) is a machine that uses mild air pressure to keep breathing airways open while you sleep.
214405093|NCT05986487|DEVICE|Monitoring and intervention in follow-up|Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.
214405094|NCT05967442|DRUG|Magnesium Sulfate|Magnesium Sulfate 2gm in 50ml D5W over 20 minutes
214405095|NCT05967442|DRUG|Metoclopramide 10mg|Metoclopramide 10mg in 50ml D5W over 20 minutes
214405096|NCT05967442|DRUG|Prochlorperazine (Compazine) Injection|Prochlorperazine 10mg in 50ml D5W over 20 minutes
215010334|NCT00250718|DRUG|VP-16|The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
215010335|NCT00250718|DRUG|Rituximab|"The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.~Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.~Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses"
215010336|NCT00250718|DRUG|Dexamethasone|Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
215010337|NCT00250718|DRUG|Levofloxacin|Levofloxacin will be administered at 500 mg PO qd.
215010338|NCT01890005|DRUG|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
215010339|NCT01890005|DRUG|Placebo|Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
215010340|NCT06245707|DRUG|prednisone,methylprednisone and cyclophosphamide|In the first month, methylprednisolone 500mg/d was given intravenously for 3 days, and then prednisone 0.5 mg/(kg d) \* for 27 days. Oral cyclophosphamide 2.0 mg/(kg d) \* 30 days in the second month. After that, the first month and the second month plan were repeated twice.
214405097|NCT06313684|OTHER|Comprehensive Initial Assessment|"Initial Assessment includes all those necessary to prescribe exercise training, as well as dietary and adherence promotion interventions.~* Functional capacity with 6MWT~* Assessment of skeletal muscle strength, flexibility, and balance.~* Assessment of function~* Assessment of dietary habits~* Assessment of self-efficacy and barriers to CR adherence.~* Screening for depression."
214405098|NCT06313684|OTHER|Continuous evaluation|Evaluations during the course of the program will be carried out to inform the progression through the CR stages, the intensity of training and education needs.
214405099|NCT06313684|OTHER|Interval Exercise|"High-intensity interval training prescribed by physical therapist:~* According to an adapted Wisloff protocol.~* Borg scale to monitor intensity.~* Training 3 times per week."
214405100|NCT06313684|BEHAVIORAL|Psychosocial support|"Based on social-cognitive theory, with self-efficacy as a focus:~* Face-to-face sessions in the first stage of the program: Education, self-monitoring and motivational interview.~* Face-to-face session in the second stage of the program: promoting behavior changes by self-control and self-monitoring~* Regular communication with patients will be supported by the use of mobile devices during the third and fourth stages of program."
214405101|NCT06313684|OTHER|Diet management|A dietary plan supported by a nutritionist will be made together with the patient.
214405102|NCT06313684|OTHER|Resistance exercise|"Resistance exercises:~* With TheraBand.~* Intensity according to the perceived exertion scale~* Twice a week."
214405103|NCT06313684|OTHER|Continuous exercise|"Moderate-intensity continuous exercise prescribed by physical therapist :~* The intensity will be moderate, as tolerated~* Borg scale to monitor intensity.~* Frequency of training of 1 to 3 times per week, until completed 20 sessions in 10-12 weeks."
214405104|NCT06313684|OTHER|Initial Assessment|"Includes all those necessary to plan exercise training, as usual:~* Functional capacity with 6MWT.~* Assessment of skeletal muscle strength."
214405105|NCT01440244|PROCEDURE|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
214405106|NCT05121207|DEVICE|Terahertz scanning|Short scans using Terahertz device
214405107|NCT05797311|OTHER|Proprioceptive Neuromuscular Facilitation (PNF)|Proprioceptive Neuromuscular Facilitation (PNF) techniques are a therapeutic exercise approach developed based on functional activities in daily life. At the stage of regaining movement and function, it creates models similar to functional activities.
214405108|NCT05797311|OTHER|Shoulder Stabilization Exercises|Scapular stabilization exercise and stabilization exercise for the shoulder joints
214405109|NCT04184102|BEHAVIORAL|education|The intervention group received pre-surgery education and training on therapeutic exercises in addition to the routine hospital care. The educational material was developed by the principal investigator (PI) and included a power point and a booklet with instructions on the exercises as well as information about the surgery and what to expect after the surgery. The educational material was based on previous research and adopted to our population after consultation with a panel of experts including two nurses and three physicians. Eligible women were approached while waiting for their appointment with their surgeon. If they showed interest in participating they signed a consent form. The PI explained the study and what is involved in participating including the weekly phone calls for women in the intervention group. Participants were told that they will visited at home by the PI to assess their ROM and to fill out a questionnaire.
214405110|NCT05349877|BEHAVIORAL|Expressive writing|Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
214504687|NCT06766838|PROCEDURE|2. Bone cutting forceps technique (Group B)|Two mosquito forceps are used to grasp the foreskin. The glans penis is squeezed back to avoid its injury. After that, bone cutting forceps is applied to the foreskin for 3 minutes, at the level of the mark, then the foreskin is excised by scalpel at the same level. Bleeding points are ligated and the cut edges are sutured with absorbable suture. Then, a dressing is applied
214504688|NCT06766838|PROCEDURE|3. Electro-cauterization (bipolar) assisted circumcision (Group C)|"The skin is held by two hemostats to elevate the foreskin, and then the kocher clamp applied at the level of the skin to be removed for circumcision. Excess foreskin will be cut by scissor with hemostasis by bipolar cauterization.~The skin retracted proximally after that to expose the glans. Sutures are made if there is separation between the skin and the mucous membrane."
214504689|NCT06766838|PROCEDURE|4. Thermal cauterization assisted circumcision (Group D)|The skin is held by two hemostats to elevate the foreskin, and then the kocher clamp applied at the level of the skin to be removed for circumcision. Excess foreskin will be cut by thermal cauterization. The skin retracted proximally after that to expose the glans. Sutures are made if there is separation between the skin and the mucous membrane.
215010341|NCT06245707|DRUG|Rituximab|The dosage of rituximab depends on peripheral blood B cells. After the treatment of rituximab, the peripheral blood B cells were in a clear state and then stopped. After monitoring the recovery of B cells, additional doses were given.
214688313|NCT07163195|DEVICE|Smart Bandage with Telemonitoring|A smart wound bandage with integrated sensors (pH, temperature, moisture) connected to a mobile telemonitoring platform. Wound data are transmitted securely to a mobile application monitored by wound care nurses. The device is applied in addition to standard wound care (compression therapy, conventional dressing, debridement when indicated, and patient education).
215010342|NCT01194700|DRUG|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
215010343|NCT01194700|DRUG|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
215010344|NCT01194700|DRUG|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
215010345|NCT01194700|DRUG|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
215010346|NCT00513630|DRUG|Glipizide|
215010347|NCT00513630|DRUG|Metformin|
215010348|NCT01666314|DRUG|Orteronel|Orteronel tablets
215010349|NCT01666314|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
215010350|NCT01666314|DRUG|Prednisone|Prednisone 5 mg
215010351|NCT01386177|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
215010352|NCT01386177|DRUG|Doxazosin|"3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os."
215010353|NCT01386177|DRUG|placebo|capsules identical to MDMA or doxazosin
215010354|NCT00167947|DRUG|Cyclosporine|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
215010355|NCT00167947|DRUG|Steroids|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
215010356|NCT00167947|DRUG|Rapamune (Sirolimus)|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
214405111|NCT05349877|BEHAVIORAL|Self-affirmation|Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
215010357|NCT05879172|DEVICE|electric tubular anastomotic device|"The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment."
215098192|NCT00971295|DRUG|Metformin|850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
215098193|NCT00971295|DRUG|Eslicarbazepine acetate|
214405112|NCT05349877|BEHAVIORAL|Placebo|Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
214405113|NCT03588975|BIOLOGICAL|MACI|autologous cultured chondrocytes on porcine collagen membrane
214405114|NCT03588975|PROCEDURE|microfracture|Arthroscopic microfracture treatment
214405115|NCT06321172|DEVICE|FES Bike|Six months of FES-cycling trainings twice a week is performed for each pilot. Each session includes at most 30 minutes of stimulation. At the beginning of the training period, a conditioning phase is performed until the pilot reaches pedalling autonomy. This period is also used to define the stimulation parameters (minimum and maximum values of current intensity and pulse width), reference cadence and gear, specific for the ability of each pilot. Then the training period starts and is performed indoor, setting the resistance of the smart trainer at 10% for all the participants. The sessions are organized as follows: a 3-minute warmup followed by four sets of 6 minutes of pedalling and a 3-minute cool down.
214405116|NCT03514589|DRUG|nasal Tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
214405117|NCT03514589|DRUG|IV tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
214405118|NCT03377036|DIAGNOSTIC_TEST|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
214405119|NCT03377036|DIAGNOSTIC_TEST|2D-FFDM|2D full-field digital mammography
214405120|NCT01387646|BEHAVIORAL|Project IMAGE|Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
214405121|NCT00632762|DRUG|mantadix|dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
214405122|NCT02440906|BEHAVIORAL|Patient-Directed Wellness Account|The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
214405123|NCT02440906|BEHAVIORAL|Health Navigator|The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
215098194|NCT01707381|DRUG|BOL-303259-X|Topical ophthalmic solution
215098195|NCT01707381|DRUG|Timolol maleate|Topical ophthalmic solution
215098196|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
214405124|NCT00652574|DRUG|Dasatinib|70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
214405125|NCT02213900|DRUG|Haloperidol|0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days
215010358|NCT05879172|DEVICE|traditional anastomotic device|Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
215010359|NCT06183528|PROCEDURE|Pericapsular Nerve Group (PENG) Block|With ultrasonography-guided PENG block, the femoral, obturator and accessory obturator nerve branches that provide sensory innervation of the anterior surface of the hip joint capsule are blocked .
215010360|NCT00309179|DRUG|E7820 plus cetuximab|Escalating doses from 40 mg/m\^2 irinotecan plus E7820 in combination with cetuximab.
215010361|NCT00652041|DRUG|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4
215098197|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
215098198|NCT00955513|DRUG|Placebo|Placebo
214405126|NCT02213900|DRUG|Placebo|
214405127|NCT05711628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
214405128|NCT05711628|DRUG|Bendamustine|Given IV
214405129|NCT05711628|DRUG|Brentuximab Vedotin|Given IV
214405130|NCT05711628|DRUG|Carboplatin|Given IV
215098199|NCT00086411|DRUG|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
215098200|NCT00086411|DRUG|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
215098201|NCT00086411|BEHAVIORAL|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
215098202|NCT00086411|BEHAVIORAL|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
215098203|NCT00086411|DRUG|placebo patch|placebo patch containing no nicotine
215098204|NCT00086411|DRUG|placebo bupropion|placebo pills
215098205|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System|The LX2.3 Laser and LED Photobiomodulation system by THOR Photomedicine Ltd is a CE marked product and has a long track record of safety, usability, and effectiveness.
214405131|NCT05711628|PROCEDURE|Computed Tomography|Undergo PET/CT and CT
214405132|NCT05711628|DRUG|Etoposide|Given IV
214405133|NCT05711628|DRUG|Gemcitabine|Given IV
214405134|NCT05711628|DRUG|Ifosfamide|Given IV
214405135|NCT05711628|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214405136|NCT05711628|BIOLOGICAL|Pembrolizumab|Given IV
214405137|NCT05711628|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214405138|NCT05711628|RADIATION|Radiation Therapy|Undergo RT
214405139|NCT05711628|OTHER|Transplant Conditioning|Receive standard preparative chemotherapy regimen
214405140|NCT05711628|DRUG|Vinorelbine|Given IV
214405141|NCT03803917|PROCEDURE|Injection with freshly collected autologous adipose tissue|
214405142|NCT01608893|DRUG|Carvedilol|6.25 po bid titrated to 25 mg bid as tolerated over a 1 month period
215098206|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System Sham-PBMT Setting|The sham setting consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
215098207|NCT00175448|PROCEDURE|physiotherapy|See Detailed Description.
215098208|NCT03218930|BEHAVIORAL|Delayed antibiotic prescription|Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
214405143|NCT01608893|DRUG|Metoprolol|titrated to 50 mg po bid as tolerated over a 1 month period
214405144|NCT03442920|OTHER|Exercise|This group made exercise for 12 week/3 times a week.
215010362|NCT00652041|DRUG|Thalidomide|Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is \<Grade 2, dose should be increased to 200 mg/24 h. in day 15
215010363|NCT00652041|DRUG|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
214405145|NCT04870164|DRUG|Ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.
215098209|NCT03218930|BEHAVIORAL|Antibiotic prescribing guidelines|Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.
214405146|NCT04870164|DRUG|Placebo|One administration at day 1 by infusion.
214405147|NCT06051162|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
215010364|NCT01076933|PROCEDURE|repetitive Transcranial Stimulation Magnetic (rTMS)|The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.
215010365|NCT01076933|PROCEDURE|sham rTMS|sham rTMS
215010366|NCT02465970|DEVICE|STARSTIM|"Multifocal transcranial direct current stimulation.~* CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~* The stimulation is applied during a 60 min session"
215010367|NCT02465970|DEVICE|sham TDCS|
215010368|NCT01624207|DRUG|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
215010369|NCT01624207|DRUG|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
215010370|NCT01117545|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Six sessions of EFT
215010371|NCT04279600|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day
215010372|NCT04279600|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 1 gram of starch powder, total dosage: 3 grams/day
214405148|NCT04113837|DIETARY_SUPPLEMENT|food range|"The food range is comprised of:~sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week"
214405149|NCT03929302|DEVICE|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used in all the three arms.
214405150|NCT04282902|DRUG|pirfenidone|Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
214405151|NCT03815916|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
214405152|NCT02114008|OTHER|Endoscopic examinations|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
214405153|NCT01685580|DEVICE|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
214405154|NCT03197311|OTHER|Mobile app|A customized mobile application will be developed and downloaded to subjects; smartphones to monitor postoperative analgesic consumption, and disposal; pain control and patient satisfaction. The mobile app will provide notifications for medications and select education links on the prescribed analgesics. Subjects will receive reminders to take medications as directed. Subjects will be able to monitor and report their pain during the first week after surgery.
214405155|NCT01600703|DRUG|Sitagliptin|Sitagliptin, 100mg, oral, single dose
214405156|NCT01600703|DRUG|Placebo|Placebo, oral, single dose
214405157|NCT04261920|DRUG|Huangqi Guizhi Wuwu decoction|"The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)."
215010373|NCT04279600|OTHER|Exercise training|4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.
214405158|NCT01123161|DEVICE|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
214405159|NCT01123161|DRUG|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
215010374|NCT06128239|BEHAVIORAL|Caring Contacts|Text message version of Motto's Caring Contacts intervention. The study will compare two versions of text-based Caring Contacts: two-way messages, to which participants can respond to receive text-based support from follow-up specialists, and one-way text messages, to which participants cannot respond.
214405160|NCT06497985|DRUG|Tucidinostat|30mg orally BIW
214405161|NCT06497985|DRUG|Sintilimab|200 mg intravenously (IV) Q3W
214405162|NCT06497985|DRUG|Bevacizumab|7.5mg/kg intravenously (IV) Q3W
214405163|NCT06497985|DRUG|Fruquintinib|5mg orally QD
214405164|NCT04927052|DEVICE|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
214405165|NCT04927052|DEVICE|Juvederm Voluma with Lidocaine.|Juvederm Voluma with Lidocaine. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine
214405166|NCT02633891|BEHAVIORAL|Balance exercise|tailored balance exercise program
214405167|NCT02633891|BEHAVIORAL|Standard care|general health education and fall prevention classes
214405168|NCT00051415|BEHAVIORAL|Flaxseed-supplemented diet|
214405169|NCT06323330|OTHER|Speech rehabilitation|Melodic Intonation Therapy- Indian Adaptation module which will be developed in the pilot phase
214405170|NCT03238482|DRUG|salmeterol-fluticasone|Seretide Diskus 50/250 µg/dose
214405171|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
214405172|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
214405173|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
214405174|NCT04602962|PROCEDURE|fertility preservation, several methods|fertility preservation using assisted reproductive techniques or not
214405175|NCT04294082|BEHAVIORAL|Mindfulness based intervention|"A four session, 120 mins per session mindfulness based course delivered weekly oer the course of four weeks. The mindfulness sessions are based on the model delineated by Kabat-Zinn (1992) and will encompass:~* an introduction to mindfulness~* body-scan exercises~* sitting meditation~* mindful movement exercises~* individual and group reflections~* homework exercises"
214405176|NCT00224796|DEVICE|V.A.C. ® System|
214405177|NCT05550974|DEVICE|Minimally Invasive Surgery|gynecological, urologic, thoracic, plastic and reconstructive and ENT etc. endoscopic and laparoscopic surgical procedures
214405178|NCT05243992|OTHER|CTS-PAD device imaging|Participants in the CTS-PAD Study will undergo a conventional ABI (cABI) evaluation, followed by the non-contact imaging evaluation with the CTS-PAD device. The supplemental CTS-PAD testing will add approximately ten (10) minutes to the overall evaluation time.
214405179|NCT01805856|DRUG|PIPC piperacillin sodium|
214405180|NCT01805856|DRUG|CEZ, cefazolin sodium|
214405181|NCT01779882|DRUG|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
215010375|NCT05423600|PROCEDURE|BES + TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
215010376|NCT05423600|PROCEDURE|Experimental: BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
215010377|NCT04230304|BIOLOGICAL|Daratumumab|Given IV
215010378|NCT04230304|DRUG|Ibrutinib|Given PO
215010379|NCT06230770|BEHAVIORAL|Bleeding data|Participants will report their daily bleeding patterns
215010380|NCT05230407|OTHER|Visual analog scale (VAS) assesment of pain|Post operation VAS score will be assessed before discharge from hospital and 24 hours post operation
214405182|NCT01779882|DRUG|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
214405183|NCT00182416|DEVICE|pacemaker|
214405184|NCT04162366|DRUG|Aprocitentan 25 mg|Tablet, oral use once daily
214405185|NCT04162366|DRUG|Placebo|Matching placebo tablet, oral use once daily
214405186|NCT05091762|BEHAVIORAL|exercise|Upper limb resistance training with blood flow obstruction
214405187|NCT05090423|OTHER|balance training alone|"The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
214688314|NCT07163195|DEVICE|Conventional Bandage|A conventional wound bandage without digital monitoring features. It is applied in addition to standard wound care (compression therapy, conventional dressing, debridement when indicated, and patient education). This represents usual care according to international guidelines.
215010381|NCT05521698|DRUG|Apalutamide|Given PO
215010382|NCT05521698|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
214405188|NCT05090423|OTHER|balance training and neurodynamic intervention for the common peroneal nerve|"The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
214405189|NCT06458738|DEVICE|Printable denture base material|The newly developed printable denture base material will be used for the production of dentures.
214405190|NCT06480656|PROCEDURE|Rehabilitation with eccentric cycling exercise|Instead of normal cycling, patients will exercise on the eccentric bike.
214405191|NCT06480656|PROCEDURE|normal rehabilitation|Normal rehabilitation will be conducted
214405192|NCT04196985|DIAGNOSTIC_TEST|PET/MRI|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
214405193|NCT04196985|DIAGNOSTIC_TEST|PET/CT|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
214405194|NCT03320109|OTHER|Vitamin D|
214405195|NCT01497444|DRUG|hypoxia-activated prodrug TH-302|
214405196|NCT01497444|DRUG|sorafenib tosylate|
214405197|NCT00186680|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
214405198|NCT05877404|OTHER|Surveys|Survey on practice patterns surrounding tumor genetic testing in endometrial cancer.
214405199|NCT02461238|OTHER|Vouchers|The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
214405200|NCT02461238|OTHER|Nutrition education|Nutrition education workshops taught by a dietician
214405201|NCT04550156|PROCEDURE|Colorectal Bundle|"1. Preoperative optimization of the nutritional status: Perform nutritional risk screening (NRS), measure albumin or prealbumin preoperatively and initiate nutritional support~2. Preoperative showering with an antiseptic agent~3. Administer preoperative antibiotic prophylaxis~4. Hair removal in the operative field with clippers~5. Peri-, intra-, and postoperative warming to maintain body temperature~6. Peri- and intraoperative glucose control~7. Usage of a wound protection device~8. Change of gloves and instruments after anastomosis~9. Anastomosis only with experienced senior surgeon present in theatre for any elective and emergency procedures"
214405202|NCT01178515|OTHER|Modification of the content of fat in milk|Comparison of three levels of fat content in cow´s milk
214405203|NCT01178515|OTHER|Modification of the content of cows milk|Comparison of three levels of fat content in cows' milk
214405204|NCT01178515|OTHER|Modification of the fat content of cows´ milk|Comparison of three levels of fat content in cow´milk
214405205|NCT05985291|COMBINATION_PRODUCT|SCS in combination with CMM|Subjects receiving BurstDR spinal cord dorsal column stimulation in combination with conservative medical management for the treatment of painful diabetic neuropathy as part of regular medical care.
214405206|NCT02142439|BEHAVIORAL|Strength training|Three times per week with strength training
214405207|NCT03465111|DRUG|ACTH (adrenocorticotropic hormone) gel|The dose of H.P. Acthar Gel is 80 Units administered subcutaneously
214405208|NCT03683355|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
214405209|NCT00249223|DRUG|Risperidone Long acting injectable|
214405210|NCT03677726|BEHAVIORAL|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
214405211|NCT03677726|OTHER|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
214405212|NCT04582357|BEHAVIORAL|Physical activity program|The physical activity program is a suite of several exercises which intend to improve muscular mass of targeted muscles.
214405213|NCT00629512|DRUG|Esomeprazole|20mg oral daily
215010383|NCT05521698|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214405214|NCT00629512|DRUG|Esomeprazole|40mg oral daily
214405215|NCT00629512|DRUG|Placebo|
214405216|NCT04222244|OTHER|No intervention will be administered. We are only performing tests and measures.|No intervention will be administered. We are only performing tests and measures.
214405217|NCT00188929|PROCEDURE|PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)|
214405218|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
214405219|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
214405220|NCT01408680|DIETARY_SUPPLEMENT|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
214405221|NCT00800124|PROCEDURE|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
215010384|NCT05521698|DRUG|Placebo Administration|Given PO
215010385|NCT05521698|OTHER|Questionnaire Administration|Ancillary studies
214405222|NCT00361309|DRUG|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
214405223|NCT05638659|BEHAVIORAL|Computerized dual-task balance and home program|Portable force plate with aluminum top plate for measuring ground reaction forces, moments and the center of pressure in biomechanics. Through software to collect data from the force plates, converts the trials into useful information and plots the results. The force plates and charge amplifiers are fully remote controlled by software thus making the system extremely flexible and easy to use.
214405224|NCT05638659|BEHAVIORAL|Medical consultation and traditional balance training|Participants were assigned to read the health education flier and were assessed directly.
214405225|NCT03909464|DEVICE|Neurosensory testing with Pressure-Specified Sensory Device|Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device.
214405226|NCT06206681|PROCEDURE|Ultra-pulsed Carbon Dioxide Laser|Excision of eyelid lesion
214405227|NCT06142240|OTHER|exercise programe|"The components of the exercise programe will be: muscle strength training and continuous-variable aerobic training or HIIT with loads between 70-90% of maximum heart rate. The aerobic training will last about 30 minutes and will then be completed with muscle training of the upper and lower limbs with loads determined according to the perception of effort (loads around 50-70%). The sessions will be monitored with pulse oximetry (heart rate and oxygen saturation), perception of fatigue and sensation of suffocation (Borg scale). The intensity of each component of the programme will be individualised according to the conditions of each subject.~Adherence to the programme will be recorded as successful when participation in the sessions is greater than 80% of the total number of sessions."
215010386|NCT05521698|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
215010387|NCT06585072|DIAGNOSTIC_TEST|All enrolled subjects completed dynamic blood glucose monitoring to obtain continuous peripheral blood glucose data.|All enrolled subjects completed dynamic blood glucose monitoring to obtain continuous peripheral blood glucose data.
215010388|NCT06028230|DRUG|SAR444656 (KT-474)|Oral Tablet
215010389|NCT06028230|DRUG|Placebo|Oral Tablet
215010390|NCT06347588|OTHER|Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA|Blood sample at baseline, week 4, month 3, 6, 9,12.
215010391|NCT00435721|BEHAVIORAL|Psychoeducation|
215010392|NCT04425395|BEHAVIORAL|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance. Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min. The procedure is safe because the hand is removed before adverse effects can occur. The participant will be given a break of 5 min in between trials, and will interchange hands between trials. During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand.~Each participant will complete no more than three trials (conditions) in a randomised order."
215010393|NCT04425395|BEHAVIORAL|Acoustic Recordings|During the experiment, the vocalizations produced will be systematically recorded for each participant and an analysis of the acoustic structure of these vocalizations will be carried out.
215010394|NCT04425395|DIAGNOSTIC_TEST|Index measurement NOL™|Four sensors placed non-invasively on one finger. of the participants will be able to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
215010395|NCT04425395|DIAGNOSTIC_TEST|Video pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
215010396|NCT06470906|DIETARY_SUPPLEMENT|Probiotic Group|The intervention is a mixture of two probiotics: 1) Lactobacillus acidophilus GLA-14 and 2) Lactobacillus rhamnosus HN001. These products will be combined into a single capsule/sachet with a dose of approximately 10\^10 colony forming units (CFUs) of GLA-14 (ATCC SD5212) and HN001 (ATCC SD5675) in a 4:1 ratio, using similar doses as recent studies using this product.
215098210|NCT03218930|BEHAVIORAL|Education|General practitioners will receive a package of educational sessions tailored towards their specific needs.
215098211|NCT03218930|BEHAVIORAL|Educational materials|Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
215098212|NCT00661947|OTHER|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
214405228|NCT02487719|DRUG|Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia|
214405229|NCT01326585|DRUG|Dexamethasone Sodium Phosphate Injection|8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
214405230|NCT01326585|DRUG|Saline Injection|2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
214405231|NCT00051311|PROCEDURE|Stem cell transplantation|Recipients will receive donor stem cells 3 days after conditioning therapy is completed.
214405232|NCT00051311|DRUG|Fludarabine|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
215010397|NCT06470906|DIETARY_SUPPLEMENT|Placebo Group|The placebo will of be Maltodextrin, a carbohydrate, packaged similarly to the intervention and having the same weight.
215098213|NCT04901091|OTHER|Not Provided|Not Provided
214405233|NCT00051311|DRUG|Cyclophosphamide|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
214405234|NCT00051311|DRUG|Etoposide|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
215098214|NCT01816802|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
215098215|NCT01441466|OTHER|Isolation|Patients in this arm are nursed together (in the same room) independent of viral agent
215098216|NCT02055287|DRUG|LY03004|
214405235|NCT00051311|DRUG|Doxorubicin|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
214405236|NCT00051311|DRUG|Vincristine|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
214405237|NCT00051311|DRUG|Prednisone|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
214405238|NCT00051311|DRUG|Methotrexate|Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD)..
214405239|NCT00051311|DRUG|Cyclosporine|Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).
214405240|NCT00051311|PROCEDURE|Apheresis|Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
214405241|NCT02286440|OTHER|AssureRx GeneSight genotyping results|
214405242|NCT02286440|OTHER|Treatment as usual|
214405243|NCT06382545|PROCEDURE|Fanta (Pepsi gold) (FPG)|endodontic treatment of posterior teeth with Fanta (Pepsi gold) (FPG)
214405244|NCT06382545|PROCEDURE|M3-pro+ Gold (assorted) (MPG)|endodontic treatment of posterior teeth with M3-pro+ Gold (assorted) (MPG) rotary files.
214405245|NCT03675711|DEVICE|Midline|Patient will receive a Midline catheter within 48h after disappearance of indication for CVC
214405246|NCT03675711|DEVICE|PVC|Patient will receive a standard PVC within 48h after disappearance of indication for CVC
214405247|NCT03671538|DRUG|Anlotinib|Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
214405248|NCT03671538|DRUG|pemetrexed|pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;
214405249|NCT03671538|DRUG|Cisplatin|Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;
214405250|NCT00350181|DRUG|Sirolimus|Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
214405251|NCT00350181|DRUG|MMF|Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
214405252|NCT00350181|DRUG|BCNU|15 mg/kg, IV
214405253|NCT00350181|DRUG|VP-16|60 mg/kg, IV
214405254|NCT00350181|DRUG|CY|For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
214405255|NCT00350181|DRUG|FTBI|1320 cGy delivered in 11 120 cGy fractions over 4 day
214504690|NCT06766838|PROCEDURE|5. Gomco clamp technique (Group E):|The prepuce is grasped using two hemostats applied at 2 and 10 o'clock. A dorsal slit at 12 o'clock is made, appropriate-sized bell is placed over the glans, and the foreskin is brought over its top. The string is placed around the foreskin and the Plastibell device at the level of the mark in a groove that acted as the string placement guide. The string is then tightened and tied in a simple square knot. The excess foreskin is trimmed from around the bell using iris scissors. The handle is then broken off the device
215010398|NCT06462573|DRUG|locally infilterating anaethesia like lidocaine|which patients will undergo ESWL under locally infiltrated anaesthetic. Using ultrasound guidance, the quadratus lumborum muscle will be identified. Then a mixture of 0.5 % bupivacaine (10 ml) and 2 % lidocaine (10 ml) will be injected into the muscle as a single shot 20 minutes before the procedure.
215010399|NCT06462573|DRUG|general anaethesia|"which patients will undergo ESWL under systemic analgesia. The latter will be achieved using one gram of paracetamol IV infusion at the beginning of the procedure.~In case of unsatisfactory pain control in either group, systemic analgesia using IV Ketorolac injection will be used on demand or the required dose will be recorded at the end of the session."
215010400|NCT06731244|OTHER|Usual Care Group|Patients will be managed as regards their anticoagulant treatment according to usual practice and in accordance with international guidelines.
214405256|NCT00350181|DRUG|BU|BU 1 mg/kg every 6hr x 4 doses, IV
214405257|NCT05646069|DEVICE|Storz Flex-XC1 Disposable Flexible Ureteroscope|Patients will receive flexible ureteroscopy with the Storz Flex-XC1 disposable flexible ureteroscope.
214405258|NCT05646069|DEVICE|Storz Flexible Digital Ureteroscope|Patients will receive flexible ureteroscopy with the Storz flexible Digital ureteroscope.
214405259|NCT00098943|BIOLOGICAL|CNGRC peptide-TNF alpha conjugate|
214405260|NCT04437108|PROCEDURE|Li-SWT (suprapubic approach)|The patient will be asked to lie in flat dorsal position. A commercially used gel for sonography will be applied to the suprapubic region. The applicator will be placed on suprapubic region with two fingers apart from the symphysis pubis tilting to 45°. Shock waves will be directed to 3 different sites; the midline (over the bladder dome) and 3 cm right and left to the midline (over bilateral bladder walls). The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
214405261|NCT04437108|PROCEDURE|Li-SWT (perineal approach)|The patient will be asked to lie in lithotomy position. A commercially used gel for sonography will be applied to the perineum. The applicator will be placed on perineal region. Shock waves will be directed to 3 different sites: the midline and 2 cm above and below the midline. The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
214405262|NCT04437108|PROCEDURE|Li-SWT (combined approach)|The patient will receive 3000 shocks; 1500 shocks through suprapubic approach (500 shocks per site) and another 1500 shocks through perineal approach (500 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
214405263|NCT04437108|PROCEDURE|Sham treatment|The same technique of Li-SWT will be used but the applicator of the shock wave device will be turned off.
215010401|NCT06731244|OTHER|shared decision-making process|"The intervention is based on a strategy based on a shared decision-making process which is a collaborative process that involves a patient and their healthcare professional working together to reach a joint decision about care (anticoagulant treatment).~The shared decision-making process will be conducted as follows:~* Step 1: prepare the risk estimates (risk of recurrent VTE, risk of bleeding) for the patient, based on time-dependent multicomponent risk prediction scores and socio-anthropological scales (TDMI) and other validated risk prediction scores and evidence-based medicine;~* Step 2: Communicating risks, benefits and consequences to the patient;~* Step 3: Make a joint decision about treatment and care, and agree together when this will be reviewed."
214405264|NCT04437108|DRUG|Solifenacin|The patients will be treated by antimuscarinics (solifenacin) which are considered as the conventional treatment of storage symptoms after prostatectomy.
214405265|NCT01971892|OTHER|Non Invasive ventilation (facial mask and NIV ventilator)|Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
214405266|NCT01971892|OTHER|Standard oxygen therapy with facial mask|facial Venturi mask
214405267|NCT06564831|OTHER|SLAM + SOC|Weekly Treatment visits for 12 weeks begin at day 0. SLAM applications with SOC until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214405268|NCT06564831|OTHER|SOC|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
214405269|NCT05927961|DIAGNOSTIC_TEST|histopathology|There is a clear boundary between adrenal adenoma and surrounding normal tissue. There is no clear boundary between adrenal hyperplasia and surrounding normal tissues.
214405270|NCT02481882|DEVICE|Magnetic Resonance Imaging|All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.
214405271|NCT02481882|DRUG|Prohance (Gadoteridol)|A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
214405272|NCT05080920|DIETARY_SUPPLEMENT|Rosmalip®|Nutritional Supplement+Usual Care
214405273|NCT05080920|OTHER|Placebo|Placebo+Usual Care
214405274|NCT05535036|DRUG|Dexamethasone 4mg|all patients had standard non-invasive monitoring including an electrocardiogram, non invasive blood pressure and pulse oxymetry. An 18-gauge intravenous cannula was inserted into the nondominant arm or hand and 500 ml of a saline solution (0.9 %) was infused. The prevention of postoperative nausea and vomiting (PONV) was assured to all patients by administering 4 mg of IV Ondansetron. Spinal anesthesia was performed according to our department protocol: L4-L5 or L3-L4 intervertebral space puncture using a 25 gauges needle, with injection of 0.5% hyperbaric Bupivacaine mixture (dose depending on patient height) associated with 2.5 ug Sufentanil and 100 ug Morphine. Before surgical incision, patients received either an intravenous injection of 8 mg (2 ml) Dexamethasone (DG) or 2 ml of a Saline solution (PG).
214405275|NCT05535036|DRUG|Placebo|patients received 2ml of intravenous saline solution
214405276|NCT00002569|DRUG|lomustine|
214405277|NCT00002569|DRUG|procarbazine hydrochloride|
214405278|NCT00002569|DRUG|vincristine sulfate|
214405279|NCT00002569|RADIATION|radiation therapy|
214405280|NCT01495780|BEHAVIORAL|Remote Health Monitoring|1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
214405281|NCT03528135|BEHAVIORAL|Project PRIDE|See arms section.
214405282|NCT00657774|DRUG|FlutiForm 250/10 ug|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
214405283|NCT00657774|DRUG|FlutiForm 100/10 ug|SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
214405284|NCT00657774|DRUG|Oral Prednisone 10mg|2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
214405285|NCT00657774|DRUG|Placebo|2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
214405286|NCT02150044|DEVICE|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
214405287|NCT04788017|DRUG|Ziresovir|"Planned treatments are:~* Cohort 1: 300 mg of ziresovir~* Cohort 2: up to 600 mg of ziresovir~* Cohort 3: up to 900 mg of ziresovir"
214405288|NCT04788017|OTHER|Placebo|"Planned treatments are:~* Cohort 1: 300 mg of placebo~* Cohort 2: up to 600 mg of placebo~* Cohort 3: up to 900 mg of placebo"
215010402|NCT04761120|DEVICE|Abbott SJM Rigid Saddle Ring|The Abbott SJM Rigid Saddle Ring is a rigid, polyester-velour-covered, titanium alloy mitral annuloplasty ring with a saddle shape intended to mimic the shape of a healthy mitral annulus during systole.
214405289|NCT01581853|DRUG|Lopinavir/ritonavir 800 mg / 200mg|Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
214405290|NCT03096119|OTHER|home blood pressure measurement|We ask participants to measure their home blood pressure 7 days or more.
214405291|NCT01223859|PROCEDURE|Interstitial soft palate surgery|Soft palate RF surgery in local anaesthesia
214405292|NCT02846818|PROCEDURE|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
214405293|NCT03917212|OTHER|No intervention|No intervention, observational study with metabolic characterisation
214405294|NCT04058314|DEVICE|Gemini IV|Eyes randomized to receive the Gemini IV device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
214405295|NCT04058314|DEVICE|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
214405296|NCT00821236|DEVICE|Excimer Laser|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
214405297|NCT00821236|DEVICE|AMO/VISX CustomVue™|Excimer Laser
214405298|NCT00821236|DEVICE|LADARVision 4000 excimer laser|Excimer Laser
214405299|NCT05649579|DRUG|Dupilumab|Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.
214405300|NCT04805151|OTHER|No intervention|No intervention
214405301|NCT00693030|DEVICE|sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)|comparison of multiple drug eluting stents
214405302|NCT00693030|DEVICE|paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)|comparison of multiple drug eluting coronary stents
214405303|NCT00693030|DEVICE|zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)|comparison of multiple drug eluting coronary stents
214405304|NCT00693030|DEVICE|Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)|comparison of DES in overlap vs BMS in overlap
214405305|NCT00889564|DEVICE|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
214405306|NCT00789061|DRUG|Proton pump inhibitor|One dosage/day/year
214405307|NCT01055782|DEVICE|Endoguide|Use of endoguide to facilitate completion of endoscopy
214405308|NCT00686621|DRUG|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
214405309|NCT00578227|BIOLOGICAL|Cervarix™|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
214405310|NCT00578227|BIOLOGICAL|Twinrix ™ Paediatric|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
214405311|NCT02353611|OTHER|6% hydrogen peroxide|
214405312|NCT02353611|OTHER|35% hydrogen peroxide|conventional peroxide whitening compound acted like control
214405313|NCT02350361|DRUG|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
214405314|NCT02350361|DRUG|Placebo|Placebo
214405315|NCT01293162|DRUG|Armolipid Prev|Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
214405316|NCT04990882|OTHER|Interpretation of FAPI-PET/CT scans|Each observer's Group will be asked to review FAPI-PET/CT scans of patients with representative cancer types.
214405317|NCT00577629|DRUG|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
214405318|NCT00577629|DRUG|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
214405319|NCT00577629|DRUG|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
214405320|NCT00577629|DRUG|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
214405321|NCT00577629|DRUG|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
214405322|NCT00577629|DRUG|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
214405323|NCT01051778|DRUG|enoxaparin 40mg plus low dose aspirin|Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
214405324|NCT01051778|DRUG|Heparin calcium5,000 U twice daily plus low dose aspirin|Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
214405325|NCT01605136|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
214504691|NCT06766838|PROCEDURE|6. Plastibell device technique (Group F):|The prepuce is grasped using two hemostats applied at 2 and 10 o'clock. A dorsal slit at 12 o'clock is made, appropriate-sized bell is placed over the glans, and the foreskin is brought over its top. The string is placed around the foreskin and the Plastibell device at the level of the mark in a groove that acted as the string placement guide. The string is then tightened and tied in a simple square knot. The excess foreskin is trimmed from around the bell using iris scissors. The handle is then broken off the device
214504692|NCT07089641|PROCEDURE|Biospecimen Collection|Undergo urine, blood, and CSF sample collection
214504693|NCT07089641|PROCEDURE|Echocardiography Test|Undergo ECHO
214504694|NCT07089641|DRUG|EGFR Inhibitor ERAS-801|Given PO
214504695|NCT07089641|OTHER|Fludeoxyglucose F-18|Given FDG
214504696|NCT07089641|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
214504697|NCT07089641|PROCEDURE|Positron Emission Tomography|Undergo FDG PET
214504698|NCT07089641|PROCEDURE|Surgical Procedure|Undergo surgical resection
214504699|NCT02609048|DRUG|Placebo Comparator|Placebo Capsule
214405326|NCT01605136|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months
214405327|NCT04878380|DEVICE|Fitbit|A consumer sleep tracker will be used to monitor sleep patterns throughout the study
214405328|NCT04878380|BEHAVIORAL|Sleep education tips|Sleep tips will be provided before the intervention phase
214405329|NCT04878380|BEHAVIORAL|Goal-setting|During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.
214405330|NCT04293991|DEVICE|High Flow Nasal Cannula|Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.
214405331|NCT04293991|DEVICE|Non Invasive Ventilation|Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
214405332|NCT00364598|DRUG|Anginera, a human tissue replacement therapy|
214405333|NCT01072929|DRUG|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
214405334|NCT01072929|DRUG|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
214405335|NCT01366196|DRUG|Pregabalin 150 mg|Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
214405336|NCT01366196|DRUG|Placebo|Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
214405337|NCT02871765|OTHER|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
214405338|NCT06053593|DEVICE|Testing of self collected urine|Each PWD will test their self-collected urine.
214405339|NCT06053593|DEVICE|Labeling Evaluation|Each PWD will complete a labeling evaluation.
214405340|NCT06053593|DEVICE|Urine Control testing|Each PWD will test four urine control solutions.
215010403|NCT04761120|DEVICE|Abbott SJM Séguin Ring|The Abbott SJM Séguin Ring is a semi-rigid, polyester-velour-covered, polyethylene mitral annuloplasty ring that varies in thickness and flexibility over its circumference, with the posterior portion of the ring having greater flexibility than the anterior portion.
215010404|NCT04761120|DEVICE|Abbott SJM Tailor Ring|The Abbott SJM Tailor Ring is a flexible, polyester-velour-covered, silicone annuloplasty ring indicated for use in surgical repair of the mitral or tricuspid valve. The Tailor Ring can be implanted as a full annuloplasty ring, or the surgeon can remove the ring's cut zone with a scalpel and use the partial Tailor Ring as a posterior annuloplasty band.
215010405|NCT04761120|DEVICE|Abbott SJM Tailor Band|The Abbott SJM Tailor Band is a flexible, polyester-velour-covered, silicone band for posterior annuloplasty indicated for use in surgical repair of mitral or tricuspid valve. The Tailor Band is identical to the Tailor Ring with the cut zone removed, save that the polyester covering is sewn closed at the ends of the band during manufacturing.
215010406|NCT06975865|DRUG|Rilzabrutinib|Pharmaceutical form:Tablet -Route of administration:Oral
215010407|NCT06975865|DRUG|Placebo|Pharmaceutical form:Tablet -Route of administration:Oral
214405341|NCT01763736|BEHAVIORAL|Music|playlist per patient preference
214405342|NCT00800371|PROCEDURE|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
214405343|NCT00244257|BIOLOGICAL|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
214405344|NCT00244257|BIOLOGICAL|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
214405345|NCT00244257|BIOLOGICAL|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
214405346|NCT00244257|BIOLOGICAL|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
214405347|NCT00244257|BIOLOGICAL|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
214405348|NCT04308447|DEVICE|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
214405349|NCT00052962|PROCEDURE|Cytoreductive surgery|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
214405350|NCT00052962|PROCEDURE|Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m\^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m\^2 and paclitaxel 125 mg/m\^2.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
214405351|NCT06108141|BEHAVIORAL|Resident Education And Counseling on Household Firearm Safety|An intervention that includes a self-directed online curriculum and virtual reality simulations, designed to teach firearm screening and counseling among clinicians.
214405352|NCT06108141|BEHAVIORAL|Modified American Academy of Pediatrics Safer|An intervention that includes a self-directed online curriculum.
214405353|NCT00116740|DRUG|APD356|
214405354|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
214405355|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
214405356|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
214405357|NCT02240875|BIOLOGICAL|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
214405358|NCT02240875|BIOLOGICAL|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
214405359|NCT02240875|BIOLOGICAL|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
214405360|NCT05227313|DIETARY_SUPPLEMENT|Eefooton oral solution|Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
214405361|NCT05227313|DIETARY_SUPPLEMENT|Placebo oral solution|oral solution matched placebo
214405362|NCT02483299|DRUG|Metformin|
214405363|NCT02483299|DRUG|Glucophage tablets and Victoza|
214405364|NCT00019318|DRUG|romidepsin|
214405365|NCT00550108|OTHER|Ethanol lavage|Ethanol lavage of pancreatic cysts.
214405366|NCT03033914|DRUG|doxorubicin|Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
214405367|NCT03033914|DRUG|Bleomycin|Bleomycin: 10 units/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
214405368|NCT03033914|DRUG|vinblastine|Vinblastine: 6 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
214405369|NCT03033914|DRUG|dacarbazine|Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
214405370|NCT03033914|DRUG|Nivolumab|nivolumab 240mg q14 days
214405371|NCT04971694|OTHER|No interventions or procedures|This is a retrospective observational study and data will be collected from the subject's existing medical record. No interventions or procedures will be required for this study.
214405372|NCT02453724|DEVICE|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
214405373|NCT03213470|OTHER|magnetic resonance imaging|
214504700|NCT02609048|DRUG|Experimental: Seladelpar 50 mg|Seladelpar 50 mg capsule
214504701|NCT02609048|DRUG|Experimental: Seladelpar / MBX-8025 200 mg|Seladelpar 100 mg capsules
214504702|NCT03571373|OTHER|No intervention|No intervention due to the observational set-up of this study.
215098217|NCT00696046|PROCEDURE|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical \& steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
214405374|NCT02374333|BIOLOGICAL|huCART19|
214405375|NCT03177187|DRUG|AZD5069|10mg and 40mg plain, beige, film-coated tablets packaged in bottles
214405376|NCT03177187|DRUG|Enzalutamide 40 MG|Enzalutamide is presented in 40mg white to off white capsules or tablets. The capsules/tablets are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules/tablets. Each carton contains 4 wallets (112 soft capsules/tablets). Or tablets in bottles (120 per bottle).
214405377|NCT06228703|DEVICE|High-flow nasal cannula device with flow setting at 40 L/min or higher|Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher
214405378|NCT05113927|DEVICE|Selene|SELENE imaging of all margins, with record of each margin assessment and an opportunity to excise tissue from the lumpectomy cavity post-imaging. The new margin will be imaged with SELENE and the surgeon will record the assessment and may take additional tissue (up to a maximum of six total shaves, including up to two shaves in each orientation) or record why no further tissue may be taken.
214405379|NCT05380739|BEHAVIORAL|Working Memory Training|A 10-session working memory (WM) training program
214405380|NCT01101906|DRUG|OSI-906|OSI-906 administered orally
214405381|NCT01101906|DRUG|Placebo|Matching placebo administered orally
214405382|NCT05935267|PROCEDURE|thoracic irrigation|We will start this study using 20% as the approximate national intervention rate, based on current literature, with the goal of detecting a 50% reduction in the experimental arm (i.e. 10% secondary intervention rate after thoracic irrigation). Therefore, we will plan to enroll 108 patients in the irrigation cohort and 324 patients in the control cohort. An interim analysis will be conducted once 54 patients have been enrolled in the irrigation cohort. The secondary intervention rate in the irrigation cohort and the standard cohort will be determined, and any adjustments to sample size will be made at that time.
214405383|NCT03880422|DIETARY_SUPPLEMENT|Dietary Intervention|Receive diet plan
214405384|NCT03880422|OTHER|Educational Intervention|Attend educational meeting
214405385|NCT03880422|BEHAVIORAL|Exercise Intervention|Complete exercise program
214405386|NCT03880422|OTHER|Quality-of-Life Assessment|Ancillary studies
214405387|NCT03880422|OTHER|Survey Administration|Ancillary studies
214504703|NCT05388838|BIOLOGICAL|Blood sample|Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
214504704|NCT07094893|DRUG|Cetuximab (EGFR inhibitor)|Administration according to the labels of each IMP.
214504705|NCT07094893|DRUG|Bevacizumab|Administration according to the labels of each IMP.
214504706|NCT07094893|DRUG|Irinotecan (CPT-11)|Administration according to the labels of each IMP.
214504707|NCT07094893|DRUG|Oxaliplatin|Administration according to the labels of each IMP.
214504708|NCT07094893|DRUG|Leucovorin and 5-FU|Administration according to the labels of each IMP.
214504709|NCT07094893|DRUG|Capecitabine|Administration according to the labels of each IMP.
215098218|NCT03221686|DIETARY_SUPPLEMENT|Intervention|The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.
214688315|NCT07163611|DRUG|Obinutuzumab administration|All participants will receive obinutuzumab 1000 mg on day 1 and 15, with two additional infusions after 6 months if the anti-PLA2R antibody IFT assay is still positive with proteinuria \> 2 gram/24 hours and stable kidney function.
215010408|NCT05424211|DEVICE|Music Therapy Mobile Application|The authorities determined by taking consultancy from TÜMATA (Turkish Music Research and Promotion Group) will be uploaded to the mobile application developed by the software specialist. The maqams (Rast, Nihavent and Neva) to be used in the application will be played to the patients 3 times in half an hour at different times of the day via the mobile application. Rast tonality will be played in the morning, nihavent tune will be played at noon and neva tune will be played in the afternoon.
215010409|NCT06038929|DEVICE|Vagal nerve stimulant|Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.
215010410|NCT00901498|DRUG|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
215010411|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
215010412|NCT00901498|DRUG|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
215010413|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
215010414|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
215010415|NCT05685004|BIOLOGICAL|TVI-Brain-1|Attenuated autologous cancer cells and activated autologous blood-derived t cells
214504710|NCT06524570|DEVICE|HIFU-HT|High-Intensify Focused Ultrasound Histotripsy
214504711|NCT06524570|DRUG|ICI|Ipilimumab and nivolumab
215010416|NCT05685004|PROCEDURE|Standard of Care|Surgery for tumor removal or debulking to minimize tumor burden
214504712|NCT05008484|DEVICE|NMES|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach
214504713|NCT05008484|DRUG|Vitamin D|2000IU oral vitamin D supplementation daily for 9 months
215010417|NCT05685004|RADIATION|Radiotherapy|Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.
215010418|NCT05685004|DRUG|Temozolomide|All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .
215010419|NCT05805605|BIOLOGICAL|Peripheral Blood Stem Cell Transplant|On day 0, a target dose of 5 x 106 CD34 cells/kg will be infused.
215010420|NCT05805605|DRUG|Allopurinol 300 MG|300 mg/day from day -7 to day 0. Allopurinol 150mg/m2/day for pediatric participants.
215010421|NCT05805605|DRUG|Fludarabine|30 mg/m2 IV over 1 hour. Administered on day -6 to day -2.
215098219|NCT03221686|DIETARY_SUPPLEMENT|Control|High quality protein supplement 14 days pre-operatively and post-operatively.
215098220|NCT02699567|OTHER|No intervention|
214504714|NCT05008484|PROCEDURE|Passive movement|Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
214504715|NCT02485925|DEVICE|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
215010422|NCT05805605|DRUG|Cyclophosphamide|Administered as a 2 hour IV infusion on day -6, +3, and +4.
215098221|NCT06051903|OTHER|Mobilization wih movement|The purpose of this study is to determine the effect of talar mobilization with movement versus acupuncture on knee pain and function in the postmenopausal women
215098222|NCT01735981|OTHER|Video game exercise using Dance Dance Revolution|use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
215098223|NCT01735981|OTHER|hand-held video game|hand-held video games
215098224|NCT01591187|OTHER|Text messaging|Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.
215098225|NCT01591187|OTHER|Questionnaire|Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.
215098226|NCT01591187|OTHER|Interviews|Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
215098227|NCT02885246|OTHER|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
215098228|NCT05897892|DIETARY_SUPPLEMENT|Clinical study on the mangrove sword bean food bar effect for older people|The treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.
215098229|NCT04102995|DRUG|Sepranolone injection low dose|Subcutaneous (SC) administration
215098230|NCT04102995|DRUG|Sepranolone injection high dose|Subcutaneous (SC) administration
215098231|NCT04102995|DRUG|Placebo injection|Subcutaneous (SC) administration
215010423|NCT05805605|BIOLOGICAL|Bone Marrow Cell Transplant|On day 0, a target dose of 3 x 108 nucleated cells/kg recipient weight will be infused.
215010424|NCT05805605|RADIATION|Total Body Irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
215010425|NCT05805605|DRUG|Sirolimus Pill|"All participants begin +5 to day +60.~Loading dose on day +5 of 5 mg/m2/day orally once (max dose of 8 mg).~Maintenance dose 2.5 mg/m2 orally daily to maintain a level of 8-12 ng/ml (max dose of 4 mg)."
215010426|NCT05805605|DRUG|Mycophenolate Mofetil|"All patients begin day +5 through day +35.~3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (maximum of 1 gram per dose) every 8 hours."
215010427|NCT05727176|DRUG|TAS-120|TAS-120 is an oral FGFR inhibitor
215010428|NCT05089916|DRUG|Osimertinib|Osimertinib: according to its marketing authorization, i.e. at daily doses of 80 mg, for a maximum of 12 months within the study.
215010429|NCT05089916|RADIATION|Radiotherapy|"Radiotherapy: according to standard of care~The target population will comprise 3 parallel cohorts, for cohort 1 and 3 a minimum of 10 subjects is planned to be enrolled:~1. Irradiation of bone, solid organ (non-lung, non-brain) or soft-tissue metastases~2. Irradiation of brain metastases (initial lesion size \< 3 cm)~3. Irradiation of lung lesions (primary tumor or metastases, lesion size \< 5 cm)"
215010430|NCT01459549|PROCEDURE|Roux-en-Y hepaticojejunostomy|All participants received routine perioperative care and followed the same surgical principles: removing affected liver segments, clearing stones, correcting strictures, and then restoring bile drainage. The primary indications for hepatectomy were unilobar or segmental diseases and the presence of the following lesions in the affected liver segment or lobe: 1) multiple stones with biliary strictures that cannot be cured via choledochoscopy, 2) atrophy, fibrosis, and multiple abscesses, and 3) suspicious neoplasia. Biliary exploration was routinely conducted to facilitate stone removal, rectify strictures, and assess the functionality of the Oddi sphincter. Following this, patients would be evaluated for eligibility and assigned accordingly. The sole distinction between the two arms was performing RYHJ or maintaining the common bile duct for bile drainage.
215010431|NCT00689143|DRUG|sargramostim|
215010432|NCT04043026|DRUG|Statin|Any statin therapy
215010433|NCT03081169|DRUG|Enoxaparin Sodium 150 MG/ML Prefilled Syringe|The same drugs and dosages will be used in both groups, with only the timing being different
215010434|NCT03081169|DRUG|Heparin|The same drugs and dosages will be used in both groups, with only the timing being different
215010435|NCT03753906|DEVICE|Osmed® hydrogel expander implantation|Under local anaesthesia, a small vertical incision, adapted to the diameter of the Osmed® sself-inflating hydrogel expander, was made with #15 scalpel blade at the mesial line angle of the adjacent tooth which started below the gingival margin extending from the keratinized tissue above the MGJ to the non-keratinized tissue beyond the MGJ. A minimally invasive preparation of a subperiosteal pouch was performed with KPA tunnelling knife. Size of the pouch was controlled with the specific surgical template to ensure the device easily fits into the prepared pouch without tension. Expanders were secured in the correct position with a bone fixation screw, at the flat end, which does not possess an expansion capability. The wound was closed with 3-0 silk suture using simple interrupted sutures.
215010436|NCT04894708|PROCEDURE|colonoscopy|addition of polyp detection algorithm by Fujifilm
215010437|NCT01737086|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 and zinc sulphate|
215010438|NCT01737086|DIETARY_SUPPLEMENT|placebo|
215010439|NCT01410253|OTHER|Combination of four techniques of physiotherapy|The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
215010440|NCT01410253|OTHER|Combination of three techniques of physiotherapy|Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
215010441|NCT01410253|OTHER|Combination of two techniques of physiotherapy|Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
215010442|NCT01410253|OTHER|standard therapy|Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
215010443|NCT02001883|DRUG|Association low-dose statin and nutraceuticals|
215010444|NCT01158677|PROCEDURE|Meniscectomy|patients undergoing meniscectomy will be asked to complete the KOOS-scale,Vas-scale, Tegner questionnaire, SF-36 questionnaire pre-operatively and at 3, 6 and 12 months post-operatively
215010445|NCT02221414|DRUG|Linagliptin/Metformin FDC|
215010446|NCT02221414|DRUG|Linagliptin|
215010447|NCT02221414|DRUG|Metformin|
215010448|NCT00513539|DRUG|porfimer sodium|
215010449|NCT00513539|PROCEDURE|biliary stenting|
215010450|NCT04718753|BEHAVIORAL|Mindful breathing intervention|Mindful breathing intervention audio, which is used in mindfulness-based interventions, will be sent to the participants once per day.
215010451|NCT02860078|DEVICE|Ultrasound|Location and function of sacral epidural space with ultrasound
215010452|NCT02860078|DEVICE|Radioscopy|Location and puncture of the sacral epidural space only with fluoroscopy
215098232|NCT04847765|DEVICE|VIPUN Gastric Monitoring System prototype|"The VIPUN Balloon Catheter prototype is a nasogastric feeding tube with integrated balloon that can be inflated with a preset volume of air. Intraballoon pressure changes are recorded outside the body. Gastric contractions can be detected in the pressure profile.~The recording lasts 30 minutes and is combined with simultaneous cine magnetic resonance imaging."
215098233|NCT05645965|DEVICE|ICD insertion|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
215098234|NCT03492034|DEVICE|IUD during CS|IUD insertion during CS
215098235|NCT03492034|DEVICE|IUD after puerperium|IUD after puerperium
215098236|NCT05426278|DEVICE|Bair hugger and Forces air warmer|The EQUATOR™ (EQ-5000) air-warmer is a convective warmer, with the average and maximum Contact Surface Temperatures of 39℃ \& 44℃ Respectively. Temperature on this device can be set at 36℃ , 40℃ , 44℃. The 3M™ Bair Hugger ™ (SW-2003) upper body blanket is used to warm the body from head till the xiphisternum
214405388|NCT05328505|RADIATION|Image-guided Radiotherapy|de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.
214405389|NCT06015646|BEHAVIORAL|Personalized lifestyle coaching and educational handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study. Participants will also receive a 30-minute focused, personalized lifestyle coaching within a week of the initial overnight shift. The lifestyle coach will be in close contact during the night shifts.
214405390|NCT06015646|BEHAVIORAL|Handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
214405391|NCT05895630|BEHAVIORAL|Interactive physical exercise|Interactive remote sessions of physical exercise in groups of 10 patients. The sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The intervention will last 12 weeks. The sessions will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
214405392|NCT05895630|BEHAVIORAL|Video physical exercise|Individual remote sessions of physical exercise based on pre-recorded videos. The video sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The videos will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
214405393|NCT06522867|OTHER|Intraocular pressure measure|The intraocular pressure of the subjects using either the Goldmann applanation tonometer, Icare or Accupen. The order of the measure is randomized.
214405394|NCT03549988|OTHER|Fecal Calprotectin (FC) measurements with IBDocTM|"Each IBDocTM kit measure one fecal calprotectin value. The IBDoc® is an in-vitro diagnostic immunoassay analyzed by a downloadable smartphone application (CalApp®). A patient is able to process their stool at home using a test cassette.~The IBDocTM test results are displayed in a light signal system as three titre categories; normal \<100 µg/g (green), 100-300 µg/g (yellow), \>300 µg/g (high). Patients' results will be sent directly to the central research coordinator through the IBDoc® Web Portal. If the FC is \>250 µg/g a second FC will be performed within 2 weeks. If this result is \<250 µg/g patients will continue to monitor their FC every 2 months. If the second result is \>250 µg/g, the attending physician will review the patient either by telephone or in the office within 7 days."
215010453|NCT02542527|PROCEDURE|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
215010454|NCT04849013|DRUG|Placebo|Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs
215010455|NCT04849013|DRUG|Mescaline 100mg|"Drug: 100mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
215098237|NCT03580980|DRUG|Paracetamol and ketamine|intravenous paracetamol and ketamine followed by ketorolac
215010456|NCT04849013|DRUG|Mescaline 200mg|"Drug: 200mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
215010457|NCT04849013|DRUG|Mescaline 400mg|"Drug: 400mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
215010458|NCT04849013|DRUG|Mescaline 800mg|"Drug: 800mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
215010459|NCT04849013|DRUG|Mescaline 800mg + Ketanserin 40mg|"Drug: 800mg Mescaline per os, single dose~Other: 40mg Ketanserin per os, single dose"
215098238|NCT03580980|PROCEDURE|Caudal levobupivacaine|an epidural injection of morphine and levobupivacaine through the caudal space
215098239|NCT03580980|DRUG|Morphine|patient controlled analgesia by morphine
215098240|NCT02900768|BEHAVIORAL|Exercise|Combination of resistance and aerobic exercises for 100 days.
215098241|NCT02069119|DRUG|OPC-108459|
215098242|NCT02069119|DRUG|Placebo|
215098243|NCT01033916|OTHER|LIBERAL|The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
215098244|NCT02902393|BIOLOGICAL|Thromboelastography|
215098245|NCT02270112|DEVICE|ECG|Patients receive a 5 Minute ECG recording and have their pulse recorded by an iPhone.
215098246|NCT02458781|DRUG|Metronidazole|Metronidazole 500mg given twice daily for 14 days
215098247|NCT02458781|DRUG|Ciprofloxacin|Ciprofloxacin 500mg given twice daily for 14 days
215098248|NCT02458781|DRUG|Placebo|Placebo given twice daily for 14 days
215098249|NCT03725813|OTHER|Person-centred inpatient care|"The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention."
215098250|NCT05795192|DRUG|SB17170|Taking SB17170 orally once a day
215098251|NCT05795192|DRUG|Placebo|Taking Placebo orally once a day
215098252|NCT05181124|DRUG|coadministration of JP-1366 and aceclofenac|An open-label, multiple-dosing, fixed sequence, 3-period design
214405395|NCT06298032|DRUG|Olamkicept Part A|"Intravenous infusion. Single dose.~Part A consists of 3 different doses~* 1200 mg~* 1800 mg~* 2400 mg"
214405396|NCT06298032|DRUG|Olamkicept Part B|"Intravenous infusion. Multiple doses.~Part B consists of 3 different doses.~* 1200 mg~* 1800 mg~* 2400 mg"
215010460|NCT02596087|OTHER|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
215010461|NCT03304288|DRUG|Rituximab|Low-dose rituximab was used in combination with ATRA or as the monotherapy
215010462|NCT03304288|DRUG|All-trans retinoic acid|ATRA was used in combination with low-dose rituximab
215010463|NCT07046117|DRUG|Tezepelumab|injection with Tezepelumab every 4 weeks
215010464|NCT07044453|DRUG|Gem/Nabpaclitaxel infusion|Downstaging and pathological response is empirically define as T1-2/N0/R0 status. If the anatomopathological analysis shows a lesion classified as T3-4 or N+ or R1, an adjuvant chemotherapy based on Gemcitabine with Nab Paclitaxel will be proposed for a period of 3 months.
215098253|NCT05181124|DRUG|coadministration of JP-1366 and meloxicam|An open-label, multiple-dosing, fixed sequence, 3-period design
215098254|NCT05181124|DRUG|coadministration of JP-1366 and naproxen|An open-label, multiple-dosing, fixed sequence, 3-period design
215098255|NCT05181124|DRUG|single-dosing of JP-1366 in Korean and Caucasian|An open-label, single-dosing, parallel design
215010465|NCT07044453|DRUG|mFOLFIRINOX infusion|Downstaging and pathological response is empirically define as T1-2/N0/R0 status. In that setting the patients will receive mFOLFIRINOX adjuvant chemotherapy 3 months.
215098256|NCT02566590|DEVICE|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
215098257|NCT02566590|DIETARY_SUPPLEMENT|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
215098258|NCT02566590|DIETARY_SUPPLEMENT|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
215010466|NCT06794411|BEHAVIORAL|Intervention group: Food habits and physical activity program|"5 dynamic face-to-face sessions to promote healthy eating and regular physical activity. The 5 sessions are structured based on the pedagogical approach of Seeing, Judging and Acting (Gibson, 1999; Rodríguez-Bailón, et al., 2016). This methodology provides a logical structure to achieve nutritional and physical activity self-analysis. It is applied based on 3 stages:~* 1st reflective stage: to raise awareness about the importance of following healthy eating and physical activity habits and identify to what extent families are close to the healthy recommendations in relation to these two habits (first two sessions).~* 2nd: more active stage, to acquire strategies and learn to put these recommendations into practice in their day-to-day lives (session 3th and 4th session).~* 3th: to plan specific actions to address and transform some aspects of improvement by freely assuming one's own commitment proposals with the aim of modifying the presented reality, if deemed appropriate (last session)."
215098259|NCT03825211|PROCEDURE|Continuous suture in the perineals lesions|A continuous suture of the vagina, muscle and skin is performed continuously, without knotting or cutting the suture thread.
215098260|NCT03825211|PROCEDURE|Discontinuous suture in the perineals lesions|Suture the muscle independently of the vagina and independently of the skin
215098261|NCT02602158|DIETARY_SUPPLEMENT|Octanoic acid (1-13C, 99%)|"13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
215098262|NCT02602158|DIETARY_SUPPLEMENT|TRIOCTANOIN (1,1,1-13C3, 99%)|"13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
214405397|NCT06298032|DRUG|Placebo|Intravenous infusion
215010467|NCT06794411|BEHAVIORAL|Usual Care Group|They will be evaluated on baseline, final and follow up, and they will recieved basic nutritional and physical activity information.
214405398|NCT06431022|BEHAVIORAL|webSTAIR|WebSTAIR is a self-paced, brief skills-focused treatment for PTSD that focused on improving one's ability to manage emotions and relationships.
214405399|NCT06431022|BEHAVIORAL|CHW coaching|CHWs will provide webSTAIR coaching, which includes motivational, problem solving, and cognitive-behavioral strategies to enhance skills practice and engagement.
214405400|NCT06268301|DRUG|Budesonide|Budesonide oral suspension
214405401|NCT01688102|DIETARY_SUPPLEMENT|Oral Vitamin D3|50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed
214405402|NCT01688102|RADIATION|Ultraviolet Light|16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes
214405403|NCT00170911|DRUG|AAE581|
214688316|NCT07164079|DIETARY_SUPPLEMENT|blackberry root|Patients in the intervention group will receive a Rubus Sanctus root extract, which they will consume with breakfast for 8 weeks. The tea will be packaged as 5 grams of Rubus Sanctus root and steeped in 200 ml of water at 80°C for 5 minutes. Participants in the intervention group will receive the Rubus Sanctus root tea along with the necessary equipment (a 200 ml beaker and thermometer). Measurements of TSH, T4, T3, anti-TPO, anti-TG, TSH receptor antibodies, liver function tests, thyroid parenchymal echogenicity, and thyroid volume will be taken at the Endocrinology and Metabolic Diseases Clinic of Muğla Training and Research Hospital before and after the study.
214405404|NCT00525694|OTHER|Glucose tolerance test|10 ounces glucose tolerance test solution
214405405|NCT00525694|OTHER|glucose tolerance test solution|75 grams glucose load
214405406|NCT00525694|OTHER|Diet Coke|10 ounces of Diet Coke
214688317|NCT07164079|DIETARY_SUPPLEMENT|black tea|Patients with Graves' disease assigned to the control group will be asked to consume black tea (Camellia sinensis) with their breakfast for 8 weeks. Black tea is a product consumed almost daily in Turkish society. Black tea will be prepared in 5-g doses and steeped in 200 ml of water at 80°C for 5 minutes. Participants in the control group will be provided with black tea bags along with the necessary equipment (a 200 ml beaker and thermometer). TSH, T4, T3, anti-TPO, anti-TG, TSH receptor antibody, liver function tests, thyroid parenchymal echogenicity, and thyroid volume will be obtained before and after the study at the Endocrinology and Metabolic Diseases Clinic of Muğla Training and Research Hospital.
215010468|NCT04179630|BIOLOGICAL|Aldafermin (NGM282)|Single 3 mg dose
215010469|NCT04002895|DRUG|Foliglurax|Single oral dose of 80 mg \[14C\]-foliglurax(93µCi/3.44 MBq), 1mg/mL oral solution (prepared from \[14C\]-foliglurax powder for oral solution)
215010470|NCT02571231|DEVICE|HFV + and - VG|High frequency ventilation with and without volume guarantuee
215010471|NCT06244901|DEVICE|Ankle Exoskeleton|Walking for twenty minutes with a wearable powered robotic ankle exoskeleton on real-world terrain every day for a week.
215010472|NCT06244901|OTHER|Normal walking|Normal walking for twenty minutes on real-world terrain every day for a week.
215010473|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
215010474|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
215010475|NCT02324595|PROCEDURE|Laparoscopic interval debulking surgery|"Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered"
215010476|NCT06097572|DIAGNOSTIC_TEST|Intranasal food challenge|Subjects will undergo an incremental intranasal challenge to initially 0.9% NaCl saline solution, and then increasing doses of the food protein
215010477|NCT06097572|DIAGNOSTIC_TEST|Mast cell activation test|Blood will be processed for mast cell activation as previously described (https://doi.org/10.1016/j.jaci.2018.01.043)
215010478|NCT03451968|OTHER|amino acid tracer injection for metabolism analysis|"the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc)."
215010479|NCT00126737|OTHER|Weight Control Nutritional Program|a week of food diary and information about dietary fat intake and proper proportions of vegetables.
215010480|NCT00126737|OTHER|Home-based exercise program|24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
215010481|NCT01926392|DRUG|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
215010482|NCT01926392|DRUG|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
215010483|NCT04539366|PROCEDURE|Biopsy Procedure|Undergo biopsy
215010484|NCT04539366|PROCEDURE|Biospecimen Collection|Undergo collection of blood
215010485|NCT04539366|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
215010486|NCT04539366|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
215010487|NCT04539366|DRUG|Cyclophosphamide|Given IV
215010488|NCT04539366|PROCEDURE|Echocardiography Test|Undergo ECHO
215010489|NCT04539366|DRUG|Fludarabine Phosphate|Given IV
215010490|NCT04539366|BIOLOGICAL|GD2-CAR-expressing Autologous T-lymphocytes|Given IV
215010491|NCT04539366|PROCEDURE|Imaging Procedure|Undergo standard imaging scans
215010492|NCT04539366|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo cardiac MRI
215010493|NCT04539366|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
215010494|NCT04539366|OTHER|Questionnaire Administration|Ancillary studies
215010495|NCT02860000|DRUG|Alisertib|Given PO
215010496|NCT02860000|DRUG|Fulvestrant|Given IM
215010497|NCT02860000|OTHER|Laboratory Biomarker Analysis|Correlative studies
215098263|NCT00903435|OTHER|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
215098264|NCT06366360|OTHER|Immersive Virtual Reality Intervention|"The immersive virtual reality rehabilitation protocol is an experimental protocol based on musical practice. This protocol will be based on the Piano Vision application, which allows several modes of music production: free or guided musical practice."
215098265|NCT06366360|OTHER|Conventional rehabilitation|The conventional rehabilitation corresponds to the classically performed in the cognitive treatment of unilateral spatial neglect. It involves training visual scanning using barrage exercises, sequence identification, scene description, and pointing.
214405407|NCT00525694|OTHER|Coke Zero|10 ounces of Coke Zero
215098266|NCT05966948|DRUG|Dextrose Solution|Prolotherapy is a regenerative tissue therapy that is considered efficacious for reducing the symptoms and morbidity of Knee Osteoarthritis (KOA) using hypertonic dextrose as an injectable substance. Treatment will be given two times, on day 1st and 30th day.
215098267|NCT05966948|DRUG|Normal Saline|Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
215010498|NCT06944223|OTHER|Kidney stone formers|"Consuming a special drink (potassium citrate) during an all-day visit to the University of Chicago research clinic~Subjects in both groups will be asked to partake in the same activities, as follows: The day before presenting to the research clinic, subjects will collect urine at home. Subjects will then come to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains potassium citrate. After this, we will collect urine and blood samples throughout the day. While at the clinic, subjects will also receive a boxed lunch at the end of the visit."
215098268|NCT03667690|DRUG|Rezafungin for Injection|Intravenous antifungal therapy
214405408|NCT00610883|DRUG|LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU|LSA4 intervention includes three phases: induction, consolidation and maintenance
215098269|NCT03667690|DRUG|Caspofungin|Intravenous antifungal therapy
214405409|NCT04625855|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (3 x 200 mg tablets) once
214405410|NCT03674840|PROCEDURE|angle kappa based SBL-3 implantation|SBL-3 implantation based on kappa angle guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
215098270|NCT03667690|DRUG|Fluconazole|Oral antifungal therapy
215098271|NCT03667690|DRUG|intravenous placebo|Normal saline
214405411|NCT03674840|PROCEDURE|0 to 180 degree SBL-3 implantation|SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
214405412|NCT01851109|BEHAVIORAL|genetic counseling|"The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:~1. A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;~2. Discuss how the results - positive or negative - affect cancer risk~3. Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);~4. Discuss how the test is conducted and what the results might be (positive, negative, uncertain);~5. Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc."
214405413|NCT02028975|OTHER|Measure the threshold of detection for linoleic acid|
214405414|NCT02028975|OTHER|Oral stimulation tests|
214405415|NCT02028975|OTHER|Venous blood samples|
214405416|NCT02028975|OTHER|Samples for genetic studies (ancillary study)|
214405417|NCT04119245|DEVICE|I-gel supraglottic airway device|After induction of general anesthesia, we will measure the Oropharyngeal leak airway pressure during controlled ventilation in supine and in positions after insertion of I-gel.
214405418|NCT02862782|DRUG|hCG (Ovitrelle 250 mcg mcg - Merck Serono)|
214405419|NCT02862782|DRUG|hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)|
214405420|NCT02396940|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
215098272|NCT03667690|DRUG|oral placebo|Microcrystalline cellulose
215098273|NCT05900492|PROCEDURE|cesarean section|caesarean delivery, is the surgical procedure by which one or more babies are delivered through an incision in the mother's abdomen
215098274|NCT00184756|DRUG|somatropin|
215098275|NCT05651815|DEVICE|Graphene spectrum light wave therapy room|Undergo 30-min of graphene adjuvant therapy every day for 7 d.
215098276|NCT01185977|DRUG|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
215098277|NCT01185977|DRUG|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
215098278|NCT01115374|PROCEDURE|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
214405421|NCT02396940|DEVICE|2D HD laparoscopy|Placebo
214688318|NCT07163091|OTHER|ankel stirrup|Ankel stirrups are a patient preferred ankel brace that allow active ankle dorsal and plantar flexion during weightbearing while maintaining lateral stability.
214688319|NCT07163091|OTHER|Foot-ankel brace (walker)|Walkers immobilise and stabilise the ankle during weightbearing.
215098279|NCT01115374|DEVICE|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
215098280|NCT05105217|OTHER|Slit2 biomarker|"1.Assessment of slit2 level in SLE patients and its correlation with disease activity.~2-Assessment of slit2 level in SSC patients and its correlation with disease activity"
215098281|NCT04488016|DRUG|Treatment A- Part 1|Subjects will receive 100 mg acalabrutinib capsule, fasted state;
215098282|NCT04488016|DRUG|Treatment B- Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
215098283|NCT04488016|DRUG|Treatment C - Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
215098284|NCT04488016|DRUG|Treatment D- Part 1|Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
215098285|NCT04488016|DRUG|Treatment A-Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
215098286|NCT04488016|DRUG|Treatment B - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
214405422|NCT06646926|OTHER|Body tempering|Participant will be positioned prone on the Body Tempering Ab Mat with their feet hanging off the end of the mat. The body tempering intervention will be applied by the same investigator for all trials. The body tempering device will be applied dynamically to each participant for 4 minutes, with the device placed on both participants' lower extremities at the same time. First, the examiner will set a timer for two minutes and begin rolling one 80-pound body tempering device along the participant's gastrocnemius-soleus complex at a rate of 30 beats per minute, traveling from the Achilles tendon (medial malleolus) to the inferior aspect of the popliteal fossa, indicated by fibular head. The participant will then take thirty seconds to transition to a supine position and receive tempering with an 80-pound tempering device along their middle to distal quadriceps, set a timer for 2 minutes.
214405423|NCT06646926|OTHER|Foam rolling self-myofascial release|Participants will be instructed via standardized script to perform self-myofascial release (SMR) on their gastrocnemius-soleus complex and quadriceps muscles. The first SMR sequence will be performed by having the participant place the foam roller behind both calves, beginning the roll at the medial malleolus and ending at the inferior aspect of the popliteal fossa, indicated by the fibular head. The participant will perform this for two minutes, rolling at a tempo of 30 beats per minute. Next, the participant will take thirty seconds to transition to a prone position, placing the foam roller just distal to the hip crease, just inferior to the AIIS, and rolling inferiorly to the area just proximal to the most superior aspect of the patella. This self-release sequence will be performed for two minutes at a tempo of 30 beats per minute. The total time should be four minutes, matching the total time of the experimental intervention group.
215010499|NCT06944223|OTHER|Control cohort|"Consuming a special drink (potassium citrate) during an all-day visit to the University of Chicago research clinic~Subjects in both groups will be asked to partake in the same activities, as follows: The day before presenting to the research clinic, subjects will collect urine at home. Subjects will then come to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains potassium citrate. After this, we will collect urine and blood samples throughout the day. While at the clinic, subjects will also receive a boxed lunch at the end of the visit."
214405424|NCT06570785|DEVICE|Intra-Operative Positioning System (IOPS)|This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.
214405425|NCT06570785|DEVICE|Conventional group|This group will be treated using standardised materials (wires, catheters) during EVAR.
214405426|NCT02783950|OTHER|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
214405427|NCT03184545|DEVICE|EMS|The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
214405428|NCT03184545|OTHER|Physical therapy|Standard physical therapy exercises
214405429|NCT06370351|COMBINATION_PRODUCT|SENS-501 administration|Administration of SENS-501 with a dedicated administration system
214405430|NCT01723774|DRUG|PD0332991|
214405431|NCT01723774|DRUG|Anastrozole|
214405432|NCT01723774|DRUG|Goserelin|
214405433|NCT01723774|PROCEDURE|Surgery (standard of care)|-Breast and axillary lymph node surgery
214405434|NCT01723774|PROCEDURE|Tumor biopsy|
214405435|NCT06515184|DRUG|PharmaNord Bio-Quinone Active CoQ10 Gold 100mg|"Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
214405436|NCT06515184|DRUG|PharmaNord Placebo|"Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
214405437|NCT06515184|DRUG|PharmaNord Bio-Quinone Active CoQ10 Gold 100mg|"Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
214504716|NCT07098624|OTHER|ACV Moringa Effervescent Tablets 4.3 g|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral"
214688320|NCT07164027|PROCEDURE|Biopsy of Prostate|Undergo biopsy
214688321|NCT07164027|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215098287|NCT04488016|DRUG|Treatment C - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
214688322|NCT07164027|PROCEDURE|Computed Tomography|Undergo PET/CT
215098288|NCT04488016|DRUG|Treatment D - Part 2|Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
215098289|NCT04984382|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
215098290|NCT05533320|DEVICE|Cold Cap Therapy|Undergo scalp cooling
215098291|NCT05533320|OTHER|Quality-of-Life Assessment|Ancillary studies
215098292|NCT05533320|OTHER|Questionnaire Administration|Ancillary studies
215098293|NCT05325346|DRUG|VLX-1005|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
214405438|NCT02399995|BEHAVIORAL|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~* Baseline sociodemographic and clinical variable data sheet (RSA)~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Post surgical follow up disease status and treatment assessment questionnaire~* At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
215010500|NCT06951490|DEVICE|PillSense™|The PillSense™ System is a prescription only device consisting of a reusable receiver and single-use ingestible capsule, intended to be used for the detection of blood in the upper gastrointestinal tract.
214405439|NCT00739453|DRUG|OSI-906|administered orally
214405440|NCT00739453|DRUG|erlotinib|administered orally
214405441|NCT05417698|OTHER|Exercise Only (Ex only)|Unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale.
214405442|NCT05417698|OTHER|Exercise and Mediterranean Diet (Ex + MedDiet)|"Participants in Ex+MedDiet arm adhere to a non-caloric restrictive Mediterranean diet throughout the 8-weeks comprising of a diet encompassing a focus on minimally processed food, incorporating a wide variety of fruits, vegetables, legumes and wholegrains, whilst utilising olive oil as the main source of fat. They will be encouraged to eat more oily and white fish, with moderate consumption of nuts, poultry and dairy products, and low consumption of red/processed meat and alcohol.~Participants will also perform unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale."
214405443|NCT06302062|DRUG|Tumor Associated Lymph node T cell|At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells (FIT003 TAL-T). After lymphodepletion, patients are infused with FIT003 TAL-T.
214405444|NCT06302062|DRUG|cyclophosphamide|A one-day intravenous injection of cyclophosphamide was administered two days prior to the initial cell transfusion.
214405445|NCT06302062|DRUG|IL-2|The IL-2 treatment will be continued for 5 days.
215098294|NCT05325346|DRUG|Argatroban|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
214405446|NCT06302062|DRUG|Serplulimab Injection|In group B, Serplulimab Injection was injected before and after cell transfusion. If two cell transfusions were performed,Serplulimab Injection were given again .
214405447|NCT06351267|OTHER|Core Stability Exercises|Core stability exercises will be used to strengthen the core muscles, which includes sets of exercises like pelvic tilts, wall squatting, bridging, bird dog and heel walking which targets core muscles.
215010501|NCT06259890|OTHER|measurement of salt intake|measurement of salt intake without intervention
215010502|NCT04464083|DIAGNOSTIC_TEST|IOP Measurment|To determine IOP readings before and after accelerated corneal collagen crosslinking (CXL)
214405448|NCT06351267|OTHER|Back Strengthening exercises|Back strengthening exercises will be used to strengthen the back muscles which include sets of exercises that target back muscles like cat-cow exercise, child pose, heel sits, and kegels.
215010503|NCT04514549|DEVICE|Emerald|The Emerald is a wireless sensor that can track the motion, breathing, and sleep of subjects without touching or requiring any interaction with the subjects, allowing them to go about their normal lives. The physical device is roughly a 30 x 35 x 5 cm box that contains directional antennas and a motherboard to process these signals. In typical operation, the device is mounted onto a wall within a clinic or home setting using peel-away (reversible) mount strips.
214405449|NCT03663712|BIOLOGICAL|Talimogene Laherparepvec|TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells
214504717|NCT07098624|OTHER|Placebo Effervescent Tablets 4.3 g|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral"
215010504|NCT05618626|OTHER|Physical exercise and dietary intervention for NAFLD|Investigators will assess the efficiency of the intervention by measuring adherence to physical exercise and nutritional diet.
215010505|NCT06263738|PROCEDURE|Whole Body Hyperthermia|Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes
215010506|NCT06263738|PROCEDURE|Cold Water Plunge|Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session in 55 degree (Fahrenheit) water, lasting up to 10 minutes.
215010507|NCT06549114|DRUG|Leniolisib|The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).
215098295|NCT04802187|OTHER|RADx CHCs testing intervention strategy|The study team will support partner CHCs to implement workflows with some combination of dedicated testing staff, off-site testing, outreach/communications to priority populations, and linkage with local contact tracing systems. Implementation support will take the form of practice facilitation, rapid cycle testing (by supporting CHCs to review their internal data to assess the impact of workflow changes), and expert consultation from the research team on testing technology and testing location design.
215098296|NCT04802187|OTHER|Usual care control|CHCs implement testing strategies in accordance with their usual supports.
215098297|NCT00258791|DRUG|Ibuprofen|
215010508|NCT04503122|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation : cryoablation or radiofrequency
214405450|NCT05768555|OTHER|Whole body vibration intervention at 40 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 40 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
214405451|NCT05768555|OTHER|Whole body vibration intervention at 25 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 25 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
214405452|NCT05768555|OTHER|Whole body vibration intervention at 0 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 0 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
214405453|NCT05842343|OTHER|Stool sample|Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness
214405454|NCT05842343|OTHER|Food intake evaluation|Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates
214405455|NCT05914324|DEVICE|Phefumla device|The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.
214405456|NCT05914324|DEVICE|LB-01 device|The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
214405457|NCT06408246|DRUG|Guanfacine|Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.
214405458|NCT06408246|DRUG|Sertraline|Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.
214405459|NCT02487446|DRUG|QVA149|QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)
215010509|NCT06210711|BEHAVIORAL|Treatment as Usual|Standard clinical treatment received by all patients admitted to BUMC, BSWMC Temple or FH/MCW trauma centers. At BUMC and FH/MCW, this may include an evaluation by a licensed psychologist or psychiatrist and continued follow-up psychotherapy and/or medication as needed. At BSWMC Temple this may include an evaluation by a licensed psychiatrist and follow up treatment as needed. In all locations this therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care.
215010510|NCT06210711|BEHAVIORAL|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes. The treatment is manualized and has been successfully implemented and evaluated in other challenging environments (i.e., Emergency Department. Trauma center). Brief PE includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo/behavioral exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises. This discussion addresses patients' unrealistic beliefs about themselves and the world. In addition, patients are given homework to complete between each session (breathing practice, listening to the session recording, and completing behavioral exposures).
215010511|NCT00358800|DEVICE|REMStar Auto with C-Flex|
215010512|NCT04981561|DRUG|GATE-251|Single dose of GATE-251
215010513|NCT04981561|DRUG|Placebo|Placebo
215010514|NCT03159949|OTHER|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
215010515|NCT03159949|OTHER|PR-REHIIT|"PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
215010516|NCT00422461|DRUG|placebo|placebo, oral, tablets, once daily, for 28 days
215010517|NCT00422461|DRUG|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
215010518|NCT00422461|DRUG|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
215010519|NCT00422461|DRUG|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
215010520|NCT05406895|DRUG|2% Lidocaine with 1:100,000 epinephrine|2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
214405460|NCT02487446|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
214405461|NCT02487446|DRUG|Placebo (umeclidinium/vilanterol)|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
215010521|NCT02455089|OTHER|GADD34 RNA level measurement.|"Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.~A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months."
215010522|NCT01471574|DRUG|Daclatasvir|Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks
215010523|NCT01471574|DRUG|Ribavirin|Tablets; oral; for patients weighing \<75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing \>75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
215010524|NCT01471574|DRUG|PEG-Interferon alfa 2a|Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
215010525|NCT03638271|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging and compare their results.
215098298|NCT04153045|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
214405462|NCT02487446|DRUG|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
214405463|NCT05147987|DEVICE|Hands free wearable breast pump|Use of a supplementary breast pump which can be discreetly worn and is hands free
214688323|NCT07164027|RADIATION|Flotufolastat F-18 Gallium|Given IV
215010526|NCT03593629|COMBINATION_PRODUCT|6-month PrEP + blood-based HIV self-test|Participants receive 6-month PrEP supply plus two blood-based HIV self-tests (Atomo Diagnostics Blood-Based HIV-1 Self-Testing Kit) for quarterly HIV testing.
215010527|NCT03593629|COMBINATION_PRODUCT|6-month PrEP + oral fluid HIV self-test|Participants receive 6-month PrEP supply plus two oral fluid HIV self-tests (OraQuick Oral Fluid-based HIV-1 Self-Testing Kit) for quarterly HIV testing.
215010528|NCT01763957|BEHAVIORAL|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
215010529|NCT01763957|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
215010530|NCT03347539|DEVICE|Nexplaon|This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.
215010531|NCT02346916|DRUG|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
215010532|NCT00003107|BIOLOGICAL|recombinant interleukin-12|
215098299|NCT02650063|DRUG|DE-117|
215098300|NCT02684149|PROCEDURE|relational touch|
215098301|NCT03487211|DRUG|Duloxetine|Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
215098302|NCT03487211|DRUG|Escitalopram|Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
215098303|NCT01669083|DRUG|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
214405464|NCT04568096|COMBINATION_PRODUCT|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|After randomization and standard treatment The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
214405465|NCT04568096|OTHER|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
214405466|NCT05617235|DEVICE|Kinesiology taping|"On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. Investigators applied kinesiology taping as described below:~1. In order to stimulate the facilitation of the diaphragmatic function~2. Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~3. In addition, kinesiology taping can be performed on the trigger pain point of the patient .~After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively."
214405467|NCT06038071|OTHER|nutrition, IYCF, WASH education|nutrition, IYCF, WASH education
214405468|NCT06038071|OTHER|scheduled anthropometric screening|anthropometric screening by health care workers at 1, 3, and 6 months
214405469|NCT06038071|OTHER|family MUAC|family MUAC training for the primary caregiver present at the time of recovery
214405470|NCT04438785|DEVICE|The intervention consists of myofunctional therapy (MT) using the AirwayGym app.|Intervention. Patient newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the App AirwayGym 20 minutes a day during 90 days.
214405471|NCT03701464|PROCEDURE|Endoscopic naso-gallbladder drainage|Using ERCP technique insert a naso-gallbladder drainage tube through common bile duct and cystic duct.
214688324|NCT07164027|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214688325|NCT07164092|DRUG|Atropine 0.05% Eye drops|The randomized eye will receive one drop of atropine sulphate 0.05% nightly for 24 months.
214688326|NCT07164092|DRUG|Placebo ophthalmic solution|The fellow eye will receive one drop of placebo (vehicle solution without active drug) nightly for 24 months.
215010533|NCT00494884|DRUG|vildagliptin|
214405472|NCT03701464|PROCEDURE|Percutaneous gallbladder drainage|Percutaneous transhepatic technique insert drainage tube into gallbladder
214405473|NCT04011033|BIOLOGICAL|iNKT cells|5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.
214405474|NCT04011033|DRUG|Human recombinated Interleukin-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
214405475|NCT04011033|PROCEDURE|TAE/TACE|TAE/TACE will be conducted to all patients at 0th week and 4th week.
214405476|NCT06065774|PROCEDURE|The Laterally Closed Tunnel Technique with SCTG|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
214405477|NCT06065774|DRUG|The Laterally Closed Tunnel Technique with collagen matrix mucograft|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
214405478|NCT06065774|PROCEDURE|Modified Coronally Advanced Tunnel Technique with SCTG.|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
214405479|NCT06065774|DRUG|Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
214405480|NCT03347838|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
214405481|NCT00689104|DRUG|Mirabegron|Tablets
214405482|NCT00689104|DRUG|Tolterodine|Capsules
214405483|NCT00689104|DRUG|Placebo to Mirabegron|Matching mirabegron placebo tablets.
214405484|NCT00689104|DRUG|Placebo to Tolterodine|Matching tolterodine placebo capsules.
214405485|NCT04692714|DEVICE|Knee prosthesis implementation with additional cement|During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot with additional cement.
214405486|NCT04692714|DEVICE|Knee prosthesis implementation without additional cement|During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot without additional cement.
214405487|NCT06203262|DEVICE|FieldForce™ Ablation System Ventricular Tachycardia|Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
215098304|NCT01669083|DRUG|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
214504718|NCT07098039|OTHER|Semi-presential or hybrid group|The hybrid format will consist of 4 in-person sessions (every two weeks) complemented by a home program until completing 3 sessions of the full program at home.
215098305|NCT01669083|DRUG|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
215098306|NCT01669083|DRUG|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
215098307|NCT05485623|DEVICE|PulseNmore FC|"Pulsenmore Ltd. has developed a small portable vaginal ultrasound device for personal use at home. The ultrasound device allows to scan and assess both the uterus and the ovaries. This ultrasound device connects to a smartphone and a user-friendly application simplifies its use. This ultrasound device is based on the company's 'Pulsenmore ES ultrasound system' which is a small abdominal ultrasound device for home and self-use by pregnant women. This (abdominal) ultrasound device allows scanning and detection of fetal pulse, count fetal movements, assess the amount of amniotic fluid and more. The device is an abdominal ultrasound probe that connects to a smartphone using a specially designed socket. The main difference between the devices is the different design of the ultrasound vaginal probe.~The device consists of 2 components: a cradle and an application (software). The cradle contains the electronic components and the ultrasound probe."
214405488|NCT06203262|DEVICE|FieldForce™ Ablation System Premature Ventricular Contractions|Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
214405489|NCT05047094|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
214405490|NCT05047094|DRUG|Pembrolizumab|200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
214405491|NCT01925781|DRUG|Nicotine polacrilex|2 mg and 4 mg gum will be used according to the FDA approved product labelling
214405492|NCT01925781|OTHER|STAM 1100mAh CE4 eGo Clearomizer|
215010534|NCT04102644|OTHER|Observation|Documentation of course and outcome of hospitalization, labor, delivery, and postpartum period
214405493|NCT03606096|BIOLOGICAL|Boostrix IPV infant acellular Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis
214405494|NCT03606096|BIOLOGICAL|Boostrix IPV infant whole Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis
214405495|NCT03606096|BIOLOGICAL|TT infant acellular Pertussis|mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis
214405496|NCT03606096|BIOLOGICAL|TT infant whole Pertussis|mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
214405497|NCT01667315|DRUG|Bupivacaine 0,375%|Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
214405498|NCT00591357|DRUG|loperamide|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
214405499|NCT00591357|DRUG|placebo|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
214405500|NCT04123860|OTHER|ultrasonic hydrodynamic maxillary sinus lift buccal pad fat|ultrasonic hydrodynamic maxillary sinus lift and buccal fat pad as grafting material followed by immediate implant
214405501|NCT04123860|OTHER|ultrasonic hydrodynamic maxillary sinus lift platelet rich fibrin|ultrasonic hydrodynamic maxillary sinus lift and platelet rich fibrin as grafting material followed by immediate implant
214405502|NCT05419674|DRUG|Vonoprazan|Potassium-competitive acid blocker
215010535|NCT02131493|DRUG|S-1, Gemcitabine|
215010536|NCT00284648|PROCEDURE|Surgical repair Achilles tendon rupture|
215010537|NCT00284648|PROCEDURE|Non-surgical repair Achilles tendon rupture|
215010538|NCT06165653|BEHAVIORAL|5-Minute, Audio-Recorded Guided Mediation Practice|"Five different meditation practices will be provided, all of which have been validated in prior research.~* The Body Scan practice consists of instruction in how to direct non-judgmental attention to different regions of the body~* The Mindful Breathing practice consists of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations~* The Mindfulness of Discomfort practice consists of instruction in how to zoom in to deconstruct discomfort and map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences~* The Savoring practice consists of instruction in identifying and amplifying pleasant memories~* The Loving-Kindness practice consists of instruction in cultivating feeling of warmth and compassion toward the self and others"
215010539|NCT05076123|OTHER|Modified Constraint Induced Therapy and Threshold Electrical Stimulation|M-CIMT emphasizes massed practice with the affected upper limb with restraining unaffected limb by a mitt. Threshold electrical stimulation is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes.
215098308|NCT02906267|OTHER|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
214405503|NCT05419674|DRUG|Rabeprazole|Proton pump inhibitor
214405504|NCT05419674|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
214405505|NCT05419674|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
214405506|NCT05419674|DRUG|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
214405507|NCT03530020|OTHER|monolithic zirconia crowns|full anatomical monolithic crowns
214405508|NCT03530020|OTHER|lithium silicate crowns|lithium silicate glass ceramics are highly resistance to chipping
215010540|NCT02549378|DEVICE|confocal microscopy|microvessel diameter measured by confocal microscopy
215098309|NCT02736916|RADIATION|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
215098310|NCT02736916|RADIATION|Conventional PCI|LD-SCLC patients with conventional PCI
214405509|NCT06231082|PROCEDURE|Group one - percutaneous (P)|Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
214504719|NCT07098039|OTHER|Hospital Cardiac Rehabilitation|The hospital cardiac rehabilitation group will attend the hospital 3 days a week for the same, for eight weeks.
215010541|NCT00864513|DRUG|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
215098311|NCT05952388|OTHER|Behavioral Patient care|chart review
215098312|NCT00306059|PROCEDURE|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
214405510|NCT06231082|PROCEDURE|Group two - EUS FNB (E)|"EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the wet suction technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the blood patch technique."
214405511|NCT02817373|OTHER|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
214405512|NCT06325943|DRUG|Rituximab|Patients will receive two doses of rituximab 1 g at two-week interval and one dose of rituximab 1 g at month 6
214405513|NCT06325943|OTHER|Placebo|Patients will receive two doses of placebo at two-week interval and one dose of placebo at month 6
215010542|NCT02296697|DEVICE|Low-level laser therapy AlGaInP|Pressure ulcers will be treated with AlGaInP 660 nm laser, wich will be used once a day, five days per week, dosed with 6 J/cm2. Laser therapy is applied punctually in each 1cm2 of the ulcer.
214405514|NCT05791877|DEVICE|pneuRIP|Respiratory sensor to measure pulmonary function
214405515|NCT04778488|DEVICE|Near-Infrared-Spectroscopy (NIRS)|Placement of 2 NIRS optodes on the patients' forehead, measurement of NIRS during cardiac arrest and up to 72h post return of spontaneous circulation
214405516|NCT04210193|DRUG|ALK Alutard 5-grasses|0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection
214405517|NCT04210193|DRUG|ALK Diluent|0.1 mL of ALK Diluent as an intralymphatic injection
214405518|NCT03412981|OTHER|pregnant mothers|we will be collecting data on a cohort of pregnant mothers
214405519|NCT01974687|DRUG|Uprifosbuvir|Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
214405520|NCT01974687|DRUG|Placebo|Matching placebo to uprifosbuvir capsule administered by mouth.
214405521|NCT01974687|DRUG|Itraconazole|Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
214405522|NCT04453787|OTHER|Arch support orthoses with forefoot medial wedge|The degree of forefoot wedge will be 3 degree. If needed, it could be adjusted. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
215010543|NCT02296697|DEVICE|High-frequency therapy with O3 formation|High-frequency laser therapy will be applied with spherical electrode, wich contains neon gas inside, from a short distance from the pressure ulcer. The application will last 15 minutes, with increasing intensity from 80 to 100% for ozone formation, once a day, five days per week.
215010544|NCT02296697|OTHER|Wound dressing with saline solution|Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.
215010545|NCT03591419|DEVICE|polymer clip|polymer clips will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
215010546|NCT03591419|DEVICE|endoloop|endoloop will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
215010547|NCT05373966|OTHER|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of robotic RNU. The Delphi questionnaire will be administered via Welphi.com.~In the first survey, panel members will outline the training program for robotic RNU.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
215010548|NCT01897389|DRUG|Treatment A|1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
214405523|NCT04453787|OTHER|Arch support orthoses|The arch support of the orthoses could be adjusted depends on the evaluation of subject. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
214504720|NCT05226364|PROCEDURE|Rubber tourniquet|The blood sample is taken with a rubber tourniquet
214504721|NCT05226364|PROCEDURE|Fabric tourniquet|The blood sample is taken with a fabric tourniquet
214504722|NCT05226364|PROCEDURE|Without tourniquet|The blood sample is taken without tourniquet
214504723|NCT07099040|BEHAVIORAL|Social support|Psychoeducation will be provided for enrolled participants and their caregivers by Community Resource, Engagement \& Support Team (CREST). Visits from CREST teams will be provided on an ad hoc basis, based on older adult participants' needs and circumstances.
215010549|NCT01897389|DRUG|Treatment B|1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
215010550|NCT01897389|DRUG|Treatment C|1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
215010551|NCT01897389|DRUG|Treatment D|1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
215010552|NCT01897389|DRUG|Treatment E|1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
215010553|NCT02022527|DRUG|Acetyl Salicylic Acid|
215010554|NCT02022527|DRUG|Warfarin|
215010555|NCT02022527|DRUG|Placebo (for Aspirin)|Sugar pill manufactured to mimic 75 mg Aspirin
214504724|NCT07099040|BEHAVIORAL|Health coaching|"Health coaching aims to control risk factors of dementia by community nurses (CMNs) and wellbeing coordinators (WBCs). These include addressing chronic conditions and lifestyle aspects (diet, exercise, habits stress management, and sleep). Care recipients are encouraged to proactively manage their health journey and establish Specific, Measurable, Achievable, Relevant, and Time-bound (SMART) goals with the support of WBCs and CMNs. This multi-faceted approach has the potential to not only address older individuals' immediate health concerns but also foster long-term lifestyle changes. The frequency of visits are once or twice a month, depending on recipients' health status and cognitive functions.~Flexible scheduling is based on individual needs and community nurses' usual practice at the Community Health Post at AACs."
214504725|NCT07099040|BEHAVIORAL|Physical Activity|Physical Activity that focuses on improving resistance and balance for care recipients. Physical activity will be conducted 2 times/week at the Active Ageing Centres (AACs) with care recipients for a duration of 1-hour and 1-2 times/week at home.
215010556|NCT03880890|PROCEDURE|sphenoidotomy versus sphenoid nasalisation|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
215010557|NCT01509924|OTHER|Physical activation on Prescription|The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
214405524|NCT04453787|OTHER|Flat insole|The flat insole used as a placebo intervention. The shape of this insole is flat, and made by soft EVA. It only provide shock absorbtion without any support. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
214405525|NCT00814489|BIOLOGICAL|GSK2231395A|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.
214405526|NCT00814489|BIOLOGICAL|Engerix-B|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.
214405527|NCT03031639|PROCEDURE|Endoscopic approach thyroidectomy|Thyroid surgery using endoscopy.
214405528|NCT02748239|BEHAVIORAL|MEDIAS 2 CT|The MEDIAS 2 CT is a education program for the initiation of a conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
214405529|NCT02748239|BEHAVIORAL|Current CT program|The Current CT program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
214405530|NCT06117475|PROCEDURE|Posterior corpectomy|Removal of posterior portion of vertebrae by posterior approach
214504726|NCT07099040|BEHAVIORAL|Cognitive activity|"Cognitive activity will be delivered to enrolled care recipients by Community Resource, Engagement \& Support Team (CREST) and AAC staff. With the incorporation of using SilverPad as part of the cognitive activities, care recipients will undergo 1-hour weekly cognitive activity. Youth volunteers will also be engaged to help facilitate the sessions.~This will be augmented with additional 1-2 times weekly home-based training sessions supervised by caregivers."
215010558|NCT04094805|DRUG|Rocaltrol|Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )
215010559|NCT04094805|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
215010560|NCT04393844|OTHER|turbo-ject PICC set|The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
215010561|NCT04553536|DRUG|Esketamine, Sulfentanil or/and Remifentanil|The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
214405531|NCT05696808|DIETARY_SUPPLEMENT|IHPD|The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.
214405532|NCT05696808|DIETARY_SUPPLEMENT|Western Diet|The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
214405533|NCT01712685|DRUG|18F-VM4-037|Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
214405534|NCT01712685|PROCEDURE|PET/CT|
214405535|NCT02613897|DRUG|Saxagliptin|Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.
215010562|NCT00113685|DRUG|Hypertonic Saline-Dextran Solution|
215010563|NCT00113685|DRUG|Lactated Ringer's Solution|
215010564|NCT03004092|PROCEDURE|blood sample|Twice weekly blood sample, and at every outpatient visit
215010565|NCT00211939|DRUG|calcium acetate|667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
215010566|NCT00211939|DRUG|sevelamer|1-3 tablets t.i.d, titrated to serum phosphorus level
215010567|NCT00211939|DRUG|atorvastatin|20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
214405536|NCT02613897|DRUG|Dapagliflozin|Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.
214405537|NCT02613897|DRUG|Placebo|Placebo
214405538|NCT06657547|OTHER|Normal conditions|Participants are administered salmeterol, after which they perform various performance tests in normal conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
214405539|NCT06657547|OTHER|Heated conditions|Participants are administered salmeterol, after which they perform various performance tests in heated conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
214405540|NCT06657547|DRUG|Salmeterol inhalation and urine samples|After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period. Two hours after inhalation, the participants collect spot urine samples at home
214405541|NCT06811532|OTHER|Blood perfusion analysis using SPY-Q software|Use of the SPY-Q analysis software during surgery to calculate bone profusion scores on several areas of the scapular tip flap (endosteum of scapula bone segments and latissimus dorsi muscle component).
214405542|NCT02773251|DRUG|hyaluronic acid-carboxymethylcellulose|
214405543|NCT03406442|PROCEDURE|Transpterygoid approaches|All patients will be operated by transpterygoid approaches which is classified into 5 major types.Type A involves thinning of the pterygoid process to access to Pterygopalatine fossa. Type B involves the removal of the medial and anterior aspect of the base of the pterygoid process to access the lateral recess of sphenoid sinus. Type C involves removing the base of the pterygoid plates to reach the petrous apex, Meckel's cave, or cavernous sinus. Type D requires removal of the pterygoid plates to access the infratemporal fossa. Type E requires the removal of the medial pterygoid plate or the entire pterygoid process, and the medial third of the Eustachian tube to acessof the lateral nasopharynx
214405544|NCT01194505|OTHER|Sciatic, femoral, obturator nerve blocks|Ultrasound guided blocks with ropivacaine
214405545|NCT01194505|OTHER|Sciatic nerve block, posterior lumbar plexus block|Ultrasound and neurostimulator nerve blocks with ropivacaine
214405546|NCT06608888|DIAGNOSTIC_TEST|MRI|"Multimodal MRI technology is a method that combines various magnetic resonance imaging techniques, providing more comprehensive images and information about human tissues and organs. These different imaging techniques include, but are not limited to:~Structural MRI (sMRI): Provides information about the types of brain tissues, such as gray matter, white matter, and cerebrospinal fluid.~Functional MRI (fMRI): Dynamically measures the hemodynamic response related to brain neural activity, commonly used to study brain functional activities.~Diffusion Tensor Imaging (DTI): Offers information on the structural connections between brain regions, which can be used to study the neural fiber pathways of the brain"
214405547|NCT06615622|DIETARY_SUPPLEMENT|Placebo|Thiotacid 300 mg tab once/day
214405548|NCT01703533|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
214405549|NCT01703533|DRUG|Placebo|Strawberry flavored solution and Water for Injection
214405550|NCT05504343|DEVICE|"Intensity SL Intraocular Lens"|Cataract surgery and intraocular lens implantation
214405551|NCT06615141|DEVICE|Oculus Quest 3|Oculus quest 3 is a standalone virtual reality headset developed by Meta. It offers precise motion tracking and offers an innovative intervention for stroke rehabilitation, enhancing upper limb motor function throug task - specific exercises.
214405552|NCT06615141|DEVICE|Neofect Smartboard and Tyromotion Myro|"Neofect Smart Board provides non-immersive VR rehabilitation through gamified, task specific exercises to improve upper limb mobility in an interactive way.~Tyromotion Myro uses non-immersive VR therapy combining sensor-based feedback and interactive games to enhance fine motor skills."
214405553|NCT06006130|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires 11 minutes in total.
215010568|NCT03458091|DEVICE|THRIVE|Oxygenation during apnea using transversal humidified oxygen
215010569|NCT03458091|DEVICE|Endotracheal intubation|Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
215010570|NCT00574951|DRUG|motesanib diphosphate|
215010571|NCT06343883|DEVICE|low-intensity focused ultrasound - low pressure|low-intensity focused ultrasound applied to the S1.
215010572|NCT06343883|DEVICE|low-intensity focused ultrasound - medium pressure|low-intensity focused ultrasound applied to the S1.
215010573|NCT06343883|DEVICE|low-intensity focused ultrasound - high pressure|low-intensity focused ultrasound applied to the S1.
215010574|NCT00937911|DRUG|YM150|oral
215010575|NCT01567020|OTHER|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
215010576|NCT02580344|DRUG|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
215010577|NCT01030575|DRUG|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
215010578|NCT01030575|DRUG|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
215010579|NCT01030575|DRUG|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
215010580|NCT01030575|DRUG|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
214405554|NCT06006130|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
214405555|NCT06401993|PROCEDURE|"The dao qi tong luo group"|"The dao qi tong luo group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. Among them, the dao qi tong luo group will make patients feel qi."
214405556|NCT06401993|PROCEDURE|The acupuncture group|The acupuncture group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. The acupuncture group will not feel qi.
214405557|NCT06602752|BEHAVIORAL|Food system and demand generation|The Vegetables for All project will create FFZs in low-income urban and peri-urban areas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will link vendors and farmers through market facilitators, support the uptake of digital solutions for vendors to access vegetables, and support district governments to improve market infrastructure. To encourage BoP parents of children 3-9 years to buy and consume more vegetables, the program will include a demand generation component.
214405558|NCT04831164|OTHER|NA (not an interventional study)|(not an interventional study)
214405559|NCT05468658|OTHER|Designing the birthing unit according to the philosophy of Feng Shui|"1. The cabinets will be painted using salmon and pastel green.~2. It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~3. Live nature videos and sounds will be projected onto the wall.~4. Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~5. Natural plants will be placed.~6. Lighting will be used.~7. Bed linen will be designed according to the Feng Shui.~8. Wooden bell will be used.~9. Turtle, elephant and Wu Lou objects will be placed.~10. The Bagua mirror will be placed.~11. Crystals will be placed.~12. Natural stones will be placed.~13. The fountain will be placed in the east compass direction of the unit.~14. Straw bamboo separator will be used."
214405560|NCT06918860|OTHER|Analysis|Analysis and review of imaging and clinical data
214405561|NCT06917937|OTHER|Exercise Program|Our exercise program in our study; (i) foot intrinsic muscle strengthening exercise (with a load of 3 kg), (ii) plantar fascia stretching with finger extension, (iii) standing gastrocnemius muscle stretching, (iv) sitting achilles tendon stretching, (v) plantar fascia and gastrocnemius stretch on the step, (vi) cold massage exercise in the arch of the foot. We stated that the group to which exercise was added should do the exercises regularly for 6 weeks, in the specified number and time.
214405562|NCT06917937|OTHER|Corticosteroid injection|"The orthopedic physician administered the corticosteroid injection as a mixture of 1 ml of arthropane (5 mg of triamcinolone hexacetonide) and 4 ml of citanest. Before the application, the physician cleaned the area to be treated with 10% povidone iodine. He made a single dose injection by entering the painful point determined by palpation around the calcaneal spur and plantar fascia from the percutaneous foot-heel lateral. The patients were in the prone position with the ankle in a neutral position.~After the application, he covered the area with a sterile cloth and said to remove it after 3 hours. He stated that patients could apply ice to the injected area if necessary for pain control, and advised patients to avoid all jogging and other high-impact activities on the day of injection. No additional treatments, including NSAIDs, orthoses, and night splints, were allowed during the study period."
214405563|NCT06919042|DEVICE|Pulsed Acoustic Cellular Expression therapy|The therapy involves the delivery of targeted acoustic energy that initiates cellular mechanotransduction pathways, inducing beneficial biological responses such as enhanced angiogenesis, modulation of fibroblast proliferation and differentiation, and reorganization of aberrant extracellular matrix components.
214405564|NCT06303778|OTHER|Stand Down mobile app|The Stand Down mobile app is a smartphone-based stand-alone intervention designed to help persons manage drinking and alcohol-related problems on their own. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support.
214405565|NCT06303778|OTHER|Standard Care|Participants assigned to the standard care condition will receive standard MAUD care delivered by their CPSs and will not receive access to SD-App. Three medications, naltrexone, disulfiram, and acamprosate, have been approved by the Federal Drug Administration and topiramate has been recommended by the VA/DoD clinical practice guidelines for SUD. MAUD includes these four medications. All medication decisions will be between the CPS and the Veteran and not influenced by study participation.
214405566|NCT06613555|OTHER|Retinal imaging|"the retinal imaging work-up includes:~* OCT-angiography~* Retinophotography~* Adaptive optics~performed at inclusion, at 6 months and then once a year for 10 years for patients Only performed at inclusion for controls"
215098313|NCT04164420|BEHAVIORAL|Oral neuromuscular training and orofacial sensory-vibration|Oral neuromuscular training is performed by using an oral device. The device is placed pre-dentally behind closed lips, and the participant is sitting in an up-right position. The participant is the instructed to hold the device against a gradually-increasing horizontal pulling force for 5-10 s, whilst trying to resist the force by tightening the lips and pressing the head backward against a head rest.
215098314|NCT04164420|BEHAVIORAL|Orofacial sensory-vibration stimulation|All participants in the control group is given orofacial sensory-vibration stimulation by using an electrical toothbrush. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
215098315|NCT05993910|OTHER|Hyperthermie Register|"* die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C),~* die Dauer der Anwendung und~* die simultane Therapie mit Chemo- und/oder Strahlentherapie"
215098316|NCT00520910|DRUG|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
215098317|NCT01629459|BEHAVIORAL|Resistance exercise and protein supplementation|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
215098318|NCT00269555|DRUG|Genistein Combined Polysaccharide (GCP)|
214405567|NCT06613555|BIOLOGICAL|Biological check-up|"it is performed at inclusion and then once a year for 10 years for patients~Only performed at inclusion for controls"
214405568|NCT06671327|DRUG|Preemptive Dexmedetomidine injection|The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and after induction continue infusion 15min.
214405569|NCT06671327|DRUG|Sodium Chloride 0.9% Inj|The Placebo group was infused with equal amounts of isochronous normal saline.
214405570|NCT01273090|DRUG|imetelstat sodium|
214405571|NCT01273090|OTHER|laboratory biomarker analysis|
214405572|NCT01273090|OTHER|pharmacological study|
214405573|NCT06688708|DEVICE|Using vibrating foot orthosis with tactile stimulation|Stimulating tactile sensation by using vibrating foot orthosis in conjunction with a random 0-100 Hz square wave pulse stimulus and pseudorandom white noise via a stochastic resonance approach.
214688327|NCT07161778|DRUG|Triamcinolone acetonide IM injection|"An initial loading dosage will be given and then every 4 weeks the patient will be given triamcinolone. Triamcinolone acetonide IM injection should be administered as per individual sites local procedures.~The number of Triamcinolone injections, the volume and the site of administration will be documented in the CRF. The initial dose can be split according to local administration procedures.~Cycle 1~Day 1 Week 1 (loading dose given once only)~o 360 mg IM injection~Subsequent cycles (given 4 weekly thereafter until progression +/-3 days)~Day 1~o 120 mg IM injection"
215010581|NCT02396797|BEHAVIORAL|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
215010582|NCT02396797|BEHAVIORAL|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
215010583|NCT02296801|DRUG|Letrozole|
215010584|NCT02296801|DRUG|palbociclib|
215010585|NCT02475057|DRUG|Degarelix (LHRH antagonist)|Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
215010586|NCT02475057|DRUG|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
215010587|NCT02475057|DEVICE|EndoPAT2000|Peripheral arterial plethysmography using an EndoPAT2000 device
215010588|NCT06531473|PROCEDURE|HoLEP|Patients will be randomized to one of the laser energy groups day of surgery.
215010589|NCT02202720|DRUG|Sevoflurane|Short term sedation with sevoflurane in ICU
215010590|NCT06040450|OTHER|Questionnaire survey|On outdoor sports practice activity, barriers to practice, impacts on well-being.
215010591|NCT05034978|OTHER|no intervention|evaluating the performance of a novel point-of-care test
215010592|NCT05560633|OTHER|No intervention|No intervention
215010593|NCT04468009|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies
215010594|NCT01795131|DIETARY_SUPPLEMENT|Vitamin B12|
215010595|NCT01795131|DIETARY_SUPPLEMENT|Placebo|
215010596|NCT05017948|OTHER|Risk score based intervention|Targeted interventions based off of risk score software
215010597|NCT01160744|BIOLOGICAL|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
215010598|NCT01160744|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
215010599|NCT01160744|DRUG|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
215010600|NCT01160744|DRUG|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
215010601|NCT01160744|DRUG|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
215098319|NCT04764227|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
215098320|NCT04764227|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
215098321|NCT04764227|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 28Fx
214405574|NCT06688708|DEVICE|Using vibrating foot orthosis without tactile stimulation|Stimulating tactile sensation by using vibrating foot orthosis with only vibration 100 Hz freqency.
214405575|NCT04854486|OTHER|GSE and Xylitol|Participants are given the experimental treatment to be used for 7 days.
214405576|NCT04854486|DRUG|Control Placebo|Saline
214405577|NCT06693024|DRUG|neratinib|neratinib 240mg qd for 1 year
215010602|NCT01160744|DRUG|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
215010603|NCT02056288|DRUG|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
215010604|NCT02056288|DRUG|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
215010605|NCT05540600|DRUG|Digoxin 0.25 mg|Patients will have the dose of one tablet of 0.25mg per day
215010606|NCT05540600|DRUG|Bisoprolol|Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
215010607|NCT01557816|DRUG|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
215010608|NCT01557816|DRUG|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
215010609|NCT03834259|PROCEDURE|sitting position|keeping the patient in a sitting position after spinal anaesthesia
215010610|NCT03834259|PROCEDURE|supine position|keeping the patient in supine position after spinal anaesthesia
215098322|NCT04967404|DIETARY_SUPPLEMENT|Phosphatidylserine|800 mg per day for 10 days
215098323|NCT01719133|DRUG|placebo|saline solution
215010611|NCT02301429|DEVICE|Model 20105|implant and follow-up of study device
215010612|NCT05086172|BEHAVIORAL|Ultrabrief Behavioral Activation|The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
214405578|NCT06697561|BEHAVIORAL|patient education program|"The intervention for the experimental group was an evidence-based educational program for hand dysfunction in patients with systemic sclerosis, which included a health education manual and multimedia videos developed through evidence translation. Additionally, individual education and consultation were provided."
214405579|NCT06696235|DEVICE|Early initiation of continuous renal replacement therapy|Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
214405580|NCT06696235|DEVICE|Standard initiation of continuous renal replacement therapy|Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
214405581|NCT04323735|DRUG|Culturelle 10 Billion CFU Capsule|"LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group."
215098324|NCT01719133|DRUG|Histamine|positive control
214405582|NCT03853798|DRUG|AG-348|Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.
214405583|NCT04601779|BEHAVIORAL|VIPP-PUF|The VIPP-PUF Intervention is developed as an add-on to the existing PUF-program to address infants with major cognitive and regulatory vulnerabilities identified at age 9-10 months and adapted to the settings of community health nurses. The intervention (VIPP-PUF) will be created from an evidence-based method, the Video-based Intervention to Promote Positive Parenting (VIPP), to comprise six therapeutic sessions delivered by the community health nurse during home visits over a three months period. The VIPP -PUF builds on teaching the health nurses to promote parents' sensitivity to meet infants' cognitive and regulatory vulnerabilities, while taking in account the particular needs of families of psycho-social disadvantage.
214405584|NCT06698224|DEVICE|Spinal cord transcutaneous stimulation|Physical therapy combined with spinal cord transcutaneous stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord stimulation is a non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.
214405585|NCT06698224|DEVICE|Paired spinal cord and peripheral nerve stimulation|Physical therapy combined with paired spinal cord-peripheral nerve stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord and peripheral nerve stimulation are both non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.
214405586|NCT06697067|PROCEDURE|modified smead jones|interrupted suture technique
214405587|NCT06697067|PROCEDURE|conventional comtinuous suture techniques|continuous suture technique
214405588|NCT06697080|DRUG|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells
214405589|NCT06713772|DEVICE|Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA|Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA
214405590|NCT06713772|DEVICE|Steri-StripsTM (3M, St. Paul, Minnesota, USA|Steri-StripsTM (3M, St. Paul, Minnesota, USA
214405591|NCT06713772|DEVICE|Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany|Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany
214405592|NCT06696872|OTHER|core exercises|The core muscle strength training program were lasted for 8 weeks and comprised of 3 training sessions per week, with a total of 24 sessions. Each session were lasted for 30 to 45 minutes, starting with a brief warm-up exercise program consisting of low-intensity core strength exercises to prepare the neuromuscular system for the training loads and ending with a cool-down program
214405593|NCT06696872|OTHER|Proprioceptive Neuromuscular Facilitation|The hold-relax proprioceptive neuromuscular facilitation stretching protocol consisted of passively moving the dominant leg into a position where the subjects felt mild discomfort and holding that position for 30 seconds. Subjects were then asked to isometrically contract the stretched muscle for 10 seconds; this were followed by muscle relaxation in the same posi¬tion for 30 seconds, before being stretched to a new point of mild discomfort. The leg were then released
214688328|NCT07162844|PROCEDURE|Liquid sclerotherapy in telangectasia and reticular veins without application of herbal gel post procedure|Liquid sclerotherapy injection of polidocanol in telangectasia and reticular veins without application of herbal gel post procedure
215010613|NCT02080728|DRUG|Ropivacaine 500mg/100ml Naropeine|
215010614|NCT02080728|DRUG|0.9% sodium chloride BAXTER|
215098325|NCT01719133|DRUG|AllerT1|synthetic peptide T1
215098326|NCT01719133|DRUG|AllerT2|synthetic peptide T2
215098327|NCT01719133|DRUG|AllerT3|synthetic peptide T3
215098328|NCT01719133|DRUG|AllerT4|synthetic peptide T4
215098329|NCT01719133|DRUG|AllerT5|synthetic peptide T5
215098330|NCT01719133|DRUG|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
215098331|NCT01719133|DRUG|mix of AllerT4-T5|mix T4-T5
215098332|NCT05446571|DRUG|Letermovir|Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
215010615|NCT05655572|OTHER|Action Observation Theraoy|After initial baseline assessment patients allocated in AOT group will undergo treatment protocol of 6 weeks having 4 stages of duration 1.5 weeks each performed 3 days per week. . Assessment will be perform at baseline after 2, 4 and 6 weeks
215010616|NCT05655572|OTHER|Functional Training|after baseline assessment participants including in this group will perform the tasks for 6 weeks (3 days per week) s and after that again assessment will be made for examining the improvements.Assessment will be perform at baseline after 2 ,4 and 6 weeks
214405594|NCT06696391|OTHER|Venous Excess Ultrasound (VEXUS)-Guided Management|"Expert operators will perform VEXUS within 6 hours of randomization and repeat the assessment every 24 hours for 3 days, or until ICU discharge or death. After each assessment, investigators will grade the severity of venous congestion using a modified version of the VEXUS score and provide updated management recommendations.~Patients without congestion will receive standard fluid management. For mild congestion, investigators will implement fluid restriction (e.g., minimizing maintenance fluids) while maintaining nutrition and blood product administration as clinically indicated. For moderate to severe congestion, investigators will 1. target negative fluid balance (-1 to -2L/24h) through fluid restriction and diuretics, 2. perform cardiac ultrasound to guide inotrope administration and optimize RV physiology, and 3. optimize PEEP for ventilated patients.~All patients will receive the standard of care based on Surviving Sepsis Campaign guidelines."
214405595|NCT06698081|OTHER|Video Multimedia|The second group will be informed of the Standard Informed Consent Form, Verbal Information, and Multimedia. In addition to the standard consent process, we planned to show a 6-minute video multimedia presentation containing information about undescended testis and orchiopexy.
214405596|NCT06710977|DRUG|Safety of intracameral levofloxacin in cataract surgery|Intracameral levofloxacin (0.1ml/0.5mg)
214405597|NCT06710977|DRUG|Use of intracameral cefazolin in cataract surgery|Intracameral cefazolin (0.1ml/1mg)
215010617|NCT00732459|DEVICE|Electro-acupuncture preconditioning|electro-acupuncture
215010618|NCT01359280|BEHAVIORAL|Adherence Counseling|5 Sessions of theory-based medication adherence counseling
215010619|NCT01359280|BEHAVIORAL|General Health Counseling|5 sessions of health improvement counseling
215010620|NCT01359280|BEHAVIORAL|Text Messages|Daily medication regimen tailored adherence reminders delivered by cell phone
215098333|NCT05446571|DRUG|Valacyclovir|Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
215098334|NCT05553392|DEVICE|StrataXRT|"StrataXRT is a full contact flexible wound dressing for the prevention and treatment of radiation dermatitis. StrataXRT is a semi-occlusive, self-drying and transparent gel.~When used as directed StrataXRT dries to form a protective layer that is gas permeable and waterproof which hydrates and protects compromised skin areas and superficial wounds from chemical and microbial invasion. StrataXRT may be directly applied to radiation dermatitis, compromised skin surfaces, superficial wounds and first and second degree burns."
215098335|NCT05553392|DRUG|Aquaphor|"Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc.~Aquaphor contains 41 percent petrolatum (or petroleum jelly), the active ingredient, temporarily protects minor cuts, scrapes, and burns; protects and helps relieve chapped or cracked skin and lips; helps protect from the drying effects of wind and cold weather."
214405598|NCT04000893|OTHER|Resistance exercise session|Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
214405599|NCT06918210|PROCEDURE|Indocyanine Green|Visualization of the bile ducts with ICG
214405600|NCT06918210|PROCEDURE|Cholangiography|Visualization of the bile ducts with intraoperative cholangiography
214405601|NCT06740357|OTHER|Tumor response monitoring program|three steps of tumor response evaluation (STEP 1 at 2 months, STEP 2 at 4 months, STEP 3 at 6 months after completion of neoadjuvant treatment): STEP 1: digital rectal examination, pelvic MRI, rectoscopy, TAP scan STEP 2: DRE, pelvic MRI, rectoscopy STEP 3: DRE, pelvic MRI, rectoscopy, TAP or PET scan
214405602|NCT06740357|OTHER|Standard evaluation of tumor response|Assessment at 2 months (+/- 7 days) after neoadjuvant treatment: digital rectal exam, pelvic MRI, rectoscopy, TAP scan
214405603|NCT06740357|OTHER|Shared decision-making|At each stage of the monitoring program and depending on the clinical and oncological results, the decision to preserve the rectum will be discussed with the patient according to a shared-decision program.
214405604|NCT06740357|OTHER|Decision-making according to national recommendations|The decision to preserve the rectum is based on assessment at 2 months after completion of neoadjuvant treatment (standard of care since the GRECCAR2 trial).
214405605|NCT06740357|OTHER|Follow-up|Every 3 months for 2 years, then every 6 months for the third year
214405606|NCT05846087|BEHAVIORAL|sleep retraining therapy|Sleep retraining therapy improves sleep efficiency (total sleep time/total time in bed) by reducing the amount of time spent in bed awake. The digitally designed version which SleepFix delivers uses an algorithm which requires the users current sleep times and ideal wake-up time to determine when one should get into bed to fall asleep and when one should get out of bed.
214688329|NCT07162844|PROCEDURE|Liquid sclerotherapy in telangectasia and reticular veins wit application of herbal gel post procedure|Liquid sclerotherapy injection of polidocanol in telangectasia and reticular veins with application of herbal gel post procedure
214688330|NCT07162844|PROCEDURE|foam sclerotherapy in telangectasia and reticular veins without application of herbal gel post procedure|foam sclerotherapy injection of polidocanol in telangectasia and reticular veins without application of herbal gel post procedure
215010621|NCT01818648|DRUG|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
215098336|NCT03775746|DRUG|Clopidogrel 75Mg Tablet|Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
215098337|NCT03775746|DRUG|Rivaroxaban 2.5Mg Tablet|Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)
215010622|NCT01818648|DRUG|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
215010623|NCT03391154|DRUG|levothyroxin|90 female received levothroxine
215010624|NCT03473158|DEVICE|Transvaginal ultrasound|using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure
214405607|NCT05846087|OTHER|sleep health education modules|educational modules about sleep and insomnia; its causes; and its impact on various aspects of life. This information is arranged into three modules which will be provided to participants over three weeks.
215010625|NCT03473158|PROCEDURE|Mechanical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
214405608|NCT04754061|DRUG|Psilocybin|"Phase 1 (week 1): all enrolled participants will take a single 1mg oral dose of psilocybin once per day on Monday and Thursday. If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 2 for week 2.~Phase 2: The participant will take a single 1mg oral dose of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 3 for week 3.~Phase 3: The participant will take two 1mg oral doses (2mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 4 for week 4.~Phase 4 (maximum allowable dose): The participant will take three 1mg oral doses (3mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday)."
214405609|NCT01201564|PROCEDURE|intraperitoneal onlay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
214405610|NCT01201564|PROCEDURE|sublay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
214405611|NCT06166511|PROCEDURE|Laparoscopic liver resection|Using Laparoscopy in liver resection
214405612|NCT06829238|DRUG|Metformin|Participants will receive Metformin ER (500mg increasing to 1000mg) or placebo for 16 weeks to assess immune restoration and inflammatory response.
214405613|NCT06829238|DRUG|Placebo|Participants will receive placebo for 16 weeks and assess immune restoration and inflammatory response.
214405614|NCT06829238|BIOLOGICAL|Jynneos|All participants will take a Jynneos (MPOX) vaccine.
214405615|NCT06829238|BIOLOGICAL|Capvaxvie|All participants will take a Capvaxvie (PCV21, pneumococcal) vaccine.
214405616|NCT06891703|OTHER|[18F]ACI-15916|\[18F\]ACI-15916 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
214405617|NCT06779149|BEHAVIORAL|Cognitive Behavioral Treatment for Insomnia (CBT-I)|Participants in this treatment group will receive CBT-I. CBT-I sessions will occur weekly for the first 4 sessions and biweekly for the last 2 sessions (treatment phase is thus 8 weeks). : Graduate level students in clinical psychology will serve as therapists for this project.
214405618|NCT06779149|DRUG|Lemborexant|Participants assigned to this group will be prescribed 5 to 10 mg of lemborexant to be taken at bedtime in 5 mg capsules. Lemborexant (Dayvigo) is a Dual Orexin Receptor Antagonist approved by Health Canada for the treatment of adult with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.
214405619|NCT06779149|DRUG|Placebo|Participants assigned to this group will be prescribed 5 to 10 mg of placebo to be taken at bedtime in 5 mg capsules identical to lemborexant. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.
214688331|NCT07162844|PROCEDURE|foam sclerotherapy in telangectasia and reticular veins with application of herbal gel post procedure|foam sclerotherapy injection of polidocanol in telangectasia and reticular veins with application of herbal gel post procedure
214688332|NCT07163338|OTHER|Collectio nof blood|Collection of an additional volume of blood in the initial blood test.
214688333|NCT07162740|PROCEDURE|Right atrial ablation|Eligible patients receive the implantation of a LuxDx® ILR and are monitored for one month by means of the Latitude Clarity data management system of the device. The usual practice of the centres is unchanged. According to their usual practice, the centre is assigned to right atrial ablation. The patients receive a right atrial procedure accordingly. As per pragmatic design, cross-over are permitted according to investigator judgment. The ablation methods and techniques are left to investigator's decision. They are reported in the CRF.
215010626|NCT03473158|PROCEDURE|Chemical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
215098338|NCT03775746|DRUG|Ticagrelor 90Mg Tablet|Prevention of atherothrombotic events in patients with acute coronary syndrome \[in combination with aspirin\]
214405620|NCT03253653|DEVICE|Differential effects of waterpipe smoking practices on toxicity of waterpipe tobacco smoke|In a repeated measures design, 50 adult male and female exclusive WP tobacco smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices as follows: 1) using room temperature water in the WP jar, 2) adding ice cubes to the water in the WP jar, and 3) using a charcoal-free electronic WP head to heat the tobacco. Six Spot first morning urine samples will be provided by participants. Two urine samples per each of the 3 smoking sessions. Urine samples will be provided on the day of the WP tobacco smoking session and the following day. Physiological measures will be taken at Baseline during the office visit and before and after each of the 3 WP tobacco smoking sessions.
214405621|NCT05700214|DRUG|Ropivacaine injection|30ml of 0.35% ropivacaine
214405622|NCT05700214|DRUG|Lidocaine IV|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
214405623|NCT06750965|DIAGNOSTIC_TEST|Serum M protein screening|Using highly sensitivity test to screen serum M protein of all participants.
215098339|NCT05378737|DRUG|BAT8006 for Injection|Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
215098340|NCT06351254|PROCEDURE|Sine sound waves|Group A 8 participants will be given sine sound waves treatment with the frequency of 80 pulses on C1 vertebrae. Treatment session will be 6 session 3 times a week followed by 6 sessions 2 times a week.
215098341|NCT06351254|PROCEDURE|Kinesthetic exercises|Kinesthetic exercises was conducted for GROUP 2 8 patients for 6 weeks. Before and after assessment was taken to track patient progress. Cervicocephalic kinesthetic sensibility tests were performed. The first test was Head-to-Neutral Head Position(NHP) repositioning test. In the second repositioning test is Head-toTarget repositioning tests.
215098342|NCT06351254|PROCEDURE|Sine sound waves plus kinesthetic exercises|Group C 8 was given combine treatment of sine sound waves and kinesthetic exercises before and after measurement was taken.
215010627|NCT00500110|DRUG|Docetaxel|30 mg/m\^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
215010628|NCT00500110|DRUG|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
215098343|NCT04920383|DRUG|ALPN-202|Various doses
215098344|NCT04920383|DRUG|pembrolizumab KEYTRUDA®|Varies
215098345|NCT04993443|DRUG|LQ036|"For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D."
215098346|NCT04993443|OTHER|Matching Placebo|Matching Placebo for LQ036: Matching Placebo
215098347|NCT02215135|DRUG|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW\> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
215098348|NCT01257945|BEHAVIORAL|Aerobic Exercise|
214405624|NCT06780293|OTHER|Laser acupuncture (LA)|The RJ-Laser acupuncture device (Reimers \& Janssen GmbH, Waldkirch, Germany) is used with a laser wavelength of 810 nm (infrared). The Bahr frequency B3 is set at 2398 Hz, with an energy output of 400 mW, operating in intermittent pulse mode. Each acupoint is irradiated for 15 seconds. A total of 8 bilateral acupoints are treated per session, with a total treatment time of approximately 120 seconds.
214405625|NCT06780293|DIAGNOSTIC_TEST|Numerical Rating Scale (NRS)|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Numerical Rating Scale (NRS).
214405626|NCT06780293|DIAGNOSTIC_TEST|Schirmer's test|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Schirmer's test.
215098349|NCT01257945|BEHAVIORAL|Flexibility and Function exercise program|
215098350|NCT01257945|BEHAVIORAL|Home exercise program|
215098351|NCT00321464|BIOLOGICAL|Denosumab|Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
215098352|NCT00321464|DRUG|Zoledronic Acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
215098353|NCT04327024|DRUG|Verinurad|"The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol."
215098354|NCT04327024|DRUG|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol
215098355|NCT04327024|DRUG|Placebo for verinurad|Matching Capsule
215098356|NCT04327024|DRUG|Placebo for allopurinol|Matching tablet
215098357|NCT06238284|OTHER|no intervention|Since it is a retrospective study, no intervention is needed.
215098358|NCT02825524|DEVICE|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
214405627|NCT06780293|DIAGNOSTIC_TEST|Ocular Surface Disease Index (OSDI)|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the OSDI test.
214405628|NCT06780293|DIAGNOSTIC_TEST|EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the ESSPRI.
215010629|NCT00500110|DRUG|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
215010630|NCT00500110|DRUG|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
215010631|NCT01502072|DRUG|Ribavirin|Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.
214405629|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) tongue diagnosis|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) tongue diagnosis.
214405630|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) pulse diagnosis|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) pulse diagnosis.
215010632|NCT01502072|DRUG|Ribavirin|One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
215010633|NCT00000538|BEHAVIORAL|diet, fat-restricted|
215010634|NCT05066139|OTHER|EPODIG-G program (coordination of supportive care)|EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)
215010635|NCT01121458|DRUG|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP\< 80 mmHg), hypertension (SBP\>150 mmHg), tachycardia (120 beats per minute), bradycardia (\<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
215010636|NCT02363127|DRUG|subcutaneous progesterone|subcutaneous progesterone 25 mg/day
215010637|NCT02363127|DRUG|vaginal progesterone|vaginal progesterone in capsules 200 mg/3 times a day
215098359|NCT03239080|DRUG|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
214405631|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) constitution questionnaire|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) constitution questionnaire.
214405632|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) heart rate variability analysis|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) heart rate variability analysis.
214405633|NCT06780293|DIAGNOSTIC_TEST|nailfold microcirculation assessment|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the nailfold microcirculation assessment.
214405634|NCT06780293|DIAGNOSTIC_TEST|iris examination|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the iris examination.
214405635|NCT06780293|OTHER|Sham Laser Acupuncture|"The RJ-Laser acupuncture device (Reimers \& Janssen GmbH, Waldkirch, Germany) is used with a laser wavelength of 810 nm (infrared). The Bahr frequency B3 is set at 2398 Hz, with an energy output of 400 mW, operating in intermittent pulse mode. Each acupoint is irradiated for 15 seconds. A total of 8 bilateral acupoints are treated per session, with a total treatment time of approximately 120 seconds.~The sham laser acupuncture procedure follows the same process as the true laser acupuncture protocol, including the positioning, cleaning of acupoints, and wearing of protective goggles. However, no laser emission is delivered during the treatment. This ensures a consistent experience for the patient while maintaining the blinding integrity of the study."
214405636|NCT06621563|DRUG|HS-20117 combined HS-20093|HS-20117 + HS-20093
214405637|NCT06621563|DRUG|HS-20117 combined Platinum-containing chemotherapy|HS-20117 + cisplatin/carboplatin + pemetrexed
214405638|NCT06621563|DRUG|HS-20117 combined HS-20093 and 5-FU|HS-20117 + HS-20093 + 5-FU
214405639|NCT06621563|DRUG|HS-20117+CAPEOX|CAPOEX: Oxaliplatin+Capecitabine
214405640|NCT06621563|DRUG|HS-20117+FOLFIRI|FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU
214405641|NCT06621563|DRUG|HS-20117+mFOLFOX6|mFOLFOX6=Oxaliplatin+Leucovorin Calcium+5-FU
215010638|NCT05363085|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during mechanical ventilation and during specific respiratory manoeuvres. No intervention is planned.
215010639|NCT02207179|DEVICE|LumaScan Image Guided Surgery|
215010640|NCT00272558|DRUG|Carboplatin and Vinorelbine|
215098360|NCT03239080|OTHER|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
214405643|NCT06906094|PROCEDURE|Selective meniscectomy|involves the partial removal of the damaged meniscus.
214405645|NCT05591703|BEHAVIORAL|Clinical Outcomes and Questionnaires|Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
215010642|NCT00151073|DRUG|Zoledronic acid|
215010643|NCT00151073|DRUG|Estramustine|
215010644|NCT00151073|DRUG|Docetaxel|
215010645|NCT03954938|BEHAVIORAL|Craving Manipulation|Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
215010646|NCT03954938|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
215098361|NCT06240104|DIAGNOSTIC_TEST|cardiac output index monitor|During the spontaneous breathing test phase, the cardiac index (CI) is continuously monitored from 15-30 minutes prior to the start of the test. Patients who have successfully completed the spontaneous breathing test and increased their CI by more than 30% and meet ordinary weaning indications can have their tracheal intubation removed.
214405646|NCT06908564|DEVICE|Experimental: Interactive balance rehabilitation based on serious games.|The intervention of the Experimental Group consists of 30 minutes (16 sessions, 4 days/week, for 4 weeks) of balance rehabilitation exercises using non-immersive virtual reality through the OAK device (Khymeia Group, Italy). The system includes exercises that require the patient to reach visual targets by shifting their Center of Pressure (COP). The exercises are categorized based on the direction of COP displacement and can be performed with increasing difficulty, as determined by the physiotherapist during the rehabilitation process.
214405647|NCT06908564|OTHER|Active Comparator: conventional balance rehabilitation without the use of technological devices.|"Intervention of the Control Group (CG) consists of 30 minutes (4 days/week, for 4 weeks) of conventional balance rehabilitation treatments without the use of technological devices. The motor exercises will focus on the rehabilitation of balance, the trunk, and the lower limbs and will be carried out with a physiotherapist who will tailor the treatment according to the patient's characteristics and needs. Primary attention will be given to recovering trunk control and seated posture. This phase will focus on restoring and maintaining muscle trophism in the anterior and posterior kinetic chains of the thigh and lower leg, as well as the hip's range of motion, through isometric exercises and gentle joint mobilizations while adhering to anti-dislocation guidelines.~The process will continue with the reacquisition of the upright stance, emphasizing proprioceptive, coordination, and balance abilities. Once the upright position is stabilized, gait re-education will be introduced."
215010647|NCT03954938|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
215010648|NCT06499909|OTHER|Hypnosis|The patient will receive a course of hypnosis
215010649|NCT04676646|DRUG|Sodium zirconium cyclosilicate|Investigational medicinal product
214405648|NCT06325670|BEHAVIORAL|BED treatment|A 12 session cognitive behavioural intervention in groups for Danish adults with type 2 diabetes and Binge Eating Disorder.
214405649|NCT06325670|OTHER|Waitlist|A waitlist control group that receives regular type 2 diabetes treatment while waiting to receive the BED treatment intervention.
214405650|NCT05968079|DEVICE|Masimo W1™ and Apple Watch Series 8|Noninvasive wearable health monitoring device
214405651|NCT05031936|PROCEDURE|cervical spinal injection with 0.2% ropivacaine|spinal injections performed in cervical pillar area to relieve chronic neck pain
214405652|NCT06920394|OTHER|Survey using a questionnaire.|In the present study, no intervention will be carried out, and only the patients recruited will complete the questionnaires set out below.
214405653|NCT06920082|OTHER|Progressive muscle relaxation exercises|A total of 18 sessions of progressive relaxation were performed, 3 days a week for 6 weeks.
214405654|NCT06918730|PROCEDURE|U-POEM|Water immersion for luminal distension of the GI tract as opposed to carbon dioxide insufflation
214405655|NCT06918730|PROCEDURE|CO2-POEM|POEM is routinely performed under carbon dioxide insufflation (CO2-POEM) as this gas is more rapidly absorbed than air.
214405656|NCT06918912|DRUG|Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)|Loncastuximab Tesirine is an antibody-drug conjugate specifically targeting CD19, a protein found on the surface of B-cells. It is designed to deliver a cytotoxic pyrrolobenzodiazepine dimer directly to CD19-expressing malignant B-cells. Unlike traditional chemotherapies, Loncastuximab Tesirine combines the precision of an anti-CD19 monoclonal antibody with a potent chemotherapy agent, offering targeted therapy for relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma (HGBCL) after failure of CAR-T therapy. It is administered intravenously every 3 weeks, with an initial higher dose of 150 μg/kg followed by a reduced dose of 75 μg/kg for up to 8 cycles, distinguishing it from other treatments by its specific targeting mechanism and dosage regimen tailored to this patient population.
214405657|NCT06918782|DRUG|Osimertinib plus platinum doublet chemotherapy|Based on the FLAURA2 study (which was not subdivided into ctDNA clearance subgroups), it is hypothesized that adding systemic chemotherapy to osimertinib will prolong PFS and OS and increase objective response rate even among the poor prognostic subgroup with failed ctDNA clearance after initial osimertinib monotherapy. By incorporating systemic chemotherapy (pemetrexed/carboplatin) to first-line osimertinib treatment among the poor prognostic group of metastatic EGFR-mutant lung adenocarcinoma with failure of plasma ctDNA EGFR mutant clearance despite initial osimertinib treatment.
214405658|NCT06919289|DRUG|Infiltration of papaverine|The study was randomized and double blinded. For randomization, the first extremity had either an infiltration of 0.5 cc of papaverine HCL (30mg/ml) for a 15mg perineural infiltration, or .5 cc of 1% lidocaine without epinephrine determined by a coin toss application.
214688334|NCT07162740|PROCEDURE|Bi-atrial ablation|Eligible patients receive the implantation of a LuxDx® ILR and are monitored for one month by means of the Latitude Clarity data management system of the device. The usual practice of the centres is unchanged. According to their usual practice, the centre is assigned to bi-atrial ablation. The patients receive a bi-atrial procedure accordingly. As per pragmatic design, cross-over are permitted according to investigator judgment. The ablation methods and techniques are left to investigator's decision. They are reported in the CRF.
214688335|NCT07161921|OTHER|lymph node metastasis|Histopathological examination confirmed the presence of at least one lymph node metastasis
215098362|NCT02501499|OTHER|Breastfeeding Buddies|a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
215010650|NCT04676646|DRUG|Placebo|Placebo comparator
215010651|NCT04676646|OTHER|Spironolactone|"Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained."
215010652|NCT02217982|DRUG|Simethicone|
215010653|NCT02217982|DRUG|Loperamide|
215010654|NCT02217982|OTHER|Peanut Butter|
215098363|NCT00668811|DRUG|SU011248, Sutent|Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
215098364|NCT04204044|DRUG|Metformin Hydrochloride|Metformin Hydrochloride is used in PCO
215098365|NCT04204044|DRUG|Myo-inositol|Myo inositol used in PCO
215098366|NCT02327988|OTHER|Cryotherapy|
214405659|NCT06919289|DRUG|Lidocaine infiltration|The study was randomized and double blinded. For randomization, the first extremity had either an infiltration of 0.5 cc of papaverine HCL (30mg/ml) for a 15mg perineural infiltration, or .5 cc of 1% lidocaine without epinephrine determined by a coin toss application.
214405660|NCT06919250|OTHER|Patients with systemic lupus erythematosus|Population: Patients with systemic lupus erythematosus. Intervention: Identification of the degree of physical activity of patients with systemic lupus erythematosus.
214405661|NCT06920316|DEVICE|Gro Health digital application|The Gro Health digital application is a personalised treatment platform proven to support sustainable weight loss. It is non-MHRA regulated as MASLD is within the device's UKCA/CE UKNI/CE marked indication. Gro Health reports 7% weight loss at 52 weeks in patients with Type 2 Diabetes Mellitus. We can set up the application so patients follow a Mediterranean diet. Over 1000 recipes of different cuisines will be available, along with weekly diet plans and shopping lists. Based on the patient's body mass index, daily calories and macronutrient targets will be calculated in line with the Mediterranean diet. Aerobic exercise can be tracked by daily step count linked by compatible smartwatches and smartphones. Physical activity can also be logged manually. Gro Health provides educational videos on aerobic and resistance exercise, along with 'follow along' videos of exercises for patients. These videos range from ones for beginners to those who have more experience with exercise.
214405662|NCT06918626|PROCEDURE|ELC + Spyglass cholangiography|Study group (Spyglass Discover). Patients will undergo ELC surgery as soon as the ACC diagnosis has been confirmed. During surgery, intra-operative cholangiograpy (IOC) will be performed in order to exclude the presence of CBDS and in case of confirmation or still suspicion of CBDS, the exploration of the common bile duct and its eventual clearance via Spyglass Discover is carried out during ELC.
214405663|NCT06918626|PROCEDURE|ERCP + Early Laparoscopic cholecystectomy (ELC) in two stage procedures|Control group (ELC sequential treatment after possible clearance of CBDS via ERCP). Following the diagnosis of ACC, patients with CBDS high/intermediate risk are introduced either directly, in case of high risk, or after performing second-level diagnostics (MNR cholangiography or endoscopic ultrasound), in the case of intermediate risk, to the ERCP with the aim of eliminating CBDS preoperatively and then the ELC will be performed.
215010655|NCT05412901|OTHER|discrimination task|Participants perform a discrimination task while their brain activity is recorded with EEG. Beta power will be estimated using spectral decomposition techniques, zooming in on subject specific bands in temporospatial windows of interest, and correlated with (1) WM content, (2) decision outcome, and (3) behavioral performance (i.e., accuracy and RT).
215010656|NCT02773823|BEHAVIORAL|Intervention group|Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
215098367|NCT02327988|DEVICE|Laser therapy|
215098368|NCT03842449|DIAGNOSTIC_TEST|BabyCO|An expired CO measurement will be performed by BabyCO and the result will be returned to the smoking pregnant woman by the consultant.
215098369|NCT03842449|OTHER|Biological samples|"The nature of the samples taken during the delivery are:~* maternal blood,~* cord blood~* placenta fragment"
215098370|NCT05169606|OTHER|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
215098371|NCT05169606|OTHER|Active Isolated Stretch|"AIS is a specific stretching program developed by Aaron Mattes. This technique is based on these four basic principles:~Isolate the muscle to be stretched. Repeat the stretch eight to 10 times. Hold each stretch for no more than two seconds. Exhale on the stretch; inhale on the release."
215098372|NCT05169606|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients
215098373|NCT05332132|DEVICE|Heracure Device|Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
214405664|NCT06914180|DRUG|esketamine group|In the esketamine group, in addition to receiving PRF treatment+pregabalin for rescue analgesia, patients will also undergo a single intravenous infusion of esketamine. A total of 0.5 mg/kg of esketamine will be diluted in 50 mL of normal saline. The infusion will commence with an intravenous injection of 10 mg of esketamine over 1 minute, followed by a maintenance dose of 8 mg/h. The infusion rate will be adjusted based on the patients' tolerance levels.
214405665|NCT06914180|DRUG|control group|In the control group, patients will receive PRF+pregabaline treatment. Pulsed radiofrequency (PRF) will be performed on GG by a designated physician in each participating center. PRF treatment (PMG-230, Baylis Medical Inc.) targeting to GG will be applied for 900 seconds. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. Regarding pregabalin, the dosage is titrated based on patients'pain intensity and tolerance. This process fully accounts for individual patient differences to optimize treatment outcomes.
215010657|NCT04378049|PROCEDURE|Total knee arthroplasty|Surgeon will perform a total knee arthroplasty procedure according to local standard of care
215010658|NCT04378049|PROCEDURE|Robot-assisted partial knee arthroplasty|Surgeon will perform a robot-assisted unicompartmental or bicompartmental knee arthroplasty procedure
215010659|NCT04270760|DRUG|Olpasiran|Dose 1 Dose 2 Dose 3 Dose 4
215010660|NCT04270760|DRUG|Placebo|Dose 5
215098374|NCT00582998|PROCEDURE|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
215098375|NCT00582998|DEVICE|Vacuum Assisted Closure Device|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
214405666|NCT06918743|DRUG|RSS0393 ointment|RSS0393 ointment 0.01%
214405667|NCT06918743|DRUG|RSS0393 ointment|RSS0393 ointment 0.03%
214405668|NCT06918743|DRUG|RSS0393 ointment placebo|RSS0393 ointment placebo
214405669|NCT06920121|OTHER|Virtual reality glasses|Virtual reality glasses Beginning 2-3 minute before the start of the procedure, the patients will be watched (5 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product.
214405670|NCT06920121|OTHER|Stress ball|Patients will be instructed to continue squeezing and relaxing the stress ball (squeezing and relaxing once, counting from one to three) for 5 minutes before and throughout the AVF cannulation procedure. Patients will be instructed to focus their attention on the stress ball and focus on squeezing the stress ball.
214405671|NCT06920277|DEVICE|Ultrasound scans|10 seconds scanning for one block region
214405672|NCT06933693|BEHAVIORAL|Mixed trials|All tasks will be randomly mixed in a single block of 400 trials.
214405673|NCT06933693|BEHAVIORAL|Blocked Trials|Each search task will be presented in a block of trials.
214405674|NCT06297564|OTHER|Progesterone primed endometrial protocol|The cases were received soft progesterone capsules (brand name: Utrogestan, 100 mg, Laboratories Besins International, France) 100 mg and 150 IU of human menopausal gonadotropin (hMG) concomitantly from the menstrual cycle (MC) day 3 until the trigger day.
214405675|NCT06297564|OTHER|Gonadotropin-releasing hormone antagonist protocol|The cases were received the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol consisting of HMG 150 IU's daily injection from MC 3 until the trigger day. GnRH-ant (Cetrotide, 0.25 mg, MerckSerono) was started when at least one of the following criteria were met: LH \>10 IU/L, the presence of at least one follicle with mean diameter \>14 mm, or serum E2 level \>600 pg/mL.
214405676|NCT05640128|OTHER|Aldosterone in HPLC-MS/MS|Aldosterone in HPLC-MS/MS
214405677|NCT04259970|DRUG|Initiation of CFTR Modulator|Inhaled contrast for MRI occurring at each 4 visits.
214405678|NCT06393634|DRUG|Testosterone injection|A single injection of testosterone
214405679|NCT06393634|DRUG|Testosterone gel|A daily dose of testosterone gel
214405680|NCT06393634|DRUG|Testosterone Oral|A twice-daily pill of testosterone pill to swallow
214405681|NCT04216225|OTHER|pre-hospital tourniquet placement|patients with extremity injuries presenting with or without pre-hospital tourniquet placement.
214405682|NCT05432479|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks
214405683|NCT05432479|DIETARY_SUPPLEMENT|Placebo|Placebo
214405684|NCT04060784|PROCEDURE|Immediate implant placement and provisionalization|Failing tooth will be extracted and immediate placed endosseous implant
214405685|NCT00662909|DRUG|Mirabegron|Oral
214405686|NCT00662909|DRUG|Placebo|Oral
214405687|NCT03709784|DRUG|Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care|This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
214405688|NCT03709784|OTHER|One time survey|One time survey
214405689|NCT03802773|PROCEDURE|CB transplantation|Myeloablative conditioning with post-transplant cyclophosphamide in patients receiving a matched CB transplant for hematological malignancies.
214405690|NCT06163222|BEHAVIORAL|Additional message with behavioural science-informed content and associated web pages|Behavioural science-informed messages sent 14-days prior to outpatient appointment which include links to re-designed web pages
214405691|NCT06163222|OTHER|Usual communication strategy|Usual communications sent from outpatient services to remind participants about their appointments
214405692|NCT03863717|OTHER|Arm Endurance Exercise Training|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
214405693|NCT03863717|OTHER|Control|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
214405694|NCT03939520|DRUG|pirfenidone and nintedanib|The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.
214405695|NCT03939520|DRUG|pirfenidone or nintedanib|The second intervention group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
214405696|NCT03939520|DRUG|pirfenidone or nintedanib|The control group will keep on the same monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
214405697|NCT05727995|DEVICE|PICO7|"The use of PICO is contraindicated in the presence of:~* Patients with malignancy in the wound bed or margins of the wound~* Previously confirmed and untreated osteomyelitis~* Nonenteric and unexplored fistulas~* Necrotic tissue with eschar present~* Exposed arteries, veins, nerves or organs~* Exposed anastomotic sites~* Emergency airway aspiration~* Pleural, mediastinal or chest tube drainage~* Surgical suction."
214405698|NCT05727995|OTHER|usual care dressing|usual care dressing
214405699|NCT01031693|DEVICE|Transcranial Magnetic Stimulation|daily sessions for 5 days
214405700|NCT02077738|DEVICE|HFCWO (Hill-Rom Vest™ Airway Clearance System)|study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
214405701|NCT04417556|DIAGNOSTIC_TEST|Sleep measurement|Sleep measurement with polysomnography, actigraphy, and Thai-version Richards Campbell Sleep Questionnaire.
214688336|NCT07163624|DRUG|UBT251 Injection 2.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
214688337|NCT07163624|DRUG|UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
214688338|NCT07163624|DRUG|UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
214688339|NCT07163624|DRUG|UBT251 Injection 6.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
214688340|NCT07163624|DRUG|Semaglutide Injection (Ozempic®)|Semaglutide Injection (Ozempic®) once weekly
214405702|NCT02029053|DEVICE|Vaginal Lubrication Ring for Vaginal Dryness|"Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.~Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.~The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.~The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.~Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study."
215010661|NCT04151498|BEHAVIORAL|Reengagement and Assessment Mobile Program|Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement. The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.
215010662|NCT04151498|OTHER|Qualitative Interview|Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
215010663|NCT03514225|OTHER|Metacognitive Therapy for Social Anxiety|The transdiagnostic Metacognitive model posits that psychological disorder stems from the activation of a perseverative thinking style called the CAS (Cognitive Attentional Syndrome). This has 3 key elements: worry/rumination, threat-focussed attention and unhelpful coping behaviours. Each of these elements results in extended cognitive responses to negative thoughts, prolonging negative emotions and maintaining an individual's sense of threat. The CAS arises from an individual's positive and negative metacognitive beliefs (beliefs about cognition). Metacognitive Therapy (MCT) aims to bring the CAS under control by modifying metacognitive beliefs and enabling individuals to develop new reactions to negative thoughts.
215010664|NCT05615441|DEVICE|Analgesia Nociception Index monitor|Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
215098376|NCT06307093|DRUG|RPH-075|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
215098377|NCT06307093|DRUG|Keytruda®|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
215098378|NCT03158441|DIAGNOSTIC_TEST|Breast MRI|comparison of DTI to dynamic MRI
215098379|NCT05645718|DRUG|Cyclophosphamide|Given by (IV) vein
215010665|NCT05615441|DEVICE|Standard monitoring|Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring
215010666|NCT05296590|DIAGNOSTIC_TEST|Monocyte Distribution Width (MDW) , observation|Observation of MDW performance blinded to treating clinical teams
215010667|NCT06012695|DRUG|NBM-BMX Capsule|Each capsule contains 100 mg of the active ingredient.
215010668|NCT06012695|DRUG|Temozolomide|TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.
215098380|NCT05645718|DRUG|Vincristine|Given by (IV) vein
215098381|NCT05645718|DRUG|Blinatumomab|Given by (IV) vein
215098382|NCT05645718|DRUG|Methotrexate|Given by (IV) vein
215098383|NCT05645718|DRUG|Cytarabine|Given by (IV) vein
215098384|NCT05645718|DRUG|Mercaptopurine|Given by (IV) vein
215098385|NCT05645718|DRUG|Prednisone|Given by PO
214405703|NCT00069862|DRUG|Deferitrin (GT56-252)|
215010669|NCT06012695|RADIATION|Standard radiotherapy|A total dose of 60 Gy will be administered in 6 weeks.
215010670|NCT04664387|DIAGNOSTIC_TEST|coronary angiography|A coronary angiography is a test to find out if there is stenosis in coronary artery.
214405704|NCT00069862|DRUG|desferoxamine (DFO)|
214405705|NCT02272699|DRUG|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
214405706|NCT02272699|DRUG|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
215010671|NCT02421510|DRUG|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
215010672|NCT02421510|DRUG|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
215010673|NCT02421510|DRUG|Placebo|Placebo, once daily, before the first meal of the day
215010674|NCT04406831|PROCEDURE|Blood draw|Individuals in the unresectable pancreatic cancer group will receive monthly blood draws. Individuals in the control group will receive one blood draw
215010675|NCT00001903|DRUG|RSV Polyclonal Immunoglobulin|
215010676|NCT02489201|DRUG|donafenib tosilate tablets|200mg,bid
215010677|NCT05145036|BEHAVIORAL|Tai-Chi|Tai Chi exercise could improve muscle performance, balance and have the benefit for fall down prevention in the elders and patients with frailty.
215098386|NCT05645718|DRUG|Pegfilgrastim|Given by (IV) vein
215098387|NCT05645718|DRUG|Inotuzumab ozogamicin|Given by (IV) vein
215098388|NCT05645718|DRUG|Rituximab|Given by (IV) vein
215098389|NCT05645718|DRUG|Dexamethasone|Given by (IV) vein
215098390|NCT06096675|BEHAVIORAL|• Cardiac Rehabilitation|Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.
215098391|NCT02272374|PROCEDURE|AVF creation|
215098392|NCT02272374|PROCEDURE|TCC placement|
215098393|NCT02272374|PROCEDURE|AVG creation|
215098394|NCT02905630|OTHER|Exercise training|high intensity aerobic interval training
215098395|NCT04849169|DEVICE|Experimental|Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.
215098396|NCT00415922|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
215010678|NCT05145036|BEHAVIORAL|Comprehensive training|There are 3 exercises. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down.
214405707|NCT02272699|DRUG|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
214405708|NCT02272699|RADIATION|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
214405709|NCT02272699|PROCEDURE|Surgery|Esophagectomy
214405710|NCT03243760|DRUG|CCI15106 7.5 mg capsule|Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
214405711|NCT03243760|DRUG|Placebo|Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
214405712|NCT03243760|DRUG|Placebo-2|Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
214405713|NCT05597098|DRUG|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
214405714|NCT01419847|DRUG|Ciclopirox|
214405715|NCT01419847|DRUG|Placebo|
215010679|NCT05993325|BIOLOGICAL|AdCLD-CoV19-1 OMI|3000 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular administration in the deltoid muscle
215010680|NCT05993325|BIOLOGICAL|Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)|1000 participants will receive investigational product (Comirnaty Bivalent) via intramuscular administration in the deltoid muscle
215010681|NCT04022694|BEHAVIORAL|Exposure to beverage health information|Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information
214405716|NCT00764179|OTHER|milk enriched in proteins (2.15 g/100ml)|"Neonates will drink the hyperproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
214405717|NCT00764179|OTHER|milk with normal protein concentration (1.45g/100ml)|"Neonates will drink the normoproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
214405718|NCT02401399|DIETARY_SUPPLEMENT|Regular diet|The patients receive regular diet 900 Kcal/day during 15 days before surgery
214405719|NCT02401399|DIETARY_SUPPLEMENT|High protein formula|The patients receive high protein formula during 15 days before surgery
214405720|NCT02401399|DIETARY_SUPPLEMENT|Immunonutrition|The patients receive Immunonutrition formula during 15 days before surgery
214405721|NCT01518257|BIOLOGICAL|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
214405722|NCT01518257|DRUG|Normal Saline|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
214504727|NCT07099755|BEHAVIORAL|Intervention Group: Name: Dynamic Neuromuscular Stabilization (DNS) Exercises|"Distinguishing Description for DNS Intervention~This intervention consists of a structured Dynamic Neuromuscular Stabilization (DNS) exercise program specifically tailored for post-partum women with mechanical low back pain. DNS emphasizes restoring functional motor patterns through:~Breathing-based core activation techniques~Developmental positions mimicking infant motor milestones (e.g., supine 90/90, quadruped, side-lying)~Coordination of the diaphragm, pelvic floor, and transverse abdominis muscles~Progressive motor control retraining over 6 weeks, 3 sessions/week~What distinguishes this intervention:~It integrates developmental kinesiology principles with respiratory-pelvic-lumbar coordination.~DNS is performed under supervised sessions by a physiotherapist, ensuring precision and progression.~This protocol replaces standard strengthening/stretching exercises and focuses on neuromuscular re-patterning, not just symptom relief."
215010682|NCT04022694|BEHAVIORAL|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
215010683|NCT01843881|DRUG|Exendin 9, 39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
215010684|NCT01843881|DRUG|Placebo|A saline infusion will be given to match the study drug infusion.
215010685|NCT02609633|DEVICE|Accu-Chek® CONNECT DMS|SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.
214405723|NCT03185429|BIOLOGICAL|Tumor Specific Antigen-loaded Dendritic Cells|Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1,3,5,11,17,23,35,47.
214405724|NCT03185429|DRUG|Cyclophosphamide|300 mg/m2 by vein before the first cell infusion.
215098397|NCT04104880|DEVICE|Continuous positive airway pressure (CPAP)|Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
214405725|NCT00924664|BIOLOGICAL|Tanezumab 20 mg|Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
214405726|NCT00924664|BIOLOGICAL|Tanezumab 10 mg|Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
214405727|NCT02395185|OTHER|Milk bottle administration|Patients are given a bottle of milk during the casting process.
214405728|NCT02395185|OTHER|Water bottle administration|Patients are given a bottle of water during the casting process.
214405729|NCT02395185|OTHER|Sucrose bottle administration|Patients are given a bottle of sucrose during the casting process.
214405730|NCT03134456|DRUG|Pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
214405731|NCT05213403|DIAGNOSTIC_TEST|Evaluation with new scoring system|"Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes"
214405732|NCT00449423|DRUG|acipimox|
215010686|NCT02609633|DEVICE|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
215010687|NCT02557893|BEHAVIORAL|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
215010688|NCT02557893|OTHER|Education|Bimonthly pregnancy education classes
215098398|NCT02641470|DIETARY_SUPPLEMENT|DA9301 (Vaccinium uliginosum extract)|
215098399|NCT02641470|DIETARY_SUPPLEMENT|Placebo|
214405733|NCT05427357|OTHER|Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)|"Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats."
214504728|NCT07099755|DEVICE|Control Group:Name: Conventional Physiotherapy (Ultrasound and Infrared Therapy)|"1-Therapeutic Ultrasonic: comparison group also received treatment through therapeutic ultrasound, which was applied three times per week. The ultrasound therapy was delivered to the paraspinal muscles of the lumbar region, using a stroking technique where each stroke overlapped by about 50% with the preceding stroke. The ultrasound used a frequency of 3 MHz and an intensity range of 1.0 to 1.5 W/cm²,The ultrasound head was placed over the L4 to L5 and L5 to S1 regions and moved in a circular motion for a total duration of 5 minutes per treatment session (Shobari et al., 2024).~infra red the infrared lamp was placed at 75 cm distance from the patient's back so that the radiation struck the surface at or near a right angle to achieve maximum penetration. The treatment duration was 15 minutes. Each woman with post-partum low back pain was treated by 20 minutes infrared irradiation 40 cm away from the low back region, from prone3 sessions per week for 6 weeks (El-Lassy and Madian, 2018"
214504729|NCT07098455|PROCEDURE|GNRFT- genicular nerve radiofrequency ablation|Ultrasound-guided genicular nerve radiofrequency ablation will be performed
215010689|NCT02557893|OTHER|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
215010690|NCT06523946|BEHAVIORAL|Diabetes Prevention Program (DPP) (shortened)|The investigators will adapt the protocol of the 'Ohana project. The 'Ohana protocol was developed based on CDC's Diabetes Prevention Program (DPP) curriculum and designed to fit PcI's cultural background. It includes a 8-lesson curriculum delivered in 8 weeks (shortened from the original 16-lesson, 24-week core curriculum of DPP while retaining all original foci and behavior change strategies). Specifically, the first four lessons, delivered every week, focus on getting the participants started on increasing PA and improving diet (e.g., introduction; getting started on PA and diet; utilizing goal setting; making the process fun). The second four classes will be taught every other week and will focus on how to handle various challenges involved in maintaining healthy lifestyle behaviors. The investigators will deliver the curriculum in group settings of 15 people in a separate room in the National Tongan American Society.
215010691|NCT03537456|DEVICE|mRDX-02-17|"mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5."
215010692|NCT03611062|BEHAVIORAL|VR Executive Functions Training|"The Windows 10-based VICT program invites children to rescue an animated character named Lubdub from a castle. The program consists of three challenging and child-friendly tasks that correspond to the three core EFs."
215010693|NCT03611062|BEHAVIORAL|VR Placebo Game|In this game, children in the control group will use the VR hand controller to cast different types of spells (bees, bouncy balls, sparkler spells) to objects in the virtual world. Objects in the VR world will all react differently to a spell being cast so as to provide children a relaxing and EF-free gaming experience.
215010694|NCT02909595|DEVICE|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter \[Extractor Pro RX \[M00547000, M00547010, or M00547020\]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
215010695|NCT02909595|DEVICE|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V \[FG-V435P or FG-V425PR\]; Olympus Corp., Shang hai,China).
215010696|NCT00027443|DRUG|Muromonab-CD3|
215010697|NCT00027443|DRUG|Cyclosporine|
215010698|NCT05349266|BIOLOGICAL|ThisCART19A|each patient will receive a dose level per body weight(kg) for only once.
215010699|NCT03701087|DRUG|Vitamin D|2800 IU daily till 26 weeks of pregnancy
215010700|NCT06195215|OTHER|Peer Counselling|7 weeks peer counselling process will be carried out.
215010701|NCT02287025|DRUG|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
215010702|NCT02287025|OTHER|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
215010703|NCT02287025|OTHER|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
215010704|NCT00385229|DRUG|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
215010705|NCT06466772|BEHAVIORAL|Hyper-personalized feedback (HPF intervention)|For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
215010706|NCT06466772|BEHAVIORAL|Targeted auditory stimulation during sleep (TASS verum intervention)|The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
215010707|NCT06466772|BEHAVIORAL|Control targeted auditory stimulation during sleep (TASS sham intervention)|Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
215010708|NCT02141724|OTHER|Positioning consultation|Assessment of pain,bedsores and postural troubles
215010709|NCT02468375|DRUG|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
214405734|NCT02949817|DEVICE|digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)|1.The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with pediatric brain injury patients. 20 of All 40 children will receive the conventional occupational therapy and additional video-game based rehabilitation therapy, 30 minutes daily 5 times per week, for 4 weeks.
214405735|NCT02949817|OTHER|Conventional OT group|2\. Conventional OT group will recieve the conventional occupational therapy and one more conventional occupational therapy additionally. The additional occupational therapy training will be performed 30 minutes daily 5 times per week, for 4 weeks.
214405736|NCT03139175|DEVICE|balance assessment with Biodex balance system|All subjects of three groups will be assessed with the evaluation device( balance system).
214405737|NCT03940261|OTHER|High Intensity Interval Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 10, 1-minute cycling intervals at 90% of peak power output, each separated by 1-min at 10% peak power output.
214405738|NCT03940261|OTHER|Continuous Moderate Intensity Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 30-50 minutes of cycling at 60% peak power output.
214405739|NCT06080711|OTHER|AI assistance|Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
214405740|NCT03446508|DEVICE|Active frontal|1\) active HD-tDCS will be administered
214405741|NCT03446508|DEVICE|Active parietal|2\) active HD-tDCS will be administered
214405742|NCT03446508|DEVICE|Sham|3\) sham HD-tDCS - no current
214405743|NCT03293862|DEVICE|prophylactic polypropilene mesh|Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
214405744|NCT03293862|PROCEDURE|Midline Fascial Closure|midline fascial closure using uninterrupted PDS 0 suture
214405745|NCT03293862|DEVICE|vacuum drainage system|Placement of a subcutaneous vacuum drainage system
214405746|NCT01739517|DRUG|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
214405747|NCT01400100|DRUG|Intraarterial application of Octreotide|500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
214405748|NCT01400100|DRUG|sterile NaCl (sodium chloride) 0,9% solution|a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
215098400|NCT02406911|DRUG|Ticagrelor|After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
215098401|NCT03794674|OTHER|No intervention.|No intervention, since this is a validation study
214405749|NCT04478175|OTHER|multidisciplinary assessment and intervention|early multidisciplinary assessment and intervention in addition to usual patient care
214405750|NCT05491161|OTHER|Longitudinal study|Longitudinal study following infant development from birth to 1 year of age
214405751|NCT00029523|DRUG|Intrathecal (injected into the spinal fluid) DepoCyt|
214405752|NCT00029523|DRUG|Intrathecal methotrexate|
214405753|NCT00029523|DRUG|Intrathecal cytarabine (also known as ara-C)|
214504730|NCT07098455|PROCEDURE|IAPRF- Intraarticular pulsed radiofrequency|Intra-articular pulsed radiofrequency will be applied under fluoroscopy guidance.
215010710|NCT01096186|DRUG|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
214405754|NCT03141164|OTHER|computerized training|Computerized training
214405755|NCT05599360|DRUG|Vyxeos|Vyxeos (daunorubicin and cytarabine) liposome for injection
215010711|NCT01096186|DRUG|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
214504731|NCT07098962|OTHER|Kinesiotaping|In this group, KinesioTaping will be applied around the thoracic drain sites alongside standard analgesic therapy. This physical therapy technique uses elastic tapes placed on the skin to support healing, reduce pain, and improve patient comfort. The tapes will remain in place for 2-3 days and will be removed together with the drains.
214504732|NCT07098962|DRUG|Dexketoprofen, tramadol|Patients in this group will be treated with painkillers consisting of tramadol and dexketoprofen.
215010712|NCT01096186|DRUG|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
214405756|NCT05599360|DRUG|Mylotarg|Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin \[Ig\] G4, kappa antibody produced by mammalian cell culture in non-secreting 0 (NS0) cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab.
215010713|NCT01096186|DRUG|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
215010714|NCT03316560|BIOLOGICAL|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
215010715|NCT04053452|DIAGNOSTIC_TEST|Peripheral nerve ultrasound|Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
215010716|NCT04053452|DIAGNOSTIC_TEST|Measurement of strength|Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
215010717|NCT00884000|DRUG|Genotropin|
215010718|NCT00884000|DRUG|Zomacton|
215010719|NCT06259838|OTHER|no intervention|no intervention
215010720|NCT04037956|PROCEDURE|Tubeless NOSES|The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).
215098402|NCT04544579|DEVICE|Stent grafts anchored in different areas|Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
215098403|NCT02843828|DEVICE|gait rehabilitation with Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
214405757|NCT02339727|DIETARY_SUPPLEMENT|Preterm infants formula|The group 1 of children will receive a preterm infants formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2/1 during the first 3 months of life. And group 2 will receive other Preterm infants formula very similar, but with a ratio of DHA and AA=1/1 also during the first 3 months of life.
214405758|NCT03882489|DRUG|Isobaric 2-chloroprocaine|The doses of isobaric 2-chloroprocaine will be administrated intrathecally and will be adjusted according to the observed responses in the previous subjects.
214405759|NCT00312078|DIETARY_SUPPLEMENT|Yogurt Supplementation|
214405760|NCT00550472|DIETARY_SUPPLEMENT|probiotics|Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
214405761|NCT04364945|DRUG|dexmedetomidine|administration of dexmedetomidine 1 mcg/kg/hr
214405762|NCT04364945|DRUG|remifentanil|administration of remifentanil 0.1-0.2 mcg/kg/min
214405763|NCT04364945|DRUG|Sevoflurane|Anesthesia is maintained using sevoflurane.
214405764|NCT00690456|DRUG|Rimonabant|Tablet, oral administration
214405765|NCT00690456|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
214405766|NCT00690456|DRUG|Metformin|Metformin continued at stable dose as background therapy
214405767|NCT04907448|OTHER|Physical Therapy|"The IsoK-ST group received their usual physical therapy program for 45 minutes, three times a week for eight successive weeks, which comprised advanced balance training, weight-bearing exercises, gait training, postural and flexibility exercises, and strength training exercises.~Additionally, the IsoK-ST group received an IsoK-ST program, thrice/week for eight successive weeks.~The control group received the usual physical rehabilitation program only for 45 minutes, three times a week for eight successive weeks."
214405768|NCT01334541|BEHAVIORAL|SAFE VET|"All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:~1. Risk Assessment~2. Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.~3. Clinical Follow-Up Protocol"
215010721|NCT04037956|PROCEDURE|traditional laparoscopic radical resection|The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
215010722|NCT01123564|DRUG|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
215010723|NCT01123564|RADIATION|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
215098404|NCT02843828|OTHER|gait rehabilitation without Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
215098405|NCT02849015|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
215010724|NCT02203786|DRUG|Haloperidol|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol."
215010725|NCT02203786|DRUG|Fluphenazine|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine."
215010726|NCT02203786|DRUG|Dexedrine|"Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine."
215010727|NCT02203786|DRUG|Placebo|"Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1."
215010728|NCT02203786|BEHAVIORAL|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
215010729|NCT04673695|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
215010730|NCT04673695|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
215010731|NCT03494192|OTHER|Scapula Retraction Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up."
215010732|NCT03494192|OTHER|Scapula Retraction +Glenohumeral Rotational Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up"
215098406|NCT02849015|BIOLOGICAL|NK immunotherapy|Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
215098407|NCT01192568|DRUG|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
215098408|NCT01192568|DRUG|Placebo|Topical gel
215098409|NCT01196351|OTHER|Dietary Supplement: water with noncalorie sweetener|
214405769|NCT02387203|DRUG|PrevPac (Prevacid, Amoxicillin, Clarithromycin)|30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
214405770|NCT03158948|DRUG|Nangibotide 0.3 mg/kg|Formulated LR12 peptide
214405771|NCT03158948|DRUG|Placebo|placebo
214405772|NCT03158948|DRUG|Nangibotide 1 mg/kg|Formulated LR12 peptide
214405773|NCT03158948|DRUG|Nangibotide 3 mg/kg|Formulated LR12 peptide
215010733|NCT02765971|OTHER|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
214405774|NCT02391909|BIOLOGICAL|Vivotif|
214405775|NCT02153788|DRUG|Temazepam|Temazepam 15 mg orally at bedtime
214405776|NCT02153788|DRUG|Placebo|
215010734|NCT02765971|DRUG|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
215010735|NCT02765971|DRUG|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
214405777|NCT04672460|DRUG|TALZENNA capsule|Current commercial talazoparib formulation 1 mg once daily given under fasting condition
214405778|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
214405779|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
214405780|NCT03575962|DRUG|GSK3640254 bis-hydrochloride salt capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
214405781|NCT03575962|DRUG|GSK3640254 Mesylate Salt Capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
214405782|NCT00059917|DRUG|polyglutamate camptothecin|
214405783|NCT05247853|PROCEDURE|Blood collection|Blood collection at enrollment visit
214405784|NCT05247853|PROCEDURE|Oral, cervicovaginal and anal specimen collection|Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits
215010736|NCT05611424|GENETIC|FT-003|Administered via intraocular injection.
215010737|NCT01545466|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
215010738|NCT00047632|DRUG|Interferon gamma-1b|100 mcg, SQ, 3x per week
215010739|NCT00122187|DEVICE|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
215010740|NCT02061592|DEVICE|etafilcon A|
215098410|NCT01196351|OTHER|Activity: With noncalorie sweetener or glucose|
215098411|NCT00652951|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
215098412|NCT00652951|BIOLOGICAL|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
215010741|NCT02061592|DEVICE|etafilcon A|
215098413|NCT00652951|BIOLOGICAL|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
215098414|NCT00652951|BIOLOGICAL|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
214405785|NCT05247853|PROCEDURE|Anoscopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent anal HPV16/18+ in WLWH
214405786|NCT05247853|PROCEDURE|Colposcopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV
214405787|NCT05247853|PROCEDURE|Ablative Treatment|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy
214405788|NCT05247853|PROCEDURE|LEEP (Loop Electrosurgical Excision Procedure)|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy that ablation ineligible
214405789|NCT00288769|DRUG|daily sublingual tablets Vitamin B12 1000 mcg versus placebo|
214405790|NCT02338037|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection
214405791|NCT02338037|PROCEDURE|Biopsy|Undergo biopsy
214504733|NCT07099729|OTHER|Volume-Controlled Ventilation (VCV) with inspiratory-to-expiratory (I:E) ratio of 1:2.|Patients received volume-controlled ventilation (VCV) with an inspiratory-to-expiratory (I:E) ratio of 1:2. Mechanical power was calculated geometrically (MPgeo) using ventilator screenshots, and results were compared with dynamic mechanical power (MPdyn) values.
214504734|NCT07099729|OTHER|Volume-Controlled Ventilation (VCV) with inspiratory-to-expiratory (I:E) ratio of 1:1.|Patients received volume-controlled ventilation (VCV) with an inspiratory-to-expiratory (I:E) ratio of 1:1. MPgeo was computed from ventilator screenshots and compared to MPdyn values to assess agreement.
215010742|NCT05877664|DRUG|ZG0895 Hydrochloride for Injection|The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m\^2 groups, subcutaneous (SC) injection once a week (QW)
215010743|NCT03338023|DRUG|LY2963016|Administered SC
215098415|NCT00708695|BEHAVIORAL|Nurse Home Visiting|Visits from nurses from mid-pregnancy to child age 2 years.
214405792|NCT02338037|DRUG|Eribulin Mesylate|Given IV
214405793|NCT02338037|PROCEDURE|Microdialysis|Undergo intracerebral microdialysis
214405794|NCT02338037|OTHER|Pharmacological Study|Correlative studies
214504735|NCT07099729|OTHER|Pressure-Controlled Ventilation (PCV) with inspiratory-to-expiratory (I:E) ratio of 1:2.|Patients received pressure-controlled ventilation (PCV) with an I:E ratio of 1:2. Mechanical power was measured using both geometric (MPgeo) and dynamic (MPdyn) methods for validation purposes.
214504736|NCT07099729|OTHER|Pressure-Controlled Ventilation (PCV) with inspiratory-to-expiratory (I:E) ratio of 1:1.|Patients received pressure-controlled ventilation (PCV) with an I:E ratio of 1:1. Geometric mechanical power calculations from ventilator screenshots were compared with MPdyn values for accuracy assessment.
215010744|NCT03338023|DRUG|Lantus®|Administered SC
215010745|NCT03338023|DRUG|Insulin Lispro|Administered SC
215010746|NCT02399800|PROCEDURE|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
215010747|NCT02399800|PROCEDURE|No Celiac Block|EUS but no celiac block performed
215010748|NCT02399800|DRUG|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
215010749|NCT03148925|BIOLOGICAL|SELA-070|Sub-cutaneous injection, multiple dose
215010750|NCT03148925|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
215010751|NCT05733533|DRUG|HRS-2261 oral tablet|HRS-2261 oral tablet, oral, BID
214405795|NCT06713161|DIAGNOSTIC_TEST|NIR-II Probe(i.e ICG-POL6326) incubation solution|After the tissues were incubated with the optimal concentration of the NIR-II probe for the appropriate time, the tissues were washed with the eluate, and then the fluorescence intensity of different tissues was detected to evaluate whether the tissues had cancer tissue invasion.
214405796|NCT05978661|DRUG|FKC288|Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
214405797|NCT06705530|BIOLOGICAL|Hem101|CAR-T lymphocytes specific to CD19 B-cell antigen
214405798|NCT01876043|DRUG|plitidepsin|"Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~* Stage 1(17 participants): if \<=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~* Stage 2 (37 participants): if \>= 11 non-progressions, Aplidin was considered promising."
214405799|NCT01032850|DRUG|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
214405800|NCT02683824|DIAGNOSTIC_TEST|Computed Tomography|Undergo CT scan
214405801|NCT02683824|OTHER|Laboratory Biomarker Analysis|Correlative studies
214405802|NCT02683824|DIAGNOSTIC_TEST|PET/MRI scan|Undergo PET/MRI scan
214405803|NCT02683824|DRUG|[18F]FP-R01-MG-F2|radioactive tracer
214405804|NCT00530374|DIETARY_SUPPLEMENT|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
214405805|NCT00530374|DIETARY_SUPPLEMENT|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
214405806|NCT00713934|BIOLOGICAL|CD133|portal vein infusion of CD133+ cells
214405807|NCT00713934|BIOLOGICAL|BM-MNC|portal vein infusion of BM-MNC
214405808|NCT05125861|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
214405809|NCT05125861|PROCEDURE|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
215098416|NCT02593825|BEHAVIORAL|START-Play intervention|The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.
215098417|NCT02593825|BEHAVIORAL|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
215010752|NCT05733533|DRUG|Matching placebo to HRS-2261|Matching placebo to HRS-2261, oral, BID
214405810|NCT03573362|DEVICE|ViziShot FLEX 19G needle|EBUS-TBNA using the ViziShot FLEX 19G needle
214405811|NCT03573362|DEVICE|Vizishot 22G needle (standard)|EBUS-TBNA using the Vizishot 22G needle (standard)
214405812|NCT02813499|OTHER|CARE Rule|Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
214405813|NCT00079937|DRUG|Omalizumab|The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
214405814|NCT00079937|DRUG|Placebo|Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
214405815|NCT00079937|DRUG|Fluticasone|Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
215098418|NCT00003364|DRUG|cisplatin|
215010753|NCT01706380|BEHAVIORAL|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
214405816|NCT01616563|BEHAVIORAL|Dietary Intervention|Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
215010754|NCT01706380|BEHAVIORAL|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
215010755|NCT01491932|DRUG|AFQ056|AFQ056 will be supplied as oral capsules.
215098419|NCT00003364|DRUG|cyclophosphamide|
215098420|NCT00003364|DRUG|doxorubicin hydrochloride|
215098421|NCT00003364|DRUG|etoposide|
215098422|NCT00003364|DRUG|vincristine sulfate|
215098423|NCT00003364|RADIATION|radiation therapy|
215098424|NCT04397562|DRUG|Levilimab|Levilimab 324 mg
215098425|NCT04397562|DRUG|Placebo|Placebo
215098426|NCT01251835|DRUG|Sitaxsentan alone|Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
214405817|NCT01616563|BEHAVIORAL|Exercise Prescription and Fitness Program|Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
214405818|NCT04965883|PROCEDURE|Excision and Grafting|reconstruction of deep burn by grafting
214405819|NCT04965883|PROCEDURE|dressing then delayed grafting|multiple dressing and delayed grafting
214405820|NCT02206685|DRUG|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
214405821|NCT02206685|DRUG|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
215098427|NCT01251835|DRUG|Sitaxsentan|Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
215098428|NCT01251835|DRUG|Rifampin|Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
215098429|NCT04519346|OTHER|intradermal injection|Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
215098430|NCT01206582|BIOLOGICAL|Hemin|10 iv infusions for 8 weeks
215098431|NCT01206582|BIOLOGICAL|Albumin|10 iv infusions for 8 weeks
214405822|NCT04448743|OTHER|Blood sample|20 Ml blood sample
214405823|NCT05955599|OTHER|ACL Injury Prevention Training|Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
214405824|NCT05955599|OTHER|Control - Shoulder Injury Prevention Training|Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
214405825|NCT02054247|DEVICE|ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
214405826|NCT02054247|DEVICE|pulsed ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
214405827|NCT02054247|DEVICE|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
215098432|NCT01054001|DRUG|sildenafil 100mg|sildenafil 100mg per oral twice a week
214405828|NCT02582203|DRUG|Ceftaroline|
215098433|NCT01157026|DIETARY_SUPPLEMENT|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
214405829|NCT02582203|DRUG|Vancomycin|
214405830|NCT01392755|DRUG|danoprevir|oral doses of danoprevir
214405831|NCT01392755|DRUG|omeprazole|oral doses of omeprazole
214405832|NCT01392755|DRUG|ranitidine|oral dose of ranitidine
214405833|NCT01392755|DRUG|ritonavir|oral doses of ritonavir
214405834|NCT00093795|DRUG|Cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles"
214405835|NCT00093795|DRUG|Docetaxel|75 mg/m2 IV every 21 days for 6 cycles
214405836|NCT00093795|DRUG|Gemcitabine|2000 mg/m2 IV every 14 days for 4 cycles
214405837|NCT00093795|DRUG|Paclitaxel|175 mg/m2 IV every 14 days for 4 cycles
215098434|NCT01157026|OTHER|placebo plus tamoxifen|20mg tamoxifen daily
215098435|NCT01609998|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
215098436|NCT01609998|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
215098437|NCT02522325|DRUG|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
215098438|NCT02522325|DRUG|Cocaine|Intranasal cocaine will be administered during experimental sessions.
215098439|NCT02522325|DRUG|Placebo|Placebo capsules will contain only cornstarch.
215098440|NCT01209078|DRUG|GSK1322322|GSK1322322 1500mg BID
215098441|NCT01209078|DRUG|Linezolid|Linezolid 600mg
215098442|NCT01209078|DRUG|GSK1322322 placebo|Placebo
215098443|NCT01209078|DRUG|Linezolid placebo|placebo
215098444|NCT00924508|DEVICE|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
215098445|NCT00924508|DRUG|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
215098446|NCT03070899|DRUG|OBE2109|OBE2109 100mg tablets for oral administration once daily
214405838|NCT00093795|DRUG|Doxorubicin|"Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles"
214405839|NCT01195675|DRUG|BI 10773 (low)|single oral dose
214405840|NCT01195675|DRUG|Moxifloxacin|single oral dose
214405841|NCT01195675|DRUG|BI 10773 Placebo|2 times single dose
214405842|NCT01195675|DRUG|BI 10773 (high)|single oral dose
214405843|NCT01106287|DRUG|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
214405844|NCT01106287|DRUG|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
214405845|NCT03299387|DRUG|Nitrofurantoin|Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
214405846|NCT03299387|DRUG|Gentamicin|Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
214405847|NCT04669613|OTHER|CUDI|Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
214405848|NCT03545490|DIETARY_SUPPLEMENT|Early nutritional intervention|Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
215098447|NCT03070899|DRUG|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
215098448|NCT03070899|DRUG|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
214405849|NCT00072475|DRUG|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
214405850|NCT05727956|PROCEDURE|Aneurysmectomy|Complete aneurysmectomy with end-to-end anastomosis for the true aneurysm or partial aneurysmectomy with a direct repair.
214405851|NCT04591899|DEVICE|CAD/CAM splints|"Each of the maxillary and mandibular cast will scanned alone and then both scanned together in the centric relation using FREEDOM HD scanner1.~The CAD/ CAM splint will be designed using Exocad software; the design will be the same as the conventional one. The surveying will be done by the software and the under-cuts blocked.~The splints will be printed using Dent2 3D printer and then cured using Dentcure. The CAD/CAM splints material will be hard resin from PhotoCentric 3D."
215098449|NCT03070899|DRUG|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
215010756|NCT05371223|DRUG|Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine|"Each combined course is constituted by two consecutive 28-day cycles of systemic chemotherapy (three adminstrations per cycle: days 1,8 and 15) and one cycle of PIPAC administered within 10-13 days from the last administration of systemic chemotherapy. Between each combined course a 7-10 days pause is observed.~The recommended dose of Nabpaclitaxel in combination with Gemcitabine is 125 mg/m2 administered endovenous over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. The concurrent recommended dose of Gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Nabpaclitaxel administration on Days 1, 8 and 15 of each 28-day cycle.~A pressurized aerosol containing Nabpaclitaxel at the dose of 112,5 mg/m2 diluted in a total volume of 200 ml of NaCl 0.9% is applied through the nebulizer inside the abdominal cavity during laparoscopy."
214405852|NCT03093610|PROCEDURE|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
214405853|NCT03093610|PROCEDURE|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
214405854|NCT04730947|DRUG|Dapagliflozin|10 mg orally once a day
215098450|NCT01462617|DRUG|GSK2269557|Study Drug
215098451|NCT01462617|DRUG|GSK2269557 matching placebo|Study Drug
214405855|NCT04730947|DRUG|Placebo|Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
215010757|NCT00387309|DRUG|Methylnaltrexone (MOA-728)|
215010758|NCT05335265|OTHER|Treatment training|"Face-to-face:Metered-DoseInhalerTraining gave 3 times on the 1st day, 2 times on the 2nd day, once on the 3rd day.During discharge, inhaler technical evaluation were done according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by using the Patient's Booklet of the Turkish Thoracic Society (TTS).The people who is evaluate the patient's inhaler technique (IT) on the day of discharge was someone different from the health personnel who provided the training. In IT control, the patient's performance was evaluated simultaneously by 2 observers.~Video training:Training gave 3 times on the 1st day, 2 times on the 2nd day,once on the 3rd day.The TTS-Virtual Training Video were used.During discharge,inhaler technical evaluation was done same with face-to-face training.The person who is evaluate the patient's IT was someone different from the training personnel.In IT observation,it was used same method with face-to-face training."
215010759|NCT00382473|BEHAVIORAL|Aerobic exercise program - 8 weeks|No drugs. Regular aerobic exercise in structured prescription format
215010760|NCT00005684|DRUG|warfarin|
215010761|NCT00005684|DRUG|heparin|
215010762|NCT02145520|DRUG|Magnesium Sulfate|The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
215010763|NCT02145520|OTHER|placebo|use of placebo with standard therapy
215098452|NCT06438055|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
215098453|NCT01510743|PROCEDURE|Catheterization of subclavian vein|Catheterization of subclavian vein
215098454|NCT01510743|PROCEDURE|Catheterization of internal jugular vein|Catheterization of internal jugular vein
215098455|NCT01152034|BEHAVIORAL|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
214405856|NCT03060187|OTHER|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
214405857|NCT06300398|DRUG|IAMA-6|IAMA-6 liquid suspension
214405858|NCT06300398|DRUG|Placebo|Placebo-to-match IAMA-6 liquid suspension
214504737|NCT07098429|DRUG|Bupivacain (Postoperative)|20ml of 0.25% bupivacaine instillation in gallbladder fossa after removal of gallbladder in laparoscopic cholecystectomy this study used less amount of drug
214504738|NCT07098429|DRUG|Normal (0.9%) saline|In 30 patients who underwent Laparoscopic Cholecystectomy , 20ml of 0.9% normal saline instillation in gallbladder fossa after removal of gallbladder.
215098456|NCT03896945|DRUG|Placebo|oral capsules
215098457|NCT03896945|DRUG|AVP-786|oral capsules
215098458|NCT05727982|DIAGNOSTIC_TEST|Venous blood samples, Biological samples analysis, Cardiology visit.|These interventions are important to study all patients recruited
215098459|NCT06464263|DRUG|Dexmedetomidine|to investigate the postoperative analgesic-sedative effect of dexmedetomidine versus fentanyl-midazolam to achieve fast-track extubation after adult valvular cardiac surgeries.
215098460|NCT05728268|DRUG|dose-dense nab-paclitaxel followed by EC|dose-dense nab-paclitaxel followed by EC
215098461|NCT03394586|DRUG|Exposure to golimumab|retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
215098462|NCT00495625|DRUG|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
215098463|NCT06051344|DRUG|Zoledronic acid|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
215098464|NCT01335269|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
215098465|NCT01912339|DEVICE|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
215098466|NCT01912339|PROCEDURE|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
215098467|NCT03870204|DIAGNOSTIC_TEST|POC-CCA rapid urine test|Fresh urine samples will be tested by POC-CCA
215098468|NCT01771796|BEHAVIORAL|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
215010764|NCT03398382|DIETARY_SUPPLEMENT|Magnesium tablet group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-artikain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected, the patient will receive magnesium citrate tablets. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
215010765|NCT03398382|DIETARY_SUPPLEMENT|Placebo tablets group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected , the patient will receive placebo tablets which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
215098469|NCT03458650|DRUG|LXI-15028 50mg|In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
215098470|NCT03458650|DRUG|LXI-15028 100mg|100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
215098471|NCT03458650|DRUG|LXI-15028 200mg|single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
215098472|NCT03458650|DRUG|Placebo|matching placebo tablets
214405859|NCT03916614|BEHAVIORAL|Screening Tool for Relief of Trauma (START)|The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,\[30\] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
214405860|NCT03916614|BEHAVIORAL|standard of care|Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
214405861|NCT05916885|OTHER|short-intensity modified CIMT and conventional therapy|an experimental group receiving short-intensity modified CIMT and conventional therapy
214405862|NCT05916885|OTHER|conventional therapy alone|a control group receiving conventional therapy alone.
214504739|NCT07099521|DEVICE|Active High-definition transcranial direct current stimulation|Participants completed 10 sessions of anodal HD-tDCS stimulation over 5 consecutive days (two 20-minute sessions per day, with a 3-hour interval between sessions). Stimulation was delivered using an HD-tES device (Soterix Medical, Inc, Woodbridge, NJ, USA), targeting the left dorsolateral prefrontal context (DLPFC). In the active HD-tDCS condition, current was ramped up to 2mA over 30 seconds, maintained for 20 minutes, then ramped down to 0mA at the end.
215098473|NCT01435629|DRUG|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
215098474|NCT04647097|BEHAVIORAL|Standard intervention only|Standard intervention (SI) will be a part of standard care in all participating centers, and will be provided for all acute pancreatitis patients, who are hospitalized and their condition is alcohol induced. A specially trained study nurse will deliver the intervention, since they were found to be the most effective regarding the decrease in alcohol consumption and smoking. The cost- effectiveness of the intervention and the feasibility were also taken into account. The Assist-linked brief intervention according to the World Health Organization (WHO) will serve as the base for the intervention, with an avarage of 30 minutes, based on a review containing 69 randomized controlled trials, which concluded that longer intervention do not have additional benefit. The patients will be also educated about the disease course of acute pancreatitis during the standard intervention.
214405863|NCT05883800|RADIATION|On-couch adaptive radiotherapy|A new treatment plan, guided by volumetric images, is created at each treatment session
214405864|NCT01461356|PROCEDURE|Minimally invasive total knee replacement|A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.
214405865|NCT01461356|PROCEDURE|Standard approach total knee replacement|A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
214405866|NCT03597308|DRUG|5mg of Oxycodone every 6 hours as needed for pain|5mg of Oxycodone every 6 hours as needed for pain
214405867|NCT03597308|DRUG|600mg of Ibuprofen every 6 hours as needed for pain|600mg of Ibuprofen every 6 hours as needed for pain
214405868|NCT03597308|DRUG|500mg of Acetaminophen every 6 hours as needed for pain|500mg of Acetaminophen every 6 hours as needed for pain
214405869|NCT00031343|DRUG|highly active antiretroviral therapy (HAART)|
214405870|NCT04559932|OTHER|Tracheostomy Training Course|A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
214405871|NCT05623280|DRUG|Indocyanine green|Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
214405872|NCT06052982|PROCEDURE|Drainage|At the end of the knee arthroplasty, a drain is placed or not at the surgical site depending on randomization result
214405873|NCT06487026|DEVICE|ArcBlate Focused Ultrasound Ablation System|MR-guided High Intensity Focused Ultrasound (MRgHIFU)
214405874|NCT01189955|PROCEDURE|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
214405875|NCT01189955|PROCEDURE|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
214405876|NCT00940017|DRUG|anidulafungin and voriconazole|Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
214405877|NCT02689375|DEVICE|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
214405878|NCT01450943|DEVICE|SECONDARY dressing gauze and tape|SECONDARY dressing gauze and tape
214405879|NCT01450943|PROCEDURE|debridement, irrigation|debridement, irrigation
214405880|NCT01450943|DEVICE|Dermagraft|Dermagraft per company protocol
215010766|NCT03398382|DIETARY_SUPPLEMENT|Magnesium lozenge group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX..) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive magnesium citrate lozenge.The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate lozenges. 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
214405881|NCT01450943|DEVICE|Oasis|Oasis per company protocol
214405882|NCT05153174|DRUG|Sulforaphane|This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
214405883|NCT04018729|DEVICE|Zephyr Endobronchial Valve|Endoscopic lung volume reduction therapy.
214405884|NCT04018729|BIOLOGICAL|Marrow-derived mesenchymal stromal cell|Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
214405885|NCT01439425|BEHAVIORAL|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
214405886|NCT01385280|BIOLOGICAL|therapeutic estradiol|Given orally (PO)
214405887|NCT01385280|DRUG|exemestane|Given PO
214405888|NCT01385280|OTHER|laboratory biomarker analysis|Correlative studies
214405889|NCT01385280|OTHER|enzyme-linked immunosorbent assay|Correlative studies
214405890|NCT03614130|DEVICE|LID011121 contact lens|Investigational silicone hydrogel contact lens
215010767|NCT03398382|DIETARY_SUPPLEMENT|Placebo lozenges group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive placebo lozenges which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo lozenges 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
215010768|NCT01642849|DIETARY_SUPPLEMENT|high protein diet|6 months on HP diet
215010769|NCT01642849|DIETARY_SUPPLEMENT|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
215010770|NCT01271166|DRUG|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
215010771|NCT03041337|DIAGNOSTIC_TEST|stress echocardiography|"stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.~The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations"
215010772|NCT04055298|DEVICE|SMASS-Triage|SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
215010773|NCT00799864|DRUG|Rilpivirine|Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged \>=12 to \<18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged \>=6 to \<12 years) or 25 mg once daily for up to 48 weeks.
215010774|NCT00799864|DRUG|Zidovudine|Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
215010775|NCT00799864|DRUG|Abacavir|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
215010776|NCT00799864|DRUG|Tenofovir disoproxil fumarate|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
215010777|NCT00799864|DRUG|Lamivudine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
214504740|NCT07099521|DEVICE|Sham high-definition transcranial direct current stimulation|Participants completed 10 sessions of sham HD-tDCS stimulation over 5 consecutive days (two 20-minute sessions per day, with a 3-hour interval between sessions). Stimulation was delivered using an HD-tES device (Soterix Medical, Inc, Woodbridge, NJ, USA), targeting the left dorsolateral prefrontal context (DLPFC). In the sham condition, the current was ramped up to 2mA within the first and last 30 seconds to mimic the sensation of stimulation, but then ramped down, with no current maintained at other times.
215010778|NCT00799864|DRUG|Emtricitabine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
214405891|NCT03614130|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
214405892|NCT02836665|PROCEDURE|Telemedicine for dermatological emergency patients|"Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site."
215010779|NCT02907957|DEVICE|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
215010780|NCT02907957|PROCEDURE|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
215010781|NCT05448547|RADIATION|Radiotherapy or surgery|see arm/ group description
215010782|NCT05448547|OTHER|initial observation|see arm/ group description
215010783|NCT05448547|DRUG|Hormone therapy|androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
215010784|NCT03507283|PROCEDURE|Double head pterygia excision and repair|Complete excision of the pterygia was done. A free conjunctival autograft was obtained. The graft was divided vertically into two parts then secured into conjunctival defects.
215010785|NCT02734147|DRUG|Ascorbic Acid|
215010786|NCT02734147|OTHER|Normal Saline|
215010787|NCT00685698|DRUG|TG-873870 (Nemonoxacin)|750 mg
215010788|NCT02213107|DRUG|Enzalutamide and Dutasteride or finasteride|"Use of either two oral drugs together~1. Enzalutamide by mouth daily and dutasteride by mouth daily or~2. Enzalutamide by mouth daily and finasteride by mouth daily"
215010789|NCT05061706|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
215010790|NCT05061706|DRUG|Placebo|Matching capsules administered orally, once daily.
215010791|NCT00724893|BIOLOGICAL|PegIFN-2b|PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
214405893|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, low dose
214405894|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, high dose
214405895|NCT05905458|DRUG|HRS9950 placebo tablets|HRS9950 placebo tablets, oral, once a week.
214405896|NCT05328973|OTHER|ELEQUIL|patch placed on skin
214504741|NCT07098884|DIAGNOSTIC_TEST|AI model|AI model developed by smartphone photos of resected tumor specimens
214504742|NCT07098598|DEVICE|PET/CT|PET/CT with FAPI-74 tracer is performed.
215010792|NCT00724893|DRUG|Ribavirin|Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
215010793|NCT04251494|DIAGNOSTIC_TEST|Carotid intima media thickness measurement (CIMT)|CIMT is a measurement of the thickness of the two inner layers of the common carotid artery wall. Using ultrasound, a linear array transducer is placed on the surface of the skin at the neck. Electrocardiogram(ECG) electrodes are placed on each wrist and one on the ankle. An image of the common carotid artery (CCA) is then produced in anterior, posterior and lateral views, and saved along with the ECG recording. The wall thickness can then be measured at the same point in the cardiac cycle using semi-automated detection software (Philips QLAB), which can reduce observer variability. The CIMT will be averaged across left and right CIMTs, as the control reference values use an average of both sides.
215010794|NCT04251494|DIAGNOSTIC_TEST|Pulse Wave Velocity measurement|The PWV measures the speed of a pulse wave travelling between two points in the vascular systems of known distance between them. PWV will be measured by the gold standard carotid-femoral PWV method which is a direct measurement of aortic stiffness. A 3-Lead ECG is connected alongside measurements of the blood velocity trace for the left CCA 2cm proximal to the bifurcation, and for the left common femoral artery origin.
215010795|NCT04251494|DIAGNOSTIC_TEST|Ankle-brachial pressure index (ABPI)|A blood pressure cuff is placed around the ankle and upper arm of the participant. A continuous wave Doppler probe is used over the surface of the skin to locate the artery distal to the cuff (such as the brachial artery in the arm, or the anterior tibial and posterior tibial arteries in the ankle). The cuff is then inflated, and the systolic pressure identified by listening cessation of the sounds produced by the probe corresponding to blood flow in the artery. The ABPI is then the ratio of the highest systolic ankle pressure divided by the highest systolic brachial pressure for the left and right sides of the body.
215010796|NCT04251494|OTHER|Diet questionnaire and diet diary|Dietary information will be collected in two formats. One will be a 14-item questionnaire (Martínez-González et al., 2012), which is a simplified version of a comprehensive food frequency questionnaire. This provides a quick measure of compliance to a Mediterranean dietary pattern and a rough measure of protective and adverse dietary factors that could affect individual CVD risk. The second will be a 3-day diet diary (3DDD). This will consist of participants recording the foods that they consume and the quantities, which will then be analysed for macro- and micronutrient composition once completed.
215010797|NCT04251494|OTHER|Routine blood samples|Blood samples will be taken from participants during their outpatient appointment. Patients routinely have blood samples taken during this clinic. The study will use the results from the routine blood tests, and also extra blood samples to collect data on other biomarkers. The laboratory facilities at Guy's and St Thomas Hospitals will be used to conduct analysis, no other laboratories will be used. Data will be collected on Phenylalanine levels, lipids, vitamin B12 and related biomarkers.
215010798|NCT04342585|DRUG|Micronised vaginal progesterone|A diary will be given to participants to ensure compliance.
215010799|NCT04342585|DEVICE|Vaginal pessary|The internal diameter size will be decided based on the clinical assessment of the cervix.
215010800|NCT02331121|BEHAVIORAL|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
215010801|NCT02331121|BEHAVIORAL|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
215010802|NCT05565404|BEHAVIORAL|mobile health|Scaling and root planing, interdental brushing demonstration and regular text messages in type 2 embrasure patients.
215010803|NCT05565404|PROCEDURE|Scaling and root planing+Interdental aid|Scaling and root planing, interdental brushing demonstration in type 2 embrasure patients.
215010804|NCT05159011|BEHAVIORAL|AGILITY (Access to Genetic Information Leveraging Innovative TechnologY)|information about genetic testing through technology
215010805|NCT03335267|DRUG|CPX-351|Cytarabine:Daunorubicin Liposome Injection
215010806|NCT02923622|OTHER|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
215098475|NCT04647097|BEHAVIORAL|Standard intervention plus repeated intervention|Standard intervention (SI) will be performed as described above. The repeated intervention will be delivered by the former mentioned same nurse and will be structured similarly to the standard intervention. Every visit and intervention will be individually altered according to the motivation of the patient, but they will follow the same structure. The sessions can be divided into three main parts: first, highlighting the harmful effects of smoking and alcohol on the pancreatic functions. Secondly, a discussion about the motivation of the patient will happen. The last portion of the session will focus on the responsibility of the individual to reach the desired goal will be highlighted. To enhance the efficacy of our intervention we wish to provide feed-back for the patient based on laboratory testing: the mean corpuscular volume (MCV) and gamma glutamyl-transferase (GGT) values will be measured right before the interview. The study nurse will not take part in patient care.
215098476|NCT03666689|PROCEDURE|surgical technique|surgical reconstruction
215098477|NCT04119596|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
215098478|NCT04119596|GENETIC|DNA-microarray genotyping|Taking a saliva sample for genotyping
215098479|NCT01811134|DEVICE|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
214405897|NCT06331962|OTHER|remote home-based exercise therapy group|"Location and Frequency: Four times per week at the individual's ownhome. Exercise Duration: Eight weeks (subject to adjustments based onactual progress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistancetraining, sensory exercises.~Note: The participant will receive a customized exercise plan based ontheir capabilities, including guidelines and exercise instructions (exercisenames, required equipment, movement sequences, repetitions,precautions)."
214405898|NCT06331962|OTHER|supervised exercise therapy group|"Exercise Location and Frequency: Physiotherapy Center (twice a week)and individual's home (twice a week).~Exercise Duration: Eight weeks (subject to adjustments based on actualprogress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistancetraining, sensory training exercises. The home-based exercise trainingcontent is partially the same as the remote home-based exercise group."
215098480|NCT01811134|DEVICE|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
215010807|NCT02923622|OTHER|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
215098481|NCT04338763|DRUG|RP72|RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
214405899|NCT06331962|OTHER|regular care group|Perform regular care for eight consecutive weeks. After the trackingperiod ends (8 weeks), provide home-based education on resistanceexercises, cardiovascular endurance exercises, and sensory trainingexercises.
214405900|NCT03203161|PROCEDURE|bariatric surgery|Roux-and-Y Gastric Bypass or Sleeve gastrectomy
214405901|NCT02680769|DIETARY_SUPPLEMENT|300 mg of citrate Mg|This group will take an oral supplementation of 300 mg of citrate magnesium
214405902|NCT02680769|OTHER|Placebo|This group will take a placebo
215010808|NCT02923622|OTHER|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
215010809|NCT01853085|DRUG|Bimatoprost Ophthalmic Solution|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
215098482|NCT04338763|DRUG|Gemcitabine|Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.
215098483|NCT00005085|DRUG|becatecarin|
215098484|NCT01623375|DRUG|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
215098485|NCT01623375|DRUG|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
215098486|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
214405903|NCT00227981|BEHAVIORAL|Interpersonal Psychotherapy|
214405904|NCT00227981|DRUG|Fluoxetine|
214405905|NCT06630923|DRUG|Human albumin|Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
214405906|NCT01218828|OTHER|LVEDP -Based hydration strategy|
214405907|NCT01218828|OTHER|Standard hydration|
214405908|NCT02728271|BIOLOGICAL|HPC cell infusion|"Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.~Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant."
215010810|NCT01937338|DRUG|AZD7624|nebuliser solution; 20 mg/mL for inhalation
215010811|NCT01937338|DRUG|Placebo|nebuliser solution for inhalation
215010812|NCT00502879|DRUG|Enbrel (etanercept)|
215010813|NCT01078545|DRUG|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
214405909|NCT03422978|DRUG|Dexmedetomidine|Single dose dexmedetomidine administered over 60 seconds post-induction.
214405910|NCT03422978|DRUG|Normal saline|Single dose normal saline administered over 60 seconds post-induction.
215010814|NCT05230927|OTHER|Multidisciplinary Rehabilitation|All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
215010815|NCT01303497|DRUG|Paclitaxel|Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)
215010816|NCT01303497|DRUG|Bevacizumab|"Bevacizumab until progression or inacceptable toxicity :~* During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV~* After 6 cycles of chemotherapy : 15 mg/kg, IV"
215098487|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
215098488|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
215098489|NCT00973323|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
215098490|NCT04916912|PROCEDURE|coronary artery bypass grafting|Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
214405911|NCT00486733|DEVICE|DermaGold|The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
214405912|NCT01525433|BEHAVIORAL|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
214405913|NCT01525433|BEHAVIORAL|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
214405914|NCT00946114|DRUG|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
215098491|NCT02812719|DRUG|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
215098492|NCT02812719|DRUG|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
215098493|NCT00001954|DRUG|Etanercept|
214405915|NCT00946114|DRUG|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
214405916|NCT04833192|DIAGNOSTIC_TEST|experimental group|DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group
214405917|NCT06163521|OTHER|Education|A training consisting of 8 sessions of 40 minutes each will be applied to the children. One session will be done every week. The training will consist of activities including information, discussion and role-playing about children with special needs. The training topics consist of; Children with Special Needs Empathy Differences, Respect for Differences Contact Activity Awareness Benevolence Social Acceptance and Behaviour What can we do?
214405918|NCT00517478|PROCEDURE|Blood Sample|
214405919|NCT00316784|DRUG|IDEA-033 (and rescue medication)|
214405920|NCT01841827|DRUG|Cilostazol|
214405921|NCT01841827|DRUG|Placebo|
214405922|NCT02304822|DRUG|Multiple-dose of Ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
214405923|NCT02304822|DRUG|Single-dose of Ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
214405924|NCT02304822|DRUG|Zero-dose of Ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
214688341|NCT07162870|DRUG|Traditional Chinese medicine (TCM)|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure is defined as taking the medication continuously for more than 3 months per year, or intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group is divided into an exposed group (TCM cohort) and an unexposed group (non-TCM cohort).
215010817|NCT02864914|DRUG|Empagliflozin|drug
215010818|NCT02864914|DRUG|DPP-4 inhibitors|drug
215010819|NCT03695835|DRUG|Immunotherapeutic Agents|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
215010820|NCT03695835|DEVICE|Ablation|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
215010821|NCT00561327|DRUG|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
215010822|NCT01774370|DRUG|Pradaxa (Dabigatran etexilate mesilate)|110 mg or 150 mg b.i.d.
215010823|NCT03051009|DRUG|Desmopressin ODT 25 μg|
215010824|NCT03051009|DRUG|Desmopressin ODT 50 μg|
215010825|NCT05436288|DRUG|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)|KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
215010826|NCT02736214|BEHAVIORAL|Reproductive Life Plan (RLP)|A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
215010827|NCT03948386|DRUG|isobaric bupivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
215010828|NCT03948386|DRUG|hyperbaric bupivacaine|TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
214405925|NCT00618280|DRUG|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
214405926|NCT06249789|PROCEDURE|Spinal Anesthesia|Participants in this arm will receive single-shot spinal anesthesia with 12-15 mg of either 0.05% or 0.75% bupivacaine (iso or hyperbaric) once before surgery. Additionally, they will undergo an ultrasound-guided nerve block called the Fascia Iliaca Compartment Block (FICB ) in combination with spinal anesthesia.
214405927|NCT06249789|PROCEDURE|General Anesthesia|Participants in this group will be given a combination of general anesthesia and a nerve block. General anesthesia involves the use of a sedative called propofol, along with devices to ensure that the airway remains open during the procedure. Additionally, they will undergo an ultrasound-guided nerve block known as the Fascia Iliaca Compartment Block (FICB) in combination with spinal anesthesia.
214405928|NCT03299491|OTHER|MWA intervention|The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.
214504743|NCT07098897|DRUG|Telitacicept 160mg|Currently monoclonal antibodies, that may affect the main axis of pathogenesis of IgA nephropathy and biological therapy such as Telitacicept, provides a new treatment option and altering or depletion or modulation of Gd-IgA1 producing B cells and plasma cells. At present, Telitacicept are used for clinical treatment in IgA nephropathy patient inside China, but still clear data on safety and effect, and patient's complete remission, repeated relapse data are unclear.
214504744|NCT07098897|DRUG|Corticosteroid|Standard Supportive Care plus Corticosteroid(≤1mg/kg/d) without immunosuppressants
214688342|NCT07162870|DRUG|Non-traditional Chinese medicine (non-TCM)|All intervention measures that do not meet the criteria for TCM exposure are regarded as non-TCM exposure.
214688343|NCT07161752|DEVICE|Anatomical face mask 1|Providing face mask ventilation in a neonatal manikin using a model of anatomical face mask
215010829|NCT03948386|DRUG|isobaric mepivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
215010830|NCT02128750|OTHER|contrast echographie with hexafluorur of sulfur|Echography of contrast after injection of product of contrast (sonovue (r))
214405929|NCT03299491|OTHER|IEC intervention|"Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences."
214405930|NCT05176353|OTHER|VAP diagnostic stewardship bundle|Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
214405931|NCT01387490|BEHAVIORAL|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
214405932|NCT01387490|OTHER|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
214405933|NCT05302843|DRUG|BPI-28592|Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
214405934|NCT03728738|PROCEDURE|Head of Bed Positioning|The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
214405935|NCT02024308|DRUG|Fludarabine|50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
214405936|NCT02024308|DRUG|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
214405937|NCT01447914|DRUG|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
214405938|NCT01447914|OTHER|Diagnostic laboratory biomarker analysis|Correlative studies
215098494|NCT01663064|DEVICE|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
214405939|NCT01447914|OTHER|Questionnaire administration|Ancillary studies
214405940|NCT01447914|PROCEDURE|Quality-of-life assessment|Ancillary studies
214405941|NCT02888613|PROCEDURE|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
214504745|NCT07098897|DRUG|ACE Inhibitor or Angiotensin receptor antagonist|Drug: ACE Inhibitor (Treatment for proteinuria suppression and blood pressure regulation) - 2-3months before randomization Drug: ARB Inhibitor (Treatment for proteinuria suppression and blood pressure regulation) - 2-3months before randomization
214504746|NCT07098052|DRUG|HDM2020|FGFR2b-ADC
214504747|NCT07098845|BEHAVIORAL|Learning to BREATHE|L2B is a group MBI designed for adolescents (Broderick \& Metz, 2009) and teaches three families of practices: focused attention (e.g., breath awareness), open awareness (i.e., awareness of sensations, thoughts, and feelings as they occur), and compassion. Each letter in BREATHE corresponds to a theme: Body, Reflections, Emotions, Attention, Tenderness, and Habits, building to the overall goal of Empowerment. Each session involves guided discussions, activities, and mindfulness practices.
214688344|NCT07161752|DEVICE|Anatomical face mask 2|Providing face mask ventilation in a neonatal manikin using another model of anatomical face mask
214688345|NCT07161752|DEVICE|Round face mask|Providing face mask ventilation in a neonatal manikin using a model of round face mask
215010831|NCT04077398|DRUG|Ropivacaine 0.5% Injectable Solution|There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
215010832|NCT00500929|DRUG|CMI X-11S|
215010833|NCT01436500|DRUG|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
215010834|NCT01436500|DRUG|Placebo|Sterile water with 5% Dextrose
215010835|NCT06093503|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
215010836|NCT06093503|DRUG|Osimertinib|Oral: Tablet
214688346|NCT07162610|DEVICE|Rejuviel V® with lidocaine|Crosslinked hyaluronic acid (HA) 22 mg/mL + 0.3% lidocaine hydrochloride.
215010837|NCT06093503|DRUG|Cisplatin|IV Infusion
215010838|NCT06093503|DRUG|Carboplatin|IV Infusion
215010839|NCT06093503|DRUG|Pemetrexed|IV Infusion
215010840|NCT01109381|DRUG|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
215010841|NCT00331149|DRUG|Ropinirole prolonged release|
215010842|NCT00331149|DRUG|ropinirole immediate release|
215010843|NCT00581997|DRUG|QAX576|
215010844|NCT00581997|DRUG|Placebo|
215010845|NCT02326688|OTHER|Kinematic analysis of trunk compensation|
215010846|NCT02105857|OTHER|grade A+ knee mobilization|grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
215010847|NCT03967665|DRUG|N-acetyl-L-cysteine|NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
215010848|NCT04134312|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
215010849|NCT04578054|OTHER|Flying transport|Patient care who requires flying transport
215010850|NCT04253678|DRUG|Vortioxetine|Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
215098495|NCT01754493|DRUG|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
215098496|NCT05099666|DRUG|Lurbinectedin|Dosage per protocol, escalation per protocol, IV over 60 minutes (± 5 minute infusion window), schedule per protocol
215010851|NCT06633510|DEVICE|massimo group|masimo is a device for the continuous noninvasive measurement of arterial hemoglobin functional oxygen saturation (SpO2), pulse rate (PR), pleth variability index (PVi) and pleth respiratory rate (Rrp) PI (perfusion index).
215010852|NCT06633510|OTHER|standart group|intraoperative fluid deficit is calculated according to the 4-2-1 rule by summing up the hourly basal fasting level, intraoperative losses depending on the degree of tissue trauma (1-2mlt/kg/h in small-sized surgeries, 2-4mlt/kg/h in medium-sized surgeries, 4-8mlt/kg/h in large-sized surgeries), blood losses, urine and losses from the nasogastric tube. Fluid is given in this way.
215010853|NCT04076137|OTHER|Targeted T-cell armed with bispecific antibody (Decitabine)|In this study, 10 patients eligible for the study were clinically screened for intravenous infusion of targeted activated T cells,every participant has a unique identification number and emergency letter which have the information of group.
215098497|NCT05099666|DRUG|Doxorubicin|Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
215098498|NCT02392455|DRUG|treatment|Docetaxel plus nintedanib until progression or intolerability
215098499|NCT04520854|OTHER|Telehealth Protocol|"The first live-video session will orient participants to the features of the software, discuss the checklist to minimize environmental distractions, gauge how participants are managing their symptoms (pain, swelling) and provide non-pharmacological alternatives to supplement their current treatment strategies.~The second live-video session will be used re-examine how the participant is managing their symptoms (pain, swelling) and re-emphasize non-pharmacological alternatives.~The remaining live-video sessions will be focused on giving participants home-based therapeutic exercises. The therapeutic exercises will target the four main areas important to ankle sprain recovery: 1) range of motion; 2) balance; 3) gait; and 4) strength. All of the therapeutic exercises are based on previously published criteria for the rehabilitation of an LAS. The progression will start with single-plane, non-weight bearing or low-force activities and will advance at the same rate."
215098500|NCT04520854|OTHER|Usual Care|The usual care group will be instructed to follow their treating physicians' orders. Participants will not receive instructions on how to self-manage symptoms nor a home-based exercise program.
215098501|NCT06087198|DIAGNOSTIC_TEST|T-TAS 01 HD Assay|Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion
215098502|NCT06799013|BIOLOGICAL|10 ug HDT 321|HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
215098503|NCT06799013|BIOLOGICAL|25ug HDT-321|HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
215098504|NCT06799013|BIOLOGICAL|50ug HDT-321|HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
215098505|NCT06105268|OTHER|flipped learning training group|flipped learning training group. Applying a flipped learning model in addition to routine training in a fully equipped simulation
214688347|NCT07162610|DEVICE|JUVEDERM® VOLUMA® with lidocaine|Crosslinked hyaluronic acid (HA) 20 mg/mL + 0.3% lidocaine hydrochloride.
214688348|NCT07162896|DRUG|Crisaborole 2%|Apply thin layer to affected skin daily for 28 days.
214688349|NCT07162896|DRUG|Tacrolimus 0.1%|Apply thin layer to affected skin daily for 28 days.
214688350|NCT07162935|OTHER|Cigarillo brand 1|Participants will be assessed on puffing behavior, subjective effects, and exhaled carbon monoxide when assigned to using one of three cigarillo brands. Additives and ingredients of the cigarillo used will also be assessed
215010854|NCT03778333|BIOLOGICAL|Autologous mesenchymal stem cells|IV therapy with autologous bone-marrow derived mesenchymal stem cells
215010855|NCT05024942|PROCEDURE|Transfemoral TAVR (Transcatheter aortic valve replacement)|Transfemoral transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis) through an incision in the groin. All FDA approved transcatheter aortic prosthesys are allowed.
215010856|NCT04534946|OTHER|This is not an intervention study|This is not an intervention study
215010857|NCT05509621|OTHER|The Effect of Supine Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
215098506|NCT05572359|DEVICE|cryo-and compression brace|patients in the intervention groups are instructed to use the cryo- and compression brace during the six postoperative weeks five times a day, for a maximum of 20 minutes. The amount of compression is dependent on a patients' own preference.
215098507|NCT06211738|OTHER|no intervention|no intervention
215098508|NCT04927897|DIAGNOSTIC_TEST|Ultrasound|3D endorectal ultrasound.
215098509|NCT04927897|DIAGNOSTIC_TEST|Rectoscopy|Rigid rectoscopy.
215098510|NCT04927897|OTHER|Scan, e.g. CT (resection specimen)|For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.
215098511|NCT05479812|DRUG|WTX-124|Investigation Product Monotherapy
215098512|NCT05479812|DRUG|pembrolizumab|Investigation Product in combination with approved therapy
215098513|NCT03172156|GENETIC|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
215098514|NCT05865912|COMBINATION_PRODUCT|Mindfulness training + real tDCS|"The MT is an established app-based programme delivered by Headspace®. During MT, participants complete guided meditation sessions which focus on mindful eating and on coping with cravings. Each MT session lasts 15 min. Participants in the MT+ real tDCS and MT+ sham tDCS groups will be given instructions to practice daily mindfulness for 3 weeks. During 10 of these sessions, MT and real/sham tDCS will be delivered concurrently.~TDCS: During tDCS, a constant weak direct current is applied via electrodes (anode and cathode) placed on the scalp. In this study, the anode will be placed over the right dorsolateral prefrontal cortex (dlPFC) and the cathode will be placed over the left dlPFC. In the real tDCS condition, stimulation will be delivered at a constant current of 2 mA with a 10 second fade in/fade out for 20 minutes. In sham tDCS, the stimulator will deliver 60 seconds of active stimulation at the start (ramping up) and end (ramping down) of the 20 minute period."
215098515|NCT05865912|COMBINATION_PRODUCT|Mindfulness training + sham tDCS|Mindfulness training + sham tDCS
215098516|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 60 mL|Subjects will receive a single 60 mL oral dose of tart cherry extract.
215098517|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 120 mL|Subjects will receive a single 120 mL oral dose of tart cherry extract.
215098518|NCT04244721|OTHER|Preschool Autism Communication Therapy (PACT)|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
215098519|NCT04244721|OTHER|Treatment As Usual (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
215098520|NCT06797583|DEVICE|Active Transcranial Photobiomodulation (TPBM)|CytonBrite, 1064nm LED
215098521|NCT06797583|DEVICE|Sham Transcranial photobiomodulation (TPBM)|Sham condition using a randomized block design involving 2 (TPBM): 1(sham) randomization.
215098522|NCT06336915|BEHAVIORAL|Physician-Nurse Dyad Rounding|Collaborative Approach to Improve Unit-Level Metrics
215098523|NCT04141449|OTHER|Potlako intervention|Combined provider, patient, and health system intervention to expedite cancer diagnosis and care.
215098524|NCT04141449|OTHER|Enhanced care|Provider education and limited patient counseling.
215098525|NCT06583434|BEHAVIORAL|core-lower extremity Pilates Training Group|Participants in this group will engage in a stabilization-based Pilates exercise program focusing on core and lower extremity stabilization. The program consists of twice-weekly sessions, each lasting 50 minutes, over a period of 8 weeks. The primary goal of the intervention is to improve gait patterns and balance in women with flexible pes planus
215098526|NCT06583434|OTHER|Non-Training Group|Participants in this group will not receive any specific intervention during the study period. They will continue their usual activities without any additional exercises provided by the study.
215098527|NCT01543776|DRUG|abiraterone acetate|Given PO
215098528|NCT06186258|DEVICE|percutaneous pulmonary valve implantation (PPVI)|The only inclusion criterion is a successful PPVI to treat RVOT dysfunction. Procedural techniques were at each operator's discretion as well as post-procedure treatments and patient's follow-up. As we sought to assess IE incidence during follow-up, patients who underwent catheterization for intended PPVI but who did not had a successful valve implantation were not included. Successful PPVI was defined as patient discharged alive without valve surgery after successful valve implantation in the RVOT.
215098529|NCT01356628|DRUG|PD-0332991|PD-0332991, 125mg, 3 cycles
215098530|NCT04949022|DEVICE|Medronic 780G insulin pump|Commercial hybrid closed loop system Medronic 780G
215098531|NCT04688788|DRUG|Rituximab|Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.
215098532|NCT04688788|DRUG|Ocrelizumab|Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.
214688351|NCT07162935|OTHER|Cigarillo brand 2|Participants will be assessed on puffing behavior, subjective effects, and exhaled carbon monoxide when assigned to using one of three cigarillo brands. Additives and ingredients of the cigarillo used will also be assessed
214405942|NCT02888613|PROCEDURE|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
214405943|NCT01483287|DIETARY_SUPPLEMENT|Alpha-Galactosidase|"The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time)."
215010858|NCT05509621|OTHER|The Effect of Prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
215010859|NCT05509621|OTHER|The Effect of left lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
214405944|NCT06629415|DRUG|Indocyanine Green|"injecting 7.5 mg (3 ml of a 25 mg/10 ml solution) intravenously in the pre-operative holding area at least 20 minutes before surgery.~Before dissecting the adhesions surrounding the hepatoduodenal ligament, fluorescence cholangiography (FC) is carried out to determine the anatomy of the extrahepatic bile ducts by converting the full-color images to fluorescence images using filter switches on the camera head and/or light source in the laparoscopic imaging system (Fig. 1). The \&amp;#34;critical view of safety\&amp;#34; is then reached by dissecting Calot\&amp;#39;s triangle and using FC to verify whether the accessory bile ducts are present or absent throughout the procedures. It is necessary to acquire fluorescence image"
214405945|NCT06629415|DRUG|Indocyanine Green Drug|1.25 mg of ICG powder was dissolved in 3 cm of saline, and the concentration was roughly 0.04 mg after each 1 cm of saline was diluted by 9 cm of saline. In order to prevent dye leakage that might result in false FC results, a veress needle was inserted through the abdominal wall and into the gall bladder fundus through the liver bed. The puncture site was then cauterized.
214405946|NCT06461741|DEVICE|Integrated Dual-task EMG Biofeedback Training (EMG-BF)|"The intervention is an exercise training that is facilitated by feedback derived from electrical muscle activity measured through electromyography (EMG). An EMG Biofeedback software uses a machine learning algorithm to identify the desired movements and reinforce them by displaying feedback on a computer monitor in the form of videogame control. The EMG acquisition hardware must have at least 4 sensor channels and a sampling rate of \>1KHz. Other than these specifications, any generic EMG amplifier can be used. The effect of the device is therefore primarily defined by the software. An in-depth description of the software and hardware systems is published in the cites study, An EMG-Based Biofeedback System for Tailored Interventions Involving Distributed Muscles. In this trail is the Explore+ ExG amplifier which is sold by Mentalab."
214405947|NCT06461741|BEHAVIORAL|Traditional Balance Exercise Training (BAL-EX)|This intervention is a time-matched active comparator for the EMG-BF intervention. A sequence of seven traditional, balance exercises, taking 1-3 minutes each, is repeated for a total of 30 minutes on each of 18 sessions in the 6-week intervention period. The exercises are ones that challenge the coordination and strength of postural muscles in the presence of various vestibular stimuli. The specific exercises are described in the Arm description.
214405948|NCT06508346|BIOLOGICAL|anti-CD19-CAR-T cells|Intravenous injection
215098533|NCT04688788|DRUG|Fexofenadine|Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
215098534|NCT04688788|DRUG|Paracetamol|Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
215098535|NCT04688788|DRUG|Methylprednisolone|Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
214405949|NCT05036772|DEVICE|Virtual reality|The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
214405950|NCT01764386|DRUG|NB|Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
214405951|NCT01764386|BEHAVIORAL|CLI|The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
214405952|NCT01764386|BEHAVIORAL|Usual Care|Usual Care is a self-directed lifestyle intervention program
214405953|NCT04454567|DRUG|ABI-H0731|Participants will receive ABI-H0731 tablets orally once daily
214405954|NCT04454567|DRUG|Placebo|Participants will receive placebo to ABI-H0731 tablets orally once daily
214405955|NCT04454567|DRUG|NrtI|Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
214405956|NCT02757885|PROCEDURE|Bone Marrow Transplant (BMT)|Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) mismatched donor through a central venous catheter.
214405957|NCT02757885|DRUG|Hydroxyurea|Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing \>125% ideal body weight.
214405958|NCT02757885|DRUG|Thiotepa|Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing \>125% ideal body weight.
214405959|NCT02757885|DRUG|Fludarabine monophosphate|Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing \> 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.
214405960|NCT02757885|DRUG|Cyclophosphamide|"Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight."
214405961|NCT02757885|OTHER|Rabbit Anti-thymocyte Globulin|Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).
214405962|NCT02757885|RADIATION|Total Body Irradiation|Participants will receive 200 cGy of TBI in a single fraction.
214688352|NCT07162935|OTHER|Cigarillo brand 3|Participants will be assessed on puffing behavior, subjective effects, and exhaled carbon monoxide when assigned to using one of three cigarillo brands. Additives and ingredients of the cigarillo used will also be assessed
215010860|NCT05509621|OTHER|The Effect of right lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
215010861|NCT05509621|OTHER|The Effect of Quarter prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
215010862|NCT02867826|DEVICE|Cap|Cap-assisted endoscopy
215098536|NCT03055013|PROCEDURE|Nephrectomy|Undergo nephrectomy
215098537|NCT03055013|BIOLOGICAL|Nivolumab|Given IV
215098538|NCT03055013|OTHER|Patient Observation|Undergo observation
215098539|NCT03055013|OTHER|Quality-of-Life Assessment|Ancillary studies
215098540|NCT03055013|OTHER|Questionnaire Administration|Ancillary studies
215098541|NCT04342078|DIETARY_SUPPLEMENT|Vitamin D|To investigate the effect of one year vitamin D supplementation in preterm born adults (4000 IU = 100 micrograms a day if serum concentration is \< 30 nmol/l, 2000 IU = 50 micrograms a day if 30-50 nmol/l and 1000 IU = 25 micrograms a day if \> 50-80 nmol/l, and no additional supplement if \> 80 nmol/l) on health outcomes (bones, teeth, muscles, heart, lungs) . The target level of vitamin D concentration by every 4 months interval is 80 - 120 nmol/l .(Preterm Adult group)
215098542|NCT02533492|DEVICE|vicryl|wound closure with vicryl suture
215098543|NCT02533492|DEVICE|Vicryl plus|wound closure with vicryl plus suture
215098544|NCT06354088|DRUG|Alpelisib 300 mg|All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.
215098545|NCT06354088|DRUG|Placebo|All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.
215098546|NCT06354088|DRUG|[1-13C] sodium acetate|All participants will receive continuous infusions of \[1-13C\] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
215098547|NCT06354088|DRUG|[6,6-2H2] D-glucose|All participants will receive continuous infusions of \[6,6-2H2\] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
215098548|NCT06354088|DIETARY_SUPPLEMENT|Nestlé BOOST Plus|All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental)
215098549|NCT02207491|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
215098550|NCT02207491|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
215098551|NCT02207491|OTHER|Placebo|1 drop QD, AM, OU
215098552|NCT05433922|DRUG|Avatrombopag|cyclosporine in combination with Avatrombopag to treat
215098553|NCT03106974|DEVICE|orotracheal intubation Macintosh Laryngoscope|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
215098554|NCT03106974|DEVICE|orotracheal intubation Totaltrack VLM|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
214405963|NCT05998590|DIETARY_SUPPLEMENT|High protein supplement|The participants received a 60g protein bolus each evening prior to sleep from week 3 to week 12 of training.
214405964|NCT05998590|DIETARY_SUPPLEMENT|Moderate protein supplement|The participants received a 20g protein bolus each evening prior to sleep from week 3 to week 12 of training.
214405965|NCT05998590|DIETARY_SUPPLEMENT|Carbohydrate placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep from week 3 to week 12 of training.
214405966|NCT05998590|OTHER|Control: No supplementation|The participants did not receive any supplementation but instead acted as a control group doing BT only
214405967|NCT03450876|OTHER|Non-Interventional|Non-Interventional
214405968|NCT04925180|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|As prescribed by the treating physician
214405969|NCT01175707|DRUG|Daptomycin|
214405970|NCT01175707|DRUG|Vancomycin|
215098555|NCT04776863|DEVICE|optical biometry measurement|The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.
215098556|NCT04130672|PROCEDURE|Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy|After hot packing nasopharyngeal irrigation with 50 C saline
215098557|NCT04130672|PROCEDURE|Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy|After cold packing nasopharyngeal irrigation with 22 C saline
215098558|NCT03515356|BEHAVIORAL|MI-Walk Intervention|Eight-week motivational enhancement therapy and home-based aerobic walking intervention
215098559|NCT03515356|BEHAVIORAL|Physical Activity Education Pamphlet|Physical activity education pamphlet only
215010863|NCT03934307|DRUG|ALN-AGT01|ALN-AGT01 will be administered by subcutaneous (SC) injection.
215098560|NCT01078649|DRUG|Debio 1143 (AT-406)|Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
215098561|NCT05096000|BEHAVIORAL|InterMob: a randomized controlled trial aimed at reducing car use in regular car users|Intermob is a theory- and evidence-based behavioral intervention that combines public transport/bicycle and motivational techniques (action planning, personalized transport advice, goal setting).
215098562|NCT05096000|OTHER|Active control: Air pollution information|The active control intervention is based on a discussion about air pollution, the effects of air pollution on health, the association between air pollution and transport.
214405971|NCT01598025|RADIATION|total-body irradiation (TBI)|
214405972|NCT01598025|DRUG|thiotepa|
214405973|NCT01598025|DRUG|fludarabine phosphate|
214405974|NCT01598025|DRUG|melphalan|
214405975|NCT01598025|BIOLOGICAL|anti-thymocyte globulin|
214405976|NCT01598025|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214405977|NCT01598025|BIOLOGICAL|peripheral blood stem cell transplantation|
214405978|NCT01598025|OTHER|laboratory biomarker analysis|
214405979|NCT05482386|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
214405980|NCT01501630|DEVICE|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
214405981|NCT00081809|DRUG|autologous human tumor-derived HSPPC-96|
214405982|NCT06489171|PROCEDURE|Received laparoscopic-assisted vaginal radical trachelectomy|"The LAVRT procedure began with laparoscopic pelvic lymphadenectomy, and all lymph nodes were removed for frozen pathological analysis. The laparoscopic-assisted vaginal radical trachelectomy procedure was continued only if the nodes were negative. The pararectal pouch was revealed, and the uterine arteries were divided from their origin to the internal iliac artery. The ureters were freed from the posterior leaf of the broad ligament down to the level where they entered the ureteral tunnel and then displaced laterally. The uterosacral ligaments, cardinal ligaments, and parametrial portions were then divided and dissected. The section of the procedure was performed laparoscopically. The vaginal epithelium was circumferentially incised approximately 3 cm distal to the endocervix. Frozen section analysis confirmed no cancer involvement at the endocervical or vaginal margin. The vaginal mucosa was sutured to the cervical stump to form a new cervical os."
214405983|NCT04286022|OTHER|Speed Loss 20% Strength Training|Strength training based on the control of speed loss in execution.
214405984|NCT04286022|OTHER|Reduced Rest Time Strength Training|Strength training based on a protocol that includes reduced rest times between sets.
214405985|NCT05939622|OTHER|Structural and functional MRI|MRI using a Siemens MAGNETOM Prisma 3T scanner before and after a course of therapy, using resting state fMRI and with cognitive paradigm.
214405986|NCT05939622|DRUG|Ethyl methyl hydroxypyridine succinate + Meldonium|Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration)
214405987|NCT05939622|DRUG|Placebo|Placebo was used in the same way
214405988|NCT06263985|DEVICE|Axis Dermis biologic mesh repair for pelvic organ prolapse|Subjects with pelvic organ prolapse will undergo a pelvic organ prolapse repair with the use of Axis Dermis biologic mesh.
214405989|NCT01359098|DRUG|Ciprodex Otic Suspension|4 gtt b.i.d. for 7 days.
214405990|NCT01359098|DRUG|Ciprodexa Otic Foam|0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
214405991|NCT06009380|OTHER|Physiotherapy and Rehabilitation|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises and activities of daily living recommendations. In addition to the program given to the control group, the dual task program will be given progressively to the study group.
215010864|NCT03934307|DRUG|ALN-AGT01-Matching Placebo|Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
215010865|NCT03934307|DRUG|Irbesartan|Irbesartan will be administered orally.
215010866|NCT03934307|DRUG|Irbesartan-Matching Placebo|Irbesartan-matching placebo will be administered orally.
215010867|NCT01993368|OTHER|flow cytometry|"These populations will be identified by different combinations of antibodies to identify:~* T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~* Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~* Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)"
214405992|NCT01616290|DRUG|PRT-201|0.03, 1, or 3 mg single adventitial administration
214405993|NCT00003377|DRUG|cisplatin|
214405994|NCT00003377|DRUG|paclitaxel|
214405995|NCT00003377|RADIATION|brachytherapy|
214405996|NCT00003377|RADIATION|radiation therapy|
214405997|NCT06335758|DEVICE|Use of ReX to dispense and monitor solid oral medication therapy.|ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
214405998|NCT03928561|DEVICE|Active intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, air cleaners are switched on. The number of air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of active air cleaners in the EEC
214405999|NCT03928561|DEVICE|Placebo Intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, placebo air cleaners are switched on. The placebo effect is obtained thanks to the removal of air cleaners filters prior to the exposure. The number of placebo air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of placebo air cleaners in the EEC.
214406000|NCT04318964|BIOLOGICAL|TAEST16001 cells|"The patients in the dose increasing part and the expanding part received the intravenous reinfusion of TAEST16001 cells on the 5th day (i.e. the interval was 4 days) after the lymphocyte elimination chemotherapy: If the dose level of reinfusion was 1 and 2, the planned total amount of TAEST16001cells (calculated by TCR-T positive cells) was given a single reinfusion on the 1st day of the study. If the dose level of reinfusion was 3 and 4,then the total amount of TAEST16001cells (calculated by TCR-T positive cells) was planned to be reinjected in 60% and 40% proportion on the first and second day of the study.~After the first reinfusion of TAEST16001 cells, the patients will be given a small dose of IL-2 subcutaneously (study day 1 to day 14), 500000 U / time. The first injection will be carried out within 30 minutes after the cell reinfusion, twice a day (interval 10-12 hours), for 14 days."
214406001|NCT02759003|PROCEDURE|Nightime NIV initiation|In-hospital vs home
214406002|NCT03002987|BEHAVIORAL|Active Pregnancy policy|Education (3 hours) of leaders in how to implement Active pregnancy policy at their departments/work places
214406003|NCT02949310|DRUG|Nefopam|
214406004|NCT02949310|DRUG|Normal Saline|
214406005|NCT02856529|OTHER|Training|The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
214406006|NCT02856529|OTHER|General session|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
214406007|NCT02920944|DEVICE|EUS-FNB with 20 gauge ProCore needle|EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
214406008|NCT02920944|DEVICE|EUS-FNB with 22 gauge ProCore needle|EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
214406009|NCT04647162|PROCEDURE|hematoma evacuation by craniotomy|The intervention method of hematoma evacuation is under craniotomy.
214406010|NCT04647162|PROCEDURE|hematoma evacuation by stereotactic puncture|The intervention method of hematoma evacuation is under stereotactic puncture.
214406011|NCT04647162|PROCEDURE|hematoma evacuation by neuroendoscopy|The intervention method of hematoma evacuation is under neuroendoscopy.
214406012|NCT04647162|OTHER|life support|The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。
214406013|NCT04151121|BEHAVIORAL|MBCT (Mindfulness Based Cognitive Therapy)|MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
214406014|NCT01495195|DRUG|High-dose donepezil|Donepezil titrated to 22.5 mg daily
214406015|NCT01495195|DRUG|Low-dose donepezil|Donepezil titrated to 10 mg daily
214406016|NCT01495195|DRUG|Selegiline|Transdermal selegiline, 6 mg daily
214406017|NCT01495195|DRUG|Placebo|microcrystalline cellulose
214406018|NCT01385865|DIETARY_SUPPLEMENT|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
214406019|NCT01385865|DIETARY_SUPPLEMENT|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
214406020|NCT05094115|BEHAVIORAL|Psychological Flexibility Training (PFT)|"A 2-day workshop lasting approximately 8 hours per day. Day 1: an overview of the training and to describe the posture or stance that prepares one to respond to challenging situations in a psychologically flexible manner.~Day 2: identifies common coping strategies that typically fail or even backfire over the long term and to practice skills that promote psychological flexibility. Experiential exercises will be integrated throughout the training.~Following the PFT, 4 optional, monthly, one-hour booster sessions to supply refresher information.~* An experiential exercise to highlight one or more process/concept that was introduced during the 2-day training.~* Questions from the attendees about applying the concepts in their lives.~* Comments and questions from the booster session facilitators to encourage application of the concepts."
214406021|NCT06103240|OTHER|Lacticaseibacillus rhamnosus LRa05|Bacterial count:100 billion CFUs Take one sachet per day for 4 weeks.
214406022|NCT02414230|DRUG|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
214406023|NCT01554254|DRUG|TXA127|300mcg/kg/day, subcutaneous injection for up to 28 days
214688353|NCT07163936|DEVICE|Citrate dialysate with magensium supplementation|Citrate-based bicarbonate dialysate containing: sodium 138 mmol/L, chloride 110 mmol/L, potassium 2 mmol/L, calcium 1.5 mmol/L, magnesium 0.75 mmol/L, citrate 1 mmol/L, glucose 1 g/L, bicarbonate 32 mmol/L.
214406024|NCT04644861|OTHER|Program of adapted physical activity|3 workouts of one hour every week during 4 months. Program will be conducted by adapted physical activity teachers and sports doctor.
214688354|NCT07163936|DEVICE|Acetate dialysate|Acetate-based bicarbonate dialysate containing: sodium 138 mmol/L, chloride 109 mmol/L, potassium 2 mmol/L, calcium 1.5 mmol/L, magnesium 0.5 mmol/L, acetate 3 mmol/L, glucose 1 g/L, bicarbonate 32 mmol/L.
214406025|NCT05718297|DRUG|Brigatinib|"Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them."
214406026|NCT05718297|DRUG|Durvalumab|Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
214406027|NCT00959803|DRUG|PF-04447943|3 mg solution, oral single dose.
214406028|NCT00959803|DRUG|PF-04447943|10 mg solution, oral single dose.
214406029|NCT00959803|DRUG|PF-04447943|25 mg solution, oral single dose.
214406030|NCT00959803|DRUG|Placebo|Solution, oral single dose.
214406031|NCT00959803|DRUG|PF-04447943|25 mg solution, oral twice daily for 7 days.
214406032|NCT00959803|DRUG|Placebo|Solution, oral twice daily for 7 days.
214406033|NCT01328587|DRUG|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
214406034|NCT00463151|DRUG|rebamipide|0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
214406035|NCT05349084|DIAGNOSTIC_TEST|PET-cCTA-cFFR|patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
214406036|NCT01570777|PROCEDURE|renal denervation and optimized medication regimen|Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
214406037|NCT01570777|PROCEDURE|optimized medication regimen|Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
214406038|NCT05173571|COMBINATION_PRODUCT|Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)|Identification of patient needs and non-pharmacological holistic approach, including education, emotion and nutrition (nurse) and optimization of physical activity (respiratory physiotherapist)
214406039|NCT03307746|DRUG|Varlilumab|"Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27."
214406040|NCT03417973|DEVICE|dorsal root ganglion neuromodulation|stimulation for neuromodulation of the dorsal root ganglion
214406041|NCT02453230|BEHAVIORAL|Lights on|Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
214406042|NCT03471468|PROCEDURE|kinetics of microparticles under chemotherapy|Blood samples done before chemotherapy and 6 hours later for each of six chemotherapies required by the protocol.
214406043|NCT00688688|DRUG|Mirabegron|Tablets
214406044|NCT00688688|DRUG|Tolterodine|Extended release capsules
214406045|NCT00688688|DRUG|Placebo to Mirabegron|Matching mirabegron placebo tablets.
214406046|NCT00688688|DRUG|Placebo to Tolterodine|Matching tolterodine placebo capsules.
214406047|NCT06290232|DEVICE|Fetoscopic Laser Photocoagulation|Pregnant patients diagnosed with type II vasa previa will undergo fetoscopic laser photocoagulation of the involved fetal vessels. FLP will be performed laparoscopically using a fetoscope (tiny telescope) and a laser device inside of the womb. This procedure will be completed at 30w0d to 32w6d gestational age.
214406048|NCT06146738|BEHAVIORAL|Palliative Care|Best supportive care without surgical intervention
214406049|NCT06146738|PROCEDURE|Tumor biopsy|Tumor biopsy
214406050|NCT06146738|PROCEDURE|Tumor resection|Maximal safe resection of the tumor
214406051|NCT02442544|DIETARY_SUPPLEMENT|Prebiotic|1:1 oligofructose: inulin 8 g orally /day
214406052|NCT02442544|DIETARY_SUPPLEMENT|Placebo|maltodextrin 3.3g orally/day
214406053|NCT01950260|DRUG|Levothyroxine|Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
214406054|NCT01950260|OTHER|Placebo|Placebo to start at 4 weeks after RAI
214406055|NCT00930189|DRUG|intravitreal injection of ranibizumab|
214688355|NCT07163754|DIAGNOSTIC_TEST|Automated Sperm Selection|This group of oocytes will be microinjected with sperm selected by the second version of SID TM (SID V2.0) wich analyses additional sperm parameters than first version of SID TM (SID V1.0).
214688356|NCT07163754|DIAGNOSTIC_TEST|Conventional Sperm Selection|Half of the oocytes will be microinjected with sperm selected by the embryologist without SID assistance, based on the conventional and visual assesment of seminal samples located at ICSI dishes.
214406056|NCT00930189|DRUG|intravitreal injection of triamcinolone|
214406057|NCT00930189|PROCEDURE|photodynamic therapy|
214406058|NCT03283553|OTHER|Checklist, MyChart, OpenNotes|1\) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.
214406059|NCT03283553|OTHER|Usual Care|Routine medical oncology care
214406060|NCT04132284|BEHAVIORAL|DBT-Based Parenting Intervention|The intervention will consist of 8-10 individual parent sessions, to be completed within one week after the teen completes the IOP program. Sessions will be 1 hour in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 10. Sessions will follow the standard agenda used for DBT skills training: 1) mindfulness practice, 2) homework review, 3) teaching of a new skill; 4) practice of the new skill; and 5) assignment of new homework (Linehan, 1993). The intervention will utilize the Middle Path module of the DBT Skills Manual for Adolescents (Rathus \& Miller, 2015), which was created by the developers of DBT for adolescents and includes both instructions for therapists and handouts for clients.
214406061|NCT04132284|BEHAVIORAL|Treatment as Usual|No parenting intervention provided beyond standard practices in DBT IOP program.
214406062|NCT00574678|OTHER|Tear collection|"A tear sample (\~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed."
215010868|NCT02487485|DRUG|Ketamine|. Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions-once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
215010869|NCT02487485|DRUG|sirolimus|Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
215010870|NCT02487485|DRUG|Placebo|Placebo oral dose
214406063|NCT03686683|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with recombinant fusion protein composed PAP linked to GM-CSF (PA2024), a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
215010871|NCT03630887|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room during different time periods.
215098563|NCT05083312|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
215098564|NCT05083312|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet
215098565|NCT04361578|DIAGNOSTIC_TEST|Magnetic resonance elastography|All patients enrolled will receive magnetic resonance elastography of the brain.
215098566|NCT05973253|DRUG|prepared drop of medroxy progestrone acetat 1%|In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
215098567|NCT04348981|DEVICE|Wearable fitness tracking device|Patients having a wearable fitness tracking device will be monitored for their level of activity after surgery. Declines in activity level will prompt a phone call from the surgical provider.
215098568|NCT00126776|BEHAVIORAL|case management|case/self management for COPD vs usual care
215098569|NCT00126776|BEHAVIORAL|usual care|usual care for COPD
215098570|NCT05921838|OTHER||
214406064|NCT03199885|DRUG|Atezolizumab|Given IV
214406065|NCT03199885|PROCEDURE|Biopsy|Undergo biopsy
214406066|NCT03199885|PROCEDURE|Bone Scan|Undergo bone scan
214406067|NCT03199885|PROCEDURE|Computed Tomography|Undergo CT scan
215010872|NCT00476541|DRUG|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
214406068|NCT03199885|DRUG|Docetaxel|Given IV
214406069|NCT03199885|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215010873|NCT01784536|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
215010874|NCT01761227|DRUG|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
215010875|NCT01761227|DRUG|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
215010876|NCT04958590|RADIATION|whole spine X-ray|Group 1 underwent whole spine X-ray in standing and sitting positions.
215098571|NCT06208995|OTHER|36-Item Short Form Survey Instrument (SF-36)|Answering 36 questions in a quality-of-life survey (RAND 36-Item Health Survey 1.0): https://www.rand.org/health-care/surveys\_tools/mos/36-item-short-form/survey-instrument.html
215098572|NCT04940962|PROCEDURE|Sampling of adipose tissue|Removal of less than 1 cm3 of adipose tissue during visceral surgery
215098573|NCT05221229|DRUG|Liraglutide plus upstream risk factors modification advice and consultation|Patients will be on treatment with daily injections of Liraglutide for a total of 65 weeks. During initial consultation for AF ablation, patients' BMI, risk factors status and baseline blood tests were performed and reviewed. Then the patients were discussed and encouraged to achieve optimal goal of risk factors modifications by non pharmacological and pharmacological measures.
215098574|NCT06251427|DIETARY_SUPPLEMENT|Multiple micronutrient fortified maize with milk|The study product is a multiple micronutrient fortified maize pap with milk
215098575|NCT04738942|DRUG|Vedolizumab|Vedolizumab 300 mg, IV infusion
215098576|NCT04606095|DIAGNOSTIC_TEST|EEG|EEG with QST (evoked Pain and Visual Stimulation Assessment)
215098577|NCT04606095|DIAGNOSTIC_TEST|Neuroimaging EEG/fMRI (Aim 1)|This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then will return to the fMRI scanner for a few additional scans.
215098578|NCT04606095|DEVICE|HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
215098579|NCT04606095|DEVICE|Sham HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
214406070|NCT03199885|DRUG|Paclitaxel|Given IV
214406071|NCT03199885|BIOLOGICAL|Pertuzumab|Given IV
214406072|NCT03199885|OTHER|Placebo Administration|Given IV
214406073|NCT03199885|OTHER|Quality-of-Life Assessment|Ancillary studies
214406074|NCT03199885|BIOLOGICAL|Trastuzumab|Given IV
214406075|NCT06209359|DRUG|Ammonium Chloride|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
214406076|NCT06209359|DRUG|Placebo|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
214406077|NCT04704102|BEHAVIORAL|Muscle energy technique (MET)|A manual therapy technique that uses the gentle muscle contractions of the patient to relax and lengthen muscles and normalize joint motion.
214406078|NCT04704102|BEHAVIORAL|Strain-counterstrain (SCS)|"It's also called the positional release technique, a manual therapy technique that passively positions the hypertonic (spasmed) muscles and dysfunctional joints in positions of shortened or comfort."
214406079|NCT04704102|BEHAVIORAL|sham SCS|SCS intervention that position with opposite site limb and direction, and with modified method as consider the easiness of a practitioner to press the tender points
214406080|NCT03255941|DRUG|DMPA|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.
214406081|NCT03255941|DRUG|Sayana Press|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
214406082|NCT05876910|BEHAVIORAL|Speech Production Tasks|View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
214406083|NCT00372060|DRUG|sitagliptin phosphate|Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
215010877|NCT03949114|BEHAVIORAL|Evaluation|Evaluate a weak debilitating phenotype screening on the patients before surgery;
215010878|NCT03949114|BEHAVIORAL|nursing care|Traditional post-operative nursing care
214406084|NCT00372060|DRUG|Comparator: sitagliptin phosphate (MK0431)|Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
214406085|NCT00372060|DRUG|Comparator: pioglitazone|pioglitazone once daily for 52 weeks
214406086|NCT00372060|DRUG|Comparator: placebo (unspecified)|Placebo once daily for 12 weeks
214406087|NCT05023720|OTHER|nonintervention|
214406088|NCT02476630|DEVICE|StO2 measurement|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
214406089|NCT02476630|OTHER|Blood Gases|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
215010879|NCT03949114|BEHAVIORAL|rehabilitation|"1. Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~2. On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days."
214406090|NCT00961493|BEHAVIORAL|Acceptance based behavioral therapy|16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
214406091|NCT00961493|BEHAVIORAL|Applied relaxation|16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
214406092|NCT00984074|PROCEDURE|blood-oxygen-level-dependent functional magnetic resonance imaging|
215010880|NCT01487161|DRUG|FX006|Single 3 mL intra-articular injection
215010881|NCT01487161|DRUG|TCA IR|Single 1 mL intra-articular injection
215010882|NCT04759092|DEVICE|transcranial direct current stimulation (tDCS)|Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.
215010883|NCT06304727|OTHER|clinical data review|Medical records review to gather and analyze demographic, clinical, care and virological data
215010884|NCT02072993|DRUG|AZD1979|Single dose, oral solution administration
214406093|NCT00984074|PROCEDURE|diffusion tensor imaging|
214406094|NCT00984074|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
214688357|NCT07163949|OTHER|Performance-based tests (such as TUG, foot posture measurements, Tandem Gait test) will be administered to children with ASD.|Children with ASD underwent balance and foot measurement tests that they could perform only by following instructions.
214406095|NCT00984074|PROCEDURE|functional magnetic resonance imaging|
214406096|NCT00984074|RADIATION|intensity-modulated radiation therapy|
214406097|NCT00984074|RADIATION|radiation therapy treatment planning/simulation|
214406098|NCT02703727|BEHAVIORAL|Extended polymedication check|"Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
214406099|NCT00285688|PROCEDURE|gastroscopic examination|gastroscopic examination for tissue biopsy and real time PCR for gene study
214406100|NCT02201563|DRUG|Minocycline|Oral minocycline (100mg twice a day) for 3 months
214406101|NCT00037999|PROCEDURE|Testosterone supplement|
215010885|NCT02072993|DRUG|Placebo to match|Single dose, oral solution administration
214406102|NCT05377099|DIAGNOSTIC_TEST|CORVIS|Measurement of the DA ratio, IR and SSI before and after for patients under gone LASIK, femto LASIK and PRK using the CORVIS device.
214406103|NCT03640013|PROCEDURE|Hall Technique PMC|Hall Technique primary fitted crowns to restore carious primary molars
214406104|NCT01034111|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.
214406105|NCT01034111|DRUG|Metformin|Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
214406106|NCT00386594|DRUG|852A|
214406107|NCT03682354|DRUG|Intercostal Nerve Block with PCIA|Intercostal nerve block consists in the injection of Ropivacaine (4 ml,0.5%) in related intercostal spaces. Patient-controlled intravenous analgesia regimen is conducted with sufentanil.
214406108|NCT03682354|DRUG|Erector Spinae Plane Block (ESPB)|Erector Spinae Plane Block consists in the injection of Ropivacaine (20ml, 0.5%), in the anatomical plane between the Erector Spinae muscles and transverse process, laterally to the spinous process of T5 . The catheter was inserted and secured in place under ecographic guidance, and a patient-controlled regional anesthesia regimen was conducted with 0.2% ropivacaine.
214406109|NCT03254069|DEVICE|Stainless Steel Crowns|SSCs were placed on children's primary molars, and bite force was registered prior to the study, and periodically after the study.
214406110|NCT05124899|DRUG|CAP UnScented|Sunscreen lip balm.
215010886|NCT03472677|OTHER|Ice Pack and Cooling Device|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
215010887|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).
215010888|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
214406111|NCT05124899|DRUG|CAP Herbal Mint|Sunscreen lip balm.
214406112|NCT05124899|DRUG|CAP Mountain Berry|Sunscreen lip balm.
214406113|NCT05124899|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
214406114|NCT00438971|DRUG|Duloxetine|Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
214406115|NCT01833975|BIOLOGICAL|Transplantation of Autologous stem cell [MNCs] .|Intra thecal transplantation of Autologous stem cell \[MNCs\],100millions per dose in 3 divided doses at interval of 10 days.
214406116|NCT04438551|BEHAVIORAL|Standard dietary counseling|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection.
214406117|NCT04438551|BEHAVIORAL|Mobile app|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection. Subjects will be given a mobile app to build grocery lists where the sodium level will be recorded and tracked in the app.
214406118|NCT05072990|DRUG|Chinese herb medicine|Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.
214406119|NCT02810561|OTHER|No Intervention|No intervention was completed with this study.
214406120|NCT03869242|DEVICE|NovoTTF-200A|newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.
215010889|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
215010890|NCT03472677|DRUG|Capsaicin|Four intradermal injections of capsaicin, two on each forearm.
215010891|NCT00086463|DRUG|Iloprost or placebo|
215010892|NCT02945046|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
214406121|NCT04635436|OTHER|Split-belt treadmill walking.|"The intervention will consist of split-belt treadmill walking. During the test session, participants will walk on a split-belt treadmill mounted on force sensors with the belts running at the same or at different velocities. They will walk freely without any support. The test sequence will be the following:~1. Baseline phase. 3 minutes walking at increasing speed, speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Habituation phase. 30 seconds walking at 0.2 m s-1.~3. Adaptation phase. The velocity of the belt under the non-affected lower limb will be increased to 0.6 m s-1, while the other belt will maintain its velocity of 0.2 m s-1 for 6 minutes.~4. Post-adaptation phase. Belts' velocities will be restored at 0.2 m s-1 for 6 minutes.~Participants will be informed before the changes in belts' velocities with a verbal warning.~Participants will repeat the same protocol with the affected lower limb on the fast belt after one week."
214406122|NCT00647348|DRUG|Simvastatin|80mg simvastatin oral once daily for 24 months
215010893|NCT02945046|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
215010894|NCT04433026|DIAGNOSTIC_TEST|N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I|Biomarkers detected in the serum of patients
215010895|NCT01619449|PROCEDURE|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
214406123|NCT00647348|DRUG|Placebo|Oral placebo tablet once daily for 24 months
214406124|NCT02987829|DRUG|TRC253|TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR. TRC253 blocks AR nuclear translocation as well as AR binding to DNA and is an antagonist of transcription for wild type AR and mutated AR. TRC253 is orally active and does not have agonist activity towards either the wild type or mutated ARs. TRC253 treatment in the Hershberger assay results in complete inhibition of androgen sensitive organ development. TRC253 is efficacious in an LNCaP xenograft model driven by F876L (also known as F877L) mutant AR.
214406125|NCT01417000|BIOLOGICAL|GVAX Pancreas|
214406126|NCT01417000|BIOLOGICAL|CRS-207|
214406127|NCT01417000|DRUG|Cyclophosphamide|
214406128|NCT04837950|PROCEDURE|Diaphragmatic traction-suture|Measurement of pleural cavity volume before pulling the diaphragmatic traction-suture Measurement of pleural cavity volume after pulling the diaphragmatic traction-suture
214406129|NCT02741843|BEHAVIORAL|Patient Education|
214406130|NCT01160991|PROCEDURE|Glucose clamp technique|euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
214406131|NCT01160991|DRUG|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
214406132|NCT01160991|DRUG|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
214406133|NCT01160991|DRUG|Placebo|Placebo capsules are given at 8:00 a.m.
214406134|NCT06294951|DIAGNOSTIC_TEST|fMRI|The fMRI is acquired using a Siemens 3.0T MRI scanner. BOLD functional images are scanned using an echo planar imaging (EPI) sequence. The scanning parameters are: TR=2s, matrix size of 64\*64, number of layers=30, layer thickness=3.75\*3.75\*4.5mm, and bottom-up interval scanning. A total of 540 whole brain functional images are acquired.
214406135|NCT02847585|DIETARY_SUPPLEMENT|Water-soluble Ubiquinol|10 mg/kg BW/d, by oral drops
214406136|NCT02734368|DRUG|Hyperpolarized Helium-3|
214406137|NCT00255021|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
214406138|NCT03098264|PROCEDURE|Simultaneous surgery|Simultaneous surgery in complicated hepatolithiasis
214406139|NCT03098264|PROCEDURE|staged surgery|staged surgery in complicated hepatolithiasis
214406140|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implant, Nanobone with PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* Alloplast bone graft material (Nanobone)~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
214406141|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implantand PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
214406142|NCT03270930|PROCEDURE|Emergency laparotomy|All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
214406143|NCT03931603|OTHER|MRI|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
214406144|NCT00447915|DRUG|ibandronic acid 0.5mg|0.5mg(i.v.)/month for 35 months
214406145|NCT00447915|DRUG|RIS placebo|0 mg(p.o.)/day for 36 months
214406146|NCT00447915|DRUG|1.0mg ibandronic acid|1.0mg(i.v.)/month for 35 months
214406147|NCT00447915|DRUG|ibandronic acid placebo|0mg(i.v.)/month for 35 months
214406148|NCT00447915|DRUG|2.5mg RIS|2.5 mg(p.o.)/day for 36 months
214406149|NCT00447915|DIETARY_SUPPLEMENT|Calcium and Vitamine D3|Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
214406150|NCT06371482|DRUG|Durvalumab|Durvalumab is an immunoglobulin G (IgG) 1-κsubtype monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 in T cells and CD80 (B7.1) in immune cells (ics). Durvalumab is developed by Astrazeneca /MedImmune for the treatment of cancer. Durvalumab is designed to reduce the cytotoxicity of antibody-dependent cells and complement dependent cytotoxicity. In vitro studies have demonstrated that Durvalumab can antagonize the inhibition of PD-L1 in human primary T cells, causing them to resume proliferation and release interferon gamma (IFNγ). To date, more than 1,800 patients have been treated with valiuzumab as a single agent or in combination with other cancer agents as part of ongoing studies. Durvalumab: 10mg/Kg, intravenously, starting at week 7 every 3 weeks for at least 1 year, or until progression, intolerance, or spontaneous withdrawal of the patient.
214406151|NCT06371482|DRUG|Chemotherapy drug of EP regimen|"Etoposide: 80-100mg/m², intravenous infusion, given at week 1, 4, 7, 10, 13, 16, a total of 6 cycles.~Carboplatin: AUC=5-6, intravenous infusion, given at weeks 1, 4, 7, 10, 13, 16, a total of 6 weeks. Or cisplatin: 75-80mg/m2 intravenously, given at weeks 1, 4, 7, 10, 13, 16 for a total of 6 weeks."
214406152|NCT06371482|RADIATION|radiotherapy|Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
214406153|NCT00797225|DRUG|Leuprorelin Acetate Depot|Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection
214406154|NCT00797225|DRUG|Elagolix|Elagolix tablets administered orally
214406155|NCT00797225|DRUG|Placebo to Elagolix|Placebo tablet administered orally
214406156|NCT00797225|DRUG|Placebo to Leuprorelin Acetate|Saline solution administered as an intramuscular injection
214406157|NCT04921761|PROCEDURE|Conventional epidural|In this group, a 20-gauge multi-orifice catheter was threaded through the cephalic-directed tip of the epidural needle 5 cm into the epidural space.
214406158|NCT04921761|PROCEDURE|Dural puncture epidural|In this group, the dura was punctured by 25G Whitacre needle. After confirmation of CSF flow, the needle was removed and the epidural catheter was threaded.
214406159|NCT06170060|OTHER|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a surgical procedure widely used in the treatment of obesity. It's a bariatric procedure, meaning its primary aim is to induce weight loss, and it has gained popularity due to its effectiveness and relatively low complication rates compared to other bariatric surgeries.
215010896|NCT06377540|DRUG|Pembrolizumab|"Patients will receive 200 mg Pembrolizumab on Day -28 and Day -6 by IV infusion.~Pembrolizumab 200 mg IV will resume at day 30+ after ASCT every 3 weeks for 1 year."
215010897|NCT06377540|PROCEDURE|Autologous stem cell transplant|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
215010898|NCT06377540|DRUG|Carmustine|Patient will receive a single dose of BCNU on day -6, dose of 300 mg/m2 by IV infusion.
215010899|NCT06377540|DRUG|Etoposide|Etoposide will be given at dose 100 mg/m2 BID intravenously on days -5, - 4, -3, and -2.
215010900|NCT06377540|DRUG|Cytarabine|Cytarabine will be given at dose 100 mg/m2 BID intravenously on days -5, -4, - 3, and -2.
214406160|NCT02954055|DRUG|Paclitaxel|Arm A
214406161|NCT02954055|DRUG|Cyclophosphamide|Arm B
214406162|NCT02954055|DRUG|Capecitabine|Arm B
214406163|NCT02954055|DRUG|Vinorelbine|Arm B
214406164|NCT03063307|PROCEDURE|Atraumatic Restorative Treatment|
215010901|NCT06377540|DRUG|Melphalan|Melphalan will be given at dose of 140 mg/m2 intravenously on day -1 in a single 20 minute infusion; dose will be based on actual body weight but capped at 3.6 mg/kg as part of BEAM conditioning.
215010902|NCT03113136|BEHAVIORAL|Low wattage E cigarette device|The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
215010903|NCT03113136|BEHAVIORAL|High wattage E cigarette device|The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
215010904|NCT03113136|BEHAVIORAL|Usual brand cigarette|The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.
215010905|NCT05009771|DRUG|Intravenous patient-control analgesia|At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.
215010906|NCT05009771|DRUG|Dinalbuphine sebacate|Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.
215098580|NCT04606095|DIAGNOSTIC_TEST|Neuroimaging EEG/fMRI (Aim 3)|This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then (for participants prior to January 2025) will return to the fMRI scanner for a few additional scans.
214406165|NCT03063307|OTHER|Silver Diamine Fluoride|
214406166|NCT00534755|OTHER|Breast Cancer database|prospective breast cancer database
214406167|NCT02905513|BEHAVIORAL|Contraceptive app instant messages|
214406168|NCT02905513|OTHER|Mobile phone app|
214406169|NCT04307979|DIETARY_SUPPLEMENT|High-fat coffee|A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.
214406170|NCT04307979|DIETARY_SUPPLEMENT|Black coffee|A regular black coffee with no added caloric content.
215010907|NCT02675452|DRUG|AMG 176|Study Drug
215010908|NCT02675452|DRUG|Azacitidine|Non-investigational product
215010909|NCT02675452|DRUG|Itraconazole|Non-investigational product
215010910|NCT06121050|OTHER|Pet visit|Intensive care patients visited by their pets for 20 minutes
215098581|NCT06570161|DEVICE|SEEUS95 Transparent mask|SEEUS95 developed transparent filtering mask
215098582|NCT06570161|DEVICE|CrystalGuard Mask|CrystalGuard transparent mask
215098583|NCT06570161|DEVICE|N95 face mask|Standard N95 style face mask
215098584|NCT06572124|PROCEDURE|universal adhesive without Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive without acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
215098585|NCT06572124|PROCEDURE|universal adhesive with Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive which contains acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
215098586|NCT06259734|BEHAVIORAL|Transfusion Camp Rwanda education|Transfusion Camp Rwanda 3 day education intervention covering all aspects of safe blood transfusion practices as per the Rwanda Biomedical Centre National Transfusion Guidelines
215098587|NCT05457868|DRUG|Salbutamol|Salbutamol claim is used as the exposure group.
215098588|NCT05457868|DRUG|LAMA|Long-acting muscarinic antagonists (LAMA) - umeclidinium, aclidinium, tiotropium, glycopyrolate, glycopyrronium - claim is used as the reference group.
214406171|NCT01363479|DRUG|Oral palonosetron|
214406172|NCT01363479|DRUG|I.V. palonosetron|
214406173|NCT01363479|DRUG|Dexamethasone|
214406174|NCT00246298|DRUG|epoetin alfa|
214406175|NCT00607516|PROCEDURE|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
214406176|NCT00607516|PROCEDURE|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
214406177|NCT01636440|DEVICE|Conditioned Pain Modulation|Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation
214406178|NCT01636440|DEVICE|Conditioned Pain Modulation|Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
214406179|NCT02673008|BIOLOGICAL|donor lymphocyte infusion|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
215010911|NCT04907240|DEVICE|GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)|Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.
215010912|NCT06964503|OTHER|Exposure: psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
215010913|NCT06964594|PROCEDURE|vNOTES adnexal surgery|New minimalinvasive technique
215010914|NCT06963372|DEVICE|True filter (4w) → Washout (2w) → Sham filter (4w)|Used a true filter for 4 weeks, followed by a 2-week washout, then used a sham filter for 4 weeks.
215010915|NCT06963372|DEVICE|Sham filter (4w) → Washout (2w) → True filter (4w)|Used a sham filter for 4 weeks, followed by a 2-week washout, then used a true filter for 4 weeks.
215010916|NCT03853837|DIAGNOSTIC_TEST|rest-exercise echocardiography|an echocardiogram performed during rest and exercise
215010917|NCT00999570|OTHER|Specialty training for knee surgeons|
215010918|NCT02919345|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
214406180|NCT04015986|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food-2|MDCF prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth
214406181|NCT04015986|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
214406182|NCT04616482|BEHAVIORAL|Digital therapeutic carbohydrate restriction (TCR) program|A 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction as for obesity and/or T2D (or risk of T2D). The program is intended to enhance the usual clinical care provided for patients.
214406183|NCT01253915|DRUG|Nasal Carbon Dioxide|10 sec/nostril up to 4 times to treat one migraine
214406184|NCT01253915|DRUG|Placebo|10 sec/nostril up to 4 times to treat a migraine
214406185|NCT02915809|BIOLOGICAL|GC3110B vaccine|0.5mL, Intramuscular
214406186|NCT02915809|BIOLOGICAL|GCFLU Quadrivalent Inj. vaccine|0.5mL, Intramuscular
214406187|NCT03148938|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 4 tests:~* walking test~* coordination test~* attention test~* vision test"
214406188|NCT03627962|OTHER|gaze-directed oculomotor training|"Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2\) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell \> 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session"
214406189|NCT00912587|DRUG|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
214406190|NCT00138632|DRUG|PTK787|Visudyne® + PTK787, 500 mg/day
214406191|NCT00138632|DRUG|PTK787|Visudyne® + PTK787 1000 mg/day
214406192|NCT00138632|DRUG|Placebo|Visudyne® + Placebo
214406193|NCT05248035|OTHER|Adult patient hospitalized in ICU|acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
214406194|NCT01102322|BEHAVIORAL|Quality|Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
214406195|NCT02744508|DRUG|palonosetron|
214406196|NCT02744508|DRUG|palonosetron with dexamethasone|
214406197|NCT06020417|DEVICE|O-ARM (Medtronic, Inc, Louisville, CO)|scanner that allows imaging of screws intraoperatively
214406198|NCT06020417|PROCEDURE|Conventional corrective surgery for arthrodesis|Conventional procedure without neuronavigation guide
214406199|NCT06268860|DRUG|Rocatinlimab vial injection|Vial solution for SC injection administered on Day 1
214406200|NCT06268860|COMBINATION_PRODUCT|Rocatinlimab prefilled syringe|Prefilled syringe solution for SC injection administered on Day 1
215010919|NCT02919345|DRUG|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
215010920|NCT02325453|PROCEDURE|Robotic Surgery|Surgical procedure performed with a robotic system.
214406201|NCT06640894|OTHER|MegaPower training|See arm/group descriptions
214406202|NCT06640894|OTHER|Usual Care|See arm/group descriptions
214406203|NCT06640751|BEHAVIORAL|Health behavior intervention|The program is a group-based intervention provided by a healthcare team consisting of researchers, cardiologists, family doctors, community healthcare workers, psychologists, and health education specialists. The intervention is structured around three modules-predisposing, enabling, and reinforcing factors-that provide a framework for educational interventions aimed at promoting healthy behaviors in hypertensive patients.
214406204|NCT06644014|BEHAVIORAL|Exercise|"Participant will communicate with a chatbot-like proprietary AI to receive exercise instructions. The AI will provide personalized advice according to the user's needs, aiming for 2-3 hours of steady-state zone 2 -effort aerobic exercise. Instructions will also be tailored to the user's exercise preferences and limitations (for example, suggest cycling, if running is not convenient)."
214406205|NCT06644014|BEHAVIORAL|Exercise|Supervised HIIT -cycling twice a week. Intensities for cycling intervals will are based on the participants fitness-level determined at first visit. Intensity will gradually increase over the 12-week period
214406206|NCT06644014|DEVICE|Smart Ring|Participants will only receive an Oura Ring, but will not change anything about their normal physical activity.
214406207|NCT05429021|DRUG|IMM-BCP-01|Single dose of IMM-BCP-01
214406208|NCT05429021|DRUG|Placebo|Placebo matching single dose of IMM-BCP-01
215010921|NCT02325453|PROCEDURE|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
215010922|NCT02325453|PROCEDURE|Open Surgery|Traditional approach for gastric cancer.
215010923|NCT02164188|BEHAVIORAL|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
215010924|NCT06411808|BEHAVIORAL|Sensory-Adapted Dental Environment|The Sensory-Adapted Dental Environment (SADE) involves altering the dental setting to reduce sensory stimuli that can cause discomfort or anxiety in children with sensory processing disorders. This includes the use of controlled lighting, ambient sounds, and non-threatening tools to create a calming atmosphere conducive to positive dental experiences.
215010925|NCT01320098|BEHAVIORAL|Home-Based Parenting Program|"The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.~1. Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.~2. Increasing the quality and quantity of positive interactions between you and your child~3. Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.~4. Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week."
215010926|NCT01320098|BEHAVIORAL|Clinic-Based Parenting Program|"The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.~The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.~Parents learn techniques and skills to promote positive interactions with their child, including:~1. Increasing the positive attention you give to your child.~2. Reducing the inappropriate use of commands, questions and criticisms.~3. Appropriate use of praise and physical attention (e.g., hugs) as rewards.~4. Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors."
215010927|NCT01320098|BEHAVIORAL|Wait-List Control Group|If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
215010928|NCT04498117|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
215010929|NCT04498117|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
215010930|NCT04498117|DRUG|Carboplatin|AUC 6 IV Day 1 x 6 cycles (every 21 days)
215010931|NCT04498117|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
215010932|NCT04498117|DRUG|Carboplatin|AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
215010933|NCT06388226|DEVICE|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
215010934|NCT06388226|DEVICE|Leg sham therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
214406209|NCT05489224|BIOLOGICAL|CT-P47|CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)
214406210|NCT05489224|BIOLOGICAL|EU-approved RoActemra|EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W
214406211|NCT04640571|DRUG|pravastatin and chenodeoxycholic acid, after metformin and placebo|single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
215098589|NCT05286892|OTHER|Diabetes LIVE JustICE|Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
215098590|NCT05286892|OTHER|Enhanced Education|See control group description above
214406212|NCT04640571|DRUG|valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo|single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
214406213|NCT04515797|DRUG|Glecaprevir and Pibrentasvir|4 weeks of treatment starting within 24 hrs of kidney transplant
214406214|NCT06068153|DRUG|Sotorasib|Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.
214406215|NCT06068153|DRUG|Lenvatinib|Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.
214406216|NCT03934905|DRUG|sulforaphane|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
214406217|NCT03934905|DRUG|Placebo Oral Tablet|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
215010935|NCT00448149|DRUG|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
215010936|NCT00448149|DRUG|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
215010937|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
215010938|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 2~10 mg/kg I.V., once every other week for 4 weeks"
215010939|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 3~15 mg/kg I.V., once every other week for 4 weeks"
215010940|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 4~21 mg/kg I.V., once every other week for 4 weeks"
215010941|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 5~27 mg/kg I.V., once every other week for 4 weeks"
215010942|NCT03923842|DRUG|Denosumab Inj 120 MG/1.7ML|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
215010943|NCT03923842|DRUG|Chemotherapy as clinical standard of care|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
215010944|NCT02939781|DEVICE|Indirect calorimetry|Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
215098591|NCT06579911|DEVICE|High-frequency micro-ultrasound target biopsy|"1. High-frequency micro-ultrasound (transrectal ultrasound, 29 Hz, ExactVu) of the prostate. If suspicious lesions (PRIMUS \>= 3) other than those already detected in multiparametric MRI are found, target biopsy will be performed. Maximum of four cores per lesion.~2. Multiparametric MRI target biopsy (PI-RADS \>= 3) of the prostate (transrectal ultrasound, 29 Hz, ExactVu). Maximum of four cores per lesion.~3. Systematic biopsy (twelve cores) of the prostate"
214406218|NCT05633771|OTHER|Hyrimoz|There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
214406219|NCT06220474|DEVICE|The Thermage FLX System|The Thermage FLX System is tested for its therapeutic efficacy and safety on treating refractory Meibomian Gland Dysfunction
215010945|NCT04267328|PROCEDURE|Elective Orthopedic Surgery|Patients having knee (unilateral primary osteoarthritis or bilateral primary osteoarthritis) surgery, hip (unilateral primary osteoarthritis or bilateral primary osteoarthritis) or shoulder (primary osteoarthritis) elective surgery.
215010946|NCT02650349|OTHER|fMRI|
215010947|NCT02569242|DRUG|Nivolumab|
215010948|NCT02569242|DRUG|Docetaxel/Paclitaxel|
215010949|NCT00689052|DRUG|pramipexole ER|
215010950|NCT00689052|DRUG|placebo|
215010951|NCT04838028|PROCEDURE|TEP|Laparoendoscopic totally extraperitoneal mesh repair of groin hernia
214406220|NCT06220474|DEVICE|Sham treatment|Sham treatment acts as a control to test the therapeutic efficacy and safety of The Thermage FLX System
215010952|NCT04838028|PROCEDURE|TAPP|Laparoscopic transabdominal mesh repair of groin hernia
215010953|NCT04838028|PROCEDURE|Other or unspecified laparoendoscopic groin hernia repair|"Other refers to any laparoendoscopic mesh repair specified as not being either TEP or TAPP, eg, intraperitoneal onlay mesh (IPOM)."
215098592|NCT06579911|DEVICE|conventional Multiparametric MRT target biopsy|"1. Multiparametric MRT target biopsy (PI-RADS \>= 3) of the prostate (conventional transrectal ultrasound, 8-10 Hz). Maximum of four cores per lesion.~2. Systematic biopsy (twelve cores) of the prostate"
215098593|NCT00599755|RADIATION|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
215010954|NCT04257253|OTHER|Targeted exercise program|Participants in this experimental intervention group will perform a combination of motor control and isolated lumbar extensor strenghtening exercises. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
215098594|NCT00599755|DRUG|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m\^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m\^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
215098595|NCT00550381|DRUG|HKI-357|Single-dose capsule
214406221|NCT01827280|DRUG|Vildagliptin|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
214406222|NCT04269070|BEHAVIORAL|Standing condition|Participants will be asked to stand an additional 6 minutes per hour above their median standing time from the observed time in the usual behavior condition.
214406223|NCT04269070|BEHAVIORAL|Light physical activity (LPA) condition|Participants will be asked to perform 6 additional minutes per hour above their median LPA time from the observed time in the usual behavior condition.
214406224|NCT04269070|BEHAVIORAL|Usual behavior condition|Participants will be asked to perform their normal work activities in their normal work environment for one week. There will be no modifications to their work environment or instructions given of what activities to partake in. This period will be used to understand their normal standing and LPA behaviors to determine the personalized changes to their standing and LPA behaviors in the other conditions.
214406225|NCT04349579|DRUG|Rifamycine|Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, extraction socket was irrigated with the solution which contains 250 mg rifamycine and the mucoperiosteal flap was repositioned by 3.0 silk sutures.
215010955|NCT04257253|OTHER|General exercise program|Participants in this active intervention group will perform a generalized exercise program comprising upper-body and lower-body and hip strengthening exercises, as well as flexibility. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
215010956|NCT05869409|BEHAVIORAL|Physical activity and sedentary behavior education|Enrolled patients will participate in an individual face-to-face education session, addressing: definitions and examples of sedentary and physical activity behaviors; physical health-related and mental health-related consequences of these behaviors; ways to break sedentary behaviors; age-adjusted physical activity recommendations (based on the guidelines of the World Health Organization).
215010957|NCT04810156|DRUG|Mycophenolate Mofetil|Day 1: MMF 500 mg twice a day Day 2: MMF 1000 mg twice a day
215010958|NCT04810156|DRUG|Solu-Medrol|2 mg/kg/day
215010959|NCT04810156|DRUG|Ursodeoxycholic acid|Patients with mixed or cholestatic liver injury pattern will also be administrated peroral UDCA according to weight
215010960|NCT04810156|DRUG|Prednisone tablet|Shift from solu-medrol IV to peroral prednisolon. A tapering plan will be performed.
215010961|NCT00761800|DRUG|Lactic acid|
215010962|NCT04955925|DIAGNOSTIC_TEST|Ultrasound examination of the optic nerve sheath diameter|The optic nerve sheath diameter is examined using ultrasonography.
215010963|NCT04058691|DEVICE|Surgical repair|Open surgery
215010964|NCT05625464|OTHER|SCTP|Real-time automated monitoring of the electronic medical record to identify suspected sepsis patients without completion of sepsis bundle measures within 1-hour of the completion deadline and generated reminder pages. Clinicians responsible for patients randomized to the intervention receive reminder pages whereas no pages are sent for control arm patients.
215010965|NCT04331405|BIOLOGICAL|Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions|"HUCBMCs samples were prepared for infusion in the specialized laboratory of Cord Blood Bank (CryoCenter Ltd) and transported to the clinic immediately within 2 hours in the Dry Shipper. All samples were chosen according to patients blood group and rhesus-factor.~All samples were examined for hemotransmissive infections and cell viability prior to the preparation.~Obtained samples were infused through the blood transfusion systems with additional filter after 3 tests for biological and individual compatibility and tolerance.~Each patient of the pilot group received 4 cell infusions (1 infusion per week) with 1 week interval during the in-hospital treatment."
215010966|NCT00080106|BIOLOGICAL|MRK Ad5 HIV-1 gag vaccine|MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
215010967|NCT00080106|OTHER|Vaccine placebo|MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
215010968|NCT02981641|RADIATION|Intraoperative radiotherapy (IORT)|Total dose: 18\~22 Gy; Single dose: 18\~22 Gy; Frequency: 1
215010969|NCT02981641|DRUG|Sequential chemotherapy|Sequential chemotherapy
214406226|NCT04349579|DRUG|Saline Solution|Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
214406227|NCT01037543|DRUG|HM10460A or placebo or Neulasta|Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
214406228|NCT05446389|DEVICE|Pacifier Activated Lullaby ®|Pacifier Activated Lullaby (PAL®) is a medical device that encourages and reinforces the development of non-nutritive sucking (NNS) of premature infants. This is accomplished by giving positive feedback in the form of music/mother's voice as an auditory input in direct response to effective sucking.
215098597|NCT04305613|OTHER|Chemoradiation|Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
214406229|NCT00832780|RADIATION|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
214406230|NCT06028048|BEHAVIORAL|PLACES|"The PLACES intervention is based on eight IPS principles, ensuring competitive employment, client choice, service integration, personalized benefits counseling, rapid job search, systematic development, and individualized support.~Coaches: Certified IPS coaches receive training from Phrenos IPS knowledge center and Re-turn. Ongoing support includes video lectures, clarifications with researchers, and biannual collective sessions. Coaches, regionally specialized, implement interventions autonomously.~Intervention Phases:~1. Intake and Assessment: Participants meet IPS coaches within three days to discuss goals, procedures, and responsibilities, continuing until objectives are met.~2. Acquisition and Application: Coaches assist job search and placement, aiming for employment within 30 days.~3. Placement and Support: Coaches offer personalized support, adapting to needs, scheduling meetings based on preferences.~The intervention ends at 12 months or when goals are achieved."
214406231|NCT03421444|OTHER|No intervention|No intervention
214406232|NCT02635659|OTHER|Encapsulated nutrients|
214406233|NCT02635659|OTHER|Placebo|
215098598|NCT06042699|DIETARY_SUPPLEMENT|Oral ferrous sulfate|Oral ferrous sulfate 325mg is used as a dietary supplement providing 65mg elemental iron.
215098599|NCT06042699|DIETARY_SUPPLEMENT|Oral placebo tablet|Oral placebo tablet provided as placebo comparator.
215098600|NCT06487975|DIETARY_SUPPLEMENT|Bacillus Subtilis|Bacillus Subtilis 1 capsule once daily in the morning (consisting of 10x10\^9 Colony Forming Units)
215098601|NCT06487975|OTHER|Placebo|1 visually identical placebo capsule once daily in the morning using the same carrier (microcrystalline cellulose) as the active (but not containing Bacillus Subtilis)
215098602|NCT05148078|OTHER|PROMISE (Pediatric Radiation Oncology with Movie Induced Sedation Effect)|Pediatric Radiation Oncology with Movie Induced Sedation Effect (PROMISE) is an interactive, incentive-based movie system that integrates with a video surveillance gating module (VisionRT) to help keep a child's attention and prevent him or her from moving during radiation treatment. This technology is being studied as an alternative sedation solution for pediatric patients needing radiation treatment. As part of the trial, patients will be attempted to have CT simulation scan and first radiation treatment(s) using PROMISE, with general anesthesia on standby should PROMISE be unsuccessful. If PROMISE is unsuccessful for a given patient, then standard of care general anesthesia will be used for that patient's radiation treatment and PROMISE will be reattempted at physician discretion with anesthesia on standby.
215010970|NCT02981641|RADIATION|Three dimensional conformal radiation therapy (3D-CRT)|Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30
215010971|NCT02981641|DRUG|Concurrent chemotherapy|Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
215098603|NCT04963075|DEVICE|multisensory rehabilitation paradigm|"In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed."
215098604|NCT03267888|BIOLOGICAL|Pembrolizumab|Given 200 mg IV.
215098605|NCT03267888|RADIATION|Radiation Therapy|Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
215098606|NCT06761170|PROCEDURE|Spray cryo therapy|normal flow, 5 seconds repeated for 3-5 cycles
215098607|NCT06761170|PROCEDURE|Standard of Care (SOC)|"1. Steroid injection~2. Radial mucosal incision~3. Balloon dilation (to normal airway diameter)"
215098608|NCT05092282|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
215098609|NCT05092282|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
215098610|NCT02893917|DRUG|Cediranib|Given PO
215098611|NCT02893917|DRUG|Olaparib|Given PO
215098612|NCT06140459|DEVICE|Conventional Toothbrushes|Oral-B Stages 3
215098613|NCT06140459|DEVICE|Pulsating Toothbrushes|Oral-B Pulsar, Colgate 360º Micro Sonic Power
215098614|NCT04985669|DRUG|Prucalopride 2mg|one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
215098615|NCT01610986|DIETARY_SUPPLEMENT|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
215010972|NCT05542602|BEHAVIORAL|Social intervention|The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff as part of the children's existing after-school program. The sessions follow a schedule and include social skills groups, social recreational games, and a reinforcement system to teach, practice, and reinforce targeted social knowledge and social skills. The sessions are manualized and include a specific instructional sequence and treatment (lesson) plan for the paraprofessional staff to implement. The children also earn points for use of the targeted skills (frequency of use) and each can earn a home or site-based reinforcer for reaching her/his targeted number of points each session. Each group is facilitated by two paraprofessionals, and includes 12-15 children including two with hfASD (the remaining will be typically-developing peers).
214406234|NCT06494423|BEHAVIORAL|Work Support (WorkS)|The WorkS intervention entails two structured visits with a research team member initiated 6-months post-HSCT, which is the earliest point at which most HSCT survivors can safely consider returning to work. The sessions are focused on 1) identifying challenges of navigating work and illness; 2) linking survivors with psychological, rehabilitative, governmental, and community resources that can promote recovery and well-being; and 3) communicating with employers regarding the necessary work modifications to achieve mutual goals.
215010973|NCT03355456|PROCEDURE|Radiofrequency ablation|Ablation procedure to eliminate atrial fibrillation
215010974|NCT02310607|OTHER|Not an interventional study|Not an interventional study
215010975|NCT06364527|DEVICE|Aptar Digital Health respiratory disease management platform|The Aptar Digital Health respiratory disease management platform is a digital health tool that combines a Healthcare Professional portal (BreatheSmart Connect) and an associated patient mobile application (BreatheSmart mobile application). The Aptar Digital Health respiratory disease management platform is intended to be used in conjunction with compatible connected sensor devices that track medication adherence and for some, technique.
215010976|NCT02069314|DIETARY_SUPPLEMENT|Whey protein supplementation|subjects are asked to consume a smoothie with whey protein added
214406235|NCT03569813|BEHAVIORAL|PrEP@Home System|"The PrEP@Home system includes a home care kit mailed quarterly to participants. The kit has components for self-collection of urine, rectal and pharyngeal swabs, microtube blood collection, and materials for return shipping. Biological tests routinely performed at PrEP follow-up (FU) visits will be done on the specimens. At months 6 and 12, the kit will include materials to assess for protective levels of emtricitabine triphosphate (FTC-TP).~The system includes a study app through which participants may track the mailing of home testing kits, access quarterly surveys, and communicate with study clinicians. The surveys will include domains that physicians assess at PrEP care quarterly FU visits (sexual risk, illicit substance use, PrEP adherence, side effects).~Study Clinicians will review Lab and survey results and if the results show no contraindications for PrEP continuation, the clinician may renew a participant's PrEP prescription. Telemedicine visits will be scheduled as needed."
214406236|NCT03569813|OTHER|Standard of Care|Control participants will receive clinic-based PrEP follow-up. After the baseline assessment, control participants will receive active linkage to standard, clinic-based PrEP care for their next PrEP care follow-up visit. Participants will also download the control version of the study app, which will contain only research elements pertinent to their participation in the control arm of the study including quarterly surveys. At months 6 and 12, control arm participants will be sent materials for DBS self-collection and return shipping to allow for measurement of the study outcome, emtricitabine triphosphate (FTC-TP).
214406237|NCT01767909|DRUG|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
214406238|NCT01767909|DRUG|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
214406239|NCT05129800|OTHER|Platelet-rich plasma|"PRP preparation involved, withdrawal 8-10ml from each patient into a tube containg either 3,8 % sodium citrate and either enoxaparin gel or thixotropic cell-separation gel. The tubes were centrifuged at either 3900 rpm for 10 minutes or at 1500g for 5 minutes, resulting in four layers: a cell-rich layer at the bottom of the tube covered by the separating gel, a PRP layer on top of the gel, and a platelet-poor plasma (PPP) layer at the top. The tube was gently agitated in order to mix the PPP with the PRP. The solution, cca 4-5ml, was withdrawn with a needle and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or an injector. According to the protocol of our hospital, the injections to the scalp were spaced 0.5-1cm apart.~PRP was applied once every month for 3 months. Macroscopic and digital phototrichographic photos were taken before the beginning of treatment, 1 month after the last injection, and 3 months after the end of treatmert."
215010977|NCT02069314|DIETARY_SUPPLEMENT|Carbohydrate (polycose) supplementation|Subjects are asked to consume a beverage with polycose added
215010978|NCT01938937|DEVICE|Transcranial bright light device|
215010979|NCT01938937|DEVICE|Transcranial sham device|
215010980|NCT02512562|DRUG|AL-335|AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
215098616|NCT01610986|DIETARY_SUPPLEMENT|Water|Only water intake during training
215098617|NCT03626545|DRUG|Canakinumab|Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)
215098618|NCT03626545|DRUG|Docetaxel|Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle
215098619|NCT03626545|OTHER|Placebo|Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
215098620|NCT01701934|DRUG|Roflumilast|500 mcg, oral, once daily for 6 months
215098621|NCT01701934|DRUG|Placebo|One placebo pill daily, for 6 months
215098622|NCT02229929|DRUG|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
215098623|NCT02229929|DRUG|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
215098624|NCT02229929|DRUG|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
214504748|NCT07098845|BEHAVIORAL|Learning to BREATHE Plus|"The in-person, group program portion of L2B PLUS and L2B are identical. But, L2B PLUS (Lucas-Thompson et al., 2020) builds on the standard L2B program with 3 additional supplements: 1) Extensive on-demand library designed by the team to be integrated with the group program and specifically to allow participants to independently practice skills that have already been introduced in the group program. 2) Intervention messages sent across the day. The team developed intervention messages to be sent 5 times a day to participants (Lucas-Thompson et al., 2020). Each week, participants receive intervention content tailored to what they have just learned in the group program. 3) JIT support. When participants indicate high stress via EMAs completed during the intervention period, tailored intervention content is delivered just-in-time during a moment of high need. These JIT messages were developed specifically to support applying or using mindfulness during periods of high stress."
215010981|NCT02512562|DRUG|ACH-3102|ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
215098625|NCT02229929|DRUG|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
215098626|NCT02229929|DRUG|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
215098627|NCT02229929|DRUG|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
215098628|NCT05245188|OTHER|Chocolate milk shakes - Product 1|11.3 glucose
215010982|NCT02512562|DRUG|Simeprevir|Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
215010983|NCT00610519|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
215010984|NCT00610519|DIETARY_SUPPLEMENT|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
215010985|NCT01249196|DRUG|SK-PC-B70M|for dosage
215010986|NCT00623129|OTHER|questionnaire administration|
215010987|NCT00623129|PROCEDURE|electroacupuncture therapy|
215010988|NCT00623129|PROCEDURE|management of therapy complications|
215010989|NCT00623129|PROCEDURE|quality-of-life assessment|
215010990|NCT01055327|DRUG|Lamotrigine monotherapy|Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
215010991|NCT01055327|DRUG|No anti-epileptic drug exposure|No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
215098629|NCT05245188|OTHER|Chocolate milk shakes - Product 2|8.84 glucose
215098630|NCT05245188|OTHER|Chocolate milk shakes - Product 3|4.24 glucose
215098631|NCT05245188|OTHER|Chocolate milk shakes - Product 4|4.36 glucose
215098632|NCT04262076|OTHER|Pulpine with Polyamidoamine Dendrimer|Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
215098633|NCT03450382|OTHER|Hans Kai Education|9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
215010992|NCT01055327|DRUG|Non lamotrigine anti-epileptic drug monotherapy|Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
215010993|NCT02468453|DEVICE|velos|VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
215010994|NCT06237491|DRUG|177Lu-LNC1003 Injection group 1|The treatment regimen will consist of a single dose 30 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
215010995|NCT06237491|DRUG|177Lu-LNC1003 Injection group 2|The treatment regimen will consist of a single dose 50 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
215010996|NCT06237491|DRUG|177Lu-LNC1003 Injection group 3|The treatment regimen will consist of a single dose 70 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
215010997|NCT03821597|PROCEDURE|Sequential compression devices (SCDs)|Application of sequential compression devices in surgery.
215010998|NCT03821597|PROCEDURE|No sequential compression.|No sequential compression devices are applied.
215098634|NCT05391022|DRUG|Pelabresib|Pelabresib monohydrate tablets
215098635|NCT00057369|DRUG|dalbavancin|
215098636|NCT03951909|BEHAVIORAL|Physiotherapy activity and awareness intervention: PAAI|10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
215098637|NCT03951909|BEHAVIORAL|Psychological intervention: Teaching recovery techniques (TRT)|TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
215010999|NCT02098551|OTHER|SPT and APT|"All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone."
214406240|NCT05129800|OTHER|Mesotherapy|"For mesotherapy, usually around 5ml of saline solution was withdrawn using a needle and released to the selected ampule containing adipose tissue stem-cell conditioned media and mixture of recombinant growth factors, in a powder form. We used preparations from two different companies, differing in the combination and concentration of ingredients. After the injection of normal saline, the ampule was gently agitated in order to disperse the powder and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or a gun injector. The injections were spaced 0.5-1cm apart.~Mesotherapy was repeated every 1-2 weeks for 6-7 times according to the protocol recommended for each preparation. Macroscopic and phototrichographic photos were taken before the beginning of treatment, a month after the last injection and 3 months after the end of treatment."
214406241|NCT04672408|DEVICE|His bundle pacing|Pacing with capture of the His bundle
215011000|NCT03003468|DRUG|Imprime PGG|Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV
215011001|NCT03003468|DRUG|MK-3475|200mg IV
215011002|NCT03003468|DRUG|Imprime PGG|Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
215011003|NCT00013325|PROCEDURE|Cardiac Disease|
215098638|NCT05933590|DIAGNOSTIC_TEST|Cervical Joint Repositioning Error Assessment|The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.
215098639|NCT01939366|DRUG|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
214406242|NCT04672408|DEVICE|Right ventricular pacing|Pacing from the right ventricular lead (septal or apical)
214406243|NCT06583837|DRUG|Orelabrutinib|Orelabrutinib was administrated for 12 weeks
214406244|NCT06583837|RADIATION|response-adapted radiation|response-adapted ultra-low dose 4Gy radiation
214406245|NCT06291701|DIAGNOSTIC_TEST|Assessment of scapular endurance|For the assessment of scapular endurance, participants will be instructed to bend their arms and elbows while keeping a wooden rod placed between their elbows, pull a spring dynamometer placed between thei
214406246|NCT06291701|DIAGNOSTIC_TEST|Prone Bridge Test|"For the Prone Bridge Test, participants will be instructed to lie face down with their hands and feet shoulder-width apart and then raise their bodies off the ground by lifting themselves up on their hands, forearms, and toes. A stopwa"
214406247|NCT06291701|DIAGNOSTIC_TEST|Side Bridge Test|"For the Side Bridge Test, participants will be asked to lie on their right side, supporting themselves on their forearm and elbow, and lift themselves off the ground. A stopwatch will be started, and the test will be terminated if there is any deviation from the position. The elapsed time will be recorded in seconds. The test will then be repeated on the left side."
214406248|NCT06291701|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|For the Closed Kinetic Chain Upper Extremity Stability Test, participants will be asked to assume a push-up position on a flat surface with their hands placed on two parallel lines drawn 90 cm apart. They will then be instructed to touch one hand to the other hand's side as many times as possible within 15 seconds. The test will be repeated three times, and the average of the scores will be calculated.
214406249|NCT06291701|DIAGNOSTIC_TEST|Seated Medicine Ball Throw Test|"For the Seated Medicine Ball Throw Test, participants will be asked to sit on the ground with their back, shoulders, and head against the wall. Holding a 2 kg medicine ball with both hands, they will start with their elbows bent and arms at their sides, then extend their elbows to throw the ball forward as far as possible. The distance between the wall and the point where the ball lands will be recorded. The test will be performed three times, and the average will be calculated."
214406250|NCT03669042|DEVICE|PhotoFix|PhotoFix Patch Implantation
214406251|NCT05407220|DRUG|HCP1904-1|take it once per period
214406252|NCT05407220|DRUG|HCP1904-3|take it once per period
214406253|NCT06204666|DIETARY_SUPPLEMENT|High Dose Hemp Fiber Bar|High dose hemp fiber bar with other ingredients
214406254|NCT06204666|DIETARY_SUPPLEMENT|Low Dose Hemp Fiber Bar|Low dose hemp fiber bar with other ingredients
214406255|NCT06204666|DIETARY_SUPPLEMENT|Placebo|Placebo bar with other ingredients
215011004|NCT04344444|DRUG|Hydroxychloroquine|tablets provided as described in Arm B
215011005|NCT04344444|DRUG|Azithromycin|tablets provided as described in Arm C
215011006|NCT04100057|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
215098640|NCT01939366|DRUG|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
214406256|NCT05869838|DEVICE|Colonoscopy|Screening or surveillance colonoscopy
214406257|NCT06233630|DRUG|Control Test - spinal anesthesia|No peripheral nerve block Only spinal anesthesia
214406258|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution ESPB|ultrasound guided erector spinae plane block (ESPB) - L2 level, unilateral
215011007|NCT04100057|BEHAVIORAL|Desensitization Therapy for insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
214406259|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution iPACK+ACB|ultrasound guided iPACK block + Adductor Canal Block
214406260|NCT06095206|DRUG|GenSci094|On the morning of day 1 pre-meal, a single SC injection of 150 μg GenSci094 was administered in the abdominal wall.
214406261|NCT04058392|BIOLOGICAL|Camu Camu Capsules|Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
214406262|NCT06505265|DRUG|Povorcitinib|Oral; Tablet
214406263|NCT05736367|DRUG|U-13C-glucose|Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue
214406264|NCT06401005|DRUG|Cadonilimab (AK104)|8Gy\*3 SBRT to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK104 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of doxorubicin 50mg/m2 (Q3W) + cyclophosphamide 600mg/m2 (Q3W) were administered, followed by four cycles of sequential albumin paclitaxel (125 mg/m2, d1, d8) and carboplatin (AUC=6, d1, Q3W) for 4 cycles. Postoperative completion of 9 cycles of immunotherapy was continued ± the need for postoperative adjuvant radiotherapy was confirmed based on the patient's preoperative status.
214406265|NCT04319094|BEHAVIORAL|PEERS|Peer mentors deliver depression care that include social support and coping skills, focused on goal setting and small behavioral changes.
214406266|NCT04319094|OTHER|Social interaction|Study staff will provide a combination of 8 social interaction visits and phone calls to the participants randomized to this condition.
214406267|NCT05112315|DEVICE|Predigraft|The Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.
214406268|NCT04956692|BIOLOGICAL|Pembrolizumab SC|SC injection
214406269|NCT04956692|BIOLOGICAL|Pembrolizumab IV|IV injection
214406270|NCT04956692|DRUG|Paclitaxel|IV injection
215011008|NCT05661968|OTHER|Online educational program|The intervention group will receive an online educational program, containing current information on low back pain management according to international clinical practice guidelines. Program content includes recommendations on assessment, diagnosis, and treatment of low back pain. The online program has 6 units of studies, with the content offered in the formats of video classes, infographics, texts, websites and clinical cases. The participant must complete the course within 6 weeks and will be able to set their own pace. Participants in the intervention group will receive their login and access password via email.
215011009|NCT01560702|DRUG|Epinephrine|10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
215011010|NCT01560702|BIOLOGICAL|Blood|5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
215011011|NCT01076517|DEVICE|Therasphere|Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
215011012|NCT00150553|DRUG|Extended-release carbamazepine|
215011013|NCT01384409|DRUG|KW-3357|Intravenous infusion once a day
215011014|NCT01717508|BEHAVIORAL|Cognitive Behavioral Therapy|12 sessions of cognitive behavioral therapy
215011015|NCT00997529|DRUG|nonmyeloablative stem cell transplant|Conditioning includes cytoxan 60mg/kg/d on Days 6 \& 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 \& 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction \& immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression \& do not have signs of GVHD, will receive a DLI
215011016|NCT02114684|DRUG|moxifloxacin|\[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)\]
215011017|NCT03362320|PROCEDURE|double layer fixation|
215011018|NCT03362320|PROCEDURE|single layer fixation|
215011019|NCT02195323|BIOLOGICAL|Intravenous injection|Intravenous injection of bone marrow derived MSC in patients with CKD.
215011020|NCT05419258|DEVICE|UPLUG Hemodialysis Connection Device|use of the device UPLUG during 1 month
214406271|NCT04956692|DRUG|Nab-Paclitaxel|IV infusion
214406272|NCT04956692|DRUG|Carboplatin|IV infusion
214406273|NCT04956692|DRUG|Cisplatin|IV infusion
214406274|NCT04956692|DRUG|Pemetrexed|IV infusion
214406275|NCT06362837|BEHAVIORAL|Education intervention on nutrition, gender equity, WASH, sexual and reproductive health rights|Educational training on nutrition, gender equity, WASH, sexual and reproductive health rights will take place in communities (including schools) for women, men, and adolescents
215011021|NCT00990769|OTHER|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
215011022|NCT06255548|OTHER|Immersive virtual reality group|The children in the IVR group were offered two video games from the Oculus Quest gallery. These games were Ocean Rift and Epic Roller Coaster-T-Rex Kingdom. Ocean Rift is the world's first VR water safari park. It has 12 different marine animals such as dolphins, sharks, and turtles and a habitat. Here one can visit a vibrant underwater world that extends all the way to the Arctic and Atlantis. Epic Roller Coaster-T-Rex Kingdom takes one on a roller coaster ride through the Age of Dinosaurs. There are more than 10 species of dinosaurs such as terrestrial, flying, herbivorous and carnivorous.
215011023|NCT06255548|OTHER|Music group|In musical interventions, it is recommended to play music chosen by individuals. Disposable ear pads were used for each child and the headphones were cleaned after each intervention.
214406276|NCT06362837|DIETARY_SUPPLEMENT|school-based iron-folic acid supplement program|The program will help support and promote the school-based programs of weekly iron and folic acid supplementation for adolescent girls, in countries where it is allowed.
214406277|NCT06362837|BEHAVIORAL|Health service training on equitable access to nutrition, health, and sexual and reproductive services|Training and support activities to make gender-equitable nutrition, health, and sexual and reproductive services in the health facilities
214406278|NCT06362837|DIETARY_SUPPLEMENT|bio-fortified crops|The program promotes and distributes bio-fortified crops, including orange-fleshed sweet potatoes, rice, beans, and corn
214406279|NCT06536036|DRUG|SIM0270|Use according to the prescribed protocol
214406280|NCT04178005|DRUG|Cladribine|All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI
214406281|NCT05305911|DRUG|SGLT-2 inhibitors|SGLT2 inhibitor once daily for six months
214406282|NCT05305911|DRUG|Placebo|Placebo once daily for six months
214406283|NCT03969277|OTHER|Graded Motor Imagery|"The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks."
214406284|NCT03969277|OTHER|Standard Rehabilitation|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
214406285|NCT03969277|OTHER|Home Exercise Program|Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
214406286|NCT03969277|OTHER|Cold Application|Cold application around the elbow joint for 15 minutes in every session.
214406287|NCT00202397|DRUG|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
214406288|NCT00202397|OTHER|placebo|capsule-shaped tablet bid for 8 weeks
215011024|NCT04679246|BEHAVIORAL|Participatory intervention|Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments
214406289|NCT06054828|BEHAVIORAL|mHELP@ICU|"The 14-day mHELP@ICU consists of the following three components:~1. Cognitive engagement twice daily: Participants will receive orienting communication, plus one of the following training on attention, memory, or function execution.~2. Physical activity once daily: Participants will receive a passive range of motion(ROM) and/or anti-gravity ROM exercise if tolerated.~3. Feeding monitor daily: The exact feeding data will be abstracted from medical records."
214406290|NCT04425148|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.
214406291|NCT04425148|DEVICE|Sham Transcranial Alternating Current Stimulation (sham tACS)|Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.
214406292|NCT05801042|DIETARY_SUPPLEMENT|Maltodextrin|Placebo product
214406293|NCT05801042|DIETARY_SUPPLEMENT|Encapsulated Lactocaseibacillus rhamnosus|Probiotic product
214406294|NCT05801042|DIETARY_SUPPLEMENT|Non-encapsulated Lactocaseibacillus rhamnosus|Probiotic product
214406295|NCT03057132|DEVICE|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
214406296|NCT01733134|DRUG|Tolvaptan|Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
214406297|NCT01733134|DRUG|placebo|Patient in the placebo group will receive tolvaptan in addition to standard therapy
214406298|NCT05087732|DEVICE|STYLAGE® M Lidocaïne|Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
215011025|NCT04308135|DIAGNOSTIC_TEST|Neuro-radiological tools:|"MRI brain: to measure white matter~c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected."
215011026|NCT04308135|DIAGNOSTIC_TEST|cognitive tests|"All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset~, and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale"
215011027|NCT04308135|DIAGNOSTIC_TEST|lab investigations|Each patient will undergo full lab investigations:\[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes\]
215011028|NCT04308135|DIAGNOSTIC_TEST|Beck depression inventory (BDI)(Arabic version)|Clinical Tool for depression
215011029|NCT04308135|DIAGNOSTIC_TEST|Clinical Tools for Urinary symptoms:|the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
215011030|NCT04308135|DIAGNOSTIC_TEST|Freezing of gait questionnaire|"Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~* .Freezing of gait questionnaire~* Berg balance scale.~* 10 meter walk test .~* Timed up and go test."
215011031|NCT04308135|DIAGNOSTIC_TEST|non-motor symptoms scales (NMSS).|Clinical Tool for assessment of non-motor symptoms of PD
215011032|NCT04308135|DIAGNOSTIC_TEST|Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):|"Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS"
215011033|NCT04308135|DIAGNOSTIC_TEST|ELIZA for alpha-synuclein|measuring serum of alpha-synuclein, tau and their autoantibodoies
215011034|NCT04308135|OTHER|transcranial color-coded duplex(TCCD)|TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
215011035|NCT04308135|OTHER|extracranial carotid duplex|to assess atherosclerosis, stenosis of carotids
215011036|NCT04308135|OTHER|The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)|Clinical tool for quality of life of PD patients
215011037|NCT04373733|DRUG|Favipiravir|Anti-viral
215011038|NCT04373733|OTHER|Standard of care management|Standard of care management for COVID-19
215011039|NCT02516436|DRUG|BEMA Buprenorphine NX|Buprenorphine with naloxone
215011040|NCT02516436|DRUG|Buprenorphine|Buprenorphine
215098641|NCT01939366|DRUG|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
215098642|NCT01939366|DRUG|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
215098643|NCT01939366|DRUG|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
215098644|NCT04623229|PROCEDURE|MCS|Manual Cataract Surgery
215098645|NCT04623229|PROCEDURE|ReLACS Early|ReLACS with early administration of anesthesia
215098646|NCT04623229|PROCEDURE|ReLACS Standard|ReLACS with standard time administration of anesthesia
215011041|NCT00929032|RADIATION|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
215011042|NCT02520466|DIETARY_SUPPLEMENT|flavanol-rich drink vs flavanol-free drink|Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
215011043|NCT05391152|DEVICE|robotic assisted total knee replacement|the study group used robotic-arm assisted total knee replacement.
215011044|NCT05391152|DEVICE|traditional total knee replacement|the control group used traditional total knee replacement
215098647|NCT01021904|BIOLOGICAL|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
215098648|NCT03122782|DRUG|Topical application Tranexamic acid|Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
215098649|NCT03122782|DRUG|Placebo (Normal saline)|5ml of normal saline will be added to every 500 ml of distension media
215098650|NCT02337192|DRUG|Curcumin|
215098651|NCT02337192|DEVICE|LED|
215098652|NCT02337192|DRUG|Surfactant|
215098653|NCT02337192|DRUG|DMSO + water|
215098654|NCT02337192|DRUG|Chlorhexidine gluconate|
215098655|NCT01743742|DRUG|Vitamin E, Vitamin C|
215098656|NCT06346522|DRUG|Gabapentin (Gaptin ®) 400mg oral capsule once|After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission
215098657|NCT06346522|DRUG|Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule|After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
215098658|NCT03747679|DRUG|200 Mg capsules of bosutinib in Water solution|200 mg (4X50) Capsules in water
215011045|NCT01320449|DRUG|recombinant human erythropoietin|rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
215011046|NCT01320449|BEHAVIORAL|Training|For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
215011047|NCT01320449|OTHER|Placebo|placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
214406299|NCT05087732|DEVICE|STYLAGE® M|Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
214406300|NCT06148766|OTHER|Manuka Health Eternal Renewal Regenerating Face Cream with Royal Jelly and Bee Venom|Face cream containing manuka honey, royal bee jelly, and bee venom.
215011048|NCT03122665|DRUG|Nefopam Low dose|Continuous intravenous infusion at 0.5 mg/ml for three hours.
215011049|NCT03122665|DRUG|Nefopam High dose|Continuous intravenous infusion at 1.0 mg/ml for three hours.
215011050|NCT04625972|DRUG|AZD7442|Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.
215011051|NCT04625972|DRUG|Placebo|Single dose (× 2 IM injections) of saline placebo on Day 1.
215011052|NCT04557644|OTHER|7-items-questionnaires addressing CI, disgust and empathy|7-items-questionnaire including numerical rating scales (NRS) ranging from 0 (no itch/disgust/empathy) to 10 (worst itch/disgust/most empathy imaginable) to rate itch, disgust and empathy they experience when treating the infested families.
215011053|NCT04557644|OTHER|Saarbrucken Personality questionnaire (SPQ) addressing empathy.|Empathy is additionally assessed by the Saarbrucken Personality Questionnaire (SPQ) ,a 16-item tool.
215011054|NCT04557644|OTHER|10-items-questionnaire addressing previous dermatological conditions, intensity of itch|10-items-questionnaire (completed by the hospitalised family) regarding demographic information (gender, age, profession), previous dermatological conditions, intensity of itch a.) on the first day of the hospitalisation, b.) when seeing the skin lesions of the other family members c.) when talking about the scabies/itch with the other family members, d.) when seeing other family members scratching themselves, and questions regarding their intensity of disgust of the scabies and empathy for the other family members (0-10 NRS).
215011055|NCT04557644|OTHER|ItchyQol-questionnaire composed of 22 items addressing itch-related symptoms, functions and emotions|ItchyQol-questionnaire to assess the itch-related quality of life impairment. The ItchyQoL is composed of 22 items addressing itch-related symptoms, functions and emotions.
215011056|NCT03457584|PROCEDURE|air arm|epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
215011057|NCT03457584|PROCEDURE|BSS arm|epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
215011058|NCT00498732|DEVICE|CPAP|CPAP treatment for 4 weeks
214406301|NCT05493371|DRUG|Empagliflozin 10 MG|10 mg once daily empagliflozin oral tablets for 12 weeks
215011059|NCT02850562|BEHAVIORAL|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
215011060|NCT02850562|BEHAVIORAL|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
215011061|NCT02919332|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
215011062|NCT02919332|RADIATION|Fludeoxyglucose F-18|Given IV
215011063|NCT02919332|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
215011064|NCT00723242|DRUG|Viraferon-peg and Rebetol|
215011065|NCT03319888|DEVICE|CPAP|continuous positive pressure in the airway
214406302|NCT05211531|OTHER|Measuring number of post-operative steps|Measuring the number of post-operative steps that inpatients take.
214406303|NCT01016353|DEVICE|NPWT|ABThera Open Abdomen Negative Pressure Therapy System
214406304|NCT01016353|DEVICE|BVPT|Barker's Vacuum Packing Technique
214406305|NCT05018273|BIOLOGICAL|VB10.NEO|The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.
214406306|NCT02518932|DRUG|Last 5 amino acids of GLP-1|To examine insulinomimetic properties of LVKGR
214406307|NCT02518932|DRUG|placebo saline|
214406308|NCT01839825|DEVICE|QuietCare|
214406309|NCT06010485|OTHER|Serial Casting|A short leg cast is applied to the serial casting group by an orthopedic specialist once every three days for three weeks.
215011066|NCT03319888|OTHER|conservative treatment|conservative treatment group with lifestyle modifications
215011067|NCT01794416|PROCEDURE|Thoracoscopic epicardial ablation|
215011068|NCT01794416|PROCEDURE|Endocardial catheter ablation|
215011069|NCT01794416|DEVICE|Implantable loop recorder|
215011070|NCT01346683|DEVICE|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
215011071|NCT03228407|PROCEDURE|Confocal endomicroscopy|Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
215011072|NCT03228407|DIAGNOSTIC_TEST|Endoscopic biopsies|Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.
215011073|NCT03228407|DIAGNOSTIC_TEST|Mucosal impedance (MI)|MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
215011074|NCT06522802|DIAGNOSTIC_TEST|balance tests, reaction time evaluation|Only 3 tests were applied to participants
215011075|NCT06390215|BEHAVIORAL|School Readiness Coaching Intervention|Two 1-hr School Readiness Coaching Session
215011076|NCT02641353|DRUG|Apremilast Tablet|30 mg tablet
214406310|NCT06010485|OTHER|Exercise|Stretching exercises, strengthening exercises, balance exercises, proprioception exercises, and heel walking exercises are applied to the physical therapy group for 3 weeks with a physiotherapist for 3 sessions a week.
214406311|NCT06330831|OTHER|Intensive, Group Based Constraint Induced Therapy (CIMT)|See arm description. Children who were in study 2 received two consecutive episodes of the intensive, group based CIMT intervention (episode 1 during the first summer, episode 2 during the following summer).
214406312|NCT05780047|DIAGNOSTIC_TEST|Mail-in Urine Test for EDCs|Million Marker provides a mail-in urine test for Bisphenol A (BPA) and phthalates. Users take a comprehensive exposure survey (via the MM app), send back their samples, view their personalized reports with tailored product recommendations, make changes to reduce their exposures, and retest to monitor their progress. Participants will also fill out surveys to assess changes in their environmental health literacy, readiness to change, and analyses of lifestyle behaviors and product use.
214406313|NCT05221398|DRUG|Immune Checkpoint Inhibitors Based Adjuvant therapy|Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy
214406314|NCT05221398|OTHER|Active surveillance|Patients in this group only receive active surveillance
214406315|NCT05039424|PROCEDURE|Endoscopic per-oral pyloromyotomy (POP)|Per-oral pyloromyotomy (POP), alternatively knows as gastric per-oral endoscopic myotomy (G-POEM), accomplishes longitudinal division of the pylorus using an endoscope. This procedure involves utilizing endoscopic electrosurgical knife to make an incision in the gastric mucosa and develop a submucosal tunnel to visualize the pyloric ring. The pyloric ring is divided longitudinally, and the mucosotomy incision is sealed with endoscopic clips.
214406316|NCT05039424|PROCEDURE|Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption|While under general anesthesia, a standard gastroscope is introduced and a diagnostic upper endoscopy is performed. The operator talks through the procedure steps as if completing POP. The gastroscope is withdrawn and the patient is extubated.
214406317|NCT04473859|DRUG|FSR Peptide 20μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
214406318|NCT04473859|DRUG|FSR Peptide 50μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
214406319|NCT04473859|DRUG|FSR Peptide 100μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
214406320|NCT04473859|DRUG|FSR Peptide 200μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
214406321|NCT04473859|DRUG|Placebo|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
214406322|NCT06214806|BEHAVIORAL|Grocery Vouchers|Participants will be given vouchers to buy groceries each month for five months.
214406323|NCT04838093|DIAGNOSTIC_TEST|PCR|"Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials."
214406324|NCT06252662|DRUG|Dexmedetomidine|block duration extension additive
214406325|NCT06252662|DRUG|Liposomal bupivacaine|Control arm, comparison for block duration with dexmedetomidine
214406326|NCT04873817|DEVICE|IonicRF Generator and compatible accessories|Participants will receive IonicRF lesion generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator
214406327|NCT03789643|DRUG|JTT-251|Active drug tablets containing JTT-251
214406328|NCT03789643|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
214406329|NCT04447781|BIOLOGICAL|INO-4800|\- Manufacturer: Inovio Pharmaceuticals Inc.
214406330|NCT04447781|DEVICE|CELLECTRA® 2000|\- Manufacturer: Inovio Pharmaceuticals Inc.
214406331|NCT04447781|OTHER|Saline-sodium citrate (SSC) buffer|\- Manufacturer: Inovio Pharmaceuticals Inc.
214406332|NCT00530192|OTHER|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
214406333|NCT03607903|BIOLOGICAL|Adalimumab ID|Adalimumab intradermal using MicronJet600 microneedle from NanoPass
214406334|NCT03607903|BIOLOGICAL|Adalimumab SC|Adalimumab subcutaneous using regular needle
214406335|NCT03607903|OTHER|Saline ID|Saline intradermal using MicronJet600 microneedle from NanoPass
214406336|NCT03607903|OTHER|Saline SC|Saline subcutaneous using regular needle
214406337|NCT02403531|DRUG|Docetaxel|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
214406338|NCT02403531|DRUG|Cisplatin|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
214406339|NCT02403531|RADIATION|Radiotherapy|definitive radiotherapy
214406340|NCT02250495|DEVICE|Sympara Therapeutic System|Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension
214406341|NCT00019890|DRUG|dendritic cell-gp100-MART-1 antigen vaccine|
214406342|NCT00019890|DRUG|sargramostim|
215011077|NCT02641353|DRUG|Apremilast Oral Suspension|30 mg oral suspension
215011078|NCT01741818|OTHER|Measuring IVC collapsibility index by bedside ultrasonography|
215011079|NCT03259308|DRUG|Ontamalimab|Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
215011080|NCT03259308|DRUG|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
215011081|NCT00893295|OTHER|informational intervention|
215011082|NCT00893295|OTHER|medical chart review|
215098659|NCT03747679|DRUG|bosunitib sorbitol|200 Mg of bosutinib sorbitol solution
215098660|NCT03747679|DRUG|Bosutinib Mannitol|Bosutinib mannitol solution
215098661|NCT03747679|DRUG|bosutinib in mannitol low sweet|bosutinib in mannitol solution low sweet
214406343|NCT04774185|DEVICE|New hearing aid loudspeaker|The new hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
215098662|NCT03747679|DRUG|bosutinib in mannitol high sweet|bosutinib in mannitol high sweet
215098663|NCT03747679|DRUG|bosutinib taste low flavour|bosutinib solution low flavour
215098664|NCT03747679|DRUG|bosutinib high flavour|bosutinib solution high flavour
215098665|NCT03747679|DRUG|bosutinib capsules in applesauce|Bosutinib capsules in applesauce
215011083|NCT00893295|OTHER|screening questionnaire administration|
215011084|NCT00893295|OTHER|study of socioeconomic and demographic variables|
215011085|NCT00893295|PROCEDURE|barium enema injection|
215011086|NCT00893295|PROCEDURE|colon imaging study|
215011087|NCT00893295|PROCEDURE|screening colonoscopy|
215011088|NCT00893295|PROCEDURE|sigmoidoscopy|
215011089|NCT03812250|PROCEDURE|ERCP assisted trans-papillary drainage for malignant biliary obstruction|ERCP assisted trans-papillary drainage for malignant biliary obstruction
215011090|NCT03812250|PROCEDURE|EUS-guide biliary drainage for malignant biliary obstruction|EUS-guide biliary drainage for malignant biliary obstruction
215011091|NCT00694122|DRUG|Lantus (glargine)|Described in Arm Description
215011092|NCT01767285|DRUG|Etonogestrel implant|This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
215011093|NCT01609140|DRUG|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
215098666|NCT03747679|DRUG|Bosutinib capsules in yogurt|bosutinib capsules in yogurt
214406344|NCT04774185|DEVICE|Standard hearing aid loudspeaker|The standard hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
214406345|NCT03004599|DEVICE|SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System|Transcatheter Aortic Valve Implantation via Transfemoral Approach
215011094|NCT01609140|DRUG|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
215011095|NCT01609140|DRUG|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
215098667|NCT03747679|DRUG|bosutinib capsules in water|sham comparator, bosutinb in water retest
215098668|NCT03747679|DRUG|Bosutinib capsules in low sweet|bosutinib capsules in low sweet
215098669|NCT03747679|DRUG|bosutinib capsules high sweet|Bosutinib capsules high sweet
215098670|NCT03747679|DRUG|bosutinib capsules low flavour|Bosutinib capsules low flavour
215098671|NCT03747679|DRUG|bosutinib capsules high flavour|bosutinib capsules in high flavour
215098672|NCT05218642|DRUG|KX- 826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
215098673|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
215098674|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
215098675|NCT05218642|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily or once daily for 24 weeks
215098676|NCT03909152|DRUG|Onapristone ER|50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.
215098677|NCT03909152|DRUG|Onapristone ER + Anastrozole|Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.
215098678|NCT05111353|BIOLOGICAL|Optimized neoantigen synthetic long peptide vaccine|Neoantigen vaccines will be provided on a patient-specific basis
215098679|NCT05111353|BIOLOGICAL|Poly-ICLC|Poly-ICLC will be supplied by Oncovir, Inc.
215098680|NCT06307535|BEHAVIORAL|Meaning-Centered Psychotherapy for Caregivers|MCP-C is a stakeholder-informed, innovative, manualized intervention designed to assist caregivers to connect to a sense of meaning and purpose in life, despite the challenges of caregiving.
215011096|NCT01609140|DRUG|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
215011097|NCT01609140|DRUG|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
215011098|NCT01609140|DRUG|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
215011099|NCT01456338|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
215011100|NCT01456338|BEHAVIORAL|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
215011101|NCT01095770|PROCEDURE|AF Ablation with Ablation Frontiers Technology|AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.
215011102|NCT01095770|PROCEDURE|AF Ablation with LASSO catheter|AF Ablation with traditional LASSO catheter
215011103|NCT01095770|DEVICE|Reveal XT|Reveal XT implantable loop recorder monitored group
215011104|NCT01095770|DEVICE|Permanent Dual Chamber Pacemaker|This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
215098681|NCT06307535|BEHAVIORAL|Supportive Psychotherapy for Caregivers|Standard of care supportive psychotherapy
214406346|NCT06026787|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added to the standard of care regimen of primary nephrotic syndrome patients
214406347|NCT04632966|BIOLOGICAL|Biological: PTP-001|allogeneic placental tissue particulate
214406348|NCT01047072|DRUG|fludarabine phosphate|Given IV
214406349|NCT01047072|RADIATION|total-body irradiation|Undergo total-body irradiation
214406350|NCT01047072|DRUG|tacrolimus|Given orally
214406351|NCT01047072|DRUG|mycophenolate mofetil|Given orally
215011105|NCT00436709|BIOLOGICAL|bevacizumab|
215011106|NCT00436709|BIOLOGICAL|pegfilgrastim|
215011107|NCT00436709|DRUG|cyclophosphamide|
215011108|NCT00436709|DRUG|doxorubicin hydrochloride|
215011109|NCT00436709|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
215011110|NCT00436709|OTHER|flow cytometry|
215011111|NCT00436709|OTHER|immunoenzyme technique|
215011112|NCT00436709|OTHER|immunologic technique|
215011113|NCT00436709|OTHER|laboratory biomarker analysis|
215011114|NCT00436709|PROCEDURE|adjuvant therapy|
215011115|NCT00436709|PROCEDURE|immunoscintigraphy|
215098682|NCT06520774|DEVICE|Concave Supra-arch Branched Stent-Graft System|To evaluate the efficacy and safety of Concave Supra-arch Branched Stent-Graft System for endovascular treatment of Aortic Arch Diseases
215098683|NCT00748254|PROCEDURE|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on finger joints with any of the scanning methods described above.
214406352|NCT01047072|BIOLOGICAL|rituximab|Given IV
214406353|NCT01047072|DRUG|cyclophosphamide|Given orally
214406354|NCT01047072|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
214406355|NCT01047072|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
214406356|NCT00665561|DRUG|Maraviroc along with an optimized background antiretroviral drug regimen|Maraviroc prescribed per approved local label.
214406357|NCT00665561|DRUG|Optimized background antiretroviral drug regimen without maraviroc|Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
214406358|NCT05678595|DEVICE|high-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
214406359|NCT05678595|DEVICE|sham high-intensity laser therapy|HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
214406360|NCT02081365|BEHAVIORAL|Computerized Dental Anxiety Treatment|The Computerized Dental Anxiety Treatment Program consists of treatment modules that are be delivered through a computer. The modules use Cognitive Behavioral Therapy (CBT) to assist the participant in preparing a personal plan for managing his/her dental anxiety. The program incorporates a range of CBT techniques, including cognitive restructuring, exposure, and motivational interviewing.
214406361|NCT00489073|DRUG|duloxetine|
214406362|NCT00489073|DRUG|placebo|
214406363|NCT06407479|OTHER|proprioceptive neuromuscular facilitation technique group|Proprioceptive Neuromuscular Facilitation Technique group; In addition to the exercises applied to the participants and the control group, combined isotonic contractions and dynamic stabilization will be used as facilitation techniques, and hold-relax technique will be used as an inhibition technique.
215011116|NCT02517229|OTHER|Parabolic flight|
215011117|NCT02517229|OTHER|balance control measurements|
215011118|NCT02517229|DEVICE|electromagnetic maneuverable postural platform|
215011119|NCT03549195|PROCEDURE|ICG|The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
215011120|NCT03549195|PROCEDURE|ICG-CP|The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
215098684|NCT00748254|PROCEDURE|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on finger joints with any of the scanning methods described above.
214406364|NCT06407479|OTHER|eccentric muscle training technique application group|Eccentric Muscle Training Technique: Participants will receive eccentric muscle training in addition to the exercises given to the control group. Before the application, 5-minute warm-up exercises will be given to the neck area. Eccentric muscle training will be applied to the muscles of the participants in the cervical region. Eccentric exercise will be strengthened in the cervical region muscles in the direction of movement in each plane, that is, flexion / extension and lateral flexion. The movements will first be explained and demonstrated to the patient.
214406365|NCT06407479|OTHER|Control|No intervention will be made.
214406366|NCT01734811|BIOLOGICAL|Biological vaccine|daily spray (2 puff of 100 µL) for six months
215011121|NCT03549195|PROCEDURE|ICG-TMTP1|The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
215011122|NCT04992286|OTHER|questionnaire|questionnaire to evaluate fragility
215011123|NCT04992286|OTHER|accelerometer|To evaluate physical activity level
215011124|NCT05563974|OTHER|Family led postnatal care|"Family-led Postnatal Care-FPNC A midwife involves families and uses a visual checklist to assess and counsel. The midwife then gives families the checklist and guides them how to retrieve a home care kit that has a blood pressure machine, infrared thermometer, and health education booklet.~At home, families assess the health of postnatal mothers and newborns for 6 days, and then return the completed checklist and home care kit to the community location."
215011125|NCT01727154|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
215098685|NCT06537414|DRUG|Daplusiran/Tomligisiran Dose Level 1|Daplusiran/Tomligisiran dose level 1 will be administered
214406367|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
214406368|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
214406369|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
214406370|NCT00062868|BIOLOGICAL|LMP2 CTLs (ALSCER - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
214406371|NCT00062868|BIOLOGICAL|LMP2 CTLs (ALSCER - Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
214406372|NCT00062868|BIOLOGICAL|LMP2 CTLs (ALSCER - Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
214406373|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Expansion - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2"
214406374|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Expansion Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2"
214406375|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Expansion Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2"
214406376|NCT04560361|OTHER|Electroacupuncture treatment|Continue the electroacupuncture treatment as described above for 30 minutes.
214406377|NCT04560361|OTHER|Sham electroacupuncture treatment|Continue the sham electroacupuncture treatment as described above for 30 minutes.
214406378|NCT00875147|DRUG|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
214406379|NCT01938417|DRUG|tobramycin|
215011126|NCT00003090|BIOLOGICAL|aldesleukin|
214406380|NCT01786343|DRUG|Decitabine|20 mg/m2 by vein daily for either 5 or 10 days.
214406381|NCT00906880|DRUG|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
215011127|NCT02819375|DRUG|Propofol|1 mg/kg propofol
215011128|NCT02819375|DRUG|Propofol+Remifentanil|0.5 mg/kg propofol+0.5 mg/kg remifentanil
215011129|NCT02819375|DRUG|Propofol+Ketamine|0.5 mg/kg propofol and 0.5 mg/kg ketamine
215011130|NCT01053052|DEVICE|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
215011131|NCT05135325|BEHAVIORAL|Patient portal message|Portal message encourages patients to donate blood
215011132|NCT05135325|BEHAVIORAL|Social responsibility|Message specifies that there is a shortage of the patient's blood type
215011133|NCT00003474|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
215011134|NCT00368485|DEVICE|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
215011135|NCT01532375|DIETARY_SUPPLEMENT|Kochujang|Kochujang (32g/day) for 12weeks.
215011136|NCT01532375|DIETARY_SUPPLEMENT|placebo|placebo(32g/day) for 12weeks
215011137|NCT03237663|BIOLOGICAL|The oral O1 / O139 cholera vaccine (enteric capsules)|
215011138|NCT05742750|DRUG|Camrelizumab and Apatinib Plus GP|"Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.~Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks.~GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason."
215011139|NCT00809146|DRUG|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
215011140|NCT00809146|DRUG|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
215011141|NCT00194090|DRUG|celecoxib|
215011142|NCT02663440|RADIATION|Hypofractionated IMRT|Hypofractionated IMRT
215011143|NCT02663440|BIOLOGICAL|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
215011144|NCT02663440|DRUG|Temozolomide|Temozolomide
215011145|NCT06471166|DIAGNOSTIC_TEST|Amh hormone|Ovarian reserve
215011146|NCT03020888|DEVICE|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
215011147|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 Low Dose
215011148|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 High Dose
215011149|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch Low Dose
215098686|NCT06537414|DRUG|Daplusiran/Tomligisiran Dose Level 2|Daplusiran/Tomligisiran dose level 2 will be administered
215098687|NCT06537414|DRUG|Bepirovirsen|Bepirovirsen will be administered
214406382|NCT03186807|DIAGNOSTIC_TEST|ultrasonographic scan of fetal brain|"1. Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).~   specific measurements as follow:~2. Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.~3. Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.~4. Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.~6\. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures."
214406383|NCT05661760|BEHAVIORAL|interdisciplinary multimodal pain treatment|A combination of physical and psychosocial treatment methods is employed, including Emotional Awareness and Expression Therapy (EAET), Pain Neuroscience Education (PNE), Acceptance and Commitment Therapy (ACT), graded activity, exposure in vivo, and experiential learning through physical training.
215011150|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch High Dose
215098688|NCT06537414|DRUG|Placebo|Placebo will be administered
215098689|NCT05937581|DRUG|CSL040|IV Administration
215098690|NCT05937581|DRUG|Placebo|0.9% w/v NaCI, IV Administration
214406384|NCT01484106|OTHER|Fluid Resuscitation|"In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR)."
214406385|NCT01484106|OTHER|Standard of Care|Standard of Care
214406386|NCT04511130|DRUG|MT-401|MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
215098691|NCT02615691|BIOLOGICAL|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII).
215098692|NCT02615691|BIOLOGICAL|ITI|Immune tolerance induction therapy
215011151|NCT04505111|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
215011152|NCT04505111|OTHER|Enhanced Recovery After Surgery|ERAS protocol
215011153|NCT05212142|BEHAVIORAL|verbal education|Participants will receive oral health anticipatory guidance in the form of verbal and written education alongside the same preventive follow up and recall appointment schedule.
215098693|NCT05635357|DRUG|Anastrozole|Anastrozole claim is used as the exposure group.
215098694|NCT05635357|DRUG|Exemestane/Letrozole|Exemestane/Letrozole claim is used as the reference group.
215098695|NCT00261573|DRUG|galantamine hydrobromide|
215098696|NCT02017522|DEVICE|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
215098697|NCT06213311|DRUG|Glofitamab|Given by IV
215098698|NCT06213311|DRUG|Obinutuzumab|Given by IV
215098699|NCT06213311|DRUG|Axi-cel|Given by IV
214406387|NCT06033131|DRUG|Metformin ER|Metformin ER, one gram three times daily taken orally. Once the participants have been recruited, they will start by taking one 500 mg tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
214406388|NCT06033131|DRUG|Placebo|Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
214406389|NCT04435730|DIAGNOSTIC_TEST|serum level of Mac 2 binding protein|"Serum levels of Mac 2 binding protein will be measured for all the study subjects using Enzyme-Linked Immuno sorbent Assay (ELISA).~2 ml of venous blood will be collected from patients and controls under complete aseptic conditions in a plain tube. Sample will be allowed to clot for 15-30 min at room temperature and then centrifuged at 2500 rpm for 10-15 min. Serum will be separated and stored at -20 C or lower till time of assessment."
214406390|NCT04435730|DEVICE|musculoskeletal ultrasound|MSUS examination will be performed for patients of all groups and control group.Gray scale (GSUS) and power Doppler (PDUS) at joints levels and entheses will be performed with the same transducer of My Lab Seven Crystalline esaote machine.
214406391|NCT00048854|DRUG|Sertraline|Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
214406392|NCT00048854|OTHER|Treatment as usual (TAU)|At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
214406393|NCT04007887|OTHER|Adult education program|A 10-hour program embodying major adult education principles, designed to achieve cognitive involvement of patients in their treatment
214406394|NCT00710723|PROCEDURE|vitrification|Vitrification using Hemi-straw carrier system.
214406395|NCT04601376|BEHAVIORAL|Mobile Monitoring Tool|a text-messaged based outcomes collection system
214406396|NCT04307550|DRUG|Isopropyl alcohol|10 inhalations of an isopropyl alcohol pad
214406397|NCT04307550|OTHER|Placebo|10 inhalations of a sterile saline pad
214406398|NCT04890145|DEVICE|RW-Precision-Coupler|Implantation of the RW-Precision-Coupler together with FMT-VORP 503
214406399|NCT03230006|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The UP will be conducted in a standardized fashion over 16 sessions, in a minimum of 16- and a maximum of 21-weeks, following the published therapist guide with minor refinements for application in the proposed comorbid population.
214406400|NCT03230006|BEHAVIORAL|Take Control|TC will be conducted over 12 sessions, in a minimum of 12- and a maximum of 16-weeks. Therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
214406401|NCT05593458|DRUG|Oxaliplatin by arterial infusion plus S-1|3 cycles oxaliplatin by arterial infusion plus S-1 every 21 days as neoadjuvant chemotherapy.
214406402|NCT05593458|DRUG|SOX neoadjuvant|3 cycles of SOX neoadjuvant chemotherapy every 21 days.
214406403|NCT05593458|DRUG|Sintilimab neoadjuvant|3 cycles of neoadjuvant immunotherapy every 21 days.
214406404|NCT05593458|PROCEDURE|gastrectomy plus D2 lymph node dissection|All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.
215011154|NCT05212142|BEHAVIORAL|verbal education, visual aids, and motivational interviewing|Participants will receive oral health anticipatory guidance through a combination preventive strategy using motivational interviewing, individualized goal setting, visual aids, and verbal education alongside a preventive follow up and recall appointment schedule
215098700|NCT05767190|BEHAVIORAL|Motivational interviewing|During the intervention, the trained-nurse will provide a motivational interviewing-based intervention consisting of one session divided into two parts: educational (the concepts of sleep apnea and the symptoms, and the CPAP treatment will be focused on) and training activity (using MI not directly advocate for behavioral change (i.e., use CPAP as prescribed), but asks key questions to help the patient explore conflicting feelings about the change, weighs the positive consequences and negatives of this change, and allows the patient to realize the discrepancy between current risk behavior (i.e. not using CPAP as directed) and the patient's self-identified goals. The intervention will be tailored on the patient's stage of change based on Prochaska and DiClemente transtheoretical model (1982), in fact, the nurse will use MI not only at the beginning of therapy but also in every contact with the patient throughout the treatment (subsequent follow-up visits, phone calls, etc.).
215098701|NCT00376766|DRUG|levetiracetam|
214406405|NCT05593458|DRUG|SOX adjuvant, Sequential S-1|"3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation."
214406406|NCT05593458|DRUG|Sintilimab adjuvant|3 cycles of adjuvant immunotherapy every 21 days.
214406407|NCT04677465|DEVICE|RheOx Bronchial Rheoplasty|bronchial rheoplasty is a staged procedure wherein pulsed electric fields are delivered to the right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.
215011155|NCT01198548|DRUG|leucovorin calcium|Given IV
215011156|NCT01198548|BIOLOGICAL|bevacizumab|Given IV
215011157|NCT01198548|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
215011158|NCT01198548|DRUG|fluorouracil|Given IV
215011159|NCT01198548|DRUG|oxaliplatin|Given IV
214406408|NCT04677465|DEVICE|Sham Procedure|staged sham procedure wherein bronchoscopy is performed, the catheter is inserted into the right lung, but energy is not delivered; then the same steps are performed in the left lung approximately 1 month later (no energy is delivered to the patient)
214406409|NCT00670540|OTHER|procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis|patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
214406410|NCT05267834|PROCEDURE|Conization and/or Hysterectomy|Women undergoing cervical conization or simple/modified/radical hysterectomy with or without pelvic lymphadenectomy
214406411|NCT00005305|OTHER|No interventions - observational study|
214406412|NCT03773055|DRUG|NPC-06|Patients will receive once a day for 7 days.
214406413|NCT00236821|DRUG|levofloxacin|
214406414|NCT00124605|DRUG|pamidronate disodium|Given IV
214406415|NCT00124605|DRUG|arsenic trioxide|Given IV
215011160|NCT01198548|OTHER|pharmacological study|Correlative studies
215011161|NCT05926193|DIETARY_SUPPLEMENT|Tailor Food Bags|The treatment group will participate in 6 nutrition workshops over the course of 6 months as well as receive weekly food bags that have been tailored for a DASH diet.
215011162|NCT02416271|DRUG|Teriparatide|Administered SC
215011163|NCT02416271|DRUG|Alendronate|Administered orally
215098702|NCT01167660|DEVICE|The Thrombo-Monitor (ThM)|Non-invasive measurement of coagulation status and comparison to standard blood coagulation tests. In healthy neonates - immediately after birth, before the administration of vitamin K. Coagulation tests will be done on an umbilical cord blood sample. In sick neonates, coagulation studies will be done according to the medical condition.
215011164|NCT02416271|DIETARY_SUPPLEMENT|Calcium|Administered orally
215098703|NCT06014099|BEHAVIORAL|Long peripheral venous catheters for blood collection|used LPC for blood collection
215098704|NCT06014099|BEHAVIORAL|Midline catheter for blood collection|used MCs for blood collection
215098705|NCT06014099|BEHAVIORAL|SPCs for blood collection|used SPCs for blood collection
214406416|NCT00124605|OTHER|laboratory biomarker analysis|Correlative studies
214406417|NCT00124605|OTHER|pharmacological study|Correlative studies
214406418|NCT03591965|DRUG|ATG-008|Approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg/QD and another 20 subjects will receive oral ATG-008 at an initial dose of 20mg/BID for 28 days each cycle.
214406419|NCT03882463|DEVICE|Continuous glucose monitoring with the stop insulin pump function|"Children with type 1 diabetes using insulin pump and continuous glucose monitoring without the stop insulin pump functionare then using the predictive system for stopping before hypoglycaemia medtronic Minimed with SmartGuard technology."
214406420|NCT05644405|DIAGNOSTIC_TEST|FloTrac Vigileo|A dedicated transducer (FloTrac TM, Edwards Lifesciences, LLC, Irvine, CA, USA) was connected to the radial arterial line on one side and to the Vigileo System (Vigileo TM Edwards Lifesciences, LLC, Irvine, CA, USA) on the other side
214406421|NCT01866917|DRUG|Ropivacaine 0.5% 20cc injectate bilaterally|
215011165|NCT02416271|DIETARY_SUPPLEMENT|Vitamin D|Administered orally
215011166|NCT02416271|DRUG|Placebo-Oral|Administered orally
214406422|NCT01866917|DRUG|Placebo|
214406423|NCT00972985|DRUG|modafinil|oral tablet, 100 mg, single acute dose
214406424|NCT00972985|DRUG|methylphenidate|oral tablet, 20 mg, single acute dose
214406425|NCT00972985|DRUG|lorazepam|oral tablet, 1 mg, single, acute dose
215011167|NCT02416271|DRUG|Placebo-SC|Administered SC
215011168|NCT04464902|DEVICE|brace1|The brace1 can provide resistance when patients want to extend their knee.
215098706|NCT00597493|DRUG|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
215098707|NCT05150938|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
214406426|NCT00972985|DRUG|placebo|oral tablet, single acute dose
214406427|NCT03896230|DRUG|Ketamine Injectable Product|Three different doses of ketamine will be administered.
214406428|NCT04124822|DRUG|Piroxicam 20 mg|Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels
214406429|NCT04124822|DRUG|prednisolone 20 mg|prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
214406430|NCT00761254|DRUG|Domperidone|Initially, 10mg of oral Domperidone will be administered 2-4 times a day as needed. This dosage may be increased or decreased depending on how the subject responds to the drug.
214406431|NCT01515319|DRUG|Y242|Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)
214406432|NCT01515319|DRUG|0.9% saline|Identical volume to that of Y242
215011169|NCT04464902|DEVICE|brace2|The brace1 can't provide resistance when patients want to extend their knee.
215011170|NCT04464902|OTHER|No Intervention|Control Group don't have any brace.
215011171|NCT06122051|RADIATION|Dynamic chest x-ray|Group A and Group B- posterior-anterior dynamic chest x-ray film (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
215011172|NCT06122051|DIAGNOSTIC_TEST|Spirometry|Group A and Group B- Spirometry lung function test (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
215011173|NCT02269488|DRUG|MEDI3250|MEDI3250
214406433|NCT03719677|BEHAVIORAL|Habit development intervention|Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
214406434|NCT06824649|BIOLOGICAL|Biologic Agents|Evidence by way of phase III clinical trials has shown efficacy of dupilumab, omalizumab, and mepolizumab to placebo, leading to regulatory approval and widespread clinical use. However, data from these clinical trials does not show universal improvement and ideal control of disease across all patients with Chronic Sinusitis with Nasal Polyps (CRSwNP). Successful completion of this trial will help answer some of the most pressing clinical questions related to biologics and CRSwNP. Specifically, findings will inform whether any one biologic has superior outcomes to another and whether clinicians can identify patients at baseline who are most likely to improve on biologic therapy.
215011174|NCT01351558|OTHER|Knee muscle strengthening exercises|Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
214406435|NCT05573113|DIAGNOSTIC_TEST|Bowel Ultrasound|Bowel Ultrasound
214406436|NCT05573113|DIAGNOSTIC_TEST|Abdominal radiograph|Abdominal radiograph
214406437|NCT01449929|DRUG|dolutegravir 50 mg OAD|1 x 50 mg tablet OAD
214406438|NCT01449929|DRUG|darunavir 800mg OAD|2 x 400mg tablets OAD
214406439|NCT01449929|DRUG|ritonavir 100mg OAD|1 x 100mg tablet OAD
214406440|NCT06070597|DRUG|Iclepertin|Iclepertin
214406441|NCT06070597|DRUG|Iclepertin Placebo|Placebo to Iclepertin
214406442|NCT06070597|DRUG|Moxifloxacin|Moxifloxacin
214406443|NCT06070597|DRUG|Moxifloxacin Placebo|Placebo Moxifloxacin
214406444|NCT06667856|OTHER|Asynchronous exercise group|Application of foot core training combined with lower extremity exercises using asynchronous telerehabilitation method.
214406445|NCT06667856|OTHER|Synchronous exercise group|Application of foot core training combined with lower extremity exercises using synchronous telerehabilitation method.
214406446|NCT06610370|OTHER|Group 1|95 children with spastic cerebral palsy were included. Gross Motor Function Measure-88 (GMFM-88) and Gross Motor Function Classification System (GMFCS) were applied to the cases before and after the Selective Dorsal Rhizotomy (SDR) surgery.
214406447|NCT04428164|OTHER|The Richards-Campbell Sleep Questionnaire (R-CSQ)|"Tool developed to assess patient satisfaction and comfort in the hospital setting.~The R-CSQ is a scale used to measure different aspects of sleep quality. This scale allows the patient to rate their quality and amount of sleep on a scale of 0-100. The R-CSQ allows the patient to rate six different components of their sleep, including sleep depth, sleep latency, awakenings, returning to sleep, sleep quality, and noise."
214406448|NCT04428164|OTHER|Revised American Pain Society Outcome Questionnaire (APS-POQ-R)|The APS-POQ-R can be utilized to measure perceived levels of pain in patients. The APS-POQ-R scale is a validated scale that is used in the hospital setting with reliable and consistent results. This scale measures five aspects of a patient's perception and experiences with pain and a sixth aspect including nonpharmacological interventions.
214406449|NCT06611761|PROCEDURE|Shoulder arthroscopy|Shoulder arthroscopy in procedures that cause intense postoperative pain
214406450|NCT05641467|OTHER|virtual reality glasses|OculusQuest 2 128GB brand virtual reality glasses will be used in our research. OculusQuest 2 128GB is the original all-in-one gaming system for virtual reality. It can only be used as desired with the VR headset and controllers. It adapts to its environment. In this way, it can be played standing and sitting in small and large areas. When glasses will be used on another pregnant women within the scope of COVID-19 measures, disinfection will be provided with 'DiverseyOxivir Plus (hydrogen peroxide)' surface disinfectant. Before the episiotomy repair, the video glasses will be opened, the video will be adjusted to suit the woman. In order for the repair method to be the same for all women, It will be planned to use absorbable, synthetic, braided, sterile surgical thread produced from 1-0 polyglactin.
214406451|NCT06426771|BEHAVIORAL|Dietary Inflammatory Index|The aim of this study was to compare the dietary habits of patients with PCOS and an AMH value of \>3.32 ng/ml, of patients with low ovarian reserve without PCOS and an AMH value of less than 1.2 ng/ml and of patients with normal AMH values (between 1.2-3.32 ng/ml) according to Dietary Nutrient Density according to Dietary Inflammatory Index, Dietary Phytochemical Index and Nutrient Rich Food Index.
214406452|NCT06426771|DIAGNOSTIC_TEST|hormone profile|In the routine practice of the PCOS clinic, about 7 ml of blood is taken in a vacuum gel tube for hormonal and biochemical analysis by medical staff. The blood samples are centrifuged by the researchers at 1000xg for 20 minutes. In the next step, the supernatant part is separated and transferred to 3 mL Ependorfs. These samples are used to determine the levels of anti-Müllerian hormone (AMH), oestradiol, LH and FSH, which are routinely determined at the PCOS clinic.
214406453|NCT06614283|BEHAVIORAL|Diabetes self management @ click|A mobile application tailored for patients with Type 2 diabetes, aiming to enhance their self-management practices will be used for the intervention arm. The app includes features such as medication tracking, appointment scheduling, patient data storage, advice for treatment and follow-ups, health education and promotion, and real-time health monitoring.
214406454|NCT06614803|DEVICE|Transcutaneous vagus nerve stimulation combined slow breathing|The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear,the screen of the device displays slow breathing guidance video at 0.1Hz, while the device delivered stimulation during the 5 seconds of exhalation.
215098708|NCT05150938|DRUG|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
215098709|NCT05150938|DRUG|vitamin K antagonist (VKA)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
215098710|NCT05150938|DRUG|other NOACs|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
215098711|NCT04638114|PROCEDURE|Mini-open DAA|Direct anterior approach hip
215098712|NCT04638114|PROCEDURE|Hip arthroscopy|arthroscopic treatment of hip pathology
215011175|NCT01351558|OTHER|Upper extremity strengthening exercises|Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
215011176|NCT01351558|OTHER|Cardiovascular fitness exercises|Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
215011177|NCT03834298|OTHER|Four Food Elimination Diet|Food allergens are thought to initiate eosinophilic inflammation and dietary elimination of trigger allergens is an effective treatment for EoE. Previous work demonstrates that in both children and adult EoE patients, the food antigens including cow's milk, wheat, egg, soy, peanut/tree nut and fish/shell fish, are the most common food triggers causing esophageal inflammation. Participants will be assigned to single arm treatment / intervention with a diet restricted of the four most common food allergens, milk, soy, wheat and egg, or a four food elimination diet (FFED). With the goal to optimize diet treatment, in Aim 2, eligible participants will undergo sequential food reintroductions based on protocol.
215011178|NCT06818708|DEVICE|Experimental Treatment|Percutaneous peripheral nerve stimulation with a frequency between 1-250 Hz, a pulse duration of 1-200 µs, and a current of 0.001-10 mA (1-10,000 µA). If the same pattern holds for the RELAY device as for previously tested peripheral nerve stimulators, we will maximize frequency, minimize pulse duration, and have participants adjust the amplitude, as needed.
214406455|NCT06614803|DEVICE|Transcutaneous vagus nerve stimulation|Without slow breathing guidance video on the stimulation device,the stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear
214406456|NCT06615440|DRUG|Alpha blocker|prazosin will be given to all children with systemic manifestations (orally or by nasogastric tube) at a dose of 30 μg/kg/dose;first repeat dose at 3 h followed by every 6 h till recovery. All patients will be monitored for clinical improvement with vital signs
214688358|NCT07161856|PROCEDURE|a novel balloon-assisted EUS-GE|The patients will receive EUS-NBAGE under general anesthesia with endotracheal intubation. Under direct visualization with a gastroscope, contrast medium is injected to determine the location and length of the stricture. A guidewire is then placed through the stricture into the jejunum, approximately 15 cm distal to the anal side of the stricture. A double-balloon device is inserted over the guidewire. The anal-side balloon is inflated with about 40 mL of air, and under fluoroscopy, the balloon is confirmed to be well inflated. A mixture of contrast medium and methylene blue in a 1:1 dilution is injected into the proximal small intestine through the water injection channel at the proximal end of the catheter. A linear echoendoscope is inserted into the mid-body of the stomach on the greater curvature side to scan the distended small intestine loop. After identifying the distended small intestine loop, a HOT-AXIOS 1.5×1.0cm LAMS is placed under direct visualization.
215011179|NCT03764553|DRUG|Liposomal Irinotecan|Iv liposomal irinotecan
215011180|NCT03764553|DRUG|Carboplatin|IV Carboplatin
215011181|NCT03764553|DRUG|Capecitabine|PO Capecitabine
215011182|NCT03764553|DRUG|Oxaliplatin|IV Oxaliplatin
215098713|NCT06166368|OTHER|Diurnal variation|Venous blood samples were obtained under standardized circumstances from 24 healthy young men every third hour through 24 hours, nine time points in total.
215098714|NCT00615030|DRUG|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
215011183|NCT03764553|DRUG|5-fluorouracil|IV 5-fluorouracil
215011184|NCT03764553|DRUG|Leucovorin|IV Leucovorin
215098715|NCT00615030|DRUG|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
215098716|NCT00615030|DRUG|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
215098717|NCT00615030|DRUG|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
215098718|NCT02021903|OTHER|V1: HGPO + meal and V2: placebo + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
215098719|NCT02021903|OTHER|V1: placebo 75mg + meal and V2: HGPO 75mg + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
215098720|NCT00151476|DRUG|Celecoxib|800 mg total daily dosing
215098721|NCT00151476|OTHER|Routine Medical Care|
215098722|NCT06250335|OTHER|Prebiotic Food-Enriched Diet|Given by PO
215098723|NCT06250335|DRUG|Ipilimumab|Given by IV
215098724|NCT06250335|DRUG|Nivolumab|Given by IV
215011185|NCT06219122|BEHAVIORAL|Creative arts and psychomotor therapies intervention for people with personality disorders|a Group (max of 9 participants) Creative arts and psychomotor therapies (CAPTS) intervention for people with personality disorders. Consisting of 10 sessions, where two CAPTS disciplines and therapists are represented each session. Each session lasts 90 minutes. Sessions are aimed at psychological adativity thru=ough the CAPTS. The sessions cover warming up in one of the CAPTS, short psycho education and a longer assigment focusing on the session goal. The first half of the interventions focusses mainly on listening to body signals, emotions and emotional needs and dealing in a healthy way with these. The second half will be more complex when dealing with challenges and adapting tot he context in a healthy way are goals of the sessions.
215011186|NCT03401333|BEHAVIORAL|Text Messaging and Brief Negotiation Interview|An in-person brief motivational intervention coupled with 4 weeks of motivational text messages
215011187|NCT01245062|DRUG|GSK1120212|MEK inhibitor
215011188|NCT01245062|DRUG|Chemotherapy|Investigator Choice of DTIC or paclitaxel
214406457|NCT06615180|BEHAVIORAL|Transcultural Nursing Course (new curriculum)|"Multinational Collaboration: Developed with input from institutions across five countries, ensuring a broad, international perspective on transcultural nursing.~Comprehensive Theoretical Framework: Integrates multiple cultural competence models (Purnell, Campinha-Bacote, Papadopoulos) with Leininger's Culture Care Theory, offering a thorough approach.~Extensive Practical Training: Includes 17 hours of hands-on experience, featuring hospital visits and interactions with healthcare professionals.~Interactive Learning Methods: Combines role-playing, reflective essays, and cultural activities (e.g., traditional clothing, dances) for dynamic, multimodal education.~Peer Education: Incorporates peer education and evaluation, enhancing collaborative learning and critical thinking.~Standardized Materials: Educational materials and teaching methods are standardized across institutions to ensure consistency and quality in instruction."
215011189|NCT06825559|DRUG|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in this open label study
215011190|NCT06025695|COMBINATION_PRODUCT|GSK's liquid oral live attenuated HRV|2 doses of GSK's liquid oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
215011191|NCT06025695|COMBINATION_PRODUCT|PCV-free liquid formulation of GSK's oral live attenuated HRV|2 doses of PCV-free liquid formulation of GSK's oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
215011192|NCT06855875|PROCEDURE|autogenous tooth graft combined with bovine bone|unilateral alveolar cleft which will be repaired using autogenous tooth graft combined with bovine bone .
215011193|NCT06855875|PROCEDURE|bovine bone|unilateral alveolar cleft which will be repaired using bovine bone .
215011194|NCT06092151|DEVICE|Silver diamine fluoride|silver diamine fluoride - maximum 1 drop to be applied per visit (manufacturer advises this would treat up to 5 teeth)
215011195|NCT06092151|PROCEDURE|Usual dental care|Usual restorative or preventative care determined by the child's dentist - for examples fillings or crowns
215098725|NCT04207437|DEVICE|Vibration therapy|vibration therapy using hand held vibration device
215098726|NCT04117243|DRUG|Misoprostol|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)
215098727|NCT04117243|DRUG|Tranexamic acid|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)
214406458|NCT06613594|OTHER|Conventional physical therapy|Patients will receive hot pack, Broom stick ROM exercises, Codman and strengthening exercises. A total of 10 sessions, 5 sessions per week for 2 consecutive weeks.
214406459|NCT06613594|OTHER|Kaltenborn traction mobilization|kaltenborn direction non specific traction mobilization for (1 minute), 3 sets of 10 reps with 1 minute rest in between will be given.
214406460|NCT06613594|OTHER|Kaltenborn translatoric glides|Kaltenborn direction specific linear tranlatoric glides, rhtymic 5reps of each glide, such anterior glide for extension and external rotation, caudal glide for abduction,post glide for flexion and internal roation,these3 sets of painless glides will performed with 10 reps,rest of 1 minutes between these sets.
215011196|NCT06859593|DIAGNOSTIC_TEST|Upper Extremity Exercise Capacity, 6-Minute Pegboard And Ring Test|Upper Extremity Exercise Capacity
215011197|NCT02837653|BEHAVIORAL|Physical Activity Counselling|
215098728|NCT04117243|DRUG|Oxytocin|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
215098729|NCT05123963|BEHAVIORAL|High-intensity interval training|3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.
215098730|NCT05052567|DRUG|CEND-1|The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine
214406461|NCT06615596|BEHAVIORAL|discontinue anticoagulation therapy|Participants in the discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
215011198|NCT02837653|OTHER|Therapeutic Exercise for LBP|
215011199|NCT02837653|OTHER|Superficial Thermotherapy|
215011200|NCT05960656|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
215011201|NCT05960656|OTHER|Placebo|Inert tablet
215011202|NCT03289000|DEVICE|iTotal Posterior Stabilized (PS) Knee Replacement System|Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
215011203|NCT06996626|DEVICE|Revealed Alerts|Bedside reveal of alerts generated by the alerting system
215098731|NCT03446456|DRUG|Arginine vasopressin|Intranasal vasopressin will be administered shortly before the fMRI experiment.
215098732|NCT03446456|OTHER|Saline|Intranasal saline will serve as a placebo for participants in the Saline Arm
215098733|NCT03446456|BEHAVIORAL|Observational learning|During the observational learning intervention, participants will learn the experience of analgesia in another person via a video. Participants will learn the analgesia nature of the placebo cream and the neutral nature of the control cream.
214406462|NCT06615596|DRUG|Anticoagulant drugs|Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles. The discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
214406463|NCT06615596|PROCEDURE|Catheter Ablation|Catheter ablation is a medical procedure used to treat atrial fibrillation (AF) by targeting and destroying small areas of heart tissue that cause irregular heartbeats. Using a specialized catheter, radiofrequency energy, cryotherapy, or pulsed field ablation (PFA) is applied to isolate the pulmonary veins or ablate other specific heart areas. The goal is to restore normal heart rhythm by electrically isolating problematic areas responsible for AF. This FDA-regulated procedure is minimally invasive and requires follow-up monitoring for AF recurrence and other potential complications. No specific ablation technique is mandated, allowing flexibility for operators to choose based on their expertise and center practices. The ablation strategy may include pulmonary vein isolation or additional procedures based on the type of AF. This approach distinguishes the study by providing real-world applicability, reflecting the diversity of ablation methods used in clinical practice.
214406464|NCT06613386|OTHER|The information-based discharge preparation service (IBDPS)|"The main modules of the IBDPS platform include:~* Establishing information records for infants and parents.~* Collaboratively identifying existing or potential caregiving challenges.~* Assessing parents' emotional and psychological states, providing support and intervention.~* Collaboratively establishing caregiving objectives with parents.~* Collaboratively formulating and executing caregiving plans.~* Assessing parental support resources, offering analysis, assistance, and necessary referrals.~* Conducting outcome assessments."
214406465|NCT03035071|PROCEDURE|minimally invasive esophagectomy|In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.
214406466|NCT03035071|PROCEDURE|open esophagectomy|in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.
214406467|NCT06613607|OTHER|Core Strengthening|"Strengthening protocol will comprise of following three phases:~Warm up phase Following exercise would be performed in warm up; Scissor skier, Criss cross crunches, , Hip circles, Bent over twist.~Strengthening:~Abdominal bracing Bracing with heel slides Bracing with leg lifts Bracing with bridging Quadruped alternate arm and leg lifts with bracing Side support with knees flexed Cool down phase: Following exercise would be performed for cood down: Child's pose, Cat cow stretch, Lower back stretch, Obliques stretch"
214406468|NCT06613646|PROCEDURE|Ultrasound-guided injection of the subacromial bursa and pectoralis minor|"Patients will first receive an ultrasound-guided injection of the subacromial bursa. After the subacromial bursa injection, patients will be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the Numeric Rating Scale (NRS), and passive range of motion will be measured.~Following the subacromial bursa injection, patients will receive an ultrasound-guided injection of the pectoralis minor muscle. After the pectoralis minor muscle injection, patients will again be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the NRS, and passive range of motion will be measured."
214406469|NCT06613646|DRUG|Lidocaine (drug)|5 mL of 2% lidocaine will be used as a local anesthetic for the subacromial bursa injection, and 4 mL of 2% lidocaine will be used for the pectoralis minor muscle injection.
214406470|NCT04313530|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS treatment fatigue is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks connectivity changes involved in the processing of fatigue signals.
214406471|NCT01871285|DRUG|Buprenorphine|
214406472|NCT01871285|DRUG|Placebo film|Matching placebo buccal film
214406473|NCT01871285|DRUG|Oxycodone|Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
214406474|NCT01871285|DRUG|Morphine sulfate|Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
214406475|NCT01871285|DRUG|Placebo capsule|Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
215011204|NCT06996626|DEVICE|Unrevealed Alerts|Alerts will be generated but not revealed.
215011205|NCT06518993|DEVICE|Total hip arthroplasty with a Trinity cup and a Meije Duo cementless stem|Subjects clinically suitable for a primary THR surgery with Trinity cup and Meije Duo cementless femoral stem.
215011206|NCT03834883|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
215011207|NCT03834883|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
215011208|NCT06517017|DRUG|Isatuximab|Subcutaneous isatuximab will be administered weekly on a 28-day cycle during the first two cycles, and every two weeks of a 28-day cycle thereafter. Dexamethasone will be administered on the days of isatuximab administration and can be discontinued after two cycles of therapy, or continued at discretion of investigator. Lenalidomide, will be added after two cycles of therapy have been completed.
215011209|NCT06524531|PROCEDURE|Pulsed RF Neuromodulation|RF neuromodulation will be applied to the L2 and L3 segments bilaterally. Each segment will receive treatment for 6 minutes, either sequentially or simultaneously on both sides.
215011210|NCT06524531|BIOLOGICAL|Leukocyte-Rich PRP Injection|Leukocyte-rich PRP will be prepared from the patient's blood and injected into the multifidus muscle at the L2 and L3 levels.
215011211|NCT06524531|PROCEDURE|Physiotherapy Alone|Standard physiotherapy regimen tailored to each participant's needs. This may include exercises to improve flexibility, strength, and endurance of the back muscles, as well as education on posture and body mechanics.
215011212|NCT01398527|OTHER|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
215011213|NCT05147571|DEVICE|Responsive stimulation|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
215011214|NCT05147571|DEVICE|Sham stimulation|For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.
215098734|NCT03446456|OTHER|fMRI data aquisition|All participants from the intranasal vasopressin and intranasal saline groups will go through a fMRI data acquisition to obtain the brain structural, brain resting-states and functional MRI scans.
215098735|NCT06139289|PROCEDURE|EVD placements in the OR versus the bedside.|Reducing EVD-related complications
214406476|NCT01959880|DEVICE|The Contour Profile Gel (CPG) breast implants|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.~The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study."
214406477|NCT06919393|OTHER|"Triple negative adul B-cell ALL"|"Samples will be studied with conventional techniques to classify and define properly the disease: morphology, immunophenotype, immunohistochemistry (IHC), conventional Cytogenetic Fluorescence in Situ Hybridization (FISH) will be used when appropriate.~● Isolation of Mononuclear cells~The following research methodologies will be applied:~* Next Generation Sequencing~* Flow cytometry analysis of 3C-up B-ALL top three markers~* Gene expression profile analysis~* Copy number Alterations analysis~* In vitro studies"
214406478|NCT04918108|BIOLOGICAL|inflammatory response|laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)
214406479|NCT01919619|BIOLOGICAL|Ipilimumab|Given IV
214406480|NCT01919619|DRUG|Lenalidomide|Given PO
214406481|NCT06682624|DEVICE|MRI|Magnetic Resonance Imaging in recognition of pediatric neurodegenerative disease patterns
214406482|NCT06685276|DRUG|Fruquintinib|Fruquintinib: 5mg qd, po, 2 weeks on/1 week off, q3w, or 3mg qd, po, q3w.
214406483|NCT06685276|DRUG|Sintilimab|Sintilimab: 200mg, iv, d1, q3w.
214406484|NCT06685276|DRUG|Chidamide|Chidamide: 30mg/m2, po, biw.
214406485|NCT06631573|OTHER|fixed all-on-four prosthesis reinforced with PEEK framework.|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with PEEK framework.
214406486|NCT06631573|OTHER|Fixed all-on-four prosthesis reinforced with Co-Cr framework|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with Co-Cr framework
214406487|NCT06628466|DRUG|Nuberol Forte|Quality of Life study
214406488|NCT06629428|DRUG|Ublituximab|The participants will receive 48 weeks of treatment with ublituximab.
214406489|NCT06137755|BIOLOGICAL|CVI-VZV-001|Investigational Product
214406490|NCT06137755|BIOLOGICAL|Shingrix|Investigational Product
214406491|NCT06696248|DRUG|Carvedilol and alverine|On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60 mg and simeticone 300 mg; manufactured by Laboratoires MAYOLY SPINDLER), at a dosage of 180 mg/day (1 capsule orally, 3 times a day), for a continuous period of 24 weeks.
214406492|NCT06697639|BEHAVIORAL|Rehabilitation Group|In addition to routine postpartum care, small-sized WAFF air cushions will be issued during the hospitalization period to guide patients in performing the WAFF pelvic-abdominal mechanical rehabilitation exercises. Patients will also be instructed to join the experimental group's WeChat group. After discharge, researchers will upload WAFF pelvic-abdominal mechanical rehabilitation instructional videos. Patients are required to complete their rehabilitation exercises twice daily, each session lasting 10-15 minutes. Patients need to upload their exercise videos twice a week, and researchers will provide motion guidance based on the video content until the patient's postpartum follow-up examination. The abdominal rectus muscle, pelvic floor muscle function, and adherence to rehabilitation exercises will be assessed for patients in both groups at 6-8 weeks and 6 months postpartum.
215011215|NCT07030270|PROCEDURE|Surfactant Administration through Laryngeal or Supraglottic Airway|"Surfactant Administration through Supraglottic Airway Devices~* Air-Q3 size 0 for neonates: \< 2 kilograms~* i-gel supraglottic airway size 1 for neonates: ≥ 2 kilograms"
215011216|NCT07030270|PROCEDURE|Surfactant Administration through Thin Catheter|Thin Catheter
215011217|NCT07030309|OTHER|Gastroschisis|"Gastroschisis (GS) is a congenital abdominal wall defect in which the intestine is located outside the abdominal cavity. The prevalence of the GS classifies it as a rare disease (ORPHA:2368) Pregnancy complicated by gastroschisis is associated with an increased risk of serious perinatal complications.~The presence of accompanying intestinal anomalies (atresia, necrosis, perforation, and volvulus), which qualifies the defect in the cGS (complex gastroschisis) group, as opposed to sGS (simple gastroschisis), where these anomalies are absent.~cGS is associated with significantly increased neonatal morbidity and mortality when compared to sGS."
214406493|NCT06697548|OTHER|Pain Neuroscience Education|Participants will watch and discuss a short (5-minute) standardized pain neuroscience education video with their treating provider. The video explains and illustrates how chronic pain is different than acute pain in that it concerns nervous system hypersensitivity more than local tissue damage. Pain neuroscience education principles from the video will then be used to throughout all interventions to coach the participants through graded exposure of activities that may have previously been painful or provoked anxiety.
214406494|NCT06697548|OTHER|Lumbopelvic and Hip Therapeutic Exercise|These motor control exercises will focus on proprioception, coordination, and sensorimotor control training and include progressive exercises that focus on transversus abdominis, lumbar multifidus, diaphragmatic, pelvic floor muscles, and deep hip stabilizers. Exercises will progress from more stabilized (e.g., pelvic tilt, cat and cow) to less stabilized and more dynamic and functional (e.g., forward bending, eccentric squat) to mimic the demands of work duty. Exercise will be trained and progressed during the clinical visits and be performed daily at home.
214406495|NCT06697548|OTHER|Extrapelvic Manual Therapy|Thrust and non-thrust manual therapy will be applied to the lumbar facet, sacroiliac, and hip joints based upon the clinical exam in a semi-standardized manner
214406496|NCT06697548|OTHER|Extrapelvic Dry Needling|Dry needling treatment to muscles of the lumbopelvic and upper thigh regions in a semi-standardized manner based upon a palpatory examination. The palpatory examination will include the erector spinae, lumbar multifidi, gluteus medius/minimus, piriformis, illiacus, and hip adductor muscles.
214406497|NCT06697548|OTHER|Deep Paced Diaphragmatic Breathing Training|The breathing intervention will start with education describing the link between the diaphragm and the pelvic floor to include awareness of any breath holding patterns and finding positions that facilitate expansion of the ribs, abdominals, and pelvic floor muscles with inhalation. Then progressive training will be given to encourage deep breathing at a pace of approximately 6 breaths per minute.
214406498|NCT06697548|OTHER|Chronic Pelvic Pain Education|During the first visit, participants will receive and briefly discuss the 2023 standardized patient educational handout created by the International Pelvic Pain Society with their treating provider. The educational handout describes chronic pelvic pain etiology, typical symptoms, examination, and treatments.
214406499|NCT06697548|OTHER|Intravaginal and intrarectal pelvic floor physical therapy|Superficial vulvar, perineal and intravaginal manual therapy and biofeedback utilizing commonly used techniques in previous research selected based on identified impairments from the pelvic floor examination will be performed.
215011218|NCT05407896|OTHER|myKIDNEY decision aid|Patients and caregivers will be counselled using myKIDNEY decision aid which includes a video. Patients will be asked to complete a values clarification exercise (VCE). If a caregiver is recruited without their patient, he/she will be asked to complete the VCE on patient's behalf (i.e., surrogate). At the end of VCE, the participant will be given real-time feedback on which treatment might be the best fit for the patient. With the patient's consent, this information will be shared with the treating physician who can then make recommendations based on the patient's preferences.
215011219|NCT05898633|DRUG|Recombinant fragment of human surfactant protein D (rfhSP-D)|Administration of rfhSP-D
215011220|NCT07036562|BEHAVIORAL|Time-restricted eating and high-intensity interval training|1-month intense periods of maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum), separated by 3-month maintenance periods of time-restricted eating on 5 days per week and minimum 1 HIIT session per week. Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly during intense periods, and once monthly during maintenance periods. The intervention period will be 12 months in total.
215011221|NCT07032480|BEHAVIORAL|Survey-Based Assessment|Participants completed standardized questionnaires including the Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), and Neck Disability Index (NDI) to evaluate psychological and functional outcomes associated with sleep quality. No experimental intervention was administered.
215011222|NCT07039331|DIETARY_SUPPLEMENT|Short Term Fasting|Short Term Fasting during the first three cycles of NACT (36h before and 24h after the end of each cycle of CT).
215011223|NCT07039331|OTHER|Free Diet|Ordinary diet during the first three cycles of NACT without any change.
215011224|NCT07037862|DRUG|ENTR-601-44|intravenous infusion
215011225|NCT07037862|DRUG|ENTR-601-44 - matching placebo|intravenous infusion
215011226|NCT06710288|DRUG|Gemcitabine|Dose: 800 mg/m2 intravenously (IV) Frequency: administered on Day 1, Day 8, and Day 15 of each cycle (every 4 weeks)
214688359|NCT07161856|PROCEDURE|direct EUS-GE|"The patients will receive EUS-DGE under general anesthesia with endotracheal intubation. Under direct visualization with a gastroscope, a guidewire and/or nasobiliary catheter is passed through the stricture into the jejunum. A mixture of contrast medium and methylene blue is injected to distend the target intestinal loop. An echoendoscope is introduced into the stomach to select the optimal puncture site.~A 19G or 22G puncture needle is used to puncture the gastric and jejunal walls. Aspiration of fluid confirms the needle tip is in the jejunum, after which the channel is dilated over the guidewire. Using the delivery system of an electrocautery-enhanced fully covered lumen-apposing metal stent (LAMS), the stent is deployed to complete the gastrojejunostomy."
215011227|NCT06710288|BIOLOGICAL|N-803|Dose: fixed dose of 1.2 mg subcutaneously (SC) Frequency: administered on Day 1 and Day 15 of each cycle starting at Cycle 2 (every 4 weeks) and when the last dose of M-CENK is administered, N-803 will be administered on Days 1 and 15 of the same cycle followed by 3 additional doses, 2 weeks apart (total of 5 N-803 doses).
215098736|NCT02982876|PROCEDURE|Dynamic Flexible Bronchoscopy|The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuvers will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle
215098737|NCT02982876|PROCEDURE|Rigid Bronchoscopy|Under general anesthesia, a rigid bronchoscope (Bryan-Dumon Series II; Bryan Corporation; Woburn, MA) will be introduced, and respiration will be maintained through jet ventilation.
215011228|NCT06710288|BIOLOGICAL|M-CENK|Dose: 0.15 to 0.75 × 109 cells per infusion intravenously (IV) Frequency: administered on Day 1 of each cycle as long as M-CENK cells are available.
214406500|NCT06697249|OTHER|Analysis of postoperative CT scans checking for the feasibility of transcatheter valve-in-root implantation|CT scans of patients after biological root replacement and root repair were assessed with the 3mensio Software (Aortic valve package, 3mensio 10.1, Pie Medical Imaging. Before carrying out the measurements, markers for alignment of the aortic root and ascending aorta were placed manually. The annular area was measured for both groups. In patients after biological root replacement the area of the annulus was defined as the ring of the initial aortic valve prosthesis. Coronary buttons were measured at their lowest and highest point to define partial or full position below the valve level and the general button size. For assessment of the annular-to-coronary distance, the lower edge of the coronary button was chosen. VTC was assessed after root replacement in patients who had at least one coronary partially under the level of the valve. For this measurement a virtually inserted valve was placed in the bioprosthetic frame.
215011229|NCT07039565|OTHER|Stretching and strengthening exercises|Strengthening exercises were progressively performed for three sets, with 10 to 15 repetitions. The stretching part of the exercises was done with the purpose of increasing the flexibility of the pectoralis and the cervical neck extensors muscles (pectoralis stretch, chin tuck). Exercises have been approved to be effective on the lengthening of the pectoralis minor, activation of the lower trapezius/middle trapezius, serratus anterior, and improvement of the posture
215011230|NCT07039565|OTHER|Diaphragm release technique|the patient will positioned in the supine position. The therapist stand at the head of the patient. The therapist make manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ) with hypothenar regions of the hands and last three fingers. During the patient's inspiration, the therapist is gently pulling the points of hands contacts toward the head and slightly laterally, while elevating the ribs simultaneously
215011231|NCT07043907|DRUG|PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy|PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy
215011232|NCT07046364|DRUG|Remimazolam|After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of remimazolam), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of remimazolam). The infusion is expected to stop 10 minutes before the end of the surgery.
215011233|NCT07046364|DRUG|Normal Saline|After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of normal saline), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of normal saline). The infusion is expected to stop 10 minutes before the end of the surgery.
215011234|NCT07045246|PROCEDURE|Coenzyme Q 10|Patients received Coenzyme Q 10 as a graft material in unilateral maxillary alveolar cleft
215011235|NCT07045246|PROCEDURE|iliac bone graft|iliac bone used as a graft for alveolar cleft reconstruction
215011236|NCT07044765|DRUG|Comparator 1|Dapagliflozin 10mg + Linagliptin 5mg
215098738|NCT02982876|DEVICE|Stent placement|Silicone Y stent or uncovered self-expanding metallic stent will be placed in the standard fashion and good fit will be confirmed visually.
215098739|NCT06414278|OTHER|Non-Interventional Study|Non-interventional study
215098740|NCT04545957|DEVICE|MRI Simulator|Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.
215098741|NCT04545957|RADIATION|Radiation Therapy|In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.
215098742|NCT06295783|OTHER|MDASI-HN|Given by Questionnaire
215098743|NCT06295783|OTHER|EORTC QLQ-C30|Given by Questionnaire
215098744|NCT06295783|OTHER|EORTC HN35|Given by Questionnaire
215098745|NCT04532931|DRUG|Paracetamol|SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed
215011237|NCT07044765|DRUG|Comparator 2|Metformin 1000mg
215011238|NCT07044765|DRUG|Test Drug|Fixed-dose combination tablet (AJU-A53)
215011239|NCT07045025|OTHER|No Clinical Intervention - Analysis of Previously Acquired CBCT Scans|This study does not involve any clinical or therapeutic intervention. It is solely based on the retrospective analysis of previously acquired CBCT scans from patients who have undergone root canal treatment. No drugs, devices, or procedures are administered or applied to participants as part of this study.
215011240|NCT07046065|DEVICE|Non-cycloplegic Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer without cyclopegia
215011241|NCT07046065|DEVICE|Non-cycloplegic conventional subjective refraction|Performed with Vision-R™
215011242|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vA with Vision-R™)|Performed with Vision-R™
215098746|NCT04532931|DRUG|Artesunate-amodiaquine|SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days
215098747|NCT04532931|DRUG|Pyronaridine-artesunate|SOC plus pyronaridine-artesunate (PA) Weight 45 to \<65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days
215098748|NCT04532931|DRUG|Favipiravir plus Nitazoxanide|SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days
215011243|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vA with Vision-S™)|Performed with Vision-S™
215011244|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vB with Vision-R™)|Performed with Vision-R™
215098749|NCT04532931|DRUG|Sofosbuvir/daclatasvir|"SOC plus sofosbuvir/daclatasvir (SOF/DCV)~1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days"
215098750|NCT02917733|DRUG|LY3039478|Administered orally
215098751|NCT06019338|OTHER|Pain Diary use|Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia
215098752|NCT06650839|DEVICE|NIUT|Treatment of moderate aortic stenosis using non-invasive ultrasound therapy delivered by Valvosoft
215098753|NCT06447506|DRUG|GSK1070806|Participants will receive GSK1070806.
215011245|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vB with Vision-S™)|Performed with Vision-S™
215011246|NCT07046065|DEVICE|Cycloplegic subjective refraction (Kids refraction software vA with Vision-R™)|Performed with Vision-R™
215011247|NCT07046065|DEVICE|Cycloplegic subjective refraction (Kids refraction software vA with Vision-S™)|Performed with Vision-S™
215011248|NCT07046065|DEVICE|Cycloplegic Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer with cyclopegia
215011249|NCT07046065|DEVICE|Non-cycloplegic Retinoscopy|Performed with a retinoscope without cycloplegia
215011250|NCT07046065|DEVICE|Cycloplegic retinoscopy|Performed with a retinoscope with cycloplegia
215011251|NCT07045506|OTHER|UVC insertion|"UVC insertion was performed under sterile conditions according to the unit protocol by a senior NICU physician. For preterm deliveries, written informed consent was obtained from a parent before enrollment in the study. In emergency cases, where the neonate required immediate UVC insertion upon admission to the NICU, a waiver of informed consent was applied. In such instances, parents were informed as soon as possible about their infant's participation in the study, provided with written information, and asked for their consent to include their infant's data in the analysis, with the option to give consent via telephone if they were unable to be present in person.~After UVC insertion, anteroposterior and lateral thoracoabdominal radiographs were performed to verify the position of the UVC tip."
215011252|NCT07046299|PROCEDURE|Endovascular Therapy Plus Best Medical Treatment|Participants assigned to the endovascular therapy arm will receive EVT in addition to best medical treatment. EVT must be initiated within 24 hours of symptom onset and completed within 3 hours of groin puncture. After evaluating vascular anatomy, neurointerventionalists will determine the most appropriate strategy based on the presence of proximal stenosis, occlusion morphology, and vessel tortuosity. Permitted interventions include mechanical thrombectomy, stent thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, and stent implantation. The choice of treatment approach is left to the discretion of the treating physician, and combinations of techniques are allowed.
215011253|NCT07046299|DRUG|Best Medical Treatment Alone|Participants in this arm will receive best medical treatment and maximal supportive care according to current stroke guidelines, without the use of mechanical thrombectomy or any intra-arterial intervention.
214406501|NCT06632262|DRUG|ABSK061 + ABSK043|Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
214406502|NCT06632262|DRUG|ABSK061+ABSK043 in combination with CAPOX|Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
214406503|NCT06697275|DEVICE|Hypnotic Virtual reality|Hypnotic Virtual reality mask Deepsen® with age-appropriate software Birdy®
214406504|NCT06697275|DEVICE|Interactive virtual reality|Interactive virtual reality mask Deepsen® with age-appropriate software Birdy®
214406505|NCT06697275|OTHER|Standard method|Use of local anesthesic cream + Nurse and/or parents distraction +/- anxioloytic gas
214406506|NCT06696495|DIAGNOSTIC_TEST|Measurement of the size and width of the foot|Assessment of the height of the plantar arch using a podoscope, and application of functional scales such as the AOFAS (Ankle and Foot Outcome Score), the FPI (Foot Posture Index) and the FFI (Foot Function Index). In addition, the distribution of plantar pressure and the centre of pressure (COP)
214406507|NCT06697795|DEVICE|Virtual Reality-Assisted Hypnotherapy|Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic neck pain.
214406508|NCT06697795|OTHER|Standard Physical Therapy|Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
215011254|NCT07046754|OTHER|type of consultation|urgence care, permance care
215011255|NCT07044427|OTHER|Strength and balance training in combination with a treadmill-based pertubation intervention|Patients receive a personalized home-based training plan with strength and balance exercises to be carried out three times a week for six months. In addition, treadmill-based pertubation training is carried out at 2 timepoints.
215011256|NCT07046533|PROCEDURE|(pulpotomy)|non invasive technique depends on remove only the coronal pulp tissue instead of remove all pulp tissue
215011257|NCT07046533|PROCEDURE|root canal treatment|invasive technique depends on remove all radicular and coronal pulp tissue
215011258|NCT07045662|BEHAVIORAL|Multidisciplinary Assessment|"The participants in the multidisciplinary assessment were followed by multidisciplinary teams from the study target-units, by individual and collective interviews, which mirror the care protocol. The frequency of individual visits was at least every six months by a nurse, a physician, and a nutritionist.~Regarding the collective activities, the educational groups met for approximately 1 hour and 30 minutes on monthly basis over a period of six months. Considering that there were two FHU in the IG, each team held one activity per month.~For the development of the collective activities, methods recognized for intensifying integration and participation, such as using simple language and confirming the participants' understanding of the information covered in the group were recommended."
215011259|NCT07044492|BEHAVIORAL|Virtual Reality (VR) with Debriefing|Participants will receive a weekly 5-minute VR session featuring immersive experiences of residents' lives within the facility, followed by a 25-minute debriefing discussion in small groups of 5\~6 participants. This will continue for three weeks.
214406509|NCT06697119|OTHER|Fecal Microbial Transplantation|Fecal suspension is delivered to duodenal 3rd portion via esophagogastroduodenoscopy
214406510|NCT06713044|DEVICE|Murottal Therapy Intervention Name: Murottal (Islamic verse recitation)|To evaluate whether murottal recitations can reduce postoperative pain intensity and lower interleukin 6 levels, which are indicative of inflammation.
214406511|NCT06713044|DEVICE|Classical Music Therapy Intervention Name: Classical Music Listening|To evaluate the impact of classical music on reducing postoperative pain intensity and interleukin 6 levels in the body, thereby managing inflammation.
214406512|NCT06713044|OTHER|Standard Care (in control arm)|To serve as a control group no intervention
214406513|NCT06696755|DRUG|Icalcaprant|Oral Capsules
214406514|NCT06696755|DRUG|Placebo for Icalcaprant|Oral Capsules
214406515|NCT04794621|DEVICE|Electroceutical Dressing Technology-EDThi|Use of EDThi for 3 weeks post enrollment
214406516|NCT04794621|DEVICE|Adding EDTlo (Procellera®) for 3 weeks after use of EDThi|Use of EDTlo (Procellera®) for additional 3 weeks
214406517|NCT06911827|DRUG|QLP2117|Specified dose on specified days
214406518|NCT06911827|DRUG|QL2107|Specified dose on specified days
214406519|NCT06920212|PROCEDURE|FMT capsule|Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
214406520|NCT06919744|DRUG|Best medical care|Acetazolamide will be introduced at the time of papilledema discovery. Weight loss will be recommended.
214406521|NCT06919744|DEVICE|Intervention (stenting)|Transverse venous sinus will be stented by neuro-radiological intervention
214406522|NCT05396547|DEVICE|Treated with Ledinbio device|Treated with Ledinbio device
214406523|NCT04286555|OTHER|DASH4D diet|"DASH stands for Dietary Approaches to Stop Hypertension. The DASH diet is a healthy dieter that lowers blood pressure. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages. The DASH4D dietary pattern is a version of the DASH diet that is lower in carbohydrate."
214406524|NCT04286555|OTHER|comparison diet|The comparison dietary pattern is based on a typical American diet, with macronutrient distributions generally at the average of typical US intake, and micronutrient targets generally near the 25th percentile of usual US intake (with the exception of sodium).
214406525|NCT04286555|OTHER|higher sodium|3700 mg/day sodium (at the 2000 kilocalorie level)
214406526|NCT04286555|OTHER|lower sodium|1500 mg/day sodium (at the 2000 kilocalorie level)
214406527|NCT06918184|BEHAVIORAL|Specific Exercise Therapy|The exercise protocol includes mobilisation and stretching with 40-minute sessions twice weekly for 8 weeks post-initiation, transitioning to a home-based maintenance phase for 4 months. All sessions will be supervised by certified physiotherapists.
214406528|NCT05096299|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
215011260|NCT07044739|BEHAVIORAL|Patient Education on the Use of Anti-Embolic Stockings|"The researcher will provide verbal information to the patients with the educational material titled Use of Anti-Embolic Stockings, the stages of wearing anti-embolic stockings will be shown to the patients, and the educational material will be left next to the patients in the intervention group. The educational content covers the purpose of using anti-embolic stockings, how to use them, and the points to be considered during use."
214406529|NCT04834024|DRUG|Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide|The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.
214406530|NCT04834024|DRUG|lenalinomide|The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.
214406531|NCT03992638|PROCEDURE|leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF|Completing root coverage by coronally advanced flap technique in combination with L-PRF.
214406532|NCT03992638|PROCEDURE|CAF|Completing root coverage by coronally advanced flap technique alone
214406533|NCT04406779|DEVICE|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
214406534|NCT01955382|DRUG|Actidose Aqua|Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
214406535|NCT01955382|DRUG|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
214406536|NCT01955382|DRUG|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
214406537|NCT06329804|OTHER|Isometric Handgrip Exercise Training (IHGT)|Each IHGT session will consist of 4 x 2-minute contractions at 30% maximal voluntary contraction, with 2-minutes of rest in between, performed with the dominant hand. Training will be performed using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong).
214406538|NCT04610684|DRUG|Carboplatin|Carboplatin 5-6 mg/mL/min AUC will be delivered over 30 - 60 minutes intravenously on Day 1 of each 21 day Cycle after completion of atezolizumab. For 4 cycles.
214406539|NCT04610684|DRUG|Etoposide|Etoposide 80-100 mg/m2 will be delivered over 60 minutes intravenously on Days 1-3 of each 21 day Cycle after completion of carboplatin (Day 1 only). For 4 cycles.
214406540|NCT04610684|DRUG|Atezolizumab|Atezolizumab 1200 mg will be delivered over 60 (± 15) minutes intravenously on Day 1 of each 21 day Cycle for 4 cycles then continue as monotherapy maintenance with the same schedule.
215011261|NCT07040943|BIOLOGICAL|IL-22BP|During the injection of IL-22BP, there were three dose groups, namely 50 μg, 100 μg, and 150 μg of mRNA, with three participants in each dose group, aiming to evaluate the safety and tolerability of the IL-22BP. The treatment will be administered by intratumoral injection. Enrolled subjects will receive inoculations of IL22BP injection according to their respective dose groups, which include 5 doses for basic immunization and subsequent personalized treatment. During the basic immunization, the first 4 doses will be given at an interval of 1 week each, and the 5th dose will be inoculated 1 month after the 4th dose.
215098754|NCT04099511|BEHAVIORAL|Usual Care Occupational Therapy-Outpatient|The control group in the proposed study will receive usual care occupational therapy services. The dosage between the experimental group and usual care will be identical with each group receiving ten 45- minute treatment sessions. The treating therapists will be unfamiliar with the experimental group intervention to avoid contamination. Each therapist will be instructed to provide care in the same manner as they typically provide in day-to-day practice for patients with similar characteristics as those in the study. The therapists will be encouraged to provide home action plans to participants. Usual care services will be monitored through a log of number of sessions, time spent in each session, and what activities were the focus of each session. The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
214406541|NCT05079217|BIOLOGICAL|High-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
214406542|NCT05079217|BIOLOGICAL|Medium-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
214406543|NCT00361998|DRUG|NITROFURANTOIN MACROCRYSTALS|
214406544|NCT02190838|DRUG|Metformin|per os 850 mg BID
214406545|NCT02190838|DRUG|Melatonin|per os 3 mg daily
214406546|NCT02190838|DRUG|Dacarbazine|IV 1 hour 1000 mg/m\^2 once in 28 days
214406547|NCT03478579|OTHER|observational|No intervention, it is observational study
214406548|NCT02998827|DRUG|Thalidomide|
214406549|NCT02998827|DRUG|infliximab, azathioprine|other treatment include infliximab, azathioprine
214406550|NCT02998827|OTHER|enteral nutrition|
214406551|NCT01471262|PROCEDURE|Right hepatectomy|Right liver resection
214406552|NCT01471262|PROCEDURE|Extended right hepatectomy|Right hepatectomy involving 5 or more segments
214406553|NCT03494699|BEHAVIORAL|Multidisciplinary prevention|group cognitive training (every month) App-based Cognitive Training at Home (using smartphone application) physical activity/body weight/smoking \& alcohol cessation monitoring and feedback
214406554|NCT00699738|BEHAVIORAL|Breastfeeding|Breastfeeding
214406555|NCT00699738|BEHAVIORAL|Bottlefeeding|Bottlefeeding
214406556|NCT02253186|DEVICE|Auto-Adjustable MOBIDERM Armsleeve|
214406557|NCT04181801|PROCEDURE|Subtotal cholecystectomy|a surgical procedure in which more than the top half of the gallbladder is removed
214406558|NCT02655692|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
214406559|NCT02655692|DRUG|Placebo/Saline|This is a saline placebo/non-active solution.
214406560|NCT04774406|DRUG|olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib|All patients treated at least with 1 PARPi (alone or in combination)
214406561|NCT01095224|BIOLOGICAL|rAd35 Env A|1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
214406562|NCT01095224|BIOLOGICAL|rAd5 Env A|1 x 10\^10 PU administered as 1 mL IM in deltoid
214406563|NCT01095224|BIOLOGICAL|rAd5 Env B|1 x 10\^10 PU administered as 1 mL IM in deltoid
214406564|NCT00716079|OTHER|Blood pressure management policies|The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
214406565|NCT03768245|BEHAVIORAL|Health Education and Physical activity program|Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
214406566|NCT03768245|DIETARY_SUPPLEMENT|Nutrition Program|Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
214406567|NCT02721511|DRUG|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
214406568|NCT01084161|DRUG|N1539|5 mg IV once per day
214406569|NCT01084161|DRUG|N1539|7.5 mg IV once per day
214406570|NCT01084161|DRUG|N1539|15 mg IV once per day
215098755|NCT04099511|BEHAVIORAL|Cognitive Orientation to daily Occupational Performance|The Cognitive Orientation to daily Occupational Performance (CO-OP) approach was developed within the field of occupational therapy and is a performance-based, problem-solving approach to address activity performance limitations. Subjects will be taught to use the global problem-solving strategy of Goal-Plan-Do-Check: identifying a specific goal (Goal), outlining a practical plan for reaching that goal (Plan), accurately performing the plan (Do), and analyzing whether the plan led to achievement of the goal and altering the plan accordingly (Check). The Goal-Plan-Do-Check process will be iteratively applied to each of the activity goals. Therapists will use guided discovery to allow the subject to self-identify their own potential solutions within an activity (develop the plan). The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
214406571|NCT01084161|DRUG|N1539|30 mg IV once per day
214406572|NCT01084161|DRUG|placebo|IV placebo once per day
215098756|NCT06636162|DRUG|DSP-0390|DSP-0390 will be administered orally with preferably 200 mL of water, or approximately one-half cup water. The patient will take DSP-0390 after a minimum of a 6-hour fast and will fast for 1 hour after taking the dose.
215098757|NCT06234436|BIOLOGICAL|Plasma exchenge|Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
215098758|NCT05245812|DEVICE|da Vinci SP Surgical System|This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
215098759|NCT00512018|DEVICE|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
215098760|NCT00512018|OTHER|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
215098761|NCT00065806|DRUG|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
214406573|NCT01084161|DRUG|Morphine|morphine 10-15 mg IV once per day
214406574|NCT01084161|DRUG|N1539|60 mg IV once per day
214406575|NCT01260974|DRUG|Caspofungin|50mg/dd for 21dd, starting within 24h from Liver Transplantation.
214406576|NCT00117611|DRUG|Anti-IgE antibody omalizumab or placebo|given subcutaneously oce or twice monthly depending on dose
214406577|NCT01217580|DRUG|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
215098762|NCT00065806|DRUG|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
214406578|NCT01217580|DRUG|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
214406579|NCT00017277|BIOLOGICAL|epoetin alfa|
214406580|NCT00017277|RADIATION|radiation therapy|
214406581|NCT02728245|DRUG|Dienogest|Dienogest 2mg po qd
214406582|NCT02728245|DRUG|Placebo drug|Placebo 1 table po qd
214406583|NCT02728245|PROCEDURE|Surgery|conservative surgery without intent to oophorectomy
214406584|NCT05759221|PROCEDURE|Bronchoscopy with airway biopsy|Forceps biopsy of peripheral airways under direct endoscopic visualisation.
214406585|NCT04609293|COMBINATION_PRODUCT|camrelizumab+apatinib+hyperfractionated radiotherapy|Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
214406586|NCT03959709|PROCEDURE|immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. A temporary implant sizer is placed in the pocket to assess the position and shape of the prepectoral pocket. The pocket is adjusted where necessary. A sheet of ADM (DermAcell) is then selected. The DermAcell will be prepared as per the manufacture's instructions and fenestrated using size 11 blade. The DermACELL piece will be trimmed to the appropriate shape and sutured to the superior medial and lateral edges of the pectoralis major muscle. The inferior edge will be sutured to the fascia at the level of the inframammary fold. Two closed suction drains will be placed (one below the mastectomy skin flap, and one below DermACELL). The implant will be inserted to the pre-pectoral pocket and several anchor sutures will be used to secure the superior-medial edge of DermACELL to mastectomy flap.
214406587|NCT03959709|PROCEDURE|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. The reconstructive operative procedure will then proceeded with (1) elevation of the pectoralis major muscle with release of inferior attachments; (2) placement of implant subpectorally; (3) placement and suturing of DermACELL to constitute the inferolateral breast pocket; (4) placement of two closed suction drains (one superiorly between the pectoralis major and skin, and one inferiorly between the DermACELL and skin); (5) removal of sizer and placement of permanent to the pocket and (6) suture the inferior edge of DermACELL to the inferior edge of the pectoral major muscle. The skin will be closed and the dressing will be applied as standard protocol.
214406588|NCT03764345|DRUG|Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
215098763|NCT06182696|BIOLOGICAL|OriCAR-017|GPCRC5D-directed chimeric antigen receptor modified T cells
215098764|NCT03587311|BIOLOGICAL|Anetumab Ravtansine|Given IV
215098765|NCT03587311|BIOLOGICAL|Bevacizumab|Given IV
215098766|NCT03587311|DRUG|Paclitaxel|Given IV
214406589|NCT04376164|RADIATION|low level laser therapy|mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months
214406590|NCT00038792|DRUG|Recombinant Human Keratinocyte Growth Factor|
214406591|NCT05395208|BEHAVIORAL|Therapeutic touch group accompanied by white noise|During the intravenous catheter intervention, approximately 15-20 minutes of white noise was applied with therapeutic touch.
215098767|NCT06026501|DRUG|PE0116,PE0105|"1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug"
215098768|NCT00581867|DRUG|Insulin Aspart|40IU insulin aspart applied intranasally
215011263|NCT07045844|DIETARY_SUPPLEMENT|Pasteurized Donor Milk for Insufficient Breastfeeding|"Participants receive pasteurized donor human milk (pHDM) as supplemental feeding when the clinician determines maternal milk supply is insufficient.~Randomization 1 will occur when the clinician determines that supplemental feeding is required due to insufficient breast milk supply."
215011264|NCT07045844|DIETARY_SUPPLEMENT|Preterm Formula for Insufficient Breastfeeding|"Participants receive preterm formula (PTF) as supplemental feeding when the clinician determines maternal milk supply is insufficient.~Randomization 1 will occur when the clinician determines that supplemental feeding is required due to insufficient breast milk supply."
215011265|NCT07045844|DIETARY_SUPPLEMENT|Routine fortification|Randomization 2 will be conducted when the total daily intake of human milk (including own mother's milk \[OMM\] and/or donor pasteurized human milk \[pHDM\] ) reaches between 60-120 mL/kg
215011266|NCT07045844|DIETARY_SUPPLEMENT|Rescue fortification|Randomization 2 will be conducted: Add fortifiers when the body weight is below the 10% growth curve.
215011267|NCT07046390|DRUG|nerve block with bupivacaine 0.25%|0.25% bupivacaine
215011268|NCT07046390|DRUG|No intervention|No intervention
215011269|NCT07046377|PROCEDURE|ACB - IPACK|will receive spinal anesthesia and ultrasound-guided Adductor canal nerve block, as well as infiltration of the space between the popliteal artery and the capsule of the posterior knee (IPACK) block.
215011270|NCT07046377|PROCEDURE|GNB - IPACK|will recieve spinal anesthesia and US guided Genicular nerves block and IPACK block.
215098769|NCT00581867|DRUG|Placebo|Placebo
215098770|NCT05479149|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
215098771|NCT05479149|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
215098772|NCT00544622|PROCEDURE|structured therapeutic chain of stroke treatment|
215098773|NCT01307293|BEHAVIORAL|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
214406592|NCT04356066|DIAGNOSTIC_TEST|serum cxcl10 by ELISA|serum sample
214406593|NCT00948844|DEVICE|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
215011271|NCT07045753|DEVICE|Transcatheter edge to edge repair|mitral valve transcatheter edge-to-edge repair
215011272|NCT06726174|DRUG|ECCEC|0.5-1x10\^6 cells/300 uL, intracameral injection.
215011273|NCT07044752|BEHAVIORAL|Anxiety Prevention Intervention|community and school based, delivered by peers from the community to educate and lower anxiety symptoms among youth
215098774|NCT03002311|DEVICE|Epharmix/CareSignal eHealth|The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
215098775|NCT02618668|DRUG|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
215098776|NCT02618668|DRUG|Propofol|2 mg/kg I.V
214406594|NCT04978363|DEVICE|BOOT|A walking boot is a common type of brace/boot that restricts ankle and foot movement.
214406595|NCT04978363|DEVICE|HFC|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands.
214406596|NCT04978363|DEVICE|SAC|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries.
215011274|NCT07044752|BEHAVIORAL|Anxiety Intervention|5-session social and behavioral intervention about managing anxiety symptoms
215011275|NCT07046169|OTHER|Ultrasound-Guided Volume Assessment and Decongestion Strategy (UVADS)|Unique Combination: Simultaneously tracks IVC collapsibility index (\>50%) + pulmonary B-line counts (≤5) to guide therapy, unlike studies using either metric alone.Thresholds Tested: Compares ESC consensus thresholds (IVC \<2.1cm) vs. exploratory Asian-optimized thresholds (IVC \<1.8cm) in Subgroup B.
215011276|NCT07046169|OTHER|clinical assessment|Discharge based on symptoms/signs alone: Clinical congestion score ≤2 + NYHA class ≤II
215098777|NCT06508736|BEHAVIORAL|Storytelling|It is aimed that adolescents gain behavioral change through stories.
215011277|NCT07046481|OTHER|Physical activity|One or two physical activities according to the participant´s preferences will be selected and prescribed and specified for frequence and intensity. The selected activity/-ies could be of any type, as long as they increase the heart rate. The activity/-ies should be performed regularly during 12 weeks, A training diary will be used to monitor and register the activities.
215011278|NCT07046026|BEHAVIORAL|Standard work pace|On two consecutive days, participants will work at a standard pace of one box per minute during the box carrying protocol
215011279|NCT07046026|BEHAVIORAL|Additional rest breaks|On two consecutive days, participants will work at the standard work pace during the box carrying protocol and have superimposed 5 minutes of rest every 30 minutes.
215011280|NCT07045207|OTHER|LLM-MDT|Leveraging large language models (LLMs) to Generate Multidisciplinary Team (MDT) Treatment Recommendations
215098778|NCT06508736|BEHAVIORAL|Training|Participants will be trained on cyberbullying in 4 sessions.
215098779|NCT03908476|DEVICE|Burst-capable SCS system|Subjects will be given Burst stimulation using a market-released Abbott SCS system. Burst stimulation may be achieved through surgical or non-surgical means.
215098780|NCT03908476|DEVICE|DRG Stimulator|Subjects will be implanted with a market-released Abbott DRG stimulation system.
215098781|NCT05550948|DEVICE|Transcranial photobiomodulation (tPBM) - Mobile System|The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
215098782|NCT05194267|DEVICE|transcranial direct current stimulation (tDCS)|tDCS alters brain excitability using a weak electric field induced through two electrodes and could potentially improve symptoms of depression
215098783|NCT03247725|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
215098784|NCT03247725|OTHER|Treatment as usual (medical)|Patients will be offered the usual treatment for their pain, which is not changed by study participation
215098785|NCT04124003|DRUG|rosuvastatin|Specified dose on specified days
215098786|NCT04124003|DRUG|BMS-963272|Specified dose on specified days
215098787|NCT00802893|DRUG|6R-BH4|6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
215098788|NCT00802893|OTHER|Placebo|placebo given BID for entire length of study
215098789|NCT02868229|DRUG|COR-001|
214406597|NCT04978363|DEVICE|HFC+BOOT|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
214406598|NCT04978363|DEVICE|SAC+BOOT|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
215098790|NCT02868229|OTHER|Placebo|
215098791|NCT04606316|DRUG|Nivolumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
214406599|NCT01251614|BIOLOGICAL|Adalimumab|Adalimumab by subcutaneous injection every other week (eow)
214406600|NCT01251614|DRUG|Methotrexate|Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
214406601|NCT01251614|BIOLOGICAL|Placebo to Adalimumab|A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
214406602|NCT01251614|DRUG|Placebo to Methotrexate|Orally once a week
215011281|NCT07057310|DRUG|semaglutide or tirzepatide|Semaglutide and tirzepatide will be dosed as per prescription labels
215011282|NCT07057310|BEHAVIORAL|Lifestyle modification intervention|All participants will be recommended the following: 1) low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day; 2) physical activity: a goal of 10,000 steps or more per day; 3) exercise: a goal of 150 minutes or more of moderate-intensity aerobic activity (cardiovascular exercise) per week; 4) limited consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).
215011283|NCT07056465|BEHAVIORAL|Intermittent Carbohydrate Restriction (ICR) Protocol|A novel intermittent carbohydrate restriction (ICR) protocol involving two consecutive low-carbohydrate days (approximately 10% total energy from carbohydrate) followed by five non-restricted days per week, sustained over a 4-week period. Participants receive individualised dietary guidance and support materials to promote adherence in free-living conditions
215098792|NCT04606316|DRUG|Nivolumab|Given as intravenous (IV) infusion into a vein.
215098793|NCT04606316|DRUG|Ipilimumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
215098794|NCT04606316|DRUG|Ipilimumab|Given as intravenous (IV) infusion into a vein.
215098795|NCT04606316|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
215098796|NCT00320424|DRUG|Fondaparinux|
215098797|NCT06151288|BIOLOGICAL|31 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-31 was administered into the deltoid muscle at Day 1
214406603|NCT00418847|DRUG|miglustat|Target dose of 320 mg/m\^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA \> 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
215098798|NCT06151288|BIOLOGICAL|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 was administered into the deltoid muscle at Day 1
215098799|NCT01086371|OTHER|Rhythmic auditory stimulation|Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
215098800|NCT01086371|OTHER|Walking exercise|Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
215098801|NCT05466331|OTHER|Mobile Tele-HCV Care|Study participants receive HCV care via telemedicine. Telemedicine appointments are performed on a mobile van.
215098802|NCT05466331|OTHER|Enhanced Usual Care|Study participants are referred to a clinician in their area for HCV care.
215011284|NCT07055919|DEVICE|Structural Heart Surgery Assist System|Following femoral venous access and transseptal puncture, the steerable guide catheter and transcatheter mitral valve clip system are inserted and mounted onto the Structural Heart Surgery Assist System. The surgeon manipulates the joystick and controls on the operator console, guided by real-time animations on the human-machine interface that confirm the direction and range of device motion. Under fluoroscopic (DSA) and echocardiographic guidance, the system assists in performing edge-to-edge mitral valve repair. The procedure achieves regurgitation reduction by either creating a double-orifice configuration (A2/P2 segments) or approximating the opposing leaflets at the A1/P1 or A3/P3 regions.
215011285|NCT07055919|DEVICE|Manual MitraClip G4|Manual MitraClip G4
215011286|NCT07055698|DIAGNOSTIC_TEST|The Navicular Height Drop (NHD) test|Evaluating the test's responsiveness and minimal clinically important difference (MCID) can help determine its clinical relevance in monitoring treatment outcomes.
215011287|NCT07057245|DIETARY_SUPPLEMENT|Protein supplementation with an animal-based protein isolate|Study participants will consume, in random order, twice daily (2 x \~20 g) a plant protein (fava bean protein isolate), animal protein (milk protein isolate) or control (cornstarch providing no extra protein)
214406604|NCT05322161|BEHAVIORAL|yoga classes|"There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~1. Yoga postures (Asana) = low impact gentle postures meant to be done individually~2. Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~3. Meditation (Dhyana) = guided meditation"
215011288|NCT07057245|DIETARY_SUPPLEMENT|Protein supplementation with a plant-based protein isolate|Study participants will consume, in random order, twice daily (2 x \~20 g) a plant protein (fava bean protein isolate), animal protein (milk protein isolate) or control (cornstarch providing no extra protein)
215011289|NCT07057245|OTHER|Control arm - cornstarch|Study participants will consume, in random order, twice daily (2 x \~20 g) a plant protein (fava bean protein isolate), animal protein (milk protein isolate) or control (cornstarch providing no extra protein)
215011290|NCT06473805|PROCEDURE|VISTA technique and 3D printed PMMA implant|Intraoral scanning and radiographic examination (CBCT) will be performed to assess the anatomy of the sub nasal area and plan the position, size and thickness of PMMA implant The data will be transferred to 3D planning software to create digital model that fit in the defect followed by 3D printing of the implant using VISTA technique
215011291|NCT06473805|PROCEDURE|VISTA technique and 3D printed PEEK implant|Intraoral scanning and radiographic examination (CBCT) will be performed to assess the anatomy of the subnasal area and plan the position, size and thickness of PEEK implant The data will be transferred to 3D planning software to create digital model that fit in the defect followed by 3D printing of the implant using VISTA technique
215011292|NCT07057024|OTHER|Clinical and eye movements|"Eye tracking in virtual reality environment:~Clinical and psychometric assessment :~* Auto-assessment scales : State-Trait Anxiety Inventory (STAI-TRAIT/ STAI-STATE), Fagerström Test For Nicotine Dependance (FTND), Annett handedness questionnaire, Alcohol Use Disorders Identification Test (AUDIT), Substance Use Risk Profile Scale (SURPS)~* Hetero-assessment scales : Mini International Neuropsychiatric Interview (MINI DSM version 5), Young Mania Rating Scale (YMRS), Hamilton Depression Scale (HDRS), Positive And Negative Scale for Schizophrenia (PANSS)"
214406605|NCT06710561|DRUG|SPN01 for Injection|After each subject was randomly assigned, different doses of SPN01 for Injection (0.02 mg/kg, 0.06 mg/kg, 0.12 mg/kg) were administered intravenously in a single dose.
214406606|NCT06710561|OTHER|Placebo|After each subject was randomly assigned, a single intravenous injection of 0.9% sodium chloride was administered
215011293|NCT07055841|DRUG|Adebrelimab|1200mg, intravenous infusion, D1， Every three weeks, there are two cycles in total.
215098803|NCT03768128|DEVICE|Journey™ II UNI Unicompartmental Knee System|"Journey™ II UNI UKS is a CE Marked medical device. The device has been designed to treat both medial and lateral unicompartmental disease.~It is a comprehensive system designed to allow surgeons to perform UKA. It is comprised of the following anatomic components: Oxidized zirconium femoral components Titanium tibial components with a grit-blasted surface Polyethylene tibial insert components The device is asymmetric and is available in oxidized zirconium to reduce wear and increase implant longevity."
214406607|NCT06710561|DRUG|SPN01 for Injection|Colorectal cancer subjects will receive intravenous injection of SPN01 0.06 mg/kg for a single dose.
214406608|NCT03286725|BEHAVIORAL|Physical Education (PE) Programme|"A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.~The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons."
214688360|NCT07163039|OTHER|Dual-Task Motor-Cognitive Training|Participants assigned to this group will undergo dual-task motor-cognitive training, which combines physical exercises with simultaneous cognitive tasks. Sessions will last 45-60 minutes, three times per week, for 8 weeks. Exercises will include gait and balance activities performed while engaging in cognitive tasks such as arithmetic, memory recall, or word association.
215011294|NCT07055841|DRUG|TP regimen|TP regimen: Docetaxel 75 mg/m2, intravenous infusion, D1， Cisplatin 75 mg/m2, intravenous infusion, D1， Every three weeks, there are two cycles in total.
215011295|NCT07055841|PROCEDURE|Surgery or radiotherapy|Surgery or radiotherapy should be performed 1-4 weeks after the completion of neoadjuvant therapy.
215011296|NCT01225302|DRUG|Linifanib|Low dose linifanib (once a day)
215011297|NCT01225302|DRUG|Linifanib|High dose linifanib (once a day)
215011298|NCT01225302|DRUG|Carboplatin|Given on Day 1 of every 21-day cycle
215011299|NCT01225302|DRUG|Paclitaxel|Given on Day 1 of every 21-day cycle
215011300|NCT06143397|DEVICE|TTNS (Transcutaneous tibial nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the tibial region will be activated, the parasacral electrodes will not be active. A Biolito (MTR+Vertriebs GmbH, Berlin) stimulator will be used to perform posterior tibial nerve stimulation. Stimulation will be delivered via two 50 mm x 50 mm adhesive electrode pads under the left medial malleolus and 5 cm proximal to the distal electrode. Appropriate electrode site will be confirmed by the presence of big toe plantar flexion during stimulation (stimulus intensity will be adjusted according to the patient's tolerance for 200 μs duration at 10 Hz frequency). Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
215011301|NCT06143397|DEVICE|PNS (Parasacral nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the parasacral region will be activated, the tibial electrodes will not be active. For parasacral region stimulation, electrodes will be positioned symmetrically in the parasacral region under the posterior superior iliac spines to stimulate the S2 and S3 nerve roots. A duration of 200 μs at a frequency of 10 Hz will be set with the Biolito (MTR+Vertriebs GmbH, Berlin) stimulator. The intensity level will be adjusted according to the tolerance of the patient. Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
214406609|NCT03426514|PROCEDURE|Three-port Laparoscopic Surgery|Patients undergo three-port laparoscopic surgery. The surgery will be completed by a surgeon and a camera-person without another assistant. The surgeon will adjust surgical position to expose the operative field with the help of gravity. All the orther operative procedures are the same as conventional laparoscopic surgery.
214406610|NCT03426514|PROCEDURE|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery（4 or more ports）.The surgery will be routinely completed by a surgeon，a camera-person and another assistant to provide counter-traction.
214406611|NCT06231628|PROCEDURE|Percutaneous cementoplasty|"Percutaneous image guided cementoplasty will be performed as follows:~Low-viscosity radiopaque bone cement will be quickly mixed and transferred to 1-ml syringes to reduce injection resistance. Injection will be initiated 2-4 min after mixing. When the resistance to cement injection becomes high in the beginning, the cement will be pushed in with a stylet, and it will go well afterward. As much bone cement as possible will be injected while avoiding leakage into the hip joint, sciatic notch, or veins under fluoroscopic monitoring. When significant cement leakage occurred at the initial stage, cement injection will be performed via another route or will be stopped and resumed when the cement viscosity increased. The cement will begin to harden after 8 min, and the operator, therefore, will aim to complete the delivery of the injection within 10 min. The injection needles must be removed before the cement hardens completely"
214406612|NCT01730417|DRUG|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
214406613|NCT00049517|BIOLOGICAL|sargramostim|Given IV or as an injection
214406614|NCT00049517|DRUG|busulfan|Given IV
214406615|NCT00049517|DRUG|cyclophosphamide|Given IV
214406616|NCT00049517|DRUG|cytarabine|Given as a continuous infusion
214406617|NCT00049517|DRUG|gemtuzumab ozogamicin (GO)|Given IV
214406618|NCT00049517|DRUG|Daunorubicin|Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
214406619|NCT00049517|PROCEDURE|Autologous HCT|Autologous hematopoietic cell transplantation
215011302|NCT06143397|DEVICE|Sham stimulation|Electrodes will be placed in three areas simultaneously. These regions are the tibial and parasacral locations and the scapular region, with a distance of approximately 4 cm between the electrodes. Of these three regions, only the channel to the scapular region will be activated, the remaining two regions will be closed. Regarding the sham group, the parameters used in the scapular region will be applied with a frequency of 100 Hz, a pulse duration of 100 μs, and 30 minutes. This configuration is known as conventional transcutaneous electrical nerve stimulation and is commonly used for non-invasive and non-pharmacological treatment of pain.Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
215098804|NCT01164553|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
215098805|NCT06548594|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
215098806|NCT06584084|DEVICE|WPM-SEMG prototype|Measurements will be done with the rigid matrix. The flexible electrode matrix will be used only on a lower percentage of volunteers depending on the results obtained with the rigid matrix
215098807|NCT02625870|DRUG|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
215098808|NCT02625870|DRUG|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
215098809|NCT01443507|OTHER|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
215098810|NCT06015724|DRUG|Daratumumab|anti-CD38 monoclonal antibody (mAb)
214406620|NCT00049517|PROCEDURE|Allogeneic HCT|Allogeneic hematopoietic cell transplantation
214406621|NCT03952481|DRUG|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
215098811|NCT06015724|BIOLOGICAL|KRAS vaccine|Stimulon QS-21 and Targovax TG01
214406622|NCT03919617|DRUG|REMD-477|4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
214406623|NCT02487290|DEVICE|Aneufix ACP-T5|The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.
214406624|NCT03044769|PROCEDURE|Malformations resection|Resection of the malformation lung sections with a healthy adjacent part
214406625|NCT00256308|DRUG|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
215098812|NCT06015724|DRUG|Nivolumab|anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)
215098813|NCT01297725|PROCEDURE|Blunt right, sharp left|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
215098814|NCT01297725|PROCEDURE|Blunt left, sharp right|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
215098815|NCT03161535|OTHER|exercise and dietary education|"1. A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a week, was administered along with weekly exercise counseling. After collecting pretrial measurements, we explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. The detailed instructions, provided at the hospital clinics, included the determination of activity intensity, demonstration of pulse measurement, criteria for scores of 6-20 on the Borg's rating of perceived exertion (RPE), prevention of exercise-related injuries, and conditions necessitating termination of an exercise session. Participants were instructed that the exercises would be effective only if they reached 60%-80% of the target heart rate, as determined by the Karvonen method, and 13-15 on the RPE.~2. Diet-teaching program (using dietary education booklet)."
215098816|NCT03161535|OTHER|weekly telephone consultations concerning exercise and diet.|For each participant, we discussed exercise regimen-related issues and diet weekly through the telephone. For instance, we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
215098817|NCT00658814|DRUG|Azacitidine|Given IV or SC during induction; given SC during consolidation and maintenance
215098818|NCT00658814|DRUG|Gemtuzumab Ozogamicin|Given IV
215098819|NCT06401044|DRUG|AMG 732|SC injection
215098820|NCT06401044|OTHER|Placebo|SC injection
215098821|NCT02916810|DEVICE|Active rTMS stimulation|Participants will receive two rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two rTMS sessions.
215098822|NCT02916810|DEVICE|Sham rTMS stimulation|Participants will receive two sham rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two sham rTMS sessions.
215098823|NCT05664880|DRUG|Paricalcitol|2 MCG Oral Capsule
214406626|NCT00256308|PROCEDURE|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
214406627|NCT06454292|DRUG|Oliceridine Fumarate|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and a starting dose of 6ug/kg/h of oliceridine fumarate was continuously pumped, and the time of oliceridine fumarate initiation was recorded as T0. Subjects were assessed for sedation using the RASS score, and for analgesia using the CPOT score. Waiting for the original sedative-analgesic drug to elute until CPOT ≥ 3 and RASS \> 0. Adjust the infusion rate of oliceridine fumarate according to the CPOT score (recommended to be adjusted by 2ug/kg/h, the range of adjustment is 2-20 ug /kg/h, and the maximum infusion rate is not more than 20 ug /kg/h) until the analgesic score of the subject is CPOT\<3. The interval between two trial drug rate adjustments should be ≧5 min, and a CPOT score should be performed before each drug adjustment.
214406628|NCT06454292|DRUG|Remifentanil|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and remifentanil was continuously pumped at a starting dose of 1.5ug/kg/h. The time of remifentanil initiation was recorded as T0. Subjects were assessed for sedation using the RASS score and analgesia using the CPOT score. We waited for the original sedative-analgesic drugs to elute until CPOT ≥ 3 and RASS \> 0. The infusion rate of remifentanil was adjusted according to the CPOT score (1.5ug/kg/h is recommended, the range of adjustment is 1.5\~12μg/kg/h, and the maximum infusion rate is not more than 12μg/kg/h) until the subject's analgesic score of CPOT\<3, and the interval between the two experimental rate adjustments of the drug should be ≧5min, and the CPOT score should be performed before each adjustment of the drug. The CPOT score should be performed before each drug adjustment.
214406629|NCT02756104|OTHER|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
214406630|NCT02756104|OTHER|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
214406631|NCT01106703|DIETARY_SUPPLEMENT|PG102, a water soluble extract from Actinidia arguta|PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks
214406632|NCT01106703|OTHER|placebo|placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks
215098824|NCT05664880|DRUG|Placebo|Matching capsule to 2 MCG Paricalcitol Oral Capsule
214406633|NCT00578435|PROCEDURE|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
215098825|NCT05837884|DIAGNOSTIC_TEST|blood sampling|Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
215098826|NCT06359756|PROCEDURE|Ischemic postconditioning in carotid surgery|After the initial declamping of the carotid artery the procedure is performed with 6 cycles of reperfusion of 30 seconds each (clamping of the internal carotid artery) which are successively followed by 6 cycles of ischemia lasting 30 seconds (clamping of the internal carotid artery). Clamping is done on the unaltered ICA, at the clamping site prior to performing CEA above the plaque termination point.
215098827|NCT06359756|PROCEDURE|Eversion Carotid Endarterectomy|Standard Eversion Carotid Endarterectomy
215098828|NCT06038227|PROCEDURE|Robotic Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using RATS.
214406634|NCT04911686|DEVICE|rod distraction|Our study entails the application of a simple method for correction of FKFD in younger children using a simple cast distraction technique. This conservative method aims at avoiding the complications of surgery in children while achieving a reasonable amount of correction.
214406635|NCT06479564|OTHER|free weight training and machine training|20 participants will be in control group who will only perform free weight and machine training
214406636|NCT06479564|OTHER|Aerobic Exercises|20 participants will be in experimental group giving them aerobic exercise training protocol along with free weight and machine training
214406637|NCT04844099|DRUG|Dihydroartemisinin Piperaquine|Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
214406638|NCT06629948|DEVICE|x ray|whole spine x ray posterioanterior and lateral views
214406639|NCT06629948|DIAGNOSTIC_TEST|the cranio-cervical flexion test|measure of deep neck flexors muscles endurance
214406640|NCT06172595|DIAGNOSTIC_TEST|FET PET|There is only one study visit during which study subjects will undergo a 18F-FET PET/CT in SGH. Following that, they will be followed up as per their routine clinical care. Data collection timepoints will be at 30 days, 4 months, 8 months and 1 year.
214406641|NCT01249300|OTHER|No intervention|No intervention
215011303|NCT06143397|BEHAVIORAL|Behavioral treatment|It includes techniques and skills to prevent incontinence and restrain the urge to urinate. It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques. Additionally, advice on proper voiding position and an exercise protocol will be given. The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions. Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds. They will be told to do it twice a day, morning and evening. Participants will perform the behavioral training protocol at home.
215011304|NCT02137811|OTHER|MICK Assay|An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
215011305|NCT00314106|BIOLOGICAL|Melanoma Reactive TIL|
215011306|NCT00314106|DRUG|Cyclophosphamide|60 mg/kg/ day x 2 days intravenous
215011307|NCT00314106|BIOLOGICAL|IL-2|720,000 IU/kg/dose every 8 hours for up to 15 doses
215011308|NCT00314106|DRUG|Fludarabine|25 mg/m\^2/day intravenous x 5 days
214406642|NCT01895140|DEVICE|Renal denervation device|
214406643|NCT03960255|OTHER|Normal standard care|Both groups will receive standardized treatment and care for diabetic foot ulcers
214406644|NCT04751747|PROCEDURE|Computed Tomography|Undergo CT simulation
214406645|NCT04751747|OTHER|Contrast Agent|Given IV
214406646|NCT01554592|DRUG|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
214406647|NCT01554592|DRUG|Statin therapy|Participants will continue on stable statin therapy.
214406648|NCT04701060|DRUG|Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
214406649|NCT03631563|DRUG|Immunosuppressive Agent|ATG-Fresenius versus ATG
214406650|NCT06278857|DRUG|Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]|The dosing regimen follows standard clinical care protocol comprising of 4 cycles every 3-weeks, a rest period of 34 weeks followed by 3 cycles every 6 weekly for a total of 7 cycles.
214406651|NCT03176030|DIETARY_SUPPLEMENT|Fortified Foods|The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
214406652|NCT00003743|BIOLOGICAL|aldesleukin|
214406653|NCT03790397|DRUG|Osimertinib|Patients treated with Osimertinib within the Special Use medication Program (SUMP).
215011309|NCT00314106|RADIATION|1200 total body irradiation (TBI)|1200 cGY total body radiation
215098829|NCT06038227|PROCEDURE|Video Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using VATS.
215098830|NCT05653817|DRUG|Carrilizumab|Carrilizumab 200mg Q3W d1
214406654|NCT06218186|DEVICE|Medical Device: Wesper Lab Home Sleep Test|Wesper Lab is a medical device that is used for the diagnosis of sleep apnea. Wesper lab is composed of two flexible biosensors that adhere to the abdomen and thorax with medical grade adhesive. A FDA approved pulse oximeter is worn on a finger.
214406655|NCT03155204|DRUG|tiotropium pMDI|inhalation
214688361|NCT07163039|OTHER|Conventional Exercise Training|Participants in this group will receive a conventional exercise program focusing on strength, flexibility, and balance without a cognitive component. Sessions will last 45-60 minutes, three times per week, for 8 weeks, and will be supervised by a physiotherapist.
214688362|NCT07161817|BEHAVIORAL|Lateral positioning|Patients allocated to lateral positioning were placed at 90° on a horizontal bed, supported with a pillow to maintain neutral alignment of the spine and avoid hyperextension or forward flexion of the neck. No preference was specified for left or right lateral decubitus positioning, allowing flexibility based on patient comfort and surgical requirements.
215011310|NCT02929004|DEVICE|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
215011311|NCT00176137|PROCEDURE|preoperative radiochemotherapy|
215098831|NCT05653817|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel 125 mg/m2 d1,8
215098832|NCT05653817|DRUG|Apatinib|Apatinib mesylate tablets for treatment: 250mg
215098833|NCT05282433|DRUG|Surufatinib|Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
214406656|NCT06469892|OTHER|Detect the expression level of miR-185 in salivary and plasma exosomes.|"Participants were instructed to refrain from eating, drinking, brushing their teeth, rinsing their mouth, or taking medications for one hour before saliva collection. They were then asked to bend over, lower their head, open their mouth, and allow saliva to flow naturally without chewing or spitting. Using a specialized container, 2 mL of unstimulated saliva was collected.~Participants fasted overnight before blood collection. Researchers used plasma tubes containing anticoagulant (EDTA) to obtain venous blood (4-5 mL) from the participants\&#39; upper arm. Subsequently, the blood was gently inverted to ensure optimal contact with the anticoagulant before centrifugation at 2000 rpm and 4°C for 10 minutes. Following centrifugation, the supernatant was extracted."
214406657|NCT05387928|DRUG|KL340399 injection|KL340399 injection is a STING-activating. The strength of KL340399 is 0.2 mg/vial，0.2 mg/vial.
214406658|NCT02197871|DIETARY_SUPPLEMENT|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
214406659|NCT06634537|DEVICE|Active Comparator: insoles hard, soft and barefoot|"Primary Outcome Measure:~1\. Stabilometry The measurements were conducted University. To assess participants' balance, the anthropometric position of the protocol proposed by the International Society for the Advancement of Cineatropometry (ISAK) was assigned: participants placed their mi Frankfort; the upper limbs remained relaxed throughout the body, with palms facing forward and thumbs separated from the rest of the toes, and were barefoot with feet externally rotated f 30 degrees and with a heel distance of 4cm.~The children were wearing sports costumes to contribute their free movement. For stabilometry data collection will use an inertial measurement instrument called Gyko® It is a state-of-the-art device that allows to measure an objective assessment of acceleration, angular velocity and with an acquisition frequency of 100Hz \[Time Frame: pre intervention, 3 months post intervention, 6 months post intervention\]"
214406660|NCT02435901|DRUG|alemtuzumab (Campath IH)|Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
214688363|NCT07161817|BEHAVIORAL|Semirecumbent positioning|Patients in the semi-recumbent position were placed in the bed and the head of the bed was raised by 30 °, allowing flexibility based on patient comfort and surgical requirements.
214688364|NCT07163871|BEHAVIORAL|Postpartum hygiene, breast milk, and breastfeeding education have been provided for new mothers.|During the first ten days after birth, the first month, and the third month, new mothers received detailed care and education through home visits in addition to routine postnatal education. Information was shared at the mother's request as needed.
214688365|NCT07163104|BEHAVIORAL|Kaleidoscope|"Immediately before the procedure, children will be given the opportunity to examine the kaleidoscope and asked what shapes they see. The kaleidoscope distraction will begin immediately before the immunotherapy procedure and continue throughout the procedure. Children will be asked detailed questions such as, What shapes do you see in the picture? What colors are there? How many eyes do you see in the picture?, which the child can only accurately answer after careful examination. After the procedure, the kaleidoscope will be wiped with 70% alcohol and preserved by the researcher for the next session. A Zapp Flex Kaleidoscope (31.5 cm) will be used in this study."
215098834|NCT04396158|RADIATION|radioactive iodine|80-200 mCi of radioactive iodine will be given to thyroid cancer patients
215011312|NCT03137004|DRUG|Docetaxel|Docetaxel 50mg/m2 in 60 min on day 1 and repeated every 14 days.
215011313|NCT03137004|DRUG|S-1|S-1 was administered orally at 40 mg/m2 twice daily on days 1-7 of each cycle. Patients with a body surface area of less than 1.25 m2 received 80 mg S-1 daily, those with a body surface area of 1.25 m2 or more but less than 1.5 m2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m2 or more received 120 mg S-1 daily.
215011314|NCT07056933|OTHER|Minoxidil solution iontophoresis|The half of the scalp of the participants will be treated with 5% minoxidil solution through Iontophoresis that will be applied at small low voltage (typically 10 V or less) continuous constant current (typically 0.5 mA/cm2 or less) to push a charged drug into skin or other tissue, twice daily at home.
215011315|NCT07056933|OTHER|saline solution iontophoresis|The other half of the scalp of the participants will be treated with placebo saline solution ( control) with the current application.
215011316|NCT07056816|OTHER|Interactive Doll|"Interactive Doll: Their hearts beat and they say hello as soon as you put it on your finger because they know it's really yours! They also have a different personality and reactions when they open and close your finger. With sensors in their head, mouth and belly, Fingerlings respond to your touch and will respond to you. You can also shake them and turn them upside down for even more reactions because they love to monkey around. And their positive tail can hang down or flip up so they can sit on your table or shelf. Kids will play with the Interactive Doll during the inhalation treatment."
215011317|NCT07056816|OTHER|Interactive Robot|Interactive Robot: It has an interactive design that improves children's music listening and learning skills. It attracts children's attention with its vibrant colors and cute design, and teaches them while having fun. It has a voice imitation feature and a response feature that makes different sounds when its head is touched. Children will play with the Interactive Robot during inhalation treatment.
215011318|NCT04526561|PROCEDURE|Latissimus dorsi flap|Breast reconstruction
215011319|NCT04526561|PROCEDURE|Thoracodorsal artery perforator flap to breast|Breast reconstruction
215011320|NCT04526561|PROCEDURE|Deep inferior epigastric perforator flap|Breast reconstruction
215011321|NCT03366584|DIETARY_SUPPLEMENT|Beta carotene|Beta carotene 25,000 IU
215011322|NCT03366584|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 IU
215011323|NCT03366584|DIETARY_SUPPLEMENT|Zinc|Zinc 50 mg
215011324|NCT03366584|DRUG|Dexamethasone|Dexamethasone 6 mg
215098835|NCT03680300|OTHER|Post Facilitation Stretch|"The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition."
215011325|NCT01271738|PROCEDURE|Remove tumor only|No additional margins (tissue) removed at the initial surgery
214406661|NCT02435901|DRUG|Fludarabine|Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
214406662|NCT02435901|DRUG|Melphalan|Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
214406663|NCT02435901|DRUG|Cyclosporine|Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
214406664|NCT02435901|DRUG|Mycophenolate mofetil|Immunosuppressant to prevent graft vs host disease is given on Day -1.
215011326|NCT01271738|PROCEDURE|Removal of tumor and tissue|5 additional margins (tissue) removed at the time of surgery
215098836|NCT03680300|OTHER|Post Isometric Relaxation|"The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times."
215098837|NCT03680300|OTHER|Friction Massage|Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
215098838|NCT03270384|DEVICE|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
215098839|NCT06561932|DEVICE|WiSE CRT System|The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
215098840|NCT03301038|DRUG|Rifampin|Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
215098841|NCT05977049|BEHAVIORAL|Takotsubo Support Group|Participants will undergo virtual group therapy/education. Participants will meet once every other week (at minimum), for 1 - 1.5 hours (on average). The frequency and/or length of the support group sessions may be adjusted according to participants' needs.
215098842|NCT06362187|DEVICE|Gut Directed VR|The VR experiences follow a protocolized gut-directed therapy
215098843|NCT06362187|DEVICE|Sham Control VR|The same Oculus Quest 2 device as the active treatment group but will use distractive therapy
215098844|NCT06969872|DIETARY_SUPPLEMENT|Placebo|Take a capsule of placebo within 30 minutes after breakfast, and once a day.
215098845|NCT06969872|DIETARY_SUPPLEMENT|Probiotics (ABKefir)|Take a capsule of ABKefir within 30 minutes after breakfast, and once a day.
215011327|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
215011328|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
215011329|NCT02927483|DIETARY_SUPPLEMENT|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
215011330|NCT02927483|DIETARY_SUPPLEMENT|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
215011331|NCT03321032|DEVICE|Polymer-free amphilimus-eluting stents|Cre8 Evo coronary stent system (CID, Saluggia, Italy)
215011332|NCT03321032|DEVICE|Biolinx Polymer-based zotarolimus-eluting stents|Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
215098846|NCT05958290|OTHER|Discontinuation of antibiotics|Discontinuation of antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total.
215098847|NCT06278883|BEHAVIORAL|Disease Risk Assessment|Undergo personal and family history-based risk assessment and make recommendations for managing risk.
214406665|NCT02435901|DRUG|Tacrolimus|Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
214406666|NCT02435901|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
214406667|NCT00291707|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
214406668|NCT00291707|DRUG|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if \>6000 cGy to be delivered)
214406669|NCT00291707|PROCEDURE|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
215011333|NCT03217825|DRUG|Rostafuroxin|This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
215011334|NCT03217825|DRUG|Losartan|COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-\[p-(o-1H-tetrazol-5-ylphenyl)benzyl\]imidazole- 5-methanol monopotassium salt.
215011335|NCT06050772|BEHAVIORAL|Immersive Virtual Reality Reminiscence|a computer-generated environment using head-mounted displays (HMDs) that provide a fully immersive, completely engaging, and realistic experience so that users feel like they are a part of the virtual world
215011336|NCT06050772|BEHAVIORAL|Traditional Reminiscence Therapy|RT is a technique that encourages older adults' positive emotions and coping mechanisms by using the recall of earlier memories and the sharing of life experiences.
215011337|NCT04344093|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
215098848|NCT06672510|DEVICE|ATC|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute P
215098849|NCT04199767|DRUG|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
215098850|NCT04199767|DRUG|40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
214406670|NCT02579512|OTHER|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
215011338|NCT06061419|OTHER|Huel Powder|Huel Powder v3.0 white, vanilla flavour
215098851|NCT06574997|DRUG|OCU400|Participants will receive a subretinal injection of OCU400 modifier gene therapy product.
215098852|NCT05498272|DRUG|Olaparib|300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)
215098853|NCT05498272|DRUG|LHRH agonist|Total duration of therapy will be for 180 days with use of agent as per institutional standards
215098854|NCT06524960|DRUG|Denosumab|Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.
214406671|NCT05879666|BEHAVIORAL|Online educational phthalate course|This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
214406672|NCT05343884|RADIATION|Myocardial perfusion imaging|Myocardial perfusion imaging
214406673|NCT01565161|BEHAVIORAL|Home-Based Health Coaching|"The 6-month intervention arm consists of 3 components:~1. In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.~2. Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.~3. Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months."
214406674|NCT01565161|BEHAVIORAL|Mailed materials|"We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.~Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials."
214406675|NCT00398502|DRUG|MOA-728|
214406676|NCT01641276|DEVICE|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
214406677|NCT04501224|DRUG|Tenofovir alafenamide fumarate|Patients would take tenofovir alafenamide fumarate, 25mg，once per day
214406678|NCT04501224|DRUG|Entecavir or Tenofovir disoproxil fumarate|Patients would take entecavir 0.5 mg once per day, or tenofovir disoproxil fumarate 300 mg once per day
214406679|NCT02963220|BEHAVIORAL|CBT-AR|20-30 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
214406680|NCT03737175|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting
214406681|NCT03737175|PROCEDURE|Carotid Endarterectomy|Carotid Endarterectomy
214406682|NCT02458846|OTHER|Crowded HOTV Acuity Test|This is one of the most sensitive tests of acuity for vision screening of young children. The child is asked to recognize a letter (H,O,T,V) that is surrounded by bars to induce the crowding effects typical of amblyopia. Children were tested monocularly and was required to achieve at least 20/32 in each eye to pass. Children already wearing glasses were tested with their glasses on.
214406683|NCT02458846|OTHER|Preschool Randot Stereoacuity Test|"This is a reliable screening test for stereo depth perception for young children. Children wear polarized stereoglasses and are asked to identify or match shapes that are hiding in the snow, which cannot be perceived if the child has abnormal binocular vision. Children were required to achieve at least 60 arcseconds of disparity to pass. Children already wearing glasses were tested with their glasses worn under the stereo glasses."
214406684|NCT02458846|DEVICE|Plusoptix Autorefractor|Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
214406685|NCT02458846|OTHER|Comprehensive Eye Exam|Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near \& far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
214406686|NCT02462655|OTHER|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
215011339|NCT00369018|DRUG|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
215011340|NCT00853047|DRUG|Telotristat etiprate|Telotristat etiprate capsules; orally 3 times daily.
215011341|NCT00853047|DRUG|Octreotide LAR Depot|A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.
214406687|NCT02462655|OTHER|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
214406688|NCT01450878|DRUG|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
215011342|NCT00853047|DRUG|Placebo|Placebo-matching telotristat etiprate capsules; orally 3 times daily.
215011343|NCT06773481|BIOLOGICAL|BC008-1A|Biological: 900 mg BC008-1A will be intravenously injected once every 3 weeks.
215011344|NCT06773481|BIOLOGICAL|BC008-1A|Biological: 1200 mg BC008-1A will be intravenously injected once every 3 weeks.
214406689|NCT00403884|PROCEDURE|Selective RPE laser treatment|interventional SRT laser treatment
214406690|NCT00512824|DIETARY_SUPPLEMENT|low calcium milk of 180 ml|twice daily for 24 weeks
215011345|NCT04792268|OTHER|Access to eCDSS on wards|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm.~An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~The key digital tool to be used for eCDSS in this study is CogStack. This eCDSS has been developed to alert clinicians automatically regarding patients admitted under their care, triggered by the presence of new, old or absent HbA1c pathology reports on the electronic health record (EHR)."
215098855|NCT06524960|OTHER|Placebo|Placebo is 1 mL of normal saline drawn up in a commercially available syringe.
215098856|NCT05383872|DEVICE|Focused Ultrasound (Exablate Model 4000)|BBB opening via Exablate Type 2 system with microbubble resonators and drawing blood before and after opening
215098857|NCT06445361|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement to determine steatosis and fibrosis.
215098858|NCT06285890|DRUG|HC-7366|Given by PO
215011346|NCT05208190|DRUG|Clozapine|treatment will occur naturalistically, as per standard clinical guidelines
214406691|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml|twice daily for 24 weeks
215011347|NCT05208190|DRUG|treatment as usual|naturalistic treatment with any other antipsychotic medication except clozapine
215011348|NCT04999397|OTHER|standards clinical management|outcomes seen in cardiac injuries post clincal care
214406692|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
215098859|NCT02686502|BEHAVIORAL|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
215098860|NCT06225466|DRUG|Rocuronium|After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.
214406693|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
215011349|NCT02687737|PROCEDURE|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
215011350|NCT02687737|PROCEDURE|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
215011351|NCT02687737|PROCEDURE|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
215011352|NCT02687737|BEHAVIORAL|Swallowing Tasks|"These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP."
215098861|NCT06225466|DRUG|Sugammadex|When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.
215098862|NCT06225466|OTHER|Anesthesia without neuromuscular blockade|Anesthesia without rocuronium or sugammadex
215011353|NCT02863042|PROCEDURE|Repair Deltoid Tendon|
215011354|NCT02863042|OTHER|Ankle Fracture Without Deltoid Tendon Repair|Standard of care
215098863|NCT04909229|DEVICE|PEAR-003b PDT Intervention|The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.
215098864|NCT04909229|DEVICE|Fitbit|Patients will receive a Fitbit and receive standard of care
215098865|NCT04909229|BEHAVIORAL|Sleep education materials|Patients will receive sleep hygiene and healthy sleep tips.
215098866|NCT06665997|DRUG|Depot medroxyprogesterone acetate (DMPA)|150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension
215098867|NCT05559853|DIAGNOSTIC_TEST|CEST-MRF|CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
215098868|NCT02219659|DRUG|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
214406694|NCT02933320|BIOLOGICAL|BI-1206 single agent dose escalation phase|BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.
214406695|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab escalation phase|An investigation of combination treatment of BI-1206 with rituximab.
214406696|NCT02933320|BIOLOGICAL|BI-1206 single agent expansion phase|BI-1206 single agent expansion phase at the RP2D.
214406697|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab expansion phase|BI-1206 in combination with rituximab at the RP2D.
214406698|NCT01436409|OTHER|echography|echography during labor
214406699|NCT00886613|BIOLOGICAL|V212|Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31
214406700|NCT00886613|BIOLOGICAL|Comparator: Zostavax™|Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31
214406701|NCT00886613|BIOLOGICAL|Comparator: Placebo|Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31
214406702|NCT00886613|OTHER|VZV Skin Test|Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.
215011355|NCT06461559|DEVICE|antegrade infusion of ileostomy content|infusing the contents of ileostomy output back into intestine of the patient
215011356|NCT00727064|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
215011357|NCT00727064|DRUG|Venlafaxine Extended Release (VEN ER)|
215011358|NCT00346528|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
215011359|NCT00346528|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
215011360|NCT00151515|DRUG|minoxidil|Topical 5% minoxidil foam, BID, for sixteen weeks
215011361|NCT07055724|BIOLOGICAL|Eque-cel CAR-T Therapy|Participants in this arm receive a single infusion of Eque-cel at a dose of 1.0 x 10\^6 CAR-T cells/kg following lymphodepletion preconditioning with fludarabine and cyclophosphamide. Eque-cel is a fully human BCMA-targeted CAR-T cell therapy designed to recognize and eliminate BCMA-expressing cells.
215098869|NCT02219659|DRUG|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
215098870|NCT02219659|DRUG|Fentanyl Push First|Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
215098871|NCT02885974|DRUG|Celecoxib|Celecoxib (100 mg daily)
215098872|NCT02885974|DRUG|Gemcitabine|1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.
214406703|NCT00886613|OTHER|Saline|One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
214688366|NCT07163104|BEHAVIORAL|Buzzy|The device contains a wing-shaped ice pack on the skin-contact portion. The ice pack is stored in a deep freezer and inserted into the device before application. After application, the ice pack is wiped with 70% alcohol and kept in the freezer until it freezes again. Cold application and vibration begin before the procedure and continue until the end. When vibration is applied, it reduces or eliminates pain by causing numbness, paresthesia, and anesthesia. Cold application reduces pain by slowing or blocking conduction in peripheral nerves. It also reduces pain by activating the gate-control mechanism, stimulating touch receptors, and increasing the release of endogenous opioids.
215011362|NCT06684002|OTHER|Pilates training|Participants in the Pilates group attended supervised 60-minute sessions twice weekly for eight weeks, led by a certified physiotherapist trained by the Australian Institute of Pilates and Physiotherapy.
215011363|NCT06684002|OTHER|Standard prenatal care and ergonomic advice|The control group received standard prenatal care and ergonomic advice, and did not participate in any exercise training.
215011364|NCT06706102|BIOLOGICAL|Biological tests|Biological tests : cell quantification et characterization
215011365|NCT06706102|DIAGNOSTIC_TEST|MRI|MRI
215011366|NCT06706102|DIAGNOSTIC_TEST|Neuropsychological tests|Neuropsychological tests
215011367|NCT06145516|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)
215011368|NCT06145516|BEHAVIORAL|Sleep education therapy (SET)|Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
215011369|NCT06914869|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
215011370|NCT06914869|DRUG|Carbamazepine|Carbamazepine will be administered per schedule specified in the arm description.
215011371|NCT06914869|DRUG|Efavirenz|Efavirenz will be administered per schedule specified in the arm description.
215011372|NCT06773507|BIOLOGICAL|BC008-1A 900mg|BC008-1A 900mg will be administered once every 3 weeks until disease progression occurs, or intolerable toxicity develops, or they are lost to follow-up, or withdraw their informed consent, or start a new anti-tumor treatment, or the investigator decides to withdraw them based on the subject's benefit situation.
215011373|NCT06773507|BIOLOGICAL|BC008-1A 1200mg|BC008-1A 1200mg will be administered once every 3 weeks until disease progression occurs, or intolerable toxicity develops, or they are lost to follow-up, or withdraw their informed consent, or start a new anti-tumor treatment, or the investigator decides to withdraw them based on the subject's benefit situation.
215011374|NCT05257707|DIAGNOSTIC_TEST|Molecular biology|"Samples will be taken as part of routine care consultations. These include~* Smears taken with cytobrushes adapted to the anatomical site (cervix, vulva, vagina, penis, anus, upper aerodigestive tract...).~* Blood samples taken to isolate plasma, cells or serum.~* CSF and effusion samples taken with a suitable puncture needle (lumbar puncture, ascites puncture, pleural puncture, etc.).~* Urine samples collected in sterile ECBU jars.~* Biopsies taken according to the recommendations of good clinical practice using specific forceps adapted to the anatomical site.~* Surgical parts.~* Eyebrows.~* Saliva samples or gargle samples."
215011375|NCT06735014|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo 3T MRI scanning of the brain and cervical spine MRIs
215011376|NCT06735014|DIAGNOSTIC_TEST|Plasma neurofilament light chain (NfL) quantification|Participants will undergo a blood draw for the quantification of plasma neurofilament light chain
215011377|NCT03597594|DRUG|Anti-thymocyte globulin (rabbit)|given intravenously
215011378|NCT03597594|DRUG|Busulfan|given intravenously
215011379|NCT03597594|DRUG|Fludarabine|given intravenously
215011380|NCT03597594|DRUG|Thiotepa|given intravenous infusion
215011381|NCT03597594|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
215098873|NCT02885974|DRUG|Cisplatin|70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
214406704|NCT05455346|DIAGNOSTIC_TEST|Ultrasound imaging|"Ultrasound B-mode images will be unilaterally collected from the biceps femoris muscle of the dominant limb for each participant using a commercial ultrasound system and linear array transducer. Standardized image locations will correspond to 33%, 50%, and 67% of the thigh length from the ischial tuberosity.~Three repeat longitudinal extended-field-of-view images of the entire biceps femoris muscle will be collected for offline analysis for fascicle length, muscle thickness, and pennation angle. Transverse extended-field-of-view images will be captured at the proximal, mid-belly, and distal locations to determine regional anatomical cross-sectional area of the biceps femoris long head muscle.~To determine changes in tissue stiffness via ultrasound shear wave speed, the same transducer will be placed in the same locations in a longitudinal view. Shear wave maps will be generated by the ultrasound system and shear wave speed measures extracted from the middle of the map."
214406705|NCT05455346|OTHER|Hamstring Eccentric Strength Testing|"Prior to each test, participants will perform a standardized 5-minute general warm-up followed by a task-specific warm-up including 3 sets of submaximal trials. Load increases (5-20%) will be added for each RDL 3-repetition maximum trial attempt until the participant cannot complete 3 repetitions through the full range of motion using proper technique. A 3-minute rest will be administered between all warm-up and testing sets to allow for full recovery.~Participants will kneel on a commercial device used to assess maximum eccentric knee flexor strength via uniaxial load cells with their ankles secured into fixed hooks. Participants will slowly lower their torso to the ground with arms crossed across their chest and without bending at the hips or spine. The maximal test will consist of 1 set of 3 maximal repetitions. If participants can control lower themselves to the ground, then they will hold barbell plates (5-10 lb increments) across their chest while performing the NHE."
214406706|NCT05455346|OTHER|Maximal 60 m Sprint|Following a standardized warm-up, inertial measurement units (IMUs) will be placed on the sternum, sacrum, and bilaterally on the thighs, legs, and foot. Each participant will perform a total of 3 maximal 60 m sprints from a standing position with 1.5-3 min rest in between each trial to minimize the effects of fatigue.
215011382|NCT03597594|OTHER|Donor Lymphocyte Infusion|given intravenous infusion
215011383|NCT06935812|OTHER|Bimanual Exercise|The bimanual exercise group consists of exercises that involve movements in which both hands are used simultaneously. The bimanual exercise group will have 40 minutes of training for 3 sessions per week for 8 weeks.
215011384|NCT06935812|OTHER|Finger Exercise|The finger exercise group consists of exercises that involve finger movements. The bimanual exercise group will have 40 minutes of training for 3 sessions per week for 8 weeks.
215011385|NCT06935812|OTHER|Virtual Reality|The virtual reality exercise group consists of hand-tracking game exercises that involve finger movements. The bimanual exercise group will have 40 minutes of training for 3 sessions per week for 8 weeks.
215011386|NCT06943144|OTHER|Dual task Training|In dual-task training, participants walk while performing cognitive tasks such as object identification, counting backward, or solving math problems. These exercises aim to improve coordination, attentional control, and dual-task performance by simultaneously engaging cognitive and motor functions. Training sessions are held twice a week, each lasting 30 minutes with breaks for rest and reflection. Tasks vary in complexity to progressively challenge participants and enhance both cognitive processing and gait stability.
215011387|NCT06943144|OTHER|Embodied Learning|Participants in the embodied learning group engage in activities such as yoga, painting, sensory play, physical storytelling, gesture-based learning, and creative storytelling. These exercises use full-body movement to support learning and cognitive development. Examples include using gestures to reinforce concepts, acting out stories to blend movement with narrative, and engaging in yoga for focus and calmness. Art and sensory activities further promote creativity and tactile exploration. Sessions are held twice a week, lasting 45 to 60 minutes, and are tailored to individual needs and progress.
215011388|NCT06404268|DEVICE|Motor relearning training|Ankle motor control relearning training under real-time feedback
215098874|NCT06762080|DRUG|Cadonilimab (AK104)|Intrathecal injection of PD-1/CTLA-4 bispecific antibody was administered every two weeks for six weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
215011389|NCT06404268|DEVICE|Passive stretching|Passive stretching under intelligent robotic control
215011390|NCT06404268|DEVICE|Gamed-based active movement training|Active movement training through movement games with robotic assistance
215011391|NCT06404268|DEVICE|Passive movement|Passive movement in the joint middle range of motion
215011392|NCT06404268|DEVICE|Active movement training|Active movement training without robotic assistance
215011393|NCT06404268|DEVICE|Ankle torque and motion measurement|Ankle torque and motion measurement with no real-time feedback
215011394|NCT04075656|BEHAVIORAL|Standard of Care|Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.
215098875|NCT06762080|DRUG|Pemetrexed (Alimta)|Pemetrexed was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
215098876|NCT06886997|DIAGNOSTIC_TEST|Pelvic Floor Ultrasound|Pelvic Floor Ultrasound will be carried out by a sonographer expert in the technique and who will be blinded from the data of clinical examination as well as the UDS results. The 3D/4D abdominal ultrasound probe will be used to perform a transperineal scan to capture midsagittal pelvic floor views. The test will be conducted both at resting state and during the maximum Valsalva maneuver.
214406707|NCT05455346|OTHER|Romanian Deadlift|The RDL intervention will be performed twice per week for 6 weeks. Participants will hinge at the hips lowering the bar to just below their patella before reversing the movement. The RDL will be performed with a 6 second eccentric component and returning to the start position with a maximal concentric hip extension.
214406708|NCT05455346|OTHER|Nordic hamstring exercise|The NHE will be performed twice per week for 6 weeks. Participants will be instructed to maintain their ankles in a dorsiflexed position, lower themselves as close to the ground as possible at a constant and controlled speed while maintaining a neutral position of the hips and trunk, and to cross their arms in front of their chest.
214406709|NCT01642940|DRUG|Prasugrel|Prasugrel 10mg/day
214406710|NCT01642940|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
214406711|NCT01996644|DRUG|Placebo vs Setraline|Placebo
214406712|NCT01996644|DRUG|Setraline|250mg DCS
214406713|NCT06629467|BEHAVIORAL|Cognitive-behavioral therapy for smoking cessation|Treatment components will include psychoeducation on the consequences of tobacco use and the benefits of quitting; therapeutic commitment; self-monitoring of cigarette smoking; brief advice on healthy eating behaviors and sleep hygiene, physiological feedback (based on CO levels), training in self-control strategies, stimulus control, management of craving with alternative activities, diaphragmatic breathing, weekly personalized physical activity objectives, and relapse prevention strategies. The protocol consists of a nicotine fading procedure, which consists of a weekly reduction in nicotine intake of 30% (based on both tobacco brands and the number of cigarettes) from the first to the fifth session.
214406714|NCT06629467|BEHAVIORAL|Personalized PA plan|The treatment provider will fix an objective (e.g. go for brisk walking for 30 minutes 3 times this week) for each participant every week according to his/her current PA level, time availability, likes, and fitness level.
214406715|NCT06629467|DEVICE|Fitbit Versa 3|Wearable activity tracker with the functionalities of a watch function, including time, date, calendar, and weather (connection to the internet is required). Physical activity monitoring (steps per day, active minutes per day, plants climbed, heart rate monitoring, time, intensity, caloric expenditure, and exercise type of exercise session), sleep monitoring (sleep time, sleep phases time, sleep quality), stress levels managing and guided breathing application are the main health-related functionalities.
214406716|NCT03349190|DRUG|ULIPRISTAL ACETATE|Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)
214406717|NCT06630481|DRUG|neoadjuvant therapy|Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
214406718|NCT03874975|DRUG|oral vitamin D|vitamin D and UVB versus UVB alone in psoriatic patients and evaluate patients by PASI score before and after treatment and measure serum vitamin D before and after treatment
214406719|NCT01760681|DEVICE|H- Coil DTMS|20 daily deep rTMS treatments
214406720|NCT01760681|DEVICE|Sham|
214406721|NCT05818813|DEVICE|Renal denervation|Renal denervation (ReCor Medical)
214406722|NCT06479460|DIAGNOSTIC_TEST|ctDNA-MRD|This study is an observational non intervention study that only tests peripheral blood samples from different treatment nodes of the subjects, without interfering with the normal clinical diagnosis and treatment process of the patients.
214406723|NCT01515956|DRUG|BMN 110|Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
215011395|NCT04075656|BEHAVIORAL|UrApp|Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
215011396|NCT05086224|DRUG|Hematoma Local Anesthetic Block Procedure with 1% Lidocaine|Inject anesthetic into the hematoma site, 20 mL of 1% lidocaine without epinephrine.
215011397|NCT05086224|DRUG|Bier Anesthetic Block Procedure with 1% Lidocaine|Intravenous anesthetic infusion, a maximum lidocaine dosing of 3 mg/kg.
215011398|NCT04753177|DRUG|Ribocyclib, fulvestrant, triptorelin|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
215011399|NCT04753177|DRUG|Doxorubicin, cyclophosphamide, paclitaxel|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
215011400|NCT05147831|OTHER|Remote Ischemic Preconditioning|Place blood pressure cuff around upper, non-dominant arm (e.g. upper left arm in a right-handed patient). Inflate blood pressure cuff to a pressure set at 50 mmHg higher than baseline systolic BP to induce ischemia of arm for 5 minutes. Completely deflate blood pressure cuff to allow for 5 minutes of reperfusion. Subjects would undergo 4 cycles of ischemia and reperfusion,
215098877|NCT06886997|DIAGNOSTIC_TEST|Urodynamic studies|Urodynamic studies (UDS) will be carried out according to the usual protocol and will include: cystometry, Valsalva leak point pressure, urethral pressure profile, and uroflowmetry.
215011401|NCT03965299|DEVICE|VERUM TTNS|"* Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
215098878|NCT06760754|DIETARY_SUPPLEMENT|Digital culinary medicine intervention|Participants will receive 30lbs of healthy foods through an on-site hospital-base food pantry
215098879|NCT06430164|OTHER|Gait Training|Gait training: One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds will be delivered without FES.
214406724|NCT06497634|PROCEDURE|25 PP|Spinal anesthesia will be performed in sitting position, with 25 G pencil point needle (Whitacre -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.
214406725|NCT06497634|PROCEDURE|25 Q|Spinal anesthesia will be performed in sitting position, with 25 G sharp edge needle (Quincke -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.
214406726|NCT06497634|PROCEDURE|27 Q|Spinal anesthesia will be performed in sitting position, with 27 G sharp edge needle (Quincke -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.
214406727|NCT06497634|OTHER|Optic Nerve Sheath Measurement|Sonographic measurement of ONSD (EsaoteMyLabFive, Cenova, Italy) for all patients will be performed by a single experienced anesthesiologist. After a thin gel layer apply to the upper eyelid, the patient in the supine position and with the eyes closed, using a 6-13 MHz linear probe, optic sheath nerve measurement will be done 3 mm behind the optic globe, with a total of three measurements of which the final value will be recorded.The measurement will be repeated five times using US guidance at the following time points: T0 (pre-anesthesia), T1 (5 minutes after spinal block), T2 (15 minutes after spinal block, T3 (tourniquet opening), and T4 (24 hours after spinal block ) respectively.
215011402|NCT03965299|DEVICE|SHAM TTNS|"* Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
215011403|NCT06482424|OTHER|intervention group|"Actions to be taken to the Intervention Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. The aromatic oil given to patients in the intervention group will be placed in 10ml dark glass bottles with droppers and a numbered label will be attached to the bottle.~Procedures to be Performed on the Placebo Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. Sesame oil given to patients in the placebo group will be placed in 10 ml dark glass bottles with droppers and a number two label will be attached to the bottle."
215011404|NCT04113486|OTHER|Blood test|About 4 ml of blood draw
215011405|NCT04212065|DRUG|buprenorphine|To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
215011406|NCT02563210|OTHER|airway resistance measurement|assessment of airway resistance
215011407|NCT05215236|OTHER|Opiate Sparing|Subjects will receive non-opiate medications for pain control
215011408|NCT05215236|OTHER|Opiate Based|Subjects will receive opiate based medications for pain control
215011409|NCT05095792|OTHER|Observational - no intervention|This is an observational study with no intervention.
215011410|NCT06694623|PROCEDURE|Apically positioned flap|The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures.
215011411|NCT06694623|PROCEDURE|Apically positioned flap with FGG strip|The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures. FGG strip was sutured to the apical end of recipient bed.
215011412|NCT02439411|DRUG|Trametinib|
215011413|NCT04840771|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
215011414|NCT06002074|BEHAVIORAL|Stress Management and Resilience Training Program|One-on-one stress management and resilience consultation by a certified SMART trainer followed by self-guided on-line training consisting of 4 modules.
215011415|NCT04527731|DEVICE|Accelerometry|Participants are asked to wear an accelerometer during the day for a period of seven days.
215011416|NCT05192785|PROCEDURE|Incentive Spirometry Group|"The inspiration and expiration applications of incentive spirometry (IS) involved 10-20 breaths every one to two hours, depending on the tolerance of the patients.~During the inspiration application of IS, the head of the bed was elevated to a 45° angle, and the patient was placed in a long sitting position. The patient was requested to surround and fix the IS mouthpiece well, ensuring no gap was left between the lips. The patient was told to breathe slowly and deeply, and was asked to hold their breath for 2-3 seconds, and then to breathe normally with the IS mouthpiece in his/her mouth. The patient was advised to repeat the exercise 5-10 times, and to try to cough after every 5 exercises.~For the applied IS expiration technique applied in the study, which had not been previously encountered in literature, the patient was requested to turn the IS upside down (clockwise,180°) and to place the mouthpiece in his/her mouth and expiration application it."
215011417|NCT01229670|OTHER|exercise|"* 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min"
215011418|NCT00160615|DRUG|Levetiracetam|"* Pharmaceutical form: Film-coating tablets~* Concentration: 250 mg/ 500 mg~* Route of administration: oral use"
215011419|NCT03166631|DRUG|BI 891065|Part A, Part B
215011420|NCT03166631|DRUG|BI 754091|Part B
215011421|NCT00060385|DRUG|CHOP regimen|
215011422|NCT00060385|DRUG|EPOCH regimen|
215011423|NCT00060385|DRUG|cyclophosphamide|
215011424|NCT00060385|DRUG|doxorubicin hydrochloride|
214406728|NCT02286661|PROCEDURE|Casting (long arm)|Casting using plaster of paris after closed reduction of distal radius fracture
214406729|NCT02286661|PROCEDURE|Casting (short arm)|
214406730|NCT04767230|OTHER|Dietary Intervention|A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months
214406731|NCT06268210|DRUG|Lazertinib+Pemetrexed+Carboplatin|Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)
214406732|NCT06268210|DRUG|Lazertinib|Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.
214406733|NCT02741011|OTHER|Radiological examination|During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
214406734|NCT05157334|DEVICE|Non-invasive auricular electrical transcutaneous vagus nerve stimulation|"A NEMOS ® stimulator (Cerbomed, Erlangen, Germany) is used for transcutaneous auricular vagus nerve stimulation. This is a handheld battery driven stimulator which stimulates conca in the outer ear. It stimulates in a serie of small electrical impulses with a pulse width at 250 us and a frequency at 25 Hz for 30 minutes in a cycle for 30 seconds on and 30 seconds off to avoid habituation. It is previously indicated that a stimulation intensity at 0,5 mA, 1 mA or 1,5 mA does not cause a significant chance in HRV, thus 0,5 mA is used in this study."
214406735|NCT05157334|OTHER|Deep breathing|The participant is first verbally introduced to the breathing exercises, and then to the visually cue (animation), which the participant have to follow throughout the session.
214406736|NCT01262495|OTHER|cryopreservation|cryopreservation of testicular tissue
214406737|NCT05014724|DRUG|Rozanolixizumab|Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.
214406738|NCT04106440|BEHAVIORAL|Application Use|Use applications after initial diagnosis to share information with study team.
214406739|NCT02821598|OTHER|Upper Limb pattern with flexion - abduction - external rotation|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
214406740|NCT02821598|OTHER|Lower Limb pattern with flexion - adduction - external rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
214504749|NCT07098845|BEHAVIORAL|HealthEd|Hey-Durham is a health education program that the team has extensive experience implementing (Lucas-Thompson et al., 2019; Shomaker, Berman, et al., 2019; Shomaker et al., 2016; Tanofsky-Kraff et al., 2014) and covers topics such as domestic violence, substance use, depression/signs of suicide, and conflict resolution. Mental health components focus only on prevalence and identification. There is no content overlap with L2B, but it is matched to L2B in format, time, frequency, in-person contact, and facilitator expertise. Inclusion of HealthEd in a future efficacy trial will allow us to test the extent to which the active ingredients of MBI (i.e,. a top-down and bottom-up focus on emotion and stress regulation(Zelazo \& Carlson, 2012)), with and without the between-session support L2B, improve mental health and stress responding, relative to an active control matched for critical characteristics but that does not include these active ingredients.
214504750|NCT07096037|OTHER|Urtica dioica cataplasm|Participants will receive a warm Urtica dioica cataplasm applied topically on the affected knee, once daily for 60 minutes, three times per week (on alternate days) over a 6-week period.
214504751|NCT07096037|OTHER|Placebo|Participants will receive a placebo cataplasm, matched in texture, color, and odor to the active treatment. The placebo is inert and safe for pediatric topical use.
215011425|NCT00060385|DRUG|etoposide|
215011426|NCT00060385|DRUG|prednisone|
215011427|NCT00060385|DRUG|vincristine sulfate|
215011428|NCT00060385|RADIATION|radiation therapy|
215011429|NCT02740582|DRUG|Tolcapone|
215011430|NCT02740582|DRUG|Placebo|
215011431|NCT01579877|DIETARY_SUPPLEMENT|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
215011432|NCT01579877|DIETARY_SUPPLEMENT|Placebo herbal extract granule|The Yukmijihwang-tang\_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
215011433|NCT06455280|DRUG|Siplizumab|Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
215011434|NCT06580769|OTHER|Physical activity|Implementation of a physical activity program, executed through immersive virtual reality
215011435|NCT03983369|DEVICE|Low-Level Laser Therapy|The LLL used is the K-Laser Cube 3. The LLL is an athermal laser beam of low power, equipped with a placebo function (dummy imitating beam laser light, emitted by the same device but without physiological effect).
215011436|NCT03983369|OTHER|Placebo|Placebo
215011437|NCT05855551|OTHER|Base cash transfer|Program beneficiaries will receive a monthly transfer of 800 BDT. A government-to-person (G2P) payment system will be used, which will transfer cash on a monthly basis. Under this new system, beneficiaries will select one of the following payment channels based on convenience: mobile financial services or through a bank transfer (which women in remote areas could access through agent banking). Each month, women will receive a text message from the government informing her that the money has been credited to her account.
214406741|NCT02821598|OTHER|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
214406742|NCT02821598|OTHER|Lifting to the right|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
214406743|NCT02821598|OTHER|Sit to Stand|"Subjects will be sitting on a chair without armrests with ankles positioned at approximately 10 degrees of dorsiflexion. Knees will be kept at approximately 100 degrees of flexion. During the task, the participant will be instructed to stand from the sitting position while keeping their arms crossed over the chest. The examiner will give the command ready - set - go. The task will be performed three times."
214406744|NCT05205993|DRUG|Intrauterine infusion|A total of 10 intrauterine infusions of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
214406745|NCT05205993|DRUG|Oral administration|per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a total of 30 days
214406746|NCT01827410|PROCEDURE|Ventral hernia repair|
214406747|NCT04721392|OTHER|Mental fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
214406748|NCT04721392|OTHER|Control (documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team.
214406749|NCT03574909|DRUG|Aspirin|Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide.
214406750|NCT03574909|DRUG|Placebos|Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
215011438|NCT05855551|BEHAVIORAL|Behavior change communication (BCC)|"The BCC strategy has two different components:~* Monthly courtyard meetings: Courtyard sessions (12 to 15 women) will be organized at a place no more than 15 to 20 minutes walking distance from the beneficiary's home. Family members (husband, mother-in-law, …) are invited to join the meeting. Sessions are part of a continuous 4-session cycle. Each session will lasts 1.5 hours and will use different didactic methods. Topics include pregnancy nutrition and care, breastfeeding, importance of different micronutrients, and nutrition and care during lactation. The importance of a healthy diet during pregnancy is repeated in each session. Pregnant women receive a take-home poster that summarizes how to eat a healthy diet during pregnancy.~* Home visits: Visits will cover the content of any sessions missed by pregnant women and will reinforce the messages regarding maternal diet on the take-home poster."
215098880|NCT06430164|DEVICE|Functional electrical stimulation (FES)|"Electrical stimulation involving the parameters and settings proposed here is commonly used in clinical practice and research for pain relief and other applications also referred to as neuromuscular or transcutaneous electrical nerve stimulation. The FES will be delivered using the UDel Stimulator, a custom-designed FES system from the University of Delaware FES lab.~Researchers will use a customized, real-time system to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains will be delivered during gait."
215098881|NCT06430164|DEVICE|Peripheral electrical stimulation paired with cortical magnetic stimulation pulses|The paired associative stimulation (PAS) will be conducted in a static posture (seated or standing), to evaluate effects on somatosensory, spinal-reflex, and/or corticospinal neurophysiology delivered with different stimulation parameters. One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds may be completed before and/or after PAS to evaluate gait performance
214406751|NCT03089619|DRUG|Human-Spongiosa|after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)
215098882|NCT04680949|DRUG|Anakinra|Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
214406752|NCT03089619|DEVICE|collacone®|after tooth extraction, the dental alveolus is filled with the bone substitute material (collacone®) and covered with a membrane (mucoderm®)
214406753|NCT00427973|DRUG|cediranib maleate|Given orally
214504752|NCT07096037|DRUG|Vitamin D|Participants will receive oral vitamin D.
214504753|NCT07096037|BEHAVIORAL|Resting conditions|Reduction in physical activity based on orthopedic advice.
215098883|NCT04680949|DRUG|Placebo|Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
214406754|NCT00427973|OTHER|laboratory biomarker analysis|Peripheral blood was obtained from all patients enrolled for studies of early changes in circulating proangiogenic and proinflammatory molecules and cells. Blood samples were collected in EDTA-containing tubes before and after cediranib therapy on days 1 and 14 of cycle 1. Circulating VEGF, placental growth factor (PlGF), sVEGFR1, basic fibroblast growth factor (bFGF), interleukin (IL)-6, IL-8, transforming growth factor a ((TNF-a), gamma interferon (IFN-g) were measured using multiplex ELISA plates from Meso-Scale Discovery. Hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), sVEGFR2, angiopoietin 2 (Ang-2), sTie2, soluble c-KIT, carbon anhydrase 9 (CAIX), and stromal cell-derived factor-1a (SDF1a) were measured using ELISA kits from R\&D Systems.
214406755|NCT00427973|PROCEDURE|computed tomography|computed tomography (CT) every 8 weeks to evaluate response and progression.
215011439|NCT05855551|OTHER|Food basket|"The monthly food basket will provide 10 kg micronutrient fortified rice , 3.5 kg of lentils, and 1000 ml of oil, valued at 800 BDT . Assuming a the ration is split equally among the 5 members of an average-sized household in rural Bangladesh and using food composition data for Bangladesh, the food basket is estimated to provide 354 kcal and 11 g of protein per person per day. The food basket will be provided once every month.~The individually packaged foods will be distributed at the Union parishad office, community clinic, or another government facility in the first week of each month. The UDW will inform the beneficiaries of the place and time of the food distribution. Recipients will only receive the food when they present their food card. The card will also be used to record receipt of each ration. If beneficiaries cannot attend the food distribution themselves, a designated nominee can pick up the ration on their behalf."
215011440|NCT05855551|OTHER|Top-up cash|"The monthly top-up cash of 1,000 BDT will be added to the base amount that is part of the standard program. For the top-up cash transfer, a person-to-person payment system is used. WFP will contract with one popular mobile banking service (either bKash or Rockets) for the monthly top-up cash transfers. About two weeks after receiving the base cash transfer, women will receive the top-up cash through a mobile account (which can also be used to receive the base cash transfer). A text message will be sent to the beneficiary to inform her that the top-up transfer has been made into her account."
215011441|NCT01558505|DEVICE|PEB|paclitaxel-eluting balloon angioplasty
215011442|NCT01558505|DEVICE|POBA|conventional balloon angioplasty
215011443|NCT03683537|DIAGNOSTIC_TEST|Glial fibrillary acidic protein|3 samples of serum are drawn from patients. The 1st Sample of patient serum is drawn before induction into anesthesia. The 2nd is drawn 24 hours after the 1st one. The 3rd sample is drawn on 3 or 4 postoperative day. All samples collected and preserved in the same temperature as required for ELISA.
215011444|NCT04731662|BEHAVIORAL|Short sleep|6-hours time-in-bed during weeknights
215011445|NCT04731662|BEHAVIORAL|Variable short sleep|Variable hours of time-in bed during weeknights
215011446|NCT06329622|COMBINATION_PRODUCT|low-protein diet + Ketosteril|low-protein diet (0.6-0.8g protein/kg body weight/day) and Ketosteril 0.12 g/kg body weight/day will be prescribed with the target energy intake of 25-30kcal/kg body weight/day.
215011447|NCT06329622|DIETARY_SUPPLEMENT|low-protein diet|low-protein diet (0.6-0.8g protein/kg body weight/day) with the target energy intake of 25-30kcal/kg body weight/day.
215011448|NCT05397405|DRUG|PCSK9 inhibitor|The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
215011449|NCT04160221|OTHER|12 hours interval|Time interval between treatments
215011450|NCT04160221|OTHER|24 hours interval|Time interval between treatments
215011451|NCT03606590|DEVICE|NovoTTF-100L(P) device|Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
215011452|NCT03606590|DRUG|Sorafenib|Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
215011453|NCT06957366|OTHER|PAUSE Perioperative DOAC Management|PAUSE management is simple and easy to apply as patients having a high-bleed-risk surgery/neuraxial procedure interrupt DOACs for 2 days before and 2 days after surgery without heparin bridging or DOAC level testing.
215011454|NCT06957366|OTHER|ASRA Perioperative DOAC Management|ASRA management is more complex, requiring 72-120 hours DOAC interruption and, in selected patients, pre-operative heparin bridging and DOAC level testing.
215011455|NCT05503732|OTHER|Energy Drink|Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
215011456|NCT05503732|OTHER|Placebo Drink|Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
215011457|NCT03456297|OTHER|Web-based clinical pedagogy program (WCP)|The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
215011458|NCT00567580|RADIATION|PBRT|1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.
215011459|NCT00567580|RADIATION|PLNRT|1.8 Gy per fraction once daily, 5 days a week, totaling 45 Gy. 3D-CRT or IMRT required.
215011460|NCT00567580|DRUG|AA|Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
215011461|NCT00567580|DRUG|LHRH agonist|Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
215011462|NCT03297060|OTHER|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
215011463|NCT05501717|DRUG|ALXN2030|ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
215011464|NCT05501717|DRUG|Placebo|Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
215011465|NCT06240143|DRUG|Ipilimumab|intradermal
215011466|NCT06240143|DRUG|Nivolumab|intradermal
215011467|NCT06240143|DRUG|Nivolumab|intravenous
215011468|NCT04524923|OTHER|visual motor integration|investigate the relation between touch screen usage and visual motor integration in preschoolers
215098884|NCT06772168|DRUG|CMG190303(Dapagliflozin/Rosuvastatin)|0-8 week: Dapagliflozin 10mg and Rosuvastatin 5mg 8-16 week: Dapagliflozin 10mg and Rosuvastatin 10mg 16-24 week: Dapagliflozin 10mg and Rosuvastatin 20mg
214406756|NCT00427973|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Magnetic resonance imaging (MRI) every 8 weeks to evaluate response and progression.
215011469|NCT04524923|OTHER|Quality of life assessment|investigate the relation between touch screen usage and Quality of life assessment in preschoolers
215011470|NCT04524923|OTHER|Cognitive Functioning|investigate the relation between touch screen usage and Cognitive Functioning assessment in preschoolers
215011471|NCT06957782|DRUG|⁶⁸Ga-FAPI-46|All patients will be administered with 1.5 MBq/kg ⁶⁸Ga-FAPI-46. ⁶⁸Ga-FAPI-46 will be injected intravenously followed by a flush injection of 10 mL of saline following routine procedures.
215011472|NCT06964581|BEHAVIORAL|Cognitive treatment delivered via telerehabilitation.|Three hours of cognitive rehabilitation per week, carried out independently and remotely using a computerized device, which is pre-programmed according to the patient's specific needs.
215011473|NCT06964581|BEHAVIORAL|In-person cognitive treatment.|Three hours of in-person cognitive rehabilitation per week using a computerized device. The participant will perform cognitive exercises on the computerized device in the presence of the therapist, who will activate the device (using credentials specifically created for them) and select the appropriate activity to administer at each session.
215011474|NCT06964659|DIETARY_SUPPLEMENT|Sulforaphan-Smart® formula|Volunteers will intake a daily dose of Sulforaphan-Smart® pill for 12 weeks (84 days)
215011475|NCT06964659|OTHER|Control (placebo) group|Volunteers will intake a daily dose of placebo pill for 12 weeks (84 days)
215011476|NCT06963515|PROCEDURE|Magnetic Resonance Imaging|3T Magnetic Resonance Imaging
215011477|NCT06963788|DRUG|Chlorhexidine 0,12%|Rinse mouth with 10ml for 30 seconds after brushing teeth for 30 minutes
215011478|NCT06963788|DRUG|0,9% Chloride Sodium|Rinse mouth with 10ml for 30 seconds after brushing teeth for 30 minutes
215011479|NCT06963788|DRUG|Silver nanoparticles mouthwash|Rinse mouth with 10ml for 30 seconds after brushing teeth for 30 minutes
215011480|NCT06964607|DRUG|Sodium-glucose cotransporter-2 Inhibitors|Patients received conventional management of acute myocardial infarction and reperfusion therapy as indicated, plus one of the available sodium-glucose co-transporter-2 Inhibitors in Egypt (Empagliflozin or Dapagliflozin), irrespective of the presence or absence of diabetes mellitus or type of heart failure(HFrEF, HFmEF, HFpEF).
215011481|NCT06964607|DRUG|Conventional treatment|Patients received conventional management of acute myocardial infarction and reperfusion therapy as indicated without adding sodium-glucose co-transporter-2 inhibitors.
215011482|NCT06963645|DEVICE|AR rehabilitation app|The intervention will consist of an 8-week home rehabilitation program during which the participant will have 1) a total of 7 weekly remote video visits with a therapist and 2) daily at-home exercises using the AR headset with rehabilitation app, done independently.
215011483|NCT06119412|OTHER|blood pressure measurement starting with standard technique or alternative new technique. manual sphygmomanometer will be used.|Each participant will have their blood pressure measured with two different techniques.
215011484|NCT06964373|DEVICE|Cervical Ripening Balloon|30 milliliter Foley balloon
215011485|NCT06964373|DEVICE|Osmotic Dilators|Dilapan-S
215011486|NCT06964529|BIOLOGICAL|Concentrated PRF|Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).
215011487|NCT06964529|BIOLOGICAL|Injectable PRF|Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).
215011488|NCT06963762|BEHAVIORAL|Conventional rehabilitation will be applied|Conventional rehabilitation will be applied for 30 minutes, 4 times a week for 4 weeks.
215098885|NCT06772168|DRUG|Comparator 1: Dapagliflozin/Rosuvastatin placebo|0-24 week: Dapagliflozin 10mg and Rosuvastatin placebo
215098886|NCT06772168|DRUG|Rosuvastatin/Dapagliflozin placebo|0-8 week: Dapagliflozin placebo and Rosuvastatin 5mg 8-16 week: Dapagliflozin placebo and Rosuvastatin 10mg 16-24 week: Dapagliflozin placebo and Rosuvastatin 20mg
215011489|NCT06963762|BEHAVIORAL|Mirror therapy will be applied along with conventional rehabilitation|In addition to conventional rehabilitation, patients in the experimental group will receive mirror therapy for 30 minutes, 4 times a week for 4 weeks.
215011490|NCT06963424|PROCEDURE|Erector Spinae Plane Block|lumbar erectro spinae block
215028973|NCT01182246|DRUG|AXP107-11|"The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa."
214406757|NCT00427973|OTHER|pharmacological study|Blood samples to characterize the steady-state PK of cediranib were drawn from a peripheral vein shortly before patients received the dose on days 8 and 15 of cycle 1 and at the following times relative to dosing on day 1 of cycle 2: 5 min and 1, 2, 4, 6, 8, and 24 hours, with the last sample collected before taking the next daily dose.
215098887|NCT07073378|DEVICE|Brain computer interface|"Families will first complete an in-person visit to review available activities, set their first goals, and learn to use BCI independently. A BCI kit will be given to each family, with a headset and the equipment and software required to pursue their identified goals. Following this, families will participate in 12 virtual sessions over 3-6 months. Scheduling will be flexible to accommodate complex family needs. Daily online support will be provided via a messaging application. Participants who choose to continue using BCI beyond 12 sessions will be provided kits and supported."
214406758|NCT02470624|OTHER|treatment following current guideline|
214406759|NCT01287338|DRUG|Olopatadine|low dose
214406760|NCT01287338|DRUG|Olopatadine|high dose
214406761|NCT04880343|DIETARY_SUPPLEMENT|Group (A)|Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 6 months
214406762|NCT04880343|DIETARY_SUPPLEMENT|Group (B)|Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 3 months
214406763|NCT02256969|DRUG|Blephamide|
214406764|NCT02256969|DRUG|GenTeal PM Night-Time|
214406765|NCT02256969|PROCEDURE|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
214406766|NCT02256969|PROCEDURE|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
214406767|NCT04516811|BIOLOGICAL|COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
214406768|NCT04516811|BIOLOGICAL|Standard of care (SOC) plus placebo|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines
214406769|NCT05238779|OTHER|Standard of care including palliative care|Usual care includes laboratory evaluations, imaging, and certain procedures and medications. In some cases of patients undergoing transplant evaluation, usual care will also include multiple visits with members of the liver transplant team. A palliative care consult will also be part of standard of care. The primary goal of the palliative care consult is not to arrange hospice (though that can be done in appropriate situations) but to identify and try to address the impacts of the disease and its symptoms on patient's life.
214406770|NCT04882462|DRUG|Nimotuzumab|Nimotuzumab, 400mg, intravenously every 3 weeks, for at least 18 weeks
214406771|NCT04882462|DRUG|Sintilimab|Sintilimab, 200mg, intravenously every 3 weeks, for at least 18 weeks;
214406772|NCT04882462|DRUG|Chemotherapy drug|Chemotherapy drugs were selected by the investigator, every 3 weeks, for 18 weeks
214406773|NCT00660166|BIOLOGICAL|NK-Cell Infusion|The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
215098888|NCT06385327|DRUG|ABI-5366|Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over the 29-day treatment period (MAD)
215098889|NCT06385327|DRUG|ABI-5366 Placebo|Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over the 29-day treatment period (MAD)
214406774|NCT02981134|PROCEDURE|Computed tomographic scan|after 1year of BVS implantation, computed tomographic scan will be performed
214406775|NCT02396030|DRUG|Magnesium sulfate 50% - 1g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
214406776|NCT02396030|DRUG|Magnesium sulfate 50% - 2g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
214406777|NCT04599452|BIOLOGICAL|Allogeneic NK cell regimen group|"10 patients with recurrent refractory elderly AML were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15."
214406778|NCT00301379|OTHER|Observation data collection study.|This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.
215011491|NCT06964204|BEHAVIORAL|Kangaroo Care|"Kangaroo care practice will be carried out in 3 stages: preparation, implementation and recording stage. Vital signs of the baby such as body temperature, heart rate, respiratory rate will be evaluated and necessary materials such as hats and covers will be prepared. In the implementation phase; the general condition of the baby will be checked, clothing and position will be adjusted, and then the baby will be transferred to the mother. After the baby is placed, his/her back will be covered with a blanket and the mother will be asked to support the baby's back with one hand and the hips with the other. When 60 minutes are completed, kangaroo care will be terminated. After the baby is placed, vital signs and general condition will be evaluated and all nursing observations will be recorded. For the babies in the other group, their mothers will sing lullabies along with kangaroo care and inclusion in the groups will be done by randomization."
214406779|NCT00402883|DRUG|Bevacizumab|15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
214406780|NCT00402883|DRUG|Pemetrexed|500mg/m2 week 1, 4, 16, 19 and 22.
214406781|NCT00402883|PROCEDURE|Radiotherapy|1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
214406782|NCT00402883|OTHER|Folic Acid|350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
214406783|NCT00402883|OTHER|vitamin B12|1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
214406784|NCT00402883|DRUG|carboplatin|AUC=5 administered intravenously weeks 1 and 4.
214406785|NCT02858934|RADIATION|Tomotherapy|"Dose prescription:~Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).~Target volumes:~Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.~Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.~CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.~Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface."
214406786|NCT06396845|PROCEDURE|robotic surgery|robotic surgery
214406787|NCT06396845|PROCEDURE|laparoscopic surgery|laparoscopic surgery
214406788|NCT03566680|DEVICE|Orthokeratology|Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
214406789|NCT00824785|DRUG|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
214406790|NCT00824785|DRUG|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
214406791|NCT00336921|DRUG|Alfuzosin|Once daily
215011492|NCT06964204|BEHAVIORAL|Kangaroo Care+lullabies|For the babies in the other group, their mothers will sing lullabies along with kangaroo care and inclusion in the groups will be done by randomization.
215028974|NCT05305651|DRUG|Sotrovimab|Sotrovimab dose and administration per standard of clinical care
214406792|NCT00336921|DRUG|Placebo|Once daily
214406793|NCT06204185|DRUG|Metformin|Locally delivered Metformin gel in the treatment of periodontitis patients
214406794|NCT06204185|DRUG|Placebo|Placebo gel consist of drug without the active component.
214406795|NCT00451698|DRUG|acyanotic erythropoietin|Single dose IV push
214406796|NCT00451698|DRUG|acyanotic placebo|Single dose IV push
214406797|NCT06340789|DRUG|Sodium Benzoate 2gram/day|the add-on sodium benzoate with conventional pharmacological treatment
214406798|NCT06340789|DRUG|Placebo|the add-on placebo with conventional pharmacological treatment
214406799|NCT04704960|OTHER|Diagnostic Test: liquid biopsy|detection of tumor DNA alteration in cf-DNA
214406800|NCT03783533|BEHAVIORAL|Behavioral Activation|Intervention: Behavioral Activation (BA) therapy is based on a functional analytic model of depression that highlights the need for increased positive reinforcement (rewards) and decreased anhedonia, or diminished motivation to seek rewards, to maintain normal mood. BA is significantly more effective than Cognitive Behavioral Therapy and comparable to antidepressant medication in reducing depressive symptoms among depressed adults (Dimidjian et al., 2006). McCauley (senior mentor) et al. (2016) adapted BA for adolescents to target anhedonia, effective problem solving and avoidant behaviors with peers, family, and school. McCauley's findings and others show BA is a promising intervention for adolescent MDD (Chu et al., 2009; Cuijpers et al.,, 2007; McCauley et al., 2015; Ritschel et al., 2011). BA focuses on targeting ideographically identified avoidant behaviors and rewarding experiences that affect mood.
214406801|NCT02862054|PROCEDURE|splenectomy|
214406802|NCT01492309|DEVICE|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
215028975|NCT02941029|OTHER|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
215028976|NCT03074669|BEHAVIORAL|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
215011493|NCT06963918|DEVICE|Expiratory muscle strength training|After the 4-week wait-to-start period during which they will not receive any intervention, will participants undergo a 4-week respiratory training program using the EMST150™ device (Expiratory Muscle Strength Trainer). EMST therapy sessions will be completed at home on 5 days (of the patients choosing) per week, performing five sets of five forceful exhalations through the EMST150™. The resistance of the device will be set to 75% of the patient's individual maximum expiratory pressure (MEP). The daily training will take approximately 15 minutes. Following the training period, patients will be observed for an additional 4 weeks to assess the sustainability of the potential training effects.
215011494|NCT06964243|DEVICE|transcranial magnetic stimulation (TMS)|A brief, short, and repeated magnetic field is generated by 2 copper coils inducing an electric current that will propagate within the targeted cortical areas.
215011495|NCT06964321|PROCEDURE|intercostal tube drainage|intercostal tube drainage in managing massive malignant pleural effusion (MPE).
215011496|NCT06964321|PROCEDURE|big tail catheter drainage|big tail catheter drainage in managing massive malignant pleural effusion (MPE).
215011497|NCT06964321|PROCEDURE|ultrasound-guided aspiration|ultrasound-guided aspiration in managing massive malignant pleural effusion (MPE).
214406803|NCT01492309|DEVICE|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
214406804|NCT01209676|DRUG|IMCgp100 injection|a monoclonal T cell receptor anti-CD3scFv fusion protein
214406805|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
214406806|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
215011498|NCT04274465|DIAGNOSTIC_TEST|digital PCR (dPCR) assay|It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA
215011499|NCT01658878|BIOLOGICAL|Nivolumab|
215011500|NCT01658878|DRUG|Sorafenib|
215011501|NCT01658878|DRUG|Ipilimumab|
215011502|NCT01658878|DRUG|Cabozantinib|
214406807|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
214406808|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
214406809|NCT05401916|DRUG|Tramadol|Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
214406810|NCT05401916|DRUG|Paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
215011503|NCT01562691|PROCEDURE|Nasopore|Bilateral nasal packing using Nasopore without airway integrated
215011504|NCT01562691|PROCEDURE|airway integrated Nasopore|post nasoseptoplasty with nasal packing using airway integrated Nasopore
215011505|NCT01562691|PROCEDURE|airway-integrated Vaseline gauze|post nasal septoplasty with packing using airway-integrated Vaseline gauze
215011506|NCT04310228|DRUG|Favipiravir Combined With Tocilizumab|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
215011507|NCT04310228|DRUG|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
215011508|NCT04310228|DRUG|Tocilizumab|The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
215098890|NCT07077226|DIAGNOSTIC_TEST|Polysomnography|Sleep studies (polysomnography and polygraphy) will be performed and reported according to current American Academy of Sleep Medicine guidelines
214406811|NCT05401916|DRUG|Ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
214406812|NCT06132321|BEHAVIORAL|Quality of life questionnaires|Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction
214406813|NCT01105494|DRUG|epoetin beta [NeoRecormon]|As prescribed by physician
214406814|NCT03379415|DEVICE|Footwear|Different types of footwear will be tested to see if these can be used to help slow the progression of osteoarthritis in meniscectomy patients or even stop it from occurring.
214406815|NCT03379415|PROCEDURE|Gait analysis|Gait analysis will be done during several different tasks wear the footwear
214406816|NCT04986540|DRUG|SHR-1906；Placebo|"Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose"
214406817|NCT00450892|DRUG|docetaxel+lapatinib|3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
214406818|NCT00450892|DRUG|docetaxel + trastuzumab|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
215011509|NCT05465876|BIOLOGICAL|EVUSHELD|EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab. The single dose, is to be administered intramuscular, each mAb sequentially into the deltoid
214406819|NCT00450892|DRUG|docetaxel + trastuzumab + lapatinib|"3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100"
214406820|NCT03381430|DRUG|Gefitinib|Gefitinib 250 mg/day oral daily
214406821|NCT05262972|OTHER|Conservatory treatment|Personalized plantar orthosis
215011510|NCT01517776|DRUG|Cilengitide|Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
215011511|NCT01517776|DRUG|Temozolomide|Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
215011512|NCT06024161|OTHER|Weight gain|≥5% weight gain
215011513|NCT06024161|OTHER|Weight loss|≥5% weight loss after arthroplasty
215011514|NCT06024161|OTHER|Weight unchanged|\<5% weight change after arthroplasty
215011515|NCT00358579|DRUG|Adrenaline|1 mg
215011516|NCT00358579|DRUG|Vasopressin|40 IU
215011517|NCT05031130|OTHER|Empowered program integrated with family support|The empowered program integrated with family support is an intervention consisted of five steps that will be given when pregnant adolescents on gestational age 32 or 33 weeks the second meeting will be when the pregnant adolescents on gestational age 34 or 35 weeks.
215011518|NCT04743596|DEVICE|High-Definition Videobronchoscopy|Endoscopic inspection and endobronchial biopsy with standard forceps during high-definition videobronchoscopy.
215011519|NCT03197935|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab was administered as per schedule described in respective arm.
215011520|NCT03197935|DRUG|Placebo|Placebo matched to atezolizumab was administered as per schedule described in respective arm.
215011521|NCT03197935|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered as per schedule described in the arms.
215011522|NCT03197935|DRUG|Doxorubicin|Doxorubicin was administered as per schedule described in the arms.
215011523|NCT03197935|DRUG|Cyclophosphamide|Cyclophosphamide was administered as per schedule described in the arms.
215011524|NCT03197935|DRUG|Filgrastim|Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
215011525|NCT03197935|DRUG|Pegfilgrastim|Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
215011526|NCT04058912|GENETIC|PTEN-AKT-FOXO3 Gene Expression|In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
215011527|NCT01768273|DRUG|Midazolam|
215011528|NCT01768273|DRUG|PA-824|
215011529|NCT01801527|BEHAVIORAL|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
215011530|NCT01728961|DRUG|Artemether/Lumefantrine (AL)|
215011531|NCT00762788|DEVICE|senofilcon A|1 week extended wear contact lens
214406822|NCT05262972|OTHER|Innovate treatment|Personalized plantar orthosis + percutaneous electrolysis
214406823|NCT03458897|DIAGNOSTIC_TEST|serial functional magnetic resonance imaging (MRI)|All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
214406824|NCT03539159|OTHER|Allogeneic conventional sized serum eye drops|allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
215011532|NCT00762788|DEVICE|lotrafilcon A|1 week extended wear contact lens
215011533|NCT00762788|DEVICE|lotrafilcon B|1 week extended wear contact lens
215011534|NCT00762788|DEVICE|balafilcon A|1 week extended wear contact lens
215011535|NCT00762788|DEVICE|comfilcon A|1 week extended wear contact lens
215011536|NCT00762788|DEVICE|etafilcon A|1 week extended wear contact lens
215011537|NCT04236466|DEVICE|hyrax appliance|Hyrax will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines.
215011538|NCT04236466|DEVICE|haas appliance|Haas will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines. Acrylic part will be added on palate
215011539|NCT05938010|DEVICE|Dailies Total1® contact lenses for astigmatism (T30fA)|Dailies Total1® contact lenses for astigmatism (T30fA)
215011540|NCT02992431|BEHAVIORAL|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
215011541|NCT02992431|OTHER|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
215011542|NCT05403515|OTHER|foot massage|foot massage
215011543|NCT05403515|OTHER|Foot massage +Aromatherapy group|foot massage and lavender oil inhalation
215011544|NCT04832308|BEHAVIORAL|Exercise Therapy|This is a health coach driven exercise prescription for patients recommending 30 minutes or more of moderate effort walking 3-5 days a week with expected walk-rest-walk-rest intervals.
215011545|NCT02834897|RADIATION|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
215011546|NCT02603029|OTHER|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
215011547|NCT02603029|OTHER|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
215011548|NCT02083263|DEVICE|Bilevel|3 months
215011549|NCT02083263|DEVICE|PEP mask|3 months
215011550|NCT04472208|DEVICE|Ambulatory monitoring solution|Subjects participating in this study will be monitored with the site's standard of care primary monitor and the evaluable device as the secondary monitor.
215011551|NCT00365963|DEVICE|Comprehensive Health Enhancement Support System|computer based support and education
214406825|NCT03539159|OTHER|Allogeneic micro sized serum eye drops|Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
214406826|NCT05553561|PROCEDURE|IPRL device|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
214406827|NCT05553561|PROCEDURE|pharmacological therapy & Eyelid hygiene|traditional methods of MGD treatment as Eyelid hygiene, topical preservative free lubricant, topical \& systemic antibiotics \& anti-inflammatory agent
214406828|NCT02157714|DRUG|PRX002|
214406829|NCT02157714|OTHER|Placebo|
214406830|NCT02374957|DRUG|Cilostazol|100 mg twice daily for 90 days
214406831|NCT03298464|BIOLOGICAL|NGM313|Subcutaneous injection
214406832|NCT03298464|DRUG|Pioglitazone|White to off-white round tablet
214406833|NCT00748969|DRUG|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
214406834|NCT06426082|BEHAVIORAL|Thermoneutral condition|Participants will be exposed 2 hours/day at 32ºC for 5 days/week
214406835|NCT06426082|BEHAVIORAL|Cold condition|Participants will be exposed 2 hours/day at 18ºC for 5 days/week
214406836|NCT06426082|BEHAVIORAL|Aerobic exercise condition|Participants will perform aerobic exercise training 5 days/week at 65% heart rate reserve for 60 minutes each training session
215011552|NCT04124510|DRUG|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
215011553|NCT06218784|DRUG|iN1011-N17 HCl Suspension (Part 1)|Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)
215011554|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 1)|Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)
215011555|NCT06218784|DRUG|Placebo Capsule (Part 1)|Dose: b.i.d for 7 days
215011556|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 2)|Dose: 400 mg QD
215011557|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 2)|Dose: 400 mg QD
215098891|NCT07077109|DEVICE|Electrophysiological monitoring|electrofysiological CTG monitoring with the Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands). The NFMS consists of a wireless and beltless electrode patch on the maternal abdomen. It monitors fetal heart rate by fetal electrocardiography, maternal heart rate by maternal electrocardiography and the electrical activity of the uterine muscle by electrohysterography.
214406837|NCT06426082|DRUG|Salbutamol|Participants will take salbutamol 12 mg/day. 7 days week
214406838|NCT01912001|OTHER|Telephone follow-up|
215011558|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
215011559|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
215011560|NCT06218784|DRUG|Placebo Capsule (Part 3)|Dose: b.i.d for 14 days
215098892|NCT07077707|OTHER|Prenatal GENEie Chatbot|Patient Educational Phone Chatbot Application for Prenatal Genetics in English \& Spanish
215098893|NCT07077707|OTHER|In-person genetic counseling|Standard in-person genetic counseling for prenatal genetics education
214406839|NCT01912001|OTHER|Sympton Assessment|
214406840|NCT05163756|DRUG|DW1903|q.d. PO, DW1903 + Placebo of DW1903-R1
214406841|NCT05163756|DRUG|DW1903-R1|q.d. PO, Placebo of DW1903 + DW1903-R1
214406842|NCT02334306|BIOLOGICAL|AMG 557/MEDI5872|Participants will receive a fixed SC dose of 210 mg MEDI5872 (AMG 557/MEDI5872) QW for 3 weeks (Days 1 to 15) and then Q2W for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, all participants from double-blind period will receive a fixed SC dose of 210 mg MEDI5872 from Day 99 to Day 183 (QW from Days 99 to 113 for participants from Placebo arm and on Days 99 and 113 for participants from MEDI5872 210 mg arm; and Q2W from Days 127 to 183 for participants from both arms).
214406843|NCT02334306|OTHER|Placebo|The SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, an additional dose of blinded placebo will be administered on Day 106 for participants who will receive MEDI5872 210mg in double-blinded period.
214406844|NCT01687270|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
214406845|NCT01687270|DRUG|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
214406846|NCT00465985|DRUG|ACZ885|
214406847|NCT00465985|DRUG|Placebo|
214406848|NCT04417712|DEVICE|KONAR-MF™ VSD Occluder|All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).
214406849|NCT00285558|BEHAVIORAL|CBT with peer-enhanced activities|
214406850|NCT00285558|BEHAVIORAL|CBT with supervised aerobic exercise|
215011561|NCT03091491|DRUG|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
215011562|NCT03091491|DRUG|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
215011563|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with counter-displaced skin-subcutaneous fascial flaps after extralevatory abdominal-perineal extirpation of the rectum|Skin-subcutaneous fascial flap on the leg is cut out from one side of the perineal wound, and deepithelized, forming a diamond-shaped perineal wound. The cut flap is immersed in the aperture of the pelvis and fixed with single sutures to the remains of levators of the opposite side. The flap width should be 3-4 cm, sufficient to fill the pelvic aperture. On the opposite side of the wound, a skin-subcutaneous fascial flap is cut out on a triangular leg equal to the width of the previously formed diamond-shaped wound. The flap is moved to the center of the wound, additionally filling wound cavity with it, combining the vertex of the triangle with the vertex of the rhombus. The perineal wound is drained through the contraperture. The flap is fixed with separate nodal seams.
214694198|NCT03542071|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
215098894|NCT07081308|DEVICE|NIRS-BCI-pneumoorthesis|"Patients recieve 10 NIRS-BCI-pneumoorthesis trainings of 16 minutes each over 2 weeks.~NIRS-BCI-pneumoorthesis Components: NIRScout hardware-software complex (16 light sources, 8 detectors); Software for brain activity classification; Korvit system for plantar support load reproduction; 22-inch monitor for task demonstration.~Training Procedure: Patient seated with lower limbs fixed in pneumatic orthoses; Task: kinesthetically imagine walking or relax; Feedback: visual (color change on screen) and tactile (support load through orthosis).~Training structure: 16 blocks alternating walking imagination and relaxation"
215011564|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with local tissues|Simple layer-by-layer suturing of the sciatic-anal and subcutaneous adipose tissue is performed using nodular sutures. The skin was sewn up with nodular sutures at the discretion of surgeons. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon.
215011565|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with mesh endoprosthesis|A mesh allograft with an adhesive coating is inserted into the bottom of the wound, positioned horizontally between the inner surfaces of the ischial bones and vertically between the sacrum and the vagina in women or between the sacrum and the prostate gland in men. The mesh was sewn from behind on both sides of the coccyx or sacrum. From the side, the mesh was attached to the remainder of the levator muscle and from the front to the transverse muscles of the perineum. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon. The sciatic-anal and subcutaneous fat are sutured using nodular sutures.
215011566|NCT00069329|DRUG|anakinra|daily injection of subcutaneous injection
215011567|NCT01562444|OTHER|Blood draw|Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)
215098895|NCT07078591|DRUG|Venetoclax|Given PO
215098896|NCT07078591|DRUG|Azacitidine (AZA)|Given SC
215098897|NCT07078591|DRUG|Daunorubicin|Given IV
215098898|NCT07078591|DRUG|Idarubicin（IDA）|Given IV
215098899|NCT07078591|DRUG|Cytarabine (Ara-C)|Given IV
215098900|NCT07078591|BIOLOGICAL|GPBMC infusion|HLA-mismatched donor GPBMC infusion
215011568|NCT02331407|DEVICE|Robotic arm therapy|Training with the ReoGo device
215011569|NCT02201576|DRUG|Bortezomib|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~3. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
215098901|NCT07080996|COMBINATION_PRODUCT|Strengthening training with biofeedback|Participants in this group trained their tongue strength with the Iowa Oral Performance Instrument (IOPI), completing 3 sets of 10 repetitions at 80% of their maximum.
215011570|NCT02201576|DRUG|Plasma exchanges and intravenous immunoglobulins|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~3. oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)"
215011571|NCT00546273|BIOLOGICAL|RUTI|dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
215098902|NCT07080996|COMBINATION_PRODUCT|Endurance training with biofeedback|Participants in this group trained their tongue endurance with the Iowa Oral Performance Instrument (IOPI), completing 3 sets of 20 repetitions at 60% of their maximum.
215098903|NCT06795906|DRUG|AZD8630|AZD8630 will be administered via dry powder inhalation (DPI).
215098904|NCT06795906|OTHER|Placebo|Placebo will be administered via DPI.
215098905|NCT06795906|DEVICE|Saphira device|AZD8630 or placebo will be administered to participants via Saphira device.
215011572|NCT00546273|BIOLOGICAL|RUTI|dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
215011573|NCT00546273|BIOLOGICAL|RUTI|dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
215011574|NCT00546273|BIOLOGICAL|RUTI|dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
215011575|NCT00546273|BIOLOGICAL|placebo of the vaccine RUTI|placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
215011576|NCT00227955|DRUG|Imipramine|
215098906|NCT07081945|DEVICE|hAM|The hAM stands for human amniotic membrane, which was used to seal inferior retinal breaks after complete vitrectomy.
215098907|NCT07083063|DRUG|Nitroglycerin (NTG)|All patients without chronic kidney disease (serum creatine \> 1.5 mg/dL) will receive rectal diclofenac 100 mg before the procedure. During the biliary cannulation, if twice or more times of pancreatic duct cannulation, a pancreatic plastic stent will be placed. Lactate ringer hydration will be provided to patients with pancreatic duct cannulation for 24 hours. After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. Before the end of the exam, diluted 1mg nitroglycerin in normal saline (1mg/10cc) will be delivered to the major papilla in the intervention group, and 10cc normal saline will be delivered to the major papilla in the standard group.
214406851|NCT03302156|DRUG|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
215098908|NCT07083063|DRUG|Normal Saline (0.9% NaCl)|All patients without chronic kidney disease (serum creatine \> 1.5 mg/dL) will receive rectal diclofenac 100 mg before the procedure. During the biliary cannulation, if twice or more times of pancreatic duct cannulation, a pancreatic plastic stent will be placed. Lactate ringer hydration will be provided to patients with pancreatic duct cannulation for 24 hours. After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. Before the end of the exam, diluted 1mg nitroglycerin in normal saline (1mg/10cc) will be delivered to the major papilla in the intervention group.
215098909|NCT07081191|BEHAVIORAL|Dance|CDP was designed based on a 12-week dance curriculum, which involves 3 separate blocks of choreography of increasing complexity and intensity. According to World Health Organization, a minimum of 150 minutes of moderate intensity exercise would result in improvement in physical health, therefore, the intervention arm would involve 2 sessions of CDP, 75 minutes per session each week.
214406852|NCT03532178|DRUG|"Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline"|"The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period."
215011577|NCT00227955|BEHAVIORAL|Interpersonal Psychotherapy|
215011578|NCT03736369|DRUG|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
215098910|NCT07081191|BEHAVIORAL|Active Control|CDP was designed based on a 12-week dance curriculum, which involves 3 separate blocks of choreography of increasing complexity and intensity. According to World Health Organization, a minimum of 150 minutes of moderate intensity exercise would result in improvement in physical health, therefore, the active control arm would only include 60 minutes of CDP (1 session) per week to assess the effect of CDP on the cognitive and physical health of older adults.
215098911|NCT07078942|DRUG|Tranexamic Acid|Tranexamic Acid 1 g intravenous preoperation
215098912|NCT07078942|OTHER|Placebo|normal saline 20 ml intravenous preoperation
214406853|NCT03532178|DRUG|"Group B. Muscle relaxant #2: succinylcholine +saline; Muscle relaxant #1: rocuronium + sugammadex;"|"The participants will be randomized to start with Muscle relaxant #2 in the first study treatment, and will switch to Muscle relaxant #1 in the second study treatment period."
214406854|NCT03206931|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
214406855|NCT04077684|DRUG|Interleukin-2|IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
214406856|NCT05392764|DRUG|Empagliflozin 10 MG|once-daily oral empagliflozin 10 mg
214406857|NCT05392764|DRUG|Placebo|Placebo matching empagliflozin 10 mg
214406858|NCT02636413|DRUG|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
214406859|NCT02636413|DIETARY_SUPPLEMENT|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
214406860|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - fast release|
215011579|NCT03736369|DRUG|DWP14012 40mg placebo|DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
214406861|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - slow release|
214406862|NCT02824367|BEHAVIORAL|Completion of scales evaluation|Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
214406863|NCT01121783|OTHER|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
214406864|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
214406865|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
214406866|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
215011580|NCT03736369|DRUG|Esomeprazole 40mg|Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks
215011581|NCT03736369|DRUG|Esomeprazole 40mg placebo|Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
215011582|NCT01163565|DEVICE|Ligasure Device|Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
215011583|NCT01795755|BEHAVIORAL|Mentalization based inpatient treatment.|1-3 month of inpatient treatment
215011584|NCT01795755|BEHAVIORAL|Horse assisted Therapy (HAT)|A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
215011585|NCT05244837|DRUG|Tislelizumab 200 mg|Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)
215011586|NCT05244837|DRUG|Carboplatin AUC 5|Carboplatin AUC 5 IV Q3W
215011587|NCT05244837|DRUG|pemetrexed 500mg/m2|Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer
215011588|NCT05244837|DRUG|Paclitaxel 175mg/m2|Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer
215011589|NCT05244837|DRUG|Nab-paclitaxel 260 mg/m2|nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer
215011590|NCT05415787|OTHER|Blood sample|2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
215011591|NCT05415787|OTHER|Urine sample|Urine sample is taken during the consultation carried out for the patient's care
215098913|NCT07083414|DEVICE|elderly participant will receive digital educational oral health program.|"* Digital 3D Model Video: A custom-designed 3D animated video illustrating proper tooth brushing techniques tailored for elderly individuals, as well as comprehensive guidance on denture care.~* Written Educational Materials: Printed resources including posters and flyers that provide key messages and visual demonstrations related to maintaining good oral hygiene practices.~* PowerPoint Presentations and Educational Videos: Visual and audiovisual materials focusing on the importance of balanced nutrition in maintaining oral and general health, and early detection of oral cancer, including risk factors, signs, and recommended screening practices.~* Hands-on Brushing Technique Training: Practical sessions utilizing dental cast models to demonstrate and allow participants to practice effective brushing techniques under supervision."
215098914|NCT07083414|OTHER|elderly participant will receive the standard oral health education in geriatric institution.|The use of traditional health promotion materials, such as leaflets and posters, remains valuable in community settings. These tools are cost-effective, easy to produce, and continue to serve as effective educational resources for adults, including the elderly. Participants in the control group will receive standard oral health information. No education sessions will be conducted during the 6 months till the final assessment. However, after the final assessment at 6 months, the control group will be offered access to the digital educational program.
215098915|NCT07083349|DRUG|NK510 : allogeneic genetic modified NK|NK510 is an allogeneic genetic modification of NK cell. NK510 will be administered at a dose of 4x10\^7 NK/kg, 8x10\^7 NK/kg and 1.2x10\^8 NK/kg by a dose-escalation design and administered IV.
215098916|NCT07086053|DEVICE|MyotonPRO|The MyotonPRO is a non-invasive handheld device that assesses the mechanical and viscoelastic properties of soft tissue (e.g., skin stiffness, elasticity, and relaxation time). In this study, it is used in patients with breast cancer-related lymphedema (BCRL). Each participant is evaluated by two blinded raters to determine intra- and inter-rater reliability.
215098917|NCT07087158|DRUG|IBR854|Every 21 days is one cycle, and IBR854 will be dosed in a route of intravenous infusion on day 1 and day 8 of each cycle with a fixed dose of 9.0×10\^9 cells.
215098918|NCT07087158|DRUG|Pazopanib|Pazopanib will be dosed orally once daily without food (at least 1 hour before or 2 hours after a meal) with a fixed dose of 800mg.
215098919|NCT00231413|BIOLOGICAL|HPV 16/18 L1 AS04|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
215098920|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 1|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
214406867|NCT06351280|OTHER|Standardised Physiotherapy Plan|"Single session of coached deep breathing and coughing exercises. 10 supervised slow flow deep breaths to total lung capacity with a 3-5 second end inspiratory hold completed with 2 end inspiratory sniffs. 2-3 supported coughs or huffs. Repeated for another set. Patients instructed to perform independently hourly. Assisted ambulation according to the following protocol:~* Stage 1 of 2 minutes.~* Stage 2 of 0-1 minute.~* Stage 3 of 1 - 3 minutes.~* Stage 4 of 3 - 6 minutes.~* Stage 5 of 6 - 10 minutes.~* Stage 6 of 10 - 15 minutes.~* Stage 7 \> 15 minutes. Total session time is the accumulative work time."
214406868|NCT00628940|RADIATION|PET images with 18F-fluoromethylcholine|sequential PET images with 18F-fluoromethylcholine
214406869|NCT02390557|OTHER|Survey|PDQS survey reports only
214406870|NCT02390557|OTHER|YESHealth|Arm 3: YESHealth and PDQS survey reports to providers
214406871|NCT01376141|DRUG|Sumatriptan|
214406872|NCT01711918|DRUG|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
215098921|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 2|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
215098922|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 3|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
214406873|NCT01612754|BEHAVIORAL|Noise reduction work place rules|"Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones."
214406874|NCT01612754|BEHAVIORAL|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
214406875|NCT03278028|DRUG|A-101 Topical Solution|A-101 Topical Solution
214406876|NCT03278028|DRUG|A-101 Vehicle Solution|A-101 Vehicle Solution
214406877|NCT02114840|PROCEDURE|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
214406878|NCT02114840|PROCEDURE|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
214406879|NCT02114840|PROCEDURE|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
214406880|NCT00247156|PROCEDURE|Acupressure treatments and NAET treatments|
214406881|NCT04900155|DRUG|Atorvastatin 80mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
214406882|NCT04900155|DRUG|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
214406883|NCT01004328|OTHER|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
214406884|NCT05482919|BEHAVIORAL|Baseline Survey|The baseline survey, initial PHQ-9 and GAD-7, could be collected prior to surgery after consent, or on the day of surgery, for participants who are undergoing elective surgery or urgent procedures and did not attend pre-operative clinic. Demographic information such as race and ethnicity, pain medications and pain history and baseline self-reported health information will be collected. It will take about 15 minutes to complete.
214406885|NCT05482919|BEHAVIORAL|Post Operative Surveys|Post operative surveys will be collected at one week, two weeks, one month, then monthly up to 6 months after surgery with total of 7 post-op surveys. Refer to Table 1 for visit windows. The study survey could be collected by phone, REDCap texting or email per the subject's preference. Survey content will also include: daily average and maximum self-reported pain scores on a 0-10 Numeric Rating Scale (NRS) pain scale, average hours of sleep, anxiety and depression screens using the PHQ-9 and GAD-7 questionnaires (Months 1, 3, and 5), pain location and quality, percentage of day spent in pain, satisfaction with recovery using a five-point Likert scale, and type, quantity and timing of any medications used for pain (including opioid alternatives).
215011592|NCT04761354|PROCEDURE|Unilateral adrenalectomy|
215011593|NCT05552495|DRUG|CKD-386(4) F1|1 Tablet
215011594|NCT05552495|DRUG|CKD-386(4) F2|1 Tablet
215011595|NCT05552495|DRUG|D013, D326, D337|D013 1 Tablet, D326 1Tablet, D337 1 Tablet
215011596|NCT06434779|DEVICE|JETi 6F and 8F Thrombectomy system|To demonstrate the efficacy and safety of the mechanical thrombectomy device (JETi 6F and 8F) for treatment of patients with symptomatic peripheral artery disease (PAD) due to acute or acute on chronic occlusions of the femoral and/or popliteal arteries and the first 10 cm of the below-the -knee arteries.
215011597|NCT02620111|DIETARY_SUPPLEMENT|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
215011598|NCT02620111|DIETARY_SUPPLEMENT|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
215011599|NCT05050838|OTHER|Transcranial Doppler (TCD)|"TCD ultrasonography is based on the principle of the Doppler effect. According to this principle, ultrasound waves emitted from the Doppler probe are transmitted through the skull and reflected by moving red blood cells within the intracerebral vessels. The difference in the frequency between the emitted and reflected waves, referred to as the Doppler shift frequency, is directly proportional to the speed of the moving red blood cells (blood flow).~Cerebral blood flow (in cm/s) of the middle cerebral artery will be measured with TCD in blood-injured ARDS patients before and one hour after prone positioning (normal ranges: 48 to 72 cm/s)."
215011600|NCT01769118|DRUG|Caffeine|Caffeine will be given according to departmental protocol
215011601|NCT00666978|BEHAVIORAL|smoking cessation intervention|
215011602|NCT00666978|DRUG|bupropion hydrochloride|
215011603|NCT00666978|GENETIC|gene expression analysis|
215011604|NCT00666978|GENETIC|polymerase chain reaction|
215011605|NCT00666978|OTHER|counseling intervention|
215011606|NCT00666978|OTHER|educational intervention|
215011607|NCT00666978|PROCEDURE|psychosocial assessment and care|
215011608|NCT05039593|OTHER|chlorhexidine|The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.
215011609|NCT04561609|OTHER|Transcutaneous CO2 application|"Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only)."
215011610|NCT04561609|OTHER|Placebo treatment|Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
215011611|NCT02386579|PROCEDURE|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
215011612|NCT04332185|PROCEDURE|vestibular socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
215011613|NCT01341548|DRUG|Civamide nasal solution 0.01%|20ug/dose, BID for 7 days 0.1 ml to each nostril
215011614|NCT03005574|BEHAVIORAL|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
215011615|NCT03005574|BEHAVIORAL|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
215011616|NCT02487706|DRUG|Dolutegravir|Dolutegravir 50mg/day per 5 days
215011617|NCT01124539|DRUG|AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)|IV AR-67 administered once daily for 5 days on an every 21-day cycle
215011618|NCT05166928|DEVICE|carriere motion appliance|after finished treatment with carrirere motion appliance in the two group (group 1 have upper wisdom teeth ,group 2 have not upper wisdom teeth ) the pre and post casts will be scanned and superimposed to determine amount upper molar distalization
215011619|NCT01590966|DRUG|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
215011620|NCT01590966|DRUG|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
215011621|NCT04240847|PROCEDURE|Skin incision|Skin incision on medial or lateral to tibial tubercle
215011622|NCT06359522|DEVICE|NIRS monitor|NIRS monitoring data will be collected to determine organ perfusion.
215098923|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 4|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
214406886|NCT05482919|BEHAVIORAL|Qualitative Interviews|Using sampling to identify adolescents who exhibit higher pain scores or prolonged opioid use compared to peers after completion of the first three surveys (pre-operative, Week 1, Week 2), the study will also select a representative sample of adolescents who are recovering as anticipated. Examples of delayed recovery include a higher proportion of moderate to severe pain scores, dissatisfaction with recovery and prolonged opioid use compared to peers. As a balancing measure, the upper limit of adolescents who are perceived to exhibit delayed recovery that are approached for interviews will be capped at a 3:1 ratio compared to those who are recovering as anticipated, and Investigators will prioritize an equal demographic distribution among the two groups. Interviews will take place over the phone or through a CHOP approved vendor at 1 and 3 months after surgery; audio will be recorded with participant consent.
214406887|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
214406888|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
214406889|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
214406890|NCT00973141|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
214406891|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
214406892|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
215011623|NCT01665378|DIETARY_SUPPLEMENT|Multiple Micronutrient|"There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)\* 2800 Iron (mg)\* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
215011624|NCT01665378|DIETARY_SUPPLEMENT|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
215011625|NCT01665378|DIETARY_SUPPLEMENT|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
215011626|NCT01908842|DRUG|BNX sublingual tablets|Buprenorphine/naloxone sublingual tablets
215011627|NCT01908842|DRUG|BNX sublingual film|Buprenorphine/naloxone sublingual film
215011628|NCT01908842|DRUG|Buprenorphine|Buprenorphine sublingual tablets
215011629|NCT00197483|DRUG|Pergolide (drug)|
215011630|NCT02568423|DRUG|Mirikizumab - IV|Administered IV
215011631|NCT02568423|DRUG|Mirikizumab - SC|Administered SC
215011632|NCT02568423|DRUG|Placebo - IV|Administered IV
215011633|NCT02568423|DRUG|Placebo - SC|Administered SC
215011634|NCT00249041|DRUG|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
215011635|NCT00249041|DRUG|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
214406893|NCT04124068|OTHER|Hydrogen peroxide teeth whitening gel|Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
214406894|NCT04124068|DEVICE|GLO Brilliant Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
214406895|NCT04124068|DEVICE|GLO Lit Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
214406896|NCT04124068|DEVICE|GLO Science Professional Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
214406897|NCT02111148|PROCEDURE|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
214406898|NCT02111148|PROCEDURE|Nitrazine|Nitrazine detection in vaginal wash
214406899|NCT02111148|DRUG|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
214406900|NCT06132919|DRUG|MC2-25 cream|Topical application
214406901|NCT06132919|DRUG|MC2-25 vehicle|Topical application
214406902|NCT05054400|DRUG|F18 Fluciclovine|Given by IV
214406903|NCT05054400|OTHER|Standard of Care|Standard of care
215011636|NCT03828669|BEHAVIORAL|Recovery Toolkits|"Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)"
215011637|NCT02184247|DRUG|anhydrous theophylline, 350 mg|
214406904|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent \[%\] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
215011638|NCT02184247|DRUG|anhydrous theophylline, 300 mg|
215011639|NCT00677287|BIOLOGICAL|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
215011640|NCT00390351|DEVICE|optical coherence tomography|
215011641|NCT00038610|DRUG|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
214406905|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
214406906|NCT01360840|OTHER|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
214406907|NCT01360840|OTHER|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
214406908|NCT04521192|DRUG|Fluzoparib|the first period: test preparation; the second period: reference preparation
214406909|NCT04521192|DRUG|Fluzoparib|the first period: reference preparation the second period: test preparation
214406910|NCT05657067|BEHAVIORAL|Emotionally Focused Family Therapy (EFFT)|The rationale behind EFFT is that mental health problems in children and adolescents often originate and/or are exacerbated by negative interaction patterns rooted in insecure attachment bonds within families. Therefore, the main treatment goal of EFFT is the development of secure attachment between parents and their children.
214406911|NCT03801772|DEVICE|Metronome|Pacing aquatic exercises to the beats per minute of a metronome. The metronome will be adjusted to each patient's pain free exertion level. Patients will start with 10-20 repetitions of the exercises depending on their physical ability. The repetitions will be progressed as the patient's strength and endurance improve and noted in the chart and the flow sheet. The metronome will be synchronized during their second aquatic therapy treatment. The beats per minute (BPM) will be increased on the metronome during the series of treatments until the patient can no longer maintain proper technique with the exercises. The exercises will continue at this BPM during future visits. The patient will be instructed to keep pace with the beat of the metronome for the duration of the exercise.
214406912|NCT01221077|DRUG|OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
214406913|NCT01221077|DRUG|Erlotinib|Erlotinib administered orally
214406914|NCT01221077|DRUG|Placebo|As of 01 March 2013, the matching placebo is no longer being administered
214406915|NCT02425683|DRUG|Regorafenib|120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
215011642|NCT00038610|DRUG|Cyclophosphamide|300 mg/m\^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m\^2) for courses 1, 3, 5, 7.
215011643|NCT00038610|DRUG|Doxorubicin|50 mg/m\^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
215011644|NCT00038610|DRUG|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
215011645|NCT00038610|DRUG|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
215011646|NCT00038610|DRUG|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
215011647|NCT00038610|DRUG|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
215011648|NCT00038610|DRUG|Mesna|600 mg/m\^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
215011649|NCT00038610|DRUG|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
215011650|NCT01027416|DRUG|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
215011651|NCT01058824|DRUG|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
214406916|NCT02300779|DIETARY_SUPPLEMENT|Low-residue diet|"Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted."
214406917|NCT02300779|DIETARY_SUPPLEMENT|Usual care|"Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made."
214406918|NCT00293462|BIOLOGICAL|sargramostim|
214406919|NCT00293462|OTHER|oral salt and soda mouthwash|Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
215011652|NCT01058824|DRUG|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
215011653|NCT05362019|DRUG|Compound Norethisterone Enanthate Injection|Combined injectable contraceptive use
215011654|NCT05362019|OTHER|One-to-one Service|"A mobile phone based service system will be used to pushing contraceptive knowledges, reminding injection, providing consultation on adverse reactions and ect."
215011655|NCT05362019|OTHER|Family Planning Service|routine family planning service and contraceptive service.
214406920|NCT04007003|BEHAVIORAL|training in optimal insulin injection technique|the training will be delivered in person as well as through online training modules via the BD and Me(TM) platform
214406921|NCT05204784|PROCEDURE|Rheopheresis treatment|After obtaining venous access, anticoagulated blood is pumped through a plasmafilter. The plasma is then run through the Rheofilter and large plasma proteins are removed. Finally, cells are reinfused, and blood is returned to the patient.
214406922|NCT05204784|DRUG|Intravenous Infusion|Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard
215011656|NCT01692587|OTHER|Protein restrictive diet|To begin a reduced protein diet
215011657|NCT02894138|DRUG|alteplase|
214406923|NCT02460887|DRUG|Gemcitabine|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
215011658|NCT02894138|DRUG|Placebo|
215011659|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
215011660|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by centralized genetic counseling group at Indiana University.
215011661|NCT05099445|DRUG|INCB000928|INCB000928 200 mg will be administered on Day 1 of each treatment period.
215011662|NCT05010967|OTHER|High intensity interval training|"HIIT 3 times a week for 8 weeks. For week 1 to 4 , Warm up 5 minutes jogging in place, 6 series of 30 seconds Burpees, 30 seconds recovery, 30 seconds skipping, 30 seconds recovery, 30 seconds lunge, 30 seconds recovery, 30 seconds 1-legged squats, 30 seconds recovery, 30 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches.~For week 5 to 8 , Warm up 5 minutes jogging in place, 6 series of 45 seconds Burpees, 45 seconds recovery, 45 seconds skipping, 30 seconds recovery, 45 seconds lunge, 30 seconds recovery, 45 seconds 1-legged squats, 30 seconds recovery, 45 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches."
215011663|NCT05010967|OTHER|Yoga Training|Yoga 3 times a week for 8 weeks. 30-50 minutes session, 5 minutes breathing, 15-35 minutes yoga poses (Cat-cow, child's pose, downward dog, plank, Cobra), followed by 10 minutes supine meditation.
215011664|NCT03722628|DIAGNOSTIC_TEST|MMP1 genotypes polymorphism|Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
215011665|NCT01496443|DRUG|TAK-875 and Glimepiride|
215011666|NCT00860431|DRUG|AST-120|6g/day (3 times a day)
215028977|NCT00526799|DRUG|Sorafenib|"Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"
215028978|NCT00526799|DRUG|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
215028979|NCT05751304|DRUG|Dexmedetomidine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg Dexametomidine.
214406924|NCT02460887|DRUG|cisplatin|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
214406925|NCT02460887|DRUG|cisplatin|Active Comparator arm: Patients receive weekly cisplatin 40 mg/m² up to 7cycles during IMRT.
214406926|NCT02460887|RADIATION|Intensity-modulated Radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
215011667|NCT05160285|DRUG|Nivolumab 100 MG in 10 ML Injection|If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
214406927|NCT00207649|BEHAVIORAL|Shared decision-making for PSA screening tool|Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
214406928|NCT06356272|OTHER|Non-Interventional Study|Non-interventional study
214406929|NCT03639441|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
214406930|NCT03639441|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
215011668|NCT05640635|PROCEDURE|Ventilator weaning first|Ventilator weaning initiated and completed before start of ECMO weaning.
215011669|NCT05640635|PROCEDURE|ECMO weaning first|ECMO weaning initiated and completed before start of ventilator weaning.
215011670|NCT01277731|DRUG|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
215011671|NCT02129881|BIOLOGICAL|Autologous regulatory T Cell Product|Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
215011672|NCT05702619|DRUG|Optional non-IMP pimonidazole|patients will be asked to ingest an oral formulation of pimonidazole hydrochloride (HCl) (Oral HypoxyprobeTM-1). Pimonidazole HCl is a marker for hypoxia in tumour tissue when ingested as an encapsulated solid. Following oral administration, pimonidazole distributes throughout the body where it covalently binds to normal and tumour tissues that have regions of low oxygen concentrations (pO2 of ≤ 10 mmHg at 37oC). The tissue binding can be visualised by immunohistochemistry / light microscopy. The capsules are to be taken within 8-16 hours (optimal timepoint 12 hours) before the planned first biopsy within Arm 1 and before radical prostatectomy for patients in Arm 2. If the patient refuses the pimonidazole, forgets to take it, or if it is not available, the patient can still participate in the study and their samples will be stained for hypoxia post-biopsy.
215028980|NCT05751304|DRUG|Ketamine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
215028981|NCT01422577|DEVICE|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
215028982|NCT01422577|DEVICE|White light Endoscopy|White light Endoscopy
215028983|NCT04003389|DRUG|fezolinetant|administered orally
215028984|NCT04003389|DRUG|placebo|administered orally
214406931|NCT04304469|OTHER|surveys|delivery of the survey at a domestic violence consultation
214406932|NCT04304469|OTHER|follow-up|follow-up of women 6 months after their consultation
214406933|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
214406934|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
214406935|NCT02311192|DEVICE|Ultrasonography B-scan|The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
214406936|NCT05323721|DRUG|Sulfadoxine pyrimethamine and amodiaquine|This is where children 3-59 months will receive SPAQ for SMC
214406937|NCT05323721|DRUG|dihydroartemisinin-piperaquine|This is where children 3-59 months will receive DP for SMC
214406938|NCT03229889|DRUG|Cialis 5Mg Tablet|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.
214406939|NCT03229889|DRUG|Flomax 0.4Mg Capsule|Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
214406940|NCT03229889|COMBINATION_PRODUCT|Cialis + Flomax|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. A combination of these two drugs may increase the relaxation effects in the ureter. Patients will be asked to 1 of each pill for 7 days prior to surgery.
215011673|NCT05702619|DIAGNOSTIC_TEST|CT-guided Bone Biopsy|A CT-guided biopsy of a bone metastasis that is deemed to be easy to biopsy and in an area without major risk for pathological fracture or bleeding will be taken during the biopsy visit. Patients will receive routine local anaesthetic of the region to be biopsied followed by thorough disinfection of the biopsy site with antiseptic wipes. Patients will be asked to fast on the day of the procedure and to have an intravenous cannula inserted to allow the use of medication causing minimal sedation (for example midazolam and/or fentanyl) during the procedure if required to alleviate discomfort or pain.
214406941|NCT03229889|DRUG|Placebo|This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
214406942|NCT01579578|DRUG|AZD8931|40 mg, oral dose twice daily
215011674|NCT05702619|DIAGNOSTIC_TEST|TRUS-guided Targeted Transperineal Prostate Biopsy|Transperineal Prostate Biopsy will be performed following standard clinical practice of local department. This will include pre-operative oral analgesia and prophylactic antibiotic treatment according to local hospital policy for transperineal prostate biopsies.
215098924|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 5|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
215098925|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 6|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
215098926|NCT02708485|OTHER|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
215098927|NCT06027346|BIOLOGICAL|Bio-008|The subjects in each dose group received the corresponding dose of BIO-008 monotherapy, administered intravenously (ivd) for a duration of 0.5 to 3 hours (the researchers can adjust the administration time according to the patient's tolerance). If there is an infusion reaction, the infusion can be suspended and completed within 12 hours. Administer on the first day of each cycle, once every 3 weeks (1 cycle, i.e. 21 days) (Q3W) until the criteria for termination of treatment or withdrawal from the study are met, whichever occurs first.
215098928|NCT07089017|DEVICE|medstrom仪器|In addition to conventional monitoring methods, such as electrocardiography (ECG), bispectral index (BIS), and train-of-four (TOF) monitoring, Medstrom instruments were utilized to assess and monitor the patient's pain, sedation, and muscle relaxation status.
215098929|NCT07088146|DRUG|Dexamethasone|Immediately after sub-arachnoid block 8mg of Dexamethasone will be administered intravenously
215098930|NCT07088146|DRUG|Placebo|2ml of Normal saline will be given intravenously immediately after administration of spinal anesthesia
215098931|NCT07087938|DRUG|Cannabichromene|Participants will be assigned (using block randomization) to begin with one of the two study doses of CBC (400mg or 600mg). Participants will be blinded to dose. They will be asked to take half of their dose in the morning and half in the evening. Participants will be administered dose one for eight weeks. After this, participants will have a two-week timeframe where they will be asked not to take any study medication and to continue refraining from cannabis use, thus providing a washout period. Then, at visit three, they will receive dose two and will take it for eight weeks, concluding the study with another two-week washout period. At each clinic visit participants will complete assessments (self-report and physical examination), urine, and blood samples.
215098932|NCT07089758|DEVICE|Cerebral open flow microperfusion|"Patients will undergo intra-operative microperfusion using Joanneum Research's cerebral open flow microperfusion (OFM) catheters, push and pull tubing, and MPP102-II pump. This process utilizes a probe (catheter) inserted into the parenchyma to collect analytes of any size and polarity from the microenvironment. The microperfusion pump peristaltically pushes and pulls perfusate with no net fluid-exchange when the pump heads are set at equal flow rates. As perfusate enters the tip of the microperfusion catheter, analytes are exchanged based on a gradient between the interstitial fluid and the perfusate. The sample is then recovered via the pull portion of the peristaltatic microperfusion pump, enabling constant sampling volumes and preventing loss of the perfusate into the tissue.~The duration is 60-80 minutes (dependent on the speed of progress resecting portions of the tumor without catheters)"
215098933|NCT07089719|DRUG|Bevacizumab Injection|Participants will receive Bevacizumab at a dose of 10mg/kg via intravenous infusion. They will receive a total of 5 injections, administered every two weeks.
214406943|NCT01579578|DRUG|Placebo|Placebo, oral dose twice daily
214406944|NCT01579578|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off.
214406945|NCT03394963|BEHAVIORAL|Food-based dietary guidelines for healthier diet|Develop and validate food-based dietary guideline and a healthy eating index
215098934|NCT07087496|OTHER|Insulin application training with mobile augmented reality|Intervention Group 2 (MAR group): Before the training, the participants were briefly informed about how the application would be performed, and their written consent was obtained. Before the insulin administration training was started, the MAR program was shown to them on the tablet by the researcher and the process steps containing QR codes prepared for insulin administration were provided on a blue flat surface and information was given about the use of the application, and a pre-test was administered to determine their knowledge levels on insulin administration. Then, the education application program prepared for insulin administration was opened and the patients were allowed to use it. The training application was performed 20-25 times. Then the post-test was administered to the participants immediately after the training. At the post-test, they were administered the Knowledge Test and Scale for Satisfaction with Patient Education.
214406946|NCT04108689|BEHAVIORAL|I-ACT|An internet-based behavioral psychotherapy intervention to enhance athletic performance in elite ice hockey players.
214406947|NCT00249483|DRUG|Venlafaxine|Venlafaxiine 300mg/day
214406948|NCT00249483|DRUG|Placebo|Placebo
214406949|NCT01235325|DIETARY_SUPPLEMENT|phylloquinone (vitamin K1)|1000 mcg phylloquinone (vitamin K1) once daily for 12 months
214406950|NCT01235325|DIETARY_SUPPLEMENT|placebo|placebo oil capsule
215028985|NCT05642975|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
215028986|NCT02603497|DRUG|ASP015K|oral
215028987|NCT03996018|OTHER|T-cell lymphocyte responses|T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
215028988|NCT05156203|DRUG|T-1301 Capsules|T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
215028989|NCT04725071|DIETARY_SUPPLEMENT|Impact Advanced Recovery|L-arginine and omega-3 rich supplement
215028990|NCT04725071|DIETARY_SUPPLEMENT|Boost High Protein|conventional supplement
215028991|NCT06002152|DRUG|Bupivacaine|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of 0.25% bupivacaine on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
215028992|NCT06002152|DRUG|Placebo|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
215028993|NCT01681875|OTHER|very low nicotine content cigarettes|
215028994|NCT03196089|PROCEDURE|Oxygen application|Supplemental oxygen via mask
215028995|NCT05841771|DRUG|Venetoclax|"Participants will receive maintenance therapy with venetoclax and azacitidine or decitabine after allogeneic stem cell transplantation.~Azacitidine will be administered once daily subcutaneously (32mg/m2/d) on days 1-5, and venetoclax will be administered once daily orally (400mg/day) on days 1-7. If the patient is refractory or allergic to azacitidine, they will receive decitabine. Decitabine will be administered intravenously (5mg/m2/d) on days 1-5. If the patient is treated with CYP450 inhibitors(such as posaconazole or voriconazole), the dose of venetoclax will reduce to 100 mg once daily on days 1-7. Maintenance therapy will start from the 60th to 120th days after allogeneic hematopoietic stem cell transplantation and repeat every 28 days for up to 10 cycles within the first year after transplantation."
215028996|NCT05841771|DRUG|Azacitidine or decitabine|azacytidine 32mg/m2 or decitabine 5mg/m2
215028997|NCT05335057|BEHAVIORAL|VR Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
215028998|NCT05335057|BEHAVIORAL|VR Alone|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone
215028999|NCT05335057|BEHAVIORAL|VR Stranger|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger
215029000|NCT05335057|BEHAVIORAL|Video Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
215029001|NCT06185803|PROCEDURE|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
214406951|NCT05159882|DRUG|THR-1442 and Dapagliflozin placebo|THR-1442 tablets 20mg and Dapagliflozin tablets placebo
214406952|NCT05159882|DRUG|Dapagliflozin 10mg and THR1442 placebo|Dapagliflozin tablets 10mg and THR-1442 tablets placebo
214406953|NCT03464643|OTHER|embryo culture|Single embryo culture means only one embryo is cultured in one drop, and the group culture refers to culture of 2-5 embryos in one drop. The main advantage of group culture may be secreting some paracrine cytokines by embryos and benefit each other; and the possible disadvantage of group culture is that embryo secreting of some harmful substances which accumulated to a certain extent will damage the developmental potential of embryos. The advantages and disadvantages of single embryo culture are contrary to group culture.
214406954|NCT03423264|DRUG|Gabapentin|"Gabapentin taken as follows:~Day 1 (evening): 600 mg Day 2 (morning): 600 mg Day 2 (evening): 600 mg Day 3 (morning): 600 mg Day 3 (evening): 900 mg Day 4 (morning): 900 mg Day 4 (evening): 900 mg Day 5 (morning): 900 mg Day 5 (noon): 900 mg Day 5 (evening): 900 mg"
214406955|NCT01893528|DRUG|REGN2009|
214406956|NCT01893528|OTHER|placebo|
214406957|NCT01988519|PROCEDURE|Closed gravity drain|passive tube drains (PFM Medical, Köln, Germany)
214406958|NCT01988519|PROCEDURE|closed suction drain|BLAKE Silicon drains (Ethicon, USA)
214406959|NCT02803840|RADIATION|Low-dose radiotherapy|2 x 2 Gy on symptomatic sites only
214406960|NCT02271282|DRUG|Toremifene|
214406961|NCT02271282|DRUG|Placebo|
214406962|NCT02271282|DRUG|GHRH/Ghrelin combined Injection|
214406963|NCT01120171|DRUG|Cyclophosphamide|"Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity."
215029002|NCT06335706|BEHAVIORAL|Fit of underpants worn|Tight or loose-fitted underpants
215029003|NCT00272246|PROCEDURE|deep brain stimulation of the internal globus pallidus|
215029004|NCT02510274|DRUG|ASP3325|oral
215029005|NCT05881798|DEVICE|Celect Platinum Vena Cava Filter|Inferior vena cava filter
215029006|NCT06043154|OTHER|Patients with severe to extreme anorexia nervosa admitted to hospital for refeeding|Clinical and biological measurements, blood and stool sample collection
215029007|NCT05475171|DRUG|Lorigerlimab|Given by vein (IV)
215029008|NCT05360602|DIETARY_SUPPLEMENT|Alpha Lipoic Acid plus the standard care for post-PCI MI|Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
215011675|NCT05702619|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy will be performed according to standard of care robotic approach and as relayed to the patient by the attending urologic surgeon. The side effects of the surgery are the ones reported in the literature and the latest participant information leaflet provided prior patient consent (e.g. risk of erection disfunction, incontinence, etc.).
215011676|NCT05702619|DIAGNOSTIC_TEST|Whole-body MRI|Whole-body MR imaging (wbMRI) will be performed once, before or after the biopsy study visit, depending on available examination slots in the Department of Radiology. WbMRI images will allow comparison of the numbers of bone metastases detected by routine bone scan and wbMRI for sensitivity assessment of both techniques for oligometastatic disease.
215029009|NCT05360602|DRUG|The standard care for post-PCI MI|will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
215029010|NCT04629196|DRUG|Ustekinumab|A second IV weight-based induction dose of Stelara at week 8
215029011|NCT04629196|DRUG|Ustekinumab|A standard 90mg subcutaneous dose of Stelara at week 8
215029012|NCT04629196|DRUG|Ustekinumab|All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0
215029013|NCT02344927|OTHER|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
215029014|NCT02344927|OTHER|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
215029015|NCT06189612|OTHER|Clinical reasoning based physiotherapy + cervical movement control training|An individualized cervical motor control training based on the positive tests of the test battery introduced by Patroncini et al. (2014).
215029016|NCT06189612|OTHER|Clinical reasoning based physiotherapy + orofacial movement control training|An individualized orofacial motor control training based on the positive tests of the test battery introduced by von Piekartz et al. (2017).
215029017|NCT06189612|OTHER|Clinical reasoning based physiotherapy + standard exercises|A generalized training regimen based on exercises which are taught in physiotherapy training for the neck and scapula region preventing the overlap with exercises of the test batteries.
215029018|NCT03792737|DEVICE|Spiral PDS Plus|The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
215029019|NCT03792737|DEVICE|Spiral MONOCRYL Plus|The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
215029020|NCT03792737|DEVICE|PDS Plus|PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
215029021|NCT03792737|DEVICE|MONOCRYL Plus|MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
215029022|NCT03792737|DEVICE|VICRYL Plus|VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
215029023|NCT01450631|DEVICE|Prevena™ Incision Management System (PIMS)|PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
215029024|NCT01450631|DEVICE|Standard-of-care Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
215029025|NCT04738266|DIAGNOSTIC_TEST|Amyloid Cardiomyopathy|Echocardiographic red flags of Amyloid Cardiomyopathy to guide the suspicion of disease and to proceed with second level diagnostic work up including cardiac scintigraphy with bone tracers and search of monoclonal component in serum and urine
215029026|NCT00835354|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
215029027|NCT00835354|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
215029028|NCT04450550|DEVICE|VeNS device|VeNS treatment
215029029|NCT04450550|DEVICE|Sham VeNS device|Sham treatment of VeNS
215029030|NCT04551053|DRUG|parsaclisib|parsaclisib will be administered QD orally
215029031|NCT04551053|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
215029032|NCT04551053|DRUG|placebo|placebo will be administered QD orally
215029033|NCT04766684|DEVICE|J-Tip with Xylocaine MPF with placebo cream|J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream
215011677|NCT05702619|DIAGNOSTIC_TEST|Prostate MRI scans|Patients within Arm 2 will be offered the option to undergo additional MR imaging of the pelvis in addition to any standard of care imaging acquired. In patients who agree to undergo additional scans, MRI scans will be performed on 2 occasions prior to the radical prostatectomy. MRI scans will be acquired on either the MR sim diagnostic scanner, on the MR Linac scanner or on both.
215011678|NCT05702619|OTHER|Baseline bloods - for germline testing|"Arm 1 -~* 1-2 x 3.5mL blood samples collected into EDTA tubes for germ line DNA extraction and processing to PBMC for banking and future profiling of immune cell populations~* 1 x 10mL serum tubes for future, biobank related research projects, ie lipidomics, metabolics and microRNA analysis~ARM 2 -~A blood sample (maximum 20ml) will be taken for standard of care blood tests prior to prostatectomy including Full Blood Count, Renal Function and PSA. At the same time these standard of care bloods are taken, additional bloods - a maximum of 30ml - will be taken for research purposes as required for the following downstream analysis:~* Germ line DNA extraction and optional processing to PBMC for banking and future profiling of immune cell populations~* Biobank related research projects, ie lipidomics, metabolics and microRNA analysis"
215011679|NCT05702619|OTHER|Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1|2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
215011680|NCT05702619|OTHER|Post-pimonidazole bloods for CTCs and ctDNA|ARM 1 - 2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
215011681|NCT00950092|DEVICE|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
215011682|NCT03886324|COMBINATION_PRODUCT|GIE Medical Drug Coated Balloon|Stricture patients treated by DCB
215011683|NCT01045265|OTHER|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
215011684|NCT02605694|DRUG|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
215011685|NCT02605694|DRUG|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
214406964|NCT01120171|DRUG|Liposomal-encapsulated doxorubicin|"Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity."
214406965|NCT00657111|DRUG|CS-8958 formulated as dry powder|CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
214406966|NCT00657111|OTHER|Placebo|placebo capsules containing 25 mg lactose
214406967|NCT05352529|DEVICE|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
214406968|NCT05352529|DEVICE|Dementia educational videos|Investigators collected publicly available educational videos regarding dementia-related caregiving and support. The videos were made available to participants through compatible tablets.
214406969|NCT05504694|DRUG|Ofatumumab|"The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion."
214406970|NCT06475170|PROCEDURE|proximal gastrectomy combined with 'λ+α' double-tract anastomosis|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. The jejunum is dissected 30 cm from the flexor ligament and the distal jejunum is lifted in an anterior colonic direction to the esophageal dissection.~4. Esophagojejunal anastomosis at 16 cm from the distal jejunal stump；~5. Residual gastrojejunostomy at 8 cm from the distal jejunal stump；"
214406971|NCT06305273|OTHER|Head position for face mask ventilation during induction supine|Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in supine position. Participants will be crossed over to the head elevated position after the first measurement is obtained.
215029034|NCT04766684|DRUG|L.M.X.4 cream with J-Tip saline injection|L.M.X.4 cream with J-Tip saline injection
215029035|NCT04194697|BEHAVIORAL|Exercise|Exercise program
215029036|NCT04194697|BEHAVIORAL|No exercise|No exercise program
215029037|NCT06568575|BEHAVIORAL|experiment of music|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by exercise program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes.
215011686|NCT02605694|DRUG|R-CHOP|"IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2)"
214406972|NCT06305273|OTHER|Head position for face mask ventilation during induction head elevated|Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in head elevated position. Participants will be crossed over to the supine position after the first measurement is obtained.
214406973|NCT01528709|DRUG|Atorvastatin 80 mg daily|Atorvastatin 80 mg daily for 1 year
214406974|NCT01528709|DRUG|Atorvastatin 10 mg daily|Atorvastatin 10 mg daily for 1 year
214406975|NCT01314495|DRUG|Abatacept|Abatacept will be administrated as a 30 minute intravenous infusion.
214406976|NCT01314495|DRUG|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
214406977|NCT04163471|DEVICE|Radial artery mechanical compression for hemostasis|Transradial hemostasis following arterial catheterization procedures
214406978|NCT02726178|DRUG|Advil® Pediatric drops for infants|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
214406979|NCT02726178|DRUG|Placebo|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
214406980|NCT05841160|DRUG|Ecopipam Hydrochloride|oral tablets
214504754|NCT07098637|BEHAVIORAL|Self-Compassionate Mindfulness Psychoeducation Program|"The researcher completed the internationally accredited institutional and practical training program titled All About Compassion in 12 Weeks: A Thousand Faces of Compassion, offered by the School of Compassion. Expert opinions were sought from the planning phase of the study for the content of the program, which was designed by the researchers. In developing the content of the Self-Compassionate Mindfulness Psychoeducation Program for Delinquent Adolescents, the opinions of three academic faculty members were consulted. Based on the suggestions received, the session titles of the psychoeducation program were determined as follows:~1. Holding Our Own Hand: Discovering Self-Compassion~2. Discovering Awareness of Thought~3. Understanding Pain, Approaching with Compassion~4. Facing Reality: Acceptance~5. Calm Waters: Forgiveness~6. Moving Forward, Farewell, and a New Beginning."
214406981|NCT05841160|DRUG|Moxifloxacin|oral tablet
214406982|NCT05841160|DRUG|Placebo|oral tablet
214406983|NCT04778384|BEHAVIORAL|Micro-training to promote self-management in pain therapy|Micro-training according to the checklist \& targeted discussion / dismantling of patient-related barriers based on the answers in the second part of the questionnaire (BQII Barriers Questionnaire) In this discussion, the nurses give their opinion on any patient-related barriers that become apparent after completing the second part of the questionnaire. This is not done according to a fixed template, but with the specialist knowledge and everyday experience of the nurse.
214406984|NCT04778384|OTHER|Sham intervention|An unstructured conversation is carried out. Patient questions are answered correctly, but there is no training, rather patient information.
214406985|NCT01068054|DRUG|tacrolimus|0.1% ointment,apply bid, 8 weeks
214406986|NCT01068054|DRUG|cyclosporins|2% eyclosporine eye drops apply 1 drop to each eye QID
214406987|NCT05426291|OTHER|BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?|In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
214406988|NCT05712811|DRUG|CRYOTHERAPY|Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
214406989|NCT05712811|DRUG|Tricholoracetic acid|Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline.
214406990|NCT01677039|DRUG|Test formulation administered with water|single dose of 20 mg of test formulation with 240 mL of water
214504755|NCT04523350|DEVICE|Instylla HES|Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)
214504756|NCT04523350|OTHER|TAE or cTACE|Bland TAE or cTACE
215011687|NCT02605694|DRUG|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
215011688|NCT00676052|DRUG|GSK233705 12.5mcg|Once daily via dry powder inhaler
215011689|NCT00676052|DRUG|GSK233705 25mcg|once daily via dry powder inhaler
215011690|NCT00676052|DRUG|GSK233705 50mcg|Once daily via dry powder inhaler
215011691|NCT00676052|DRUG|GSK233705 100mcg|Once daily via dry powder inhaler
214406991|NCT01677039|DRUG|Test formulation administered with 20% ethanol|single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
214406992|NCT01677039|DRUG|Test formulation administered with 40% ethanol|single dose of 20 mg of test formulation with 240 mL of 40% ethanol
215011692|NCT00676052|DRUG|GSK233705 200mcg|Once daily via dry powder inhaler
215011693|NCT00676052|DRUG|Placebo|Once daily via dry powder imhaler
215011694|NCT02774720|BEHAVIORAL|Centre-based exercise|Participants will come to a centre (University of Waterloo or Toronto Rehabilitation Institute) for a one-hour, small group exercise class each week. The classes will include progressive aerobic and resistance exercise. They will be prescribed additional exercise to be performed independently (either at home or in the community).
215011695|NCT02774720|BEHAVIORAL|Home-based exercise|Participants will be prescribed aerobic and resistance exercise to be performed independently (either at home or in the community). They will receive monthly phone calls to discuss achievements and barriers and to tje adjust exercise prescription.
215011696|NCT04578977|BEHAVIORAL|Functional assessment of surgical treatment of terrible triade injury of the elbow|Functional assessment of surgical treatment of terrible triade injury of the elbow
215011697|NCT04319536|OTHER|no intervention|self-sampling
215011698|NCT02930941|DRUG|Tranexamic Acid|TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
214406993|NCT02688361|DRUG|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
214406994|NCT02688361|DRUG|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
215011699|NCT02930941|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
215011700|NCT03173508|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
214406995|NCT01278537|BEHAVIORAL|Information|Booklet, motivational interviewing, brief advice
214406996|NCT00716573|DRUG|everolimus|0,75 mg bid, 24 months
214406997|NCT04850365|PROCEDURE|Hysteropexy|"Abdominal Sacral cervicopexy:~The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.~Vaginal Sacrospinous cervicopexy:~This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion."
214406998|NCT05883319|OTHER|manuel therapy|approaches will be applied for 3 days / week for 6 weeks.
214406999|NCT05883319|OTHER|exercises|approaches will be applied for 3 days / week for 6 weeks.
215011701|NCT03173508|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
215011702|NCT05100147|PROCEDURE|Uterine closure during Cesarean section|The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
215011703|NCT02979054|DEVICE|T4020|
214407000|NCT03906474|BIOLOGICAL|Blood-stage controlled human P. falciparum malaria infection|Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.
214407001|NCT03155191|BIOLOGICAL|TBI-1501|"Phase-I portion:~Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg).~Phase-II portion:~Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501."
214407002|NCT05410535|DRUG|Patients who continued UDCA 300mg medication|patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
214407003|NCT05410535|OTHER|Patients who discontinued UDCA 300mg prescription|patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
214407004|NCT02117869|OTHER|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
214407005|NCT02117869|OTHER|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
214407006|NCT02117869|OTHER|Water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
214407007|NCT02554175|DRUG|Propofol|Propofol was administered to achieve target propofol Ce
214407008|NCT00714233|DRUG|Metformin|Metformin 425mg. capsules, 2 capsules BID x 24 weeks
214407009|NCT00714233|DRUG|Oral Contraceptive Pills (Yasmin)|Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
214407010|NCT00714233|BEHAVIORAL|Lifestyle Modification|weekly classes x 24 weeks for training in diet, exercise and behavior modification skills
214407011|NCT00714233|DRUG|placebo|placebo to the active metformin arm. 2 capsules BID x 24 weeks.
215011704|NCT02979054|DEVICE|Placebo|
215011705|NCT00289978|DRUG|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
215011706|NCT00289978|DRUG|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
215011707|NCT00289978|DRUG|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
215011708|NCT02569775|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
215011709|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 0.5 mg/kg Q2W
215011710|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 2 mg/kg Q2W
215011711|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 5 mg/kg Q2W
215011712|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 10 mg/kg Q2W
215011713|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200 mg Q2W
215011714|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q3W
215011715|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q2W
215011716|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200mg Q2W
215011717|NCT05587647|OTHER|Transition to Adulthood Education Program|"YEGEP was developed by the authors based on the information in the literature, based on the needs of mothers of children who have reached adulthood or are going through. Three training modules are planned in line with current requirements. Education will also be supported by audio-visual and written materials. It is planned that the trainings, which will last for 3 weeks in total, for 1 hour a week for each group, in the form of 3 sessions of 1 hour with these contents, will be held at a disabled center. Titles of training modules:~1. Developmental Period Characteristics of Young Adults with Intellectual Disabilities (Transition to Adulthood, Future Planning / Social Life (employment, peers, etc.)~2. Protecting and Sustaining the Health of Young Adult with Intellectual Disabilities~3. Coping with Stress"
215011718|NCT00645138|PROCEDURE|Paravertebral Block|"Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be walked off the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered."
215011719|NCT00645138|PROCEDURE|General Anesthesia|Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.
215011720|NCT04249635|DIETARY_SUPPLEMENT|DHA|Women received supplementation of Based on Schizochytrium oil, 100% DHA (DSM) from 14 weeks of pregnancy until delivery.
215011721|NCT04324697|PROCEDURE|Horizontal alveolar bone augmentation|Horizontal augmentation in anterior maxilla using allograft shell and autogenous chips with no need for a second surgical site
215011722|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal brushing|Duodenal mucosal brushing will be performed at duodenal bulb.
215011723|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal biopsy|Duodenal mucosal biopsy will be performed at duodenal bulb.
215098935|NCT07087496|OTHER|insulin administration training with brochure|"The Intervention Group 1 (Brochure group): Before the training, the participants were informed about the study, and their written consent was obtained.~Before insulin administration training, a knowledge test was given as a pre-test to determine the participants' knowledge levels on insulin administrations. After the pre-test, a 15-20 minute practical training was given using the brochure prepared for insulin administrations. Immediately after the training, the knowledge test and Scale for Satisfaction with Patient Education were administered as a post-test. After the post-test, the participants were asked to self-administer insulin. The insulin administration skills of the patients were assessed by the researcher using the Insulin Administration Skill Assessment Checklist. After the assessment, the participants were informed about their deficiencies, or incorrect performances."
215098936|NCT07089368|DRUG|Zn(II)-phthalocyanine gel|Topical application of RLP068/Cl 0.3% gel (Zn(II)-phthalocyanine) at a dose of 1 mL per 25 cm² under occlusion for 30 minutes, followed by red light irradiation at 630 nm (60 J/cm²) for 8 minutes. Sessions will be repeated twice weekly until clinical response is achieved.
215098937|NCT07087392|PROCEDURE|Inverted-Ω Anastomosis|After meeting the inclusion and exclusion criteria, duodenum-preserving pancreatic head resection or mid-pancreatic resection will be performed, and inverted-Ω anastomosis will be carried out during the operation for the reconstruction of the digestive tract
214407012|NCT01351038|DRUG|Epirubicine, Oxaliplatin, Capecitabine, Panitumumab|3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
214407013|NCT00699933|OTHER|CT-guided percutaneous drainage technique|Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
214407014|NCT03405415|DEVICE|Blood glucose monitoring system and continuous interstitial glucose monitoring system|"At enrolment, participants are provided with BGM (Blood Glucose Monitoring) and CGM (Continuous Glucose Monitoring) systems. They will use the systems throughout the study. Participants will visit the study site three times. During the first visit, a standardized oral glucose tolerance test will be performed to ensure that participants do not have diabetes mellitus and to obtain glucose concentration data from people without diabetes mellitus during a glucose challenge. On another two days, participants will visit the study site for standardized breakfast and lunch meals to provide glucose concentration data under standardized conditions.~Outside of the study site visits, participants are asked to eat similar meals on two days to obtain glucose concentration data under repeated conditions that represent daily life.~During the study, participants are asked to document meals, physical activity and addition comments to provide context to the recorded glucose concentration data."
214407015|NCT00890474|PROCEDURE|Moxibustion of the BL67 acupoint|Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
215011724|NCT03751748|DEVICE|AFR implantation|Implantation of atrial flow regulator (AFR) device
215098938|NCT07087483|BEHAVIORAL|The fathers who receive training|We will provide training to fathers on how they can improve and support their fatherhood skills with their newborns, and the control group will only receive the brochure about the basic fatherhood skills.
215098939|NCT07087483|BEHAVIORAL|Fatherhood Skill Training|"FATHERHOOD TRANSITION TRAINING PROGRAM • Explanation of the goals and objectives of the training~* Introduction to the training program~* Newborn's physiological characteristics (weight, height, head circumference, fontanelles, body temperature, sleep, feeding, urination, meconium, genital organs, reflexes, sleeping position, safety, hygiene)~* Infant feeding and burping the baby~* Changing baby's clothes, giving a bath, diapering, and general care of the eyes, ears, mouth, umbilical cord, and skin~* Importance and benefits of breast milk~* Breastfeeding positions and techniques~* Methods of expressing, storing, and increasing breast milk~* Information about vaccinations, hearing and heel-prick screening, developmental hip dysplasia, and jaundice~* General information on gender roles~* Importance of father-infant bonding and its short- and long-term outcomes"
214407016|NCT03487874|PROCEDURE|Conventional interscalene block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are blocked.
214407017|NCT03487874|PROCEDURE|Interscalene block with C8 root block|Under ultrasound guidance, the 5th to 8th cervical nerve roots are blocked.
214407018|NCT03487874|DRUG|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
214407019|NCT05004480|DEVICE|Treadmill|Electronic treadmill, Hammer T-2000 Treadmill, 2,5 HP - 140 Kilograms
214407020|NCT03967561|OTHER|Progressive water-based aerobic training|The intervention will comprise walking/running in shallow pool with progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
214407021|NCT03967561|OTHER|Non-progressive aerobic training|The intervention will comprise walking/running in shallow pool without progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
214407022|NCT02700685|DIETARY_SUPPLEMENT|Pycnogenol|Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
214407023|NCT02700685|DRUG|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release.
214407024|NCT02700685|OTHER|Placebo|Placebo treatment (identical capsules containing excipients only)
214407025|NCT02284464|DRUG|Prednisone withdrawal|Withdrawal of steroids
214407026|NCT02284464|DRUG|Prednisone continuation|Continuation of steroids
214407027|NCT05165069|DRUG|Mecobalamin 5 MG Disintegrating Oral Tablet|Mecobalamin 0.5mg / time, 3 times / day,was taken continuously for 6 months
214407028|NCT05165069|DRUG|placebo|placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
214407029|NCT01145144|DRUG|dehydroepiandrosterone crystalline fine powder|
214407030|NCT03122964|DIAGNOSTIC_TEST|AssureMDx|combined panel of methylation and mutation markers for the detection of bladder cancer
214407031|NCT05102903|DRUG|BR1016A|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
214407032|NCT05102903|DRUG|BR1016B|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
214407033|NCT00746928|OTHER|Chronic Intermittent Hypoxia|Chronic Intermittent Hypoxia mimicking the CIH undergone by patients suffering from Sleep Apnea Syndrome, is applied to Healthy subject during 8 hours a day (nights) for a 14 days period. The cycle of intermittent Hypoxia is 30 drop in SaO2 per hours with a 10% decrease in SaO2.
214407034|NCT02743663|PROCEDURE|Bronchodilator response|Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
214407035|NCT02743663|PROCEDURE|Allergy Skin Test|Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
214407036|NCT02743663|PROCEDURE|Multiple-Breath Washout|Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach \~2%. Each test in duplicate and average is calculated.
214407037|NCT02743663|PROCEDURE|Forced Oscillation Technique|Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
215098940|NCT07087925|DRUG|Haloperidol|A single dose of haloperidol (1-2 mg) was administered intravenously during the intraoperative period to patients undergoing surgery under subarachnoid block (RA-SAB). This intervention was designed to evaluate its effectiveness in preventing postoperative nausea and vomiting (PONV). Both patients and providers were blinded to the assignment.
214407038|NCT02743663|PROCEDURE|Spirometry|Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
214407039|NCT02743663|DRUG|salbutamol|Given during bronchodilator response.
214407040|NCT02743663|PROCEDURE|Nasal Brush|Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
214407041|NCT02743663|PROCEDURE|Blood sample|8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
214407042|NCT02743663|PROCEDURE|Basophil activation test|Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
214407043|NCT02743663|PROCEDURE|Nasal swab|Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
214407044|NCT01813422|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
214407045|NCT01813422|DRUG|Placebo|Administered by subcutaneous injection
215011725|NCT03751748|DEVICE|Sham procedure|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
215011726|NCT05281640|BEHAVIORAL|Affect Dysregulation intervention|See relevant study arm for description
215011727|NCT05281640|BEHAVIORAL|Negative Self Concept intervention|See relevant study arm for description
215011728|NCT05281640|BEHAVIORAL|Disturbed Relationships intervention|See relevant study arm for description
215098941|NCT07087925|DRUG|Ondansetron 4mg|A single dose of ondansetron (4 mg) was administered intravenously during the intraoperative period to patients undergoing surgery under subarachnoid block (RA-SAB). This intervention served as the active comparator to haloperidol in evaluating the prevention of postoperative nausea and vomiting (PONV). The study was conducted in a double-blind manner.
215098942|NCT07089563|BEHAVIORAL|Calisthenics Exercise Program|The exercises were administered twice a week for eight weeks alongside their regular swimming training, with each session lasting approximately 30 minutes. Calisthenics exercise included crunch, reverse crunch, plank, super plank, superman, sumo squat, and squat jump movements.
214407046|NCT06528977|OTHER|Western Diet|Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
214407047|NCT02212886|DRUG|GA Depot 80 mg|Recruitment completed
214407048|NCT02212886|DRUG|GA Depot 40 mg|Recruitment completed
214407049|NCT01653743|DRUG|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa \[recombinant human Chorionic Gonadotropin, r-hCG\]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (\>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of \>=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
214407050|NCT01653743|DRUG|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of \>=18 mm; not more than 3 follicles each with a mean diameter of \>=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
214407051|NCT01653743|DRUG|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
214504757|NCT05995977|BEHAVIORAL|Nursing interventions based on protection motivation theory in patients with hypertension|The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging, and motivating patients to maintain medication adherence and healthy lifestyle changes.
215011729|NCT00221325|DRUG|Intraventricular Rituximab Plus MTX|"Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.~First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.~If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.~Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing."
215011730|NCT00267319|DRUG|Glatiramer acetate|
215011731|NCT05829733|DEVICE|SYNOLIS VA 80/160|SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
215011732|NCT06539650|OTHER|Fractal Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with fractal external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
215011733|NCT06539650|OTHER|Isochronus Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with isochronus external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
215011734|NCT06539650|OTHER|Self Paced|The intervention consists in a single session of strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, at at participants' own self pace (with no metronome). The rest between sets will be set at 2 minutes of rest between sets.
215011735|NCT01341938|DRUG|Commit® nicotine lozenges (4 mg) & self-help materials|"Participants provided with instructions on standard use of lozenge for nicotine replacement therapy (NRT) \& instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
215011736|NCT01341938|BEHAVIORAL|Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + lozenge nicotine replacement therapy (NRT) + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
215011737|NCT01341938|BEHAVIORAL|Phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
215011738|NCT00443287|DRUG|ataciguat (HMR1766)|oral administration
215011739|NCT00443287|DRUG|placebo|oral administration
215011740|NCT00443287|DRUG|cilostazol|oral administration
215011741|NCT00559117|DRUG|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
215011742|NCT04017910|DEVICE|EchoMark/EchoSure|Each subject will have an EchoMark implanted at the time of arteriovenous fistula creation, and undergo EchoSure and duplex imaging follow-up.
215011743|NCT02661373|DRUG|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
215011744|NCT02661373|DRUG|Cobicistat|Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
215011745|NCT05113602|DEVICE|URGOnight|EEG dry electrodes portable device
215011746|NCT05113602|DEVICE|Enobio|EEG wet electrodes portable device
215011747|NCT01967277|DEVICE|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
215011748|NCT01967277|DEVICE|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
215011749|NCT01676350|PROCEDURE|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
215011750|NCT04322045|DIAGNOSTIC_TEST|multi-parametric MRI|Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
215011751|NCT00727337|BEHAVIORAL|LACE-computer|Computerized Auditory Training
215011752|NCT00727337|BEHAVIORAL|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
215098943|NCT07089563|BEHAVIORAL|Life Kinetik Exercise Program|The exercise program was conducted twice a week for eight weeks alongside regular swimming training, with each session lasting approximately 30 minutes. It included various exercises designed to improve hand-eye coordination, balance, reaction time, and motor control, such as throwing, catching, and dribbling balls with both the right and left hands. Exercises involved catching the ball mid-air or after a bounce, tossing tennis balls simultaneously with both hands, and throwing balls against a wall with different catching techniques and hand usages to provide varied challenges.
215098944|NCT07087418|DIAGNOSTIC_TEST|Kaplan-Meier analysis with log-rank testing|The non-inferiority of the virtual endoscopy group will be verified by comparing the predictive performance for prognostic indicators (e.g., clinical remission rate, recurrence risk) between the two groups during follow-up.
215098945|NCT07089355|DEVICE|Toro 88 Super Bore Aspiration Catheter|The Toro 88 Super Bore Aspiration Catheter is a neurovascular device designed for clot aspiration during mechanical thrombectomy procedures.
215098946|NCT03266172|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
215098947|NCT03266172|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
215098948|NCT05696574|DRUG|Vaginal Misoprostol|Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
215098949|NCT05696574|DRUG|Oral Misoprostol|Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
214407052|NCT05769374|DEVICE|cooperative versus competitive AVG play|The duration of the study was 8 weeks and the frequency was 60 minutes three times a week. In the first two weeks, three games, Golf, Just Dance and Tennis, will be selected to experiment on easy and normal difficulty respectively. In the three weeks from week 3 to Week 5, Bowling, Shape Boxing and Table tennis will be selected for the experiment with easy, normal and difficult difficulties respectively. In the last three weeks, Rowing, Family ski and Baseball will be selected to carry out experiments with easy, ordinary and difficult difficulty respectively.Additionally,participants in control group did not participate in any AVG intervention and maintained their daily physical activity behaviors
214407053|NCT04807179|DEVICE|Experimental: RF Device Arm|Non-invasive radiofrequency Alexandrite laser
214407054|NCT03068286|BEHAVIORAL|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
214407055|NCT03068286|BEHAVIORAL|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored.Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
214407056|NCT03068286|BEHAVIORAL|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
214407057|NCT03748771|DEVICE|ApneaLink Air|"The ApneaLink Air device is indicated for use by Health Care Professionals (HCP), where it may aid in the diagnosis of sleep disordered breathing for adult patients.~ApneaLink Air records the following data: patient respiratory nasal airflow, snoring, blood oxygen saturation, pulse and respiratory effort during sleep. The device uses these recordings to produce a report for the HCP that may aid in the diagnosis of sleep disordered breathing or for further clinical investigation. The device is intended for home and hospital use under the direction of a HCP."
214407058|NCT04889118|BIOLOGICAL|Pembrolizumab|IV infusion
214407059|NCT04889118|DRUG|Lenvatinib|Oral capsule
214407060|NCT04889118|DRUG|Placebo for lenvatinib|Oral capsule
214407061|NCT00562393|OTHER|Nutritional|Overfeeding high fat diet for 28 days
214407062|NCT05053308|DRUG|Intravenous Infusion|IV PCA(fentanyl) Fentanyl bolus = MME \* 15%
214407063|NCT05053308|DRUG|Sublingual Tablet|subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
215098950|NCT06766357|DRUG|Cyclosporine ophthalmic gel|Administer to eyes
214407064|NCT02817503|DRUG|Standard BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
214407065|NCT02817503|DRUG|Moderate BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
215098951|NCT06766357|DRUG|Cyclosporine ophthalmic gel vehicle|Administer to eyes
215098952|NCT02643732|DRUG|Methylphenidate (overencapsulated)|10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
215098953|NCT02643732|DRUG|Placebo (Over-encapsulated tablet)|Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
215011753|NCT00727337|BEHAVIORAL|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
215011754|NCT00727337|BEHAVIORAL|Lace-DVD|DVD based Auditory Training
215098954|NCT07087821|BEHAVIORAL|UPLIFT|"UPLIFT is an 8-week epilepsy self-management programs delivered to small groups of people with epilepsy (PWE) by Webex. UPLIFT is focused on self-management of depressive symptoms.~Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and a home practice assignment."
214407066|NCT02817503|DRUG|Intensive BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
214407067|NCT05238597|DRUG|A197 Ophthalmic Solution|A197 Ophthalmic Solution
215011755|NCT04847921|DRUG|Dalbavancin|long-acting lipoglycopeptide antibacterial agent
215011756|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)|Patients will be receiving proton SBRT
215011757|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients will receive proton SBRT.
215011758|NCT03539198|DRUG|Nivolumab 3 mg/kg IV q2 weeks|Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.
215098955|NCT07087821|BEHAVIORAL|PACES|"PACES is an 8-week epilepsy self-management programs delivered to small groups of people with epilepsy (PWE) by Webex. PACES focuses on general epilepsy self-management.~Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and a home practice assignment."
215098956|NCT07087821|BEHAVIORAL|Enhanced Usual Care|Participants receive referrals to local epilepsy support groups.
214407068|NCT05238597|DRUG|A197 Vehicle Control|A197 Vehicle Control
215011759|NCT03539198|RADIATION|Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
215011760|NCT01975649|DRUG|Tribulus Terrestris|patients will use 750 mg/day during 120 days
215011761|NCT01975649|OTHER|Placebo|patients will use placebo pills with the same shape of the drug
215011762|NCT06130202|DEVICE|Echocardiographic findings|Echocardiographic findings as Markers of Subclinical Cardiac dysfunction in Patients with Non-Alcoholic Fatty Liver Disease
214407069|NCT05238597|DRUG|Active Comparator|Active Comparator
214407070|NCT05603026|DEVICE|Self-expanding valve (Medtronic Evolut FX)|Bioprothesis Medtronic Evolut FX supra-annular self-expanding valve
215098957|NCT07088055|DEVICE|Chewing device only|This group will be administered the Myo Munchee and be given a protocol to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.
215098958|NCT07088055|DEVICE|Myo Munchee and Oral Motor Therapy Treatment|This group will be administered an Oral Motoro Therapy program as well as a Myo Munchee protocol to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.
215098959|NCT07088055|OTHER|Oral Motor Therapy Treatment Arm|This group will be administered an Oral Motor Therapy program to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.
214407071|NCT05603026|DEVICE|Balloon-expanding valve (Edwards Sapien 3 Ultra)|Bioprosthesis Edwards Sapien 3 Ultra valve
214407072|NCT02994550|DRUG|FSH/LH|
214407073|NCT05077631|DRUG|ACD856|Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
214407074|NCT05077631|DRUG|Placebo|Placebo oral solution
214407075|NCT05077631|DRUG|ACD856 (fed cohort)|Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
214407076|NCT00508885|DRUG|Niacinamide|Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
214407077|NCT00508885|DRUG|Placebo|Placebo
214407078|NCT02397889|DRUG|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
215011763|NCT04094636|BEHAVIORAL|In-bed cycling|Patients will daily perform 30 min of supervised in-bed cycling
215011764|NCT04094636|BEHAVIORAL|Exercise booklet|Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
215011765|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
215011766|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
215011767|NCT00103506|DRUG|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
215011768|NCT00585585|DRUG|betahistine dihydrochloride|oral, 50-300 mg, daily
215011769|NCT06260839|PROCEDURE|magnetic resonance neurography|preoperative magnetic resonance neurography and assisted design of surgical approach
215011770|NCT06260839|PROCEDURE|no magnetic resonance neurography|Preoperative magnetic resonance neurography was not performed, and general minimally invasive surgery was performed
214407079|NCT02397889|DRUG|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
214407080|NCT06044961|RADIATION|CT scan|All pre-operative CT scan collected
214407081|NCT04942470|OTHER|Aloe vera and propolis applied|Suitable of sterile pads containing aloe vera and propolis to the area with pressure sores
214407082|NCT00000988|DRUG|Stavudine|
214407083|NCT04656470|DRUG|Dexmedetomidine|Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.
214407084|NCT06008067|RADIATION|tricuspid annular plane systolic excursion (TAPSE)|Echocardiography
215011771|NCT06323720|OTHER|Quantitative Sensory Testing|Assessment of the heat and cold pain thresholds, temporal summation, conditioned pain modulation, pressure pain thresholds, electrical pain thresholds, and withdrawal reflex.
215011772|NCT00585169|DRUG|Memantine Hydrochloride|10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
215011773|NCT05214950|DEVICE|ORI monitoring|Oxygen reserve index monitoring during the surgery
215011774|NCT05740384|DEVICE|Sonotubometry Assessment|"The exact order of the measurements will be randomised:~* Recording type 1: No sound applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Recording type 2: White noise applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Ask for subjective feedback (did you hear a change in the sound in your ear on swallowing?) after each recording~* This is repeated using the contralateral ear and nostril. After successful recording, the microphone will be removed.~For comparison, tubomanometry measurements will be performed on each ear. Tubomanometry is an alternative method to assess the middle ear and Eustachian tube. Afterwards, the participant's involvement in the study will be complete. The entire involvement will take about 50 minutes."
215011775|NCT05916924|OTHER|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting
214407085|NCT04198961|OTHER|opioid prescribing|Individualized taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
214407086|NCT01857453|DRUG|carboplatine|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
214407087|NCT01857453|DRUG|Etoposide|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
214407088|NCT01857453|RADIATION|radiation therapy|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
214407089|NCT04827225|BEHAVIORAL|questionnaires|Questionnaires (EPDS, HADS, PPQ, MIBS, etc.) will have to be completed by the parents at different stages of their child's development (38 weeks of amenorrhea, 3 months and 24 months).
214407090|NCT02955862|OTHER|Vietnam Cryptococcal Retention in Care Study (CRICS)|"Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.~Other Names:~• Fluconazole"
214407091|NCT04500821|DEVICE|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
214407092|NCT05717985|PROCEDURE|modified combined approach|A thin layer of epithelium will be excised from the harvested graft. This epithelium will be replaced at the donor site and sutured.
215011776|NCT02288871|RADIATION|Cardiac CT-scan|"ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves."
215011777|NCT00710970|DRUG|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
215098960|NCT04366375|DIAGNOSTIC_TEST|PTX-3|Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
215098961|NCT00238459|DRUG|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
215098962|NCT00238459|DRUG|multiple licensed drugs not randomized|
215098963|NCT00238459|DRUG|multiple licensed antiretroviral drugs; not randomized|
214407093|NCT05717985|PROCEDURE|de-epithelized gingival graft|Only dressing material will be placed at the donor site after graft harvesting
214407094|NCT06121570|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
214407095|NCT06121570|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
214407096|NCT06121570|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
214407097|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
214407098|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
214407099|NCT06121570|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
214407100|NCT06121570|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|Participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
215011778|NCT01028560|BIOLOGICAL|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
215011779|NCT01028560|OTHER|Standard of care|standard of care asthma and allergy treatment
215011780|NCT01894646|RADIATION|Positron Emission Tomography (PET) Imaging|
215011781|NCT05656976|OTHER|Provision of self sampling device by the GP|In a group of 45 GP practices, over a course of 9 months, all long-term unscreened women with a GMD will be addressed by their GP when they consult for any reason. The GP will discuss the pros and cons of screening for cervical cancer, the various options for screening for cervical cancer including the possibility of using a SSD. For this, the GP can use on accessible brochure and video materials. After the woman agrees, she is given a self-taking kit that she can use when and where it suits her and send it to the lab with the prepaid envelope. The woman is informed of the result of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g. via letter, by phone or during the next consultation).
215011782|NCT05656976|OTHER|Provision of self sampling device by letter|In the second arm, a second group of 45 GP practices in Flanders will be recruited. With the intervention of the Centre for Cancer Prevention (Flanders), 25 at randomly selected long-term unscreened women with a Global Medical Form (in dutch: 'Globaal Medisch Dossier, GMD) in one of these practices will receive an envelope containing a letter of invitation from their GP for cervical cancer screening, a brochure with the advantages and disadvantages of cervical cancer screening and more specifically the use of a self-taking kit, and a self-taking kit. If the woman wishes, she can use the kit when and where it suits her and send it to the lab with the pre-paid envelope. As in arm A, the woman will be informed of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g., by letter, by phone or during the next consultation). All women will receive a study-related reminder letter after 4 months.
215011783|NCT03055221|DRUG|Intravenous Treprostinil|Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
215011784|NCT04264962|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
215011785|NCT04264962|OTHER|Routine medical care|Routine medical care
215011786|NCT01243424|DRUG|linagliptin|linagliptin tablets 5mg QD
215011787|NCT01243424|DRUG|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
215098964|NCT00238459|OTHER|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
215098965|NCT02551419|DIETARY_SUPPLEMENT|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
215098966|NCT02551419|DIETARY_SUPPLEMENT|placebo|6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
215098967|NCT05204433|OTHER|no intervention|no intervention
214407101|NCT06121570|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
214407102|NCT06121570|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
214407103|NCT00498537|DRUG|spironolactone|
215098968|NCT00997620|DRUG|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
215098969|NCT00997620|DRUG|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
215098970|NCT01554514|BIOLOGICAL|rituximab|rituximab intravenously 100 mg every week for four doses
215098971|NCT04758520|DEVICE|FLOAT upper limb exoskeleton|The FLOAT device is composed by a wearable exoskeleton assembled on a poly-articulated arm that, in turn, is mounted on a support base with unlockable wheels. The exoskeleton includes 5 motors arranged in a way that, when generating movement, ensures the optimal involvement of all the articulations of the shoulder complex, particularly the glenohumeral and the scapulothoracic joints. According to the chosen modality of use of the exoskeleton, the device allows patient's passive or active-assisted mobilization. The poly-articulated arm supporting the exoskeleton is capable to compensate exoskeleton weight in every configuration and, if configured appropriately, permits exoskeleton use both in seated and standing positions. The support base of the device has unlockable wheels that, if unlocked, permit the free movement of the patient in the workspace, enabling the performance of more complex functional activities while assisted by the exoskeleton.
215098972|NCT05153213|PROCEDURE|Finger lengths|Vernier caliper was used to measure finger length
215098973|NCT05153213|PROCEDURE|Conventional method|Gillis gauge was used to measure occlusal vertical dimension
215098974|NCT05222555|DRUG|Tafasitamab|tafasitamab will be administered intravenously at protocol defined timepoints
215098975|NCT05222555|DRUG|Lenalidomide|lenalidomide will be administered orally at protocol defined timepoints
215098976|NCT00885781|DRUG|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
214407104|NCT01928940|DRUG|dabrafenib|150 mg twice daily
214407105|NCT01928940|DRUG|trametinib|2 mg once daily
214504758|NCT05523375|BEHAVIORAL|Intensive Lifestyle Intervention|"Trained health coaches deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
215011788|NCT01243424|DRUG|linagliptin placebo|linagliptin placebo
214407106|NCT06107621|BEHAVIORAL|iCBT for Gambling Disorder and psychiatric comorbidities|The iCBT, is based on the gambling pathways model. As a clinical conceptualization, the treatment build on loss of control, but also include additional interventions (e.g., emotion regulation and impulse control) targeting the etiological co-morbidity factors in the pathways model for emotionally vulnerable and impulsive gamblers (pathways subtypes 2 and 3).
215098977|NCT03134781|BEHAVIORAL|DoIT workout|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.
215098978|NCT03134781|BEHAVIORAL|DoIT workout - Detraining|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.
215098979|NCT03134781|BEHAVIORAL|Control - No training|No training was performed during a 40-week period. Participation only in measurements.
215098980|NCT02903394|DEVICE|mLCI Device|imaging of cervical epithelium using mLCI device
214407107|NCT06456931|BEHAVIORAL|Traditional Buddhist mindfulness|Details are provided in the arm/group descriptions.
214407108|NCT06456931|BEHAVIORAL|secular mindfulness based cognitive therapy|Details are provided in the arm/group descriptions.
214407109|NCT02408965|DRUG|Methergine|0.2 mg of methylergonovine maleate
214407110|NCT02408965|OTHER|placebo|saline placebo to maintain blinding
215011789|NCT01243424|DRUG|glimepiride placebo|glimepiride placebo
215011790|NCT04401631|DEVICE|Blood Collection|"Between-Run Reproducibility K3-EDTA venous whole blood 3 mL 1 venous draw~Operator-to-operator imprecision (abioSCOPE) K3-EDTA capillary whole blood 0.05 mL/draw; 0.15 mL total 3 finger sticks (3 different fingers)~Sample type comparison (abioSCOPE) K3-EDTA capillary whole blood, venous serum, venous K3-EDTA plasma 0.35 mL (finger stick), 9 mL of whole blood to get a minimum of 3 mL of serum and 9 mL of whole blood K3-EDTA to get a minimum of 3 mL of plasma 1 finger stick; 1 venous draw into serum tube (9 mL) and 1 venous draw into K3-EDTA plasma tube (9 mL), in total 18 mL~Method comparison (abioSCOPE and ImmunoCAP/Phadia) K3-EDTA capillary whole blood, venous K3-EDTA plasma 0.05 mL (finger stick), 9 mL of whole blood to get a minimum of 3 ml of plasma 1 finger stick; 1 venous draw into K3-EDTA plasma tube (9 mL tube)"
215011791|NCT03614585|BEHAVIORAL|12 weeks of High-intensity Interval Training|Cardiovascular exercise
215011792|NCT03614585|BEHAVIORAL|12 weeks of Moderate-Intensity Continuous Training|Cardiovascular exercise
215011793|NCT02598999|DRUG|ALX-009|Solution for inhalation administered through nebulization
215011794|NCT02598999|DRUG|OSCN-|Solution for inhalation administered through nebulization
215011795|NCT02598999|DRUG|bLF|Solution for inhalation administered through nebulization
215011796|NCT02598999|DRUG|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
215011797|NCT05862441|DRUG|AV2-SA2|AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
215011798|NCT05862441|DRUG|SA|Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
215011799|NCT02011464|DRUG|Exparel|Exparel is infiltrated into posterior compartment for pain control
215098981|NCT03067376|DRUG|[14C]-CORT125134|
215098982|NCT00300365|DRUG|Pioglitazone|Pioglitazone, initially 30 mg, then titrated to 45 mg/day
215011800|NCT02011464|OTHER|Saline|Saline is infiltrated into posterior compartment for control
215098983|NCT00300365|OTHER|Placebo|Pioglitazone placebo
214407111|NCT02922972|DEVICE|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
215098984|NCT00300365|DRUG|Niacin ER|Niacin ER 2.0 g/day
215098985|NCT00300365|DRUG|Aspirin|asprin 325 mg/day
215098986|NCT04487457|OTHER|Blood samples|Blood samples
214407112|NCT06459661|OTHER|Diet|Intake of unrefined, intact plant foods
215098987|NCT04777266|BEHAVIORAL|Music therapy and treatment as usual|The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
215098988|NCT04318600|DRUG|human amniotic mesenchymal stem cell|human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
215098989|NCT04980365|BEHAVIORAL|Mindfulness|Participants will be asked to use the app Mindfulness Coach daily for 10 minutes. Participants will follow app instructions for brief guided meditation sessions for 14 days.
215098990|NCT04980365|BEHAVIORAL|Gratitude|Participants will be asked to use the app Grateful daily for 10 minutes. Participants will follow app instructions and will be answering to prompts related to gratitude provided by the app daily, for 10 minutes for 14 days.
215098991|NCT04980365|BEHAVIORAL|Food Journal|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
214407113|NCT05478122|DEVICE|Trachospray for awake videolaryngoscopy|Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
214407114|NCT00363285|BIOLOGICAL|gonadotrophin releasing hormone|
214407115|NCT00363285|DRUG|cyproterone acetate|
214407116|NCT00363285|PROCEDURE|quality-of-life assessment|
214407117|NCT00250224|DEVICE|Radiotherapy stent|
215011801|NCT03973593|BEHAVIORAL|Enhancing contraceptive counseling on method continuation and switching|Health care workers and Community Health Volunteers will be trained on a contraceptive counseling package that enhances information on method continuation and switching. This will be done in the ten intervention facilities prior to enrollment of clients into the cohort study.
215011802|NCT00732693|DRUG|Ethinylestradiol / Norethisterone|"Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days"
215011803|NCT00732693|DRUG|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
215011804|NCT01390935|OTHER|guideline adherence|guideline adherence of physician
215011805|NCT02645708|PROCEDURE|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
215011806|NCT02645708|PROCEDURE|EPVL after RIRS|Patients in Group 2 undergo EPVL after RIRS
215011807|NCT00754039|DRUG|colesevelam HCl tablets and fenofibrate tablets|Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
215011808|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
215011809|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
215011810|NCT03896360|BEHAVIORAL|Food order behavioral intervention plus standard care|Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.
215011811|NCT03896360|BEHAVIORAL|Standard Care|Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
215011812|NCT05991479|OTHER|Pilates exercises|"Pilates exercises:~The subjects will receive Pilates training (3 sessions/week) for 8 weeks. The Pilates training protocol will take 60 min per session, including 10 min of warm up prior to initiating the Pilates technique, 40 min for Pilates exercises and 10 min for cool down. The number of repetitions will be 10 times. The patient will perform the following Pilates exercises: (Hundred exercises, spine stretch, single leg stretch , double leg stretch, criss cross, swimming, one leg kick, side kick, clam, one leg circle, shoulder bridge, hip twist, roll up and down and standing footwork)."
215098992|NCT05517798|PROCEDURE|Alveolar ridge preservation|Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
215098993|NCT04955418|DEVICE|Epi-No®|evaluation, 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device and revaluation six months after delivery.
214407118|NCT05972239|OTHER|Standard pulmonary rehabilitation program|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load (watts) determined starting from the 6MWT using the Hill equation and will be increased to reach a perception of moderate-intense fatigue and/or dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be calibrated to allow the execution of 12 consecutive repetitions and will be progressively increased by 0.5 kg in order to cause a moderate/intense fatigue and/or dyspnea. Group exercises aimed at improving flexibility of the trunk, lower and upper limbs, lasting at least 30 minutes, 5/6 days a week, for a total of 12-14 sessions.
215011813|NCT05991479|OTHER|Traditional physical therapy programme:|"All patients will receive a traditional physical therapy programme consisting of 45 minutes per session of a supervised and individualized exercise programme for three sessions per week for eight weeks which will include:~Stretching exercises for calf and hamstring muscles. Strengthening exercises for hip, knee, ankle, and foot muscles. Deep friction massage for scar management."
215011814|NCT01368770|OTHER|Coronary CTA|Coronary CTA using standard protocols
215098994|NCT04955418|DIAGNOSTIC_TEST|Evaluation|evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.
214407119|NCT05972239|OTHER|Balance training added on standard pulmonary rehabilitation|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load determined from the 6MWT (Hill equation) and will be increased based on dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be progressively increased. Supervised balance training sessions lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The sequence of the exercises will be personalized according to the result of the Berg Balance Scale and modified according to the progress.
214407120|NCT01313598|DRUG|GLPG0187|continuous IV infusion
214407121|NCT01352507|DRUG|Tadalafil|Administered Orally
214407122|NCT01352507|DRUG|Sildenafil|Administered Orally
214407123|NCT04231461|PROCEDURE|Cardiac Surgery|Routine or urgent cardiac surgery
214407124|NCT06219603|OTHER|survey|questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases
214407125|NCT00409864|PROCEDURE|Endoscopic biliary stenting, Percutaneous biliary stenting|percutaneous 10 F stent, endoscopic 10 F stent insertion
214407126|NCT03968237|DRUG|Buprenorphine/Naloxone|Controlled substances
214407127|NCT03018145|DEVICE|Wagon|
214407128|NCT03018145|DEVICE|Standard stretcher car|
215011815|NCT01368770|OTHER|Stress MPI SPECT|Stress MPI using standard protocols
215011816|NCT00397930|PROCEDURE|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
215011817|NCT00397930|PROCEDURE|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
215011818|NCT01960842|DRUG|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
215011819|NCT01960842|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
215011820|NCT01960842|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
215011821|NCT01960842|DEVICE|J-tube|jejunal tube
215098995|NCT01283685|OTHER|breathing helium-hyperoxia|40% O2, 60% He
215098996|NCT01283685|OTHER|breathing supplemental oxygen|oxygen (4 L/min) provided by nasal cannula
215098997|NCT01395407|RADIATION|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~1. 21 18 15~2. 23 20 17~3. 25 22 19"
215098998|NCT04029818|BIOLOGICAL|Bifidobacterium BSL_PS404|Each participant will consume 1 capsule daily at lunch for 8 weeks.
215098999|NCT04029818|BIOLOGICAL|Placebo|Each participant will consume 1 capsule daily at lunch for 8 weeks.
214407129|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG and L-PRF|immediate implant placement using ATBG as a graft material, with L-PRF
214407130|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without L-PRF
214407131|NCT01511250|BIOLOGICAL|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
214407132|NCT01511250|BIOLOGICAL|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
214407133|NCT00142766|BEHAVIORAL|Nurse Implemented Goal-Directed Comfort Algorithm|See description
214407134|NCT00980278|PROCEDURE|Sinus lift augmentation and dental implant|transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
214407135|NCT00980278|BIOLOGICAL|Aastrom BRCs|sinus augmentation, BRC application, dental implant
214407136|NCT06107920|DRUG|Neoadjuvant chemotherapy|Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy
214407137|NCT01619254|BEHAVIORAL|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
214407138|NCT02148809|RADIATION|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
214407139|NCT05068713|OTHER|Usual Care + High Target of Mean Arterial Pressure|Targeting the weaning of vasopressors to a mean arterial pressure of 85-90mmHg in the first 24h after liver trasnplant.
215011822|NCT02391584|DEVICE|XprESS|Balloon dilation of the Eustachian tube
215011823|NCT02391584|OTHER|Control|Continued medical management
215011824|NCT01215240|DEVICE|Peritoneal dialysis|Prophylactic peritoneal dialysis
215011825|NCT03843970|DRUG|Levobupivacaine Hydrochloride 0.5%|The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
215011826|NCT03843970|DRUG|Isobaric bupivacaine 0.5%|The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
215099000|NCT03469024|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
215011827|NCT03418974|DRUG|Pitavastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
215011828|NCT03418974|DRUG|Atorvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
215011829|NCT03418974|DRUG|Rosuvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
215011830|NCT00805220|OTHER|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
215011831|NCT01972971|OTHER|patient education|one by one patient education
215011832|NCT05595395|DRUG|Enteral Dose Form|"In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be Elomel isoton."
215011833|NCT05595395|DRUG|Intravenous Infusion|"In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be Elomel isoton."
215011834|NCT03854448|DEVICE|holter monitoring|"Transthoracic Echocardiography (TTE) Left atrial ( LA) volume will be measured using standard apical two- and four-chamber views on the frame just prior to mitral valve opening and as specified by current American Society of Echocardiography guidelines (10) LA volume is indexed to body surface area. Mitral inflow velocity is obtained in the apical four-chamber view by placing a pulsed-Doppler sample volume between the tips of the mitral leaflets. Mitral annular velocity is assessed during the early phase of diastole(e=) using pulsed-wave Doppler sampling of septal mitral annular motion from the four chamber view.~24 to 48 hours Holter monitoring after 1 month after PCI"
215011835|NCT00552162|PROCEDURE|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
215011836|NCT00552162|PROCEDURE|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
215011837|NCT03012152|PROCEDURE|Standard conservative breast surgery|
215011838|NCT03012152|PROCEDURE|Oncoplastic breast surgery|
215011839|NCT04354688|DEVICE|T3 Certain Tapered Implant|Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
215011840|NCT03243188|OTHER|Qualitative interview|Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
215011841|NCT01641666|DRUG|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
215011842|NCT01641666|DRUG|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
215099001|NCT03469024|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
215099002|NCT04767152|DIAGNOSTIC_TEST|MRI|The quantitative assessment of MRI parameters, The macromolecular proton fraction (MPF) (%) in brain tissue. Before the start of therapy - the starting point. Point 2. 36 ± 3 days after the start of the therapy. Point 3. After completing three courses of consolidation chemotherapy. Point 4. After confirmation of remission status, optionally provided.
215099003|NCT02238834|DRUG|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
215099004|NCT02238834|DRUG|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
215099005|NCT02238834|DRUG|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
215099006|NCT02238834|DRUG|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
215099007|NCT00464659|DEVICE|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
215099008|NCT00464659|DEVICE|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
215099009|NCT00038779|PROCEDURE|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
215099010|NCT04326088|OTHER|Reconstruction group|Patients with primary tumor which underwent free flap reconstruction group.
215099011|NCT04326088|OTHER|Recurrent group|Patients with recurrent tumor which underwent free flap reconstruction group.
215011843|NCT01641666|DRUG|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
215011844|NCT03682393|DRUG|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
215011845|NCT03682393|DRUG|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
215011846|NCT01881633|DRUG|ISU302|
215011847|NCT01881633|DRUG|Placebo|
215011848|NCT05639439|DEVICE|"Ventilation using the Fastrach intubating laryngeal mask airway and glottic view using fibrescope - Group A"|"Insertion of the intubating laryngeal airway device Fastrach, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
214407140|NCT05068713|OTHER|Usual Care|Targeting the weaning of vasopressors to a mean arterial pressure of 65-70mmHg in the first 24h after liver trasnplant.
214407141|NCT00857142|DRUG|oxymorphone hydrochloride|
214407142|NCT00857142|DRUG|Opana|
214504759|NCT04181788|DRUG|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.
214504760|NCT06831227|DEVICE|High power Laser Therapy|"A total course protocol: 18 sessions, for 6 weeks ,3 sessions per week. Patients will receive High power Laser treatment. manually set to bio stimulation mode with high peak power (5 - 6 W), energy per impulse 150 mJ/c2, wavelength measuring 1064 nm, and spot beam diameter area of 1 cm2.~The hand piece was positioned in contact with and perpendicular to the treated area with the patient inside lying position with knee to chest. Scanning will perform transversely and longitudinally paravertebral region on the lower lumbar area at the level of the disc concerned. Each session included three phases (fast scan, sensitive trigger points, slow scan) and had a total duration of 20 minutes. During each session, a total energy of 3000 J was applied through three phases of treatment."
215011849|NCT05639439|DEVICE|"Ventilation using the Proseal laryngeal mask airway and glottic view using fibrescope- Group B"|"Insertion of the laryngeal airway device Proseal, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
215011850|NCT05639439|DEVICE|"Ventilation using the I-gel supraglottic airway device and glottic view using fibrescope- Group C"|"Insertion of the supraglottic airway device I-gel, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
215011851|NCT05639439|DEVICE|"Ventilation using the Protector laryngeal airway device and glottic view using fibrescope- Group D"|"Insertion of the laryngeal airway device Protector, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
215011852|NCT01820104|DRUG|lansoprazole, 30 mg per day for 6 days|
215011853|NCT01377311|PROCEDURE|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
215011854|NCT03737032|DEVICE|Intermittent Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
215011855|NCT03737032|DEVICE|Continuous Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
215011856|NCT03737032|DEVICE|Sham Theta Burst Stimulation|For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
215011857|NCT01141868|BEHAVIORAL|Internet Intervention|online treatment for insomnia
215099012|NCT01587092|BEHAVIORAL|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
215099013|NCT01587092|BEHAVIORAL|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
215099014|NCT03342625|DEVICE|High Instensity Focused Ultrasound|High Intensity Focused Ultrasound guided by MRI
215099015|NCT01581619|RADIATION|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
215099016|NCT06243120|DRUG|Lidocaine IV|The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.
215099017|NCT03960723|OTHER|Questionnaire|A questionnaire asking the patients for several questions related to the Informed Consent Form they have signed before surgery, will be administered.
215099018|NCT04080323|DRUG|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
215099019|NCT04080323|DRUG|placebo|1 vaginal tablet of placebo 60 minutes before surgery
215099020|NCT01818492|BIOLOGICAL|NI-0501|
215099021|NCT03974295|BEHAVIORAL|Vaginal unprotected intercourse|Patients will allowed to engage in vaginal unprotected intercourse as many times as desired after 24 hours of pelvic rest after a frozen embryo transfer.
215099022|NCT03292276|DEVICE|Amadeo Training|"To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups."
215099023|NCT05600582|BIOLOGICAL|CodaLytic|CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009
214407143|NCT05794373|PROCEDURE|Standard physiotherapy for low back pain in a municipality setting|Patients (N=100) referred to a municipality-based rehabilitation for low back pain are included. The physiotherapists choose the rehabilitation strategy based on what they consider relevant for the patients. After the first 100 patients have been discharged from municipality care, the physiotherapists will participate in an educational intervention (12 sessions) focusing on the management of low back pain within a multidimensional framework. In the educational intervention, the participants will learn how to identify the presence of unhelpful thoughts and emotions and how to address these as part of the intervention. The course will thus be a mix of theoretical and practical teaching, including case supervision and feedback. Following the educational intervention, an additional 100 patients referred to the rehabilitation program will be included. The intervention is aimed at the physiotherapists where the patients will receive the best available care, before or after the intervention.
214407144|NCT06112704|DRUG|HS-20093|Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
214407145|NCT04519450|DEVICE|Mindray TE7 ultrasound machine|The study was performed using a Mindray TE7 ultrasound machine with the depth of the linear probe at 70 mm and gain of 90 dB; settings remained unchanged during the study. Measurements of the right m. sternocleidomastoideus, the right m. trapezius, and the right upper leg were taken, with the final value being the average of three measurements for each. The probe was set at the musculoskeletal ultrasound setting.
214407146|NCT06645249|DRUG|Amiodarone (Antiarrhythmic drug)|Comparing 2 regimes of amiodarone pre-electrical cardioversion witn ECG monitoring
214407147|NCT04824131|DRUG|Oral cabotegravir (CAB)|30 mg tablets
214407148|NCT04824131|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
214407149|NCT04824131|DRUG|Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|300 mg/200 mg fixed-dose combination tablets
214407150|NCT04805346|DEVICE|autoRIC®|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada).17 The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol
214407151|NCT02130492|RADIATION|FDG|The intervention arm consists of treatment with increasing doses of \[18F\]-Fluorodeoxyglucose.
214407152|NCT04651348|DRUG|Recombinant Humanized Monoclonal Antibody MIL95|"PART A :The patients confirming to the eligibility criteria will be assigned to the 4 dose groups (0.1mg/kg, 0.3mg/kg, 0.8mg/kg, 1.0mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL95 every week on Day 1 for a maximum of Twelve weeks.~PART B:One recommended dose as a priming dose will be selected from 4 dose groups(0.1mg/kg、0.3mg/kg、0.8mg/kg、1.0mg/kg) based on results of PART A. Each patient will receive a priming dose of MIL95 on Day 1 Cycle 1.The patients will be assigned to the 5 maintenance dose groups (3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 45mg/kg, respectively) based on the sequence of inclusion. The maintenance dose was given on Day 8,15,22 Cycle 1 and on Day 1,8,15,22 Cycle 2+. Each cycle was 28 days."
214407153|NCT06148753|OTHER|Manuka Health Eternal Renewal Regenerating Face Serum with Royal Jelly and Bee Venom|Face serum containing manuka honey, royal bee jelly, and bee venom.
214407154|NCT06577857|DEVICE|Inferonasal Minimally Invasive Micro Sclerostomy|The Inferonasal MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the inferonasal quadrant of the eye.
214407155|NCT04887285|DEVICE|Virtual reality|Subjects in the virtual reality group will be offered a variety of immersive environments to choose from (mountains, beach, rainforest and temperate forest) in addition to local anesthetic.
214407156|NCT04887285|DRUG|Intravenous sedation|Sedation will be administered using low-dose midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). Sedation will be titrated to effect by a board-certified or eligible anesthesiologist so that patients remain responsive to verbal stimuli.
214407157|NCT04887285|OTHER|Standard care|Patients will receive superficial local anesthetic with 1% lidocaine. Local anesthetic will be administered by the physician performing the procedure titrated to patient comfort.
214407158|NCT05683301|DRUG|Amlodipine + Perindopril|Single pill combination of dual antihypertensive agent
214407159|NCT05683301|DRUG|Perindopril + Indapamide|Single pill combination of dual antihypertensive agent
214407160|NCT05683301|DRUG|Amlodipine + Indapamide|Single pill combination of dual antihypertensive agent
214407161|NCT03116204|OTHER|Assessment of score SAS|Assessment of a score assessing physical and cognitive activities of patients in follow-up care and rehabilitation departments
214407162|NCT05000190|DIETARY_SUPPLEMENT|Active capsule|1 capsule daily for 28 days
214407163|NCT05000190|OTHER|Placebo capsule|1 capsule daily for 28 days
214694199|NCT03542071|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
214407165|NCT04939428|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules taken by mouth.
214407166|NCT04939428|DRUG|Placebo|Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
214407167|NCT05938868|DEVICE|Low intensity pulsed ultrasound (LIPUS)|LIPUS will be delivered intra-orally using a probe applied on the buccal aspect of the implant site. The probe is in contact with the buccal attached gingiva with a thin film of intra oral gel intervening between them, acting as a transmitting medium. It will be applied twice a week for 20 minutes each session that commenced after surgery on the second day and continued for 10 weeks. The intensity of ultrasound therapy used was 30 mW/cm2 with a frequency of 1.5 MHz and temporal average power of 20 Mw
214407168|NCT05938868|DEVICE|low level diode laser therapy|The patients will be irradiated with low level diode laser therapy (GaAs) (Chattanooga, model 27841, USA) .Patient will be irradiated with low level diode laser therapy with parameters: wavelength 850 nm and power of 200 mw in continuous mode will be applied in six points in non-contact method 10 mm away from the peri-implant soft tissue after suturing. The laser irradiations will be administered at six sites that included mesiobuccally, distobuccal, midbuccal, midlingual, mesial, and distal areas around implant for a duration of 10 seconds for each site. The total energy delivered was 6 J per session. And is based on a previous study by Gulati et al., 2020
215099024|NCT03759106|OTHER|home written exercise program|exercises such as picking up objects, placing objects, frequently prescribed at discharge
215099025|NCT03759106|OTHER|telerehabilitation/exergame system|Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
215099026|NCT03077204|BIOLOGICAL|1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
215099027|NCT03077204|DEVICE|Aviator Anterior Cervical Plating System|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
215099028|NCT03649204|BEHAVIORAL|HY-PAD|Hybrid intervention that includes supervised on-site and home-based components in people with PAD
215099029|NCT00683969|DRUG|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
214407169|NCT05938868|OTHER|Standard Care|Patients in all three groups will receive the standard care which includes: (1) Extra-oral ice packs during the first 2 days every two hour; (2) maintain daily routine oral hygiene after surgery; (3) Patients will be instructed to eat a soft diet for one weeks; (4) Broad spectrum oral antibiotics in a dose of one capsule every twelve hours for a week; (5) Non-steroidal anti-inflammatory drugs at a dose of one tablet every 8 hours for four days; (6) Warm chlorhexidine gluconate solution as a mouthwash for a period of 2 weeks to enhance plaque control.
214407170|NCT04486638|BIOLOGICAL|Dengue Tetravalent Vaccine, Live|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous
214407171|NCT03099785|DRUG|Rifamycin SV 600mg t.i.d.|Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet
215011858|NCT05181631|OTHER|Biobanking|"Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL. "
215011859|NCT02058407|DRUG|GSK2793660 solution|Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
215011860|NCT02058407|DRUG|GSK2793660 capsule|Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
215011861|NCT02058407|DRUG|Placebo solution|Matching placebo to GSK2793660 solution
215011862|NCT02058407|DRUG|Placebo capsule|Matching placebo to GSK2793660 capsule
215011863|NCT03882372|DEVICE|Nasal high flow|See arm description.
215011864|NCT00295412|DRUG|quetiapine (drug)|
215011865|NCT03612895|BEHAVIORAL|Internal Care Coordination|This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.
215099030|NCT00683969|DRUG|placebo|po bid for 36 weeks
215099031|NCT05014113|DEVICE|DELTA-ST cup in combination with MINIMA stem|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
215099032|NCT00109577|DRUG|MCN36 (nutritional supplement)|nutritional supplement
215099033|NCT00109577|DRUG|Placebo|nutritional supplement
215099034|NCT06507683|RADIATION|simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib|"A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).~ripretinib: oral 150mg QD"
215099035|NCT00587847|DRUG|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
215099036|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with in person meetings.
215099037|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with emails.
215099038|NCT02839239|DIETARY_SUPPLEMENT|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
214407172|NCT03099785|DRUG|Rifamycin SV b.i.d. + Placebo|Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet
215011866|NCT03612895|BEHAVIORAL|External Community Referral|Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
215011867|NCT03612895|BEHAVIORAL|Usual Care|Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
214407173|NCT03099785|DRUG|Placebo t.i.d.|Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
214407174|NCT06041997|BEHAVIORAL|Smartphone restriction|The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
214407175|NCT02691065|DRUG|Integrase Inhibitor|Raltegravir
215011868|NCT05267002|PROCEDURE|Suture removal timing|Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
215011869|NCT00337961|PROCEDURE|Optic Nerve Sheath Fenestration|
215011870|NCT06272682|PROCEDURE|Systemic bethametasone injection|betamethasone intramuscular injection in the treatment of carpal tunnel syndrome
215099039|NCT02839239|DIETARY_SUPPLEMENT|Drops with vitamin D3|Oil suspension with vitamin D3
215099040|NCT01150201|DRUG|Aliskiren|For CKD treatment
215099041|NCT01150201|DRUG|Losartan|Control
215099042|NCT01860898|OTHER|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
215099043|NCT05320198|DRUG|DISC-0974|DISC-0974 is administered subcutaneously.
215099044|NCT02100306|BEHAVIORAL|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
215099045|NCT02100306|BEHAVIORAL|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
215099046|NCT03570320|OTHER|Modification of opioid prescription method|Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
215099047|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
215099048|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
214407176|NCT02696785|DRUG|Ixekizumab|Administered SC
215099049|NCT01154751|DEVICE|SUPERA Interwoven self-expanding nitinol stent|Insertion of stent at stenotic area
215099050|NCT04900285|DEVICE|Delta Dental Oral Device|"The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described."
215099051|NCT02986854|BIOLOGICAL|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
215099052|NCT03385330|OTHER|LOWER oxygen saturation target group|We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
214407177|NCT02696785|DRUG|Placebo|Administered SC
214407178|NCT02696785|DRUG|Adalimumab|Administered SC
214407179|NCT04863898|BEHAVIORAL|Drug-use stigma reduction intervention for HIV care and treatment clinic staff|We will adapt the HP+ health facility HIV stigma-reduction intervention to focus on drug stigma in HIV CTCs. The intervention will address key stigma drivers, including fear, awareness of stigma, and stigmatizing attitudes and beliefs, through a participatory training approach that involves all levels of staff and is grounded in social cognitive theory principles. The approach seeks to reduce stigma through fostering empathy, interpersonal interactions (contact strategies) and building efficacy for stigma reduction through awareness, skills, and knowledge building. The intervention consists of five-2.5 hour participatory training sessions.
214504761|NCT06831227|DEVICE|physical therapy exercise program and hot pack|this group will receive the same selected physical therapy exercise program (45 minutes) and hot pack (10 min) for 18 session. All patients will attend the physical therapy clinic three times weekly for 6 weeks
214504762|NCT06910709|DRUG|AMG 378|Oral tablet
215011871|NCT06272682|PROCEDURE|Local bethametasone injection|Local betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome
215011872|NCT02731768|BEHAVIORAL|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
215011873|NCT02731768|BEHAVIORAL|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
215011874|NCT02731768|DEVICE|Fitbit Zip|
215011875|NCT02731768|DEVICE|Digital body weight scale|
215011876|NCT03646188|DRUG|Placebo-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
214504763|NCT06910709|DRUG|Placebo|Oral tablet
215011877|NCT03646188|DRUG|25 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
214407180|NCT03093363|OTHER|Pharmacist's intervention|"Pharmacist's intervention with asthmatic patients:~* Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)~* Explanation of asthma and inflammation~* Explanation of triggers and how to avoid it~* Explanation of asthma treatments~* Explanation of the inhalation technique with a physical demonstration~* Emphasis on treatment adherence~* Assessment of comorbidities and their treatment~* Emphasis on influenza vaccination"
214407181|NCT03093363|OTHER|Questionnaires for control group|\- Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
214407182|NCT03328520|BEHAVIORAL|WILD 5 Wellness Intervention|"Behaviors in 6 areas of wellness: Sleep, Social Connectedness, Exercise, Nutrition, Mindfulness and HERO (Happiness, Enthusiasm, Resilience, Optimism)"
214407183|NCT00320476|DRUG|Velcade|
214407184|NCT00317538|DRUG|infliximab, etanercept|
214407185|NCT01537250|DRUG|Levofloxacin 500 mg placebol|oral form,,once adily,7\~10 days
214407186|NCT01537250|DRUG|Levofloxacin 500 mg placebol|oral form,,once adily,7\~10 days
214407187|NCT01537250|DRUG|Nemonoxacin 3 tablets|oral form,once daily,7\~10 days
214407188|NCT02618629|DRUG|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
214407189|NCT00770211|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
214407190|NCT00770211|DRUG|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
214407191|NCT05705050|DRUG|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.
214407192|NCT05705050|OTHER|Control group|Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.
215011878|NCT03646188|DRUG|50 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
215011879|NCT03646188|DRUG|100 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
215011880|NCT03646188|DRUG|200 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
215011881|NCT05001412|DRUG|Camrelizumab; apatinib; carboplatin; etoposide|2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
215011882|NCT01638299|DEVICE|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
215011883|NCT00252473|DEVICE|MedTec S-frame Immobilization Masks|
215011884|NCT00617903|DRUG|Azelaic acid|15% foam to be applied topically twice daily
215011885|NCT00617903|DRUG|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
215011886|NCT05768464|DRUG|Toripalimab|240mg intravenously every 3 weeks
215011887|NCT05768464|DRUG|Axitinib|5mg orraly twice daily
215011888|NCT05156125|DRUG|VTX002|Dose A tablet administered orally once daily
215011889|NCT05156125|DRUG|VTX002|Dose B Tablet administered orally once daily
215011890|NCT05156125|DRUG|Placebo|Placebo Tablet for VTX002 administered orally once daily
215011891|NCT04863807|PROCEDURE|Regional Anaesthesia|Thoracic epidural/Erector Spinae block/Serratus Anterior block
215011892|NCT06053476|PROCEDURE|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
215011893|NCT06053476|PROCEDURE|Single-shot paravertebral block|At the beginning of surgery, before pleurectomy, a single shot PVB will be placed at 10 levels (T2-T11) by the surgeon with Ropivacaine 7.5mg/mL and 2-3mL per site under direct thoracoscopic vision. The injection site will be chosen at the paravertebral space, just lateral adjacent to the sympathetic trunk.
215011894|NCT06053476|PROCEDURE|Late chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be left in place during a fixed period of 3 postoperative days. The chest tube will be removed at the earliest at POD 3 in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of bloody drainage by the Thopaz+ system"
215011895|NCT06053476|PROCEDURE|Early chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be removed at the earliest at 4 hours postoperatively in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of pure blood drainage by the Thopaz+ system"
215011896|NCT00768638|DRUG|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
215011897|NCT00768638|DRUG|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
215011898|NCT00556959|DRUG|high dose clonidine HCl sustained release|high dose clonidine HCl sustained release tablets for 8 weeks
215011899|NCT00556959|DRUG|low dose clonidine HCl sustained release|low dose clonidine HCl sustained release tablets for 8 weeks
215011900|NCT00556959|DRUG|placebo|placebo tablets for 8 weeks
214407193|NCT02496988|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
215011901|NCT03110276|DRUG|EYP001a|10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
214407194|NCT02496988|BIOLOGICAL|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
214407195|NCT01364220|DRUG|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
214407196|NCT01364220|OTHER|Placebo tablet|Placebo tablet, once daily, for 14 days
214407197|NCT03356015|DRUG|4L Polyethylene Glycol|4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.
214407198|NCT03356015|DRUG|3L Polyethylene Glycol|3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
214407199|NCT02641210|PROCEDURE|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
214407200|NCT02641210|DRUG|Albendazole|All participants took Albendazole 400 mg before the intervention.
214407201|NCT02911272|DEVICE|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
214407202|NCT02911272|DRUG|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
214407203|NCT02911272|PROCEDURE|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
214407204|NCT02911272|DEVICE|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
214407205|NCT02509403|DRUG|Essential oils infused Perineal Hygiene wipe|Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
215011902|NCT03110276|DRUG|Placebo|Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
215099053|NCT03385330|OTHER|HIGHER oxygen saturation target group|We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
215099054|NCT06377891|OTHER|Emotional Resilience training|Primiparous pregnant women in the experimental group will be given emotional resilience training in the last trimester.
215099055|NCT01972789|DRUG|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
214407206|NCT05547802|BIOLOGICAL|BBIBP-CorV and/or BNT162b2 vaccine|Booster immunization was carried out at least 4 months after the first two doses of basic immunization.
214407207|NCT01988987|OTHER|Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
214407208|NCT01102296|BIOLOGICAL|Hepatitis A vaccine|2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.
214407209|NCT03109106|DEVICE|PCT Arm|PCT-guided antibiotic therapy per study protocol
214407210|NCT01822821|DRUG|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
214407211|NCT01822821|DRUG|Placebo|Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
214407212|NCT04544540|OTHER|Units of transfusion|Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions
214407213|NCT01939938|DEVICE|Nasal and Oronasal PAP Mask|Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
214407214|NCT03557255|DRUG|Levosimendan|Preoperative 24 hours infusion of levosimendan for chronic heart failure patients prior to major abdominal cancer surgeries.
214407215|NCT03557255|DRUG|Saline|Preoperative 24 hours infusion of normal saline for chronic heart failure patients prior to major abdominal cancer surgeries.
214407216|NCT00764868|DRUG|Lisdexamfetamine Dimesylate (LDX)|optimal dose of 30, 50 or 70 mg once daily
214407217|NCT05571930|PROCEDURE|Secondary TEVAR after initial FET procedure|Under general anesthesia, via percutaneous femoral access, the investigators implant a TEVAR in the endovascular part of a FET. This secondary connexion is indicated in case distal thoracic aortic involvement such as aneurysm or dissection.
215011903|NCT02996786|DIETARY_SUPPLEMENT|Danggui Buxue Tang|Danggui Buxue Tang purchased from Kaiser Pharmaceutical
215011904|NCT02996786|OTHER|Placebo|Consisting of corn starch and carboxymethyl cellulose
215011905|NCT03166956|DIETARY_SUPPLEMENT|Glutamine and vitamin C enteral supplement|Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
215011906|NCT01332162|DEVICE|Biventricular pacing|All patients will be pacing during two years
215011907|NCT01332162|DEVICE|No Pacing|No Pacing during the first year. In the second year all patients will be pacing
215011908|NCT00471042|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
215011909|NCT05075772|DRUG|BI 765080|BI 765080
215011910|NCT01685554|DEVICE|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
215099056|NCT01877889|DRUG|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).
214407218|NCT05716633|DIAGNOSTIC_TEST|MRI|Serial MRI scans will be performed starting at day 15 from date of pain. Subsequent scans will be performed at 5 days interval till the clinically significant encapsulation (for all the collections in an individual patient) is seen.
215099057|NCT01877889|DRUG|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
215099058|NCT03033199|DRUG|Probiotic Agent|probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
214407219|NCT05764512|OTHER|Endorphin massage|"With the anterior surface of the fingertips of the hand, a V will be drawn slowly, starting from the sacral region and towards the ribs. The same process will be continued from the sacral region until the 7th cervical vertebra.~From the 7th cervical vertebra, the front surface of the fingertips will be descended first to the shoulders and then to the dorsal region of the upper and forearms in turn.~Starting from the dorsal region of the forearm, the first stage of the massage will end by descending to the upper arm, shoulders, 7th cervical vertebra, spine and sacral region with the back of the thumbs. These massage steps will be repeated until 20 minutes are completed.~Endorphin massage will be applied every 2 hours."
214407220|NCT06148714|DIETARY_SUPPLEMENT|Provitalize Natural Menopause Probiotic|Supplement containing a Probiotic blend of Bifidobacterium breve, Lactobacillus Gasseri, and Bifidobacterium animalis subsp. Lactis.
214407221|NCT06148714|OTHER|Placebo|Placebo comparator containing Pure hydroxypropyl methylcellulose (HPmC) with food dye.
214407222|NCT00308061|BIOLOGICAL|FMP1/AS02A|FMP1 antigen contained 62.5 ug of lyophilized protein with 3.1 percent lactose as cryoprotectant. It's reconstituted in approx. 600 uL AS02A adjuvant manufactured by GSK. AS02A contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. All AS02A vials contained 0.65 to 0.75 mL of liquid.
214407223|NCT00308061|BIOLOGICAL|Imovax Rabies Vaccine|Sterile, stable, freeze-dried suspension of rabies virus prepared from the strain PM-1503-3M, obtained from the Wistar Inst. in Philadelphia. Each 1 mL dose of vaccine contained 100 mg of human albumin, \<150g of neomycin sulfate, and \>2.5 IU of rabies antigen.
214407224|NCT05040243|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
214407225|NCT05040243|OTHER|placebo acupoint application|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
215011911|NCT01685554|DEVICE|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
215011912|NCT04303637|BEHAVIORAL|Phone use|Objective and subjective reports of smartphone use (e.g., number of hours, number of pick-ups, how phones are used)
215011913|NCT00858052|DEVICE|Saline-filled breast implant [IDEAL IMPLANT (R)]|Breast augmentation
215011914|NCT03061019|PROCEDURE|Oral Myofunctional Therapy with exercices|Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
215011915|NCT03061019|PROCEDURE|Oral Myofunctional Therapy with soft oral appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
215011916|NCT01225744|DRUG|Cetuximab|"Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.~Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA \> 2 m2 ."
215011917|NCT01225744|DRUG|Irinotecan|Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
215099059|NCT03033199|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
215099060|NCT04692142|OTHER|Flipped classroom teaching method|Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
215099061|NCT03175146|RADIATION|Stereotactic Body Radiation Therapy|5 treatments given over 2 weeks
215099062|NCT02597140|DRUG|lidocaine|Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
215011918|NCT01225744|DRUG|Oxaliplatin|Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
214407226|NCT05736770|OTHER|Respiratory rehabilitation and out of bed mobilization|The Respiratory rehabilitation and out of bed mobilization group will perform following exercises: pre operative out of bed mobilization, active cycle breathing techniques, forced expiratory technique and volume based incentive spirometery
214407227|NCT05736770|OTHER|conventional treatment|The conventional exercise program group will perform :Flow based Incentive spirometery, Chest percussion if needed
215011919|NCT01225744|DRUG|UFT|UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
215011920|NCT01684800|DRUG|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
215011921|NCT01684800|DRUG|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
214407228|NCT00595283|BEHAVIORAL|Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
214407229|NCT00595283|BEHAVIORAL|Developmental Education Parenting Intervention (DEPI)|DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
214407230|NCT05470660|PROCEDURE|Root coverage using coronally advanced flap combined with micro-needling|modified coronally advanced flap will be performed in sites of recession defects, then micro-needling will be performed after 1 month from the coronally advanced flap procedure to ensure the initial flap healing.
214407231|NCT05470660|PROCEDURE|coronally advanced flap combined with Alloderm|modified coronally advanced flap will be performed in sites of recession defects in Association with alloderm to cover the exposed root and 3 mm of connective tissue mesial and distal to it.
214407232|NCT02453646|DEVICE|NexSite HD Patients|Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
214407233|NCT03810885|OTHER|Bread with reduced salt content|Bread with gradually lowered salt content
215011922|NCT01684800|DRUG|C: Placebo|1 orally disintegrating tablet every night during study period
215099063|NCT02597140|DRUG|normal saline|Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
215099064|NCT02597140|DRUG|propofol|Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
214407234|NCT03810885|BEHAVIORAL|Dietary advice|Participants will receive information on how to lower salt and increase potassium intake
214407235|NCT03810885|OTHER|Bread with standard salt content|Bread with normal salt content
214407236|NCT05612529|DEVICE|US , Echocardiography|"* Carotid ultrasonography: Parameters will be measured by single blinded independent examiner using an ultrasound device. Baseline carotid FTc, ΔVpeak, will be measured.~* Echocardiography: Stroke Volume will be measured by transthoracic echocardiography.~* Renal and splenic Doppler resistivity index.~* Inferior vena cava collapsibility and distensibility indices.~* Central venous pressure estimation by central venous catheter, and central - Lung ultrasound for detection of lung congestion~* Lung ultrasound for detection of lung congestion."
214407237|NCT06089187|PROCEDURE|Endotracheal intubation using an endotracheal tube with cuff inflated with air|After endotracheal intubation, the endotracheal tube cuff is inflated with air
214407238|NCT06089187|PROCEDURE|Endotracheal intubation using an endotracheal tube with cuff inflated with saline|After endotracheal intubation, the endotracheal tube cuff is inflated with saline
214407239|NCT00165152|PROCEDURE|Genetic Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
214407240|NCT00165152|PROCEDURE|Informed Consent Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
214407241|NCT03005288|DRUG|BYM338 10 mg/kg|intravenous infusion every four weeks
214407242|NCT03005288|OTHER|Placebo|intravenous infusion every four weeks
214407243|NCT05136742|OTHER|aerobic exercise and diet program|It is an interventional study in which 60 women estimated to enrol according to random allocation and assigned into two groups equal. The study group will receive aerobic exercises in addition to diet recommendations while the control group will receive diet recommendations. the aerobic exercises in form of treadmill training intensity of exercises high intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX)time of session 40 min initial 10 min warm up exercise on treadmill in low intensity and active phase20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks .insulin resistance will be measured by HOMA -IR index and sex hormones (estridol ,testosterone. sex hormone binding globin ) pre and post intervention and use zung self-rating depression scale to assess depression
214407244|NCT05136742|OTHER|diet program|balanced restricted diet
214407245|NCT02393261|OTHER|2500ml Huaren peritoneal dialysate|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
215011923|NCT02917499|DEVICE|TMS|Transcranial magnetic stimulation
215099065|NCT00375167|BEHAVIORAL|Recovery Workbook Training (psychoeducational training)|The Recovery Workbook uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning, build personal support, and develop goals and plans of action. The intervention period of 30 weekly sessions recommended by Spaniol and colleagues was shortened to 12 weekly sessions to accommodate for clinical and participant commitment. No workbook content was excluded, and all practice exercises were covered.
214407246|NCT02393261|OTHER|2000ml peritoneal dialysate|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
214407247|NCT05981456|OTHER|patient safety competency|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the competence levels of the students.
214407248|NCT05981456|OTHER|satisfaction with the training method|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the satisfaction levels of the students from the education methods.
215099066|NCT00375167|BEHAVIORAL|ACT as usual|Assertive Community Treatment services provided as per established and evidence-based fidelity standards.
215099067|NCT02449590|DIETARY_SUPPLEMENT|Onion powder|Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
214407249|NCT06346145|PROCEDURE|Bariatric surgery|Type of surgery assigned by surgeon in consultation with patient
214407250|NCT06346145|PROCEDURE|Standard care|Standard care can consist of dietary intervention, physiotherapy or drug treatment in accordance to the care given in the region of Sweden where the patient resides.
214407251|NCT00771628|DEVICE|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
214407252|NCT00771628|DEVICE|Standard malleable stylet|Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
214407253|NCT00548964|DRUG|Lithium|600-900mg of Li carbonate
214407254|NCT00548964|DRUG|Ketamine|0.5mg/kg of ketamine
214407255|NCT06506240|OTHER|Acupuncture|Treatment will be administered by licensed practitioners with over five years of experience, in separate rooms to prevent patient interaction. The selected acupuncture points include LI11 (Quchi), SP10 (Xuehai), ST36 (Zusanli), SP6 (Sanyinjiao), LR3 (Taichong), LI4 (Hegu), ST25 (Tianshu), CV4 (Guanyuan), GV20 (Baihui), and superior GV29 (superior Yintang). Patients will receive acupuncture or sham acupuncture three times weekly for 6 weeks.
214407256|NCT06419946|DRUG|Temozolomide|In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
214407257|NCT06419946|DRUG|Lomustine|In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
215011924|NCT02843386|DRUG|Adjuvant chemotherapy by Fotemustin|"Fotemustin is given for 6 cycles :~* One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~* Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21."
215011925|NCT02843386|OTHER|Intensive surveillance|"Intensive surveillance~* Total duration: 3 years.~* liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months."
214407258|NCT01579019|DRUG|RO5024048|1500 mg po bid, 24 or 26 weeks
214407259|NCT01579019|DRUG|RO5024048|1000 mg po bid, 24 or 26 weeks
214407260|NCT01579019|DRUG|danoprevir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
214407261|NCT01579019|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc qw, 24 or 26 weeks
214407262|NCT01579019|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg po daily, 24 or 26 weeks
214407263|NCT01579019|DRUG|ritonavir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
215011926|NCT05189197|DRUG|Zanubrutinib + R-CHOP|"Zanubrutinib 160 mg BID administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved CR will continue to receive zanubrutinib 160mg BID for 1 year."
215011927|NCT00158457|DRUG|Tenofovir (TDF)|
215099068|NCT02449590|DIETARY_SUPPLEMENT|Placebo|Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
214407264|NCT00461565|DRUG|Sildenafil|A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
214407265|NCT00461565|DRUG|Placebo|A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
214407266|NCT00461565|DRUG|Vardenafil (Levitra, BAY38-9456)|B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
214407267|NCT00461565|DRUG|Placebo|B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
214407268|NCT01033396|DRUG|PF-03654764|PF-03654764 single dose 5 mg
214407269|NCT01033396|DRUG|Allegra|Fexofenadine single dose 60 mg
214407270|NCT01033396|DRUG|PF-03654764|PF-03654764 single dose 5 mg
214407271|NCT01033396|DRUG|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
214407272|NCT01033396|DRUG|Placebo|Placebo single dose
214407273|NCT02269436|DRUG|sNN0029 infusion solution|4 µg/day, continuous i.c.v administration
214407274|NCT01668979|DEVICE|new system to detect Near Falls|We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
214407275|NCT02659644|DRUG|Oral L-citrulline|There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
214407276|NCT02555007|DRUG|Vinorelbine|
214407277|NCT02765243|BIOLOGICAL|Anti-GD2 CART|Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells
214407278|NCT02662738|DIETARY_SUPPLEMENT|Natural fruit extract|
214407279|NCT02662738|OTHER|Placebo|
214407280|NCT02662738|OTHER|Glucose solution|
214407281|NCT03824236|BIOLOGICAL|RTS,S/AS01E (SB257049)|Subjects from the P-Fx and NP-Fx groups will receive one Fx booster dose of RTS,S/AS01E at Day 1.
215011928|NCT00158457|DRUG|Emtricitabine (FTC)|
215011929|NCT00158457|DRUG|Efavirenz (EFV)|
215011930|NCT03123588|DRUG|Ruxolitinib|Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
215011931|NCT03123588|DRUG|Anagrelide|Anagrelide administered orally at a starting dose of 1 mg BID.
215011932|NCT03123588|DRUG|Placebo|Anagrelide-placebo administered orally BID
214407282|NCT05477862|BEHAVIORAL|Clinically Designed Improvisatory Music|Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients.
214407283|NCT00701311|DRUG|CC-10004|CC-10004 20 mg per day
214407284|NCT01133613|DRUG|Bone morphogenetic protein 7|Single intraarticular injection of BMP-7 or placebo on Day 1
214407285|NCT03236233|DRUG|PC786 - Single doses|Safety and tolerability of single doses
214407286|NCT03236233|DRUG|Placebo - Single doses|Safety and tolerability of single doses
215011933|NCT03123588|DRUG|Placebo|Ruxolitinib-placebo administered orally BID.
214407287|NCT03236233|DRUG|PC786 - Repeat doses|Safety and tolerability of repeat doses
214407288|NCT03236233|DRUG|Placebo - Repeat doses|Safety and tolerability of repeat doses
214407289|NCT01076218|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
214407290|NCT04549051|DEVICE|Tenex|Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis
214407291|NCT04549051|DRUG|Local anesthetic|Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
214407292|NCT03418779|DRUG|The Yi-Qi-Qing-Jie herbal compound|The compounds are blends of individual herbal extracts from YQF (consisting of Astragalus membranaceus, Saposhnikovia divaricata (turcz.) Schischk, Flos lonicerae, Angelica sinensis, Dioscorea nipponica, Hedyotis diffusa Willd, rhubarb, Spatholobus suberectus, with the effect of reinforcing Qi and activating blood, clearing away heat and poison, dissolving dampness and downbearing turbid) dissolved in 150 ml boiled water and taken orally twice a day for the duration of the treatment and follow-up phases.
214407293|NCT03418779|DRUG|Immunosuppressants|Immunosuppression therapy comprises oral prednisolone (0.5-0.8 mg/kg/day; exact dose decided by the investigator, maximum dose not exceeding 60 mg/day) for 8 weeks, then tapered by 5-10 mg/day every 4 weeks, with a total treatment period of 24-32 weeks. Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8-1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks, total dose of not exceeding 8 g (exact dose decided by the site investigator). If severe CTX-related adverse events occur, such as alanine transaminase (ALT) exceeding the upper limit of two times, infections requiring hospitalization, granulocytes \< 3.0 × 109/L and platelets \< 50.0 × 109/L, CTX will stop being administered, symptoms will be treated, and adverse events recorded. Also, the frequency of detection will be increased to once every 2 weeks and the affected participant will be withdrawn if persistent infection or myelosuppression occurs.
214407294|NCT03418779|OTHER|Optimized Supportive Care|"The optimized supportive care included:~1. Lifestyle: low-salt, restricted protein dietary with sufficient calorie supply, smoking cessation, moderate alcohol consumption and keeping a healthy weight~2. The use of renin-angiotensin system blockade: lowering blood pressure to a target below 135/85 mmHg, during which treatment was adjusted to ensure that patients were receiving the maximum labelled or tolerated dose of RAS blockade~3. Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c≤ 7.0%~4. Received uricosuric agents or xanthine oxidase inhibitors as necessary to achieve serum uric acid \<6 mg/dL in female, \<7 mg/dL in male"
214407295|NCT03418779|OTHER|Yi-Qi-Qing-Jie herbal compound placebo|Patients will receive Yi-Qi-Qing-Jie herbal compound placebo instead for the duration of the treatment and follow-up phases. The major component of the placebo is malt dextrin which looks, smells and tastes like YQF compound, and it comes in packaging with a similar appearance to YQF compound; it is also dissolved in 150 ml boiled water and taken orally twice a day.
215011934|NCT01127360|DRUG|Bevacizumab|Intravitreal injections
215011935|NCT01127360|DRUG|Ranibizumab|Intravitreal injections
215011936|NCT04126668|DRUG|CM082 with fed or fasting|The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
215011937|NCT05430295|PROCEDURE|phacoemulsification|cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients
215011938|NCT05430295|PROCEDURE|monofocal intraocular lens implantation|implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
215011939|NCT00004032|BIOLOGICAL|ALVAC-hB7.1|Given IP
215011940|NCT00004032|BIOLOGICAL|recombinant interferon gamma|Given IP
214407296|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (low dose)|Participants are administered 125 µg indacaterol + mometasonefluroate
214407297|NCT06067100|DRUG|Placebo|Participants are administered placebo
215011941|NCT00004032|OTHER|laboratory biomarker analysis|Correlative studies
215011942|NCT02117817|DRUG|BKM120|
215011943|NCT02117817|DRUG|Nabpaclitaxel|Given IV
215011944|NCT04162275|DRUG|Finamine tablets|taken Finamine tablets orally
215011945|NCT04162275|DRUG|Placebo tablets|taken Placebo tablets orally
215011946|NCT02993302|DRUG|1α-D3|patients were given PTU and 1α-D3
215011947|NCT02993302|DRUG|Placebos|patients were given PTU and placebos
215011948|NCT02298283|DRUG|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
215011949|NCT02298283|DRUG|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
215011950|NCT02298283|DRUG|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
215011951|NCT02298283|DRUG|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
215011952|NCT02298283|DRUG|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
215011953|NCT02298283|DRUG|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
215011954|NCT02298283|DRUG|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
215011955|NCT02298283|DRUG|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
215011956|NCT02298283|DRUG|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
214407298|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (high dose)|Participants are administered 500 µg indacaterol + mometasonefluroate
214407299|NCT04767646|PROCEDURE|Intensive rehabilitation program with CPNB|"The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB.~The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program"
215011957|NCT02298283|RADIATION|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
215099069|NCT03327194|DEVICE|ADHEAR Audio Processor|"ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark."
215099070|NCT02760641|OTHER|Egg-based diet (EBD)|Participants will be asked to consume a carbohydrate-restricted diet including whole eggs for 8 weeks. Eggs will be provided.
214407300|NCT01924234|DRUG|Morphine|
214407301|NCT01924234|DRUG|Remifentanil|
214407302|NCT00674947|DRUG|BIIB015|IV infusion once every 3 weeks until disease progression or unacceptable toxicity
214407303|NCT06132776|DEVICE|HiToP 191 PNP|High tone therapy
214407304|NCT06132776|DEVICE|Placebo device|Placebo therapy
214407305|NCT03316443|DEVICE|Glidescope|"The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter).~For endotracheal intubation with glidescope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.~Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation."
214407306|NCT03316443|DEVICE|Macintosh|The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first. The laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced.Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation.Maximal arterial blood pressure and heart rate changes will be recorded
214407307|NCT06556004|BIOLOGICAL|TRIMELVAX|The safety of this immunotherapeutic compound will be tested in patients with advanced melanoma and will secondarily evaluate the induced immune response.
214407308|NCT05476211|DEVICE|BTL-785F|Radiofrequency
214407309|NCT06603402|RADIATION|low-dose involved-field radiotherapy combined with immunochemotherapy|low-dose involved-field radiotherapy combined with immunochemotherapy
214407310|NCT00442663|DEVICE|Transcervical Foley Catheter|
215011958|NCT01698008|OTHER|Diabetes Doctor Mobile app|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
215099071|NCT02760641|OTHER|Carbohydrate-based diet (CBD)|Participants will be asked to consume a low fat, carbohydrate-based diet for 8 weeks. Breakfast food items will be provided.
215099072|NCT03528226|BEHAVIORAL|Exercise Training Procedure|Exercise training: 3 sessions - 2 supervised and 1 unsupervised - per week of 30-60 min at 65% - 80% of maximum heart rate (4 months)
215099073|NCT03528226|BEHAVIORAL|Normal life procedure|No supervised exercise training during the 4 month period.
215099074|NCT00583687|DEVICE|Vigileo TM / Flotrac TM (Minimally invasive cardiac output system consisting of arterial line sensor and cardiac output monitor)|Attachment of the arterial line sensor and pulse contour cardiac output monitor to the arterial line of the patient.
215099075|NCT00583687|OTHER|Passive leg raising|Passive leg raising for prediction of fluid responsiveness with arterial pulse contour analysis.
215099076|NCT00583687|OTHER|Volume challenge / Change of vasoactive drugs or inotropics|Either a volume challenge (using colloids or crystalloids) or a change in the dosage of of vasoactive drugs or inotropics, or a combination of them, as proposed by the treating physician.
215099077|NCT00583687|DEVICE|Inspectra TM/O-To-See TM (Tissue oxymetry with near infrared spectroscopy and laser-Doppler)|Tissue oxymetry continuously measured with near infrared spectrometry and laser Doppler during the whole study period.
214407311|NCT00442663|DEVICE|Transcervical Foley Catheter with an EASI|
214407312|NCT00565682|DRUG|etoricoxib 120 mg|etoricoxib 120 mg, tablet, orally, OD
214504764|NCT04535414|DEVICE|Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes|Participants of both study arms will undergo confocal endomicroscopy of the gastric mucosa until sufficient data for statistically accurate and reliable application of machine learning (i.e., computer models), currently believed to total the first 50 enrolled participants.
215011959|NCT01339182|DRUG|Pegylated-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
214407313|NCT06608121|OTHER|Upper limb isokinetic forces measurements|The trial is a single-center prospective interventional study. Patients aged 18 to 85 years hospitalized in a French rehabilitation center for stroke, multiple sclerosis or traumatic tetraplegia and presenting a motor deficit ≤3/5 at the shoulder and elbow will be included. MVF measurements will be performed using an isokinetic ergometer during a single session. Concentric and eccentric MVF, as well as the forces generated during passive motion, will be measured in shoulder external-internal rotation and in elbow flexion-extension, in the seated position. The demographic, anthropometric and medical data required for the study will be extracted from medical records. Patients' residual muscle strength will be described and modeled. Explanatory factors for model quality will be determined.
214407314|NCT01953510|BIOLOGICAL|PCV10|PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein
214407315|NCT01953510|BIOLOGICAL|PCV13|PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
214407316|NCT06611137|COMBINATION_PRODUCT|SBRT+Toripalimab Plus Docetaxel and Cisplatin|All participants will receive SBRT (18Gy/3 fractions, QOD ) to gross tumor and metastatic lymph nodes, followed by neoadjuvant chemoimmunotherapy of Toripalimab (240mg) Plus Docetaxel (75mg/m2, q3w) and Cisplatin (75mg/m2, q3w) for 3 cycles. If tumor has complete or partial response at 2 weeks after the last course of neoadjuvant chemotherapy, participants will then receive intensity modulated radiotherapy (54Gy/27 fractions). If tumor is stable or progressive, participants will receive radical resection with or without postoperative intensity modulated radiotherapy when necessary.
214407317|NCT05707182|DRUG|18F-rhPSMA-7.3|18F-rhPSMA-7.3 PET/MR
215011960|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
215011961|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
214407318|NCT06615583|DEVICE|Surgical device|The C-REX device consists of an invasive surgical part, including two anastomotic rings, and surgical instruments for assisting the placement of the anastomotic ring to intestine. The rings are loosen from the inside of the intestinal wall and expelled with faeces per rectum once the anastomosis is healed in approximately ten days.
214407319|NCT06613503|DEVICE|AI-supporter|rticipants in the experimental group will use the AI-supporter, an intelligent excretion management robot. This device utilizes AI-driven visual recognition technology to automatically detect urine and feces, followed by a cleaning and drying process. When the AI-supporter detects excretion, it activates an automated sequence that washes, dries, and sanitizes the perineal area without requiring the caregiver to remove the diaper. The AI-supporter also records relevant data, such as the time, frequency, and weight of excretion, for further analysis. This intervention is designed to reduce the incidence of urinary tract infections (UTIs) and incontinence-associated dermatitis (IAD), as well as lessen the workload for caregivers
215099078|NCT04063969|OTHER|Assessment of radiation safety climate|"The rating tool contains 28 statements which cover 5 dimensions (Leadership, communication, commitment, resources, risk awareness) of the radiation safety climate. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety climate score is calculated by adding ratings on all items.~Minimum scale score 28 - Maximum scale score 140"
214407320|NCT06271200|OTHER|Strategic lifestyle and drug interventions|"Participants in the Intensive Lifestyle Intervention (ILI) group will follow a program including:~1. time-restricted eating with a 16:8 pattern (eating within an 8-hour window, fasting for 16 hours),~2. walking over 10,000 steps daily, and~3. a daily calorie reduction of 500 kcal (with macronutrient distribution: 40-55% carbohydrates, 15-20% protein, 20-30% fat).~Participants in the Usual Lifestyle Intervention (ULI) group will maintain their habitual meal timing.~After the initial 24-week lifestyle program, ILI participants will be randomized (1:1) to receive either a GLP-1 receptor agonist (Rybelsus) or an SGLT-2 inhibitor (Forxiga) for 26 weeks, while continuing their lifestyle regimen. This phase will assess the impact of medication-with or without prior lifestyle intervention-on weight loss and liver fat. All participants will then be followed for an additional 52 weeks to evaluate long-term weight maintenance."
214407321|NCT06271200|OTHER|Control|"Participants in the ULI group will maintain their usual lifestyle without intervention during the first 24 weeks.~After the initial 24-week usual lifestyle intervention, participants in the ULI group will be randomly assigned in a 1:1 ratio to receive either Rybelsus (GLP-1 receptor agonist) or Forxiga (SGLT-2 inhibitor) for a duration of 26 weeks. This phase aims to assess the effects of these medications on weight reduction and liver fat content without prior intensive lifestyle intervention. All participants will be followed for an additional 52 weeks to evaluate the long-term sustainability of weight loss."
214407322|NCT06668480|PROCEDURE|Conventional Physical Therapy|It will comprise of hot pack for 10 minutes, TENs at 80-100 Hz over trapezius for 10 minutes.Strengthening of deep neck flexors
214693915|NCT01766570|OTHER|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
215011962|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
215011963|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
214407323|NCT06668480|PROCEDURE|Strengthening Exercise|Strengthening exercises of lower fibers of trapezius
214407324|NCT06668480|PROCEDURE|SNAG'S|Sustained natural apophysial glides will consist of frequency: 4 sets of 3-5 repetition per session for 2 weeks
214407325|NCT06118710|DRUG|Dexamethasone|Dexamethasone prior to paclitaxel infusion according to local care standards.
214407326|NCT06118710|DRUG|H1 Antihistaminics|Clemastine or Cetirizine prior to paclitaxel infusion according to local care standards
214407327|NCT02359968|DRUG|FOLFOX|radiochemotherapy before surgery
214407328|NCT02359968|DRUG|CarboP-pacliT|radiochemotherapy before surgery
214407329|NCT06614088|DIAGNOSTIC_TEST|serum calprotectin|A blood sample is collected at time of admission to detect serum level of calprotectin
214407330|NCT06613620|OTHER|Standard Treatment|"All participants will receive 4 weeks of intervention with a frequency of 3 times/week i.e. 10minutes of hot pack followed by post facilitation stretching and strengthening protocol.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
214407331|NCT06613620|OTHER|Visual and auditory feedback on SEMG biofeedback unit|Patients will receive SEMG biofeedback assisted post facilitation stretching and strengthening. Patients will receive 50-80%of their maximum voluntary contraction as per the biofeedback and gradually the contraction time will be increased.
214407332|NCT06613620|OTHER|Electrical muscle stimulation|Electrical muscle stimulation will be provided in addition to visual and auditory feedback by the SEMG biofeedback unit to the weak muscles until the patients achieve the desired level of contractions.
214407333|NCT06615414|OTHER|participants are not assigned an intervention as part of the study|participants are not assigned an intervention as part of the study
214407334|NCT05039203|DEVICE|Indwelling urinary catheter|Removal of indwelling urinary catheter
214407335|NCT06614075|BEHAVIORAL|Questionnaire and anthropometric measurement|Questionnaire including sociodemographic characteristics, lifestyle habits, body weight, height, dietary assessment and diabetes risk; Anthropometric measurement including waist circumference
214407336|NCT06613776|DRUG|Amoxicillin|4 capsules of amoxicillin 500mg, 2 grams in total, one hour before surgery
214407337|NCT06613776|DRUG|Placebo|4 empty capsules of amoxicillin 500mg (placebo), one hour before surgery
214407338|NCT06612606|OTHER|observational study|This was an observational study with no intervention.
214407339|NCT06613581|OTHER|Home-based follow-up|Follow-up after surgery for colorectal carcinoma, performed from home, within the bounds of the Dutch National guidelines
214407340|NCT06682117|DRUG|DC Vaccine|"Patients will receive Neo-DC vaccine infusion either by dose 1 (1×10\^7 cells/time) or dose 2 (5×10\^7 cells/time) every 7 days, four cell infusions are one treatment cycle.~The dose limited toxity observation time is within 28 days after the first Neo-DC vaccine infusion.~If the efficacy is evaluated as clinical benefit (CR/PR/SD) or immune unconfirmed progress ( iUPD), treatment cycle can be continued until the completion of four Neo-DC vaccine administrations or disease progression (iCPD by iRECIST) or start new anti-tumor treatment or stop treatment by other reasons."
214407341|NCT06827860|DRUG|Talquetamab|SC monotherapy starting with three step-up doses followed by the standard 800 μg/kg dose every other week. Cycles will be 28 days long.
214407342|NCT06827860|DRUG|Daratumumab|SC at the standard dose (weekly for 2 cycles, every other week for 4 cycles, monthly thereafter)
214407343|NCT04541901|OTHER|Massage|12 minutes of effleurage and petrissage on the upper limbs
214407344|NCT04541901|OTHER|Cold water immersion|12 minutes of cold water immersion at the shoulder level with water temperature between 11 to 15°C
214407345|NCT04504903|BEHAVIORAL|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will go to 12 weekly group sessions and will learn healthy thinking about work, positive behavioral coping related to work, and will form a work success plan based on their work goals.
214407346|NCT04504903|BEHAVIORAL|Psychoeducation|Veterans will go to 12 weekly group sessions and will learn more information about their mental health conditions. Psychoeducation modules are from the Illness Management and Recovery program.
214407347|NCT04191161|DEVICE|Wearing the rigid brace|Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
214407348|NCT05263141|PROCEDURE|retro-auricular single-site endoscopic thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
214407349|NCT05263141|PROCEDURE|traditional open surgery thyroidectomy|The strap muscles were separated in the midline to expose the thyroid gland. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified， a lobe of thyroid specimen and central lymph nodes were dissected.
214407350|NCT04074954|PROCEDURE|Cataract surgery|Patients will receive cataract surgery
214407351|NCT05512260|DEVICE|Individual decision aid (iDA)|A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
214407352|NCT00359619|BIOLOGICAL|CervarixTM|Subjects were administered three doses of HPV vaccine
214407353|NCT00359619|BIOLOGICAL|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
214407354|NCT00878384|DRUG|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of \<80bpm and \<110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
214693916|NCT01766570|OTHER|Placebo|
215011964|NCT05416281|OTHER|Robotic Vacuum|Participants will be provided with a Roomba iRobot vacuum and will be asked to use the vacuum in their home for 8 weeks. Exposure to environmental exposures will be evaluated before and after the intervention using silicone wristbands.
214407355|NCT00878384|PROCEDURE|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
214407356|NCT05406934|BIOLOGICAL|Infliximab|obseravation with investigation
214407357|NCT02807753|OTHER|Ankle and Knee Ultrasound Joint Assessment|Ultrasound Examination of the ankles and knees
214407358|NCT02807753|OTHER|Ankle and Knee Magnetic Resonance Imaging|Ankle and Knee Magnetic Resonance Imaging
214407359|NCT01419717|DRUG|Denosumab|Administered by subcutaneous injection every 4 weeks (Q4W)
214407360|NCT02857283|OTHER|Ozone|Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08
214407361|NCT02857283|OTHER|Filtered Air|Participants will be exposed to filtered clean air
214407362|NCT02857283|DEVICE|Health and Exposure Tracker (HET)|Ozone and heart rate tracker
214407363|NCT04885595|PROCEDURE|Forceps biopsy and cryobiopsy|Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.
214407364|NCT03698136|OTHER|Stimulation of denervated muscles|The study investigates the effect of electrical stimulation on denervated muscles in the forearm and hand regarding muscle structure and thickness. The study will be performed on tetraplegics who have either paralysed the wrist extensor, the short thumb spreader or the muscle between the thumb and index finger.The study lasts 12 weeks and consists of an ultrasound examination at the beginning and end of the study and an intermediate stimulation phase.The stimulation takes place either during an inpatient stay or at home for 12 weeks, 5 times a week 33 minutes.
214407365|NCT05949372|OTHER|Giving a biological breastfeeding position|The mother is half-sitting, in the most comfortable position where she can make eye contact with her baby. The baby's head is placed on the mother's chest with her legs on the mother's stomach. With this position, gravity fixes the baby's whole body to that of its mother.
215011965|NCT03279965|DIAGNOSTIC_TEST|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
214693917|NCT00272636|PROCEDURE|Radiofrequency catheter ablation|
215011966|NCT00508300|PROCEDURE|Epidural analgesia|Thoracic epidural analgesia until day 2
215011967|NCT00508300|PROCEDURE|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
215011968|NCT03968627|OTHER|Rehabilitative intervention|intensive multidisciplinar rehabilitation
215011969|NCT00520442|DRUG|ibuprofen|
215011970|NCT00520442|DRUG|acetamin w codeine|
215011971|NCT00949663|DRUG|Placebo|Intravenous infusion of 1% human albumin in normal saline
215011972|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
215011973|NCT00949663|DRUG|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
215011974|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
215011975|NCT05406999|DRUG|ADT|The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
215011976|NCT05406999|DRUG|Abiraterone Acetate|1000 mg (250 mg×4 tablets) once daily, orally
215011977|NCT05406999|DRUG|Prednisolone tablets|5 mg once daily, orally.
215011978|NCT05406999|DRUG|Enzalutamide|160 mg (40 mg× 4 tablets) once daily, orally.
215011979|NCT05406999|DRUG|Apalutamide|240 mg (60 mg×4 tablets) once daily, orally.
215011980|NCT05406999|DRUG|Darotamide|600 mg (300 mg × 2 tablets) twice daily, orally.
214407366|NCT05949372|OTHER|Giving a football ( armpit) position|The mother sits upright, leaning back, and the baby's bottom and the right or left side of the mother is supported by pillows from whichever side she will breastfeed. The baby's head is placed on the breast that is breastfed and the feet are laid flat so that they pass under the armpit of the breastfed side. While the mother's hand on the breastfeeding side holds the baby's head, the other hand directs the breast towards the baby and breastfeeding is initiated.
214407367|NCT01663610|BEHAVIORAL|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
214407368|NCT02018666|DEVICE|NAVA endotracheal tube|
215011981|NCT05406999|DRUG|Rezvilutamide|240 mg (80 mg × 3 tablets) once daily orally
215011982|NCT05406999|DRUG|PARP inhibitor|The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
214407369|NCT00114803|DRUG|Calcitonin nasal spray (salmon)|
214693918|NCT00272636|DRUG|Amiodarone and cardioversion|
214693919|NCT03585699|DIAGNOSTIC_TEST|Fluoroscopy Guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
215011983|NCT05406999|PROCEDURE|Robot-assisted radical prostatectomy|Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
215011984|NCT02324322|DEVICE|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
215011985|NCT02324322|OTHER|Muscle Biopsies|"Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking."
215011986|NCT02324322|OTHER|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
215099079|NCT04063969|OTHER|Assessment of radiation safety behavior|The rating tool contains 2 statements which cover 2 dimensions of the radiation safety behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety behavior score is calculated by adding ratings on both items Minimum scale score 2 - Maximum scale score 10
214407370|NCT04444180|DIAGNOSTIC_TEST|Virtual hand illusion (VHI)|Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
214407371|NCT04107519|BEHAVIORAL|Goal-Directed Resilience Training|This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
214407372|NCT01207908|DRUG|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
215011987|NCT01436292|DRUG|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; \< 10 gr/L: 150 g of 5% HAS."
215011988|NCT01755637|DRUG|Albendazole|Albendazole tablets 400 mg
215011989|NCT00668564|PROCEDURE|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
215011990|NCT00668564|DRUG|Cyclophosphamide|"Days before Transplant Drug Frequency~* 4 Cyclophosphamide Once, given over 2 hours~* 3 Cyclophosphamide Once, given over 2 hours~* 2 Cyclophosphamide Once, given over 2 hours~* 1 Cyclophosphamide Once, given over 2 hours"
214407373|NCT06306859|BEHAVIORAL|Using m-health for monitoring and education provision|The intervention group will be given access to m-health. The m-health aims to monitor patient's status i.e blood pressure, heart rate, fluid intake, dietary intake. In addition, there will be education provided through the m-health. The education will be on fluid and diet adherence
215011991|NCT00668564|DRUG|Campath-1H|"Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours"
215099080|NCT04063969|OTHER|Assessment of radiation safety knowledge and motivation|"The rating tool contains 2 statements which cover the radiation safety knowledge and behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement.~Minimum item score 1 - maximum item score 5"
215099081|NCT04063969|OTHER|Data collection|Collection of patient-related data points Demographic information: ASA-classification, BMI Procedure related information: Procedural time, approach, contrast usage case difficulty Radiation safety parameters: Air Kerma, DAP, fluoroscopy time
215099082|NCT05307042|DIAGNOSTIC_TEST|Deamino Arginine Vasopressin (dDAVP)|After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
215099083|NCT00464503|DRUG|Rosuvastatin-Crestor|
215099084|NCT00464503|DRUG|Pravastatin-Pravasine|
214407374|NCT06306859|OTHER|Standard care|The comparator group will be given standard and routine care
214407375|NCT03881254|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
214407376|NCT03881254|OTHER|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
214407377|NCT03881254|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
214407378|NCT03881254|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
214407379|NCT05080192|DRUG|Fenofibrate|145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
215099085|NCT06080685|BEHAVIORAL|Character Strengths Intervention|Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Cultivate your inner self + Loving-Kindness Meditation Session 4. Gratitude Letter + Three Good things Session 5. Conclusion Each session will consist of 1-hour, which will be delivered once a week for 5 weeks. Moreover, participants will be given homework which they will practice the rest of the week.
215099086|NCT06376578|BEHAVIORAL|Exercise intervention|Exercise training will progress incrementally, increasing the duration of exercise on the treadmill by 5 minutes every 2 weeks whereby the final duration on the treadmill will be 35 minutes and the total duration will map onto recommended guidelines of 150 minutes per week. Throughout the 8-weeks, the duration of exercise on the cycle ergometer will remain at 15 minutes. Exercise intensity will progress throughout the 8-week intervention on both the treadmill and the cycle ergometer by 5% every 2 weeks, whereby exercise during the final week will be at 70% VO2max.
215099087|NCT06376578|BEHAVIORAL|Polar A380 wristwatch physical activity tracker|The research team will monitor individual exercise training weekly using virtual/electronic methods and a 30 minute telephone call. The researcher will provide feedback about how the participant's activity compares to physical activity recommendations, and encouragement and support will be provided verbally.
215099088|NCT03052244|DEVICE|tDCS+VI|2mA will be delivered over 20min to M1 via neuroConn DC stimulator combined with video presenting walking legs.
215099089|NCT03052244|DEVICE|tDCS Sham+VI Sham|2mA will be delivered up to 30 sec to M1 via neuroConn DC stimulator combined with video presenting graphical illustration or nature movie for total duration of 20 min.
214407380|NCT05080192|DRUG|Placebo|Matching placebo (once/day) for 10 days
215011992|NCT00668564|DRUG|Busulfan|"Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day"
215099090|NCT05958680|BEHAVIORAL|ASDactive|An integrated theory-based intervention to promote habitual physical activity behaviours in autistic youth
215011993|NCT01814332|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
215099091|NCT05127239|BEHAVIORAL|Smartphone Application with lifestyle modification Intervention|The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
215099092|NCT06543888|BEHAVIORAL|passive exoskeleton- assisted gait training programs|Participants will wear an exoskeleton during the training. Each 30-minute Passive exoskeleton-assisted gait training session include range of motion exercise, movement facilitation, strengthening exercise, coordination exercise, and task-oriented training for activities of daily living
215099093|NCT06543888|BEHAVIORAL|Conventional gait training|Each 30-minute conventional gait training session include range of motion exercise, movement facilitation, strengthening exercise, coordination exercise, and task-oriented training for activities of daily living.
215099094|NCT00226824|DRUG|galantamine|
215099095|NCT03840707|BEHAVIORAL|LIFEwithIBD|"LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease"
215099096|NCT00475748|PROCEDURE|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
215099097|NCT00752193|OTHER|Probiotic lactobacilli|Probiotic lactobacilli in combination with antibiotic therapy
215099098|NCT00752193|OTHER|Placebo|Placebo in combination with antibiotic therapy
215011994|NCT01814332|DRUG|Placebo|Placebo compound treatment for comparison with IP
214407381|NCT05074498|DRUG|TB006|intravenous infusion
214407382|NCT05074498|DRUG|Placebo|intravenous infusion
215011995|NCT05551897|DRUG|Camizestrant|Subjects will be administered a single oral dose of Camizestrant on Day 1 of treatment period 1 and treatment period 3.
215011996|NCT05551897|DRUG|Itraconazole|Subjects will be administered Itraconazole twice a day on Day 1 and once daily on Day 2 and Day 3 of treatment period 2, and once daily on Day 1, 2 and 3 of treatment period 3.
215011997|NCT02246985|DIETARY_SUPPLEMENT|Control|The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.
214407383|NCT04944693|OTHER|Different ATS values.|"Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts."
214407384|NCT03610477|DIETARY_SUPPLEMENT|Medium chain triglycerides|Gel capsules, each containing 1 gram
214407385|NCT03610477|DIETARY_SUPPLEMENT|Long chain triglycerides|Gel capsules, each containing 1 gram
214407386|NCT00161447|DRUG|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
214407387|NCT00161447|DRUG|Testosterone Gel|Testosterone Gel (10 g daily
214407388|NCT00161447|DRUG|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 \& month 3
215011998|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.
215011999|NCT02246985|DIETARY_SUPPLEMENT|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
215012000|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread with plain mayonnaise|A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
215012001|NCT05891327|DIETARY_SUPPLEMENT|Maca|2.25 g Lepidium meyenii (Maca) extract twice per day for 12 weeks
215012002|NCT05891327|DIETARY_SUPPLEMENT|Placebo|Placebo
215099099|NCT01965730|DRUG|epsilon-aminocaproic acid (EACA)|
215099100|NCT00575965|DRUG|Simvastatin|Oral tablets taken daily
214407389|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
214407390|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
214407391|NCT00287573|DEVICE|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
215012003|NCT00693459|DEVICE|Circular Anal Dilator for Transanal Hemorrhoidectomy|The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
215012004|NCT04048083|BEHAVIORAL|Mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.
215012005|NCT04048083|BEHAVIORAL|Computer-aided trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.
215012006|NCT04048083|BEHAVIORAL|Computer-aided and mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).
215099101|NCT04294030|DEVICE|Diagnostic Test: NOWDx HSV-2 Test|For this observational trial, the intervention of interest is the NOWDx HSV-2 Test.
215099102|NCT00183326|BEHAVIORAL|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
214407392|NCT00287573|PROCEDURE|Brachytherapy (beta source)|Brachytherapy (beta source)
214407393|NCT06306846|RADIATION|SBRT+immunochemotherpy|SBRT radiotherapy，followed with PD-1 monoclonal antibody and TP chemotherapy
214407394|NCT06306846|DRUG|Immunochemotherapy|PD-1 monoclonal antibody and TP chemotheapy
215099103|NCT00183326|BEHAVIORAL|Child-centered supportive therapy (CCT)|CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
214407395|NCT06306846|DRUG|cetuximab+immunochemotharpy|PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab
214407396|NCT04599114|BEHAVIORAL|VIRTUES|VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
214407397|NCT00027612|DRUG|carmustine|IV
214407398|NCT00027612|DRUG|irinotecan hydrochloride|IV
214407399|NCT00027612|RADIATION|radiation therapy|
214407400|NCT02098902|BEHAVIORAL|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
214407401|NCT04859777|DRUG|MPT-0118|MPT-0118 is an inhibitor of MALT1 protease
214407402|NCT04859777|DRUG|MPT-0118 + pembrolizumab|MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
214407403|NCT06277622|DEVICE|PFUN|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
214407404|NCT06277622|DEVICE|PFNA|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
214407405|NCT03273530|OTHER|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
214407406|NCT02967016|BEHAVIORAL|Actigraph|following delivery a ActiGraph will be offered to patients to track their steps
214407407|NCT06145256|DEVICE|MRI brain, MSCT brain, Transcranial Ultrasound|MRI, MSCT and transcranial Ultrasound are an important diagnostic modalities in the assessment of severity and outcome of HIE
215012007|NCT04048083|OTHER|No trainings|Healthy controls without any kind of training
215099104|NCT04086914|PROCEDURE|Nerve Block|This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
214407408|NCT03423394|BEHAVIORAL|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment. The first MET session intervention will involve a counselor using motivational interviewing (MI) strategies to establish an empathic therapeutic relationship and focus learning about the PTSD symptoms the participant is experiencing and exploring ambivalence about seeking treatment services. MET sessions 2 and 3 will focus on identifying and responding to risk factors for dropping out of treatment (increases in ambivalence, avoidance behavior, concerns about stigma, life chaos), identifying and responding to barriers to participant's active engagement in treatment, and facilitating enrollment in alternate therapeutic resources if necessary.
215012008|NCT00332098|BEHAVIORAL|Family-Focused Treatment Plus Pharmacotherapy|Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
215012009|NCT00332098|BEHAVIORAL|Enhanced Care Plus Pharmacotherapy|Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
215012010|NCT01035307|GENETIC|gene expression analysis|
215012011|NCT01035307|GENETIC|microarray analysis|
215012012|NCT01035307|GENETIC|proteomic profiling|
215012013|NCT01035307|OTHER|laboratory biomarker analysis|
215012014|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 5*10^10 vp|Participants will receive Ad26.ZIKV.001 at a dose of 5\*10\^10 vp via IM route.
215012015|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at a dose of 1\*10\^11 vp via IM route.
215012016|NCT03356561|BIOLOGICAL|Placebo|Participants will receive placebo via IM route.
214407409|NCT03423394|BEHAVIORAL|Treatment as Usual|TAU will include a written referral list comprised of PTSD resources including information on in-person treatments, self-help, web-based and bibliotherapy options. At the completion of the study, participants in the TAU condition will be offered the MET intervention.
214407410|NCT02764307|DEVICE|Constant jet nebulizer|A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
214407411|NCT02764307|DEVICE|Breath enhanced nebulizer|A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
214407412|NCT02764307|DEVICE|Manual-actuated nebulizer|A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
214407413|NCT02764307|DEVICE|Breath-actuated nebulizer|A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
214407414|NCT06411145|DRUG|OXERVATE® 0.002%|Cenegermin-bkbj (20 mcg/mL) is an ophthalmic solution contained in a multiple-dose vial. The topical drops are administered 6 times/day for a 8-week course.
214407415|NCT04746859|OTHER|Prevention Visit|Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.
214504765|NCT04535414|DEVICE|Olympus Graphics Interchange Format (GIF) 190 endoscope|Participants will undergo white light endoscopy. The mucosa of the stomach may be thoroughly washed before examination, as medically indicated, and inspection will include repeated inflation and deflation to check distensibility and any abnormal appearing areas will additionally be biopsied. Nontargeted biopsies will be obtained as indicated per the assigned Arm.
214504766|NCT04535414|PROCEDURE|Gastric mucosal biopsy|As clinically indicated.
215012017|NCT01283425|DEVICE|InsuPatch|Heaters for single use and a permanent control unit.
215012018|NCT04376632|DIETARY_SUPPLEMENT|Pecan ADD|Raw pecan halves without dietary substitution instructions
215012019|NCT04376632|DIETARY_SUPPLEMENT|Pecan SUB|Raw pecan halves with instructions to substitute pecans with isocaloric foods in the habitual diet
215012020|NCT01367756|DRUG|RO4995819|multiple oral doses, Days 10-16
215012021|NCT01367756|DRUG|citalopram|multiple oral doses, Days 1-16
215012022|NCT01367756|DRUG|placebo|multiple oral doses, Days 10-16
215012023|NCT05690191|DRUG|Chidamide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
215099105|NCT02618161|RADIATION|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
215099106|NCT02618161|RADIATION|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
215099107|NCT02771717|DRUG|Budesonide (Pulmicort)|Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily
215099108|NCT02771717|DRUG|Placebo - dummy inhaler|Placebo - dummy inhaler to be taken 1 puff twice daily.
215012024|NCT05690191|DRUG|Lenalidomide|Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
215012025|NCT05690191|DRUG|Rituximab|Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
215012026|NCT06107673|DRUG|Dalpiciclib|Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.
215012027|NCT06107673|DRUG|Aromatase inhibitor|AI: Take according to the instructions provided.
215012028|NCT06107673|DRUG|Docetaxel injection|Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
215099109|NCT00932906|OTHER|Different self-training methods|Self training with MiniAnne Training Kit
215099110|NCT00932906|OTHER|Standard training|Instructor-based training meeting ERC directions
214407416|NCT04746859|BEHAVIORAL|Peer health coaching|Patients will be invited to register with the software platform used to facilitate peer health coaching. Once they have registered, they will be matched to a peer health coach who will connect with the patient to initiate the process. The coach will work collaboratively with the patient to help her follow through on a step-wise, personalized plan to achieve health goals that were developed with their prevention practitioner. The coach's approach will be informed by principles of brief action planning and motivational interviewing. Coaches will also provide social support, help to navigate to relevant information and community resources, and advise about options for self-monitoring. Coaching will occur over 12-16 sessions via phone calls, text messages, video calls and/or in-person meetings as desired/convenient and in accordance with local public health guidelines.
214407417|NCT04550650|OTHER|Training groupe|Using virtual training
214407418|NCT04550650|OTHER|PNF|PNF technique was used
214407419|NCT04550650|OTHER|Spinning grp|They only worked with spinning bikes.
214407420|NCT04550650|OTHER|Balance|Balance development was done
214407421|NCT01211665|DRUG|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
214407422|NCT01211665|DRUG|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
215099111|NCT04407741|DRUG|SHR2554+SHR1701|SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
214407423|NCT01551836|DRUG|Paracetamol formulation 1|formulation 1
214407424|NCT01551836|DRUG|Paracetamol formulation 2|Formulation 2
214407425|NCT01576315|DRUG|Itraconazole/voriconazole|The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.
214407426|NCT04675411|DEVICE|Smart care|Home based nursing intervention with smart assisted technology
214407427|NCT04675411|DEVICE|usual care|Routine hospital care with only in-hospital rehabilitation
214407428|NCT05232136|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
214407429|NCT01496196|DRUG|tranexamic acid|500 mg/5 ml 3-4 times a day
214407430|NCT01496196|DRUG|tranexamic acid|500 mg/5 ml 3-4 times a day
214407431|NCT03076801|BEHAVIORAL|Choral Singing|In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
214407432|NCT01459315|DRUG|dolutegravir|Subjects will take a GSK1349572 (dolutegravir) 50mg tablet by mouth once daily for 8 days. GSK1349572 concentrations will be measured in blood plasma, seminal fluid, rectal fluid, and rectal tissue over 24 hours after a single dose and over two 24 hour periods once steady state is reached. Blood plasma will be collected pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours after dosing. Each subject will also provide a total of 9 seminal and rectal fluid samples and have 2 rectal tissue biopsies performed pre-dose or at 1, 3, 6, 12, 18, or 24 hours after receiving single or multiple doses.
214407433|NCT02685293|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
214407434|NCT02685293|DRUG|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
214407435|NCT04093128|OTHER|herbal tea intervention|herbal tea intervention for 7 weeks
214407436|NCT00498186|DRUG|Rotigotine|"Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)"
215099112|NCT04407741|DRUG|SHR1701|SHR1701: 30mg/kg, IV, over 30 minutes
215099113|NCT04149561|OTHER|communication skill measurement with self report questionnaire|Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
214407437|NCT05406492|OTHER|Residual blood|Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
214693920|NCT03585699|DIAGNOSTIC_TEST|CT guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
214693921|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
215099114|NCT03268941|DRUG|TAK-906 Maleate|TAK-906 Maleate Capsules
215099115|NCT03268941|DRUG|Metaclopramide|Metaclopramide Tablets
215099116|NCT03268941|DRUG|TAK-906 Maleate Placebo|TAK-906 placebo-matching Capsules
215099117|NCT05639192|BIOLOGICAL|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
215099118|NCT05639192|OTHER|Placebo|Placebo will be administered once per week as an i.v. infusion
215099119|NCT04062591|DRUG|Piroxicam group|patients will receive 0.4 mg/kg piroxicam IM
215099120|NCT04062591|DRUG|Placebo|saline IM in the same dose of piroxicam
215099121|NCT01324791|PROCEDURE|anti-reflux surgery|
214407438|NCT05846711|DIAGNOSTIC_TEST|BPPV diagnostic|Supine Roll Test and Dix-Hallpike Test
214693922|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
214693923|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
215099122|NCT03749772|BEHAVIORAL|Cognitive Training|The intervention was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). Participants held the training sessions on an HP 250 G3 Notebook PC (Windows 10), with a 15-inch screen, and a resolution of 1366x768x40 Hz. The performance achieved by each participant in each session was recorded to analyze the evolution of the subjects. The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
215099123|NCT04327947|OTHER|Hyaluronic acid - Research product 1|Health care product (intimate gel)
215099124|NCT04327947|OTHER|Hyaluronic acid - Research product 2|Health care product (intimate gel)
215012029|NCT06107673|DRUG|Epirubicin Hydrochloride Injection|Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
214407439|NCT05846711|DEVICE|TRV chair|Mechanical rotational chair
215012030|NCT06107673|DRUG|Cyclophosphamide injection|Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
215099125|NCT04327947|OTHER|Hyaluronic acid - Comparator product|Health care product (intimate gel)
215099126|NCT01216683|BIOLOGICAL|rituximab|Given IV
215099127|NCT01216683|DRUG|Bendamustin|Given IV
215099128|NCT01216683|DRUG|bortezomib|Given IV
215099129|NCT01216683|DRUG|lenalidomide|Given orally
215099130|NCT04295239|PROCEDURE|MRI|Pre and Post operative MRI
214407440|NCT05846711|DEVICE|VNG goggles|Goggles for video nystagmography
214407441|NCT05846711|DEVICE|IMU sensor|A sensor that measures triaxial acceleration and triaxial angular velocity.
214407442|NCT05846711|PROCEDURE|Manual BPPV diagnostics|Bedside BPPV diagnostics
214407443|NCT05039736|DRUG|Cabozantinib|Given by PO
214407444|NCT05039736|DRUG|Nivolumab|Given by IV
214407445|NCT00672152|BIOLOGICAL|WT1 derived peptides|"WT1 derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg GM-CSF in a total volume of 2ml:~* WT peptide #1: HLA-A2 restricted: RMFPNAPYL~* WT peptide #2: HLA-A24 restricted: CMTWNQMNL~* WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~* WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
214407446|NCT01390857|DRUG|Valaciclovir|
214407447|NCT05247216|DRUG|Hemay007 800 mg QD group|daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
215099131|NCT00223483|GENETIC|Isolation of genomic DNA|One time blood draw
215099132|NCT03244163|DEVICE|Spyglass DS cholangioscope|The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening
214407448|NCT05247216|DRUG|Hemay007 1200 mg QD group|daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
214407449|NCT05247216|DRUG|Hemay007 600 mg QD group|daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
214407450|NCT05247216|DRUG|Hemay007 placebo group|daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
214407451|NCT04029740|BEHAVIORAL|CBT- both internet and face to face|There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert \& Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.
214407452|NCT04029740|OTHER|No intervention|Healthy controls will not receive any intervention.
214504767|NCT05182177|DEVICE|SurgiMend PRS|SurgiMend® PRS and SurgiMend® PRS Meshed are intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend® PRS and SurgiMend® PRS Meshed are specifically indicated for plastic and reconstructive surgery, including breast reconstruction.
214407453|NCT03712293|DEVICE|BBB Disruption with Chemotherapy Arm|The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.
214504768|NCT06914297|DRUG|TQB2450 injection + oral progestin|TQB2450 (1200 mg q3w ivgtt) + megestrol acetate (MA, 160 mg qd po)/megestrol acetate (MPA, 500 mg qd po)
214504769|NCT02053662|PROCEDURE|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
214504770|NCT03504241|BIOLOGICAL|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
214504771|NCT03504241|DRUG|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
214693924|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
215012031|NCT00947388|DRUG|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
215012032|NCT00947388|BIOLOGICAL|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
215012033|NCT02959892|DRUG|Amphetamine|Amphetamine tablets.
215012034|NCT02959892|DRUG|TAK -041|TAK-041 oral suspension.
215012035|NCT02959892|DRUG|[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)|\[11C\]PHNO injection.
215012036|NCT05507229|BIOLOGICAL|Hillchol vaccine|HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
215099133|NCT03244163|DEVICE|BML|Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
215099134|NCT03774030|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of 3 hearing aid algorithms in a virtual 3-D complex audio Environment.
215099135|NCT01413139|DEVICE|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
215099136|NCT00191230|DRUG|gemcitabine|
215099137|NCT00191230|DRUG|carboplatin|
214407454|NCT05928182|BEHAVIORAL|El Faro Treatment Intervention|"Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. \[All rating scales are parent-report unless noted otherwise\]~Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks.~Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. \[All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise\]."
214407455|NCT05165914|DRUG|Intravenous midazolam before emergence from general anesthesia|Intravenous administration of 0.03 mg/kg midazolam just before emergence from anesthesia.
214407456|NCT05165914|DRUG|Intravenous normal saline before emergence from general anesthesia|Intravenous administration of normal saline just before emergence from anesthesia.
215012037|NCT05507229|BIOLOGICAL|Shanchol Vaccine|Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
215012038|NCT00006135|DRUG|acyclovir|
215099138|NCT00191230|DRUG|cisplatin|
214407457|NCT05091164|PROCEDURE|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis.
214407458|NCT06184789|DIAGNOSTIC_TEST|Echocardiographic assessment|Echocardiographic and hemodynamics assessment of Mitraclip results
214407459|NCT04551417|PROCEDURE|Free graft urethroplasty|Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
214407460|NCT03797235|PROCEDURE|Dominant Arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
214504772|NCT03504241|DRUG|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
214504773|NCT03504241|DRUG|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
214504774|NCT03504241|DRUG|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
214504775|NCT03504241|DRUG|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
214504776|NCT03504241|DRUG|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
215012039|NCT06009354|OTHER|Rehabilitation|The control group will receive post-operative usual practices. The study group will receive multi-component education in addition to the usual practices.
215099139|NCT01237613|DEVICE|Artelon|Artelon Tissue Reinforcement
215099140|NCT03563196|RADIATION|Chest Radiograph|Chest radiogram will be obtained on day 1
215099141|NCT03563196|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be done on day 1
214504777|NCT03662659|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
215099142|NCT01526395|DRUG|Propofol|"The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week."
215099143|NCT00837343|DRUG|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
215099144|NCT00214916|DRUG|intensive insulin therapy (Actrapid IV to normoglycemia)|intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
215099145|NCT00214916|DRUG|conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)|conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
215099146|NCT03123016|DRUG|Apremilast|Apremilast 30 mg orally, twice daily. (oral tablet)
215099147|NCT03123016|PROCEDURE|NB-UVB phototherapy|treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
214407461|NCT03797235|PROCEDURE|Non-dominant arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
214407462|NCT06631365|DEVICE|PrEPsmart mobile app|"The PrEPsmart mobile app is an innovative and comprehensive app to support sexual minority men (SMM) using on-demand pre-exposure prophylaxis (PrEP) or daily PrEP. The PrEPsmart app consists of the following components:~1. PrEP 211 dosing/sex diary and reminders~2. Feedback on PrEP protection levels~3. Quick tips~4. Bi-directional secure messaging"
214407463|NCT06631365|DRUG|Truvada|Combination medication used in Human immunodeficiency virus (HIV) prevention, it blocks virus pathways to infection.
214407464|NCT06429410|DIETARY_SUPPLEMENT|fortified formula milk powder|Fortified formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, β-hydroxy-β-methylbutyrate, and sodium hyaluronate per day orally for 24 weeks.
214504778|NCT03662659|BIOLOGICAL|Nivolumab|Specified dose on specified days
214504779|NCT03662659|DRUG|XELOX|Oxaliplatin + capecitabine
214504780|NCT03662659|DRUG|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
215012040|NCT06025058|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
215012041|NCT03099863|DRUG|Cystoscopic Fluid containing Neosporin G. U. Irrigant|Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
215012042|NCT03099863|PROCEDURE|Cystoscopy|Diagnostic cystoscopy performed during pelvic floor surgery
214688367|NCT07163104|BEHAVIORAL|Cognitive behavioral intervention|The researcher will suggest various distraction techniques (counting, singing, reading poetry, answering questions, etc.) to shift the child's focus during the procedure. The distraction technique chosen by the child will be used during the procedure. This method will be chosen during the preparation and briefing phases of the procedure. Cognitive behavioral intervention application will begin before subcutaneous application and will last 15-20 minutes, after which subcutaneous application will begin. After subcutaneous administration, children will rate their pain levels during and after the procedure with the Wong Baker Scale, their anxiety levels with the Children's State Anxiety Scale (CSA), and their fear levels with the Children's Fear Scale (CFS). A parent present with the child will observe the child's behavioral state during the procedure and will rate the child's fear level during and after the procedure with the CFS and their anxiety level with the CSA.
214688368|NCT07162376|BEHAVIORAL|Personal Information Disclosure|Each profile also contains non-health related personal information that the patient has disclosed (e.g., nickname, hobbies).
215012043|NCT03099863|DRUG|Cystoscopic Fluid/Placebo|Normal saline cystoscopic fluid
215012044|NCT05424809|BEHAVIORAL|Shared decision-making model|"The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation"
215099148|NCT04712708|DEVICE|Rebound Therapy|Rebound therapy is the therapeutic use of full sized trampoline or mini sized trampoline. It provides opportunities for exercise recreation and therapy; and it is distinct from gymnastic trampolining. It is used for facilitating movements, improving balance, enhancing coordination and promoting motor performances in children with different disorders includes learning disabilities, communication disorders and motor dysfunction (Rebound Therapy South Africa, 2020; The Chartered society of Physiotherapists, 2016).
214504781|NCT03662659|DRUG|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
214504782|NCT06922643|DRUG|Peginterferon Alfa-2A|180 mcg, subcutaneous injection, once weekly
214504783|NCT06922643|DRUG|Ribavirin Oral Product|15 mg/kg daily, oral (1200 mg/day for body weight \>80 kg)
214504784|NCT03695952|DRUG|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
214688369|NCT07162714|RADIATION|radiotherapy|The patients receive pelvic radiotherapy: Intensity-Modulated Radiation Therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT), with a total dose of 25 Gy delivered in 5 fractions. Radiotherapy is to start on day 1 and to finish on day 5.
215012045|NCT02659228|DEVICE|EEG recording|EEG recording with anesthetic (DIPRIVAN)
215012046|NCT02659228|DRUG|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
215099149|NCT04712708|OTHER|Physical Therapy Program|"The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:"
215099150|NCT03157284|DIETARY_SUPPLEMENT|Rice Flour|For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.
215099151|NCT03157284|DIETARY_SUPPLEMENT|Placebo|For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.
215099152|NCT02041338|DRUG|Paclitaxel and carboplatin|
215099153|NCT02041338|DRUG|Paclitaxel|
215099154|NCT02041338|DRUG|Epirubicin and Paclitaxel|
214407465|NCT06429410|DIETARY_SUPPLEMENT|formula milk powder|Formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, and sodium hyaluronate per day orally for 24 weeks.
214407466|NCT06429410|DIETARY_SUPPLEMENT|regular milk powder|Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
214407467|NCT01954043|DRUG|Dabrafenib 150 mg twice a day (BID)|Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
214407468|NCT01954043|DRUG|Rabeprazole 40 mg once daily (OD)|Rabeprazole dosed at 40mg each morning on Days 16 to 19
214407469|NCT01954043|DRUG|Rifampin 600 mg OD|Rifampin dosed at 600mg each morning on Days 20 to 29
214407470|NCT04442659|DIAGNOSTIC_TEST|pre hospital triage tool|EMS workers fill in an application containing 10-13 vclinical items
214504785|NCT06247774|BEHAVIORAL|Cardiac Rehabilitation|Participation in a 12-week cardiac rehabilitation program
214407471|NCT02741479|OTHER|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
215012047|NCT05100966|OTHER|FitJoints Multi-modal Intervention|"Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization."
215012048|NCT06422858|DRUG|Serplulimab|Serplulimab will be administered as a fixed dose of 300 mg via intravenous infusion every three weeks, continuing for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
215012049|NCT06422858|DRUG|Tegafur-gimeracil-oteracil potassium capsule(S1)|S1 will be administered at a dose of 60 mg/m2 per day, taken orally in two divided doses on day 1 concurrent with radiotherapy, repeated every 28 days; and from day 1 to day 14 of each 21-day cycle, for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
215012050|NCT06422858|RADIATION|Radiotherapy|Radiotherapy will be delivered as a total dose of 50.4 Gy in 28 fractions over six weeks using techniques such as IGRT, IMRT, VMAT, or TOMO, targeting the primary tumor and associated lymph nodes
215012051|NCT06422858|DRUG|Cisplatin|Cisplatin will be administered at a dose of 75 mg/m\^2 on day 1 concurrent with radiotherapy, repeated every 28 days
215012052|NCT03536377|OTHER|very low calorie liquid diet|Phase 1: very low calorie liquid formulation Phase 2: Nutritionally balanced solid diet Phase 3: Educational material
215012053|NCT00910741|DRUG|Nanoplatin (NC-6004) and Gemcitabine|
215012054|NCT02200575|DRUG|Telmisartan|
215012055|NCT02346370|DRUG|PEGylated recombinant human hyaluronidase PH20|
215012056|NCT02346370|DRUG|Docetaxel|
215012057|NCT06009497|DRUG|Romiplostim|Romiplostim 10 µg/kg, subcutaneous injection, once a week.
215012058|NCT06009497|DRUG|Ciclosporin|Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml.
215012059|NCT03024164|OTHER|Treatment following current guidelines|Treatment following current guidelines
215012060|NCT05931601|DRUG|Noradrenaline|See arm description
215012061|NCT06179680|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|"MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition."
215012062|NCT06960616|OTHER|Changes in traditional follow-up|Traditional follow-up includes the following visits after activation: 1-week, 1-month, 3-months, 6-months and 1 year. With the intervention used, the 1-week follow-up is removed.
215012063|NCT06960616|OTHER|Population mean mapping|Traditional mapping at activation involves the measurement of at least 5 electrodes (both T-levels and C-levels). The intervention uses a population mean mapping strategy where there is a pre-set dynamic range of 46 CL with a spot check of C-levels.
214407472|NCT01079455|DRUG|Corticosterone|Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
215012064|NCT05098236|OTHER|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
215012065|NCT05098236|OTHER|Training in the Sighted Field|This training will take place in lab at the University of Rochester Medical Center. Subject will perform one daily training session, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the visual field. The computer program will automatically create a record of patient performance during each training session. Subjects will train daily (about 30-40 minutes total), 5 to 7 days per week for at 7 - 14 days.
215099155|NCT06457867|PROCEDURE|microfragmented adipose tissue loaded on bovine graft|microfragmented adipose tissue loaded on bovine graft on ridge preservation
215099156|NCT02503501|DRUG|Insulin glulisine|
215099157|NCT02503501|DRUG|Placebo|Bacteriostatic 0.9% Sodium Chloride
215099158|NCT01740401|DRUG|Cyclophosphamide|This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
214504786|NCT06247774|BEHAVIORAL|Attention Control|Participants will receive regular phone calls in place of cardiac rehabilitation visits
214407473|NCT05414565|DEVICE|Vivity IOL|Commercially available extended vision IOL
214407474|NCT05414565|DEVICE|Aspheric monofocal IOL|Commercially available aspheric IOL
214407475|NCT05518513|DRUG|Bupivacain|adductor canal block with 0.25% bupivacaine
214407476|NCT02708459|DEVICE|surgically inserted Transversus abdominus plane catheter|at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
214407477|NCT02708459|DRUG|Intravenous morphine|Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
214407478|NCT02708459|DRUG|Bupevecaine|
214407479|NCT02708459|DRUG|Dexmedetomedine|
214407480|NCT04541186|DRUG|Pegozafermin|Subcutaneous injection
215012066|NCT05561933|BEHAVIORAL|Healthy Minds Program Foundations Training|"The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose."
214407481|NCT04541186|DRUG|Placebo|Matching placebo
214407482|NCT06445231|DIAGNOSTIC_TEST|Implementation of echocardiography in nursing homes|An ultrasound will be carried out in the EHPAD, the result of which will be interpreted by a cardiologist then sent to the establishment and the attending physician with instructions to follow.
214504787|NCT05246930|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
215012067|NCT03528577|DRUG|Zero-dose|Treatment A
214504788|NCT05214989|BEHAVIORAL|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
214504789|NCT06762600|DRUG|HRS-4729 injection|HRS-4729 injection
214504790|NCT06762600|DRUG|HRS-4729 injection placebo|HRS-4729 injection placebo
215012068|NCT03528577|DRUG|90 mcg of PROAIR® HFA|Treatment B
215012069|NCT03528577|DRUG|180 mcg of 90 mcg of PROAIR® HFA|Treatment C
215012070|NCT03528577|DRUG|90 mcg of albuterol sulfate inhalation aerosol|Treatment D
215012071|NCT06236997|DRUG|Adebrelimab|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
215012072|NCT06236997|RADIATION|Radiation Therapy|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
215012073|NCT06236997|DRUG|etoposide, carboplatin(EC)|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
215012074|NCT02407977|OTHER|Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter ( nanoFOD) for real time dosimetric monitoring of external beam radiotherapy.
215012075|NCT04882215|BEHAVIORAL|GMT combined with WMU Training|"GMT teaches the use of mental strategies to support sustained attention during complex (multi-step) task performance following an interactive programme. GMT is structured into nine modules, with interactive discussions and homework assignments. It will be conducted on a group basis.~WMU training consists of computerised working memory updating tasks in which trial accuracy and response time are recorded. Two tasks will be trained: 1. a visuo-spatial Matrix Updating (MU) and 2. a verbal Keep Track (KT). For both training tasks, level of difficulty can be modulated by increasing or decreasing the update level, i.e., the number of updates on each trial."
215012076|NCT02192697|DRUG|ASP8273|Oral administration
215012077|NCT01931631|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
215012078|NCT01931631|BEHAVIORAL|ADA diet|Diet in accordance with the American Diabetes Association
215012079|NCT03110432|DRUG|PCSK9 Inhibitor [EPC]|drug use according to the respective product labelling
215012080|NCT03110432|DRUG|Standard lipid lowering therapy|drug use according to the respective product labelling
215012081|NCT04098302|DRUG|Dutasteride Capsules|1 mg/day oral dutasteride (2 x 0.5 mg capsules)
215012082|NCT04098302|DRUG|Placebo Capsules|Placebo capsules with matching appearance as Dutasteride Capsules
214407483|NCT00094250|BEHAVIORAL|Resistance and Aerobic Training|
214407484|NCT04370236|DRUG|INB03|Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
214407485|NCT04370236|DRUG|Placebo|Patients will receive up to two once per week subcutaneous injections of Placebo
214407486|NCT04543344|DRUG|Recifercept|recifercept powder for solution for injection
214407487|NCT04543344|OTHER|Placebo|solution for injection
214504791|NCT06762600|DRUG|HRS9531 injection|HRS9531 injection
214504792|NCT06762600|DRUG|HRS9531 injection placebo|HRS9531 injection placebo
214504793|NCT06762600|DRUG|Acetaminophen|Acetaminophen
214504794|NCT03426059|OTHER|No Intervention|No Intervention. This is an observational study.
214504795|NCT06354387|DRUG|Alectinib (Alecensa), Nivolumab (Opdivo)|Alectinib (Alecensa) in Combination with Nivolumab (Opdivo)
214504796|NCT06932874|DRUG|Glucophage (Metformin Hydrochloride Tablets)|Metformin hydrochloride tablets combined with other oral hypoglycemic drugs for 24 weeks treatment.
214407488|NCT02224833|BEHAVIORAL|Pharmacist intervention|"Systematic review of treatments:~Identification of reasons for PPI.~* Determination of recommended pharmacotherapeutic alternatives.~* Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP."
214407489|NCT00691028|DRUG|TA-650 3 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
214407490|NCT00691028|DRUG|TA-650 6 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
214407491|NCT00691028|DRUG|TA-650 10 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
214407492|NCT02349113|DRUG|Estrogens (Climara)|Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
215012083|NCT05123417|DIAGNOSTIC_TEST|Follow up|Each group participants will be tested with questionnaire before the training and two weeks after the training they will get post test with the same questionnaire.
214407493|NCT03085017|DEVICE|BoneSeal|BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
214407494|NCT03085017|DEVICE|Ostene|OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
214407495|NCT00058058|PROCEDURE|MRI|Breast contralateral to the breast diagnosed with cancer was scanned prior to initiation of chemotherapy and within 90 days of a negative mammogram of the study breast. A recent (within 90 days) negative or benign mammogram (defined by final BI RADS category 1 or 2) and negative or benign clinical breast exam of the study breast were required for entry into the study.
214407496|NCT01528124|DRUG|LY3025876|Given as a subcutaneous injection
215012084|NCT03067415|DRUG|D565H(Latanoprost 25㎍/㎖)|D565H twice daily
215012085|NCT03067415|DRUG|D565(Latanoprost 50㎍/㎖)|D565 once daily
215099159|NCT06090084|OTHER|Evaluation|Functional capacity, balance, core muscle strength, trunk muscle structure, lower extremity muscle strength, upper extremity functions, fatigue and respiratory muscle strength will be evaluated.
215099160|NCT02806960|DRUG|Nasal Glucagon|Administered intranasally.
215099161|NCT05729243|DRUG|Cytisine|Cytisine is a nicotinic acetylcholine receptor partial agonist and is a natural health product approved by Health Canada. Cytisine has been used for a long time in Europe for smoking cessation.
215099162|NCT05729243|OTHER|Placebo|A placebo identical in appearance to cytisine will be used
215099163|NCT00039858|DRUG|Argatroban|
214407497|NCT01528124|DRUG|Placebo|Given as a subcutaneous injection
214407498|NCT06300840|DEVICE|BalanceBelt|The vibrotactile belt (i.e., Elitac BalanceBelt®) supports patients with severe balance disorders by substituting the missing balance information with vibrations (haptic feedback).
214407499|NCT00743405|DRUG|GSK1034702|Oral or liquid
214407500|NCT00743405|DRUG|Placebo|To match GSK1034702
214407501|NCT00233129|BEHAVIORAL|Top Down|Six months
214407502|NCT00233129|OTHER|cognitive rehabilitation day treatment program|six months
214407503|NCT06141746|DEVICE|Lung ultrasound|Early detection of fluid accumulation in alveolar, interstitial and intracellular compartments of the lung due to intravascular absorption of irrigation fluid of PNL guided by lung ultrasound by detection of sonographic B lines.
214407504|NCT05939726|OTHER|Moisturising cream with vitamin E concentrate|The vitamin E moisturising cream contains 3% w/w of palm-oil-derived vitamin E concentrate, consisting of the following isomers: alpha-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. This formula provides a total of 1.2g tocotrienols per 100g product.
214407505|NCT05939726|OTHER|Moisturising cream without vitamin E concentrate|This moisturising cream is a similar moisturising cream but without the addition of the vitamin E concentrate
215099164|NCT00742716|DRUG|CTA018 Injection|Comparison of different dosages of drug
215099165|NCT03444935|BEHAVIORAL|Follow-up phone call|Please see arm/group description.
214407506|NCT05939726|OTHER|Urea cream|Urea cream (10%w/w) is used as the standard of care for PPE.
214407507|NCT06492356|DEVICE|Tripolar radiofrequency therapy|Twenty patients underwent weekly TriPollar RF treatment, using a new RF technology with three or more electrodes. Glycerin was applied to the treatment area before and after each session, with the procedure lasting 15 minutes. The technology uses a sequence of electrical modulation to prevent overheating and requires no active cooling of the electrodes or skin.
214407508|NCT06492356|DRUG|medical treatment|Twenty patients will receive medical treatment by dermatologist.
214407509|NCT04378582|OTHER|risk factors|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
215012086|NCT06359561|DEVICE|cervical lead placement|implant of cervical lead neurostimulation, using saluda medical devices
215012087|NCT01584388|DRUG|Rituximab|Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
215012088|NCT04998110|OTHER|Ambulatory Supportive Care|Ambulatory supportive care visits monthly for six months - a monthly visit with an ambulatory palliative care provider educated in kidney disease
215012089|NCT01810952|DRUG|Glargine insulin|In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.
215099166|NCT03042260|DRUG|Trimethoprim-Sulfamethoxazole|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
214407510|NCT02874261|DEVICE|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
214407511|NCT06042114|BEHAVIORAL|Surah Inshirah|Patients in the experimental group will be listened to the Surah al-Inshirah after surgery and its effect on pain and anxiety levels will be evaluated.
214407512|NCT02375321|BEHAVIORAL|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
214407513|NCT00360126|DRUG|lamotrigine|
214407514|NCT01695343|BIOLOGICAL|KB001-A|
214407515|NCT01695343|DRUG|Placebo Comparator|
215012090|NCT01810952|DRUG|Lispro insulin|In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
215012091|NCT01810952|DRUG|NPH Insulin|NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
215012092|NCT01290731|DRUG|TMC435|100-mg capsule once daily for 12 weeks
215012093|NCT01290731|DRUG|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
215012094|NCT01290731|DRUG|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
215012095|NCT03390192|DEVICE|Dual-mode stimulation|1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.
215099167|NCT03042260|DRUG|Placebo Oral Tablet|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
215099168|NCT05082311|OTHER|Observational study|This is an observational study
214407516|NCT03049696|BEHAVIORAL|ENCOURAGEING START|16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
214407517|NCT02596906|DEVICE|tDCS|Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. A brief engaging film is shown to participants during the 20 minute session.
214407518|NCT02596906|DEVICE|Sham tDCS|For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group.
214407519|NCT03255018|BIOLOGICAL|Pembrolizumab|Administered intravenously (IV) at a fixed dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity; treatment may continue indefinitely if clinical benefit with options for treatment interruption if responding disease and re-treatment upon relapse.
215099169|NCT04358965|DRUG|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
215099170|NCT04358965|DRUG|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
215099171|NCT04358965|DRUG|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
215099172|NCT05665296|OTHER|cervicothoracic mobilization|Each participant in study group will receive cervicothoracic mobilization (central PA and transverse Grade III or grade IV) with comprehensive corrective exercise. The duration will eight weeks three sessions per week.
215012096|NCT03390192|DEVICE|Single sham stimulation|1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
215012097|NCT04027621|DEVICE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
215012098|NCT04027621|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
214407520|NCT04835584|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
214407521|NCT04835584|DRUG|Dasatinib|Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
214407522|NCT04835584|DRUG|Nilotinib|Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
214407523|NCT05693662|BEHAVIORAL|Session 1|"* Ensuring group interaction, allowing parents to meet each other,~* Providing information in line with the Awareness-Based Self-Compassion Training Booklet for Parents of Children with Autism Spectrum Disorder prepared as training material,"
214407524|NCT05693662|BEHAVIORAL|Session 2|"* Making explanations about the contents of the training sessions to be held with parents,~* Teaching proper breathing techniques,~* Visual demonstration and application of relaxation techniques"
214407525|NCT05693662|BEHAVIORAL|Session 3|"* Breathing break with kindness application,~* Thinking and evaluating how threat, impulse and soothing systems develop in individuals' own lives,~* Safe place application,~* Applying kindness meditation,"
215012099|NCT00285675|DRUG|DN-101 (calcitriol) - Drug|
215012100|NCT05821595|DRUG|JYB1907|for injection
215012101|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|TID
215012102|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|QID
215012103|NCT00560638|DRUG|vehicle of loteprednol etabonate|TID or BID according to the randomization
215012104|NCT03057301|DEVICE|iCare home tonometer|All subjects will be taught to use the home care tonometer.
215099173|NCT05665296|OTHER|CCE|"Each participant will receive comprehensive corrective exercise include three phases: Initial phase -Improvement phase and Maintenance phase.~The initial phase exercises progress in frequency and intensity during this phase, as long as participants are able to demonstrate good quality movement. The initial phase duration is 2 weeks and the exercises will be performed for seven sets of 10-s hold .~Improvement phase exercises are progressed by considering individual characteristics of each participant and by observing the overload principle and the progression in the number of repetitions of each set during the 4 weeks of the improvement phase. The exercises will be performed from five sets of ten repetitions to six sets of 15 repetitions .~Maintenance phase exercises:The exercises are the same as in the improvement phase without any progression in intensity and frequency. The maintenance phase duration is 2 weeks"
215099174|NCT03051386|BIOLOGICAL|VEE Vaccine|0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
214407526|NCT05693662|BEHAVIORAL|Session 4|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with resistance,~* Kindness meditation: a do-gooder application,~* A hand on the heart application,~* A compassionate companion application,"
214407527|NCT05693662|BEHAVIORAL|Session 5|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with desire,~* Guided meditation to discover the inner pattern practice,~* Kindness meditation: a good friend application,"
214407528|NCT05693662|BEHAVIORAL|Session 6|"* Pretending practice regarding parents' awareness,~* An expanded version of the practices carried out in previous sessions to raise awareness, the internalizing compassion practice,~* Kindness meditation: a neutral person, kindness towards your body and walking with kindness practices, which are based on mindfulness practices and increase body awareness and mindful movement,"
214407529|NCT05693662|BEHAVIORAL|Session 7|"* A compassionate letter application, which is carried out by asking parents to think about a situation they have encountered recently or some time ago that still causes distress,~* Kindness meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices,~* Researching how parents can cope with difficulties and implementing a compassionate breath break without words,"
215012105|NCT04619082|DRUG|Tenofovir alafenamide|Tenofovir alafenamide 25 mg once per day for one year
215012106|NCT05571592|DRUG|Cannabidiol|Oral Capsule Formulation of CBD dissolved in a self-emulsifying drug technology called nanodomains, encapsulated within 1-ml softgel capsules, with a CBD purity ≥98%. Imported from Ananda Scientific
215012107|NCT05571592|DRUG|Placebo|"Drug: Placebo~Placebo softgel capsule formulation."
215012108|NCT01399099|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
215099175|NCT06442670|DEVICE|Electroencephalography|Phase synchrony during the completion of the semantic memory task
215099176|NCT03495102|DRUG|Dulaglutide|Administered SC
215099177|NCT06455865|OTHER|TPACK-Based Blended Learning Instruction|The control group employed traditional in-person teaching methods, including face-to-face classroom instruction, reading from printed textbooks, and completing homework assignments. The curriculum covered the fundamental theories and skills related to information resource retrieval and usage but did not specifically utilize the TPACK framework. Students primarily received lectures and guidance from the instructor during class and completed assignments and learning tasks independently after class.
215099178|NCT01706588|DRUG|Diclofenac sodium|One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
215099179|NCT00317304|BEHAVIORAL|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
214407530|NCT05693662|BEHAVIORAL|Session 8|"* Revisiting the good application to enable parents to experience the five senses in a pleasant way,~* Practices of self-forgiveness, asking for forgiveness, forgiving others, gratitude, which can be a way of mending the cracks in parents' relationships with themselves and others,~* Expanding the practice into kindness meditation: groups and all beings,"
214688370|NCT07162714|DRUG|Ivonescimab (20mg/kg Q3W)|The first dose of vonescimab (AK112) was administered 1 week after the completion of radiotherapy. Ivonescimab (AK112) was initiated at a dose of 20 mg/kg via intravenous infusion on Day 1 of each 21-day cycle, for a total of 6 cycles.
214688371|NCT07162714|OTHER|Non-operative Management|Subjects who achieve cCR after radiation and 6 cycles treatment of Ivonescimab can, after discussion with the local investigator, decline surgery and opt for a non-operative management.
214688372|NCT07162714|PROCEDURE|Surgery|For patients who do not achieve cCR at the end of 6 cycles treatment of Ivonescimab, TME surgery is recommended.
215012109|NCT05396170|PROCEDURE|phlebotomy|500ml of blood phlebotomized per standard of care to reduce symptoms from polycythemia
215012110|NCT06140641|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium Longum BL21 or placebo for 8 weeks.
215012111|NCT05235607|BIOLOGICAL|Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration|subcutaneous administration
215012112|NCT05232526|OTHER|Mental imagery (MI) and exercise program|Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample
215012113|NCT05232526|DEVICE|Mental Imagery and Exercise program|Questionnaires and functional tests are going to be used to evaluate balance, functional status, cognitive ability, depression and quality of life of the sample.
215012114|NCT03248804|BEHAVIORAL|Soy group|
215012115|NCT03248804|BEHAVIORAL|Non-soy group|
215012116|NCT01668537|BIOLOGICAL|LF formulation of IMVAMUNE®|
215012117|NCT01668537|BIOLOGICAL|FD formulation of IMVAMUNE®|
215012118|NCT03848468|PROCEDURE|Hemorrhoidectomy|excision of 3rd and 4th degree hemorrhoids
215099180|NCT02482116|OTHER|malaria or pneumonia diagnosis|Diagnostic approaches for malaria (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, rapid diagnostic tests, Giemsa microscopy); Diagnostic approaches for pneumonia (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, chest x-ray)
214407531|NCT05693662|BEHAVIORAL|Session 9|"* The practice of allowing parents to choose a day in their lives for a few minutes to pause mindfully,~* A breather for wise and compassionate action practice,~* Calmness meditation application,~* Sharing the joy meditation application,"
215012119|NCT02083211|DRUG|mAb Nimotuzumab|This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
215012120|NCT02083211|DEVICE|Placebo|This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
215012121|NCT01828684|OTHER|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
215012122|NCT01828684|OTHER|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
215012123|NCT02580552|DRUG|Cobomarsen|
214407532|NCT05693662|BEHAVIORAL|Session 10|"* Evaluating the entire education by telling parents about the practices they can use where help is needed to develop compassion towards self-healing skills,~* River of Life application, which evaluates awareness in depth,~* Saying goodbye."
214407533|NCT03601143|OTHER|Blood samples prior to a new line of AR-targeted therapy|Blood will be drawn at baseline prior to a new line of AR-targeted therapy.
214407534|NCT01495507|PROCEDURE|MPFL- Reconstruction|
214407535|NCT02365896|PROCEDURE|TLDG or LADG|
214407536|NCT03504449|OTHER|neoadjuvant chemoradiotherapy|
214407537|NCT00790062|DRUG|Oxytocin|See arms
214407538|NCT00874796|DRUG|GS-9450|Taken as one capsule by mouth once daily
214407539|NCT00874796|DRUG|Placebo|Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
214407540|NCT01343173|DRUG|Imatinib stop|To stop imatinib after inclusion.
214407541|NCT00073970|DRUG|celecoxib|400mg, given twice daily
214407542|NCT05506709|DEVICE|Seawater nasal spray|Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
215012124|NCT03331406|OTHER|Physical Activity Program|12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
215012125|NCT00601237|BEHAVIORAL|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
215099181|NCT05921175|DEVICE|RGT+ tSCS + conventional physiotherap|Subject will undergo 16 sessions of robotic gait training (RGT) + tSCS+ conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment. During tSCS, cathodes will be placed on the T11 and L1 spinous process. Reference/Ground electrodes placed over the ASIS It will be on biphasic mode with an overlap frequency of 10kHz, Burst Frequency of 30Hz, Pulse width of 1ms. Stimulation intensity ranges from 5-100 mA and will be adjusted according to the patient's response. The tSCS stimulation duration for each session will be 45 minutes in conjunction with the RGT training.
214407543|NCT03681691|DRUG|Estradiol patch|transdermal 17β-estradiol patch
214407544|NCT04679363|OTHER|Active release technique|ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.
214407545|NCT04679363|OTHER|Post isometric relaxation|PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
214407546|NCT01153750|DRUG|Glivec|
214407547|NCT00280033|BIOLOGICAL|Aluminum hydroxide|Provided in vials that contain 0.8 mL volume per vial.
214407548|NCT00280033|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (Chiron)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
214407549|NCT00280033|BIOLOGICAL|MF-59|Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
214407550|NCT00280033|DRUG|Placebo|Saline placebo.
214688373|NCT07161843|DRUG|QRX-3|Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
215012126|NCT00601237|BEHAVIORAL|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
215012127|NCT00051727|BEHAVIORAL|Bridges to High School Project|
215012128|NCT01838889|BEHAVIORAL|Culturally adapted psychological intervention (Positive Health Programme)|This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
215012129|NCT05025917|DIETARY_SUPPLEMENT|Shatavari|Shatavari root powder
214688374|NCT07163897|DEVICE|Cobra Ankle Arthrometer|This is a prototype portable ankle arthrometer designed to measure the laxity of the ankle joint.
214407551|NCT05939557|PROCEDURE|Jones technique|is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)
214688375|NCT07162103|OTHER|GMART|Group Mandala Art Therapy
214688376|NCT07162389|DEVICE|Shallow-Threaded Short Implant (SHI)|A 7mm long, 4.2mm diameter dental implant with shallow thread (\<0.5mm depth) Macrodesign, surgically placed in the jawbone to restore missing teeth
215012130|NCT05025917|DIETARY_SUPPLEMENT|Magnesium stearate|Magnesium stearate powder
215012131|NCT02417181|OTHER|Care provided by Physician Assistants|Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
215012132|NCT02974426|RADIATION|PORT-first|PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
215012133|NCT02974426|RADIATION|PORT-last|PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
215012134|NCT02974426|DRUG|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
215012135|NCT00897845|GENETIC|RNA analysis|
215012136|NCT00897845|GENETIC|microarray analysis|
215012137|NCT00897845|OTHER|immunohistochemistry staining method|
215012138|NCT00897845|OTHER|laboratory biomarker analysis|
215012139|NCT05064800|DRUG|Dabigatran|A single dose of Dabigatran on Day 1
215012140|NCT05064800|DRUG|PF-07321332/ritonavir + Dabigatran|PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2
215012141|NCT05064800|DRUG|Ritonavir + Dabigatran|Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2
215012142|NCT04909255|DRUG|mirabegron|use beta-3 agonist for sjogren syndrome patient
215012143|NCT04909255|DRUG|oxybutynin, tolterodine, solifenacin|use anti-muscarinic agent for patient with overactive bladder syndrome
215012144|NCT03307070|BEHAVIORAL|Cognitive Behavioral Therapy for individuals with TBI|Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
215012145|NCT03307070|OTHER|Waitlist Control|Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
215012146|NCT01158586|DRUG|Levobupivacaine|patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
215099182|NCT05921175|DEVICE|RGT+ conventional physiotherapy|Subject will undergo 16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment.
215099183|NCT01161537|DRUG|VX-770|Tablet.
215099184|NCT01161537|DRUG|Placebo|Tablet.
215099185|NCT05912972|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
215012147|NCT02411955|DRUG|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
215012148|NCT02411955|DRUG|Tazorac®|Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
215012149|NCT02411955|DRUG|Placebo|Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
215012150|NCT03044561|DRUG|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
215012151|NCT03044561|DRUG|matching placebo|orally, 4 times per day for 21 days
215099186|NCT00544219|BIOLOGICAL|rituximab|375 mg/m2 i.v. per cycle
215099187|NCT00544219|DRUG|cyclophosphamide|750 mg/m2 i.v. per cycle
215012152|NCT04477486|DRUG|Ibrutinib|Capsule; Oral
215012153|NCT04477486|DRUG|Venetoclax|Tablet; Oral
215012154|NCT06493565|DEVICE|Routine endoscopic anastomosis inspection|"The routine care pathway for early detection of anastomotic leakage includes:~* C-reactive protein guided imaging~* Rectoscopy of the anastomosis three to six days after surgery~* Rectoscopy of the anastomosis two to three weeks after surgery"
215012155|NCT00512083|DRUG|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
215012156|NCT04724200|DIAGNOSTIC_TEST|Echocardiogram|Echocardiography plays a crucial role in the diagnosis of HF; it is the standard of care imaging modality used to confirm the diagnosis, it permits real-time imaging of the heart and quantitative assessment of cardiac structure and function, crucial for diagnosis.
215099188|NCT00544219|DRUG|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
215099189|NCT00544219|DRUG|prednisone|100 mg/day p.o. per cycle
215099190|NCT00544219|DRUG|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
215099191|NCT00544219|PROCEDURE|positron emission tomography|PET Scan during treatment
215099192|NCT06254287|DRUG|Avatrombopag|Avatrombopag was given 40 mg/ time, once a day, orally, for 3 months.
215012157|NCT02966925|DEVICE|Cellular Matrix BCT-HA Kit|Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
214407552|NCT05939557|DEVICE|Kinesiotape|KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
214407553|NCT01701154|OTHER|respiratory muscle strength training|
214407554|NCT03180190|DRUG|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
214407555|NCT04399707|DEVICE|Transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
214407556|NCT04399707|DEVICE|Placebo transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
215012158|NCT05797090|DRUG|Crystalloid Cardioplegic solution|To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
214407557|NCT04031417|OTHER|Hypoxia|
214407558|NCT04031417|OTHER|Low Humidity|
214407559|NCT02543450|OTHER|Cardiovascular and task-oriented training|
214407560|NCT02543450|OTHER|Upper limb strength training program|
214504797|NCT06932874|DRUG|New sustained-release metformin tablets (Ⅲ)|The experimental group received treatment with New Metformin Sustained-release Tablets (Ⅲ) combined with other oral hypoglycemic drugs for 24 weeks.
214688377|NCT07162389|DEVICE|Shallow-Threaded Standard Implant (SDI)|A 11mm long, 4.2mm diameter dental implant with shallow thread (\<0.5mm depth) macrodesign, surgically placed in the jawbone to restore missing teeth.
215012159|NCT00779883|BIOLOGICAL|ISF35|Subjects participating in this study will receive a single dose of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells.
215012160|NCT00513864|DRUG|Dextromethorphan|one time dose - 0.3mg/kg PO
215012161|NCT00513864|DRUG|Codeine|one time dose - 2mg/kg PO
215012162|NCT00513864|DRUG|Morphine|one time dose - 0.15mg/kg IV
215012163|NCT04915066|OTHER|Medical data collection|Collection of medical data from patients'medical records
215012164|NCT03745456|DIAGNOSTIC_TEST|Blood samples for ROTEM and platelet function.|Thormoboelastometry is based on the measurement of elasticity of blood by continuous graphical logging of the firmness of a blood clot during clot formation and subsequent fibrinolysis
215012165|NCT01524458|PROCEDURE|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
215099193|NCT06254287|DRUG|Avatrombopag +rhTPO|Avatrombopag: 40 mg/ time, once a day, orally; rhTPO: 15000U/ time, once a day, subcutaneous injection; Both were 3 months.
215099194|NCT05204030|OTHER|HPV Twitter Education Program - Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine narrative messages (i.e., stories). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
215099195|NCT05204030|OTHER|HPV Twitter Education Program - Non-Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine non-narrative messages (i.e., scientific information - numbers and facts). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
215012166|NCT04038658|BEHAVIORAL|Move-It|
215012167|NCT00372515|DRUG|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
215012168|NCT04725981|PROCEDURE|Total laparoscopic hysterectomy|Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
215099196|NCT01755455|DRUG|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
215099197|NCT01755455|DRUG|Placebo|Matching placebo capsule
215099198|NCT01900587|DRUG|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
215099199|NCT01900587|DRUG|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
215099200|NCT01609504|PROCEDURE|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
215099201|NCT01609504|PROCEDURE|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
215099202|NCT00856726|DRUG|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
215099203|NCT06030167|BEHAVIORAL|Insecure attachment and psychosocial functioning in autistic adults|Questionaires about attachment, psychosocial functioning, depressive symptoms, paranoid ideation, and emotion regulation were administered to 83 autistic adults (50 males, 33 females).
215099204|NCT04934657|OTHER|no intervention|no intervention
215012169|NCT06192745|BEHAVIORAL|no screen control with dim light and calming activities|Non-screen-based quiet activities for 1 hour before bed in room lighting 40-50 lux
215012170|NCT06192745|BEHAVIORAL|unfiltered Bright tablet screen|Bright light screen media exposure will be delivered on an iPad Pro provided by the research team which will be set to the brightest light intensity setting for 1 hour before bed in room lighting 40-50 lux
215099205|NCT03464019|DRUG|Etripamil|Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
214407561|NCT00552734|DEVICE|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
214407562|NCT02771418|DRUG|Propofol|Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
214407563|NCT02771418|DRUG|Sevoflurane|Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
214407564|NCT02771418|PROCEDURE|Elective carotid endarterectomy|
215012171|NCT06192745|BEHAVIORAL|Filtered dim tablet screen|Filtered dim light screen media exposure will be delivered for 1 hour before bed in room lighting 40-50 lux on an iPad Pro provided by the research team. A blue light filter will be used to alter the spectral distribution of the emitted light and the screen brightness will be dimmed to the lowest possible setting
215012172|NCT06192745|BEHAVIORAL|Exciting content|We will create a 1-hour recording of movie clips containing exciting content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
215012173|NCT06192745|BEHAVIORAL|Calming Content|We will create a 1-hour recording of movie clips containing calming content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
215012174|NCT00004163|DRUG|Trastuzumab|
214407565|NCT00440986|PROCEDURE|Eritrocytoapheresis|
214407566|NCT04201015|DEVICE|Heart rate optimisation using force frequency data|Programming heart rate rise according to the force frequency relationship
214504798|NCT05900570|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
215012175|NCT05208632|OTHER|INTERSCALEN BLOCK APPLICATION WITH USG|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
215012176|NCT05610839|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
215012177|NCT05022862|BEHAVIORAL|Usual Care|Medication is dispensed to participant at each visit in 30-60 day supplies by Baltimore City Health Department (BCHD) nurses. For study participants, medication dispensation will occur in medication bottles with MEMS Caps, supplied by the study.
215012178|NCT05022862|BEHAVIORAL|Video Directly Observed Therapy alone|Usual care plus Video-DOT using the emocha platform, a HIPAA compliant commercial platform for video based DOT. The app allows a secure/encrypted video recording to be taken as the participant ingests the medication. Electronic text reminders will be sent to the participant on the smart phone when it is time to take the medication. The participant will record a video of the pill ingestion process. Study staff will verify each video to confirm the video shows the correct person and that the pill was ingested appropriately (according to standardized approach involving visualization of the pills, ingestion and observation of an empty mouth after ingestion).
215012179|NCT05022862|BEHAVIORAL|Video Directly Observed Therapy plus Financial Incentives|Usual care plus video-DOT and financial incentives contingent on adherence verified by video DOT. The amount of the financial incentive that can be earned for future verified doses decreases after a missed dose (video). The amount of the financial incentives increases incrementally back to baseline amount after verification of medication ingestion according to the prescribed schedule for several consecutive doses.
215012180|NCT02497755|BEHAVIORAL|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
215012181|NCT02497755|DEVICE|smartphone|
215012182|NCT02555098|DEVICE|Sapphire contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
215012183|NCT02555098|DEVICE|senofilcon A contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
215012184|NCT02804646|DRUG|recombinant human endostatin|endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
215012185|NCT02804646|DRUG|pemetrexed plus cisplatin or carboplatin|the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
215099206|NCT03464019|DRUG|Placebo|Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
215099207|NCT03464019|DRUG|Etripamil Test Dose|During the Test Dose, etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
215099208|NCT00511134|DRUG|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
214504799|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~4. Trilaciclib: 240mg/m2, d1, d2, d8 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
214504800|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
215099209|NCT00511134|DRUG|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
215099210|NCT06403917|OTHER|Evaluation of breast screening|Evaluation of breast screening program at egyptian women health intiaive
214504801|NCT06507930|OTHER|Telehealth Hospice Visits|Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.
214504802|NCT02678455|BIOLOGICAL|TV005 vaccine|Delivered by subcutaneous injection; contains 10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31, and 10\^3 PFU of rDEN4Δ30.
214504803|NCT02678455|BIOLOGICAL|Placebo|Delivered by subcutaneous injection
215012186|NCT03849989|PROCEDURE|Skin biopsy|"Skin biopsy:~Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.~Steps:~* Skin desinfection with chlorhexidine digluconate 1% solution~* Local anaesthesia with lidocaine hydrochloride 1%~* Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)~* Biopsy specimens are retrieved with sterile pincer and cut with sterile blade~* Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).~* Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks~* In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage."
215012187|NCT04215575|DEVICE|glaucoma implant procedure (Baerveldt)|A 350 mm2 Baerveldt glaucoma implant was placed in the superotemporal quadrant in 25 patients randomized to BGI group. A limbus-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
215012188|NCT04215575|DEVICE|glaucoma implant procedure (Ahmed)|A 184 mm2 Ahmed glaucoma implant was placed in the superotemporal quadrant in 56 patients randomized to AGV group. A fornix-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. The Ahmed tube left patent and viscoelastic substance injected into anterior chamber. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
215012189|NCT01937442|DRUG|Thalidomide Celgene™|200mg once daily and by mouth
214504804|NCT03532139|DRUG|Enoxaparin|Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
214504805|NCT03532139|DRUG|Enoxaparin + Rosuvastatin|"Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness"
214504806|NCT03532139|OTHER|Thromboprophylaxis|standard of care therapy
214688378|NCT07163793|DRUG|Azacitidine|Given Day 1-7 with Venetoclax Day 1-14 every 28 days until off study
214688379|NCT07163793|DRUG|Decitabine|Given Day 1-5 with Venetoclax Day 1-14 every 28 days until off
214688380|NCT07163793|DRUG|Venetoclax|Venetoclax up to 400mg a day on Day 1-14 every 28 days until off in combination with Azacitidine or Decitabine
215012190|NCT03886623|PROCEDURE|4-day systematic oral hygiene|he intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
215012191|NCT03886623|OTHER|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
215012192|NCT05254210|DEVICE|RF Device (Potenza™)|Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.
215012193|NCT03167398|BIOLOGICAL|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
215012194|NCT05483634|DRUG|Vaginal estrogen supplement|Daily vaginal estrogen supplement, then twice per week. Continue for three months.
215012195|NCT05483634|PROCEDURE|Platelet-rich plasma injection|Monthly platelet-rich plasma injection for three months
215012196|NCT01208909|PROCEDURE|diagnostic 5-ALA and MRI for tumor resection|diagnostic 5-ALA and MRI for tumor resection
215012197|NCT03228576|COMBINATION_PRODUCT|Extended release Tacrolimus-Everolimus association|Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus
215012198|NCT03570138|DEVICE|FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System|Specific therapeutic education for diabetes self management
215012199|NCT03570138|DEVICE|Usual self monitoring Blood Glucose device|Standard therapeutic education for diabetes self management
215012200|NCT00736736|OTHER|Additional Hip Muscle Strengthening to Leg Press Exercise|
215012201|NCT00736736|OTHER|Leg Press Exercise|
215012202|NCT04992741|OTHER|education and motivational interview|The control group will remain subject to the routine process without any intervention.
215012203|NCT05670197|OTHER|No intervention. Participants will take part in a qualitative interview|No intervention. Participants will take part in a one-off, audio-recorded qualitative interview, lasting up to 60 minutes. The interviewer will ask about participants' views on complex digital remote monitoring.
215012204|NCT05357378|DEVICE|Hip Innovation Technology Reverse Hip Replacement System|Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
215012205|NCT05357378|DEVICE|Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.|"Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~* DePuy Synthes CORAIL® or DePuy Synthes ACTIS™ Total Hip System in combination with DePuy Synthes PINNACLE™Complete Acetabular Hip System.~* Zimmer Biomet Taperloc®, Zimmer Z1™ Cementless Femoral Hip Stem System or Zimmer Biomet AVENIR® Complete Hip System in combination with Zimmer Biomet G7® Acetabular System.~* Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~* Smith \& Nephew ANTHOLOGY® Total Hip System in combination with Smith \& Nephew R3® Acetabular System"
215099211|NCT01949090|BIOLOGICAL|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
215099212|NCT01949090|BIOLOGICAL|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
215099213|NCT05575193|OTHER|Acupressure|The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes.
215099214|NCT03373838|OTHER|Census|Survey and interview
215099215|NCT04371939|DRUG|Romiplostim|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II."
215099216|NCT04371939|DRUG|Eltrombopag|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (\>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I."
215099217|NCT02024139|OTHER|Chewing Sugarless Gum|Chewing sugar free gum three times per day for 5-10 minutes
214407567|NCT04471987|DRUG|IL12-L19L19|"Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications."
214407568|NCT04471987|DRUG|IL12-L19L19|Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
214407569|NCT01373047|BIOLOGICAL|anti-CEA 2nd generation designer T cells|Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
214407570|NCT00264680|DRUG|lamotrigine|
214407571|NCT00264680|DRUG|valproic acid|
214407572|NCT02369523|DRUG|Exparel|Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
214407573|NCT02369523|DRUG|Ropivacaine cocktail (PIC)|400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
214407574|NCT02369523|DRUG|Bupivacaine|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine"
214407575|NCT01743651|DRUG|arbaclofen|40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day
214407576|NCT01743651|DRUG|baclofen|80 mg/day as 20 mg baclofen administered orally 4 times per day
214688381|NCT07163390|COMBINATION_PRODUCT|Sideral Folico|Pregnant women will be enrolled from 24 to 32 weeks of gestation whether their hemoglobin levels are comprised between 8.5 and 10.5 g/dl. They start oral supplementation with Sucrosomial iron® 30 mg (Sideral® Folico), 2 sticks for twice a day for 15 days, followed by Sucrosomial iron ® 30 mg (Sideral® Folico), 1 stick for twice a day for the next 15 days
215099218|NCT02024139|OTHER|Using Mouthwash|Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
215099219|NCT04694027|DRUG|Omega 3 fatty acid|omega 3 1000 mg
215099220|NCT04694027|DRUG|VitaE|vitamin e 400 mg
215099221|NCT01517464|GENETIC|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
214407577|NCT01743651|DRUG|Placebo|arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
214407578|NCT02849262|DRUG|Omiganan (CLS001) topical gel|
214407579|NCT02849262|DRUG|Vehicle topical gel|
214407580|NCT05421845|BEHAVIORAL|mobile-based combining with hospital-based lifestyle interventions|The same as that stated in arm descriptions.
214407581|NCT00252993|DRUG|DDP225|
215012206|NCT05853913|BEHAVIORAL|Exercise|Exercise will be walking/jogging at a medium to hard intensity for 1 hour.
215012207|NCT04786600|DEVICE|Signatera ctDNA assay|Subjects will be tested with the Signatera ctDNA assay every 2 weeks.
215012208|NCT04786600|DRUG|pre-specified sequence of FDA-approved drugs and drug combinations|Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
214407582|NCT05078385|DRUG|AGLE-102|AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
214407583|NCT01883765|BEHAVIORAL|Neurofeedback active|
214407584|NCT01883765|BEHAVIORAL|Neurofeedback sham|
214407585|NCT01883765|BEHAVIORAL|Metacognitive Training|
214407586|NCT03432533|DRUG|romosozumab HCP administration with PFS|210 mg romosozumab SC QM by HCP administration with 2 PFS
214407587|NCT03432533|DEVICE|romosozumab self-administration with AI/Pen|210 mg romosozumab SC QM by self-administration with 2 AI/Pens
214407588|NCT00462553|DRUG|sunitinib malate|Given orally
214407589|NCT00462553|DRUG|gemcitabine hydrochloride|Given IV
214407590|NCT06231485|BEHAVIORAL|STEPS2|One of the two health education curricula as described in arm/group descriptions.
215012209|NCT03774654|GENETIC|CD19.CAR-aNKT cells|"Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose..~Dose Level 1: 1 x 10\^7/m2. Dose Level 2: 3 x 10\^7/m2. Dose Level 3: 1 x 10\^8/m2. Dose Level 4: 3 x 10\^8/m2."
215012210|NCT01140373|BIOLOGICAL|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
215099222|NCT01478334|BEHAVIORAL|high intensity interval training|"First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.~Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period."
214407591|NCT06231485|BEHAVIORAL|STYH|One of the two health education curricula as described in arm/group descriptions.
214407592|NCT00816582|PROCEDURE|Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline|A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.
214407593|NCT00816582|PROCEDURE|Diagnostic Imaging: 18F-FES PET/CT - Baseline|A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.
214407594|NCT00816582|PROCEDURE|Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up|A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.
214407595|NCT02742051|DRUG|Everolimus|Neoadjuvant endocrine therapy
214407596|NCT02742051|DRUG|Letrozole|Neoadjuvant endocrine therapy
214407597|NCT02742051|DRUG|Fluorouracil|Neoadjuvant chemotherapy
214407598|NCT02742051|DRUG|Epirubicin|Neoadjuvant chemotherapy
214407599|NCT02742051|DRUG|Cyclophosphamide|Neoadjuvant chemotherapy
214407600|NCT01781910|DIETARY_SUPPLEMENT|Branched Chain Amino Acid drink supplement|
214407601|NCT01781910|DIETARY_SUPPLEMENT|Placebo|
214407602|NCT06118619|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
214407603|NCT00372970|DRUG|Botulinum toxin A|200 U given by injection into the pylorus.
214407604|NCT00372970|DRUG|Placebo|saline injection into pylorus.
214407605|NCT05761067|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
214407606|NCT00828620|OTHER|Imaging study|PET-CT
214407607|NCT05127395|OTHER|To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.|The study center utilize Epic ® electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be extracted from. Each study center will obtain individual IRB approval prior to data collection. SSM - St. Clare will serve as the lead center for the study with all other centers sending collected and de-identified data to this central site for analysis.
214407608|NCT05087238|BEHAVIORAL|CBT|Cognitive Behavior Therapy for PVC-specific anxiety education, in-vivo exposure, interoceptive exposure, behavioral activation, relapse prevention
214407609|NCT02113111|BEHAVIORAL|Fasting|Fasting therapy was adapted from Buchinger, including a fasting period of 7 days. After 2 prefasting days with 800kcal per day from vegetables and rice/potatoes, fasting starts with the ingestion of an oral laxative. During fasting patients receive small quantities of juice and herbal teas, and a vegetable broth for lunch, altogether no more than 350kcal per day. At the end, fasting is broken by an apple or cooked potato, and for the following 3 days nutrition returns to normocaloric diet.
214407610|NCT04846062|BEHAVIORAL|nutrition behavior intervention|Iodized salt utilization and iron dietary intake behavior
214407611|NCT02899637|DEVICE|Active high-frequency Transcranial Magnetic Stimulation|Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week
214407612|NCT02899637|DEVICE|Sham high-frequency Transcranial Magnetic Stimulation|Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
214407613|NCT03768544|BEHAVIORAL|Self-help guided by a lay provider|Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.
214407614|NCT03768544|BEHAVIORAL|Waiting list where participants wait for delayed treatment|Participants have a 15-week wait period during which they receive a 15-minute telephone call from the local professional research assistant on three occasions separated by four-week intervals. The purpose of these calls is to encourage the participant to persevere until the start of treatment and to identify potential negative effects that could be associated with the waiting period. Participants receive self-help guided by a lay provider after the waiting period.
214407615|NCT01631708|PROCEDURE|Erythrocytapheresis|"To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.~An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to \~100 ug/L in accordance with current guidelines."
214407616|NCT01631708|PROCEDURE|Plasmapheresis|An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
214407617|NCT05906329|RADIATION|Low-dose radiotherapy combined with conventional fractionated radiotherapy|Select the primary lesion, the largest metastatic lesion, or the lesion causing symptoms, and perform routine segmentation (1.8-2Gy/f, 40Gy-60Gy). For the remaining lesions, at least one easily assessable and measurable lesion should be selected as the observation lesion. Unselected lesions (≤ 10) should be given 1.6Gy/f, 1f/w, 4-6 times in total.
214407618|NCT01438437|PROCEDURE|PAI|Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
214407619|NCT01438437|PROCEDURE|RFA|Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
214407620|NCT05357196|DRUG|PT-112|"Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg."
214407621|NCT01134809|PROCEDURE|Major abdominal surgery|All adult patients having major abdominal surgery
214407622|NCT02527889|OTHER|Exercise training|8-week resistive exercise training
214407623|NCT04582045|DEVICE|silver impregnated dressing|comparison of Mepilex versus our standard techniques
214407624|NCT00257816|DRUG|Topotecan|"(First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual."
214407625|NCT00257816|DRUG|Cisplatin|40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
214407626|NCT01827228|OTHER|Assays|May vary across sites
214407627|NCT01827228|OTHER|HIV medical care|This will be expedited and assisted via community outreach for Recents and Acutes
214407628|NCT01827228|OTHER|Social network and venue tracing|This is described in Arms 1 and 2
215012211|NCT01140373|DRUG|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 10\^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
215012212|NCT05071898|DRUG|Semaglutide Pen Injector [Ozempic]|Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.
215012213|NCT05011383|DRUG|High dose testosterone|High dose testosterone is administered subcutaneously once monthly until progression or toxicity
215099223|NCT01478334|BEHAVIORAL|Control|"First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.~Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion."
214407629|NCT01827228|OTHER|Community alerts|When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
214407630|NCT01827228|OTHER|Community education|Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
214407631|NCT01827228|BEHAVIORAL|HIV counseling|As part of HIV testing, we will provide participants with standard counseling
214407632|NCT00487721|DRUG|Silibin-Phytosome|Subjects will take Silibin-Phytosome for 2-10 weeks. The dose of Silibin-Phytosome is 13 grams daily, in three divided doses. Patients will be asked to mix 1 level teaspoon and 1 heaping ¼ teaspoon of Silybin-Phytosome powder into 6 tablespoons of applesauce for each dose.
214407633|NCT00004870|BIOLOGICAL|oblimersen sodium|
214407634|NCT00004870|DRUG|irinotecan hydrochloride|
215099224|NCT00122408|DIETARY_SUPPLEMENT|Ergyphilus|5 pills a day of Ergyphilus or placebo
214407635|NCT04208737|PROCEDURE|recruitment maneuver|30 cmH2O pressure 15 seconds
214407636|NCT05765032|DRUG|SHR-A1921；|Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion
214407637|NCT03738358|DIETARY_SUPPLEMENT|Trehalose|80 mL pouch/day for 12 weeks, containing trehalose 5 g, water 74.92 g and scent additive 0.08 g
214407638|NCT03738358|OTHER|Placebo|80 mL pouch/day for 12 weeks, containing water 79.92 g and scent additive 0.08 g
215099225|NCT06039748|OTHER|AngioQFA|FFR measured by pressure wire, AngioQFA computed by coronary angiographic images
215099226|NCT03459365|DEVICE|Euflexxa|Aspirations performed before each injection and at six weeks.
215012214|NCT04579198|BEHAVIORAL|Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE)|The intervention, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), consists of four components: First, all caregivers of PTI patients (ages 0-11) will be given brief education in the hospital related to children's and caregivers' emotional recovery. Second, all families will receive an in-hospital risk-reduction session. These sessions will address avoidance and trauma triggers; scheduling of pleasurable activities; and coping strategies. Third, all caregivers will receive the CAARE app-based components before discharge. The app will engage caregivers for 30 days via an automated SMS system. MHealth components of care will reinforce risk-reduction strategies. Fourth, 30 days post-discharge, a brief behavioral health screen will be completed by caregiver and child to assess need for more intensive screening by a mental health provider. Caregivers/children reporting elevated symptom levels will receive a comprehensive screening and referral process.
215012215|NCT03402087|DRUG|Methotrexate|Specified dose on specified days
215012216|NCT03402087|DRUG|Leucovorin|Specified dose on specified days
215012217|NCT03402087|DRUG|BMS-986165|Specified dose on specified days
215012218|NCT04322695|BEHAVIORAL|Rehabilitation Education Care Program|The RECP contained the following domains: (1) assessment and detection of disability; (2) home exercise; (3) activities to improve mobility; (4) dietary management; (5) patient education; and (6) vocational counseling.
215012219|NCT02846428|DRUG|5-Fluorouracil|5-FU will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
215012220|NCT02846428|DRUG|Capecitabine|Capecitabine will be administered at 900 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
215012221|NCT02846428|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
215099227|NCT03291990|DRUG|Temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
215099228|NCT00769509|OTHER|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
214407639|NCT01853358|BIOLOGICAL|NK Cell infusion|"* level 1: 1 x 10e6 NK cells /kg;~* level 2: 5 x 10e6 NK cells /kg;~* level 3: \> 5.10e6 and ≤ 5.10e7 cellules NK/kg"
215099229|NCT00769509|OTHER|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
215099230|NCT06583616|DIAGNOSTIC_TEST|Anion Gap|Patient with acute pulmonary embolism who not survive after hospitalization
215099231|NCT05603598|DRUG|LEAP-2 Protein, Human|Intravenous infusion, mixed meal test, ad libitum meal test
215099232|NCT06095609|OTHER|Early mobilization plus chest physiotherapy|"Early mobilization:early mobilization has been confirmed its positive effectiveness on cutting down the MV use days and mortality rate, attenuating the side effect such as muscle strength loss and functional activity dysfunction resulting from ICU acquired weakness among the patients with mechanical ventilation.~Chest physiotherapy:a common technique to reduce the respiratory complications in ICU, has been proved certain positive influence on airway clearance and hospital lengths of stay."
215099233|NCT02979223|DRUG|sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid|"sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group"
215099234|NCT06530966|DRUG|ICP-332 Tablets|Eligible patients will receive ICP-332 tablets orally as per the protocol
214407640|NCT02723357|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
214407641|NCT02723357|BEHAVIORAL|Access to Social Service Referrals|Access to referrals for common social needs.
214407642|NCT00257777|PROCEDURE|Myocardial protection techniques|
214407643|NCT02745769|DRUG|Ramucirumab|Administered IV
214407644|NCT02745769|DRUG|Merestinib|Administered orally
214407645|NCT02745769|DRUG|Abemaciclib|Administered orally
214407646|NCT00602160|DRUG|FAHF-2 (TM)|"We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy."
214407647|NCT01582243|DRUG|Vildagliptin|Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
214688382|NCT06238466|DRUG|AZD1705|Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.
214688383|NCT06238466|OTHER|Placebo|Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.
215099235|NCT06530966|DRUG|ICP-332 Placebo Tablets|Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
215099236|NCT02146001|OTHER|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
214407648|NCT01154686|BEHAVIORAL|Cogmed|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. Training is implemented with a software program (RoboMemo©). It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
214407649|NCT05587140|DEVICE|Acupuncture like TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes
214407650|NCT05587140|DEVICE|Conventional TENS|Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes
214407651|NCT05587140|DEVICE|Sham TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
215099237|NCT02146001|OTHER|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
215099238|NCT04431492|PROCEDURE|CABG|aminoacids and NO levels
214407652|NCT02143531|DRUG|4 mg of Ondansetron IV|
214407653|NCT02143531|DRUG|1mg of Haloperidol IV|
214407654|NCT03351309|BEHAVIORAL|Telephone-based Cognitive Behavioral Therapy (CBT)|Four session telephone CBT protocol.
214407655|NCT04596761|DEVICE|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
214407656|NCT04596761|DEVICE|Control placebo with no RF|Placebo control, toothbrush with no RF
214407657|NCT00119587|DRUG|darbepoetin alfa|
214407658|NCT06137313|OTHER|questionnaire|completion of a questionnaire
214407659|NCT05945082|OTHER|biopsy|biopsy of a colorectal cancer site
214407660|NCT02309840|BEHAVIORAL|choice architecture|"1. Place vegetables at the beginning of the lunch line.~2. Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.~3. Promote fruits and vegetables with prominently displayed signage and images.~4. Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level."
214407661|NCT02309840|OTHER|Chef-enhanced meals|meals prepared by a professional chef with enhanced palatability
214407662|NCT05823987|DRUG|H101|a modified human recombinant type 5 adenovirus with genetic modifications
214407663|NCT05823987|DRUG|Tislelizumab|a PD-1 immune check inhibitor
214407664|NCT05823987|DRUG|Lenvatinib|Lenvatinib capsules
214407665|NCT02493790|OTHER|Cognitive and motor performances|
214407666|NCT02803294|PROCEDURE|transcatheter aortic valve replacement|
214407667|NCT04690283|DRUG|Mimetic granules of Yiqi-Wenjing prescriptions|The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.
214407668|NCT04690283|DRUG|Huangqi-Guizhi-Wuwu granules|The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.
214407669|NCT04690283|DRUG|Danggui-Sini granules|The intervention relates to a traditional Chinese prescription granules, which contains angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root.
214407670|NCT01757509|OTHER|Intervention group|"Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling."
214407671|NCT02967666|RADIATION|FDG ligand|
214407672|NCT02967666|RADIATION|DOTANOC ligand|
215099239|NCT04922138|DRUG|Aumolertinib|All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
215099240|NCT02575170|DRUG|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
215099241|NCT02575170|DRUG|Ringer's lactate solution|200 ml of Ringer's lactate solution
215099242|NCT05508919|DEVICE|Biofeedback|EMG, RESP, and TEMP Biofeedback Training
215099243|NCT05508919|OTHER|Writing Sessions|The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week
214407673|NCT05057754|BEHAVIORAL|Cooling|Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C
214407674|NCT05057754|BEHAVIORAL|Heating|A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.
214407675|NCT05057754|BEHAVIORAL|Exercising|Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.
214407676|NCT05057754|BEHAVIORAL|Typing|All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.
215099244|NCT06206018|PROCEDURE|PROM_R knee rehabilitation program|"The rehabilitation program consists of 5 weekly sessions for 4 weeks, supervised by a specialized physiotherapist at every session.~All patients follow the same order of treatment and exercises, starting with massage and mobilization, followed by the corresponding exercise program, and ending with Neuromuscular Electrical Stimulation (NMES) and cryotherapy."
215099245|NCT03877302|OTHER|reflexology|foot reflexology
215099246|NCT00567359|DRUG|Erlotinib|Oral drug taken daily around the same time. Starting dose is 150mg once daily.
215099247|NCT00254670|DRUG|Naltrexone|
214407677|NCT05057754|BEHAVIORAL|Using a mouse|"Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software."
214407678|NCT05057754|BEHAVIORAL|Cooking|Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
214407679|NCT02896608|DEVICE|measure of neuronal excitability|
214407680|NCT02723656|BEHAVIORAL|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
214407681|NCT02723656|BEHAVIORAL|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
215012222|NCT02846428|DRUG|Docetaxel|Docetaxel will be administered at 100 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
215012223|NCT02846428|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
215099248|NCT00785980|DRUG|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) administered on the morning of Day 1 after an overnight fast of at least 10 hours.
215099249|NCT00785980|DRUG|Ciprofloxacin 500 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
215099250|NCT00785980|DRUG|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
215099251|NCT02459678|BEHAVIORAL|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
215099252|NCT02459678|OTHER|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
215099253|NCT03646474|DRUG|tranexamic Acid infusion|The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
214407682|NCT00253214|DRUG|galantamine hydrobromide|
214407683|NCT02215798|DRUG|Cymbalta|
214407684|NCT04768790|OTHER|multidisciplinary program|multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
215012224|NCT03626675|PROCEDURE|phaco- trabeculectomy|combined phaco-trabeculectomy surgery
215012225|NCT00859846|PROCEDURE|Arterial line placement|"The following measures will be collected and compared.~1. Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~2. number of attempts, defined as forward advancements of needle, required to cannulate the artery.~3. number of separate skin punctures.~4. number of arteries into which entry is attempted."
215099254|NCT03646474|DRUG|saline infusion|In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
215099255|NCT05041270|DRUG|normal saline|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline)."
214407685|NCT04768790|OTHER|General program|exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
215012226|NCT02547935|DRUG|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
215012227|NCT02547935|DRUG|Saxagliptin 2.5 mg|Tablets administered orally once daily for 24 weeks.
214407686|NCT03668067|DEVICE|2WIN photoscreener|conventional infrared off-axis photoscreener
215012228|NCT02547935|DRUG|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
215012229|NCT01647685|DRUG|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
215012230|NCT01647685|DRUG|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
215012231|NCT01647685|DRUG|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
214407687|NCT02793609|OTHER|Intervention is to let patient to go home.|Intervention is to let patient to go home.
214407688|NCT02793609|OTHER|Intervention is to observe women in the ward.|Intervention is to observe women in the ward.
214407689|NCT06048341|PROCEDURE|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
214407690|NCT06048341|DRUG|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
214407691|NCT06048341|DRUG|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
214407692|NCT01125202|BEHAVIORAL|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
215099256|NCT05041270|DRUG|Dexmedetomidine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)."
215099257|NCT05041270|DRUG|Nalbuphine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)."
215012232|NCT02487836|DEVICE|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
215012233|NCT03650270|DRUG|Phenobarbital|Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
215012234|NCT03599466|DRUG|BF-Lisinopril Tablets 20mg|BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
215099258|NCT04459520|BEHAVIORAL|Positive COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested positive (PCR) for an active COVID-19 infection and that their physician has clinically diagnosed them with COVID-19.
215099259|NCT04459520|BEHAVIORAL|Negative COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested negative (PCR) for an active COVID-19 infection.
215099260|NCT04459520|BEHAVIORAL|Unavailable COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that testing is not available for active COVID-19 infections but that their physician has clinically diagnosed them with COVID-19.
215099261|NCT06066398|PROCEDURE|medical thoracoscope|Medical thoracoscopy will be performed during which pleural brush will be used first followed by forceps biopsy to obtain pleural specimens from suspect areas under visual control and pleural lavage will be performed by injecting 300 mL of normal saline
215099262|NCT06066398|DIAGNOSTIC_TEST|Forceps biopsy and pleural brush histopathology|Forceps biopsy and pleural brush will be obtained for histopathological examination for diagnosis
214407693|NCT01125202|BEHAVIORAL|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
214407694|NCT06331754|OTHER|Technology-enabled blood pressure management|The intervention will consist of a technology-enabled remote hypertension management program.
214407695|NCT02747264|DEVICE|eRAPID|eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
214407696|NCT01101919|DRUG|CP-690,550|Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
214407697|NCT03864484|DEVICE|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.
214407698|NCT03864484|BEHAVIORAL|Usual rehabilitation|The control group receives usual rehabilitation.
215012235|NCT03599466|DRUG|Zestril Tab 20mg|Zestril Tab 20mg will be used as a reference drug in this study
215012236|NCT03168997|DRUG|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
215012237|NCT03068520|DIAGNOSTIC_TEST|PET MR|PET MR with 18 Fluorodopa (\[18F\]-DOPA) will be performed on patient at set intervals
215012238|NCT05508594|DRUG|CT001|Intranasal
215012239|NCT05508594|DRUG|Placebo|Intranasal
215012240|NCT05508594|DRUG|Sufentanil|Intranasal
215012241|NCT05508594|DRUG|Ketamine|Intranasal
215012242|NCT03461861|DRUG|AGB101 220 mg|AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
215012243|NCT03461861|OTHER|Placebo|Placebo, oral capsule given once-daily.
215012244|NCT04692051|DRUG|Nab-paclitaxel + Cisplatin|Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
215012245|NCT04692051|DRUG|Gemcitabine + Cisplatin|Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
215012246|NCT01411371|PROCEDURE|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
215099263|NCT06066398|DIAGNOSTIC_TEST|pleural lavage cytology|pleural lavage will be obtained for cytological examination for diagnosis
215099264|NCT04036526|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
215099265|NCT04036526|OTHER|Placebo|Placebo
214407699|NCT01112072|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
214407700|NCT05298670|DRUG|MetFORMIN 1000 Mg Oral Tablet|Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.
215012247|NCT01411371|DRUG|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
215099266|NCT04885413|DRUG|Niraparib in Combination With Anti-PD1 Antibody|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
215099267|NCT01974011|PROCEDURE|Performing dorsal penile nerve block (DPNB)|
215099268|NCT02301026|DRUG|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
214407701|NCT05298670|DRUG|Interferon beta-1a|Disease Modifying Therapies (DMTs)
214407702|NCT02775617|DRUG|Ivermectin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
214407703|NCT02775617|DRUG|Azithromycin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
214407704|NCT02775617|DRUG|Permethrin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
214407705|NCT03332966|DIAGNOSTIC_TEST|Psychiatric questionnaires|"Participants will fill in the following questionnaires as part of routine intake assessments:~Generalised Anxiety Disorder Assessment (GAD-7); Mini-Social Phobia Inventory; Beck Depression Inventory 21A; Pittsburgh Sleep Quality Index; Insomnia Severity Index; Youth Experiences and Health Questionnaire; Adolescent Dissociative Experiences Scale (abbr.); Adolescent Peer Relations Instrument (APRI-B + cyberbullying, abbr.); Adolescent Trauma and Dissociation Scale (abbr.); Alcohol Use Disorders Identification Test; Alcohol, Smoking and Substance Involvement Screening Test - Lite (extended); Nicotine Questionnaire incl. Heavy Smoking Index; Internet Addiction Test (abbr.); European School Survey Project on Alcohol and Other Drugs 2015 Social Media Use and Computer Gaming; McMaster Family Assessment Device - General Functioning positive items; Multidimensional Scale of Perceived Social Support; Brief Resilience Scale; The Short Warwick-Edinburgh Mental Well-Being Scale"
214407706|NCT03332966|DIAGNOSTIC_TEST|Semi-structured psychiatric interview|Kiddie Schedule for Affective Disorders and Schizophrenia, version K-SADS-PL 2013.
214407707|NCT02831400|BEHAVIORAL|Walking test|Walking test to increase cardiac output, maximum 12 minutes
214407708|NCT02831400|BEHAVIORAL|Standard Meal|After the walking test, volunteers eat a standard warm meal
214407709|NCT04547543|OTHER|Videoconsultation|Patient randomized on video-consultation group will have a video-consultation with the investigator within 3 months after the randomization. During this consultation, the investigator performs a clinical interrogation in order to collect anthropometric parameters: (sex, age, weight, height, body mass index (BMI)), blood pressure (by blood pressure monitor at home), the level of physical activity (by Actimetry over 7 days), smoking status and alcohol status
214407710|NCT05831280|BEHAVIORAL|Laughter Yoga|"* Warm-up exercises (5 minutes),~* Deep breathing exercises (5 minutes),~* Childlike playfulness (5 minutes),~* Laughter exercises (15 minutes)."
214407711|NCT04144985|OTHER|Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.|Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
214407712|NCT04896255|DRUG|peginterferon alpha based regimen|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
214407713|NCT04896255|DRUG|nucleos(t)ide|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
214407714|NCT04055896|OTHER|Medication Reduction|Systematic approach to reduction in polypharmacy
215012248|NCT03639051|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
215012249|NCT03639051|OTHER|Optimal Medical Care|Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
215012250|NCT04899128|DRUG|Pyrotinib|Pyrotinib-based therapy
215012251|NCT02539693|DRUG|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
215012252|NCT02539693|DRUG|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
215012253|NCT02539693|DRUG|Lidocaine|3 ml lidocaine 1% is injected at each block site
215012254|NCT02539693|PROCEDURE|Pilonidal sinus|Removal of pilonidal sinus
215012255|NCT02679092|DRUG|Misoprostol|400 mcg buccal 60-90 minutes prior to procedure
215012256|NCT02679092|DRUG|Mifepristone|200 mg PO on the day prior to D\&E
215012257|NCT02679092|DEVICE|Hygroscopic cervical dilators|osmotic cervical dilators inserted through the internal os
215012258|NCT07046000|DIAGNOSTIC_TEST|MRI|MRI to assess graft maturation
215099269|NCT00528801|BEHAVIORAL|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
215099270|NCT00528801|PROCEDURE|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
215012259|NCT07055932|BEHAVIORAL|"Interactive Oral Health Education Program"|"The interactive program in this study is distinguished by its multi-modal, hands-on approach and its sustained, bi-weekly delivery over two months, whereas most other school-based interventions rely on a single lecture or short-term animation. Specifically, our program:~Combines interactive lectures with live demonstrations (brushing/flossing on models), group discussions, and educational puzzles to reinforce learning through active participation rather than passive listening.~Uses anatomical tooth-and-gum replicas alongside PowerPoint slides and photographs to bridge theory and practice within each 30-45-minute session.~Addresses periodontal risk factors (e.g., smoking, diet) in dedicated sessions, integrating behavioural change techniques (e.g., problem-solving brainstorming, personalized feedback) rather than focusing solely on plaque removal.~Is delivered in six sessions (one every 10 days) to maximize retention and allow for iterative skill practice, unlike brief brush-along"
215012260|NCT07056452|PROCEDURE|hydrodissection technique|injecting a solution of physiological saline containing 0.5% lidocaine along the cutting line
215012261|NCT07057271|DRUG|CJC-1134-PC Injection|Double-blind Treatment Period: 0.2ml (2mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
214407715|NCT04155853|PROCEDURE|Interposition Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
214407716|NCT04155853|PROCEDURE|Hematoma and Distraction Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
214407717|NCT00188240|DRUG|Pegasys; Copegus.|
214407718|NCT04818320|DRUG|Favipiravir|Day 1: 1800mg BD, day 2-5: 800mg BD
214407719|NCT02742142|OTHER|water as placebo|topical application of water as a placebo in the control arm
214407720|NCT02742142|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
215012262|NCT07057271|DRUG|Placebo|Double-blind Treatment Period: 0.2ml (0mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
215012263|NCT07056426|OTHER|Exercises|"Joint mobilization exercises:~-Active ankle range of motion exercises~Ankle strengthening with resistance band (Thera-band®):~* Resisted dorsiflexion~* Resisted plantar flexion~* Resisted inversion~* Resisted eversion~* Leg muscle strengthening exercises:~* Heel raises (standing)~* Heel raises (sitting)~* Toe raises (standing)~* Toe raises (sitting)~Hip and pelvis stabilizer muscle strengthening exercises:~* Pelvic bridge~* Side leg lifts with hip and knee at 0°~* Side leg lifts with hip and knee at 90°~Stretching exercises:~* Calf stretch with towel~* Gastrocnemius stretch (standing)~* Soleus stretch (standing)~* Anterior compartment leg stretch~These exercises will be applied three times a week in 40-minute sessions, for a total of 12 sessions."
215099271|NCT00344500|BEHAVIORAL|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~* Be given a 7% weight loss goal~* Be assisted in obtaining a 500 calorie reduction per day~* Exercise for at least 30 min/day, at least 5 days a week~* Maintain weekly food and exercise diaries~* Be quizzed on their knowledge of healthy eating habits and nutrition"
215099272|NCT00377208|BEHAVIORAL|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
215099273|NCT03691870|PROCEDURE|Standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
215099274|NCT03691870|PROCEDURE|Trans-Venous Embolization (TVE)|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion."
215099275|NCT04785924|DRUG|Imipenem+Relebactam|Antibiotic treatment for KPC producing CRE-containing gram-negative infections
215099276|NCT05705362|PROCEDURE|Simple Crossover|Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
215099277|NCT05705362|PROCEDURE|Side branch opening|According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
215099278|NCT01237236|DRUG|LEE011|
215099279|NCT01958983|BEHAVIORAL|Music Therapy Group Session|
214407721|NCT01572077|RADIATION|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
214407722|NCT05356026|OTHER|Online postpartum follow-up|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
214407723|NCT01441778|DRUG|NSS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
214407724|NCT01441778|DRUG|BHS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
214407725|NCT03404609|DEVICE|MagPro X100 by MagVenture|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
214407726|NCT02931162|OTHER|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
214407727|NCT02931162|OTHER|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
214407728|NCT02800161|DRUG|Trehalose|Trehalose 70g/die
214407729|NCT02800161|DRUG|Maltose|Maltose 70g/die
214407730|NCT02507310|OTHER|thermostat|ambient temperature as modified by thermostat
214407731|NCT04548609|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
214407732|NCT00240643|DRUG|SB424323|
214407733|NCT04390464|DRUG|Ravulizumab|Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
214407734|NCT04390464|DRUG|Baricitinib|Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.
215012264|NCT07056426|OTHER|ESWT|"The Extracorporeal Shock Wave Therapy (ESWT) will be administered once a week for a total of four sessions. Each session will deliver 2000 pulses at a pressure of 2.5 bar and a frequency of 8 Hz using radial shock wave technology. The total energy flux density per session is planned to be approximately 200 mJ/mm².~Patients will be positioned in a supine lying position during the treatment. A generous amount of ultrasound gel will be applied to the medial tibial border and surrounding tissues to ensure effective transmission of shock waves and patient comfort.~The application of shock waves will follow the clinical focusing principle: treatment will start from the point of greatest tenderness and maximal pain on the medial tibial border, progressing in a circular motion from medial to lateral. The treatment area will typically cover a region approximately 2-4 cm in width and 4-8 cm in length."
215012265|NCT07056426|OTHER|Deep Tissue Massage|The deep tissue massage begins with the patient lying on their side, the affected leg on top, knee flexed at about 45 degrees, and the medial surface of the tibia facing upward. The sensitive line along the medial tibia is identified by palpation, and the area is prepared with petroleum jelly. The massage starts with 4-5 superficial strokes along the medial calf using the palm, followed by 2-3 deep strokes to assess muscle tone and patient tolerance. Moderate pressure is applied with the thumb perpendicular to the tibial line, moving slowly from just above the medial malleolus toward the medial tibial plateau. Then, the thumb shifts one finger width posteriorly and moves upward along the soleus muscle with similar pressure. These two steps are repeated 6-8 times, each lasting 10-15 seconds, with pain adjusted to 7-8 on the VAS scale. A 10-second rest is given between applications, and the massage ends with 4-5 superficial strokes.
215012266|NCT06898463|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|0.1 mg/kg oral melatonin was administered twice
215012267|NCT06898463|DRUG|Ketamine|0.3 mg/kg intravenous ketamine was administered during anesthesia induction.
215012268|NCT06068400|BIOLOGICAL|BCMA/GPRC5D double CAR-T|BCMA/GPRC5D double CAR-T is a new type CAR-T cells therapy for patients with Multiple Myeloma.
215012269|NCT01365572|DEVICE|Xiene V stent, Endeavor Resolute stent|for each lesion, randomized either Xience V stent or Endeavor Resolute stent
215012270|NCT04692688|DRUG|APX3330|APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
215012271|NCT04692688|DRUG|Placebo|Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
215012272|NCT03213704|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215012273|NCT03213704|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
215012274|NCT03213704|PROCEDURE|Bone Scan|Undergo a bone scan
215012275|NCT03213704|PROCEDURE|Computed Tomography|Undergo a CT scan
215012276|NCT03213704|DRUG|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
215012277|NCT03213704|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215012278|NCT03213704|PROCEDURE|Radionuclide Imaging|Undergo a MIBG scintigraphy
215012279|NCT03213704|PROCEDURE|X-Ray Imaging|Undergo an x-ray
215099280|NCT05977764|OTHER|Ultrasound|Contrast enhanced ultrasound
215099281|NCT06134167|DEVICE|Transdermal Compress Device|Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.
215099282|NCT00793169|PROCEDURE|Blood Draw|Serum levels were measured
215099283|NCT05809063|OTHER|observational|document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units
215099284|NCT01324869|BIOLOGICAL|KH902|Intravitreal injection of 0.5mg/eye/time KH902
214407735|NCT04390464|OTHER|Standard of care|Regular standard of care for COVID-19 patients
214407736|NCT05905289|OTHER|observational study|no intervention as it is an observational study
214407737|NCT04706247|OTHER|thoracic combined spinal epidural anesthesia|A combined spinal-epidural anesthesia set will be used for the block. Using the loss of resistance to saline technique, an 18 G Tuohy needle will be advanced to the T2-3 vertebral interspace with the mid-line approach. After confirming the epidural space, a 26 G pencil point spinal needle will be inserted slowly through the Tuohy needle to puncture the dura. After free flow of cerebrospinal fluid will be observed, local anesthetic wil be injected into the subarachnoid space over 15 secs. Then, an epidural catheter will be inserted into the epidural space.
214504807|NCT06524232|OTHER|Practice Facilitation (PF)|Practices will meet with practice facilitators monthly and apply tests of change using a Plan-Do-Study-Act approach, guided by the PF team. Facilitators will confirm that practices have established workflows for substance use disorder (SUD) screening and interventions and perform checks periodically to ensure progression. PF will entail: implementing protocols/algorithms for evidence-based screening and interventions, promoting decision support tools and templates to support practice workflow, optimizing electronic health record (EHR) use to pull clinical data monthly to guide the improvement process, developing patient registries (e.g., for those with SUD) to identify needed care and optimize delivery of evidence-based interventions, encouraging proactive, team-based care with assigned roles and responsibilities, and enhancing the understanding of evidence-based SUD interventions, including counseling and referral resources to ensure practices have appropriate intervention options.
215012280|NCT05136430|BEHAVIORAL|Self-Regulation strategies + large changes (SR)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on teaching self-regulation and efforts to produce a 10 lb weight loss to buffer against anticipated post-cessation weight gain. Participants will be taught the core self-regulation skills for controlling their weight. In order to produce an initial weight loss buffer, they will be instructed to self-monitor their intake, given a daily calorie goal, and taught strategies for reducing caloric intake. Structured physical activity, such as brisk walking will also be prescribed and self-monitored. During smoking cessation treatment (weeks 9-16), participants will be asked to continue to use self-regulation skills for monitoring their weight and to use a color zone system (red, yellow, green) to determine what course of action to follow based on whether changes in weight have occurred.
215012281|NCT05136430|BEHAVIORAL|Healthy Lifestyle Education (LE)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on living a healthy lifestyle. Information provided will include education on why weight gain happens while quitting smoking, principles of healthy eating (e.g., simple versus complex carbohydrates), physical activity guidelines, and other topics related to living a healthy lifestyle. Participants can choose to use the healthy lifestyle information and education provided however they would like. Participants will not be asked to use self-regulation strategies during either part of the 16-week program.
215012282|NCT05136430|OTHER|Smoking Cessation Treatment|The second 8 weeks (weeks 9-16) of the 16-week program will include weekly group counseling sessions focused on smoking cessation. The smoking cessation treatment provided will be the same in both arms of the study. In preparation of quitting, nicotine replacement therapy lozenges will be provided for 3 weeks prior to quitting (weeks 6-8). A group quit day will occur on week 9. During the smoking cessation portion of treatment (weeks 9-16), participants will be provided with combination nicotine replacement therapy (patches + lozenges) and daily supportive text messages.
215012283|NCT03539705|OTHER|There is no intervention|There is no intervention
215012284|NCT05860400|BEHAVIORAL|Healthy life style|Healthy diet, regular exercise, and quitting smoking
215012285|NCT05860400|DRUG|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
215012286|NCT05860400|DRUG|Immunosuppressive therapy|Glucocorticoids and/or immunosuppressive agents
215012287|NCT05860400|PROCEDURE|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
215012288|NCT05860400|DRUG|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
215012289|NCT04876950|COMBINATION_PRODUCT|Virtual care with remote automated monitoring|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
215012290|NCT05379985|DRUG|RMC-6236|Oral Tablets
215012291|NCT00816673|DRUG|placebo Circadin|Placebo tabs of Prolonged release melatonin
215012292|NCT00816673|DRUG|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
215012293|NCT05516966|DRUG|HRS9531|Administrated SC
215012294|NCT05516966|DRUG|Placebo|Administrated SC
215012295|NCT05516966|DRUG|Dulaglutide Injection|Administrated SC
215012296|NCT04837846|OTHER|Differing Tube Voltage Administration|Subjects will undergo CCTA utilizing a scan and contrast media injection protocol that will be tailored to individual body habitus.
215012297|NCT06035328|OTHER|Wheat (Four times per week)|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
215012298|NCT04825587|PROCEDURE|Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.|By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
215012299|NCT05228015|DRUG|IK-930|tablets for oral administration
215012300|NCT05228015|DRUG|Osimertinib|tablets for oral administration
215012301|NCT03554473|DRUG|M7824|Arm A \& B: 2400mg intravenous (IV) over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
215012302|NCT03554473|DRUG|Topotecan|Arm B: 1 mg/m(2) intravenous (IV) over 30 minutes days 1-5 on a 3-week cycle.
214407738|NCT04422925|PROCEDURE|Living Donor Hepatectomy|On living donor hepatectomy (preoperative), the first following day of surgery, 3rd day, and 7th day, blood will be taken for the measurement of S100β, NSE, and GFAP levels in the postoperative period. The plasma of the blood taken will be separated and stored at -800C. Values will be measured by the ELISA method. During the hospitalization, the delirium status of the patients will be evaluated with the delirium evaluation scale (Delirium Rating Scale-Revised - 98 Turkish version). Functional and cognitive information and other results will be collected at each follow-up point.
214407739|NCT05249179|OTHER|Pacifier|Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.
214407740|NCT05249179|OTHER|Oral stimulation|Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
214407741|NCT06183047|DIAGNOSTIC_TEST|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
214407742|NCT00006265|DRUG|ara-C|3 g/sq m IV infusion over 3 hours Days 1-5
214407743|NCT00006265|BIOLOGICAL|gemtuzumab ozogamicin|9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, \& IV); \& D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) \& D 14 (Cohort II)
214407744|NCT00618358|DEVICE|Vascular Sealant System|The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
214407745|NCT00618358|OTHER|Gelfoam/Thrombin|
214407746|NCT04612595|OTHER|serum urea nitrogen to creatinine ratio|According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.
214407747|NCT01674569|DRUG|X-82 oral|X-82 oral for 24 weeks or until unacceptable toxicity develops
214407748|NCT01674569|DRUG|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
214407749|NCT01454362|DRUG|Nicotine|Inhalation of nicotine.
214407750|NCT03244566|DIAGNOSTIC_TEST|positron emission tomography|patients who had esophagectomy with 3-field lymphadenectomy underwent examination of positron emission tomography prior to surgery within 2 weeks.
214407751|NCT02609555|PROCEDURE|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
214407752|NCT02419521|DEVICE|Resolute Onyx Stent - 2.25 mm - 4.0 mm|
214407753|NCT02267980|DRUG|Sevoflurane|Inhalation anesthetic agent
215012303|NCT03554473|DRUG|Temozolomide|Arm C and progressive disease patients on Arm A: 200 mg/m(2) by mouth (PO) days 1-5 on a 4-week cycle.
214407754|NCT02267980|DRUG|Ketamine|Intravenous anesthetic agent
214407755|NCT02267980|DRUG|Saline|Isotonic solution for placebo group
214407756|NCT03054220|DRUG|Dextromethorphan 5 MG|
214407757|NCT03054220|DRUG|Tramadol 10 mg|
214407758|NCT03054220|DRUG|Duloxetine 60mg|
214407759|NCT03054220|DRUG|Paroxetine 20 mg|
214407760|NCT06416280|OTHER|Assessment of the TRiP(cast) score|"In patients presenting to the emergency department with trauma to a lower limb, the TRiP(cast) score is assessed in accordance with the recommendations. If the patient does not object. The attending physician will then be asked to fill in his implicit assessment of the risk of venous thromboembolism on a paper CRF and then to complete his assessment of the TRiP(cast) score. He will then be free to decide whether or not to anticoagulate the patient.~At the same time, a doctor not involved in the patient's care will assess the TRiP(cast) score and record it on a paper CRF. The second doctor's assessment will be independent and will have no impact on the patient's management.~The CRFs will then be analysed and stored. Data will be anonymised during data collection and each patient will be assigned an anonymity number."
215012304|NCT03554473|DIAGNOSTIC_TEST|EKG|Screening and baseline.
215012305|NCT03554473|DIAGNOSTIC_TEST|CT scan|Computed tomography (CT) scan performed at Screening and after every 2 cycles (6 weeks) per Study Calendar for Arm B 3.5.2, Arm B 3.5.2, and/or Arm C 3.5.3 as applicable.
215012306|NCT03554473|DIAGNOSTIC_TEST|PET scan|Positron emission tomography (PET) not mandatory - If a computed tomography (CT) scan is not sufficient to assess response, a PET scan may be added per Study Calendar for Arm A 3.5.1, Arm B 3.5.2, and/or Arm C 3.5.3 as applicable.
215012307|NCT03554473|DRUG|Acetaminophen|For infusion related reaction, 500-1000 mg by mouth (PO) prior to infusion.
215012308|NCT03554473|DRUG|Antihistamines|As medically indicated.
215012309|NCT03554473|DRUG|Diphenhydramine|For infusion related reaction, 50 mg by mouth (PO) prior to infusion.
214407761|NCT02248142|DRUG|Pramipexole|
214407762|NCT03881631|BEHAVIORAL|Mindfulness Based Stress Reduction Program|Group-based intervention
214407763|NCT03881631|BEHAVIORAL|Living Well Program|Group-based intervention
214407764|NCT03956199|PROCEDURE|pulpotomy|removal of the pulp from pulp chamber
214407765|NCT03956199|PROCEDURE|Root canal treatment|Removal of at the entire content of the root canal system and root canal obturation
214407766|NCT05092932|OTHER|Normal Foot Force|LoadSol Insoles will be inserted into the participants shoes. The device measures the pressure distribution on the bottom of the foot. Participants will then be asked to walk normally, use crutches, use a walker, and use a wheeled knee scooter. The pressure placed throughout the foot will be analyzed and compared under different conditions. This testing will take approximately 10 minutes.
214407767|NCT03084861|DRUG|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
214407768|NCT03084861|DRUG|Conventional treatment|"1. Artificial tears: Lubristil ®~2. Therapeutic Contact lens: Air Optix Night\&Day"
215012310|NCT03554473|DRUG|Dexamethasone|As medically indicated.
215012311|NCT03554473|DRUG|Epinephrine|As medically indicated.
214407769|NCT04173845|DRUG|Tianqi Pingchan Granule|Tianqi Pingchan Granule are given twice a day
214407770|NCT04173845|DRUG|Tianqi Pingchan Granule Placebo|Tianqi Pingchan Granule Placebo
214407771|NCT04651244|DIAGNOSTIC_TEST|MRI|Gold standard for identifying inflammatory changes in patients with acute pyelonephritis
214407772|NCT04651244|DIAGNOSTIC_TEST|Ultrasound performed by a radiologist|US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).
214407773|NCT04651244|DIAGNOSTIC_TEST|Point of care ultrasound|Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
214407774|NCT01119703|BIOLOGICAL|Tetanus & Diphtheria booster vaccine (Td)|Tetanus \& Diphtheria booster vaccine (Td), single intramuscular dose
215099285|NCT02489669|DEVICE|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
215099286|NCT05311267|OTHER|Action observation training|Subject is asked to observe videos with motor contents
215099287|NCT04489082|DEVICE|Near Infrared Laser Stimulation|10 minutes of transcranial near infrared laser stimulation
215099288|NCT00680797|DRUG|Testosterone|Testosterone gel
215099289|NCT00680797|DRUG|Estrogen|Estrogen patch
215099290|NCT06208774|PROCEDURE|Ultrasound-guided PENG or ISBP block|The diaphragmatic excursion will be measured in the supine position before the block and after surgery. A curvilinear US probe (5-7 MHz) will be placed at the subcostal area in the anterior axillary line, below the costal margin of the eighth and ninth ribs. The probe will be directed medially, cephalad, and dorsally to make the US beam reach the posterior third of the diaphragm perpendicularly. The probe will then be scanned along the long axis of the intercostal spaces, using the liver as the acoustic window on the right side and the spleen as on the left side. M-mode sampling line will be positioned perpendicularly to the diaphragm, and the diaphragmatic excursions could be measured during quiet and deep breathing.The measurement will be repeated three times, and the average value will be taken. After measurement of diaphragmatic excursion, patients will receive either a PENG block or an LV-ISBP block before induction of general anesthesia.
215012312|NCT05893030|PROCEDURE|anesthesia guided by sedation and analgesia monitoring|"Anesthesia guided by sedation and analgesia monitoring The level of sedation will be monitored by~* Monitoring System BIS™ : Bispectral index (BIS) between 45 and 60 AND Suppression Ratio (SR) at 0;~* or SedLine® Sedation Monitor : Patient State Index (PSi) between 25 and 50;~* or Entropy Sensor™: State entropy (SE) between 45 and 60 AND Burst Suppression Ratio (BSR) at 0;~and the level of nociception by :~* Nociception monitor PMD-200® : Nociception Level (NoL) between 10 and 25."
215012313|NCT05893030|PROCEDURE|anesthesia performed according only to the clinical judgment of the anesthetist as usual practice|Administration of anesthesia will be performed according to the clinical judgment of the anesthetist as usual practice without sedation and analgesia monitoring
215012314|NCT05882903|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
215012315|NCT05882903|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
215012316|NCT02704832|OTHER|Geriatrician Intervention|Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
215012317|NCT01501513|DRUG|PEG-3350 based bowel preparation|solution for oral administration prior to colonoscopy
215099291|NCT04680975|DRUG|Belumosudil|10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
214407775|NCT01119703|BIOLOGICAL|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM \[Hepatitis A Inactivated \& Hepatitis B (Recombinant) Vaccine\], intramuscular, two doses of standard three dose regimen (opposite arms)
215099292|NCT01171391|DRUG|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
215099293|NCT01171391|OTHER|Placebo|Placebo on Day 1
214407776|NCT01119703|BIOLOGICAL|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
214407777|NCT06418906|OTHER|Self-reported questionnaires|After participants agree to participate in this study, they will first fill out the set of questionnaires once. After two weeks, the research team will send them reminders to fill out the same set of questionnaires again.
214407778|NCT00279058|PROCEDURE|Immunotherapy treatment for melanoma|
214407779|NCT06478043|DRUG|ivonescimab|20mg/kg, IV, D1, Q3W
214407780|NCT06478043|DRUG|irinotecan liposome|56.5mg/m\^2, IV, D1, Q2W
214407781|NCT04623723|OTHER|PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips
215012318|NCT01501513|DRUG|BLI800 approved preparation regimen|solution for oral administration prior to colonoscopy
214407782|NCT04623723|OTHER|Conventional (FS-407, EMS® Piezon, Switzerland)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)
214407783|NCT02729324|DRUG|Medical Radiation Protectants (FORRAD®)|Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
214407784|NCT02729324|DRUG|Trolamine (Biafine)|Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
214407785|NCT01380119|BIOLOGICAL|V7|experimental arm
214407786|NCT01380119|OTHER|placebo|placebo pill
214407787|NCT00908674|DRUG|Cyproterone acetate (Androcur)|"The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).~Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.~Administration period: 12 months."
214407788|NCT02096003|DRUG|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
214407789|NCT02096003|DRUG|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
214407790|NCT02078830|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
214407791|NCT02078830|DEVICE|Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
215012319|NCT01501513|DRUG|BLI800 investigational preparation regimen|solution for oral administration prior to colonoscopy
215012320|NCT03834116|DEVICE|Inspiratory muscle training|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
215012321|NCT05966194|DRUG|RRx-001|RRx-001 for injection (4 mg or 8 mg)
215012322|NCT05966194|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy of up to 72 Gy
215012323|NCT05966194|DRUG|Cisplatin for injection 100 mg/m2|Cisplatin for injection 100 mg/m2
215012324|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate (Formulation 725: Water soluble.Contains sorbitol)
215012325|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Oil based tincture formulation|30 mg CBD isolate in MCT oil,1:1 ratio of CBD to Medium Chain Triglycerides oil. (Formulation 088: Not water soluble. Contains medium chain triglyceride coconut oil.)
215012326|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation|10% CBD Gum Arabic, maltodextrin base(Formulation 126: Water soluble. Contains gum arabic and maltodextrin)
215012327|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, sorbitol base formulation|10% CBD Gum Arabic, sorbitol base (Formulation 213: Water soluble. Contains gum arabic and sorbitol)
215012328|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Isolate in water formulation|Pure CBD as crystalline powder (\>99% purity) (Formulation 625 Not water soluble)
215012329|NCT04971837|DIETARY_SUPPLEMENT|CBD matching Placebo|Matching Placebo
215012330|NCT04618965|DRUG|control group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
215012331|NCT04618965|DRUG|Intrathecal dexmedetomidine|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
214407792|NCT02923128|DRUG|Dexmedetomidine|Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
214407793|NCT02923128|DRUG|Sufentanyl|Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
214407794|NCT02923128|DRUG|Saline|Saline is used to dilute other drugs
214407795|NCT00438906|PROCEDURE|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
214407796|NCT00438906|DRUG|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
214407797|NCT03610633|DRUG|Oxytocin|The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
214407798|NCT03610633|DRUG|Placebo|Saline solution.
214407799|NCT01802203|DEVICE|truFreeze Spray Cryotherapy|spray cryotherapy
214407800|NCT06001684|BIOLOGICAL|IBR854 Cell Injection|The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
215012332|NCT04618965|DRUG|Intravenous dexmedetomidine|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
215012333|NCT03004131|DRUG|Azelastine hydrochloride + fluticasone propionate nasal spray|
214407801|NCT04517994|BEHAVIORAL|Active Treatment|See arm description.
214407802|NCT04517994|BEHAVIORAL|Supportive Treatment|See arm description.
215012334|NCT03004131|DRUG|Placebos|
214407803|NCT04670575|PROCEDURE|Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL|Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
214407804|NCT01460992|PROCEDURE|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
214407805|NCT03795701|DRUG|Saxenda®|Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
215012335|NCT03004131|DRUG|fluticasone propionate nasal spray + loratadine|
215012336|NCT06963970|OTHER|Remote Community Health Worker support|trained/certified community health worker supporting care partner remotely
215012337|NCT06964152|DIAGNOSTIC_TEST|Computational electrocardiography and cardiac computed tomography mapping|Use of non-invasive computational ECG and cardiac CT models to localize arrhythmia origins
215012338|NCT06964178|DEVICE|Experimental: antimicrobial photodynamic therapy (aPDT) after extraction of third molar|In the test, a photoactive substance activated with laser light (20 mW, 660 nm) was applied to the post-extraction site for 60 seconds before suturing, to promote healing and disinfection
215012339|NCT06160440|DRUG|SC1011|Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
215012340|NCT05064670|BEHAVIORAL|Exercise|A twice weekly, 3-month supervised exercise program of whole body resistance training using body weight and a resistance band, and moderate to high intensity aerobic activities, consisting of a consecutive series of timed exercises performed one after the other (14-18 on the Borg scale). Classes are conducted live in groups through Microsoft Teams. Participants will not receive any contact or exercise support in the 3-month follow-up period following the initial 3-month intervention
215012341|NCT06322862|OTHER|Indocyanine green|Intraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses
215012342|NCT05348694|DIETARY_SUPPLEMENT|Pendulum WBF-038|"All bacteria contained in Pendulum WBF-038 are commensal organisms that have been repeatedly documented to inhabit the human gastrointestinal tract under normal circumstances. Pendulum's WBF-038 is a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
215012343|NCT05348694|DIETARY_SUPPLEMENT|Pendulum Placebo|Pendulum placebo capsules containing magnesium stearate
215012344|NCT05691439|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
215012345|NCT05691439|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
215012346|NCT00382070|DRUG|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
215012347|NCT00382070|OTHER|Placebo|Placebo tablet taken orally once daily for 5 years
215099294|NCT05522257|DIAGNOSTIC_TEST|[18F]-JK-PSMA-7 PET/CT scan|A \[18F\]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). We expect to make a \[18F\]-JK-PSMA-7 PET/CT scan in 15 out of 60 patients per cohort.
215099295|NCT03887715|DEVICE|Vagus Nerve Stimulation (VNS)|VNS is an implantable device that delivers stimulation to the vagal nerve.
215099296|NCT04857957|DRUG|Oral dose CNTX-6016 or oral dose Placebo|CNTX-6016 or Placebo
214407806|NCT03795701|OTHER|Placebo|Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
214407807|NCT03243656|DRUG|Eltrombopag|An oral thrombopoietin receptor agonist
214407808|NCT04069546|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric device with cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times.
215012348|NCT06114550|OTHER|High intensity resistance training|The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.
215012349|NCT06114550|OTHER|Low intensity resistance training|For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.
215099297|NCT06343909|OTHER|Hip abductor strengthening exercise|in this group 15 participants will perform hip abductor streghtning along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 reputations will be performed.
215012350|NCT04947267|DRUG|3% Mepivacaine Hydrochloride|1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
215012351|NCT04947267|DRUG|2% Mepivacaine with 1:100,000 epinephrine|1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
215012352|NCT01552889|BEHAVIORAL|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
215012353|NCT05197621|BIOLOGICAL|mRNA COVID-19 vaccine (Pfizer or Moderna)|mRNA vaccine received at any time during pregnancy course
215012354|NCT04908527|BEHAVIORAL|Walking to OR|Patients, after being prepared for the OR, walk to the operating room
214407809|NCT01763047|DEVICE|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
215012355|NCT00312962|BEHAVIORAL|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
215012356|NCT00312962|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
215012357|NCT03083730|OTHER|Narrow band UVB treatment (NB-UVB)|NB-UVB light treatment NB-UVB light treatment for 3x/week for 12 weeks (36 visits)
215099298|NCT06343909|OTHER|Intrinsic foot muscle strengthening along with conventional exercises|in this group 15 participants will perform Intrinsic foot muscle strengthening along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 repitations will be performed.
215012358|NCT06633406|OTHER|Age-appropriate Wechsler Intelligence Test|"2.5-6 years: Wechsler Preschool and Primary Scale of Intelligence for children (WPPSI IV)~7-16 years: Wechsler Intelligence Scale for Children (WISC V)~\>17 years: Wechsler Adult Intelligence Scale (WAIS IV)"
215012359|NCT06633406|OTHER|Disruptive Behavior Disorders Rating Scale|Dutch version of the Disruptive Behavior Disorders Rating Scale
215012360|NCT06633406|OTHER|Social Responsiveness Scale|"3-18 years: social responsiveness scale 2 (SRS-2)~\>19 years: Social Responsiveness Scale - Adult version (SRS-A)"
215012361|NCT04088357|DRUG|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
215012362|NCT04088357|DRUG|Topical Vehicle Gel|TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
215012363|NCT05080543|DRUG|Albumin 20% and terlipressin|Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
215012364|NCT04148755|PROCEDURE|Endoscopic ultrasound guided fine needle aspirate|All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions
215012365|NCT05715346|DRUG|LEV102 1.0%|Oxymetazoline ophthalmic gel
215012366|NCT05715346|DRUG|LEV102 2.0%|Oxymetazoline ophthalmic gel
215012367|NCT05715346|DRUG|Vehicle|Vehicle ophthalmic gel
215012368|NCT03843216|OTHER|observation|patients not treated
215012369|NCT03843216|OTHER|Physiotherapic scoliosis specific exercise|Specific exercise according to the SEAS (Scientific Exercises Approach to Scoliosis) protocol
214407810|NCT01763047|DEVICE|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
214407811|NCT01784380|DRUG|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
214407812|NCT00611065|DEVICE|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
214407813|NCT04241796|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
214407814|NCT01112735|BIOLOGICAL|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
214407815|NCT01112735|PROCEDURE|Standard of care|Standard of care
214407816|NCT05647356|DRUG|Bicalutamide 50 mg|Bicalutamide at a dose of 50mg once daily for 28 days.
214407817|NCT00205894|DEVICE|bion microstimulator|
215012370|NCT03843216|DEVICE|brace|different kind of braces being elastic, rigid or very rigid. All devices are custom made. The hours of application per day varied from 18 to 24h.
215012371|NCT04685122|PROCEDURE|Phacoemulsification and intraocular lens implantation for cataract|Phacoemulsification and intraocular lens implantation for cataract
215099299|NCT06290661|DEVICE|Active electrostimulation|Maintain the electrical stimulation state, and according to the patient's feeling to set the appropriate stimulation parameter range (pain relief and no obvious numbness and discomfort), the programme will be written into the patient's self-control remote control, by the patient according to their own pain situation for the independent control of the stimulation current.
215099300|NCT06290661|DEVICE|Placebo electrostimulation|No actual electrostimulation
214407818|NCT02782988|OTHER|olfactory tests, otoacoustic emissions (OAE)|Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
214407819|NCT00846781|DRUG|Denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
214407820|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
214407821|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
214407822|NCT00438425|DIETARY_SUPPLEMENT|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
215012372|NCT00284934|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
214407823|NCT06188260|DRUG|Systane COMPLETE Lubricant Eye Drops|Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant
214407824|NCT00916006|DRUG|PEP005 Gel|0.015%, three day treatment
214407825|NCT00916006|DRUG|Vehicle gel|Vehicle gel, three day treatment
214407826|NCT02550054|DRUG|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
214407827|NCT02550054|DRUG|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
215012373|NCT00284934|DRUG|Tacrolimus|
215012374|NCT00284934|DRUG|Corticosteroids|At a dose of at least 5 mg/day.
215012375|NCT00071331|DRUG|Tolvaptan|
215012376|NCT01291875|PROCEDURE|non-surgical periodontal treatment|Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
215012377|NCT01291875|PROCEDURE|Supragingival biofilm control|Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
215012378|NCT03957057|DRUG|Iron Carboxymaltose|Intravenous iron carboxymaltose application
215012379|NCT03957057|DRUG|Iron Isomaltoside|Inravenous iron isomaltoside application
214407828|NCT03381391|BEHAVIORAL|Personalized Feedback Intervention|The current intervention included personalized feedback regarding their alcohol consumption, alcohol-related consequences, gender-specific normative drinking comparisons, personal risk factors (e.g., dependence symptoms, family history of alcoholism), and alcohol expectancies. The intervention also included didactic material related to alcohol (e.g., effects at different BAC levels, tolerance) and drinking moderation strategies. The feedback was presented graphically in a feedback report with the individual's information.
215099301|NCT03179774|DEVICE|Endovascular revascularization|All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
215099302|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Cognitive Behavioral Therapy|10-session LGBTQ-affirmative psychotherapy using CBT techniques
215099303|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Treatment-As-Usual|10-session LGBTQ-affirmative psychotherapy
214407829|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
214407830|NCT01121874|PROCEDURE|Ligament Reconstruction with Tendon Interposition (LRTI)|commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
215099304|NCT06287515|DEVICE|Stereotactic Radiosurgery|Given by Radiation Therapy
215099305|NCT06801236|DRUG|ACE-232 tablets|ACE-232 tablets will be administered orally daily as a continuous regimen together with Dexamethasone and Fludrocortisone. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
215099306|NCT06024590|DEVICE|Irrisept|Standard of care wound treatment with 150 mL of IrriseptTM irrigation of the wound at each follow up visit.
214407831|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
214407832|NCT05854628|PROCEDURE|skin biopsy|Skin biopsies will be obtained at different time points.
214407833|NCT03529864|OTHER|Exercise Therapy|
214407834|NCT03127345|DRUG|Omegaven|Intravenous omega 3 fatty acid administration
214407835|NCT03127345|DRUG|Intralipid|Standard of care
214407836|NCT00263679|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus and pertussis|
214407837|NCT05536284|DRUG|Bisoprolol Fumarate Tablets|Antihypertensive drug used for acute coronary syndrome patients
214407838|NCT06339905|PROCEDURE|Sonic Activation with EndoActivator|sonic activation
214407839|NCT06339905|PROCEDURE|Control Needle Irrigation|control group
214407840|NCT03999944|DEVICE|positive airway pressure system|Positive Airway Pressure System
214407841|NCT03033732|DRUG|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
215099307|NCT06024590|DEVICE|Saline|Standard of care wound treatment with 150 mL ration of Normal saline irrigation of the wound at each follow up visit
215099308|NCT06172075|BEHAVIORAL|Brief video intervention (Black Woman)|A brief social contact-based video. The video presented a young Black woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Black woman with depression and raising themes of recovery and hope.
214407842|NCT03033732|DRUG|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
214407843|NCT03605329|OTHER|to explore the severity of NAC in case of OSAS|"After overnight polysomnography, cardiovascular autonomic neuropathy will be evaluated by different methods: study of HRV, cardiovascular autonomic reflex test (Ewing), measurements of urinary levels of catecholamines and measurements of sweat gland dysfunction using Sudoscan.~The severity of CAN will be evaluated in T1D patients with moderate to severe OSAS (apnea hypopnea index (IAH) ≥15 / hour) compared to T1D patients with IAH \<15 / hour."
214407844|NCT00479180|BIOLOGICAL|Vascugel|One time implant on the day of surgery
214407845|NCT00479180|BIOLOGICAL|Placebo Comparator|One time implant on the day of surgery
214407846|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm ON|The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.
214407847|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm OFF|
214407848|NCT06280729|OTHER|AI-Analyis|The study will investigate classification (ie logistic regression, decision tree, random forest, support vector machine, K nearest neighbour, naive bayes) ML models and treatment effect estimation ML models (T-learner, X-learner..).
214407849|NCT03771326|BIOLOGICAL|Kisspeptin-10|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
214407850|NCT04315220|OTHER|Corestability training|"Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats."
214407851|NCT04315220|OTHER|No Intervention|No Intervention
214407852|NCT04749693|DEVICE|DBLG1 System|Use of DBLG1 System in real life condition
214407853|NCT02763553|DIETARY_SUPPLEMENT|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
215099309|NCT06172075|BEHAVIORAL|Brief video intervention (Latinx Woman)|A brief social contact-based video. The video presented a young Latinx woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Latinx woman with depression and raising themes of recovery and hope.
215099310|NCT06172075|BEHAVIORAL|Brief video intervention (White Woman)|A brief social contact-based video. The video presented a young White woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a White woman with depression and raising themes of recovery and hope.
215099311|NCT06172075|BEHAVIORAL|Vignette Control|A brief vignette control condition with a script about a young woman who describes her struggles with depression and raises themes of recovery and hope.
215099312|NCT04368702|RADIATION|Viewray MRIdian® Linac|MR-image guided radiation will be administered per disease site standards.
215099313|NCT06152341|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
215099314|NCT02546661|DRUG|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
215012380|NCT03957057|DRUG|Ferrous sulphate|Oral ferrous sulphate application
214407854|NCT02763553|DIETARY_SUPPLEMENT|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
214407855|NCT02980380|OTHER|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication."
215099315|NCT02546661|DRUG|MEDI4736|MEDI4736
215099316|NCT02546661|DRUG|Olaparib|MEDI4736 (durvalumab) + Olaparib
215099317|NCT02546661|DRUG|AZD1775|MEDI4736 (durvalumab) + AZD1775
215099318|NCT02546661|DRUG|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
215099319|NCT02546661|DRUG|AZD9150|MEDI4736 (durvalumab) + AZD9150
215012381|NCT00795405|BEHAVIORAL|Exposure to sporting events|Exposure to sporting events
215012382|NCT00795405|BEHAVIORAL|No exposure to sporting events|No exposure to sporting events
215099320|NCT02546661|DRUG|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
215099321|NCT04673916|DRUG|Healing evaluation|Treatments were topically applied for 5 days
215099322|NCT03150784|OTHER|EPIC Club|Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
215099323|NCT01750359|DRUG|curcumin|500 mg/day for 6 week
215099324|NCT04721340|OTHER|Test Group|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
215099325|NCT04721340|OTHER|Control Grup|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
214407856|NCT03061344|BIOLOGICAL|DVIU treated with liquid buccal mucosal graft|DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
214407857|NCT04161222|OTHER|Experimental group|Experimental group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
214407858|NCT04161222|OTHER|Control group|Control group will perform a typical warm-up of competitive football
215012383|NCT05520177|DRUG|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
215012384|NCT05520177|DRUG|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
215012385|NCT04654052|DRUG|Clopidogrel|Clopidogrel during 11 months
215012386|NCT04654052|DRUG|Previous treatment|non-intervention
215012387|NCT00004485|DRUG|cyclosporine|
215012388|NCT00004485|DRUG|fludarabine|
215099326|NCT00226135|DRUG|lithium or lamotrigine|
215099327|NCT04081272|DRUG|Sodium Chromate Cr51|Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
215012389|NCT00004485|DRUG|mycophenolate mofetil|
215012390|NCT00004485|PROCEDURE|Bone Marrow Transplantation|
215012391|NCT01142687|DIETARY_SUPPLEMENT|dihydrocapsiate capsule|"* Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner"
215012392|NCT02454764|DRUG|Tenofovir + Interferon alpha 2b|
215099328|NCT00219960|DRUG|North American Ginseng (Panax Quinquefolius)|
215099329|NCT01370759|OTHER|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
215099330|NCT00390663|PROCEDURE|Nasal Cautery|
215099331|NCT05714644|OTHER|FIT kit Screening Test|FIT kit mailed to the patient's home
215099332|NCT05714644|OTHER|Cologuard Screening Test|Cologuard test mailed to the patient's home
215099333|NCT06232577|DRUG|Hydrocodone|Given by PO
215099334|NCT06232577|DRUG|Tramadol|Given by PO
215099335|NCT06232577|DRUG|Oxycodone|Given by PO
215099336|NCT04615884|DIETARY_SUPPLEMENT|Chinese herbs formula: Shu Yu Wan|Shu Yu Wan Formula is a combination of 23 natural chinese herbs.This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.
215012393|NCT02454764|DRUG|Tenofovir disoproxil Fumarate|
215012394|NCT01172301|DIETARY_SUPPLEMENT|Essential amino acid intake + Leucine vs total AA supplement|7 g as bolus
215012395|NCT05328895|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day."
215012396|NCT06042660|OTHER|the prevalence of comorbid conditions|analysis of history of comorbidities at the time of CML diagnosis
215012397|NCT01245751|BIOLOGICAL|Zoster Vaccine, Live|Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
214407859|NCT00598013|DRUG|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
214407860|NCT02616367|DRUG|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
214407861|NCT02616367|DRUG|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
214407862|NCT00870259|DIETARY_SUPPLEMENT|Optifast VLCD|Meal replacement, three times daily for 8 weeks
214407863|NCT01787994|GENETIC|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.|
214407864|NCT03518983|DEVICE|Dornier Aries2 device|The Dornier Aries2 device and will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft and the 2 crura(two sites).
215012398|NCT04686409|BIOLOGICAL|COVID-19 vaccines|Participants will be vaccinated with one of the approved COVID-19 vaccines
215012399|NCT05788328|DRUG|Dabigatran etexilate (DE)|Dabigatran etexilate (DE) as oral capsule
215012400|NCT05788328|DRUG|Rosuvastatin|Rosuvastatin as oral tablet
215012401|NCT05788328|DRUG|PF-07081532|PF-07081532 as oral tablets
215012402|NCT02227264|DRUG|Cinacalcet|Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
215012403|NCT02227264|PROCEDURE|parathyroid adenomectomy|surgical removal of pathologic parathyroid tissue
215012404|NCT04644757|OTHER|Music Listening|The study will employ an individual receptive relaxation music method with participants selecting music based on their preference from a selection of various styles from the MUSIC CARE© app. The music intervention will last 20 minutes per session and will be administered twice daily for 4 consecutive days. Participants will be given an electronic tablet with the MUSIC CARE© app loaded on it and trained on how to access the app to select their preferred style of music.Participants will be instructed to use the provided headphone during all interventions and to sit in a quiet area while wearing an ocular mask to avoid distractions.The PI will remotely monitor each of the music intervention sessions in real-time monitoring via a secured video conferencing interface to ensure adherence to study protocol.
215012405|NCT00882388|DRUG|aspirin|aspirin 100 mg qd for 7 days
215012406|NCT00882388|DRUG|celecoxib|celecoxib 200 mg bid \* 7 days
215099337|NCT04615884|OTHER|Placebo capsules|Placebo
215012407|NCT00882388|DRUG|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
215012408|NCT00882388|DRUG|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
215012409|NCT00882388|DRUG|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
215012410|NCT05082155|DRUG|Bupivacaine 0.25%|Bupivacaine 0.25% will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
215099338|NCT02702414|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
214407865|NCT03518983|DEVICE|Dornier Aries2 device (sham probe)|The Dornier Aries2 device and will be used for the purpose of the study but the active probe will be replaced by an identical sham probe.
214407866|NCT00062062|DRUG|carboplatin|
214407867|NCT00062062|DRUG|gefitinib|
214407868|NCT00062062|DRUG|paclitaxel|
214407869|NCT03693755|PROCEDURE|In-plane Group|Placement of femoral nerve catheter under ultrasound control
214407870|NCT03693755|PROCEDURE|Out-of-plane Group|Placement of femoral nerve catheter under ultrasound control
214407871|NCT01594060|DRUG|Insulin, regular - act rapid|4 shots of regular insulin: 3 before meals and one at bedtime.
214407872|NCT01594060|DRUG|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
214407873|NCT03452306|DRUG|Metformine|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition"
214407874|NCT03452306|DRUG|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition"
214407875|NCT03452306|DRUG|Metformin|"Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
214407876|NCT03452306|DRUG|Glucophage® Long|"Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
214407877|NCT04766437|DRUG|Prasugrel 10mg|Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
215012411|NCT05082155|DRUG|Normal Saline|Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
215012412|NCT05014230|DIETARY_SUPPLEMENT|Open Placebo|Zeebo
215012413|NCT05014230|OTHER|Opioid medication as part of standard care|Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
215099339|NCT03291392|GENETIC|Gene expression or biomarkers exploration|
215099340|NCT05746156|DIAGNOSTIC_TEST|lymphatic mapping|"1. Peritumoral injection of \[99mTc\]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~2. Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine."
214407878|NCT04766437|DRUG|Ticagrelor 90mg|Twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
215012414|NCT02082483|OTHER|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
214407879|NCT06389318|DRUG|buccal midazolam +oral placebo syrup|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
214407880|NCT06389318|DRUG|oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
215099341|NCT02271945|DRUG|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
215099342|NCT02271945|DRUG|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
215012415|NCT04545138|OTHER|cognitive training combine treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight), and ensures that patients can be cognitively trained at the same time. The cognitive training tasks will be projected on the screen and the participant have to answer the task orders during treadmill training simultaneously.
215012416|NCT04545138|OTHER|Treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight).
215012417|NCT02797535|PROCEDURE|Endoscopy procedures|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
215012418|NCT02357485|BIOLOGICAL|ADSC|Single injection of ADSC
215012419|NCT04209842|DEVICE|gastric balloon|non surgical weight loss via placement of gastric balloon
215012420|NCT03874403|PROCEDURE|DSA|The changes on DSA on NIVATS and VATS
215012421|NCT02459925|BEHAVIORAL|CBT- Mental Health Program|Manualized Stress Management class; brief individual behavioral counseling.
215012422|NCT02459925|BEHAVIORAL|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
215012423|NCT00145327|DRUG|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
215012424|NCT00145327|DRUG|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
215099343|NCT02271945|DRUG|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
215099344|NCT03442582|BIOLOGICAL|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
215012425|NCT00661154|DRUG|Bevacizumab|2-12microCi IV injection
215099345|NCT02343718|DRUG|Vinblastine|
215012426|NCT05881330|DEVICE|ArtiAid Intra-articular Injection|Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
215012427|NCT05931900|DEVICE|moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients|Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
215099346|NCT02343718|DRUG|Temsirolimus|
215012428|NCT02802865|DRUG|Clomiphene|
215012429|NCT02802865|DRUG|Letrozole|
215012430|NCT05071833|DIETARY_SUPPLEMENT|Peppermint oil.|Peppermint oil.
215012431|NCT05071833|OTHER|Placebo|Placebo
215012432|NCT06458166|OTHER|Assessment of low frequency fatigue using low frequency eletrical stimulation|Pre-programmed muscle electrical stimuli will be applied via Myocene® software using 3 electrodes: 1 cathode (5 x 10 cm) placed transversely over the proximal quadriceps femoris, and 2 anodes (5 x 5 cm) over the distal vastus medialis and vastus lateralis. Sixteen sets of stimuli will be administered with 5 seconds between sets. Each set consists of a single pulse, a train of 5 stimuli at 20 Hz, and a train of 18 stimuli at 120 Hz, with 1-second intervals between. The stimulation intensity starts at 25 mA and increases by 1 mA per set, reaching 40 mA in the final set. The Myocene® software calculates the ratio of low- to high-frequency evoked forces within each set. The outcome (Powerdex) is the median value of these 16 ratios for each leg. This evaluation will be conducted on both legs, taking 2 minutes per leg.
215012433|NCT05051358|PROCEDURE|Therapeutic Endoscopic Ultrasound|Therapeutic Endoscopic Ultrasound or Interventional Endoscopy for Gastrointestinal Indications
215099347|NCT05162469|DRUG|SHR-1909 injection|SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
215099348|NCT00910169|OTHER|inpatient treatment|Hospitalisation modalities are described but are naturalistic
215099349|NCT02161107|BIOLOGICAL|Grass-SPIRE|Intradermal injection
215099350|NCT02161107|BIOLOGICAL|Placebo|Intradermal injection
215099351|NCT01662947|DEVICE|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
214407881|NCT00883350|BEHAVIORAL|RIDE e-health application|The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
214407882|NCT03392337|DEVICE|Narrowband UVB phototherapy|Ultraviolet B phototherapy
214407883|NCT05553041|DRUG|18F-Fluciclovine PET-MRI|18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
215012434|NCT06366958|PROCEDURE|excision of dorsal wrist ganglion|open and arthroscopic excision of dorsal wrist ganglion
215012435|NCT06314035|OTHER|COPD Patient Decision Aid|Participants in this group will receive two 60-minute intervention sessions in one month. The COPD PDA consists of three main parts: The first component, clinical counselling, guides the participants in reviewing the common EOL scenarios. The second component, an evidence-based decision aid, is presented as an option grid in a booklet and a video to provide information about outcome probabilities of various treatment options and survival estimates in a balanced and unbiased manner. The information is presented in plain language for laypersons. The third component, decision coaching, introduces the concept of ACP and guides deliberation through value clarification.
215012436|NCT06314035|OTHER|General Health Coaching Intervention|The participants in the control group will receive two 60-minute health coaching sessions developed by the PI for another project as an attention placebo control. Trained research personnel will use the same amount of interaction time and similar formats to avoid threats to the study's internal validity. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes. The trained research personnel will give the guidebook consisting of general self-management advice to participants in this group.
214407884|NCT04963621|BEHAVIORAL|Child-Adolescent Emotion and Stress Intervention Program|Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
214407885|NCT06247098|PROCEDURE|Sinus Lift augmentation|Randomised Sinus Lift augmentation either with Xenograft - Autogenous ratio 1:4 (test) or Xenograft alone (Control)
214407886|NCT06247098|DEVICE|Cone-beam computed tomography systems (CBCT)|An research only use of CBCT at visit 2 to review healing status.
214407887|NCT05882318|DEVICE|eCoin Peripheral Neurostimulator System|The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
214407888|NCT04685343|BEHAVIORAL|Quantitative Sensory Testing|Quantitative sensory testing (QST) consisting of 4 pain induction and sensory sensitivity tasks (i.e., pressure applied to the thumbnail, arms, shoulders, and lower abdomen, a cold water task, and one video-watching task).
214407889|NCT04685343|OTHER|fMRI|Functional magnetic resonance imaging (fMRI) session consisting of structural and functional brain scans.
214407890|NCT05913739|OTHER|Oxygen Therapy|Nocturnal oxygen therapy minimum 6 hours
214407891|NCT05408455|OTHER|EMST150 (Expiratory muscle training)|Respiratory exercise device (Expiratory muscle trainer) developed for the expiratory muscles, and resistant expiratory muscle training were applied. Threshold loading was applied to the cases at approximately 30% of the respiratory muscle strength values measured in the 1st week. In respiratory muscle training, the pressure value was increased according to the tolerance of the patient and training was given at a pressure value between 50-75%. The subjects were asked to do 10 vigorous expirations at the adjusted pressure value by doing normal inspiration for expiratory muscle training in a comfortable sitting position. This program was applied in 3 sets in the same way for approximately 30 minutes. It was continued 3 days a week for 8 weeks
214407892|NCT05408455|OTHER|Sham EMST150 (Expiratory muscle training)|The subjects were asked to perform normal inspiration and then exhale 10 times for expiratory muscle training without threshold loading. This program was applied in 3 sets in the same way for approximately 30 minutes. It will continue 3 days a week for 8 weeks
214407893|NCT01222247|DRUG|Betamethasone|The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
214407894|NCT01222247|DRUG|Placebo|Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
214407895|NCT04968782|OTHER|Patients with acute appendicitis|No intervention, single survey
214407896|NCT00480805|DRUG|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
214407897|NCT00480805|DRUG|Comparator : ramipril /Duration of Treatment : 8 Weeks|
214407898|NCT06174896|PROCEDURE|Group 1|The LMA Proseal will be inserted directly by hand, without the use of any laryngoscope, as recommended in the instruction manual. The cuff will be gently guided along the hard palate where it is pushed into the hypopharynx and increased resistance is felt, and the cuff will be placed towards the hypopharynx.
214407899|NCT06174896|PROCEDURE|Group 2|Appropriately sized laryngoscope blade will be used and after the location of the epiglottis is determined, the tongue and epiglottis will be lifted forward. Then, LMA Proseal will be placed at the point where resistance is felt at a level where the proximal edge of the mask can be seen.
214407900|NCT06174896|PROCEDURE|Group 3|After the video laryngoscope is placed with an appropriately sized blade, the location of the epiglottis and vocal cords will be determined and the LMA Proseal will be placed at the point where slight resistance is encountered after the epiglottis is lifted. proximal aspect of LMA
214407901|NCT03374046|PROCEDURE|Apneic Oxygenation|Supplemental oxygen will be provided via nasal cannula during intubation attempt
215012437|NCT03160807|DRUG|Levofloxacin|Levolet 500 mg OD for 5 days
215012438|NCT03160807|DRUG|Levofloxacin|Levolet 500 OD for 10 days
215099352|NCT01662947|DEVICE|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
215099353|NCT00290498|DRUG|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
215099354|NCT00290498|DRUG|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
215099355|NCT00290498|DRUG|Doxorubicin|Arm A: Doxorubicin 50 mg/m\^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
214407902|NCT04639947|DEVICE|EyeCheck|EyeCheck is a newly developed device to provide intraocular pressure (IOP) measurements of the eyes.
214407903|NCT04639947|DEVICE|Traditional Tonometer (Goldmann and Tonopen)|Standard of care intraocular pressures will be taken using the Goldmann and Tonopen to compare to the EyeCheck.
214407904|NCT02735252|OTHER|Systemic therapy|Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.
215012439|NCT04416685|PROCEDURE|primary repair|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
215012440|NCT04416685|PROCEDURE|segmental resection|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
214407905|NCT02735252|DEVICE|StrataNGS|CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added
214407906|NCT05478863|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants.
214407907|NCT05478863|DRUG|Oral THC|THC will be orally self-administered by study participants.
214407908|NCT05478863|DRUG|Oral CBD|CBD will be orally self-administered by study participants.
214407909|NCT05478863|DRUG|Oral Caffeine|Caffeine will be orally self-administered by study participants.
214407910|NCT05683262|PROCEDURE|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection|Ultrasound guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position with a pillow under the abdomen to flatten the lumbar curvature. Lower extremities should be internally rotated while feet are inverted to help flatten the gluteal region. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Ultrasonography gel was applied on the probe and the probe was wrapped with a transparent thin sheath and cleaned with povidone iodine. Sterile gel is applied on the skin. The sacrococcygeal ligament, the sacrococcygeal and intercoccygeal joints were visualized. The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When it was seen that the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
214407911|NCT05683262|PROCEDURE|Ultrasound-guided coccygeal nerve block|Patients are placed in the prone position with a pillow under the abdomen. Lower extremities are internally rotated while feet are inverted. Injection site and the probe are cleaned thrice with povidone iodine %10 solution. Sterile gel is applied. The prob was placed on coccygeal cornu and the coccygeal nerve was visualized superomedial to the CC in the subcutaneous tissue layer. Hydrodissection was made by administering 5 ml of 5% dextrose + 1 ml of 2% lidocaine via an in-plane approach with a 23 gauge 6 cm long needle, targeting the short axes of the bilateral coccygeal nerves.
214407912|NCT05683262|PROCEDURE|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection after coccygeal nerve block|After the coccygeal nerve block, when the pain with palpation of the coccygeal region was reduced by at least 50%, the sacrococcygeal ligament, sacrococcygeal and intercoccygeal joints were visualized.The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
215012441|NCT04416685|PROCEDURE|graft reconstruction|Regarding Level III tumors, complete resection of the tumor was done either by tangential excision or by partial venous excision and subsequent reconstruction. To maintain a secure anastomosis, the mesenteric root was mobilized completely or/and splenic vein was divided.
215012442|NCT02197104|DRUG|citocoline|Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
215099356|NCT00290498|DRUG|Vincristine|"Arm A: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
215099357|NCT00290498|DRUG|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
215099358|NCT00290498|DRUG|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
215099359|NCT00290498|DRUG|Cytarabine|Arm B: Cytarabine 3 g/m\^2 by vein over 2 hours every 12 hours X 4 doses on days 3 \& 4, cycle 2 and alternating cycles.
215099360|NCT00290498|DRUG|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
215099361|NCT02641717|OTHER|vaginal swab|
215099362|NCT00294255|DRUG|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
215099363|NCT02846012|OTHER|CSCM2|
215099364|NCT03957876|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
214407913|NCT03486197|OTHER|Laboratory Biomarker Analysis|Correlative studies
214407914|NCT03486197|BIOLOGICAL|Pembrolizumab|Given IV
214407915|NCT03486197|RADIATION|Radiation Therapy|Undergo neutron radiation therapy
214407916|NCT01011790|BEHAVIORAL|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
214407917|NCT00877851|BEHAVIORAL|Computer-based Program|The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the computer-based program and some instructions on how to navigate around the different sections of the program. As a minimum level of use, participants will be asked to use the self-monitoring and goal setting aspects of the computer-based program on at least a weekly basis.
214407918|NCT06167382|OTHER|Questionnare|Demographic Survey Form,the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+),Goniometric Measurements, Digital Dynamometer Measurements, Hand Grip Measurements, Hand Reaction Measurements, Dexterity and Function Measurements, Jamar Handheld Dynomometer Measurement, Pinchmeter Measurement, Purdue Pegbord Test, Minnesota Manuel Skill Test, Nelson Hand Reaction Test, Modified Borg Scale
214407919|NCT06167382|OTHER|Device: Arm Ergometer|Participants will sign a consent form approved by the ethics comittee. Before data collection height, weight, daily computer usage time, dominant hand, body mass index, heart rate, blood pressure and saturation values be recored. Before arm ergometer exercise, the muscle strength, hand grip strength, joint range of motion, dexterity and reaction speed will be evaluated. The dexterity and reaction speed will be done with Minnesota Manuel Skill Test, Purdue Pegbord Test and Nelson Hand Reaction Test.Participants will be training at least 24 hours apart at 60%, 70%, and 80% of exercise intensity maximum heart rate on arm ergometer. The tests will repeat at the same time with a maximum deviation of 1 hour on 3 different days. At the end of arm ergometer exercise, the necessary evaluations will be made again and the participants will be rest for 15 minutes. 15 minutes after the participants rested, the necessary evaluations will be made again.
214407920|NCT01861782|OTHER|Dead Sea Solar and Water Treatment|
214407921|NCT01861782|OTHER|Sulfur Pool & Medicinal Mud|
214407922|NCT03662893|BEHAVIORAL|behavioural therapy with written checklist form to complete|Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes
214407923|NCT03662893|DRUG|Antimuscarinic drugs used in overactive bladder|Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
214407924|NCT03662893|BEHAVIORAL|behavioural therapy with written guideline|behavioural therapy with written guideline,which are the same as those in the checklist
214407925|NCT04021056|OTHER|No intervention|
214407926|NCT02800811|DRUG|FR104|GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.
214407927|NCT02800811|DRUG|Placebo|The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
214407928|NCT03424239|DRUG|Zoledronic Acid|5mg zoledronic acid
214407929|NCT03424239|DIETARY_SUPPLEMENT|Calcium citrate + vitamin D|Chewable 500mg calcium citrate with 500 International Units (IU) Vitamin D3
214407930|NCT03424239|DIETARY_SUPPLEMENT|Vitamin D3|1000IU Vitamin D3 gummy
215012443|NCT04096885|DIAGNOSTIC_TEST|Blood and urine samples, skin and stool swabs|Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
215012444|NCT00985192|DRUG|everolimus|
214407931|NCT01258387|DRUG|Glial growth factor 2/ Neuregulin 1β3|
215012445|NCT00985192|OTHER|laboratory biomarker analysis|
214407932|NCT01258387|OTHER|Placebo|
214407933|NCT02121704|DEVICE|Magnetic Endoscope Imaging (Scope Guide)|
214407934|NCT03328559|DIAGNOSTIC_TEST|ISET® - Isolation by Size of Tumor cells|early stage bronchial cancer patient will have a blood collection
215012446|NCT01498666|DIETARY_SUPPLEMENT|L. reuteri protectis|1 tablet once daily for 4 weeks
215012447|NCT01498666|DIETARY_SUPPLEMENT|Placebo tablet|1 tablet once daily for 4 weeks
215012448|NCT02296359|BIOLOGICAL|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
215012449|NCT03929055|DEVICE|Physiological assesment|"1. Arterial blood gas analysis.~2. esophageal pressure variation during inspiration and expiration~3. Arterial blood pressure, central venous pressure (CVP), heart rate.~4. diaphragmatic contraction detected by ultrasound"
215012450|NCT01454063|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
214407935|NCT03328559|DIAGNOSTIC_TEST|ISET® - Isolation by Size of Tumor cells|advanced stage bronchial cancer patient will have a blood collection
214407936|NCT04871373|BEHAVIORAL|Motivational interviewing|A periodontist was trained and evaluated by two expert psychologists in MI, who also supervised the interviewer to ensure that the intervention was properly applied. The periodontist conducted sessions of motivational interviewing monthly to the participants of the experimental group.
214407937|NCT04871373|BEHAVIORAL|Oral Hygiene Instructions|A periodontist delivered OHI to all the participants of both studied groups. Also, every single patient received a G.U.M. kit with special orthodontic hygiene tools.
214407938|NCT00168181|PROCEDURE|Submandibular gland Transfer|
214407939|NCT00168181|DRUG|Salagen|
214407940|NCT04890756|OTHER|observational|"The reliability was determined (n=100) by filling out the mBQ, two times, one week apart (test-retest).~For validation (n=45), the scores between the modified Baecke Questionnaire and the International Physical Activity Questionnaire were compared and the correlation between the modified Baecke Questionnaire and VO2max(via Astrand-Rhyming Cycle Ergometer Test) and between mBQ and interview (via METS) were assessed."
214407941|NCT02301234|DRUG|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
214407942|NCT02301234|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
214407943|NCT02301234|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
214407944|NCT02301234|DRUG|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
214407945|NCT02301234|DRUG|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
214407946|NCT03276364|DIAGNOSTIC_TEST|Ultrasound|Point-of-care ultrasound examination by pulmonary and critical care fellow
214407947|NCT03724474|BEHAVIORAL|Be SMART|The behavioral intervention will examine 12-week changes in sleep metrics and physical activity, compared to baseline measures, between subjects randomly assigned to a treatment (Be SMART) and an active control (Fitbit Only) condition (n=30, respectively).
215012451|NCT01454063|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
215012452|NCT04337073|DRUG|Propofol|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
215012453|NCT04337073|DRUG|normal saline|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
215012454|NCT02707744|OTHER|no intervention|
215012455|NCT02429739|BEHAVIORAL|Working memory Training|"The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30 - 45 minutes and the family has 6 weeks to complete the training. Each session consist 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.~Other name: Cogmed RoboMemo"
215012456|NCT05125627|DRUG|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
215012457|NCT05125627|DRUG|Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
215012458|NCT01161121|DRUG|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
215012459|NCT01161121|DRUG|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
215012460|NCT06253208|PROCEDURE|postoperative pain|Postoperative analgesia in laparoscopic sleeve gastrectomies: laparoscopic versus ultrasound-guided transversus abdominis plane block
215012461|NCT06088628|DIAGNOSTIC_TEST|Facial expression; Electroencephalogram; MRI|Recording facial expressions of participants, EEG recordings, and MRI scans.
215012462|NCT00509600|DRUG|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
214407948|NCT02919085|PROCEDURE|Early ambulation|Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
214407949|NCT00142220|DRUG|Defined percentage of omega-3-fatty acids|
214407950|NCT02185664|PROCEDURE|landmark technique|The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
214407951|NCT02185664|DEVICE|Static Ultrasound technique|Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
214407952|NCT02521064|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition (EEN)|Patients will be treated with 8 weeks of Exclusive Enteral Nutrition (EEN). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
214407953|NCT02521064|DRUG|Prednisone|Patients will be treated with 8 weeks of prednisone (corticosteroid). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
214407954|NCT02540941|OTHER|non|
214407955|NCT02042443|DRUG|Capecitabine|Given PO
214407956|NCT02042443|DRUG|Fluorouracil|Given IV
214407957|NCT02042443|OTHER|Laboratory Biomarker Analysis|Correlative studies
214407958|NCT02042443|DRUG|Leucovorin Calcium|Given IV
215012463|NCT02549300|OTHER|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
215012464|NCT00252889|DRUG|Topotecan and pegylated doxorubicin|Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
214407959|NCT02042443|DRUG|Trametinib|Given PO
215099365|NCT01826435|BEHAVIORAL|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
215012465|NCT06500728|DIAGNOSTIC_TEST|Fluorescein and Indocyanine green Angiography|The ophthalmologist frequently recommends fluorescein (FAG) and indocyanine green angiography (ICGA) at baseline (T0) to evaluate retinal and choroidal vascularisation. They can be repeated also after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4) or 26 ± 2 weeks (T5).
215012466|NCT06500728|DIAGNOSTIC_TEST|High-resolution Optical Coherence Tomography|The ophthalmologist often suggests performing HR-OCT initially (T0) to assess the width of the macula and optic nerve with potential signs of ischemic lesions in these areas. This assessment can also be repeated after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
215012467|NCT06500728|DIAGNOSTIC_TEST|Angio-Optical Coherence Tomography|The ophthalmologist often suggests OCT-A at the beginning (T0) to assess the retinal and choroidal vascularization. These tests can also be done after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
215012468|NCT05939609|OTHER|Ballistic Stretching Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
215012469|NCT05939609|OTHER|Extender Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
215012470|NCT05939609|OTHER|Kinesiotaping|It will be applied 4 times a week for 6 weeks and before starting on-water training.
215012471|NCT06277830|DEVICE|Wearable sensor|Participants will wear a pendant sensor for 7 days and then participate in an on-site examination with using a tablet designed to evaluate weakness in MG.
215012472|NCT03055195|DRUG|Mepolizumab 100 mg|Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
215099366|NCT04294771|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
214407960|NCT03000712|BIOLOGICAL|Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml|biological : Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml drug: saline solution
214407961|NCT05946746|DIETARY_SUPPLEMENT|PeptiStrong|PeptiStrong is a protein hydrolysate derived from Vicia faba. It is a free-flowing powder, pale yellow in colour. For the purposes of the trial, PeptiStrong will be encapsulated in size '00' hydroxypropyl methylcellulose capsules.
214407962|NCT05946746|DIETARY_SUPPLEMENT|Placebo SMCC silicated micro-crystalline cellulose|Placebo - SMCC silicated microcrystalline cellulose (INCI name: MCC, cellulose gel), For the purposes of the trial, SMCC will be encapsulated in size '00' hydropropyl methylcellulose.
214407963|NCT01235585|DRUG|Placebo|Oral doses, once a day for 52 weeks
215099367|NCT01716104|DRUG|Afalaza|Safety and Efficacy
214407964|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
215012473|NCT03055195|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
215012474|NCT03615898|OTHER|Medication errors analysis|TEN YEAR ANALYSIS OF MEDICATION ERRORS IN THE SPANISH INCIDENTS REPORTING SYSTEM IN ANAESTHESIA
214407965|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
214407966|NCT02320253|BEHAVIORAL|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
214407967|NCT02320253|BEHAVIORAL|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
215012475|NCT05875077|DRUG|Dexmedetomidine|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
215012476|NCT05875077|DRUG|Propofol|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
215099368|NCT01716104|DRUG|Placebo|Safety and Efficacy
215099369|NCT06142006|OTHER|Diabetes Staging System (DSS) use among Primary Care Teams|Evaluate the feasibility of using the DSS in PACT clinics to increase SGLT2i and/or GLP-1 agonist use in Veteran DM2 patients with cardiovascular disease
215099370|NCT00665769|OTHER|Hypercapnia|transcutaenous CO2 50-60 mm Hg
215012477|NCT00720083|DRUG|cisplatin|Given IV
215012478|NCT00720083|DRUG|vandetanib|Given orally
215012479|NCT00720083|RADIATION|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
215012480|NCT03008577|OTHER|Change in ambient operating room temperature|
215099371|NCT00665769|OTHER|Normocapnia|transcutaneous CO2 35-45 mm Hg
215099372|NCT01364701|DRUG|Sildenafil 100 mg|4 tablets for on demand use
215099373|NCT01364701|DRUG|Tadalafil 20 mg|4 tablets on demand
215012481|NCT05001503|DEVICE|Stability UO|STABILITY UO is a standalone software, based on a Bayesian model, which quantifies the risk of an individual patient developing severe oliguria (0.3mg/kg/hr for 6 hours). The model identifies at risk patients by predicting future urine output, using only previously recorded urine output values for that individual, allowing clinicians to see the predicted risk of a patient developing severe oliguria in real time.
215012482|NCT00045955|DRUG|Fexofenadine, Comparator = Montelukast|
215099374|NCT01364701|DRUG|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
215099375|NCT03129360|DRUG|Levetiracetam|Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
215099376|NCT03129360|DRUG|Placebo|Prepared in capsules to appear identical to levetiracetam.
215099377|NCT04516551|BIOLOGICAL|anti-CD19 allo-CAR-T cells|The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
215099378|NCT02209623|BIOLOGICAL|TDAP|
215012483|NCT02832947|DRUG|Rivaroxaban 10 mg|At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
215012484|NCT02021604|DRUG|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
215012485|NCT04619030|OTHER|Augmented Reality|The patient leaflet has an Augmented Reality model that appears out of the leaflet when viewed with a smartphone
215012486|NCT04619030|OTHER|Traditional leaflet|Traditional leaflet with no Augmented Reality capability
215099379|NCT03832608|OTHER|No intervention|There is not intervention to be administered, only collection of data through various tests and questionnaires.
215099380|NCT05026853|BEHAVIORAL|PRO Integration into Clinical Practice|HCPs will document their discussion and recommendations/referrals in MiChart (Epic EMR)
215099381|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
215099382|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
215099383|NCT03006887|DRUG|lenvatinib|lenvatinib capsules
215012487|NCT05992740|DEVICE|bronchoscope|bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy
215012488|NCT03926598|BEHAVIORAL|Patient and/or Family Member Intervention|On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.
215012489|NCT03926598|BEHAVIORAL|Certified Diabetes Educator Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
215012490|NCT03926598|BEHAVIORAL|Physician Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.
215099384|NCT03006887|DRUG|pembrolizumab|pembrolizumab intravenous infusion
215099385|NCT04928560|DIAGNOSTIC_TEST|SMI|ULTRASOUND
215099386|NCT00001909|DRUG|Soluble recombinantly produced IL-4R|
215099387|NCT04467970|PROCEDURE|Unicompartmental Knee Replacement|Unicompartmental Knee Replacement involves replacement of the medial compartment of the knee in patients with anteromedial osteoarthritis.
215099388|NCT04467970|PROCEDURE|High Tibial Osteotomy|High Tibial Osteotomy involves medial wedge opening high tibial osteotomy in cases of anteromedial osteoarthritis.
215099389|NCT06087900|OTHER|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
214407968|NCT02320253|BEHAVIORAL|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
214407969|NCT05654649|DRUG|0.9%sodium chloride|Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
214407970|NCT05654649|DRUG|Dexamethasone|Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
214407971|NCT06528132|BEHAVIORAL|Mindfulness-based intervention (MBI) (enhanced with peer supporters)|Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders. On-site support and regular follow-up by peer supporters.
214407972|NCT06528132|BEHAVIORAL|Experimental: social worker-led MBI (without peer supporters)|Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
214407973|NCT03889899|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
215012491|NCT03926598|BEHAVIORAL|Front Desk Staff Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
214407974|NCT04794179|DEVICE|Naida Link CROS|Individuals 18+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
214407975|NCT04181775|DIAGNOSTIC_TEST|ADE-RED scoring tool|The ADE-RED scoring tool will reduce the incidence of future visits to the ED or future admissions by identifying patients who are at high risk for ADE-related readmissions.
214407976|NCT06180382|DRUG|Adalimumab|Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.
215099390|NCT06087900|OTHER|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
215012492|NCT03926598|BEHAVIORAL|Nurse Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
215099391|NCT06087900|OTHER|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
215099392|NCT06087900|OTHER|Control|The CON group did not have any intervention but usual care.
215099393|NCT03836677|COMBINATION_PRODUCT|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
214407977|NCT06180382|DRUG|Vedolizumab|Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.
214693925|NCT06070740|DRUG|Durvalumab and Chemotherapy(oxaliplatin and capecitabine)|"Combination therapy includes:~Durvalumab: intravenous infusion with a fixed dose of 1500 mg on day 1, repeated every 3 weeks ± 3 days; Chemotherapy: Oxaliplatin 130mg/m2 intravenous infusion on day 1, capecitabine 1000mg/m2, orally, twice a day, from day 1 to day 14; repeated every 3 weeks ± 3 days;~After 6 cycles of combination therapy, maintain with durvalumab 1500 mg every 4 weeks ± 3 days for 2 years. Terminate the trial if confirmed disease progression, initiation of other anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent or other reasons considered by the investigators."
215099394|NCT03836677|COMBINATION_PRODUCT|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
215099395|NCT03381313|BEHAVIORAL|Conditioned word repetition training|In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
215099396|NCT05338203|OTHER|tandem breastfeedıng|mother mılk wıll collected from mothers and they wıll be analyzed in laboratuar.
215012493|NCT00108537|DRUG|bupropion and transdermal patch|
215012494|NCT00108537|DRUG|transdermal patch and nicotine inhaler|
215099397|NCT01606033|OTHER|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
215099398|NCT01606033|OTHER|questionnaire|understanding of the implications of participating in a clinical trial
215099399|NCT03233126|DRUG|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
215099400|NCT06221748|DRUG|Disitamab Vedotin Injection|Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks
215012495|NCT02003027|DRUG|BT injection|
215012496|NCT04294849|OTHER|Magnetic Resonance Imaging|A. Phosphorous 31 MR Spectroscopy to evaluate skeletal muscle metabolism via measurement of depletion and recovery of phosphocreatine (PCr) B. Non-invasive arterial spin labeling MRI to evaluate lymphatic flow velocities and venous flow
215012497|NCT04294849|OTHER|Bicycle Ergometry|To measure peak VO2 as a representation of global aerobic fitness
215099401|NCT06221748|DRUG|Cadonilimab Injection|Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.
215099402|NCT06221748|DRUG|Paclitaxel Injection|Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
214407978|NCT05669833|DRUG|Guselkumab|Guselkumab (GUS) subcutaneous injection
214407979|NCT05669833|DRUG|Golimumab|Golimumab (GOL) subcutaneous injection
214407980|NCT03362619|BIOLOGICAL|CC-EIEs|2 to 4 infusions, once a week, for 1x10\^5\~1x10\^7 CTLs/kg via IV, abdominal cavity or intratumoral injection each time
214407981|NCT02460029|OTHER|Ventral hernia|Visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromusculare incisional hernia repair with the visible CICAT mesh (Dynamesh®).
214407982|NCT05993208|DIAGNOSTIC_TEST|optical coherence tomography,multifocal electroretinogram. VA measurment|retinal photography
214407983|NCT05983692|DEVICE|Magnesium based wire|Mg wire will be used as a braiding suture to braid tendon graft, which is a standard preparation of graft and is not related to fixation of the tendon graft
214407984|NCT00741273|DRUG|Proellex|Proellex 25 mg capsule, single dose
215099403|NCT05760534|DRUG|Remimazolam|0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
215099404|NCT01092962|DRUG|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
214407985|NCT04488874|DRUG|Sodium Lactate|"Sodium lactate is administered at 2.5mL/kg during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.~Sodium Lactate and Mannitol 20% are used at an equimolar dose"
214407986|NCT04488874|DRUG|Mannitol 20% Infusion|Mannitol 20% is administered intravenously at a dose of 5mL/kg, so 1g/kg, during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.
215012498|NCT04294849|OTHER|Lab Panel|A. Inflammatory lab panel (IL-6, IL-8, TNF alpha, P-selectin, high sensitivity CRP, IL-6 receptor, TNF R1/R2) drawn at diagnosis B. Thrombin Generation Assay to measure hypercoagulability and Thromboelastography prior to initiating anticoagulation
215012499|NCT04294849|BEHAVIORAL|Questionnaires|A. Dalhousie Dyspnea Scale B. Godin Leisure Time Exercise Questionnaire C. Pediatric Venous Quality of Life Questionnaire
215099405|NCT01092962|DRUG|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
215099406|NCT05629910|DEVICE|O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
215099407|NCT03041363|DRUG|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
215099408|NCT06475040|DEVICE|transcranial magnetic stimulation|non-invasive form of brain stimulation accelerated intermittent theta burst stimulation (aiTBS)
215099409|NCT02170766|DRUG|BIBR 1048 low1|
215099410|NCT02170766|DRUG|BIBR 1048 low2|
214407987|NCT01536353|DRUG|AGSAV301|tablet, q.d.
215012500|NCT00578058|OTHER|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
215099411|NCT02170766|DRUG|BIBR 1048 medium|
215099412|NCT02170766|DRUG|BIBR 1048 high|
215099413|NCT02170766|DRUG|Pantoprazole|
215099414|NCT01300988|DRUG|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
215099415|NCT01300988|DRUG|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
215012501|NCT03443544|PROCEDURE|Aggressive debridement|Aggressive debridement of the tissues undergoing fascitis
215012502|NCT04224051|DRUG|Metformin|Metformin target dose 2 g daily
214407988|NCT01536353|DRUG|Exforge 10/160|Tablet, q.d.
214407989|NCT03605186|OTHER|Chamomile oral cryotherapy|The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
215012503|NCT04224051|OTHER|Standard care|Abdominal aortic aneurysm surveillance
215012504|NCT05663788|OTHER|E-learning module|"The intervention is a structured e-learning module on a web-based platform (www.trainingopticaldiagnosis.com) that consists of:~* 10 modules, including theoretical knowledge and multiple exercises.~* 2 seminars with a tutor (after Module 5 and Module 10)~* feedback from the tutor on three cases recorded by the participant.~* 20-images test before and after the content described above (10 Modules, 2 seminars with tutors and feedback on three cases)~All the Gastroenterologists participating in the study will predict deep submucosal invasion in their routine colonoscopies and will register clinical outcomes during 12 months. The randomisation and intervention will be conducted 6 months after starting to predict deep submucosal invasion and registering clinical outcomes."
215012505|NCT03043820|DRUG|Raloxifene|Oral selective estrogen receptor modulator (SERM).
215012506|NCT03043820|DRUG|Placebo|Tablets identical in form and color to intervention.
215012507|NCT00657501|DRUG|testosterone gel|once daily transdermal gel, 300 mcg
215012508|NCT00657501|DRUG|placebo gel|once daily transdermal placebo gel
215012509|NCT03053830|DRUG|Ketamine|0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
215099416|NCT02499042|DRUG|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
215099417|NCT05896813|DRUG|CMOP+Chidamide|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
215099418|NCT00069355|DRUG|Propranolol|
215099419|NCT05406869|DEVICE|Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic Generater|Deliver Pulsed Sonic Balloon Dilatation Catheter to the target vessel prior to placing a coronary stent or others
215099420|NCT00304005|DRUG|laromustine|
215099421|NCT00100594|DRUG|Efavirenz|
215099422|NCT00100594|DRUG|Lamivudine/zidovudine|
215099423|NCT03841370|PROCEDURE|endodontic treatment|Color measurements of endodontically treated teeth (incisors, canines or premolar) will be collected regardless of technique, treatment time and sealer used.
215099424|NCT00136669|PROCEDURE|Acupuncture|
215099425|NCT04940884|BEHAVIORAL|Supervised exercise training|SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session
215099426|NCT04940884|BEHAVIORAL|Aerobic exercise training|All recruited subjects were instructed to walk \>=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.
214407990|NCT03605186|OTHER|Oral cryotherapy|The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
215012510|NCT04784780|DRUG|Elobixibat 10mg|Patients with chronic constipation are administered Elobixibat 10mg for 12 weeks
214407991|NCT01091181|PROCEDURE|hysterotomy at cesarean|incision to open the uterus at cesarean.
214407992|NCT01077661|DRUG|Nebivolol|patients administrated Nebivolol according to the prescribing information
214407993|NCT01258361|PROCEDURE|echocardiography|Echocardiography is performed for all patients
214407994|NCT03986606|BIOLOGICAL|PSB205|PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
214407995|NCT05688371|DRUG|standard dose morphine|Receiving 0.05 mg morphine/kg as a bolus.
214407996|NCT05688371|DRUG|low dose morphine plus dexmedetomidine|Receiving 0.02 mg morphine/kg as a bolus dose + 0.2 microgram/kg dexmedetomidine
214407997|NCT04150835|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
214407998|NCT04150835|DRUG|Xingnaojing placebo injection|Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
214407999|NCT04150835|OTHER|Standard care|Guidelines-based standard care for acute ischemic stroke.
214408000|NCT05251285|PROCEDURE|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
215012511|NCT04784780|DRUG|Placebo|Patients with chronic constipation are administered placebo for 12 weeks
215012512|NCT04366583|DEVICE|argon plasma coagulation|Olympus electrosurgical unit/argon plasma coagulation unit (PSD-60/Endoplasma, Olympus Corp., Tokyo, Japan)
215012513|NCT04366583|DEVICE|hemoclipping|clipping device (Olympus HX 110/610, Olympus Corp., Tokyo, Japan)
215012514|NCT03128164|DRUG|HMPL-689|Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
215012515|NCT02957227|DEVICE|No intervention is part of this study but patients use an EEG device during observational data collection.|
215099427|NCT03370562|DRUG|Dexmedetomidine|Administration of 10 mcg intravenous dexmedetomidine
215099428|NCT03370562|DRUG|Placebo|Administration of normal saline
215099429|NCT02625714|DRUG|Renexin®|Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
214408001|NCT03071497|DIAGNOSTIC_TEST|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
214408002|NCT04631549|DRUG|SHR3680|SHR3680, PO, single dose
214408003|NCT06030687|OTHER|Ad libitum data collection|Food purchase, prep, eat and toss data
214408004|NCT05159908|DRUG|NBI-921352|Tablets for oral administration
214408005|NCT05159908|DRUG|Placebo|Matching placebo tablets for oral administration
214408006|NCT03230591|OTHER|Echocardiography|LV vortex flow in Echocardiography
214408007|NCT05550337|DRUG|Trifarotene 0.005 % Topical Cream|Cream
214408008|NCT05550337|DRUG|AKLIEF®|Cream
214408009|NCT05550337|DRUG|Placebo|Cream
214408010|NCT04783415|DRUG|Acalabrutinib|Given PO
214408011|NCT04783415|BIOLOGICAL|Ublituximab|Given IV
214408012|NCT04783415|DRUG|Umbralisib|Given PO
214408013|NCT03115346|OTHER|Decision aid|Decision aid for repair type for aortic abdominal aneurysms
214408014|NCT05117034|DRUG|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
214408015|NCT05117034|DRUG|Nacl 0.9%|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
214408016|NCT05506345|BEHAVIORAL|Creative Drama Workshop|"* The host introduces the theme and stressor scene of this workshop~  * Nursing students group discussion~    * Nursing student group performance practice ④Nursing group formal performance ⑤Nursing student group discussion ⑥The representative of the nursing student group made a speech ⑦ The host summarizes the positive coping methods of nursing students in stressor events"
214408017|NCT04816526|BIOLOGICAL|Descartes 08|Car T-cells
214408018|NCT03869853|BEHAVIORAL|Entrepreneurial stimulation and integrated education|one month cycle of stimulation of business with integrated education on nutrition, health, and gender empowerment
214408019|NCT03869853|BEHAVIORAL|control|no intervention
214408020|NCT01442974|DRUG|Gemcitabine plus nab-paclitaxel|Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
215012516|NCT03915054|DRUG|AREG-TRIGGER|"Oocytes in AREG-TRIGGER medium will be mature in AREG + FSH + HSA + Insulin + Estradiol medium.~Per case (6mL) 5940 µL Basal Medium~* 60 µL IVM MIX Do not need to filtrate media."
215012517|NCT03915054|DRUG|CONTROL-TRIGGER|"Oocytes in CONTROL-TRIGGER medium will be mature in FSH + hCG + GH + HSA medium.~Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)"
215012518|NCT05573737|OTHER|education|education about ubilical cord care
215012519|NCT01441414|BIOLOGICAL|PF-04856884|15 mg/kg/week intravenously \[IV\] until toxicity or disease progression
215012520|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
215012521|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
215012522|NCT04286503|DRUG|Carrimycin|Carrimycin
215099430|NCT02625714|DRUG|SID142|Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
215099431|NCT03125460|DEVICE|Xpert Bladder Cancer Monitor|in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
215099432|NCT03028935|BEHAVIORAL|Exercise Intervention|Undergo instructor-led exercise program
215099433|NCT03028935|BEHAVIORAL|Nutritional Intervention|Undergo instructor-led nutritional education program
214408021|NCT03341806|DRUG|Avelumab|Avelumab will be administered intravenously every 2 weeks at a dose of 10 mg/kg for 2 cycles
214408022|NCT03341806|COMBINATION_PRODUCT|MRI-guided LITT therapy|(Part B) prior to receiving Avelumab 10 mg/kg every 2 weeks + LITT
214408023|NCT04218643|OTHER|Ultrasound-guided technique|IV inserted via ultrasound guidance
214408024|NCT04218643|OTHER|Standard technique|IV inserted via standard technique
214408025|NCT02912039|DEVICE|TetraGraph|A sequence of 3 sets of Train of four (TOF) stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
214408026|NCT02912039|DEVICE|TOF Watch|A sequence of 3 sets of TOF stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
214408027|NCT01416909|OTHER|Laxative Treatment|Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
214408028|NCT01416909|OTHER|Standard of Care|Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
214408029|NCT01416909|OTHER|Assessment Questionnaires|Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
214408030|NCT05014620|OTHER|Semi-directive interview|semi-structured exploratory interview
214408031|NCT06093529|DIAGNOSTIC_TEST|complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.|"1. Full history~2. Thorough clinical examinations~3. Laboratory investigations will include:~   1. complete blood count with focus on platelet count, platelet distribution width and mean platelet volume. Platelet count will be confirmed by direct blood film and blood smear.~  2. Measurements of CD3+, CD4+, CD8+ and natural killer cells (CD16+, CD56+) will be conducted using flow cytometry.~  3. Serum IFN-γ levels will be determined using an ELISA kit.~4. Response to the treatment will be assessed according to The International Working Group criteria which defines Response as platelet count ≥ 30 x 10⁹/L and \>2-fold increase in platelet count from baseline and absence of bleeding, measured on 2 occasions greater than 7 days apart. No response is characterized by a platelet count \<30 x 10⁹/L or a less than 2-fold increase in platelet count from baseline, or the presence of bleeding."
214408032|NCT03727360|OTHER|Exercise Training|Supervised exercise conducted four days per week for six months.
214408033|NCT03727360|OTHER|Flexibility Control|Supervised exercise conducted four days per week for six months.
214408034|NCT01702038|DRUG|Rituximab|1000 mg administered intravenously
215012523|NCT04286503|DRUG|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
215012524|NCT04286503|DRUG|basic treatment|basic treatment
215012525|NCT02441257|PROCEDURE|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
215012526|NCT02441257|PROCEDURE|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
215012527|NCT01773889|DRUG|Denileukin Diftitox/SC Pegylated IFNα-2a|
215012528|NCT04955093|DEVICE|Biofeedback|Technology to provide Heart Rate Variability Biofeedback
215012529|NCT05092503|DRUG|JINZHEN Granules for Oral Solution|JINZHEN granules will be dissolved in drinking water and administered orally.
215012530|NCT05092503|DRUG|Placebo|Placebo granules will be dissolved in drinking water and administered orally.
215012531|NCT03749174|PROCEDURE|Long acting Supraclivicular block vs Short acting Supraclavicular block|"Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block"
215012532|NCT02618733|DRUG|Ticagrelor|90mg, twice a day
215012533|NCT02618733|DRUG|Clopidogrel|75mg, once a day
215012534|NCT00315029|BEHAVIORAL|evidence based decision aid|evidence based decision aid
215012535|NCT00315029|BEHAVIORAL|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
215012536|NCT01271829|DIETARY_SUPPLEMENT|Avocado supplement|Calories from avocados replace calories of the control lunch
215012537|NCT01271829|DIETARY_SUPPLEMENT|Avocado included|Calories from avocados will be added to calories from the control lunch
215012538|NCT01451788|DEVICE|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
215012539|NCT00976391|BIOLOGICAL|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
215012540|NCT00976391|DRUG|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
215012541|NCT01544075|BEHAVIORAL|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
215012542|NCT01544075|BEHAVIORAL|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
215012543|NCT00281853|PROCEDURE|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
215012544|NCT03115658|BEHAVIORAL|Physical Activity|12 week print based intervention
215012545|NCT02783989|OTHER|white wine|A dietary beverage: a market white wine, 13º alcohol
215012546|NCT02783989|DIETARY_SUPPLEMENT|tyrosol|tyrosol in capsules
215012547|NCT02018887|DRUG|LY2969822|Capsules administered orally
215012548|NCT02018887|DRUG|Placebo|Capsules administered orally
215012549|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin|Drugs was given a few days after multimodal thermal therapy
215012550|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin|Drugs was given a few days after multimodal thermal therapy
214408035|NCT05910931|DRUG|ICG angiography|"* A first injection with the patient asleep before starting the intervention to visualize the vascular anatomy of each patient and assess the pedicles and incisions.~* A second bolus after breast resection to assess the viability of skin flaps and glandular pedicles.~* A third injection to obtain an angiography after implant placement and wound closure.~For angiography, the SPY System with the SPY-Q software will be used."
214408036|NCT05051397|BIOLOGICAL|HYPERCAPNIA|Controlled moderate hypercapnia PaCO2 50mmHg under general anesthesia with mechanical ventilation
215012551|NCT01286649|OTHER|Human autologous hair follicle cells|Human autologous hair follicle cells suspended in cell medium
215012552|NCT01286649|OTHER|Cell medium|Cell medium
214408037|NCT05051397|BIOLOGICAL|NORMOCAPNIA|Controlled normocapnia PaCO2 40mmHg under general anesthesia with mechanical ventilation
214408038|NCT01024205|DRUG|sunitinib malate|
214408039|NCT01024205|OTHER|laboratory biomarker analysis|
214408040|NCT01024205|PROCEDURE|adjuvant therapy|
214408041|NCT01024205|PROCEDURE|neoadjuvant therapy|
214408042|NCT01024205|PROCEDURE|therapeutic conventional surgery|
214408043|NCT04837495|PROCEDURE|right stellate ganglion block|The skin should be anaesthetised with lidocaine 2%. Using a lateral approach and in-plane imaging, a blunt regional anaesthesia needle should be advanced deep to the carotid sheath towards the longus colli muscle. Following careful aspiration, inject 10 ml lidocaine 2% that will result in expansion of the fascia of the longus colli. Confirmation of the SGB success can be detected by warming of left upper limb and left Horner's syndrome.
214408044|NCT04244591|DRUG|methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
214408045|NCT04244591|OTHER|Standard care|Standard care
214408046|NCT06122064|OTHER|Best Practice|Receive standard of care
214408047|NCT06122064|OTHER|Communication Intervention|Use shared decision-making conversation tool
214408048|NCT06122064|OTHER|Electronic Health Record Review|Ancillary studies
214408049|NCT06122064|OTHER|Survey Administration|Ancillary studies
214408050|NCT06122064|OTHER|Video Recording|Ancillary studies
214408051|NCT06122064|OTHER|Audio Recording|Ancillary studies
215099434|NCT04383275|DRUG|capecitabine and trastuzumab|In IRIS-A cohort, patients who met the inclusion criteria(ER，PR\<10%, T≤2cm or ER,PR ≥10% 1cm\<T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
215099435|NCT04383275|DRUG|endocrine therapy and trastuzumab|In IRIS-B cohort, patients who met the inclusion criteria(ER,PR ≥10% T≤1cm) would be given endocrine therapy (premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane) combined with standard trastuzumab for 1 year and complete endocrine therapy for 5 years.
214408052|NCT01140347|BIOLOGICAL|Placebo|8 mg/kg IV every 2 weeks
214408053|NCT01140347|BIOLOGICAL|Ramucirumab DP (IMC-1121B)|8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
214408054|NCT01140347|OTHER|BSC|Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
214408055|NCT00828919|DRUG|axitinib|BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
214408056|NCT00828919|DRUG|crizotinib|BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
214408057|NCT06169436|PROCEDURE|Nephroureterectomy|Removal of cancer mass by urether and kidney complete resection.
214408058|NCT04909008|OTHER|Exercise Training|10 weeks of supervised exercise training, 3 sessions per week at the cardiac rehab clinic at Mayo Clinic Florida.
214408059|NCT05959655|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
214408060|NCT06423599|DRUG|Semaglutide Injectable Product|Weight loss using Semaglutide
214408061|NCT06423599|DIETARY_SUPPLEMENT|Calorie-restricted diet|Weight loss by calorie-restricted diet program followed by a weight loss maintenance follow-up program
214408062|NCT05035264|DEVICE|Laryngeal mask insertion|Laryngeal mask insertion in neutral position
214408063|NCT05035264|DEVICE|Laryngeal mask insertion|Laryngeal mask insertion in sniffing position
214408064|NCT05035264|DEVICE|Laryngeal mask insertion|Laryngeal mask insertion in beyond sniffing position
214408065|NCT01423903|DRUG|OPB-51602|A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
214408066|NCT06659887|DEVICE|nasal cannula|After induction, bag-mask ventilation with 100% oxygen and flow rates of 6 L/ min will be carried out until the expired oxygen concentration will be \>90%, saturation of oxygen was 100%, and end tidal carbon dioxide was 30-40 mmHg. Once this will be reached, bag-mask ventilation will be stopped and apneic oxygenation will be initiated for 3 minutes
215012553|NCT01677065|DRUG|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
215012554|NCT01677065|DRUG|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
215012555|NCT04346238|OTHER|Reuse of existing data from patients' medical records|Reuse of existing data from patients' medical records
215012556|NCT01058005|DRUG|BG00002 (natalizumab)|300 mg intravenous injection every 4 weeks
215012557|NCT01058005|DRUG|interferon beta-1a|44 mcg subcutaneous injection 3 times per week
215012558|NCT01058005|DRUG|glatiramer acetate|20 mg subcutaneous injection once daily
215012559|NCT05848375|PROCEDURE|Arthroscopic rotator cuff repair|The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.
215012560|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
215099436|NCT02325297|OTHER|Letter of condolence|
215099437|NCT03437824|DRUG|Cyanocobalamin|1,000 mg, Once
215099438|NCT03437824|DRUG|Placebo|0.9% Sodium Chloride, Once
215099439|NCT01729208|DEVICE|Dual Focus Soft Contact Lens|
215099440|NCT01729208|DEVICE|Single Vision Soft Contact Lens|
215099441|NCT03821116|OTHER|Milk|Swedish milk from cow.
215012561|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
214408067|NCT06607965|DIETARY_SUPPLEMENT|Whey Protein and Carbohydrates|"Experimental Group:~6 hours before surgery, patients orally consumed 250 ml of a full-nutrition liquid (220 ml homogenized diet, 50 g; containing 31.4 g carbohydrates, 8 g protein, and 215 kcal).~2 hours before surgery, patients orally consumed 200 ml of a clear liquid (50 g enzymatically hydrolyzed rice powder + 0.5 g low-sodium salt; containing 47.7 g carbohydrates, 6.5 g whey protein, and 193 kcal).~After surgery, once there were no symptoms such as dizziness or vomiting, patients could start consuming clear liquids (containing 47.7 g carbohydrates, 6.5 g protein, and 221 kcal) orally every 30 minutes, 4 times on the day of surgery.~Starting from the first day after surgery, patients consumed 200 ml of fat-free nutritional liquid (50 g enzymatically hydrolyzed rice powder + 7.5 g isolated whey protein + 0.5 g low-sodium salt; 223 kcal) per serving, 4 to 6 times per day as needed."
214408068|NCT06193161|BEHAVIORAL|Therapist-supported internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure for eight weeks.
214408069|NCT00759824|DRUG|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
214408070|NCT06610357|OTHER|Group 1|42 diparetic children with cerebral palsy were included in the study. The Modified Ashworth Scale (MAS), the Children's Functional Independence Measure (WeeFIM)-Mobility section and the Gross Motor Function Measure-88 (GMFM-88) were applied before and after SDR surgery.
214408071|NCT00117377|DRUG|Pimecrolimus|Pimecrolimus cream 1 % bid
214408072|NCT00117377|DRUG|Placebo|Placebo application bid
214408073|NCT06614153|DRUG|HRG2010(I)|HRG2010(I)
214408074|NCT06614153|DRUG|HRG2010(II)|HRG2010(II)
214408075|NCT06614153|DRUG|Sustained-release Carbidopa/Levodopa|Sustained-release Carbidopa/Levodopa
214408076|NCT06615687|PROCEDURE|Inverted T shape Free Gingival Graft|"the preparation of the recipient site commenced by making a horizontal incision at the mucogingival junction (MGJ) as well as two vertical incisions extending to the adjacent teeth and about 3-4 mm beyond the MGJ. A sharp split-thickness flap will be reflected, and the surfaces between these incisions will be de-epithelialized. Also, all the surfaces of the interdental papilla up to the lingual side will be de-epithelized using a 15c blade and microsurgical scissor .(Harvesting of the palatal donor site will be designed 2 mm away from the gingival margin using a template in the form of an inverted T-shape, taking into consideration the position of the greater palatine blood vessels at 5 mm. 2 mm is required for the width of the interproximal extension with 3 mm length to obtain an even thickness of 1-1.5 mm .~Placement of the graft : The Inverted T FGG will be inserted between the teeth to cover interproximal tissue defect and sutured lingually into the lingual marginal gingiva"
214408077|NCT06615687|PROCEDURE|Free Gingival Graft|"Preparation of the recipient site :Following an intrasulcular incision, 2 mm-long horizontal incisions at the level of the CEJ will be performed bilaterally. From these, vertical releasing incisions will be placed in a diverging manner, extending well into the alveolar mucosa, a thin partial thickness flap will be subsequently raised then excised. The dimension of the resulting site will be measured to obtain a rectangular foil template .~Harvesting of the Graft :Using the foil template, graft dimensions will be outlined in the palate adjacent to the premolars and first molar. A partial thickness graft consisting of epithelium and a thin layer of underlying connective tissue will be harvested (intended total thickness of graft: 1.5 mm), maintaining a distance of ≥2 mm to the maxillary teeth."
215012562|NCT00327132|DRUG|Omeprazole, Amoxicillin, Clarithromycin|
215012563|NCT00927186|DRUG|Teriparatide|"20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
215012564|NCT00927186|DRUG|Zoledronic Acid|"5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
215012565|NCT05551221|DRUG|Silodosin Capsules|Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
215012566|NCT05551221|DRUG|Ningmitai capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
215012567|NCT05551221|DRUG|Tamsulosin|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
215012568|NCT01145222|DRUG|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
215012569|NCT01145222|DRUG|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
215099442|NCT03821116|OTHER|Soured milk (filmjölk)|Swedish soured milk (from cow milk).
215099443|NCT06307236|BEHAVIORAL|Emotional Freedom Techniques|Emotional Freedom Technique (EFT), which is included in the energy psychotherapy similar to the cognitive behavioral therapy method, is an easily applicable method that is used to relieve mental problems such as anxiety and stress and has positive results, which has just started to be used in the world and in our country. EFT can be applied safely to all ages and groups.
215099444|NCT01008124|OTHER|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
215099445|NCT01008124|OTHER|Placebo maneuver|3 cycles placebo maneuver initial session.
215099446|NCT03358134|DRUG|Secukinumab|anti IL17 therapy (subcutaneous)
215099447|NCT00828789|DRUG|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
215099448|NCT02424682|OTHER|No intervention|No intervention administered in this study
215099449|NCT05574465|DEVICE|High resolution solid state manometry|The use of esophageal manometry device during removal of endotracheal tube by anesthesia
215099450|NCT00317590|DEVICE|Rapid Diagnostic Test for Malaria (Paracheck®)|
214408078|NCT06528782|OTHER|Pecha Kucha method|The Pecha Kucha method will be prepared in the form of a presentation consisting of 20 slides each shown for 20 seconds. The Pecha Kucha presentation lasts 6 minutes and 40 seconds, and most slides present only images. This method is planned to be used in breastfeeding education as it will be more memorable because it contains more visual, auditory and short information.
215012570|NCT01145222|DRUG|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
215012571|NCT01145222|DRUG|D. Midazolam|Initial standardized dose plus supplemental doses as necessary.
215012572|NCT01507389|DRUG|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
215012573|NCT01421134|DRUG|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
215012574|NCT01421134|DRUG|Placebo|Placebo
215012575|NCT04447066|OTHER|No intervention|No intervention - VHIT will be used but without intervention
215012576|NCT04378088|OTHER|Validation of CEBuS|Validation of a new score for bubbles in the colon.
215012577|NCT00580294|DRUG|Oxymorphone|IV PO
215012578|NCT03407911|OTHER|Harvested|Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis
215012579|NCT05832814|BEHAVIORAL|Integrated training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm. For singing training, patients follow the audios and videos to take training at home, which are recorded by singing teachers and physiotherapists prior to the trial. Each session includes technical instructions in order to achieve better respiratory control during singing.
215012580|NCT05832814|BEHAVIORAL|Rhythm-guided exercise training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking test(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm.
215012581|NCT06134895|DRUG|Tramadol with Ketamine|Tramadol with Ketamine is being provided randomly using prospective, double-blind
215012582|NCT06134895|DRUG|Tramadol|Tramadol alone is being provided randomly using prospective, double-blind
215012583|NCT06384703|DIAGNOSTIC_TEST|Taking blood for kit study|Taking blood for kit study (Elisa kit)
215012584|NCT05611905|COMBINATION_PRODUCT|11C-para-aminobenzoic acid PET/CT|A bolus of 20 mCi of 11C-PABA followed by PET/CT
215012585|NCT05611905|DRUG|Probenecid|Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.
215012586|NCT04080232|DEVICE|lung MRI|lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.
215012587|NCT06150014|DRUG|Placebo|TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.
215012588|NCT06150014|DRUG|TQA3605 tablets|TQA3605 inhibits viral replication.
215012589|NCT06150014|DRUG|Entecavir dispersible tablets|Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
215012590|NCT06150014|DRUG|Tenofovir disoproxil fumarate tablet|Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
215012591|NCT06150014|DRUG|Tenofovir alafenamide fumarate tablet|Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
215012592|NCT06290024|DEVICE|A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function|Using the use of pain visual analog scale (VAS), digital pain grading method (NRS), neuropathic pain assessment scale (DN4), sleep quality (Pittsburgh sleep quality index, Ascens insomnia scale), social support assessment scale (SSQ), Montreal cognitive assessment scale (MoCA), Barrett impulse scale (BIS), anxiety and depression score (GAD-7, PHQ-9), emotional tasks, cognitive function (N-back, time perception, delay-discount), electroencephalogram (EEG), near-infrared brain function imaging (fNIRS) and other indicators to study the dynamic changes of various factors in the process of acute pain.
215012593|NCT04263532|DEVICE|Modified BiPAP A40 with Vector Algorithm (Vector)|The Modified BiPAP A40 with Vector Algorithm (Vector) is intended to provide non-invasive ventilatory support to treat patients weighing over 10 kg (22 lbs) with Obstructive Sleep Apnea (OSA) or Respiratory Insufficiency. It is intended to be used within the home, institutional/ hospital, and diagnostic laboratory environments. This device is not intended for life support. The BiPAP A40 EFL screening and therapy is intended for patients weighing over 30 kg (66 lbs) with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with primary cause being Chronic Obstructive Pulmonary Disease (COPD) to screen for the presence, and abolishment of Expiratory Flow Limitation (EFL).
215099451|NCT01951313|OTHER|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (\< 2g) and low carotenoid (\< 2000µg) meal as the 2nd meal.
214408079|NCT06616506|DEVICE|newly-invented AI model|Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.
214408080|NCT06615648|BEHAVIORAL|PMT|7-minute PMT intervention video
214408081|NCT06615648|BEHAVIORAL|Non-contact Control|6-minute alternative video
215099452|NCT03249103|DRUG|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
215099453|NCT03249103|DRUG|Placebo oral capsule|Matching placebo capsules.
215099454|NCT02428413|DEVICE|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
215099455|NCT02428413|DEVICE|Standard oxygen mask|Provide supplemental oxygen
214408082|NCT06614556|OTHER|Resistance Training|Participants in the training groups performed bilateral hand grip resistance training three times per week for four weeks using a specialized hand-grip kit provided to them. Participants were provided with pictures and instructions for each exercise upon completion of the initial testing (PRE) session. They were asked to perform 12 training sessions (approximately 30-45 mins) over the 4 weeks according to their schedule. Each participant was asked to keep a training log to assist with accountability. Those assigned to the control groups were asked to maintain their normal daily activities throughout the four weeks.
214408083|NCT06614686|DRUG|U87 autologous CAR T-cell|Treatment with U87 chimeric antigen receptor T-cell infusion.
214408084|NCT06698016|DRUG|Nemtabrutinib|Oral administration
214408085|NCT06698016|DRUG|Efavirenz|Oral administration
214408086|NCT06696625|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution."
214408087|NCT06696625|DRUG|0.1% sodium hyaluronate eye drop|Participants received 0.1% sodium hyaluronate eye drop (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany).
214408088|NCT06697366|DRUG|Irinotecan liposome injection Ⅱ|56.6 mg/m2，Q3W
214408089|NCT06697366|DRUG|Sintilimab|200mg，Q3W
214408090|NCT06698029|OTHER|VIM Targeting|Targeting with the use of VIMRS-LAT-1.0
215099456|NCT01469403|BEHAVIORAL|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
214408091|NCT06696976|OTHER|Telerehabilitation|"A qualified physiotherapist himself used the digital platform Zoom (Zoom Video Communications or WhatsApp video communication) to deliver synchronic online sessions (60 min each), sending each participant a link by email, half an hour before the weekly meetings. The patients were also invited to present themselves in comfortable gymnastic clothing and with tools useful for the motor program: a chair, a stick, a bottle full of water (or small weights if the patient had them), and a mat.~Nerve gliding exercises: These 5 Nerve gliding exercises will perform 3 times a week requiring 10 minutes to complete.~Balance exercises: Balance exercise include 10 exercises and take 20 minutes of completion, 2minute for each exercise.~Resistance training using Thera Band will performed with the presence of the researcher as an instructor.The main upper-extremity movements consisted of chest press, shoulder press etc and in lower extremity such as leg press ,back thgh press etc. in patient."
214408092|NCT06696976|OTHER|Clinical rehabilitation|"A qualified physiotherapist himself used the digital platform Zoom (Zoom Video Communications or WhatsApp video communication) to deliver synchronic online sessions (60 min each), sending each participant a link by email, half an hour before the weekly meetings. The patients were also invited to present themselves in comfortable gymnastic clothing and with tools useful for the motor program: a chair, a stick, a bottle full of water (or small weights if the patient had them), and a mat.~Nerve gliding exercises: These 5 Nerve gliding exercises will perform 3 times a week requiring 10 minutes to complete.~Balance exercises: Balance exercise include 10 exercises and take 20 minutes of completion, 2minute for each exercise.~Resistance training using Thera Band will performed with the presence of the researcher as an instructor.The main upper-extremity movements consisted of chest press, shoulder press etc and in lower extremity such as leg press ,back thgh press etc. in patient."
215012594|NCT04263532|DEVICE|Modified BiPAP A40 with Standard of Care Settings|The Modified BiPAP A40 with Standard of Care settings is intended to provide non-invasive ventilatory support to treat patients weighing over 10 kg (22 lbs) with Obstructive Sleep Apnea (OSA) or Respiratory Insufficiency. It is intended to be used within the home, institutional/ hospital, and diagnostic laboratory environments. This device is not intended for life support. The BiPAP A40 EFL screening and therapy is intended for patients weighing over 30 kg (66 lbs) with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with primary cause being Chronic Obstructive Pulmonary Disease (COPD) to screen for the presence, and abolishment of Expiratory Flow Limitation (EFL).
215012595|NCT03365908|PROCEDURE|Adductor Canal Nerve Block|An adductor canal nerve block with 15 mL of 0.5% ropivacaine will be performed pre-operatively by Anesthesiology.
215012596|NCT03365908|DRUG|Ropivacaine injection|15 mL of 0.5% ropivacaine will be administered for the adductor canal block
215012597|NCT03911687|BEHAVIORAL|CONCERN CDS system notification|"The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months"
215012598|NCT00143520|DRUG|Rivoglitazone|
215012599|NCT00143520|DRUG|Pioglitazone|
215012600|NCT00143520|DRUG|Placebo|
215012601|NCT03362957|DEVICE|Geniculate Artery Embolization|Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.
215012602|NCT03362957|DIAGNOSTIC_TEST|Sham Procedure|Patients will receive a sham procedure, which will include a diagnostic angiogram
215099457|NCT05898230|DEVICE|Mitral Valve Replacement|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
215012603|NCT04010253|DEVICE|SIMEOX|Instrumental airway clearance by the medical device SIMEOX
215012604|NCT04010253|OTHER|Autogenic drainage|Manual aiway clearance by autogenic drainage
215099458|NCT04190797|DEVICE|Photobiomodulation + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
215099459|NCT04190797|DEVICE|Placebo + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
215099460|NCT05490108|BIOLOGICAL|ZR202-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype)
215099461|NCT05490108|BIOLOGICAL|ZR202a-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (variant)
215099462|NCT05490108|BIOLOGICAL|Comirnaty®|Comirnaty® (Pfizer-BioNTech)
215099463|NCT05019391|DEVICE|transcranial doppler|it provides an accurate, noninvasive, and simple method for the diagnosis of VBI. Through the diagnosis results, it will be clear about the blood flow status of single vessel and vascular compliance, which is helpful for accurate reflection of the subtle changes of VBI
215099464|NCT00594594|OTHER|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
215099465|NCT05503888|DRUG|Almonertinib combined with SHR-1701|"Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral"
215099466|NCT05503888|DRUG|Almonertinib|"Phase Ⅱ:~Almonertinib: tablets, oral"
215099467|NCT03841136|DRUG|anlotinib|anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1\~D3
215099468|NCT01286103|DRUG|Canagliflozin 300 mg once daily and 150 mg twice daily|Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
215012605|NCT05970406|OTHER|high intensity dysphagia therapy|Intensive swallowing interventions with Speech Language Pathologists to begin within 24 hours of video swallow study results. Daily treatment will include two 30-minute sessions, 5-6 days a week which will include the evidence-based dysphagia exercises focusing on tongue resistance, head lift/chin tuck against resistance and expiratory muscle strength training tasks
215012606|NCT05288257|BEHAVIORAL|Learning Module|Safe Cholecystectomy Learning Module
215012607|NCT04267315|PROCEDURE|Trigger point injection|1mL injections of 1% lidocaine in the muscles identified active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
215099469|NCT01286103|DRUG|Canagliflozin 100 mg once daily and 50 mg twice daily|Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
215012608|NCT04267315|PROCEDURE|Subcutaneous saline injection|0.2mL subcutaneous saline injections superficial to the muscles identified with active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
215099470|NCT02025439|DEVICE|rTMS|
215099471|NCT02025439|DRUG|Amantadine|
215099472|NCT04129385|PROCEDURE|20 degree Trendelenburg position|The patients in the intervention group will be placed in trendelenburg position postoperatively.
215099473|NCT01869660|BEHAVIORAL|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
215099474|NCT00461461|PROCEDURE|meeting nurses / physicians, quality improvement sessions|"For each iatrogenic indicator, the interventions are:~1. Meeting with the ICU staff to discuss the epidemiology of patients on each theme.~2. Pocket card with guidelines on the theme and ICU protocol in each study ICU.~3. Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject."
215099475|NCT01257607|DRUG|MIM-D3 Ophthalmic Solution|28 Days, BID
215099476|NCT01257607|DRUG|Placebo Ophthalmic Solution|28 Days, BID
215099477|NCT00468975|DRUG|PF-610,355|
215099478|NCT00468975|DRUG|Salmeterol|
215099479|NCT01816555|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
215099480|NCT02073669|PROCEDURE|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)|
215099481|NCT04288700|DRUG|oral propranolol|oral propranolol therapy at a dose of 1 mg/kg/d (Inderal 20 mg/5 mL) in three divided doses. If the child will tolerate the treatment with no side effects, therapy will continue in an outpatient clinic. Blood glucose level will be also measured in a periodic manner during therapy. The dose will be increased gradually to 2 mg/kg/d in three divided doses if there will be no adverse effects from the initial therapy.
215099482|NCT04288700|DRUG|Oral Captopril|A test dose of 0.1 mg kg) will be administered orally with pulse rate and blood pressure monitored at 0.5, 1 and 2 h and at each follow up. If the test dose is tolerated, captopril administration will start at 0.15 mg kg) per dose 8-hourly. Pulse rate and blood pressure will be monitored 4-hourly and doses will be withheld if hypotension is documented. After 24 h, the dose will be increased to 0.3 mg kg) per dose 8-hourly .
215099483|NCT04288700|DRUG|intralesional propranolol injection|intralesional propranolol injection 1 mg/mL
215099484|NCT04288700|DRUG|topical Timolol maleate 0.5% eye drops|To be Applied on the surface of the lesions three times daily
215099485|NCT00559676|DRUG|capecitabine|
215099486|NCT00559676|DRUG|fluorouracil|
215099487|NCT00559676|DRUG|irinotecan hydrochloride|
215099488|NCT00559676|DRUG|leucovorin calcium|
215099489|NCT00559676|DRUG|oxaliplatin|
215099490|NCT00559676|OTHER|laboratory biomarker analysis|
215099491|NCT00559676|OTHER|pharmacological study|
215099492|NCT03683888|BEHAVIORAL|HealthSnap|HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
215099493|NCT03683888|BEHAVIORAL|dietary counseling|Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
215012609|NCT04267315|OTHER|Comprehensive Rehabilitation program|Patients in both groups will undergo standard of care rehabilitation delivered by a Physiatrist, which may include Physical Therapy, Occupational Therapy, Exercise Physiologist, Rehabilitation Nurse, Psychologist, as per Physiatrist's prescription. Both the comprehensive rehabilitation program and pain medications will continue to be managed by participant's Physiatrist, who will be blinded to patient's allocation. The researchers will be responsible for TPI and for data collection.
215012610|NCT04772235|DRUG|Repotrectinib|"Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib~Part B: at the RP2D for all patients in combination with osimertinib."
214408093|NCT06696937|OTHER|Tai chi|Tai chi is a practice that involves a series of slow gentle movements and physical postures, a meditative state of mind, and controlled breathing. Tai chi originated as an ancient martial art in China. Over the years, it has become more focused on health promotion and rehabilitation.
215099494|NCT02195167|DRUG|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
214408094|NCT06696937|OTHER|full body vibrator|Advocates say that as little as 15 minutes a day of whole-body vibration three times a week may aid weight loss, burn fat, improve flexibility, enhance blood flow, reduce muscle soreness after exercise, build strength and decrease the stress hormone cortisol.
214408095|NCT06698315|OTHER|Observation|Medical Records Chart Review
214408096|NCT06697288|OTHER|Tested product group|Apply the test product per zone at least twice a day on the face, neck (neck \& nape), décolleté and back of the hand in the morning and at midday whatever the weather conditions and the activities of the day
215099495|NCT01026740|DRUG|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
215099496|NCT01009866|BIOLOGICAL|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
215099497|NCT01093066|DRUG|optimal TURB|The TURB will always try to be optically complete.
215099498|NCT00556270|DRUG|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
215099499|NCT00673283|DEVICE|bi-plane chest radiography|Bi-plane radiography of the thorax
215099500|NCT01627028|PROCEDURE|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
215099501|NCT04077931|OTHER|exercises|Walking on treadmill with fixed 0% grade inclination
215099502|NCT04237246|DRUG|Tacrolimus|"24 hour long acting advegraf"
215099503|NCT03688100|BEHAVIORAL|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
215099504|NCT03688100|DRUG|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
215099505|NCT01786252|DRUG|human chorionic gonadotropin (hCG)|"500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)"
215099506|NCT01786252|DRUG|Placebo Comparator (for hCG)|"50ul of IVF medium (Global-trademark) to mimic hCG infusion"
215099507|NCT03108508|DIETARY_SUPPLEMENT|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
215099508|NCT03108508|DIETARY_SUPPLEMENT|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
215099509|NCT03108508|DIETARY_SUPPLEMENT|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
215099510|NCT02345330|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
215099511|NCT02345330|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
215099512|NCT00494507|DRUG|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
215099513|NCT00494507|DRUG|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
215099514|NCT00494507|DRUG|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
215099515|NCT00547027|BEHAVIORAL|print-based physical activity intervention|individually-based, print-based physical activity intervention
214693926|NCT04903964|OTHER|family-centered nutrition education|There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.
214693927|NCT02420223|DRUG|Propranolol|
214408097|NCT06697288|OTHER|Control group|Maintain their normal routine of using cosmetics (cleansers and moisturizers) and normal sun protection habits (if applicable)
214408098|NCT06698211|DRUG|Posaconazole tablet|Posaconazole tablet will be given at a dose of 300mg q12h on day 1 and 300mg qd from day 2 for patients who receive HSCT as the primary prophylaxis of IFD, after which the Posaconazole plasma concentration on day 5 will be examined. Once patients developed GI GVHD, first line therapy and second line treatment will be reviewed according to the condition, besides which the Posaconazole plasma concentration would be detected again on the first, third and fifth day after onset of GI GVHD symptoms to monitor the impact of GI GVHD on the Posaconazole plasma concentration.
214408099|NCT06696144|DIAGNOSTIC_TEST|Skin swabs for multi drug resistant bacteria|Swabs from personal items or skin will be obtained from stuff and analyzed to detect CVE or VRE bacteria using Automated Susceptibility Testing
214408100|NCT06697886|DRUG|Antiwei Granules|During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
214408101|NCT06697886|DRUG|Antiwei Granules Placebo|During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
214408102|NCT00147043|PROCEDURE|Leukapheresis|
214408103|NCT00147043|PROCEDURE|Infusion of stem cells via image guided scan|
214408104|NCT06711471|DRUG|trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab|Patients enrolled in this study will receive trifluridine/tipiracil in combination with bevacizumab and camrelizumab, with a treatment cycle of 14 days, until disease progression, death, intolerable toxicity, or other criteria for discontinuation of study treatment as specified in the protocol (whichever occurs first).
214408105|NCT05108051|DRUG|ZSP1273|ZSP1273 tablets 600mg administered orally once daily
214408106|NCT05108051|DRUG|Oseltamivir|Oseltamivir 75mg administered orally twice daily
214408107|NCT03717259|PROCEDURE|Open nephrectomy|The surgical technique for open nephrectomy consists of placing the donor in the lateral decubitus position and making an incision with or without rib resection that allows retroperitoneal access.
214408108|NCT03717259|PROCEDURE|Hand-assisted laparoscopic nephrectomy|The hand-assisted technique begins with the incision for the introduction port of the hand, the renal artery and vein are divided using endoscopic staples and the graft is manually removed.
214408109|NCT03717259|PROCEDURE|Laparoscopic nephrectomy|In the pure laparoscopic technique the patient is placed in the same position of lateral decubitus and after introducing the trocars in the abdomen, the colon is mobilized and the renal capsule is divided, the kidney is removed after performing the cut of the renal artery and vein through a suprapubic incision.
214408110|NCT06919276|OTHER|Vaping Device Labeling|"Participants will view one vape image (experimental stimulus) and are randomized to a label presented and the color/flavor of the vaping device presented.~The label conditions are:~1. plain (i.e., no labeling on device)~2. contains THC~3. contains 80% THC~4. contains 80% THC - HIGH POTENCY~5. contains nicotine~6. contains 5% nicotine~7. contains 5% nicotine - HIGH STRENGTH The color/flavor conditions are: mint/mint, white/original, blue/blueberry."
215012611|NCT04772235|DRUG|Osimertinib|"Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted.~Part B: at the RP2D level in combination with repotrectinib"
214693928|NCT00985556|DRUG|capecitabine|Given orally
214693929|NCT00985556|DRUG|oxaliplatin|Given IV
215012612|NCT04168710|DRUG|ESP block with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
215012613|NCT04168710|OTHER|Saline control/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
215012614|NCT00183898|DRUG|oxaliplatin, capecitabine|cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
215012615|NCT03506126|OTHER|Leucine|There are 8 different leucine test levels ranging from 20 to 120 mg of leucine per kilogram body weight per day (20-120 mg/kg/d)
215012616|NCT00294788|BIOLOGICAL|Fluvax|
215012617|NCT00294788|DRUG|PCC® (Lactobacillus fermentum VRI 003)|
215012618|NCT00854854|BIOLOGICAL|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
215012619|NCT04607447|BEHAVIORAL|low intracranial pressure strategy treatment|"1. Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.~2. Abdominal belt compression"
215012620|NCT04607447|DRUG|Atorvastatin plus Dexamethasone|Atorvastatin plus Dexamethasone
215012621|NCT00629642|DRUG|Solifenacin Succinate|Oral, 10mg
215012622|NCT00629642|DRUG|Solifenacin Succinate|Oral, 5mg
215012623|NCT00629642|DRUG|Oxybutynin Hydrochloride|Oral, 15mg
215012624|NCT00629642|DRUG|Placebo|Oral
215012625|NCT04294238|BEHAVIORAL|Aerobic exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
215012626|NCT04867070|DIAGNOSTIC_TEST|NAS score|Participants will be recorded according to the NAS and W-BAS pain scores
215012627|NCT00663143|PROCEDURE|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
215099516|NCT00547027|BEHAVIORAL|usual care|print-based materials of nutritional information
215099517|NCT06508229|DRUG|Adebrelimab|adebrelimab, IV
214408111|NCT06919237|OTHER|HIIT Intervention|Over the first 4 weeks, participants will perform 4 bouts of 2 min of high-intensity exercise at 80-90% heart rate reserve (HRR), during the next 4 weeks, participants will perform 6 bouts of 2 min of high-intensity exercise at 80-90%HRR, while in the last 4 weeks participants will perform 6 bouts of 2 min of high-intensity exercise at 90%HRR). Exercise bouts will be interspersed by 2 min of active recovery at 50-60% HRR.
215012628|NCT06100835|OTHER|Complex intervention involving physical activity and behaviour change techniques|"The intervention protocol derives from a previous, extensive, co-creation phase involving end-users as well as relatives, experts, professionals working working with older adults, university students and researchers.~It will be based on a structured group-based PA programme supervised by trained professionals, tailored to participants' needs to include joyful components combined with self-management strategies to encourage behaviour change also beyond the sessions. All participants (including end-users but not only) will also be encouraged to join virtual communities of practice (VCoP) for further support and knowledge exchange."
215012629|NCT04617223|PROCEDURE|Endoscopic sinus evacuation|Evacuation of the sinus by using endoscope
214408112|NCT06919237|OTHER|MICT Intervention|Over the first 4 weeks participants in MICT will perform continuous exercise at 50-60% HRR (2x10'), during the next 4 weeks participants will perform continuous exercise at 50-60% HRR (2x12'), while in the last 4 weeks participants will perform continuous exercise at 60-70% HRR (2x15').
215012630|NCT04813874|DRUG|Nitrous Oxide|Nitrous Oxide Inhalational Agent
215099518|NCT06508229|DRUG|albumin paclitaxel|albumin paclitaxel, iv
215012631|NCT04813874|PROCEDURE|Neuraxial analgesia|Epidural Labor Analgesia Placement
215012632|NCT02130011|OTHER|with feeding/fluid instruction|No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
215099519|NCT06508229|DRUG|Nedaplatin|Nedaplatin，IV
215099520|NCT03783494|DRUG|Target control infusion with propofol|Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
215099521|NCT01180517|PROCEDURE|Percutaneous coronary intervention (PCI)|balloon angioplasty
215099522|NCT01180517|PROCEDURE|PCI|balloon angioplasty
215099523|NCT03948919|DRUG|Fecal microbiota|Lyophilized encapsulated fecal microbiota given daily for 8 weeks.
215012633|NCT05451888|BEHAVIORAL|Spa treatment|A 40 minute period of lying in the spa treatment pool
215012634|NCT01851369|DRUG|TRC102|Methoxyamine hydrochloride (TRC102) has been shown to potentiate the activity of temozolomide by preventing base excision repair (BER) and allowing cleavage of TRC102 bound deoxyribonucleic acid (DNA), which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with Temozolomide (TMZ) and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
215012635|NCT01851369|DIAGNOSTIC_TEST|CT scan|CT scans will be performed at baseline, and repeat scans will be performed every 2 cycles (every 3 cycles for participants on study more than one year).
215012636|NCT01851369|OTHER|Lomotil|If diarrhea develops and does not have an identifiable cause other than study drug administration, anti-diarrheal's such as Lomotil (diphenoxylate hydrochloride (HCl) 2.5 mg + atropine sulfate 0.025 mg/tablet) dosed according to package insert or loperamide 4 mg by mouth (po) after the first unformed stool with 2 mg po every 2 hours as long as unformed stools continue (4 mg every 4 hours while asleep). No more than 16 mg of loperamide should be taken in during a 24-hour period.
215012637|NCT01851369|OTHER|Prochlorperazine|If a participant develops nausea/vomiting, an anti-emetic such as prochlorperazine may be given.
215012638|NCT01851369|OTHER|Metoclopramide|If a participant develops nausea/vomiting, an anti-emetic such as metoclopramide may be given.
215012639|NCT01851369|OTHER|5-HT3 antagonist|If a participant develops nausea/vomiting, an anti-emetic such as 5-HT3 antagonist may be given.
215012640|NCT01851369|OTHER|Aprepitant|If a participant develops nausea/vomiting, an anti-emetic such as aprepitant may be given.
215012641|NCT01851369|PROCEDURE|Biopsy|Tumor biopsies will be optional during the escalation phase.
215012642|NCT00928005|BEHAVIORAL|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
214693930|NCT00985556|DRUG|tegafur-gimeracil-oteracil potassium|Given orally
214693931|NCT04466501|DEVICE|ACR LAB|"The ACR \| LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm."
215012643|NCT00928005|BEHAVIORAL|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
215099524|NCT03948919|DRUG|Placebo|Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.
215099525|NCT02437084|DRUG|Atorvastatin|Study subjects will receive atorvastatin 40 mg for 10 weeks.
215099526|NCT04738630|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
215099527|NCT06507384|OTHER|AI-Based Risk Assessment Model|Bukret AI Risk Assessment Model is a sophisticated decision support system that evaluates clinical data and patient history to generate personalized risk scores and classify patients into risk group categories for those undergoing plastic surgery. This AI model analyzes various risk factors, including BMI, age, smoking habits, and medical history, to identify potential complications. Based on the AI-generated risk group and specific risk factors, the model provides tailored recommendations for preoperative management, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to minimize surgical risks and improve outcomes. This intervention aims to enhance surgical planning and patient safety by offering personalized, actionable recommendations.
215099528|NCT04542720|PROCEDURE|Observational: Decompression|Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
214408113|NCT06919237|OTHER|HRV-Guided Intervention|"Following a 10-day initial characterization period, where the HRV is measured with plethysmography continually during the night, with Whoop (https://www.whoop.com) device, the individual HRV profile is defined, still, participants will use the Whoop during all intervention to allow the updating of HRV profile. Then, considering the daily individual autonomic regulation, following a decision-making schema modiﬁed from Kiviniemi et al., (2007) \[21\], exercise intensity will be defined for the training session, i.e., if LnRMSSD7day-roll-avg remained inside the smallest worthwhile change (SWC) (SWC = 0.5 × standard deviation), high intensity or moderate-intensity training sessions is prescribed, if LnRMSSD7day-roll-avg fell outside SWC, low intensity or rest is prescribed, leading to different workloads from the predefined training programs."
214408114|NCT05397106|DEVICE|CODMAN CERTAS Plus Programmable Valve|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
214408115|NCT02501811|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
214408116|NCT02501811|BIOLOGICAL|c-kit+ cells|15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
214408117|NCT02501811|BIOLOGICAL|Placebo (Plasmalyte A)|15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
214408118|NCT06211257|OTHER|Dematerialized Personalized Care Plan (ePCP)|Post-treatment support with standard support combined with dematerialized support
214408119|NCT04094064|DEVICE|Continuous Glucose Monitor|Use of a continuous glucose monitor during study period.
215012644|NCT04107363|PROCEDURE|Oropharyngeal aspiration before changing the position of the patient|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes. After the oropharyngeal aspiration was completed, the patient's position was changed."
215012645|NCT04107363|OTHER|Control group:|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
215012646|NCT04869917|BEHAVIORAL|Decision Aid intervention|"* Displays information about the benefits and risks of ILI and metformin~* Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~* Prompts patients to commit to immediate next steps~* Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen"
215012647|NCT04869917|BEHAVIORAL|Text Messaging intervention|"* Defines prediabetes and includes individualized A1c values~* Present benefits and risks of intensive lifestyle intervention and metformin~* States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~* Encourages initiating intensive lifestyle intervention or discussing metformin with provider~* Include selected behavioral content from diabetes prevention program~* Initial message with automatic opt-in, allows opt-out for messages~* Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming"
215012648|NCT04869917|BEHAVIORAL|Usual Care|Patients receiving care at non-intervention clinic sites will not be exposed to treatment intervention.
215012649|NCT02453191|DRUG|Talimogene Laherparepvec|Talimogene Laherparepvec
215012650|NCT02453191|RADIATION|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
215012651|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy
215012652|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
215012653|NCT00007501|BIOLOGICAL|Varicella-zoster vaccine|Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
215012654|NCT00007501|BIOLOGICAL|Placebo|Placebo vaccine
215012655|NCT03364686|BIOLOGICAL|Biotin-Labeled Red Blood Cells|We will collect 500 mL of blood. The blood will be processed and split into two bags and labeled with a naturally occurring vitamin, biotin. The blood will then be re-infused back into the same participant at 2 time points (5-7 days and 35-42 days after storage).
215012656|NCT05632900|PROCEDURE|Endoscopic ultrasound guided drainage of walled off pancreatic necrosis|It is Therapeutic procedure to treat walled off pancreatic necrosis.
215012657|NCT00954655|GENETIC|mutation analysis|
215012658|NCT00954655|GENETIC|polymorphism analysis|
215012659|NCT00954655|OTHER|laboratory biomarker analysis|
215012660|NCT03255590|BEHAVIORAL|Configuration task|Training the impaired hand on a configuration task
215012661|NCT00791882|BEHAVIORAL|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
215012662|NCT04651374|DEVICE|geko T3|The device stimulates the peroneal nerve.It will be applied for the entire duration of ICU stay and replaced once every 24 hours.
215012663|NCT01104272|DEVICE|LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)|Study of Adipose Tissue Treatment Using Focused Ultrasound
215012664|NCT05163535|DRUG|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
215012665|NCT05163535|OTHER|ELPIDA®|Elsulfavirine capsules
215012666|NCT01098357|DRUG|Biochaperone PDGF-BB Low dose|BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
215012667|NCT01098357|DRUG|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
215012668|NCT01098357|DRUG|Regranex|Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
214408120|NCT03470987|PROCEDURE|Phase I Periodontal therapy|Oral hygiene instuction, scaling and root planning
214408121|NCT03470987|DIETARY_SUPPLEMENT|Metabolic control|Calorie restricted diet
214408122|NCT05224362|DEVICE|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability.|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. Bertec force plate analysis will be performed to assess the acute effects on balance and stability. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/ dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
214408123|NCT02770040|DRUG|Infliximab|INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
215012669|NCT01098357|DRUG|Biochaperone PDGF-BB Very Low Dose|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
215012670|NCT03922971|OTHER|Option 1: National comparison|Ability to view center's rate compared with all others.
215012671|NCT03922971|OTHER|Option 2: National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
215012672|NCT02636322|DRUG|Cyclophosphamide|Given IV
215012673|NCT02636322|DRUG|Doxorubicin Hydrochloride|Given IV
215012674|NCT02636322|DRUG|Etoposide|Given IV
215099529|NCT04542720|PROCEDURE|Observational: Extension Fusion|Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
215099530|NCT00487370|PROCEDURE|Implantation of gold beads around a knee through needles|
215099531|NCT00487370|PROCEDURE|Sham implantation: Insertion of needles around a knee|
215099532|NCT03324919|BEHAVIORAL|HRQL|Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
215099533|NCT00647660|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
215099534|NCT00647660|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
215099535|NCT03729245|BIOLOGICAL|bempegaldesleukin|Specified dose on specified days
215099536|NCT03729245|DRUG|sunitinib|Specified dose on specified days
215099537|NCT03729245|BIOLOGICAL|nivolumab|Specified dose on specified days
215099538|NCT03729245|DRUG|cabozantinib|Specified dose on specified days
215099539|NCT03273660|DEVICE|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
215099540|NCT00875940|OTHER|Diagnostic imaging procedures.|
215099541|NCT01605318|DRUG|Labetuzumab Govitecan (LG)|Administered as a slow intravenous (IV) infusion.
215099542|NCT01433094|BEHAVIORAL|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
214693932|NCT05634096|DIAGNOSTIC_TEST|Oximetry|Children underwent oximetry simultaneously with video-polygraphy or video-polysomnography in routine clinical practice. The data are retrospectively collected from the patient's recording.
214693933|NCT04738500|PROCEDURE|PENG Block combinated with PCA|After spinal anesthesia PENG block will be performed
214693934|NCT04738500|PROCEDURE|PCA|PCA will be applied after surgery
214693935|NCT05062616|PROCEDURE|Toenail surgery|modified Winograd procedure
215012675|NCT02636322|DRUG|Ibrutinib|Given PO
215012676|NCT02636322|DRUG|Lenalidomide|Given PO
215012677|NCT02636322|DRUG|Prednisone|Given PO
215012678|NCT02636322|BIOLOGICAL|Rituximab|Given IV
215012679|NCT02636322|DRUG|Vincristine Sulfate|Given IV
215012680|NCT04983498|DRUG|Ondansetron 4 MG|PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis.
215012681|NCT04983498|DRUG|Lactated Ringers, Intravenous|Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).
215012682|NCT04983498|OTHER|Early Mobilization|Patient transferred up to the chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters and patient safety.
215099543|NCT01433094|BEHAVIORAL|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
214408124|NCT03972293|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications have 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. To increase the category of interest, the notifications use two types of messages: life insights and tips. Life insights provide participants information on their historical data (for a given category) in order to help them self-monitor. Tips are non-data based notifications which provide general advice for improving the category of interest.
214408125|NCT03972293|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
214408126|NCT04004702|DRUG|Levetiracetam|Levetiracetam 500mg twice a day
214408127|NCT01218503|BEHAVIORAL|CHOICES - obese|Standard group behavioral weight loss treatment
214408128|NCT04759339|DRUG|AG-920|AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%
214408129|NCT04045366|OTHER|Sample collection|Plasma and BAL sample collection
214408130|NCT05137951|DEVICE|Rebee sensor|Rebee is a wearable motion sensor package of sensor with its own mobile application, which measures range of joint movement in different planes easily which the patient able to wear the sensor and move easily to measure ROM and record the measurement at the application software Digital goniometer Goniometry has been described as a tool to measure angle. It gives the physician a useful method to diagnose musculoskeletal function in terms of ROM, monitor the progress of an intervention, record the data for future follow-up, and meet statutory and legal requirements for impairment rating and disability determinations where applicable
214408131|NCT04267094|DEVICE|Iterative reconstruction at reduced radiation dose|Evaluating Agatston coronary calcium score using reduced dose acquisitions reconstructed using iterative reconstruction
214408132|NCT04879134|DRUG|Apomorphine Injectable Solution|"Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo"
215012683|NCT04983498|OTHER|Early PO Intake|Patient will be offered PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters and patient safety.
215012684|NCT04656080|BEHAVIORAL|CPET exercise testing|"* The cardiopulmonary exercise testing (CPET) is done.~* EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET."
215012685|NCT00512044|PROCEDURE|Local anesthesia (pudendal block)|local anesthesia as indicated
215012686|NCT00512044|PROCEDURE|general anesthesia (spinal and general)|general according to guidelines
215012687|NCT01032278|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
215012688|NCT01032278|BEHAVIORAL|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
215012689|NCT04295265|DEVICE|smartphone message|Receive daily whatsapp/ SMS message to remind the drug intake
215012690|NCT02502071|DRUG|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
215012691|NCT00917982|OTHER|vision therapy|
215012692|NCT00158470|DRUG|efavirenz|
215012693|NCT00158470|DRUG|didanosine|
215012694|NCT00158470|DRUG|lamivudine|
215012695|NCT02336503|DRUG|BBI-4000 Gel, 5%|BBI-4000 Gel, 5%
215012696|NCT02336503|DRUG|BBI-4000 Gel, 10%|BBI-4000 Gel, 10%
215012697|NCT02336503|DRUG|BBI-4000 Gel, 15%|BBI-4000 Gel, 15%
215012698|NCT02336503|DRUG|Vehicle|Placebo, BBI-4000 Gel, 0%
215012699|NCT00094666|DRUG|MK0928, gaboxadol / Duration of Treatment - 6 weeks|
215012700|NCT00094666|DRUG|Comparator: placebo / Duration of Treatment - 6 weeks|
215012701|NCT01260753|DRUG|UR-63325|UR-63325
215012702|NCT01260753|DRUG|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray
215012703|NCT01260753|DRUG|Placebo|Placebo to UR 63325 and fluticasone propionate nasal spray
215012704|NCT05486702|OTHER|Time Restricted Eating|Time restricted eating (TRE) can be divided into early TRE (eTRE) and late TRE (lTRE), depending on the time of day of the eating window.
215012705|NCT04744532|DRUG|Bosutinib (Phase 1 part)|Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.
215012706|NCT04744532|DRUG|Bosutinib (Phase 2 part)|Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.
215012707|NCT03058016|OTHER|Personalized recommendations for diet|Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
215012708|NCT02358395|DRUG|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
215012709|NCT02358395|DRUG|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
215012710|NCT03428555|BEHAVIORAL|Integrated Care Pathway|The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions
215012711|NCT03428555|BEHAVIORAL|Treatment As Usual|Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
215012712|NCT00324194|DRUG|MGCD0103|MGCD0103 oral dose given 2 times per week.
214408133|NCT04879134|DRUG|Placebo|"0.9% saline placebo injection~Other Names:~• Saline"
214408134|NCT00450502|DRUG|Batracylin|
214408135|NCT02844764|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Day 7, 14 and 30 \[PRP\]
215099544|NCT05949489|DIAGNOSTIC_TEST|WOMAC pain subscale|"The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale is a self-reported questionnaire that is used to measure pain in people with osteoarthritis (OA). The subscale consists of five items that ask about the intensity, frequency, and duration of pain in the hip and knee joints.~The WOMAC Pain Subscale has been shown to be a reliable and valid measure of pain in people with OA. It has been used in a number of clinical trials and is considered to be a standard measure of pain in OA.~The WOMAC Pain Subscale is scored on a scale of 0 to 4, with 0 indicating no pain and 4 indicating severe pain. The total score for the subscale is the sum of the scores for the five items. A higher score indicates more pain."
215099545|NCT05849519|DRUG|Coenzyme I for Injection + conventional treatment|The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
215099546|NCT05849519|DRUG|Conventional treatment|The control group was treated with conventional treatment
215012713|NCT06339762|BEHAVIORAL|Self-Compassion Training|Self-Compassion Training
215012714|NCT05854264|DIETARY_SUPPLEMENT|standard enteral nutrition|standard enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
215012715|NCT05854264|DIETARY_SUPPLEMENT|specialized nutrition|specialized enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
214408136|NCT04205032|DEVICE|Test of the different devices integrated in cardiospace II|"The different devices included in CARDIOSPACE II will be tested~* Electrocardiogram~* Vascular Doppler~* LaserDoppler and iontophoresis~* Brachial blood pressure~* Continuous blood pressure recorded at the finger level~* Ultrasound~* Ambulatory Electrocardiogram / SAO2 (arterial oxygen saturation)"
214408137|NCT03647475|COMBINATION_PRODUCT|Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT|To evaluate the clinical safety of the Resolute Onyx stent with use of one-month DAPT in subjects deemed at high risk for bleeding and/or medically unsuitable for more than one-month DAPT treatment.
214408138|NCT05293301|DEVICE|Use of Periodontal Endoscope (Perioscopy®) to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using a Periodontal Endoscope or Perioscopy® for enhanced visualization, on teeth in one half of the mouth
214408139|NCT05293301|DEVICE|Use of traditional loupes to enhance magnification to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using tradional loupes for enhanced visualization on teeth, in the other half of the mouth
214408140|NCT03374111|DRUG|Colla corii asini|15 g Colla corii asini granule daily for 8 weeks
215012716|NCT02809781|BIOLOGICAL|Intravenous infusion of MSCs|Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
215012717|NCT02809781|DRUG|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
215012718|NCT05161156|COMBINATION_PRODUCT|Test Product (tiotropium bromide inhalation powder)|A single dose of test product
214408141|NCT03374111|DRUG|a Simulate Agent of Colla corii asini granule|15 g a Simulate Agent of Colla corii asini granule daily for 8 weeks
214408142|NCT03660605|OTHER|Rhythmic Auditory Stimulation|Participants will complete 6 weeks of walking training (3x/week). During each session, participants will walk on a treadmill for up to 20 minutes (stepping to a metronome at 85% of typical cadence) followed by overground walking for up to 15 minutes (stepping to a metronome at 115% of typical cadence).
214693936|NCT01540461|DRUG|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
214693937|NCT00330863|DRUG|Risperidone microspheres|Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
214693938|NCT00330863|DRUG|Risperidone|Target dose is 4 mg/day.
215012719|NCT05161156|COMBINATION_PRODUCT|18 mcg of Spiriva (Reference Product)|A single dose of reference product (Spiriva)
215012720|NCT05161156|COMBINATION_PRODUCT|Placebo|A single dose of placebo
215012721|NCT03712618|BIOLOGICAL|Platelet Transfusion - LONG Platelet Transfusion|Platelets transfused over 4-HOURS
215012722|NCT03712618|BIOLOGICAL|Platelet Transfusion - SHORT Platelet Transfusion|Platelets transfused over 60-minutes
215012723|NCT04213638|OTHER|Single Microneedle Radiofrequency therapy|Subjects are treated with three consecutive sessions of Single Microneedle Radiofrequency therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment. Each treatment session took approximately 30-60 minutes.
215012724|NCT04213638|OTHER|Photodynamic therapy|Subjects are treated with three consecutive sessions of Photodynamic therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment.
214408143|NCT04575805|BEHAVIORAL|Internet-delivered Combined Cognitive Bias Modification (iCBM-C)|The iCBM-C is online CBM intervention which is the combination of iCBM-I and iCBM-A interventions for obsessive-compulsive symptoms delivered in eight sessions, twice per week for 4 weeks. The presentation order of the two intervention components will be counterbalanced to allow exploration of any order effects. Thereby, half of the participants in iCBM-C group will complete the iCBM-A task followed by iCBM-I, while the other half will complete the iCBM-I task followed by iCBM-A during each session.
214408144|NCT04575805|BEHAVIORAL|Internet-delivered Cognitive Bias Modification-Interpretation (iCBM-I)|The iCBM-I is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of OCD related scenarios taking place over eight sessions, twice per week for 4 weeks.
214408145|NCT04575805|BEHAVIORAL|Internet-delivered Cognitive Bias Modification-Attention (iCBM-A)|The iCBM-A is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of the modified dot-probe task taking place over eight sessions, twice per week for 4 weeks.
214408146|NCT03972423|OTHER|With or wiyhout a checklist|The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice
214408147|NCT04857450|DRUG|Etomidate|Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by Etomidate 0.05 mg/kg IV and repeated when needed.
214408148|NCT04857450|DRUG|Ketamine Hydrochloride|Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
214408149|NCT00710164|DRUG|XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)|14 days of XSCR capsule
214408150|NCT00710164|DRUG|Placebo|14 days of Placebo
214408151|NCT00045695|DRUG|bortezomib|PS-341 bolus intravenous injection twice weekly\* for 2 out of every 3 weeks
214693939|NCT00330863|DRUG|Olanzapine|Target dose is 15 mg/day.
214693940|NCT00330863|DRUG|Quetiapine|Target dose is 600 mg/day.
214693941|NCT00330863|DRUG|Ziprasidone|Target dose is 120 mg/day.
215012725|NCT00047268|DRUG|cytarabine|
215012726|NCT00047268|DRUG|mercaptopurine|
215012727|NCT00047268|OTHER|laboratory biomarker analysis|
215012728|NCT00047268|PROCEDURE|allogeneic bone marrow transplantation|
215012729|NCT00047268|PROCEDURE|biopsy|
215012730|NCT00047268|PROCEDURE|peripheral blood stem cell transplantation|
215012731|NCT00001082|DRUG|Levocarnitine|500 mg tablet taken orally daily
215012732|NCT00001082|DRUG|Adefovir dipivoxil|120 mg tablet taken orally daily
215012733|NCT00001082|DRUG|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
215012734|NCT03969758|DRUG|Ciprofloxacin|will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
215012735|NCT03969758|DRUG|Cefixime|will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
215012736|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
215012737|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
215012738|NCT00984633|DRUG|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
215012739|NCT00984633|DRUG|Propofol|4-10 mg/kg/hr maintenance anesthesia
215012740|NCT02968875|DEVICE|Endurance Training|40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
215012741|NCT02968875|OTHER|therapeutic education meetings|Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
215012742|NCT04394559|BEHAVIORAL|Discharge Order Sets|Discharge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery.
215012743|NCT04394559|BEHAVIORAL|Pharmacist-Led Discharge Counseling and Communication|Two visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan.
215012744|NCT04394559|BEHAVIORAL|Post-discharge Pain Management Follow-up|An outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use.
215012745|NCT04394559|BEHAVIORAL|Patient Engagement Pain Management App|A mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder.
215012746|NCT00375310|DRUG|Gemcitabine, Sorafenib|"Gemcitabine is given IV~Sorafenib is given orally of varying doses:~1. Sorafenib 200 mg po qd ( during combination therapy)~2. Sorafenib 400 mg po qd ( during combination therapy)~3. Sorafenib 400 mg po bid ( during combination therapy)"
215012747|NCT00375310|PROCEDURE|Radiotherapy|1.8 Gy CTV daily for 5 weeks
215012748|NCT00485849|DRUG|Atomoxetine Hydrochloride|
215012749|NCT02539407|OTHER|Pharmacokinetics|
215012750|NCT00626860|BIOLOGICAL|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
215012751|NCT06122961|OTHER|No treatment given|No treatment given
215012752|NCT02737787|BIOLOGICAL|WT1 Vaccine|
215012753|NCT02737787|DRUG|Nivolumab|Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
215012754|NCT02737787|BIOLOGICAL|NY-ESO-1 Vaccine|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.
215012755|NCT01936974|DRUG|Gemcitabine|Patient to receive gemzar
215012756|NCT01936974|DRUG|Bevacizumab|Patient to receive avastin
215012757|NCT01936974|DRUG|Carboplatin|Patient to receive carboplatin
215012758|NCT01936974|DRUG|Cisplatin|Patient to receive cisplatin
215012759|NCT01936974|DRUG|Oxaliplatin|Patient to receive Oxaliplatin
215012760|NCT04323566|DRUG|Rituximab|"Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)"
215099547|NCT04827303|OTHER|Kinesio taping|A 10-15 cm sized I band was applied to the trapezius muscles of the first group patients with the patient's neck in lateral flexion. Then, while the patient's neck is flexed, a Y-shaped 15-20 cm tape will be affixed between C1-7 with the arms of the Y up, and I tape of 5-10 cm is attached on the arms. In group 2 patients, 1 cc lidocaine diluted with 4 cc saline (SF) was applied to the trigger points palpated manually in the trapezius muscles. After the trigger point was squeezed between the thumb and index finger, a few cc of local anesthetic mixture was applied into the trigger point with the injector and exited. In the 3rd group patients, a few cc local anesthetic mixture will be applied intradermally over the trigger point without entering into the trigger points palpated manually in the trapezius muscles. Patients were checked 72 hours and 1 week after the first applications.
215099548|NCT03876665|OTHER|No intervention|No intervention
215012761|NCT00986583|DRUG|Succinylcholine|Succinylcholine will be administered pre-induction over a period of 5 seconds
215012762|NCT05783765|BEHAVIORAL|Heightened Drive to Eat|Participants' eating rate and eating in the absence of hunger will be assessed during a videotaped experimental meal. The relative reinforcing value of food will be assessed using a computerized behavioral choice task.
214408152|NCT01259687|DEVICE|Non-invasive cardiac output monitoring|During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
215012763|NCT06330519|DRUG|Dexamethasone sodium phosphate injection|Patients receive 0.8ml of dexamethazone by periodontal ligament injection 30 minutes before the inferior alveolar nerve block
215012764|NCT06330519|OTHER|1,1,1,2 tetrafluoroethane|EndoIce (1,1,1,2 tetrafluoroethane) applied on the buccal, lingual (3 s/surface), and occlusal surfaces (4 s) for a total of 10 s then standard IANB was administered
215012765|NCT06330519|OTHER|intraoral soft tissue cryotherapy|Small ice packs (wrapped in sterile gauze) placed intraorally in the mouth on the vestibular surface of the treated tooth for 5 minutes then standard IANB was administered
215012766|NCT04584554|BEHAVIORAL|BETTER Transitional Care Intervention|Patient and family will receive pre- and post-discharge support and education from interventionist.
215012767|NCT06057428|PROCEDURE|Decompressive surgery|Decompressive surgery for lumbar spinal stenosis
215012768|NCT03958604|PROCEDURE|Neurostimulation|Spinal cord stimulation with burst modality for discogenic low back pain
215012769|NCT02253238|BEHAVIORAL|Quality of Life Survey|Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
215012770|NCT02253238|BEHAVIORAL|Health Management Surveys|Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
215012771|NCT02253238|OTHER|Monitoring Devices|Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
215012772|NCT02253238|BEHAVIORAL|Symptoms Surveys|"Behavioral: Symptoms survey 1; completed at weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.~Behaviorial: Symptoms survey 2; completed at baseline, weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT."
215012773|NCT02253238|BEHAVIORAL|Device Usability Survey|Device usability survey; completed at weeks 1, 3, 5, and 7 days after RT.
215012774|NCT02506439|DIETARY_SUPPLEMENT|10 mcg Vitamin D3|Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
215012775|NCT02506439|DIETARY_SUPPLEMENT|20 mcg Vitamin D3|Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
215012776|NCT02506439|DIETARY_SUPPLEMENT|Placebo|Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
215012777|NCT01087619|PROCEDURE|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
215012778|NCT00063999|DRUG|Carboplatin|Given IV
215012779|NCT00063999|DRUG|Cisplatin|Given IV
215012780|NCT00063999|DRUG|Doxorubicin Hydrochloride|Given IV
215099549|NCT00614484|RADIATION|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
215099550|NCT00614484|DRUG|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
214408153|NCT02492594|OTHER|Peripheral blood sampling|"Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~* at the start of neutropenic fever~* after 24 hours~* after 48 hours~* before the start of antimycotic therapy, if pertinent~* at the end of antimycotic therapy, if pertinent"
214693942|NCT00330863|DRUG|Aripiprazole|Target dose is 20 mg/day.
215012781|NCT00063999|BIOLOGICAL|Filgrastim|Given SC
215012782|NCT00063999|OTHER|Laboratory Biomarker Analysis|Correlative studies
215012783|NCT00063999|DRUG|Paclitaxel|Given IV
215012784|NCT00063999|BIOLOGICAL|Pegfilgrastim|Given SC
215012785|NCT00063999|OTHER|Quality-of-Life Assessment|Ancillary studies
215099551|NCT00614484|DRUG|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
215099552|NCT06129929|BEHAVIORAL|Hospital Jujutsu Group, HJJ Group|The aim of this study, procedures, methodology, and the subject's rights were well explained to the eligible nursing staff according to the informed consent form. Written informed consent was obtained from each participant before data collection.
215099553|NCT01218399|DRUG|Symbicort|
215012786|NCT02192086|OTHER|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
215012787|NCT02192086|OTHER|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg \* wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
214408154|NCT01245777|DRUG|ferric carboxymaltose|20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
215012788|NCT02634697|BEHAVIORAL|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
215099554|NCT00989781|RADIATION|3-D Ultrasound|One time pelvic ultrasound
215012789|NCT01647880|DRUG|Verum arm receiving Gilenya®|
215012790|NCT01647880|DRUG|Active Comparator receiving Extavia®|
215012791|NCT00976300|DRUG|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
215099555|NCT00989781|DRUG|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
215099556|NCT00989781|DRUG|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
214408155|NCT04698291|PROCEDURE|Blood Donation|The blood donation will take place at the Gene \& Health clinical assessment centre facilities. A trained member from Gene \& Health program will be responsible for taking the blood samples.
215012792|NCT00976300|DRUG|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
215012793|NCT01458145|BEHAVIORAL|Minding the Baby Home Visiting Program|Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
215012794|NCT03306121|DRUG|TPF+CCRT|"Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
215012795|NCT03306121|DRUG|CCRT+ PF|"Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
215012796|NCT00031005|PROCEDURE|modified stem cell transplant|
215012797|NCT02096536|DRUG|Vancomycin|vancomycin administration based on decision of treating physician
215012798|NCT00816270|PROCEDURE|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
215099557|NCT00989781|DRUG|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
215099558|NCT00989781|DRUG|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
215099559|NCT00989781|DRUG|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
215099560|NCT00189501|DRUG|Sensipar®|
215099561|NCT00694304|DRUG|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
215099562|NCT06219395|PROCEDURE|Endoscopy|Patients will be examined with gastroscopy, colonoscopy and WCE and the diagnostic yield of combined gastroscopy/colonoscopy will be compared to WCE
215099563|NCT05401318|PROCEDURE|Tumor tissue sampling for organoid development|Fresh tissue from colorectal tumors will be sampled and cultivated in 3D cultures for drug testing.
214408156|NCT04686643|DRUG|AGSAVI|S-amlodipine, Valsartan, Indapamide
214408157|NCT04686643|DRUG|AGLS|S-amlodipine, Valsartan
214408158|NCT06161883|OTHER|Soffritto|The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
214408159|NCT03614858|BIOLOGICAL|CART-19/22|Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19/22 cells/kg).
214408160|NCT00932919|BEHAVIORAL|Thought field therapy|5 sessions with Thought field therapy
214408161|NCT00932919|BEHAVIORAL|Cognitive therapy|12 sessions of Cognitive therapy
215099564|NCT00034736|DRUG|Levofloxacin|
215099565|NCT04595162|BIOLOGICAL|GC019F|GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
215012799|NCT00968942|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
214408162|NCT00932919|BEHAVIORAL|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
214408163|NCT02893540|DRUG|Capecitabine|we are going to compare two maintenance treatment models with capecitabine in this study
215012800|NCT00968942|DRUG|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
215012801|NCT03767894|DEVICE|EMG Band|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear an EMG band to control and activate the MyHand orthosis.
215012802|NCT03767894|DEVICE|Shoulder harness|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear a shoulder strap to control and activate the MyHand orthosis, either with shoulder elevation or shoulder depression.
215099566|NCT02722265|DRUG|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
215099567|NCT05423392|PROCEDURE|Tooth extraction of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Tooth extraction will be following up with the methodological procedures in order to define the effectiveness of anesthetics during indicated dental procedure.
215099568|NCT05423392|PROCEDURE|Endodontic dental treatment of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Endodontic dental treatment will be following up with the methodological procedures in order to define the effectiveness of anesthetics during dental treatment.
215099569|NCT05423392|PROCEDURE|Conservative tooth restoration of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Conservative tooth restoration will be following up with the methodological procedures in order to define the effectiveness of anesthetics during conservative tooth restoration.
214408164|NCT05396495|DEVICE|NeurolyserXR|Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
214408165|NCT01260662|DRUG|Propofol|1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
214408166|NCT01260662|DRUG|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
214408167|NCT01260662|DRUG|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
215012803|NCT04243837|DRUG|LYT-100 BCRL|BCRL patients will receive LYT-100 BID for 6 months
215012804|NCT04243837|DRUG|Placebo BCRL|BCRL patients will receive Placebo BID for 6 months
215012805|NCT05481281|DRUG|Dexmedetomidine|I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion
215012806|NCT05481281|DRUG|Ketamine|0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
215012807|NCT02845492|OTHER|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
215012808|NCT02845492|OTHER|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
215012809|NCT02558751|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
215012810|NCT02558751|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
215012811|NCT05236127|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
215012812|NCT05236127|OTHER|Intermittent Fasting|The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
215012813|NCT02280499|DEVICE|standard PROMOS prosthesis|
215012814|NCT01903044|PROCEDURE|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
215012815|NCT06132997|PROCEDURE|Thoracoscopy procedure|is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.
215099570|NCT04777292|DEVICE|Use of a mobile health application until app completion|Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
215099571|NCT00791596|OTHER|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
214408168|NCT03049111|BIOLOGICAL|Der f|Inhalation of Der f in mild asthmatics who are sensitive to Der f.
214408169|NCT02518906|BEHAVIORAL|Adolescent Identity Treatment|"Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013."
214408170|NCT02518906|BEHAVIORAL|DBT-A|Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
214693943|NCT00330863|DRUG|Paliperidone|Target dose is 6 mg/day.
214693944|NCT05565976|DRUG|Dapagliflozin 10mg Tab|10mg PO q24h for 12 months
215012816|NCT06132997|PROCEDURE|Chest tube thoracostomy|Insert chest intercostal tube without thoracoscopy
215012817|NCT04799665|DIAGNOSTIC_TEST|Breast CT|This is a cross-sectional clinical study to determine the feasibility of breast CT for breast density assessment and association of CT-derived density measures with metabolic syndrome in overweight/obese Mexican-origin women in Southern Arizona. There is no intervention.
215099572|NCT03004755|OTHER|Tissue Harvest|
215099573|NCT04566692|BIOLOGICAL|IGSC 20%|SC infusion pump.
214408171|NCT01719289|BEHAVIORAL|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
214408172|NCT01868867|BEHAVIORAL|Intervention|On line tutorial followed by text messaging during treatment and iPad for patient education
214408173|NCT05954169|DRUG|SHR4640|SHR4640 single-dose
215099574|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
215099575|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
215099576|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
215099577|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
215099578|NCT03254355|PROCEDURE|Multimodal physiotherapy|12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
215099579|NCT05979168|BEHAVIORAL|Phone call and text Messages|The intervention consists of recommended lifestyle counselling (on a healthy diet, physical activity, smoking, alcohol intake, medication adherence and continuity of care). This counselling will be provided through the research nurse at baseline and for six months (tentative plan phone call once a month; frequency and duration will be finalized based on formative study) by calling on participants' given mobile numbers. In addition, text message reminders on the same topics will be delivered regularly (2-3 times a week) for six months. The counselling and message will focus on three domains of COM-B; capabilities needed, opportunities and practical tools, and motivation strategies informed by behaviour change techniques.
215099580|NCT05277038|DRUG|Clonidine 0.1mg pill|Routine prescription for insomnia
215099581|NCT05277038|DRUG|Clonidine 0.2mg pill|Routine prescription for insomnia
215099582|NCT05277038|DRUG|Zopiclone 3.75mg pill|Routine prescription for insomnia
215099583|NCT05277038|DRUG|Zopiclone 7.5mg pill|Routine prescription for insomnia
215099584|NCT00000466|DRUG|estrogens, conjugated|
215099585|NCT00000466|DRUG|medroxyprogesterone|
214408174|NCT05331495|DEVICE|Intraoperative Hemoperfusion|During the operation, the hemoperfusion device and the membrane oxygenator of the extracorporeal circulation device were operated in parallel.
215012818|NCT02882516|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
215012819|NCT00120848|BIOLOGICAL|HPV 16/18 VLP AS04|
215012820|NCT05916066|DIETARY_SUPPLEMENT|Nicotinamide|Tabletts of 500mg Nicotinamide (B3-vitamin)
215099586|NCT00000466|DRUG|progesterone|
215099587|NCT00000466|DRUG|estrogen replacement therapy|
214408175|NCT03151421|BEHAVIORAL|Home air quality monitoring and feedback|Two-hundred smokers (50 in each country) will be recruited and offered low-cost, simple to operate particle counting instruments to measure and log SHS levels in their home for a period of 30 days. During this time near real-time, personalised feedback will be provided to, and discussed with, the smoker along with target-setting and exploration of suitable methods of behaviour-change. Feedback will be given via text message to mobile phones, emails and personal voicecalls. A final visit will gather data on changes made while a proportion of participants (10-20%) in each country will take part in a further qualitative interview by phone to gather data on their experience of the intervention.
215012821|NCT00576342|DRUG|AL-3862+timolol ophthalmic suspension|
215012822|NCT00576342|DRUG|Dorzolamide+timolol ophthalmic solution|
215099588|NCT01671631|OTHER|Measurement of intracoronary pressure|
215099589|NCT00671437|PROCEDURE|FDG-PET/CT|
215099590|NCT00671437|DRUG|Cetuximab|
215099591|NCT02208349|DEVICE|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
215099592|NCT02208349|DEVICE|traditional direct laryngoscopy (DL)|
215099593|NCT03537313|PROCEDURE|Vagina douching|Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery
215099594|NCT03537313|PROCEDURE|Vagina painting|Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml
215099595|NCT00815828|OTHER|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
215099596|NCT02880150|OTHER|Stress test|
215099597|NCT05117177|DRUG|Inupadenant|Oral administration
215099598|NCT05117177|DRUG|Inupadenant|Oral administration
215099599|NCT05117177|DRUG|Inupadenant|Oral administration
215012823|NCT06240559|DEVICE|External imaging panel|The IP will be placed on the side of the treatment table and will acquire data during the whole treatment, which will be compared against information derived from the treatment plan. The IP based method can detect errors and information about motion and treatment uncertainties that are not currently available.
215012824|NCT02730286|OTHER|observational study|application of several standard instruments in patients with rheumatoid arthritis
214408176|NCT03016897|OTHER|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
214408177|NCT03382743|DRUG|Endocervical Lidocaine spray|5 sprays of endocervical Lidocaine spray (10%) is used 3 minutes before office hysteroscopy
214408178|NCT00248612|DRUG|Venlafaxine|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
214408179|NCT00248612|BEHAVIORAL|CBT|CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
214408180|NCT00248612|OTHER|Progressive muscle relaxation therapy (PMR)|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
214408181|NCT00248612|OTHER|Placebo medication|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
214408182|NCT03106025|DEVICE|Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
214693945|NCT05565976|DRUG|Statins (Cardiovascular Agents)|Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h
214693946|NCT05565976|DRUG|Platelet Antiaggregant|Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h
215012825|NCT04199039|OTHER|Effect on Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction|"When the study started, the first 43 patients were assigned to the control group and the following 43 patients were assigned to the study group in the CVS ICU. ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted. ET fixation of the patients in the study group was performed with an ET holder (AnchorFast Oral Endotracheal Tube Fastener, Hollister, Liberlyville, USA) when they arrived at the CVS ICU.~The patients' SBP, DBP, HR and SpO2 values, which were displayed on the bedside monitor (Nihon Kohden, Tokyo), were recorded on the Hemodynamic Parameters Form just before, during, and at the end of endotracheal suction, and in the following 5th and 15th minutes."
215012826|NCT04561531|OTHER|3%NaCl|Intervention is infusion of 3%NaCl which is defined in arms of experiment.
215012827|NCT03830970|DIETARY_SUPPLEMENT|Canned beans of multiple varieties|Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
215012828|NCT03830970|DIETARY_SUPPLEMENT|White Rice|Minute Rice Long Grain White Rice
215012829|NCT01482286|DRUG|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
215012830|NCT01482286|BEHAVIORAL|Dietary Restriction|Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
215012831|NCT01482286|BEHAVIORAL|Exercise Training|"For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).~The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch."
215012832|NCT02826551|DRUG|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
215012833|NCT02826551|OTHER|Ice|
215012834|NCT02826551|DRUG|Percocet|
215012835|NCT02826551|DEVICE|Knee Brace and Crutches|
215012836|NCT05610267|DEVICE|Retrospective chart review|The retrospective chart review will include the full consecutive series of patients between 22 years and 80 years old who underwent abdominal wall reconstruction for achart hernia with Integra Gentrix® Surgical Matrix during the time period between November 1, 2017, and present (90 days prior to the start of data collection).
215012837|NCT05648916|OTHER|Celecoxib|Retrospectively comparing patients with and without heterotopic ossification who have been exposed to celecoxib and underwent cementless total hip joint replacement surgery.
215012838|NCT00977561|DRUG|figitumumab|Figitumumab (20 mg/kg)
215012839|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
215012840|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
215012841|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
215012842|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
215012843|NCT04942509|BEHAVIORAL|Coloring as a brief mindfulness-based intervention|Participants watched an instructional video on mindful coloring at the beginning of the intervention and colored mindfully for at least 5 days or 100 minutes in total during a 10-day period. The intervention included a coloring booklet that contained mandala patterns for coloring.
215012844|NCT04453254|OTHER|Whole Food Meal|Isocaloric/ macronutrient whole food meal
215012845|NCT04453254|OTHER|Supplement Food Meal|Isocaloric/ macronutrient supplement food meal
214408183|NCT03106025|OTHER|Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
214408184|NCT02126397|PROCEDURE|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
214408185|NCT02126397|PROCEDURE|polyps resection with bipolar electrode|
214408186|NCT00119743|BIOLOGICAL|undecavalent pneumococcal-protein D conjugate vaccine|
214408187|NCT06328946|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
214408188|NCT06328946|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214408189|NCT06328946|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
214408190|NCT04472871|DEVICE|Left atrial appendage closure|The left atrial appendage (LAA) is a small, ear-shaped sac in the muscle wall of the left atrium (top left chamber of the heart). It is unclear what function, if any, the LAA performs. In patients with heart failure and atrial fibrillation, reduced left atrial appendage (LAA) emptying velocities leads to LAA thrombus formation therefor a higher rate of stroke and embolism are observed even on oral anticoagulants. FDA approved devices for left atrial appendage closure will be used under guidance of angiography and trans-esophageal echo with highly efficient and trained personnel.
214408191|NCT05337072|DIAGNOSTIC_TEST|Microbiome study|Investigation of the vaginal and endometrial microbiome
214408192|NCT01995370|DRUG|aspirin|Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
214408193|NCT01995370|DRUG|clopidogrel|Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
214408194|NCT01995370|DRUG|cilostazol|Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
214408195|NCT03888820|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
214408196|NCT03888820|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
214408197|NCT06059313|OTHER|Submission of the NEO-PI-3 questionnaire|The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).
214408198|NCT06059313|OTHER|Submission of the Interpersonal Reactivity Index questionnaire (IRI)|The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.
214408199|NCT05137912|BIOLOGICAL|Immunotherapy|"Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.~Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy."
214408200|NCT03583437|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
214408201|NCT05186545|DRUG|surufatinib + fulvestrant + chidamide|surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
214408202|NCT03570255|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
214408203|NCT01124162|DRUG|Losartan|100 mg Tablet
214693947|NCT05565976|DRUG|Antidiabetic|Previously established medical treatment for type 2 diabetes will be maintained.
214693948|NCT03241563|DRUG|Sodium Deoxycholate|
214693949|NCT03241563|DRUG|Triamcinolone|Triamcinolone 40mg/ml
214693950|NCT00918086|DIETARY_SUPPLEMENT|Vitamin D pill|Oral tablet taken for 16 weeks
214693951|NCT00918086|DIETARY_SUPPLEMENT|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
215012846|NCT03134638|DRUG|SY-1365 (Part 1)|"Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:~* Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.~* Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle."
215012847|NCT03134638|DRUG|Carboplatin|Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)
215012848|NCT03134638|DRUG|Fulvestrant|Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
215012849|NCT03134638|DRUG|SY-1365 (Cohort 2)|In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)
214408204|NCT01124162|DRUG|Cozaar®|100 mg Tablet
215012850|NCT03134638|DRUG|SY-1365 (Cohort 5)|In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
215012851|NCT03134638|DRUG|SY-1365 (Part 2 Single Agent)|SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
215012852|NCT02825537|DEVICE|Compression stocking|A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
215012853|NCT02825537|OTHER|No use of compression stocking|No use of compression stocking
215012854|NCT02540434|DEVICE|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
215012855|NCT02540434|OTHER|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
215012856|NCT02540434|DRUG|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
215012857|NCT01261377|DEVICE|Bi-level positive airway pressure (BPAP)|The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
215012858|NCT01261377|DRUG|Oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
215012859|NCT01261377|DEVICE|CPAP|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
215012860|NCT04696770|BEHAVIORAL|Mindfulness|Mindfulness techniques will be taught to the participants
215012861|NCT00083707|DRUG|Thalidomide|
215012862|NCT03826004|DRUG|Clemastine|Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
215099600|NCT01836393|DRUG|Plavina cream|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
215099601|NCT03589755|BEHAVIORAL|Mindfulness meditation|The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
215099602|NCT04650425|BEHAVIORAL|Cognitive tasks|Patients will perform the coffee-tea task and the virtual T-maze task, both in the acute and chronic phase after stroke.
215099603|NCT01310829|BEHAVIORAL|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
215099604|NCT01310829|BEHAVIORAL|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
215099605|NCT01310829|BEHAVIORAL|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
215099606|NCT04375176|DIAGNOSTIC_TEST|Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2|Phenotypic and functional analysis of monocytes and NK cells
215099607|NCT02943616|DEVICE|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~* Scaffold diameters: 2.5, 3.0, and 3.5 mm~* Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
214408205|NCT05461924|OTHER|questionnaire survey|questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR
214408206|NCT02680756|DRUG|Ferric Maltol|
215012863|NCT03826004|DRUG|Saline Solution|Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
214408207|NCT02680756|DRUG|Ferric Carboxy Maltose|
214408208|NCT03107702|DIAGNOSTIC_TEST|melatonin|the relationship between melatonin level and analgesia requirement.
214408209|NCT03988062|DEVICE|TrelliX Embolic Coil System|Embolic coil with shape memory polymer
215012864|NCT04386837|OTHER|Turkish Aphasia Rapid Test|Same
215012865|NCT00000975|DRUG|Itraconazole|
215012866|NCT00202995|DRUG|Glatiramer Acetate|20 mg s.c. daily
215012867|NCT00202995|DRUG|Betaseron|250 mg every other day
215012868|NCT00202995|DRUG|Rebif|44 ug 3 times a week
215012869|NCT00852982|BEHAVIORAL|Exercise|Nordic walking, with walking poles, five hours per week during four months
215012870|NCT00565760|DRUG|Q8003|Capsules
215012871|NCT00565760|DRUG|Placebo|Capsules
214408210|NCT00886808|DRUG|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
214408211|NCT00387062|DEVICE|Computer-based Cognitive Training|
215012872|NCT00003501|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
215012873|NCT02285309|PROCEDURE|Cardiac Surgery and enoximone|Does diastolic function change with cardiac surgery +/- enoximone
215012874|NCT01968785|RADIATION|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
215012875|NCT01968785|RADIATION|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
215012876|NCT02787798|DRUG|valsartan/sacubitril 100 mg|Treatment with 100 mg tablets during 2 to 4 weeks
215012877|NCT02787798|DRUG|valsartan/sacubitril 200 mg|Treatment with 200 mg tablets during 2 to 4 weeks
215099608|NCT06098664|DIAGNOSTIC_TEST|AI-enabled ECG score for Atrial Fibrillation (DNN score)|"A 12-lead ECG, performed within 24 hours before the Pulmonary Vein Isolation (PVI) procedure, will be used to calculate the DNN score.~(DNN score details: https://doi.org/10.1016/j.jacep.2023.04.008)"
214408212|NCT03983343|DEVICE|exofin®|Perineal skin will be closed by adhesive glue - exofin® (Octyl-2-cyanoacrylate).
215012878|NCT02787798|PROCEDURE|Microneurography|Microneurography recording of sympathetic nervous system activity in muscle destiny
215012879|NCT04479384|OTHER|Manual therapy - osteopathic techniques|"* HVLAT if any somatic dysfunction in T1-T5~* Stretch intrathoracic fascia x 3~* Recoil sternum x 3~* Cranial base release, 4 phases"
215012880|NCT00051350|OTHER|CARB|
215012881|NCT03492268|BIOLOGICAL|BCMA-CART|After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells
215012882|NCT00117000|DRUG|testosterone undecanoate|
215012883|NCT06344286|DIETARY_SUPPLEMENT|Minimal enteral nutrition|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
215012884|NCT06344286|DIETARY_SUPPLEMENT|Distilled water|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
215012885|NCT04313439|OTHER|Online cognitive therapy (I-CT)|"The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual The treatment of Obsessions by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform."
215099609|NCT06098664|DIAGNOSTIC_TEST|Atrial voltage map in sinus rhythm|An atrial voltage map will be constructed prior to the PVI procedure.
215099610|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
215099611|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
214408213|NCT03613129|DRUG|CT38|Infusion
214408214|NCT00938340|DIETARY_SUPPLEMENT|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
214408215|NCT00938340|DIETARY_SUPPLEMENT|Walnut Oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
214408216|NCT00938340|DIETARY_SUPPLEMENT|Walnut Skins|Separated, ground walnut skins incorporated into inert food carrier
214408217|NCT00938340|DIETARY_SUPPLEMENT|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
214408218|NCT06027112|OTHER|musculoskeletal injuries|This research will be conducted to identify the factors that increase the risk of musculoskeletal injuries in university students,
214408219|NCT00608348|PROCEDURE|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
215012886|NCT02645162|BEHAVIORAL|Community-based Preschool|"* Preschool sessions in community-based preschool~* Run by trained community youth leaders from the same village."
215012887|NCT02333968|BEHAVIORAL|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
215012888|NCT06197295|DRUG|Solifenacin with vaginal estrogen cream|Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg
215012889|NCT06197295|DRUG|Combination pharmacotherapy|Solifenacin 5mg and Mirabegron 25mg
215099612|NCT06949969|DEVICE|OSA LLLT treatment device|The Alesis OSA-1 is a LLLT that uses 635nm wavelength to stimulate the mitochondria to open cell spaces and allow oils, lipids, and fluids to drain into the body systems.
215099613|NCT06949969|DEVICE|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment while allowing the cooling fans to operate for the treatment period, giving the appearance of treatment with invisible light.
215099614|NCT02033239|DRUG|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
215099615|NCT02033239|DRUG|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
215099616|NCT02186704|DEVICE|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
215099617|NCT03203291|DEVICE|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
215099618|NCT04524624|DEVICE|AI-based CDSS|"1. Automatically identifying acute ischemic stroke lesions on DWI.~2. Classification of stroke subtypes and mechanisms.~3. Evidence-based alerts and guidelines for early stroke management.~4. Guideline-recommended secondary stroke prevention strategies."
215099619|NCT00498121|DEVICE|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
215099620|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
215012890|NCT03950388|BEHAVIORAL|Intervention|Wards randomly assigned to receive the intervention will have a Band 8a Psychologist based on the ward for 0.5FTE for 7 months. During this time, all patients will be involved with the proposed stepped model of care intervention at one of three levels. The level the patient receives will be decided by the multidisciplinary ward team. At Step one, all patients will have a psychological formulation developed by the psychologist in conjunction with the patient or members of the ward team. At Step 2, all qualified nurses will be trained and supervised to deliver guided self-help material of psychological interventions targeting key problem areas for patients. At Step 3, patients will be offered up to 16, one-to-one therapy sessions with the psychologist.
214408220|NCT00608348|PROCEDURE|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
214408221|NCT03751878|BEHAVIORAL|Evaluation of reporting inconsistencies|"1. The completed CONSORT checklist submitted by authors of manuscripts randomised to the intervention group will be assessed by the lead investigator (DB) as to whether it is consistent with the information that was actually reported in the manuscript. This evaluation will be focused on 8 core CONSORT items.~2. DB will produce a standardised report containing precise requests for authors in order to improve the completeness of reporting of the items where reporting inconsistencies were found. This report will consist of a brief introduction followed by a point by point description of the inconsistencies found together with precise requests related to the information missing and examples extracted from CONSORT. DB will upload this report to the submission on the managing system of the journal (Scholar One) to make it accessible to the handling editor of the manuscript.~3. This editor will include the report in the letter to authors alongside the standard peer review reports."
215099621|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
214408222|NCT03751878|BEHAVIORAL|Standard Peer Review.|Manuscripts will undergo the usual peer review process.
214408223|NCT05392738|DEVICE|I-Stent implantation|I-Stent implantation
214408224|NCT00465751|DRUG|chenodeoxycholic acid|chenodeoxycholic acid 500 mg capsules tid po
215099622|NCT00440830|DRUG|placebo|placebo patch applied to smokers
214504808|NCT06524232|OTHER|Learning Collaborative (LC)|Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A. Participant-generated ideas for topics to be covered during virtual LC sessions will be encouraged. Some specific topics will include optimal SUD screening approaches; prescribing medications for opioid use disorder (OUD) in primary care; pragmatic issues around integrated SUD care within primary care such as compliance with state and federal requirements, note templates/visit frequency, and when/how to escalate care for patients with severe or worsening SUD; medications for alcohol use disorder (AUD); and motivational interviewing.
215099623|NCT00440830|DRUG|placebo|placebo patch applied to nonsmokers
215099624|NCT04082780|DRUG|Rifamycin SV MMX|Intervention arm
215099625|NCT04082780|OTHER|Placebo|Placebo arm
215099626|NCT00630227|BIOLOGICAL|Biologic Lung Volume Reduction|20 mL Hydrogel
215099627|NCT04683120|DIAGNOSTIC_TEST|Zenith FLIM Diagnostics|In-vitro
215099628|NCT04651829|OTHER|oral food challenge 1|First oral food challenge after a short period of several weeks of avoidance of CMP to confirm diagnosis of CMPA
215099629|NCT04651829|OTHER|oral food challenge 2|Second oral food challenge to test tolerance after 4 months of age if confirmed CMPA
215099630|NCT03765827|DRUG|Vitamine E Acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
215099631|NCT03765827|DRUG|No application of vitamin E acetate|Vitamin E acetate ointment will not be applied in this group
215099632|NCT00377364|DRUG|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
215012891|NCT03264950|DIAGNOSTIC_TEST|Elastography|"an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well"
215012892|NCT03757676|BEHAVIORAL|No Play|Participants in this group were asked not to download or play Pokémon Go during the study period and were asked to simply continue with their normal daily activities. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
214408225|NCT00465751|DRUG|placebo capsules|placebo capsules containing mannitol tid po
214408226|NCT00147355|DRUG|ondansetron, ibuprofen, paracetamol|ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
214408227|NCT00147355|DRUG|Ondansetron, ibuprofen, paracetamol|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
214408228|NCT00147355|DRUG|metoclopramide, ibuprofen, paracetamol|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
214408229|NCT00147355|DRUG|Metoclopramide, codeine phosphate, ibuprofen, paracetamol|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
214408230|NCT03136263|DRUG|Oxytocin nasal spray|Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
215099633|NCT06256653|DIETARY_SUPPLEMENT|Freeze-dried blueberries|"* Participants will be supplied with an 8-week supply of Study Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Study Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Study Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
215099634|NCT06256653|DIETARY_SUPPLEMENT|Placebo|"* Participants will be supplied with an 8-week supply of Placebo Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Placebo Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Placebo Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
215099635|NCT03048877|DRUG|Apatinib Oral Tablet|Apatinib Mesylate Tablets
215099636|NCT03048877|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
215099637|NCT00003658|BIOLOGICAL|filgrastim|
214408231|NCT03136263|DRUG|Placebo nasal spray|Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
214408232|NCT00102414|DRUG|Gemcitabine|
214408233|NCT05975294|DRUG|amixture 0.125% bupivicaine with fentanyl|ultrasound guided continuous erector spinae plane block with abolus 0.3ml /kg of amixture 0.125% bupivicaine with fentanyl of 2 mic per ml then Infusion of 0.1 ml /kg/hr of the same mixture.
215099638|NCT00003658|BIOLOGICAL|rituximab|
215099639|NCT00003658|DRUG|cyclophosphamide|
215099640|NCT00003658|DRUG|pentostatin|
215099641|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 7 Tesla|An MRI performed as part of the project
215099642|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 1,5 Tesla|An MRI performed as part of the care
215099643|NCT04059107|DEVICE|3D Printed Myoelectric Prosthetic Device|3D Printed Myoelectric Prosthetic Device
215099644|NCT02437370|DRUG|Pembrolizumab|Given IV
215099645|NCT02437370|DRUG|Docetaxel|Given IV
215099646|NCT02437370|DRUG|Gemcitabine Hydrochloride|Given IV
215099647|NCT02169856|BEHAVIORAL|EFTs (emotional freedom techniques)|The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
215099648|NCT02169856|DRUG|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
215099649|NCT02169856|DRUG|Inj. Midazolam 0.7mg/kg|Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
215099650|NCT02169856|DRUG|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
214408234|NCT05975294|DRUG|100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset|PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
214408235|NCT04037735|DEVICE|ATTUNE S+ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy
214408236|NCT04037735|DEVICE|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
214408237|NCT02192034|BEHAVIORAL|Navigation|
214408238|NCT06421090|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation，Intervention group25Hz，Control group1Hz
214408239|NCT05886751|OTHER|Black Doctor Screening Video|Participants will view an online video with a Black doctor speaking about prostate cancer screening.
214408240|NCT05886751|OTHER|White Doctor Screening Video|Participants will view an online video with a White doctor speaking about prostate cancer screening.
214408241|NCT05886751|OTHER|Black Patient Screening Video|Participants will view an online video with a Black patient speaking about prostate cancer screening.
214408242|NCT05886751|OTHER|White Patient Screening Video|Participants will view an online video with a White patient speaking about prostate cancer screening.
214408243|NCT05886751|OTHER|Black Doctor Clinical Trials Video|Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.
214408244|NCT05886751|OTHER|White Doctor Clinical Trials Video|Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.
214408245|NCT05886751|OTHER|Black Patient Clinical Trials Video|Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.
214408246|NCT05886751|OTHER|White Patient Clinical Trials Video|Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
215012893|NCT03757676|BEHAVIORAL|At Will Play|Participants in this group were asked to download Pokémon Go and play for at least 30 minutes initially, then play as much or as little as desired during the 4 week intervention period, with no specific instruction or goals for play. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
215099651|NCT02169856|DRUG|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia
215099652|NCT02169856|DRUG|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
215099653|NCT02169856|DRUG|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
215099654|NCT02169856|DRUG|Drug: Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
215099655|NCT02169856|DRUG|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
214504809|NCT06524232|OTHER|Performance Incentives (PI)|We will work closely with key stakeholders and the Steering Committee to co-design the PI strategy, refining the specific performance metrics to ensure that they align with other ongoing efforts in our partnering organizations. We plan to base the incentive on achieving a threshold target for the percentage of eligible adult patients screened for SUD, or the percentage improvement in screening, for quarters 1 and 2. For quarters 3 and 4, after practices have had time to implement and improve their processes for screening for SUD, the incentives will evolve to become a composite of (1) patients screened for SUD (the same as used in quarters 1 and 2) and (2) achieving a threshold target for the percentage of persons with SUD who received evidence-based interventions.
215099656|NCT05011526|BIOLOGICAL|MVC-COV1901|Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
215099657|NCT05011526|BIOLOGICAL|AZD1222|Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
215099658|NCT05533710|PROCEDURE|erector spinae plane block|Patients will receive ESB. In the lateral decubitus, after skin sterilization, ESP block will be performed at the level of T9
215099659|NCT05533710|PROCEDURE|transversus abdominis plane block|patients will receive TAP block in supine position after skin sterilization, TAP block will be performed between internal oblique and transversus abdominis muscles
215099660|NCT01720238|DRUG|Entecavir|0.5mg qd
215099661|NCT01720238|DRUG|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
215099662|NCT04903366|DRUG|Timolol Maleate|timolol maleate 0.5% gel-forming solution
215099663|NCT03628729|OTHER|Embrace™ WetBond™ Pit & Fissure Sealant|pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
215099664|NCT03628729|OTHER|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Fluoride releasing resin based pits and fissures sealant
215099665|NCT04566406|PROCEDURE|Laparoscopic adrenalectomy|Preoperative staging in all cases consisted of computed tomography or/and magnetic resonance imaging. Prior to surgery, a routine panel of laboratory tests was carried out. The catecholamines metabolites (metanephrine, normetanephrine, and methoxytyramine) were measured from 24-hour urine collection. All patients were preoperatively treated with phenoxybenzamine or alternative doxazosin.Additionally, beta-blockers in case of coexisting tachycardia were given. In the morning of the operation, preinduction blood pressure was measured. Pneumoperitoneum was achieved by insufflating CO2 gas to an intraperitoneal pressure of 12 mmHg. The operative method in our department was laparoscopic transperitoneal lateral total adrenalectomy. Intraoperatively SBP and diastolic blood pressure (DBP) were measured and recorded every 10 minutes. To treat hypertensive and hypotensive episodes, intravenous doses of urapidil, ephedrine, nitrates, MgSO4, norepinephrine, or ß-blockers were administered.
215099666|NCT03903939|DRUG|Iloprost|continuously infusion for 72 hours 1 ng/kg/min
215099667|NCT03903939|DRUG|Isotonic saline|continuously infusion for 72 hours equal volume to Iloprost
215099668|NCT04042727|DRUG|Dexmedetomidine Hydrochloride|Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.
215099669|NCT04042727|OTHER|Normal Saline|0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.
214504810|NCT03297125|DEVICE|Standard Magnetic Resonance Imaging (MRI)|Standard MRI.
214504811|NCT03297125|DEVICE|Advanced MRI.|Perfusion and diffusion MRI.
214408247|NCT04353037|DRUG|Group 1 HCQ|Enrolled participants randomized in Group 1 receive the HCQ drug
214408248|NCT04353037|DRUG|Group 2 Placebo|Enrolled participants randomized in Group 2 will receive a placebo drug
214504812|NCT06350097|DRUG|Osimertinib|"Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet ."
215099670|NCT05231707|BEHAVIORAL|A couples-focused intervention for HIV prevention and care in South Africa|From a sample of 272 male-female couples (544 individuals, 272 men and 272 women) recruited from rural KaZulu-Natal, South Africa, couples will be randomized to receive either individual a package of dyadic counseling and testing (intervention arm) or an attention matched control.
215099671|NCT03576573|DEVICE|PROCOTYL® C|Hip Arthroplasty
215099672|NCT04915417|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.
214408249|NCT04147416|DRUG|HSK3486 0.1-0.2 /0.3 mg / kg group|Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
215012894|NCT03757676|BEHAVIORAL|Goal Oriented Play|Participants in this group were asked to download and play Pokémon Go and achieve a minimum player level of 20 within the game during the study period. They were given materials that described game features and functions to show them how to play the game. There were no restrictions on which features to pursue within the game to achieve this goal nor on how long or how frequent their play sessions should be. Upon reaching their goal (Level 20), participants were encouraged to continue to play as much or as little as they desired. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
215012895|NCT02588755|PROCEDURE|TACE+Tegafur|Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
215012896|NCT02588755|PROCEDURE|TACE|TACE alone
215012897|NCT06449248|OTHER|Checking of appropriateness of OLP diagnosis|The above mentioned interventions will be carried out through the accurate analysis of patients' clinical records
215012898|NCT03656575|BIOLOGICAL|synovial fluid biomarker concentrations|Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
215012899|NCT00640432|DRUG|Diclofenac|75 mg oral capsule twice daily for 7 days
215012900|NCT00640432|DRUG|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
215012901|NCT02955550|DRUG|rhIL-2|Human recombinant Interleukin-2
215012902|NCT02955550|BIOLOGICAL|PNK-007|PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
215012903|NCT01127477|DRUG|1: Hydroxyethyl starch 130/0.4, 6 %|1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
215012904|NCT03786055|BEHAVIORAL|Somatic Yoga and Meditation (SYM)|A Hanna somatics and somatic yoga and meditation (SYM) protocol was designed to address sensory-motor amnesia and reduce trauma which creates reflex patterns that lead to chronic muscular contractions. The movements use voluntary muscular contraction and slow controlled eccentric contraction, with the constant focus on sensation to increase the resting length of muscles. Movements are performed slowly and gently with the least possible effort and are never forced. The protocol is endorsed by the US Army Surgeon General as treatment for chronic pain. The meditations are trauma informed and evidence based supporting pain modulation, healing and well-being.
215012905|NCT05663593|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
215012906|NCT05663593|DRUG|Placebo, tablet|Matching placebo
215012907|NCT01457430|DRUG|Icatibant|30 mg subcutaneous dose of Icatibant
215012908|NCT01636544|PROCEDURE|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
215012909|NCT01765881|DRUG|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
215012910|NCT01765881|DRUG|Dinoprostone|administration of one sustained released pessary of 10 milligrams by intravaginal route
215012911|NCT03598764|PROCEDURE|Classic head extraction during Cesarean section|by putting the fingers of the right inside the lower uterine segment to deliver the head
215012912|NCT03598764|PROCEDURE|External pop out technique|The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
215012913|NCT04947904|OTHER|Reduction of the patient's fluid intake during the first 7 days|The volume of fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in the intensive care unit according to a protocol with instructions to reduce fluid intake as far as possible in terms of maintenance fluids, dilution of medication and artificial nutrition. This protocol will be begun immediately following the patient's inclusion on Day 1 and pursued for 7 days after inclusion (i.e. from Day 1 - to Day 7). The fluid restriction strategy does not involve the administration of any medication (i.e. diuretics). A clinical pharmacist will help the intensive care teams apply the fluid restriction protocol with a daily check. If the restrictive strategy leads to hypovolemia and / or a electrolyte anomaly (sodium, potassium, chloride, etc.), the physician in charge will be authorised to treat these anomalies in conformance with the protocol recommendations.
215012914|NCT04903509|DRUG|BI 1820237|BI 1820237
215012915|NCT04903509|DRUG|Placebo|Placebo
215099673|NCT01759823|BIOLOGICAL|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
214408250|NCT04147416|DRUG|Propofol 0.5-1.0/1.5 mg/kg group|Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
214504813|NCT06350097|DRUG|Datopotamab Deruxtecan|Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
214693952|NCT04361643|DRUG|Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
215012916|NCT04903509|DRUG|Saxenda®|Saxenda®
215012917|NCT04903509|DRUG|Paracetamol-ratiopharm®|Paracetamol-ratiopharm®
214408251|NCT01227642|OTHER|An ultrasound-based technique to identify prostate cancer|The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
214408252|NCT01227642|OTHER|pre-implant transrectal ultrasound images and planning|an ultrasound-based technique to identify cancer-containing areas within the prostate.
215012918|NCT04055389|DRUG|Antithrombin III|"Patients with reversal of flow or sluggish flow in the main portal vein (\<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life \~4 days) at a weight-based dosage according to the following formula:~\[Desired level of AT (100%) - Subject level of AT (%)\] \* subject weight (kg) 1.4~or placebo for 24 weeks of therapy."
215012919|NCT04055389|OTHER|Placebo|No study drug
215012920|NCT06059079|OTHER|No Intervention|No Intervention
215012921|NCT04844346|DIETARY_SUPPLEMENT|Plant stanol mini drinks|Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
215012922|NCT04844346|DIETARY_SUPPLEMENT|Placebo mini drinks|Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
215012923|NCT04844346|BIOLOGICAL|COVID-19 vaccine|First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
215012924|NCT02103946|PROCEDURE|Serratus Anterior Muscle Plane block (SAM block)|The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
215012925|NCT02103946|PROCEDURE|Paravertebral Block|After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
215012926|NCT01983904|DEVICE|deep brain stimulation with short & long pulse width|surgical implantation for bilateral electrodes and stimulation using short and long pulse width
215012927|NCT00529581|DRUG|C105|
215012928|NCT00400205|DRUG|Docetaxel|Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
215099674|NCT01759823|OTHER|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
215099675|NCT01759823|BIOLOGICAL|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
214408253|NCT01227642|OTHER|ultrasound-based cancer-specific images|ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
214408254|NCT05579080|DEVICE|noninvasive ventilation|The medical records whose patients used some type of non-invasive ventilatory device and devices that promote oxygen supplementation will be analyzed.
214408255|NCT05165030|GENETIC|Blood Sample|clinical-radiological evaluation, genetic analysis by whole exome sequencing and constitution of a bio-collection
214408256|NCT00507208|DEVICE|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
214408257|NCT00507208|OTHER|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
214408258|NCT01221142|DEVICE|"Cincinnati Sub-Zero, Blanketrol III"|
214408259|NCT02082405|DRUG|bortezomib|Given SC or IV
214408260|NCT02082405|DRUG|cyclophosphamide|Given PO
214408261|NCT02082405|DRUG|dexamethasone|Given PO
215012929|NCT00400205|DRUG|Cisplatin|Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
215012930|NCT00400205|DRUG|5-fluorouracil|5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
214408262|NCT02082405|OTHER|laboratory biomarker analysis|Optional correlative studies
214408263|NCT02082405|OTHER|quality-of-life assessment|Ancillary studies
214408264|NCT00067639|DRUG|Pegfilgrastim (Neulasta)|12 mg single injection of pegfilgrastim under the skin prior to apheresis.
214408265|NCT00067639|PROCEDURE|Apheresis|Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
215012931|NCT02455323|OTHER|Suboccipital inhibitory|According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
215012932|NCT02455323|OTHER|Spinal manipulative|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
215099676|NCT06523257|DIAGNOSTIC_TEST|Spirometry|"Spirometry is a simple test used to diagnose and monitor lung diseases by measuring how much air a person can breathe out in one forced breath.~After the baseline spirometry, and only if there is clear evidence of an airflow limitation/obstruction, i.e., if the FEV1/FVC (forced expiratory volume in the first second/forced vital capacity) ratio is less than 70% or less than the 5th percentile of the distribution of values measured in the reference population, a bronchodilator test will be performed using standardised post-bronchodilator spirometry (200 µg salbutamol), in order to identify persistent airflow limitation/obstruction."
214408266|NCT04572672|OTHER|Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting|"Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study."
214408267|NCT00363116|DRUG|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
214408268|NCT01023919|DEVICE|Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Cypher stent or YinYi stent randomly implanted in coronary artery disease
214408269|NCT03578640|DRUG|Elbasvir, Grazoprevir 50-100Mg Oral Tablet|Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
214408270|NCT03199417|DRUG|Multiprofen|A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
214408271|NCT03199417|OTHER|Placebo|An identically packaged placebo cream
214408272|NCT06581926|OTHER|Behavioral assessment|nutrition knowledge reward-related eating body awareness
214408273|NCT05550480|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring for 50 days
214408274|NCT05309486|OTHER|Online and Face-to-face Pilates trainings|Key elements of Pilates, including breathing, focusing, rib cage position, shoulder position, and head and neck positions, will be taught in both groups on the first day. Individuals will be asked to maintain the smoothness of these critical elements throughout the exercises. Different imagery techniques will be used in the exercises, and the exercises will be combined with breathing exercises. The intensity of the exercises will be increased by using different positions and elastic bands (Theraband Elastic Band Hygienic Corporation, Akron, Ohio). Band Resistances will be increased in biweekly periods. Stretching and posture exercises will be used during the cool-down period. The subjects in pilates group will be informed about the side effects such as shortness of breath, dizziness, headache, and muscle pain. Participants will be asked to stop the exercise in case of any side effects.
214408275|NCT04096157|DRUG|Isavuconazonium sulfate IV|Intravenous (IV) via nasogastric (NG) tube
214408276|NCT04096157|DRUG|Isavuconazonium sulfate capsules|Oral
214408277|NCT01989637|DIETARY_SUPPLEMENT|Strawberry Meal|High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder
214408278|NCT01989637|DIETARY_SUPPLEMENT|Control Meal|High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
214408279|NCT00180518|DEVICE|Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system|"Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).~The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.~The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients."
215012933|NCT02455323|OTHER|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
215012934|NCT02455323|OTHER|Control group.|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
215012935|NCT00137280|BEHAVIORAL|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
215012936|NCT02173366|BEHAVIORAL|Change Club Intervention|
214408280|NCT03956173|OTHER|Hypoglycemic combined with either normo or hyperglycemic clamp.|Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
214408281|NCT03349684|DRUG|Acarbose|Uptitrated in the treatment phase from 50 mg per day for 1 week, followed by 100 mg per day for another week, and 150 mg per day for the rest 14 weeks, oral, with the first mouthful of main meal
214408282|NCT03349684|DRUG|Metformin|500 mg 3 times daily, oral, with the first mouthful of main meal
214408283|NCT03349684|DRUG|Placebo|Acarbose matching placebo, oral
214408284|NCT00343798|DRUG|cyclophosphamide|Given IV
214408285|NCT00343798|DRUG|fludarabine phosphate|Given IV
214408286|NCT00343798|DRUG|cyclosporine|Given IV
215012938|NCT05484557|DRUG|Apixaban|treatment for 6 to 12 weeks
215012939|NCT05484557|DRUG|Enoxaparin Sodium|treatment for 6 to 12 weeks
215012940|NCT05001165|OTHER|Proactive Panel Management Clinics for HFrEF|Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.
215012941|NCT03116867|OTHER|sonosalpingography|transvaginal ultrasound with saline infusion
215012942|NCT04000724|BEHAVIORAL|Text Messaging (Text+Step)|Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
215099677|NCT03841760|DIAGNOSTIC_TEST|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
214408287|NCT00343798|DRUG|mycophenolate mofetil|Given IV or PO
214408288|NCT00343798|OTHER|ex-vivo umbilical cord blood expansion|Undergo double-unit umbilical cord blood transplantation
214408289|NCT00343798|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo double-unit umbilical cord blood transplantation
214408290|NCT00343798|PROCEDURE|biopsy|Optional correlative studies
214408291|NCT00343798|OTHER|immunologic technique|Correlative studies
214408292|NCT00343798|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
214408293|NCT02148406|BEHAVIORAL|Yoga Skills Training (YST)|Undergo YST
214408294|NCT02148406|OTHER|questionnaire administration|Ancillary studies
214408295|NCT02148406|OTHER|fatigue and depressive symptom assessment and management|Ancillary studies
214408296|NCT02148406|OTHER|psychological stress assessment|Ancillary studies
214408297|NCT02148406|OTHER|laboratory biomarker analysis|Correlative studies
215099678|NCT01257035|OTHER|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
215099679|NCT01179165|OTHER|Diagnostic|Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
215012943|NCT04000724|BEHAVIORAL|WebApp (App+Step)|Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
214408298|NCT02148406|OTHER|Attention Control|
214408299|NCT03881358|DEVICE|ortho-k lenses and thinner spectacles|Conventinally designed (Emerald) ortho-k lenses (target for -4.00D) and thinner specs during day time
214408300|NCT03881358|DEVICE|newly designed ortho-k lenses|Newly designed (Topaz) ortho-k lenses for high myopia (target for full correction)
214408301|NCT04087044|DEVICE|Computerized Rotational Head Impulse Test ( crHIT)-Vertical|"1. Oculo-Motility and Positional Testing,~2. Caloric Testing"
214408302|NCT03393520|DRUG|Placebo|oral capsules
214408303|NCT03393520|DRUG|AVP-786|oral capsules
214693953|NCT04361643|DRUG|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
214408304|NCT05535582|DIAGNOSTIC_TEST|Investigation of clinical, laboratory and imaging profile|Complete and comprehensive medical interview will be conducted in each eligible patient after revascularization. In addition, patient's laboratory data will be recorded on admission and during hospitalization. Furthermore, each patient will undergo a full echocardiographic examination with a specific protocol.
214408305|NCT02243007|DRUG|FOLFIRINOX|
214408306|NCT02243007|DRUG|Gemcitabine/nab-Paclitaxel|
214408307|NCT02243007|RADIATION|Radiation therapy|
214408308|NCT02243007|DRUG|Capecitabine|
214408309|NCT02950545|DEVICE|Placebo Lenses|AcuVue Oasys Bandage Lenses with no prescription
214408310|NCT02950545|DEVICE|Spherical Lenses|1-DAY ACUVUE® MOIST contact lenses
214408311|NCT02950545|DEVICE|Toric Lenses|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
214408312|NCT06405074|DEVICE|low intensity focused ultrasound (LIFU)|"Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects."
214408313|NCT05766163|DEVICE|DaVinci RARP|Assisted-robotic radical prostatectomy.
214408314|NCT05766163|DEVICE|Hugo RARP|Assisted-robotic radical prostatectomy.
214408315|NCT05766163|DEVICE|Versius RARP|Assisted-robotic radical prostatectomy.
214408316|NCT01728389|PROCEDURE|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
214408317|NCT03355053|DRUG|Dexmedetomidine|"Dex (Precedex, Dexmedetomidine HCl Injection) is produced by Pfizer Inc, NY, Ny (formerly Hospira). Dex is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dex is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1mg) of dexmedetomidine and 9 mg of sodium chloride in water. The solution is preservative-free and contains no additives or chemical stabilizers. The MGH Pharmacy currently obtains Dex from the supplier as a solution in 50 mL clear-glass bottles, as a clear liquid, at a concentration of 4mcg/mL."
214408318|NCT03355053|DRUG|Placebo|"From the package insert: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is produced by Pfizer Inc, NY, Ny (formerly Hospira). It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+ ) 154 mEq; chloride (Cl- ) 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH is 5.6 (4.5 to 7.0). This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. 0.9% Sodium Chloride Injection, USP is a parenteral fluid and electrolyte replenisher. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H2O."
214408319|NCT01351610|BIOLOGICAL|PTA + Infusion of MSC_Apceth|percutaneous transluminal angioplasty followed by infusion of MSC\_Apceth
214408320|NCT01351610|PROCEDURE|PTA|percutaneous transluminal angioplasty only
214408321|NCT02694679|BEHAVIORAL|CBNH|The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
215099680|NCT01626417|DEVICE|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
214408322|NCT05650294|DIETARY_SUPPLEMENT|PL+ omega 3 fatty acids|PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.
214408323|NCT05650294|DIETARY_SUPPLEMENT|FO EE fatty acids|A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.
214408324|NCT04100954|DEVICE|Reinforced prosthesis|Implementation of a reinforced prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
214408325|NCT04100954|DEVICE|Standard prosthesis|Implementation of a standard prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
214408326|NCT03398356|DRUG|Metformin|"for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg~for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg."
214408327|NCT04643353|DEVICE|Non-ablative vaginal Erbium YAG laser treatment|Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia) with SMOOTH mode setting, which enables non-ablative, thermal-only operation. The parameters are selected based on extensive preclinical and clinical studies.
214408328|NCT04643353|OTHER|PFE|PFE will be prescribed as it is already implemented in clinical practice (i.e. up to 2x 9 sessions with a pelvic floor physiotherapist of choice). Type of physiotherapy, number of completed sessions and duration of therapy will be recorded.
214408329|NCT05101330|DEVICE|Bilingual prescription medication labels|The bilingual PML contains English and Chinese medication-related instructions for participants.
214408330|NCT04034121|DEVICE|DESolve Cx drug eluting coronary scaffold system|percutaneous coronary intervention
215012944|NCT04000724|BEHAVIORAL|Information/No Step|Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
215012945|NCT02507999|DEVICE|Flotrac|Flotrac guided intervention
215012946|NCT00455455|DRUG|Optifree RepleniSH Multipurpose Disinfecting Solution|lens care system
215012947|NCT00455455|DRUG|ReNu Multiplus Multipurpose Solution|lens care system
215099681|NCT06515262|BIOLOGICAL|Anti-BCMA-GPRC5D CAR-T cells infusion|Subiects who meet the enrollment conditions will receive intravenous infusion of anti-BCMA-GPRC5D CAR-T Cells after lymphodepleting therapy.
214408331|NCT02362633|DEVICE|real tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
215012948|NCT06473428|BEHAVIORAL|respiratory muscle training|Inspiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
215012949|NCT06473428|BEHAVIORAL|Expiratory Muscle Training|Expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
215012950|NCT06473428|BEHAVIORAL|Placebo-Controlled Expiratory Muscle Training|Placebo-controlled expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
215012951|NCT06116032|DIAGNOSTIC_TEST|Methylation Cytometry|Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
215012952|NCT00481104|DRUG|Tesofensine|
215012953|NCT01196234|DRUG|Paclitaxel/Carboplatin/Gefitinib|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
215012954|NCT01196234|DRUG|Paclitaxel/Carboplatin|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
215099682|NCT02540265|DRUG|N1539|
215099683|NCT02540265|DRUG|Intravenous Placebo|
215099684|NCT04132674|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Taking one oral tablet of B/F/TAF once-daily for 72 weeks
215099685|NCT00510978|BIOLOGICAL|Bifidobacterium infantis 35624|1 sachet/day for one year
214408332|NCT02362633|DEVICE|sham tDCS|Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
214408333|NCT04170426|BIOLOGICAL|autologous adipose derived stem cells|Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
214408334|NCT01648283|DRUG|IV racemic methadone HCl|IV racemic Methadone HC1 6 mg
214408335|NCT01648283|DRUG|Oral racemic methadone HCl|oral d5-methadone HCl 11 mg
214408336|NCT01942083|DRUG|OPB-111077|
214408337|NCT04038281|OTHER|Sensory tests|Fat, bitter taste sensitivity and food preference measurement
214408338|NCT00226200|DRUG|Omalizumab|
214408339|NCT05543096|DEVICE|Adroit Guiding Catheter, Cordis Transradial Access Devices, Cordis Diagnostic Catheters, Cordis Guidewires|Observation
214408340|NCT04880070|DEVICE|Shockwave Treatment|Self-controlled, single-arm group using the Shockwave device.
214408341|NCT03907605|OTHER|anti- mullerian hormone|All patients belong to the same group. The blood samples will be collected at the time of surgery and 3 months after surgery from the patients who need uterine artery ligation for PPH. The blood samples will be centrifuged within 2 hours after being obtained and assessed on the same day. AMH concentrations will be measured with an enzymatically amplified two-sided immunoassay
214408342|NCT04865562|DRUG|testosterone propionate|1mg/0.1mL solution, to be administered intranasally
214408343|NCT04865562|DRUG|0.5% cholorbutanol, saline|125 mg 0.5% cholorbutanol, 50mg saline
214408344|NCT02060279|OTHER|Lifestyle intervention and carotenoid supplements|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
214408345|NCT02060279|OTHER|Lifestyle intervention and placebo|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
214408346|NCT05284058|OTHER|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
214408347|NCT03506490|OTHER|Aerobic exercises|The training session lasted 45 minutes and was composed of running exercises.
214408348|NCT04582175|PROCEDURE|angioplasty|angioplasty of all non-culprit lesions
214408349|NCT03587194|DRUG|Otezla|Otezla 30mg BID
214408350|NCT00407940|DEVICE|Lower extremity Atherectomy and Cryoplasty|
214408351|NCT00073957|BIOLOGICAL|rituximab|
215012955|NCT02523638|DRUG|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
214408352|NCT00073957|DRUG|cytarabine|to be used for CNS prophylaxis
214408353|NCT00073957|DRUG|liposomal cytarabine|to be used as CNS prophylaxis
215099686|NCT00510978|BIOLOGICAL|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
214408354|NCT00073957|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
214693954|NCT05142332|OTHER|Covid-19 vaccine education materials|videos and flyers containing Covid-19 vaccine educational information
215012956|NCT06016660|OTHER|Physiotherapy|Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation
215012957|NCT03312166|DEVICE|Compression device|"interventions on patient are :~* surgical excision of ear lobe keloid~* application of compression device on sutured skin"
215012958|NCT04915300|DRUG|Apabetalone|Apabetalone 100mg p.o. (tablets) BID for 24 weeks treatment period.
215099687|NCT00510978|BIOLOGICAL|Placebo|1 sachet per day for 1 year
214408355|NCT02312440|DRUG|0.9% sodium chloride|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
214408356|NCT02312440|DRUG|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
214693955|NCT00433732|DRUG|sumatriptan|
214693956|NCT00433732|DRUG|naproxen sodium|
215012959|NCT04915300|DRUG|Placebo|Placebo p.o. (tablets) BID for 24 weeks treatment period.
215012960|NCT00239291|DRUG|Gefitinib, radiotherapy|
215099688|NCT04203420|OTHER|screening and confirmatory tests|screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test
215099689|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
215099690|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
215099691|NCT05563831|OTHER|national registry|The investigators will collect demographic, clinical, biological and imaging characteristics of patients with PROS.
214408357|NCT02312440|DRUG|tranexamic acid|"The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure."
214408358|NCT05304520|DRUG|Natalizumab|Administered as specified in the treatment arm.
214408359|NCT02823496|OTHER|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
214408360|NCT02823496|OTHER|Untreated skin|One site is patched without treatment as control
214408361|NCT00547261|DRUG|SSR97225|every 3 weeks
214408362|NCT02992665|DRUG|Ca Ionophore A23187|Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters
215012961|NCT03006575|RADIATION|split-course radiotherapy|split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
215012962|NCT03006575|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
215012963|NCT02039570|OTHER|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
215012964|NCT01827943|DRUG|Temsirolimus|Temsirolimus
215012965|NCT01029873|DRUG|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
215012966|NCT01029873|BIOLOGICAL|ALT-801|"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)"
215012967|NCT01356485|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
215012968|NCT01356485|DRUG|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
215012969|NCT06500689|DRUG|Allisartan Isoproxil/Sustained-Release Indapamide|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil/Sustained-Release Indapamide.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
215012970|NCT06500689|DRUG|Allisartan Isoproxil|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
215012971|NCT05141747|DRUG|MRG002|Administrated intravenously
215012972|NCT00236964|DRUG|Iron Sucrose + Erythropoietin|The total dose of iron sucrose was 1,000 mg. Participants also received erythropoietin 2,000 units subcutaneously on Days 1, 8, 15, 22, 29, and 36.
215012973|NCT00236964|DRUG|Oral Iron + Erythropoietin|Oral iron 325 mg three time daily for 29 days. Participants also received erythropoietin 2,000 units subcutaneously on Days 1, 8, 15, 22, 29, and 36.
215012974|NCT06331481|OTHER|Fullicular fluid for cytology and biocemical analysis|"The fullicular fluid in the oocyte retrieval process is consider to medical waste. This fluid contains a verity of proteins, mitochondria and verity of cells.~The investigators using this fluid to learn about the evironment of the oocyte and its quality."
215099692|NCT05224037|DIAGNOSTIC_TEST|iLivTouch|Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day
215099693|NCT03157037|BIOLOGICAL|Imlifidase|One dose of 0.25 mg/kg body weight imlifidase on study day 1
215099694|NCT01919216|DRUG|Citalopram|
215099695|NCT02102399|BEHAVIORAL|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
214408363|NCT02992665|OTHER|Placebo|Placebo is used to control Ca ionophore group
214408364|NCT00530777|DRUG|valacyclovir|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
214408365|NCT00530777|DRUG|placebo|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
214408366|NCT04066998|OTHER|Tears sampling|Tears sampling
214408367|NCT04066998|OTHER|Lashes sampling|Lashes sampling
215012975|NCT04063137|DIETARY_SUPPLEMENT|Anthocyanin fortified bread with beef patty (35% fat)|Bread is fortified at a 4% level using 25% (w/w) anthocyanin black rice extract. It is served with a beef patty (35% fat) to simulate a high-fat diet.
214408368|NCT01800955|DEVICE|resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)|The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.
214408369|NCT01800955|OTHER|sham placebo resistive capacitive diathermy treatment|"The sham treatment is administered with the diathermy device set on on but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group"
214408370|NCT02359058|DRUG|Ramucirumab|Administered IV
214408371|NCT02359058|DRUG|Capecitabine|Administered orally
214408372|NCT02359058|DRUG|Cisplatin|Administered IV
214408373|NCT02359058|DRUG|S-1|Administered orally
215012979|NCT05549453|DEVICE|Nexstim SNBT use|Active device use
215099696|NCT02102399|BEHAVIORAL|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
215099697|NCT06325319|OTHER|Community engagement using M-MAMA Champions to improve awareness on obstetric danger signs, bith preparedness and complication readiness among pregnant women|Community engagement using M-MAMA Champions to improve awareness of obstetric danger signs, birth preparedness, and complication readiness among pregnant women. The empowered M-MAMA Champions will deliver the intervention to pregnant women in their communities. A total of three (3) sessions will be held, whereby each will take two (2) hours. The sensitization will take place at one of the study participant's residential area, where women will gather up and be sensitized on the subject by the M-MAMA Champion as a facilitator using a well-prepared brochure (package).
214408374|NCT02359058|DRUG|Oxaliplatin|Administered IV
214408375|NCT03163992|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
214408376|NCT02926742|DEVICE|EkoSonic Endovascular System|Ultrasound catheter-directed thrombolysis.
214408377|NCT03829280|BEHAVIORAL|Cognitive Adaptation Training|Psychosocial treatment using environmental supports to bypass cognitive and motivational problems and improve adaptive behavior
214408378|NCT03829280|BEHAVIORAL|Community Treatment|Medication follow-up and case management as provided in usual community care in the setting
215012980|NCT05938192|PROCEDURE|vaccination|Patients will have surgery (followed by vaccination) for managing HPV-related lesions
215012981|NCT06091345|DRUG|Midodrine|• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10%
215099698|NCT04591236|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
215099699|NCT04591236|DEVICE|Treadmill gait training|Treadmill gait training was applied to Parkinson patients.
215099700|NCT00472966|DRUG|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
214408379|NCT05660850|DRUG|GDC-6599|GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets
214408380|NCT05660850|OTHER|GDC-6599-matching placebo|GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets
214408381|NCT05660850|DIAGNOSTIC_TEST|Mannitol|Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7
214408382|NCT01104103|DEVICE|BOA(R)-Constricting IV Band|Device applied in accordance with manufacturer's instructions
214408383|NCT01104103|DEVICE|Standard elastic constricting band|Standard therapy
214408384|NCT05207787|DRUG|HS-10365|Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
214408385|NCT03267147|OTHER|no intervention is given|no intervention is given
214408386|NCT02060097|DIETARY_SUPPLEMENT|Cocoa flavanol beverage|
214408387|NCT02060097|DIETARY_SUPPLEMENT|Placebo beverage|
214408388|NCT02833454|PROCEDURE|direct insertion anterior cruciate ligament reconstruction|ACL reconstruction based on direct insertion of ACL.
214408389|NCT02833454|PROCEDURE|single bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using single bundle technique
214408390|NCT02833454|PROCEDURE|double bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using double bundle technique
215012982|NCT06091345|BIOLOGICAL|albumin|• Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is \< 3.5 gm/dl
215012983|NCT06091345|OTHER|Standard Medical Treatment|Standard Medical Treatment
215099701|NCT02644382|OTHER|qualitative data collection|qualitative data collection
215099702|NCT02644382|OTHER|survey|survey pre and post-surgical consult
215099703|NCT02644382|OTHER|decision aid|web-based decision aid post-surgical consult
215099704|NCT03101085|DRUG|S-equol and Placebo|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
215012984|NCT05872945|DIAGNOSTIC_TEST|Electrocardiogram|Study by Artificial Intelligence the biosignal or biodata from profesional football players
215012985|NCT06460051|PROCEDURE|Maxillary nerve block|Ultrasound-guided, suprazygomatic approach, infrazygomatic window
215099705|NCT03101085|DRUG|Placebo and S-equol|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
215099706|NCT00456651|DEVICE|CPAP (Continuous Positive Airway Pressure)|
214408391|NCT05009485|DEVICE|Current Health platform|A remote patient monitoring system which includes a small footprint device and tablet, combined with an AI-powered, cloud-based system driving advanced real-time and predictive analytics related to a patient's clinical condition. The wearable records heart rate, respiratory rate, oxygen saturation, skin temperature and step count.
214408392|NCT03771235|BEHAVIORAL|Mindfulness-based Intervention for Tics|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practices.
214408393|NCT03771235|BEHAVIORAL|Tic Information and Coping Strategies|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
214408394|NCT03382821|PROCEDURE|Transforaminal ESI with dexamethasone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with dexamethasone sodium phosphate 1.5 mL (10 mg/mL) and 1 ml 1% lidocaine (total volume 2.5 mL).
214408395|NCT03382821|PROCEDURE|Transforaminal catheter-targeted ESI with triamcinolone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with triamcinolone acetonide 2 mL (40mg/mL) and 1 ml 1% lidocaine (total volume 3 mL).
214408396|NCT03382821|DRUG|Dexamethasone Sodium Phosphate 10 MG/ML|Transforaminal ESI with dexamethasone 1.5 mL of dexamethasone sodium phosphate in group #1
214408397|NCT03382821|DRUG|Lidocaine|1 mL of 1% lidocaine as diluent for the steroid in both group #1 and group #2
214408398|NCT03382821|DRUG|Triamcinolone Acetonide 40mg/mL|Transforaminal catheter-targeted ESI with triamcinolone acetonide 2 mL in group #2
214408399|NCT00151619|DRUG|Amlodipine|
214408400|NCT03365856|OTHER|observational study|as clinical practice
214408401|NCT00577447|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|Capsule containing 200mg of DHA
215012986|NCT06392191|PROCEDURE|Rhombic intercostal nerve block(Received liposomal bupivacaine 93 mg and bupivacaine 25 mg diluted to 20 ml)|The patient was placed in lateral recumbency and placed medial to the medial border of the scapula in the oblique sagittal plane using a line array ultrasound probe to identify ultrasound landmarks, trapezius, obliques, intercostals, pleura, and lungs, The block needle was then entered in-plane at the T5 level, with the margins retracting on insertion, and the nerve block perforating needle was imaged and then inserted into the fascial gap between the trapezius and the external intercostal muscles. Receive liposomal bupivacaine 93 mg and bupivacaine 25 mg diluted to 20ml.
215099707|NCT00518193|DRUG|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
215099708|NCT01458028|DRUG|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
215099709|NCT01458028|DRUG|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
215099710|NCT03323190|BEHAVIORAL|Inpatient COPD education|
215099711|NCT04057885|DEVICE|Orthosensor™ VERASENSE™ Knee System|A group of patients will receive a total knee arthroplasty using the Orthosensor device
215099712|NCT00067782|DRUG|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
214408402|NCT00577447|DIETARY_SUPPLEMENT|Placebo|Placebo capsule containing corn and soybean oil
214408403|NCT04088994|OTHER|AOT Pathological Model Experimental Group|The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.
214408404|NCT04088994|OTHER|AOT Healthy Model Control Group|The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
214408405|NCT04296240|DRUG|Oxaliplatin and capecitabine|Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months
214408406|NCT04296240|PROCEDURE|Total Mesorectal Excision|Patient receive total mesorectal excision after neoadjuvant chemotherapy
215099713|NCT00067782|DRUG|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
215099714|NCT00861328|DRUG|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
214408407|NCT00578695|DRUG|lixivaptan|Oral Capsule
214408408|NCT00578695|DRUG|Placebo|Oral Capsule
214408409|NCT01805323|DRUG|Dexamethasone Intravitreal Implant|Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
214408410|NCT03867864|DEVICE|Necklace with essential oil for the first 4 weeks|The necklaces contain essential oil.
214408411|NCT03867864|DEVICE|Necklace without essential oil for the first 4 weeks|The necklaces do not contain essential oil.
214408412|NCT03867864|OTHER|Washout|Washout (do not wear the necklace) for one week for two groups, then two groups cross-over.
214408413|NCT03867864|DEVICE|Necklace with essential oil for last 4 weeks|The necklaces contain essential oil.
214408414|NCT03867864|DEVICE|Necklace without essential oil for last 4 weeks|The necklaces do not contain essential oil.
214408415|NCT04484688|DRUG|perindopril-bisoprolol|outpatients with permanent atrial fibrillation and with preserved ejection fraction
214408416|NCT06096129|PROCEDURE|Spy PTC|Percutaneous transhepatic cholangioscopy with SpyGlass DS system
214408417|NCT04438915|BEHAVIORAL|Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery|The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
214408418|NCT00282438|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
214408419|NCT00282438|BIOLOGICAL|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
214408420|NCT03247348|BEHAVIORAL|ReSeT-FM intervention|The ReSeT-FM intervention focuses on behavior changes strategies aimed at reducing sedentary time and includes: education, goal setting, self-monitoring of behavior and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings with study coaches.
214408421|NCT01447797|DRUG|HCP0912 / Irbesartan and Atorvastatin|Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
214408422|NCT03354533|DRUG|L-fucose|Oral ORL-1F
214408423|NCT00471211|DRUG|PBT2|
214408424|NCT00106808|DRUG|Muraglitazar|
214408425|NCT00106808|DRUG|Pioglitazone|
214408426|NCT00875641|OTHER|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
214408427|NCT02778308|DRUG|Gemcitabine + Cisplatin|Day 1 and day 8 Gemcitabine Day 1 cisplatin
214408428|NCT03214887|BIOLOGICAL|RV-P1501|Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
214408429|NCT04888455|DIAGNOSTIC_TEST|Quantitative sensory testing (QST)|Demographic data, pain characteristics, health status, emotional well-being, personality and lifestyle are assessed by questionnaires. Additionally, all patients underwent a clinical neurological examination and quantitative sensory testing (QST) according to the German Research Network on Neuropathic Pain (DFNS).
214408430|NCT00587132|DRUG|Synthetic Human Secretin|0.2mcg/kg one time dose.
215099715|NCT00861328|DRUG|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
215099716|NCT05238805|RADIATION|Observational heart and kidney on siemens TEP scan|Same as arm description
215099717|NCT03009084|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
215099718|NCT03753399|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
214408431|NCT03178201|DRUG|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
214408432|NCT02095158|DRUG|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
215099719|NCT01085032|DRUG|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
214688384|NCT06525064|OTHER|Health-E You app|"When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app.~Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required."
215099720|NCT01085032|DRUG|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used."
215099721|NCT04563013|DEVICE|Transcutaneous vagus nerve stimulation|the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
214408433|NCT05171933|BEHAVIORAL|Survey|This study is based on a survey made on COVID-19
214408434|NCT04866056|DRUG|Jaktinib|Jaktinib PO BID
214408435|NCT04866056|DRUG|azacitidine|Azacytidine SC
214408436|NCT01008748|DRUG|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke \>10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
214408437|NCT01008748|BEHAVIORAL|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
214408438|NCT01008748|BEHAVIORAL|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
214408439|NCT01008748|BEHAVIORAL|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
214408440|NCT06095310|BEHAVIORAL|New computer vision methods|Clinical interview: Hamilton scale using multi-modal sensors (cameras, audio, bracelet, fNIRS)
214408441|NCT00514332|PROCEDURE|stent|stent placement for colorectal cancer obstruction
214408442|NCT01270789|DRUG|Liraglutide|Liraglutide administered as once daily sc injection
214408443|NCT01270789|DRUG|placebo|placebo administered as once daily sc injection
214408444|NCT06444009|DRUG|Ivonescimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
214408445|NCT06444009|DRUG|Cadonilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
214408446|NCT06444009|DRUG|Penpulimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
214408447|NCT01567059|DRUG|tosedostat|Given PO
214408448|NCT01567059|DRUG|cytarabine|Given IV
214408449|NCT01567059|DRUG|decitabine|Given IV
214693957|NCT04043182|PROCEDURE|ultrassound|The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
214693958|NCT02218814|PROCEDURE|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
215099722|NCT04651127|DRUG|Toripalimab + Chidamide|In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
215099723|NCT00115895|DRUG|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
215099724|NCT02441556|DEVICE|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
215099725|NCT02441556|OTHER|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
215099726|NCT05895539|OTHER|An automated patient-reported outcome data collection and adverse event surveillance tool|Patients received a short prompt to provide information on treatment satisfaction and side effects
215099727|NCT06543329|PROCEDURE|polyglactin 910|75 PARTICIPANT, Vicryl suture was used in subcuticular suture
215099728|NCT06543329|PROCEDURE|poliglecaprone 25|75 PARTICIPANT, monocryl suture was used in subcuticular suture
215099729|NCT06543329|PROCEDURE|polypropylene|75 PARTICIPANT, Prolene suture was used in subcuticular suture
215099730|NCT06543329|PROCEDURE|polyester|75 PARTICIPANT, Polyester suture was used in subcuticular suture
215099731|NCT03131882|DRUG|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
215099732|NCT03131882|DRUG|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
214408450|NCT02775435|BIOLOGICAL|Pembrolizumab|IV infusion
214408451|NCT02775435|DRUG|Paclitaxel|IV infusion
214408452|NCT02775435|DRUG|Nab-paclitaxel|IV infusion
214408453|NCT02775435|DRUG|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
215099733|NCT06543927|DIAGNOSTIC_TEST|serum creatinine|Detection of renal impairment in patients receiving anticoagulants
214408454|NCT02775435|DRUG|Saline placebo for pembrolizumab|IV infusion
214408455|NCT05811728|RADIATION|Low level laser therapy|The low-level laser applied will be a Diode laser\* emitting infrared radiation at a wavelength of 980 nm, in a continuous mode. On the experimental side, subjects will receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter, till the termination of the study period (3 months).
214408456|NCT05811728|OTHER|without beam emission|The laser tip will be held passively on the control side without beam emission, providing a placebo effect.
214408457|NCT02282527|BIOLOGICAL|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
214408458|NCT02282527|BIOLOGICAL|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
214408459|NCT04216303|DIAGNOSTIC_TEST|hemoglobin A1c|The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.
214408460|NCT02759198|DRUG|YH23537|Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
214408461|NCT02759198|DRUG|Celecoxib|Drug: Celecoxib 200mg
214408462|NCT02759198|DRUG|YH23537 placebo|Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
214408463|NCT03059082|BEHAVIORAL|Recovery Navigator on an as needed basis up to 6 months|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months and then have a 3 month and 6 month follow-up visit."
214408464|NCT03059082|BEHAVIORAL|Recovery Navigator prior to hospital discharge|This group will undergo one interaction with Recovery Navigator prior to hospital discharge and then have a 3 month and 6 month follow-up visit.
214408465|NCT03059082|OTHER|No interaction with Recovery Navigator|This group will not have any interaction with Recovery Navigator. They will have a 3 month and 6 month follow-up visit.
215099734|NCT06543927|DIAGNOSTIC_TEST|INR|Detection of bleeding in patients with choronic kidney disease receiving anticoagulants
215099735|NCT00992823|DRUG|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
215012987|NCT06392191|PROCEDURE|Rhombic intercostal nerve block(Receive standard bupivacaine 105 mg diluted to 20 ml with dexamethasone 5 mg.)|The patient was placed in lateral recumbency and placed medial to the medial border of the scapula in the oblique sagittal plane using a line array ultrasound probe to identify ultrasound landmarks, trapezius, obliques, intercostals, pleura, and lungs, The block needle was then entered in-plane at the T5 level, with the margins retracting on insertion, and the nerve block perforating needle was imaged and then inserted into the fascial gap between the trapezius and the external intercostal muscles. A mixture of standard bupivacaine 105 mg diluted to 20 ml with dexamethasone 5 mg was received.
214408466|NCT03198546|BIOLOGICAL|GPC3 and/or TGFβ targeting CAR-T cells|Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
214408467|NCT00941031|DRUG|AIN457|
214408468|NCT00941031|DRUG|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
214408469|NCT00941031|DRUG|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
214408470|NCT00941031|DRUG|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
214693959|NCT02218814|PROCEDURE|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
215012988|NCT00675363|PROCEDURE|Protocolized Sedation|Nurse-directed protocol for administering sedation and/or analgesia.
215012989|NCT00675363|PROCEDURE|Protocolized sedation, with daily interruption|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
215099736|NCT00992823|BIOLOGICAL|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
215099737|NCT00607399|DRUG|SGX523 Capsules|This is a dose escalation study
215099738|NCT00240383|DRUG|Muraglitazar|
215099739|NCT04496011|OTHER|Aerobic training with cycle ergometer|Patients start with an initial warm-up of 2 minutes, with rotations per minute free, without load. Progressively, the load of the exercise cycle increases every minute up to the supported limit or up to 60% - 70% of maximum heart rate (HRmax). The training will be carried out for 20 continuous minutes, being interrupted whenever the heart rate (HR) reaches 90% of the maximum expected for the age and / or the loss of effort perceived in the BORG scale, above 8 on a scale of 0 to 10.
215099740|NCT03271905|DRUG|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
215099741|NCT03271905|DEVICE|Mesh nebulization|Nebulization with Mesh device.
215099742|NCT06459336|OTHER|Intensive constraint-induced movement therapy|Intensive protocol of CIMT will be given for 6hrs for 6 days to make total of 36 hours
215099743|NCT06459336|OTHER|Distributed constraint-induced movement therapy|Distributed protocol of CIMT will be given for 2.25hrs two times a week for 8 weeks making total of 36 hours
215099744|NCT00005107|DRUG|N-monomethyl-L-arginine|
215099745|NCT00695864|DRUG|Ondansetron and Placebo crossover|
215099746|NCT01704456|BEHAVIORAL|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
215099747|NCT01704456|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
215099748|NCT00718770|DRUG|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
215099749|NCT00898456|GENETIC|gene expression analysis|
215099750|NCT00898456|GENETIC|molecular genetic technique|
215099751|NCT00898456|GENETIC|polymorphism analysis|
215099752|NCT00898456|GENETIC|protein expression analysis|
215099753|NCT00898456|OTHER|diagnostic laboratory biomarker analysis|
215099754|NCT00498355|DRUG|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
214408471|NCT04056221|OTHER|Acupuncture|Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.
214408472|NCT04056221|OTHER|Sham acupuncture|The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.
214408473|NCT05082883|DIAGNOSTIC_TEST|Risk Assessment Cognitive Screening|Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks
214408474|NCT00097253|BEHAVIORAL|Exposure to relaxant and stimulant odors|A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
214408475|NCT00841282|PROCEDURE|Colonoscopy for colorectal cancer screening|
214408476|NCT00841282|PROCEDURE|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
214408477|NCT00841282|PROCEDURE|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
214408478|NCT04750629|DEVICE|POC CoviDx™ Rapid Antigen Test|All patients will have a nasal swab for CoviDx™ Rapid Antigen testing
214408479|NCT00690469|OTHER|Laboratory Biomarker Analysis|Correlative studies
214408480|NCT00690469|OTHER|Questionnaire Administration|Ancillary studies
214408481|NCT03124108|DRUG|Elafibranor 80 mg|Two coated tablets daily for 12 weeks
214408482|NCT03124108|DRUG|Elafibranor 120 mg|Two coated tablets daily for 12 weeks
214408483|NCT03124108|DRUG|Placebo|Two coated tablets daily for 12 weeks
214408484|NCT05191251|DIAGNOSTIC_TEST|HEMSTOP questionnaire|A HEMSTOP questionnaire is obtained during the anesthesia consultation.
214408485|NCT01495637|DRUG|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
214408486|NCT04882722|OTHER|Questionnaire|Self-questionnaire reported before the first PPFR session and after the last session
214408487|NCT00533416|DRUG|ON 01910 Na|
215099755|NCT04958226|DRUG|Capivasertib|Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.
215099756|NCT04958226|DRUG|Midazolam|Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
214408488|NCT06226987|DIAGNOSTIC_TEST|68Ga-DOTATATE PET/MRI|PET/MRI scanning
214408489|NCT03699735|DEVICE|Bolero B90-SP|Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
214408490|NCT00385658|DRUG|Fluvastatin extended release, fenofibrate|
214408491|NCT00385658|DRUG|Fixed combination simvastatin/ezetimibe|
214408492|NCT00631917|DRUG|Aliskiren|Aliskiren 300 mg once a day
214693960|NCT05277870|DEVICE|Nanodropper adaptor|Patients will use their standard prescription for open-angle glaucoma or ocular hypertension with a Nanodropper attachment on the medication bottle.
215099757|NCT05210426|OTHER|Pilates exercises|The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
215099758|NCT02481609|DRUG|N-acetyl cysteine (NAC)|
215099759|NCT04816058|BEHAVIORAL|Determining the level of ankle instability|Ankle instability
215099760|NCT03881904|DRUG|0.075mg gestodene/0.03mg ethinylestradiol|OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
215099761|NCT02758327|DRUG|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
215099762|NCT00001410|DRUG|Lysodase|
215099763|NCT04583956|OTHER|Placebo|Risankizumab placebo will be given at an equal volume at the same schedule.
214408493|NCT00631917|DRUG|Ramipril|Ramipril 10 mg once a day
214408494|NCT00631917|OTHER|Placebo to Ramipril|Placebo capsules to match ramipril.
214408495|NCT00631917|OTHER|Placebo to Aliskiren|Placebo tablets to match aliskiren.
214408496|NCT01954940|DEVICE|Whole Body Vibration Therapy|
214408497|NCT01646502|BIOLOGICAL|Esp protein|
215099764|NCT04583956|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
214408498|NCT01646502|OTHER|Standard wound care|
214408499|NCT03433261|DIETARY_SUPPLEMENT|Ketogenic Diet|Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.
214408500|NCT02766504|DEVICE|airway ultrasound|airway assessment using ultrasound
214408501|NCT02196012|BEHAVIORAL|Intervention group|
214408502|NCT02196012|BEHAVIORAL|attention control condition|
214408503|NCT00145535|DEVICE|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, \~50 spots over 180°
214408504|NCT00145535|DEVICE|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, \~50 spots over 180°
214408505|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
214408506|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
214408507|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
214408508|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
214408509|NCT01219855|DRUG|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
214408510|NCT01219855|DRUG|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
214408511|NCT01219855|DRUG|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
214693961|NCT05277870|DEVICE|control|Patients will use their prescribed IOP-lowering medication using standard eyedropper on the medication bottle.
214693962|NCT02976376|OTHER|The Box|The Box contains four smartphone compatible devices. Patients will measure their vital signs and automatically send them to the hospital.
215099765|NCT04583956|BIOLOGICAL|Risankizumab|Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
214408512|NCT04097899|OTHER|implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients|"Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~* Antibiotics cost.~* Appropriates of antibiotic use (initiation, duration \& time of discontinuation).~* Rate of resistance~* Clinical outcome, infection rate \&length of stay."
214408514|NCT00064571|PROCEDURE|vocal fold medialization|
215099766|NCT05481047|DEVICE|HPI|based on HPI values, clinicians will administer drugs or fluids in order to avoid arterial hypotension
214408515|NCT00064571|PROCEDURE|vocal fold reinnervation|
214408516|NCT01167036|DEVICE|FascialEdge instrument|Stroking massage to patient tolerance over the muscle
215012990|NCT05310643|DRUG|Nivolumab|"Induction therapy with nivolumab 240 mg; 4 infusions, every 3 weeks.~Maintenance therapy with nivolumab 480 mg; 21 infusions, every 4 weeks."
215012991|NCT05310643|DRUG|Ipilimumab|Induction therapy with ipilimumab 1 mg/kg; 4 infusions, every 3 weeks.
214408517|NCT01167036|OTHER|Placebo electric point stimulation|Detuned electric point stimulation over the involved muscle
215012992|NCT04689009|DEVICE|EmoLED|The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.
215012993|NCT04689009|PROCEDURE|current Standards Of Care|"The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out."
215099767|NCT01143584|DRUG|Cabergoline|"In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point."
215099768|NCT01143584|DRUG|cabergoline|"In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~1. mg twice a week - second week 1.5 mg twice a week - third week~2. mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also \>50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk."
215099769|NCT03461081|DRUG|telmisartan/amlodipine and atorvastatin|Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days
214408518|NCT04088513|DRUG|Aspirin|This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
214408519|NCT04088513|DRUG|Clopidogrel|This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
215099770|NCT00988364|DRUG|Simvastatin|Simvastatin 20mg daily for 3 months.
215099771|NCT00988364|DRUG|Vytorin|Vytorin 20/10mg daily for 3 months.
214408520|NCT02634216|DIETARY_SUPPLEMENT|Capros|250 mg BID
214408521|NCT05912751|OTHER|Exercise Then Foam Roll|Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.
214408522|NCT05912751|OTHER|Foam Roll Then Exercise|Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
214408523|NCT06183710|BEHAVIORAL|Contingency management|Psychosocial intervention
214408524|NCT00590603|DRUG|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I~Loading:~1. Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~2. Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~1. ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~2. Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~3. Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
214408525|NCT05481294|OTHER|Transpersonal Supportive Coaching|Coaching is given for four months (two times a month) with a 45-minute duration per coaching by a professional coach
214408526|NCT05481294|OTHER|Standard Support|Standard support is given for four months using a support system provided by Peer Support Foundation
215012994|NCT04445571|PROCEDURE|Thin catheter technique or standard ET-tube for surfactant administration|Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.
215012995|NCT01266083|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
215099772|NCT00988364|DRUG|Placebo|Placebo one tablet daily times 3 months.
215099773|NCT00988364|DRUG|Ezetimibe|Ezetimibe 10mg daily for 3 months.
214408527|NCT04808635|OTHER|no intervention, this is a cross sectional questionnaire based study.|no intervention, this is an observational cross sectional study
214408528|NCT02191852|DRUG|Seresis®|
214408529|NCT03061955|BIOLOGICAL|influenza vaccination|administration of influenza vaccination
214408530|NCT02952950|OTHER|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
214408531|NCT00956449|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Influenza Vaccine Surface Antigen, Inactivated
214408532|NCT04392349|DEVICE|Haag-Streit EYESTAR 900|The EYESTAR 900 is a new device developed by HAAG-STREIT AG which utilises Optical Coherence Tomography (OCT) for quantitative measurements of the geometry of the eye. As a successor to the LENSTAR 900, it represents the most recent in a series of successful biometry devices.
215099774|NCT01178424|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
214408533|NCT04392349|DEVICE|Tomey CASIA 2|The CASIA2 is a testing application for Cataract / Glaucoma / Cornea Surgery already established on the market. It is a representative device for measurement of anterior and posterior corneal curvature (anterior and posterior corneal topography) by optical coherence tomography, and for measurement of crystalline lens tilt by optical coherence tomography.
214408534|NCT04392349|DEVICE|Oculus PENTACAM HR|The Pentacam HR is a high-resolution rotating Scheimpflug camera system for anterior segment analysis already established on the market. It is used as representative device for advanced anterior segment analysis such as anterior and posterior corneal topography and corneal pachymetry.
215012996|NCT01266083|BIOLOGICAL|GM-CSF|subcutaneous injection
215012997|NCT01266083|OTHER|Montanide|adjuvant
215012998|NCT06544148|DEVICE|Electrical impedance tomography|In addition to routine critical care with a pulmonary artery catheter already in place (PAC), an electrical impedance tomography (EIT) belt will be placed in patients enrolled in this study. Data will be analyzed offline and clinical trajectory and/or decisions will not be impacted by this additional monitoring. EIT is a non-invasive, safe, and radiation-free medical imaging modality.
215012999|NCT06779604|PROCEDURE|Infraclavicular Block with Dexmedetomidine and Dexamethasone|"Infraclavicular block with Dexmedetomidine and Dexamethasone was performed at least 30 min before the start of the operation. The patient was positioned in a supine position arms at the sides or in 90 degree abduction, head turned to the other side. Infraclavicular block was performed with the lateral sagittal technique, while the USG probe was placed under the clavicle and medial to the coracoid process, providing a brachial plexus image in the form of a hyperechoic outer ring and hypoechoic circles, like a classic honeycomb image. A local anesthetic mixture was injected with a 100 mm block needle with negative aspiration and its spread in tissue planes was observed.~If the VAS score was 3 or above, tramadol 1 mg kg-1 was administered as an analgesic drug."
215099775|NCT01178424|BEHAVIORAL|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
215099776|NCT00154882|DRUG|Paclitaxel (Phyxol) , Cisplatin|
214408535|NCT04392349|DEVICE|Zeiss ATLAS 9000|ATLAS is a corneal topography system used as representative device for measurement of anterior corneal curvature (anterior corneal topography).
214408536|NCT02396992|OTHER|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
214408537|NCT05650333|DRUG|Ritlecitinib 20 mg|orally administered, Ritlecitinib 20 mg once daily (QD)
214408538|NCT05468333|OTHER|Cigarette trial|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time (and would be detrimental to the study if details were disclosed during recruitment).
214408539|NCT00994149|DRUG|Diazoxide|10mg/kg/d divide every 8 hours
214688385|NCT06525701|OTHER|Execise Group|SCORE workout: eight exercises done sequentially: bicycles, balancing dog, windshield wipers, three-point plank, kayaker, super push-ups, bridge, and side plank. These workouts are modified from the core regimen recommended by Steve House and Scott Johnston in their book Training for the New Alpinism: A Manual for the Climber as Athlete (House 2014). Each exercise is done until fatigue: when the individual is no longer able to complete the exercise with good form. The participant then rests for approximately thirty to sixty seconds before beginning the next exercise. Passive stretching can be performed during the rest periods. The workout is complete at twenty minutes. Those individuals who complete all eight exercises in less than twenty minutes begin again with the first exercise (bicycles) and continue until reaching twenty minutes. The workout is thus adaptive-seamlessly increasing in repetitions as an individual's strength and endurance increase.
215099777|NCT05060965|DRUG|Nicotine lozenge|Nicotine replacement therapy
215099778|NCT05060965|DRUG|Nicotine gum|Nicotine replacement therapy
214408540|NCT00994149|DRUG|Ora-plus|placebo, give every 8 hours.
214408541|NCT00005106|DRUG|Lamivudine/Zidovudine|
214408542|NCT00005106|DRUG|Abacavir sulfate|
214408543|NCT00005106|DRUG|Nelfinavir mesylate|
214408544|NCT00005106|DRUG|Lamivudine|
214408545|NCT00005106|DRUG|Stavudine|
214408546|NCT06518837|DRUG|Tirzepatide|The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.
214408547|NCT04795089|PROCEDURE|Shunt surgery|Patients are evaluated before and after shunt surgery which is a standard intervention in the clinical practice. HI do not undergo intervention.
214408548|NCT03703479|OTHER|autologous blood clot made from the patient own clot without any additive|advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
214408549|NCT04727723|DRUG|Lutathera®|Treatment with Lutathera® will be independent from participation in this observational study and must not be initiated for the purpose of participating in this study. The decision to treat patients with Lutathera® will occur before patients are enrolled in the study.
214408550|NCT03058783|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
214408551|NCT03058783|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
214408552|NCT03677947|BEHAVIORAL|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.
214408553|NCT03677947|OTHER|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
215099779|NCT05060965|DRUG|Nicotine patch|Nicotine replacement therapy
215013000|NCT06964308|PROCEDURE|thoracoscopic pleural biopsy.|This intervention aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.
215013001|NCT06963385|DIAGNOSTIC_TEST|Radiomics|To correlate radiomic features obtained from ultrasound images with the molecular/genomic profiling to identify new hallmarks for stratification of endometrial cancer patients into different classes of risk
214408554|NCT04688411|BEHAVIORAL|MED-Go App|A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
214408555|NCT04348331|DIAGNOSTIC_TEST|Dual echo MRI sequence|new MRI sequences for imaging of joints
214408556|NCT06029751|OTHER|No intervention|No intervention
214408557|NCT02271607|DEVICE|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
214408558|NCT02403323|DRUG|Etrolizumab|105 mg etrolizumab subcutaneous administration once every 4 weeks
214408559|NCT05764824|DIETARY_SUPPLEMENT|Blueberry powder|20 g per day of blueberry powder
214408560|NCT05764824|OTHER|Controlled and matched powder|20 g per day
215013002|NCT06963294|DRUG|Ketamine|Ketamine will be administered as an intravenous infusion at 0.1 mg/kg/hour during surgery
215013003|NCT06963866|BIOLOGICAL|autologous stem cell transplantation|Patients in this arm will receive autologous hematopoietic stem cell transplantation (ASCT). Prior to ASCT, the patients underwent 3-4 cycles of induction chemotherapy.
215013004|NCT06963866|BIOLOGICAL|CAR-T|The T cells are genetically modified to express a chimeric antigen receptor targeting BCMA and are infused 3 days after ASCT at a target dose of ≥2.0×10\^6 cells/kg.
214408561|NCT06200636|DEVICE|Use of the PELSA System for dISF extraction|Dermal interstitial fluid will be extracted using the investigational device, for further analysis.
215013005|NCT06964724|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy with stent retriever
215013006|NCT05397873|DEVICE|Biofeedback training|The training of oculomotor functions is done on the biofeedback module of a microperimeter MAIA.
215013007|NCT00545948|DRUG|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
215013008|NCT00545948|DRUG|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
215013009|NCT01810107|PROCEDURE|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
215013010|NCT03467945|DRUG|Metformin/Gliclazide Fixed Combination|Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
215013011|NCT03467945|DRUG|Metformin|Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
215013012|NCT03467945|DRUG|Gliclazide|Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
215013013|NCT00153478|BEHAVIORAL|Brief Motivational Counseling|
215013014|NCT05996731|PROCEDURE|Skin biopsy|A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
215013015|NCT05137340|OTHER|Nasal continuous positive airway pressure|Preterm infants with spontaneous breathing are stabilized on non-invasive respiratory support (PEEP of 6 cmH2O and FiO2≤0.40) in the delivery room and during admission to NICU, and then randomly selected to start NCPAP within 30 minutes of birth. Under NCPAP, the calf pulmonary surfactant will be administered via MISA method within 120 minutes after birth if infants are clinically diagnosed with RDS.
215013016|NCT05137340|OTHER|Non-invasive positive pressure ventilation|Preterm infants with spontaneous breathing are stabilized on non-invasive respiratory support (PEEP of 6 cmH2O and FiO2≤0.40) in the delivery room and during admission to NICU, and then randomly selected to start NIPPV within 30 minutes of birth. Under NIPPV, the calf pulmonary surfactant will be administered via MISA method within 120 minutes after birth if infants are clinically diagnosed with RDS.
214408562|NCT00018525|PROCEDURE|Lung Volume Reduction Surgery|
214408563|NCT03885596|DRUG|CA-008|Drug: CA-008 4.2 mg reconstituted in saline
215099780|NCT05060965|OTHER|Maryland Quitline|Telephone-based tobacco cessation service
215099781|NCT05060965|OTHER|John Hopkins Tobacco Treatment Clinic|Clinic-based tobacco cessation service
214408564|NCT03885596|DRUG|Ketorolac|30 mg IV at the onset of anesthesia
214408565|NCT03885596|DRUG|Acetaminophen IV|1 g at the onset of anesthesia
214408566|NCT03885596|DRUG|Fentanyl|100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
214408567|NCT03885596|DRUG|Bupivacaine Hydrochloride|0.25% 30 mL (75 mg) prior to surgery
214408568|NCT03885596|DRUG|Lidocaine HCl|1.5% 12 mL at the end of surgery
214408569|NCT03885596|DRUG|Celecoxib|200 mg PO bid each day postoperative
214408570|NCT03885596|DRUG|Acetaminophen Oral|1 g postoperative
214408571|NCT03885596|DRUG|Lidocaine Hydrochloride|2% 15 mL at the end of surgery
214408572|NCT03885596|DRUG|Exparel|Bupivacaine liposome injection suspension
214408573|NCT03852433|DRUG|Bulevirtide|Administered via subcutaneous injections
214408574|NCT03852433|DRUG|Peginterferon Alfa-2a (PEG-IFN alfa)|Administered via subcutaneous injections
214408575|NCT06234280|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
214408576|NCT01076335|DRUG|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
214408577|NCT01076335|DRUG|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
215099782|NCT02402283|DRUG|Metronidazole benzoate oral granules|Single oral dose of 400 mg
214408578|NCT03092557|OTHER|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
214408579|NCT00731380|DRUG|ABI-007|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
214408580|NCT06067490|DRUG|RC1416(SAD)|RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
215099783|NCT02402283|DRUG|Flagyl 400 mg Tablets|Single oral dose of 400 mg
215099784|NCT02727491|DRUG|Dextromethorphan|Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).
214408581|NCT06067490|DRUG|Placebo(SAD)|Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.
214408582|NCT05154799|BEHAVIORAL|Proprioception and tactile localization with manual or ocular response and/or free hand grasp|"In the first part of the study, the subject must designate a target in 2 ways: manual pointing or ocular saccadic response.~In the second part of the study the subject will have to reach and grasp a rectangular block of wood placed on the table at a distance of 35 cm. He will have to catch the wooden block, lift it a few centimeters and put it back on the table. Tool use and control phases: the subject grasps the wooden block with a tool or without the tool but with a weighted bracelet loading his wrist by the same amount as the tool."
214408583|NCT06323668|PROCEDURE|Cardiac implantable electronic device extraction|The CIED removal will be done as soon as possible within 7 days.
214408584|NCT02616263|OTHER|Foot exercise|
215099785|NCT02727491|DRUG|Placebo|Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
215099786|NCT00122044|DRUG|trihexyphenidyl|
215099787|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks.
214408585|NCT02616263|OTHER|Shoulder exercise|
215099788|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
215099789|NCT02518191|DRUG|GnRHa|3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
215099790|NCT03936972|PROCEDURE|ilizarov circular frame and uni-planarexternal fixator|both are types of external fixators, but one is circular frame and other is uni-planar frame
215099791|NCT05323097|OTHER|Drowning-related OHCA|Drowning-related out-of-hospital cardiac arrest (OHCA): YES
215099792|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
214408586|NCT05832723|DEVICE|650 nm low-level red-light|Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
214408587|NCT03444779|DEVICE|Tibial Tuberoplasty|Kyphoplasty ballon
214408588|NCT03444779|DEVICE|Open technique|Cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope.
214408589|NCT06324955|BEHAVIORAL|Standard/common language during induction|The anesthesiologist taking care of the patient will use scripted common/standard language during the induction.
214408590|NCT06324955|BEHAVIORAL|Positive language during induction|The anesthesiologist taking care of the patient will use scripted positive language during the induction.
215099793|NCT04161001|DRUG|Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
214408591|NCT04872959|OTHER|HealthReveal|"In the Intervention arm, for each study visit, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' EHR.~The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.~In the Usual Care arm, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed."
214408592|NCT06631599|OTHER|Physical training|The intervention consisted of physical exercise according to various protocols
215099794|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
214408593|NCT06632093|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
215013017|NCT01509807|DRUG|IV morphine sulfate or Sponsor-approved equivalent|Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
215013018|NCT01509807|DRUG|EXPAREL|Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
215013019|NCT06099275|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Cardiac output measured by transthoracic echocardiography (TTE)
214408594|NCT06632093|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
214408595|NCT06630507|BEHAVIORAL|Educational module|1 hour pre-recorded educational module created by Dr. Sharma.
214408596|NCT05390645|DRUG|MFA-370|MFA-370 is a treatment with a combination of two approved pharmaceuticals
214408597|NCT02513914|DEVICE|Dural Venous Sinus Stenting|See Dural Venous Sinus Stenting arm.
215013020|NCT02187055|DRUG|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
215099795|NCT04407234|DRUG|Tirzepatide|Tirzepatide administered SC.
214408598|NCT02513914|DEVICE|Cerebrospinal Fluid Shunting|See Cerebrospinal Fluid Shunting arm.
214408599|NCT02862418|OTHER|UTE MRI|One MRI with UTE settings will be acquired.
214408600|NCT03686384|DRUG|SVT-15652|1 vial twice daily
214408601|NCT03686384|DRUG|Placebo|1 vial twice daily
214408602|NCT06030089|OTHER|Pharmacokinetic sampling|4 blood withdrawals ( before treatment, Day 5, Day 9 and relapse or 12 months after start of treatment) for the plasma dosage of VEN and inhibition of its Bcl-2
214408603|NCT06030089|OTHER|Vital status determination|Survival situation 12 months after start of treament
214408604|NCT06030089|OTHER|Toxicity assessments|Toxicity events
214408605|NCT06030089|DRUG|Venetoclax and azacitidine combination|Response to treatment
214408606|NCT03461042|DRUG|Ramelteon 8mg|Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent
214408607|NCT03461042|DRUG|Placebo|Placebo capsule once daily before bedtime for 12 weeks since informed consent
214408608|NCT06058637|DEVICE|Eye screening|Nurse-assisted eye-screening will take place with the Easee app, which is implemented on the tablet or laptop of the community nurse. The nurse's smartphone will function as a remote control by which he/she submits input to a computer screen that displays the test. If the participant can do the test by him or herself, the nurse will merely supervise to ensure correct application. Standard audio instructions guide the nurse and participant through the test. The test will start with triage questions, which are used to set up a correct referral. During the test, both eyes are tested consecutively, covering one eye at a time. The participant will wear his/her spectacles, if present. The participant is presented a sequence of optotypes (i.e. tumbling-E and triangle-circle optotypes) that the participant must correctly identify, in addition to various grate sizes, both near and at a distance. The Amsler grid test is performed to detect any macular problems.
214408609|NCT05939947|DRUG|ALE.F02|Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
214408610|NCT05939947|DRUG|Placebo|Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
214688386|NCT06525701|OTHER|Control Group|No additional exercises or tasks are requested of control participants. Control group participants will perform or not perform exercise as they otherwise would outside of the study.
215013021|NCT02187055|DRUG|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
215013022|NCT02187055|BIOLOGICAL|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
215013023|NCT01718067|DEVICE|VAKÜM system|15 minutes, twice a day.
215013024|NCT01718067|OTHER|conventional manual ELTGOL technique|20 minutes twice a day
215013025|NCT03722888|DEVICE|smokeSCREEN video game|smokeSCREEN video game is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
215013026|NCT04159480|DEVICE|Experimental - Cogito Companion|Cogito Companion
215013027|NCT04159480|BEHAVIORAL|Active Control|Use of MyCAP
215013028|NCT03520387|PROCEDURE|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves, using electrode placement parallel to the medial branches, 18G electrodes or larger, and 2 lesions per nerve.
215099796|NCT04407234|DRUG|Acetaminophen|Acetaminophen administered orally.
215099797|NCT00727558|DEVICE|nelfilcon A|spherical soft contact lens
214408611|NCT05861089|DIAGNOSTIC_TEST|end-tidal CO2 measurement|Measurements will take place day before surgery, under resting conditions (while sitting in a quiet room with no disruptions) using the Capnography monitor from Nonin Medical (breath by breath data will be recorded and analyzed). Patients will be allowed to get used to the nasal cannula for the first two minutes. Mean end-tidal CO2 value will then be calculated from the following two minutes of spontaneous breathing.
214408612|NCT05876585|DRUG|Ondansetron 8 mg ampoule|Study drug
215013029|NCT03520387|PROCEDURE|Simulated LRFA with targeted steroid injections|Performed in an identical fashion to the experimental arm (LRFA), except for medial branch lesioning, which will not be done in simulated LRFA, and 2) the simulated LRFA control group will receive an injection of triamcinolone acetonide at each site where a radiofrequency lesion would normally be applied.
215099798|NCT00727558|DEVICE|narafilcon A|spherical soft contact lens
215099799|NCT01705912|OTHER|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
215099800|NCT01705912|OTHER|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
215013030|NCT03520387|BEHAVIORAL|AcTIVE-CBT|AcTIVE-CBT involves a standardized CBT protocol for pain, delivered via a video telehealth interface. AcTIVE-CBT also incorporates use of an activity tracker to provide objective feedback on activity levels, which can inform participants' and providers' impressions of goals and progress.
215013031|NCT03520387|BEHAVIORAL|TBSCE|TBSCE control is a focused program of CBT involving an initial 60-minute telephone education session by a psychologist; the provision of printed educational materials on chronic pain self-management, and a workbook for CBT self-management; and structured, written plans for weekly practice, reading and homework using the workbook.
215013032|NCT03336866|DRUG|Placebo|Normal saline
215013033|NCT03336866|DRUG|IXT-m200|IXT-m200 is an anti-methamphetamine monoclonal antibody
215013034|NCT06081062|BIOLOGICAL|Fabagal® (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
215013035|NCT06081062|DRUG|Active comparator (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
215013036|NCT03185351|DRUG|Bupivacaine|20 ml of 0.5% bupivacaine using supraclavicular BPB.
215013037|NCT03185351|DRUG|Midazolam|midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB
215013038|NCT03185351|DRUG|Midazolam|0.03 mg/kg of midazolam by I.V. route
215013039|NCT06063343|DRUG|KAND145|In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.
215013040|NCT06063343|DRUG|Placebo|Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.
215013041|NCT00373087|DRUG|entacapone|entacapone
215099801|NCT02280317|DRUG|VAL201|VAL201-001 Sub-cutaneous injection.
215013042|NCT00373087|DRUG|l dopa versus placebo|l dopa versus placebo
215099802|NCT04736615|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
215099803|NCT04736615|BEHAVIORAL|Behavior change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
215099804|NCT01949610|DRUG|14C-JNJ26489112|Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
214408613|NCT05876585|DRUG|Metoclopramide 10 mg ampoule|Comparator drug
214408614|NCT03643965|DRUG|Nefecon|Nefecon 16 mg for daily administration by mouth for 9 months.
214408615|NCT03643965|DRUG|Placebo oral capsule|Placebo capsules for daily administration by mouth for 9 months.
214408616|NCT05676996|OTHER|attachment-based support|attachment-based support application; It includes video-based trainings on attachment via mobile application and breastfeeding and skin-to-skin contact support for mothers on postpartum day 0.
214408617|NCT06306274|DRUG|Tacrolimus|Tacrolimus (0,1%) ointment
214408618|NCT06306274|DRUG|Placebo|Placebo ointment
214408619|NCT04761393|PROCEDURE|Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI|Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds
214408620|NCT02098031|OTHER|Improving nutrition knowledge among mothers|
214408621|NCT06178315|PROCEDURE|EUS-guided celiac plexus block|Under EUS-guidance, celiac plexus block will be performed with injection of bupivacaine and triamcinolone into the area of celiac plexus.
215013043|NCT00541775|DRUG|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
215013044|NCT00541775|DRUG|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
215013045|NCT00541775|DRUG|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
215099805|NCT02903732|OTHER|observational|registry
215099806|NCT03526510|RADIATION|Conventionally Fractionated versus Hypofractionated Boost|
215013046|NCT00541775|DRUG|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
215013047|NCT00032487|DRUG|Insulin|Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
215013048|NCT00032487|DRUG|Glimepiride|Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
214408622|NCT06178315|PROCEDURE|Sham procedure|Celiac plexus will not be performed in this arm.
214408623|NCT03593759|DRUG|Prednisone or Prednisolone|Oral prednisone/prednisolone tablet
214408624|NCT03593759|DRUG|Methotrexate|Oral, subcutaneous, or intramuscular methotrexate
214408625|NCT06570551|DEVICE|i3 CGM(continuous glucose monitor)|The i3 CGM consists of a Sensor Pack (including probe, iCGM-S3), a Transmitter Pack (iCGM-t3), and an application (iCGM-APP (released version: V02)).application (i3 CGM App). The user can view their glucose data on the i3 CGM App running on a compatible mobile device.
214408626|NCT02820051|DEVICE|Transcutaneous CO2 monitor|Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.
215099807|NCT02107157|DEVICE|755nm Laser with Cap Array|
215099808|NCT02181114|BEHAVIORAL|Expert System Coaching|Patients will receive coaching and feedback over the phone and stag-appropriate educational materials (i.e. paphlets, brochures, personalized feedback report) based on their answers to the survey questions and where they are in their kidney transplant evaluation process.
215099809|NCT00033488|OTHER|cytology specimen collection procedure|
215013049|NCT00032487|DRUG|Rosiglitazone|Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
215013050|NCT00032487|DRUG|Metformin|Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
215013051|NCT05301777|DEVICE|Computed tomography|Computed tomography
215099810|NCT00033488|PROCEDURE|annual screening|
215099811|NCT00033488|PROCEDURE|comparison of screening methods|
215099812|NCT02100475|DRUG|insulin degludec/liraglutide|"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted."
215099813|NCT02100475|DRUG|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
215099814|NCT05342272|DRUG|Betaine taurine PVP gel|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
215099815|NCT05342272|DRUG|Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
215099816|NCT03066414|PROCEDURE|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
215099817|NCT05479240|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 cycles.
214408627|NCT02820051|DRUG|Midazolam|The initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
214408628|NCT02820051|DRUG|Propofol|The initial dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
214408629|NCT02820051|DRUG|Nalbuphine|The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
214408630|NCT02820051|DRUG|Lidocaine|Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
214408631|NCT00715806|DEVICE|Open MRI scanner.|Imaging in an Open MRI scanner.
214408632|NCT00715806|DEVICE|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
214408633|NCT06222619|PROCEDURE|Potal vein embilization|Portal vein of involved bile duct is embolized to increase the volume of remnant liver.
215013052|NCT02323061|PROCEDURE|BCI using EEG signals|A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
215013053|NCT00270166|DRUG|epoetin alfa|
215013054|NCT02830633|PROCEDURE|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
215013055|NCT02830633|PROCEDURE|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
215013056|NCT00810745|PROCEDURE|starr|stapled transanal rectal resection
215013057|NCT04723069|DRUG|Control Group|metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
215013058|NCT04723069|DRUG|Test Group|metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
215099818|NCT05479240|DRUG|Capecitabine|Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
215099819|NCT05479240|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.
214408634|NCT02938650|DRUG|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
214408635|NCT01149135|DEVICE|Blue enriched light with a low intensity|30 minutes in the morning, 750 lux
214408636|NCT01149135|DEVICE|standard light treatment|standard light treatment, 30 minutes, 10 000 lux
214408637|NCT01683695|DRUG|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
214408638|NCT01683695|DRUG|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
214408639|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
214408640|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
214408641|NCT03141658|DRUG|Placebo|Multiple doses of placebo once daily for 6 days
214408642|NCT03141658|OTHER|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
214408643|NCT05653570|DIAGNOSTIC_TEST|Electrical stimulation|Electrical stimulation will be used to confirm needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
214408644|NCT05653570|DIAGNOSTIC_TEST|Ultrasound|Ultrasound guidance will be used to visualize needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
215099820|NCT05479240|RADIATION|short-range radiotherapy|5\*5Gy，d1-d5
215099821|NCT02184923|OTHER|presentation of visual vertical|
215099822|NCT05584280|DEVICE|Orsiro stent on shelf|Cluster randomization to Orsiro stent on shelf vs. control
215099823|NCT05584280|DEVICE|Promus stent on shelf|Cluster randomization to Promus stent on shelf vs. treatment
215099824|NCT05967650|BIOLOGICAL|standard hepatitis B vaccine|IBD patients with negative HBV will be diveded in to two arms first arm vaccinated with standard HBV vaccine regemin( dose 0.2.6)
215099825|NCT05967650|BIOLOGICAL|accelerated HBV Vaccine|IBD patients with negative HBV will be diveded in to two arms second arm vaccinated with accelerated HBV vaccine regemin( dose 1.2.3)
215099826|NCT05317065|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
215013059|NCT04309448|BEHAVIORAL|Perturbation-based balance training with functional electrical stimulation|The PBT program will consist of repetitive practice of reactive stepping for one hour. The participants will be equipped with the Odstock 2-Channel stimulator on one or both sides depending on their deficits. One channel of stimulation may be applied to the common fibular nerve to elicit a flexor withdraw reflex and elicit a step. The second channel of stimulation may be applied to the quadriceps muscles to assist with the supporting phase of the reactive step, as required. Participants will experience about 60 perturbations per session during balance exercises. To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness around the participant's trunk. Throughout the hour-long session, participants will complete challenging balance tasks, customized to their ability level, during standing and walking. The training will be supervised by a licensed physiotherapist and administered by a licensed physiotherapist or registered kinesiologist.
215013060|NCT02269605|OTHER|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
215013061|NCT02269605|DRUG|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
215013062|NCT02269605|DRUG|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
215099827|NCT03634163|BEHAVIORAL|Neighbourhood exchange|Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
215099828|NCT03634163|BEHAVIORAL|Quality of Life Assessment|Completion of baseline measures
214408645|NCT05842850|BEHAVIORAL|Caloric restriction intervention|The intervention consist of 4-weeks limiting daily food intake to a window of 8 hours (8am to 4pm) and water-fasting for the remaining hours of the day. Participants (LBW NAFLD individuals only) will be instructed to eat a balanced diet according to the current dietary guidelines reduced by 20% calories to ensure energy deficit.
214408646|NCT05842850|OTHER|No intervention|No intervention
214408647|NCT05995171|OTHER|Questionnaire|Quality of life questionnaires will be used specifically for this research: Pediatric Quality of Life Invertory and EA-QoL
214408648|NCT05302791|DEVICE|Muscle Cooling|Cooling wrap will be set to 10°C
214408649|NCT05302791|OTHER|Resistance Exercise|Resistance Machines (Leg Press and Knee extension). 12 rep Max
214408650|NCT06008678|DEVICE|RXiBreeze PAP System, Model RXiBreeze 20A|The RXiBreeze PAP System is a prescription-only positive airway pressure (PAP) ventilator used to treat obstructive sleep apnea (OSA). It is a microprocessor-controlled device that provides mechanical ventilation to a subject.
214408651|NCT06339983|OTHER|Manual Scar Mobilization Therapy:|In this therapy, deep pressure on some point of the area of the scar will be given which will be perpendicular to the skin and will be followed by skin rolling
214408652|NCT06339983|OTHER|Myofascial Cupping Therapy:|A disposable plastic cup (5cm) will be positioned at THE selected area of the cesarean scar. Then, negative pressure will be applied using a mechanical vacuum pump, the cup will be gently slid around the selected area rhythmically to get a massage-like effect
214408653|NCT03541603|DRUG|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
214408654|NCT03541603|DRUG|Matching Placebo|A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
215013063|NCT03044288|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.
215099829|NCT04519463|DRUG|Xylocaine Mucosal Product|Xylocaine 10% Nasal Spray
215099830|NCT04519463|DRUG|Placebo|Sodium Chloride 0.9%
215099831|NCT03562312|OTHER|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
215099832|NCT03562312|OTHER|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
214408655|NCT05183555|DRUG|68Ga-DOTATOC PET/CT|68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
214408656|NCT05837026|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~Outreach (via phone or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if the participant has suicidal thoughts, and (c) discuss plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals provide to patients who present with suicidal thoughts."
214408657|NCT05837026|OTHER|Care as Usual (CAU)|Participants will receive standard care that hospitals provide to patients who present with suicidal thoughts.
214408658|NCT06555432|DRUG|LIVTENCITY|LIVTENCITY tablet.
214408659|NCT04001114|COMBINATION_PRODUCT|Sampling Research Cigarettes|Participants sample two research cigarettes, which differ in typical tobacco smoke constituents such as tar, nicotine, carbon monoxide, etc. In the Cigarette Discrimination Session, participants sample both types of cigarettes repeatedly, guess their identity (A or B) with regard to reference cigarettes, and rate their subjective effects. In the Ad Libitum Smoking Session, participants can smoke one of these cigarette types as much or as little as they like for eight hours.
214408660|NCT02911571|DEVICE|MMprofiler SKY92 gene signature|"MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis"
214408661|NCT05821907|BEHAVIORAL|data collection group|The scale development process generally consists of three stages as item production, theoretical analysis and psychometric analysis. The researcher provides theoretical support to the item pool during item production. In the theoretical analysis stage, the content validity of the new scale is evaluated and the first item pool is ensured to reflect the desired structure. In the final stage of the psychometric analysis, the researcher evaluates whether the new scale establishes validity and reliability.
214408662|NCT06444347|DEVICE|Biosynthetic Mesh|The biosynthetic mesh group will undergo hiatal hernia repair with Phasix Mesh (Becton Dickinson, Franklin Lakes, NJ) reinforcement, secured with permanent suture.
214408663|NCT06444347|PROCEDURE|Hiatal Hernia Repair|The non-mesh group will undergo hiatal hernia repair with permanent suture only.
214408664|NCT01464294|DEVICE|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
214408665|NCT01464294|DEVICE|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
215013064|NCT03044288|OTHER|Standard adhesive strip|this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
215013065|NCT02673385|OTHER|Brazelton scale|
215013066|NCT04599335|DEVICE|2% HA|2% HA
215013067|NCT01559285|DRUG|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
215013068|NCT01559285|DRUG|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
215013069|NCT01559285|DRUG|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
215013070|NCT06581666|OTHER|No special intervention, all participants will be asked to complete same set of questionnaire.|No special intervention, all participants will be asked to complete same set of questionnaire.
215013071|NCT03808454|DRUG|PRP|The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
215013072|NCT03808454|OTHER|Rehabilitation|strengthening ex, posture training,...
215013073|NCT03808454|COMBINATION_PRODUCT|PRP+Rehabilitation|combine PRP and Rehabilitation
215013074|NCT04891653|DRUG|BR790|Subjects will receive oral administration of BR790.
215013075|NCT00114478|DRUG|Epinephrine|
215013076|NCT00114478|DRUG|albuterol (salbutamol)|
215013077|NCT00000483|DRUG|estrogen|
215013078|NCT00000483|DRUG|clofibrate|
215013079|NCT00000483|DRUG|dextrothyroxine sodium|
215013080|NCT00000483|DRUG|niacin|
215013081|NCT05020522|DIAGNOSTIC_TEST|Luminal Index MRI (LI-MRI)|Multiecho T2 sequence; eventual biopsy of lesion(s) detected with LI-MRI only.
215013082|NCT05020522|DIAGNOSTIC_TEST|LI-MRI targeted prostate biopsy|Biopsy targeted to suspicious lesions detected with LI-MRI only
215013083|NCT05020522|DIAGNOSTIC_TEST|Plasma methylation signature (ctMethSig)|Blood sample.
215013084|NCT05812599|OTHER|Educational Module|The COVID Test Learning Module will present four multi-part character scenarios that someone might experience when considering testing for COVID-19. Participants will answer questions about the character's behavior. Accurate guidelines will be provided in response to each scenario to educate participants about what to do in nuanced COVID testing decision-making situations.
215013085|NCT03075943|DIETARY_SUPPLEMENT|InSea2|Daily supplement: 2 capsules of InSea2
215013086|NCT03075943|DIETARY_SUPPLEMENT|Placebo|Daily supplement: 2 capsules of Placebo
215013087|NCT02975700|DRUG|PLX3397|1000 mg/day (400 mg in the morning and 600 mg in the evening)
215013088|NCT03384485|DIAGNOSTIC_TEST|antiphospholipid syndrome|blood test for enzyme test,plasma and Lys-3-3 plasma
215013089|NCT03568071|DRUG|MOR 106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
215013090|NCT03568071|DRUG|Placebo|A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
215013091|NCT04981756|OTHER|observation|This observational study does not have any intervention.
215013092|NCT04501445|BEHAVIORAL|Written Summary of Rounds|The summary was organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
215013093|NCT01541254|DEVICE|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
215013094|NCT05660538|DRUG|Suzetrigine|Tablets for oral administration.
215013095|NCT05660538|DRUG|Pregabalin|Capsules for oral administration.
215013096|NCT05660538|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
214408666|NCT06321159|OTHER|mobile application|mobile application for diet, exercises and medication adherence
214408667|NCT05990881|DRUG|Botulinum toxin|Patients in this group will receive an injection of Botulinum toxin.
214408668|NCT05990881|DRUG|Standard-of-care corticosteroid injections|Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.
214408669|NCT02155582|DRUG|Copanlisib (BAY80-6946)|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
214408670|NCT03166592|DEVICE|Magnetic resonance imaging with contrast|injection of gadolinium contrast then acquisition of images with magnetic resonance imaging then spectroscopy
214408671|NCT03941574|DRUG|HLX10|HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
214408672|NCT00614744|PROCEDURE|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
214408673|NCT00614744|PROCEDURE|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
214408674|NCT05634889|RADIATION|De-escalation|No regional radiotherapy. Radiotherapy is given to the remaining breast after breast conserving surgery. Chest wall radiotherapy after mastectomy only in case of wide spread multifocality.
214408675|NCT02451280|PROCEDURE|Unilateral Hybrid Intervention|For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).
214408676|NCT02451280|PROCEDURE|Bilateral Hybrid Intervention|For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.
214408677|NCT02451280|PROCEDURE|Robot-Assisted Training|The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with bilateral protocols for 90 minutes. The tasks will be tailored according to the level
214408678|NCT03302806|OTHER|Non interventional Study|
214408679|NCT05282342|DIAGNOSTIC_TEST|Diagnostic tests|No intervention will be carried out. Participants of the whole groups will be underwent the same tests.
214408680|NCT00793806|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
214408681|NCT03620929|DRUG|Estradiol Valerate|In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
214408682|NCT05425797|OTHER|In-Person Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place in-person at the PP's office.
214408683|NCT05425797|OTHER|Video-Call Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place virtually via a secure video system.
214408684|NCT05425797|OTHER|Phone Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place via telephone.
214408685|NCT05060471|DRUG|Toripalimab|Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
214408686|NCT04423731|DRUG|Folfirinox|Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist.
214408687|NCT06544928|DEVICE|RESP Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
215013097|NCT05660538|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
214408688|NCT05785897|DEVICE|Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation|"'All-comer' subjects with acute STEMI undergoing primary PCI according to current ESC guidelines will be eligible.~Eligible subjects will be pre-treated with DAPT consisting of aspirin (loading dose: 150-300 mg orally or 80-500 mg intravenously, maintenance dose: 75-100 mg daily orally) and a potent P2Y12 receptor inhibitor, either ticagrelor (loading dose: 180 mg orally, maintenance dose: 90 mg bd orally) or prasugrel (loading dose: 60 mg orally, maintenance dose: 10 mg od orally or 5 mg od orally if age \>75 years or weight \<60 kg) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI.~Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation and final residual stenosis \<30% by visual estimation or 20% by QCA."
214408689|NCT06104865|BEHAVIORAL|Tinnitus Sound Therapy using (Resound Tinnitus relief) mobile application|Patient exposure to relieving sound(wind, rain, ocean waves, etc) of his own choice from the mobile phone application and using this effect with time to accommodate the brain to neglect the negative effects of tinnitus.
215013098|NCT05415527|OTHER|Presence of sarcopenia evaluated prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management(dietician and APA).|"Sarcopenia will be evaluated by CT-scan. This method will be combined with a bone mineral density test which is also a way of entering into a more specific approach to sarcopenia screening.~The patients will receive optimised treatment by nutritional monitoring and adapted physical activity (APA) in addition to follow-up for sarcopenia."
215099833|NCT02246907|OTHER|Exercise|All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
214408690|NCT00444574|DRUG|Methylphenidate Transdermal System|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
214408691|NCT00444574|DRUG|Placebo|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
214408692|NCT00444574|DRUG|Concerta|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
214408693|NCT03563638|DIAGNOSTIC_TEST|75gOGTT|oral glucose tolerance test (OGTT) was conducted on all participants between the 24th and 28th gestation weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
214408694|NCT02125513|DRUG|carboplatin and paclitaxel followed by surgery|
214408695|NCT03297983|DRUG|M7583|Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.
214408696|NCT00818025|BEHAVIORAL|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
214408697|NCT03688854|DIETARY_SUPPLEMENT|SCFA mixture|Intracolonic administration
214408698|NCT00589862|DRUG|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
214408699|NCT04242394|PROCEDURE|ERCP|Routine ERCP procedures with gallbladder in situ patient
214408700|NCT02266420|PROCEDURE|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
214408701|NCT06136806|DIAGNOSTIC_TEST|Ferumoxytol Enhanced Magnetic Resonance Angiography（ FE-MRA）；Coronary/Renal /Lower artery Arteriography|When the patient is suspected with multisite artery disease, FE-MRA and angiography will be performed according to the patient's clinical manifestation. For example, when the patient is suspected with coronary artery disease, coronary FE-MRA and angiography will be performed; when the patient is suspected with renal artery stenosis, renal artery FE-MRA and angiography will be performed; and when the patient is suspected with the lower extremity artery occlusion, the lower extremity artery FE-MRA and angiography will be performed.
214408702|NCT06136806|DIAGNOSTIC_TEST|Ferumoxytol Enhanced Magnetic Resonance Venography（ FE-MRV）, Computed Tomography Pulmonary Angiography, Ultrasound for Lower Extremity Deep Vein.|When the patient is suspected with venous thromboembolism, the lower extremity vein FE-MRV, pulmonary FE-MRA and ultrasound for lower extremity deep vein as well as computed tomography pulmonary angiography will be taken to ensure whether the patient with thrombus or not.
215013099|NCT05249465|BEHAVIORAL|Core behavioral weight loss intervention|"All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely."
215013100|NCT05249465|BEHAVIORAL|Self-monitoring diet|Participants randomized to receive this component will be instructed to self-monitor their dietary intake daily via the Fitbit mobile app. Participants will receive a daily calorie goal.
215013101|NCT05249465|BEHAVIORAL|Self-monitoring weight|Participants randomized to receive this component will be instructed to self-monitor their body weight daily via a wireless e-scale (e.g., the Fitbit Aria Scale).
215013102|NCT05249465|BEHAVIORAL|Self-monitoring steps|Participants randomized to receive this component will be instructed to self-monitor their step count daily via a wrist-worn Fitbit activity monitor. A daily step goal will be given that will adapt based on progress.
215013103|NCT00090428|BEHAVIORAL|Gluten- and casein-free diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
215013104|NCT00090428|BEHAVIORAL|Placebo controlled diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
215013105|NCT04939935|DRUG|Metformin XR|Extended release metformin.
215013106|NCT04939935|OTHER|Control|Placebo is inactive tablets that is identical to the intervention Metformin tablets.
215013107|NCT02082288|OTHER|Edessy ICSI Outcome Embryo Score|"EIOS:~Age (ys) \>35 (0) 30-35 (1) \<30 (2) No of retrived oocyte \<5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos \<2 (0) 2-4 (1) \>4 (2) No of good quality embryos \<3 (0) 3-5 (1) \>5 (2) No of embryos transferred -------- (0) ≤2 (1) \>2 (2)"
215013108|NCT04518410|BIOLOGICAL|bamlanivimab 7000mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
215013109|NCT04518410|BIOLOGICAL|BRII-196+BRII-198|1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
215013110|NCT04518410|BIOLOGICAL|AZD7442 (IV)|300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
215013111|NCT04518410|BIOLOGICAL|AZD7442 (IM)|Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
215013112|NCT04518410|DRUG|SNG001|1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
215013113|NCT04518410|DRUG|Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
214408703|NCT05803824|OTHER|exercise therapy program|"patients will receive Baduanjin Qigong exercise plus selected exercise. the subjects will recive Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks.~The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .~Selected Exercise Program: Patients will receive~* balance exercises is composed of three phases, including warm-up, balance training and cool down.~* Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises"
214408704|NCT00219921|DRUG|Intrathecal morphine at surgery, 0.1mg and placebo|
215013114|NCT04518410|BIOLOGICAL|BMS-986414 + BMS-986413|Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
214408705|NCT00219921|DRUG|Patient Controlled Analgesia with iv morphine and placebo|
214408706|NCT00219921|DRUG|intrathecal morphine AND patient controlled analgesia with iv morphine|
214408707|NCT04493437|DEVICE|Telerehabilitation|Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
215013115|NCT04518410|BIOLOGICAL|SAB-185 (3,840 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
215013116|NCT04518410|BIOLOGICAL|SAB-185 (10,240 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
215013117|NCT04518410|DRUG|CASIRIVIMAB + IMDEVIMAB|600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
215099834|NCT04142294|DIETARY_SUPPLEMENT|Histidine|ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
215099835|NCT03605446|DIETARY_SUPPLEMENT|Biscuit acceptance|Acceptance of high protein biscuits
215099836|NCT05691114|BIOLOGICAL|hAESCs|human Amniotic Epithelial Stem Cells
215099837|NCT05742607|DRUG|IPH5201 + durvalumab + standard chemotherapy|"Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab."
215099838|NCT01548508|OTHER|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
214408708|NCT04569578|OTHER|Policy|"The intervention will include:~i. Formalized physical activity policies implemented in preschools including the following:~1. A minimum of 3 hours of total daily outdoor time scheduled both in the morning and in the afternoon~2. At least 10 minutes teacher-led active play per day~3. A minimum of 1 weekly outdoor excursion~4. Meet the children outdoors when they arrive at preschool and/or picked up by their parents~5. Only use screen tablets and computers for educational teaching purposes~6. Communicating to, and encouraging, the parents to actively transport their children to and from preschools~ii. A study website with an activity bank also serving as a platform for inter-professional education that preschool teachers can share and communicate about engaging activities and experience~iii. Weekly follow-up and feedback by web-based questionnaires"
214408709|NCT00198874|BEHAVIORAL|Integrated Family and Cognitive-Behavioral Therapy|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
215013118|NCT04518410|DRUG|Placebo for Bamlanivimab 7000mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
215013119|NCT04518410|DRUG|Placebo for Bamlanivimab 700mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
215013120|NCT04518410|DRUG|Placebo for BRII-196+BRII-198|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
215013121|NCT04518410|DRUG|Placebo for SNG001|Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
215013122|NCT04518410|DRUG|Placebo for Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
215013123|NCT04518410|DRUG|Placebo for SAB-185 (low dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
215099839|NCT01548508|OTHER|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
214408710|NCT00198874|OTHER|Education|Drug education curriculum was delivered to participants assigned to this condition.
214408711|NCT02283645|DRUG|3 % minoxidil lotion|
214408712|NCT02283645|DRUG|Placebo|
214408713|NCT01650337|OTHER|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
214408714|NCT00002620|DRUG|carmustine|
214408715|NCT00002620|DRUG|chemotherapy|
214408716|NCT00002620|DRUG|mitolactol|
214408717|NCT00002620|RADIATION|low-LET cobalt-60 gamma ray therapy|
214408718|NCT00002620|RADIATION|low-LET photon therapy|
215013124|NCT04518410|DRUG|Placebo for BMS-986414 + BMS-986413|Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
215013125|NCT04518410|DRUG|Placebo for AZD7442 (IV)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
215013126|NCT04518410|DRUG|Placebo for AZD7442 (IM)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
215013127|NCT04518410|DRUG|Placebo for SAB-185 (high dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
215013128|NCT04518410|BIOLOGICAL|bamlanivimab 700mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
215013129|NCT06342752|DIAGNOSTIC_TEST|Breath test|Early detection of volatile organic compounds (VOCs) in breath from preterm infants, collected at several timepoints within the first 4 weeks of life to predict BPD before diagnosis is made at 36 weeks PMA.
215013130|NCT06342752|OTHER|Throat swabs|A throat swab will be taken on several timepoints within the first 4 weeks of life to detect airway mucin expression. A second throat swab will be taken as proxy for the airway microbiome.
215013131|NCT06342752|OTHER|Placental samples|After birth, placental biopsies will be collected for headspace VOCs analysis. A placental swab and a biopsy will be taken for microbiome analysis.
215013132|NCT06342752|OTHER|Vaginal swab|A vaginal swab will be taken before birth for microbiome analysis.
215013133|NCT06342752|OTHER|Endotracheal aspirates|Collection of aspirates, as part of routine care, to detect mucin expression and the lung microbiome.
215013134|NCT02455011|BIOLOGICAL|REMD-477|
215013135|NCT02563431|DEVICE|SYSTAM - SP-ED|"* Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~* Daily passive mobilisation of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
214408719|NCT01231282|OTHER|diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
215013136|NCT02563431|DEVICE|Ultrasling ER 15°Donjoy - 4P-ED|"* Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~* A training of the patient and members of family on pathology, risk, use of material~* Daily passive mobilization of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
215013137|NCT02123875|OTHER|Physiotherapy|
215013138|NCT02123875|OTHER|Control arm|Routine hospital based physiotherapy
214408720|NCT05892913|DRUG|Slow dose preemptive Atropine|it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
214408721|NCT05892913|DRUG|Ephedrine|For sympathetic blockade (SBP\<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
214408722|NCT00768066|BIOLOGICAL|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
214408723|NCT00768066|BIOLOGICAL|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
214408724|NCT00768066|BIOLOGICAL|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
214408725|NCT04831775|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice and will be held over 8 weeks. The classes will be taught by a GRA. Classes 1 \& 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 \& 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. Each online class will follow the same format: (1) introduction/revisiting content from the previous class; (2) review of progress on computer exercises; (3) practicing cognitive strategies in class; and (4) a weekly topic. The GRA will also prescribe exercises for the following weeks.
215013139|NCT05737745|BEHAVIORAL|Self-monitoring|Tracking physical activity and fruit/vegetable intake.
214408726|NCT04831775|BEHAVIORAL|Brain Games|The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Participants will only need a computer, smart phone, or tablet with Internet access to securely log onto the website. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on.
214408727|NCT04838210|BEHAVIORAL|EleVATE Group Care|10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG. In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life. Groups are facilitated by an obstetric clinician.
214408728|NCT04838210|BEHAVIORAL|Individual Prenatal Care|The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician. Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery. Visits focus on routine screening tests and prenatal care.
214408729|NCT03001986|BIOLOGICAL|inactivated EV71 vaccine (KMB-17 cells)|Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
214408730|NCT04455048|OTHER|Cervicothoracic thrust manipulation|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.
214408731|NCT04455048|OTHER|Cervicothoracic thrust manipulation sham|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
215099840|NCT03060200|OTHER|Self-administered online CBT plus therapist check in|The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.
215099841|NCT03060200|OTHER|Sham self-administered online CBT plus therapist check in|The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
215013140|NCT05737745|BEHAVIORAL|Group-dynamics|Survivors act as team captains, facilitating interactions between themselves and their support team members and providing goal directed feedback.
215013141|NCT05737745|BEHAVIORAL|Weekly virtual sessions- Standard|Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of physical activity.
215013142|NCT05737745|BEHAVIORAL|Newsletters- Standard|Weekly newsletters support attainment of physical activity and nutrition goals.
214408732|NCT05984641|DEVICE|CONAN® Proctological Cream|The active treatment samples used for the duration of the study were allocated at the site involved and consisted in 30 g tubes with an endorectal applicator, identified by the batch number, expiry date and information on the study on dedicated labels. The treatment of patients randomized to Group A consisted in applying the local treatment (1 application 3 times/day) for 30 days. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
214408733|NCT01205750|OTHER|Glucose clamp|450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
214408734|NCT02477826|DRUG|Nivolumab|
214408735|NCT02477826|DRUG|Ipilimumab|
214408736|NCT02477826|DRUG|Carboplatin|
214408737|NCT02477826|DRUG|Cisplatin|
214408738|NCT02477826|DRUG|Gemcitabine|
214408739|NCT02477826|DRUG|Pemetrexed|
214408740|NCT02477826|DRUG|Paclitaxel|
214408741|NCT00597883|PROCEDURE|Carotid endarterectomy|(non-experimental) carotid endarterectomy (CEA) for treatment of carotid artery stenosis
214408742|NCT00597883|OTHER|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
214408743|NCT06576895|OTHER|No intervention|No intervention
215013143|NCT05737745|BEHAVIORAL|Newsletters- Yoga|Weekly newsletters support attainment of physical activity and nutrition goals, while including mindfulness principles.
215013144|NCT05737745|BEHAVIORAL|Weekly virtual sessions- Yoga|Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of yoga.
215013145|NCT04512183|OTHER|High-Fidelity Simulation|Teaching strategy based on high-fidelity simulation, which simulates the reality of health care to promote meaningful learning.
215013146|NCT04512183|OTHER|Low-Fidelity Simulation|Teaching strategy based on low-fidelity simulation, which simulates the reality of health care using less technological and less interactive mannequins.
215013147|NCT01253356|DEVICE|IABP|Insertion of intra-aortic balloon \< or = 3 hours before noncardiac surgery and maintained \> or = 12-24 hours after surgery
215013148|NCT05760677|DRUG|pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone|the pioglitazone group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
215013149|NCT05760677|DRUG|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)
215013150|NCT02609906|DEVICE|PhilosTM with augmentation (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)."
215013151|NCT02609906|DEVICE|MultiLoc®-Nail (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes)."
215013152|NCT06214962|BEHAVIORAL|(multiple training modalities, MTM)|"1. Invite experts to discuss the course content of each unit of MTM, and then invite teachers to take pictures , and combine them into one course for the benefit of the elderly in the institution.~2. Select 3 units to try out in the dementia base, and make corrections based on the feedback of the elders and the base staff.~3. Continue to complete other units based on the experience of the first 3 units.~(2) In the Rizhao part, experts are mainly used to develop various course modules suitable for the elderly with dementia in Rizhao, and each module unit is tested on the elderly with dementia and then revised The planning task is mainly to establish a solution strategy. The method is to set up an activity course module planning or design group to develop various course modules suitable for Rizhao demented elders."
215013153|NCT06964126|OTHER|Horticulture activities|In the study, the elderly individuals in the experimental group will have a total of 8 sessions of gardening activities once a week (on Thursday) for 2 months. Before the gardening activities, the garden and environment will be prepared by the researcher, the elderly individuals will be informed about the day's activities and, if necessary, videos about the activities will be watched and photographs related to the sessions will be shown.
214408744|NCT04989439|OTHER|Electrical impedance tomography and ultrasonography of the lung|Both EIT and LUS are non-invasive methods and do not pose any additional risk for the patient. The LuMon System with pediatric EIT belts (LuMon Belt, Sentec, Landquart, Switzerland) will be used. The belt will be placed on the thorax circumference of the infant and connected to the LuMonConnector (Sentec, Landquart, Switzerland). Small electrical currents (3 mA, 198 kHz) will be repetitively injected in rotation through adjacent electrode pairs, and voltage changes will be measured by all passive electrodes pairs (scan rate 48 Hz). Changes in lung electrical impedance will be continuously recorded for 5 minutes. EIT data will be analyzed off-line using Matlab (Mathworks, Natick, Massachusetts, USA). The regional tidal volume distribution, the homogeneity of tidal ventilation distribution, regional respiratory system compliance, and alveolar overdistension and collapse will be assessed. LUS will be performed by experienced users, with a 10 MHz linear transducer.
214408745|NCT05457244|DEVICE|single-port robotic surgery|Colorectal surgery using the da Vinci SP System will be performed via the umbilicus, McBurney's site or the reverse McBurney's site depending on the sites of lesion. All of these patients will undergo a standard minimally invasive resection in the same fashion as would be carried out with multiport laparoscopic or robotic surgery.
214408746|NCT01737268|DRUG|FK949E|Oral tablet
214408747|NCT01458275|DRUG|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
214408748|NCT01458275|DRUG|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
214408749|NCT01458275|DRUG|Placebo|Placebo - one actuation per nostril
214408750|NCT01190670|DRUG|Tacrolimus|Oral and Intravenous
215099842|NCT05692102|OTHER|Evaluate quality of life after gynaecological malignancies diagnosis and treatment|diagnosis and treatment
215099843|NCT02990039|BEHAVIORAL|Counseling letter|The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
215099844|NCT03179397|DEVICE|Model SC9|Experimental
215099845|NCT03179397|DEVICE|Model LI61SE|Active Comparator
215099846|NCT02745808|BIOLOGICAL|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
215099847|NCT02745808|BIOLOGICAL|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
215099848|NCT06279832|OTHER|trascriptomic profiling|The mutational and copy number analyses will be complemented by transcriptomic profiling. RNA will be extracted from FFPE samples using miRNAeasy FFPE kit (Qiagen) and checked for quality and quantify by 2100 Bioanalyzer instrument (Agilent) and Qubit Fluorometer (ThermoFisher), respectively. Transcriptome analyses will be performed by RNA-seq. We will apply total RNAseq using the Illumina® TruSeq Stranded Total RNA workflow that provides a solution allowing the detection of whole transcriptome, splicing variants, and transcript fusions of human RNA isolated from FFPE samples. Libraries will be run using the Illumina's Novaseq6000 system, with a least 50 millions of reads/sample, the minimum read depth for the correct evaluation of low expressed transcripts.
214408751|NCT01190670|DRUG|ASP015K|Oral
214408752|NCT01576237|OTHER|blood donation|blood donation with preparative hemapheresis
214408753|NCT01743274|PROCEDURE|OCT|"Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.~OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution."
214408754|NCT03697460|DRUG|INCB018424|INCB018424 PHOSPHATE CREAM 1.5%, topical application, twice daily on lesions of cutaneous LP.
214408755|NCT01819090|DEVICE|Elysee 150 ventilator|
214408756|NCT01819090|DEVICE|Elysee 150 ventilator with a ventilation switch control|
214408757|NCT02451293|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|
214408758|NCT02451293|DRUG|Placebo|
214408759|NCT04973618|BIOLOGICAL|APVO436|"APVO436~Dosage: APVO436 will be administered at a fixed dosage of 18 mcg after a weekly ramp up during Cycle 1 (Step-up dosing: C1D15: 6 mcg over 22 hours, C1D22: 12 mcg over 8 hours, C2D1: 18 mcg over 6 hours, C2D8: 18 mcg over 4 hours), totaling 18 µg in Cycle 1 and 72 µg/cycle for Cycles 2-4 for a total of 234 µg for the projected 4-cycle treatment course.~Dosage Form: IV Solutions for Intravenous Administration~Frequency: Weekly"
214408760|NCT02569229|OTHER|Diagnostics for glucose tolerance with 3 different methods.|"1. A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).~2. An oral glucose tolerance test done within the 7 day period of CGMS.~3. Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS."
214408761|NCT02266329|DRUG|prazosin hydrochloride|Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
214408762|NCT02266329|DRUG|placebo|Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
214408763|NCT06081101|DRUG|Methylprednisolone Injection|Medication will be injected into SI joint under ultrasound guidance
214408764|NCT06081101|DRUG|Ketorolac Injection|Medication will be injected into SI joint under ultrasound guidance
214408765|NCT02178436|DRUG|gemcitabine hydrochloride|Given IV
214408766|NCT02178436|DRUG|Selinexor|Given IV
214408767|NCT02178436|OTHER|Pharmacological Study|Correlative studies
214408768|NCT02178436|OTHER|Laboratory Biomarker Analysis|Correlative studies
214408769|NCT02178436|DRUG|Nab paclitaxel|Given IV
214408770|NCT01807819|OTHER|Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
215013154|NCT06964386|OTHER|The traditional physical therapy rehabilitation exercises|"It included 30 minutes of exercises as:~* Incorporated stretching (adductors, calf, and hamstring muscles)~* Range of motion for hip, knee, and ankle joints.~* Core stability exercises.~* climbing stairs and weight-bearing activities for strengthening, such as sit-to-stand and attaining standing position by half kneeling"
215013155|NCT06964386|OTHER|balance training on traditional balance board|Balance training included: - Side stepping - Stepping backward - Changing the center of gravity in one-foot balance.
214408771|NCT04742244|DIETARY_SUPPLEMENT|Lvemon verbena extract|Each capsule contained 200 mg of lemon verbena extract 2 capsules/day, 14 days
214408772|NCT04742244|DIETARY_SUPPLEMENT|maltodextrin|Each capsule contained 0 mg of lemon verbena extract 2 capsules/day, 14 days
214408773|NCT04004858|RADIATION|External beam radiation therapy|Patient will receive 60Gy in 20 fractions as per standard practice
214408774|NCT00365417|DRUG|Bevacizumab|15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
214408775|NCT00365417|DRUG|Doxorubicin|60 mg/m\^2 IV every 21 days x 4 cycles
215099849|NCT04402723|DRUG|Donafenib|In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
214408776|NCT00365417|DRUG|Cyclophosphamide|600 mg/m\^2 IV every 21 days x 4 cycles
214408777|NCT00365417|DRUG|Capecitabine|Following clinical response assessment, 650 mg/m\^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
214408778|NCT00365417|DRUG|Docetaxel|Following clinical response assessment, 75 mg/m\^2 IV every 21 days x 4 cycles
214408779|NCT00350961|DRUG|Gemcitabine|
214408780|NCT00350961|DRUG|Oxaliplatin|
214408781|NCT00350961|DRUG|Capecitabine|
214408782|NCT03524820|DRUG|Cetuximab|Administration of drug
214408783|NCT03795974|BIOLOGICAL|MNC|Hematopoietic stem cells derived from allogenic umbilical cord
214408784|NCT03795974|BIOLOGICAL|MSC|Mesenchymal cells derived from allogenic umbilical cord
214408785|NCT03795974|PROCEDURE|Control|control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .
214408786|NCT04807660|OTHER|middle ear fluid sample|middle ear fluid sample for each enrrolled children
214408787|NCT02723877|DRUG|PQR309|Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
214408788|NCT02723877|DRUG|Eribulin|non.taxane microtubule dynamics inhibitor
214408789|NCT03008343|DEVICE|Irreversible Electroporation|One kind of electric ablation machine from Angiodynamic company (USA)
214408790|NCT03008343|BIOLOGICAL|Natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
214408791|NCT03499600|BEHAVIORAL|Clinical Assessment and CFI|CA and CFI families will participate in the Cultural Formulation Interview prior to their standard intake.
214408792|NCT03499600|BEHAVIORAL|Clinical Assessment|CA families will participate their standard intake procedures.
214408793|NCT06109532|OTHER|hyponatremia|hyponatremia at admission in dengue infected patients
214408794|NCT03918135|DRUG|Paracetamol|"1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 100 patients~Other Names:~* Perfalgan~* Paracerol"
214408795|NCT03918135|DRUG|Ibuprofen|"400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients~Other Names:~Dorifen"
215099850|NCT04599465|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
215099851|NCT04599465|DRUG|IVA|Tablets for oral administration.
214408796|NCT00258479|DRUG|ModafinilNicotine Replacement Therapy|A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
215013156|NCT06964386|OTHER|program on special form of balance board|"Standing holding on the sticks of balance board (first by two sticks, then graduated by one stick).~2- Changing the grasp of hand on sticks (reciprocal catching the sticks by right and left hand).~3- Stride standing on balance board. 4- Make exercises advanced by remove sticks and throwing the ball. 5- All previous exercises do with eye closed and eye opened"
214408797|NCT00258479|DRUG|Modafinil|See Modafinil Intervention Description above.
215013157|NCT05299632|DIAGNOSTIC_TEST|99mTc-MIBI planar imaging and SPECT/CT.|Participants will undergo a Tc-MIBI scan and management will be as per the finding of the Tc MIBI scan which is the standard of care.
215099852|NCT05177367|OTHER|Sequential Variety|3 courses each consisting of a different food
215099853|NCT05177367|OTHER|Simultaneous Variety|3 courses each consisting of 3 foods
215099854|NCT05177367|OTHER|Single Food|3 courses each consisting of the same food
214408798|NCT00524147|PROCEDURE|Pigtail drainage|
214408799|NCT05437471|DRUG|GNRH Analoge, Duphaston, Letrozole|GNRH Analoge, Duphaston, Letrozole
214408800|NCT00445692|DRUG|Clarithromycin|Given Orally (PO)
214408801|NCT00445692|DRUG|Dexamethasone|Given PO
214408802|NCT00445692|DRUG|Lenalidomide|Given Orally (PO)
215013158|NCT05299632|DIAGNOSTIC_TEST|F- 18PSMA PET/CT imaging study|F-18 PSMA is an FDA-approved imaging agent used for PET/CT for evaluating metastatic prostate cancer. The findings of the images of F-18 PSMA will be shared with the referring /treating surgeon. However, the findings will not influence the management.
215013159|NCT02169401|DEVICE|Implantation with the commercially available Axium Neurostimulator|
215013160|NCT02149160|DRUG|FRM-0334|
215013161|NCT02149160|DRUG|Placebo|
215013162|NCT04289298|BEHAVIORAL|Engage-A|Therapist will encourage participants to engage in physical and social activities that are pleasurable or rewarding. Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
215099855|NCT05177367|OTHER|Small portion|Small meal portion size
215099856|NCT05177367|OTHER|Large Portion|Large meal portion size
214408803|NCT05399979|PROCEDURE|Labor Neuraxial Analgesia|Labor Neuraxial Analgesia
214408804|NCT05260840|OTHER|Evaluation study - provision of an online questionnaire|Evaluation study - provision of an online questionnaire
214408805|NCT04614077|OTHER|ex vivo organ bath testing, preservation of vein sections without contact to patient|1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath
214408806|NCT03883685|DIETARY_SUPPLEMENT|Probiotane|probiotics capsules of blended strains including Lactobacillus acidophilus, L. casei and L. rhamnosus
214408807|NCT03883685|DIETARY_SUPPLEMENT|Placebo|Placebo
214408808|NCT01821911|BIOLOGICAL|Zagreb2-1-1|Injection on day 0、7、21
215099857|NCT04079998|DEVICE|Procellera®|Application of Procellera® dressing.
215099858|NCT04079998|OTHER|Standard of Care|Application of standard of care dressings as prescribed.
215099859|NCT02056327|DEVICE|A novel monitoring suite of sensors will be inserted into the standard oral device.|
215099860|NCT00309270|DRUG|Campath-1H|
215099861|NCT04188704|PROCEDURE|Interference screw|Anterior cruciate ligament reconstruction (anterior screw fixation or posterior screw fixation)
215099862|NCT02736435|DEVICE|Magnetic Resonance Guided High Intensity Focused Ultrasound|Direct treatment of uterine fibroids with MR-HIFU
215099863|NCT02736435|DRUG|leuprolide acetate for depot suspension|Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
215099864|NCT04070417|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
215099865|NCT04979117|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.
215099866|NCT02290041|DRUG|Infusion of MSC|Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).
215099867|NCT02290041|DRUG|Infusion of placebo|Infusion of placebo (weeks 0-4-8-20)
215099868|NCT04820413|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
215013163|NCT04289298|OTHER|Training and utilizing Engage-A therapy|Therapist will be trained in Engage-A therapy and given supervision while utilizing this therapy.
215013164|NCT05067244|DRUG|MDMA|MDMA assisted psychotherapy
215013165|NCT04558138|OTHER|Discharge timing|Patients will be discharged home on the day of surgery as opposed to POD #1
215013166|NCT04970589|OTHER|Mango|400g of mango/day
215013167|NCT04970589|DIETARY_SUPPLEMENT|Probiotics|1 probiotics capsule/day
215013168|NCT04970589|OTHER|Placebo|1 Placebo capsule/day
215099869|NCT05246800|OTHER|Structured 8-week mHealth mindfulness program|The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
215099870|NCT01037686|RADIATION|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
214408809|NCT01821911|BIOLOGICAL|Essen|Injection on day 0、3、7、14、28
214408810|NCT04952272|COMBINATION_PRODUCT|CpG-ODN|CAR-T cells secreting scFv against OX40
214408811|NCT05792046|DEVICE|Visual field|test for detecting loss in visual function
214408812|NCT03331328|DEVICE|MonaLisa Touch|MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
214408813|NCT02928939|OTHER|drug-drug or drug-disease interaction|
214408814|NCT02939001|DEVICE|iris recognition scanner|
214408815|NCT03425539|DRUG|Lucerastat|Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.
214408816|NCT03425539|DRUG|Placebo|Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
214408817|NCT01137292|DRUG|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (\<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
214408818|NCT02014558|DRUG|Gilteritinib|Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.
214408819|NCT02014558|DRUG|Voriconazole|Participants received 200 mg voriconazole tablets daily every 12 hours starting from day 16 of cycle 1 through day 1 of cycle 2.
214408820|NCT02014558|DRUG|Midazolam|Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.
215013169|NCT04989517|DRUG|AT193|Topical
215013170|NCT03574714|OTHER|Extracellular pH|Extracellular pH gradient
215099871|NCT01037686|BEHAVIORAL|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
215099872|NCT01037686|DEVICE|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
214408821|NCT02014558|DRUG|Cephalexin|Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.
214408822|NCT00186810|DRUG|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
214408823|NCT00186810|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
214408824|NCT04703699|DEVICE|Myval Transcatheter Heart Valve Series|Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.
215013171|NCT04632342|DRUG|HL301 tablet 300mg|"* Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day"
215013172|NCT04632342|DRUG|Placebo of HL301 tablet|2 tablets at once, three times a day
215013173|NCT06076226|OTHER|No intervention, observation study|No intervention, observation study
215013174|NCT00283985|DRUG|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
215013175|NCT00283985|DRUG|Methotrexate|3 gr/m2 at J1
215013176|NCT00283985|DRUG|Dexamethasone|40 mg/ per os at J1, J2 and J4.
215013177|NCT00283985|DRUG|Erwinase|"In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
215013178|NCT04229381|PROCEDURE|Physical Therapy|Undergo physical therapy
215013179|NCT04229381|OTHER|Quality-of-Life Assessment|Ancillary studies
215013180|NCT04229381|OTHER|Questionnaire Administration|Ancillary studies
215013181|NCT04229381|PROCEDURE|Relaxation Therapy|Undergo progressive muscle relaxation
215013182|NCT06391086|DEVICE|NaviFUS® Neuronavigation-guided focused ultrasound system|The treatment protocol consists of once daily treatment for consecutive five tFUS sessions.
214408825|NCT02894307|DRUG|Rivaroxaban|In patients with mechanical valves and unstable INR
215013183|NCT02218151|OTHER|Patient-Centered Medical Home (PCMH)|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
215013184|NCT02218151|OTHER|Standard Care|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
215013185|NCT05649553|BEHAVIORAL|digital game and video animation based diabetes education|While creating the digital game and video animation, an agreement was made with a software company and this company was responsible for the software and repair of the game. Digital games and video animations cover the basic educational topics of Type 1 diabetes. Expert opinions were received from experts in the field of Child Health and Disease Nursing to ensure the suitability of the content of the educational material. The name of the game site and how to use it were explained to the children in the intervention group by the researcher. In addition, children in the intervention group were given usernames and passwords to log in to the site. Game Sections; What is Diabetes? Medical Nutrition Treatment in Diabetes, Insulin Treatment and Application, Exercise and Physical Activity in Diabetes, Complications of Type 1 Diabetes Mellitus, Diabetes Management at School.
215013186|NCT01846143|BIOLOGICAL|pBCAR3-phosphopeptide|
215013187|NCT01846143|BIOLOGICAL|pIRS2-phosphopeptide|
214408826|NCT01472536|BEHAVIORAL|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
214408827|NCT04756050|DRUG|Bupivacaine HCl 0.5% Injectable Solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
214408828|NCT04756050|DRUG|Prilocaine HCl % 2 injectable solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
214408829|NCT04756050|DRUG|adrenaline amp 0.5mg|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
214408830|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance. Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
214408831|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket + intracluster approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance .10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
214408832|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block multi approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
215013188|NCT01846143|BIOLOGICAL|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
215013189|NCT01063582|OTHER|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
215013190|NCT01063582|PROCEDURE|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
215013191|NCT00454142|DRUG|pazopanib hydrochloride|Given PO
215013192|NCT00454142|OTHER|pharmacological study|Correlative studies
215013193|NCT00454142|PROCEDURE|computed tomography|Correlative studies
215013194|NCT05826158|DIAGNOSTIC_TEST|18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)|18F-mFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
215013195|NCT02560415|DEVICE|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
215013196|NCT02560415|BEHAVIORAL|Comparator|Treatment as usual
215013197|NCT02569905|DRUG|parecoxib sodium|parecoxib sodium 40mg
215013198|NCT02569905|DRUG|flurbiprofen|flurbiprofen 50mg
215013199|NCT02569905|DRUG|saline|normal saline
215099873|NCT04188093|OTHER|PACU discharge criteria and continuous monitoring on the ward|"* PACU discharge criteria (modified aldrete score).~* Continous monitoring of vital signs 96 postoperative hours"
215099874|NCT03680443|OTHER|assembly in THA revision|A single-center continuous series of 62 patients receiving such an assembly in THA revision was assessed retrospectively at a minimum 5 years' follow-up. Failure due to aseptic loosening or instability and implant survival at last follow-up were analyzed.
215099875|NCT04427020|DIETARY_SUPPLEMENT|Milk protein + GBI-30|Both conditions matched flavor, color, and serving size
215099876|NCT04427020|DIETARY_SUPPLEMENT|Milk protein|Both conditions matched flavor, color, and serving size
215099877|NCT00757822|DRUG|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
215099878|NCT00757822|DRUG|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
215099879|NCT05447481|DIETARY_SUPPLEMENT|chicory inulin-type fructan|Dietary supplement: chicory inulin-type fructan
215099880|NCT06222528|BEHAVIORAL|Brief video intervention (Black Girl)|A brief social contact-based video. The video presented a young Black girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
214408833|NCT04756050|PROCEDURE|diagraphma muscle evaluation with ultrasound|"All patients will be evaluated with USG in a head-up position facing the side to be operated before and 30 minutes after the block is performed.~The probe will be placed perpendicular to the chest wall, in the eighth or ninth intercostal space, between the anterior axillary and midaxillary lines, 0.5 to 2 cm below the costophrenic sinus."
214408834|NCT03861455|DRUG|Dupilumab|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
215013200|NCT02726269|DRUG|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
215013201|NCT02726269|DRUG|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
215099881|NCT06222528|BEHAVIORAL|Brief video intervention (Black Boy)|A brief social contact-based video. The video presented a young Black boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
215099882|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Girl)|A brief social contact-based video. The video presented a young Latinx girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
215099883|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Boy)|A brief social contact-based video. The video presented a young Latinx boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
215099884|NCT06222528|BEHAVIORAL|Brief video intervention (White Girl)|A brief social contact-based video. The video presented a young White girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
215099885|NCT06222528|BEHAVIORAL|Brief video intervention (White Boy)|A brief social contact-based video. The video presented a young White boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
215099886|NCT06222528|BEHAVIORAL|Brief video intervention (Nonbinary or transgender)|A brief social contact-based video. The video presented a young nonbinary or transgender adolescent, a professional actor, sharing their scripted personal story of struggles with depression and raising themes of recovery and hope.
215099887|NCT06222528|BEHAVIORAL|Control Condition|A video that will provide information about depression and how to seek help but does not include a personal story.
215099888|NCT03870399|DRUG|Tamoxifen|The treatment to be used will be tamoxifen 20mg orally once daily.
215099889|NCT04924270|BIOLOGICAL|Faecal microbiota transplantation|The capsule FMT transplant consists of faeces obtained from a thoroughly screened, unpaid, anonymous stool donor. Each FMT product is made from 50g faeces diluted in sterile saline (0.9% NaCl) and glycerol, blended, centrifuged and filtered to remove particulate material before transfer to double-layered capsules. The FMT capsules will be stored at - 80 ⁰C until use. On the day of the FMT, the FMT capsules will be thawed to room temperature before treatment.
215099890|NCT04924270|OTHER|Placebo|Placebo capsules consist of NaCl (0.9%) and glycerol added brown food colouring.
215099891|NCT04492111|PROCEDURE|post-extraction dental implant|Insertion of a dental implant immediately after tooth extraction.
215099892|NCT02269930|DRUG|peginterferon beta-1a|Administered as subcutaneous injection
215013202|NCT00004201|DRUG|carboplatin|
215099893|NCT02269930|DRUG|Rebif|Administered as subcutaneous injection
214408835|NCT03861455|DRUG|placebo|patient receive placebo
214408836|NCT04580407|BIOLOGICAL|TAK-672|B-Domain Deleted Recombinant Porcine Factor VIII
214408837|NCT04868396|PROCEDURE|Tumor biopsy|Tumor material will be derived from 'left-over' tumor tissue that is not needed for standardised diagnostics (immune histochemistry and molecular testing).
215013203|NCT00004201|DRUG|cisplatin|
215013204|NCT00004201|DRUG|gemcitabine hydrochloride|
214408838|NCT06483022|BEHAVIORAL|BELIEVE IPE Training|The IPC training will be delivered to health team members who provide intrapartum and/or postpartum maternity care at each facility. Individuals with roles as maternity care providers, nurses, lactation consultants or doulas whose primary inpatient clinical assignment is maternity care will be included in the training. The training will consist of a pre-session module (about 60 minutes), a 90-minute interprofessional collaboration session, delivered using virtual reality head-sets, and post-session modules (about 60 minutes). The pre- and post-session modules will be delivered through an online learning platform.
215013205|NCT02362932|OTHER|Sanitation|Shared sanitation
215013206|NCT04132466|DEVICE|Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system|defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
215013207|NCT06341283|DRUG|Abemaciclib and Letrozole/Anastrozole|Take the treatment with Abemaciclib and Letrozole/Anastrozole at the same time.
215013208|NCT06341283|DRUG|Letrozole or Anastrozole|Take the treatment with Letrozole or Anastrozole.
215013209|NCT06341283|DRUG|Abemaciclib and Fulvestrant|Take the treatment with Abemaciclib and Fulvestrant at the same time.
215013210|NCT06341283|DRUG|Fulvestrant|Take the treatment with Fulvestrant only.
215013211|NCT01599676|DIETARY_SUPPLEMENT|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
215013212|NCT01599676|DIETARY_SUPPLEMENT|Non essential amino acid|Non essential amino acid supplementation
215013213|NCT04986813|DRUG|Tranexamic acid injection|1 g of TXA in 100 ml of normal saline
215013214|NCT04986813|OTHER|Normal Saline|100 ml
215013215|NCT05890586|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
215013216|NCT05890586|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
215099894|NCT03261609|OTHER|preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term (-\> 37 weeks)
215099895|NCT02814175|DRUG|methotrexate (MTX)|
215099896|NCT02814175|BIOLOGICAL|adalimumab (ADA)|
215099897|NCT06256263|PROCEDURE|total laryngectomy|pharyngeal repair after total laryngectomy
214408839|NCT06483022|OTHER|Usual Care|Prior to implementation of the IPC training, birthing people at the facilities will receive treatment-as-usual
214408840|NCT04865302|PROCEDURE|SSC|"Incubator phase I: After feeding the neonates will be brought in a prone position in the incubator and the NIRS sensor will be applied on the forehead for continuous cStO2 measurements throughout the study period. The neonate will rest in this position for 60 minutes.~SSC phase: The neonate will be brought on the mother's or father's chest (skin to skin) in a prone position and will stay in this position for 60 minutes.~Incubator phase II: The neonates will be brought back into the incubator for another 60 minutes in prone position. After 180 minutes the study period is over and the NIRS sensor will be removed."
214408841|NCT00747929|DRUG|S-2367 Placebo|four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks,
214408842|NCT00747929|DRUG|S-2367 800 mg|two 400 mg S-2367 tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks
214408843|NCT00747929|DRUG|S-2367 1600 mg|four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for total of 54 weeks,
214408844|NCT00747929|OTHER|Reduced Calorie Diet|A diet with restricted calorie content
215013217|NCT03989570|PROCEDURE|transversus abdominis plane block|The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
215013218|NCT03989570|PROCEDURE|erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
215013219|NCT03989570|OTHER|control group|placebo
215013220|NCT03769974|BEHAVIORAL|Motor imagery|Two series of 30 seconds training of motor imagery in each manual engine gesture
215013221|NCT03769974|BEHAVIORAL|Action observation|Two series of 30 seconds training of action observation training in video format in each manual engine gesture
215013222|NCT03769974|BEHAVIORAL|Placebo intervention|Two series of 30 seconds of observation and imagination of a landscape during for each manual motor sequence
215013223|NCT03611465|OTHER|Pace-mapping|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
215013224|NCT03611465|OTHER|Standard pace-mapping examination|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
215013225|NCT03216291|BEHAVIORAL|biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems. Complete training sessions once a week for 6 weeks in the office.
215013226|NCT03216291|DEVICE|Home Biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems, but instead of an office therapy, the subject will use a biofeedback device to gain strength in their anorectal muscles. This device will be taught how to use in the first session and then the subject will take it home to complete at least 1 session a day for 6 weeks.
215013227|NCT00353015|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
215013228|NCT00353015|DRUG|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
215013229|NCT03008330|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
215013230|NCT02545127|DRUG|Merotocin|Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
215013231|NCT02545127|DRUG|Placebo|Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
215013232|NCT02415803|DRUG|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
215013233|NCT02415803|DRUG|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
215013234|NCT02415803|DRUG|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
215013235|NCT03513146|PROCEDURE|Oropharyngeal Administration of Mother's Milk (OPAMM)|0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol
214408845|NCT01245413|DEVICE|SenSura|Adhesive to stoma bag
214408846|NCT01245413|DEVICE|Athena|Adhesive to stoma bag
214408847|NCT02530151|DRUG|Morphine with clonidine|see arm description
214408848|NCT02530151|OTHER|Normal saline|see arm description
214408849|NCT06713187|BIOLOGICAL|interleukin 23|assessment of interleukin 23 in Sera of patients using ELIZA
214408850|NCT05567159|DRUG|Donanemab|Administered IV.
214408851|NCT06605677|OTHER|Questionnaire|An online questionnaire will be sent through e-mail to participants. It is divided into 4 sections: demography and general information 9 questions, knowledge 10 questions, attitude 10 questions and practice 10 questions. No previous similar studies were conducted in the United Arab Emirates (UAE) or internationally based on a search in PubMed and Cochrane library. Hence a validated questionnaire is lacking. Therefore, the questionnaire for this study is designed based on questions encountered daily by colleagues during the consultation, and it can serve the purpose of this study. Consent will be obtained and signed electronically by participants before starting the questionnaire. Participation involves minimal risk. Responses will be anonymous and confidential. Participants' involvement is voluntary, and they can withdraw at any time without any consequences. The time to complete the questionnaire is around 10-15 minutes. Each response will be saved using a unique identifier number.
214408852|NCT00179608|DRUG|CC-5013|
214408853|NCT05348824|DIETARY_SUPPLEMENT|Moringa oleifera leaf|Leaf extract preparation
214408854|NCT05348824|DRUG|Sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
214408855|NCT03314337|DEVICE|Pancreatic stent: PSOF COOK®|After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
214408856|NCT00117754|DRUG|Terbinafine hydrochloride|
214408857|NCT01374490|DRUG|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
214408858|NCT06650696|BEHAVIORAL|PCE promotion|The intervention requires parents to complete a weekly parent-child interaction task online designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
214408859|NCT06650696|BEHAVIORAL|Psychoeducation|Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
214408860|NCT06650696|BEHAVIORAL|Emotiaonl skill enhancement|This intervention combines online material with practical, emotion-focused activities. Participants will receive training online on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
214408861|NCT06601907|BEHAVIORAL|alivis|alivis is an interactive online program for independent use by users with Borderline Personality Disorder. It focuses on recognized treatment elements from Dialectical Behavior Therapy, Schema Therapy, Acceptance and Commitment Therapy, and Mindfulness Self-Compassion Therapy.
214408862|NCT06601387|PROCEDURE|choledochoduodonostomy|surgical drainage procedures
214408863|NCT06601387|PROCEDURE|hepaticojejunostomy|surgical intervention
214408864|NCT03466840|PROCEDURE|The coronally advanced lingual flap|": A full-thickness crestal incision is performed from the distal surface of the more distal tooth to retromolar pad and finishing with releasing incision. On the lingual side, a full-thickness muco-periosteal flap was elevated until reaching mylohyoid line. Then using a blunt instrument, it was localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. It is inserted into the inner part of the lingual flap about 5mm from the crest in an apical direction. The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe, the amount of advancement is measured."
214408865|NCT03466840|PROCEDURE|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured."
214408866|NCT05674643|DIAGNOSTIC_TEST|Gastric Ultrasound Baseline Scans|The patient's abdomen will be scanned using the ultrasound device by an expert scanner and novice scanner for baseline assessment of the antral CSA and gastric volume using Perlas US qualitative grading assessment.
214408867|NCT05674643|DIAGNOSTIC_TEST|Acetaminophen Absorption Test (AAT)|"Prior to starting the AAT, a baseline plasma acetaminophen level (250 microliters) will be obtained from the intravenous catheter. The subject will then be given 12.5 mg/kg or max 650mg of single batch 32mg/mL acetaminophen followed by 6oz of water PO. Up to 3 additional small volume blood samples will be drawn for acetaminophen levels.~These additional blood samples (250 microliters each) will be obtained to measure acetaminophen plasma levels at the following goal intervals after acetaminophen administration.T1:10-20 mins, T2:35-45 mins, T3: 60mins. At the time of each lab draw gastric ultrasound will be assessed by the expert scanner to correlate gastric ultrasound with the acetaminophen absorption test as a gold-standard of gastric emptying."
214408868|NCT05674643|DIAGNOSTIC_TEST|Gastric Ultrasound Serial Scans|Cohort 1 will have multiple scans as part of assessing gastric emptying. These sequential scans after the baseline assessment will be done in line with the Acetaminophen Absorption Test timeline (T1:10-20 mins, T2:35-45 mins, T3: 60mins) and will be performed by an expert scanner only.
214408869|NCT03067051|DRUG|Verteporfin|In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
214408870|NCT03067051|DEVICE|SpectraCure P18 System|Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
214408871|NCT05402579|GENETIC|Genomic analysis|Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)
214408872|NCT06614322|DRUG|Pregabalin|300mg/day pregabalin capsule
214408873|NCT06614322|DRUG|Duloxetine|60mg/day duloxetine capsule
214408874|NCT06614322|OTHER|Placebo|Placebo capsule
214408875|NCT06615466|RADIATION|Partial Breast Irradiation|26Gy/5.2Gy/5f
214408876|NCT06613997|DRUG|Albendazole 400mg|Albendazole 400mg per days for 21 consecutive days
214408877|NCT06613997|DRUG|Placebo|Placebo for 21 consecutive days
215013236|NCT01447771|BEHAVIORAL|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
215013237|NCT05259176|DEVICE|transcranial Direct Current Stimulation (tDCS)|Direct current transcranial stimulation will be applied for 20 minutes over the left posterior parietal cortex with an intensity set to 2 mA.
215013238|NCT05259176|DEVICE|Sham stimulation (sham-tDCS)|The same positioning of electrodes as the stimulation condition will be used, but the current will be applied for 30 seconds and then progressively reduced.
215013239|NCT05259176|DEVICE|Behavioural|Treatment for upper limbs ideomotor apraxia (Smania et al., 2000)
215099898|NCT04406025|PROCEDURE|participation in Regional Anesthesia Seminar|this group of anesthesiologists attended the Regional Anesthesia Seminar
215099899|NCT04406025|PROCEDURE|no participation in Regional Anesthesia Seminar|this group of anesthesiologists did not attend the Regional Anesthesia Seminar
215013240|NCT04594083|DEVICE|Palm Stimulator|The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
214408878|NCT06614452|DEVICE|EUS-FNB|"Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the slow-pull, the dry suction, or the wet suction, will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.~The rapid-on site cytological evaluation (ROSE) will not be available in this study."
214408879|NCT05471232|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
214408880|NCT05471232|OTHER|EHR-Based Network Model|EHR-based network will be created to predict psychiatric outcomes in youth with IDDs
214408881|NCT06614530|DEVICE|Chilipad Docker Pro|The Chilipad Dock Pro is an advanced sleep system designed to optimize sleep by dynamically adjusting the bed\&#39;s surface temperature. It consists of a mesh mattress pad and a Dock Pro control unit that circulates water through the pad, allowing users to customize the temperature between 55°F and 115°F. The system offers both single and dual control, making it ideal for individual or shared use. Equipped with AI-driven features, the Dock Pro can monitor sleep patterns and environmental factors to make real-time adjustments, ensuring optimal sleep conditions throughout the night. This intelligent temperature management system is enhanced when paired with the optional Sleepme Tracker, creating a personalized sleep experience.
214408882|NCT06919107|OTHER|Survey of athletes|Data will be collected on the number of injuries (muscle and tendon), lower limb injuries in the last 3 athletic seasons, as well as age, sex, weekly training load with and without AFT, weekly training frequency, completion of a complementary toning program and foot size.
214408883|NCT06614816|BIOLOGICAL|Oka strain varicella attenuated live vaccine|lyophilized powder, subcutaneous injection
215099900|NCT02406170|DRUG|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
215013241|NCT04594083|DEVICE|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
215013242|NCT01553500|DIETARY_SUPPLEMENT|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
215013243|NCT01553500|BEHAVIORAL|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
215013244|NCT00664040|OTHER|Aspirin|The aspirin intervention (81 mg per day) will last a total of 14 days. Pills will be provided in a pre-loaded pillbox. The field team will visit the subject at his/her home at least once to insure adherence to the aspirin intervention and to monitor for adverse side effects. On day 14 of the aspirin intervention, the subject will visit the clinic for a fasting blood draw for platelet aggregation and inflammatory marker studies. A pill count will be performed to assess adherence. The subject can miss up to four aspirin doses over the two-week period; however, an aspirin must be taken each day for the three days prior to clinic visit 2. The aspirin intervention can be extended for up to three days (17 days total) to meet the latter criteria. If more than four doses were missed, then the physician should be contacted and the patient should be withdrawn from the aspirin intervention. Platelet aggregation will be measured 1 hour after the last dose of aspirin.
215013245|NCT00664040|OTHER|Cold Pressor Test|This intervention consists of the participant placing his or her hand and wrist into ice water for 2½ minutes. The blood pressure is taken before and after the arm is removed from the water. An ultrasound machine is used to take pictures of the brachial artery in the left arm before and after the arm is removed from the water.
215013246|NCT00664040|OTHER|High Fat Meal|The participants are given a high fat milk shake consisting of 83% fat. Blood samples are drawn from a catheter placed in the participant's arm prior to the test. The samples are drawn before the milk shake and at 1, 2, 3, 4, and 6 hours after the milk shake is consumed. Before and at 2, 4 and 6 hours following the meal the ultrasound is used to obtain images of the brachial artery.
215013247|NCT00664040|OTHER|Dietary Salt|The salt intervention will consist of 6 days of an isocaloric high salt diet (270 mmol/d) followed by a washout period of at least 8 days and then a low salt diet (40 mmol/d). All food will be prepared by a registered dietician and dietary technicians in a specially equipped kitchen. The specific foods will consist of approximately 50% carbohydrates, 35% fat, and 15% protein. Dietary potassium will remain constant at 120 mmol/d. A food diary will be kept for each diet and subjects will be instructed to eat only the food provided. A field nurse will visit the home on days 3 and 5 of each diet to insure that neither diet is acutely affecting the health status of the subject. A first AM void spot urine will be obtained to measure sodium, potassium and creatinine on the 4th, 5th, and 6th days of each diet to insure compliance. Blood pressure will be measured using an ambulatory blood pressure monitor for 24 hours on the last day of each diet.
215013248|NCT02196909|OTHER|motor function and strength assessment|
215013249|NCT02196909|OTHER|NMR assessment|
215013250|NCT02196909|OTHER|24h urine and serum collection|
215013251|NCT05150886|DIAGNOSTIC_TEST|rox index|After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.
215099901|NCT02406170|DRUG|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
215099902|NCT04406558|OTHER|Questionnaire|An online questionnaire on the experience of the period of confinement and deconfinement will be sent to the cohort of adolescents followed at the CHI Creteil for a chronic disease or not. Forty adolescents will be randomly selected for a remote interview on the experience and memorization of the period of confinement and deconfinement.
214408884|NCT06453109|DEVICE|low intensity focused ultrasound (LIFU)|"Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects."
214408885|NCT05854992|DRUG|Acute migraine treatment with any prescribed triptans|Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.
214408886|NCT05854992|DRUG|Standard of care management of acute migraine without triptans|Any standard of care management without triptans
214408887|NCT05965362|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
214408888|NCT06696807|DRUG|glucocorticosteroids and/or intravenous immunoglobulin|methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day
214408889|NCT06696742|DRUG|Clostridium Butyricum Tablets|Gemcitabine and Cisplatin combined with Clostridium Butyricum Tablets
214408890|NCT06696742|DRUG|Cisplatin|Gemcitabine and Cisplatin
214408891|NCT05336552|OTHER|Validated questionnaire : Social Phobia Inventory ( SPIN ) questionnaire|Social Phobia Inventory ( SPIN ) questionnaire which is consisted of 17 items. . The answers of each item ranged from 0 ( Not at all ) to 4 ( Extremely ). The total score will be calculated to determine the severity of the problem .
214408892|NCT06697665|BIOLOGICAL|LM103|Patients were treated with PD-1, cyclophosphamide and fludarabine, LM103 and IL-2 treatment.
214408893|NCT06698159|DEVICE|Cryoablation with cryoballoon 28 mm|Pulmonary vein isolation using 28 mm balloon cryoablation
214408894|NCT06698159|DEVICE|Cryoablation with cryoballoon 31 mm|Pulmonary vein isolation using 31 mm balloon cryoablation
215013252|NCT06021444|DEVICE|DKM420|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
215013253|NCT06021444|DEVICE|Conjuran|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
215013254|NCT00520572|DRUG|AZD9056|
215099903|NCT03416127|DRUG|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
215099904|NCT03416127|DRUG|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
215099905|NCT03416127|DRUG|Placebo|Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
215099906|NCT05228483|DEVICE|CO2 fractional laser|CO2 fraction laser
215099907|NCT05228483|COMBINATION_PRODUCT|5-aminolevulinic acid (5-ALA) with red light illumination|5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).
215013255|NCT00520572|DRUG|Etanercept|
215013256|NCT00520572|DRUG|Placebo|
214408895|NCT06698185|DEVICE|Materna Prep Device|Materna Prep Device
214408896|NCT06698185|DEVICE|Sham Control|Sham Control
214408897|NCT06697769|OTHER|virtual reality|breastfeeding simulation with virtual reality glasses
214408898|NCT06713291|PROCEDURE|Sliding compression locking plate|The patients with femoral neck fracture were treated with three cannulated compression screws or sliding compression locking plate.
215013257|NCT04633304|DEVICE|EndoAVF System for endovascular AV fistula creation|AV fistula creation
215013258|NCT04635163|OTHER|None intervention|None intervention
215013259|NCT03315689|DRUG|Vehicle|Vehicle Topical Solution
215013260|NCT03315689|DRUG|ATI-50002|ATI-50002 Topical Solution
215013261|NCT05448027|DEVICE|Low intensity laser therapy|It will be applied for Group (A), by a pulsed diode low intensity laser device (Endolaser 422 Cp 400, Enraf - nonius apparatus) (Enraf, Rootterdam, Netherlands). with a wave length of 905 nm, mean power output of 400 mWatt, frequency of 10000 Hz and dose of 300 J/cm² . Laser probe will be applied perpendicularly and directly with an irradiation time of 30 sec for each point
215013262|NCT05448027|DEVICE|High intensity laser therapy|It will be applied for Group (B), by pulsed high intensity laser therapy with pulsed Nd:YAG laser produced by HIRO 3.0 devices (ASA, Arcugnano, Vicenza , Italy). The high intensity laser therapy apparatus used postulates (Nd:YAG), with pulsed emission of wave length ( 1064nm ), very high power peaks (3kW), high intensity obtained (up to 15,000 W/cm2), high level of fluency/energy density (510-1,780 mJ/cm), very short pulse duration (120-150 μs), low frequency (10-40 Hz), duty cycle of about 0.1 % and total energy of 880 J
215013263|NCT04624997|OTHER|biological sample|biological sample
215013264|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
215013265|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
215013266|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
215013267|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
215013268|NCT00669331|DRUG|Inhaled mannitol|400mg dose of Mannitol BD (twice a day) for 52 weeks
215013269|NCT00669331|DRUG|Matched control|50mg dose of Mannitol BD (twice a day) for 52 weeks
215013270|NCT04402814|DIAGNOSTIC_TEST|Clungene rapid test cassette|Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.
215099908|NCT05228483|DRUG|Mometasone furoate (MMF) 0.1% ointment|0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
215099909|NCT04472455|DIAGNOSTIC_TEST|HRME|
215099910|NCT00532688|DRUG|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
215099911|NCT02484352|DRUG|saline|different dosage of IV oxycodone was given before intubation
215099912|NCT02484352|DRUG|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
215099913|NCT02484352|DRUG|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
215099914|NCT02484352|DRUG|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
214408899|NCT06713291|PROCEDURE|Three cannulated compression screws|The patients with femoral neck fracture were treated with three cannulated compression screws.
214408900|NCT06137469|DRUG|Acetaminophen/SHR20004|SHR20004 was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
214408901|NCT06137469|DRUG|Acetaminophen/Placebo|Placebo was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
214408902|NCT06744426|DRUG|BR1015|One tablet administered alone
214408903|NCT06744426|DRUG|BR1015-2|One tablet administered alone
214408904|NCT06744426|DRUG|BR1015-3|One tablet administered alone
214408905|NCT06824402|DEVICE|Forceps Biopsy|10-12 transbronchial lung biopsies will be obtained using standard of care biopsy forceps: Olympus disposable EndoJaw (FB-211), Olympus, USA
214408906|NCT06824402|DEVICE|Cryoprobe Biopsy|3 transbronchial lung biopsies of two separate lobes will be obtained using a flexible cryoprobe: single-use, ø 1.1 mm (Erbe Elektromedizin GmbH, 20402-401) used with ERBECRYO 2 (Erbe Elektromedizin GmbH, 10402-000
215013271|NCT03699800|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
215013272|NCT01610401|DRUG|Metformin|metformin 500 mg three times a day, for 3 days
215013273|NCT01610401|DRUG|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
215013274|NCT01610401|DRUG|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
215013275|NCT05055336|OTHER|Gastric emptying breath test|The gastric emptying breath test is used to diagnose gastroparesis. Participants ingest spirulina in a meal and samples are taken every 45 minutes for 4 hours.
215013276|NCT05055336|OTHER|Stomach ultrasound|Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.
215013277|NCT02133677|DRUG|temozolomide 100mg|WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
215013278|NCT04865458|DRUG|HEC89736|HEC89736 tablets QD every 28 days for each cycle
215013279|NCT02405637|DRUG|simulated amniotic fluid 20cc/kg/day enterally|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
215013280|NCT02405637|DRUG|distilled water|distilled water 20 ml/kg/day for maximum of 7 days.
215013281|NCT04514276|OTHER|consecutive fetoneonatal healthcare pathway|(1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
215013282|NCT01346241|BEHAVIORAL|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
215013283|NCT05172310|DRUG|68Ga-FAPI-46|"* \[68Ga\] Ga-FAPI-46 Solution for Injection is manufactured at the Karolinska University Hospital Radiopharmacy facilities, for imaging studies with Positron Emission Tomography (PET).~* It is a radiolabelled Fibroblast Activation Protein Inhibitor (FAPI) used for PET of a number of different cancer entities.~* Depending on the labelling yield 50 - 370 megabecquerel (MBq) of \[68Ga\] Ga-FAPI-46 Solution for Injection will be administered intravenously 60 minutes prior to whole-body PET image acquisition."
215013284|NCT05172310|DEVICE|PET/CT|"* Combined PET and computed tomography (CT) imaging with 68Ga-FAPI-46 will be performed using the same protocol on a Biograph 6 PET/CT scanner (Siemens, Erlangen, Germany) and General Electrics (GE) Discovery 710, Milwaukee, Wisconsin, USA at the Department of Nuclear Medicine, Karolinska Huddinge within 2 weeks before surgery.~* PET/CT imaging will be performed in dynamic mode at one bed position centered over the primary tumor for 45 minutes.~* At 60 minutes post injection, a whole-body PET will be acquired."
215013285|NCT03561740|DRUG|capecitabine|additional metronomic chemotherapy of capecitabine
215099915|NCT02484352|DRUG|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
214408907|NCT06917976|BEHAVIORAL|to compare the effect of environment and attitude of dentist in children visiting specialized pediatric dental clinic and general dental clinic .|the investigators will measure salivary cortisol and salivary alpha amylase and using children fear dental survey schedule - dental subscale
214408908|NCT06918457|DIAGNOSTIC_TEST|AI EEG analysis system|The first stage, physicians independently diagnose pediatric epilepsy with EEG; the second stage, Artificial intelligence EEG analysis system assisted physicians to diagnose pediatric epilepsy
214408909|NCT02335021|DIETARY_SUPPLEMENT|Sucralose|2 packets per 12 fl oz
214408910|NCT02335021|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
214408911|NCT02335021|DIETARY_SUPPLEMENT|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
214408912|NCT02335021|DIETARY_SUPPLEMENT|Sucralose + Sucrose|half the amount of sucralose plus equicaloric sucrose
214408913|NCT00672256|BEHAVIORAL|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
214408914|NCT02072226|DRUG|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
214408915|NCT02072226|DRUG|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
214408916|NCT02072226|DRUG|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
214408917|NCT02072226|DRUG|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
214408918|NCT03720340|DRUG|Recombinant Human Interleukin-11|Recombinant Human Interleukin-11 was administed through respiratory tract.
215013286|NCT02614027|OTHER|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
214408919|NCT03720340|DRUG|Saline|saline was administed through respiratory tract
214408920|NCT03220139|OTHER|fat intake|Observational study on fat intake and mortality
214408921|NCT06240039|OTHER|Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon|"The experimental days consist of four study days:~1. Assessment of liver fat and visceral fat by magnetic resonance imaging (MRI; 6-point Dixon) (study day A)~2. Somatostatin infusion (4 hours) plus amino acid infusion (45 minutes) (study day B)~3. Saline infusion (4 hours) plus amino acid infusion (45 minutes) (study day C)~4. Somatostatin infusion (4 hours) plus saline infusion (45 minutes) (study day D)~The subjects will participate in the experimental days (study day B to D) in randomized order on three different days. For study day B to D, at timepoint t = -75, subjects will receive either; a 240-minute intravenous infusion of a somatostatin analogue (at 200 ng/kg/min (infusion rate will not exceed 1000 µg/hour) or saline. After 75 minutes (timepoint t = 0), the subjects will receive a 45-minute intravenous infusion of amino acids or saline at 3.885 ml/kg/hour.~In total, blood will be sampled 11 times over a period of 6 hours and 15 minutes."
214408922|NCT05334082|OTHER|FIFA 11+|15 progressive exercise drills for training preparation (warm-up)
214408923|NCT04053829|DEVICE|HOLOBalance|"The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists."
214408924|NCT04053829|OTHER|OTAGO Home Exercise Programme|The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 8 week programme.
214408925|NCT01364519|DRUG|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
214408926|NCT01364519|DRUG|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
214408927|NCT00810303|DRUG|Ezetrol (ezetimibe) multiple dose|administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15 and a pharmakokinetic on study day 15 (0-24 h blood sampling, 0-24 h urine sampling and 5 d feces sampling (study day 11-15))
214408928|NCT00810303|DRUG|Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) on study day 16-20 and 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 16 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 16-20)
214408929|NCT00810303|DRUG|Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) and 2 capsules/day Sustiva(R) (2x200 mg efavirenz) on study day 21-30 and with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) on study day 30 and feces sampling on study day 26-30)
214408930|NCT00810303|DRUG|Sustiva (efavirenz) single dose|administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 1-5)
215013287|NCT02614027|OTHER|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
215013288|NCT03794544|DRUG|Durvalumab|Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
215013289|NCT03794544|COMBINATION_PRODUCT|Oleclumab|Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
215013290|NCT03794544|COMBINATION_PRODUCT|Monalizumab|Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
215013291|NCT03794544|COMBINATION_PRODUCT|Danvatirsen|Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
215013292|NCT02550210|DEVICE|Breast Cancer Locator (BCL)|This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
215013293|NCT05232305|DIETARY_SUPPLEMENT|Pomegranate Peel|Standard bread and test breads (with added pomegranate peel) to be used in the study will be produced by Asst. Prof. Özlem ÖZPAK AKKUŞ in the Nutrition Principles Laboratory of Toros University. For standard bread, 900 ml of water, 42 fresh yeast, 12 g of salt and 12 g of sunflower oil will be added to 1000 g of sifted whole wheat flour and the prepared bread mixture will be divided into 40 equal parts. To make bread with pomegranate peel added, 1000 g of sifted whole wheat flour, 20 g of pomegranate peel powder, 914 ml of water, 42 g of fresh yeast, 12 g of salt and 12 g of sunflower oil will be added and the prepared bread mixture is divided into 40 equal parts with 500 mg of pomegranate peel powder in each piece).
215013294|NCT02320825|RADIATION|single-fraction SRS|
215013295|NCT02320825|RADIATION|high-dose hypofractionated SRS|
215013296|NCT02320825|BEHAVIORAL|Quality of Life Measures|
215013297|NCT03848351|BEHAVIORAL|Oral Hygiene Instruction (OHI)|OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
215013298|NCT03848351|PROCEDURE|Professional supragingival scaling and polishing|Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
215013299|NCT04336800|DEVICE|LiverMultiscan|The LiverMultiscan is a quick 15 min, contrast free scan that non-invasively provides three metrics of liver health namely liver fat, iron and fibro-inflammation
215013300|NCT06253429|DRUG|Thioctic Acid 333 MG Oral Capsule|Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes
215013301|NCT06253429|DRUG|Captopril 25Mg Tab|Oral angiotensin-converting enzyme inhibitors
215013302|NCT03106402|DRUG|topical bromfenac sodium hydrate|
215013303|NCT06450340|BEHAVIORAL|Moderate-intensity aerobic exercise refers to rhythmic and long-lasting exercise with increased heart rate, slight sweating and slight wheezing.|Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups.
215013304|NCT01426659|BEHAVIORAL|parental stimulation according to protocol|"verbal stimulation every day image of the Protocol Dire et Faire"
214408931|NCT02731521|DEVICE|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
215013305|NCT04557137|DRUG|Somatostatin analog|120 mg ipstyl every 28 days
215013306|NCT02334410|DEVICE|Whole body vibration (WBV)|Side-alternating WBV
215013307|NCT02361684|BEHAVIORAL|Blended CBT treatment|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
215099916|NCT05917990|BEHAVIORAL|Dyadic Text-Messaging Micro-Intervention|Participants receive text-messages consisting of information and skills relevant to improving couples' communication and relationship functioning.
214408932|NCT02731521|DEVICE|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
214408933|NCT03002844|DRUG|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
214408934|NCT03002844|DRUG|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
215013308|NCT02361684|OTHER|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
215013309|NCT00661219|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
215013310|NCT00661219|DRUG|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
215013311|NCT00929097|OTHER|Implementation aids|"* Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~* Clinicians receive the guidelines and a risk communication tool, as well as education"
215013312|NCT00929097|OTHER|Control|Dissemination of guidelines
215013313|NCT03098407|DRUG|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
215013314|NCT03098407|DRUG|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
215013315|NCT00120250|DRUG|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
214408935|NCT03002844|DRUG|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
215013316|NCT02968290|PROCEDURE|Cataract Surgery|Implant of intraocular lens hydrophobic or Implant of intraocular lens hydrophilic (Device)
215013317|NCT02968290|DEVICE|Alcon AcrySof SA60AT|Implant of intraocular lens hydrophobic
215013318|NCT02968290|DEVICE|Bausch Lomb AkreosA|Implant of intraocular lens hydrophilic
215013319|NCT03818932|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
215013320|NCT03818932|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
215099917|NCT06583499|BEHAVIORAL|Sustainable nutrition education based on the transtheoretical model|"Before the intervention begins, the Sustainable Nutrition Behaviour Change Stage Survey will be administered to determine participants' training stage. In addition, the Transtheoretical Model (TTM) Based Sustainable Nutrition Scales will be administered to evaluate the effectiveness of the training programme.~TTM Based Nutrition Training Programme consists of 11 modules developed according to the stages of the model.The methodology and tools used are aligned with the objectives of the training programme.The training modules are offered twice a week, with each session lasting a maximum of 40 minutes and continues for a total of 5 weeks. Participants may attend more than one training session in order to develop behaviours that increase adherence to a sustainable diet. At the end of the training programme, data from the Transtheoretical Model-Based Sustainable Nutrition Behaviour Scale will be collected again and evaluated by comparison with the baseline data set.."
214408936|NCT05015517|PROCEDURE|Erector spinae plain block|Patients will be placed in the lateral position.Ultrasonography will be performed by an experienced anesthetist.The 4th lumbar vertebral level will be determined using the conventional method (imaginary line between two iliac crests). The low frequency convex probe (2-5MHz) will then be placed at the mid-vertebral line in the sagittal plane. It will be shifted from the midline, 3.5-4 cm lateral to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-plane technique a 22G/80-mm block needle will be advanced until it reaches the transverse process. After negative aspiration, 0.5-1 ml of the prepared local anaesthetic solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%) and 10 ml normal saline will be administered for hydrodissection to confirm correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when injecting local anesthesia
215099918|NCT02314832|PROCEDURE|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
215013321|NCT03818932|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
215013322|NCT03818932|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
215013323|NCT03818932|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
215013324|NCT03818932|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
215013325|NCT04555369|GENETIC|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
215013326|NCT03300336|BEHAVIORAL|STRIDE|Implementation of STRIDE inpatient hospital mobility program
215099919|NCT02314832|PROCEDURE|femoral nerve block|ultrasound guided femoral nerve block
215099920|NCT04240158|DRUG|IW-6463|IW-6463 Tablet
215099921|NCT04240158|DRUG|Matching Placebo|Matching Placebo Tablet
215099922|NCT06423924|OTHER|no intervention|no intervention
215099923|NCT02702180|DRUG|Molgramostim|300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
215099924|NCT02702180|DRUG|Placebo|Placebo nebulizer solution for inhalation
215099925|NCT02702180|DEVICE|PARI eFlow nebulizer system|PARI eFlow nebulizer system
215099926|NCT02397057|DRUG|Injectafer|
215099927|NCT02397057|OTHER|Placebo|
215099928|NCT04120272|PROCEDURE|Spine surgery|Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
215099929|NCT00966251|DRUG|CT-011|CT-011
215099930|NCT04473248|DEVICE|Spartan COVID-19 System|PCR analysis of patient samples using the Spartan COVID-19 System
215099931|NCT04359979|DRUG|Tamsulosin|selective alpha1 receptor antagonist
215099932|NCT00625781|DRUG|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose \>5.0 mmol/l or post meal value \>6.5 mmol/l according to study protocol.
215013327|NCT01404260|DRUG|Gefitinib|Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
215013328|NCT01404260|DRUG|Gemcitabine +Carboplatin|Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
215013329|NCT02623270|DEVICE|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
215013330|NCT02623270|DEVICE|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
215013331|NCT01495273|PROCEDURE|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
215013332|NCT01495273|PROCEDURE|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
215013333|NCT03987880|PROCEDURE|4.0 mm treatment|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
215099933|NCT04473664|DRUG|Quizartinib|Single oral dose, 30 mg tablet
215013334|NCT03987880|PROCEDURE|3.5 mm treatment|PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
215099934|NCT00450645|DRUG|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
215099935|NCT03392649|DEVICE|Parasym|Tragus stimulation was done using the Parasym device.
215099936|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
215099937|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
215099938|NCT02339194|PROCEDURE|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
215099939|NCT01483911|BIOLOGICAL|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
215099940|NCT01483911|BIOLOGICAL|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
215099941|NCT03118089|DIETARY_SUPPLEMENT|Biscuit style oral nutritional supplement|
215099942|NCT03162081|DIAGNOSTIC_TEST|Substance misuse screening|Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)
215099943|NCT03162081|DIAGNOSTIC_TEST|EQ-5D|Health related Quality of life
215099944|NCT03162081|DIAGNOSTIC_TEST|Impulsivity screening|Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test
215013335|NCT00961012|PROCEDURE|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
215013336|NCT02246036|DEVICE|APD probe|The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
215013337|NCT00008268|BIOLOGICAL|filgrastim|
215099945|NCT03162081|DIAGNOSTIC_TEST|Cognitive screening|Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test
215099946|NCT03162081|DIAGNOSTIC_TEST|Functional tests|Timed up and go (TUG), Single leg balancing test (SLB)
215099947|NCT03162081|DIAGNOSTIC_TEST|Cognistat|Assessment of cognitive domains
215099948|NCT03162081|DIAGNOSTIC_TEST|Neuropsychological profiling|Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test
215099949|NCT03162081|OTHER|Clinical interview|Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale
215099950|NCT03162081|OTHER|Medication use|Detailed screen of used medications, interactions, side effects in electronic patient registry
214408937|NCT05015517|PROCEDURE|Fascia Iliaca block|"Patients will be placed in supine position. Ultrasonography will be performed by an experienced anesthetist using ultrasound device equipped with a low frequency (2-5 MHz) convex probe and an echogenic 21 G/ 10 cm needle will be used.~The probe will be placed in the inguinal crease. Scan will be started laterally from the femoral artery and nerve in the inguinal crease to identify the Sartorius muscle. The muscle will then be traced until its origin at the anterior superior iliac spine is identified and the shadow of the bony of iliac crest \& iliacus muscle will be seen. Injection will be performed at the plane deep to the fascia iliaca and above the lateral part of the iliacus muscle. After negative aspiration, the prepared local anaesthetic solution (15 ml bupivacaine 0.5%, 15 ml normal saline) will be injected incrementally, aspirating every 5 ml."
214408938|NCT03988387|BEHAVIORAL|Peer Support (PS)|Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.
215013338|NCT00008268|DRUG|melphalan|
215099951|NCT03162081|OTHER|Comorbidity|Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
215099952|NCT01359189|DEVICE|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
215099953|NCT03408184|DRUG|Lumbar paravertebral group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
215099954|NCT03408184|DRUG|The field block group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
215099955|NCT00174369|DRUG|PD-0325901|15 mg BID
215099956|NCT00753454|DRUG|Certolizumab pegol|Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 \& Week 4, followed by 200 mg every 2 weeks).
215099957|NCT01982461|DRUG|Rosuvastatin|10mg,once daily
215013339|NCT02074137|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
215013340|NCT02074137|DRUG|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
215013341|NCT02074137|DRUG|Prednisolone|Pharmaceutical form:Tablet Route of administration: Oral
215099958|NCT01982461|DRUG|Crestor®|10mg,once daily
215099959|NCT03927144|DRUG|AMG334|Subcutaneous Injection
215099960|NCT03927144|DRUG|Oral Prophylactic|SOC Oral Tablet/Capsule
215099961|NCT05346653|DRUG|SGLT2i|dapagliflozin (10 mg daily)
215099962|NCT05346653|OTHER|No SGLT2i|No SGLT2i
215099963|NCT04084847|DIETARY_SUPPLEMENT|berberis vulgaris=barberry|10 grams of barberry powder will be consumed daily for 8 weeks.
215099964|NCT04084847|DIETARY_SUPPLEMENT|Placebo|Placebo powder
215099965|NCT06339931|OTHER|SMWLM combined Spinal traction with belt|Group A, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Wrap the traction belt around both your hips and the proximal aspect of the patient's thighs.Apply traction by leaning backward and shifting your body weight onto your posterior leg.
215099966|NCT06339931|OTHER|SMWLM combined spinal traction without belt|Group B, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Manual traction is applied by placing the patient over a rolled pillow while lying sideways. The roll should be 6-8 inches in diameter and should be placed at the level of the spine where the traction or separation is to occur. Pull the patient's legs toward you as you lean your body backward to apply a traction force.
215013342|NCT01034527|OTHER|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
215013343|NCT04803435|OTHER|Telemedicine Consultation|Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.
215013344|NCT04803435|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
215013345|NCT03708289|RADIATION|DXA scan|total and hip and spine dual energy x-ray absorptiometry
215099967|NCT00756782|DRUG|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
215099968|NCT00756782|DRUG|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
215099969|NCT04910035|OTHER|Exercises Training|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
214408939|NCT03988387|BEHAVIORAL|Reminder and Resource Transfer (RRT)|"Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points."
214408940|NCT03988387|DRUG|daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]|All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) \[FTC/TDF\] for the first month of enrollment.
214408941|NCT01551615|DRUG|Metformin 1000 mg|2 x 500 mg oral tablets
214408942|NCT01551615|DRUG|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
214408943|NCT04290585|OTHER|Questionnaire Administration|Ancillary studies
214408944|NCT04290585|BEHAVIORAL|Telephone-Based Intervention|Receive text message reminders
214408945|NCT04122807|PROCEDURE|Cardiac catheter ablation|Cryoablation
214408946|NCT00580437|PROCEDURE|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
214408947|NCT05560828|OTHER|Zio XT service|There will be no intervention. Standard of care at participating NHS organizations will not be affected.
215013346|NCT03708289|OTHER|Achilles bone US|
215013347|NCT03708289|OTHER|Medical body composition measurements|
215099970|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
215013348|NCT03708289|OTHER|Resting energy expenditure measurement|
215013349|NCT04819620|DRUG|PN-232|Active Drug
215013350|NCT04819620|DRUG|Placebo|Matching Placebo
215013351|NCT02669537|DEVICE|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
215013352|NCT01197235|DRUG|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
215013353|NCT01197235|DRUG|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
215013354|NCT06516731|DIETARY_SUPPLEMENT|pH Balanced Cleanser|Participants will use the pH Balanced Cleanser daily during showers. The cleanser should be applied to the vulva with clean hands, gently worked into a lather, and rinsed clean. Participants will complete baseline and weekly questionnaires and vaginal pH tests over an 8-week period to evaluate the effects on vulvar and vaginal health, including odor and pH levels, and assess the tolerability of the product.
215013355|NCT03612700|OTHER|CPFA-rich foods|Daily consumption of Grana Padano cheese (50 g) and whole milk (250 mL) for 3 weeks.
214408948|NCT01145456|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
214408949|NCT01145456|DRUG|gemcitabine hydrochloride|Given IV
214408950|NCT01145456|OTHER|pharmacological study|Correlative studies
214408951|NCT01145456|OTHER|laboratory biomarker analysis|Correlative studies
215013356|NCT03588000|OTHER|Strengthen self-monitoring of blood glucose|Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
214408952|NCT05817331|OTHER|Carer Treatment Preference Myelodysplasia Questionnaire|Caregiver-reported outcome measure in MDS
214408953|NCT05817331|OTHER|Clinician Treatment Preference Myelodysplasia Questionnaire|Clinician-reported outcome measure in MDS
214408954|NCT05817331|OTHER|Patient Treatment Preference Myelodysplasia Questionnaire|Patient-reported outcome measure (PROM) in MDS
214408955|NCT00088673|DRUG|3APS|
214408956|NCT04475224|DRUG|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
214408957|NCT00857480|DRUG|NRL972|Single intravenous administration of 2 mg NRL972
214408958|NCT00857480|DRUG|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
214408959|NCT00857480|DRUG|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
214408960|NCT00002937|DRUG|paclitaxel|
214408961|NCT00002937|DRUG|valspodar|
214408962|NCT03761654|DIAGNOSTIC_TEST|Global Longitudinal Strain measure|Global Longitudinal Strain measure on day 1 of hospitalization
215099971|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
214408963|NCT05390476|DRUG|Capecitabine|500mg orally three times a day (continuously)
214408964|NCT05390476|DRUG|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
214408965|NCT05795829|DEVICE|disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument|Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.
214408966|NCT01600911|OTHER|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
214408967|NCT05125367|PROCEDURE|coronary stent implantation|coronary stent implantation using everolimus-eluting balloon expandable stents
214408968|NCT05125367|PROCEDURE|bypass grafting|coronary artery bypass graft
214408969|NCT01923857|DRUG|Androxal 25 mg|
214408970|NCT04288492|BEHAVIORAL|Respiratory biofeedback|Repeat the inspiration and exhalation breaths for a fixed period of time using a biofeedback device (ResCalm)
214408971|NCT02323386|DEVICE|Primary Total Knee Arthroplasty (ATTUNE Knee System)|"The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected."
214408972|NCT00268606|BEHAVIORAL|cognitive-behavioral therapy|
214408973|NCT02702921|DEVICE|Surgeon's 'standard of care' stapler|
215013357|NCT02532946|BEHAVIORAL|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
215013358|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use"
215013359|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use"
214408974|NCT02702921|DEVICE|Ethicon Powered Vascular Stapler|
214408975|NCT05580796|DRUG|KSH01 injection|TCR-T cell injection
214408976|NCT05584046|OTHER|CDAM|Novel drugs such as Traditional Chinese Medicine (TCM) formula that can suppress inflammation may augment tissue healing and reduce activity-related pain in patients suffering from plantar fasciitis. Our team has experiences of using TCM for the treatment of plantar fasciitis. Based on our previous experience, our group has developed a new proprietary topical TCM herbal formula, CDAM, containing Carthami Flos , Dipsaci Radix , Aconiti Lateralis Radix Praeparata and Herba Menthae for the treatment of plantar fasciitis.
214408977|NCT00387491|DRUG|MOA-728|
214408978|NCT03635112|DRUG|Placebo|Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
214408979|NCT03635112|DRUG|TD-1473|TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
214408980|NCT06392932|DEVICE|QDOT Micro ablation catheter|QDOT Micro ablation catheter
214408981|NCT06392932|DEVICE|ST SF ablation catheter|ST SF ablation catheter
214408982|NCT00225719|DRUG|rHDL|
214408983|NCT00533234|DEVICE|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
214408984|NCT05593822|PROCEDURE|primary percutaneous intervention|percutaneous catheterization through peripheral arteries to coronary arteries
214408985|NCT02881125|DRUG|Nortriptyline Hydrochloride|Given PO
214408986|NCT02881125|DRUG|Paclitaxel|Given IV
214408987|NCT01133132|BEHAVIORAL|Survivorship CHESS|Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
214408988|NCT01133132|OTHER|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
214408989|NCT01520350|DRUG|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
214408990|NCT01520350|DRUG|placebo|Placebo
214408991|NCT03241654|PROCEDURE|flow trigger|The flow trigger will be adjust during the pressure assist ventilation.
214408992|NCT00134511|DRUG|Torcetrapib/atorvastatin|
214408993|NCT00698191|BIOLOGICAL|Allogeneic MSC (AlloMSC)|"Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
214408994|NCT02446223|DRUG|Inggenol Mebutate 0.015%|
214408995|NCT03923101|DIAGNOSTIC_TEST|Topographic, tomographic and biomechanical analysis.|"The study is based upon data obtained during routine medical follow-ups using~1. the Pentacam high resolution (Oculus, Wetzlar, Germany)~2. the Corvis ST (Oculus, Wetzlar, Germany)~3. the Anterior-Segment Optical Coherence Tomograph (AS-OCT) Casia 2 (Tomey, Nagoya, Japan)~4. the Ocular Response Analyzer (Reichert Technologies, New York, USA)."
214408996|NCT03006341|DRUG|Dabigatran etexilate|observed upto 12 months
214408997|NCT03006341|DRUG|Warfarin|Observed upto 12 months
215013360|NCT05803954|OTHER|Sustained natural apophyseal glides (SNAGS)|SNAGS will be applied with the patient sitting comfortably on a stool. The therapist stand behind the patient and the medial border of one thumb's distal phalanx is placed on the articular pillar on the chosen side of the suspected site of lesion. The thumb nail slope at approximately 45 degree (in the direction of the eyeball). SNAGS mulligan will be given by active movement followed by passive overpressure based on the movement restricted by frequency of treatment will be three sets of ten repetitions. SNAG the anteroposterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s depending on response. A maximum of 6 repetitions will be given if there is a reduction in headache intensity at the time of the first application. A total of 20 oscillations (1 oscillation/1 second) will be given to each joint with a total duration of 15 minutes
215013361|NCT05803954|OTHER|Neural mobilization|Neural mobilization will be applied with grade three neural mobilization and traditional therapy: Subjects will be placed in supine position and remained relaxed with the feet uncrossed. The patient will be slightly angled obliquely for easier access to the scapula. The therapist will be depressed the scapula with concomitant upper extremity joint positioning as per median nerve bias i.e., ULTT2 (shoulder abduction, elbow extension with forearm supination, wrist and fingers extended and ulnar deviated and thumb abduction). The wrist will be used as a tension factor and at the point where tension was felt by the therapist and perceived by the subject. Grade 3 oscillations were given rhythmically and slowly to each joint from proximal to distal. A total of 20 oscillations (1 oscillation/1 second) were given to each joint with a total duration of 15 minutes.
215099972|NCT06167876|RADIATION|Stereotactic Body Radiotherapy (SBRT) Treatment|The intervention in this study utilizes Stereotactic Body Radiotherapy (SBRT) for treating Hypertrophic Obstructive Cardiomyopathy (HOCM). The process begins with precise localization and planning, employing CT scans, Cardiac MRI (CMR), and echocardiography to accurately identify the target area in the interventricular septum, while avoiding critical structures like the aortic valve, His bundle, and left ventricular papillary muscles. Pre-treatment preparation involves using customized fixation devices to limit patient movement and breathing, coupled with cone-beam CT scans for accurate alignment with the Treatment Planning System (TPS). The treatment itself is delivered using image-guided linear accelerators, administering a single, focused dose of 25 Gy to the targeted area. This approach ensures precise radiation delivery, maximizing treatment efficacy while minimizing risks to surrounding cardiac tissues.
215099973|NCT06167876|OTHER|Sham Procedure|The sham procedure in this study is designed to closely mimic the actual Stereotactic Body Radiotherapy (SBRT) process without delivering any radiation. Participants in this arm are subjected to the same initial steps as those in the SBRT group, including precise alignment with the linear accelerator using CT scans and the application of customized fixation devices to limit movement and breathing. However, in this sham intervention, the linear accelerator is activated but does not emit any radiation. The procedure replicates the environmental aspects of the actual treatment, such as the equipment's sounds and lighting, to maintain the study's single-blind nature. This method ensures that participants in the sham group experience a procedure identical in appearance and feel to the SBRT treatment, without receiving any therapeutic dose, thereby serving as an effective control for evaluating the true impact of SBRT in treating HOCM.
215013362|NCT05803954|OTHER|Traditional physical therapy|traditional therapy will be applied in the form of stretching for bilateral upper and middle trapezius muscles and bilateral neck rotators and isometric strengthening exercises for neck rotators, extensors, side bending muscles. Exercise was repeated for ten repetitions per session. In addition to hot pack was placed over the neck and upper part of shoulders musculature. This was being applied for ten min, over middle trapezius trigger Point itself.
215013363|NCT00463775|DRUG|Topiramate|SSRI plus topiramate SSRI plus placebo
215013364|NCT06225752|DRUG|Probucol|Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
215099974|NCT06578065|DEVICE|Echelon Circular™ Powered Stapler|Echelon Circular™ Powered Stapler will be used in colorectal anastomosis.
215099975|NCT06578065|DEVICE|2-row circular staplers manual|2-row circular staplers manual will be used in colorectal anastomosis.
215099976|NCT03230565|DRUG|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
215099977|NCT03230565|DRUG|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
215099978|NCT04951466|BEHAVIORAL|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
215099979|NCT04951466|BEHAVIORAL|Healthy lifestyle intervention|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
215099980|NCT05298800|BIOLOGICAL|Vaccine|Different arms were administrated different vaccines
215099981|NCT01452919|DRUG|LY2140023|Administered orally
215099982|NCT01452919|DRUG|Placebo|Administered orally
215099983|NCT03320590|DIAGNOSTIC_TEST|Time Lapse (material to observe embryonic development)|The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
215099984|NCT01635803|DRUG|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
215099985|NCT01635803|DRUG|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
215099986|NCT03964688|DRUG|Vitamin C|vitamin C intravenous during hospitalization, after oral, total 6 weeks.
215099987|NCT03964688|DRUG|Placebos|placebo intravenous during hospitalization, after oral, total 6 weeks
215099988|NCT02750839|PROCEDURE|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
214408998|NCT02575235|DRUG|Cetylpyridinium Chloride (CPC)|Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.
215013365|NCT06225752|DRUG|Placebo probucol|Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
214408999|NCT02575235|DRUG|placebo|Control group takes the placebo for the same period.
214409000|NCT03617107|OTHER|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
214409001|NCT03255642|DRUG|Melatonin 2mg|4 weeks of 2mg prolonged release melatonin (Circadin)
214409002|NCT03255642|DRUG|ClonazePAM 0.5 MG|4 weeks of 0.5mg clonazepam (Rivotril)
214409003|NCT06026358|DRUG|Tirbanibulin|subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
214409004|NCT05304390|BEHAVIORAL|Patient Navigation|Receive patient navigation intervention
214409005|NCT05304390|OTHER|Questionnaire Administration|Ancillary studies
214409006|NCT05304390|BEHAVIORAL|Smoking Cessation Intervention|Receive an intervention for smoking cessation
214409007|NCT05304390|PROCEDURE|Carbon Monoxide Measurement|Undergo carbon monoxide measurement
214409008|NCT01187303|DRUG|Ofatumumab|300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
214409009|NCT04680702|DIAGNOSTIC_TEST|Sims Score|Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
215013366|NCT00710554|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
215013367|NCT00710554|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
215013368|NCT00335192|DRUG|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
215013369|NCT00335192|DRUG|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
215099989|NCT02396368|DRUG|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
214409010|NCT03101592|OTHER|Three-month ART dispensing|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
214409011|NCT03101592|OTHER|Six-month ART dispensing|Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
214409012|NCT00003543|BIOLOGICAL|monoclonal antibody A33|
214409013|NCT00003543|DRUG|carmustine|
215013370|NCT00335192|DRUG|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
214409014|NCT00003543|DRUG|fluorouracil|
214409015|NCT00003543|DRUG|streptozocin|
214409016|NCT00003543|DRUG|vincristine sulfate|
214409017|NCT06047262|DRUG|Dapansutrile|Patients receive investigational product.
215013371|NCT05562635|COMBINATION_PRODUCT|5% polymer gel with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
215013372|NCT05562635|COMBINATION_PRODUCT|10% polymer gel with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
215013373|NCT05562635|COMBINATION_PRODUCT|Placebo intervention|Application of placebo without CBD
215013374|NCT06251830|DIAGNOSTIC_TEST|MRI exam with Magnetic Resonance Fingerprinting|"Acquisition of MRI data with technique Magnetic Resonance Fingerprinting"
215013375|NCT05485350|DRUG|Anlotinib Hydrochloride|12 mg/d, d1-14, q3w
215013376|NCT05485350|DRUG|penpulimab|200mg, ivgtt, d1, q3w
215013377|NCT05485350|RADIATION|SBRT|55-180Gy
215013378|NCT02491450|DRUG|Heterosofir|1 tablet contains 400 mg sofosbuvir
215013379|NCT02491450|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
215013380|NCT04228315|DRUG|Primaquine|radical cure dosing
215013381|NCT01433978|DRUG|Eltrombopag|
215013382|NCT01433978|DRUG|Avatrombopag|
214409018|NCT06047262|DRUG|Placebo|Patients receive placebo.
214409019|NCT06179095|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI just before the intrauterine device insertion procedure, and again with STAI after the procedure.
214409020|NCT04555330|DEVICE|Physical activity measurement|"To assess physical activity two small tri-axial accelerometers embedded in medical Band-Aids will be used. The accelerometers are discretely worn on the lateral aspect of the thigh.~The accelerometers sample accelerations continuously during hospitalisation and are connected wirelessly to a tablet that via an inbuilt algorithm classify the recordings as bedridden (lying down), sitting, standing, and walking."
214409021|NCT04555330|DEVICE|Visual Feedback|The tablet will be placed on the patients bedside table and provides feedback on the amount of physical activity and motivational imagesand texts that will be visible for the patients, the health care staff and visitors.
214409022|NCT01770860|DEVICE|6660|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
214409023|NCT01770860|DEVICE|4314|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
214409024|NCT01770860|DEVICE|8336|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
214409025|NCT01770860|DEVICE|4840|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
214409026|NCT02276131|DEVICE|Vigilant Diabetes Management Application|Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
215013383|NCT01433978|DRUG|Standard of care|"Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
214409027|NCT03461887|BEHAVIORAL|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
214409028|NCT02341534|DEVICE|BioMonitor|Patients will be implanted with the BioMonitor + Home Monitoring feature
214409029|NCT06344455|BEHAVIORAL|School Retention and Completion Incentive Savings via Modified Iowa Gambling Task A|Participants will engage in a modified version of the Iowa Gambling Task with visual stimuli that are aligned with the Pé-de-Meia program's requirements. Advantageous cards will display images that are congruent with the program's criteria, while disadvantageous cards will feature images that are contrary to the Pé-de-Meia program's requirements.
214409030|NCT06344455|BEHAVIORAL|Iowa Gambling Task|The participants will play the unmodified Iowa Gambling Task.
214409031|NCT06344455|BEHAVIORAL|School Retention and Completion Incentive Savings via Modified Iowa Gambling Task B|"The participants will play the modified IGT (Iowa Gambling Task). For the disadvantageous cards, images that align with the requirements of the Pé-de-Meia program will be presented, while for the advantageous cards, images that contradict the criteria of the Pé-de-Meia program will be shown."
214409032|NCT05237193|DIAGNOSTIC_TEST|The level of CIN|The extracted DNA from bile will be analyzed by UCAD to determine the level of CIN. And the patient will be followed for up to 2 years.
214409033|NCT01048151|BIOLOGICAL|TNFerade™ Biologic|AdGVEGR.TNF.11D
214409034|NCT03091712|DEVICE|Glooko Mobile Insulin Dosing System(MIDS)|Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
214409035|NCT00740285|DRUG|Lidocaine 2% without vessel constrictor|"* first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~* next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days"
215013384|NCT04258098|DRUG|Oral antibiotics ( Streptomycin ,metronidazole )|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
215013385|NCT06110182|DIETARY_SUPPLEMENT|enteral or parenteral nutritional support|Parents will be classified based on whether they received enteral or parenteral nutritional support during treatment.
215099990|NCT02396368|RADIATION|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
215099991|NCT00386165|DRUG|larazotide acetate|larazotide acetate 4 mg capsules
215099992|NCT03390309|OTHER|Partially Hydrolyzed Formula|Partially Hydrolyzed Whey Protein Infant Formula
215099993|NCT03390309|OTHER|Normal Formula|Normal Formula
215099994|NCT05157139|DRUG|Oral Capsule|Oral Capsule of vanillin \& wheat germ oil
214409036|NCT00740285|OTHER|Placebo - physiological solution 0,9%|first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
215099995|NCT02421588|DRUG|Lurbinectedin (PM01183)|
215099996|NCT02421588|DRUG|Pegylated liposomal doxorubicin (PLD)|
215099997|NCT02421588|DRUG|Topotecan|
215099998|NCT04494126|DRUG|Tranexamic acid|Drug: Tranexamic Acid Injectable Solution the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia before incision.
215099999|NCT04494126|DRUG|Placebo|Other: Placebo (normal saline 0.9%) An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
215100000|NCT03792568|OTHER|ALK Inhibitor|Any ALK inhibitor like crizotinib, alectinib and so on.
215100001|NCT06583603|BEHAVIORAL|Barriers to Implementing Sensory Strategies Survey|Survey, see arm description
214409037|NCT01522339|DEVICE|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan(s) for no longer than 60 minutes
214409038|NCT01738711|BEHAVIORAL|Cognitive behavioural therapy|Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
215100002|NCT06584058|DRUG|HPP737|\[14C\]HPP737 oral preparation, 20mg（150μCi）, once
214409039|NCT06310564|RADIATION|SABR|"A biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected \[10\]; if not possible, a BED schedule no lower than 100 Gy10 should be administered. In compliance with these instructions, treatment schedules, total dose and fractionation will be prescribed according to the clinical practice of each participating Center. The constraints for the organs at risk will be respected according to the available data.~In any case, biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected; if not possible, a BED schedule no lower than 100 Gy10 should be administered.~SABR will be administered before systemic treatment start, or before starting the second systemic treatment cycle at the latest."
215013386|NCT03203707|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
215013387|NCT02722603|DRUG|gabapentin|75 mg/ml gabapentin syrup
214409040|NCT06526728|DRUG|Hyperbaric oxygen|Participants will be subjected to seven once-daily sessions of hyperbaric oxygen therapy. Each session will last 115-120 minutes whereby the chambre will be pressurized to 2.4 ATA during which participants will breathe 100% (pure) oxygen.
215013388|NCT02722603|DRUG|tramadol|100 mg/ml tramadol oral drops
215100003|NCT06584201|PROCEDURE|Erector Spinae Plane Block (ESP)|The ESP block will be administered before the VATS procedure, aiming to manage postoperative pain and minimize the impact on early lung function test (SFT) parameters. The block will be performed using standard techniques under ultrasound guidance to ensure accurate placement.
215100004|NCT06584201|PROCEDURE|Paravertebral Block (PVB)|The PVB will be administered prior to the VATS procedure, with the objective of managing postoperative pain and assessing its impact on early postoperative lung function (SFT) parameters. This block will also be performed using standard techniques and ultrasound guidance for precision.
215100005|NCT01743820|DRUG|dihydroartemisinin-piperaquine|
215100006|NCT01743820|DRUG|0.125 mg/kg Primaquine|
215100007|NCT01743820|DRUG|0.5 mg/kg Primaquine|
215100008|NCT01743820|DRUG|0.25 mg/kg Primaquine|
215100009|NCT01743820|DRUG|0.0625 mg/kg Primaquine|
215100010|NCT00950898|OTHER|decaff|2 mugs of decaffeinated coffee
215100011|NCT00950898|OTHER|caffcoff|2 mugs of caffeinated coffee
215100012|NCT00950898|OTHER|caffeine|2 mugs of hot water containing caffeine
215100013|NCT00950898|OTHER|placebo|2 mugs of hot water
215100014|NCT04040829|BEHAVIORAL|Cognitive remediation therapy (CR)|Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
214409041|NCT03983161|DRUG|Fedratinib|Fedratinib
215100015|NCT04040829|BEHAVIORAL|Supported education (SE)|Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
214409042|NCT01257165|DRUG|Zopiclone|Zopiclone pill 5 or 10 mg, given orally as a single dose.
214409043|NCT01257165|DRUG|Ethanol|50 mg per 70 kg body weight, given orally as a single dose
214409044|NCT01257165|DRUG|Placebo pill|Placebo pill identical to zopiclone pill, given orally as a single dose
214409045|NCT01257165|DRUG|Placebo drink|Placebo drink, given orally as a single dose
214409046|NCT05531825|DEVICE|A device for detecting arteriovenous fistula vascular function|An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels
215013389|NCT02722603|OTHER|placebo tramadol|placebo tramadol oral drops
215013390|NCT02722603|OTHER|placebo gabapentin|placebo gabapentin syrup
215013391|NCT02266862|RADIATION|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
215013392|NCT00378560|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
215013393|NCT00378560|BIOLOGICAL|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
215013394|NCT05285163|BEHAVIORAL|palliative care educatiom|The patients in the intervention group were presented palliative care training in addition to their usual care
215013395|NCT05812157|DIETARY_SUPPLEMENT|Daily dietary supplementation with Fibruline|Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day
215100016|NCT04040829|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
215100017|NCT05462418|PROCEDURE|electrosurgery|incisions completed using use the unipolar diathermy from Whiteline till we reach the parietal peritoneum (cutting the Whiteline then coagulation till reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
215100018|NCT05462418|PROCEDURE|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
215100019|NCT01145339|DRUG|Lactase|1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
215100020|NCT03322917|BIOLOGICAL|PRP autologous|Autologous platelet rich plasma: 1 drop / 6 times a day during 6 weeks
215013396|NCT05812157|DRUG|Anti-IL-17 therapy|Patients in both groups will be on anti-IL-17 therapy
215013397|NCT02867852|DRUG|Abiraterone acetate|Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 \[CYP17\]), a key enzyme required for testosterone synthesis. This enzyme is found in the testes, adrenals, prostate tumors
214409047|NCT04512742|OTHER|biting by Phlebotomus duboscqi infected with Leishmania major|The first six subjects will be exposed to biting by Phlebotomus duboscqi infected by Leishmania major and assess the 'take rate', that is the number of subjects developing parasitologically confirmed cutaneous leishmaniasis (PCCL) lesions. If 6/6 subjects develop PCCL lesions no further recruitment will take place; if only \< 6 subjects develop PCCL lesions, then an adaptive design will be followed.
214409048|NCT03364959|OTHER|Corticosteroids inhalation|Flixotide inhalation followed by Qvar inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
215013398|NCT02852434|DRUG|Lidocaine Gel (2%)|
215013399|NCT02852434|DRUG|Lidocaine Paracervical Block (1%)|
215013400|NCT05708222|DEVICE|MEB-001|The study is for the development of a software medical device. The study participant will complete study specific questionnaires and undergo a routine sleep study. The medical device will not provide any treatment or interventions.
215013401|NCT06194994|BEHAVIORAL|Parent Management Training|Behavioral parent training program aimed at increasing compliance and positive behaviours while decreasing disruptive behaviours
215100021|NCT05310981|BEHAVIORAL|iCanChange|iCC is a psychological app based intervention that will be delivered in form of up to 24 brief (10-15 minutes) interactive modules developed based on the principles of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). During the intervention, participants will be offered MI and CBT-based activities (i.e., modules and strategies) aiming at facilitating change in cannabis use. At any point during the intervention, participants can reference modules that had been completed. Due to the frequency of behavioral stage changes in this population (e.g., regression in behavioral stage of change), stage of change will be monitored regularly throughout the intervention. During the follow-up period (i.e., Week 12-24), participants will have continuous access to the smart phone application and all built-in add-ons as described above. During this period, they will have access to 3 booster session.
215013402|NCT06194994|BEHAVIORAL|Tuning Your Temper|Cognitive behavioural treatment for children focusing on arousal reduction, problem solving and cognitive restructuring.
215013403|NCT03631121|DRUG|Basalin to Lantus|continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
215013404|NCT04574557|DIAGNOSTIC_TEST|micro RNA|"miRNA was isolated from serum using a miRNeasy Mini Kit (Qiagen, Cat; 217004)cDNA was isolated from obtained miRNA samples using a miScript Reverse Transcription Kit (Qiagen, Cat; 218060) Quantitative Real-Time PCR (qPCR) will be done using (miScript SYBR Green PCR Kit Qiagen Cat. No: 218073)The qPCR assays were performed in duplicate The relative expressions of Three miRNAs were selected for RT-PCR validation Two were selected from over-expressed miRNAs (miR-34a, miR-146b), one from under-expressed miRNAs (miR-122) were analyzed using the standard 2-ΔΔCT method. These miRNAs were selected due to their pathophysiological relation with NASH.~Predicted gene targets of all differentially expressed miRNAs will be identified. Genes with functions that are potentially relevant to the pathogenesis of NASH and gene targets that are commonly studied e.g. lipogenesis (e.g. FAS), inflammation (c-JUN kinase) will be included in the study"
215013405|NCT03203512|DIETARY_SUPPLEMENT|Fish oil capsules|Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
215013406|NCT03203512|DIETARY_SUPPLEMENT|High-oleic safflower oil capsules|High-oleic safflower oil capsules for 12 weeks
215013407|NCT06193967|BEHAVIORAL|Caregiver Praise|Caregivers will provide praise for child's engagement in dietary self-monitoring behaviors as a form of positive reinforcement
215013408|NCT06193967|BEHAVIORAL|Gamification|DSM logs will include gamification (points, levels, virtual pets) as positive reinforcement for child's engagement in dietary self-monitoring behaviors
215013409|NCT06634615|OTHER|VR patient education video|The educational video is created by converting the information provided by the service nurses into a video when the patient is admitted to the ward for surgery. The video will show a 2-3 minute animation of a nurse giving information. In a patient room, the service nurse will come to the newly admitted patient and explain the concept of cholecystectomy, the reasons for removing the gallbladder, how laparoscopic cholecystectomy is performed, the advantages of laparoscopic surgery compared to open surgery, the preparation process before and on the day of surgery, the conditions to be monitored after surgery, the importance of nutrition and fluid intake, defecation, the importance of early mobilization and discharge.
215013410|NCT06634615|OTHER|VR family interview|Patients will have a 5-minute video call with their families in a 360° designed home environment using virtual reality glasses in the operating room waiting area.
215013411|NCT02931110|DRUG|CBL0137|CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
215013412|NCT00910390|OTHER|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
215013413|NCT00910390|OTHER|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
215013414|NCT00910390|OTHER|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
215013415|NCT00250861|DRUG|Rituximab|
215013416|NCT00250861|DRUG|Aldesleukin|
215013417|NCT00454402|DRUG|Alfuzosin|
215013418|NCT03266484|DIETARY_SUPPLEMENT|Probiotic Mixture|The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.
215013419|NCT03266484|DIETARY_SUPPLEMENT|Placebo|A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
214409049|NCT03364959|OTHER|Corticosteroids inhalation|Qvar inhalation followed by Flixotide inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
214409050|NCT00423774|BEHAVIORAL|Problem-Solving Education|
214409051|NCT00601640|DRUG|Diclofenac Na gel|Given topically twice daily on days 1-90
214409052|NCT00601640|DRUG|Eflornithine HCL ointment|Given topically twice daily on days 1-90
214409053|NCT06426654|DRUG|sintiliman plus LDRT|"All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another three cycles of sintilimab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles."
214409054|NCT05192824|DEVICE|Orthokeratology lens|The intervention was according to the design of different optical zone and peripheral reverse curve
214409055|NCT04830254|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS) device|The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
214409056|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias|control group: Ablation of ventricular arrhythmias
214409057|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias + renal denervation|Intervention group: Ablation of ventricular arrhythmias + renal denervation
214409058|NCT05161702|OTHER|MAG-SPM treatment on isolated PBMC cells|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
214409059|NCT05161702|OTHER|Isolated PBMC cells without treatment.|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
214409060|NCT02347917|DRUG|BBI608|480 mg orally twice daily (960 mg total daily dose)
214409061|NCT02347917|DRUG|Pemetrexed|500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
215013420|NCT01571609|OTHER|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:\[9,10-3H\]-palmitate 0,3 µCi/min. Duration 60 minutes."
215013421|NCT02053584|DEVICE|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
215013422|NCT02053584|DEVICE|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
215013423|NCT01427946|DRUG|IPI-504|
215013424|NCT01427946|DRUG|Everolimus|
215013425|NCT01011283|DRUG|decitabine|decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days
214409062|NCT02347917|DRUG|Cisplatin|75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
214409063|NCT03542708|PROCEDURE|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. The patient will be under IV sedation. Record of which ovary was injected will be kept in the online research database and not in the clinical chart.
214409064|NCT03419780|BIOLOGICAL|Blood Transfusion|Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
215013426|NCT01011283|DRUG|azacitidine|azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days
215013427|NCT00132483|BEHAVIORAL|Instruction in physical training program|Instruction in physical training program.
215013428|NCT00950924|DEVICE|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
215013429|NCT00950924|DEVICE|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
215013430|NCT02822287|DRUG|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
215013431|NCT02933476|DEVICE|Vibrotactile Stimulation|The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
215013432|NCT03233685|BEHAVIORAL|Visual Training|The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
215013433|NCT03233685|BEHAVIORAL|Normal Training|Normal training routine
215013434|NCT01556100|DRUG|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
215013435|NCT00416754|OTHER|counseling intervention|subjects will receive genetic counseling
215013436|NCT01272895|DEVICE|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
215013437|NCT05391074|DIETARY_SUPPLEMENT|postbiotics (IGENH35.3A)|postbiotics to induce microbiota epigenetic factors
215013438|NCT05391074|DIETARY_SUPPLEMENT|vitamins (AREDS formulation and recommended daily dose)|vitamins (AREDS to prevent AMD progression
215013439|NCT04091308|OTHER|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
215013440|NCT04091308|OTHER|Usual Care with Protein Supplementation|The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.
214409065|NCT03680014|DIAGNOSTIC_TEST|CUSH|Machine learning assisted remote monitoring/ telehealth platform to predict and prevent falls
215013441|NCT04091308|OTHER|Individualized Physical Exercise Training with Protein Supplementation|Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.
215100022|NCT01359943|BIOLOGICAL|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
215100023|NCT01359943|DRUG|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
215100024|NCT00217568|BIOLOGICAL|pegfilgrastim|
215100025|NCT00217568|DRUG|carboplatin|
215100026|NCT00217568|DRUG|docetaxel|
215100027|NCT00006249|BIOLOGICAL|pegylated interferon alfa|
215100028|NCT00006249|PROCEDURE|adjuvant therapy|
215100029|NCT01898039|BIOLOGICAL|A2/4-1BBL melanoma vaccine|On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.
215100030|NCT01898039|PROCEDURE|DNP sensititzation|"Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.~On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm."
215100031|NCT01898039|DRUG|Cyclophosphamide|On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
215100032|NCT06257173|BEHAVIORAL|Education|The experimental group will receive 2 hours of patient safety training with a peer educator.
215100033|NCT03781505|DRUG|Paracetamol +caudal ropivacaine|Paracetamol + Ropivacaine
215100034|NCT03781505|DRUG|Placebo|Caudal ropivacaine
215100035|NCT06429774|OTHER|Neurological function|Neurological function will be examined using Glasgow Coma Scale (GCS) and Extended Glasgow Outcome Scale (GOSE).The GOSE was created as an advancement from the original GOS. The GOSE score categorizes the prognosis of patients with traumatic brain injury into eight categories.The 8 categories are: Dead, Vegetative State, Lower Severe Disability, Upper Severe Disability, Lower Moderate Disability, Upper Moderate Disability, Lower Good Recovery, and Upper Good Recovery.
215100036|NCT06429774|OTHER|Mental State, cognitive function, and life quality assessment|Mental State, cognitive function, and life quality will be examined using the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9(PHQ-9), Rivermead post-concussion symptoms questionnaire(RPQ), PTSD Checklist-5 Version(PCL-5)，Six-Item Screener（SIS） and 12-Item Short-Form Health Survey version 2(SF-12v2).
214688387|NCT06023680|BEHAVIORAL|Continuous sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be gradually combined into one 30-minute bout over the course of 20 days."
215100037|NCT06429774|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
215100038|NCT06429774|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
215100039|NCT00773240|DRUG|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
215100040|NCT00773240|DRUG|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
215013442|NCT02911467|DRUG|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
215013443|NCT02911467|DEVICE|MRI|MRI scan following the Pyruvate injection
215013444|NCT02604667|OTHER|Blood tests|"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
215013445|NCT02604667|OTHER|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
215013446|NCT00665886|DEVICE|Open Intravenous System - Vasocan®|Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.
215100041|NCT01936415|DEVICE|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
215100042|NCT01936415|DEVICE|Regenerex|
215100043|NCT00652080|DRUG|API 31510|Topical Cream; 3% active; AM \& PM application
214409066|NCT03017456|BEHAVIORAL|Survivorship Care Plan|"SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors."
214409067|NCT03095209|DRUG|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
214409068|NCT03095209|DRUG|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
214409069|NCT03095209|RADIATION|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
214409070|NCT02887378|DEVICE|hot clamps|reusable hot biopsy forceps
214409071|NCT02887378|DEVICE|normal clamps|
215013447|NCT00665886|DEVICE|Closed Intravenous System - Nexiva®|BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
215013448|NCT02610257|DEVICE|Mechanical stimulus (vibration) applied on the forearm|"Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports."
215013449|NCT04865978|DRUG|Apixaban|Patients randomized to apixaban will be started on a dose of 5 mg BID.
215013450|NCT04865978|DRUG|Warfarin|Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.
214409072|NCT03681730|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
214409073|NCT01501214|DRUG|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
214409074|NCT01501214|DRUG|Normal saline|Normal saline given
214409075|NCT03840070|DEVICE|Potenfill|Maximum: 22ml
214409076|NCT01872611|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|
214409077|NCT01872611|OTHER|Vehicle|Inactive ingredients used as placebo comparator
214409078|NCT01872611|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
214409079|NCT03645356|DEVICE|Fixed Appliances|Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way
214409080|NCT03645356|DEVICE|Clear Aligners|Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
214409081|NCT02516176|BEHAVIORAL|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
214409082|NCT02637544|OTHER|acupuncture|classical acupuncture therapy
214409083|NCT06239662|BEHAVIORAL|Therapeutic Group|The first part of each meeting, lasting 45 minutes, will be held only with children and young people, while parents will wait in the waiting room. At the end of the first part, for each meeting, the children will be asked to make a commitment relating to the topics covered, which will be verified in the following meeting. Once the part with the patients has concluded, they will be accompanied to an adjacent environment where a pediatrician volunteer will be waiting for them and will offer fun and socialization activities. In the meantime, the parents will be seated and will address, together with the team staff, the same issues discussed with their children, again for a duration of approximately 45 minutes. Parents will also be invited to make a commitment similar to that required of children.
214409084|NCT06239662|BEHAVIORAL|Usual care|The dietician will meet individually each child together with parents. Dietician will provide nutritional advices.
214409085|NCT01513642|BEHAVIORAL|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
214409086|NCT00276328|DRUG|Diosmectite (Smecta®)|
215013451|NCT04865978|DEVICE|LVAD implant|Subjects will undergo HeartMate 3 LVAD implant prior to randomization
215013452|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1 mg/kg CDP6038 IV"
215013453|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~0.1mg/kg CDP6038 IV"
215013454|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1.0mg/kg CDP6038 SC"
215013455|NCT01009242|OTHER|Placebo IV|"Single dose:~Placebo IV"
215013456|NCT01009242|OTHER|Placebo SC|"Single dose:~Placebo SC"
215013457|NCT01009242|DRUG|CDP 6038 SC|Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
215013458|NCT01009242|DRUG|Methotrexate|Individual stable doses of methotrexate.
215013459|NCT05638139|BIOLOGICAL|SygeLIX-F + SygeLIX-G|SygeLIX-F (plug) is inserted through the internal orifice while cryptoglandular space is filled by SygeLIX-G (gel).
215013460|NCT06691516|PROCEDURE|horizontal and vertical bone augmentation using computer guided cortical shell technique|Computer-guided cortical shell technique in anterior mandible 3d defect using bone harvesting guide and fixation guides
214409087|NCT04159948|DIETARY_SUPPLEMENT|Carbohydrate drink|"This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes."
215013461|NCT06691516|PROCEDURE|free hand cortical shell technique in anterior 3d defect|vertical and horizontal ridge augmentation in anterior mandible using free hand cortical shell technique
215013462|NCT06014892|DEVICE|Snoo smart bassinet|Participants in the intervention arm will be shipped a Snoo bassinet during their third trimester. The bassinet must be returned to the company at 6 months
215013463|NCT06014892|DEVICE|Willow wearable breast pump|Participants in the intervention arm will be shipped a Willow wearable breast pump and milk storage bags during the third trimester, which participants may keep
215013464|NCT06014892|BEHAVIORAL|Maven Clinic on-demand perinatal consultation|Participants in the intervention arm will receive immediate access to Maven Clinic for 24/7 on-demand consultation with perinatal specialists.
215013465|NCT06014892|BEHAVIORAL|Faculty mentor|After enrollment, participants in the intervention arm will be paired with a faculty mentor who is also a mother to discuss issues related to work-family integration during pregnancy and early infancy.
215013466|NCT03835117|DRUG|Wide-spectrum nutritional supplement|Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
215013467|NCT03835117|OTHER|Placebo|Inactive placebo comparator
215013468|NCT06444542|BEHAVIORAL|Guardant Shield|Blood-based colorectal cancer screening
215013469|NCT05949216|BEHAVIORAL|Musical engagement sessions|Musical engagement sessions will be 2 hours long and involve improvisation and sight-reading of sheet music. Participants will supply their own instrument of choice to play. There will be four sessions total.
215013470|NCT05712889|DRUG|VIP236 (Q3W)|VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.
215013471|NCT05712889|DRUG|VIP236 (Q2W)|VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle.
215013472|NCT04900935|BEHAVIORAL|POISE|POISE (Patient-centered, Optimal Integration of Survivorship and palliative carE) is a brief, population-specific intervention that consists of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues and health-promoting behaviors of patients with long, uncertain cancer trajectories.
215013473|NCT04572841|DRUG|SAR441344|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
215013474|NCT04572841|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
215013475|NCT00428077|BIOLOGICAL|bcr-abl peptide vaccine|Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.
215013476|NCT00428077|GENETIC|reverse transcriptase-polymerase chain reaction|"A baseline reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a baseline circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction."
215013477|NCT03847090|DRUG|Reloxaliase|Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day
215013478|NCT03847090|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
215013479|NCT01433588|DEVICE|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
215013480|NCT01433588|OTHER|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
215013481|NCT05198362|OTHER|Placebo|Inactive comparator
215013482|NCT05198362|DRUG|Tesomet|Fixed-dose combination
215013483|NCT01414829|PROCEDURE|Gastroscopy|The reason for gastroscopy will be not related to the study
215013484|NCT02544815|DRUG|Digoxin|Digoxin 0.25 mg pills
215013485|NCT02544815|DRUG|Placebo|Placebo pills
215013486|NCT00609973|DRUG|Ciprofloxacin|Ciprofloxacin 500 mg oral bid for 6 months
215013487|NCT00609973|DRUG|Placebo|Placebo bid for 6 months
215013488|NCT04935294|DRUG|Danicopan|Oral tablet.
215013489|NCT06054464|DRUG|PC14586|Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.
215013490|NCT06054464|DRUG|Rabeprazole|Part 1: Daily oral dose of rabeprazole on days 11-14.
215013491|NCT06054464|DRUG|Famotidine|Part 2: Twice daily oral dose of famotidine on days 11-13. Single, oral dose of famotidine on day 14.
215013492|NCT05688709|BEHAVIORAL|WhatsApp peer support group|YLHIVA assigned to the WhatsApp group will interact with each other and their peer counsellors through one-on-one private communications and on the group chat. The group chat will allow YLHIVA to ask questions, post comments, and reply to one another at any time. We shall share education videos once a week at a time agreed upon with study participants to optimize assimilation of information. In addition, peer counsellor will engage in private WhatsApp calls with youth once a week, to monitor psychosocial state, medication adherence, identify barriers to adherence and counsel YLHIVA. However, youth may initiate in more private communications' when need arises. The peer counsellor will also engage with YLHIVA daily through WhatsApp messages. We will tailor the messages to young people's treatment schedules, clinic appointments, and psychosocial state. Again, youth may text a peer counsellor whenever they wish to do so.
215013493|NCT04268966|DRUG|Brincidofovir|
215100044|NCT02408263|PROCEDURE|Total Hip Replacement (THR) and Total Knee Replacement (TKR)|Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
215100045|NCT03487497|PROCEDURE|Lateral column lengthening osteotomy|Lengthening osteotomy of the lateral column of the foot
214409088|NCT05989737|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
214409089|NCT01090609|DEVICE|Stent implantation|Stent implantation
214409090|NCT00623922|BEHAVIORAL|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
214409091|NCT05793099|OTHER|Effect of aqueous propolis gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given aqueous propolis gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing aqueous propolis gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
214409092|NCT05793099|OTHER|Effect of placebo gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given placebo gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing placebo gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
214409093|NCT05200650|COMBINATION_PRODUCT|TumoCure|TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.
214409094|NCT01738867|DRUG|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
214409095|NCT01738867|DRUG|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
214409096|NCT01738867|DRUG|Placebo|Matching placebo capsules to GSK1521498 or NTX
214409097|NCT04793139|DRUG|Camrelizumab|Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
214409098|NCT03537651|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
214409099|NCT03537651|DRUG|IVA|Tablet for oral administration.
214409100|NCT00340613|DRUG|glargine insulin|
214409101|NCT04903002|DRUG|24-IU oxytocin|Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
214409102|NCT04903002|DRUG|48-IU oxytocin|Patients will self-administer a 2-week course of 48-IU intranasal oxytocin \[4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
214409103|NCT04903002|DRUG|Placebo|Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.
214409104|NCT05037994|PROCEDURE|Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine|"The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap."
214409105|NCT03749291|OTHER|Obemat2.0 therapy|"Lifestyle (diet \& physical activity) structured recommendations through a motivational interview.~Duration: 12(+3) months Description: 1 visit/month \& 3 Workshops in primary care centers Providers: pediatricians and nurses trained to perform motivational interview The interviews are structured as follows: First, checking the accomplishment of objectives to motivate the participant. Second, a specific topic per visit is explained to the participant. Third, a task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight \& physical activity are defined to be accomplished until the next visit."
214688388|NCT06023680|BEHAVIORAL|Bouted sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be maintained over the course of 20 days."
215013494|NCT05610761|BEHAVIORAL|Core stabilization exercises with Kegel exercises|Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.
215100046|NCT00612560|DRUG|Anastrozole|1 mg per day
215100047|NCT00612560|DIETARY_SUPPLEMENT|flaxseed|25 g per day ground
215100048|NCT00612560|DRUG|Placebo|Placebo pill 1 per day
215100049|NCT00759408|DRUG|BQ-123|6-120 µg/min
215100050|NCT06000865|BEHAVIORAL|Action video game training|20 sessions of AVG over 10 weeks (45 minutes per session, 2 sessions per week)
215100051|NCT06000865|BEHAVIORAL|Conventional physical training|20 sessions of physical training over 10 weeks (45 minutes per session, 2 sessions per week)
215100052|NCT05693506|OTHER|Cooking workshops|Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants
215100053|NCT02578056|DEVICE|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
215100054|NCT02578056|PROCEDURE|Genital prolapse surgery|Surgical correction of genital prolapse
215100055|NCT03954613|COMBINATION_PRODUCT|Ebicomb|Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
215100056|NCT06173908|PROCEDURE|cell treatment|Autologous epidermal basal cells were used to repair nonhealing postoperative wound
215100057|NCT06173908|PROCEDURE|control treatment|anyother treatments except autologous epidermal basal cells were used to repair nonhealing postoperative wound
215013495|NCT05610761|BEHAVIORAL|Kegel exercises|"Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds)."
215013496|NCT03039985|DEVICE|Zirconia crowns (Prettau®)|Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
215013497|NCT03039985|DEVICE|lithium disilicate crowns (IPSe.max®)|lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
215013498|NCT00601185|PROCEDURE|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
215013499|NCT02668315|BIOLOGICAL|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
215013500|NCT04824287|OTHER|pelvic floor muscle exercise|pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
215013501|NCT01225224|DRUG|peficitinib|oral
215013502|NCT01225224|DRUG|Placebo|oral
215013503|NCT01293955|DRUG|JOINS 200mg|1 tablet at each time, 3 times a day
215013504|NCT01293955|DRUG|Placebo|placebo of Joins 200mg
215013505|NCT02585180|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
215013506|NCT02585180|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
215013507|NCT05068830|DRUG|ExPlas|"ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max \>50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
215013508|NCT05068830|DRUG|Octaplasma|"Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point .~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
215013509|NCT05068830|DRUG|Saline|"Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
215013510|NCT05908656|PROCEDURE|Investigational procedure|Subjects that consent will have a single blood draw either via a finger stick or via venous blood draw (blood will be placed on a 5 spot blood card) used to determine whether they have Gaucher Disease or ASMD
215013511|NCT06333652|DRUG|Ravulizumab|Intravenous infusion 100 mg/ml
215013512|NCT06481969|PROCEDURE|Conventional IVF|Conventional In Vitro Fertilization (IVF) procedure and standard assisted reproductive treatments.
215100058|NCT01590693|DRUG|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
214409106|NCT03749291|OTHER|Usual Clinical Practice|Lifestyle (diet and physical activity) Duration: 12 (+3) months Description: 1visit/month to the primary care centers. Providers: pediatricians \& nurses. Children assigned to the control group receive the usual treatment conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity \[Spanish Ministry of Science and Innovation\], 2009). At visits, the family receive recommendations to carry out a balanced diet, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports is advised.
214409107|NCT03298113|DEVICE|Cavilon Advanced Skin Protectant|Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.
214688389|NCT05513053|BIOLOGICAL|Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH|Pharmaceutical form: Solution for injection Route of administration: intramuscular
214688390|NCT04239703|DIAGNOSTIC_TEST|MMDx|Portion of kidney transplant indication biopsy
215100059|NCT01436474|DRUG|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
215100060|NCT01436474|DRUG|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
215100061|NCT01375023|RADIATION|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
215100062|NCT01375023|BIOLOGICAL|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
215100063|NCT04228094|OTHER|TDApp1: an eHealth intervention|TDApp1 is a tool that uses GRADE heuristics to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
214409108|NCT03298113|DEVICE|IAD Hospital Standard Care|Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
214409109|NCT06546696|BEHAVIORAL|Competency Based Approaches to Community Health (COACH)|COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
214409110|NCT02939183|DRUG|Immediate Release (IR) Formulation|Immediate Release (IR) Formulation
214409111|NCT02939183|DRUG|Gastro-Retentive (GR) Formulation|Gastro-Retentive (GR) Formulation
214409112|NCT02939183|DRUG|Dexamethasone|Dexamethasone
214409113|NCT02939183|DRUG|Pomalidomide|Pomalidomide
214409114|NCT05096117|DRUG|ASP8062|ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
214409115|NCT05096117|DRUG|Placebo|1 x per day for 6 weeks
214688391|NCT04239703|DIAGNOSTIC_TEST|Prospera|Transplant patient blood sample
215100064|NCT03539991|OTHER|Internet-Based Intervention|Complete online courses
215100065|NCT03539991|OTHER|Meeting|Participate in virtual meetings
215100066|NCT03539991|OTHER|Survey Administration|Ancillary studies
215100067|NCT00880594|DRUG|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
215100068|NCT03263260|DEVICE|implant|coronary stent implantation
214409116|NCT06219213|OTHER|Glyceryl Eicosapentaenoate serum|Daily application of serum on both targeted skin areas for 14 consecutive days. Serum must be applied before the Cream on clean skin.
214409117|NCT06219213|OTHER|Glyceryl Eicosapentaenoate Cream A|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
214409118|NCT06219213|OTHER|Glyceryl Eicosapentaenoate Cream B|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
214688392|NCT04239703|DIAGNOSTIC_TEST|HLA antibody|Transplant patient blood sample
214688393|NCT06123013|BEHAVIORAL|Music Assisted Relation Intervention (MARI)|A standardized 30-minute MARI intervention, personalized to the participant's music and imagery preferences. During the MARI intervention, the board certified music therapist (MT-BC) will provide live guitar accompaniment personalized to the participant's music preferences and read from a standardized script directing the participant to relax muscles of the body, practice deep breaths, and explore a relaxing place.
214688394|NCT06962891|DIAGNOSTIC_TEST|CKD progression biomarker|We will evaluate the CKD progression biomarker at baseline and evaluate 1-year CKD progression afterwards.
214409119|NCT06219213|OTHER|Glyceryl Eicosapentaenoate Cream C|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
214409120|NCT06122935|DEVICE|Aurora Xi New Nomogram Software 2.0|Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.
215013513|NCT06481969|PROCEDURE|Lower abdominal liposuction and preparation of SVF|After lower abdominal liposuction (the liposuction volume is about 100 ml), the preparation and quality inspection of SVF will be completed by a laboratory with good manufacturing practice-approved facilities immediately. The adipose tissue will be cut into pieces of about 1mm3, and the equal volume of 0.1% collagenase I will be added to digest the adipose tissue. The digestion will be terminated after 40 minutes, followed by isolation, filtration, centrifugation, resuspension and dilution to obtain the SVF suspension. The test items, including bacteria, fungi, viruses and endotoxin, will be tested, and the expression of SVF surface markers, including CD45, CD34, CD31, CD11b, CD44, CD73, CD105 and CD90, will be detected by flow cytometry to ensure the quality of the SVF suspension. After about 4 hours of quality control and detection, the SVF suspension will be transported to the operating room on ice in a sealed incubator.
215013514|NCT06481969|PROCEDURE|Ovarian injection|Under ultrasound guidance, the SVF suspension will be injected into patients' bilateral ovaries. SVF with a total amount of (1\~2)×107 cells from autologous fat tissue will be transplanted into each side of ovary. There are 3 injection points on each side of ovary, and 330±10μl SVF suspension will be administered at each point. The administration volume of each ovary will be 1ml in total. After injection, the patients will be required to lie flat for 2 hours to observe whether there would be adverse events.
215013515|NCT01115621|OTHER|Glutenfree diet during the first year of life|Glutenfree diet during the first year of life
215013516|NCT00005774|DRUG|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
215013517|NCT00005774|DRUG|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
215013518|NCT04308694|DRUG|Pharmacy-based methadone administration and dispensing|Eligible participants receiving between 6- and 13-days of methadone take-home doses will have methadone administration and dispensing transferred from the opioid treatment program to the partnered community pharmacy. Each participant will be assessed monthly for 3 months (at 1, 2, and 3 months following intake/baseline) to explore the feasibility of transferring their methadone administration and dispensing to the select community pharmacy.
215013519|NCT01941056|BIOLOGICAL|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
215013520|NCT01941056|OTHER|laboratory biomarker analysis|Correlative studies
215013521|NCT03780725|DRUG|BI 754111|Solution for infusion
215013522|NCT03780725|DRUG|[89Zr]Zr-BI 754111|Solution for infusion
215013523|NCT03780725|DRUG|BI 754091|Solution for infusion
215013524|NCT00543465|DRUG|MK0782|
214409121|NCT06122935|DEVICE|Aurora Xi Currently Approved Software 1.3|Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System
214409122|NCT05896306|OTHER|No intervention|No intervention
214409123|NCT05962125|OTHER|periodic alveolar recruitment maneuvers|A stepwise increment of tidal volume was used for each ARM.
214409124|NCT05962125|OTHER|positive end-expiratory pressure|a PEEP of 6 to 8 cm H2O
215013525|NCT05967910|OTHER|chronic psychological stress|Chronic psychological stress includes symptoms of anxiety and depression.
215013526|NCT02794779|DRUG|Oxytocin|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
215013527|NCT00347945|PROCEDURE|Pencil Push-ups|
215013528|NCT00347945|PROCEDURE|Office-based Vision Therapy|
215013529|NCT00347945|PROCEDURE|Placebo Office-based Vision Therapy|
215013530|NCT02553070|OTHER|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
215013531|NCT03559309|DIAGNOSTIC_TEST|Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing|Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.
214409125|NCT03276793|OTHER|MRI scan|Patients will undergo an MRI scan
214409126|NCT03276793|BEHAVIORAL|Behavioral testing|Patients will complete a series of cognitive tasks
214409127|NCT04398459|DRUG|Ibrutinib|Each recruited subject will accept Ibrutinib treatment.
214409128|NCT05980793|PROCEDURE|PIP joint denervation|Surgical denervation of the PIP joint
214409129|NCT05980793|PROCEDURE|Patient education plus exercise|An education plus exercise program
214409130|NCT04081545|DRUG|Opioid Anesthetics|see arm/group description
214409131|NCT04081545|DRUG|Non Opioid Analgesics|see arm/group description
214409132|NCT03528629|DRUG|Zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion.
214409133|NCT05455996|DRUG|MDMA|MDMA-assisted therapy
215013532|NCT03242733|OTHER|Ultrasound assessment of gastric contents|Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
215013533|NCT00113126|DRUG|Treatment interruption|
215013534|NCT04281719|OTHER|Mobile Application (working name: Bright Path)|The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
214409134|NCT05413928|BEHAVIORAL|Time Restrictive Eating- late|Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.
214409135|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early|Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.
215013535|NCT03888079|DRUG|Local anesthetic|1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
215013536|NCT03888079|DRUG|general anesthetic|Endotracheal intubation, intravenous narcotic agents, and inhaled agents
215013537|NCT04919343|BEHAVIORAL|BBC Education Tiny Happy People videos|This intervention involves regular texting of BBC Education Tiny Happy People videos to parents
215013538|NCT04919343|BEHAVIORAL|Physical health control intervention|This intervention involves regular texting of publicly available videos about supporting infant physical and dental health to parents
215013539|NCT04828525|DRUG|Dexamethasone|adjuvant dexamethasone treatment
215013540|NCT04828525|DRUG|normal saline|placebo
215013541|NCT03148639|BEHAVIORAL|Avatar therapy|Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
215013542|NCT03148639|OTHER|Treatment-as-usual|Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
215013543|NCT03360968|PROCEDURE|Variable-PS|Variable-PS mode switched on for 1 hour
215013544|NCT03360968|PROCEDURE|SPN-CPAP/PS|SPN-CPAP/PS mode switched on for 1 hour
214409136|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early with early caloric intake|Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.
215013545|NCT03360968|PROCEDURE|Variable-PS|Variable-PS mode switched on for 1 hour
215013546|NCT02587286|OTHER|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
215013547|NCT00191152|DRUG|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
215013548|NCT00191152|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
215013549|NCT00191152|DRUG|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
215013550|NCT00140114|DRUG|Misoprostol (Cytotec®)|50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
215013551|NCT05895500|DRUG|Injection for SC administration (120mg/syringe)|Injection
215013552|NCT05895500|DRUG|Tablet (50mg/tablet), oral|Tablet
215013553|NCT04219774|PROCEDURE|Endovascular intervention|Endovascular angioplasty of the occluded carotid using balloon angioplasty and reconstruction with stents: coronary stents distally (Rebel, Boston Scientific; Vision, Abbott Vascular) and carotid stents proximal (Acculink and Xcat, Abbott Vascular) Patients will stay on their aspirin 325 mg and clopidogrel 75 mg
215013554|NCT04219774|DRUG|Aspirin and Clopidogrel (maximal medical Therapy)|Best Medical Management: daily dual antiplatelet therapy (aspirin: 325 mg p.o. qd and Clopidogrel: 75 mg p.o. qd), optimization of systolic blood pressure (120 -140 mmHg), and smoking cessation.
215013555|NCT00114777|DRUG|Cyclosporin A|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
215013556|NCT00114777|DRUG|Belatacept Less Intensive Regimen (LI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
215013557|NCT00114777|DRUG|Belatacept More Intensive Regimen (MI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
215013558|NCT04448080|DEVICE|Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)|Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
215013559|NCT01334853|OTHER|No drug will be used|Biomarker
215013560|NCT01334853|OTHER|No drug will be used|Biomarker
215013561|NCT03090295|DEVICE|Palpation and Accuro|Identify placement for spinal
215013562|NCT01986322|BIOLOGICAL|DTP/HB/Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
215013563|NCT01986322|BIOLOGICAL|DTP/HB and Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
215013564|NCT02717715|BEHAVIORAL|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
215100084|NCT02540668|DRUG|Lanabecestat|Administered orally
215100085|NCT02540668|DRUG|Warfarin|Administered orally
215100086|NCT03596684|DIETARY_SUPPLEMENT|citrulline supplementation|2.5 g per os of citrulline on the morning and the evening (5 g/ jour) during 4 weeks.
215100087|NCT03596684|DIETARY_SUPPLEMENT|placebo supplementation|2.5 g of the product in the morning and in the evening during 4 weeks.
215100088|NCT03596684|PROCEDURE|glucose tolerance test|2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
214409137|NCT05413928|OTHER|Macronutrient-controlled meals|Meals with a determined amount of protein, carbohydrates, and fat.
214409138|NCT00654238|DRUG|sorafenib|400mg PO BID daily
214409139|NCT00906490|DEVICE|Intravenous Blood Glucose monitoring system|Insertion of blood glucose monitoring sensor into peripheral vascular IV line.
215013565|NCT05771623|DEVICE|Iontophoresis drug delivery device|"Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.~This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months)."
215013566|NCT05771623|BEHAVIORAL|Traditional physical therapy|Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).
215013567|NCT03238872|BEHAVIORAL|Cognitive Behavioural Therapy|
215013568|NCT03238872|OTHER|Treatment as usual|
215013569|NCT05428228|OTHER|TP1|Participants will be administered TP1 during one of the experimental visits.
214409140|NCT06168604|BEHAVIORAL|Pain Identification and Communication Toolkit|The Pain Identification and Communication Toolkit (PICT) is a multicomponent (6 module) intervention for family caregivers of persons with Alzheimer's disease and related dementias (ADRD). PICT consists of 4 weekly telephone sessions (30-60 minutes each) delivered by a trained interventionist
214409141|NCT06168604|BEHAVIORAL|Health Promotion Program|The attention control (AC) condition is referred to as the Health Promotion Program (HPP). The HPP will consist of 4 weekly telephone sessions (30-60 minutes each) but focus on caregiver health promotion topics, such as nutrition, exercise, and sleep.
214409142|NCT03664323|BIOLOGICAL|Evaluate the improvement in response from the end of anti-PD-1 monotherapy|Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).
214409143|NCT03318913|OTHER|Placebo|5g of the sucralose administered as white plastic capsules
214409144|NCT03318913|OTHER|Fish protein hydrolysates|5g of the FPH dissolving in 100 mL of water
214409145|NCT01538446|DRUG|Modification of Prasugrel based on a biological assay|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
214409146|NCT01538446|DRUG|prasugrel / clopidogrel|fixed dose of prasugrel 5 mg
214409147|NCT01538446|DEVICE|Verify Now|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
214409148|NCT05871242|DIETARY_SUPPLEMENT|Probiotic Lactobacillus crispatus M247|Patient who have received probiotic Lactobacillus crispatus M247
214409149|NCT05133167|PROCEDURE|Balloon Tamponade or B-Lynch|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by measuring the amount of blood collected in Foley balloon tamponade bag, in milliliters. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by the weight difference of the pads before and after patient use (1-gram weight difference = 1 ml blood volume lost). Mean blood loss within first 24 hours post procedure, was compared in both the groups for outcome measurement.
214409150|NCT00003957|BIOLOGICAL|filgrastim|
214409151|NCT00003957|BIOLOGICAL|recombinant human stem cell factor|
214409152|NCT00003957|DRUG|cyclophosphamide|
214409153|NCT00003957|DRUG|cytarabine|
214409154|NCT00003957|DRUG|etoposide|
214409155|NCT00003957|DRUG|melphalan|
214409156|NCT00003957|DRUG|mitoxantrone hydrochloride|
214409157|NCT00003957|DRUG|paclitaxel|
215013570|NCT05428228|OTHER|TP2|Participants will be administered TP2 during one of the experimental visits.
215013571|NCT05428228|OTHER|Placebo|Participants will be administered placebo during one of the experimental visits.
215013572|NCT03447145|DRUG|TQ-B3203|dose escalation, 2/4/6/10/14/18mg/m2
215013573|NCT06162234|OTHER|observational|none (observational study)
215013574|NCT00333307|DRUG|recombinant human relaxin|
214409158|NCT00003957|PROCEDURE|peripheral blood stem cell transplantation|
214409159|NCT01446003|DRUG|MK-8457|10 x 10-mg capsule BID for 10 days
214409160|NCT01446003|DRUG|Placebo for MK-8457|10 x 10-mg capsule BID for 10 days
215013575|NCT02106559|DRUG|porfimer sodium|Given IV
215013576|NCT02106559|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection and/or radical pleurectomy
215013577|NCT02106559|DRUG|photodynamic therapy|Undergo PDT
214409161|NCT00318656|DRUG|rosiglitazone-metformin fixed dose combination|
214409162|NCT00318656|DRUG|metformin + glimepiride|
214409163|NCT05498311|RADIATION|Intraoperative Radiotherapy (IORT)|The Intrabeam Photon Radiosurgery System will deliver 20 Gy in the act of breast surgery
214409164|NCT05498311|PROCEDURE|Breast conservative surgery|Breast conservative surgery with the aim of resecting breast tumour and with or without oncoplastic surgery
214409165|NCT05498311|RADIATION|External Beam Hypofractionated Radiotherapy (EBRT)|A External Beam Hypofractionated Radiotherapy will be administered after surgery. y. The dose per fraction will be 2.67 Gy per session. EBRT will be performed daily from Monday to Friday for fifteen fractions.
214409166|NCT03031704|PROCEDURE|Endoscopic mucosectomy|Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
214409167|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
215013578|NCT00629239|DRUG|AZD4818|Dry Powder, inhalation, b.i.d., 4 weeks
215013579|NCT00629239|DRUG|Placebo|
215013580|NCT02526394|BIOLOGICAL|Meningococcal vaccine|Meningococcal vaccination
215013581|NCT02526394|DRUG|Pertussis containing vaccine|Pertussis containing vaccination
215013582|NCT02326090|DRUG|cis-UCA ophthalmic solution 1.0%|
214409168|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles
214409169|NCT03905135|BIOLOGICAL|Avelumab|Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
214409170|NCT01740557|BIOLOGICAL|Aldesleukin|Given IV
214409171|NCT01740557|BIOLOGICAL|CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
214409172|NCT01740557|DRUG|Cyclophosphamide|Given IV
214409173|NCT01740557|DRUG|Fludarabine Phosphate|Given IV
214409174|NCT01740557|OTHER|Laboratory Biomarker Analysis|Correlative studies
214409175|NCT01740557|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
214409176|NCT01740557|OTHER|Quality-of-Life Assessment|Ancillary studies
214409177|NCT01481935|OTHER|Enhanced cleaning of surfaces in ICU rooms|Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.
214409178|NCT01481935|OTHER|Sham enhanced cleaning of surfaces in ICU rooms|While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
214409179|NCT02998489|OTHER|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
214409180|NCT02998489|OTHER|Traditional milk advancement|20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
214409181|NCT03888911|DIETARY_SUPPLEMENT|High dose IQP-LU-104 (5120mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
214409182|NCT03888911|DIETARY_SUPPLEMENT|Low dose IQP-LU-104 (2560mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
214409183|NCT03888911|DIETARY_SUPPLEMENT|Placebo|1 sachet to be taken 2 times daily orally, together with 2 main meals
214409184|NCT02138513|BEHAVIORAL|Mindfulness Based Cognitive Therapy|This MBCT protocol consists of 8 weekly sessions of 2,5 hours each and a silent day of 6 hours of meditation practice. Similar to group MBCT, in the online MBCT group, participants will be asked to practice at home for 45 minutes, 6 days a week. They will receive files with meditation and yoga exercises to support this.
214409185|NCT01248221|DRUG|[13C]-Spirulina platensis and 99mTc sulfur colloid|The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
214409186|NCT05457361|DRUG|VEN combined with azacitidine plus homoharringtonine|VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
214409187|NCT05457361|DRUG|VEN combined with azacitidine|The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
214409188|NCT03394248|DEVICE|Vector Mouthguard|The mouthguard will be used by athletes to measure the magnitude and number of impacts throughout one season.
214409189|NCT03533855|DIAGNOSTIC_TEST|CS plus FRFSE|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
214409190|NCT03563781|PROCEDURE|Sentinel node detection|Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
214688395|NCT06068270|PROCEDURE|Micro-ostoperforations (MOPs)|3 MOPs will be performed in the bone next to the root of the experimental tooth. MOPs will be performed using the Excellerator® (Propel Orthodontics, Denstply, Sirona)
215013583|NCT02326090|DRUG|cis-UCA ophthalmic solution 2.5%|
215013584|NCT02326090|DRUG|Placebo ophthalmic solution|
215013585|NCT02696577|DRUG|Low dose aspirin|
215013586|NCT02696577|DRUG|Omega 3|
215013587|NCT02460380|DRUG|Vitamin D3|Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
215013588|NCT02460380|OTHER|Placebo|Women in the placebo arm received once capsule of placebo once weekly for eight weeks
215013589|NCT06427174|DRUG|Fascia iliaca block|For the group who will receive the fascia iliaca block …. After induction of the general anesthesia and before skin incision, fascia iliaca block will be performed in the patient while he is in the supine position
215013590|NCT06427174|DRUG|Caudal block|second group will receive the caudal block, we use bupivacaine 0.5 mg / kg.
215013591|NCT00682838|BEHAVIORAL|Self-management|Self-management
215013592|NCT00682838|BEHAVIORAL|Telemonitored care|Telemonitored care
215013593|NCT00581789|DRUG|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
215013594|NCT02957123|DRUG|Intranasal auto-M2-BFs|Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
215013595|NCT02912520|DRUG|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
215013596|NCT03566550|DIAGNOSTIC_TEST|MRI scans|Repeated MRI scans imaging digestion of standard meals
214688396|NCT05280379|OTHER|no intervention will take place|no intervention will take place
215013597|NCT03095976|PROCEDURE|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
215013598|NCT02618187|DRUG|SER-287|
215013599|NCT02618187|DRUG|Placebo|
215013600|NCT02618187|DRUG|Placebo Pre-Treat|
215013601|NCT02618187|DRUG|Vancomycin Pre-Treat|
215013602|NCT02614768|DEVICE|Glucose Sensor|"The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received conformité européenne (CE) certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled for investigative use only."
215013603|NCT03488485|DRUG|Direct Acting Antivirals|DAAs given in patients with viremic chronic hepatitis C
215013604|NCT04916665|DRUG|Teduglutide|bridging intestinal failure with teduglutide until reconstruction
215013605|NCT06213805|PROCEDURE|Minimally invasive microsclerostomy|"MIMS is a filtering glaucoma surgery, which consists of creating a sclero-corneal drainage channel, to allow the flow of aqueous humor and therefore the reduction of intraocular pressure.~This surgery is extremely quick, lasting 3 to 5 minutes, according to recent MIMS studies, in contrast to the duration of a trabeculectomy, the classic glaucoma surgery, which varies between 20 and 60 minutes."
215013606|NCT00052715|DRUG|poly ICLC|
215013607|NCT01210443|DRUG|Sitaxentan|sitaxentan sodium 100 mg
215013608|NCT06209086|DEVICE|skeletal anchored twin block|"This appliance was constructed as the modified Twin Block used for the first group in addition to the following modifications:~* Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~* Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~* Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally."
215013609|NCT04174820|OTHER|Functional Magnetic Resonance Imaging (fMRI)|list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests
215013610|NCT03730701|BEHAVIORAL|Prevention program for stroke|The prevention program include individual and group intervention sessions supported by a digital platform. The program will be personally tailored in relation to what the person needs and what to change and the individuals rediness for change. The digital platform will support the person during and in between sessions by prompting goals and goal-fulfilment, logging activities, step counts and provide a forum for sharing and reflection.
215013611|NCT05311982|DEVICE|DLPFC-R (F4) TDCS|direct current brain stimulation- The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A), combined tDCS in DLPFC-L (F3) and DLPFC-R (F4) simultaneously (Block B) or sham-tDCS (Block C) with equal electrode configuration guaranteed blindness. After the procedures, each participant received the following intervention in the order ABC, BCA or CAB with a period of 1 week between each one. Each block took 3 weeks, organized into: 1) Assessment; 2) Application of stimulation; 3) Reassessment and washout week. Adding 1 more week of final evaluation, the study totaled the period of 10 weeks. During this period, patients were instructed to continue their behavioral/educational treatment and medication routines.
215013612|NCT05311982|DEVICE|DLPFC-L (F3) and DLPFC-R (F4) TDCS|DLPFC-L (F3) and DLPFC-R (F4) (Bock B)
215013613|NCT05311982|DEVICE|sham-tDCS|sham-tDCS (Block C) with equal electrode configuration guaranteed blindness
215013614|NCT02807181|DRUG|Cisplatin-gemcitabine|Systemic chemotherapy
215013615|NCT02807181|DEVICE|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
215013616|NCT06144502|BEHAVIORAL|5Ways@School|"The 5Ways@School intervention is a teaching material consisting of five elements; Take notice, Be active, Keep Learning, Connect, and Give. The intervention will be given in an ordinary classroom setting by the class' main teacher in two school hours of 45 minutes each week for six consecutive weeks, i.e., a total of 12 school hours. The teaching sessions will consist of presentations of the five elements, videos, reflection exercises, focused group discussions, creative group work, and giving the pupils small challenges to practice what they have learned between the weekly sessions."
215013617|NCT04202783|OTHER|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
215013618|NCT05708378|OTHER|Rocker board training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
215013619|NCT05708378|OTHER|Stable surface training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
215013620|NCT02113046|PROCEDURE|pancreatico-jejunal anastomosis|
215013621|NCT02113046|PROCEDURE|traditional anastomosis|
215013622|NCT00290628|DRUG|anti-thymocyte globulin|
215013623|NCT00290628|DRUG|busulfan|
215013624|NCT00290628|DRUG|cyclophosphamide|
215013625|NCT00290628|DRUG|cyclosporine|
215013626|NCT00290628|DRUG|filgrastim|
215013627|NCT00290628|DRUG|melphalan|
215013628|NCT00290628|DRUG|methylprednisolone|
215013629|NCT00290628|DRUG|mycophenolate mofetil|
215013630|NCT00290628|PROCEDURE|radiation therapy|
215013631|NCT00290628|PROCEDURE|umbilical cord blood transplantation|
215013632|NCT00100750|DRUG|Gemcitabine Hydrochloride|Given IV
215013633|NCT00100750|DRUG|Tipifarnib|Given PO
214693963|NCT01472172|DEVICE|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
215013634|NCT00100750|OTHER|Laboratory Biomarker Analysis|Correlative studies
214409191|NCT05577962|DRUG|T group|OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
214409192|NCT00490555|DRUG|Testosterone gel|Testosterone gel 10 g
214409193|NCT00490555|DRUG|Dutasteride|dutasteride 0.5 mg orally
215100089|NCT03270891|DIAGNOSTIC_TEST|PGx test|A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
215100090|NCT05799417|OTHER|Acoustic stimuli|During different states of sedation/anaesthesia and sleep, acoustic stimuli will be presented and compared to a within-subject baseline.
215100091|NCT02716181|DEVICE|"Атопик Soothing Cream"|Topical application of a study cream to involved skin areas twice a day.
214409194|NCT00490555|DRUG|Depo-Medroxyprogesterone (DMPA)|300 mg DMPA injection on Day 0 IM (into the muscle)
214409195|NCT00490555|OTHER|Placebo Testosterone gel|Place gel applied daily for 12 weeks
214409196|NCT00490555|OTHER|Placebo dutasteride|placebo pill for 12 weeks
214409197|NCT00490555|OTHER|Placebo DMPA|placebo DMPA injection Once
214409198|NCT03782038|DEVICE|MCD|Micro coring skin removal with automated coring device
214409199|NCT03313089|BEHAVIORAL|"Papas más nutritivas (PSAN)"|"Activities of the project Papas más nutritivas"
215013635|NCT01466231|DRUG|Everolimus|Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
215100092|NCT02716181|DEVICE|Placebo|Topical application of a study placebo cream to involved skin areas twice a day.
215100093|NCT00407017|DRUG|Gatifloxacin|
215100094|NCT00407017|DRUG|Ketorolac LS|
215100095|NCT00407017|DRUG|Pred Forte|
215100096|NCT00407017|DRUG|Moxifloxacin|
215100097|NCT00407017|DRUG|Nepafenac|
214409200|NCT02429609|DEVICE|Moorfields Acuity Chart|
214409201|NCT00671463|PROCEDURE|Pancreatic duct stenting|In the treatment arm, patients will have a pancreatic duct stent placed prior to having their distal pancreatectomy.
214409202|NCT05922436|DRUG|QLG2071|intravenous injection
214409203|NCT05922436|DRUG|Cleviprex®|intravenous injection
215013636|NCT04841798|OTHER|[11C]SL25.1188 PET radiotracer|Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using \[11C\]SL25.1188 PET
215100098|NCT00407017|DRUG|EconoPred Plus|
215100099|NCT02251938|DRUG|DE-109 440 μg|Medium Dose
214409204|NCT06061484|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (RUTF)|Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
214409205|NCT06061484|DRUG|Amoxicillin|Standard weight-based dosing per Ehtiopian national guidelines
214409206|NCT04252820|DEVICE|WarmTouch total body blanket, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room
214409207|NCT01268566|DRUG|MEDI-575|MEDI-575 as an IV infusion.
214409208|NCT02806895|DRUG|JZP-110|
214409209|NCT02806895|DRUG|Placebo|
214409210|NCT03537885|DIAGNOSTIC_TEST|Transcranial Direct Current Stimulation|Electrodes are placed on that head to deliver a non-invasive brain stimulation to the target area.
214409211|NCT03537885|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|A coil is held tangential to the head in order to deliver a non-invasive brain stimulation to the target area.
214409212|NCT03537885|DIAGNOSTIC_TEST|Electroencephalography (EEG)|A cap is placed on the head with sensors to detect brain activity during the intervention.
215100100|NCT04456192|BEHAVIORAL|Indoor Cycling Interval Exercise Training|"The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax."
215100101|NCT05612334|BEHAVIORAL|exercise (5 minutes warm-up-30 minutes walking-5 minutes cooling down)|the breathing exercise group, which constituted the placebo control group, were first informed by the researcher about the correct breathing techniques and was given an informative training brochure prepared by the researcher containing the correct breathing exercise information.
215100102|NCT06245252|OTHER|passive stretching for group A|A description of stretch is performed 3 times per week for 12 weeks. The stretches included (in the order they were applied): Seated knee flexor (bilateral); Seated knee flexor-hip adductor (bilateral); Seated shoulder lateral flexor (bilateral); Supine hip flexor- knee extensor (unilateral). Seated hip external rotators, extensor (unilateral); Seated shoulder extensors, adductors, retractors (unilateral). Supine knee flexor-plantar flexor (unilateral); Prone hip flexor (unilateral); Seated shoulder flexors, depressors (bilateral); Seated shoulder and elbow flexors (unilateral).
215100103|NCT06245252|OTHER|electrical stimulation for group b|reated by 30 minutes electrical stimulation three times per week for 12 weeks
215013637|NCT03673228|BEHAVIORAL|Comprehensive Relapse Prevention Intervention|"This intervention consists of 4 components:~1. Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~2. Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~3. Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~4. Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations"
215013638|NCT03673228|BEHAVIORAL|Standard Treatment Counseling|Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
215013639|NCT03673228|DRUG|Nicotine Replacement Therapy (NRT)|Patients in both arms will be encouraged to receive NRT
215013640|NCT00467467|DRUG|Alfuzosin Hydrochloride|
215013641|NCT02084186|OTHER|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
215013642|NCT02084186|OTHER|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
215013643|NCT00033475|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215013644|NCT05264675|PROCEDURE|primary suture|Primary suture of the EPL-tendon
215013645|NCT05264675|PROCEDURE|EIP-transfer|transfer of the EIP-tendon to the EPL-tendon
215013646|NCT05500846|DEVICE|The Visual Ice Cryoablation System|Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.
215013647|NCT04593329|DRUG|TIRADENTES ASSOCIATION|Tiradentes association tablet
215013648|NCT04593329|DRUG|DIPYRONE|Dipyrone 500 mg
215013649|NCT04593329|DRUG|TRAMADOL|Tramadol 50 mg
215013650|NCT04593329|OTHER|TIRADENTES ASSOCIATION PLACEBO|Tiradentes association placebo tablet
215013651|NCT04593329|OTHER|DIPYRONE PLACEBO|Dipyrone placebo tablet
215013652|NCT04593329|OTHER|TRAMADOL PLACEBO|Tramadol placebo capsule
214409213|NCT00928200|DRUG|Erwinase|"The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion."
215013653|NCT04480580|DIAGNOSTIC_TEST|SARS-CoV-2 Ab|Patient test for specific antibodies for SARS-CoV-2
215013654|NCT01163500|DIETARY_SUPPLEMENT|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
215013655|NCT01163500|OTHER|Placebo|Placebo controlled (dextrin)
214409214|NCT00928200|DRUG|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
214409215|NCT00928200|DRUG|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14.
214409216|NCT00928200|DRUG|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
214409217|NCT00928200|DRUG|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
214409218|NCT00928200|DRUG|Methotrexate|Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
214409219|NCT00928200|DRUG|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
215013656|NCT01866735|OTHER|Standardized Rehabilitation Therapy|
215013657|NCT01063881|DRUG|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
215013658|NCT00186797|PROCEDURE|Allogeneic stem cell transplant|
215013659|NCT00186797|DRUG|Fludarabine, Cyclophosphamide|
215013660|NCT06169670|DEVICE|Viality|"Viality is a lipoaspirate wash system designed to be used in the operating room in conjunction with, and attached to, a user-provided liposuction cannula, a vacuum source, and a waste canister.~Viality is to be used to filter and wash aspirated, harvested autologous adipose tissue for aesthetic body contouring. The system should be used with a legally marketed vacuum or aspirator apparatus as a source of suction. If harvested fat is to be re-implanted, the harvested fat is to be used without any additional manipulation. Viality is not intended to process autologous adipose tissue other than for aesthetic body contouring uses."
215013661|NCT01171573|PROCEDURE|Venepuncture|Venepuncture - Taking blood
215013662|NCT01309100|DEVICE|Investigational Lens|Bausch \& Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
215013663|NCT01309100|DEVICE|Acuvue Oasys Lens|Johnson \& Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
215013664|NCT01309100|DEVICE|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
215013665|NCT01851512|DRUG|T-R (Test-Reference drug)|
215013666|NCT01851512|DRUG|R-T (Reference-Test drug)|
215013667|NCT03556176|BEHAVIORAL|Exercise|Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
215013668|NCT03556176|BEHAVIORAL|Quiet rest|Quiet rest during 30 min
215013669|NCT01895647|DEVICE|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
215013670|NCT00005922|BEHAVIORAL|Partial schedule of pharmacotherapeutic reinforcement|Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
215013671|NCT00005922|DRUG|Dose control for Arm B|Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
215100104|NCT04651491|DRUG|Kagocel|"The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days."
215100105|NCT05633979|DRUG|Trastuzumab deruxtecan|Given by IV (vein)
215100106|NCT05633979|DRUG|Valemetostat|Given by PO
215100107|NCT06041152|DRUG|Psilocybin|2 macrodoses of 25mg separated by one week.
215100108|NCT06041152|DRUG|Placebo|2 doses of placebo separated by one week.
215100109|NCT02516592|DRUG|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
215100110|NCT02516592|DRUG|Salmeterol/fluticasone 50/500 microgrammes|Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
215100111|NCT02395523|RADIATION|Proton Beam Therapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~* Clinical target volume (CTV) = GTV + internal target volume~* Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~* Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
215100112|NCT05916469|DRUG|Levonorgestrel Intrauterine System|52 mg levonorgestrel intrauterine system
215013672|NCT00005922|OTHER|Standard pharmacotherapeutic protocol|Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
215013673|NCT03434366|DRUG|ketamine and dexmedetomidine|intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder
215100113|NCT05916469|DRUG|Norethindrone Acetate|norethindrone acetate 5 mg daily
215100114|NCT02486965|DEVICE|thermode (TSA-II model)|thermal stimulation with test thermode
215100115|NCT02486965|OTHER|Adapted Physical Activity|
215100116|NCT02486965|OTHER|Physical activity|
215100117|NCT06980623|DRUG|Tirzepatide|Exposure group
215013674|NCT03434366|DRUG|ketamine|intranasal ketamine for treatment for autism spectrum disorder
215013675|NCT03434366|DRUG|Saline|intranasal saline for treatment for autism spectrum disorder
215013676|NCT03366415|DRUG|gemcitabine and cisplatin (Induction and adjuvant chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before IMRT and after IMRT.
215013677|NCT03366415|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor
215013678|NCT03366415|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before concurrent chemoradiotherapy.
215013679|NCT03366415|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4Gy to the primary tumor, concurrently with cisplatin 30mg/m² every week.
215013680|NCT01526746|DRUG|Tasimelteon|20mg capsule, once
215013681|NCT01526746|DRUG|Tasimelteon|20mg, once
215100118|NCT06980623|DRUG|Semaglutide|Referent group
215100119|NCT05269550|RADIATION|High-Intermediate Risk Patients-cohort 1|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Six months of androgen deprivation therapy will commence with the end of radiotherapy (concurrent plus adjuvant)
215100120|NCT05269550|RADIATION|High Risk or Very High-Risk Patients-cohort 1|Patients will receive 35Gy/5 fractions to the whole prostate (25Gy to whole Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Pelvic lymph nodes will receive 25Gy/5 fractions synchronous with prostate treatment with a simultaneous boost to imaging involved nodes to a maximum of 35Gy/5 fractions. Eighteen months of androgen deprivation therapy will commence with the end of radiotherapy (concurrent plus adjuvant)
215100121|NCT05269550|RADIATION|High-Intermediate Risk Patients-cohort 2|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Androgen deprivation therapy will commence 3 months before radiotherapy (concurrent plus adjuvant) and will continue for a total of 6 months.
215100122|NCT05269550|RADIATION|High Risk or Very High-Risk Patients-cohort 2|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Androgen deprivation therapy will commence 3 months before radiotherapy (concurrent plus adjuvant) and will continue for a total of 18 months.
214409220|NCT00928200|DRUG|Dexrazoxane|Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
214409221|NCT00568503|DRUG|QAX028|
215100123|NCT01691040|DRUG|NOX-H94|intravenous injection
215100124|NCT01691040|DRUG|Placebo solution|intravenous injection
215100125|NCT01359228|DRUG|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
215100126|NCT01359228|DRUG|Placebo|Placebo 1 tablet three times a day for 14 days.
215013682|NCT00792389|OTHER|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
215013683|NCT00792389|OTHER|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
215013684|NCT00084279|DRUG|Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin|interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
215013685|NCT00674232|DRUG|600 mcg misoprostol|single dose of misoprostol taken orally
215013686|NCT00674232|PROCEDURE|Surgical treatment|Either dilation and curettage or manual vacuum aspiration, as per local protocol
215013687|NCT02845180|PROCEDURE|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
215013688|NCT04367935|DRUG|Pentoxifylline|Pentoxifylline tablets 400mg three times daily for 2 months
215013689|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland
215013690|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^10 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland
215100127|NCT06682494|BEHAVIORAL|Traditional Education|Participants will receive traditional educational handouts focusing on increasing awareness of oral cancer risks, preventive strategies, and the importance of regular dental check-ups. Participants will be provided time to read the handouts based on calculated reading time.
215100128|NCT06682494|BEHAVIORAL|AI-powered Chatbox|The chatbot interaction will be initiated through a provided link, allowing participants to access information and ask questions related to oral health and cancer prevention. The chatbot is programmed to provide accurate information on oral cancer risks, symptoms, preventive measures, and the importance of regular dental check-ups. Participants will be encouraged to interact with the chatbot for a specified duration
214409222|NCT00568503|DRUG|Placebo|
215013691|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland
215013692|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (both glands)|intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland
215013693|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland
214409223|NCT00568503|DRUG|Tiotropium bromide|
214409224|NCT00568503|DRUG|QAX028|
215013694|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland
215013695|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland
215013696|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland
214409225|NCT00568503|DRUG|QAX028|
214409226|NCT03982420|PROCEDURE|Transcarotid Revascularization (TCAR)|Carotid revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
215013697|NCT05581264|BEHAVIORAL|Diabetes Self-Management Education Program|diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
215013698|NCT05845190|OTHER|aerobic exercises|aerobic exercises in form of walking on treadmill
215013699|NCT05845190|OTHER|resistance exercises|60% of One-repetition maximum 3 sets ( 8 to 12 ) repetitions
215013700|NCT00502515|DRUG|SSR180575|Oral, once daily dosing
215100129|NCT03592563|BEHAVIORAL|Neuro-QoL questionnaire|Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
215100130|NCT03922178|DEVICE|Pressure/Volume Combination Catheter|Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.
215013701|NCT00502515|DRUG|Placebo|Oral, once daily dosing
215013702|NCT05275244|DEVICE|KD Intra-Articular® gel|Depending on the joint, 3 injections will be administrated to the patient: KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%) in the case of shoulder and hip, or KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%) in the case of the ankle and base of the thumb. The administration of the infiltrations will be with an interval of one week.
214409227|NCT03222284|DEVICE|Cornerstones4Care Powered by Glooko App|Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
214409228|NCT00601965|DRUG|Escitalopram|20 mg daily oral escitalopram
214409229|NCT00601965|DRUG|Placebo|Placebo pill of daily oral escitalopram
214409230|NCT00601965|BEHAVIORAL|Cognitive behavioral therapy (CBT)|16 weekly 1-hour sessions
214409231|NCT01890161|DRUG|AXP1275|AXP1275 50 mg (2 × 25-mg capsules)
214409232|NCT01890161|DRUG|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules)
214409233|NCT04071522|OTHER|no intervention|no intervention
214409234|NCT02949648|DEVICE|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
214409235|NCT06187974|OTHER|observation|observation
214409236|NCT02897284|BEHAVIORAL|Mindfulness 8 weeks|8 sessions of mindfulness
214409237|NCT02897284|BEHAVIORAL|Mindfulness 2 weeks|2 sessions of mindfulness
214409238|NCT00272285|DRUG|Ramosetron|IV, concomitant administration with dexamethasone
214409239|NCT00272285|DRUG|Granisetron|IV, concomitant administration with dexamethasone
214409240|NCT05350436|BEHAVIORAL|Balance Conditions|"Balance Conditions: (\~ 5 minutes in total)~* Balance Condition 1 (Feet 20cm apart)~* Balance Condition 2 (Feet together)~* Balance Condition 3 (Tandem stance)~Initial measurements of balance conditions serve two purposes: it generates a postural control baseline for us without the attribution of singing conditions, furthermore it allows us to separately measure long-term singing experience's effect on postural control, by assessing tasks differing in difficulty level. Balance conditions will be randomised to prevent a learning effect."
214409241|NCT05350436|BEHAVIORAL|Singing|"Singing Conditions: (\~ 15 minutes)~* Warmup - including jaw and breathing exercises~* Singing Condition 1 (Spoken Happy Birthday - Traditional Tempo)~* Singing Condition 2 (Sung Happy Birthday - Traditional Tempo~* Singing Condition 3 (Spoken Happy Birthday - Fast Tempo)~* Singing Condition 4 (Sung Happy Birthday - Fast Tempo)~* Singing Condition 5 (Spoken Happy Birthday - Slow Tempo)~* Singing Condition 6 (Sung Happy Birthday - Slow Tempo)~Link to singing instructional video:~https://www.dropbox.com/s/tro58i6vx6i6w3a/Singing%20Balance%20Exercise%20Video.mp4?dl=0~Time stamps for the video:~* Warmup (including jaw exercises and breathing exercises) - beginning at 2:55 until 6:06~* Happy Birthday protocol - beginning at 15:26 until 20:21"
214409242|NCT06217029|OTHER|physiotherapy and maxillary traction|"1. Mobility exercises~2. Ultrasound or electric stimulation~3. Application of equipment, such as braces, slings and taping~4. Registered massage therapy~5. Trigger point and myofascial release"
214409243|NCT03106376|OTHER|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
214409244|NCT03106376|OTHER|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
214409245|NCT02112929|DRUG|Hyperpolarized xenon|Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
214409246|NCT00205530|BEHAVIORAL|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
214409247|NCT04357418|OTHER|it is a survey|this interview can be carried out face to face or remotely.
214409248|NCT06100029|DRUG|Lavender|The lavender aroma (L. angustifolia ssp. Angustifolia) is provided by Pranarom International, Ghislenghien, Belgium. Lavender aroma will be contained in a 10 ml glass bottle with a drop stopper and place the bottle within 20 cm of the patient's pillow so that the aroma can reach the patient. The entire course of treatment lasts 5 days.
214409249|NCT06100029|BEHAVIORAL|A2F bundle|A: assess, prevent, and manage pain; B: both spontaneous awakening and breathing trials; C: choice of analgesia and sedation; D: delirium assessment, prevention, and management; E: early mobility and exercise; and F: family engagement/empowerment
214409250|NCT02735187|DEVICE|Blue light treatment|Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
214409251|NCT02735187|DRUG|Vitamin D|Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
214409252|NCT03595943|DIETARY_SUPPLEMENT|Low glycemic index, pulse-based diet|Diet that includes pulses (i.e. meals that contain chickpeas, lentils, beans, or peas)
215013703|NCT02642276|OTHER|Exercise training|Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
215013704|NCT04145271|DEVICE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive damage control procedure for life-threatening abdominal and/or pelvic haemorrhage. It involves temporary occlusion of the aorta with an endovascular balloon, providing proximal control to the site of vascular injury whilst supporting cerebral and myocardial perfusion
214409253|NCT03595943|DIETARY_SUPPLEMENT|Moderate glycemic index hospital diet|Diet that is derived from a regular hospital menu for patients
214409254|NCT03661554|BIOLOGICAL|BCMA CAR-T Cells|The Chinese name of CAR-T cells is chimeric antigen receptor T cells. It is through gene transfection technology, so that patients with T lymphocytes can carry B cell-specific antigens, so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.
214409255|NCT03049436|OTHER|Program of adapted physical activity|
214409256|NCT01348087|DRUG|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
214409257|NCT01007149|DRUG|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
214409258|NCT01007149|DRUG|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
214409259|NCT01105572|DEVICE|Intel Health Guide|An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
214409260|NCT01105572|OTHER|Case Management|Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
214409261|NCT00431795|DRUG|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m\^2 IV every 4 weeks for 6 consecutive cycles
214409262|NCT00431795|DRUG|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m\^2 IV every 3 weeks for 6 consecutive cycles
214409263|NCT01403792|DRUG|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
214409264|NCT01913340|DRUG|Erythropoietin|1000 U/kg/dose IV x 5 doses
215013705|NCT01049672|DRUG|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
214409265|NCT01913340|DRUG|Normal saline|placebo: NS IV x 5 doses
215013706|NCT01049672|DRUG|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
215013707|NCT04875273|DEVICE|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine
215013708|NCT04875273|DEVICE|Kinesiology Tape application|Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine
215013709|NCT02818062|BIOLOGICAL|Cytokines dosage in Aqueous humor|Specify details not covered in associated Arm Description.
215013710|NCT04677036|OTHER|No intervention is given|No intervention given
214409266|NCT02784704|DRUG|Eravacycline|
214409267|NCT02784704|DRUG|Meropenem|
214409268|NCT02784704|DRUG|Placebo|
214409269|NCT05398120|BEHAVIORAL|Skills Group|Adolescents and young adults with a CHR syndrome ages 13-18 will complete feasibility and outcome measures while participating in a weekly skills group for 6 months.
214409270|NCT03034733|DRUG|Dexamethasone|intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
214409271|NCT03034733|DRUG|Sodium Chloride, (24)NaCl 0,9%|intravenous placebo
214409272|NCT06134505|PROCEDURE|Use of Barrier cream group 1 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that Barrier cream 1 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
215013711|NCT01270867|DEVICE|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
215013712|NCT03705611|DIAGNOSTIC_TEST|HIV self-testing only|Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
215013713|NCT03705611|BEHAVIORAL|HIV self-testing secondary accuracy|A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
215013714|NCT00360854|DRUG|erlotinib hydrochloride|
215013715|NCT00360854|GENETIC|mutation analysis|
215013716|NCT00360854|GENETIC|polymorphism analysis|
215013717|NCT00360854|OTHER|laboratory biomarker analysis|
215013718|NCT00360854|OTHER|pharmacological study|
215013719|NCT00360854|RADIATION|radiation therapy|
215013720|NCT01047397|DRUG|1278863A|25mg, 50mg, 100mg
215013721|NCT01047397|DRUG|Placebo|matching placebo
215100131|NCT03922178|DEVICE|Transthoracic echocardiography|A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
215100132|NCT03922178|DEVICE|Transesophageal echocardiogram|A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
215013722|NCT04146909|DIAGNOSTIC_TEST|Hyperinsulinemic-euglycemic clamp|After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ∼90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.
215013723|NCT00000544|BEHAVIORAL|diet therapy|
215013724|NCT03135795|DRUG|Sufentanil|Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.
215013725|NCT03135795|DRUG|dexmedetomidine|Patients received intravenous dexmedetomidine 1μg/Kg for induction.
214409273|NCT06134505|PROCEDURE|Use of Barrier cream 2 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that barrier cream 2 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
214693964|NCT05801809|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
215013726|NCT03135795|DRUG|propofol|Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.
215013727|NCT03135795|DRUG|Rocuronium|Patients received intravenous rocuronium 0.6mg/Kg for induction.
215013728|NCT03135795|DRUG|sevoflurane|Patients received inhalation of sevoflurane (1-2%) for maintenance.
215013729|NCT03135795|DRUG|remifentanil|Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.
215013730|NCT03135795|DRUG|Parecoxib|Parecoxib 40mg was given single intravenously before incision.
215013731|NCT03808909|OTHER|Continuous Labor Support|Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
215013732|NCT00299754|DRUG|Misoprostol|
215013733|NCT06293859|OTHER|Probiotic oat flakes|2 x 10\^9 cfu/g Lactococcus cremoris immobilized on oat flakes
215013734|NCT06293859|OTHER|Conventional oat flakes|Commercial oat flakes
215013735|NCT03335566|DRUG|Sonazoid™|Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
215100133|NCT04735991|BEHAVIORAL|Kapok Initiative|"The detailed process is:~1. After randomization, the Kapok assistant will contact the patient's family~2. The family of the patient joins the Kapok Initiative. They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation."
215100134|NCT00815594|DRUG|bevacizumab|0.05ml, 1.25mg
215100135|NCT01286740|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
215100136|NCT00510744|DRUG|pancreatic enzyme supplement|4 caps with meals, 2 with snacks
215013736|NCT03335566|DRUG|SonoVue®|Single Dose of SonoVue® 2.4 mL as I.V. injection.
215013737|NCT01084135|DRUG|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
215013738|NCT01084135|OTHER|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
215100137|NCT06893939|OTHER|Limited Trophic Feeds (1 day of trophic feeds)|Advancing enteral feeds after 1 day of trophic feeds of 20-25 mL/kg birthweight/day. Advancement of enteral feeds will be by approximately 30 mL/kg birthweight/day until achieving at least 140 mL/kg birthweight/day of enteral feeds. Enteral feeds will consist of parent's own milk or donor human milk.
215013739|NCT00663351|DEVICE|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
215013740|NCT00663351|DEVICE|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
215013741|NCT05371093|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
215013742|NCT05371093|DRUG|Cyclophosphamide|Administered intravenously
215013743|NCT05371093|DRUG|Fludarabine|Administered intravenously
214409274|NCT06134505|PROCEDURE|Use of olive oil in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that olive oil would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
214409275|NCT05717075|BEHAVIORAL|Parents Round|The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.
214409276|NCT00603538|DRUG|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
214409277|NCT05010304|DRUG|Amoxicillin|Two-dose amoxicillin challenge
214409278|NCT05975996|DRUG|Cyclophosphamide added to standard immunosuppressive therapy with herombopag|Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
214409279|NCT05750745|DRUG|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity \& Gum toothpaste is containing 0.454% w/w SnF2.
214409280|NCT05750745|DRUG|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million (ppm) fluoride as Sodium fluoride (NaF).
214409281|NCT05750745|DRUG|Sensodyne Repair and Protect|Sensodyne Repair and Protect toothpaste is containing 5.0% w/w calcium sodium phosphosilicate (CSPS).
214409282|NCT05064761|DEVICE|Sculptra new dilution|Treatment to improve appearance of cellulite.
214409283|NCT05592431|DEVICE|High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).
214409284|NCT05592431|DEVICE|High Frequency Oscillatory Ventilation (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
214409285|NCT03848481|DRUG|CBDV Compound|CBDV is obtained from the Cannabis sativa L. plant and contains a negligible quantity (less than 0.2%) of THC
214409286|NCT03848481|DRUG|Placebo|Placebo oral solution contains matching excipients.
215013744|NCT05371093|DRUG|Lenalidomide|Administered orally
215013745|NCT05371093|DRUG|Rituximab|Administered intravenously
215013746|NCT05371093|DRUG|Doxorubicin|Administered intravenously
215013747|NCT05371093|DRUG|Vincristine|Administered intravenously
214409287|NCT06141668|OTHER|Neurostimulation|Electrical stimulation
214409288|NCT05825417|DRUG|Selexipag|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
214409289|NCT05825417|DRUG|Riociguat|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
214409290|NCT05825417|DEVICE|CardioMEMS pulmonary artery pressure monitor|Implantation and remote monitoring established with patient initiated daily readings
214409291|NCT05825417|DEVICE|Confirm Rx|Implantation and remote monitoring established with automated daily readings / downloads
214409292|NCT02389426|DEVICE|TCD baseline|"Measurement of cerebral circulation parameters with transcranial doppler baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
215013748|NCT05371093|DRUG|Prednisone|Administered orally
215013749|NCT05371093|DRUG|Bendamustine|Administered intravenously
215013750|NCT02362412|DRUG|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
215013751|NCT05103566|DEVICE|gammaCore|Participants will receive two 2-minute non-invasive stimulations to the cervical branch of the vagus nerve (nVNS) three times daily with gammaCore, an FDA cleared device for the acute treatment and prevention of migraine and cluster headache. Intervention will begin within 72 hours post-rupture and end at 10 days post-rupture or discharge, whichever occurs first. The dosing regimen is supported by preclinical models and clinical data.
215013752|NCT04877054|BEHAVIORAL|Adherence Treatment Program|4 telehealth sessions including a combination of psycho/medical education plus a motivational interviewing component.
215013753|NCT04877054|BEHAVIORAL|Education only|The control group will receive an education-only session. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
215013754|NCT06278649|BEHAVIORAL|Relaxation and Guided Imagery|Listening to a 15 minute relaxing pre-recorded script while laying down on an exercise mat
215013755|NCT06126575|DRUG|Elacestrant dihydrochloride|A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).
215013756|NCT03462563|DEVICE|INTERCEED™|when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
214409293|NCT02389426|DEVICE|TCD after bosentan administration|"Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
215013757|NCT03462563|DEVICE|Placebo|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
215013758|NCT06289218|DEVICE|interferential current|IFC plus exercise
215013759|NCT06289218|OTHER|kinesio taping|KT plus exercise
215013760|NCT06289218|OTHER|exercise|exercise only
214409294|NCT02389426|DEVICE|NIRS baseline|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
214409295|NCT02389426|DEVICE|NIRS after bosentan administration|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
214409296|NCT03057561|DRUG|Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)|Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
215013761|NCT06195163|DRUG|Transdermal Gel in Sachet Dosage Form|Transdermal testosterone gel application prior to ovarian stimulation in the study group.
215013762|NCT06195163|DRUG|No pretreatment|No pretreatment prior to the ovarian stimulation in the control group.
215100138|NCT06893939|OTHER|Extended Trophic Feeds (3 days of trophics)|Advancing enteral feeds after 3 days of trophic feeds of 20-25 mL/kg birthweight/day. Advancement of enteral feeds will be by approximately 30 mL/kg birthweight/day after 3 days of trophic feeds. Advancement will occur until achieving at least 140 mL/kg birthweight/day of enteral feeds. Enteral feeds will consist of parent's own milk or donor human milk.
215100139|NCT06750484|DRUG|Trastuzumab Deruxtecan|Participants will receive the study drug trastuzumab deruxtecan (T-DXd) by IV infusion every 21 days. The number of treatment cycles will depend on how participants respond to treatment.
215100140|NCT07058207|BEHAVIORAL|Multimodal weight management program|"This intervention consists of three components:~* Nutritional Counseling:~  * A personalized hypocaloric and high-protein diet is prescribed, based on individual energy requirements with a 20% caloric reduction.~ * The protein intake target is 1.5 g/kg/day to promote fat loss while maintaining muscle mass.~* Exercise Program~  * Home-based, supervised aerobic and resistance training sessions conducted 3 times per week.~ * Each 60-minute session includes: 5 minutes flexibility, 25 minutes aerobic training, 25 minutes resistance training, and 5 minutes balance exercises.~* Behavioral Support~  * Patients receive training in problem-solving strategies, motivation, and emotional self-regulation to improve adherence to both dietary and exercise goals.~ * Health professionals delivering the intervention are trained in behavior change techniques by a clinical psychologist."
215100141|NCT07060339|BEHAVIORAL|Exercise Programme|Midwifery care, breathing exercises, massage and exercise applications were performed on pregnant women in this group during the active phase of labour. Following breathing exercises, massage was applied for 10 minutes using different techniques according to rest and contraction intervals. Pain levels were assessed using the VAS before and after massage. After the massage, the exercise session began; the pregnant woman was first walked along a 50-metre corridor, followed by squatting, squat, four-legged positions, wall stretching movements, and pelvic tilt, swaying, and leg stretching exercises using a Pilates ball. Pain levels were measured using the VAS before and after all exercise applications.
214409297|NCT03057561|DRUG|Cardiac MRI with contrast agent, Gadovist|Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
214409298|NCT03929731|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Intravenous injection of dye-indocyanine green
214409299|NCT01420367|DRUG|metronidazole and cephalzolin|IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
214409300|NCT05227469|BEHAVIORAL|myofunctional therapy|In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
214409301|NCT06383884|DRUG|Patritumab Deruxtecan|Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day cycle as a fixed dose regimen of 5.6 mg/kg Q3W.
214409302|NCT02636881|PROCEDURE|Autologous Chondrocyte Implantation|Implantation of the patients own cartilage cells in a chondral defect of the knee
214409303|NCT02636881|PROCEDURE|Arthroscopic Debridement|Arthroscopic diagnosis and debridement of the lesion, without cartilage therapy. Removal of lose bodies etc.
214409304|NCT06411665|DRUG|Oliceridine|Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.
214409305|NCT06411665|DRUG|Morphine|Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.
214409306|NCT06585020|DRUG|Arikayce|Treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin with ARIKAYCE® during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
214409307|NCT06585020|DRUG|standard treatment|treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
215013763|NCT05103332|DRUG|Indapamide|Indapamide administered orally
215013764|NCT05103332|DRUG|Amlodipine|Amlodipine administered orally
215013765|NCT05103332|DRUG|Olmesartan|Olmesartan administered orally
215013766|NCT05103332|DRUG|Placebo|Placebo administered by SC injection
215013767|NCT05103332|DRUG|Zilebesiran|Zilebesiran administered by SC injection
215013768|NCT06351189|DEVICE|Observation|Patients will be filmed in sitting position in the NETTI DYNAMIC chair, either in static mode or dynamic mode for a period of 3 hours each time.
214409308|NCT05433948|DIAGNOSTIC_TEST|Simultaneous EEG and CRT|"EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal."
214409309|NCT03968991|DIAGNOSTIC_TEST|VISIODOL® (Diagnostic tool)|Tool for assessing pain in the blind subject (with congenital or acquired deficiency)
214409310|NCT01573143|DRUG|Rosuvastatin|Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
214409311|NCT01573143|DRUG|Placebo|Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
214409312|NCT03050840|BEHAVIORAL|Way to Health|An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.
214409313|NCT05585112|DRUG|Lidocaine 2%|The child will be injected with lidocaine 2%,after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker faces pain rating scale
214409314|NCT05585112|DRUG|Articaine 4%|The child will be injected with 4% Articaine, after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and Wong-Baker faces pain rating scale
214409315|NCT02977143|PROCEDURE|Fluid loading of volulyte 300 ml|Administration of volulyte 300 ml and measurement of increase in cardiac index
214409316|NCT03194061|RADIATION|Hypofractionated Radiotherapy|20 fractions of 275cGy 5 days/week
214409317|NCT03194061|DRUG|Weekly cisplatin|Concomitant weekly cisplatin 35mg/m2 x 4 weeks
214409318|NCT00913432|DRUG|masitinib|3 mg/kg/day oral route
214409319|NCT00913432|DRUG|masitinib|masitinib 6 mg/kg/day oral route
214409320|NCT02809911|DEVICE|Provant|
215013769|NCT05611047|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
215013770|NCT05611047|OTHER|Classical cognitive evaluation of several domains:|Information processing speed (IPS) Working memory (WM) Executive functions (EF) Episodic memory (EM) Premorbid intelligence quotient (IQ) Multidomain or complex task
215013771|NCT05611047|OTHER|Ecological evaluation|Virtual reality task : Urban DailyCog©
215013772|NCT05611047|BEHAVIORAL|Patent reported outcomes (PRO's)|"Patent reported outcomes (PRO's) : Beck Depression Inventory (BDI), European Quality of Life-5 Dimensions (EQ-5D-5L) for Health-Related Quality of Life (HRQOL), Multiple Sclerosis Impact Scale-29 Items (MSIS-29), French version of the Modified Fatigue Impact Scale (EMISEP) and State trait anxiety inventory (STAI).~Subjective cognitive deficits: Perceived Deficits Questionnaire (PDQ) and Cognitive Activities Questionnaire (DCAQ)"
215013773|NCT05611047|OTHER|Telerehabilitation : active procedure|The Cognitive rehabilitation (CR) consists of weekly 45 minutes online individual session with the unblinded Speech Therapist.
215013774|NCT05611047|OTHER|Telerehabilitation : comparator procedure|Once per week over a 12-week period completed by daily online exercises performed by the patient 4 days a week.
214409321|NCT04732039|OTHER|Measurement of peak oxygen uptake|Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).
214409322|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
214409323|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
214409324|NCT05502380|DRUG|Standard antibiotic prophylaxis|One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection
215013775|NCT03870321|OTHER|Core training|"In the first week different types of abdominal exercises will be performed: standard, with trunk rotation, extension of the back raising the upper extremity of the body and legs, extension of the back raising one arm and the contralateral leg. In the same way, the subject will raise from the quadruped position one arm and the contralateral leg on each side, and we will ask for the exercise of the front plate, positioning itself in a position of four support points: feet and elbows. When performing the rear bridge exercise the subject will raise the trunk resting on both feet, while in the lateral bridge exercise will be done with support on the right and left side. All exercises will be done for 30 seconds, in 3 series).~During the next three weeks we will continue with the same training, but for each week we will increase 10 seconds per exercise."
215013776|NCT04835753|DEVICE|shock wave|true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)
215013777|NCT04835753|OTHER|traditional physical therapy program|lower limbs muscles stretch and strength in addition to balance and gait training
215013778|NCT02218268|DRUG|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
215013779|NCT02218268|DRUG|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
215013780|NCT04469530|DRUG|Sirolimus|Sirolimus is given at a dose of 2 mg/m2 once daily. The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. The solution can be drunk or administered at once to assure delivery of all of the medication. It is safe for administration through a nasogastric or G-tube. For tablets, the tablet should not be crushed, split, or otherwise altered. As with the liquid dosing form, the tablets should be given within two hours each day and should be at consistent intervals with regard to meals.
215013781|NCT04469530|DRUG|Cyclophosphamide|"A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube."
215013782|NCT04469530|DRUG|Etoposide|A semisynthetic derivative of podophyllotoxin which functions as mitotic inhibitor but does not interfere with microtubular assembly. The drug is administered orally daily, in the formulation appropriate for age.
214409325|NCT06404762|PROCEDURE|tSCTG+ CAF|In the tSCTG group, at the distal end of a second maxillary molar, an incision will be made using a double-bladed scalpel (SKU 10-130-05D; Hu-Friedy, Chicago, IL, USA) bucco-palatally, forming a 1,5 mm thick parallel line. Secondary incisions will be made to separate the graft using a 15c blade on the buccal and palatal sides. Later, the graft will be de-epithelialized extra-orally using a blade
214409326|NCT06404762|PROCEDURE|pSCTG+ CAF|In pSCTG group; the graft will be harvested through a single-incision approach at the lateral palatal mucosa
214409327|NCT00518375|DRUG|Rapamune® (Sirolimus)|
214409328|NCT00518375|DRUG|Neoral® (Cyclosporine)|
214409329|NCT00518375|DRUG|Corticosteroids|Left up to local practice but steroids are typically used perioperatively
214409330|NCT06585540|DRUG|Amisulpride IV Prevention|Patients in this arm will receive Amisulpride 5mg IV as a preventative dose after the induction of anesthesia
214409331|NCT06585540|DRUG|Amisulpride IV Treatment|Patients in this arm will receive Amisulpride 10mg IV for first-line treatment of Post-Operative Nausea and Vomiting in the post-anesthesia care unit.
214409332|NCT06585540|DRUG|Placebo Preventative|Patients in this arm will receive placebo (Normal Saline) while under general anesthesia
215100142|NCT07060339|BEHAVIORAL|Hot Shower Programme|In addition to midwifery care, breathing exercises, massage, and hot showers were administered in this group. Massage was administered for 10 minutes after the breathing exercises, and pain levels were measured using the VAS before and after the massage. After the massage, considering the risk of the pregnant woman falling, she was seated on a stool in the shower, and warm water at a temperature of 36.5-37.8 °C was applied to the lower abdomen and sacrum region during contractions for 15 minutes. To prevent chills, the application was repeated at 10-minute intervals, and pain levels before and after were again assessed using the VAS.
214409333|NCT06585540|DRUG|Placebo Treatment|Patients in this Arm will receive placebo as first line treatment of Post-Operative Nausea and Vomiting in the Post Anesthesia Care Unit
214409334|NCT01249742|BEHAVIORAL|Internet intervention|Our intervention, Sugarsquare, is a secured treatment environment only accessible by patients of the KDCN and members of the treatment team. Sugarsquare consists of two main sections. The first section is a semi-public setting on which adolescents can exchange experiences with their diabetes (care) through a forum and a real time chat-application. All patients and treatment team members can see all messages posted here. The second section consists of patients' individual pages with treatment overview and an application for private interaction with the treatment team. Patients can only access their own individual page; treatment team members can access pages of all patients. Sugarsquare is a secured webpage, accessible only through computers equipped with the right certificate (access device) and by using the appointed username-password combination.
215013783|NCT04469530|DRUG|Celecoxib|The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
214409335|NCT06197880|OTHER|Anterior teeth retraction|En masse retraction of the upper and lower anterior segments using maximum anchorage
214409336|NCT03796494|PROCEDURE|Straight abutment|This is the classic abutment, straight and anti-rotational for dental implants which have been tested before
214409337|NCT03796494|PROCEDURE|Slim abutment|This is the new concept of the prostheses abutment, slim and anti-rotational to improve the width of biologic space
214409338|NCT02221479|DRUG|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
214409339|NCT02221479|DRUG|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
214409340|NCT02994706|PROCEDURE|Home Monitoring|Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
214409341|NCT02994706|OTHER|Clinical Care|Participants selected for this arm will continue to receive routine clinical care.
214693965|NCT02645383|DEVICE|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
215013784|NCT04419142|PROCEDURE|Total infrapatellar fat pad excision|Exposure for total knee arthroplasty (TKA) commonly includes total excision of the infrapatellar fat pad (IPFP). The rationale behind this is to obtain improved access to the lateral tibial plateau allowing a more accurate bone cut, baseplate placement and easier management of soft tissue interposition in the bone and cement interface. However, there is growing concern that as the IPFP is a highly vascularized and innervated fibrous adipose tissue filling the anterior compartment of the knee, its complete excision may have a detrimental effect on knee biomechanics and ultimately, TKA outcome. The reason for this effect has been suggested to be patellar tendon (PT) scarring and shortening via ischemic contracture following impaired vascularization, maintenance and biological repair of the tendon.
214409342|NCT03548922|OTHER|Tanner stage|a scale of pubertal development in children, adolescents
214409343|NCT03548922|OTHER|Risser stage|a measure showing the growth left in the spine
214409344|NCT03548922|OTHER|Pressure of correction|an indirect parameter of the chest wall's flexibility. It is defined as the pressure applied to the patient, in the most protruding area of the chest, needed to accomplish a proper shape of the thorax.
214409345|NCT03548922|OTHER|Pectus carinatum protrusion|distance from the point of maximum protrusion to the estimated normal level of chest wall
214409346|NCT01092624|DRUG|Solifenacin|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
214409347|NCT01092624|DRUG|Placebo|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
214409348|NCT01092624|DEVICE|Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
214409349|NCT04958187|DRUG|ANG-3777|Arm assigned to this intervention will receive 2 mg/kg, IV
214409350|NCT00791531|DRUG|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
214409351|NCT00783692|DRUG|vedolizumab|Vedolizumab for intravenous infusion
214409352|NCT00783692|OTHER|Placebo|Placebo intravenous infusion
214409353|NCT03750656|DRUG|Hyoscyamine|Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent
214409354|NCT03750656|DRUG|Tamsulosin|Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
214409355|NCT03265704|OTHER|AGA - Control group|Data processing from Patient Medical Files
214409356|NCT03265704|OTHER|SGA - Control group|Data processing from Patient Medical Files
214409357|NCT03265704|OTHER|AGA-PIH Study group|Monitoring PIH-related changes in the newborn
214409358|NCT03265704|OTHER|SGA-PIH Study group|Monitoring PIH-related changes in the newborn
214409359|NCT03591289|DRUG|NMB with rocuronium bromide|Moderate versus deep neuromuscular block Not a device study
214409360|NCT03906747|OTHER|Interviews, questionnaire and focused group discussions|"To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged."
214409361|NCT03906747|OTHER|Review of medical records|"Electronic medical records will be reviewed to collect the following data:~1. Proportion of patients who fits criteria of EOL who died within 48 hours;~2. Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~3. Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~4. Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration"
214409362|NCT03226730|BEHAVIORAL|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
214693966|NCT02645383|DEVICE|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
214693967|NCT05479409|RADIATION|Neoadjuvant radiotherapy|radiation therapy combined with chemotherapy prior to surgery
214409363|NCT03226730|BEHAVIORAL|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
214409364|NCT00420472|DRUG|mycophenolate mofetil [CellCept]|
214409365|NCT05167747|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.).~Oral administration: 2 tablets/day at evening meal"
214409366|NCT05167747|OTHER|Placebo|Oral administration: 2 tablets/day at evening meal
214409367|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
214409368|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
214409369|NCT01096056|BIOLOGICAL|Fluarix|Intramuscular administration, 1 dose
214409370|NCT03237221|DRUG|Treat patient according to Global Initiative for Asthma (GINA) guideline|Treat patient according to Global Initiative for Asthma (GINA) guideline
214409371|NCT02237079|DRUG|Bazedoxifene/Conjugated Estrogens (BZA/CE)|Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
214409372|NCT02237079|DRUG|Placebo Oral Tablet|Daily placebo tablet
215013785|NCT04419142|PROCEDURE|Partial infrapatellar fat pad excision|It has been suggested in the literature that partial infrapatellar fat pad excision instead of total excision would diminish the potential negative effect on patellar tendon and knee biomechanics. However, there is only limited data in the literature and choice of total/partial infrapatellar fat pad excision in TKA remains debatable.
215013786|NCT06560905|DRUG|68Ga-PSMA|This is an imaging radionuclide tracer and is in chemical form. Up to 200 MBq. Route of administration is Intravenous.
215100143|NCT07060339|BEHAVIORAL|Combined Application (Exercise + Hot Shower)|In addition to midwifery care, breathing exercises, massage, exercise and hot shower treatments were performed for this group. As in Groups 1 and 2, the application began with breathing exercises, followed by massage, exercise, and hot showers in sequence. Pain levels were assessed using the VAS before and after each application, and measurements were taken again during the massage. Ten-minute breaks were given between applications to allow the pregnant women to rest, and the applications were continued alternately.
215100144|NCT07060339|BEHAVIORAL|Pharmacological Intervention|In this study, the fourth group was evaluated as the intervention 4 group and was followed up in accordance with standard interventions frequently applied during the birth process. Pregnant women in this group received routine midwifery care, massage treatments to promote relaxation, and breathing exercises in accordance with hospital protocols. In addition, pharmacological pain management methods commonly used in the clinic were also applied in this group.
215100145|NCT07089498|OTHER|Dietary Intervention (Low Fodmap Gluten Free Diet)|The intervention provides the administration of a Low Fodmap Diet to celiac or non celiac patients with functional gastrointestinal disorders
215100146|NCT07089108|BEHAVIORAL|Arabic NODA Video-Based Diagnostic Assessment|NODA (Naturalistic Observation Diagnostic Assessment) is a telehealth-based diagnostic tool for Autism Spectrum Disorder (ASD) that guides caregivers to record structured home videos of their child's behavior using a smartphone app. In this study, a culturally adapted Arabic version of NODA was used to capture four standardized behavioral scenarios, which were later reviewed by licensed clinicians for diagnostic evaluation.
215100147|NCT07088042|DRUG|Limitless Allzyme|Received Limitless Allzyme Max® Trypsin/Chymotrypsin/Bromelain(15 microkatal/42microkatal/240 GDU)
214409373|NCT03020355|PROCEDURE|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
214409374|NCT03020355|PROCEDURE|not Placental Blood Drainage|In the control group, the clamped cord will not released.
214409375|NCT00362752|DRUG|Norfloxacin|400 mg po bid
214409376|NCT00362752|DRUG|Placebo|Placebo 400 mg po bid
214409377|NCT05492890|DEVICE|Dexcom G6|Continuous glucose monitoring
214409378|NCT02113163|DRUG|Metformin Eicosapentaenoate|
214409379|NCT02113163|DRUG|Metformin HCl and Vascepa|
214693968|NCT03226223|DRUG|Intranasal Methamphetamine|Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
215013787|NCT05704036|DRUG|Transdermal estrogen|Transdermal estradiol 0.1 mg/day, applied once weekly
214693969|NCT03317275|DEVICE|18F-Fluoride-PET/MRI|facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.
215013788|NCT05704036|DRUG|Progesterone|Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
215100148|NCT07088042|DRUG|Oral tablets of Alphintern®|received (Trypsin/Chymotrypsin 5 micro Katals/14 micro Katals)
215013789|NCT03651336|DEVICE|ARGOS-IO Sensor Pressure System|The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
215013790|NCT02223130|BEHAVIORAL|Cognitive Behavioral Therapy techniques|Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
215013791|NCT04860583|OTHER|Renal ultrasound|
215013792|NCT01284088|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
215013793|NCT01284088|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
215013794|NCT01740427|DRUG|PD-0332991|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
215013795|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
215013796|NCT01740427|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
215013797|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
215013798|NCT05800847|DRUG|Gabapentin|Gabapentin will be administered for 2 days at 100 mg q8h for titration to avoid side effects. The next 12 days, gabapentin will be taken at 300 mg q8h.
215013799|NCT05800847|DRUG|Placebo|Placebo will follow the same dosing pattern as gabapentin to allow for blinding. Placebo will be encapsulated with a gelatin capsule to mimic the look of gabapentin.
214409380|NCT02708862|DEVICE|Preoxygenation|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
215013800|NCT02051283|OTHER|RFA|RFA
215013801|NCT05890677|PROCEDURE|Surgical Intervention|LVA (Lymphovenous Anastomosis) and VLNT (Vascularised Lymph Node Transfer) are two advanced microsurgical techniques that are increasingly implemented in clinical practice in specialized centers and that are already carried out after health insurance application according to local standard of care. They have been studied in their respective mode of action as well as in their effectiveness in treating chronic BCRL (Breast Cancer-Related Lymphedema) in a multitude of mostly observational and single center studies with highly encouraging results. Patients in the interventional arm A will receive surgery with one of the two approaches or a combination of both, in a one or two-stage method, at the discretion of the treating surgeon. Depending on local standards one or both of the above might be combined with liposuction to the affected arm in a one or two-stage approach as well.
215100149|NCT07088042|DRUG|Cataflam® 50 coated tablet|of Cataflam 50 mg as part of their treatment protocol
215100150|NCT07089160|BEHAVIORAL|Online Survey (Decision Fatigue Scale and Emotional Exhaustion Scale)|Participants will complete an online survey including demographic questions, the Decision Fatigue Scale (DFS), and the Emotional Exhaustion subscale of the Maslach Burnout Inventory.
215100151|NCT07087717|DEVICE|Split-Mouth Placement of an implant with a moderately rough surface (DCC).|Surgical placement of a dental implant in canine area (left or right, assigned by flipping a coin) of the mandibular bone of the patient.
215100152|NCT07087717|DEVICE|Split-Mouth Placement of an implant with a hybrid surface (MSC).|Surgical placement of a dental implant in canine area (left or right, assigned by flipping a coin) of the mandibular bone of the patient.
215100153|NCT05425680|OTHER|Core muscle training|Combining virtual reality technology and waist wearable sensors, training the pelvis and lumbar spine movements as the main training goal, it is estimated that two 1-hour training sessions per week, a total of 6 weeks of training, to improve the core muscle of patients with lumbar degenerative diseases muscle strength.
214409381|NCT03571243|OTHER|no intervention|observational study
215013802|NCT05890677|PROCEDURE|Conservative Complex Physical Decongestion Therapy|Patients randomized to the control arm will receive CDT (Conservative Complex Physical Decongestion Therapy), which currently is considered as the best available standard of care. For this, patients will be referred to one of the dedicated LE (physical/skin) therapy clinics, if not already treated by one, according to their place of residence for continuation of standard conservative therapy. Recommendations to the procedures and treatment frequency of the conservative therapy will be made, but CDT will be done at the discretion of the treating physiotherapist.
215013803|NCT06549374|OTHER|blood sampling|"After informing eligible patients (or their trusted support person, relative/guardian/curator where applicable) and in the absence of any opposition, they are included in the research.~Blood samples from an arterial catheter already in place will be taken every day from D1 to D7, then every 72 hours until discharge from intensive care, or until D28. For each of these samples, a maximum volume of 4 ml will be collected in a heparinized tube. Samples will not be taken if the hemoglobin level is below 7g/dl. For patients undergoing controlled surgery, the D1 sample will be taken as soon as possible after induction of anaesthesia.~Patients will be monitored until discharge from intensive care, or until D28 at the latest. Apart from the blood samples included in this study, all other examinations will be carried out as part of routine management. Data will be collected exclusively from medical records."
215100154|NCT07088536|OTHER|Occupational Status Survey and Telephone Follow-up and Quality-of-Life Assessment in a subset of patients|Collection of demographic, employment, and clinical data at hospital admission, with additional EQ-5D-5L quality-of-life questionnaire and telephone follow-up for occupationally active patients undergoing major uro-oncological surgeries or urinary tract stone procedures.
214409382|NCT02758262|DEVICE|Noninvasive brain stimulation|
215013804|NCT06100042|DRUG|BDP/FF/G|"BDP/FF/G is an extrafine single inhaler triple therapy available in two dosage strengths:~* Medium strength (MS) containing 100 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide);~* High strength (HS) containing 200 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide)."
215013805|NCT06462586|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
215013806|NCT06462586|DRUG|Placebo|Matching capsules administered orally, once daily
215013807|NCT04906421|DRUG|TVB-2640|Oral dose, tablet
215013808|NCT04906421|OTHER|Placebo|Oral dose, tablet
215013809|NCT05240885|OTHER|Stable tracer infusion in a postabsorptive state|Multiple stable-labeled tracers of amino acids, ketoacids, glycerol, short-chain fatty acids
215013810|NCT04796207|DIETARY_SUPPLEMENT|Fish Oil (DPA+EPA 2:1 ratio) Capsules|The Treatment Arm intervention consists of providing participants with 3 grams of DHA and EPA (2:1 weight ratio) in capsular form. In order to meet the required 3 grams of DHA and EPA, participants were given 6 capsules to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 5 times a week during the regular football season.
215013811|NCT04796207|DIETARY_SUPPLEMENT|High Oleic Safflower Oil Capsules|"The Placebo Arm intervention consists of providing participants with 3 grams of high-oleic safflower oil in a 1:1 allocation ratio in capsular form. In order to maintain the study masking, participants in the Placebo Arm were given 6 capsules (the same as the Treatment Arm) to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 5 times a week during the regular football season."
215013812|NCT02084342|DRUG|tranexamic acid and sodium chloride injection|10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
215013813|NCT02084342|DRUG|normal saline|100ml, IV for 30min,before incision.
215013814|NCT02084342|DRUG|desmopressin acetate injection|0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
215013815|NCT04443608|DRUG|Patiromer Powder for Oral Suspension [Veltassa]|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
215013816|NCT04443608|DRUG|Placebo|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
215013817|NCT00000335|DRUG|Morphine|
215013818|NCT04828967|OTHER|Hypnosis|Hypnosis is added to the conventional group
214409383|NCT04380844|OTHER|Beprevent|10 will become part of the intervention group. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
215013819|NCT01738178|DRUG|Caffeine|
215013820|NCT01738178|DRUG|Placebo|
215013821|NCT01221909|DRUG|Tranexamic acid|Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
214409384|NCT05536466|PROCEDURE|bariatric surgery|bariatric surgery
215013822|NCT01221909|DRUG|saline solution|5cc saline solution
215013823|NCT00115388|PROCEDURE|Screening for chlamydia using self-taken vaginal swabs|Women in the intervention group will be tested for chlamydia and those found to be infected will be referred for treatment and partner notification
215013824|NCT01663376|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 \~3x10e8 cells
215013825|NCT03394573|OTHER|OCT guided treatment arm|Intravitreal injection of Aflibercept for DME OCT guided
215013826|NCT03394573|OTHER|VA guided treatment arm|Intravitreal injection of Aflibercept for DME VA guided
214409385|NCT02594176|DEVICE|FLEXISEQ®|applicable gel
215013827|NCT03509584|RADIATION|hypofractionated radiotherapy|Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction
215013828|NCT03509584|DRUG|nivolumab|administration of nivolumab
215013829|NCT03509584|DRUG|Ipilimumab|administration of ipilimumab
215013830|NCT02473744|OTHER|subcutaneous drainage|After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
215013831|NCT00001931|DRUG|N-0923|
215013832|NCT04299620|DEVICE|Digital Image Analysis|Analysis of images
215013833|NCT04299620|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
215013834|NCT04299620|PROCEDURE|Transrectal Ultrasound|Undergo transrectal ultrasound
215013835|NCT02455180|DRUG|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
215013836|NCT03975114|DRUG|Chemotherapy|Any approved first line chemotherapy regimen at Investigators' choice
215013837|NCT03975114|DRUG|Durvalumab|Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
215013838|NCT03975114|DRUG|Tremelimumab|Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)
215013839|NCT03294655|BEHAVIORAL|Pilot Resilience Building Intervention|The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.
215013840|NCT00425139|BEHAVIORAL|Re-Mission|
215013841|NCT03407586|DIAGNOSTIC_TEST|Point-of-care STI testing|All participants underwent point-of-care STI testing (GeneXpert), and if diagnosed with a STI were offered immediate therapy, and expedited therapy, if indicated.
214409386|NCT02594176|DEVICE|Placebo|applicable gel
214409387|NCT00000821|DRUG|Aldesleukin|
214409388|NCT03568162|DRUG|ISB 830 - Part 1 Group 1|Subcutaneous injection (SC) every 2 weeks
214409389|NCT03568162|DRUG|ISB 830 - Part 1 Group 2|Subcutaneous injection (SC) every 2 weeks
214409390|NCT03568162|DRUG|ISB 830 - Part 1 Group 3|Subcutaneous injection (SC) every 2 weeks
214409391|NCT03568162|DRUG|Placebo - Part 1 Group 4|Subcutaneous injection (SC) every 2 weeks
214409392|NCT03568162|DRUG|ISB 830 - Part 2 Group 5|Subcutaneous injection (SC) every 2 weeks
214409393|NCT03568162|DRUG|Placebo - Part 2 Group 6|Subcutaneous injection (SC) every 2 weeks
214409394|NCT04914312|DIETARY_SUPPLEMENT|Maqui berry/omeg-3 fatty acids|2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
214409395|NCT04914312|DIETARY_SUPPLEMENT|Placebos|4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
215013842|NCT04994236|DRUG|Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)|The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
215013843|NCT03022214|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
215013844|NCT03022214|DIETARY_SUPPLEMENT|Intervention|"Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~* EnduraCell broccoli sprout powder: 3 capsules~* Bulk Powders Green tea extract: 1 capsule~* Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal"
215013845|NCT00362609|DRUG|pantoprazole|
215013846|NCT00508846|BEHAVIORAL|Questionnaire|Two-part telephone questionnaire lasting about 60 minutes total.
215013847|NCT00311805|BIOLOGICAL|Autologous Stem Cells (CD34+)|Intramuscular Injections
215013848|NCT01746160|DRUG|C1 Implant|Patients treated with dental implants.
214409396|NCT01368120|DEVICE|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
215013849|NCT05138640|OTHER|Not applicable. The study is designed as an observational cohort study|Not applicable. The study is desigend as an observational cohort study
215013850|NCT00559351|PROCEDURE|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
215013851|NCT00559351|DRUG|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
214409397|NCT01368120|DEVICE|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
214409398|NCT01368120|DEVICE|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
214409399|NCT01793272|OTHER|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
214409400|NCT01110174|DIAGNOSTIC_TEST|HD PET/CT|imaging
214409401|NCT02471391|DRUG|ABT-199|
214409402|NCT02471391|DRUG|Ibrutinib|
214409403|NCT04827459|BEHAVIORAL|Sleep Coach App|Participants will be encouraged to interact with the mobile app daily for as much time as they wish, or for as little as 5 - 10 minutes, over a 7-week period.
215013852|NCT00559351|RADIATION|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
215013853|NCT03897192|DRUG|Bevacizumab|Anti-vascular endothelial growth factor (VEGF)
215013854|NCT02622022|DRUG|Morphine hydrochloride|
215013855|NCT02622022|OTHER|Placebo|
215013856|NCT03572114|DIAGNOSTIC_TEST|3Tesla MRI|"1. A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content~2. Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).~3. 1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)~4. conventional FLAIR sequence"
215013857|NCT03572114|BEHAVIORAL|Burke-Fahn-Marsden Dystonia Rating scale|internationally standardized examination/quantification of dystonia
215013858|NCT03572114|BEHAVIORAL|MDS-United Parkinsons Disease Rating Scale, Part III|most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society
214409404|NCT02801929|DRUG|Coppertone (BAY987518)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - SR15-72\_V27-010).
214409405|NCT00002784|BIOLOGICAL|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
214409406|NCT00002784|DRUG|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
214409407|NCT00002784|DRUG|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
214409408|NCT00002784|DRUG|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
214409409|NCT00002784|DRUG|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
214409410|NCT00002784|DRUG|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
214409411|NCT00002784|DRUG|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
214409412|NCT00002784|DRUG|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
214409413|NCT00002784|DRUG|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
215013859|NCT03572114|BEHAVIORAL|Beck Depression Inventory|internationally standardized examination to quantify traits of anxiety and depression
215013860|NCT03572114|BEHAVIORAL|MoCA: Montreal Cognitive Assessment:|internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism
215013861|NCT01807104|PROCEDURE|Anterior Approach / Posterior Approach|compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
215013862|NCT01807104|PROCEDURE|Anterior versus Posterior Approach for total hip replacement|Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
215013863|NCT05033600|DEVICE|S.C.I.O.|The devices read, emit and entrain Electromagnetic waves of the body.
215013864|NCT05618847|DEVICE|Acapella,ACBTS|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
215013865|NCT05618847|OTHER|ACBTs|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
215013866|NCT02137681|DRUG|Rituximab|Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
215013867|NCT02278237|BEHAVIORAL|VME Group|Received inhaler education through VME (virtual education module)
215013868|NCT01663805|DRUG|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
215013869|NCT03084679|OTHER|Aerobic exercise in treadmill|30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.
215013870|NCT03084679|OTHER|Local strengthening exercises|15 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.
215013871|NCT03084679|OTHER|Stretching exercises|5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)
215013872|NCT00443326|DRUG|AMG 714|Dosing Regimen is 6 Doses over 3 Months
214409414|NCT00002784|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
214409415|NCT00002784|RADIATION|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
214409416|NCT00002784|RADIATION|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
214409417|NCT00925730|DRUG|Pimecrolimus|
214693970|NCT03317275|PROCEDURE|facet injection|facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively
214693971|NCT03317275|OTHER|pain assessment by VAS|VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
214693972|NCT01963299|DRUG|5 ml Ropivacaine 10% + physiological saline|
214693973|NCT01963299|DRUG|5 ml Ropivacaine 10% + Clonidine 1 µg/kg|
215013873|NCT06294353|DEVICE|WELT-ED (CBT based DTx)|The product delivers Cognitive Behavioral Therapy for Eating Disorders (CBT-ED) through a software interface (iOS and Android), designed to engage patients in a structured and interactive manner. It operates by analyzing patterns in the patient's lifestyle and eating data, identifying problematic behaviors associated with their eating disorder. Based on this analysis, the software sets daily learning objectives aimed at fostering positive cognitive and behavioral habits. By providing tailored guidance and support, the product seeks to assist patients in making sustainable changes, ultimately contributing to the improvement of eating disorder symptoms. This approach combines the principles of CBT-ED with the convenience and accessibility of digital technology, offering a personalized therapeutic experience to support patients in their recovery.
215013874|NCT06294353|BEHAVIORAL|Standard Treatment|In the control group, from screening/baseline (Visit 1) to 8 weeks (Visit 5), counseling and support therapy will be conducted at all visits. Participants can continue taking SSRI medications and other antipsychotic drugs that they were already taking for the treatment of eating disorders during the trial period. However, the intake of any additional antipsychotic drugs, other than those already being taken (including SSRIs), is prohibited during the trial period.
215013875|NCT01416051|DIETARY_SUPPLEMENT|Olibra|Fractionated palm oil and fractionated oat oil in the proportion of 95:5
215013876|NCT01416051|OTHER|Placebo|100% milk fat
215013877|NCT06538493|BEHAVIORAL|JUMPSTART-ANAI|"Patient questionnaire about experiences, preferences, and concerns regarding ACP followed by feedback form with tips for initiating ACP conversation with provider at next clinical visit."
215013878|NCT04483947|DRUG|AZD2693|Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
215013879|NCT04483947|OTHER|Placebo|Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
215013880|NCT05280808|DEVICE|Experimental phone app used for self-fitting of hearing aids|This software allows participants to set up hearing aids as appropriate for their hearing loss
215013881|NCT06100445|BEHAVIORAL|Semi structured interviews|Gaining qualitative data
215013882|NCT04291859|DRUG|Lu AF28996|capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
214409418|NCT04355130|DIETARY_SUPPLEMENT|Iron, vitamin B12 and acid folic supplementation|Vitamin and iron supplementation is administered one-two weeks before donation, and consist of iron supplementation (i.v. infusion of 20 mg/Kg ferric carboxymaltose in saline 100 ml), s.c. injection of 1 mg of vitamin B12 and acid folic 5 mg/die per os until day +15 post BM donation. BM collection is carried out by the transplant team and a maximal dose of 20-22 ml/Kg of the donor body weight is collected under general anesthesia (induction with fentanyl 1-3 mcg/Kg, Propofol 2-3 mg/Kg, rocuronium 0,6 mg/Kg and mantenaince with sevoflurane 0,8 MAC). Noninvasive cardiac output, blood pressure and hemoglobin monitoring are carried out during the entire procedure and in in the recovery room using the ClearSight™ system (Edwards Clinical) and the Radical Pulse co oxymeter (Masimo). After discharge from the hospital, donors will be revaluated on day + 7 after BM collection, and blood tests will be repeated in outpatient setting.
214409419|NCT03717194|DRUG|Ertugliflozin|Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
214409420|NCT03717194|DRUG|Placebo|Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
214409421|NCT00725413|DRUG|etonogestrel implant (Implanon)|subdermal etonogestrel implant
214409422|NCT03994146|DRUG|Remifentanil|"Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
215013883|NCT01374464|OTHER|Interscalene brachial plexus block|"4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine"
214409423|NCT03994146|DRUG|Sodium Chloride 9mg/mL|"Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
214409424|NCT05950113|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
214409425|NCT05950113|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
214409426|NCT05950113|PROCEDURE|Computed Tomography|Undergo PET/CT
214409427|NCT05950113|DRUG|Cyclophosphamide|Receive IV
215013884|NCT00484900|DRUG|Co-Arinate FDC|
215100155|NCT07088029|PROCEDURE|Indirect occlusal veneer (Occlusal veneer of lithium disilicate)|Split-mouth design, (right/left posterior tooth) will be restored with an Indirect occlusal veneer (Occlusal veneer of lithium disilicate). Indirectly fabricated occlusal veneers of lithium disilicate allow better control and design of the occlusal anatomy and proximal contacts, in addition to possessing better mechanical properties and fracture strength when compared to direct occlusal veneers. However, indirect occlusal veneers are lab fabricated, consequently, more clinical visits are required.
214409428|NCT05950113|PROCEDURE|Echocardiography|Undergo ECHO
214409429|NCT05950113|DRUG|Fludarabine|Receive IV
214409430|NCT05950113|OTHER|Fludeoxyglucose F-18|Receive IV
214409431|NCT05950113|OTHER|Immunotherapy|Receive CART-BCMA/CS1 cells IV
214409432|NCT05950113|PROCEDURE|Leukapheresis|Undergo leukapheresis
214409433|NCT05950113|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214409434|NCT05950113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214409435|NCT06006091|DRUG|Letrozole|Different endothelial preparations according to groups, see arm descriptions for details
214409436|NCT03743922|DRUG|Calciferol|calciferol capsule
214409437|NCT03743922|DRUG|Placebo|placebo capsule
214409438|NCT04160585|OTHER|There is no intervention.|There is no intervention.
214409439|NCT03788291|DRUG|Acalabrutinib|100 mg by mouth twice a day starting on day 8 of cycle 1
214409440|NCT03788291|DRUG|Rituximab|Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.
214409441|NCT05588791|DIAGNOSTIC_TEST|whole-body computed tomography|whole-body computed tomography prescription in the emergency department : an identification tool for low risk patients
214409442|NCT06118736|PROCEDURE|Temporary Medial Hemi-epiphysiodesis of the proximal femur|Temporary Medial Hemi-epiphysiodesis of the proximal femur
214409443|NCT05503420|DEVICE|Masticatory muscle training exerciser|In addition to the normal stroke rehabilitation training, the participants will be instructed on an active range of motion (AROM) exercise to improve coordination of the masticatory muscles. This part will be performed with a 5-second hold at the end of the range of motion for each motion, with 10 repetitions performed for each motion. In addition, each participant will be provided with a device, a U-shaped apparatus covered by silicon and having 3 small springs inside to provide resistance during chewing to be placed inside the mouth for carrying out a chewing exercise. The participant will be instructed to perform a chewing exercise using the device for around 10 minutes each time, twice a day, and 7 days per week. The exercise includes isotonic and isometric muscle training.
215013885|NCT00484900|DRUG|Coartem|
215013886|NCT05067270|DRUG|Sodium Citrate|Administered SC infusion.
215013887|NCT05067270|DRUG|Treprostinil|Administered SC infusion.
215013888|NCT05067270|DRUG|Humalog diluent|Administered SC infusion.
215013889|NCT05067270|DRUG|Magnesium Chloride|Administered SC infusion.
215013890|NCT05577104|PROCEDURE|Negative pressure wound therapy (NPWT)|For patients in the NPWT group, the wound bed preparation was facilitated by vacuum-assisted closure (VAC).
215013891|NCT05577104|PROCEDURE|conventional moist dressings|For patients in the control group, the wound bed preparation was facilitated by conventional dressing change method (with alginates ).
215013892|NCT02050295|PROCEDURE|Nerve block washout|Saline will be infused through the perineural catheter to reverse motor block.
215013893|NCT02050295|PROCEDURE|Sham washout|Infusion of saline to maintain catheter patency.
215013894|NCT02050295|DRUG|Saline|
215013895|NCT06132750|OTHER|No intervention|No intervention
215013896|NCT04419974|DIAGNOSTIC_TEST|Molecular Diagnosis|Double-blind molecular diagnosis for the SCA3/MJD mutation.
215013897|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Baseline|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
215013898|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Baseline|"Blood collection on baseline for evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
215013899|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Baseline|Participants fill out 2 self-reported quality of life questionnaires.
215013900|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 12 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
215013901|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 12 months|"Blood collection 12 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
215013902|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 12 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
215013903|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 24 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
215013904|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 24 months|"Blood collection 24 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
215013905|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 24 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
215013906|NCT00469027|BIOLOGICAL|eNOS transfected EPCs will be delivered via a PA line|incremental dosing over 3 days
215013907|NCT02186171|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection once a month.
215013908|NCT02186171|DRUG|Placebo|Administered by subcutaneous injection once a month.
215013909|NCT06814093|PROCEDURE|Robotic surgery|Robotic surgery for radical resection of middle and low rectal cancer
215100156|NCT07088029|PROCEDURE|Direct occlusal veneer ( Occlusal Veneer of Composite resin)|Split-mouth design, (right/left posterior tooth) will be restored with an occlusal veneer composite resin (Direct occlusal veneer). Directly fabricated occlusal veneers are a conservative approach, however, it requires a great skill from the operator to assure good margins and occlusal anatomy. Direct veneers are fabricated from composite resin and can be finished in a single visit, but longer chair time is required, in addition to the low wear resistance compared to ceramics. However, direct occlusal veneers have the benefit of resiliency close to that of natural dental tissue.
214409444|NCT01155999|DRUG|T1225|one drop twice daily (morning and evening) in each eye from Day 0 to Day 2
214409445|NCT01155999|DRUG|Tobramycin|1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6
215013910|NCT06814093|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery for radical resection of middle and low rectal cancer
215013911|NCT05695482|OTHER|Neuromuscular training exercises|The 6-week exercise intervention consists of 25-minute group sessions of Neuromuscular training supervised by a researcher.
215013912|NCT05695482|OTHER|Hip abductors muscular strength exercises|The 6-week exercise intervention consists of of 20-minute group sessions of progressive resistance training, supervised by a researcher.
215013913|NCT04309630|PROCEDURE|intercostal block|pain control by intercostal block
215013914|NCT04309630|PROCEDURE|erector spina plane block|pain control by erector spina plane block
215013915|NCT03591796|DEVICE|HFOV|Ventilated infants were randomized to HFOV
215013916|NCT03591796|DEVICE|CMV|Ventilated infants were randomized to CMV.
215013917|NCT01767389|OTHER|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
215013918|NCT01767389|OTHER|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
215013919|NCT01767389|OTHER|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
215013920|NCT07044726|DRUG|Povidone-Iodine|Providone-Iodine for periurethral preparation
215013921|NCT07044726|DRUG|Sterile water|Sterile water for periurethral preparation
215013922|NCT07046208|OTHER|physiothreapy protocol|Aerobic training (treadmill or exercise bike) for 15 minutes, anaerobic training at the weight training station, performing exercises for the upper limbs (bench press and front pull) and lower limbs (180º leg press and extension chair) with weight determined by the 1 Repetition Maximum (1RM) test, performing 3 sets of 12-15 repetitions (depending on the session) and respiratory muscle training using POWERbreathe (30-40% of the MIP performed in the manovacuometry test).
214409446|NCT04636697|DRUG|Intramuscular injection|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
214409447|NCT04636697|BIOLOGICAL|Intramuscular vaccine|Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
214409448|NCT05900453|OTHER|Clinical decision support (CDS) tool|"The web-based clinical decision support (CDS) tool uses patient information (e.g., age, sex, BMI, perioperative status) to create personalized predictions of recovery following knee replacement. The CDS tool predicts range of motion, physical function, and pain recovery. Clinicians can use these predictions to (1) inform patients of their expected prognosis, (2) monitor patients' recovery against their predicted recovery, and (3) tailor treatments according to individual patients' needs.~Clinicians were provided with basic training for how to use the CDS tool, and were given examples of how to integrate it into clinical care. However, the CDS tool did not dictate any treatment decisions; clinicians were free to use the CDS tool at their discretion to inform decision making."
214409449|NCT00609141|BIOLOGICAL|cixutumumab|Given IV
214409450|NCT00609141|OTHER|pharmacological study|Correlative studies
214409451|NCT00609141|OTHER|laboratory biomarker analysis|Correlative studies
214409452|NCT04271384|COMBINATION_PRODUCT|nivolumab|Combined neoadjuvant therapy consisting of nivolumab + SABR
214409453|NCT03310229|RADIATION|plain chest x-ray|the participants will be subjected to plain chest x-ray with other tools to help diagnose pulmonary hypertension in haemodialysis patients
214409454|NCT01190176|PROCEDURE|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
214693974|NCT05295368|OTHER|Multicomponent intervention|Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure video sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
214693975|NCT01264094|DRUG|Clevudine|clevudine 30 mg qd
214693976|NCT04585295|DIETARY_SUPPLEMENT|Betaine|50 mg/kg Betaine consumed twice daily for 7 days.
215013923|NCT07045623|OTHER|centralized management and education group|If assigned to the test group (centralized management and education group), two instructors, one nurse and one nutritionist, will receive an hour of diabetes and high blood pressure 1:15, and will receive an hour of lipid disorder disease and impact 1:15 group education. You will receive a total of 2 hours of education, and you will receive 1 hour of lipid abnormality education conducted in 0 months through a visit in the third month. The dyslipidemia education was conducted in the form of 1:15 small group education or 1:87 group education, which was conducted in 0 months. In particular, the 1:87 form of large-scale education will be operated as a dialogue-oriented lecture that asks and answers questions, and will be conducted by doctors. And in 2 months and 4 months, education on diabetes, high blood pressure, and dyslipidemia will be shortened for 3 minutes through non-face-to-face management phone calls, not face-to-face.
215013924|NCT07044882|PROCEDURE|conventional osteotome technique|Patients indicated for internal sinus lifting with simultaneous implant placement, where sinus elevation is conducted with regular manual osteotomes.
215013925|NCT07044882|PROCEDURE|Hydrodynamic Piezoelectric technique|Patients indicated for internal sinus lifting with simultaneous implant placement, where sinus elevation is conducted with Hydrodynamic Piezoelectric technique.
215013926|NCT07045415|BEHAVIORAL|Pelvic Floor Muscle Exercises.|A structured pelvic floor muscle training (PFME) program provided by a nurse, based on EAU and AUA guidelines, consisting of 20-minute sessions delivered 3 times a week
215013927|NCT07045376|OTHER|evidence-based multi-strategy educational training program on surgical smoke|"Based on evidence from the literature, the content of the evidence-based multi-strategy educational training program includes:~Providing a surgical smoke protection handbook and displaying environmental education posters.~Using an official LINE account to disseminate knowledge about surgical smoke, protective techniques, and related information.~Organizing a hands-on workshop on surgical smoke hazard prevention, allowing participants to practice operating smoke evacuation equipment."
215013928|NCT07044791|BEHAVIORAL|Nutritional counseling. No drug treatment will be administered in this study.|Nutritional counseling. No drug treatment will be administered in this study.
215013929|NCT07044960|DRUG|KHN702 tablet or placebo|Subject will receive a single KHN702 tablet or matching placebo orally in fasted state.
215013930|NCT07044960|DRUG|KHN702 tablet or placebo|All participants will receive KHN702 tablet or matching placebo orally once a day for 7 days in fasted state.
215013931|NCT07046650|COMBINATION_PRODUCT|cisplatin-based chemotherapy|Patients were required to have a creatinine clearance of more than 60 and to receive standard doses of cisplatin and gemcitabine (gemcitabine 1000mg /m2 on day 1.8 and cisplatin 70 mg /m2 on day 1, q3w). A total of 4-6 courses of treatment were performed.
215013932|NCT07044375|BEHAVIORAL|Going Places|Going Places is a community driven intervention to increase transportation self-efficacy among low-income youth, enabling access to community-based programs that promote physical activity and improve long term cardiometabolic health. The intervention incorporates a multi-level approach that includes 1) workshops on navigating local transportation systems; 2) field trips and participatory assets mapping activities; and 3) youth transportation advocacy.
215013933|NCT07045714|PROCEDURE|Unilateral Laminotomy with Bilateral Lumbar Decompression (ULBLD)|Unilateral laminotomy with bilateral lumbar decompression (ULBLD) using endoscopic uniportal technique
215013934|NCT07046598|BEHAVIORAL|Drop Jump Protocol|A standardized drop jump (DJ) protocol involving 100 total jumps from a 60 cm platform. Participants performed five sets of 20 jumps, with a 10-second rest between jumps and a 2-minute rest between sets. The protocol was designed to induce muscle damage through eccentric loading.
215013935|NCT07044947|DRUG|Oteseconazole (VT-1161) 150mg capsule|Subjects with SVVC will be treated by Oteseconazole with 600 mg (150 mg per capsule) on D1, 450 mg on D2
215013936|NCT06729073|DRUG|Diclofenac sodium gel|topical administration
215013937|NCT06729073|DRUG|Diclofenac diethylamine 1.16% gel|Topical administration
214409455|NCT01190176|BIOLOGICAL|Cervarix|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
214409456|NCT01190176|BIOLOGICAL|Placebo control|Subjects received 3 doses of the control \[Al(OH)3\] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
214409457|NCT00943423|RADIATION|Involved Field Radiotherapy|IFRT 30Gy delivered in daily fractions of 1.8 - 2.0Gy
214409458|NCT00943423|OTHER|No further treatment|
214409459|NCT01836458|DRUG|KAE609|Patients will receive KAE609 single dose at a different dose level in each cohort.
214409460|NCT03807505|PROCEDURE|Interscalene brachial plexus nerve block|An interscalene brachial plexus nerve block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
214409461|NCT03807505|PROCEDURE|Erector spinae plane block|An erector spinae plane block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
214409462|NCT02081391|DRUG|Tapentadol oral solution 4 mg/mL|"Participants aged 6 months to less than 18 years old with a body weight below 20 kg received tapentadol oral solution 4 mg/mL by mouth every 4 hours for up to 72 hours.~Participants from birth to less than 6 months received tapentadol oral solution, diluted 4 fold."
214409463|NCT02081391|DRUG|Tapentadol oral solution 20 mg/mL|Participants aged from 6 months to less than 18 years with a body weight greater than or equal to 20 kg received tapentadol oral solution 20 mg/mL by mouth every 4 hours for up to 72 hours.
214409464|NCT02081391|OTHER|Placebo|Matching placebo oral solution was administered by mouth every 4 hours up to 72 hours.
214409465|NCT04504084|OTHER|Decision aid|Patient Decision Aid is a tool that helps patient with ureteral stone become involved in decision making on choosing treatment for ureteral stone. Patient Decision Aid provides information about the options and outcomes, and by clarifying personal values.
214409466|NCT05143242|PROCEDURE|Hard tissue augmentation at the buccal aspect of single implants.|One or two releasing incisions are made. The periosteum is released and multiple bone perforations are made in the buccal bone prior to the application of deproteinized bovine derived xenograft. A Creos® membrane (Nobel Biocare, Gothenburg, Sweden) is used to cover the occlusal part of the alveolar crest and the xenograft particles. Finally, multiple single monofilament sutures are used for primary tension-free wound closure.
215013938|NCT07056361|DEVICE|Direct cortical stimulation and deep brain stimulation of motor thalamus|All participants enrolled will undergo implantation of deep brain stimulation electrode leads for treatment of movement disorders. In addition to standard-of-care subcortical mapping using micro-electrode recording (MER) and macrostimulation mapping during DBS placement, cortical local field potentials (LFPs) will be simultaneously recorded from primary motor (M1) and somatosensory (S1) cortical areas by placement of a temporary strip electrode (1X6) in the subdural space. The strip electrode over M1 will be used to produce motor evoked potentials to contralateral hand muscles from direct cortical stimulation (DCMEPs). Cortical and subcortical LFPs will be obtained alongside electromyographic (EMG) data while the patient performs contralateral upper extremity movement tasks and a variety of articulation exercises.
215100158|NCT07088484|DRUG|ICI-chemotherapy and LIMT|gemcitabine, docetaxel, paclitaxel, cisplatin, platinum, capecitabine, S1; Tislelizumab.
215100159|NCT05771038|PROCEDURE|socket preservation using sodium alendronate gel|"sockets will be preserved by sodium alendronate gel before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
214409467|NCT05143242|PROCEDURE|Soft tissue augmentation at the buccal aspect of single implants.|A CTG is taken from the palate and transplanted to the buccal side between the alveolar bone and the buccal flap. The CTG is secured with single monofilament sutures.
214409468|NCT00339625|OTHER|low fat, high fiber, high fruit and vegetable eating plan|Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
214409469|NCT05547659|DRUG|Pregabalin 150mg|Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group
214409470|NCT05547659|DRUG|Acetaminophen 1 G Oral Tablet|Acetaminophen 1 G Oral Tablet preoperative in multi-modal group
214409471|NCT05547659|DRUG|Celecoxib 400Mg Oral Capsule|Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
214409472|NCT05830695|DRUG|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
214409473|NCT05830695|DRUG|Mineral Trioxide Aggregate|mineral trioxide aggregate was used as control
214409474|NCT02189863|DEVICE|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
214409475|NCT02189863|DEVICE|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
215100160|NCT05771038|PROCEDURE|socket preservation using sticky bone|"sockets will be preserved by sticky bone as mentioned before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
215100161|NCT04029571|DRUG|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
215100162|NCT04029571|OTHER|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
215100163|NCT04797871|BEHAVIORAL|Resistance training|Participants will complete a 2-days-a-week training routine: Resistance training (RT, 50-75% 1RM (one-repetition maximum), 4 sets, 8-12 repetitions, 4 exercises). The warn up include Light Intensity Continuous Training (8-10 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by Physiotherapists and Graduated in Sports Sciences.
215100164|NCT04797871|BEHAVIORAL|Standard care|This group will be allocated to standard care and therefore no supervised exercise regimen according to scientific guidelines for general physical activity and return to sport provided by the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease.
215100165|NCT01110382|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
215100166|NCT01110382|DRUG|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
215100167|NCT01110382|DRUG|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
215100168|NCT01110382|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
215100169|NCT01110382|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
215100170|NCT04361305|DRUG|Dapoxetine|30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
215100171|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
215100172|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
215100173|NCT03897842|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
215100174|NCT02134288|DRUG|Belatacept|
215100175|NCT02134288|DRUG|Everolimus|
215100176|NCT03305393|DEVICE|Adaptiv CRT|Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
215100177|NCT05400421|DEVICE|System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure|Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
215100178|NCT03891368|OTHER|Virtual Learning Collaborative|InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
215100179|NCT03891368|OTHER|Technical Assistance|Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
215100180|NCT02110797|OTHER|biological markers and evaluation of the mineral density at the lumber spine using DEXA|
215100181|NCT04161170|DEVICE|Digital integrated healthcare platform|Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
215100182|NCT06097546|DIAGNOSTIC_TEST|laboratory test (RAI14 and MACC-1 )|Measurement of serum RAI14 and serum MACC-1 levels by immunochemical assays
215100183|NCT03339973|BIOLOGICAL|allo-APZ2-PAOD|Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe
215100184|NCT03339973|DRUG|Placebo|Solution for injection in pre-filled syringe
214409476|NCT02189863|DEVICE|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
214409477|NCT02189863|DEVICE|Comfilcon A MF|Multifocal contact lenses worn in both eyes
215013939|NCT07056907|PROCEDURE|Lumbar drain placement|This intervention involves temporary cerebrospinal fluid (CSF) drainage via lumbar drain in acute ischemic stroke patients with MRI-confirmed hemodynamic failure. The lumbar drain is inserted at the bedside or in a procedural suite under sterile conditions and connected to a pressure-regulated, closed drainage system. Drainage is continuous for 48-72 hours, with volume and pressure carefully monitored. This intervention is distinct in targeting stroke patients without hydrocephalus, using CSF drainage as a novel method to improve cerebral perfusion and vascular reserve. The effect is evaluated with serial BOLD-CVR MRI performed before and after the drainage period, making this one of the first interventional stroke studies to use functional MRI as a physiological endpoint.
215013940|NCT07056439|DRUG|HRS-1738 Injection|HRS-1738 injection.
215013941|NCT05937282|DRUG|Dexmedetomidine|Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.
215013942|NCT05937282|DRUG|Propofol|Patients will receive propofol infusion in the dose of 3 mg/kg/hr. 25 ml propofol 1% (10 mg /ml) in 50 ml syringe pump.
215013943|NCT05937282|DRUG|Lidocain|Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr.25 ml lidocaine 1% (10 mg/ml) in 50 ml syringe pump.
215013944|NCT05937282|DRUG|normal saline|Patients will receive infusion of 25 ml normal saline in 50ml syringe pump (control group).
215013945|NCT06173648|DEVICE|Laser and ICG solution.|Intervention consists of addition of a combined laser absorption solution and infrared diode laser. The solution is introduced into the prepared pulp chamber and root canals, allowed to dwell for 1 minute, followed by exposure to the laser energy delivered via a fiber optic introduced into the root canal, and while activating the laser at 2.5 watts of optical output with a pulse duration of 100 msec and a pulse gap of 300 msec, the solution and residual structures in the root and pulp chamber are exposure over the course of 30 seconds, moving and relocating the fiber tip throughout the canals and chamber during that time. The laser is halted and a wait time of 30 seconds is applied. The laser fiber is then reintroduced and another 30 second exposure, repeating the same settings and technique.
215013946|NCT07056985|OTHER|Ankle joint mobilization technique|Combined posterior and lateral mobilization techniques
215013947|NCT07056985|OTHER|Placebo|Placebo interventions simulated with superficial hand contact and minimal manipulation
215013948|NCT07055815|DIAGNOSTIC_TEST|Progression of Myopia|The widespread use of digital devices among children has raised concerns about the potential impact on their eye health. Excessive screen time can cause prolonged near focus, reduced outdoor time, and increased blue light exposure, all of which may contribute to myopia progression. Understanding the relationship between digital screen time and myopia progression is crucial for developing effective prevention and intervention strategies to mitigate the growing burden of myopia in children.
215013949|NCT07057154|DEVICE|Hbg and RDW|Hbg and RDW as prognstic indicator in critical ill patients
215013950|NCT00394667|DRUG|Tesofensine|
215013951|NCT06765889|BEHAVIORAL|Mindfulness intervention|The mindfulness intervention will consist of three tracks of mindfulness practice adapted from a traditional Mindfulness-Based Stress Reduction (MBSR) protocol. The three mindfulness tracks will incorporate essential elements of mindfulness practice: a) cultivating attentional stability by directing focus to present-moment bodily experiences (Moore et al., 2012), and b) fostering mindful meta-awareness by nonreactively and nonjudgmentally observing and accepting experiences (Dahl et al., 2015).
215100185|NCT01195493|OTHER|Essential Oils solution|(Essential oils solution, Listerine®, Johnson \& Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
215100186|NCT01195493|OTHER|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
215100187|NCT03529279|DRUG|CNG Chemotherapy|"CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA \> 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years."
214409478|NCT02189863|DEVICE|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
214409479|NCT05567666|DEVICE|Optilume Catheter System|Optilume Catheter System, which is a Dilation Drug Coated Balloon (DCB) Catheter
214409480|NCT03413774|PROCEDURE|vaginal swab|high vaginal and Endocrvical swabs for bacterial, protozoal and chlamydial infection- examined by PCR
214409481|NCT06097104|OTHER|electrolytes - serum blood samples|"CBC - Kidney function tests - liver function tests - ABG - levels of serum sodium, potassium, magnesium, phosphorus, ionized calcium and chloride, with maximum 5 mm blood sampling per day"
214693977|NCT04585295|DIETARY_SUPPLEMENT|BCAA Big 6|1 level scoop (\~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.
214688397|NCT05790668|BEHAVIORAL|Traditional Schedule Thinning|During traditional schedule thinning during functional communication training with discriminative stimuli (e.g., multiple schedules, chained schedules), practitioners correlate a unique stimulus with reinforcement (e.g., a green card) and another for extinction (e.g., a red card). When the reinforcement and extinction stimuli are presented, the child's communication responses are honored or not honored, respectively. Behavior analysts begin with a brief period of extinction (e.g., 2 s) and gradually increase that duration as the child displays low levels of destructive behavior and high levels of discriminated communication responses (i.e., communication requests during reinforcement components only) until the child reaches a terminal schedule informed by caregiver/child preference (e.g., 2.5-min reinforcement, 10-min extinction). Typically, the starting extinction period is brief and arbitrarily selected and there are no competing stimuli programmed.
215013952|NCT06765889|BEHAVIORAL|Control condition|The sham meditation group will aim to be indistinguishable from meditation practice for newcomers (Zeidan et al., 2015). Non-specific elements of meditation, such as a soothing instructor's voice and terminology designed to create the expectation of authentic mindfulness meditation for those unfamiliar with the practice, will be emphasized. However, the instructions will deliberately exclude the training of the two fundamental cognitive/meta-cognitive processes crucial in mindfulness practice. This intentional omission will involve 1) removing any attentional stability by providing participants with no specific point to anchor their attention and 2) offering no guidance on cultivating mindful meta-cognitive qualities of attention. Participants in the mindfulness group will be taught to observe and accept their present-moment experience without judgment or reaction. In contrast, sham instructions will provide no such guidance.
215013953|NCT06756139|PROCEDURE|cognitive behavioural therapy mobile application|The CBT mobile application enables patients to conduct cognitive therapy independently.
215013954|NCT06756139|DRUG|Flupentixol and Melitracen Tablets|patients take Flupentixol and Melitracen Tablets
215013955|NCT04551131|DRUG|Ruxolitinib|Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks
215100188|NCT03529279|DRUG|NCCN Chemotherapy|"UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy."
215100189|NCT03529279|RADIATION|CNG Radiation|"IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr."
215100190|NCT03529279|RADIATION|NCCN Radiation|"IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord."
215013956|NCT04551131|DRUG|Dexamethasone|Given intravenously (IV) or orally (PO) twice a day for 8 weeks
215013957|NCT04551131|DRUG|Etoposide|Given intravenously (IV) once a week for 8 weeks
215013958|NCT06838936|OTHER|Binaural Beats|Mobile application for binaural beats listening
215013959|NCT06729957|BEHAVIORAL|Care Navigation|Care navigation is an intervention that seeks to help patients engage in substance use treatment by increasing motivation and reducing barriers to accessing treatment. The care navigator helps the patient engage in the treatment plan established by the mental health care coordinator.
215013960|NCT04330781|DEVICE|Intraoral stent|Radiotherapy with intraoral stent
215100191|NCT00143377|DRUG|tolterodine SR, overactive bladder|
214409482|NCT05441020|OTHER|Administration of patient questionnaire|Patients undergoing maintenance hemodialysis complete electronic questionnaires on a tablet computer during this study to assess patient reported outcomes.
214409483|NCT03251651|DRUG|Propofol|Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
214409484|NCT03251651|DRUG|Dexmedetomidine|Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
214409485|NCT04629144|DRUG|Belimumab|"Belimumab administered subcutaneously 200mg weekly from week 1 to week 24.~Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
214409486|NCT04629144|DRUG|Placebo|"Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
214409487|NCT03087721|BEHAVIORAL|HIIT-LV|"Supervised endurance treadmill training as walking/running uphill, 3 times/week during 12 weeks starting at 85-90% of previously determined maximum oxygen consumption (VO2 max). Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week."
214409488|NCT03087721|BEHAVIORAL|CAE|Supervised moderate intensity treadmill training, 3 times/week for 12 weeks starting at 70% of VO2 max. Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.
215013961|NCT04330781|OTHER|No intraoral stent|Radiotherapy without intraoral stent
214409489|NCT01111591|DRUG|Cox2 inhibitor (Celecoxib)|From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.
214409490|NCT04035759|BEHAVIORAL|APPEAL|Three-session, individually administered program, with sessions spaced monthly. Optional weekly contacts with participants to support engagement in program exercises/activities.
214409491|NCT01559090|DRUG|MEDI-546|Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
215013962|NCT06917508|DRUG|EDP-323|Subjects will receive EDP-323 once daily on Days 5-15
215013963|NCT06917508|DRUG|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
215013964|NCT06917508|DRUG|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
215013965|NCT06917508|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
214409492|NCT01559090|DRUG|MEDI-546|Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
215013966|NCT06938971|OTHER|Exercise training|Participants allocated to the exercise intervention group will receive standard care plus an exercise intervention. The exercise intervention will consist moderate-to-high intensity supervised and unsupervised home-based exercise training (bicyling, walking, or running) 5 times/week for 18 weeks.
215013967|NCT06396299|OTHER|No intervention|No intervention
215013968|NCT02616302|DRUG|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
215013969|NCT03278340|BEHAVIORAL|Sun Safe Workplaces - Technology|After randomization, program staff will contact managers at the recruited employer and schedule the initial web-enabled visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption, and managers will schedule employee education using the SSW-T online training. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2). Electronic materials will be published on KB's state-of-the-art web server for employers to access and use.
214693978|NCT04585295|DIETARY_SUPPLEMENT|Placebo|50 mg/kg Placebo consumed twice daily for 7 days.
214693979|NCT01495338|DRUG|AC-170 0.17%|1 drop in one eye at one timepoint
215013970|NCT03278340|BEHAVIORAL|Sun Safe Workplaces -In Person|After randomization, program staff will contact managers the recruited employer and schedule the initial in-person visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption; managers will schedule employee education with SSW-IP project staff. Printed materials will be sent to SSW-IP employers 3 times during the intervention. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2).
215013971|NCT06097481|BEHAVIORAL|Narrative Intervention for Chronic Illness-Heart Failure|The Narrative Intervention for Chronic Illness-Heart Failure includes narrative-based, strengths-based, solution-focused brief therapy, and Unitary Caring Science to improve depression (primary outcome) and anxiety (secondary outcome) for people living with heart failure.
215013972|NCT06097481|OTHER|Attention Control|Automated emails at similar time points to the intervention will be sent to participants in this arm. Emails will ask participants to reflect on their illness experience and offer general information about heart failure using standardized handouts from the American Heart Association and Up-To-Date.
215013973|NCT05894746|DIETARY_SUPPLEMENT|gluten-free|see info in arm description
215013974|NCT05894746|DIETARY_SUPPLEMENT|probiotic|see info in arm description
215013975|NCT05894746|DIETARY_SUPPLEMENT|gluten|see info in arm description
215013976|NCT05206604|DRUG|PF-07295324|Ointment
215013977|NCT05206604|DRUG|PF-07259955|Cream
215013978|NCT05040542|OTHER|maternal exposure during pregnancy|maternal exposure during pregnancy (e.g., environmental exposures and maternal inflammatory states)
215013979|NCT05956392|BEHAVIORAL|Screen-use reduction + Sleep extension|60 minutes of a participants' daily screen-use time on school days will be repurposed for more sleep time.
215013980|NCT03808467|BEHAVIORAL|Cognitive Remediation Therapy|Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
215013981|NCT03808467|OTHER|Treatment as usual|According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
215100192|NCT00973492|OTHER|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later."
215100193|NCT00899158|OTHER|immunologic technique|
215100194|NCT00899158|OTHER|laboratory biomarker analysis|
215100195|NCT00899158|PROCEDURE|biopsy|
215100196|NCT06362122|OTHER|identification anatomo-clinico-biological profiles|to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature
215100197|NCT05047146|OTHER|Morphological classifications of HCC|Morphological classifications of Hepatocellular carcinoma
215100198|NCT02522442|DEVICE|CPAP|Continuous positive airway pressure
215100199|NCT02522442|DEVICE|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
215100200|NCT02896270|DRUG|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
215100201|NCT01753401|DRUG|Acthar|Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
215100202|NCT01753401|DRUG|Placebo|Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
215100203|NCT01753401|DRUG|Steroid Drug|The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
215100204|NCT03668405|DRUG|Lu AF20513|Injection
214409493|NCT01559090|DRUG|MEDI-546|Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
214693980|NCT01495338|DRUG|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
215100205|NCT06934382|BIOLOGICAL|Allogeneic anti-CD7 CAR-T cells (BEAM-201)|The investigational agent in this protocol is allogeneic anti-CD7 CART cells (BEAM-201). BEAM-201 is comprised of allogeneic anti-CD7 CAR-T cells edited by 4 gRNAs and a single mRNA encoding a CBE, then transduced with a lentiviral vector (LVV) encoding the anti-CD7 chimeric antigen receptor (CAR) molecule.
215100206|NCT00005014|DRUG|Risperidone|
215100207|NCT01232985|DEVICE|RD047-26|RD047-26 emollient gel
215100208|NCT03329261|DRUG|Clopidogrel|COPIGREL® - clopidogrel dosed at 75 mg per tablet
215100209|NCT04622813|DRUG|nefopam, ketoprofen, paracetamol|Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
215100210|NCT04622813|DRUG|saline infusion, ketoprofen, paracetamol|Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery
215100211|NCT01353911|DRUG|Grazoprevir|Orally once daily in AM. Blinded or open-label depending on treatment arm.
214409494|NCT01317017|DRUG|Actimmune|"* All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.~* Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.~* Patients will return at one to two weeks for suture removal.~* Clinical assessments done at every visit.~* Patients will also be evaluated at each visit for any adverse events."
214409495|NCT03272646|PROCEDURE|surgery|gastric resection or total gastrectomy
215100212|NCT01353911|DRUG|Boceprevir|Four 200 mg capsules orally three times daily.
215100213|NCT01353911|DRUG|Placebo for Grazoprevir|Orally once daily in AM.
215100214|NCT01353911|DRUG|Placebo for Boceprevir|Four capsules orally three times daily.
215100215|NCT01353911|DRUG|Peg-interferon alfa-2b|1.5 μg/kg/week subcutaneous injection.
215100216|NCT01353911|DRUG|Ribavirin|300 mg to 700 mg orally twice daily.
214693981|NCT01495338|DRUG|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
214409496|NCT02653274|OTHER|Breakfast porridge|220 kcal breakfast porridge served with 240 mL glass of water
214693982|NCT01495338|DRUG|Olopatadine hydrochloride 0.2%/Tears Naturale II|1 drop in one eye at one timepoint
215100217|NCT02152774|DRUG|Rho-Kinase Inhibitor|
215100218|NCT05647785|DEVICE|Long-term follow-up of cerena™|Long term follow-up for eligible participants from the RESTORE study
215100219|NCT05647785|DEVICE|Long-term follow-up of attune™|Long term follow-up for eligible participants from the RESTORE study
215100220|NCT04003987|DRUG|Liposomal bupivacaine|20ml
215100221|NCT04003987|DRUG|bupivacaine, 0.125%|60ml
215100222|NCT01946126|OTHER|No Intervention|There is no intervention in this study.
215100223|NCT02706587|DEVICE|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
215013982|NCT05500131|BEHAVIORAL|Observation|"Ankle joint dorsiflexion was evaluated with the Weight-bearing lunge test through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). Subjects were instructed to try to bring the knee to touch the metal rod (initially placed at a distance of 10 cm) without lifting the heel off the ground. The distance achieved was recorded in centimeters.~Single-leg squat test was analyzed through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). It consists of performing a monopodial squat to test dynamic knee valgus. They were to perform a single-leg squat to 30° knee flexion. The knee was considered to be aligned if the patella was over the second toe."
215013983|NCT03735498|OTHER|Psychological Intervention|Promote effective coping and reduce caregiving burden
215013984|NCT00713180|PROCEDURE|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
215013985|NCT05370144|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiation 23 Gy in 5 fractions with a simultaneous integrated boost of 26 Gy in 5 fractions to the gross tumor volume (GTV) given concurrently over 1 week during week 3 of chemotherapy.
215013986|NCT05235256|PROCEDURE|bilateral sphenopalatine ganglion block|peripheral n block
215100224|NCT02706587|DEVICE|Sham control|No electrostimulation
215013987|NCT05235256|PROCEDURE|bilateral greater occipital nerve block|bilateral greater occipital nerve block
215013988|NCT05235256|DRUG|lidocaine plus dexamethasone|lidocaine plus dexamethasone
215013989|NCT02793778|DRUG|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
215013990|NCT02793778|DRUG|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
215013991|NCT03785847|DIAGNOSTIC_TEST|Ventica|Impedance pneumography measurement
215100225|NCT00462748|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
215100226|NCT00462748|DRUG|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
215100227|NCT00462748|DRUG|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
215100228|NCT04110080|PROCEDURE|multimodal pain management|Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.
215100229|NCT04110080|OTHER|goal directed fluid management|Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.
215100230|NCT04110080|OTHER|preoperative carbohydrate loading|Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.
215100231|NCT04110080|PROCEDURE|Donor nephrectomy|All patient will have laparoscopic nephrectomy procedure with transplant surgery.
215100232|NCT04110080|PROCEDURE|regional anesthesia|transabdominal plane and rectus sheath nerve block
215100233|NCT06379282|BEHAVIORAL|HIT|Exercise training only
215100234|NCT06379282|BEHAVIORAL|EXE+ Nutritional Guidance|Exercise Training + Nutritional Guidance
215100235|NCT03778385|OTHER|Exercise|Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
215100236|NCT04059432|DIAGNOSTIC_TEST|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
215100237|NCT03233438|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
215100238|NCT03233438|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
215100239|NCT03429543|DRUG|Metformin|At least 1000 mg/day or up to a maximal tolerated dose.
215100240|NCT03429543|DRUG|Insulin|Basal or multiple dose injection.
215013992|NCT01665105|DEVICE|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
215013993|NCT03439878|DIETARY_SUPPLEMENT|Galactose|Co-ingestion of d-galactose with a high-fat meal
215013994|NCT03439878|DIETARY_SUPPLEMENT|Glucose|Co-ingestion of d-glucose with a high-fat meal
215013995|NCT06197711|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants; PRISMA has four sessions."
215100241|NCT03429543|DRUG|Placebo|1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.
215100242|NCT03429543|DRUG|Linagliptin|1 film-coated tablet Linagliptin once daily, until end of treatment.
215100243|NCT03429543|DRUG|Empagliflozin|1 film-coated tablet of Empagliflozin once daily, until end of treatment.
215100244|NCT00036257|DRUG|CP-461|
215100245|NCT05890482|BEHAVIORAL|Islamic Trauma Healing|Manualized, lay-led psychosocial intervention
215100246|NCT05684185|BIOLOGICAL|Intramuscular (IM) rabies post-exposure prophylaxis|one-site, 0.5 mL at Day 0, D3, D7 and D14
215100247|NCT05684185|BIOLOGICAL|Intradermal (ID) rabies post-exposure prophylaxis|two-site, 0.1 mL at Day 0, D3 and D7
215100248|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
215013996|NCT00709345|BEHAVIORAL|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
215013997|NCT00709345|BEHAVIORAL|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
215013998|NCT00480311|OTHER|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
215013999|NCT05675020|BEHAVIORAL|Zoom Intervention|"This educational program will be delivered via a 45-minute presentation via Zoom.~* The educational presentation will be recorded and emailed to participants within 1 week of intervention to re-watch/review.~* The educational program will promote a healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines.~* We will compare the effects of an educational program on healthy lifestyle knowledge and behaviors pre-and post-program (after one month) via a REDCap survey for the adolescent and their parent/legal guardian."
215014000|NCT00293982|BEHAVIORAL|Physician knowledge of parental expectations for the visit|
215014001|NCT06222294|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
215014002|NCT06222294|DRUG|Propofol Medium and Long Chain Fat Emulsion Injection|Loading dose: 0.3-0.5mg/kg Maintenance dose: IV Propofol Medium and Long Chain Fat Emulsion Injection, dose range 0.3-4.0mg/kg/h, increment or decrement of 0.3-0.6mg/kg/h
215014003|NCT04250402|PROCEDURE|Resection|Radical resection.
215100249|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
214693983|NCT06082752|PROCEDURE|Massage session|Participants in the intervention group are provided with the 5-minute massage session in the medial and lateral gastrocnemius muscle (dominant leg).
214693984|NCT02780765|DEVICE|heated humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
214409497|NCT00425542|OTHER|Outpatient care (vs traditional inpatient care)|Patients randomized to the outpatient arm are discharged from the emergency department within 24 hours after randomization. Patients randomized to the inpatient arm are admitted to the hospital and are discharged based on the decision of the managing physician at the hospital.
214409498|NCT03909581|PROCEDURE|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization (50 participants)
214409499|NCT03909581|PROCEDURE|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator (50 participants)
214409500|NCT05586217|OTHER|INCENTIVE SPIROMETRY|"* Sit up and hold the device.~* Then Place the mouthpiece spirometer in mouth and make a good seal over the mouthpiece with lips.~* Breathe out (exhale) normally.~* Breathe in (inhale) slowly. A piece in the incentive spirometer will rise as you breathe in. And try to get this piece to rise as high as you can.~* Usually, there is a marker placed by your doctor that tells you how big of a breath you should take.~A smaller piece in the spirometer looks like a ball or disk.~* Your goal should be to make sure this ball stays in the middle of the chamber while you breathe in.~* If you breathe in too fast, the ball will shoot to the top.~* If you breathe in too slowly, the ball will stay at the bottom. Hold your breath for 3 to 5 seconds. Then slowly exhale."
214409501|NCT05586217|OTHER|Active cycle of breathing|"Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways"
214409502|NCT03571594|DRUG|ONO-5788|Investigational drug
214409503|NCT03571594|DRUG|ONO-5788 Placebo|Placebo Comparator
214409504|NCT03571594|DRUG|Octreotide|Active Comparator in Part D
215014004|NCT04408209|PROCEDURE|Convalescent Plasma|"Convalescent Plasma - early treatment of patients with severe COVID-19. Clinical and laboratory data of patients will be collected before initiation of the procedure, 30 minutes after the first dose, 30 minutes after the second dose and 30 minutes after the third plasma dose and then on days 1-7, 14, 21, 28, 35 from the start of treatment. In case of adverse reactions during transfusion such as acute shortness of breath, haemodynamic instability or high pre-existing and non-disease-related fever, the transfusion will be interrupted and detailed recording of the event as well as updating the Adverse Events Management Committee will be performed.~In addition to the standard assessments, the titer of neutralizing anti-SARS-CoV-2 antibodies will be measured in a sample drawn prior to plasmapheresis.~All donors will be tested for:~1. the titer of IgG anti-SARS-CoV-2 antibodies (Pasteur Institute)~2. the titer of neutralizing anti-SARS-CoV-2 antibodies (Pasteur Institute)"
215014005|NCT05999552|OTHER|Eye exercises|The treatment will be applied in three sessions a week for eight weeks and each session will be approximately 20 minutes. Individuals will do each exercise shown at home as a home program on other days (days when the physiotherapist does not perform the exercise by video call).
215014006|NCT03787212|DEVICE|MiBo ThermoFlo|Test Device
214409505|NCT05518825|DIETARY_SUPPLEMENT|Fortimel/Nutridrink Compact Protein|Twice daily serving of the study product
214409506|NCT03805958|PROCEDURE|realtime ultrasonography|Applying realtime ultrasound during the combined anesthesia
214409507|NCT03805958|PROCEDURE|prescan ultrasonography|Applying realtime ultrasound before the combined anesthesia
214409508|NCT00901056|DEVICE|Extracorporeal Shockwave Therapy|Energy Density - 0.02 - 0.15 mJ/mm2
214409509|NCT06254599|DRUG|SY-3505 Capsules|A third-generation ALK tyrosine kinase inhibitor
214409510|NCT06254599|DRUG|Crizotinib Capsules|An oral ALK tyrosine kinase inhibitor
214409511|NCT02513433|DRUG|Bupivacaine|Local anesthetic
215014007|NCT03787212|DEVICE|Bruder Mask|Control Device
215014008|NCT03556384|DRUG|Temozolomide|"Temozolomide 85 mg/m2 will be administered orally for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters"
215014009|NCT02014103|DRUG|Prograf|Administration of each formulation will be determined by sequence.
214409512|NCT02513433|DRUG|Levobupivacaine|Local anesthetic
214409513|NCT02513433|DRUG|Ropivacaine|Local anesthetic
214409514|NCT03677375|DEVICE|INVSENSOR00026|Noninvasive pulse oximeter sensor
214409515|NCT06232161|DEVICE|Red-light therapy device|Red-light therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average.
215014010|NCT02014103|DRUG|Tacrolimus, Sandoz|Administration of each formulation will be determined by sequence.
215014011|NCT02014103|DRUG|Tacrolimus, Reddy Laboratory|Administration of each formulation will be determined by sequence.
215014012|NCT02014103|DRUG|Tacrolimus, Mylan|Administration of each formulation will be determined by sequence.
215014013|NCT02014103|DRUG|Tacrolimus, Accord|Administration of each formulation will be determined by sequence.
215014014|NCT02014103|DRUG|Tacrolimus, Pancea Biotech Limited|Administration of each formulation will be determined by sequence.
215014015|NCT06496100|DRUG|Triticum Aestivum|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
215014016|NCT06496100|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
214409516|NCT06232161|DEVICE|Spectacles|Single focus spectacles, that is to say, wearing glasseses with minus power lens
214409517|NCT02023203|PROCEDURE|Totally Extraperitoneal laparoscopic inguinal hernia repair|Laparoscopic hernioplasty
215014017|NCT04605146|BEHAVIORAL|Tele-monitoring|"The tele-monitoring will consist in filling in a specific questionnaire once a week in the first 6 months, every 2 weeks until 12 months, and on-demand (in case of upcoming toxicity, at any time). These questionnaires will be reviewed by a coordinating nurse. According to the result of the questionnaire, the coordinating nurse will adapt patients' management, either by giving them a phone call, or inviting them to directly contact their medical department, or even plan an emergency hospitalization if necessary. The coordinating nurse will closely work with the investigator to adapt patients' management.~Quality of life questionnaire (FACT-G) will also be filled in at inclusion, M3 and M12."
215014018|NCT05240976|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.
215014019|NCT05240976|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
215014020|NCT05802537|BEHAVIORAL|Home-based exergame program|The home-based exergame program was conducted using the Nintendo Switch and Ring Fit Adventure program at participants' homes. The program included a 10-minute warm-up, 30 minutes of main exercise, and a 10-minute cool-down, lasting a total of 50 minutes per session. Sessions were held three times per week for eight weeks. The exercises targeted lower extremity strength, balance, and flexibility and included yoga, leg exercises (e.g., squats, knee lifts), and other activities performed in a gamified virtual environment. Participants received guidance on using the console, and family members were involved to support proper execution of the exercises.
214409518|NCT00974298|PROCEDURE|Total elbow replacement arthroplasty|Total elbow arthroplasty using pressfit technique in which no cement is used.
215100250|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
215100251|NCT02702687|BEHAVIORAL|PEF Feedback|Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.
215100252|NCT02702687|BEHAVIORAL|Control Feedback|Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
215100253|NCT02945813|DRUG|Metformin|850mg PO BID; 48 weeks
215100254|NCT02945813|RADIATION|Salvage Radiotherapy SRT|SRT 35 x 2Gy; 7 weeks
214409519|NCT02622139|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|MSOT for the evaluation of disease activity in IBD patients
214409520|NCT01188317|DRUG|aleglitazar|repeated daily doses
214409521|NCT01188317|DRUG|placebo|repeated daily doses
214409522|NCT01188317|DRUG|ibuprofen|repeated daily doses
214409523|NCT00264589|BEHAVIORAL|8 weeks individualized training program|no drugs added
214409524|NCT04145102|OTHER|hesperidine|used for antibacterial and reminerlization assesment
214693985|NCT02780765|DEVICE|mist humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
215100255|NCT05755555|BEHAVIORAL|Visit a doctor|Test messages based on concepts from behavioural economics that aim to make information on screening more salient by using the concept of social proof (person like you) and an authoritative source (a diabetes specialist)
214409525|NCT04145102|OTHER|propolis|used for antibacterial and reminerlization assesment
214409526|NCT04145102|OTHER|silver diamine fluoride|used for antibacterial and reminerlization assesment
214409527|NCT01051011|DRUG|insulin glargine|initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks
214409528|NCT01051011|DRUG|metformin|as prescribed
214409529|NCT01051011|DRUG|taspoglutide|10mg sc weekly, 24 (-52) weeks
214409530|NCT01051011|DRUG|taspoglutide|10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
214409531|NCT02141581|BIOLOGICAL|Fluzone® (IM)|This vaccine is given intramuscularly (IM)
214409532|NCT02141581|BIOLOGICAL|Fluzone® Intradermal (ID)|This vaccine is given intradermally (ID)
214409533|NCT02141581|BIOLOGICAL|2011-2012 FluMist®|This vaccine is given intranasally
214409534|NCT01781702|DRUG|Pelubiprofen 30 mg|
214409535|NCT01781702|DRUG|Celebrex 200 mg|
214409536|NCT02134275|BEHAVIORAL|Whole body vibration training|Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.
214409537|NCT02134275|BEHAVIORAL|Control group|Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
215100256|NCT04511065|OTHER|Newsletter using a virtual mode of delivery|Newsletter creation where topics in the newsletter are chosen by participants in the intervention group.
214409538|NCT03031028|OTHER|ketogenic diet|Ketogenic Diet is a high fat, low carbohydrate diet.
214409539|NCT00056641|DRUG|tipranavir|
215014021|NCT05802537|BEHAVIORAL|Online education on fall prevention and musculoskeletal health management|The online education intervention consisted of weekly sessions conducted for 50 minutes over an eight-week period, focusing on fall prevention and musculoskeletal health management. Participants joined the sessions via a video-conference platform. The content covered education on aging, musculoskeletal disorders, fall prevention strategies, and understanding falls and fractures. These sessions aimed to enhance participants' awareness and knowledge, thereby helping them adopt preventive behaviors.
214409540|NCT00056641|DRUG|ritonavir|
214409541|NCT00056641|DRUG|saquinavir|
214409542|NCT00056641|DRUG|amprenavir|
214409543|NCT00056641|DRUG|lopinavir|
214409544|NCT00126113|BEHAVIORAL|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
214409545|NCT00126113|BEHAVIORAL|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
214409546|NCT05975320|DRUG|Warfarin|Patients receiving oral anticoagulants will be followed up for 6 months to detect occurrence of any major bleeding events include (spontaneous epistaxis , spontaneous bleeding per gums , hematemesis , bleeding per rectum , intracranial hemorrhage and internal hemorrhage ). Then, incidence of bleeding events using both (HAS-BLED) \& (ORBIT) SCORES will be calculated and compared for all cases .
214409547|NCT06143761|DRUG|PD-1 inhibitor+carboplatin+albumin-bound paclitaxel|A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.
214409548|NCT05687942|DEVICE|REBUILD|3.1.1. REBUILD is an investigational medical device provided as a sterile, single use set containing 10 suture Anchors and two non-implantable Carriers, with reusable stainless-steel instruments for deployment supplied separately.
214409549|NCT04415268|BEHAVIORAL|Exercise|Surpervised exercise program: Includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions.
214409550|NCT04415268|BEHAVIORAL|Unsupervised exercise|Unsupervised exercise program: The same exercise program learned during the supervised phase will be practiced at home.
214409551|NCT04415268|DRUG|CFTR Modulators|"Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES"
214409552|NCT06217731|COMBINATION_PRODUCT|Laser+clonazepam|treated with the Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month and Rivotril 0.25mg once every 24 hours for a month
214409553|NCT06217731|DEVICE|Laser Sham|INACTIVE Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
214693986|NCT01894477|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
215014022|NCT05548452|DRUG|Intestinal Microbiota Transplant (IMT) Capsules|Capsules containing freeze-dried intestinal microbiota from healthy human donors
215014023|NCT05548452|DRUG|Placebo Capsules|"Capsules containing an inactive substance (sugar pill)"
215014024|NCT06334341|BEHAVIORAL|Computer-based simulation training for providers|"A Computer-Based Simulation training for providers, based on the Centers for Disease Control and Prevention Guide for Healthcare Professional: Discussing Sexual Health with Your Patients, current PrEP information, and the Social Cognitive Theory. This is a single-session, 30-minute training module contains educational information with animated narration about PrEP, how to take a sexual health history, understanding internal bias, potential patient barriers to PrEP as well as recorded video-simulated encounters, in which providers view different types of patient/provider interactions."
215014025|NCT06334341|BEHAVIORAL|Best Practice Alert|A Best Practice Alert will alert providers to patients who are part of the Centers for Disease Control and Prevention PrEP priority populations.
215100257|NCT03474783|BEHAVIORAL|Health education|Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
215100258|NCT03615066|DRUG|Placebo|Tablet(s) administered orally every 7 days for 24 doses in fasted state
215100259|NCT03615066|DRUG|Selgantolimod|Tablet(s) administered orally every 7 days for 24 doses in fasted state
215100260|NCT03615066|DRUG|TAF|Tablet(s) administered orally once daily with food
214409554|NCT06217731|DEVICE|Laser|Active Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
214409555|NCT06217731|DRUG|Clonazepam|Rivotril 0.25mg once every 24 hours for a month
214409556|NCT01750996|BEHAVIORAL|Strongest Families|Behavioural intervention
214409557|NCT01085487|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
214409558|NCT01085487|DRUG|Hormonal treatment|Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
214409559|NCT01085487|DRUG|Antifibrinolytic treatment|Antifibrinolytic treatment (such as tranexamic acid)
214409560|NCT03604861|OTHER|Not applicable - no defined intervention|Participants who received at least one injection of RBP-6000 or placebo and either withdrew from or completed the Phase III clinical program which included studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003) were eligible for the RECOVER Study.
214409561|NCT03055845|DRUG|STA363|STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
214409562|NCT03055845|DRUG|Placebo|Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
214409563|NCT03971357|DRUG|Netarsudil|netarsudil opthalmic solution 0.02%
214409564|NCT03971357|DRUG|Placebo|Placebo eye drops
214409565|NCT05196594|DIAGNOSTIC_TEST|collection of stools for genetic analysis|Intestinal microbiome analysis
214693987|NCT01894477|DRUG|Fludarabine Phosphate|Intravenously administered Fludarabine Phosphate
214693988|NCT01894477|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
214693989|NCT01894477|RADIATION|Total-Body Irradiation|Undergo TBI
215014026|NCT06334341|BEHAVIORAL|HIV Risk Assessment|A risk assessment tool that considers the behaviors - i.e., types of sexual activities, protective behaviors (condoms, PrEP, ART), and other factors (HIV status, sexually transmitted infections) of the respondent.
215014027|NCT06334341|BEHAVIORAL|PrEP Informational Video|A short informational video, tailored to the local Detroit context with themes that will focus on introducing PrEP, stigma surrounding taking PrEP, and potential barriers and how to overcome them.
215100261|NCT04755452|PROCEDURE|Low intra-abdominal pressure|7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
215014028|NCT03186157|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy is a surgical procedure used to treat patients with acute intractable intracranial hypertension. It includes removing a large portion of lateral skull wall in order to alleviate the effects of increased intracranial pressure and allow the brain to expand.
215100262|NCT04755452|PROCEDURE|High (standard) intra-abdominal pressure|12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
215014029|NCT03186157|PROCEDURE|Cranioplasty|Cranioplasty is a routine neurosurgical procedure to repair the continuity of the bone tissue of the skull with autologous bone or synthetic bone flap from heterologous material.
215014030|NCT04165486|DRUG|ION464|ION464 will be administered by IT injection.
215014031|NCT04165486|DRUG|Placebo|ION464-matching placebo will be administered by IT injection.
215014032|NCT06023368|DRUG|Num Vapocoolant Spray|Spray applied around port prior to access
215014033|NCT06023368|DRUG|EMLA Cream|cream applied around the port prior to access
215014034|NCT05265637|DEVICE|Visian|Visian implantable collamer lens (ICL)
215014035|NCT06260618|DEVICE|Gelfoam|GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine skin, Gelatin USP Granules and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids.
215014036|NCT06260618|DEVICE|Chitodex|"The Chitogel Endoscopic Sinus Surgery Kit contains components and equipment for the preparation of a nasal gel to be applied to the sinus cavities via a supplied and specifically designed malleable cannula.~The Gel preparation will take approximately 30 minutes, so preparation must start sufficiently in advance of when the Gel is expected to be used in surgery.~Once the Gel has been prepared it should be applied to the sinus cavities on both sides within six hours using the malleable cannula supplied with the Kit.~The Gel must be prepared on a sterile surface following these instructions. There are two main components to the Gel.~1. Dextran Aldehyde (B), which is a dry powder, and is reconstituted into a liquid form through mixing the powder with a liquid Sodium Phosphate Buffer (A). Both of these components are supplied sterile.~2. The second component Chitosan Succinamide (C), is a liquid and is also supplied sterile."
215014037|NCT06019819|OTHER|strengthening exercise|Perform general physical training activities conducted in schools including upper limb forward elevation, lateral elevation, touching toes in standing and cervical range of motion, strengthening exercise will be performed for 3days a week for 4 weeks.
215014038|NCT06019819|OTHER|Postural correction exercises|Chin Tuck, Strengthening shoulder retractors, Stretching sternocleidomastoiD, Pectorals stretch For strengthening exercises 3 sets of 10 repetitions were performed with 6 seconds rest period between each set and a hold of 6 seconds. Stretching exercises will be performed in 3 sets of 10 repetitions ,30 seconds hold and 30 seconds rest period between each exercise. The exercises were performed 3days a week for 4 weeks.
215014039|NCT06964048|DEVICE|Cold Atmospheric Plasma treatment|Participants in the intervention group will be treated with cold plasma therapy with Plasana One®, as an add-on to the standard of care.
215014040|NCT06964022|OTHER|Sham-BFR|Six-week prehabilitation program (2/week): Unilateral Leg Press and Leg extension exercise with 30% of the individual 1RM by using a sham-BFR intervention with 20mmHg exercise pressure.
215014041|NCT06964022|OTHER|BFR|Six-week prehabilitation program (2/week): Unilateral Leg Press and Leg extension exercise with 30% of the individual 1RM by using a BFR intervention with an exercise pressure corresponding to 60% of the individual LOP.
215100263|NCT00005994|DRUG|ondansetron|
215100264|NCT04953624|DIAGNOSTIC_TEST|Appetite rating scale CNAQ|Chinese version of Appetite rating scale CNAQ
215100265|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 8 weeks with specific exercises to target low back pain.
215100266|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 4 weeks with specific exercises to mitigate persistent post mastectomy pain ahead of the surgery.
215100267|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Migraine|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 6 weeks with specific exercises to target migraine pain.
215100268|NCT02180477|DRUG|UHAC 62 XX - TF1 tablet|
215100269|NCT02180477|DRUG|UHAC 62 XX - TF2 tablet|
215100270|NCT02180477|DRUG|UHAC 62 XX - capsules|
215100271|NCT03441503|OTHER|Child HCAHPS: Automated day-of-discharge survey|Child HCAHPS surveys will be administered on the day of discharge via an electronic interactive patient care system on inpatient televisions.
215100272|NCT05246813|OTHER|Blood and bone marrow cell collection|Collection of blood and bone marrow
215014042|NCT06964542|PROCEDURE|Multicomponent exercise intervention|Patient will be under the complete supervision of physical therapist in a clinical setup.A total of 18 sessions of supervised multicomponent exercise training, thrice a week on alternate days for 6 consecutive weeks, session will be of 45 mins. Multicomponent exercise training including strength and progressive resistance training exercises, actvities will inc. Seated Marching,heel raises,toe raises, sit - to-stand. And balance training activities will involve tandem stands,single leg stance,weight shifting and resistance activities including weight lifting according to feasibility.
215100273|NCT01054625|BIOLOGICAL|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
215100274|NCT04502368|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|FOB under full sedation (RASS sedation scale -5) and full paralysis.
215100275|NCT04502368|PROCEDURE|Bronchoalveolar Lavage (BAL)|BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.
215100276|NCT04502368|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|Realtime thoracic impedance coupled with ventilation parameters recording.
215100277|NCT04502368|DIAGNOSTIC_TEST|Arterial Blood Gas test (ABG)|Multiples Arterial Blood Gas test (ABG) via arterial catheter.
215100278|NCT03085186|DRUG|Crizotinib|
215100279|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
215100280|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
215100281|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
215100282|NCT01143194|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo twice a day
215100283|NCT03074682|DEVICE|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
215100284|NCT03074682|DEVICE|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
215100285|NCT03074682|DEVICE|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
215100286|NCT03009318|OTHER|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
215100287|NCT00410306|DRUG|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
215100288|NCT05339230|DIETARY_SUPPLEMENT|Salovum and SPC-flakes active or placebo|Foods for specific medical purposes or corresponding placebo
214409566|NCT06103422|DIAGNOSTIC_TEST|Whole mouth taste tests|Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering whole mouth taste tests. In the whole mouth taste test, one ml of the specific solution was drawn into the syringe and sprayed into the mouth of the patient circularly. After each administration, patients spat out the solutions and reported whether they perceived any taste and, if so, which taste it was.
215014043|NCT06964542|PROCEDURE|Non Supervised|In non supervised group , patient will receive all the intervention with the help of exercise diary and guidance provided by the physical therapist. Patient will perform 18 sessions, thrice a week on alternative days, for 6 consecutive days for 45 mins. In diary patient is provided the tick mark table in which patient will mark the attendance on days ptn will perform the exercise. Diary is a complete guidance for home based exercise program which include QR based videos of performance of all exercises and complete guidelines are provided in urdu for the better understanding along with pictorial information. In this program activities that patient will perform includes; stairs climbing, sit to stand, leg raises, side stepping, leg raises with weight on ankles starting from 1kg to 3kg. Walk starting from 20 minutes to 40 minutes till 6 weeks. Resistance and other activities will be included.
215014044|NCT06963333|BEHAVIORAL|Breathing guided exercise|Breathing guided exercise are divided into six sections: relaxing standing, two fields breathing, regulating lung and kidney, turning side finger, running kidney hall and nourishing qi and collecting gong. Exercise time: 5 days a week, 1 to 2 times a day, a total of 24 weeks.
215014045|NCT06963333|BEHAVIORAL|Flat walking training|Flat walking training can be performed either outdoors or on flat indoor surfaces at a steady pace of 80 to 120 steps per minute for at least 30 minutes each session, raising the heart rate to the target range and maintaining it for over 10 minutes. This should be done 3 to 5 times a week, with 1 to 2 sessions each day, for a total of 24 weeks. The intensity of the exercise is moderate. The target heart rate based on heart rate reserve is calculated as (maximum heart rate during exercise - resting heart rate) × (40-60)% + resting heart rate.
215014046|NCT03508297|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
215014047|NCT05980455|DEVICE|Enterra® Therapy System|The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
215014048|NCT00620035|DRUG|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
215014049|NCT04889651|DRUG|BR9004|BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
214693990|NCT01894477|DRUG|Treosulfan|Intravenously administered Treosulfan
214693991|NCT01894477|OTHER|Laboratory Biomarker Analysis|Correlative Studies
214693992|NCT02916030|DIETARY_SUPPLEMENT|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
215014050|NCT04889651|DRUG|BR9004-1|BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
215014051|NCT05299970|OTHER|Fermented porridge|A millet porridge (fermented or not, depending on group allocation) serving will be provided to participants daily, for consumption. consumption will be directly observed.
215014052|NCT01292265|BIOLOGICAL|Certolizumab Pegol|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
215014053|NCT05792930|BEHAVIORAL|cognitive-behavioral therapy and biofeedback therapy|Complete eight sessions of cognitive-behavioral therapy and biofeedback therapy within three months.
215100289|NCT00651625|DEVICE|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
215100290|NCT00651625|DEVICE|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
215100291|NCT00257972|DRUG|aripiprazole|
215100292|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular
215100293|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular
215100294|NCT03288363|DEVICE|tDCS|20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)
214409567|NCT06103422|DIAGNOSTIC_TEST|Localized taste tests|Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering localized taste tests. In the localized mouth taste test, the highest concentration solution of one of the four flavors was administered. In each application, 0.25 ml of solution was absorbed on a sterile cotton swab and applied on 6 test areas on the palate and tongue.
214409568|NCT04287751|DEVICE|CheckMeO2 Oximeter|Simultaneous recording with a current standard oximeter (Minolta i300) and prolonged recording device. Comparison of data from first night and incidence of obstructive sleep apnoea identified from additional nights of recording identified.
214409569|NCT02376933|PROCEDURE|Vertebroplasty|Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.
214409570|NCT02376933|RADIATION|Radiotherapy|Radiotherapy of metastatic lesions to the spine.
214409571|NCT04157166|DIAGNOSTIC_TEST|to record a whole body 3D of 25 minutes in camera VERITON-CT ™|The procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT) will be added to conventional recording followed by complementary images SPECT/CT
214693993|NCT04868006|PROCEDURE|End-range Maitland mobilization + proprioception training|End-range Maitland mobilization performed in end position of internal rotation of the shoulder accompanied with 8--week long proprioception training
215100295|NCT03031067|DEVICE|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
215100296|NCT02953886|DEVICE|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
215100297|NCT05158790|OTHER|Questionnaire|Administration of a questionnaire
215100298|NCT05957614|PROCEDURE|Traditional rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture, including immobilization, early weightbearing ankle motion exercise and isolated early ankle motion exercises.
214693994|NCT04868006|PROCEDURE|Non end-range Maitland mobilization + proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
215100299|NCT05957614|PROCEDURE|Acupuncture-assisted Rehabilitation Protocol|Add acupuncture treatment on the basis of traditional rehabilitation protocol.The acupuncture procedure is as follows, acupuncture treatment is carried out for half an hour every day in two weeks after surgery. The acupoints on the affected side are ST36(ZuSanLi), GB34(YangLingQuan) and SP9(YinLingQuan), and the acupoints on the healthy side are Ki3(TaiXi), bl60(KunLun) and PC7(DaLing).
215014054|NCT03588429|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
215100300|NCT02163421|DRUG|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
215100301|NCT02163421|DRUG|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
215100302|NCT03650790|DIAGNOSTIC_TEST|Blood test|For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
215100303|NCT04004013|DIETARY_SUPPLEMENT|Lifenol®|"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~\+ 1000 mg of calcium and 800 IU of vitamin D per day"
215014055|NCT03588429|DRUG|Isoflurane|Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
215014056|NCT04481438|OTHER|Acupunch Exercises|The acupunch exercise program was developed based on Jing-Luo theory of tranditional Chinese Medicine. The experiment group will receive Acupunch exercise for 40 minute sessions, 3 times a week, for 24 weeks
215014057|NCT04193176|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
214409572|NCT03860077|DRUG|Very Low Nicotine Content Cigarettes|Very Low Nicotine Content Cigarettes
214409573|NCT03860077|DRUG|Normal Nicotine Content Cigarettes|Normal Nicotine Content Cigarettes
214409574|NCT03687385|DEVICE|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
214409575|NCT03687385|DEVICE|low-flow nasal oxygenation (LFNO)|Active comparator LFNO: O2 flow 5L/min, FiO2 40%
214409576|NCT01853917|OTHER|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
214409577|NCT00430677|DRUG|Corticosteroids (prednisone or prednisolone)|tablets, oral, 0.5-0.8 mg/kg, daily
214409578|NCT00430677|DRUG|Abatacept|intravenous solution, injectable, 30 mg/kg, every 28 days
214409579|NCT00430677|DRUG|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
215100304|NCT04004013|DIETARY_SUPPLEMENT|Placebo|"Maltodextrin = 500 mg/capsule~\+ 1000 mg of calcium and 800 IU of vitamin D per day"
215014058|NCT04193176|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
215014059|NCT05792722|PROCEDURE|Prostate capsule-sparing radical cystectomy|Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
215014060|NCT05792722|PROCEDURE|Nerve sparing radical cystectomy|Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
215014061|NCT04377919|DIETARY_SUPPLEMENT|Cranberry|The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
215014062|NCT04377919|DIETARY_SUPPLEMENT|Placebo|The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
215014063|NCT01629563|DRUG|PGL4001 5 mg|PGL4001 5 mg daily administration
215014064|NCT01629563|DRUG|PGL4001 10 mg|PGL4001 10mg daily administration
215014065|NCT03165500|DRUG|Diazepam|"Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
214409580|NCT00430677|DRUG|Mycophenolate mofetil (MMF)|tablets, oral, 1.5 to 2 g, daily
214409581|NCT00430677|DRUG|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
215014066|NCT03165500|DRUG|Midazolam|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
215100305|NCT04232436|OTHER|Survival at discharge|Survival at discharge
215100306|NCT04232436|OTHER|Survival without severe morbidity|Survival without severe morbidity (IVH, severe BPD, NEC, ROP)
214409582|NCT06083714|OTHER|Scapular Stabilization Exercises|Home-based scapular stabilization exercises (Inferior Glide, Low Row, Scapular Clock, Wall Push Up, Wall Slide and Squat Robbery) will be performed once or twice a day, 3 sets x 20 repetitions, 3 days a week for 8 weeks.
214409583|NCT06083714|OTHER|Schroth Exercises|It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
214409584|NCT02770664|DRUG|Placebo|Placebo
214409585|NCT02770664|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
214409586|NCT02770664|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
214409587|NCT02770664|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
214409588|NCT00254475|DRUG|simvastatin|
214409589|NCT00254475|DRUG|valsartan|
214409590|NCT05058794|OTHER|Blood flow Restriction/Resistance Training|During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and limb occlusion pressure (LOP) was calculated in the body position that the Blood flow Restriction (BFR) stimulus would be applied. Blood Flow Restriction BFR pressure was set at 50% occlusion. Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.
214409591|NCT05058794|OTHER|Conventional Therapy Group|Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.participants will perform 2 sets with 15 repetitions in (0 to 90 degree.)
214409592|NCT06434428|DRUG|dexmedetomidine (IV)|Administration of IV dexmedetomidine
214409593|NCT06434428|DRUG|dexmedetomidine (IN)|Administration of IN dexmedetomidine
215014067|NCT03165500|DRUG|Nitrous Oxide + Oxygen Gas|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971)."
215014068|NCT03165500|PROCEDURE|Third molar extraction|Anxious patients in need of third molar extraction
215014069|NCT03811119|DEVICE|MANTA vascular closure device|Collagen based vascular closure device
215014070|NCT03811119|DEVICE|Suture based vascular closure device|Suture based vascular closure device (ProGlide)
215014071|NCT05085756|BEHAVIORAL|Puma|One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.
215100307|NCT05735756|DRUG|Citalopram 20mg|Citalopram 20mg once a day for 12 weeks
215100308|NCT05735756|DRUG|Placebo|Placebo once a day for 12 weeks
215100309|NCT00230152|DEVICE|Imaging|
215100310|NCT00576576|DRUG|Atorvastatin|Atorvastatin 80 mg a day
215100311|NCT01010152|DRUG|Codeine Sulfate|30 mg Tablet
214409594|NCT01333514|DRUG|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
214409595|NCT01333514|DRUG|aspart- Insulin|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
214409596|NCT05013164|DRUG|Folinic Acid|Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks
215100312|NCT05850923|OTHER|speech competition training|Speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction.
215100313|NCT05850923|OTHER|the soothing music|the soothing music
215100314|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^3 dose of rDEN3-3'D4delta30 vaccine.
214409597|NCT04038476|DIAGNOSTIC_TEST|Standard monitoring + transcutaneous CO2 monitoring|The transcutaneous CO2 Monitoring measures the CO2 partial pressure of the skin and in condition of good circulation these values approximate the arterial/venous CO2 partial pressure. The sensor is placed on the forehead. The physician adapts the sedation Management according to the transcutaneous CO2 monitoring.
214409598|NCT04038476|DIAGNOSTIC_TEST|Standard monitoring|The transcutaneous CO2-sensor is also positioned on the patients' forehead, but the transcutaneous CO2-monitoring is not available for the physician to adapt the sedative management.
214409599|NCT04535375|DIAGNOSTIC_TEST|Doppler Ultrasound of venous cerebral circulation|No additional ultrasound examinations, specifically for the purpose of this study, will be performed. Instead, with each routine ultrasound examination, additional images on top of the routine frames will be collected. Those images will document the velocity and flow in the internal cerebral veins bilaterally using the standard Color Doppler tech-nique. Taking these additional images will prolong the time of ultrasound examination only minimally (with a few minutes).
214409600|NCT02851147|DEVICE|SL-D301|Slit Lamp
214409601|NCT02851147|DEVICE|DC-4|Digital Camera Attachment
214409602|NCT02851147|DEVICE|SL-3G|Slit Lamp
214409603|NCT00836810|DRUG|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
214409604|NCT00836810|DRUG|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
214688398|NCT05790668|BEHAVIORAL|PIA-Informed Schedule Thinning|This intervention involves the same general components as Traditional Schedule Thinning. However, rather than starting with an arbitrary duration of the extinction component (e.g., 2 s), the behavior analyst empirically derives the starting point based on a progressive-interval assessment (PIA). The PIA involves rapidly increasing the duration of the extinction component within a single session to determine the leanest schedule of reinforcement that does not produce untoward effects. Behavior analysts will progress through the following extinction durations within a single session: 3 s, 11 s , 21 s, 34 s, 50 s, 70 s, 95 s, 126 s, 164 s, 213 s, and 270 s. For example, if the participant displays destructive behavior at 164 s consistently, but not at 126 s, the experimenters will start schedule thinning with a 126-s extinction component. There will be no competing stimuli programmed in this intervention.
215014072|NCT01691911|PROCEDURE|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
215014073|NCT05861453|DRUG|Epeleuton|Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
215100315|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^5 dose of rDEN3-3'D4delta30 vaccine.
215100316|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^1 dose of rDEN3-3'D4delta30 vaccine.
214409605|NCT00112112|BIOLOGICAL|FluMist|"The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
214409606|NCT00112112|BIOLOGICAL|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
214693995|NCT04868006|PROCEDURE|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
214693996|NCT00869765|DRUG|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
215014074|NCT06636331|OTHER|Continuous Suprainguinal Fascia Iliaca Compartment Block|Using PCRA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
215014075|NCT06636331|OTHER|Continuous Epidural|Using PCEA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
215014076|NCT06053411|DRUG|Diclofenac|25 mg capsule
215014077|NCT06053411|DIETARY_SUPPLEMENT|curcumin|2,000 mg tablet
215100317|NCT00002299|DRUG|Interferon beta-1b|
215100318|NCT00002299|DRUG|Ganciclovir|
215100319|NCT01432990|DEVICE|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
215100320|NCT01432990|OTHER|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
215100321|NCT04942990|OTHER|calisthenic exercises|these exercises are a kind of exercise for increasing cardiovascular endurance
215100322|NCT05322330|DRUG|Selinexor|40-60mg QW,w-3～d-3,PO
215100323|NCT05322330|DRUG|Flu|25-30 mg/m2，d-5 ～d-3，qd，ivgtt
214409607|NCT04733300|BEHAVIORAL|Mindfulness-Based College for Young Adults|"MB-College (MBC) is a 9-week, 9 session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to young adults (18-29). The curriculum, which is based on the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum is designed to teach participants how to integrate and apply mindfulness in their everyday lives to the range of challenges arising from medical and psychological conditions and life stresses.~MBC will be administered live, online via a video conferencing platform to participants enrolled in the active arms of the study: (1) standard dose MBC and (2) low-dose MBC. Standard dose MBC meets once a week for 2.5 hours for 9 weeks, while low-dose MBC meets for 1.5 hours per week for 9 weeks. There is an all-day retreat that takes place around week six of the program that applies to both MBC programs."
214409608|NCT04733300|OTHER|Health Education for Young Adults|The health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
214409609|NCT01155245|DRUG|Forteo|Forteo pen
214409610|NCT06054789|DRUG|68Ga-PSMA-33|Subjects will receive one injection of 68Ga-PSMA-33/PSMA-617 (3-7mCi ), a PET radiopharmaceutical selective for Prostate-Specific Membrane Antigen. 68Ga-PSMA-33/PSMA-617 injection will be followed by a 10 ml saline flush.
215014078|NCT05940636|OTHER|Activity-based rehabilitation+electrical stimulation|Balance training will occur three times per week for four weeks, totaling 12 two-hour sessions. In both groups, you will be asked to stand on a force plate while playing visual feedback training (VFT) games as part of the standing balance training. A force plate is similar to a bathroom scale that you can stand on which measures your body sway during movement. Visual feedback training (VFT) is a type of activity that includes weight-shifting movements in the upright stance. VFT will be done in both groups. There will be different games as shown in figure 1 and the order of the games will be randomly chosen in each session. During each game, there will be targets that will be presented on the screen and you will have to navigate toward them . You will be able to rest between games as needed.
215014079|NCT04725903|RADIATION|High-Dose Rate Brachytherapy|Receive high-dose rate brachytherapy boost
214409611|NCT02286856|BEHAVIORAL|diet intervention|The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
214409612|NCT00895024|BEHAVIORAL|Phone Interview/Questionnaire|35-minute questionnaire over the phone.
214409613|NCT04692948|OTHER|Chimeric antigen receptor T cells (car-t)|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
214409614|NCT00389519|DRUG|ramipril|once a day oral ramipril capsules given for 4 weeks
214409615|NCT00389519|DRUG|placebo|once a day oral placebo capsule for 4 weeks
214409616|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
214409617|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
214409618|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
214409619|NCT00880490|DRUG|Inhaled placebo|single dose, inhaled
215100324|NCT05322330|DRUG|CTX|250-500 mg/m2，d-5 ～d-3，qd，ivgtt
215100325|NCT05322330|DRUG|CAR-T|2-5×10\^6 CAR-T/kg，ivgtt。
215100326|NCT03870425|OTHER|Distribution pattern of dietary proteins (minced meat)|Study effect of an even or skewed distribution pattern of dietary protein
215100327|NCT05932368|OTHER|evaluation|examining files and taking records
215100328|NCT05976009|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
215100329|NCT00016549|BIOLOGICAL|Bevacizumab|
214409620|NCT00880490|DRUG|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
214409621|NCT00607035|DRUG|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
215014080|NCT04725903|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam therapy
215014081|NCT04725903|OTHER|Quality-of-Life Assessment|Ancillary studies
215014082|NCT04725903|OTHER|Survey Administration|Ancillary studies
215100330|NCT05833451|OTHER|Reiki|Reiki, one of integrative practices, is an energy therapy involving the use of energy that flows naturally from the hands of the practitioner to strengthen the body's ability to heal itself in order to increase well-being. Reiki improves well-being in many areas, ensures that blood and lymph circulation is maintained properly, regulates blood pressure and pulse rate by stimulating the autonomic nervous system, increases comfort, reduces depression and anxiety levels. In this way, Reiki facilitates physical and mental relaxation and promotes health
215100331|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
215100332|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
215100333|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
215100334|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
215100335|NCT04018313|BIOLOGICAL|US-licensed Xolair|150 mg/mL, Solution for injection in PFS
215100336|NCT03936751|DEVICE|CPAP|This is the standard treatment for OSA.
215100337|NCT03936751|DEVICE|Nasal Strips|Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
215100338|NCT00708760|BEHAVIORAL|paper based training|read selected material, test skills learned in simulator lab
214409622|NCT00607035|DRUG|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
215014083|NCT02370394|BEHAVIORAL|ROSE Program|The ROSE Program was specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It was tailored to the current IPV risk assessment, pregnancy or postpartum status of each participant, was designed to reach participants across levels of motivation for change. The content of ROSE was theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
214409623|NCT02040844|DRUG|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
214409624|NCT02040844|DRUG|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
214409625|NCT02040844|DRUG|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
214409626|NCT03663101|DRUG|Lidocaine|0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
214409627|NCT03663101|BIOLOGICAL|Botulinum toxin type A|0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
214409628|NCT03663101|DRUG|Placebo|Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
214409629|NCT03663101|DRUG|Placebo|Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
214409630|NCT05843656|OTHER|Non-invasive brain stimulation|based on sleep-physiology (slow-wave and spindles)
214409631|NCT05472649|BIOLOGICAL|Gene-Modified Cell Therapy|No investigational cell product will be administered
214409632|NCT03924245|DRUG|Entinostat|Given by mouth
214409633|NCT03924245|DRUG|Olaparib|Given by mouth
214688399|NCT05790668|BEHAVIORAL|PIA-Informed Schedule Thinning with Competing Stimuli|This intervention is identical to PIA-Informed Schedule Thinning except that behavior analysts will program competing activities (e.g., alternative activities like toys or therapist attention) during extinction components. The competing stimuli will be derived from a competing stimulus assessment in which destructive behavior is analyzed across various conditions in which only the activity is manipulated during the extinction period (e.g., a session with action figures during extinction, a session with tablet during extinction). The items that produce the highest levels of child engagement and lowest levels of destructive behavior are known as highly competing items.
214409634|NCT03661970|OTHER|Cognate Speech Synthesizer sound percepts|The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
215014084|NCT03302611|BEHAVIORAL|Physical Activity-based Interventions|Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
214409635|NCT05765591|OTHER|Balneotherapy and aquatic exercises|Information has already been included in arm/group descriptions
214409636|NCT04122924|OTHER|Abdominal muscle training|The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
214688400|NCT06839976|BIOLOGICAL|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.
215014085|NCT01148420|DRUG|Medroxyprogesterone 17-Acetate|Medroxyprogesterone 20mg orally 3 times a day for 3 days
215014086|NCT01148420|DRUG|medroxyprogesterone acetate|Depo Provera 150mg Intramuscular injection
215014087|NCT05249920|DRUG|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
215014088|NCT05249920|DRUG|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
215014089|NCT02042001|DRUG|Immediate switch to TDF/FTC/RPV|
214409637|NCT04362319|DIAGNOSTIC_TEST|Questionnaire forms|Assessment of demographics, burnout, depression and self-perceived medical errors
214409638|NCT00609648|BEHAVIORAL|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
214409639|NCT00609648|BEHAVIORAL|Pamphlet|A pamphlet reassuring patients about dental injections.
214688401|NCT04736173|DRUG|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
214688402|NCT04736173|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
214688403|NCT04736173|DRUG|Carboplatin|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
214688404|NCT04736173|DRUG|Paclitaxel|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
214688405|NCT04736173|DRUG|Pemetrexed|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
214688406|NCT04736173|DRUG|Pembrolizumab|Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor
215014090|NCT02042001|DRUG|Switch to TDF/FTC/RPV after 24 weeks|Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
215014091|NCT01996540|OTHER|Interventional arm: Early best palliative care|Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
215100339|NCT00708760|BEHAVIORAL|web based training|read and view selected web based material, test skills learned in simulator lab
215100340|NCT00488904|DIETARY_SUPPLEMENT|supportan|2 sip feed pr. day
215100341|NCT00488904|DIETARY_SUPPLEMENT|supportan placebo|2 sip feed pr. day
215100342|NCT03461094|DEVICE|Preload assessment and volume expansion|Fluid therapy perform
214409640|NCT01353638|DRUG|Dipeptiven (Alanyl-glutamine-dipeptide)|Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
214409641|NCT03518541|PROCEDURE|Femoral Derotation Osteotomy (FDO)|Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
215100343|NCT05920772|BEHAVIORAL|KickAsh! intervention|The general aim of the KickAsh! intervention is to prevent smoking initiation in adolescents living in vulnerable socioeconomic situations. The intervention exists of different components concerning smoking prevention. Most components have a direct influence on smoking initiation by affecting several determinants of the adolescents. These components include smoke-free games, mood boards, a smoke-free camp, the Kick some Ash!-challenge and exercises concerning self-efficacy and skills. Yet, some of the components target adolescents by influencing their environment, i.e. smoking policy in the organisation and youth workers as role models. All components are developed using a combination of theoretical methods to change or influence these determinants or environmental factors.
214409642|NCT04784013|PROCEDURE|Conventional CLOSE-guided pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.
215014092|NCT01842178|PROCEDURE|scratching|"Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control."
214409643|NCT04784013|PROCEDURE|High power short duration pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
214409644|NCT05579886|DEVICE|Control Lens|Daily disposable multifocal soft lens with 2 add design (2ADD) for 2 weeks
214409645|NCT05579886|DEVICE|Test Lens|Daily disposable multifocal soft lens with 3 add design (3ADD) for 2 weeks
214409646|NCT01560949|DRUG|Oxaliplatin|75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
214409647|NCT01560949|DRUG|Irinotecan|150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
214409648|NCT01560949|DRUG|5-FU|2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
214409649|NCT01560949|DRUG|Gemcitabine|350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
214688407|NCT04802850|OTHER|Mulligan mobilization with movement|
214688408|NCT00532961|DRUG|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
214688409|NCT00532961|DRUG|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
214688410|NCT00139334|BIOLOGICAL|Rotavirus|
214688411|NCT01029431|DEVICE|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted \& the evaluation described below will be conducted. The first LMA will then be removed \& the other device inserted \& assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment \& before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, \& inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
214688412|NCT04684550|DRUG|Stabilized hypochlorous acid|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
214688413|NCT04684550|DRUG|Placebo|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
215014093|NCT00685282|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
215014094|NCT00856102|BEHAVIORAL|Exercise|Home-base walking program
214409650|NCT01560949|RADIATION|Radiation Therapy|External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
214409651|NCT05139732|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
214409652|NCT03181724|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
214409653|NCT03032159|BEHAVIORAL|Text2Breathe Study Group|
214409654|NCT02572778|PROCEDURE|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
215014095|NCT00856102|BEHAVIORAL|Control|Usual care
215014096|NCT01927289|PROCEDURE|Proximal Brachial Plexus vs Distal Forearm Block|"Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.~Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach"
215014097|NCT03367585|DIETARY_SUPPLEMENT|Physical exercise + Vitamin D3|Strength exercise + Supplementation of vitamin D3 50,000 IU / week
215014098|NCT03367585|OTHER|Physical exercise|Strength exercise
215014099|NCT06324578|DIAGNOSTIC_TEST|AT Testing|Analysis of blood specimens and neck ultrasonography
215014100|NCT00615316|DRUG|Guaraná|Guaraná extract 75mg/day
215014101|NCT00615316|DRUG|Placebo|Placebo 1tab/d
215014102|NCT00188838|BEHAVIORAL|Psychoeduction|
215014103|NCT00188838|BEHAVIORAL|Cognitive-Behavioral Therapy|
215014104|NCT02676622|DRUG|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
215014105|NCT02676622|OTHER|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
215014106|NCT02676622|DRUG|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
215014107|NCT02676622|OTHER|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks"
215014108|NCT02676622|DRUG|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is \> 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
215014109|NCT01014156|DRUG|epoprostenol|titration up to 4 ng/kg/min
215014110|NCT02117154|DEVICE|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
215014111|NCT00218894|PROCEDURE|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
214688414|NCT04310215|BIOLOGICAL|CARTISTEM®|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture~2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)"
215014112|NCT03796130|PROCEDURE|Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (1): myomectomy will be performed before ART~In group (2):women will have their trial of ART without myomectomy~In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
215014113|NCT04574505|DIETARY_SUPPLEMENT|Eufortyn Colesterolo Plus|Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.
215014114|NCT04574505|DIETARY_SUPPLEMENT|Placebo|Placebo
215014115|NCT01622335|DRUG|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
215014116|NCT01622335|OTHER|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
215014117|NCT06348212|DIETARY_SUPPLEMENT|Lactobacillus paracasei PS23|2 caps daily use
215014118|NCT06348212|DIETARY_SUPPLEMENT|microcrystalline cellulose|2 caps daily use
215014119|NCT02015936|BEHAVIORAL|Six Week Physical Activity Intervention|Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
215014120|NCT02015936|OTHER|Progress Reporting|Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
215014121|NCT02137356|RADIATION|standard dose pelvic radiation therapy|"radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy"
215014122|NCT02137356|DRUG|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
215014123|NCT02137356|DRUG|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
215014124|NCT03927430|PROCEDURE|pars plana vitrectomy with membrane peeling|23-gauge pars plana vitrectomy with peeling of the epiretinal and internal limiting membrane as well as air- or gastamponade
215014125|NCT02398474|DRUG|TFP block ropivacaine|
215014126|NCT02398474|DRUG|ropivacaine infiltration of the iliac crest bone|
215014127|NCT00260390|DRUG|Testoviron|
215014128|NCT04607785|DRUG|Miswak mouthwash group|Twice daily for seven days for two months
215014129|NCT04607785|DEVICE|Chlorhexidine gluconate mouthwash|Twice daily for seven days for two months
215014130|NCT04026451|DEVICE|Sedation guided by SEF95 (10-13 Hz) from SedLine® monitor|Dosage of propofol and fentanyl will be guided by SEF95 value between 10-13 Hz. If SEF95 is lower than 10 Hz, the infusion rate of propofol and fentanyl will be diminished; if SEF95 is higher than 13 Hz, the infusion rate of propofol and fentanyl will be increased; and if SEF95 is between 10-13 Hz, then the infusion rate will be kept.
215014131|NCT04026451|BEHAVIORAL|Sedation guided by SAS scale (1-2)|Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.
215014132|NCT04026451|DRUG|Deep sedation with propofol andfentanyl|Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
215014133|NCT04026451|PROCEDURE|Mechanical Ventilation|Critically ill patients will be ventilated mechanically following the clinical indication.
215014134|NCT04679025|OTHER|Exposure - postoperative hyperglycemia|Postoperative hyperglycemia (blood or capillary glucose \> 10.0 mmol/L) within 72 hours of a surgical procedure
215014135|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Tobramycin Sulfate|Seven-day local antibiotic irrigation with tobramycin sulfate via the VT-X7 Knee or Hip Spacer.
215014136|NCT04662632|DRUG|Standard of Care|Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
215014137|NCT04662632|PROCEDURE|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
215014138|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Vancomycin Hydrochloride|Seven-day local antibiotic irrigation with vancomycin hydrochloride via the VT-X7 Knee or Hip Spacer.
215014139|NCT05804292|OTHER|Questionnaire administration|Questionnaire administration
215014140|NCT01902303|DRUG|Matching Placebo|Sublingual micro dosing of placebo for 7 days
215014141|NCT01902303|DRUG|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
215014142|NCT02383485|BEHAVIORAL|Exercise|Heart rate monitors worn by each child at each session
215014143|NCT02383485|BEHAVIORAL|After-school program|Supervised recreational program with token economy
215014144|NCT05298501|OTHER|No intervention/exposure|No interventions/exposures will be administered or evaluated
215014145|NCT03884036|BIOLOGICAL|Vitamin D|Vitamine D
215014146|NCT03274349|PROCEDURE|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
215014147|NCT03274349|PROCEDURE|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
215014148|NCT02821000|BIOLOGICAL|Pembrolizumab|Intravenous infusion
215014149|NCT04634903|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
215014150|NCT04634903|BEHAVIORAL|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
215014151|NCT04634903|BEHAVIORAL|Growth Mindset SSI|Online, 30-minute self-administered program for youth
215014152|NCT01794169|DRUG|Azacitidine|
215014153|NCT01794169|DRUG|DA|
215014154|NCT05639205|DIAGNOSTIC_TEST|Lateral Flow Device|Regular asymptomatic staff testing with a Lateral Flow Device including support payments if unwell.
215014155|NCT00875407|OTHER|Scintigraphy in 123I-IBZM|
214409655|NCT02914067|OTHER|Neurocognitive testing|
214409656|NCT02914067|DEVICE|rsfcMRI|The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross
214409657|NCT03902340|DEVICE|ActiTENS|ActiTENS is a rechargeable box, weighing 64g attached by Velcro to an adhesive support, which can be positioned on the skin at any position chosen by the patient. The patient will use the programme (P4) prescribed by his doctor and will regulate the intensity of stimulation using an application downloaded to his smartphone which will communicate with the box via Bluetooth.
214409658|NCT03902340|DRUG|Level 2 Analgesic Treatments|"There are 4 level 2 oral analgesic treatments indicated for chronic nociceptive pain of moderate to severe intensity (between 4 and 7 on a simple numerical scale of 11 points) (12):~* Tramadol immediate release formulation (IR, one intake every 6 hours) or prolonged release formulation (PR, one intake every 12 hours); maximum posology 400mg/24h.~* Dihydrocodeine: 60mg every 12 hours; maximum posology 120mg/24h.~* Combination of paracetamol and codeine in a fixed combination every 6 hours; maximum posology of codeine: 300mg/24h.~* Combination of paracetamol and tramadol in a fixed combination; maximum posology of tramadol: 8 tablets/24h ie 300mg/24h."
214409659|NCT02068885|BEHAVIORAL|Feeding study|Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
214409660|NCT00137956|DEVICE|Emphasys Endobronchial Valve (EBV) Device and Procedure|
214409661|NCT00681811|DRUG|HGT-1111|Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.
214409662|NCT01642264|BEHAVIORAL|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
214688415|NCT04310215|PROCEDURE|Microfracture|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1\. Procedure: Microfracture"
215014156|NCT02255695|OTHER|School-based exercise program|The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
215014157|NCT05673655|DRUG|intraoral trigger point injection by botox|intraoral injection of trigger point of masseter muscle by botulinum toxin
215014158|NCT05673655|DRUG|transcutaneous trigger point injection by botox|transcutaneous injection of masseter muscle by botulinum toxin
215014159|NCT04252118|BIOLOGICAL|MSCs|3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
215014160|NCT03416933|OTHER|Blood sampling|2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
215014161|NCT03279419|DIAGNOSTIC_TEST|Thermal imaging|Use of thermal imaging camera to capture images of peripheral vasculature (hands).
214688416|NCT06166095|OTHER|high-dose|Participants will be asked to perform a high-dose (HD) (i.e., 300 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
215014162|NCT05655897|DEVICE|GeminiOne Transcatheter Valve Edge-to-Edge Repair System|The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
214688417|NCT06166095|OTHER|Walking attention control|The attention control group will be asked to wear the Fitbit activity tracker to monitor their sleep each night for 10 weeks.
214688418|NCT06166095|OTHER|moderate-dose|Participants will be asked to perform a moderate-dose (MD) (i.e., 150 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
215014163|NCT01389284|DRUG|Naproxen Sodium ER (BAYH6689)|660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
215014164|NCT01389284|DRUG|Naproxen Sodium IR (Aleve, BAYH6689)|220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
215014165|NCT01389284|DRUG|Naproxen Sodium ER Placebo|Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
215014166|NCT01389284|DRUG|Naproxen Sodium IR Placebo|Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
215014167|NCT00601016|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
215014168|NCT01144351|DRUG|ELND002|
215014169|NCT01144351|DRUG|Placebo|
215014170|NCT00476788|DEVICE|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
215014171|NCT04162314|DRUG|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
215014172|NCT04162314|DRUG|Placebos|Placebos
215014173|NCT00394472|DRUG|AZD3355|
215014174|NCT05359757|OTHER|Effect of Naturalistic Teaching Strategies in Children with autism spectrum disorder|"In this group, the patients will be provided with both the naturalistic therapeutic techniques the PECS Therapy.~A baseline of the kids in this group will be made using the portage guide and PECS~* Incidental teaching trial, natural language paradigm, and time delay concepts will be incorporated in the therapy sessions and communication using picture cards will be made.~* 40 minutes session will be conducted in which 20 minutes session will be for naturalistic teaching techniques and 20 minutes will be for PECS.~* This will be followed for 30 sessions"
215014175|NCT05359757|OTHER|PECS Therapy only|"A baseline will be developed using the portage guide and PECS.~* Communication strategies using the PECS picture cards will be made~* 30 minutes session will be conducted~* This will be followed for 30 sessions"
215014176|NCT03701178|OTHER|BioHPP PEEK|milled BioHPP PEEK in a new material can be used as a dental restoration
215014177|NCT06124677|DRUG|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
215014178|NCT02181621|DEVICE|Iodosorb|Cadexomer iodine gel
214409663|NCT03759171|OTHER|Guitars for Vets Intervention|This was an active intervention providing veterans with an acoustic guitar, guitar pick, tuning instruments, a music book, practice CDs, and individual and group sessions of music instruction during a 6-week intervention period. Six tailored 1-hour individual guitar instruction sessions were scheduled (1 session per week). In addition to the 6 tailored individual lessons, the intervention provided 3 group sessions. Veterans were given a guitar that they could keep upon completion of the program. The same instructor was assigned to a subject for the duration of the study, and group sessions were supervised by the Education Director of Guitars for Vets.
214409664|NCT01698671|DEVICE|InterGard Synergy Vascular Graft|
214409665|NCT00928109|BEHAVIORAL|CBCT|Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
214688419|NCT02775760|BEHAVIORAL|Cardiovascular endurance|Physical exercise at the Boston University Fitness and Recreation Center
214688420|NCT02775760|BEHAVIORAL|Strength, balance, and flexibility|Physical exercise at the Boston University Fitness and Recreation Center
214688421|NCT01760941|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
214688422|NCT01760941|OTHER|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
214688423|NCT01760941|OTHER|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
215014179|NCT02181621|DEVICE|Solosite gel|Hydrogel
215014180|NCT02697929|DRUG|sugammadex|
215014181|NCT02697929|DRUG|Neostigmine|
215014182|NCT02585102|OTHER|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
215014183|NCT02585102|OTHER|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
215014184|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
215014185|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
215014186|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
215014187|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
215014188|NCT00908388|DEVICE|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
215014189|NCT02327780|OTHER|FODMAP diet|
215100344|NCT04491760|OTHER|Inspiratory Muscle Training|The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
214409666|NCT00928109|BEHAVIORAL|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
214409667|NCT01365338|DRUG|Placebo|Administered as specified in the treatment arm
214409668|NCT01365338|DRUG|PF-04958242|Administered as specified in the treatment arm
214409669|NCT03921528|BIOLOGICAL|SRK-015|SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
214409670|NCT04928157|DEVICE|Positive Airway Pressure (PAP)|A device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
214409671|NCT03526445|DRUG|Glucagon|Glucagon (4 ng/kg/min)
214409672|NCT03526445|DRUG|Saline|Placebo
214409673|NCT01268761|DRUG|GnRH antagonist (Cetrorelix)|•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
215014190|NCT01217138|DEVICE|Epinephrine autoinjector|We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
215014191|NCT00795795|PROCEDURE|Preimplantation Genetic Screening|Preimplantation Genetic Screening
215100345|NCT01846650|DRUG|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
215100346|NCT01846650|DRUG|XELODA|Single oral XELODA 2000mg qd
214409674|NCT01268761|DRUG|Placebo (saline solution)|• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
214409675|NCT01562743|DRUG|SPM 962|Tansdermal patch
214409676|NCT01634919|DEVICE|chronic hepatitis C|acoustic radiation force impulse ultrasonography
214409677|NCT05714670|DRUG|Curcumin Oral Capsule|Curcumin 1000 mg Oral Capsule beside the standard of care
214409678|NCT04684342|DIAGNOSTIC_TEST|Routine Laboratory investigations|"1. Complete blood picture~2. Liver function test and prothrombine time \& concentration.~3. Blood urea and creatinine~4. Blood glucose, serum Na and K~5. CRP and ESR~6. Clinical specimens will be collected from patients according to the suspected site of infection (e.g. blood, urine, ascitic fluid, sputum or endo- tracheal aspirates) VITEK 2Compact inflammatory markers"
214409679|NCT06141239|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
214409680|NCT06141239|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration
214409681|NCT06141239|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
214409682|NCT06664112|DEVICE|AIDA Analysis|The women will be followed until and after the birth, under intrapartum ultrasound monitoring, with all clinical, ultrasonographic and obstetric parameters, analyzed by AIDA method.
214409683|NCT05286541|PROCEDURE|Lateralized buccal cortex with xenograft|the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance
214409684|NCT05286541|PROCEDURE|Lateralized buccal cortex with autogenous particulate|lateralized buccal cortex with autogenous particulate
214409685|NCT02299921|OTHER|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
214409686|NCT06361940|DRUG|Aromatase inhibitors or tamoxifen|Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.
214409687|NCT06615271|PROCEDURE|Neurosurgery|Patients who have undergone neurosurgery form more than 3 hours.
214409688|NCT03250325|BIOLOGICAL|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.
214409689|NCT03250325|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
214688424|NCT05023655|DRUG|Tazemetostat|800mg po twice daily
214688425|NCT04502810|RADIATION|High-level laser therapy|Nd:Yag 1064 nm pulsed high-level Laser will be applied to the vulvar area.
215014192|NCT00795795|PROCEDURE|IVF without PGS|IVF without PGS
215014193|NCT04951453|OTHER|None (observational)|None (observational)
215014194|NCT03845673|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber (Konsyl; Konsyl Pharmaceuticals, Easton, Md)
215014195|NCT03845673|DIETARY_SUPPLEMENT|Bowel recipe|consisted of 1 cup of unprocessed wheat bran, 1 cup of applesauce, and 1/4 cup of prune juice.
215014196|NCT00919490|DRUG|ABT-333|Tablet, see arms for interventional description
215014197|NCT00919490|DRUG|Placebo|Tablet, see arms for interventional description.
215014198|NCT02914678|OTHER|Fentanyl|Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
215100347|NCT01805037|DRUG|brentuximab vedotin|Given IV
215100348|NCT01805037|BIOLOGICAL|rituximab|Given IV
215100349|NCT01805037|OTHER|laboratory biomarker analysis|Correlative studies
215100350|NCT00085332|DRUG|docetaxel|
215100351|NCT02562807|DRUG|TAS-303 18mg single-dose|
215100352|NCT02562807|DRUG|Placebo 18mg single-dose|
215100353|NCT02562807|DRUG|TAS-303 9mg single-dose|
215100354|NCT02562807|DRUG|Placebo 9mg single-dose|
215014199|NCT03816137|BIOLOGICAL|ConM SOSIP|Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
215014200|NCT03816137|BIOLOGICAL|EDC ConM SOSIP|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC ConM SOSIP. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
215014201|NCT03816137|BIOLOGICAL|ConS UFO|Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle
215014202|NCT03816137|BIOLOGICAL|EDC ConS UFO|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
215100355|NCT05832749|DEVICE|Ophtesis Bio 3% ophthalmic viscosurgical device|Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.
215100356|NCT05832749|DEVICE|Healon Endocoat 3% ophthalmic viscosurgical device|"Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including:~* Cataract surgery with an intraocular lens~* Cataract surgery without an intraocular lens~* Secondary intraocular lens implantation~Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation."
214409690|NCT06617065|DRUG|Addition of 1 mL of 50% dextrose solution to the usual local anesthetic solution of choice for each patient.|"The principal investigator will use a palpation-guided approach to select the injection sites. Injection solutions will be prepared by the assisting nurse. For each patient, 1 mL of a 50% dextrose solution (Pfizer Canada ULS, Kirkland, Québec) will be added to the usual local anesthetic solution of choice.~Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio."
214409691|NCT06920290|DEVICE|Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence|"1. Natural Eye Movement To the best of our knowledge, this is the first visual field perimeter software that allows users to move their eyes naturally during the test. Previous visual field tests required that patients maintain a central gaze throughout the test as test points flashed in the periphery of their vision; our test allows patients to look directly at these test points.~2. Simplified Data Capture To the best of our knowledge, this is the first visual field perimeter software that reliably eliminates the need for a hand-held clicker to register test points as the user sees them.~3. Attention Monitoring In previous tests, staring at a central spot could induce sleepiness and inattention; our test employs a software monitor that pauses the test, gives encouragement when appropriate, and allows the patient to regain focus. This allows for far greater accuracy in data reporting.~4. Artificial Intelligence (AI) Our test uses AI to optimize the test parameters."
214409692|NCT06621329|COMBINATION_PRODUCT|Transnasal sphenopalatine ganglion block|Transnasal sphenopalatine ganglion blocks will be performed using the Tx360 device. Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.
214688426|NCT01488942|OTHER|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
214688427|NCT01371487|DRUG|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
214688428|NCT06545747|RADIATION|DCE-MRI based split-course hypo-RT|Tumor delineation will be based on DCE-MRI and CT. MRI help define the tumor boundary. Different radiation doses will be delivered based on the Ktrans value of the tumor area on DCE-MRI.
215014203|NCT03816137|BIOLOGICAL|Mosaic SOSIPs|Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
214688429|NCT06545747|RADIATION|CT based split-course hypo-RT|Tumor delineation will be based on CT. The total dose for both the first and boost courses of hypo-RT to the tumor area will be constant.
214688430|NCT06545747|DRUG|Concurrent chemotherapy|Concurrent Chemotherapy consists of weekly albumin-bound paclitaxel 50mg/m2, d1 plus cisplatin 25mg/m2，d1.
215100357|NCT04896372|OTHER|ACT comprehensive of standard care|"The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement."
214409694|NCT06615323|BEHAVIORAL|Polyphonic Lullaby Group|After discharge, mothers will be asked to play the Dandini Dandini Dastana lullaby by vocal artist Mircan Kaya, which they downloaded from the YouTube application, and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by switching the phone to airplane mode just before sleep. In the event of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the polyphonic lullaby volume will be gradually reduced. The polyphonic lullaby will be played at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effects of confounding factors, mothers in the polyphonic lullaby group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the study.
214409695|NCT06615323|OTHER|Pish Pish Sound Group|After discharge, mothers will be asked to turn on the Piş Piş sound downloaded from the YouTube application and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by turning the phone to airplane mode just before sleep. In case of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the piş piş sound will be gradually reduced. The polyphonic lullaby played will be at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effect of confounding factors, mothers in the piş piş sound group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the scope of the research.
214409696|NCT06685107|OTHER|Standard of Care Analgesia|Analgesia as determined by the treating physician
214409697|NCT06685107|OTHER|Standard of Care Analgesia + Virtual Reality|Analgesia as determined by the treating physician and Virtual Reality experience that will use a geriatric-focused VR platform that has age appropriate VR content and will run for approximately 5-10 minutes
215100358|NCT04896372|OTHER|TAU only|adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
215100359|NCT03974373|PROCEDURE|BFP removal|The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
214409698|NCT05436054|DRUG|Picoprep|200 patients will be randomised to this arm
215014204|NCT03816137|BIOLOGICAL|763 SOSIP|HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
215014205|NCT03816137|BIOLOGICAL|AMC011 SOSIP|HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
215014206|NCT01652105|DIETARY_SUPPLEMENT|Standard diet versus standard VLCD (Prodimed)|
214409699|NCT05436054|DRUG|Plenvu|200 patients will be randomised to this arm
214409700|NCT05513235|OTHER|Digital personal health record|The digital personal health record is a mobile application ('app') entitled Caremap. The mobile app will be downloaded and accessible by parents/caregivers to help coordinate care.
214409701|NCT04159506|BEHAVIORAL|mindfulness, emotion didactics, interpersonal skills, experiential learning|mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
214409702|NCT02449044|DRUG|Tolvaptan|Once Daily
214409703|NCT06629285|PROCEDURE|Continuous compression cryotherapy|Using continuous compression cryotherapy around knee after anterior cruciate ligament reconstruction for 3 postoperative days
214409704|NCT06629285|PROCEDURE|Conventional ice treatment|Using icepack around knee after anterior cruciate ligament reconstruction for 3 postoperative days
214409705|NCT06628479|OTHER|interleukin, enzyme, hormone|Relaxin, MMP-2 and IL-6 values from vaginal washing fluid, peritoneal washing fluid and serum samples
214409706|NCT06629194|DIAGNOSTIC_TEST|interferon gamma releasing assay (IGRA)|All patients who suspected CD or TB will be tested for interferon-gamma releasing assay. An interferon-gamma release assay is a blood test that measures the body\&#39;s immune response to Mycobacterium tuberculosis, the bacteria that causes tuberculosis.
214688431|NCT06545747|DRUG|Consolidative immunotherapy|Consolidative PD-1/PD-L1 inhibitors
214688432|NCT05955209|DRUG|Disitamab Vedotin（RC48-ADC）|Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death.
215014207|NCT00274794|BIOLOGICAL|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
214409707|NCT06631196|PROCEDURE|Jacobson's PMRT|each child in the intervention group will perform five sessions of Jacobson's PMRT. Each session lasted for 15-20 minutes under the supervision of the researcher.
214409708|NCT06629337|GENETIC|H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)|Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol because these dose of oral fexofenadine and famotidine reaches its peak concentration at around 1 h and 2 h, respectively
215014208|NCT00274794|BIOLOGICAL|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
214409709|NCT06696859|DRUG|Antibiotics|Bacterial culture (sputum ,blood and pleural fluid) Antibiotics sensitivity tests
214409710|NCT03315221|OTHER|Test product|HMF with added lipids - Intervention group
214409711|NCT03315221|OTHER|Control product|Commercially available HMF (without lipids) - control group
214409712|NCT06696885|OTHER|Mobile based video games and task based training|The experimental group received a mobile-based applications for 20 minutes and tasks-based training for 20 minutes per day (a total of 40 minutes), 6 days a week for 17 weeks. The time between each game was divided accordingly to work on improving hand function. The games and tasks were divided into three broad categories, Easy, Moderate, Difficult. Each category is applied for 6 weeks
214409713|NCT06697834|PROCEDURE|Histotripsy ultrasound session|The study will be performed with the MINDRAY DP-10 ultrasound device equipped with a linear probe and histotripsy functionality.
214409714|NCT06697834|OTHER|VAS questionnaire|Pain assessment with the EVA questionnaire
214409715|NCT06697834|OTHER|AOFAS questionnaire|AOFAS questionnaire at visit 1 and visit 4 (75 days after the first visit).
214409716|NCT06697210|DEVICE|• Dental Floss (Vitis®, Dentaid, Barcelona, Spain).|Dental Floss: A piece of dental floss approximately 40-50 cm in length was taken and placed between the index and middle fingers of each hand, leaving about 2-3 cm free in the middle. The floss was then inserted, embracing the mesial and distal surfaces, and moved up and down three times on each side
214688433|NCT06500494|DRUG|Vinorelbine Tartrate Oral|The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.
214688434|NCT06410612|DRUG|regional anesthesia and PAI|this is the block portion of the study
214688435|NCT06410612|DRUG|PAI|this is the no block portion of the study
215014209|NCT03387046|DIETARY_SUPPLEMENT|D-aspartate|D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.
215014210|NCT03387046|DRUG|Placebo|Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
215014211|NCT03387046|BIOLOGICAL|IFN beta-1a|IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
215014212|NCT03387046|DRUG|Methylprednisolone|Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
215014213|NCT06299072|OTHER|Survey|Quantitative questionnaire
215014214|NCT04078516|DIAGNOSTIC_TEST|Perception Threshold Tracking (PTT)|low-current electrical stimulation of both large- and small nerve fibers.
215100360|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
215100361|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
214409717|NCT06697210|DEVICE|• Superfloss (Oral B®, Procter & Gamble, USA)|Superfloss: The stiffened end was used to introduce the thread and the spongy-floss into the interproximal area on both the mesial and distal parts, and a gentle back-and-forth motion was applied to remove bacterial plaque. The spongy-floss was then pulled through to the regular floss section and gently slid under the gumline, followed by an up-and-down motion. These movements were repeated three times on each side.
214409718|NCT06697210|DEVICE|• Oral irrigator (Waterpick®, Water Pik, Inc., CO., USA)|Oral Irrigator: The finest tip was selected and placed in the mesiobuccal, distobuccal, mesiolingual, and distolingual interproximal spaces. The irrigator was activated at medium power (2/3), and the process was repeated three times on each side for five seconds.
214409719|NCT06697210|DEVICE|• Interproximal brushes (Interprox®, Vitis, Dentaid, Spain)|Interproximal Brush Group: According to the interproximal space, the appropriate size was selected for each case. The brush was then placed horizontally in the interproximal space mesially and distally, and a back-and-forth movement was performed three times on each side.
214409720|NCT06697613|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|Patients diagnosed with FIGO Stage 3 or stage 4 ovarian cancer received hyperthermic intraperitoneal chemotherapy with cisplatin following cytoreductive surgery including primary debulking surgery, interval debulking surgery and secondary debulking surgery.
214693997|NCT00869765|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
214693998|NCT05306158|OTHER|CC+ECIG Condition|Participants will push CC- and ECIG-related pictures.
215014215|NCT04078516|DIAGNOSTIC_TEST|Axon-flair mediated respons|Laser-doppler examination of small blood vessels in the peripheral skin.
215014216|NCT04078516|DIAGNOSTIC_TEST|Heart rate variability|4 measurements of heart rate.
215014217|NCT04078516|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.
215014218|NCT04078516|DIAGNOSTIC_TEST|Peripheral blood pressure and transcutaneous oxygen tension|Ankle/brachial index, toe/brachial index, TcpO2.
215014219|NCT04078516|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.
215014220|NCT04078516|DIAGNOSTIC_TEST|Questionnaires|Questionnaires for detecting painful neuropathy
215100362|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
215014221|NCT04078516|DIAGNOSTIC_TEST|Corneal Confocal Microscopy /CCM)|Confocal microscopy of the cornea measuring NBD, NFD, NFL
215014222|NCT05135780|OTHER|Osteopathic manual treatment|Between 5 and 8 sessions of osteopathy will be carried out, and the time interval between sessions may vary depending on the need and individual evolution of each child, assessed by the team of osteopaths.
215014223|NCT05135780|OTHER|Social education|"* Intervention in children:~  * During the school year there will be activities of two days per week with a duration of 2.5 hours per session in the afternoon.~ * The activities will focus on school reinforcement, facilitating snacks and having a recreational space.~ * Groups will be made by age ranges (from 4 to 6 and from 7 to 12) of maximum 10 children, due to the current COVID situation. The number could vary in the event of a change in measures at the institutional level.~* Family intervention:~  * Quarterly tutoring spaces between the coordinators and the team of social educators to evaluate needs, specify objectives and assess evolution.~ * Monthly group spaces for mothers managed by the team of educators where they will exchange experiences and create an informal support network.~ * Monthly spaces shared between parents and children accompanied by the educational team, where family ties will be worked through play."
214409721|NCT05118932|BEHAVIORAL|Mindful Movement Intervention|"There are five components that together make-up the Mindful Movement Intervention: Biomechanical Warm-ups, Yoga postures, modified Tai Chi sequence, Imaginative Play, and Reflection. During the year, participants will learn a Simplified Form of a classic Tai Chi sequence. Yoga movements will be used to prepare participants for the nuanced movements of Tai Chi practice, with both Yoga and Tai Chi providing a physical framework in which participants can track their own progress and begin to understand how to better regulate their attention, behavior and emotional responses. Imaginative Play and Reflection Activities are used to stimulate a deeper curiosity in participants about the everyday use and employment of mindfulness practice and to engage participants."
214409722|NCT06713018|PROCEDURE|Three cannulated compression screws by navigation system|Patients with femoral neck fractures treated with three cannulated compression screws assisted by a navigation system
214409723|NCT06713018|PROCEDURE|Traditional three cannulated compression screws|Patients with femoral neck fractures treated with traditional three cannulated compression screws
214409724|NCT06711289|DIAGNOSTIC_TEST|Carotid ultrasound measurement|Pulsed-wave Doppler acquisition of the carotid artery. One acquisition will be made with the slow-speed setting (33 mm/s) and one with the medium-speed setting (66 mm/s).
214409725|NCT06711289|DIAGNOSTIC_TEST|Vital sign measurement|Measurement of noninvasive blood pressure, at different time points before and after the induction of spinal anesthesia.
214409726|NCT06711289|DRUG|Spinal anesthesia|Following the standard of care, the patients received spinal anesthesia. The type and dosage of the local anesthetic were at the discretion of the treating anesthesiologist.
214409727|NCT06478654|PROCEDURE|Bilateral Modified Pectoral Nerve Block (PECS II).|"The procedure will be done bilateral with the patient lying in the supine position and the ipsilateral arm will be abducted and externally rotated, and the elbow flexed 90°.~The block will be managed by in-plane technique. After confirming the location of the needle with 2-3 mL of saline, 10 mL of 0.25% bupivacaine will be injected. Then, the needle will be advanced to the interfascial plane between the pectoralis minor and serratus anterior muscle, and 20 mL of 0.25% bupivacaine will be administered with the same procedure. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine"
214409728|NCT06478654|PROCEDURE|Bilateral Thoracic Erector spinae plane block (ESPB).|Under all aseptic precautions and sonar guided, ESP block will be managed at T4 or T5 bilateral using a high-frequency linear ultrasound probeWe will inject 20ml of bupivacaine 0.25% into interfacial plane below to erector spinae, a manifest linear pattern will be visualized uplifting the muscle. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine.
215100363|NCT03972956|OTHER|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
215014224|NCT01512537|RADIATION|Narrowband UVB|UVB 3 times a week
215014225|NCT01512537|DIETARY_SUPPLEMENT|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
215014226|NCT04456283|BEHAVIORAL|Survival|5 year survival after Chemoradiation theraphy for Rectal Cancer
215014227|NCT03710733|RADIATION|Sequential boost|Boost (10 Gy/4 fx/1 week) is given after whole breast irradiation
214409729|NCT05601466|DRUG|QN-023a|NK cell therapy
214409730|NCT05601466|DRUG|Cyclophosphamid|Lympho-conditioning Agent
215014228|NCT03710733|RADIATION|Concomitant boost|Boost (8 Gy/15 fx/3 weeks) is given with whole breast irradiation
215014229|NCT06428474|OTHER|Health education|Oral health education program designed for orphans children
215100364|NCT03645512|BEHAVIORAL|Corporate Athlete Resilience (CAR) Training Program|A 1-day training program developed by the J\&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
214409731|NCT05601466|DRUG|Fludarabine|Lympho-conditioning Agent
214409732|NCT05601466|DRUG|Cytarabine|Lympho-conditioning Agent
214409733|NCT05763004|DRUG|IOS-1002|monotherapy
214409734|NCT05763004|DRUG|IOS-1002 + KEYTRUDA® (pembrolizumab)|combination therapy
215014230|NCT05333744|DRUG|Prednisone|Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.
215014231|NCT05333744|DRUG|Recombinant Human TPO|rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100\^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
215014232|NCT04443777|OTHER|Resistance Training|Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.
215014233|NCT03794323|DRUG|BI 764122|Tablet
215014234|NCT03794323|DRUG|Placebo|Tablet
215014235|NCT04541342|PROCEDURE|initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal|It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.
215014236|NCT02612467|OTHER|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
215014237|NCT02612467|OTHER|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
215100365|NCT04734587|DIAGNOSTIC_TEST|Blood serum Neuron-specific Enolase measurement|The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
215100366|NCT00935441|BEHAVIORAL|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
215100367|NCT00935441|BEHAVIORAL|usual case management|telephone contact with a case manager
215100368|NCT03251950|BEHAVIORAL|healthy eating and gardening|15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
215100369|NCT02964585|DRUG|Canagliflozin|100 mg
215100370|NCT02964585|DRUG|Placebo|1 tablet daily for 16 weeks
215100371|NCT04409093|PROCEDURE|Nail bed repair with eponychial sent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will be secured under the eponychial fold with suture. The stent can be the native nail plate, suture container foil, or nonadherent gauze (i.e. Xeroform). If the injury avulsed the nail plate and the patient presents without it, either the foil from the suture wrapper/container or a piece of nonadherent gauze (i.e. Xeroform) will be used as a stent. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
215100372|NCT04409093|PROCEDURE|Nail bed repair without eponychial stent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will not be secured under the eponychial fold. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
215100373|NCT03040115|OTHER|Non-Interventional Study|
214409735|NCT02624778|BIOLOGICAL|LY3002813|Administered IV
214409736|NCT02624778|DRUG|Placebo|Administered IV
214409737|NCT06026189|DIAGNOSTIC_TEST|urine-first strategy|Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
214409738|NCT01565538|DRUG|Erlotinib|150 mg Given orally
214409739|NCT01565538|DRUG|Pemetrexed|500mg/m2 Given IV
214409740|NCT06518005|DRUG|Imlifidase|Imlifidase: single administration (dose is confidential), Lyophilized powder for concentrate for solution for infusion
214409741|NCT06518005|DRUG|GNT0003|GNT0003: single administration 5E+12 VG/kg, Sterile concentrate for solution for infusion
214409742|NCT01537133|DRUG|fluticasone|Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
214409743|NCT01537133|DRUG|Placebo|Dry Powder Inhaler: Placebo
214409744|NCT00610753|BEHAVIORAL|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
215100374|NCT02177838|BIOLOGICAL|cetuximab|Given IV
215100375|NCT02177838|DRUG|cisplatin|Given IV
215100376|NCT02177838|RADIATION|external beam radiation therapy|Undergo EBRT
215100377|NCT02177838|OTHER|laboratory biomarker analysis|Correlative studies
215100378|NCT00328250|BEHAVIORAL|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
214693999|NCT05306158|OTHER|CC Condition|Participants will push CC-related images and push and pull ECIG-related pictures equally often.
214694000|NCT05306158|OTHER|Sham Condition|Participants will pull and push CC- and ECIG-related pictures equally often.
215014238|NCT01598220|BEHAVIORAL|Computer-assisted cognitive remediation therapy|"Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient."
215014239|NCT01598220|OTHER|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
215014240|NCT02677285|OTHER|Different type of wound|
214409745|NCT00610753|BEHAVIORAL|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
214409746|NCT04740255|DEVICE|Straberi Epistamp|The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
214409747|NCT01626274|DEVICE|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
214409748|NCT05169281|OTHER|Medication Disposal Packet|The disposal packet (DisposeRx Inc.) contains a powder that sequesters unused opioids in a polymer gel. The kits reached patients four days following their surgery based on prior data to leverage availability bias, or a tendency to think or act on things that are most present in one's mind, and provided patients with a disposal technique when they were likely to be finished with their opioids. The process of mailing the disposal packet is simple, low cost (\~$1.50/ mailed packet) and scalable.
214409749|NCT02039700|DRUG|Lesinurad 400 mg|
214409750|NCT02039700|DRUG|[14C]lesinurad (100 μg per 10 mL)|
214409751|NCT01348321|DRUG|Levamisole|Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
214409752|NCT00306683|DRUG|DIAZOXIDE|
214409753|NCT02723851|DEVICE|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
214409754|NCT04792099|PROCEDURE|Continuous positive airway pressure|After study entry, CPAP will be provided via mask or binasal prongs in order to have a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery. A PEEP of 5 will be used for uniformity.
214409755|NCT04792099|PROCEDURE|Nasal Cannula|After study entry, flow will be set to 0.5 L/kg with 1L maximum while on NC during the study period to reduce the risk of inadvertent PEEP with higher flows. Initial FiO2 can be titrated to achieve target saturations, and may be increased up to 100% while on NC.
214409756|NCT04413279|PROCEDURE|LipiFlow Thermal Pulsation|To manage patients with dry eye disease secondary to MGD
215014241|NCT03283995|OTHER|Cardiac Volume Monitoring VolumeView|hemodynamic measure
215014242|NCT03283995|DEVICE|echocardiography|hemodynamic measure
215014243|NCT01438944|DRUG|Nicabate 21mg transdermal NRT|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
215014244|NCT01052142|BIOLOGICAL|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
214409757|NCT04413279|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation|to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
214409758|NCT06368180|DEVICE|Robotic assisted gait training|is a robotic treadmill training system that uses body weight support to suspend patients by attaching their legs to robotic legs that help them walk
214409759|NCT06368180|DEVICE|Body weight supported treadmill training|The Biodex Unweighting System was used to support the child's body weight, by an adjustable harness placed, over the treadmill.
214409760|NCT02886988|DRUG|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
214409761|NCT02886988|DRUG|normal saline|0.1mlof normal saline will be injected with a 30G needle.
214694001|NCT05691075|PROCEDURE|Arthrodesis of the metatarsophalangeal joint|Isolated surgery of the first ray of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach
215014245|NCT01301001|DRUG|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
215014246|NCT01301001|DRUG|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
215014247|NCT05682469|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~All participants will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
215014248|NCT05682469|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
215014249|NCT06024265|DRUG|ER2001 injection|The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
215014250|NCT00025311|DRUG|topotecan hydrochloride|
215014251|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Citrulline|Measured plasma amino-acids levels
215014252|NCT02520440|DEVICE|Intra-abdominal pressure monitoring|Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
215014253|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Arginine and Glutamine|Measured plasma amino-acids levels
215014254|NCT01520662|OTHER|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
215014255|NCT04787120|DEVICE|SQUIDperi|Liquid embolic delivery syringes and micro-catheter
215014256|NCT01560988|DRUG|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
215014257|NCT01560988|DIETARY_SUPPLEMENT|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
215014258|NCT04093700|DEVICE|SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
215014259|NCT02455856|DRUG|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6.
215014260|NCT02455856|DRUG|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.
215014261|NCT01407978|BIOLOGICAL|Vaccination with Fluval P monovalent influenza vaccine|"* Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
215014262|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB|"* Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
215014263|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB Novo|"* Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
215014264|NCT01428973|DRUG|Mycophenolate mofetil|Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
215014265|NCT01428973|DRUG|Sirolimus|Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
215014266|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|"Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation."
215100379|NCT05172804|BEHAVIORAL|Progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement \[11\].
214409762|NCT02851030|BEHAVIORAL|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
214409763|NCT00731107|PROCEDURE|laparoscopic surgery|XCEL bladeless trocar laparoscopic entry
214409764|NCT00731107|PROCEDURE|laparoscopic surgery|Veress Needle laparoscopic entry
214409765|NCT06098027|DRUG|[14C]CS0159|Single oral administration of 4mg \[14C\]CS0159
214409766|NCT04248764|OTHER|Foam roller application|Following the fatigue protocol, foam roller application will be applied to the quadriceps femoris muscle for five minutes in the prone position.
214409767|NCT04248764|OTHER|Massage application|Following the fatigue protocol, sports massage will be applied to the quadriceps femoris muscle for five minutes.
214409768|NCT05709457|BEHAVIORAL|Cash transfer in prior study|Women were offered a cash transfer conditional on attending prenatal and postnatal visits and delivering in a facility
214409769|NCT04355637|DRUG|Inhaled budesonide|adding budesonide to standard of care for pneumonia in COVID19 positive patients
214409770|NCT02870543|DRUG|Phytolacca decandra|Treatment of bruxism
214409771|NCT02870543|DRUG|Melissa officinalis|Treatment of bruxism
214409772|NCT02870543|DRUG|Phyt.decandra + Melissa offic.|Treatment of bruxism
214409773|NCT06021574|DRUG|VDJ001|a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody
214409774|NCT06021574|DRUG|Placebo|Placebo
214409775|NCT03152799|PROCEDURE|RIPC Remote Ischaemic Pre-Conditioning|intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
214409776|NCT03152799|OTHER|Sham Control|intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
214409777|NCT03401788|DRUG|Belzutifan|120 mg once daily (three 40 mg oral tablets once daily).
214409778|NCT02793297|OTHER|refined wheat crisp bread|Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
214409779|NCT02793297|OTHER|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
214409780|NCT02793297|OTHER|unfermented rye crisp bread|Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
214409781|NCT02799212|DRUG|somatostatin infusion|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.
214409782|NCT02799212|DRUG|placebo infusion|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
215014267|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|"Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation."
215014268|NCT01894360|DRUG|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
215014269|NCT02194088|DRUG|Diclofenac and Atropine combination drug|Diclofenac will be associated with a small dose of atropine 1.2mg
215014270|NCT02194088|DRUG|Placebo|For each capsule of active medication, a capsule of placebo will be provided, identical looking.
215014271|NCT05033535|DRUG|Sacubatril Allisartan medoxomil|Sacubatril Allisartan medoxomil ：A randomized, double-blind, placebo and positive drug parallel controlled, multi-center phase II clinical study on the effectiveness and safety of treating mild and moderate essential hypertension
214409783|NCT04691544|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Delivered by enema
214409784|NCT02611648|OTHER|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
214409785|NCT02611648|OTHER|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
215014272|NCT05033535|DRUG|Olmesartan Medoxomil|Efficacy for lowering blood pressure of Olmesartan medoxomil
214409786|NCT06631963|BEHAVIORAL|Emotional Awareness and Expression Therapy|Emotional Awareness and Expression Therapy (EAET) is a form of psychotherapy designed to help individuals identify, process, and express emotions that may be linked to physical symptoms or chronic pain. It emphasizes the role of unresolved emotional experiences, such as trauma or interpersonal conflicts, in contributing to physical distress. Through EAET, patients learn to connect their emotions to their physical symptoms, express those emotions in a healthier way, and ultimately reduce both emotional and physical suffering. This therapy has been shown to be effective in treating conditions such as chronic pain, irritable bowel syndrome, and fibromyalgia.
214688436|NCT06414499|DRUG|rhTNK-tPA|rhTNK-tPA 0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds. Additionally, placebo oral aspirin and clopidogrel are given. Aspirin 100 mg and clopidogrel 300 mg are administered within 6 ± 2 hours following thrombolytic therapy.
214688437|NCT06414499|DRUG|Control group (Aspirin combined with clopidogrel)|Dual antiplatelets with aspirin 100mg and clopidogrel 300mg, plus placebo intravenous rhTNK-tPA. Placebo oral aspirin and clopidogrel are administered within 6 ± 2 hours following intravenous placebo.
214688438|NCT05574400|DRUG|Dextrose Water|Dextrose 5% in water
215014273|NCT06174532|PROCEDURE|Traditional Medthod|Before surgery, the patient's lower jawbone tumor is replicated using a 3D-printed original model without adjustments. Then, the model undergoes manual modification by drilling and adjusting the jawbone model at the tumor site using drills and manual instruments. Subsequently, the reconstructed model is formed preoperatively based on this modified model. During surgery, the patient isn't guided by surgical guides, and the incision lines are relatively dependent on the surgeon. Additionally, while fixing the remaining bone after the sectioning, the surgeon uses pre-bent fixation plates made earlier to assist in stabilizing the bone.
214409787|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in CT|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
214688439|NCT05574400|DRUG|Caffeine citrate|Low-dose caffeine citrate (1.5 mg/kg)
214688440|NCT05574400|DRUG|Caffeine citrate|High-dose Caffeine citrate (3 mg/kg)
214688441|NCT01520324|DEVICE|oral delivery mucosal stain|200mg methylene blue MMX tablet taken prior to colonoscopy
214688442|NCT02786732|BIOLOGICAL|210mg Brodalumab|Brodalumab 210mg administered subcutaneously
214688443|NCT02786732|BIOLOGICAL|140mg Brodalumab|Brodalumab 140mg administered subcutaneously
214688444|NCT02786732|BIOLOGICAL|Ustekinumab|Ustekinumab 45mg or 90mg adminstered subcutaneously
214688445|NCT02786732|BIOLOGICAL|Placebo|Placebo administered subcutaneously
214688446|NCT04716166|OTHER|Volume-oriented incentive spirometry|3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
214409788|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in CT|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
214409789|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in CT|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
214409790|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in MRI|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
214409791|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in MRI|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
214409792|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in MRI|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
214409793|NCT06631859|OTHER|Cosmetic products containing 0% Assam tea|Cosmetic products containing 0% Assam tea
214409794|NCT06631859|OTHER|Cosmetic products containing 2.5% Assam tea|Cosmetic products containing 2.5% Assam tea
214409795|NCT04760444|BEHAVIORAL|Peer Leader Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
214409796|NCT04760444|BEHAVIORAL|Virtual Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom, Med platform.
214409797|NCT00192192|BIOLOGICAL|CAIV-T|
214409798|NCT04488653|DIETARY_SUPPLEMENT|Oligopin®|French Maritime Pine Bark Extract - 100mg/day
214409799|NCT04488653|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214409800|NCT05507463|DRUG|KBP-7072|KBP-7072
214409801|NCT05507463|DRUG|Placebo|Placebo
214409802|NCT02404454|PROCEDURE|Hysteroscopic metroplasty|
214409803|NCT02404454|DEVICE|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
215100380|NCT05172804|BEHAVIORAL|Guided Imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin \[11\].
215100381|NCT05172804|BEHAVIORAL|Mindfulness Meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting) \[11\]."
215100382|NCT05172804|OTHER|Control group|Participants in the control condition will be instructed to sit with their eyes closed and relax during the intervention periods. Participants in the control group will follow an identical procedure and time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
214409804|NCT02404454|PROCEDURE|Office second look hysteroscopy|Second-look hysteroscopy after three months
214409805|NCT02856711|BEHAVIORAL|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
214409806|NCT00030381|DRUG|4'-iodo-4'-deoxydoxorubicin|Given IV
214409807|NCT00030381|OTHER|pharmacological study|Correlative studies
214409808|NCT00362193|BEHAVIORAL|Telephonic diabetes care|
214409809|NCT04471467|PROCEDURE|Fixed tracheal tube|Tracheal tube fixation is determined by the surgeon according to the needs of the operation and is an independent process. Our research simply installed a monitoring device between the tube and the nose. The tube fixation takes place whether the observation of pressures is agreed to or not, as per standard protocol.
214409810|NCT06053788|DIAGNOSTIC_TEST|PocDoc|Point of care digital lipid test
215014274|NCT06174532|PROCEDURE|Virtual surgical planning|Before surgery, the patient's lower jawbone is 3D-printed, designed to remove the tumor mass, and create a suitable margin for reconstructive plate bending. Subsequently, the reconstruction plate is pre-bent preoperatively based on this model. During surgery, the patient is guided by specific surgical guiding tools: cutting guides. Additionally, while fixing the remaining bone after sectioning, the surgeon is assisted by bone fixation instruments to stabilize the alignment of the two bone fragments according to anatomical structure and then proceeds to use pre-bent reconstruction plates to secure the bone.
215014275|NCT03630510|OTHER|Ventilator hyperinflation|The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
215014276|NCT01933516|DRUG|GP2013|GP2013
215100383|NCT00881465|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
215100384|NCT00881465|BEHAVIORAL|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
215100385|NCT03517566|DRUG|Placebo|once daily from baseline until week 16
214409811|NCT00623506|DRUG|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
214688447|NCT04716166|OTHER|Flow-oriented incentive spirometry|3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
214688448|NCT01119274|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
214688449|NCT01119274|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
215100386|NCT03517566|DRUG|ZPL389 3mg|ZPL389 3 mg oral powder; once daily from baseline to week 16
215100387|NCT03517566|DRUG|ZPL389 10mg|ZPL389 10 mg oral powder; once daily from baseline to week 16
215100388|NCT03517566|DRUG|ZPL389 30mg|ZPL389 30 mg oral powder; once daily from baseline to week 16
215100389|NCT03517566|DRUG|ZPL389 50mg|ZPL389 50 mg oral powder; once daily from baseline to week 16
215100390|NCT00506168|DRUG|Irinotecan, Capecitabine|
214688450|NCT04649203|DRUG|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.
215100391|NCT04040621|DRUG|Ceftazidime-avibactam|Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.
214688451|NCT04649203|DRUG|Placebo|The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
215100392|NCT01879046|PROCEDURE|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
215100393|NCT02547168|DEVICE|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
215100394|NCT04495725|OTHER|Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products|We will randomize participants to one of the following four conditions for discounted vouchers: 1) a discounted voucher for a placebo soft-gel capsule product, 2) a discounted voucher for a high THC:low CBD soft-gel capsule product, 3) a discounted voucher for an equal THC:CBD soft-gel capsule product, or 4) a discounted voucher for a low THC:high CBD soft-gel capsule product. We will stratify randomization by history of cannabis use (no use in the past year, used in the past year and not near-daily or daily (used in the past year and \<20 days out of the last 30 days), near-daily or daily (\>= 20 days out of the last 30 days) baseline opioid analgesic prescription (chronic opioid treatment vs. not chronic opioid use), and primary pain condition (neuropathy, not neuropathy). Chronic opioid treatment is defined as prescribed opioids ≥90 non-overlapping days in the past 182 days. Randomization will occur in blocks to ensure equal randomization over time.
215100395|NCT02854254|DEVICE|peripherally inserted central catheter|peripherally inserted central catheter
215100396|NCT02854254|DEVICE|peripherally venous access|standard over-the-needle intravenous catheter
215100397|NCT06002568|PROCEDURE|Silent|Apply wave file created in silence.
214688452|NCT06464367|DRUG|Psilocybin|synthetic psilocybin 10 mg (oral)
214688453|NCT06464367|DRUG|Placebo|synthetic THC 2.5 mg (oral)
214688454|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Once Daily|
214688455|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Twice Daily|
214688456|NCT02293018|DRUG|1.5% (w/w) MTC896 Gel Once Daily|
214688457|NCT01724983|DRUG|ketamine|
214688458|NCT01724983|DRUG|fentanyl|
215100398|NCT06002568|PROCEDURE|Binaural beats|Apply wave file which is intended to generate binaural beats by applying waves of different frequency (1Hz difference) in each ear.
215014277|NCT01008527|DRUG|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
214409812|NCT00623506|DRUG|Placebo|"Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
214409813|NCT04664777|DEVICE|Masimo Model RDS7A|Masimo monitoring platform equipped with Radical-7 Pulse CO-Oximeter fingertip probe for measurement non-invazive hemoglobin level (SpHb) an perfusion index (PI)
214409814|NCT02510534|DRUG|Menopur 150 international units|Menopur 150 international units given x 1 dose
214409815|NCT02510534|DRUG|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
214409816|NCT06491095|DIETARY_SUPPLEMENT|0 g Flax|175 g yogurt with no flax product
214409817|NCT06491095|DIETARY_SUPPLEMENT|40 g whole ground flaxseed|175 g yogurt with 40 g whole ground flaxseed
214409818|NCT06491095|DIETARY_SUPPLEMENT|40 g roasted then ground whole flaxseed|175 g yogurt with 40 g roasted then ground whole flaxseed
214409819|NCT06491095|DIETARY_SUPPLEMENT|40 g of whole intact flaxseeds|175 g yogurt with 40 g of whole intact flaxseeds
214409820|NCT06491095|DIETARY_SUPPLEMENT|28 g flax hulls|175 g yogurt with 28 g flax hulls
214409821|NCT01244984|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
215100399|NCT01496755|DRUG|Placebo|Single/multiple doses
215014278|NCT01008527|BIOLOGICAL|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
215014279|NCT01008527|BIOLOGICAL|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
215014280|NCT01128920|BEHAVIORAL|Skin and Needle Hygiene Intervention|Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
215014281|NCT01128920|OTHER|No intervention - assessment-only condition|No intervention is assigned in this condition
215014282|NCT02950974|DRUG|Sterofundin|Fluid loading
215014283|NCT02950974|DRUG|NSS|Fluid loading
215014284|NCT01011231|PROCEDURE|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
215014285|NCT05055427|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|"Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. In additional, patients also receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.~Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.~Daily dose: 1 bag per time, 2 times per day"
215014286|NCT03702595|OTHER|Hip flexors stretching protocol|Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
215100400|NCT01496755|DRUG|RG7667|Single/multiple ascending doses
215100401|NCT05067738|OTHER|same day discharge|same day discharge
214409822|NCT01244984|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
214688459|NCT01626911|PROCEDURE|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
215100402|NCT01426776|PROCEDURE|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
215100403|NCT00169091|DRUG|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
214409823|NCT00816335|PROCEDURE|PET/CT scan|For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
214409824|NCT00816335|DRUG|18F-FDG Injection|Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
214688460|NCT01626911|OTHER|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
214409825|NCT00816335|PROCEDURE|Preoperative 18F-FDG PET/CT Scan|Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
215014287|NCT04334681|PROCEDURE|Un-roofing curettage method|In this method, the roof of the pilonidal cyst is opened, and the inside is cleaned, and curettage is performed. The wound is closed with a dressing after hemostasis.
214409826|NCT00816335|DRUG|18F-FDG for patients with Bladder Cancer|Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
214409827|NCT00816335|PROCEDURE|Surgical Procedure|Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
214688461|NCT02586753|OTHER|Paclitaxel plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
215014288|NCT04334681|PROCEDURE|Modified Limberg Flap Group|In this method, the pilonidal cyst is excised with a rhomboid incision and closed with the modified Limberg flap method.
215014289|NCT00049309|DIETARY_SUPPLEMENT|dietary intervention|
215014290|NCT00049309|DIETARY_SUPPLEMENT|flaxseed|
215014291|NCT05038514|OTHER|musıc therapy|After the prone position was given to the patients, according to the randomization table, the intervention group was given 30 minutes by the nurse. nature-based music therapy will be applied.
215014292|NCT00458705|DRUG|bortezomib|
215014293|NCT00458705|DRUG|dexamethasone|
215014294|NCT00458705|DRUG|pegylated liposomal doxorubicin hydrochloride|
215014295|NCT00458705|DRUG|thalidomide|
215014296|NCT04195672|DEVICE|NIPE (MDoloris®) and CBS values|"During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care"
215014297|NCT04884074|PROCEDURE|Standard Sleeve Gastrectomy plus Anterior Crural Repair|The procedure is performed in a similar fashion as standard sleeve gastrectomy. After gastric mobilization is completed as standard sleeve gastrectomy, the anterior phrenoesophageal ligament is divided and distal 3cm esophagus is mobilized. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist and the hiatus opening is closed with 2/0 non-absorbable suture over the bougie anterior to the esophagus. The hiatus repair was sized by comfortably placement a dissection forceps adjacent to the esophagus without tension. Sleeve gastrectomy is then performed as the standard technique.
215014298|NCT04884074|PROCEDURE|Standard sleeve gastrectomy (SSG, the control group)|"The procedure is performed in French position with a standard 5-port approach and a pneumoperitoneum not exceeding 15mmHg.~The greater omentum is then completely detached from the greater curvature of stomach using either ultrasonic or bipolar shear device. All adhesion between posterior gastric wall and pancreatic capsule is freed and the cardia is completely free with left crura completely exposed. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist with its balloon tip reaching the gastric antrum and insufflated with 50cc of air. Sleeve gastrectomy is then performed using laparoscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up cardia at about 1cm lateral to the angle of His, along the Mid-sleeve tube which is lying against the lesser curve of stomach. The staple line is reinforced with absorbable sutures. Distal stomach is anchored at retroperitoneum with non-absorbable stitch."
215014299|NCT00205634|DRUG|Biaxin ( clarithromycin)|
215014300|NCT03963622|OTHER|Respiratory Mechanics|"Different maneuvers based on respiratory mechanics will be assessed at the bedside and will be used to individualize ventilator parameters. Recruitability will be assessed with a one breath decremental PEEP maneuver, and search for airway closure with a low-flow pressure volume or pressure-time curve. If the patient has airway closure, the minimal PEEP will be set at the airway opening pressure to avoid closure. If the patient is considered recruitable, the goal is to set PEEP at or above 15cmH20 to maximize alveolar recruitment, until the plateau pressure reaches the safety limit. Volume control ventilation at 6ml·kg-1 will be used.~Once spontaneous breathing has started, the occlusion pressure (P0.1) will be maintained within targets."
215014301|NCT03963622|OTHER|Standard Ventilation Strategy|Patients randomized to the control arm will receive standard care. The PEEP is adjusted for oxygenation based on a PEEP-FiO2 table, either the low PEEP-FiO2 or the high PEEP-FiO2 table. Volume targeted ventilation with initial VT 6 mL·kg-1 and Plateau pressure at 30 cmH2O or below, targeting PaO2 60-80 or SpO2 90-95%, adjusted as per the protocol. Pressure-support ventilation is at physician's discretion, but recommended when FiO2 \<60%, and is titrated VT 6-8 mL·kg-1.
215014302|NCT00935207|OTHER|Pediatric Pain Diary|Pain diary designed for pediatric patients
215014303|NCT02172261|DRUG|BI 10773|
215014304|NCT02172261|DRUG|Glimepiride|
215014305|NCT05521282|DRUG|Treatment group|Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
214409828|NCT00816335|PROCEDURE|Specimen PET/CT Scan|Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
214409829|NCT04477798|DIAGNOSTIC_TEST|PCT-DIA/MS|PCT-DIA/MS will be validated to classify FNA biopsy specimens
214409830|NCT01205282|DRUG|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
214409831|NCT01205282|DRUG|Placebo|There will be a 2 week period of placebo run-in.
214688462|NCT02586753|OTHER|S1 plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).~Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
214688463|NCT01258972|DEVICE|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
215100404|NCT00169091|DRUG|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
215100405|NCT01288547|DIETARY_SUPPLEMENT|theobromine|700 mg theobromine in gelatin capsules given one time only
215100406|NCT01288547|DIETARY_SUPPLEMENT|Caffeine|120 mg caffeine in capsules given one time only
215014306|NCT05233059|BEHAVIORAL|FitEx|FitEx is an 8 week goal-setting, behavior tracking, physical activity intervention with a low dose of social support which will be delivered virtually.
215014307|NCT05233059|BEHAVIORAL|Weekly Yoga Sessions|30 minutes of optional guided yoga online led by a 500 hour yoga teacher once a week for participants in the walking plus yoga arm. Also accompanied by a yoga based newsletter.
215100407|NCT01288547|DIETARY_SUPPLEMENT|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
215100408|NCT01288547|DIETARY_SUPPLEMENT|placebo|cellulose in capsules given one time only
215100409|NCT05673525|DEVICE|Transcatheter Aortic Valve Implantation (KOKA-VALVE)|Transcatheter Aortic Valve Implantation
215100410|NCT05808413|BEHAVIORAL|Informational Video|This video emphasizes that vaccination against COVID-19 continues to be important, highlights the importance of seeking accurate information, and provides statistics about the estimated number of lives saved by vaccination and reported adverse events following vaccination in Canada.
215014308|NCT05233059|BEHAVIORAL|Weekly Movement Sessions|30 minutes of optional guided movement online led by a 500 hour yoga teacher once a week for participants in the walking arm. Also accompanied by a movement based newsletter.
215100411|NCT05808413|BEHAVIORAL|Altruistic Video|This video presents a vignette about a young adult woman who has many social interactions during her daily life. It shows that her decision to stay up-to-date on COVID-19 vaccination could help to protect those people she comes into contact with, who may be at greater risk from COVID-19 infection. Statistics are used to show that up to one-in-four people in Canada have underlying conditions that make them more vulnerable to COVID-19, and to quantify the number of surgeries that were delayed by pandemic-related disruptions.
215100412|NCT05808413|BEHAVIORAL|Individualistic Video|This video presents a vignette about a young adult man who is very health-conscious. He is unsure about staying up-to-date on COVID-19 vaccination until he learns that COVID-19 infection can have serious and disruptive consequences even if someone is younger. Statistics are used to quantify the increased risk of severe symptoms in young adults who are not up-to-date on vaccination.
215100413|NCT06191107|DEVICE|Removable Partial Denture|Integration of removable partial dentures made of PEEK for the treatment of tooth loss.
214688464|NCT01258972|DEVICE|POBA|Balloon angioplasty
215014309|NCT06000904|OTHER|Exergame-based balance training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute balance exercise, and 15-minute ground walking as a cool-down.
215014310|NCT06000904|OTHER|Upper limb and trunk training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute upper-limb and trunk exercise, and 15-minute ground walking as a cool-down.
215014311|NCT02505672|RADIATION|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
214409832|NCT04440969|BEHAVIORAL|Multi-domain intervention|"Participants will undergo dual-task physical exercises and small group activities comprising of quizzes, puzzles and simulate daily living activities that have been gamified (Mindfun and MindGym, ProAge,Singapore). They will also play games on a touch screen device (computerised cognitive training) that aims to improve cognition in the domains of attention, memory, spatial ability, decision making and cognitive flexibility (Memorie, Neeuro, Singapore) while wearing the Senzeband, which emits low frequency signals on the forehead picked up by four individual sensors, allowing participant to play certain games without touching the device but by attention and focus (https://www.neeuro.com/senzeband).~Dietary guidance will be delivered via a dietary app (Glycoleap). Participants are expected to take photos of their meals daily and upload them onto the app. Certified dieticians will give advice and tips on their choice of food and how to make healthier choices through the app."
214409833|NCT02763020|OTHER|Fruit extracts high in polyphenols|
214409834|NCT02763020|OTHER|placebo|
214409835|NCT04651179|OTHER|observation|not applicable, observational study
214409836|NCT05619887|DRUG|Fentanyl|Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.
215014312|NCT00638391|DRUG|Anastrozole|
215014313|NCT04794478|DEVICE|Dexcom Continuous Glucose Monitoring System|Dexcom Continuous Glucose Monitoring System
214409837|NCT05619887|OTHER|Saline|An equal volume (as above) of saline will be administered into the intrathecal (spinal) space. This has no effect of cardiorespiratory responses at rest or during exercise; it is to control for the invasiveness of the procedure required to suppress muscle feedback in the experimental condition.
214409838|NCT03871998|OTHER|Skin barrier protection in the first 2 months of life|Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
214409839|NCT04683497|OTHER|Contrast-enhanced Intraoperative Ultrasound|Intraoperative ultrasound with the administration of a contrast agent I.V.
215014314|NCT02565186|DRUG|Lasmiditan|oral tablet
214409840|NCT02999282|DEVICE|Anodal transcranial direct current stimulation|10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)
214409841|NCT02999282|DEVICE|Sham transcranial direct current stimulation|10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)
214409842|NCT06233955|DEVICE|Low Level laser therapy|is a non-invasive light source treatment that generates a single wavelength of light. It emits no heat, sound, or vibration. It is also called photobiology or bio-stimulation
214409843|NCT06233955|OTHER|Maitland mobilization technique|is a process of examination; assessment and treatment of musculoskeletal disorders by manipulative physiotherapy where a chain of oscillatory joint mobilization grades based on the pathological limit of tissue are used
214409844|NCT01168401|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)"
214409845|NCT01168401|BIOLOGICAL|Saline|Two doses 28 days apart
214409846|NCT04219293|DEVICE|Microneedling w/ and w/o PRP|i. Split face comparison. Vertical line drawn midline nose extending upwards to hairline and downwards to jawline separating face into two equal treatment areas. The patients determined side of face will be treated with SkinPen Microneedling and PRP the other (nondetermined from randomization) will be treated with SkinPen Microneedling and glide. The patient side of face that will not use PRP will be treated first. The following settings will be used as treatment protocol. Topical anesthetic Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% will be applied covering entire treatment area. The anesthetic will remain on skin for 30 minutes.
215014315|NCT00209638|DRUG|irinotecan|
215014316|NCT00209638|DRUG|S-1|
215014317|NCT06181058|BEHAVIORAL|escape room game|Participants will be informed about the game (15 minutes). They will complete the game by solving puzzles within the framework of the oncology patient scenario (approximately 30 minutes). There will be a debriefing session at the end of the escape game (15 minutes).
215014318|NCT02931227|PROCEDURE|temperature obtained by the non-invasive method of zero-heat flux|
215014319|NCT02931227|PROCEDURE|esophageal temperature|
215014320|NCT02931227|PROCEDURE|intracerebral temperature|
215014321|NCT02931227|PROCEDURE|arterial temperature|
215014322|NCT04843839|DRUG|Nepafenac 0.1% Oph Susp|Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months
215014323|NCT04843839|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
215014324|NCT05758142|DIETARY_SUPPLEMENT|Potassium Chloride|Oral administration of potassium chloride tablets
215014325|NCT05758142|OTHER|Placebo|Oral administration of inert placebo tablets
215014326|NCT03976141|DIAGNOSTIC_TEST|mri|knee mri
215014327|NCT00306280|DEVICE|Phototherapy|
215014328|NCT01518036|DRUG|somatropin|2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
215014329|NCT01518036|DRUG|somatropin|4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
215014330|NCT02683798|DIETARY_SUPPLEMENT|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
215014331|NCT02683798|DIETARY_SUPPLEMENT|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
215014332|NCT02091830|DRUG|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
215014333|NCT02091830|OTHER|Physiotherapy|
214409847|NCT06235879|OTHER|Control Group (Interscalene brachial plexus block)|"Patients will receive ultrasound guided interscalene brachial plexus block after induction of general anesthesia.~Scanning with SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) will be started just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle.~the transducer will be moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles at the level of the sixth cervical vertebra deep to the sternocleidomastoid muscle.~The needle will be then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction.~After negative aspiration and assurance that high resistance to injection is absent, 0.25% bupivacaine hydrochloride will be injected in a 5-ml increment below the lower root, between the 3 roots, and above the upper root.(Total amount is 15 ml of 0.25% bupivacaine hydrochloride)."
214409848|NCT06235879|PROCEDURE|Pericapsular nerve group (PENG) block|"Patients will receive ultrasound guided Pericapsular nerve group (PENG) block after induction of general anesthesia.~Using SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) ,A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head.~After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle can't be advanced further.~The needle tip will be placed between the deltoid muscle and subscapularis tendon, after a careful aspiration, 15 ml of 0.25% bupivacaine hydrochloride will be injected."
214409849|NCT03218956|DIETARY_SUPPLEMENT|Dietary supplement: Protein intake|"Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.~The last 4 meals will in addition contain labelled labelled 13C phenylalanine."
214409850|NCT04461223|DIAGNOSTIC_TEST|contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)|CMR T1 mapping, T2mapping, T2\* mapping, LGE, ECV
214409851|NCT04107337|OTHER|Vocal work session with straw exercises|"* Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath in the straw ; (1 minute) Phonation in the straw ; (2 minutes) Make a siren in the straw ; (4 minutes) Vocalizations in the straw on the arpeggio of Rossini.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
214409852|NCT04107337|OTHER|Vocal work session with open mouth exercises|"* Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath on a \[f\] with open mouth ; (1 minute) Phonation on the vowel \[a\] with open mouth ; (2 minutes) Make a siren on the vowel \[a\] with open mouth ; (4 minutes) Vocalizations on the vowel \[a\] on the arpeggio of Rossini with open mouth.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
215014334|NCT02091830|DRUG|Cortisone Injection|
214409853|NCT03463811|DIAGNOSTIC_TEST|Lactate concentration in vaginal fluid|Lactate concentration in vaginal fluid
214409854|NCT00000772|DRUG|Ribavirin|
214409855|NCT00000772|DRUG|Didanosine|
214409856|NCT02980679|DRUG|CTC|After injection of CTC, a whole body and thyroid scan will be performed.
214409857|NCT02980679|DRUG|G-PERT|After injection of G-PERT, a whole body and thyroid scan will be performed.
214409858|NCT06549894|PROCEDURE|Performing endoscopic examinations|Performing endoscopic examinations in the conventional framework of patient follow-up. No patient data is collected. The physician performing the act is the subject of the study.
214409859|NCT00483912|DEVICE|Molecular adsorbent recirculating system|
214409860|NCT03832660|BEHAVIORAL|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
214409861|NCT03832660|DRUG|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
214688465|NCT02094872|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
214688466|NCT02094872|DRUG|MEK 162 therapy or molecularly targeted therapy|molecularly targeted therapy, MEK 162 therapy
214688467|NCT02094872|PROCEDURE|therapeutic procedure|
215014335|NCT02091830|OTHER|Others|
215014336|NCT05604157|OTHER|Use of Tourniquet|Application of tourniquet or not in adults undergoing a primary total knee replacement.
215014337|NCT03357445|OTHER|Avantage Reload cup|Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty
215014338|NCT06034431|OTHER|Ride Share|"The Investigators' proposed study addresses the Prostate Cancer Research Program overarching challenge of Advancing Health Equity and Reducing Disparities in PCa by examining and addressing travel burden to PCa treatment centers. Investigators will focus on Black men (including those of Caribbean descent), a high-risk population experiencing poorer health outcomes for unjust and preventable reasons.~This research will inform efforts to reduce travel burden in the healthcare acquisition process and improve the timeliness of treatment in Black men with PCa in Massachusetts and other states. This project will improve the quality of life and enhance outcomes and overall health and wellness for this group. Investigators will use findings from this pilot study to obtain future funding for a multicenter randomized clinical trial that will estimate the effect of equity - oriented programs that remove transportation barriers to treatment and reduce Black-White disparities in PCa outcomes"
214409862|NCT06480422|OTHER|Segmental breathing technique|To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly. Blow patient's nose and huff, cough to clear your upper airways to mucus. This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath. Hold the breath for three seconds. With some gentle force exhale all the air out of your lungs. Repeat three times. Do not cough untill after the third breath. Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, 20 and 45 minutes.
214409863|NCT06480422|OTHER|autogenic drainage|"To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly.Blow ptient's nose and huff, cough to clear your upper airways to mucus.This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath.Hold the breath for three seconds.With some gentle force exhale all the air out of your lungs. Repeat three times.Do not cough untill after the third breath.~Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, which should take between 20 and 45 minutes."
214409864|NCT01288638|OTHER|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
214409865|NCT01288638|OTHER|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
214409866|NCT01721564|DRUG|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
215014339|NCT05800626|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|ERCP performed for clinical practice
215014340|NCT05597605|DEVICE|The SHINE SYSTEM|The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
215014341|NCT00002809|BIOLOGICAL|anti-thymocyte globulin|
215014342|NCT00002809|BIOLOGICAL|filgrastim|
215014343|NCT00002809|BIOLOGICAL|sargramostim|
215014344|NCT00002809|BIOLOGICAL|therapeutic immune globulin|
215014345|NCT00002809|DRUG|cyclophosphamide|
215014346|NCT00002809|DRUG|methotrexate|
215014347|NCT00002809|DRUG|tacrolimus|
215014348|NCT00002809|PROCEDURE|allogeneic bone marrow transplantation|
215014349|NCT00002809|RADIATION|radiation therapy|
215014350|NCT02926846|DRUG|Intravenous vancomycin & gentamicin with adjunctive lavage|"Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
214409867|NCT02909751|DRUG|Epirubicin 90 mg/m2 iv|Max. 3 months
214409868|NCT02909751|DRUG|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
214409869|NCT02909751|DRUG|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
214409870|NCT02909751|DRUG|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
214409871|NCT02909751|DRUG|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
214409872|NCT02909751|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily|Max. 6 months
214688468|NCT02094872|OTHER|laboratory biomarker analysis|Correlative studies
214688469|NCT02094872|OTHER|quality-of-life assessment|Ancillary studies
215014351|NCT02926846|DRUG|Intraperitoneal vancomycin & gentamicin|"Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
215014352|NCT03001739|DRUG|Urapidil Hydrochloride Injection|Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
215014353|NCT04370847|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle
215014354|NCT04370847|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
215014355|NCT04370847|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
215014356|NCT04370847|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
215014357|NCT04370847|RADIATION|lung ultrasound scans|lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.
215014358|NCT04370847|OTHER|Ultrasound Assessment of the Inferior Vena Cava|The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.
215014359|NCT04370847|OTHER|Optic nerve sheath diameter|Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.
215014360|NCT04370847|DRUG|ringer acetate|1000 ml ringer acetate will be administered over 2 hours.
215014361|NCT04370847|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
215014362|NCT04370847|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
214409873|NCT03083522|DRUG|Ojeok-San|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
214409874|NCT03083522|DRUG|Placebo|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
214409875|NCT06196528|DEVICE|WristArt implant|implantation of the WristArt implant
214409876|NCT04298840|DIETARY_SUPPLEMENT|Creatine Monohydrate Supplementation|Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.
214409877|NCT04298840|DIETARY_SUPPLEMENT|Placebo Supplementation|Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.
214409878|NCT06211140|DEVICE|tACS|tACS in 4 weeks, once per weekday for 40 minutes each, 20 sessions. The treatment group will receive transcranial alternating current stimulation at a gamma frequency (77.5Hz) with a peak amplitude of 15mA.
215100414|NCT01890668|OTHER|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility…) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
215100415|NCT01890668|OTHER|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
215014363|NCT05586087|OTHER|Experimental group|The High-Speed Resistance Training program has 16 weeks, with three sessions per week with 50-60min, each session being comprised of five-six exercises, two-three sets, and six-ten reps/exercise. The intensity is gradually increased after each session in accordance with the movement velocity (\>1.3 to 0.75 m/s) representing approximately 20% to 60% of one repetition maximum. Participants execute the exercises rapidly and explosively making all repetitions for each shortening phase (concentric phase) performed as quickly as possible with the lengthening phase of the muscle (eccentric phase) being controlled for 2-3 s. The velocity of the concentric phase in each exercise is monitored through a BEAST™ sensor (Beast Technologies, Brescia, Italy).
215014364|NCT04719923|BEHAVIORAL|Children with autism spectrum disorders|Subjects affected by autism spectrum disorders
215014365|NCT02170012|DRUG|PF-06743649|20 mg tablet once daily dosing for 14 days
215014366|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
214409879|NCT06211140|OTHER|Control|Without the tACS stimulation in this group.
214409880|NCT03841019|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)
215014367|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
215014368|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
215014369|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
215100416|NCT05136261|DEVICE|Ceradan ® Advanced Cream|Ceradan ® Advanced Cream
215014370|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
215014371|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
215014372|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
215014373|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
215014374|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
215014375|NCT00337194|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
215014376|NCT00337194|OTHER|placebo|Given IV
215014377|NCT00337194|DRUG|vinorelbine tartrate|Given IV
215014378|NCT00337194|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
215014379|NCT00337194|DRUG|gemcitabine hydrochloride|Given IV
215014380|NCT00337194|OTHER|laboratory biomarker analysis|Correlative studies
215014381|NCT00337194|OTHER|pharmacological study|Correlative studies
214409881|NCT03841019|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
214409882|NCT06343155|OTHER|Therapeutic Group|Pelvic tilt exercise:Participant will be supine position on the floor with your knees bent. Flatten your back against the floor by tightening your abdominal muscles and bending your pelvis up slightly. Lumbar flexion(single knee to chest): Participants will be supine position with knees bent and feet flat on the floor. The right knee will be brought closer to your chest and held with the hands. Lumbar flexion(double knee to chest) : Participants will be supine position with both legs flat on the floor. One hip and knee will be bent first to the chest, then the other to the chest. The knees will be grasped with the hands. Straight Leg Raise: Participants will be supine position with hips and legs comfortably on the floor. By contracting the quadriceps muscle the straight leg will be fixed. Inhaling slowly, the straight leg will be lifted six inches off the floor. Spine twist: Participants will turn their hips and knees to one side as much as possible in a supine position.
215014382|NCT03188705|DRUG|Clopidogrel|Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
215014383|NCT03188705|DRUG|Aspirin|Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
215014384|NCT01640561|BEHAVIORAL|MISC|The Mediational Interventions for Sensitizing Caregivers
214409883|NCT06343155|OTHER|Rocabado's Group|Rest position of tongue: Making a 'clucking' sound positions the tongue against the hard palate in the correct resting position for appropriate nasal and diaphragmatic breathing. Once the activity is practiced, the patient is to attempt to maintain appropriate tongue / jaw resting position throughout normal activity. Shoulder retraction:Sitting up nice and tall, squeeze your shoulder blades back and together. Stabilized head posture:Place your hands behind your hand with fingers interlocked.Gently bring head forward with gentle overpressure from hands.Axial extension of the neck: Sitting up nice and bring your chin backward as if trying to make a double chin. Rotation control of temporomandibular joint: Place tongue at the roof of your mouth just behind your front teeth and place fist underneath chin. Gently open mouth into fist and hold for a few seconds. Rhythmic stabilization:Patients apply resistance to opening, closing, and lateral deviation with the jaw in a resting position.
214409884|NCT05044130|DIETARY_SUPPLEMENT|High-fat mixed-meal tolerance test (HF-MMTT)|The test meal consists of a standardized HF-MMTT (791 cal) with 197 g cream (38 % fat), 18 g sugar and 1 g vanilla sugar for taste (75 g fat, 25 g carbohydrate and 4 g protein)
214409885|NCT02988596|OTHER|Multidimensional Active Rehabilitation|Participants will be asked to complete activities aimed at: stabilization of symptoms, impairment reduction, activity integration, recovery acceleration and sport specific application during a 20 minute session at least 4 times a week. Activities will be selected by the supervising clinician with respect to the specific impairment presentation of each participant. Session logs will be completed by each clinician and will include the following information: initial symptom checklist, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
214409886|NCT02988596|OTHER|Enhanced Graded Exertion|Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich/Berlin Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
214409887|NCT01335789|DRUG|Oxytocin|40 IUs
214409888|NCT01335789|DRUG|Saline|40 IUs
214409889|NCT00272610|DRUG|0.4% Retinol Cream|
214409890|NCT04483882|DEVICE|Tactile Labels for Drug identity and dose frequency|The tactile labeling proposed in this protocol is rigid labeling. A ring-clip has an inner diameter of 12.5cm, an outer diameter of 16 cm, and a height of 1.5 cm. The ring is cut at 2 cm to form a semi-circle allowing it to be clipped onto the bottleneck. The ring clip fits most if not all prescription eye drop bottles. The individual protrusions with shapes at the end can be cut off by the pharmacist to match the frequency of administration prescribed.
215014385|NCT01640561|BEHAVIORAL|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
215014386|NCT02019537|PROCEDURE|Steroid injection into the subacromial space|"* Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance."
215014387|NCT02019537|PROCEDURE|Allogeneic PRP injection into the subacromial space|"* Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance."
215014388|NCT05628272|OTHER|Intravenous infusion of cord blood mononuclear cells|On the basis of the application of granulocyte stimulating factor, the research group was given intravenous infusion of umbilical cord blood mononuclear cells, each infusion ≥1×10\^8, once a week
215014389|NCT05628272|DRUG|application of granulocyte stimulating factor|application of granulocyte stimulating factor
215014390|NCT00231933|BEHAVIORAL|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
215014391|NCT00231933|BEHAVIORAL|Community integration (CI)|CI includes recovery group sessions and community integration activities.
215014392|NCT00231933|BEHAVIORAL|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
215014393|NCT02794805|DEVICE|¹³C-Octanoate Breath Test|Octanoate Breath Test to be performed on subjects with suspected HCC
215014394|NCT04738162|DRUG|5-Aminolevulinic Acid Hydrochloride, Oral|Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible
215014395|NCT04776876|BIOLOGICAL|Retifanlimab|Given IV
215014396|NCT04776876|DRUG|Telotristat Ethyl|Given PO
215014397|NCT03428854|DRUG|LNG-IUS|Levnorgestrel containing IUD
215014398|NCT01674855|DRUG|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
215014399|NCT01674855|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
215014400|NCT02852733|OTHER|end-of-life emergencies' management|
215014401|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
215100417|NCT05136261|DEVICE|Basic cream|Basic cream
215100418|NCT03147638|DRUG|Warfarin, NOAC|duration of treatment
215100419|NCT01722656|DRUG|Aflibercept|
214409891|NCT04157842|PROCEDURE|total hip replacement with subtrochanteral osteotomy|applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve
215014402|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
215014403|NCT01159353|DRUG|Insulin glulisine|Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
215014404|NCT01159353|DRUG|Insulin aspart|Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
215014405|NCT03994120|OTHER|RTMS|Altering the connectivity of trans-synaptic pathways
215014406|NCT00510562|PROCEDURE|Cranial osteopathic manipulation|This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
214409892|NCT04157842|PROCEDURE|total hip replacement with no osteotomy|just total hip replacement
215014407|NCT00510562|PROCEDURE|Sham/Placebo|A laying on of hands with no treatment being performed.
215014408|NCT05659420|BEHAVIORAL|Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor|aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
215014409|NCT03122366|DIAGNOSTIC_TEST|Detection of single nucleotide polymorphisms (SNP)|Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood
215014410|NCT05496699|BEHAVIORAL|Mckenzie Exercises|"1. Cervical Retraction Exercise in Sitting Position The participant sits on the chair, puts the second and third fingers on his chin and pushes his head posteriorly and inferiorly.~2. Cervical Rotation Exercise in Sitting Position~3. Cervical Retraction Exercise in Supine Position~4. Cervical Rotation Exercise in Supine Position The participant turns his head to the right and left, respectively, while taking his head back in the supine position with his head out of the bed.~5. Cervical Lateral Flexion Exercise~6. Cervical Flexion Exercise in Sitting Position"
215014411|NCT05496699|BEHAVIORAL|Mulligan Exercise|"The exercises to be applied are listed below.~1- C1-C2 Self Mobilization Slip is applied for natural apophyseal cervical right rotation. The belt is put on level C1. At the same time, the participant actively pulls the belt and turns his head to the right. To facilitate the rotation of the belt in C1, pressure is applied to the belt in the same direction as C2 and rotation of the head towards the restricted side is requested. It waits like this for 3 seconds. These movements are done in the painless range."
215014412|NCT04886609|DEVICE|ORISE gel|To establish if ORISE Gel an effective and feasible submucosal injecting solution during endoscopic resection of large colorectal polyps
215014413|NCT05257018|DRUG|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~* Rituximab 375 mg / m\^2，D1~* Cyclophosphamide 750 mg / m\^2，D2~* Doxorubicin Hydrochloride Liposome Injection 35mg / m\^2，D2~* Vincristine 1.4mg/m\^2 (dose capped at 2 mg)，D2~* Prednisone 50 mg， bid D2-6~* Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）"
215014414|NCT02868528|GENETIC|chromosome screening with NGS technology|
215014415|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
215014416|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
215014417|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
215014418|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
215014419|NCT04623060|OTHER|Combination of Low-volume interval treadmill training and Resistance Training|"Low-volume interval training (LV-ITT) protocols included a 5 min warm-up (30%-50%VO2peak) up to 20min of LV-ITT and a 5 min cooling down (30%-50% VO2peak). The LV-ITT will repeat 60s bursts of fast treadmill walking at maximum tolerate speed (0% incline), alternate with pre-specified recovery periods about 4 minutes according to protocol. Each time the participants completed a burst successfully, treadmill speed will be increased by 0.1 mph for the next burst. The recovery periods will be 4 minutes. The intervention will be conducted for about 30 minutes.~Resistance training will be conducted by using a horizontal leg press machine. They are encouraged to focus on an explosive concentric movement and a controlled eccentric movement such that the time on each phase was in the ratio 1:2."
215014420|NCT06184763|OTHER|6-minute walk test|"6-minute walk test in a 40-metre corridor. Included patients are used to performing this test, which is part of the standard care performed during patient follow-up, at least once a year.~Parameters collected during the test: distance walked, minimum SpO2, average SpO2, maximum heart rate, average heart rate, average heart rate over the last 2 minutes, dyspnea scale."
215014421|NCT02527083|DRUG|Propofol|
215014422|NCT02527083|DRUG|Sevoflurane|
215014423|NCT02527083|DRUG|Remifentanil|
215014424|NCT02527083|DRUG|Ketamine|
215014425|NCT03511066|DRUG|CT-P27 90 mg/kg|Influenza A treatment drug.
215014426|NCT03511066|DRUG|CT-P27 45 mg/kg|Influenza A treatment drug.
215014427|NCT03511066|DRUG|Placebo|Placebo.
214409893|NCT05951595|DRUG|Artemether-Lumefantrine-Amodiaquine (ALAQ)|A new fixed-dose combination containing artemether, lumefantrine and amodiaquine (ALAQ) will be used in the trial. Each paediatric (dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine, 40 mg amodiaquine. Adult (hard) tablets will contain either 50 mg or 60 mg of artemether, 300 or 360 mg of lumefantrine and 100 or 120 mg of amodiaquine. The treatments will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine, 22.5-45 mg/kg of amodiaquine).
214409894|NCT05951595|DRUG|Artemether-Lumefantrine (AL)|A fixed-dose combination of AL will be used in the trial. Each paediatric (dispersible) or adult (non-dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine and will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine).
214409895|NCT05951595|DRUG|Artesunate-Amodiaquine (ASAQ)|ASAQ will also be administered as a fixed dose combination. The tablets will contain 25 mg of artesunate and 67.5 mg of amodiaquine in the paediatric formulation and 100 mg artesunate, 270 mg amodiaquine in the adult formulation. The dosing will be administered once a day for 3 days at H0, H24 and H48 according to the schedule currently recommended by the WHO.
214409896|NCT03559361|DIETARY_SUPPLEMENT|EPA-rich|6 months omega 3 supplementation
214409897|NCT03559361|DIETARY_SUPPLEMENT|DHA-rich|6 months omega 3 supplementation
214409898|NCT03559361|DIETARY_SUPPLEMENT|Olive oil Placebo|6 months placebo supplementation
214409899|NCT03422510|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
214409900|NCT06185400|DRUG|Disitamab Vedotin|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC
214409901|NCT06185400|DRUG|third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression
215014428|NCT01509209|DRUG|Pseudoephedrine / Levocetirizine|tablet, BID everyday
214409902|NCT06185400|DRUG|pyrotinib|RC48+pyrotinib after EGFR-TKIs progression
214409903|NCT06417489|DRUG|Combination therapy|Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day.
214409904|NCT06417489|DRUG|Sequential treatment group|Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)\&gt;7mmol/L, postprandial blood glucose (PPG)\&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG\&gt;7mmol/L, PPG\&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added
214409905|NCT02931149|DRUG|Platelet-rich plasma|Submucosal injection with PRP was performed prior to endoscopic resection
214409906|NCT00010881|DRUG|antioxidants|
214409907|NCT00010881|BEHAVIORAL|stress reduction|
214409908|NCT03465007|DRUG|Hydrocortisone|we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
214409909|NCT03465007|DRUG|Normal saline|we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
214409910|NCT03129035|PROCEDURE|Cesarean hystrectomy|Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal
214409911|NCT03129035|PROCEDURE|Internal iliac artery ligation|The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin. Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side
214409912|NCT05980468|OTHER|music therapy|Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session.
214409913|NCT01702896|DRUG|Interleukin-2|Interleukin-2
214409914|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
214409915|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
214409916|NCT00000871|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
214409917|NCT00000871|BIOLOGICAL|rgp120/HIV-1 SF-2|
214409918|NCT03474562|DRUG|Duowell®|Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
214409919|NCT03474562|DRUG|Monorova® + Amlopin®|Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
214409920|NCT02138331|BIOLOGICAL|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
214409921|NCT01141933|OTHER|Cognitive-existential intervention|Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
214409922|NCT01141933|OTHER|Usual care|This group receive the usual treatment only.
214409923|NCT02135458|OTHER|Telemonitoring|
215014429|NCT05999370|BEHAVIORAL|Nutrition|"The nutrition intervention will be based on needs assessed by indirect calorimetry, patient-generated subjective global assessment, and 24hr recall conducted at baseline, enabling individualized caloric and protein targets.~Deficits in nutrient intake will be addressed with one-on-one dietary counselling and supplementation at baseline in a quantity that matches the estimated deficit in intake. Adherence will be monitored using 24-hr recalls and weight status by the dietitian weekly."
215014430|NCT05999370|BEHAVIORAL|Exercise|The exercise intervention will include both a resistance and an aerobic component to be performed a total of 5 times a day, 5 times per week, 5 minutes each session, totaling 125 minutes per week. The ability to perform exercises as prescribed will be monitored with a weekly in-person or virtual supervised session.
215014431|NCT05905055|DRUG|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
215014432|NCT05905055|DRUG|co-administration of aztreonam and nacubactam|2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
215014433|NCT05905055|DRUG|BAT|Dosage of BAT will be based per site's standard of care
214409924|NCT02135458|OTHER|Conventional care|
214409925|NCT03594331|DRUG|Low-dose PvP001|Low-dose PvP001
214409926|NCT03594331|DRUG|Medium-dose PvP001|Medium-dose PvP001
214409927|NCT03594331|DRUG|High-dose PvP001|High-dose PvP001
214409928|NCT03594331|DRUG|Placebo|100 mL liquid with no drug
214409929|NCT04346524|OTHER|sampling of microbiome|women will sample from vagina, feces, and saliva during pregnancy
214409930|NCT00469300|DRUG|Iontophoretic delivery of acyclovir|
214409931|NCT01180621|BIOLOGICAL|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
214409932|NCT04884399|DRUG|CMAB818|vascular endothelial growth factor (VEGF) inhibitor
214409933|NCT04884399|DRUG|Lucentis®|vascular endothelial growth factor (VEGF) inhibitor
214409934|NCT01149681|DRUG|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
214409935|NCT05830604|PROCEDURE|Occlusal Splint Treatment- Non Invasive treatment|Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.
214409936|NCT01949909|BIOLOGICAL|CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
214409937|NCT01949909|BIOLOGICAL|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
214409938|NCT01949909|BIOLOGICAL|TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
214409939|NCT01949909|BIOLOGICAL|TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
214409940|NCT01949909|BIOLOGICAL|TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
215014434|NCT06539351|OTHER|Skin biopsy|4mm skin punch biopsy
215100420|NCT05115916|BEHAVIORAL|MyChart Priming Message|In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
215100421|NCT00634790|DRUG|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
215100422|NCT00768482|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
214409941|NCT01949909|BIOLOGICAL|TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
214409942|NCT01949909|BIOLOGICAL|TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
214409943|NCT03710564|BIOLOGICAL|Brolucizumab|6 mg/0.05mL solution for intravitreal injection
214409944|NCT03710564|BIOLOGICAL|Aflibercept|2 mg/0.05mL solution for intravitreal injection
214409945|NCT00241540|DRUG|Esomeprazole|
214409946|NCT05652530|DRUG|Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)|This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
214409947|NCT02540135|OTHER|fluorescein|fluorescein and conventional neuro-navigation
214409948|NCT02540135|OTHER|intraoperative MRI|conventional neuro-navigation and iMRI
214409949|NCT00000676|DRUG|Clotrimazole|
215014435|NCT06964438|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation training twice daily (30 minutes per session), during postoperative days 1-4. The training will be carried out using a handheld device. Training will be carried out by the participant themselves, with researcher supervision until independently able to do so.
215014436|NCT06964438|DIETARY_SUPPLEMENT|Protein supplement drink|"Whey protein isolate drink, to provide a total of 60 g protein per day (2 x30 g).~The supplement will be provided in a powder form to participants. Participants will be asked to consume the supplement around the time of NMES training."
215014437|NCT06043570|DEVICE|Remote Monitoring arm|Patients will be follow-up using remote monitoring. In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification.
214409950|NCT00000676|DRUG|Fluconazole|
214409951|NCT03086512|DEVICE|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
214409952|NCT03086512|DEVICE|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
214409953|NCT05612659|PROCEDURE|Transcranial Electrical stimulation|Noninvasive electrical stimulation of lateral frontal cortex.
214409954|NCT05612659|PROCEDURE|Transcutaneous direct current stimulation|Noninvasive electrical stimulation of the T10 spinal column.
214409955|NCT00456274|PROCEDURE|Frequent baseline blood sampling|3 ml of blood sampled every 10 minutes for a total of 8-12 hours
214409956|NCT02470936|BEHAVIORAL|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
214409957|NCT04484402|BIOLOGICAL|mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution
214409958|NCT04484402|BIOLOGICAL|limbal stem cells|Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution
214409959|NCT04484402|OTHER|standard treatment|Standard treatment according to the Clinical protocols
214409960|NCT06554171|OTHER|Hippotherapy group|In addition to conventional physiotherapy, training will be given in the Hippotherapy Simulator for 15 minutes a day, 5 days a week for 4 weeks. The hippotherapy simulator serves a wide range of purposes from recreational use that mimics the movements of a real horse or can make similar movements, to fitness, exercise, sports, education and therapy and is suitable for use by individuals with cerebral palsy.
214409961|NCT06554171|OTHER|Control group|In addition to conventional physiotherapy, the control group will be allowed to sit in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks. However, the simulator will be kept in closed position to prevent oscillations.
215100423|NCT00768482|DRUG|Sublingual Buprenorphine|16 mg/day, QD
215100424|NCT06430515|PROCEDURE|Intratumoral Injection of Chemotherapy|This project intends to investigate the clinical efficacy of intra-tumoural injection of chemotherapeutic agents (e.g. cisplatin, oxaliplatin, etc.)via fine needle aspiration guided by CT or ultrasound in patients with advanced solid cancers to validate the safety and efficacy.
214409962|NCT00518362|DRUG|TW|TW,120 mg/d
214409963|NCT02993471|DRUG|Drug Cocktail|Administered orally
214409964|NCT02993471|DRUG|Ixekizumab|Administered SC
214409965|NCT03837769|DEVICE|Aktiia OBPM PulseWatch wrist device|The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
214409966|NCT06097429|DIAGNOSTIC_TEST|blood sample for platelet aggregation|evaluate platelet aggregation using light-transmission aggregometry and adenosine diphosphate (ADP)
214409967|NCT03426696|BEHAVIORAL|psychological condition|Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
215014438|NCT06222424|OTHER|outpatient prescription issues|Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge
215014439|NCT00656812|DRUG|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
214409968|NCT00853424|PROCEDURE|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
214409969|NCT00853424|OTHER|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
215014440|NCT00656812|DRUG|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
215014441|NCT04622319|DRUG|DS-8201a|Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
215014442|NCT04622319|DRUG|T-DM1|Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
215014443|NCT02478788|DRUG|mixed amphetamine salts-extended release (MAS-XR)|MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
215014444|NCT02478788|DRUG|Placebo|Pills with no medication in it
215014445|NCT04028505|DRUG|Terlipressin Injectable Product|"Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH."
215014446|NCT05153434|DRUG|ARD-101|Twice Daily, Oral Administration
215014447|NCT04791020|DRUG|Lidocain topical + paracervical blockade|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade
215014448|NCT04791020|DRUG|Lidocaine topical|5mL of lidocaine gel applied topically to cervix previous to clamping, No paracervical blockade will be applied.
215014449|NCT02838238|DRUG|Capecitabine|
215014450|NCT02838238|DRUG|Placebo|
215014451|NCT01501097|PROCEDURE|Continuous Renal Replacement Therapy|Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
215014452|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
215014453|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
215014454|NCT05443854|DRUG|Aminoglycosides intervention|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
215100425|NCT03754829|BEHAVIORAL|Her Sey Kontrol Altinda (HSKA)|HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
215100426|NCT03927404|DEVICE|Active vacuum test prosthesis|The adaptive vacuum prosthesis is sold as a commercial device by the company Willow Wood with suggested U.S. L-Code L5781. The device is designated as a Class 1 Medical Device and 510(K) Exempt. This category is part of a low or moderate risk to patient safety and health. The Prosthetic socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
215100427|NCT01017445|OTHER|Boonme stick exercise|individual exercise daily
214409970|NCT02128789|OTHER|Elder Tree website|Elder Tree is a private, secure information, support and communication website developed for this study.
214409971|NCT05060679|OTHER|Supportive therapy at the ICU|Non-septic ICU patients received adequate supportive treatment (fluid resuscitation, respiratory, anticoagulation, antimicrobial and vasopressor therapy along with sedation, ulcer prophylaxis and nutrition. Blood sampling for non-septic patients were the first (T1) and third (T3) postoperative morning at the ICU. Besides, 23 healthy outpatients were documented without sepsis or sepsis-related organ dysfuntion as a control group.
214409972|NCT05060679|OTHER|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis and nutrition. Blood samples were collected at the ICU from this patient group at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
214409973|NCT05060679|OTHER|Sepsis-related organ dysfunction therapy|Patient management of sepsis and sepsis-related organ dysfunction followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis, nutrition and renal replacement therapy (if needed). In this patient group, blood sampling was performed at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
214409974|NCT02808442|BIOLOGICAL|UCART19|
214409975|NCT00930813|DEVICE|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
214409976|NCT00930813|DEVICE|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
214409977|NCT04667065|OTHER|Physical activity|Physical activity with the remotely guidance of physical activity teachers
215014455|NCT05443854|BEHAVIORAL|Lack of protective isolation intervention|"Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.~Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods.~A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated"
214409978|NCT03973424|BEHAVIORAL|Simple|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
214409979|NCT03973424|BEHAVIORAL|Standard|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
214409980|NCT00882635|DRUG|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance \< 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
214409981|NCT00882635|DRUG|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
214409982|NCT00315120|PROCEDURE|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
215014456|NCT05443854|OTHER|No systematic aminoglycosides intervention - standard arm|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides."
215014457|NCT05443854|OTHER|Protective isolation intervention - standard arm|"Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide:~1. High-efficiency air filtration \[filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better\]~2. Geographical isolation in an individual room~3. Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the best available level of isolation in line with recommendation, while not delaying ICU admission and patients' care"
215014458|NCT06449664|BEHAVIORAL|ADT-train|A new training concept is tested on men with prostate cancer receiving androgen deprivation therapy
215014459|NCT04203056|DRUG|Aripiprazole Lauroxil|12 month longitudinal aripiprazole lauroxil treatment and assessment follow-through
215014460|NCT04203056|DRUG|ARI-ORAL|oral aripiprazole
215014461|NCT04203056|DRUG|AL-NCD|Aripiprazole Lauroxil 675 MG/2.4 ML Intramuscular Suspension, Extended Release
215100428|NCT04311463|DRUG|Paroxetine hydrochloride|Paroxetine hydrochloride will be administered.
215100429|NCT04311463|DRUG|PAXIL (Paroxetine hydrochloride )|PAXIL will be administered.
215100430|NCT02392936|PROCEDURE|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
215100431|NCT03104257|DRUG|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
215100432|NCT00209794|DRUG|Sulfadoxine-Pyrimethamine (Fansidar)|
215100433|NCT00803062|BIOLOGICAL|Bevacizumab|Given IV
215100434|NCT00803062|DRUG|Cisplatin|Given IV
215100435|NCT00803062|OTHER|Laboratory Biomarker Analysis|Correlative studies
215100436|NCT00803062|DRUG|Paclitaxel|Given IV
215100437|NCT00803062|OTHER|Quality-of-Life Assessment|Ancillary studies
215014462|NCT05701735|BEHAVIORAL|CECIL Patient Decision Aid|"The CECIL patient decision aid explicitly identifies the disease, the index decision, and the treatment options, describes the positive and negative features and consequences of each option, and guides the patient in examining personal values and preferences, to arrive at a quality and realistic decision.~The decision aid will be developed and validated according to the guidelines and standards published by the International Patient Decision Aids Standards (IPDAS) Collaboration."
215014463|NCT03100292|OTHER|Sleeve gastrectomy or Roux-en-Y gastric bypass|
215014464|NCT04113993|DRUG|Bazedoxifene Acetate|Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
215014465|NCT04113993|DRUG|Placebo|Identically packaged placebo capsule daily
215014466|NCT01044199|BIOLOGICAL|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
215014467|NCT01044199|BIOLOGICAL|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
214409983|NCT00315120|PROCEDURE|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
214409984|NCT00315120|PROCEDURE|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
214409985|NCT00315120|PROCEDURE|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
214409986|NCT04009226|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
214409987|NCT01320436|DIETARY_SUPPLEMENT|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
214409988|NCT01320436|DRUG|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
214409989|NCT05522699|BEHAVIORAL|Cough suppressive therapy|"The cough suppressive therapy based on the treatment regime Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough (PSALTI) developed by S. Chamberlain et al (Thorax. 2017 Feb;72(2):129-136)."
214409990|NCT05522699|BEHAVIORAL|General healthy lifestyle instructions|The general healthy lifestyle instructions are based on the recommendations from the The Public Health Agency of Sweden.
214409991|NCT05996757|PROCEDURE|Wet clothing removal|The participants in the intervention group will have their clothing removed prior to insulation.
214409992|NCT03142646|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
215100438|NCT00803062|OTHER|Questionnaire Administration|Ancillary studies
215014468|NCT01972984|DRUG|Anastrozole|Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
215100439|NCT00803062|DRUG|Topotecan Hydrochloride|Given IV
215100440|NCT00756210|OTHER|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
214409993|NCT01693419|DRUG|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m² IV on day 1, 8~2. Erlotinib 100 mg/day PO on day 1~3. S-1 60 mg/m²/day PO on day 1-14"
214409994|NCT02823548|DRUG|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
214409995|NCT02823548|DRUG|Placebo|Placebo
214409996|NCT02002819|DRUG|levetiracetam|
215014469|NCT05788380|OTHER|EXERCİSE|EXERCISE FOR HEALTH AND PAIN IMPROVEMENT
215014470|NCT00303797|DRUG|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
215014471|NCT00303797|DRUG|sorafenib tosylate|
215014472|NCT04682613|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, active teachers"|"Prevention program: young In Favor of Myself, with teacher participation"
214409997|NCT03999554|BIOLOGICAL|LD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
214409998|NCT03999554|BIOLOGICAL|MD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
214409999|NCT03999554|BIOLOGICAL|HD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
214410000|NCT03999554|BIOLOGICAL|LD Bris10 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.
214410001|NCT03999554|OTHER|Placebo|This group will receive saline placebo administered intranasally.
214410002|NCT06347952|PROCEDURE|Use of Acoustic and color imaging doppler during surgery for breast cancer|The intervention (post pilot study) is to systematically record the effect of routine use of acoustic as well as color imaging doppler during mammoplasty for breast cancer (for both the therapeutic and symmetrising breast reduction).
215014473|NCT04682613|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, no teacher involvement"|"Prevention program: young In Favor of Myself, without teacher participation"
215014474|NCT04267042|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
215014475|NCT04267042|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
214410003|NCT03138473|DIAGNOSTIC_TEST|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, creatinine clearance (CrCl) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of CrCl below 60 ml/min/1.73 m2 (1 point for CrCl between 59 and 50, 2 points for CrCl between 49 and 40 and 3 points for CrCl between 39 and 30 ml/min/1.73 m2). The CrCl is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
214410004|NCT03138473|DIAGNOSTIC_TEST|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-\[rSS/bSS\]) ×100.
214410005|NCT02715063|BEHAVIORAL|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
214410006|NCT02715063|BEHAVIORAL|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
215014476|NCT04267042|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
214410007|NCT02715063|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
214410008|NCT02715063|OTHER|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
214410009|NCT05634317|BEHAVIORAL|Smartphone delivered Behavioral activation|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 Review the present use of time and use the monitoring form~Session 2 Brain-storm pleasant events and schedule pleasant activities~Session 3 Review scheduling of events and discuss how to improve~Session 4 Review modifications and consolidate gains on scheduling~Session 5 Review present social support and explore new sources of support~Session 6 Examine communication skills and explore new options~Session 7 Review new communications and discuss how to improve~Session 8 Review modification and consolidate gains on support"
214410010|NCT05634317|BEHAVIORAL|Smartphone delivered Mindfulness|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 The Raisin exercise (eating meditation) and12-min body scan~Session 2 Exercises on thoughts and feelings 12-min body scan~Session 3 Exercises focusing on unpleasant experiences, practicing seeing and hearing , sitting meditation, 3-min breathing space, and mindful stretching and breath meditation~Session 4 Practicing seeing and hearing, mindful communication, 3-min breathing space, and sitting meditation~Session 5 Mindful walking, 3-min breathing space, and sitting meditation~Session 6 Sitting meditation, exercises on thoughts and alternative viewpoints, and 3-min breathing space (responsive)~Session 7 Sitting meditation, activity and mood exercise, identifying habitual emotional reactions to difficulties, and 3-min breathing space (responsive)~Session 8 12-min body scan, exercise on looking forward, and exercise on preparing for the future"
214410011|NCT03697733|PROCEDURE|fractional curettage|Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
214410012|NCT02118506|OTHER|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
214410013|NCT02118506|OTHER|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
215014477|NCT04864769|DIETARY_SUPPLEMENT|Krill protein hydrolysate|Ingestion of 35 g Krill protein hydrolysate
215014478|NCT04864769|DIETARY_SUPPLEMENT|Soy protein isolate|Ingestion of 35 g Soy protein isolate
215014479|NCT04864769|DIETARY_SUPPLEMENT|Whey protein isolate|Ingestion of 35 g Whey protein isolate
214410014|NCT02862327|DRUG|intravenous dexamethasone|intravenous injection of dexamethasone
214410015|NCT02862327|DRUG|intravenous placebo|intravenous injection of placebo
214410016|NCT02862327|DRUG|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
215014480|NCT04864769|DIETARY_SUPPLEMENT|Water|Ingestion of water (control)
215014481|NCT00165698|DRUG|menatetranone|15 mg three times a day orally for 12 months
215014482|NCT00165698|DRUG|alfacalcidol|0.25 μg twice a day orally for 12 months
215014483|NCT03679884|DRUG|Daridorexant 10 mg|Daridorexant 10 mg film-coated tablets
215014484|NCT03679884|DRUG|Daridorexant 25 mg|Daridorexant 25 mg film-coated tablets
215014485|NCT03679884|DRUG|Daridorexant 50 mg|Daridorexant 50 mg film-coated tablets
215014486|NCT03679884|DRUG|Placebo|Matching placebo film-coated tablets
215014487|NCT05013775|DIAGNOSTIC_TEST|Computed tomography|Computed tomography to gauge response after preoperative chemotherapy cycles and excluded the development of interval metastases or irresectable disease
215014488|NCT05013775|DIAGNOSTIC_TEST|Diagnostic laparoscopy with peritoneal lavage|Diagnostic laparoscopy lavage to exclude (small-volume) metastases and determine local resectability
215014489|NCT01107457|BIOLOGICAL|Ixekizumab|Administered subcutaneously
214410017|NCT02862327|OTHER|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
215014490|NCT01107457|DRUG|Placebo|Administered subcutaneously
215014491|NCT01026038|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
215014492|NCT01793922|PROCEDURE|PD|pneumodilation
215014493|NCT01793922|PROCEDURE|POEM|peroral endoscopic myotomy
215100441|NCT04505579|DEVICE|Anterior Vertebral Body Tethering|Anterior Vertebral Body Tethering (AVBT) is a technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side).
215100442|NCT01943240|DRUG|Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels|
215100443|NCT01943240|DRUG|10 cc of 0.375% ropivacaine pectoral nerve block|
215100444|NCT00705887|BEHAVIORAL|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
214410018|NCT04582877|DEVICE|FFR measurement|FFR is measured sequentially with the test article and the predicate device.
214410019|NCT00897637|OTHER|laboratory biomarker analysis|Correlative studies
214410020|NCT04630652|DRUG|Risankizumab-Rzaa|Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods
215014494|NCT04585360|OTHER|Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life|"Realization of specific questionnaires evaluating:~* psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire)~* fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment)~* quality of life (SF36 self-assessment questionnaire)"
215014495|NCT03360669|OTHER|Sequence: Clinical/Research|Participants will be assigned to a sequence of: research visit first/clinical visit second.
215014496|NCT03360669|OTHER|Sequence: Research/Clinical|Participants will be assigned to a sequence of: clinical visit first/research visit second.
215014497|NCT05587153|OTHER|perfusion index in all parturient recruited for the study|Using perfusion index and positional hemodynamic changes for the prediction of postspinal hypotension in all parturient recruited for the study
215014498|NCT02204735|BEHAVIORAL|Eat majority of calories in the morning|
214410021|NCT04630652|PROCEDURE|Punch biopsies of the skin at baseline visit|Two 6 mm punch biopsies of the skin at baseline visit
214410022|NCT04630652|PROCEDURE|Punch biopsies of the skin at week 28 visit|One 6 mm punch biopsy of the skin at week 28 visit
215014499|NCT02204735|BEHAVIORAL|Eat the majority of calories in the evening|
215014500|NCT03601052|DRUG|Remlarsen|Intradermal injection at site of one excisional wound
215014501|NCT03601052|DRUG|Placebo|Intradermal injection at site of second excisional wound
215100445|NCT00787501|DRUG|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI \< 2) and tolerability is adequate. Nonresponse at week 10 (CGI \< 2) will be cause for medication switch or augmentation.
214410023|NCT01501435|DRUG|CJ-30039|single dose
214410024|NCT01501435|DRUG|fenofibric acid|single dose
215014502|NCT06462872|OTHER|observational study|It is an observational study
215014503|NCT05330377|DRUG|Gilteritinib 40 MG Oral Tablet|Gilteritinib is an oral FLT3 inhibitor, and is active against both FLT3-ITD and FLT3-TKD mutations. Gilteritinib will be given orally according to the assigned phase I dose cohort starting day 6 until day 19. Participants will be given the daily dose with water as at the same time each morning. Gilteritinib should be taken at least 2 hours after or 1 hour before consuming food.
215014504|NCT05330377|DRUG|Cladribine|Cladribine is given intravenously at a dose of 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5.
214410025|NCT03530553|OTHER|Hunt Motivational Scale|The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
214410026|NCT00003656|BIOLOGICAL|recombinant interferon alfa|
215014505|NCT05330377|DRUG|Cytarabine|Cytarabine is given intravenously at a dose of 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.
215014506|NCT05330377|DRUG|Filgrastim|Filgrastim (GCSF) or biosimilar, will be given at a dose of 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is \> 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.
215014507|NCT05330377|DRUG|Mitoxantrone|Mitoxantrone is given intravenously at a dose of 10 mg/m2 I.V. over 2 hours once per day on days 1 to 3.
215014508|NCT03996213|OTHER|head down position|Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
214410027|NCT00003656|DRUG|tretinoin liposome|
215014509|NCT03996213|OTHER|leg elevation position|Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
215014510|NCT00477022|DEVICE|Vasotrain-447|
215014511|NCT04691232|BIOLOGICAL|Regulatory T cells|Autologous, ex vivo expanded, regulatory T cells
214410028|NCT03055767|DRUG|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
214410029|NCT03055767|OTHER|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
214410030|NCT03275896|OTHER|Descemet Membrane Transplantation|The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
214410031|NCT06554964|PROCEDURE|performing chromotubation during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube|Performing chromotubation )injection of blue dye to the fallopian tube via cevical catheter) during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube
214410032|NCT00630513|DRUG|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
214410033|NCT00630513|DRUG|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
214410034|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
214410035|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
214410036|NCT00939848|DRUG|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
214410037|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
214410038|NCT00939848|DRUG|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
214410039|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
214410040|NCT05982600|DIAGNOSTIC_TEST|Single Assessor Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.
214410041|NCT05982600|DIAGNOSTIC_TEST|2 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
214410042|NCT05982600|DIAGNOSTIC_TEST|3 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
215014512|NCT03640377|DRUG|Praziquantel|Praziquantel given as crushed tablets (40 or 80 mg/kg)
215014513|NCT05122819|PROCEDURE|Mandibular Molar Extraction Under Local Anesthesia|"Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS)."
215014514|NCT01817478|OTHER|microbiologic sample|
215014515|NCT00837330|DRUG|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
214410043|NCT05982600|DIAGNOSTIC_TEST|5 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
215014516|NCT01402466|BEHAVIORAL|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
215014517|NCT01402466|BEHAVIORAL|Project Bridge|Arm 2
215014518|NCT02509702|BEHAVIORAL|Connected to Care|10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment
215014519|NCT05833932|DRUG|Suhexiang Pill|Suhexiang Pill is an approved traditional Chinese patent medicine.
215014520|NCT01408498|DRUG|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
214410044|NCT02661997|BEHAVIORAL|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
214410045|NCT02661997|BEHAVIORAL|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
214410046|NCT00763282|BEHAVIORAL|Self Management (SM)|Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
214410047|NCT00763282|BEHAVIORAL|Motivational Interviewing (MI)|Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
214410048|NCT00763282|BEHAVIORAL|Education (ED)|The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
214410049|NCT04741971|DIETARY_SUPPLEMENT|Probiotics group|Will give Probiotics with Vitamin D3 one drop per day for 90 days
214410050|NCT04741971|DIETARY_SUPPLEMENT|Non-probiotics group|Will give Vitamin D3 five drops per day for 90 days
214410051|NCT06495411|OTHER|pranayama-|Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
214410052|NCT06495411|OTHER|deep breathing-|Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
214410053|NCT06495411|OTHER|control|Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
215014521|NCT05922280|OTHER|subtalar and talo-crural mobilization|"Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines."
215014522|NCT05922280|OTHER|International Working Group of the Diabetic Foot care guidelines|"Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension"
214410054|NCT00742274|DEVICE|Gore TAG Endoprosthesis|Implant Gore TAG device with Best Medical therapy per physician discretion
214410055|NCT00742274|OTHER|Best Medical Therapy|Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
214410056|NCT00413491|PROCEDURE|MR mammography|MR mammography
215014523|NCT05466253|PROCEDURE|Fixed Orthodontic treatment|All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group (EARLY)10 days after periodontal surgery whereas the control group will receive orthodontic intervention (DELAYED) 3 months after periodontal surgery.
215014524|NCT01227395|DRUG|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
214410057|NCT00413491|PROCEDURE|MR|MR
215014525|NCT00593255|DRUG|soluble human insulin|
215014526|NCT00593255|DRUG|insulin aspart|
215014527|NCT00593255|DRUG|insulin NPH|
215014528|NCT01090206|DIETARY_SUPPLEMENT|Vitamin D and calcium|Doses will be based on Vitamin D levels
214410058|NCT01073098|OTHER|Vascular occlusion test|Reperfusion slope after vascular occlusion test
214410059|NCT04892810|PROCEDURE|Percutaneous ablation|Hepatic Percutaneous Ablation with radiofrequency or microwave
214410060|NCT03281343|BEHAVIORAL|Motivational Interviewing & Patient Navigator|The specific content, structure, and implementation approach for MI-NAV will be guided by IDIs conducted during Phase 1 and Phase 2. Our initial plan is to deliver MI-NAV in two waves. The first wave will be aimed at promoting uptake of PrEP at the prison, through the use of motivational interviewing. The second wave will be aimed at linking at-risk women to community-based PrEP care upon release from incarceration, by utilizing a patient navigator approach.
214410061|NCT03281343|BEHAVIORAL|Standard of Care (SOC)|SOC will consist of a pamphlet regarding PrEP during incarceration, an offer of PrEP while incarcerated, and referral to community-based PrEP care upon release.
215014529|NCT03964129|PROCEDURE|Avance Nerve Graft with Autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.
215014530|NCT03432689|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
215100446|NCT00787501|BEHAVIORAL|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
214410062|NCT02427737|BEHAVIORAL|Comfort Talk® Training|Personnel of MRI units is trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This entails 16 hrs classroom work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
214410063|NCT06378879|DRUG|Propofol 100 MG in 10 ML Injection|Sedation induction time (minutes), total dose of propofol (mg), recovery time (minutes), any involuntary patient movement, quality of sedation (VAS) and adverse events
214410064|NCT01904357|DRUG|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and \< 50 kg will receive the 1g dose.
214410065|NCT01904357|DRUG|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
214410066|NCT06366893|DIETARY_SUPPLEMENT|DHA/AA emulsion supplement for preterm infant|Enteral supplementation of DHA/AA emulsion
214410067|NCT00138164|BIOLOGICAL|denileukin diftitox|
214410068|NCT01894347|OTHER|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
214410069|NCT04358328|OTHER|Comprehensive geriatric assessment (CGA) and care|Comprehensive geriatric assessment and care including geriatric-, nursing-, physiotherapist-, and dietician assessments followed by appropriate interventions.
214410070|NCT04358328|OTHER|Standard care|Standard pre-, peri- and post operative care.
214410071|NCT03288350|DRUG|mDCF + Avelumab|Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
214410072|NCT02506426|PROCEDURE|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
214410073|NCT02506426|PROCEDURE|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
214410074|NCT00478556|DRUG|Omnipaque|Oral CT contrast
214410075|NCT00478556|DRUG|Gastroview|Oral CT contrast
214410076|NCT04636086|DRUG|Cholecalciferol|Vitamin D supplementation
214410077|NCT04636086|OTHER|Placebo|Placebo comparator
215014531|NCT03432689|DRUG|Cycloserine|Cycloserine 100mg
215014532|NCT03432689|DRUG|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
215014533|NCT00668408|OTHER|LTOT (oxygen therapy)|Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
215014534|NCT00668408|OTHER|Pharmacological therapy of COPD and CHF|"Optimal pharmacologic treatment will include :~* Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)~* Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)~* Beta-blockers~* Diuretics~* Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics~* Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).~The treatment of the deseases will follow the international guidelines."
215100447|NCT01112111|DRUG|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
215100448|NCT05583032|DEVICE|ScanNav Anatomy PNB|AI-powered device that highlights anatomy of interest during ultrasound scans.
215100449|NCT04117698|DRUG|Antitubercular treatment (RIFATER ©)|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group."
214410078|NCT02974010|DRUG|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
214410079|NCT02974010|DRUG|Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
214410080|NCT02974010|DRUG|Ketamine Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
214410081|NCT02974010|DRUG|Saline Solution Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
214410082|NCT03771027|OTHER|The low FODMAP diet.|The low FODMAP group had reduced the intake of FODMAP. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
214410083|NCT03771027|OTHER|The diet based on NICE guidelines.|The control group based on NICE guidelines received diet contained products with different FODMAP content. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
214410084|NCT06398223|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA): Surgical procedure to remove the plaque buildup in the carotid artery.
214410085|NCT06398223|PROCEDURE|Carotid artery stenting|Carotid artery stenting: Treatment of the stenosis with a stent. The plaque in the artery wall is not removed but the narrowing is dilated.
214410086|NCT05062590|OTHER|Recommendations|Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP
214410087|NCT05540990|DEVICE|Robot assisted gait training|15 sessions of robot-assisted gait training (two times per week with a maximum of 45 minute each).
214410088|NCT05540990|OTHER|Conventional physiotherapy|individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
214410089|NCT05060185|DEVICE|the Flow Diverter|Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
214410090|NCT02952755|DRUG|Co-administration of DWC20155/DWC20156|
214410091|NCT02952755|DRUG|DWC20162|
214410092|NCT02214108|OTHER|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
214410093|NCT04745702|COMBINATION_PRODUCT|Low Calorie Meals Rich in Plant Components|Twice a day reduced calorie frozen ready meals (rich in plant components) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
214410094|NCT04745702|COMBINATION_PRODUCT|Low Calorie Balanced Meals|Twice a day reduced calorie frozen ready meals (balanced composition) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
214410095|NCT04238104|OTHER|no intervention|it's only observational study. No interventions.
215014535|NCT01673945|DEVICE|EUS-guided fine needle aspiration|Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
215014536|NCT04650945|OTHER|isCGM group|As previously described
215014537|NCT02722291|DEVICE|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
215014538|NCT03432962|OTHER|no intervention - recoding of food recall only|recoding of food recall
214410096|NCT01941316|DRUG|Carfilzomib|20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
214410097|NCT01941316|DRUG|Irinotecan|125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
214410098|NCT00320489|DRUG|olanzapine|10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
214410099|NCT00320489|DRUG|olanzapine pamoate depot|405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
214410100|NCT03363256|BEHAVIORAL|TES-NAV|Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
214410101|NCT03363256|BEHAVIORAL|TAU|Standard outpatient addiction treatment
214410102|NCT01989442|DEVICE|binasal prongs|patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
214410103|NCT01989442|DEVICE|nasal mask|patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
214410104|NCT03244176|DRUG|Avelumab|"All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
215014539|NCT03204825|DEVICE|Active TENS|TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.
215100450|NCT04117698|DRUG|Ethambutol|Ethambutol
215100451|NCT04117698|DRUG|RIFINAH ©|RIFINAH ©
215100452|NCT05544149|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors
215100453|NCT02759991|DRUG|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
215100454|NCT02759991|DRUG|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
215100455|NCT01599741|RADIATION|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
215014540|NCT03204825|BEHAVIORAL|Patient-Centred Education|Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking
215014541|NCT03204825|DEVICE|Placebo TENS|TENS device use with setting so that the stimulation delivered is ineffective
215014542|NCT01325766|OTHER|Yoga|Yoga 2 sessions per week for 8 weeks
215014543|NCT04721262|DEVICE|Hyperfine Portable MRI|The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
214410105|NCT06368609|DIAGNOSTIC_TEST|IgG RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
214410106|NCT06368609|DIAGNOSTIC_TEST|IgG4 RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
214410107|NCT03441984|DRUG|Treatment A|TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
215014544|NCT05033457|PROCEDURE|unilateral biportal endoscopy technique or percutaneous endoscopic transforaminal discectomy|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group.Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group.
215014545|NCT02025036|DRUG|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
215014546|NCT02025036|DRUG|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
215014547|NCT02025036|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
215100456|NCT01599741|RADIATION|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
215100457|NCT00003027|BIOLOGICAL|aldesleukin|
214410108|NCT03441984|DRUG|Treatment B|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
214410109|NCT03441984|DRUG|Treatment C|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/3TC 30 mg, orally as direct-to-mouth.
214410110|NCT03441984|DRUG|Treatment D|"DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth."
214410111|NCT03441984|DRUG|Treatment E|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
214410112|NCT03441984|DRUG|Treatment F|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
215014548|NCT01398475|DRUG|LY3009104|Administered orally
215014549|NCT01341041|BIOLOGICAL|chlorine dioxide|one time wash with 50ppm CD solution
215014550|NCT01341041|BIOLOGICAL|saline|one time wash with 50-100 cc normal saline
215014551|NCT06398639|OTHER|Polygenic Risk Score (PRS)|"Participants will be put into PRS cohorts based on their genetic data.~All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score."
215014552|NCT05367830|BEHAVIORAL|the Bone@BC app|The bone@BC app is a diary for patients with breast cancer that they can use if they want to.
215014553|NCT00105508|DRUG|Sarizotan|Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
215014554|NCT00105508|DRUG|Placebo|Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
215014555|NCT01574560|BEHAVIORAL|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
215014556|NCT01574560|BEHAVIORAL|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
215100458|NCT00003027|BIOLOGICAL|filgrastim|
215100459|NCT00003027|BIOLOGICAL|recombinant interferon alfa|
215100460|NCT00003027|DRUG|cisplatin|
215100461|NCT00003027|DRUG|dacarbazine|
215100462|NCT00003027|DRUG|vinblastine|
215100463|NCT02195804|DRUG|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
215100464|NCT02195804|DRUG|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
215100465|NCT02195804|DRUG|Ranitidine hydrochloride|
215100466|NCT00737633|DRUG|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
215014557|NCT00086307|DRUG|Pramipexole|Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
214410113|NCT05457842|DRUG|pudexacianinium chloride|Intradermal injection
214410114|NCT05750095|BEHAVIORAL|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
214410115|NCT05750095|BEHAVIORAL|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
214410116|NCT05692258|OTHER|Acupuncture|"Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint).~Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011."
214410117|NCT00100659|DRUG|Pegylated Interferon/ribavirin|
214410118|NCT02180087|DRUG|Ketoprofen|
214410119|NCT05685758|OTHER|FTP-based therapeutic mobile-app|Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
214410120|NCT01675830|DEVICE|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
214410121|NCT05998668|OTHER|Genital hygiene training|In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Two weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method.
214410122|NCT05402228|DIAGNOSTIC_TEST|temporomandbular joint disorders|no intervention
214410123|NCT03192085|DIAGNOSTIC_TEST|SITA FAST VISUAL FIELD TEST|Diagnostic test for glaucoma
214410124|NCT03192085|DIAGNOSTIC_TEST|SITA STANDARD VISUAL FIELD TEST|Diagnostic test for glaucoma
215014558|NCT00086307|DRUG|Escitalopram|Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
215014559|NCT00683384|DRUG|Etanercept (Enbrel)|
215014560|NCT02926612|OTHER|Next Generation Genomic Sequencing|DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
215014561|NCT03888274|DEVICE|ClearUP Sinus Pain Relief|Microcurrent Device Treatment
215014562|NCT06466265|DRUG|DNP002|Anti-CEACAM6 monoclonal antibody
215014563|NCT03334266|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
215014564|NCT03334266|OTHER|Injury Prevention Education (IPE)|The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
215100467|NCT00002580|DRUG|cyclophosphamide|
215100468|NCT00002580|DRUG|fluorouracil|
215100469|NCT00002580|DRUG|goserelin acetate|
215100470|NCT00002580|DRUG|leuprolide acetate|
215100471|NCT00002580|DRUG|methotrexate|
215100472|NCT00002580|DRUG|tamoxifen citrate|
215100473|NCT00002580|PROCEDURE|conventional surgery|
215100474|NCT00002580|PROCEDURE|laparoscopic surgery|
215100475|NCT00002580|PROCEDURE|oophorectomy|
215100476|NCT00002580|RADIATION|radiation therapy|
215100477|NCT06349668|DRUG|spinal analgesia with morphine and bupivacaine|single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery
215100478|NCT06349668|DRUG|lidocaine infusion|intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
215100479|NCT01300260|BIOLOGICAL|LY2189265|Administered subcutaneously
215100480|NCT01300260|DRUG|Placebo|Administered subcutaneously
215100481|NCT01300260|DRUG|Insulin|Administered intravenously
215100482|NCT01300260|DRUG|Glucose|Administered intravenously
215100483|NCT01300260|DRUG|Glucagon|Administered intravenously
215100484|NCT00188006|DEVICE|heparin-coated cardiopulmonary bypass|
215100485|NCT04194073|DEVICE|Pulse oximeter calibration population (NightOwl)|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
215100486|NCT02800265|DIETARY_SUPPLEMENT|Avmacol|Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
215100487|NCT02784769|OTHER|measurement of skin autofluorescence|
215100488|NCT02784769|OTHER|skin biopsy collection|
215100489|NCT02528682|BIOLOGICAL|MiHA-loaded PD-L-silenced DC Vaccination|Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
215100490|NCT03230682|DRUG|antidepressant|regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
214410125|NCT00372216|DRUG|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
215014565|NCT03334266|OTHER|Optimized Standard Care (OSC)|OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
215100491|NCT02145351|DEVICE|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
215100492|NCT02145351|DEVICE|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
215100493|NCT00785174|DEVICE|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
215100494|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
215100495|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
215100496|NCT02128074|DRUG|KRX-0502|1g tablets of KRX-0502
215100497|NCT04678791|DRUG|Nimotuzumab|Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
215100498|NCT04678791|DRUG|Cisplatin|Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
215100499|NCT04678791|RADIATION|External-beam radiation|Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
215100500|NCT04678791|RADIATION|Brachytherapy|Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 \~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
215100501|NCT02667470|DRUG|Solifenacin|Oral
215100502|NCT00439374|DRUG|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
215100503|NCT00439374|OTHER|Placebo Oil|Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
214410126|NCT04088188|DRUG|Cisplatin|Given IV
214410127|NCT04088188|DRUG|Gemcitabine|Given IV
214410128|NCT04088188|DRUG|Ivosidenib|Given PO
214410129|NCT04088188|DRUG|Pemigatinib|Given PO
214410130|NCT06510283|DRUG|Taitacept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.
214410131|NCT06079593|PROCEDURE|Gasless Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering
214410132|NCT06079593|PROCEDURE|Standard Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
215014566|NCT00120874|BEHAVIORAL|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
215014567|NCT00120874|DRUG|Memantine|Patients receive 10 milligrams of memantine twice daily.
214410133|NCT02199145|PROCEDURE|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
214410134|NCT00445406|DRUG|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
215100504|NCT01204762|DRUG|pegIFN|Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
215100505|NCT01204762|DRUG|pegIFNα-2a|Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
214410135|NCT00445406|DRUG|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
214410136|NCT05805345|DEVICE|Delefilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
214410137|NCT05805345|DEVICE|Lehfilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
214410138|NCT05805345|DEVICE|Lotrafilcon B toric soft contact lens|Commercially available silicone hydrogel contact lens
214410139|NCT05805345|DEVICE|Verofilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
215014568|NCT00922389|PROCEDURE|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
215014569|NCT00922389|DRUG|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
215014570|NCT00922389|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
214410140|NCT04545606|BEHAVIORAL|In-Person CBT for insomnia in children with autism|"7 modules administered in-person~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
214410141|NCT04545606|BEHAVIORAL|Remote CBT for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
214410142|NCT04545606|BEHAVIORAL|Remote sleep hygiene and related education (SHARE) for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Education~2. Sleep Architecture \& Parasomnias~3. Physical Activity \& Sleep~4. Nutrition, My Plate, \& Breathing during Sleep~5. Stress, Sleep, Dreams, \& Nightmares Connections~6. Mood, Self-Esteem, \& Sleep~7. Light \& Dark Cycle"
214410143|NCT05286424|PROCEDURE|fat grafting|Fat will be removed from abdomen or legs, processed and re-injected into grafting sites.
214410144|NCT01496209|BIOLOGICAL|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
214410145|NCT01496209|BIOLOGICAL|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
214410146|NCT04898322|DRUG|SY-005|2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
214410147|NCT04898322|DRUG|SY-005|5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
215014571|NCT02130141|DIETARY_SUPPLEMENT|Dark chocolate|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
215014572|NCT02130141|OTHER|Dietary counselling|Usual snacks are limited.
215014573|NCT00845000|DRUG|SCH 420814 10 mg|one 10-mg capsule, orally, at hour 0 of treatment period
215100506|NCT01204762|DRUG|PegIFN lambda|Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
214410148|NCT04898322|DRUG|SY-005|10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
214410149|NCT04898322|DRUG|Placebo|Placebo
214410150|NCT02606734|DEVICE|Coronary Angiography|The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
215014574|NCT00845000|DRUG|SCH 420814 100 mg|single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
215014575|NCT00845000|DRUG|Placebo|Placebo capsule, oral, at hour 0 of treatment period
215014576|NCT00845000|DRUG|Levodopa|levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
215014577|NCT00845000|DRUG|Carbidopa|one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
215014578|NCT03107000|PROCEDURE|Trabeculectomy|Incisional surgery for glaucoma
215014579|NCT03107000|PROCEDURE|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
215014580|NCT04428593|DRUG|Treamid 5 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
215014581|NCT04428593|DRUG|Treamid 15 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
215014582|NCT04428593|DRUG|Treamid 50 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
215100507|NCT01204762|DRUG|Entecavir|Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
215100508|NCT05339282|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
215100509|NCT03289117|DEVICE|Novel gel installation device procedure|Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
215014583|NCT04428593|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
215014584|NCT04002427|DRUG|Intravenous Infusion|30 µg \[14C\]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
215014585|NCT04002427|DRUG|Inhaled dose|A single inhalation on one occasion.
215014586|NCT00335621|DRUG|Inhaled Tiotropium|
215014587|NCT03667729|BEHAVIORAL|progressive muscle relaxation|intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
215100510|NCT03289117|DEVICE|Standard procedure|Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
214410151|NCT05046158|DEVICE|Transforming Powder Dressing|Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.
214410152|NCT05046158|OTHER|Standard of care topical wound agents and dressings|Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.
214410153|NCT00548119|BIOLOGICAL|NeoCart|autologous tissue implant
214410154|NCT00548119|PROCEDURE|microfracture|microfracture
214410155|NCT01269606|DRUG|insulin aspart|At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
214410156|NCT01269606|DRUG|insulin human|At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
214410157|NCT01269606|DRUG|insulin aspart|At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
215014588|NCT00295243|DRUG|Topotecan|
215014589|NCT06547801|DIETARY_SUPPLEMENT|2'-Fucosyllactose|3 g/day of powder orally once daily
215014590|NCT06547801|DIETARY_SUPPLEMENT|Maltodextrin|3 g/day of powder orally once daily
215014591|NCT05374993|DEVICE|3TBA|Induce third molar tooth bud agenesis
215014592|NCT00511290|OTHER|no generic names|
215014593|NCT06017375|OTHER|Questionnaire based intervention|Three validated questionnaires amended from hepatitis B to D (Chronic liver disease questionnaire, self-stigma scale and HBV virus knowledge scale) will be used.
215014594|NCT00300495|DRUG|Amiodarone|Perioperative orally administered
215014595|NCT00300495|OTHER|Control arm, standard care|Control
215100511|NCT00293020|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
214410158|NCT01269606|DRUG|insulin human|At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
215014596|NCT02166788|PROCEDURE|Inguinal Lymphadenectomy|
215014597|NCT02166788|PROCEDURE|Ilio-inguinal Lymphadenectomy|
215014598|NCT04364971|PROCEDURE|singleradius and multiradius total knee arthroplasty|singleradius and multiradius total knee arthroplasty
215014599|NCT03833843|DIAGNOSTIC_TEST|imaging|ECG, Echocardiography and cardiac magnetic resonance imaging
215014600|NCT00002836|BIOLOGICAL|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
215014601|NCT00002836|DRUG|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
215014602|NCT00002836|DRUG|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
215014603|NCT00002836|DRUG|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
215014604|NCT00002836|DRUG|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
215014605|NCT00002836|DRUG|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
215014606|NCT00002836|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
215100512|NCT02533726|OTHER|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
215100513|NCT02533726|OTHER|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
215100514|NCT02533726|OTHER|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
215100515|NCT05254873|OTHER|Long term follow-up|Long term follow-up for patient who completed the EYE-TAR(MA) study.
215100516|NCT01147848|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
215100517|NCT01147848|DRUG|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
214410159|NCT04904757|DEVICE|Contrast-enhanced spectral mammography (CESM)|CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.
214410160|NCT02960542|BEHAVIORAL|HELP Prevent Cancer Intervention|This Behavioral: Lifestyle Weigh Loss Intervention involves a dietary weight-loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight-loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight-loss of .3 kg/week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 minutes/week.
215014607|NCT03368560|OTHER|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga (SKY): A 12-week training course conducted by certified instructors from the Art of Living Foundation. SKY training will take place in group-format (group sizes of 8-15 participants) in an appropriately sized and accessible community hall in London, Ontario.SKY training involves attending a week-long (5 days) course that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period and log practice frequency and any other noteworthy observations in a log sheet that will be provided to them . Nutritional snacks will be provided during the 5 day SKY training course.
215014608|NCT03632720|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL
215014609|NCT03632720|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL
215014610|NCT03632720|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine|Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
215014611|NCT03632720|BIOLOGICAL|Human rotavirus RIX4414 strain vaccine|Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
215014612|NCT03632720|BIOLOGICAL|Pneumococcal 13-valent polysaccharide conjugate vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
215014613|NCT03896932|OTHER|minipooled- Intravenous immunoglobulin(MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
215014614|NCT04806945|DRUG|HLX10|IV infusion.
215014615|NCT04806945|DRUG|Paclitaxel|IV infusion
215014616|NCT04806945|DRUG|Cisplatin|IV infusion
214410161|NCT05495646|PROCEDURE|Central catheter insertion|The data will be obtained through the review of the medical records and the clinical follow-up of each patient to evaluate the technique of inserting the device, the possible risk factors of catheter-related infection, its clinical manifestations and the data microbiological.
214410162|NCT01670019|DRUG|Asenapine 5-20 mg daily|5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
214410163|NCT01670019|DRUG|Placebo 1-4 tablets daily|One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
215014617|NCT04806945|DRUG|Carboplatin|IV infusion
214410164|NCT00580801|DRUG|Telaprevir|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
215014618|NCT04806945|DRUG|Placebo to HLX10|IV infusion
215014619|NCT00682435|DRUG|Hydromorphone|"1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
215014620|NCT06397066|PROCEDURE|White light endoscopy group|White light endoscopy observe the characteristics of mucosa under white light
215014621|NCT06397066|PROCEDURE|Magnifying endoscopy group|NBI+ME to observe the non atrophic area of the gastric fundus gland. The results depend on the ratio of gastric fundus gland.
215014622|NCT02739646|DEVICE|Functional MRI scan|7.0 Tesla functional MRI scan
215014623|NCT06034314|DRUG|Dronabinol Capsules|Two 10 mg Dronabinol capsules will be administered orally, for a total of 20mg, on test day.
214410165|NCT00580801|DRUG|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
214410166|NCT00580801|DRUG|Placebo|Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
214410167|NCT00580801|DRUG|Ribavirin|Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
214410168|NCT00516711|DRUG|Sevoflurane|
215014624|NCT00664677|DRUG|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
215014625|NCT00112853|DRUG|tipifarnib|Given orally
215014626|NCT00112853|DRUG|etoposide|Given orally
215014627|NCT06091605|PROCEDURE|Soft tissue augmentation around dental implants.|Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.
215014628|NCT00902525|DRUG|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
214410169|NCT01877616|OTHER|diagnostic test|Polysomnography
214410170|NCT01877616|OTHER|Diagnostic test|overnight polysomnography
214410171|NCT05603442|PROCEDURE|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
215014629|NCT06655337|DEVICE|Smartphone Application for Post-Discharge Symptom Monitoring|This intervention involves the use of a smartphone application designed for symptom monitoring. The app enables participants to log daily health data, including symptoms and vital signs, for 7 days following discharge. It provides automated prompts and guidance for self-management, including when to seek medical assistance. The app does not provide direct medical intervention but facilitates remote symptom tracking to reduce readmissions and emergency hospitalizations. Follow-up consultations are conducted at day 7 and day 28.
215100518|NCT01147848|DRUG|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
215100519|NCT01147848|DRUG|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
214410172|NCT00988286|PROCEDURE|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
214410173|NCT01062880|BEHAVIORAL|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
214410174|NCT02586454|PROCEDURE|Transmuscular quadratus lumborum block|
214410175|NCT02586454|DRUG|morphine|
214410176|NCT02586454|DRUG|ropivacaine|
214410177|NCT01771887|BEHAVIORAL|education program|education program in 6 hours and monitoring phone every 15 days
214410178|NCT05407519|DRUG|Tislelizumab + Sitravatinib|Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI
214410179|NCT04590794|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activator Receptor|Participants will undergo sampling of peripheral venous blood, immediately after admission. Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until later measurement. Plasma suPAR levels will be determined using the suPARnostic® ELISA assay (ViroGates, Denmark), which is based on a simplified double monoclonal antibody sandwich ELISA assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells. The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples. suPAR concentrations are determined as ng/mL plasma.
214410180|NCT03601507|DRUG|Alpelisib|Given PO
214410181|NCT03601507|OTHER|Laboratory Biomarker Analysis|Correlative studies
214410182|NCT03601507|OTHER|Pharmacodynamic Study|Correlative studies
215014630|NCT00290238|DEVICE|Vertis Percutaneous Neuromodulation Therapy (PNT)|"* Ten PNT sessions in eleven weeks~* On average, one PNT session per week~* Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Continuous 50 Hz current~ * Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~ * Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level"
215100520|NCT05314959|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale responses are shared with their physician.
215100521|NCT05314959|OTHER|Usual Care|The patients' pre-visit Control Preference Scale responses are not shared with their physician.
215100522|NCT02886559|DRUG|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
215014631|NCT00290238|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"* Ten TENS sessions in eleven weeks~* On average, one TENS session per week~* Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Current at 2 Hz-low frequency~ * Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~ * Intensity titrated according to subject's sensory threshold~ * To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device."
215014632|NCT06658184|BEHAVIORAL|sleep restriction and stimulus control|"Sleep restriction: a) Reduce bedtime to match actual sleep time, but ≥4.5 hours, and adjust bedtime according to sleep efficiency; b) Avoid daytime naps and maintain a regular wake-up time.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
215014633|NCT06658184|BEHAVIORAL|sleep hygiene education|"Sleep hygiene education:~1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight."
215014634|NCT05730673|DRUG|700mg leronlimab weekly dose|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5
215014635|NCT05730673|DRUG|80mg Regorafenib at week 1|Regorafenib is a small-molecule multiple kinase inhibitor
215014636|NCT05730673|DRUG|120mg Regorafenib at week2|Regorafenib is a small-molecule multiple kinase inhibitor
215100523|NCT04538079|DEVICE|Multimodal objective non-invasive Monitoring|Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
215100524|NCT02356679|DRUG|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
214410183|NCT03601507|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
214410184|NCT00073138|DRUG|ABT-751|
214410185|NCT00243334|OTHER|Integration of advanced clinical decision support with ambulatory computerized physician order entry|Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
214410186|NCT03807102|BIOLOGICAL|Tumor Vaccine|NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
214410187|NCT01043549|DEVICE|rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
214410188|NCT01043549|DEVICE|Sham rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
214410189|NCT02540642|DIETARY_SUPPLEMENT|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
215100525|NCT02356679|DRUG|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
214410190|NCT03061513|DRUG|Ubiquinol|Ubiquinol caplets 600mg/day
214410191|NCT03061513|DIETARY_SUPPLEMENT|Placebo|placebo
214410192|NCT03478501|BEHAVIORAL|Decision Aid|This intervention is a tablet based Lethal Means Decision Aid with proposed use to augment lethal means counseling in emergency departments for patients at risk of suicide.
214410193|NCT02107014|DRUG|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
214410194|NCT00370799|DRUG|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
214410195|NCT00370799|DRUG|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
214410196|NCT00370799|DRUG|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
214410197|NCT00370799|DRUG|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
214410198|NCT03237936|DRUG|1mg/mL ciclosporin|IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
214410199|NCT00104754|DRUG|liposomal SN-38|
215014637|NCT05730673|DRUG|160 mg Regorafenib at week 3|Regorafenib is a small-molecule multiple kinase inhibitor
215014638|NCT03166254|DRUG|Pembrolizumab|-Pembrolizumab will be given intravenously over the course of 30 minutes
215100526|NCT03180307|DRUG|OTL38|0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
215100527|NCT03180307|DEVICE|near infrared camera imaging system|Infrared imaging used to excite OTL38 for fluorescence
215100528|NCT03180307|PROCEDURE|laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
215100529|NCT03599479|DEVICE|Virtual reality group|Virtual reality group The study intervention is to provide acute pain management for the subject undergoing fluoroscopic pain intervention by using the virtual reality program provided by the collaborator through virtual reality device (headset, headphone, and smartphone) that are commercialized on the market.
215100530|NCT01909765|OTHER|Dorsal slit|Skin and mucosa incision made together
215100531|NCT01909765|OTHER|Double incision|Skin and mucosa incision made separately
214410200|NCT00478855|DRUG|Tazocin (Piperacillin/Tazobactem)|
214410201|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
214410202|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields (PEMF)|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
214410203|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) High Dose|Participants will consume 4 capsules (600 mg green kiwi powder) daily for 28-days
214410204|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg green kiwi powder) daily for 28-days
214410205|NCT03462199|DIETARY_SUPPLEMENT|Control Formula (Actazin green kiwi powder + PreticX prebiotic)|Participants will consume 4 capsules (150 mg green kiwi powder + 250 mg PreticX prebiotic) daily for 28-days
214410206|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) High Dose|Participants will consume 4 capsules (600 mg gold kiwi powder) daily for 28-days
215014639|NCT03166254|BIOLOGICAL|NEO-PV-01 vaccine|-Generation of the vaccine is expected to take approximately 12 weeks
215014640|NCT03166254|PROCEDURE|Biopsy|-Surgical or core needle biopsy of an accessible site for DNA and RNA sequencing, immunological analysis, and generation of NEO-PV-01 vaccine
215014641|NCT03166254|DRUG|Poly ICLC|-NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.
215014642|NCT03166254|PROCEDURE|Leukapheresis|-Peripheral blood mononuclear cells (PBMCs) for comprehensive immune system monitoring will be obtained from leukapheresis samples collected up to 7 days prior to initiation of NEO PV-01 vaccination and at 7 days (Week 20) following the first NEO-PV-01 booster vaccination.
214410207|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg gold kiwi powder) daily for 28-days
215014643|NCT03166254|PROCEDURE|Peripheral blood samples|-Blood samples (80 mL) for immune monitoring will be obtained prior to study treatment and at Weeks 6, 14, 16, 24, 36, 48, 63, 75, 87, and 99.
215014644|NCT06215586|DRUG|Tovinontrine (CRD-750|Tablets administered orally
215014645|NCT06215586|DRUG|Placebo|Tablets administered orally
215014646|NCT05111119|BEHAVIORAL|Making PrEP Smart|"The Making PrEP Smart intervention is a mobile-based application with the following components:~* Notification-based PrEP Reminders and Adherence Self-Monitoring~* HIV self-testing facilitation, interpretation of results, and testing support~* HIV partner testing facilitation, interpretation of results, and testing support~* Nearby HIV clinic contact information"
215014647|NCT06658171|BEHAVIORAL|Relaxation training and stimulus control|"Relaxation training: Progressive muscle relaxation; Breathing relaxation; Imagery training; Mindfulness relaxation.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
215014648|NCT06658171|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
215014649|NCT00055965|DRUG|carboplatin|
215014650|NCT00055965|DRUG|cisplatin|
215014651|NCT00055965|DRUG|gemcitabine hydrochloride|
215014652|NCT07004192|DRUG|HCG injection|5000 IU hCG injection
215014653|NCT07004192|OTHER|No intervention|No hCG administered in this group.
215014654|NCT05970796|BEHAVIORAL|Pelvic floor muscle training|"The pelvic floor muscle training program will be provided via an intra-vaginal biofeedback device - Smart Kegel Trainer, which will be connected to the product application installed on the mobile phone or tablet so the participants can monitor their pelvic floor contractions in real time and directly in the application. Participants will be asked to complete three sets of 8 to 12 maximal pelvic floor muscle contractions and three to ten fast contractions per training session. The home program will be tailored to each participant and include pelvic floor safe exercises recommended by the Continence Foundation of Australia."
215014655|NCT06868667|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate.
215014656|NCT06868667|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody.
215014657|NCT06868667|DRUG|Bortezomib|Proteasome Inhibitor.
215014658|NCT06868667|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity.
215014659|NCT06690931|DEVICE|Brain-Computer Interface with FES and VR|"The intervention utilizes the recoveriX PRO system. This is a neurofeedback therapy device that combines Brain-Computer Interface based motor imagery, functional electrical stimulation (FES), and virtual reality (VR). This approach enables participants to engage in motor imagery exercises while receiving real-time feedback based on neural signals.~Participants will complete a total of 24 recoveriX sessions, scheduled at 6 sessions per week, with each session lasting 1 hour."
215014660|NCT06690931|DEVICE|Motor imagery with Functional Electrical Stimulation and Virtual Reality feedback|"The participants will train the Motor Imagination (MI) combined with Functional Electrical Stimulation (FES) and Virtual Reality (VR) feedback. Feedback provided to the patients will not be linked to the neural signals.~The amount of stimulation delivered by the feedback devices (FES and VR) will be similar to the experimental group."
214410208|NCT03462199|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|Participants will consume 4 capsules containing no active ingredients daily for 28-days
214410209|NCT02092844|BEHAVIORAL|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
214410210|NCT02225600|DRUG|40 IU Intranasal Oxytocin|40 IU intranasal oxytocin
214410211|NCT02225600|DRUG|Placebo|Intranasal Placebo
214410212|NCT02225600|DRUG|24 IU intranasal Oxytocin|
214410213|NCT00295867|DRUG|Zoledronic Acid|Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway
214410214|NCT02734628|DRUG|Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)|30 g of 5% of the active ingredient dexpanthenol plus other ingredients as ointment
215014661|NCT07018258|PROCEDURE|Erector Spinae Plane (ESP) Block|Ultrasound-guided bilateral erector spinae plane (ESP) block performed at the T7 vertebral level. The intervention will be applied in three different patient positions-lateral, prone, or sitting-prior to laparoscopic cholecystectomy.
215014662|NCT05330429|DRUG|Magrolimab|Administered intravenous infusion
215014663|NCT05330429|DRUG|Bevacizumab|Administered intravenous infusion
215014664|NCT05330429|DRUG|Irinotecan|Administered intravenous infusion
215014665|NCT05330429|DRUG|Fluorouracil|Administered intravenous infusion
215014666|NCT05330429|DRUG|Leucovorin|Administered intravenous infusion
215014667|NCT01294930|OTHER|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
214410215|NCT02734628|DRUG|Placebo|Placebo to Bepanthen® ointment without active ingredient dexpanthenol
214410216|NCT06555523|OTHER|Ultrasound guided injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The linear probe (PLT-704SBT, 7.5 MHz) of the ultrasound device will be kept parallel to the trapezoidal fibers on the marked trigger point and the dental-tipped needle will be directed to the targeted point in plane with real-time imaging
214410217|NCT06555523|OTHER|Blinded injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The needle will be directed to the most sensitive point and advanced until it will be reached the trigger point.
214410218|NCT03610958|DEVICE|Epitomee Device|A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
215014668|NCT07028424|DRUG|Nal-IRI|NAL-IRI 50 mg/m2, administered over 80-100 minutes, on day 1 of a 14-days cycle
215014669|NCT07028424|DRUG|Ciprofloxacin|6 capsules/cycle : 500 mg twice daily on days 1, 8, 15 (on day of gemcitabine infusion) for a maximum of 6 months
214410219|NCT00143936|BEHAVIORAL|Low- Carbohydrate -Atkins Diet|Low Carbohydrate Diet
215014670|NCT07028424|DRUG|Paclitaxel|80 mg/m2 weekly on days 1, 8, 15 of each 28-days cycle (at the discretion of investigator)
215014671|NCT07028424|DRUG|Gemcitabine|1,000 mg/m2 intravenously (IV) over 30 minutes weekly on days 1, 8, 15 of each 28-days cycle
215014672|NCT07028424|DRUG|Oxaliplatin|60 mg/m2 (starting 2 hours later, administered over 110-130 minutes) on day 1
215014673|NCT07028424|DRUG|Leucovorin|"As part of NALIRIFOX -for 8 cycle treatment: (L + D racemic form) 400 mg/m2 on day 1 (equivalent to 200 mg/m2 levoleucovorin) (starting 30 minutes after oxaliplatin, administered over 25-35 minutes)~As part of LV5FU2 maintenance treatment: 400 mg/m2 IV infusion over 30 min on day 1 (equivalent to 200 mg/m2 levoleucovorin). LV could be administered over 2 hours to oxaliplatin according to The National Thesaurus of Digestive Oncology (TNCD) https://www.snfge.org/sites/www.snfge.org/files/tncd/2024-05/tncd\_chap-09-cancer-pancre%CC%81as\_2024-05-17\_1.pdf, at investigator's discretion"
215014674|NCT07028424|DRUG|5-Fluorouracil|"As part of NALIRIFOX -for 8 cycle treatment: 2400 mg/m² IV initiated on day 1, with continuous infusion over 46 hours (no bolus infusion with 5-FU)~As part of LV5FU2 maintenance treatment: 400 mg/m2 bolus over 10 min then 2,400 mg/m2 IV infusion over 46h"
215014675|NCT07028424|OTHER|Placebo|6 capsules/cycle : 500 mg twice daily (morning and evening; 12 hours should elapse between two doses) on days 1, 8, 15 (on day of gemcitabine infusion) for a maximum of 6 months
215014676|NCT07033338|BEHAVIORAL|Occupational Activities and Finger Exercise Program|The intervention group received the program three days a week (Wednesday, Thursday, and Friday), once daily, with sessions held from 10:00 to 12:00 in the morning and from 14:00 to 16:00 in the afternoon. The participants were divided into two subgroups (13 participants in the first group, 12 in the second). The intervention consisted of a combined occupational activities and finger exercise program. Each session began with finger exercises, followed by occupational activities. The finger exercises involved movements requiring the participation of the fingers, hands, and arms, and were performed in 10 progressive steps. These movements were designed to promote engagement without causing fatigue or discomfort in elderly participants. Occupational activities included threading beads, completing line patterns, sewing buttons, assembling wooden blocks, performing cutting exercises, limited painting, dough manipulation, cutting and gluing, wrapping rope, tying rope between two points, stack
215100532|NCT01057563|DEVICE|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
215100533|NCT01057563|DEVICE|bare-metal stent (BMS)|BMS implantation
215100534|NCT01057563|DEVICE|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
215100535|NCT05460156|BEHAVIORAL|Bridges Self-management Support|Self-management support intervention tailored for people with neuromuscular diseases
214410220|NCT00143936|BEHAVIORAL|Low Calorie Diet|Maintain a low calorie diet
215014677|NCT07040306|DRUG|Methimazole(MMI)|Determine the enrolled GD patients and adjust the dosage of methimazole according to the 2016 American Thyroid Association guidelines. Conduct thyroid function, liver function, TRAb, and blood routine tests during outpatient follow-up to observe the treatment effect and provide medication guidance.
215100536|NCT00259207|PROCEDURE|Pulmonary valve insertion|Pulmonary valve insertion
215100537|NCT00259207|PROCEDURE|medical surgery hybride|medical surgery hybride
215100538|NCT01005927|DIETARY_SUPPLEMENT|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
215100539|NCT00997360|DRUG|PKI-179|
215100540|NCT00565799|PROCEDURE|Omentectomy|Removing the omentum
215100541|NCT00565799|OTHER|No intervention|Only LAGB without Omentectomy
215100542|NCT00642317|BEHAVIORAL|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
215100543|NCT04279665|DEVICE|Virtual Reality (VR)|20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
215014678|NCT02968394|DRUG|omalizumab|
215014679|NCT07046130|BEHAVIORAL|Resistance Training|The mininum resistance training volume (12 sets/week) will be applied.
215100544|NCT01181258|DRUG|Rituximab|375 mg/m\^2 administered intravenously (IV) weekly \* 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
215014680|NCT07045922|BEHAVIORAL|Motor-Cognitive Training Program|"Participants assigned to the intervention group participated in a structured motor-cognitive training program in addition to their regular physical education (PE) classes. The training was designed to integrate physical movement with cognitive engagement in a game-based format, suitable for the preschool age group.~The program was conducted twice weekly for eight weeks, with each session lasting approximately 25-30 minutes. Activities progressed in complexity over time, incorporating elements of motor planning, executive functioning, and balance control. Sessions consisted of:~Warm-up phase: Light aerobic activities such as jogging, dynamic stretching, and coordination drills (e.g., knee pulls, toe walking).~Main training phase:~Activities targeting core cognitive-motor domains:~Running drills (forward, backward, lateral)~Jumping and landing mechanics~Ball handling and coordination tasks (e.g., passing, tennis ball exercises)~Balance and proprioceptive challenges (e.g., walking"
215014681|NCT07045922|OTHER|Regular Physical education classes|Participants in the control group continued with their regularly scheduled physical education (PE) classes as mandated by the school curriculum. They did not receive any additional motor-cognitive or structured exercise training. Furthermore, they were instructed not to engage in any external physical activity programs outside of the regular PE sessions throughout the study duration. This restriction was monitored to ensure group consistency.
215014682|NCT07045857|BEHAVIORAL|follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence|follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence and influential factors for recurrence
215014683|NCT07045220|BEHAVIORAL|TTMCR|A trans-theoretical model (TTM)- based multidisciplinary CR program (TTMCR) to improve behavior change and cardiac rehabilitation outcomes
215014684|NCT07046715|DRUG|DA-5222|single dose administration (DA-5222 one tablet once a day)
215014685|NCT07046715|DRUG|DA-5222-R1|single dose administration (DA-5222-R1 one tablet once a day)
215014686|NCT07046715|DRUG|DA-5222-R2|single dose administration (DA-5222-R2 one tablet once a day)
215014687|NCT07046715|DRUG|DA-5222-R3|single dose administration (DA-5222-R3 one tablet once a day)
215014688|NCT07044609|DRUG|Clonidine extended release oral suspension|The study is blinded and the active clonidine extended-release oral suspension will look just like the placebo comparator.
215014689|NCT07044609|DRUG|Placebo|Placebo suspension
215014690|NCT07046091|BEHAVIORAL|20-minute mindfulness-based breathing exercise|Mindfulness-based approaches help to focus attention and teach individuals strategies for coping with challenging situations, accepting experiences, building self-confidence, and disengaging. Mindfulness-based practices increase an individual's level of awareness and distance them from current or potential stress factors. In recent years, non-pharmacological complementary and integrative interventions have become more widely used in disease management. Studies supporting the use of mindfulness-based interventions, particularly for the management of acute and chronic pain, have demonstrated biological and psychological improvements. In this study, the aim of the 20-minute mindfulness-based breathing exercise program is to reduce dyspnea and fatigue levels and improve sleep quality in heart failure patients who face many challenging situations. After a pre-test, the experimental group will receive the mindfulness-based breathing exercise program. The program will last for 6 weeks, with e
215014691|NCT07046091|BEHAVIORAL|Control (Standard treatment)|No intervention would be applied to patients in this group and only pre-test and post-test data would be collected.
215014692|NCT05583305|DIAGNOSTIC_TEST|Imaging assessment|Investigators shall perform cranial MRI examinations. The scanning protocol will employ an MRI scan protocol with T1-weighted, T2-weighted, FLAIR, susceptibility weighted imaging, diffusion weighted imaging, and time-of-flight magnetic resonance angiography (MRA) sequences. In addition, high-resolution magnetic resonance vessel wall imaging (HRMRI) allows assessment of the vessel wall using specific the SPACE sequence and the MATCH sequence. Assessors of the HRMRI images shall be blinded to the group allocation and clinical information.
215014693|NCT05583305|DIAGNOSTIC_TEST|Neurosonology assessment|Investigators shall perform carotid duplex ultrasonography (CD) assessment, focusing on the peak systolic (PSV) and end diastolic velocity (EDV) of bilateral extracranial internal carotid arteries (ICA) Brightness mode imaging shall gauge the intimal thickness and plaque characteristics (if any) of bilateral ICAs.
215014694|NCT05583305|DIAGNOSTIC_TEST|Blood Test|Nine milliliters of EDTA blood will be drawn during the research clinic visit for evaluation of the degree of neurovascular inflammation. Serum plasminogen activator inhibitor-1 (PAI-1) and high-sensitive C-reactive protein (hsCRP) are markers of vascular inflammation, atherosclerosis, and thrombotic risk. Serum neurofilament light chain (NfL) is a biomarker for neuroaxonal injury that correlates with small vessel disease.
215014695|NCT07045259|OTHER|The Neuromuscular Exercise Training program|The Neuromuscular Exercise Training program will be carried out in groups of 5 people for 45 minutes/2 days/8 weeks. The exercise program will consist of warm-up, loading and cooling phases. The warm-up phase will consist of flexibility exercises, mini squat and roll down etc. exercises to prepare the individual for exercise. The loading phase will consist of a cognitive-based neuromuscular exercise program aiming to provide stabilization, increase in balance, neuroplasticity and motor control and is planned to include strengthening exercises, stabilization exercises, balance-proprioceptive exercises and neuromuscular control exercise training with visual feedback. The exercises will progress gradually from easy to difficult with increasing repetition and set numbers.
215100545|NCT01181258|BIOLOGICAL|Interleukin-2|subcutaneously administered 9 million international units (IU) every other day \* 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight \< 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
215100546|NCT01181258|BIOLOGICAL|Natural killer cells|administered intravenously 1.5 to 8 \* 10\^7 cells/kg on Day 0 (day of NK cell infusion)
215100547|NCT01181258|DRUG|Cyclophosphamide|60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
215100548|NCT01181258|DRUG|Methylprednisolone|1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
215100549|NCT01181258|DRUG|Fludarabine|25 mg/m\^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
215100550|NCT01150968|BEHAVIORAL|End of life education|Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
215100551|NCT00945230|PROCEDURE|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
215100552|NCT02346513|DEVICE|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
214410221|NCT05893303|OTHER|1st Group|1st group is going to undergo scapula-oriented PNF techniques (diagonal) which are anterior elevation and posterior depression - posterior elevation and anterior depression with 20 repetitions with rhythmic initiation and repeated contractions facilitation techniques during all patterns. In addition to PNF techniques, gait training is going to be applied as standing with balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
214410222|NCT05893303|OTHER|2nd Group|2nd group is going to undergo only gait training and balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
214410223|NCT00896948|GENETIC|Southern blotting|
214410224|NCT00896948|GENETIC|TdT-mediated dUTP nick end labeling assay|
214410225|NCT00896948|GENETIC|gene expression analysis|
215014696|NCT07045259|OTHER|Exergaming Exercise Training|In our study, Xbox 360 Kinect game console and Kinect sensor will be used within the scope of Exergaming. Exergaming program will be carried out in groups of 5 people for 45 minutes/ 2 days/ 8 weeks. It will consist of warm-up, loading and cooling phases. The games to be used for the Exergaming program were selected from games that include locomotor and cognitive repetitive tasks. Just Dance, a movement-based dance/rhythm game accompanied by dance choreography, will be preferred in the warm-up phase. In the loading phase, games such as Reflex Ridge, River Rush, Ralleyball from Microsoft Kinect Adventures game series for lower extremity functions; Bowling, Table Tennis, Swim Out, Fruit Ninja from Microsoft Kinect Sports game series for upper extremity functions will be included. As the sessions progress, game levels will be gradually made more difficult, progressing from easy to difficult.
215014697|NCT07045688|DRUG|Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection|we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient.
215014698|NCT07045688|DRUG|Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection|we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
215014699|NCT07045688|DRUG|Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection|we assess the efficacy of PPI based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
215100553|NCT02346513|DEVICE|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
215100554|NCT05602077|DEVICE|POCUS|"POCUS: The ultrasound examination of the injured elbow includes seven standard settings. The probe is placed on the joint in four ventral and in three posterior positions. If hemarthrosis is detected, this is always suspicious of a possible intra-articular fracture. Even the smallest amounts of blood can be detected sonographically. The surfaces of the bones involved in the joint (humerus, ulna, radius) are accurately displayed in all seven sonography settings. Disrupted bone surface indicates a fracture.~XR: The conventional radiograph of the injured elbow consists of three standard views: ap, lateral and Norman oblique.~CBCT: The injured elbow is placed in an almost most extended position in the CBCT tube."
215100555|NCT05009667|DEVICE|Angiography-derived Index of Microcirculatory Resistance|"caIMR will be measured by pressure sensors which are produced by Suzhou Rainmed Medical Technology Co., Ltd.~caIMR is calculated based on angiography images and Hyperemic Pa estimated from resting Pa according to prespecified equation."
215100556|NCT05009667|DEVICE|Pressure wire-based Index of Microcirculatory Resistance|"IMR will be measured by thermodilution method with pressure wire and arterial physiological detector which are produced by St. Jude Medical.~IMR = Pd ∙Tmn"
215100557|NCT04349033|BEHAVIORAL|Emotional Disclosure and Brain Education|Patients are interviewed about a number of aspects of their lives (stress, other illnesses, personality, adverse childhood experiences), and these are explored as part of education of the brain's role in their pain.
214410226|NCT00896948|GENETIC|protein expression analysis|
214410227|NCT00896948|OTHER|flow cytometry|
214410228|NCT00896948|OTHER|fluorescent antibody technique|
214410229|NCT00896948|OTHER|immunoenzyme technique|
214410230|NCT00896948|OTHER|immunohistochemistry staining method|
214410231|NCT00896948|OTHER|immunologic technique|
214410232|NCT02642419|DRUG|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"* Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~* Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~  * Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~ * Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~ * Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
214410233|NCT02642419|DRUG|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
214410234|NCT05582057|BEHAVIORAL|Strengths to Grow: Preteen|An online, strength based parenting program for parents of preteens (aged 9-14).
214410235|NCT06555029|BEHAVIORAL|EHR Changes|"Practice-Level:~Changes to the Epic EHR system will include the AAAC process to ask 5 oral health questions, advise for dental attendance, assess the type of referral, and connect with referral and resources"
214410236|NCT06555029|BEHAVIORAL|Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training|"Provider-Level:~Medical staff to complete EHR training and then deliver the ask, advise, assess, connect (AAAC) strategies to screen, refer, and provide resources for oral health.~Clinician will receive Common-Sense Model of Self- Regulation (CSM) and Social Cognitive Theory based education and skills training for the physician/nurse practitioner to communicate core OH facts to the patient and provide reinforcement of the importance of dental visits to overall health. Clinicians will also document the encounter in EHR."
215014700|NCT07046286|PROCEDURE|Compare the two brands of radiofrequency ablation catheters for the treatment of lower limb varicose veins.|"1. Surgical Procedures: Standardized radiofrequency ablation (GSV/SSV closure) was carried out in both groups by the same team. Catheter parameters were set as 120°C and 1 cm/min withdrawal speed. The treatment segment of the great saphenous vein was required to be \>1 cm from the skin before anesthesia. For calf varicose veins, treatment was done after great saphenous vein ablation.~   * Experimental Group: Utilized Xianruida's catheter with advanced features. Surgical and device - related information was recorded.~  * Control Group: Used Medtronic's catheter. Similar data were recorded as in the experimental group.~2. Postoperative Management: Consistent for both groups.~   * Compression: Applied elastic bandage + Class II compression stockings.~  * Medication: Patients took oral anticoagulants and painkillers as needed, with usage details recorded during follow - up."
215014701|NCT07045805|DRUG|QL1706 combined with paclitaxel and bevacizumab|"Phase 1:~Plan to enroll 6 subjects to receive QL1706 7.5 mg/kg, paclitaxel 150 mg/m², and bevacizumab 7.5 mg/kg, d1, Q3W. Subjects will undergo a 3-week Dose-Limiting Toxicity (DLT) evaluation period.~If ≥2 DLTs occur among the 6 subjects, QL1706 5 mg/kg will be selected as the Recommended Phase 2 Dose (RP2D) for Phase 2.~Otherwise, QL1706 7.5 mg/kg will be the RP2D for Phase 2.~Phase 2:~Plan to enroll 54-60 subjects. Starting from Cycle 1, QL1706 will be administered intravenously at the RP2D determined in Phase 1. Subjects will receive:~QL1706 (RP2D) Paclitaxel 150 mg/m² Bevacizumab 7.5 mg/kg All agents administered on day 1 of each Q3W cycle. Treatment Duration for All Subjects: Continues until disease progression, intolerable toxicity, withdrawal of informed consent, death, or initiation of new antitumor therapy-whichever occurs first."
215014702|NCT07048405|OTHER|Cooling|Participants will undergo cold exposure during the baseline and final visits (2.5 hours each visit), as well as throughout the 10-day cold acclimation period (2 hours per day). This will be achieved using water-perfused blankets set to individualized temperatures, selected to elicit comparable physiological responses across participants.
215014703|NCT07048405|PROCEDURE|Biopsies|"Under local anesthesia, biopsies will be obtained from the following sites:~* Brown adipose tissue from the supraclavicular (collarbone) region, guided by computed tomography (CT).~* White adipose tissue from the abdominal (periumbilical) area.~* Skeletal muscle from the outer thigh, specifically the vastus lateralis.~These biopsies will be performed both before and after the 10-day cold acclimation protocol."
215014704|NCT07048405|RADIATION|Injection of 18F-FDG|Intravenous injection of 18F-FDG will be performed after 2 hours of cold exposure. This will be followed by a 30min dynamic total PET/CT scan while cold exposed using water-perfused blankets. These procedures will take place before and after the 10 day-cold acclimation protocol.
215014705|NCT07048405|OTHER|Indirect calorimetry|Participants will rest quietly while oxygen consumption and carbon dioxide production are continuously recorded using a indirect calorimeter. These data will be used to calculate energy expenditure and respiratory exchange ratio. This procedure will take place before and after the 10 day-cold acclimation protocol.
215014706|NCT07048405|OTHER|Electromyogram|Skin surface electrodes will be placed on major skeletal muscles to measure shivering and muscle activity during both warm and cold conditions. This procedure will take place before and after the 10 day-cold acclimation protocol.
215014707|NCT07048405|OTHER|Core and skin temperature monitoring|"Participants will ingest an electronic capsule that wirelessly and continuously monitors core body temperature. This procedure will be conducted before and after the 10-day cold acclimation protocol.~Additionally, wireless temperature sensors will placed at multiple standardized sites on the body to measure skin temperature. This procedure will be performed before, during, and after the 10-day cold acclimation protocol."
214410237|NCT06555029|BEHAVIORAL|Standard ADA Oral Health Training|"Provider-Level:~Clinician only: Clinicians will receive standard American Dental Association (ADA) based oral health hygiene training (brushing, flossing, fluoridated water, cleaning dentures) and asked to follow their current oral health care with their patients. The usual care currently is to address oral health issues if the patient complains or has a question. The clinicians will not have skills training nor visual resources for the patient encounter."
214410238|NCT01981850|BIOLOGICAL|RO7490677|IV infusion
214410239|NCT01981850|DRUG|Ruxolitinib|IV infusion
214410240|NCT03419208|OTHER|SPIN-HAND Program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
214410241|NCT03641950|DRUG|Botulinum toxin type A|Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U (0.05ml \~ 0.1ml per site).
214410242|NCT04854993|DRUG|Sugammadex 6 mg/kg|i.v. injection of an increased (by 50%) dose of sugammadex to reverse dNMB
214410243|NCT04854993|DRUG|Sugammadex 4 mg/kg|i.v. injection of a standard dose of sugammadex to reverse dNMB
214410244|NCT04868799|BIOLOGICAL|Mass spectrometry|Characterization of the proteomic and phosphoproteomic landscape using mass spectrometry
214410245|NCT06630962|OTHER|Financial Navigation Program|"A salaried financial navigator will be hired by the study sites. All responsibilities of the navigator will revolve around the structured financial navigation program. There is currently no research indicating that such a role has been incorporated at cancer centers in sub-Saharan Africa.~Through this program, the financial navigator will educate participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies."
215100558|NCT04349033|BEHAVIORAL|Emotional Disclosure Only|Patients are interviewed about a number of aspects of their lives, but without brain education
214410246|NCT05926271|DRUG|Clopidogrel|See arm description earlier.
214410247|NCT06489249|DRUG|Placebo|Oral placebo tablet
214410248|NCT06489249|DRUG|Salsalate 750 MG Oral Tablet [DISALCID]|Oral salsalate tablet
215014708|NCT07057180|OTHER|Observation by the Researcher and Self-evaluations by nurses|Observation by the Researcher
215014709|NCT07057180|BEHAVIORAL|This involves nurses' self-assessment of their caregiving behaviors and perceptions|This refers to the clinical observation performed by the nurse researcher
214410249|NCT03480971|DRUG|Tempol|Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
214410250|NCT03480971|DRUG|Placebo Solution|The placebo contains the same excipients as the active product plus FD\&C Yellow #6 for color matching.
214410251|NCT06250816|OTHER|The hospital gown with cartoon characters|The patient will be asked to choose one of the hospital gowns with cartoon characters they want to wear and put it on with parental assistance.
214410252|NCT03168438|DRUG|Letetresgene autoleucel|Letetresgene autoleucel (GSK3377794) as an IV infusion
215014710|NCT07056595|DRUG|Finerenone|Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist. Planned dose - 10 mg/day
215100559|NCT04349033|BEHAVIORAL|Pain Information Control|Patients are interviewed about their pain history and other basic, non-disclosure information about their health.
215100560|NCT04530500|GENETIC|COVID-19 Androgen Sensitivity Test (CoVAST)|The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
214410253|NCT03168438|DRUG|Letetresgene autoleucel with pembrolizumab|Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
214410254|NCT03168438|DRUG|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
214410255|NCT03168438|DRUG|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
214410256|NCT03168438|DRUG|Pembrolizumab|Pembrolizumab is available as an IV infusion
214410257|NCT06629246|DRUG|Conventional heart failure treatment|Conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition.
215014711|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
215014712|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
215014713|NCT05771493|OTHER|Measurement of baseline characteristics|Calculation of the correlation between BMI, WC and PI
215014714|NCT00862589|OTHER|GLP-1 infusion|physiological effect of GLP-1
215014715|NCT02994680|DEVICE|Three-burner LPG stove|The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
215014716|NCT02994680|OTHER|Delivery of LPG tanks|One year supply of LPG fuel, in the form of delivery of 20 kg tank that holds 10 kg of LPG. Delivered to homes.
215014717|NCT02994680|OTHER|Vouchers for LPG tanks|One year supply of LPG, in the form of vouchers to obtain a free LPG tanks from a distribution center. (Beginning one year after enrollment, for one year)
215014718|NCT07056530|BEHAVIORAL|Telenursing Counseling|Structured weekly phone-based counseling sessions delivered by a trained nurse for 8 weeks, focusing on medication adherence, healthy lifestyle behaviors, stress management, and self-monitoring of blood pressure.
215014719|NCT07056387|OTHER|A nurse-led community-based sailing programme|A nurse-led community-based sailing programme is validated by an expert panel including professionals from various fields, such as a registered nurse, academia, and qualified sailing instructors, delivered in a group of 6 participants, incorporating experiential learning, with the aid of materials including dinghies with Universal design, safety boats, buoys, buoyancy aids, supplementing with a waterproof sailing booklet. The intervention is developed and facilitated by a registered nurse (principal investigator).
215100561|NCT03549559|DRUG|11C-Martinostat|Imaging probe for evaluating the activity of histone deacetylase in the heart
215100562|NCT03549559|DEVICE|PET-MRI|Siemens PET-MR Scanner (Biograph MMR)
215100563|NCT01364909|OTHER|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
215014720|NCT07056387|OTHER|Crafting activities|Participants in the attention control group will participate in crafting activities. Activities match the time and attention dedicated by the intervention group. Activities are designed to have no impact on resilience.
215014721|NCT00123877|DRUG|GPX-100 (13-deoxydoxorubicin)|
215014722|NCT02037074|DRUG|Drug: EVP-6308|Arms 1, 2, 3
215014723|NCT02037074|DRUG|Placebo|Arm 4
215014724|NCT03362593|DRUG|MEDI7219|Experimental Drug
215014725|NCT03362593|DRUG|Placebo|Placebo
215100564|NCT01364909|OTHER|Usual practice|These patients will not receive exercise early in their intensive care admission
215100565|NCT01202058|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|"Design Original Protocol~Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting."
214410258|NCT06629246|DRUG|Pogejiuxin decoction combined with conventional heart failure treatment|In addition to receiving standard heart failure treatment, patients are also administered Pogejiuxin Decoction.The formula of Pogejiuxin Decoction is as follows : Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
214410259|NCT06631352|OTHER|Hepatopancreatoduodenectomy|Pancreatoduodenectomy with liver resection
214410260|NCT06629792|OTHER|Gentle Cleanser|The cleanser was instructed to be used twice daily over the course of 12 weeks
214410261|NCT06629792|OTHER|Facial Moisturizer|The Moisturizer was instructed to be applied to the global face twice daily over the course of 12 weeks.
214410262|NCT06629792|OTHER|sunscreen SPF 30|The Sunscreen was instructed to be applied once daily in the morning, with re-application with extended sun exposure per FDA guidelines over the course of 12 weeks.
214410263|NCT06253325|DIAGNOSTIC_TEST|Measuring tissue oxygenation|Measuring oxygen content of arteries, capillaries and veins
215100566|NCT01202058|DEVICE|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
215100567|NCT05899296|DEVICE|dental syringe ( NumBee)|assess the capability of NumBee to reduce anxiety and pain during injection
215100568|NCT05899296|DEVICE|Traditional dental syringe|compare the level of anxiety of the traditional dental syringe and the Number dental syringe
215100569|NCT03033264|DRUG|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
215100570|NCT03033264|DEVICE|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
215100571|NCT02136056|BEHAVIORAL|Self-management program (SMP)|A self-management course
215014726|NCT03362593|DRUG|Formulation without Active Drug|Formulation without Active Drug
215014727|NCT04394832|BEHAVIORAL|Brief cognitive intervention|See the information provided in the experimental arm description.
215014728|NCT04652843|PROCEDURE|Rectosignoidoscopy|Rectosignoidoscopy for colonic biospsies collection
215014729|NCT04652843|PROCEDURE|Coloscopy|Coloscopy for colonic biospsies collection
215014730|NCT06466044|BEHAVIORAL|Auricular acupressure in concha area|The method of pressing beans on auricular points is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, relevant auricular points are selected, and appropriate stimulation such as kneading, pressing, pinching and pressing is given to the seeds of Vaccaria seed attached to the concha auricularis, so that the auricular points can produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.
215014731|NCT06466044|BEHAVIORAL|Auricular acupressure in earlobe|The auricular point pressing bean method is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, the relevant auricular points are selected, and the seeds attached to the ear lobe, which is the least innervated part of vagus nerve, are given appropriate stimulation such as kneading, pressing, pinching and pressing, so that the auricular points produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.
215014732|NCT02594878|DRUG|Pamidronatdinatrium|
215014733|NCT02594878|OTHER|Natrium chloride 9mg/ml|
215014734|NCT04601909|DRUG|FX-322|active comparator
215014735|NCT04601909|OTHER|placebo|placebo
215014736|NCT06713317|DRUG|HLB3-002|Recombinant Hyaluronidase
215014737|NCT06713317|DRUG|0.9% NaCl|0.9% Normal saline
215100572|NCT03596450|DRUG|Semaglutide|Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
215100573|NCT03596450|DRUG|Standard of care|Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
215100574|NCT04114110|OTHER|RTLS data|data extraction from RTLS
215100575|NCT05082415|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
215100576|NCT02924909|DRUG|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
215100577|NCT02332291|DRUG|Escitalopram|Escitalopram 10-20mg daily
215100578|NCT02332291|DRUG|Bupropion XL|Bupropion XL 150-450mg daily
215100579|NCT03821194|OTHER|Gua sha|Scrape the skin around the knee joint
215100580|NCT03821194|OTHER|hot pack|hot pack
214410264|NCT06253325|DIAGNOSTIC_TEST|Procalcitonin|Blood test
215100581|NCT04751877|DRUG|Isatuximab|Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
215100582|NCT04751877|DRUG|Lenalidomide|Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
215100583|NCT04751877|DRUG|Bortezomib|Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
215100584|NCT04751877|DRUG|Dexamethasone|Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
215100585|NCT03328351|OTHER|manual therapy|"1. Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).~   1. Cervical postero-anterior vertebral mobilization glides:~      a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .~  2. Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.~2. Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times."
215100586|NCT03328351|OTHER|Superficial soft tissue massage|"1\. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times"
214410265|NCT06253325|DIAGNOSTIC_TEST|Mid-regional proadrenomedullin|Blood test looking at inflammation in the body
214410266|NCT06253325|DIAGNOSTIC_TEST|Hand-held video microscope|A handheld video microscope that looks at blood flow through the capillaries of the tongue
214410267|NCT05015478|DEVICE|Tailored Rhythmic Lighting Intervention|40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.
214410268|NCT05015478|DEVICE|Placebo Rhythmic Lighting Intervention|Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered at randomly varying frequencies of 20 Hz and 50 Hz, specifically avoiding the frequency of 40 Hz. The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
214410269|NCT03618472|DRUG|Metformin Hydrochloride 850 MG|Regular strength metformin (850 mg/tab)
214410270|NCT03618472|DRUG|Placebo Oral Tablet|Starch based placebo manufatured to mimic Metformin 850 mg
214410271|NCT03966716|DEVICE|Arthroplasty|Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.
214410272|NCT03966716|DEVICE|Internal Fixation|Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
214410273|NCT02341989|DRUG|Bleomycin Etoposide and Cisplatin|
214410274|NCT02341989|DRUG|Carboplatin|
214410275|NCT06030427|BEHAVIORAL|Behavioral Dietary Intervention|Participate in weight management program
214410276|NCT06030427|OTHER|Educational Intervention|Receive patient education handouts
214410277|NCT06030427|OTHER|Health Promotion and Education|View behavioral educational PowerPoint presentation
214410278|NCT06030427|OTHER|Internet-Based Intervention|Complete virtual behavioral weight management with an integrated mindfulness component program
214410279|NCT06030427|OTHER|Interview|Ancillary studies
214410280|NCT06030427|OTHER|Medical Device Usage and Evaluation|Wear Fitbit
214688470|NCT03938441|OTHER|Intermittent Fasting|"The version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies.~On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories.~Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day."
215014738|NCT06499948|DRUG|Treatment with Spironolactone followed by Dapagliflozin followed by their combination|After titrating the renin-angiotensin-system inhibitor dose, patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Dapagliflozin will be started. Patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone 25 mg and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
215014739|NCT06499948|DRUG|Treatment with Dapagliflozin followed by Spironolactone followed by their combination|After titrating the renin-angiotensin-system inhibitor dose, patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Spironolactone will be started. Patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
214410281|NCT06030427|BEHAVIORAL|Mindfulness Relaxation|Complete mindfulness components
214410282|NCT06030427|OTHER|Physical Performance Testing|Ancillary studies
214410283|NCT06030427|OTHER|Questionnaire Administration|Ancillary studies
214410284|NCT05278988|DRUG|PRS Regimen V|PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)
214410285|NCT05278988|DRUG|MDR-TB Treatment Regimen(WHO)|Treatment according to WHO MDR-TB treatment guidelines (2019)
214410286|NCT06466473|DRUG|Phenytoin (Ascoli)|Phenytoin 50mg chewable tablets
214410287|NCT06466473|DRUG|Phenytoin (Vega Baja)|Phenytoin 50mg chewable tablets
214410288|NCT04087096|DRUG|Denosumab|Denosumab will be administered at postoperative months 1, 7, and 13
214410289|NCT04087096|DRUG|Placebo|Placebo will be administered at postoperative months 1, 7, and 13
214688471|NCT02729558|RADIATION|local SRT|local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
214410290|NCT04087096|DRUG|Zoledronic Acid|Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
215014740|NCT05546931|BEHAVIORAL|Coaching application|A digital application for providing education and support for home-based blood pressure monitoring.
215014741|NCT05546931|OTHER|WebMD|Smartphone-based application for health education and/or monitoring.
215014742|NCT05546931|BEHAVIORAL|Home-based blood pressure monitoring|Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
214410291|NCT04436029|BIOLOGICAL|Descartes 11|Car T-cells
214410292|NCT02749331|DRUG|AdVince|Virus solution for infusion in intrahepatic artery
214410293|NCT01515358|DRUG|Placebo|Administered orally
214410294|NCT01515358|DRUG|LY3000328|Administered orally
214410295|NCT02632916|DRUG|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months
215014743|NCT06846723|OTHER|Stress ball|In addition to the routine treatment and care practices of the outpatient clinic, the patients included in the study group will be applied stress ball during ESWL. The researcher (CK) will explain and show the patients how to apply the stress ball 10 minutes before the procedure. The stress ball will be applied during the ESWL session and a round, medium-hard, high-quality silicone ball with an average diameter of 6 cm will be used. Patients will be asked to take the ball in the palm of their hand and squeeze and release the ball once after counting to three. Patients will be instructed to continue this practice until the end of the ESWL procedure and to pay attention to the stress ball during the procedure. The ball will be washed and cleaned after each use and wiped with disposable asepsis wipes before being given to the patient.
215014744|NCT06903130|DIAGNOSTIC_TEST|Blood samples for sNfL and sGFAP levels|Blood samples for sNfL and sGFAP levels
215014745|NCT06926842|DRUG|Petrelintide|Petrelintide will be taken by participants once weekly subcutaneously.
215014746|NCT06926842|OTHER|Placebo|Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
215014747|NCT06332573|OTHER|Onco-sexology support|Initiation of onco-sexology support before the introduction of systemic oncology treatment
215014748|NCT06332573|OTHER|Onco-sexology support|Initiation of onco-sexology support after the introduction of systemic oncology treatment (2-3 months after the start of treatment).
215014749|NCT05892718|DRUG|HCB101|HCB101 administered via. intravenous (IV) infusion.
215014750|NCT06511674|OTHER|Cognitive-emotional and pain assessments|Data collection on cognitive-emotional and pain parameters using questionnaires.
215014751|NCT03234556|PROCEDURE|Biopsy of Prostate|Undergo SR-Bx
215014752|NCT03234556|OTHER|Laboratory Biomarker Analysis|Correlative studies
215014753|NCT03234556|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Undergo MRI
215014754|NCT03234556|DIAGNOSTIC_TEST|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
214410296|NCT02632916|DRUG|Denosumab|Subcutaneous denosumab 1.0mg/kg at baseline, 6 months, 12 months and 18 months
214410297|NCT03082885|DRUG|Thymosin-α1|1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.
214410298|NCT01639443|OTHER|Predictive no-show overbooking|"During intervention period, every Veteran scheduled for an endoscopy will be offered fast-track offer, which gives them a chance to get their endoscopy procedure done earlier than usual scheduling by overbooking their appointment in a predictive no-show slot."
214410299|NCT02684084|DRUG|Ozurdex|OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
214410300|NCT02684084|DRUG|Lucentis|LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
214410301|NCT05165238|BEHAVIORAL|Impact of four week coaching program on dietary habits|A registered dietitian will provide dietary coaching via online groups to participants.
214688472|NCT05247619|DRUG|Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin|Tisleliumab 200mg, Bevacizumab 7.5mg/kg, Paclitaxel 175mg/m2, and Cisplatin 50mg/m2 (or Carboplatin AUC5) IV on day 1 of every 21-day cycle.
214688473|NCT00358995|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
215014755|NCT06623188|OTHER|Auricular neuromodulation|3 neuromodulation sessions over 12 weeks
215014756|NCT06623188|OTHER|Sham auricular neuromodulation|3 neuromodulation sessions over 12 weeks
215014757|NCT04820257|BEHAVIORAL|Home based exercise|Exercise at home and behavioural change to increase daily exercise
215014758|NCT06232460|DIETARY_SUPPLEMENT|H80|5g, 10g \& 20g
215014759|NCT06764654|PROCEDURE|Dental implant placement|Placement of two dental implants in the jaw.
215014760|NCT06908889|OTHER|Skin's lesion patients|Skin swabs will be obtained from the patient's facial lesional (FLS) and perilesional sites (FPS) using a sterile cotton swab. The microbiota of the same anatomical face regions will be collected on volunteers, once the 10 SMH patients have been enrolled. The swab is premoistened in a specific cocktail solution and rubbed onto the skin surface for 45sec. The pressure during the sampling involves rubbing the area of interest with a smear over the entire zone. The skin reddens slightly under the exerted pressure.
215014761|NCT06908889|OTHER|Skin's lesion vulunteers|Skin swabs will be obtained from the patient's facial lesional (FLS) and perilesional sites (FPS) using a sterile cotton swab. The microbiota of the same anatomical face regions will be collected on volunteers, once the 10 SMH patients have been enrolled. The swab is premoistened in a specific cocktail solution and rubbed onto the skin surface for 45sec. The pressure during the sampling involves rubbing the area of interest with a smear over the entire zone. The skin reddens slightly under the exerted pressure.
215014762|NCT06097273|BIOLOGICAL|mRNA-1083|Suspension for injection
215014763|NCT06097273|BIOLOGICAL|Placebo|0.9% sodium chloride suspension for injection
214410302|NCT01273558|DRUG|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
215100587|NCT05477797|DRUG|Ixazomib DX/Lenalidomide DX|After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
215100588|NCT03954262|BEHAVIORAL|observation of propofol ANS response|received an induction bolus or TCI infusion of propofol
215100589|NCT03234491|DEVICE|DiAS|Diabetes Assistant (DiAS) hybrid closed loop system.
215100590|NCT03234491|DRUG|Afrezza low dose|Afrezza inhaled insulin low dose.
214410303|NCT06548477|DRUG|Human albumin|Patients in intervention arm will also receive intermittent boluses of 20 percent human albumin (in addition to standard fluid therapy) that will be administered with dosage regimen of 1.25gm/kg of body weight per 24 hours. The maximum total calculated dose/volume of albumin for the patient will be infused @ 34 ml/hour (over 3 hours) and will be divided in 3 boluses, spaced at 8 hours intervals. During intervention period, duration of treatment (7-day study period) will cover the peak period of cerebral vasospasm from day 4th until 10th day. Albumin administration will be tailored according to the targeted values set for euvolemic fluid balance in each patient. Before randomization (within 72 hours post-ictus) and after day-10 (from day 11th-14th, patient will only receive standard fluid therapy.
214410304|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
214410305|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
214410306|NCT01649427|DRUG|Prograf|Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
215100591|NCT03234491|DRUG|Afrezza high dose|Afrezza inhaled insulin high dose.
215014764|NCT06097273|BIOLOGICAL|Influenza Vaccine|Commercially available formulation (Suspension for injection \[pre-filled syringe\])
215014765|NCT06097273|BIOLOGICAL|COVID-19 Vaccine|Commercially available formulation (Suspension for injection)
215014766|NCT06470828|DRUG|TAK-861|Oral tablet.
215100592|NCT00001967|DRUG|HAART|
215100593|NCT02929082|RADIATION|IRM with a 5-minute- additional sequence to measure FRM|IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
215100594|NCT02349750|PROCEDURE|endometrial scratch injury|ESI using No.8 neonatal feeding tube
215100595|NCT03042130|OTHER|Standard of care|standard of care
215100596|NCT03042130|DRUG|Iron Carboxymaltose|Two IV doses
215100597|NCT03052023|PROCEDURE|dual approach laparoscopic inguinal hernioplasty|after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached
215100598|NCT03052023|PROCEDURE|TAPP|pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation
215100599|NCT03052023|PROCEDURE|(lichtenstein) repair|inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
215100600|NCT04394650|BIOLOGICAL|CC-98633|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633.~During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection."
214410307|NCT01649427|DRUG|Tacrolimus Hexal|"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."
214410308|NCT02739568|DRUG|Pitolisant (BF2.649)|
214410309|NCT02739568|DRUG|Placebo|
214410310|NCT05630495|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
215014767|NCT06470828|DRUG|Placebo|TAK-861-matching placebo tablet.
215014768|NCT04740424|DRUG|FS222|Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
215014769|NCT00551356|DRUG|Insulin lispro mix 25|Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
215014770|NCT00551356|DRUG|Glargine|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
215100601|NCT04879173|DEVICE|RS85 Ultrasound device|RS85 Ultrasound device manufactured by Samsung Medison
215100602|NCT04672915|DIAGNOSTIC_TEST|test of HBV DNA|Real time PCR or nested PCR to check
215100603|NCT03517462|DRUG|Ivermectin 3Mg Tab|ivermectin tablet
215100604|NCT01990859|BIOLOGICAL|Ipilimumab|
215100605|NCT02924012|OTHER|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
215014771|NCT06885268|DRUG|noradrenaline infusion for management blood pressure|A single concentration of noradrenaline (10 μg/ml) will be initiated 15-60 seconds prior to the induction of anaesthesia, then titrated and maintained until 4 hours after surgery to meet pre-specified mean arterial pressure (MAP) targets. The drug infusion will be started at a dose of 0.01 μg/kg/min and will be titrated to a maximum of 0.1 μg/kg/min. Anaesthesiologists will be advised to use the lowest possible dose of noradrenaline. Avoidance of MAP decreases of \>20% from baseline values or \<60-70 mm Hg will be required in both groups. Individual baseline MAP value will be defined as resting blood pressure obtained in at least two measurements at the surgery ward on the day before surgery. Noradrenaline will be administered peripherally in all patients who do not have a central venous catheter in place.
215100606|NCT02924012|OTHER|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
215100607|NCT02924012|OTHER|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
215100608|NCT00771056|DRUG|Hydroxychloroquine|400mg by mouth daily x 1 year
215100609|NCT02262754|DRUG|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
215100610|NCT02262754|DRUG|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
215100611|NCT02262754|DRUG|Naproxen|500 mg BID for 4 weeks
215014772|NCT06885268|COMBINATION_PRODUCT|standard blood pressure management|Patients in the control group will receive standard blood pressure management reactive to blood pressure values. In the light of the current ESA/ESC 2022 guidelines, all patients in the control group will be treated to avoid MAP \<60-70 mm Hg. Ephedrine boluses (5 mg each, up to 25 mg total intravenous dose) will be recommended as a first-line hypotension treatment. Subsequent treatment will involve administering peripheral noradrenaline. Notwithstanding, there is a variation in clinical practice regarding the choice and timing of vasopressors and fluids to be administered during and after surgery, therefore, hypotension treatment will not be further protocolized to increase the feasibility and generalizability of the trial.
214410311|NCT03957980|OTHER|Occupational therapy|Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
214410312|NCT02292667|PROCEDURE|TAP block|The aim of the Transversus Abdominis Plane (TAP) Block is to deposit local anesthetic in the plane between the internal oblique and the transversus abdominis muscles targeting the spinal nerves in this plane. The local anesthetic used in the ETAP study is Ropivacaine 0.375%. 2 ultrasound-guided injections of 10 ml will be performed on each side of the abdominal wall: 1 subcostal injection and 1 supra-iliac injection.
214410313|NCT02292667|DRUG|PCA with Chlorhydrate of Morphine|Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.
214410314|NCT02292667|DRUG|Acetaminophen|1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
214410315|NCT01147770|DRUG|progesterone|duration
214410316|NCT06174480|OTHER|Cryostimulation|Cryostimulation (-50°C, forced ventilation for 3 minutes) during 20 sessions over 2 weeks.
215014773|NCT06932471|DRUG|MY008211A tablets|MY008211A tablets Participants will receive MY008211A at a dose of 400 mg orally b.i.d
215014774|NCT03181009|DRUG|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
215014775|NCT03181009|DRUG|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
215014776|NCT06939439|DRUG|Tislelizumab + SOX Chemotherapy|The intervention in this study involves the use of tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody, in combination with the standard SOX chemotherapy regimen for postoperative adjuvant therapy in patients with stage III gastric or gastroesophageal junction adenocarcinoma who are ctDNA-MRD positive. Tislelizumab is administered at a dose of 200 mg intravenously every 3 weeks for a total duration of 1 year, alongside 6-8 cycles of SOX chemotherapy. The SOX regimen includes oxaliplatin (130 mg/m² intravenously every 3 weeks) and tegafur, with the dose of tegafur determined based on body surface area and administered orally twice daily for 14 days every 3 weeks.
215014777|NCT06939439|DRUG|SOX Chemotherapy|The control group will receive standard SOX chemotherapy alone, serving as an active comparator to evaluate the incremental benefit of adding tislelizumab. This design ensures a rigorous comparison while maintaining alignment with current standard-of-care practices.
214410317|NCT00441675|PROCEDURE|Symptom Score|Symptom Score
214410318|NCT00441675|PROCEDURE|Symptom Score and PD20|Symptom Score and PD20
214410319|NCT06087068|DRUG|Thyroxine|The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
214410320|NCT02138916|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
214410321|NCT02138916|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
214410322|NCT02138916|DRUG|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
215014778|NCT06942611|DEVICE|transcranial electrical stimulation treatment.|Stimulation targeting the primary motor cortex, current intensity is 1-2mA, duration is 30 minutes, once daily for 5 consecutive days
215100612|NCT00459654|DRUG|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
215100613|NCT00459654|DRUG|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
214410323|NCT06265168|OTHER|Simulation|Physicians will participate in a simulated scenario of an adult comatose patient. The intervention will be presented as a learning situation where the physician interacts with a high-fidelity mannequin. The mannequin simulating the patient will manifest a Glasgow Coma Score of 3 (improving over time to a GCS of 4) and a range of physiological and pathological symptoms. Physicians will have access to emergency equipment, including intubation equipment, a defibrillator, and medications. A trained nurse will be present to assist with the simulation. After 20 minutes the patient will regain consciousness in order to avoid a frustrating experience for the physicians. After simulation termination, a senior physician will join the resident and ask him to report the current scenario and will stop the simulation. The entire scenario will be video-recorded.
214410324|NCT05837780|OTHER|Nasoalveolar molding device|comparison between using conventionally and digitally constructed nasoalveolar molding devices
214410325|NCT05717335|DRUG|TachoSil|Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
214410326|NCT05066451|OTHER|%5 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
214410327|NCT05066451|OTHER|%15 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
214410328|NCT00964717|PROCEDURE|real chiropractic|real chiropractic manipulation
214410329|NCT00964717|PROCEDURE|Sham Chiropractic|Placebo stimulation using 'activator' thumper
214410330|NCT05216237|DRUG|Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)|for 2-6 cycles followed by Sindilizumab plus Tegafur gimeracil oteracil potassium capsules.
214410331|NCT06566586|DRUG|TQB3702 tablets+Chemotherapy regimen|"TQB3702 tablets: Tyrosine kinase inhibitor；~Chemotherapy regimen：inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis；"
214410332|NCT00555581|DRUG|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
214410333|NCT05964257|DRUG|Botulinum toxin type A|Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
214410334|NCT05964257|DRUG|normal Saline|Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
215014779|NCT02428647|DIETARY_SUPPLEMENT|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
215014780|NCT02428647|DIETARY_SUPPLEMENT|preventive zinc supplement|7 mg zinc daily as dispersible tablet
214410335|NCT05822440|DRUG|PF-07817883|Single oral dose (period 1) or co-administered with itraconazole (period 2)
215014781|NCT02428647|DIETARY_SUPPLEMENT|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
215014782|NCT02428647|DIETARY_SUPPLEMENT|preventive placebo supplement|dispersible daily placebo tablet
215014783|NCT02428647|DIETARY_SUPPLEMENT|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
214410336|NCT05822440|DRUG|Itraconazole|Interacting drug which will be given for 7 days in period 2
214410337|NCT01609894|DIETARY_SUPPLEMENT|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
214410338|NCT01609894|DIETARY_SUPPLEMENT|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
214410339|NCT05805124|DIAGNOSTIC_TEST|Preop evaluation|"All preop evaluations prescribed in the preadmission clinic will be recorded, especially:~* renal function tests~* hematologic tests~* coagulation tests~* hepatic function tests~* ECG~* cardiac function tests~* pulmonary function tests~* endocrine function tests"
214410340|NCT05365386|DEVICE|Tixel C|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology.
214410341|NCT06440850|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214410342|NCT06440850|DRUG|Cobimetinib|Given PO
214410343|NCT06440850|PROCEDURE|Computed Tomography|Undergo CT scan
214410344|NCT06440850|PROCEDURE|Diagnostic Imaging|Undergo I-123 diagnostic scan
214410345|NCT06440850|PROCEDURE|I-131 Uptake Test|Undergo I-131 whole body scan
214410346|NCT06440850|RADIATION|Iodine I-131|Given PO
214410347|NCT06440850|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214410348|NCT06440850|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214410349|NCT06440850|BIOLOGICAL|Recombinant Thyrotropin Alfa|Given IM
214410350|NCT06440850|PROCEDURE|Ultrasound Imaging|Undergo neck ultrasound
214410351|NCT06440850|DRUG|Vemurafenib|Given PO
214410352|NCT00117988|DRUG|tanespimycin|
214410353|NCT02387749|GENETIC|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
214410354|NCT02196051|OTHER|one bout of 45 minutes exercise|45 minutes of exercise on an elliptical exercise machine
215014784|NCT02428647|DIETARY_SUPPLEMENT|placebo powder|placebo powder
215014785|NCT01355367|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
214410355|NCT02525510|OTHER|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
214410356|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Right Kidney|"Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.~Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation."
214410357|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
215014786|NCT06951048|OTHER|Group I (Neural Mobilization)|"Participants will undergo a neural mobilization program targeting the sciatic, femoral, and tibial nerves. Exercises are designed to promote nerve sliding through specific movement patterns and are performed bilaterally. Each nerve mobilization is applied in 4 sets of 10 repetitions, three times per week on non-consecutive days, with 30-second rest intervals.~Sciatic nerve: Performed in side-lying; ankle dorsiflexion with neck extension followed by dorsiflexion release and neck flexion.~Femoral nerve: In side-lying; simultaneous movements of the hip, knee, and neck in flexion and extension.~Tibial nerve: In supine; coordinated ankle, toe, and cervical spine movements with controlled hip/knee positioning."
214410358|NCT02525510|OTHER|Not Pump Eligible - Normothermia|"Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.~Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol"
214410359|NCT02525510|OTHER|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
215014787|NCT06951048|OTHER|Group II (Neural Mobilization + Dynamic Stretching)|Participants in this group will engage in the same neural mobilization protocol applied in Group I, combined with a structured dynamic stretching program targeting lower extremity flexibility and neuromuscular performance. The dynamic exercises include active straight leg raises (SLR), vertical jumps, and 10-meter sprints. Each activity will be performed in three sets of ten repetitions, aiming to enhance muscular activation, mobility, and functional readiness.
215014788|NCT06951048|OTHER|Group III (Dynamic Stretching Only)|This group will engage exclusively in a dynamic stretching protocol comprising active straight leg raises (SLR), vertical jump exercises, and 10-meter sprint drills. Each exercise will be performed in three sets of ten repetitions, focusing on enhancing lower extremity mobility, muscle activation, and functional movement capacity without any neural mobilization intervention.
215014789|NCT00232921|DRUG|caudal volume 1|
215014790|NCT00232921|BIOLOGICAL|caudal volume 2|
215014791|NCT00232921|DRUG|caudal volume 3|
215014792|NCT06949111|RADIATION|radiotherapy|Radiotherapy: Administer three-dimensional conformal/intensity-modulated/TOMO radiotherapy with a conventional fractionation schedule of 36-41.4 Gy in 20-23 fractions (1.8 Gy per fraction).
214410360|NCT05196737|BEHAVIORAL|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
214410361|NCT05096884|DRUG|Metoprolol Succinate|The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
214410362|NCT02787967|DRUG|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
214410363|NCT02787967|DRUG|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
214410364|NCT01605968|DEVICE|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
215014793|NCT06949111|DRUG|CAPOX|4 cycles, Oxaliplatin 130 mg/m², Capecitabine 825 mg/m²
214410365|NCT01605968|DEVICE|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
214410366|NCT03310463|DRUG|ETX2514SUL|Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
215014794|NCT06949111|DRUG|Capecitabine|Administer Capecitabine at a dose of 825 mg/m², twice daily, orally on radiotherapy days
215014795|NCT06949111|DRUG|Iparomlimab and Tuvonralimab Injection|IV, 5 mg/kg every 3 weeks
215014796|NCT00411658|DEVICE|Investigational Device|
215014797|NCT00411658|DEVICE|Experimental|
215014798|NCT00411658|OTHER|Cryopreserved|
215014799|NCT02421965|BEHAVIORAL|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
215014800|NCT02421965|BEHAVIORAL|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
215014801|NCT05894564|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
215014802|NCT05894564|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
215014803|NCT03882801|DRUG|Gefapixant|In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.
215014804|NCT03882801|DRUG|Placebo|In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
214410367|NCT02694848|DRUG|Salvianolate injection|Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
214410368|NCT02694848|DRUG|Aspirin|Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
214410369|NCT04927975|DRUG|Upadacitinib|Oral tablets
214410370|NCT04927975|DRUG|Placebo|Oral tablets
214410371|NCT05214794|DRUG|nemolizumab|nemolizumab will be administered subcutaneous injection
214410372|NCT05365607|DEVICE|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
214410373|NCT05365607|DEVICE|Sham NightWare|NightWare device will not deliver an intervention (i.e., no vibration)
214410374|NCT04942054|DRUG|Part 1|Dose escalation cohort
215014805|NCT06380400|BEHAVIORAL|Foot bath|Pregnant women were given footbaths for 20 minutes during the active phase of the first stage of labour (after cervical dilatation of 4 cm) and 20 minutes during the transitional phase of the second stage of labour (cervical dilatation of 9 cm). Pregnant women who completed two footbath sessions were assessed for pain using the visual comparison scale. In addition, the data collection process will be completed by applying the Birth Comfort Scale after the two stages of labour.
215014806|NCT01932424|DEVICE|Pelorus 1500|a bedside blood propofol measurement device
215100614|NCT05623358|OTHER|Pharmacist-led HFrEF medication optimization|In addition to usual care, participants randomized to the intervention arm will receive co-management of medications by a clinical pharmacist with advanced training and expanded scope of practice, with the aim of achieving optimal medical therapy (OMT) for HFrEF as outlined by the 2021 Canadian Cardiovascular Society (CCS) HF guidelines. This will consist of, where possible, the combination of an angiotensin receptor-neprilysin inhibitor (ARNI), evidence-based beta-blocker, mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter 2 inhibitor (SGLT2i) at target doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines, unless the patient is unable to tolerate these agents/doses.
215100615|NCT05623358|OTHER|Usual care|Both the intervention group and comparator group will receive usual care by the multidisciplinary HF clinic, including standard-of-care clinical pharmacy services. The standard pathway in the HF clinic consists of an initial consultation with the multidisciplinary team (cardiologist, physician trainees, registered nurse and clinical pharmacist), follow-up visits approximately every 3 months with the nurse and cardiologist until discharge, along with telehealth nurse calls for medication titrations.
215100616|NCT06141759|OTHER|Exercise|Cheneau brace and Schroth Best Practice exercise
215100617|NCT02746185|DRUG|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
215100618|NCT02746185|DRUG|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
215100619|NCT04372459|BEHAVIORAL|Online integrated and stepped psychosocial care|"This program features four levels of care, increasing in intensity of psychosocial care as patients move from one level to the next one.~Step 1: Screening and monitoring of several psychosocial variables through the central mobile application of the program (App ICOnnecta't).~Step 2: Online guided and self-help psychoeducation Campus in which patients can consult videos and online resources, co-constructed between health professionals and patients, containing reliable and rigorous information related to the oncological process.~Step 3: Online community of psychosocial support. Participants can choose from 12 cancer-related discussion forums and share with the community any health-related question that worries them fostering, thus, debate and stimulating peer-support.~Step 4: Intensive online group psychotherapy (App ICOnnecta't Videoconsultation), based on the Group Positive Psychotherapy program for cancer survivors (Ochoa, Sumalla, Maté, Castejón, Rodríguez et al., 2010)."
214410375|NCT04942054|DRUG|Part 2|Pharmacodyanamic (PD) dose exploration cohorts
214410376|NCT04942054|DRUG|Part 3|Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
214410377|NCT05042063|DEVICE|Hyfe Cough Tracker|"Hyfe Cough Tracker is a digital acoustic surveillance system that uses an artificial intelligence system to discriminate cough from non-cough sounds. Hyfe is an AI-enabled mobile app that records short snippets (\<0.5 seconds) of putative cough explosive sounds and then classifies them as cough or non-cough using a convolutional neural network (CNN) model. Briefly, the acoustic characteristics of recorded sounds are converted into an image file, which is then processed by an algorithm trained to identify graphical differences in images. This creates an adjustable prediction score, with values above it, resulting in a sound being classified as cough, and those below being classified as non-cough."
215014807|NCT01932424|DRUG|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
215014808|NCT06369662|DIAGNOSTIC_TEST|Flow cytometric immunophenotyping|CD155 expression by flow cytometric immunophenotyping
215014809|NCT06369662|DIAGNOSTIC_TEST|Complete blood count|Complete blood count with peripheral blood smear examination
215014810|NCT06369662|DIAGNOSTIC_TEST|Bone marrow aspiration|Bone marrow aspiration at both diagnosis and follow up of patients
215014811|NCT06369662|DIAGNOSTIC_TEST|Cytogenetic testing|Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients
215014812|NCT06369662|DIAGNOSTIC_TEST|FLT3-ITD using High resolution melting curve (HRM) analysis|Detection of FLT3-ITD mutation in AML patinets
215014813|NCT01091883|DEVICE|Exablate treatment|MR Guided Focused Ultrasound
215014814|NCT01091883|RADIATION|Radiation|External Beam Radiation
215100620|NCT04372459|BEHAVIORAL|Usual psychosocial care|This active control group will receive the standard psychosocial treatment for cancer survivors in the participating centers, led by a clinical psychologist and consisting of 8 individual, 45/60-minute sessions, each of which every 1-2 months, focused on providing emotional support and psychoeducation during the first year of primary cancer treatment.
215100621|NCT03697681|DRUG|Tranexamic acid|Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.
215100622|NCT03697681|DRUG|0.9% NaCl (normal saline)|The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
215100623|NCT00081211|BIOLOGICAL|PV701|Given intratumorally
215100624|NCT03479710|BIOLOGICAL|FMT infusion|Fecal microbiota transplantation via OGD
215014815|NCT06695676|DIAGNOSTIC_TEST|Global Longitudinal Strain|Global longitudinal strain measurement is a more objective method to determine left ventricular systolic function than traditional eyeballing method. It helps to detect and quantify subtle changes even so it is an emerging method to evaluate the cardiotoxicity of chemotherapeutic drugs. It is planned to compare each selected patient's GLS measurement before starting to use lurasidone and after six months of using it. Hereby our aim is to find if lurasidone has any effect on left ventricular systolic function.
215014816|NCT06694350|DRUG|Pembrolizumab+Flutamide|Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h
214410378|NCT05042063|DEVICE|Hyfe Air|Hyfe Air is a wearable device with an incorporated wireless lapel microphone. The device´s recordings can be run through the same cough-detection algorithm used by Hyfe Cough Tracker, while its results are directly stored in a remote database and are not displayed to participants.
214410379|NCT06329869|DRUG|Sacituzumab govitecan|Sacituzumab govitecan, 10 mg/kg intravenous infusion (the first infusion is to be administered over 3 hours; subsequent infusions may be administered over 1 to 2 hours if previous infusions were well tolerated) on day 1 and 8 of 21-day cycle.
214410380|NCT01542619|BIOLOGICAL|rVIIa-FP|Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
215014817|NCT03514693|PROCEDURE|PVI|Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.
215014818|NCT03514693|PROCEDURE|PVI plus additional ablation|In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
215014819|NCT05761483|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography, placement of stents using a duodenoscope and making an access through the papilla of Vater
215014820|NCT06454487|OTHER|Isometric Hand Grip Training|IHG training will be performed with an inflatable ball three days per week for 12 weeks (with at least a day of rest between each session) with intensity set based on RPE (Borg CR-10 scale).
215014821|NCT06454487|OTHER|CR|Standard of Care
215014822|NCT05165966|BIOLOGICAL|High-dosage of COVID-19 vaccine (Vero cell), Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
215014823|NCT05165966|BIOLOGICAL|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
215100625|NCT04725487|OTHER|Standard integration program with social and health promoting intervention|"* Basic language course, internships, courses in Labour market knowledge and Danish culture~* Physical activity workshops~* Community gardening (garden workshops)~* Entrepreneurship course~* MindSpring course~* Family excursions~* Danish language workshops"
215100626|NCT04725487|OTHER|Standard integration program|Standard integration program (basic language course, internships, courses in Labour market knowledge and Danish culture)
214410381|NCT01542619|BIOLOGICAL|Placebo (0.9% normal saline)|Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
214410382|NCT02484365|OTHER|No treatment|Attach adhesive probe on thumb or index finger
215014824|NCT03076164|DRUG|Trametinib|Trametinib 1.5mg once daily by mouth
215014825|NCT03076164|DRUG|Erlotinib|Erlotinib 75mg once daily by mouth
215014826|NCT02912611|PROCEDURE|Education and Protocol based management|
214410383|NCT06470776|BEHAVIORAL|Chatbot counselling|Access to a chatbot that provides smoking cessation counselling based on the 5A's (Ask, Advice, Assess, Assist, Arrange follow-up) and 5R's (Risk, Relevance, Rewards, Relevance, Roadblocks, Repetition) tobacco intervention models from baseline to 3-month post-baseline.
215014827|NCT00226044|DRUG|Omeprazole rectally 1mg/kg|A single dose of 1 mg/kg rectally administered omeprazole.
215014828|NCT06222047|OTHER|breast milk|give breast milk before the OG catheter insertion
215014829|NCT06222047|OTHER|dextrose|give %20 dextrose before the OG catheter insertion
215014830|NCT01845415|BEHAVIORAL|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
215014831|NCT01845415|BEHAVIORAL|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
215014832|NCT01925820|DRUG|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
215100627|NCT02577016|DRUG|Sitagliptin|50 mg tablet administered orally
215100628|NCT02577016|DRUG|Placebo|Placebo to sitagliptin administered orally
215014833|NCT04457778|DRUG|M6223|Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.
215014834|NCT04457778|DRUG|Bintrafusp alfa|Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.
215014835|NCT04457778|DRUG|M6223|Participants will receive an IV infusion of M6223 at escalated doses Q2W on Day 1 of each Cycle (Each cycle is of 21 days) according to the recommendation of the SMC until the MTD has been reached or confirmed disease progression.
214410384|NCT06470776|BEHAVIORAL|Peer counselling|Usual treatment provided by the Youth Quitline, i.e., telephone counselling for smoking cessation based on the 5As and 5Rs models delivered by trained peer counsellors at baseline and 1 week, 1 month and 3 months post-baseline
214410385|NCT04327037|BIOLOGICAL|Expanded Haploidentical Natural Killer cells|One dose (from 20x to \>100x 10\^6 /kg) of expanded haploidentical NK cells
214410386|NCT04327037|DRUG|IL-2|6 doses of IL-2 (1 × 10\^6 units/m2) from -1 day every other day.
214410387|NCT01289743|DRUG|Etanercept|Etanercept 25 mg subcutaneously twice a week
215100629|NCT02577016|DRUG|Ipragliflozin|50 mg tablet administered orally as background medication
215100630|NCT04770844|OTHER|Acquisitions|"Three acquisitions of 1 hours during hospitalization will be realized:~* a few days after hospitalization,~* in the middle of the hospitalization,~* a few days before hospital discharge. The child will be lying on his back in a heated cradle and filmed with a specific camera. The signal will be obtained by 2k ZED 2 stereo camera in order to obtain a three-dimensional location of the child"
214410388|NCT05239702|BIOLOGICAL|CD7 CAR T-cells|Each subject receive CD7 CAR T-cells by intravenous infusion
214410389|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
214410390|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
214410391|NCT03781804|DRUG|OPN-375|OPN-375, BID
215014836|NCT00893581|DRUG|Quetiapine & Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
215014837|NCT00893581|DRUG|Lithium and Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
215014838|NCT00893581|OTHER|Healthy Controls|Healthy control (patients given placebo -- sugar pill intended to mimic drug)
215014839|NCT03532490|DRUG|Roflumilast 500 Mcg Oral Tablet|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
215014840|NCT03532490|DRUG|Placebo oral capsule|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
215014841|NCT04143438|PROCEDURE|EOS 3D imaging protocol pre- and post-surgery|Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
215014842|NCT02319083|PROCEDURE|Coronary artery bypass surgery|Patients will undergo coronary artery bypass grafting
215014843|NCT02716142|DRUG|rectal misoprostol|patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
215014844|NCT02716142|DRUG|sublingual misoprostol|patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
215014845|NCT00409227|DRUG|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
215014846|NCT00409227|DRUG|placebo|placebo once a day for 3 months or stone free
215014847|NCT04421664|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
215014848|NCT04421664|DRUG|Placebo oral tablet|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
215014849|NCT00831896|BIOLOGICAL|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
215014850|NCT02534623|PROCEDURE|Spinal anesthesia|
215014851|NCT02534623|PROCEDURE|General anesthesia|
215014852|NCT02534623|DRUG|bupivacaine|
215014853|NCT02534623|DRUG|fentanyl|
215014854|NCT02534623|DRUG|propofol|
215100631|NCT02126839|DRUG|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
214410392|NCT00337818|BIOLOGICAL|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
214410393|NCT04678830|DRUG|Placebos|Placebos
214410394|NCT04678830|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
214410395|NCT01668212|PROCEDURE|Doppler ultrasound|Doppler Ultrasound
214410396|NCT00333060|DRUG|OT-551 ophthalmic solution|
214410397|NCT00336232|DRUG|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
214410398|NCT06152029|DEVICE|Temporary PNS system|This system remains in place up to 60 days, then removed.
214410399|NCT06044948|DEVICE|Delefilcon A contact lenses|Daily disposable, silicone hydrogel spherical contact lenses
215014855|NCT02534623|DRUG|sevoflurane|
215014856|NCT03548415|DRUG|IONIS-GHR-LRx|IONIS GHR-LRx administered subcutaneously.
215100632|NCT02126839|DRUG|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
215100633|NCT02126839|DRUG|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
214410400|NCT05590871|DEVICE|FlashPoint renal denervation system|Radio-frequency ablation of renal arterial sympathetic nerves
215014857|NCT03548415|DRUG|Placebo|Placebo administered subcutaneously.
215014858|NCT01573728|BEHAVIORAL|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
215014859|NCT01573728|BEHAVIORAL|Public Health Exercise|At least 150 minutes at moderate intensity
215014860|NCT02330263|DIETARY_SUPPLEMENT|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
215014861|NCT02835521|PROCEDURE|Reception|
215014862|NCT02835521|DRUG|Joint injection with triamcinolone hexacetonide|joint injection with corticosteroids
215014863|NCT04491708|OTHER|Pilates exercises|The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.
215014864|NCT04138082|OTHER|Exposition to high-dB soundtrack|Already stated
214410401|NCT05590871|OTHER|Sham|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
214410402|NCT04216433|PROCEDURE|endovascular surgery|"an innovative, less invasive procedure used to treat problems affecting the blood vessels, such as an aneurysm, which is a swelling or ballooning of the blood vessel. The surgery involves making a small incision near each hip to access the blood vessels."
214410403|NCT03563053|COMBINATION_PRODUCT|EryDex System|"EryDex System was a combination product that was used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which was infused into the patients.~EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg (mean ± standard deviation) of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T.~The dose of EryDex treatment was selected to allow collection of long-term safety data on the dose of erythrocyte encapsulated DSP that was considered more effective among the two different doses that were employed in the ATTeST study, based on the analysis of the ATTeST blinded, Phase 3 study data."
214410404|NCT06519370|DRUG|FDA018-ADC|Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
214410405|NCT06519370|DRUG|Eribulin|1.4mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
214410406|NCT06519370|DRUG|Capecitabine|1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest
214410407|NCT06519370|DRUG|Gemcitabine|800 to 1200 mg/m\^2 will be administered IV on day 1 and Day 8 of each 21 day cycle
214410408|NCT06519370|DRUG|Vinorelbine|25 mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
214410409|NCT03137316|DIAGNOSTIC_TEST|intact parathyroid hormone level|obtain intact parathyroid hormone level from patients records.
215014865|NCT04802915|PROCEDURE|Intraoperative ERM and ILM staining with their assessment and removal|ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
215014866|NCT01803737|BEHAVIORAL|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
215014867|NCT01803737|BEHAVIORAL|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
215014868|NCT04630626|DEVICE|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
215014869|NCT04630626|OTHER|ACDF|Historical ACDF control data
215014870|NCT01748552|DRUG|Placebo|Administered orally as capsules
215014871|NCT01748552|DRUG|LY2922083|Administered orally as capsules
215014872|NCT03723525|COMBINATION_PRODUCT|Package of HIV care|"A. Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI). Detail information mentioned in the manual (refer to uploaded protocol).~B. Rapid ART Initiation~1. PLHIV without suspicion or active OI: Initiate ART within seven days or same day after HIV serology disclosure~2. PLHIV with suspicion or active OI: Defer initiation if clinical symptoms suggest tuberculosis or cryptococcal meningitis. Detail information mentioned in the manual (refer to uploaded protocol).~C. Enhanced Adherence/Retention Support: mHealth: Receive text messages in mobile regarding appointment reminder (pill pick up, CD4 test, viral load test, early infant diagnosis (EID) test etc.) and general awareness messages (positive prevention, the importance of regular health check-up etc.). PLHIV with advanced HIV disease will also receive weekly/biweekly home-based adherence/ retention support linked to community care centre and community home-based care."
215100634|NCT00812565|DRUG|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
215100635|NCT00812565|BIOLOGICAL|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
215100636|NCT03471741|RADIATION|IMRT with concomitant boost|
215100637|NCT03471741|RADIATION|3D-RT with sequential boost|
215100638|NCT00310622|DEVICE|HyperQ Signal recording|
215100639|NCT00332891|DRUG|SR58611A|
215014873|NCT03723525|COMBINATION_PRODUCT|Standard HIV care|Standard of HIV care includes screening and management of OI (OI- tuberculosis (TB), bacterial pneumonia, herpes, and candidiasis), baseline assessment (CD4 and other blood tests- complete blood count, hemoglobin, platelets, liver function test, renal function test, urine for albumin, chest x-ray), at 6 months CD4 test, viral load (twice a year) and then on a yearly basis, additional lab test at 3 months, 6 months, antiretroviral (ARV) toxicity monitoring like hemoglobin (Zidovudine), Serum Glutamic-Pyruvic Transaminase (Nevirapine/Efavirenz), Creatinine (Tenofovir), prophylaxis (Co-trimoxazole preventive therapy CD4\<350 and WHO stage III and IV and Isoniazid preventive therapy if eligible) and ART / follow up (generally monthly/ bimonthly).
215014874|NCT01526369|DRUG|Trastuzumab|
215014875|NCT01526369|DRUG|Paclitaxel|
215014876|NCT01526369|DRUG|Lapatinib|
215014877|NCT06256874|BEHAVIORAL|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
215014878|NCT04558853|DRUG|autologous NK cells|Autologous ex vivo expanded and activated NK cells
215014879|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
215014880|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
214410410|NCT01013974|DRUG|GSK573719 250 μg|Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
214410411|NCT01013974|DRUG|GSK573719 500 μg|Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
214410412|NCT01013974|DRUG|GSK573719 1000 μg|Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
214410413|NCT01013974|DRUG|GSK573719 matching Placebo|Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
215100640|NCT02752373|DEVICE|Brain Sentinel Seizure Detection and Information System|The Brain Sentinel® GTC Seizure Detection and Information System is an ambulatory system designed to continuously monitor and perform real-time analysis of surface electromyography (sEMG) data to detect GTC seizures and to provide an alarm to alert caregivers within 30 seconds of bilateral, appendicular, tonic extension that a seizure is occurring. The System is for recording and storing sEMG data, which is subsequently reviewed by a trained healthcare professional in the outpatient clinical setting. The Brain Sentinel® GTC Seizure Detection and Information System is intended for real time monitoring of pediatric and adult patients who have an arm circumference ranging from at least 16 cm to no greater than 51 cm at the biceps. It may be used in the home or healthcare facilities for real-time monitoring during the day, night, or for continuous monitoring, including during the titration of, or the withdrawal from anti-epileptic drugs.
215100641|NCT04739579|DIAGNOSTIC_TEST|C-Reactive Protein|C-Reactive Protein trend in post-operative course
215100642|NCT03977493|DRUG|Xeomin|One injection of 2.5 to 40 U in each muscle. Injection repeated after 6 weeks if considered necessary
214410414|NCT04530474|DRUG|Ivermectin Pill|Ivermecin as a one-time dose
215014881|NCT03123562|COMBINATION_PRODUCT|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
215014882|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
215014883|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
215014884|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
215014885|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
215014886|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
215014887|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
215014888|NCT05541471|DRUG|VX-548|Tablets for oral administration.
215014889|NCT05541471|DRUG|Midazolam|Syrup for oral administration.
215014890|NCT05541471|DRUG|Digoxin|Tablets for oral administration.
215014891|NCT03824054|PROCEDURE|colorectal resection|Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
215100643|NCT03977493|DRUG|Placebo - Concentrate|One injection in each muscle.
215100644|NCT01433562|DRUG|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
214410415|NCT04530474|DRUG|Placebo|Inactive medication as a one time dose
215014892|NCT01727427|DRUG|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
215014893|NCT05647382|DIAGNOSTIC_TEST|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
214410416|NCT06629480|DRUG|Bictegravir|The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir based-regimen. A randomized open clinical trial was developed with men PLH who started ART randomized to BIC/FTC/TAF or DTG/3TC/ABC.
215014894|NCT02913859|RADIATION|Radiotherapy to the pelvis|Radiotherapy to the pelvis and prostate
214410417|NCT02479867|DRUG|Cefadroxil|1 tablet from test vs 1 tablet from reference
214410418|NCT05694507|OTHER|Mental Well-being Chatbot|The chatbot contents are developed by Clinical psychologists and well-being promotion officers. Content includes relationships, stress, value, emotion, and positive psychology.
214410419|NCT00399282|DRUG|Omega-3 and Vitamin E supplementation|
214410420|NCT01084421|BEHAVIORAL|Computer-based parent-adolescent HIV communication|The parental intervention consists of a 60 minute computer-based program delivered in two sessions (one per week). The DVD ROM provides information about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general. The computer based education program is provided in Spanish.
214410421|NCT05347537|OTHER|Mulligan mobilization|Mulligan Mobilization designed to reduce pain and improve the patient's range of motion. Mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
214410422|NCT05347537|OTHER|clamshell exercise|As a general exercise, the clamshell can help strengthen your medial glutes, bringing more power and stability to your hips. This group treated with mulligan's mobilization with movement and clamshell exercises.
214410423|NCT02659995|OTHER|No intervention|No interventions will be performed on these patients.
214410424|NCT01339221|PROCEDURE|Stool samples|Stool samples collected and checked for the presence of rotavirus
214410425|NCT03184428|OTHER|Postoperative observation and survey|For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
214410426|NCT03369951|DRUG|Minocycline|Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
214410427|NCT03213041|DRUG|Carboplatin|Given IV
214410428|NCT03213041|OTHER|Laboratory Biomarker Analysis|Correlative studies
214410429|NCT03213041|BIOLOGICAL|Pembrolizumab|Given IV
215014895|NCT02913859|DRUG|Hormonal therapy (LHRH agonist and/or antiandrogens)|life-long hormonal therapy (LHRH agonist and/or antiandrogens)
215014896|NCT01324466|DRUG|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
215014897|NCT01324466|DRUG|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
215014898|NCT04667728|DEVICE|Professional continuous glucose monitoring (CGM) sensor (iPro™2)|Professional continuous glucose monitoring (CGM) sensor (iPro™2) following treatment adjustments and personalized diet plan
215014899|NCT00004228|DRUG|asparaginase|Given IV
215014900|NCT00004228|DRUG|cyclophosphamide|Given IV
215014901|NCT00004228|DRUG|cytarabine|Given IV
215014902|NCT00004228|DRUG|daunorubicin hydrochloride|Given IV
215014903|NCT00004228|DRUG|dexamethasone|Given IV
215014904|NCT00004228|DRUG|doxorubicin hydrochloride|Given IV
215014905|NCT00004228|DRUG|leucovorin calcium|Given IV
215014906|NCT00004228|DRUG|mercaptopurine|Given IV
215014907|NCT00004228|DRUG|methotrexate|Given IV
215014908|NCT00004228|DRUG|prednisone|Given IV
215014909|NCT00004228|DRUG|thioguanine|Given PO
215014910|NCT00004228|DRUG|vincristine sulfate|Given IV
214410430|NCT02404246|BEHAVIORAL|Peer support program|
214410431|NCT02926937|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet;~Route of administration: oral"
214410432|NCT02926937|DRUG|Placebo|"Pharmaceutical form: tablet;~Route of administration: oral"
214410433|NCT05697965|DRUG|Vancomycin|applying 1 gm of vancomycin powder intracapsularly during primary total knee and hip arthroplasty to prevent periprosthetic joint infection
214410434|NCT05697965|PROCEDURE|Total knee or total hip arthroplasty|Primary total knee or total hip arthroplasty without using local vancomycin
214410435|NCT02165423|BEHAVIORAL|myFAMI iPad application|
215014911|NCT00004228|RADIATION|radiation therapy|
215014912|NCT01506336|DRUG|masitinib|masitinib 12 mg/kg/day
215014913|NCT01506336|DRUG|sunitinib|sunitinib 50 mg/day
215014914|NCT00558480|DRUG|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
215014915|NCT00558480|DRUG|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
215014916|NCT03765359|DRUG|metforminhydrochloride|metformin 500 mg tablets and insulin
215014917|NCT03765359|DRUG|Placebo Oral Tablet|Placebo tablets mimic metformin 500 mg tablets and insulin
215014918|NCT05414253|DEVICE|Parallel Assignment|Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
215014919|NCT06501183|BIOLOGICAL|Anti-CDH17 CAR-T cells|Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.
215014920|NCT06433063|DIAGNOSTIC_TEST|F-MISO PET|Evaluation of tumor hypoxia with F-MISO PET
215014921|NCT01304719|BEHAVIORAL|Computer Assisted Healthy Families America Home Visitation|Computer modules added to home visitation protocol for Healthy Families America
215014922|NCT01304719|BEHAVIORAL|Healthy Families America Home Visitation|Healthy Families America Home Visitation Treatment as Usual
215014923|NCT05963919|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
215014924|NCT05963919|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) by ATS/ERS criteria. Forced expiratory volume in 1 second (FEV1) and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
214410436|NCT04463953|DRUG|Zanubrutinib,Ixazomib and Dexamethasone|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15；Ixazomib and dexamethasone every 4 weeks of a cycle, with induction of 6 cycles, and then maintain every 12 weeks, up to 6 cycles (96 cycles in total). Zanubrutinib is taken orally twice a day for up to 96 cycles, with a reduction in the last ID cycle. ZID regimen will continue 6 cycles after reaching the maximum response after introduction section.
214410437|NCT04705974|PROCEDURE|Fascia iliaca block|Fascia iliaca block will be performed under ultrasound guidenance.
214410438|NCT04705974|PROCEDURE|Femoral nerve block|Femoral nerve block will be performed under ultrasound guidenance.
214410439|NCT04705974|PROCEDURE|Pericapsular nerve group block (PENG block)|Pericapsular nerve group block (PENG block) will be performed under ultrasound guidenance.
214410440|NCT03356067|PROCEDURE|Gastric endoscopic peroral pyloromyotomy|"G-POEM is, in principle, adaptation of POEM (per-oral endoscopic myotomy) in the stomach. The procedure consists of:~1. Mucosal incision at the greater curvature 3-5 cm from the pylorus~2. Submucosal tunnelling~3. Finding pyloric sphincter~4. Myotomy (2-3 cm) of the pyloric muscle~5. Incision closure (endoclips or suture device)"
214688474|NCT00358995|BEHAVIORAL|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
214688475|NCT00423085|DRUG|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
214688476|NCT00423085|DRUG|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
214688477|NCT03904641|RADIATION|aPDT|For aPDT, PapacarieMblue (Fórmula e Ação) will be used. It will be left for 5 minutes in the cavity. The carious tissue will be removed and the application of the PapacarieMblue will be repeated. The tissue will then be irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ.
214688478|NCT03904641|PROCEDURE|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
214688479|NCT04561713|PROCEDURE|Virtual reality task|Virtual reality application in an immersive room (CAVE) in three dimensions to assess child's sustained attention in a dynamic environment that is as close as possible to everyday situations.
214688480|NCT02260466|OTHER|a basal LV septum biopsy|During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
214688481|NCT06048406|COMBINATION_PRODUCT|Health education|The intervention group will receive a health education intervention focused on influenza vaccination literacy, while the control group will continue with their standard school health education without any additional intervention. An influenza vaccination health education including topics such as the importance of influenza vaccination, benefits of vaccination, and vaccination methods, will be developed and reviewed by an expert group. The package for the intervention group will include educational activities, distribution of promotional materials, vaccination services, and distribution of vaccination souvenirs.
214688482|NCT02365493|DRUG|Beta-Lactam|
215014925|NCT05963919|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
215014926|NCT05963919|OTHER|Lower extremity muscle strength test|The 30-Second Chair Test is administered using a folding chair without arms, with a seat height of 17 inches (43.2 cm). The chair, with rubber tips on the legs, is placed against a wall to prevent it from moving. The participant is seated in the middle of the chair, back straight; feet approximately a shoulder width apart, and placed on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance. Arms are crossed at the wrists and held against the chest. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.
215014927|NCT04627753|DRUG|Rituximab, lenalidomide|Maintenance for 2 years
214688483|NCT02163993|DRUG|Galcanezumab|Administered SQ
214688484|NCT02163993|DRUG|Placebo|Administered SQ
214688485|NCT00853489|DEVICE|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
214688486|NCT00853489|PROCEDURE|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
214688487|NCT00539253|DRUG|gadobenate dimeglumine (MultiHance)|The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
215014928|NCT04442750|PROCEDURE|Erector spinae plane block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will be then rotated into a longitudinal orientation 2-3 cm lateral to vertebral column. The lumbar skin region will be sterilized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex A'; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a cranial-to-caudal direction until contact will made with the L4 transverse process. Local anesthetic solution will be injected and its type will be selected according to the studied group and patients were placed in a supine position and general anesthesia will be started.
214410441|NCT03356067|PROCEDURE|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope
214410442|NCT01061905|BEHAVIORAL|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
214410443|NCT01061905|BEHAVIORAL|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
214410444|NCT01061905|BEHAVIORAL|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
214410445|NCT01021644|BEHAVIORAL|aerobic exercise-training|3 times per week for 6 months
214410446|NCT01021644|BEHAVIORAL|stretch exercise|3 times per week for 6 months
214410447|NCT00616161|DRUG|Istaroxime|0.5 microgram/kg/min IV for 6 hours
214410448|NCT00616161|DRUG|Istaroxime|1.0 microgram/kg/min IV for 6 hours
214410449|NCT00616161|DRUG|Istaroxime|1.5 microgram/kg/min IV for 6 hours
214410450|NCT00616161|DRUG|Placebo|Placebo
214410451|NCT00561574|DRUG|Esmirtazapine|One tablet daily
214410452|NCT04314661|BIOLOGICAL|Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
214410453|NCT04314661|BIOLOGICAL|Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
214410454|NCT04314661|BIOLOGICAL|Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
214410455|NCT04314661|BIOLOGICAL|Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
215014929|NCT04442750|PROCEDURE|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 1-1.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium o.1 m\\kg will be provided every 30 minutes.~Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of baseline levels.~At the end of surgery, residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and will extubation be performed after complete recovery of the airway reflexes."
215014930|NCT04442750|DRUG|Bupivacaine 0.5%|The patient will receive 30ml bupivacain 0.5% in erector spinae block
215014931|NCT04442750|DRUG|Bupivacaine 0.375%|The patient will receive 30ml bupivacain 0.375% in erector spinae block
215014932|NCT04442750|DRUG|Bupivacaine 0.25%|The patient will receive 30ml bupivacain 0.25% in erector spinae block
215014933|NCT01032343|DIETARY_SUPPLEMENT|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
215014934|NCT01032343|DIETARY_SUPPLEMENT|Gelatine|One capsule daily for 3 months
215014935|NCT01942980|RADIATION|Radiation therapy Brain metastasis in breast cancer|Radiation
215014936|NCT03410537|DRUG|Taurine|
215014937|NCT03410537|DRUG|Placebo|
215014938|NCT02324907|DEVICE|Procedure/Surgery|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
215014939|NCT05316051|DEVICE|Inverted foot orthoses|Inverted functional orthoses will be used in this study based on Blake (1986) inverted orthotic technique. Two groups of foot orthosis will be fabricated with two different inverted angles: 25° inverted angle and 15° inverted angle.
215014940|NCT04717583|PROCEDURE|Intense pulsed light (IPL) treatment|"After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
215100645|NCT01433562|DRUG|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
214410456|NCT02064751|DEVICE|CRT with MultiPoint Pacing|
214410457|NCT02064751|PROCEDURE|Hemodynamic measurements for CRT device programming|
214410458|NCT01796977|DEVICE|OxyGenesys Dissolved Oxygen Dressing|
214410459|NCT01796977|DEVICE|Standard Gauze Dressing|
214410460|NCT01525979|BEHAVIORAL|Task-related unilateral arm training|The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.
214410461|NCT01525979|BEHAVIORAL|Task-related bilateral arm training|This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.
214410462|NCT01525979|BEHAVIORAL|Robot-assisted bilateral arm training|The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.
215100646|NCT03772262|DIETARY_SUPPLEMENT|goldenseal|Oral 500 mg capsules
215014941|NCT03914014|OTHER|connective tissue manipulation|From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.
214410463|NCT01525979|BEHAVIORAL|Robot-assisted unilateral arm training|The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
214410464|NCT02646046|BEHAVIORAL|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
214410465|NCT02646046|BEHAVIORAL|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
214410466|NCT01546571|BIOLOGICAL|POL-103A|POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
214410467|NCT01546571|BIOLOGICAL|POL-103A without API|Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
214410468|NCT06168123|BEHAVIORAL|Quality of life questionnaires will be assessed in addition to standard care|Quality of life questionnaires will be assessed in addition to standard care
214410469|NCT03693222|DRUG|Tramadol Hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
214410470|NCT03693222|DRUG|Morphine Sulfate|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
214410471|NCT02147990|DRUG|Rociletinib|Rociletinib will be administered to patients orally
214410472|NCT02793882|DRUG|18F-Fluorocholine PET/CT|
215014942|NCT03914014|OTHER|placebo ultrasound|From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
215014943|NCT03043937|OTHER|registry|
214410473|NCT02924454|DRUG|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
214410474|NCT02924454|DRUG|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
215014944|NCT01975584|BEHAVIORAL|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
215014945|NCT01749566|DRUG|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
215100647|NCT03772262|DRUG|Metformin|Oral solution
215100648|NCT03772262|DRUG|Furosemide|Oral solution
215100649|NCT03772262|DRUG|Midazolam oral solution|Oral syrup
215100650|NCT03772262|DRUG|Rosuvastatin Oral Tablet|Oral tablet
214410475|NCT02924454|DRUG|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
214410476|NCT02924454|DRUG|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
214410477|NCT02831153|PROCEDURE|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
215014946|NCT02329275|PROCEDURE|Testicular biopsy|
215014947|NCT04429971|OTHER|PrEP screening program|ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
215014948|NCT04429971|OTHER|PrEP starter pack|emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil
215100651|NCT05629130|DEVICE|embolization with spherical microparticles embosphere|embolization of affected joints with spherical microparticles embosphere
215100652|NCT03800238|BEHAVIORAL|Telehealth Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered via telehealth.
215100653|NCT03800238|BEHAVIORAL|Standard Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered in the traditional in-person format.
215014949|NCT01603511|DEVICE|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
215014950|NCT02868710|OTHER|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
215014951|NCT03255499|BEHAVIORAL|Exercise|Exercise
215014952|NCT03255499|BEHAVIORAL|Cognitive|Cognitive
215014953|NCT03255499|BEHAVIORAL|Active control|Active control, including a blend of computer games, board games, quizzes, trivia
215014954|NCT01935505|BEHAVIORAL|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
215014955|NCT01935505|DRUG|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
215014956|NCT01935505|BEHAVIORAL|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
214410478|NCT00630864|DRUG|Fx-1006A|During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
214410479|NCT05991505|OTHER|Physical exercise|Multimodal exercises twice a week
214410480|NCT00124982|DRUG|Abatacept|IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
215014957|NCT01935505|BEHAVIORAL|Consulting+Telephone+Drug intervention|Include all the above interventions
215014958|NCT02533674|DRUG|Gemcitabine plus PM060184|
215014959|NCT00002226|DRUG|SU5416|
215014960|NCT04266314|DEVICE|Maternal-fetal monitoring|Maternal-fetal monitoring evaluates fetal and maternal heart rate, maternal respirations, fetal movement, and maternal skin conductance (a way to monitor emotional response)
215014961|NCT04266314|OTHER|NICU Network Neurobehavioral Scale|Evaluates neurobehavioral organization, neurological reflexes, motor development, and signs of stress and withdrawal of substance-exposed infants.
215014962|NCT03225222|DIAGNOSTIC_TEST|biopsy|prostate biopsy
215014963|NCT02799290|BIOLOGICAL|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
215014964|NCT02799290|BIOLOGICAL|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
215014965|NCT01216280|DRUG|placebo capsule|2 x 10 mg placebo capsules administered orally with water, b.i.d.
215014966|NCT01216280|DRUG|10 mg Natura-alpha capsule and 10 mg placebo capsule|10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
215014967|NCT01216280|DRUG|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
215014968|NCT01292473|DRUG|Placebo|Placebo was supplied lyophilized in vials.
214410481|NCT00124982|DRUG|Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)|During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
214410482|NCT00124982|DRUG|Anti-Tumor Necrosing Factor (TNF) Therapy|Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
214410483|NCT05008341|DRUG|Solriamfetol 150 mg Oral Tablet|Single-dose 150 mg tablet orally administered.
215014969|NCT01292473|DRUG|Omalizumab|Omalizumab was supplied lyophilized in vials.
215014970|NCT04242654|PROCEDURE|Handheld fetal doppler ultrasound|Handheld fetal doppler ultrasound will be used to assess heart rate in high-risk neonates.
215014971|NCT02238327|PROCEDURE|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
215014972|NCT02238327|PROCEDURE|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
215014973|NCT02238327|PROCEDURE|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
215014974|NCT02238327|PROCEDURE|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to \<88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
214410484|NCT01237392|DEVICE|Contact ultrasonic debridement device|Cavitational ultrasound wound debridement device
214410485|NCT03638219|OTHER|Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020.|Data collection, follow up and bioscore calculation at the end of study
214410486|NCT06612554|DIETARY_SUPPLEMENT|zinc acetate|Participants in Control group. They will continue the SoC + 3 tablets of placebo and participants in Zinc supplementation group. Tablets will be separated 12h (just in case the ART is based in Integrase Inhibitors (INSTI)) during supplementation for 16 weeks with 3 tablets of zinc (83mg Zinc acetate/tablet).
214410487|NCT06612554|OTHER|Placebo|participants in Control group. They will continue the SoC + 3 tablets of placebo. 3 tablets separated 12h from ART during 16 weeks
215014975|NCT02238327|RADIATION|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
215014976|NCT02238327|PROCEDURE|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
215014977|NCT02238327|PROCEDURE|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
215014978|NCT00548691|DRUG|Ferric Carboxymaltose|
215014979|NCT00548691|DRUG|Standard Medical Care (SMC)|
215014980|NCT00393380|DRUG|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC\>2000/microL: PTH 100 mcg
215014981|NCT00602784|BIOLOGICAL|IC41|
215014982|NCT05045599|BEHAVIORAL|Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health|Community engagement to improve awareness, and use of family planning products and services
214410488|NCT06613750|DRUG|Sitagliptin and Gliclazide|Participants in this arm will receive sitagliptin phosphate 100 mg once daily combined with gliclazide sustained-release tablets 30-120 mg once daily for 12 weeks
214410489|NCT06613750|DRUG|Metformin|Participants in this arm will receive metformin 500 mg to 2000 mg per day, divided into two doses, for 12 weeks
214410490|NCT06615167|DEVICE|ALZGUARD|A digital therapeutic(DTx) application that uses artifical intelligence to analyze cognitive function and provide a diagnosis of dementia.
214688488|NCT05936034|OTHER|Patients suffering from chemotherapy-induced ototoxicity|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Control group: standard support; Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
214688489|NCT05936034|OTHER|Patients suffring from chemotherapy-induced ototoxicity wearing hearing aids|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Experimental group: standard treatment with hearing aids (wearing a hearing aid).~Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
215014983|NCT01401075|DRUG|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
215014984|NCT01401075|DRUG|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
215100654|NCT04241484|DEVICE|Piezowave 2|Piezowave Myofascial Acoustic Compression Therapy (MyACT), which provides mechanical stimuli delivery to improve circulation and provide relief of pain. The focused sound waves produced by the Piezowave MyACT device are classified by a pressure surge, which is followed by a drop in pressure and a brief negative pressure phase low energy/low pressure application. It is this transformation of mechanical stimuli into biochemical signals, or mechanotransduction, which yields the treatment of myofascial and musculoskeletal pain
215100655|NCT04345315|OTHER|serological test|serological test assessing IgM and IgG directed against SARS-CoV-2
215100656|NCT04345315|OTHER|Rapid molecular test|Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab
215100657|NCT04345315|GENETIC|Next generation Sequencing (NGS) analysis|analysis of genetic variability of virus and host
215100658|NCT04345315|OTHER|serum chemistry analysis|Analysis of serum chemistry factors and coagulation panel in blood samples
215100659|NCT03009617|BEHAVIORAL|the educational program and counseling|to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
215100660|NCT03909308|BEHAVIORAL|Beach Tennis session|The Beach Tennis training session will be composed by a warm up of 5 min of BT in which technical exercises (i.e., serve, volley, forehand and backhand) will be performed After that, 3 BT small games of 12 min with a 2 minute interval between games using the conventional rules of sport will be performed. Before the session and after each small game, data regarding heart rate, blood pressure and rate perceived exertion will be recorded.
215014985|NCT00766103|OTHER|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
214410491|NCT06614140|BIOLOGICAL|Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors|"This intervention involves a personalized neoantigen peptide vaccine composed of peptides containing tumor-specific mutations, such as SNVs, indels, and frameshift mutations. Neoantigens are selected based on criteria that enhance expression and immunogenicity.~The vaccine is administered alongside Poly-ICLC, a TLR3 agonist, to enhance immune activation. After the initial vaccine doses, checkpoint inhibitors (e.g., anti-PD-1 or anti-PD-L1) are introduced once neoantigen-specific T-cell responses are detected, preventing immune exhaustion and sustaining a strong immune response.~During the follow-up phase, both checkpoint inhibitors and Poly-ICLC are continued to maintain immune activity and ensure a lasting anti-tumor effect."
214410492|NCT06614439|PROCEDURE|proximal gastrectomy|proximal gastrectomy
215100661|NCT01354925|DRUG|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
215100662|NCT01354925|DRUG|Standard of care|Standard of care during Ramadan according to physicians decision
214410493|NCT06614439|PROCEDURE|total gastrectomy|total gastrectomy
214410494|NCT06615336|BEHAVIORAL|Intensive Sleep retraining|Intensive Sleep Retraining treatment consisted of 42 sleep onset trials over a 21-hour sleep deprivation period
214410495|NCT06615336|BEHAVIORAL|Total Sleep Deprivation|Total Sleep Deprivation treatment consisted of an equivalent 21-hour sleep deprivation period without sleep onset trials
214410496|NCT06615362|PROCEDURE|preparation of dentin membrane from hopeless tooth for Guided Bone Regeneration in Immediate Implant|tooth extraction , preparation of dentin membrane ,immediate implantation ,Xenogeneic bone graft material, application of dentin derived barrier membrane
214410497|NCT06615362|PROCEDURE|Collagen Membrane for Guided Bone Regeneration in Immediate Implant|like group one but with application of collagen membrane
214410498|NCT06615193|DRUG|HDM2005|HDM2005 will be administered via IV infusion.
214410499|NCT04155424|DRUG|Eculizumab|Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
214410500|NCT06614569|DRUG|AXO-AAV-GM2|Participants who received AXO-AAV-GM2 will be tracked in long term follow up
214410501|NCT05531370|OTHER|Breathing Retraining|"Conforming the real-world setting, all participants will continue standard asthma care, i.e., acute and planned visits at GP or pulmonologist.~BR aims to normalize the inhaled volume, nasal inhalation, exhalation to the resting position of the chest (functional residual capacity, FRC), use of the diaphragm muscle, and to move lower parts of the chest in a frequency of 12-16 per minute. This pattern is initially trained in rest (e.g., side lying or sitting), then during physical activity (e.g., walking). Uncontrolled coughing, frequent yawning or sighing is handled by a suppression technique. Relaxation technique is introduced as a separate activity but to be combined with the breathing pattern method to be used in both resting and as possible during physical activity."
214410502|NCT05322980|DIAGNOSTIC_TEST|Microcephaly|Those with a z score of birth head circumference \< -2 (primary microcephaly) are classified into the Microcephaly group.
214410503|NCT04209127|PROCEDURE|Microwave treatment via needle antenna|Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated
214410504|NCT04209127|PROCEDURE|Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)|Embolization via percutaneous catheter
214410505|NCT03015740|OTHER|Laboratory Biomarker Analysis|Correlative studies
214410506|NCT03015740|BIOLOGICAL|Nivolumab|Given IV
214410507|NCT03015740|OTHER|Quality-of-Life Assessment|Ancillary studies
214410508|NCT03015740|OTHER|Questionnaire Administration|Ancillary studies
215014986|NCT03904186|BEHAVIORAL|QUIT|QUIT is a transdiagnostic Cognitive Behavioral Therapy-based smoking cessation protocol designed to address distress intolerance, anxiety sensitivity, and anhedonia in people living with HIV who smoke. QUIT is delivered in 9 60-minute individual weekly sessions over a 10-week period. Sessions are active, with treatment components practiced within and outside of the session. Participants will also receive the transdermal nicotine patch for 8 weeks, starting when they attempt to quit smoking during week 7 of the study.
214410509|NCT03015740|DRUG|Sitravatinib|Given PO
214410510|NCT06625762|OTHER|Nantes bariatric surgery cohort|The participants will be individuals living with obesity undergoing bariatric surgery
214688490|NCT06203912|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214410511|NCT01981161|PROCEDURE|biological samples and clinical data|
214410512|NCT06614244|PROCEDURE|Oral immunotherapy (OIT)|OIT in DOPA group will be implemented as follows. Both the first micro-dose of the offending food and the subsequent micro-increments will be administered at home. Any interruptions and resumptions of OIT, due to intercurrent events (e.g. infections), will be managed via email with or without medical visit via video call. Patients will be provided with ondansetron (sublingual film) and instructions for its use. An explanatory letter will also be provided in case of need for emergency room access.
214410513|NCT06614244|DIETARY_SUPPLEMENT|Culprit food elimination diet|The Diet group consists of a population of children affected by acute persistent FPIES subjected to the traditional measure, i.e. the elimination diet of the incriminated food.
214410514|NCT06687460|OTHER|Brief electrical stimulation|During the nerve micro-reconstruction surgery, electrical stimulation is given to the distal end of the damaged nerve for 30 minutes.
214410515|NCT06687460|OTHER|no nerve electrical stimulation|only nerve microsurgical reconstruction, no nerve electrical stimulation
214410516|NCT02338622|DRUG|olaparib|olaparib BD
214410517|NCT02338622|DRUG|AZD5363|AZD5363 BD
214688491|NCT06203912|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
214688492|NCT06203912|DRUG|Cyclophosphamide|Given IV
215100663|NCT01964625|OTHER|PET-CT Scan|PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
215100664|NCT02737345|OTHER|Rotem|
215100665|NCT01835665|DRUG|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
215100666|NCT02754258|DRUG|MPH|60 days on oral methylphenidate administered 2 times daily before lunch and supper.
215100667|NCT02754258|DRUG|Placebo|60 days on oral placebo administered 2 times daily before lunch and supper
215100668|NCT00954499|BEHAVIORAL|Tactile stimulation added to Standard care|"* Parent rubs the infant's skin near the injection site just before, during and after the injection.~* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
215100669|NCT00954499|BEHAVIORAL|Standard care|"* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
215100670|NCT00463619|DRUG|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
214688493|NCT06203912|DRUG|Dexamethasone|Given PO
214688494|NCT06203912|PROCEDURE|Echocardiography|Undergo echocardiography
215014987|NCT03904186|BEHAVIORAL|Time-Matched Control (TM)|Participants will receive a standard smoking cessation treatment, based on the clinical practice guidelines from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence. Treatment will be delivered in nine, 60-minute sessions over a ten-week period. The treatment is based on a treatment protocol developed and used previously by Dr. Zvolensky. Because clinical guidelines recommend that all smokers attempting to quit smoking receive pharmacotherapy, participants will also receive the transdermal nicotine patch for 8 weeks.
215014988|NCT01717859|DRUG|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 \> 3.2, dosage will be escalated to 8 mg/kg.
215100671|NCT05334407|PROCEDURE|Implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
215100672|NCT05334407|BEHAVIORAL|Dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
215100673|NCT05334407|PROCEDURE|Delayed implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Delayed (4 months) implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
215100674|NCT05334407|BEHAVIORAL|Delayed dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
215100675|NCT02567565|OTHER|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
214688495|NCT06203912|BIOLOGICAL|Isatuximab|Given IV
214688496|NCT06203912|OTHER|Questionnaire Administration|Ancillary study
214688497|NCT06203912|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
215014989|NCT04590183|DRUG|FK-506 (Drug)|Twice a day
215014990|NCT04590183|DRUG|Prednisolone Acetate 1% Oph Susp|Four times a day
215014991|NCT03114397|DEVICE|transcranial direct current stimulation - active|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.
215014992|NCT03114397|DEVICE|transcranial direct current stimulation - sham|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
215014993|NCT04389671|DRUG|Lucinactant|Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
214688498|NCT04869904|PROCEDURE|dental and plaque sampling|sampling of dental plaque and saliva during the treatment
214688499|NCT00981383|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
215014994|NCT01870570|OTHER|Reference Glucose|
215014995|NCT01870570|OTHER|Food Product A: Corn Flakes|
215014996|NCT01870570|OTHER|Food Product B: Ginger Bread|
214410518|NCT04861051|DRUG|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
214410519|NCT06627439|BEHAVIORAL|Comadres Saludables|Comadres Saludables is a web-based healthy living training for community health workers aimed at addressing obesity in Latinas. Comadres Saludables will combine both theory and evidence-based practices to provide participants with the self-efficacy, knowledge, and skills required to effectively implement an obesity intervention for Hispanic women. Participants (CHWs) will build their skillset through interactive quizzes, exercises, and video role-playing scenarios. Additionally, Comadres Saludables allows participants to utilize interactive mHealth tools to enhance implementation with Hispanic women. Participants will access the training for three months.
214410520|NCT06627439|BEHAVIORAL|Control|Participants will access the web-based HHS Promoting Healthy Choices and Community Changes that includes a variety of content via text, audio, and video. The information is designed to educate CHWs on how to implement health interventions for positive community change. They are asked to review it for three months.
214410521|NCT06627907|OTHER|fluid challenge|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
214410522|NCT06627907|DIAGNOSTIC_TEST|end-expiratory occlusion test|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
214410523|NCT06692985|OTHER|Clinical and epidemiological data|Collection of clinical and epidemiological data on day 0
214688500|NCT00981383|OTHER|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
214688501|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
214688502|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
214688503|NCT03798145|PROCEDURE|Surgical Retinotomy|Surgical removal of small areas of retinal to increase outflow through the posterior drainage pathway.
215014997|NCT01870570|OTHER|Food Product C:Sandwiched Breakfast Biscuit|
215014998|NCT01870570|OTHER|Food Product D: Crackers Nature|
215100676|NCT01421953|DEVICE|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
215100677|NCT00994006|DIETARY_SUPPLEMENT|Magnesium oxide|520 mg of elemental magnesium q.d.
215100678|NCT00994006|DIETARY_SUPPLEMENT|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
215014999|NCT01870570|OTHER|Food Product E: Breakfast Biscuit|
215015000|NCT01870570|OTHER|Food Product F: White Bread|
215015001|NCT04429594|OTHER|blood sampling|blood sampling at J0, M6, M12, M24, M36, M48, M60
215015002|NCT01111292|DRUG|Inositol|Given PO
215015003|NCT01111292|OTHER|Placebo|Given PO
215015004|NCT03881800|OTHER|titration- blood sample|Ceftazidime titration
215015005|NCT03719937|DEVICE|weight on the anterior chest of the patient|The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
215015006|NCT03357705|PROCEDURE|alveolar ridge preservation with synthetic bone|after tooth extraction
215015007|NCT03357705|PROCEDURE|alveolar ridge preservation with bovine collagen|after tooth extraction
215015008|NCT01954173|RADIATION|3D conformal radiation therapy|Undergo conformal radiation therapy
215015009|NCT00673114|BIOLOGICAL|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
215015010|NCT02326246|OTHER|multi-parametic MRI|
215015011|NCT01487785|DRUG|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
215015012|NCT00567801|PROCEDURE|conventional embolectomy/thrombectomy|
215015013|NCT00567801|PROCEDURE|embolectomy/thrombectomy with controlled reperfusion|
215015014|NCT01260792|OTHER|questionnaire|The teachers or the professors complete questionnaires on the child on their behavior in classes
215015015|NCT01260792|OTHER|Questionnaire|The parents complete a questionnaire on the behavior of their child and on their own behavior
215015016|NCT06092983|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
214410524|NCT06692985|OTHER|Parasitological samples|Parasitological samples : smear for on-site analysis and swabs to be sent to the Cayenne Hospital for PCR at day 0
214410525|NCT06692985|OTHER|Assessment of clinical course and response to treatment|Follow-up visit with assessment of clinical course and response to treatment at M6
214410526|NCT06692985|OTHER|DLQI questionnaire|DLQI questionnaire at M6
214410527|NCT06693882|DEVICE|EYETRONIC Nextwave System|"Eyetronic Nextwave is a neurostimulation device that stimulates the optic nerve non-invasively using transcranial alternating current stimulation delivered through goggles in patients presenting with glaucoma.~Eyetronic is approved in Europe for the treatment of glaucoma to possibly delay progression of visual field (VF) loss for at least 12 months. The indication for use in Europe includes all patients suffering from neuropathies of the optic nerve resulting in loss of VF. Two studies conducted in Europe have demonstrated improvement in visual fields following 10-days of optic nerve stimulation treatment with this device. In the current study, the Eyetronic system will be used to treat only those individuals who have visual field loss from glaucoma."
215015017|NCT06092983|DRUG|HS-10383 Placebo|HS-10383 Placebo administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
215015018|NCT00163735|DRUG|Administration of wine fined with potential food allergens|
215015019|NCT00271570|DRUG|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
215015020|NCT00271570|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
215100679|NCT04927403|OTHER|multimodal integrative naturopathic therapy concept|Use of conventional medicine, naturopathic approaches and complementary medical therapy methods
215100680|NCT03430960|OTHER|Phone Call|Participants will be followed-up via phone call by Acute Pain Research Nurse
215100681|NCT03430960|OTHER|Mobile App Survey|Participants will be followed-up via mCare mobile app
215100682|NCT05865717|BEHAVIORAL|Quantitative sampling|A questionnaire asks about demographics, lifestyle (including cigarette smoking) \& desk job hours, eating habits, sleep patterns, mental health, and motivation. Data on the frequency and size of regular food consumption will be gathered by completing a survey. Physical activity will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University (Lifestyle Assessment Short Form, 2018).
215100683|NCT05865717|OTHER|Qualitative interviews|Thematic analysis will be done dividing into 4 different themes Personal life, professional life, Concept of Healthiness, Improving Lifestyle
215100684|NCT03764306|PROCEDURE|Carotid Artery Stenting|Carotid artery stenting was considered successful if there was no residual stenosis greater than 20%, and there was no dissection of target artery following the procedure.
215100685|NCT03764306|PROCEDURE|Endarterectomy carotid artery|Surgical endarterectomy was considered successful if there was no residual stenosis after procedure, without symptoms.
215100686|NCT00765063|DRUG|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
215100687|NCT03614325|OTHER|Virtual Reality Immersive Relaxation|The software developed by VRHealth allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
215100688|NCT03874039|DEVICE|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
215015021|NCT06274476|OTHER|implant placement|ridge splitting piezo surgery and implant placement
215015022|NCT02636491|DEVICE|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
215015023|NCT02636491|DEVICE|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
215100689|NCT03874039|DEVICE|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
214410528|NCT04895345|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214410529|NCT04895345|RADIATION|Intensity modulated radiotherapy|Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
214410530|NCT02662192|OTHER|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
215015024|NCT04998149|DEVICE|Peanut Ball positioning device|Peanut Ball manufactured by Clinton industries at graylinemedical.com https://www.graylinemedical.com/products/clinton-industries-peanut-ball-peanut-ball-40-cm-yellow-8540?\_pos=3\&\_sid=d6e52e63c\&\_ss=r
215015025|NCT06190665|DEVICE|DEB-TACE with visualable microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with visualable microspheres
215015026|NCT06190665|DEVICE|DEB-TACE with PVA microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with polyvinyl alcohol microspheres
215015027|NCT01655212|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
214410531|NCT02662192|OTHER|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
214410532|NCT04086758|DRUG|zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion
214410533|NCT06631066|RADIATION|neoadjuvant chemoradiation|Neoadjuvant chemoradiation will be prescribed as: 4 cycles of Adriamycin and Cyclophosphamide followed by radiotherapy concurrently with taxanes/ taxanes and carboplatin. followed by surgery as indicated.
214410534|NCT06631794|BEHAVIORAL|A short talk about the importance of HPV vaccination|"Investigator plan to set up a short talk to 3rd grade classes in addition to the usual sexual health training. The issue of HPV vaccination will be systematically addressed for 10 minutes to encourage catch-up vaccination.~The usual training include different themes such us : definition of sexual health, anatomy, sexually transmitted infections contraception/condoms, menstrual cycles, voluntary interruption of pregnancy, consent, sexual abuse/violence/harassment, pornography, anti-discrimination....~A 45-minute talk will include 2 or 3 topics from the above list. A ten minutes of talk will be added to the usual training to explain the HPV vaccination (a topic not usually addressed in sexual health training), covering the following elements: definition of HPV infection"
214410535|NCT06629532|OTHER|medical management, surgical interventions, and rehabilitative strategies|By leveraging a wide array of treatment data - including medical management, surgical interventions, and rehabilitative strategies - the RESEARCH registry intends to provide a granular view of current treatment landscapes and their direct impact on patient recovery and quality of life.
214410536|NCT06630182|OTHER|Bortner self-questionnaire|14 items
214410537|NCT06630182|OTHER|Self-questionnaire BFI-10|10 items
214410538|NCT06629883|BEHAVIORAL|REPS w/BANDS|This theory-informed, one-arm proof-of-concept study provided participants (n=10) with an SHVD, exercise equipment (exercise bands, stability ball), and 2 supervised RE sessions per week for 12 weeks via the SHVD's video feature and incorporated strategies from self-determination theory to meet the psychological needs of autonomy, competence, and relatedness. Participants were randomly paired with a buddy.
214410539|NCT06711224|BEHAVIORAL|Digital intervention for adolscents with ADHD|The aim of the digital intervention is to promote coping of ADHD. The intervention has a duration of 6 weeks and will be delivered as a mobile app including weekly phone calls from a therapist. The intervention includes text, interactive exercises, animations, and coping skills. The themes of the intervention includes psychoeducation on ADHD, healthy habits (sleep, exercise, food), social skills, and emotion regulation. The adolescents have the possibility to choose some of the themes they want to work on during the intervention.
214410540|NCT06711653|DIAGNOSTIC_TEST|Vestibular evoke myogenic potential|routine Vestibular test
214410541|NCT06697574|BEHAVIORAL|Hypnosis aimed at stress reduction and health of the oral mucosa|"* Induction.~* Hypnotic relaxation and escalating deepening of hypnotic trance.~* Suggestions for healing and wellness of the oral mucosa and for balanced and optimal performance of the immune system, tailoring metaphors and images based on interview with patients.~…the interior of the mouth is soft, healthy pink, intact and whole. It functions optimally as it should - enabling joyful eating and tasting, speaking with ease for any needed expression, any function of the mouth that needs to be used can be done so easily.~The immune system is very wise - it knows perfectly how to function in a balanced and harmonious way. Its wisdom enables it to act if the body needs defense and to standby and rest if it does not.~* Ego strengthening.~* Anchoring - using a predetermined mark selected by the patient.~* Dehypnotisation."
214410542|NCT06697574|BEHAVIORAL|Psychoeducation|A short explanation about the psycho-neuro-immune system and its part in oral lichen planus
214688504|NCT01712087|DEVICE|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
215015028|NCT02681042|PROCEDURE|Left atrial appendage closure|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
215015029|NCT02681042|DEVICE|SentreHeart Lariat®|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
215015030|NCT05928208|DIAGNOSTIC_TEST|no intervention|no intervention
215015031|NCT00419432|OTHER|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
215015032|NCT00419432|OTHER|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
215015033|NCT04297267|DRUG|Gemcitabine|Gemcitabine 1250mg/m2,d1,d8,every 3 weeks
215015034|NCT04297267|DRUG|Cisplatin|Cisplatin 75mg/m2,d1，every 3 weeks
215015035|NCT05130021|DRUG|MAX-40279-01|MAX-40279-01 50mg/70mg
215015036|NCT05130021|DRUG|regorafenib|regorafenib
215015037|NCT00198614|DRUG|Carvedilol versus Metoprolol|
215015038|NCT04032431|BEHAVIORAL|Telerehab VR intervention|Training with VR system using software specifically designed to reproduce activities of daily living
215015039|NCT03240432|DEVICE|Dexcom CGM|CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
215015040|NCT06170866|BEHAVIORAL|Socially supported physical activity|Use of a culturally and linguistically tailored intervention that uses mobile health technology plus social support to increase engagement in physical activity in the management of Parkinson´s disease.
215015041|NCT05463705|BEHAVIORAL|Intervention to address diffusion of responsibility|PCPs will receive an email from a peer offering encouragement and support in prescribing SGLT-2is and GLP-1RAs that includes specific components designed to reduce diffusion of responsibility. Specifically, these elements will be adapted from interventions that mitigate diffusion of responsibility in other contexts, including: (1) assigning responsibility to individuals or smaller groups, (2) increased perceived harm of the situation to be addressed (3) highlighting competence to act, and (4) modeling the desired behavior. The email will also contain a link to clinical and administrative information to support prescribing and an offer for direct support from the peer.
214410543|NCT06714149|DIAGNOSTIC_TEST|Immunoreactivity testing|Blood samples will be collected and used to determine the intensity of the allergenicity of the subject toward different types of pollen. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.
214410544|NCT06714149|DIAGNOSTIC_TEST|Immunoreactivity testing (negative control)|Blood samples will be collected and used to determine the background activity of our immunoreactivity tests. The investigators will use samples from negative controls to demonstrate that non-allergic individuals do not react to our assays, confirming that our pollen extracts have no background reactivity. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.
214410545|NCT06711978|DRUG|Mirogabalin|Participants will receive Mirogabalin at a dose of twice daily for 4 weeks to manage CIPN pain.
214410546|NCT06711978|DRUG|Duloxetine|Participants will receive Duloxetine at a dose of once daily for 4 weeks to manage CIPN pain.
214410547|NCT06712979|PROCEDURE|Adapted Lee Silverman Method|Exercise protocol with 6 steps that the voice professionals adapted from Lee Silverman Method
214410548|NCT06712979|DEVICE|Lung volume recruitment technique - LVRT|The adapted Lee Silverman Method will have a addiction of LVRT technique. Lung inflation begins, reaching an optimal inspiratory peak of 30 cmH2O. From this point, the sound /HA/ begins to be emitted until the most comfortable low sound, where the emission should be maintained for as long as possible, making sure that this time is not less than 12 seconds, trying to emit a high and comfortable vocal intensity. When performing the emissions, the mouth should be kept wide open with the tongue, jaw and neck relaxed, repeating 5 emissions in 3 series. Between series, the participant will be instructed to drink 50 ml of water exactly as in the previous emissions.
214410549|NCT06805058|OTHER|comedy therapy|Patients will be shown 10-minute Turkish comedy films prepared by the researchers
214410550|NCT05859997|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
214410551|NCT04377633|PROCEDURE|Oral handover|Anesthesia handover during surgery will be performed as usual, i.e., oral exchange of pertinent clinical information.
214410552|NCT04377633|PROCEDURE|Checklist handover|Anesthesia handover during surgery will be performed according to a structured handover checklist.
214410553|NCT05927480|BEHAVIORAL|Audio distraction|Music on an mp3 player will be provided to the patient for them to listen to while having the traction pin placed.
214410554|NCT01489176|DRUG|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
214410555|NCT01169805|DRUG|Ondansetron|Ondansetron/single injection/4 mg/IV
214410556|NCT01169805|DRUG|Ramosetron|Ramosetron HCl/single injection/0.3mg/IV
214410557|NCT01169805|DRUG|Palonosetron|Palonosetron HCl/single injection/0.075mg/IV
214410558|NCT01169805|DRUG|Normal saline inj|normal saline injection 2ml
214410559|NCT05881785|BIOLOGICAL|GR1501 low dose|3×low dose GR1501 every 2 weeks,then low dose GR1501 monthly
214410560|NCT05881785|BIOLOGICAL|GR1501 high dose|3×high dose GR1501 every 2 weeks,then high dose GR1501 monthly
214410561|NCT05881785|BIOLOGICAL|placebo|"* Core treatment period:placebo~* Maintenance treatment period: GR1501 injection"
214410562|NCT05541497|DRUG|Varenicline Tartrate|Days 1-3: 0.5mg study pill once per day, Days 4-7: 0.5mg study pill twice per day, Weeks 2-8: 1mg study pill twice per day
214410563|NCT05541497|DRUG|Placebo|Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
214410564|NCT04990674|BEHAVIORAL|REMOTION|REMOTION is an internet-based program focusing on emotion regulation and aimed at reducing patient symptom severity and improving emotion regulation. It consists of six modules and the structure is based on the extended process model of emotion regulation by Gross (2015). The intervention is currently being studied in an outpatient psychotherapy setting (Bielinski et al., 2020).
214410565|NCT04990674|BEHAVIORAL|TAU|Treatment as usual (TAU), refers to standard treatment in an acute inpatient care setting at the Universitäre Psychiatrische Dienste Bern. This treatment includes different standard inpatient psychiatric care components (integrative psychiatric care).
214410566|NCT00982254|DRUG|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
214410567|NCT00982254|DRUG|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
214410568|NCT03618095|DEVICE|LOTUS Edge Valve System|TAVR with the LOTUS Edge Valve System
214410569|NCT05798104|BEHAVIORAL|Collaborative nurse-pharmacist counseling|At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
214410570|NCT05300555|DRUG|Rivaroxaban 20 MG Oral Tablet|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
214410571|NCT05300555|DRUG|Warfarin|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
214688505|NCT02658994|BEHAVIORAL|Thinking Healthy Program Peer Delivered Plus|
214688506|NCT02658994|OTHER|Enhanced Usual Care|
214688507|NCT05966909|DIAGNOSTIC_TEST|Doppler Ultrasound|Ultrasound diagnosi of asymptomatic and symptomatic upper extremities vein thrombosis
214410572|NCT02552550|PROCEDURE|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
214410573|NCT00867347|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
214410574|NCT00867347|RADIATION|radiation therapy|Patients undergo radiotherapy
214410575|NCT04587479|DRUG|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
214410576|NCT05094284|DEVICE|BioFreedom Ultra|this is a registry only
214410577|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
214410578|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
214410579|NCT01286415|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
214410580|NCT01286415|BEHAVIORAL|Group Present Centered Therapy|Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
214410581|NCT02324114|DEVICE|Hsp90|Detect plasma Hsp90α concentration
214410582|NCT00606866|DRUG|placebo|Placebo for four weeks
214410583|NCT00606866|DRUG|Sorafenib|Sorafenib 200 mg twice daily
214410584|NCT00606866|DRUG|Sorafenib|Sorafenib, 400 mg twice daily
214410585|NCT04513028|DIETARY_SUPPLEMENT|Beta-Glucan|500mg (1 capsule) by mouth twice a day for 21 days.
214410586|NCT00587288|BIOLOGICAL|Reslizumab|
214410587|NCT00587288|OTHER|Saline|
214410588|NCT04702503|DRUG|WP1220|Topical administration 2x daily for 84 consecutive days
214410589|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample every 6 months for 1 year which is not part of health routine care
214410590|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample at baseline.
214410591|NCT06550193|DEVICE|Ultrasound-guided procedure using AR/VR technology|Participants will receive the intervention, which involves utilizing AR/VR technology during ultrasound-guided procedures (e.g., regional anesthesia, line placement). All participants will receive standard pre- and post-block or line care as they normally would for the ultrasound-guided procedure.
214410592|NCT00797862|DRUG|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
214410593|NCT00797862|DRUG|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
214410594|NCT00797862|DRUG|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
214410595|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
214410596|NCT00531479|DRUG|anidulafungin|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
214410597|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
214410598|NCT01898676|DRUG|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
214410599|NCT01898676|DRUG|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
214410600|NCT01743729|DRUG|Lifitegrast|Lifitegrast Ophthalmic Solution 5.0%
214410601|NCT01743729|DRUG|Placebo|Placebo for Lifitegrast Ophthalmic Solution 5.0%
214410602|NCT03910543|DRUG|Tofacitinib 5 mg twice daily|Tofacitinib will be administered at a dose of 5 mg twice daily
214410603|NCT04442984|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
214410604|NCT04442984|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
214410605|NCT04442984|DRUG|5-FU|d1-2 5-FU 2200 mg/m² every two weeks
214410606|NCT04442984|DRUG|5-FU|d1 5-FU 250 mg/m² every two weeks
214410607|NCT04442984|DRUG|Leucovorin|d1 Leucovorin 400 mg every two weeks
214410608|NCT04442984|DRUG|5-FU|d1 5-FU 400 mg/m² every two weeks
214410609|NCT04442984|DRUG|5-FU|d1-2 5-FU 2400 mg/m² every two weeks
214688508|NCT02056535|BEHAVIORAL|Brief Motivational Intervention|A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
214688509|NCT01013909|DRUG|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
214410610|NCT03742219|BEHAVIORAL|Lifestyle Modification|"1. Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~2. Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters."
214410611|NCT03136276|OTHER|IPS Empress CAD|standard etchable glass ceramics
214410612|NCT03136276|OTHER|polished Celtra Duo|new glass ceramic material
214410613|NCT03137914|BIOLOGICAL|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
214410614|NCT03137914|PROCEDURE|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
214410615|NCT05642000|BEHAVIORAL|SASEA HUB|SASEA HUB website, an intervention tool to increase COVID-19 testing
214410616|NCT03193346|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
214410617|NCT03193346|DRUG|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® \[Sodium chloride 0.9 mg\] IM injections in head/neck areas.
214410618|NCT02008864|DRUG|Senna|(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
214410619|NCT02008864|DRUG|Placebo|Placebo tablet/ 2 times per day
215100690|NCT03986528|DRUG|Kanglaite Injection+Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.
214410620|NCT00001129|DEVICE|Electronic Medication Reminder System|
214410621|NCT00001129|BEHAVIORAL|Medication Manager|
214410622|NCT06477926|DRUG|ABBV-668 IR|• Oral Capsule
214410623|NCT06477926|DRUG|ABBV-668 ER|• Oral Tablets
214410624|NCT00535977|DIETARY_SUPPLEMENT|Broccoli|400g ITC-enriched broccoli per week for 12 months
214410625|NCT00535977|DIETARY_SUPPLEMENT|Peas|400g frozen garden peas per week for 12 months
214410626|NCT05060614|PROCEDURE|Hip fracture surgery|Hip fracture surgery
214410627|NCT05753293|OTHER|breathing exercise|"Buteyko breathing technique developed to control hyperventilation and anxiety which leads to shortness of breath. It uses series of exercises to teach patients to breathe less deeply and less rapidly /Bhastrika Bellow Breathing is diaphragmatic breathing - deep breathing involving the diaphragm rather than the accessory muscles. Regulated pranayama exercises require inhalation, maintaining isometric contraction of respiratory muscles and forceful expiration. These techniques will strengthen respiratory muscles"
214410628|NCT01693094|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
214410629|NCT04167709|OTHER|Education in clinical competence in detecting signs of postpartum depression in immigrant mothers|Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
214410630|NCT06630403|OTHER|Demographic Data|Demographic data (age, height, weight, BMI) will be collected verbally through an assessment form.
214410631|NCT06630403|OTHER|Disease History|The number of exacerbations in the last 1 year, hospitalization and medications used will be questioned.
214410632|NCT06630403|OTHER|Pulmonary Function Test|Pulmonary Function Test will be performed with a spirometer.
214410633|NCT06630403|OTHER|Reaction Time|Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.
214410634|NCT06630403|OTHER|Functional Capacity|Functional capacity will be evaluated with 6 minute walk test
214410635|NCT06630403|OTHER|Dyspnea Perception|Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea
214410636|NCT06630403|OTHER|Quality of Life|"Quality of life will be assessed with the Quality of Life Scale for Children\&#34;"
214410637|NCT06630403|OTHER|Fear of movement|Fear of movement will be evaluated with Tampa Kinesiophobia Scale
214410638|NCT06630403|OTHER|Ability of Motor Imagery|Motor Imagery ability will be assessed by Movement Imagery Questionnaire-3 and Vividness of Movement Imagery
214410639|NCT06630403|OTHER|Cognitive Functions|Cognitive functions will be assessed with Trail Making Test and Stroop Test
214410640|NCT06628817|RADIATION|The Intensive Care Bundle with Mortality Reduction|a continuous automated medical quality monitoring and feedback system on the online platform, self-feedback and teamwork based on video conferencing, multidisciplinary online education, offline on-site supervision, and standardized intervention in the behavior of medical actors in the process of stroke treatment.
214410641|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation according to body weight every other day
214410642|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation dose according to body weight daily
214410643|NCT06631612|DRUG|Albendazole.|both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week
214410644|NCT00713739|DRUG|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
214410645|NCT00713739|DRUG|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
214410646|NCT00713739|DRUG|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
214410647|NCT00713739|DRUG|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
214410648|NCT02653079|OTHER|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
214410649|NCT02222415|DIETARY_SUPPLEMENT|Exercise + Protein drink|
214410650|NCT05120440|OTHER|Breakfast omission|Breakfast omission will consist of not eating breakfast on the morning of afternoon resistance training performance assessment.
214410651|NCT05120440|OTHER|Breakfast consumption|Breakfast consumption will consist of eating a standardized breakfast on the morning of afternoon resistance training performance assessment.
214410652|NCT05070104|DRUG|CPI-613|250-1000mg/m2 -14 day cycle
214410653|NCT05070104|DRUG|modified FFX|Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
214410654|NCT05070104|DRUG|Bevacizumab|5mg/kg IV
214688510|NCT01013909|DRUG|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
214688511|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
214688512|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
214688513|NCT01013909|DRUG|Lamisil Once|One application of Lamisil Once
215015042|NCT05463705|BEHAVIORAL|Intervention to address diffusion of responsibility + simplification of prescribing|"PCPs will receive the same contact addressing diffusion of responsibility as in the Intervention to address diffusion of responsibility arm, but will additionally have access to an experienced administrative team for diabetes medication insurance authorization support, by routing their clinic note through the EHR. PCPs will be informed, suing the same email outreach, how to access the administrative team, which consists of medical and administrative assistants and currently supports prescribing within the endocrinology division. The team will follow up with the pharmacy to determine coverage, complete prior authorizations, determine alternate covered options, and track progress."
215015043|NCT05548777|DRUG|Andexanet alfa|Andexanet alfa
215015044|NCT05548777|DRUG|4F-PCC|Four-Factor Prothrombin Complex Concentrate (4F-PCC)
215015045|NCT02583061|OTHER|There is no intervention. An exposure of interest is glucose tolerance status in pregnancy|
215015046|NCT06567873|OTHER|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
215015047|NCT05618613|DRUG|Elacestrant|Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.
215015048|NCT05618613|DRUG|Onapristone|Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.
215015049|NCT05574764|BEHAVIORAL|Cultivating Awareness and Resilience in Education (CARE)|CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.
215015050|NCT03442465|BEHAVIORAL|Toronto Extremity Salvage Score|Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.
215015051|NCT03442465|BEHAVIORAL|Musculoskeletal Tumor Society Score|Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.
214410655|NCT04300933|BEHAVIORAL|Electroencephalogram-based neurofeedback|In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.
215015052|NCT03442465|BEHAVIORAL|Timed Get Up and Go Test|Validated functional measurement, for lower extremities only. The patient is observed and timed while s/he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The test predicts the patient's ability to go outside alone safely and quantifies functional mobility. The test requires no special equipment and will take less than one minute to complete.
215015053|NCT03442465|DIAGNOSTIC_TEST|Orthogonal Radiographs|The distance of bone transport is measured, accounting for calibration of the radiographs. The presence of bone regenerate between the transported segment is determined by the presence of continuous calcified callus from the proximal segment to the distal segment. Each of the orthogonal radiographs is used to visualize two cortices: the AP radiographs visualizes the medial and lateral cortices and the lateral radiograph measures the anterior and posterior cortices. Each continuous calcified cortex is counted with a range from 0 to 4 cortices intact.
215015054|NCT03442465|DIAGNOSTIC_TEST|Weight Bearing for lower extremities only|As part of the current standard of care, patients are asked to stand on a scale with the affected lower extremity on the scale and the unaffected extremity on a block which is level with the scale. The patient is asked to place as much weight as possible on the affected extremity and this weight Is recorded. Each patient's total weight is then measured and the percent of weight bearing is calculated as the amount of weight bearing over the total body weight.
215015055|NCT03442465|DIAGNOSTIC_TEST|Range of Motion|As part of the current standard of care, the joints of the affected extremity are assessed for passive range of motion at each follow up visit by the clinician. If surgery is on the femur, the hip and knee joints are assessed for range of motion. Whereas for the tibia, the knee and ankle joints are assessed. These assessments would be measured using a goniometer placed alongside the extremity and recorded for each direction of movement. Hip range of motion includes flexion, extension, abduction, internal rotation and external rotation. Knee range of motion includes flexion and extension. Ankle range of motion includes dorsiflexion and plantarflexion.
215100691|NCT03986528|DRUG|Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
215100692|NCT04435028|DRUG|Ketotifen 1 MG|Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months
214410656|NCT00432653|DRUG|rituximab|
214410657|NCT05914558|DIAGNOSTIC_TEST|Clinical appointment|One clinical interview and examination to confirm the diagnosis of trigeminal neuralgia and temporomandibular disorder.
214410658|NCT06313723|OTHER|Prenatal education management delivered via podcast|Pregnant women assigned to the intervention group (52) will be listened to podcasts on a Samsung Galaxy J7 Prime brand phone while undergoing a 20-minute NST procedure
214410659|NCT00887640|DRUG|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
215100693|NCT06583915|PROCEDURE|TENS|Non-pharmacological method which is widely used by medical and paramedical professionals for the management of acute and chronic pain using electric pulse generator, lead wires and electrodes.
214410660|NCT00887640|DRUG|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
214410661|NCT01711047|PROCEDURE|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
214410662|NCT01711047|PROCEDURE|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
214410663|NCT02909439|DRUG|Sugammadex|Sugammadex will be given for reversal of neuromuscular blockade.
214410664|NCT02909439|DRUG|Neostigmine|Neostigmine will be given for reversal of neuromuscular blockade.
214410665|NCT03127358|DEVICE|AiCure|Smartphone App
214410666|NCT03127358|DEVICE|AiCure with gamification|Smartphone App with gaming.
214688514|NCT03363243|OTHER|STOP Therapy Treatment group|Testing of the STOP Therapy protocol
214688515|NCT03363243|OTHER|Treatment as usual (TAU) group|Treatment as usual in the community through group therapy
214688516|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg|Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
214688517|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Placebo (tablet)|Selective serotonin reuptake inhibitor (SSRI) + placebo
215015056|NCT03767231|DIAGNOSTIC_TEST|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|The investigators will randomly assign eligible and consented patients to either to HCV POC VL Group or Reference Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the HCV POC VL Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 1 to 1½ hours of the testing.
215015057|NCT05432960|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
215015058|NCT05432960|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution)
215015059|NCT05783960|OTHER|administration questionary|Questionnaire will be compared to 24h sodium and potassium urinary excretion (reference). A Bayesian network and a multiple regression will be used to validate the questionary
215015060|NCT04702672|DIETARY_SUPPLEMENT|100% wheat (control)|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
215015061|NCT04702672|DIETARY_SUPPLEMENT|100% Lean-baking barley®|"Intake of 250 ml of tap water and 100 g of bread baked with 100% Lean-baking barley® flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flou"
215015062|NCT04702672|DIETARY_SUPPLEMENT|100% regular barley|"Intake of 250 ml of tap water and 100 g of bread baked with 100% regular barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
215015063|NCT05233917|DIETARY_SUPPLEMENT|Olive oil use|Olive oil, 25-30g/d by day for 6 month
215015064|NCT05233917|DIETARY_SUPPLEMENT|MLCT oil use|MLCT oil, 25-30g/d by day for 6 month
215015065|NCT04072432|DRUG|RBT-3|intravenous administration
215015066|NCT06512727|BEHAVIORAL|PROACTIVE Intervention|Duration: Once-weekly face-to-face sessions Session Time: 1.5-2 hours Intervention: (1) culturally congruent self-management (SM) education and + SM resource toolkit, (3) active prayer support, and (3) financial counseling/insurance navigation Reinforcement: daily ecological momentary intervention support using Apple smartwatches
215100694|NCT06583915|PROCEDURE|Dry Needle|Invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.
215100695|NCT01041287|DRUG|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is \>125/80 for the remaining 8 weeks
215100696|NCT01041287|DRUG|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is \>125/80 for the remaining 8 weeks
215100697|NCT04087577|OTHER|conventional physical therapy|includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
215100698|NCT04087577|OTHER|mirror therapy|mirror therapy
215100699|NCT00305539|DRUG|adalimumab|40 mg sc / for 3 months
215100700|NCT00305539|DRUG|placebo|placebo
215100701|NCT00119366|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
215100702|NCT00119366|DRUG|fludarabine phosphate|Given IV
215015067|NCT04460794|BEHAVIORAL|Ballet-inspired workouts|8 weeks, delivered by volunteers with a self-directed resource package
215015068|NCT04460794|OTHER|Usual care|Usual care and general recommendations on basic stretching and leg exercises for stroke survivors
215015069|NCT05290818|DEVICE|MAKO™ Partial Knee Arthroplasty|The robotic-arm will be used to position a partial knee arthroplasty.
215015070|NCT05290818|DEVICE|Triathlon (Stryker) Total Knee Arthroplasty|Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert.
215015071|NCT03445845|DRUG|Secukinumab|Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
215015072|NCT03445845|DRUG|TNF blocker|"TNF blocker (originator or biosimilar) :~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (\>100kg) an inadequate response, 100mg every month is allow."
215015073|NCT03445845|BIOLOGICAL|blood specimen|Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
215100703|NCT00119366|RADIATION|total-body irradiation|Undergo TBI
215100704|NCT00119366|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
215100705|NCT00119366|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
215100706|NCT00119366|DRUG|cyclosporine|Given IV or PO
215100707|NCT00119366|DRUG|mycophenolate mofetil|Given PO
215100708|NCT00119366|OTHER|laboratory biomarker analysis|Correlative studies
215100709|NCT01438450|DRUG|Oral|"Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week"
215100710|NCT01438450|OTHER|Supportive|No specific therapy will be given
214410667|NCT03347045|COMBINATION_PRODUCT|Trimodal Prehab & ERP|"1-hr daily exercise will be completed a total of 5d/week, of which 2 of these sessions are completed through a community fitness center. Following these sessions, the participant will consume a high-protein oral supplement.~Additionally, during the program, participants will be given the option of attending a stress-reduction group and will receive a take-home anxiety-reduction program. They will have access to a physiotherapist, kinesiologist, registered dietitian, and physician throughout the program.~The total length of this program is 8-weeks and is timed to occur in the waiting period between the consent for surgery and operation date."
214410668|NCT03347045|OTHER|No Prehab; ERP Alone|1-hr daily exercise with a self-completed home-exercise program. The participant will be given nutritional education material and a take-home anxiety-reduction program. They will be responsible for maintaining a journal of their activity.
214410669|NCT00409708|DRUG|Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|
215015074|NCT04705337|DRUG|Levosimendan|administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
214410670|NCT00409708|BEHAVIORAL|Behavior Therapy|
214410671|NCT00208104|BEHAVIORAL|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
214410672|NCT05809076|DEVICE|real tACS|tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.
214410673|NCT05809076|DEVICE|sham tACS|In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
215015075|NCT04705337|OTHER|Placebo|administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
215015076|NCT06962085|PROCEDURE|sacral erector spinae plane block group|In the block group, bilateral sacral erector spinae plane block (10 mL 0.25% bupivacaine (Marcaine %0,5. AstraZeneca Ltd, İstanbul, Türkiye) + 5 mL 1% lidocaine (Lidon 100 mg/ 5mL. ONFARMA İlaç San. Ve Tic. A.Ş, Ankara, Türkiye) will be performed in the lateral position with the help of ultrasound before surgery.
215015077|NCT06962085|DRUG|Opioid Analgesics|Sacral arrector spine block will not be performed in this group. After general anesthesia, hemodynamic values (noninvasive blood pressure, heart rate, peripheral oxygen saturation) and total remifentanil (Rentanil 2 mg. VEM İlaç San. Ve Tic. A.Ş, İstanbul, Türkiye) use will be recorded during the operation. Additionally, numerical pain scores and total meperidine (Aldine 100mg/2mL. VEM İlaç San. Ve Tic. A.Ş, İstanbul, Türkiye) use at 0, 2, 4, 6, 12 and 24 hours after the operation will be recorded. At the 24th hour, the Turkish version of the Quality of Recovery-15 (QoR-15T) Questionnaire will be filled out and recorded.
215015078|NCT06961513|OTHER|Women's health physiotherapy|Women's health physiotherapy for pelvic-floor dysfunction
215015079|NCT04717908|DRUG|Bedaquiline|400 mg once daily for 2 weeks then 200mg 3 times per week;
215015080|NCT04717908|DRUG|Pyrazinamide|1500 mg daily
215015081|NCT04717908|DRUG|Linezolid|600 mg daily
215015082|NCT04717908|DRUG|Cycloserine|≤50kg 500 mg daily, \>50kg 750mg daily;
215015083|NCT04717908|DRUG|Clofazimine|100 mg daily;
215015084|NCT01744418|DEVICE|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
214410674|NCT05908799|DRUG|Pembrolizumab + Pemetrexed-Platinum|Medication records in EHR database used to define exposure group
214410675|NCT05908799|DRUG|Pemetrexed-Platinum|Medication records in EHR database used to define comparator group
214410676|NCT06067178|BEHAVIORAL|Health Dialogue Intervention|"1. Lifestyle assessment: All participants fill out a questionnaire to assess behavioral risk factors for CVD and undergo blood tests for cholesterol and blood glucose.~2. Lifestyle health dialogue: When presenting in person at the primary care center, blood pressure, BMI, and waist-hip ratio will be measured. The results from the questionnaire, blood tests, blood pressure, and body measurements will be summarized using a visual tool, in which risk factors are graded into risk levels to estimate CVD risk. The visual tool will then be used in the health dialogue to discuss risk factors. The health dialogue is conducted by a licensed healthcare professional who has been trained in the methodology. The dialogue will be conducted in a person-centered manner and will aim to motivate and support lifestyle behavior changes when needed. If necessary, medical treatment will be provided according to existing guidelines."
214410677|NCT06067178|OTHER|Opportunistic Screening|"1. Risk factor assessment: Opportunistic screening entails screening for risk factors (blood pressure, BMI, blood tests for cholesterol and blood glucose, and smoking) among patients visiting the primary care center for another reason. Screening is conducted by a healthcare professional at which the patient has an appointment.~2. Detected risk factors for CVD are treated according to the existing care programs and guidelines at the primary care center, which should always include lifestyle advice as the first intervention and medication if hypertension is established. In this intervention, there is a more limited assessment of behavioral risk factors; that is, patients are asked about smoking, but assessment of diet, physical activity, or alcohol consumption is not included in the opportunistic screening."
214410678|NCT04899284|OTHER|Early Intensive Bimanual Stimulation|Early intensive bimanual stimulation program for infants showing early signs of UCP, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.
214410679|NCT00785772|DRUG|Gabapentin|100-200mg once a day
214410680|NCT00785772|DRUG|Gabapentin|200-500mg once a day
214410681|NCT00785772|DRUG|Gabapentin|400-1000mg (200-500 mg twice a day)
214410682|NCT04632368|BEHAVIORAL|Transcendental Meditation|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
214410683|NCT00328523|DRUG|MK-0653, ezetimibe|
214410684|NCT00328523|DRUG|Duration of Treatment: 3 months|
214410685|NCT04618458|BEHAVIORAL|Power to Prevent|Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
214410686|NCT00202358|DRUG|atenolol|
214410687|NCT00202358|DRUG|placebo|
214410688|NCT06431035|DIETARY_SUPPLEMENT|caffeine|The participants chewed either caffeine gum (5 mg/kg for 10 minutes per chew) or a placebo (10 minutes per chew, using regular gum).
214410689|NCT04338165|DRUG|Evolocumab 140 MG/ML [Repatha]|3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
214410690|NCT04477538|OTHER|Post-mastectomy breast reconstruction physical well-being survey|-The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.
214410691|NCT06037187|DIAGNOSTIC_TEST|Blood Draw|Standard coagulation assays (aPTT, INR, ACT), viscoelastic coagulation profiles (rotational thromboelastometry (ROTEM)/thromboelastography (TEG), tPA-challenged ROTEM/TEG), and molecular profiling
214410692|NCT01287052|DRUG|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
214410693|NCT00328393|DRUG|Pioglitazone|45 mg 8 weeks
214410694|NCT00328393|DRUG|Placebo|Placebo
214410695|NCT04653350|OTHER|High Intensity Exercises|Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
214410696|NCT04653350|OTHER|General Exercises|Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training \& balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
214410697|NCT01606384|DRUG|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
214410698|NCT01606384|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
214410699|NCT05925712|DEVICE|AeroFit Seal-In Liner / Socket|Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.
214410700|NCT05925712|DEVICE|Seal-In Silicone Liner|Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
214410701|NCT04622527|OTHER|Random assigned paradigm viewing order|Participants experience the paradigm in a random order
214410702|NCT05471167|BIOLOGICAL|BCG|Exposure is defined as having received the BCG vaccine during the first year of life.
215015085|NCT05220930|OTHER|Foot bath for heel warming|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap.
215015086|NCT05220930|OTHER|Ineffective heel warming with thermofor|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
215015087|NCT05927298|OTHER|Non-interventional|Standard of care intervention
215015088|NCT02822755|OTHER|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
214410703|NCT03872297|DIETARY_SUPPLEMENT|Placebo supplement|"Consumption of a non active food complement during 3 months.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
214410704|NCT03872297|DIETARY_SUPPLEMENT|Naticol supplement|"Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
214410705|NCT01306669|BIOLOGICAL|Trivalent influenza vaccine|single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
214410706|NCT01306669|BIOLOGICAL|Normal saline|Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
214410707|NCT00697892|DRUG|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
214410708|NCT00697892|DRUG|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
214410709|NCT00697892|DRUG|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
214410710|NCT02007083|PROCEDURE|Bilateral laminotomy (BL)|
214410711|NCT02007083|PROCEDURE|Unilateral laminotomy with crossover (UL)|
214410712|NCT02007083|PROCEDURE|Spinous Process Osteotomy (SPO)|
214410713|NCT03908047|OTHER|magnetic resonance imaging|functional magnetic resonance imaging and diffusion tensor imaging after tibialis nerve stimulation
214410714|NCT05270824|COMBINATION_PRODUCT|radical surgery after neoadjuvant immunotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
214410715|NCT05270824|COMBINATION_PRODUCT|radical surgery after neoadjuvant chemotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
214410716|NCT01159158|DRUG|Nateglinide|Nateglinide Tablets 120 mg
214410717|NCT03211598|PROCEDURE|TACE with Surefire|Subjects that consent to the study will receive their TACE procedure through the Surefire Infusion System
214410718|NCT00472147|PROCEDURE|shock efficacy|
214410719|NCT04510337|DRUG|standard rocuronium dose|0.6 mg/kg rocuronium during induction of anesthesia
214410720|NCT04510337|DRUG|Magnesium sulfate|50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium
215015089|NCT01530997|RADIATION|Intensity Modulated Radiotherapy (IMRT)|All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
215015090|NCT01530997|DRUG|Cisplatin|Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
215015091|NCT01530997|PROCEDURE|Limited surgical evaluation|4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
215015092|NCT05156242|DEVICE|Active-tDCS priming MCE|tDCS is used to enhance cortical excitability before motor control exercises.
215015093|NCT05156242|DEVICE|Sham-tDCS priming MCE|tDCS will be set at 0 mA for 20 minutes before motor control exercise.
215015094|NCT05156242|DEVICE|NMES priming MCE|NMES is used to enhance lumbar multifidus motor unit recruitment before motor control exercise.
214410721|NCT06080958|DEVICE|NPWT|the NPWT dressing applied to fasciocutaneous flap
214410722|NCT06080958|OTHER|Conventional dressing|Conventional dressing ( topical care ) applied to fasciocutaneous flap
214410723|NCT04236713|OTHER|Dietary intervention 1|Limiting dietary exposure to ethylenediaminetetraacetic acid, erythorbate, propionate and related food additives; limiting eating out to a maximum of 2 days per week.
215100711|NCT05490940|DRUG|Tisseel®|"The investigational medical product (IMP) in this study is Tisseel®, which is a tissue sealer consisting of two components:~1. Sealer protein: Human fibrinogen as glue component and synthetic Aprotinin, which delays fibrinolysis.~2. Human thrombin: Thrombin is an unique molecule that functions both as a procoagulant and anticoagulant. It activates platelets through its receptor on the platelets and regulates its own. generation by activating coagulation factors V, VIII and even XI resulting in a burst of thrombin formation.~Its indications are a better hemostasis, enforcement of vessel/gastrointestinal sutures and tissue sutures (mesh grafts, flaps etc)."
215100712|NCT01716741|OTHER|Enzyme analysis|
214410724|NCT04236713|OTHER|Dietary intervention 2|Limiting dietary exposure to nitrites, sulfites and related food additives; limiting eating out to a maximum of 2 days per week; limiting drinking wine to a maximum of 2 days per week.
214410725|NCT05085184|DRUG|administration of UI018|Test
214410726|NCT05085184|DRUG|co-administration of UIC201806 and UIC201602|Reference
214410727|NCT01809379|DRUG|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
214410728|NCT02485964|OTHER|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
214410729|NCT04164628|OTHER|Quality of life assessment|Quality of life will be assessed with Nottingham Health Profile
214410730|NCT01474538|DRUG|Insulin Lispro|Insulin lispro (100 U/mL) administered by CSII pump
214410731|NCT01474538|DRUG|Insulin Aspart|Insulin aspart (100 U/mL) administered by CSII pump
214410732|NCT06282835|DRUG|Eravacycline Injection|Eravacycline at the recommended dose and administration method according to the instructions: 1 mg/kg intravenous administration, every 12 hours. The intravenous infusion duration is approximately 60 minutes. For patients with severe liver impairment (Child-Pugh class C), administer 1 mg/kg of this product every 12 hours on the first day, followed by 1 mg/kg every 24 hours starting from the second day.
214410733|NCT05165290|DRUG|Latanoprost ophthalmic solution, 0.005%|Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control
214410734|NCT05165290|DRUG|TC-002 latanoprost ophthalmic solution, 0.005%|TC-002 is formulated using the commercially available latanoprost drug substance; delivered drop to the eye is preservative-free.
215100713|NCT00487071|DEVICE|Anal fistula plug|
215100714|NCT00674414|BIOLOGICAL|trastuzumab|Trastuzumab (Herceptin®) IV once weekly
215100715|NCT00674414|DRUG|everolimus|Oral everolimus once daily
214410735|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment|Compound level meeting
214410736|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
214410737|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
214410738|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
214410739|NCT02055482|DRUG|Molidustat (BAY85-3934)|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
214410740|NCT02055482|BIOLOGICAL|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
214410741|NCT00009685|DRUG|VRC4302|
214410742|NCT01456780|DRUG|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
215015095|NCT05156242|OTHER|Conventional physical therapy|Conventional physical therapy includes modality for pain control, general exercise to improve muscle strength, endurance, and flexibility, and functional training (sit to stand, walking, etc.).
215015096|NCT03075631|OTHER|Questionnaire|Questionnaires
215015097|NCT04089085|BEHAVIORAL|STRONGer Together|STRONGer (Successes/Strengths, Triggers, Remember your medications, Ongoing communication, Never give up!, Gratitude) Together is an asthma educational and cognitive behavioral skills intervention for children between 8 - 12 years of age. The intervention is implemented in small groups in 30-minute sessions.
215015098|NCT05274035|DRUG|Perampanel|"For children ≥4 years old, the initial dose is 2 mg per day, the titration interval is ≥2 weeks, the daily dose is increased by 2 mg each time (based on clinical response and tolerability), and the maintenance dose is ≥4 mg per day, up to a maximum dose of 12 mg per day.~For children \<4 years old, the initial dose is 0.04 mg/kg per day, the titration interval is ≥ 2 weeks, the daily dose is increased by 0.04 mg/kg each time (based on clinical response and tolerability), and the maintenance dose is ≥ 0.08 mg/day per day kg, the highest dose is 0.24 mg/kg per day.~According to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
215015099|NCT04769778|DRUG|Valsartan 80Mg Oral Tablet|treatment with 80mg /day of valsartan
215100716|NCT00674414|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
215100717|NCT05242172|DIAGNOSTIC_TEST|CRP/Albumin ratio|it is aimed to investigate prognosis and severity of covid-19 infection with using CRP/Albumin ratio in pregnant patient
215100718|NCT06537947|PROCEDURE|Endovascular intervention using the SENTANTE endovascular robotic system|"1. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography.~2. Percutaneous transluminal angioplasty (PTA)/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure.~3. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel."
215100719|NCT01318837|DRUG|solifenacin|oral
215100720|NCT05582174|DRUG|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
215100721|NCT05582174|DRUG|esomeprazole|A high dose PPI infusion (esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours), and frorm day 4-30 oral esomeprazole daily
215100722|NCT01673620|DRUG|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
215100723|NCT01673620|DRUG|Placebo|Matching placebo tablet administered once daily
215100724|NCT02643238|DEVICE|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
215100725|NCT03887273|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
215100726|NCT02693041|DRUG|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
214410743|NCT01456780|DRUG|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
214410744|NCT01456780|DRUG|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
214410745|NCT03645174|DEVICE|Using long tube|Fiberoptic-guided intubation through LMA, using long tube
214410746|NCT03645174|DEVICE|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
214410747|NCT03298932|PROCEDURE|Aortic valve surgery|Aortic valve surgery
214410748|NCT04285996|PROCEDURE|PET Scan|
214410749|NCT03095911|OTHER|News items with spin|Interpretation of news items with spin
214410750|NCT03095911|OTHER|News items without spin|Interpretation of news items without spin
214410751|NCT00782041|DRUG|Oxaliplatin|85 mg/m²
214410752|NCT00782041|DRUG|5-FluoroUracil|2,000 mg/m²
214410753|NCT00782041|DRUG|Folinic acid|20 mg/m²
214410754|NCT06268028|BEHAVIORAL|Training|Discharge training
214688518|NCT00441441|DRUG|fluticasone propionate|fluticasone propionate 100mcg HFA
214410755|NCT01151254|DRUG|Isoflurane/sevoflurane|Volatile for sedation in the CVICU while intubated
214410756|NCT01151254|OTHER|Propofol|Propofol for sedation in the CVICU
214410757|NCT04372992|OTHER|Timing of stoma closure|Defining the best timing of stoma closure in relation to adjuvant therapy compliance
214410758|NCT01601314|DRUG|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
214688519|NCT00441441|DRUG|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
215015100|NCT02470871|BIOLOGICAL|Eptacog alfa (activated) or pdFVII|"Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study."
215015101|NCT02470871|BIOLOGICAL|CSL689|Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
215100727|NCT02693041|DRUG|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
215100728|NCT04137185|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection|rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.
214410759|NCT01601314|OTHER|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
215100729|NCT00610311|DRUG|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
215100730|NCT00610311|DRUG|fludarabine phosphate|25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
214410760|NCT03392662|DEVICE|Hemopatch|Patients received product at the discretion of their surgeon.
215100731|NCT00610311|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.
214410761|NCT06435572|OTHER|Suction|Each patient will be evaluated as both the experimental and control group. In the study, open suction applied to the patient will be evaluated as control, and closed suction will be considered as the experimental group. The first suction of the same patient during the day will be done as open suction, and the second suction will be done as closed suction.
214410762|NCT02416674|PROCEDURE|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
214410763|NCT02416674|DRUG|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
214410764|NCT02501629|DRUG|Reslizumab|Reslizumab 110 mg was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
214410765|NCT02501629|DRUG|Placebo|Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
214410766|NCT02501629|DRUG|Non-Oral Corticosteroid (non-OCS) Asthma Medication|Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
214410767|NCT02501629|DRUG|Oral Corticosteroid (OCS)|After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
214410768|NCT01501929|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
214410769|NCT01501929|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
214410770|NCT01501929|PROCEDURE|Non-invasive measurement of Cardiac Output (CO)|Cardiac Output (CO) will be measured non-invasively at rest and during exercise by thoracic electrical bioimpedance. Stroke volume will be derived from change in impedance/time measured during electrical systole. Cardiac output will be determined as the product of stroke volume and heart rate.
215100732|NCT00610311|BIOLOGICAL|ALVAC gp100 Vaccine|0.5 ml containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2mL)
215100733|NCT00610311|BIOLOGICAL|anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)|3 x 10\^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10\^8 cells will be given.
214410771|NCT01501929|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
215015102|NCT05555693|OTHER|Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
215100734|NCT04705246|BEHAVIORAL|Psychoeducation|The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
215100735|NCT05706571|OTHER|control group (skill laboratory), experimental group 1 (Banner model) and experimental group2 (augmented reality mobile application)|In the research, the control group will form the control group of both experiment one and experiment two. In the creation of quantitative and qualitative data, it will be formed in three groups, two of which are the experimental group and one is the control group. While forming the experimental and control groups of the research, it is planned to ensure homogeneity between the groups by making random and unbiased selection. It is planned to do a pre-test before applying the child patient end-of-life care module of nursing students of teaching with augmented reality and Benner model to the experimental and control groups.
215100736|NCT04729335|DIAGNOSTIC_TEST|phonocardiac spectrometry|Detection and application of organic disease with phonocardiac spectrometry
214410772|NCT01501929|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
214410773|NCT02004613|DRUG|Dexmedetomidine|Dexmedetomidine
214410774|NCT02004613|DRUG|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
214410775|NCT03007459|OTHER|Psychological health|Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
214410776|NCT03007459|OTHER|Physiological health|Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
214410777|NCT02214667|BEHAVIORAL|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
214410778|NCT02214667|BEHAVIORAL|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
214410779|NCT02214667|BEHAVIORAL|Jail and community-based behavioral health services|Existing behavioral health service programs
214410780|NCT00666120|OTHER|Enfamil LIPIL with iron|cow's milk based infant formula
214410781|NCT00666120|OTHER|Good Start Supreme with DHA and ARA|partially hydrolzed cow's milk protein
214410782|NCT02873884|BEHAVIORAL|Case-management|
214410783|NCT00354094|DRUG|[S,S]-Reboxetine|
214410784|NCT03239925|RADIATION|Electromagnetic field of cell phone in ''on'' mode.|In experimental group, participants would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
214410785|NCT03239925|RADIATION|Electromagnetic field of cell phone in 'off' mode.|In control group, participants would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode.
214410786|NCT00868231|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
214410787|NCT00868231|DRUG|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
214410788|NCT00868231|DRUG|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
215015103|NCT04702139|DEVICE|shoulder arthroplastis|\- Group (Treatment): Placement of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
214410789|NCT00004209|DRUG|cisplatin|
214410790|NCT00004209|DRUG|mitomycin C|
214410791|NCT00004209|DRUG|vinblastine sulfate|
214410792|NCT00971009|BEHAVIORAL|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
214410793|NCT00971009|BEHAVIORAL|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
214410794|NCT02359838|OTHER|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
214410795|NCT02359838|OTHER|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
214410796|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
214410797|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
214410798|NCT05507281|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|ultrasound-guided ipsilateral Erector Spinae Plane Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
214410799|NCT05507281|PROCEDURE|Retrolaminar Block|ultrasound-guided ipsilateral Retrolaminar Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
214410800|NCT05507281|PROCEDURE|Control|General anesthesia
214410801|NCT05602857|OTHER|Balance Training|"The BT program has multiple difficulty levels, and each child will progress at an individual pace tailored to their balance skills. Training sessions will emphasize top-down control of balance and contain a combination of dynamic and static balance exercises. Children and their parents will receive written step-by-step instructions, with photos, verbal and/or video instructions on their private OneDrive folder.~To monitor compliance, whether the exercises were done properly, and evaluate a child's progress, the parent/guardian will film the sessions, and upload the video to OneDrive, so we can score the child's performance and provide them with a progress tracking chart.~Every child will be given the equipment needed to do the balance exercises: two wooden beams that will make a 12-foot balance beam, four small wooden cubes that will raise the balance beam 5 inches off the ground, a wobble board, a hopscotch mat, one roll of painter's tape, one measuring tape, a bell, a small book."
214688520|NCT05271019|DEVICE|Threshold load device|"Inspiratory Muscle Training (IMT) for 3 months:~Though a threshold loading device (5 sets of 6 repetitions, 1session/day, 5 days/week). the inspiratory load will start at 30% of MIP, or up to the maximum patient-tolerable load (max 60% of MIP), no more than 3-5/10 on the modified Borg scale."
214688521|NCT00262080|DRUG|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
215015104|NCT04702139|DEVICE|shoulder arthroplastis|\- Group (Control): Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
215100737|NCT04156035|DRUG|Lamotrigine|Orally; 300 mg
215015105|NCT00965991|DRUG|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
215015106|NCT00965991|DRUG|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
215100738|NCT04156035|DRUG|Ketamine|Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min
215100739|NCT04156035|DRUG|Placebo Pretreatment|Lamotrigine Placebo
215100740|NCT04156035|DRUG|Placebo Infusion|Ketamine Placebo
215100741|NCT01756118|DRUG|BEZ235|A minimum of 3 dose levels
215100742|NCT03765203|DIAGNOSTIC_TEST|Natera KidneyScan|Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
215100743|NCT03765203|OTHER|Clinical Performance and Value Vignettes|Online renal allograft simulated patients
215100744|NCT01085370|OTHER|Early psychological intervention|3 modules: psychoeducation, reconstruction of the trauma, coping skills
215100745|NCT05432401|BIOLOGICAL|T cell injection targeting FLT3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10\^8, 2.0 × 10\^8 and 4.0 × 10\^8 CAR-T groups in order of sequence. And the subjects will be administered once.
215100746|NCT01597635|DRUG|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
215100747|NCT01597635|DRUG|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
215100748|NCT01597635|DRUG|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
215100749|NCT01597635|DRUG|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
215100750|NCT01597635|DRUG|Placebo (saline)|Administered intravenously to match intervention
214688522|NCT00262080|DRUG|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
215015107|NCT05573009|BEHAVIORAL|cognitive behavioral approach-based stress reduction program|"Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~Session main topics are:~Session 1 - Introducing the purpose and content of the program - Stress Psychoeducation Session 2 - Cognitive restructuring Session 3 -Behavioral coping Session 4 - Problem solving training Session 5-Upcoming parenthood"
215015108|NCT03776786|BIOLOGICAL|TY014|TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)
215015109|NCT03776786|OTHER|0.9% Saline|Placebo
215015110|NCT02181738|DRUG|Nivolumab|Specified dose on specified days
215015111|NCT02181738|DRUG|Doxorubicin|Specified dose on specified days
215015112|NCT02181738|DRUG|Vinblastine|Specified dose on specified days
215100751|NCT02624427|DEVICE|Measurement of intraocular pressure (IOP)|Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
215100752|NCT03981068|RADIATION|Re-irradiation|Cisplatin for all eligible patients, nimorazole for all SCC
215100753|NCT00966212|BEHAVIORAL|parent education|Especially for Daughters audio-cd parent education
215015113|NCT02181738|DRUG|Dacarbazine|Specified dose on specified days
215100754|NCT01162811|BEHAVIORAL|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
215100755|NCT06106919|OTHER|surveys (Fertiqol and WHOQOL-BREF)|surveys (Fertiqol and WHOQOL-BREF)
215100756|NCT04533867|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape
215100757|NCT04533867|DRUG|Palonosetron 1mcg/kg|Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
215100758|NCT04533867|DRUG|Ondansetron 1 mg/kg, max dose 8 mg|Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
215015114|NCT02689479|PROCEDURE|Positron-Emission Tomography|Dynamic scanning is performed for 60 minutes. Image acquisition is performed in 3D and reconstructed using an iterative OSEM VUEPOINT algorithm
215100759|NCT01916343|PROCEDURE|Study Laparoscopic Curriculum|
215100760|NCT03956212|DRUG|Doxycycline 7 days|Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
214410802|NCT05602857|OTHER|Music Training|"Children assigned to MT will be asked what kind of music and what performers they like best, and what songs they like most. After those open-ended questions, they will be asked about specific songs, guided somewhat by the child's previous answers, and will watch short excerpts from music videos to see which the child would like to listen to and watch during Week 1 of the MT program. This is all to guide the selection of music videos the child will enjoy and might give some thought to.~They will receive 10 music videos per week, through the child's private OneDrive folder, from which they can choose 4 to watch every session. Children will be instructed to not do anything else, but simply watch the videos or listen with their eyes closed.~To monitor compliance, and to check if the child was paying attention to the music videos or just having them play in the background while doing something else, the parent/guardian will film the MT sessions, and upload the video to OneDrive."
214410803|NCT03451643|PROCEDURE|ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT|PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
214410804|NCT05409404|OTHER|Aerobic exercise + hot water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of hot water immersion at 40°C.
215015115|NCT02689479|BIOLOGICAL|11C-5-HTP|150-400 MBq \[11C\]5-HTP (approximately 2-5 MBq/kg) is administered manually as an intravenous bolus in a intravenous catheter in the arm prior to PET imaging.
215015116|NCT02689479|PROCEDURE|Magnetic Resonance Imaging|Analysis will focus on adipose tissue distribution and composition in the liver.
215100761|NCT03956212|DRUG|Doxycycline 14 days|Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
215100762|NCT06114927|BEHAVIORAL|Validation of a questionnaire|The Conceptualization of Pain Questionnaire (COPAQ-S) Spanish version consist of 15 items and asks respondents to respond if they believe the items/statements to be true or false, although they are allowed to respond undecided. A score of 0 is given to incorrect responses and those marked as undecided; the sum of all the correct answers gives the total score. The higher the score, the better the participant understands the concept of pain.
215100763|NCT02222376|DRUG|Pirfenidone|Twice a day topical application
215100764|NCT02222376|PROCEDURE|Debridement|Weekly ulcer debridement
214410805|NCT05409404|OTHER|Aerobic exercise + thermoneutral water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of thermoneutral water immersion at 34°C.
214410806|NCT05245487|DIAGNOSTIC_TEST|DNA repair gene mutation analysis|Prospective monitoring of patients with next-generation sequencing for blood mutations
215015117|NCT02689479|PROCEDURE|Mixed-Meal Tolerance Test (MMTT)|
215015118|NCT02689479|PROCEDURE|Continuous Glucose Monitoring System® (CGMS)|CGMS involves the subcutaneous (SC) placement of a glucose sensor connected by tubing to a pager-sized monitoring device that stores glucose data. Subjects will have the sensor placed in the clinic and wear it continuously for 72 - 84 hours (Gold) or 72-144 hours (iPro2).
215015119|NCT02689479|PROCEDURE|Glomerular Filtration Rate Testing|
215100765|NCT00133666|BEHAVIORAL|Asthma Communication Education|
215100766|NCT00133666|BEHAVIORAL|Standard Asthma Education|
215100767|NCT01890408|DRUG|wound infusion ropivacaine|"Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
215100768|NCT03332836|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
215100769|NCT01363661|DRUG|Coruno|Molsidomine 16 mg tablet, per os, once a day
214410807|NCT00931229|DRUG|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
215015120|NCT02689479|PROCEDURE|Blood draw|
215015121|NCT05482243|DIETARY_SUPPLEMENT|Whey protein|Throughout 1 week (either in week 1 or 2), all participants will perform a 1-week resistance type exercise-training program, consisting of two different exercises. Leg press and leg extension exercise will be performed on regular weightlifting machines (Technogym, Rotterdam) at 3 days during the 1-week period (e.g. Monday-Wednesday-Friday). During the resistance exercise training protocol, participants will continue their habitual diet as usual. However, patients with CKD will be provided with a protein supplement following the exercise sessions.
215015122|NCT00581204|DEVICE|Near-Infrared Diffuse Optical Spectroscopy|Early predictor of hemorrhagic shock
215100770|NCT01363661|DRUG|Placebo|Placebo (16 mg tablet, per os; once-daily)
214410808|NCT03683472|BEHAVIORAL|Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety"
214410809|NCT04565249|DRUG|PLN-74809|PLN-74809
214410810|NCT04565249|DRUG|Placebo|Placebo
214410811|NCT04813393|OTHER|Questionnaire Development|To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
214410812|NCT04585347|DRUG|ALZ-801 170 mg Fasting|
214410813|NCT04585347|DRUG|ALZ-801 205 mg Fasting|
214410814|NCT04585347|DRUG|ALZ-801 205 mg After Food|
214410815|NCT04585347|DRUG|ALZ-801 342 mg Fasting|
214410816|NCT03120676|DRUG|Atezolizumab|All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
214410817|NCT00814853|DEVICE|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
214410818|NCT02337010|DEVICE|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
214410819|NCT02337010|DEVICE|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
214410820|NCT02337010|DRUG|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
214410821|NCT02337010|DRUG|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
214410822|NCT00926393|DRUG|Quetiapine Immediate Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
214410823|NCT00926393|DRUG|Quetiapine Extended Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
214410824|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by 4 hour creatinine clearance|4 hour creatinine clearance is used to decide colistin maintenance dosage.
214410825|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by creatinine based eGFR|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
214410826|NCT00326027|DRUG|Pantoprazole|Efficacy of Pantoprazole
214410827|NCT00738075|DEVICE|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
214410828|NCT05496049|DEVICE|Triburter|Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.
215015123|NCT02746939|BEHAVIORAL|InSciEd Out Fitness and Nutrition Curriculum|Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
215015124|NCT00855478|DEVICE|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
215015125|NCT04234230|OTHER|Prevalence Survey|Questionnaire survey on self-management
215015126|NCT02908321|BEHAVIORAL|CBT|The group based manualised CBT intervention consists of The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD).
215015127|NCT02890186|DEVICE|Narcotrend|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
215015128|NCT02890186|OTHER|experience|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
215015129|NCT06469372|DEVICE|Cardiac amyloidosis deep learning model|This is a deep learning algorithm which intakes a patient's age, sex, clinical factors known to be related to amyloidosis and their ECG and echocardiogram results and determines their estimated risk for having cardiac amyloidosis.
214410829|NCT05496049|DEVICE|Incentive spirometry|They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.
214410830|NCT02271048|DEVICE|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
214410831|NCT00174720|DRUG|Ciclesonide (XRP1526)|
214410832|NCT04163666|BEHAVIORAL|Mirror therapy|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for mirror therapy, while the remaining 30 minutes will be for task-oriented motor learning
214410833|NCT04163666|BEHAVIORAL|Cognitive therapeutic exercise|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for cognoscitive therapeutic exercise, while the remaining 30 minutes will be for task-oriented motor learning
214410834|NCT03315403|DIAGNOSTIC_TEST|LytA targeted quantitative polymerase chain reaction (qPCR)|LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
214410835|NCT00353067|DRUG|veliflapon (DG-031)|
214410836|NCT00716664|OTHER|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
214410837|NCT00716664|OTHER|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
214410838|NCT05505929|DEVICE|Biofreedom Ultra|The BioFreedomTM Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
215015130|NCT01053468|BEHAVIORAL|Physical Activity Resource Kit|"The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.~Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration)."
214410839|NCT00333541|BEHAVIORAL|Using internet/E-mail for follow-up|follow-up via email link to survey
215015131|NCT01053468|BEHAVIORAL|Standard Materials|Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency
215015132|NCT05472298|BEHAVIORAL|self-management intervention|lifestyle modification, goal setting, coaching and peer support, problem-solving
215100771|NCT05411289|PROCEDURE|acupressure|"Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6).~pressure was applied gradually for 30 seconds on the above mentioned points. Then this pressure was slowly intensified to the extent that the patient felt tingling, numbness, heaviness, and strain in the surrounding area."
214410840|NCT01759979|PROCEDURE|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
214410841|NCT01759979|PROCEDURE|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
214410842|NCT02551354|DEVICE|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
214410843|NCT02135809|DEVICE|WallFlex Pancreatic Stent|Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.
214410844|NCT06106659|DEVICE|Mini Midline|"The tube was placed in the upper arm in the test group and in the forearm in the control group. The veins were selected according to anatomical criteria (vein diameter and depth), and the puncture site was protected with a sterile cavity towel. The cannulation nurse wore sterile gloves and injected local anesthesia (1 mL of lidocaine) before venipuncture. Venipuncture was always performed using real-time ultrasound-guided visualization of the vein-guiding needle using an out-of-plane approach, and once the tip of the needle was visualized within the vein and the blood flowed back through the needle, a guidewire was introduced and the needle was removed. After the needle is removed, the cannula is advanced into the vein, the guidewire is removed, and the cannula is attached to an extension cord closed with a needleless connector."
214410845|NCT01935258|OTHER|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
214410846|NCT01935258|OTHER|care as usual|usual care of the general practitioner
214410847|NCT03997006|DRUG|IV Aminophylline|IV Aminophylline (100 mg/8h)
214410848|NCT03997006|DRUG|IV Neostigmine Methylsulfate + Atropine Sulphate|IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
214410849|NCT00415675|PROCEDURE|Motion CT Scans|A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
215015133|NCT00001818|DRUG|Hydroxyurea|
215015134|NCT02298491|DRUG|H.P. Acthar Gel|80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
215015135|NCT05420025|OTHER||
215015136|NCT04886037|OTHER|sestrin|Serum sestrin levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group.
215015137|NCT04710433|DEVICE|Non-invasive Neuromodulation|Sacral nerve stimulation via two adhesive electrodes (single current).
215015138|NCT04710433|OTHER|Medical and Behavioral Therapy|Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
215015139|NCT03255954|OTHER|Interpersonal Counseling for University Counseling Centers|Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
215015140|NCT00793065|OTHER|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
215100772|NCT05411289|PROCEDURE|sham acupressure|Pressures were applied on sham points consecutively
215100773|NCT02202343|BEHAVIORAL|school based health and nutrition education|
215100774|NCT01971008|DEVICE|Elastic abdominal binder|
215100775|NCT01971008|DEVICE|Placebo binder|
214410850|NCT06630416|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
214410851|NCT06630416|PROCEDURE|Computed Tomography|Undergo CT
214410852|NCT06630416|DRUG|Pemetrexed|Given IV
214410853|NCT06628492|DEVICE|stainless steel printed surgical guide|the patient will wear the stainless steel surgical guide for the insertion of one implant
214410854|NCT06628492|DEVICE|resin printed surgical guide|the patient will wear the resin surgical guide for insertion of adjacent another implant implant
215015141|NCT00793065|OTHER|Medical Home redesign|Implementation of NCQA Level III Medical Home
215015142|NCT00002619|BIOLOGICAL|filgrastim|
215015143|NCT00002619|DRUG|carboplatin|
215015144|NCT00002619|DRUG|thiotepa|
215015145|NCT00002619|PROCEDURE|autologous bone marrow transplantation|
215015146|NCT00002619|PROCEDURE|peripheral blood stem cell transplantation|
215100776|NCT05873972|DRUG|Cetuximab|"AEM A：The specialist's decision to add cetuximab to chemotherapy will be based on their own judgment~ARM B：The patient's CT imaging,genetic mutation information were input into the signature, and the FOLFOX+cetuximab regimen was selected when the output label was 1. FOLFOX+bevacizumab chemotherapy regimen was selected when the output label was 0"
215100777|NCT03775512|DEVICE|RF Ablation with QDOT Micro|Subjects will be ablated using QDOT Micro catheter
215015147|NCT03606070|DIAGNOSTIC_TEST|PET-MRI|"* a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~* a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
215015148|NCT01837888|DEVICE|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
214410855|NCT04162509|OTHER|AR app|Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
214410856|NCT04841486|OTHER|Data collection|evaluation of women's stress
214410857|NCT04185519|DEVICE|AI (model)|The process of the experiment (brief describe) This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose. Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl. Once the failed rate by AI is higher than the physician is 5%, , the study will be terminated. There will be three periods, namely ry 3 months.
214410858|NCT03361592|PROCEDURE|Spinal Manipulative Therapy|Lumbar (SMT) was performed using Diversified techniques, aiming to correct vertebral dysfunctional lumbar segments. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
214410859|NCT03361592|PROCEDURE|SHAM|"The SHAM (pre-load positioning SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
214410860|NCT02333630|OTHER|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
214410861|NCT02333630|OTHER|Asthma education|A website with links to written asthma education and videos
215015149|NCT02656342|DRUG|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
215015150|NCT02656342|DRUG|Placebo|Predicted to have no enhancing effect
215015151|NCT03430570|BEHAVIORAL|Tablet TRAC Emotion Regulation Intervention|The intervention focuses on developmentally appropriate strategies for emotion regulation during difficult situations, particularly those related to risk, using 3 primary groups of strategies identified during qualitative work in Project TRAC (R34 MH078750): 1) getting away (physically or cognitively) from triggers for strong emotions, 2) releasing emotional energy in healthy ways (physically or verbally) or 3) changing cognitions and appraisals about emotional triggers. Using strategies effective in TRAC, teens will engage in games to practice and apply strategies to risk scenarios, as well as personalize content learned.
215015152|NCT03066076|DRUG|Antithyroid Drug|Antithyroid drug
215015153|NCT03066076|PROCEDURE|Total thyroidectomy|Operation
215015154|NCT04920292|DRUG|Oxfendazole|Oxfendazole is a benzimidazole anthelminthic drug.
215015155|NCT04920292|DRUG|Placebo|The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
215015156|NCT05089175|DRUG|Low-dose aspirin|FIGO adopts and supports that in high-risk women, defined by the first-trimester combined test, aspirin \~150 mg/night should be commenced at 11-14+6 weeks of gestation until either 36 weeks of gestation, when delivery occurs, or when pre-eclampsia is diagnosed.
215015157|NCT02046200|DRUG|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
215015158|NCT02046200|DRUG|Placebo|Matched placebo
215015159|NCT02046200|DRUG|Alcohol|
215015160|NCT03753503|BEHAVIORAL|exercise|exercised three times a week in the 8-week HIIT program
215015161|NCT03753503|BEHAVIORAL|conventional physical therapy|
215015162|NCT03865251|DEVICE|Kinesiology tape|Application for 0%, 50%, and 100% of maximal KT stretch to the calf muscle during lying and standing positions
215015163|NCT04599257|DEVICE|BTL-899|The device applicator combines high-intensity focused electromagnetic procedure and radiofrequency energy to induce visible muscle contractions along with heating of the subcutaneous fat.
215015164|NCT03902990|OTHER|Dual task|The patients in the dual task group received cognitive tasks during treadmill training sessions.
215015165|NCT03902990|OTHER|Treadmill Training|Standard treadmill training
215015166|NCT03902990|OTHER|Standard exercise programme|Standard exercise programme for Parkinson Disease
215015167|NCT02172599|BEHAVIORAL|Sit-stand workstation provision|The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
215015168|NCT05528666|OTHER|High Efficacy Therapy (HET)|HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
215100778|NCT03704259|OTHER|Ceramic coating|coating the laparoscope lens with commercial brand ceramic coating, bought from car service centers specialized in such applications
215015169|NCT05528666|OTHER|Non High Efficacy Therapy (Non-HET)|Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
215100779|NCT05223049|OTHER|painDETECT questionnaire|The painDETECT questionnaire was specifically developed to detect neuropathic pain components in adult patients with low back pain. It is also used in detecting the neuropathic pain in rheumatic diseases. A score between ≤12 represents a nonneuropathic pain, ≥13 and ≤18 represents a possible neuropathic pain, while a score of ≥19 represents a neuropathic pain.
215015170|NCT01413646|DIETARY_SUPPLEMENT|Walnut Supplementation|Eight weeks of walnut supplementation
215015171|NCT01413646|DIETARY_SUPPLEMENT|No walnut supplementation|Eight weeks without walnut supplementation
215100780|NCT05223049|OTHER|Douleur Neuropathique 4 questionnaire (DN4)|DN4 is a clinician-administered questionnaire consisting of 10 items. Seven items related to pain quality (i.e. sensory and pain descriptors) are based on an interview with the patient and 3 items based on the clinical examination. A score of ≥4 represents a neuropathic pain.
215100781|NCT05223049|OTHER|Short form-36|The 36-Item Short Form Survey (SF-36) is a self-reported measure of health. It comprises 36 questions which cover eight domains of health. 1) Limitations in physical activities because of health problems. 2) Limitations in social activities because of physical or emotional problems 3) Limitations in usual role activities because of physical health problems 4) Bodily pain 5) General mental health (psychological distress and well-being) 6) Limitations in usual role activities because of emotional problems 7) Vitality (energy and fatigue) 8) General health perceptions. Each domain is scored between 0 and 100 and a higher score represents a better outcome.
215100782|NCT05223049|OTHER|Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC)|SPARCC was created as a measure for enthesitis in spondyloarthritis in general. It assesses 16 enthesial sites. Total number of the enthesitis is the total score of the evaluation. Total score is between 0 and 16, and higher scores represent a worse outcome.
215100783|NCT05223049|OTHER|Numeric Rating Scale|Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.
215100784|NCT05223049|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
215100785|NCT00746434|DRUG|Roflumilast cream|Roflumilast cream 0.5%
215100786|NCT00746434|DRUG|Placebo cream|Placebo cream
215100787|NCT01378325|DRUG|Phenylephrine|Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
215100788|NCT01378325|DRUG|saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
215100789|NCT01712425|BIOLOGICAL|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
214410862|NCT05095623|OTHER|Natural History Observation|This is a natural history study.
214410863|NCT05349864|DRUG|PF-07284890 Treatment A|PF-07284890 tablet by mouth while fasting
214410864|NCT05349864|DRUG|PF-07284890 Treatment B|PF-07284890 tablet after low fat meal
214410865|NCT05349864|DRUG|PF-07284890 Treatment C|PF-07284890 tablet after high fat meal
214410866|NCT05963776|DEVICE|spirometry|pulmonary function tests using spirometry
214410867|NCT04157712|DRUG|ALZ-801 or matching placebo|
215015172|NCT00353574|DRUG|Darusentan|Darusentan capsules administered orally once daily
215015173|NCT04275414|DRUG|Bevacizumab Injection|Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
215015174|NCT02614664|DEVICE|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
215100790|NCT01712425|BIOLOGICAL|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
215100791|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
215100792|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
215100793|NCT00280085|PROCEDURE|MR imaging|
215100794|NCT00280085|PROCEDURE|Glucose clamp|
215100795|NCT00280085|DRUG|Arginine|
214410868|NCT03613103|DEVICE|Video laryngoscopy|Intubation with videolaryngoscopy with highly curved blade
214410869|NCT03613103|DEVICE|Direct laryngoscopy|Intubation with direct laryngoscopy with macintosh blade
214410870|NCT04439513|DEVICE|Hemostasis|Compression device to achieve hemostasis.
214410871|NCT03425292|DRUG|Temozolomide|concomitant and 5-day adjuvant temozolomide
214410872|NCT03425292|RADIATION|conformal brain radiation therapy|standard radiation therapy for newly diagnosed glioblastoma
214410873|NCT03425292|DRUG|Nivolumab|nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
214410874|NCT03425292|DRUG|Ipilimumab|ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses
214410875|NCT03425292|DRUG|Bevacizumab|bevacizumab 5 mg/kg IV every 2 weeks (up to 10 mg/kg at treating physician's discretion)
215015175|NCT01691482|DRUG|Albuterol/salbutamol|Albuterol/salbutamol (daily)
215015176|NCT01691482|DRUG|Ipratropium|Ipratropium (daily)
215015177|NCT00183391|DRUG|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
215015178|NCT00183391|DRUG|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
215100796|NCT06201286|OTHER|Mulligan Concept|"Mulligan Concept was applied by the physiotherapist who received A-B module trainings. Mulligan techniques were performed with 3 sets of 10 repetitions and 15-20 seconds rest between sets. Mobilisations were applied to the spinous process of each vertebra of the lumbar region with 3 sets of 10 repetitions of SNAG and 3 sets of 10 repetitions of NAGS techniques. In the standing position, the physiotherapist took a position next to the patient and stabilised the patient by grasping the abdomen with one arm.~Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds."
214410876|NCT03425292|DRUG|5-day Temozolomide|150 mg/m\^2 oral, once daily on Days 1-5 of each 28-day cycle (stepwise titration every cycle up to 200 mg/m\^2 permitted)
214410877|NCT03425292|DRUG|5-day Temozolomide|100 mg/m\^2 oral, once daily on Days 2-6 of each 6 week course (stepwise titration every cycle up to 200 mg/m\^2 permitted)
214410878|NCT03425292|DRUG|Lomustine|100 mg/m\^2 oral, on Day 1 of each 6 week course
214410879|NCT03425292|DRUG|Nivolumab monotherapy|nivolumab 300 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
215015179|NCT00096408|PROCEDURE|Total Abdominal Hysterectomy|For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
215015180|NCT00096408|PROCEDURE|Total Laparoscopic Hysterectomy|The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
215015181|NCT05299450|DIETARY_SUPPLEMENT|Beet It shots|In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
215015182|NCT05299450|BEHAVIORAL|Exercise|In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
215100797|NCT06201286|OTHER|Stretching and strengthening exercises|Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds.
215100798|NCT01905449|BEHAVIORAL|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
214410880|NCT02416635|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
214410881|NCT02416635|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
214410882|NCT03748732|PROCEDURE|sclerectomy|scleral flap
214410883|NCT01369589|DRUG|P-552|P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
215015183|NCT05299450|OTHER|Control group|Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
215015184|NCT01987674|DIETARY_SUPPLEMENT|Pre-meal protein drink|
215015185|NCT01987674|OTHER|Water drink|
215015186|NCT03097471|DEVICE|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
215015187|NCT00649571|DRUG|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
215100799|NCT02270554|DEVICE|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
215100800|NCT03587441|DRUG|Neostigmine Methylsulfate|20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution
215100801|NCT03587441|DRUG|Dextrose 5% in water|intrathecal
215100802|NCT01963845|DRUG|Sitagliptin|
215100803|NCT01963845|DRUG|Placebo|
214410884|NCT01369589|DRUG|Placebo|Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
214410885|NCT00984282|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
214410886|NCT00984282|DRUG|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
214410887|NCT04553302|OTHER|This study does not contain any intervention.|This study does not contain any intervention.
214410888|NCT03013842|DEVICE|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
214410889|NCT02329041|DEVICE|McGrath Series 5|one kind of videolaryngoscopes, which are widely used in airway management.
214410890|NCT02329041|DEVICE|Airtraq|another kind of videolaryngoscopes, which are also widely used in airway management.
214410891|NCT04138771|DEVICE|An artificial intelligence system for postoperative management of cataract patients|This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
214410892|NCT02223793|BEHAVIORAL|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
214410893|NCT02223793|BEHAVIORAL|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
214410894|NCT02223793|BEHAVIORAL|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
215100804|NCT02298400|DEVICE|Acuvue® Oasys® Lenses (senofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
215100805|NCT02298400|DEVICE|30-Day Bausch + Lomb PureVision (balafilcon A)|Contact lenses placed in each eye during the day for about 8 hours
214410895|NCT02950194|PROCEDURE|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
214410896|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (EnzySystem HemA version A - whole blood)|Whole blood obtained by venipuncture is immediately tested with the EnzySystem HemA version A), before and 0, 30, 120 and 240 minutes after administration of FEIBA.
214410897|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma)|Whole blood is centrifuged to obtain plasma. The fresh plasma is tested using the Ceveron s100.
214410898|NCT06357572|DIAGNOSTIC_TEST|Additional coagulation tests|"Plasma samples are frozen for later coagulation testing. The following tests are performed:~Factor VIII activity von Willebrand Factor antigen levels von Willebrand Factor ristocetin activity levels Prothrombin Fragment 1+2 levels ADAMTS13 activity FVIII antigen levels Nijmegen Hemostasis Assay"
214410899|NCT00106431|DRUG|romidepsin (depsipeptide, FK228)|Study patients received romidepsin at a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
214410900|NCT04518566|BEHAVIORAL|Nudges|Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
214410901|NCT05324631|DRUG|SHR0302|SHR0302, oral, once daily
214410902|NCT05324631|DRUG|SHR0302 placebo|SHR0302 placebo, oral, once daily
214410903|NCT04319796|OTHER|Data set as defined by the ERN Research Workgroup of the European Commission|"The ERN-RND registry will be restricted to the minimum data set as defined by the ERN Research Workgroup of the European Commission. This includes the following data:~* Name of specialist center~* Pseudonym:~* Date of birth: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of birth~* Sex~* Date of death: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of death~* Age of onset~* Orphacode for specific rare disease: https://www.orpha.net/consor/cgi-bin/Disease\_Search.php?lng=DE~* Online Mendelian Inheritance in Man (OMIM) code as defined for genetic diseases: https://www.omim.org/~* Human Phenotype Ontology (HPO) terms for key features: https://hpo.jax.org/app/~* Agreement to be contacted for research purposes: Yes/No~* Biological samples (Yes / No)~* Link to a biobank (Link / No)~* Classification of disability (Disease group specific score)"
214410904|NCT04395755|BEHAVIORAL|Generalized Anxiety Disorder-7 (GAD-7)|The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.
214410905|NCT04395755|BEHAVIORAL|Patient Health Questionnaire-9 (PHQ-9)|The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
214410906|NCT05312541|PROCEDURE|pre emptive local anaesthetic wound infiltration|Before skin incision by 15 min the surgeon will infiltrate the wound by syringe containing 20 ml mixture of (10 ml xylocaine 2%and 10 ml bupivacaine 0. 5%) in both groups
214410907|NCT02359435|DRUG|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
214410908|NCT02359435|DRUG|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
214410909|NCT00315055|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
214410910|NCT00315055|BIOLOGICAL|DTaP-IPV//PRP~T combined|0.5 mL, IM
214410911|NCT00315055|BIOLOGICAL|Hepatitis B vaccine|0.5 mL, IM
214410912|NCT00523731|PROCEDURE|Angiogenic Cell Precursors (ACPs) or Vescell TM|
214410913|NCT00233740|DEVICE|OPTEASE Vena Cava Filter|
214410914|NCT03946813|OTHER|Autologous PRP preparation|For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide
214410915|NCT05092906|OTHER|LP with complementary hypnoanalgesia|The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.
214410916|NCT05092906|OTHER|LP with standard of care|"The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~* EMLA (Lidocain+Prilocain) Cream/Patch~* Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~* Nitrous oxide"
214410917|NCT05759585|BEHAVIORAL|person-centered lifestyle intervention|Lifestyle intervention is a combined approach that encourages individuals to change their lifestyles by increasing participation in meaningful readings. This program aims to facilitate the individual's self-development of healthy routines and habits; It includes techniques such as patient education, occupational self-analysis, problem-solving, motivation generation, and implementation of behaviors to prevent and manage disease-related symptoms.
214410918|NCT00735800|BEHAVIORAL|Family Intervention:Telephone Tracking Support- Caregiver|Family-based problem solving treatment
214410919|NCT00735800|BEHAVIORAL|Telephone Support|Supportive telephone counseling about caregiving
214410920|NCT00496379|DRUG|ZK219477|Given intravenously over approximately 30 minutes once every 3 weeks
214410921|NCT02287649|OTHER|blood sample|
214410922|NCT00719017|PROCEDURE|Upper vaginectomy|Laparoscopic surgery with upper vaginectomy
214410923|NCT00719017|RADIATION|Post-operative brachytherapy|Laparoscopic surgery followed by brachytherapy
214410924|NCT00719017|PROCEDURE|Standard procedures|Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
215100806|NCT02298400|DEVICE|Clariti® 1-Day (Somofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
215100807|NCT00767806|DRUG|Duloxetine|60 mg orally once daily for 12 weeks
215100808|NCT00767806|DRUG|Placebo|Placebo once daily orally for 12 weeks
215015188|NCT00649571|DRUG|Adoxa Tablets 100 mg|100mg, single dose fasting
215100809|NCT03482037|DRUG|Rec 0/0438 1 mg or Rec 0/0438 2 mg|Each vial content will be administered via the catheter used for the self-catheterization
214410925|NCT01289119|DRUG|Alogliptin|Alogliptin tablets
215100810|NCT03482037|DRUG|placebo|Each vial content will be administered via the catheter used for the self-catheterization
215015189|NCT00647023|DRUG|metformin|1000 mg metformin x 2 daily during 8 months
215100811|NCT05990361|DIAGNOSTIC_TEST|clinical diagnostic test|"The clinical diagnosis tests are Active Straight Leg Rise ASLR, Posterior Pelvic Pain Provocation, Long Dorsal Sacroiliac Ligament Palpation (LDSLP), Pelvic Compression, Pelvic Distraction, Patrick-Faber Test (PF), and Gaenslen Test (GT).~The subjects who had at least one positive result from ASLR and P4 Tests; and at least two positive results from the Pelvic Compression and Distraction, PF, GT and LDSLP tests are classified as with PGP group."
215100812|NCT02489942|DRUG|Jardiance|Empagliflozin
215100813|NCT00858208|DRUG|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
215100814|NCT02196155|DRUG|Botulinum toxin A|"Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.~In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc.."
215100815|NCT02196155|DRUG|cortisone|
215100816|NCT02196155|DRUG|Saline|
215100817|NCT02374567|DRUG|Phenobarbital|
215100818|NCT02374567|DRUG|Phenytoin|
215100819|NCT02374567|DRUG|Carbamazepine|
214410926|NCT01289119|DRUG|Placebo to alogliptin|Alogliptin placebo-matching tablets.
214410927|NCT01289119|DRUG|Metformin|Stable metformin dose
214410928|NCT01289119|DRUG|Pioglitazone|Stable pioglitazone dose
214410929|NCT00165139|DRUG|Vincristine|Described under detailed description
215015190|NCT06478940|DRUG|3 mixtatin pulpotomy|pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
215015191|NCT06478940|DRUG|MTA pulpotomy|pulp treatment with applying MTA
215015192|NCT05192083|BEHAVIORAL|Self-management and Support|A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
214410930|NCT00165139|DRUG|Cyclophosphamide|Described under detailed description
214410931|NCT00165139|DRUG|Adriamycin|Described under detailed description
214410932|NCT00165139|DRUG|Etoposide (VP-16)|Described under detailed description
214410933|NCT00165139|DRUG|Cisplatin|Described under detailed description
214410934|NCT00165139|DRUG|Carboplatin|Described under detailed description
214410935|NCT00165139|DRUG|Melphalan|Described under detailed description
214410936|NCT00165139|DRUG|Ifosfamide|Described under detailed description
215015193|NCT03978208|DRUG|ATB-346 low dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
215015194|NCT03978208|OTHER|Placebo|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
215015195|NCT03978208|DRUG|ATB-346 mid-dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
215015196|NCT03978208|DRUG|ATB-346 standard dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
215015197|NCT04867330|OTHER|Toxicities reduced treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
215015198|NCT04697992|DRUG|vitamin c 20%|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
215015199|NCT04697992|DRUG|Tranexamic acid 5mg/ml|one eye was treated with tranexamin acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling)
215015200|NCT01183286|BEHAVIORAL|CFFONE|A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
215100820|NCT02374567|DRUG|Oxcarbazepine|
215100821|NCT02374567|DRUG|Valproic Acid|
215100822|NCT02374567|DRUG|Lamotrigine|
215100823|NCT02374567|DRUG|Topiramate|
215100824|NCT02374567|DRUG|Gabapentin|
215100825|NCT02374567|DRUG|Levetiracetam|
215100826|NCT02374567|DRUG|Pregabalin|
215100827|NCT02374567|DRUG|Lacosamide|
215100828|NCT02374567|DRUG|Clonazepam|
214410937|NCT00165139|DRUG|G-CSF (granulocyte-colony stimulating factor)|Described under detailed description
214410938|NCT00165139|DRUG|Mesna|Described under detailed description
214410939|NCT02414919|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|Levonorgestrel-releasing intrauterine device 20 mcg/day
214410940|NCT02414919|DRUG|ParaGard|Copper T380A
214410941|NCT02414919|DRUG|Implanon/Nexplanon|Etonorgestrel contraceptive implant
214410942|NCT05822271|PROCEDURE|Orthognathic Surgery|Type of surgery performed to correct skeletal malocclusions
215100829|NCT02374567|DRUG|Biperiden|
215100830|NCT02374567|DRUG|Levomepromazine|
215100831|NCT02374567|DRUG|Fluphenazine|
215100832|NCT02374567|DRUG|Perphenazine|
215100833|NCT02374567|DRUG|Perazine|
215100834|NCT02374567|DRUG|Thioridazine|
215100835|NCT02374567|DRUG|Haloperidol|
215100836|NCT02374567|DRUG|Melperone|
215100837|NCT02374567|DRUG|Pipamperone|
215100838|NCT02374567|DRUG|Bromperidol|
215100839|NCT02374567|DRUG|Benperidol|
214410943|NCT02389192|DRUG|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
215015201|NCT01183286|BEHAVIORAL|CF website|A CF-related educational website which has some areas of CF information and services relevant to adolescents.
215015202|NCT01986751|DRUG|Clonidine|
214410944|NCT03675139|DRUG|Medroxyprogesterone Acetate|At a dosage of 10mg/day
214410945|NCT03675139|DRUG|Dydrogesterone 10 MG|At a dosage of 20 mg/day
214410946|NCT02074956|BIOLOGICAL|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
214410947|NCT02074956|BIOLOGICAL|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
214410948|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
214410949|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
214410950|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
214410951|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
214410952|NCT02611414|DEVICE|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
214410953|NCT02611414|DEVICE|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
214410954|NCT04661670|DEVICE|occlusal stabilization splints|an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
215015203|NCT01986751|DRUG|ropivacaine|
214410955|NCT01407601|DIETARY_SUPPLEMENT|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
214410956|NCT04579510|BIOLOGICAL|Novel monovalent oral poliovirus vaccine type 2 (nOPV2)|nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.
214410957|NCT04579510|BIOLOGICAL|Bivalent oral poliovirus vaccine (bOPV)|The live types 1 \& 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 \& 3 attenuated Polio viruses (Sabin strains).
214410958|NCT05122312|DRUG|Olinanoseal|it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
214410959|NCT05122312|DRUG|Curodont D'senz|This agent contains p 11-4 peptide in addition to fluoride
214410960|NCT01756417|DRUG|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
215015204|NCT02388789|OTHER|active movement|same as arm description
214410961|NCT01756417|DRUG|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
214410962|NCT06480409|OTHER|VR Mindfulness and Stress Reduction Program|"Intervention Procedure:~Duration and Frequency: Participants will engage in 15-minute VR relaxation sessions, held five times a week over a period of one month.~VR Content: The VR sessions will feature high-quality 360° videos with therapeutic audio, including guided relaxation, calming music, and nature sounds.~Physiological Monitoring: Throughout the sessions, participants' physiological responses will be monitored using Polar H-10 sensors to measure heart rate variability (HRV), providing data on autonomic nervous system activity.~Psychological Assessment: Participants will complete the Perceived Stress Scale (PSS-10) before and after the intervention to evaluate changes in stress levels.~Cybersickness Monitoring: The occurrence of any adverse effects, such as cybersickness, will be monitored and recorded."
214410963|NCT04364880|DEVICE|TBS|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
214410964|NCT04364880|DEVICE|Sham|The sham-TBS coil produced a similar sound without a magnetic pulse.
214410965|NCT04311619|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
214410966|NCT04311619|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
214410967|NCT00530335|DRUG|Atomoxetine|40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
214410968|NCT02321540|DRUG|Ibrutinib|"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."
214410969|NCT01649791|DRUG|lenalidomide|Given orally
214410970|NCT01649791|OTHER|laboratory biomarker analysis|Correlative study
214410971|NCT01649791|PROCEDURE|lymph node biopsy|Correlative study
215015205|NCT01478087|DEVICE|Mysorba|Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
215015206|NCT03275272|DIAGNOSTIC_TEST|level of IGF-1 in infants|Measurment of blood level of IGF-1 in infants
215015207|NCT04576949|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
215015208|NCT04576949|DRUG|Placebo|film-coated oral tablets containing matched placebo
215015209|NCT04576949|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
214410972|NCT01649791|PROCEDURE|bone marrow aspiration|Correlative study
214410973|NCT01649791|OTHER|pharmacological study|Correlative study
214410974|NCT01649791|OTHER|flow cytometry|Correlative study
214410975|NCT04097886|OTHER|Morning Exercise|moderate intensity exercise (70% VO2 max) each morning for 5 days
214410976|NCT04097886|OTHER|Evening Exercise|moderate intensity exercise (70% VO2 max) each evening for 5 days
214410977|NCT04577183|DEVICE|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
214410978|NCT05475470|PROCEDURE|finger-blade technique|laparoscopic access technique for group a
214410979|NCT05475470|PROCEDURE|Hasson's technique|laparoscopic access technique for group b
215015210|NCT04188509|DRUG|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).
215015211|NCT05511480|BEHAVIORAL|Interference through learning of a competing motor skill.|Interference through the learning of a competing motor skill.
215015212|NCT05511480|BEHAVIORAL|No interference|No interference through the continuation of learning same motor skill
215015213|NCT00279513|DRUG|Traumeel S|
215100840|NCT02374567|DRUG|Sertindole|
215015214|NCT03855839|DEVICE|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.
215015215|NCT03855839|DEVICE|Compression shirt|Compression shirts are designed for recreational sport activities and can be bought in any local sports store
215015216|NCT00051142|DRUG|Travoprost|
215015217|NCT00051142|DRUG|Latanoprost|
215015218|NCT06501261|BEHAVIORAL|CALM psychotherapy|psychotherapy sessions
214410980|NCT05475470|PROCEDURE|veress needle technique|laparoscopic access technique for group c
214410981|NCT03352388|DIETARY_SUPPLEMENT|Dairy- and berry-based snacks|High-protein dairy-based products and energy-enriched berry products for three months
215015219|NCT04195477|BEHAVIORAL|vDPP|virtual Diabetes Prevention Program
215100841|NCT02374567|DRUG|Ziprasidone|
215100842|NCT02374567|DRUG|Flupentixol|
215015220|NCT01084720|DRUG|V0034 CR|
215100843|NCT02374567|DRUG|Chlorprothixene|
215100844|NCT02374567|DRUG|Zuclopenthixol|
214410982|NCT02860923|DRUG|Exenatide|
214410983|NCT02860923|DRUG|Placebo|
214410984|NCT00004886|DRUG|docetaxel|
214410985|NCT00004886|DRUG|dofequidar fumarate|
214410986|NCT03661190|OTHER|Grammatical Reasoning|START measures the ability to determine the relationships among different shape combinations which are assigned to grammatical statements about them which can be either correct or incorrect. It is a measure of attention, working memory and executive control.
215015221|NCT00205062|PROCEDURE|PET-CT|
215015222|NCT02726295|DRUG|E. coli Nissle 1917(Mutaflor®)|
215015223|NCT02726295|DRUG|Placebo|
215015224|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)"
215015225|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)"
215100845|NCT02374567|DRUG|Fluspirilene|
215100846|NCT02374567|DRUG|Pimozide|
215100847|NCT02374567|DRUG|Clozapine|
215100848|NCT02374567|DRUG|Olanzapine|
215100849|NCT02374567|DRUG|Quetiapine|
215100850|NCT02374567|DRUG|Sulpiride|
215100851|NCT02374567|DRUG|Tiapride|
214410987|NCT03661190|OTHER|Card Pairs|A basic picture-matching task.
214410988|NCT03297749|OTHER|Observational study (no intervention)|No interventions
215015226|NCT00407030|DRUG|Placebo|Placebo
215015227|NCT03017287|DEVICE|GlucoMe App|Assessment of the the GlucoMe App
215015228|NCT04489056|GENETIC|Swabs for microbiome analysis|After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.
215100852|NCT02374567|DRUG|Amisulpride|
215100853|NCT02374567|DRUG|Prothipendyl|
215100854|NCT02374567|DRUG|Risperidone|
215100855|NCT02374567|DRUG|Aripiprazole|
215100856|NCT02374567|DRUG|Paliperidone|
215100857|NCT02374567|DRUG|Diazepam|
215100858|NCT02374567|DRUG|Oxazepam|
215100859|NCT02374567|DRUG|Lorazepam|
215100860|NCT02374567|DRUG|Bromazepam|
215100861|NCT02374567|DRUG|Clobazam|
215100862|NCT02374567|DRUG|Alprazolam|
215100863|NCT02374567|DRUG|Hydroxyzine|
215100864|NCT02374567|DRUG|Buspirone|
215100865|NCT02374567|DRUG|Chloral Hydrate|
215100866|NCT02374567|DRUG|Flurazepam|
215100867|NCT02374567|DRUG|Nitrazepam|
215100868|NCT02374567|DRUG|Triazolam|
215100869|NCT02374567|DRUG|Lormetazepam|
215100870|NCT02374567|DRUG|Temazepam|
215100871|NCT02374567|DRUG|Midazolam|
215100872|NCT02374567|DRUG|Brotizolam|
215100873|NCT02374567|DRUG|Zopiclone|
215100874|NCT02374567|DRUG|Zolpidem|
215100875|NCT02374567|DRUG|Zaleplon|
214410989|NCT00660374|DRUG|insulin NPH|"Soft-treat-to-target dose titration scheme, injection s.c."
214410990|NCT00660374|DRUG|EX1000|"Soft-treat-to-target dose titration scheme, injection s.c."
215015229|NCT05351034|DEVICE|Anorectal manometry|Anorectal manometry in diagnosis of Functional anorectal disorders
214410991|NCT02260739|OTHER|Blood samples|
214410992|NCT03079375|OTHER|basic intervention|medication review
214410993|NCT03079375|OTHER|extended intervention|medication review, medication interview before discharge and follow-up
214410994|NCT03818061|DRUG|Atezolizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
214410995|NCT03818061|DRUG|Bevacizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
214410996|NCT00395434|DRUG|Combretastatin A4 Phosphate (CA4P)|
214410997|NCT00395434|DRUG|Bevacizumab (Avastin)|
214410998|NCT06413940|BEHAVIORAL|Myofunctional Therapy|Oropharyngeal and tongue exercises : strengthening upper airway muscle 20 minutes
215015230|NCT05253534|DEVICE|GlaucoT Glaucoma Treatment Device|"In this study, flicker light therapy, the effectiveness of which was investigated in the treatment of glaucoma based on some methods used in different diseases, is described for the first time in glaucoma.~Studies investigating the neurodegenerative properties of glaucoma have found similarities in the pathophysiology of Alzheimer's disease and glaucoma.~40 Hz flicker of light Alzheimer 's the positive effects on the knitted cortex have also been shown in studies. 40 Hz flicker light is aimed to reduce glaucoma and retinal ganglion cell loss due to glaucoma, by reducing neurodegeneration by decreasing amyloid and metabolite accumulation by increasing both microglial phagocytic activation effect and retinal blood flow."
215015231|NCT03749863|PROCEDURE|Serial PRP injections|Autologous platelet-rich plasma will be injected into the vocal fold mucosa in a serial fashion, once per month for a total of 4 injections.
215100876|NCT02374567|DRUG|Melatonin|
214410999|NCT06413940|BEHAVIORAL|Inspiratory Muscle Training|Respiratory muscle strengthening:inspiratory muscle strengthening by resistive loading of 50% maximum inspiratory pressure.
214411000|NCT06413940|BEHAVIORAL|Aerobic Exercise|Exercise intensity :40%-60% HRmax , 3-5 days/week
214411001|NCT02321748|DRUG|Montelukast|
214411002|NCT02321748|DRUG|ASP2151|
214411003|NCT04045119|OTHER|Topical Moisturizer|The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
214411004|NCT01268891|DRUG|Placebo|Once daily; tablet; orally; 18 weeks
214411005|NCT01268891|DRUG|Azilect®|1 mg daily; tablet; orally; 18 weeks
214411006|NCT00991276|DRUG|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
214411007|NCT00991276|DRUG|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
214411008|NCT00991276|DRUG|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
214411009|NCT04619459|OTHER|Kangaroo Mother Care (KMC)|Kangaroo mother care is a method of care of infants. The method involves infants being carried, usually by the mother, with skin-to-skin contact. Kangaroo mother care (KMC). early after delivery have better success at breastfeeding and achieve this success sooner. In this method The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. The KMC session was continued for 3 hours.
214411010|NCT04222387|DEVICE|OCT-B scan|OCT-B scan (Optical coherence tomography)
214411011|NCT02553382|DIETARY_SUPPLEMENT|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
214411012|NCT02553382|DIETARY_SUPPLEMENT|Positive Control|Oat bran blend and wheat bran capsules
214411013|NCT02850627|DRUG|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
215015232|NCT01981928|DRUG|ASP7962|Oral
215015233|NCT01981928|DRUG|Placebo|Oral
215100877|NCT02374567|DRUG|Clomethiazole|
215100878|NCT02374567|DRUG|Diphenhydramine|
215100879|NCT02374567|DRUG|Promethazine|
215100880|NCT02374567|DRUG|Imipramine|
215100881|NCT02374567|DRUG|Clomipramine|
215100882|NCT02374567|DRUG|Opipramol|
215100883|NCT02374567|DRUG|Trimipramine|
214411014|NCT02850627|DRUG|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
214411015|NCT03172403|DIAGNOSTIC_TEST|Height and weight|Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)
214411016|NCT03172403|DIAGNOSTIC_TEST|Blood samples|Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)
214411017|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle force|Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
214411018|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
215015234|NCT01446653|BEHAVIORAL|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
215015235|NCT01446653|BEHAVIORAL|Video|Video arm will provide information via documentary video
215015236|NCT01446653|BEHAVIORAL|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
215100884|NCT02374567|DRUG|Amitriptyline|
215100885|NCT02374567|DRUG|Nortriptyline|
215100886|NCT02374567|DRUG|Doxepin|
215100887|NCT02374567|DRUG|Maprotiline|
215100888|NCT02374567|DRUG|Amitriptyline oxide|
215100889|NCT02374567|DRUG|Fluoxetine|
215100890|NCT02374567|DRUG|Citalopram|
215100891|NCT02374567|DRUG|Paroxetine|
215100892|NCT02374567|DRUG|Sertraline|
215100893|NCT02374567|DRUG|Fluvoxamine|
215100894|NCT02374567|DRUG|Escitalopram|
215100895|NCT02374567|DRUG|Tranylcypromine|
214411019|NCT03172403|DIAGNOSTIC_TEST|Muscle biopsy|Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
215015237|NCT04613570|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy|"In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~* Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~* EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~* If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~* If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~* Antrum, incisura and corpus fragments should be sent in 3 separate vials;"
214411020|NCT01214902|DEVICE|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
214411021|NCT01214902|BEHAVIORAL|play|play which encourages the use of the hemiplegic hand
214411022|NCT05526508|DEVICE|Rebound exercise|Exercise training on the rebounder/ mini-trampoline with stability handles attached
214411023|NCT03615001|DEVICE|TDOC NXT|Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
214411024|NCT02387346|DEVICE|Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation|
214411025|NCT02387346|DEVICE|Magstim Rapid 2 Sham Stimulation|
214411026|NCT05695573|DIAGNOSTIC_TEST|ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile|Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis
214411027|NCT02634008|DRUG|Paritaprevir/ritonavir/ombitasvir|
214411028|NCT02634008|DRUG|Dasabuvir|
214411029|NCT02634008|DRUG|Ribavirin|
214411030|NCT02634008|DRUG|Glecaprevir/pibrentasvir|
214411031|NCT00403208|PROCEDURE|Analgesia based sedation in ICU patients|
214411032|NCT03450109|DRUG|LY01005|One gluteal IM injection
214411033|NCT03450109|DRUG|Zoladex|One Subcutaneous injection in the abdominal wall
214411034|NCT03353272|BEHAVIORAL|Patient Engagement Education and Restructuring of Cognitions|This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
214411035|NCT00533039|DRUG|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
215015238|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
215015239|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Orsiro DES)|stenting
215015240|NCT02390375|DRUG|DW-0929|5/10mg
215015241|NCT02390375|DRUG|DW-0929|10/10mg
215015242|NCT02390375|DRUG|DW-0929|20/10mg
215015243|NCT02390375|DRUG|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
215015244|NCT02390375|DRUG|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
215015245|NCT02390375|DRUG|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
215015246|NCT06386120|OTHER|PEEP setting strategy|The attending physician selects different PEEP setting strategies
215015247|NCT01666405|DEVICE|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
215015248|NCT01489358|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
215015249|NCT00736476|BIOLOGICAL|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
215015250|NCT00736476|BIOLOGICAL|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
215015251|NCT03666793|OTHER|global care|Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
215015252|NCT03193307|DRUG|Microgynon® 30|Run in period \& Treatment Period
214411036|NCT00533039|DRUG|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
214411037|NCT05114044|OTHER|Core stability training|The core stability training were performed 5 days a week for 15 min over a period of 3 weeks. The conventional therapy were performed 5 days a week for 30 min (remaining time of each session) over a period of 3 weeks. Duration of each session was 45 min.
214411038|NCT05114044|OTHER|Conventional therapy|The conventional therapy were performed 5 days a week for 45 min over a period of 3 weeks. Duration of each session was 45 min
214411039|NCT00197457|PROCEDURE|serum pepsinogen|
214411040|NCT00197457|PROCEDURE|urea breath test|
214411041|NCT02157402|BEHAVIORAL|Social marketing activities and pop-up events to promote healthy lifestyles|
214411042|NCT03241498|OTHER|Medicines optimisation|
215015253|NCT03193307|DRUG|BI 409306|Day 18 \& 29 (Treatment Period)
215015254|NCT01984060|OTHER|HOME-EX|"Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.~Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise"
215015255|NCT03845868|OTHER|Dietary and environmental exposure (Observational study)|
215015256|NCT05807750|OTHER|Post-discharge income supplement|$300 income supplement
215015257|NCT05807750|OTHER|Enhanced care planning|Enhanced care planning provided by a nurse care manager
215015258|NCT02018809|BEHAVIORAL|Medication Adherence Partner|
215015259|NCT02018809|DEVICE|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
214411043|NCT04660084|DIAGNOSTIC_TEST|Ultra-rapid molecular point-of-care testing|"Ultra-rapid molecular testing (UR-MT) comprises automated detection using the new BioFire® FilmArray® Pneumonia plus platform (Biomérieux). The total turn-around time is \<2 hrs.~The UR-MT is combined with standard of care, comprising:~Microbiological processing per current standard of care entails culture of respiratory tract samples according to national protocols to detect respiratory bacteria, identified using biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF MS). Respiratory viruses are identified using real-time PCR (for metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza 1-3, RSV and SARS-CoV-2). The total turn-around time is up to 48 hrs."
214411044|NCT02831114|OTHER|Acupuncture|Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
214411045|NCT01005992|PROCEDURE|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
214411046|NCT01005992|PROCEDURE|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
214411047|NCT05189587|DEVICE|transcranial electrical stimulation (TES)|Transcranial electrical stimulation (tES) is a noninvasive brain stimulation technique that passes an electrical current through the cortex of the brain to alter brain function. The electrical current is applied to an individual's scalp usually via two or more electrodes, and whilst a large amount of the current is conducted between electrodes through soft tissue and skull (Vöröslakos et al. 2018), a portion of the current penetrates the scalp and is conducted through the brain, where it can alter neuronal excitability. By altering the activity of brain regions involved with a behaviour of interest, investigators can observe the resulting behavioral changes and so establish a causal link between the two (Reed et al. 2018).
214411048|NCT06548334|COMBINATION_PRODUCT|Advanced Physiotherapy|The physiotherapist used the regression techniques for 1 hour of session 2 times for 8 weeks. The caudal component involved the spinous process of the treated segment touching the therapist's hand and not applying force as though mobilising the segment at grade 2. These were applied if there is a suspected case of a posterolateral disc prolapse where the aim is to increase the diameter of the foramen and decrease the tension exerted on the nerve root. Applied posteroanterior was used to distract the anterior intervertebral end plate and to approximate the posterior end plates so as to pull back the protruded nuclear material by creating a negative pressure.
214411049|NCT06548334|OTHER|Conventional Physiotherapy Techniques|In traditional physiotherapy, the patient underwent two sessions per week for eight weeks. Each session lasted one hour and included 20minutes of TENS treatment. The flexibility exercises consisted of hamstring stretches and single and double knee-to-chest stretches. The strengthening exercises were partial sit-ups, quadruped lifts, and double leg hold; pelvic tilts were performed with 10-15 repetitions, each held for 20-30 seconds and repeated three times.
214411050|NCT05773612|OTHER|Rock Steady Boxing Class|Rock Steady Boxing is a non-contact fitness program designed specifically for people with Parkinson's Disease.
214411051|NCT04101123|OTHER|Non-Interventional|Non-Interventional
214411052|NCT01720043|DRUG|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
214411053|NCT06045637|BEHAVIORAL|Group included in a psychoeducational program based on the cognitive behavioral approach (experiment)|The 9-session cognitive behavioral approach-based psychoeducation program will last 5 weeks. Sessions; It will be carried out in the form of acquaintance, recognition of trauma and its effects, emotion and thought behavior analysis, cognitive errors, automatic thoughts and alternative thought generation, cognitive emotion regulation strategies, coping with negative emotions, instilling hope and termination session.
214411054|NCT04927598|DEVICE|plasmapheresis|patients of Gullian Barrie syndrome undergo plasmapharesis
214411055|NCT00021112|DRUG|cisplatin|
214411056|NCT00021112|DRUG|etoposide|
214411057|NCT00021112|PROCEDURE|conventional surgery|
214411058|NCT00021112|RADIATION|radiation therapy|
215015260|NCT03066557|PROCEDURE|TACE and Apatinib|TACE and Apatinib 250mg po qd
215015261|NCT03066557|PROCEDURE|TACE|TACE
214411059|NCT05753137|OTHER|Acupuncture|The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation.
214411060|NCT05753137|OTHER|Acupuncture placebo|A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.The control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation.
214411061|NCT01688973|DRUG|Erlotinib Hydrochloride|150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
214411062|NCT01688973|OTHER|Laboratory Biomarker Analysis|Correlative studies
214411063|NCT01688973|DRUG|Tivantinib|360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
215015262|NCT05449262|OTHER|functional resistance training GROUP A|"Session of 45-60 min. Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
215015263|NCT05449262|OTHER|functional resistance training GROUP B|"Session of 45-60 min Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
215100896|NCT02374567|DRUG|Moclobemide|
215100897|NCT02374567|DRUG|Mianserin|
215100898|NCT02374567|DRUG|Trazodone|
214411064|NCT04550416|OTHER|ProMark Information and Test Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
215015264|NCT03518203|DRUG|Eculizumab|Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
215015265|NCT01129895|BEHAVIORAL|Health promotion|In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
215015266|NCT02829957|DRUG|Apixaban|10mg BID for 7 days, then 5mg BID for three months
215015267|NCT02829957|DRUG|Rivaroxaban|15mg BID for 7 days, then 20mg daily for three months
215015268|NCT00129558|DRUG|PT-523 for Injection|
215015269|NCT05469308|OTHER|questionary|When the patients renew their treatment in community pharmacy, they have an adherence record with a pharmacist who calculates the PDC score, and perform questionaries on adherence to the DOACs, and collects data about clinical history and pharmacological information on the prescribed DAOCs, demography.
215015270|NCT01181765|BIOLOGICAL|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
215015271|NCT02576366|DRUG|Voriconazole|
215015272|NCT02576366|DRUG|Rifampin|
215015273|NCT00002370|DRUG|Itraconazole|
215015274|NCT00158431|PROCEDURE|Arthroscopy plus Medical Management|Arthroscopic Surgery
215015275|NCT00158431|OTHER|Medical Management|education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
215015276|NCT00625729|BIOLOGICAL|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
215015277|NCT00625729|BIOLOGICAL|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10\^7 cells/kg).
215015278|NCT00625729|BIOLOGICAL|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m\^2
215015279|NCT00625729|DRUG|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
215100899|NCT02374567|DRUG|Mirtazapine|
215100900|NCT02374567|DRUG|Bupropion|
215100901|NCT02374567|DRUG|Venlafaxine|
215100902|NCT02374567|DRUG|Reboxetine|
215100903|NCT02374567|DRUG|Duloxetine|
214411065|NCT00762658|DRUG|AN2728 Ointment, 5%|
214411066|NCT00762658|DRUG|AN2728 Ointment, 2%|
214411067|NCT00762658|DRUG|AN2728 Ointment, 0.5%|
214411068|NCT00762658|DRUG|AN2728 Ointment Vehicle|
215100904|NCT02374567|DRUG|Agomelatine|
214411069|NCT00762658|DRUG|Betnesol®-V Creme, 0.1%|
214411070|NCT00762658|DRUG|Protopic® Ointment, 0.1 %|
215015280|NCT00625729|DRUG|fludarabine phosphate|Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
215015281|NCT01578720|DRUG|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
215015282|NCT04560309|DRUG|L-alanyl-L-glutamine dipeptide|Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.
215015283|NCT04560309|DRUG|Placebo|Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
215015284|NCT05684614|OTHER|Negative mood induction procedure|"The negative mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce negative mood: 1) Velten's tasks, consisting of interactive phrase formulations with negative thoughts and beliefs about the self (e.g., I don't have any future); 2) visualizing International Affective Pictures; and 3) recalling a negative autobiographical memory related to a significant loss (e.g., a person, a pet)."
215015285|NCT05684614|OTHER|Spontaneous emotion regulation task|Participants are instructed to use whatever strategy they want by doing, saying, and/or thinking whatever they want to feel better for 2 min
215015286|NCT05684614|OTHER|Positive mood induction procedure|"The positive mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce positive mood: 1) Velten's tasks, consisting of interactive phrase formulations with positive thoughts and beliefs (e.g., Life is wonderful); 2) visualizing International Affective Pictures; and 3) recalling a positive autobiographical memory"
215015287|NCT05085405|BEHAVIORAL|Clinician notification|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
215015288|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
215100905|NCT02374567|DRUG|Pyritinol|
215100906|NCT02374567|DRUG|Piracetam|
215100907|NCT02374567|DRUG|Donepezil|
215100908|NCT02374567|DRUG|Rivastigmine|
215100909|NCT02374567|DRUG|Galantamine|
215100910|NCT02374567|DRUG|Memantine|
215100911|NCT02374567|DRUG|Nicergoline|
215100912|NCT02374567|DRUG|Acamprosate|
215100913|NCT02374567|DRUG|Lithium|
215015289|NCT05085405|BEHAVIORAL|Clinician Notification / Patient Activation|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
215100914|NCT03277027|OTHER|interventional study|The participants wear a monitoring equipment (Actigraph) for a week. And parents do Child Health Questionnaire Parent Form 50 (CHQ-PF50), and Korean Parenting Stress Index-Short Form (K-PSI-SF)
215100915|NCT02435420|DEVICE|EMPERION Modular Primary Stem|Primary total hip arthroplasty using the EMPERION Modular Primary Stem
215100916|NCT01260597|BEHAVIORAL|IVR intervention|If individuals report having any smoking in the previous 30 days, the IVR will deliver questions to identify barriers to quit line re-enrollment and motivational messages to promote the re-enrollment
215100917|NCT01260597|BEHAVIORAL|IVR control|If individuals report any smoking in the last 30 days the IVR will thank them for their time and the call will end
214411071|NCT02022462|BEHAVIORAL|Health Navigation|"Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention."
214411072|NCT00140166|DRUG|niacinamide|
214411073|NCT00140166|DRUG|pyridoxine|
214411074|NCT00140166|DRUG|ascorbate|
214411075|NCT02090309|DRUG|Hydrocortisone|100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
214411076|NCT02090309|DRUG|normal saline 0.9%|IV injection of 5 ml normal saline 0.9% as a single bolus.
214411077|NCT00707590|DRUG|BMS-767778 or Placebo|
214411078|NCT04451889|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
214411079|NCT04586192|OTHER|Common Elements Toolbox- Adult version (COMET-A)|COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.
214411080|NCT04586192|OTHER|Self-awareness Control|A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
214411081|NCT04371926|DRUG|Hydroxychloroquine Sulfate|"Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff will receive HCQ sulfate 400mg/week for 4 weeks"
215100918|NCT05055817|OTHER|bloody stool group|bloody stool appear in the hospitalized neonate
215100919|NCT05055817|OTHER|non-bloody stool group|bloody stool do not appear in the hospitalized neonate
215100920|NCT00099658|BIOLOGICAL|Pneumococcal polysaccharide-protein conjugate vaccine|Injection administered three times before the age of 24 weeks
215100921|NCT02352623|RADIATION|DXA scan|DXA scan
215100922|NCT02352623|PROCEDURE|Clinical examination|Clinical examination
215100923|NCT04312347|DRUG|Tamoxifen dose adjustment|Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
215100924|NCT01632436|DRUG|Pixantrone|Experimental Drug
215100925|NCT03781453|BEHAVIORAL|POWERPLAY|"Employees from participating worksites will be invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
215100926|NCT01393639|DRUG|PF-04171327|1 mg tablet once daily (QD) for 8 weeks
215100927|NCT01393639|DRUG|PF-04171327|5 mg tablet once daily (QD) for 8 weeks
214411082|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation and medication at the same instant
214411083|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation is given without administering medication
214411084|NCT02212717|PROCEDURE|EUS-guided gallbladder drainage (EGBD)|The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
215100928|NCT01393639|DRUG|PF-04171327|10 mg tablet once daily (QD) for 8 weeks
215100929|NCT01393639|DRUG|PF-04171327|15 mg tablet once daily (QD) for 8 weeks
215100930|NCT01393639|DRUG|prednisone|5 mg capsule once daily for 8 weeks
215100931|NCT01393639|OTHER|prednisone|10 mg capsule once daily for 8 weeks
215100932|NCT01393639|OTHER|placebo|placebo (tablet or capsule) once daily (QD) for 8 weeks
215100933|NCT01657734|OTHER|MR imaging|MR imaging
215100934|NCT00679172|BIOLOGICAL|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
215100935|NCT00679172|BIOLOGICAL|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
214411085|NCT02212717|PROCEDURE|Percutaneous cholecystostomy (PC)|Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
214411086|NCT04744597|BEHAVIORAL|Real execution of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task
214411087|NCT04744597|BEHAVIORAL|Motor imagery of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.
214411088|NCT04744597|BEHAVIORAL|Skip counting|Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
214411089|NCT04660370|DRUG|CKD-348|QD, PO
214411090|NCT04660370|DRUG|CKD-828, D097, D337|QD, PO
214411091|NCT02560103|OTHER|Transmeridian travel across multiple time zones|
214411092|NCT05283369|DEVICE|Videogame therapy|The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.
215015290|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation / Patient Activation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
215015291|NCT05645185|DIAGNOSTIC_TEST|Diagnosis test|Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
215015292|NCT01737619|PROCEDURE|Computed Tomography|Undergo PET/CT
215015293|NCT01737619|DRUG|Indocyanine Green Solution|Given via superficial and deep cervical injection
215015294|NCT01737619|OTHER|Laboratory Biomarker Analysis|Correlative studies
215015295|NCT01737619|PROCEDURE|Lymph Node Mapping|Undergo lymph node mapping
215015296|NCT01737619|PROCEDURE|Lymphadenectomy|Undergo full lymphadenectomy
215015297|NCT01737619|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215015298|NCT05755945|OTHER|eHealth Application|"Custom phone application that integrates data from smart watch. Subjects will complete daily To-Do-Lists where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache."
215015299|NCT05856747|DRUG|TBP-PI-HBr|TBP-PI-HBr tablets.
215015300|NCT03623100|BEHAVIORAL|Speech Production Treatment.|Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.
215100936|NCT00679172|BIOLOGICAL|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
214411093|NCT05283369|OTHER|Conventional therapy|The usual dose of physical and occupational therapy, for 8 weeks.
214411094|NCT04285125|OTHER|cerebral MRI|Patients who agree to participate in the study will perform an MRI with ultra high resolution sequences added by the research MRI of control will be done at one year and two years
214411095|NCT00779571|BEHAVIORAL|Crispbread|8 week low calorie diet
214411096|NCT02210702|DRUG|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
214411097|NCT02210702|DRUG|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
214411098|NCT00182520|DRUG|Topiramate|25 mg - 400 mg/day x 12 weeks
214411099|NCT00182520|DRUG|placebo|25 - 400 mg/day x 12 weeks
214411100|NCT01054430|DRUG|avanafil|200 mg avanafil tablets QD
214411101|NCT02805387|DIETARY_SUPPLEMENT|Treatment|Bicarbonate was ingested
214411102|NCT04642261|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg daily
214411103|NCT04642261|DRUG|Placebo pills|Identical in appearance to empagliflozin 10mg daily
215100937|NCT00679172|BIOLOGICAL|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
215100938|NCT00679172|OTHER|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
215100939|NCT00793325|DRUG|Somatropin|"Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
215100940|NCT05880498|BEHAVIORAL|Mindfulness Intervention|Self-guided mindfulness training using a customized version of the Healthy Minds app
215100941|NCT01815840|DRUG|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
215100942|NCT01815840|DRUG|Placebo|Vismodegib placebo orally once daily
214411104|NCT04281264|BEHAVIORAL|Passive Hypoxia|During 30 minutes of session, the participants will perform an intellectual activity while they will be exposed to normobaric hypoxic conditions in a hypoxic chamber (CAT 310, Lousiville, Colorado). They will inspire oxygen fraction (FiO2) set to 16.1% (0.16)
215015301|NCT03623100|BEHAVIORAL|Speech Production + Speech Perception Treatment.|This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
215015302|NCT01783236|DRUG|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
215015303|NCT01783236|DRUG|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
215015304|NCT00002246|DRUG|Stavudine|
215015305|NCT03219736|PROCEDURE|Standard of Care therapies|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
215015306|NCT03219736|DEVICE|NiPPV Therapy|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
215015307|NCT03219736|PROCEDURE|Routine Respiratory Care|It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
215015308|NCT00842036|BEHAVIORAL|Community Reinforcement and Family Training|Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
215100943|NCT06297382|BEHAVIORAL|ChatGPT Based Nursing Process Training|"ChatGPT Based Nursing Process Training topics:~Lesson 1: Use of artificial intelligence and ChatGPT in healthcare Lesson 2: Using ChatGPT in determining nursing diagnoses and goals Lesson 3: Using ChatGPT to determine nursing interventions Lesson 4: Things to consider and ethical principles when using ChatGPT when creating a nursing process."
215100944|NCT02144025|DRUG|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
215100945|NCT05496569|DRUG|TQB3616 capsule|TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
215100946|NCT05496569|DRUG|TQB3616 placebo|Placebo
215100947|NCT00901199|DRUG|Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
215100948|NCT01181869|DEVICE|oxygen|oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
215100949|NCT03221842|DRUG|C1-esterase inhibitor|C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
215100950|NCT03221842|DRUG|Placebo|Excipients of C1-INH plus albumin
215100951|NCT05809492|OTHER|step test|"The step speed of 18 steps/min was chosen for the first level because it is suitable for all subjects and prevents them from being too fast at the end of the test.~the slow standardized initial tempo at Level 1 of 72 beats/min allowed familiarity with the coordinated cascading technology of the tests (step up and down in time with the metronome beat). Regular replacement of the leading leg was encouraged to prevent unilateral leg fatigue and November muscle pain.~pwCF selected 1-minute stage times for each level in accordance with the maximum exercise test (CPET) recommendations in 18; at each new level, the test speed was increased by two steps / minute to ensure a progressive change in exercise parameters; a suitable end test time of 16 minutes was achieved along with an initial speed of 18 steps/min. The fast pace of 194 beats/min (48 steps/min at Level 16), which was eventually reached, it was physically possible to perform safely."
215100952|NCT00003883|DRUG|fluconazole|
215100953|NCT00003883|DRUG|itraconazole|
215100954|NCT00334984|DRUG|glutamine|
215100955|NCT00334984|PROCEDURE|chemoprotection|
215100956|NCT00334984|PROCEDURE|management of therapy complications|
215100957|NCT00334984|PROCEDURE|therapeutic nutritional supplementation|
215100958|NCT03520907|DRUG|Transversalis Fascia Plane Block|block will be performed under real-time ultrasound guidance
215100959|NCT03520907|DRUG|Ilioinguinal/iliohypogastric Nerve Block|block will be performed under real-time ultrasound guidance
215100960|NCT00704288|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
215100961|NCT02396563|PROCEDURE|epidural analgesia|
215100962|NCT02396563|DRUG|Ropivacaine|
215100963|NCT02435927|DRUG|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
215100964|NCT02435927|DRUG|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
215100965|NCT06388603|DEVICE|Bioactive Glass|Bonalive Granules and Bonalive Putty will be used (according to their IFU and CE certification) to fill the bone void after the debridment of infected tissue as they have osteoconductive and osteostimulative properties that allow bone rigeneration. Moreover, Bonalive Granules also present some bacteria growth inhibiting properties to combact bone infection propoer of Ostemyelitis.
215100966|NCT06388603|OTHER|Standard of Care|The investigators are left free to proceed according to the normal standar procedure they normally use. The procedures can vary according to investigator judgment also depending on the state of Osteomylitis.
215100967|NCT00000228|DRUG|Buprenorphine|
215015309|NCT00842036|BEHAVIORAL|Treatment Entry Training|Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
215015310|NCT00842036|BEHAVIORAL|12- step Al/Nar- Anon Facilitation|The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
215015311|NCT02086045|DEVICE|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System|percutaneous coronary
215015312|NCT01370538|DRUG|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
215015313|NCT00875901|RADIATION|Peripherally located lung tumor|12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
215015314|NCT00875901|RADIATION|Centrally located lung tumor|6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
214411105|NCT04281264|BEHAVIORAL|Normoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
214411106|NCT04281264|BEHAVIORAL|Hypoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
214411107|NCT04281264|BEHAVIORAL|Normoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performed on platform.~Subjects will inspire FiO2 of 21.0% (0.21)"
214411108|NCT04281264|BEHAVIORAL|Hypoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performance on the platform.~Participants will inspire a fraction of inspired oxygen (FiO2) of 16.1% (0.16)"
214411109|NCT04697251|DIAGNOSTIC_TEST|FOT measurements in newborns and small infants|Measurements will be performed using the device TremoFlo N-100, at bedside, with the infant in the supine position during quiet natural sleep. After proper cleaning and decontamination, the face mask of the device will be preheated at 37oC (to avoid awakening) and will be placed on infant's face. The duration of each measurement will be predetermined at 10 s. At least 3 technically acceptable measurements will be performed per infant, with 30 s intervals between them. The validity of each measurement will be assessed according to the coherence function (automatically determined by the operating system of the device).
214411110|NCT00123747|PROCEDURE|Positron Emission Tomography (PET) scan Imaging|
215015315|NCT04193527|DRUG|DaTSCAN™ Ioflupane (123I) Injection|All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.
215015316|NCT04573075|PROCEDURE|Ghost ileostomy|a loop of the small bowel is marked with a silicone strap and externalized through the abdominal wall to avoid a loop ileostomy
215015317|NCT04573075|PROCEDURE|loop ileostomy|a protective loop ileostomy is applied after after colorectal resection and forming of a primary anastomosis
215015318|NCT04573075|PROCEDURE|no outlet|no further intervention is used after colorectal resection and forming of a primary anastomosis
215015319|NCT02366130|DRUG|Ra-223 dichloride|55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
215015320|NCT02366130|DRUG|Denosumab|120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
215015321|NCT02366130|DRUG|Hormone Therapy|A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
214411111|NCT00364442|DRUG|fluticasone propionate/salmeterol|investigational drug
214411112|NCT06214468|COMBINATION_PRODUCT|Acetaminophen and Nicotinamide Riboside|Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside
214411113|NCT06214468|DRUG|Acetaminophen|Collection of urine at different time intervals following ingestion of Tylenol only
214411114|NCT04832646|PROCEDURE|atrial fibrillation ablation|persistent atrial fibrillation ablation with both AF and sinus rhythm map available
214411115|NCT02700867|DEVICE|NIO|Intraosseous access device NIO (Defibtech)
215015322|NCT04740879|BEHAVIORAL|Be Mindful|The online 4-week Be Mindful intervention was designed to follow the same outline as typical in-person 8-week MBCT courses. Week 1 and Week 2 introduce the topic of mindfulness and encourage its daily use, whereas Week 3 and Week 4 teach the individual to decenter from thoughts and utilize mindfulness when coping with stressors. Each week focuses on a separate mindfulness topic, which is initially presented to the individual in a short (under 5 minute) video containing didactic information and an overview of the experiential activities that will be introduced in subsequent videos. The intervention is provided entirely through audio, video, and text provided on the Be Mindful website (BeMindfulOnline.com).
214411116|NCT04658849|DRUG|Pioglitazone 30 Mg Oral Tablet|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
215015323|NCT00567112|DRUG|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
215015324|NCT00567112|DRUG|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
215015325|NCT00567112|DRUG|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
215015326|NCT00567112|DRUG|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
215015327|NCT03562637|BIOLOGICAL|adagloxad simolenin combined with OBI-821|In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.
215015328|NCT03562637|DEVICE|Globo H IHC Assay|The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.
215015329|NCT03562637|OTHER|Standard of care treatment|Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.
215015330|NCT02315326|DRUG|Ibrutinib|"Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A."
215015331|NCT02315326|DRUG|HD- Methotrexate (MTX)|Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
215100968|NCT05942443|PROCEDURE|Pre-treatment|The custom MCP blocking orthosis was made of a 1.6-mm-thick thermoplastic material that extends from the palm over the MCP joint and includes a ring around the proximal phalanx. It is designed to block the MCP joint in flexion of 10°-20° while allowing full range of motion of the proximal and distal interphalangeal joints.
215100969|NCT05942443|PROCEDURE|Post-treatment|The RME orthosis was fabricated from 3.2-mm-thick thermoplastic material with the affected finger positioned at an extension of approximately 10°-20° relative to the adjacent fingers.
215100970|NCT03306511|OTHER|Repeated-sprint test|6x30-meter sprint interspersed with 90-s rest
215100971|NCT03405649|BEHAVIORAL|Group A|Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.
214411117|NCT04658849|DRUG|Pioglitazone placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
215100972|NCT03405649|BEHAVIORAL|Group B|Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
215100973|NCT04681963|OTHER|Clinical Assessment within 4 hours of admission|Demographics, Symptoms, Severity scores (Triage at admission, confusion, urea, respiration, blood pressure, age (CURB 65) and pneumonia severity score (PSI), clinical parameters, blood testing, chest x-rays, comorbidities, electro-cardiogram
214411118|NCT01176799|DRUG|Arm A|Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
214411119|NCT01176799|DRUG|Arm B|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
214411120|NCT02661035|DRUG|Allopurinol|300 mg/day (for peds -150 mg/m\^2/day), day -6 and continue through day 0 or longer if clinically indicated
214411121|NCT02661035|DRUG|Fludarabine|30 mg/m\^2 IV over 1 hour, day -6, -5, -4, -3 and -2
214411122|NCT02661035|DRUG|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
214411123|NCT02661035|DRUG|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
215100974|NCT01836302|OTHER|Observation|
215100975|NCT04395690|PROCEDURE|Dental Implant Placement in the posterior mandible|Surgery done in the posterior mandible with missing teeth for placing dental implants.
215100976|NCT00197899|DRUG|E. Coli endotoxin|
214411124|NCT02661035|RADIATION|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
215100977|NCT04610398|DRUG|Dexamethasone 4mg|s. arm/group description
214411125|NCT02661035|DRUG|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~* Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~* Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
214411126|NCT02661035|DRUG|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, MMF will continue as long as clinically indicated."
214411127|NCT02661035|BIOLOGICAL|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
214411128|NCT02661035|BIOLOGICAL|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10\^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
214411129|NCT01360190|DRUG|fluoxetine|fluoxetine 20 mg. daily
214411130|NCT03557385|DRUG|Iopamidol|"aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~* Rate of 4 mL/sec, volume of 10 cc (left coronary system)~* Rate of 3 mL/sec, volume of 6 cc (right coronary system)."
214411131|NCT03557385|DRUG|adenosine|FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
214411132|NCT03557385|DEVICE|Navvus® Catheter|the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
214411133|NCT03557385|DEVICE|CVi® Contrast Delivery System|The CVi® Contrast Delivery System will be used to deliver the contrast medium
214411134|NCT00447434|DRUG|Natto extract (Nattokinase)|
214411135|NCT01516892|BIOLOGICAL|onabotulinumtoxinA|Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
214411136|NCT00413868|PROCEDURE|LASIK|
215015332|NCT02315326|DRUG|Rituximab + HD- Methotrexate (MTX)|Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
215015333|NCT02315326|DRUG|procarbazine|Arm D: THIS IS THE ONLY ARM RECRUITING: : Oral procarbazine (100mg/m2/day) will be given on Day 1 through 7 during each cycle. Patients will be maintained on a tyramine-free diet during procarbazine administration.
215015334|NCT04684485|DRUG|Placebo|Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
215015335|NCT04684485|DRUG|SCD-044_Dose 1|SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
214411137|NCT00413868|PROCEDURE|PRK|
214411138|NCT00413868|BEHAVIORAL|Small target contrast sensitivity and disability glare|
214411139|NCT01769781|DRUG|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
214411140|NCT01769781|DRUG|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
214411141|NCT03688828|DRUG|Saccharomyces boulardii|500mg bid
214411142|NCT03688828|DRUG|Esomeprazole|20mg bid
214411143|NCT03688828|DRUG|Amoxicillin|1.0g bid
214411144|NCT03688828|DRUG|Clarithromycin|0.5g bid
214411145|NCT03688828|DRUG|Bismuth potassium citrate|0.22g bid
215015336|NCT04684485|DRUG|SCD-044_Dose 2|SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
215015337|NCT04684485|DRUG|SCD-044_Dose 3|SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
215015338|NCT05769335|OTHER|eCR|Eating time window from 8:00 to 16:00
215015339|NCT05769335|OTHER|dCR|Eating time window from 12:00 to 20:00
215015340|NCT05769335|OTHER|CR|Eating time window from 8:00 to 20:00
215015341|NCT05272696|DRUG|Nab-paclitaxel, cisplatin and Pembrolizumab combination|Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy
215015342|NCT05272696|PROCEDURE|surgery|Patients with PR but the maximum diameter of tumor \> 3cm or SD or PD can receive surgery directly.
215015343|NCT05272696|RADIATION|Adjuvant Chemoradiotherapy|After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.
215015344|NCT05272696|DRUG|Radical concurrent chemoradiotherapy|Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
215015345|NCT06964646|DRUG|Vaginal Hyal gel 2.5g|vaginal gel 2.5g
215015346|NCT06963541|OTHER|No intervention; Observational study|No interventions are associated with either group. This is an observational study without experimental procedures.
215015347|NCT06964763|PROCEDURE|surgery + laser|laser
215015348|NCT06964763|PROCEDURE|surgery + fibrine glue|fibrine glue
215015349|NCT06964334|DRUG|Lansoprazole|oral lansoprazole (1 mg/kg per day, max. 30 mg bid)for 14 day
215015350|NCT06964334|DRUG|amoxicillin|amoxicillin (50 mg/kg per day, max. 1 g bid) for 14 day
215100978|NCT04610398|DRUG|NaCl 0.9%|s. arm/group description
215100979|NCT02689115|OTHER|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
215100980|NCT00321815|DRUG|PF-3512676 + Erlotinib|"PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity"
215100981|NCT00321815|DRUG|Erlotinib|Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
215100982|NCT06486896|OTHER|Pelvic floor training|It will be in the form of pelvic floor relaxation with biofeedback, as well as stretching exercises for the pelvic floor and the adjacent muscles. The patient will be asked to lie in a comfortable crock lying position. She will be instructed to do diaphragmatic breathing exercises. The vaginal electrode of the biofeedback will be gently introduced into the vagina to start pelvic floor relaxation training. Then, the patient will be asked to perform pelvic floor relaxation by slightly contracting the pubococcygeus muscle. After 10 minutes of pelvic floor relaxation training, the patient will then be instructed to return to the active state gradually, the treatment procedure will be performed 3 times/ week for 8 weeks. Stretching exercises for the pelvic floor and the adjacent muscles: Levator ani \& perineal muscles stretch, hip adductor muscles stretch, piriform muscle stretch, hip flexor muscles stretch, and obturator internus muscle stretch.
215100983|NCT06486896|DEVICE|Interferential current|Each female in the experimental group will receive interferential current, 3o minutes per session, 2 sessions per week, for 8 weeks. The applied parameters will be a frequency of 2000Hz, a modulated amplitude of frequency of 80Hz, pulse width of 200μs, and the intensity is modulated according to the sensory level of each participant. While the participant is in a comfortable crock lying position with abducted hips, the position of the electrodes will be maintained in all sessions
215100984|NCT06486896|BEHAVIORAL|General advice|The patients in both groups will follow general advice to help vaginismus for 8 weeks
214411146|NCT06080373|BEHAVIORAL|PROBECO|"Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.~German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention."
214411147|NCT06080373|BEHAVIORAL|Formulation-based cognitive behavioral therapy|"The CBT program includes these core modules:~A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.~B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.~C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.~D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges."
214411148|NCT05381662|BIOLOGICAL|CD19 CAR-T cells and CD19 positive feeder T cells|Detailed Description: Patients were divided into two groups, group 1 and group 2, and each group was enrolled in 5 patients. Group 1 patients did not receive any pretreatment, and group 2 patients received pretreatment with cyclophosphamide and fludarabine prior to reinfusion. Then Patients were given Chimeric Antigen Receptor T-Cell ( CAR-T) and CD19-positive T cells.
214411149|NCT05701462|DIAGNOSTIC_TEST|biopsy under sonographic gidance|pleural biopsy under sonographic guidance
214411150|NCT05836935|RADIATION|Multislice CT scan of the paranasal sinuses.|MSCT scan using GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) , Toshiba Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Or Canon Aquilion Prime SP 160 -multidetector- row CT scanner (Canon Medical Systems, Tochigi, Japan) Thin slice Axial scans will be taken at 0.625-1.0 mm slice thickness, commencing from the hard palate till above the end of frontal sinuses, coronal and sagittal multiplanar reconstruction images will be obtained.
214411151|NCT05836935|RADIATION|MRI examination of the paranasal sinuses|MRI imaging using Philips Achieva 1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea 1.5T MRI device (Siemens Healthineers, Germany) for suspected intracranial and orbital complications.
214411152|NCT02702024|PROCEDURE|Double uterine incision technique in uterus preserving surgery for placenta percreta|
214411153|NCT03155490|BEHAVIORAL|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
215015351|NCT06964334|DRUG|clarithromycin|oral clarithromycin (15 mg/kg per day, max. 500 mg bid) for 14 day
215015352|NCT06964334|DRUG|vitamin D|vitamin D therapy of 4000-5000 units daily in patients over 12 months old.
215015353|NCT06171399|BEHAVIORAL|"All Natural descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
215100985|NCT02120391|OTHER|iPhone Application|All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
215100986|NCT05562258|BEHAVIORAL|Parent Coaching and Patient Education|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to a coach and patients will have access to weekly educational material.
215100987|NCT05562258|BEHAVIORAL|Parent Education and Patient Coaching|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to weekly educational material and patients will have access to a coach.
215100988|NCT01186055|BEHAVIORAL|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
214411154|NCT02594215|DRUG|MK-7075 (miransertib)|MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome.
214411155|NCT03789799|OTHER|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
214411156|NCT03789799|OTHER|Placebo|Placebo vaginal capsule, composition: Sodium Hyaluronate, Aloe Barbadensis Extract
214411157|NCT02786771|DEVICE|Spire|
214411158|NCT02786771|DEVICE|Muse headband|
215015354|NCT06171399|BEHAVIORAL|"Gluten-free descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
215015355|NCT06171399|BEHAVIORAL|"Vegan descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
215015356|NCT06171399|BEHAVIORAL|"100% Organic descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
215015357|NCT06171399|BEHAVIORAL|"Handcrafted descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
215015358|NCT06171399|BEHAVIORAL|"Made with live resin descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
215015359|NCT06171399|BEHAVIORAL|"Fast-acting descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
215015360|NCT06171399|BEHAVIORAL|"Relax descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
215015361|NCT06171399|BEHAVIORAL|"Energy Boost descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
214411159|NCT00551772|DRUG|SB-742457|
214411160|NCT02796092|DEVICE|Fibered platinum coils|
214411161|NCT02796092|DEVICE|Vascular plugs|
214411162|NCT05779514|DRUG|Mirabegron|Health Volunteers ：Mirabegron p.o. 28 days 100mg qd./ Tumor patients ：Mirabegron p.o. 28 days 100 mg qd or 200 mg qd.
214411163|NCT04278820|DRUG|TQA3526|Tablet(s) administered orally once daily
214411164|NCT04278820|DRUG|Placebo to match TQA3526|Tablet(s) administered orally once daily
215015362|NCT06171399|BEHAVIORAL|No descriptor (control)|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
215015363|NCT03070886|DRUG|Bicalutamide|Given orally (PO)
215015364|NCT03070886|DRUG|Degarelix|Given IM
215015365|NCT03070886|DRUG|Docetaxel|Given IV
215015366|NCT03070886|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
215015367|NCT03070886|DRUG|Flutamide|Given PO
215015368|NCT03070886|DRUG|Goserelin|Given IM
215015369|NCT03070886|DRUG|Goserelin Acetate|Given IM
215015370|NCT03070886|OTHER|Laboratory Biomarker Analysis|Correlative studies
215015371|NCT03070886|DRUG|Leuprolide|Given intramuscularly (IM)
215015372|NCT03070886|DRUG|Leuprolide Acetate|Given IM
214411165|NCT02534896|DRUG|Treatment I|Sunpharma1505 and Placebo
214411166|NCT02534896|DRUG|Treatment II|Sunpharma1505 and Placebo
214411167|NCT02534896|DRUG|Treatment III|Reference1505 and Placebo
214411168|NCT01365403|DRUG|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
214411169|NCT01365403|DRUG|carbamazepine|multiple oral doses, Days 1-24 of study period 2
214411170|NCT03771846|DRUG|irinotecan, oxaliplatin , fluorouracil, and leucovorin|administration of irinotecan, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
214411171|NCT03771846|DRUG|gemcitabine and oxaliplatin|administration of gemcitabine and oxaliplatin via vein
214411172|NCT02306564|DRUG|Cabergoline|given to patients at high risk for OHSS
214411173|NCT00017004|RADIATION|External Beam Radiation Therapy|Undergo radiation
214411174|NCT00017004|DRUG|Cisplatin|Given IV
214411175|NCT00017004|RADIATION|Internal Radiation Therapy|Undergo radiation
214411176|NCT00017004|BIOLOGICAL|Epoetin Alfa|Given SC
214411177|NCT04923139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Dosage at the discretion of the treating physician
214411178|NCT00323752|PROCEDURE|rHuEpo|Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.
214411179|NCT05961670|DEVICE|Neer Infrared Spectroscopy|Premature infants will be studied with brain and lung NIRS before and after surfactant administration
214411180|NCT01107626|DRUG|Paclitaxel|Given IV
214411181|NCT01107626|DRUG|Carboplatin|Given IV
215015373|NCT03070886|DRUG|Nilutamide|Drug
214411182|NCT01107626|BIOLOGICAL|Bevacizumab|Given IV
214411183|NCT01107626|DRUG|Pemetrexed Disodium Heptahydrate|Given IV
214411184|NCT00711646|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
214411185|NCT00711646|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
215015374|NCT04595370|DRUG|AZD9977|Participants will receive AZD9977 as per the arms they are randomized.
215015375|NCT04595370|DRUG|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized.
215015376|NCT01017315|DRUG|Baby talcum|50 grams apply locally prior cast application
215015377|NCT02745405|OTHER|Fat Suit|Participants wear a fat suit.
215015378|NCT02745405|OTHER|Control Condition|Participants wear same clothing as intervention, but in their own size.
215015379|NCT03528850|OTHER|Telemedicine evaluation|Weekly virtual visits and daily biometric readings of blood pressure, weight, oxygen saturation and pulse
215015380|NCT03934879|BEHAVIORAL|FitClub|Participants will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
215015381|NCT03934879|OTHER|Regular School Activities|Students will participate in regular school activities.
215015382|NCT01945242|DRUG|Alogliptin|Alogliptin tablets
215015383|NCT06050512|DRUG|Mezigdomide|Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.
215015384|NCT06050512|DRUG|Ixazomib|Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.
215015385|NCT06050512|DRUG|Dexamethasone|Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
215015386|NCT02478502|DRUG|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
215015387|NCT02512445|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
215015388|NCT02512445|BEHAVIORAL|Supportive Care Therapy|Supportive therapy
215015389|NCT05050214|DRUG|Obinutuzumab|Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
215015390|NCT01170130|DRUG|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
215015391|NCT05768711|DRUG|Venetoclax|Combination of Azacitidine and Venetoclax
215015392|NCT05655169|PROCEDURE|Piezosurgery and GaALAs diode laser|"One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.~After six weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied."
215015393|NCT05655169|PROCEDURE|Piezosurgery|One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.
215015394|NCT05655169|OTHER|Fixed orthodontic appliance|"After the levelling and alignment phase is completed, the rectangular stainless steel archwires (0.019 × 0.025) will be inserted, then after two weeks, the en masse retraction will be started via closed nickel-titanium coil springs applying 250 g of force per side."
215015395|NCT05698628|PROCEDURE|Distal perfusion catheterization|Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.
215015396|NCT05661734|DRUG|Suzetrigine|Tablets for oral administration.
215015397|NCT04569097|OTHER|standard of care lingual strengthening|standard or care lingual strengthening approaches with outcome measured with novel pressure metrics
215015398|NCT03037008|DEVICE|Perineal Sonography|In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.
215015399|NCT01670149|DRUG|Rifaximin|Tablets
215015400|NCT01670149|DRUG|Placebo|Tablets
215015401|NCT05720520|OTHER|Technological education method|Students in the experimental group will play the mobile application developed for stoma and peristomal skin care and are expected to learn the skill in this way. The students in the control group, on the other hand, will learn stoma and peristomal skin care on a model in the traditional skill laboratory and are expected to learn the skill in this way. Afterwards, the knowledge and skill scores of the two groups will be compared and the results will be reported.
215015402|NCT03968003|DIETARY_SUPPLEMENT|Inulin|The intervention group (group A) consumed 10 g of inulin extracted from Thai Jerusalem artichoke by our patent technique (Patent no. 15858) administered once daily before dinner. The placebo group (group B) received isocaloric maltodextrin, while the dietary fiber advice group (group C) received guidance based on age-appropriate intake recommendations.
214411186|NCT05237219|PROCEDURE|Passive heating|Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
214411187|NCT05237219|PROCEDURE|Thermoneutral|Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
214411188|NCT05982353|DEVICE|PTFE application|Polytetrafluoroethylene membrane used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
214411189|NCT05982353|DEVICE|Gelatin sponge|gelatin sponge used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
215015403|NCT01775709|DEVICE|PE tube with Duckbill Valve|PE tube with Duckbill Valve
214411190|NCT02485379|PROCEDURE|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
215015404|NCT00536614|GENETIC|cetuximab|Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
215015405|NCT02602197|DRUG|Paracetamol|After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.
214411191|NCT04238000|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
215100989|NCT05731479|OTHER|Diathermy + exercise group|The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.
215015406|NCT02602197|DRUG|Dexketoprofen|After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
215015407|NCT00669344|DRUG|Exelon (rivastigmine)|Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
215015408|NCT00669344|DRUG|Placebo|Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
215015409|NCT03180372|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
215015410|NCT00922051|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|
215015411|NCT00922051|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Placebo
215100990|NCT05731479|OTHER|Diathermy placebo + exercise group|The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
214411192|NCT04381494|DEVICE|Multiparametric Mobile Technology|Using a spirometer, an armband, and a tablet to collect data.
214411193|NCT03992495|OTHER|Exercise|All participants will be exposed to aerobic/strengthening exercises
214411194|NCT04310579|DRUG|Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day."
214411195|NCT04310579|DRUG|Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
214411196|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
215015412|NCT05644418|DEVICE|Flow Controlled Ventilation (FCV)|FCV is started with the same settings as PCV (PEEP, Ppeak, FiO2) and after 30 minutes FCV is optimized concerning the driving pressure and PEEP using the dynamic compliance. After a total of 60 minutes the flow is adjusted based on the arterial blood gas.
215100991|NCT02692755|DRUG|Palbociclib + Letrozole or Fulvestrant|Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
215015413|NCT00204789|DRUG|Difluoromethylornithine|
215015414|NCT01125748|DRUG|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
215015415|NCT01125748|DRUG|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
215015416|NCT01125748|DRUG|Asthma therapies|Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
215100992|NCT03387020|DRUG|Everolimus|Given PO
215100993|NCT03387020|OTHER|Laboratory Biomarker Analysis|Correlative studies
214411197|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
215100994|NCT03387020|OTHER|Pharmacological Study|Correlative studies
214411198|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
214411199|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
214411200|NCT00186420|DRUG|Taxotere|
215015417|NCT01641432|BEHAVIORAL|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
215015418|NCT01641432|BEHAVIORAL|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
215015419|NCT02405962|BEHAVIORAL|ACT|Four sessions of group-based ACT integrated with asthma education. Each session will compose of pediatric asthma education based on guidelines of Global Strategy for Asthma Management and Prevention Revised 2011, plus group-based Acceptance and Commitment Therapy (ACT). The goal of ACT is to enhance the psychological flexibility of the parents, enabling them to (1) become aware of their thoughts and feelings regarding their child's asthma and its management, (2) accept and adapt flexibly to challenging situations, and (3) take actions to achieve valued goals in childhood asthma management.
215015420|NCT02405962|BEHAVIORAL|Control|One session of educational talk about pediatric asthma care, as the usual care. To ensure the equivalency of the assigned sessions between groups, after attending the talk in the first week, the parents in the Control group will receive three telephone calls, starting from the second week on a weekly basis. This arrangement can also minimize the interference of the usual care naturalistically available in the study setting.
215015421|NCT01454999|BEHAVIORAL|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
215015422|NCT00839826|DRUG|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
215015423|NCT00839826|DRUG|Enoxaparin|40 mg bid
215100995|NCT03387020|DRUG|Ribociclib|Given PO
215100996|NCT00077324|GENETIC|proteomic profiling|
215100997|NCT00077324|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
215100998|NCT00077324|PROCEDURE|biopsy|
215100999|NCT00077324|PROCEDURE|surgery|
215015424|NCT02928432|DRUG|Steroids switch|Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
215101000|NCT02139488|OTHER|Fiducial markers|
215101001|NCT02139488|OTHER|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
215101002|NCT02496299|DRUG|Dexamethasone|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
215101003|NCT02496299|DRUG|Bupivacaine|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
215101004|NCT05045300|PROCEDURE|Ultrasound guided Selective trunk block|High definition ultrasound images that were acquired during USG SeTB are routinely stored in the hard disk of ultrasound machine in DICOM (Digital Imaging and Communications in Medicine) format will be used for this review. The images of principal investigator's previous research studies with Clinical trial registration: NCT04752410 and NCT04773405 will also be retrieved. The ultrasound imaging was performed before (scout scan), during and immediately after the USG SeTB. As is the principal investigator's standard practice, all ultrasound scan was performed in a sequential manner (SUIT: Sequential Ultrasound Imaging Technique) with the orientation marker of the transducer directed laterally so as to obtain a transverse oblique view of the brachial plexus block at the supraclavicular fossa. Approximate 50 cases who had undergone USG SeTB for surgical anesthesia during upper extremity surgery since January 1 2020 to June 30, 2021 will be evaluated by two anesthesiologists.
215101005|NCT00434642|DRUG|Carboplatin|Carboplatin was provided as commercially available drug.
215101006|NCT00434642|DRUG|Gemcitabine|Gemcitabine was provided as commercially available drug.
215101007|NCT00434642|DRUG|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL \[25 mg/mL\]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
215101008|NCT00434642|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
214411201|NCT01644773|DRUG|Crizotinib|"Starting dose level:~* Initial Treatment Plan: 130 mg/m\^2 per dose~* Modified Treatment Plan per Amendment 1.0: 165 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day"
214411202|NCT01644773|DRUG|Dasatinib|"Starting dose level: 50 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day"
214411203|NCT05190913|OTHER|Instrumental perineal massage|In the active phase of labor, perineal massage will be performed with an instrument twice with an interval of one hour.
214411204|NCT05190913|OTHER|manual perineal massage|In the active phase of labor, manual perineal massage is performed twice an hour apart.
214411205|NCT00604006|DRUG|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
214411206|NCT00604006|DRUG|Placebo|Placebo (lactose in capsules for blinding) once daily
214411207|NCT01603719|DIETARY_SUPPLEMENT|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
215101009|NCT04139356|PROCEDURE|Deep breaths|Patients will undergo a 6 minutes protocol. Baseline: 1 minute normal breaths. Intervention: 1 minute with 10 deep breaths, 1 each 6 secs. Pulse-oxymetry will be continuously recorded.
214411208|NCT05082649|OTHER|Face to Face Exercise|Face to face (in clinic) progressive spinal stabilization exercises.
215015425|NCT02757014|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - R84-087)
214411209|NCT05082649|OTHER|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
214411210|NCT02375581|DRUG|Icotinib|125mg, Po, TID during RT
214411211|NCT02375581|RADIATION|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
214411212|NCT04662840|PROCEDURE|Geniculate artery embolization|Under fluoroscopic guidance and angiographic imaging, a microcatheter is used to select all the arteries feeding the affected knee and Embosphere (100-300um) particles are injected to obtaining pruning of the hypervascular tissues arteries.
214411213|NCT04662840|PROCEDURE|Geniculate nerve ablation|Under fluoroscopic guidance, a Cool-tip RFA ablation needle is advanced such that it touches the femur at the condylar convexity on each side and the tibia at the tibial plateau convexity on the medial side. The ablation is performed to obtain an approximate zone of ablation of 2cm.
214411214|NCT04662840|PROCEDURE|Skin infiltration of local anesthetic at groin and knee|Freezing of the skin will be performed at the groin (as prior to an arterial access for embolization procedure) and at three areas around the knee (as prior to insertion of the ablation needles for nerve ablation procedure).
215015426|NCT01028391|DRUG|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
215015427|NCT01028391|DRUG|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
215015428|NCT01028391|DRUG|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
215015429|NCT03402412|OTHER|narrow-band UVB|Standard established treatment for atopic dermatitis with narrow-band UVB will be used in this study but initially only on a small amount of skin to assess what changes takes place in the skin.
215015430|NCT02978768|OTHER|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
215015431|NCT02978768|DEVICE|Computer-based cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
215015432|NCT02978768|DEVICE|Physico-Mental rehabilitation Wii|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
215015433|NCT03542357|DRUG|Calcitonin Gene Related Peptide|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
215015434|NCT03542357|DRUG|Sumatriptan 50 mg|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
215015435|NCT03542357|DRUG|Placebo Oral Tablet|CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
215015436|NCT00053742|DRUG|Modified Vaccinia Virus Ankara TBC-MVA|
215015437|NCT02939664|DEVICE|Banded (with polypropylene mesh) gastric bypass|The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.
215015438|NCT02939664|PROCEDURE|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
215015439|NCT01951027|DRUG|GX-G3 12.5 μg/kg or Placebo|Single SC injection
215015440|NCT01951027|DRUG|GX-G3 25 μg/kg or Placebo|Single SC injection
215015441|NCT01951027|DRUG|GX-G3 50 μg/kg or Placebo|Single SC injection
215015442|NCT01951027|DRUG|GX-G3 100 μg/kg or Placebo|Single SC injection
215015443|NCT00062504|DRUG|Talampanel|10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
215015444|NCT00670384|BIOLOGICAL|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Sublingual drops
215015445|NCT00670384|BIOLOGICAL|Placebo|Sublingual drops
215015446|NCT04616352|OTHER|Resistance to cefuroxime|Non susceptibility in vitro testing
215015447|NCT00033345|DRUG|Indole-3-carbinol|400 mg pill taken daily
215015448|NCT00033345|DRUG|Indole-3-carbinol|800 mg pill taken daily
215015449|NCT00033345|OTHER|Placebo|Placebo pill taken daily during run-in period
215015450|NCT02208622|DIETARY_SUPPLEMENT|Study 1: Whey Supplement Day 1|Whey supplement was given on day 1, control diet on day 2
215015451|NCT02208622|DIETARY_SUPPLEMENT|Study 1: Whey Supplement Day 2|Control diet was given day 1, whey supplement was given day 2
215015452|NCT02208622|DIETARY_SUPPLEMENT|Study 2: Whey Supplement|Whey supplement was given as part of diet for both day 1 and 2 of study
215015453|NCT05873621|PROCEDURE|ICG-guided lymphadenectomy|Excision of ICG-fluorescent lymph nodes in addition to standard laparoscopic total mesorectal excision in rectal cancer patients after neoadjuvant chemoradiation
215015454|NCT04833608|DEVICE|Vktory insoles|Patients were randomized into either the Carbon fiber insole group or Morton's extension group.
215015455|NCT04833608|DEVICE|Morton's extension insoles|Patients were randomized into either the Vktory carbon fiber insole group or Morton's extension insole group.
215015456|NCT01529216|DEVICE|DIAMOND System|Electrical stimulation to the fundus
215101010|NCT04120363|DRUG|Testosterone Undecanoate|single intramuscular injection of 750 mg testosterone undecanoate
215101011|NCT04120363|DRUG|Sesame Oil|single intramuscular injection of 750 mg sesame oil solution
215101012|NCT03424356|DRUG|Rocuronium Bromide|0.15 mg/kg rocuronium bromide
215101013|NCT03424356|DRUG|Saline Solution|1-2 ml saline solution
215015457|NCT01184118|DRUG|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
215015458|NCT04626531|OTHER|Web-Based Education|Participants in the intervention group had unlimited access to the Web site, free of charge. The Web site was designed to run on personal computers and smartphones.
214411215|NCT03121131|OTHER|Clinical Exam Findings|Findings found on clinical exam of a patient the radiologist will be reading CT scans of.
214411216|NCT03121131|OTHER|Inaccurate Clinical Exam Findings|Inaccurate findings are given to the radiologists
215101014|NCT03424356|DRUG|Fentanyl|1mcg/kg for induction
215101015|NCT03424356|DRUG|Propofol|2-3mg/kg for anaesthetic induction
215101016|NCT03424356|PROCEDURE|cystoscopy|patients will treated with this surgical procedure
215101017|NCT04680429|DRUG|RP7214|Participants will receive single and multiple ascending doses of RP7214
215015459|NCT04626531|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
215015460|NCT03816826|OTHER|physical therapy|both are physical therapy intervention technique used to treat the soft tissue acute injuries
215015461|NCT01300065|DEVICE|Experimental- Soflens|A new pair of lenses will be worn each day while the subject is in the study
215015462|NCT01300065|DEVICE|Marketed - Soflens|A new pair of lenses will be worn each day while the subject is in the study.
215015463|NCT00307255|DRUG|gemcitabine hydrochloride|1000 mg/m2 on days 1 and 8 of each 21 day cycle
215015464|NCT00307255|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)
215015465|NCT03853200|DRUG|QMix Root Canal Irrigant|Endodontic irrigant recommended for final irrigation
214411217|NCT03121131|OTHER|No clinical exam findings|No clinical exam findings are given to the radiologists
214411218|NCT02327039|DRUG|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
214411219|NCT02327039|DRUG|Placebo|Tables of Dapagliflozin placebo
214411220|NCT05406180|BIOLOGICAL|VaxigripTetra inj.|Suspension for injection in a pre-filled syringe Injection intramuscular
214411221|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
215015466|NCT03853200|DRUG|17%EDTA+2%Chlorhexidine|two endodontic irrigants will be used in this group in a sequential manner
215015467|NCT03853200|OTHER|EDTA|17% EDTA irrigation solution
215015468|NCT00686218|DRUG|imatinib mesylate|Given orally
215015469|NCT00686218|DRUG|panobinostat|Given orally
215015470|NCT00686218|GENETIC|polymerase chain reaction|Testing
215015471|NCT00686218|GENETIC|protein expression analysis|Testing
215015472|NCT00686218|GENETIC|western blotting|Testing
215015473|NCT00686218|OTHER|flow cytometry|Testing
215015474|NCT00686218|OTHER|laboratory biomarker analysis|Testing
215015475|NCT00686218|OTHER|pharmacological study|Testing
215015476|NCT06541028|BEHAVIORAL|Rapid-Start ART (RS-ART)|ART initiation within 7 days of HIV diagnosis. (RS-ART intervention to be informed and developed in Aims 1 and 2.) RS-ART is a strategy that focuses on clinical decision-making generally based solely on clinical criteria, and later organizing support for mental health, adherence, and management of comorbid conditions only after the patient has initiated ART.
215015477|NCT04902144|OTHER|Electronic Health Record Review|Medical data collected
215015478|NCT04902144|OTHER|Questionnaire Administration|Complete questionnaires
215015479|NCT04902144|BEHAVIORAL|Behavioral Intervention|Receive coaching
215015480|NCT03106805|PROCEDURE|early insertion|insertion at 4th postpartum week
215015481|NCT03106805|PROCEDURE|late insertion|insertion at 6th postpartum week
215015482|NCT02129556|DRUG|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
215101018|NCT04680429|DRUG|Placebo|Participants will receive single and multiple ascending doses of matching placebo
215101019|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
215101020|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
215101021|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
215101022|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
215101023|NCT02354872|DRUG|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
214411222|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
214411223|NCT02155686|DEVICE|Biosensors|Device: Biometric sensors; Home automation; telecare
214411224|NCT02155686|DEVICE|Home automation|
214411225|NCT00331214|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
214411226|NCT00331214|DRUG|placebo patch|placebo patch replaced every 3-4 days for 6 months
214411227|NCT06446674|PROCEDURE|mini monaka|mini monaka,perforated plugs
214411228|NCT06099821|DRUG|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
214411229|NCT06099821|DRUG|Regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
214411230|NCT06099821|DRUG|Apatinib|Apatinib is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. It has been also reported to have anti-tumor efficacy in other kinds of digestive system cancers.
215101024|NCT02354872|BEHAVIORAL|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
215101025|NCT02354872|BEHAVIORAL|5Rs Motivation Counseling|"The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions."
214411231|NCT04379986|DEVICE|Senbiosys|The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
214411232|NCT02365298|DEVICE|etafilcon A|etafilcon A soft contact lens
214411233|NCT02365298|DEVICE|nelfilcon A|nelfilcon A
214411234|NCT04393103|DRUG|Intralipid, 20% Intravenous Emulsion|"Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~* Group A (Control Group) : Follow Up of 30 patients.~* Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart."
214411235|NCT04393103|DRUG|Intravenous Atropine Sulfate|Atropine will be administered to ALL PATIENTS in Group A and group B by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till complete atropinization. Following this, an infusion of 10-20% of the atropinizing dose was given every hour.
214411236|NCT00998816|DRUG|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
214411237|NCT05767073|BEHAVIORAL|Lifestyle InterVEntion (LIVE)|"The lifestyle intervention Coaching on Lifestyle (CooL) (van Rinsum 2018)),formed the basis of LIVE and was adapted to specific dysfunctional elements in depressed patients regarding motivation and self-management.~The focus is on reducing depressive symptoms, enhancing the quality of life and possibly achieving weight loss.~The lifestyle intervention lasts six months, with 13 weekly 1.5 to 2 hour group sessions and five 45 to 60 -minute individual sessions with at least one person from the patient's support network of friends or family (preferably sharing the same household). All sessions end with individual homework exercises, and each session starts with a 10 to 15-minute positive psychology intervention (PPI) and 5 to 15 minutes of physical activity. These sessions are followed by two booster sessions after about two and six months. Groups consist of 4-8 people."
214411238|NCT01339702|OTHER|The National Prehospital TBI Management Guidelines|"In the post-implementation (after) cohort, implementation of the entire bundle of the TBI treatment guidelines with special emphasis on prevention and treatment of hypotension (IV crystalloids), prevention and treatment of hypoxia (pre-oxygenation with high-flow O2 via non-rebreather mask, bag-valve-mask, extraglottic airways/intubation when basic maneuvers have failed), and prevention of hyperventilation (in intubated patients) and prevention/treatment of hypoventilation (in all patients)."
214504814|NCT04725266|BEHAVIORAL|Family-based intervention|The intervention aims to motivate drug abusers to stay drug abstinence and improve family functioning with the support of their own families. In the component of engagement, we will use effective and appropriate skills to engage clients, understand their concerns, and provide necessary resources to them. In the component of role identification, we will help drug abusers identify their family roles through providing education on family roles and responsibilities. The component of affection is designed to learn affective responsiveness and enhance their emotional bonds with each other, while in the component of competence, we will enhance their competency to take care of the family. The intervention will be conducted in group sessions with 4-6 families per group. A total of 17 sessions will be delivered with 1.5-2 hour for each session (6 sessions for Engagement, 3 sessions for Role identification, 3 sessions for Affection, and 3 sessions for Competence).
214504815|NCT04725266|OTHER|routine care|Routine care includes individual-session components of engagement, case assessment, drug education, service referral, family support, and etc.
215015483|NCT01049828|OTHER|No intervention|No treatment for tinnitus will occur in this study.
215015484|NCT01006408|PROCEDURE|Low Level Laser|Low Level Laser twice a week for 8 weeks
215015485|NCT01006408|PROCEDURE|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
215015486|NCT02958670|OTHER|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
215015487|NCT06165965|DRUG|SGLT2 inhibitor|SGLT2 dual inhibitor
215015488|NCT04102982|DRUG|Camrelizumab|Patients will be treated with camrelizumab alone.
215015489|NCT04102982|OTHER|Camrelizumab plus microwave ablation|In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
215015490|NCT05697003|DRUG|Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
215015491|NCT05697003|DRUG|ADVAIR DISKUS 100/50|2 inhalations in one study period
215015492|NCT06603831|PROCEDURE|patients treated using 3D technology and Patient-Specific Instrumentation|"3D Digital surgery includes:~* 3D Surgical Planning using biomedical engineering software; 3D visualization of the patients anatomy and surgical simulation.~* Use of personalized surgical guides created through additive manufacturing.~* Use of personalized implants created through additive manufacturing.~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
215015493|NCT06603831|PROCEDURE|Patients treated with conventional surgery, without using 3D technology|"Conventional surgery includes:~* 2D planning using TC and x-rays~* Free-hand surgery~* Use of generic, non-personalized implants~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
215015494|NCT05228340|PROCEDURE|Flexor tenotomy|Minimally-invasive percutaneous needle flexor tenotomy of the long digital flexor tendon
215015495|NCT05028088|DRUG|sugammadex|This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.
215015496|NCT05944510|DRUG|Dextromethorphan|Dextromethorphan 30mg will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
215015497|NCT05944510|DRUG|Placebo|Matched placebo will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
215015498|NCT04922528|PROCEDURE|Laparoscopic Cholecystectomy with Fluorescent Cholangiography|Indocyanine green is a fluorophore molecule which is metabolized by the liver and excreted exclusively through the biliary system. Intra-operatively, near-infared imaging via the laparoscope will be used to visualize the biliary anatomy in the intervention arm, as an adjunct to standard of care white-light imaging.
215015499|NCT04922528|PROCEDURE|Laparoscopic Cholecystectomy with White Light Imaging|As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.
215101026|NCT02354872|BEHAVIORAL|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
215101027|NCT02354872|OTHER|No Treatment|No Treatment
215101028|NCT00288236|DRUG|Rimonabant (SR141716)|
215101029|NCT00288236|DRUG|Placebo|
215101030|NCT00629811|DRUG|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~* Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~* Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
214411239|NCT03545789|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
214411240|NCT04872712|PROCEDURE|Press needles|Manual acupuncture using press needles
214411241|NCT04872712|PROCEDURE|Filiform Needles|Manual acupuncture using filiform needles
215015500|NCT06658158|BEHAVIORAL|Cognitive correction and stimulus control|"Cognitive correction:~a) correcting unrealistic sleep expectations; b) maintaining a natural sleep onset; c) avoiding worry about losing control oversleep; d) not associating nocturnal dreaming with adverse daytime consequences; e) avoiding feelings of frustration due to one night of poor sleep; f) developing tolerance to the impact of insomnia and avoiding compensatory behaviors.~Stimulus control:~1. Minimize wakefulness during time in bed and establish a positive association between sleepiness and the bed.~2. Use the bed only for sleep and sexual activities.~3. Go to bed only when feeling sleepy at night or at the designated sleep time.~4. If unable to fall asleep within approximately 20 minutes of being in bed, leave the bedroom, engage in relaxing activities, and return to bed when feeling sleepy. Repeat this process if unable to fall asleep within approximately 20 minutes.~5. Wake up at the same time every morning, including weekends."
215101031|NCT00629811|DRUG|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
215101032|NCT03876119|DRUG|Intraarterial alteplase|See arm/group descriptions.
214411242|NCT03114722|DRUG|Citrate 4%|In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
214411243|NCT03114722|DRUG|Heparinised saline (10U/ml)|In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
214411244|NCT03431779|PROCEDURE|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
214411245|NCT03431779|PROCEDURE|Surgical excision|Excision of painful areas
214411246|NCT03780309|BEHAVIORAL|Exercise Self-Monitoring|Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
215015501|NCT06658158|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
215015502|NCT00954135|DRUG|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
215015503|NCT00954135|DRUG|letrozolo+sorafenib+cyclophosphamide|"Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months"
215015504|NCT06257121|DEVICE|OSMS position management|Patient position management in real time during radiation using an optical Surface Management System (OSMS) (Vision RT)
215101033|NCT03876119|DRUG|Placebo|See arm/group descriptions.
215101034|NCT05979922|BEHAVIORAL|Mindfulness-based Cognitive Coping|Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.
215101035|NCT05979922|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
215101036|NCT02191332|DRUG|Viramune|
215101037|NCT02282280|DRUG|Prilocaine Chlorhydrate|Use of prilocaine in spinal anesthesia
215101038|NCT05307809|OTHER|Blood sample collection|Blood sample collection
215101039|NCT05307809|OTHER|Skin sample collection|Skin sample collection
215101040|NCT04183608|DRUG|Adalimumab|Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)
215101041|NCT04183608|DIAGNOSTIC_TEST|Calprotectin|Fecal calprotectin dosing at home with IBDoc
214411247|NCT03780309|BEHAVIORAL|Blood Pressure Self-Monitoring|Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
214411248|NCT01886469|DRUG|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
214411249|NCT01886469|DRUG|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
214411250|NCT01886469|DRUG|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
214411251|NCT01750957|DRUG|Placebo|orally daily, 12 weeks
214411252|NCT01750957|DRUG|RO4917523|Dose A orally daily, 12 weeks
214411253|NCT01750957|DRUG|RO4917523|Dose B orally daily, 12 weeks
214411254|NCT02718469|BIOLOGICAL|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
215101042|NCT04183608|OTHER|e-Monitoring|"e-Monitoring at Week 6, Week 10, Week 14, Week 18, Week 22, Week 26, Week 34, Week 38, Week 42 and Week 48~The patient must complete the first 2 questions of the Mayo score:~* Stool frequency~* The frequency of bleeding~He must also complete the information on his injections"
215101043|NCT04183608|OTHER|Therapy Education|Patient Education at W0, W2, W14, W26 and W38.
215101044|NCT04512976|OTHER|Control (no cooling modalities)|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.
214411255|NCT02718469|BIOLOGICAL|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
214411256|NCT02718469|BIOLOGICAL|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
214411257|NCT02718469|BIOLOGICAL|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
214411258|NCT00154713|BIOLOGICAL|CEA pulsed dendritic cells|
214411259|NCT03142789|DRUG|Initial bolus (Certa and standard catheter groups)|10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
214411260|NCT03142789|DRUG|Initial bolus (Single bolus group)|20 ml of ropivacaine 0.75%
214411261|NCT03142789|DRUG|Intermittent boluses (Certa and standard catheter groups)|20 ml of ropivacaine 0.2% every 8 hour in the catheter
214411262|NCT03142789|DRUG|Intermittent boluses (Single bolus group)|0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
214411263|NCT02519296|BEHAVIORAL|Prolonged Exposure Therapy|8 sessions with prolonged exposure therapy and fMRI.
214411264|NCT02519296|BEHAVIORAL|Observation|fMRI.
214411265|NCT02519296|DEVICE|fMRI|Functional Magnetic Resonance Imaging of the brain
214411266|NCT06076343|BEHAVIORAL|DBT skills-training and Family Connections interventions|"DBT skills-training program includes four modules: 1. Mindufulness, 2. Distress Tolerance, 3. Emotion Regulation, 4. Interpersonal effectiveness.~FC program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills."
214411267|NCT00854139|DRUG|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
215015505|NCT00574353|RADIATION|Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission|You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
215015506|NCT05587751|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test to measure lung function
215015507|NCT05587751|DIAGNOSTIC_TEST|Plethysmography|Pulmonary function test to measure lung volume
215015508|NCT06401551|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
215101045|NCT04512976|OTHER|Water Spray Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the skin wetting modality.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
215101046|NCT04512976|OTHER|Fan Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the fan cooling modality.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout."
215101047|NCT04512976|OTHER|Water Spray and Fan|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
214411268|NCT00854139|PROCEDURE|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
214411269|NCT00854139|RADIATION|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
214411270|NCT00854139|PROCEDURE|Bone marrow transplant from a related donor|• Donor bone marrow (\> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is \> 60 seconds, the protamine treatment shall be repeated
214411271|NCT02722356|DRUG|Oxytocin|Oxytocin administered per oxytocin group or standard practice group (see above)
214411272|NCT02380729|GENETIC|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
214411273|NCT02380729|GENETIC|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
214411274|NCT05317962|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Abbreviated transthoracic echocardiogram
214504816|NCT02556918|DRUG|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
215101048|NCT03127423|PROCEDURE|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
215101049|NCT03127423|PROCEDURE|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
214504817|NCT02556918|DRUG|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
215015509|NCT06401551|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
215101050|NCT00527982|DRUG|Celecoxib|600 mg by mouth daily for a total of 12 months.
215015510|NCT06401551|PROCEDURE|Cataract Surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
215015511|NCT05720975|DEVICE|iNstroke|Patients to undergo thromboaspiration with iNstroke.
215015512|NCT03772340|DRUG|Tradipitant|Oral capsule
215015513|NCT03772340|DRUG|Placebo|Oral capsule
215015514|NCT00334399|DRUG|Miglitol|
215015515|NCT02857959|DRUG|Benzathine Penicillin G|
215101051|NCT00771524|DRUG|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
215101052|NCT00003711|DRUG|irinotecan hydrochloride|
215101053|NCT00003711|DRUG|pemetrexed disodium|
215101054|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
215015516|NCT02946996|DRUG|Metformin|
215015517|NCT02946996|OTHER|OPC|OPC is a derivative of grape seed extract
215015518|NCT06181851|OTHER|Analysis of microbiome and metabolomics|Analysis of microbiome and metabolomics through the assessment of blood and semen parameters
215015519|NCT02898506|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
215015520|NCT02898506|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
215015521|NCT05968885|PROCEDURE|Intradetrusor Botox® (onabotulinumtoxinA) injection|The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
215015522|NCT05968885|DRUG|Combine Mirabegron and Solifenacin.|Combination pharmacotherapy
215101055|NCT00789672|DEVICE|patching|2 hours daily patching
215101056|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
215101057|NCT05216471|RADIATION|chest X-ray|Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory
215101058|NCT05977829|DIAGNOSTIC_TEST|Ultrasound|Transvaginal ultrasound to carry out uterine surveillance
215101059|NCT05977829|DIAGNOSTIC_TEST|Hysteroscopy|Outpatient hysteroscopy to carry out uterine surveillance
215101060|NCT03300921|DRUG|Paricalcitol|"Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily"
215101061|NCT03472144|DRUG|gel loaded with steroids (momentasone)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local corticosteroids (momentasone) after balloon sinuplasty for chronic sinusitis patients.
215101062|NCT03472144|DRUG|gel loaded with antibiotic (Levofloxacin)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
215101063|NCT03472144|DRUG|gel loaded with both steroids and antibiotic|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local both steroids (momentasone)and antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
214411275|NCT04059562|COMBINATION_PRODUCT|Combination of Lonsurf® and Irinotecan|"Trifluridine/Tipiracil (Lonsurf®) and Irinotecan~* Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~* Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose."
214411276|NCT00124956|DRUG|Doxorubicin|
215015523|NCT07000513|BEHAVIORAL|ITEST-LAI|The ITEST-LAI intervention includes male peer-led HIVST distribution and promotion, linkage to male-friendly clinics for confirmatory testing and follow-up care, peer support and technical assistance to address implementation challenges, and continuous monitoring and feedback for male peer educators and research facilitators (MPERFs).
215015524|NCT01887392|OTHER|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
215015525|NCT02851524|OTHER|posturography|
215015526|NCT05052645|PROCEDURE|Auricular acupuncture|Placement of acupuncture needles in specific points on the ear in two consecutive treatments spaced 7 days apart.
215015527|NCT04967417|DRUG|Pemetrexed, Carboplatin, Pembrolizumab|"* Pemetrexed 500mg/m2~* Carboplatin AUC 5.0~* Pembrolizumab 200mg"
215015528|NCT04967417|DRUG|Paclitaxel, Carboplatin, Pembrolizumab|"* Paclitaxel 200mg/m2~* Caboplatin AUC 6.0~* Pembrolizumab 200mg"
215015529|NCT00985374|DRUG|RAD001|5mg or 10mg po daily
215015530|NCT00985374|DRUG|RG1507|16mg/kg iv every 3 weeks
215015531|NCT07018102|OTHER|Trunk Control Care Program|"1. The intervention group underwent a 4-week bedside trunk control care module intervention based on routine care in a rehabilitation ward.~2. trunk control care module: combine the care strategies of arm training, butterfly technique, shoulder control, diaphragmatic breathing and body awareness, practice twice a day, each time for 20-30 minutes, and can be adjusted according to the patient's condition."
215101064|NCT00785343|DEVICE|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
215101065|NCT00785343|PROCEDURE|Conventional Therapy|Occupational therapy that is the current standard of care
215101066|NCT01289054|DRUG|Tasigna|
215101067|NCT01289054|DRUG|Gleevec|
215101068|NCT05336149|PROCEDURE|Alveolar ridge preservation using whole-tooth dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft
214504818|NCT02556918|DRUG|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
215015532|NCT06693492|DEVICE|Ultrasound technique for diagnosis; Focused Ultrasound Stimulation for intervention|Both chronic and post-acute patients are evaluated through the ultrasound technique to further characterize the mechanisms underlying DOC following acquired brain injuries (e.g., stroke, traumatic brain injury, anoxic events). Furthermore, the predictive value of structural and functional markers for DOC chronicization is explored by following up post-acute DOC patients 1 year after the acute event. Finally, to innovate the therapeutic approach to DOC patients, we adopt the low-intensity focused ultrasound (FUS) on a group of selected 10 patients out of the 100 DOC patients enrolled in the study to modulate brain networks' functioning targeting key brain structures for the recovery of consciousness.
215015533|NCT06696222|DIETARY_SUPPLEMENT|Vegetarian yogurt|Vegetarian yogurt alternative will be uesd.
215015534|NCT06696222|DIETARY_SUPPLEMENT|Placebo|Ordinary diet with dairy based yogurt
215015535|NCT06696222|DIETARY_SUPPLEMENT|Vegetarian meat alternative|Vegetarian meat alternative consumed
215015536|NCT06696222|DIETARY_SUPPLEMENT|Ordinary meat diet|Ordinary meat diet used as placebo
215101069|NCT05336149|PROCEDURE|Alveolar ridge preservation using particulate dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
214411277|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
214411278|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
214411279|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
215101070|NCT01620814|DRUG|Dinoprostone|
214411280|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
214411281|NCT02718118|DEVICE|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
214411282|NCT02718118|DEVICE|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
214411283|NCT05043818|OTHER||This study is an observational study and does not involve intervention.When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full scale check once（Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), modified Mayo score for patients with ulcerative colitis/ simplified CDAI score for patients with Crohn's disease , Stool characteristics, degree of abdominal pain, gastrointestinal symptom scale (GSRS), etc.）. The stool sample will be collected once and 16S rRNA sequencing.
214411284|NCT04555044|DRUG|Clinolipid|Lipid injectable emulsion, USP 20%
214411285|NCT04555044|DRUG|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion. 20% (lipid injectable emulsion, USP)
214411286|NCT01888718|DRUG|Fexofenadine Hydrochloride|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
214411287|NCT00041795|DRUG|leteprinim potassium (Neotrofin)|
214694002|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using ND:YAG laser|A free running, pulsed, 1064 nm wavelength-specific ND:YAG laser will be used. A thin 300 μm laser fiber optic will be placed parallel to the root surface, allows easy access into deep periodontal pockets. The initial pass with the laser is known as Laser Troughing, and it is done with a micro-short duration pulse, with a 4.0 watt power, 150 μs duration in pulsed mode and 20Hz frequency. Ultrasonic scaler will be then used to remove calculus. The second pass is carried out with 650 μs pulse duration, 10-30 seconds for each tooth, 4.0 watt power and 20HZ frequency, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed. Relieving the occlusion is the last step of the LANAP protocol.
215015537|NCT07028086|DRUG|VAM_GROUP|Mitoxantrone Liposome 24mg/m², IV, administered as a single dose or divided doses at the investigator's discretion based on the patient's condition; Azacitidine 75mg/m², IV drip, Day 1 to Day 7; Venetoclax 100mg on Day 1, 200mg on Day 2, and 400mg on Day 3 to Day 14.
215015538|NCT06695104|BEHAVIORAL|YMCA Produce Rx (YPRx) Program Only (Control)|Participants in the control group will receive weekly, home-delivered produce bags of fresh vegetables and fruits and sized for each participants' household. Produce deliveries will be administered for 52 weeks.
215101071|NCT01620814|DRUG|misoprostol|
215101072|NCT01620814|DRUG|control|
215101073|NCT05006027|PROCEDURE|Percutaneous coronary intervention via the distal radial approach|Percutaneous coronary intervention using a 7-Fr thin walled sheath (Prelude IDeal, MERIT MEDICAL, South Jordan, UT, USA) via the distal radial approach
215101074|NCT03636646|DEVICE|X.ray|Surgical treatement of posterior acetabular wall fractures
215101075|NCT01286025|BEHAVIORAL|video case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate
215101076|NCT01286025|BEHAVIORAL|Text case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
215101077|NCT00437411|BEHAVIORAL|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
215101078|NCT01320592|DRUG|PD0332991|
215101079|NCT01320592|DRUG|Paclitaxel|
215101080|NCT03400163|DRUG|BMS-986036|BMS-986036 20 mg QD
215101081|NCT03400163|DRUG|Placebo|Placebo QD
215101082|NCT02241343|DEVICE|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
214411288|NCT04505124|BEHAVIORAL|FutureMe App|The FutureMe app provides visual and consequential feedback through a future-self avatar, meaning that the avatar changes its body shape and some additional characteristics based on the participants' activity and food purchasing behaviors. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
214411289|NCT04505124|BEHAVIORAL|Conventional TrackingApp|The Control Conventional Tracking app provides numeric and factual feedback through conventional data-dashboards. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
214411290|NCT02768805|BIOLOGICAL|15 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
214411291|NCT02768805|BIOLOGICAL|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
215015539|NCT06695104|BEHAVIORAL|YMCA Produce Rx (YPRx) Program + the Diabetes Prevention Program (DPP)|Participants will receive weekly, home-delivered produce bags of fresh vegetables and fruits and sized for each participants' household. Produce deliveries will be administered for 52 weeks. Additionally, participants will be registered for a free, year-long YMCA membership and enrolled in the DPP. Through the DPP, participants will receive health education, coaching, and peer support via 26 virtual group sessions over a year.
215015540|NCT06687018|OTHER|Kaltenborn mobilisation|Kaltenborn mobilisation Grade 3 along with common treatment for 3 minutes, repeated 3 sets with rest of 1 minutes, three sessions per week for four weeks. Conventional treatment comprises a hot pack for 10 minutes, SWD for 5 minutes, and nerve and tendon gliding exercises.
215015541|NCT06687018|OTHER|Mulligan mobilisation|Mulligan mobilisation with 10 repetitions with 3 sets and three sessions per week for four weeks. Conventional treatment comprises a hot pack for 10 minutes, SWD for 5 minutes, and nerve and tendon gliding exercises
215015542|NCT06714448|DRUG|Sodium valporate|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
215015543|NCT07034131|OTHER|Osteo-Buddy|"Osteo-Buddy is a Virtual Health Assistant (VHA) accessible on mobile phones that helps users with:~1. Evaluating their risk level of osteoporosis~2. Recommending screening and referrals~3. Lifestyle interventions through motivation, education and tailored guidance~As a 24/7 VHA, it offers real-time, personalised advice based on user inputs and health data."
215015544|NCT07034131|OTHER|Usual Care|Access to digitalised educational materials on osteoporosis, titled 'Healthy Bones'
215015545|NCT00651807|DRUG|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
215101083|NCT04800237|DRUG|VQW-765|oral capsule
214411292|NCT02768805|BIOLOGICAL|15 µg/strain of the licensed quadrivalent vaccine|Single dose of the licensed quadrivalent vaccine
214411293|NCT04120337|DEVICE|RemovAid device + lidocaine patch|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.
215015546|NCT00651807|DRUG|Placebo|Every day one tablet up to 8 weeks
215015547|NCT07031635|OTHER|Hydrotherapy (Warm Shower)|Pregnant women who met the inclusion criteria and agreed to participate in the intervention group received a warm shower once cervical dilation reached 5 cm. Based on their preference, participants either stood or sat during the 30-minute shower.
214411294|NCT04120337|PROCEDURE|Standard technique + lidocaine injection|Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.
214411295|NCT04120337|DEVICE|RemovAid device + lidocaine injection|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.
214411296|NCT01234194|DRUG|rising remifentanil concentrations|remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
214411297|NCT01234194|DRUG|falling remifentanil concentrations|remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
214411298|NCT00503074|BEHAVIORAL|TV modification|Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.
214411299|NCT00503074|BEHAVIORAL|safety and injury prevention|Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
214411300|NCT03034382|DRUG|Morphine|5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
214411301|NCT03034382|DRUG|Nalbuphine|5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
214411302|NCT03034382|DRUG|Bupivacaine 0.5%|10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block
215015548|NCT07038967|OTHER|Coloured photography|Coloured photography will be performed preoperatively and at 3 and 6 months postoperatively.
215015549|NCT07038967|OTHER|Fluorescein angiography|Fluorescein angiography will be performed preoperatively and at 3 and 6 months postoperatively. The following features will be recorded on each angiography:
215101084|NCT04800237|DRUG|Placebo|oral capsule
215101085|NCT00122174|BEHAVIORAL|Stress Busting Program for family caregivers|
215101086|NCT05025878|DIETARY_SUPPLEMENT|[U-13C]Glucose|Patients are intravenously infused with 28g of \[U-13C\]glucose over a 5 hour period. Briefly, \[U-13C\]glucose will be provided by intravenous line containing 8g of \[U-13C\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \[U-13C\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.
215101087|NCT02997059|DRUG|Fluconazole|200 mg/ day
215101088|NCT02997059|OTHER|Placebo|
215101089|NCT03579277|PROCEDURE|Radial Forearm Free Flap|Subjects in this arm will undergo a radial forearm free flap.
215101090|NCT03579277|PROCEDURE|Ulnar Forearm Free Flap|Subjects in this arm will undergo an ulnar forearm free flap.
214411303|NCT03034382|DRUG|Lidocaine Hydrochloride 1% and epinephrine 1:400,000|10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
214411304|NCT02942147|DEVICE|TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
215015550|NCT07038967|OTHER|Optical coherence tomography|Optical coherence tomography (OCT) scanning will be performed using the optical coherence tomography scanner OCT (OPTOVUE OCT). OCT will be performed preoperatively and at 3 and 6 months postoperatively.
215015551|NCT07041450|DIAGNOSTIC_TEST|Digital MoCA|A digital version of the Montreal Cognitive Assessment used to evaluate cognitive function. Administered on a tablet at Visit 1 or Visit 2 (randomized).
215015552|NCT07041450|DIAGNOSTIC_TEST|XpressO|A digital cognitive pre-screening tool used to screen for cognitive function. Administered on a tablet at Visit 1.
215015553|NCT07041450|DIAGNOSTIC_TEST|MoCA|The standard paper-baed Montreal Cognitive Assessment used to evaluate cognitive function. Administered at Visit 1 or Visit 2 (randomized), opposite the digital MoCA.
215015554|NCT07041450|DIAGNOSTIC_TEST|Blood-based Biomarkers (BBM)|Participants provide a blood sample that is analyzed for Alzheimer's disease-related biomarkers, including PrecivityAD2 and MTBR. These biomarkers are used to assess the biological stage of disease and support diagnostic triage and eligibility assessment for disease-modifying therapy (DMT)
215015555|NCT07041450|OTHER|Amyloid Treatment Screening Tool (ATST)|A questionnaire administered to assess eligibility for amyloid-targeted therapies. Both clinician and patient-centered versions are used.
214688523|NCT04815304|DIAGNOSTIC_TEST|peripheral lymphocytes subsets|The data were collected during the first and the second wave of epidemic in COVID-19 patients with acute respiratory distress syndrome. At the moment of hospitalization, at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans (lung ultrasound score, diaphragmatic thickness and motion), arterial blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation ), and pain assessed by using numeric rating scale. Macroscopic and microscopic hypopharynx and larynx damages were also evaluated by video-laryngoscopy and light miscoscopy.
214688524|NCT02928549|BEHAVIORAL|semi-structured interviews|
214688525|NCT02273752|DRUG|Everolimus|Given PO
215015556|NCT07041450|OTHER|MoCA Brain Health Questionnaire (MBHQ)|A questionnaire designed to capture participants' physical health, emotional well-being, diet, exercise, and social engagement as it relates to cognitive health. Responses are used as part of exploratory analyses to evaluate associations with cognitive status and Alzheimer's disease diagnosis.
215101091|NCT00614848|DEVICE|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
215101092|NCT06321770|DIETARY_SUPPLEMENT|Bioactive collagen peptides|2,5 g collagen peptides
215101093|NCT06321770|DIETARY_SUPPLEMENT|Placebo|Placebo sachet daily
215101094|NCT03858530|DIAGNOSTIC_TEST|Ultrasound Examination|Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
215101095|NCT01463072|OTHER|Laboratory Biomarker Analysis|Correlative studies
215101096|NCT01463072|DRUG|Nab-paclitaxel|Given IV
215101097|NCT01463072|OTHER|Questionnaire Administration|Ancillary studies
215101098|NCT06962800|DRUG|Felzartamab|Administered intravenously
214411305|NCT02942147|PROCEDURE|Conventional or Pulse Radiofrequency|In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
214411306|NCT03530280|DRUG|pregabalin (lyrica)|preoperative pregabalin and the postoperative sham block will perform.
214411307|NCT03530280|DRUG|Placebo oral tablet|The preoperative placebo oral tablet and the postoperative sham block will perform.
215015557|NCT07041450|OTHER|MoCA Medical Questionnaire|A structured questionnaire administered to participants to gather information on their medical history, including prior diagnoses, medications, and other health conditions. This data helps to contextualize cognitive symptoms and support diagnostic decision-making in the study.
215101099|NCT06962800|DRUG|Tacrolimus|Administered orally
214411308|NCT03530280|DRUG|adductor canal block including bupivacaine|The preoperative placebo oral tablet and adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
215015558|NCT07041450|OTHER|Functional Activities Questionnaire+ (FAQ+)|A questionnaire designed to assess the participant's ability to perform daily activities, providing insights into their functional status and cognitive impairment. It is a longer version of the original FAQ questionnaire. It is used as part of the screening and exploratory analysis to better understand the relationship between functional abilities and Alzheimer's disease progression.
215101100|NCT06962800|DRUG|Standard of Care IST|Administered intravenously and orally
215101101|NCT03829722|DRUG|Nivolumab|Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.
215101102|NCT03829722|DRUG|Carboplatin|Given IV once per week during radiation therapy (AUC=1).
215101103|NCT03829722|DRUG|Paclitaxel|Given IV once per week during radiation therapy (30mg/m\^2)
215101104|NCT03829722|RADIATION|Radiation Therapy|Given 5 days/week for a total of 35 doses (70 gray total).
215101105|NCT02877498|OTHER|Adaptive support ventilation|Adaptive support ventilation during invasive mechanical ventilation
215101106|NCT02877498|OTHER|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
215101107|NCT03240159|DRUG|Degarelix|"Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix"
215101108|NCT03287037|DEVICE|tDCS over DLPFC|We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator\_plus\_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
215101109|NCT05882461|BEHAVIORAL|90Second Caregiver health letter|Participant receives the weekly health letter via email
215101110|NCT06551259|DRUG|Dexmedetomidine|Intravenous infusion of 0.6μg/kg load dose of dexmedetomidine within 10 minutes after intubation, followed by continuous infusion at a rate of 0.4 μg/kg/h until 30 minutes before the end of surgery
215101111|NCT06551259|DRUG|physiological saline|physiological saline
215101112|NCT06338592|BEHAVIORAL|MyLungHealth|MyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal.
214411309|NCT00002589|BIOLOGICAL|aldesleukin|
214411310|NCT00002589|BIOLOGICAL|muromonab-CD3|
214411311|NCT00002589|BIOLOGICAL|therapeutic autologous lymphocytes|
214411312|NCT00002589|PROCEDURE|adjuvant therapy|
214411313|NCT02228603|BEHAVIORAL|high-intensity exercise training|
214411314|NCT02228603|BEHAVIORAL|web-based follow-up program|
214411315|NCT02228603|BEHAVIORAL|usual care|
214411316|NCT00547976|DRUG|[C-11]PBR28|
214688526|NCT00266721|DRUG|Pancrelipase (Creon) 2 tablets with each meal|
214688527|NCT05798689|COMBINATION_PRODUCT|Probiotic administration and gluten|Probiotic preparation including multi-species strains of Lactobacillus and Bacillus. The probiotic was administered at baseline and interrupted after 32 days. At the same time the other arm received placebo. Gluten was provided after 10 days of gluten free diet in increasing amounts
215101113|NCT06338592|BEHAVIORAL|DecisionPrecision+|DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders.
215101114|NCT04541628|COMBINATION_PRODUCT|SIG-001|Laparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.
215101115|NCT03538366|OTHER|Donor FMT|Fecal transplant from unrelated, healthy donors using enemas
215101116|NCT00003515|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
215101117|NCT02781480|BIOLOGICAL|AAV RPE65|Comparison of different dosages of AAV RPE65
215101118|NCT04119128|DEVICE|Active Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.
214411317|NCT05423080|DRUG|Bolus injection of remimazolam|Participants in this group are administered 0.2 mg/kg remimazolam via the bolus injection method for 20 seconds during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will administer additional doses of 0.05 mg/kg repeatedly until LOC occurs.
214411318|NCT05423080|DRUG|Infusion of remimazolam|Participants in this group are administered remimazolam at a rate of 6 mg/kg/hr via the continuous infusion method during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will escalate infusion dose to 12 mg/kg/hr until LOC occurs.
214411319|NCT04813211|PROCEDURE|mobile artificial cervical vertebrae replacement|"1. Position: The patient is in a supine position with the neck hyperextended, ensuring his/her neck and shoulders in a stable and neutral position before surgery and the cervical spine in a physiological curvature position.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebral body between them will be removed. A curette is used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. Intraoperatively, the midlines of the segment and the vertebra to be replaced should be mapped out. When decompression, the midline for decompression should not be deviated from the planned midlines."
214411320|NCT04813211|PROCEDURE|anterior cervical corpectomy and fusion|"1. Position: The patient is in a supine position with the neck hyperextended.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebrae between them will be removed. A curette will be used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. The removed vertebral bone will be trimmed into cancellous bone particles and filled in a cervical titanium cage with an appropriate size. The titanium cage will be implanted into the vertebral space, and fixed with adjacent vertebrae using anterior cervical titanium plates and screws."
214411321|NCT00515138|DRUG|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
214411322|NCT02393664|DRUG|propofol, bupivacaine|Nonintubated technique for thoracoscopic surgery using propofol infusion, intercostal and vagal blocks with bupivacaine infiltrations.
214411323|NCT02393664|DRUG|sevoflurane, rocuronium|Conventional intubated general anesthesia for thoracoscopic surgery using sevoflurane and rocuronium, and tracheal intubation with a double-lumen tube or a endobronchial blocker.
214411324|NCT03411811|OTHER|Usual Care|Therapeutic ultrasound, myofascial release of extensor and flexor muscles of forearm and stabilization exercises for the wrist.
214411325|NCT03411811|PROCEDURE|Dextrose|Injection of 1 ml of 12.5% dextrose in 1% lidocaine at 0, 3 and 6 weeks in 5 locations: Origin of ulnar collateral ligament, insertion of ulnar collateral ligament on the triquetrum, insertion of the extensor carpi ulnaris on the base of the 5th metacarpal, triquetral hamate ligament and ulnotriquetral joint space.
214411326|NCT02439255|OTHER|Laboratory Biomarker Analysis|Correlative studies
214411327|NCT02439255|DIETARY_SUPPLEMENT|Phytochemical|Given black raspberry (BRB) nectar per oral (PO)
214411328|NCT02439255|OTHER|Placebo|Given PO
214411329|NCT02439255|OTHER|Screening Questionnaire Administration|Ancillary studies
214411330|NCT00002179|DRUG|Indinavir sulfate|
214411331|NCT00002179|DRUG|Lamivudine|
214411332|NCT00002179|DRUG|Zidovudine|
214411333|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 10000 IU|Tablet of 5000 IU of vitamin D3 given twice daily
214411334|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 1000 IU|Tablet of 1000 IU of vitamin D3 given once daily
214411335|NCT03722446|DEVICE|Arrow Catheter Kit.|The group will be randomized to receive this labor analgesia kit.
214411336|NCT03722446|DEVICE|B.Braun Catheter Kit|The group will be randomized to receive this labor analgesia kit.
214411337|NCT01113229|DRUG|Misoprostol|two misoprostol tablets taken orally (400µg)
214411338|NCT01779375|DRUG|Metformin|
214411339|NCT01779375|DRUG|Glargine|
214411340|NCT00406289|PROCEDURE|18F-FDG-PET radiotherapy|
214411341|NCT04459832|PROCEDURE|stretch hamstring|Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
214411342|NCT05803967|BEHAVIORAL|Baduanjin exercising|baduanjin will be applied 5 times per the week, under supervision, for 12 weeks,
214411343|NCT00819910|DRUG|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
214411344|NCT00819910|DRUG|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
215015559|NCT06726239|OTHER|Progressive relaxation exercises|The aim of relaxation exercises is to help individuals recognize the difference between tension and relaxation and to enable them to relax in situations of stress. These exercises are performed with light background music and verbal instructions, allowing patients to mentally focus on the process. The progressive relaxation technique involves the voluntary contraction and subsequent relaxation of muscle groups, typically starting from the hands and progressing to the feet, with each muscle group activated in sequence. During the exercise, the instructions and steps from the 'Relaxation Exercises' CD published by the Turkish Psychologists Association will be followed.
214411345|NCT00819910|DRUG|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
214411346|NCT00819910|DRUG|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
214411347|NCT02537899|DRUG|NeuroAiD|
214411348|NCT00013650|DRUG|Cyclophosphamate|
214411349|NCT06341374|BIOLOGICAL|Influvac Tetra|All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.
214411350|NCT01577043|DRUG|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
215015560|NCT02600793|DRUG|Ceftaroline|Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
215015561|NCT07046104|OTHER|implant retained overdenture prosthesis|implant retained only prosthesis
215015562|NCT07046104|OTHER|implant canine retained overdenture prosthesis|prosthesis retention from implant and canine
215015563|NCT07046455|DRUG|Sacituzumab Govitecan (SG)|After enrollment, before subjects receive TROP-2 ADC treatment, after 2 cycles of treatment, and at the time of progression, in these three phases, subjects will undergo 89Zr-DFO-hSR7 and 18F-FDG examinations once respectively (subjects will first undergo the 18F-FDG examination, and then the 89Zr-DFO-hSR7 examination within 1 week).
215015564|NCT07045350|PROCEDURE|Platelet-rich fibrin (PRF)|Application of autologous platelet-rich fibrin (PRF) prepared from peripheral blood with or without the addition of 4 mg dexamethasone directly into the blood collection tube prior to centrifugation. PRF was applied into the extraction socket after impacted mandibular third molar surgery. The test group received PRF prepared from blood enriched with dexamethasone, while the control group received standard PRF without dexamethasone, to evaluate postoperative pain, edema, and trismus.
214411351|NCT01577043|OTHER|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
214504819|NCT02556918|DRUG|Insulin glargine|"Patients that required continuous insulin infusion (CII) at a rate \>1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between \>180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG \>241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal"
215015565|NCT07046273|DRUG|F027|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
215015566|NCT07046273|DRUG|Ozempic®|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
215101119|NCT04119128|DEVICE|Sham Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.
215101120|NCT03312842|DRUG|CS1001|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type."
215101121|NCT03842059|DEVICE|Computer-aided detection|We developed an artificial intelligent computer system with a deep neural network (PX-1) to analyze real-time video signals from the endoscopy station
214411352|NCT05548530|PROCEDURE|Stereotactic intracranial hematoma puncture|Check the CT scan of the patient's brain, find out the largest hematoma level of the patient, measure the coordinates of the puncture center, locate and mark the skull surface according to the coordinates obtained from the measurement, select the puncture point under the stereotaxic instrument, and mainly avoid important blood vessels , nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.
214411353|NCT05548530|PROCEDURE|decompressive craniectomy|Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.
214411354|NCT05548530|PROCEDURE|Neuroendoscopic|The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.
214411355|NCT04451733|PROCEDURE|Endotracheal intubation|Perform the endotracheal intubation during CPR
214411356|NCT02216786|DRUG|AZD2014|Oral tablet
214411357|NCT02216786|DRUG|Everolimus|Oral tablet
214411358|NCT02216786|DRUG|Fulvestrant|Im injection
214411359|NCT01141140|BEHAVIORAL|Healthy|Favourable nutritional characteristics.
214411360|NCT01141140|BEHAVIORAL|Diet|Benefits of an ingredient/nutrient for weight management
214411361|NCT01141140|BEHAVIORAL|Unhealthy|Hedonic characteristics and less healthy ingredients.
214411362|NCT00898274|OTHER|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
214411363|NCT00898274|OTHER|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
214411364|NCT05209542|PROCEDURE|Hysterosalpingo-Foam Ultrasonography|"* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection"
214411365|NCT05209542|PROCEDURE|Laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
214411366|NCT02121574|DEVICE|Zero flux and ingestible thermometers|
214411367|NCT01571089|BEHAVIORAL|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
214411368|NCT03102242|DRUG|Atezolizumab|Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.
214411369|NCT05464589|OTHER|Transcutaneous tibial nerve stimulation along with pelvic floor muscle srengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.~Transcutaneous electrical stimulation of Tibial Nerve:~Transcutaneous Tibial nerve stimulation is a form of treatment technique that involves the use of electrical impulses to address urinary symptoms and target the lower urinary tract."
214411370|NCT05464589|OTHER|Pelvic floor muscles strengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening."
215101122|NCT03842059|DEVICE|Standard colonoscopy|Standard colonoscopy
215101123|NCT05011058|DRUG|Nanatinostat in combination with valganciclovir|"Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles~Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles"
215101124|NCT01950312|DRUG|gevokizumab|
215101125|NCT00256516|OTHER|Eco-Atkins diet (high vegetable protein and vegetable fat)|
215101126|NCT00256516|OTHER|NCEP diet|
215101127|NCT01192412|PROCEDURE|Intervention is blood pressure management approach|1\) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is \>105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP \<100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
215015567|NCT07045961|OTHER|Supervised Station-Based Strength Circuit Training & Self-directed aerobic training|"Anaerobic training sessions follow a circuit design alternating upper body, lower body, and core exercises with dumbbells, barbells, and kettlebells. Participants complete 3 sets of 10-15 repetitions per exercise, performed consecutively without rest, at 60-80% of their one-repetition maximum (1RM). Two participants perform the same exercise simultaneously at each station. Load progression is applied by increasing resistance by 10% after successfully completing 3 sets of 12 repetitions across two consecutive sessions.~Sessions begin with a 5-minute warm-up at 50-65% of maximal heart rate (HRmax), followed by nine resistance exercises: kettlebell squats, static plank, bench press, weighted lunges, quadruped superman, seated row, weighted glute bridge, leg raises, and shoulder press. Exercises alternate muscle groups to optimize recovery.~Additionally, participants engage in self-selected aerobic exercise (walking, running, rowing, swimming, or stationary cycling) twice weekly at 65-80"
215101128|NCT01192412|PROCEDURE|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is \<80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is \>85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
215101129|NCT05131230|DEVICE|CytoSorb® treatment|Patients with Acute on Chronic Liver Failure (ACLF) due to Severe Alcoholic Hepatitis in combination with systemic inflammation and ACLF grade ≥2 will be enrolled in this study. Every patient that is screened, fulfills the inclusion/exclusion criteria, and consents to the study, will be allowed to enter the study. Patients will receive Standard of Care treatment for alcoholic hepatitis plus treatment with the CytoSorb® 300 mL device.
214411371|NCT01049139|BEHAVIORAL|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
214411372|NCT01049139|BEHAVIORAL|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
215101130|NCT06583694|BEHAVIORAL|Health promotion campaigns to correct the health problems|
215101131|NCT06584500|OTHER|Dry needling|"Dry needling will be performed on the pelvitrochanteric musculature, targeting those muscles where the patient reports mechanical hyperalgesia points upon palpation that reproduce familiar and recognizable pain. No more than 3 different muscles will be treated, and no more than 2 needles will be used per muscle to reduce irritability. The Gluteus Medius muscle will be needled in all patients, and the Gluteus Minimus, Tensor Fasciae Latae (TFL), Piriformis, and obturator muscles will also be examined.~Dry needling will be performed using monofilament needles of different sizes, 0.30mm x 7.5mm, 6mm, and 4mm (AGUPUNT, APS®), depending on the muscle being treated.\&#34;~During the dry needling procedure, an attempt will be made to provoke a local twitch response (LTR). Once achieved, the needle will be manipulated with rapid in-and-out movements in different directions until 4 to 6 LTRs are obtained, or if the participant verbally requests the intervention to stop."
215015568|NCT07045961|OTHER|Music Medicine|During the warm-up phase, participants will engage in individual passive music listening, tailored to their personal musical preferences. The music will be delivered via MP3 players or smartphones, where a personalized playlist containing the participant's favorite tracks has been preloaded. Subsequently, during the circuit training session, a group background music playlist will be played through speakers. This heterogeneous playlist is compiled based on the collective musical preferences of all participants. Finally, during the cool-down phase, a common background music selection will be used, featuring a different repertoire from earlier phases. The cool-down will include guided muscle relaxation and breathing exercises assisted by the background music.
215015569|NCT06889493|BIOLOGICAL|Seneca Valley Virus-001 (SVV-001)|"SVV-001 will be administered intratumorally as a single dose on Day 1; or as multiple doses on Days 1, 15, 29, 43, 57, and 71. The virus dose levels per SVV-001 treatment are as follows:~* 2.2 × 10\^8 Viral Genomes (VG) (starting dose)~* 2.2 × 10\^9 VG~* 2.2 × 10\^10 VG"
215015570|NCT06889493|DRUG|Nivolumab|Nivolumab will be administered via intravenous (IV) injection at a dose of 240 mg, once every two weeks starting on Day 15 until Day 85 during SVV-001 therapy. Nivolumab will be administered once every four weeks during the maintenance period for up to 2 years.
215015571|NCT06889493|DRUG|Ipilimumab|Ipilimumab will be administered via intravenous (IV) injection at a dose of 1 mg/kg, once every six weeks starting on Day 15 until Day 85 during SVV-001 therapy. Participants will continue on 1 mg/kg ipilimumab IV every 6 weeks for two additional doses or unacceptable toxicity and/or participant withdrawal.
215015572|NCT07045038|DEVICE|Acupuncture LLLT:|"Acupuncture LLLT:~This mode of therapy will be conducted for study group B as follows:~A therapeutic unit (M6 MLS from ASA laser, Italy) with wavelength 905 nm, output 5-20 MW, laser beam spot size 0.785 cm2, energy density 91 J/cm2, energy delivered 28 J, and frequency 500HZ. Laser probe will be placed in intercostal space both anteriorly and posteriorly on chest wall.~Each acupuncture point will be stimulated with a laser for 60 s, three weekly sessions over 12 successive weeks. Anterior chest wall acupuncture points are {LU1, LU2, CV17, (Ren17)}, posterior chest wall from a prone or setting position of the patient {UB13, (BL13), UB 17(BL17)}."
215101132|NCT06584500|OTHER|Sham Dry Needling|The intervention protocol for sham dry needlig will be just as to the real dry needling procedure, but instead of inserting the needle into the muscle, the needle is manipulated to touch the skin without penetrating it. This may involve the use of retractable needles or simply making contact with the skin
215101133|NCT06584227|DRUG|Adebrelimab and Chidamide Combined with Gemcitabine and S1|Chidamide：20mg，po，biw，（d8、11、15、18）； Adebrelimab: 1200mg，d8，q3w； Gemcitabine：800-1000mg/m2，bid，d1、d8，q3w； S1：40mg/50mg，bid，d1-14，q3w.
214411373|NCT02727621|DRUG|Dexmedetomidine|Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
214411374|NCT02727621|DRUG|propofol|Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
214411375|NCT02957292|DRUG|Levonorgestrel (13,5 mg) intrauterine device|
214411376|NCT02957292|DEVICE|Cooper (380mm2) intrauterine device|
215015573|NCT07045038|OTHER|Blood flow restricted resistance exercise:|"The subject will warm up and cool down for at least five to seven minutes each, (before and after exercise).~The patients will perform blood flow restricted resistance exercise (BFRRE) at 40-80% of 1RM with 50% limb occlusion pressure (LOP), while placing cuff on midthigh and perform four sets of bilateral knee extension exercise, each set consist of 15 repetitions with 30-60 second rest in between sets and relieve cuff pressure in rest period, three weekly sessions over 12 successive weeks"
215015574|NCT07045038|DRUG|Medical treatment|"All patients will enroll to maximum doses guideline medical treatment that include (Beta blockers-Aspocid- Ator-Concor-Tritace).~Also all patients will adhere to routine cardiac rehabilitation:~The patients will enroll in CR program for 12 weeks, three times per week for 12 week. Moderate-intensity treadmill exercise training achieving a target heart rate of 40-60% of HR reserve (calculated from pre-exercise symptom-limited treadmill exercise stress test by modified Bruce protocol). The duration of each session was 30- 45 minutes (5-10 minutes of treadmill warm up, followed by 20-30 minutes of aerobic continuous treadmill training and terminated by 5-10 minutes of cooling down"
215015575|NCT07045129|OTHER|Cold water immersion|10 sessions of 15-minute Cold water bath (12°C) after the 10 first physiotherapy sessions.
215015576|NCT07045129|OTHER|Hot water immersion|10 sessions of 30 to 45-minute hot water bath (12°C) after the 10 first physiotherapy sessions.
215015577|NCT07045129|OTHER|Physiotherapy only|Control group. Patients of this group will follow the classic rehabilitation treatment proposed by the physiotherapist and physician of Aspetar without thermal intervention.
215101134|NCT06584214|DIAGNOSTIC_TEST|Diagnostic test: Determine™ Syphilis Advanced test|The Determine™ Syphilis Advanced test is intended as an aid in detecting antibodies to Treponema pallidum in individuals with current or past infection.
215101135|NCT06583369|DRUG|Liangxue ointment（Traditional Chinese Ointment）|"The main ingredients of Liangxue Ointment include: Lithospermum sibiricum, Sanguisorba Sanguis, Rehmannia glutinosa, Gardenia, rhubarb, skullcap, borneol, dragon's blood, olibanum and myrrh.~Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses."
215101136|NCT06583369|DRUG|Urea cream|Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
215101137|NCT02103777|DRUG|Caffeine citrate|Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
215101138|NCT02085278|DEVICE|Apollo Micro Catheter device|Detachable Tip Micro catheter
215101139|NCT00927238|DEVICE|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
215101140|NCT00927238|OTHER|Lumbar fusion surgery|Lumbar fusion surgery
215101141|NCT05013203|DIAGNOSTIC_TEST|Tissue culture|Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic
215015578|NCT07044986|OTHER|no intervention|no intervention
215015579|NCT07044921|DRUG|Irinotecan Liposomes (II)+Cetuximab+Bevacizumabl|"Irinotecan Liposomes (II) injection：Intravenous infusion, 60 mg/m2, Day 1, Q2W. The recommended initial dosage of irinotecan liposomes (II) for patients with the UGT1A1 \* 28/\* 6 homozygous mutation is 47.1 mg/m2.~Cetuximab injection：Intravenous infusion, 500 mg/m2, Day 1, Q2W. Bevacizumabl: Intravenous infusion, 5mg/kg, Day 1, Q2W."
215101142|NCT05013203|DIAGNOSTIC_TEST|Next Generation Sequencing|Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
215101143|NCT05670158|BIOLOGICAL|Blood sampling|Blood will be collected into 2 EDTA and 1 heparin tube. The 2 EDTA tubes (4ml of blood in each) will be transported on ice to the proteomics platform in the next three hours, centrifuged and stored on -80 degrees Celcius in low-binding tubes for further molecular analysis. 1 heparin tube (5mL) will be sent to the Bacteriology-Virology Department for the active PBMC counting.
215101144|NCT05670158|PROCEDURE|Perilymph sampling|The perilymph collection will be performed during the cochlear implantation surgery at the same time as the round window opening. 5 to 15 microliters will be aspirated using an atraumatic spinal needle mounted onto 1 ml insulin syringe.
215101145|NCT00038233|DRUG|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
215101146|NCT06168682|DEVICE|SuperNO2VA™ Et by Vyaire Medical, Inc.|SuperNO2VA™ Et provides a nCPAP between 3 to 10 cmH20 using a oxygenflowrate of 6l/O2
215101147|NCT06168682|DEVICE|nasal oxygen cannula|Standard Operating Procedure (SOP) for endoscopy: Using a nasal oxygen cannula with oxygenflowrate of 6l/O2
215101148|NCT00383942|DRUG|Misoprostol|Misoprostol,25 micrograms every 4 hours.
214411377|NCT03357224|DRUG|Atezolizumab|Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
214411378|NCT02639429|DRUG|Vaginal Misoprostol|
215101149|NCT00383942|DEVICE|Catheter|A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
215101150|NCT03219632|DRUG|Fimasartan|Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
215101151|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
215101152|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
215101153|NCT02357121|DEVICE|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
215101154|NCT03433417|DEVICE|Cutera truSculpt|One truSculpt treatment delivered 0 to 90 days before scheduled Abdominoplasty to one side of the tissue to be removed during abdominoplasty
215101155|NCT06303219|OTHER|RADITIONAL MODERATE INTENSITY TRAINING|"It consists of patients who will receive High-intensity interval training, including running as well as walking at 80% to 95% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes"
215101156|NCT06303219|OTHER|HIGH INTENSITY INTERVAL TRAINING|"It consists of patients who will receive Moderate-intensity interval training, including running as well as walking at 60% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes ("
214411379|NCT02639429|DEVICE|Foley Balloon + Vaginal Misoprostol|
214411380|NCT02214459|BEHAVIORAL|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
214411381|NCT00733460|DRUG|BFPET|
214411382|NCT06244108|OTHER|Occupational therapy home program|"After evaluating the children, an occupational therapy home intervention program will be developed for each child. The program will be monitored through telephone and computer interviews, as well as video, photo, and audio recordings. The interventions in this study were selected based on successful occupational therapy home programs for children with disabilities. The program consists of five steps.~Step 1 is to establish collaborative relationships with parents. Step 2 is to determine the most appropriate goals for the child and their family. Step 3 involves selecting the most suitable therapeutic activities to achieve these goals. Step 4 is to educate and support parents in performing these therapeutic activities. Finally, Step 5 involves measuring the results and providing feedback."
214411383|NCT06250075|DIETARY_SUPPLEMENT|Formulation with probiotics|Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
214411384|NCT06250075|OTHER|Non-intervention for Clinical Outcomes -G5|only observation of clinical outcomes in the postoperative period
214411385|NCT06146985|COMBINATION_PRODUCT|20 mg Famitinib & 1200 mg Adebrelimab|Famitinib is a novel multi-targeted tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. Adebrelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to human PD-L1
214411386|NCT00946192|DRUG|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
214411387|NCT00946192|DRUG|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
214411388|NCT00946192|DIETARY_SUPPLEMENT|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
214411389|NCT00146978|PROCEDURE|intra-arterial treatment|
214411390|NCT04001504|BIOLOGICAL|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV (30µg Hemagglutinin)
214411391|NCT04001504|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV (15µg Hemagglutinin)
214411392|NCT02959151|DRUG|CAR-T cell|CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
214411393|NCT01080131|DRUG|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
215015580|NCT06734026|BEHAVIORAL|Cafe Therapy|Participants will be volunteer workers for two hours per day, three days per week for 6-8 weeks, alongside a trained researcher. Participants will complete at least 18 sessions of training within the time frame. Participants will run the Café with supervision from a researcher, serving customers prepackaged food and drinks per our protocol, along with guidance and direction from a therapist, once a week. Participants will be responsible for interacting with customers and arranging supplies. On a weekly basis, participants will be asked how they feel (for example tired, stressed, overwhelmed, etc) before and after their session and to rate how well they performed in the café.
215015581|NCT07046234|DEVICE|Lung ultrasound|Lung ultrasound software.
215015582|NCT07045324|DEVICE|Vagus Nerve Stimulation (nVNS)|Arm 1 (Vagus Nerve Stimulation (nVNS)) is an experimental intervention, as it tests a novel approach (non-invasive vagus nerve stimulation) for trigger point treatment.
215015583|NCT07045324|PROCEDURE|Ischemic Compression|Arm 2 (Ischemic Compression) is an active comparator, as it uses a standard treatment (trigger point massage) commonly applied for myofascial pain.
215015584|NCT07045324|BEHAVIORAL|Exercise (Control)|Arm 3 (Exercise (Control)) is explicitly labeled as the control group in your document, using a standard exercise program, which aligns with an active comparator (since it's an active intervention rather than a placebo or no intervention).
215015585|NCT06727227|DRUG|trastuzumab deruxtecan|T-DXd
215015586|NCT07045597|DRUG|intranasal normal saline for preanasthetic sedation for Adenotonsillectomy|preschool children that will undergo adenotonsillectomy will receive intranasal normal saline equivalent volume who take midazolam intranasal by dose 1 ml saline by insulin syringe as a control group
215015587|NCT07045597|DRUG|intranasal midazolam for preanasthetic sedation for Adenotonsillectomy|preschool children that will undergo adenotonsillectomy will receive intranasal midazolam by dose 0.2 mg/kg
214411394|NCT01080131|DRUG|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
214411395|NCT01080131|DRUG|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
214411396|NCT01080131|DRUG|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
214411397|NCT03677206|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
214411398|NCT03677206|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
214411399|NCT05482854|OTHER|Analytical Treatment Interruption (ATI)|"Analytical Interruption of Treatment for 24-48 weeks~ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria"
214688528|NCT05798689|COMBINATION_PRODUCT|Placebo administration and gluten|The placebo was administered at baseline and interrupted after 32 days. At the same time the other arm received probiotic. Gluten was provided after 10 days of gluten free diet in increasing amounts
215015588|NCT07046247|PROCEDURE|Microvascular decompression for trigeminal neuralgia|Microvascular decompression for trigeminal neuralgia comparing two different forms to apply the Teflon implant
214411400|NCT02687646|DRUG|Adult Allogeneic Mesenchymal cells from adipose tissue.|"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"
214411401|NCT04257279|PROCEDURE|ExcelsiusGPS™|The ExcelsiusGPS™ is a Robotic Positioning System that includes a computer controlled robotic arm, hardware, and software that enables real time surgical navigation and robotic guidance using radiological patient images (pre-operative CT, intra-operative CT and fluoroscopy), using a dynamic reference base and positioning camera.
214411402|NCT01426945|GENETIC|protein expression analysis|
214411403|NCT01426945|OTHER|immunohistochemistry staining method|
214411404|NCT01426945|OTHER|laboratory biomarker analysis|
214411405|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
214411406|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
214411407|NCT03646669|BEHAVIORAL|PEF Feedback|Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
214411408|NCT03646669|BEHAVIORAL|Asthma education|General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
214411409|NCT02292043|DRUG|HTEA|HTEA
214411410|NCT04936217|OTHER|Data collection|For each patient, the following data will be collected and analyzed: age at operation, sex, Body Mass Index (BMI), ASA score, ASIA score, type of bladder dysfunction assessed by urodynamic evaluation, urinary abnormalities assessed by morphological examination (ultrasound and / or computed tomography) and cystoscopy, creatinine clearance, operative indications, initial mictional mode, surgical assembly, immediate and later complications.
214411411|NCT04936217|OTHER|Interview using a validated questionnaire|A telephone survey will be conducted by means of a questionnaire in order to evaluate the patient's quality of life.
214411412|NCT05798208|DIAGNOSTIC_TEST|blood pressure measurement|Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
214411413|NCT03458780|DRUG|Yellow Fever Vaccine|Yellow Fever Vaccine .5 ml
215015589|NCT07055581|DRUG|Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance|"Drug: Durvalumab~Induction Phase: Durvalumab (1500mg D1 IV Q3W) combined with EP \[cisplatin or alternatively Carboplatin (AUC 5-6 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks\] for minimum two cycles prior to thoracic radiotherapy Consolidation Phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities or for a maximum of 24 months, whichever occurs first.~Drug: Chemotherapy Concomitant chemoradiotherapy consists of further four cycles Etoposide (100 mg/m² D1-3), cisplatin (75 mg/m² D1) /carboplatin (AUC 5-6 D1) q3w~Radiation: Thoracic Radiotherapy Radiotherapy to the primary tumor is recommended to start with the 3rd cycle of EP, which can be delayed appropriately per investigator's decision. 60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) or other biologically equivalent regimens will be delivered."
215101157|NCT06017791|OTHER|tunnel technique with a 3D printed PEEK shell to fill the skeletal subnasal depression|"The area will be anesthetized using infiltration technique with 1.5ml of anesthetic solution containing Articaine Hydrochloride 68 mg/1.7 ml with Adrenaline 0.017 mg/1.7 ml~Two bilateral full thickness vertical incisions will be created using a #15 blade. One on each side of the frenum~A subperiosteal tunnel connecting the two vertical incisions will be created using a periosteal elevator/tunneling knife until the complete communication between the two ends is established~The custom made PEEK framework will be inserted from the incision on one side and eased through until it sits in the subnasal concavity.~Once fitted in place the shell will be fixed in place using two mini screws bilaterally, one on each side.~The two vertical incisions will be closed by interrupted sutures 6-0 Polyglycolic acid suture material"
215101158|NCT06303323|OTHER|Qigong Exercise|"Baduanjin Exercise will be performed which consists of 8 standing postures. At least 30 minutes per time. 10-13 min for a set of Badaunjin.~In the first 2 weeks, two sets of Baduanjin will be performed. Total Duration: 6 weeks Frequency: for 3 days/week. (alternative days) Intensity: low-intensity exercise Total Time: 50 Minutes Type: aerobic training"
214411414|NCT03425604|PROCEDURE|Intrauterine insemination|
214411415|NCT02442466|DRUG|Endothelin Receptor B inhibitor BQ788|
214411416|NCT02442466|DRUG|PBS|
214411417|NCT00664846|DRUG|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
214411418|NCT00664846|DRUG|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
214411419|NCT01301664|OTHER|total knee / hip replacement|Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.
214688529|NCT03660813|DIAGNOSTIC_TEST|Follicle measurment|Follicle will be measured before aspiration
214688530|NCT03660813|DRUG|Ovitrelle ( Hcg 250 mcg)|Drug used for triggering
215015590|NCT07055750|DIAGNOSTIC_TEST|Knee Pain With High-Impact Workouts|Individuals who have been attending the gym regularly for at least 3 months having knee pain will be assessed With High-Impact Workouts
214411420|NCT02606292|PROCEDURE|Photoacoustic endoscopy|
214411421|NCT02606292|PROCEDURE|Endoscopic ultrasound (standard of care)|
215015591|NCT07056478|DRUG|Denosumab (Prolia)|60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
215015592|NCT07056478|DRUG|Zoledronic acide (Aclasta)|5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
215015593|NCT07056738|DIAGNOSTIC_TEST|imaging|OCT, OCTA, RNFL-OCT, fundus autofluorescence, fundus imaging, flaremeter, fundus and slit lamp examination
215015594|NCT06734754|DEVICE|fetal heart sound listening|The pregnant women in the experimental group and their partners listened to fetal heart sounds for 7 days. After obtaining pre-test data from the participants in the intervention group, the midwifery intervention to be implemented was explained. A fetal heart rate monitoring device, which will be given to couples to listen to the fetal heart sound before sleep, was introduced. They were told that they had to listen to the fetal heart sound at least 7 times using this device. A supporting application was downloaded to the pregnant woman's phone for the installation of the fetal heart rate monitoring device. The way of using the application and the operation steps were introduced. It was explained to the couples that the application can detect the baby's heartbeat within seconds thanks to its smart search technology, and also provides step-by-step guidance by giving live feedback.
215015595|NCT06786052|DIETARY_SUPPLEMENT|Probiotic|After randomization, participants will consume the probiotic for 3 months.
215015596|NCT06786052|DIETARY_SUPPLEMENT|Placebo|After randomization, participants will consume the placebo for 3 months.
215015597|NCT05963230|OTHER|Ultrasound scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
215015598|NCT04462172|DEVICE|FNS|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
215015599|NCT04462172|DEVICE|MCS|three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
215015600|NCT00306722|DRUG|AQUAVAN® (fospropofol disodium) Injection|
215015601|NCT03572218|BEHAVIORAL|BWL|The BWL sessions will be based on the Diabetes Prevention Program (DPP) manual. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 12 weeks will include self-monitoring, stimulus control, slowing eating, social support, cognitive restructuring, portion sizes, and goal-setting. Those during weeks 13-26 will focus on continued self-monitoring and skills required for weight loss maintenance and relapse prevention. Physical activity will be prescribed at a level consistent with data showing that \>250 min/wk is associated with improved long-term weight loss. BWL sessions will last 60 minutes.
215015602|NCT03572218|BEHAVIORAL|BIAS|Following 60 minutes of BWL treatment, the BIAS intervention will devote 30 minutes to stigma-related content. Session topics will include: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to weight management. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies in the context of weight management.
215015603|NCT02937922|OTHER|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: \[(HR max - HR rest) x desired intensity\] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
215015604|NCT02937922|OTHER|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60 % of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
215015605|NCT02937922|OTHER|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
215015606|NCT03110835|RADIATION|Radioiodine|Administration of radioiodine
215015607|NCT02249780|PROCEDURE|Postoperative parathyroid function test|Calcium and parathormone dosage at 24 hours and ten day after surgery
215015608|NCT02249780|PROCEDURE|No postoperative parathyroid dosage and supplementation|The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.
215015609|NCT02249780|PROCEDURE|ICG parathyroid angiography|Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
215015610|NCT02249780|DRUG|Parathyroid supplementation|Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
214411422|NCT02606292|PROCEDURE|Endoscopic surgery (standard of care)|
214411423|NCT03377855|OTHER|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
214411424|NCT06454773|DIETARY_SUPPLEMENT|NCT/NFT|extract from black pepper and hemp hull
214411425|NCT04371718|DRUG|JKB-122|JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
215015611|NCT00286455|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
214411426|NCT04371718|OTHER|Placebo|A capsule has same component but active drug
214411427|NCT04371536|DRUG|Ferrous Sulfate|Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
214411428|NCT04371536|BEHAVIORAL|IRONCHILD|"Delivery of the intervention at each visit should take 15 minutes or less.~* Baseline visit (Session 1) content will be viewed~* At 1-month follow-up visit, additional (Session 2) content will be viewed~* At 3-month final visit, patients will view final (Session 3) content"
214411429|NCT02165891|DRUG|insertion of a chest drain with urokinase instillation|Other interventions except drainage procedure are the same in both arms
214411430|NCT02165891|PROCEDURE|primary video-assisted thorascopic surgery|
215015612|NCT00286455|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
215015613|NCT00286455|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
215015614|NCT01094093|DRUG|AMG 139|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
215015615|NCT01852136|DEVICE|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
215015616|NCT01852136|DEVICE|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
215015617|NCT01852136|DEVICE|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
215015618|NCT03939832|OTHER|Fraction of inspired oxygen level|A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
215015619|NCT06215937|OTHER|No Intervention|No intervention
215015620|NCT06117137|DRUG|SGLT2 inhibitor|"Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin~Group dapa:standard treatment of type 2 Diabetes mellitus and dapagliflozin"
215015621|NCT04826731|OTHER|Incentive Spirometer/Respiratory Exerciser|"A patient is considered acceptable for the Incentive Spirometer Group if the patient can use an incentive spirometer and/or a respiratory exerciser at least four times per day. A pulmonary medicine specialist will confirm the proper usage of the device."
215015622|NCT00757900|BIOLOGICAL|MUTAGRIP|Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
215015623|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only via proteomic analysis"|Proteomic profiles are established for each patient using plasma and serum samples
215015624|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only according to a metacholine test"|A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
215015625|NCT04853875|DRUG|Tetracycline, Metronidazole, Bismuth subcitrate|52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
215015626|NCT04853875|DRUG|Amoxicillin, Metronidazole, Clarithromycin|52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
215015627|NCT06134700|PROCEDURE|Laparoscopic Surgery|"* Surgery will then proceed at either 8 - 10 or 12 - 15 mmHg pneumoperitoneum pressure depending on study group the patient falls into~* Port Placement~* Reflection of colon~* Isolation of ureterogonadal packet~* Upper pole dissection~* Hilar dissection~* Vessel clipping and division~* Dissection of kidney~* Delivery through either Pfannenstiel or iliac fossa incision"
215015628|NCT02054949|DRUG|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
215015629|NCT03404375|DEVICE|Gauss Triton system|"The Triton system (Gauss Surgical, Inc., Palo Alto, CA) is a novel mobile monitoring platform that combines mobile computing with Gauss Feature Extraction Technology (FET) to directly assess Hb mass (mHb) absorbed by surgical sponges from an image. The device is an iPad like imaging device that will assess blood loss via imaging of the surgical sponges used in the surgery.~The device will be used to calculate blood loss on every patient enrolled in the study."
215015630|NCT00448032|DRUG|PPM-204|
215015631|NCT04077359|DIAGNOSTIC_TEST|CT|the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
215015632|NCT00696150|PROCEDURE|determination of method with highest efficacy (ultrasound or nerve stimulator)|Use of ultrasound to guide the insertion of anterior psoas compartment block
215015633|NCT00696150|PROCEDURE|nerve stimulator|The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
215015634|NCT00696150|PROCEDURE|loss of resistance|Use of ultrasound to guide the insertion of anterior psoas compartment block
215015635|NCT06271980|OTHER|ENCORE|A panel of microRNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
215015636|NCT06211790|DRUG|Anlotinib, Everolimus and Tislelizumab|Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)
215015637|NCT06145555|BEHAVIORAL|Acute psychological sleep stabilization|See above (arm description)
215015638|NCT06145555|BEHAVIORAL|Sleep hygiene education|See above (arm description)
215015639|NCT03020082|DRUG|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
215015640|NCT03020082|DRUG|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
215015641|NCT03020082|DRUG|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
215015642|NCT03020082|DRUG|RBV|RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
215015643|NCT06936501|DIETARY_SUPPLEMENT|Traditional flavor ONS (vanilla or strawberry, by choice)|Receives a traditional flavor ONS (vanilla or strawberry, by choice) on days 1 and 2, then switches to a refreshing and stimulating flavor ONS (mango-peppermint or lemon-mint, by choice) on days 3 and 4.
214411431|NCT00553215|PROCEDURE|quality-of-life assessment|
214411432|NCT00553215|PROCEDURE|questionnaire administration|
214411433|NCT04594330|DRUG|virgin coconut oil (VCO)|15 mL of VCO twice a day for 14 days
214411434|NCT04594330|OTHER|placebo|15 mL of placebo twice a day for 14 days
215015644|NCT06936501|DIETARY_SUPPLEMENT|Refreshing and stimulating flavor ONS (mango-peppermint or lemon-mint, by choice)|Receives a refreshing and stimulating flavor ONS (mango-peppermint or lemon-mint, by choice) on days 1 and 2, then switches to a traditional flavor ONS (vanilla or strawberry, by choice) on days 3 and 4.
215015645|NCT01293877|PROCEDURE|Laparoscopy surgery for morbid obesity|The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
215101159|NCT06303323|OTHER|Wu Dang Tai Chi|"Wu Dang 13 form postures will be performed. Initially, each posture will be performed 3 times then progressively increase to more according to the patient's discomfort.~Total Duration: 6 weeks Frequency: 3 times/ week (alternative day ) Intensity: Low to Moderate Intensity Time: 50 Minutes Type: aerobic training"
215101160|NCT00308074|DRUG|Aripiprazole|open-label, flexible-dosing
214411435|NCT00504114|PROCEDURE|ACL Reconstruction Surgery|
214411436|NCT00504114|PROCEDURE|Cartilage Resurfacing Surgery|
214411437|NCT00504114|PROCEDURE|Total Knee Replacement|
214411438|NCT05014555|BIOLOGICAL|COVID-19 Vaccine|Three-dose mRNA COVID-19 vaccine per standard of care
214411439|NCT01092806|DRUG|Tacrolimus|Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
214411440|NCT03923725|DRUG|Artemether-lumefantrine+ Amodiaquine (AL+AQ)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
214411441|NCT03923725|DRUG|Artemether-lumefantrine + placebo (AL+PBO)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
214411442|NCT03923725|DRUG|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately.~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
214411443|NCT03923725|DRUG|Artesunate-mefloquine+placebo (AS-MQ+PBO)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
214411444|NCT03441360|DRUG|Eribulin mesylate|Intravenous infusion
214411445|NCT00269399|DRUG|Rifaximin (Xifaxan)|
214411446|NCT00269399|DRUG|Vancomycin|
214411447|NCT03639324|DRUG|Dose combination 1-1|100 mg QD of idelalisib + 100 mg QD of venetoclax
214411448|NCT03639324|DRUG|dose combination 1-2|100 mg QD of idelalisib + 200 mg QD of venetoclax
214411449|NCT03639324|DRUG|Dose combination 1-3|100 mg BID of idelalisib + 200 mg QD of venetoclax
214411450|NCT03639324|DRUG|dose combination 1-4|150 mg BID of idelalisib + 200 mg QD of venetoclax
215101161|NCT03103035|OTHER|Blog|Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
215101162|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.
214411451|NCT03639324|DRUG|Sub-Trial: Dose combination 2-1|100 mg BID of idelalisib + 100 mg QD of venetoclax
214411452|NCT03639324|DRUG|Sub-Trial: Dose combination 2-2|150 mg BID of idelalisib + 100 mg QD of venetoclax
214411453|NCT01760291|DEVICE|WATCHMAN LAA Closure Technology|
214411454|NCT00198848|DRUG|Iron-folic acid supplement|
214411455|NCT05753852|DRUG|Tauroursodeoxycholic Acid|Tauroursodeoxycholic acid (TUDCA) 250 mg capsules Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal Mode of administration: orally Duration: 18 months
214688531|NCT03660813|DRUG|Decapeptyl ( GnRH Agonist 0.1 mg*2 )|Drug used for triggering
214688532|NCT03065712|DRUG|F-18 Fluoroestradiol|F-18 Fluoroestradiol will be administered for PET/CT scan.
215101163|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.
215101164|NCT04706728|OTHER|Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment
214688533|NCT03065712|PROCEDURE|Computed Tomography|Undergo PET/CT
215015646|NCT04968145|OTHER|Home To Stay Mobile Health Application|"Home to stay is an integrated discharge monitoring system with a mobile application. Features of the application include a Daily Health Check to report on post-operative recovery, picture taking capability to photograph incisions/wounds and educational information on post-operative care at home.~Patients will complete a Daily Health Check on post-discharge Day #1-14, #21 and #30. The Daily Health Check consists of a series of questions specific to colorectal surgery as well as the Quality of Recovery (QoR-15) questionnaire. After completion, the participant will receive a list of recommendations tailored to their responses including relevant education modules, to contact the surgical team or in urgent cases to go to the nearest emergency room. The participants' responses will be monitored daily via a secure web site. Any participants' responses in the extreme ranges are automatically red flagged and notify the health care team that a follow up telephone call is required."
214411456|NCT04315454|DRUG|Levobupivacaine|A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
214411457|NCT03467724|DEVICE|Fractional Radiofrequency (FRF)|Fractional radiofrequency will be delivered to the area of the surgical scar.
214411458|NCT00319943|PROCEDURE|Computer-based training for Mild Cognitive Impairment (MCI)|
214411459|NCT01385384|DEVICE|NeuRx RA/4 diaphragmatic pacemaker|"Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.~The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.~Sites that provide the optimal response (greater region and magnitude) are noted.~Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed."
214411460|NCT04124263|OTHER|Educational short message texts|Educational messages for patient engagement
214411461|NCT04124263|OTHER|Adherence short message texts|Reminder messages of medication use time
214411462|NCT01325870|DEVICE|ACD-CPR|
214411463|NCT01325870|DEVICE|ITPR|standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
215015647|NCT06025227|DRUG|Etrasimod|tablets
214411464|NCT01325870|PROCEDURE|S-CPR|standard manual CPR
214411465|NCT01325870|DEVICE|Impedance Threshold Device (ITD)|
215015648|NCT06214481|DRUG|Rocatinlimab|Administered SC.
215015649|NCT05664815|BIOLOGICAL|Human Amniotic Membrane|"After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges.~With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone.~For closure after hAM grafting : 2 options are possible:~Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa."
215015650|NCT05664815|OTHER|Conventional/Standard treatment|"Surgical procedure: Endo-oral approach:~* Trimming of the mucous edges if they are necrotic or inflamed (granulation tissue)~* For the bone: either simple sequestrectomy (the mobile sequestered bone is grabbed using forceps); either reaming until bleeding is obtained; either resection with the rongeur; either monobloc resection of the entire necrotic fragment with a saw or with a piezzotome (ultrasound); or a combination of different techniques. Rq: the resection of the necrotic bone (according to the practices of the center) will operate until the appearance of an apparently healthy bone (bone bleeding, clean appearance of the bone site)~* Closure of the mucosa with possible incision of the periosteum to provide laxity: Suture points by points separated in one plane with non-absorbable braided thread of the 3.0 silk thread type and round needle."
214411466|NCT02071979|DEVICE|Autologous PRP Gel|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
214411467|NCT02071979|DEVICE|Autologous PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
214688534|NCT03065712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
214688535|NCT03065712|OTHER|Laboratory Biomarker Analysis|Correlative studies
214688536|NCT01503060|BEHAVIORAL|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
215015651|NCT00773110|DRUG|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
215015652|NCT00773110|DRUG|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
214411468|NCT02071979|DEVICE|Autologous PRP Gel plus PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
214411469|NCT02071979|PROCEDURE|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
214411470|NCT00343824|PROCEDURE|aquacel AG hydrofiber versus acticoat burn dressing|Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
214411471|NCT01672840|DIETARY_SUPPLEMENT|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
214411472|NCT01672840|DIETARY_SUPPLEMENT|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
215015653|NCT02323581|DEVICE|Endovascular treatment of Thoracoabdominal Aortic Aneurysm|"A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached.~This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called fenestrations) that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm."
215015654|NCT02323581|DEVICE|Endovascular treatment of Aortic Arch Aneurysms|"An aortic arch aneurysm is an abnormal enlargement (ballooning out) of the main artery (the aorta). The ascending aorta and aortic arch is the first part of the vessel as it exits the heart and makes a turn around the area of the collar bone. This part of the aorta gives branches that supply the head, brain and arms.~The arch branch endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively."
215015655|NCT05272774|BEHAVIORAL|FOREST+|The intervention will be delivered as an online stress recovery intervention consisting of six weekly modules. Modules include an introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These modules have been chosen after considering the themes that could be most useful for healthcare workers under high stress. Each module consists of a psychoeducational and an exercise component.
215015656|NCT02388256|DEVICE|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
215015657|NCT02388256|OTHER|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
215015658|NCT02883933|OTHER|Data collection|
215101165|NCT02092311|PROCEDURE|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
214411473|NCT02049866|DRUG|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
215015659|NCT00138242|DRUG|carboplatin|
215015660|NCT00138242|DRUG|docetaxel|
215015661|NCT00138242|PROCEDURE|adjuvant therapy|
215015662|NCT05212935|BIOLOGICAL|Rotavirus Vaccine|administration of the 3 doses of Rotavirus human bovine pentavalent reassortant vaccine
215015663|NCT04594603|OTHER|Phacoemulsification for cataract|Phacoemulsification for removal of cataract
215015664|NCT01872208|BIOLOGICAL|HAV implantation|Patients will be implanted with a Human Acellular Vessel (HAV) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques.
215015665|NCT04082442|DRUG|Evolocumab|420 mg evolocumab.
215015666|NCT04082442|DRUG|Placebos|Matching placebo.
215101166|NCT02092311|PROCEDURE|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
214688537|NCT01503060|BEHAVIORAL|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
214688538|NCT01503060|DRUG|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
214411474|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - GUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones). Participants in this arm will receive weekly feedback from counselors through the web software used.
214411475|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - UNGUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones).
214411476|NCT04547348|DRUG|Denosumab Injection|Injections made subcutaneously per standard description
214411477|NCT04208243|BEHAVIORAL|Creative Arts Therapy|"The intervention will consist of approximately weekly CAT in the infusion center during cancer therapy. The interventionist is a Master's prepared, licensed dance/movement therapist who is experienced in music and art therapies as well. The CAT includes dance/movement such as playing with a parachute, simple yoga breathing and postures, and work with physioballs. The music includes singing, listening to music, and playing instruments. The art consists of drawing, finger painting, working with clay. The CAT may occur in individual sessions in private infusion rooms, or in groups in the middle of the infusion center. The CAT is not only a distraction, but also a therapeutic process addressing the stressors of cancer and its treatment. The dose of CAT will be recorded (number and type of sessions) and will be factored into the analysis."
214411478|NCT02955069|DRUG|PDR001|PDR001 was administered at a dose of 400 mg via intravenous infusion once every 4 weeks (Q4W). PDR001 was administered on Day 1 of every cycle. Each cycle was 28 days.
214411479|NCT00677248|DRUG|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
214411480|NCT00677248|DRUG|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
214411481|NCT00697814|DRUG|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
214411482|NCT03701230|OTHER|low temperature rota-flush solution|Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
214411483|NCT03178396|DIETARY_SUPPLEMENT|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
214411484|NCT05585567|BIOLOGICAL|V-01/V-01-B5|Contains 10μg of V-01 and 10μg of V-01-B5
214411485|NCT05585567|BIOLOGICAL|V-01-351/V-01-B5|Contains 10μg of V-01-351 and 10μg of V-01-B5
214411486|NCT05585567|BIOLOGICAL|V-01|Contains 10μg of V-01
214411487|NCT01379287|DRUG|Iso-Fludelone|Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
214411488|NCT03700658|DRUG|TV-46046|TV-46046 will be administered per dose and schedule specified in the arm.
214411489|NCT03700658|DRUG|Depo-subQ 104|Depo-subQ 104 will be administered per dose and schedule specified in the arm.
214411490|NCT03700658|DRUG|TV-46046 Placebo|TV-46046 Placebo will be administered per schedule specified in the arm.
214411491|NCT06502769|BEHAVIORAL|Therapeutic Exercise|A therapeutic exercise program will be carried out
215015667|NCT06582641|BEHAVIORAL|Peer Group Connection - Middle School (PGC-MS)|Peer Group Connection - Middle School (PGC-MS) is the treatment condition. PGC-MS is a school-based positive youth development program for students entering the transition year into middle school (6th or 7th grade). PGC-MS aims to improve school engagement and social-emotional learning skills that support adolescent health and educational outcomes for program participants. Participants receive 45-minute outreach sessions held 3 to 4 times per month for the full school year. Schools are expected to implement a minimum of 18 outreach sessions over the school year. PGC-MS outreach sessions are delivered by older peer leaders (8th, 9th, or 10th graders) who are carefully selected by faculty advisors and trained on how to deliver program content.
215015668|NCT06027892|RADIATION|Two-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a dose biologically comparable to 40 Gy in 5 treatments, but in only 2 treatments
214411492|NCT06502769|BEHAVIORAL|Pain Neurophysiology Education|A PNE program will be carried out
214411493|NCT03794804|DEVICE|ColdZyme|"ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap."
214411494|NCT03794804|DEVICE|ColdZyme Placebo|The placebo mouth spray solution has the following composition: ethanol (\<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
214688539|NCT01503060|DRUG|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
214688540|NCT01503060|DRUG|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
215101167|NCT03864913|DRUG|Testosterone injection|SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
215101168|NCT03864913|BEHAVIORAL|PedsQL questionnarie|Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
215101169|NCT03864913|OTHER|Masculinizing effects questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
215101170|NCT03864913|OTHER|Medication experience questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
214688541|NCT01503060|DRUG|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
214688542|NCT01274741|BEHAVIORAL|Creating Change (CC)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
214688543|NCT01274741|BEHAVIORAL|Seeking Safety (SS)|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
214411495|NCT03076736|BEHAVIORAL|Singing group + resource pack|SPA is a community-based, 10 weekly singing group. Each SPA session comprises 30 minutes of settling in/wrap-up and departure, and 60 minutes of group singing. Sessions will be led by a community music leader, co-facilitated by a person with aphasia, and involve the group singing from a songbook. Musical accompaniment will be provided by the facilitator(s). Small percussion instruments will be available for participants, enabling involvement of those with limited singing ability. Intervention content integrates the Information-Motivation-Behavioural (IMB) skills model of health behaviour change to support individuals in developing the social skills and confidence needed to improve psychosocial outcomes. Participants will also receive the resource pack.
214411496|NCT03076736|BEHAVIORAL|Resource pack|Resource pack with information on living with aphasia and local community activities.
214411497|NCT02709616|BIOLOGICAL|Personalized cellular vaccine|Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
214411498|NCT04148937|DRUG|LY3475070|Administered orally
214411499|NCT04148937|DRUG|Pembrolizumab|Administered IV
214411500|NCT03807557|OTHER|Robotic Constraint-induced movement therapy|"i.Robotic repetitive task-specific training followed by task-oriented practice: during each session, participants first receive 60 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of functional practice using shaping technique.~ii.Restraint of the unaffected limb: Patients will wear a mitt to restrict the unaffected hand during training at clinic for 0.5 hours of functional practice each session, 3 sessions per week for 8 weeks.~iii. Transfer package: The transfer package aims at transferring the therapy gains to the participant's real world by use of a set of behavioral techniques. This is intended to have the participant responsible for adhering to the treatment requirements and encourage active engagement in the functional practice outside of the clinic setting. The participants will be given appropriated home assignment practicing daily activities outside of the clinic."
214411501|NCT03807557|OTHER|conventional UE rehabilitation training|focusing on UE training and including neuro-developmental techniques(Bobath, 1990), trunk-arm control (ie, practice UE tasks during standing), weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
214411502|NCT00730002|PROCEDURE|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
214411503|NCT00730002|PROCEDURE|Magnetic resonance imaging|MR spectroscopy
214411504|NCT00730002|PROCEDURE|MRA|MRA of the brain
214411505|NCT00730002|PROCEDURE|MRA|
214411506|NCT00730002|PROCEDURE|diffusion Imaging|MRA of the Brain
214411507|NCT00730002|PROCEDURE|perfusion imaging.|MRA of the brain
214688544|NCT03443843|DRUG|loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)|Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
214688545|NCT03443843|DRUG|Placebo tablet|Placebo tablet orally
214688546|NCT03443843|DRUG|Fluticasone Propionate|Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
214688547|NCT03443843|DRUG|Placebo spray|Placebo Nasal Spray, 2 sprays per nostril
214688548|NCT02808312|DRUG|Cilofexor|Tablet(s) administered orally in a fed state on Day 1
214688549|NCT03009656|OTHER|No study specific interventions|
214688550|NCT02713230|DRUG|bupivacaine liposome injectable suspension|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
214688551|NCT02713230|DRUG|bupivacaine liposome injectable suspension|20 mL EXPAREL (bupivacaine liposome injectable suspension)
214688552|NCT02713230|DRUG|Placebo|20 mL normal saline as single-injection
214688553|NCT03849040|PROCEDURE|Endobronchial Ultrasound|All patients will undergo EBUS-TBNA as per routine care, except for the one difference where the procedures will be video-recorded so that they can be used for computer analysis at a later time. Static images will be obtained from EBUS videos in order to perform segmentation. Segmentation will be conducted by both an experienced endoscopist and NeuralSeg.
214688554|NCT04257110|DRUG|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.
215015669|NCT06027892|RADIATION|Five-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a standard stereotactic dose of 40 Gy in 5 treatments
215015670|NCT02605538|BIOLOGICAL|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
215015671|NCT05376553|DRUG|Cemiplimab|350mg intravenous infusion over 30 minutes
215015672|NCT05376553|DRUG|Cisplatin|"100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)"
215015673|NCT05376553|DRUG|Docetaxel|"75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)"
215015674|NCT02347956|PROCEDURE|Reduced port robotic distal gastrectomy|
215015675|NCT03112369|BEHAVIORAL|Narrative Exposure Therapy (NET)|An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
215015676|NCT03112369|BEHAVIORAL|Motivational Interviewing w/Skills Training (MIST)|Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
215015677|NCT04359680|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
215015678|NCT04359680|DRUG|Placebo|Placebo administered orally twice daily for six weeks
214688555|NCT00442247|DEVICE|Pelvicol|
215101171|NCT00246246|DRUG|risperidone|
215101172|NCT00733681|DEVICE|PFC Sigma RP TC3 Revision knee system|Orthopaedic implant system for revision total knee replacement
214411508|NCT03171896|OTHER|clown|A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
214411509|NCT03171896|OTHER|Sham|No clown will be present in the room during labor
214411510|NCT00365027|PROCEDURE|Delayed embryo transfer|
214411511|NCT03355495|PROCEDURE|Colonoscopy - Position Change|Colonoscopy is the gold standard for detecting precancerous lesions. We are proposing that changing positions will provide better visualization for detecting such lesions. We will test our intervention of patients positioned in the Right Lateral Decubitus Position to the gold standard of Left Lateral Decubitus Positioning, hypothesizing better visualization in the right lateral decubitus position.
214411512|NCT02488317|OTHER|Decision Aid|Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
214411513|NCT00921076|BEHAVIORAL|Gait Analysis|A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
214411514|NCT03640273|DRUG|Prapchompoothaweep remedy|Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.
214411515|NCT03640273|DRUG|Loratadine 10 Mg|Take Loratadine 10 mg once a day before meals.
214411516|NCT06364033|BIOLOGICAL|serologic response evaluation|Blood samples collection
214411517|NCT04300816|BEHAVIORAL|CBT for Uncertainty Tolerance|"Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis."
214411518|NCT04300816|BEHAVIORAL|Traditional CBT|Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
214411519|NCT00968240|DRUG|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
214411520|NCT00757718|DEVICE|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
215015679|NCT04359680|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
215015680|NCT04570280|OTHER|Aerobic Exercises|Aerobic exercises with treadmill will be applied 3 times a week for 12 weeks.
215015681|NCT04570280|OTHER|Resistive Exercises|Resistive exercises with sandbag will be applied 3 times a week for 12 weeks.
214411521|NCT00757718|DEVICE|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
214411522|NCT05285514|DIAGNOSTIC_TEST|Comparison of macro- and microcirculatory parameters|"Microcirculation examination using sublingual videomicroscopy, tissue O2 saturation (StO2) by NIRS and transcutaneous CO2 pressure (tcpCO2) monitoring, in conjunction with macrocirculatory parameters measures including cardiac output, arterial pressure and pulsed O2 saturation, in order to establish the relationship between the macrocirculatory changes in blood pressure and cardiac output and the microcirculatory flow and capillary density during vasoactive agent use. . Participants receive interventions as part of routine medical care to restore Cerebral Perfusion pressure (CPP) to appropriate levels (60-70 mmHg)"
214411523|NCT05097469|DEVICE|Carbon dioxide laser|3 consecutive sessions of carbon dioxide laser treatment
214411524|NCT05097469|DEVICE|Sham laser treatment|3 consecutive sessions of sham laser treatment
214411525|NCT01680276|BEHAVIORAL|PBS based staff training|"Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219"
214688556|NCT04840654|PROCEDURE|Caudal Block|"A caudal block is a procedure that will help lessen a child's pain after an operation.~100 subjects will be randomized to this block procedure."
215015682|NCT04570280|OTHER|Range of Motion Exercises|Range of Motion Exercises will be applied 3 times a week for 12 weeks.
215015683|NCT02245893|PROCEDURE|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
215015684|NCT00832962|GENETIC|Genotyping|Whole blood sample
215015685|NCT00832962|OTHER|Usual prophylaxis|Prophylactic anti-RhD
215015686|NCT04430621|DRUG|Follicle Stimulating Hormone|FSH will be administered s.c. in the morning to male healthy subjects
215015687|NCT00002316|DRUG|Lobradimil|
215015688|NCT00002316|DRUG|Amphotericin B|
214411526|NCT01680276|OTHER|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
214688557|NCT04840654|PROCEDURE|Pudendal Block|"form of local anesthesia commonly used in the practice of obstetrics to relieve pain during the delivery of baby by forceps.~100 Subjects will be randomized to this block procedure."
215015689|NCT04129970|DEVICE|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
215015690|NCT00360100|DRUG|Zmax|
215015691|NCT01812018|DRUG|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
215015692|NCT01812018|DRUG|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
215015693|NCT01812018|DRUG|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
215015694|NCT03931785|DRUG|MD-7246|Oral tablet
215015695|NCT03931785|DRUG|Placebo|Matching oral tablet
215015696|NCT03254147|DRUG|warfarin|warfarin
215015697|NCT03254147|DRUG|dabigatran|Non-vitamin K dependent oral anti-coagulants (NOACs)
215101173|NCT00741403|DRUG|CPI-613|CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
215101174|NCT00732108|DRUG|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
215101175|NCT00732108|DRUG|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
215101176|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
215101177|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
215015698|NCT03254147|DRUG|Apixaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
215015699|NCT03254147|DRUG|Edoxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
215015700|NCT03254147|DRUG|Rivaroxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
215015701|NCT03521609|BEHAVIORAL|Emotional intelligence intervention|Brief group intervention based on emotional intelligence
215015702|NCT02504775|DRUG|Mejoral® 500 Tablets|500 mg tablet of paracetamol
215015703|NCT02504775|DRUG|Tylenol® Caplets|500 mg tablet of paracetamol
215015704|NCT02262221|OTHER|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
215015705|NCT05171335|DRUG|Lenvatinib|"Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of \<60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time."
215015706|NCT05171335|PROCEDURE|Transcatheter Arterial Chemoembolization|Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
215101178|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
215101179|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
215101180|NCT05994079|DEVICE|High intensity focused ultrasound|"Parameters:~Transducer frequency 7-2-mhz 1.5-9.0-mm focal depth. The pulse duration for each individual exposure ranged from 25 to 40 milliseconds.~Energy per ultrasound pulse ranged from 1.0 to 1.5 J"
215101181|NCT05994079|OTHER|topical firming creams|medical topical firming creams
215101182|NCT06530771|DIAGNOSTIC_TEST|ultrasound|Conventional US, SWE, and AP of thyroid nodules were conducted successively with a Supersonic Aixplorer system (SuperSonic Imagine, Aix-en-Provence, France) using a 5-14 MHz linear transducer.
215101183|NCT05901883|DRUG|CEL383|Subjects will receive CEL383
215101184|NCT05901883|DRUG|Placebo|Subjects will receive placebo
215101185|NCT04957368|DRUG|Nitrous Oxide 99 %|Nitrous oxide will be administered at an inspiratory concentration of 50% with concurrent intravenous saline (100ml) for one hour.
215101186|NCT04957368|DRUG|Oxygen + Midazolam|Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour
215101187|NCT04918732|DIAGNOSTIC_TEST|FibroScan|The FibroScan device developed by Echosens (France) measures the liver stifness and steatosis based on a pulse of sound waves that goes through the liver.
215101188|NCT00007891|BIOLOGICAL|filgrastim|
215101189|NCT00007891|PROCEDURE|autologous bone marrow transplantation|
215101190|NCT00007891|PROCEDURE|peripheral blood stem cell transplantation|
215101191|NCT00007891|RADIATION|indium In 111 monoclonal antibody BrE-3|
214411527|NCT04262414|DEVICE|Functional Electrical Stimulation|"The device used was a prototype closed-loop FES system to improve standing balance by activating the ankle plantar flexors and dorsiflexors (i.e. A-FES system). As a closed-loop system, the body's position and velocity are continually monitored, and the level of stimulation adjusted accordingly on a moment-to-moment basis. This differs from currently available FES units, which do not monitor body movement and therefore, provide a constant level of stimulation unless manually adjusted by the user/PT. The control strategy used in the A-FES system mimics the physiological control system in able-bodied people, meaning it has the potential to re-educate normal movement patterns."
214411528|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets|
214411529|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
214411530|NCT02184325|DRUG|Comparator product|active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
214411531|NCT05826834|DEVICE|ball-rolling (Myostorm ball)|the intervention group
214411532|NCT02467491|DEVICE|Jintronix|The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
214411533|NCT00913913|BIOLOGICAL|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
214411534|NCT00913913|DRUG|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
214411535|NCT00913913|BIOLOGICAL|IL-2|IL-2 18 MiU/m2 CI 5 days
214411536|NCT00913913|BIOLOGICAL|IFN|IFN 6 MiU subc TIW
214411537|NCT01137799|DRUG|JNJ-39393406|50mg nanosuspension (sort of liquid formulation) once daily (single dose)
214411538|NCT01137799|DRUG|placebo|Once daily (single dose)
214411539|NCT01137799|DRUG|JNJ-39393406|200mg nanosuspension (sort of liquid formulation) once daily (single dose)
214411540|NCT01137799|DRUG|JNJ-39393406|100mg nanosuspension (sort of liquid formulation) once daily (single dose)
214411541|NCT01137799|DRUG|JNJ-39393406|10mg nanosuspension (sort of liquid formulation) once daily (single dose)
214411542|NCT01137799|DRUG|JNJ-39393406|30mg nanosuspension (sort of liquid formulation) once daily (single dose)
214411543|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
214411544|NCT03107611|DRUG|Placebo Cream|
214411545|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
214411546|NCT00201695|DRUG|Doxil®|40 mg/m2 IV day 1
214411547|NCT00201695|DRUG|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
214411548|NCT00201695|DRUG|Dexamethasone|40 mg PO days 1-4
214411549|NCT00201695|DRUG|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
214411550|NCT01043471|OTHER|Chewing gum|Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
214411551|NCT01043471|OTHER|Water|Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
214411552|NCT05949554|OTHER|Ketamine infusion|"Continuous measurement of burst suppression (BS) (%) and 95% spectral frequency front (SEF95) on frontal EEG Sedline® Masimo Corporation, USA).~EEG recording will start 10 minutes before the beginning of infusion until the total amount of 10 milligrams of Ketamine has been infused.~The duration varies depending on patient's weight.~Each patient will receive a dose of 0,5 mg/kg over a period of time of 2 or 4 hours."
214411553|NCT02145182|DRUG|Eculizumab|Eculizumab is a complement component 5 inhibitor.
214411554|NCT02145182|DRUG|Placebo|0.9% sodium chloride
214411555|NCT01971788|DEVICE|Optical Coherence Tomography of the infarct related artery|
214411556|NCT00016913|DRUG|carboplatin|AUC=6 week one of each 4 week cycle
214411557|NCT00016913|DRUG|estramustine|2 tablets tid PO 5 of 7 days per week each 4 week cycle
214411558|NCT00016913|DRUG|paclitaxel|80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
214411559|NCT00016913|RADIATION|radiation therapy|77.4 Gy in 1.8 Gy fractions
214411560|NCT00016913|DRUG|leuprolide or goserelin acetate|7.5 mg IM injection once every 4 weeks for 6 months
214411561|NCT00588419|BEHAVIORAL|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
214411562|NCT00588666|DRUG|Bevacizumab|
214411563|NCT00588666|DRUG|Carboplatin|
214411564|NCT00588666|DRUG|Gemcitabine|
214411565|NCT06350045|COMBINATION_PRODUCT|PCNL|percutaneous nephrolithotomy
214411566|NCT03615248|DEVICE|BreatheSuite|"BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~1. the dose was given,~2. the metered dose inhaler was properly shaken,~3. the metered dose inhaler is properly aligned,~4. the flow of medication is appropriate and~5. there is no accidental exhalation into the inhaler."
214411567|NCT03150563|OTHER|Passive static stretch|Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
214411568|NCT05416671|BEHAVIORAL|guided narrative technique-writing|The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
215015707|NCT03142204|DRUG|[18F]F-AraG|Single dose IV injection of \[18F\]F-AraG for each imaging day.
215015708|NCT04605588|DRUG|Nitazoxanide|Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
215015709|NCT04605588|DRUG|Placebo Nitazoxanide|Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
215015710|NCT04605588|DRUG|Ribavirin|Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
215015711|NCT04605588|DRUG|Placebo Ribavirin|Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
214411569|NCT05571358|DEVICE|Virtual Reality (Nature Trek)|"At the end of each session, participants will experience an immersive virtual landscape displayed by Nature Trek VR software (httpp://naturetreksvr.com/). First, participants will be placed in a sit down position and guided for their breathing control during 5 minutes (meditation Lotus option). After that, they will be encouraged to freely move around a relaxing virtual environment during 15 minutes taking special attention to soothing sounds of nature. The themes environment will be selected based on the preferences of the participants.~At the beginning of the study, advice is given on general care, in physical activity and issues concerning drug intake. Patients are advised to refrain from any other specific training during the intervention period. Any deviations from the adherence and practice of the VRi are recorded daily, noting any adverse incidents."
214411570|NCT04405713|PROCEDURE|from the onset of symptoms within the first 3 days|ELC within 3 days of onset of ACC
214411571|NCT04405713|PROCEDURE|: from the onset of symptoms within the 4-7 days|ELC 4-7days of onset of ACC
214411572|NCT04405713|PROCEDURE|from the onset of symptoms beyond 7 days|ELC after 7days of onset of ACC
214411573|NCT02104648|OTHER|Placebo RO4602522|Daily oral doses
214411574|NCT02104648|DRUG|RO4602522|Daily oral doses
214411575|NCT02104648|DRUG|RO4602522|Single, oral dose
214411576|NCT02104648|DRUG|moxifloxacin|400 mg oral dose given on Day 1 or 11
214411577|NCT02104648|OTHER|moxifloxacin placebo|Dose given orally on Days 1 and/or 11
214411578|NCT02274493|DEVICE|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
214411579|NCT02274493|PROCEDURE|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
214411580|NCT02274493|PROCEDURE|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
214411581|NCT02274493|BEHAVIORAL|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
214411582|NCT05534633|OTHER|Choice of STBBI test(s)|Participants may receive a point of care HIV test, and/or point of care HCV test, and/or dry blood spot test, which can test for HIV, HCV, and syphilis, at the participants' choice.
214411583|NCT03102710|DEVICE|transcranial direct current stimulation (tDCS)|tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
214688558|NCT04998669|DRUG|Loncastuximab tesirine|"Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle."
215015712|NCT04605588|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
215015713|NCT04605588|DRUG|Placebo Hydroxychloroquine|Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
215015714|NCT01230814|DRUG|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
215015715|NCT01230814|DRUG|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
214411584|NCT03102710|OTHER|Lidocaine cream|Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
214411585|NCT03102710|OTHER|Capsaicin cream|Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
214411586|NCT03102710|OTHER|Control cream|A neutral cream will be applied on the arm as a control.
214411587|NCT06582563|DIAGNOSTIC_TEST|Whole Blood Clotting Time|Comparator
214411588|NCT05591079|DRUG|CS0159 (Linafexor)|Oral QD
214411589|NCT05074615|OTHER|Cranio-Cervical Flexion Training|"Participants of this group will receive conventional training along with Cranio-cervical flexion training:~* The pressure cuff is placed behind the neck just next to the occiput and inflated up to a baseline pressure of 20 mmHg. The patient is asked to perform Cranio-Cervical Flexion (CCF) to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the patient is instructed to maintain the contraction for 10 sec for 10 repetitions with brief rest periods between each contraction i.e., 3-5 seconds. Once a set of 10 repetitions of 10 sec is achieved at one target level, the exercise is progressed to train at the next target level up to the final target level at 30 mmHg.~Conventional therapy will be given along with home plan. Exercise protocol will consist of 30 minutes. Exercise will have total 3 sessions/week for 3 weeks."
214411590|NCT05074615|OTHER|Conventional Therapy|"Participants of this group will receive only conventional therapy and home plan will be given which includes;~* Hot pack placed on the posterior neck for 15 minutes.~* Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~* Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~* Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~* Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks"
214411591|NCT03780790|DRUG|Bupivacaine|% 0,25
214411592|NCT02759731|DRUG|Baricitinib|Cycle=28 days: Baricitinib: 1mg-4mg by mouth (PO) every day (QD)
214411593|NCT03284749|OTHER|Copper impregnated wound dressing|Copper impregnated wound dressing
214411594|NCT03284749|OTHER|Normal wound dressing|Normal wound dressing
215015716|NCT02527265|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
215015717|NCT02182453|DRUG|BI 10773 - single rising dose|
215015718|NCT02182453|DRUG|Placebo|
215015719|NCT01534715|DRUG|IMGN529|
215015720|NCT03428269|OTHER|simulation by gaming (LabForGames Warning)|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
215015721|NCT03428269|OTHER|traditional education|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
215015722|NCT04512625|BIOLOGICAL|Desensitizers|The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.
215015723|NCT00170755|DRUG|Darifenacin|Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
215015724|NCT01330524|DRUG|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
215015725|NCT01330524|OTHER|placebo|2mg placebo
214411595|NCT03284749|OTHER|Copper impregnated maternity pads|Copper impregnated maternity pads
214411596|NCT03284749|OTHER|Normal maternity pads|Normal maternity pads
214411597|NCT04370782|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
214411598|NCT04370782|DRUG|Azithromycin|Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
214411599|NCT04370782|DRUG|Zinc Sulfate|Zinc sulfate 220mg once daily for 5 days
214411600|NCT04370782|DRUG|Doxycycline|Doxycycline 200 mg once daily for 5 days
215015726|NCT02738398|RADIATION|FDG PET/CT|
215015727|NCT05169957|DRUG|Ipilimumab|Ipilimumab administered IV over 85-100 minutes at 3 mg/kg (combined with nivolumab administered IV over 30-60 minutes at 1 mg/kg) every 3 weeks for a total of 4 doses or until progression or unacceptable toxicity.
215015728|NCT05169957|DRUG|Nivolumab|Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the combination therapy or until progression or unacceptable toxicity. Subjects may receive maintenance dosing of nivolumab alone administered IV over 30-60 minutes at 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 52 weeks or until progression or unacceptable toxicity.
215015729|NCT05169957|PROCEDURE|Stereotactic Body Radiation Therapy|24-45 Gy delivered in three fractions to up to 4 liver metastases
215015730|NCT03882359|DIAGNOSTIC_TEST|Echocardiogram|"Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3."
215015731|NCT03882359|DRUG|MVT-100|After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
215015732|NCT03882359|DRUG|Definity|After randomization, Definity, the active comparator, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
214411601|NCT05693155|BEHAVIORAL|Voluntary self-exclusion from gambling ('Spelpaus')|Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')
214411602|NCT05638230|DIAGNOSTIC_TEST|Left atrial reservoir strain|"LA strain measurements can be obtained by two dimensional (2D) speckle tracking echocardiography (STE). Longitudinal strain and strain rate curves are generated for each of six atrial segments, obtained from the apical four and two chamber views.~In the reservoir phase, as the LA fills and stretches, there is positive atrial strain that reaches its peak in systole at the end of LA filling, prior to opening of the mitral valve. Following this, passive LA emptying ensues with opening of the mitral valve resulting in decreased atrial strain with negative deflection of the strain curve up to a plateau period which is analogous to diastasis. LA reservoir strain (LARS), or peak atrial longitudinal strain or LA systolic strain, is measured at the end of the reservoir phase."
214411603|NCT03245060|BEHAVIORAL|Adapted Solution Focused Brief Therapy|Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
215015733|NCT05463471|DRUG|Compound sodium acetate ringer injection|Quickly infuse 500ml of compound sodium acetate ringer injection for volume expansion within 20-30 minutes
215015734|NCT05463471|DRUG|Albumin|Quickly infuse 500ml of albumin for volume expansion within 20-30 minutes
214411604|NCT03936829|DRUG|Cyclophosphamide|Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
214411605|NCT04638387|DIETARY_SUPPLEMENT|PB125|Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.
214411606|NCT04638387|DIETARY_SUPPLEMENT|Placebo|Placebo comparator to P125
214411607|NCT00104611|DEVICE|Repetitive Transcranial Magnetic Stimulation|
214411608|NCT01101165|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken without food
214411609|NCT01101165|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
214411610|NCT06549517|BEHAVIORAL|Cognitive training|MTT24.5 consists in the learning of 40 new datas or knowledges, along 24.5 hours distributted on classes or sessions, during which an average of 3.5 new pieces of knowledge are taught and reinforced through training. Participants are trained using 4 techniques assigned to each new piece of information from a total of 100 available techniques. These techniques include the use of non-dominant skills, literacy in Braille for sighted individuals, and performing 5 actions simultaneously. Each technique is designed to aid in the memorization and learning of new knowledge
215015735|NCT03149380|BEHAVIORAL|Web-based education|The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
215015736|NCT02596893|DRUG|GED-0301|
214411611|NCT01912703|OTHER|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
214411612|NCT00507637|DRUG|NT 201|Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
214411613|NCT02364518|PROCEDURE|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
214411614|NCT00055432|DRUG|Gemzar and Alimta|
214688559|NCT04998669|DRUG|Rituximab|"Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician."
215015737|NCT02596893|DRUG|Placebo|
215015738|NCT06092957|DRUG|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
215015739|NCT06092957|DRUG|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
215015740|NCT06092957|RADIATION|Reduced-dose IMRT|GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy
215015741|NCT06092957|RADIATION|Standard-dose IMRT|GTVnx：69.96Gy/33Fr/2.12Gy；CTV1：60.60Gy/33Fr/1.82y；CTV2：54.12Gy/33Fr/1.64Gy
215015742|NCT06092957|DRUG|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
215015743|NCT01679665|BIOLOGICAL|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval
215015744|NCT01679665|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 4 weeks interval
215015745|NCT05861401|GENETIC|Janus Kinase 1 and 2|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
215015746|NCT03112187|DRUG|Iron Supplement|Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
215015747|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 400 IU|Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
215015748|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 800 IU|Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
215015749|NCT01103115|DIETARY_SUPPLEMENT|Placebo|placebo tablets
215015750|NCT03052257|BEHAVIORAL|Educational - glaucoma|Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
214411615|NCT03655483|DRUG|GLS-010|Full-human anti-pd-1 monoclonal antibodies
214688560|NCT01132573|DRUG|entinostat|Given PO
215015751|NCT03052257|BEHAVIORAL|Dose monitoring and reminder|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated."
215015752|NCT03052257|BEHAVIORAL|Educational - general|The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
215015753|NCT03052257|BEHAVIORAL|Dose monitoring|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
214688561|NCT01132573|DRUG|clofarabine|Given IV
214688562|NCT01132573|OTHER|pharmacological study|Correlative studies
214411616|NCT04517591|BEHAVIORAL|The Take a STAND for health|A 4-month parallel-group randomised controlled trial will be performed, in which patients post-bariatric surgery will be assessed at baseline pre-surgery (PRE-BAR), 3 months after surgery and pre-intervention (PRE-INT) and 4 months after intervention (POST). Moreover, a sub-sample of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 5-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.
214411617|NCT00800163|OTHER|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
214411618|NCT06189742|BIOLOGICAL|Tezepelumab|Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).
214411619|NCT04172844|DRUG|Azacitidine|75mg/m\^2 Days 1-7 given IV
214411620|NCT04172844|DRUG|Venetoclax|100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
214411621|NCT04172844|DRUG|Pevonedistat|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
214411622|NCT02799056|DEVICE|Thoracic ultrasound|The ultrasound will be performed using the ultrasound system GE Logiq XP equipped with a linear probe of 10 MHz. The diaphragm is visualized as two parallel echogenic lines at the eighth intercostal space in the mid-axillary line. The images will be captured during the inspiratory and expiratory tidal volume to and during maximum inspiration and expiration. Each image will be frozen in B mode and the diaphragm thickness will be measured from the center line pleural half the peritoneal line. The fraction of diaphragmatic thickening it is calculated by the formula: diaphragmatic thickness at the end of inspiration - thickness to diaphragmatic at the end of exhalation / diaphragmatic thickness at the end of exhalation x 100. The number of areas with lines B also will be measured.
214411623|NCT00651885|DRUG|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
214411624|NCT00651885|DRUG|Placebo|Placebo
214411625|NCT05288101|DIETARY_SUPPLEMENT|Proteinex and Enterex DBT Victus Laboratories|The supplement was provided five days per week. Three days a week, the supplement was given at the beginning of the HD session and the patients were instructed to consume it slowly during the next 3 hours. The remaining two days, the supplement was consumed at home and instructed to be consumed between meals. The ONS consisted of one can of polymeric formula (Enterex DBT, Victus Laboratories) and 5.6 g of a protein powder supplement (Proteinex, Victus Laboratories). The final mixture provided 240 kcal, 17 g protein, 8.1 g lipids, 25 g carbohydrates, 4 g dietary fiber, 201 mg sodium, 490 mg calcium, 356 mg phosphorus and 371 mg potassium
214411626|NCT05288101|PROCEDURE|Dry weight adjustment through BIVA|Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.
214411627|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
214411628|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
214411629|NCT00297765|DRUG|Tacrolimus, Prograf®|
214411630|NCT02258295|DRUG|Intragel|Intragel has an average molecular weight of 800-1200 kDaltons.
214411631|NCT02258295|DRUG|Saline|Saline
214411632|NCT04551157|OTHER|Video Viewing|Two patient information videos containing practical advice from staff about the recovery process, images of the wound throughout the healing process and ways to cope with the range of emotional responses that patients report following an open fracture.
214411633|NCT00955461|PROCEDURE|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
214411634|NCT00955461|PROCEDURE|Fractionated Laser treatment|
214411635|NCT00852228|DRUG|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
214411636|NCT00852228|DRUG|HAI chronomodulated chemotherapy|"Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks."
214688563|NCT01132573|OTHER|laboratory biomarker analysis|Correlative studies
214688564|NCT01762540|DRUG|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
215015754|NCT02759263|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
215015755|NCT00038246|DRUG|Estramustine|140 mg by mouth (po) three times a day on Days 1-5, 8-12
215015756|NCT00038246|DRUG|Thalidomide|200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
215015757|NCT00038246|DRUG|Paclitaxel (Taxol)|100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10
215015758|NCT01529112|DRUG|Lenvatinib|
215015759|NCT01529112|DRUG|Lenvatinib matched placebo|
215015760|NCT01529112|DRUG|BSC|
214411637|NCT00852228|DRUG|HAI conventional chemotherapy|"Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks."
214411638|NCT01281761|DRUG|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- \[C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min\] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV \[over 90min\] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
214411639|NCT02782182|DRUG|FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)|FOLFIRINOX administered preoperatively and postoperatively
214411640|NCT00335556|DRUG|Doxorubicin Hydrochloride|Given IV
214411641|NCT00335556|DRUG|Irinotecan Hydrochloride|Given IV
214411642|NCT00335556|PROCEDURE|Conventional Surgery|Patients undergo resection
214411643|NCT00335556|DRUG|Cyclophosphamide|Given IV
214411644|NCT00335556|DRUG|Etoposide|Given IV
214411645|NCT00335556|DRUG|Carboplatin|Given IV
214411646|NCT00335556|BIOLOGICAL|Dactinomycin|Given IV
214411647|NCT00335556|DRUG|Vincristine Sulfate|Given IV
214411648|NCT00335556|RADIATION|Radiation Therapy|Undergo radiotherapy
214411649|NCT00335556|OTHER|Laboratory Biomarker Analysis|Correlative studies
214411650|NCT04669405|DEVICE|High intensity laser therapy|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
214688565|NCT01762540|DRUG|Calcium Supplement|Placebo
214688566|NCT00909142|DRUG|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
214688567|NCT02165657|DEVICE|Excimer laser treatment|Excimer laser irradiation twice a week for up to 20 treatments.
214688568|NCT03443726|PROCEDURE|Nerve block technique|Inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve for third molar extraction.
215015761|NCT03816917|OTHER|cutaneous parameters of psoriasis (exposure)|characteristic of the cutaneous domains of the psoriasis: age at start, disease duration, current and previous treatment PASI, BSA, nail involvement
214411651|NCT04669405|OTHER|Therapeutic Exercise|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
215015762|NCT03816917|OTHER|comorbidity (exposure)|medical and medication history, current and previous comorbidity
215015763|NCT03816917|OTHER|family history (exposure)|Family history of PsC, PsA, IBD, AS, and uveitis
214411652|NCT01273701|BEHAVIORAL|Psychosocial intervention|"The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1."
214411653|NCT01273701|BEHAVIORAL|Telephone reminding|Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
214411654|NCT03898687|DEVICE|SLN Biopsy with Magtrace®/Sentimag®|Identification of SLN by means of Magtrace®/Sentimag® and SPIO-MRI
214688569|NCT03443726|PROCEDURE|Infiltrative technique|Infiltrative anesthesia buccally between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc lingually to the third molar using the same anesthetic solution.
214688570|NCT03443726|DRUG|4% articaine 1:100.000 epinephrine|Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
214688571|NCT03443726|PROCEDURE|Third molar extraction|Third molar extraction under local anesthesia.
214688572|NCT01797198|DRUG|ASP3652|Oral
214688573|NCT01797198|DRUG|Gemfibrozil|Oral
214688574|NCT01797198|DRUG|Repaglinide|Oral
214688575|NCT03100942|DRUG|Lanraplenib|1 x 30 mg tablet administered orally once daily
215015764|NCT03816917|OTHER|lifestyle (exposure)|"* Intoxications~* Lifestyle: occupation and injuries, sport and physical hobbies"
215015765|NCT03816917|OTHER|patient reported outcomes (exposure)|VAS-score on fatigue, PsC severity, joint pain and general well-being
215015766|NCT03816917|OTHER|inflammatory markers (exposure)|Measurements of inflammatory and bone remodeling markers in serum and plasma
215015767|NCT03816917|OTHER|genetic (exposure)|Assessment of known HLA- and SNP-associations with PsA or PsA
215101192|NCT00007891|RADIATION|yttrium Y 90 monoclonal antibody BrE-3|
215101193|NCT02188654|DRUG|Metformin|500mg/day retarded formulation of metformin
215101194|NCT02188654|DRUG|Placebo|500 mg/day of placebo tablets
215101195|NCT03513627|PROCEDURE|Post-occlusive reactive hyperemia test (PORH test)|Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
215101196|NCT00185224|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
214411655|NCT05893043|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral capsules.
215101197|NCT00185224|DRUG|SH D00264A (Triquilar)|7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
215101198|NCT03560167|DEVICE|AccuCinch® Ventricular Restoration System|AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
215101199|NCT03215199|OTHER|NAPT|Web-based depression and distress monitoring application
214411656|NCT05893043|OTHER|Placebo|Participants will receive matching placebo oral capsules.
214411657|NCT04018417|DRUG|Amphotericin B|Drug concentration: 0.255 μg/mL
215101200|NCT02942485|DRUG|Metronidazole|P/r suppositories
215101201|NCT02942485|DRUG|Tinidazole|P/o tablets
215101202|NCT00687674|DRUG|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
215101203|NCT00687674|DRUG|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
215101204|NCT00687674|DRUG|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
215101205|NCT05654454|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
215101206|NCT05654454|DRUG|Paclitaxel|Paclitaxel 175 mg/m2
215101207|NCT05654454|DRUG|Carboplatin|Carboplatin AUC 6
215101208|NCT04518540|DRUG|lipoic acid group|"The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day."
215101209|NCT04518540|DRUG|control group|The patients will take domestic riluzole tablets 50mg orally, twice a day.
215101210|NCT01379196|DRUG|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
215101211|NCT02186678|OTHER|PET-CT|
215101212|NCT05096689|OTHER|MRI|Magnetic Resonance Imaging
215101213|NCT05100576|DEVICE|Telemedicine system users|Telemonitoring by medical devices connected to a software system with a router.
215101214|NCT04369950|DRUG|2% lidocaine with 1:200,000 epinephrine and epidural morphine|Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
215101215|NCT04369950|DRUG|3% 2-chloroprocaine and epidural morphine|Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
214411658|NCT06226974|OTHER|Static Stretching|"* Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
214411659|NCT00986271|PROCEDURE|EVLI was determinated by PiCCO plus system.|
214504820|NCT02556918|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG greater than 400 mg/dL; 7-9 units of insulin lispro"
215101216|NCT06038734|DIAGNOSTIC_TEST|gastric ultrasound|Utilize POC gastric ultrasound to identify the presence of retained gastric contents.
215101217|NCT00139919|DRUG|Bifeprunox|
215101218|NCT00989963|DRUG|Beraprost Sodium Modified Release|60µg Tablets, twice a day for 12 weeks
215101219|NCT03326206|OTHER|COPE Program|The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
215101220|NCT06122038|DIETARY_SUPPLEMENT|Tart Cherry Extract Powder|Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
215101221|NCT06122038|DIETARY_SUPPLEMENT|Placebo|Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
215101222|NCT05485337|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
215101223|NCT05350852|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
215101224|NCT00269867|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
215015768|NCT02255279|BIOLOGICAL|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
214411660|NCT05753709|PROCEDURE|Hand sewn end-to-end anastomosis|Hand sewn end-to-end anastomosis (EE) Holding sutures were taken through a seromuscular bite with PDS (Polydiaxonone) 3-0 or Silk 2-0 RB (Round Bodied needle), one each at the mesenteric and antimesenteric ends of the stoma. A posterior layer of Lembert sutures was taken first. The first bite was taken at the anti-mesenteric end and a knot was applied. A Connell stitch was applied at the corner and then the posterior layer was closed using an inverting interlocking continuous stitch till the mesenteric end. Another Connell stitch was applied here to secure the corner and the suture was continued on to the anterior layer which was then closed in a similar manner using a continuous interlocking stitch. The final bite crossed the initial knot and the final knot was applied. An anterior layer of Lembert sutures was taken to reinforce the anastomotic line.
214411661|NCT05753709|PROCEDURE|Hand sewn side-to-side anastomosis|Hand sewn side-to-side anastomosis (HSSA) Each end of the stoma was closed using either a single layer of inverting interlocking continuous sutures with PDS 3-0 or Silk 2-0 RB, or a Linear Stapling device. The two closed stumps were then brought adjacent to each other in an anti-peristaltic arrangement. A posterior layer of Lembert sutures was applied using Silk 2-0 RB. The bowel wall was incised using electrocautery close to the suture line. The incision was lengthened up to a width of at least 5-6 cm. The posterior and anterior layer was now closed using the same technique as in HS using PDS 3-0. An anterior layer of Lembert sutures was applied. The mesenteric defect was then closed using a superficial interrupted layer of Silk 2-0 RB.
214411662|NCT05753709|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis or Functional End-to-end anastomosis (SSSA/FEEA) The two limbs of a Linear Cutter SR55 are placed into the proximal and distal bowel loops of the stoma, facing as far away from the mesenteric border as possible and then fired. If both lumens are of similar size, traction sutures are applied with Silk 2-0 RB at the anterior and posterior termination ends of the staple line. The two ends are pulled away from each other, and a Linear Cutter SR75 is applied just below the edge of the bowel and fired. However, in case of an ileo-colostomy, after the first linear cutter SR55 is fired, the two suture lines are approximated in such a way that they do not get apposed but rather lie adjacent to each other. The lumen is then clamped in SR75 which is then fired.
214411663|NCT01878890|DRUG|Efavirenz 600mg|Efavirenz 600 mg (oral daily intake)
214411664|NCT01878890|DRUG|Efavirenz 1200 mg|Efavirenz 1200mg (oral daily intake)
214411665|NCT01878890|DRUG|Efavirenz 1800 mg|Efavirenz 1800mg (oral daily intake)
214411666|NCT01878890|DRUG|Efavirenz 2200 mg|Efavirenz 2200mg (oral daily intake)
214411667|NCT01244100|DRUG|PL2200 fasted|Fasted state
215015769|NCT02255279|BIOLOGICAL|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
215015770|NCT03279068|OTHER|Teaching and EFM Paper|Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
214411668|NCT01244100|DRUG|PL2200 fed|Fed state
215015771|NCT00144508|DRUG|MRA (Tocilizumab)|8mg /kg /4week for 52 weeks
215015772|NCT00144508|OTHER|current treatment|continue current treatment
215015773|NCT03859856|OTHER|hormone panel and ultrasonography|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH, LH, E2 and AMH hormone levels and ultrasonography for antral follicle count and ovarian volume measurement will be done.
215015774|NCT03718403|DRUG|Theophylline|Theophylline will be given to maintain a peak level between 10-15 mcg/mL
215015775|NCT04928066|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
215015776|NCT04928066|DRUG|Tofacitinib|Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
215015777|NCT04928066|DRUG|Pred|Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
215015778|NCT02846454|OTHER|inulin|Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
215015779|NCT02846454|OTHER|arabinoxylan|Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
214688576|NCT03100942|DRUG|Filgotinib|1 x 200 mg tablet administered orally once daily
214688577|NCT03100942|DRUG|Tirabrutinib|1 x 40 mg tablet administered orally once daily
215015780|NCT01120444|DEVICE|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
215015781|NCT01120444|DEVICE|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
215015782|NCT00252148|BIOLOGICAL|ADMVA|experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
215015783|NCT03607695|OTHER|Gait training|Walking on a treadmill and receiving audio cues to improve gait
215015784|NCT00884598|DRUG|cilengitide|
215015785|NCT00884598|OTHER|pharmacological study|
215015786|NCT00884598|RADIATION|radiation therapy|
215015787|NCT01333566|BEHAVIORAL|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
214411669|NCT04054661|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
214411670|NCT04054661|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
214411671|NCT04054661|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
215015788|NCT01333566|BEHAVIORAL|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
214411672|NCT03767114|DIAGNOSTIC_TEST|RT-PCR for ERAP1 detection|Reverse transcriptase -Polymerase Chain Reaction for ERAP1 detection
214411673|NCT00542022|DRUG|MK0812 / Duration of Treatment: 12 Weeks|
214411674|NCT00542022|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
214411675|NCT04816890|DRUG|M1 Pram P037|Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.
214411676|NCT04816890|DRUG|Insulin lispro|Subcutaneous administration of insulin lispro in combination with a basal insulin.
214411677|NCT03985709|OTHER|Probiotic product|Probiotic (Lactobacillus casei) once daily taken by 3 months.
214411678|NCT01588704|DRUG|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
214411679|NCT03971747|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|Autologous T cells transduced with lentivirus encoding AFP specific TCR gene
214411680|NCT01002443|DRUG|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
214411681|NCT01002443|DRUG|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
214411682|NCT02127476|DRUG|KHK6640|Single ascending dose and multiple ascending doses administration
214411683|NCT02127476|DRUG|Matching Placebo|Single ascending dose and multiple ascending doses administration
214411684|NCT05295082|PROCEDURE|guided trephination-based drilling protocol|the implant site preparation in this group will be done by guided trephination protocol which uses the surgical guide to trephine the implant site then remove the guide and continue the drilling in a freehand manner
214411685|NCT05295082|PROCEDURE|guided Conventional drilling-based protocol|the implant site preparation in this group will be done by a guided conventional drilling protocol which uses the surgical guide to guide the sequential drills up to the final drill
215015789|NCT03268161|DIAGNOSTIC_TEST|Mutational analysis of clonal B cells|"Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.~Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought."
215015790|NCT02741193|DEVICE|The Magstim Rapid2,|"Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).~single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability."
215015791|NCT01640535|DRUG|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
215015792|NCT01640535|DRUG|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
215015793|NCT01640535|DRUG|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
215015794|NCT02567032|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
215015795|NCT02567032|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
215015796|NCT03402581|DEVICE|c-mac laryngoscope|type of laryngoscopes
215015797|NCT00036465|BEHAVIORAL|Treatment regimen change|
215015798|NCT05017402|DRUG|Alglucosidase Alfa|Standard dose: 20-25 mg/kg every other week; Higher dose: \>25 mg/kg every other week.
215015799|NCT05137145|DRUG|Linaclotide|The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
215015800|NCT05137145|DRUG|Compound Polyethylene Glycol Electrolyte Powder|The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
215015801|NCT00118859|BEHAVIORAL|Integrative care for low back pain|
215015802|NCT00118859|BEHAVIORAL|Conventional treatment for low back pain|
215015803|NCT06035198|OTHER|Stroke|No intervention
215015804|NCT06500221|BEHAVIORAL|incentive spirometry|The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
214411686|NCT03404843|DRUG|Fasudil Hydrochloride|10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
214411687|NCT03404843|OTHER|Saline|100 mL saline bag.
214411688|NCT00814281|OTHER|placebo|Placebo
214411689|NCT00814281|DRUG|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
215101225|NCT00269867|DRUG|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
215101226|NCT00269867|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
215101227|NCT04385134|OTHER|No intervention|No intervention
215101228|NCT04548791|BIOLOGICAL|Coagulation Factor VIIa variant|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes
214411690|NCT01715909|DRUG|Oseltamivir|Participants will receive standard dose (30 to 75 milligrams \[mg\]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for \</= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (\>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
214411691|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
214411692|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
215015805|NCT02502383|BEHAVIORAL|ACTION PAC|School-based health center providers will use motivational interviewing to assist students with adopting strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI and other health results discussion with clinical providers. Adolescents with overweight/obesity will meet with providers for 16 sessions over 2 years.
215015806|NCT02502383|BEHAVIORAL|Communication with parents|A letter containing BMI and other health results and obesity prevention recommendations will be sent to parent/guardians.
215015807|NCT00366613|PROCEDURE|Cataract surgery with Perfect Capsule and Sodium Chloride|
215015808|NCT00327431|GENETIC|Cheek swab samples for DNA|
215015809|NCT02555358|DRUG|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
215015810|NCT02555358|DRUG|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
215101229|NCT01240200|DRUG|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
215101230|NCT01240200|DEVICE|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
215101231|NCT00068302|DRUG|sirolimus|3-6 subjects will be enrolled into each dose level
215101232|NCT03548467|BIOLOGICAL|VB10.NEO|VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).
214411693|NCT00567164|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
214411694|NCT02543216|DIETARY_SUPPLEMENT|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
214411695|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IM)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
215015811|NCT03167424|DEVICE|Treatment of restenosis|Treatment of in-stent restenosis
215015812|NCT00477724|BEHAVIORAL|exercise and respiratory therapy|exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
215015813|NCT00477724|OTHER|sedentary control group|control group with no specific training
215015814|NCT01137565|DRUG|AMG 853|Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
215015815|NCT01137565|DRUG|Placebo|Placebo to AMG 853
215101233|NCT03548467|DRUG|Bempegaldesleukin|0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
215101234|NCT02195141|RADIATION|conventional fraction|capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
215101235|NCT02195141|RADIATION|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
215101236|NCT04269356|DRUG|BMS-986256|Specified dose on specified days
215101237|NCT04269356|DRUG|Milk of magnesia|Specified dose on specified days
215101238|NCT04808739|BIOLOGICAL|Adalimumab|Analysis of survival of adalimumab biosimilar in clinical practice
215101239|NCT01529034|DRUG|USL261|
215101240|NCT06426836|OTHER|Amoxicillin-clavulanate|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
215101241|NCT06426836|OTHER|Piperacillin-tazobactam|blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
215101242|NCT06426836|OTHER|Meropenem|blood sampling in patients receiving meropenem as part of routine clinical care.
215101243|NCT06426836|OTHER|Cefazolin|blood sampling in patients receiving cefazolin as part of routine clinical care.
214411696|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IT)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
214411697|NCT00390403|DRUG|R-(-)-gossypol acetic acid|
214411698|NCT00390403|DRUG|temozolomide|
214411699|NCT00390403|GENETIC|gene expression analysis|
214411700|NCT00390403|GENETIC|mutation analysis|
214411701|NCT00390403|GENETIC|protein expression analysis|
214411702|NCT00390403|OTHER|laboratory biomarker analysis|
214411703|NCT00390403|OTHER|pharmacological study|
214688578|NCT03100942|DRUG|Lanraplenib placebo|1 x tablet administered orally once daily
215015816|NCT00363467|DRUG|G-CSF|"Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.~Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously."
215015817|NCT00363467|DRUG|Leukapheresis|leukapheresis
215101244|NCT06426836|OTHER|Vancomycin|blood sampling in patients receiving vancomycin as part of routine clinical care.
215101245|NCT06426836|OTHER|Teicoplanin|blood sampling in patients receiving teicoplanin as part of routine clinical care.
215101246|NCT06426836|OTHER|Ciprofloxacin|blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
214411704|NCT00390403|PROCEDURE|adjuvant therapy|
214411705|NCT00390403|RADIATION|radiation therapy|
214411706|NCT03653975|OTHER|no intervention|no intervention
214411707|NCT05776576|BEHAVIORAL|Evaluation|Within the scope of the evaluation, first of all, physical activity levels of children and adolescents with physical disabilities, barriers that prevent them from participating in physical activity, and motivators that can increase their participation will be determined, accompanied by an interactive roundtable meeting. Afterwards, posture analyzes of children and adolescents with special needs with physical disabilities will be performed by physiotherapists.
214411708|NCT05776576|BEHAVIORAL|Education|"In the education part, interactive informative seminars titled Physical Activity in Individuals with Special Needs will be given and after the objective posture assessments, postural disorders of children and adolescents with special needs will be determined and accordingly, posture and ergonomics training will be given to the participants individually."
214688579|NCT03100942|DRUG|Filgotinib placebo|1 x tablet administered orally once daily
214688580|NCT03100942|DRUG|Tirabrutinib placebo|1 x tablet administered orally once daily
215015818|NCT00363467|DRUG|Busulfan|Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2
215015819|NCT00363467|PROCEDURE|Stem cell reinfusion|autologous stem cell transplant
215015820|NCT01899287|BEHAVIORAL|group education|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
215015821|NCT01272778|DRUG|Lorazepam|Oral capsule, 0.2 mg, single acute dose
215015822|NCT01272778|DRUG|Lorazepam|oral capsule, 0.5 mg, single acute dose
215015823|NCT01272778|DRUG|Lorazepam|oral capsule, 1.0 mg, single acute dose
215015824|NCT01272778|DRUG|Lorazepam|oral capsule, 2.0 mg, single acute dose
215015825|NCT01272778|DRUG|Placebo|oral capsule, single acute dose
215015826|NCT00903344|DRUG|Vitamin D3|4000IU vitamin D3 tablet taken daily
215015827|NCT00903344|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
215015828|NCT06386549|BEHAVIORAL|tele-rehabilitation|Using the social networking tool WeChat, families of children with burns are educated and trained through texts, photos, voice messages, and live videos, twice a week for a total of 12 weeks
215015829|NCT03747263|PROCEDURE|Catheter ablation|Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
215015830|NCT01031615|BEHAVIORAL|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
215015831|NCT01031615|BEHAVIORAL|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
215015832|NCT01524705|DRUG|Insulin Glargine|Glargine-injectable, variable, once daily (QD), 6 months
215015833|NCT01524705|DRUG|Metformin|Metformin-oral, up to 1000mg, twice daily (BID), 6 months
215015834|NCT01524705|DRUG|Prandial insulin|Aspart or glulisine or lispro
215015835|NCT01524705|DRUG|Exenatide|Injectable, 5mcg, twice daily (BID), 6 months
215015836|NCT00874809|DEVICE|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
215015837|NCT00152854|DRUG|Acetaminophen|acetaminophen 1g po qid
214688581|NCT01134692|DRUG|Propranolol, Norfloxacin, VSL#3|Propranolol: as per heart rate titration Norfloxacin: 400mg BD
214688582|NCT05992363|DEVICE|ureteral stent\s insertion|ureteral stent\\s insertion in the operating room
215015838|NCT00152854|DRUG|acetaminophen|acetaminophen 1g po qid for 7 days
215101247|NCT06426836|OTHER|Amikacin|blood sampling in patients receiving amikacin as part of routine clinical care.
215101248|NCT01991522|BEHAVIORAL|Curriculum Group|
215101249|NCT01991522|BEHAVIORAL|Self-directed learning group|
215101250|NCT03018639|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
215101251|NCT04985318|DRUG|Cablivi®|Intervention with Cablivi® take place outside of the study
215101252|NCT01065701|DRUG|Dexmedetomidine|Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
215101253|NCT03422497|OTHER|Male sex|Male sex-as listed in the discharge abstract database
214411709|NCT05776576|OTHER|Experimentation|In the experimentation part, group exercises, dance therapy programs and technology-supported exercise educations with various technological equipment will be implemented in the company of physiotherapists, taking into account the posture assessments.
214411710|NCT00013026|BEHAVIORAL|CHF Self-management Education (Web-based Education)|
214411711|NCT02639962|RADIATION|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
214411712|NCT04469218|DEVICE|SafeBreak Vascular|SafeBreak Vascular is a breakaway connector that screws into peripheral IV lines using luer connectors on each end. The device is designed to separate when a harmful force is placed on an IV line. Upon separation, valves on each side of the device close. On the patient side of the device, the valve closes to prevent the loss of blood and on the IV pump side of the device, the valve closes to stop the flow of medication. The valve closing on the IV pump side of the line causes the pump's occlusion alarm to sound and notify nurses that the IV needs attention. The nurse is able to throw away the separated SafeBreak Vascular, install a new SafeBreak, and restart the patient's infusion without the negative cascade of events that can occur when a peripheral IV fails.
214411713|NCT04017884|COMBINATION_PRODUCT|Remin Pro Forte|a combination of chemicals with natural products cream .
214411714|NCT04017884|COMBINATION_PRODUCT|Remin Pro|a combination of chemicals
214411715|NCT05492474|PROCEDURE|Cranial Point of Care Ultrasound|Cranial ultrasound involves 2-dimensional B mode imaging of the brain parenchyma in the axial plane using a 1-2 MHz probe through the thin temporal bone. Upload of cPOCUS images will occur over DICOM® based Health Insurance Portability and Accountability Act (HIPAA) compliant platforms accessible via Cloud. Currently all handheld machines use Tricefy® or their own cloud based remote image access application.
214411716|NCT01949584|DEVICE|nasal continuous positive airway pressure less than or equal to 6 cm H2O|Low level continuous positive airway pressure delivered during sleep.
215015839|NCT00152854|DRUG|placebo, sugar pill|
215015840|NCT00001311|DEVICE|heparin-surface modified intraocular lens|
215015841|NCT05666856|BEHAVIORAL|Community Reinforcement And Family Training|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
215015842|NCT05666856|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
215015843|NCT04250675|DEVICE|Intermittent pneumatic leg compressions|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (120 mmHg) of both legs for 2 hours daily for 3 months.
215015844|NCT04250675|DEVICE|Sham|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (30 mmHg) of both legs for 2 hours daily for 3 months.
215015845|NCT04040855|OTHER|Medication review|Multi-professional medication review
215015846|NCT02691377|DEVICE|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
215015847|NCT02691377|DEVICE|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
215015848|NCT01534403|BIOLOGICAL|Epratuzumab|Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
215015849|NCT01530256|BIOLOGICAL|ALD518|160 mg IV q 4 weeks for 4 doses
215101254|NCT03422497|OTHER|Female sex|Male sex-as listed in the discharge abstract database
215101255|NCT05489367|BIOLOGICAL|sars cov 2 biontec vaccine|volunteers will be expected to receive 2 doses of vaccine
215101256|NCT03319004|DEVICE|apply phase lag entropy sensor|apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
215101257|NCT03123328|DEVICE|Radical-7 Pulse CO-Oximeter and sensor|Noninvasive device that measures hemoglobin.
214411717|NCT00679276|PROCEDURE|Prolift|surgical repair of vaginal prolapse
214411718|NCT03588065|DIAGNOSTIC_TEST|FMS|"The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception"
214688583|NCT04520763|OTHER|5min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-80% MVV 15-30min after ingestion of 75g of glucose
215101258|NCT05830071|DRUG|CHF5993|BDP/FF/GB 100/6/12.5 μg pMDI
215101259|NCT05830071|DRUG|CHF5259|GB 12.5 μg pMDI
215101260|NCT05830071|DRUG|Moxifloxacin 400mg|400 mg Oral Tablets
215101261|NCT05830071|DRUG|CHF5993 Placebo|placebo pMDI
214411719|NCT03588065|OTHER|TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
214411720|NCT03588065|OTHER|CONFERENCE|The face-to-face educational intervention (conference) consisted of four educational sessions, distributed over four weeks during the sports transition period of the Equity sub-20 team. During these sessions, workshops (conferences) were held with the players following a face-to-face methodology . All these activities were concerted with the multidisciplinary team of the Equity football team and were carried out by the researcher at the University of La Sabana, a physiotherapist, who was studying the needs of the prevention of musculoskeletal injuries in football.
214411721|NCT02266810|DEVICE|PROPEL Mini Sinus Implant.|Placement of sinus implant following frontal sinus surgery
214411722|NCT02266810|PROCEDURE|Sinus Surgery alone|Sinus surgery only, without implant placement
214688584|NCT04520763|OTHER|15min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-70% MVV 15-30min after ingestion of 75g of glucose
215015850|NCT01530256|BIOLOGICAL|ALD518|320 mg IV q 4 weeks for 4 doses
214688585|NCT03153215|OTHER|treatment|We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.
214411723|NCT02266810|DEVICE|Propel Nova Sinus Implant|Placement of sinus implant following frontal sinus surgery
214411724|NCT05338242|DEVICE|Real-Time Exposure Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
214688586|NCT03153215|OTHER|Placebo|Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
214411725|NCT02648425|DRUG|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
214688587|NCT02259036|OTHER|Ecological Momentary Treatment Enhancement|Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
214688588|NCT04263142|DRUG|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
214688589|NCT04263142|DRUG|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
215015851|NCT01530256|BIOLOGICAL|ALD518|640 mg IV q 4 weeks for 2 doses
215015852|NCT03750084|OTHER|questionary|The intervention consists of a digitally distributed questionary.
214411726|NCT02648425|DRUG|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
214411727|NCT02648425|DRUG|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
214411728|NCT05112250|DEVICE|Percutaneous Coronary Intervention|Intravascular lithotripsy (IVL)
214411729|NCT02702674|DRUG|propranolol|propranolol 20 mg given before induction of labor
214411730|NCT02702674|DRUG|placebo|starch tablet containing no active drug material given before induction of labor
214411731|NCT02702674|DRUG|Oxytocin|intravenous infusion of oxytocin
214688590|NCT00038701|DRUG|TNP-470|
215015853|NCT01791400|DRUG|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
215015854|NCT01791400|DRUG|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
215015855|NCT00527748|DEVICE|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
215015856|NCT05032599|BIOLOGICAL|CD5 CART|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
215101262|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen).
215101263|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen).
215101264|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen).
215101265|NCT03194646|OTHER|Standard of care|Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
215101266|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
215101267|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
215101268|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
215101269|NCT00002230|DRUG|Hydroxyurea|
215101270|NCT00002230|DRUG|Efavirenz|
215101271|NCT00002230|DRUG|Stavudine|
215101272|NCT00002230|DRUG|Didanosine|
215101273|NCT00258804|DRUG|Insulin glargine|
214411732|NCT00502593|BIOLOGICAL|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
214411733|NCT00502593|BIOLOGICAL|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
214411734|NCT00479141|BEHAVIORAL|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
214411735|NCT00479141|BEHAVIORAL|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
214411736|NCT05222750|OTHER|Pre-COVID-19|Pre-COVID-19
214411737|NCT05222750|OTHER|COVID-19|COVID-19
215015857|NCT02376335|BIOLOGICAL|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
214411738|NCT05222750|OTHER|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out
214411739|NCT01724255|OTHER|questionnaire|
214411740|NCT06096428|DEVICE|Pulsed-field ablation|Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.
214411741|NCT06096428|DEVICE|Radiofrequency ablation|Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).
214411742|NCT05105152|BIOLOGICAL|SC-DARIC33|Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration
214411743|NCT03802786|DRUG|Imeglimin|Single administration dose of imeglimin
215015858|NCT02376335|OTHER|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
215015859|NCT04461535|DRUG|Adrenocorticotropic hormone|Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
215015860|NCT06368362|BEHAVIORAL|Benign cognitive bias modification for interpretation|Benign cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as neutral or benign rather than pain-related.
214411744|NCT01664104|DRUG|Tocilizumab|Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
214411745|NCT02939495|DRUG|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
214411746|NCT03761784|DRUG|S6G5T-3|Once a day topical cream
214411747|NCT03761784|DRUG|S6G5T-8|Once a day topical cream
214411748|NCT04245319|DRUG|Acitretin|The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
214688591|NCT00638326|DRUG|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
214688592|NCT00638326|DRUG|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
215015861|NCT06368362|BEHAVIORAL|Pain-related cognitive bias modification for interpretation|Pain-related cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as pain-related.
214411749|NCT04245319|OTHER|Narrow band ultraviolet B|Patients receive nbUVB session 3 times per week
215015862|NCT02164721|DEVICE|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
215015863|NCT02719860|DIETARY_SUPPLEMENT|Green tea|4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
215015864|NCT02719860|DIETARY_SUPPLEMENT|Black tea|4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
215015865|NCT02719860|DIETARY_SUPPLEMENT|Placebo tea|4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
214411750|NCT02992275|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
214411751|NCT02992275|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
214411752|NCT00586339|BIOLOGICAL|Cervarix|Intramuscular injection, 3 doses
214411753|NCT00586339|BIOLOGICAL|Placebo Control|Intramuscular injection, 3 doses
214411754|NCT04135209|DIAGNOSTIC_TEST|Optical coherence tomography angiography OCTA|Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
214411755|NCT05756426|OTHER|Prospective|Single arm, healthy adult volunteers for blood donation.
214411756|NCT03588845|OTHER|Treatment Protocol|Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of \< 5.
214411757|NCT03588845|OTHER|Standard of Care|Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.
214688593|NCT02308345|OTHER|Pre-chemotherapy visit summary Video|
214411758|NCT06556134|DRUG|Intravenous Iron Sucrose|Intravenous iron-hydroxide sucrose complex administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 months
214411759|NCT06556134|DRUG|Oral Iron|One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid
214411760|NCT04428320|PROCEDURE|Pelvic floor injection|Injection of 10 cc of bupivacaine
214411761|NCT03697213|OTHER|Online study|20 hypothetical patient summaries
214411762|NCT05130060|BIOLOGICAL|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Given SC
214411763|NCT05130060|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
214411764|NCT05379868|PROCEDURE|Posterior column osteotomy|Apical full facet joint resection. Study intervention does not involve a device.
214411765|NCT05379868|PROCEDURE|No osteotomies|Standard treatment
214411766|NCT03643042|OTHER|Transfusion|Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
214411767|NCT05880732|DRUG|Magnesium Sulfate|Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
214411768|NCT05880732|DRUG|normal saline isotonic solution|only 250 ml of normal saline isotonic solution 30 minutes before induction,
214411769|NCT05875350|PROCEDURE|Intraligamental local anesthetic injection|The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
214411770|NCT00029926|DRUG|2-deoxy-2 [F-18] fluoro-2-d-glucose|
214411771|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intravenously|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
214411772|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intranasally|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
214411773|NCT05121506|COMBINATION_PRODUCT|CBD and THC with GT4 technology|A single topical dose of CBD and THC will be administered with GT4 technology. The material will be provided in a single use pre-filled syringe.
214411774|NCT00223314|BEHAVIORAL|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
215015866|NCT03479346|DRUG|GGT|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
215015867|NCT03479346|DRUG|Placebo|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
215015868|NCT00370136|DRUG|ultrasound contrast|
215015869|NCT01467284|BEHAVIORAL|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
215015870|NCT01467284|BEHAVIORAL|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
215015871|NCT02244528|DRUG|Sildenafil|
215015872|NCT03690999|DIETARY_SUPPLEMENT|Placebo|Placebo product
215015873|NCT03690999|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic supplement
215015874|NCT00276393|DRUG|Basal insulin|
215015875|NCT05364489|DRUG|Bevacizumab combined with Oxaliplatin and TAS-102|"Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
214411775|NCT03350737|OTHER|Physical rehabilitation|Standard treadmill exercise session
215015876|NCT03912805|BIOLOGICAL|botulinum toxin, Type A|topical liniment
215015877|NCT03912805|BIOLOGICAL|Vehicle|Vehicle Formulation
215015878|NCT01091415|PROCEDURE|calcium phosphate bone cement injection|volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
215015879|NCT01093885|DRUG|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
214411776|NCT03350737|DRUG|Heparin|Heparin i.v.
214411777|NCT03350737|OTHER|Placebo|Sodium Chloride 0.9% i.v.
214688594|NCT03747835|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.
215015880|NCT02440399|DRUG|Tramadol hydrochloride|Please see arm description
214411778|NCT06313138|OTHER|The Individual and Family Enhancement Program|The program is a group-based intervention which will be developed by the researcher based on the Individual and Family Self-Management Theory (IFSMT) (self-management skills) and the principle of Medagogy (PITS model: Pathophysiology, Indications, Treatments, Specifies) to improve patients' and their families' understanding of disease-related information and self-management skills consisting of goal setting and action plan, self-monitoring, solving problems and decision-making, and emotional control.
214411779|NCT02050958|DRUG|OXP001|
214411780|NCT02050958|DRUG|Ibuprofen|
214411781|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
214411782|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
214411783|NCT00197236|BIOLOGICAL|Havrix™|2 intramuscular injections, 6 months apart
214411784|NCT00197236|BIOLOGICAL|Infanrix™|1 intramuscular injection
214411785|NCT00197236|BIOLOGICAL|ActHIB™|1 intramuscular injection
214411786|NCT04034901|DEVICE|Monitoring of cardiorespiratory parameters with BORA Band|"The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~* Activity~* Step count~* Heart rate~* Respiratory rate~* Skin temperature~* SpO2"
214411787|NCT00746330|DRUG|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
214411788|NCT00746330|DRUG|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
214411789|NCT00746330|DRUG|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
214411790|NCT00746330|DRUG|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
214411791|NCT00746330|DRUG|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
214411792|NCT02733250|BIOLOGICAL|Pembrolizumab|200mg IV Day 1 of each 21 cycles
214411793|NCT02733250|DRUG|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
214411794|NCT01114919|BEHAVIORAL|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
214411795|NCT01114919|BEHAVIORAL|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
214411796|NCT04851730|PROCEDURE|Orthopedic Physical Therapy Intervention|"First, a deep slow breathing protocol is intended to increase the expansion of the pelvic floor, utilizing the relationship between the diaphragm and the pelvic floor, resulting in a gentle stretching of the pelvic floor.~Next, abdominal soft tissue mobilization, or scar mobilization of the lumbopelvic abdominal area will take place.~Next, manual therapy to the thoracic or lumbar spine or the hips will be performed based on the impairments found in the orthopedic evaluation.~The participant will be given a home exercise program to support breath training, and manual therapy. During the initiation of the second visit each participant will watch a standardized pain education video on the tablet, Understanding pain in less than 5 minutes and what to do about it The above plan of care will be completed 2 times/week for 4 weeks for a total of 8 visits."
214411797|NCT04851730|DEVICE|Dry Needling|"Third, the investigator will dry needle appropriate muscles. Dry needling treatment technique will include insertion of a sterile, disposable, solid filament needle into the muscle belly in the area palpated as listed below. A 0.30 × 0.50mm, or specified size below, stainless steel Seirin J-type or Myotech needle will be used (Dommerholt 2011). Clean technique will be employed throughout the treatment procedure which includes hand washing, clean latex-free glove use, and skin-surface preparation with an alcohol swab ( Baima \& Isaac 2008). Each muscle will receive a maximal number of 2 insertions and each insertion consists of up to 5 seconds of a pistoning (in and out motion) technique in an attempt to elicit a local twitch response. Standard protocol for each muscle will be established prior to beginning data collection.~Details about the dry needling protocol can be found in Appendix L."
214688595|NCT03747835|BEHAVIORAL|Motivational Interviewing|"Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions."
215015881|NCT02440399|DRUG|Morphine|Please see arm description
215015882|NCT02440399|DRUG|Paracetamol|
214688596|NCT06235463|OTHER|Osteopathic Pedal Pump|Participants randomized to this condition will receive 5 minutes of myofascial release to the thoracic inlet and 5 minutes of the pedal pump technique.
215015883|NCT02440399|DRUG|Diclofenac|
215015884|NCT02440399|DRUG|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
215015885|NCT04621786|DEVICE|Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface|The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.
215015886|NCT00841074|DRUG|chlorhexidine|0.12% chlorhexidine mouthwash spray, \~1.3 ml, twice a day.
215015887|NCT00841074|DRUG|Placebo mouthwash|Placebo mouthwash spray application of \~1.3 ml twice a day.
215015888|NCT03815604|BEHAVIORAL|Independent Housing and Support (IHS)|Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.
215015889|NCT03815604|BEHAVIORAL|Residential Care Settings and other Treatment as Usual (RCS/TAU)|Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.
215015890|NCT04356001|PROCEDURE|Socket preservation|'One-Piece' autologous tuberosity graft combining hard and soft tissue, harvested from the maxillary tuberosity, placed in extraction sockets.
214411798|NCT00909935|DRUG|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
214411799|NCT03250104|OTHER|Infection Control|The infection control bundle will include staff training, hand hygiene programs, disinfection measures, and contact isolation. Physicians will be discouraged to prescribe proton pump inhibitors (PPIs) where not explicitly needed. The intervention bundle will be defined based on current literature. For implementation, the investigator will adapt the bundle to specific local needs, discuss with the responsible department heads and ward staff, perform training and disseminate standards of care.
214411800|NCT03250104|OTHER|Antibiotic Stewardship|"Antibiotic stewards will develop local standards of procedure based on the provided training and guidelines. They will then train the responsible staff and disseminate guidelines as best suited for the local work environment, e.g. as pocket cards, posters, or electronically. Point-prevalence investigations and antibiotic visits will assure adherence to guidelines."
214411801|NCT01649635|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
214411802|NCT01649635|DRUG|Prednisone|Pharmaceutical form: tablet Route of administration: oral
214411803|NCT01649635|DRUG|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
214411804|NCT01649635|DRUG|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
214411805|NCT03761966|OTHER|Pregnant women|
214411806|NCT06530875|BEHAVIORAL|training on hesitations regarding childhood vaccinations|Training will be given to expectant mothers on childhood vaccination hesitations
214411807|NCT04753463|OTHER|Survey|The on-line questionnaire which assess the subjective feelings of residents of pandemic impact on ophthalmology training programs
214411808|NCT05723991|DRUG|Disitamab Vedotin and Gemcitabine|Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every two weeks. After completing 3 cycles of neoadjuvant combined therapy, imaging evaluation was performed. If the tumor is T0, radical surgery for bladder cancer was performed; Otherwise, perform radical surgery for bladder cancer after completing 1-3 cycles of treatment (total cystectomy+standard/extended lymph node dissection)
214411809|NCT06227286|DEVICE|EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, initiates with 0.030MPa.
214411810|NCT06227286|DEVICE|Sham-EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, constant to 75 mmHg.
214411811|NCT01958099|BEHAVIORAL|Education|
214411812|NCT02524288|DRUG|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
214411813|NCT01405235|DRUG|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
215015891|NCT05257161|DEVICE|Emboshield NAV6™|Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™
214411814|NCT01405235|DRUG|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
214411815|NCT02107378|BIOLOGICAL|DCVAC/OvCa|DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
214411816|NCT02107378|DRUG|Standard of Care (Paclitaxel or topotecan or doxorubicin)|Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
214411817|NCT00517933|DRUG|Sildenafil Citrate|Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
214411818|NCT00517933|OTHER|Placebo|Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
215015892|NCT05257161|DEVICE|Mo.Ma™|Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
215015893|NCT06433544|OTHER|6-week online mindfulness course|The experimental group received a 6-week online mindfulness course, once a week for 90 minutes each session.
214411819|NCT03360422|OTHER|Survey|Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
214504821|NCT02556918|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG greater than 400 mg/dL; 7-9 units of insulin aspart"
215101274|NCT02949063|BEHAVIORAL|Comfortable Cafeteria Program|6-week program integrated into the cafeteria lunchtime to build capacity of supervisors and students to create a positive social and emotional atmosphere so that students can enjoy eating their lunch and socializing with peers.
214411820|NCT03360422|OTHER|Focus Group|After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
214504822|NCT04837937|BEHAVIORAL|Caregiver vs. Patient [Beginner]|Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.
215015894|NCT05750004|PROCEDURE|computer guided immediate implant placement|Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents, followed by customized healing abutments. after 3 months, Impressions for final prosthesis will be done
215015895|NCT01210911|DRUG|gemcitabine|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
214411821|NCT03360422|OTHER|Usability study|After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
214411822|NCT00380705|DRUG|MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks|
215101275|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and 16 weeks (+/-4 weeks) after 2nd dose of vaccine and serological testing for IgG antibody. Participants who have a scheduled vaccination date shall undergo an MRI brain 16 weeks (+/-4 weeks) after the second dose of COVID-19 vaccination (either SinoVac or BioNTech). A face-to-face assessment 16 weeks (+/-4 weeks) will also be conducted after the 2nd dose of COVID-vaccine for evaluation of any clinical events, followed by a phone visit every 6 months. Cognitive assessment by MoCA will be performed at baseline, 16 weeks (+/-4 weeks) then every 12 months after the 2nd dose of COVID-19 vaccine.
215101276|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and serological testing for IgG antibody to exclude past COVID-19 infection. The timing of the second MRI brain, laboratory tests, clinical and cognitive assessment will be matched with the timing in the vaccination group are available.
215101277|NCT05854342|OTHER|bicarbonate-calcium water|water with high content of bicarbonate and calcium, low sodium
215101278|NCT04313270|DRUG|Evolocumab|12 weeks of treatment with Evolocumab
215101279|NCT03749278|BEHAVIORAL|Latina Friends Motivating the Soul (ALMA)|In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed
215101280|NCT00975949|OTHER|Survey|Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
215101281|NCT02649894|DEVICE|Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter|
214411823|NCT02732314|DRUG|Investigational OTC Cream|
214411824|NCT02732314|OTHER|Cosmetic Eczema Cream|
214411825|NCT02732314|DRUG|0.05% Desonide Cream|
214411826|NCT02732314|OTHER|Placebo Cream|
214688597|NCT06235463|OTHER|Light Touch Treatment|Participants randomized to receive the sham treatment will receive light touch from the operator on the base of the neck and the balls of the feet. This light touch is meant to mimic the pedal pump through touching the same areas of the body but without palpating so that no lymphatic fluid is removed from the lower limbs.
215015896|NCT01210911|DRUG|erlotinib|Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
215015897|NCT01210911|DRUG|metformin|Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
215015898|NCT01210911|DRUG|placebo|Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
215015899|NCT03899597|DRUG|Oxytocin|The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
215015900|NCT03899597|OTHER|Normal saline|The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
215015901|NCT06569277|OTHER|A mobile application|Those who agreed to download a mobile app for colonoscopic bowel preparation on their smartphones.
215015902|NCT06569784|DRUG|[14C]HSK31858|A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.
214411827|NCT01022489|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
214411828|NCT01022489|DEVICE|Placebo (sham coil) treatment|Sham coil treatment
214411829|NCT01835899|DRUG|Placebo|Placebo to BI 1015550
214411830|NCT01835899|DRUG|BI 1015550|medium dose 1 powder for oral solution
215015903|NCT02635789|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
215015904|NCT02635789|DRUG|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
215015905|NCT06570408|BEHAVIORAL|Western Ontario and McMaster University Osteoarthritis Index (WOMAC)|1\. WOMAC is widely used in the evaluation of Hip and Knee Osteoarthritis. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales
215101282|NCT02649894|DEVICE|Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|
215101283|NCT05728398|OTHER|Music|Music played within the fluoroscopy suite during an interventional radiology procedure.
215101284|NCT05728398|OTHER|No Music|No music played within the fluoroscopy suite during an interventional radiology procedure.
215101285|NCT06491784|OTHER|Exercise Therapy|12 week personalised exercise, nutrition and wellbeing programme
214411831|NCT01835899|DRUG|BI 1015550|medium dose 2 powder for oral solution
214411832|NCT01835899|DRUG|BI1015550|low dose 2 powder for oral solution
214411833|NCT01835899|DRUG|BI 1015550|low dose 1 powder for oral solution
214411834|NCT02664194|DEVICE|Proteus® Cooling System|Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
214411835|NCT02664194|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary percutaneous coronary intervention
214411836|NCT05412030|BIOLOGICAL|AFX3772|AFX3772 administered intramuscularly 4 times within 12 months
214411837|NCT05412030|BIOLOGICAL|Prevnar 13|PCV13 administered intramuscularly 4 times within 12 months
214411838|NCT05412030|BIOLOGICAL|Prevnar 20|PCV 20 administered intramuscularly 4 times within 12 months
214411839|NCT03114904|OTHER|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
214411840|NCT02993510|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
214411841|NCT02993510|DEVICE|Chondro-Gide sutured|Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy
215015906|NCT06570408|BEHAVIORAL|Visual Analogue Scale (VAS)|2\. VAS is one of the pain rating scales used in epidemiologic and clinical research to measure the intensity or frequency of various symptoms.
214411842|NCT02993510|DEVICE|Chondro-Gide glued|Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
214411843|NCT05598528|OTHER|Genomic profiles detection|The Paraffin-embedded tumor tissue at diagnosis is collected and assessed by Next- generation gene sequencing
214411844|NCT05598528|OTHER|circulating tumor DNA detection|The Plasma at diagnosis and at 1-month treatment are collected and assessed by Next-generation gene sequencing
214411845|NCT01521624|DRUG|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
214411846|NCT04795544|PROCEDURE|Intracuff pressure measurement|Intracuff pressure is measured by a pressure manometer.
214411847|NCT06094205|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
214411848|NCT04807517|DRUG|Buspirone|All participants in the study will receive open-label treatment with orally administered buspirone for the full duration of the 16-week trial. Buspirone has high affinity for serotonin 5-HT1A and 5-HT2 receptors and moderate affinity for dopamine D2 receptors. It is approved for the management of generalized anxiety disorder in adults.
214504823|NCT04837937|BEHAVIORAL|Caregiver vs. Caregiver|Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.
215015907|NCT06570408|DIAGNOSTIC_TEST|Kellgren Lawrence Grading Scale (KL score)|3\. KL score is the most widely used clinical tool for the radiographic diagnosis of OA.Each radiograph was assigned a grade from 0 to 4,
215015908|NCT06570408|BEHAVIORAL|Quality of Life Questionnaires and Assessments:|4\. Quality of Life Questionnaires and Assessments: include quality of life, intestinal tract, conscious assessment of pain relief.etc.
215015909|NCT00676754|PROCEDURE|Statens Serum Institut RT23 2TU tuberculin|
215015910|NCT01210209|OTHER|genome-wide association study|
215015911|NCT04315207|BEHAVIORAL|Telephone call|"All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
215101286|NCT01139177|DEVICE|Stenting of atherosclerotic lesion(s)|Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
214411849|NCT04077281|OTHER|Medication Coordinated care|"* Clinical Pharmacology \& Toxicology consult~* CPT team completes detailed circle of care communication~* Telemedicine followup by CPT team (approximately 48 hrs post-discharge \& 1 week to1 month post-discharge)"
214411850|NCT04478305|DRUG|Duavive 0.45Mg-20Mg Tablet|Duavee, marketed as Duavive in Canada.
214411851|NCT06032234|OTHER|This is an observational study|This is an observational study
214411852|NCT05889390|DEVICE|Oncotherm EHY-2030|Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
214411853|NCT05889390|DRUG|Paclitaxel|weekly paclitaxel for 12 weeks
214411854|NCT05889390|DRUG|Carboplatin|added to weekly paclitaxel if patient has triple-negative breast cancer
214411855|NCT05889390|DRUG|Cyclophosphamide/Doxorubicin|according to the AC protocol
214411856|NCT05889390|PROCEDURE|Breast cancer removal surgery|Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
214411857|NCT05560399|DRUG|Iberdomide|Route of administration: oral pill. Schedule: Taken Once daily on days 1-21. Dose: will be tested at 1 mg, 1.3 mg, and 1.6mg. 1mg dose may be reduced to 0.75mg if not tolerated.
214504824|NCT04837937|BEHAVIORAL|Caregiver vs. Physician|Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.
214504825|NCT04837937|BEHAVIORAL|Caregiver vs. Patient [Advanced]|"Participants will be assigned a 'Caregiver vs. Patient \[Difficult\]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict."
214504826|NCT04128514|DEVICE|Panoptix Toric|Cataract surgery and IOL implantation
214504827|NCT05465954|PROCEDURE|Biospecimen Collection|Correlative studies
214504828|NCT05465954|BIOLOGICAL|Efineptakin alfa|Given IM
215101287|NCT04189549|DIAGNOSTIC_TEST|CNA Rapid Sepsis Dx|Novel biomarker based on circulating cell-free DNA (cfDNA) in the human blood stream
215101288|NCT00381147|DRUG|Clarithromycin|
215101289|NCT06490042|BEHAVIORAL|Questionnaire|A questionnaire about helmet use and attitude towards helmet use.
215101290|NCT00722956|DRUG|AZD5672|100 mg once daily, 10 days
214504829|NCT05465954|BIOLOGICAL|Pembrolizumab|Given IV
215101291|NCT00722956|DRUG|atorvastatin|one single dose of 40 mg on day 10
215101292|NCT00719680|BIOLOGICAL|IgPro20|
214411858|NCT05560399|DRUG|Elotuzumab|Route of administration: IV Dose: 10 mg/kg for cycles 1 and 2. 20 mg/kg for cycle 3 and beyond. Schedule: Days 1, 8, 15, and 22 for cycles 1 and 2. Then taken on Day 1 (every 28 days) of each cycle thereafter.
214411859|NCT05560399|DRUG|Dexamethasone|"Route of administration: Oral pill or IV Dose: 36 mg within 24 hrs of day 1 of each cycle and day 8, 15, and 22 of cycle 1 and 2.~40 mg on days 8, 15, 22 of cycle 3 and all subsequent cycles. (20 mg for \> 75 years old).~Schedule: On days that Elotuzumab is administered, Dexamethasone to be taken 28mg orally (for ≤75 years old) or 8mg orally (for \> 75 years old) between 3 and 24 hours before Elotuzumab plus 8 mg IV between 45 and 90 minutes before Elotuzumab for all patients.~On days that Elotuzumab is not administered but a dose of Dexamethasone is scheduled (Days 8, 15, and 22 of cycle 3 and all subsequent cycles), 40 mg orally for ≤75 years older and 20 mg for"
214411860|NCT03246581|DRUG|Tiotropium|inhalation
214411861|NCT06630702|DEVICE|SCS electrode stimulation 1|300Hz/300us
214411862|NCT06630702|DEVICE|SCS electrode stimulation 2|130Hz/300us
214411863|NCT06630702|DEVICE|SCS electrode stimulation 3|60Hz/300us
214411864|NCT06630429|OTHER|Biospecimen Collection|Undergo collection of blood and stool samples
214411865|NCT06628739|DRUG|Imatinib|The long-term maintenance dose of every patient was determined by the physician based on the guidelines and the patients' individual conditions such as adverse reactions.
214411866|NCT06631495|OTHER|Observation|not available-observation study
214411867|NCT06628544|BIOLOGICAL|BCG vaccination|BCG vaccination
214411868|NCT06628544|DRUG|Metformin is administered on the day 0|Metformin is administered on the day 0
214411869|NCT06628544|OTHER|Placebo|Placebo
214411870|NCT06628544|DRUG|Metformin is administered on the day 9|Metformin is administered on the day 9
214411871|NCT06628544|DRUG|Metformin is administered on the day 85|Metformin is administered on the day 85
214411872|NCT06631248|OTHER|Coordinative exercise protocol|During the eight-week period, all children in the structured coordinative exercise intervention group participated in 30-minute sessions twice a week on the same day and time. The purpose-oriented basic movement patterns created in the coordinative exercise content were organised in a play-oriented manner suitable for the preschool age range.
214411873|NCT06631885|PROCEDURE|regenerative endodontic procedure using blood clot according to AAE|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using AAE protocol
214411874|NCT06631885|PROCEDURE|regenerative endodontic procedure using photo activated nanochitosan 2%|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using photosensitized nanochitosan for root canal disinfection
214411875|NCT06630715|DRUG|Upadacitinib 15 MG [Rinvoq]|15 mg/ day
215015912|NCT04315207|BEHAVIORAL|In-person meeting|"All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
214411876|NCT06629402|DRUG|PF614|Experimental oxycodone prodrug
214411877|NCT06629402|DRUG|Placebo|Inactive medication
214411878|NCT06631625|DRUG|Lidocaine Intravenous Infusion|Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.
214504830|NCT05465954|PROCEDURE|Biopsy|Undergo tumor biopsy
215015913|NCT00132912|DRUG|SCH 530348|
215015914|NCT04743895|DEVICE|Stainless Steel Wire Cerclage|Wire cerclage used to close sternum after cardiothoracic surgery.
215015915|NCT01232842|GENETIC|cytogenetic analysis|
215015916|NCT01232842|OTHER|HUMARA assay|
215015917|NCT01232842|OTHER|fluorescence activated cell sorting|
215015918|NCT01232842|OTHER|laboratory biomarker analysis|
215015919|NCT00752362|DEVICE|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
215015920|NCT00752362|DEVICE|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
215015921|NCT00752362|DEVICE|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
215015922|NCT00151463|DRUG|sildenafil citrate|
215015923|NCT01744626|DRUG|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
215015924|NCT01744626|DRUG|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
215015925|NCT02123511|DRUG|acetylcysteine|Oral rinse
215015926|NCT02123511|OTHER|placebo|Oral rinse
215015927|NCT02123511|OTHER|quality-of-life assessment|Ancillary studies
215015928|NCT02123511|OTHER|questionnaire administration|Ancillary studies
215015929|NCT00265005|DRUG|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
215015930|NCT03903770|DEVICE|Upper extremity rehabilitation|Participants receive the SUPER intervention 3 times per week for 1 hr, during 4 weeks. For participants with a low recovery potential for hand function, the SUPER interventions consists in robot-assisted reaching movements and unilateral and bilateral VR activities. The robot-assisted activity consists of a reaching task to six targets placed at maximal reach distance. For the VR activity, we use a reach and grasp VR activity based on a shopping task. Participants with good potential for hand recovery also receive 30 min of electromyography-triggered muscle stimulation, combined with the VR activity. The muscle stimulation is triggered when the participant attempts to grasp a virtual object and helps with hand opening movements.
215015931|NCT01183182|DEVICE|ActiSight Needle Guidance System|Three different groups of patients defined per lesion size
215015932|NCT06344169|DRUG|Sebacoyl Dinalbuphine Ester|SDE will be dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance
215015933|NCT06344169|DRUG|Morphine|A single dose of morphine (0.15mg) will be administered along with bupivacaine during spinal anesthesia.
215015934|NCT02688335|DEVICE|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
214411879|NCT06631625|DRUG|Lidocaine and ketamine|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.
214411880|NCT06631625|DRUG|lidocaine and dexmedetomidine infusion|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.
214411881|NCT06628973|BEHAVIORAL|Social prescribing|The intervention consists of SP, wherein patients identified as having significant SDOH-related vulnerabilities on the SPARK questionnaire or during an interview will have a consultation with a LW who will provide them with social prescriptions. LWs are individuals who LINK individuals with social needs to existing community supports and services within the community
214411882|NCT03578731|DEVICE|app|"The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~* Interview during regular consultation with doctor~* Web-App for gathering doctors data~* Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~* Well-being through a patient rating on a visual analog scale~* Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app"
214411883|NCT04713514|DRUG|OSE2101|subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
214411884|NCT04713514|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
214411885|NCT06384430|DIAGNOSTIC_TEST|Shoulder functional tests and ultrasound|On the day of the study, demographic data will be collected from patients with a clinical diagnosis of impingement and who agree to participate in the study, then DASH and Constant Murley scores will be calculated and subacromial bursa thickness, supraspinatus tendon thickness, acromiohumeral distance, supraspinatus tendon thickness/acromiohumeral distance ratio will be calculated on ultrasound.
214411886|NCT03137966|DRUG|Deferoxamine|Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
214411887|NCT03137966|DRUG|Placebo|Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
214411888|NCT04210024|OTHER|Diabetes Empowerment Education Program|Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
214411889|NCT00121199|BIOLOGICAL|rituximab|Given IV
214411890|NCT00121199|BIOLOGICAL|bevacizumab|Given IV
214411891|NCT00121199|DRUG|cyclophosphamide|Given IV
214411892|NCT00121199|DRUG|doxorubicin hydrochloride|Given IV
214411893|NCT00121199|DRUG|vincristine sulfate|Given IV
214411894|NCT00121199|DRUG|prednisone|Given PO
214411895|NCT00121199|OTHER|laboratory biomarker analysis|Correlative studies
214411896|NCT02518893|OTHER|Demographic Data|Demographic data will be collected from up to 50 service members who have participated in health research or who have previously declined research participation.
214411897|NCT02518893|OTHER|Interview|Up to 40 service members will participate in individual, in-depth, semi-structured interviews in person or via telephone.
214411898|NCT01250951|DRUG|Deferasirox|
214411899|NCT04749433|DRUG|[11C]CPPC Injection|A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
214411900|NCT05191797|DRUG|Bomedemstat|Given PO
214411901|NCT05191797|BIOLOGICAL|Atezolizumab|Given IV
214411902|NCT01018511|DRUG|Placebo tamsulosin hydrochloride OCAS 0.4 mg|tablet
214411903|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|tablet
214411904|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tablet
214411905|NCT01018511|DRUG|tamsulosin hydrochloride OCAS 0.4 mg|tablet
214411906|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tablet
214411907|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|tablet
214411908|NCT06104657|OTHER|Non-Interventional Study|Non-interventional study
214411909|NCT05048355|DEVICE|Power Knee Mainstream Dynamic|Powered Microprocessor controlled prosthetic knee. The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face.
214411910|NCT05048355|DEVICE|Passive microprocessor controlled knee|Any passive microprocessor controlled prosthetic knee on the market
214504831|NCT05689502|DEVICE|Treatment|Subjects will participate in 6 hours of therapy a day, 5 days a week, for 3 consecutive weeks. These sessions will include 2 hours of occupational therapy, 2 hours of physical therapy, and 2 hours of guided individual work. Some of these sessions will be in a group setting. The therapy sessions will be individualized to the subject's personal goals and will focus on improving the function of the arm most affected by the stroke. Sessions may include electrical stimulation of the muscles, if it is determined to be safe. At the end of each week, the therapists will recommend exercises for the subjects to continue to work on at home on the weekend.
214411911|NCT06533254|OTHER|Predicting choice of dialysis|"Language data collected using survey 1, will be analyzed using Scaled Insights Behavioral AI solution to identify personality attributes and values. The resulting individual scores will be plotted on a graph and be used to identify specific personality clusters of patients.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses.~The open-ended questions will gather a natural language sample of 100-300 words for analysis using Scaled Insights Behavioral AI approach. This language sample will be analyzed using Scaled Insights Behavioral AI system to identify personality attributes and values. Patients will also be asked their likelihood of selecting PD over HD."
214411912|NCT06533254|BEHAVIORAL|Behavioral nudges|"Patients with Chronic Kidney Disease, participants will be provided with their predicted personalized nudge to increase their likelihood of either maintaining their choice of peritoneal dialysis, or switching from hemodialysis to peritoneal dialysis.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses."
214411913|NCT06150885|BIOLOGICAL|HLA-G-CAR.BiTE allogeneic γδ T cells|"Phase I is a multiple escalating dose, single arm, open-label and 3+3 design that implemented with five cohorts: low dose for single administration, low dose for twice administrations for 2 weeks, low, middle and high dose for 4 repeated administrations for 4 weeks.~Phase IIa is a single-arm, open-label and dose-expansion study and the effective dose of CAR-positive cells will be administered to 27 evaluable subjects with TNBC, NSCLC, CRC or GBM via intravenous infusion weekly for 4 weeks."
214411914|NCT01786746|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy. 12 sessions.
214411915|NCT01786746|BEHAVIORAL|culturally adapted cognitive behavioral therapy|culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
214411916|NCT05464108|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the EGGIM score independently when the patients is eligible. In addition, they can not see the OLGIM score of the patients.
214411917|NCT04114396|DRUG|Anti-IL5 Antibody|Asthma group: Anti-IL5 treatment Control group: No biologic.
214411918|NCT04114396|PROCEDURE|Bronchoscopy|Optional for both arms
214411919|NCT00658411|DRUG|deferoxamine|Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
214411920|NCT06199401|PROCEDURE|Vascular Grafts Eversion and Built-in Technique(XJ-Procedure)|A 1.5-2cm wide bovine pericardial patch and graft ring will be placed inside and outside the aortic root and against the aortic wall, respectively, and continuously sutured near the commissure using 5-0 polypropylene. Then an eversion about 15mm of vascular graft will be intermittently sutured to full layers of aortic vascular with 2-0 pad polyester suture. Finally, the eversion and aortic wall will be continuously sutured together in one more turn.
214411921|NCT01870609|DRUG|defactinib (VS-6063)|
214411922|NCT01870609|DRUG|Placebo|Sugar pill manufactured to mimic defactinib tablet
215015935|NCT01546779|DEVICE|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
214411923|NCT01688544|DRUG|Ilaprazole|Ilaprazole 10 mg for 7 days
214411924|NCT04548232|PROCEDURE|Laparoscopic sleeve gastrectomy|bariatric surgery
214411925|NCT02755922|BIOLOGICAL|Application of autologous mesenchymal stem cells|within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12
214504832|NCT04572451|DRUG|nivolumab|"Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)~Treatment must be within 7 days of the last dose of radiation."
214504833|NCT04572451|DRUG|BMS-986253|"BMS-986253 (Anti-IL-8), 2,400 mg intravenous (every 2 weeks)~Treatment must be within 7 days of the last dose of radiation."
215015936|NCT06107686|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
215015937|NCT02607163|DRUG|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
215015938|NCT02607163|DRUG|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
215101293|NCT05762406|DEVICE|Respiratory protective mask|"Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)"
215015939|NCT01291160|DEVICE|Epiflo|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
215101294|NCT00158691|DRUG|Ethyol|
215101295|NCT01248637|DRUG|Pimonidazole hydrochloride|Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 \<= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
214411926|NCT04887272|OTHER|Supervised Exercise Training Protocol|EXT: Supervised EXT will include a progressive individualized program that combines aerobic and resistance protocols. Volume progression will begin with 3-days of supervised training sessions/wk and will increase by 1 session/wk to a maximum of 5-days/wk. Each EXT session will include 30 minutes of aerobic training (15 minutes cycling; 15 minutes treadmill walking/running/elliptical) and 30 minutes of resistance training (specifics below). Considering individual fatigue will be a concern, therefore similar to exercise training standards in COPD, the duration of rest periods may be extended (\~1-3 min) as needed, however, all exercise durations will be completed within a 1.5-hour time slot. On days that EXT and IMET interventions overlap, the training and IMET will be spread out over a 2-hour session as opposed to the 1.5-hour time slot.
214411927|NCT04887272|OTHER|Inspiratory Muscle and Exercise Training|Inspiratory Muscle Training (IMT): All IMT sessions will be performed similar to EXT, with the exception of having 2-3-sessions of at-home IMT training depending on where in the exercise progression the individual is (i.e., Week1 vs week 6). On the days that IMT and exercise training overlap, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle and end of the session. Each week will include a measure of Maximal Inspiratory Pressure (MIP) and a Test of Inspiratory Respiratory Endurance (TIRE). The intensity of the IMT will be 50% of the weekly MIP, thus progressive increases in IMT threshold intensity will remain at 50% of the weekly MIP. In contrast, the TIRE protocol will assess respiratory endurance based on the relative baseline intensity. Thus TIRE testing will begin at a MIP intensity of 50% (weeks 1-2), and then progressing to 65% (weeks 3-4), and 80% (weeks 5-6).
214411928|NCT03400098|DRUG|Inotersen|Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm
214411929|NCT04305912|DEVICE|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses.
214411930|NCT04305912|DEVICE|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses.
214411931|NCT04340245|OTHER|NA (Observational)|No interventions will be carried out. Comparisons will be made between patients whose cancer has progressed over the course of one year and patients whose cancer hasn't.
214411932|NCT01686295|DEVICE|iRestore Hair Rejuvenation System|This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
214411933|NCT01686295|DEVICE|sham device|This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
214411934|NCT04550039|DEVICE|Body-weight-supported treadmill|Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist
214411935|NCT04550039|DEVICE|Ekso Bionics EksoNR exoskeleton|Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
214504834|NCT04572451|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Stereotactic Body Radiotherapy (SBRT) (varying doses)~SBRT: Initial Dose fractionation of 3 or 5 fractions of radiation as determined by the location of the metastases to be irradiated, to at least 1 but no more than 4 metastatic lesions. There will be a minimum of 40 hours between treatments for an individual metastasis.~SBRT must be completed within a 14-day window, separate from the screening phase. Treatment with nivolumab and BMS-986253 must be within 7 days of the last dose of radiation."
214504835|NCT03383302|RADIATION|Stereotactic body radiotherapy|Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.
215015940|NCT01291160|OTHER|Moist Wound Therapy|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
215015941|NCT01975285|DRUG|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
215101296|NCT04872660|DRUG|Gushen Antai Pill|The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
215101297|NCT04872660|DRUG|Placebo pill|The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
215101298|NCT02406404|BEHAVIORAL|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
215101299|NCT04979494|OTHER|ultrasound examination|We conduct abdominal ultrasound examinations for each patient.
215101300|NCT01083589|DRUG|Imatinib Mesylate|Oral 400 mg daily
215101301|NCT01083589|DRUG|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
215015942|NCT01975285|DRUG|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
215015943|NCT05388175|DEVICE|Rigid catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
215015944|NCT05388175|DEVICE|Soft catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
215015945|NCT02993341|DRUG|Tranexamic Acid|
215015946|NCT02993341|OTHER|Saline Wash|
214411936|NCT02882503|DEVICE|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
214411937|NCT00740272|PROCEDURE|AF ablation + pacemaker implantation|regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
215101302|NCT05838092|DRUG|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
215101303|NCT05838092|DRUG|Placebo|Placebo
215101304|NCT06124391|OTHER|Long-term follow-up|Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.
214411938|NCT00740272|PROCEDURE|Pacemaker implantation|regular pacemaker implantation
214411939|NCT03514199|OTHER|Mediterranean-type diet|"Recommendations: ingest whole grains; three or more servings/day (various fresh fruits/vegetables); three or more servings/week of fish or seafood; white meat to red and processed meat (red meat to one serving or less/day); oilseed mix - 30g/day (nuts: 15g/day, almonds: 7.5g/day, hazelnuts: 7.5g/day); extra virgin olive oil (30ml/day: 2 soup spoons/day) as the main source of fat in the salads; two or more servings per week of sofrito; two servings/day of low-fat dairy products; limit to one serving/week the intake of fatty and cured cheeses; recommendation of 7 glasses per week of red wine (recommendation for habitual drinkers): 1 cup/day of 100ml for women and 1-2 cups/day of 150ml for men; limit to one serving/week the intake of chocolate with more than 50% cocoa."
214411940|NCT03514199|OTHER|Low fat diet|Recommendations: choose grilled, cooked, baked or soaked preparations; avoid frying (sweet or salty); avoid excess fat in the preparations and season the foods with herbs at will (marjoram, basil, oregano, onion, green seasoning, sweet pepper, sage, etc.); avoid frequent ingestion of sausages such as ham, turkey breast, among others; avoid eating fatty meats and strip the skin of poultry before preparation; avoid eating sweets and fatty foods; avoid ingesting bakery products, such as leafy, tart, savory pasta.
214411941|NCT02842658|OTHER|A high-intensity interval exercise group|To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
214411942|NCT02842658|OTHER|An Attention-Control Group|Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
214411943|NCT05586451|BEHAVIORAL|Traditional High Load Resistance Exercise (HLRE)|Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.
214411944|NCT05586451|BEHAVIORAL|Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)|Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
214411945|NCT05586451|BEHAVIORAL|Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)|Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
214411946|NCT03603418|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone is a synthetic glucocorticoid that is commonly used in human medical practice as potent anti-inflammatory, immunosuppressive and analgesic agent.
214411947|NCT03603418|OTHER|Distilled water|Distilled water
214411948|NCT05689216|BEHAVIORAL|Awake timed prone and repositioning|"Patients were instructed to adopt a timed prone and repositioning strategy with 4 sessions for four consecutive days.~Session 1, lying on the belly; Session 2, lying on the right side; Session 3, sitting up; Session 4, lying on the left side; then back to session 1 (30 minutes to two hours for each session). The daily duration of timed prone and repositioning is strongly recommended for 8-10 hours."
214411949|NCT01762371|OTHER|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
215015947|NCT03615534|OTHER|Therapeutic Lifestyle Changes|Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.
215015948|NCT03615534|OTHER|Placebo|
215015949|NCT03615534|DRUG|Fenofibrate|
215015950|NCT03615534|DIETARY_SUPPLEMENT|Wax Matrix Extended Release Niacin (WMER Niacin)|
215015951|NCT03581747|DEVICE|Nevisense|Measurement of electrical impedance
215101305|NCT06205082|DRUG|LIT-00814|LIT-00814 is an oral tablet.
215101306|NCT04625764|PROCEDURE|Blood sampling and analysis|Blood sampling for pharmacokinetics (Plasma ticagrelor concentrations and its metabolite) and MEA platform testing (ADPtest, TRAPtest)
214411950|NCT05899764|DRUG|Brivaracetam|"* Intravenous administration: 25 mg or 50 mg will be administered depending on its effects on epileptic activity during a hospital stay where simultaneous EEG and depth electrode recordings will be measuring epileptic activity.~* Oral administration: Subjects will take 25mg or 50mg twice a day for 12 months. The dosage will depend on its effects on epileptic activity. Brivaracetam levels will be measured on months 3, 6 and 12."
215015952|NCT00604383|DRUG|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
215015953|NCT00604383|DRUG|placebo|1 tablet, orally, daily, up to 42 months
215015954|NCT05688657|DEVICE|Lens A|Monthly Replacement Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
215015955|NCT05688657|DEVICE|Lens B|Daily Disposable Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
215015956|NCT03640182|OTHER|Health management model of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
215015957|NCT02105870|DRUG|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
215015958|NCT02920567|DRUG|Octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
215015959|NCT02920567|DRUG|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
215101307|NCT02141360|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
215101308|NCT06167707|DRUG|SCP-111|Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose
214411951|NCT05450783|OTHER|Biocollection|serum
214411952|NCT04714411|DRUG|Omadacycline|Omadacycline monotgherapy
214411953|NCT02735265|BEHAVIORAL|Virtual reality|12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.
214411954|NCT02735265|BEHAVIORAL|Standard treatment|CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
214411955|NCT04888585|DRUG|ABBV-154|Subcutaneous Injection
214411956|NCT04888585|DRUG|Placebo|Subcutaneous Injection
214411957|NCT01585181|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
214411958|NCT01585181|BIOLOGICAL|Placebo|Approx 2 grams of lactose reconstituted in water
214411959|NCT04107649|BEHAVIORAL|Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives|As part of TAC(MI)+FI, participants speak with a health coach at Brigham and Women's Hospital once a week via telephone for weeks 6-13 following surgery, and once every other week for weeks 14-31 after surgery. Participants in this arm can receive financial rewards for achieving weekly physical activity goals, as well as bonus rewards for achieving goals multiple weeks in a row. Over the course of this 6-month long TAC(MI)+FI intervention period, these participants are able to receive up to $680 for meeting physical activity goals, and up to $95 in bonus rewards.
214411960|NCT04107649|BEHAVIORAL|Wrist based activity tracker wear|Activity tracking data will be collected on a weekly basis. Participants who receive this intervention are eligible to be entered into a lottery to win one of two $25 rewards for every week they wear their wrist-based activity tracker \>10 hours for \>4/7 days a week, beginning 6-weeks after surgery.
214411961|NCT04107649|OTHER|Basic Study Activities|Basic study activities begin two-weeks before TKR and end approximately 24-months after TKR. Basic study activities include: two in-person visits at the local clinic site (2 weeks before TKR and 32-weeks after TKR), having check-in calls with study staff weekly from weeks 1-13 after surgery and every other week for weeks 14-31, completing 6 surveys, and wearing an ActiGraph activity tracker (waist-worn) for five one-week periods throughout the study (2-weeks before-TKR, 32-weeks post-TKR, one-year post-TKR, 18-months post-TKR, two-years post-TKR). All participants will be eligible to receive up to $235 for completing these activities over the course of two years.
214411962|NCT01066260|DIETARY_SUPPLEMENT|Probiotic formulation|Twice a day for 24 days
214411963|NCT01066260|OTHER|Placebo|Twice a day for 24 days
214411964|NCT01912495|DRUG|Boceprevir|
214411965|NCT02908464|DEVICE|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
214411966|NCT00150566|DRUG|Lanthanum carbonate|
215015960|NCT05919251|BEHAVIORAL|Ageless Grace|This unique program attempts to combine multiple aspects that easily fit together including music and a group setting for socialization. The use of music to improve cognition as has been shown in other research studies to improve participation in exercise program. By linking cognitive retraining, low intensity exercise, group activities and music, the researchers of this project can determine if a movement program with these attributes can benefit individuals as a program of wellness once their rehabilitation plans have been completed. The researchers are specifically interested in the effect on balance, activity and incidence of falls in people with chronic stroke. Additionally, the researchers will investigate the differences that this structured program will make on older adults who will act as a comparison group. This will bring insight into some of the additional challenges that people with stroke encounter on a daily basis.
215015961|NCT06369051|OTHER|Self-employment support intervention|A new intervention developed to assist stroke survivors in becoming self-employed by developing entrepreneurial skills. It consists of one home visit, three online individual sessions, and four online group sessions held once a week for eight weeks.
215015962|NCT05112588|BEHAVIORAL|Intervention|The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit accort´ding to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).
215015963|NCT02487355|DRUG|Dexmedetomidine|Dexmedetomidine 1 μg/ kg
215015964|NCT02487355|DRUG|Magnesium Sulphate|Magnesium Sulphate 50 mg
215015965|NCT02487355|DRUG|Bupivacaine|1ml/kg of 0.25%of bupivacaine
215015966|NCT02487355|DRUG|Dexmedetomidine + Magnesium Sulphate + Bupivacaine|Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
215015967|NCT00441740|DRUG|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
215101309|NCT06167707|DRUG|Furosemide USP|Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later
214411967|NCT00140673|BIOLOGICAL|Rotavirus|
214411968|NCT01994161|PROCEDURE|intracranial stenting|"all the participants in this group will be performed with intracranial stenting~\--------------------------------------------------------------------------------"
214411969|NCT04566874|DEVICE|ALIF|Anterior Lumbar Interbody Fusion
215101310|NCT02692001|OTHER|Intervention MealTrain menu|"Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls."
215101311|NCT03791775|DRUG|Polidocanol foam (Atossisclerol® 3%)|The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
214411970|NCT03920163|OTHER|Enhanced Recovery Measures|Perioperative measures
214411971|NCT03528954|DRUG|Propofol|Those who received intravenous propofol
214411972|NCT06058182|DIAGNOSTIC_TEST|blood draws|Pre-procedure, post-procedure (12-24 h), 6-month, and 12-month blood draws
214411973|NCT02441075|OTHER|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
214411974|NCT06556212|OTHER|Real-time feedback using smart swim goggles|Smart swim goggles (Form Athletica Inc.) with activity metrics (such as heart rate, swimming pace, and workout instructions) displayed in real-time during a swimming activity.
214411975|NCT04129424|DEVICE|Insulin pump (Microtech, Equil®)|Those patients of different types of diabetes mellitus were assigned to different groups, those groups were classified by the time to reach target blood glucose .
214411976|NCT00069459|DRUG|Extended-release Bupropion Hydrochloride|Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
215015968|NCT00441740|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
215015969|NCT00441740|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
215015970|NCT00441740|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
215015971|NCT00474968|DEVICE|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector \[SoftPAP(R)\]
215015972|NCT00474968|DEVICE|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
215015973|NCT05849974|OTHER|Structural and fonctional phynotyping|"The additioan acts in this research are:~Fonctionnal phenotyping:Retinal sensitivity and fixation stability assessment using microperimetry, assessment of long-term fixation stability Structural Phenotyping: Anterior segment examination with OCT anterior Blood sample collection"
215015974|NCT02491060|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
215015975|NCT02491060|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
215015976|NCT01383824|DEVICE|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
215015977|NCT06433011|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
215015978|NCT06433011|DRUG|r-tPA|Pulse spray and infusion
215015979|NCT05375266|OTHER|Sampling|This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.
215015980|NCT01750281|DRUG|Selumetinib 75 mg|Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
215015981|NCT01750281|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
214411977|NCT03076450|DEVICE|Lung Ultrasound|Adjust PEEP real-time in term of LUS-RAS chang.
214411978|NCT03076450|DIAGNOSTIC_TEST|Maximum Oxygenation|Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
214411979|NCT06082076|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
215015982|NCT01750281|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
215015983|NCT01750281|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily.
215015984|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
215015985|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
215015986|NCT03569007|DRUG|Larazotide|Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
214411980|NCT06082076|DRUG|Ketamine|Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
214411981|NCT06082076|DRUG|Meperidine|If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine
214411982|NCT00817050|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
214504836|NCT03383302|DRUG|Nivolumab|Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).
215015987|NCT03569007|DRUG|Matching Placebo|enteric-coated beads in gelatin capsules
215015988|NCT00482456|DRUG|Nitrous oxide|
215015989|NCT00201773|DRUG|Exemestane|25 mg orally once per day for 16 weeks.
215015990|NCT00201773|DRUG|Celecoxib|given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
215015991|NCT00201773|OTHER|Correlative studies|
215015992|NCT01851304|DIETARY_SUPPLEMENT|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
215015993|NCT01851304|DIETARY_SUPPLEMENT|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
215101312|NCT01891474|DEVICE|U-health care|voice inception technique based U-healthcare service
215101313|NCT05641415|OTHER|Imaging|MRI and x-ray of both shoulders
215101314|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
215101315|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
215101316|NCT04071158|BIOLOGICAL|RSV Vaccine|RSV vaccine
214411983|NCT00817050|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
214411984|NCT05320913|PROCEDURE|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 120 mg of ropivacaine, epinephrine 0.2 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 40 mL. + PENG block with ropivacaine 40 mg and epinephrine 0.1 mg with normal saline to a total volume of 20 mL
214411985|NCT05320913|PROCEDURE|isolated periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 150 mg of ropivacaine, epinephrine 0.3 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 50 mL
214411986|NCT01772719|DRUG|Simvastatin and zoledronic acid|"1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
214411987|NCT01311713|DRUG|CEP-9722|CEP-9722 will be administered per dose and schedule specified in the arm description.
214411988|NCT01391013|DRUG|Darunavir(DRV)|Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
215101317|NCT04071158|BIOLOGICAL|Tdap|Tetanus, Diphtheria, and Acellular Pertussis Vaccine
215101318|NCT04071158|BIOLOGICAL|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
214411989|NCT01391013|DRUG|Ritonavir|Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
214411990|NCT01391013|DRUG|2 nucleoside reverse transcriptase inhibitors (NRTIs)|2 NRTIs will be administered as per the package inserts.
214411991|NCT02017106|PROCEDURE|Endovenous Laser ablation and concomitant phlebectomies|
215101319|NCT03439930|OTHER|Balance training|6 weeks lasting balance training program
215101320|NCT03288636|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
215101321|NCT03288636|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
214411992|NCT02017106|PROCEDURE|Endovenous Laser ablation and sequential phlebectomies|
214411993|NCT05616221|BIOLOGICAL|AP-PA02|Bacteriophage administered via inhalation
214411994|NCT05616221|OTHER|Placebo|Inactive Placebo administered via inhalation
214411995|NCT04215913|OTHER|The investigators will extract total protein, DNA and RNA from PSC patients.|The investigators will extract total protein, DNA and RNA from PSC patients.
214411996|NCT05268198|DRUG|APR002|Active Investigational Product
214411997|NCT05268198|DRUG|Placebo|Placebo
214411998|NCT04393896|BEHAVIORAL|WeChat-based integrative family intervention (WIFI)|The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
214411999|NCT00070954|DRUG|ginkgo biloba|EgB 761
214412000|NCT00070954|OTHER|matched placebo|Inactive look-alike placebo
214412001|NCT02315885|OTHER|Alcohol administration; Placebo administration|consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days
214412002|NCT03416751|BIOLOGICAL|Fecal Microbial Transplant|Fecal transplant from a donor in the OpenBiome Registry
214412003|NCT03416751|OTHER|Placebo|Placebo enemas
214412004|NCT04543513|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
214412005|NCT01710150|PROCEDURE|CTI ablation alone|
214412006|NCT01710150|PROCEDURE|CTI ablation and Pulmonary vein isolation (PVI)|
214412007|NCT02990858|DRUG|PRO 140 SC injections|
214412008|NCT00731211|DRUG|Pazopanib|800 mg of pazopanib orally each day continuously
214412009|NCT04729244|DRUG|CBD|Hemp Oil
215101322|NCT03288636|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
215101323|NCT03288636|DRUG|Placebo|Placebo
215101324|NCT01178099|DRUG|Prasugrel|Oral, daily for 12 days
215101325|NCT01149720|DRUG|Tivantinib (ARQ 197) Capsule|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
215101326|NCT01149720|DRUG|Tivantinib (ARQ 197) Tablet|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
215101327|NCT01149720|DRUG|Tivantinib (ARQ 197) Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
214412010|NCT02180113|DEVICE|Fibroscan® examination|Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
214412011|NCT01643291|PROCEDURE|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
214412012|NCT04018118|BIOLOGICAL|Biological sample|Additional blood samples for biobanking
214412013|NCT00618319|DRUG|BIIB021|Dose, schedule, and duration specified in protocol
214412014|NCT06092931|DRUG|DC-806|Oral tablets
214412015|NCT06092931|DRUG|Midazolam|Oral syrup
214412016|NCT06092931|DRUG|Repaglinide|Oral tablets
214412017|NCT06092931|DRUG|Digoxin|Oral tablets
214412018|NCT06092931|DRUG|Rosuvastatin|Oral tablets
214412019|NCT02741167|PROCEDURE|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
215015994|NCT05391087|OTHER|Mean arterial pressure based management|Mean arterial pressure group: Low MAP will be intervened in accordance with the protocol as described in the arm
215015995|NCT05391087|OTHER|Cardiac index based management|Cardiac index group: Low CI will be intervened in accordance with the protocol as described in the arm. Additionally, if MAP is lower than target MAP along with a normal CI, this will be intervened with noradrenalin infusion/titration
215015996|NCT03917264|PROCEDURE|Peri-implantitis debridement|Mechanical cleaning of titanium implants, peri-implantitis debridement.
215015997|NCT03917264|OTHER|Dental hygiene procedures|Titanium scalers and nylon brushed used for implant cleaning
215015998|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
215015999|NCT00281580|DRUG|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
215016000|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
215016001|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
215016002|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
215016003|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
215016004|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
215016005|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
215016006|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
215016007|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
215016008|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
215016009|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
215016010|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
215016011|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
215016012|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
215016013|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
215016014|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
215016015|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
214412020|NCT02841891|DEVICE|Sylys® Surgical Sealant|Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant
214412021|NCT02841891|PROCEDURE|Stapled Anastomosis Colectomy Procedure|Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
214412022|NCT05553119|BEHAVIORAL|Home Rehabilitation Monitoring System|Established home-based pulmonary rehab system consists of three commercial devices (Garmin Vívofit™ activity monitor, Nonin 3150 WristOx2® Pulse Oximeter, Android tablet) and two software applications for telemonitored home pulmonary rehabilitation.
214412023|NCT05553119|BEHAVIORAL|Health coaching calls|Coaching calls based on motivational interviewing principles will occur weekly for twelve weeks following a standard protocol, lasting no more than 5-10 minutes.
214412024|NCT01130064|BIOLOGICAL|QAX576|every 3 weeks via intravenous infusion
214412025|NCT01130064|DRUG|Placebo|every 3 weeks via intravenous infusion
215016016|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
215016017|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
215016018|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
215016019|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
215016020|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
215016021|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
215016022|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
215016023|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
215016024|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
215016025|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
215016026|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
215016027|NCT02427217|BIOLOGICAL|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
215016028|NCT04385836|DRUG|alpha one antitrypsin inhalation|\- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
215016029|NCT03107299|OTHER|Communication methods to encourage adherence|Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
215016030|NCT02520947|DEVICE|BIS|Bispectral index monitoring
215016031|NCT02520947|DRUG|Desflurane|volatile agent for maintenance of anesthesia
215016032|NCT01122680|DRUG|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
215016033|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
215016034|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
215016035|NCT01122680|DRUG|Placebo|placebo inhalation solution
214412026|NCT02840994|BIOLOGICAL|CV301|
214412027|NCT02840994|BIOLOGICAL|Pembrolizumab|
214412028|NCT02840994|BIOLOGICAL|Nivolumab|
214412029|NCT00001999|DRUG|Globulin, Immune|
214412030|NCT00001999|DRUG|Ganciclovir|
214412031|NCT04720599|DIAGNOSTIC_TEST|ExoDx Prostate(IntelliScore)|The ExoDx Prostate test result supports the biopsy decision process by stratifying patients based on risk for high grade prostate cancer
214412032|NCT00299702|DRUG|Abilify|10-30 mg once daily for 104 weeks
214412033|NCT00299702|DRUG|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
214412034|NCT00966199|DRUG|anti-hypertensive medication|8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
214412035|NCT01985399|BEHAVIORAL|Neuropsychological testing|Neuropsychological testing
214412036|NCT00114933|DRUG|Stopping nucleosides and continuing lopinavir/ritonavir monotherapy|
214412037|NCT03702543|BEHAVIORAL|SymTrend, Inc.|Use of SymTrend and Apple Health apps with feedback and strategies provided.
214412038|NCT01066741|DRUG|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
214412039|NCT01066741|DRUG|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
214412040|NCT00237107|PROCEDURE|Curretage|
214412041|NCT03121963|DRUG|Oxycodone|oxycodone tablet
214412042|NCT03121963|DRUG|Acetaminophen|acetaminophen tablet
215016036|NCT06221254|BEHAVIORAL|COBMINDEX digital application|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques and practices using digital application.
215016037|NCT06221254|BEHAVIORAL|Human therapist (Control)|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques from a human therapist (the comperator for learning from the application) and practices using digital application.
214412043|NCT03121963|DRUG|Gabapentin|gabapentin tablet
215016038|NCT04739774|DRUG|CHF6001 DPI|Single dose of CHF6001
215016039|NCT04739774|DRUG|Itraconazole|Repeated doses of oral Itraconazole
215016040|NCT00004856|BIOLOGICAL|trastuzumab|Given IV
215016041|NCT04032262|DIAGNOSTIC_TEST|Gastrointestinal and Parkinson's Disease|Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
215016042|NCT01433965|DRUG|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
215016043|NCT00026403|DRUG|cisplatin|
215016044|NCT00026403|DRUG|gemcitabine hydrochloride|
215016045|NCT00026403|RADIATION|radiation therapy|
215016046|NCT04656431|DRUG|Hyperpolarized pyruvate (13C)|Given intravenously (IV) injection prior to imaging
214412044|NCT03121963|DRUG|Celecoxib|celecoxib tablet
214412045|NCT03121963|DRUG|Hydrocodone-Acetaminophen|hydrocodone 5 mg/acetaminophen 325 mg tablet
214412046|NCT00042588|DRUG|Recombinant Chimeric Monoclonal Antibody|
214412047|NCT00751036|DRUG|Nilotinib|Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
214412048|NCT00751036|DRUG|Imatinib|Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
214412049|NCT05652608|BEHAVIORAL|Immune Strength|Multi-week wellness program provided by the Cleveland Clinic
214412050|NCT06486974|DRUG|NaF|Group 1 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
214412051|NCT06486974|DRUG|Na MFP|Group 2 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
214412052|NCT05038969|DRUG|Stomopral|1 capsule contains 40 mg Esomeprazole
214412053|NCT05038969|DRUG|Nexium|1 capsule contains 40 mg Esomeprazole
214412054|NCT05460663|BEHAVIORAL|Stress Management and Resilience Training (SMART)|The Stress Management and Resilience Training (SMART) program was developed by Dr. Amit Sood. SMART focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. The SMART program incorporates practices that focus on six individual factors that have been found to promote individual-level resilience: positive coping, positive affect, positive thinking, realism, behavioral control, and altruism. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) and in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks.
214412055|NCT03545386|OTHER|Fecal microbiota transplantation|Stool from healthy donor administered via enema
214412056|NCT03545386|OTHER|Placebos|Saline with food coloring administered via enema
214412057|NCT03150368|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
214504837|NCT05680259|OTHER|Maela connected follow-up|Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
215016047|NCT04656431|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete
215016048|NCT01235416|DRUG|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
215016049|NCT01550965|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
215016050|NCT03760640|DRUG|LY900014|Administered SC
215016051|NCT03760640|DRUG|Insulin Lispro|Administered SC
215016052|NCT03016403|BEHAVIORAL|Stepped-Care Intervention|The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
215101328|NCT03688464|DRUG|Melatonin|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
215101329|NCT03688464|DRUG|Diphenhydramine|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
215101330|NCT03688464|DRUG|Placebos|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
215101331|NCT05748457|BEHAVIORAL|Non-manualised family therapy.|Family therapy provided by qualified therapists without reference to a specific therapy manual.
215101332|NCT05748457|BEHAVIORAL|Family Based Treatment|"Family therapy implemented according to the published Treatment manual for anorexia nervosa: A family-based approach by Lock \& Le Grange (2nd edition, 2015)."
215101333|NCT04138680|BEHAVIORAL|Active Biofeedback|"The active biofeedback session will be done within the 7T MRI. It will include a pre-training run, 3 training runs, and a post-training run. Each run will be comprised of MOTIVATE and REST trials. During each MOTIVATE trial, subjects will be instructed to generate a heightened state of motivation. Participants will be encouraged to identify strategies that are personally relevant or useful and to monitor the efficacy of the strategies. Subjects will simultaneously view a progress bar on the screen during MOTIVATE trials that represents their VTA activity and they will be trained to try to increase the level of the bar by motivating themselves. For the active VTA biofeedback group, the progress bar will be updated every second to accurately convey level of VTA signal activation. During REST trials, all subjects will be instructed to count backwards. During the post-training 'test' run, subjects will be instructed to use the strategies they found to be most effective."
215101334|NCT04138680|BEHAVIORAL|Sham Biofeedback|The sham biofeedback session resembles the active condition, however, the thermometer seen during the MOTIVATE trials will represent yoked sham values.
215101335|NCT06574516|DRUG|Ibuprofen 200 mg|Ibuprofen every 8 hours for three days post operatively
215101336|NCT06574516|DRUG|paracetamol|Paracetamol PRN for three days
215016053|NCT03016403|BEHAVIORAL|Enhanced Usual Care|Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
215016054|NCT04495998|DIAGNOSTIC_TEST|Brief Motor Scale_portuguese version (BMS_pt)|translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
215016055|NCT02812537|OTHER|patients with conduct disorders|interview with a specialist
215016056|NCT04604366|DRUG|misoprostol|it stimulates uterine contractions
215016057|NCT05344274|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
215016058|NCT05344274|BIOLOGICAL|Isocapnic Oxygen|Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
214412058|NCT05273801|DEVICE|Heart Rate Recording from Multiple Participants, No Visual Feedback|Heart rates are recorded from multiple participants during the group sessions. However during this intervention, it will not be cast to a TV for feedback to the participant or clinician.
214412059|NCT05273801|DEVICE|Visual Feedback of Multiple Participant Heart Rates|Visual feedback of HR is provided through a TV monitor. Multiple heart rates can be displayed and recorded simultaneously allowing for group encouragement, continuous monitoring and adjustment of all participants to ensure reaching appropriate target intensity.
215016059|NCT05344274|DIAGNOSTIC_TEST|Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)|Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
215016060|NCT04086615|DEVICE|NMES and exercise supplemented with high BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 80% of LOP, the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
215101337|NCT00307788|PROCEDURE|acupuncture|acupuncture
215101338|NCT05198843|DRUG|Dasatinib|Given PO
215101339|NCT05198843|DIETARY_SUPPLEMENT|Icosapent Ethyl|Given PO
215101340|NCT05652712|DRUG|Toripalimab|"Toripalimab injection, recommended dose is 3 mg/kg, intravenous infusion every 2 weeks or 240 mg fixed dose, intravenous infusion every 3 weeks.~Other treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients."
215101341|NCT04921332|DEVICE|Bright Light Therapy (BLT) Lamp|With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
215101342|NCT03038854|OTHER|Test GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
215101343|NCT03038854|OTHER|Standard GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
215101344|NCT03038854|OTHER|Cows' milk|Homogenized store-bought full fat cow's milk.
215101345|NCT01088022|DRUG|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
215101346|NCT01088022|DRUG|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
215016061|NCT04086615|DEVICE|NMES and exercise supplemented with low BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 20mmHG venous pressure (no blood flow restricted), the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
215016062|NCT00225758|DRUG|Lapatinib|1500 mg po daily for 26 weeks or longer
215016063|NCT02618395|DRUG|SPARC001A|
215016064|NCT02618395|DRUG|SPARC001B|
215016065|NCT02618395|DRUG|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
215016066|NCT01514435|DEVICE|Electroconvulsive therapy|treatment for major depression
214412060|NCT06091436|DRUG|GenSci094|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
215016067|NCT01514435|DEVICE|18-Fluoro-desoxy-glucose positron emission tomography|"intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique."
214412061|NCT06091436|DRUG|Placebo RecFSH / follitropin alfa|powder-injection, but without the active ingedient, SC injection . Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
214412062|NCT06091436|BIOLOGICAL|Biological: RecFSH / Follitropin alfa (Days 1 to 7)|Daily SC injections with 150IU or 225IU recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
214412063|NCT06091436|DRUG|Placebo GenSci094|Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
214412064|NCT06091436|BIOLOGICAL|RecFSH / Follitropin alfa (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.
214412065|NCT06091436|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
214412066|NCT06091436|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
214412067|NCT06091436|DRUG|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
215016068|NCT00310479|DEVICE|Magnetic Resonance Spectroscopy (3Tesla)|
215016069|NCT03686982|OTHER|Active Nitrate Bar|Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione
215016070|NCT03686982|OTHER|Placebo Bar|No active ingredients
215016071|NCT06274437|DRUG|BND-35|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
215016072|NCT06274437|DRUG|Nivolumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
215016073|NCT06274437|DRUG|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
215016074|NCT06207851|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
215016075|NCT03367351|BEHAVIORAL|Web-Based Education|Completion of a CGM specific web-based educational intervention that includes a series of online learning modules.
215016076|NCT03367351|BEHAVIORAL|Social Support|Engagement in peer-led CGM specific discussion boards
215016077|NCT03367351|BEHAVIORAL|Standard of Care|Standard of Care - serves as the control group for the treatment arm
215016078|NCT06372483|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
215016079|NCT06372483|DRUG|Placebo|VMX-C001 matched placebo
215016080|NCT06372483|DRUG|Rivaroxaban 20 mg Oral Tablet|Fxa DOAC
215016081|NCT06372483|DRUG|Apixaban 5 mg Oral Tablet|Fxa DOAC
215016082|NCT06372483|DRUG|Edoxaban 60 mg Oral Tablet|Fxa DOAC
215016083|NCT05685407|DRUG|Caffeine|300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
215016084|NCT05685407|OTHER|Placebo|A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
215016085|NCT00892450|DRUG|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
215016086|NCT04579419|DRUG|Sodium Bicarbonate|Botulinum Toxin diluted in Sodium Bicarbonate
215016087|NCT04579419|DRUG|Normal Saline|0.9 NaCl
215016088|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
215016089|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
215016090|NCT02380157|DRUG|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
215016091|NCT02380157|DRUG|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
215016092|NCT00122863|DRUG|Duloxetine Hydrochloride|
215016093|NCT00122863|DRUG|placebo|
215016094|NCT00083447|DRUG|TransMID™|
215016095|NCT01501500|DRUG|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
215016096|NCT01501500|DRUG|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
215101347|NCT00909597|DRUG|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
215101348|NCT00909597|DRUG|taspoglutide|10mg sc once weekly
215101349|NCT00909597|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
215101350|NCT01280578|DEVICE|Transcatheter PFO Closure|Transcatheter PFO Closure
214412068|NCT03820986|BIOLOGICAL|Pembrolizumab|IV infusion
214412069|NCT03820986|DRUG|Lenvatinib|Oral capsule
215101351|NCT04977219|BEHAVIORAL|Prism Adaptation Training|Therapists administering PAT followed the protocol developed by the Kessler Foundation (2014).PAT sessions lasted approximately 30 minutes during which patients with left sided neglect don 20 diopter prism goggles deviating their visual field to the right while aiming their finger at a series of visual targets.
215101352|NCT05821725|DEVICE|Hyaluronic acid|Hyaluronic acid and hemostatic sponge
215101353|NCT05821725|DEVICE|Control|Hemostatic sponge
215101354|NCT03191253|OTHER|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
215101355|NCT00485966|DRUG|CX-3543|360 mg/m2 daily x 5 q 21 days
215101356|NCT02929212|OTHER|Solid Meal|Subjects will receive solid meals during meal study
215101357|NCT02929212|OTHER|Liquid Meal|Subjects will receive liquid meals, during meal study
215101358|NCT02929212|DRUG|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
215101359|NCT02929212|OTHER|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
215101360|NCT02929212|OTHER|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
215101361|NCT01641822|DRUG|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
215101362|NCT01641822|DRUG|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
215101363|NCT01641822|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
214412070|NCT03820986|DRUG|Placebo for lenvatinib|Oral capsule
214412071|NCT06654700|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
214412072|NCT02999217|DRUG|Iron isomaltoside|"Intravenous injection 1 g given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
214412073|NCT02999217|DRUG|Saline|"Intravenous injection given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
214412074|NCT05993403|OTHER|Intercultural Sensitivity Education Program|The training program consists of three sessions. In the Intercultural Sensitivity training for nurses, it was aimed to develop the level of intercultural sensitivity, and it was aimed to provide proficiency in providing services to raise awareness and knowledge about intercultural sensitivity.
215016097|NCT01018056|DRUG|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
215016098|NCT01018056|DRUG|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
215101364|NCT00454584|DRUG|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
215101365|NCT00454584|DRUG|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
215101366|NCT00454584|DRUG|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
215101367|NCT03813381|BEHAVIORAL|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
215101368|NCT00215865|DRUG|PEGIntron plus ribavirin|
215101369|NCT04149678|DRUG|Ozanimod|Ozanimod
215101370|NCT04149678|DRUG|Cyclosporine|Cyclosporine
215101371|NCT02421601|DRUG|Condoliase|1.25 U, intradiscal injection, one time
214412075|NCT02516774|DRUG|Adalimumab|
214412076|NCT02370732|OTHER|Alcohol|A weight based dose of alcohol will be administered during each study day.
214412077|NCT06611722|OTHER|Psychological and Functional Assessment|Assessment of Pain Sources: Patients are grouped based on intra-articular, extra-articular, or combined intra- and extra-articular hip pain.Psychological Assessment: Depression and anxiety are assessed using standardized questionnaires (e.g., BDI for depression, SAS for anxiety).Functional Assessment: Joint function and pain are evaluated using clinical and patient-reported outcome measures.
214412078|NCT06611514|DRUG|Prasterone (DHEA)|Prasterone 6.5 mg vaginal tablets
214412079|NCT05279963|PROCEDURE|electroacupuncture|"The prespecified acupoints applied here will include bilateral Sanyinjiao(SP6), Shenshu(BL23), Ciliao(BL32), Zhongliao(BL33), Zhibian(BL54) .~Acupuncture treatment is carried out by acupuncturists who have been well trained. Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China). Electroacupuncture procedures will be performed with electronic instruments (Hans-100A, Nanjing Jisheng Medical TechnologyCo., Ltd, China). Two paired of acupoints (i.e., two Shenshu(BL23) and two Ciliao(BL32), respectively) are connected to the EA apparatus. Alternating-frequency mode is selected and frequency is 2/100 Hz. EA intensity is determined in accordance with patients' endurance. EA will last for 30 min for each treatment. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks."
215016099|NCT01018056|DRUG|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
215016100|NCT04269785|DEVICE|Cryoballoon ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)
214412080|NCT05279963|DRUG|Amitriptyline|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of individual participants will be recorded on diary cards.
214412081|NCT05279963|PROCEDURE|sham electroacupuncture|"In the trunk region, the points are 5 cm away from respective acupoints. In the lower limb region, the point is 3 cm away from Sanyinjiao(SP6). All points will only receive shallow insertion.~Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China).The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the electric needle group."
215016101|NCT04269785|DEVICE|Radiofrequency ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
215016102|NCT03142334|BIOLOGICAL|Pembrolizumab|IV infusion
215101372|NCT00810784|BEHAVIORAL|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
215101373|NCT02145598|DRUG|Lenalidomide|after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
215101374|NCT02145598|DRUG|Placebo|after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
215016103|NCT03142334|DRUG|Placebo|IV infusion
215016104|NCT06638164|OTHER|Control|No attempt was made to increase knowledge, skills and satisfaction. Standard procedure (oral explanation) was applied.
215016105|NCT06638164|OTHER|Virtual reality glasses|In order to increase knowledge, skills and satisfaction, isolation training was given with virtual reality glasses.
215016106|NCT03982693|DRUG|Edetate Disodium|The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
215016107|NCT03982693|OTHER|Placebo|Placebo infusions consist of 500 ml normal saline.
215016108|NCT05922098|OTHER|Texture Modified Foods Manual for chewing dysfunctions in older adult|Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
215016109|NCT03071965|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
215016110|NCT03071965|PROCEDURE|Surgery|Surgery to implant device for NT-501
215016111|NCT03071965|PROCEDURE|Surgery|Sham surgery
215016112|NCT04939805|DEVICE|Selective CRP apheresis using the PentraSorb®-CRP system|Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
215016113|NCT06248177|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
215016114|NCT06248177|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
215016115|NCT02065804|DRUG|Bupivacaine|injection, once, 5 min
215101375|NCT03381417|DRUG|pegcyte|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
215101376|NCT03381417|DRUG|Neulastim|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
215101377|NCT03631420|BIOLOGICAL|Human Umbilical Cord Derived-Mesenchymal Stem Cells|Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
215101378|NCT01665352|DRUG|TTP054|Administered orally once daily for 12 weeks.
215101379|NCT01665352|DRUG|Placebo|Administered orally once daily for 12 weeks.
215101380|NCT01608503|PROCEDURE|lung deflation|lung was deflated during respiration cycle
215101381|NCT01608503|PROCEDURE|lung inflation|lung was inflated during respiratory cycle
215016116|NCT04103970|BEHAVIORAL|Graded Activity and Pain Education (GAPE)|"GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement."
214412082|NCT06606613|PROCEDURE|Intraurethral injection|"Procedure: Intraurethral injection~Patients are positioned in the lithotomy position during the procedure. General and/or local anesthesia is administered depending on the investigator\&amp;amp;#39;s preference. An applicator developed for intraurethral injection will be used. This device comprises a holder that is placed into and fixates the urethra (i.e., it distends the urethral circumference, thus smoothing out the longitudinal folds), allowing the use of four syringes to inject cross-linked hyaluronic acid/dextranomer at approximately the 2, 4, 8, and 10 o'clock positions.~Drug: Cross-linked hyaluronic acid/dextranomer"
214412083|NCT06606613|PROCEDURE|Mid-urethral sling|"Procedure: Starting with the dorsal lithotomy position, a foley catheter is inserted to the urethra. Starting with 1-1.5 cm below the urethral meatus, a 1.5-2 cm vertical incision is made. Following the dissection of anterior vaginal mucosa, pubocervical fascia should be dissected sharply .~Dissection is continued laterally to the ischiopubic ramus. Starting downwards from the tendinous insertion of the adductor longus muscle at the level of clitoris, a 1cm incision is made close to the bone. The needle is placed in to the incision and passed medially through the obturator membrane. It has to be considered that the needle is passed very close to the bone in order not to damage the obturator vessel-nerve bundle. With the guidance of the opposite hand's index finger in the vaginal incision the tip of the needle has to be palpated afterwards passing with a 45-degree angle rotation. The next manoeuvre is passing the tip of the needle beside the urethra through the vaginal incision ."
214412084|NCT06614621|DRUG|Adebrelimab +Etoposide+Platinum-based drugs|Adebrelimab：20mg/kg或1200mg ivgtt ，d1 ，Q3W Etoposide injection (E): 100mg/m2, ivgtt, d1,d2,d3,Q3W Platinum-based drugs：75mg/m2， ivgtt， d1,d2,d3,Q3W
214412085|NCT06614621|DRUG|Maintenance treatment period:|Adebrelimab：20mg/kg或1200mg，IV, Q3W； Apatinib Mesylate Tablets：250mg，P.O，qod
214412086|NCT06614972|DEVICE|Balloon-expandable drug-eluting stent|Balloon-expandable drug-eluting stent (BDES) is the device comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
214412087|NCT06613932|PROCEDURE|pulpotomy|removal of the coronal pulp tissue and preservation of the radicular portion to ensure continuation of growth and vitality of tooth structure
214412088|NCT06622148|DRUG|Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)|For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) .
214412089|NCT06622148|DRUG|Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)|For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
214412090|NCT06622499|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
214412091|NCT06628882|PROCEDURE|Infraclavicular Block|types of anesthesia used in upper extremity surgeries
214412092|NCT06628882|PROCEDURE|Wide-Awake Local Anesthesia with No Tourniquet|types of anesthesia used in upper extremity surgeries
214412093|NCT06630052|OTHER|adductor canal clinical examination|clinical examination of the adductor canal in patients with knee pain not matching the radiological changes
214412094|NCT06631261|OTHER|No intervention; Observational study|No intervention
214412095|NCT06630351|BEHAVIORAL|Behavioral Counseling|Participate in MCP-C
214412096|NCT06630351|OTHER|Discussion|Participate in virtual group discussions
214412097|NCT06630351|OTHER|Health Promotion and Education|Receive reading exercises and workbook materials
214412098|NCT06630351|OTHER|Interview|Ancillary studies
214412099|NCT06630351|OTHER|Questionnaire Administration|Ancillary studies
215016117|NCT02828085|BIOLOGICAL|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
215016118|NCT01991535|DEVICE|Spontaneous Ventilation Mode|"Respiratory rate and duration of inspiration are controlled by the patient.~Device model: Stellar 150® (ResMed, Australia)."
215016119|NCT01991535|DEVICE|Controlled Ventilation Mode|"Ventilator maintains the positive end-expiratory pressure until the patient inspires. At that point, the ventilator reaches the support pressure in a predetermined time. The patient fixes the respiratory rate and the duration of inspiration, triggering all the cycles.~Device model: Stellar 150® (ResMed, Australia)."
215101382|NCT05200689|DEVICE|Kinesiotaping (KT)|"Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin."
215101383|NCT00013169|BEHAVIORAL|Strong Patient Focus|
214412100|NCT06698302|BEHAVIORAL|Questionnaires|Administer translated COMPAT-SF questionnaires to Spanish-speaking CP patients
214412101|NCT06697054|DIAGNOSTIC_TEST|Sentinel node biopsy with either ICG or carbon dye injection to cervix|Either laparatomy or laparoscopy wil be performed to detect sentinel node stained with either ICG or carbon dye injected to cervix. A hemipelvis in which a sentinel is not found will be subjected to full lymphadenectomy.
215101384|NCT03222947|GENETIC|Deoxyribonucleic acid analysis|This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
214412102|NCT06697002|OTHER|lower trapezius strenghtening excercise|32 participants will be in control group who will perform strenghtening excerise of lower trapezius
214412103|NCT06697002|OTHER|scapular mobility exercise|32 participants will be in experimental group who will perform scapular mobility exercise
214412104|NCT06697938|RADIATION|Preoperative SBRT for the Primary Lesion of Breast Cancer|SBRT for Primary Lesion of Breast Cancer, Radiation Dose: Primary Lesion ≤3 cm, GTV 24Gy/3F; Primary Lesion \>3 cm, GTV 30Gy/5F.
214412105|NCT06696664|DRUG|PEG-IFN-α|chronic hepatitis B (CHB) who were continuously treated with pegylated interferon (PEG-IFN - α) for more than 24 weeks
215016120|NCT01991535|DEVICE|Simulator Ventilation Mode|"Ventilator maintains a continuous positive airway pressure during the entire cycle.~Device model: Stellar 150® (ResMed, Australia)."
215101385|NCT02462993|DRUG|Aloe Vera|Local drug delivery of aloe vera gel
215101386|NCT00470418|DRUG|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
215101387|NCT00470418|DRUG|Placebo|placebo comparator
215016121|NCT01217047|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
215101388|NCT00938691|PROCEDURE|Intradermal Suture|
215101389|NCT00938691|PROCEDURE|Intradermal Suture|
215101390|NCT00599638|DRUG|pregabalin|75mg bid titrating to 150mg bid on day 4
215101391|NCT00599638|DRUG|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
215101392|NCT00599638|DRUG|Placebo|Placebo
215101393|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
215101394|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
215101395|NCT01436266|DRUG|Misoprostol|400 mcg buccally 2 hours prior to procedure
215101396|NCT01436266|OTHER|Folic acid|2mg buccally 2 hours prior to procedure
215101397|NCT04857411|BEHAVIORAL|Peers LEAD plus HLWD|Combined Peers LEAD and Healthy Living with Diabetes is a culturally-appropriate program to increase medication adherence
214412106|NCT06696339|DEVICE|PreemptiveAI SDK|Use the PreemptiveIAI SDK to measure heart rate.
214412107|NCT06630572|DRUG|Rifaximin|Patients randomized to receive Rifaximin for 14 days
214412108|NCT06630572|DRUG|Placebo|Patients randomized to receive Placebo for 14 days
214412109|NCT03867617|OTHER|Regulatory T cells|Single infusion of expanded regulatory T cells.
214412110|NCT03867617|DRUG|Tocilizumab|Treatment during first month post-transplant.
214412111|NCT03867617|OTHER|Bone marrow|Infusion of donor bone marrow cells.
214412112|NCT03867617|PROCEDURE|Kidney transplant|Living donor kidney transplantation.
214412113|NCT03867617|OTHER|Immunosuppressive drug therapy|Immunosuppressive drug therapy.
215016122|NCT01217047|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
215016123|NCT01217047|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
215101398|NCT01508260|PROCEDURE|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
215101399|NCT01508260|DRUG|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
215101400|NCT04462965|COMBINATION_PRODUCT|Toripalimab|Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
215101401|NCT04462965|COMBINATION_PRODUCT|Temozolomide|Placebo：Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
215101402|NCT03514433|OTHER|TRIP Patient Navigation Intervention|The TRIP intervention will replace the current standard of care at the 5 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
215101403|NCT04629846|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
215101404|NCT04629846|DRUG|QL1209|QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
215101405|NCT04629846|DRUG|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
215101406|NCT04629846|DRUG|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
215101407|NCT04629846|PROCEDURE|surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
215016124|NCT01217047|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
215016125|NCT04465305|PROCEDURE|entraped treatment|patients with tarlov cysts treated by entraped and plasty nerve root
215016126|NCT04465305|PROCEDURE|plasty treatment|patients with tarlov cysts treated by plasty nerve root
215016127|NCT05529173|DRUG|Povidone-Iodine 10%|Nasal swab stick application of Povidone-Iodine 10% prior to surgery
214412114|NCT06698367|OTHER|Standard rehabilitation|Protocol based on the best available evidence and to be used in all participants in both groups. The standard rehabilitation protocol will consist of three postoperative phases: Mobilization (0 to 4 weeks), Strengthening (4 to 8 weeks) and Functional phase (8 to 12 weeks). Sessions will be held 3 times a week for 12 weeks. Each session will last 1 hour and will consist of different modalities of therapeutic exercise and cryotherapy.
215101408|NCT04484207|OTHER|A short video intervention|Three minutes video of a veteran that shares his personal story
215101409|NCT04484207|OTHER|A vignette intervention|A written description of the content of the video
215101410|NCT03037983|DEVICE|Repetitive transcranial magnetic stimulation|rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.
215016128|NCT05529173|DRUG|0.9% NaCl Solution|Nasal swab stick application of 0.9% NaCl Solution prior to surgery
215016129|NCT05587998|DRUG|Morphine|Participants will receive IV dose of Morphine as stated in arm description.
215016130|NCT05587998|DRUG|AZD4041|Participants will receive oral doses of AZD4041 as stated in arm description.
215101411|NCT03037983|DEVICE|Sham|Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
215101412|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with PRF|Papilla reconstruction would be done with platelet rich fibrin
215101413|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with subepithelial connective tissue graft|Papilla reconstruction would be done with subepithelial connective tissue graft
215101414|NCT05032339|DIAGNOSTIC_TEST|IUO Plasma Cell Disorders Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders.
215101415|NCT04071678|BEHAVIORAL|Careful examination during endoscopic procedures to identify lesions|When the AI model alarms, check carefully to confirm the lesion
215101416|NCT02968147|DEVICE|High frequency jet ventilation|General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
215101417|NCT02968147|DEVICE|Conventional ventilation|General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
215101418|NCT04883814|DIAGNOSTIC_TEST|18F-fluoroestradiol PET/CT|Estrogen receptor targeted imaging
215101419|NCT05228561|OTHER|Mobile Application Supported Nutrition and Diabetes Education|With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
215101420|NCT04058886|BEHAVIORAL|Telephone-delivered Mindfulness|The telephone-delivered mindfulness training intervention that will incorporate the following elements: 1) training for primary caregivers (CG) and their caregiving partner (CP) in a telephone-based mindfulness training intervention; 2) groups of up to eight participants (four CG-CP pairs) plus an instructor, on a shared telephone line; and 3) training in a 8-week, modified MBSR program, which places additional emphasis on training in the following: a) mindful experiencing, including mindfulness of feelings and body sensations; b) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking; and c) mindful compassion for self and others. Additionally, homework assignments will involve listening to exercises on a dial-in telephone line; and assignments for CG-CP dyads (e.g. mindful listening and communication practices) as well as CG mindfulness practices in the presence of care recipients (e.g. mindful eating, and mindful listening).
214412115|NCT06698367|OTHER|Unilateral high-intensity strength exercise|Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an eccentric exercise for the pronosupinator muscles with a dumbbell with adjustable weights. The training will start with an intensity of 60% of 1RM, until reaching 80% 1RM.
214412116|NCT06698367|OTHER|Unilateral mobility exercises|Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an active mobility exercise for the pronation-supination muscles using a plastic rod.
215016131|NCT05587998|OTHER|Placebo|Participants will receive oral doses of placebo as stated in arm description.
215016132|NCT04149457|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.
215016133|NCT04149457|OTHER|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
215016134|NCT05763862|GENETIC|Genetic testing|Same information as details in the experimental arm.
215016135|NCT05013229|DRUG|IcoSema|Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
215101421|NCT05930691|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement|Prediction of intracranial pressure by using Ultrasonography on optic nerve sheath diameter.
215101422|NCT04855383|DRUG|The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles|Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
214412117|NCT05592613|DEVICE|Next-generation Reader and ID-Cap System|The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.
214412118|NCT05592613|DRUG|Truvada for pre-exposure prophylaxis (PrEP)|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.
214412119|NCT05592613|DRUG|Biktarvy for antiretroviral therapy (ART)|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.
214412120|NCT00116870|DRUG|lovastatin|
214412121|NCT01867853|DEVICE|PLR|passive leg raising test was done before and at the end of SBT
214412122|NCT06696651|DEVICE|Electrical myostimulation|Electrical myostimulation in form of suit as in fig. Blue lines demonstrate areas of electrodes inside suit. twenty females will receive EMS session per week ( 20mins / week ) and following healthy diet for 6 weeks . 20 min = 1 min warm up, 6min upper body training, 6min lower body training, 6min core training, 1 min cooling down.
214412123|NCT06696651|DEVICE|Electronic cupping|Twenty females will undergo two weekly myofascial release sessions and a healthy diet for six weeks, using electronic cupping to ensure equal pressure on tender points.
214412124|NCT06696651|OTHER|healthy diet|The MedDiet diet focuses on high fat intake, primarily from extra-virgin olive oil, in vegetable dishes, and a high consumption of low-glycemic index carbohydrates like wholegrain cereals, legumes, nuts, fruits, and vegetables. Moderate to high fish consumption is also encouraged, with moderate to small amounts of poultry and dairy products. Red meat and meat products are limited or avoided.
215016136|NCT05013229|DRUG|Insulin glargine|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
215016137|NCT05013229|DRUG|insulin aspart|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
215016138|NCT03964909|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
215016139|NCT03964909|PROCEDURE|Magnetic Resonance Imaging|Undergo CVR MRI
215016140|NCT03964909|PROCEDURE|Resting State Functional Connectivity Magnetic Resonance Imaging|Undergo rs-fMRI
215016141|NCT06126653|DRUG|Low Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.2 mg/kg dosing.
215016142|NCT06126653|DRUG|High Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.
215016143|NCT06126653|DRUG|Placebo|Titratable, liquid formulation, taken orally.
215016144|NCT04650841|DRUG|Placebo Cream with Naloxone|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
215016145|NCT04650841|DRUG|Control Cream with Naloxone|Participants will be informed that the spray is saline.
215016146|NCT04650841|DRUG|Placebo Cream with Saline|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
215016147|NCT04650841|DRUG|Control Cream with Saline|Participants will be informed that the spray is saline.
215016148|NCT06342960|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
215016149|NCT06342960|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
215016150|NCT06641401|PROCEDURE|Endoscopic Flexor Hallucis Longus transfer for Acute Achilles tendon rupture|All patients have already undergone the same operation for the same disease. All data are to be collected retrospectively
215016151|NCT06643546|OTHER|theoretical training|received only theoretical breastfeeding training
215016152|NCT06643546|OTHER|model simulation training|theoretical breastfeeding training and model simulation training accompanied by scenarios
215016153|NCT06643546|OTHER|live-simulation|theoretical breastfeeding training and live simulation training with scenarios
215016154|NCT06645262|OTHER|Cryotherapy|cryotherapy, therapeutic exercises, the use of braces, and the Bowen technique.
215016155|NCT04139499|PROCEDURE|Drug-induced sleep endoscopy (DISE)|DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.
215016156|NCT04139499|PROCEDURE|High-resolution manometry (HRM):|After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.
215016157|NCT00610948|BIOLOGICAL|panitumumab|Given IV
215016158|NCT00610948|DRUG|everolimus|Given orally
215016159|NCT00610948|DRUG|fluorouracil|Given IV
215016160|NCT00610948|DRUG|leucovorin calcium|Given IV
215016161|NCT00610948|DRUG|oxaliplatin|Given IV
215101423|NCT00254891|DRUG|PF-3512676 + Paclitaxel + Carboplatin|"* PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.~* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
215101424|NCT00254891|DRUG|Paclitaxel + Carboplatin|"* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
215101425|NCT03184285|PROCEDURE|baseline alert 1|measurement in supine position
215101426|NCT03184285|PROCEDURE|Anti-Trendelenburg-position (ATB)|measurement under ATB
215101427|NCT03184285|PROCEDURE|ATB in narcosis|measurement under ATB in narcosis
215101428|NCT03184285|PROCEDURE|baseline in narcosis 1|measurement in supine position in narcosis
215101429|NCT03184285|PROCEDURE|passive leg raising|measurement under passive leg raising
215101430|NCT03184285|PROCEDURE|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
215101431|NCT03184285|PROCEDURE|baseline in narcosis 2|measurement in supine position
215101432|NCT03184285|PROCEDURE|start capnoperitoneum|measurement in supine position
215101433|NCT03184285|PROCEDURE|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
215101434|NCT03184285|PROCEDURE|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
215101435|NCT03184285|PROCEDURE|ATB loss of capnoperitoneum|measurement under ATB
215101436|NCT03184285|PROCEDURE|baseline|measurement in supine position
215101437|NCT03184285|PROCEDURE|baseline alert 2|measurement in supine position
214412125|NCT06697522|DRUG|Atropine Sulfate|low concentration atropine (0.01%)
214412126|NCT06697522|DRUG|Placebo|Blank comparator
214412127|NCT06698055|OTHER|Flywheel Resistance Exercise|FW is conducted in a leg extension machine (LegExx, Exxentric, Stockholm, Sweden) and leg press machine (YoYo™ Leg Press, nHANCE, Sweden).
214412128|NCT06698055|OTHER|Weight Stack Resistance Exercise|WS is conducted in a leg extension machine (Seated leg press, Nordic Gym, Bollnäs, Sweden) and a leg press machine (Seated leg extension, Nordic Gym, Bollnäs, Sweden)
214412129|NCT06697860|DEVICE|Radial Shockwave Therapy|In Group A, Radial Shockwave Therapy (RST) was given to the plantar fascia for 5 minutes, with each session consisting of 5-10 shock wave pulses of varied intensity. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each stretch. This therapy procedure was followed out in weekly sessions for 8 weeks, each lasting 40 minutes in total.
215101438|NCT03184285|PROCEDURE|torso position rising 30° at the beginning|measurement in the recovery unit
215101439|NCT03184285|PROCEDURE|torso position rising 30° at the end|measurement in the recovery unit
215101440|NCT05262647|DIAGNOSTIC_TEST|18F-FAPI|Patients with chronic liver disease underwent 18F-FAPI-04 PET/CT and percutaneous liver biopsy.
215101441|NCT03310385|DRUG|GHX02|Herbal medicine originating from gualouhengryunhwan
215101442|NCT03310385|DRUG|Placebo|Placebo tablets
215101443|NCT04016077|DRUG|PF-06651600 30 mg|PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
215101444|NCT02474407|DRUG|diazepam nasal spray|
215101445|NCT02474407|DRUG|diazepam rectal gel|
215101446|NCT04894890|DRUG|secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.
215101447|NCT00779207|BEHAVIORAL|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
215101448|NCT00779207|BEHAVIORAL|weight loss|10 percent weight loss through diet and behavioral modification
215101449|NCT05318911|DIETARY_SUPPLEMENT|Novel yogurt drink|Novel ovine yogurt drink containing polar lipids
215101450|NCT05318911|OTHER|Placebo Drink|Placebo drink (skimmed milk)
215101451|NCT05036967|DRUG|HF medication|Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
215101452|NCT04118595|BEHAVIORAL|Educational Video|Educational Video: Development of the original video was funded by the John A. Hartford Foundation and used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script was developed for a grade level 5.5 and will be shown to the patient within 24 hours of the acute care visit. A link to the video is emailed or texted to the patient.
214412130|NCT06697860|DEVICE|Graston Instrument|Group B employed Graston Instrument-Assisted Soft Tissue Mobilization (IASTM) for 5-10 minutes to target and break down plantar fascia adhesions. The therapist used a specialized device to apply controlled, precise pressure to the fascia. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each. The entire therapy procedure was carried out in weekly sessions for 8 weeks, each lasting 40 minutes in total..
214412131|NCT06696989|OTHER|Frenkel's exercises|In this group, participants will receive Frenkel's exercises, and the total treatment session will be 60 minutes of routine physical therapy, i.e., breathing, stretching, ROM's, and joint mobility, with rest intervals in between for 20 minutes. To begin the intervention, the investigator will perform Frenkel's exercises for 40 minutes in total, with rest intervals between each exercise, initially performing 5 repetitions and then gradually progressing to 10 and then 15 repetitions, respectively, after 2 weeks.
214412132|NCT06696989|OTHER|Core stability exercises|This group participants will receive core stability exercises, and the total treatment session will also be 60 minutes. The routine physical therapy includes breathing, stretching, joint rotations, ROM's, and frequent periods of rest in between the treatment sessions. To begin the intervention the investigator will perform core stability exercises for 40 minutes in total with rest intervals between each exercise and initially performing 5 repetitions and then gradually progressing to 10 and then 15 repetitions, respectively after 2 weeks.
214412133|NCT06701838|DIAGNOSTIC_TEST|11C-Methionine PET/CT|After a 3-month period of eucortisolaemia, patients will undergo a second MRI of the pituitary gland and 11C-methionine PET/CT scan with SUVmax ratio analysis of the presumed corticotroph pituitary adenoma.
214412134|NCT06703424|OTHER|Sit-cycling|Sit-cycling for 5 mins
214412135|NCT06703424|OTHER|Stand-twisting|Stand-twisting for 5 mins
214412136|NCT06702839|OTHER|BETY (Cognitive Exercise Therapy Approach )|"Individuals with rheumatism were included in BETY sessions after the first session, which included functional gain with function-focused trunk stabilization exercises for their complaints and chronic pain management training based on neuroscience. BETY sessions included function-focused trunk stabilization exercises, chronic pain management, mood information management (dance therapy - authentic movement) as innovative. Individuals were included in a separate session of sexual information management and sleep education.~3 days a week for 3 months"
214412137|NCT06702839|OTHER|Home exercise program|Exercises have been shown and a brochure has been given The individuals in this group were mostly individuals from out of town who were given home exercise recommendations directed by a rheumatologist.
214412138|NCT06705023|BIOLOGICAL|Uncultured, autologous, adipose-derived regenerative cells (UA-ADRCs)|Intracardial venous injection of fresh, uncultured, autologous, adipose-derived regenerative cells isolated from lipoaspirate at the point of care.
215101453|NCT04118595|BEHAVIORAL|Telecare|Telecare will be provided via a protocol-guided phone call from a nurse care manager 48-72 hours after discharge from the ED or orthopedic urgent care. The call is designed to support patient decision-making regarding analgesics and behaviors following the content presented in the video. Topics covered in the call will include discussion of goals and priorities the patient has for their pain management, current prescriptions and analgesic use (and adjustments if needed), non-pharmacologic methods of pain management, warnings about potential side effects, current healthcare utilization, and open-ended questions to address additional patient care needs. Conversations will be guided by a shared decision making framework in which the nurse suggests pain management options, discusses their pros and cons, and actively elicits feedback from the patient. The telecare call is designed to last 15 minutes.
215101454|NCT04118595|BEHAVIORAL|Correspondence with Primary Care Provider|Following the telecare conversation, a note will be sent directly to the patient's primary care provider using a secure email or an electronic message that includes: 1) The date, time, location and reason for the index visit; (2) Results of diagnostics studies; (3) Discharge prescriptions/ recommendations; (4) A summary of and link to the video, explaining the emphasis on patient knowledge and SDM; (5) A summary of the telecare conversation; and (6) Encouragement for follow-up. PCPs will be asked to confirm receipt of this message.
215101455|NCT04078984|OTHER|Experimental|"* Daily measures of End Inspiratory Pressure with respiratory synchronisation optimised by use of EAdi~* Daily spontaneous breathing trial using low levels of pressure support~* Pplat, Respiratory System Compliance, Driving Pressure, PEEP, Tidal Volume will be monitored daily as well as clinical and other routine ventilatory data. Data concerning initial severity of ARDS, and duration of ARDS, controlled mechanical ventilation, sedation and neuromuscular blockade and date of first spontaneous breathing trial will be collected. A weaning test will be conducted daily."
215101456|NCT00218972|BEHAVIORAL|Aerobic interval training|
215101457|NCT00218972|BEHAVIORAL|moderate intensity training|
214412139|NCT06705023|OTHER|Continuation of patient's best guideline based medical treatment|Patients will receive continuation of their best guideline based medical treatment.
214412140|NCT06712654|DRUG|AP306 75mg TID|receiving orally AP306 75mg (one tablet), three times a day
214412141|NCT06712654|DRUG|AP306 100mg TID|receiving orally AP306 100 mg (one tablet), three times a day.
214412142|NCT06712654|DRUG|AP306 125mg TID|receiving orally AP306 125 mg (one tablet), three times a day
214412143|NCT06712654|DRUG|AP306 125mg BID|receiving orally AP306 125 mg (one tablet), three times a day, among which one is a placebo tablet
214412144|NCT06712654|DRUG|AP306 150mg BID|receiving orally AP306 150 mg (one tablet), three times a day, among which one is a placebo tablet
214412145|NCT06712654|DRUG|Placebo TID|receiving orally one placebo tablet of AP306, three times a day
214412146|NCT06711679|DRUG|Low-dose ropivacaine|0.5 ml/Kg ropivacaine
214412147|NCT06711679|DRUG|Medium-dose of ropivacaine|1ml/Kg ropivacaine
214412148|NCT06711679|DRUG|High-dose ropivacaine|1.5 ml/Kg ropivacaine
214412149|NCT06711354|DRUG|Anti-CD20 Monoclonal Antibody|Injection of monoclonal anti-CD20 antibody as immunomodulatory treatment of multiple sclerosis
214412150|NCT06707701|OTHER|acupuncture|Whether or not a patient has been treated with acupuncture will be one of the exposure factors of interest in the study
214412151|NCT06711562|DRUG|Anti-Infective Drugs|Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
214412152|NCT06711159|DEVICE|continuous positive airway pressure|Initiation of treatment with continuous positive airway pressure for obstructive sleep apnea
214504838|NCT05680259|OTHER|traditional follow-up|medical recommendations and prescriptions at hospital discharge. Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
214504839|NCT03808610|DRUG|Cyclophosphamide|Given IV
214412153|NCT06712524|PROCEDURE|Breast-conserving plastic surgery|The commonly used breast conserving plastic surgery includes tennis racket, bat wing, V/J breast plasty, Grisotti and so on.
214412154|NCT06712524|PROCEDURE|Traditional breast surgery|Traditional breast surgery
214412155|NCT06707675|OTHER|Assessment|The patients' demographic information, weight and height measurements, occupational activities and desk work time, daily screen usage time, pain intensity (with VAS), cervical joint range of motion examination, pain threshold (with pressure algometer), functional status (with Neck Pain Disability Scale), sleep quality (with Pittsburgh Sleep Quality Scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspects of pain (with Pain Catastrophizing Scale) will be evaluated. The patients' chronotype preferences will be evaluated with Morningness Eveningness Questionnaire.
214504840|NCT03808610|DRUG|Cytarabine|Given IV
214504841|NCT03808610|DRUG|Dexamethasone|Given IV or PO
214504842|NCT03808610|DRUG|Methotrexate|Given IV
214504843|NCT03808610|DRUG|Nelarabine|Given IV
214504844|NCT03808610|DRUG|Pegaspargase|Given IV
214504845|NCT03808610|DRUG|Prednisone|Given PO
214504846|NCT03808610|BIOLOGICAL|Rituximab|Given IV
214504847|NCT03808610|DRUG|Venetoclax|Given PO
214504848|NCT03808610|DRUG|Vincristine|Given IV
214412156|NCT06711419|PROCEDURE|f caudal neuroplasty using epidural catheter combined with Pulsed Radiofrequency (PRF) versus Pulsed Radiofrequency (PRF) alone|"Fluoroscopic guidance was used in all cases with a C-arm system. The patient was prone with a pillow under the lower abdomen. Anteroposterior (AP) images were taken to identify the target level. The C-arm was angled 15-30° to project the spinous process over the contralateral facet (scotty dog view). Skin was infiltrated with lidocaine, and a 22-gauge RF cannula was advanced under fluoroscopy. The tip was positioned in the dorsal-cranial quadrant of the intervertebral foramen on lateral images. PRF was applied with 4 cycles at 42°C for 8 minutes after sensory/motor testing. Injections of lidocaine and triamcinolone followed. In caudal neuroplasty, an epidural catheter was placed using the sacral hiatus as a guide. Fluoroscopy confirmed catheter position. Contrast was injected to confirm spread, and hyaluronidase and lidocaine were administered. Afterward, the catheter was removed."
214412157|NCT06697457|OTHER|Craniocervical Flexion Exercise Group|"The patient will first be taught to contract the deep cervical flexors. Patients will be placed in a supine position (without a pillow) to ensure a neutral neck position. Patients will be asked to perform slow, controlled head and upper cervical flexion by bringing the chin closer to the chest (yes movement). The stabilizer will be inflated to 20 mmHg. Gradual training will be given to increase the pressure value by 2 mmHg between 20 and 30 mmHg. Each pressure value (22, 24, 26, 28 mmHg) will be held for 10 seconds and repeated 10 times. The exercise will be performed with 10 repetitions, 10 seconds of contraction and 5 seconds of relaxation. Exercise training will begin with 20 mmHg and once the patient can hold it for 10 seconds with 10 repetitions, the next level on the pressure stabilizer will be moved on.Treatments will be performed 3 days a week for 8 weeks."
214412158|NCT06697457|OTHER|Conventional Treatment Group|TENS will be applied with a TENS device at an intensity of 10-30 mA and a frequency of 80 Hz for 20 minutes. A pair of surface electrodes will be placed on the painful area of the neck. The intensity of TENS will be adjusted according to the patient's sensory thresholds so that the patient is not disturbed by a numb feeling. After TENS, continuous ultrasound will be applied to the cervical region to produce thermal effects. The intensity will be 1.5 W/cm² and the duration will be 5 minutes. Hotpack will be applied to the trapezius muscle for 10 minutes. Chin tuck exercise will be applied to the cervical region.Treatments will be performed 3 days a week for 8 weeks.
214412159|NCT06697457|OTHER|Dynamic Isometric Exercise Group|The exercises will be performed by the patient with an elastic band. The progression of the exercises will be performed using different colors of Thera-bands with different resistances. It will start with the red Thera-band with the lowest resistance and then move on to the green and then blue Thera-bands with increasing resistance. Cervical isometric exercises will be performed with elastic resistance bands, maintaining the chin tuck position, forward, backward, crosswise, right and left. There will be 10 repetitions for 10 seconds for each. Progression in Therabands will be according to the patient. When the patient does 10 repetitions for 10 seconds, the next Theraband will be used.Treatments will be performed 3 days a week for 8 weeks.
214412160|NCT06697457|OTHER|Static Isometric Exercise Group|The patient will perform isometric exercises with maximal effort against neck flexion, extension, lateral flexion and rotation with his/her hand in a sitting position. Each exercise will be performed for 10 seconds, with 15-second breaks in between, for 10 repetitions. Each patient will start with submaximal resistance to help them adapt to isometric exercises, and then progress will be checked until the patient reaches the maximum resistance that can be tolerated by each session. It will consist of cervical flexion, cervical extension, right lateral flexion, left lateral flexion, right rotation, left rotation exercises. Progress in the exercises will be according to the Rating of Perceived Exertion Borg (RPE) Scale according to the weeks.Treatments will be performed 3 days a week for 8 weeks.
214412161|NCT06714422|PROCEDURE|apple group|Doctors will bring apples during night shift
214412162|NCT06714422|PROCEDURE|no apple group|No apples during night shift
214412163|NCT06713122|BEHAVIORAL|İntervention Group- Group receiving Symptom Management Training with Mobile Application|"The application to be developed in the research will be both Android and IOS supported.~Monitoring the active use of the patients from the interface by the researcher and receiving individual and collective notifications in line with the profile that the patients receiving chemotherapy will create in the application will increase the usability of the application. Thus, the benefit that users receive after active use can be determined.~The content of the Let's fight the symptoms together module will be created by experts in the field and people will be able to actively use these methods while struggling with the symptoms they experience.~Patients may not always have the opportunity to reach a nurse or health professional. In symptom management with the mobile application, artificial intelligence will be trained by the researcher and integrated into the application will help patients reach the right information without wasting time."
214504849|NCT02883361|BEHAVIORAL|Motivational enhancement therapy|Counseling meant to enhance motivation and decrease ambivalence about change, including asking open-ended questions, eliciting change-talk, and identifying discrepancies between current behaviour and valued behaviour
214504850|NCT02883361|BEHAVIORAL|Attention Control|Having participants come into the lab and fill out questionnaires with a researcher in-person
215016162|NCT01536509|BEHAVIORAL|Telehealth Behavioral Treatment (TBT)|Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
215016163|NCT01536509|BEHAVIORAL|Education Only (EO)|Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
215101458|NCT00218972|BEHAVIORAL|Recommendation of regular exercise|
215101459|NCT01505439|DRUG|solifenacin|oral
214412164|NCT06714500|DEVICE|LuxValve PLlus|The LuX-Valve (Jenscare Biotechnology) is a radial force-independent orthotopic TTVR device. The feasibility and efficacy of this device have been reported by several studies (11-13). However, this valve was implanted through right atrial access, where a small incision of the right chest and right atrium is needed. The LuX-Valve Plus valve replacement system is the second-generation version of the LuX-Valve and can be implanted through the jugular vein.
214412165|NCT06712108|PROCEDURE|tranplant|double unit cord blood transplnat
214412166|NCT06711432|DRUG|Norepinephrine or phenylephrine|Intraoperative use of norepinephrine or phenylephrine (norepinephrine 0.01-0.1ug/kg/min, or phenylephrine 0.15-1.1 ug/kg/min). The actual infusion speed depends on reaching the target MAP(\>=80mmHg).
215101460|NCT01407445|DRUG|Placebo|1 tablet/ oral/ 3 times a day for 90 days
214412167|NCT06705491|BEHAVIORAL|TIPPI-R|The TIPPI-R intervention protocol consists of a one session, during which time the interventionist offers psychoeducation related to the following content areas: procedural pain related to oncology treatment, factors that may affect the perception of pain, evidenced-based tools for assessing and monitoring pain, cognitive and behavioral pain management interventions, and resources to facilitate family to advocacy for pain management in a medical setting. During this session, the interventionist discusses opportunities for families to utilize skills throughout treatment, and addresses family questions as needed. A follow-up session 4 weeks after the initial intervention session will assess family knowledge and skills and offer a referral for a mental health provider, if further pain management support is needed. TIPPI-R is designed to be delivered by a psychologist, psychology trainee, or social worker working in the oncology context.
214504851|NCT03580629|BEHAVIORAL|Liver Live Donor Champion Program|Even with adequate education of live donation, many liver transplant candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide instrumental support. A Live Donor Champion (LDC) is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed the Liver Live Donor Champion program to provide education and advocacy training to waitlist candidates and their LDCs. The support provided by the LDC bridges a critical link between education and action. Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
214504852|NCT05281588|PROCEDURE|Micro-osteoperforations|All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
214504853|NCT05943054|OTHER|Temporal perception tasks|"A long temporal perception task in which the duration of the stimulus, around 2 min, is materialized by a video. For each trial, two videos are displayed to the participants, and then the task of the participant is to indicate the longest video and to give his level of confidence in his answer. A short temporal perception task which will take place in the same way as the long task except that the duration of the stimulus, around 2 seconds, is materialized by still frames from the videos used in the previous task."
214504854|NCT03900286|DIETARY_SUPPLEMENT|Total Dietary Replacement|Total Dietary Replacement
214504855|NCT03736889|DRUG|Tislelizumab (BGB-A317)|Anti-PD-1 Antibody
214504856|NCT06703476|PROCEDURE|Stent placement|Surgeon may choose to use a single or double J ureteral stent (6- to 8.5-fr in size) or an alternative ureteral stent of the surgeon's choice.
214504857|NCT06703476|DRUG|Alvimopan|Patient will receive alvimopan as a fixed 12-mg dose, with the first dose administered 0.5 to 5 h before the start of surgery; administration will be continued with twice daily oral doses postoperatively until hospital discharge or a maximum of 7 days (15 in-hospital doses).
214504858|NCT04640805|DIETARY_SUPPLEMENT|Protein supplementation|Liquid protein fortifier (Similac) will be added at 1ml per 25ml of PDHM at 130ml/kg/day of feed volume.
214504859|NCT04640805|OTHER|Analysis with Miris Human Milk Analyzer|PDHM macronutrient content will be analyzed using the Miris Human Milk Analyzer and PDHM with fat content of 3.8g/dL or higher will be selected and provided.
214504860|NCT05910762|BEHAVIORAL|Associative inference|Participants will engage in an associative inference paradigm. Memory will be assessed behaviorally and neural representations will be assessed using functional magnetic resonance imaging.
214504861|NCT05910762|BEHAVIORAL|Category learning|Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).
214504862|NCT05910762|BEHAVIORAL|Sleep|Participants will sleep after engaging in a category learning paradigm while electroencephalography data are collected, and memory will be assessed behaviorally after sleep.
214504863|NCT04374474|OTHER|Olfactory retraining|Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.
214504864|NCT04374474|DRUG|corticosteroid nasal irrigation|Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
215101461|NCT01407445|DRUG|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
215101462|NCT04928118|OTHER|Evaluate the blood flow and pressure into kidneys|"Renal artery pressure and flow measures will be obtained using dedicated equipment positioned into the renal artery under fluoroscopic guidance.~A pulmonary artery catheter will be used to measure the pressure inside participant's renal vein and to collect small blood samples to measure oxygen content."
215101463|NCT02854748|DRUG|Empagliflozin 25mg|Empagliflozin 25 mg QD for 5 days
215101464|NCT02854748|DRUG|Lobeglitazone 0.5mg|Lobeglitazone 0.5mg QD for 5 days
215101465|NCT02854748|DRUG|Empagliflozin 25mg/Lobeglitazone 0.5mg|Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
214412168|NCT06706063|OTHER|Ultrasonography of muscles|The biceps brachii, flexor digitorum superficialis and profundus muscles and gastrocnemius muscles of the participants on the affected and unaffected sides will be evaluated ultrasonographically. Two researchers (with at least 5 years of experience in ultrasound imaging) blinded to the clinical evaluations of the patients and previous measurements will evaluate the same patients at two different times to test interobserver reproducibility. Muscle thickness, fascicle length and pennation angle will be recorded on B-mode imaging. In addition, elastographic evaluation will be performed on the same muscles and strain rate will be recorded.
214412169|NCT06712771|DRUG|VSA003|subcutaneous injections
214412170|NCT06712771|DRUG|Placebo|subcutaneous injections
214412171|NCT06711094|DRUG|Dalpiciclib|"Dalpiciclib: 125mg orally, with a treatment cycle every 28 days, with continuous administration for the first 3 weeks (days 1 to 21) and rest (no medication) for the second 1 week (days 22 to 28). It is recommended to take Dalpiciclib at about the same time every day.~Albumin-bound paclitaxel for injection: 125mg/m2, intravenous infusion for 30 minutes, D1, D8, every 28 days for a treatment cycle, at least ≥6 treatment courses.~Endocrine therapy: Endocrine therapy drugs are selected by the investigator"
215101466|NCT06334068|OTHER|Short-term glycemic control group|Patients will be admitted to the hospital for 2-3 days before surgery. During this pilot study, patients will be admitted to the intermediate care unit to monitor and control preoperative blood glucose. We aim to maintain moderate glucose control (140-180 mg/dl) using the basal-bolus insulin protocol, plus correctional doses as needed.
215101467|NCT06334068|OTHER|Standard-of-care group|Patients will be admitted the day before surgery with the usual patient treatment.
214412172|NCT06712303|DEVICE|MRI ,ct|"Every patient will be subjected to~1\. MSCT examination: All patients will undergo MSCT (Siemens somatom 32 slice ,16 slice ,GE bright speed 16 slice ) Non contrast high-resolution CT of the temporal bone with the following parameters:{ 0.75-mm collimation, 130 kvp, 20 mA, topogram length 265}. Patients will be scanned in the supine position with craniocaudal direction. Scanning will be parallel to the orbito-meatal line from the lower margin of the external auditory meatus and extended upward to the arcuate eminence of the superior semicircular canal, as seen on the lateral topogram. Followed by image reconstruction in both the axial and coronal planes to evaluate the inner ear and its malformations, The initial data sets will be reconstructed at 0.6 mm slice thickness. The raw axial image data set can be reconstructed with a section thickness of as little as 0.3 mm to obtain high-quality coronal reformatted images. A 512 × 512 matrix is used, and all the images are reviewed wit"
214412173|NCT06711081|DEVICE|low level laser device cryotherapy|using new device direct on the pulp tissue
214412174|NCT06711783|BEHAVIORAL|Family based therapy|Family based therapy following the Maudsley model
215016164|NCT06345118|BEHAVIORAL|Otago exercise program|"The OEP consists of 17 strength and balance exercises and a walking program performed thrice a week by the older adult at home.~Program Prescription The program is designed to be delivered over 6 months and includes a minimum of 5 visits. The first visit is Day 1 of Otago when performance of the functional measures is assessed, and the exercises are prescribed at the Rehabilitation Center of the National Geriatric Hospital. Then, the therapist will see the patient for 4 visits over an 8-week period (typically every other week). This is considered the initial bolus of Otago. Then, the therapist will follow the patient via phone calls every week and make a visit at three months, four months, five months, and six months to reassess the patient's training ability and compliance.~Monitoring:~Calendars can be completed each month to document any falls. A calendar or diary can be used to monitor compliance with the exercise programme"
215016165|NCT01449032|BIOLOGICAL|MSC|No of cells after culture expansion
215016166|NCT01449032|BIOLOGICAL|Saline|3 cc saline
215016167|NCT06085209|DEVICE|The truFreeze Spray Cryotherapy|A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
215016168|NCT06085209|DEVICE|Ballon dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.
215016169|NCT06085209|DEVICE|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
215016170|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day
215016171|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
215101468|NCT02220712|DRUG|OPC-14597 IMD|Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
215101469|NCT00609739|DRUG|cyclosporine|Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients \>40 kg with normal renal function (creatinine \<1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
215101470|NCT00609739|DRUG|cytarabine|3000 mg/m\^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m\^2/day) on days -9 through -4.
215101471|NCT00609739|DRUG|filgrastim|Patients with absolute neutrophil count (ANC) \<0.2 x 10\^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10\^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
214504865|NCT04374474|OTHER|smell household Items|Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items
214504866|NCT04374474|OTHER|Nasal Irrigation|Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
215016172|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
215016173|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
215016174|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day
215016175|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
215016176|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
215016177|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
215016178|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day
215016179|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
215016180|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
214412175|NCT06714227|GENETIC|Molecular analysis of genomic DNA (exome sequencing) from peripheral blood sample|The first level of investigation will focus on genes already described in cases of pathogenic germline variants of prostate cancer and/or DNA repair system genes. The second level of investigation will consider variants in genes known to confer increased risk of cancer development, e.g., genes listed in the UK health system's solid tumor predisposition gene panel. Finally, pathogenic/probably pathogenic variants in the exome in genes attributable to increased risk will be evaluated on the basis of molecular pathway and findings in the scientific literature.
214412176|NCT06713629|PROCEDURE|cardiac surgery via median sternotomy|For both groups, the same median sternotomy cardiac surgery procedure
214412177|NCT06713512|OTHER|No intervention|No Intervention
215016181|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
215016182|NCT02363491|DRUG|OPN-305|For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
215016183|NCT04121013|OTHER|mothership|Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence
215016184|NCT02203760|DRUG|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
215101472|NCT00609739|DRUG|methotrexate|MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m\^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m\^2 IV on days +3, +6, and +11.
214412178|NCT06713980|OTHER|sham acupuncture|In the sham acupuncture group, sham acupuncture was applied at 14 specific non-acupuncture points on the back.
214412179|NCT06713980|OTHER|acupuncture|acupuncture:the choice of acupoints was based on the theory of traditional Chinese medicine (TCM). All needles were manually manipulated to achieve the deqi sensation
214504867|NCT05980598|DRUG|TransCon TLR7/8 Agonist|TLR7/8 agonist prodrug
214504868|NCT05980598|DRUG|Pembrolizumab|A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding
214504869|NCT05980598|DRUG|TransCon IL-2 β/γ|Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells
214504870|NCT05714774|DEVICE|HIFU treatment of prostate cancer|HIFU treatment using Focal One (EDAP TMS) combined with the acquisition of additional ultrasound images before, between, and after HIFU shots will be performed.
215016185|NCT02203760|DRUG|Pazopanib|Pazopanib 800 mg orally once daily
215016186|NCT01477411|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
215016187|NCT01477411|DRUG|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
215016188|NCT03132272|DEVICE|Immunoadsorption with Globaffin|Immunoadsorption for treatment of persons with Alzheimer Dementia
215016189|NCT00003685|PROCEDURE|fatigue assessment and management|
215016190|NCT00003685|PROCEDURE|nausea and vomiting therapy|
215016191|NCT00003685|PROCEDURE|pain therapy|
215016192|NCT00003685|PROCEDURE|quality-of-life assessment|
215016193|NCT00003685|RADIATION|radiation therapy|
215016194|NCT02000037|DEVICE|IR Reflexotherapy|"18 IR reflexotherapy sessions :~* Once a week for 12 weeks at the beginning of the study~* Once a week for 3 weeks, 9 months after the beginning of the study~* Once a week for 3 weeks, 15 months after the beginning of the study"
215016195|NCT02000037|BEHAVIORAL|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
215016196|NCT01103518|DRUG|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
215101473|NCT00609739|DRUG|methylprednisolone|Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
215101474|NCT00609739|DRUG|mitoxantrone hydrochloride|10 mg/m\^2 over 30 minutes intravenously (IV) on days -9 through -7.
215101475|NCT00609739|PROCEDURE|allogeneic bone marrow transplantation|Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 \>10\^8/kg recipient weight. Infused on Day 0.
215101476|NCT00609739|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
215101477|NCT00609739|DRUG|Cis-Retinoic acid|Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m\^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
215101478|NCT00760838|DRUG|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
215016197|NCT06569264|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. Followed by inspection of extraction socket integrity, using a William's graduated periodontal probe. Extracted teeth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries or restorations using a high-speed fine finishing stone and saline irrigation. The pulp chamber will be cleaned with sterile endodontic files. Teeth will be ground, using hand bone mill.The (ADDG) particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralized then washed twice in saline and dried with sterile gauze. For i-PRF blood will be withdrawn in plastic tubes. The tube will be centrifuged at around 700 RPM for 3 minutes, and extraction socket will be filled with the graft material.
214412180|NCT06714175|BEHAVIORAL|Lower Limb Strength Training Program with Visual Feedback|This lower limb explosive strength training system integrates visual feedback games and is equipped with angle and force sensors to simultaneously output the power of the left and right legs, as well as maximum explosive force and pushing force. Users can immediately understand the balance of leg strength and make adjustments, making it particularly suitable for the elderly to improve lower limb strength or for rehabilitation training. The gamification of the system enhances the fun of training, while data quantification allows progress tracking, making the training more precise and effective. Additionally, after the game ends, data can be exported to Excel for further analysis to identify issues in the pushing process and optimize the training plan.
214412181|NCT06713785|DRUG|Amlodipine|Amlodipine 1mg/ml Oral Solution
215016198|NCT06569264|PROCEDURE|Alveolar ridge preservation using vitamin C with dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. 25mM of pure vitamin C in Fresh blood, and the tube will be centrifuged at around 700 RPM for 3 minutes. Extraction socket will be filled with the corresponding graft material and the dentin graft.
215016199|NCT03892915|COMBINATION_PRODUCT|evidence-based depression treatment|We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9\>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
215016200|NCT06327256|DRUG|BI 3000202|BI 3000202
215016201|NCT06327256|DRUG|Placebo|Placebo-matching BI 3000202
215016202|NCT06327256|DRUG|Midazolam|Midazolam
214412182|NCT06713473|OTHER|Rehumanized Intervention|"Participants will:~1\. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of feeling less than human and mechanisms for reclaiming human identity. The summary will reveal general themes of humanness based on participant responses including body and soul awareness, agency, connection, and creativity.~1. write a 30-minute reflective essay on how did the rehumanization efforts described in the survey make people feel more human? where they will be encouraged to use examples from their own lives~2. asked to create videos based on the insights shared in the essays. The researchers will explain, We would like to record you reading your essay on camera. We believe it would be especially impactful for clinicians developing these interventions to hear directly from someone who has recently navigated similar experiences."
214412183|NCT06713473|OTHER|Control Intervention|"Participants will:~1\. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of political attitudes and routes to political sophistication. The summary will reveal general themes of political sophistication based on participant responses including gathering information through diverse news outlets, analyzing policy and legislation, and participation in civic engagement~1. write a 30-minute reflective essay on how did the political efforts described in the survey refine political attitudes? where they will be encouraged to use examples from their own lives~2. asked to create videos based on the insights shared in the essays. The researchers will explain, We plan to take excerpts of what you write here and share it with future voters to aid in developing political attitudes."
214412184|NCT06713473|DIAGNOSTIC_TEST|Clinical Interview|Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
214412185|NCT06713473|OTHER|Self-Report Measures|Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
214412186|NCT06713473|OTHER|Blood Draw|Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled EDTA tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
214412187|NCT06713850|DEVICE|Shockwave balloons|To evaluate the effectiveness and safety of the Shockwave intraperipheral shockwave catheter system in peripheral arterial angioplasty.
214412188|NCT06714084|DRUG|Neoadjuvant Chemotherapy (NACT)|Two cycles of carbonilumab plus TP regimen neoadjuvant chemotherapy will be implemented to patients with advanced cervical cancer
214412189|NCT06714084|DRUG|maintenance therapy|one years of maintenance therapy with carbonilumab alone will be implemented to patients with advanced cervical cancer receiving standard concurrent chemoradiotherapy
215016203|NCT05995366|DRUG|ABBV-903|Solution; Oral
215016204|NCT03399123|OTHER|Tidal volume|After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
215101479|NCT00760838|DRUG|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
215101480|NCT06350305|OTHER|questionnaire survey|subjects fill out questionnaires
214412190|NCT06713174|DIAGNOSTIC_TEST|Assessment of Interleukin 8 and 10 Level Changes Before and During Root Canal Treatment for Necrotic Pulp with Apical Periodontitis|This study will be performed to investigate interleukin-8 (IL-8) and interleukin-10 (IL-10) level changes in gingival crevicular fluid (GCF) and periapical fluid before and during root canal treatment (RCT) in patients with necrotic pulp and apical periodontitis. The null hypothesis tested will be There is no significant difference in (IL-8) and (IL-10) levels in gingival crevicular fluid (GCF) and periapical before and during root canal treatment (RCT) for necrotic pulp with apical periodontitis.
214412191|NCT06713109|BEHAVIORAL|Motivational interview techniques|Motivational interviews will be conducted 4 times. As a result of these interviews, the breastfeeding problem or anxiety in the mother will be evaluated and the effectiveness of the interview will be solved.
214412192|NCT06712381|DRUG|Fluorouracil|Carac (fluorouracil) Cream, 0.5% is used by adults to treat skin conditions on the face and front part of the scalp called solar keratosis or actinic keratosis.
214412193|NCT06712381|PROCEDURE|Photodynamic therapy|Photodynamic therapy (PDT) is a procedure that uses a photosensitizing drug to apply light therapy selectively to target pre-skin cancer, acne and sun damage.
214412194|NCT06712381|PROCEDURE|Carac in combination with PDT|
215016205|NCT04631978|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
215016206|NCT01181128|DRUG|Factor VIII (rFVIIIFc)|
214412197|NCT04571333|DEVICE|Mi2000 Totally Implantable Cochlear Implant|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
214412198|NCT02620072|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
215101481|NCT03534622|DRUG|Delafloxacin|In this study, thirty subjects who meet the entry criteria will be assigned to 1 of 5 groups (A, B,C, D, or E) to receive 300 mg delafloxacin IV every 12 hours for a total of 7 doses over 4 days
215101482|NCT03989401|OTHER|Multimedia video health education|The experimental group conducted multimedia video education while admission.
215101483|NCT05321251|DRUG|Insulin|see arm description
215101484|NCT05321251|PROCEDURE|Tarsorrhaphy|see arm description
215101485|NCT05908201|BEHAVIORAL|early time restricted eating|The intervention group will eat in a prescribed daily feeding window (9am-5pm) and follow their normal exercise and resistance training routines. We will allow up till +/-1 hour for the eating window start and end times while aiming for an 8 hour eating window.
214412199|NCT02620072|OTHER|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
215101486|NCT03624127|DRUG|BMS-986165|Specified dose on specified days
215101487|NCT03624127|OTHER|Placebo|Specified dose on specified days
215101488|NCT03624127|DRUG|Apremilast|Specified dose on specified days
214412200|NCT02799706|DRUG|Degarelix|a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
214412201|NCT02799706|DRUG|approved GnRH agonist|A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
214412202|NCT02799706|RADIATION|Radiotherapy|.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
214412203|NCT01729819|DRUG|Tolterodine tartrate extended release capsules|
214412204|NCT01729819|DRUG|Desmopressin orally disintegrating tablets|
214412205|NCT01729819|DRUG|Placebo orally disintegrating tablets|
215016207|NCT01181128|DRUG|Advate®|
215016208|NCT02371252|DRUG|Generic alendronate|The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
215016209|NCT02813720|RADIATION|HR-pQCT High resolution peripheral quantitative CT-scan|"HR-pQCT is a powerful device providing low dose irradiation already used in bone field.~It is a high resolution tool (voxel size=82µm) that the investigators adapted to look after the distal joint involved by onycholysis. An anteroposterior scout view is used to define the region of interest (ROI), which spanned from the top of the distal phalange to the distal part of the intermediate phalange in order to contain the distal joint of the target finger. Images are then analysed for erosions, osteophytes and volumetric bone mineral density."
215101489|NCT00153192|DRUG|Marinol (dronabinol)|
215101490|NCT02999633|DRUG|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
215101491|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:pills Route of administration: oral
215101492|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
215101493|NCT02999633|DRUG|acetaminophen|Pharmaceutical form:pills Route of administration: oral
215101494|NCT02999633|DRUG|ranitidine|Pharmaceutical form:solution Route of administration: intravenous
215101495|NCT02999633|DRUG|diphenhydramine|Pharmaceutical form:solution Route of administration: intravenous
215101496|NCT05338879|OTHER|Non-Interventional|No study treatment will be administered on this study.
215101497|NCT02607228|DRUG|Alobresib|Tablet administered orally once daily.
215101498|NCT02607228|DRUG|Enzalutamide|Capsules administered orally once daily.
215016210|NCT03309059|DEVICE|water and soap|Use of soap and water in the area and subsequent diaper placement disposable.
215016211|NCT03309059|DEVICE|zinc oxide|Use of soap and water sanitation and application of zinc oxide.
215016212|NCT03309059|DEVICE|Non-Irritant Barrier Film|Use of soap and water hygiene and application of Non Irritant Barrier Film.
215016213|NCT05901961|DRUG|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
215016214|NCT05901961|DRUG|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
214412206|NCT05829174|BEHAVIORAL|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
214412207|NCT05829174|BEHAVIORAL|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
214412208|NCT05829174|BEHAVIORAL|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
214504871|NCT04939012|BEHAVIORAL|MyPath Intervention|MyPath is a novel patient-centered, reproductive planning decision support tool developed by the research team used to facilitate postpartum contraceptive decision-making among women with SUDs. Designed to facilitate high-quality decisions regarding pregnancy and contraception, MyPath helps women a) review their thoughts about pregnancy and children, b) learn about fertility and preconception health and c) prioritize their preferences for various contraceptive method characteristics (e.g. effectiveness, side effects). As such, MyPath uses a patient-centered approach to help women frame their contraceptive decisions in the context of their goals and health and is a critical first step towards addressing reproductive health inequities among women with SUDs.
214504872|NCT04939012|BEHAVIORAL|Usual care|Standard of Care
215101499|NCT03687606|DRUG|Human Chorionic Gonadotropin|White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
214412209|NCT05829174|BEHAVIORAL|Behavioral module: Pomodoro Time Management Technique|Working in 25 minutes time intervals
214412210|NCT02912195|DRUG|Intravenous lidocaine|Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes
214688598|NCT03297099|PROCEDURE|Robot-assisted Laparoscopic operation|Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
215016215|NCT05901961|DRUG|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
215101500|NCT03687606|DRUG|human menopausal gonadotropin|White freeze-dried cake or powder with specification of 75IU.
214412211|NCT02912195|DRUG|Intravenous morphine|Emergency department provider chooses appropriate dose of intravenous morphine
214504873|NCT03258866|DRUG|Rituximab|given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
214504874|NCT03258866|DRUG|Rituximab|given with a single dose of 375mg/m2
214504875|NCT02423005|DEVICE|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
214504876|NCT02423005|DEVICE|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
214504877|NCT03954106|DRUG|Defibrotide|"* Part 1: Defibrotide 2.5 mg/kg/dose or 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7).~* Part 2 Recommended Phase 2 Dose: Defibrotide 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7)."
214504878|NCT06093490|DEVICE|Eysz Hyperventilation Recorder|App used to guide and record hyperventilation
214504879|NCT06280469|DEVICE|Single-Balloon Enteroscopy|The inflated balloon is supposed to fix the intestine to the endoscope system.Pushing the endoscope deeper into the small bowel with the balloon and enteroscope.
214504880|NCT02064699|BIOLOGICAL|CMV Infection|"Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.~Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV."
214504881|NCT06006455|DEVICE|Erchonia LunulaLaser|405nm violet and 635nm red laser light therapy.
215016216|NCT00777673|DRUG|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|"Eligible patients will receive:~* nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~* Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~* Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~* Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~\- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~\- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
215016217|NCT06309329|BEHAVIORAL|Strength at Home Parents|Strength at Home parents is an 8 week trauma-informed and cognitive behavioral tele-health group intervention that aims to improve parenting behaviors and overall parent-child and family functioning among U.S. military Veterans with post-traumatic stress disorder symptoms
214412212|NCT02966743|DRUG|Midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
214412213|NCT02966743|DRUG|Dexmedetomidine|administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
214688599|NCT03297099|PROCEDURE|open surgery|surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
215016218|NCT06309329|BEHAVIORAL|VA treatment as usual|VA treatment as usual includes referral to the online resources at veterantraining.va.gov/parenting .
214688600|NCT05020652|DRUG|TQ05105 tablets|TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.
214688601|NCT05020652|DRUG|Hydroxycarbamide tablets|Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.
214688602|NCT02568033|DRUG|Pemetrexed|
214688603|NCT02568033|DRUG|Carboplatin|
214688604|NCT02568033|DRUG|Cisplatin|
214688605|NCT02568033|DRUG|Docetaxel|
214688606|NCT02568033|DRUG|Paclitaxel|
214688607|NCT02568033|RADIATION|stereotactic radiosurgery|
214688608|NCT05641792|DEVICE|CGM (Dexcom G6)|Dexcom G6 system consists of a transmitter and sensor that measure interstitial glycaemia every 5 minutes. Measurements are transmitted via Bluetooth to a compatible device, that uploads the data on a virtual drive. This allows for remote real-time glycaemia monitoring on another device.
214688609|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
214688610|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
215016219|NCT01362270|DEVICE|Verum Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
214688611|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
214688612|NCT00162305|DRUG|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
214688613|NCT01623531|DRUG|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
214688614|NCT02947516|PROCEDURE|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
215016220|NCT01362270|DEVICE|Sham Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
214688615|NCT02947516|PROCEDURE|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
215016221|NCT02298569|BEHAVIORAL|multi-pronged program to improve early postpartum discharge|"Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.~Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration)."
215016222|NCT00715897|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
215016223|NCT01867476|OTHER|Automated Adherence Monitoring System|
214412214|NCT00471640|DRUG|dexamethasone|4 days 5 mg
214412215|NCT02295475|DRUG|Apixaban|
214412216|NCT02295475|DRUG|Warfarin|
214412217|NCT02893228|PROCEDURE|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
214412218|NCT02893228|DRUG|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
214412219|NCT00583843|PROCEDURE|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
214688616|NCT00861367|DRUG|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
214688617|NCT01672606|DRUG|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
214688618|NCT03620266|DIETARY_SUPPLEMENT|Bilberry|The dietary intervention will continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
214688619|NCT03620266|DIETARY_SUPPLEMENT|Placebo|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
214688620|NCT03620266|DIETARY_SUPPLEMENT|Bioprocessed oat bran|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
215016224|NCT02802085|DEVICE|VEGA Knee|TKA
215016225|NCT02318277|DRUG|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
215016226|NCT02318277|DRUG|INCB024360|INCB024360: Oral daily dosing
214412220|NCT00162071|DRUG|apadenoson|
214412221|NCT06127888|OTHER|Interviews|Semi-structured interviews
214412222|NCT06127888|OTHER|Surveys|Estructured survey
215016227|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (hyaluronic acid) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
215016228|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Platelet-Rich-Plasma) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
215016229|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (methylprednisolone acetate) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
215016230|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Serum Saline) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
215016231|NCT01520714|DEVICE|Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead|1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
214412223|NCT05926050|DIETARY_SUPPLEMENT|Treatment (CopaPrime+ (USANA Health Sciences)|Participants received and consumed 2 treatment tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained extracts of Bacopa monnieri (150 mg), Coffea arabica (50 mg), and Panax quinquefolius L. (50 mg)
215016232|NCT01213771|PROCEDURE|Preoperative preparation 2010|Preoperative optimisation Supportive care LEAN in patient pathways
215101501|NCT05583760|PROCEDURE|Experimental: Osteopathic manipulation TUG for scaphoid bone|The sequence of execution of the scaphoid TUG technique shall be applied as follows. Patient in the supine position. The inner hand of the intervener makes contact with the pisiform through the hypothenar eminence and ulnar border of the hand over the scaphoid tubercle, the outer hand reinforces the contact. The thumbs are directed to the sole of the patient's foot. The parameters are sought by bringing the sole of the foot into eversion, thus bringing the scaphoid into internal rotation (the direction of correction). In order to reduce the slack, the operator drops his body weight backwards while increasing the internal rotation parameter of the scaphoid. The manipulation is performed by associating a rapid traction movement with an increase of the correction parameter towards the internal rotation of the scaphoid.
215101502|NCT05583760|PROCEDURE|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|The intervention will be performed in the same way as the intervention group, without actually performing the TUG manipulation on the scaphoid bone, only placing it in tension.
214412224|NCT05926050|OTHER|Placebo|Participants received and consumed 2 placebo tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained microcrystalline cellulose. The size, shape and appearance of the placebo tablet was identical to the treatment tablet.
214412225|NCT02762318|OTHER|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:~Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.~A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.~For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
214412226|NCT03155152|OTHER|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
214412227|NCT03155152|OTHER|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
214412228|NCT01817036|DIETARY_SUPPLEMENT|Placebo|placebo
214504882|NCT03919851|DRUG|Antibiotics|Administration of antibiotics
214504883|NCT01087346|BEHAVIORAL|Reading Information|Reading information about risk factors for obesity among children
214504884|NCT06563505|DRUG|Mosunetuzumab|Given by IV
214504885|NCT06563505|DRUG|Zanubrutinib|Given by IV
214504886|NCT06634927|DRUG|Ozempic®|Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.
214504887|NCT06634927|DRUG|HDG1901|Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.
214504888|NCT06073587|DIAGNOSTIC_TEST|Scintigraphy scan|Scans will be performed as specified in the arm description.
214504889|NCT06014671|BEHAVIORAL|Interpersonal Psychotherapy|Intervention Group were took interpersonal psychotherapy
214504890|NCT01767688|DRUG|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
214504891|NCT01942954|OTHER|Mobile health cognitive stimulation|
214504892|NCT01444365|DRUG|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
214504893|NCT01444365|DRUG|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
214504894|NCT02795741|DEVICE|Cooling Bolero|a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
214504895|NCT05537532|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
214504896|NCT05537532|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
215016233|NCT04331379|DEVICE|Nasal Elevator|A device aiming to elevate the clefted nostril extraorally and fixed on the forehead.
214412229|NCT01817036|DIETARY_SUPPLEMENT|Vitamin D|400 IU vitamin D per pill
214412230|NCT05001919|PROCEDURE|GTR|intrabony defects treated by surgery and bone graft +collagen membrane
214412231|NCT05001919|PROCEDURE|concentrated growth factor|intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
215016234|NCT04331379|DEVICE|Taping Alone|Horizontal tape alone.
215016235|NCT01111487|DEVICE|Expiratory positive airway pressure (EPAP) by face mask.|Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
215016236|NCT05754112|OTHER|B lymphocyte profiling|All individuals will undergo peripheral venous blood sampling and ultrasound-guided synovial tissue biopsy following a standardized procedure. B-lymphocytes will be sorted from PBMCs isolated by Ficoll gradient method using magnetic CD19-microbeads whereas tissue B-lymphocytes will be isolated from synovial tissue biopsies digested with Liberase. CD19 positive cells from PBMC will be incubated with pro-inflammatory molecules in presence or absence of Ubadacitinib. After stimulation, CD19 positive cells will be collected and processed for single cell RNA sequencing. Moreover, the impact of JAK-1 selective inhibition on B-lymphocyte cultures stimulation will be tested using ELISA method for the assessment of cytokines/chemokines production. Synovial tissue and synovial tissue B-lymphocyte subpopulations will be assessed through FACS analysis using IgD/CD27 classification. Finally, we will compare the transcriptomic profile of synovial tissue B lymphocytes from 5 subject groups.
215016237|NCT02112175|DRUG|Lenalidomide|
215016238|NCT04728464|PROCEDURE|Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Fixed appliance will be placed for every patient, then surgical procedure will be applied after reflecting a full-thickness labial flap.
214412232|NCT00519129|DEVICE|3D-imager|3D-imager vs fluoroscopy during coloscopy
214412233|NCT02785744|OTHER|Gaucher disease DNA mutation analysis|
214412234|NCT03069781|DRUG|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
214412235|NCT03069781|DRUG|Polycose|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
214412236|NCT00929591|DRUG|cyclophosphamide|
214412237|NCT00929591|DRUG|doxorubicin hydrochloride|
214504897|NCT05537532|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
214504898|NCT06340191|OTHER|Pilates with cueing|"The Pilates with a cueing component of the intervention involved a specialized approach to Pilates training. Participants in this group underwent an initial phase of training before the main sessions began, which consisted of two smaller group sessions focused on learning explicit verbal and tactile cues. These cues were designed to assist participants in maintaining proper body alignment, engaging specific muscle groups more effectively, and refining their movement techniques to enhance the overall efficacy of the Pilates exercises.~During the actual Pilates sessions, the instructors, who were certified and brought extensive experience to the program, provided real-time feedback to the participants. This feedback was based on the cueing instructions, aiming to optimize the execution of the Pilates exercises."
214504899|NCT06340191|OTHER|Pilates without cueing|"The Pilates without cueing portion of the study involved participants following the same comprehensive Pilates program as the Pilates with cueing group, with a significant distinction: they did not receive any additional training on cueing. This group engaged in 60-minute Pilates sessions twice a week for 8 weeks, under the supervision of certified and highly experienced Pilates instructors. The program included a variety of exercises, both mat-based and utilizing props, designed to improve participants\&#39; physical condition and wellness.~However, unlike their counterparts in the first group, these participants were not given explicit instructions on how to enhance their body alignment, muscle engagement, or movement techniques through verbal and tactile cues. They performed the Pilates exercises following the standard regimen, without the nuanced guidance and real-time feedback focused on optimizing exercise execution through cueing."
215016239|NCT01111188|DRUG|PD 0332991|"PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.~(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg"
215016240|NCT01111188|DRUG|bortezomib|"Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.~(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2"
215101503|NCT04480216|DEVICE|MAGUS|"An upper endoscopy will be performed with the use of fluoroscopy. The MAGUS will be placed under fluoroscopy. The good positioning and the absence of any complications will be confirmed by gastroscopy.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 2 and mashed food up to 7 days post procedure"
214412238|NCT00929591|DRUG|endocrine therapy|
214412239|NCT00929591|DRUG|endocrine-modulating drug therapy|
214412240|NCT00929591|DRUG|fluorouracil|
214412241|NCT00929591|DRUG|tamoxifen citrate|
214412242|NCT00929591|RADIATION|brachytherapy|
214412243|NCT00929591|RADIATION|low-LET electron therapy|
214412244|NCT00929591|RADIATION|low-LET photon therapy|
214412245|NCT00929591|RADIATION|radiation therapy|
214504900|NCT01655563|DRUG|Tacrolimus|Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
214504901|NCT02344680|DRUG|Anti-HIV Agents|
214504902|NCT05125224|DRUG|Dihydropyridine calcium channel blocker|Dihydropyridine calcium channel blocker claim is used as the exposure group.
214412246|NCT00957086|DRUG|Nimotuzumab|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
214412247|NCT00957086|DRUG|Placebo|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
214412248|NCT03015974|DRUG|Corticosteroid|
214412249|NCT03015974|DRUG|Cyclophosphamide|
214412250|NCT03015974|DRUG|Mycophenolate mofetil|
214412251|NCT03015974|DRUG|Dipyridamole|
214412252|NCT03015974|DRUG|ACE Inhibitor or Angiotensin receptor antagonist|
214412253|NCT01735240|DRUG|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
214412254|NCT01735240|DRUG|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
214412255|NCT01225939|DRUG|AZD8329|tablet
214412256|NCT01225939|DRUG|AZD8329|Solution
214412257|NCT02454543|PROCEDURE|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
214412258|NCT02454543|DRUG|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist."
214412259|NCT05395949|DRUG|conservative treatment|Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
214412260|NCT02404064|DRUG|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
214412261|NCT02404064|DRUG|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
214412262|NCT02404064|DRUG|Placebo|No perioperative antibiotics
214412263|NCT01272648|BEHAVIORAL|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
214412264|NCT04374708|DIAGNOSTIC_TEST|fMRI|fMRI: body morph test and neurocognitive testing
214412265|NCT06390891|OTHER|Persons with pancreatic resection in a hospital with at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with at least 50 pancreatic resections annually (observational)
214412266|NCT06390891|OTHER|Persons with pancreatic resection in a hospital not performing at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with not at least 50 pancreatic resections annually (observational)
214412267|NCT02753413|BIOLOGICAL|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
214412268|NCT02753413|BIOLOGICAL|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
214412269|NCT06116162|DEVICE|SVF-gel Filling and CO2 fractional laser|"SVF-gel preparation and filling:The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. Then the lipoaspirate was centrifuged at 1200g for 3 minutes to obtain Coleman fat in the middle layer. The Coleman fat was then transferred between two syringes until the Coleman fat converted into a uniform emulsion, and then processed by centrifugation at 2000g for 3 min. Finally, the remaining substance under the oil layer was SVF gel. We used a 22G sharp-tip injector to inject the SVF-gel into the dermis of acne scars, and the injected materials were diffusely distributed.~CO2 fractional laser treatment: After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage. Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage."
214412270|NCT02853474|BEHAVIORAL|Early Palliative Care visit|"A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.~Five PC visits are scheduled in this arm."
214412271|NCT02853474|OTHER|EORTC-QLQ-C30 questionnaire|The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
214412272|NCT02853474|OTHER|HADS score|The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
214412273|NCT04464421|BEHAVIORAL|Contingency Management (CM)|Participants were able to draw a gift card from a virtual fishbowl when their urine toxicology results are positive for buprenorphine metabolites. Gift card values were $25, $50, or $100.
214412274|NCT04464421|BEHAVIORAL|Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)|Participants had one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, the importance of substance-free activities, and mindfulness skills.
214412275|NCT02245854|DEVICE|Exacto™|Cold snare polypectomy
214412276|NCT02749045|RADIATION|SPECT imaging|myocardial perfusion imaging
214412277|NCT01020838|DRUG|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
214412278|NCT04340284|BIOLOGICAL|autologous adipose tissue derived stromal vascular fraction (SVF)|"liquid and solid portion of lipo-aspirate after non enzymatic processing yields SVF.~This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ ,~, the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC, 20%), plus a wide number of CD34+ hematopoietic cells (40%)."
214412279|NCT03674190|PROCEDURE|Anterior Lumbar Interbody Fusion|Anterior Lumbar Fusion(ALIF)
214412280|NCT03674190|PROCEDURE|Total Disc Replacement|Total Disc Replacement
214412281|NCT05086809|DEVICE|Device A|Participant wear Device A and evaluate the performance of the device.
214412282|NCT05086809|DEVICE|Device B|Participant wear Device B and evaluate the performance of the device.
214412283|NCT01167426|DRUG|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
215016241|NCT04874441|DIAGNOSTIC_TEST|Diagnosis strategy based on C. glabrata / krusei PCR|For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
215016242|NCT03987607|DEVICE|neuromuscular blockade monitoring|Neuromuscular blockade monitoring via two different types of monitoring devices
214412284|NCT01167426|DRUG|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
214412285|NCT04922658|DRUG|Surufatinib|Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
214412286|NCT04922658|DRUG|Surufatinib Plus Vinorelbine|Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
214412287|NCT01930019|DRUG|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
214412288|NCT06348186|OTHER|Guidebook|Folder that will be given to the participant to carry out 5 minutes of intervention daily
214412289|NCT06348186|OTHER|Guidebook and Myofascial Reorganization® (RMF).|The intervention will be carried out once a week for 30 minutes for 6 weeks. It will include passive, active-assisted moments (with and without load). In addition to a folder that will be given to the participant to carry out 5 minutes of intervention daily.
214412290|NCT01363362|PROCEDURE|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
214412291|NCT02616861|DRUG|IW-1973|IW-1973 Tablet
214412292|NCT02616861|DRUG|Matching Placebo Tablet|Matching placebo tablet
214412293|NCT01524536|DRUG|prednisone|Glucocorticoids (GC) are considered the first- line therapy for hypereosinophilic syndrome.
214412294|NCT00722215|DRUG|BQ-123 (selective endothelin A receptor antagonist)|Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
215016243|NCT01146444|OTHER|UV A and B irradiation|UV irradiation
215016244|NCT04505280|DRUG|Lidocaine 1% Injectable Solution|Greater occipital nerve and cervical region injections once a week for 4 weeks
215016245|NCT00395512|DRUG|Alogliptin|Alogliptin tablets.
215016246|NCT00395512|DRUG|Pioglitazone|Pioglitazone tablets.
214412295|NCT00722215|DRUG|0.9 % saline|Single 15ml 0.9% saline infused for 15 mins as placebo control
215016247|NCT00395512|DRUG|Placebo|Matching placebo tablets.
215016248|NCT04757844|DEVICE|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
215016249|NCT03299335|OTHER|Blood collection|assay of CPK and anti-cN-1A antibodies
214412296|NCT00722215|DRUG|Nifedipine|Single dose of nifedipine 10 mg given orally as active control
214412297|NCT01908634|DIETARY_SUPPLEMENT|Milk-based Strawberry Beverage without meal|
214412298|NCT01908634|DIETARY_SUPPLEMENT|Water-Based Strawberry Beverage without meal|
214412299|NCT01908634|DIETARY_SUPPLEMENT|Milk-based strawberry Beverage with meal|
214412300|NCT01908634|DIETARY_SUPPLEMENT|Water-Based strawberry Beverage with meal|
214412301|NCT04176458|DEVICE|Methacetin Breath Test (MBT)|The hypothesis is that MBT CPDR 20 in the Fontan patient is abnormal as a result of alterations in liver perfusion, liver cell metabolic capability and transhepatic resistance secondary to hemodynamics unique to the Fontan as well as end-organ liver damage. Due to lack of robust biomarkers or other risk stratification schemes, we aim to determine whether there is prognostic value in hepatic MBT CPDR 20 in the Fontan patient.
214504903|NCT05125224|DRUG|Hydrochlorothiazide|Hydrochlorothiazide claim is used as the reference group.
214504904|NCT01487460|DRUG|TAP311|
214504905|NCT03486574|DIAGNOSTIC_TEST|Positive result from pathological test|Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test
214504906|NCT02890524|DEVICE|night guard|60 days before and after intervention with the night guard
214504907|NCT02890524|DEVICE|placebo night guard|60 days before and after intervention with the placebo night guard
215016250|NCT03855371|DRUG|Decitabine|20mg/m2/d, intravenously, d1-d5, q4w
215016251|NCT03855371|DRUG|Arsenic Trioxide|0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
214412302|NCT04744779|BEHAVIORAL|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
214504908|NCT02148705|DRUG|NexoBrid|
214504909|NCT02148705|PROCEDURE|Standard of Care (SOC)|
214504910|NCT02148705|DRUG|Gel Vehicle|
214504911|NCT01462175|DRUG|RO5503781|
214504912|NCT01583166|DRUG|Bupivacaine|10ml 0.5% bupivacaine
214504913|NCT01583166|DRUG|Saline|10ml 0.9% sodium chloride
214504914|NCT01583166|DRUG|Epinephrine|1:200,000 epinephrine
214504915|NCT04464031|OTHER|electronic alert|The e-alert system was developed by the divisions of Nephrology and Information Management of Guangdong Provincial People's Hospital (Patent Application 201610001950.5). The alert system made a diagnosis of acute kidney injury according to Kidney Disease: Improving Global Outcomes criteria. Then, the doctor receives an alert of acute kidney injury.
214504916|NCT03272412|DIAGNOSTIC_TEST|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
215016252|NCT03303066|DRUG|FG-4592|Oral
215016253|NCT03303066|DRUG|Placebo|Oral
215016254|NCT02810132|DRUG|Metformin|See above
215016255|NCT02810132|DRUG|Placebo|See above
215016256|NCT00185900|DRUG|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
215016257|NCT00185900|DRUG|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
215016258|NCT01077895|PROCEDURE|CVVH|"CVVH is started using following parameters:~* Blood flow is started at 150 mL/min~* Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~* In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~* Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
215016259|NCT01077895|PROCEDURE|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol~* Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~* Vasopressor or inotrope medication dose is increased by \> 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~* When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV \> 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~* If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
214412303|NCT03931044|PROCEDURE|Image-Guided Robotic Gastrectomy|The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.
214412304|NCT02638415|PROCEDURE|HVPG-guided therapy|"Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails."
214412305|NCT02638415|OTHER|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
214412306|NCT02638415|DRUG|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
214688621|NCT03620266|DIETARY_SUPPLEMENT|Combination bilberry/oats|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
214412307|NCT05001828|DRUG|ADI-PEG 20|ADI-PEG 20 in combination with venetoclax and azacitidine
214412308|NCT04531488|PROCEDURE|Powered Mobility Training Simulator|Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.
214504917|NCT05948774|DRUG|MT200605 for Injection|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
214504918|NCT05948774|DRUG|MT200605 Placebo|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
214688622|NCT01429792|DRUG|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
214688623|NCT01429792|DRUG|ribavirin [Copegus]|standard treatment, orally daily
214688624|NCT04179968|DRUG|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
214504919|NCT01833455|DRUG|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
214504920|NCT01833455|DRUG|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
214504921|NCT00247351|PROCEDURE|Cryoablation|
214504922|NCT02206867|BIOLOGICAL|LBAL|Anti-inflammatory agents
214504923|NCT02206867|BIOLOGICAL|Humira|Anti-inflammatory agents
214504924|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
214504925|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
214504926|NCT00887224|DRUG|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
214688625|NCT04179968|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
214688626|NCT06126874|OTHER|Patient Education|Individuals in both study groups will be provided with patient education through verbal and visual presentations. In the content of patient education; information about the importance of the research topic and the content of the study through anatomical models and short animations, lifestyle recommendations for urinary incontinence symptoms (avoiding bladder irritants such as alcohol, caffeine, tea, spicy foods, acidic foods and chocolate, regulating water / fluid consumption, recommendations for attention to bowel regularity and increasing physical activity levels) and recommendations for sexual functioning (coitus positions that facilitate erection, recommendations for reshaping the sexual schema, recommendations for the physical dimension of sexual health) will be given.
215016260|NCT01077895|PROCEDURE|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
215016261|NCT00754559|DRUG|Tocilizumab|8mg/kg iv every 4 weeks
214412309|NCT04531488|OTHER|Training with Powered Wheel Chair|Training with Powered Wheel Chair
214412310|NCT03510091|BEHAVIORAL|Counseling|A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
215016262|NCT01663987|DRUG|tiotropium bromide|18 mcg once a day (QD)
215016263|NCT01663987|DRUG|Placebo|once a day (QD)
214412311|NCT05593952|OTHER|Dual task|exercise with dual task + usual treatment
215016264|NCT05418920|PROCEDURE|left-opening single-flap technique|left-opening single-flap technique
215016265|NCT05418920|PROCEDURE|double-flap group technique|double-flap group technique
214412312|NCT05593952|OTHER|Single task|exercise without dual task + usual treatment.
214412313|NCT00304980|DRUG|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
214412314|NCT01570751|DRUG|insulin degludec|Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
214412315|NCT01570751|DRUG|insulin glargine|Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
214504927|NCT03883828|DRUG|Chlorhexidine gluconate solution|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
215016266|NCT01829503|DRUG|decitabine and cytarabine|
215016267|NCT01829503|OTHER|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
215016268|NCT04305652|OTHER|The Progressively Lowered Stress Threshold Model|PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
215016269|NCT00002238|DRUG|Interferon beta-1b|
215016270|NCT00002238|DRUG|Zidovudine|
215016271|NCT05077111|PROCEDURE|Thoracic Epidural Anesthesia|Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.
214412316|NCT00452465|BEHAVIORAL|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
214412317|NCT05025124|DEVICE|Entia Liberty|Home monitoring system
214412318|NCT02013986|DRUG|etomidate|0.3mg/kg IV only once during induction of general anesthesia
214504928|NCT03883828|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
214504929|NCT05902936|PROCEDURE|Pulpotomy for mature permanent mandibular molars|Performing pulpotomy for mature teeth that involves removal of the coronal pulp tissue that is diseased or inflammed followed by placement of a biocompatible material with the intent of maintaining the vitality of the remaining radicular pulp tissue.
214504930|NCT02915211|DIETARY_SUPPLEMENT|Keyo|Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
214504931|NCT01399450|DRUG|paliperidone|paliperidone augmenting on ongoing medication
214412319|NCT02013986|DRUG|midazolam|midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
214412320|NCT02013986|DRUG|propofol|2mg/kg IV only once during induction of general anesthesia
214412321|NCT00223119|DEVICE|Absorbable Sutures|
214412322|NCT02321813|BEHAVIORAL|quality of life pathway|Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
214412323|NCT02321813|OTHER|placebo control|Quality of life measurement
214412324|NCT05923762|BEHAVIORAL|OHRQoL|"Oral health-related quality of life will be measured by the Oral Impact on Daily Performance (OIDP)"
214412325|NCT00449657|DRUG|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
214412326|NCT00449657|PROCEDURE|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.~Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
214412327|NCT00449657|DRUG|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 \& 9
214412328|NCT00449657|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 \& 9
214412329|NCT01424332|DRUG|Darexaban|oral
214412330|NCT01424332|DRUG|Acetyl Salicylic Acid (ASA)|oral
214412331|NCT02740530|DEVICE|Magstim® Rapid 2 machine|See Arms description
214412332|NCT06169904|DRUG|Cisplatin injection|We observed the UC patients from Zhongshan Hospital receiving or not receiving adjuvant cisplatin-based chemotherapy after radical cystectomy.
214412333|NCT03318536|DRUG|Granisetron Hydrochloride|Patients received Granisetron.
214412334|NCT03318536|DRUG|No Granisetron|Patients who did not receive Granisetron.
214412335|NCT01457560|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
215016272|NCT05077111|PROCEDURE|General Anesthesia with One Lung Ventilation|Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
214412336|NCT01457560|BIOLOGICAL|OPV|One dose administered orally
214412337|NCT03487042|DRUG|Bimatoprost 0.03% ophthalmic solution|"Each patient will be subjected to the following:~One side will be treated by narrow band ultraviolet rays B sessions twice weekly for 3 months + topical bimatoprost 0.03% solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays B sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months.~Patients' Evaluation:~The recruited patients will be subjected to:~A) Full history taking. B) General clinical examination. C) Dermatological examination of the skin lesions. D) Vitiligo area scoring index score will be calculated for each patient E) Clinical photographs will be taken at baseline, after each month during treatment and after the end of treatment by 3 months.~F) A skin biopsy from the treated lesions for histochemical examination. F) Dermoscopic evaluation of the treated sites every 2 weeks."
214412338|NCT03991949|OTHER|Experimental Infant Formula|Formula fed Ad libitum
214412339|NCT02000999|OTHER|brushing of bile duct strictures for cytology|
214412340|NCT01942967|OTHER|Echocardiography|"Measurement of:~* Left ventricular output (LVO).~* Right ventricular output (RVO).~* Assessment of the Mesenteric Artery Flow."
214412341|NCT01942967|OTHER|Near Infrared Spectroscopy Monitoring|Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
214412342|NCT04097626|OTHER|nutrition education|The experimental group will receive nutrition education once during the study. It will occur at the beginning of the second week. This will consist of a 30-minute interactive lecture and a 15-minute question-and-answer session. The information covered will be basic nutrition principles for good health and to support regular exercise.
214412343|NCT04097626|OTHER|no nutrition education|This group will not receive nutrition education.
214412344|NCT05790408|DEVICE|Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG)|The Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb during transconjunctival needle revision of trabeculectomy bleb.
214412345|NCT05790408|DEVICE|Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)|The Spectralis Anterior-segment OCT (AS-OCT) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb in the office.
214412346|NCT05479539|BEHAVIORAL|Action observation therapy|Participants will watch 12-minute video-clips followed by 8 minutes of motor imagery. Video-clips observation and imagination will be focused un shoulder tasks occuring on the three planes of motion.
215016273|NCT04236947|BEHAVIORAL|SCPP-YA|SCPP-YA includes two modules. In the first module of ten sessions, students will learn to employ a 6-step social information processing framework for solving a wide range of real-life problems. The six-step process consists of 1) stop, clam down, and think before you act; 2) say the problem and how you feel; 3) set a positive goal; 4) think of many solutions; 5) think ahead to the consequences and 6) go ahead and try the best plan. The second module offers 1) current and accurate information about the health, social, and legal consequences of substance use, 2) correct mistaken beliefs that students have about substance use, 3) enhances awareness of social and media influences; and 4) teachers assertiveness and critical thinking skills to resist peer pressure.
215016274|NCT01016041|DEVICE|everolimus stent|stenting
214412347|NCT06173570|DRUG|AZD0780|AZD0780 administered orally, once daily for 12 weeks
214412348|NCT06173570|DRUG|Placebo|Placebo administered orally, once daily for 12 weeks
214412349|NCT06060418|OTHER|aromtherapy|aromatherapy with essential oil is being used as a non-pharmacological nursing intervention within the health care setting. This approach aims to manage the patient's discomfort and alleviate the symptoms of postoperative nausea and vomiting. One of the most beneficial oils is Lavender Essential Oil (LEO), which is used to treat a variety of digestive issues.
214412350|NCT02161653|DRUG|Prednisone plus Metadoxine|
214412351|NCT02161653|DRUG|Pentoxifylline plus Metadoxine|
215016275|NCT01016041|DEVICE|paclitaxel stent|stenting
215016276|NCT06021379|DRUG|Trastuzumab|AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
215016277|NCT05254860|PROCEDURE|LPS Ventral Rectopexy|Continuous Locked Suture vs Traditional 6-points suture for Laparoscopic Ventral Rectopexy to verify if the operative time of a standard laparoscopic ventral rectopexy for the treatment of severe rectal prolapse could be further reduced using continuous locked suture vs traditional 6-points suture for mesh fixation
214412352|NCT04726046|DRUG|Cefotetan|Cefotetan (as Disodium) 1 GM Injection before surgery
214504932|NCT01439906|PROCEDURE|Surgical correction of the deformity|"Three different surgical techniques are used:~* lumbar fusion vs thoraco-lumbar fusion~* iliac fixation vs fixation to the sacrum~* posterior + interbody fusion vs posterior interbody fusion"
214504933|NCT02860949|DRUG|0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL|
214504934|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)|
214412353|NCT06165185|OTHER|Water|Please see the associated arm description
214412354|NCT06165185|OTHER|Coffee|Please see the associated arm description
214412355|NCT06165185|OTHER|Control|Please see the associated arm description
214412356|NCT04423484|OTHER|Data collection|Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
214412357|NCT01916889|OTHER|RACY test|
214412358|NCT05061953|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
214412359|NCT00138606|DRUG|vildagliptin|
214412360|NCT00903019|BEHAVIORAL|Tele-Problem-Solving Therapy|Six sessions of tele-PST
214412361|NCT00903019|BEHAVIORAL|In-Person PST|Six sessions of in person PST
214412362|NCT00903019|BEHAVIORAL|Attention control|Six weekly telephone calls
214412363|NCT05691660|DRUG|TAS3731 Dose1|Oral administration,1 day,QD
214412364|NCT05691660|DRUG|TAS3731 Dose2|Oral administration,7 days,QD
214412365|NCT05691660|DRUG|TAS3731 Dose3|Oral administration,7 days,BID
214412366|NCT05691660|DRUG|Placebo|Oral administration, 1 day,QD
214412367|NCT05691660|DRUG|Placebo|Oral administration, 7 days,QD
214412368|NCT05691660|DRUG|Placebo|Oral administration, 7 days,BID
214412369|NCT02480335|DRUG|bosentan|62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
214412370|NCT02485626|PROCEDURE|2D tissue doppler echocardiography|
214412371|NCT00248391|BEHAVIORAL|upright feeding|
214412372|NCT02809300|BIOLOGICAL|blood collection|
215016278|NCT05158803|RADIATION|ultrasound and C.T|lung ultrasound in comparison to C.T
215016279|NCT06447051|OTHER|Kasai Surgery|As per institute treatment protocol
215016280|NCT03413917|OTHER|Analysis of genomic markers in uterine atony|No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.
215101504|NCT02980627|BEHAVIORAL|Therapy with Mobile App Enhancement|"Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies."
214412373|NCT06106087|OTHER|Mixed methods quality improvement intervention|Quality improvement training for frontline PCH staff
214412374|NCT00562913|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
214412375|NCT01886014|DRUG|Oxytocin|
214412376|NCT01886014|OTHER|placebo|
214412377|NCT00938535|BEHAVIORAL|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
214412378|NCT00221351|PROCEDURE|CRP point of care testing|
214412379|NCT06465680|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver push notifications. The notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of five therapeutic approaches: 1) CBT-Behavioral, 2) CBT-Cognitive, 3) Distanced Self-Talk, 4) Mindfulness, 5) Motivational Interviewing.
214412380|NCT03768856|RADIATION|Temporally Feathered Radiation Therapy (TFRT)|Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
214412381|NCT06327919|DIETARY_SUPPLEMENT|Probiotic supplement|multi-strain probiotics were used in this study. Each probiotic capsule contains Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus reuteri, Lactobacillus rhamnosus, magnesium stearate and maltodextrin. 1.8 × 109 CFU / capsule. 2 capsules per day, for 12 weeks
214412382|NCT06327919|OTHER|Placebo supplement|The placebo capsule contains 300 mg of starch. 2 capsules per day, for 12 weeks
214412383|NCT03172533|DRUG|ethinyl estradiol 0.03mg and dienogest 2 mg (combination)|approved oral contraceptive (Germany): Maxim
214412384|NCT03172533|DRUG|Placebo oral capsule|placebo
214412385|NCT03168191|DRUG|Nicotine|Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
214412386|NCT03168191|OTHER|Experimental Flavor|Experimental fruit flavored e-cigarette for lab session
214412387|NCT03168191|OTHER|Menthol Flavor|Menthol flavored e-cigarette for lab session
214412388|NCT02947568|OTHER|non-interventional study|
214412389|NCT04835038|DRUG|Sodium Bicarbonate Ringer's Injection|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
214412390|NCT04835038|DRUG|Sodium Lactated Ringer's Injection|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
214412391|NCT05348226|DIAGNOSTIC_TEST|Additional Cardiac Magnetic Resonance Scan|Standard of care medical treatment with sacubitril/valsartan (Entresto). Additional Cardiac Magnetic Resonance Imaging (CMR) Scan after 4-6 months of treatment.
214412392|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with TPRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the TPRF as a sole grafting material.
214412393|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with PRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the PRF as a sole grafting material.
214412394|NCT00964314|OTHER|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done."
214504935|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL|
214504936|NCT02386332|PROCEDURE|transplantation|
214412395|NCT03804086|PROCEDURE|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement|"will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~* The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~* After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze."
214412396|NCT03804086|PROCEDURE|Open flap debridement|a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
214412397|NCT03856541|DRUG|SHR-A1403|SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min
214412398|NCT05622188|OTHER|Elevated ambient heat|Temporary exposure to increased ambient temperature +10°C (the effect of the intervention is fully and spontaneously reversible)
214412399|NCT05622188|OTHER|Elevated relative humidity|Temporary exposure to increased ambient relative humidity +40% (max. 90%) (the effect of the intervention is fully and spontaneously reversible)
214412400|NCT05622188|OTHER|Exertion|Temporary exertion on an ergometer (1W/kg body weight) (the effect of the intervention is fully and spontaneously reversible)
214412401|NCT02465086|OTHER|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
214412402|NCT01863004|DRUG|Bortezomib|
214412403|NCT00699686|DRUG|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
214412404|NCT00699686|DRUG|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
214412405|NCT03533036|DEVICE|applied VR headset|Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D\&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
214412406|NCT00335023|OTHER|Red blood cell transfusion|At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
214412407|NCT00558363|DRUG|Avodart|0.5 mg administered orally once daily
214412408|NCT00558363|OTHER|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
214412409|NCT00396058|DRUG|Methylphenidate|
214412410|NCT06582251|BEHAVIORAL|High-intensity functional training|Participants assigned to this group will undergo 8 weeks of high-intensity functional training.
214412411|NCT06582251|BEHAVIORAL|Traditional resistance training|Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training.
214412412|NCT06582251|BEHAVIORAL|Concurrent training|Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training followed by high-intensity interval aerobic training.
215016281|NCT04803903|DEVICE|Flotraq Sensor with EV1000 incorporating the HPI algorithm|"The HPI algorithm is only available on the EV1000, Hemosphere and Flotrac monitoring systems and requires the use of a Flotrac sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The Flotrac sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart . If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immedietaly. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere/EV1000 with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension."
215016282|NCT04825899|OTHER||
215016283|NCT00004015|DRUG|sodium borocaptate|
215016284|NCT00004015|PROCEDURE|adjuvant therapy|
215016285|NCT02662465|PROCEDURE|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
214504937|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
214504938|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
214504939|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
214504940|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
215016286|NCT01823887|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
215016287|NCT03109392|DRUG|Nebulized Lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
214504941|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
214504942|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
215016288|NCT03109392|DRUG|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
214412413|NCT01295918|DIETARY_SUPPLEMENT|L reuteri in children on antibiotics|Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.
214412414|NCT04012853|DEVICE|transcranial direct current stimulation|Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks. During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
214412415|NCT04962334|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
214412416|NCT04962334|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (powder added to water) without added vitamins and minerals
214412417|NCT05555264|BEHAVIORAL|Self-Guided|Clients who select or are assigned the self-guided condition will be able to contact the Online Therapy Unit regarding any technical issues through the secure treatment platform; monitoring staff will respond by secure message to messages received however, no psychological intervention will be provided by monitoring staff as part of the ACCE treatment intervention. If there is a significant clinical issue requiring attention (e.g., a sudden increase in symptoms) monitoring staff will make a telephone call and crisis support will be provided if necessary.
214412418|NCT05555264|BEHAVIORAL|Therapist-Guided|Therapists will spend \~15 minutes/week communicating with each client who selects the therapist-guided condition, primarily using secure messages. Phone calls will only be made if there is a significant clinical issue requiring attention that the therapist does not feel can be addressed in a message (e.g., a question about the materials that cannot be easily addressed in a text format, a sudden increase in symptoms, increased suicide risk).
214412419|NCT02685280|DEVICE|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
214412420|NCT03883438|PROCEDURE|Modified coronally advanced flap and acellular dermal matrix graft|Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I\&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
214412421|NCT04969822|DEVICE|iDAScore®|A system that studies time lapse images obtained from the embryo culture system, Embryoscope, throughout the development to blastocyst. The system uses data acquired from a sequence of embryo images and has taught itself to identify the embryos with the highest likelihood of implanting and leading to fetal heart-beat detection.
214412422|NCT00100984|DRUG|FUZEON [enfuvirtide]|
214412423|NCT05307991|DRUG|PrEP|HIV pre-exposure prophylaxis (or PrEP) will include the Malawi-approved PrEP regimen at time of study enrollment. At time of submission, the only Malawi-approved regimen includes Tenofovir/emtricitabine (TDF/FTC) containing 300 mg of TDF and 200 mg of FTC. If additional PrEP regimens become available in Malawi during the study recruitment or follow-up, participants will be able to choose from any regimen that they are eligible to receive per Malawi PrEP guidelines.
214412424|NCT05307991|DEVICE|STI testing|Urine specimens will be tested for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) using GeneXpert® (Cepheid, Sunnyvale, CA) Xpert® CT/GC platform and cartridge and syphilis RPR titer (BD Macro-VUE™, Becton, Dickinson and Company, Franklin Lakes, NJ \[FDA approved\]) with confirmatory Treponema pallidum particle agglutination (TP-PA) (Serodia Fujirebio Inc, Malvern, PA \[CE mark\]) if RPR is positive.
214504943|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
214688627|NCT06126874|OTHER|Pelvic Floor Muscle Training|In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program. In the first 2 weeks of PFMT, individuals will perform 3 sessions of exercise per day. In each 2-week control, the number of sessions will be increased by 1 session and PFMT application will be completed with 5 sessions per day in the study.
215016289|NCT03109392|DRUG|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
215016290|NCT02245724|BIOLOGICAL|Stem Cell|Autologous bone marrow mononuclear cell transplantation
215016291|NCT04799717|BEHAVIORAL|Gaming session|Participants will be provided the option to play an online game with the clinician for the first half of the session through an online platform.
215016292|NCT04460261|OTHER|Functional Inspiratory Muscle Training|Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT. Foundation IMT was applied during the first 4 weeks of training. The participants were asked to sit in a comfortable upright position. Following the foundation IMT, all participants underwent four weeks of functional IMT. Initially, all participants were taught diaphragmatic breathing and activating abdominal wall musculature. Each training session started with warm-up exercises and ended with cool-down exercises. During the loading phase, core stability, dynamic trunk activation and postural control exercises were applied together with IMT.
215101505|NCT01032031|DIETARY_SUPPLEMENT|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
215101506|NCT01032031|DIETARY_SUPPLEMENT|Placebo capsule|One capsule daily for 3 months
215101507|NCT01497782|OTHER|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
215101508|NCT03679026|OTHER|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
215101509|NCT02567045|PROCEDURE|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
215101510|NCT02567045|PROCEDURE|colonoscopy with sedation|One-time Colonoscopy with sedation.
214412425|NCT05307991|BEHAVIORAL|Assisted partner notification|"Participants will be asked to provide the name and locator information for all sexual partners in the preceding 6 months. Participants will be asked to refer sexual partners to the clinic and will be provided with cards to distribute to partners. Each card will request that the recipient report to the STI clinic with the card and will contain a linking number that links them back to the index participant.~Sexual Partner Tracing: In accordance with the contract referral approach, if the named partners do not present to an STI clinic within 7-14 days, community outreach workers will contact the partners and counsel them to visit the clinic. Contact may be made through telephone, text message, or in person, as needed and will not disclose the name or identify of the index patient."
214412426|NCT05307991|DIAGNOSTIC_TEST|Acute HIV testing|Persons initiating or re-initiating PrEP will also be screened for acute HIV infection (AHI) using Abbott RealTime HIV-1 Assay (Abbott Laboratories, Chicago, IL) or Xpert® HIV-1 Viral Load (GeneXpert, Cepheid, Sunnyvale, CA).
214412427|NCT00002111|DRUG|Saquinavir|
214412428|NCT03874455|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
214412429|NCT00273676|PROCEDURE|Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment|
214412430|NCT03460574|BEHAVIORAL|INFORMATION|After receiving expectation-disconfirming positive performance feedback, participants receive standardized information that stresses the relevance of this experience. In particular, participants are told that the performance test they worked on is highly relevant for both professional success and personal life satisfaction.
214412431|NCT03460574|BEHAVIORAL|SALIENCE|After receiving expectation-disconfirming positive performance feedback, partcipants in this condition are instructed to remember how well they performed on the performance test. Using a visual analogue scale, they were asked to specify how they performed relative to the other participants.
214688628|NCT06126874|OTHER|Aerobic Exercise Training|Aerobic exercise training will be planned 3 days a week, 1 day on the routine clinic day with a treadmill ergometer and 2 days as a home program in the form of brisk walking outside the clinic (e.g. outdoors or in a suitable environment).The intensity of aerobic exercise training will be planned according to the Maximal Heart Rate (MHR) method and Modified Borg Scale (MBS). In the first 2 weeks in the clinic, training will be started with 50 min (+10 min warm-up and cool-down) at 60% of the MHR, the exercise intensity will be increased by 5% every 2 weeks, and the program will be terminated by providing exercise training at 85% of the MHR in the 10th-12th week. Patients will be asked to adjust the intensity of aerobic exercise outside the clinic to correspond to the 12-14 (slightly difficult) degree of perceived fatigue according to the MBS.
214688629|NCT06126874|OTHER|Resistance Exercise Training|Resisted exercise training will be planned 2 days a week, 1 day in the clinic and 1 day outside the clinic as a home program, and 12 different exercises for large muscle groups with dumbbells and weight sets, resistance bands (therabands) will be used in the training. These exercises are leg press, leg extension, leg curl, squat, seated row, lateral pull down, biceps curl, triceps extension, dumble fly, lateral raises, bench press and abdominal crunch. Exercises will be performed with free weights (dumbbells), resistance bands (therabands) or body weight.
214688630|NCT04218916|DRUG|Rhodiola Rosea Capsules|0.28g per capsule, 0.56g once (2 capsules), three times a day
214688631|NCT04218916|DRUG|Placebo|2 placebo capsules once, three times a day
214688632|NCT04119726|BEHAVIORAL|Usual Text Messages|Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
214688633|NCT04119726|BEHAVIORAL|Personalized reminders|Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.
215016293|NCT03931811|DEVICE|Short wave diathermy|SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device).
215016294|NCT03931811|OTHER|Prolotherapy|Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
215016295|NCT03721965|DRUG|Itacitinib|Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.
215016296|NCT03721965|DRUG|Corticosteroids|Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
215101511|NCT05367128|OTHER|Dual task training|All participants will receive cognitive dual task training for 30 min/session, 2-3 sessions/week for 4-6 weeks (a total of 12 sessions). The cognitive dual task training includes 15 min of cognitive task combining with standing task and 15 min of cognitive task combining with walking task. The differences among group are the instructions of task prioritization given by the therapist
215016297|NCT06377592|OTHER|Sample collection without intervention|No Intervention
214412432|NCT03460574|BEHAVIORAL|ATTENTION|Before working on the performance test, participants are instructed to pay attention to the feedback they receive. In particular, they are asked to enter what would be a personally good result for them. It is supposed that this shift of attention increases the salience of the expectation-disconfirming feedback.
214412433|NCT03460574|BEHAVIORAL|CONTROL|This group does not receive any further intervention. Instead, participants of this group pass through the standard procedure of the EXPEC paradigm.
214412434|NCT00359957|BEHAVIORAL|Pediatric Obesity Intervention (STANDARD)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
214412435|NCT00359957|BEHAVIORAL|Pediatric Obesity Intervention + High Activity (ADDED)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
214412436|NCT02775981|DRUG|RX0041-002|
214412437|NCT00015457|DRUG|Amlodipine plus Botulinum toxin|
214412438|NCT04397198|DIAGNOSTIC_TEST|Speckle Tracking echocardiography|"Diagnostic tests:~Speckle Tracking echocardiography with analyzing the myocardial strain, myocardial velocities, 128-multislice CCTA with the evaluation of the Calcium Scoring (total and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability degree, assess polar maps of the myocardium.~MRI for the evaluation of the percentage of myocardial scar, also the percentage of the viable myocardial tissue using contrast late enhancement sequences, measuring myocardial fibrosis using Q-mass software.~Diagnostic tests:~Laboratory assessment for the evaluation of the level of hs-CRP and myocardial necrosis biomarkers"
214412439|NCT03519321|DEVICE|MID-C|The MID-C system is being connected to the spine via standard unilateral posterior approach. Pedicle screws above and below the main curve are being used to attach the device to the selected vertebra.
214412440|NCT03047733|DEVICE|The XTRAC Excimer Laser System|Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.
214412441|NCT03047733|DRUG|Topical tacrolimus 0.1% ointment|Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
214412442|NCT04463264|DRUG|Nitazoxanide|NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
214412443|NCT04463264|DRUG|Placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
214412444|NCT02317705|DRUG|OTL38|
214412445|NCT02317705|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
214412446|NCT02317705|PROCEDURE|Laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
214412447|NCT02219490|DRUG|ABT-450/r/ABT-267|Tablet for oral use
214412448|NCT02219490|DRUG|ABT-333|Tablet for oral use
214412449|NCT02219490|DRUG|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
214688634|NCT04119726|BEHAVIORAL|Internet-based counselling|"The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database"
214688635|NCT04790474|DRUG|ixazomib-pomalidomide-dexamethasone|"Cycles 1-3: during each 21-day cycle:~* ixazomib 3 mg on Days 1, 4, 8 and 11~* pomalidomide 4 mg on Days 1 through 14~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~* ixazomib 4 mg on Days 1, 8 and 15~* pomalidomide 4 mg on Days 1 through 21~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23"
214688636|NCT04184622|DRUG|Tirzepatide|Administered SC
214688637|NCT04184622|DRUG|Placebo|Administered SC
214688638|NCT02719418|DRUG|Tinzaparin|3500 Unit or 4500 Unit subcutaneous once daily
215016298|NCT06446323|DRUG|0.2 ml dose of sucrose|Both interventions aim to provide pain relief to neonates following minor procedures by administering sucrose solution orally. The study evaluates the efficacy of each dose (0.2 ml vs. 0.5 ml) in reducing post-procedural pain intensity, as measured by the Premature Infant Pain Profile (PIPP). Additionally, any adverse events associated with the administration of sucrose solution are documented and analyzed as part of the study.
215016299|NCT06220266|DRUG|Phytoestrogen|consume 1 capsule twice a day for 2 months which one capsule composed of dry weight 50 mg of Pueraria Mirifica 1or Pueraria Mirifica 2 or Pueraria Mirifica 3
215016300|NCT06220266|DRUG|Diet control & life style modification|Diet control \& life style modification
215101512|NCT04708002|OTHER|early integrated palliative approach model|From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
214412450|NCT01014338|DRUG|Fosinopril|10mg od
215101513|NCT05873491|OTHER|Music therapy|The music therapy sessions will offer sensory workshops of immersive musical listening, digital and acoustic music creation and shared improvised music.
214412451|NCT01014338|OTHER|lactose|placebo
214412452|NCT00620581|DRUG|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
214412453|NCT04363762|BEHAVIORAL|Internet-based multimodal pain program|A guided internet-based multimodal pain program for chronic TMD pain
214412454|NCT04363762|DEVICE|Occlusal splint|Occlusal splint, standard
214412455|NCT03383211|OTHER|RNAseq|Transcriptome profiling of peripheral blood using RNA sequencing technology
214412456|NCT04123002|OTHER|Miswak chewing sticks|Chewing stick are routinely used by this population
214504944|NCT01279694|DRUG|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
214504945|NCT01279694|DRUG|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
214504946|NCT01279694|DRUG|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
214504947|NCT00418119|DRUG|erythropoietin|
214412457|NCT05974943|OTHER|Problem Solving And Decision Making Education|"The Problem-Solving and Decision-Making Training Program, which was based on developing problem-solving and decision-making skills of nurse managers in the experimental group (n=30), was prepared. 2 faculty members and the researcher organized the training program consisting of four modules and 16 hours.~In the content of the Training Program; the definition of the concept of problem-solving and decision-making, the process of problem-solving and decision-making and decision-making models, the impact of decision-making on employee, patient and organizational outcomes, and the importance of managers' roles in decision-making, the importance of the role of nurse managers in decision making, the impact of managerial decisions on patient care outcomes, the impact of managerial decisions on nurse outcomes, the impact of administrative decisions on organizational results/performance, problem-solving, and decision-making techniques and case studies."
214412458|NCT01599325|DRUG|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
214412459|NCT02934035|DRUG|Antidepressant|
214412460|NCT03879642|BEHAVIORAL|REDCHiP|10 week video-based telemedicine intervention to reduce hypoglycemia fear
214412461|NCT05015972|BIOLOGICAL|CTA30X UCAR-T injection|CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.
214412462|NCT00504920|BEHAVIORAL|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
214412463|NCT02648529|PROCEDURE|MRI|"Patients are investigated with the following sequences:~* High-resolution 3D T1-weighted anatomical MRI.~* DTI with 48 directions (to examine white matter)"
214412464|NCT02648529|PROCEDURE|functional MRI (fMRI)|"fMRI investigations will be focused on :~* language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~* Social cognition: investigations on social cognition skills~* Memory :~* Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~* Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups."
214412465|NCT02648529|BEHAVIORAL|neuropsychological assessment|Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
214412466|NCT04160689|BIOLOGICAL|implantology|placing of implant
214412467|NCT00012987|BEHAVIORAL|Quality Improvement|
214412468|NCT00710307|PROCEDURE|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
214412469|NCT00710307|GENETIC|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
214504948|NCT01256359|DRUG|Docetaxel and AZD6244|Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
214504949|NCT01256359|DRUG|Docetaxel and placebo|Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
214504950|NCT01429454|DRUG|Omega-3 Long Chain Fatty Acid|: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
214504951|NCT01429454|DRUG|Placebo|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
214504952|NCT01653652|DIETARY_SUPPLEMENT|Probiotic|
214504953|NCT01653652|DIETARY_SUPPLEMENT|Maltodextrin|
214504954|NCT00310609|DRUG|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
214504955|NCT02000752|DEVICE|Acupuncture|
214504956|NCT02000752|DEVICE|Sham acupuncture|Sham point acupuncture
214504957|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
214504958|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
215016301|NCT05520450|BEHAVIORAL|Telematic support group|The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
215016302|NCT02262273|OTHER|Data Collection|Colleciton of data from medical records only
215016303|NCT04808895|DRUG|Acetylsalicylic acid|administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
214412470|NCT04590989|OTHER|Personalized Nutrition Plan|"* Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~* Personalized behavioral change program via electronic push notifications by ONMI"
214412471|NCT04590989|OTHER|Non-Personalized Nutrition Plan|"* Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~* Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization)."
214412472|NCT02552277|BIOLOGICAL|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
214412473|NCT02552277|DRUG|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
214412474|NCT04312568|DRUG|Fadanafil|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
214412475|NCT04312568|DRUG|Placebo|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
214412476|NCT02577484|DEVICE|RXi System|"Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.~Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.~The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics."
214412477|NCT02577484|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
214412478|NCT05138172|DEVICE|"Forced Air Heating Temperature control Twinwarm II"|"For this purpose, we will use a device that is already routinely used in all operation rommss at MHH, the so-called warm air device Twinwarm, Generation III. This device has a valid CE mark and will be used according to its purpose pre-, intra- and postoperative maintenance of the normothermic body temperature of the patient. The device will be used strictly according to the existing in-house SOP Heat Management of 04/2021 of the Department of Anesthesiology and Intensive Care Medicine of the MHH.~Convective air heating has been shown to be effective in many studies and can be used flexibly with a variety of different ceiling models."
214412479|NCT00137605|BIOLOGICAL|Pneumovax|
214412480|NCT00137605|BIOLOGICAL|Prevnar|
214412481|NCT00944801|DRUG|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
214412482|NCT00420589|DRUG|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
214412483|NCT00420589|DRUG|Comparator: placebo|Placebo capsules once daily. Treatment for 52 weeks
214688639|NCT06300619|BEHAVIORAL|Pilates+4|12 weeks of seated Pilates twice weekly. In weeks 1-3, participants receive training on hip and shoulder cuff activation. This occurs through active isometric pressure on the stabilizing limb (not the moving limb during a Pilates movement) for 3 seconds at 30% strength using the participants' own hand (e.g., pressure on the outside of the knee with knee pressing against hand) prior to engaging in each exercise. Following the first 3 weeks, participants in the Pilates+4 group engage in the same Pilates protocol as the comparator group, however, they receive 4-quadrant cues for hip and shoulder cuff activation as they learned in weeks 1-3.
214688640|NCT06300619|BEHAVIORAL|Pilates|12 weeks of seated Pilates twice weekly. 18 exercises standard in Pilates instruction will be provided with standard Pilates cues (i.e., core activation, cuing the moving limb, breathing synchronization).
214688641|NCT05420467|DRUG|Docetaxel|75 mg/m2, d1, q3w,6 cycles
214688642|NCT05420467|DRUG|Carboplatin|AUC 6, d1, q3w,6 cycles
214688643|NCT05420467|DRUG|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
214688644|NCT05420467|DRUG|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
214688645|NCT05420467|DRUG|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
214688646|NCT05420467|DRUG|Epirubicin|90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
214688647|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
214688648|NCT05420467|DRUG|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
214688649|NCT05420467|DRUG|Epirubicin|90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
214688650|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
215016304|NCT04808895|DRUG|Placebo|administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
214688651|NCT05420467|DRUG|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
214688652|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 6 cycles
214688653|NCT00812916|PROCEDURE|RF ablation, using specialized CFAE software|RF ablation
214688654|NCT00769704|BIOLOGICAL|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
214688655|NCT00769704|BIOLOGICAL|GM-CSF|125 µg/m² subcutaneous injection
214688656|NCT04051593|OTHER|Cervical stabilization exercise|The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
214688657|NCT00011193|BEHAVIORAL|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
215016305|NCT00251966|DRUG|Esomeprazole|
214412484|NCT02197689|DEVICE|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
214412485|NCT03015831|DRUG|Colchicine|Colchicine will be given to open heart surgery patients
214412486|NCT03015831|DRUG|Placebo Oral Tablet|Placebo Oral Tablet will be given to open heart surgery patients according to randomization
214412487|NCT01611909|DRUG|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
214412488|NCT02537392|DIETARY_SUPPLEMENT|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
214412489|NCT02537392|DIETARY_SUPPLEMENT|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
215016306|NCT01574495|OTHER|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
214412490|NCT02537392|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid.
214412491|NCT00803426|PROCEDURE|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
214412492|NCT03877471|GENETIC|Cell therapy|Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.
214412493|NCT03679962|BEHAVIORAL|Triple Chronotherapy|"Day 0: One night of total sleep deprivation. The first 24 hours are spent with 1:1 nursing care for provision of comfort measures to stimulate wakefulness and to encourage completion of the intervention.~Day 1-4: Sleep phase advancement Day 1: Sleep from 6 PM to 1 AM Day 2: Sleep from 8 PM to 3 AM Day 3: Sleep from 10 PM and 5 AM Day 4: Awaken at 5 AM; discharge following light therapy~On days 1-4 patients will receive bright light therapy at 7am to 7:30am using a 10,000 Verilux light box. At discharge patients will be given a light box, strongly advised to continue the maintenance sleep schedule and bright light therapy at 7am daily for 30 minutes. Patients will be scheduled for follow-up appointments at 1-week, 1-month and 2-month following discharge."
214412494|NCT03679962|BEHAVIORAL|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
214412495|NCT01468324|DRUG|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
214412496|NCT04138433|DEVICE|Real tDCS|Anodal tDCS 2 ma
214412497|NCT04138433|DEVICE|Sham tDCS|Sham tDCS 2 ma
214412498|NCT00927342|OTHER|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
214412499|NCT00927342|OTHER|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
214412500|NCT02430532|DRUG|dimethyl fumarate|capsule
214688658|NCT03010423|DRUG|Nicorandil|Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
214412501|NCT02430532|OTHER|Placebo|matched placebo capsule
215016307|NCT01171937|DRUG|Risperidone|children get randomized to either placebo or active risperidone
215016308|NCT01171937|DRUG|Placebo|Children get randomized to either placebo or risperidone
215101514|NCT04029103|OTHER|knowledge, behaviour, self efficacy|Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
215101515|NCT00967096|DRUG|Rifaximin|Rifaximin for Bone marrow transplant patients
215101516|NCT00877396|BIOLOGICAL|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
215101517|NCT00877396|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
214412502|NCT04762342|OTHER|Power training|"First a brief warm up on a stationary bike and uni-lateral knee raises is completed.~Power training: Involves exercises performed with fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.~Functional- and balance exercises are included from week 9-24.~Progression:~Week 1-4: 3 sets of 12 repetitions at a load of 14 repetitions maximum (RM) with focus on introducing resistance exercise and familiarizing participants with exercises.~Week 5-8: 3 sets of 12 repetitions at a load of 14 RM the power training component.~Week 9-16: 3 sets of 10 repetitions at a load of 12 RM. Week 17-24: 3 sets of 8 repetitions at a load of 10 RM~Strengthening exercises:~* Bilateral leg-press~* Bilateral plantar flexion~* Bilateral knee extension~* Unilateral banded dorsal flexion~* Bilateral lying leg curl~* Back extension~* Shoulder press~* Seated row~* Chest press~* Lat pull-down"
214412503|NCT00082719|BIOLOGICAL|Recombinant Interferon Alfa|"In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose."
214412504|NCT01899222|DEVICE|Handheld fundus photography|diagnostic imaging with two types of retina camera
214412505|NCT00000746|BIOLOGICAL|rgp120/HIV-1 SF-2|
214412506|NCT00000746|BIOLOGICAL|Env 2-3|
214412507|NCT00000746|BIOLOGICAL|HIVAC-1e|
214412508|NCT00000746|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
214412509|NCT05730764|DIAGNOSTIC_TEST|Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making|With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results
214688659|NCT01351077|OTHER|CHICA DevScreen Module|This module assists in the diagnosis and management of developmental screening
215016309|NCT05610150|DEVICE|Myobrace Functional Appliance|An Appliance for treating growing Class II patients with mandibular deficiency
215016310|NCT05610150|DEVICE|Twin Block|An Appliance for treating growing Class II patients with mandibular deficiency
215016311|NCT05128344|DRUG|AMZ002 injectable solution, 0.5mg/mL|Injectable solution
215016312|NCT05128344|DRUG|Vigabatrin, oral|Oral administration
215016313|NCT00000810|DRUG|Delavirdine mesylate|
215016314|NCT00000810|DRUG|Zidovudine|
215101518|NCT00788710|DRUG|etoricoxib (MK0663) 120 mg|120 mg of etoricoxib (MK0663) for a total of 5 days
214412510|NCT05730764|DIAGNOSTIC_TEST|Clinicians follow a routine protocol|Treatment is performed by the clinician according to the usual protocol.
214412511|NCT02962336|DRUG|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|Oral, crossover
214412512|NCT02962336|DRUG|Tribenzor Tablets of Daichi Sankyo Inc, USA|Oral, crossover
214412513|NCT00832884|DRUG|Lacosamide|"0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes"
214412514|NCT05098340|GENETIC|Quantitative Real-time polymerase chain reaction|Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).
214412515|NCT03735771|DRUG|Bupivacaine|0.25% bupivacaine plus fentanyl 8 mcg/ml
214412516|NCT05464134|RADIATION|x-ray|plain radiographs of lower limb anteroposterior and lateral views , lumbar spine plain radiographs (anteroposterior, lateral, lateral in flexion and lateral in extension views )
214412517|NCT04490148|DEVICE|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
214412518|NCT04490148|DEVICE|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
214412519|NCT04490148|BEHAVIORAL|Nurse Respiratory Health Coaching (NRHC)|"Nurse Respiratory Health Coaching - The NRHC intervention follows the teamlet model described by Bennett et al. \[Bennett2010\], made up of the research coordinator who performs respiratory testing, and the nurse practitioner who coaches using the GROW (goals, realities, options, wrap-up) model."
214412520|NCT06057220|OTHER|No intervention sample collection only|No intervention
214412521|NCT02205931|OTHER|Ketogenic diet|The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.
214412522|NCT02205931|DRUG|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
214412523|NCT05001906|BEHAVIORAL|Exercise group|The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
214412524|NCT03255772|DIAGNOSTIC_TEST|Magnetocardiography|Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
214412525|NCT00119899|PROCEDURE|FDG-PET scan|
214688660|NCT05553756|DIETARY_SUPPLEMENT|Maltodextrin|200 ml maltodextrin given 2 hours before cesarean section
214688661|NCT05163990|OTHER|transcutaneous acupoint electrical stimulation|The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
214412526|NCT06135831|OTHER|Functional olive paste|Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.
214412527|NCT06135831|OTHER|Calciovitmag (CDCaMg)|Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day
214412528|NCT06135831|OTHER|Phosporovitmag (PDCaMg)|Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily
214412529|NCT06135831|OTHER|Control|Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily
214412530|NCT01879371|DRUG|Ibuprofen+caffeine FDC|oral dose
214412531|NCT01879371|DRUG|Ibuprofen (Nurofen Immedia®)|oral dose
214412532|NCT01879371|DRUG|Ibuprofen (Brufen®)|oral dose
214412533|NCT01723670|DRUG|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
214412534|NCT01723670|DRUG|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
214412535|NCT01723670|DRUG|Placebo|oral tablet,once a day for 24 months
214412536|NCT00624546|DRUG|Prevacid Solutabs|BID Prevacid Solutabs
214412537|NCT00624546|PROCEDURE|Antireflux surgery|Lap Nissen
214412538|NCT06266650|OTHER|Osteopathic Treatment Technique- Muscle Energy Treatment|Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.
214412539|NCT03014050|DEVICE|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
215016315|NCT00000810|DRUG|Didanosine|
215016316|NCT02660346|DRUG|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
215016317|NCT02660346|DRUG|Vancomycin|Control Arm Treatment
215016318|NCT02660346|DRUG|Ceftaroline|Study Arm Treatment
214412540|NCT04034758|PROCEDURE|Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)|heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
214412541|NCT04034758|PROCEDURE|placebo capsule|Oral administration of 30 placebo capsule containing edible pigmented starch
214412542|NCT04187157|DEVICE|Blue-light filtering intraocular lens|Bilateral implantation of blue light-blocking intraocular lens
214688662|NCT03548597|DEVICE|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
214412543|NCT04187157|DEVICE|Conventional intraocular lens|Bilateral implantation of conventional intraocular lens
214412544|NCT01492387|OTHER|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
214412545|NCT02945267|DRUG|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
214412546|NCT02945267|DRUG|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
214412547|NCT05045872|DRUG|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
214688663|NCT02743403|DEVICE|Neurodyn Portable activeTENS, IBRAMED®|Randomization and secret Allocation active TENS (GI / n = 27)
214412551|NCT05450029|DRUG|Sintilimab|6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
214688664|NCT02743403|DEVICE|Neurodyn Portable placeboTENS, IBRAMED®|Randomization and secret Allocation placebo TENS (GII / n = 27)
214688665|NCT02743403|DEVICE|Carboxyderm S20-1C|Randomization and secret Allocation control group (CG / n = 27).
214688666|NCT01531491|PROCEDURE|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
214688667|NCT01531491|PROCEDURE|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
214688668|NCT04801537|OTHER|normal body temperature and warm extremities|environmental temperature is set according to the standard method to keep normal body temperature and warm extremities
214412552|NCT06166719|OTHER|No intervention|No intervention
215016319|NCT01415687|DRUG|Polyethylene Glycol-Based Lavage|"Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours."
214688669|NCT04801537|OTHER|normal body temperature and cold extremities|environmental temperature is set according to the standard method to keep normal body temperature, but cold extremities
214688670|NCT01171547|DRUG|Daptomycin|once daily over 5 days
214688671|NCT00389896|DRUG|MK0733 / Duration of Treatment: 18 Weeks|
214688672|NCT00389896|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
214688673|NCT02122861|BIOLOGICAL|ID-LV305|pembrolizumab
214688674|NCT01617681|DRUG|VAL489|Valsartan 3mg/kg oral solution
214688675|NCT01617681|DRUG|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
215016320|NCT01415687|DRUG|Pico-Salax (Magnesium Citrate) plus Bisacodyl|"If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre."
214688676|NCT02599766|OTHER|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
214688677|NCT02599766|OTHER|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
214688678|NCT00549237|DIETARY_SUPPLEMENT|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
214688679|NCT00549237|OTHER|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
214688680|NCT03311607|DRUG|AmBisome|A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
214688681|NCT00556361|DRUG|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
214688682|NCT00556361|DRUG|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
214688683|NCT01883440|DRUG|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
214412553|NCT04035512|OTHER|Expressive writing|"The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004."
214412554|NCT06366594|BEHAVIORAL|Authentic leadership training program|37 first-line nurse managers received authentic leadership training program
214412555|NCT02121418|DRUG|Cytarabine|Given IV
214412556|NCT02121418|DRUG|Decitabine|Given IV
214412557|NCT02121418|OTHER|Laboratory Biomarker Analysis|Correlative studies
214412558|NCT04856228|DIAGNOSTIC_TEST|diagnostic posterior interosseous nerve lidocaine injection|ultrasound guided posterior interosseous nerve and lateral epicondyle 1 ml 2% lidocaine injection
214412559|NCT03906630|DIAGNOSTIC_TEST|Telehealth clinical exam|This is a pseudo telehealth clinical exam for patients presenting with shoulder pain
214412560|NCT03906630|DIAGNOSTIC_TEST|Standard clinical exam|This is a standard in-person clinical exam for patients presenting with shoulder pain
214412561|NCT00946751|DRUG|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
214412562|NCT00946751|DRUG|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
214412563|NCT04087746|DRUG|Aflibercept|Intra-vitreal injection of AVEGF AFLIBERCEPT in group I
214412564|NCT04087746|DRUG|Ranibizumab|Intra-vitreal injection of AVEGF Ranibizumab in group 2
214412565|NCT03762330|BEHAVIORAL|COPD structured self-management plan.|Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations
214412566|NCT03691961|OTHER|Hair sampling|After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.
214412567|NCT03691961|DIAGNOSTIC_TEST|Hair's drug concentrations|The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.
214412568|NCT01913119|DRUG|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
214412569|NCT02929511|PROCEDURE|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
214412570|NCT02929511|PROCEDURE|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
214412571|NCT02929511|PROCEDURE|Active comparator Protaper multi-file system|
214412572|NCT01134419|OTHER|Computerized handoff tool|Informatics tool to aid in transfer of patient care information
214688684|NCT01883440|DRUG|Saline+glucose|Placebo arm
214412573|NCT01134419|OTHER|Team training|Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
214412574|NCT01923948|DRUG|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
214412575|NCT01923948|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
214412576|NCT00004192|BIOLOGICAL|filgrastim|
214412577|NCT00004192|BIOLOGICAL|pegfilgrastim|
214412578|NCT00004192|DRUG|cisplatin|
214412579|NCT00004192|DRUG|cytarabine|
214412580|NCT00004192|DRUG|etoposide|
214412581|NCT00004192|DRUG|methylprednisolone|
214412582|NCT00540813|DEVICE|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
214412583|NCT03978533|BEHAVIORAL|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
214412584|NCT00002290|DRUG|Zidovudine|
214412585|NCT00002290|DRUG|Acyclovir|
214412586|NCT03533556|DIETARY_SUPPLEMENT|L-theanine|Oral administration of 2.5 mg/kg body weight of L-theanine dissolved in 100 ml of water
214412587|NCT03533556|DIETARY_SUPPLEMENT|Caffeine|Oral administration of 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
214412588|NCT03533556|DIETARY_SUPPLEMENT|L-theanine-Caffeine Combination|Oral administration of a combination of 2.5 mg/kg body weight of L-theanine and 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
214412589|NCT03533556|OTHER|Placebo|Oral administration of 100 ml of water
214412590|NCT00683410|BIOLOGICAL|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
214412591|NCT01848548|PROCEDURE|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
214412592|NCT02580448|DRUG|Seviteronel|Seviteronel given daily with evening meal in 28 day cycles
214412593|NCT00500500|DRUG|EGb 761® (Tanakan®)|
214412594|NCT04980261|PROCEDURE|ORIF + autograft|Patients will undergo a standard open reduction internal fixation (ORIF) procedure with autograft implantation (from the iliac crest).
214412595|NCT04980261|PROCEDURE|ORIF + FD BHA/Secretome|Patients will undergo an ORIF procedure and subsequently receive freeze-dried bovine hydroxyapatite/secretome composite implantation.
214412596|NCT03068611|BEHAVIORAL|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
214412597|NCT03068611|BEHAVIORAL|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
215016321|NCT03044912|DRUG|mirabegron|To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome
214412598|NCT02144350|PROCEDURE|Hyperbaric oxygen|patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
214412599|NCT02144350|PROCEDURE|Sham Hyperbaric Air|Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
214412600|NCT05653037|DRUG|RBD4059|Subcutaneously Administered RBD4059 in Healthy Subjects.
214412601|NCT05653037|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
214412602|NCT00002932|DRUG|cisplatin|
214412603|NCT00002932|RADIATION|radiation therapy|
214412604|NCT03241888|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
214688685|NCT03411746|OTHER|Subarachnoid haemorrhage|Data on the type of patients enrolled have been described already in other sections.
215016322|NCT06500936|OTHER|SMS|The intervention included two series of SMS messages. First, women of IG received one weekly SMS messages for 2 weeks. Those women that did not register a mammography in SITAM 45 days after the 2nd message, received the second series, consisting of one weekly SMS message over two weeks.
214412605|NCT03241888|DEVICE|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
214412606|NCT06630312|DIETARY_SUPPLEMENT|Alpha galactosidase|Alpha galactosidase capsule, 600 GALU, manufacturer Equate brand, Walmart. Powder contents from one capsule were stirred into 16 g spaghetti sauce and served before the main meal.
214412607|NCT06630312|DIETARY_SUPPLEMENT|Placebo|Placebo is 16 gm of spaghetti sauce served before the meal in a condiment cup. It is the same set up as the intervention except the \&#39;intervention\&#39; contains the AGS.
214412608|NCT06629935|PROCEDURE|orthognathic surgery|Le Fort I surgery
214412609|NCT06631742|OTHER|Exergaming on Dividat Senso|"The active dance video game is played with the Dividat Senso (Dividat \| Senso: cognitive-motor training). It consists of a dance disc with four arrows (up, down, left, right), and the game is played on a large screen (which is connected to the PC). The screen indicates which arrow the person should step on, thus controlling the game through body movements. The games give the person feedback in the form of auditory, visual, and somatosensory stimuli."
214412610|NCT06631742|OTHER|Usual Care|Standardised care with meal service, individual activities (e.g. hiking group, walking group, exercise group, handicrafts, gardening group, singing, painting or lunch) and customized care and support as required.
214412611|NCT04674449|DIAGNOSTIC_TEST|Disclosure of IDP results|The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.
214412612|NCT04674449|OTHER|IDP performed but results not disclosed|The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
214688686|NCT03200457|DEVICE|1,5 Tesla abdominal MRI|Measurement of the fat and iron
214412614|NCT04005521|BEHAVIORAL|Preventive intervention|Preventive, structured exercise protocol
214412615|NCT05926505|DRUG|Placebo|Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
214412616|NCT05926505|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
214412617|NCT03999021|DRUG|NAC effervescent tablets|After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
214412618|NCT02232763|DRUG|Losartan|12 weeks of losartan or placebo with crossover to the other
214412619|NCT02232763|DRUG|Placebo|12 weeks of losartan or placebo with crossover to the other
214412620|NCT05258006|PROCEDURE|Autogenous demineralized dentin nanoparticles|Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
214412621|NCT02540044|BEHAVIORAL|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
214412622|NCT02540044|BEHAVIORAL|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
214688687|NCT03200457|DEVICE|3 Tesla abdominal MRI|Measurement of the fat and iron
215016323|NCT06796062|DRUG|Psilocybin|One capsule (1 mg, 20 mg, or 30 mg) administered once orally
215016324|NCT05807893|DRUG|Serplulimab combined with bevacizumab and first-line chemotherapy|Serplulimab combined with bevacizumab and first-line chemotherapy
215016325|NCT03168815|DEVICE|High Flow Nasal Cannula or Low Flow Nasal Cannula|HFNC vs LFNC
214412623|NCT01103973|BEHAVIORAL|Mind/Body Program|Ten week group mind/body program
214412624|NCT01103973|BEHAVIORAL|Control|Spa gift certificates
214412625|NCT05335681|BEHAVIORAL|WARM SHOWER APPLICATION|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen and groin areas will be applied. Since possible complications may be encountered, pregnant women The researcher will be accompanied and sit safely in the chair. will be provided. VAS scale twice, before and after the intervention will be applied. Birth satisfaction scale before discharge will be applied.
214688688|NCT00035425|DRUG|linezolid|600mg every 12 hours
214688689|NCT00035425|DRUG|vancomycin|1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
214412626|NCT04109118|BEHAVIORAL|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a psychosocial intervention. It is paired with a benzodiazepine taper. The aim of the psychosocial intervention is to improve individuals' ability to tolerate distress in order to assist benzodiazepine discontinuation in patients treated with OAT. There will be 5 sessions between therapist and participant prior to the start of the benzodiazepine taper. The taper for both the intervention and control conditions occurs over 9 weeks and involves weekly meetings with a benzodiazepine prescriber during which a gradual benzodiazepine dose reduction will take place. The DT-BD intervention combines elements of existing psychosocial interventions. Specifically, interoceptive exposure techniques will be paired with elements of acceptance and commitment therapy (ACT) and relapse prevention (RP).
214412627|NCT04109118|DRUG|BZD discontinuation protocol|All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
214412628|NCT01830842|DRUG|Nicotine polacrilex|nonsmokers will be measured following nicotine administration
214412629|NCT01830842|DRUG|Placebo|nonsmokers will be measured following placebo administration
214412630|NCT01830842|OTHER|satiety|smokers will be measured in a smoking satiated condition
214412631|NCT01830842|OTHER|abstinence|smokers will be measured following 24-hours of smoking abstinence
214412632|NCT03235349|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
214412633|NCT04432974|DEVICE|Automatic closed-loop anesthesia|Total intravenous anesthesia performed with the ACTIVA automatic control system
214412634|NCT03553615|DRUG|Ivermectin Pill|oral anti-parasitic agent taken as a weekly dose for four weeks
214412635|NCT05601583|DEVICE|Continuous Glucose Monitor (CGM)|FDA-cleared FreeStyle Libre Glucose Monitoring System manufactured by Abbott. Integrated continuous glucose monitoring system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts.
214412636|NCT05202080|OTHER|Opioid Counseling and Pain Coping Skills Video|The intervention will be in the form of a video of a PowerPoint presentation with instructions and exercises designed to coach patients about catastrophizing, coping skills, mindfulness and behavioral modification techniques, in addition to providing education regarding postoperative analgesia and opioid use.
214412637|NCT06156007|BEHAVIORAL|progressive muscle relaxation exercises|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
215101519|NCT00788710|DRUG|Comparator: Placebo|Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
214412638|NCT03879447|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.
214412639|NCT03879447|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
214412640|NCT03879447|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
214412641|NCT03879447|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
214688690|NCT03514303|DIAGNOSTIC_TEST|Spiriplex Allergenex Microassay|A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
215016326|NCT04421768|BEHAVIORAL|cervical exam training|Each nurse will then examine 1 sets of 10 high-fidelity silicone task trainers approximately three per week for a maximum of 20 sessions (200 repetitions total). For each set of 10 exams, the estimates will recorded on an answer sheet. A cumulative summation analysis will be performed on each participant. When an individual nurse achieves competence her training will be suspended
215016327|NCT04535011|BEHAVIORAL|PPKAY (brief intervention)|PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.
215016328|NCT04535011|BEHAVIORAL|Standard Booster|After discharge from the hospital, a standard motivational text message will be sent to their cell phone twice monthly for the duration of the study. In a rotating fashion, one of four standard motivational texts translated into Swahili will be sent to their cell phones.
215101520|NCT00788710|DRUG|etoricoxib (MK0663) 90 mg|90 mg of etoricoxib (MK0663) for a total of 5 days
215101521|NCT00324376|DRUG|Sevelamer hydrochloride|
215101522|NCT01978626|BEHAVIORAL|App modules|
215016329|NCT04535011|BEHAVIORAL|Personalized Booster|After discharge from the hospital, a personalized motivational text message will be sent to participant cell phones twice monthly for the duration of the study. In a rotating fashion, one of four personalized motivational texts will be sent to their cell phones. Personalized texts will be created with the content obtained from the motivational interview sessions. At each session, the research nurse conducting the intervention will record four messages based on the content of the session to be sent as the Personalized Booster.
215016330|NCT06964568|DRUG|PD-1 inhibitor|PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.
215101523|NCT01978626|BEHAVIORAL|Traditional CBT-I|
214412642|NCT03879447|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214412643|NCT03879447|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
214412644|NCT03879447|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
214412645|NCT03879447|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
214688691|NCT03526003|DIAGNOSTIC_TEST|Measurement of esophageal pressure|Measurement of esophageal pressure during posture changes and pneumoperotoneum
215101524|NCT04995861|PROCEDURE|Adductor canal block and IPACK block|Peripheral nerve blocks
214688692|NCT02241395|BIOLOGICAL|Intrathecal autologous bone marrow mononuclear cell transplantation|
214688693|NCT03696758|PROCEDURE|Pulmonary Function Testing|Subjects will undergo spirometry, Plethysmography, and diffusion capacity.
214688694|NCT03696758|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
214688695|NCT03696758|PROCEDURE|Cardiac Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
214688696|NCT03696758|DRUG|Metoprolol|Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
214688697|NCT03696758|DRUG|Sildenafil|Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
214688698|NCT02083510|DRUG|Colchicine|
215016331|NCT06964568|RADIATION|TDLN-sparing radiotherapy|Tumor draining lymph nodes-sparing radiotherapy 50.4Gy/28Fx
215016332|NCT06964568|RADIATION|Unlimited radiotherapy|Unlimited radiotherapy 50.4Gy/28Fx
215016333|NCT02458300|OTHER|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
215016334|NCT02458300|OTHER|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
215101525|NCT05974813|DIETARY_SUPPLEMENT|L-Citrulline|6 g (3 g every 12 h) of L-citrulline for six days
214412646|NCT05749029|BEHAVIORAL|Four Week Self-Compassion Course|"This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~1. The Foundations of Self-Compassion~2. Developing your Compassionate Self~3. Deepening the Compassionate Relationship with Yourself~4. Self-compassion in Everyday Life."
214412647|NCT05761509|DRUG|Doravirine|The study treatments will used during 28 days according to the routine care of each investigator center.
214412648|NCT06111508|DEVICE|Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs|A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform
214688699|NCT00587821|OTHER|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
214688700|NCT02422953|DIETARY_SUPPLEMENT|Wheat Soya Blend (WSB)|A monthly ration of 5 Kg of Wheat Soya Blend (WSB) will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
214688701|NCT02422953|DIETARY_SUPPLEMENT|Wawa Mum|Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
214688702|NCT02422953|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|Children 24-59 months of age will receive a sachet of Micronutrient Powders (MNP) in alternate days
214688703|NCT02422953|BEHAVIORAL|Behavior change and preventive health massages|Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
214688704|NCT03657680|OTHER|Evaluation|The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
214688705|NCT04386564|DIAGNOSTIC_TEST|mRNA in urine test|Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
214688706|NCT01785433|DRUG|Tiotropium HFA BAI 4.5 mcg|
214688707|NCT01785433|DRUG|Tiotropium HFA BAI 9.0 mcg|
214688708|NCT01785433|DRUG|SPIRIVA® HandiHaler® 18 mcg/day|
214688709|NCT01785433|DRUG|Spiriva® Respimat® 5 mcg/day|
214688710|NCT01613287|DEVICE|TheraSorb® - Ig flex|"TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.~5 treatments performed over 5 to 8 consecutive days."
214688711|NCT02939144|DIETARY_SUPPLEMENT|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
215101526|NCT05974813|DIETARY_SUPPLEMENT|Placebo|6 g (3 g every 12 h) of maltodextrin for six days
215101527|NCT02689167|DRUG|Sunitinib|
215101528|NCT00102427|BEHAVIORAL|Telephone-based collaborative care management|
214412649|NCT06310993|OTHER|Exercise|Exercise programme is the intervention for this study
214412650|NCT06641778|OTHER|Fecal Microbiota Transplantation|Patients in the experimental group received conventional antibiotic therapy plus fecal microbiota transplantation, and the efficacy was compared with that in the control group
214688712|NCT03899129|PROCEDURE|simultaneous working length control using E-CONNECT S|E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).
214412651|NCT03834844|BEHAVIORAL|Meditation|Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
214412652|NCT03834844|OTHER|AF Education|6 weekly education modules on topics related to AF
214688713|NCT03899129|PROCEDURE|separate length determination and root canal preparation using Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
214688714|NCT01649739|DRUG|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
214412653|NCT03834844|OTHER|Phone Calls|Weekly phone call to discuss patient concerns or questions
215016335|NCT02458300|OTHER|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
215016336|NCT02458300|OTHER|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
215016337|NCT02458300|OTHER|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
215016338|NCT06406478|BEHAVIORAL|Schedule Change|This 4-day workweek is defined by any 4 ten hour shifts between Sunday and Saturday. It will be up to the discretion of participants in the intervention group to coordinate which 4 days they work. The 4 days will most likely be weekdays, but some participants may work weekends. If participants do any work from home, they will clock in remotely to account for the time.
215016339|NCT06406478|BEHAVIORAL|No Schedule Change|The control group will continue to work five days per week, receiving standard practice for the schedule policies at the participating study sites.
215016340|NCT03925714|OTHER|life style|life sryle control only
215016341|NCT03925714|DRUG|Metformin|metformin twice daily
215016342|NCT03925714|DRUG|Nigetella salivata|NS twice daily
215016343|NCT05352113|DRUG|SSRIs|SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
215101529|NCT02693379|DEVICE|D-VIA|"D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.~Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment."
214412654|NCT01021930|DEVICE|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
214412655|NCT03918577|OTHER|Caloric Vestibular Stimulation|Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (\<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.
214412656|NCT05735847|PROCEDURE|Total Knee Arthroplasty (TKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.
215101530|NCT01935414|DEVICE|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
215101531|NCT01935414|DEVICE|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
214412657|NCT05735847|PROCEDURE|Unicompartmental Knee Arthroplasty (UKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.
214412658|NCT06277817|OTHER|expiratory rib cage compression|Expiratory rib cage compression: The hands are placed on the lower third of the rib cage. During expiration, the end and sides of the patients' rib cage are gradually compressed with the hands.At the end of expiration, compression is released from the thorax to allow patients to take a free inspiration. After each compression, the patient is allowed to perform 3 breathing cycles.Expiratory rib cage compression is applied for 5 minutes.
214688715|NCT01057199|GENETIC|RNA analysis|
214688716|NCT01057199|GENETIC|gene expression analysis|
214688717|NCT01057199|GENETIC|mutation analysis|
214688718|NCT01057199|GENETIC|protein expression analysis|
214688719|NCT01057199|OTHER|fluorescence activated cell sorting|
214688720|NCT01057199|OTHER|laboratory biomarker analysis|
214688721|NCT02231658|DRUG|Liraglutide|
214688722|NCT02231658|DRUG|Lixisenatide|
215101532|NCT01338584|BEHAVIORAL|Pelvic floor muscle training 3 weeks before radical prostatectomy|Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
215101533|NCT01338584|BEHAVIORAL|Intensive preoperative pelvic floor muscle training|Patient started to learn pelvic floor muscle 3 weeks before surgery
215016344|NCT05352113|PROCEDURE|acupuncture|This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
215016345|NCT05352113|PROCEDURE|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
215016346|NCT05352113|DRUG|placebo|Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
215016347|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 500 mg given by intravenous infusion over 15 min
215016348|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 500 mg given by intramuscular injection
214412659|NCT06277817|OTHER|percussion vibration|Percussion :Percussion is performed 3-5 times on each area from a height of approximately 10 cm with the domed hand. . It starts from the right and left lower lobes and goes up.Vibration:The hand is firmly/strongly placed on the application area. The arm and shoulder are stretched and the fingers are gently vibrated or shaken gently. While the patient is exhaling, vibration is performed 3-5 times in each area, starting from the right and left lower lobes.
215016349|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 250 mg given by intramuscular injection
214412660|NCT02443792|PROCEDURE|Unicirc with tissue adhesive|As above
214412661|NCT02443792|PROCEDURE|Open Surgical|As above
214412662|NCT02900027|DRUG|APOC-III-L-Rx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
214412663|NCT02900027|DRUG|Placebo Comparator|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
214412664|NCT01560143|DRUG|Tigecycline|100 mg IV as a single infusion over 30 minutes
214688723|NCT01835496|DRUG|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
214412665|NCT04523181|DRUG|Antroquinonol|double-blind for antroquinonol and Placebo with same out-look and same frequency.
214412666|NCT04523181|OTHER|Placebo|Capsule without active compound
214412667|NCT00919438|DEVICE|AVIVO™ Mobile Patient Management System|Non Invasive monitoring device
214412668|NCT01102361|PROCEDURE|Robotic Transperineal Biopsy|Saturation biopsy for previous negative patients
214412669|NCT01462019|DEVICE|Photobiomodulation|"the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.~The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions."
214688724|NCT01856595|DRUG|PF-06291874|The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
215016350|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 60 min
215016351|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 30 min
215016352|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 15 min
215016353|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab up to 3000 mg given by intravenous infusion over 90 min
215016354|NCT03492112|DEVICE|HCV RNA Point of Care|Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
215016355|NCT03492112|DRUG|Sofosbuvir/velpatasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
215016356|NCT03492112|DRUG|Glecaprevir/pibrentasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
215016357|NCT03499665|BEHAVIORAL|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.
215016358|NCT03499665|BEHAVIORAL|Myofascial Releasing Maneuvers and Home Exercises Group|In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.
215016359|NCT03499665|BEHAVIORAL|Control Group|In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
214412670|NCT04391309|BIOLOGICAL|anti-CD14|4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
214412671|NCT04391309|OTHER|Placebo|Placebo administered intravenously on Days 1-4
214412672|NCT04391309|DRUG|remdesivir|Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
214412673|NCT04682756|DIAGNOSTIC_TEST|The model of machine learning|Early diagnosis of NTEMI patients by machine learning model
214412674|NCT04485741|DEVICE|RESP|The RESP device will be placed on the patient for periodic recording of auscultory sound.
214688725|NCT01856595|DRUG|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
214688726|NCT04426825|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
214688727|NCT04426825|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
214412675|NCT00207129|DRUG|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
214412676|NCT00207129|DRUG|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
214412677|NCT06488599|RADIATION|Peri-apical radiographs on the implants|Peri-apical radiographs on the implants supporting the prosthesis
214412678|NCT01155869|DRUG|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
214412679|NCT01155869|DRUG|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
214412680|NCT01756287|OTHER|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
214412681|NCT05803330|DRUG|Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma|Abandonment of intravenous volume expansion with alpha-blockers during preoperative preparation in patients with pheochromocytoma
214412682|NCT00885508|DRUG|Lenalidomide|"1. Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~2. Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~3. Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
214412683|NCT01843465|OTHER|Maneuvers for documenting the disconnection|
214412684|NCT06007144|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only~Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
214688728|NCT06387888|OTHER|Listening to mother's voice|During the care, from the beginning to the end, mother's voice was played to the newborns. It took about 20 minutes. The mini Bluetooth speaker and the decibel meter were disinfected with the rapid surface disinfectant used in the clinic. The speaker was placed 30 cm away from the infant's ear and the sound level in the incubator was adjusted to be 50-60 dB by using a decibel meter (Official Gazette, 2018). Mother's voice was played from the beginning of the provision of care and continued for 15 minutes after the end of the provision of care. During the provision of care, COMFORTneo scores, pain scores, and vital signs were measured and recorded on the vital signs follow-up form.
214688729|NCT00395252|DRUG|Cetuximab (Erbitux®) and Gemcitabine|"Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion"
214688730|NCT02002442|OTHER|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
214688731|NCT02882399|OTHER|Shortystrap|
214412685|NCT04811287|DEVICE|Carpal Tunnel Release with Platelet-Rich Plasma|CTR is performed with adjuvant PRP placed intra-operatively.
214412686|NCT04811287|PROCEDURE|Carpal Tunnel Release without Platelet-Rich Plasma|CTR is performed without adjuvant PRP placed intra-operatively.
214412687|NCT05623995|DRUG|PCSK9 inhibitor|Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..
214412688|NCT05623995|DRUG|Statin|Guideline recommended statin therapy.
214412689|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
214412690|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
214412691|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
214412692|NCT03396913|DEVICE|IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
214412693|NCT03396913|DEVICE|Sham IPL|Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
215101534|NCT04463667|OTHER|exercise|Collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.
215101535|NCT05409937|OTHER|Water-saturated Improved Hot Weather Combat Uniform|Water-saturated Improved Hot Weather Combat Uniform
215101536|NCT05409937|OTHER|Water-saturated Army Combat Uniform|Water-saturated Army Combat Uniform
215101537|NCT05409937|OTHER|Water-saturated Army Combat Uniform + Silk Weights|Water-saturated Army Combat Uniform + Silk Weights
215101538|NCT06197763|DRUG|Colesevelam|625 mg tablets - 3 tables twice per day of Colesevelam or placebo for 6 weeks (crossover), interspersed by 8 week of washout time.
215101539|NCT06197763|OTHER|Control Arm|No Treatment: baseline assessment only
214412694|NCT03396913|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
214412695|NCT00303849|DRUG|Carboplatin|Given IA
214412696|NCT00303849|DRUG|Etoposide|Given IV
214688732|NCT04346628|DRUG|Favipiravir|Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).
214688733|NCT04346628|DRUG|Placebo|Placebo to match favipiravir administered orally through day 10.
215016360|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 1|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
215016361|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 2|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
215016362|NCT06466603|DIETARY_SUPPLEMENT|Placebo Group|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
215016363|NCT03238157|DRUG|Fluocinolone Acetonide (FA) implant|Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
215016364|NCT04518670|DEVICE|Comaneci Embolization Assist Device|assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm.
215016365|NCT05199155|BIOLOGICAL|NerVFIX|Decellularized, freeze-dried and sterile allogeneic graft of artery or vein from umbilical cord use by the investigator as a nerve regeneration conduit
215016366|NCT04381377|DRUG|azoximer bromide|Investigational medicinal product
215016367|NCT04381377|OTHER|Placebo|Placebo
215016368|NCT06964139|OTHER|Surgical video grading|Videos of fellow surgical cases will be randomized in sequence and provided to a masked grader who will review cases and record primary and secondary endpoints.
214412697|NCT00303849|DRUG|Etoposide Phosphate|Given IV
215016369|NCT03142958|DEVICE|Integra Cadence Total Ankle System|Primary or revision on total ankle replacement
215016370|NCT05420454|DRUG|Docetaxel|75 mg/m2, d1, q3w,6 cycles
215016371|NCT05420454|DRUG|Carboplatin|AUC 6, d1, q3w ,6 cycles
215016372|NCT05420454|DRUG|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w ,6 cycles
215016373|NCT05420454|DRUG|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w,6 cycles
215016374|NCT05420454|DRUG|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
215016375|NCT05420454|DRUG|Epirubicin|90 mg/m2,d1, q3w × 4 cycles,followed by docetaxel
215016376|NCT05420454|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel
215016377|NCT05420454|DRUG|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
214412698|NCT00303849|OTHER|Laboratory Biomarker Analysis|Correlative studies
214412699|NCT00303849|DRUG|Mannitol|Given IA
215016378|NCT05420454|DRUG|Epirubicin|90 mg/m2,d1, q2w × 4 cycles,followed by nab-paclitaxel
215016379|NCT05420454|DRUG|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
215016380|NCT05420454|DRUG|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
215016381|NCT02819544|DRUG|Sodium chloride administration|Sodium chloride administration
214412700|NCT00303849|DRUG|Melphalan|Given IA
214412701|NCT00303849|OTHER|Quality-of-Life Assessment|Ancillary studies
214412702|NCT00303849|DRUG|Sodium Thiosulfate|Given IV
214412703|NCT04989322|DRUG|Pembrolizumab|200 mg Q3W
214412704|NCT04989322|DRUG|Lenvatinib|8 mg daily
214412705|NCT04989322|DRUG|Pemetrexed|500 mg/m2 Q3W
214412706|NCT04989322|DRUG|Carboplatin|AUC5 Q3W
214412707|NCT06217354|DRUG|Carbetocin 100 Microgram/mL Solution for Injection|All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[PabalVR, Ferring AG, Baar, Switzerland\]).then assess uterine contractility and postpartum bleeding measuring
214688734|NCT04346628|OTHER|Standard of care treatment|Standard of care treatment for COVID-19 infection
214688735|NCT00260637|PROCEDURE|Acupuncture|
214688736|NCT00227383|DEVICE|Electroacupuncture (device)|
214688737|NCT01763905|BIOLOGICAL|Evolocumab|Subcutaneous injection
214688738|NCT01763905|DRUG|Placebo to Evolocumab|Subcutaneous injection
214688739|NCT01763905|DRUG|Ezetimibe|Tablet for oral administration
214688740|NCT01763905|DRUG|Placebo to Ezetimibe|Tablet for oral administration
214688741|NCT00646971|DEVICE|CPAP device|for 4 weeks
214688742|NCT00646971|DEVICE|Placebo device|for 4 weeks
215016382|NCT02819544|DRUG|Ropivacaine administration|Ropivacaine administration
215016383|NCT06276348|GENETIC|Whole genome sequencing|Standard diagnostic whole genome sequencing will be performed.
215016384|NCT06276348|GENETIC|BeginNGS test|Genomic sequencing that screens for 434 genetic diseases.
215101540|NCT00006400|DRUG|Hydroxyurea|Participants will receive hydroxyurea.
215101541|NCT00006400|DRUG|Placebo|Participants will receive placebo.
215101542|NCT02933502|DRUG|DSXS topical product|treatment daily for 28 days
214412708|NCT00557843|DRUG|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
214688743|NCT03926559|DRUG|Morphine.|Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural. This will be a one time dose immediately postpartum.
214412709|NCT00557843|DRUG|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
214688744|NCT00878657|DRUG|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
214688745|NCT00878657|RADIATION|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
214688746|NCT00083070|DRUG|temozolomide|
214688747|NCT06122428|DRUG|modified hyaluronic acid 0.1% covalently linked to Riboflavin|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
214688748|NCT06122428|DRUG|hyaluronic acid 0.1%|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
214688749|NCT04514237|DRUG|BOS172767 enantiomer E1 or E2|Oral tablets
214688750|NCT04514237|DRUG|Placebo|Oral tablets
214688751|NCT06519006|PROCEDURE|Pelvic floor exercise|Exercises aimed at this issue consist of identification and isolated contraction of the pelvic floor muscles as well as their activation during complex movements and daily activities. During the engagement of the pelvic floor muscles, the correct engagement of the respiratory activity is important. Within the exercise units, exercises are used from sphincter contraction, through the gradual activation of individual pelvic floor layers in various ways, to their complex involvement in movement activities. Exercises are practiced repeatedly, at different frequencies and intensities that gradually increase, 4-5 times per day.
214688752|NCT02640846|DRUG|Norepinephrine|Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
214688753|NCT02640846|DRUG|Milrinone|Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
214688754|NCT02640846|DRUG|Levosimendan|Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
214688755|NCT03051334|OTHER|diagnosed as bicuspid aortic valve|
214688756|NCT01000194|DIETARY_SUPPLEMENT|High fat meal|A high fat milkshake containing 55g of fat
215016385|NCT06276348|GENETIC|WES|Whole exome sequencing will be performed.
214412710|NCT02793427|BIOLOGICAL|blood sample collection|
214412711|NCT03342924|OTHER|Flanker Test and physical fitness test|Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
215016386|NCT02489045|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
215101543|NCT01201226|OTHER|Removal of half an ovary|Removal of half an ovary
215101544|NCT00087854|DRUG|Amonafide L-malate (drug)|
215101545|NCT04365452|DEVICE|Invia Motion|Invia Motion NPWT system at cesarean delivery
214412712|NCT03719209|OTHER|HealthVoyager|HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.
214688757|NCT05270538|DEVICE|Mask Zero Seam Virus Bac-Off Lupo® 98% Polyamide and 2% Elastane|The 26 participants allocated as G2 had to perform the physical exercise using the Zero Sewing Virus Bac-Off Virus® 98% Polyamide and 2% Elastane, in order to totally seal the nose and mouth.
215016387|NCT01341990|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
215016388|NCT01341990|DEVICE|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
215101546|NCT05391256|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|"Totally n=6 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 12 months Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.~An interventional package directed to the dispatchers is distributed and consists of an e-learning program, an AED -trainer placed at the dispatch center. Within the dispatcher decision tool - there is information how to inform the caller to retrieve the AED. The HEMS-coordinator reminds the dispatcher during the call on operational information. Monthly information to staff of project progress is provided."
215016389|NCT01341990|DEVICE|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
215016390|NCT03269786|DIAGNOSTIC_TEST|Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)|Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes
214412713|NCT03719209|OTHER|Standard Practice|Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
214412714|NCT02023372|OTHER|NuCel with Autograft|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
214412715|NCT05909943|DRUG|Ruxolitinib|Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.
214412716|NCT00296426|PROCEDURE|New technology - PAML|
215016391|NCT03269786|DEVICE|biannual ultrasonography|portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes
215016392|NCT06563349|DRUG|Intravenous magnesium sulfate|Intraoperative intravenous magnesium sulfate infusion.
215016393|NCT06563349|DRUG|Normal saline infusion|Intraoperative intravenous normal saline infusion.
214412717|NCT00005581|DRUG|cyclophosphamide|
215016394|NCT00077012|DRUG|QLT0074|
215016395|NCT00077012|DRUG|Photodynamic therapy|
215016396|NCT01701635|BEHAVIORAL|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
215016397|NCT01701635|BEHAVIORAL|usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
215016398|NCT04933227|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously (IV) on Day 1 of each 21-day cycle.
215016399|NCT04933227|DRUG|Tiragolumab|Tiragolumab 600 mg will be administered IV on Day 1 of each 21-day cycle.
215016400|NCT04933227|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle during Cycles 1-4.
215016401|NCT04933227|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2/d will be administered orally (PO) twice daily (bid) on Days 1-14 during Cycles 1-4.
215016402|NCT03014388|OTHER|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
215016403|NCT03014388|OTHER|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
215016404|NCT05623514|COMBINATION_PRODUCT|Trans-vaginal ultrasound|Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum
215016405|NCT06032715|BEHAVIORAL|BI (Brief Intervention)|Short structured individual behavioral intervention to reduce inappropriate usage of Z-hypnotics
215016406|NCT06651190|OTHER|Pain Caregiver Resource (PainCaRe)|The purpose of the PainCaRe mobile health app is to support parents of young children with cancer (between the ages of 2-11 years) to manage their cancer-related pain at home. The app will ask caregivers to completed a brief 6-question pain assessment once daily and complete ad hoc assessments as needed. Based on the results of the pain assessment, real-time, evidence-based pain management suggestions, including will be provided to parents. The purpose of the pilot randomized controlled trial (RCT) is to evaluate the feasibility of implementing PainCaRe in a future RCT. Please find attached the study protocol for reference.
215016407|NCT04150757|DRUG|Intranasal ketamine|Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
215016408|NCT05694637|BEHAVIORAL|Screening, Brief Intervention and Referral to Treatment (SBIRT) intervention consisting of the 5As, (Ask, Advise, Assess, Assist, Arrange)|"Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline."
215101547|NCT01577342|DRUG|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
215101548|NCT05049109|BEHAVIORAL|Integrated Telehealth After Stroke Care|"• 3 week and 8 week follow up visits with pharmacy through telehealth~Patients will provide home blood pressure monitoring kits at discharge for the first three months. The telemonitor that can send blood pressure readings, wirelessly or through telephone, to a secure server where study staff can look at the readings. Any blood pressure readings that are not within normal range will trigger an alert to be sent to study staff who will then follow up with the patient. A trained staff member will show the patient how to use the blood pressure monitor. Patients will be asked to take blood pressure at least 3 days per week and transmit the readings to study staff.~Patients will also be asked to wear an activity monitor starting at 4 weeks."
215101549|NCT05049109|BEHAVIORAL|Usual post-stroke follow-up care|"* 1-2 weeks follow up visit with primary care.~* 4-6 week and 12 week follow up visit with stroke practitioner~* At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life"
214412718|NCT00005581|DRUG|epirubicin hydrochloride|
214412719|NCT00005581|DRUG|fluorouracil|
214412720|NCT00005581|DRUG|paclitaxel|
214412721|NCT02391662|DRUG|Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 days 1,8 \& 15 in a 28 days cycle
214412722|NCT02391662|DRUG|Gemcitabine 1000 weeks 1,2,3/4|Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
214412723|NCT02796976|OTHER|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
214412724|NCT00475813|DRUG|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
214412725|NCT01300832|PROCEDURE|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
214412726|NCT03183024|BIOLOGICAL|benralizumab|open-label treatment
214412727|NCT03183024|BIOLOGICAL|placebo|sterile water to mimic benralizumab
214412728|NCT05019781|OTHER|Therapeutic tape|Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, \& Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.
214412729|NCT05019781|OTHER|Placebo tape|The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
214412730|NCT02814825|OTHER|ViviGen|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
214412731|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) (classic technique)|During CS , placement of CuT380 IUD at the top of the uterine fundus with ring forceps or manually; before closing the uterine incision, the strings were placed in the lower uterine segment. If the cervix was closed, dilatation from above with ring forceps or manually. Strings passed through the cervix with ring forceps, then checking that IUD remains at the fundus of the uterus prior to closing the uterine incision. The surgeon took a good care not to include IUD strings within the sutures. Six weeks postpartum; Patients will be questioned for any symptoms of complications or side effects. Pelvic examination (per speculum) and transvaginal ultrasound will be performed. Patient satisfaction will be assessed: pain using (VAS score), missed threads.
215016409|NCT05694637|DRUG|Varenicline|Referral to treatment with varenicline will be provided to those identified as needing more than a brief intervention. Participants will initiate medication treatment with varenicline for smoking cessation with a quit date scheduled for day 8 following first study dose of the medication. Participants will meet with the study clinician at baseline who will provide medical clearance and sign off on prescription orders. All medication will be provided to participants by the study team. Participants will receive a weekly supply of medication for the first four weeks to ensure proper dosing and monitor for adverse events. For the subsequent 8 weeks, participants will return every 4 weeks to receive the next month's supply of medication. Dosage adjustments will be permitted in an effort to control adverse effects throughout the trial. This will allow us to balance internal validity with good clinical practice. Varenicline will be dosed in accordance with package labeling.
215016410|NCT05028660|DIAGNOSTIC_TEST|GAG score|blood and urine samples to determine GAG scores
215101550|NCT04536207|OTHER|Cryotherapy (apparatus)|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
215101551|NCT04785599|BEHAVIORAL|Exercices|An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
215101552|NCT04785599|BEHAVIORAL|Informative talk|An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
214504959|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
215101553|NCT04785599|DEVICE|Compression garment|"Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity."
214504960|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
215016411|NCT04304703|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep, resting heart rate, and heart rate variability.
215016412|NCT06203964|OTHER|No intervention|No intervention
215016413|NCT02690376|DEVICE|Magnetic Assisted Capsule Endoscopy|Swallowed magnetic capsule for endoscopy purposes
214412732|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) ( New technique)|During CS, the plunger will be removed, the introducer remains in place and the arms of the IUD were released to be in a transverse position. The introducer will be inserted in the cervical canal through the uterine incision, threads might be shortened if needed or if couldn't be advanced into the cervical canal, The introducer containing the IUD will be then pushed upwards , towards the uterine fundus.The IUD will be placed at the uterine fundus and the IUD will be stabilized at its fundal position by grasping the fundus between the thumb anteriorly and the other fingers posteriorly. The uterine incision was closed while the introducer is in situ , then the introducer will be removed vaginally at the end of CS. Six weeks postpartum; Patients will be followed as in the classic technique group.
215016414|NCT01765998|DRUG|Probiotic|Clinical evaluation according to the Crohn's activity scale
214412733|NCT05756998|PROCEDURE|cesarian section|Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment \& the fetus is extracted , followed by the placenta \& membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis \& closure of the abdomen in layers .
214412734|NCT02431663|DRUG|Ketamine|Intravenous administration in continuous
214412735|NCT06340126|OTHER|Active release techniques|Active release techniques are soft tissue systems or movement-based techniques. It is used to treat muscles, nerves, fascia, ligaments, and tendons.
214412736|NCT06340126|OTHER|Relaxation exercises|Relaxation exercises include breathing exercises, pelvic floor exercises, and postural exercises. Exercises will be done in a sitting position
214412737|NCT03853733|RADIATION|rectal cancer radiotherapy|Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
214412738|NCT06550115|BEHAVIORAL|Time-restricted eating|Night shift workers will participate in 4 weeks of fasting during the biological nighttime while remaining awake during overnight work shifts.
214412739|NCT06550115|BEHAVIORAL|Control eating|Night shift workers will participate in 4 weeks of Control eating across the daytime and nighttime hours while remaining awake during overnight work shifts.
215101554|NCT00453804|DRUG|injectable naltrexone|
215101555|NCT00453804|DRUG|oral naltrexone|
214412740|NCT06390488|OTHER|Transcutaneous medial plantar nerve stimulation (T-MPNS)|T-MPNS will be conducted unilaterally in the supine position using the electrotherapy device with surface electrodes. Two round self-adhesive electrodes will be positioned, with the negative electrode near the metatarsal-phalangeal joint of the great toe on the medial aspect of the foot and the positive electrode approximately 2 cm inferior-posterior to the medial malleolus (in front of the Medio-Malleolar-Calcaneal axis). Channel 1 will provide active stimulation, while channel 2 will remain inactive.
215016415|NCT01765998|DRUG|Placebo|
215016416|NCT05276453|DEVICE|GMove Suit|12 week, home-based programme whereby participants are encouraged to use the GMove suit daily, for at least 30 minutes a day. Recommended activities include walking, sit-to-stand and step-ups
215101556|NCT06416254|OTHER|Fibre-enriched diet|The fibre-enriched diet contains fibre-enriched foods in which a portion of digestible carbohydrates are replaced with isolated dietary fibres. The fibre-enriched study foods are consumed as part of a full meal plan provided to participants.
215101557|NCT06416254|OTHER|Control diet|The control diet contains non-fibre-enriched study foods. The control study foods are consumed as part of a full meal plan provided to participants.
215101558|NCT06099834|OTHER|Patients selection|Patient selection were selected according to selected criteria.
215101559|NCT06099834|OTHER|Implnat placement|dental implants were applied as recommended by the manufacturer.
214412741|NCT06390488|OTHER|Sham Transcutaneous medial plantar nerve stimulation (T-MPNS)|Sham T-MPNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the T-MPNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
214412742|NCT05824351|DEVICE|Tanzanian beeswax-pine resin|Thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
214504961|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
214504962|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
215016417|NCT05276453|BEHAVIORAL|Normal therapy|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 30 mins a day of physical activity and have active physical therapy (physiotherapy) sessions.
215016418|NCT05265676|DRUG|Enoxaparin Sodium (Venus Remedies Limited)|The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
215016419|NCT05265676|DRUG|Enoxaparin Sodium (Sanofi)|The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
215016420|NCT02676427|PROCEDURE|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
214412743|NCT05824351|DEVICE|Domestic beeswax-pine resin|Thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
214412744|NCT05824351|DEVICE|Hollister's AdaptTM Barrier Rings|Thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
214412745|NCT02728986|DEVICE|Profore|Profore multilayer compression bandage + standard regimen for wound care according to investigator's choice
214412746|NCT02728986|DEVICE|Coban2|Coban2 compression system + standard regimen for wound care according to investigator's choice
214412747|NCT04913649|DRUG|Ferric Derisomaltose 100 MG/ML|Postoperative treatment with a single dose IVI (ferric derisomaltose), with a dose of 20mg/kg in approximately 60 minutes.
214412748|NCT04913649|DRUG|Sodium chloride|Postoperative treatment with a single dose NaCl 0.9% in approximately 60 minutes.
214412749|NCT05974605|BEHAVIORAL|MM+HighC|In this intervention, participants will be trained on a available mindfulness meditation app, followed by a working memory updating game, developed by Dr. Chandramallika Basak. This game requires high degree of attentional control (Unpredictable Bird Watch), also known as High-C. The app and the game are delivered through an Android tablet for this home-based training.
214412750|NCT06466499|BEHAVIORAL|The intervention group|Is described in arm
214412751|NCT05390580|DEVICE|transcutaneous auricular vagal nerve stimulation|Stimulus of the auricular branch of the vagal nerve with the transcutaneous auricular vagal nerve stimulation.
214412752|NCT05390580|DEVICE|Sham transcutaneous vagal nerve stimulation|Patients assigned to the controls arm will have no electricity applied to the Auricular Branch of the Vagus Nerve. Stimulus will be provided to the lobule of the ear, which is not innervated by the Auricular Branch of the Vagus Nerve.
214412753|NCT05953350|DRUG|600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib|hydroxychloroquine group of 600mg bid combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.
214412754|NCT05953350|DRUG|RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.|After the exploration of 600mg bid dose of hydroxychloroquine combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of 600mg bid dose of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
214412755|NCT05857293|DEVICE|Catheter-guided PDA stent implantation|PDA stent is the primary treatment for patients with duct-dependent pulmonary circulation. It serves as a temporary bridge for later surgical repair by keeping the duct patent to improve oxygen saturation
214412756|NCT00828945|DEVICE|Lipid Self Test|Self test for lipid levels, twice during study period
214412757|NCT00012467|DRUG|Itraconazole|
214412758|NCT00012467|DRUG|Flucytosine|
214688758|NCT04336592|BEHAVIORAL|Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)|Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.
214688759|NCT06324994|DRUG|Linperlisib in combination with Obinutuzumab and Venetoclax|Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles。 Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.
214688760|NCT04898374|DRUG|Gemcitabin/cisplatin|chemotherapy combination
214688761|NCT00256048|PROCEDURE|Nasojejunal feeding|
214688762|NCT00492947|BIOLOGICAL|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
215016421|NCT01678690|DRUG|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
214412759|NCT00012467|DRUG|Fluconazole|
214412760|NCT00012467|DRUG|Amphotericin B|
214412761|NCT00012467|DRUG|Interferon gamma-1b|
214412762|NCT06434857|PROCEDURE|Strength training in older adults with mild or non existent cognitive impairment|Strength training program applied to strength training group
214412763|NCT06434857|PROCEDURE|Multimodal excercise in older adults with mild or non existent cognitive impairment|Multimodal exercise program applied to multimodal exercise group
214412764|NCT01113515|DRUG|Esmolol hydrochloride|
214412765|NCT01113515|DRUG|Esmolol hydrochloride|
214412766|NCT01113515|DRUG|Esmolol hydrochloride|
214412767|NCT01113515|DRUG|Placebo gel|
214412768|NCT03319589|DIETARY_SUPPLEMENT|Supplement|locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
214412769|NCT02482233|BEHAVIORAL|ENDD (NJOY)|As described above.
214412770|NCT02482233|DRUG|NRT (NicoDerm CQ)|As described above.
214412771|NCT02482233|BEHAVIORAL|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
214688763|NCT04551573|DRUG|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
215016422|NCT02974231|RADIATION|Intensity-modulated radiation therapy|
215016423|NCT01309191|OTHER|Minoxidil|Over the counter Rogaine, twice a day for 8 weeks
215016424|NCT01309191|OTHER|Placebo|
215101560|NCT06099834|OTHER|Recall visits|Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W\&H, Sweden) devices.
215101561|NCT02403232|PROCEDURE|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
214412772|NCT02482233|BEHAVIORAL|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
214412773|NCT02482233|BEHAVIORAL|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure\_%20For%20Posting.pdf"
214412774|NCT03578523|OTHER|3 Tesla multiparametric MR|Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.
214412775|NCT03578523|OTHER|renal histopathology scoring|Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)
214412776|NCT03578523|BIOLOGICAL|Blood and urine sampling|"Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis"
214412777|NCT03578523|BIOLOGICAL|Iohexol clearance test|Iohexol clearance to measure GFR within 1 week of the scan session
214412778|NCT03917329|OTHER|ACT and PBS group workshop|Acceptance and Commitment Therapy and Positive Behaviour Support Group Workshop. Three sessions of approximately three hour duration. Groups will consist of 5-10 parents or 5-10 members of education staff. The group will include both didactic and experiential elements.
214412779|NCT06375356|BEHAVIORAL|Resistance Training|Strength exercises (3-4 sets each exercise) videos delivered electronically, participant self-tracks and self-progresses based on effort reported.
214504963|NCT05108363|BEHAVIORAL|Lifestyle modification program|Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.
214504964|NCT03903692|DEVICE|Marine polysaccharide dressing|The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
214688764|NCT04551573|DRUG|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
214688765|NCT02225444|OTHER|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
214694003|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using diode laser|"Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm attached with a power average set at 0.5-1.5 watt will be used.~The first pass laser troughing is done using a thin flexible fiber-optic cable 300 μm placed parallel to the root surface, attached with a power average set at 0.5-1 watt, in continuous mode. Ultrasonic scaler will be then used to remove calculus which present on the root surface. The second pass is carried out with 1-1.5 watt power in continuous mode, 10-30 seconds for each tooth, and, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed in order to enhance the healing"
215016425|NCT01751685|BEHAVIORAL|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
215016426|NCT01751685|OTHER|Control|monthly educational lectures on various topics
215101562|NCT02403232|DEVICE|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
215101563|NCT02403232|DEVICE|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
214412780|NCT04345523|OTHER|Blood and derivatives.|Administration of fresh plasma from donor immunized against COVID-19
214412781|NCT04345523|DRUG|Standard of Care|Standard of care for the treatment of COVID-19 in hospitalized patients
214412782|NCT03116282|BEHAVIORAL|E-alcohol therapy|Conversational therapy sessions provided via video conference by a professional alcohol therapist.
214412783|NCT03822351|DRUG|Durvalumab + Oleclumab|Durvalumab + Oleclumab
215101564|NCT00605345|DRUG|Darbepoetin alfa|As prescribed
214412784|NCT03822351|DRUG|Durvalumab|Durvalumab
214412785|NCT03822351|DRUG|Durvalumab + Monalizumab|Durvalumab + Monalizumab
214412786|NCT05367674|BEHAVIORAL|Summer Harvest Adventure|Biobehavioral intervention focusing on nutrition and lifestyle behaviors.
214412787|NCT05367674|BEHAVIORAL|My Summer Plate (MSP)|My Summer Plate (MSP)
214412788|NCT02882646|DEVICE|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
214412789|NCT06228742|OTHER|Unilateral leg immobilization|Participants will have one leg immobilized using a rigid knee brace. Participants will be expected to keep the knee brace on for 5 days and remain non-weight bearing on the immobilized leg. Participants will use crutches to remain non-weight bearing on the immobilized leg.
214412790|NCT06228742|OTHER|Contralateral active leg|One leg will remain non-immobilized and active during the study. Participants will use this leg to walk with crutches.
214412791|NCT02582411|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
214412792|NCT02582411|DEVICE|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
214412793|NCT02851810|BEHAVIORAL|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
215101565|NCT00605345|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
214412794|NCT02851810|BEHAVIORAL|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
214412795|NCT02851810|BEHAVIORAL|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
215101566|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS real treatment
214412796|NCT02851810|BEHAVIORAL|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
214412797|NCT02851810|BEHAVIORAL|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
214412798|NCT04272151|BIOLOGICAL|BCMA CAR-T cells|A single infusion of BCMA CAR-T cells will be administered intravenously.
214412799|NCT01227356|DRUG|imatinib and pegylated interferon|imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
214412800|NCT00369135|PROCEDURE|combined intervention|
214412801|NCT02157493|BEHAVIORAL|Arrowhead Business Group Curriculum|Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.
214412802|NCT02157493|BEHAVIORAL|Recreational League Control Condition|The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
215101567|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS SHAM treatment
215101568|NCT02956798|RADIATION|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
214412803|NCT03274102|BIOLOGICAL|Concomitant administration of EV71 vaccine with EPI vaccines|"1. The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
214504965|NCT03903692|DEVICE|Carboxymethylcellulose dressing|The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
214504966|NCT03646266|DRUG|Rocuronium Bromide|Titration with rocuronium bromide until tidal volume 6ml/kg PBW
214504967|NCT01209156|DRUG|[18F] PBR111|Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.
215101569|NCT01892891|DRUG|VBY-036|Cathepsin S inhibitor
215101570|NCT05759897|DRUG|HRS-7535|HRS-7535
214504968|NCT06132009|PROCEDURE|Surgery of endometriosis|Cystectomy or unilateral oophorectomy due to endometriosis
214504969|NCT03444415|OTHER|Motivational interviewing in groups|Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children.
214504970|NCT03444415|OTHER|Usual care|Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits
214504971|NCT02431741|DEVICE|Mepilex Transfer Ag|
214504972|NCT02052687|DRUG|LFX453 H1|LFX453 high dose cream 1
214504973|NCT02052687|DRUG|LFX453 L1|LFX453 low dose cream 1
214504974|NCT02052687|DRUG|LFX453 H2|LFX453 high dose cream 2
214504975|NCT02052687|DRUG|LFX453 L2|LFX453 low dose cream 2
214504976|NCT02052687|DRUG|Imiquimod|Imiquimod cream
214504977|NCT02052687|DRUG|Placebo 1|Placebo cream 1
214504978|NCT02052687|DRUG|Placebo 2|Placebo cream 2
214504979|NCT06353620|DIAGNOSTIC_TEST|High Density EEG recording|Recording of resting state high density EEG (128 channels)
214504980|NCT06353620|DIAGNOSTIC_TEST|Rey Complex Figure Test|Memeory functioning evaluation
214504981|NCT03408028|OTHER|Medical File consultation|Medical File consultation
214504982|NCT01685268|DRUG|AT13387|Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
214412804|NCT03274102|BIOLOGICAL|Single injection of EPI vaccine|"1. The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
214412805|NCT03274102|BIOLOGICAL|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
214412806|NCT00462943|DRUG|Omacetaxine mepesuccinate|"Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study."
214688766|NCT04628013|DEVICE|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied with a pair of 2x3 inch electrodes placed orthogonally to the knee joint line with one electrode on the medial and lateral sides of the knee. The device is a commercially available unit(Chattanooga Continuum, DJO Global, Vista CA) and the parameters of the NxES include: 400 μs biphasic square wave pulses delivered at 50-100 pulses/second, using a cycle time of 10-seconds on, with a 2-second ramp-up in intensity, followed by a 10-second off period. The current intensity will be dosed over the first 2-minutes of stimulation to find the sensory perception threshold and the threshold for the first perception of a sharp, prickly buzzing sensation that they would identify as painful. Next, the current intensity will gradually be increased until the participant reports a sharp or prickly buzzing sensation that achieves a pain rating of not more than a 5/10 using a numeric pain rating scale.
214688767|NCT05943977|DRUG|MB-102 DMID|130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
215016427|NCT04351815|BEHAVIORAL|Short term prehabilitation (2 weeks)|"* Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patient will be asked to follow a 2 weeks prehabilitation program~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
215016428|NCT04351815|OTHER|No specific intervention|"* Standard care: Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patients will be asked to maintain regular physical activity without support~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
215016429|NCT00002051|DRUG|Thymopentin|
214412807|NCT05186454|DRUG|Morphine Sulfate|analgesia
215016430|NCT02186067|OTHER|Referral System|"Primary Level:~Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)~Secondary Level:~Community health center at Aga Khan University will serve as the secondary care center.~Family physician will manage patients with CVD, CKD or more than 3 drugs.~Tertiary care:~Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.~Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months"
215016431|NCT01666613|DRUG|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
215016432|NCT01666613|DRUG|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
215016433|NCT01666613|DRUG|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
215016434|NCT01666613|DRUG|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
215016435|NCT01940146|DRUG|SPARC Placebo|Placebo
214412808|NCT05186454|DRUG|Bupivacaine|Analgesia
214412809|NCT05186454|DRUG|dexamethasone, morphine, midazolam|1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
214412810|NCT04784741|OTHER|Conventional static hamstring muscle stretching|Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.
214412811|NCT04784741|DEVICE|Low amplitude whole body vibration therapy|"Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.~Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle."
214412812|NCT04784741|DEVICE|Biodex Balance System|Pre and post balance assessment by Biodex balance system
214412813|NCT04784741|PROCEDURE|Range of motion of hamstring muscle|Straight Leg Raising to check pre and post Range of Motion by using Goniometer
214412814|NCT03166319|DIAGNOSTIC_TEST|MRI, including intracranial vessel wall imaging|MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
215016436|NCT01940146|DRUG|SPARC1310 I|SPARC1310 I
215016437|NCT01940146|DRUG|SPARC1310 II|SPARC1310 II
215016438|NCT01940146|DRUG|SPARC1310 III|SPARC1310 III
215016439|NCT01113957|DRUG|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
214412815|NCT05751200|OTHER|No Intervention.|No Intervention.
214412816|NCT01403675|PROCEDURE|Ovarian autotransplantation|There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
214412817|NCT02929069|BEHAVIORAL|ESTEEM|ESTEEM is a 10-session intervention based on the Unified Protocol, an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
214412818|NCT02929069|BEHAVIORAL|CMHT|CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
214412819|NCT02929069|BEHAVIORAL|VCT|Voluntary Counselling and Testing (VCT).
214412820|NCT03042793|BIOLOGICAL|PD-L1 peptide vaccine|PD-L1 peptide given subcutaneously with Montanide ISA-51
214412821|NCT05093712|OTHER|Educational Intervention|Watch educational video
214412822|NCT05093712|OTHER|Survey Administration|Complete surveys
214412823|NCT04742855|DIETARY_SUPPLEMENT|Probiotics|Study product is packaged as powders in a sachet. Participants and their parents will be instructed to dissolve the powder in water or milk, and to drink it in the morning and/or evening.
214412824|NCT04977960|DRUG|Potassium Canrenoate|potassium canrenoate for 7 days in addition to maximal medical treatment
214412825|NCT06037135|DRUG|dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery. The research nurse, who did not participate in the study other than the management and preparation of the study medication, prepared 50mL of 0.9% normal saline for the control group and a mixture of dexmedetomidine 2 mL and 0.9% normal saline 48 mL (at a concentration of 4 μg/mL) for the dexmedetomidine group.
214412826|NCT06037135|DRUG|0.9% normal saline|In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
214412827|NCT00469118|DEVICE|DRX9000™|Nonsurgical spinal decompression
214412828|NCT02454907|OTHER|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
214412829|NCT02611232|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
214412830|NCT02611232|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
214412831|NCT01845896|BEHAVIORAL|Training|
214412832|NCT01644162|DEVICE|iVAPS ventilation|3 months of ventilation on iVAPS mode
214412833|NCT04347499|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
214412834|NCT00044928|DRUG|Piperacillin/Tazobactam|
214412835|NCT02631499|PROCEDURE|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
214688768|NCT05943977|DRUG|MB-102 OMID|130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
214412836|NCT02631499|DRUG|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
214412837|NCT02631499|DRUG|lipiodol|lipiodol is a kind of embolization material used in TACE
214412838|NCT06182319|DRUG|Gastrografin|Administration of WSC (Gastrografin) 2 hours after placement of NGT.
214412839|NCT06182319|DRUG|Saline|Administration of Saline 2 hours after placement of NGT.
214412840|NCT06182319|PROCEDURE|SBO Treatment Without NG Tubes|Patients who decline to have NG tubes placed will be enrolled and followed with the same outcomes protocol as the other patients in the trial
214412841|NCT04164563|DEVICE|Even-Up|Orthotic shoe lift worn on contralateral foot to increase leg length
214412842|NCT01025869|DEVICE|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
215016440|NCT01113957|DRUG|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
215016441|NCT01113957|DRUG|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
214412843|NCT05092412|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
214412844|NCT05092412|DRUG|Durvalumab|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.
214412845|NCT05092412|DRUG|Etoposide, and cisplatin/carboplatin|Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.
215016442|NCT02712242|OTHER|Platelet Rich Fibrin|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
214412846|NCT06494748|OTHER|Follow up Decision|"0: No need to follow up in Intensive Care Unit~1: Need to follow up in Intensive Care Unit"
214412847|NCT02999581|DIETARY_SUPPLEMENT|C4 Extreme, C4 Extreme (without Advantra Z)|
215016443|NCT02712242|OTHER|Butyl cyanoacrylate|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
214412848|NCT06650787|OTHER|Ultrasound was used to locate the end of the gastric tube|"1. Inform the family of the purpose and method of using bedside ultrasound to guide the placement of the gastric tube, and determine the position of the end of the tube.~2. The ultrasound machine was connected to the power supply and placed on the right side of the patient.~3. Select the appropriate type of gastric tube and measure the length of the indwelling gastric tube by nursing staff before inserting the tube.~4. Nurses who had been trained in ultrasound performed ultrasound judgment on the neck and abdomen of the children. Sonographers, intensive care physicians and nursing staff jointly judged the ultrasound images.~5. Conventional judgment method was used to determine the position of gastric tube~6. Bedside chest radiography, with results obtained by a radiologist.~7. Keep your child safe at all times."
215016444|NCT02712242|OTHER|Wet gauze|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
215016445|NCT01249443|DRUG|vorinostat|Given PO
215016446|NCT01249443|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
215016447|NCT01249443|OTHER|pharmacological study|Correlative studies
215016448|NCT01249443|DRUG|carboplatin|Given IV
215016449|NCT01249443|DRUG|paclitaxel|Given IV
215016450|NCT05181657|BEHAVIORAL|COVID-19 education|This session will be completed within 45 minutes. The LinkUP intervention will be available in English and Spanish.
215016451|NCT01019551|DRUG|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
214412849|NCT06650787|OTHER|Conventional placing nasogastric tube group|"1. Choose the appropriate type of gastric tube, and measure the length of the indwelling gastric tube by the nursing staff before the tube insertion.~2. The gastric tube was inserted by the conventional blind insertion method.~3. The conventional judgment method was used to determine the position of the gastric tube.~4. Bedside chest radiography, with results obtained by a radiologist.~5. Keep your child safe at all times."
214412850|NCT05934773|DEVICE|KineAssist robotic treadmill|"A formal standardization procedure will be used. Prior to testing, the participant's weight, height, age, blood pressure, and resting heart rate will be recorded. Each session will take place over a 1 hour period. All of our participants will have 1 evaluation sessions prior to the training sessions (overground) and 1 evaluation sessions at the end of the training sessions (overground).~Each participant will have the training sessions up to 3 times each week. The total number of training sessions would be 12-16 sessions (based on duration of stay) of robotic treadmill training for, distributed equally over each specific training modality (Endurance x 4, Strength x 4, Speed x 4, and Dynamic Balance x 4)."
214412851|NCT05767450|DIETARY_SUPPLEMENT|Probiotic Vivomixx®|The correct number of Vivomixx® sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
214412852|NCT05767450|DIETARY_SUPPLEMENT|Placebo|The correct number of Placebo sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
214504983|NCT01685268|DRUG|abiraterone acetate|1000 mg PO daily.
214504984|NCT01685268|DRUG|Prednisone|5 mg PO twice daily.
214504985|NCT04921709|OTHER|Medical tests|Blood tests
214504986|NCT02124252|BEHAVIORAL|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
215016452|NCT01019551|BIOLOGICAL|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
215016453|NCT06114966|OTHER|CADCAM|Milling of Final prosthesis over dental implants using CADCAM milling machine
215016454|NCT04902066|OTHER|Cognitive Behavioural Virtual Reality Therapy.|Cognitive Behavioural Therapy augmented with Virtual Reality.
215016455|NCT04902066|OTHER|Traditional Cognitive Behavioural Therapy|Traditional Cognitive Behavioural Therapy for psychosis.
215016456|NCT03297827|OTHER|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic \& hemorrhagic stroke.
215016457|NCT04779723|PROCEDURE|Comparison of two Techniques of bariatric surgery|We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB
215016458|NCT04726488|PROCEDURE|Periareolar Approach in Minimally Invasive Cardiac Surgery (PAMI Technique)|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
215016459|NCT04726488|PROCEDURE|inframammary approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
215016460|NCT01978574|BEHAVIORAL|Intellectual Enrichment daily activities|A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
215016461|NCT01978574|BEHAVIORAL|Intellectual Enrichment documentary videos|Participants watch daily documentary videos.
215016462|NCT04701320|DRUG|Conventional glass ionomer|Conventional glass ionomer with enhanced mechanical and esthetic proberties
215016463|NCT04701320|DRUG|Nano hydroxyapatite reinforced glass ionomer|Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
215016464|NCT03053999|OTHER|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
215016465|NCT03053999|OTHER|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
215016466|NCT01594684|DEVICE|balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)|balloon inflation
215016467|NCT01594684|DEVICE|drug coated balloon inflation (Cotavance, Medrad Inc.)|Balloon inflation
215016468|NCT01594684|DEVICE|uncoated balloon (e.g. Admiral, Medtronic)|balloon inflation
215016469|NCT01594684|DEVICE|balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)|ballon inflation
214412853|NCT06437002|BEHAVIORAL|Mental Motor Chronometry (MMC) Task Hands and Feet and Whole Body|"The MMC will be used as a measure of MI and it is adapted for use in hands, feet, and the whole body as well as for online experimentation. The task is comprised of two conditions, MI, and motor execution, in which respectively participants will be asked to imagine and execute a movement sequence with both hands and feet and the whole body.~Hand movements: index and thumb opposition; thumb extension from the fist; middle finger crossed on the index finger; and extension of the index and the little fingers.~Foot movements: foot internal rotation, foot external rotation, foot dorsiflexion, and foot plantarflexion.~Whole-body movements: take a small bow, lift arms over the head and stand on the tips of the toes (stretch), extend hands forward and lower the backside (squats) and a small jump.~The types of movements required to be executed by participants are simple and do not require much energy. Therefore, people affected by AN and BN should be able to perform them without problems."
214412854|NCT05756439|DRUG|Intravenous Sedatives with or Without Analgesia|Participants having dental surgery with conscious intravenous sedation
214412855|NCT05756439|DRUG|No IV sedation|Participants having dental surgery without conscious intravenous sedation
214412856|NCT05838664|DRUG|No OAC|AF Patient who were not exposed to oral anticoagulation
214412857|NCT05838664|DRUG|VKA|AF patients who received VKA
214412858|NCT05838664|DRUG|apixaban|AF patients who received apixaban
214412859|NCT05838664|DRUG|rivaroxaban|AF patients who received rivaroxaban
214412860|NCT05838664|DRUG|dabigatran|AF patients who received dabigatran
214412861|NCT03519373|BIOLOGICAL|TDaP|Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
215016470|NCT02855983|PROCEDURE|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
215016471|NCT04214236|DEVICE|ciNPT group|Closed-incision negative pressure therapy (ciNPT) will be applied for 7 day using continuous suction at 125 mmHg. To deliver ciNPT we will use a commercially available, FDA-approved device, used according to the manufacturer' indications (PREVENA™ Incision Management System (KCI, San Antonio, Texas, USA). After the first 7 post-operative days, subjects will discontinue the ciNPT and follow a standard wound care protocol.
215016472|NCT04214236|OTHER|Control group|Standard non-adherent surgical dressing (Vaseline petrolatum gauze) will be used for management of incisional wounds in the control group. Dressing changes will be performed per standard wound care protocol.
215016473|NCT05823454|DRUG|Different drug dosage|Choice of Anesthesia
215016474|NCT04503200|PROCEDURE|Double guidewire|After the 3rd passage of the guidewire into the pancreatic duct, the catheter will be removed leaving the guidewire in place. The catheter will be re-inserted and a second guidewire will be used and directed above the pancreatic wire in the 11-12 o'clock direction to attempt cannulation of the common bile duct.
215101571|NCT05759897|DRUG|Placebo|Placebo
214412862|NCT00813488|DRUG|Fentanyl Buccal Tablet|"FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician."
214412863|NCT00813488|DRUG|Immediate release oxycodone|"Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules)."
214412864|NCT04985383|DEVICE|AKST1210 S-15 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 250mL/min
214412865|NCT04985383|DEVICE|AKST1210 S-15 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 450mL/min
214412866|NCT04985383|DEVICE|AKST1210 S-25 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 250mL/min
214412867|NCT04985383|DEVICE|AKST1210 S-25 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 450mL/min
214412868|NCT04985383|DEVICE|AKST1210 S-35 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 250mL/min
214412869|NCT04985383|DEVICE|AKST1210 S-35 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 450mL/min
214412870|NCT05601843|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS pads will be applied in a frame pattern around the area of maximal pain, as pointed out by the patient. The pads will be no more than 6 cm and no less than 3 cm away from the subjective area of maximal pain. The frequency of the TENS machine will be set to 100 Hz and the patient will be instructed on how to increase and decrease the amplitude based on their comfort. The patient will also be instructed on how to turn off the machine if they wish for any reason. Research assistants will be standing by during the intervention period to intervene if the patient requires assistance with the device.
214412871|NCT02207361|DRUG|Paclitaxel, Carboplatin|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
214412872|NCT02207361|DRUG|Paclitaxel, Epirubicin|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
214412873|NCT04068545|DEVICE|Device: Thoraguard Surgical Drainage System|Fluid drainage following thoracic surgery
215016475|NCT04503200|PROCEDURE|Transpancreatic precut|After the 3rd passage of the guidewire unintentionally into the pancreatic duct, the guidewire will be left in the pancreatic duct, a sphincterotome will be used to cut in the direction of 11-12 o'clock attempting to deroof the pancreatic duct and gain access into the common bile duct. The wire will then be retracted and reinserted in the direction of the cut to attempt cannulation of the common bile duct.
215016476|NCT05132452|DIAGNOSTIC_TEST|The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)|Participants swallowed one cracker for the TOMASS. They swallowed 150 mL of water for the TWST.
215016477|NCT04947280|RADIATION|Fractionated Stereotatic Radiation Therapy|Participants prescribed to receive 9 Gy x 3 or 10 Gy x3 image-guided fractionated stereotatic radiation therapy.
215016478|NCT02470767|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
214412874|NCT04100356|OTHER|Exercise|Exercise program - indoor bicycle interval exercise, duration 60 min 3x week
214412875|NCT04100356|OTHER|Normal Diet|Normal diet recommended by the health authorities
214412876|NCT04100356|OTHER|LCHF Diet|LCHF Diet, a modified Atkins diet with high percentage of fat and very low percentage of karbohydrates
214412877|NCT04145687|DRUG|Metformin|Metformin 500mg tid
214412878|NCT05617339|BEHAVIORAL|I am (internet approach to migraine)|I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
214688769|NCT05943977|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.
214688770|NCT00377143|DRUG|Warfarin Dosing|
214688771|NCT00411788|DRUG|Rapamycin|oral rapamycin 6 mg daily
214688772|NCT00411788|DRUG|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
214688773|NCT02194400|BIOLOGICAL|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
214412879|NCT00006480|BIOLOGICAL|aldesleukin|
214412880|NCT00006480|BIOLOGICAL|therapeutic autologous lymphocytes|
214504987|NCT02124252|BEHAVIORAL|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
214504988|NCT00042965|DRUG|capecitabine|
214504989|NCT00042965|DRUG|gemcitabine hydrochloride|
214504990|NCT04497545|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
214688774|NCT02146079|DRUG|semaglutide|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
214688775|NCT02146079|DRUG|placebo|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
214504991|NCT04497545|DEVICE|lower limb rotor|The duration of the overall therapeutic intervention in both groups will be the same.
214412881|NCT00006480|DRUG|chemotherapy|
214412882|NCT00006480|DRUG|ganciclovir|
214412883|NCT02675855|OTHER|GrafixPRIME®|Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
214412884|NCT02675855|PROCEDURE|Dressing Application|Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
214504992|NCT01052766|PROCEDURE|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (\~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
214412885|NCT02675855|DEVICE|Off-loading (walking boot)|Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
214412886|NCT04805645|OTHER|No intervention (Retrospective Cohort Observational)|No intervention as this study is a Retrospective Cohort Observational
214412887|NCT01729871|DRUG|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
214412888|NCT01729871|DRUG|uninterrupted vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
214412889|NCT03455361|PROCEDURE|Stark Implant with low primary stability|
214412890|NCT01143077|DRUG|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
214412891|NCT04228770|BEHAVIORAL|Meeting with pharmacist|Meeting with pharmacist to support drug management following their routine surgery.
214412892|NCT04671628|BEHAVIORAL|Relaxing music|Participants will be asked to listen to relaxing music for 30 minutes each day. They will allowed to choose between several playlists based on their preference.
214412893|NCT01671475|DEVICE|microEEG (Bio-Signal microEEG)|"At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1."
214412894|NCT00897767|OTHER|biologic sample preservation procedure|
214412895|NCT03199716|OTHER|Parent mentors|Parent mentors are to meet up with their assigned intervention group 4 times in 1 year and call the families monthly to document any diabetic complications
214412896|NCT04094909|DRUG|Rh-endostatin|"Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +\[nab\]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period."
214412897|NCT05750511|DIAGNOSTIC_TEST|molecular tissue analysis|
214412898|NCT03882515|OTHER|Myofascial Release|With the right hand in hand exerts caudal pressure in the superior fibers of the muscle, both sides by a minute and a half each. In the ventral decubitus, apply pressure and slip from T12 to the base of the skull nine times. Thumb in the individual's acromion and with the other to hold the pressure and slide in the direction of the other acromion three times. Hand at the base of the skull and with the contralateral tenar region perform pressure and slip in caudal direction on both sides by three times. Hand at the base of the skull and with the contralateral thumb exerting pressure and slip of C3 the distal insertion of the upper fibers on both sides. Thumbs at the base of the skull, exerting lateral traction of the fascia in opposite directions. Dorsal decubitus, thumbs above clavicles, perform detachment of fibers for one and a half minutes. Patient sitting, support the head of the metacarpals beside the spinous process from T1 to T12 and exert pressure and slip three times each.
214504993|NCT06475079|OTHER|• FHP app (Pyeongtaek, South Korea) mobile application|FHP app (Pyeongtaek, South Korea) mobile application ,is mobile application to asses cranio vertebral angle
215016479|NCT06376227|PROCEDURE|with or without Left Colic Artery Preservation|low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA
215016480|NCT00408915|DRUG|Continuous Subcutaneous Lisuride Infusion|
215016481|NCT03043469|OTHER|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
214504994|NCT02509715|PROCEDURE|Intraoperative nerve monitoring|Intraoperative nerve monitoring during thyroid surgery
214504995|NCT04938453|DRUG|nintedanib 25 mg|soft gelatin capsule
214504996|NCT04938453|DRUG|nintedanib 100 mg|soft gelatin capsule
214504997|NCT05069038|DRUG|Palbociclib 125mg|Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days on 7 days off schedule (meaning: on Days 1-21of each 28-day cycle). If a subject misses a day's dose entirely, she must be instructed not to make it up the next day but just take her regular dose at the next assigned time. If a subject vomits any time after taking a dose, she must be instructed not to retake the dose but resume subsequent dosing at the next assigned time. If a subject inadvertently takes an extra dose during a day, she must be instructed to not take the next day's dose.
214504998|NCT02966652|DRUG|DITEST|Lipid formulation of native oral testosterone.
214504999|NCT02966652|DRUG|Testosterone undecanoate|Generic treatment for patients with primary or secondary male hypogonadism
214505000|NCT03169933|RADIATION|Combined, intensified and modulated adjuvant radiotherapy|
215016482|NCT03043469|OTHER|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
215016483|NCT03043469|OTHER|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
215016484|NCT03043469|OTHER|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
215016485|NCT03043469|OTHER|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
215016486|NCT03043469|OTHER|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
215016487|NCT03043469|OTHER|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
214412899|NCT03882515|OTHER|Continuous Surface Slip Technique|"1. Individual in the ventral decubitus, position the entire palmar surface bilaterally in the spinous process of T1 in the caudal direction, performing superficial smoothing in a smooth and rhythmic movement up to T12.~2. Return of the hands from the caudal direction towards the cranial direction, bypassing the lateral borders of the trapezius muscle following the direction of the inferior, middle and superior fibers.~3. Continue surface smoothing with a smooth and rhythmic movement until the distal insertion of the trapezius upper fibers into the skull and resume step 1 slowly and continuously for 10 minutes."
214412900|NCT03882515|OTHER|Without intervention|Evaluation and re-evaluation without intervention
214412901|NCT03390556|OTHER|Nurse-delivered education|"The nurse will:~1. Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications.~2. Give caregivers information about asthma management written at or below 6th grade reading levels.~3. Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use.~4. Demonstrate MDI/spacer technique with teach-back.~5. Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility.~6. Ask patients to make a 1 month follow-up appointment for asthma care."
214412902|NCT02158065|OTHER|Coaching program|The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
214412903|NCT00635817|DRUG|Leuprolide acetate 11.25 mg|Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
214412904|NCT00635817|DRUG|Leuprolide acetate 30 mg|Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
214412905|NCT03477682|OTHER|Early ambulation|Patients who are in the experimental arm will have a shorter duration of bedrest restriction following sartorius surgery (1 day) versus the standard group (5 days bedrest).
214412906|NCT05926791|OTHER|Cosmetic product|The educated group receives the cosmetic product SPF50+ according to the randomization list established at V1 and returns the products at V2
214412907|NCT01452490|DEVICE|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
214412908|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Zirconia Implant|Orbital floor reconstruction with Patient Specific Zirconia Implant will be done
214412909|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Titanium Implant|Orbital floor reconstruction with Patient Specific Titanium Implant will be done
214412910|NCT00809874|DIETARY_SUPPLEMENT|Casein|
214412911|NCT00809874|DIETARY_SUPPLEMENT|Whey Isolate|
214412912|NCT00809874|DIETARY_SUPPLEMENT|Whey Hydrolysate|
214412913|NCT00809874|DIETARY_SUPPLEMENT|Alphalact-Albumin|
214412914|NCT05005169|DIAGNOSTIC_TEST|SGB PCR|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
214412915|NCT05005169|DIAGNOSTIC_TEST|SGB culture|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
214412916|NCT00903721|DRUG|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months"
214412917|NCT03486340|PROCEDURE|Cardiologic assessment|Aggressive ischemic risk factor management
214412918|NCT04449744|OTHER|MySafeRx Inspire Plus|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
214412919|NCT04449744|OTHER|MySafeRx Inspire Flex|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study by their clinical team.
214412920|NCT00836069|DRUG|No drug name provided by Sponsor; drug referenced as PD 0332334|Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.
214412921|NCT00836069|DRUG|Paroxetine|FDA Approved medication for generalized anxiety disorder, oral tablet, at 20mg, once daily for 8 weeks and then 2 weeks of dose tapering.
214412922|NCT00836069|DRUG|Placebo|inactive substance, oral tablet, once per day, for 10 weeks.
215016488|NCT03043469|OTHER|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
214412923|NCT04401722|PROCEDURE|PANCREATICODUDENECTOMY|dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ
214412924|NCT00003891|DRUG|lurtotecan liposome|
214412925|NCT04179240|OTHER|audio and animated cartoon questionnaire|participants were asked to complete a questionnaire audio and animated cartoon on a platform
214412926|NCT03229798|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
214688776|NCT00633581|DIETARY_SUPPLEMENT|Ascorbic acid (Vitamin C)|Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
214688777|NCT00633581|DIETARY_SUPPLEMENT|Normal saline|Single intravenous injection of 120ml of normal saline over 30 minutes
214688778|NCT06551857|OTHER|Chemotherapy, chemoradiation, radiation therapy|Cancer treatment
214688779|NCT03993691|DEVICE|Tomo-E scan|High-resolution limited-angle tomography positioning and examination will vary depending on injury.
214688780|NCT03993691|DEVICE|Radiograph|Standard of Care radiographic imaging of wrist.
214412927|NCT03229798|COMBINATION_PRODUCT|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
214412928|NCT00871429|OTHER|Lindi skin care products|"Subjects will then be instructed to apply all three products daily for 1 month.~The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C)."
214412929|NCT06285175|OTHER|Tele-REINVENT|Tele-REINVENT consists of EMG-biofeedback of the affected arm to control games on a computer screen.
214412930|NCT02304653|OTHER|Clinical descision making|Chage in diagnosis before and after the presentation of the reults of CRP and Leucocytes
214412931|NCT03323840|OTHER|Incentivized Care|Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
214412932|NCT00196170|PROCEDURE|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
214412933|NCT00196170|PROCEDURE|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
214688781|NCT04118686|OTHER|CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)|CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
214688782|NCT04118686|OTHER|CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)|CT program with Computerized cognitive training (CoRe) plus sham stimulation
214688783|NCT04867135|DRUG|Amikacin Sulfate Injection|The dose and frequency of amikacin was defined by each hospital.
214688784|NCT01428063|DRUG|Daclatasvir|
214688785|NCT01428063|DRUG|Asunaprevir|
214688786|NCT01428063|DRUG|Pegylated interferon alfa-2a|
214688787|NCT01428063|DRUG|Ribavirin|
214688788|NCT01326169|BEHAVIORAL|Brief intervention|Telephone-delivered counseling
214688789|NCT01326169|BEHAVIORAL|Standard care|No intervention
214688790|NCT03793140|DRUG|CPI-613|CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)
214688791|NCT02557971|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
214688792|NCT05279833|DRUG|dronedarone|Pharmaceutical form is tablet and route of administration is oral
214688793|NCT05279833|DRUG|sotalol|Pharmaceutical form is tablet and route of administration is oral
214412934|NCT00196170|PROCEDURE|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
214688794|NCT05806385|DEVICE|Cryoablation|Tumor ablation before neoadjuvant chemotherapy
215016489|NCT03043469|OTHER|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
215016490|NCT03043469|OTHER|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
215016491|NCT03043469|DIAGNOSTIC_TEST|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
214412935|NCT00196170|PROCEDURE|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
214412936|NCT02109393|OTHER|MIRT|"It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.~All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks."
214412937|NCT02109393|OTHER|MIRT+Lokomat|It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
214412938|NCT05380232|BEHAVIORAL|Leisure-time physical activity|Self-reported leisure-time physical activity, categorized as; zero (reference), \>0-7.49 MET-hrs/week, 7.5-14.9 MET-hrs/week, or ≥15 MET-hrs/week.
214412939|NCT05542680|DEVICE|cushion|In the intervention group, the special cushion for semi recumbent position was used
214412940|NCT04277689|PROCEDURE|Brain signal data collection|Collection of speech related electrophysiological data at the time of DBS.
214688795|NCT05806385|COMBINATION_PRODUCT|Cryoablation combined with PD1 Inhibitor|Combination of cryoablation with PD1 inhibitor before neoadjuvant chemotherapy
214688796|NCT00235846|PROCEDURE|vein harvest|Conventional open vein harvest or endoscopic vein harvest
214688797|NCT06037356|DEVICE|Prostatic Urethral Lift|Prostatic urethral lift uses permanent implants to retract the prostate lobes away from the prostate urethra to allow unobstructed passage of urine. These implants are made of Nitinol, non-absorbable monofilament suture material (Poly Ethylene Terephthalate), Stainless Steel
214688798|NCT06037356|PROCEDURE|TURP|Using monopolar or bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH
214688799|NCT06370455|PROCEDURE|comparison of septal advancement flap effect on nasal tip in primary rhinoplasty to columellar strut technique|All patients will be operated on under general anesthesia through an open rhinoplasty then will undergo 2 different procedures according to each group.
214688800|NCT05282953|DRUG|KIO-301|KIO-301 intravitreal injection at ascending doses
214688801|NCT05888090|OTHER|Prone, right lateral, and semi-elevated supine positions|Each participant will be followed during three feedings and the prone, right lateral, and semi-elevated supine positions will be applied once.
215016492|NCT03043469|OTHER|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
215016493|NCT03043469|OTHER|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
215101572|NCT05894447|DRUG|Naptumomab Estafenatox|5 or 10 µg/kg IV naptumomab estafenatox will be given on the first four days of every 21-day treatment cycle for 6 cycles
214688802|NCT05888090|OTHER|Semi-elevated supine, prone, and right lateral positions|Each participant will be followed during three feedings and the semi-elevated supine, prone, and right lateral positions will be applied once.
215016494|NCT03043469|OTHER|Breath-hold test|Holding the breath a few times for as long as possible.
215016495|NCT03043469|OTHER|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
214688803|NCT05888090|OTHER|Right lateral, semi-elevated supine, and prone positions|Each participant will be followed during three feedings and the right lateral, semi-elevated supine, and prone positions will be applied once.
215016496|NCT03043469|OTHER|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
215016497|NCT01348490|DRUG|Ruxolitinib|Ruxolitinib (INCB018424), 5 mg bid
215016498|NCT04002557|OTHER|Interview-Questionnaire|Questionnaire
215016499|NCT00073047|DRUG|Daclizumab|
215016500|NCT00711204|DRUG|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
215016501|NCT01117350|DRUG|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
215016502|NCT01117350|DRUG|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
215016503|NCT01117350|DRUG|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
215016504|NCT03389750|DRUG|Intravenous Challenge Drug|Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
215016505|NCT02211157|DRUG|BIBR 796 BS|
215101573|NCT05894447|DRUG|Pembrolizumab|200 mg IV pembrolizumab will be given on day 2 of each 21 day cycle for up to 24 cycles
215016506|NCT02211157|DRUG|Placebo|
215016507|NCT02211157|OTHER|high fat breakfast|
215101574|NCT05894447|DRUG|Obinutuzumab|Two doses of 1,000 mg IV obinutuzumab given prior to starting pembrolizumab and naptumomab estafenatox
215101575|NCT05066165|GENETIC|Arm 1: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
215101576|NCT05066165|GENETIC|Arm 2: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
215101577|NCT05760859|OTHER|Initial cue|"Symptom volunteered by the patient"
215101578|NCT02484755|DRUG|Gefitinib|See Arm Description
214412941|NCT04486729|OTHER|High PEEP with end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system with end inspiratory pause addition in volumen control ventilation
215016508|NCT04636944|OTHER|web-based COMPASS intervention|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). COMPASS is tailored to gain an understanding of the difficulties that LTC patients experience and provide information and tools on how to manage these. This qualitative study will explore participants' perspectives on using COMPASS for managing depression and anxiety in heart failure.
215016509|NCT05558670|OTHER|PET-fMRI-EEG|Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap
215016510|NCT04595578|DEVICE|Cerebellar repetitive transcranial magnetic stimulation|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
215016511|NCT06604598|DRUG|IBU-PCT-DEX|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.
215016512|NCT06604598|DRUG|IBU-PCT-placebo|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, and 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the IBU-PCT-placebo intervention
215016513|NCT06604598|DRUG|PCT-placebo-placebo|Paracetamol (Bernofarm) 2x1 gr iv, 2xplacebo (normal saline alike paracetamol), 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the PCT-placebo-placebo intervention.
215016514|NCT02608606|DRUG|Tacrolimus|compared oral administration versus sublingual administration of tacrolimus.
215016515|NCT01491165|PROCEDURE|stem cell transplantation through interventional procedures|one time interventional procedures
215016516|NCT00394537|DRUG|Labetalol 10mg iv|
215016517|NCT00800384|DEVICE|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
215016518|NCT02452658|OTHER|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
214412942|NCT04486729|OTHER|Low PEEP - FiO2 high|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 96-98%
214412943|NCT04486729|OTHER|High PEEP without end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system without end inspiratory pause addition in volumen control ventilation
214412944|NCT04486729|OTHER|Low PEEP - FiO2 low|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 88-92%
214412945|NCT02676297|DRUG|tiotropium|four inhalations
214412946|NCT02549443|DIETARY_SUPPLEMENT|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
214412947|NCT02470104|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
214412948|NCT06191406|DIAGNOSTIC_TEST|6 minute walk test|Test for physical functions and cognitive functions
214412949|NCT04043611|OTHER|Conservative physical therapy management|Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold), Hamstring, Piriformis McKenzie Prone Extension Exercises
214412950|NCT04043611|OTHER|ELDOA|ELDOA positions (hold for 1 minute,4 alternate days a week) under supervision during session Conservative physical therapy management Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold),Hamstring,Piriformis
214505001|NCT05984667|BEHAVIORAL|C-SMART|The C-SMART intervention includes approximately 8 individual therapy sessions, each approximately 60 minutes in length, delivered weekly. C-SMART intervention components include cognitive rehabilitation and mindfulness training.
214505002|NCT04115553|DIAGNOSTIC_TEST|MRI examination|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. Standard MRI examination using a 32-channel head coil consists of angiographic, morphological and phase-contrast 2D flow sequences. The flow planes are set perpendicularly to the structure axis (blood or CSF regions). The velocity measured in the pixels inside the region of interest allow the calculation of a mean flow rate as well as the volume displaced during a cardiac cycle.
214505003|NCT04115553|DIAGNOSTIC_TEST|ECG|A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
214505004|NCT05059106|BIOLOGICAL|Half dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.
214505005|NCT05059106|BIOLOGICAL|Standard dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.
214505006|NCT02997410|DEVICE|Ozone|
214505007|NCT02997410|DEVICE|Placebo (for Ozone)|
214505008|NCT02997410|DEVICE|Dental treatment with occlusal splint|
215016519|NCT06812013|OTHER|assessment of foot print and balance|"For static and dynamic balance assessment, Biodex Medical Systems Inc., Shirley, New York, USA (serial n.: 13020193) was used. The device consists of a circular foot platform that permits tilting in all directions, height-adjustable support rails, height adjustable display screen, and a printer. Balance assessment by the Biodex system is a valid and reliable objective measurement.~For assessment of foot print symmetry Tekscan HR walkway Mat™ pressure measurement system, Tekscan Inc. USA will be use. It is made up of a digital mat inserted into a wooden walkway, sensors (4 senses/cm2) embedded in the mat, and a computer running the Tekscan Software (version 7) for data extrapolation."
214412951|NCT06615089|OTHER|balance training|the elderly patients will receive balance training in the form of proprioceptive and vestibular training components. proprioceptive training include Standing static balance, lateral weight transfer, Lateral weight transfer near to chair, tandem closed eyes, walking on toes, Postural control using ball. Vestibular training in the form of Balance with head movement, seated lateral step in addition to Insoles inside the subjects' own regular shoes
214412952|NCT06615089|OTHER|orthotic prescription|the elderly patients will receive Insoles inside the subjects' own regular shoes
214412953|NCT05760755|BEHAVIORAL|Stick Together|The intervention consists of 12 online modules, completed flexibly during and immediately after primary cancer treatment. The intervention contains interviews with other couples, psychoeducational information, and interactive exercises on themes such as dyadic coping and communication, being diagnosed at a young age, fertility and children, and life after treatment.
214412954|NCT06697392|OTHER|ultrasound examination|The investigators intend to perform ultrasound examinations for the participants with CTS.
214412955|NCT06697262|DEVICE|Remote temperature monitoring device|"* Use of the Tucky® remote monitoring device for continuous temperature monitoring at home,~* In combination with education sessions on temperature monitoring and the device."
214412956|NCT06697262|DIAGNOSTIC_TEST|Home temperature monitoring by a nurse|"* Home temperature monitoring by a nyrse, twice a day,~* In association with education sessions on temperature monitoring."
214412957|NCT05974839|OTHER|Ocrelizumab|Non-interventional
214412958|NCT06698068|OTHER|Equine-assisted therapy|15 equine therapy sessions, twice a week, over 7 to 8 weeks. Each session will last 60 minutes, including various activities such as emotional expression, contact with the horse, grooming, activities on foot or on horseback, and a debriefing time.
214412959|NCT06712277|OTHER|Video training|After the procedure, caregivers will be trained on tube care and patient feeding by demonstrating and performing the procedure on an iPad.
214412960|NCT06711016|OTHER|fluid resuscitation, vasoactive drug dose,hemoglobin transfusion,sedative analgesic muscle relaxant drugs, antiepileptic drugs, etc|ECMO flow, IABP , ventilator support parameters, temperature management level and time
214412961|NCT06711822|DEVICE|Shockplus-10|Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of ShockPulse-10 treatment by their physicians
214412962|NCT06712394|PROCEDURE|IPACK|The IPACK block involves infiltration of the space between the popliteal artery and the posterior knee joint capsule with 20 ml of 0.25% local anesthetic (bupivacain) under ultrasound guidance.
214412963|NCT06711328|DEVICE|New oropharyngeal airway|This product is produced and sold by Shanghai Elifu Medical Technology Co., LTD., and has been officially put into clinical use in March 2023.The product is named oropharyngeal airway for disposable endoscope, which is composed of nasal plug, bite, oropharyngeal channel, oxygen supply tube, lanyard and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.The model used in this study is JK (Oropharyngeal airway for endoscope with end-expiratory carbon dioxide Collection) with L/M/S three specifications, which is used to prevent airway obstruction caused by backward tongue fall during endoscopic surgery/examination, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time
214412964|NCT06714110|DEVICE|Intramedullary Limb Lengthening Device|The Precice IMLL System is composed of the Precice nail, screws, and uses an external remote controller (ERC) for rod distraction. The Precice IMLL System is designed to fit the anatomy of long bones and is intended to be placed internally in an intramedullary manner. It achieves limb correction through gradual lengthening or compression and providing intramedullary fixation for fractures of long bones.
214412965|NCT06714110|DEVICE|External Fixator Limb Lengthening Device|External fixator devices consist of an external frame (ring, half-ring, monolateral, and rail); bone fixation is accomplished by the transcutaneous bone fixations implants (pins, wires, cables, screws), and the lengthening is accomplished by the vertical components (struts). Generally, femoral lengthening devices are monolateral and tibial lengthening devices have ring or half-ring frames. The external fixators are made of a variety of materials, including stainless steel, titanium, carbon fiber, and aluminum.
214505009|NCT03087890|DRUG|Cotrimoxazole|Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
215016520|NCT01433770|DRUG|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
215016521|NCT04039438|OTHER|No intervention|No intervention will be provided during the study nor participants will be receiving any intervention anywhere else.
214505010|NCT03087890|DRUG|Placebo|Patients will receive 2 tablets placebo daily for 48 weeks
214505011|NCT06412094|OTHER|Standard care|Recommendation of standard treatment plan, according to the clinical severity of the AD, and. are instruction to contact the doctor via messenger for any questions related to treatment recommendations.
215016522|NCT02119000|DRUG|PEG/electrolytes 2L/2L split dose|Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
215101579|NCT02185066|DRUG|Atorvastatin 20mg and Metformin XR 500mg (Reference)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
214505012|NCT06412094|BEHAVIORAL|"Access to the AtopicApp mobile application"|"Access to the AtopicApp mobile application with 1 day after enrollment."
214505013|NCT06412094|BEHAVIORAL|Virtual oversight through the AtopicApp|Notification of doctor's virtual oversight through the AtopicApp mobile application.
214412968|NCT06398626|DRUG|Etrasimod|As provided in real world practice
214412969|NCT05267977|DRUG|Cephalosporin 1St Generation|
214412970|NCT05267977|DRUG|Aminoglycosides|
214412971|NCT02777983|BEHAVIORAL|Educational Video App|The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
214412972|NCT05789472|BEHAVIORAL|Assessment|Executive functions and reaction times of all participants will be measured.
214412973|NCT02554240|DRUG|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
214412974|NCT02554240|DRUG|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
214412975|NCT02554240|DRUG|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
214412976|NCT01922570|DIETARY_SUPPLEMENT|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
214412977|NCT02339779|PROCEDURE|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~1. First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~2. Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~3. Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
214412978|NCT02339779|PROCEDURE|breast implant|"Implant-based reconstruction typically will occur as follows:~1. During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~2. The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~3. When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
214412979|NCT05266352|OTHER|Supervised exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises under control of the physiotherapist in the clinic."
214412980|NCT05266352|DIAGNOSTIC_TEST|Home exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises at home. Patients will visit the clinic every 2 weeks and progression of exercise program will be made."
214412981|NCT01162655|BEHAVIORAL|Cognitive-behavioral therapy for Insomnia (CBT)|6-week course of CBT delivered either using internet or telehealth
214412982|NCT06100705|DRUG|Testosterone Cypionate|Testosterone Cypionate is an androgen and anabolic steroid medication which is used mainly in the treatment of low testosterone levels in men.
214412983|NCT06100705|DRUG|Sipuleucel-T|Sipuleucel-T is the first FDA-approved immunotherapy in treatment of mCRPC. It is a therapeutic cancer vaccine composed of activated autologous dendritic cells loaded with an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor, PAP-GMCSF, also called PA2024. This cellular product is prepared in three steps: (1) leukapheresis to isolate CD54+ dendritic cells, (2) the cells and harvested and cultured with PA2024 ex vivo, and (3) re-infusion of the activated DC into the original patient. The preparation and administration of this autologous cellular product are done every 2 weeks for a total of three infusions and is designed to elicit an immune response to prostatic acid phosphatase.
214505014|NCT02205515|DRUG|Everolimus|Everolimus is a novel derivative of rapamycin.
214505015|NCT00192959|DRUG|Xenon vs propofol|
214505016|NCT03543332|DIAGNOSTIC_TEST|Measures of physical activity and kinesiophobia|Groups will be compared regarding kinesiophobia with TSK heart.
214505017|NCT01087710|OTHER|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
214505018|NCT01087710|OTHER|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
215016523|NCT02119000|DRUG|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|"Bisacodyl 15 mg x 3~At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:~PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes"
215016524|NCT03361072|DIETARY_SUPPLEMENT|Oral immunotherapy|Milk, peanut or egg oral immunotherapy
215016525|NCT05274451|BIOLOGICAL|LYL797|LYL797 is an autologous, genetically (Gen-R™) and epigenetically (Epi-R™) reprogrammed ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy
214505019|NCT04130490|DEVICE|ANTERION|3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
214505020|NCT01404000|DRUG|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
215016526|NCT06687044|BEHAVIORAL|Sleep restriction|Go to bed before 23pm
214412984|NCT04977856|BEHAVIORAL|Behavioral activation (BA)|The main goal of the BA is to increase engagement in values-based activities and decrease avoidant behaviors that serve to maintain depression. The adolescent will learn about depression, how behavioral activations works, monitor their own activities, plan and do more values-based activities and deal with obstacles to getting in touch with positive reinforcement, such as avoidance behaviors.
214412985|NCT04977856|OTHER|Regular care within primary or secondary mental health care for children|Regular care (supportive therapy, waitlist, psychological treatments, drugs, or a combination of different interventions)
214412986|NCT05779722|DEVICE|Vapor barrier|Vapor barrier
214412987|NCT05526911|DRUG|TBAJ-876|"* Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~* Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~* Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~* Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
214412988|NCT05526911|DRUG|Midazolam|Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
214412989|NCT05526911|DRUG|Digoxin|Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
214412990|NCT05025449|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST)|The Focused Assessment with Sonography for Trauma (FAST) exam is widely used and accepted as part of Advanced Trauma Life Support (ATLS) protocol. After consent, a baseline FAST exam will be performed and documented. This FAST will be distinct from the initial ATLS resuscitation FAST in order to avoid any interference in the trauma evaluation. The investigator will use a phased array or curvilinear transducer to record video of their baseline FAST exam.
214412991|NCT05025449|DRUG|Bubble-Enhanced FAST (BEFAST)|Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by the American Association for the Surgery of Trauma (AAST) criteria.
214412992|NCT03804411|DRUG|Automatic system guided treatment|Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide
214412993|NCT03804411|DRUG|Standard treatment|"Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide"
214412994|NCT02518711|BEHAVIORAL|Behavioral Teacher Program|This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
214412995|NCT02652234|DRUG|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
214412996|NCT02652234|DRUG|Chemotherapy|
214412997|NCT04903483|OTHER|bispectral index monitoring|intraoperative single-channel electroencephalography monitoring of the depth of anesthesia
214412998|NCT03612115|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)"
214412999|NCT01353482|DRUG|Cisplatin|Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
214688804|NCT00578864|DRUG|Protracted Oral Etoposide|"Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~* Hour 0: Etoposide 50 mg/m2 po daily~* Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~* Etoposide 50 mg/m2 po once daily"
214688805|NCT00578864|DRUG|Doxorubicin|"Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes"
215016527|NCT06687044|BEHAVIORAL|Stimulation control|Avoid drugs, alcohol, caffeine, and nicotine
215016528|NCT06687044|BEHAVIORAL|Cognitive therapy|Listen to 30 minutes of soothing music every night for 8 weeks
215101580|NCT02185066|DRUG|CJ-30056 20/500mg (Test)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
215101581|NCT00007358|DRUG|Dexamethasone or other corticosteroid|Administered during the third trimester of pregnancy
214413000|NCT01353482|DRUG|Pemetrexed|Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
214413001|NCT01353482|DRUG|Vorinostat|The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
214413002|NCT01353482|DRUG|Placebo|Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
214413003|NCT00388011|DRUG|Intranasal Morphine (MNS075) 3.75 mg|Intranasal Morphine (MNS075) 3.75 mg
214413004|NCT00388011|DRUG|Intravenous Morphine 7.5 mg|Intravenous Morphine 7.5 mg
214413005|NCT00388011|DRUG|Intranasal morphine (MNS075) 7.5 mg|Intranasal morphine (MNS075) 7.5 mg
214413006|NCT00388011|DRUG|Intranasal morphine (MNS075) 15 mg|Intranasal morphine (MNS075) 15 mg
215016529|NCT06687044|BEHAVIORAL|Sleep principles discussion|The principles of sleep hygiene are discussed, but without the application of stimulus control or sleep restriction
215016530|NCT04484701|DRUG|68Ga-PSMA-11|PET/CT scan with radiotracer 68Ga-PSMA-11
215016531|NCT03724227|DRUG|ACE-011|ACE-011 will be administered subcutaneous injection
215016532|NCT05222789|PROCEDURE|TAP|The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
215101582|NCT06410456|OTHER|Schroth exercises|Traditional exercise
214413007|NCT00388011|DRUG|Intranasal morphine (MNS075) 30 mg|Intranasal morphine (MNS075) 30 mg
214413008|NCT00388011|DRUG|Intranasal placebo|Intranasal placebo
214413009|NCT02345200|PROCEDURE|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
215016533|NCT06564766|OTHER|Debriefing|"In the experimental group, an expert instructor conducted a structured debriefing lasting about 10-15 minutes for each clinical scenario, while in the control group, no additional intervention was provided.~The debriefing used in this study has the following characteristics: brief (≤ 15 minutes), educator present, educator experienced in debriefing, focused on healthcare management or decision-making, and used the Plus-Delta method, where participants are asked to reflect on the simulation event and assess their performance by identifying what went well and areas for improvement."
214413010|NCT02345200|PROCEDURE|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
214413011|NCT05502211|DRUG|Fentanyl|induction of anaesthesia using fentanyl
214413012|NCT05502211|DRUG|Lidocaine IV|induction of anesthesia using lidocaine
214413013|NCT01839903|OTHER|EDIS|Changes made to EDIS system to improve tracking and treatment of smoking in the ED
214413014|NCT01839903|OTHER|Care as usual|Care as usual in the ED will be tracked
214413015|NCT05088226|DRUG|Ruxolitinib combined with Chidamide.|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
214413016|NCT03238729|BEHAVIORAL|Heart Failure Education and Management App|Patients will be provided with an app on a smartphone that provides a daily checklist with items like reminders for logging weight and food, as well as educational components about heart failure and it's management.
214413017|NCT03238729|BEHAVIORAL|Heart Failure Literature|Patients will be provided standard literature about heart failure and the management of heart failure.
214413018|NCT00301509|DRUG|peginterferon and ribavirin|
214413019|NCT01953809|DRUG|GSK1322322|Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
214413020|NCT01953809|DRUG|EE/NE|Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
215016534|NCT01153542|DRUG|VX-770|In period 1, subjects will receive a single oral dose of desipramine on Day 1.
214413021|NCT01953809|DRUG|GSK1322322 Placebo|GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
215016535|NCT01153542|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
215016536|NCT06089746|OTHER|NIPT|Coordinated suite of DME and training to support continuous maintenance of flexion posture during the 6 week trial.
215016537|NCT06240208|BEHAVIORAL|Inactivity|Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
215016538|NCT05995561|OTHER|no intervention is planned.|no intervention is planned.
215016539|NCT00370955|PROCEDURE|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
214413022|NCT01953809|DRUG|EE/NE Placebo|EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
214413023|NCT03640455|DEVICE|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; placebo (dummy stimulation), according to the patient's randomization arm.
214413024|NCT03640455|DEVICE|Anodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in anodal polarity, according to the patient's randomization arm.
214413025|NCT03640455|DEVICE|Cathodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in cathodal polarity, according to the patient's randomization arm.
214413026|NCT00569946|DRUG|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
214413027|NCT04276987|BIOLOGICAL|MSCs-derived exosomes|5 times aerosol inhalation of MSCs-derived exosomes (2.0\*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
214413029|NCT05039723|DRUG|Radiesse, Xeomin, Belotero|Rejuvenation with Radiesse, Xeomin, Belotero
215016540|NCT05592743|DRUG|Vorasidenib|Oral therapy
215016541|NCT03000803|BEHAVIORAL|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
215016542|NCT03000803|BEHAVIORAL|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
215016543|NCT06064526|OTHER|No intervention|Non-interventional study based on secondary use of hospital medical records
214413030|NCT03071185|PROCEDURE|femoral nerve block, common peroneal nerve block|For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
214413031|NCT05040750|OTHER|laboratory investigation|observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients
214413032|NCT04257851|DRUG|Theophylline Anhydrous Oral Tablet|Theophylline tablet (150 mg/12h)
214413033|NCT04257851|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan tablet (25 mg/12h)
214413034|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes and polyphenols|Participants will consume a meal including 200g of yogurt enriched with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of functional yogurt on postprandial glycemia and lipemia
214413035|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes|Participants will consume a meal including 200g of yogurt with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
214413036|NCT05612243|OTHER|Consumption of a meal with plain Yogurt with oat flakes|Participants will consume a meal including 200g of plain yogurt containing 1g of oat flakes, as a placebo, as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
215101583|NCT06410456|OTHER|Traditional exercises|Adolescents with idiopathic scoliosis performed conventional exercises four days a week for six months.
214688806|NCT00578864|DRUG|IV Bolus Etoposide|"Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2"
214688807|NCT00578864|DRUG|Cisplatin|Cycle 1, 2, and 4
214688808|NCT00578864|DRUG|Cyclophosphamide|Cycle 3 and 5 with doxorubicin
214688809|NCT00578864|DRUG|Mesna|Standard weight-based dosing with cyclophosphamide
214688810|NCT00578864|DRUG|Hematopoietic Factor|Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
214688811|NCT00578864|PROCEDURE|Primary tumor resection|Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
214688812|NCT00088868|DRUG|alvespimycin hydrochloride|
215016544|NCT02754037|RADIATION|Fluorodeoxyglucose (FDG) positron emission tomography (PET)|This imaging method uses radiotracers for functional analysis of liver inflammation. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
215101584|NCT00939458|DRUG|Lamotrigine|
214413037|NCT03755440|DRUG|PD-1 antibody (SHR-1210)|PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
214413038|NCT02496975|DRUG|Cyclosporine A|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
214413039|NCT02496975|OTHER|Placebo|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
214413040|NCT05582616|DEVICE|Transcranial Direct Current Stimulation|See treatment arm description
214413041|NCT05582616|DEVICE|Sham Transcranial Direct Current Stimulation|See sham comparator arm description
214688813|NCT05505968|OTHER|Virtual Reality Headset|Virtual Reality Headset of the society Healthy Mind and is a CE Class 1 medical device. This virtual reality headset is a Pico G2 4K and corresponds to the model A7510 and is connected to a Bose Sound Link 2 AE headset.
214688814|NCT05111899|BEHAVIORAL|Newborn Health Education|Community influencers will receive training and give community education to women and their families regarding newborn health.
214688815|NCT03167580|PROCEDURE|restricted PEEP|Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
214688816|NCT03167580|PROCEDURE|liberal PEEP|Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
215016545|NCT02754037|OTHER|Magnetic resonance imaging (MRI)|Novel non-invasive MRI based tools to assess liver fat and fibrosis. Potential risks include a sensation of claustrophobia. No contrast dye is used and thus no risk of contrast allergy. Inflammation of the liver may be assessed by MRI software after processing of images and does not require additional patient involvement or change in MRI protocol.
215101585|NCT06435923|DRUG|[14C]-darigabat|Oral capsule
215101586|NCT00438165|BEHAVIORAL|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
215101587|NCT00742417|BIOLOGICAL|Albutein 5%|"18 Plasma Exchanges using Albutein 5%:~* three weeks of intensive treatment with two plasma exchanges per week~* six weeks of maintenance treatment with one weekly plasma exchange~* three months of maintenance treatment with one plasma exchange every two weeks"
215101588|NCT00742417|OTHER|Control|Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
214688817|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice|1x daily intake of 70 mL red beetroot juice
214688818|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice without nitrate|1x daily intake of 70 mL red beetroot juice without nitrate
214688819|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink plus potassium nitrate|1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
214688820|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink|1x daily intake of 70 mL placebo control drink
214688821|NCT02195791|DRUG|Pioglitazone|Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
214413042|NCT04669249|BEHAVIORAL|PROCare|PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
214413043|NCT06631781|OTHER|GOLD-Cog+|6 weeks of combined cognitive intervention (GOLD-Cog+),which includes participation in 9, one hour long Cognitive-Orientation to Occupational Performance(CO-OP)-based group sessions and 24 individual and independent 30-minute computerized cognitive training (CCT) program using the Effectivate platform (Israeli-based CCT developed for older adults. Available in both Hebrew and English).
214413044|NCT06629727|OTHER|VR Group|the experimental group was shown a video through VRG during the lithotripsy procedure.
214413045|NCT06629727|OTHER|Control group|Patients received standard care during the procedure
214688822|NCT02195791|DRUG|Placebo|Placebo (oral) 1 tab once daily for 7 days
214688823|NCT02858609|OTHER|Nasopharyngeal Swab|
214688824|NCT03915899|BEHAVIORAL|WIN (Welcome Incoming Neighbor)|WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
215101589|NCT02255994|DEVICE|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
215101590|NCT02255994|PROCEDURE|No mesh.|Patients in this arm had subvesical plication without reinforcement.
215101591|NCT00627367|DRUG|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
215101592|NCT00627367|DRUG|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
215101593|NCT00680459|DRUG|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
215101594|NCT00680459|DRUG|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
215101595|NCT04566601|DRUG|BI 1358894|Film-coated tablet
214688825|NCT06234735|BEHAVIORAL|Physical activity in the community|Supervised and guided PA sessions in the community setting using public resources such as parks, sports facilities, etc.
214688826|NCT06234735|BEHAVIORAL|Conventional intervention|Conventional protocol for lung cancer and PA recommendations.
214688827|NCT03288272|RADIATION|Whole Brain Radiotherapy|Radiotherapy of the whole brain
214688828|NCT03288272|OTHER|Best Supportive Care|Best Supportive Care including nutrition, pain medication, steroids as needed
214688829|NCT00210015|DRUG|INS37217 Nasal Spray|
214688830|NCT04090281|GENETIC|CYP2C19 genotyping|Upon hospital discharge, patients will undergo CYP2C19 genotyping to guide initial P2Y12 inhibitor selection. At 14 days, post discharge, patients will undergo on treatment platelet reactivity phenotyping to further guide deescalation of P2Y12 inhibitor therapy
215101596|NCT04566601|DRUG|Placebo|Film-coated tablet
215101597|NCT03833466|DRUG|metformin and chemotherapy|"Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle."
214688831|NCT01905319|OTHER|Blood collecting for storage of samples|
214688832|NCT04683198|DRUG|camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
214688833|NCT04683198|DRUG|Apatinib Mesylate|Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.
214688834|NCT04683198|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).
214688835|NCT04683198|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
214688836|NCT04151537|BEHAVIORAL|Personal Activity Intelligence|The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.
214688837|NCT04151537|BEHAVIORAL|Physical Activity Guidelines|The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
215016546|NCT02754037|RADIATION|PET Explorer|Similar to the regular PET-Scan, this imaging method uses radiotracers to scan multiple organs of the body. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
214413046|NCT06628596|DIETARY_SUPPLEMENT|Paraxanthine 200mg and 300mg|Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.
214413047|NCT00356317|BEHAVIORAL|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
214413048|NCT00356317|BEHAVIORAL|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
214413049|NCT06480123|DRUG|Skin drug prepared with exome originated from stem cell|Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.
214413050|NCT06629922|OTHER|No intervention|This is a observational study and the participants will not receive any intervention
214413051|NCT04844957|DRUG|Vitamin D|Clinical Study
214413052|NCT04844957|DEVICE|Full automatic chemiluminescence measuring instrument|Chemiluminescence immunoassay
214413053|NCT02915055|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
214413054|NCT02915055|DRUG|standard oxycodone/acetaminophen|
214413055|NCT02780245|DRUG|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
214413056|NCT02780245|PROCEDURE|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
214413057|NCT02032719|BEHAVIORAL|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
214413058|NCT02032719|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
214413059|NCT04244604|OTHER|Acute Salt (sodium chloride)|Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure
214413060|NCT03903081|DRUG|HEC110114 tablet|administered orally once daily
214413061|NCT03903081|DRUG|Placebo Oral Tablet|Placebo will be administered orally at a dose and frequency matched to HEC110114
214688838|NCT00006222|DRUG|cilengitide|
215016547|NCT06123676|DEVICE|Y90-PET-CT scan|40 min extra PET-CT scan - no extra injection of radiotracer. We image the Y90-microspheres administered to these patients during the therapy
215016548|NCT04139902|DRUG|Dostarlimab (TSR-042) (singly)|"If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks."
214413062|NCT06165731|BEHAVIORAL|Diaphragmatic Breathing Exercises|Mindful deep breathing cycle comprised of a 3-second inhale causing abdominal wall movement followed by a 5-second exhale, which will be completed for a total of 10 minutes of daily exercise
215101598|NCT04373005|DIAGNOSTIC_TEST|Nasopharyngeal (NP) swab|A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
215101599|NCT05835180|DRUG|TVB-2640 - 50 mg|TVB-2640 -50 mg administered orally once daily
214413063|NCT06165731|BEHAVIORAL|Bladder Hygiene Education|Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
214688839|NCT03326219|PROCEDURE|Clarivein|The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
214688840|NCT01087528|DEVICE|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
215101600|NCT05706441|OTHER|Point-of-Care Ultrasound|Ultrasonographic scans of the lung and right hemidiaphragm were acquired after 30 min from the beginning of the SBT, or immediately before reconnecting the patient to the ventilator in the case of SBT failure occurring before
214413064|NCT02491736|DRUG|Ketoprofen|2.5% ketoprofen gel
214413065|NCT02491736|OTHER|Placebo|Placebo gel
214413066|NCT02305485|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
214413067|NCT02305485|DEVICE|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
214413068|NCT04886180|DEVICE|Oxiris membrane|Hemofiltration treatment with Oxiris membrane connected to the ECLS circuit for 24 hours.
214413069|NCT04886180|DEVICE|Prismaflex membrane|Treatment by hemofiltration with PrismaFlex ST150 membrane connected to the ECLS circuit for 24 hours.
214413070|NCT04886180|BIOLOGICAL|Blood tests|Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
214413071|NCT01144949|DRUG|silodosin|one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
214413072|NCT01144949|DRUG|placebo|one placebo capsule orally, once daily, with food for up to 4 weeks
214413073|NCT04213222|DRUG|Bevacizumab|bevacizumab combined with chemotherapy
214413074|NCT04166682|BEHAVIORAL|Home-based cardiac rehabilitation|cardiac rehabilitation done at home
214413075|NCT04166682|BEHAVIORAL|Routine care|Routine care and followup
214413076|NCT06421948|DRUG|Linperlisib and chidamide|A combination of linperlisib and chidamide will be administered for 6 cycles in patients responded to treatment.
214413077|NCT06421948|DRUG|cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone|A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.
214413078|NCT00831597|DRUG|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
214688841|NCT02500199|DRUG|Pyrotinib|Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
215016549|NCT04139902|DRUG|Dostarlimab (TSR-042) and TSR-022 (combination)|"If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
214413079|NCT00831597|DRUG|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
214413080|NCT03580967|DRUG|Vortioxetine|Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.
214413081|NCT01619943|OTHER|no intervention|clinical follow up
214413082|NCT01619943|OTHER|no intervention|no intervention
214413083|NCT00234143|BEHAVIORAL|Darbepoetin and Filgrastim|Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response
214688842|NCT03775018|PROCEDURE|Transversus abdominis plane blockade|Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.
214688843|NCT03775018|DRUG|Intravenous analgesia|Acetaminophen 1g/6h iv will be administered
214413084|NCT00234143|DRUG|Darbepoetin|Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
214413085|NCT00602589|DRUG|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
215016550|NCT03885206|OTHER|Level of healthcare services|Patiens judged to be eligible for admittance to a municipal acute care wrad will be admitted to hospital as an intervnetion, to be able to compare same patient groups.
215016551|NCT01027754|DRUG|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
215016552|NCT01027754|DRUG|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
215016553|NCT03796286|OTHER|Medium-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
215101601|NCT01616680|DRUG|brentuximab vedotin|Given IV
214413086|NCT03552770|DRUG|Bevacizumab|pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
214413087|NCT02167646|PROCEDURE|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
214688844|NCT05580172|DRUG|RH324|polymolecular
215016554|NCT03796286|OTHER|High-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
215016555|NCT03796286|OTHER|Control bar (0 g fiber)|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
214413088|NCT02716909|DEVICE|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
214413089|NCT04411446|DRUG|Vitamin D|5 capsules of 100.000 UI Vitamin D orally given all at once. One dose.
214413090|NCT04411446|DRUG|Placebo|5 capsules of containing placebo orally given all at once. One dose.
215016556|NCT02637674|PROCEDURE|Uterus Transplant|
214413091|NCT03491956|DEVICE|DFPP|Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
214688845|NCT01519622|OTHER|Questionnaire|Questionnaire to be distributed among sick elderly in the community
214688846|NCT03020758|DIETARY_SUPPLEMENT|Dried Fruit|Mixture of equal parts 4 dried fruits (figs, raisins, dates, plums) totaling 3/4 cup daily.
215016557|NCT02411045|BEHAVIORAL|Take and send a selfie|Direction to take and send a selfie.
215016558|NCT02411045|BEHAVIORAL|Workout gears|Direction to wear workout gears.
215016559|NCT02411045|BEHAVIORAL|Exercise|Direction to complete a 30 minute workout.
215016560|NCT05504083|DRUG|D-0120|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
215101602|NCT01616680|OTHER|laboratory biomarker analysis|Correlative studies
215101603|NCT01616680|OTHER|pharmacological study|Correlative studies
215101604|NCT03749811|DEVICE|Pupillometry|After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.
215101605|NCT04807335|DRUG|CT001|nasal spray
215101606|NCT04807335|DRUG|Ketamine|iv single dose
214413092|NCT02943655|DRUG|combined contraceptive pills (microcept)|oral combined contraceptive once daily
214413093|NCT02943655|DRUG|medroxyprogesterone acetate (progest)|oral 5 mg medroxyprogesterone acetate daily
214688847|NCT03020758|OTHER|High Carbohydrate Snack|Calorie-matched carbohydrate-rich snack.
214688848|NCT01601054|DEVICE|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
214688849|NCT03838172|OTHER|Family impact scale|The family Impact Scale (FIS) will be completed by the parents
214688850|NCT03450369|BIOLOGICAL|NB01|Use an existing therapy designed to kill existing facial bacterial followed by populating facial skin with a single application of NB01
214688851|NCT01223872|OTHER|interview|"* Standard Interview (2-15 years from last treatment)~* Demographic data interview (pre-initial study interview)"
214688852|NCT01223872|OTHER|clinic visit and interview|"* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
214413094|NCT02943655|DRUG|mefenamic acid (ponstan forte)|oral 500 mg mefenamic acid three times per day
214688853|NCT01223872|OTHER|interviews and clinic visit|"* Pre-REACH Clinic Interview(2-15 yrs from last treatment)~* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview(1mo from initial clinic visit)~* Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
214688854|NCT03403998|OTHER|Exercises|The treatment will consist of an 8-week progressive exercise program of neck flexors and extensors exercises supervised by a physical therapist for 30-45 min twice a week per 8 weeks as described in Arm/group descriptions.
214688855|NCT03403998|OTHER|Placebo|The placebo treatment will be for 30-45 min twice a week for 8 weeks, as for the intervention group. ( see details in arm description)
214413095|NCT00470626|DEVICE|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
214413096|NCT03833102|OTHER|biological analysis|ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
214413097|NCT01499108|DRUG|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
214413098|NCT04240730|PROCEDURE|Transvaginal natural orifice endoscopic surgery for endometrial cancer staging|Cases of extreme obese patients with early stage endometrial cancer who underwent v-NOTES
214413099|NCT02891629|DEVICE|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
214413100|NCT00633412|DRUG|Esomeprazole|20mg oral daily
214413101|NCT00633412|DRUG|Ranitidine|150mg oral twice daily
214413102|NCT00633412|DRUG|Esomeprazole|40mg oral tablet daily
214413103|NCT01749787|DRUG|PRTX-100 at 1.5 mcg/kg|
214413104|NCT01749787|DRUG|PRTX-100 at 3.0 mcg/kg|
214413105|NCT01749787|DRUG|PRTX-100 at 6.0 mcg/kg|
214688856|NCT00767156|OTHER|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
214688857|NCT00767156|OTHER|Base cream|The subjects use the base cream on the face, twice per day
214688858|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
214413106|NCT01749787|DRUG|PRTX-100 at 12.0 mcg/kg|
214413107|NCT01749787|DRUG|PRTX-100 at 240 mcg|
214413108|NCT01749787|DRUG|Placebo|Placebo administered via infusion once per week for 5 weeks
214413109|NCT01749787|DRUG|PRTX-100 at 420 mcg|
214413110|NCT01061229|DRUG|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
214413111|NCT01061229|OTHER|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
214413112|NCT05928364|PROCEDURE|Buccal mucosa for proximal ureter stricture|Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping
214688859|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
214688860|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement A|1, 2 or 4 capsules daily of oral supplement A for 3 days
214688861|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement B|4 capsules daily of oral supplement B for 3 days
214688862|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement C|1,2 or 4 capsules daily of oral supplement C for 3 days
214688863|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement D|1 or 2 tablets daily of oral supplement D for 3 days
214688864|NCT03707652|DIETARY_SUPPLEMENT|Oral Supplement D in combination with oral supplement C|1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
214688865|NCT03420378|DIETARY_SUPPLEMENT|vitamin D|Vitamin D replacement
214688866|NCT04005820|OTHER|Radiologic Centralized Review|The patient's imaging will be examined in one of the examination centers
214688867|NCT04005820|OTHER|Tissue sample (tumor, sung, urine)|all the samples will be made during the patients care
215016561|NCT05504083|DRUG|Benzbromarone|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
215101607|NCT04807335|DRUG|sufentanil|iv single dose
215101608|NCT02630511|DRUG|Mannitol|Mannitol consists of inhaling 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg
215101609|NCT02630511|DRUG|Methacholine|Methacholine consists of inhaling 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL
215101610|NCT02630511|DRUG|Placebo|Placebo consists of inhaling humidified air
214413113|NCT01194778|DIETARY_SUPPLEMENT|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
215016562|NCT00326495|DRUG|Cetuximab|Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
215016563|NCT00326495|DRUG|BAY 43-9006|Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
214413114|NCT01194778|DIETARY_SUPPLEMENT|vitamin K1|15 µg vitamin K1 per day during 12 weeks
214413115|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|15 µg vitamin K2 per day during 12 weeks
214413116|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|30 µg vitamin K2 per day during 12 weeks
214413117|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|45 µg vitamin K2 per day during 12 weeks
214413118|NCT01861678|PROCEDURE|High tie of IMA|Conventional technique
214688868|NCT00962000|OTHER|Dialysis Flow Rate Start 600mL/min|ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
214688869|NCT00962000|OTHER|Dialysis Flow Rate Start 800mL/min|BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
214688870|NCT02702193|BEHAVIORAL|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
215016564|NCT05386836|DEVICE|Pulse oximeter validation population|Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
215016565|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) with the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw with the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
215016566|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) without the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw without the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
215016567|NCT05311410|OTHER|Non-bloody dental procedures (control group)|Control group composed of 30 positive patients for SARS-CoV-2, from the same ICU, submitted to non-bloody procedures.
215016568|NCT05311410|PROCEDURE|Bloody dental procedures (study group)|Study group consisting of 30 patients who require open dental treatment and with a positive PCR test for SARS-CoV-2 prior and admitted to the Intensive Care Unit.
215016569|NCT00344669|DRUG|Albendazole 400 mg, given 6 monthly|
215016570|NCT01855568|PROCEDURE|Single-dose Methotrexate|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell \<15% between day 11 and 14."
215101611|NCT02630511|OTHER|Rest|
214413119|NCT01861678|PROCEDURE|Low tie of IMA|Technique for preserving left colic arterial perfusion
214413120|NCT04311229|DEVICE|Negative-Pressure Wound Therapy group|The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.
215101612|NCT02630511|OTHER|Exercise|
215101613|NCT04996251|DRUG|Bupivacaine Injection|0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy
214413121|NCT04311229|OTHER|contol group|Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
214413122|NCT02787109|BIOLOGICAL|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
214413123|NCT02787109|BIOLOGICAL|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
214413124|NCT02787109|BIOLOGICAL|Placebo|Saline
214413125|NCT02714127|OTHER|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
214413126|NCT02714127|OTHER|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
214413127|NCT00101725|DRUG|crofelemer|
215016571|NCT01855568|PROCEDURE|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell \<15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
214413128|NCT04866407|OTHER|Mentha x piperita|2% solution of Mentha x piperita diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Mentha x piperita' group.
214413129|NCT04866407|OTHER|Eucalyptus globulus|2% solution of Eucalyptus globulus diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Eucalyptus globulus' group.
214413130|NCT01801930|DRUG|OCV-103 and OCV-104|0.3 mg of each
214413131|NCT01801930|DRUG|OCV-103 and OCV-104|1 mg of each
215101614|NCT00356343|DEVICE|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
214413132|NCT01801930|DRUG|OCV-103 and OCV-104|3 mg of each
215016572|NCT00660959|DRUG|lixivaptan|oral capsule
215016573|NCT00660959|DRUG|placebo|oral capsule
215016574|NCT04125758|BEHAVIORAL|Mindfulness training|Brief audio recordings discussing mindfulness or guided mindfulness practices.
215016575|NCT04125758|BEHAVIORAL|Tracking time spent on mobile device|Participants will record each day how much time they estimate they spent on their smart phone in the past 24 hours.
215016576|NCT04210076|BEHAVIORAL|MBAT-T|The MBAT-Team program builds on the basic 4-week, 8-hour MBAT-Soldier program. In addition to the basic program, MBAT-Team includes exercises promoting the cultivation of attention and emotion regulation in the service of effective team interactions (e.g., mindful communication and listening; monitoring and attention to the activities and emotional states of others, and additional practices to promote collective mindfulness).
215016577|NCT04210076|BEHAVIORAL|MBAT-I|The MBAT-Individual program is based on the basic 4-week, 8-hour MBAT-Soldier curriculum.
215016578|NCT00710788|DRUG|sevelamer phosphate-binders|1600 mg/day for 2 years
215016579|NCT00710788|DRUG|Calcium Carbonate|Calcium carbonate 1 g/day for 2 years
215016580|NCT01723839|DRUG|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide|19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
215016581|NCT01713322|BEHAVIORAL|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
215016582|NCT01713322|BEHAVIORAL|No pain management education|Control - parents receive general information about childhood immunization.
215016583|NCT03280615|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
215016584|NCT03280615|DIETARY_SUPPLEMENT|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
215101615|NCT00356343|OTHER|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
215101616|NCT05347706|DIETARY_SUPPLEMENT|formula|Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed
215101617|NCT04602442|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
215101618|NCT04602442|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
214413133|NCT01801930|DRUG|OCV-103 and OCV-104|6 mg of each
215101619|NCT04602442|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
214413134|NCT01654705|DRUG|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
214413135|NCT01654705|DRUG|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
214413136|NCT00266097|DRUG|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
214413137|NCT00266097|DRUG|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
214413138|NCT00266097|DRUG|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
214413139|NCT00266097|RADIATION|radiation therapy|5040 cGy, every week, up to 6 weeks
214413140|NCT00266097|DRUG|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
214413141|NCT00266097|DRUG|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
214413142|NCT00004560|DEVICE|defibrillator|
214413145|NCT04312776|OTHER|none intervention|
214505021|NCT06522139|PROCEDURE|Implantation of Episealer Talus Implant|Subjects will be on study for up to 60 months after their talus implant surgery. Treatment: Implantation of Episealer Talus Implant Follow-up: 60 months The total duration of the study is expected to be 75 months. 12 months for subject recruitment, 60 for final subject follow-up and 3 for data analysis and production of the final report.
214505022|NCT06509230|OTHER||The fibrosis grades were grouped without drug intervention
214505023|NCT03890653|BEHAVIORAL|Performance-Based Financing|Incentive-based payments
214413146|NCT02678624|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
214413147|NCT03937687|DRUG|Caffeine+TeaCrine+Dynamine|combination of caffeine, TeaCrine, and Dynamine
214413148|NCT03937687|DRUG|Placebo|Placebo
214413149|NCT03937687|DRUG|Caffeine|Caffeine
214413150|NCT03523910|DEVICE|Magnetic Resonance Imaging (MRI) with exercise|MRI scan with a novel exercise device.
214413151|NCT03962192|OTHER|Attitudinal measures|A collection of 3 distinct attitudinal instruments comprise this survey.
214413152|NCT03380975|DRUG|Montelukast 10mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
214688871|NCT01016106|GENETIC|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
215016585|NCT02369679|DEVICE|Precast Adjustable Compression Wrap (Circaid)|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
215016586|NCT02369679|DEVICE|Multilayer Compression Bandages|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
215101620|NCT02235896|BEHAVIORAL|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
215101621|NCT02809378|DRUG|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
215101622|NCT02809378|DRUG|sevoflurane|Inhalational anesthetics Halogenated.
215101623|NCT02809378|DRUG|remifentanil|ultra-short acting opioid anesthetics
215101624|NCT02809378|DRUG|pentothal sodium|intra-venous anesthetics for anesthesia induction
215101625|NCT02809378|DRUG|propofol|intra-venous anesthetics for anesthesia induction and maintenance
214413153|NCT04209881|OTHER|ovarian reserve for Ankylosing spondylitis and control groups|"Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
214505024|NCT03890653|BEHAVIORAL|Decentralized Facility Financing|Financing not linked to service delivery.
214505025|NCT00797056|DRUG|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
214505026|NCT00797056|DRUG|Placebo|Saline SQ daily for 10 days
214505027|NCT00797056|DRUG|Aspirin|Aspirin 75 mg/day for 14 days
214505028|NCT00797056|DRUG|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
214505029|NCT01386372|DRUG|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
214505030|NCT01386372|OTHER|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
214505031|NCT00986869|PROCEDURE|Doppler echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
214505032|NCT00273052|DRUG|Carvedilol Phosphate modified release formulation|
214505033|NCT00273052|DRUG|metoprolol succinate|
214505034|NCT03043443|DRUG|Melatonin|Natural health product for sleep problems treatment
214505035|NCT03043443|DRUG|Placebo|Lactose containing pills
214505036|NCT03783936|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
214505037|NCT03783936|DRUG|Leucovorin|Leucovorin 400 mg/m2
214505038|NCT03783936|DRUG|5 fluorouracil|5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
214505039|NCT03783936|DRUG|Trastuzumab|Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
214505040|NCT03783936|DRUG|Avelumab|Avelumab 800 mg
214505041|NCT00454194|DRUG|pemetrexed disodium|given IV
214505042|NCT00454194|DRUG|sorafenib tosylate|given orally
214505043|NCT05461755|COMBINATION_PRODUCT|Fractional radiofrequency and topical Tretinoin|Treatment of striae with fractional radiofrequency and topical tretinoin in combination
214505044|NCT05461755|DRUG|Topical Tretinoin|Treatment of striae with topical tretinoin alone
214505045|NCT05461755|DEVICE|Fractional radiofrequency|Treatment of striae with fractional radiofrequency alone
215016587|NCT03357172|BIOLOGICAL|Blood Sample|Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2
214413154|NCT04311203|BEHAVIORAL|Mental Health First Aid|The intervention has 3 parts:1.Two-day MHFA training provided by MHFA England. A manualised programme designed to provide individuals with: an in-depth understanding of mental health and the factors that can affect wellbeing, practical skills to spot triggers and signs of mental health issues, confidence to step in, reassure and support a person in distress, enhanced interpersonal skills such as non-judgemental listening, knowledge to help someone recover their health by guiding them to further support - whether that's self-help resources, through their employer, the NHS, or a mix. 2.Raising awareness of the presence of MHFA in the organisation. 3.The application of MHFA to participants in the workplace using the manualised five-stage approach, ALGEE: Approach the person, assess and assist with any crisis; Listen and communicate non-judgementally; Give support and information; Encourage the person to get appropriate professional help and Encourage them to seek other forms of support.
214413155|NCT01265758|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
214413156|NCT01432158|BIOLOGICAL|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
214413157|NCT01432158|BIOLOGICAL|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
214413158|NCT01552018|DRUG|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
214413159|NCT01552018|DRUG|Placebo|Placebo, 1 tablet per day for 3 months.
214413160|NCT04672473|BIOLOGICAL|DC-CTL|DAC combined with Ag-CTL
214413161|NCT02509780|OTHER|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
214413162|NCT01976754|DRUG|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
214413163|NCT05857436|OTHER|apical periodontitis|Of these patients, 60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
214413164|NCT05251688|OTHER|Cryoanalgesia|"On the first day of the study, the PI met the participants and assessed their level of consciousness using the Modified Glasgow Coma Scale to ensure that they were unconscious and reviewed the medical records to collect their sociodemographic data. After that, the participants received routine care before the arterial puncture. The PI assessed their pain scores during the puncture.~In the second meeting (on the same day or the following day), the PI prepared the ice packs by crushing small pieces of ice and wrapping them in smooth gauze to avoid skin damage and moisture in the puncture area. Before the arterial puncture, the ice pack was applied over the selected puncture site (radial, brachial, or femoral artery) for 5 minutes in addition to the routine care. After removing the ice pack, the nurse palpated the artery, wiped of the residue of ice vapor present on the skin, and took the arterial blood sample. During the puncture, the PI assessed the participants' pain scores."
214413165|NCT01487564|DRUG|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
214413166|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
214413167|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
214413168|NCT01402271|DRUG|carboplatin|
214413169|NCT01402271|DRUG|paclitaxel|
214688872|NCT00016523|DRUG|Inhaled nitric oxide|Started at 5 ppm and could be increased to 10 ppm
215101626|NCT00372697|DRUG|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
214413170|NCT01402271|DRUG|pazopanib hydrochloride|
214413171|NCT01402271|OTHER|laboratory biomarker analysis|
214413172|NCT01402271|OTHER|pharmacological study|
214413173|NCT06375824|DRUG|Bufei Recipe|Bufei Recipe: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.
214413174|NCT06375824|DRUG|Bufei Recipe placebo|The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
214413175|NCT06553560|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2 cm lateral to the sternal border to visualize the T2-T4 intercostal space and to identify the pectoralis major muscle, intercostal muscle, and pleura. 10 ml of 0.25% bupivacaine local anesthetic is administered between the pectoralis major and intercostal muscle using an in-plane approach with a 100 mm needle. In addition, a Recto-Intercostal Fascial Plane Block is performed with a high-frequency linear USG probe. The probe is placed 2-3 cm lateral to the xiphoid so that the rectus abdominis muscle and 6-7th cartilages are visualized. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique and 1-2 ml of saline is injected. After observing the spread to the target plane, 20 ml of 0.25% bupivacaine is applied. The same process is repeated bilaterally.
214413176|NCT02215044|DRUG|BI 2536, intravenous|
214688873|NCT00016523|DRUG|Placebo|Started at 5 ppm and could be increased to 10 ppm
214688874|NCT05517603|DRUG|AJ201|Administered orally
214688875|NCT05517603|DRUG|Placebo|Administered orally
215016588|NCT03357172|BIOLOGICAL|Bone marrow aspiration|Additional bone marrow aspiration before graft, D30, D90, Y1
215016589|NCT03357172|BIOLOGICAL|Blood sample|Before donation
215016590|NCT03357172|BIOLOGICAL|Allogeneic hematopoietic stem cell sample|Allogeneic hematopoietic stem cell sample
215016591|NCT03788928|DIAGNOSTIC_TEST|serum mitochondrial DNA|serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis
215016592|NCT04987450|DRUG|Methylprednisolone, prednisone|The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
214688876|NCT04516018|OTHER|Cold exposure|Subjects will be exposed to shivering thermogenesis for at least 1 hour for 10 days
215101627|NCT06409143|DEVICE|HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
215016593|NCT03002857|DEVICE|LMA-C|LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
215101628|NCT06409143|DEVICE|Sham HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
215101629|NCT06409143|OTHER|UE rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
214413177|NCT02215044|DRUG|Gemcitabine, intravenous|
214413178|NCT05264467|BIOLOGICAL|Platelet rich fibrin on colorectal anastomosis|Platelet rich fibrin on colorectal anastomosis
214413179|NCT01413113|DRUG|pazopanib hydrochloride|Given PO
214505046|NCT05388045|OTHER|Patient Reported Outcome Measure|A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.
214505047|NCT02827201|DRUG|FOLFIRI.3|For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
214694004|NCT06358937|PROCEDURE|Scaling and Root Planing using ultrasonic and curettes|Scaling and root planing (SRP) using ultrasonic device at a moderate setting and with the appropriate tips and curettes will be also used where indicated and time spent in SRP on each tooth will not be restricted.
214413180|NCT01413113|RADIATION|iodine I 131|Given IM
214413181|NCT06216730|PROCEDURE|Endoscopic papillectomy|"patients undergoing endoscopic papillectomy will be included and treated according to the study algorithm.~* A papillary adenoma (abnormal tissue growth/ tumour at junction of bile duct \& intestines) will be removed completely by cutting \& removing abnormal tissue growth using a flexible tube containing a camera through the mouth.~* After the procedure you will be admitted in the hospital for at least 24 hours for observation,~* You will be asked to use medications which decrease acid production (PPIs- proton pump inhibitors) in stomach for 2 weeks to decrease the risk of bleeding."
214413182|NCT04157257|DRUG|TDF tablet|TDF tablet 300mg QD
214413183|NCT04157257|DRUG|Entecavir Tablet|Entecavir tablet 0.5mg QD
214413184|NCT04157257|DRUG|QL-007|QL-007 tablets 200mg BID
214413185|NCT00908947|DEVICE|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
214413186|NCT04542369|DRUG|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Inductive/neoadjuvant therapy: Tislelizumab + EP Maintenance/adjuvant therapy: Tislelizumab + EP
214413187|NCT04228055|BEHAVIORAL|CLIPP2|Diabetes Prevention Program and Comprehensive Lifestyle Improvement Program with emphasis on a low carbohydrate and Keto diet, physical activity, sleep optimization and stress management.
214413188|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
214413189|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
214413190|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
214413191|NCT06138951|OTHER|Endurance exercise|On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.
214413192|NCT04861610|BEHAVIORAL|Brief mindfulness based program|An intervention promotes the acceptance and emotion regulation in caregiving for frail older adults
214413193|NCT04861610|BEHAVIORAL|Psychoeducation|An intervention promotes the coping and problem solving in caregiving for the frail older adults
214413194|NCT02906878|PROCEDURE|Platelets transfusion|Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter
214413195|NCT01239563|DRUG|antithymocyte globulin|Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose
214413196|NCT01239563|DRUG|Basiliximab|Intravenous 20mg, day 0\&4
214413197|NCT03396835|DEVICE|INVSENSOR00009|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
215016594|NCT03002857|DEVICE|Baska Mask|Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
215016595|NCT03002857|DEVICE|I-gel|I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
214413198|NCT00422019|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
214413199|NCT00422019|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
214413200|NCT02052648|DRUG|Indoximod|
214413201|NCT02052648|DRUG|Temozolomide|
214413202|NCT02052648|DRUG|Bevacizumab|
214413203|NCT02052648|RADIATION|Stereotactic Radiation|
214413204|NCT03721016|DRUG|MT10109L|MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
214413205|NCT03721016|DRUG|Placebo|Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
214413206|NCT02931123|DRUG|lattulose and rifaximine|
214413207|NCT02232178|DRUG|2 100mg Xaracoll implants|
214413208|NCT02232178|DRUG|3 100mg Xaracoll implants|
214413209|NCT02232178|DRUG|150mg Bupivacaine HCl injection|
214413210|NCT00817635|DRUG|LCI699|LCI699 oral capsules
214413211|NCT00817635|DRUG|Eplerenone|Eplerenone oral capsules
214688877|NCT02018952|OTHER|Ultrasonography assessment|"All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).~Day 0 :~* Information of patient and no opposition getting~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day 4 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day15 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~M3 :~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~* Functional outcome"
214688878|NCT05462769|DEVICE|Percutaneous vascular closure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
214688879|NCT02512003|DEVICE|Fantom Scaffold|
214688880|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
214413212|NCT00817635|DRUG|LCI699-matching Placebo|LCI699-matching placebo oral capsules
214413213|NCT00817635|DRUG|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
214413214|NCT04117451|OTHER|Propolis|Investigating the impact of propolis mouthwash on oral and cardiovascular health
214413215|NCT01842971|PROCEDURE|two stage hepatectomy|
214413216|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|solution for intramuscular injection, 1 dose (0.5 mL)
214688881|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
214688882|NCT04402268|DEVICE|Cardioverter-defibrillator|We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.
214413217|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
214413218|NCT05903963|DRUG|Midazolam|midazolam infusion by 0.03-0.3mg/kg in increments of 1-2.5mg followed by Maintenance dose: 0.03-0.2mg/kg/hour for midazolam.
214413219|NCT05903963|DRUG|dexmedetomidine|dexmedetomidine infusion 1 µg/kg dexmedetomidine for 10 minutes followed by a continuous IV infusion at 0.2-0.3 µg/kg/hour .
214413220|NCT01720446|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
214413221|NCT01720446|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
214413222|NCT01720446|DRUG|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
214413223|NCT02496793|BEHAVIORAL|Peer-facilitated community support group|Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
214413224|NCT02612584|DEVICE|Pinhole Soft Contact Lens apply for presbyopia|
214413225|NCT03862833|DRUG|IL2|"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"
214413226|NCT03862833|DRUG|Zoledronic Acid|4 mg at day +15 post graft
214413227|NCT05339971|OTHER|block perforation|The bone block used for lateral bone augmentation will be perforated several times.
214413228|NCT02925052|DEVICE|Gastric Tube Guide|
214413229|NCT02925052|DEVICE|Conventional placement|
214413230|NCT02175212|DRUG|Short term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months"
214688883|NCT01201798|DRUG|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
214688884|NCT01201798|DRUG|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
214413231|NCT02175212|DRUG|Long term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
214413232|NCT02175212|RADIATION|Short term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
214413233|NCT02175212|RADIATION|Long term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
214413234|NCT02874118|BEHAVIORAL|Fried scale for frailty assessement|
214413235|NCT05616559|COMBINATION_PRODUCT|Treatment Package for First-Episode Depression|The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
214413236|NCT06152484|OTHER|Pentacam, Corvis ST and CASIA2|morphological and biomechanical parameters of corneal were obtain by CASIA2, Pentacam and Corvis ST
214413237|NCT02508896|BIOLOGICAL|AFFITOPE® AT04A+adjuvant|subcutaneous injection
214413238|NCT02508896|BIOLOGICAL|AFFITOPE® AT06A+adjuvant|subcutaneous injection
215016596|NCT04612231|BEHAVIORAL|TEACCH School Transition to Employment and Postsecondary Education (T-STEP)|The T-STEP Program is a 12-week transition intervention targeting specific challenges that young adults with ASD experience in executive function, social communication, and emotion regulation including group intervention, internship, and counseling services
215016597|NCT04612231|BEHAVIORAL|Counseling Services Alone|The Counseling Services Alone Intervention will receive 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
215016598|NCT02756091|OTHER|No study-specific intervention|
214413239|NCT02508896|BIOLOGICAL|Adjuvant without active component|subcutaneous injection
214413240|NCT01072357|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
215016599|NCT06521593|PROCEDURE|Applying a tourniquet for either a short or long time during total knee replacement|All patients underwent spinal anesthesia and the tourniquet was applied to the middle of the thigh; in group one who underwent long-duration application of a tourniquet, it was applied only before the skin incision by inflating it to 150 mmHg above the systolic blood pressure of the patients and deflation finishing of bone cementation while in group two who underwent short duration application of a tourniquet, the tourniquet was only applied just before cementation, was inflated also to 150 mmHg above the systolic blood pressure of the patients, and was deflated after bone cementation.
215016600|NCT04960943|DRUG|Pyrotinib with or without trastuzumab|After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
215016601|NCT06353932|OTHER|keeping the endotracheal tube cuff pressure within a certain range|The endotracheal tube cuff pressures of the study group patients were kept within the range of 20-25 cm H2O.
215016602|NCT01265147|DRUG|Cisplatin|40mg/m2/w
215016603|NCT01265147|DRUG|Nedaplatin|40mg/m2/w
215016604|NCT00432991|DRUG|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
215016605|NCT00432991|DRUG|Saline Placebo|0.5 mL, IM (in the muscle), one time
215016606|NCT01890538|DRUG|Administration of 100 mg dimenhydrinate intravenous|
214413241|NCT01072357|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
214413242|NCT01876511|DRUG|MK-3475|MK-3475 10 mg/kg every 14 days
214413243|NCT00728637|BEHAVIORAL|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
215016607|NCT01890538|DRUG|2 g piracetam intravenous|
215016608|NCT02225795|OTHER|Hematopoietic stem cell transplantation|"Immuno-ablative regimen for HSCT:~Day Treatment~* 6 r-ATG 2 mg/kg~* 5 r-ATG3 2 mg/kg~* 4 r-ATG3 2 mg/kg~* 3 Cyclophosphamide with Mesna~* 2 Cyclophosphamide with Mesna~* 1 REST 0 PBSC infusion~  * 3 Cyclophosphamide with Mesna~ * 4 Cyclophosphamide with Mesna~ * 6 Start GCSF"
215016609|NCT05706285|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
215016610|NCT05179005|DEVICE|RibFix Advantage|Intrathoracic rib fracture stabilization
214413244|NCT00728637|BEHAVIORAL|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
214413245|NCT02390258|DRUG|10mg XEN-D0103|
214413246|NCT02390258|DRUG|Placebo|
214413247|NCT02390258|DRUG|30mg XEN-D0103|
214505048|NCT02827201|DRUG|nab-paclitaxel+ gemcitabine|For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
214505049|NCT00005799|DRUG|fludarabine phosphate|Given IV
214505050|NCT00005799|RADIATION|total-body irradiation|Undergo low-dose TBI
214505051|NCT00005799|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
215016611|NCT06255938|DIAGNOSTIC_TEST|smears|PCR smears for HPV testing will be performed
215016612|NCT02500342|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
215016613|NCT02500342|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
215016614|NCT05382325|BIOLOGICAL|MK-1484|Subcutaneous (SC) injection
215016615|NCT05382325|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
215016616|NCT03486106|OTHER|Music|Music will be provided via Spotify, which is an Internet streaming music service, and will be played through headphones; this way, no other individual in the operating room will be distracted or influenced by the patient's music selection.
214413248|NCT02390258|DRUG|60mg XEN-D0103|
214505052|NCT00005799|PROCEDURE|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
214413249|NCT02390258|DRUG|120mg XEN-D0103|
214413250|NCT02390258|DRUG|200mg XEN-D0103|
214413251|NCT02390258|DRUG|150mg XEN-D0103|
214413252|NCT05126719|DRUG|MRG003|Administered intravenously
214413253|NCT05126719|DRUG|Capecitabine tablets|Administered peros
214505053|NCT00005799|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
214505054|NCT00005799|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
214505055|NCT00005799|DRUG|cyclosporine|Given PO
214505056|NCT00005799|DRUG|mycophenolate mofetil|Given PO
214505057|NCT00005799|OTHER|pharmacological study|Correlative studies
214505058|NCT00005799|OTHER|laboratory biomarker analysis|Correlative studies
214505059|NCT05499767|BEHAVIORAL|HEPPI|Homebound Elderly People Psychotherapeutic Intervention
214505060|NCT03345979|COMBINATION_PRODUCT|Aripiprazole Lauroxil|Intramuscular injection; study drug provided using a pre-filled syringe
214505061|NCT03345979|DRUG|Paliperidone Palmitate|Intramuscular injection
214505062|NCT04927078|OTHER|Observation of breathing pattern|Observations will be collected using a remote vision based patient monitoring and management system.
214505063|NCT04968509|DRUG|PCSK9 inhibitors and statins with or without ezetimibe|Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
214505064|NCT04968509|DRUG|Statins with or without ezetimibe|Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
214505065|NCT02279485|DRUG|Perampanel|
214505066|NCT02673359|DRUG|Progesterone|Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day
214505067|NCT02673359|PROCEDURE|Cervical cerclage|Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
214505068|NCT03829553|RADIATION|Hypofractionated radiotherapy|4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast
214505069|NCT03829553|RADIATION|Conventional radiotherapy|5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast
214505070|NCT01814605|PROCEDURE|Infragluteal space group|"Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
214505071|NCT01814605|PROCEDURE|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
214505072|NCT06134557|PROCEDURE|conventional stents|performed the study to compare the safety and efficacy between flow diverters and conventional stents in IVADA patients undergoing endovascular therapy. Stent-assisted coiling is the preferred option for most surgeons. In addition,It is believed that dense packing is not necessary as long as the aneurysm neck is covered to isolate the dissection. How ever,whether it is really necessary to adjunct coil,and if it is necesary, what is the ideal packing density of coils, there is no clear conclusion at present.This study aimed to compare the safety and efficacy between flow diverter and conventional stents in patients with IVADA, determine the ideal packing density of coils after FD stent placement,and to observe the hemodynamic changes before and after the treatment of FD stent.
214505073|NCT03730688|DEVICE|Conventional compartment pressure measurement|Compartment pressure will be measured using the conventional compartment pressure measurement system.
214505074|NCT03730688|DEVICE|Experimental compartment pressure measurement|Compartment pressure will be measured using the newly-developed compartment pressure measurement system.
214413254|NCT05126719|DRUG|Docetaxel injection|Administered intravenously
214413255|NCT04286165|OTHER|Brief Peer Supported webSTAIR|The BPS webSTAIR program is an online platform where individuals are taught skills in emotion regulation. In this program they will learn how to recognize the emotions they are feeling by assessing their own body language, being attentive to their thought processes, and attempting to replace negative behaviors with positive. Throughout the platform they will engage in written exercises to help them solidify the lessons with their own life experiencing. They will also have the support of peers throughout the program to help them when they need clarification or having a difficult time applying the lesson(s).
214413256|NCT06553222|BIOLOGICAL|Putty bone - Tricalcium phosphate with Collagen gel|Minimally invasive debridement periodontal flap and Bone graft placement to augment the lost alveolar bone
214413257|NCT02400151|DRUG|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
214413258|NCT02400151|DRUG|Placebo|Patients randomized to this group will receive placebo for 90 days.
214413259|NCT02400151|OTHER|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
214413260|NCT02400151|OTHER|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
214413261|NCT05609448|PROCEDURE|MRI-guided radioembolization|Catheter placement will be performed using fluoroscopy, after which patients are transferred to the MRI scanner, where holmium microspheres are administered based on MRI dosimetry. Thereby, patients get a personalized dose administration.
214413262|NCT03774914|DRUG|Alemtuzumab (GZ402673)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
214413263|NCT06432842|OTHER|Laser Treatment|In the study group, low-dose laser treatment was applied in addition to conventional treatment. Chattanoga Group Therapeutic Laser device was used for laser treatment. Laser treatment was applied to 8 sensitive points around the knee for 1 minute, for a total of 8 minutes. Laser treatment was applied continuously, with a wavelength of 830nm and a power of 6J.
214413264|NCT04950855|DIAGNOSTIC_TEST|Optical Coherence Tomography,Optical Coherence Tomography Angiography(Topcon)|Optical coherence tomography optical coherence tomography angiography
215016617|NCT03486106|OTHER|Headphones|All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
214688885|NCT02125487|BEHAVIORAL|Teaching using Hybrid Simulation of breast examination|"Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)"
214688886|NCT02125487|BEHAVIORAL|Teaching using traditional method|"Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE."
214688887|NCT05151341|DIAGNOSTIC_TEST|Urine collection (150ml)|Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)
214688888|NCT05151341|OTHER|Blood sample (20 ml)|"Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research."
214413265|NCT03988504|DIAGNOSTIC_TEST|Routine check up including genetic testing|Intervention is a routine check up including preemptive genetic testing
214413266|NCT02182414|DRUG|BI 207127 NA (TF-I)|200 mg tablet
214413267|NCT02182414|DRUG|BI 207127 NA (TF-II)|400 mg tablet
214413268|NCT02182414|DRUG|BI 207127 NA delayed release|400 mg tablet
214688889|NCT04571008|OTHER|Placebo|Intervention will last at least 16 weeks in the form of two capsules.
215016618|NCT03486106|DRUG|Propofol|All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
215016619|NCT03862053|DRUG|Manuka honey|manuka eyedrops applied to the ocular surface
215016620|NCT00008333|DRUG|vinorelbine tartrate|
214413269|NCT02182414|DRUG|BI 207127 NA extended release (10% HPMC)|400 mg tablet
214688890|NCT04571008|DIETARY_SUPPLEMENT|Treatment|Intervention will last at least 16 weeks in the form of two or three NMN capsules (total of 300 or 450 mg/day).
214688891|NCT03919292|DRUG|Neratinib|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
215016621|NCT01755156|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
214413270|NCT02182414|DRUG|BI 207127 NA extended release (15% PEO)|400 mg tablet
215016622|NCT01755156|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
215016623|NCT01755156|DRUG|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
215016624|NCT01755156|DRUG|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
214413271|NCT02182414|DRUG|BI 207127 NA extended release (20% HPMC)|400 mg tablet
214413272|NCT02434718|DRUG|Aducanumab|As described in the treatment arm
214413273|NCT02434718|DRUG|Placebo|IV administration of 0.9% sodium chloride
214413274|NCT04102449|DRUG|Apremilast|Single arm receiving Apremilast and ultrasound examinations
214413275|NCT05043987|DRUG|CPO102|Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
214413276|NCT03875690|DRUG|Injection of methylprednisolone|Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.
214413277|NCT03875690|DRUG|Injection of sodium chloride|patients in the placebo group will receive 50 mL of sodium chloride 0.9% in a ready-to-use bag during 30 minutes at anaesthesic induction.
214413278|NCT03875690|BIOLOGICAL|Blood samples|electrolyte panel and glycemia performed within the first 24 hours after surgery.
214413279|NCT06152198|DEVICE|Treatment|Allocation to hip arthroplasty or internal fixation. The choice between hemi- or total hip arthroplasty in the arthroplasty group and type of osteosynthesis are the surgeon preference.
214413280|NCT00618540|BIOLOGICAL|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
214413281|NCT00618540|DRUG|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age \<12 months)
214505075|NCT02027584|OTHER|collection of remnant of clinically indicated blood sample|collection of remnant of clinically indicated blood sample
214505076|NCT01263132|DRUG|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
214505077|NCT01263132|DRUG|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
215016625|NCT01755156|DRUG|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
215016626|NCT01755156|DRUG|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (\>= 1500 mg daily) throughout the study.
215016627|NCT02144246|OTHER|Non-hormonal period|
215016628|NCT02144246|DRUG|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
215016629|NCT03049397|OTHER|Communication Intervention|Complete Enhancing Connections program
215016630|NCT03049397|OTHER|Questionnaire Administration|Ancillary studies
215016631|NCT00090402|DIETARY_SUPPLEMENT|Fish Oil|Fish oil capsule
215016632|NCT00090402|DIETARY_SUPPLEMENT|Lipoic Acid|Lipoic acid capsule
214413282|NCT00618540|DRUG|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age \<12 months)
214413283|NCT00618540|PROCEDURE|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
214413284|NCT01854437|DRUG|Mg Oxide|250 mg orally for 4 weeks
214413285|NCT00606580|DRUG|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
214413286|NCT00606580|DRUG|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
214413287|NCT00606580|DRUG|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
214413288|NCT03326479|DIAGNOSTIC_TEST|Caris Molecular Intelligence Profile|A comprehensive biomarker testing
214413289|NCT02887261|DEVICE|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
214413290|NCT02887261|DEVICE|Conventional Port|not for power injection for contrast media.
214505078|NCT04094207|DRUG|Placebo oral tablet|Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
214505079|NCT04094207|DRUG|Pentoxifylline|Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
214505080|NCT04413526|PROCEDURE|radiofrequency|radiofrequency combined with liver resection
214505081|NCT04413526|PROCEDURE|TACE|only TACE treatment
214505082|NCT04413526|PROCEDURE|TACE+radiofrequency|TACE followed by radiofrequency
215016633|NCT00090402|OTHER|Fish Oil Placebo|Soybean oil placebo capsule
215016634|NCT00090402|OTHER|Lipoic Acid Placebo|Lipoic acid (LA) placebo capsule containing no LA
215101630|NCT06409143|DEVICE|HD-tES (Bilateral)|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds.
215101631|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
215101632|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
215101633|NCT01055314|BIOLOGICAL|Cixutumumab|Given IV
214413291|NCT05416450|DEVICE|intravaginal electrical stimulation added to bladder training|BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.
214413292|NCT06463171|DRUG|Almonertinib|"Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.~Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off."
215016635|NCT00382928|DEVICE|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
215016636|NCT06353516|DRUG|Propofol|delivered via intravenous route
214413293|NCT01282775|BEHAVIORAL|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
214413294|NCT01282775|BEHAVIORAL|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
214413295|NCT05037344|BEHAVIORAL|Cognitive-behavioral psychotherapy|The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
215016637|NCT06353516|DRUG|Sevoflurane|delivered via inhalation route
215016638|NCT04772924|BEHAVIORAL|fasting|more than 12 hour of fasting as ceremony of Ramadan
215016639|NCT04772924|BEHAVIORAL|not fasting|preferred not to take long term fasting
215016640|NCT00946036|DRUG|Sertraline Hydrochloride|
214413296|NCT02876146|DRUG|Benzimidazole|Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
214413297|NCT04974489|BEHAVIORAL|Emotion-based messages about the harm of VLNC|Participants in this arm will receive 3 emotion-based messages about the harm of VLNC during the survey data collection.
214413298|NCT04974489|BEHAVIORAL|Continued-harm-framed messages about the harm of VLNC|Participants in this arm will receive 3 continued-harm-framed messages about the harm of VLNC during the survey data collection.
214413299|NCT04974489|BEHAVIORAL|Myth-refuting messages about the harm of VLNC|Participants in this arm will receive 3 myth-refuting messages messages about the harm of VLNC during the survey data collection.
214413300|NCT04974489|BEHAVIORAL|Control messages about littering|Participants in this arm will receive 3 control messages about littering during the survey data collection.
214413301|NCT01396109|PROCEDURE|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA\* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
214413302|NCT01396109|PROCEDURE|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
214413303|NCT04301388|PROCEDURE|Transvaginal ultrasound|Transvaginal ultrasound to measure cervical length if persist regular uterine contraction
214505083|NCT04179526|BEHAVIORAL|Transdiagnostic Internet-delivered REBT|The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
214505084|NCT05154955|DRUG|10XB-101 Solution for Injection|One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
214505085|NCT05154955|DRUG|10XB-101 Vehicle Solution for Injection|This is the placebo control
214505086|NCT03063021|DRUG|N-Acetyl Cysteine (NAC)|Oral tablets of N-acetyl-cysteine
215016641|NCT01084759|DRUG|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. \> 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
215016642|NCT01084759|DRUG|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
215016643|NCT01528774|OTHER|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
215016644|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 1|The study foresees the intake of 1 capsule per day during 84 days
215016645|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 2|The study foresees the intake of 1 capsule per day during 84 days
215016646|NCT06032598|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 84 days
215016647|NCT03048019|DRUG|Tirofiban|Patients will receive Tirofiban during the PCI procedure
215016648|NCT03048019|DRUG|Cangrelor|Patients will receive Cangrelor during the PCI procedure
215101634|NCT01055314|DRUG|Cyclophosphamide|Given IV
214413304|NCT01794377|BEHAVIORAL|30 minutes of high intensity training|"This group will carry out a 5-min warm-up period on bicycle ergometer at an intensity corresponding to 50% of Vo2max before performed eight times the intermittent training exercise as follows:~* 30 sec at 120% of Vo2max,~* 1 min at 50% of Vo2max,~* 15 sec at 30-40 revolutions per minute of strength training at 100% of the maximal anaerobic power, which will be first determined by means of a force-velocity test on a Monark ergometer,~* 1 min at 50% of Vo2max.~The training session will be terminated by a 3-min cool-down period at 40% of Vo2max.~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
214413305|NCT01794377|BEHAVIORAL|40 of an endurance training|"The moderate-intensity continuous exercise group will carry out a 40-min session of continuous cycling at a moderate intensity (50 % of Vo2max).~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
214413306|NCT01105884|PROCEDURE|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
214688892|NCT03919292|DRUG|Divalproex Sodium|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
214413307|NCT01105884|PROCEDURE|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
214413308|NCT01105884|PROCEDURE|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
214413309|NCT01105884|PROCEDURE|Hydrogel|All the subjects in this group will be treated with Hydrogel
214413310|NCT01105884|PROCEDURE|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
214413311|NCT02028130|PROCEDURE|LAA electrical isolation + occlusion|LAA electrical isolation + Watchman device implantation to occlude LAA
214688893|NCT04028492|DRUG|Tradipitant|BID
214688894|NCT04028492|DRUG|Placebo|BID
214688895|NCT04028492|DRUG|Open Label Tradipitant|BID
214688896|NCT05153733|DEVICE|RIFRAM implant|Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
214688897|NCT04742946|OTHER|Digital Physiotherapy Practice (Telerehabilitation)|Online Physiotherapy services
214688898|NCT05610995|DEVICE|SENSIUM Patch|The SENSIUM device is a tool to monitor vital signs by applying a connected skin patch whose objective is to detect complications early. The health data is transmitted to the practitioner and in case of disturbance of the parameters, an alert is sent. The patient can be called for consultation or hospitalization if necessary. This device has been tested under real clinical conditions in surgical units. The continuous monitoring of vital signs resulted in earlier detection of sepsis, earlier administration of antibiotics, shorter average length of stay and lower 30-day readmission rates.
214688899|NCT04222439|DEVICE|AI for the Diagnosis of Gastrointestinal Diseases|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
214688900|NCT04278729|DRUG|Apixaban 5 MG|1 - 5 mg tablet taken orally twice a day
215016649|NCT02596984|DRUG|Caspofungin|Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
215016650|NCT06039800|OTHER|No intervention|No intervention
215016651|NCT04919551|DRUG|vicagrel|Oral administration after fasting/high-fat meal/low-fat meal
215016652|NCT02004275|DRUG|pomalidomide|given PO
215016653|NCT02004275|DRUG|ixazomib|given PO
215016654|NCT02004275|DRUG|dexamethasone|given PO
215016655|NCT05224648|DEVICE|TOF scan train of four ratio monitoring|Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
214413312|NCT01250002|DRUG|Placebo|Placebo will receive the same volume of saline infusion.
214413313|NCT01250002|DRUG|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
214413314|NCT02430181|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
214688901|NCT06556277|DRUG|Metyrapone And Hydrocortisone|"Drug: Metyrapone 250 mg Oral Tablets~During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Hydrocortisone 19,9mg/12mg s.c., pulsatile with a flow rate of 10μl/s~Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 in a total daily dose of 19.9mg and 12mg on day 7"
214688902|NCT06556277|DRUG|Placebo|"Drug: Placebo 250 mg Tablets~During another phase of the study: identical looking placebo pills starting Day 1 During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Placebo (0,9% NaCl solution)~Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 and 12mg on day 7"
214688903|NCT03609359|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
214413315|NCT02430181|DRUG|peginterferon alfa-2a|immunomodulator
215016656|NCT05224648|DEVICE|ITF device tetanus stimulation monitoring|Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
215016657|NCT03908008|DRUG|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
214413316|NCT02430181|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
214413317|NCT04776486|DRUG|Iohexol|"Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).~Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose."
214413318|NCT02888158|OTHER|Robotic assistance|Robotic assistance will be implemented during Pelvic Trainer training sessions.
214413319|NCT02888158|OTHER|Pelvic Trainer|The standard Pelvic Trainer simulator for surgical training.
214413320|NCT05203055|DRUG|Peginterferon alpha-2b|180μg/w
214413321|NCT05203055|DRUG|Nucleotide Analog|Etecavir 0.5mg qd or Tenofovir 300mg qd
214413322|NCT05203055|DRUG|pulse peginterferon alpha-2b|180μg/w for 8 consecutive weeks and cessation for 4 weeks
214413323|NCT00923676|DRUG|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
214413324|NCT00923676|DRUG|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
214688904|NCT03609359|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, every 3 weeks (25 minutes to 40 minutes are acceptable).
214688905|NCT06643845|PROCEDURE|arthroplasty|In the surgery arm, patients will have their surgery (arthroplasty), as originally planned.
214688906|NCT06643845|OTHER|Medical and non-medical treatments|In the medical care arm, patients will follow multimodal medical strategies to prevent surgery in a population of patients with knee osteoarthritis having a first indication of knee prosthesis
214688907|NCT06268886|DRUG|BMS-986446|Specified dose on specified days
215016658|NCT03908008|DRUG|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
214413325|NCT00923676|DRUG|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
214413326|NCT04322656|DEVICE|Lipiflow treatment|Patients will be treated on one eye with Lipiflow
214413327|NCT06293547|DRUG|Silver Diamine Fluoride|Silber Diamine Fluoride, a colorless, odorless alkaline solution, effectively halts carious lesions in various populations, including children and elderly patients, or those averse to invasive treatments. Its high fluoride content facilitates remineralization, caries arrest, and prevention. SDF application is simple, non-invasive, cost-effective, and does not stain intact enamel, making it suitable for treating dentin hypersensitivity. Its ease of use is advantageous for children, patients with special needs, and the elderly. Particularly beneficial for high-risk patients with salivary dysfunction or multiple carious lesions, SDF offers potential in pediatric dentistry and community oral health by streamlining procedures, requiring rapid application without sharp instruments or anesthesia.
214413328|NCT01972139|DEVICE|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
214413329|NCT01972139|OTHER|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
214413330|NCT01972139|DEVICE|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
214413331|NCT00382135|DRUG|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
214413332|NCT00382135|DRUG|placebo|Placebo tablet taken by mouth once a day for 40 weeks
214413333|NCT01398930|OTHER|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
214413334|NCT00704756|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
214413335|NCT00704756|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (\<65 kg : 800 mg, 65 - 85 kg : 1000 mg, \>85 kg : 1200 mg) orally for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
214413336|NCT03492632|OTHER|Hormone panel|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.
214413337|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Test Drug|Investigational Medicinal Product
214413338|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Reference Product|Daflon (Trademark)
214413339|NCT02518243|OTHER|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games"
214413340|NCT00454662|DRUG|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
214413341|NCT00454662|DRUG|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
214413342|NCT02302209|DRUG|Oxytocin|
214688908|NCT06268886|OTHER|Placebo|Specified dose on specified days
214688909|NCT04950582|DIAGNOSTIC_TEST|Spectral characteristics assessment|Urine sample analysis for evidence of urinary tract infection
214688910|NCT00083239|DRUG|talabostat (PT-100) tablets|
214413343|NCT02302209|OTHER|Placebo Comparator|
214688911|NCT02833649|DEVICE|Toric Implantable collamer Lens|The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
215016659|NCT05539911|DRUG|Fentanyl|50 mic fentanyl added as an adjuvant
214413344|NCT02601703|DRUG|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
214413345|NCT02601703|DRUG|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
214688912|NCT03213613|BEHAVIORAL|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
214694005|NCT03460067|RADIATION|Omission of Radiation|No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence
215016660|NCT03307096|PROCEDURE|Microperc surgery|Parents are treated by Microperc Percutaneous Nephrolithotomy
215016661|NCT03307096|PROCEDURE|FURS|Parents are treated by FURS
215016662|NCT00292370|DRUG|Open Label (OL) Paroxetine|Open-label Paroxetine
215016663|NCT00292370|DRUG|Placebo|Double-blind placebo taken with OL paroxetine
215016664|NCT00292370|DRUG|Quetiapine|Double-blind quetiapine taken with OL paroxetine
215016665|NCT02961582|DEVICE|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
215016666|NCT02961582|OTHER|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
215016667|NCT05342688|BEHAVIORAL|Task-specific practice of upper extremity functions|The intervention will consist of training of items from the Wolf motor function test.
215016668|NCT05130957|OTHER|Massage Application with clove oil|The experimental group is given a massage with clove oil,
215016669|NCT05130957|OTHER|Massage Application without any oil|The control group is given a massage without any oil as a standard midwifery care.
215016670|NCT05889000|OTHER|questionnaire responses|questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
215016671|NCT00440739|DRUG|etoricoxib|etoricoxib 120 mg
215016672|NCT00440739|DRUG|flavoxate|flavoxate 200 mg 3 times
215016673|NCT00440739|DRUG|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
215016674|NCT00440739|DRUG|placebo|placebo once and placebo 3 times
215016675|NCT00465283|DRUG|Donepezil|Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
215016676|NCT04799639|DRUG|Sindilimab +paclitaxel+ cisplantin|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
215016677|NCT04760236|BIOLOGICAL|Oral Cholera Vaccine Simplified (OCV-S)|"* Manufacturer: EuBiologics Co., Ltd.~* Oral administration"
214413346|NCT02601703|DRUG|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
215016678|NCT04760236|BIOLOGICAL|Shanchol™|"* Manufacturer: Shantha Biotechnics~* Oral administration"
215016679|NCT00005078|DRUG|carboplatin|
215016680|NCT00005078|DRUG|paclitaxel|
215016681|NCT00005078|DRUG|tirapazamine|
215016682|NCT00782379|DRUG|busulfan|110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
215016683|NCT00782379|DRUG|cyclophosphamide|14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
215016684|NCT00782379|DRUG|fludarabine phosphate|30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
215101635|NCT01055314|BIOLOGICAL|Dactinomycin|Given IV
215101636|NCT01055314|DRUG|Doxorubicin Hydrochloride|Given IV
215101637|NCT01055314|DRUG|Etoposide|Given IV
215101638|NCT01055314|DRUG|Ifosfamide|Given IV
215101639|NCT01055314|DRUG|Irinotecan Hydrochloride|Given IV
214694006|NCT04922788|BIOLOGICAL|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant
215016685|NCT00782379|DRUG|mycophenolate mofetil|15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
215016686|NCT00782379|DRUG|tacrolimus|0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
215016687|NCT00782379|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patients to received unmanipulated PBSCs on Day 0
215016688|NCT00782379|PROCEDURE|peripheral blood stem cell transplantation|patients to receive unmanipulated PBSCs on day 0
215101640|NCT01055314|OTHER|Laboratory Biomarker Analysis|Correlative studies
215101641|NCT01055314|DRUG|Temozolomide|Given PO
215101642|NCT01055314|DRUG|Vincristine Sulfate Liposome|Given IV
215101643|NCT05248880|DRUG|AGN-151586|Intramuscular Injection
215101644|NCT05248880|DRUG|Placebo|Intramuscular Injection
215101645|NCT04701567|DIAGNOSTIC_TEST|Magnetic resonance imaging|Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
215101646|NCT00572013|DRUG|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
214688913|NCT03213613|BEHAVIORAL|Active Control|Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move an object to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
214413347|NCT00077883|DRUG|TLK286, cisplatin|TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).
214413348|NCT00392418|DRUG|Multiple micronutrient supplement (iron)|
214688914|NCT03213613|BEHAVIORAL|Low-dose Adaptive Attention Training|Participants in the low-dose training group will play a reduced number of sessions as the Adaptive Attention Training group. Specifically, they will train for two 30-minute sessions at the start and middle of a six-week period. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
214413349|NCT00415558|DEVICE|Microwave Ablation System|
214413350|NCT00312312|BIOLOGICAL|Specific immunotherapy|
214413351|NCT00346593|DEVICE|Silicone hydrogel contact lens|
214413352|NCT00586014|PROCEDURE|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
214413353|NCT01594502|DRUG|Dutasteride|0.5 mg daily
214413354|NCT01594502|DRUG|Placebo|Placebo Comparator
215101647|NCT00572013|DRUG|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
214688915|NCT01035255|DRUG|LCZ696 200 mg BID|LCZ696 200 mg BID
214413355|NCT01539603|DEVICE|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
214413356|NCT01539603|DEVICE|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
214413357|NCT03046290|PROCEDURE|circumcision|
214413358|NCT03046290|DRUG|Lidocaine|
215016689|NCT01818310|BIOLOGICAL|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
215101648|NCT00572013|PROCEDURE|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
214413359|NCT03046290|DRUG|Ropivacaine|
214413360|NCT00438555|BEHAVIORAL|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
214413361|NCT00438555|BEHAVIORAL|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
215101649|NCT00098683|DRUG|amifostine trihydrate|
215101650|NCT05739461|OTHER|Dental implant|Dental implants with triangular cross-section neck design
215101651|NCT06112691|DEVICE|taking fundus photos using non-mydriatic fundus camera - FundusScope Rodenstock|using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
214413362|NCT00000456|DRUG|naltrexone (Revia)|
214413363|NCT00000456|BEHAVIORAL|cognitive behavior therapy|
214413364|NCT00000456|BEHAVIORAL|motivational enhancement therapy|
214413365|NCT00198172|DRUG|Cisplatin plus Epirubicin|
214413366|NCT01700790|DRUG|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
214413367|NCT06200402|DRUG|Antibiotic loaded|This is the intervention for the study group. It involves the use of bone cement mixed with antibiotics (typically gentamicin or similar) in the hip prosthesis surgery. The purpose of this intervention is to assess whether the antibiotic-loaded cement reduces the incidence of postoperative infections compared to standard cement
214413368|NCT06200402|OTHER|Placebo|Placebo
214413369|NCT05818800|DEVICE|digital solution|randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions
214688916|NCT01035255|DRUG|Enalapril 10 mg BID|Enalapril 10 mg BID
214694007|NCT04922788|BIOLOGICAL|Placebo|0,5 mg Aluminum adjuvant
214694008|NCT02052778|DRUG|Futibatinib|oral once daily dosing, 21-day cycle
214694009|NCT04235257|BIOLOGICAL|HPV vaccine|Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
215016690|NCT01818310|BIOLOGICAL|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
215101652|NCT01279616|DRUG|Fludarabine monophosphate|180 mg/m2 over 6 days.
215101653|NCT01279616|DRUG|Rituximab|375 mg/m2 on day -13 and day -3
215016691|NCT01818310|BIOLOGICAL|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
215101654|NCT01279616|DRUG|Busulfan|AUC 1000-1200 microM.mt
215101655|NCT01279616|DRUG|ATG|2.5 mg/kg for 3 days
215101656|NCT01279616|DRUG|Cyclophosphamide|50 mg/kg on day +3
215101657|NCT01279616|DRUG|Mycophenolate mofetil|15 mg/kg q 8 hours
215101658|NCT01279616|DRUG|Tacrolimus|0.03 mg/kg /d
215101659|NCT02462720|DRUG|Varithena®|Varithena® treatment in accordance with full prescribing information and instructions for use
214413370|NCT05818800|OTHER|Standard Care|randomised controlled trial where patients with hypertension will be randomised r to standard care
214694010|NCT06097650|OTHER|cold snare polypectomy|Histological analyses suggest that cold snare polypectomy causes less damage to blood vessels in the submucosal layers, which results in a reduced incidence of hemorrhage
215016692|NCT01818310|PROCEDURE|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
215016693|NCT06164600|DIETARY_SUPPLEMENT|Bovine colostrum|A powdered form of the first 6 hours bovine colostrum \[65 mg lactoferrin, lactoperoxidase: 2.8 unit and immunoglobulins in the form of 350 mg IgG, 35.3 mg of Ig A and 25.3 mg Ig M\]
215016694|NCT06164600|DRUG|Placebo|Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
215016695|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
215016696|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
215016697|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
215016698|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
215016699|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
215016700|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
215016701|NCT00392275|DRUG|Ofloxacin 0.3%|
215016702|NCT00392275|DRUG|Ciprofloxacin 0.3%|
215016703|NCT00392275|DRUG|Levofloxacin 0.5%|
215016704|NCT00392275|DRUG|Ofloxacin 400mg|
215016705|NCT00392275|DRUG|Ciprofloxacin 400mg|
215016706|NCT00392275|DRUG|Levofloxacin 250mg|
215016707|NCT02284854|DRUG|BIA 2-093|
215101660|NCT02462720|DEVICE|Radiofrequency ablation|Radiofrequency ablation conducted per physicians' standard of care.
215101661|NCT03112655|DIAGNOSTIC_TEST|RNA and neopterin detection|Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.
214413371|NCT04056923|PROCEDURE|3D-printing guided|3D printed navigational template guided
214694011|NCT06097650|OTHER|hot snare polypectomy|According to current clinical guidelines, hot snare polypectomy is the recommended standard technique for the resection of pedunculated colorectal polyps.
215101662|NCT04467281|DRUG|89Zr-DFO-daratumumab|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
214413372|NCT04056923|PROCEDURE|CT-guided|CT-guided
214413373|NCT04056923|DRUG|Indocyanine Green|The results are shown by comparison of different colors.
215016708|NCT02284854|DRUG|Carbamazepine|
215016709|NCT01951456|BEHAVIORAL|Resistance training|
215016710|NCT01951456|BEHAVIORAL|Health and Wellness|
215016711|NCT01133977|DRUG|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
215016712|NCT01133977|DRUG|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
215016713|NCT01133977|DRUG|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
215016714|NCT05532163|DRUG|Natalizumab|Administered as specified in the treatment arm
215016715|NCT03385642|DEVICE|ChondroMimetic|ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
215016716|NCT05996705|OTHER|Determining the relationship of fatigue with some parameters|Determining the relationship of fatigue with physical function, pain values at rest and in motion, gender, age, pain, disease activity, gender and disease duration in RA patients.
215016717|NCT00662038|DRUG|pirfenidone|Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
215016718|NCT03606213|BIOLOGICAL|PENNVAX-GP|PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.
215016719|NCT03606213|BIOLOGICAL|INO-6145|INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.
215016720|NCT03606213|BIOLOGICAL|INO-9012|The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
215016721|NCT03606213|DEVICE|CELLECTRA® 2000|Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
215016722|NCT01560559|PROCEDURE|Peroral endoscopic myotomy|"An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.~This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips."
215016723|NCT06564480|DEVICE|MI-R1 lower limb walking machine assisted training device|The training is conducted under partial weight support training conditions, performing passive movements on the lower limbs through motor drive, improving the joint activity of the patient's hip and knee joints, and achieving sitting, standing, and walking functions.
215016724|NCT06564480|OTHER|Walking rehabilitation training under the guidance of therapists|Each patient undergoes training under the guidance of a rehabilitation therapist
214413374|NCT04056923|DRUG|Methylene blue|The results are shown by comparison of different colors.
214413375|NCT04056923|PROCEDURE|Preoperative|Preoperative localization.
214413376|NCT04056923|PROCEDURE|Intraoperative|Intraoperative localization.
214413377|NCT00787956|BEHAVIORAL|Internet Chronic Disease Self-Management Program (ICDSMP)|
214413378|NCT05114109|DRUG|Isatuximab Injection|Isatuximab will be given intravenously at 10mg/kg at day 0, week (W)1, W2, W3, and W4 then every 2 weeks for a total of 12 infusions.
214413379|NCT02096289|DRUG|Thioridazine|
214413380|NCT05129982|DEVICE|whole body vibration|whole body vibration is a modality of physical therapy
214413381|NCT05566847|OTHER|Physician Education|The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
214413382|NCT05566847|OTHER|Accountable Population Manager outreach|Patients will be referred to an Accountable Population Manager (APM) for proactive outreach, including supporting medication adherence and educational and overall support for T2D management. An APM is a non-physician clinician (for example, a clinical pharmacist) supporting diabetes management.
214413383|NCT04164524|DRUG|Gentamycin|Gentamycin 160 mg spray applied over the mesh
214413384|NCT06486818|PROCEDURE|Ablation of idiopathic monomorphic PVCs|3D carto ablation of idiopathic monomorphic PVCs
214413385|NCT02280655|BIOLOGICAL|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
214413386|NCT02280655|BIOLOGICAL|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
214413387|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
214413388|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
214413389|NCT03995810|DIETARY_SUPPLEMENT|Carnosine, capsulle, 2 g/day, 8 weeks|We will administer supplemental carnosine (2 grams per day) for 8 weeks
214413390|NCT00271258|DRUG|SODIUM DIVALPROATE|
214413391|NCT03256344|BIOLOGICAL|Talimogene Laherparepvec|Virally based anti-cancer immunotherapy given by direct injection into tumors.
214413392|NCT03256344|BIOLOGICAL|Atezolizumab|A monoclonal antibody given by intravenous injection.
214413393|NCT04954430|DIAGNOSTIC_TEST|pupillometer|The dynamic changes of PLR were measured using the PLR-3000 pupillometer (NeurOptics, CA, USA), a hand-held portable device. Determination of PLR with automated pupillometry can be performed with a rubber cup covering the measured eye and the subject's hand covering the non-measured eye. A flash of visible white light with a duration of 0.8 sec and a pulse intensity of 50 µW is delivered to induce a pupillary reflex, and repeated video images at more than 30 frames/sec are stored for 6.65 sec. The device provided the examiner with maximum and minimum pupil size (Init and End), constriction percentage (%PLR), latency (LAT), constriction and dilation velocity (CV and DV), and T75.
215016725|NCT06055699|OTHER|Fecal sampling|"Stool samples are a collection of products derived from the human body that is not invasive in any way and samples not taken as part of usual care.~Stool samples will be collected at home within 7 days of the visit M0, M3 and M6 and within 14 days of the visit M12 in an ethanol tube and in DNA/RNA shield, and transported at room temperature to Saint-Antoine Hospital (CRB SAT, AP-HP, Pr. SIMON ), samples will be aliquoted (3 aliquots per tubes) and stored at -80°C for a period of 5 years (renewable) At the end of the research, stool samples will be analysed using metagenomics sequencing.~DNA extraction will be performed following the standards of the The International Human Microbiome Standards . DNA will be stored at -80°C."
215101663|NCT04467281|DIAGNOSTIC_TEST|PET/CT|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
215101664|NCT02914665|DRUG|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
215101665|NCT02914665|DRUG|Placebo|Placebo administered intravenously once daily for 7 consecutive days
215101666|NCT00972530|BEHAVIORAL|immobilisation in a triangular sling|"Intervention group: Immobilisation 48 hours in a triangular sling (mitella)~Control group: normal activity without restrictions"
215101667|NCT06582134|BEHAVIORAL|Sham BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g., 1-2-3 and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
214413394|NCT04461106|OTHER|Social Marketing Campaign|aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (\<5yrs) and pregnant/lactating women
214413395|NCT04747106|BIOLOGICAL|plasma exchange|when ADP inhibition \>30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
214413396|NCT00691951|DRUG|budesonide and budesonide/formoterol|
214413397|NCT02885051|PROCEDURE|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
214413398|NCT01859312|DRUG|Hydrocortisone (Solucortef)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
214413399|NCT01859312|DEVICE|Insulin pump (Medtronic)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA)
214694012|NCT05967468|BEHAVIORAL|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
215101668|NCT06582134|BEHAVIORAL|BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g. A-B-C and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
215101669|NCT05572164|PROCEDURE|TRADITIONAL EPIDURAL|epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia)
215016726|NCT06055699|OTHER|Blood sampling|"Blood samples (serum, 15 ml) are an additional and minimal collection performed following a sample taken as part of usual care.~Blood samples (serum) will be collected during the visit at M0, M3 (± 7 days), M6 (± 7 days) and M12 (± 7 days).~In the hours following collection, the samples must be aliquoted and stored at -80°C in a secure place in the participating centre."
215016727|NCT01251211|DRUG|botulinum toxin type A|BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
214413400|NCT04312191|OTHER|Mantra Meditation|Mantra-based meditation will be taught using a standard one-word mantra (Om). Om is a non-English word that will help with focus as opposed to an English word which may cause distraction based on the word itself.
214413401|NCT01597518|DRUG|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
214413402|NCT01597518|DRUG|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
214413403|NCT06213051|DEVICE|• COPAN Self-collection FLOQSwabs® (COPAN, Italy)|COPAN swabs evaluated on Roche COBAS and Cepheid Xpert PCRs
214413404|NCT00866996|DRUG|Methylphenidate extended-release; Atomoxetine|
214413405|NCT04406168|PROCEDURE|urinary diversion|follow up outcomes of urinary diversion
214413406|NCT06317688|DIETARY_SUPPLEMENT|Extra-Virgin Coconut Oil|Active ingredients act as a destructor of bacteria, viruses and fungus
214413407|NCT03152149|DRUG|Tiotropium & olodaterol|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
214413408|NCT03152149|DRUG|fluticasone furoate & vilanterol|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
214413409|NCT01506362|DRUG|BL-7040|"BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.~Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.~BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days."
214413410|NCT04140058|DRUG|Ondansetron|ondansetron was administered 20 minutes prior to spinal anesthesia.
214413411|NCT04140058|DRUG|Normal saline|Placebo of 10 mL normal saline was administered.
214413412|NCT03585361|BEHAVIORAL|Health centers provide PPFP counseling and services|Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
214413413|NCT03585361|BEHAVIORAL|HEWs provide PPFP counseling and services|HEWs trained in PPFP counseling with a refresher on implant insertion skills. Training also included how to use tools to document PPFP services, method choice, and pregnancy risk at every contact during pregnancy and up to 12 months after birth. Follow up supervision ensured skill improvement and retention.
214413414|NCT03585361|BEHAVIORAL|Volunteers (Development Army) promote PPFP|HEWs orient volunteers on promoting PPFP and how to use a pictoral tool to remind women to access ANC, immunization, and PPFP services and to document women's method preferences and pregnancy risk at every contact during pregnancy and up to 12 months after birth.
214413415|NCT03585361|BEHAVIORAL|Health centers conduct data reviews|Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.
215016728|NCT02531711|OTHER|Diet A|Experimental analgesic dietary intervention
215016729|NCT02531711|OTHER|Diet B|Healthy comparator diet
215016730|NCT00397046|DRUG|neratinib|HKI-272
214413416|NCT03585361|BEHAVIORAL|HEWs and volunteers track PPFP|HEWs and volunteers track PPFP counseling, choice of method, receipt of methods, and pregnancy risk starting in pregnancy through 12 months postpartum. HEWs and volunteers meet and review data.
214413417|NCT01624636|DRUG|Placebo|
214413418|NCT01624636|DRUG|LFG316|
215016731|NCT06135012|DEVICE|Cavitron ultrasonic surgical aspirator (CUSA)|Transection of pancreatic tissue with cavitron ultrasonic surgical aspirator (CUSA).
215016732|NCT06135012|OTHER|Scalpel|Transection of pancreatic tissue with scalpel.
215016733|NCT01749293|PROCEDURE|Haploidentical Transplant|Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
215101670|NCT05572164|PROCEDURE|DURAL PUNCTURE EPIDURAL|group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
215101671|NCT04086095|DEVICE|Neofact application aid|The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
215101672|NCT02384733|RADIATION|Loco-regional RT|
214413419|NCT01624636|DRUG|LFG316|
214413420|NCT00851942|DRUG|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
214413421|NCT06278064|OTHER|Gastric Cancer|Patients diagnosed with gastric cancer, including early stage gastric and advanced gastric cancer
215101673|NCT05163652|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
215101674|NCT00183625|BEHAVIORAL|Individual Placement and Support (Supported Employment)|
215101675|NCT00183625|BEHAVIORAL|Social Skills Training|
215101676|NCT00183625|DRUG|Olanzapine|
215101677|NCT00183625|DRUG|Risperidone|
215101678|NCT00156416|BEHAVIORAL|Mindfulness Meditation|8 weeks of meditation training
215101679|NCT04022252|DEVICE|Cheese dental laser|810 nm GaAlAs diode laser device
215101680|NCT04022252|DEVICE|OrthoPulse|850 nm LED (light emitting diode)
215101681|NCT04022252|OTHER|Placebo|810 nm GaAlAs diode laser device
215101682|NCT02681471|OTHER|5% Mannitol|Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
214413422|NCT06278064|OTHER|Esophagus Cancer|Patients diagnosed with esophagus cancer, including early esophagus gastric and advanced esophagus cancer
214413423|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of the energy drink (Red Bull®)|Ingestion of 250 ml of the energy drink (Red Bull®)
214413424|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of mineral water|Ingestion of 250 ml of mineral water (Minalba®)
214413425|NCT00680472|DRUG|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
214413426|NCT00680472|OTHER|Placebo Patch|Treatment with Placebo Patch
214413427|NCT03244787|BEHAVIORAL|patient navigation|Current standard of care is for PNs to work with patients from health centers who are referred by providers. Intervention patients will appear on a PN list without any referral by providers. Control high risk patients will proceed normally and will be eligible to transfer to a PN list after the 6-month study period.
214413428|NCT00843193|DRUG|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
214413429|NCT00843193|DRUG|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
214413430|NCT00843193|DRUG|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
214413431|NCT02578212|OTHER|Placebo|
214413432|NCT06022536|DRUG|SSS40|Subjects injected with SSS40
214413433|NCT06022536|DRUG|Placebo|Subjects injected with Placebo
214413434|NCT02561403|BEHAVIORAL|EVO multitask video game|Participants will play a multitasking game for 4 weeks
214413435|NCT02561403|BEHAVIORAL|EVO words video game|Participants will play a word puzzle game for 4 weeks
214413436|NCT06582628|DRUG|Enzalutamide capsule|Enzalutamide capsules 160 mg orally daily
214413437|NCT06582628|DRUG|Enzalutamide capsule and Talazoparib capsule|Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily
214413438|NCT04966572|DEVICE|Presurgical vacuum formed nasoalveolar molding aligners|at first visit, the infants will receive this appliance which is a maxillary vacuum plate incorporated with palatal screw, the infant's parents will be instructed to activate the screw and apply horizontal tap which will be placed at the base of nose in order to approximate lip segments and to change tape daily. After that, The infants will be recalled one week after the first visit to add the nasal stents into the appliance.
214413439|NCT04966572|DEVICE|Conventional Grayson acrylic formed nasoalveolar molding appliances|"at first visit, the infants will receive this appliance which is a maxillary acrylic plate without adding taping, the infants will be recalled bi weekly for activating the appliance.~When the cleft alveolar gap is reduced to 6mm or less, a pair of nasal stents will be added to mold the nasal cartilage. the infants will be followed up for 4-6 months."
214413440|NCT00544440|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
214413441|NCT00544440|DRUG|Prednisone|Prednisone 5 mg tablet taken orally twice daily
214413442|NCT00454792|OTHER|Exercise|Back exercise: At home every day. In groups once a week. Duration 10 weeks.
214413443|NCT00454792|OTHER|Restitution|Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
214413444|NCT02971306|DRUG|standard medical therapy|Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
214413445|NCT02971306|DRUG|G-CSF|G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
215016734|NCT01749293|DRUG|Fludarabine|Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
214413446|NCT02971306|DRUG|n-Acetylcysteine|n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
214413447|NCT01007344|DIETARY_SUPPLEMENT|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
214413448|NCT01007344|DIETARY_SUPPLEMENT|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
214413449|NCT04744519|OTHER|Collect data|\- Controlled ovarian stimulation with GnRH antagonists effected to the patients in order to get their eggs through follicular puncture, which will be trigger by GnRH analogue. The eggs will be isolated and processed according to the standard protocol.
214413450|NCT05703204|DRUG|QLF32101|The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
214413451|NCT03354169|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
214413452|NCT03875248|DEVICE|Blood pressure measurement|Measure optically the blood pressure through the use of a smartphone
214413453|NCT03526081|OTHER|Chamomile Tea|Chamomile Tea in 300mL hot water
214413454|NCT03526081|OTHER|Parsley based drink|3.2 g dried parsley in 300mL hot water
214413455|NCT03526081|OTHER|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
214413456|NCT03526081|OTHER|Apigenin|Apigenin capsule mixed with 300mL hot water
214413457|NCT03526081|OTHER|Parsley-based drink (II)|3.2 g dried parsley in 300mL hot water
214694013|NCT05967468|BEHAVIORAL|Bibliotherapy, low therapist contact SPACE|Parent-based bibliotherapy for treating anxiety disorders in youth
215016735|NCT01749293|DRUG|Busulfan|Subjects in this trial will receive Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
215016736|NCT01749293|RADIATION|Total Body Irradiation|Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
215016737|NCT01749293|DRUG|Cyclophosphamide|Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
215016738|NCT05579522|PROCEDURE|Fat graft injection|Fat graft injection in the interdental papilla.
214413458|NCT04227990|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
214413459|NCT04227990|DRUG|Pegfilgrastim|Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
214413460|NCT04227990|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
214413461|NCT00513734|OTHER|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
214413462|NCT00513734|OTHER|Lacrilube ointment|lubricant put into eye (inferior formix)
214413463|NCT05837468|BEHAVIORAL|BETTERapp|The BETTER app offers a 'tailor-made' lifestyle programme including the option of personal coaching for a duration of 6 weeks. The BETTER app is an automated and digitised lifestyle programme based on the previously developed and evaluated BETTER programme.
214413464|NCT01025206|BIOLOGICAL|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
214413465|NCT05739929|DRUG|Colchicine 0.5 MG Oral Tablet|0.5 mg colchicine tablets twice daily.
214413466|NCT05739929|DRUG|Placebo|Placebo tablets twice daily
214413467|NCT05544578|BEHAVIORAL|Nurses Taking On Readiness Measures (N- TORM)|The intervention group will be educated about household emergency preparedness via a presentation and the Korean version of a New York City community-specific booklet called Ready New York: My Emergency Plan (NYC Emergency Management, 2022). The intervention will begin with instructing the participant to start the booklet during class 1 and completing it for homework. The class content will complement the booklet and the K-HEPI. The booklet includes preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. During class 2, study personnel will check for completion of the booklets, answer any questions that the participants may have about the evacuation and communication plans and disaster kits, and facilitate group discussion to foster social support from other community members.
214413468|NCT05054062|DIAGNOSTIC_TEST|Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
214413469|NCT02866214|DRUG|Febuxostat|Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session
214413470|NCT02866214|DRUG|Placebo|"Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) ."
214413471|NCT03586167|DEVICE|LID014341 contact lenses|Investigational monthly replacement silicone hydrogel contact lenses with water gradient coating
214413472|NCT03586167|DEVICE|Comfilcon A contact lenses|Silicone hydrogel contact lenses
214413473|NCT01607619|DIETARY_SUPPLEMENT|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
214413474|NCT06279819|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|"The dietary intervention used the dietary intervention plan constructed in Phase 2, on the basis of which each study participant's individual dietary habits, food preferences and economic level were taken into account.~The dietary intervention was delivered by sending fresh ingredients. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings.~Ingredients will be delivered three times a week for a 12-week intervention period. The initial food items to be sent include: 90g of fish rich in omega-3 fatty acids; 300g of vegetables and/or legumes, and 200g of fruits; 30g of nuts; and a cup of probiotic yogurt.~Guided dietary follow-up was conducted through video viewing and WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance by sending videos every two weeks."
214413475|NCT00591838|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
214413476|NCT02973243|DEVICE|Automatic RR Measurement|Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
214413477|NCT05289830|DRUG|Escitalopram|Participants will receive Escitalopram 2 weeks: 10 mg/day (1 capsule) 8 weeks: 20 mg/day (2 capsules) 2 weeks: 10 mg/day (1 capsule)
214505087|NCT00439218|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
215016739|NCT05579522|PROCEDURE|Hyaluronic acid injection|Hyaluronic acid injection in the interdental papilla
215016740|NCT02250573|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
215016741|NCT04125719|BIOLOGICAL|PVSRIPO|Intralesional injection of PVSRIPO
215016742|NCT04125719|DRUG|Nivolumab|Nivolumab infusion
215016743|NCT03418363|DIETARY_SUPPLEMENT|DHEA Oral Capsule|Daily 100mg DHEA supplement
215016744|NCT03418363|OTHER|Placebo Oral Capsule|Daily oral capsule
215016745|NCT02898831|OTHER|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
215016746|NCT03074643|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
215016747|NCT03074643|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
215101683|NCT02681471|OTHER|0,9% Sodium chloride|Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
215101684|NCT02681471|DEVICE|monopolar resectoscope|
215016748|NCT03074643|DIETARY_SUPPLEMENT|Carbohydrate supplement for months 0-6|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (\~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
214413478|NCT05289830|OTHER|Placebo|Participants will receive placebo supplements 2 weeks: 1 capsule 8 weeks: 2 capsules 2 weeks: 1 capsule
214413479|NCT04026191|DEVICE|OrthoVisc®-T (OVT)|Sodium hyaluronate supplied as a 2 mL (15mg/mL) unit dose in a 3 mL glass syringe.
214413480|NCT05818306|DRUG|BL-001|Live biological product BL-001
214413481|NCT05818306|DRUG|Placebo|Placebo
214413482|NCT02774538|OTHER|Agreement between oral and cervical HPV infection|"A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.~A second oral brushing up to 18 months will be performed during a standard follow-up visit."
215101685|NCT02681471|DEVICE|bipolar resectoscope TURis|
214688917|NCT04592432|OTHER|SIGN@L-A|Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).
214688918|NCT04592432|OTHER|SIGN@L-B|The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.
214688919|NCT06072872|DEVICE|Use of portable CPAP|Patients use portable CPAP during exercise
214688920|NCT05186883|BIOLOGICAL|Allogenic parathyroid cells|Allogenic parathyroid cells
214688921|NCT05186883|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
215016749|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for months 0-6|Participants in the higher protein / lower CHO diet groups (6-mon HiProt and 18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
215016750|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for follow-up months 7-18|Participants in the higher protein / lower CHO diet (18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 12-month follow-up.
215016751|NCT02441699|BEHAVIORAL|Improved water supply and sanitation|Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
215016752|NCT06477510|PROCEDURE|non-surgical periodontal therapy|change in self perception of esthetics and clinical periodontal parameters will be assessed after non-surgical periodontal therapy.
215101686|NCT02769910|DRUG|Capsaicin 24 Hours|Dermal patches for transdermal application of Capsaicin, applied for 24 hours
214688922|NCT05428072|OTHER|Sugar test|All participants will take two sugar tests ( sugar cocktail consisting of mannitol \& lactulose) subjects within 2-3 days of the initial sugar test.
214688923|NCT05428072|DRUG|Aspirin Challenge|All participants will take a sugar test after 2 doses of aspirin, 1.3 g each given at 12 \& 1 hour before the sugar drink.
214688924|NCT02244450|BIOLOGICAL|SCID screening|
214688925|NCT04749979|DRUG|Agonist (decapeptyl )|giving agonist
214688926|NCT04749979|DRUG|HCG ( eg. Choriomon )|giving HCG
214688927|NCT02126904|DRUG|IVA group|
214688928|NCT04202861|DIAGNOSTIC_TEST|In vitro antibiotic combination testing (iACT)|CRGNB isolates from the index culture will be transported to the Pharmacy Research Lab,SGH for iACT testing. iACT results will be sent to the physicians and ID specialist managing the patient once completed. A subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and or the consulting infectious disease doctor may wish to continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement for the patient.
214413483|NCT01814644|BEHAVIORAL|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
214688929|NCT00003943|BIOLOGICAL|filgrastim|5 ug/kg
215016753|NCT01641783|DRUG|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
215101687|NCT02769910|DRUG|Capsaicin 1 Hour|Dermal patches for transdermal application of Capsaicin, applied for 1 hour
215101688|NCT02769910|OTHER|Qutenza Demo Patch|Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
214413484|NCT01814644|BEHAVIORAL|Standard Care|Individual assessment, lifestyle counseling
214413485|NCT02512042|DRUG|Test-Brinzolamide 1% Ophthalmic suspension|
214413486|NCT02512042|DRUG|Reference-Brinzolamide 1% Ophthalmic suspension|
214413487|NCT06555224|DEVICE|Systane Hydration MDPF eye drops|Systane Hydration MDPF eye drops 4x daily for 3 months additional to routine medication after cataract surgery
214413488|NCT05252624|DRUG|placebo|Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
214413489|NCT05252624|DRUG|Henagliflozin 5Mg Tab|Single oral tablet
214688930|NCT00003943|DRUG|carboplatin|AUC 5
214688931|NCT00003943|DRUG|cyclophosphamide|3 gm/m2
214688932|NCT00003943|DRUG|paclitaxel|250 mg/m2
214688933|NCT00003943|DRUG|topotecan hydrochloride|10 mg/m2
214688934|NCT00003943|PROCEDURE|peripheral blood stem cell transplantation|harvest via apheresis
214694014|NCT05967468|OTHER|Relaxation and Mentorship|Relaxation based treatment
214694015|NCT05457933|DRUG|Dapagliflozin|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
214413490|NCT04163458|DRUG|MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL|Solution for injection in pre-filled pen, subcutaneous administration
214413491|NCT04163458|DRUG|MENOPUR powder and solvent for solution for injection, 75 IU|Solution for injection in vials (powder and diluent), subcutaneous administration
214413492|NCT04163458|OTHER|Placebo (for MENOPUR solution for injection in pre-filled pen)|Solution for injection in pre-filled pen, subcutaneous administration
214413493|NCT04163458|OTHER|Placebo (for MENOPUR powder and solvent for solution for injection)|Solution for injection in vials (powder and diluent); subcutaneous administration
215016754|NCT03748563|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE:~The ds-MCE system mainly consists of two parts: the NaviCam magnetically maneuvered capsule endoscopy system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. After completing the esophageal examination, the capsule could be detached from the string through injecting air into the hollow string with the syringe. Then, the examination of stomach under magnetic control and small bowel under the natural action of gastrointestinal peristalsis follows.~Procedure of EGD:~The esophagogastroduodenoscopy (EGD) will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
214688935|NCT03007953|BEHAVIORAL|Palliative Care|Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
214688936|NCT02817542|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
215016755|NCT02715752|DIETARY_SUPPLEMENT|Gene-Eden-VIR/Novirin|
214413494|NCT06552494|OTHER|L-mHealth program|The intervention group receiving the L-mHealth program plus care as usual. Data will be collected at baseline (T0), 1 months (T1) and 3 months (T2) after the intervention.
214413495|NCT02498158|DEVICE|MRI scans|"20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:~1. anatomical scan according to standard protocol~2. functional scan according to the standard protocol of rest-state fMRI.~scans of 10 healthy subjects will be taken from existing scans at the imaging department."
214413496|NCT00812136|BEHAVIORAL|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
214413497|NCT01586299|DRUG|Ibuprofen|10 mg/kg every 8 hours until 24 hours after resolution of fever
214688937|NCT04575662|RADIATION|STAR Treatment|Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.
215016756|NCT03275610|GENETIC|Blood sample|5 mL of blood withdrawn from patients with history of pulmonary embolism post total hip arthroplasty or total joint arthroplasty
215016757|NCT00593073|BEHAVIORAL|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
215016758|NCT00593073|BEHAVIORAL|General Reminder Message|General CRC health education message and reminder to get screened.
214688938|NCT01856634|DRUG|100 mg Delamanid|100 mg Delamanid BID for 10 days
214688939|NCT01856634|DRUG|50 mg Delamanid|50 mg Delamanid BID for 10 days
214413498|NCT01586299|DRUG|Acetaminophen|15 mg/kg every 6 hours until 24 hours after resolution of fever
214413499|NCT05147506|DEVICE|CNRM DTx|A mobile application intervention adapted from the CBT for Depression and CBT for TBI manuals.
215016759|NCT05573360|OTHER|NGF5-A test formulation|One drop of investigational product instilled on the eye
215016760|NCT05573360|OTHER|NGF4-B test formulation|One drop of investigational product instilled on the eye
214413500|NCT05147506|OTHER|Psychoeducation Comparison|A mobile application that consists of psychoeducational material regarding depression and brain injury.
214688940|NCT01856634|DRUG|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 10 days
215016761|NCT05573360|OTHER|NGF6-B test formulation|One drop of investigational product instilled on the eye
214413501|NCT01641172|PROCEDURE|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
214413502|NCT01641172|PROCEDURE|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
214413503|NCT01641172|PROCEDURE|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
214688941|NCT01856634|DRUG|10 mg Delamanid Pediatric Formulation|Patients \> 10 kg will receive DPF 10 mg BID for 10 days
214688942|NCT01856634|DRUG|5 mg Delamanid Pediatric Formulation|"Patients \> 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days"
214688943|NCT01856634|DRUG|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
214688944|NCT06312007|OTHER|Semi seated position|The patient is positioned 45-90 degrees
215016762|NCT05573360|OTHER|NGF6-E test formulation|One drop of investigational product instilled on the eye
215016763|NCT05573360|OTHER|Systane eye drop|One drop of commercial product instilled on the eye
214413504|NCT01641172|PROCEDURE|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
214413505|NCT01641172|DIETARY_SUPPLEMENT|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
214413506|NCT01641172|BEHAVIORAL|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
214413507|NCT01641172|BEHAVIORAL|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
214413508|NCT00542087|DRUG|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
214413509|NCT00542087|DRUG|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
214413510|NCT00624312|DRUG|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit"
214413511|NCT00624312|DRUG|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo"
214413512|NCT03967925|DRUG|Belimumab|Sub-cutaneous injection
214413513|NCT03967925|DRUG|Rituximab|IV infusion 1g x 2
214413514|NCT03967925|DRUG|Prednisolone|20mg prednisolone tapering dose
214413515|NCT02129933|DRUG|Bevacizumab-IRDye800CW|"Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~\* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)"
214413516|NCT02129933|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
214413517|NCT01559506|DEVICE|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
214688945|NCT06312007|OTHER|side lying position|Side lying position
214688946|NCT04624893|DRUG|Polatuzumab Vedotin-Piiq|Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
214688947|NCT06203678|OTHER|Kinesio taping|therapeutic tape application
214688948|NCT06203678|OTHER|Exercise|Cervical stretching and strengthening exercises home program
214688949|NCT06203678|OTHER|Sham taping|patch tape application
214688950|NCT05585437|PROCEDURE|gastric cancer specialist training program|The gastric cancer specialist training program includes technical training and non-technical training. The technical training includes 1. The whole process of laparoscopic gastric cancer surgery technical teaching 2. Operation practice 3. Operation video review, non-technical training includes 1. Difficult case discussion 2. Specialists Session 3. Lymph node sorting training.
214688951|NCT00722540|DRUG|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
214688952|NCT00722540|DRUG|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
214688953|NCT00722540|DRUG|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
214688954|NCT00722540|DRUG|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214688955|NCT00722540|DRUG|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214688956|NCT00722540|DRUG|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214688957|NCT00722540|DRUG|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214688958|NCT00722540|DRUG|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214688959|NCT00722540|DRUG|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
214688960|NCT00722540|DRUG|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
214694016|NCT05457933|DRUG|Glargine|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
215016764|NCT00270075|DRUG|epoetin alfa|
215016765|NCT04040673|PROCEDURE|thyroid lobectomy|routine surgical removal of thyroid for biopsy
215016766|NCT04040673|DEVICE|Raman spectroscopy probe measurement|The measurement of Raman spectra from the excised tissue
214413518|NCT03376399|OTHER|Gastroparesis Cardinal Symptom Index Questionnaire|Patients with an established diagnosis of Diabetic Gastroparesis that are interested in a sleeve gastrectomy for weight loss will be asked to participate in the registry. Once the consent process is complete the patient will be asked to complete the Gastroparesis Cardinal Symptom Index Questionnaire prior to weight loss surgery and 30 days, 3 months, 6 months and 12 months after surgery.
214413519|NCT05312866|PROCEDURE|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
214413520|NCT05312866|PROCEDURE|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
214413521|NCT02428088|DRUG|Dasotraline|Dasotraline 2 mg once daily
214413522|NCT02428088|DRUG|Dasotraline|Dasotraline 4 mg once daily
214413523|NCT02428088|DRUG|Placebo Comparator|Placebo once daily
214413524|NCT05739513|DIAGNOSTIC_TEST|miRNA analysis in plasma|blood sample
214413525|NCT04067960|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
214413526|NCT04067960|OTHER|Genetic Testing|Undergo pharmacogenomics testing
214413527|NCT04067960|OTHER|Quality-of-Life Assessment|Ancillary studies
214413528|NCT04067960|OTHER|Questionnaire Administration|Ancillary studies
215016767|NCT06401772|BEHAVIORAL|Intracranial Hypotension Targeted(IHT) Body Posture|IHT therapy requires CSDH patients to raise their lower limbs 30° higher over the horizontal level of their head.For patients with unilateral CSDH, the head should be tilted towards the hematoma affected side and opposite side lying should be avoided as much as possible. For patients with bilateral CSDH, there is no need for the head lateralization.To avoid food reflux and aspiration pneumonia, IHT therapy was strictly prohibited within 2 hours after each meal
215016768|NCT04189588|DRUG|Cetirizine HCl 10 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
215101689|NCT04924517|BEHAVIORAL|Extended Evening Fasting|Participants will undertake 4 days of extended evening fasting (feeding between 8am-4pm). The participants will visit the laboratory on day 1, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
214505088|NCT02142595|DRUG|dexmedetomidine|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
214505089|NCT02142595|DRUG|Midazolam|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
214505090|NCT03176407|DIAGNOSTIC_TEST|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
214505091|NCT03342261|DRUG|DAA treatment|Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
214505092|NCT03339544|DRUG|Celebrex premedication|celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
214505093|NCT03339544|DRUG|Placebo|placebo is given as a tablet before initiation of endodontic treatment
214505094|NCT04817826|DRUG|Durvalumab|durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
214505095|NCT04817826|DRUG|Tremelimumab|tremelimumab 300 mg single administration (day 1)
214505096|NCT03591588|OTHER|diet|The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
214505097|NCT01375699|DRUG|Doxorubicin|As prescribed by treating provider.
214505098|NCT01375699|DRUG|Sildenafil|Given PO, by mouth
214505099|NCT05360537|DRUG|Insulin Degludec / Liraglutide Injectable Product|administration of Insulin Degludec/Liraglutide
214505100|NCT05360537|DRUG|Insulin Glargine|Administration of glargine insulin
214413529|NCT04178954|DIAGNOSTIC_TEST|semen fluid analysis|semen fluid analysis
215101690|NCT04924517|BEHAVIORAL|Control|Participants will undertake 4 days of a standard western feeding pattern (feeding between 8am-8pm). The participants will visit the laboratory on day 1, following a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
214413530|NCT04643405|DRUG|APG-1387 for Injection|APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
214413531|NCT04643405|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
214413532|NCT04643405|DRUG|Nab paclitaxel|Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
214413533|NCT01461213|DRUG|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
214413534|NCT00100100|DRUG|Modafinil|
214413535|NCT00983164|DIETARY_SUPPLEMENT|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
214413536|NCT00570869|OTHER|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
214413537|NCT04243213|OTHER|Vibration Plate|Vibration at 15° tilt, which means the patients partly use their own body weight (resistive vibration exercise).
214413538|NCT04243213|OTHER|Tilt at 15°|To compare if a possible effect derives from the vibration or the tilting only, a second group was added who will only receive 10 min of 15° tilt without the vibration.
214413539|NCT04243213|OTHER|Standard hospital mobilization|early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients
214413540|NCT02179281|DEVICE|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
214413541|NCT01129778|DRUG|Zegerid (proton pump inhibitor)|
214413542|NCT01129778|PROCEDURE|Bravo pH monitoring|
214413543|NCT02558218|DRUG|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
214413544|NCT02558218|DRUG|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
214413545|NCT00807430|DEVICE|Grindcare (Active)|Active treatment
214413546|NCT00807430|DEVICE|Grindcare (Placebo - the device is not activated)|Placebo treatment
214413547|NCT05292599|OTHER|Experimental|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
214413548|NCT05292599|OTHER|Control|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
214413549|NCT01467700|DRUG|Ramelteon SL|Ramelteon SL tablets
214413550|NCT01467700|DRUG|Placebo|Ramelteon placebo-matching tablets
214413551|NCT03272113|BEHAVIORAL|SKIP-IT|A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
214413552|NCT04136236|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|Suspected esophageal mucosal lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI. After a washout period, nonexpert endoscopists take the second assessment with AI assistance.
214413553|NCT02971930|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
214413554|NCT05037851|DRUG|Opelconazole|Nebulizer suspension
214413555|NCT05037851|DRUG|Standard of Care|Standard of Care
214413556|NCT01293604|OTHER|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
214505101|NCT02323945|OTHER|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
214505102|NCT02323945|OTHER|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
214505103|NCT02323945|OTHER|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
214505104|NCT00670488|DRUG|MK-2206|MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
214505105|NCT00523900|DIETARY_SUPPLEMENT|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
214505106|NCT06554184|DRUG|HR20013 + dexamethasone + palonosetron placebo|HR20013 + dexamethasone + palonosetron placebo
214413557|NCT05975788|DRUG|Staphylococcus and Neisseria Tablets|Staphylococcus and Neisseria tablets is used as an adjuvant treatment drug for respiratory disease in acute attack period, such as chronic tracheitis, bronchitis and various types of colds. It has been proved to effectively shorten the course of disease. In this study, Staphylococcus and Neisseria tablets will be administered with 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months according to clinicians.
214413558|NCT03651713|BEHAVIORAL|GLU+EX|Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
214413559|NCT03651713|DIETARY_SUPPLEMENT|GLU|Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
214413560|NCT04321642|DRUG|Entonox|Entonox gas with mouth piece
214413561|NCT04321642|DRUG|Not receive Entonox|Not receive any gas
214413562|NCT03168646|PROCEDURE|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
214413563|NCT03168646|PROCEDURE|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
214413564|NCT06644430|PROCEDURE|Ablation|Ablation including (microwave ablation, radiofrequency ablation, cryoblation), this surgery was conducted under CT guidence. The pulmonary was completely ablated.
215016769|NCT04189588|DRUG|Diphenhydramine 50 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
214413565|NCT06644430|DRUG|system therapy|Paticipants received systemic therapy according the instructions.
214688961|NCT04688567|BEHAVIORAL|Patient-driven iCBT|1\) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.
215016770|NCT04189588|DRUG|anti-CD20 such as Rituximab or Paclitaxel|Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
215016771|NCT00002101|DRUG|Ethambutol hydrochloride|
215016772|NCT00002101|DRUG|Clarithromycin|
215016773|NCT00002101|DRUG|Rifabutin|
215016774|NCT02594852|DEVICE|+ laser|Use of laser in the treatment
215016775|NCT04727827|OTHER|Pharmacogenomic-guided supportive care|Patients undergoing hematopoietic stem cell transplantation will be genotyped and supportive care therapies tailored to identified drug-gene pairs and guideline recommendations
215016776|NCT01634750|DRUG|ManNAc|Single dose
214413566|NCT05372380|DRUG|BR1017-1|Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose
214413567|NCT05372380|DRUG|BR1017-2|Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.
214413568|NCT00292383|PROCEDURE|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
214413569|NCT00384436|DRUG|escitalopram|
214413570|NCT01966055|DRUG|Solithromycin|
214413571|NCT01253226|DRUG|LY2127399 (Tabalumab)|Administered subcutaneously
214413572|NCT01253226|DRUG|Placebo|Administered subcutaneously
214413573|NCT02036931|DEVICE|Metal on Polyethylene articulation|G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)
214413574|NCT02036931|DRUG|Ceramic on Polyethylene articulation|G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
214413575|NCT02036931|DEVICE|Ceramic on Ceramic articulation|G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
215016777|NCT01081938|DRUG|INSULIN GLARGINE|"Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine"
215016778|NCT01081938|DRUG|INSULIN GLULISINE|"Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"
215016779|NCT03640988|DEVICE|dermaPACE|Shockwave application
215016780|NCT01266057|DRUG|Hydroxychloroquine|Starting dose of 200 mg by mouth every day for a 21 day cycle.
215016781|NCT01266057|DRUG|Sirolimus|Starting dose of 2 mg by mouth every day for a 21 day cycle.
215016782|NCT01266057|DRUG|Vorinostat|Starting dose of 200 mg by mouth per day for a 21 day cycle.
215016783|NCT00170365|BEHAVIORAL|Restorative Yoga|
215016784|NCT05897502|BEHAVIORAL|multimedia education|"The experimental group use multimedia education, 20 minute nutrition education courses each time, a total of 8 courses.~The control group use routine education."
215016785|NCT03683498|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
215016786|NCT01602458|PROCEDURE|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
215016787|NCT01602458|PROCEDURE|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
214413576|NCT00046995|DRUG|carboplatin|
214413577|NCT00046995|DRUG|fluorouracil|
215016788|NCT00576407|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Cultured thymus tissue for implantation (CTTI) (previously described as transplantation) is done using allogeneic cultured postnatal tissue from unrelated thymus donors. Thymus tissue, the thymus donor, \& thymus donor's birth mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were implanted into the recipient's quadriceps. Dose was number of grams of cultured thymus tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of CTTI, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-CTTI, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
214413578|NCT00046995|DRUG|leucovorin calcium|
214413579|NCT00046995|PROCEDURE|adjuvant therapy|
214505107|NCT06554184|DRUG|Palonosetron + dexamethasone + HR20013 placebo|Palonosetron + dexamethasone + HR20013 placebo
215101691|NCT05215834|DRUG|Remifentanil|"1. Remimazolm and Remifentanil (RR group): anesthesia was induced with remimazolam 6 mg/kg/h by continuous intravenous (IV) infusion and with the effect-site concentration of remifentanil 4 ng/ml and until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h and remifentanil 3 ng/ml until the end of surgery.~2. Propofol and Remifentanil (PR group), anesthesia was induced with the effect-site concentration of propofol of 6.0 μg/ml and remifentanil 4 ng/ml, and until the loss of consciousness (LoC), followed by the effect-site concentration of propofol of 2-4 μg/ml and remifentanil 3 ng/ml until the end of surgery."
215101692|NCT01969955|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
215016789|NCT00621322|BIOLOGICAL|GSK Biologicals' AS01B adjuvant|Intramuscular injection, 2 doses
215016790|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1|Intramuscular injection, 2 doses
215016791|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2|Intramuscular injection, 2 doses
214505108|NCT06836479|OTHER|NOURISH Diet|NOURISH meals will be prepared by NOURISH chefs for seven days. Both South Asian and Filipino meal plans will be prepared, vegetarian, vegan and non-vegetarian options available for all. Participants will pick-up NOURISH meals at a Stanford facility and consume three meals (breakfast, lunch, and dinner) and two snacks over one week. There will be no caloric restriction, the calories in each meal will be informed by the average intake for the participants gender and BMI.
214505109|NCT06836479|OTHER|Self-Selected Diet (Control)|The participants will eat their routine meals without any involvement of the investigators. Participants will be required to wear the CGM during this time and keep a detailed food log through Tastermonial.
215016792|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3|Intramuscular injection, 2 doses
215016793|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1|Intramuscular injection, 2 doses
215101693|NCT01633658|DIETARY_SUPPLEMENT|cholecalciferol|a single dose of 2500 micrograms of cholecalciferol
215016794|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2|Intramuscular injection, 2 doses
214413580|NCT04609618|DEVICE|Appscent Device|computer-controlled, low pressure compressed air based, with disposable odorant capsules solution provided an odor environment at the nose,
214413581|NCT00561743|DRUG|Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone|
214413582|NCT01425983|DIETARY_SUPPLEMENT|amino acid composition (asn01)|"Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
214413583|NCT01425983|OTHER|Placebo|"Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
214413584|NCT00988637|DRUG|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
214413585|NCT00988637|DRUG|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
214413586|NCT05153135|DRUG|Ribociclib|Participants who initiated CDK4/6i therapy
214413587|NCT05153135|DRUG|Palbociclib|Participants who initiated CDK4/6i therapy
214413588|NCT05153135|DRUG|Abemaciclib|Participants who initiated CDK4/6i therapy
214413589|NCT00745446|PROCEDURE|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
214413590|NCT06453356|DRUG|Zavegepant 10mg|intransal spray 10mg
214505110|NCT01455779|DEVICE|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
214505111|NCT00301054|DRUG|Ferrous sulphate|
214505112|NCT00301054|DRUG|Sulphadoxine-Pyrimethamine|
214413591|NCT01205620|DEVICE|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
214413592|NCT01205620|OTHER|No intervention|No intervention will be performed in the control group
214413593|NCT05581160|DIAGNOSTIC_TEST|Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)|"Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form).~During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to:~* Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices.~* Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs.~The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique.~A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C."
214413594|NCT04204408|DRUG|NNC0365-3769 (Mim8)|Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
214413595|NCT04204408|DRUG|Placebo (Mim8)|Mim8 placebo administered subcutaneously (s.c., under the skin)
214413596|NCT03593070|BEHAVIORAL|Chronic Grief Management Intervention-Video|The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
214413597|NCT06339918|OTHER|KegelExercise|Kegel exercises (also called pelvic floor exercises)will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
214413598|NCT06339918|OTHER|4-7-8 breathing technique|This can be performed in the following way: Participants taking part should locate a comfy spot to sit. Inhale to the count of 4. Hold their breath for 7 counts. To the count of 8, release air via their mouth.
214413599|NCT04813952|DRUG|Sevoflurane inhalant product|The sevoflurane dose differed in both groups in relation to the fresh gas flow. Since the fresh gas flow is less in group M, the concentration of sevoflurane consumed by the patient at the end of the case will be less.
214413600|NCT06630468|OTHER|Task-oriented occupational therapy (TOOT)|The task-oriented occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
215016795|NCT05235828|BEHAVIORAL|Sudarshan Kriya Yoga (SKY)|This is the experimental arm of the study, where participants will be trained in a form of breathing based meditation that incorporates different breathing techniques centred around controlling arousal and attention. Participants will be encouraged to learn all of the techniques that are covered during these sessions and also utilize the techniques that are most appropriate for their personal needs. After some initial training sessions, participants will be encouraged to practice their new SKY techniques in environments and situations that they have been avoiding. They would begin with situations that are less triggering, and progress to more difficult situations. At each group session, participants will describe their experiences and discuss ways to continue to incorporate the SKY techniques into their daily lives, until it reaches a point of being natural to use these skills throughout the day, both in practice, and in application.
215016796|NCT06522529|OTHER|Multifaceted implementation strategy|The multifaceted implementation strategy consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local context analysis, identifying barriers to improvements in clinical practice, and developing and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
215016797|NCT02591407|PROCEDURE|TAP Block|This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
215016798|NCT02591407|PROCEDURE|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion
214413601|NCT06630468|OTHER|Control group|Routine upper-extremity-based occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
214413602|NCT06630910|PROCEDURE|Pancreaticojejunostomy without stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall without stenting or omental patch.
214413603|NCT06630910|PROCEDURE|Pancreaticojejunostomy with stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall, a nelaton stent 6f was inserted into the pancreatic duct and jejunum of each patient receiving PJ. The larger omentum was separated longitudinally over an avascular zone, and one or two omental branches of the gastroepiploic arteries were preserved using pedicle omental flaps. The omental flap was pushed between the posterior surface of PJ and the portal vein, then wrapped over the anterior surface of PJ. The omentum was rolled up and secured with a few PDS sutures.
214413604|NCT06630988|OTHER|Failure rates|Describe the management failure rate for hand infections, including panariasis, phlegmons and arthritis.
214505113|NCT02232997|OTHER|Standard Hydration|Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \< 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
214413605|NCT06631911|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Emotional Awareness and Expression Therapy (EAET) is a manualized, short-term psychodynamic therapy that, in this instance, is delivered in a group format.~The core of Emotional Awareness and Expression Therapy (EAET) involves helping individuals identify, understand, and express their emotions in a therapeutic setting. The therapy emphasizes the connection between unprocessed emotions and physical symptoms, encouraging participants to explore the emotional underpinnings of their distress. Through guided discussions, psychoeducation, and expressive exercises, participants learn to recognize patterns of emotional avoidance, develop self-compassion, and improve interpersonal communication. This process aims to reduce somatic symptoms and enhance overall emotional well-being by fostering a greater awareness of emotional experiences."
214413606|NCT06630754|OTHER|No Intervention: Observational Cohort|No intervention; observation cohort study
214413607|NCT06631300|DRUG|Prednisone|A prednisone taper will be given to the subjects as follows: prednisone 40mg for 3 days, prednisone 30mg for 3 days, prednisone 20mg for 3 days, prednisone 10mg for 3 days, prednisone 5mg for 3 days, then off for a total of 15 days.
214413608|NCT06631300|DRUG|Placebo|A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.
214413609|NCT06631651|PROCEDURE|Brachioradialis release|During distal radius fracture surgery (open reduction+internal fixation) partial brachioradialis release from the insertion of brachioradialis muscle was performed in order to perform reduction of fracture
215016799|NCT05265364|RADIATION|IMRT with SIB|moderate hypofractioation using 2.5gy/fr in prostate cancer patients usig IMRT SIB technique
214413610|NCT06631651|PROCEDURE|Brachioradialis not released|During distal radius fracture surgery (open reduction+internal fixation) brachioradialis release was not performed.
214413611|NCT06631703|OTHER|Group receiving Oral Colostrum Administiration|Description: Colostrum secreted in the first 3-5 days was oropharyngeal administered to the intervention group by withdrawing 0.2 ml of colostrum to be taken from the mother with the help of an insulin injector every three hours before each feeding meal in accordance with the literature.In the premature infants in the intervention group in which oropharyngeal colostrum was administered, the application was performed as follows: The oropharyngeal colostrum administration technique consists of slowly inserting a sterile 1 mL syringe without a needle with the tip of the syringe into the baby's mouth along the right buccal mucosa (0.1 mL) towards the oropharynx, then moving the syringe towards the inside of the cheeks and on the tongue, and repeating the same procedure on the left buccal mucosa (0.1 mL) without removing it (slow administration in approximately 1 minute). The routine feeding procedure was then continued
214413612|NCT06631690|OTHER|Isokinetic and functional balance tests|Isokinetic and functional balance tests
214413614|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Inulin-fructan 15mg/day for 28days
214413615|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Daily consumption of 15g inulin-fructan for 28 days
214413616|NCT03614234|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
215016800|NCT00705965|BEHAVIORAL|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
215016801|NCT00705965|BEHAVIORAL|Information session|One information session about living with heart disease.
215016802|NCT00705965|OTHER|Usual cardiological care|Usual cardiological care
215016803|NCT02980900|DIETARY_SUPPLEMENT|Post exercise protein-polyphenol supplement|Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
215016804|NCT02980900|DIETARY_SUPPLEMENT|Post exercise placebo supplement|Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
215016805|NCT02980900|DIETARY_SUPPLEMENT|Pre bed protein-polyphenol supplement|Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
215016806|NCT02980900|DIETARY_SUPPLEMENT|Pre bed placebo supplement|Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
215016807|NCT00756444|DRUG|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
215016808|NCT00756444|DRUG|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
215016809|NCT00756444|DRUG|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
215016810|NCT02694055|OTHER|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.
214413617|NCT04936789|DEVICE|IMES|Surgical implantation of IMES
214413618|NCT06629571|OTHER|Education|Training for the patient before surgery
214413619|NCT06631456|OTHER|PRP injection|A total of 3 doses of intra-articular PRP were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
214413620|NCT06631456|OTHER|Ozone therapy|A total of 3 doses of intra-articular ozone therapy were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
214413621|NCT01582945|DRUG|Ketamine|Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
214413622|NCT02680093|OTHER|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
214413623|NCT00910702|DEVICE|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
214413624|NCT04917432|PROCEDURE|intravascular ultrasound (IVUS)|Intravascular imaging using a specialized catheter delivered through intra-arterial approach to reach the coronaries to guide CTO-PCI procedure and optimize the results after wire crossing.
214413625|NCT04917432|PROCEDURE|Conventional CTO PCI (non-IVUS guided)|Non-IVUS guided CTO PCI for wiring but may be used for results optimization after wire crossing
215016811|NCT02694055|OTHER|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
214413626|NCT01855464|PROCEDURE|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
214413627|NCT01855464|PROCEDURE|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
214413628|NCT05169255|DRUG|Antibiotic administration|Individuals received either azithromycin or amoxicillin for 3 or 7 days
214413629|NCT01019616|DRUG|paclitaxel/anthracycline|standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
214413630|NCT00574886|BIOLOGICAL|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
214413631|NCT06053931|BEHAVIORAL|white noise music|"Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=5NFHiKMCPvw\&t=6478s)."
214413632|NCT06053931|BEHAVIORAL|lullaby music|"Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=h0QO8bgysPg)"
214413633|NCT03066596|BEHAVIORAL|PRAGMATIC|Provider educational seminar, EHR prompt, outreach-worker care coordination
214413634|NCT05766098|GENETIC|Genotyping|Characterization of genetic profile of tumor tissues
214688962|NCT04688567|BEHAVIORAL|Standardized iCBT (TAU)|2\) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.
215016812|NCT02694055|OTHER|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
215016813|NCT02694055|OTHER|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
215016814|NCT02694055|OTHER|Training of primary health centre staff|"Health center staff will receive targeted training in~* Integrated management of childhood illness~* Diagnosis and treatment of simple and severe cases of malaria~* Helping babies breathe~* Managing post-partum haemorrhage~* Gestational dating using frontal height, last menstrual period and ultrasound~* Family planning counselling and administration of long-acting contraceptives~* Pharmacy stock management~* Health center management"
214413635|NCT05557721|PROCEDURE|Topical lidocaine|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage.
214688963|NCT05762939|BEHAVIORAL|Chatbot|Participants in this condition were asked to use Fido, a Polish therapy chatbot, for two weeks. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
215016815|NCT00180700|BEHAVIORAL|Hypnosis|
214413636|NCT05557721|PROCEDURE|MP-TLT|"Micro pulse transscleral laser treatment will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations.~In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning."
214413637|NCT06460363|DEVICE|Transcranial alternating current stimulation (TACS)|Transcranial alternating sinusoidal current at frequency of 40 Hz applied for 60 min through a pair of saline-soaked surface sponge electrodes.
214413638|NCT06460363|DEVICE|Sham TACS|Sham treatment with few seconds of actual electrical current and same electrode configuration
214413639|NCT06000969|DEVICE|Lung Recruitment Conventional|the recruitment maneuver will be performed by manual inflation with a pressure of 30 cmH2O for 30 seconds.
214413640|NCT06000969|DEVICE|Lung Recruitment Ultrasound|the recruitment maneuver will be performed under the direct real-time guidance of ultrasound if atelectasis (defined as LUS of ≥ 2 for any of the 12 regions) is present. This will be done by manual inflation with a pressure of 10 cmH2O for 10 seconds, increased 10 cmH2O every 10 seconds until no collapsed areas are visible on the ultrasound, the maximum airway pressure will be limited to 40 cmH2O. This could be repeated if needed.
214413641|NCT04559724|DEVICE|Indego Therapy|Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
214413642|NCT01766856|OTHER|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
215016816|NCT05196503|BIOLOGICAL|Treatment|"Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF."
214413643|NCT05391126|DRUG|Irinotecan|Usual dosing per package insert.
214413644|NCT06555965|OTHER|Non-interventional study|There is no planned intervention in this study
214413645|NCT04427098|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Subcutaneous enoxaparin 40 mg once daily for 14 days.
214413646|NCT04427098|DRUG|Enoxaparin|Subcutaneous enoxaparin for 14 days: 60 mg once daily in case of body weight of 45 to 60 kg; 80 mg once daily in case of weight from 61 to 100 kg; 100 mg once daily in case of bodyweight \>100 kg
214413647|NCT06314594|PROCEDURE|Conventional treatment|Patients will randomly assigned to routine treatment group (control group) and individualized treatment model group (intervention group). All patients will observed and intervened for 4 months. Patients in the control treatment group will follow the treatment plan in the 2016SOSORT guidelines
214413648|NCT06314594|BEHAVIORAL|intervention treatment|"Patients will be input into the health management platform. The optimal treatment scheme will be then determined through data calculation and sent to individuals (or their families) or schools for implementation under the guidance of the platform. It is important to note that the specific treatment plan varied from person to person. Patients were observed and intervened for a period of 4 months.~1. Massage therapy~2. Posture guidance~3. Schroeder\&#39;s gymnastics therapy~4. Bioelectric stimulation therapy"
214413649|NCT06141057|BIOLOGICAL|Matrix M with RH5.1|50 µg of Matrix-M adjuvant with RH5.1 at different doses on days 0 and 28.
214413650|NCT05887323|DEVICE|Implantation of the Tendril 2088 lead in the LBBA|Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.
214413651|NCT05893121|OTHER|Cardiac coherence session|A cardiac coherence session consists of an exercise of six breaths per minute during five minutes.
214413652|NCT05893121|OTHER|Information note about MRI|explanatory note about MRI examination
214413653|NCT00870350|BIOLOGICAL|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
214688964|NCT05762939|BEHAVIORAL|Control (book)|Participants in this condition were told to read selected chapters from a self-help book during the two-week intervention period. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
215016817|NCT04494737|BEHAVIORAL|Active Comparator: Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
215016818|NCT04494737|BEHAVIORAL|Active Comparator: Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
215016819|NCT03834662|DRUG|AVID200|A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
215016820|NCT01326637|OTHER|Patient Overview Document|"The Intervention has two components:~1. Pre-visit care coordination:~   * 5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~  * The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~2. Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
215016821|NCT01578746|PROCEDURE|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
215016822|NCT01578746|PROCEDURE|Anterior approach|The use of anterior approach in total hip arthroplasty
214413654|NCT00870350|BIOLOGICAL|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
214413655|NCT02783183|DRUG|YHD1119|2 by 2
214413656|NCT02783183|DRUG|Lyrica|2 by 2
214413657|NCT01986374|DRUG|HCG is introduced|must have good blastocysts
214413658|NCT05684003|OTHER|Neuromuscular exercise based injury-prevention program|Neuromuscular exercise based injury-prevention program
214413659|NCT01751997|DRUG|Transplants from 8/8-matched Unrelated donors|"* Myeloablative conditioning~  1. Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~ 2. Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~ 3. Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* Reduced-intensity conditioning; older patients (age \> 55 years) and/or patients with comorbidities~  1. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m\^2)~ 2. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~ 3. Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
214413660|NCT01751997|DRUG|Transplants from family-mismatched/haploidentical donors|"* Reduced-intensity conditioning~  1. Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~ 2. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m\^2)~ 3. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
214413661|NCT02573740|DRUG|ABT-957|
214413662|NCT02573740|OTHER|Placebo|
214413663|NCT06176144|DRUG|Desflurane|Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled desflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), and sufentanil (administered by intermittent injection).Towards the end of surgery, desflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Desflurane inhalation will be stopped at the end of surgery.
214688965|NCT00003210|BIOLOGICAL|recombinant interleukin-12|Given subcutaneously
214688966|NCT00003210|OTHER|laboratory biomarker analysis|Correlative studies
215016823|NCT06035549|BEHAVIORAL|Culturally Tailored Digital Resilience-Building|The Culturally Tailored Digital Resilience-Building intervention consists of 6 modules, including an introduction of advance care planning and resilience skills that specifically address cultural beliefs and barriers.
215101694|NCT01633658|DIETARY_SUPPLEMENT|25(OH)D|a single dose of 625 micrograms of 25(OH)D
215016824|NCT06033859|DIAGNOSTIC_TEST|Clinical measurements|With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
215016825|NCT06033859|DIAGNOSTIC_TEST|Radiographic measurement|A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
215016826|NCT06033859|PROCEDURE|Dental prophylaxis or maintenance|Dental prophylaxis or maintenance will be performed every 3 months.
214688967|NCT02203838|DRUG|RBP-7000|"120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner."
214688968|NCT00003356|BIOLOGICAL|aldesleukin|
214688969|NCT00003356|BIOLOGICAL|rituximab|
214413664|NCT06176144|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection).Towards the end of surgery, sevoflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
214413665|NCT01656304|BIOLOGICAL|bevacizumab|Given IV
214413666|NCT01656304|OTHER|laboratory biomarker analysis|Correlative studies
214413667|NCT01580943|DRUG|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
214413668|NCT01580943|DRUG|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
214413669|NCT00322699|PROCEDURE|Whole bladder laser light treatment as an alternative to radical cystectomy|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
214413670|NCT00322699|DRUG|Photofrin|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
214413671|NCT01126840|BEHAVIORAL|Telephone Interview|The phone interview should take 30-45 minutes to complete.
214413672|NCT01126840|BEHAVIORAL|Questionnaire|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
214413673|NCT00057382|DRUG|T138067 intravenous|
214413674|NCT00057382|DRUG|doxorubicin intravenous|
214413675|NCT03459183|DEVICE|Infrasound (85 dB; 6Hz) source|the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB
214413676|NCT03459183|DEVICE|Ultrasound (10dB below hearing threshold; 22.4 kHz) source|the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep
214413677|NCT03459183|DEVICE|Infrasound dummy source|the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound
214413678|NCT03459183|DEVICE|Ultrasound dummy source|the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
214413679|NCT03025464|DEVICE|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
214413680|NCT02292394|BEHAVIORAL|Multicomponent Cognitive Behavioral Telephone Intervention|
214413681|NCT02292394|BEHAVIORAL|Telephone Intervention Pleasant Activities|
214413682|NCT02908620|COMBINATION_PRODUCT|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
214413683|NCT02908620|DRUG|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
214413684|NCT02908620|COMBINATION_PRODUCT|Two sprays CTY-5339-A|Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
215016827|NCT03241550|DRUG|isavuconazonium sulfate - intravenous|IV infusion
215016828|NCT03241550|DRUG|isavuconazonium sulfate - oral|Oral
215016829|NCT01391299|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
215016830|NCT01391299|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
215016831|NCT02319915|DRUG|Tranexamic Acid|
215016832|NCT02319915|DRUG|Adrenalin|
215016833|NCT06637384|DRUG|Hyaluronic Acid (HA)|Gengigel Gingival Gel 20ml, Ricerfarma, Milan, Italy
215016834|NCT06637384|DRUG|Corticosteroid Injection|Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals, Pakistan
215016835|NCT06642779|BEHAVIORAL|VFQ- 25 (Visual Function Questionnaire)|VFQ-25 questionnaire was used to evaluate patient satisfaction at the M3 and M12 visits.
215016836|NCT06642779|DIAGNOSTIC_TEST|Optical Biometry|Axial length, anterior chamber depth and corneal keratometric values K1-K2. All these parameters were measured at the screening visit and at the month 3 follow-up visit, using the ARGOS® Biometer or the ANTERION® Cataract App
215101695|NCT00626171|PROCEDURE|Allergen Challenge|Allergen challenge
215016837|NCT06642779|DIAGNOSTIC_TEST|Slit lamps / Fundoscopy / Biomicroscopy|The fundus and other ocular structures, such as the cornea, anterior chamber, iris, pupil, crystalline lens / IOL alignment, corpus ciliare and choroid were examined at screening visit, on the day of the surgery, and at the follow up visits D1, M1, M3, M6, and M12, using the slit lamp binocular indirect ophthalmoscopy.
214413685|NCT02908620|DRUG|One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)|A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
214413686|NCT04548622|DEVICE|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to both the left and right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
214413687|NCT02131740|OTHER|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest \& eye rubbing for a further 1 minute.
214413688|NCT02131740|OTHER|No eye rubbing|This eye will not be rubbed
214413689|NCT05921409|DIETARY_SUPPLEMENT|Extra Virgin Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Extra Virgin Olive Oil (treatment group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
214413690|NCT05921409|DIETARY_SUPPLEMENT|Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Olive Oil (placebo group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
214413691|NCT02983214|DRUG|Clopidogrel|
214413692|NCT02983214|DRUG|Cilostazol|
214413693|NCT05584020|PROCEDURE|ACL Repair|Patients are undergoing arthroscopic anterior cruciate ligament repair. The native ACL is repaired using very strong sutures. This device is used to repair the native ACL and restore knee stability.
214413694|NCT05584020|PROCEDURE|ACL Reconstruction|Patients are undergoing arthroscopic anterior cruciate ligament reconstruction. The torn ligament is removed and replaced with a band of tissue that usually connects muscle to bone. The graft tendon is taken from another part of your knee or from a deceased donor.
215016838|NCT06642779|DIAGNOSTIC_TEST|UDVA|Monocular and binocular Uncorrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
215016839|NCT06642779|DIAGNOSTIC_TEST|CDVA|Monocular and binocular Corrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
215016840|NCT06642779|DIAGNOSTIC_TEST|UIVA / DCIVA|Uncorrected and Distance Corrected Intermediate Visual acuity (UIVA / DCIVA) was evaluated postoperatively at M1, M3, M6 and M12, using an intermediate chart from 67 cm.
215016841|NCT06642779|DIAGNOSTIC_TEST|UNVA / DCNVA|Uncorrected and Distance Corrected Near Visual acuity (UNVA / DCNVA) was evaluated postoperatively at M1, M3, M6 and M12, using a near chart from 40 cm.
215016842|NCT06642779|DIAGNOSTIC_TEST|Manifest Refraction|Manifest refraction was the monocular subjective refraction (Sph, Cyl, Axis) giving the best distance corrected visual acuity. It was measured at the screening visit and the follow-up visits Day 1, Month 1, Month 3, Month 6 and Month 12.
215016843|NCT06642779|DIAGNOSTIC_TEST|IOP|Intraocular pressure (IOP) was measured at all visits (preoperative, D1, M1, M3, M6 and M12), using a non-contact tonometer.
215016844|NCT06642779|DIAGNOSTIC_TEST|VADC|Visual Acuity Defocus Curve (VADC) was taken monocularly at M3, monocularly and binocularly at M6 and binocularly at M12, using the Multifocal Lens analyzer - MLA application.
215016845|NCT06642779|DIAGNOSTIC_TEST|CSDC|Contrast Sinsitivity Defocus Curve (CSDC) was taken under photopic conditions at M6 and M12, using the Multifocal Lens Analyzer - MLA application
215016846|NCT06642779|DIAGNOSTIC_TEST|CSV-1000|"Contrast Sensitivity was measured using the CSV-1000 with distance correction in place at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd). Measurements were taken under four different light conditions:~* Photopic (M3 monocular and binocular, M6 binocular and M12 monocular)~* Mesopic (M6 binocular)~* Photopic with backlight (M6 binocular)~* Mesopic with backlight (M6 binocular)"
215016847|NCT06642779|DIAGNOSTIC_TEST|Tear film stability|Tear film stability was assessed at screening visit and at follow-up visits M1, M3, M6, and M12 using the non-invasive Tear break Up Time (TBUT) with fluorescein dye.
215016848|NCT06642779|DEVICE|IOL implantation|The investigational device (877PEY) and the comparator (877PAY) intraocular lens models were implanted, using sutureless, small-incision phacoemulsification surgery.
215016849|NCT04879732|DEVICE|ACTIS|ACTIS Hip stem
215016850|NCT06640582|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
214688970|NCT01332929|DRUG|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
214688971|NCT00002826|DRUG|paclitaxel|
215101696|NCT00414518|DRUG|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
214688972|NCT00002826|DRUG|valspodar|
214413696|NCT00639613|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
214413697|NCT00639613|OTHER|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
214413698|NCT01201187|DRUG|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
214413699|NCT01201187|DRUG|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
214413700|NCT01888406|BEHAVIORAL|Guided Self-Help|
214413701|NCT01888406|BEHAVIORAL|Pure Self-Help|
214413702|NCT02466295|OTHER|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
214413703|NCT02466295|OTHER|Pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
214413704|NCT00967369|DRUG|Bortezomib|Given IV
214688973|NCT04489524|BEHAVIORAL|individualized counselor-led MI sessions|Intervention consisted of four 60-min in-person sessions of AMI counseling and a packet of self help smoking cessation materials.
215016851|NCT06640582|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
215016852|NCT06640582|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
215016853|NCT06640582|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
215016854|NCT06640582|DRUG|Pembrolizumab|Intravenous (IV) infusion
215101697|NCT00414518|DRUG|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
215101698|NCT05249569|DRUG|Axitinib|Axitinib to be administered orally BID
215101699|NCT05249569|DRUG|Avelumab|Avelumab to be administered as a 1-hour IV infusion on Day 1 and Day 15 of each 28-day cycle.
215101700|NCT05249569|DRUG|Bavituximab|Bavituximab to be administered weekly on Days 1, 8, 15 and 22 of the 28-day cycle.
214413705|NCT00967369|DRUG|Carboplatin|Given IV
214413706|NCT00967369|DRUG|Etoposide|Given IV
214413707|NCT00967369|DRUG|Ifosfamide|Given IV
214413708|NCT00881335|DEVICE|flutter mucus clearance device|five minutes every sessions, three sessions per day
214688974|NCT04489524|BEHAVIORAL|general health education session|four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco.
214688975|NCT04489524|BEHAVIORAL|NRT|nicotine replacement therapy
215101701|NCT03781440|PROCEDURE|Bilateral ESP catheter with lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
215101702|NCT03781440|PROCEDURE|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
214688976|NCT01554878|PROCEDURE|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
214688977|NCT03196297|DRUG|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
214688978|NCT03196297|DRUG|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
215016855|NCT06641622|DIAGNOSTIC_TEST|Prediction of delayed graft function|Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence
215101703|NCT00868127|DRUG|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
214413709|NCT01963026|OTHER|ToCUEST featuring a 'variable practice' approach.|Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module \[17\] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. \[17\]. Intervention B will be called 'ToCUEST variability' in the present project.
214413710|NCT01963026|OTHER|ToCUEST featuring a 'constant practice' approach.|Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
214413711|NCT04757103|PROCEDURE|Resection of the retrorectal tumor|Surgical resection of the retrorectal mass
214413712|NCT04681417|DRUG|Melphalan or Melphalan + Topotecan|IAC: 2-6 cycles every 1 month (number based on the local tumor evolution), performed using radio-guided catheterization and delivery at the ostium of the ophthalmic artery, in neuroradiology operating room, and under General Anesthesia (GA). IAC will be administered at the Fondation Rothschild Hospital in collaboration with the Interventional Neuroradiology team.
214413713|NCT04681417|DRUG|etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy|2 to 6 cycles of combined etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy : thermotherapy and/or cryotherapy and/or iodine-125 plaques and/or intravitreal chemotherapy injections
214413714|NCT04681417|DRUG|Carboplatin administered on Day 1|Chemothermotherapy : Intravenous injection by carboplatin
214413715|NCT04681417|DEVICE|Thermotherapy (local treatment)|Thermotherapy after carboplatin administered on Day 1
214688979|NCT01659944|DRUG|Eliglustat|Capsules for oral administration
214413716|NCT04681417|DEVICE|Cryotherapy (local treatment)|Cryotherapy (local treatment)
214413717|NCT04681417|DEVICE|Iodine-125 plaques (local treatment)|Iodine-125 plaques (local treatment)
214413718|NCT04681417|DRUG|Intravitreal Melphalan chemotherapy injections (local treatment)|Intravitreal Melphalan chemotherapy injections (local treatment)
214413719|NCT03722433|DRUG|Vigiis 101-LAB and sequential therapy|Vigiis 101-LAB is the probiotic containing Lactobacillus paracasei subsp. Paracasei, which is the isolate from Taiwanese by Prof. Pan. This strain is resistant to gastric acid and bile acid. Therefore, its survival rate in the gastrointestinal tract could be as high as 95%. Previous studies showed that Vigiis 101-LAB can modulate the gut microbiota, with 10% increase in Bifidobacterium species and 20% reduction in Clostridium difficile.
215016856|NCT06641934|OTHER|No intervention; Observational study|No intervention
215101704|NCT00868127|DRUG|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
214413720|NCT03722433|DRUG|Placebo and sequential therapy|Placebo without Vigiis 101-LAB component
214413721|NCT04717882|DEVICE|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient.
214413722|NCT02524444|DRUG|Mefloquine|Tabs Mefloquine 250mg
214688980|NCT01659944|DRUG|Metoprolol|Tablets for oral administration
214413723|NCT02524444|DRUG|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
214413724|NCT00477412|DRUG|Bortezomib|Given IV
214413725|NCT00477412|DRUG|Cyclophosphamide|Given IV
214413726|NCT00477412|DRUG|Cytarabine|Given IV
214413727|NCT00477412|DRUG|Dexamethasone|Given PO or IV
214413728|NCT00477412|DRUG|Doxorubicin|Given IV
214413729|NCT00477412|DRUG|Methotrexate|Given IV
214413730|NCT00477412|BIOLOGICAL|Rituximab|Given IV
214413731|NCT00477412|DRUG|Vincristine|Given IV
214413732|NCT04541641|PROCEDURE|New Reverse Drilling technique|a new technique of dental implant drilling that promote osseodensification by rotating the drills anti-clockwise rather than clockwise to promote bone condensation rather than bone cutting
214413733|NCT04541641|PROCEDURE|osteotome technique|a technique for dental implant placement by using the osteotome to condense the bone and create an osteotome rather than cutting the bone
214413734|NCT00555867|DRUG|Anastrozole|oral
214413735|NCT01221337|OTHER|heparin free haemodialysis|"Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH)."
214413736|NCT02248454|DRUG|Lispro|Increasing insulin doses
214413737|NCT03146351|OTHER|Family based early intervention program (NDT-Bobath based)|Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
214413738|NCT04678934|PROCEDURE|TAVR|Transcatheter aortic valve replacement
214413739|NCT02377206|OTHER|ADAS-Cog evaluation|\[18F\]DPA-714 PET imaging
214688981|NCT00088010|DRUG|Arzoxifene|20mg, oral, tablet, once a day for 36 months
214688982|NCT00088010|DRUG|Placebo|oral, tablet, once a day for 36 months
214688983|NCT02954835|DEVICE|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
214688984|NCT02954835|DEVICE|Traditional Dressing|Sterile gauze dressing secured by tape.
215016857|NCT01704989|PROCEDURE|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
215016858|NCT01704989|DRUG|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (\>35 mmHg) or advanced damage at presentation.
214413740|NCT01943162|BEHAVIORAL|CPT|
214413741|NCT00089258|BIOLOGICAL|beta-glucan|
214413742|NCT00089258|BIOLOGICAL|monoclonal antibody 3F8|
214413743|NCT00089258|BIOLOGICAL|sargramostim|
214413744|NCT00089258|DRUG|isotretinoin|
214688985|NCT00829166|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
214688986|NCT00829166|DRUG|Lapatinib|Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
214688987|NCT00829166|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
214688988|NCT00672542|BIOLOGICAL|Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|The safety and toxicity of vaccination with tumor antigen RNA-transfected dendritic cells (DC), derived from either untransfected or siRNA-transfected monocytes, will be evaluated in subjects with metastatic melanoma. Subjects will undergo leukapheresis and monocytes will be isolated. These monocytes will then be left untreated (Study Arm A) or transfected with either control siRNA (Study Arm B) or siRNA targeting immunoproteasome subunits LMP2, LMP7, and MECL1 (Study Arm C), then differentiated into DC in vitro . After the induction of maturation, these DC will be transfected with RNA encoding defined melanoma antigens MART, MAGE-3, tyrosinase, and gp100. These RNA-transfected autologous DC will be cryopreserved, then used to vaccinate subjects with metastatic melanoma, each of whom will receive a total of six intradermal (ID) injections using 1x10e7 DC at each cycle, administered weekly.
215016859|NCT05500534|DEVICE|Laser lithotripsy with stone recognition|Application of Revolix HTL+ which features automatic real-time stone recognition
215016860|NCT05500534|OTHER|Laser lithortripsy|Standard laser lithotripsy
215016861|NCT06642870|OTHER|Non-interventional study|The study will consist of focus groups and a large scale patient survey
215016862|NCT06642532|DEVICE|TCD group|Transcranial Doppler ultrasound to examine bilateral hemodynamic parameters of middle cerebral artery(MCA), terminal internal carotid artery(TICA), (anterior communicating artery)ACA, and posterior cerebral artery(PCA) (Vs, Vd, Vm, PI index, RI index) from temporal window
215016863|NCT06639737|PROCEDURE|preoperative stroke volume optimization|Stroke volume optimization using transthoracic echocardigraphy (sub aortic velocity time integral) before induction of total intravenous anesthesia. Fluids bolus of 250 ml of cristalloids will be successively administered until the sub aortic velocity time integral increase will be \< 10%
215016864|NCT06639737|PROCEDURE|Post induction stroke volume optimization|Optimization of stroke volume following induction of general anesthesia using oesophageal stroke volume measurement. 250 ml bolus of cristalloids succesively administered until the stroke volume increase \<10%
215016865|NCT06539260|DRUG|Vitamin D|Take 400 units of vitamin D3, twice daily, for a duration of 3 months.
215016866|NCT06539260|DRUG|Placebo|Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.
215016867|NCT03603184|DRUG|Atezolizumab|Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
215016868|NCT03603184|DRUG|Placebos|Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
215016869|NCT03603184|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.
215016870|NCT03603184|DRUG|Carboplatin|Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.
215016871|NCT06440746|DRUG|Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)|Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.
215016872|NCT06440746|DRUG|SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL|Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.
215016873|NCT01655069|DRUG|Solifenacin succinate suspension|Oral suspension
215016874|NCT05694208|BEHAVIORAL|Education Group|In the first pre-operative interview at the gynecological oncology outpatient clinic of the relevant hospital, the purpose of the research will be explained to the patients and an informed consent form will be filled. The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
215016875|NCT03041870|DEVICE|PET-fMRI scan|fMRI scan include MR sequences: BOLD and fMRI. The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of \[11C\]DASB bolus.
214413745|NCT03429855|OTHER|trunk training|Bobath based trunk training
214413746|NCT03429855|OTHER|physiotherapy|conventional physiotherapy
214413747|NCT00237341|DRUG|fentanyl|
214413748|NCT03438487|BIOLOGICAL|Flucelvax Trivalent Influenza Vaccine|"Flucelvax is a cell culture seasonal trivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage or B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
214413749|NCT03438487|BIOLOGICAL|Flucelvax Quadrivalent Influenza Vaccine|"Flucelvax Quadrivalent is a cell culture seasonal quadrivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage, 4) B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
214688989|NCT04729452|OTHER|blood test|blood test to test immune response to SARS-CoV-2
214413750|NCT02279342|DRUG|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
214413751|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
214413752|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
214413753|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
214413754|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
214413755|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
214413756|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
214413757|NCT01372163|DRUG|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
214688990|NCT04367337|OTHER|No intervention|Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
215016876|NCT05075681|DRUG|Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide.~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
214413758|NCT02712866|DRUG|Vedolizumab|Administration of intravenous Vedolizumab in inflammatory bowel disease patients
215016877|NCT04249739|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
215016878|NCT02159404|BIOLOGICAL|Immunotherapy|
215016879|NCT04771871|DRUG|Epirubicin|Epirubicin is an antitumor antibiotics with good activity on breast cancer. It has less cardiotoxic effect than doxorubicin
215016880|NCT04771871|DRUG|Cyclophosphamide|Cyclophosphamide is a cytoxic drug indicated for the treatment of many malignancies including breast cancer
214413759|NCT02063607|BIOLOGICAL|Peginterferon lambda|
214413760|NCT01844544|OTHER|inspection of medical records|
214413761|NCT03231436|DRUG|Fixed dose of 12.5mg bupivacaine|Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
214413762|NCT03231436|DRUG|Height-adjusted dose of bupivacaine|Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
214413763|NCT06309342|OTHER|PREVFUNKTION|Functional profile and advice concerning cardiovascular fitness level, strength, mobility, balance and posture. Motivational interview and support in goalsetting to make lifestyle changes.
214413764|NCT06309342|OTHER|Control|Physical activity measured with accelerometers. Functional examination. Medical examination and advice concerning weight measures, blood pressure and standard blood tests.
214413765|NCT06613945|PROCEDURE|ERCP biliary drainage|bilateral metallic stents insertion will be attempted through ERCP to secure biliary drainage
214413766|NCT06613945|PROCEDURE|Combined ERCP and EUS-HGS biliary drainage|unilateral metallic stent will be inserted on right side by ERCP and a hepaticogastrostomy transmural stent will be inserted on left side by EUS to secure biliary drainage.
214413767|NCT01960803|RADIATION|Intraoperative Electron Radiotherapy|Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
214413768|NCT05846165|DEVICE|Field-Cycling Imaging (FCI)|FCI scan
214413769|NCT05948098|BEHAVIORAL|Facilitated Tucking Position|a sub-form of method of nesting the baby and the procedure of bringing the body to middle or even close position by holding the upper and lower extremities of the baby in flexion with hands
214413770|NCT05948098|BEHAVIORAL|Gentle Human Touch|It is a form of healing touch
214413771|NCT06696378|DIETARY_SUPPLEMENT|Melatonin 6 mg|wo capsules per day; Each capsule includes 3mg Melatonin Nutrifoods® Laboratories, Barcelona, Spain) by the Magistral Formulation Laboratory of a Pharmacy (Soria, Spain), following the rules of the Royal Spanish Pharmacopoeia (Ministry of Health, Government of Spain). Melatonin has a technical data sheet that guarantees its composition and purity (Reference No.: DIE-134).
214688992|NCT04590937|DRUG|BI 730357|Film-coated tablet
214688993|NCT04590937|DRUG|CRESTOR®|Film-coated tablet
214688994|NCT04590937|DRUG|Lenoxin®|Tablet
214688995|NCT04590937|DRUG|MetfoLiquid GeriaSan®|Oral solution
214688996|NCT04590937|DRUG|Lasix®|Oral solution
214688997|NCT02316093|OTHER|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
214688998|NCT04742153|DRUG|MRG002|Administrated intravenously
214688999|NCT01635933|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
214413772|NCT06696378|OTHER|Placebo|Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Melatonin tablets to ensure blinding.
214413773|NCT06711120|PROCEDURE|Radiofrequency ablation and microwave ablation are used to treat small saphenous varicose veins, respectively|During the procedure, 2% lidocaine was injected subcutaneously along the course of the saphenous vein under ultrasound guidance, and after local anaesthesia, an incision was made at the ankle joint of the saphenous vein to locate the saphenous vein, and a radiofrequency guidewire and catheter sheath were introduced.The saphenous vein was incised at the ankle joint under local anaesthesia. Under ultrasound monitoring, the radiofrequency catheter was placed in the saphenous popliteal vein at a distance of 1\~2 cm and the position of the catheter was fixed, and then anaesthesia and swelling fluid was injected into the fascial tissues around the main trunk of the small saphenous vein in segments.The two groups were treated with radiofrequency ablation and microwave ablation surgery, respectively.
214413774|NCT06714097|DEVICE|AI|STRATIF-AI apps will be used as an integral part of the dialogue with patients during thesecondary prevention phase
214413775|NCT06714097|OTHER|healthy dialogue|Patients allocated to arm 2 will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA
215016881|NCT04771871|DRUG|Paclitaxel|Paclitaxel is a taxane chemotherapy agent indicated for the treatment of many cancers including breast cancer. It can be used alone or in combination with other drugs
214413776|NCT06712953|OTHER|the peer assessment group|Students in the peer assessment group were paired (by randomization, on their request) to have a teammate of the same sex before the extremity examination experience. In the following process, the students were asked to perform extremity examinations in line with the specified objectives. Students in the standardized patient group were asked to perform extremity examinations per the specified objectives in standardized patient.
214413777|NCT06714266|DRUG|Trilaciclib|"Trilaciclib 240mg/m2, intravenous infusion for 30 minutes, completed within 4 hours before daily chemotherapy; Chemotherapy regimen: FP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; 5-FU 1000 mg/m2, intravenous infusion, D1-4; Q3W); TP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; Docetaxel 75mg/m2 or albumin paclitaxel 200mg, IV infusion, D1, 8; Q3W). The specific dose can be adjusted according to the situation.~Immunotherapy: Pembrolizumab 200mg q2w Targeted therapy: cetuximab (400mg/m2 qw 250mg/m2 qw) Some patients can be treated with maintenance therapy, and the treatment regimen is immunotherapy or targeted therapy combined with Trilaciclib"
214413778|NCT06711029|OTHER|Conventional needle irrigation|Conventional needle irrigation method was applied. As a final irrigation, 6 ml NaOCl was applied with 60 seconds of needle irrigation followed by 60 seconds of rest.
215016882|NCT04771871|DRUG|Carboplatin|Carboplatin is a platinum compound indicated for the treatment of many types of malignancies including breast cancer
215016883|NCT03883451|OTHER|Helmet Model|helmet model worn by football players
214413779|NCT06711029|OTHER|Passive Ultrasonic Irrigation with 3*20 sn|In the final irrigation, 6 ml (3×2 ml) NaOCl was activated by PUI for 20 seconds in 3 cycles (60 seconds total). Before each cycle, 2 ml of NaOCl solution was refreshment.
215101705|NCT06510010|DRUG|Oxaliplatin With S-1 (SOX) Combined H. Pylori Eradication (Amoxicillin + clarithromycin + omeprazole + colloidal bismuth subcitrate)|"Oxaliplatin With S-1 (SOX) regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle.~H. pylori eradication regimen:~H. pylori eradication was performed using a quadruple regimen for 14 d. Omeprazole 20 mg bid+Colloidal bismuth subcitrate 220mg bid+Amoxicillin 1g bid+Clarithromycin 500mg bid."
214413780|NCT06711029|OTHER|Passive Ultrasonic Irrigation with 6*10 sn|For the final irrigation, 6 ml (6×1 ml) NaOCl was activated with PUI for 10 seconds in 6 cycles (60 seconds total). Before each cycle, 1 ml of NaOCl solution was refreshment.
214413781|NCT02494830|DRUG|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
214413782|NCT06421597|DRUG|Prednisolone|prednisoline 25 mg/day for seven days
214413783|NCT06421597|DRUG|Placebo|Placebo treatment for seven days
214413784|NCT01838200|BIOLOGICAL|Bacillus Calmette-Guérin (BCG) vaccine|BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.
214413785|NCT01838200|DRUG|Ipilimumab|Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
214413786|NCT01838200|DRUG|Isoniazid|Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
214413787|NCT06353243|BEHAVIORAL|Bilateral alternating stimulation|positive touch intervention provided by parent to infant using alternating stimulation
214413788|NCT00557804|DEVICE|MUSE clinical system|non-invasive external monitoring device
215016884|NCT06380530|PROCEDURE|Deformity correction|Surgeries to correct bone defomity, supported by the use of preoperative planning and/or patient-specific instruments
215016885|NCT05639803|DRUG|PEGIFNα1b|100μg/vial
215016886|NCT05639803|DRUG|Placebo|0.5ml/vial
215016887|NCT06031051|DEVICE|Pillcam Crohn's Capsule Endoscopy|Patients with scheduled colonoscopy are invited to a previous exploration with capsule endoscopy
215016888|NCT05093166|DRUG|"Ex vivo expanded autologous human oral epithelium containing stem cells"|The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
215101706|NCT06510010|DRUG|Oxaliplatin With S-1 （SOX）|"Oxaliplatin With S-1 （SOX） regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle."
215101707|NCT02450162|PROCEDURE|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
215101708|NCT00337090|DRUG|YM178|
214413789|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Active|A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
214413790|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Sham|The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.
214413791|NCT03947086|BEHAVIORAL|Cognitive Training|"Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, \& Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao \& Maurer, 2009; Dillon, Kannan, Dean, Spelke, \& Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved."
214413792|NCT02707224|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
214413793|NCT02707224|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
214413794|NCT02707224|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
214413795|NCT00686023|PROCEDURE|internal fixation (DHS - richard nail)|internal fixation
214413796|NCT00686023|PROCEDURE|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
214413797|NCT00676533|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
214689000|NCT01635933|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
214689001|NCT05283083|DRUG|Dexmedetomidine|A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.
215016889|NCT05373836|DIAGNOSTIC_TEST|prognostic nutritional index calculated from laboratory parameters|Calculated nutritional index using laboratory results of serum albumin, lymphocyte count, and cholesterol
215016890|NCT05477641|PROCEDURE|Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block|Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
215016891|NCT05477641|PROCEDURE|Fascia Iliaca Compartment Block|Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
215016892|NCT04991597|OTHER|Cold Compress Pack|Palmar aspect of forearm will have a cold compress pack placed on it.
215016893|NCT04991597|OTHER|Room Temperature Compress Pack|Palmar aspect of forearm will have a room temperature compress pack placed on it.
215016894|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
215016895|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
215016896|NCT03288935|BEHAVIORAL|TICM|The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R\&P service period (i.e., 60 days).
215016897|NCT03288935|BEHAVIORAL|TICO|The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation \& resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
215016898|NCT03062436|OTHER|Stopping the standard drug therpy|Stopping the standard drug therapy of CML patients and monitoring their treatment free remission status
215016899|NCT03062436|DIAGNOSTIC_TEST|Quantitative bcrabl recording every month for first 6 months|Monthly recording of quantitative bcrabl by RQPCR on patients peripheral blood derived RNA. RQPCR will have minimum sensitivity of log4.5
215016900|NCT06399471|DEVICE|Microprocessor prosthetic knee|Microprocessor prosthetic knees for use in a transfemoral prosthesis
215016901|NCT05347797|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
215016902|NCT05738291|DRUG|BI 1839100|BI 1839100
214413798|NCT05198089|OTHER|Internet-Based Intervention|Use MyInspiration website
214413799|NCT05096806|OTHER|Acupuncture|Acupuncture is a non-pharmacological technique that consists in the stimulation of specific points located in the skin surface. Points are stimulated by piercing the skin with fine needles.
214689002|NCT03272477|DRUG|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
214689003|NCT03272477|DRUG|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
214689004|NCT03272477|DRUG|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
214689005|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
215016903|NCT05738291|DRUG|Placebo matching BI 1839100|Placebo matching BI 1839100
215016904|NCT05738291|DRUG|midazolam|midazolam
215016905|NCT05738291|DRUG|digoxin|digoxin
215016906|NCT05738291|DRUG|rosuvastatin|rosuvastatin
215016907|NCT05860296|DRUG|SLC-391|SLC-391 is an AXL inhibitor
215016908|NCT05860296|BIOLOGICAL|pembrolizumab|Immunotherapy
214413800|NCT05096806|DEVICE|TENS|TENS is a therapy that uses low voltage electrical current to provide pain relief. A TENS unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. The electrodes are placed at or near nerves where the pain is located or at trigger points.
214413801|NCT00639366|BIOLOGICAL|trastuzumab|
214413802|NCT00639366|DRUG|chemotherapy|
214413803|NCT00639366|RADIATION|radiation therapy|
214413804|NCT01367561|DRUG|Naloxone|
214413805|NCT01367561|DRUG|IV Methylnaltrexone (MNTX)|
214413806|NCT01367561|DRUG|Placebo|
214413807|NCT02165605|DRUG|HylaCare|cream
214413808|NCT02165605|DRUG|Placebo|placebo
214413809|NCT01549379|RADIATION|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
214413810|NCT02089243|PROCEDURE|Vagus nerve stimulation therapy|The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
214413811|NCT02089243|PROCEDURE|Resective surgery|The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
214413812|NCT02072005|OTHER|mSMART smartphone application|This application is an interface that provides subjects with information and questionnaires related to their medication.
214413813|NCT01879904|PROCEDURE|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
214413814|NCT03556605|OTHER|OneTouch Reveal® Mobile APP system|Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).
214413815|NCT03556605|OTHER|Current Blood Glucose Monitor|Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.
214413816|NCT00192153|BIOLOGICAL|CAIV-T or TIV|
214413817|NCT00762463|DRUG|Celecoxib|capsule, 200 mg QD, 6-12 weeks
214413818|NCT00762463|DRUG|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
214413819|NCT00271765|DRUG|INO-1001|
215016909|NCT05792462|DRUG|Baricitinib|Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
214413820|NCT03758339|DRUG|tucatinib|Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity
214413821|NCT04413565|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeon bilateral TKA group
214413822|NCT04413565|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
214413823|NCT00876044|DRUG|aflibercept (AVE0005)|Intravenous route
214413824|NCT00876044|DRUG|placebo|Intravenous route
214413825|NCT06232226|OTHER|Patients suffering from the co-occurrence of ADHD and addiction(s)|All eligible patients over 15 years and 3 months (age limit between child psychiatry and adult psychiatry), presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)
214413826|NCT01306331|DRUG|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
214413827|NCT01306331|DRUG|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
214413828|NCT06165926|DRUG|15% hypertonic dextrose|"The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed."
214413829|NCT06165926|DRUG|Normal saline|The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.
214413830|NCT06165926|OTHER|physical therapy|Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.
214413831|NCT02772614|DRUG|BIA 3-202 (200 mg)|200 mg powder for oral use of unlabelled BIA 3-202
214413832|NCT03766438|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
214413833|NCT05821322|OTHER|Physical activity trial intervention|60 minutes aerobic ergocyle exercice at 60% VO2 Peak
214413834|NCT00535067|BEHAVIORAL|Questionnaire|Questionnaires taking 60 minutes total to complete.
214413835|NCT01064843|DEVICE|Imtec MDI|4 Imtec MDI
214413836|NCT01703923|DRUG|FP01|
214413837|NCT01703923|DRUG|placebo|
214413838|NCT01101685|DRUG|Escitalopram|7 days dosing of 10mg per day
214413839|NCT01101685|DRUG|Placebo|7 days dosing at 10mg daily
214413840|NCT00172185|DRUG|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
214413841|NCT00172185|DRUG|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
214413842|NCT04048135|DRUG|Pegozafermin|Subcutaneous injection
214413843|NCT04048135|OTHER|Placebo|Subcutaneous injection
214413844|NCT06364839|OTHER||
214413845|NCT03811587|OTHER|Fasting Mimicking diet|The fasting mimicking diet is though to activate the metabolism as fasting would do, although the diet does include several meals a day and more calories than conventional fasting diets.
214413846|NCT01677936|OTHER|Raisins|1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
214413847|NCT01677936|OTHER|Snacks|100 calorie snack packs will be administered to the subjects in the snack group
214689006|NCT03272477|DRUG|Epirubicin|12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
214689007|NCT03272477|DRUG|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
214689008|NCT03272477|DRUG|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
214689009|NCT03272477|DRUG|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
215016910|NCT06007248|DIAGNOSTIC_TEST|Protocol-defined Examinations|Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, Birmingham Vasculitis Activity Score (BVAS-3), 6-minute walk test, 1-minute squat test, vascular ultrasound, fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT), coronary angiography, optical coherence tomography (OCT), tests for exploratory biomarkers.
215016911|NCT05965466|PROCEDURE|Distal gastrectomy and radical resection|Distal gastrectomy and Roux-en-Y anastomosis
215016912|NCT05965466|PROCEDURE|Total gastrectomy and radical resection|Total gastrectomy and Roux-en-Y anastomosis
214413848|NCT02633423|PROCEDURE|Use of PEEP before and after CPB|PEEP will be set in order to reach an airway pressure of 5 cmH2O
215016913|NCT06707038|BEHAVIORAL|AATAP intervention|AATAP is a program created to address the barriers that Black patients face when accessing transplantation. AATAP providers resources in cultural congruency, trust, psychosocial support, and health literacy to provide patients with the individualized support needed to access the kidney transplant waitlist
215016914|NCT03371225|DEVICE|Active tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. 20 minutes of tDCS will be applied.
215016915|NCT03371225|PROCEDURE|Active Exercise|Participants will walk briskly in a treadmill (as to keep at 60-70% maximum heart rate) for 30 minutes
215016916|NCT03371225|DEVICE|Sham tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. Only 30 seconds of current will be applied for the sham condition.
214413849|NCT02633423|PROCEDURE|No use of PEEP before and after CPB(ZEEP)|No PEEP will be used
214413850|NCT02633423|PROCEDURE|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB
214413851|NCT02633423|PROCEDURE|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
214413852|NCT00394407|DRUG|sliding scale regular insulin|SSRI acqhs
214413853|NCT00394407|DRUG|glargine basal insulin and glulisine prandial insulin|glargine insulin once a day and glulisine insulin three times a day as long as patient eating
214413854|NCT03879967|DEVICE|Allograft block graft|The graft used is a mineralized, cortico-cancellous, delipidized, lyophilized allogenic block.
214413855|NCT02059044|OTHER|ISTOP-ADE|Interactive Voice Response System + Pharmacist
214413856|NCT00982098|PROCEDURE|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
214413857|NCT06630975|DEVICE|Hemiepiphysiodesis|8 plate
214413858|NCT06630975|PROCEDURE|Eight-Plates first described by Stevens are simple to use|fewer complications in terms of implant loosening and fracture can be expected.Good results as well as low rebound and complication rates have been recorded
214413859|NCT06630975|DEVICE|Hemiepiphysiodesis by eight Plate|Extraperiosteal eight plate insertion
214413860|NCT04358549|DRUG|Favipiravir|Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets
214413861|NCT04358549|OTHER|Standard of Care|Standard of Care for individual study site as determined by each hospital's protocol
214413862|NCT04275817|OTHER|Data collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
214413863|NCT03895034|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
214689010|NCT03272477|DRUG|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
214689011|NCT03272477|DRUG|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
214689012|NCT03272477|DRUG|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
214689013|NCT03272477|DRUG|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
214689014|NCT03272477|DRUG|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
214689015|NCT03272477|DRUG|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
215016917|NCT03371225|PROCEDURE|Sham Exercise|Participants will walk in a treadmill (as to keep at 10% within their baseline heart rate) for 30 minutes.
214413864|NCT05661162|DEVICE|CR 500™ SINGLE-DOSE GEL|CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
214413865|NCT05206890|DRUG|fluzoparib monotherapy or combination therapy|patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
214413866|NCT03479034|OTHER|ScalaMed ePrescription application|Mobile phone application (Android and Apple) for storing electronic prescriptions
214413867|NCT01926002|DRUG|Low-Dose MK-8351|Single administration of low-dose MK-8351.
214413868|NCT01926002|DRUG|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
214413869|NCT01926002|DRUG|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
214413870|NCT03264742|OTHER|Ghrelin|The patients are assigned within the scope of the admission according to emergency to the treatment and clarification on the Stroke Unit of the KSW. There the patients are enclosed in the study and are examined according to the draught on the Stroke Unit within the scope of the complex treatment. The inclusion of the patients occurs after clarification and in the consent of the patients. In the morning after the admission day the decrease of the first blood test occurs within the scope of the blood sample as a matter of routine to be carried out for the Ghrelinbestimmung. Also 48 H occurs after the first withdrawal and 3 months after the stroke a blood sample to the regulation of Ghrelin.
214413871|NCT03923946|BEHAVIORAL|Compassion focused therapy|Compassionate Imagery intervention based on compassionate imagery exercises in The Compassionate Mind Workbook by Irons and Beaumont, 2017
214413872|NCT01118377|DRUG|Capecitabine|Capecitabine was supplied as film-coated tablets.
214413873|NCT01118377|RADIATION|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
214689016|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
215016918|NCT05222581|DEVICE|Prototypes of breast shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump.
215016919|NCT06325852|OTHER|DBS programing|The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.
215016920|NCT06800183|DRUG|Four-Chamber Tartrazine Patch across 3 Body Sites|This is a chamber patch comprising four increasing doses of tartrazine (0.15M, 0.3M, 0.6M, 1.2M). This will be applied on the forearm, abdomen, and back to represent different skin thicknesses.
214413874|NCT03297346|OTHER|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
214413875|NCT02085356|BEHAVIORAL|Protect your family|"Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)"
214413876|NCT06221618|OTHER|High-frequency carotid arteries ultrasound, CCTA, Cranial MRA|CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines
214413877|NCT03244696|BEHAVIORAL|Step Tracking|The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
214413878|NCT03244696|BEHAVIORAL|Water Tracking|The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
214689017|NCT03272477|DRUG|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
214689018|NCT03272477|DRUG|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
214689019|NCT03272477|DRUG|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
215016921|NCT06378190|BIOLOGICAL|CAR-T cells therapy|CAR-T cells therapy
215016922|NCT05828901|OTHER|S1PR analysis on immune cells|S1P receptor 1 and 5 expression will be measured on immune cells
215016923|NCT06162312|OTHER|Antenatal perineal massage|Participants at 34-35 weeks of gestation were received training in self-perineal massage and performed a daily 5-minute massage using water-based jelly until delivery to compare with standard obstetric care on postpartum morbidities
215016924|NCT04034056|DRUG|Obinutuzumab|Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
215016925|NCT04967274|PROCEDURE|Startling acoustic stimulus|StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.
214413879|NCT01510912|DRUG|Diclofenac|35 mg bid or tid Capsules
214413880|NCT05714735|RADIATION|Cerebral Venography|Cerebral Venography Observation by DSA examinations
214413881|NCT00157014|DRUG|Tacrolimus|Oral
214413882|NCT00157014|DRUG|Cyclosporine|Oral
214413883|NCT00157014|DRUG|Mycophenolate mofetil|Intravenous and Oral
214413884|NCT00157014|DRUG|Methylprednisolone|Intravenous
214413885|NCT00157014|DRUG|Prednisone|Oral
214413886|NCT02318381|PROCEDURE|Dissection of the superior transverse scapular ligament|After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
214413887|NCT05904535|OTHER|Cerbrospinal fluid sampling.|Routine sampling of cerebrospinal fluid from the proximal external ventricular drain port.
214413888|NCT05216692|PROCEDURE|La Tour Hospital Foot Strengthening Protocol|"First exercise : NMES forward lean doming. Doming exercise assisted by NMES placed on the IFM. 8 sec of contraction (6 sec rest) moving the trunk forward. 12 repetitions, 3 sets. Progressive increase of the intensity of NEMS during 4 weeks and increase of body load while decreasing the number of repetitions.~Second exercise : MTP joint flexion. Isometric MTP joint flexion contractions. 4 contractions of 5 sec (10 sec rest), 3 sets. Progressive increase of the number of MVIC during 4 weeks and of increase body load while keeping the same intensity.~Third exercise : Foot-ankle rebound. Multiple jumps with only plantar flexion. Keeping the knee stiff and straight and pushing off the ground with only ankle and MTP plantar flexion by a forefoot contact with the ground. 10 seconds of jump (1 min of rest) during 5 sets. Progressive increase of body load while keeping the same intensity."
214413889|NCT05216692|PROCEDURE|Standard Literature Foot Strengthening Protocol|"During the 1st week, the participants will perform the Short foot exercise (SFE) during 3 series of 10 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 2nd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 3rd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing bipedal position. 1 minute of rest will be give between series.~During the 4th week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing unipedal position. 1 minute of rest will be give between series.~The progression of the exercise during the protocol will be based on passing from a sitting position to a unipedal standing position."
214413890|NCT03181958|DEVICE|NHFOV|Nasal high frequency oscillation ventilation (NHFOV) is used as the noninvasive supporting mode after extubation.
214413891|NCT03181958|DEVICE|NCPAP|Nasal continuous positive airway pressure(NCPAP) is used as the noninvasive supporting mode after extubation.
214413892|NCT03181958|DEVICE|NIPPV|Nasal intermittent positive pressure ventilation(NIPPV) is used as the noninvasive supporting mode after extubation.
214413893|NCT02502396|OTHER|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
214413894|NCT05003570|DRUG|Remifentanil|Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
214413895|NCT05003570|DRUG|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
214413896|NCT04710017|DRUG|Tranexamic acid|will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
214413897|NCT04710017|DRUG|Medroxyprogesterone Acetate 150 MG/ML|will be given MPA at 150 mg once intramuscular injection
214413898|NCT04143919|DIAGNOSTIC_TEST|NYHA assessment|The New York Heart Association (NYHA) functional classification of HF
215016926|NCT06431646|BEHAVIORAL|A web-based education intervention developed for university students with PMS|The web-based education program includes the definition, prevalence, importance, causes, symptoms, diagnosis, risk factors, management strategies and treatment options of PMS. The education emphasizes non-pharmacological strategies for managing PMS, including diet, exercise and body mass index (BMI), sleep hygiene, smoking cessation, stress management, as well as vitamin and mineral supplements, herbal therapy, acupuncture, acupressure and reflexology.
215016927|NCT04344860|DRUG|Recombinant Von Willebrand factor|Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
215016928|NCT04344860|DRUG|Tranexamic Acid Injection [Cyklokapron]|Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
215016929|NCT06246721|BEHAVIORAL|Self-management of vaginal pessary|Self-management of vaginal pessary
215016930|NCT06077747|PROCEDURE|Coil Embolization of the Lumbar Vein|Catheter based venography will first confirm Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus congestion. The lumbar vein will then be coil embolized.
215016931|NCT03270163|DIAGNOSTIC_TEST|Transcutaneous electrical stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple electrical stimulations,~* three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
214413899|NCT04143919|PROCEDURE|Serum NT-proBNP concentration|Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
214413900|NCT04143919|DIAGNOSTIC_TEST|Transthoracic Ecocardiogram|Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
214413901|NCT00005113|DRUG|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
214413902|NCT00005113|DRUG|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
214413903|NCT00005113|DRUG|Tacrolimus|dosage is in oral form titrated to target trough level
214689020|NCT03272477|DIAGNOSTIC_TEST|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
214689021|NCT03272477|PROCEDURE|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
214413904|NCT02313090|OTHER|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
215016932|NCT03270163|DIAGNOSTIC_TEST|Magnetic stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple magnetic stimulations,~* three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
214689022|NCT02818153|OTHER|Self questionnaire for allergic rhinitis control|
215016933|NCT03270163|DIAGNOSTIC_TEST|ultrasound measurement|The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
215016934|NCT06009978|DEVICE|Neuromuscular electrical stimulation (NMES)|Neuromuscular electrical stimulation (NMES) 2 times a day á 15 minutes from the third to the eight week after injury. The additional treatment will be perform in the patients home by themselves
215016935|NCT04598919|DRUG|Saracatinab|125 mg once daily by mouth for 24 weeks
215016936|NCT04598919|DRUG|Placebo|once daily by mouth for 24 weeks
214689023|NCT00573326|DRUG|Imatinib|200 mg p.o. once a day for 6 months
215016937|NCT06641440|DRUG|Prednisone|patients will be treated for three months in the two groups with the two different protocols for three months both
215016938|NCT06640452|OTHER|RecoveryFun system|The system components were: VR headset; wereable biosensors, clinical platform, caregiver app and smart services.
215016939|NCT06637475|DEVICE|Electric stimulation|"Patients with baseline assessments will be followed up for 8 weeks within a planned treatment program. Treatment protocol for the ES group:~external ES wearable apparatus will be applied three days a week for 30 minutes with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 s contraction and 5 s rest, with a current intensity ranging from 0-100 mA while the patients are in the supine position. The device will be attached to the patients in such a way that it wraps around the upper thigh, the electrodes will be attached to the anterior and posterior of the right and left thigh, the right-left pelvic side and the right-left gluteal region. The current intensity in each session will be determined as the maximum current intensity that will not cause pain and discomfort in individuals."
214413905|NCT01091233|PROCEDURE|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
215016940|NCT06639113|BEHAVIORAL|Self-administration medicines|Management of drugs' administration by the patient
215016941|NCT06643910|BIOLOGICAL|Single drug group A|9x10\^10 BST08 cells, Intravenous infusion，3 subject is planned to be enrolled
215016942|NCT06643910|BIOLOGICAL|Combined treatment group B|9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled
214413906|NCT03696771|DRUG|NJH395|Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
214413907|NCT02315391|DIETARY_SUPPLEMENT|isolated whey protein|isolated whey protein
215016943|NCT06644976|PROCEDURE|femoral neck CRIF|femoral neck fracture CRiF while under noac. no special intervention beside taking blood test for drug levels
215016944|NCT06354764|OTHER|no intervention|no intervention
214413908|NCT02315391|DIETARY_SUPPLEMENT|micellar whey protein|micellar whey protein
214413909|NCT02315391|DIETARY_SUPPLEMENT|glycine|glycine
214413910|NCT02315391|DIETARY_SUPPLEMENT|citrulline|citrulline
214689024|NCT04525222|OTHER|Health Promotion and Education|Receive motivational messages and smoking cessation information via text notifications
214689025|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Actify app)|Use Actify app
214689026|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Current Standard Care app)|Use (USCPG) Current Standard Care app
214689027|NCT04525222|OTHER|Survey Administration|Ancillary studies
214689028|NCT06427681|DRUG|BH006 for injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
214689029|NCT06427681|DRUG|Fosaprepitant for injection+Palonosetron hydrochloride injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
214689030|NCT04340830|PROCEDURE|Free gingival graft|Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
215016945|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.1 Usage|Participants will use their Radicle Relief Active Study Product 1.1 as directed for a period of 6 weeks.
215016946|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.2 Usage|Participants will use their Radicle Relief Active Study Product 1.2 as directed for a period of 6 weeks.
215016947|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
214413911|NCT05823350|OTHER|Abdominal massage|Abdominal massage after colonoscopy
214413912|NCT01257503|DRUG|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
214413913|NCT01257503|DRUG|placebo|liquid made to look like the active homeopathic remedy
214413914|NCT01805414|OTHER|Modified Carbohydrate Breakfast|
214689031|NCT03873129|BEHAVIORAL|mobile health app (mHealth)|A-CHESS is a mobile health app for participants to interact with their treatment team for 12 months.
214689032|NCT00282165|DRUG|naratriptan|four weeks double blind experimental treatment using oral naratriptan
214689033|NCT00282165|DRUG|placebo|four weeks double blind placebo treatment
214689034|NCT00409630|DRUG|fluticasone|
215016948|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 2.1 Usage|Participants will use their Radicle Relief Active Study Product 2.1 as directed for a period of 6 weeks.
215016949|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
215016950|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
215016951|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.1 Usage|Participants will use their Radicle Relief Active Study Product 3.1 as directed for a period of 6 weeks.
215016952|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.2 Usage|Participants will use their Radicle Relief Active Study Product 3.2 as directed for a period of 6 weeks.
215016953|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.3 Usage|Participants will use their Radicle Relief Active Study Product 3.3 as directed for a period of 6 weeks.
215016954|NCT04401475|BIOLOGICAL|SOC plus 15mg/kg EB05 IV|Standard of care plus single IV infusion of 15mg/kg of EB05.
215016955|NCT04401475|OTHER|SOC plus Placebo IV|Standard of care plus a single IV infusion of placebo.
215016956|NCT02213536|RADIATION|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
215016957|NCT02657941|BEHAVIORAL|Motivational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines"
215016958|NCT02657941|BEHAVIORAL|educational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions"
215016959|NCT03390673|DRUG|HD204|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
215016960|NCT03390673|DRUG|Avastin|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
215016961|NCT03225989|DRUG|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
215016962|NCT05144997|DRUG|Lorlatinib|ALK-positive NSCL treatment
214413915|NCT01805414|OTHER|Control Breakfast|
215016963|NCT00358280|DRUG|Ropivacaine|
215016964|NCT00358280|DRUG|Bupivacaine|
215016965|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
215016966|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
215016967|NCT06289881|DRUG|Sildenafill-Test product|Test-Product: Sildenafil 100 mg tablets Manufactured by: Actigen Co., Ltd., Thailand
215016968|NCT06289881|DRUG|Sildenafill-Reference product|Reference-product: Viagra 100 mg tablets Manufactured by: FAREVA AMBOISE, France
215016969|NCT00601107|DRUG|Doxercalciferol|
214689035|NCT02985125|DRUG|LEE011|Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
214689036|NCT02985125|DRUG|Everolimus|Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
214694017|NCT04427761|BEHAVIORAL|Measurement of Transitions in Cancer Scale (MOT-CA) Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit) The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
215016970|NCT00601107|DRUG|Placebo|
214413916|NCT00219687|OTHER|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
214413917|NCT00219687|OTHER|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
214413918|NCT05942768|DRUG|regorafenib plus anti-PD-1 antibodies|The patients were treated orally with regorafenib (80 mg once daily for 21 days on/7 days off, over a 28-day cycle), combined with 1 of the 5 anti-PD-1 antibodies (i.e., nivolumab, pembrolizumab, camrelizumab, sintilimab, or toripalimab). The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks
214413919|NCT04296513|DIAGNOSTIC_TEST|High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by
214413920|NCT04296513|DIAGNOSTIC_TEST|High-definition magnification with digital chromoendoscopy.|Subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
214413921|NCT01343290|DRUG|Canagliflozin|Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
214413922|NCT01384240|DRUG|Proflavine Hemisulfate|3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
214413923|NCT04867902|BEHAVIORAL|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
214413924|NCT02787161|DEVICE|Hemodiafiltration|High volume online HDF
214413925|NCT02787161|DEVICE|Hemodialysis|High-flux HD
214413926|NCT00568659|PROCEDURE|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
214413927|NCT05051449|DRUG|Ketamine Hydrochloride|Ketamine will be administered by a nurse in a 2-week treatment phase, during which participants will receive six IV infusions of 0.5 mg/kg (over 40-50 minutes) ketamine three times per week. Infusion days for patients will be on Mondays, Wednesdays, and Fridays, +/- 1 day. Ketamine infusions will take place at the UMB General Clinical Research Center (GCRC). The GCRC nurse will deliver ketamine within a private exam room. The infusions will last 40-50 min, and the participant will be observed by the GCRC clinical staff for 2 hours post-infusion. Vital signs will be monitored throughout the treatment; specifically, blood pressure, pulse ox and heart rate will be checked prior to treatment, q20 minutes during infusion, and q30-60 minutes after infusion for up to three hours.
214413928|NCT05355116|DEVICE|Physiolab S1|A cryocompression device capable of circulating ice-water through a cuff at 6-12℃ with either a static pressure of 25mmHg or dynamic pressure of 25-50 mmHg or 25-75mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
214413929|NCT05355116|DEVICE|Breg Vpulse|A cryocompression device capable of circulating ice-water through a cuff at no lower than 5.5℃ with a dynamic peak pressure of 50 mmHg. The temperature of the ice-water, and the applied pressure, is not modifiable by the user.
214694018|NCT04427761|BEHAVIORAL|Distress Thermometer Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit).The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
214694019|NCT03346369|DRUG|Lanthanum Carbonate|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
214413930|NCT05355116|DEVICE|Aircast Cryo/Cuff|A cryocompression device capable of circulating ice-water through a cuff at an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
214413931|NCT05355116|DEVICE|GameReady|A cryocompression device capable of circulating ice-water through a cuff at 1-12℃ with a dynamic pressure of 5-15 mmHg, 5-50 mmHg, or 5-75 mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
214413932|NCT05355116|DEVICE|Physiolab Gel Therapy Wrap|A cryocompression cuff that applies an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
214413933|NCT06221332|OTHER|% 0.25 bupivakain 20cc|Pregnant women in group S will be given 0.25% bupivacaine, 10 cc on each side.
214413934|NCT06221332|OTHER|20 cc saline|Pregnant women in Group K will be given 10 cc of saline on both sides.
215016971|NCT00384150|DRUG|galiximab in combination with rituximab|galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
215016972|NCT05349773|PROCEDURE|Pneumatic tourniquet, endoscopic left radial artery harvesting|"Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes."
214413935|NCT02931656|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
214413936|NCT00501241|DRUG|ATI-7505|Tablet,placebo, BID
214413937|NCT00501241|DRUG|ATI-7505|ATI-7505 20 mg BID for 4 weeks
214413938|NCT00501241|DRUG|ATI-7505|tablet, 40 mg, BID, $ weeks
214413939|NCT00501241|DRUG|ATI-7505|80 mg ATI-7505, BID for 4 weeks
214413940|NCT00501241|DRUG|ATI-7505|120 mg ATI-7505, BID, for 4 weeks
214413941|NCT04417270|DEVICE|Freestyle Libre 14 day CGM system|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
214413942|NCT04417270|DEVICE|Accuchek Inform II platform|The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
214413943|NCT02380742|DRUG|lidocaine-prilocaine cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
214689037|NCT04122768|BEHAVIORAL|Multi-component physical activity tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
215016973|NCT03791697|OTHER|Telehealth 2 week postoperative visit|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes. (Intent to treat)"
215016974|NCT03004495|DRUG|CHF5259 and CHF6001|b.i.d. for 14 days
214413944|NCT02380742|DRUG|Placebo cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
214413945|NCT03646370|DRUG|Tenofovir Alafenamide|Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
214413946|NCT00151996|DRUG|Methylphenidate + SPD503 (Guanfacine hydrochloride)|
214413947|NCT00151996|DRUG|Amphetamine + SPD503|
215016975|NCT03004495|DRUG|CHF5259 + placebo|b.i.d. for 14 days
215016976|NCT03004495|DRUG|CHF6001 + placebo|b.i.d. for 14 days
215016977|NCT03004495|OTHER|Placebo|b.i.d. for 14 days
215016978|NCT02430610|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
215016979|NCT02430610|DEVICE|NanoKnife|
215016980|NCT00874016|DEVICE|Airtraq|Intubation using Airtraq
215016981|NCT00874016|DEVICE|Direct Laryngoscopy|Intubation using direct laryngoscopy
215016982|NCT00285714|PROCEDURE|3D stereophotogrammetric imaging|
215016983|NCT00285714|PROCEDURE|3D CT-imaging with cone-beam CT|
215016984|NCT00285714|PROCEDURE|Case report form|
215016985|NCT03902210|BEHAVIORAL|Online Yoga|60 minutes per week of online yoga through Udaya.com
215016986|NCT03902210|BEHAVIORAL|Podcast|60 minutes per week of podcasts
215016987|NCT05052307|DRUG|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
215016988|NCT05052307|DRUG|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
215016989|NCT05052307|DRUG|ChAdOx1 nCoV-19 Covid-19 Vaccine|ChAdOx1 nCoV-19 Covid-19 Vaccine
215016990|NCT05052307|DRUG|Ad26.COV2.S COVID-19 Vaccine|Ad26.COV2.S COVID-19 Vaccine
215016991|NCT00445120|DRUG|Lactobacillus Rhamnosus GG|patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
215016992|NCT00445120|DRUG|placebo (sugar)|Placebo will be administered to patients once daily for six months
215016993|NCT00510471|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
215016994|NCT06131593|DRUG|TAPB with dexamethasone as an adjuvant to local anesthetics|patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics
214413948|NCT01544140|DRUG|Midazolam|Oral syrup 7.5 mg, single dose
214413949|NCT01544140|DRUG|vandetanib|Oral tablets, 800 mg, single dose
215016995|NCT06131593|DRUG|TAPB with methylprednisolone as an adjuvant to local anesthetics|patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
214413950|NCT01434303|DRUG|Entinostat|Given PO
214413951|NCT01434303|OTHER|Laboratory Biomarker Analysis|Correlative studies
214413952|NCT01434303|DRUG|Lapatinib Ditosylate|Given PO
214413953|NCT01434303|BIOLOGICAL|Trastuzumab|Given IV
214413954|NCT01188629|BEHAVIORAL|Safety Training|IT intervention focuses on safety in the home.
214413955|NCT01188629|BEHAVIORAL|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
214413956|NCT05140564|BEHAVIORAL|STEADY intervention|STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
214413957|NCT04069182|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.
214413958|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program|The internet-based parenting support program is based on social learning theory. A foundation is the Family Check-up program (FCU), which includes approaches from motivational interviewing (MI). The parenting support is also based on similar CBT-parenting strategies as in other evaluated face-to-face CBT-parenting support programs (e.g., Comet) as well as internet-based programs (e.g., iComet; ParentWeb).
214413959|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program with additional parental support|The internet-based parenting program includes the same contents and chat-function as in the other condition. The focus for the digital/phone meetings is to explore potential questions, problem-solve around potential challenges, and motivate parents to practice strategies and complete modules.
215016996|NCT03422471|OTHER|Hyperinsulinemic Hypoglycemic Clamp|Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
214413960|NCT04622826|BIOLOGICAL|immune plasma|immune covid 19 plasma infusion
214505114|NCT02232997|OTHER|Simplified Hydration|Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \<35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
214505115|NCT02823340|DEVICE|Fractional microneedle RF(United, Peninsula Medical, China)|
214505116|NCT01760005|DRUG|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
214505117|NCT01760005|DRUG|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
214505118|NCT01760005|DRUG|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
215016997|NCT03587103|BEHAVIORAL|Protocol initiate with A|The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
215101709|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using conventional plates|"le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion."
215016998|NCT03587103|BEHAVIORAL|Protocol initiate with C|The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
215016999|NCT03587103|BEHAVIORAL|Protocol initiate with D|The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
215017000|NCT01935154|DRUG|Vx-001|
215017001|NCT01935154|DRUG|Placebo|
214505119|NCT01760005|DRUG|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
215017002|NCT00655798|DIETARY_SUPPLEMENT|Placebo|plain yogurt and capsules containing cellulose
215017003|NCT00655798|DIETARY_SUPPLEMENT|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
215017004|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
215101710|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using patient specific plates|"The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws."
214413961|NCT04409210|BEHAVIORAL|Establishment of individual health records|Patients could upload self-test data (such as blood pressure, blood glucose, heart rate and weight) and medical institution examination data (such as blood lipids, ECG, echocardiography, etc.) through App. AND then the App can automatically generate health reports to reflect the dynamic changes of the data in the form of charts and whether the data is normal or not. It is convenient for patients to have a clear understanding of their health management, and if there are outliers, they can intervene in time.
214413962|NCT04409210|BEHAVIORAL|Cardiovascular risk assessment|The China-PAR risk prediction tool can be used to stratify the 10-years atherosclerotic cardiovascular disease (ASCVD) risk. Those with predicted risks of \<5%, 5-10%, and ≥10% could be classified into categories of low-, moderate-, and high-risk for ASCVD, respectively. It is a risk prediction tool for Chinese developed by the team of Professor Gu Dongfeng of Fuwai Hospital of the Chinese Academy of Medical Sciences. When patients are aware of their risk of cardio-cerebrovascular diseases, it is helpful for patients to take the initiative to manage their cardio-cerebrovascular health.
214413963|NCT04409210|BEHAVIORAL|Popularization of medical knowledge|Health education is divided into nine modules, such as introduction of cardio-cerebrovascular diseases, diet, exercise, sleep, psychology, medicine, cardiopulmonary resuscitation and cardiac self-rescue technology. The presentation of health education includes three modules: text, video and voice. Video and voice modules are more suitable for illiterates or people are inconvenient to read text. It mainly takes into account the fact that most of the high-risk population of cardio-cerebrovascular diseases are the elderly.
214413964|NCT04409210|BEHAVIORAL|Personalized Reminders|"1. Abnormal data reminder App can automatically judge whether the data is normal. If abnormal data is found, it will inform the patient in red font and remind the patient to consult the doctor in time. Patients can consult their family doctors directly online through App or go to the hospital.~2. Medication reminder After patients upload their own medication information, the App will automatically generate a medication alarm clock to remind patients to take the drugs.~3. Follow-up reminder According to the clinical diagnosis and conditions of patients, make personalized follow-up time. Family physicians could use the App to remind patients to fill in the follow-up form or go to the hospital."
214413965|NCT04409210|DRUG|Routine treatment|Family physicians conduct the corresponding treatment and management according to the diagnosis and conditions of the patients.
214413966|NCT05578352|OTHER|Add oral hyppoglycemia drug|Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
214413967|NCT05578352|OTHER|Add GLP-1 receptor agonist|Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
214413968|NCT05578352|OTHER|Change insulin|Change premix insulin to long-acting insulin
214413969|NCT01282437|RADIATION|Prophylactic Cranial Irradiation|"* 18 fractions of 2Gy~* 12 fractions of 2.5Gy~* 10 fractions of 3 Gy"
215017005|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
214413970|NCT01570660|DRUG|Pioglitazone|12 weeks of pioglitazone treatment
214505120|NCT01760005|DRUG|Gantenerumab|Open-label administered Subcutaneously every 4 weeks at escalating doses
214505121|NCT01760005|DRUG|E2814|Administered intravenously in a blinded fashion
214505122|NCT01760005|DRUG|Lecanemab|Administered intravenously
214505123|NCT01760005|DRUG|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
214505124|NCT04482556|DEVICE|Q-NRG+ Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
214505125|NCT04482556|DEVICE|V(max) Encore Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
214505126|NCT05600439|BEHAVIORAL|CareME|"CareME program was planned to integrate 12 group session (90 minutes), implemented fortnightly during a 6-month period, and facilitated by two psychologists and expert researchers on attachment framework. Components included psychoeducation (description of core concepts such as attachment, secure base, safe haven, emotion regulation, mentalization, trauma, and discussion of research on professional caregiving in YRC); experiential and relational exercises (roleplay; cases discussion, film script discussion).~The program has 7 moduli: (i) adolescents' pain-based behaviors and attachment theoretical lens; (ii) adolescence and main developmental challenges (iii) setting rules and limits; (iv) trust \& secure base (figures and environment); (v) professionals' stories of attachment \& caregiving (vi) personal and structural characteristics that prevent a secure caregiving environment and (vii) professional impairment and strategies promoting healthy secure base provision."
214505127|NCT00108589|DRUG|S-adenosylmethionine|
214505128|NCT02294994|DRUG|tirofiban|
214505129|NCT04530370|BIOLOGICAL|recovered covid 19 patients plasma|we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
215017006|NCT05683275|OTHER|IASTM|IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute.
215101711|NCT03331757|OTHER|Glucose as reference food|Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
215017007|NCT05683275|OTHER|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application.
215017008|NCT05683275|OTHER|Home Exercise|Special static stretching and eccentric strengthening exercises for the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks.
215101712|NCT03331757|OTHER|Fir honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214413971|NCT03439124|DRUG|ceftobiprole medocaril|"Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole).~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment."
214413972|NCT03439124|DRUG|IV standard-of-care cephalosporin|"Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days.~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.~At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
214413973|NCT01802229|PROCEDURE|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
214413974|NCT01802229|PROCEDURE|Fascial suture|The port-site hole is closed with simple suture of the fascia
215017009|NCT03073304|DRUG|Crystalloid based prime solution|Crystalloid based prime solution
215101713|NCT03331757|OTHER|Heather honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of heather honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214413975|NCT06030908|PROCEDURE|Reconstruction of Achilles tendon insertion|knotless double-row anchor fixation of the achilles tendon insertion
214413976|NCT02236559|DEVICE|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 \> 88%."
214413977|NCT02236559|DEVICE|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 \> 88%.
214505130|NCT03466216|DRUG|AlphaMedix|There is only a single treatment intervention.
214505131|NCT06117891|DRUG|Atezolizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
214505132|NCT06117891|DRUG|Bevacizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
214505133|NCT06117891|DRUG|Durvalumab|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
215017010|NCT03073304|DRUG|Erythrocyte based prime solution|Erythrocyte based prime solution
215017011|NCT00940511|BEHAVIORAL|Coordinated care|
215017012|NCT02636036|BIOLOGICAL|enadenotucirev|
215017013|NCT02636036|BIOLOGICAL|nivolumab|
215017014|NCT03839680|PROCEDURE|Endoscopy|The endoscopy procedure uses an endoscope to examine the interior of a hollow organ or cavity of the body.
215017015|NCT02993432|DEVICE|Foley catheter filled to 80cc|A Foley catheter is inserted through the cervix and filled to 80cc
215017016|NCT02993432|DRUG|prostaglandin of the clinician's choice|Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
215017017|NCT00002135|DRUG|Ganciclovir|
215017018|NCT04367454|OTHER|Use of Personal Protective Equipment|As described in the arm descriptions
215017019|NCT01880775|DRUG|Prilocaine|experimental
215017020|NCT01880775|DRUG|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
215017021|NCT03378934|DRUG|Berberine|Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).
215017022|NCT03378934|DRUG|Standard treatment|Standard treatment for 12±1 weeks.
215017023|NCT03378934|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
215017024|NCT03378934|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
215017025|NCT04130425|DEVICE|Hely & Weber MTC Fracture Brace|Prefabricated muenster orthosis
215017026|NCT04130425|DEVICE|Thermoplastic orthosis|Muenster orthosis fabricated out of thermoplastics and secured with Velcro
214413978|NCT04260750|BEHAVIORAL|Internet-administered Cognitive behavioral therapy (ICBT)|"The intervention consists of fifteen modules, each having a specific focus on a problem (e.g. comorbid worry alongside the depression) or containing a specific strategy or element (e.g. behavioral activation).~The fifteen modules are:~Introduction/Psychoeducation about depression, Behavioral activation 1, Behavioral activation 2, Cognitive restructuring, Acceptance, Psychoeducation about emotions, Anxiety and exposure, Comorbid social anxiety, Comorbid worrying and generalized anxiety, Comorbid panic disorder, Sleep problems, Perfectionism, Stress management, Relaxation, and Relapse prevention.~The first and last module are assigned to all participants. The rest is picked either by the participants themselves or by the therapist conducting the intake interview."
214413979|NCT04106141|OTHER|6 weeks changing of archwire|changing the archwire after 6 weeks instead of 4 weeks
214413980|NCT04106141|OTHER|4 weeks changing of archwire|changing the archwire every 4 weeks
214413981|NCT06336486|DEVICE|intermittent pneumatic compression +pregabalin group|The investigators divided the patients into two equal groups , some of the patients were given an intermittent pneumatic compression program at a pressure of 35 mmhg for 30 min to the lower extremity for 10 days of extreme alternation in our clinic and pregabalin treatment was continued.
214413982|NCT06336486|OTHER|pregabalin group|only pregabalin treatment was continued.
214413983|NCT04120051|DIETARY_SUPPLEMENT|Fermented canola-seaweed|A daily sachet with 5 gram FCS-granulate for 6 weeks
214413984|NCT04120051|OTHER|Placebo|A daily sachet with 5 gram rye cereal for 6 weeks
214413985|NCT01835340|DEVICE|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
214413986|NCT04820582|OTHER|Delphi Questionnaire|Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
214413987|NCT02516644|BEHAVIORAL|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
214413988|NCT02516644|BEHAVIORAL|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
214413989|NCT02599844|DRUG|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
214413990|NCT02599844|PROCEDURE|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
214413991|NCT02599844|PROCEDURE|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
214413992|NCT02599844|PROCEDURE|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
214413993|NCT02599844|DRUG|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
214694020|NCT01409031|DRUG|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
215017027|NCT04130425|DEVICE|Delta cast orthosis|Muenster orthosis fabricated out of Delta Cast and secured with Velcro
215101714|NCT03331757|OTHER|Citrus honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214413994|NCT00608673|DRUG|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
214413995|NCT00608673|DRUG|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
214413996|NCT02321306|DRUG|LUM001|LUM001 administered orally once each day.
214413997|NCT05301400|DEVICE|Bti Unit|Comparison with or without the device
214413998|NCT02454205|DRUG|Linezolid|600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
214413999|NCT02454205|DRUG|Bedaquiline|400mg po daily for 2 weeks, followed by 200mg three times per week .
214414000|NCT02454205|DRUG|Levofloxacin|750mg (\<50kg) 1000mg (\>50kg)
214414001|NCT02454205|DRUG|Pyrazinamide|1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
214414002|NCT02454205|DRUG|Isoniazid|high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
214414003|NCT02454205|DRUG|Ethionamide|15mg/kg (max 900mg)
214414004|NCT02454205|DRUG|Terizidone|750mg (40-70kg) 750-1000mg (71-90kg)
214414005|NCT02454205|DRUG|Moxifloxacin|400mg po daily.
214414006|NCT02454205|DRUG|Kanamycin|500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
214414007|NCT06358066|DRUG|self assembling peptide p11-4 with fluoride|"Self-assembling peptide (P11-4) fluoride plus will be applied according to the manufacturer's instructions by pushing the two cylinders together and will left for 5 min till the tooth surface appears dry to insure its diffusion~The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment"
214414008|NCT06358066|DRUG|5% sodium fluoride varnish|Fluoride varnish will be applied under manufacturer instructions by applying thin layer of varnish with a brush in strokes The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment
214414009|NCT00009984|DRUG|fludarabine phosphate|Given IV
214414010|NCT00009984|DRUG|thalidomide|Given orally
214414011|NCT05582317|DRUG|Biodentine|Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide
214414012|NCT05582317|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
214689038|NCT04122768|BEHAVIORAL|Light coaching intervention|"A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period)."
214689039|NCT00716404|DEVICE|Targeted Renal Therapy|Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
214689040|NCT03208192|PROCEDURE|liver transection during laparoscopic liver resection|liver transection during laparoscopic liver resection
214689041|NCT04922125|COMBINATION_PRODUCT|Pulse flour|Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.
214414013|NCT05386446|DRUG|Interferon gamma human recombinant (IFN-G)|nasal form
214414014|NCT00943605|DEVICE|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
214414015|NCT00943605|DEVICE|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
214414016|NCT00036933|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
214689042|NCT04922125|COMBINATION_PRODUCT|Pre-processed pulse flour|Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
214414017|NCT00036933|BIOLOGICAL|QS21|
214689043|NCT02615717|BEHAVIORAL|Attention Bias Modification|comparison of treatment versus control
214689044|NCT02026271|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection or 1.0 x 10\^12 viral particles (vp) per injection~* one intratumoral injection of Ad-RTS-hIL-12"
214689045|NCT02026271|DRUG|veledimex|"* 4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)~* 14 oral daily doses of veledimex~* 1 Expansion cohort at a single dose level at or below MTD"
214689046|NCT04333433|DEVICE|PRESERFLO® MicroShunt|Device surgically implanted
214689047|NCT04333433|PROCEDURE|Trabeculectomy|The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.
214689048|NCT05611684|DRUG|Polyethylene Glycol Losenatide|Treatment 0.2mg QW for 12 weeks
214689049|NCT00320385|DRUG|Lapatinib|oral lapatinib once daily
214689050|NCT00320385|BIOLOGICAL|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
214689051|NCT06442917|BEHAVIORAL|Breathing Exercise|"32 the Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth was completed before the pregnancy intervention and the VAS was measured. Breathing exercise training and application were carried out during the latent phase process. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made.~During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed every 30 minutes from the beginning of contraction until the end of contraction. During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 15 minutes from the beginning of contraction to the end of contraction."
214694021|NCT01409031|OTHER|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
215017028|NCT06410807|OTHER|Focus groups|The present study consists of 5 focus groups over 3 waves to inform the development and refinement of internet-based mindfulness (iMBSR) and lifestyle education (iLifeEd) protocols for use in future clinical trials. 50% females and 50% minoritized participants will be recruited to ensure representation across sex and race. For all focus groups, adults (over the age of 50 years) who report SCD will be recruited. Specifically, the Everyday Cognition Questionnaire (E-Cog) will be administered to quantify informant-reported deficits in cognitive functioning.
215017029|NCT05839821|BEHAVIORAL|noF-noRAS|resting state, that is, without finger-tapping and without listening to RAS
214414018|NCT04103671|PROCEDURE|Prompt panretinal photocoagulation|Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
214414019|NCT04103671|PROCEDURE|25G Pars-plana vitrectomy|Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
214414020|NCT06231069|DIETARY_SUPPLEMENT|Multi-nutrient supplement|12 weeks of supplement intake of milk proteins, N-3 PUFAs, creatine, and vitamin D at levels previously shown to augment muscle protein synthesis in young individuals.
215017030|NCT05839821|BEHAVIORAL|F-noRAS|finger-tapping without listening to RAS
215017031|NCT05839821|BEHAVIORAL|noF-100RAS|listening to RAS with the 100% of the baseline tempo and without finger-tapping
215017032|NCT05839821|BEHAVIORAL|F-100RAS|finger-tapping and listening to RAS with 100 % of baseline tempo
214414021|NCT06231069|OTHER|Exercise|12 weeks of short-duration mixed endurance and resistance exercise.
214505134|NCT06117891|DRUG|Tremelimumab,|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
214505135|NCT02994524|PROCEDURE|Rerouting technique for transsphincteric perianal fistula|
214505136|NCT05804357|BEHAVIORAL|Manual Therapy|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion
214505137|NCT05804357|BEHAVIORAL|Exercise|It is an approach that is combined with diaphragmatic breathing, activating the passive-active musculoskeletal and neural systems. In this approach, transversus abdominis and multifudus muscles are activated as deep core muscles.
214414022|NCT05150613|OTHER|No Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
214414023|NCT05150613|OTHER|Surgical Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
214414024|NCT05150613|OTHER|N95 Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
214414025|NCT03686813|DRUG|Sildenafil Citrate|Oral sildenafil, 50 mg
214414026|NCT03686813|DRUG|Placebo Oral Tablet|Placebo
214414027|NCT02298140|OTHER|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
214414028|NCT04232592|BIOLOGICAL|Inject a solution of stem cell preparation|The control group was injected with a solution of stem cell preparation
214414029|NCT04232592|BIOLOGICAL|Inject stem cells|Three dose groups were designed: low dose group, medium dose group and high dose group.
214414030|NCT02989012|DRUG|GanMaoKangNing Granules|3 times a day, 2 bags each time.
214414031|NCT02989012|DRUG|Analogous Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
214414032|NCT02989012|DRUG|Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
214414033|NCT02989012|DRUG|Analogous GanMaoKangNing Granules|3 times a day, 2 bags each time.
214414034|NCT01921140|DRUG|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
214414035|NCT01921140|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
214414036|NCT01921140|OTHER|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
214414037|NCT01921140|OTHER|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
214414038|NCT04206046|PROCEDURE|Spinal anaesthesia|Patients will receive a spinal anaesthetic
214414039|NCT04206046|PROCEDURE|General anaesthesia|patients will receive a general anaesthetic and a femoral nerve block
214414040|NCT02033096|DRUG|Stannsoporfin|No intervention was administered during this observational study
214414041|NCT02033096|DRUG|Placebo Control|No intervention was administered during this observational study
214414042|NCT02033096|OTHER|Phototherapy (as needed)|No intervention was administered during this observational study
214414043|NCT06260696|OTHER|No treatment is given|No treatment is given
214414044|NCT06345612|BEHAVIORAL|hypoxia|eccentric training program conducted within normobaric hypoxic chamber
215017033|NCT05839821|BEHAVIORAL|F-105RAS|finger-tapping and listening to RAS with 105 % of baseline tempo
215017034|NCT05839821|BEHAVIORAL|F-110RAS|finger-tapping and listening to RAS with 110 % of baseline tempo
215017035|NCT01558375|DRUG|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
214414045|NCT06345612|BEHAVIORAL|normoxia|eccentric training program conducted within normoxic conditions
214414046|NCT06345612|DIETARY_SUPPLEMENT|creatine supplementation|5g of creatine per day
214414047|NCT06345612|DIETARY_SUPPLEMENT|no creatine supplementation|no creatine supplementation
214414048|NCT01606553|DEVICE|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
214414049|NCT01606553|DEVICE|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
214414050|NCT00338858|OTHER|walking and balance performance evaluation|
214414051|NCT00338858|PROCEDURE|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
214414052|NCT03093792|OTHER|Control|
214414053|NCT03093792|OTHER|American Heart Association plus exercise|
214414054|NCT03093792|OTHER|Curves Complete - I plus exercise|
214414055|NCT03093792|OTHER|Curves Complete - II plus exercise|
214414056|NCT03416465|BEHAVIORAL|medical questionnaire|The patient will complete a questionnaire of 10 questions before leaving hospital. This questionnaire concerns the care pathway for hospitalized patients.
214414057|NCT02419261|DRUG|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
214414058|NCT02419261|PROCEDURE|Arthroscopic surgical repair of the anterior cruciate ligament|
214414059|NCT00145002|DRUG|VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|
214414060|NCT00145002|DRUG|biweekly-CHOP with G-CSF and intrathecal prophylaxis|
214414061|NCT04436055|OTHER|No Intervention will be used|Since this is an observational study, there are no interventions.
214414062|NCT06411405|OTHER|Maternal medical history|See above; multiple factors to be collected broadly grouped into maternal medical, obstetric, and sociodemographic/lifestyle factors.
214414063|NCT00361517|BEHAVIORAL|Galactomannan antigen monitoring, Aspergillus PCR|There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
214414064|NCT00361517|OTHER|blood draws|Blood is drawn for monitoring of Galactomannan antigen in the blood
214414065|NCT00361517|OTHER|blood draws for GM monitoring|blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
214414066|NCT00361517|DRUG|Amphotericin-B deoxycholate|1-1.5mg/kg, i.v, once a day
214414067|NCT00361517|OTHER|blood test|Blood will be tested twice a week for the presence of Galactomannan.
214414068|NCT00361517|OTHER|Blood test|Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
214414069|NCT01615835|OTHER|EnSite NavX System|EnSite NavX system is a 3D Mapping system
214414070|NCT02529696|DEVICE|Accelerometer|Measures patient movement
214414071|NCT05679830|DRUG|Cannabidiol|Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
214414072|NCT01393353|OTHER|Cognitive Training|
214414073|NCT01393353|OTHER|computer game|
214414074|NCT06450977|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
214414075|NCT06450977|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
214414076|NCT02131324|DRUG|DFD06 Cream|
214414077|NCT02131324|DRUG|Clobetasol Propionate Cream 0.05%|
214414078|NCT04753099|BEHAVIORAL|occupation-based coaching|"Occupation based coaching is an intervention proven to be an effective intervention in family-centered practice. OBC is a strength-based approach that emphases collaboration with clients in goals setting and attainment to increase overall health and quality of life. Clients are the central focus of the intervention and generate their own strategies to address goals as part of the coaching process. In their role as coach, the therapists employ techniques such as reflective questioning and comments to support clients in identifying existing routines and rituals that impact goal attainment and to increase knowledge and access to resources that can promote improved caregiver quality of life after a child's diagnoses with T1D. Occupation based coaching can be divided into the following steps: (1) setting goals, (2) exploring options, (3) planning action, (4) carrying out the plan, (5) checking performance, and (6) generalizing(Little et al., 2018, p.2)."
215017036|NCT01558375|DRUG|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
215017037|NCT05813834|PROCEDURE|Genicular Nerves Block|US guided genicular nerves block
214414079|NCT05039606|DRUG|Nedaplatin|Nedaplatin is a second-generation platinum-like derivative, which is a cell cycle non-specific drug, with a mechanism of action and efficacy similar to cisplatin, and a wide anti-cancer spectrum
214414080|NCT05039606|DRUG|Cisplatin|Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug
214414081|NCT00891618|OTHER|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
214414082|NCT02248025|OTHER|Observational study: No special intervention will be made.|No special intervention will be made, only data will be collected before, and after a passive leg raising and a fluid challenge decided and performed by the attending physician.
214414083|NCT01693614|DRUG|Buparlisib|100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
214414084|NCT00844571|OTHER|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
214414085|NCT05655442|PROCEDURE|early APM|early APM within 3 and 6 month knee pain symptoms
214414086|NCT05655442|PROCEDURE|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
214414087|NCT03812354|OTHER|THRIVE 4L/kg/min|High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
214414088|NCT03812354|OTHER|THRIVE 2L/kg/min|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
214414089|NCT02650596|DRUG|GLP-1|Liraglutide were taken daily for 3 months
214414090|NCT02650596|DRUG|Placebo|Placebo were taken daily for 3 months
214414091|NCT05870241|OTHER|Ga-As Laser|Patient sits on a chair with back support and the two GA-AS laser ( 5 milli Watts \& 904 nm) probe will be applied one on the shoulder tip for 5 minutes and the other application another 5 minutes will be on the center of deltoid muscle. The main power of the laser switch will be turned on. The duration of the treatment will be 10 minutes.
214414092|NCT05870241|OTHER|Microcurrent Electrical Stimulation|The patient sits on a chair with back support and the two electrodes from Microcurrent 850 unit device will be applied one on the shoulder tip and the other electrode on the center of the deltoid muscle. A wet cloth was placed between the electrode and the patient's skin. An adhesive tape was used to hold the electrode over the treated areas. The main power switch will be turned on. The treatment duration will be for 10 minutes.
215017038|NCT04898543|BIOLOGICAL|M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)|M-CENK will be administered up to 10 times weekly via intravenous (IV) infusion starting on study day 1 with a minimum of 7 days between each M-CENK dose. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.
215017039|NCT04898543|BIOLOGICAL|N-803 (Cohort 2 part B)|N-803 15 μg/kg will be administered subcutaneously prior to every other dose of M-CENK for up to 5 doses of N-803.
215017040|NCT04898543|OTHER|Apheresis collection of MNCs (part A)|Subjects in cohort 1A will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.
215017041|NCT05714631|OTHER|Placebo Patch|Transdermal placebo patch
215017042|NCT05714631|DRUG|4% Lidocaine Patch|Transdermal patch
214689052|NCT06442917|BEHAVIORAL|Affirmation Method|"32 pregnant women who were admitted to the hospital for childbirth and were in the latent phase (0-3 cm) filled out the pre-intervention Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth, and the VAS was measured. During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained. During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and the affirmation phrases were repeated and used by the researcher every 30 minutes from the beginning of the contraction until the end of the contraction.~During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and affirmation sentences and support sentences were said every 15 minutes from the beginning of the contraction to the end of the contraction."
214414093|NCT05870241|OTHER|traditional therapy|the patients will receive traditional physical therapy in the form of manual lymphatic drainage , compression bandage, exercise to increase lymphatic drainage, skin care. and ROM exercises to improve shoulder mobility
214414094|NCT02882048|PROCEDURE|NADA Protocol|NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
214414095|NCT02882048|OTHER|Medication management|Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
214414096|NCT02918786|DEVICE|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
214414097|NCT02918786|DEVICE|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
214414098|NCT00090298|DRUG|MK0653A, ezetimibe (+) simvastatin|
214414099|NCT00090298|DRUG|Comparator: Rosuvastatin|
214414100|NCT06202599|DRUG|Fruquintinib|For patients with pulmonary metastasis only, we mostly gave them fruquintinib with 7 mg in adults and 3-5 mg in children (\<10 years) orally per day (5 days on and 2 days off). If patients were extrapulmonary metastasis, we usually used combinations with metronomic chemotherapy (2/3 or 3/5 or even 1/2 of the usual dose) or immunotherapy.
214414101|NCT02272400|OTHER|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
214414102|NCT00480012|DEVICE|rTMS|repetitive transcranial meagnetic stimulation of the brain
214414103|NCT01048788|DRUG|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
214414104|NCT04344613|DEVICE|ABODpoct device|The device has been developed by a consortium including the Université Libre de Bruxelles, research centers (SIRRIS, CER), a private company (CISEO), and the spin-off Antigon S.A..The device includes a reader and a disposable disk (ABOD disk) for testing one patient et a blood bag. Four blood drops from the patient are deposited on one side of the disk and 4 blood drops from the blood bag one the other side. The disk correctly filled is inserted in the reader and after 2 minutes the result is displayed on the screen as a message GO or No GO. In case of incompatibility or any other problem a red Stop message will appear on the screen.
214414105|NCT03360552|OTHER|Multidimensional fragility index questionnaire RAI-Home Care|Questionnaire for assessing deficits in Alzheimer's disease
214414106|NCT03360552|OTHER|Usual care|Usual clinical evaluation
214414107|NCT05657041|DRUG|Clopidogrel|Body weight adjusted clopidogrel dosing
215017043|NCT02241772|DRUG|TA-8995|
215017044|NCT02241772|DRUG|Placebo|
215017045|NCT04785807|OTHER|Post traumatic, Anxiety and depression evaluation|Family member of person or trust of patient who had a limitation or discontinuation of treatments will be identified and asked to fulfilled a hospitalized anxiety and depression scale and the revised Impact Event scale 7 and 30 days after the limitation or discontinuation of treatments announcement
215017046|NCT01798823|PROCEDURE|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
214414108|NCT00328055|BEHAVIORAL|AD-Easy (Advance Directive-Easy)|
215017047|NCT02005926|PROCEDURE|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
214414109|NCT00328055|BEHAVIORAL|AD-Standard (Advance Directive-Standard)|
214414110|NCT00530517|DEVICE|Intraject Sumatriptan|needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
214414111|NCT02156687|DEVICE|Y mesh|Y mesh
214414112|NCT02156687|DEVICE|Dual flat mesh|Dual flat mesh
214414113|NCT05677178|OTHER|observational|This study is an observational study without any intervention.
214414114|NCT00420316|BIOLOGICAL|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
214414115|NCT00420316|BIOLOGICAL|Placebo (primary vaccination study)|Two liquid oral doses of placebo
214414116|NCT00307450|DRUG|Levetiracetam|up to 200 mg per day in two dosages per day.
214414117|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2321138A|intramuscular injections
215017048|NCT02169999|OTHER|Personalized Diabetes Care Website|Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
214414118|NCT01196988|BIOLOGICAL|FluarixTM|intramuscular injections
214414119|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2604409A|intramuscular injections
214414120|NCT05419557|BEHAVIORAL|Virtual Family-Based Healthy Plate Club|IHPC provides produce boxes, nutrition and meal-preparation, education, and supportive counseling to address barriers related to obtaining produce and food. The intervention provides participants with a bi-weekly produce box for 12 weeks and helps families identify sustainable ways to obtain vegetables once the produce boxes end. The CHW will support families by coaching them on how to prepare these unfamiliar vegetables, give tips on finding sales at grocery stores, as well as by navigation to food assistance sites including food pantries. Parents will learn strategies to increase vegetable consumption by addressing perceived barriers - such as the child doesn't like vegetables. Curriculum will also include topics such as how to increase physical activity and reduce screen time.
214414121|NCT05036746|OTHER|No intervention|No intervention
214414122|NCT06461637|BEHAVIORAL|Stepped Care Mental Health for Foreign Domestic Helpers (SCMH-FDH)|The SCMH-FDH intervention consists of 4 steps. Step 1 involves a self-help intervention (through 12 mental health booklets) delivered in 6 sessions and an online peer support group. Those who did not respond to Step 1 will be referred to Step 2 (group-based resilience workshop). The intervention will be also be delivered in 6 weekly sessions lasting 1-1.5-hours. Those who did not respond to Step 2 will be referred to Step 3 (guided self-help cognitive behavioral therapy, CBT) with guidance from a trained therapist. Self-help materials will be provided. The sessions are spread out over six weeks, with each sessions lasting 30-45 minutes. Those who did not respond to Step 3 will be referred to Step 4 (high intensity interventions provided by mental health professionals). Stepping up is determined by the IAPT-minimum data set. If assessment scores after previous treatment exceeds the defined threshold (PHQ-9 ≥ 10 or GAD-7 ≥ 8), then participants need to step up to the next intervention.
214414123|NCT01337869|PROCEDURE|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
214414124|NCT01337869|PROCEDURE|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
214414125|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (high dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
214414126|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (low dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
214414127|NCT04846491|DRUG|TDF|Patients will take TDF orally for the first 48 weeks, and then one can choose to continue the single-TDF treatment up to 144 weeks, or may choose to change to receive peginterferon alfa-2b combined TDF therapy for the later 96 weeks, peginterferon alfa-2b will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 weeks a cycle. And then followed for 24 weeks after treatment.
214414128|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
214414129|NCT03824262|DEVICE|HICO-VARIOTHERM 550|Warming during perioperative period.
214414130|NCT03824262|DEVICE|Mistral-Air Plus forced air warming device|Warming during perioperative period.
214414131|NCT00601848|DRUG|chemotherapy|
215017049|NCT05734807|DRUG|Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)|Subjects will receive NrtIs therapy for 24 weeks.
215017050|NCT05734807|DRUG|HH-003 and NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.
215017051|NCT05734807|DRUG|HH-003, NrtIs and PEG-IFN-α|Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
215017052|NCT01982227|DRUG|indocyanine green|intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
215017053|NCT01906164|DRUG|ALS-008176|
215017054|NCT01906164|DRUG|Placebo|
215017055|NCT04667429|OTHER|Food|HEC83518 40mg will be taken orally fasted or with food
215017056|NCT04667429|DRUG|HEC83518|HEC83518 will be taken orally before sleep for 15 days
215017057|NCT04667429|DRUG|placebo|The placebo will be administered before sleep for 15 days.
214414132|NCT00601848|DRUG|porfimer sodium|
214414133|NCT00601848|OTHER|immunohistochemistry staining method|
214414134|NCT00601848|OTHER|laboratory biomarker analysis|
214414135|NCT00601848|PROCEDURE|spectroscopy|
214414136|NCT00601848|PROCEDURE|therapeutic conventional surgery|
214414137|NCT06354738|PROCEDURE|total hysterectomy with bilateral salpingo-oophorectomy, lymph node staging and comprehensive peritoneal staging|"Surgical treatment will consist of total hysterectomy with bilateral salpingo-oophorectomy according to international guidelines.~In low- and intermediate-risk EC patients, staging will include a sentinel lymph node (SLN) procedure. In high intermediate-risk and high-risk EC patients, lymph node staging will involve SLN procedure and/or pelvic and para-aortic lymph node dissection (LND), depending on the local protocol.~The Study-related procedures include infracolic omentectomy or two separate omental representative biopsies, biopsies of all suspicious lesions as well as six peritoneal sites (bladder, pouch of Douglas, bilateral paracolic gutter and bilateral diaphragm).~Stage IV patients will be treated according to European guidelines. When feasible, full surgical intervention (i.e. debulking) is recommended. If this cannot be achieved, a radiologic and/or histologic confirmation of tumor spread beyond the uterus will be accepted."
214414138|NCT03126656|DRUG|Testosterone Undecanoate|just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
214414139|NCT00868192|DRUG|Pemetrexed|
214414140|NCT00868192|DRUG|Bevacizumab|
214414141|NCT03256812|DEVICE|ICT-based ECG monitoring|Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.
214414142|NCT03256812|DEVICE|Holter monitoring|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
214414143|NCT04304534|DRUG|BAY2433334|Tablet, taken orally once a day.
214414144|NCT04304534|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
214414145|NCT06555471|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1
214689053|NCT06442917|BEHAVIORAL|Breathing Exercise and Affirmation Method|During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained and the application was made with breathing exercise training. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made. During the active phase process (4-7 cm), the Congenital Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 30 minutes from the beginning of contraction to the end of contraction, and the affirmation phrases were repeated and used by the researcher
215017058|NCT05111769|DRUG|Recombinant human brain natriuretic peptide|1\. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
214414146|NCT06555471|DRUG|S-1|po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time)
214414147|NCT06555471|DRUG|Capecitabine|1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.
214414148|NCT06555471|RADIATION|Extraperitoneal radiation therapy|once a day, five times a week, at a dose of 1.8-2 Gy/f, for a total of 45-50.4 Gy. Radiation therapy starts from the first cycle of Sintilimab Injection combined with chemotherapy
214414149|NCT00464672|BIOLOGICAL|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
214414150|NCT00464672|BIOLOGICAL|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
214414151|NCT00641472|DRUG|Budesonide inhalation suspension|0.5mg
214414152|NCT00641472|DRUG|Montelukast Sodium|4mg or 5mg
214414153|NCT03101436|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil and Red Wine|"Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)~Washout Period: 15 days~Phase II: Red Wine (270 ml per day) (1 month)"
214414154|NCT02970708|DEVICE|EFG group|88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.
214689054|NCT04844047|OTHER|Exercise|refer to arm descriptors
215017059|NCT03465605|DIAGNOSTIC_TEST|frailty test|questionnaire
215017060|NCT05257044|DRUG|Cannabigerol|Participants will ingest CBG and placebo in a double-blind randomized cross-over design
215017061|NCT05257044|OTHER|Placebo|Placebo
215101715|NCT03331757|OTHER|Pine honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of pine honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
215101716|NCT03331757|OTHER|Thyme honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of thyme honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
214414155|NCT02970708|DEVICE|Patching group|88 anisometropic amblyopia will be recruited to receive patching treatment.
214414156|NCT02515682|DIETARY_SUPPLEMENT|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
214414157|NCT02515682|DIETARY_SUPPLEMENT|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
214414158|NCT02515682|DIETARY_SUPPLEMENT|Placebo|Participants will be give placebo for 24 weeks.
214414159|NCT01063023|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
214414160|NCT01063023|DRUG|BMS-650032|Tablets, Oral, 600 mg, BID
214414161|NCT00957229|DRUG|GDC-0449|capsule, 150 mg, one pill daily, 18 months
214689055|NCT04844047|OTHER|Exercise|refer to arm descriptors
214689056|NCT00069082|DRUG|Civamide (Zucapsaicin)|Nasal Solution 0.01%
215017062|NCT03722030|OTHER|Baseline Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
215017063|NCT03722030|BEHAVIORAL|Strength-Training|2 sessions per week (20-40 min), home-based resistance training
214414162|NCT00727584|RADIATION|radiation therapy|Patients undergo external beam radiotherapy
214414163|NCT03744117|OTHER|Palliative care consultation|A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
215017064|NCT03722030|OTHER|Mid-point Measures|Accelerometer (steps)
214414164|NCT00623246|BEHAVIORAL|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
214414165|NCT00623246|BEHAVIORAL|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
214414166|NCT03389581|BEHAVIORAL|awareness and anxiety|before operation awareness and anxiety will recorded with STAIX-I score
214414167|NCT01168453|BEHAVIORAL|head position change|AL-US distance measure using the ultrasound in two different head position
214414168|NCT00466791|DRUG|Methylphenidate Transdermal System|Placebo
214414169|NCT01319435|PROCEDURE|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
214414170|NCT00029380|DRUG|Sangstat|
214414171|NCT00029380|DRUG|Cyclophosphamide|
214414172|NCT00029380|DRUG|Busulfan|
214414173|NCT00029380|DRUG|Mycophenolate Mofetil|
214414174|NCT00029380|DRUG|Cyclosporine|
214414175|NCT00029380|PROCEDURE|Cord Blood Transplantation|
214414176|NCT05800821|PROCEDURE|Carotid revascularization|Carotid revascularization
214414177|NCT01297972|BIOLOGICAL|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
215017065|NCT03722030|OTHER|Post-Study Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
214414178|NCT05290740|DRUG|Norepinephrine 5 mcg|norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
214414179|NCT05290740|DRUG|Norepinephrine 10 mcg|norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
214414180|NCT02665130|OTHER|Tai-chi plus Indacaterol|Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
214414181|NCT02665130|OTHER|Pulmonary rehabilitation plus Indacaterol|Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
214414182|NCT04127539|BEHAVIORAL|Strong & Steady exercise program|The community-based group exercise program S\&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S\&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S\&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
214414183|NCT03014687|DRUG|Placebo|PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
214414184|NCT03014687|DRUG|Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole|Oral antibiotics (cefdinir \[Omnicef®\] 300 mg PO BID or trimethoprim/sulfamethoxazole \[Bactrim DS™\] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
214414185|NCT01188486|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Standard of care diagnostic radiotherapy procedure
214414186|NCT01188486|RADIATION|Computed Tomography (CT)|For each participant, 3 chest CT scans will be obtained, 1 before and 2 after interstitial injection of the water-soluble contrast
214414187|NCT01188486|DEVICE|Cyberknife|Linear accelerator for producing high energy x-rays for radiation therapy.
214414188|NCT01188486|DEVICE|Trilogy|Linear accelerator for producing high energy x-rays for radiation therapy.
214414189|NCT01188486|DEVICE|True Beam|Linear accelerator for producing high energy x-rays for radiation therapy.
214414190|NCT01188486|DRUG|Iohexol|Aqueous solution of a nonionic, water-soluble radiographic contrast medium in prefilled cartridges with a molecular weight of 821.14 (iodine content 46.36%), available at 140, 180, 240, 300, and 350 mgI/mL.
214414191|NCT01188486|DRUG|Iodixanol|Aqueous solution of a nonionic, water-soluble, dimeric, isosmolar, radiographic contrast medium with a molecular weight of 1550.20 (iodine content 49.1%), available in 2 concentrations, (270 mgI/mL and 320 mgI/mL.
214689057|NCT00069082|DRUG|Sodium Chloride|Nasal Solution 10%
215017066|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
215017067|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
215017068|NCT00224354|BIOLOGICAL|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
214414192|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
214414193|NCT01316978|DRUG|Ibuprofen|A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
214414194|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
214414195|NCT01276990|DRUG|BI 224436|Oral drinking solution
214689058|NCT01598727|DEVICE|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
214689059|NCT02429596|DRUG|Experimental|Switch from brand to generic
214689060|NCT00376402|BIOLOGICAL|H5N1 Pandemic Influenza Vaccine|
214689061|NCT04743635|DEVICE|Avéli device|Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
214689062|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
214689063|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
214689064|NCT02055027|OTHER|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
214689065|NCT04240067|DIAGNOSTIC_TEST|READ-MA Multimarker Approach|The presence or absence of ALSHF (gold standard used in the READ study) : diagnosis by 2 experts (cardiologist and emergency physician) based on data collected in the ED and during hospitalization (clinical examination, history, usual treatment, haemodynamic parameters, ECG, chest X-ray, emergency treatment, clinical and paraclinical results during hospitalization), biological assays (except NT-proBNP) and echocardiography (Left Ventricular Ejection Fraction, segmental kinetic, potential valvulopathy, transmitral flow, tissue doppler E' velocity) performed by a cardiologist within 24 hours of admission.
214689066|NCT06377644|DIAGNOSTIC_TEST|Kinesio taping|Kinesio taping is a physiotherapy method employed to provide support and stability to muscles and joints while allowing freedom of movement (ROM). The elastic nature of kinesio tape closely resembles that of human skin. After application, kinesio tape rebounds, generating a pulling force that acts as the primary stabilizer for the specific area. Physiotherapy treatments often involve a combination of stretching and strengthening exercises, along with electrotherapy modalities. Additionally, Joint mobilization is a form of passive movement in a broad spectrum of exercise used to treat painful and stiff synovial joints.
214689067|NCT06377644|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a minimally invasive technique involving the use of a single filament or acupuncture needle to penetrate painful soft tissue areas. From a neurophysiological standpoint, Dry Needling might stimulate A-delta nerve fibers (group III), which could activate inhibitory dorsal horn interneurons containing enkephalin, leading to pain suppression and relief through opioid mechanisms. (DN) may affect microcirculation. Numerous studies have shown that inserting needles into muscles can increase blood flow in both the skin and the muscle in the treated area. It can lead to an immediate reduction in local and referred pains, as well as enhance range of motion (ROM) and correct muscle activity patterns.
214689068|NCT00713401|DRUG|Tecadenoson|Tecadenoson administered intravenously (i.v.)
214689069|NCT00713401|DRUG|Esmolol|Esmolol low dose infusion according to manufacturer's instructions
214414196|NCT01276990|DRUG|BI 224436|Oral drinking solution
214414197|NCT01276990|DRUG|BI 224436|Oral drinking solution
214414198|NCT01276990|DRUG|BI 224436|Oral drinking solution
214414199|NCT01276990|DRUG|BI 224436|Oral drinking solution
214414200|NCT01276990|DRUG|BI 224436|Oral drinking solution
214414201|NCT01276990|DRUG|BI 224436|Oral drinking solution
214414202|NCT01276990|DRUG|BI 224436|Oral drinking solution
214689070|NCT04470310|DRUG|Glimepiride|
214689071|NCT04470310|DRUG|Alogliptin 25Mg Tab|
214689072|NCT04470310|DRUG|Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet|
214414203|NCT01276990|DRUG|BI 224436|Oral drinking solution
214414204|NCT01276990|DRUG|Placebo|Oral drinking solution
214414205|NCT00578214|DRUG|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
214414206|NCT00578214|OTHER|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
214414207|NCT00578214|DRUG|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
214414208|NCT00578214|DRUG|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (\>45 to 77 kg, 10 mg; \>77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
214414209|NCT02162238|DEVICE|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
214414210|NCT00238316|DRUG|letrozole|2.5 mg PO daily for 1 year
214414211|NCT00238316|OTHER|Placebo|2.5 mg PO daily for one 1 year
214414212|NCT02615522|DEVICE|BPK-S Integration|
214414213|NCT00589732|DRUG|Valsartan|Valsartan 160mg per day
214414214|NCT00667693|DEVICE|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
214414215|NCT00667693|DEVICE|Pentax AWS|Intubation with Pentax AWS
214689073|NCT01704781|DRUG|Lenalidomide|In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
214689074|NCT01704781|DRUG|Lenalidomide placebo|Capsules are identical to the active Lenalidomide capsules used.
214689075|NCT01704781|DRUG|Vacc-4X|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
214414216|NCT02020018|DEVICE|Prevena Incision Management System|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
214414217|NCT02020018|OTHER|Conventional sterile dry wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after sternotomy
214414218|NCT04675463|DRUG|BGF Inhalation Aerosphere|Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time
214414219|NCT04675463|DRUG|GFF Inhalation Aerosphere|Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
214414220|NCT03976609|PROCEDURE|Maxillary Expansion|The patients with maxillary transverse deficiency were treated with Haas expander is a tooth and tissue-borne appliance with a jackscrew located at the anterior region of the arch with its arms bent posteriorly and soldered to the first permanent molar bands. Once activated, the appliances opens the palatal suture and increase the transverse dimension of the maxilla.
214414221|NCT04002128|OTHER|Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.|Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
214414222|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
214414223|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
214414224|NCT01320709|DRUG|Placebo|Single dose of placebo (i.e., 4 placebo capsules)
214414225|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
214414226|NCT04044664|DRUG|Placebo oral capsule|Matching placebo capsules.
214414227|NCT04044664|DRUG|NYX-783|NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
214414228|NCT06140849|DIAGNOSTIC_TEST|artificial intelligence model|artificial intelligence model of anterior open bite diagnosis
214414229|NCT00001575|BIOLOGICAL|Y-90 Humanized Anti-Tac|10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
214414230|NCT00001575|DRUG|Calcium-DTPA|Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
214414231|NCT00045916|PROCEDURE|High dosage electroconvulsive therapy|Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
214689076|NCT01704781|DRUG|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
214689077|NCT00113802|DRUG|Epratuzumab (hLL2- anti-CD22 humanized antibody)|
214414232|NCT00045916|DRUG|Nortriptyline|Participants will receive nortriptyline.
214414233|NCT00045916|DRUG|Venlafaxine|Participants will receive venlafaxine.
214414234|NCT00045916|DRUG|Lithium|Participants will receive lithium.
214414235|NCT00045916|PROCEDURE|Low dosage electroconvulsive therapy|Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
214414236|NCT01700569|DRUG|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
214414237|NCT01700569|DRUG|folinic acid at pharmacological dose is the escalated drug|
214414238|NCT01700569|RADIATION|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
214414239|NCT03658941|PROCEDURE|No dural tenting techniques|Not applying dural tenting sutures during closure of a craniotomy
214414240|NCT03658941|PROCEDURE|Dural tenting techniques|Applying at least 3 dural tenting sutures during closure of a craniotomy
214414241|NCT01106729|DIETARY_SUPPLEMENT|Cyanidin 3 glucoside|Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
214414242|NCT05583240|DRUG|Essences and Essential Oils|Participants will received Essential Oils through a nasal stick during 4 weeks.
214689078|NCT05029076|DRUG|Liraglutide injection|Human glucagon-like peptides-1 analogue
215017069|NCT00224354|BIOLOGICAL|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
215017070|NCT00224354|BIOLOGICAL|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
215017071|NCT00224354|DRUG|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
215017072|NCT00224354|BIOLOGICAL|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
214414243|NCT02605434|DRUG|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
214414244|NCT02605434|DRUG|Sinemet®|Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
214414245|NCT02605434|DRUG|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
214414246|NCT02605434|DRUG|Placebo- Sinemet|Placebo for Sinemet tables
214414247|NCT03736785|DRUG|LY3209590|Administered SC
214414248|NCT03736785|DRUG|Insulin Degludec|Administered SC
214414249|NCT01982643|DRUG|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
214414250|NCT01236989|PROCEDURE|anatomical liver resection|anatomical liver resection by means of IOUS-finger compression
214414251|NCT01236989|PROCEDURE|Non-anatomical liver resection|non-anatomical liver resection
214414252|NCT01801319|DEVICE|Libra Deep Brain Stimulation System|
214414253|NCT00728845|BIOLOGICAL|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
214689079|NCT05029076|DRUG|Victoza|Human glucagon-like peptides-1 analogue
214689080|NCT02702908|OTHER||Historical Reference group.
214689081|NCT01222338|BIOLOGICAL|V-5 immunitor|once per day dosing for 2 months
214414254|NCT00728845|DRUG|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
215017073|NCT00700089|BEHAVIORAL|Assertive intervention|8-20 assertive contacts after suicide attempt
214414255|NCT00728845|DRUG|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
214414256|NCT00728845|DRUG|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
214414257|NCT00300456|DRUG|ABT-335|135 mg, daily, 12 weeks
214414258|NCT00300456|DRUG|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
214414259|NCT00300456|DRUG|Placebo|Daily, 12 weeks, see Arm Description for placebo information
214414260|NCT06161064|DRUG|Hyaluronic acid|hyaluronic acid is temporary material using for augmentation of vocal folds in patients with glottal insufficiency
214414261|NCT02667730|DRUG|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
214414262|NCT02667730|DRUG|Naproxen|naproxen 500mg twice daily for 7 days
214414263|NCT02667730|DRUG|Celecoxib|celecoxib 100mg twice daily
214414264|NCT02667730|OTHER|physiotherapy only|physiotherapy only (no drug)
214414265|NCT02458534|OTHER|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
214414266|NCT02458534|OTHER|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
214414267|NCT02458534|OTHER|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
214414268|NCT01744691|DRUG|Ibrutinib|All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
214414269|NCT02086708|DEVICE|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
214414270|NCT02426320|OTHER|Sedation Interruption Protocol|
214414271|NCT02426320|OTHER|Standard Sedation Protocol|
215017074|NCT00700089|OTHER|Standard treatment|In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
214414272|NCT01190150|DRUG|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
214414273|NCT02797405|RADIATION|Standard treatment|Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
214414274|NCT02576418|OTHER|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
214414275|NCT04675255|PROCEDURE|Frequently sampled glucose tolerance testing|Frequently sampled glucose tolerance testing
214414276|NCT04675255|PROCEDURE|abdominal subcutaneous adipose tissue biopsy|abdominal subcutaneous adipose tissue biopsy
215017075|NCT00776425|DRUG|Epoetin beta|Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
215017076|NCT03451305|OTHER|Pillow|A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
215017077|NCT01628809|BEHAVIORAL|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
215101717|NCT03331757|OTHER|Chestnut honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of chestnut honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
215101718|NCT03907150|DIAGNOSTIC_TEST|Strain ultrasound|Post-interpretation of recorded ultrasound loops
214414277|NCT04675255|PROCEDURE|MRI scan to assess intrahepatic triglyceride content|MRI scan to assess intrahepatic triglyceride content
214414278|NCT01738555|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
214414279|NCT01738555|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
214414280|NCT04656236|BIOLOGICAL|3-hydroxybutyrate|3-hydroxybutyrate is a metabolite, produced in the human body.
214414281|NCT02392156|BIOLOGICAL|rFVIIIFc|As described in the treatment arm
214414282|NCT02392156|BIOLOGICAL|rFIXFc|As described in the treatment arm
214414283|NCT02392156|DRUG|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
214414284|NCT02392156|DRUG|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
214414285|NCT02870270|OTHER|Cancer treatment|Patients undergoing treatment for cancer in the head and neck region
214414286|NCT04238234|DEVICE|IVC Ultrasonography|Ultrasound measurements will be performed using a curved transducer set to abdominal mode (1-5 MHz; Acuson x300; Siemens Healthcare, Seoul, Korea). IVC variation will be assessed using ultrasound in the long-axis (sagittal) view. IVC diameter will be measured 1 cm distal to its junction with hepatic vein either by 2-D or M modes via a subcostal approach according to the methodology described by the American Society of Echocardiography . A two-dimensional image of the IVC as it enters the right atrium will be first obtained.
214414287|NCT04238234|DEVICE|Plethysmographic variability index (PVI) and perfusion index readings (PI)|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA).~PVI (%) is a measure of the dynamic change in PI that occurs during one or more complete respiratory cycles, calculated as:~PVI= \[(PImax-PImin)/PImax\] x100"
214414288|NCT02864238|OTHER|electronic milestone pathway|an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
214689082|NCT03382899|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Pembrolizumab
215101719|NCT00252603|DRUG|Galantamine|
214414289|NCT05159141|BEHAVIORAL|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
214414290|NCT02834182|BEHAVIORAL|IRMf|
214414291|NCT02834182|BEHAVIORAL|Mini International Neuropsychiatric Interview|
214414292|NCT02834182|BEHAVIORAL|Positive And Negative Syndrom Scale|
215017078|NCT02742974|DEVICE|FloTrac™ and EV1000™|Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
214414293|NCT02834182|BEHAVIORAL|Young Mania Rating Scale|
214414294|NCT02834182|BEHAVIORAL|Hamilton Depression Scale|
214414295|NCT03034252|PROCEDURE|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
214414296|NCT03425890|BEHAVIORAL|SURE program|SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy
214414297|NCT05771090|DEVICE|Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
214414298|NCT04767035|DRUG|midazolam / ketamine sublingual tablet|sublingual tablet
214414299|NCT02181348|DRUG|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
214414300|NCT02181348|DRUG|placebo (edible oil)|
214414301|NCT04898192|OTHER|questionnaire|questionnaire - the complex of 6 questionnaires aimed to recognize the fear of delivery, perinatal anxiety, depressive disorder, obsessive-compulsive disorder, general anxiety disorder, postpartal depression and domestic violence.
214414302|NCT03445130|OTHER|Lavandula Angustifolia oil (LO)|two drops on the inside of an oxygen face mask for 15 minutes.
214414303|NCT03445130|OTHER|Michelia Alba Leaf oil (MA)|two drops on the inside of an oxygen face mask for 15 minutes.
214414304|NCT03445130|OTHER|Almond oil (AO)|two drops on the inside of an oxygen face mask for 15 minutes.
214414305|NCT03445130|OTHER|Water|two drops on the inside of an oxygen face mask for 15 minutes.
214414306|NCT02628691|OTHER|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
214414307|NCT02041676|PROCEDURE|Chest physiotherapy|
214414308|NCT02041676|PROCEDURE|Usual surveillance|Usual surveillance of the non invasive ventilation without chest physiotherapy.
214414309|NCT05994092|BEHAVIORAL|Voluntary Isocapnic Hyperpnea|The protocol of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position.
214414310|NCT02900365|PROCEDURE|early cataract surgery & IOL implantation|first week cataract extraction and IOL implantation.
214414311|NCT02900365|PROCEDURE|late cataract surgery & IOL implantation|first month cataract extraction and IOL implantation.
214689083|NCT03382899|DRUG|Pembrolizumab|Pembrolizumab Alone
215017079|NCT05431751|DIETARY_SUPPLEMENT|Whole Algae|Whole Euglena gracilis algae, produced by proprietary fermentation.
215017080|NCT05099276|DRUG|Tranexamic Acid Pill|1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
215017081|NCT05099276|DRUG|Placebo|Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
214414312|NCT03917706|OTHER|Questionnaire|Patients will be contacted by phone in order to fill in a questionnaire regarding their quality of life.
214414313|NCT01881919|DIETARY_SUPPLEMENT|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
214414314|NCT01881919|DIETARY_SUPPLEMENT|Control|Address: Fagron GmbH\&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
214414315|NCT00578617|DRUG|Rate Control|Metoprolol 50-100mg
214414316|NCT00578617|DEVICE|Ablation Therapy|
214414317|NCT00578617|DRUG|Rate Control|Atenolol 50-100mg,
214414318|NCT00578617|DRUG|Rate control|Propranolol 40-80mg
214414319|NCT00578617|DRUG|Rate control|Acebutolol 200mg
214414320|NCT00578617|DRUG|Rate control|Carvedilol 6.25mg
214414321|NCT00578617|DRUG|Rate Control|Diltiazem 180-240mg
214414322|NCT00578617|DRUG|Rate Control|Verapamil 180-240mg
214414323|NCT00578617|DRUG|Rate Control|Digoxin 0.125mg
214414324|NCT00578617|DRUG|Rhythm Control|Propafenone 450mg
214414325|NCT00578617|DRUG|Rhythm control|Flecainide 200mg
214414326|NCT00578617|DRUG|Rhythm control|Sotalol 240mg
214689084|NCT02526927|DEVICE|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
214689085|NCT02526927|DEVICE|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (\< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
214689086|NCT02526927|OTHER|Blood samples|
214689087|NCT01355068|DRUG|Epanutin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
214689088|NCT01355068|DRUG|Dilantin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
214689089|NCT03387124|OTHER|Breastfed infants|Breastmilk
214414327|NCT00578617|DRUG|Rhythm control|Dofetilide 500mcg
214414328|NCT00578617|DRUG|Rhythm control|Amiodarone 200mg
214414329|NCT00578617|DRUG|Rhythm control|Quinidine 600-900mg
214414330|NCT02814305|BEHAVIORAL|Financial|Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy
214689090|NCT05590195|DRUG|Preforpro|Preforpro will be investigated to improve vaginal health in women with BV.
214689091|NCT05590195|OTHER|Placebo|Placebo capsules manufactured to look like Preforpro capsules
214689092|NCT02110810|DRUG|Indomethacin|Indomethacin suppository of 100 mg immediately afterwards while still under sedation
214689093|NCT02110810|DRUG|2.6-g suppository of glycerin|to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
214689094|NCT00524745|BIOLOGICAL|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
214689095|NCT03702582|DRUG|Rivaroxaban|Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation
214689096|NCT03702582|DRUG|Warfarin|Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation
214689097|NCT02689336|BIOLOGICAL|Erlotinib|
214689098|NCT02689336|DRUG|Temozolomide|
214689099|NCT02028364|DRUG|Everolimus|10mg orally daily
214689100|NCT02028364|DRUG|Exemestane|25mg orally daily
214689101|NCT04350658|PROCEDURE|Transcatheter aortic valve implantation required for symptomatic aortic stenosis|The procedure is performed via transfemoral or transcarotid access; Patients were confirmed to be eligible for TAVR by a multidisciplinary heart team including at least an interventional cardiologist, a cardiothoracic surgeon and an anesthetist. All TAVR implantation procedures were performed with the Edwards SAPIEN 3 THV or the MEDTRONIC CoreValve EVOLUT . For all patients, both vascular access and aortic valve were evaluated before the procedure by multislice computerized tomographic angiography (MSCT) of the entire aorta using vascular windows settings. The prosthesis and the vascular access were left to the discretion of the operating team. Transfemoral access was the first choice when possible. All TAVR procedures were performed in the same hybrid room (in Montpellier University Hospital), Most TAVR were performed under sedation or general anesthesia using mild low profile 14-16 French delivery systems and using percutaneous or surgical vascular access.
214689102|NCT00872170|DRUG|Sildenafil|"Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"
215017082|NCT05615961|DIETARY_SUPPLEMENT|Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)|The intervention is a unique blend of probiotic cultures from a well-established manufacturer.
215017083|NCT05615961|DIETARY_SUPPLEMENT|Placebo|Placebo Tablets
215101720|NCT06034561|DRUG|Bortezomib|Patients should receive one or two courses of this regimen, aiming to achieve complete remission as a bridge to proceed with allogeneic HSCT.
214414331|NCT02814305|BEHAVIORAL|Educational|Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
214414332|NCT04782999|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Standard test of glucose tolerance with ingestion of 75 g glucose followed by blood sampling.
214414333|NCT04782999|DIAGNOSTIC_TEST|Hyperglycemic clamp with infusion of saline, GLP-1 or GIP|"Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~* Saline~* GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~* GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min)."
214414334|NCT05629364|DRUG|KIO-101|Randomized, Controlled
214414335|NCT00921830|DRUG|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
214414336|NCT00820118|DRUG|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~* atazanavir : 300 mg/d~* ritonavir : 100 mg/d~* abacavir 600 mg and lamivudine 300 mg : once a day~* tenofovir 245 mg and emtricitabine 200 mg : once a day"
214689103|NCT00540449|DRUG|TMC278|25 mg tablet once daily for 96 weeks
214689104|NCT00540449|DRUG|Efavirenz|600mg once daily for 96 weeks
214689105|NCT03801304|DRUG|Atezolizumab|Atezolizumab in IV infusions
214689106|NCT03801304|DRUG|Vinorelbine|Vinorelbine capsules
214689107|NCT05873101|DIAGNOSTIC_TEST|Mobilization With Movement (MWM)|Mobilization With Movement
214689108|NCT05873101|DIAGNOSTIC_TEST|Kelternborn Treatment Technique|Kelternborn Treatment Technique
214689109|NCT03590262|DRUG|Metformin|take the metformin 500mg twice or three times a day
214689110|NCT02329873|BEHAVIORAL|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
214689111|NCT03160404|DRUG|Zolpidem|The ZOLPIDEM group will be treated with zolpidem 10mg/night
214689112|NCT03160404|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
214689113|NCT04527016|PROCEDURE|Microbiota and eosinophils based therapy|"1. Blood eosinophils ≥3%+ mixed airway microbiota: 3 month course of FP 50 ug twice daily via spacer~2. Blood eosinophils\<3%+ Moraxella species\>40% in airway microbiota: Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~3. Blood eosinophils ≥3%+ Moraxella species\>40% in airway microbiota: 3 month course of FP 50 ug twice daily via spacer and Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~4. Blood eosinophils\<3%+ mixed airway microbiota: intermittent budesonide inhalation suspension (1mg twice daily) and terbutaline inhalation suspension for 7 days during wheeze episode.~The participants will be followed up for one year after the intervention."
215101721|NCT04674488|BIOLOGICAL|TILs|a single center, single-arm, open label, interventional study
214414337|NCT05523258|BEHAVIORAL|Computerized cognition training|The researchers distribute tablet computers for the patients. The patients in this group receive cognitive function training under the guidance of a full-time cognitive function trainer. The training time is about 45-60 minutes every time, and the frequency is twice a day until the operation. After the operation, cognitive function training should be started as soon as possible when the patient meets the following conditions including Glasgow score ≥ 12, no mechanical ventilation and no sedative drugs. The training intensity is the same as that before operation, generally starting from the 2nd to 3rd day after operation and continuing to discharge or the 7th day after operation.
214414338|NCT05523258|BEHAVIORAL|Basic training based on tablet computer|The researchers distribute the same tablet computer to the patients. The patients in this group receive basic training under the guidance of a full-time cognitive function trainer. The training duration is the same as that of the test group.
214689114|NCT04527016|DRUG|Clinical guidelines based therapy|"The children will be treated as directed by their paediatrician ( The clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016).The treatment protocols include:~1. regular inhaled FP 50 ug twice daily via spacer for 3 months;~2. montelukast(4mg od for 3 months)~3. intermittent budesonide inhalation suspension (1mg twice daily for 7 days during wheeze episode).~The participants will be followed up for one year after the intervention."
214414339|NCT00921739|RADIATION|Esophageal sparing IMRT|6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
214414340|NCT04511650|DRUG|Razuprotafib Subcutaneous Solution|Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
214689115|NCT06198621|DEVICE|cardiometry|cardiometry is noninvasive method, while swan ganz is invasive method in hemodynamic parameters assessment
214414341|NCT04511650|DRUG|Placebo Subcutaneous Solution|Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
214689116|NCT00252902|BEHAVIORAL|Behavior change counseling|
214689117|NCT04352634|OTHER|Exposure to the SARS-CoV-2 and its consequences|This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
214689118|NCT03136549|OTHER|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
214689119|NCT03136549|OTHER|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
215017084|NCT05558254|OTHER|Robert - intervention to enhance muscle strength|"Intervention:~Training will be conducted with the robot ROBERT®. 3 times a week for 8 weeks the patient will conduct 60 repetitions of hip flexion of one leg. The patient is lying supine. ROBERT is attached to the patient's lower leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. The ROBERT is attached to the patient's lower leg and thereby eliminating the gravity of the leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. ROBERT is set in active or guided mode and will be individually adjusted. When practice starts the patient get visual feedback to the range of movement of the hip flexion plus the amount of repetitions conducted and persisting."
215017085|NCT02257021|DRUG|BILR 355 BS|
215017086|NCT02257021|DRUG|Tipranavir|
215017087|NCT02257021|DRUG|Low dose of ritonavir|
215017088|NCT02257021|DRUG|High dose of ritonavir|
215017089|NCT03480516|DEVICE|SDF|38% silver diamine fluoride solution
215017090|NCT03480516|DEVICE|Fluoride varnish|5% sodium fluoride varnish
215017091|NCT00147537|DRUG|CP-751,871|"Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles"
215017092|NCT00147537|DRUG|paclitaxel|"Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles"
215017093|NCT00147537|DRUG|carboplatin|"Phase 2 Arm A:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles"
215017094|NCT00147537|DRUG|CP-751,871|Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
215017095|NCT00147537|DRUG|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
215017096|NCT00147537|DRUG|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
215017097|NCT00147537|DRUG|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
215017098|NCT05469178|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
215017099|NCT05469178|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.
215017100|NCT05469178|DRUG|Pemetrexed|Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
215017101|NCT05469178|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.
215017102|NCT03041480|DIAGNOSTIC_TEST|serum lipid levels and Lp-PLA2|Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
215017103|NCT05922735|BEHAVIORAL|Questionnaire|Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox
215017104|NCT06130033|DEVICE|Neuromonitoring|"Multimodal Neuromonitoring:~Transcranial Doppler - middle cerebral artery blood flow velocity Jugular venous bulb oximetry - hemoglobin oxygen saturation at the jugular venous bulb Arterial blood pressure monitoring - mean arterial, systolic and diastolic pressure monitoring at the radial artery via an in situ radial arterial line catheter Pulmonary artery catheter - to measure continuous cardiac output and mixed venous oxygen saturation Near infrared spectroscopy - to measure regional cerebral saturation of oxygen"
215017105|NCT00406731|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
215101722|NCT05412368|OTHER|Focus Groups|Focus Groups
214414342|NCT05272124|OTHER|Hip Abductor Strengthening|"Elastic resisted training of Hip Abductors (5-10 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
215017106|NCT00406731|DRUG|Endothelin-1 (ET-1)|5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
214414343|NCT05272124|OTHER|Traditional Physical Therapy|"Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
214414344|NCT04806113|BIOLOGICAL|Moderna COVID-19 vaccine|Two doses from the Moderna vaccine will be administered intramuscularly. The time between dose 1 and dose 2 of the vaccine will be 28 days.
214414345|NCT00590850|PROCEDURE|ORIF with Plate and Screws|ORIF with plate and screws
214414346|NCT00590850|PROCEDURE|Pin Fixation|Clavicle fixation with clavicle pin
214414347|NCT04878796|DIAGNOSTIC_TEST|Serum collection, adverse events collection|Measuring Abs variation at different timepoints compared to baseline. LIAISON SARS-Cov-2 TrimericS IgG and Elecsys anti-SARS-Cov-2 tests will be adopted. The level of Abs will be evaluated at baseline and 30(±7), 180(±7),365(±7)days after the 2nd dose of vaccine
214414348|NCT06360016|BEHAVIORAL|Recreation Activity Program|Students in the study group were subjected to a 24-session RAP, including entertaining games. This program was conducted by the first-name researcher, who had completed their undergraduate education in preschool education and was supported by the second and third-named researchers as assistant instructors. The 24-session program, which included rhythm, balance, and patience acquisition games, was planned according to a game theory model that primarily aimed to entertain children. The program, aimed at developing children's self-regulation skills based on fundamental reflections of the model, would consist of simple rule-based entertaining games. Before the program's application, researchers provided information about the research and program to the experimental group, and verbal consent was obtained.
214414349|NCT02646670|DRUG|Ranibizumab|\- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
214414350|NCT02646670|DRUG|Aflibercept|\- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
214414351|NCT02646670|DRUG|Ranibizumab and Aflibercept|\- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
214414352|NCT02646670|DRUG|Aflibercept and ranibizumab|\- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
214414353|NCT03651531|DRUG|Insulin|Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.
214414354|NCT03651531|DRUG|Metformin|Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
214414355|NCT02247258|DRUG|Azathioprine|See arm/group descriptions
214414356|NCT02247258|DRUG|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
214414357|NCT02247258|PROCEDURE|Ileocolonoscopy|See arm/group descriptions
214414358|NCT02247258|PROCEDURE|Small bowel follow trough|See arm/group descriptions
214414359|NCT03099824|DRUG|GC4711 Oral Capsule G-101|82 mg (1 capsule)
215017107|NCT00406731|DRUG|Physiologic saline solution (placebo control)|intravenous infusion over 20 minutes; twice on 1 study day
215017108|NCT00406731|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
215017109|NCT00406731|DEVICE|Goldmann applanation tonometer|Intraocular pressure measurements
215017110|NCT00406731|DEVICE|HP-CMS patient monitor|blood pressure and pulse rate measurements
214414360|NCT03099824|DRUG|IV GC4419|GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
214414361|NCT03099824|DRUG|GC4711 Oral Capsule G-101|164 mg (2 capsules)
214414362|NCT03099824|DRUG|GC4711 Oral Capsule G-101|246 mg (3 capsules)
214414363|NCT03099824|DRUG|GC4711 Oral Capsule G-111|175 mg (1 capsule)
214414364|NCT03099824|DRUG|GC4711 Oral Capsule G-112|145 mg (1 capsule)
214414365|NCT03099824|DRUG|GC4711 Oral Capsule G-119|233 mg (1 capsule)
214414366|NCT03099824|DRUG|GC4711 Oral Capsule G-125|233 mg (1 capsule)
214414367|NCT03099824|DRUG|IV GC4711|GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
214414368|NCT04619303|DRUG|Dexamethasone intravitreal implant|Intravitreal injection of 0.7mg dexamethasone implant
214414369|NCT04619303|DRUG|Bevacizumab Injectable Product|Invtravitreal injection of 1.25mg/0.05mL bevacizumab
214414370|NCT05939648|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
214414371|NCT05939648|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
214414372|NCT03610997|PROCEDURE|Photorefractive keratectomy|
215017111|NCT00406731|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
215017112|NCT03958487|BEHAVIORAL|Video feedback, Feedback online|The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
215017113|NCT00013299|DEVICE|Prevention of Diabetic Ulcers|
214414373|NCT05826678|DEVICE|Continuous Glucose Monitor|The Clinical Diabetes Educator (CDE) will follow up with the participants at Month 1 after the baseline study visit, at the study midpoint (Month 3), and at the end of the study (Month 6) to check CGM usage, including timely calibration and change adherence. At the end of the study, participants will be invited to complete a survey and participate in virtual interviews to assess changes in their health behaviors and the acceptability of CGM devices.
214414374|NCT05826678|BEHAVIORAL|Finger stick glucose monitoring|Participants will adhere to the standard care protocol and continue self-monitoring of blood glucose through fingersticks as per usual practice\[46\]. The Clinical Diabetes Educator (CDE) will monitor and provide follow-up to the control group participants as per the same schedule followed for the intervention group.
214414375|NCT06479733|PROCEDURE|buccal pedicle flap|For the first group (buccal pedicle flap group), outlining the full-thickness palatal flap 1 mm greater than the diameter of the underlying cover screw will be done, making a partial incision at the hinge portion of the created mini-pedicle flap to facilitate buccal rolling, de-epithelializing the mini-pedicle flap, then two small vertical incisions will be performed similarly mesial and distal to the screw border as wide as possible preserving the papilla and extending labially to include all the keratinized mucosa, elevating a full-thickness flap, then rolling of the pedicle flap into the created buccal pouch. The flap will be then sutured all around in place using a 5/0 vicryl suture
214414376|NCT06479733|PROCEDURE|connective tissue graft|For the second group (free CTG group), masticatory mucosa on the palate between palatal raphae and maxillary posterior teeth is the most common location for the donor site for free CTG. It will be obtained by harvesting and de-epithelializing FGG asbeing a CTG derived from de-epithelialization of FGG mainly composed of lamina propria. Then the donor site will be covered by gel foam , sutured and protected.
214414377|NCT06479733|PROCEDURE|acellular dermal matrix|"* For the third group (ADM group) , The matrix will be trimmed so that it is gently adapted to the artificial envelope created on the buccal aspect of the ridge.The matrix will be trimmed and beveled to make its adaptation into the artificial envelope easier. Before placement, matrix will be hydrated for 10 minutes in fresh human blood collected after flap elevation in each patient.~* For both second and third groups, graft will be carefully positioned under the buccal pouch, sutured to it, light pressure will be applied over the inserted graft with moist gauze for 10 minutes to minimize blood clot and dead space formation between the graft and the underlying bone."
214414378|NCT06479733|PROCEDURE|control group|only placement of dental implant without soft tissue augmentation
214414379|NCT02932358|OTHER|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
214414380|NCT02932358|OTHER|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
214414381|NCT05936892|OTHER|upper extremity aerobic training|upper extremity aerobic training \& baseline treatment will be given. Overall session time will be 40-45 minutes
214414382|NCT05936892|OTHER|upper extremity resistance training|upper extremity resistance training Overall session time will be 40-45 minutes
214414383|NCT00546520|DRUG|Ciclesonide|
214414384|NCT03045900|OTHER|Shaded bulk-fill resin composite|Dental bulk-fill resin composite with shades A1, A2, A3
215017114|NCT03768674|OTHER|Assessment of diagnoses, functioning and health services|Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services
215017115|NCT00699166|DRUG|DNK333|25 mg and 100 mg oral doses, each taken twice daily
215017116|NCT05866601|OTHER|Role-playing for learning the clinical interview|"Thirty-one first-year physiotherapy students will carry out the role-playing methodology to learn how to take a clinical history in physiotherapy.~Before and after the realization, they will be measured by means of a validated questionnaire in Spanish, the language in which they study, the variable of empathy and anxiety."
214414385|NCT03469154|OTHER|Dyad training method|The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.
214414386|NCT03469154|OTHER|Instructor led training method|The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
214414387|NCT00001886|PROCEDURE|Real time 3-dimensional stress echocardiography|
214414388|NCT05853224|DEVICE|Crosslinked Hyaluronic Acid (CLHA) Hydrogel with and without Lidocaine|The injection should be performed at variable depth of the skin (dermal or subdermal), depending on the area to be treated and on the product variants, in accordance to the IFU of the IPs
214414389|NCT00560014|DIETARY_SUPPLEMENT|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
214414390|NCT00560014|DIETARY_SUPPLEMENT|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
214414391|NCT01967407|PROCEDURE|Irreversible Electroporation (IRE)|Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
214414392|NCT02606409|DRUG|Dexmedetomidine|Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
214414393|NCT02606409|DRUG|Propofol|Propofol sedation at a starting dose of 10-70 µg/kg/hour.
214689120|NCT05108909|DEVICE|MRI, CT, and serum biomarkers|magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
215017117|NCT05351489|DRUG|Dexmedetomidine|Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .
215017118|NCT02523040|DRUG|Lenalidomide|
214414394|NCT05933122|OTHER|sexologist consult|"in the cohort called here, after the diagnosis of rectal cancer, patients will be seen by a sexologist before any kind of treatment for rectal cancer. Sexual dysfunctions will be assessed by a sexologist. After the surgery of rectal cancer, the sexologist will see them again to assess sexual dysfunctions after such a management of rectal cancer. If there is any discovery of a sexual dysfunction or aggravation of a previous one or alteration of sexual life, the sexologist will help the patients to improve their sexual quality of life."
214414395|NCT05933122|OTHER|standart of care|"in the cohort called elsewhere , patients will be treated according to standards of care, without specific care by a sexologist"
214414396|NCT04241224|DEVICE|Atherectomy|Endovascular treatment of peripheral arterial disease
214414397|NCT06041893|DRUG|ATG-LDPTCy|antithymocyte globulin with low dose post-transplant cyclophosphamide
214414398|NCT02012543|DIETARY_SUPPLEMENT|Agar jelly|
214414399|NCT03727854|DIETARY_SUPPLEMENT|Premeal protein enriched bar|Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
214414400|NCT03727854|BEHAVIORAL|Dietary modification|Subjects in this group will follow diabetes diet education.
214414401|NCT05005065|DRUG|IN-C005 X mg|Oral capsule
214414402|NCT05005065|DRUG|IN-A001 Y mg|Oral tablet
214414403|NCT05005065|DRUG|IN-C005 Y mg|Oral capsule
214414404|NCT05005065|DRUG|IN-C005 Z mg|Oral capsule
214414405|NCT00889694|DRUG|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
214414406|NCT00889694|DRUG|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
215017119|NCT01183637|DEVICE|Kensey Nash Corp. Cartilage Repair Device|To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
215101723|NCT03817112|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min
214689121|NCT01571037|DRUG|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
215017120|NCT01183637|PROCEDURE|Microfracture|To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
215017121|NCT05217966|RADIATION|Radiation: Single Pre-Operative Radiation Therapy|Ablative preoperative partial breast radiation therapy
214414407|NCT00889694|DRUG|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
214414408|NCT01640821|BEHAVIORAL|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
214414409|NCT06442254|OTHER|Virtual Reality|In the application, which will be done with VR glasses, a video of walking on Istiklal Street in Istanbul's Beyoğlu district will be watched.
214414410|NCT06513234|DRUG|Orelabrutinib and obinutuzumab|Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg
215017122|NCT02006654|DRUG|Placebo|Once daily, matching placebo capsules, orally
215101724|NCT03817112|DRUG|Propofol 10 MG/ML|Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
215101725|NCT03722524|DRUG|amlodipine / indapamide / perindopril arginine FDC|CCB / diuretic / ACE inhibitor
215101726|NCT02321761|DRUG|Amantadine hydrochloride|Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
215101727|NCT01764828|DRUG|Refametinib (BAY86-9766)|
214414411|NCT04696250|DRUG|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
214414412|NCT03699293|DRUG|celecoxib 200mg capsule|celecoxib 200mg twice a day for 4 weeks
214414413|NCT03699293|DRUG|naproxen sodium 550mg tablet|naproxen sodium 550mg twice a day for 4 weeks
214414414|NCT03699293|DRUG|Aspirin 81mg tablet|81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
215101728|NCT01764828|DRUG|Gemcitabine|
214414415|NCT05481411|DRUG|Olpasiran|Subcutaneous injection
214414416|NCT04951518|OTHER|VAN Stroke Scale|V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
214414417|NCT01081145|DRUG|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
214414418|NCT01081145|OTHER|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
214414419|NCT02197234|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
214414420|NCT02197234|DRUG|Simvastatin|Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
214414421|NCT02197234|DRUG|AZD9291 tablet dosing|AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
214414422|NCT02197234|PROCEDURE|Pharmacokinetic sampling - simvastatin|Blood sampling to measure simvastatin levels
214414423|NCT02197234|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
214414424|NCT01711307|PROCEDURE|operative|
214414425|NCT01711307|PROCEDURE|non-operative|casting within 48 hrs
214414426|NCT00953485|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
214414427|NCT01007708|DRUG|IDP-108|Topical application once a day for 48 weeks
214414428|NCT01007708|DRUG|Vehicle|Topical application once a day for 48 weeks
214414429|NCT01615809|DRUG|AMPHOTERICIN B|The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.
214414430|NCT04846101|OTHER|OMNISHADE|Anterior dental cavities (Class III, Class IV) will be restored with an omnishade composite material
214414431|NCT04846101|OTHER|MULTISHADE|Anterior dental cavities (Class III, Class IV) will be restored with conventional multishade composite material.
214414432|NCT04846101|DIAGNOSTIC_TEST|Instrumental Shade Analysis|Assessment will be performed by single operator using spectrophotometer (EASYSHADE) to detect color difference between tooth and restoration
214414433|NCT04846101|OTHER|Visual Shade Analysis|Visual assessment will be performed by two calibrated specialists to evaluate shade matching between the tooth and restoration
214689122|NCT01571037|DRUG|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
214689123|NCT03767205|DEVICE|Ankle Assist Robot|"1. overground walking in three conditions (with robot-torque on/with robot-torque off/without robot). During overground walking, gait function was measured using motion analysis, sEMG, and force plate~2. treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot). During treadmill walking, the metabolic energy expenditure was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy)."
214689124|NCT05360277|DRUG|Tislelizumab + Capecitabine|"Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
214689125|NCT05360277|OTHER|Best supportive care|Best supportive care
214689126|NCT02659111|OTHER|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
214689127|NCT02659111|OTHER|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
214689128|NCT06261138|DRUG|Transarterial chemoembolization|A 5-French RH catheter was then introduced to the celiac artery, superior mesenteric and artery common hepatic artery for angiography to determine tumor location, quantity, size, and vascularity. After confirmation by C-arm cone-beam computed tomography (CBCT), chemoembolization was administered by superselective catheterization of the branches of the tumor-feeding arteries using a 2.8-French coaxial microcatheter. For cTACE, oxaliplatin, raltitrexed and an emulsion containing idarubicin and ethiodized oil were infused for over 20 minutes, followed by combined embolization with blank embolic microspheres. For DEB-TACE, DC/LC Beads® (Biocompatibles, Farnham, Surrey, UK), as drug carriers and embolic materials, were loaded with doxorubicin hydrochloride and mixed with nonionic contrast medium. Real-time assessment of embolization was performed with the assistance of CBCT.
215017123|NCT02006654|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
215017124|NCT05206435|DRUG|Electronic Cigarette|Electronic Cigarettes are provided to replace tobacco cigarettes
215017125|NCT05206435|DRUG|Nicotine Lozenge|Nicotine Lozenges are provided to replace tobacco cigarettes
214414434|NCT04846101|OTHER|Patient satisfaction|Patient satisfaction of the final shade match will be assessed on a visual analogue scale
214414435|NCT05826431|DEVICE|Cubii elliptical|Low impact, portable, and compact elliptical for seated use.
214414436|NCT06298188|DRUG|Risankizumab|Risankizumab
214414437|NCT04654936|BEHAVIORAL|MIND diet|12 week MIND diet study: Participants access a website that is theory driven using the Behaviour Change Wheel to help motivate and promote MIND diet adherence. Participants are to consume MIND diet foods daily and meet MIND diet weekly recommendations
214414438|NCT04654936|BEHAVIORAL|MIND diet with no support|Participants are to consume MIND diet food recommendations over a 12 week period with no support except for a self-monitoring resource and MIND diet guidelines
214414439|NCT02375516|BEHAVIORAL|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
214414440|NCT00215306|DEVICE|CHARITÉ Artificial Disc|
214414441|NCT00215306|DEVICE|Anterior Interbody Fusion with BAK Cage|
214414442|NCT00127647|DRUG|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
214414443|NCT00127647|DRUG|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
214414444|NCT03357549|OTHER|Brief Motivational Intervention|The Brief Motivational Intervention is an intervention that use strategies are typical of patient-centered interventions. These strategies will help the interviewer to listen, to elicit important information, and to build rapport with the patient and should be used throughout the intervention. The four strategies are Open-Ended Questions, Affirmations, Reflections and Summaries. The objective of de BMI is to increase the client motivation to adopt healthy initiatives, and to increase their self-efficacy to reach their own objectives.
214414445|NCT03357549|OTHER|Breastfeeding education|It's a common educational intervention about breastfeeding. The women will receive the information by a leaflet with information about breastfeeding and community resources and they will receive verbal information during 20-30 minutes to resolve their doubts.
214414446|NCT04771273|DRUG|Survodutide|Survodutide
214414447|NCT04771273|DRUG|Placebo|Placebo
214414448|NCT00164489|BEHAVIORAL|Weight control and physical activity promotion|
214414449|NCT06631924|DEVICE|Implant|Intramedullary headless hardware systems were utilized to place hardware in85 a retrograde manner from the metacarpophalangeal joint.
214414450|NCT01543685|DRUG|Indomethacin|40 mg TID capsules
214414451|NCT01543685|DRUG|Indomethacin|40 mg BID capsules
214414452|NCT01543685|DRUG|Indomethacin|20 mg TID capsules
214414453|NCT01543685|DRUG|Celecoxib|200 mg capsules
214414454|NCT01543685|DRUG|Placebo|Capsules
214414455|NCT02321358|BEHAVIORAL|Two-time implementation intention|Will be given intervention and booster at six weeks
214414456|NCT02321358|BEHAVIORAL|One-time implementation intention|Will only be given the intervention once
214414457|NCT02321358|BEHAVIORAL|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
214414458|NCT02321358|BEHAVIORAL|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
214414459|NCT03739411|RADIATION|Hyperpolarized Carbon C 13 Pyruvate|Given IV
214689129|NCT06261138|OTHER|Systemic treatment|"sorafenib (Bayer HealthCare, Berlin, Germany), lenvatinib (Eisai, Tokyo, Japan), apatinib (Hengrui Pharmaceuticals, Lianyungang, China) and donafenib (Zelgen Biopharmaceuticals, Suzhou, China), while a minority of patients received bevacizumab (Innovent Biologics, Suzhou, China).~sintilimab (Innovent Biologics, Suzhou, China), toripalimab (Junshi Biosciences, Suzhou, China), camrelizumab (Hengrui Pharmaceuticals, Lianyungang, China), tislelizumab (BeiGene, Shanghai, China), pembrolizumab (Merck Sharp \& Dohme, NewJersey, USA), nivolumab (Bristol Myers Squibb, New York, USA), atezolizumab (Roche, Basel, Switzerland) and envafolimab (Alphamab Biopharmaceuticals, Suzhou, China)."
215017126|NCT05396391|DRUG|IAP0971|IAP0971 should be subcutaneous injected，q2w
215017127|NCT03176199|DRUG|Oxycodone|Every 12 hours for control-released oxycodone (OxyContin®)
215017128|NCT03176199|DRUG|Oxycodone|Every 6 hours for immediate-released oxycodone (OxyNorm®)
214414460|NCT03739411|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214414461|NCT03739411|RADIATION|Radiation Therapy|Undergo radiation therapy for cancer outside of this study.
214414462|NCT03739411|DRUG|Chemotherapy|Undergo chemotherapy for cancer outside of this study.
214414463|NCT06123585|OTHER|Invisalign® SmileView™|Pretreatment smiles were captured using the Invisalign® SmileView™ to simulate their new smiles before treatment was started.
214414464|NCT06123585|OTHER|Invisalign aligners|Patients were then treated using upper and lower Invisalign aligners with average treatment time of 12±3 months.
214414465|NCT05754463|OTHER|The effect of plyometric training on balance and proprioception in athletes in different branches|Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
214414466|NCT01871818|BEHAVIORAL|Combined program|Combined program with physiotherapy, endurance training and resistance training
214414467|NCT01871818|BEHAVIORAL|Physiotherapy in private practice|Physiotherapy in private practice
214414468|NCT02967237|DRUG|insulin glargine (U300)|Pharmaceutical form: solution Route of administration: subcutaneous
214414469|NCT02163915|DRUG|TAK-137|TAK-137 tablets
214414470|NCT02163915|DRUG|TAK-137 Placebo|TAK-137 placebo-matching tablets
214414471|NCT02013037|DRUG|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
214414472|NCT01394809|BEHAVIORAL|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
214414473|NCT06659289|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~The hemoperfusion procedure is performed at the time of cardiopulmonary bypass during cardiac surgery. The therapy (Efferon LPS hemoperfusion) is performed once. The duration of the procedure is limited by the time ofcardiopulmonary bypass."
214414474|NCT05201768|OTHER|balance tests,questionnaire|Individuals will be tested and recorded.
214414475|NCT06599021|BEHAVIORAL|Muscular strengthening training|6 weeks daily muscular strengthening training.
214414476|NCT06599021|BEHAVIORAL|Skill-based training|15 sessions skill based swallowing training lead by a speech and language pathologist during 3 weeks.
214414477|NCT02465359|DRUG|Immune Globulin Subcutaneous (Human)|Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
214414478|NCT01425762|OTHER|Drug Dose|100 versus 200 mcg IT morphine
214414479|NCT01304147|DRUG|Ketamine|A single dose of intranasal ketamine up to 50 mg
214414480|NCT01304147|DRUG|placebo|Single dose of saline intranasal
214414481|NCT00705991|PROCEDURE|ROTEM|
215017129|NCT02852746|BEHAVIORAL|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
215017130|NCT01298466|DRUG|Pregabalin|The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
214414482|NCT00865956|BEHAVIORAL|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
214414483|NCT00865956|OTHER|Case management|Nurse case manager assigned to participant
214414484|NCT00689156|DRUG|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
214414485|NCT00689156|DRUG|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
214414486|NCT03537573|BEHAVIORAL|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
214689130|NCT03362346|DEVICE|intracranial pressure monitoring|The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
214689131|NCT02458079|DRUG|Pentoxiphylline|
214689132|NCT02458079|DRUG|Stool microbiota transplantation|
215017131|NCT01391949|BEHAVIORAL|Detailed feedback|Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.
214414487|NCT03537573|BEHAVIORAL|Opioid Justification|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
214414488|NCT03537573|BEHAVIORAL|Provider Comparison|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (\> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (\> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
214414489|NCT06611176|DRUG|Local levobupivacaine|submucosal injection of levobupivacaine during esophageal esad
214414490|NCT06609876|PROCEDURE|Thermal ablation|Thermal ablation of tumors
214414491|NCT06609876|DRUG|Donafenib|Donafenib ( 100 mg，bid)
214414492|NCT06609863|PROCEDURE|dTACE-HAIC|dTACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then drug-eluting microspheres were used (100-300um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
214414493|NCT06610799|DRUG|IBI363|IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W
214689133|NCT04323709|OTHER|Data collection|Clinical data are collected from the medical record of the institution. At admission, date were collected on age, gender, body mass index, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment, hypertension, diabetes, hypercholesterolemia, smoking, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, Left Ventricular Ejection Fraction(LVEF), Tricuspid Annular Plane Systolic Excursion, mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump and biochemical parameters. During hospitalization data were collected on reason for initiation of VA-ECMO and its characteristics (duration, type, flow L/min, RPM, FiO2), length of stay in ICU, catecholamines and inotropes maximal dose and length of administration, patients with heart transplantation or LVAD. In patients with levosimendan treatment, timing of administration regarding ECMO canulation was collected
214689134|NCT04323709|OTHER|Data analysis|Continuous variables were presented as mean ± standard deviation and compared using Student's t-test or Mann-Whitney U-test depending on their normality. Categorical variables were presented as counts and percentages and compared using Pearson's chi-squared test or Fisher's exact test, as appropriate. Survival at day 28 was estimated using the Kaplan-Meier method and compared using the log rank test. Investigators conducted a multivariable logistic regression with propensity score matching, which was defined as the probability of exposure to levosimendan. Results were reported as odd ratios (ORs) together its 95%CI assuming a 5% level of statistical significance. All analyses were carried out using STATA 15.0 (Stata Corp, College Station, Texas 77845 USA).
214414494|NCT04092985|DEVICE|iECG recording|iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smart watch (Apple Watch Series 4) with the ECG application
214689135|NCT06673069|DRUG|ION269|Administered as intrathecal (IT) injection.
214689136|NCT03400696|BEHAVIORAL|Lower carbohydrate diet|Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
214689137|NCT03400696|BEHAVIORAL|Higher fiber diet|Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
215017132|NCT01391949|BEHAVIORAL|Basic feedback|Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
215017133|NCT02451735|BEHAVIORAL|Video and Booklet|Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
215017134|NCT02451735|BEHAVIORAL|Factsheet|Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
214414495|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
214414496|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
214414497|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transfemoral access and requiring a 29mm valve.
215017135|NCT00478140|BIOLOGICAL|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
215017136|NCT00478140|OTHER|laboratory biomarker analysis|Correlative studies
215017137|NCT03116815|OTHER|Direct input of home blood pressure readings via MyChart|Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
215017138|NCT02077712|DRUG|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
214414498|NCT02525705|BIOLOGICAL|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
214414499|NCT06613464|DIAGNOSTIC_TEST|diagnosis confirmation|The patients diagnoses will be confirmed though imaging methods like computed tomography chest x-ray and anamnesis
214414500|NCT06615297|DIAGNOSTIC_TEST|ultrasonographic evaluation|facial nerve thickness (right/left), depressor labi inferior, depressor anguli oris, buccinator and risorius muscles will be evaluated.
214414501|NCT06613425|COMBINATION_PRODUCT|Combined platelets|1 therapeutic dose combined platelet contained no less than 2.5 ×10\^11 platelets as a quality standard.
214414502|NCT06613399|PROCEDURE|MTI-TME|Multi-Technology Tntegrated Total Mesorectal Excision，MTI-TME
214414503|NCT06613399|PROCEDURE|C-TME|Conventional Total Mesorectal Excision，C-TME
214414504|NCT06614413|OTHER|Neurodevelopment and behaviour assesment 2 years old|Mothers: Monthly visits guided or not by nutritionist (intervention vs control group) will consist in food questionnaires and 3-day food diary collection during pregnancy. Every three months during lactation. Children: From one year of age onwards, the KIDMED questionnaire will be administered quarterly Neurodevelopment and behavior assessment 18-24 months of age
214414505|NCT06613919|DRUG|Anti-Tuberculosis Treatment|Standard, weight adjusted anti-TB therapy for six months
214414506|NCT06613919|DRUG|Anti-Tuberculosis Treatment|Standard, weight-adjusted anti-TB therapy for nine months
214414507|NCT06613815|OTHER|radiofrequency of the geniculate nerves|radiofrequency of the geniculate nerveswith a scopy-guided technique versus the ultrasound-guided technique
214414508|NCT06614023|PROCEDURE|coronary artery bypass grafting|surgical coronary revascularization
214414509|NCT06615453|DEVICE|Thermo-mechanical action based peri-orbital fractional skin treatment|Participants will receive three Tixel® treatments at 2-weeks intervals
214414510|NCT06615453|DEVICE|Sham treatment|Participants will receive three sham treatments at 2-weeks intervals
214414511|NCT00708097|DRUG|NaF|Fluoride
214414512|NCT00708097|DRUG|Placebo|Placebo
214414513|NCT00708097|DRUG|NaMFP|Fluoride
214414514|NCT06615492|DEVICE|Routine ECMO|Routine intraoperative venoarterial ECMO during lung transplant
214414515|NCT06615492|DEVICE|On-demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative venoarterial ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion despite volume resuscitation and vasopressor administration and in the absence of readily correctable cause~2. Inability to tolerate pulmonary artery clamping~3. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~4. Inadequate exposure to the surgical field~5. The transplant team is concerned about the ability to maintain organ perfusion or ventilate with a lung protective strategy, even if the aforementioned criteria are unmet.~6. Concerns about donor lung quality and a desire to protect the implanted lung from single lung perfusion"
214414516|NCT06614387|DRUG|Infliximab|Patients meeting the inclusion criteria and not having any of the exclusion criteria will be randomized 1:1 to one of two study arms - intravenous administration of blinded active drug, infliximab or vedolizumab at weeks 0, 2, 6 and 14. Infliximab will be administered at a dose 5mg/kg body weight, and vedolizumab at a dose of 300 mg (body mass \> 40 kg) and 10 mg/kg (body mass \< 40kg).
214414517|NCT00759200|DRUG|alb-interferon alfa 2b|900 mcg every 4 weeks
214414518|NCT00759200|DRUG|alb-interferon alfa 2b|1200 mcg every 4 weeks
214414519|NCT00759200|DRUG|alb-interferon alfa 2b|1500 mcg every 4 weeks
214414520|NCT00759200|DRUG|alb-interferon alfa 2b|1800 mcg every 4 weeks
214414521|NCT00759200|DRUG|peg-interferon|Peg-interferon alfa 2a: 180 mcg 1x per wk.
214414522|NCT05218915|DRUG|Dulaglutide|Dulaglutide once weekly subcutaneous
215017139|NCT06178913|OTHER|Exercise intervention|The exercise intervention method is a circuit training method that combines strength training and aerobic exercise forms and consists of a total of 12 movements. Performing movements 1 to 12 in order is 1 set. After completing the set, when the heart rate returns to the plateau (less than 59% of maximum heart rate), proceed to the next set, for a total of 3 sets.
215017140|NCT01933425|DRUG|rocuronium|
215017141|NCT01933425|DRUG|sugammadex|
215017142|NCT01933425|DRUG|placebo|
215017143|NCT03864549|DIETARY_SUPPLEMENT|Femina II|2 capsules per day until delivery
215017144|NCT03864549|OTHER|Placebo|2 capsules per day until delivery
215017145|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the first postoperative day
215017146|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the sixth postoperative day
215017147|NCT05174702|RADIATION|Irradiation collected at the end of the operation on the active dosimeter|Mesure of the irradiation collected at the end of the operation on the active dosimeter for the surgeon, the patient and the operating team
215017148|NCT05697692|DRUG|Heparin sodium|Lung transplantation on central veno-arterial ECMO with standard additional heparin
215017149|NCT05697692|DRUG|Placebo|Lung transplantation on central veno-arterial ECMO without additional heparin
215017150|NCT00676689|DEVICE|SAPIEN Transcatheter Valve Implantation|Device Implantation
214414523|NCT05218915|DRUG|Insulin Degludec|Insulin degludec once daily
214414524|NCT05218915|DEVICE|Continuous glucose monitor|Dexcom G6 CGM system
214414525|NCT06609850|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
214414526|NCT06609850|PROCEDURE|Ablation|Ablation (radiofrequency ablation, microwave ablation, cryoablation), ablation followed TACE within 6-8 weeks and Lenvatinib continued. Percutaneous ablation was performed by ultrasound or CT. The ablation success is evaluated by achieving an ablative margin of 0.5 cm or more than the tumor size.
214414527|NCT06609850|DRUG|Lenvatinb|Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day )
215017151|NCT04492293|DRUG|ICP-192|ICP-192 is a white, round, uncoated table
214505138|NCT05816707|BIOLOGICAL|PRF|"Teeth will be extracted a-traumatically as possible to avoid any soft tissue or bony damage.~The extracted sockets will be debrided by bone curettes and saline. The three extraction sockets will be divided into three groups: control group, curcumin group, and PRF group.~After curcumin/ PRF placement, all sockets will be closed by simple interrupted suture"
214505139|NCT05816707|BIOLOGICAL|Curcuma Longa gel|Curcuma Longa gel
215017152|NCT04999293|DRUG|Ticagrelor|Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
214505140|NCT05816707|OTHER|extraction socket|extraction socket
214505141|NCT03233997|OTHER|FT21018|An electronic cigarette
215017153|NCT03471949|OTHER|CGM in a population with normal OGTT|The population with normal OGTT will use CGM and document their values as well as be documenting a capillary blood glucose value
215017154|NCT00429455|BEHAVIORAL|Survey|3-Part Questionnaire
215017155|NCT04108260|DRUG|Albutrepenonacog Alfa 1 UNT [IDELVION]|Clinical data will be collected from patients who suffered from hemophilia B, and switch from other FIX products to Idelvion as prophylaxis, prevention of bleeding (e.g. surgery) or treatment of bleeding.
215017156|NCT05516407|DRUG|FEN164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
215017157|NCT00225602|BEHAVIORAL|Assertive Community Treatment|
215017158|NCT00225602|BEHAVIORAL|Treatment in Community Mental Health Center|
215017159|NCT01570582|DRUG|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
215017160|NCT06478615|PROCEDURE|Coring out Fistulectomy with Closure of Internal Sphincter Opening|The patient was laid in the lithotomy position. Skin preparation and draping were done. Normal saline irrigation was performed. The anal canal was sufficiently dilated to permit the introduction of a self-retaining retractor. With H2O2 injection into the fistula tract, the internal opening and tract of the fistula will be identified. The incision was made around the external opening, and the tract was all cored out along the tract from the external opening to the internal sphincter. Meticulous hemostasis will be performed, stay suture by PDS 4/0 around fistiolous opening at the internal sphincter, excision of fistulous tract above stay suture, then closure of internal sphincter defect by PDS 3/0. Anal packing with 4 × 4 epinephrine gauze and sterile protective dressing was performed. After the operation, a stool softener and pain controller were prescribed, and patients were discharged.
215017161|NCT06478615|PROCEDURE|Lay Open Fistulotomy and Primary Sphincter Repair|Patients were put in a lithotomy position and the skin was then draped. After identification of the external fistula orifice probing of the fistula tract with identification of the fistulous tract and internal orifice with H2O2 injection into the fistula tract. The fistula was laid open and fistulectomy was then conducted and dissected with diathermy cautery help. Then Primary repair of the sphincter with PDS 3/0 with proper hemostasis using coagulation diathermy.
215017162|NCT00730600|PROCEDURE|Thai Traditional massage|Thai traditional massage for 2 hours by a single masseuse.
215017163|NCT03438656|BEHAVIORAL|Behavioral Activation|The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
214505142|NCT03233997|OTHER|FT21033|An electronic cigarette
214505143|NCT03233997|OTHER|FT21034|An electronic cigarette
214505144|NCT03233997|OTHER|FT21035|An electronic cigarette
214505145|NCT06176014|PROCEDURE|implant placement|5 implant were placed in intraforaminal area using surgical guide
214505146|NCT01037868|OTHER|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
214505147|NCT00000178|DRUG|Prednisone|
214505148|NCT04266626|OTHER|kinesiotaping therapy|Kinesiotaping is a new therapeutic technique that gives support to the lip and tongue base muscles without restricting range of motion or blood flow.
214414528|NCT04332276|DRUG|A-dopamine|"During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days."
214414529|NCT04332276|DRUG|optimized oral treatment|The patient will received his usual dopaminergic treatment.
214414530|NCT06615128|DIAGNOSTIC_TEST|blood sampling|blood sample to detect sCD25 from systemic sclerosis and Healthy control.
214414531|NCT06615310|OTHER|ultrasonograpic evaluotion|The distance between the hyoid and thyroid cartilage, the volume of the geniohyoid, digastric anterior, sternohyoid and thyrohyoid muscles will be evaluated by ultrasound.
214414532|NCT01244828|DRUG|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
214414533|NCT06614426|PROCEDURE|Test group 1 (T1)|Test group 1 (T1): Open flap debridement using electrolysis decontamination
214414534|NCT06614426|PROCEDURE|Test group 2 (T2)|Test group 2 (T2): Open flap debridement using electrolysis decontamination combined with L-PRF application
214414535|NCT06614426|PROCEDURE|Control group (C)|Conventional open flap debridement
214414536|NCT06615024|DIAGNOSTIC_TEST|G6pd enzyme sickling test|Measuring the enzyme level of G6PD and presence of Hbs
214414537|NCT06615024|DIAGNOSTIC_TEST|G6PD enzyme and sickling test|Measuring enzyme level of G6PD and level of HbS
214414538|NCT06615024|DIAGNOSTIC_TEST|G6PD enzyme and HPLC|Measuring G6PD enzyme level in neonates and measuring level of HbS
214414539|NCT06527768|BEHAVIORAL|Theory-based health behaviour change interventio|The online individual education sessions are related to MetS, CKD, healthy dietary and PA, displayed in the form of texts and pictures, and online instant conversations via WeChat. The online group music-paced brisk walking training includes a 5-minute warm-up, 30-minute music-paced brisk walking, and 5-minute stretching exercises to promote cool-down. The group discussion is related to current health status, recommended dietary regimens, and exercise and personal goals. The telephone follow-up after the group discussion is to reinforce the predetermined goals and the practice of healthy dietary and music-paced brisk walking, and to provide opportunities for answering any questions related to the practice of healthy dietary and music-paced brisk walking. All the education session contents are based on a well-structured health handbook. The self-music-paced brisk walking is required to be performed for 30 minutes/day, 5 days/week.
214414540|NCT03484182|BEHAVIORAL|Web-based Home Exercise Program|Home exercises that are guided by a web-based program
214414541|NCT03484182|BEHAVIORAL|Standard Home Exercise Program|Standard paper-based home exercise program
214414542|NCT05397470|DRUG|Losmapimod|Losmapimod 15 mg will be administered BID by mouth along with food.
214414543|NCT05397470|DRUG|Placebo oral tablet|Placebo will be administered BID by mouth along with food.
214414544|NCT06616688|OTHER|Organoid-guided treatment|After specimen removal as per clinical practice and pathological examination, a small piece of tumor tissue will be sent to the Axo-Glial Interaction Unit and cultured to build up organoid cultures
214414545|NCT06607731|OTHER|Collecting data from medical records|Data collected: clinical data (particularly pain), biological data, imaging.
215017164|NCT05692557|DEVICE|Virtual reality|"The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there."
215017165|NCT05692557|PROCEDURE|Progressive muscle relaxation|The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
214689138|NCT03400696|BEHAVIORAL|Physical activity focused|Focused on aerobic and resistance exercise, while following dietary guidelines \<https://www.choosemyplate.gov\>
215017166|NCT00684554|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
214414546|NCT06598852|OTHER|TPVB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB Group received thoracic paravertebral nerve block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
214414547|NCT06598852|OTHER|ESPB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ESPB Group received erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
214414548|NCT06598852|OTHER|TPVB combined ESPB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB combined ESPB group received thoracic paravertebral block combined with erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
215017167|NCT00052897|BIOLOGICAL|HspE7|
214414549|NCT06598852|OTHER|ICNB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ICNB Group received intercostal nerve block for postoperative analgesia.
214414550|NCT05565521|RADIATION|Dose escalation + Reduced Margin Adaptive Radiotherapy|Concurrent chemoradiation with temozolomide (TMZ) over 3 weeks (40 Gy in 15 fractions). The gross tumor volume (GTV) plus margin will be boosted simultaneously (SIB) to 52.5 Gy in 15 fractions. Radiation will be delivered on the MR-Linac with a reduced clinical target volume (CTV) margin of minimum 5 mm and a weekly online adaptive approach.
214689139|NCT01225640|DRUG|PNU-100480|600 mg twice daily (BID) for 14 days
214689140|NCT01225640|DRUG|PNU-100480|1200 mg once daily (QD) for 14 days
214689141|NCT01225640|DRUG|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
214414551|NCT06668740|BEHAVIORAL|The use of Virtual Reality Glasses in Elderly|The group first completed a pretest, after which they watched 360-degree VR videos, such as nature walks and trips, for 10 minutes once a week over four weeks. Following this, a posttest was conducted. The outcomes will be used to measure changes in Quality of Life.
214414552|NCT05621655|BIOLOGICAL|Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine|0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
214414553|NCT05621655|BIOLOGICAL|High dose Recombinant Trivalent Subunit Rotavirus Vaccine|0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
214414554|NCT05621655|BIOLOGICAL|Placebo|0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.
214414555|NCT06614335|OTHER|After 6 months of observation, there was still a residual inclination of more than 15 prism degrees which needed to be corrected by a second operation|All IE patients enrolled were patients who had undergone corrective surgery for strabismus. Postoperative strabismus with 10 prism degrees of overcorrection or undercorrection is within the normal range. During postoperative follow-up, patients with more than 10 prism degrees of residual esotropia were treated conservally with foot orthoscopy according to their refractive status. After 6 months of observation, there were still more than 15 prism degrees of residual esotropia that needed to be corrected by a second operation. For extropia with overcorrection greater than 10 prism degrees, cross-eye training, negative mirror + prism stimulation and conservative observation and fusion training are given in the early stage, and can not be improved within 6 months, requiring a second surgical correction.
214414556|NCT06614634|OTHER|Remotely supervised exercise at home or outdoors|Aerobic and strengthening exercise program at home/outdoors at least three days a week for four weeks using a Polar H9 heart rate monitor and elastic band.
214414557|NCT06614634|OTHER|Hospital-based exercise program|The aerobic and strengthening exercise program three days a week for four weeks under supervision in our cardiopulmonary rehabilitation unit.
214414558|NCT06614634|BEHAVIORAL|Cardiovascular risk modification|Psychosocial support for physical activity counselling, heart-healthy diet, referral for smoking cessation and stress management.
214414559|NCT06614634|OTHER|Phone calls with reinforcement feedback|Calls once a week that include symptom inquiries and encouraging feedback on exercise logs.
215017168|NCT01269320|DRUG|Femarelle|Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
215017169|NCT00563316|DRUG|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
215017170|NCT00563316|DRUG|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
215017171|NCT00906750|BIOLOGICAL|FluMist|FluMist is a live attenuated intranasal influenza vaccine
214414560|NCT05518110|DRUG|Trametinib|2mg of Trametinib (orally) daily.
214414561|NCT05518110|DRUG|Hydroxychloroquine|1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
214414562|NCT01278862|DEVICE|DVS veneer|CAD/CAM milled porcelain veneer for Lava crown
214414563|NCT01278862|DEVICE|Conventional Veneer|CAD/CAM milled Lava crown with lab fabricated veneer
214414564|NCT06622408|OTHER|HypnoVR© virtual reality headset|Adherence to the use of the virtual reality headset will be reported by a percentage of use at each stage of care.
214414565|NCT05799222|DIETARY_SUPPLEMENT|Bariatrix Meal Replacement Products|Meal replacement products offered through the Massachusetts General Hospital Weight Center.
214414566|NCT03808922|DRUG|DAS181|DAS181 4.5mg nebulized qd x 7 OR 10 days
214414567|NCT03808922|DRUG|Placebo|Placebo nebulized qd x 7 OR 10 days
214414568|NCT03808922|DRUG|DAS181 COVID-19|DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
214414569|NCT03808922|DRUG|DAS181 OL|DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days \< 40kg
215017172|NCT00906750|BIOLOGICAL|Inactivated influenza vaccine|Inactivated influenza vaccine
215017173|NCT01155310|DRUG|Helium/Oxygen 78%/22%|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
215017174|NCT01155310|DRUG|Air/Oxygen|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
215017175|NCT05336760|DIAGNOSTIC_TEST|Iowa Oral Performance Instrument (IOPI)|IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.
215017176|NCT05336760|DIAGNOSTIC_TEST|Mann Assessment of Swallowing Ability (MASA)|MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.
215017177|NCT05336760|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).
215017178|NCT05336760|DIAGNOSTIC_TEST|Respiratory function measurements|Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
215017179|NCT04972175|DRUG|50-Hour Intervention - Rapid Insulin lispro|Subcutaneous-delivery of insulin lispro using pump therapy.
214414570|NCT05870930|OTHER|Carob beverage|Volunteers will consume 2 tablespoons of carob powder in 200mL drinking water.
214414571|NCT04968574|DRUG|taladegib|hedgehog pathway inhibitor dosed once daily
214414572|NCT04968574|DRUG|placebo|identical tablets to the experimental arm with no active ingredient
214414573|NCT05210894|BIOLOGICAL|Anti-IL8|
215017180|NCT04972175|DRUG|50-Hour Intervention - BC LisPram|Subcutaneous-delivery of BC LisPram using pump therapy.
215017181|NCT04217057|DRUG|64Cu-DOTA-ECL1i|Will be produced by the Cyclotron Facility at Washington University School of Medicine
214414574|NCT02952261|DEVICE|template-guided localization|Based on CT data, digital model of the navigational template was created using CAD software and imported to 3D printer. The navigational template serves as a guider to the localizer in lung nodule localization.
214414575|NCT02952261|OTHER|CT-guided localization|Percutaneous lung nodule localization was conducted under the real-time guidance of CT scan. This is the conventional method of transthoracic lung nodule localization.
215017182|NCT02468700|DRUG|Dexamethasone|
214414576|NCT06613958|BEHAVIORAL|Physical activity timing|The investigators will compare our interventions to a 14-day period of sedentary behavior, during which the participant will refrain from any moderate to vigorous exercise. Next, participants will participate in two interventions consisting each of a 14-day physical activity regimen. The active morning and active evening interventions are equal in content. Both groups will be instructed to refrain from any moderate to vigorous exercise for the rest of the day. Per intervention, a total of eight Vitality Club training session comprising of a combination of aerobic endurance training and resistance exercise training will be given by a trained sports coach or physical therapist specialized in geriatric physical therapy. During the weekends, participants will be asked to perform a 'relative rest' session with some light activity during the training time window of the intervention arm.
214414577|NCT06614257|DRUG|LG-TAP block with local anesthetic|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
214414578|NCT06614257|PROCEDURE|Port site infiltration|Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon
214414579|NCT06614257|DRUG|LG-TAP block with saline solution|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
214414580|NCT00603447|DRUG|Carfilzomib|Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
214414581|NCT00603447|DRUG|Lenalidomide|Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
214414582|NCT00603447|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
214414583|NCT06614231|DRUG|Tislelizumab Combined With Chemotherapy|Tislelizumab 200mg Q3W，Platinum-containing dual drug chemotherapy
214414584|NCT06615063|OTHER|Hasi's Splint|A splint made up of cotton and gauze piece rolled over a hard cardboard piece and covered by adhesive tape was applied to the limb immediately after fixing the cannula, as per the standardised method, to prevent movement at the underlying joint. Dimensions of the splints used were standardised as length extending two and a half inches on either side of the joint and width equal to the width of the limb just proximal to the joint.
214414585|NCT02165059|PROCEDURE|Surgical Full Thickness Biopsy|Eligible subjects will undergo a surgical full thickness biopsy of the stomach and/or proximal jejunum as part of their planned surgery.
214414586|NCT03193567|BIOLOGICAL|HEKT cell|3 cycles of HEKT cell treatment
214414587|NCT05233085|DRUG|AZD4041|Participants will receive oral solution of AZD4041 as stated in arm description.
214414588|NCT05233085|OTHER|Placebo|Participants will receive oral solution of placebo as stated in arm description.
214414589|NCT06693739|PROCEDURE|Platelet rich fibrin|PRF membrane is placed as a scaffold inside the canal with no hyaluronic acid
214414590|NCT06693739|PROCEDURE|hyaluronic acid|hyaluronic acid gel is placed as a scaffold inside the canal with no PRF
214414591|NCT06693739|PROCEDURE|no scaffold|initiate bleeding using hand files size beyond apex with sharp strokes with no PRF or hyaluronic acid placed
214414592|NCT06692556|RADIATION|Adjuvant radiotherapy|"Patients will receive an adjuvant radiotherapy corresponding to an equivalent dose of 45 to 50 Gy (Equivalent Dose in 2 Gy Fractions \[EQD2\] with a tumor alpha/beta ratio of 10 Gy) delivered on the operating bed.~Patients will be treated by :~* either external radiation therapy using high-energy electrons or photons:~  * 45 Gy in 15 fractions of 3 Gy~ * 50 Gy in 25 fractions of 2 Gy~* or interstitial brachytherapy or brachytherapy via skin applicators:~  * 36 Gy in 8 fractions of 4.5 Gy~ * 36 Gy in 9 fractions of 4 Gy~ * 40 Gy in 8 fractions of 5 Gy~Radiation therapy should be started within 8 weeks after surgery (or 10 if delayed healing).~Patients will be monitored regularly until the date of the first relapse (local, regional or metastatic), or until the date of death (if no relapse).~Regardless of the type of relapse, remedial treatments will be left to the the investigator's discretion up to the first metastatic relapse."
214414593|NCT05416749|DRUG|8MW2311|All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
214414594|NCT00798265|BIOLOGICAL|Gardasil|.5 mL dose injected intramuscular (IM) at 0, 2 and 6 months
214414595|NCT00798265|BEHAVIORAL|Survey|Administration of online risk behavior and knowledge survey done at week 0.
214505149|NCT04266626|OTHER|oral motor manipulation therapy|Manipulation therapy include tapping and massage of oral motor muscles including orbicularis oris and base of tongue.
214505150|NCT06055491|DRUG|Vitamin D3 or Saline injection at ipsilateral deltoid muscle|study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection
214505151|NCT01427816|DRUG|KCT-0809|
215017183|NCT02468700|OTHER|Placebo Vehicle|
215017184|NCT01217411|PROCEDURE|Cognitive Assessment|Ancillary studies
215017185|NCT01217411|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
214505152|NCT01427816|DRUG|KCT-0809|
214505153|NCT01427816|DRUG|Placebo|
214505154|NCT00546156|DRUG|Doxorubicin|Standard chemotherapy regimen
214505155|NCT00546156|DRUG|Cyclophosphamide|Standard chemotherapy regimen
215017186|NCT01217411|OTHER|Laboratory Biomarker Analysis|Correlative studies
215017187|NCT01217411|RADIATION|Stereotactic Radiosurgery|Undergo SRS
215017188|NCT01217411|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
214414596|NCT05177341|OTHER|Determining Preferred Walking Speed|In the beginning, sensors of the gait analysis system (RehaGait®), which can record the time-distance characteristics of consecutive multiple steps (step length, step width, double step length, and timing information, etc.) will be installed. The 7 sensors of this system are attached to the shoes of the individual, proximal to the ankle, distal thigh, and sacroiliac joint level (Aminian et al., 2014). Individuals will be required to wear casual athletic shoes and comfortable, non-knee-covering shorts. Next; Each individual will walk freely on the treadmill at their own pace. To find the preferred walking speed of the individual, Hinton et al. protocol will be used (Hinton et al., 2018). The speed of the treadmill will be increased or decreased in line with the direction of the participants. After being determined according to the protocol, the individual will practice walking at this speed for 4-5 minutes. The individual will rest as much as he or she wants.
214414597|NCT06629545|OTHER|irrigation activation with PUI|The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device. The power setting of the ultrasonic device was 30% (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 2.5% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 1 mm behind the working length without touching the canal walls.
214414598|NCT06629545|OTHER|irrigation with sonic activation|A suitable-size activator tip (#25/.04) attached to an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA) was inserted into the canal 1 mm short of the working length. 3 ml of 2.5% NaOCl solution was activated in three periods of 20 s (1 ml of 2.5% NaOCl in each cycle). Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
214414599|NCT06628726|DIAGNOSTIC_TEST|Liver biopsy|surgical biopsy from liver
214414600|NCT06630520|COMBINATION_PRODUCT|Periarticular injection|"A 50ml periarticular injection was introduced intraoperatively before the time of closing. The injection contained 150mg bupivacaine (3mg/mL), 60mg ketorolac(1.2mg/mL) and 1mg morphine.~Before wound closure, periarticular cocktail was injected around the knee joint including the adductor canal from the hamstring harvest side in PAI group. All patients had oral paracetamol 500mg, 4 times/day and diclofenac 75mg, 1 times/day after surgery."
214414601|NCT06629636|DIETARY_SUPPLEMENT|NMN capsule|Total of 900mg/day for 8 weeks
214414602|NCT06629636|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
214414603|NCT06630559|BIOLOGICAL|CT-P55|CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).
214414604|NCT06630559|BIOLOGICAL|EU-approved Cosentyx|European Union (EU)-approved Cosentyx, 300 mg by 2 SC injections of 150 mg/mL via PFS every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by Q4W for 11 doses (up to Week 48).
214414605|NCT06629909|DRUG|Secretome|3 ml Injection of secretome for 8 times two weeks apart
215017189|NCT05406570|PROCEDURE|Standardized ventilation|Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group
215017190|NCT05406570|PROCEDURE|Personalized ventilation|Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
215017191|NCT02573896|DRUG|Dinutuximab|17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
214414606|NCT06631118|PROCEDURE|pericapsular nerve group block for group A,low dose intravenous Propofol [0.7mg/kg] over 30 seconds for group B|Patients in group A will receive ultrasound guided pericapsular nerve group block (PENG) while patients in group B will receive low dose intravenous Propofol0.7mg/kg\] over 30 seconds followed by spinal anesthesia in both groups
214414607|NCT06698172|OTHER|Virtual Reality rehabilitation|"The study includes 12 weekly 45-minute visual rehabilitation sessions using a Virtual Reality device with Visionary Sport software. Originally designed for sports visual training, this software features gamified exercises to improve visual response times under professional supervision. Activities include games to enhance fixation, ocular motility, peripheral vision, and vergence.~The Peripheral Attention activity trains reaction times to static stimuli perceived in the peripheral retina, adjustable to the patient's visual field defect. Stimuli can be placed at 10, 20, or 30 degrees in the peripheral field. The VR headset (Vive Focus 3) includes an eye tracker to monitor and adapt stimuli based on patient performance.~Patients also perform 30 minutes of daily exercises at home, using proprietary software and Tobii 4C and 5C eye-tracking devices for ocular monitoring."
214505156|NCT00546156|DRUG|Paclitaxel|Standard chemotherapy regimen
214505157|NCT00546156|DRUG|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
214689142|NCT01721408|DRUG|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
215017192|NCT02573896|BIOLOGICAL|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
215017193|NCT02573896|DRUG|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
215017194|NCT04910503|DRUG|Dexamethasone intravitreal implant|Implant every 4 months if necessary
215017195|NCT04910503|DRUG|Fluocinolone Acetonide Intravitreal Implant|Implantation
215101729|NCT05787925|DRUG|Topical corticosteroid and Vitamin E|"26 patients who will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase \* three times daily for 8 weeks applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application. In addition to one capsule of 400 mg oral systemic vitamin E supplement\* will be prescribed once daily at the morning"
215017196|NCT04702750|BEHAVIORAL|Targeted memory reactivation (odors)|I will unobtrusively and repeatedly present learning-related odors during sleep using an olfactometer. This method was shown to improve memory in various tasks. The odors will be presented in blocks with short breaks in-between. Odors will be pleasant as to not wake the participant up. The odors will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The odors presented will be non-congruently associated with instructions in a previous learning task. This manipulation is within-subject - all participants will be exposed to all the odors during sleep, but odors will be associated with different instructions for each participant (counterbalanced).
215017197|NCT04702750|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will be exposed to sounds, but different specific sounds will be presented for each individual participant.
214689143|NCT01721408|DRUG|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
214689144|NCT03436446|OTHER|Interview|Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
214689145|NCT05313932|OTHER|Sleep deprivation|Participants wake after six hours so that they are deprived of 2 hours of sleep
215017198|NCT05736614|BEHAVIORAL|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
215101730|NCT05787925|DRUG|Topical corticosteroid|"26 patients will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase three times daily for 8 week that will be applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application"
214414608|NCT06698094|BEHAVIORAL|Sustainable lifestyle|To encourage and nudge a sustainable lifestyle in an office context in order to improve public health and combat climate change.
214414609|NCT06698094|BEHAVIORAL|Healthy lifestyle|To encourage and nudge a healthy lifestyle in an office context, the participants in this arm will function as a control group receiving general recommendations based on NNR 2014 nutritional recommendations and WHO physical activity recommendations.
214689146|NCT02426658|OTHER|Laboratory Biomarker Analysis|Correlative studies
214689147|NCT02426658|DRUG|Pemetrexed Disodium|Given IV
215101731|NCT04844268|BIOLOGICAL|Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT (HDT-301)) at a dose of 1 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
214414610|NCT06696833|BIOLOGICAL|QH10304-BAL-01|dose escalation (3+3) : dose 1 (3 × 10\^8cells/kg) ,dose 2 (1 × 10\^9 cells/kg) ,dose 3 (3 × 10\^9cells/kg)
214414611|NCT06696833|DRUG|Fludarabine|Intravenous fludarabine 30mg/m2 on days-6 to -3,the infusion dose is adjusted according to the subject's condition
214414612|NCT06696833|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 1000mg/m2 on days -5 to -3, the infusion dose is adjusted according to the subject's condition
214414613|NCT06698198|BIOLOGICAL|Pneumococcal Conjugate Vaccine|Suspension for Intramuscular injection
214689148|NCT02426658|OTHER|Quality-of-Life Assessment|QOL studies
214689149|NCT00524316|DRUG|doxorubicin hydrochloride|Transarterial chemoembolization
214689150|NCT00524316|DRUG|sunitinib malate|Given Orally
214689151|NCT00524316|OTHER|laboratory biomarker analysis|Correlative Study
214689152|NCT00524316|PROCEDURE|hepatic artery embolization|Surgical procedure
214689153|NCT00524316|PROCEDURE|quality-of-life assessment|Correlative Study
214689154|NCT02619019|DRUG|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
214689155|NCT02619019|DRUG|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
214689156|NCT02619019|DRUG|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
214689157|NCT01402284|DRUG|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
214689158|NCT01402284|DRUG|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
214689159|NCT01402284|DRUG|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
214689160|NCT01402284|DRUG|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
214689161|NCT01402284|DRUG|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
214689162|NCT01199263|OTHER|Laboratory Biomarker Analysis|Correlative studies
214689163|NCT01199263|DRUG|Paclitaxel|Given IV
214689164|NCT01199263|BIOLOGICAL|Pelareorep|Given IV
214689165|NCT04937816|DRUG|Placebo|Placebo
214689166|NCT04937816|DRUG|Empagliflozin|Empagliflozin once daily
214689167|NCT06920368|PROCEDURE|septoplasty with nasal packs|Septoplasty to all the patients will be done using general hypotensive anesthesia via cuffed oral endotracheal tube. The patient will be positioned in a slight reverse Trendelenburg position. Local hemostasis will be achieved by injection of lidocaine with epinephrine (1:100000) with placement of topical epinephrine soaked cotton (1:1000) then nasal packs in inserted at the end of operation for prevention of post operative complication
214414614|NCT06698198|BIOLOGICAL|Prevnar 13®|Suspension for Intramuscular injection
214414615|NCT06700993|BEHAVIORAL|Treatment as Usual in Collaborative Care or Integrated Behavioral Health|Treatment as Usual will be whatever primary care and behavioral health services are standardly implemented for adolescents or young adults experiencing suicidality
214414616|NCT06700993|BEHAVIORAL|Connections model|The Connections model applies the Aeschi Model of suicide care to Collaborative Care or other Integrated Behavioral Health by centering the patient's clinical narrative, focusing treatment on the patient's unique drivers of suicide, and maximizing collaboration while maintaining the standards of suicide assessment and management expected by accrediting bodies.
214414617|NCT06696703|DRUG|Human urinary kininogenase(HUK)|Experimental group (HUK plus routine clinical treatment): administered within 48 hours of AIS onset, 0.15PNA unit was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day.
214689168|NCT06920368|PROCEDURE|septoplasty with intra-nasal silicon splint|Septoplasty to all the patients will be done using general hypotensive anesthesia via cuffed oral endotracheal tube. The patient will be positioned in a slight reverse Trendelenburg position. Local hemostasis will be achieved by injection of lidocaine with epinephrine (1:100000) with placement of topical epinephrine soaked cotton (1:1000) then intra-nasal silicon splint is inserted at the end of operation for prevention of post operative complication
214689169|NCT06920368|PROCEDURE|septoplasty with trans--septal quilting sutures|Septoplasty to all the patients will be done using general hypotensive anesthesia via cuffed oral endotracheal tube. The patient will be positioned in a slight reverse Trendelenburg position. Local hemostasis will be achieved by injection of lidocaine with epinephrine (1:100000) with placement of topical epinephrine soaked cotton (1:1000) then trans-septal quilting sutures is done at the end of operation for prevention of post operative complication
214689170|NCT06918977|DEVICE|InPen Smart insulin pen|InPen is a reusable pen injector which allows the user to dial the desired dose of insulin to be administered. The dose calculator a component of the InPen app calculates an insulin dose or carbohydrate intake based on user entered data. Prior to use, the patient -specific target blood glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters are to be programmed into the software.
214689171|NCT06918977|OTHER|traditional/standard insulin pen|personal prescribed insulin pen
214689172|NCT06677892|OTHER|No Intervention|This is non-interventional study.
214414618|NCT06696703|OTHER|Placebo|Placebo group (Normal sodium chloride injection plus routine clinical treatment): Normal sodium chloride administered within 48 hours of AIS onset, by intravenous infusion for not less than 50 minutes, once a day.
214689174|NCT06618235|BIOLOGICAL|THEO-260|Oncolytic Virus
215017199|NCT05736614|BEHAVIORAL|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
215017200|NCT05026619|OTHER|Information about age-related fertility|"The following information is provided:~Age and fertility IVF success rates and side effects"
215017201|NCT05026619|OTHER|Information about policy initiatives|"The following information is provided:~Assisted reproductive technology treatment subsidies Other fertility-related policies"
215017202|NCT05026619|OTHER|Information about diabetes|"The following information is provided:~Diabetes risk factors and treatment Diabetes-related policies"
215017203|NCT05554003|DRUG|Temozolomide capsule|Metronomic temozolomide 60 mg/die continuously
214689175|NCT07007559|DRUG|Evorpacept (ALX148)|IV infusion
214689176|NCT07007559|DRUG|Trastuzumab|IV infusion
214689177|NCT07007559|DRUG|Paclitaxel|IV infusion
214689178|NCT07007559|DRUG|Capecitabine|Oral administration
215017204|NCT04899466|DEVICE|ActiGraft|Whole blood clot (WBC) gel
215017205|NCT06358443|DIETARY_SUPPLEMENT|Jarlsberg cheese|Jarlsberg cheese + Vitamin D ampulles + Calcium
215017206|NCT03503799|OTHER|Observation|"Visit 1 Informed consent Medical history Demographics Result of EndoPredict® Test Status of menopause Disease status Tumor board decision Planned anti-tumor-therapy~Visit 2, 1 year after inclusion This visit will be documented at the study site Status of menopause Disease status Anti-tumor therapy Survival~Following visits For these visits, patients will be asked directly through the Center for Clinical Trials of the Philipps-University Marburg (KKS Marburg) via phone.~Status of Menopause Disease status Anti-tumor therapy Survival~Treatment after end of the study The patient will be treated during and after end of study by physician's choice."
215017207|NCT04332393|DRUG|Metformin|Metformin tablets according to glycemic control. Initial dose: 425 mg before meals (breakfast, lunch and supper) and 1700 mg around 22:00. Modifications may take place according to glycemic control
214414619|NCT06705413|OTHER|Aerobic exercise|a program consists of 10 minutes warming up, 30 minutes of aerobic exercises in the form of core strengthening exercises and stretching exercises and finally 10 minutes of cooling down. The participant will receive the aerobic program 4 sessions /week for three consecutive menstrual cycles.
214689179|NCT07007559|DRUG|Eribulin|IV infusion
214689180|NCT07007559|DRUG|Gemcitabine|IV infusion
214689181|NCT07007559|DRUG|Vinorelbine|IV infusion
214689182|NCT07132385|BEHAVIORAL|Guidelines-based moderate-intensity continuous exercise|Through a combination of exercise trainer-led in-person and virtual sessions, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity (total intervention is 6 weeks)
214689183|NCT07132385|BEHAVIORAL|High-intensity interval training|Through a combination of exercise trainer-led in-person and virtual sessions, participants will be guided to achieve 75 weekly minutes of high-intensity interval training.
214689184|NCT07132385|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
214689185|NCT06677229|DRUG|Eletriptan HBr 40 mg|Oral administration of Eletriptan HBr in the form of tablets, 40 mg once daily (q.d.) for a total of 6 days, together with their usual SOC treatment.
214689186|NCT05513612|BIOLOGICAL|Autologous CAR-T cells|CAR-T cells will be infused intravenously.
214414620|NCT06705413|OTHER|Microbiome diet|The participants will receive Microbiome diet for three consecutive menstrual cycles. A three-phase diet (21-day phase, 28-day phase and maintenance phase) will be followed by the experimental group which contains some food restrictions and addition for certain food types which may improve gut health.
214414621|NCT06705439|DEVICE|Nelli|Nelli detects and registers activity that is indicative of seizure events. Nelli captures, stores, and processes video and audio recordings from each patient. Biomarker data is collected during periods of rest for the length of an examination period, which may span several days or months (when used inside and outside of a hospital setting, respectively), as prescribed by a treating physician.
214414622|NCT06712212|PROCEDURE|Inguinal Hernias repair: Desarda|A splitting incision is made in this sutured medial leaf, partially separating a strip 1.5-2 cm wide. This splitting incision is extended medially up to the pubic symphysis and 1-2 cm beyond the abdominal ring laterally. The medial insertion and lateral continuation of this strip is kept intact. The upper free border of the strip is now sutured to the internal oblique with number 1 Monofilament Polydioxanone Violet continuous sutures all along its length. This will result in the strip of the EOA being placed behind the cord to form a new posterior wall of the inguinal canal. The spermatic cord is placed in the inguinal canal and the lateral leaf of the EOA is sutured to the newly formed medial leaf of the EOA in front of the cord. As before, number 1 Monofilament Polydioxanone Violet continuous sutures were used. Undermining of the newly formed medial leaf on both its surfaces and excision of the bulky cremasteric muscle facilitate its approximation to the lateral leaf
214689187|NCT05513612|DRUG|Fludarabine|Administered according to package insert
214689188|NCT05513612|DRUG|Cyclophosphamide|Administered according to package insert
214689189|NCT03312946|DEVICE|Modellata|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
215017208|NCT05415397|DRUG|Celecoxib 400mg|Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
215017209|NCT05415397|DRUG|Placebo|Placebo add-on to treatment as usual (standard antidepressant treatment)
215017210|NCT06964074|DEVICE|Nebulization with OPEP device|"During hospitalization due to exacerbation of the bronchopulmonary disease, patients performed inhalations twice a day using one of two devices: PARI PEP® S System (produced by PARI, Germany) with a dedicated Pari LC Sprint nebulizer or the Aerobika\*OPEP Device (produced by TRUDELL MEDICAL INTERNATIONAL) with a dedicated Aero Eclipse XL nebulizer, or they were in the control group where they performed inhalations in the standard way using the Pari LC Sprint nebulizer (produced by PARI, Germany). Frequency: twice daily. Inhalation duration: 10 minutes. Immediately after inhalation, each patient performed physiotherapy in the same scheme using the Pari OPEP device, 15 exhalations, and autogenic drainage technique according to the method's concept, with the drainage duration ranging from 15 to 30 minutes."
215017211|NCT06964074|DEVICE|Nebulization with PEP device|"During hospitalization due to exacerbation of the bronchopulmonary disease, patients performed inhalations twice a day using one of two devices: PARI PEP® S System (produced by PARI, Germany) with a dedicated Pari LC Sprint nebulizer or the Aerobika\*OPEP Device (produced by TRUDELL MEDICAL INTERNATIONAL) with a dedicated Aero Eclipse XL nebulizer, or they were in the control group where they performed inhalations in the standard way using the Pari LC Sprint nebulizer (produced by PARI, Germany). Frequency: twice daily. Inhalation duration: 10 minutes. Immediately after inhalation, each patient performed physiotherapy in the same scheme using the Pari OPEP device, 15 exhalations, and autogenic drainage technique according to the method's concept, with the drainage duration ranging from 15 to 30 minutes."
215017212|NCT06964074|DEVICE|Nebulization with Pari LC Sprint|"During hospitalization due to exacerbation of the bronchopulmonary disease, patients performed inhalations twice a day using one of two devices: PARI PEP® S System (produced by PARI, Germany) with a dedicated Pari LC Sprint nebulizer or the Aerobika\*OPEP Device (produced by TRUDELL MEDICAL INTERNATIONAL) with a dedicated Aero Eclipse XL nebulizer, or they were in the control group where they performed inhalations in the standard way using the Pari LC Sprint nebulizer (produced by PARI, Germany). Frequency: twice daily. Inhalation duration: 10 minutes. Immediately after inhalation, each patient performed physiotherapy in the same scheme using the Pari OPEP device, 15 exhalations, and autogenic drainage technique according to the method's concept, with the drainage duration ranging from 15 to 30 minutes."
215017213|NCT06964295|DEVICE|Macintosh videolaryngoscope|Used to perform nasotracheal intubation under general anesthesia. The Macintosh videolaryngoscope is introduced orally to visualize the glottis, and a preformed nasotracheal tube is inserted through the nostril.
215017214|NCT06964295|DEVICE|Flexible bronchoscope|Used to perform nasotracheal intubation under general anesthesia. The bronchoscope is inserted through a lubricated nasotracheal tube and advanced into the trachea.
215017215|NCT06963593|DRUG|Nanocrystal Megestrol Acetate in Combination with First-Line Standard Immuno-Chemotherapy Regimen|Megestrol Acetate Nanocrystal Oral Suspension Group: Nanocrystal Megestrol Acteate Oral Suspension (QD, up to 16 weeks from the initiation of immuno-chemotherapy) + PD-1 inhibitor (Q3W, until PD) + Chemotherapy regimen (TP regimen or XELOX regimen or SOX regimen selected based on cancer type, Q3W, as per package insert)
215017216|NCT06963593|DRUG|First-Line Standard Immuno-Chemotherapy Regimen|PD-1 inhibitor (Q3W, until PD) + Chemotherapy regimen (TP regimen or XELOX regimen or SOX regimen selected based on cancer type, Q3W, as per package insert)
215017217|NCT06964477|BEHAVIORAL|XR-Based Leisure Intervention|"The XR-based leisure intervention was developed based on occupational therapy principles and the therapeutic use of leisure to support engagement, volition, and emotional regulation in individuals with chronic mental illness. The intervention content was designed using the AR2VR platform and the MAKAR marker-based AR development system. Leisure scenarios were created by capturing real-world environments using 360-degree panoramic video and embedding interactive elements, such as contextual prompts, virtual objects, and multimedia cues, to enhance immersion and engagement.~Sessions are guided by trained occupational therapists and follow a standardized protocol to ensure consistency. A simple cardboard VR viewer is used to reduce sensory overload and avoid adverse effects common with electronic head-mounted displays, such as dizziness or nausea. Activities target various leisure domains, including physical movement, creative expression, social activities, and cognitive play. Weekly con"
215101732|NCT04844268|BIOLOGICAL|Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 5 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
214414623|NCT06712212|PROCEDURE|Inguinal hernia repair: Darn|Skin and fascia are incised using a regular, oblique inguinal incision to expose the external oblique aponeurosis (EOA) the inguinal canal is opened into by dividing the external oblique aponeurosis through the external ring. After dealing with the hernia sac, a 0-size monofilament suture was used to reconstruct the inguinal bed with a tension-free darn starting with a good strong bite of the tough tendinous structures near the pubic tubercle and emerging out through the lateral edge of the internal oblique/rectus sheath from one side and through the inguinal ligament on the other side. The loosely interwoven bites continued laterally and the back-forming two rows of continuous stitches were placed in a staggered manner to spread the tension between the fibres of the inguinal ligament. Afterwards, the external oblique and other superficial layers with the skin are classically closed
214414624|NCT06712225|BEHAVIORAL|Anomia therapy: semantic feature analysis and phonological components analysis;|After the initial assessment + functional Magnetic Resonance Imaging (fMRI), participants will first receive their usual speech therapy rehabilitation for 10 to 15 sessions (baseline phase), and then enter the experimental phase: 18 sessions (3 per week) of either anomia therapy alone or anomia therapy + executive function training, according to the arm they were assigned to. All sessions will last 45 minutes. Naming skills will be repeatedly measured during both phases. A second assessment of language + fMRI will then be conducted and participants will return to their usual rehabilitation. Four weeks later, a final assessment of naming and discourse will be conducted.
214414625|NCT06712225|BEHAVIORAL|Executive function training: computerized equipment|Executive function training will be conducted by means of a computerized material specifically designed for the study, consisting of verbal and nonverbal exercises targeting, always in the same order, inhibition, shifting, working memory and planning functions, with a gradient of difficulty. Training will always be done at the beginning of the session, during 20 minutes, before anomia therapy.
214414626|NCT06708325|OTHER|Resistance Training Program|The 12-week resistance training program consisted of three supervised sessions per week, each lasting approximately 55-60 minutes. Sessions were structured as follows: 5-7 minute dynamic warm-up, 35-40 minutes of resistance training, and 4-5 minutes of stretching for active recovery.Participants were paired based on similar strength fitness levels and progressed according to the principle of periodized progressive overload. Training was delivered using a circuit protocol with 2-3 sets per exercise. The initial 4-week phase included 2 sets per exercise, with 8-20 repetitions and 1-2 minutes rest between sets. .The program incorporated functional exercises targeting the lower extremities, core, and upper extremities, utilizing equipment such as resistance bands, medicine balls, jump ropes, dumbbells, bars, and stability balls. Participants performed exercises in a circuit sequence, with the intensity, number of sets, and repetitions
214414627|NCT06711848|BEHAVIORAL|A web-based educational intervention on oral cancer|This intervention will involve administering education, via a website, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
214689190|NCT05239286|PROCEDURE|General anaesthesia|"All patients in supine position will receive breathing 100% oxygen, induction of anaesthesia will be achieved using propofol (2 mg/Kg), 1-2 mcg/kg of fentanyl and atracurium (0.5 mg/Kg). Endotracheal tube will be inserted after 3 minutes of mask ventilation. Patients who will experience prolonged airway instrumentation due to a difficult intubation will be excluded from further data analysis because of excessive stimulation. Then mechanical ventilation will be performed using a tidal volume of 6-8 mL/kg of ideal body weight at an inspiratory to expiratory ratio of 1:2 without positive end-expiratory pressure. The ventilatory frequency will be adjusted to maintain an end-tidal carbon dioxide tension of 35-40 mmHg.~Anaesthesia will be maintained by isoflurane (1-1.5%), atracurium 10 mg intravenous increments every 20 minutes and morphine 0.1 mg/kg intravenous will be given as a long acting analgesia."
214689191|NCT05239286|DRUG|Conventional fluid managment|Ringer solution at the dose of 5 ml/kg/h infused throughout the surgical procedure by taking the parameters such as Heart rate (HR), mean arterial pressure (MAP) and urine output, Hypotension was defined as a condition in which the MAP was below 30% of the baseline MAP of the patient. In this case, bolus of 250 ml crystalloids (0.9% NaCl) was given and in case of hypotension persistence, 5 mg I.V. ephedrine administered and repeated every 5 min till the MAP increased over 70% of baseline.
214689192|NCT05239286|DRUG|PVI dependant goal directed fluid therapy|"After the induction of anesthesia, Ringer solution infused at the dose of 2 ml/kg/h started as a basal rate of infusion. If the PVI was higher than 13% for more than 5 min, a 250-ml bolus of crystalloids administrated. If the PVI was still higher than 13% after the bolus, it was repeated every 5 min until the PVI was less than 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~In the cases where PVI was less than \< 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~Then the patient was turned to prone position and the same steps according to Massimo readings were repeated."
214689193|NCT06829420|BEHAVIORAL|Mirror speech entrainment|Speech entrainment with the user's own voice using auditory-only and auditory-visual modalities.
214689194|NCT06829420|BEHAVIORAL|Traditional speech entrainment: auditory-only|Traditional speech entrainment (speech entrainment using an external agent's voice) using the auditory-only modality (users only listen and speak along to auditory stimuli)
215017218|NCT06964347|DEVICE|Ropivacaine 0.2% + nerve stimulator set|Patients will receive a continuous local anesthetic (LA) infusion through the popliteal sciatic nerve block catheter using an infusion of ropivacaine 0.2% at a rate of 8-12 ml/h for at least 3 postoperative days. In addition, patients will receive a low-frequency peripheral nerve stimulation (PNS) via a nerve stimulator set to the pre-determined setting of adequate clinical response (determined in the preoperative area).
215017219|NCT06964347|DRUG|Ropivacaine 0.2%|Patients will receive a continuous local anesthetic infusion through the popliteal sciatic nerve block catheter using an infusion of ropivacaine 0.2% at a rate of 8-12 ml/h for at least 3 postoperative days. In addition, patients will have an inactive PNS button for the purposes of blinding.
215017220|NCT05128448|OTHER|Cross-body stretch (CBS)|CBS is a self administered stretch that aims to stretch posterior shoulder structures
215017221|NCT05128448|OTHER|Mobilisation with movement (MWM)|WMW is a musculoskeletal procedure that aims to improve restricted and/or painful range of movement
214689195|NCT06829420|BEHAVIORAL|Traditional speech entrainment: auditory-visual|Traditional speech entrainment (speech entrainment using an external agent's voice) using the auditory-visual modality (users listen and speak along to both auditory and visual stimuli (mouth movements)
214689196|NCT07077902|DRUG|Topical roflumilast 0.3% foam|Topical roflumilast is a potent phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, seborrheic dermatitis and atopic dermatitis
214414628|NCT06711848|BEHAVIORAL|A mobile health app-based educational intervention on oral cancer|This intervention will involve administering education, via a mhealth application prototype, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
214414629|NCT06711185|DRUG|Dapagliflozin 10 mg|Patients in this group will receive 1 tablet of 10mg dapagliflozin daily for 9 months, starting 7-10 days before chemotherapy treatment.
214414630|NCT06711185|OTHER|Placebo|Patients in this group will receive 1 placebo tablet per day, with identical characteristics to the group receiving dapagliflozin, for 9 months, starting 7-10 days before the start of chemotherapy treatment
214414631|NCT02162446|DRUG|satoreotide trizoxetan|
214414632|NCT04046523|DEVICE|Video ophthalmoscope|Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.
214414633|NCT03570957|DRUG|MT-2990|MT-2990 solution for injection in vial
214414634|NCT03570957|DRUG|Placebo|Placebo solution for injection in vial
214414635|NCT03465488|DRUG|Albendazole Pill 400mg (GSK)|One single dose of 400mg Albendazole is provided at baseline.
214414636|NCT02833155|DRUG|Entinostat|Given PO
214414637|NCT02833155|DRUG|Exemestane|Given PO
214414638|NCT01553513|OTHER|[18F]-FDG positron emission computed tomography|"Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest."
214414639|NCT01553513|PROCEDURE|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
214414640|NCT01553513|PROCEDURE|Intravascular ultrasound and virtual histology|"During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.~A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.~Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque."
214414641|NCT01553513|OTHER|Serum biomarkers|"A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers."
214414642|NCT04095403|OTHER|Tarp Assisted Cooling|Body cooling utilizing a tarp and water
214414643|NCT04095403|OTHER|passive cooling|Supine rest.
214414644|NCT01255033|DEVICE|Monitoring of tissular oxygenation|"Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices~Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device"
214414645|NCT03221569|DRUG|Intravenous ketamine|0.3mg/kg IVPB over 15 minutes
214414646|NCT03221569|DRUG|Ketorolac|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
214414647|NCT03221569|DRUG|Normal saline|"Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine."
214414648|NCT03221569|DRUG|Normal saline|1ml intravenous push as placebo for double-blinding purposes
214414649|NCT05599399|DIETARY_SUPPLEMENT|Gum acacia|25 grams of gum acacia powder is administered on daily-basis
214689197|NCT07084740|DIAGNOSTIC_TEST|PeriCam and PeriFlux measurements|PeriCam and PeriFlux measurements
215017222|NCT03589053|DEVICE|Limb remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
215017223|NCT03589053|DEVICE|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
215017224|NCT00787488|DEVICE|Hyperthermia|Every 3 weeks
214414650|NCT01505101|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
214414651|NCT01505101|BEHAVIORAL|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
214414652|NCT00739102|DEVICE|S.M.A.R.T. ® Stent|The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
214414653|NCT00868595|BIOLOGICAL|BPX-101|Vaccine
214414654|NCT00868595|DRUG|AP1903|Activating agent, infusion
214414655|NCT00271167|DRUG|INO-1001|
214689198|NCT07083895|BEHAVIORAL|Modified RICHH|"The RICHH intervention is an educational-behavioral and counseling intervention that promotes caregivers' knowledge, skills and motivation to engage in CVD risk reduction. The intervention is delivered individually to caregivers in their homes using video-conferencing technology on mini-iPads. The program consists of 12 weekly sessions \[30-45 minutes\] that will be held at the caregivers' preferred times. RICHH consists of 6 interactive modules (i.e., self-management for heart health, depressive symptom management, heart healthy eating, physical activity, co-morbid condition management, and adherence to medication and smoking cessation).~The modified RICHH intervention utilizes focus group outcomes to employ modifications needed to target custodial grandparents from varied backgrounds (e.g., high ACEs, SDoH groups)."
214689199|NCT07083895|BEHAVIORAL|Standard of Care (SOC)|Referral to primary care provider
214689200|NCT07083427|OTHER|CAPA-IVM|In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.
214689201|NCT07085052|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|10-week online MBSR program, involving 10 weekly 2.5-hour group sessions, a day-long online retreat, and approximately 45 minutes of home practice assignments six days per week.
214689202|NCT06635629|DRUG|Desmopressin|Stimulates ACTH release in Cushing disease
214689203|NCT06635629|DRUG|Dexamethasone|Inhibits ACTH release in Cushing disease and healthy volunteers
214689204|NCT06018025|DRUG|CGRP antibody|treatment with CGRP antibody for 4 months
214689205|NCT06892756|DRUG|CHF6001 dry powder inhaler (DPI)|CHF6001 DPI single dose administration followed by a 14 to 17-day wash-out period before Treatment Period 2
214689206|NCT06892756|DRUG|Cyclosporine|Oral cyclosporine single dose administration
214414656|NCT02772315|OTHER|omics|diagnostic procedures applying omics results
214414657|NCT03284905|DIETARY_SUPPLEMENT|Probiotic supplement|Capsule containing freeze dried probiotic bacteria together with maize starch
214414658|NCT03284905|DIETARY_SUPPLEMENT|Placebo supplement|Capsule containing maize starch
214414659|NCT02139748|PROCEDURE|Dental Implant & ADM|A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
214414660|NCT02139748|PROCEDURE|Dental Implant & ADM & bone xenograft|A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
214414661|NCT01158196|DEVICE|infra-red diode laser|"laser treatment of scar after keloid excision~laser treatment of surgery scar"
214414662|NCT04981015|DIAGNOSTIC_TEST|Three-day bladder diary|A three-day bladder diary for recording voiding-flow pattern of a women
214414663|NCT03784963|DRUG|Omega 3 fatty acids|Patients will receive 4 grams fish oil once daily
214414664|NCT03784963|OTHER|Placebo|Standard of care
214414665|NCT03179787|DRUG|Aripiprazole oral product|oral administration of aripiprazole
214689207|NCT06892756|DRUG|CHF6001 DPI|CHF6001 DPI single dose administration after oral cyclosporine single dose administration
214689208|NCT06513026|DIETARY_SUPPLEMENT|Lactose-Containing Milk|"Participants will be asked to drink 1% regular milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit."
214689209|NCT06513026|DIETARY_SUPPLEMENT|Lactose-Free Milk|"Participants will be asked to drink 1% lactose-free milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit."
215017225|NCT05656573|DRUG|CART-PSMA cells|"This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation).~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~Cohort 1： CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 2： CART-PSMA cells 1-3x10\^8/M\^2 (body surface area); Cohort 3： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 4： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^8/M\^2 (body surface area)."
214414666|NCT05990517|BIOLOGICAL|YD01-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
214414667|NCT01496521|DRUG|Aspirin|100mg qd for 6 months.
214414668|NCT01496521|DIETARY_SUPPLEMENT|Tea Polyphenols|300mg bid for 6 months.
214414669|NCT03353467|PROCEDURE|Endoscopic surgery|Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
214414670|NCT03353467|RADIATION|Intensity-modulated radiotherapy|All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.
215017226|NCT06380504|BEHAVIORAL|R-SWITCH integrated intervention package|"1. Monthly group meetings of Alliance for Development (AFD) community groups) and their members (caregivers of children 0-59 months of age):~   * Introduction and refresher of Family-led MUAC~  * Active screening of wasting by AFD~  * Group SBCC on Infant and Young Child Feeding (IYCF), health and Water, Sanitation and Hygiene (WaSH) with a focus on SAM~  * Promotion of health services such as GMP~2. Introduction of weight-for-age Z-score \<-3 as screening criterion for passive screening by health extension workers at any contact with children (e.g. during GMP)~3. Promotion of Family-led MUAC screening and SAM awareness to fathers during male agricultural/pastoralist extension activities and by community and religious leaders (creating social support)~4. Follow-up and counselling during home visits by AFD leaders of i) earlier referred cases of SAM, ii) cases enrolled in SAM OTP, iii) and recovered SAM cases discharged from OTP~5. Strengthening communication between HEW and AFDs"
214414671|NCT05883475|OTHER|Disabilities of the Arm, Shoulder, and Hand Questionnaire|Upper limb function was assessed with the Turkish version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). The questionnaire DASH is a self-report instrument with 30 items. The total score ranges from 0 to 100, with higher scores indicating a worse upper limb function.
214414672|NCT05883475|OTHER|Arm Motor Ability Test|The test assesses hemiparetic upper extremity functional tasks.The increase in the scores of both subparameters of the scale, which is composed of the parameters of functional ability and quality of movement, indicates an improvement in the motor functions of the upper limbs.
214414673|NCT05883475|OTHER|Nine Hole Peg Test|Fine motor skills of the upper extremities were assessed.The patient was asked to insert the nine sticks in the box on the table into the holes in the other box as quickly as possible and then remove them immediately. As time increases, fine motor skills of the upper extremities decrease
214414674|NCT05883475|OTHER|Pittsburg Sleep Quality Index|"Sleep quality was assessed using the this test.This scale, which provides a quantitative measure of sleep quality, is a 19-item self-report scale. The total score greater than 5 indicates poor sleep quality."
214414675|NCT05883475|OTHER|Functional Independence Measure|This test assessed functional capacity in activities of daily living.The higher a person's score, the higher the level of independence.
214414676|NCT04619914|DRUG|Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt|CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)
214414677|NCT04619914|DRUG|letrozole (Femara; Novartis pharma AG, Basle, Switzerland)|Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
214414678|NCT04778124|PROCEDURE|Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)|All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.
214414679|NCT04778124|PROCEDURE|Excision of thrombosed hemorrhoid / Hemorrhoidectomy /|One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
214414680|NCT03680391|PROCEDURE|Cesarean section|"Both groups cesarean section will be held with the same technique:~* spinal anethesia~* pfennenstiel imcision~* lower segment cesarean section~* suturing uterus in two layers while exterionezed~* gentle manibulation~* no towels in gutters will be used"
215017227|NCT05784597|DRUG|[68Ga]Ga-OncoFAP administration|All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
215017228|NCT06084286|BIOLOGICAL|Dual-targeting CLDN18.2 and PD-L1 CAR-T cells|The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
215017229|NCT04619888|DIAGNOSTIC_TEST|HeartLogic|In case of HeartLogic index ≥16, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment. The management will be standardized across centers according to the Manage-HF protocol.
215017230|NCT04438512|DRUG|Midomafetamine|Administration of 80 or 120 mg midomafetamine HCl in combination with manualized therapy and a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively
215017231|NCT04438512|BEHAVIORAL|Psychotherapy|Manualized therapy performed by therapist team
215017232|NCT06125548|OTHER|Lactation Management Model|The mother provides skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes by hand milking, 2 minutes by breast massage). Head stimulation, stroking for 3 minutes) were asked.
214414681|NCT05307614|DRUG|Moksi® 400mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
214414682|NCT05307614|DRUG|Drug: Avelox® 400Mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
214414683|NCT01958541|BEHAVIORAL|Sleep Intervention I|Insomnia-focused behavioral treatment (4 sessions).
214414684|NCT01958541|BEHAVIORAL|Sleep Intervention II|Insomnia-focused behavioral treatment (4 sessions).
214414685|NCT03935308|RADIATION|MR guided Linear Accelerator|The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
214414686|NCT01090024|DRUG|BI 671800|BI 671800
214414687|NCT01090024|DRUG|Placebo|Placebo matching BI 671800
214414688|NCT03643029|DEVICE|Video-laryngoscopy following SAD insertion|Following insertion of a supraglottic airway device (SAD), the placement and performance tests are carried out. If the tests are successful, a video-laryngoscopy will be performed to confirm the placement of the SAD in the hypopharynx.
215017233|NCT03346317|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
214689210|NCT02859545|BEHAVIORAL|Emotional Validation Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
214689211|NCT02859545|BEHAVIORAL|Chronic Pain Education Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
214689212|NCT06766500|DRUG|Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets|1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablet
214689213|NCT06766500|DRUG|Synjardy® 5 mg/850 mg film-coated tablets|1 tablet of Empagliflozin+Metformin 5 mg/850 mg filmcoated tablets
214689214|NCT06893653|DEVICE|Focal muscle vibration|FMV will be applied to the muscle belly along with the conventional physical therapy
214689215|NCT06893653|DEVICE|tDCS|tDCS will be applied to M1 area of brain along with the conventional physical therapy
214689216|NCT06893653|OTHER|Physical Therapy|Conventional physical therapy will be provided
214689217|NCT06893653|DEVICE|Focal muscle vibration & tDCS|Focal muscle vibration with tDCS and conventional physical therapy will be provided.
215017234|NCT03346317|PROCEDURE|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
215017235|NCT03346317|DRUG|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
214689218|NCT07094204|DRUG|ASP5834|Intravenous infusion
215017236|NCT04560114|DRUG|Essential oils|"The patient will be invited to inhale the essential oils via the stick:~* 4 times a day before each meal and snack.~* if necessary when nausea appears, as many times as he deems necessary."
215017237|NCT03536065|BEHAVIORAL|Opioid Reduction Intervention|Patient education discharge sheet, nursing education, opioid prescription reduction based on Pre-Intervention data
215017238|NCT03536065|BEHAVIORAL|Current Care|Current unchanged care provided; unchanged provider prescribing and unchanged education of patients prior to intervention
215017239|NCT05497882|BEHAVIORAL|E-Learning Prototype for Dementia Care|Usability testing System Usability Scale
215017240|NCT02552654|BEHAVIORAL|Stress Film|Film scene with severe physical and sexual violence.
215017241|NCT02552654|DRUG|Hydrocortisone|10mg
215017242|NCT02552654|DRUG|Placebo|
215017243|NCT03531502|PROCEDURE|Ventricular Tachycardia Ablation|Ventricular Tachycardia Ablation
215017244|NCT03531502|OTHER|Standard Medical Therapy|For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.
215017245|NCT03531502|PROCEDURE|Non-Invasive Programmed Stimulation (NIPS)|All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
215017246|NCT01219075|DIETARY_SUPPLEMENT|soy isoflavones|Given orally
215017247|NCT01219075|OTHER|placebo|Given orally
215017248|NCT01219075|OTHER|questionnaire administration|Ancillary studies
214414689|NCT02008292|DRUG|Physostigmine|All subjects will receive physostigmine to induce elevated ACh levels in the brain.
214414690|NCT00003311|BIOLOGICAL|filgrastim|
214414691|NCT00003311|DRUG|cyclophosphamide|
214414692|NCT00003311|DRUG|cytarabine|
214414693|NCT00003311|DRUG|dexamethasone|
214414694|NCT00003311|DRUG|doxorubicin hydrochloride|
214414695|NCT00003311|DRUG|methotrexate|
214414696|NCT00003311|DRUG|vincristine sulfate|
214414697|NCT01371201|DRUG|Sunitinib|sunitinib 37.5 mg per day
214414698|NCT01371201|DRUG|Placebo|Placebo 37.5 mg per day
214414699|NCT02122848|DEVICE|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
214414700|NCT00253240|PROCEDURE|Screening|
214414701|NCT00253240|PROCEDURE|Management|
214689219|NCT07094204|DRUG|panitumumab|Intravenous infusion
215017249|NCT01219075|PROCEDURE|magnetic resonance imaging|Correlative studies
215017250|NCT01219075|PROCEDURE|biopsy|Correlative studies
215017251|NCT01219075|OTHER|immunohistochemistry staining method|Correlative studies
215017252|NCT01219075|OTHER|laboratory biomarker analysis|Correlative studies
215017253|NCT01219075|PROCEDURE|mammography|Correlative studies
215101733|NCT04844268|BIOLOGICAL|Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 25 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
214414702|NCT03728725|DEVICE|Cepheid Gene Xpert MTB/XDR|The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
214414703|NCT04470102|PROCEDURE|mitral valve repair by edge-to-edge technique|transaortic access for mitral valve repair edge-to-edge
214414704|NCT04470102|PROCEDURE|Septal myectomy|isolated extended septal myectomy
214689220|NCT07102121|PROCEDURE|luting material applaication with Modified Glass Ionomer Cement (RMGIC)|The intervention involves the use of two different types of luting cements-resin-modified glass ionomer cement (RMGIC) and conventional glass ionomer cement (GIC)-for the cementation of fixed dental prostheses. The objective is to compare post-cementation sensitivity between the two materials. All clinical procedures, including tooth preparation, isolation, and cementation, will follow standardized protocols. Sensitivity will be measured using the Visual Analog Scale (VAS) at 24 hours and 7 days post-procedure. The study will maintain consistency across both groups, with the only variable being the type of cement used.
215017254|NCT03383133|DRUG|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
215017255|NCT02014454|DRUG|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group."
215101734|NCT04844268|BIOLOGICAL|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
215101735|NCT01122693|DEVICE|eZono - high-quality 2D ultrasound images|higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
214414705|NCT02195557|DRUG|Synvisc®|
214414706|NCT04836793|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
214414707|NCT03359031|OTHER|Patient education|This group will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
214414708|NCT04588285|DRUG|Ambroxol|Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
214414709|NCT04588285|DRUG|Placebo|Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
214414710|NCT03645850|DEVICE|Vismed gel Multi 0.3% eye drops|Ophthalmic use. Vismed gel Multi 0.3% eye drops. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
214414711|NCT03645850|DEVICE|Vismed Multi 0.18% eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
214414712|NCT05155371|OTHER|Titration of Optimal Positive End-expiratory Pressure|Titration of Optimal Positive End-expiratory Pressure with two different methods
214414713|NCT00777556|DRUG|DR-104|One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
214414714|NCT03838796|DRUG|lenvatinib|for patients \<60kg, lenvatinib 8mg bid po for patients \>60kg, lenvatinib 12mg bid po
215101736|NCT01122693|DEVICE|standard 2D ultrasound images|current standard in two-dimensional (2D) ultrasound images
215101737|NCT03933228|PROCEDURE|Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
215101738|NCT03933228|PROCEDURE|Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
215101739|NCT05839249|OTHER|JJ urological stents|recording complications of JJ stents during COVID19 pandemics
215101740|NCT02830321|OTHER|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
215101741|NCT00765570|RADIATION|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
215101742|NCT00765570|RADIATION|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
215101743|NCT00765570|RADIATION|Standard radiation|15 Standard radiation treatments
215101744|NCT00765570|RADIATION|Standard radiation|standard radiation treatment
215101745|NCT06583278|DEVICE|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
215101746|NCT01119092|OTHER|"Sham (laying of hands) intervention"|The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
214414715|NCT03838796|PROCEDURE|TACE|The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
215017256|NCT05791149|DIAGNOSTIC_TEST|saliva tube|1 tube of saliva (\~2 ml) will be collected from all patients enrolled in the study. For operated OSCC patients a second tube will be collected during the routine hospital visit 4 weeks after surgery
214414716|NCT05550922|BEHAVIORAL|Healthcare Transition-Based Education|The goal is for asthmatic adolescents to take responsibility for their own disease, be prepared for transition to adult pulmonology services, increase their self-efficacy, and gain management skills as a result of health care transition education.
214414717|NCT02794948|OTHER|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province
214414718|NCT02794948|DIETARY_SUPPLEMENT|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province.
214414719|NCT02492464|DIETARY_SUPPLEMENT|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
214414720|NCT02492464|DIETARY_SUPPLEMENT|Placebo|
214414721|NCT03284411|DEVICE|Spinal Cord Stimulation|Programming
214414722|NCT05699213|DIAGNOSTIC_TEST|Lung MRI|MRI of the lung
214414723|NCT05699213|DIAGNOSTIC_TEST|Blood Draw|Blood Draw
214414724|NCT00130819|BEHAVIORAL|Clinic-based substance abuse treatment with buprenorphine|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
214414725|NCT00130819|BEHAVIORAL|Case management and referred substance abuse treatment|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
214414726|NCT05963308|BEHAVIORAL|Healthy Minds|"The group intervention (approximately 5 participants per group, 8 groups) is facilitated by two clinicians and consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective:~Week1: Coping with work stress at work W2 and W3: Recognizing and modifying my dysfunctional beliefs linked to work W4: Overcoming obstacles linked to work functioning and maintaining work W5: To put in place needed work accommodations with the support of the immediate supervisor W6: My strengths and competencies related to work W7: Accepting criticism and asserting myself appropriately W7: My strengths and related skills W8: My best coping strategies for work Both intervention and control participants receive their standard individualized care from their clinician. However, for the experimental participants, the Healthy Minds intervention is an added component to their regular care."
214414727|NCT04667988|DIAGNOSTIC_TEST|JAK expression|JAK2 assessment in blood by PCR
215017257|NCT04849000|DRUG|SHR-1209|SHR-1209
215017258|NCT04849000|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
214414728|NCT04074148|BEHAVIORAL|Diabetes Prevention Education Program|An educational lifestyle modification program, offering 4 sessions of 30 minutes theory and 30 minutes practice each, total duration 6 months
214414729|NCT04074148|BEHAVIORAL|Diabetes Prevention Education brochure|An educational lifestyle modification brochure
214414730|NCT03182036|DEVICE|Portable pulsed oxygen|Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
214414731|NCT00796068|DRUG|Cyclosporine|Given IV or PO
214414732|NCT00796068|DRUG|Fludarabine Phosphate|Given IV
215017259|NCT05306145|PROCEDURE|High freqnence Irreversible electroporation|High freqnence Irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with benign prostatic hyperplasia
215017260|NCT05306145|PROCEDURE|Trans Urethral Resection Prostate|Trans urethral resection prostate will be performed under general anaesthesia to the patient with benign prostatic
215017261|NCT01311583|BEHAVIORAL|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
215017262|NCT03221296|BEHAVIORAL|Vestibular Training (Intervention Group)|Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
215017263|NCT03306290|DRUG|Serum dosage of antibiotic prophylaxis CEFOXITIN|"Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~1. Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (\~30 min), 1 tube (5 ml) of blood will be withdrawn~2. Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~3. Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn"
215017264|NCT01282554|DEVICE|electrostimulation program (Rehab 400)|"electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.~Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.~Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months."
214414733|NCT00796068|OTHER|Laboratory Biomarker Analysis|Correlative studies
214414734|NCT00796068|DRUG|Mycophenolate Mofetil|Given IV
214414735|NCT00796068|RADIATION|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
214414736|NCT00796068|DRUG|Treosulfan|Given IV
214414737|NCT00796068|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
214414738|NCT00835016|BEHAVIORAL|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
215017265|NCT05759364|DRUG|IV Papaverine 80 mg|Opium alkaloid antispasmodic drug
214414739|NCT03721432|DRUG|Pregabalin 150mg|pregabalin 150 mg capsules (Lyrica®,Pfizer) given 60 minutes prior to epidural anesthesia
214414740|NCT03721432|DRUG|Placebo oral capsule|Placebo oral capsule given 60 minutes prior to epidural anesthesia
214414741|NCT05181579|OTHER|Manuel therapy|Some sacroiliac manipulation and mobilization techniques will be applied to patients by an experienced physiatrist. Patients in the manual therapy group will receive 5 sessions of sacroiliac joint manipulation once a week.
214689221|NCT06911073|DIETARY_SUPPLEMENT|Postbiotic|"Active ingredients:~Vitamin D (as cholecalciferol) - 10 mcg Vitamin B12 (as methylcobalamin) - 200 mcg Chromium (as chromium picolinate) - 600 mcg resM™ Postbiotic (L. plantarum RSB11® HI - 16B cells) - 40 mg White mulberry (Morus alba) leaf extract - 250 mg Fenugreek (Trigonella foenum-graecum) seed extract - 200 mg~Inactive ingredients:~Microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, silica, water, carrageenan, potassium acetate"
214689222|NCT06911073|DIETARY_SUPPLEMENT|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, silica, water, carrageenan, potassium acetate"
214689223|NCT06833281|DRUG|SPG302|small synthetic molecule
214689224|NCT01562015|DRUG|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
214689225|NCT06797063|BEHAVIORAL|BEST4Baby|BEST4Baby consists of prenatal and post-delivery breastfeeding education and support for mothers provided by community-based peer counselors who are trained in a modified 5-day WHO/UNICEF Breastfeeding Counselling Course and supported by an mHealth application.
215101747|NCT01119092|OTHER|Grade IV AP joint mobilizations|3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
214689226|NCT06797063|BEHAVIORAL|Usual Care|Participants in the control clusters will continue with local practice for antenatal breastfeeding support and referral to facilities. It is expected that they will receive routine health education recommended by the national health system during the prenatal and postnatal period and offered through PHC and community level workers, including ASHAs. ASHAs may visit a woman after delivery to provide lactation support, as needed, with visits ceasing at 42 days post-delivery. Breastfeeding mothers requiring advanced lactation support may be referred to a community subcenter for care with more skilled clinicians.
214689227|NCT03137394|OTHER|Observation|Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.
214689228|NCT07117734|OTHER|An Evaluation of the Quality and Informational Content of Balance Exercise Training Videos Published on YouTube.|"In the study, there will be no participant groups; YouTube videos searched using the keyword balance exercise will be evaluated based on specific criteria."
214689229|NCT06924801|BEHAVIORAL|Snipperfingers|Snipperfinger is a self developed engagement focused software platform designed to encourage participation in pediatric physical therapy.
214689230|NCT06922032|DEVICE|Mystics Pet|Participants will receive the game intervention and be instructed to wear a Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in Mystic Pets software game (Stanford Chariot Program, Palo Alto, CA) that is specifically designed to promote overall distraction and emotional distress reduction.
214689231|NCT00436215|DRUG|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
214689232|NCT00436215|DRUG|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
215017266|NCT05759364|DRUG|Placebo|Placebo
215017267|NCT04401293|DRUG|Enoxaparin|Full Dose LMWH anticoagulation therapy
215017268|NCT04401293|DRUG|Prophylactic/Intermediate Dose Enoxaparin|Prophylactic/Intermediate Dose LMWH or UFH therapy
215017269|NCT03116269|DRUG|Cilostazol 100mg|
215017270|NCT03116269|DRUG|Aspirin|
215017271|NCT01813643|DRUG|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
215017272|NCT01813643|DRUG|Aripiprazole|Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
214414742|NCT05181579|OTHER|Sacroiliac joint injection|Corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine) will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy) by an experienced physiatrist. It will be applied just one time.
214414743|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|50 µmol capsules, taken orally, once a day for 28 days
214414744|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|100 µmol capsules, taken orally, once a day for 28 days
214414745|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|200 µmol capsules, taken orally, once a day for 28 days
214414746|NCT04330950|OTHER|Neurocognitive tests|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
214689233|NCT06929702|DRUG|Beta-lactam antibiotic|amoxicillin-clavulanic acid, piperacillin-tazobactam, meropenem treatment
214689234|NCT06929702|DEVICE|Beta-lactam model-informed precision dosing|A dosing calculator is used for the prediction of starting doses (a priori dose predictions) and follow-up doses (a posteriori calculations), using a target 100% fT\>MIC.
215017273|NCT04042428|DRUG|Somatropin injection|Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
215017274|NCT02713620|BIOLOGICAL|recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)|Different HBV vaccine regimen in each group
215017275|NCT00694161|DRUG|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
215017276|NCT00557102|BIOLOGICAL|cetuximab|
215017277|NCT00557102|BIOLOGICAL|filgrastim|
215017278|NCT00557102|DRUG|fluorouracil|
215017279|NCT00557102|DRUG|irinotecan hydrochloride|
215017280|NCT00557102|DRUG|leucovorin calcium|
214414747|NCT01101152|DRUG|Desvenlafaxine succinate|"Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day"
214414748|NCT04492631|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5|Sachets containing Streptococcus salivarius DB-B5 will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks. The participants will consume 10 billion colony forming units (CFU) per day.
214414749|NCT04492631|OTHER|Placebo|Sachets containing a placebo (probiotic carrier) will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks.
215017281|NCT06305065|PROCEDURE|KUNWU Navigation TKA procedure|"In terms of technical specifications, KUNWU is the only robotic arm with seven degrees of freedom, while other systems have a maximum of six. The ergonomic and user-friendly design of the system contributes to physical relief and simplified instrument handling, which enhances surgical precision and reduces cognitive stress.~KUNWU's navigation system boasts a refresh rate of 335Hz, which is significantly higher than the current 60Hz rate of other navigation systems. This high refresh rate provides a clear and visually captivating display of the navigation procedure, eliminating blurriness and indecipherable output. It enables surgeons to react promptly during live procedures, enhancing safety for both clinicians and patients and reducing potential complications and hospitalization."
215017282|NCT06305065|PROCEDURE|CORI Surgical System TKA procedure|The CORI Surgical System (Smith and Nephew®) represents one of such recent advances in robotics that it can assist surgical planning, and increase the accuracy of implant position due to real-time feedback during the procedure (bone resection, implant position, ligamentous balance).
215017283|NCT06305065|PROCEDURE|Conventional TKA procedure|Total knee arthroplasty (TKA) is a highly successful and frequently performed surgical treatment to reduce disability caused by end-stage osteoarthritis and other conditions affecting articular cartilage. Technical outcomes for TKA are excellent, with favorable postoperative health-related quality of life. Also, survivorship of primary knee replacements is excellent with reported survivorship of 82.3% at 25 years. TKA has traditionally been indicated in the elderly population with relatively sedentary lifestyles, but more active, younger patients (\<55) are receiving TKA due to the desire for a pain-free, active lifestyle with the demand projected to continue to increase for this group. A recent systematic review has shown that functional outcomes are similar in this population compared to elderly patients with no increase in the burden of revision.
215017284|NCT02505971|DRUG|Nadolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
215017285|NCT02505971|DRUG|Propranolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
215017286|NCT04481282|DRUG|Terbutaline|2.5mg po tid for 12 weeks
215017287|NCT04481282|DRUG|Danazol|200mg po bid for 12 weeks
215017288|NCT00323544|DRUG|zidovudine and lamivudine (Combivir®)|
215017289|NCT00323544|DRUG|emtricitabine and tenofovir DF|
214414750|NCT05880316|BEHAVIORAL|Intermittent Fasting|3:4 regime
214505158|NCT03367416|BEHAVIORAL|NIATx model|"The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~1. educating executives on how to promote effective process change techniques~2. training staff teams in the theory and practice of organizational change techniques~3. training staff to develop and implement a process improvement intervention~4. implementing a sustainability plan to institutionalize change and avoid reverting to previous methods"
214505159|NCT03717207|OTHER|ecg Holter,|all patients before to perform an head up tilt test for syncope evaluation will be steadied by ecg Holter to assess heart rate, heart rate variability.
214505160|NCT03717207|DIAGNOSTIC_TEST|cardiac scintigraphy|all patients before to perform an head up tilt test for syncope evaluation will receive a the 123I-MIBG, which is a norepinephrine analogous, to calculate the late heart-to-mediastinum ratio (H/Mlate) and washout rate (WR). Thus, we evaluated the H/Mlate as the index of global neuronal function due to norepinephrine uptake and the WR as the index of sympathetic tone.
214505161|NCT01124045|DRUG|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
214505162|NCT01124045|DRUG|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
214505163|NCT03579875|DRUG|Total Body Irradiation (TBI) (Plan 1)|300 cGy with thymic shielding on day -6
214505164|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 1)|10 mg/kg IV daily on days -5, -4, -3, and -2
214505165|NCT03579875|DRUG|Fludarabine (FLU)|35 mg/m2 IV daily on days -5, -4, -3, and -2
214505166|NCT03579875|DRUG|Methylprednisolone (MP)|1 mg/kg IV q12h on days -5, -4, -3, -2, and -1
214505167|NCT03579875|DEVICE|Donor mobilized PBSC infusion|T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0
214505168|NCT03579875|DRUG|G-CSF|Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days or single day ANC \>3000 Arm 1 and Arm 3)
214505169|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 2)|5 mg/kg IV daily on days -5, -4, -3, and -2
214505170|NCT03579875|DRUG|Rituximab|200 mg/m2 IV once on day -1
215017290|NCT02273466|DRUG|Desipramine tablet|
215017291|NCT02273466|DRUG|Crobenetine infusion|
214505171|NCT03579875|DRUG|Busulfan|Busulfan 0.6 mg/kg if \> 4 years old and/or \>12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.
214505172|NCT03579875|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)
214505173|NCT03579875|DRUG|Melphalan|If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients ≥10 kg (2.35 mg/kg for patients \<10 kg\^) IV for one dose over 30 minutes.
215017292|NCT02273466|DRUG|Placebo infusion|
215017293|NCT05095337|DRUG|[14C]SHR1459|Patients will receive single dose of orally \[14C\]SHR1459 on Day 1.
215017294|NCT03790969|DEVICE|26 gauge needle|smaller gauge needle
215017295|NCT03790969|DEVICE|23 gauge needle|control group
215017296|NCT05187637|DRUG|intravenous iron|One dose of intravenous iron carboxymaltose calculated according to ganzoni's formula. If after thirty days of the first dose, a second dose of 500mg will be administered if the patient continues to meet the inclusion criteria.
215017297|NCT05177263|OTHER|Placebo|Sterile Water
215017298|NCT05177263|DRUG|10% Oral Dextrose Solution|10% Oral Dextrose Solution
215017299|NCT05177263|DRUG|20% Oral Dextrose Solution|20% Oral Dextrose Solution
215017300|NCT05177263|DRUG|30% Oral Dextrose Solution|30% Oral Dextrose Solution
215017301|NCT03111732|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle
215017302|NCT03111732|DRUG|Oxaliplatin|130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
215017303|NCT03111732|DRUG|Capecitabine|750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
215017304|NCT01108055|DRUG|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
215017305|NCT01108055|DRUG|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
214505174|NCT03579875|DRUG|Rituximab|Rituximab will be given once on treatment plans 1-3 on day -1.
214505175|NCT00729547|BEHAVIORAL|Neurofeedback|enhance relative activity level of left frontal activity
214505176|NCT00729547|BEHAVIORAL|Psychotherapy placebo|These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
214505177|NCT03298087|PROCEDURE|radical prostatectomy|surgical removal of the prostate
214505178|NCT03298087|RADIATION|stereotactic body radiotherapy|Highly targeted radiation
214505179|NCT03298087|DRUG|Leuprolide|Lowers serum testosterone
214505180|NCT03298087|DRUG|apalutamide|antiandrogen
214505181|NCT03298087|DRUG|abiraterone|Inhibits androgen synthesis
214505182|NCT03089905|DRUG|Sevoflurane|Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
214505183|NCT03089905|DRUG|Remifentanil|Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
214505184|NCT03089905|DRUG|Dexmedetomidine|Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
214505185|NCT03935152|DRUG|Dydrogesterone|dydrogesterone capsule
214505186|NCT03935152|DRUG|placebo|placebo capsule
214505187|NCT03939416|OTHER|Experimental|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease~POLD~1. Rhythmic transversal muscle mobilization in posterior chain musculature.~2. General vertebral decompression from the sacrum and pelvis~3. Metameric subcutaneous mobilization~4. Rhythmic vertebral mobilization from the spinous processes."
214505188|NCT03939416|OTHER|Control|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease"
214505189|NCT06130605|OTHER|Data collection|Data collection
214505190|NCT06029842|OTHER|Collaborative approach of clinical pharmacist with physicians in a medical center|For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.
214505191|NCT04228952|COMBINATION_PRODUCT|Modified Natural American Spirit-Tan or Green cigarettes injected with labeled NNK|American Spirit cigarettes will be modified by adding 0.300 μg \[pyridine-D4\]NNK to each cigarette so that the amount of total (deuterated plus unlabeled) NNK in these cigarettes is below 0.700 μg/g tobacco.
214505192|NCT05552157|DRUG|Remternetug (SC)|Administered subcutaneously every 12 weeks
214505193|NCT05552157|DRUG|Matching Placebo (Remternetug)|Administered as subcutaneous injection of placebo every 12 weeks
214505194|NCT00515060|OTHER|Sensory Tests|Tests to find the threshold at which perceive stimuli.
214505195|NCT06229418|OTHER|DFR AED Pilot Program|Integrate AED drone delivery into an existing FAA-approved drone-as-first-responder programs
214505196|NCT04419519|DRUG|Venetoclax monotherapy|Venetoclax monotherapy
214505197|NCT04419519|DRUG|Venetoclax with anti CD20 monoclonal antibody|Venetoclax with anti CD20 monoclonal antibody
214505198|NCT06045247|DRUG|Prednisone|Given by IV (vein)
214414751|NCT05737238|BEHAVIORAL|Intervention during phase B: Compensatory brain game supporting Goal Management Training intervention|The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently at their own home. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
214414752|NCT00076986|DRUG|IL13-PE38QQR|
214414753|NCT00076986|PROCEDURE|surgery and catheter placement (2 procedures)|
214689235|NCT06930521|DIAGNOSTIC_TEST|Intervention - Low Risk Group OR Intermediate Risk Group|"Participants will be randomized to judicious imaging (decreased imaging frequency based on HF risk category) or SOC (imaging every 3 months). Participants who do not have any HF risk factors will be categorized as low risk, while participants with at least one risk factor will be categorized as intermediate risk for HF.~Low Risk (zero risk factors): imaging before cycles 1 and 9 of HER2-TT (i.e., at baseline and near the halfway mark, corresponding to 2 fewer studies than SOC in Year 1), then after the end of HER2TT. This translates to imaging every 6 months for uninterrupted adjuvant HER2TT.~Intermediate Risk (any risk factors): imaging before cycles 1, 6, and 12 of HER2-TT (i.e., at baseline and near the 1/3 and 2/3 marks, corresponding to 1 fewer study than SOC in Year 1), then at end of HER2TT. This translates to imaging every 4 months for uninterrupted adjuvant HER2TT."
214689236|NCT06930118|DRUG|chidamide, regorafenib, and iparomlimab/tuvonralimab|All patients were treated with the following regimen: Chidamide: 30mg per dose, twice a week; Regorafenib: 80mg per dose, once a day, orally for 3 weeks, followed by a 1-week rest, and repeated every 4 weeks; Iparomlimab/Tuvonralimab: 5mg/kg, once every 3 weeks, intravenous infusion.
214689237|NCT07132775|DEVICE|Active full-body stimulation|Participants will receive active stimulation through a full-body suit with embedded electrodes that deliver a low-grade electrical stimulation to muscle groups.
214689238|NCT07132775|OTHER|Sham full-body stimulation|Participants will receive sham stimulation through a full-body suit with embedded electrodes that deliver a low-grade electrical stimulation to muscle groups.
214689239|NCT01915810|BEHAVIORAL|Exercise Intervention|Complete SCwPA intervention
214689240|NCT01915810|OTHER|Laboratory Biomarker Analysis|Correlative studies
214689241|NCT01915810|DRUG|Nicotine Patch|Receive nicotine patch
214689242|NCT01915810|OTHER|Questionnaire Administration|Ancillary studies
214689243|NCT01915810|OTHER|Tobacco Cessation Counseling|Receive smoking cessation counseling
214689244|NCT06930053|OTHER|Core stability training|"The study group will receive core stability exercises, which consist of three levels. Each level took 4 weeks. The difficulty of each level varies in proprioception, balance, and stability as it started from exercising on a stable surface mat and ended with unstable surface physioball. The first simple level involves supine abdominal draw (3 sets per 20 repetitions), abdominal draw-in with a double knee to chest (3 sets/20 repetitions), and supine twist (3 sets per 20 repetitions). The second medium level involves pelvic bridging (3 sets per 3-5 repetitions) and twists with a medicine ball (3 sets per 10-20 repetitions). The third difficult level involves bridging with head-on physioball holding this position for 3-5 seconds, then slowly relaxing (3 sets per 10-20 repetitions), and prone bridging (3 sets per 3-repetitions). There was a 30-second rest between sets . The program will be applied 30 minutes a day for 3 days a week for 12 weeks. in addition to 30 minutes of a standard"
214689245|NCT06930053|OTHER|Action observation therapy|The examined group got 30 minutes of a standard,selected physical therapy program in addition to 30 minutes of AOT on the upper limb (total session time: 1 hour), 3 sessions per week for three consecutive months (total therapy time: 3 hours/week). Action observation was executed with therapist guidance and repeated practice (3 repetitions for each task). The child has been requested to perform the watched task with the same tool after observing a 3-minute video for each task on an adjustable monitor screen positioned one meter infront of him or her from forward, sideways, and backward directions. The therapist sat beside the child to provide verbal comments during the excursion and to guide the child's movement.The AOT for the examined group included six unimanual tasks and six bimanual tasks. The unimanual tasks included pressing a rubber stamp, stacking cups, drinking water from a cup, grabbing a pen, flipping cards, and putting things on a stick. The bimanual tasks were opening a bo
214414754|NCT00076986|DRUG|prolifespan 20 with carmustine implant (GLIADEL® Wafer)|
214414755|NCT00076986|PROCEDURE|surgery and wafer placement (1 procedure)|
214414756|NCT02854761|DRUG|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
214414757|NCT04502511|DIAGNOSTIC_TEST|Standard diagnosis test|Care as usual
214414758|NCT01703130|PROCEDURE|Dose of of ropivacaine 0.75% used in block procedure|
214414759|NCT00241930|BEHAVIORAL|Integrating drug treatment into HIV services|
214414760|NCT03375255|DRUG|SRP-5051|Single dose of SRP-5051 administered as an intravenous (IV) infusion.
214414761|NCT04486222|DEVICE|Repeated Transcranial Magnetic Stimulation|Magstim® Super Rapid² Transcranial Magnetic Stimulation System
214414762|NCT00035542|DRUG|Glucovance (metformin HCl/glyburide)|
214689246|NCT06930053|OTHER|combination of Action observation therapy and core stability training .|combination of Action observation therapy and core stability training .
214689247|NCT05437029|DRUG|Q-Griffithsin 3.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of low dose Q GRFT intranasal spray DP
214689248|NCT05437029|DRUG|Q-Griffithsin 6.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of high dose Q GRFT intranasal spray DP
214689249|NCT04416776|DRUG|Strabismus diagnostic system.|An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
214689250|NCT00309777|DRUG|Pitavastatin|Pitavastatin once daily
214689251|NCT00309777|DRUG|Simvastatin|Simvastatin once daily
215017306|NCT06163638|BEHAVIORAL|GRANDPACT Project|To investigate whether grandparents and grandchildren are more co-physically active, have a better cognitive and physical function, psychosocial well-being, quality of the family relationship due to the intervention, we compare the intervention phase (B) with a pre phase (A), a in between period (A) and another intervention period (B)
214414763|NCT00035542|DRUG|metformin HCl|
215017307|NCT02504385|DEVICE|Virtual Reality Timocco|Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
215017308|NCT02504385|OTHER|Conventional OT intervention|Traditional Occupational Therapy intervention will be givven to the control group.
215017309|NCT01366105|DEVICE|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
215017310|NCT00964444|DEVICE|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
215017311|NCT04674800|BIOLOGICAL|MYL-1701P, a proposed biosimilar to Eylea|Open label and single arm
215017312|NCT00063232|DRUG|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
214414764|NCT00035542|DRUG|glyburide|
214414765|NCT03010553|PROCEDURE|Detection and resection of sentinel lymph node|
215017313|NCT00328809|DRUG|spironolactone|spironolactone administered to ESRD patients at low dose
214414766|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions at sea|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) at sea Standard pharmacological treatment usually provided to patients with fibromyalgia."
214414767|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions in nature|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) in nature Standard pharmacological treatment usually provided to patients with fibromyalgia."
214414768|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
214414769|NCT03945942|DEVICE|Near infrared spectroscopy with INVOS device|somatic and cerebral oximetry by INVOS in pediatric liver transplantation
214414770|NCT03945942|DEVICE|Near infrared spectroscopy with Foresight device|somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
214505199|NCT06045247|DRUG|Rituximab|Given by IV (vein)
214505200|NCT06045247|DRUG|Cyclophosphamide|Given by IV (vein)
214505201|NCT06045247|DRUG|Vincristine|Given by IV (vein)
214505202|NCT06045247|DRUG|Epcoritamab|Given under the skin
214505203|NCT06113692|BIOLOGICAL|mRNA-1273|intramuscular injection
214505204|NCT04645680|OTHER|Dietary Intervention|Consume isocaloric whole foods diet higher in fiber
214505205|NCT04645680|OTHER|Dietary Intervention|Whole foods diet
214505206|NCT04645680|OTHER|Quality-of-Life Assessment|Ancillary studies
214505207|NCT04645680|OTHER|Questionnaire Administration|Ancillary studies
214505208|NCT05925036|DRUG|Mesenchymal stem cells|Autologous bone marrow derived MSCs
214505209|NCT05925036|OTHER|Placebo|Controls
214505210|NCT05298423|BIOLOGICAL|pembrolizumab/vibostolimab|Administered as an intravenous (IV) infusion
214505211|NCT05298423|BIOLOGICAL|durvalumab|Administered as an IV infusion
214505212|NCT05298423|DRUG|cisplatin|Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3
214505213|NCT05298423|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only
214505214|NCT05298423|DRUG|etoposide|Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;
214505215|NCT05298423|DRUG|carboplatin|Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
214505216|NCT05298423|DRUG|paclitaxel|Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
214505217|NCT05298423|RADIATION|thoracic radiotherapy|60 Gray \[Gy\] in 2 Gy fractions for 30 days total administered as an external beam radiation
214505218|NCT01979393|DRUG|Cabozantinib|
214505219|NCT01979393|DRUG|Placebo|
214414771|NCT05189340|OTHER|Educational Videos|Series of six videos each covering a specific aspect of post-transplant care related to medication use or monitoring
214414772|NCT00920686|DRUG|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
215017314|NCT03339453|DRUG|Nasal Glucagon|Administered nasally
214414773|NCT00920686|DRUG|placebo|administered as 3 placebo hard gelatin capsules
214414774|NCT00920686|DRUG|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
214414775|NCT06225999|DRUG|Irinotecan liposome injection (S095013)|Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
214414776|NCT06225999|DRUG|Oxaliplatin|Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
214414777|NCT06225999|DRUG|LLV (levoisomer form of leucovorin)|LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
214414778|NCT06225999|DRUG|5- FU (5-Fluorouracil)|5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
214414779|NCT01313182|DRUG|mupirocin calcium ointment, 2%|"Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares."
214414780|NCT01313182|DRUG|3M Skin and Nasal Antiseptic|The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
214414781|NCT01695317|DRUG|Acetyl-L-carnitine|Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
214414782|NCT03795740|DIAGNOSTIC_TEST|3-D CT scanning|For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
214414783|NCT04900142|PROCEDURE|Micropulsed laser trabeculoplasty|Trabeculoplasty
214414784|NCT01645917|DEVICE|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
214414785|NCT05581654|PROCEDURE|Salpingectomy|Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
214414786|NCT03584646|DEVICE|Nokia GO Wearable StepTracker|All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.
214414787|NCT03584646|OTHER|Medication Reminder|Medication reminders are sent to participants in Arm 2 on a daily basis.
214414788|NCT03584646|OTHER|Weekly Check-in appointment with study team or provider|Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
215017315|NCT03339453|DRUG|Intramuscular Glucagon|Administered IM
215017316|NCT02644811|DRUG|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
215017317|NCT02644811|DRUG|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
214414789|NCT01927835|BIOLOGICAL|DNA-HIV-PT123 vaccine|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM
214414790|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM
214414791|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM
214414792|NCT01927835|BIOLOGICAL|AIDSVAX B/E vaccine|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM
214414793|NCT01927835|BIOLOGICAL|Placebo for DNA/NYVAC/AIDSVAX|Sodium Chloride for injection, 0.9%; administered IM
214414794|NCT00825435|PROCEDURE|Coronary CT Angiogram|Coronary CT Angiogram
215017318|NCT02644811|PROCEDURE|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
215017319|NCT02644811|DRUG|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
215017320|NCT02644811|DRUG|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
215017321|NCT02644811|DEVICE|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
214414795|NCT00462969|PROCEDURE|Sonohysterography|Sonohysterography
214414796|NCT01161719|BEHAVIORAL|parent training|Behavioral management skill training
214414797|NCT03906734|PROCEDURE|Septal myectomy|Transaortic septal myectomy
214414798|NCT03906734|PROCEDURE|alfieri stich|Transaortic Mitral valve repair using alfieri technique
214414799|NCT03906734|PROCEDURE|Subvalvular intervention|Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release
214414800|NCT02981186|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
214414801|NCT02981186|DEVICE|IOL implantation comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
214414802|NCT04580303|DRUG|collagenase clostridium histolyticum|Delivered via uniform grid injection techniques.
214414803|NCT00000646|DRUG|Pentoxifylline|
215017322|NCT02644811|DEVICE|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
215017323|NCT06460909|OTHER|Psychological support|An interview with the psychologist before surgery.
215017324|NCT03377127|BEHAVIORAL|Pharmacy Managed Diabetes Clinic (PMDC)|The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.
214414804|NCT04042519|DIAGNOSTIC_TEST|Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.|This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.
214414805|NCT04042519|DIAGNOSTIC_TEST|Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.|We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.
214414806|NCT04042519|DIAGNOSTIC_TEST|Routine blood test|Blood routine test results include CRP, PCT, white blood cell count, red blood cell count, neutrophil percentage, eosinophil, basophil, et al.
214414807|NCT05037032|DRUG|Naltrexone Pill|50 mg PO one-time only
214414808|NCT05037032|DRUG|Placebo|Matching placebo for naltrexone
214414809|NCT01444287|DEVICE|narafilcon B|test product
214414810|NCT01444287|DEVICE|Polymacon|marketed product
214689252|NCT07148063|OTHER|Measurement of Preoperative Inflammatory Biomarkers|Blood samples will be collected preoperatively to measure inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index, monocyte-to-lymphocyte ratio (MLR), and systemic inflammation response index. These values will be analysed in relation to the incidence of postoperative nausea and vomiting within the first 6 hours after pediatric orchiopexy. No experimental drug or device will be administered as part of the study; all procedures will be conducted within the scope of standard perioperative care.
214689253|NCT07162792|DEVICE|bioresorbable scaffold|75 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of BRS.
214689254|NCT07162792|DEVICE|drug-coated balloon|75 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of DCB.
214689255|NCT07163143|DRUG|Isoniazid (H)|H, weight based, 150-375mg
214414811|NCT01444287|DEVICE|Lotrafilcon A|marketed product
214689256|NCT07163143|DRUG|Rifampicin (R)|R, weight based, 300-750mg
214689257|NCT07163143|DRUG|Pyrazinamide (Z)|Z, weight based, 800-2000mg
214689258|NCT07163143|DRUG|Ethambutol (E)|E weight based, 550-1375mg
214689259|NCT07162077|PROCEDURE|Sodium hypochlorite 5.25%|In the test group, the investigators will be applied sodium hypochlorite 5.25% by using cotton wad on the opacity before treatment, then after the first and second etching cycles (application of the Icon-Etch (ICON® -Etch; DMG, Hamburg, Germany) and Icon-dry (ICON® -Dry; DMG, Hamburg, Germany) according to the manufacturer's recommendations) as irrigation step and following the third -Etch etching cycle Icon-infiltrant (ICON® -Infiltrant; DMG, Hamburg, Germany) will be applied.
214689260|NCT07162077|PROCEDURE|ICON resin infiltration Material group in vivo|In control group, the investigators will be applied the same protocol of test group but without using sodium hypochlorite
214414812|NCT01444287|OTHER|Spectacles|None - subject used own spectacles
214689261|NCT07161739|BEHAVIORAL|Behavioural Nudge (Influenza Risk Reduction)|A behavioural nudge via mailed letter that discusses the benefits of the influenza vaccine in preventing influenza infection and reducing cardiovascular risk.
214414813|NCT05451199|DRUG|ICP-488|ICP-488 will be administered as tablet
214414814|NCT05451199|DRUG|Placebo|Matching placebo will be administered as tablet
214414815|NCT00665379|OTHER|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
215017325|NCT03377127|OTHER|Standard of Care (SOC)|Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
215017326|NCT01236807|PROCEDURE|MR perfusion guidance|Coronary revascularization guided by MR perfusion imaging
215017327|NCT01236807|PROCEDURE|FFR guidance|Coronary revascularization guided by invasive angiography and FFR
214414816|NCT00665379|OTHER|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
214414817|NCT02773017|DRUG|Dexmedetomidine A|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
215017328|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).
214414818|NCT02773017|DRUG|Dexmedetomidine B|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
214414819|NCT02773017|DRUG|Dexmedetomidine C|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
214689262|NCT07161739|BEHAVIORAL|Behavioural Nudge (Travel Vaccination Benefit)|A behavioural nudge via mailed letter that discusses the benefits of travel vaccines in preventing travel-related illnesses.
214689263|NCT07162688|DRUG|Omega-3 Lipid Emulsion|Intravenous Omega-3 lipid emulsion administered at a dose of 2 mL/kg/day (equivalent to 0.2 g/kg of fish oil), starting from the conditioning phase prior to hematopoietic stem cell infusion and continuing daily until neutrophil and platelet engraftment or up to Day +35 post-transplantation. The emulsion is infused over 4-6 hours and combined with medium- and long-chain triglyceride emulsion as part of parenteral nutrition.
214689264|NCT07162597|DEVICE|Pulsed Field Ablation|Pulsed Field Ablation
214689265|NCT07163364|DRUG|Hydroxocobalamin Chloride Injection|1 - 20 mg per dose, 1 - 5 times per week
214414820|NCT00434278|DRUG|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
214414821|NCT00434278|DRUG|placebo|2.5 mg inhalation dose twice daily for 14±2 days
215017329|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|
214689266|NCT07161804|DRUG|Homoeopathic medicines|Thuja officinalis Vaccininum Causticum Argentum nitricum Tuberculinum Stramonium Staphysagria Arum triphyllum Bacillinum Cina Carcinocin Cuprum Metallicum Ambera grisea Calcarea carbonica Crocus sativus Hepar sulphur Hyoscymus Kali Bromatum Lac Vaccininum Medorrhinum Natrum phosphoricum Thyroidinum
214689267|NCT07161804|BEHAVIORAL|Therapy|Occupational Therapy / Speech Therapy
214689268|NCT07161804|DRUG|Placebo|Saccharum lactis
215017330|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|35mg/35 infusion time is 3.5 minutes
215017331|NCT05605080|DEVICE|Gelfoam|Use Gelfoam as a hemostatic agent after anal surgery.
215017332|NCT05605080|OTHER|Bosmin gauze|Use bosmin gauze as a hemostatic agent after anal surgery.
215017333|NCT02734914|DEVICE|SF-URS with automatic control of RPP|A new F-URS monitoring and control of RPP using intelligent pressure control device
214414822|NCT05145517|DEVICE|Open repair|Open repair of the aorta and peripheral arteries
215017334|NCT02734914|DEVICE|conventional F-URS|Ureteroscopy will be conducted using the ureteral access sheath from Cook Medical to treat renal calculi.
214414823|NCT01536730|BEHAVIORAL|Homework Intervention Strategy|"Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention."
214414824|NCT00439933|BEHAVIORAL|low fat and polysaccharide rich diet|
214414825|NCT00439933|BEHAVIORAL|specific physical training program for obese children|
214414826|NCT02299635|DRUG|PF-03084014|Tablet, 10 mg, twice a day.
215017335|NCT03397758|DEVICE|Study population|First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
215101748|NCT01447732|DRUG|CEP-37250/KHK2804|"Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1."
214414827|NCT02299635|DRUG|PF-03084014|Tablet, 50 mg, twice a day
214414828|NCT02299635|DRUG|PF-03084014|Tablet, 100 mg, twice a day
215101749|NCT03063281|OTHER|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
215101750|NCT00663403|DRUG|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
214414829|NCT00927823|DRUG|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
215101751|NCT01465815|DRUG|erlotinib hydrochloride|Given PO
214414830|NCT01424579|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
214689269|NCT07161934|BEHAVIORAL|Guided Imagery Training|Participants received guided imagery sessions of 15 minutes after each football training, three times per week for 12 weeks (36 sessions). Sessions included relaxation, visualization of technical movements, and reinforcement of motivation and confidence.
214689270|NCT07161934|BEHAVIORAL|Standard Football Training|Participants received only regular football training three times per week for 12 weeks (36 sessions). Each session lasted 60 minutes and focused on technical skills. To match contact time, a 15-minute team evaluation meeting was held after each practice.
214689271|NCT05622864|DRUG|HRS-9821|HRS-9821
214689272|NCT05622864|DRUG|HRS-9821|HRS-9821
214689273|NCT05420129|DEVICE|MAD Therapy|Participants will be treated with a Mandibular Advancement Device therapy
214689274|NCT05420129|DEVICE|CPAP Therapy|Participants will be treated with a Continuous Positive Airway Pressure therapy
214689275|NCT01113398|DRUG|AMG 102|AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
214689276|NCT01113398|DRUG|Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
214689277|NCT03824925|DRUG|Placebo oral Zinc capsule|Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
214689278|NCT03824925|DRUG|Zinc Sulfate 220 MG|Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
215017336|NCT02769052|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
215017337|NCT00483392|DRUG|metformin, rosiglitazone|
215017338|NCT05231941|DRUG|Lidocaine IV|Bolus and infusion of lidocaine will be administered
215017339|NCT05231941|DRUG|Ropivacaine|Bilateral TAP block will be given to these patients
215101752|NCT01465815|DRUG|linsitinib|Given PO
215101753|NCT01465815|DRUG|placebo|Given PO
215101754|NCT01465815|RADIATION|radiation therapy|Undergo radiation therapy
215101755|NCT01465815|PROCEDURE|therapeutic conventional surgery|Undergo planned surgery
215101756|NCT01465815|OTHER|laboratory biomarker analysis|Correlative studies
215101757|NCT00646399|DRUG|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
215101758|NCT00646399|DRUG|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
215101759|NCT00351065|DRUG|SK3530|
215101760|NCT02703480|BIOLOGICAL|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
215101761|NCT02703480|BIOLOGICAL|Ti-mesh|Titanium mesh
214414831|NCT01424579|OTHER|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
214414832|NCT01424579|OTHER|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
214414833|NCT05104905|DRUG|bexmarilimab|A single neoadjuvant dose will be administered prior to surgery.
214414834|NCT02565056|OTHER|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
214414835|NCT04837313|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
214414836|NCT00028132|DRUG|Tenofovir|
214414837|NCT02943382|OTHER|Fingerprick autologous blood (FAB)|Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
214689279|NCT05848037|DEVICE|cymactive™ catheter device (CCD)|"The cymactive™ catheter (manufactured by Ingenion Medical Ltd) received CE marking on the 28th March 2024, as a Class IIb device (n. ECM24MDR002 rev.0, Single Registration Number (SRN) of the Manufacturer UK-MF-000041065) and will be available in the UK market, subject to local arrangements.~The cymactive™ catheter is designed to remain in situ for up to 30 days, does not extend outside the patient's body except for 2 removal strings, and has an integral, magnetically controlled valve that allows the user to control their own urination. The study participant will each be supplied with a magnetic Actuator (a separate Class I device supplied by Ingenion Medical) so they are in control of valve and their own voiding. The magnet is strong and care will need to be taken to keep it at least 6 inches from magnetically-sensitive items, i.e. mobile phones, laptops and credit cards. Study participants should also avoid contact with MRI machines."
214689280|NCT05848037|DEVICE|Foley-type catheter device|Routine standard of care. Usually replaced \~ 3 monthly
214689281|NCT06182475|BEHAVIORAL|EPPComm Provider Training|A curriculum will be developed to educate patients about LDKT and promote the search of potential living donors while supporting patients' values and cultural preferences. The curriculum will consist of two components: didactic education and skills-based communication. The didactic component provides evidence of the impact of patient-provider communication and LDKT process outcomes for Black and Caucasian patients. The skills-based component will build communication confidence leading discussions about LDKT. It provides instructions for the key communication skills needed to confidently assuage patients' concerns about LDKT/live donation and motivates patients to search for living donor. The following will be covered: providing LDKT information/answering questions, highlighting LDKT benefits, refuting live donation misinformation, and encouraging patients to seek living donors.
214414838|NCT06474806|DRUG|64Cu-DOTA-AE105|AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.
214414839|NCT04128839|DIETARY_SUPPLEMENT|Aronia berry juice|A juice blend of three different cultivars was used: Viking, MacKenzie and Autumn Magic. Raw juice was heat pasteurized before provided to participants. Participants consumed 100 mL of juice per day.
214414840|NCT04128839|OTHER|Sham comparator|The placebo was flavor, color, and carbohydrate-matched to aronia juice. The placebo consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL of juice per day.
214414841|NCT00828672|DRUG|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
214689282|NCT04704895|DIETARY_SUPPLEMENT|Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
215017340|NCT02863172|BEHAVIORAL|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
214689283|NCT04704895|DIETARY_SUPPLEMENT|Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
214689284|NCT00492856|DRUG|mercaptopurine|Given orally
214414842|NCT00828672|DRUG|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
214414843|NCT00828672|DRUG|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
214414844|NCT00828672|RADIATION|radiotherapy|Total dose 45Gy
214414845|NCT02239796|DEVICE|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
214414846|NCT02239796|DEVICE|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
214414847|NCT03901729|DRUG|BAY 1753011|Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
214689285|NCT00492856|DRUG|methotrexate|Given orally
214689286|NCT00492856|DRUG|tretinoin|Given orally
214414848|NCT03901729|OTHER|Placebo BAY 1753011|Tablet; Once daily in the morning; Oral
214414849|NCT03901729|DRUG|Furosemide|Tablet; 40mg unit; 80mg once daily in the morning; Oral
214414850|NCT03901729|OTHER|Placebo Furosemide|Tablet; Once daily in the morning; Oral
214414851|NCT04470817|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil
214414852|NCT01006746|OTHER|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
214414853|NCT05608967|DEVICE|PREHapp|Prehabilitation programme through the PREHapp platform
214414854|NCT01735929|PROCEDURE|Neck Liposuction and Ultrasound Treatment|
214414855|NCT01735929|PROCEDURE|Sham Treatment|
214689287|NCT06347341|DIETARY_SUPPLEMENT|Clinical study comparing a gluten-containing diet to a gluten-free diet|The study includes a basal period of 2 weeks, 2 test periods of a maximum duration of 1 week and a wash-out period of 2 to 3 weeks.
214414856|NCT01382810|DRUG|Altaire Gel forming solution|Three times a day for two months
214414857|NCT01382810|DRUG|Refresh Tears|Three times a day for two months
214414858|NCT03148054|DEVICE|Computer Tomography and Endoscopy|"Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system."
214414859|NCT00774111|DRUG|GSK1349572|GSK1349572 50 mg in combination with Etravirine
214414860|NCT00569738|PROCEDURE|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
214414861|NCT06441656|PROCEDURE|Vitrectomy with ILM flap|In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH
214414862|NCT03369587|BEHAVIORAL|Handwriting Practice|Self-directed home handwriting practice daily for 6 weeks
214414863|NCT03163862|PROCEDURE|Endometrial scratch|the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
214414864|NCT03163862|DRUG|G-CSF administration|1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
214414865|NCT03163862|DRUG|Saline Solution|saline infusion every day from the day of embryo transfer through the day of beta HCG test
214414866|NCT02709343|DRUG|Bone-marrow derived MSCs|Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells
214414867|NCT02709343|DRUG|Placebo|Placebo product visually very similar to mesenchymal stromal cells
214689288|NCT01350960|DRUG|SPC5001|3 weekly SC injections
215017341|NCT02863172|PROCEDURE|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
215017342|NCT02922660|DRUG|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure
215017343|NCT02922660|PROCEDURE|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
215017344|NCT02922660|PROCEDURE|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
215017345|NCT02922660|DRUG|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
215017346|NCT02922660|DRUG|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
215017347|NCT03298100|OTHER|Scoring model|Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
214414868|NCT05230875|BEHAVIORAL|self-administered questionnaire|"All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program."
214414869|NCT00078533|BIOLOGICAL|CMV CTL infusion|Three dose levels will be explored. The lowest dose level will be 1x10\^7cells/m2 and the highest will be 1x10\^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
214414870|NCT01228851|OTHER|Balance Training|Group balance training sessions three times a week for 8 weeks
214414871|NCT00831792|DRUG|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
214414872|NCT00247143|DRUG|Kaletra (drug)|
214414873|NCT04258774|OTHER|Carbon Dioxide|The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
214414874|NCT06554132|OTHER|Scleroderma Group|Scleroderma patients will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
214689289|NCT01350960|DRUG|Saline 0.9%|3 weekly SC injections
214689290|NCT01350960|DRUG|SPC5001|3 weekly SC injections
214689291|NCT01350960|DRUG|SPC5001|3 weekly SC injections
214689292|NCT01350960|DRUG|SPC5001|3 weekly SC injections
214689293|NCT01350960|DRUG|SPC5001|3 weekly SC injections
214689294|NCT02513368|DEVICE|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
214689295|NCT02513368|PROCEDURE|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
214689296|NCT00857753|DRUG|Fentanyl patch 25 ug/nr Sandoz|
214689297|NCT00857753|DRUG|Duragesic|
214414875|NCT06554132|OTHER|Healthy group|Healthy people will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
214414876|NCT02837380|DRUG|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
214414877|NCT02837380|DRUG|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
214414878|NCT04874571|OTHER|Muscle Energy Technique group|In addition to the home exercise program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the MET(Musculer Energy Technique) group.
214414879|NCT04991259|PROCEDURE|Continuous Renal Replacement Therapy (CRRT)|Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.
214414880|NCT04991259|OTHER|Standard Medical Treatment|In the L- ICU, patients will be managed by a multidisciplinary team. Intubation and ventilation will be undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema on CT-scan. Fluid management will be done with crystalloids, with the use of colloids (5% albumin) in patients with severe hypoalbuminemia (serum albumin less than 2.5gm/dl). Norepinephrine will be the primary vasopressor used to target a mean arterial pressure of 65-70 mm of Hg. with adjunctive use of intravenous low dose hydrocortisone and vasopressin in patients not responsive to initial therapy.
214414881|NCT01168011|DRUG|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
214689298|NCT05165511|BEHAVIORAL|PBT-EF|PBT-EF will be delivered to parents only. Parents will be taught general behavioral weight loss skills to apply to their child and themselves including decreasing caloric intake and increasing physical activity, self-monitoring, and goal setting. Additionally, parents will learn compensatory strategies surrounding organization, habit learning, planning, and problem-solving to generalize FBT skills to real-world behaviors (e.g., self-monitoring of food intake). Each session will include interactive exercises to help train an aspect of EF. Skills taught will be presented to be practiced with real-world applications.
214689299|NCT06451380|PROCEDURE|orthopaedic surgery|orthopaedic surgery of the upper limb under anaesthesia
215017348|NCT06375720|BEHAVIORAL|Lower frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
215017349|NCT06375720|BEHAVIORAL|Higher frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
215101762|NCT04068116|PROCEDURE|Primary per-cutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty \& coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion \& reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
214689300|NCT06451380|DRUG|propofol anesthesia|The initial dose of propofol and the refractory period will be determined according to a standardized protocol used in current practice.
214689301|NCT05732532|DRUG|Bupivacaine|2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
214689302|NCT05732532|DRUG|Lidocaine|0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
214689303|NCT05732532|DRUG|Dexamethasone|0.5 mL of dexamethasone (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
214689304|NCT05732532|DRUG|Normal saline|0.5 mL of normal saline 0.9% injected at the origin of each bilateral greater and lesser occipital nerves
214689305|NCT05732532|PROCEDURE|Greater/lesser occipital nerve blocks|Subjects will receive a total of 12 mL injectate divided equally between the 4 injection sites of the bilateral greater and lesser occipital nerves using the landmark-based technique.
214689306|NCT02519049|OTHER|No intervention|This is an observational study
214689307|NCT05569304|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty
214689308|NCT03488472|DEVICE|NovoTTF-200A|Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.
214689309|NCT03488472|RADIATION|Stereotactic Radiosurgery (SRS)|SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.
214689310|NCT06405022|OTHER|Brain Endurance Training|Six week period with three weekly blocks with a 20 min brain endurance training program following a regular HIT session. Before the HIT session questionnaires are completed to measure the motivation for the HIT session and the current state of mood. In between the HIT session and the RCA session, questionnaires are completed to measure the experienced workload of the HIT session, the current state of mood, and the motivation for following the RCA session. Immediately after the RCA session, questionnaires are completed to measure the experienced workload of the RCA session and the current state of mood.
214689311|NCT06405022|OTHER|Control|No intervention
214689312|NCT03121222|DRUG|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
214689313|NCT03121222|DRUG|Lactose|The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
214414882|NCT01895257|DEVICE|HAI-90Y radioembolization (SIR-spheres injection)|"Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.~1. Hepatic Angiogram~2. Liver-Lung Break-Through Nuclear Scan"
214414883|NCT01895257|DRUG|systemic chemotherapy LV5FU2|"Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure."
214414884|NCT02805244|DRUG|JTZ-951, 14C-JTZ-951|
214414885|NCT03742713|DRUG|CPC634 (CriPec® docetaxel)|Docetaxel containing CriPec® nanoparticles
214414886|NCT05097573|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, stretch marks, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
214414887|NCT04251351|DRUG|Paracetamol|Paracetamol 15 mg/kg/dose IV 6 hourly for 72 hours
214414888|NCT04251351|PROCEDURE|Mechanical antipyresis|"Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.~If a temperature \>38.5°C persists despite mechanical antipyresis, or if deemed necessary by the treating clinician, then paracetamol can be administered according to local practice (paracetamol IV 15 mg/kg as needed)."
214414889|NCT02703129|OTHER|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
214414890|NCT00742573|DRUG|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
214414891|NCT00742573|BEHAVIORAL|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
214414892|NCT04912362|DEVICE|YAG iridotomy|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
214414893|NCT03278197|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
214414894|NCT03278197|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
214414895|NCT03278197|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
214414896|NCT03278197|OTHER|Interviews with stakeholders|Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
214414897|NCT00647205|DEVICE|QuantiFERON TB Gold In-Tube|
214414898|NCT00647205|DEVICE|T-SPOT.TB®|
214414899|NCT03208101|BIOLOGICAL|DTP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
214414900|NCT03208101|BIOLOGICAL|DTP-HepB-Hib vaccine & IPV|Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)
214414901|NCT01724788|DRUG|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
214414902|NCT01724788|DRUG|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
214414903|NCT02509390|PROCEDURE|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
214414904|NCT02701361|BEHAVIORAL|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
214414905|NCT02701361|BEHAVIORAL|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
214414906|NCT02701361|BEHAVIORAL|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
214414907|NCT01034943|PROCEDURE|External fixation|Operation with external fixation and optional addition of k-wire
215017350|NCT06375720|BEHAVIORAL|Lower frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
215101763|NCT02473367|DRUG|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
214414908|NCT01034943|PROCEDURE|Volar plate|Operation with a Synthes volar two column plate (TCP)
214414909|NCT02175537|BEHAVIORAL|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
214414910|NCT04898803|OTHER|conventional DGVS training|see above
214414911|NCT04898803|OTHER|extended simulator training|see above
214414912|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
214414913|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
214414914|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
214414915|NCT01142713|RADIATION|Patient Position During Radiotherapy|Two simulations, one in the supine position on a flat table and another in the prone position on belly board
214414916|NCT04591301|DRUG|HEC113995 PA•H2O tablets|Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
214414917|NCT04591301|DRUG|Placebo tablets|Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
214414918|NCT00640666|BEHAVIORAL|Exercise Behavior Change|Multidisciplinary
214414919|NCT00697229|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 or 3 doses
214414920|NCT00697229|BIOLOGICAL|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
214414921|NCT03327155|DRUG|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)|One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
214414922|NCT03775447|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
214414923|NCT03370055|DEVICE|LeucoPatch®|LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood
214414924|NCT03370055|OTHER|Control,|Usual wound care in a specialized clinic
214414925|NCT04599582|DEVICE|Hip Arthroplasty|Patients are operated with hip replacement.
214414926|NCT04588480|BIOLOGICAL|BNT162b2|BNT162b2 (intramuscular injection)
214414927|NCT04588480|OTHER|Placebo|Placebo (intramuscular injection)
214414928|NCT00246012|DRUG|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
214414929|NCT00246012|DRUG|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
214414930|NCT00246012|DRUG|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
214689314|NCT05431517|PROCEDURE|Analysis of ERCP records|Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.
214689315|NCT06553508|PROCEDURE|Trochanteric bursa repaired|As a routine procedure in our centre, the trochanteric bursa is left unrepaired after a hip arthroplasty.
214414931|NCT02860091|DRUG|Ropivacaine infusion|Delivered via paravertebral nerve block catheter.
214689316|NCT06553508|PROCEDURE|Trochanteric bursa unrepaired|For the experimental arm, the trochanteric bursa is repaired after a hip arthroplasty. The conventional joint closure is performed after reduction and then the bursa is retrieved and repaired.
214689317|NCT05726019|DRUG|Colchicine|Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
214689318|NCT03773341|OTHER|research questionnaire|Patient personal data History taking clinical knee examination
215017351|NCT06375720|BEHAVIORAL|Higher frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
215017352|NCT06375720|BEHAVIORAL|Standard Health Education|Participants would take standard health education 0.5 hour/ session, 2 sessions/month for 6 months.
214414932|NCT04045743|DRUG|MABp1 (Bermekimab) OR Placebo|Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks
214414933|NCT04045743|DRUG|MABp1 (Bermekimab)|Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks
214414934|NCT05513690|PROCEDURE|Amnioinfusion at room temperature (intervention arm)|Routine amnioinfusion and intrauterine temperature probe sensor
214414935|NCT01242085|PROCEDURE|trumatch group|these patient will have CT based customized knee instruments used for surgery
214414936|NCT01242085|PROCEDURE|control group|these patients will have standard instrumentation used for for knee replacement
214414937|NCT03511885|OTHER|There is no intervention|
214505220|NCT03416959|PROCEDURE|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment for long bone metastases with intramedullary nail or endoprosthetic reconstruction
214689319|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
214414938|NCT04708743|DIAGNOSTIC_TEST|Automatic Tongue Diagnosis System|tongue image capture tongue images by Automatic Tongue Diagnosis System
214414939|NCT03828162|DRUG|Anticoagulants|
214505221|NCT04745156|DEVICE|RNS System Implantation|Following resection consistent with SoC, if there is evidence of residual tumor which cannot be resected due to invasion of hand-M1 but which is small enough to be covered by two four-electrode strips, these strips will be placed on the functional cortex of interest and secured to the dura. The location of the leads will be registered into the navigation software (either Medtronic Stealth or Brainlab). The dura will then be closed as watertight as possible, and the RNS System will be incorporated into the craniotomy on closure Prior to closure, four bone screws will be placed and registered to the intraoperative navigation system as internal fiducials to be retrieved for future procedures.
214505222|NCT06800404|DRUG|Autologous HB-adMSCs|Autologous HB-adMSCs
214505223|NCT05553366|DRUG|SUZ|Tablets for oral administration.
214505224|NCT05553366|DRUG|HB/APAP|Capsules for oral administration.
215101764|NCT02473367|DRUG|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
215101765|NCT02473367|DRUG|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
215017353|NCT04264195|OTHER|Constraint-induced movement therapy: PEPS-MIT|"All participants of control and experimental groups received standard stroke rehabilitation. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~• Specific for the experimental group was that patients performed all manipulation tasks with forced use of the paretic hand/arm by wearing a soft-padded mitten at the non-paretic hand, preventing manipulation with that hand. Patients were encouraged to wear the mitten also for 3 hours/day at home, while performing ADL and learned exercises. Behavioural strategies included a treatment contract and daily use of the home activity checklist which was checked by patient's caregiver and signed by both patient and caregiver. Each treatment day the activity checklist was submitted to the therapist who gives feedback."
215017354|NCT04264195|OTHER|Bimanual manipulation exercises (PEPS-Bimanual)|"All participants of control and experimental groups received standard stroke. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~Specific for the control group was that patients performed all manipulation tasks bimanually, as they used to do in occupational therapy activities. Patients were also asked to document their 'at home' activities in an activity checklist that was regularly checked by the therapists."
214414940|NCT05424159|RADIATION|Carbon ion radiotherapy|Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
214414941|NCT01178762|DRUG|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
214689320|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
214689321|NCT03635398|DEVICE|Sipnose device|SipNose's intranasal drug delivery platform uses an innovative mechanism that is suposed to improves efficacy, patient compliance and safety
215101766|NCT06094790|DRUG|CORT125134 150 mg|CORT125134 150 mg (3 X 50 mg current capsule formulation)
215101767|NCT06094790|DRUG|CORT125134 250 mg|CORT125134 250 mg (5 X 50 mg current capsule formulation)
215017355|NCT02521194|BEHAVIORAL|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
215017356|NCT00000446|DRUG|sertraline (Zoloft)|
215017357|NCT03460964|DEVICE|Adhesive glucose sensor|"Will assess sensor's performance by comparing readings from an adhesive glucose sensor with those from a glucometer.~pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat"
215017358|NCT03460964|DRUG|Pilocarpine|Pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat; will apply a minimum of 2 doses to each participant.
215017359|NCT04933058|DRUG|IV acetaminophen|Pain management
215017360|NCT04933058|DRUG|IV fentanyl|Pain management
214414942|NCT05100329|DRUG|Mitoxantrone Hydrochloride Liposome injection|20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
215017361|NCT04007874|DRUG|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
215017362|NCT04007874|DRUG|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
215017363|NCT03661580|BEHAVIORAL|Behavioural Activation|The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.
215017364|NCT03661580|BEHAVIORAL|Treatment as Usual|The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
215101768|NCT06094790|DRUG|CORT125134 dose to be determined|CORT125134 current capsule formulation, dose to be determined
215101769|NCT02110862|OTHER|Transittime. Defecography|
215101770|NCT03682692|DRUG|ACEI/CCB|benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
215101771|NCT03682692|DRUG|ACEI/DIU|benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
215101772|NCT02225834|DRUG|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
215101773|NCT01389037|BEHAVIORAL|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
215101774|NCT01389037|BEHAVIORAL|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
214414943|NCT01819038|PROCEDURE|continuous renal replacement therapy|
214414944|NCT02301221|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
214414945|NCT02301221|DRUG|Vancomycin and bowel lavage|An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
214414946|NCT04990791|DRUG|Aspirin 75mg|Aspirin 75mg OD for 14 days
214414947|NCT04990791|DRUG|Aspirin 20mg|Aspirin 20mg BD for 14 days
214689322|NCT03635398|DEVICE|MAD (Mucosal Atomization Device)|MAD (Mucosal Atomization Device)
214689323|NCT03635398|DRUG|midazolam|oral administration of midazolam
214689324|NCT00189241|DRUG|imiquimod|
215017365|NCT04928404|PROCEDURE|tongue base suspension using barbed suture|all patients will undergo multi-level surgeries .Therefor, Anterolateral advancement pharyngeoplasty (ALA) or Barbed Reposition Pharyngoplasty (BRP) will be applied to improve retro-palatal obstruction and tongue base suspension using barbed suture for retro-lingual obstruction.
214414948|NCT04990791|DRUG|Rivaroxaban 2.5 mg|Rivaroxaban 2.5mg BD
214414949|NCT01003015|DRUG|BAY73-4506|160 mg BAY73-4506
215017366|NCT00666471|PROCEDURE|MICE|MICE
214414950|NCT03787875|PROCEDURE|periodontal treatment|In the study group, periodontal scaling and root planning treatment of the 4 quadrants was performed for two consecutive weeks without the use of antiseptics or antibiotics, and the patients were instructed in oral hygiene, including both brushing techniques and proximal hygiene.
214414951|NCT03489265|DRUG|Eluxadoline 100 mg|100 mg capsule-shaped tablet by mouth taken twice per day
214414952|NCT03489265|OTHER|Placebo|Matching capsule-shaped placebo tablets taken by mouth twice per day
215017367|NCT00666471|PROCEDURE|SPA ligation|SPA ligation
214414953|NCT00065390|DRUG|Pyrimethamine|
214414954|NCT04258410|DRUG|Placebo oral soft chew|placebo identical to experimental drug contained in soft chew
214414955|NCT04258410|DRUG|Quercetin|experimental drug contained in soft chew
214414956|NCT01174316|DEVICE|AutoVPAP™|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
215017368|NCT02473874|DEVICE|Skin Spect dermoscope|Skin imaging
215017369|NCT02473874|DEVICE|Spatially modulated quantitative|Skin imaging
215017370|NCT04921163|DIETARY_SUPPLEMENT|sodium aluminium phospate (SALP)|1 pancake daily for 4 days
215017371|NCT04921163|DIETARY_SUPPLEMENT|Aluminium-free pancake|1 pancake daily for 4 days, without aluminium
215017372|NCT04017975|DRUG|Fluorescite|1 mL of Fluorescite will be diluted into 1L of saline. Up to 5mLs of the 1:1000 diluted solution will be applied topically to the cardiac tissue prior to imaging.
214414957|NCT01174316|DEVICE|VPAPIIIST-A™|Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
214414958|NCT00996372|DRUG|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
214414959|NCT00996372|DRUG|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
215017373|NCT04017975|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|The microscopy system will image cardiac tissue.
214414960|NCT02637271|OTHER|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
214505225|NCT05553366|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
214505226|NCT05553366|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
215017374|NCT05756907|BIOLOGICAL|SON-1010|SON-1010 +/- Atezolizumab
215017375|NCT04230239|DRUG|CPX-351|"CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine"
215017376|NCT02151604|DRUG|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
215017377|NCT00991562|DRUG|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
215017378|NCT05860530|DRUG|The test olaparib tablet (T)|The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours
214505227|NCT03833440|DRUG|Durvalumab (MEDI4736)|"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
214505228|NCT03833440|DRUG|Monalizumab (IPH2201)|"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
214505229|NCT03833440|DRUG|Oleclumab (MEDI9447)|"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
214505230|NCT03833440|DRUG|Ceralasertib (AZD6738)|"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
214505231|NCT03833440|DRUG|DOCETAXEL|"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
214505232|NCT03833440|DRUG|Savolitinib|"600 mg QD~1 cycle = 28 days"
214505233|NCT04726449|OTHER|Screening for acute confusional state|The intervention will consist of two psychometric test to screen for acute confusional state with the usual physical examination by the emergency physician. The neurological examination abnormalities will be noted
214505234|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
214505235|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
214505236|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
214505237|NCT05808595|DIETARY_SUPPLEMENT|AlphaWave® L-Theanine|One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
214505238|NCT05808595|OTHER|Placebo|One capsule of Placebo will be taken twice daily for 28 days.
214505239|NCT04725136|BIOLOGICAL|FURESTEM-AD inj|Repeated administration group: 3 times high or low dose at 4 week intervals. Single administration group: 1 time high or low dose, 2 times placebo injection at 4 week intervals Placebo: 3 times placebo injection at 4 week intervals.
214505240|NCT03877575|OTHER|No specific intervention. Collection of clinical data|
215017379|NCT05860530|DRUG|The reference olaparib tablet (R)|The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours
214414961|NCT02637271|OTHER|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
214414962|NCT02410291|OTHER|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
214414963|NCT01638624|DRUG|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
214414964|NCT01638624|DRUG|Placebo|
214414965|NCT04246697|DRUG|Tylenol|Used for both arms, scheduled
214414966|NCT04246697|DRUG|Oxycodone|Used for both arms PRN
214414967|NCT04246697|DRUG|Morphine|Used for both arms PRN
214414968|NCT04246697|DRUG|Gabapentin|Used for Arm B
214414969|NCT04246697|DRUG|toradol|Used for Arm B
214414970|NCT04246697|DRUG|Bupivacaine|Used for Arm B - anesthesia block
214414971|NCT04181632|DEVICE|Buzzy Bee with Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.
214414972|NCT04181632|DEVICE|Buzzy Bee without Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.
214414973|NCT04181632|DEVICE|Shot Blocker|Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
214689325|NCT05505643|DEVICE|Endocare SlimLine Cryoprobe|"The Endocare(TM) SlimLine (TM) Cryoprobe is a single use, disposable device designed for use with Endocare Cryocare Surgical Systems. Endocare cryoprobes are designed to deliver cold temperatures for cryoablation using high-pressure argon gas circulated through the cryoprobe, followed by active thawing using helium gas.~The Cryocare CS Surgical System is intended for use in open, minimally invasive, or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, ENT, proctology, pulmonary surgery, and thoracic surgery. The system is designed to freeze/ablate tissue by the application of extreme cold temperatures."
214689326|NCT05505643|PROCEDURE|Lumpectomy|Patients randomized to cryoablation who experience disease recurrence may undergo crossover to lumpectomy.
214689327|NCT02991950|DRUG|Parnaparin Sodium|Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
214414974|NCT04940676|DRUG|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
214414975|NCT04940676|DRUG|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
215017380|NCT01279993|PROCEDURE|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
215101775|NCT04384939|DEVICE|magnetic-end Double-J ureteral stent|"* Inserting the ureteral stent with magnet (same process as classic ureteral stent)~* Removing the ureteral stent with magnet without general anaesthesia. Usually, the classic ureteral stent removed during a general anaesthesia."
214414976|NCT00317655|DRUG|Glucosamine sulphate|
214414977|NCT00317655|DRUG|Ginger|
214414978|NCT00317655|DRUG|Ginger-Avocado-Soya|
214414979|NCT00317655|DRUG|Ginger-ibuprofen|
214414980|NCT00904527|BEHAVIORAL|relaxation (Schultz)|Patients have relaxation consultations during 2 months
214414981|NCT00440284|DRUG|conventional vs. flexible, intensive insulin therapy|
214414982|NCT02997618|BEHAVIORAL|Community based exercise programme|20 week community (home or gym based) exercise programme
214414983|NCT02997618|OTHER|Control|Usual care consisting of advice.
214414984|NCT02422121|DRUG|RNS60|
214414985|NCT02422121|DRUG|Placebo|
214689328|NCT04282226|DEVICE|active transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.
215017381|NCT04469283|OTHER|caffeine and movement disorders|Caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
215017382|NCT00563563|DRUG|NB32|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
215017383|NCT00563563|BEHAVIORAL|Ancillary therapy|During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
214414986|NCT01651949|BIOLOGICAL|9vHPV Vaccine|9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
214414987|NCT03149406|OTHER|Comparing the expression of miRNAs|by PCR, in symptomatic and asymptomatic carotid plaques.
214414988|NCT00000433|DRUG|Anti-Tumor Necrosis Factor|
214414989|NCT00346931|PROCEDURE|Phacoemulsification, implantation of intraocular lens|
214414990|NCT00346931|PROCEDURE|Phacoemulsification, Implantation of IOL, trabeculotomy|
214414991|NCT01806714|OTHER|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
214414992|NCT01806714|OTHER|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
214414993|NCT02867046|DRUG|S1 transforaminal epidural steroid(dexamethasone) injection|"medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen"
214414994|NCT02469064|OTHER|Respiratory muscle training|Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
214414995|NCT02469064|OTHER|Cardiopulmonary Physical Therapy|Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
214414996|NCT04564313|DRUG|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
214414997|NCT01407900|DRUG|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
214689329|NCT04282226|DEVICE|sham transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
214414998|NCT01407900|DRUG|5% Dextrose in Water|four hour infusion IV
214689330|NCT01248234|DRUG|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
214689331|NCT01248234|DRUG|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
214689332|NCT01248234|DRUG|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
214689333|NCT01253681|DRUG|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
214689334|NCT05332912|BEHAVIORAL|Spatial Ability Experience|Participants will engage in puzzle construction, block play, visual search, hide and seek
214689335|NCT01998581|DEVICE|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
214689336|NCT01998581|DEVICE|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
214414999|NCT00866762|DRUG|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
214689337|NCT03665376|DIETARY_SUPPLEMENT|Carbohydrate drink load|Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
214689338|NCT03665376|COMBINATION_PRODUCT|Enhanced Recovery After Surgery (ERAS)|The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
214689339|NCT01251276|BIOLOGICAL|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
214689340|NCT01345123|BEHAVIORAL|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
214689341|NCT01345123|BEHAVIORAL|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
214689342|NCT04348136|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
214689343|NCT03073681|DEVICE|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
215017384|NCT02783937|BIOLOGICAL|Filgrastim|"Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:~Phase A:~Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.~Phase B:~Injection of saline SC injection twice daily for five consecutive days."
214415000|NCT04272073|OTHER|High-Protein Mediterranean Diet|As in arm/group descriptions
214415001|NCT04272073|OTHER|Resistance Exercise|As in arm/group descriptions
214415002|NCT04272073|OTHER|Standard Dietary Advice|As in arm/group descriptions
215017385|NCT02783937|DRUG|Saline|Injection of saline SC injection twice daily for five consecutive days
215017386|NCT04495478|DRUG|Ramucirumab - IV|Administered IV.
215017387|NCT04495478|DRUG|Placebo - IV|Administered IV.
215017388|NCT04495478|DRUG|Ramucirumab - SC|Administered SC.
215017389|NCT04495478|DRUG|Placebo - SC|Administered SC.
215017390|NCT07056829|DEVICE|Mandibular Advancement Appliance (Invisalign MA)|"Clear aligner system with integrated buccal precision wings to posture the mandible forward.~Advancement protocol: 2 mm increments every 8 weeks. Total active treatment duration: \~8.15 months, followed by retention phase. Patients instructed to wear aligners ≥20 h/day, removing only for eating and oral hygiene."
215017391|NCT07056829|DEVICE|Activator Appliance|"Traditional removable functional appliance fabricated on a standardized bite registration.~Patients instructed to wear appliance 24 h/day except during meals and sports. Total active treatment duration: \~7.15 months, followed by retention phase."
214415003|NCT04272073|OTHER|Standard Cardiac Rehabilitation Exercise|As in arm/group descriptions
214415004|NCT05971355|DEVICE|LimpiAD cream 2,5% plus|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
214415005|NCT05971355|OTHER|Vehicle|"Vehicle of LimpiAD cream 2.5 % plus which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus cream but without the HAc-40 component."
215017392|NCT07055958|DRUG|Metformin|Metformin's chemical name is 1,1-Dimethylbiguanide, a molecular formula of C4H11N5. Beyond its well established antihyperglycemic impact, metformin demonstrated anti-oxidant and anti-inflammatory activities contributing its potential benefits in conditions associated with inflammation and oxidative stress. Furthermore, metformin rapidly crosses the blood brain barrier and disperses into several brain regions presenting an ideal therapeutic option for the treatment of PD.
214415006|NCT05971355|OTHER|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
214415007|NCT00678795|DRUG|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
214415008|NCT00678795|DRUG|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
214505241|NCT02022657|DRUG|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
214505242|NCT06434064|PROCEDURE|Biopsy|Undergo tumor biopsy
214505243|NCT06434064|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214505244|NCT06434064|PROCEDURE|Computed Tomography|Undergo CT scan
215017393|NCT07055958|OTHER|placebo|placebo of tab. Metformin of same shape
215101776|NCT06172725|OTHER|Dietary and exercise intervention|"The healthy older adults will follow a twelve-week high-protein vegetarian diet or high-protein omnivorous diet both in combination with a resistance exercise program.~All participants will receive blended dietary counselling. Blended dietary counselling is based on tele-coaching and face-to-face coaching performed by dieticians."
215101777|NCT00771771|OTHER|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
215101778|NCT00771771|OTHER|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
215101779|NCT06127628|PROCEDURE|Ultrasound-guided scalp block with ropivacaine 0.375%|Scalp block will be performed under USG guidance, using the technique described by Tsan et al. The block needle used will be an echogenic block needle, with a length of 50 mm, and a diameter of 22 G. Trained personnel comprising of the investigators in this study will perform the scalp block. Using ultrasound to identify landmarks, ropivacaine 0.375% will be administered in volumes of 1.5 ml to 3 ml. The nerves targeted will be the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater auricular, lesser occipital, greater occipital and third occipital nerves.
214415009|NCT02678104|PROCEDURE|Tooth extraction|Tooth removal
214415010|NCT02678104|DRUG|Chlorhexidine mouth wash|Chlorhexidine mouth wash
214415011|NCT02678104|DRUG|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
214415012|NCT01549496|DRUG|Amlodipine|amlodipine 2.5 mg QD
214415013|NCT01549496|DRUG|Diltiazem|diltiazem 120 mg qd
214505245|NCT06434064|PROCEDURE|Echocardiography|Undergo echocardiography
214505246|NCT06434064|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215101780|NCT06726187|OTHER|Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).|Screening questionnaire
215101781|NCT06739044|DRUG|Ozempic®|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
214415014|NCT04007302|OTHER|measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)|measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
214415015|NCT04007302|OTHER|completion of questionnaires|igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
214415016|NCT04007302|OTHER|completion of questionnaires for pain|analogical visual and numerical scale and Borg scale
214505247|NCT06434064|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214505248|NCT06434064|DRUG|Tamoxifen|Given PO
214505249|NCT00081913|GENETIC|Cell Therapy - Autologous CD34 Positive Cells|
214505250|NCT06108635|PROCEDURE|McKenzie Exercises|"These can be performed in sitting and the protocol includes,~1. Retraction and extension~2. Retraction and extension with rotation~3. Postural correction~There will be 2 sets of 5 repetitions in week 1 and 3 sets of 10 repetitions in week 2 followed by alternative days in a week. Each set is 30 seconds and each repetition is given in 2 seconds."
214505251|NCT06108635|PROCEDURE|Maitland mobilization|The grade I and II Maitland mobilizations are given in week 1 and then progressed to grade III and IV in week 2
214505252|NCT06108635|PROCEDURE|Heat Therapy|Moist heat therapy with hot pack.
214505253|NCT03177824|DRUG|Sildenafil Citrate 25Mg Tab|Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
214505254|NCT03177824|DRUG|Placebo Oral Tablet|Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
214505255|NCT05080036|OTHER|Medio-lateral imbalance|Thrust on the pelvis in the medio-lateral direction in order to create a balance perturbation
214505256|NCT05683834|DRUG|Matrix-M1 Adjuvant|Matrix-M1 is composed of 2 types of 40 nm-sized particles each with a different saponin fraction (fraction A and fraction B) combined with cholesterol and phospholipid.
214505257|NCT05683834|DRUG|EBV gp350-Ferritin Vaccine|The EBV gp350-Ferritin vaccine is composed of Helicobacter pylori non-heme ferritin fused to EBV gp350 which self-assembles to form a nanoparticle. The vaccine is supplied in single-use vials at a concentration of 250 micrograms/mL in 1.7 mM KH2PO4, 5 mM Na2HPO4, 150 mM NaCl, 5% sucrose, pH 7.4 (diluent).
215017394|NCT07055763|COMBINATION_PRODUCT|Nigella sativa (black seed)|Participants in Group 1 (intervention group) will receive Nigella sativa (black seed) oil at a dosage of 0.5 ml, administered orally twice daily-once before breakfast and once before bedtime-for a duration of 12 weeks. The oil, sourced from a standardized local supplier, is rich in thymoquinone, known for its antioxidant and vasodilatory properties. Blood pressure will be measured at baseline and biweekly intervals using a calibrated digital sphygmomanometer to monitor changes in systolic and diastolic values. Participants will also be monitored regularly for any adverse effects.
215017395|NCT06901089|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the hip joints with an additional two-second tension
215101782|NCT06739044|DRUG|HDG1901|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
214415017|NCT00966966|DRUG|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
214415018|NCT02750709|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
214415019|NCT02750709|DRUG|Nitisinone 10 mg Tablet High Compritol|A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
215101783|NCT06894654|PROCEDURE|Skin punch biopsy|Skin punch biopsies are 5mm for this study. Participants with SSc will undergo 4 biopsies (2 in diseased area, 2 in non-diseased area if available). Healthy Volunteers will undergo 2 biopsies.
215101784|NCT06894654|OTHER|blood sampling|10mls blood will be taken for analysis and DNA sequencing
214415020|NCT02750709|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
214415021|NCT00588965|DRUG|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
214415022|NCT00588965|DRUG|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
214415023|NCT01317134|DEVICE|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
214415024|NCT01317134|BIOLOGICAL|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
214415025|NCT00404079|DRUG|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
214415026|NCT00404079|DRUG|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
214415027|NCT01120275|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
214415028|NCT01120275|OTHER|laboratory biomarker analysis|Correlative studies
214415029|NCT04269850|BIOLOGICAL|allogeneic fecal microbiota|Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.
214415030|NCT04269850|DRUG|Ruxolitinib|Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
214415031|NCT04269850|DRUG|Methylprednisone|Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
214415032|NCT03736005|OTHER|Exposure of significant critical illness|Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
214415033|NCT04103736|DIETARY_SUPPLEMENT|Beet It Sport Shot|Source of naturally occurring dietary nitrates
214415034|NCT04103736|DIETARY_SUPPLEMENT|Nitrate-depleted placebo|Placebo
214415035|NCT06121310|OTHER|Survey|Non interventional. Pediatric anesthesia satisfaction scale validity and reliability is going to investigate by survey analyses
214415036|NCT00431808|BIOLOGICAL|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
214505258|NCT05683834|OTHER|Placebo Comparator|Normal Saline
214505259|NCT04122885|COMBINATION_PRODUCT|PIPAC with oxaliplatin|Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure
214505260|NCT04122885|PROCEDURE|Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy|If complete cytoreduction possible (CC-0). Application time 60 min, T 41-43 °C
214505261|NCT05618951|OTHER|Lower Trapezius Strengthening Exercises|"Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
214415037|NCT00431808|BIOLOGICAL|AMA1|50 micrograms of AMA1
214415038|NCT01208467|OTHER|Laboratory Biomarker Analysis|Correlative studies
214505262|NCT05208034|DRUG|Methotrexate|Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.
214505263|NCT01530334|DRUG|Gefitinib 250mg|Gefitinib 250mg once daily
214505264|NCT00797212|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
214505265|NCT03220334|DRUG|Platelet rich plasma|The experimental group was treated with PRP for artificial gastric ulcer after ESD.
214505266|NCT03220334|DRUG|Normal saline|The control group was treated with normal saline for artificial gastric ulcer after ESD.
214689344|NCT06958653|DEVICE|Brief-BESTest assessment|Uses the traditional Brief-BESTest to assess the balance ability of the participants.
215017396|NCT06901089|OTHER|Placebo|This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension
215017397|NCT06901089|OTHER|Exercise|The following exercise will be performed: lunges
214415039|NCT04408287|OTHER|WebEx Physical Activity Program|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
214415040|NCT02306343|DEVICE|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
214415041|NCT02887313|DRUG|mFOLFOX6|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
214415042|NCT02887313|RADIATION|Radiotherapy|Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
214415043|NCT02905968|DEVICE|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
214415044|NCT02595398|DRUG|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints
214415045|NCT02595398|DRUG|Sham Procedure|Sham procedure administered at 2 timepoints
214415046|NCT01087177|OTHER|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
214505267|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
214689345|NCT06958653|DEVICE|Digital balance assessment tool|Uses the digital balance assessment tool, which is the digitalized Brief-BESTest, to assess their balance ability.
214689346|NCT05936385|BEHAVIORAL|Healthy Lifestyle|Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.
215017398|NCT02743858|OTHER|Bilateral arm measurements|Pts treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder \& the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed before surgery, post-operatively \& at timepoints of 6,12,18, \& 24 months after surgery for 2 years will be obtained using the Perometer (Model 350 NT Perometer, Per-System) for bioimpedance measurements. Pts who have not yet developed lymphedema by 2 years, an additional measurement at approx 3 years post-surgery will be performed. If pt is diag with lymphedema at the 3-year visit, she will be asked to continue on study for an additional year. Pts treated with SLNB alone, following re-consent, a long-term follow-up volumetric arm measurement will be obtained using the perometer \& circumferential arm measurements at a minimum of 2 years post-surgery.
215017399|NCT02743858|OTHER|Body mass index (BMI)|Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.
215017400|NCT02743858|BEHAVIORAL|Quality of Life Questionnaire|
215101785|NCT06894654|BEHAVIORAL|Questionnaire|All participants are required to complete a questionnaire with information on demographics, lifestyle, medical and medication history.
215101786|NCT05716347|BIOLOGICAL|the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine|one booster dose intramuscularly in the deltoid muscle of the upper arm.
214415047|NCT04509713|BEHAVIORAL|Collection of odour samples|Samples of breath odours will be passively collected while participants wear the mask while breathing naturally, for at least 3 h. Skin odours will be passively collected by participants wearing the shirt and nylon socks for at least 12 h.
214415048|NCT04175886|DRUG|Tofacitinib|Patients will be treated with tofacitinib
214415049|NCT01573858|OTHER|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
214415050|NCT01573858|OTHER|Acupuncture treatment 2|Needles will be inserted to a depth of \<5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
214689347|NCT05936385|BEHAVIORAL|Standard of Care|Weight checks and lifestyle counseling with primary care provider every other month.
214689348|NCT05384626|DRUG|Neladalkib (NVL-655)|Oral Tablet of Neladalkib (NVL-655)
214689349|NCT06836401|PROCEDURE|Root scaling|Scaling and root planing is a deep cleaning below the gumline used to remove plaque and tartar that cover the root in the periodontal pockets. This intervention is carried out in both control and experimental sites
214689350|NCT06836401|DRUG|Topical Gel|A gel (experimental: metronidazole VS control: carbopol) is introduced in the recently cleaned periodontal pocket. The allocation of either experimental or control gel was distributed randomly, being masked both the patient and the clinician.
215017401|NCT02743858|OTHER|Blood draw|Patients enrolled in the translational study (Cohort 3) will undergo blood draws for serum collection preoperatively and 12-24 months postoperatively to test for FGF2, IL4, IL10, TGFB, Leptin, IL6, and CRP. At both timepoints, up to 20 mL of blood will be collected.
214415051|NCT01573858|OTHER|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
214415052|NCT01573858|OTHER|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
214415053|NCT04564391|DIETARY_SUPPLEMENT|protein supplement|protein supplement, daily 60 g of protein, 3 weeks of intervention; blinded to patients
214415054|NCT04564391|DIETARY_SUPPLEMENT|placebo supplement|Placebo supplement, daily intake of placebo, 3 weeks of intervention; blinded to patients
214415055|NCT00614406|DRUG|Celebrex|One 400mg tablet daily.
214415056|NCT00614406|DRUG|Placebo|One tablet daily.
214415057|NCT00197015|BIOLOGICAL|Havrix®|2 doses administered intramuscularly
214415058|NCT00197015|BIOLOGICAL|M-M-R®II|1 dose administered subcutaneously
214415059|NCT00197015|BIOLOGICAL|VARIVAX®|1 dose administered subcutaneously
214415060|NCT00240916|BIOLOGICAL|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
214415061|NCT00240916|BIOLOGICAL|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
214415062|NCT00003435|BIOLOGICAL|anti-thymocyte globulin|
214415063|NCT00003435|DRUG|melphalan|
215101787|NCT02105038|OTHER|Spinner knob|
215017402|NCT05270902|DEVICE|CytoSorb Adsorber|Polymer based adsorber system for the elimination of cytokines
215101788|NCT02105038|OTHER|No Knob|
215101789|NCT02678923|DRUG|MDCO-216|
214415064|NCT00003435|PROCEDURE|antiviral therapy|
214415065|NCT00003435|PROCEDURE|bone marrow ablation with stem cell support|
214415066|NCT00003435|PROCEDURE|peripheral blood stem cell transplantation|
214505268|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
214415067|NCT00003435|PROCEDURE|umbilical cord blood transplantation|
214415068|NCT00003435|RADIATION|radiation therapy|
214415069|NCT01191463|OTHER|Mung Bean Meal|50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
214415070|NCT01191463|OTHER|Guava|A fresh Guava fruit will be provided raw (approx 100g fresh weight)
214415071|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
214415072|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
214415073|NCT03525041|PROCEDURE|CABG|CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
214415074|NCT03525041|PROCEDURE|mitral valve annuloplasty|Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
214415075|NCT00880906|PROCEDURE|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
214415076|NCT00880906|DRUG|Steroid and Proton Pump Inhibitor Therapy|
214505269|NCT03103048|DIAGNOSTIC_TEST|Without bandages|All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
214505270|NCT03103048|DIAGNOSTIC_TEST|With placebo|All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
214505271|NCT03103048|DIAGNOSTIC_TEST|With bandage|All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
215017403|NCT06212323|OTHER|Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.|"Patients with high-risk smoldering myeloma will be prospectively followed and chart review will be performed to determine if progression events happen, and how they happen.~All patients on the study are recommended to undergo the following standard of care surveillance protocol:~* Complete Blood Count (CBC), Complete Metabolic Panel (CMP), myeloma blood tests (serum kappa/lambda light chains, monoclonal protein evaluation, immunoglobulin levels), to be done monthly for first year, and then every two months for the second year.~* WB DW-MRIs every 6 months during the study period.~* 24-hour urine Immunofixation/electrophoresis is expected to be completed approximately every 6 months.~* Bone marrow biopsy will be performed annually during the study time-period."
215017404|NCT06413134|DEVICE|TheraPAP|TheraPAP is a novel CPAP-based therapy in which pressure is dropped as much as 5 cmH2O starting at the beginning of inspiration and extending through the end of expiration where it rises back up to the true therapy pressure for a short period. It improves comfort by providing pressure only when it is needed and maintaining it at a low level the rest of the time. Normal CPAP/APAP therapy keeps pressure at the therapy level during the entire breath cycle, except with some alternate approaches where pressure is decreased but only during the expiratory phase.
215017405|NCT06413134|DEVICE|APAP|Standard CPAP therapy where therapy pressure is automatically adjusted to prevent respiratory events from occurring. The TheraPAP prototype device will be used to operate in the APAP mode in addition to the TheraPAP intervention mode.
214415077|NCT00221078|DEVICE|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
214415078|NCT03985917|OTHER|Singing Group Intervention Program|Each session will start with (1) relaxation, vocal warm-up and breething exercises; (2) vocal technique training; (3) memorization and interpretation of music and lyrics; (4) session breaks of 20 minutes for socialization; (5) preparation of a final choir show; (6) vocal tuning tests.
214415079|NCT03985917|OTHER|Alternative Social and Leisure Activities|Day care centers provide social and leisure activities opportunities for older adults. The control group is free to enroll in these activities.
214415080|NCT03097237|OTHER|Wholegrain rye|Cereal products based on wholegrain rye
214415081|NCT03097237|OTHER|Refined wheat|Cereal products based on refined wheat
214415082|NCT02622230|DRUG|Mianhuahua Flavonoids Tablets|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)"
214505272|NCT03103048|DIAGNOSTIC_TEST|With tensioned bandage|All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
214505273|NCT01485887|DRUG|Venlafaxine ER|Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
215017406|NCT01543230|DEVICE|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
215101790|NCT02678923|DRUG|Placebo|
215101791|NCT01002274|DRUG|MCS-2|2 soft-gel capsules Qd for 40 weeks
215101792|NCT06141291|DIETARY_SUPPLEMENT|High protein diet|Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects.
215101793|NCT06141291|DIAGNOSTIC_TEST|OGTT|Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
215101794|NCT02883101|BEHAVIORAL|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
215101795|NCT01533662|DRUG|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
214415083|NCT02622230|DRUG|Placebo|Placebo to match with experimental groups
214505274|NCT01408394|DRUG|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
214505275|NCT01408394|DRUG|90 mg controlled release form|This is the 90 mg controlled release form
214505276|NCT01408394|DRUG|180 mg controlled release form|This is the 180 mg controlled release capsule
214505277|NCT00891631|BEHAVIORAL|iSBIRT|Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
214505278|NCT00891631|BEHAVIORAL|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
214505279|NCT02108171|DRUG|Dexmedetomidine|intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
214505280|NCT02108171|DRUG|placebo|0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
214505281|NCT03340909|DRUG|Prednisolone|Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
215017407|NCT05457205|OTHER|Electrical neuromodulation|Electrical neuromodulation intervention using transcutaneous spinal stimulation: two self-adhesive semicircle electrodes (forming a 5cm round electrode) will be centered midline over the T11-12 spinal processes, and two 8×13 cm electrodes will be placed paraumbilical and interconnected to serve as a counter electrode. A current-controlled stimulator will deliver symmetric biphasic pulses (500-μs/phase). Electrical stimulation will be applied according to the description in each study arm.
215017408|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
215017409|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
215017410|NCT01825252|BEHAVIORAL|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
215017411|NCT01825252|BEHAVIORAL|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
215017412|NCT01992939|OTHER|Specialized pulse oximetry probe with external heat pack|Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
215017413|NCT01992939|OTHER|Standard of Care Pulse Oximetry Probe|Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
215017414|NCT06098352|BEHAVIORAL|PEBL Continuous Performance Task|A PEBL version of the Conners Continuous Performance Task
215017415|NCT04216550|DRUG|Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
215101796|NCT01533662|DRUG|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
215101797|NCT02169765|OTHER|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and \>50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
214415084|NCT04163224|DEVICE|RibFix Advantage|Class II device in the United States; consists of bridges (with locking posts) and locking caps for the thoracoscopic fixation and stabilization of ribs. These implants are manufactured from commercially pure titanium and titanium alloys. When fully assembled, the bridge plate is placed on the underside of the rib (pleural cortex); the threaded locking posts extend through pre-drilled holes in the rib, and the locking caps are fixed to the locking post on the anterior (cutaneous) side of the rib. The combined threaded locking post and cap provides for fixation of the bridge and stabilization of the fracture.
214415085|NCT04998799|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge
214415086|NCT01534910|DRUG|aged garlic extract|2400 mg a day
214415087|NCT01534910|DRUG|placebo|placebo
214415088|NCT05027087|DIETARY_SUPPLEMENT|Blueberry gummy|Gummy bear containing blueberry powder
215017416|NCT03768050|OTHER|Advanced care for frail elderly|"Home-based case management group receives advanced nursing care meeting the health and social needs of patient and/or carer. It is carried out through a process of evaluation, planning\&coordination, facilitating the provision, monitoring and evaluation of the options and resources necessary for the resolution of the case. It is person-centred. The service also provides palliative care.~Home hospitalisation/early discharge dispenses medical and nursing care at home on a transient basis after hospitalisation when patients still need surveillance and assistance. It is done in the acute, subacute or post-acute phase. In the last phase the focus is on functional recovery.~The geriatric residences group is assisted by health care teams with expertise in geriatrics. They coordinate with primary care and health professionals of the residences to improve the attention. They are highly accessible, have high-resolutive capacity and can activate the resources of the healthcare network."
215017417|NCT03696186|DRUG|Luminal type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
215017418|NCT03696186|DRUG|Luminal type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
215017419|NCT03696186|DRUG|Neuroendocrine type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
215017420|NCT03696186|DRUG|Neuroendocrine type-2|Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
215017421|NCT03696186|DRUG|Atypical type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
215017422|NCT03696186|DRUG|Atypical type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
215017423|NCT00594308|DRUG|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
215017424|NCT00594308|DRUG|Fludarabine|25mg/m2/day for 5 consecutive days
215017425|NCT00594308|DRUG|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
215017426|NCT00594308|DRUG|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
214415089|NCT05027087|DIETARY_SUPPLEMENT|Placebo gummy|Gummy bear with no active ingredients
214505282|NCT03340909|OTHER|Placebo|Placebo tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
214415090|NCT00564967|BEHAVIORAL|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
214415091|NCT00564967|BEHAVIORAL|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
214415092|NCT00432029|PROCEDURE|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
214415093|NCT00432029|DEVICE|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
214415094|NCT03682328|PROCEDURE|vertebroplasty|Cement augmentation of the vertebral body
214415095|NCT03682328|PROCEDURE|kyphoplaty|Cement augmentation of the vertebral body
214505283|NCT02797587|DRUG|Varenicline|1 week starter kit followed by 1mg twice daily for 12 weeks.
215017427|NCT00594308|DRUG|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
215017428|NCT00295503|DRUG|bevacizumab|15 mg/kg IV every 3 weeks
215017429|NCT00295503|DRUG|cisplatin|75 mg/m2 IV every 3 weeks
215017430|NCT00295503|DRUG|pemetrexed|500 mg/m2 every 3 weeks
215101798|NCT02169765|OTHER|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
215101799|NCT00455143|DRUG|Precedex (Dexmedetomidine)|Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
215101800|NCT00455143|DRUG|Placebo|Matching placebo given prior to surgery and continued for 24 hours postoperatively
215101801|NCT01553643|DRUG|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
215101802|NCT01553643|DRUG|placebo|at a rate of 3g two times per day
214415096|NCT03581968|DEVICE|Artificial Pancreas|"The system is composed of 3 main components:~1. Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~2. Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~3. MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump."
214415097|NCT05334758|DEVICE|Bio-Self COVID-19 Antigen Home Test|At home COVID-19 antigen test kit
214415098|NCT05334758|DEVICE|Standard of Care COVID-19 Test|Standard of care
214415099|NCT05334758|DIAGNOSTIC_TEST|RT-PCR Test|High Sensitivity RT-PCR COVID-19 Test
214415100|NCT02047851|OTHER|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
214415101|NCT02637908|BEHAVIORAL|Mindfulness training|6-weeks of group-based mindfulness training for parents
214415102|NCT02982213|OTHER|Companion Present|A companion will be present during the epidural catheter placement.
214415103|NCT06345534|DEVICE|Questionnaire|"Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life.~The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years."
214415104|NCT01549652|DRUG|Ondansetron|Ondansetron 8 mg oral tablet
214415105|NCT01549652|DRUG|Placebo|Placebo to Match Ondansetron
214415106|NCT01549652|DRUG|Morphine|Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved
214415107|NCT01549652|DRUG|Naloxone 0.4 mg/70 kg|Naloxone 0.4 mg/70 kg intravenous
214415108|NCT01549652|DRUG|Naloxone 0.8 mg/70 kg|Naloxone 0.8 mg/70 kg intravenous
214415109|NCT06435338|BEHAVIORAL|Patient decision aid|The patient decision aid for HPV vaccination among mid-adults, named HPV Decide. It is delivered online on a website.
214415110|NCT06435338|BEHAVIORAL|Control|Vaccine information sheet on HPV vaccination. Attention control condition.
215017431|NCT06372041|DEVICE|transcranial Alternating Current Stimulation|tACS will be performed by using a Conformite Europeenne (CE) marked stimulator device (Starstim ®, Neuroelectrics, Barcelona, Spain). By applying alternating current at the gamma frequency band (range 30-80), known to be associated to motor performance, tACS can entrain or synchronize neural oscillations in the targeted brain regions. By modulating cortical excitability of the cerebellum, a region strongly involved in motor learning and coordination, tACS is expected to influence the strength and coordination of motor responses elicited during the training. tACS will be delivered through two saline-soaked surface sponge electrodes (dimension: 25cm2 each), one placed over F3 (left frontal region) and the other over the right cerebellar hemisphere. The intensity will be set to 1mA, and this value will be gradually reached with a ramping-up phase of 30 secs. The frequency of the stimulation will match the IGF identified during the EEG recording performed at rest.
215017432|NCT02571881|PROCEDURE|Caesarean section|After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication
215017433|NCT02571881|DRUG|Oxycodone|
215017434|NCT02571881|DRUG|oxycodone-naloxone|
215017435|NCT03312114|DRUG|Avelumab|Avelumab\* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
215017436|NCT02295579|OTHER|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
215017437|NCT04627974|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
215017438|NCT06564727|PROCEDURE|Uniportal VATS approach|Uniportal VATS resection for simple pulmonary aspergilloma
214415111|NCT01972152|DRUG|G-Pen(TM) 1 mg|
214415112|NCT01972152|DRUG|Lilly Glucagon(TM) 1 mg|
214415113|NCT01972152|DRUG|G-Pen(TM) 0.5 mg|
214415114|NCT01080599|PROCEDURE|obturator nerve block|
214415115|NCT05527236|OTHER|Breathing Exercise|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercises again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.
214415116|NCT05527236|OTHER|Virtual Reality|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm) the virtual reality group watched a 10-minute video with virtual reality glasses. Once the virtual reality glasses were removed from experimental groups Visual Analogue Scale was applied. Birth satisfaction was evaluated with the Birth Satisfaction Scale within the first 4 hours after the delivery was completed.
214415117|NCT00789919|PROCEDURE|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
214415118|NCT03211637|COMBINATION_PRODUCT|Wounds Protocol|Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
214415119|NCT03203356|DRUG|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
214415120|NCT02883088|PROCEDURE|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
214415121|NCT05337657|DRUG|GB491+Letrozole|Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
214415122|NCT03707678|DRUG|GSK2245035|GSK2245035 will be administered weekly once as a nasal spray solution with dosing strength of 10 ng per actuation. GSK2245035 will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
214415123|NCT03707678|DRUG|Placebo|Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
214415124|NCT03707678|DRUG|FP-DPI|FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.
214415125|NCT03707678|DRUG|Albuterol/Salbutamol|Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.
214415126|NCT03707678|OTHER|eDairy|Subjects will record all the alerts indicative of worsening of asthma in eDairy.
214415127|NCT03707678|OTHER|ACQ-6|ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.
214415128|NCT00559949|OTHER|Laboratory Biomarker Analysis|Correlative studies
214415129|NCT00559949|DRUG|Selumetinib|Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
214415130|NCT00132717|DRUG|MK0653A (ezetimibe [+] simvastatin)|
214415131|NCT00132717|DRUG|Comparator: atorvastatin|
214415132|NCT00132717|DRUG|Comparator: fluvastatin|
214415133|NCT00132717|DRUG|Comparator: lovastatin|
214415134|NCT00132717|DRUG|Comparator: pravastatin|
214415135|NCT00132717|DRUG|Comparator: rosuvastatin|
214415136|NCT00132717|DRUG|Comparator: simvastatin|
214415137|NCT00950144|OTHER|medical chart review|
215017439|NCT06564727|PROCEDURE|VATS approach|VATS resection for complex pulmonary aspergilloma
214415138|NCT00950144|OTHER|questionnaire administration|
214415139|NCT00950144|OTHER|study of socioeconomic and demographic variables|
215017440|NCT00944645|DRUG|niacin (+) laropiprant (Source 1)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
215017441|NCT00944645|DRUG|Comparator: niacin (+) laropiprant (Source 2)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
214415140|NCT00950144|PROCEDURE|quality-of-life assessment|
214415141|NCT04299230|DEVICE|Cortium C3|
214415142|NCT06360042|DRUG|Adebrelimab plus Apatinib|Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
214415143|NCT06360042|DRUG|Adebrelimab plus Bevacizumab|Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
214415144|NCT06360042|DRUG|Camrelizumab plus Apatinib|camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
214415145|NCT02001714|BEHAVIORAL|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
214415146|NCT03329742|OTHER|Low protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
214415147|NCT03329742|OTHER|Control protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
215017442|NCT04441515|DEVICE|Ipod with music|music of patient's preference provided 2 hours daily
215017443|NCT04441515|DEVICE|ipod with books to listen|2 hours of daily listening to books
215017444|NCT04441515|DEVICE|ipod only with usual care|participants given device only
215017445|NCT03995147|DRUG|Pembrolizumab|"Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.~Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years)."
214415148|NCT01830010|DRUG|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
214415149|NCT01830010|DRUG|Study Part 2: KRP203 lower dose|
214415150|NCT01830010|DRUG|Study Part 2: KRP203 higher dose|
214415151|NCT00635895|OTHER|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
214415152|NCT00414648|DRUG|Sirolimus|A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.
214415153|NCT00414648|DRUG|Placebo|A placebo dose of 2 tablets per day for 1 year.
215017446|NCT03995147|DRUG|R-CHOP Protocol|R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
215017447|NCT04560296|BEHAVIORAL|Community-based E-Health Program|Community-based E-Health Program will be developed to engage and empower older adults to manage the chronic conditions effectively.
215017448|NCT04560296|BEHAVIORAL|usual self-management and follow up with doctors/nurse|usual self-management and follow up with doctors/nurse as planned in the community nurse post.
215017449|NCT05988229|OTHER|Toolkit to improve discharge equity|Linguistically appropriate discharge teaching aids: a medication calendar, pictographics added to the after visit summary (AVS), and an audio recording of the discharge teaching.
214415154|NCT01513135|BIOLOGICAL|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
214415155|NCT01513135|BIOLOGICAL|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
214415156|NCT00065052|BEHAVIORAL|Behavior modification|
214415157|NCT01194258|DRUG|Insulin lispro|
214415158|NCT01194258|DRUG|Insulin aspart|
214415159|NCT01194258|DRUG|Recombinant human hyaluronidase PH20|
214415160|NCT01194258|DRUG|Insulin glulisine|
214415161|NCT01194258|DRUG|Insulin glargine|
214415162|NCT04881136|DEVICE|Reveal LINQ™|The physical device is the Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data that will be used for gait analysis.
214415163|NCT04617353|PROCEDURE|NO-based treatment of sterno-mediastinitis|"Preparation of a postoperative wound in case of infectious complications. A mandatory sampling material for culture and antibiotic sensitivity is collected before and after the air plasma flow treatment.~Direct effect of the air-plasma flow on the entire wound surface in sterilization mode with an exposure of 2-3 minutes for each surgical wound, until the level of bacterial contamination decreases to 10-5 and below.~The technique of using air-plasma flow when closing a wound after preventing infectious complications in it.~In the postoperative period, daily air-plasma flow treatment in sterilization mode along the suture line for 3 minutes. Penetrating drainage NO supply in the biological stimulation mode daily for 10 days, with an exposure of 1-2 minutes up to 10 days, with a volume of up to 2 liters per minute.~Collecting wound culture from the drainage containers on 1-3-7-12 days to detect pathogens and the bacterial number."
214415164|NCT04617353|PROCEDURE|Treatment of sterno-mediastinitis|patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage
214415165|NCT04366882|PROCEDURE|CT-scan with minimal invasive autopsy|CT-guided biopsies will be performed directly following the diagnostic CT-scan. Biopsies will be taken from heart, liver, lungs, spleen, kidneys and abdominal fat according to a standard operation procedure. Biopsies will be taken for further histological examination and storage in the biobank. Of the lung, additional samples will be taken for microbiological examination. Additional samples will be taken in case of (focal) abnormalities on CT-imaging. In case of pleural, cardiac or abdominal fluid, this will be aspirated for further cytological, biochemical and microbiological examination. Finally, 15 cc blood will be drawn from the heart.
214415166|NCT00005840|DRUG|Paclitaxel|Given IV
214415167|NCT00005840|DRUG|Cisplatin|Given IV
214415168|NCT00005840|RADIATION|Radiation Therapy|Undergo whole abdominal radiation therapy
214415169|NCT04184804|BEHAVIORAL|Behavioral Intervention|"The intervention package will be consisted of:~1. Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~2. Signs in school areas about organic fruits and vegetables~3. Workshops and interactive games for children~4. Seminars for parents"
214415170|NCT03523962|DRUG|DuraPrep|The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.
214415171|NCT03523962|DRUG|ChloraPrep|The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® \[CareFusion Inc., Leawood, KS, USA\] will be the product used.
214415172|NCT01094041|OTHER|Gluten free diet|A 4-week gluten free diet provided
214415173|NCT01094041|OTHER|Gluten rich diet|A 4-week gluten rich diet is provided
214415174|NCT00484575|DRUG|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
214415175|NCT00484575|DRUG|propofol|propofol given intravenously for sedation in control group
214689351|NCT05972070|DEVICE|ROMTech Portable Connect|The ROMTech PortableConnect Rehab System is a continuous rehabilitative exercise therapy device that uses assisted movement to measure, evaluate, exercise, re-educate and strengthen muscles, and to increase joint range of motion.
215017450|NCT03537729|BEHAVIORAL|Salient Cues|Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
214415176|NCT02243813|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
214415177|NCT05633368|OTHER|Questionnaires|"Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~* Patient Health Questionnaire (PHQ-9)~* Clinical Global Impression (CGI)~* Scaling question regarding depressive symptomatology"
214415178|NCT01777893|BEHAVIORAL|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
214415179|NCT01777893|BEHAVIORAL|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
214415180|NCT01777893|BEHAVIORAL|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
214415181|NCT01777893|BEHAVIORAL|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
214415182|NCT01220336|BEHAVIORAL|Health coaching by medical assistants in primary care|Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model \[Bodenheimer 2007\] for 12 months.
214415183|NCT03897309|BIOLOGICAL|VXA-G1.1-NN|Monovalent GI.1 tableted vaccine
214415184|NCT03897309|BIOLOGICAL|VXA-G2.4-NS|Monovalent GII.4 tableted vaccine
214415185|NCT03897309|BIOLOGICAL|Placebo Tablets|Tablets matching in number and appearance to active vaccine doses
214415186|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made
214689352|NCT06445959|DRUG|Olutasidenib|Given by PO
214689353|NCT06445959|DRUG|Venetoclax|Given by PO
214689354|NCT06445959|DRUG|Decitabine|Given by IV
214689355|NCT06445959|DRUG|Decitabine/cedazuridine|Given by PO
214689356|NCT03583762|DIAGNOSTIC_TEST|Mass spectrometry|Molecular diagnostic test for bacterial identification from bacterial colony
214415187|NCT00684034|OTHER|Sampling of blood|A sampling of bood will be made before the dialysis
214415188|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made.
214415189|NCT02647749|DEVICE|Cardioinsight® mapping system|
214415190|NCT02647749|OTHER|Conventional method without non-invasive mapping|
214415191|NCT05246956|OTHER|Intradialytic exercise|Intradialytic exercise group
214415192|NCT06073171|BIOLOGICAL|Blood sample|7.5 mL will be sampled on EDTA tube for each patient
214415193|NCT06073171|BIOLOGICAL|Cutaneous biopsy|4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients
214415194|NCT06073171|GENETIC|High troughput sequencing of human's exome|Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
214415195|NCT02920359|DRUG|LEUPRORELIN ACETATE|
214415196|NCT04285762|OTHER|LVEEA|lymphaticovenous end-to-end
214415197|NCT04285762|OTHER|LVESA|lymphaticovenous end-to-side
214415198|NCT04285762|OTHER|LVSEA|lymphaticovenous side-to-end
214415199|NCT01805349|RADIATION|Hand X-rays|Hand X-rays to assess the digital arthrosis
214415200|NCT03098030|BIOLOGICAL|Dinutuximab|Dinutuximab injection, for intravenous (IV) use
214415201|NCT03098030|DRUG|Irinotecan|Irinotecan injection, IV infusion
214415202|NCT03098030|DRUG|Topotecan|Topotecan for injection
214415203|NCT01726023|DRUG|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
214415204|NCT01726023|DRUG|metronidazole|Metronidazole 500mg/100ml solution for infusion
214415205|NCT01726023|DRUG|Meropenem|Meropenem powder for solution for infusion 1000mg
214415206|NCT04479254|DIETARY_SUPPLEMENT|Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)|Enteral nutrition feeding formula is used in powder form and will be reconstituted by attending nurses, Continuous feeding is commonly used which will be prescribed by the attending clinicians, Energy and protein intake from EN will be estimated by multiplying the volume of feed given to energy (kcal) and protein (g) in 1 ml of standard dilution, and for Standard PN product, energy and protein intake will also be calculated based on the volume infused.
214415207|NCT02560818|OTHER|collection of a blood sample and breast and ovarian tissue|a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)
214415208|NCT02560818|OTHER|use of a previous blood collection for patients|
214415209|NCT00816829|DRUG|Placebo|Fenofibrate-matching placebo tablet
214415210|NCT00816829|DRUG|Fenofibrate|145 mg NanoCrystal tablet
214415211|NCT03394027|DRUG|ONC201|625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
214415212|NCT05556356|DRUG|Acetaminophen|pre-operative acetaminophen (1000mg)
214415213|NCT05556356|OTHER|Placebo: Multivitamin|pre-operative Multivitamin
214415214|NCT04756401|DRUG|Carfilzomib|Given IV
214415215|NCT04756401|BIOLOGICAL|Daratumumab|Given IV
214415216|NCT04756401|DRUG|Dexamethasone|Given PO
214415217|NCT04756401|OTHER|Quality-of-Life Assessment|Ancillary studies
214505284|NCT02797587|DRUG|Cytisine|Multi-daily dosing, range 3-9 mg daily for 25 days.
215101803|NCT07088497|BEHAVIORAL|dietary control|Subjects are required to have dinner at a specific time on the night before the test and to remain fasting on the next day until the test.
214415218|NCT04756401|DRUG|Selinexor|Given PO
214415219|NCT05300451|BIOLOGICAL|Daratumumab and hyaluronidase-fihj|Daratumumab and hyaluronidase-fihj for subcutaneous (under the skin) injection has different dosing and administration instructions compared to daratumumab for intravenous (in the vein) infusion. Daratumumab and hyaluronidase-fihj contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes. Subjects will receive a 1800mg/30000u injection subcutaneously weekly for a total of 8 doses
214415220|NCT05515770|DRUG|Cabotegravir Injection|Long action cabotegravir injection
214689357|NCT03583762|DIAGNOSTIC_TEST|Microarray assay|Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
214415222|NCT06316674|BEHAVIORAL|sixth finger illusion|Participants will undertake the sixth finger illusion that is a body illusion which elicits the presence of an extra numerary finger due to visuo-tactile stimulation.
214415223|NCT04789850|DRUG|Itacitinib|200 mg oral for 360 days
214415224|NCT04789850|DRUG|Placebo|200 mg oral for 360 days
214415225|NCT04968132|OTHER|Multicomponent opioid reduction and pain management pathway|Pre-operative pain education and expectation setting, identification and modification of risk factors in high risk patients, postoperative individualized analgesic prescriptions, and continued support for pan control and recovery facilitated by an interventions coordinator.
214415226|NCT04968132|OTHER|Standard care|Standard perioperative care, surgical treatment, and pain medications.
214415227|NCT04858425|DRUG|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
214415228|NCT04858425|DRUG|Placebo|Matched placebo tablets 400 mg 3 times daily for 14 days
214415229|NCT02710968|DEVICE|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
214505285|NCT02797587|DRUG|Nicotine Replacement Therapy|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
214505286|NCT02797587|DRUG|Varenicline Placebo|1 week starter kit followed by 1 pill twice daily for 12 weeks.
214505287|NCT02797587|DRUG|Cytisine Placebo|Multi-daily dosing for 25 days.
214505288|NCT02797587|DRUG|Nicotine Replacement Therapy Placebo|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
214505289|NCT02013700|BIOLOGICAL|Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|
214505290|NCT02013700|BIOLOGICAL|matched placebo|The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
214689358|NCT00264316|PROCEDURE|bone marrow-derived stem cell transfer|
214415230|NCT04163484|OTHER|Iodinated contrast|Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
214689359|NCT03643822|DRUG|Dexamethasone 4mg|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
214689360|NCT03643822|DRUG|Dexmedetomidine|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
214415233|NCT06583590|DRUG|Botulinum toxin A|Botulinum toxin (BoNT) is One of the most potent toxins known to humans produced by Clostridium botulinum that has been used to treat several striated and smooth muscle disorders. Because the pathophysiology and the reason for patients' lack of response to PDE5I is insufficient smooth muscle relaxation and veno-occlusive disorder (VOD) , BTX-A may prove to be a viable treatment for this patient population due to its availability to facilitate long-acting cavernosal smooth muscle relaxation by inhibition of the release of noradrenaline from the adrenergic neurons acting on the cavernosal smooth muscle. Thus, the dominant sympathetic basal tone of the cavernosal smooth muscle is essentially removed, facilitating the occurrence of an erection.
214415234|NCT06583590|DRUG|Tadalafil 5mg|Tadalafil is one of 5-phosphodiesterase inhibitors that used to treat male sexual function problems (impotence or erectile dysfunction-ED). In combination with sexual stimulation, tadalafil works by increasing blood flow to the penis to help a man get and keep an erection.Tadalafil is also used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tadalafil is thought to work by relaxing the smooth muscle in the prostate and bladder.
214415235|NCT05199025|DIAGNOSTIC_TEST|Biomarker|Perioperative biomarker analyses
214505291|NCT04734600|DEVICE|Electronic Treadmill device|"group A:PN-7001M Panasonic Treadmill 130 kg, frequency 50 HZ, input voltage AC220 V, input power 100W+\_ 10 will usefor aerobic training program ,start by 1pbm grading to 2pbm speed and increase according to patient abilities during sessions ,0% treadmill inclination angle for two month as a total treatment period for study group patients.~Patients in this group will participate in aerobic training as march walking on treadmill for 45 mints duration for session 3 times per week, start with 5 mints warm up beginning and 5 mints cooling down at end session, in addition to their medical program and burger exercises"
214505292|NCT04734600|OTHER|myofascial release technique|"group B:The myofascial release technique group will receive a 45 mints session time, for3 times per week for two months in addition to their medical program and burger exercises. Before the MF will starte, patient will rested in a relaxed prone position for 15 to 30 mints and also after end session time, MF protocol will applied as follow sequence over all period of total treatment sessions (8) week.:~thoracolumbar cross hand facial release technique for at least 5 mints for every barrier depth area, started by one hand will place on high thoracic area with pressure applied cephalic, the other hand was placed directly on the lower lumbo -sacrum area pushing caudal and arms are crossed to maximize as leverage as the barrier sense of softening will occurre and release sense on fascia under hand (release done at transverse alternative with longitudinal direction)alternation same methods to affected leg"
214505293|NCT02616276|OTHER|Control breakfast|It consists of 350 ml of water at room temperature.
214505294|NCT02616276|OTHER|High glycemic index breakfast|It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
214505295|NCT02616276|OTHER|Low glycemic index breakfast|It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
214505296|NCT03680638|OTHER|Control (Lactated Ringer's)|This intervention is meant to serve as a control by which the experimental sites are compared to, to assess effectiveness.
214505297|NCT03680638|DRUG|Tempol|This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
214505298|NCT03680638|DRUG|Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.
214505299|NCT03680638|DRUG|Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
214505300|NCT02067689|DEVICE|Transcranial Direct Current Stimulation|Application of a weak electrical current to the scalp
214505301|NCT01868230|BEHAVIORAL|Lifestyle Intervention|
214505302|NCT02376309|BEHAVIORAL|Inactivity|Inactivity
214505303|NCT02376309|DRUG|ND|1 nandrolone decanoate injection
214505304|NCT02376309|DIETARY_SUPPLEMENT|Leu|Leucine supplements
214505305|NCT00213278|DRUG|vinblastine sulphate injection|Vinblastine dose: 6 mg/m\^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
214689361|NCT03643822|OTHER|Saline|Control/Placebo intervention
214689362|NCT02679248|DIETARY_SUPPLEMENT|Neo40 Daily®|
214689363|NCT02679248|DIETARY_SUPPLEMENT|Placebo|
215017451|NCT03537729|BEHAVIORAL|Spaced Retrieval Education|Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
214415236|NCT04798521|OTHER|Tele-HCV|Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
214415237|NCT04798521|OTHER|Community Linkage to Care|Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
214415238|NCT03368001|BEHAVIORAL|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
214415239|NCT03368001|BEHAVIORAL|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
214415240|NCT05917717|PROCEDURE|Neuroprotective 'bundle of care'|"This includes the 3 devices:~* Head up cardiopulmonary resuscitation (HUP-CPR)~* Active compression decompression CPR~* Impedance threshold device (ITD)"
214415241|NCT04074499|OTHER|No intervention|There is no intervention.
215017452|NCT03829488|DRUG|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
214415242|NCT06549309|DRUG|JMKX003801|"For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohort of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation."
215017453|NCT03829488|DRUG|0.9% SODIUM CHLORIDE 9g/L injection BP|Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
215017454|NCT05968742|BEHAVIORAL|Abstinence of oral hygiene on select teeth|Study participants abstain from oral hygiene on a select set of four teeth for a period of 21 days
215017455|NCT01480765|DRUG|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
215017456|NCT01480765|DRUG|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
215017457|NCT01480765|DRUG|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
215017458|NCT01480765|DRUG|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
215017459|NCT04668599|OTHER|Cardiopulmonary rehabilitation|Patients will undergo standardized cardio-pulmonary rehabilitation program.
215017460|NCT05599321|DIAGNOSTIC_TEST|Virtual Navigation System|The Virtual Navigator guidance computer is interfaced to the bronchoscopy hardware to tap off the live bronchoscopy and EBUS video feeds. The standard OR medical team (technicians, clinical fellows, et al.) is on hand, and standard clinical facilities (e.g., fluoroscopy, CT/PET image viewer) are available. Our technical team is also present to record all procedural video and computer display information. It also operates the guidance computer during the guided procedure and offers any assistance in case of unanticipated issues. The participant's clinical bronchoscopy will be recorded by the radiology imaging management system.
215017461|NCT06457217|DIAGNOSTIC_TEST|Magnetic resonance spectroscopic imaging|High-resolution 3D metabolic imaging was performed using the SPICE 1H-MRSI sequence.
215017462|NCT06023264|PROCEDURE|Dry needling|It is a minimally invasive treatment modality. Its effectiveness has been confirmed in numerous studies. It consists of applying an antiseptic in the puncture area and inserting the needle in the required aseptic conditions. During puncture, the patient's physical response is observed at all times, in order to control the local spasmodic responses in each muscle. After applying the technique, we assessed jaw pain, mouth opening, and the appearance of headaches. The adverse effects of the technique are the following: pain after puncture (1.7%), local bleeding at the puncture site (6.1%) and syncopal responses (0.7%).
215017463|NCT06306157|DRUG|Low dose naltrexone|While naltrexone is FDA-approved for treatment of alcohol or opioid addition, this study will be looking at how naltrexone, when dosed very low, may reduce the painful symptoms associated with CRPS. Naltrexone is not FDA-approved for pain management treatment of CRPS at this time, and therefore the study intervention is using the drug in an off-label manner.
215017464|NCT06306157|DRUG|Placebo sugar capsules|The external appearance of the capsules prepared by the pharmacy will be identical to the LDN capsules. The inactive capsule ingredients will be microcrystalline cellulose (MCC) and Magnesium stearate
215017465|NCT02845349|DRUG|Vortioxetine|The study drug, vortioxetine received approval from the U.S. Food and Drug Administration (FDA) to treat adults with major depressive disorder. This study is being done to determine its effectiveness in a specialized population, i.e. those who have developed major depression after a traumatic brain injury. As patients who have sustained a TBI are medically fragile and sensitive to side-effects of medications, it is important to test the effectiveness and safety of vortioxetine in this population.
215017466|NCT02845349|DRUG|Placebo|A placebo comparator will be used in one subset of patients.
215017467|NCT02562040|PROCEDURE|Early Adenotonsillectomy (eAT)|Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
214415243|NCT06549309|DRUG|Placebo|"For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohorts of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation."
214415244|NCT05866510|DRUG|Utidelone and anlotinib|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days."
214415245|NCT00501020|DRUG|Rosiglitazone|
214415246|NCT01243801|DRUG|Ketamine|Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
214415247|NCT06037616|OTHER|powerpoint and tutor|Powerpoint on indication of skin suture and tutor for the skill to perform skin suture
214415248|NCT06037616|OTHER|video skill|Video showing skill to perform a skin suture
214415249|NCT06037616|OTHER|video errors|Video showing errors of skin suture
214415250|NCT02884583|OTHER|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
214415251|NCT02373228|OTHER|Audio signal processing (applied offline before playback)|
214415252|NCT00782639|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
214415253|NCT00782639|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
214415254|NCT04705857|COMBINATION_PRODUCT|"Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene"|gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
214415255|NCT01624168|BEHAVIORAL|Anxiety Management Education|written materials on management of anxiety for self-study
214415256|NCT01624168|BEHAVIORAL|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
215017468|NCT02562040|BEHAVIORAL|Watchful Waiting with Supportive Care (WWSC)|Information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
214415257|NCT01624168|BEHAVIORAL|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
214415258|NCT05744128|BIOLOGICAL|Zirconium 89Zr crefmirlimab berdoxam|Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.
214415259|NCT00608933|OTHER|educational intervention|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
214415260|NCT00608933|OTHER|questionnaire administration|Patients complete questionnaires
214415261|NCT00282776|BEHAVIORAL|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
214505306|NCT04970732|PROCEDURE|Gum chewing|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
214505307|NCT03114215|DRUG|MD1003|capsules 100mg 3 times per day
214505308|NCT03114215|DRUG|Placebo oral capsule|capsules 100mg lactose 3 times per day
214505309|NCT00659373|DRUG|Tamoxifen|
214505310|NCT00659373|DRUG|triptorelin|
214505311|NCT00659373|DRUG|Exemestane|
214415262|NCT00282776|BEHAVIORAL|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
214505312|NCT01098409|DRUG|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
214505313|NCT01098409|DRUG|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
214505314|NCT04353856|OTHER|quality of life assessment|quality of life assessment using the EQ5D questionnaire once a month
214505315|NCT04364230|DRUG|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
214505316|NCT04364230|DRUG|NeoAg-mBRAF|BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
214505317|NCT04364230|DRUG|PolyICLC|polyICLC, local adjuvant
214505318|NCT04364230|DRUG|CDX-1140|CDX-1140, local adjuvant
214505319|NCT00060502|DRUG|Infliximab; Gemcitabine|
214505320|NCT00351026|DRUG|Methadone|short-term methadone maintenance
214505321|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
215017469|NCT04997421|DEVICE|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).
214415263|NCT05203913|DRUG|Nivolumab|The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
214415264|NCT05203913|DRUG|Nab paclitaxel|The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
214505322|NCT00070642|DRUG|dacarbazine|dacarbazine 850mg/m2 in three-week cycles until disease progression
215017470|NCT04997421|DEVICE|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)
214505323|NCT00070642|DRUG|Chemotherapy|"Chemotherapy in three-week cycles until disease progression:~dacarbazine 850mg/m2"
215017471|NCT00523666|DRUG|Galantamine (Reminyl®)|8mg - 24mg
215017472|NCT00523666|DRUG|Placebo/Galantamine (Reminyl®)|"Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg"
215017473|NCT04775524|BEHAVIORAL|Storytelling Through Music (STM)|6 week expressive arts-based program
214415265|NCT05203913|DRUG|Cisplatin|The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
214505324|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
214505325|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
214505326|NCT02382640|DRUG|Febuxostat XR|Febuxostat extended-release (XR) capsules
214505327|NCT02382640|DRUG|Maalox Advance Regular Strength liquid|Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
214505328|NCT02356198|DRUG|EXPAREL|transversus abdominis plane injection
214415266|NCT05203913|RADIATION|Radiotherapy|Radiotherapy will be delivered over approximately 5 weeks.The total radiotherapy dose will be: 60 Gray in 25 fractions over 5 weeks on original bladder tumour, 50 Gray in 25 fractions over 5 weeks on whole bladder and pelvic nodes if included, administered as concomitant boost. Radiation therapy will be delivered once daily (Monday-Friday) continuously without a planned break for tumour response assessment during treatment.
214505329|NCT02356198|DRUG|Intrathecal hydromorphone|Intrathecal opioid administration
214505330|NCT03471117|DRUG|Pioglitazone|Pioglitazone 15mg daily for 1 month
214505331|NCT03471117|OTHER|Placebo|Placebo pills for 1 month
214505332|NCT05850793|BEHAVIORAL|Sensorimotor Exercise|Balance, perturbation , aging and strengthing exercise will be performed for knee
214505333|NCT05850793|BEHAVIORAL|Conventional Exercise|Range of motion, strengthing and stretching exercise will be performed for knee
214505334|NCT05850793|BEHAVIORAL|Progressive Motor Imagery Exercise|Different types of exercises will be applied targeting muscle strength, proprioceptive sense or brain neurons for knee
214505335|NCT03162614|BIOLOGICAL|RTS,S/AS01E|Subjects will receive intramuscular injection of RTS,S/AS01E.
214505336|NCT03162614|BIOLOGICAL|RTS,S/AS01B|Subjects will receive intramuscular injection of RTS,S/AS01B.
214505337|NCT03162614|PROCEDURE|Sporozoite-infected mosquitoes challenge.|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs."
214505338|NCT01607697|BEHAVIORAL|Mindfulness Training|Mindfulness Training
214505339|NCT01920191|BIOLOGICAL|IMA 950|
214505340|NCT01920191|BIOLOGICAL|Poly ICLC|
214505341|NCT01920191|OTHER|Immunomonitoring|Blood samples, DTH analysis
214505346|NCT05703919|DRUG|Titrated Oxygen|Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%
214505347|NCT05703919|DRUG|Standard Oxygen|Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators
214505348|NCT05698693|BEHAVIORAL|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.
215017474|NCT04775524|BEHAVIORAL|Wait List / Storytelling Through Music-Hybrid|2 week song listening program
215017475|NCT03342794|PROCEDURE|cataract surgery|To diagnose the preexisting posterior capsule defects in congenital cataracts after the cataracts are removed by surgery and observe the characteristics
215017476|NCT05121922|BEHAVIORAL|Metacognitive Therapy|Psychological treatment provided by the patient's regular general practitioner
214415267|NCT06155253|PROCEDURE|Erector spinae plane block|"ESP block is a paraspinal fascial plane block that involves injection of local anesthetic underneath the anterior fascia of the erector spinae muscles.~Local anaesthetic mixture (lignocaine 2% with adrenaline, bupivacaine 0.25%) will be delivered with insulated needle in bolus(es) to above-mentioned levels (L1 in 1ESP group, T12 \& L1 in 2ESP group)"
214505349|NCT05698693|BEHAVIORAL|Contact Control|This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
214505350|NCT00432016|DRUG|zidovudine|
214505351|NCT00432016|DRUG|amdoxovir|
214505352|NCT00432016|PROCEDURE|pharmacokinetic sampling|
215017477|NCT00863460|RADIATION|cranial radiotherapy|40 Gy
215017478|NCT00863460|DRUG|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
214415268|NCT01874184|OTHER|counseling intervention|Take part in weekly group counseling sessions
214415269|NCT01874184|BEHAVIORAL|behavioral dietary intervention|Set goals for changing dietary habits
215017479|NCT00863460|DRUG|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
214415270|NCT01874184|BEHAVIORAL|exercise intervention|Attend group exercise activities
214415271|NCT01874184|OTHER|questionnaire administration|Ancillary studies
214415272|NCT01874184|OTHER|laboratory biomarker analysis|Correlative studies
214415273|NCT02814266|OTHER|difficult intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
214415274|NCT02814266|OTHER|easy intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
215017480|NCT02684474|BIOLOGICAL|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
215017481|NCT06445595|OTHER|patients with traumatic brain injury|Patients will be contacted by phone
215017482|NCT03735901|DRUG|IMP Levodopa 100mg/Carbidopa 25mg|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning."
215017483|NCT03735901|DRUG|Matching placebo|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning."
214415275|NCT00126009|DRUG|Amisulpride|
214415276|NCT01285258|PROCEDURE|hysterectomy|excluding the uterus with saving ovaries
214415277|NCT04480814|DIAGNOSTIC_TEST|PIK3CA kit|Prospective investigation of clinical samples for evaluation of IVD clinical performance
214415278|NCT01322958|DEVICE|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
214505353|NCT03175159|BEHAVIORAL|IMPACT|Ten counseling sessions
214505354|NCT03175159|BEHAVIORAL|Standard of Care|Two counseling sessions
214505355|NCT02251301|DIETARY_SUPPLEMENT|Skim Milk|250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
214505356|NCT02251301|BEHAVIORAL|High intensity interval training|All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
214505357|NCT02251301|OTHER|Placebo|250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
214505358|NCT02251301|DIETARY_SUPPLEMENT|Macronutrient isoenergetic control|250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
214505359|NCT00380250|DRUG|Lubiprostone|
214505360|NCT00380250|DRUG|Placebo|
214505361|NCT01350167|PROCEDURE|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
214689364|NCT04093518|DRUG|Estradiol|2 transdermal patches to be changed twice a week for the duration of 16 weeks
214689365|NCT04093518|DRUG|Placebo|2 transdermal patches to be changed twice a week for the duration of 16 weeks
214689366|NCT01583998|BEHAVIORAL|e-MBC|antidepressant treatment
214689367|NCT06115421|DRUG|Roxadustat|hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs)
214415279|NCT06165549|OTHER|Light therapy|The light therapy will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at 5000 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
214415280|NCT06165549|OTHER|Light placebo therapy|The light placebo intervention will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at less than 200 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
214415281|NCT06165549|OTHER|Emotion Bias Modification Training|The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, selecting a fixed word of the word-pair will be associated with a high probability (eighty percent) of getting a monetary reward and a low probability (twenty percent) of no reward, and probabilities will be reversed for the other word. Each training run will comprise 100 gaming picture trials and 100 healthy-activity picture trials, presented in a pseudo-randomized order. Participants will receive two training runs every day. The whole training includes 14 days.
214415282|NCT03328949|DEVICE|IVL Coronary Lithotripsy System|The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
214415283|NCT02048709|DRUG|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
214415284|NCT05414929|DIAGNOSTIC_TEST|HPV self-sampling|HPV self-sampling (Cobas Uniswab)
214415285|NCT00604721|DRUG|selumetinib|Given orally
214415286|NCT00604721|OTHER|pharmacological study|
214415287|NCT04776213|DRUG|Mavenclad®|This low interventional extension study involves the follow up of participants in the parent study. The participants were followed up for an additional 2 year period (until 4 years after initial administration of Mavenclad® tablets), during which the participants were not treated with Mavenclad®, as per European Medicines Agency (EMA) label of Mavenclad®.
214415288|NCT00051974|DRUG|VELCADE™ (bortezomib) for Injection (formerly PS-341)|
214415289|NCT02681276|PROCEDURE|Irrigation with 3% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
214415290|NCT02681276|PROCEDURE|Irrigation with 0.5% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
214415291|NCT01139697|OTHER|Hair sampling|Hair sampling for the measurement of cortisol and testosterone
214415292|NCT02704481|DRUG|Mifepristone|200mg oral mifepristone
214415293|NCT02704481|DRUG|Misoprostol|800mcg buccal misoprostol
214415294|NCT02704481|DRUG|Placebo mifepristone|Matching placebo pill of 200mg mifepristone
214415295|NCT02704481|DRUG|Placebo misoprostol|Matching placebo pills of 800mcg misoprostol
214415296|NCT00124826|DRUG|Insulin|
214415297|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
214415298|NCT02317016|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
214415299|NCT02317016|DRUG|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
214415300|NCT02317016|PROCEDURE|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
214415301|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
214415302|NCT03165149|DRUG|group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
214415303|NCT03165149|DRUG|group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
215017484|NCT00355550|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
214415304|NCT03165149|DRUG|group (c)|patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
214415305|NCT00536380|DRUG|5-mg Desloratadine|5-mg desloratadine tablets, once daily for four weeks.
214415306|NCT00536380|DRUG|10-mg Desloratadine|10-mg desloratadine tablets, once daily for four weeks.
214415307|NCT00536380|DRUG|20-mg Desloratadine|20-mg desloratadine tablets, once daily for four weeks.
214415308|NCT00778804|BEHAVIORAL|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
214415309|NCT04066738|DIAGNOSTIC_TEST|Cardiac MRI with gadolinium contrast|Imaging of left ventricular scar and coronary sinus venous system
214415310|NCT04066738|DIAGNOSTIC_TEST|3D reconstruction and location of coronary sinus venous system relative to myocardial scar|Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
214415311|NCT04066738|DIAGNOSTIC_TEST|Acute haemodynamic measurements during CRT implant|Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
215017485|NCT00355550|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
215017486|NCT03189511|DRUG|Fluvastatin|Fluvastatin 40 mg twice daily per mouth for 14 days.
215017487|NCT03211845|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self-measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
215017488|NCT03092011|DRUG|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
215101804|NCT03198806|OTHER|Treadmill aerobic exercise in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
214415312|NCT04343807|PROCEDURE|PECS Block|PECS nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
214415313|NCT04343807|OTHER|Control Group|No nerve block will be performed and only intravenous nalbuphine will be given.
214415314|NCT00195078|DRUG|ZD1839 (IRESSA)|
214415315|NCT00195078|DRUG|Cisplatin|
214415316|NCT00195078|PROCEDURE|Radiation Therapy|
214415317|NCT03693742|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT scan|"Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes."
214415318|NCT03693742|OTHER|Placebo drink|Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
214415319|NCT03693742|OTHER|MSG drink|Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
214415320|NCT02589210|OTHER|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
214415321|NCT04167891|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
214415322|NCT03728036|BEHAVIORAL|conventional rehabilitation|The investigated cohort will be exposed to 'standard care' including conventional rehabilitation therapy.
214415323|NCT04735354|DRUG|sacubitril/valsartan|There was no treatment allocation. Patients administered sacubitril/valsartan by prescription that started before inclusion of the patient into the study were enrolled.
214415324|NCT00776711|DRUG|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
214689368|NCT04319289|OTHER|aerobic interval training and Vitamin D supplementation,|"The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~* Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day ."
215017489|NCT03092011|DRUG|Morphine Sulfate|Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
215017490|NCT01654250|DRUG|NWP09|Methylphenidate, variable dose, daily dosing, 1 week duration
215017491|NCT01654250|DRUG|Placebo|Placebo
215017492|NCT01862029|DRUG|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
214415325|NCT00776711|DRUG|VRC-AViDNA036-00-VP|
214415326|NCT02931396|DEVICE|FES|
214505362|NCT04816006|BEHAVIORAL|Aerobic Exercise Training|Breast cancer survivors in the intervention group will participate in a 24-week moderate intensity exercise program led by community-based fitness center personal trainers. Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Treadmill walking is the primary mode of exercise. However, participants will be permitted to use other cardiovascular equipment (e.g., elliptical machines, stationary bicycles) as prescribed by their exercise trainer. The trainer will supervise three weekly exercise sessions in Weeks 1-2, two in Weeks 3-4, one in Weeks 5-8, biweekly across weeks 9-16, and monthly in Weeks 17-24 (N=20 supervised sessions).
215017493|NCT00403065|DRUG|dexamethasone|
214415327|NCT06055712|DRUG|Cefazolin|Intravenous dose(s).
214415328|NCT06055712|DRUG|Cephalexin|Five days oral.
214415329|NCT02132702|DEVICE|Ekso|
214415330|NCT03245164|OTHER|Physiotherapy group exercises|Physiotherapy exercises had aerobic, balance, strength exercises with music.
215017494|NCT00403065|PROCEDURE|quality-of-life assessment|
215017495|NCT00403065|RADIATION|radiation therapy|
215017496|NCT03380481|OTHER|observational only-no intervention|Observational only and no predesigned interventions in this study.
215017497|NCT04422834|OTHER|Questionnaire|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
214415331|NCT03245164|OTHER|Basketball program|Basketball education presented the techniques about playing basketball and basketball games were played.
214415332|NCT04375644|OTHER|Questionnaires on psychological quality of life|Assessement of evolution of the psychological quality of life of health professionals during the confinement period linked to the COVID-19 pandemic by two questionnaires (one during the confinement period and the second one month after the end of the confinement period)
214415333|NCT04139694|DIETARY_SUPPLEMENT|Food plan with cinnamon supplementation|cinnamon twice daily plus follow Cardiometabolic diet
214415334|NCT04139694|BEHAVIORAL|Food plan without cinnamon supplementation|Cardiometabolic diet only
214415335|NCT05956600|DRUG|Amisulpride 50 MG|Amisulpride 50 mg titrated to dose range of 50 to 1200 mg
214415336|NCT01477619|DRUG|Tasimelteon|20mg single dose on Day 1
214415337|NCT00961142|DRUG|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
214415338|NCT06652763|OTHER|Minnesota Living with Heart Failure Questionnaire|Self-administered, validated questionnaire to assess symptoms of heart failure
214415339|NCT06652763|DIAGNOSTIC_TEST|Echocardiogram|Resting transthoracic echocardiogram to exclude valvular pathology and the assess indices of systolic and diastolic function and speckle tracking for strain
214415340|NCT06652763|DIAGNOSTIC_TEST|Six-minute walk test|Standardised, objective assessment of exercise capacity
214415341|NCT06652763|DIAGNOSTIC_TEST|Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy|Using a 3-Tesla scanner, 31P magnetic resonance spectroscopy will be performed to obtain information regarding cardiac energetics. An intravenous infusion of manganese dipyridoxyl diphosphate (mangafodipir, MnDPDP) will be commenced at a rate of 1mL/min using a dose of 5µmol/kg (0.1mL/kg).
214415342|NCT06652763|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance scan|Scan including adenosine stress perfusion
214415343|NCT06652763|DIAGNOSTIC_TEST|Blood tests|Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses
214415344|NCT03981549|BIOLOGICAL|Autologous Bone Marrow CD34+ Stem Cells|Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
214415345|NCT03981549|BIOLOGICAL|Sham Therapy|Sham bone marrow aspiration procedure that penetrates the skin, but does not penetrate the bone followed by sham intravitreal injection without penetration of the eye
214415346|NCT05264337|OTHER|Self-reported lymphedema|Lymphedema as reported by LymQOL questionnaire.
214415347|NCT05264337|OTHER|Dielectric constant ratio|Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
214415348|NCT05264337|OTHER|Limb volume|Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
214415349|NCT06374056|DEVICE|Kintsugi Voice Device|"The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression.~The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs."
215017498|NCT01919476|OTHER|Bagel|
215017499|NCT01919476|OTHER|Cream Cheese|
215017500|NCT01919476|OTHER|Almond Butter|
215017501|NCT04880889|DRUG|BL 3000|capsule 500 mg
214415350|NCT03932617|DEVICE|end tidal carbon dioxide by capnography|"Moreover, since PETCO2 is mainly determined by tissue CO2 production (VCO2), alveolar ventilation and CO, when stable metabolic conditions are assumed and minute ventilation is kept constant, acute changes in PETCO2 have been shown to correlate strongly with changes in CO.~Thus, PETCO2 has been suggested as a simple economic and noninvasive alternative for continuous assessment of CO in different shock states."
214415351|NCT06713733|DRUG|Dexamethasone|local infiltration
214415352|NCT06713733|DRUG|Chymotrypsin|orally given
214415353|NCT00123799|PROCEDURE|Positron Emission Tomography Imaging|
214415354|NCT03074851|DIETARY_SUPPLEMENT|low sodium salt|To give free low sodium salt intervention for 2 months
214415355|NCT03074851|OTHER|informational intervention|to give reporter informational intervention.
214415356|NCT03059992|DRUG|Ibrexafungerp|Experimental Study Drug
214415357|NCT02082366|DEVICE|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
214415358|NCT00968331|DRUG|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
214415359|NCT04573374|PROCEDURE|Pulpotomy|Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.
214415360|NCT06696911|PROCEDURE|Core stability Exercises|"The exercises have been divided into three difficulty categories based on the level of difficulty.~Level I: When the patients were unable to sit independently, level I core stability therapy was administered. First-level exercises were done in a supine position on a plinth. The workout program mostly included side bridging movements, leg crosses, one-leg curl-ups, and straight and diagonal reaching activities. Patients can move to level once they can sit on a plinth edge unsupported for one minute while flexing their knees and hips to 90 degrees.~Level II: Exercises included straight-arm curl-ups, diagonal-arm curl-ups, and arm curl-ups with the arms crossed. The patient will go to stage three once they can sit on an unstable surface for thirty seconds.~Level III: Using a physio ball, the exercises were done while seated. The exercises performed with the ball consisted push-ups, bird dog, side Bridge, abdominal curl-ups, and bridge movements"
214505363|NCT04816006|OTHER|Health Education (Active comparator)|Breast cancer survivors in the Health Education group will participate in education sessions with a health educator and receive monthly newsletters/webinars (N=20 total contacts) across 24 weeks. The program will include cancer support and discussion of cancer-related wellness topics (e.g., stress management, coping). Control group participants will be offered a 6-month fitness center membership upon study completion.
214505364|NCT02630966|DRUG|Vedolizumab|Vedolizumab 300 mg IV infusion
214505365|NCT02630966|DRUG|Placebo|0.9% sodium chloride IV infusion
215017502|NCT04880889|DRUG|Reference Pantogar|capsule
215017503|NCT04880889|DRUG|BL3000 Placebo|capsule 500 mg
215017504|NCT04880889|DRUG|Pantogar - Placebo|capsule
215017505|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet once daily
215017506|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet once daily
215017507|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet two times a day
214415361|NCT06696911|PROCEDURE|Motor Imagery|"The motor imagery program will be performed in three steps. STEP 1 Subjects will be instructed to watch the video provided and recorded by investigator. Two types of videos will be available to watch. One recording normal movements and the other film will contain recording the patient movements. Patient will be asked to watch the video and analyze the differences.~STEP 2 In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.~STEP 3 Participants will be than instructed to carry out the task in verbal commands given whenever necessary. During the recall process components of movement deviating from normal will be emphasized. The difficulty level of activities and the analysis of movement components will be increased gradually according to the patient's capacity."
214415362|NCT06696898|PROCEDURE|Somatosensory Motor Control Exercises|The Somatosensory motor control training protocol assembled into three components, 1) PNF exercises (Each patient alternately contracted trunk extensors and flexors isometrically for 10 seconds against maximum resistance while seated, then contracted trunk agonists alternately in a concentric and eccentric manner against manual resistance without relaxing, then moved his or her trunk in a twisting and diagonal orientation against maximum resistance), 2) Somatosensory exercises in which a wobbling board was used and six types of exercises were performed including hallowing, one lower limb elevation, opposite upper and lower limb elevation from a four-limb supported position (quadruped), abdominal reinforcement, maintaining a bridging posture, and one lower limb elevation from the bridging posture, and 3) finally Vestibular training which involved exercises to improve gaze focus, exercises for enhancing eye movements.
214415363|NCT06696898|PROCEDURE|Myofascial Release Technique|Manual therapy technique that applies sustained pressure to myofascial tissues around the lumbar spine and pelvis to release tension and improve mobility.Myofascial Release Technique MFR is given with the ulnar border from proximal to distal direction with a light gentle pressure over the hamstring muscle until the slack in the skin is loosened. (2) Every strike is to be held for 30 seconds, 5 repetitions per session
214415364|NCT06696898|PROCEDURE|Sensorymotor training|The Somatosensory motor control training protocol assembled into three components, 1) PNF exercises (Each patient alternately contracted trunk extensors and flexors isometrically for 10 seconds against maximum resistance while seated, then contracted trunk agonists alternately in a concentric and eccentric manner against manual resistance without relaxing, then moved his or her trunk in a twisting and diagonal orientation against maximum resistance), 2) Somatosensory exercises in which a wobbling board was used and six types of exercises were performed including hallowing, one lower limb elevation, opposite upper and lower limb elevation from a four-limb supported position (quadruped), abdominal reinforcement, maintaining a bridging posture, and one lower limb elevation from the bridging posture, and 3) finally Vestibular training which involved exercises to improve gaze focus, exercises for enhancing eye movements.
214415365|NCT06696547|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Coil
214415366|NCT06696547|DEVICE|Transcranial Magnetic Stimulation Sham|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Sham Coil
214415367|NCT02482493|DEVICE|Sigma PFC|patients will receive either an all polyethylene tibial component or a metal- backed component
214415368|NCT06712056|BEHAVIORAL|Mindfulness|study of focusing attention
214415369|NCT06709677|BEHAVIORAL|Arabic version of The Nordic Musculoskeletal Questionnaire (NMQ) is a standardized questionnaire used to assess musculoskeletal symptoms and disorders in the workplace|"The Nordic Musculoskeletal Questionnaire (NMQ) is a standardized questionnaire used to assess musculoskeletal symptoms and disorders in the workplace. It is commonly used in occupational health and ergonomic assessments to gather information about the prevalence and severity of musculoskeletal issues such as pain, discomfort, and limitations in movement. The NMQ typically includes questions about specific body regions (e.g. neck, shoulders, back, wrists) and asks individuals to report any symptoms they may be experiencing in those areas. This information can help identify potential risk factors for musculoskeletal disorders and guide interventions to prevent or manage these conditions in the workplace (Namnik et al., 2016).~• Section 1: a general questionnaire of 40 forced-choice items identifying areas of the body causing musculoskeletal problems. Completion is aided by a body map to indicate nine symptom sites being neck, shoulders, upper back, elbows, low back, wrist/hands, hips/thi"
214415370|NCT06696560|OTHER|Minimal Invasive Approaches in Aortic surgeries.|Minimal Invasive Approaches For Aortic Valvular and Subvalvular Surgeries
214415371|NCT06713135|DRUG|vamorolone 40 mg/mL oral suspension|Vamorolone is administered at a dose range between 2 mg/kg/day and 6 mg/kg/day for boys weighing \<40 kg. For boys weighing 40 kg or above, the dose range will be 80 mg to 240 mg once daily. Doses can be adjusted within the dose range as determined by the Investigator based on tolerability. The highest tolerated dose should be used.
214415372|NCT06711003|DEVICE|enhanced external counterpulsation|Enhanced External Counterpulsation (EECP) is a non-invasive treatment primarily used for patients with angina or heart failure. It involves the application of pressure cuffs to the legs, which inflate and deflate in sync with the cardiac cycle. This enhances blood flow to the heart during diastole, the phase when the heart is resting between beats. The increased pressure promotes coronary artery perfusion, helping to improve oxygen delivery to the heart muscle, reduce angina symptoms, and enhance cardiovascular function. EECP is typically recommended for patients who are not good candidates for invasive procedures like angioplasty or bypass surgery, or for those seeking supplementary treatment for angina. Over time, it may promote the development of new blood vessels (collateral circulation), further improving heart health. The treatment is generally administered over several weeks in outpatient settings, with each session lasting around one hour.
214415373|NCT06711003|PROCEDURE|post acute care|Post-Acute Care (PAC) for stroke patients focuses on improving functional independence, reducing disability, and preventing secondary complications.
214415374|NCT06708429|DIAGNOSTIC_TEST|LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)|"A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)"
214415375|NCT06711575|DRUG|Anti-Infective Drugs|Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
214415376|NCT06711250|PROCEDURE|khoury technique|autogenous bone augmentation
214689369|NCT04319289|DRUG|Vitamin D supplementation only|One capsule containing (cholecalciferol 400 IU) was taken every day .
214415377|NCT06711250|PROCEDURE|khoury technique with i-PRF injections|autogenous bone augmentation with repeated i-PRF injections
214415378|NCT06713057|DRUG|Cyclophosphamide+Pemetrexed+5-Fluorouracil|IV or PO
214415379|NCT06713057|DRUG|Cyclophosphamide+Doxorubicin+5-Fluorouracil|IV or PO
214415380|NCT06713057|DRUG|Vindesine + Cisplatin|IV or PO
214415381|NCT06713057|DRUG|Doxorubicin + Cisplatin|IV or PO
214415382|NCT06713057|DRUG|Doxorubicin + Cyclophosphamide + Cisplatin|IV or PO
214415383|NCT06713057|DRUG|Docetaxel + Doxorubicin|IV or PO
214415384|NCT06713057|DRUG|Paclitaxel + Carboplatin|IV or PO
214415385|NCT06713057|DRUG|Paclitaxel + Doxorubicin|IV or PO
214415386|NCT06713057|DRUG|Paclitaxel + Cisplatin|IV or PO
214415387|NCT06713057|DRUG|Gemcitabine alone|IV or PO
214415388|NCT06714032|DRUG|TCM plus conventional drug|All patients were treated according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.
214415389|NCT06714032|DRUG|TCM placebo plus conventional drug|All patients were treated according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.
214415390|NCT06711341|DEVICE|Whole-body Vibration (WBV) Training|"Participants use the Compex Winplate, designed specifically for vibration training. The device is set with a frequency of 30 Hz and an amplitude of 4 mm. Participants perform a total of 5 exercises consisting of static and dynamic squat exercises, with a 30-second rest period between sets and between different exercises. The exercises and progression over the weeks are as follows:~Week 1:~* Static squat with knees flexed at 30° - 2 sets of 30 seconds each~* Dynamic squat with knees flexed between 0-60° - 2 sets of 30 seconds each~* Fingertip-to-sole partial dynamic squat with knees flexed at 30° - 2 sets of 30 seconds each~* Consecutive weight transfer with knees flexed at 45° - 2 sets of 30 seconds each~* Single leg static squat with knees flexed at 30° - 30 seconds per leg~Subsequent Weeks: The duration of each set increases by 10 seconds each week. Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises."
214415391|NCT06711341|BEHAVIORAL|Progressive Resistance Exercise (PRE)|"Training Duration: Participants undergo approximately 15-20 minute training sessions, 3 days per week for 3 weeks.~Exercise Regimen: The training focuses on strengthening the quadriceps muscles using ankle weights. The load is determined using the DeLorme principle:~* At the beginning of each week, the 10-repetition maximum (10RM) is measured.~* During that week, participants perform their training sets as follows:~  * First set: 50% of 10RM~ * Second set: 75% of 10RM~ * Final set: 100% of 10RM Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises."
214415392|NCT06711341|BEHAVIORAL|Home-Based Exercise|"Protocol: Participants receive a printed document with instructions for home exercises and are instructed on how to perform the exercises.~Training Duration: Sessions are conducted three days per week for 3 weeks.~Exercise Regimen: The exercises include:~* Bilateral Quadriceps Isometric Exercise: Participants lie on their backs with a roll below each knee, pressing for 10-second holds, totaling 20 repetitions.~* Knee Extensions: Participants performed knee extensions while seated, holding each extension for 5 seconds, completing 10 repetitions per leg.~* Knee Range of Motion (ROM) Exercises: Participants lie face down and alternately bend their knees, completing 10 repetitions.~Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises"
214689370|NCT04319289|OTHER|aerobic interval training only|"The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~* Frequency: 3 days/week. The whole training lasting for 12 weeks"
214689371|NCT05590234|DRUG|Dexmedetomidine injection|1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%
215017508|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet two times a day
214415393|NCT06713252|BEHAVIORAL|Art therapy|Through music, painting, dance and other forms, art therapy can not only help patients regulate their emotions, relieve anxiety and depression, but also activate different areas of the brain to promote neuroplasticity, thereby promoting the recovery of motor function
214415394|NCT06713252|BEHAVIORAL|Regular therapy|Standard treatment
214415395|NCT06713564|DRUG|LS301-IT|LS301 is composed of: 1) a cyclic peptide that binds phosphorylated Annexin A2 (ANXA2) which is found on the surface of malignant cells typically located in solid tumors and in malignant lymph nodes; and 2) cypate, a near infrared (NIR) molecule conjugated to the peptide, which fluoresces when illuminated using NIR light.
214415396|NCT06714669|DRUG|propofol|"Control Group (Propofol Anesthesia Arm):~Patients in this arm will receive Propofol as the primary anesthetic agent for general anesthesia. Propofol is a well-established anesthetic drug commonly used in clinical practice for its rapid onset and short duration of action. Similar to the experimental group, the dosing regimen and administration protocol for Propofol will be tailored to the individual patient's needs and the surgical procedure. Hemodynamic stability and other vital signs will also be closely monitored in this group to assess the safety and effectiveness of Propofol in comparison to Remimazolam."
214415397|NCT06714669|DRUG|Remimazolam|"Experimental Group (Remimazolam Anesthesia Arm):~Patients in this arm will receive Remimazolam as the primary anesthetic agent for inducing and maintaining general anesthesia. Remimazolam belongs to a new class of benzodiazepines and acts by enhancing the activity of GABAA receptors, leading to sedation and anesthesia. The specific dosing regimen and administration protocol for Remimazolam will be determined based on the patient's characteristics and the surgical procedure being performed. Close monitoring of the patient's vital signs, particularly hemodynamic parameters, will be conducted throughout the anesthesia period to ensure safety and efficacy."
214415398|NCT06714331|DIETARY_SUPPLEMENT|Supplements|Supplements provided to subjects 2 hours prior to testing and drank at 2 hours, 90 minutes and 45 minutes before testing.
215017509|NCT00504556|DRUG|warfarin|warfarin tablets
215017510|NCT01778231|DIETARY_SUPPLEMENT|Nutrof Total|Antioxidant and trace element supplement
214415399|NCT06713915|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography|Only patients in the prospective cohort will undergo CEM in addition to breast ultrasound.
214415400|NCT06714474|OTHER|Virtual Simulation Game|The Virtual Simulation Game (VSG) is an interactive, scenario-based digital training tool designed to enhance venous blood sampling (VBS) skills. Participants engage with the VSG platform to complete modules that simulate real-life clinical scenarios, allowing them to refine decision-making and procedural skills in a safe, controlled environment. This intervention is used in addition to traditional training to reinforce learning through repetition and feedback.
214415401|NCT06714474|OTHER|Traditional Training|Traditional training consists of theoretical instruction and hands-on practice sessions conducted in a laboratory setting. Participants observe VBS demonstrations, followed by supervised practice on peers to develop their procedural skills. This intervention represents the standard educational approach for VBS and serves as the comparator in this study.
214415402|NCT06714383|DRUG|Trilaciclib|Trilaciclib: 240mg/m2, IV, within 4 hours before each chemotherapy agent infused.
214415403|NCT06714383|DRUG|Pirarubicin|Pirarubicin: 60 mg/m2，IV，d1-2
214415404|NCT06714383|DRUG|Lobaplatin|LobaplLatin: 40 mg/m2,，IV，d1
214415405|NCT06714409|DIAGNOSTIC_TEST|VExUS guided decongestion|Treatment team will be provided information about venous organ congestion status.
214415406|NCT06714487|OTHER|cognitive stimulation through games|cognitive stimulation through games
214415407|NCT06711913|DRUG|Dexmedetomidine|intravenous dexmedetomidine given in form of 100ml infusion over 10 minutes
214689372|NCT05590234|DRUG|Bupivacaine 0.25% Injectable Solution|20 ml of bupivacaine 0.25%,
214689373|NCT05590234|DRUG|normal saline|20 ml of normal saline 0.9%.
214689374|NCT03852888|BIOLOGICAL|Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level|Each patient will have to complete a total of 8 urine samples after treatment with methotrexate. The 8 samples will be taken over one week (just before taking, then 2 hours after taking treatment and then on D3, D4, D5, D6, D7, D8 before the new dose of methotrexate).
214689375|NCT02664636|PROCEDURE|Physiotherapy|"Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.~This is part of routine care."
215017511|NCT01778231|DIETARY_SUPPLEMENT|Placebo|
215017512|NCT04957927|DRUG|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
214415408|NCT06711913|OTHER|Normal Saline (Placebo)|control group receive normal saline as placebo
214415409|NCT06712368|DEVICE|virtual reality glasses|Designed cardiac physical therapy program applied through virtual reality glasses for study group
214415410|NCT06712368|OTHER|Designed cardiac physical therapy program|Designed cardiac physical therapy program without virtual reality glasses
214415411|NCT06711172|OTHER|Health coaching intervention|The health coaching intervention will consist of seventeen, 30 to 60-minute telehealth sessions that were dispersed over six months. Participants will work closely with a health coach to create a plan for making appropriate lifestyle changes and for accomplishing the clinical recommendations that were received from their comprehensive evaluation at the War Related Illness and Injury Study Center.
214415412|NCT06706882|BEHAVIORAL|Experimental Training: VIRTRAEL/LUCCIDY|"Cognitive stimulation of the different cognitive functions to be addressed will be conducted in the following sessions:~* Session 1: Shopping lists. Balls. Gift shopping. Long-term memory of the Shopping List.~* Session 2: Disordered objects. Whats different? Semantic series. Logical series. Puzzle pieces. Semantic analogies.~* Session 3: Classifiable objects. Gift shopping. Bag of objects.~* Session 4: Shopping lists. Balls. Disordered objects. Long-term memory of the Shopping List.~* Session 5: Semantic series. Logical series. Puzzle pieces. Semantic analogies. Gift shopping.~* Session 6: Classifiable objects. Bag of objects. Disordered objects.~* Session 7: Shopping lists. Semantic series. Logical series. Puzzle pieces. What\&amp;#39;s different? Semantic analogies. Long-term memory of the Shopping List.~* Session 8: Disordered objects. Gift shopping. Balls.~* Session 9: Bag of objects. Semantic series. Logical series. Whats different? Semantic analogies. Classifiable objects."
214415413|NCT06706882|BEHAVIORAL|Active Comparator: Standard Training: Reflection Group (TAU) (Andalusian Institute of Women, 2010)|This 9-session program explores how societal norms shape women\&amp;#39;s roles and identities. In Session 1, it discusses how women are socially positioned as caretakers in relationships and introduces the concept of the self in relation. Session 2 delves into gender conflicts, focusing on the tension between societal demands and personal desires. Session 3 explores guilt when women fail to meet expected roles, and the fear of being selfish when prioritizing their own needs. Session 4 examines how dependence is fostered by seeking external validation for self-worth. Session 5 critiques romantic love as a cultural tool to prioritize men desires over women. Session 6 analyzes how intimate partner violence (IPV) emerges as a means to maintain power imbalances in relationships. Session 7 looks at the family role in socializing women, while Session 8 explores fears of abandonment. Finally, Session 9 focuses on building life skills and concludes the program.
214689376|NCT02664636|PROCEDURE|Occupational therapy|"Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.~This is part of routine care."
214689377|NCT02664636|PROCEDURE|Functional near-infrared spectroscopy|During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
214689378|NCT03022305|BEHAVIORAL|Group one - standard therapy|Group two - standard physical therapy treatment for shoulder and hip maladjustment.
214689379|NCT03022305|BEHAVIORAL|Group two - neuromuscular therapy|Use of physical therapy treatment for shoulder and hip maladjustment.
214689380|NCT03344731|BEHAVIORAL|Cognitive evaluation|Cognitive task
214415414|NCT06710574|DRUG|PD-RBD|Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time, keep the original anti Parkinson's drugs
214415415|NCT06710574|DRUG|iRBD|Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time.
214415416|NCT06713681|DIAGNOSTIC_TEST|TTP-ICG incubation solution|Fresh breast massed and lymph nodes will be incubated with TTP-ICG with different concentrations and times
214415417|NCT06707324|PROCEDURE|drug injected between the rectus abdominis muscle and the transversus abdominis muscle|20 ml of 0.25% bupivacaine + 8 mg dexamethasone between the rectus abdominis muscle and the transversus abdominis muscle on both sides
214415418|NCT06707324|PROCEDURE|drug injected in the external oblique intercostal plane on both sides|20 ml of 0.25% bupivacaine+ 8 mg dexamethasone into the external oblique intercostal plane on both sides
215017513|NCT05356429|OTHER|Small molecule LCDM|The cocktail of small molecules includes four chemical components of LCDM were added to GV oocyte culture medium.
215017514|NCT05041582|DEVICE|tDCS|dual tDCS with ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation, 2 weeks after SSRI treatment
214415419|NCT06714604|DRUG|FOLFIRINOX or gemcitabine-nab-paclitaxel|4 months if treatment
214415420|NCT06714604|DRUG|FOLFIRINOX or gemcitabine-nab-paclitaxel|6 months of treatment
214415421|NCT06712030|DRUG|Sacubitril / Valsartan|Dose titration of Sacubitril/Valsartán to the maximum tolerated dose (maximum 97/103 mg)
214415422|NCT04341298|OTHER|11-point pain scale|Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.
214415423|NCT04341298|OTHER|Headache diary|Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.
214415424|NCT04341298|DEVICE|Avulux®|Avulux® device
214415425|NCT04341298|DEVICE|Sham Avulux®|Sham Avulux®
214415426|NCT05708261|BEHAVIORAL|MR Intervention|Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.
214415427|NCT05708261|OTHER|Be Well Attention Match|Attention match control arm providing one-way SMS of general health content delivered once per week during the first 5 weeks after enrollment.
214415428|NCT05974072|DRUG|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
214415429|NCT05974072|OTHER|PAINDOC Program|"The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of two parts: an education session called Empowered Relief (ER) and two pain neuroscience education (NDT) sessions.~* Psychotherapy: The psychotherapy part consists of one group session of one hour, face-to-face and with groups of up to 15 people, given by the psychologist of the pain unit.~* Mindfulness Meditation: The Mindfulness Meditation consists of one group session of one hour, face-to-face and with groups of up to 15 people. These are given by a nurse from the pain unit. T~* Therapeutic exercise: The therapeutic exercise module consists of three sessions of one hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
214415430|NCT06711445|OTHER|Tele-assessment|"The participants were evaluated in two settings on different days (24-48 h apart): (i) in clinical settings (face-to-face) and (ii) at home via 'WhatsApp' phone application (both asynchronized and synchronized tele-assessment).~The evaluations steps were as follows:~1. Face-to-face/ Clinic assessment: Rater 1 completed all clinical assessments.~2. Synchronized tele-assessment: Rater 1 repeated the same evaluations via video calls to the patients (these were recorded to be used in step 3).~3. Asynchronized tele-assessment: Rater 2 evaluated the recordings of the remote evaluations (made in step 2).~4. Retest of synchronized tele-assessment: Rater 1 evaluated patients via video calls (these were recorded to be used in step 5).~5. Retest of asynchronized tele-assessment: Rater 2 evaluated the recordings of the remote evaluations (made in step 4)."
214415431|NCT06711263|OTHER|Mouthwash Product|"* In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).~* They will be asked to follow their routine oral hygiene habits. They will be asked to come back after 2 weeks for plaque and gingival bleeding scores recording for the second visit and again after 2weeks post the second visit for the third and final visit to record their plaque and gingival bleeding scores."
214415432|NCT06711549|PROCEDURE|Serratus Posterior Superior Plane Intercostal Plane block|Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus posterior superior plane and the ribs
214415433|NCT06711549|PROCEDURE|Serratus Anterior Plane block|Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus anterior and the external intercostal muscles and ribs
214505366|NCT01334840|DIETARY_SUPPLEMENT|Bicarbonated mineral water|"Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal"
215017515|NCT05041582|DRUG|Citalopram|total 3 months, since 2-4 weeks after stroke
215017516|NCT05041582|BEHAVIORAL|Rehabilitation|hospitalized rehabilitation, 3 hours daily
215101805|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
215101806|NCT03198806|OTHER|Treadmill aerobic exercise in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
214415434|NCT06714643|DEVICE|Active tDCS|The active tDCS protocol consist of 15 excitatory tDCS sessions distributed over 3 weeks (5 sessions per week, from Monday to Friday), at the same time each day, administered by the same operators and under identical experimental conditions. Each session last 30 minutes, with the Anode electrode placed on the left dorsal lateral prefrontal cortex (DLPFC) and the Cathode electrode on the right DLPFC at an intensity of 2 mA. The electrodes are positioned according to the 10-20 electroencephalography system (Anode on F3 and Cathode on F4).
214415435|NCT06714643|DEVICE|Sham treatment|The sham-tDCS intervention consist of a placebo 15 tDCS sessions distributed over 3 weeks (5 sessions per week, from Monday to Friday), at the same time each day, administered by the same operators and under identical experimental conditions. Each session last 30 minutes, with the Anode electrode placed on the left dorsal lateral prefrontal cortex (DLPFC) and the Cathode electrode on the right DLPFC. During the sessions only a 15-second initiation current is applied, providing the patient with the sensation of receiving an electric current on the scalp. Participants will also experience sounds and stimuli similar to those produced by active tDCS.
214415436|NCT06713434|BIOLOGICAL|ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops)|ELK-003 eye drops are a standardized amniotic fluid secretome formulation. It contains essential extracellular matrix proteins, such as collagen type VII and laminin-332, which are critical for maintaining corneal integrity in EB patients. In addition, ELK-003 also includes growth factors that stimulate corneal healing and tissue regeneration. This combination of matrix proteins and growth factors aims to enhance corneal surface stability.
214415437|NCT06457607|DEVICE|LinearZ|High Intensity Focues Ultrasound
214415438|NCT05971225|OTHER|remote monitoring only|remote monitoring only can replace in-office device monitoring
214415439|NCT06406101|OTHER|Floor|Uninterrupted 2-minute chest compressions on a manikin that has been moved from the bed to the floor in a simulated scenario of out-of-hospital cardiac arrest
214689381|NCT03344731|DEVICE|Non-invasive brain stimulation|Transcranial Magnetic Stimulation (TMS)
214689382|NCT05853562|OTHER|structured vestibular rehabilitation program|The structured Vestibular rehabilitation protocol consisted of a structured vestibular rehabilitation program that included vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises, and posture exercises.
214689383|NCT03653611|OTHER|On-site Practice Assessment|The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
214689384|NCT03653611|OTHER|Clinical Staff Questionnaires|"Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff."
214689385|NCT03653611|OTHER|Patient Opinion Surveys|200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
215017517|NCT05671679|OTHER|SNAQ app|SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image. The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g. foods, ingredients, sauces, herbs or seasonings). Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database. Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function. The user can always adapt proposed nutritional contents at their own discretion. Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices. The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
215017518|NCT05671679|OTHER|Traditional carbohydrate counting|Patients will follow their traditional methods of carbohydrate counting during the control period. In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
215101807|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
214689386|NCT03653611|OTHER|Modular online COPD Education|Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
214689387|NCT03653611|OTHER|COPD in Primary Care/CAPTURE Introduction Focus Groups|Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
214689388|NCT00335504|DRUG|oligofructose-enriched inulin|Given orally
214689389|NCT00335504|DRUG|sulindac|Given orally
214689390|NCT00335504|DRUG|placebo|Given orally
214689391|NCT00335504|DRUG|atorvastatin calcium|Given orally
214689392|NCT00335504|OTHER|laboratory biomarker analysis|Correlative studies
215017519|NCT03373513|PROCEDURE|Robotic single-site Hysterectomy|Robotic assisted Periumbilical single incision hysterectomy
215017520|NCT03373513|PROCEDURE|Laparoscopic hysterectomy|Multiport laparoscopic hysterectomy
215017521|NCT01693237|OTHER|Group psychotherapy|20 sessions of systemic and narrative group therapy
215101808|NCT02376023|OTHER|mHealth|Text and voice messages sent to study participants reminding them to schedule a PAP smear.
215101809|NCT07087379|DRUG|Intensive statin treatment|"Intensive statin group:~Atorvastatin 80mg, orally administered 12 hours before surgery Atorvastatin 80mg, orally administered 2 hours before surgery"
215101810|NCT07087379|DRUG|Placebo Control|Placebo, tablets, oral administration 12 hours before surgery Placebo, tablet, oral administration 2 hours before surgery
214415440|NCT06406101|OTHER|Bed|Uninterrupted 2-minute chest compressions on a manikin that is laying on bed in a simulated scenario of out-of-hospital cardiac arrest
214415441|NCT01764451|DRUG|Simvastatin|
214415442|NCT04423588|DIAGNOSTIC_TEST|dexlansoprazole serum concentration|6 blood samples are collected at fixed time Points after oral Administration of 1 dose of dexilant at regular patients visits preoperatively and 3 and 6 months post-surgery.
214415443|NCT04423588|DIAGNOSTIC_TEST|upper endoscopy|6 and 12 months after surgery the occurrence of marginal ulcers in the same Patient Group is examined by upper endoscopy. The 12-month endoscopy is part of the Routine postoperative diagnosis, the 6-month endoscopy is for study purpose.
214415444|NCT03426280|DEVICE|Apple Watch Series 1|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
214415445|NCT03208270|DRUG|Antithrombin supplementation|antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%
214415446|NCT03208270|DRUG|No antithrombin supplementation|"supplementation of antithrombin will not be provided unless heparin resistance occurs"
214415447|NCT02117401|DRUG|mivacurium chloride|intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
214415448|NCT02117401|DRUG|midazolam|"Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
214415449|NCT02117401|DRUG|ketamine|"mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
214415450|NCT02117401|DRUG|propofol|Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
214415451|NCT02117401|DRUG|Remifentanil|Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
214415452|NCT05438732|DEVICE|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
214415453|NCT02738840|PROCEDURE|MRI scan|MRI scan
214415454|NCT05780788|DEVICE|Monitoring Tooth Movement|Monitoring Canine Retraction
215017522|NCT01693237|OTHER|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
215017523|NCT01138306|GENETIC|gene expression analysis|
215017524|NCT01138306|GENETIC|mutation analysis|
215017525|NCT01138306|OTHER|flow cytometry|
215017526|NCT01138306|OTHER|laboratory biomarker analysis|
215017527|NCT00339365|BEHAVIORAL|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
215017528|NCT00339365|BEHAVIORAL|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
215017529|NCT02909114|RADIATION|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
214415455|NCT04476472|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery.
214415456|NCT01801449|DRUG|Rilonacept|
214415457|NCT01326039|DRUG|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
214415458|NCT01326039|DRUG|saline|perineural isotonic saline 20 ml
214415459|NCT01082289|DRUG|Lurasidone|
214415460|NCT01327469|DRUG|Albendazole, 2 x 400mg|Albendazole 2 x 400mg
214689393|NCT03430687|OTHER|Laboratory Biomarker Analysis|Correlative studies
215017530|NCT03967574|DEVICE|Transcranial direct current stimulation|"The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped."
215017531|NCT00002046|DRUG|Zidovudine|
214415461|NCT01327469|DRUG|Albendazole 400mg|Albendazole 400mg
214415462|NCT01327469|DRUG|Mebendazole 500mg|Mebendazole 500mg
214415463|NCT01327469|DRUG|Mebendazole 2 x 500mg|Mebendazole 2 x 500mg
214415464|NCT01327469|DRUG|Pyrantel-oxantel + mebendazole|Pyrantel-oxantel + mebendazole
214415465|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.
214689394|NCT03430687|BIOLOGICAL|Talimogene Laherparepvec|Given intravesically
215017532|NCT01013870|DRUG|Atorvastatin|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
215101811|NCT05700032|DIAGNOSTIC_TEST|high MI impulses|patients will receive intermittent high MI impulses(\>1.0) in addition to low MI imaging. LVOT VTI will be measured at different times per protocol.
214689395|NCT02514928|PROCEDURE|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
214689396|NCT02514928|PROCEDURE|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
215017533|NCT01013870|DRUG|Placebo|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
215017534|NCT02441816|DRUG|Aflibercept|
214415466|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion
214415467|NCT01357044|DIETARY_SUPPLEMENT|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
214415468|NCT01357044|DIETARY_SUPPLEMENT|Placebo|Tablets, two in the morning and two in the evening
214415469|NCT01645111|DRUG|Clevidipine|
214415470|NCT00181909|BEHAVIORAL|Smoking cessation counseling delivered by telephone|
214415471|NCT04755530|DIETARY_SUPPLEMENT|Regular whole milk|400 g/day of regular whole milk
214415472|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with live bacteria|400 g/day of yogurt with live bacteria
214415473|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with inactivated bacteria|400 g/day of yogurt with inactivated bacteria
214415474|NCT04755530|DIETARY_SUPPLEMENT|Acidified whole milk|400 g/day of yogurt with acidified whole milk
214415475|NCT04820621|DRUG|Runcaciguat (BAY1101042)|Given as 1 x 15 mg modified release \[MR\] tablet
214415476|NCT02391246|OTHER|Positron Emission Tomography Imaging|Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
215017535|NCT02441816|OTHER|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
214415477|NCT05605743|BEHAVIORAL|breathing exercise|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
214415478|NCT04010643|BEHAVIORAL|online cognitive behavioural therapy|oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey \& O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
214415479|NCT04010643|BEHAVIORAL|online neurocognitive remediation therapy|NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
214415480|NCT01366898|DRUG|Dexamethasona, Idarubicine, ARA-C, Methotrexate|
214415481|NCT04810260|BEHAVIORAL|Use mobile health app (WellXcel) to increase knowledge|Download the app (WellXcel) to the mobile device
214415482|NCT02995460|BEHAVIORAL|interval training|4x4 high intensity interval training
214415483|NCT04036162|BEHAVIORAL|Cognitive tasks|MagnetoEncephaloGraphy (MEG) records
214689397|NCT04569474|DEVICE|Transparent dressing|Use of sterile transparente dressing
214689398|NCT04861480|BIOLOGICAL|C-4-29 Cells|Drug: C-4-29 Cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
214689399|NCT02493816|DRUG|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
214689400|NCT04414657|OTHER|blood sampling for biobank|blood sampling for biobank
215017536|NCT01386645|OTHER|low glycemic index (LGI) diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab
215101812|NCT05700032|DIAGNOSTIC_TEST|low MI impulses|patients will receive low MI imaging only. LVOT VTI will be measured at different times per protocol.
214415484|NCT02211898|DRUG|BNS003|
214415485|NCT04655118|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.
214415486|NCT04655118|DRUG|Placebo|Placebo to match TL-895
214415487|NCT02695381|DRUG|Etodolac-lidocaine topical patch|Once daily
214415488|NCT02695381|DRUG|Placebo|Once daily
214415489|NCT02550067|DRUG|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
214415490|NCT02550067|DRUG|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
214415491|NCT02550067|DRUG|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
214415492|NCT04057196|BEHAVIORAL|Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)|The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.
214415493|NCT02959957|DRUG|Temocillin|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
214505367|NCT01334840|DIETARY_SUPPLEMENT|Mineral water low in mineral content (control)|"Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal"
215017537|NCT01386645|OTHER|high glycemic index (HGI) diet plus placebo (PLAC)|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
214505368|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
215017538|NCT01386645|DRUG|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
215017539|NCT00785447|OTHER|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
215017540|NCT03977298|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
215017541|NCT03977298|PROCEDURE|CTG|CTG will be positioned in the buccal aspect of the peri-implant tissue
215017542|NCT00918398|DRUG|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
214505369|NCT00641537|DRUG|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
214505370|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
214505371|NCT00641537|DRUG|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
214505372|NCT00641537|DRUG|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
214505373|NCT02073500|OTHER|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
214505374|NCT01138384|DRUG|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
214505375|NCT01138384|DRUG|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
214505376|NCT02704416|PROCEDURE|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
214415494|NCT02959957|DRUG|Cefotaxime|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
214415495|NCT01391442|BIOLOGICAL|blood and urine samples|58 ml of blood 120 ml of urine
214415496|NCT01391442|GENETIC|blood sample|11 ml of blood
214415497|NCT01391442|OTHER|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
214505377|NCT01801007|DEVICE|Flow Re-Direction Endoluminal Device (FRED)|
214505378|NCT05027633|DRUG|Pembrolizumab|given by IV
214505379|NCT05027633|DRUG|Docetaxel|given by IV
214415498|NCT01391442|OTHER|Stanislas ancillary study : MRI examination with GRICS technique|
214415499|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
215101813|NCT07087639|DEVICE|Self-expanding Venous Cannula|"The intervention consists of a self-expanding venous drainage cannula made of polyurethane and reinforced with a flexible metallic mesh. It is designed for transfemoral insertion during on-pump cardiac surgery, including minimally invasive procedures. Once positioned, the cannula expands to its functional diameter to facilitate efficient blood drainage into the extracorporeal circulation system. The configuration used in this study is 680/730 mm in length, 24 Fr, 3/8 diameter. The device is sterile, single-use, and is inserted once on the day of surgery (Day 0) and removed at the end of the procedure. The cannula is used continuously during cardiopulmonary bypass for a maximum duration of 6 hours and is not reused."
215101814|NCT07089732|DIETARY_SUPPLEMENT|GLP-1 formula liquid drink|One glass jar (50 g) of the GLP-1 formula liquid drink was administered once daily, 30 minutes prior to the first meal of the day.
215101815|NCT07089732|DIETARY_SUPPLEMENT|Placebo|One glass jar (50 g) of the placebo liquid drink was administered once daily, 30 minutes prior to the first meal of the day.
214689401|NCT06515041|OTHER|brain well-being|Each volunteers will be subjected to an evaluation of his well-being using a previously well established well-being scale, through a list of questions, prior, during and after the visit to the museum. All volunteers will be also equipped with a non invasive NIRS system to measure their emotions (measure of tissus oxygenenation), with a non invasive system of eye tracking glasses to measure where their eyes are looking and with a non invasive system to measure their heart rate.
214689402|NCT02179528|DRUG|Etoposide|
214689403|NCT03165721|DRUG|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
214689404|NCT02078882|BIOLOGICAL|abatacept|125 mg subcutaneously each week for 24 weeks
214689405|NCT04053543|DRUG|CXA-10|(10-nitro-9(E)-octadec-9enoic acid)
215101816|NCT04766554|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions|In the intervention group, an alarm threshold below 15% of the baseline rSO2 value will be established. Based on the predetermined algorithm the rSO2 will be maintained at or above 85% of the baseline measurements. If the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed to restore rSO2 to baseline levels.
215101817|NCT01439178|DRUG|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
214415500|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
214415501|NCT03285685|DEVICE|sham tDCS|The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
214505380|NCT05027633|DRUG|Cisplatin|given by IV
214505381|NCT05027633|DRUG|Carboplatin|given by IV
214689406|NCT00449111|DRUG|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
215017543|NCT00918398|DRUG|AZD1981|514 mg oral solution, single dose
214505382|NCT00665392|DRUG|cisplatin|75 mg/m², day 1. 3 cycles
214689407|NCT01863849|BIOLOGICAL|Vaccination with Fluval AB suspension for injection|Single intramuscular injection with Fluval AB suspension for injection in both age groups
214505383|NCT00665392|DRUG|docetaxel|75 mg/m² Day 1. 3 cycles
214505384|NCT00665392|DRUG|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
214505385|NCT00665392|DRUG|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
214689408|NCT01457118|DRUG|NKTR-102 145 mg/m2|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
215017544|NCT00918398|DRUG|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
215017545|NCT00918398|DRUG|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
215017546|NCT00423462|BEHAVIORAL|Brief dynamic psychotherapy|
215017547|NCT01972178|DRUG|PRC-4016|
215017548|NCT01972178|DRUG|Placebo|
215017549|NCT01972178|DRUG|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
214505386|NCT02024854|BEHAVIORAL|skin-to-skin|
214505387|NCT02024854|BEHAVIORAL|standard care|
214505388|NCT03431129|DIAGNOSTIC_TEST|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
215017550|NCT00059280|BIOLOGICAL|Myozyme|20 mg/kg qow or 40mg/kg qow
214415502|NCT02108743|DRUG|Albuterol.|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
214505389|NCT06041386|DRUG|Mepolizumab|Mepolizumab will be prescribed based on physician decision.
214505390|NCT06041386|OTHER|Spirometry|Lung function via spirometry will be collected.
214689409|NCT01457118|DRUG|NKTR-102 120 mg/m2|A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
214689410|NCT01457118|DRUG|NKTR-102 95 mg/m2|A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
215017551|NCT03615430|PROCEDURE|serratus plane block with local anesthetic|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml 0.25% ropivacaine was administered.
215017552|NCT03615430|PROCEDURE|serratus plane block with saline|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml saline was administered.
215017553|NCT00770094|DEVICE|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
215017554|NCT00770094|DEVICE|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
215101818|NCT06522399|PROCEDURE|TAMIS mucosectomy|internal Delorme's procedure using TAMIS
215101819|NCT02004977|BEHAVIORAL|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
215101820|NCT03764267|DRUG|Remifentanil|"Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain"
214415503|NCT02108743|DRUG|Normal saline placebo|Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
214689411|NCT01457118|DRUG|NKTR-102 50 mg/m2|A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
214415504|NCT02457702|OTHER|Orally administered labeled glycerol|Oral administration of labeled glycerol
214415505|NCT05289466|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
214689412|NCT06092242|DRUG|Tas-102(Suyuan) combined with bevacizumab|Tas-102: po 35 mg/m2, bid, d1-5, d8-12, Q4 wks; bevacizumab: intravenous drip 5 mg/kg, D1, D15, Q4 wks.
215017555|NCT00770094|DEVICE|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
215017556|NCT03759197|DRUG|188-0551 Spray|Topical Spray containing active drug
215017557|NCT03759197|DRUG|Vehicle Spray|Topical Spray containing no active drug
215017558|NCT00626665|DRUG|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
215017559|NCT04738669|OTHER|mHealth|The mHealth intervention includes telephonic call and SMS.
214415506|NCT05289466|PROCEDURE|Oncoplastic partial mastectomy|Breast Conserving Therapy
214415507|NCT03617653|DIAGNOSTIC_TEST|Group A|Refer to detailed study Description
214505391|NCT06524648|DIAGNOSTIC_TEST|niPGT-A|"Embryos will be cultured, from oocyte fertilization up to day 6/7 of development, in a time lapse system following the standard practice. On day 6/7, embryos will be vitrified and the embryos's media will be collected for niPGT-A analysis.~Patients will undergo a single embryo transfer (SET) following the niPGT-A report indications. In the event of 1 or more embryos with the same niPGT-A score, the embryo for transfer will be determined by the site standard practice (morphology or time-lapse score).~Patients who do not achieve a pregnancy after a niPGT-A guided SET can undergo as many niPGT-A guided SET or COS+niPGT-A cycles as they need to get pregnant, while the study recruitment phase is active."
214415508|NCT05553613|DRUG|Ticagrelor 90 MG Oral Tablet|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
214415509|NCT05553613|DRUG|Clopidogrel tablet|efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.
214415510|NCT03196167|DRUG|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
214415511|NCT03196167|OTHER|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
214505392|NCT00243867|DRUG|Taxoprexin|Administered by intravenous infusion over 1 hour infusion
214689413|NCT00200499|DRUG|Nebivolol|
214689414|NCT06423287|DIETARY_SUPPLEMENT|Lactobacillus plantarum LP-KFY04|Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.
214689415|NCT06423287|OTHER|Take placebo in addition to the limited diet.|Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks'trial.
214689416|NCT04761887|DRUG|Cool Ropivacaine Block|Ropivacaine is cooled.
214689417|NCT04761887|DRUG|Room Temp Ropivacaine Block|Room Temp Block
214689418|NCT05274113|DRUG|Dexamethasone 4mg|4 mg of Dexamethasone will be given before surgery
215017560|NCT04738669|BEHAVIORAL|Teach-back|While the teach-back includes counselling session related to discharge instruction including medication adherence.
214689419|NCT05274113|DRUG|Ropivacaine|Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery
214689420|NCT03540134|DEVICE|Intracerebral Infusion of Autologous Cerebral Spinal Fluid|Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
215017561|NCT00974532|DIETARY_SUPPLEMENT|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
215017562|NCT00974532|DIETARY_SUPPLEMENT|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
215017563|NCT04109482|BIOLOGICAL|MB-102|"The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered."
215017564|NCT04109482|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~* A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min)."
215017565|NCT04109482|DRUG|Cyclophosphamide|Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
215017566|NCT01489826|DRUG|Dexanabinol|Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
215017567|NCT01489826|OTHER|Cremophor|Drug vehicle.
215017568|NCT03418480|DRUG|BNT113|Intradermal vaccine
215017569|NCT01991574|DRUG|Calcium acetate|
215101821|NCT03764267|DRUG|general anesthetic|general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
214415512|NCT04455399|DEVICE|Intravitreal injection guide (Malosa)|A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion
214415513|NCT04455399|DEVICE|Dual Blade Eyelid Speculum|A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.
214415514|NCT03837028|OTHER|FSFI|Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
214415515|NCT01091454|DRUG|brostallicin|Given IV
214415516|NCT01091454|DRUG|cisplatin|Given IV
214415517|NCT04043767|PROCEDURE|Measurements of thyromental distances, hyomental distances and neck circumferences|thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
214415518|NCT05498337|OTHER|calcium hydroxide|Dental pulp medicament material
214415519|NCT05498337|OTHER|MTA|Dental pulp medicament material
214415520|NCT05498337|DEVICE|Diode Laser|Device used in pulp therapy
214415521|NCT04771793|BEHAVIORAL|new physical restraint protocols|new physical restraint protocols
214415522|NCT00646451|DRUG|pregabalin (Lyrica)|75 mg bid to 300 mg bid based on per subject tolerability
214415523|NCT00646451|DRUG|placebo|up to 4 capsules bid as tolerated
214415524|NCT01204528|DRUG|Zemplar|Vitamin D receptor activator (VDRA)
214415525|NCT04542148|DRUG|Sliding Scale Insulin|After antenatal corticosteroid administration, women will continue to receive long- and short-acting subcutaneous insulin injections as prescribed at home. In addition, they will receive supplemental short-acting insulin using a sliding scale based on postprandial glucose values. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
214415526|NCT04542148|DRUG|Up-Titration of Home Insulin|After antenatal corticosteroid administration, women will receive long- and short-acting subcutaneous insulin injections at increased dosages compared to that prescribed at home. Insulin will be increased by 30% on the day that they receive their 1st dose of antenatal corticosteroids (day 1), 50% on day 2, 50% on day 3, 30% on day 4, and 15% increase on day 5. On day 6 they will return to their home insulin regimen. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
214415527|NCT04542148|DRUG|Continuous Insulin Infusion|After antenatal corticosteroid administration, women will discontinue their home insulin regimen and be placed on a continuous insulin infusion with insulin boluses and titration of infusion rate per institutional L\&D protocol. Capillary blood glucose values will be measured with fingersticks every hour.
214415528|NCT04542148|DEVICE|Dexcom G6 Professional Continuous Glucose Monitor|Masked Dexcom G6 Pro devices will be worn for 10 days.
214415529|NCT03849495|DRUG|CKD-370|Test drug
214689421|NCT05489822|DEVICE|VERTICALE® Cervical System|"All measures and devices mentioned in the study protocol correspond to routine clinical practice with the exception of the following questionnaires:~NDI (Neck Disability Index) NRS (Numerical Rating Scale) neck pain (cervical spine) and NRS arm pain mJOA (modified Japanese Orthopaedic Association) Score"
214415530|NCT03849495|DRUG|D745|Reference drug
214415531|NCT03745118|DEVICE|EpiTel EpiLog|Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel
214415532|NCT03745118|DEVICE|Byte Flies Sensor Dots|Plastic pads that will be adhered to your chest area
214415533|NCT03745118|DEVICE|Empatica E4|wearable seizure detection wristband
214415534|NCT03745118|DEVICE|Biovotion Everion|wearable seizure detection device armband that is attached to upper arm
214415535|NCT03745118|DEVICE|GeneActiv|wearable seizure detection watch
214415536|NCT05377151|OTHER|Mobile application|"Nutrition intervention using either mHealth interventions or conventional methods will be carried out among pregnant women).~Subjects will be allocated into three groups, namely, two interventions group which are:~Group 1: mHealth intervention group (98 subjects)~Group 2: mHealth intervention group + dietitian consultation (98 subjects)~Group 3: control group (98 subjects)"
214415537|NCT01362491|DRUG|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
214415538|NCT01362491|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
214415539|NCT01362491|DRUG|Placebo|Single-dose of placebo
214415540|NCT00575523|DRUG|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
214689422|NCT02300415|BIOLOGICAL|blood sample|Dosage of presepsine
214689423|NCT04264455|DEVICE|Biomonitor|Patients receive a Biomonitor only
214415541|NCT00575523|DRUG|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
214415542|NCT04358354|DRUG|Irinotecan|Irinotecan 150 mg/m2
214415543|NCT04358354|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
214689424|NCT04264455|DEVICE|Life Vest|Patients receive a Wearable Cardioverter-Defibrillator; a Biomonitor is implanted additionally
214689425|NCT04264455|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Patients receive an Implantable Cardioverter-Defibrillator (ICD)
214689426|NCT03456713|BIOLOGICAL|LY3074828|Administered SC
214689427|NCT04792437|PROCEDURE|surgery|surgery
214689428|NCT01405313|DEVICE|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
214415544|NCT04358354|DRUG|5-fluorouracil|5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours
214415545|NCT00394069|DRUG|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
214415546|NCT02830152|DEVICE|LAAO|The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
214415547|NCT02830152|DRUG|Medical Therapy|Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
214415548|NCT02030028|DRUG|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
214415549|NCT05583539|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography is a viscoelastic test that measures the dynamics of blood clotting on whole blood samples.
214415550|NCT01970358|BIOLOGICAL|Poly-ICLC|
214415551|NCT01970358|BIOLOGICAL|Peptides|
214689429|NCT01405313|DEVICE|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
214689430|NCT03025334|DEVICE|High-definition transcranial direct current stimulation|brain stimulation to increase neuronal excitability in the targeted regions
214689431|NCT00448253|BIOLOGICAL|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."
214689432|NCT00064467|DRUG|Extended-release bupropion (HCl)|
214689433|NCT01263691|BIOLOGICAL|BioThrax|BioThrax
215017570|NCT01991574|DIETARY_SUPPLEMENT|Iron Hydroxide Adipate|
215017571|NCT01991574|DRUG|Placebo|methylcellulose capsules
215017572|NCT03142451|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
215017573|NCT03142451|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
215017574|NCT01758471|DRUG|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
214415552|NCT04800224|DRUG|Standardized Brazilian Green Propolis Extract|900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
214415553|NCT04800224|DRUG|Placebo|900mg/day of Placebo for 10 days.
214415554|NCT06353958|DRUG|MiSaver|"MiSaver vials was thawed using a thermostat-controlled mini bath, drawn into a 20ml syringe, and diluted with normal saline and intravenous infused following standard operating procedures, consecutively, until reasching the dosage.~Patients were premedicated with intravenous antihistamines (such as diphenhydramine) and corticosteroids (such as hydrocortisone) 30-60 minutes before the stem cell infusion. Any unused solution was discarded, and the total volume of injected solution was adjusted to accommodate the total daily fluid volume administered."
214415555|NCT02118935|OTHER|Previously marketed cow's mlik-based infant formula|
214415556|NCT02118935|OTHER|Marketed cow's milk-based infant formula with prebiotics|
214415557|NCT03970811|PROCEDURE|Immediate Implants|dental implants are immediately placed after tooth extraction
214415558|NCT03970811|PROCEDURE|temporary restoration|temporary restoration will be placed immediately after implant placement
214415559|NCT03970811|PROCEDURE|final restoration|final restoration (loading) will be placed 3 months postsurgical
214415560|NCT04687553|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)
214415561|NCT00567879|DRUG|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m\^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
214689434|NCT01263691|BIOLOGICAL|AV7909 Formulation 1|AV7909 Formulation 1
214415562|NCT00567879|DRUG|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
214689435|NCT01263691|BIOLOGICAL|AV7909 Formulation 2|AV7909 Formulation 2
214689436|NCT01263691|BIOLOGICAL|AV7909 Formulation 3|AV7909 Formulation 3
214689437|NCT01263691|BIOLOGICAL|AV7909 Formulation 4|AV7909 Formulation 4
214689438|NCT01263691|DRUG|Control|Saline control
214689439|NCT02012608|DRUG|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
214415563|NCT01517542|OTHER|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
214415564|NCT01768143|BEHAVIORAL|unexperienced endoscopy nurses|
214689440|NCT02012608|DRUG|Placebo|For subjects undergoing breast conserving therapy
214689441|NCT06291116|DRUG|standard care + rotigotine at 4 mg/24h for 24 months.|standard care + rotigotine at 4 mg/24h for 24 months.
214689442|NCT06291116|DRUG|standard care for 24 months.|standard care for 24 months.
215017575|NCT01758471|DRUG|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
215017576|NCT01755754|COMBINATION_PRODUCT|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
215017577|NCT01755754|DEVICE|Female Condom|Female condom
215017578|NCT00901563|DRUG|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
215017579|NCT00901563|OTHER|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
215017580|NCT01141790|OTHER|Music and voice message|
215017581|NCT00941395|OTHER|Survey Administration|Complete surveys
214415565|NCT01768143|BEHAVIORAL|Experienced endoscopy nurses|
214415566|NCT01025583|DIETARY_SUPPLEMENT|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
214415567|NCT01025583|DIETARY_SUPPLEMENT|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
214415568|NCT02721225|DIETARY_SUPPLEMENT|Fructooligosaccharide|"A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
214415569|NCT02721225|DIETARY_SUPPLEMENT|Pocari-Sweat|Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
214415570|NCT04137874|DIAGNOSTIC_TEST|eSTROKE model|The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician
214415571|NCT04137874|OTHER|Control|Conventional prehospital care
214415572|NCT02104609|DRUG|Levonorgestrel 1.5mg by mouth once|Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
214415573|NCT00373555|PROCEDURE|Bronchoscopy|
214415574|NCT00207844|DRUG|Selenium as sodium selenite|
214415575|NCT02540551|PROCEDURE|Injection of radioactive tracer combined with Patent Blue|Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
214415576|NCT00462410|OTHER|counseling intervention|
214415577|NCT00462410|PROCEDURE|psychosocial assessment and care|
214415578|NCT05280964|BEHAVIORAL|Better Together Physician Coaching|6 month, online group coaching program
214415579|NCT00087269|DRUG|erlotinib hydrochloride|Given orally
214415580|NCT00087269|PROCEDURE|therapeutic endoscopic surgery|Undergo surgical resection
214415581|NCT00087269|OTHER|laboratory biomarker analysis|Correlative studies
214415582|NCT02904707|OTHER|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
214415583|NCT02869620|OTHER|Data collection|
214415584|NCT03563391|OTHER|New Infant Formula|New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
214415585|NCT06630208|OTHER|Myofascial release|The experimental group will undergo a 5-day consecutive myofascial release treatment, administered as Osteopathic Manipulative Treatment (OMT), with each session lasting a maximum of 15 minutes. The treatment will consist of three phases targeting the entire mediastinum: Thoracic Inlet (Indirect) Myofascial Release, Rib Raising with continued stretch of the paraspinal muscles to the L2 vertebral level, and Soft Tissue Cervical Paraspinal Muscle Stretch with Suboccipital Muscle Release. Participants will be positioned in a supine posture to enhance diaphragmatic excursion, with each session following a fixed, prearranged sequence of these techniques.
214415586|NCT06630208|OTHER|Breathing exercises|Following the 3 phases of myofascial release, breathing exercises will be done for patients.
215101822|NCT05558462|DRUG|XC8|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
215101823|NCT02092766|DRUG|artesunate|
215101824|NCT02092766|DRUG|quinine|
214415587|NCT06630208|DRUG|Pharmacological treatment|Patients will take pharmacological treatment prescribed by the cardiologist.
214415588|NCT01249092|DRUG|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
214415589|NCT00751491|DRUG|Adenosin|Intracoronary Adenosin 50 microg;
214415590|NCT00751491|OTHER|placebo|no intervention
214415591|NCT00751491|DRUG|Clopidogrel|Clopidogrel 300/600 mg
214415592|NCT06188962|BEHAVIORAL|CBT-informed school-based counselling|Knowledge Insight Tools (KIT) is a CBT-based model of one-to-one therapy for secondary school pupils who are struggling with low mood and/or anxiety. KIT incorporates the key features of CBT (e.g., agenda setting, formulation around maintenance cycles, inter-session work involving exposure and/or behavioural activation) but is delivered in a semi-structured way that meets the young person's needs and pace of learning. Whilst there is an emphasis on symptom reduction, the primary focus is on the young person's goals for living and co-producing an understanding of how symptoms can interfere with these goals. Practitioners are encouraged to incorporate different therapeutic tools and modalities that complement the young person's strengths and ways of learning, including non-verbal forms of expression like arts and crafts, music, and dance. By being flexible, person-led, goal-focused, and integrative, KIT was designed to suit the needs of secondary school students.
214415593|NCT00802919|DRUG|Varenicline|Varenicline 1-2 mg/day
214415594|NCT00802919|DRUG|Placebo for varenicline|Placebo
214415595|NCT00580073|DRUG|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
214415596|NCT00580073|DRUG|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
214415597|NCT01714557|DRUG|Piperacillin|4.0g q8h 3-5 days
214415598|NCT01714557|DRUG|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
215101825|NCT05920408|DRUG|EXS21546|EXS21546 Granule in Capsule
215101826|NCT02974049|DRUG|Albendazole|"Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole"
215101827|NCT02974049|DRUG|Ivermectin|Subjects in Arms 1 and 4 will receive 200mg/kg body weight
215101828|NCT02974049|DRUG|Diethylcarbamazine|Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
214415599|NCT02294929|PROCEDURE|Atrial fibrillation ablation|Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
214415600|NCT04740359|OTHER|Functional training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The functional reach (forward-lateral-cross), trunk rotation exercises were performed in the sitting positions.(25min) Facilitation of trunk extension and elongation in the prone position (10 min). Thoracic mobilization on exercise ball (10min).
214415601|NCT04740359|OTHER|Routine training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The strengthening exercises were applied on the mat (3x10 for the first 4 weeks and 3x15 repetition for the last 4 weeks). Eyes open-closed perturbation training was performed for trunk control in sitting and standing positions (10 min.).
214415602|NCT04602936|DRUG|Solriamfetol|Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.
214415603|NCT04602936|DRUG|Placebo|"A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill)."
214415604|NCT00424320|DRUG|Sodium bicarbonate|
214415605|NCT05358197|OTHER|yoga|laughter yoga
215017582|NCT04859231|OTHER|Control|Cow's milk-based formula
214689443|NCT06046716|BEHAVIORAL|Mindful compassion based on behavioural change taxonomy experimental group|Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
214689444|NCT04552379|BIOLOGICAL|Peginterferon beta-1a|"Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at \~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use."
214689445|NCT00103545|BIOLOGICAL|ACA 125|
214689446|NCT01151592|DRUG|Iron Sucrose|Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
214689447|NCT03625427|DIETARY_SUPPLEMENT|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, administered as two 1-gram capsules per day. Packaged as single-serve packets containing 2 capsules for each daily dose.
214689448|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 500 mg (Dose 1)|Palmitoleic acid (POA) 1 gram capsules containing 500 mg POA
214689449|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 1,000 mg (Dose 2)|Palmitoleic acid (POA) taken as two 1 gram capsules each containing 500 mg POA
214689450|NCT01202227|DRUG|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
214689451|NCT06256783|DRUG|Baozhu Keli|Once enrolled, participants will be administrated Baozhu Keli
215017583|NCT04859231|OTHER|Investigational|Cow's milk-based formula with added source of enriched whey protein
215017584|NCT03684785|DRUG|Cavrotolimod|Intratumorally dosed cavrotolimod.
214415606|NCT00778739|DRUG|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
214415607|NCT00324506|DRUG|Mycophenolate Mofetil (CellCept)|
214415608|NCT04408274|BEHAVIORAL|Emotional Processing Training|
215017585|NCT03684785|BIOLOGICAL|Pembrolizumab|Pembrolizumab dosing as per the US prescribing information.
214415609|NCT04408274|BEHAVIORAL|Placebo Control|
214415610|NCT00203580|DRUG|Tinzaparin sodium|
215017586|NCT03684785|BIOLOGICAL|Cemiplimab|Cemiplimab dosing as per the US prescribing information.
215017587|NCT03684785|DRUG|Cavrotolimod|Subcutaneously dosed cavrotolimod
215017588|NCT02016885|DRUG|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
215017589|NCT02016885|DRUG|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
215017590|NCT02016885|DRUG|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
215017591|NCT02016885|DRUG|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
215017592|NCT02016885|OTHER|Vehicle|Vehicle Topical Wipes
215017593|NCT06570499|OTHER|Implant impression|definitive impressions on implants
215017594|NCT01649583|DEVICE|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
215017595|NCT03912415|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
215017596|NCT03912415|BIOLOGICAL|Bevacizumab|IV infusion
215017597|NCT03912415|DRUG|Paclitaxel|IV infusion
215017598|NCT03912415|DRUG|Cisplatin (or Carboplatin)|IV infusion
215017599|NCT03912415|OTHER|Placebo|Placebo
215017600|NCT00949078|DRUG|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
215017601|NCT01429935|DRUG|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
215017602|NCT01429935|DRUG|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
215017603|NCT01429935|OTHER|placebo|capsules contain starch
215017604|NCT00562198|DRUG|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
215017605|NCT00562198|DRUG|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
215017606|NCT04760457|PROCEDURE|Implant placement with flapped surgery|Four mini implants will be placed reflecting a flap.
215017607|NCT04760457|PROCEDURE|Implant placement with flapless surgery|Four mini implants will be placed without reflecting a flap.
215017608|NCT04760457|PROCEDURE|Implant immediate loading|Four mini implants will be immediately loaded.
214415611|NCT03814395|OTHER|No intervention|This is an observational study without any intervention
214415612|NCT01568749|DRUG|Paracetamol|Paracetamol
214415613|NCT01568749|DRUG|Paracetamol formulation 1|Paracetamol
214415614|NCT01568749|DRUG|Paracetamol Formulation 2|Paracetamol
214415615|NCT01568749|DRUG|Paracetamol formulation 3|Paracetamol
214415616|NCT01568749|DRUG|Paracetamol formulation 4|paracetamol
214415617|NCT04752735|OTHER|endovascular treatment|all enrolled patients must receive endovascular treatment.
214415618|NCT04178109|DRUG|Dexketoprofen/tramadol (27mg/75mg)|Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
214415619|NCT04178109|DRUG|Tramadol hydrochloride|Patients in group B received IV tramadol 75mg every 8h
214415620|NCT04178109|DRUG|Paracetamol|Patients in group B received IV paracetamol 1g every 8h
214415621|NCT04178109|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients
214415622|NCT04178109|DRUG|Levobupivacaine Hydrochloride|10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
214415623|NCT03887546|DEVICE|Inspiratory muscle trainer|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
214415624|NCT03887546|PROCEDURE|Respiratory exercise|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
214415625|NCT02930343|DRUG|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
214415626|NCT02930343|DRUG|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
214415627|NCT02930343|DRUG|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
214415628|NCT02930343|DRUG|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
214689452|NCT06362499|DEVICE|Experimental Group|After the initial assessment, all volunteers will receive a POWERbreathe® classic light resistance device (POWERbreathe®, Nsc, Brazil), to carry out the training, and will be individually guided on how to use it and how to complete the protocol. They will perform a trial session to familiarize themselves with the device that will not be considered for analysis. Every week, volunteers will receive a telephone call from researcher 2, who will not participate in the evaluation, to confirm whether the exercise with the POWERbreathe® will be performed appropriately at the recommended frequency, intensity, and duration and whether there are any questions regarding the protocol. At the end of each week, participants will receive a video call from researcher 2 to adjust the device according to G1's weekly load progression.
215017609|NCT04760457|PROCEDURE|Implant delayed loading|Four mini implants will be loaded after a 6-week healing period.
215017610|NCT01901757|DRUG|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
215017611|NCT01901757|DRUG|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
214415629|NCT02930343|DRUG|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
214415630|NCT02930343|DRUG|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
214415631|NCT05356923|RADIATION|68Gallium FAPI PET/MR scan|68Gallium FAPI PET/MR scan
214415632|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 1|Each subject will use this product during one of the five treatment periods in the crossover study design.
214415633|NCT06140745|DRUG|1100 ppm NaF Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
214415634|NCT06140745|DRUG|1500 ppm NaMFP Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
214415635|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 2|Each subject will use this product during one of the five treatment periods in the crossover study design.
214415636|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 3|Each subject will use this product during one of the five treatment periods in the crossover study design.
214415637|NCT00837499|BEHAVIORAL|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
214415638|NCT01717794|PROCEDURE|Thunderbeat technology|
214415639|NCT01717794|PROCEDURE|Standard bipolar electrosurgery|
214415640|NCT04473638|PROCEDURE|Arthroscopic Deltoid Repair|. A 4.5 mm arthroscopic set was used to clean the joint and assess medial and associated injuries. After deltoid injury confirmation through the method already mentioned, the medial gutter was prepared. The ideal positioning for the bone anchor in the medial malleolus followed Vega's recommendations and was located in the inferolateral quadrant created by the intersection of two lines: (1) tibia-talar joint line and (2) tangent line to the medial malleolus joint surface.(14). Sutures were passed respecting the safe zone illustrated by Acevedo at al, at the area between the posterior tibial tendon and the saphenous vein (16-25mm) (15). Sutures were passed but not tightened.
214415641|NCT04405063|DEVICE|Paclitaxel Coated PTCA Balloon Catheter|Drug coated balloon
214415642|NCT05185921|BEHAVIORAL|Trial-based Cognitive therapy|The virtual CBT will be provided by 02 psychotherapists, who will follow a protocol developed for this study. The number of sessions will be eight, which will be held weekly, projecting an intervention time of 2 to 3 months considering the possibility of rescheduling any of the sessions for reasons derived from the participant People with relevant cognitive impairment that prevents them from answering the questionnaire questions or providing informed consent are excluded.
214415643|NCT00043264|DRUG|Rifampin|
214415644|NCT00043264|DRUG|Azithromycin|
214415645|NCT03174054|PROCEDURE|Biopsy|Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
214415646|NCT04738565|DIETARY_SUPPLEMENT|Probiotic preparation|The mixture of Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919 administered once a day at a dose of one billion for 3 months.
214415647|NCT04738565|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.
214415648|NCT02824939|OTHER|Transversus Abdominis Plane (TAP) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
214415649|NCT02824939|OTHER|Quadratus Lumborum (QL) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
214415650|NCT04575493|DIETARY_SUPPLEMENT|Crano-cure|Research literatures have revealed that Tribulus terrestris (Gokhro), Vaccinium macrocarpon (karonda), Cuminum cyminum (Zeera sufaid), Rheum emodi (Revand chini) and Piper cubeba (Kabab chini) are important therapeutic plants. Many pharmacological researches have been done on these plants. For instance, antioxidant, antiseptic, anti-microbial, anti-bacterial, anticancer etc. In the above claims and facts, the study is conducted to formulate and evaluate the polyherbal capsule and to find out the most effective combination having anti-bacterial activity.
214415651|NCT04575493|DRUG|Ciprofloxacin 500 mg|Being a standard drug as antibiotic and will be used in Control group.
214415652|NCT01725854|BEHAVIORAL|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
214415653|NCT02379546|DRUG|Desflurane|Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
214415654|NCT02379546|DEVICE|Bispectral index monitoring|Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
214415655|NCT01941277|BEHAVIORAL|Current Recommendations Exercise Group|
214415656|NCT01941277|BEHAVIORAL|Intensive Exercise Group|
214415657|NCT02548221|DEVICE|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
214415658|NCT01750554|OTHER|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
214415659|NCT00678158|RADIATION|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
214415660|NCT00954707|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
214415661|NCT00954707|DRUG|Placebo & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
214689453|NCT00803010|DRUG|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
214689454|NCT00803010|DRUG|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m\^2, and a dose of 10 mg/m\^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
214689455|NCT00803010|DRUG|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
214689456|NCT00066664|GENETIC|proteomic profiling|
214689457|NCT04402008|DRUG|Poziotinib Once Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
214689458|NCT04402008|DRUG|Poziotinib Twice Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
215101829|NCT02971150|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|
214689459|NCT04402008|DRUG|Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
214689460|NCT04346264|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design only a diagnostic testing|Only a diagnostic test (serum blood and antibody measurement) is planned
214689461|NCT05800106|DRUG|Sunitinib malate capsules generic product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
214689462|NCT05800106|DRUG|Sunitinib malate capsules reference product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
214689463|NCT06098209|DRUG|Dexmedetomidine|Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
214689464|NCT06098209|DRUG|Propofol|Patient will receive propofol 0.3-4 mg/kg/h.
214415662|NCT06412406|PROCEDURE|External Oblique Intercostal (EOI) block|EOI block technique A linear ultrasound transducer placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, The transducer was then rotated so the cranial end was directed slightly medially and the caudal end laterally to produce a paramedian sagittal oblique view with a short-axis view of the ribs, The following structures were identified, from superficial to deep: subcutaneous tissue, external oblique muscle, intercostal muscles between ribs, pleura, and lung. The skin entry point for the injection was cranial to the sixth rib level just medial to the anterior axillary line, with ultrasound opaque needle advanced in plane from a superomedial-to-inferolateral direction, through the external oblique muscle hydrodissecting the tissue plane between the sixth and seventh ribs, and then the needle was directed caudally toward the eighth rib. and inject 20 ml volume of (0.25 % bupivacaine).
214415663|NCT06412406|PROCEDURE|Transversus abdominis plane (TAP) block|"TAP block technique:~abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest (18) . Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. and ingect 20 ml volume of (0.25 % bupivacaine). If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
214415664|NCT00516503|DRUG|baclofen/amitriptyline/ketamine gel|Applied topically
215101830|NCT01423916|DRUG|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
214415665|NCT00516503|OTHER|placebo|Applied topically
215017612|NCT04343768|DRUG|Hydroxychloroquine|This Drug will be used in all arms.
215017613|NCT04343768|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms.
214415666|NCT06405867|PROCEDURE|delayed cord clamping (> 60 sec)|In the DCC group, cord pulse was checked without allowing clamping. Waited until the cord pulse stopped. It was wrapped in a sterile and warm cloth and dried. The cord was clamped when the pulse stopped. The cord clamping time was noted on the case report form. In DCC, the baby was placed on the mother's legs in cesarean section (C/S) births and on the mother's mons pubis region in normal vaginal births. The baby was administered a routine delivery room neonatal resuscitation program (NRP) by the pediatrician. After cord clamping, the baby was handed over to the pediatric team.
214415667|NCT05478772|DRUG|CTP-543|12 mg on Day 1 and Day 7
214415668|NCT05478772|DRUG|Fluconazole|200 mg once daily on Days 3 through to Day 8
214415669|NCT03787706|OTHER|Dry Needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
215101831|NCT01423916|DRUG|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
214415670|NCT03787706|OTHER|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
215017614|NCT04343768|DRUG|Interferon Beta-1A|This drug will be only used in Arm 1.
215017615|NCT04343768|DRUG|Interferon Beta-1B|This drug will be only used in Arm 2.
215017616|NCT00714363|PROCEDURE|LASIK|Refractive surgery
214415671|NCT00666939|DRUG|Gabapentin|Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
214415672|NCT00666939|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
214415673|NCT00666939|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
214415674|NCT03145337|BIOLOGICAL|FlexHD ADM (Cohort A)|Tissue assisted breast reconstruction with FlexHD pliable perforated ADM
214415675|NCT03145337|BIOLOGICAL|AlloDerm RTU ADM (Cohort B)|Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
214415676|NCT02987543|DRUG|olaparib|300 mg (2x 150 mg tablets) twice daily
214415677|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg capsules) once daily
214415678|NCT02987543|DRUG|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
214415679|NCT02987543|DRUG|abiraterone acetate|1,000 mg (2 x 500 mg tablets) once daily
214415680|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg tablets) once daily
214415681|NCT01552304|OTHER|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
214415682|NCT01552304|OTHER|Control group|
214415683|NCT00092599|DRUG|MK0653, ezetimibe|
214415684|NCT00092599|DRUG|Comparator: ezetimibe, placebo|
215017617|NCT00714363|PROCEDURE|SBK|Refractive surgery
215017618|NCT02758080|OTHER|Matching on the basis of molecular analysis|
215017619|NCT02758080|OTHER|Matching on the basis of physician's choice|
215017620|NCT04238182|OTHER|wet cupping|This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.
215017621|NCT04238182|OTHER|dry cupping|The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
215101832|NCT01423916|DRUG|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
215101833|NCT01423916|DRUG|Placebo|OPC-34712 placebo
215101834|NCT01636349|OTHER|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
215101835|NCT01587365|BIOLOGICAL|BMS-962476|
215101836|NCT01587365|BIOLOGICAL|Placebo matching with BMS-962476|
215101837|NCT03468582|COMBINATION_PRODUCT|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
215101838|NCT00641082|DRUG|Clevudine|30mg for 48 weeks
215101839|NCT00641082|DRUG|Adefovir dipivoxil|10mg for 48 weeks
215017622|NCT00676637|DRUG|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
214415685|NCT03980964|DEVICE|Active NMES|Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
214415686|NCT04630457|DEVICE|Conventional ankle prosthesis|At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.
214415687|NCT04630457|DEVICE|Meridium® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
214415688|NCT04630457|DEVICE|RoFT® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
214505393|NCT00243867|DRUG|Carboplatin|Administered by intravenous infusion over 30 minutes. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate (GFR) + 25).
214505394|NCT00243867|DRUG|Paclitaxel|Administered by intravenous infusion over 3 hour infusion
214505395|NCT02159716|BIOLOGICAL|CART-meso|CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
214505396|NCT02798341|OTHER|Biospecimen Collection|
214505397|NCT06798701|OTHER|Best Practice|Undergo standard care
214505398|NCT06798701|OTHER|Interview|Ancillary studies
214505399|NCT06798701|OTHER|Survey Administration|Ancillary studies
215017623|NCT00676637|DEVICE|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
215017624|NCT01531803|DRUG|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin)."
215017625|NCT01531803|DRUG|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
215017626|NCT05914259|OTHER|No Intervention|Following the manner of observational study, no intervention will be provided in the study.
215017627|NCT00538278|OTHER|Database|database
215017628|NCT02898675|DEVICE|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
215017629|NCT02898675|DEVICE|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
215017630|NCT05296655|OTHER|Reflux Symptom Index Inventory (diagnostic survey)|Kazakh versions of the Reflux Symptom Index Inventory will be filled patients
215017631|NCT05296655|OTHER|Reflux finding score|laryngoscopy with a score RFS
215017632|NCT05795712|OTHER|Therapy Change from Baseline|The patient will be followed up from the point of view of therapy according to symptoms and flare-ups irrespective of systemic or peripheral eosinophil assessment
215017633|NCT04704128|OTHER|Salivic sample|Collection of total saliva not stimulated
215017634|NCT04990310|DRUG|[14C]-CORT113176|\[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
215017635|NCT04695782|RADIATION|Pencil beam proton radiotherapy|Doseescalated pencil beam proton Therapy
215101840|NCT01274520|DEVICE|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
214505400|NCT06798701|PROCEDURE|Virtual Reality|Use VR device
214505401|NCT03742414|COMBINATION_PRODUCT|Tri-lipid skin barrier cream (Epiceram)|The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
214505402|NCT03742414|COMBINATION_PRODUCT|Fluticasone propionate Cream 0.05%|Proactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
214505403|NCT03742414|OTHER|Standard of Care|Participants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.
214505404|NCT06501001|BEHAVIORAL|High-Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 45 minutes. The intervention period will be sixteen weeks.
214505405|NCT06501001|BEHAVIORAL|Experimental: Time-Restricted Eating|Restricted daily window of caloric intake to a maximum 10 hours. The intervention period will be sixteen weeks.
214505406|NCT06335173|DRUG|sabirnetug|Intravenous sabirnetug
214505407|NCT06335173|DRUG|Placebo|Intravenous Placebo
214505408|NCT04982926|DRUG|TAS2940|Study participants with solid tumors and EGFR or HER2 aberrations will receive TAS2940 tablets daily at increasing doses until MTD is reached.
214505409|NCT04982926|DRUG|TAS2940|Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.
214505410|NCT04810546|DIETARY_SUPPLEMENT|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
214505411|NCT06143709|OTHER|DNA sample collection|Patients will be asked to provide a blood or mouth wash sample for DNA extraction
214505412|NCT02422524|DRUG|PA-824|Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
214415689|NCT05864482|OTHER|Psychosocial nursing intervention|The sessions were planned to be at least 45 minutes in a time suitable for the groups, with the bed curtains drawn if possible. Session 1: The purpose of this session; Brief CIS information will be provided. Session 2: The session starts with mood control of individuals. It is discussed whether they have experienced an event that occupies their minds and is likely to affect their illness. Session 3: It starts with mood control of individuals. They are asked if there is anything from the places where the guests are. Cognitive reviews are reviewed. It aims to describe recent stressful observations, negative automatic outcome descriptions, and evaluation of such experiences. 4.Session: The session starts with the mood control of the patient. It is discussed whether the patient has experienced an event that occupies his mind. Continuous analysis of negative thoughts and review of cognitive techniques and coping mechanisms are provided.
214415690|NCT01990937|DRUG|Oral midazolam|5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
215017636|NCT05810649|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
215017637|NCT05775575|DRUG|TQB3909 tablets|TQB3909 is an inhibitor targeting BCL-2 protein
215017638|NCT04744129|DRUG|NN414|To investigate the role of NN414 on cerebral hemodynamic in migraine patients
215017639|NCT04744129|DRUG|Saline|To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.
215017640|NCT05667402|DRUG|TBF regimen|The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.
215017641|NCT05667402|DRUG|modified BuCY2 regimen|The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.
215017642|NCT02551809|BIOLOGICAL|UB-311|Intramuscular injection
215017643|NCT02551809|DRUG|Placebo|Intramuscular injection
215017644|NCT03777176|DRUG|Dasiglucagon|Glucagon analog
214415691|NCT02899286|BIOLOGICAL|PEG-BCT-100|PEGylated recombinant human arginase
214415692|NCT02305082|OTHER|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
214415693|NCT05139264|OTHER|Observational|Observation of diet, physical activity, sleep and interstitial glucose
214415694|NCT02860884|PROCEDURE|liver biopsy|
214415695|NCT02860884|OTHER|infrared spectroscopy|
214415696|NCT06532760|OTHER|Blood sampling|Blood sampling to study sodium fragment kinetics
214415697|NCT03669562|DRUG|Alprostadil Liposome for Injection|intravenous infusion Alprostadil Liposome
214415698|NCT03669562|DRUG|Placebo|intravenous infusion liposome control
214415699|NCT04127058|DRUG|Iloperidone|Oral Tablet
214415700|NCT02541643|DRUG|Elotuzumab|"Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.~A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:~* H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent~* H2 blocker: ranitidine (50mg IV) or equivalent~* acetaminophen (650-1000mg PO)"
214415701|NCT02535624|PROCEDURE|PACKING|By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
214415702|NCT02535624|PROCEDURE|ANGIO|Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
214415703|NCT04809402|OTHER|remote monitoring after cataract surgery|remote monitoring after cataract surgery
214415704|NCT04156724|DEVICE|Helmet vetilation|We will apply non-invasive positive pressure ventilation via a helmet as interface
215017645|NCT03777176|OTHER|Standard of Care|Standard of care according to site and/or country
215017646|NCT01594814|PROCEDURE|RFA|radiofrequency ablation of slow pathway or accesory pathway
215017647|NCT00322426|DEVICE|Sensory Cueing Device|
215017648|NCT05230654|DRUG|Fosaprepitant|Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.
215017649|NCT05230654|DRUG|Placebo(normal saline)|Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
215017650|NCT03881878|DRUG|TAHP and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (420mg, IV)"
215017651|NCT03881878|DRUG|TAHP plus AC and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
215017652|NCT03023683|BIOLOGICAL|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
215017653|NCT02062255|DRUG|Aspirin|
215017654|NCT02062255|DIETARY_SUPPLEMENT|Omega 3 FFA|
215101841|NCT06253169|DIAGNOSTIC_TEST|HPV DNA self-test|HPV DNA swab from the cervix performed by the patient herself.
214415705|NCT05167253|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
214689465|NCT05880407|PROCEDURE|SERI osteotomy|Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
215017655|NCT06535776|OTHER|Matrix Rhythm Therapy|Individuals in this group will be taught home exercises face-to-face in a single session as in the home-based exercise group and will be asked to perform the exercises themselves at home for 3 non-consecutive days a week for 6 weeks. In addition to home-based exercises, a total of 12 sessions of face-to-face matrix rhythm therapy will be performed, 2 non-consecutive days a week for 6 weeks. Matrix rhythm therapy applications will be applied by a specialist physiotherapist who has received training with the matrix rhythm therapy vibromassage device.
214415706|NCT04965467|DIAGNOSTIC_TEST|Screening for Fabry disease|A questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.
214415707|NCT05725889|DEVICE|recation time test|visual-finger tapping and auditory reaction time tests
214415708|NCT04928872|COMBINATION_PRODUCT|Predefined meal|Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
214415709|NCT00024531|DRUG|Atorvastatin calcium|
215017656|NCT06535776|OTHER|Home-based Exercise|Home-based exercise program will be explained to patients diagnosed with axSpA by a physiotherapist. All exercises will be repeated with the physiotherapist and explained until understood. Patients will be asked to perform these exercises on their own 3 non-consecutive days a week for 6 weeks. Patients will be called by the physiotherapist on each exercise day and their home exercises will be monitored and recorded in the exercise tracking chart created for each patient. In addition, the patients will be given an exercise follow-up chart and they will be asked to fill in the existing chart and submit it at the end of the 6-week training.
214415710|NCT00370448|BEHAVIORAL|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
214415711|NCT00309452|BEHAVIORAL|Cognitive Behavioral Group Therapy|once per week
214415712|NCT00309452|BEHAVIORAL|Cognitive remediation|as needed
214415713|NCT00309452|DRUG|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
215017657|NCT04314180|DEVICE|Taking slit-lamp images|The participant only needs to take several slit-lamp images as usual.
215017658|NCT04869410|PROCEDURE|Modification Broselow Tape|Intubation using modified Broselow Tape prediction for predicting ETT size
215017659|NCT04869410|PROCEDURE|Cole Formula|Intubation using Cole Formula prediction for predicting ETT size
215017660|NCT03902483|DEVICE|renal doppler ultrasound|renal doppler ultrasound measuring renal resistive index
215017661|NCT03958097|COMBINATION_PRODUCT|NK cell and PD-1 antibody|Each patient enrolled the study will received both NK cell and PD-1 antibody.
214505413|NCT01321073|DEVICE|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
214505414|NCT05594524|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a three-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10-20 girls. The sports organizations will work with the community partner and researchers on how to schedule the intervention over a three-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sports organization. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Knowledge (20 mins), The Skills (20 mins), and The Final Score (15 mins). A variety of activity modalities will be utilized to convey learning outcomes, including group and individual activities and discussion-, writing-, and movement-based activities.
214505415|NCT00544115|DRUG|busulfan|
214505416|NCT00544115|DRUG|cyclophosphamide|
214505417|NCT00544115|DRUG|cyclosporine|
214505418|NCT00544115|DRUG|etoposide|
215017662|NCT00450840|DRUG|Simvastatin|
214505419|NCT00544115|DRUG|fludarabine phosphate|
214505420|NCT00544115|DRUG|melphalan|
214505421|NCT00544115|DRUG|methotrexate|
214505422|NCT00544115|DRUG|mycophenolate mofetil|
214505423|NCT00544115|DRUG|sirolimus|
215017663|NCT02540902|DEVICE|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
215017664|NCT02773537|DRUG|Femoral nerve catheter and sciatic nerve block|This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.
215017665|NCT02773537|DRUG|Adductor canal catheter and selective tibial block|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
215101842|NCT00367276|DRUG|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
214505424|NCT00544115|DRUG|tacrolimus|
214505425|NCT00544115|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214505426|NCT00544115|PROCEDURE|peripheral blood stem cell transplantation|
214505427|NCT00544115|RADIATION|total-body irradiation|
214505428|NCT05206942|DIAGNOSTIC_TEST|Doppler ultrasound|Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner
214689466|NCT05880407|PROCEDURE|percutaneous osteotomy according to Chevron|Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
214415714|NCT00309452|BEHAVIORAL|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
214415715|NCT00309452|BEHAVIORAL|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
214415716|NCT00309452|OTHER|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
214689467|NCT00107770|DRUG|sodium phenylbutyrate|histone deacteylase inhibitor
214415717|NCT04242758|DRUG|Dapagliflozin 10 MG|SGLT2-inhibitor: Diabetic oral drug with diuretic properties
214415718|NCT04242758|DRUG|Hydrochlorothiazide 12.5mg|Best known thiazide class diuretic.
214415719|NCT04881318|OTHER|Waist-High Compression Tights|Waist-high compression tights providing 15-40 mmHg of pressure.
214415720|NCT04881318|OTHER|Abdominal Compression Garments|Abdominal compression garment compressing the abdomen, buttocks, and upper thighs.
214415721|NCT04881318|DRUG|Medications that modulate heart rate and blood pressure|Medications that modulate heart rate and blood pressure that participants regularly take. These medications include beta-blockers, midodrine, ivabradine and stimulants.
214415722|NCT00590668|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Measurement of peak diastolic flow velocity
214415723|NCT00149279|PROCEDURE|Surgery: D2 dissection|
214415724|NCT00149279|PROCEDURE|Surgery: D2+paraaortic dissection|
214415725|NCT04414878|DEVICE|VitaFlow™ II Transcatheter Aortic Valve System|VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
214415726|NCT04582344|BIOLOGICAL|CoronaVac|Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
214415727|NCT04582344|BIOLOGICAL|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
214415728|NCT06249633|DRUG|Nitric Oxide|Inhaled nitric oxide
214415729|NCT00174317|DRUG|Celecoxib|
214415730|NCT00174317|DRUG|Diclofenac|
214415731|NCT04776993|DRUG|Methimazole|Methimazole for 72 weeks
214415732|NCT04776993|PROCEDURE|Radioiodine or thyroidectomy|Treatment with radioiodine or with thyroidectomy
214415733|NCT01906060|DEVICE|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
214415734|NCT01557998|BEHAVIORAL|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
214415735|NCT01557998|DRUG|HCV+PWID|Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.
214415736|NCT01557998|BEHAVIORAL|Control - No intervention|
214415737|NCT04588337|DRUG|rhTNK-tPA|Thrombolysis
214689468|NCT05821257|OTHER|Evaluation of the arm swing during gait|Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.
214689469|NCT05821257|OTHER|Functional Tests|To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
214689470|NCT06288672|OTHER|True avoidance diet|Food patch test-directed avoidance diet for 16 weeks where participant avoids avoid eating the food(s) to which they are allergic
214415738|NCT02012166|DRUG|MK-0893 10 mg|MK-0893 10 mg administered orally in 240 mL of water
214415739|NCT02012166|DRUG|MK-0893 40 mg|MK-0893 40 mg administered orally in 240 mL of water
214415740|NCT02012166|DRUG|MK-0893 200 mg|MK-0893 200 mg administered orally in 240 mL of water
214415741|NCT02012166|DRUG|MK-0893 1000 mg|MK-0893 1000 mg administered orally in 240 mL of water
214415742|NCT02012166|DRUG|Placebo|Placebo administered orally in 240 mL of water
214415743|NCT02012166|BIOLOGICAL|Sandostatine®|Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
214415744|NCT02012166|BIOLOGICAL|Insulin|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
214415745|NCT02012166|BIOLOGICAL|Glucagon|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
214415746|NCT05376930|DRUG|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
214415747|NCT00105794|PROCEDURE|Psychiatric Advance Directives intervention|
214689471|NCT06288672|OTHER|Sham avoidance diet|Avoidance diet for 16 weeks of randomly selected foods to which the patch testing did not show an allergy
214689472|NCT00861484|DRUG|GSK958108|Coated Tablets 1 mg
214689473|NCT00861484|DRUG|Placebo|Coated tablets
214689474|NCT02876939|OTHER|kinesiology tape around the hip, knee and ankle joints|We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
214415748|NCT00541606|OTHER|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
214415749|NCT00541606|OTHER|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
214415750|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and A|A single dose of Vitamin A and Vitamin D will be given.
214415751|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and Placebo|A single dose of Vitamin D plus a placebo will be given.
214415752|NCT05351372|RADIATION|Ultra-low dose protocol|
214415753|NCT05351372|RADIATION|Standard dose protocol|
214415754|NCT04957654|OTHER|VST with collagen plug soaked in blood|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with collagen plug soaked in blood
214415755|NCT04957654|OTHER|VST with Allograft Demineralized bone matrix Grafton|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with Allograft Demineralized bone matrix Grafton
214415756|NCT04957654|OTHER|VST with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles
214415757|NCT05574530|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|6-week intervention of one dietary supplement a day, containing vitamin B2 (10mg), vitamin B3 (4mg), vitamin B6 (1.4mg), vitamin B9 (400μg), vitamin C (200mg) and vitamin D3 (15ug).
214415758|NCT05574530|DIETARY_SUPPLEMENT|Placebo supplement|6-week intervention of one dietary supplement a day, containing 200 mg of microcrystalline cellulose.
215017666|NCT02773537|DRUG|Adductor canal catheter only|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
215017667|NCT02542579|GENETIC|16S rRNA pyrosequencing analysis|Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).
215017668|NCT01840163|OTHER|Static version of CanSORT tool|
215017669|NCT01840163|OTHER|CanSORT Online Tool|
215017670|NCT05591287|PROCEDURE|Contrast enhanced harmonic Endoscopic Ultrasound|Solid pancreatic masses suspected for PDAC detected by cross-sectional imaging and confirmed at EUS will be enrolled. The
215017671|NCT05531344|DEVICE|Composite Steep-pulse Treatment Device|Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia
214415759|NCT02485041|DRUG|Dapoxetine 30mg|Tablet, Orally administered
214415760|NCT02485041|DRUG|Mirodenafil 100mg|Table, Orally administered
214415761|NCT01315899|DRUG|ORM-12471 30mg|Given as a single dose once during the crossover study as per Williams design
214415762|NCT01315899|DRUG|ORM-12471|Given as a single dose once during the study as per Williams crossover design
215017672|NCT05531344|DRUG|Tamsulosin Hydrochloride Capsules|Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
215017673|NCT00383565|DRUG|romidepsin|Given IV
214415763|NCT01315899|DRUG|placebo|Given once as a single dose during the study as per Williams crossover design
215017674|NCT00276315|BIOLOGICAL|Botulinum toxin type A|
215017675|NCT05820555|BEHAVIORAL|Timed evening technology and digital media use (tablet use)|timing of children's evening tablet device use relative to bedtime
215017676|NCT05820555|BEHAVIORAL|no technology and digital media use (screen media use)|no screen media use relative to bedtime (Tablets, computers, TV, moble devices, smart phone)
214415764|NCT04009070|DEVICE|Acupuncture Pres Needle: 0.22x1.5 mm needle|Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.
214415765|NCT03874156|DRUG|Atorvastatin 40mg|Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
214415766|NCT03874156|DRUG|Placebo Oral Tablet|Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
214415767|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|40 mg, QD
214415768|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|80 mg, QD
214415769|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|160 mg, QD
214415770|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|240 mg, QD
214415771|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|320 mg, QD
214415772|NCT00753168|DRUG|OT-730 ophthalmic solution|one eye drop twice daily
214415773|NCT00753168|DRUG|timolol maleate ophthalmic solution|one eye drop twice daily
214415774|NCT00753168|DRUG|OT-730 placebo|one eye drop twice daily
215017677|NCT03990337|DEVICE|Ultrasound|Ultrasonography of cricoid cartilage.
215017678|NCT03090542|DIETARY_SUPPLEMENT|clinoptilolite|randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
215017679|NCT00748527|DRUG|carboplatin|Given IV
215017680|NCT00748527|DRUG|decitabine|Given IV
215101843|NCT03429257|OTHER|Exposures of interest: Maternal EED and Aflatoxin Exposure|Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
214415775|NCT01977612|DEVICE|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
214415776|NCT01977612|DEVICE|Stainless steel staples|Skin closure using stainless steel staples.
214415777|NCT00079664|BEHAVIORAL|Tai Chi|
214415778|NCT02188758|OTHER|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
214415779|NCT06320119|OTHER|PDO Group|Patients in the intervention gruop with set a personalized outcome within a usual asthma review consultation
214415780|NCT01451814|BEHAVIORAL|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
214689475|NCT02876939|OTHER|No kinesiology tape around the hip, knee and ankle joints|Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
215101844|NCT03848767|DEVICE|AID System|AID System
215101845|NCT03848767|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
214415781|NCT01451814|DRUG|Nicotine polacrilex|8 weeks of nicotine patch
214415782|NCT01451814|BEHAVIORAL|Relaxation training|Instructions in progressive muscle relaxation
214415783|NCT01451814|BEHAVIORAL|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
214415784|NCT02356549|BEHAVIORAL|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
214415785|NCT02356549|BEHAVIORAL|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
214505429|NCT05206942|DIAGNOSTIC_TEST|Long Ensemble Angular-coherence Doppler [LEAD] ultrasound|Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner
214505430|NCT05206942|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
214505431|NCT01638000|DRUG|Mirabegron|oral tablet
214505432|NCT01638000|DRUG|Solifenacin succinate|oral tablet
214505433|NCT04220021|DRUG|Metformin|Metformin is a widely used, well-tolerated drug that has been used for decades as a first-line defense for treating type 2 diabetes. Its safety has been well established. Subjects will begin treatment with Metformin at a dosage of 500mg with an escalation of dosage by 500mg every week to a maximal dosage of 2000mg. Dosing will be twice daily.
214505434|NCT03141060|DRUG|Delamanid|Administered orally; dosing will be based on participants' age and weight.
214505435|NCT03141060|DRUG|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
214505436|NCT06071468|DEVICE|UltraGuideCTR (Device) with Ultrasound Guided Carpal Tunnel Release (CTR-US)|The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically \< 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.
214505437|NCT06071468|PROCEDURE|Endocscopic CTR|"Endoscopic CTR makes one or two short incisions to introduce instruments for visualizing. The key procedural steps involved in Endoscopic CTR are listed below.~1. Following the delivery of anesthesia, the surgeon makes a small wrist incision (usually less than 1.5 cm), with or without a small palmar incision (usually less than 1.5 cm, depending on whether they are using a single portal or double portal technique, respectively.~2. A series of dilators and raspers are used to create space in the carpal tunnel and clear synovial tissue from the undersurface fo the TCL.~3. A camera attached to a narrow tube (endoscope) is inserted into the carpal tunnel.~4. The transverse carpal ligament (which forms the roof of the carpal tunnel) is identified.~5. Using specialized cutting instruments and endoscopic guidance, the surgeon transects the TCL.~6. Endoscopic visualization and/or probing are used to confirm a complete release.~7. The wound(s) is/are typically closed with sutures."
214505438|NCT06071468|PROCEDURE|Open CTR|"OCTR is the most commonly used CTR technique in the United States.The key procedural steps involved in OCTR are listed below.~1. Following the delivery of anesthesia, an incision is made in the palm directly over the carpal tunnel.~2. The surgeon cuts through the palmar fascia to identify the TCL.~3. The surgeon transects the TCL with a scalpel and/or similar cutting instruments.~4. The surgeon inspects the carpal tunnel to ensure proper decompression.~5. The wound is closed with sutures."
214505439|NCT05253846|DRUG|Irinotecan|chemotherapy treatment
214505440|NCT05253846|DRUG|Oxaliplatin|chemotherapy treatment
214505441|NCT05253846|DRUG|Lederfolin|treatment
214505442|NCT05253846|DRUG|5-Fluorouracil|chemotherapy treatment
214505443|NCT05253846|RADIATION|Short-course radiotherapy|RT
214505444|NCT05253846|PROCEDURE|TME|surgery
214505445|NCT06475274|DRUG|RMC-035|Protein, a recombinant variant of A1M. Concentrate for solution for infusion.
214505446|NCT06475274|DRUG|Placebo|Identical to RMC-035 intervention devoid of the active substance.
214505447|NCT06025344|DRUG|PanCytoVir™ 100 mg/mL oral suspension|Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
214505448|NCT06025344|DRUG|Probenecid 500 mg|Single oral dose of 1000 mg under fasted conditions
214415786|NCT02356549|BEHAVIORAL|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
214415787|NCT04228536|PROCEDURE|Totally ExtraPeritoneal (TEP) repair|
214415788|NCT04228536|PROCEDURE|TransAbdominal PrePeritoneal (TAPP) repair|
214689476|NCT06370936|OTHER|Standardized diet with commercially available animal meats (comparator products)|Fully controlled standardized diet with commercially available meats from animal origin. Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
214415789|NCT04228536|PROCEDURE|Open anterior mesh repair (OAM)|
214415790|NCT04228536|PROCEDURE|Combined Anterior and Posterior technique (CAP)|
214415791|NCT04228536|PROCEDURE|Open PrePeritoneal Mesh technique (OPPM)|
214415792|NCT04228536|PROCEDURE|Sutured Repair|
214415793|NCT04635358|BEHAVIORAL|Hypnosis|Setting up hypnosis sessions
214415794|NCT04635358|BEHAVIORAL|Psychological support|Setting up psychological support
214415795|NCT04635358|BEHAVIORAL|Nutrional support|Setting up nutritional support
214415796|NCT02504619|BIOLOGICAL|CordIn|CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
214415797|NCT01886430|OTHER|Functional electrical stimulation|Functional electrical stimulation for 10 days
214415798|NCT01886430|OTHER|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
214689477|NCT06370936|OTHER|Standardized diet with commercially available PBMAs (intervention products)|Fully controlled standardized diet with commercially available Plant-Based Meat Analogues (PBMAs). Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
214689478|NCT01533935|DRUG|Placebo|placebo matching tiotropium + olodaterol
214689479|NCT01533935|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
214689480|NCT01533935|DRUG|tiotropium + Olodaterol|tiotropium 5 mcg + olodaterol 5 mcg once daily
214689481|NCT01533935|DRUG|Tiotropium|tiotropium
214689482|NCT01533935|DRUG|Olodaterol|Olodaterol 5 mcg once daily
214689483|NCT01533935|DEVICE|Respimat|Respimat inhaler
214689484|NCT03916250|DRUG|PF-06700841 cream|PF-06700841 will be applied topically
215101846|NCT02904148|PROCEDURE|Shoulder mobilisation|early shoulder mobilisation
215101847|NCT01896583|DRUG|ASP7147|300 mg, tablet, twice per day for 4 weeks oral
215101848|NCT01896583|DRUG|Placebo|
215101849|NCT04684953|PROCEDURE|Throid autotransplantation|Operative
215101850|NCT04684953|DRUG|Hormone|thyroid hormone replacement therapy
214415799|NCT01280591|DRUG|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
214415800|NCT01280591|DRUG|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
214415801|NCT01280591|DRUG|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
214415802|NCT01280591|DRUG|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
214415803|NCT04619654|PROCEDURE|Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold|Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
214415804|NCT02396979|DRUG|Methadone|
214415805|NCT02396979|BEHAVIORAL|Holistic Health Recovery Program|
214415806|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
214415807|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
214415808|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
214415809|NCT05323682|OTHER|Individualized physical exercise program|An individualized physical exercise program was programmed, monitored remotely by e-mail or the use of an activity wristband
214415810|NCT05323682|OTHER|NO Individualized physical exercise program|Usual medication
214415811|NCT01672619|PROCEDURE|dynamic craniotomy|Surgical technique of craniotomy spiral without detachment of dura mater
214415812|NCT03426683|OTHER|Intestinal Microbiota Transplantation|the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
214415813|NCT00950404|DRUG|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
214415814|NCT00950404|DRUG|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
214415815|NCT00950404|DRUG|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
214415816|NCT00950404|DRUG|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
215101851|NCT01966445|BIOLOGICAL|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
215101852|NCT01656070|DRUG|oral cholecalciferol 1000000 UI (vitamin D3)|
215017681|NCT06549127|DEVICE|Soft Wearable Robot|This study aims to enroll 20 participants who will receive assistance in flexion and extension of the knee and hip during overground walking adaptation training. Following the initial assessment, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered hip assistive device over two weeks. After completing these sessions, Post-intervention Assessment 1 will be conducted. Then, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered knee assistive device over two weeks, followed by Post-intervention Assessment 2. Each participant will have a total of nine visits, including three functional assessments and six adaptation training sessions. The first visit will involve scheduling subsequent visits. The familiarization process will occur two to three times per week, adjustable for participants' convenience, with each set of three visits completed within three weeks.
214415817|NCT05178758|DEVICE|Virtual Reality (VR)|Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.
215017682|NCT06536855|BIOLOGICAL|Gardasil 9|"GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.~GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11."
215017683|NCT03992482|DRUG|Intravenous Immune Globulin (IVIG)|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
215017684|NCT03992482|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
215017685|NCT03364257|DIAGNOSTIC_TEST|iDTECT Blood|Next generation sequencing-based shot-gun metagenomic test for the diagnosis of viral or bacterial infections using blood samples
215017686|NCT03636269|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
215017687|NCT03636269|DRUG|Placebo|IV placebo administered three times/week
215017688|NCT05441345|OTHER|questionnaires with collection of stool and urine|questionnaires will be completed (GPAQ, SarQoL, EQ-5D-3L, SF36), with collection of stool (for care and research) and urine
215017689|NCT02044146|DRUG|Ticagrelor, Prasugrel, Clopidogrel|
215017690|NCT03008213|DRUG|Netupitant and Palonosetron|300 mg of netupitant and 0.5 mg of palonosetron
214415818|NCT00117871|DRUG|Resiquimod|
214505449|NCT05958017|BEHAVIORAL|reSET|Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.
214505450|NCT05958017|OTHER|Standard of care|Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
215017691|NCT00298701|BIOLOGICAL|ALK Grass tablet|
215017692|NCT05001555|DRUG|Dexketoprofen/Vitamin B|1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
215017693|NCT05001555|DRUG|Dexketoprofen|1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
215017694|NCT05795660|BIOLOGICAL|platelet rich plasma|platelet rich plasma injection
215017695|NCT04891861|DRUG|Apixaban|Direct Oral Anticoagulation all at label dose and frequency
215101853|NCT01656070|DRUG|Placebo|
214415819|NCT01883492|DEVICE|Femoral Stem|JMDN classification/Class III device
214505451|NCT03099356|DRUG|Cyclophosphamide|Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
214505452|NCT03099356|DRUG|Sirolimus|Sirolimus 4 mg, PO, days 1-28
214505453|NCT06268015|DRUG|Botensilimab|75 mg IV every 6 weeks for up to 4 doses
214505454|NCT06268015|DRUG|Balstilimab|240 mg IV every 2 weeks
214505455|NCT06268015|DRUG|Oxaliplatin|85 mg/m2 IV every 2 weeks
214505456|NCT06268015|DRUG|Leucovorin|400 mg/m2 IV every 2 weeks
214505457|NCT06268015|DRUG|Fluorouracil|400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks
214505458|NCT06268015|DRUG|Bevacizumab|5 mg/kg IV every 2 weeks
214505459|NCT06268015|DRUG|Panitumumab|6 mg/kg IV every 2 weeks
214505460|NCT05352230|DEVICE|Free style libre-2|A cross-over design will allow estimation of feasibility and acceptability of patients using CGM vs patients using blood glucose meter monitoring (conventional therapy). The study will consist on two phases, the first will last three months, then it will be a two months of washout period followed by the crossover, then the second phase will last another three months. Patients in the conventional therapy group will also use masked CGM (CGM professional) during the first two and last two weeks of their study phase with the purpose of collecting CGM-parameters information. The cross over randomization will be stratified by donor type (live vs deceased) using a web-based randomization tool. During the washout period the patients will continue using blood glucose meter monitoring
214689485|NCT03916250|DRUG|White petrolatum|White petrolatum will be applied topically
214689486|NCT03587038|DRUG|OKN 007|400 mg OKN-007/mL in a phosphate buffer
214415820|NCT01883492|DEVICE|Acetabular Cup|JMDN classification: Class III device
214415821|NCT01883492|DEVICE|Acetabular Liner|JMDN classification: Class III device
214415822|NCT03357341|DEVICE|Mobile spirometer|Mobile spirometer will be used to measure FEV1 values weekly.
214415823|NCT03357341|DEVICE|Device sensor|Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
214415824|NCT03357341|DRUG|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
215101854|NCT02435706|PROCEDURE|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
215101855|NCT02435706|PROCEDURE|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
215101856|NCT02435706|DEVICE|Implant and temporary crown|Both groups receive this intervention
214415825|NCT03357341|DEVICE|Activity monitor|Subjects will be required to wear activity monitors daily to record their physical activity.
214415826|NCT03357341|OTHER|electronic diary card|Electronic diary card will be completed daily by subjects in COPD cohort.
214415827|NCT03357341|OTHER|CAT|Subjects will be required to complete CAT monthly.
214415828|NCT03357341|OTHER|ACT|Subjects will be required to complete ACT monthly.
214415829|NCT05042791|COMBINATION_PRODUCT|radiation combined with pyrotinib and capecitabine|This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases
214415830|NCT00386204|DEVICE|Q-switched Ruby Laser|
214415831|NCT00010946|PROCEDURE|Acupuncture|
214415832|NCT03709628|DRUG|EB8018 (First-in-class FimH blocker)|"Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker~• In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13."
214415833|NCT01259102|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
214415834|NCT06492889|DRUG|Levonorgestrel|Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel
214415835|NCT06492889|DRUG|Mifepristone|Participants in both groups will receive one tablet of 200 mg mifepristone
214415836|NCT06076434|OTHER|The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region|The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).
214415837|NCT01060137|DRUG|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
214415838|NCT02162667|DRUG|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
214415839|NCT00878618|DRUG|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
214415840|NCT00878618|DRUG|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
214415841|NCT01541358|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
214415842|NCT01541358|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
214415843|NCT01956669|DRUG|Pazopanib|Pazopanib was supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension was a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
214415844|NCT05407480|OTHER|Observational|Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome
214415845|NCT02932709|BEHAVIORAL|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
214415846|NCT05193188|DRUG|Anlotinib hydrochloride|Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
214415847|NCT05193188|DRUG|PD-1 inhibitor|Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
214415848|NCT02410538|OTHER|"list of FAQ"|
214415849|NCT04765163|DEVICE|Intelligent Operating Handle|Intelligent Operating Handle
214415850|NCT03106142|PROCEDURE|Academic detailing visit arm|General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
214415851|NCT01284907|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
214415852|NCT01284907|DIETARY_SUPPLEMENT|Placebo Drops|
214415853|NCT04538755|DRUG|Placebo oral capsule|Placebo before sleep
214415854|NCT04538755|DRUG|DAW2020 oral capsule|DAW2020 34 mg 4 h before sleep, single night administration
214415855|NCT01233050|DRUG|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
214415856|NCT01233050|DRUG|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
214415857|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
214415858|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
214415859|NCT01807858|OTHER|Maltodextrin|Maltodextrin
214415860|NCT01807858|DIETARY_SUPPLEMENT|İnulin|900 mg inulin per day will be given
214415861|NCT04674332|DRUG|Long acting insulin|long acting insulin analogue once daily at bed time
214415862|NCT04674332|DRUG|multiple dose regimen|intermediate and short acting insulin
214415863|NCT01771666|DEVICE|SPY Elite Imaging|A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes
214415864|NCT01771666|DRUG|Indocyanine Green|"started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
214415865|NCT01771666|DRUG|Isosulfan blue|"3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
214415866|NCT01771666|DRUG|99technetium-sulfur colloid radiolabel|
214415867|NCT05672446|OTHER|simulation with standardized child patient|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients. In the simulation, a school-aged child was used as the standard patient.
214415868|NCT00887835|DEVICE|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
214415869|NCT02804516|BEHAVIORAL|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
214415870|NCT02804516|BEHAVIORAL|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
215017696|NCT05470296|BEHAVIORAL|Move & Eat 2 Live|American Indians suffer disproportionately from several chronic diseases that may be prevented with healthier modifiable factors. Nutrition, physical activity and a healthy weight are key factors that may prevent and reduce risk of disease incidence. The major goals of this project are to develop a culturally adapted intervention that addresses barriers and uses positive cultural values as guiding principles for behavior changes to enhance program retention and improve behaviors. This project will pilot a 12-week standard lifestyle intervention in American Indians.
214415871|NCT02533908|DRUG|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
214505461|NCT03991234|BEHAVIORAL|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction to build skill on letter-sound associations, decoding, sight words, \& contextualized reading.
215017697|NCT03774810|DRUG|Zolpidem tartrate|Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.
215017698|NCT00200083|DEVICE|Transcend II Model 8848|"All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up."
215017699|NCT02212977|DEVICE|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
215017700|NCT02212977|PROCEDURE|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
215017701|NCT04767412|DEVICE|aerobic exercise training, inspiratory muscle training|All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
215101857|NCT05885802|OTHER|No specific intervention other than routine anesthesia protocol|No specific intervention other than routine anesthesia protocol
214415872|NCT02533908|DRUG|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
214415873|NCT01590836|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
214415874|NCT01590836|DRUG|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
214415875|NCT06400446|OTHER|Standard care|The babies in this group will receive the standard care of the unit. The vital signs and pain scores of the babies will be recorded before the mother's visit for seven days. The vital signs and pain scores of the infants who received the standard care of the unit during one hour, which is the time of the mother's visit, will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
214505462|NCT03991234|BEHAVIORAL|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge \& counting strategies to build arithmetic skill.
214505463|NCT03991234|BEHAVIORAL|Coordinated Intervention|Coordinated intervention provides 15 weeks (30-minute sessions per week) of explicit instruction addressing the similar skills as in the reading intervention arm \& similar objectives as the math intervention arm.
214505464|NCT02010957|OTHER|FDG positron emission tomography|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
214505465|NCT02010957|OTHER|Iodometomidate imaging|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
215017702|NCT00330278|DRUG|Cefazolin|
215017703|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
215017704|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
215101858|NCT00733941|BEHAVIORAL|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
214415876|NCT06400446|OTHER|Kangaroo care|Kangaroo care will be applied to the experimental group for seven days. Kangaroo care will be started for the babies in the intervention group when the baby is extubated, when the baby starts oral feeding and when the chest incision is closed. Consistent with previous research, mothers will provide skin-to-skin contact for at least 1 hour per day for seven days, starting immediately after feeding. The vital signs and pain scores of the babies will be recorded during the kangaroo care of the mother for seven days. During the kangaroo care, vital signs and pain scores of the infants will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
214415877|NCT04809090|BEHAVIORAL|SMT|Standard 8 SMT (Stress Management Training) psychological interviews.
214415878|NCT04809090|DEVICE|App CA|An APP together a CA (Conversational Agent).
214415879|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
214415880|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
214689487|NCT03587038|DRUG|Temozolomide|75 mg/m2
214689488|NCT03587038|RADIATION|Photon/Proton IMRT|standard of care treatment to be given 1 to 2 hours after OKN-007
215101859|NCT00733941|BEHAVIORAL|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
215101860|NCT01374178|DRUG|LY2963016|Administered subcutaneously
215101861|NCT01374178|DRUG|Lantus|Administered subcutaneously
215101862|NCT00524017|BIOLOGICAL|cetuximab|given IV
214415881|NCT02704819|OTHER|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~1. Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~2. Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
214415882|NCT02704819|OTHER|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
214415883|NCT02704819|OTHER|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~1. Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~2. Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
214415884|NCT02704819|OTHER|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
214415885|NCT02704819|OTHER|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
214415886|NCT04187664|BEHAVIORAL|Postoperative Monitoring|Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.
214415887|NCT04187664|DIAGNOSTIC_TEST|High-sensitivity cardiac troponin testing|High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
214505466|NCT05403658|BEHAVIORAL|Family Navigation|FN will be delivered by navigators who will provide support and services that complement obesity management care provided by multidisciplinary teams at the study clinical sites. With advanced training in motivational interviewing and patient- / family-centered care, navigators will access a bundle of logistical and relational strategies to help families derive the greatest possible benefit from their care, which will include working to reduce barriers to care, improve access, and optimize treatment outcomes related to obesity management that is part of their Usual Care. Navigators will provide various resources/supports to study participants including, but not limited to, offering communication via text message, flexible navigator appointments, parking/transit passes, community-based resources, and liaising with members of the multidisciplinary clinical teams at each site.
214689489|NCT05434689|DRUG|Iberdomide|Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
214505467|NCT05403658|BEHAVIORAL|Usual Care|Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.
214505468|NCT06527755|DRUG|Eplontersen Solution for Injection|an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg.
215017705|NCT02848352|OTHER|Placebo nasal spray|
215017706|NCT02848352|OTHER|Film Sequence|
215101863|NCT05788497|DRUG|Hemorrane plus|Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine
214505469|NCT03235245|DRUG|Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
214505470|NCT03235245|DRUG|Encorafenib + Binimetinib|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
214689490|NCT05434689|DRUG|Daratumumab|Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
214689491|NCT05434689|DRUG|Dexamethasone|Corticosteroid active against multiple myeloma in combination with other agents
214689492|NCT05434689|DRUG|Carfilzomib|Second generation proteasome inhibitor with activity in multiple myeloma
215017707|NCT06284837|OTHER|Access site|The SAFER-TAVI trial is randomized study comparing secondary access via a transradial versus transfemoral approach among patients undergoing transfemoral TAVI for aortic valve disease. Secondary access is gained along with primary access at the commencement of the TAVI procedure and is used for aortography before and after valve deployment and for assessment of the primary femoral access site after closure to confirm haemostasis. For patients assigned to radial access, the radial sheath will be removed using a radial band at the end of the procedure. For patients assigned to femoral access, the puncture site will be obtained under ultrasound guidance and fluoroscopic landmark identification. Unless contraindicated, the use of vascular closure devices will be recommended for all femoral cases. The choice of closure device is at the discretion of the operator. Catheters used in the access groups will be 5 or 6 French size at the discretion of the operator.
215017708|NCT00499538|DRUG|SKI-606|
215101864|NCT05788497|DRUG|Hemorrane|Hemorrane 10 mg/g rectal ointment
215101865|NCT05788497|DRUG|Placebo|Rectal ointment
215101866|NCT02756494|BIOLOGICAL|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
215101867|NCT03277365|OTHER|Receive genetic risk information|Risk scores are provided by ResearchKit app.
215101868|NCT04856904|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks
214415888|NCT02708069|OTHER|e-Unstuck|An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
214415889|NCT02708069|OTHER|Unstuck and On Target|An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
215017709|NCT05328232|OTHER|Olive oil|The parents of the babies included in the experimental group were asked to fill in the questionnaires. The infant's skin condition was assessed using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants. Each time the diaper was changed, the diaper area was cleaned with water and cotton wool and dried, 1-2 cc of natural extra virgin olive oil was applied, and the new diaper was fastened. At the end of each day, the diaper area was evaluated by the researcher and a nurse by using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants.
214415890|NCT02411942|DRUG|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
214415891|NCT02411942|DRUG|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
215017710|NCT00290758|DRUG|placebo|Given orally
215017711|NCT00290758|DRUG|genistein|Given orally
215017712|NCT00290758|OTHER|laboratory biomarker analysis|Correlative studies
215017713|NCT03436420|DRUG|Gemcabene|Participants will take 300 milligrams (mg) of gemcabene, once per day for 12 weeks.
215017714|NCT06190015|BIOLOGICAL|Advanced platelet rich fibrin (APRF) clots|15 minutes before surgery, phlebotomy will be performed and two vacutainers containing 10ml of blood will be placed in the centrifuge for 8 min and 200g. Acquired APRF clots will be placed in the extraction alveolus
215017715|NCT06190015|DEVICE|Enamel matrix derivative (EMD) group|After third molar removal, Pref Gel (EDTA) will be placed on the root surface for 2 min and then removed. Emdogain (EMD) will be placed on the collagen sponge (Botiss, Collacone) and then applied in the wound so that the side of the sponge which is covered with Emdogain is in contact with the root surface.
215101869|NCT04856904|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
214415892|NCT02411942|DRUG|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
214415893|NCT01611831|BEHAVIORAL|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
214415894|NCT01611831|BEHAVIORAL|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
214415895|NCT03597841|DRUG|Combination therapy|Patients who are given combination therapy will be allocated to this group.
214415896|NCT00257283|DRUG|Omega-3-acid ethyl esters 90|
214415897|NCT00337545|DRUG|RAD001|
214505471|NCT06176443|PROCEDURE|One anastomosis gastric bypass with combined fundoplication|FundoRingOAGB
214505472|NCT06176443|PROCEDURE|One anastomosis gastric bypass without combined fundoplication|OAGB
214505473|NCT06965595|OTHER|Routine care|This group will be the control group. Routine care practices carried out in the hospital (vital sign monitoring, administration of analgesics, anti-inflammatory and antibiotics when necessary, and mobilization starting from the 6th hour) will be applied and the data will be recorded.
214505474|NCT06965595|OTHER|Routine care + Physiotherapy|"In addition to routine care practices, this group will receive physiotherapy and rehabilitation. During the postoperative period, the intervention will be applied twice a day.~Posture training: Information about posture will be provided in different positions and training will be conducted.~Breathing training (Diaphragmatic breathing, thoracic expansion exercises)~In-bed mobilization (Lower and upper extremity exercises, foot-ankle exercises (dorsiflexion-plantar flexion / inversion-eversion), hip and knee flexion-extension exercises, cervical region joint range of motion and stretching exercises, upper extremity exercises (shoulder elevation, circumduction, elbow and wrist flexion-extension exercises), pelvic floor training and exercises)~Out-of-bed mobilization (Sitting, standing, walking training after the 6th hour)"
214505475|NCT06965595|OTHER|Routine care + Vagal stimulation|In addition to routine care practices, this group will receive vagal stimulation. The stimulation will be applied to the cervical region at 10 Hz, 200 μs for 20 minutes, twice a day.
214505476|NCT06965595|OTHER|Routine care + Physiotherapy + Vagal stimulation|In addition to routine care practices, this group will receive physiotherapy and rehabilitation, along with vagal stimulation.
214505477|NCT05143957|DRUG|sapablursen|Sapablursen will be administered by SC injection.
214505478|NCT06769685|DRUG|Basal therapy|Group A was treated with basal therapy including drugs such as interleukin-11, Ricocin, and Epsilon, and was administered until the PLT was ≥75×109/L.
214505479|NCT06769685|DRUG|rhTPO combined with Heptabopa treatment(group B)|In group B, they were treated with rhTPO and Heptabopa, and were medicated until their PLT was ≥75×109/L.
214505480|NCT06769685|DRUG|rhTPO combined with Heptabopa treatment(group C)|Ctit patients with platelet counts \<50×109/L were included in group C. All were treated with rhTPO and hypertrombopa and medicated until PLT ≥75×109/L.
214689493|NCT03868709|DRUG|Penehyclidine inhalation|Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients
214415898|NCT03347942|BEHAVIORAL|Intervention group|Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.
214415899|NCT03347942|OTHER|Control group|The control group will also serve the dish of the form, but can serve additional portion without waiting.
214415900|NCT06000618|DEVICE|Intrapulmonary Percussive ventilator|The volunteers will undergo three minutes low frequency and high frequency intrapulmonary percussive treatments.
214415901|NCT04517331|PROCEDURE|Thoracic paravertebral block-single injection|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
214689494|NCT03868709|DRUG|Placebo inhalation|Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
214415902|NCT04517331|PROCEDURE|Thoracic paravertebral block-double injection|The blocks were performed at both T2-T3 and T4-T5 levels bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
214415903|NCT01368406|BEHAVIORAL|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
214415904|NCT01539655|DRUG|vandetanib|Oral tablets, 300 mg, single dose
214415905|NCT01539655|DRUG|omeprazole|Oral capsules, 40 mg, multiple doses
214415906|NCT01539655|DRUG|ranitidine|Oral tables, 150 mg, multiple doses
214415907|NCT03203018|BEHAVIORAL|Interactive workshop based on community specific needs|"Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results."
214415908|NCT02850055|OTHER|Conventional Physiotherapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home."
214415909|NCT02850055|OTHER|Specific Manual Therapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home.~4. Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
214415910|NCT03258619|BIOLOGICAL|Aldosterone / renin dosage|Plasma levels of aldosterone and renin
214415911|NCT03258619|BIOLOGICAL|Natriuresis|natriuresis levels
214415912|NCT04538248|OTHER|Combined rehabilitation during hemodialysis|Combined rehabilitation during hemodialysis
214415913|NCT03014830|DRUG|Alirocumab|150 mg SQ every 2 weeks
214415914|NCT03014830|DRUG|Placebos|Placebo injections SQ every 2 weeks
214415915|NCT03551132|OTHER|Exercise test|Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
214415916|NCT02521844|DRUG|ETC-1922159|Oral administration
214415917|NCT02521844|DRUG|Pembrolizumab|IV administration
214415918|NCT02309567|OTHER|Blood Collection|
214415919|NCT02931435|PROCEDURE|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
214415920|NCT02931435|PROCEDURE|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
214415921|NCT02253719|PROCEDURE|cryotherapy, further biopsy, LEEP, surgery as indicated|These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
214415922|NCT04910919|DIETARY_SUPPLEMENT|Honey|Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
214415923|NCT04910919|OTHER|Standard of Care|The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
214415924|NCT05218408|BIOLOGICAL|CYNK-001 systemic and Intra cavity administration|"Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10\^9 or 3.6 x10\^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a"
214415925|NCT04172948|DEVICE|Oculus go headset/virtual reality headset|10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.
214415926|NCT04172948|BEHAVIORAL|Diaphragmatic breathing|10 minute tutorial on diaphragmatic breathing by a medical professional.
214415927|NCT01559480|DRUG|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
214415928|NCT01559480|DRUG|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
214415929|NCT05639023|OTHER|Manipulation Techniques|Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week.
214689495|NCT04824196|OTHER|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirrorAnterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear
215017716|NCT02512159|PROCEDURE|drenovac handcrafted|under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.
214415930|NCT05639023|OTHER|Physiotherapy Scoliosis-Specific Exercise|Subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
214689496|NCT04824196|OTHER|propriocetion exercise|"1. Alternate knee flexion-extension with extended trunk posture using both hands for support.~2. Hip and knee flexion-extension with swiss ball between the back and wall.~3. Hip raises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises. then all exercise are perfomed on gym ball"
214689497|NCT05195333|OTHER|The exercise program|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient.
214689498|NCT05195333|OTHER|The exercise program|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy.
214689499|NCT02894047|BIOLOGICAL|blood|measurement of CaSR expression levels on synovial fluid monocytes
215017717|NCT02512159|PROCEDURE|Healing|"Were handled as follows:~1. Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.~2. healing of skin ulcers were performed every 24 hours.~3. the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables."
215017718|NCT00003812|BIOLOGICAL|filgrastim|
215017719|NCT00003812|DRUG|carboplatin|
215017720|NCT00003812|DRUG|etoposide|
215017721|NCT00003812|DRUG|paclitaxel|
215017722|NCT00003812|DRUG|topotecan hydrochloride|
215017723|NCT00003812|RADIATION|radiation therapy|
215017724|NCT01386320|PROCEDURE|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
215017725|NCT01386320|PROCEDURE|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
215017726|NCT02681432|DRUG|HIPEC|Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
215017727|NCT02681432|PROCEDURE|No HIPEC|Cytoreductive surgery without HIPEC
215017728|NCT04914000|BEHAVIORAL|Self-help Materials|Self-help booklet targeted by cancer type to increase smoking cessation motivation
215017729|NCT03720275|GENETIC|Systematic screening of TTR mutations|The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
215017730|NCT01429623|DRUG|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
214415931|NCT05388344|OTHER|Booklet reading|Submission of the questionnaire before and after booklet reading
214415932|NCT00810550|OTHER|Carotid ultrasound|Measurement of intima-media thickness
214415933|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: ropivacaine|The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally
214415934|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: bupivacaine|The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.
214415935|NCT05824338|DRUG|General anesthesia for lumbar surgery|Patient will be intubated and ventilated under general anesthesia.
214689500|NCT06638021|BEHAVIORAL|Targeted EHR-based Communication of Diagnostic Uncertainty (TECU)|The Targeted EHR-based Communication about Uncertainty (TECU) strategy will be activated in the electronic health record (Epic) every time an ED clinician enters an uncertain diagnosis for a patient being discharged, and will notify the clinician to counsel the patient about uncertainty while additionally triggering automated 1) insertion and printing of the patient handout and 2) provision of a hyperlink for the clinician-facing checklist to guide the discharge conversation.
214689501|NCT05647902|DIAGNOSTIC_TEST|Serum samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum samples will be collected from both groups for biochemical analysis.
214689502|NCT06374264|DEVICE|MR-C-014|Use of device 3 times per week (for 30 minutes) for 8 weeks - for a total of 24 sessions.
214689503|NCT04855201|DRUG|Bocidelpar|Oral
214689504|NCT04855201|DRUG|Placebo|Oral
214689505|NCT03430245|DEVICE|VelaShape III|The VelaShape III device combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with vacuum.
214689506|NCT03430245|DEVICE|UltraShape Power|The UltraShape Power device uses focused ultrasound energy for lipolysis (breakdown of fat) via a non-thermal mechanism of action.
214689507|NCT01208896|DRUG|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
214689508|NCT05453396|BIOLOGICAL|Loncastuximab Tesirine|Given IV
214689509|NCT03613415|OTHER|Expansion|non invasive technique to increase thickness of thin ridge
214689510|NCT03925389|PROCEDURE|External septorhinoplasty|A surgical procedure to repair defects or deformities of both the nasal septum and the external nasal pyramid through an external incision at the columella.
214415936|NCT06140680|BEHAVIORAL|LifelongU|"The LifelongU intervention is an abbreviation name from LifelongU: Cultivating Physical Literacy for University \& Beyond. LifelongU is a unique and coined term that symbolizes the program's commitment to promoting physical literacy as a lifelong journey. It combines the words Lifelong and University to represent an intervention that focuses on physical literacy development not only during the university years but also throughout a person's entire life. The name is designed to convey the idea that physical literacy is an asset that will benefit individuals in all aspects of life, even after they leave the university."
214415937|NCT06140680|BEHAVIORAL|Physical education|The control group received 12-week traditional physical education lesson as usual.
214415938|NCT03087539|BIOLOGICAL|Abciximab|
214415939|NCT03087539|BIOLOGICAL|Placebo|
214415940|NCT02064569|GENETIC|GS010|
214415941|NCT06230874|BEHAVIORAL|HOME Protocol|The HOME Protocol is a newly developed nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Five components of the HOME Protocol include Reflect (1 minute of self-reflection and self-talk), Reset (2 minutes for breathing with stillness/silence and body check), Reach (3 minutes for stretching and progressive muscular relaxation), Renew (2 minutes for breathing with meditation/gratitude), and Re-engage (1 minute for self-reflection and self-talk).
214415942|NCT06230874|BEHAVIORAL|Control Journaling Protocol|The control journaling protocol is a nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness self-talk and journaling strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Three components of the control journaling protocol include Reflect (1 minute of self-reflection and self-talk), Write (journaling), and Re-engage (1 minute for self-reflection and self-talk).
214415943|NCT06337110|DRUG|Lu AF28996|Oral solution containing radiolabelled \[14C\]-Lu AF28996.
214415944|NCT06409637|DRUG|FOLFOX4 regimen|FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2; 5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours. Each cycle lasts for 4 weeks, repeated every 4 weeks for a total of 6-8 cycles.
214415945|NCT06409637|DRUG|lenvatinib|Lenvatinib: For patients with a body weight \<60 kg, the recommended daily dose of lenvatinib is 8 mg (2 capsules of 4 mg each), once daily; for patients with a body weight ≥60 kg, the recommended daily dose of lenvatinib is 12 mg (3 capsules of 4 mg each), once daily. Treatment should be continued until disease progression, intolerable adverse effects, or the end of the study.
214415946|NCT01466881|DRUG|Alisertib|Given PO
214415947|NCT01466881|OTHER|Laboratory Biomarker Analysis|Correlative studies
214415948|NCT01466881|OTHER|Pharmacological Study|Correlative studies
214415949|NCT00130741|DRUG|CHT - herbal therapy|
214415950|NCT01228448|PROCEDURE|PET scan|In-Room PET scan
214415951|NCT03496649|DRUG|Dysport 500 Unit Powder for Injection|Dysport administered by intramuscular injection
214415952|NCT00130780|DRUG|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
214415953|NCT00130780|DRUG|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
214415954|NCT02817217|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
214689511|NCT04156997|OTHER|No intervention is involved in this study|No intervention is involved in this study
215017731|NCT01429623|DRUG|Placebo|Placebo comparator
215017732|NCT03831555|BEHAVIORAL|PREP-C|"The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:~1. Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment~2. Information: knowledge about HCV treatment and one's own HCV disease status~3. Medication Adherence: current prescribed medications and adherence to them in the prior month~4. Self-efficacy: self-confidence about adhering to HCV treatment~5. Social Support and Stability: stability of financial, housing, and social support resources~6. Alcohol and substance use: alcohol and substance use behaviors and current treatment~7. Psychiatric Stability: current psychiatric status, previous and current treatment~8. Energy Level: sleep and fatigue~9. Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory."
214415955|NCT02817217|DRUG|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
214415956|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.~The focus group to last from 60 to 90 minutes."
214415957|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.~We expect the focus group to last from 60 to 90 minutes."
214415958|NCT00662324|BEHAVIORAL|focus groups|"MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.~Expect the focus group to last from 60 to 90 minutes."
214415959|NCT04590924|PROCEDURE|Hip arthroscopy|Patients that had hip arthroscopic surgery 5 years ago will be invited for 5 year follow up. The surgical procedures consisted of femoral osteoplasty, labral refixation and acetabular osteoplasty
214415960|NCT03835572|OTHER|CircaHealth: a course on circadian rhythms and health|Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.
214415961|NCT03835572|OTHER|Sleep hygiene materials|Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
214415962|NCT03015454|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
214415963|NCT03015454|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
214415964|NCT03812003|DRUG|Remifentanil|remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
214415965|NCT02960139|DEVICE|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
214415966|NCT01065636|BEHAVIORAL|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
214415967|NCT01065636|BEHAVIORAL|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
214415968|NCT01065636|BEHAVIORAL|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
214415969|NCT02964429|DEVICE|Diacap Pro High-Flux|During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
214415970|NCT00234377|DRUG|Seroquel SR|
214689512|NCT05398003|DEVICE|Implantation of the WAVEWRITER ALPHA ™ device|"The 12 patients will be implanted by the WAVEWRITER ALPHA ™ device. Then, the order of the three stimulation modes will be randomly selected and will be composed of 5 modalities:~* tonic stimulation LF: In tonic mode, the electrical stimulation of the sensory fibres of the posterior cords of the spinal cord induces local paresthesias~* high frequency stimulation (1000 Hz) High Frequency.~* stimulation in bursts (or Burst)"
214689513|NCT02846376|DRUG|Nivolumab|Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
214689514|NCT02846376|DRUG|Ipilimumab|Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
214689515|NCT02085239|DRUG|Lidocaine Ropivacaine|"* 8-10 ml of Lidocaine given by subcutaneous injection~* 8-10 ml of Ropivacaine given by subcutaneous injection"
214689516|NCT02085239|DRUG|Lidocaine alone|
215017733|NCT05714228|PROCEDURE|Surgical Mitral Valve Repair|Mitral valve is repaired using open surgical approach
215017734|NCT05714228|PROCEDURE|Transcatheter Mitral Valve Repair|Mitral valve is repaired using Mitraclip transcatheter device
215017735|NCT02217553|DRUG|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
214689517|NCT03697928|OTHER|Exercise metabolism|Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
214689518|NCT03965663|DEVICE|Vibro-tactile Feedback|The device measures the force between the prosthetic food and the ground. With this signals, vibratators are triggered. The vibrators are housed by the prosthetic socket and stimulate the stump.
214689519|NCT02004912|OTHER|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
215017736|NCT01834651|DRUG|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
215017737|NCT00004931|DRUG|leucovorin calcium|Given IV
214689520|NCT06335121|BEHAVIORAL|POWER Up strategies -|Clinics will implement adapted POWER Up intervention strategies when a patient is flagged as PrEP eligible.
215017738|NCT00004931|DRUG|fluorouracil|Given IV
215017739|NCT00004931|DRUG|oxaliplatin|Given IV
215017740|NCT00004931|OTHER|laboratory biomarker analysis|Correlative studies
215017741|NCT02728726|DRUG|Sugammadex|Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
214689521|NCT01353833|DRUG|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
214689522|NCT05344508|DRUG|Brensocatib|Brensocatib tablets
215017742|NCT02728726|DRUG|Placebo|Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
215017743|NCT01169909|DRUG|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
215017744|NCT03556280|DEVICE|GammaSense Stimulation System (Active Settings)|Proprietary auditory and visual sensory stimulation device.
215017745|NCT03556280|DEVICE|GammaSense Stimulation System (Sham Settings)|Proprietary auditory and visual sensory stimulation device.
215017746|NCT01060969|DRUG|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
214415971|NCT00190216|DEVICE|Magnetic stimulator|
214415972|NCT05784155|DRUG|Test Drug(JW0302) or Reference Drug(C2206)|"Test Drug: single administration of JW0302 Reference Drug: single administration of C2206~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
214415973|NCT06314256|BIOLOGICAL|Injection|İnterdental papilla will be injected by i-PRF.
214415974|NCT06314256|DRUG|Injection|Interdental papilla will be injected by Tesoyal PureSense Glabal Action HA gel.
214415975|NCT00288964|DEVICE|Hattler Respiratory Assist Catheter|
214415976|NCT01134575|DRUG|CMC-544 (Inotuzumab Ozogamycin)|"First patients \> 16 years and \< 16 years receive CMC-544 at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2."
214415977|NCT01134575|DRUG|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m\^2 IV (by vein) over 2-6 hours every 3-4 weeks.
214415978|NCT02047461|DRUG|ORGN001 (formerly ALXN1101)|IV infusion
214415979|NCT01970943|OTHER|Placebo|Placebo will be compared to No Intervention.
214415980|NCT05415930|OTHER|Psychosocial assistance|Firs evaluation at Acceptess-T locals by a health mediator specialised in transidentity : advice for administrative procedures (health insurance, residency permit, housing, etc.) management of others social issues Orientation to Acceptess-T sexual health space for medical evaluation Orientation to Acceptess-T mental health space if needed : special focus on sexual health and gender related issues
214415981|NCT05415930|OTHER|Medical care|Sexual health clinics at Acceptess-T health space First STI risk evaluation: HIV, HCV, HBV, syphilis TROD realisation Spanish speaking Infectious Diseases (ID) specialist (from ID Department of Bichat hospital) first evaluation Proposition of PrEP if indicated Orientation for hospital follow-up in dedicate PrEP clinics Prescription and follow-up of a feminazing hormonal therapy if needed
214415982|NCT05415930|OTHER|Legal-Administrative Assistance|Legal counselling, provided by a sex worker union representative Access to FAST (fond action social trans) which give an economic help to TW in high precarity situations
214689523|NCT01180374|DRUG|Cannabidiol|Active Cannabidiol 5mg.
214689524|NCT01180374|DRUG|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
214689525|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
214689526|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
214689527|NCT00461266|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
215017747|NCT01060969|DRUG|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
215017748|NCT00793611|BEHAVIORAL|Behavioral therapy standard of care|controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
215017749|NCT00793611|OTHER|hypnotherapy|Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
215017750|NCT02256800|GENETIC|UGT1A1 genotyping (6,6)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2."
215017751|NCT02256800|GENETIC|UGTIA1 genotyping (6,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2."
214689528|NCT00461266|DRUG|Antiretroviral therapy|As prescribed
214689529|NCT03501706|BEHAVIORAL|Sequenced Recall of Digits--Auditory|Auditory digit sequence AT memory component.
214689530|NCT03501706|BEHAVIORAL|Sequenced Reverse Recall of Digits--Auditory|Reversed auditory digit sequence AT memory component.
214689531|NCT03501706|BEHAVIORAL|Sequenced Recall of Words--Visual|Visual word sequence AT memory component
214415983|NCT05415930|OTHER|Focus Group|"A group of 10-15 TW, identified through convenience sampling, along with the Acceptess-T Health Space multidisciplinary team will be invited to participate in an Human Centered Design (HCD) project.~The project will be led by a team of anthropologists and sociologists and exchanges will be recorded and fully transcribed and analysed by a person competent in qualitative methodology.~The objective will be to co-create tailored solutions that meet the needs of TW and are viable to implement within the health system, so TW can be better managed The solutions ideated will work synergistically towards improving TW PrEP access and adherence and health system retention.This is an adaptative program : if new solutions to face PrEP barriers are created during the study follow-up, new mesures will be added to the intervention."
214415984|NCT03078920|DEVICE|Naída CROS|At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
214415985|NCT06378372|BEHAVIORAL|Music therapy based on piano learning|The intervention will consist of pianistic training. Patients will receive piano classes adapted to their competence designed to achieve motor, sensory and behavioral control.
214415986|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
214415987|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
214415988|NCT05711498|OTHER|Transcutaneous spinal direct current stimulation (tsDCS)|tsDCS will be carried out using a direct current stimulator (DC-Stimulator Plus, neuroConn, Ilmenau, Germany), with one electrode placed above the thoracic spinal cord and the other electrode placed on the right shoulder. We will employ rectangular electrodes of 7 x 5 cm size (neuroConn, Ilmenau, Germany) covered by electrode paste (Ten20 Conductive Paste, Weaver and Company, Aurora, USA). Stimulation will consist of the following phases: a fade-in period of 15 seconds, a plateau period of 20 minutes (with stimulation at 2.5mA either anodally or cathodally) and a fade-out period of 15 seconds. Sham stimulation will follow the anodal montage with 15-second fade-in and fade-out periods, but only 45 seconds of plateau stimulation at 2.5 mA. Such a combination of stimulation and electrodes results in a current density of 0.071mA/cm2, well below thermal and histological limits for current density.
214415989|NCT03092440|OTHER|serious game|"During three hours, each learner will play with the three different cases of the LabForGames Warning serious game."
214415990|NCT02588482|DEVICE|high-density electroencephalography|Auditory stimulations during electroencephalography recording
214415991|NCT02588482|DEVICE|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
214415992|NCT01429779|DRUG|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
214415993|NCT03047590|BEHAVIORAL|Choice-based Exercise Intensity|Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.
214415994|NCT03047590|BEHAVIORAL|Positive Affect Focus|Participants are instructed to focus on feeling good while exercising.
214415995|NCT03047590|BEHAVIORAL|Heart rate-based Exercise Intensity|Participants are instructed to regulate their exercise intensity based on their heart rate.
214689532|NCT03501706|BEHAVIORAL|Verbal Memory--Visual|word recognition AT memory component
214689533|NCT03257072|BIOLOGICAL|50 Necator americanus L3 larvae|1x50 Necator americanus L3 larvae
214415996|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
214415997|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
214415998|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
214689534|NCT03257072|BIOLOGICAL|100 Necator americanus L3 larvae|2x50 Necator americanus L3 larvae
214689535|NCT03257072|BIOLOGICAL|150 Necator americanus L3 larvae|3x50 Necator americanus L3 larvae
214689536|NCT00398541|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
215017752|NCT02256800|GENETIC|UGTIA1 genotyping (7,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2."
215017753|NCT02256800|GENETIC|UGT1A1 non-genotyping|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks."
215017754|NCT02256800|DRUG|bevacizumab (Avastin)|bevacizumab as target therapy
215017755|NCT02256800|DRUG|irinotecan|irinotecan as escalating dose according to UGT1A1 genotyping
215017756|NCT02256800|DRUG|Leucovorin|combined with 5-FU
215017757|NCT02256800|DRUG|5-FU|combined with irinotecan
215017758|NCT02597361|DRUG|Irbesartan|Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
215017759|NCT02597361|DRUG|Placebo|Placebo o.d. to match 150mg or 300mg irbesartan tablets
215017760|NCT03944005|PROCEDURE|Spinal Anesthesia + ACB continious catheter + iPACK + Sham LIA|"ACB - On identification of adductor canal,10ml ropivacaine 0.5% with 1:400,000 epinephrine will be injected to surround the femoral artery.Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr 0.2% ropivacaine will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of femoral condyle and popliteal artery, 20ml ropivacaine 0.5% with 1:400,000 epinephrine will be infiltrated in muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients in Group 1 will receive local infiltration 100ml of normal saline around the knee capsule of 100ml of normal saline by the surgeons as a Sham injection."
214415999|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 1\*10\^11 viral particles (vp).
214416000|NCT02325050|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline.
214416001|NCT05674370|DEVICE|GRIP Electronic Diagnostic Chip|Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab
214416002|NCT05674370|DIAGNOSTIC_TEST|Laboratory-based nucleic acid amplification tests (NAATs)|Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab
214416003|NCT02780947|PROCEDURE|Ventricular tachycardia substrate ablation|"Study protocol~1. Baseline programmed ventricular stimulation performed from the LV~2. High density endocardial LV mapping using CARTO® 3 System~3. Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~4. Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
214416004|NCT01710514|DRUG|FE 999913 vaginal tablet|
214416005|NCT03368378|PROCEDURE|Early DVC ligation|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
214416006|NCT04601311|BEHAVIORAL|Guided self-determination|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.~A relative may take part in one session completing an analogue reflection sheet as preparation.~Participants continue usual care."
214416007|NCT04601311|BEHAVIORAL|Personal support in goal-pursuing|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.~Participants continue usual care."
214416008|NCT02265731|DRUG|azacitadine|75 mg/m2 by IV infusion or subcutaneous dosing
214416009|NCT02265731|DRUG|venetoclax|Step-up doses of venetoclax to the designated cohort dose
214416010|NCT02265731|DRUG|rituximab / IDEC-C2B8|375 mg/m2 on Week 6
214416011|NCT02265731|DRUG|rituximab / IDEC-C2B8|500 mg/m2 Week 10 Day 1 and thereafter
214416012|NCT02005666|DRUG|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
214416013|NCT02005666|DRUG|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
214416014|NCT02005666|DRUG|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
214416015|NCT04975243|DEVICE|GentleMax Pro Plus 755nm and 1064nm laser system|The GentleMax Pro Plus is a 755nm and 1064nm laser system. The GentleMax Pro PlusTM is indicated for stable long-term or permanent hair reduction using varying spot sizes and fluences.
214416016|NCT01909232|DEVICE|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
214416017|NCT01909232|DEVICE|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
214505481|NCT06507189|OTHER|Combined endurance and resistance training|ET will consist of 3x/wk training (MWF) with MF being steady state cycling, treadmill, or elliptical at 70-75% HRR for 30 min and the W session being a 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) targeting 85-90% HRR. The treadmill and elliptical on M or F will be provided for variety but the mainstay will be cycle ergometry. On MF participants will complete 3 sets x 8-12 repetitions for leg press, knee extension, hamstring curl, chest press, seated row, overhead press, lat pulldown, triceps push-down, and biceps curl in superset fashion \[i.e., alternate between opposing muscle groups without rest (chest press followed by seated row)\] with a 60 s rest between supersets. Sets will be performed with load progression to ensure volitional fatigue in the 8-12 rep range. Core exercises (trunk flexion and extension) will also be included using bodyweight only for 3 sets.
214505482|NCT02224105|DRUG|BI 653048 BS|
214416018|NCT05465811|OTHER|Program of physical exercises and health education by telerehabilitation|"To carry out the telerehabilitation program, the Google Meet platform will be used in order to provide the synchronous service model. This will occur for a period of 16 weeks, three weekly sessions lasting 50 minutes, (total of 48 sessions). The sessions will be given by physiotherapists and students in their final year of graduation in physiotherapy, which will consist of the following phases: initial rest, warm-up, resistance exercises, stretching exercises, relaxation and final rest.~In addition, in exchange for the warm-up phase, every 12 sessions, the telerehabilitation program also will have an approach through health education, using presentations, digital booklets and direct conversation between therapist and participants. The themes exhibited (importance of physical exercise in the pandemic context, reduction of the risk of falls through changes in the home environment and physiological changes resulting from aging) will intend to make them aware of better lifestyle habits."
214416019|NCT02186405|DRUG|LEVOTHYROXINE|administration of levothyroxine
215017761|NCT03944005|PROCEDURE|Spinal Anesthesia + LIA + Sham Blocks|"ACB - On identification of adductor canal, 10ml of saline as a sham solution will be injected to surround the femoral artery. Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr of saline will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of the femoral condyle and popliteal artery, 20ml of saline will be infiltrated in the muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following the nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine injected at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients will receive local infiltration by the attending surgeon intraoperatively with 300mg of ropivacaine (100ml of 0.3% ropivacaine),30 mg of ketorolac, and 10mg of morphine around the knee capsule."
214416020|NCT02916719|DEVICE|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
215101870|NCT06358092|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|HVPG is a measurement used to assess portal hypertension, a condition characterized by increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. HVPG measurement involves inserting a catheter into the hepatic vein via jugular vein puncture to directly measure the pressure within the liver. By comparing the pressure in the hepatic vein with that in the portal vein, HVPG provides valuable information about the severity of portal hypertension and helps in predicting clinical outcomes in patients with liver cirrhosis and related conditions. HVPG measurements are crucial in guiding treatment decisions, assessing treatment response, and predicting the risk of complications such as variceal bleeding and liver failure.
215101871|NCT06358092|DIAGNOSTIC_TEST|Two-Dimensional Shear Wave Elastography|2D-SWE is a non-invasive imaging technique used to assess tissue stiffness, particularly in the liver. This technology utilizes ultrasound to generate shear waves within the tissue being examined. By measuring the speed of these shear waves as they propagate through the tissue, 2D-SWE can provide quantitative information about tissue elasticity or stiffness. In the context of liver disease, including cirrhosis and fibrosis, 2D-SWE is valuable for evaluating the degree of liver stiffness, which correlates with the severity of liver fibrosis. This information aids in diagnosis, staging, and monitoring of liver diseases, allowing for early detection of complications and assessment of treatment response. Compared to traditional biopsy-based methods, 2D-SWE offers the advantage of being non-invasive, rapid, and repeatable, making it a preferred modality for assessing liver stiffness in clinical practice.
214416021|NCT02520570|DRUG|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
214416022|NCT05905406|OTHER|Electrical estimulation|Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec
214416023|NCT02155829|DRUG|Riluzole|
214416024|NCT02155829|DRUG|Placebo (for Riluzole)|
214416025|NCT05701592|PROCEDURE|DB-PCLR|DB-PCLR with reconstruction of both PCL bundles: anterolateral and posteromedial bundle will be performed.
214416026|NCT06421688|DRUG|Ascorbic acid|After participants underwent induction of anesthesia, Ascorbic acid (Vitamin C Injection) was administered at a dosage of 50 mg/kg, diluted to 50 ml using saline, with a total amount not exceeding 4 g; pumping was performed using a micro pump at a rate of 25 ml/h.
214416027|NCT06421688|DRUG|Saline|After participants underwent induction of anesthesia, 50 ml of saline was used and pumped using a micro pump at a rate of 25 ml/h.
214416028|NCT04570644|DRUG|ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)|"Drug : ALZT-OP1a~1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~ALZT-OP1b anti-inflammatory~Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study."
214416029|NCT00759837|DRUG|Bosutinib|
214416030|NCT02303444|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
214416031|NCT02303444|DRUG|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
214505483|NCT02224105|DRUG|Prednisolone low|
214505484|NCT02224105|DRUG|Prednisolone high|
214505485|NCT02224105|DRUG|Placebo|
214505486|NCT02224105|DRUG|sodium chloride infusion|
214505487|NCT02224105|DRUG|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|
214416032|NCT01919697|DRUG|Plecanatide|
214416033|NCT01760044|DEVICE|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
214416034|NCT03960983|DEVICE|Treatment with tongue scraper|Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.
214505488|NCT02983266|DEVICE|InTENsity MicroCombo|An electrotherapy device.
214505489|NCT00346320|RADIATION|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
214505490|NCT04493359|DRUG|Renin-angiotensin system inhibitors|switch anti-hypertensive class
214505491|NCT01683409|DRUG|Baricitinib|Administered orally
214505492|NCT01683409|DRUG|Placebo|Administered orally
215017762|NCT03592992|DRUG|Spinal Hydromorphone|75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
215101872|NCT02924740|BEHAVIORAL|Pelvic Floor Muscle Training|Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
214689537|NCT06555055|OTHER|CT trochlear thickness change|"Preoperative and postoperative CT scan measuring trochlear thickness of PFJ was defined as distance from deepest part of trochlea and line tangential to the anterior aspect of the femoral cortex. It was assessed on the sagittal cuts.~CT images will be viewed using Sante DICOM viewer version 5.4.2 and image fusion will be done using Overlay multiple image software.~Two observers will measure the angles and the intraobserver and interobserver reliabilities will be assessed for consistency by the intraclass correlation coefficient (ICC) and reliability coefficient using the SPSS software"
214689538|NCT02151006|DRUG|DHEA|
214689539|NCT05974735|BEHAVIORAL|Wellness trail|"Setting up wellness trails based on four distinct themes:~* Food, Nutrition and Micronutrition~* Physical activity~* Sleep~* Stress and well-being"
215017763|NCT03592992|DRUG|Spinal Morphine|150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
214505493|NCT04728841|GENETIC|Injection of GS001|"Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is \< 5 IU/dL.The dose levels are as follows:~1. 2×10\^12 vg/kg~2. 6×10\^12vg/kg or other recommended doses~3. 2×10\^13 vg/kg or other recommended doses"
214505494|NCT00076674|DRUG|Intravenous Levodopa|
214505495|NCT03118206|DEVICE|lumbar traction|
214505496|NCT03118206|PROCEDURE|spinal manipulation|
214505497|NCT03118206|PROCEDURE|surgery|
214505498|NCT05652868|DRUG|MYTX-011|MYTX-011 will be administered as an intravenous infusion every 21 days.
214505499|NCT06225570|DRUG|Isotretinoin|This arm aims to study the effectiveness, side effects and patient satisfaction of taking isotretinoin on a weekly basis as opposed to current standard daily dosing.
214505500|NCT06225570|DRUG|Tetracycline|This arm aims to serve as the comparison group. Tetracycline antibiotics are the current standard of care for the treatment of moderate acne.
214505501|NCT04823468|DIETARY_SUPPLEMENT|Abbott®Ensure|Abbott®Ensure: 55.8 g each time, three times a day, from the beginning to the end of radiotherapy
214505502|NCT04823468|RADIATION|Intensity Modulated Radiation Therapy|The prescribed dose was 68-76 Gy to Planning target volume of the primary tumor (PTVnx), 66-70 Gy to Planning target volume of the cervical lymph node (PTVnd), 60-64 Gy to planning target volume 1 (PTV1), and 50-54 Gy to planning target volume 2 (PTV2) in 30-33 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
214505503|NCT04823468|DRUG|cisplatin|80-100 mg/m² cisplatin given intravenously every 3 weeks concurrently with radiotherapy.
214505504|NCT06969833|OTHER|Constitution of a biological collection|"* Left-over tissue samples (tumor tissue of different nature) frozen and secured in paraffin, and derived from standard care, are collected at study entrance until the end of oncologic treatment.~* One blood sample of 28mL is collected at time of inclusion"
214505505|NCT06969833|OTHER|Assessment of Quality of Life and level of anxiety/depression|Questionnaires QLQ-C30, OV-28 and HADS are completed by the patients at inclusion, after 3 and 6 cycles of systemic treatment, and every 3 months up to 2 years after inclusion
214505506|NCT04218864|BEHAVIORAL|Strength for U in Relationship Empowerment (SURE)|A brief computer-based intervention (one session plus one booster session) based on motivational interviewing.
214505507|NCT04218864|BEHAVIORAL|Attention, time, and information matched control|A brief computer based intervention (one session plus booster session) that involves viewing of popular television shows
214505508|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
214505509|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
214505510|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
214505511|NCT01634789|DRUG|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
215017764|NCT06291961|GENETIC|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
215017765|NCT05446155|DIAGNOSTIC_TEST|Imaging|Diagnostic and prognostic imaging, omics and machine learning methods will be applied
215017766|NCT02334254|DRUG|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
214416035|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
214416036|NCT03960983|RADIATION|Photodynamic Therapy|Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step
214416037|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
214416038|NCT05095675|BEHAVIORAL|psychological questionnaires|Participants have to fulfill psychological questionnaires in different time points during medical oncological treatment
214416039|NCT06206473|OTHER|mEEG assessment|mEEG assessment (V1) will be performed at the patient's bed within 72 hours of the diagnosis of delirium. The mEEG recording, which lasts approximately 2 hours, will be performed by one of the investigators with expertise in electrophysiological acquisition. This non-invasive assessment consists of placing an EEG net on the scalp of the participants and earphones through which the auditory stimuli will be delivered.
215017767|NCT02334254|DRUG|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
215101873|NCT02924740|BEHAVIORAL|Vaginal Tampon Training|Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
214416040|NCT05333887|BEHAVIORAL|PFC+|Therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support. Emphasis throughout the program is placed on parents' connection and engagement with the material and therapist.
215101874|NCT01211314|DRUG|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
214416041|NCT01693965|OTHER|sputum samples|
214416042|NCT05318950|BEHAVIORAL|E-learning|8 lessons about nutrition and lifestyle
214416043|NCT05318950|DIETARY_SUPPLEMENT|Diet|Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
214416044|NCT01645852|DIETARY_SUPPLEMENT|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
214416045|NCT01234532|DRUG|entinostat|orally
214416046|NCT01234532|DRUG|anastrozole|Given PO
214416047|NCT01234532|OTHER|diagnostic laboratory biomarker analysis|"Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
214416048|NCT01234532|PROCEDURE|therapeutic conventional surgery|Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
214416049|NCT03678116|DRUG|Sugar Pill (placebo)|Taken orally in capsule form
214416050|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine and Cayenne)|Taken orally in capsule form
214416051|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine)|Taken orally in capsule form
214416052|NCT02886793|DRUG|fludeoxyglucose|
215017768|NCT05616780|OTHER|Physiological test|Lung volume measurements will be obtained using nitrogen washout and body plethysmography
215017769|NCT03154112|DEVICE|Measurement of oxygen consumption and caloric expenditure|This study will involve an \~1 hour, single point in time measurement of oxygen consumption, carbon dioxide production, resting energy expenditure, and respiratory quotient using two methods while patients are breathing an FiO2 of 40%. These measurements will be measured using the novel, responsive device and compared with gas collected simultaneously collected from a Douglas bag.
214416053|NCT00404794|DRUG|prednisolone and mycophenolate mofetil|
214416054|NCT00404794|DRUG|prednisolone and tacrolimus|
214416055|NCT06059820|OTHER|rehabilitation treatment|3-month immobilization period, hyperextension braces for specific fractures, therapeutic exercises, and gradual activity restoration.
214416056|NCT06059820|PROCEDURE|Spine fusion|Pedicle screw fixation or fusion; anterior plate fusion
214416057|NCT06204796|DRUG|vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case. In addition, a vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
214416058|NCT06204796|DRUG|Systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case.
214505512|NCT03506945|BEHAVIORAL|mPEP|Behavioral Activation Therapy
215017770|NCT03502772|OTHER|Pilates exercises|Clinical Pilates training program will be given one session in a week for 8 weeks plus two days home exercise program. Group exercise sessions will be performed. The sessions will be supervised by a physiotherapist who is certified.
215017771|NCT03502772|OTHER|Home exercise program|written exercises that matched the aims of the Pilates exercises, 3 times per week for 8 weeks. These exercises reflect routine clinical practice (flexibility, strength, and balance exercises).
215017772|NCT00948935|DRUG|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
215017773|NCT05099588|OTHER|Other: observational study|Observational study
215017774|NCT00183612|DRUG|Olanzapine|
214416059|NCT03939572|BEHAVIORAL|Accurate step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.
214416060|NCT03939572|BEHAVIORAL|Deflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count deflated by 40% (i.e., their step count multiplied by 0.6).
215017775|NCT04559672|PROCEDURE|Cervical laminoplasty surgery|The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation
215017776|NCT04559672|PROCEDURE|Cervical laminectomy and fusion surgery|The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
214416061|NCT03939572|BEHAVIORAL|Inflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count inflated by 40% (i.e., their step count multiplied by 1.4).
214416062|NCT03939572|BEHAVIORAL|Accurate feedback + mindset intervention|"After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.~Additionally, participants in this arm will receive a meta-mindset intervention in the first weekly survey on day 7, which consists of a series of videos and reflection exercises to teach participants about the power of mindsets and encourage them to choose adaptive mindsets that will benefit their health. There are also short booster reflection exercises in all subsequent daily and weekly surveys, reinforcing the message about adaptive mindsets."
214416063|NCT02377505|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on"
214416064|NCT02377505|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off"
214416065|NCT00290732|DRUG|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
214416066|NCT00290732|DRUG|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
214416067|NCT02087306|DRUG|Brincidofovir|BCV administered twice weekly, dose depending on weight.
214416068|NCT05420168|OTHER|Automatic tool to identify inappropriate antibiotic prescriptions|The system will identify inappropriate antibiotic prescriptions.
214416069|NCT02909699|OTHER|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
214416070|NCT00685893|BEHAVIORAL|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
215017777|NCT02526316|BIOLOGICAL|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16\_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
215017778|NCT02526316|BIOLOGICAL|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16\_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
215017779|NCT01061710|DRUG|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
215017780|NCT00885898|PROCEDURE|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
215017781|NCT00885898|PROCEDURE|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
215017782|NCT04431778|DRUG|Ethosuximide|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
215017783|NCT04431778|DRUG|Placebo|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
215017784|NCT04071483|PROCEDURE|Cervical transforaminal epidural steroid injection|Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.
214416071|NCT00685893|BEHAVIORAL|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
214416072|NCT00685893|BEHAVIORAL|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
214416073|NCT00685893|BEHAVIORAL|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
214416074|NCT00685893|BEHAVIORAL|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
214416075|NCT00684528|DRUG|Metformin 1500 mg daily|500 mg thrice daily
214416076|NCT00684528|DRUG|Metformin + Janufer (Janumet)|Titration up to 1500/150 mg daily
214416077|NCT00542386|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
214416078|NCT00542386|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
214416079|NCT02703155|DEVICE|Home Oral Glucose Tolerance Test kit|Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
214416080|NCT03269019|DIAGNOSTIC_TEST|HIT with thrombosis|Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
214505513|NCT03506945|BEHAVIORAL|Bibliotherapy|Provide educational material on coping strategies pertinent to caregivers
214505514|NCT01852006|DEVICE|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
214505515|NCT03000257|DRUG|Venetoclax|Tablet taken orally
215017785|NCT06032975|OTHER|Questionnaires|The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer
215017786|NCT06172049|OTHER|treatment|the actual treatment CRC patients have reveived
215017787|NCT05023174|PROCEDURE|Hiatal Hernia Repair with Platelet Rich Plasma|Platelet rich plasma will be injected into the crura of the diaphragm and coating the mesh placed during surgery.
215017788|NCT05023174|PROCEDURE|Hiatal Hernia Repair without Platelet Rich Plasma|Surgery will be performed without the addition of platelet rich plasma injection
215017789|NCT03757715|DRUG|Bupivacaine|20 mL of 1.3% bupivacaine
215017790|NCT03757715|DRUG|Dexamethasone|2 mg dexamethasone
214505516|NCT03000257|DRUG|Rovalpituzumab Tesirine|Intravenous infusion
214505517|NCT03000257|DRUG|ABBV-181|Intravenous infusion
214505518|NCT02804815|DRUG|Aspirin 100mg|Aspirin 100mg
215017791|NCT03156621|DRUG|Alirocumab|Alirocumab SC Q2W
215017792|NCT03156621|DRUG|Placebo|Matching placebo SC Q2W
215017793|NCT03087123|BEHAVIORAL|P-Mobile App|The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
215017794|NCT02533128|DRUG|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 60 mmHg
215017795|NCT02533128|DRUG|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 75 mmHg
215017796|NCT00337688|DEVICE|isometric joystick|isometric joystick
215101875|NCT01812512|BEHAVIORAL|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
215017797|NCT03065738|OTHER|tibial reduction osteotomy in total knee replacement|reduction osteotomy :downsizing of tibial tray with lateralization
215017798|NCT03302936|DRUG|Phenazopyridine|to be given preoperatively
215017799|NCT05571163|DRUG|AMG 510|Tablets
214416081|NCT00339469|DIETARY_SUPPLEMENT|LIFE|We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
214416082|NCT04897737|BEHAVIORAL|HIVST and enhanced adherence biofeedback|"The intervention includes the provision of an OraQuick HIV self-test (HIVST) for the woman and one test for each of her reported sex partners, along with instructions on how to use and interpret the results. Women were asked to report back within one month if their partner was able to test via a SMS, WhatsApp or by bringing in the test to confirm that he had tested.~Women then received adherence based feedback following the urine lateral flow assay (that measures recent tenofovir use in past 48 hours). Study counsellors requested that women provide a urine sample that was tested using the UrSure/Orasure test that provides feedback on the result in 2-3 minutes. Counselors provided counseling based on the results including how to improve daily adherence (for women without tenofovir present in their urine) and importance of condom use."
214416083|NCT04897737|DIAGNOSTIC_TEST|Orasure/UrSure test|See above
215017800|NCT00930332|DRUG|methadone hydrochloride|"Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)"
215017801|NCT00930332|OTHER|questionnaire administration|within 48 hours of registration
214416084|NCT00250562|DRUG|valsartan plus hydrochlorothiazide|
214416085|NCT00434018|BEHAVIORAL|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
214416086|NCT00434018|BEHAVIORAL|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
214416087|NCT06341491|BEHAVIORAL|Pé-de-Meia Program|"The Pé-de-Meia Program was established by the Brazilian Federal Government with the aim of encouraging the retention of low-income students in high school by providing maintenance scholarships and savings opportunities. To be eligible for the program, a young person must: Be properly enrolled in a regular public high school course, be between 14 to 24 years old, come from a low-income family, and be registered in the Bolsa Família Program. The Program offers four types of incentives:~An enrollment grant registered at the beginning of the academic year, paid once a year in the amount of 200 BRL.~A minimum school attendance of 80% of the total class hours, paid in nine installments throughout the year at 200 BRL each.~Proven participation in the National High School Exam (ENEM), paid once to the student enrolled in the third year of high school, in the amount of 200 BRL.~Completion of the high school academic years, paid in a single installment of 1,000 BRL."
214416088|NCT03930823|OTHER|Interview|One to one interview
214416089|NCT00057850|DRUG|cisplatin|
214416090|NCT00057850|DRUG|ixabepilone|
214416091|NCT00048828|DRUG|Olanzapine|Participants will receive olanzapine for 12 weeks.
214416092|NCT00048828|DRUG|Clozapine|Participants will receive 12 weeks of clozapine.
214416093|NCT03724838|DRUG|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day
214416094|NCT03724838|DRUG|Sildenafil Citrate|Patients will take Sildenafil Citrate 40mg every 8 hours
214416095|NCT03724838|DRUG|Placebo to Esomeprazole|Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day
214416096|NCT03724838|DRUG|Placebo to Sildenafil Citrate|Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
214416097|NCT00481234|DEVICE|Heart Rate Variability analysis|
214416098|NCT06187480|PROCEDURE|total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)|The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.
214416099|NCT05731648|DEVICE|Intrathecal balofen pump|Management of spasticity
214416100|NCT00937846|DRUG|GSK1034702|Single oral 5 mg dose in liquid formulation
215017802|NCT00930332|PROCEDURE|management of therapy complications|if required
215017803|NCT04299425|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
215017804|NCT06483217|BEHAVIORAL|Patient-directed follow up|Patients will be instructed to follow up for repeat injection based on bladder symptomatology at their own self-determined time interval.
215101876|NCT04956458|PROCEDURE|Lumbar motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
215101877|NCT04956458|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
215101878|NCT01137253|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
214416101|NCT00540202|DRUG|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
214416102|NCT00540202|DRUG|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
214416103|NCT05359224|DRUG|Prasugrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given prasugrel 5mg once. And aspirin 100mg and prasugrel 5mg will be maintained for 30 days.
215017805|NCT05447858|OTHER|SWEA|Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.
214416104|NCT05359224|DRUG|Clopidogrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given pletaal 100mg once. And aspirin 100mg and clopidogrel 75mg mg will be maintained for 30 days.
214416105|NCT05844748|OTHER|diabetes education with motivational interview technique|Techniques such as developing empathy, developing disengagement, turning with resistance, supporting self-efficacy, avoiding advice, a simple decision, importance-trust scale, open-ended questions, reflection and segmentation in motivational interviews.
215017806|NCT05447858|OTHER|Neck-specific exercise|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
215017807|NCT02350998|DRUG|OTO-201|
215017808|NCT00926705|DRUG|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
214416106|NCT02438124|BEHAVIORAL|Neuropsychological evaluation|The subjects are submitted in one hearing stimulus while they realize a walking test
214416107|NCT01191788|BEHAVIORAL|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
214416108|NCT01191788|BEHAVIORAL|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
214416109|NCT04081506|OTHER|Individualized perfusion targets|Targeting +/-5mmHg of the optimal mean arterial pressure
214416110|NCT03082430|BIOLOGICAL|autologous PRP.|one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
215017809|NCT00926705|DRUG|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
215017810|NCT01259024|DEVICE|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
215017811|NCT06361446|DRUG|Zonisamide 50 MG|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
215017812|NCT06361446|DRUG|Propranolol|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
215017813|NCT03403127|DIAGNOSTIC_TEST|PET/CT Scans|PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).
215017814|NCT05488353|DRUG|Disitamab Vedotin for Injection,Penpulimab Injection|"After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection."
215017815|NCT06497829|DIETARY_SUPPLEMENT|geranylgeraniol|GG Pure (Extendlife Natural Products) containing GG gold®30 Annatto Extract, 500 mg capsule, use for 3 months, once daily
215017816|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
215017817|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
214416111|NCT02559258|DRUG|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
214416112|NCT02559258|DRUG|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
214416113|NCT02559258|DRUG|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
214416114|NCT02559258|DRUG|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
215017818|NCT01657500|OTHER|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
214416115|NCT02559258|DRUG|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
214416116|NCT01456819|BIOLOGICAL|Mononuclear and mesenchymal stem cells|Intramuscular administration into the ischemic limb
214416117|NCT01456819|BIOLOGICAL|Mononuclear cells|Intramuscular administration into the ischemic limb
214416118|NCT00374699|DRUG|Velcade|
214416119|NCT02668263|PROCEDURE|Surgery alone|Surgery
214416120|NCT02668263|PROCEDURE|Surgery and Drain(s)|Drains inserted as per standard practice
214416121|NCT02668263|PROCEDURE|Surgery and Quilting Sutures|Quilting sutures to mastectomy flaps
214416122|NCT00931593|DEVICE|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):~* Subject selection~* Obtaining of written informed consent~Visit V1 (day 0):~* Fasting subject~* Randomization to determine the examination order~* Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~* Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study"
214416123|NCT06010888|DRUG|Fruquintinib+mFOLFOX6/FOLFIRI|Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard)
214416124|NCT01606163|BIOLOGICAL|GC1102|"1. Description: GC1102 IV bolus injection during 10\~ 30 seconds.~2. Amount: group1-3ml, group2-5ml, group3-8ml~3. Subject number: group1-8, group2-8, group3-8~4. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
214416125|NCT01606163|OTHER|JW normal saline|"1. Description: Normal saline IV bolus injection through 10\~ 30 seconds.~   * Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~2. Subject number: 9~3. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
215017819|NCT01657500|OTHER|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
215017820|NCT05792345|PROCEDURE|Transversus Thoracic Muscle Plane Block|The transversus thoracic muscle plane block It is most commonly performed following cardiothoracic surgeries (or any surgeries requiring sternotomy) to provide analgesia to the anterior chest wall. he TTMPB, and thoracic fascial plane blocks, are increasingly being employed as part of enhanced recovery after surgery (ERAS) protocols for cardiothoracic procedures. They have been shown to significantly reduce both the time to extubation and the incidence of acute and chronic perioperative pain
215017821|NCT05792345|PROCEDURE|Control|Infiltration by surgeon
215017822|NCT04817800|DRUG|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|It will be nasaly administered
214416126|NCT05379881|BEHAVIORAL|Common Elements Toolbox (COMET)|COMET is an unguided single-session intervention (SSI) combining elements of cognitive-behavioral therapy (CBT) and positive psychology.
214416127|NCT00607503|DRUG|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
214416128|NCT02596035|DRUG|Nivolumab|
214416129|NCT02066441|DIETARY_SUPPLEMENT|Bio-D-Mulsion Forte®|According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
214505519|NCT02804815|DRUG|Aspirin 300mg|Aspirin 300mg
214416130|NCT02066441|OTHER|Placebo|
214416131|NCT00855153|OTHER|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
214416132|NCT00855153|DRUG|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
214416133|NCT00929721|PROCEDURE|Blood draw|culture for Streptococcus pneumoniae Frequency-1
214416134|NCT00929721|PROCEDURE|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
214416135|NCT00929721|PROCEDURE|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
214505520|NCT02804815|DRUG|Placebo 100mg|Placebo 100mg
214505521|NCT02804815|DRUG|Placebo 300mg|Placebo 300mg
214505522|NCT03692845|PROCEDURE|Transforaminal Lumbar Interbody Fusion either open or minimally invasive|Spinal fusion procedure through the intervertebral foramen
215017823|NCT00631241|PROCEDURE|Single Photon Emission Computed Tomography|First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
215017824|NCT00631241|PROCEDURE|Intraoperative Lymphatic Mapping|Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
215017825|NCT02669641|DIETARY_SUPPLEMENT|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
215101879|NCT01137253|DRUG|Placebo|Response to intrabrachial vasodilators during IV saline infusion
215101880|NCT04029298|BEHAVIORAL|Lifestyle Interventions|Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
215017826|NCT04403126|OTHER|forgiveness education intervention|The forgiveness education intervention primarily teaches the concept of forgiveness through stories. We chose the kind of stories that should appeal to children ages 10 through 12. Each lesson is planned according to the following procedure: story-telling/movie-watching, discussion, and in-class activities.
214416136|NCT00929721|PROCEDURE|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
214416137|NCT00929721|PROCEDURE|sputum|culture for Streptococcus pneumoniae Frequency-1
214416138|NCT04956224|BIOLOGICAL|VLA2001|"whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain)~2 vaccinations 28 days apart~Booster Vaccination on Visit B1"
215017827|NCT03728231|OTHER|Complete blood count|taking blood sample from venous blood
214416139|NCT00956306|DRUG|Udenafil|100mg Single Oral Dose of Udenafil
215101881|NCT04190277|DEVICE|Open-loop condition|Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
215101882|NCT04190277|DEVICE|Closed-loop condition|Closed-loop algorithm system paired with continuous glucose monitoring sensor
215017828|NCT02998320|DRUG|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
215101883|NCT04619498|DEVICE|PediAppRREST|PediAppRREST is a new audiovisual interactive app for tablets developed to support the management of pediatric cardiac arrest. It sequentially displays directions on recommended management interventions. It was specifically designed to guide the team leader to perform resuscitation interventions in the sequence/timing and modality reported by the American Heart Association Pediatric Advanced Life Support (AHA-PALS) guidelines.
214416140|NCT06269536|OTHER|HRV biofeedback|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
214416141|NCT05230641|OTHER|No intervention|This is a prospective observational study
214416142|NCT05906225|PROCEDURE|EEG guided anesthesia|Monitoring of electroencephalogram via Sedline probe by MASIMO corporation. Adjust concentration of inhalational sevoflurane during anesthesia, according to component of slow\&delta wave and alpha wave, so that slow/delta oscillation (with or without alpha oscillation) is maintained.
214416143|NCT05906225|PROCEDURE|Conventional anesthesia|Adjust concentration of inhalational sevoflurane during anesthesia, according to vital signs, so that mean blood pressure and heart rate are maintained between 80% and 120% of baseline values measured at ward before anesthesia.
215017829|NCT02920047|DRUG|Fimasartan/Amlodipine|Treatment B
215017830|NCT02920047|DRUG|Fimasartan + Amlodipine|Treatment A
215017831|NCT00063362|DRUG|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
215101884|NCT04619498|OTHER|AHA-PALS pocket reference card|It is a 10 cm x 16.5 cm, full-color, 2-sided, 6-panel card that shows the American Heart Association Pediatric Advanced Life Support (AHA-PALS) treatment algorithms. By providing a quick reference tool, it serves as a cognitive aid for healthcare providers who either direct or participate in the management of pediatric respiratory and/or cardiovascular emergencies, including cardiac arrest.
215101885|NCT03094715|DEVICE|Thrombectomy|Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
215101886|NCT03094715|OTHER|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
214689540|NCT02407951|BEHAVIORAL|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians."
214416144|NCT01235949|BIOLOGICAL|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
214416145|NCT01235949|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses
214689541|NCT02407951|BEHAVIORAL|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians."
214689542|NCT01262300|BIOLOGICAL|Varicella Zoster Virus Vaccine (Zostavax)|Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
214689543|NCT04786873|DRUG|Macimorelin|Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.
215101887|NCT06136065|DIAGNOSTIC_TEST|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography scan
215101888|NCT00902174|DRUG|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
215101889|NCT00902174|DRUG|Placebo|Placebo to imatinib 100 mg film coated tablets
215101890|NCT00439036|BEHAVIORAL|Behavior Therapy|The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
214416146|NCT01235949|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
214416147|NCT01235949|DRUG|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
214416148|NCT01235949|DRUG|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
214416149|NCT01671241|DEVICE|Polyethylene wrap|
214416150|NCT01671241|DEVICE|Polyethylene wrap|
214416151|NCT04963049|OTHER|Protocol with Mask|Look at differences in group with facemask and no mask
215101891|NCT00439036|BEHAVIORAL|Drug Counseling|
214416152|NCT04173572|BEHAVIORAL|PACE-Life|PACE-Life Groups will occur twice per week for 15 minutes in the first two weeks, progressing to 30-minute walking sessions over the course of the intervention without changes in frequency. The intensity of virtual walks will increase throughout this intervention in a stepwise fashion to create an exercise dose response to maximize impact on CRF.
214416153|NCT04173572|BEHAVIORAL|Exercise Intervention|Data from Fitbit devices will be synced and accessed through Fitbit.com. Participants will be provided account information to view data but will be asked not to change any of the settings as the investigators will be using data for tracking steps/day and minutes spent walking.
214416154|NCT01105143|BEHAVIORAL|multimodal lifestyle intervention|multimodal lifestyle intervention will be performed to reduce body weight
214416155|NCT01105143|BEHAVIORAL|placebo|no intervention, only follow up
215101892|NCT02501200|DRUG|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
215101893|NCT02501200|DRUG|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
215101894|NCT01111279|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days, during 29 days.
215101895|NCT01111279|BIOLOGICAL|gpAST+TM/adjuvant|1 subcutaneous injection every 7 days, during 29 days
215101896|NCT01111279|BIOLOGICAL|Placebo solution|1 subcutaneous injection every 7 days, during 29 days
215101897|NCT02578173|DEVICE|AVERT PLUS|
215101898|NCT02488746|DEVICE|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
215101899|NCT02830620|OTHER|Dosage of chimiokines|
215101900|NCT01278082|DRUG|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
215101901|NCT01278082|DRUG|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
215101902|NCT00077649|DRUG|ribavirin [Copegus]|600mg po bid for 48 weeks
215101903|NCT00077649|DRUG|ribavirin [Copegus]|800mg po bid for 48 weeks
215101904|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|180 micrograms sc weekly for 48 weeks
215101905|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|270 micrograms sc weekly for 48 weeks
215101906|NCT03044184|DRUG|Tranexamic Acid|Transamine is an antifibrinolytic medication given systemically via the intravenous route
215101907|NCT02821364|OTHER|Advanced Life Support|IV FLUIDS, INTUBATION
215101908|NCT04448353|DIAGNOSTIC_TEST|vascuCAP|adverse event and phenotype classification model
215101909|NCT01174212|PROCEDURE|Prophylactic Antibiotics|Preoperative Antibiotics
215101910|NCT01174212|PROCEDURE|Control Antibiotics|Antibiotics will be held until intraoperative cultures have been obtained.
214416156|NCT02469337|DRUG|Dichloroacetate|Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria
214416157|NCT02469337|DIETARY_SUPPLEMENT|Carbohydrate drinks|preoperative carbohydrate drinks
214416158|NCT02469337|BEHAVIORAL|Moderate intensity exercise|30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
215017832|NCT00063362|DRUG|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
215017833|NCT00063362|DRUG|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
215017834|NCT00063362|DRUG|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
214416159|NCT06040333|OTHER|Exercise|Dynamic Neuromuscular Stabilisation Exercise
214416160|NCT06040333|OTHER|Standard therapy|Patient education, massage, diaphragmatic breathing, kegel exercise
214416161|NCT04807725|GENETIC|Analysis of genetic polymorphisms|For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).
214416162|NCT04807725|OTHER|Biochemical analysis|For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.
214416163|NCT01598636|PROCEDURE|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
214416164|NCT01839877|DRUG|HIA DEBIRI + systemic FOLFOX|
214416165|NCT06631040|BIOLOGICAL|anti CD19 CAR NK cells|Ten eligible patients with relapsed Acute Lymphoblastic Leukemia will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of anti-CD19 CAR NK cells with close monitoring using one of the following dose levels: • Dose Level 1: 1×10\^7/Kg • Dose Level 2: 5×10\^7/Kg • Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow International Lymphoma Party (LWP) Group guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease.
214416166|NCT04352452|PROCEDURE|laparoscopic surgery|differences in musculoskeletal and cognitive stress
214416167|NCT02158481|DIETARY_SUPPLEMENT|A capsule containing both polyphenols and carotenoids|
214689544|NCT04786873|DIAGNOSTIC_TEST|Arginine|For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.
215017835|NCT00470808|DRUG|POMx|
215017836|NCT04179656|DRUG|Pyrotinib|400 mg administered orally, once daily, continuously in 21 day cycles
215017837|NCT00808756|DIETARY_SUPPLEMENT|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
215017838|NCT00808756|OTHER|Standard infant formula.|Standard infant formula.
215101911|NCT00804934|DRUG|Lucentis|0.5mg Lucentis every four months
215101912|NCT03275948|OTHER|whole grain|whole grain rye
215101913|NCT03275948|OTHER|reference|white wheat bread
215101914|NCT06135610|DIAGNOSTIC_TEST|Postive SAR-CoV-2 PCR nasopharyngeal swab|Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
215101915|NCT00480870|DRUG|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
214416168|NCT02158481|DIETARY_SUPPLEMENT|Placebo intervention|Placebo intervention
215017839|NCT00619242|DRUG|sorafenib|2 tablets with water by mouth twice a day for two weeks.
215101916|NCT00480870|DRUG|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
215101917|NCT06050785|DRUG|Vancomycin|ACL graft will be soaked in vancomycin versus gentamycin
215101918|NCT02266212|PROCEDURE|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
215101919|NCT01272765|OTHER|Placebo|Placebo
215101920|NCT01272765|DIETARY_SUPPLEMENT|IHBG-10|500 mg IHBG-10
215101921|NCT02303106|DRUG|Lamotrigine|
215101922|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
215101923|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
215101924|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
215101925|NCT00774020|DRUG|Zoledronic acid|5mg, i.v. single dose
214416169|NCT03502278|BEHAVIORAL|Islamic Trauma Healing|A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles
214416170|NCT05211063|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
214416171|NCT05211063|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 42 days.
214416172|NCT05903066|PROCEDURE|Magnetic Resonance Enterography (MRE)|MRE performed as part of the standard of care follow up of the patient, the exam will be recorded for the study and analysed by central readers.
214416173|NCT01224678|DIETARY_SUPPLEMENT|vitamin D|Given orally
214416174|NCT01224678|OTHER|placebo|Given orally
214416175|NCT05108896|DIAGNOSTIC_TEST|3-Screenings Protocol|The 3-Screenings Protocol is a modified bedside swallow exam (BSE) consisting of a study developed five-item decision tree algorithm including voice quality assessment and a 2-ounce water consistency assessment, the Yale Swallow Test, with a scored 3-ounce Water Swallow Test (3-WST), and the Toronto Bedside Swallowing Screening Test (TOR-BSST).
215017840|NCT03102528|OTHER|No intervention|No intervention
215017841|NCT01250327|DEVICE|Melody|insertion of a pulmonic valved stent
215017842|NCT01250327|DEVICE|bare stent|insertion of a bare metal stent
215017843|NCT01250327|PROCEDURE|Surgery|conventional surgery methode
215017844|NCT05877365|DIETARY_SUPPLEMENT|Standard Process 21-Day Purification Program|Purification, also known as detoxification, may help remove natural toxins from the body, while maintaining a healthy weight. The toxin load humans are exposed to daily may take a toll on physical and emotional well-being. Internally, human bodies produce waste byproducts because of normal metabolic function. Although the body is designed to rid itself of these toxins naturally, it can become overburdened. Purification may offer the body additional support to expel these toxins and manage weight, which is important to maintaining health and vitality.
215017845|NCT06223009|DRUG|cNP8|cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
215017846|NCT06223009|OTHER|Placebo|Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo.
215017847|NCT03852693|OTHER|Histopathological review|Histopathological review
215017848|NCT02621853|DEVICE|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
215017849|NCT06641752|DIAGNOSTIC_TEST|Blood drop sampling|The process: blood drop sampling Technique: capillary sampling Frequency: Once Time: 5 minutes Sample collection volume: 1mL Total collection volume: 1 mL
215017850|NCT06367153|DRUG|BI 1569912|BI 1569912
215017851|NCT06367153|DRUG|repaglinide|repaglinide
215017852|NCT06367153|DRUG|midazolam|midazolam
215017853|NCT06367153|DRUG|bupropion|bupropion
215017854|NCT04797481|PROCEDURE|Exercise|Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.
215017855|NCT04797481|PROCEDURE|Self-managed exercise|Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
215017856|NCT06582771|DRUG|Sotorasib|Sotorasib 960 mg (8 pills) daily
215017857|NCT03133780|DRUG|Ketamine|Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
214416176|NCT05108896|DIAGNOSTIC_TEST|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
214416177|NCT05108896|DIAGNOSTIC_TEST|Tracheal Ultrasound|Ultrasound imaging of the trachea, measuring tracheal diameter and endotracheal tube (ETT) size ratio within 72 hours prior to extubation
214416178|NCT02687243|DEVICE|Interactive Virtual Application|Online application via tablet
215017858|NCT03133780|DRUG|Midazolam|Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
215017859|NCT06362642|DRUG|PC14586|First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.
215017860|NCT06362642|DRUG|Itraconazole|Antifungal treatment that is a potent inhibitor of CYP3A4.
215017861|NCT01595178|BEHAVIORAL|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
215017862|NCT06396403|OTHER|Collection of venous blood samples|collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL
215017863|NCT04284436|BEHAVIORAL|Treadmill walking|Treadmill walking 4 days per week for 30 minutes in the target heart rate
215017864|NCT05087680|BEHAVIORAL|ACTPrEP|ACTPrEP will include a 60-minute initial session and a series of 30-minute follow-up sessions. Sessions will focus on the Thoughts, Emotions, Associations, Memories, and Sensations (TEAMS) relevant to PrEP uptake and adherence.
215017865|NCT05087680|BEHAVIORAL|Enhanced Standard of Care|Enhanced Standard of Care (ESOC) will include one 30-minute PrEP education session.
215017866|NCT06083467|DIAGNOSTIC_TEST|Brain MRI Scan|MRI scan of the brain
215017867|NCT06083467|BEHAVIORAL|Neurologic exam|Neurologic exam and assessments, including video interview
215017868|NCT00986102|DRUG|doripenem|500mg vial by injection every 8 hours for 5 to 14 days
214416179|NCT05671198|DIAGNOSTIC_TEST|Ultrasound of the diaphragm|"Sonographic parameters of the diaphragm:~* Thickening Fraction (TF); (Diaphragm thickness end-inspiration- Diaphragm thickness end-expiration) / Diaphragm thickness end-expiration. (continuous variable).~* Diaphragm end-expiratory thickness: Diaphragm thickness at end-expiration (continuous variable)~* Diaphragm excursion (DE): diaphragm inspiratory amplitude during deep breathing (continuous variable)."
214416180|NCT05457491|BIOLOGICAL|Human platelet extract (cosmetic product)|A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
214416181|NCT05457491|OTHER|Vanicream Gentle Facial Cleanser|A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
214416182|NCT05457491|OTHER|EltaMD UV Daily Broad-Spectrum SPF 40|A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
214416183|NCT05457491|OTHER|EltaMD PM Therapy Facial Moisturizer|A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
214416184|NCT05457491|OTHER|Vanicream Lite Lotion|Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
215017869|NCT06083493|DEVICE|LIFUP excitation|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-excitation) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
215017870|NCT06083493|DEVICE|LIFUP inhibition|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-inhibition) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
214416185|NCT04536077|DRUG|CDX-301|The drug will be supplied free of charge by Celldex
214416186|NCT04536077|DRUG|CDX-1140|The drug will be supplied free of charge by Celldex
214416187|NCT04536077|PROCEDURE|Research blood draw|At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery
214416188|NCT05995782|DRUG|FB418|Oral dose
214416189|NCT05228860|BEHAVIORAL|Vida Sana (a Group Lifestyle Intervention)|"Vida Sana is a Group Lifestyle intervention that has been shown to be effective among patients with type 2 diabetes (T2DM). Vida Sana includes 23 group sessions with a trained health coach:~* Months 1-4: 1 family-wide orientation + 12 weekly sessions~* Months 5-6: 4 bimonthly group sessions~* Months 7-12: 6 monthly group sessions~All regular primary care and diabetes care will remain as usual."
214505523|NCT03511612|DIAGNOSTIC_TEST|Measure ankle brachial index (ABI)|This is a head-to-head comparison of 2 methods of determination of the ABI, taking the Doppler method as the standard and the oscillometric device AVP as the challenger
214505524|NCT02568553|BIOLOGICAL|Blinatumomab|Given IV
214505525|NCT02568553|DRUG|Lenalidomide|Given PO
214505526|NCT04784715|DRUG|Trastuzumab deruxtecan|Administered by intravenous infusion
214416190|NCT05228860|BEHAVIORAL|Supplemental Healthy Food Deliveries|"Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)"
214416191|NCT03356483|DRUG|Psilocybin (0.25mg/kg)|Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
215017871|NCT06633666|DEVICE|Acupuncture|"1. Fatigue Principal points: Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Baihui (GV 20), Guanyuan (RN 4), Zusanli (ST 36), Sanyinjiao (SP 6)~2. Anxiety/ depression Principal points: Yintang (EX-HN3), Baihui (GV 20), Taichong (LR 3), Neiguan (PC 6), Danzhong (RN 7)~3. Cognitive impairment/ memory loss Principal points: Baihui (GV 20), Sishencong (EX-HN1), Fengfu (GV 16), Taixi (K 13), Xuanzhong (GB 39), Zusanli (ST 36)~4. Insomnia Principal points: Zhaohai (K 16), Shenmai (BL 62), Shenmen (HT 7), Sanyinjiao (SP 6), Anmian (EX-HN22), Sishencong (EX-HN1)"
215017872|NCT02060188|DRUG|Ipilimumab|Specified dose on specified days
214416192|NCT03356483|DRUG|Niacin (250mg)|A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.
215017873|NCT02060188|DRUG|Nivolumab|Specified dose on specified days
214416193|NCT00362843|DRUG|[15-O]water|
214505527|NCT04784715|DRUG|Placebo|Administered by intravenous infusion
214505528|NCT04784715|DRUG|Taxane|Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
214505529|NCT04784715|DRUG|Pertuzumab|Administered by intravenous infusion
214505530|NCT04784715|DRUG|Trastuzumab|Administered by intravenous infusion
214505531|NCT02674841|OTHER|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
214505532|NCT02674841|OTHER|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
214505533|NCT02674841|OTHER|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
214505534|NCT01227421|DRUG|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
214505535|NCT01227421|DRUG|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
214505536|NCT01227421|DRUG|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
214505537|NCT02847520|BEHAVIORAL|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
215017874|NCT02060188|DRUG|Cobimetinib|Specified dose on specified days
215017875|NCT02060188|DRUG|Daratumumab|Specified dose on specified days
215017876|NCT02060188|DRUG|BMS-986016|Specified dose on specified days
214416194|NCT05484726|OTHER|perioral sensory motor stimulation|"Step 1 - 6 over 5 minutes~1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek~2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek~3 Move index finger from one corner to opposite one over both lips separately 7x each lip~4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum~5 Move the finger from front to back on the hard palate while applying gentle pressure 7x~6 Displace the center of the tongue with gentle pressure 7x~7 Offer pacifier at the end 2 minutes~Note: 7x means 7 times"
214416195|NCT04415112|BEHAVIORAL|Mediterranean Diet|A list of foods high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, moderate consumption of fish and poultry and low consumption of full fat dairies, red meat and its products and homemade sweets.
214416196|NCT04415112|BEHAVIORAL|Low Fat Diet|These children are forbidden to eat high-fat foods such as fried foods, butter, cream cheese, while foods such as fruits, vegetables (starchy and non-starch), cereals, poultry, lean meat and low-fat dairy products are allowed.
214416197|NCT02824432|DRUG|TAK-085|TAK-085 capsules
214416198|NCT05511454|OTHER|Salivary and crevicular samples|The samples will be taken from patients in both groups who meet the selection criteria during consultations at the Montpellier University Hospital's Odontology Department. During these consultations, a sample will be taken after rinsing the oral cavity with a glass of water. The samples will be taken before the periodontal assessment in order to avoid bleeding.
214416199|NCT00554801|PROCEDURE|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
214416200|NCT01521585|DRUG|SEN0014196|50 mg oral once daily tablet
214416201|NCT01521585|DRUG|SEN0014196|200 mg oral once daily tablet
214416202|NCT01521585|DRUG|Placebo|oral once daily tablet
214416203|NCT03143192|COMBINATION_PRODUCT|Micropulse Laser|Aflibercept injection with Micropulse laser.
214416204|NCT03143192|DEVICE|Sham Laser|Aflibercept injection with Sham Laser
214416205|NCT04658615|PROCEDURE|Non-surgical periodontal therapy|A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
214416206|NCT01413594|BEHAVIORAL|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
214416207|NCT04436120|PROCEDURE|De novo tumor tissue biopsy|De novo tissue biopsy performed following disease progression
214416208|NCT04436120|PROCEDURE|Research blood draws|Blood biospecimens collected following disease progression
214416209|NCT05724173|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
214416210|NCT03185663|OTHER|traction-stuck|continuous pulling method: tensile force is exerted directly on the skin by means of adhesive strips, connected to weight
214416211|NCT03185663|OTHER|a pillow between the legs|setting up a pillow between the legs before the care
214416212|NCT04313452|OTHER|the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged|to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
214416213|NCT04797533|DEVICE|The Body Information Management Systems (BIMS)|"The Body Information Management Systems (BIMS) are advanced biological sensors which monitor human behaviour, activity and basic vital signs. There is a combination of four separate ultra-sensitive weighing scales attached to each of the individual legs of a hospital bed measuring:~* Micro-changes in weight distribution~* Activity/sleep pattern~In addition to the bed-based system, there will be a wrist worn wearable (Samsung fit gear) that will monitor participants when they are both in and out of bed. These are about the size of a small watch, light weight, water resistant, and will be worn 24/7 by participants. These measure:~* Movement and sleep~* Heart rate"
214416214|NCT01151033|DEVICE|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
214416215|NCT03593291|DIAGNOSTIC_TEST|Anti Xa|Levels of Anti Xa measure
214505538|NCT03395600|DRUG|B1S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
215017877|NCT04578418|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Hydrolyzed collagen supplementation twice daily
215017878|NCT04578418|OTHER|Heavy slow resistance training|Heavy slow resistance training 3 times weekly
215017879|NCT04578418|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation twice daily
215017880|NCT05887661|PROCEDURE|hypovolemic phlebotomy|hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
215017881|NCT06636851|DEVICE|Pacemaker and defibrillator|Permenant pacemaker implantation with lead fixed to the RV Septal location
215017882|NCT06636851|DEVICE|Pacemaker and defibrillator|Description: Permenant pacemaker implantation with lead fixed to the RV Apical location
215017883|NCT06642987|DRUG|Vonoprazan Test 20mg|1 tablets orally once a day
215017884|NCT06642987|DRUG|Vonoprazan Reference 20mg|1 tablets orally once a day
215017885|NCT06644872|OTHER|Bedrest|Investigation of the effect of short-term bed rest (3 hours) on heart function, measured by cardiac magnetic resonance, in healthy participants ( males and females)
215017886|NCT01932463|DEVICE|ExAblate Transcranial System|MR Guided Focused Ultrasound
215017887|NCT03093870|DRUG|Varlitinib|Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
215017888|NCT03093870|DRUG|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
215017889|NCT03093870|DRUG|Placebo (for Varlitinib)|oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
215017890|NCT01660685|BEHAVIORAL|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
214416216|NCT06359054|DIAGNOSTIC_TEST|18F FDG PET/CT|"18F-FDG PET/CT Imaging: Preparation: Participants will be instructed to fast for at least 6 hours before the procedure to ensure low insulin levels and high FDG uptake by cancer cells.~Radiopharmaceutical Administration: Each participant will receive an intravenous injection of 18F-FDG, dosed at approximately 5.2 MBq/kg (0.14 mCi/kg) of body weight.~Imaging Protocol: After the injection, participants will rest in a quiet and dimly lit room for approximately 60 minutes to allow for optimal distribution and uptake of 18F-FDG by the tissues. Subsequently, they will be positioned on the PET/CT scanner bed, and imaging will be performed from the vertex to the proximal thighs. The scan will include a low-dose CT for attenuation correction followed by PET imaging, with the acquisition time adjusted based on the specific protocol (typically 2-3 minutes per bed position)."
214689545|NCT04786873|DIAGNOSTIC_TEST|Clonidine|"For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg.~After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally."
214689546|NCT05420272|BEHAVIORAL|Trunk performance and endurance lower extremity biomechanic|Trunk performance and endurance lower extremity biomechanic
214689547|NCT05553431|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
214689548|NCT04591470|DIAGNOSTIC_TEST|Mar test|Study of antisperm antibodies
214689549|NCT04500314|DEVICE|whole body vibration device|20 patients will receive vibration training on vibration platform (Power Plate International, Irvine, California, USA) at a frequency of 25-30 Hz and amplitude of 3-5mm, plus traditional physical therapy program 3 sessions per week for total period of 8 weeks. The total duration of the WBV training stimulus will 10 min in first week and progress gradually to 25 min in the 8th week with regular increase by 5 minutes after each 2 successive weeks
214689550|NCT04500314|OTHER|routine physical therapy treatment|The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
214689551|NCT02891031|DRUG|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
215017891|NCT01660685|BEHAVIORAL|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
215017892|NCT01660685|BEHAVIORAL|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
215017893|NCT01660685|BEHAVIORAL|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
215017894|NCT00980629|DRUG|M516102|Twice a day
215017895|NCT00980629|DRUG|placebo|Twice a day
215017896|NCT00005775|DRUG|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
215017897|NCT00005775|DRUG|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
215017898|NCT04008069|DRUG|Sarilumab|Sarilumab 200 mg administered subcutaneously
215101926|NCT00642863|DIETARY_SUPPLEMENT|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
215101927|NCT00642863|DIETARY_SUPPLEMENT|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
215101928|NCT00642863|DIETARY_SUPPLEMENT|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
215101929|NCT01501552|OTHER|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
215101930|NCT01501552|OTHER|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
214689552|NCT02891031|DRUG|Placebo|500 mg twice daily after meal for 6 weeks
214689553|NCT00339014|DRUG|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
214689554|NCT00339014|OTHER|Placebo|Identical placebo
214689555|NCT06262555|PROCEDURE|Transbronchial PDT peripheral lung tumor ablation|Transbronchial lung tumor ablation with Photodynamic therapy
215017899|NCT04008069|DRUG|Placebo|Placebo administered subcutaneously
215101931|NCT01501552|OTHER|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
215101932|NCT00122655|DRUG|non-nucleoside reverse transcriptase inhibitors|
215101933|NCT00122655|DRUG|nucleoside reverse transcriptase inhibitors|
215101934|NCT00122655|DRUG|protease inhibitors|
215017900|NCT02921282|GENETIC|Genotype dopamine|Laboratory investigations of nicotine reinforcement
215017901|NCT02921282|GENETIC|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
215017902|NCT03227627|DEVICE|VitalStim|One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.
215017903|NCT03227627|OTHER|Traditional Therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
215017904|NCT00005995|DRUG|shark cartilage extract AE-941|
215017905|NCT02767687|OTHER|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
214689556|NCT05655390|BEHAVIORAL|Safety Intervention Planning|The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
214689557|NCT02180503|DRUG|BI 1356 BS PIB - low dose|
214689558|NCT02180503|DRUG|BI 1356 BS tablet - low dose|
214689559|NCT02180503|DRUG|BI 1356 BS PIB - high dose|
214689560|NCT02180503|DRUG|BI 1356 BS tablet - high dose|
215017906|NCT02155972|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotic supplement
215101935|NCT03336385|DIETARY_SUPPLEMENT|Naxus|Non-digestible polysaccharides arabinoxylan (Naxus)
215101936|NCT03336385|DIETARY_SUPPLEMENT|Oatwell|Non-digestible polysaccharides oat beta-glucan (Oatwell)
215101937|NCT03336385|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
214416217|NCT06359054|DIAGNOSTIC_TEST|68Ga DOTATATE PET/CT|"68Ga-DOTATATE PET/CT Imaging: Preparation: No specific fasting is required for 68Ga-DOTATATE PET/CT. However, participants may be advised to hydrate well before the procedure.~Radiopharmaceutical Administration: Participants will receive an intravenous injection of 68Ga-DOTATATE, dosed at approximately 2.2 MBq/kg (0.06 mCi/kg) of body weight.~Imaging Protocol: Similar to the 18F-FDG protocol, after receiving 68Ga-DOTATATE, participants will wait for about 60 minutes to allow for sufficient uptake of the tracer. They will then undergo PET/CT scanning in a supine position, covering the same body regions as the FDG scan. A low-dose CT scan will be conducted first for attenuation correction, followed by the PET scan, with acquisition parameters tailored to the optimal detection of somatostatin receptor expression."
214689561|NCT02180503|DRUG|BI 1356 BS tablet - high dose with food|
214689562|NCT04856436|DRUG|Benzodiazepine|Exposure to benzodiazepine during early pregnancy
214689563|NCT05426707|DEVICE|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
214689564|NCT05426707|DEVICE|Sham-RIC|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
214689565|NCT00316303|DRUG|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
214689566|NCT00316303|BEHAVIORAL|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
214689567|NCT03064776|DEVICE|m-RESIST Patients|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
214689568|NCT03064776|DEVICE|m-RESIST Caregivers|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
214689569|NCT03023982|DRUG|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
215017907|NCT02155972|OTHER|Placebo|Placebo capsules
215017908|NCT01843504|BIOLOGICAL|platelet rich plasma|A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
215017909|NCT01843504|OTHER|saline|A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
215101938|NCT02445066|DIETARY_SUPPLEMENT|Vitamin D3|
215101939|NCT05028270|PROCEDURE|Balloon technology;Microcatheter technology|Describe each group's intervention in sufficient detail, including how and when to give the intervention Suspend or modify the criteria for interventions that have been assigned to the subject (such as changing the dose of the drug due to hazards or subject requirements or improvement/deterioration of the condition, etc.) Strategies to improve the compliance of intervention programs, and other measures to monitor compliance (such as the return of drug tablets, laboratory inspections, etc.) Related care and interventions allowed or prohibited during the trial
215101940|NCT00166491|DRUG|Insulin|
215101941|NCT02825212|DRUG|Harvoni|12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
214689570|NCT03023982|DEVICE|Ultrasound|All blocks will be done under ultrasound
214689571|NCT03023982|PROCEDURE|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
214689572|NCT03023982|DRUG|Opioids|standard pain control with opioids
214689573|NCT03023982|DRUG|NSAID|standard pain control with NSAIDs
214689574|NCT00850759|DEVICE|virtual pedestrian environment|a computer-driven virtual pedestrian environment
214689575|NCT00850759|DEVICE|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
214689576|NCT00850759|BEHAVIORAL|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
214689577|NCT05369416|OTHER|Low sodium diet|Subjects will be started on a low sodium (food will be provided) for two weeks.
215017910|NCT03847805|OTHER|Scapulothoracic and glenohumeral stabilization exercises|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue. Three series, with 10 repetitions of each exercise, with one minute rest between series.
215017911|NCT03847805|OTHER|Glenohumeral stability exercises|the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
215017912|NCT05853159|OTHER|Basic Laboratory investigations , Cerebrospinal fluid analysis|to detect severity and prognostic factors of Acute Necrotizing Encephalopathy
215017913|NCT05860868|DRUG|2 cycles induction chemotherapy|"Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
215017914|NCT05860868|DRUG|3 cycles induction chemotherapy|"Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
215017915|NCT00803907|DRUG|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
215017916|NCT00997191|PROCEDURE|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
215017917|NCT00997191|DRUG|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
215017918|NCT00997191|DRUG|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
215017919|NCT02134028|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
215017920|NCT02517138|OTHER|Parabolic flight|
215017921|NCT02517138|OTHER|Measurements of eye movements and perception|
215017922|NCT01891838|PROCEDURE|Volume controlled ventilation|
215017923|NCT01891838|PROCEDURE|Pressure-controlled ventilation|
215017924|NCT04506710|BEHAVIORAL|Audio recording of the counseling conversation|The patient will have an audio-recorded counseling conversation. Audio recording will be carried out using a portable recorder ZOOM H2n. The audio recordings of the counseling conversations will be performed by the health workers selected to participate in the study.
215017925|NCT00305279|OTHER|Dietary|Dietary
215017926|NCT00305279|OTHER|Dietary|Dietary
215017927|NCT00305279|OTHER|Dietary|Dietary
215101942|NCT02825212|DRUG|Epclusa|once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
214689578|NCT05369416|OTHER|high sodium diet|Subjects will be started on high sodium diet (regular diet supplemented with salt tablets to reach a daily intake of \> 4200 mg/Day) for two weeks.
214689579|NCT03062904|DRUG|Inhaled Bronchodilators +/- Inhaled Methacholine|"1. Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~2. Inhaled Methacholine based on international recommendations"
215017928|NCT00449007|DRUG|fluoxetine|6 months
215017929|NCT00449007|DRUG|bupropion|6 months
215017930|NCT03486639|OTHER|IPSS questionnaire|IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
215017931|NCT01029197|BEHAVIORAL|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
215017932|NCT01029197|OTHER|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
215017933|NCT02221297|DIETARY_SUPPLEMENT|Supplement product with plant stanol ester|2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
215017934|NCT03941262|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
215017935|NCT03941262|DRUG|Avelumab|Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
215017936|NCT03941262|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
215017937|NCT00819832|PROCEDURE|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
215017938|NCT00819832|PROCEDURE|Vertebroplasty|Medical cement will be injected into broken back bone.
215017939|NCT00819832|DEVICE|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
214689580|NCT00456963|BEHAVIORAL|Diet|total fat \< 5%, saturated fat \< 10%, vegetables, fruit
214689581|NCT00456963|BEHAVIORAL|Moderate exercise|30 min at least 5 times/week
214689582|NCT00456963|DRUG|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
214689583|NCT00456963|DRUG|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
214689584|NCT00456963|DRUG|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
214689585|NCT00065741|DRUG|silymarin|
214689586|NCT00532948|DRUG|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
215017940|NCT02229292|DRUG|Tranexamic Acid|"Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure."
214689587|NCT00374374|BEHAVIORAL|Administration of probiotic|
214689588|NCT01103817|DIETARY_SUPPLEMENT|Vitamin D|"Dosing If the 25 OH Vitamin D level at Baseline/Screening is less than 20 nmol/L then the subject will receive 2000 IU daily.~If the 25 OH Vitamin D level at Baseline/Screening is between 20 and 37.5 nmol/L then the subject will receive 1000 IU daily."
214689589|NCT06475235|DRUG|Pembrolizumab|Humanized immunoglobin G4 monoclonal antibody, 4 mL vials, via intravenous infusion (into the vein) per protocol.
214416218|NCT03321955|DRUG|Ziconotide 100 MCG(microgram)/ML Intrathecal Solution|Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.
215017941|NCT02229292|DRUG|Saline|"Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure."
214416219|NCT03321955|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
214416220|NCT03321955|DIAGNOSTIC_TEST|Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor|Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
214416221|NCT01199237|DRUG|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
214416222|NCT01199237|DRUG|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
214416223|NCT01199237|DRUG|Rocuronium|
214416224|NCT01199237|DRUG|Neostigmine|
214505539|NCT03395600|DRUG|B125S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
214505540|NCT03395600|DRUG|B1S10|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
215017942|NCT01002729|OTHER|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI \< 30 given Oseltamivir
215017943|NCT01002729|OTHER|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI \> 40 given Oseltamivir
215017944|NCT04062604|OTHER|surgery|surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
215017945|NCT00930787|DEVICE|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
215017946|NCT00930787|DEVICE|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
215017947|NCT04885010|DIETARY_SUPPLEMENT|probiotics|participants will be given probiotics twice a day for 15 days
214505541|NCT06233552|PROCEDURE|conventional denture conversion|conventional workflow usually done to do immediate loading for full arch implant cases
214505542|NCT06233552|PROCEDURE|digital denture conversion|An alternative workflow for construction of the fixed interim requires impressions, model production, and jaw relation records then digitizing all these data then designing and milling the restoration.
214689590|NCT06475235|DRUG|Methotrexate|Anti-metabolite, 50 mL vials, via intravenous infusion per protocol.
215017948|NCT04885010|DIETARY_SUPPLEMENT|placebo|participants will be given a placebo twice a day for 15 days
214689591|NCT06475235|DRUG|Temozolomide|Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsules, taken orally per protocol.
214505545|NCT02499328|DRUG|AZD9150|AZD9150
214505546|NCT02499328|DRUG|MEDI4736|MEDI4736
214505547|NCT02499328|DRUG|AZD5069|AZD5069
214505548|NCT02499328|DRUG|tremelimumab (treme)|tremelimumab
214689592|NCT06475235|DRUG|Rituximab|Anti-CD20 antibody, 10 or 50 mL single-use vials, via intravenous infusion per standard of care.
214689593|NCT01636024|DRUG|AZD7594|Suspension inhaled via Spira nebuliser
215017949|NCT06148285|DEVICE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
215017950|NCT00259701|DEVICE|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
215017951|NCT02924402|BIOLOGICAL|XmAb13676|Biological
215017952|NCT03897010|DEVICE|Socket Graft|5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
215017953|NCT03246594|DEVICE|Placement of oesophageal probe for temperature measurement|The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
215017954|NCT03246594|DEVICE|Power limitation of RF generator|no probe utilized; Limit the RF Generator Output to 25W
215017955|NCT04957082|BEHAVIORAL|Culturally Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans.
215017956|NCT04957082|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information
215017957|NCT04269187|DRUG|Theophylline|Theophylline oral 200 mg daily for 12 days
215017958|NCT02719366|DEVICE|comfilcon A Extended Range test lens|contact lenses
215017959|NCT02719366|DEVICE|comfilcon A control lens|contact lenses
215017960|NCT01400152|DEVICE|Additional active warming|Chemical heat pad applied to the upper torso
215017961|NCT02241915|PROCEDURE|Open Colorectal Surgery|
215017962|NCT02241915|PROCEDURE|Laparoscopic Surgery|
215017963|NCT06232031|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
215017964|NCT01260311|DRUG|Fesoterodine|Any dose of Fesoterodine
214689594|NCT01636024|DRUG|Placebo to match|Matching placebo inhaled via Spira nebuliser
214689595|NCT02604927|DIETARY_SUPPLEMENT|Beta-alanine|
214689596|NCT02604927|DIETARY_SUPPLEMENT|Dextrose|
214689597|NCT03535233|DRUG|Triamcinolone Acetonide|
214416225|NCT01199237|DRUG|Glycopyrrolate|
214416226|NCT00023218|DRUG|Lopinavir/Ritonavir|
214416227|NCT00023218|DRUG|Efavirenz|
214689598|NCT03535233|DRUG|Minoxidil 5 % Topical Spray|
214689599|NCT03535233|DRUG|clobetasol propionate|
214689600|NCT02686606|DIETARY_SUPPLEMENT|Vital 1.5|Oral nutritional supplement
214689601|NCT02686606|DIETARY_SUPPLEMENT|Ensure Plus|Oral nutritional supplement
214689602|NCT01753076|DRUG|Ozanezumab|Ozanezumab injection solution
214689603|NCT01753076|DRUG|Placebo|Normal saline (0.9% sodium chloride) infusion
214689604|NCT00678106|DRUG|Dalbavancin|Subjects weighing \> 60 Kg: 1 gram IV single dose Subjects weighing \< 60 Kg: 15 mg/Kg IV
214416228|NCT05388565|BEHAVIORAL|Domestic Violence Enhanced Perinatal Care Program|Our intervention consists of four major components: a) information about IPV and its effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.
214416229|NCT05388565|BEHAVIORAL|Standard of Care|Usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV and mental health resources)
215017965|NCT05756309|DEVICE|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
214416230|NCT06628414|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation
214416231|NCT04288193|DRUG|Recommendation to Deprescribe|Recommendation to Deprescribe
214416232|NCT03392532|DEVICE|Lotrafilcon B toric contact lenses with HYDRAGLYDE|Silicone hydrogel soft contact lenses for astigmatism
214416233|NCT03392532|DEVICE|Lotrafilcon B toric contact lenses|Silicone hydrogel soft contact lenses for astigmatism
214416234|NCT04796285|DEVICE|Lab Clasp|Finger-based interstitial fluid assessment device
214689605|NCT06113185|OTHER|survey|Demographic and clinical information of the participants will be recorded using a standardized form. The cognitive status of the patient will be evaluated according to the answers to the questions asked to the patient during the questioning of demographic data and reading and signing the consent form. The participants will be asked to complete a series of questionnaires to assess pain intensity and characteristics, pain-related functional disability, and pain-related fear-avoidance behavior. To record the presence and severity of pain behaviors exhibited during physical performance tests, patients will be asked to complete 5 functional tests (repetitive trunk flexion, repetitive sit-to-stand, timed get-up-and-go test, reach with load, 50-step walk test) and observers will simultaneously complete the Pain Behavior Scale. Each participant will be asked to attend two testing sessions separated by one week and occurring before the start of treatment.
214689606|NCT04708652|OTHER|No intervention|No intervention
214689607|NCT02801630|DEVICE|PainShield SAW Patch Device|The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.
214689608|NCT02575079|DEVICE|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
214689609|NCT02918266|DRUG|Scopolamine|Scopolamine subcutaneous injection
214689610|NCT02918266|DRUG|TAK-071|TAK-071 DIC
214689611|NCT02918266|DRUG|Donepezil|Donepezil over-encapsulated tablet
214689612|NCT02918266|DRUG|Scopolamine Placebo|Scopolamine placebo-matching subcutaneous injection
215017966|NCT05823883|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition"
215017967|NCT02708368|OTHER|blood withdrawal|3 times
215017968|NCT03464448|DRUG|Teriflunomide|AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.
214416235|NCT00556543|DEVICE|U-plate fracture repair system|All subjects meeting inclusion criteria will undergo surgery for the repair of their fractured rib/s using the U-plate device. Subjects will be monitored daily during the entire course of their hospitalization for adverse experiences. Subjects will be contacted by phone to complete the MPQ and SF-36 Health Survey. Subjects will be asked if and when they have returned to work or to their previous level of functioning. Subjects will be asked if they had any complications or problems associated with their surgery.
214689613|NCT02918266|DRUG|TAK-071 Placebo|TAK-071 placebo-matching DIC
215017969|NCT03494842|DEVICE|Transcutaneous nerve stimulation (TENS)|The active TENS unit (delivers electrical stimulation) with indicator light
215017970|NCT03494842|DEVICE|Placebo Transcutaneous nerve stimulation (TENS)|the placebo TENS unit (delivers no electrical stimulation) with indicator light
214416236|NCT02993497|DEVICE|Infrared camera|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an Infrared camera.
214416237|NCT02993497|DEVICE|RVM(Respiratory Volume Monitor)|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an RVM(Respiratory Volume Monitor).
214689614|NCT02918266|DRUG|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
214689615|NCT04891991|DRUG|Intravitreal infliximab|1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
214689616|NCT04891991|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy
214689617|NCT03235596|DEVICE|tDCS|cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
214689618|NCT01914419|DRUG|Oxytocin|
214689619|NCT01897961|OTHER|Anticorps anti-PLA2R1|
214689620|NCT00300469|DRUG|ABT-335|135 mg, daily, 12 weeks
214689621|NCT00300469|DRUG|Atorvastatin|Daily, 12 weeks, see Arm Description for dosage information
214689622|NCT00300469|DRUG|Placebo|daily, 12 weeks, see Arm Description for placebo information
214689623|NCT01259856|DRUG|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
214689624|NCT01259856|DRUG|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
214416238|NCT05052411|OTHER|App usage assessments and analytics|All participants will be given a brief overview of the purpose of the study followed by a survey on participant characteristics and barriers to accessing HIV testing and PrEP uptake and P/SUD support services. The participant will be observed downloading the JomPrEP app and instructed with a brief tutorial on the onboarding process. The participant will be told to keep the app for 1 month and encouraged to use all app components. At 30 days, the participant will complete a post-survey, to which the Systems Usability Scale will be added. App analytics will also be collected (e.g., the number of logins). Participants will be asked to provide feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention.
215101943|NCT02553408|DEVICE|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
215101944|NCT02895945|BIOLOGICAL|Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)|In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
214416239|NCT04006860|DRUG|SHC014748M Capsules|SHC014748M Capsules: 200mg
214689625|NCT01259856|DRUG|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
214416240|NCT01838551|DRUG|Levoketoconazole|Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
214416241|NCT00508690|DRUG|cefmetazole|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
214416242|NCT00508690|DRUG|kanamycin/metronidazole|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
214416243|NCT01026662|PROCEDURE|Ablation and skin resurfacing|Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
214416244|NCT01026662|DEVICE|eMatrixCO2|
214416245|NCT04266561|OTHER|hernia repair|Two 3-mm needle holders were used for stitching the wide IIR. Then the suture was continued along the upper margin of IIR, but in a deeper plane to include the peritoneum and the deeper fascia transversalis.
214689626|NCT01758393|DRUG|Prednisone|
214416246|NCT05497869|OTHER|active release group|Patient is in supine lying position with 15-20° shoulder abduction. Then place finger tips under Pectoralis minor tendon and position the arm in 90°/90° shoulder abduction and elbow flexion. Apply the pressure while stroking the tender area and ask the patient to adduct the arm then bring shoulder backward while maintain the pressure 3 sets of 10 repetition/ 4 days per week for 3 weeks.
214416247|NCT05497869|OTHER|active control group|Conventional treatment- includes gentle shoulder ROMs i.e. flexion, extension, abduction, adduction, internal rotation and external rotation with-in pain free range, 10 repetitions each for 3 times a day
214689627|NCT00412698|DRUG|rimonabant|"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant"
214689628|NCT00412698|DRUG|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
214689629|NCT01636752|BEHAVIORAL|Deprexis|Online self-help with and without e-mail-support
214689630|NCT04405505|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
214689631|NCT04405505|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
214689632|NCT04405505|DRUG|Paclitaxel for Injection (albumin bound)|a anti-microtubule drug.
214416248|NCT04210856|OTHER|Contemplative landscape exposure|landscapes classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to non-contemplative ones.
214689633|NCT03988257|DIETARY_SUPPLEMENT|Imunoglukan PH4|Children allocated to experimental group will receive Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
215017971|NCT04757857|DRUG|Rivaroxaban 10 mg|Rivaroxaban pharmaceutical form will be tablets of 10 mg
215017972|NCT04188626|BEHAVIORAL|Driving simulator sessions|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving. This autonomous driving will be interrupted by take-over requests related to events that disrupt autonomous driving. During autonomous driving, the driver will have to disengage from driving by performing non-related driving tasks. During each non-related driving tasks, a take-over request will be sent. Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioural data will be recorded before, during and after the take-over control.
215017973|NCT01609387|DIETARY_SUPPLEMENT|Fit For me|
215017974|NCT01609387|DIETARY_SUPPLEMENT|Davitamon|
215017975|NCT06041828|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
215017976|NCT06041828|OTHER|Standard oral hygiene|Standard oral hygiene instructions
215017977|NCT01428141|DRUG|E7050|Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
215017978|NCT05392660|OTHER|assumed upright position during first stage of labor|The study group assumed one of upright positions during first stage of labor, defined as walking , sitting, standing, kneeling \& squatting positions )
215101945|NCT04768803|BIOLOGICAL|acylated and unacylated ghrelin dosages|realization of plasma samples to evaluate of levels of ghrelin and collection of plasma and cells
215101946|NCT03730415|PROCEDURE|Viscoelastic (VE) Guided Transfusion|A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
214416249|NCT05236543|DRUG|AZD4831|Subjects will receive single oral dose only on Day 1 and Day 11.
214416250|NCT05236543|DRUG|Itraconazole|Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
214416251|NCT04651361|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
214416252|NCT04651361|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
214416253|NCT02780362|DRUG|Prodactariv|1 tablet contains 60 mg Daclatasvir
214416254|NCT02780362|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
214505549|NCT06435169|DIAGNOSTIC_TEST|Lasegue's, Freiberg's and, FAIR (Flexion Adduction Internal Rotation) tests.|The Straight Leg Raise test or Lasegue test, is also crucial in detecting disc herniation and neural compression. Lasègue's sign is said to be positive if the angle to which the leg can be raised (upon straight leg raising) before eliciting pain is \<45°.The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests. Freiberg's test elicits pain by passively internal rotation of the extended hip, when the patient is in supine. The purpose of this test is on the one hand stretching of the irritated Piriformis Muscle (PM), on the other hand provoking sciatic nerve compression. The FAIR test is a sensitive and specific test for detection if irritation of the sciatic nerve by the piriformis. FAIR stands for flexion, adduction and internal rotation. Also known as piriformis test.
215017979|NCT01237405|DRUG|99mTc-EC20|Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at \~1 minute) SPECT/CT of both knees; a late phase (at \~60 minutes) SPECT/CT image of both knees; and a late phase (at \~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
215017980|NCT05154162|DIAGNOSTIC_TEST|PSMA PET/CT|PSMA PET/CT (limited to the pelvis)
215017981|NCT05154162|PROCEDURE|Transperineal template prostate biopsy|Transperineal template prostate biopsies will be performed as per treating urologist's usual practice. No specific template for biopsy is prescribed for the purposes of the study. However, template sampling of the prostate is required, with a minimum of 12 cores, dependent on prostate volume. MRI will be available for any additional targeted biopsies required. Transperineal template biopsies must be labelled appropriately and sent for histopathological analysis.
215017982|NCT05154162|PROCEDURE|Transperineal targeted prostate biopsy|If the PSMA PET/CT is normal, transperineal prostate biopsy would be omitted If the PSMA PET/CT is abnormal, transperineal prostate biopsies would be performed targeting the MRI (done prior to study) and PSMA PET/CT images
215017983|NCT03030209|PROCEDURE|Distal pancreatectomy|Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
215017984|NCT01452789|DRUG|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
215017985|NCT01452789|DRUG|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
215017986|NCT03584386|DEVICE|V-CAMS (aka Jaspr)|V-CAMS is an integrated software system for use on any device by suicidal patients.
215017987|NCT00198744|BEHAVIORAL|Medifast FIT! for Kids|
215017988|NCT00198744|BEHAVIORAL|standard recommendations for dietary intake in children|
215017989|NCT00198744|BEHAVIORAL|both diet plans with and without a parent dieting|
215017990|NCT02285244|DRUG|sotrastaurin acetate|Given PO
215017991|NCT02285244|OTHER|pharmacological study|Correlative studies
215017992|NCT02285244|OTHER|laboratory biomarker analysis|Correlative studies
215017993|NCT01444170|DIETARY_SUPPLEMENT|dicreatinol sulfate|nutritional supplement
215017994|NCT01444170|DRUG|placebo sugar pill|
215017995|NCT05740592|PROCEDURE|micro-osteoperforations ,microincision|Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.
215017996|NCT05345158|PROCEDURE|Robotic Retroperitoneal Lymph Node Dissection (RPLND)|Robotic RPLND performed using the DaVinci robotic surgical system.
215017997|NCT04419350|PROCEDURE|Microneedling|One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
215017998|NCT00369863|DRUG|Triamcinolone acetonide|
215017999|NCT00066170|DRUG|Xyrem|Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.
215018000|NCT00066170|DRUG|Xyrem Placebo|Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
215018001|NCT00066170|DRUG|Modafinil at established dose|Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.
215018002|NCT00066170|DRUG|Modafinil (Placebo)|Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
215018003|NCT03817515|DRUG|ABI-009|Sirolimus Albumin-bound Nanoparticles
215018004|NCT01297114|DRUG|Florbetaben|This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
215018005|NCT00552500|DRUG|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
215018006|NCT00098293|DRUG|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
215018007|NCT00098293|DRUG|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
214416255|NCT00822913|DRUG|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
214416256|NCT04247711|BEHAVIORAL|OTCH|OTCH is structured in three phrases (i. engagement and initial needs assessment, ii. ongoing intervention and monitoring, and iii. transition to long-term services) and lasts an average of two years. OTCH will maintain the central characteristics of the OnTrack model, as well as its core principles, which include (1) Person-centered care, (2) Shared decision-making, (3) Recovery orientation, and (4) Culturally-competent care.
214416257|NCT04247711|BEHAVIORAL|Usual FEP Services|These include services such as psychiatric medication, psychotherapy, and psychoeducation for people with FEP and are usually provided at outpatient mental health clinics.
214416258|NCT02989961|OTHER|Resticutis|Autologous, Activated-Platelets type of Preparation
214416259|NCT02989961|OTHER|Platelet-Poor Plasma (PPP)|A preparation of low platelet plasma obtained by a high-speed centrifugation step.
214416260|NCT01981356|BEHAVIORAL|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
214416261|NCT01981356|OTHER|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
214416262|NCT05851768|DRUG|Bupivacaine|Bupivacaine 0.25%
214416263|NCT05851768|DRUG|Bupivacaine + Magnesium|Bupivacaine 0.25% + Magnesium
214416264|NCT05851768|DRUG|Bupivacaine + Dexmedetomidine|Bupivacaine 0.25% + Dexmedetomidine
214416265|NCT02486588|OTHER|Messaging|See detailed study description for overview of the different messaging interventions in this study
214416266|NCT02486588|OTHER|Financial incentives|See detailed study description for overview of the different financial incentive-based interventions in this study
214416267|NCT06485596|DEVICE|XVIVO Heart Assist Transport System|Direct procurement of donor hearts from DCD donation
214416268|NCT06706518|PROCEDURE|Single-shot ablation technologies|"Comparison of fluoroscopy time and dose-area product (DAP) between different single-shot ablation technologies.~* PolarFit balloon catheter with adjustable diameter 28 to 31 mm. This catheter will be used in patients with persistent AF and dilated left atrium, where the ability to encompass more of the atrial myocardium at the level of the antrum of the pulmonary veins allows a greater number of potential AF perpetuating regions to be covered.~* ArcticFront Advance Pro 28 mm diameter balloon catheter\*.~* 28 mm diameter PolarX balloon catheter\*."
214416269|NCT06711380|OTHER|Peer Ambassador|Patient mentor (patient with history of gynecologic cancer who has experience with clinical trials) one on one discussion with patient mentee (patient receiving standard of care treatment for gynecologic cancers).
214416270|NCT06709209|PROCEDURE|Colonoscopy after bowel cleansing|Colonoscopy will be performed using HD-WLE; TXI; RDI and NBI.
214416271|NCT06709209|PROCEDURE|Intestinal biopsies|During colonoscopy, at least 2 biopsies from each segment will be taken as standard of care to assess inflammation in UC
215101947|NCT03225924|DRUG|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
214416272|NCT06709209|DIAGNOSTIC_TEST|blood sampling|Blood samples will be taken for standard of care by appropriately trained members of the clinical research team. The results of the standard of care blood will be used in the research.
214416273|NCT06709209|DIAGNOSTIC_TEST|Stool|The stool sample will be sent to the laboratory for Faecal Calprotectin (FCP) as a marker of disease activity.
214689634|NCT03988257|DIETARY_SUPPLEMENT|Placebo (vitamin C syrup)|Children allocated to control group will receive a placebo: a vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
214416274|NCT06709209|OTHER|Clinical follow-up|Patients will be followed-up at 6 and 12 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. Partial Mayo Score (PMS) and occurrence of clinical outcomes will be evaluated.
214416275|NCT06712238|PROCEDURE|NB-UVB|Comparison between serum Level of Gelsolin (GSN) in Psoriatic Patients and controls and correlate its level with PASI.
215018008|NCT00098293|DRUG|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
215018009|NCT01730976|DIETARY_SUPPLEMENT|Vitamin D 2,000 I.U.|
215018010|NCT03112850|DEVICE|Hearing aid|LOF hearing aid
215018011|NCT03112850|BEHAVIORAL|Auditory Training|
215101948|NCT03225924|DRUG|Rituximab|cycles of 21 days - 375mg/m²
215101949|NCT03225924|DRUG|Cyclophosphamide|cycles of 21 days - 750 mg/m²
215101950|NCT03225924|DRUG|Doxorubicin|cycles of 21 days - 50mg/m²
215018012|NCT03385486|BIOLOGICAL|TBX-3400|Autologous transfusion
215018013|NCT05303974|OTHER|Ultrasound guided joint injection|The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.
215018014|NCT01370642|DRUG|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
215018015|NCT01370642|DRUG|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
215018016|NCT01370642|BIOLOGICAL|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
215018017|NCT01370642|DRUG|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
215101951|NCT03225924|DRUG|Vincristine|cycles of 21 days - 1.4mg/m²
215101952|NCT03225924|DRUG|Prednisone|cycles of 21 days - 40mg/m²
214416276|NCT06696482|DRUG|Escitalopram 10mg|Escitalopram 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
214416277|NCT06696482|DRUG|Placebo 10 mg|Placebo 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
214416278|NCT06706505|BEHAVIORAL|Mindfulness-based art therapy|"MBAT combines art therapy and mindfulness to promote self-awareness and emotional well-being. It uses art to express thoughts and feelings, while cultivating mindfulness skills. MBAT addresses stress, anxiety, and emotional regulation. Grounded in research, it's an effective therapeutic approach.~The mindfulness-based art therapy sessions were designed based on the literature, drawing on the researches. By integrating art therapy techniques and mindfulness practices, the sessions were developed. Expert opinions were sought from specialists in the field to ensure the content validity of the sessions, and necessary adjustments were made accordingly. The MBAT application consists of five sessions in total. Each session has a specific theme and is designed to last 90-120 minutes."
214416279|NCT06712173|DRUG|linperlisib and SHR2554|Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.
214416280|NCT03354390|BIOLOGICAL|cell infusion|This is a phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
214416281|NCT03227757|DEVICE|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
214416282|NCT05904340|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) uses machines to generate electric current, flows through the skin and conducts to the nerves, triggers a chain reaction of nerves through a new stimulus source, and achieves the effect of pain relief. Using different frequencies and intensities will Produce different effects and trigger different physiological mechanisms.
214416283|NCT01356069|OTHER|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
214416284|NCT01356069|OTHER|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
214416285|NCT01716858|DIETARY_SUPPLEMENT|Sulforaphane-rich Broccoli Sprout Extract|
214416286|NCT03806907|RADIATION|Computed tomography lung subtraction iodine mapping|Subtraction of the non-contrast CT from the contrast-enhance CTPA produces the CT-LSIM
214416287|NCT00407082|DRUG|fluocinolone acetonide intravitreal implant|Fluocinolone acetonide ocular implant 0.59mg
214416288|NCT00407082|DRUG|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
214416289|NCT02414906|OTHER|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
214416290|NCT02210806|DRUG|A006 DPI|Single dose 110 mcg, 1 inhalation
214416291|NCT02210806|DRUG|A006 DPI|Single dose 220 mcg, 1 inhalation
214416292|NCT02210806|OTHER|Placebo DPI|Placebo, 1 inhalation
214416293|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 1 inhalation
214416294|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 2 inhalations
214416295|NCT02703714|DRUG|Pembrolizumab|200 mg given intravenously (IV)
214416296|NCT02703714|DRUG|Sargramostim|250 µg given subcutaneously (SC)
214416297|NCT01875250|BIOLOGICAL|PROSTVAC-F (Fowlpox)/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
214416298|NCT01875250|BIOLOGICAL|PROSTVAC-V (Vaccinia)/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
214416299|NCT01875250|DRUG|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
214416300|NCT03547791|DRUG|Betamethason Sodium Phosphate|The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.
214416301|NCT03547791|DRUG|Normal saline|Intramuscular injection of normal saline 3ml twice 24hours apart
214416302|NCT03482804|OTHER|Questionnaires|"Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.~The questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password."
214416303|NCT02273986|DRUG|Digoxin|
214416304|NCT02273986|DRUG|K-877|
214689635|NCT04825236|OTHER|MyVoice:CF|"Participants will be given access to MyVoice:CF, a web-based decision aid (DA). This tool includes information about fertility, genetics, parenting, pregnancy, and breastfeeding within the context of cystic fibrosis (CF). The tool includes interactive elements designed to give users the ability to assess and reflect on their own reproductive goals and experiences and promote self-efficacy to engage in shared decision-making with their CF and women's health providers.~Upon completion of use of the decision aid, a summary sheet is generated based on the user's interaction with the tool. This summary is supplied to the provider prior to the next appointment."
215018018|NCT03666702|OTHER|Upper limb physiotherapy programme|Web-based physio programme
214416305|NCT03872362|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
214416306|NCT06120699|OTHER|Pelvic floor muscle training with 360 degree expanded diaphragm exercises|Women in this group will be taught 360-degree expanded diaphragm exercises with the Ohmbelt device. Two Ohmbelt devices will be used in this study. The anterior sensor will be placed in the inguinal cavity to visualize the expansion of the anterior abdominal wall, and the posterior sensor will be placed contralaterally in the upper lumbar triangle to visualize the expansion of the posterior wall. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied.
215018019|NCT03666702|OTHER|Usual care|Usual physiotherapy care
214505550|NCT04847375|DRUG|exogenous surfactant|Nebulized Surfactant would be administered by face mask which has a nebulizer
214505551|NCT04603508|DRUG|BERLIM 25/10 association|Berlim 25/10 association coated tablet.
215101953|NCT04713501|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
215101954|NCT04913740|OTHER|Ointment and dressing for external use|"1. pay attention to the protection of exposed skin, so that it is local dry.~2. Do a good job of facial moisturizing work before work use moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~3. Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~4. After work, avoid using irritants to clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
215101955|NCT00953940|DRUG|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
215101956|NCT03286283|DEVICE|J-Plasma|Dermal resurfacing procedure with J-Plasma.
215101957|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered 20-30 IU/kg 3 times a week
215101958|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered only for bleeding episodes
215101959|NCT05113914|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test|An incremental running test was conducted on the treadmill. Initially, the exercise protocol included standing still for 3 min and walking for 3 min at a constant speed of 4 km/h. After this introductory part, the speed was increased to 8 km/h and then every 3 min by 2 km/h until the volitional exhaustion was reached. During all procedure oxygen consumption was measured with the use of a portable breath-by-breath ergospirometer.
215101960|NCT04005079|DRUG|Pilocarpine|2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
215101961|NCT04005079|DRUG|Ofloxacin|Standard of care
215101962|NCT04005079|DRUG|Prednisolone|Standard of Care
215101963|NCT02706379|OTHER|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
215101964|NCT04882787|DEVICE|BTE hearing aid|Amplification
215101965|NCT03117413|OTHER|Positron emission tomography scan|"* Binaural hearing assessments: speech recognition in noise and sound source localization~* Voice perception assessment: voice/non-voice discrimination task, free categorization task~* Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)"
215101966|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
214505552|NCT04603508|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
214505553|NCT04603508|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 10 mg coated tablet.
214505554|NCT04603508|OTHER|BERLIM 25/10 ASSOCIATION PLACEBO|Berlim 25/10 association placebo coated tablet.
214505555|NCT04603508|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
215018020|NCT00676962|BEHAVIORAL|External facilitation|Study facilitator meets regularly with therapists to aid implementation of CBT
215018021|NCT04168138|DRUG|rhTPO|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)\>20\*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet\>50\*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
215018022|NCT05253235|BEHAVIORAL|SAAF|A 7 session online intervention designed to augment protective processes associated with deterrence of substance use
215018023|NCT05253235|OTHER|Receipt of parenting book|Parents will receive a copy of the book, Parenting for Liberation: A Guide for Raising Black Children
215018024|NCT02071654|DEVICE|Venus P-valve transcatheter implantation|Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
214505556|NCT04603508|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin placebo coated tablet.
214505557|NCT03350698|BIOLOGICAL|Gardasil-9|3 vaccine series
215018025|NCT01796470|DRUG|Entospletinib|Entospletinib tablets administered orally twice daily
215101967|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
215101968|NCT06010407|OTHER|Survey|"* Working Alliance Inventory~* Attitude Towards Psychiatry-30 Scale"
215101969|NCT03211013|DRUG|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
215101970|NCT03211013|DRUG|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
215018026|NCT01796470|DRUG|Idelalisib|Idelalisib tablets administered orally twice daily
215018027|NCT01928576|DRUG|Azacitidine|
215018028|NCT01928576|DRUG|Entinostat|
215018029|NCT01928576|DRUG|Nivolumab|
214416307|NCT06120699|OTHER|Pelvic floor muscle training with standard diaphragm exercises|"Women in this group will be taught standard diaphragm exercises. In the supine position, with the head and knees supported by a pillow, the patient will first be asked to close his or her eyes to focus. With one hand on the chest and the other hand on the abdomen, Take a deep breath through your nose and direct all the air as much as possible under your lower hand. inflate your belly. Now exhale all the air slowly through your mouth. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied."
214416308|NCT01013012|DRUG|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
214416309|NCT01013012|DRUG|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
214416310|NCT02388139|PROCEDURE|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
214416311|NCT02388139|PROCEDURE|coronarography|
214416312|NCT02388139|PROCEDURE|coronary angioplasty|
214416313|NCT02388139|PROCEDURE|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
215018030|NCT01928576|DRUG|CC-486 300|
215018031|NCT00370604|DEVICE|19g Tuohy-type epidural needle, 23g catheter|Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
215018032|NCT00370604|DEVICE|=> 18g Tuohy-type needle|Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
214416314|NCT02388139|PROCEDURE|body composition monitoring|using Fresenius device
214416315|NCT02888535|OTHER|Internal Medicine consultation|
215018033|NCT03810794|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. The electric stimulator will be applied to DU 24, GB 12, HT 7, and LR 3 or SP 6 with a disperse-dense wave of 2/50 Hz, 0.5-1.0 mA. There are three sessions per week with each session lasting for 30 min. There will be 12 weeks of treatment for each participant in total.
215018034|NCT03810794|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks. After the clinical trial, participants will be given conventional treatment clinically.
215018035|NCT05863364|DRUG|Low-dose of Rifaximin|The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks
214416316|NCT06315777|GENETIC|cumulus cell oocytes complex (COC) among women with poor ovarian reserve|level of expression of Gremlin-1 (GREM1), Hyaluronic acid synthetase-2 (HAS2), and Prostaglandin-endoperoxide synthase-2 (PTGS2) in cumulus cell oocytes complex (COC) among women with poor ovarian reserve were analyzed
214416317|NCT02749968|DRUG|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
214416318|NCT02749968|DRUG|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
214416319|NCT01796093|DRUG|Digoxin and ivabradine|No more details
215018036|NCT05863364|DRUG|Conventional dose of Rifaximin|the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks
215018037|NCT03785132|PROCEDURE|Cardiac surgery|The relationship between performance measurement of blood pressure during cardiac surgery (before, during and after cardiopulmonary bypass) and postoperative mortality
215018038|NCT01927861|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
215018039|NCT02844712|OTHER|Evaluation of reexposure to a negatively tested betalactam|
215018040|NCT00987935|DRUG|Sorafenib|400 mg twice daily
215018041|NCT00987935|DRUG|BIBF 1120|Twice daily
215018042|NCT04883554|OTHER|Olfactory therapeutic|The sessions of the olfactory sensory therapy group take place according to the care framework at a frequency of one session of 45 minutes per week
215018043|NCT04883554|OTHER|Body therapy|very specific stages at a weekly frequency and lasts 1 hour. Kinesic time or time to set the body in motion (20 min) Kinesthetic time: time of slow movements (20 min) Talk time (20 min)
215018044|NCT01089543|DRUG|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
215018045|NCT01089543|DRUG|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
215018046|NCT01089543|DRUG|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
214416320|NCT03068468|DRUG|BIIB092|BIIB092 intravenous infusion on specified days
214416321|NCT03068468|DRUG|Placebo|Placebo intravenous infusion on specified days
214416322|NCT02555449|DRUG|[¹⁴C]-LY3202626|Administered as solution by mouth
214416323|NCT02466516|DRUG|SEL|SEL tablet administered orally once daily
214416324|NCT02466516|BIOLOGICAL|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
214416325|NCT00129948|DRUG|Troxatyl™ (troxacitabine)|
214416326|NCT03712930|DRUG|Pamiparib|60 mg orally twice daily (BID)
214416327|NCT02986906|DRUG|5% dextrose|Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
215018047|NCT01089543|DRUG|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
214416328|NCT02986906|DRUG|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
214416329|NCT02986906|DEVICE|Ultrasound|The ultrasound was used for injection guidance
214416330|NCT03861221|DEVICE|CBBCT|To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
214416331|NCT03573999|DRUG|Mannitol|4.6 ml/kg will be administered before dura opening
214416332|NCT03573999|DRUG|NaCl 7.5%|2 ml/kg will be administered before dura opening
214416333|NCT01332058|BEHAVIORAL|Motivational Interviewing|8 possible weeks of motivational interviewing sessions
215018048|NCT03325803|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
214416334|NCT05068037|OTHER|ACUPUNCTURE|standard acupuncture TCM (analgesia, vomiting)
214505558|NCT00934817|DRUG|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
214416335|NCT05068037|OTHER|ANTIEMETICS|NO ACUPUNCTURE, WITH ANTIEMETICS
214416336|NCT05068037|OTHER|NOTHING|NO ACUPUNCTURE, NO ANTIEMETICS
214416337|NCT01250548|BIOLOGICAL|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
214505559|NCT00934817|DRUG|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
214416338|NCT01250548|OTHER|Placebo|
214416339|NCT00914823|DRUG|kisspeptin 112-121|One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
214416340|NCT00914823|DRUG|GnRH|One or more IV doses of GnRH, and/or SC administration of GnRH
214416341|NCT03126084|DRUG|Acetaminophen|1000 mg of intravenous acetaminophen will be administered twice a day
214416342|NCT03126084|DRUG|0.25% Bupivacaine|20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
214416343|NCT03126084|DRUG|0.5% Bupivacaine+Glucose|15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
214416344|NCT03126084|DRUG|Tramadol HCl|50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
214416345|NCT03126084|PROCEDURE|Inguinal Hernia Repair|Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
214416346|NCT03126084|DRUG|0.25% Bupivacaine|10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
214416347|NCT03583021|DRUG|Sugammadex Injectable Product|Sugammadex of 3 mg/kg is injected.
214416348|NCT03583021|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
214416349|NCT01414231|DRUG|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
214416350|NCT05826444|DIAGNOSTIC_TEST|Echocardiography|Echocardiography with afterload change
214416351|NCT05826444|DIAGNOSTIC_TEST|Magnetic resonance imaging|Stress-MRI
214416352|NCT05826444|DIAGNOSTIC_TEST|Magnetocardiography|Magnetocardiography
214416353|NCT05826444|DIAGNOSTIC_TEST|Histology|Histological analysis
214416354|NCT05826444|DIAGNOSTIC_TEST|Genetics|miRNA sequencing
214416355|NCT05826444|DIAGNOSTIC_TEST|calcium signaling|cardiomyocyte calcium signaling
214416356|NCT05826444|DIAGNOSTIC_TEST|IMR|Index of microvascular resistance measurement
214416357|NCT05826444|DIAGNOSTIC_TEST|Angio-IMR|Angiography derived post-processing index if microvascular resistance
214416358|NCT04565522|OTHER|Prospective observation|Prospective observation until one year follow-up
214505560|NCT05631808|OTHER|Epicardial adipose tissue volume and attenuation|Epicardial adipose tissue volume and attenuation assessed by CT are the exposure factors in this study.
214505561|NCT02036177|DEVICE|SCu300A IUB intrauterine device|Spherical copper IUD
214505562|NCT02036177|DEVICE|T380A IUD|T-shaped copper IUD
214505563|NCT04554108|OTHER|therapeutic strategy|Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy
215018049|NCT03325803|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 150 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
215018050|NCT03325803|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
214416359|NCT05396976|BEHAVIORAL|Yoga and Muscle Relaxation Exercise Practices|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
214416360|NCT02178020|DEVICE|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
214416361|NCT02178020|DEVICE|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
214416362|NCT03619616|DRUG|ZSP1603 7.5 mg|ZSP1603 capsule administered orally once daily under fasted condition.
214416363|NCT03619616|DRUG|ZSP1603 12.5 mg|ZSP1603 capsule administered orally once daily in the fasting state.
214416364|NCT03619616|DRUG|Placebo 12.5mg|Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.
214416365|NCT03619616|DRUG|ZSP1603 25 mg|ZSP1603 capsule administered orally once daily under fasted condition.
214416366|NCT03619616|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
214416367|NCT03619616|DRUG|ZSP1603 50 mg|ZSP1603 capsule administered orally once daily under fasted state.
215018051|NCT03325803|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
215018052|NCT03325803|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
215018053|NCT00005596|DRUG|cyclophosphamide|
215018054|NCT00005596|DRUG|cytarabine|
215018055|NCT00005596|DRUG|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
215018056|NCT00005596|DRUG|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
215018057|NCT00005596|DRUG|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
215101971|NCT05670509|DRUG|administration of Nasal midazolam in home group as a rescue medication for seizure control.|Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
214416368|NCT03619616|DRUG|Placebo 50mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
214416369|NCT03018119|OTHER|Survey|
214416370|NCT00695006|OTHER|Sham Traction|Traction \<5lbs
214416371|NCT00695006|OTHER|Traction|Standard supine intermittent traction
214416372|NCT05734924|DEVICE|low Frequency High Intensity magnetic therapy|low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
214416373|NCT03147456|DIETARY_SUPPLEMENT|(Cubitan Protein, Nutricia, Netherlands).|Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.
214416374|NCT03147456|DIETARY_SUPPLEMENT|(preOp, Nutricia, Netherlands).|contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
214416375|NCT02695290|DRUG|Afatinib|
214416376|NCT01462058|DIETARY_SUPPLEMENT|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
215018058|NCT00005596|DRUG|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC \> 500/μL and platelets \> 75,000/uL
215018059|NCT00005596|DRUG|methotrexate|"IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22."
215018060|NCT00005596|DRUG|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; \> or = 1 day after the IT MTX
215018061|NCT00005596|DRUG|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC \> or = 500/ul and platelets \> or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
215018062|NCT00005596|DRUG|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
214416377|NCT01462058|DRUG|Placebo|Placebo, daily, 12 weeks
214416378|NCT05184361|BEHAVIORAL|Intermittent energy restriction (IER)|"Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.~Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.~In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.~The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks."
215018063|NCT04065854|BEHAVIORAL|Intervention|Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
215101972|NCT05670509|DRUG|administration of Buccal midazolam in home group as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
214416379|NCT05184361|BEHAVIORAL|Continuous energy restriction (CER)|A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
214416380|NCT01304849|DRUG|Escalated BEACOPP|"Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm"
214416381|NCT04491032|PROCEDURE|Caudal anesthesia|Caudal epidural injection will be performed after induction of general anesthesia.
214416382|NCT03778593|DRUG|5-Fluorouracil|D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks
214416383|NCT03778593|DRUG|Leucovorin|D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
214416384|NCT03778593|DRUG|Irinotecan|D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks
214416385|NCT03778593|DRUG|Oxaliplatin|D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks
214416386|NCT03778593|DRUG|5% dextrose water|mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin
215018064|NCT06356597|DRUG|Tislelizumab with Fruquintinib, Metronidazole|"Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day.~Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle."
214416387|NCT01921543|DEVICE|ITP Stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
214416388|NCT01921543|DEVICE|CI/BNST stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
214416389|NCT01921543|DEVICE|No stimulation|
214416390|NCT03720990|DRUG|Cholic Acid|Participants will be treated with cholic acid for 8 weeks
214416391|NCT02338739|BEHAVIORAL|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
214416392|NCT02338739|BEHAVIORAL|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
214416393|NCT02338739|BEHAVIORAL|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
215018065|NCT02222181|OTHER|Pharmacotherapy Management|"* assessment of patient characteristics as alcoholic, smoker, food, drugs~* Pharmacotherapy follow-up~* to evaluated medication adherence~* Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention."
214416394|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
214416395|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
214416396|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
214416397|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
214416398|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
214416399|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
214416400|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
214505564|NCT03150446|DEVICE|flexible cystoscopy|After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
214689636|NCT06527612|OTHER|Pulmonary rehabilitation exercise programme|In addition to standard medical treatment, the EGr will undergo an exercise program. The initial exercise training will be conducted in the hospital, followed by online exercise sessions via video conferencing three times a week during the first week. From the second week onwards, they will be asked to perform their exercises at home three times a week using provided exercise videos and will be monitored for one year. Compliance with the exercise regimen will be assessed through a weekly survey shared in a WhatsApp group established for the exercise group patients.
214416401|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
214416402|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
214416403|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
214416404|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
214416405|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
214416406|NCT01711710|DEVICE|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
214416407|NCT01603784|BEHAVIORAL|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at \~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
214416408|NCT01603784|BEHAVIORAL|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
214416409|NCT01603784|BEHAVIORAL|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
214416410|NCT01603784|BEHAVIORAL|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
214416411|NCT01936753|BEHAVIORAL|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
214416412|NCT00424216|PROCEDURE|DC Polarization|
214416413|NCT00486759|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
214416414|NCT00486759|DRUG|Rituximab|Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
214505565|NCT06328868|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
214689637|NCT00788775|DRUG|Nilotinib|
214689638|NCT01233401|OTHER|Survey|Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
214689639|NCT00149656|DIETARY_SUPPLEMENT|Multivitamins|dietary supplement of multivitamins
214689640|NCT00149656|DIETARY_SUPPLEMENT|Selenium|dietary supplement of selenium only
214689641|NCT00149656|OTHER|Placebo|placebo pill
214689642|NCT02796534|OTHER|Diagnosis of sleep apnea by oxymetry|
214689643|NCT00651976|DRUG|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
214689644|NCT00651976|OTHER|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
214689645|NCT00651976|PROCEDURE|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
214689646|NCT00370695|DEVICE|Precision Spinal Cord Stimulation System|Stimulation turned on from implant throughout the Study
214689647|NCT00664300|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
215018066|NCT03206385|RADIATION|Radiation treatment|50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
214416415|NCT00486759|DRUG|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
214416416|NCT00486759|DRUG|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
214416417|NCT02657629|OTHER|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
214416418|NCT02657629|OTHER|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
214416419|NCT00004367|PROCEDURE|Clinical vestibular tests|
214416420|NCT03823534|DRUG|Ketorolac|IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.
214416421|NCT03823534|DRUG|Normal saline|An IV normal saline placebo prepared by the hospital pharmacy.
214416422|NCT03823534|DRUG|Acetaminophen|acetaminophen 500 mg PO Q4 hours PRN for mild pain
215018067|NCT03206385|RADIATION|CK Boost Pelvis|Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
214416423|NCT03823534|DRUG|Oxycodone Acetaminophen|oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
215018068|NCT06539377|PROCEDURE|Living donor liver transplantation|"Liver transplantation from living donor donation (SII/III as left-lateral donation during a two stage-procedure or left lobe donation or right lobe donation) in patients with unresectable intrahepatic cholangiocarcinoma."
214416424|NCT03823534|DRUG|Morphine|morphine IV PRN (or other opioid) for severe breakthrough pain
214416425|NCT03823534|DRUG|Hydrocodone/Acetaminophen|At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
214416426|NCT03823534|DRUG|Oxycodone|Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
214416427|NCT01299974|OTHER|Parents and Residents in Session|Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
214416428|NCT02001623|DRUG|Tisotumab Vedotin (HuMax-TF-ADC)|
214416429|NCT02452242|DRUG|ABX464|25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
215018069|NCT02100033|DEVICE|acupuncture|
215018070|NCT05507164|DRUG|Temporomasseteric Nerve Block|The TMNB injection is a local anesthetic injection technique that targets the anterior deep temporal and masseteric branches of the mandibular division of the Trigeminal Nerve. The surface landmark for the twin block injection site is located by palpating for the depression created by the greater wing of the sphenoid bone at the superior border of the zygomatic process and approximately 1 cm posterior to the posterior border of the frontal process of the zygomatic bone. This site is first disinfected with alcohol wipes prior to inserting a 27- or 25-gauge long dental needle (32 mm). Angled 35-45° away from the calvarium (skull) and perpendicular to the zygomatic arch (along the coronal plane), the needle is advanced to its length before injecting 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
215018071|NCT06238700|DIETARY_SUPPLEMENT|pregnenolone|Pregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.
214416430|NCT02452242|OTHER|Placebo|1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
214416431|NCT05112146|DIETARY_SUPPLEMENT|Whey protein isolate|Oral administration
214416432|NCT05112146|DIETARY_SUPPLEMENT|Whey protein microgel|Oral administration
214416433|NCT05112146|DIETARY_SUPPLEMENT|Water|Oral administration
214416434|NCT04323995|OTHER|Sprint Interval Training|Sprint interval training of 2 weeks and more.
214416435|NCT03427255|BEHAVIORAL|CBT group treatment-plus|The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
214416436|NCT03427255|OTHER|Waiting-list control condition|Waiting-list control condition during length of active treatment (6 months).
214416437|NCT03943719|DIAGNOSTIC_TEST|FilmArray blood culture identification panel|FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
214416438|NCT06125106|DRUG|Blinatumomab|Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
214416439|NCT00686517|BIOLOGICAL|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
214416440|NCT00686517|DRUG|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
214416441|NCT05153551|OTHER|Play-based assessment (RITA-T)|"The RITA-T is a play-based assessment that involves nine different activities that can be done safely with a child seated in the exam room. After scoring the RITA-T, the PEARS PCP will immediately provide feedback to the parent regarding results and next steps.~In addition, parents will complete certain assessments/surveys during the study to evaluate the program."
214416442|NCT00652119|DRUG|Paclitaxel|Cycle 1 = 60 mg/m\^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m\^2 IP weekly over 1 hour x 3 weeks of each cycle.
214416443|NCT00652119|DRUG|Carboplatin|Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
214416444|NCT00652119|DRUG|Avastin|Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
214416445|NCT00572078|DRUG|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
214416446|NCT00888108|DRUG|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
214416447|NCT00888108|DRUG|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
214416448|NCT05896319|DEVICE|Hyaluronic acid gel|"Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area."
214416449|NCT02675920|DRUG|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
214416450|NCT01188252|DRUG|Roniciclib (BAY1000394)|Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
214416451|NCT02615912|OTHER|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
214416452|NCT02615912|OTHER|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
214416453|NCT02615912|OTHER|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
214416454|NCT02615912|OTHER|Silwet* DA-63 (Momentive) 1.5%|
214416455|NCT02615912|OTHER|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
214416456|NCT02615912|OTHER|Water (control)|
214416457|NCT02925000|DRUG|TLC178|TLC178
214416458|NCT04416971|PROCEDURE|AVF puncture|For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.
214416459|NCT04584489|OTHER|iron stores assessment.|assessment of iron stores by measuring serum ferritin level (mandatory), serum iron and transferrin saturation.
214416460|NCT05227066|OTHER|adding lower extremity weights|All children in the two groups received physical therapy protocol for 30 minutes in addition to half kg of sandbags weights attached for each leg
214416461|NCT05227066|OTHER|traditional physical therapy group|traditional physical therapy group
214416462|NCT04440124|OTHER|Incremental shuttle walk test|All patients were reviewed by a physiotherapist during their pre-assessment clinic one week prior to surgery to complete an incremental shuttle walk test (ISWT). The ISWT was completed according to a standardised protocol and involved patients walking around 2 cones set up 9 metres apart. Patients were asked to cover the distance between the cones in time to auditory cues. Oxygen levels and heart rate were recorded during the assessment with the use of a portable pulse oximeter. The test was stopped when patients could no longer keep pace with the auditory cues or were too breathless to continue. The total distance mobilised was recorded.
214416463|NCT06553014|OTHER|Endovascular Plug Embolization|Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome
214416464|NCT01698255|BEHAVIORAL|ENGAGE|
214416465|NCT01698255|BEHAVIORAL|Standard of Care Psychotherapy|
214416466|NCT02281318|BIOLOGICAL|Mepolizumab|Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
214416467|NCT02281318|DRUG|Placebo|Sterile 0.9% sodium chloride solution
214416468|NCT02281318|DRUG|SOC|Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
215018072|NCT06238700|OTHER|placebo|Placebo pills are identical-appearing capsules containing cellulose
215018073|NCT03931512|DEVICE|transcranial direct current stimularion|aplication of direct current stimulation on the scalp wiht sponge electrodes
214416469|NCT02890368|DRUG|TTI-621 Monotherapy|"TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages."
214416470|NCT02890368|DRUG|TTI-621 + PD-1/PD-L1 Inhibitor|TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
214416471|NCT02890368|DRUG|TTI-621 + pegylated interferon-α2a|TTI-621 will be given in combination with pegylated interferon-α2a. Subjects in this cohort must have a cancer diagnosis for which pegylated interferon-α2a is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
214505566|NCT06328868|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
214505567|NCT06328868|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
214505568|NCT00468156|BEHAVIORAL|written materials only|related to fruit/vegetable servings/day
214505569|NCT00468156|BEHAVIORAL|written materials|related to fruit/vegetable servings/day
214505570|NCT00468156|BEHAVIORAL|telephone support|related to fruit/vegetable servings/day
214689648|NCT02327286|BEHAVIORAL|Promote and support healthy behaviors|"* Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~* Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~* Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~* A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
214505571|NCT05224557|OTHER|No intervention|No intervention
214505572|NCT03759249|OTHER|Sleep medical treatment|"The participant ungo Standard Sleep medical diagnostics. If a sleep disorder is diagnosed in the interventional Group the applicable therapy is conducted.~If the participant is randomized in the waiting Group the applicable Therapy is initiated after study completion."
214505573|NCT00145470|DRUG|Asenapine|Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
214505574|NCT00145470|DRUG|Placebo|Placebo fast dissolving SL tablets, BID
214505575|NCT02540525|DEVICE|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
214416472|NCT02890368|OTHER|TTI-621 + T-Vec|TTI-621 will be given in combination with talimogene laherparepvec (T-Vec). Subjects in this cohort must have unresectable melanoma.
214416473|NCT02890368|OTHER|TTI-621 + radiation|TTI-621 will be given following radiation to the target plasmacytoma. Subjects in this cohort must have relapsed multiple myeloma with bony or soft tissue plasmacytoma(s).
214416474|NCT05876130|RADIATION|POHIM_EM|hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)
214416475|NCT04379349|BEHAVIORAL|SMS text messaging - interactive check-in|Interactive SMS text message check-ins delivered once weekly to participants.
214416476|NCT04379349|BEHAVIORAL|SMS text messaging - inactive control|Minimally interactive SMS text message delivered once weekly to participants.
214416477|NCT00812877|DRUG|Mineral Trioxide Aggregate|Pulp capping agent, Mineral TrioxideAggregate
215018074|NCT01742052|DRUG|MT-1303-Low|
215018075|NCT01742052|DRUG|MT-1303-Middle|
215018076|NCT01742052|DRUG|MT-1303-High|
215018077|NCT01742052|DRUG|Placebo|
215018078|NCT05592730|GENETIC|AMHR2 polymorphism in blood|1 tube of blood taken at the first application
215018079|NCT05592730|GENETIC|AMHR2 polymorphism in granulosa cell|Extraction of granulosa cell from the follicle fluid obtained during OPU
214416478|NCT00812877|DRUG|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide
214416479|NCT00130013|DRUG|Oral Amoxicillin|
214416480|NCT01000129|OTHER|Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)|Planning CT scan performed by qualified planning radiographers
214416481|NCT01000129|OTHER|Cone beam CT acquisition|Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.
214416482|NCT06375291|OTHER|splint /steroid injection/both|pregnant women treated in pain department by splint /steroid injection/both
215018080|NCT05151965|PROCEDURE|Bankart Repair and Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
214416483|NCT01064817|DRUG|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
214416484|NCT01064817|DRUG|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
214416485|NCT04178291|DEVICE|Ultrasonic scaler and Gracey currettes|Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes
215018081|NCT05151965|PROCEDURE|Latarjet Coracoid Transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
215018082|NCT06359535|DRUG|HSK21542|This study is an economic study and does not interfere with patients' medical treatment.
215018083|NCT06359535|DRUG|Placebo|Placebo
214416486|NCT04178291|DEVICE|Air polishing with erythritol powder|Air flow PLUS
214416487|NCT01130467|DRUG|methylphenidate|IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
214416488|NCT01130467|DRUG|Atomoxetine|Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
214416489|NCT01130467|BEHAVIORAL|behavioral modification|Parenting and teaching skill education
215018084|NCT01248468|DRUG|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
215018085|NCT01248468|DRUG|Sumatriptan|100 mg Sumatriptan
215018086|NCT01248468|DRUG|Placebo|placebo
215018087|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
215018088|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
215018089|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
215018090|NCT02608346|PROCEDURE|Blood sampling|"Patients will have a blood draw at each visit to the hospital,~* with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~* with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation"
215018091|NCT03124602|DEVICE|Red Diamond Disposable Pulse Oximeter Sensor|Noninvasive Pulse Oximeter Sensor
215018092|NCT03801109|OTHER|Hyperbaric group|Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
215018093|NCT03801109|OTHER|Magnetic group|There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
215018094|NCT03801109|OTHER|Physical group|A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
214416490|NCT00334594|DRUG|Cisplatin|Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
214416491|NCT00334594|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days
214416492|NCT00334594|PROCEDURE|Therapeutic conventional surgery|Extrapleural pneumonectomy
214416493|NCT00334594|RADIATION|Radiotherapy|CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
215018095|NCT03801109|OTHER|Baseline group|This group will be the control group that did not take any action, perform the activities of daily life
214416494|NCT02267967|DRUG|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
214416495|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
214416496|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
215018096|NCT06249477|DEVICE|Wrist activity tracker and scale|Wrist activity tracker used to evaluate number of steps, heart rate, and frequency of usage of the devices to monitor activity. Scale used to record a patient's weight value.
215018097|NCT06249477|BEHAVIORAL|Nutritional Coaching group sessions|Nutritional coaching group sessions held via zoom and performed by a certified clinical nutritionist regarding nutrition, and physical activity specific for weight loss.
214416497|NCT04375449|DIETARY_SUPPLEMENT|Pep2dia|what is the effect of Pep2dia on postprandial glycemia after a meal rich in carbohydrates (75g)
214416498|NCT04375449|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin
214416499|NCT05714358|BEHAVIORAL|Education|"* The patients were given face-to-face training on nutrition, physical activity and drug use in chronic renal failure .~* After the training, the biochemical parameters of the patients were followed for 6 months.~* In this process, the questions asked by the patients in order not to hinder their right to receive information were answered."
214416500|NCT01213706|DEVICE|Whole Body Periodic Acceleration (WBPA)|Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.
214416501|NCT01213706|DEVICE|Sham WBPA|The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
214416502|NCT03899818|DEVICE|drug-eluting balloon|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
214416503|NCT03899818|DEVICE|drug-eluting stent|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
214416504|NCT00579189|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
214416505|NCT00579189|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
214416506|NCT00579189|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
214416507|NCT00112983|BIOLOGICAL|eculizumab|
214416508|NCT00610688|DRUG|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
214416509|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
214416510|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
214416511|NCT03728595|DIAGNOSTIC_TEST|Venepuncture|A blood sample will be taken for serum bicarbonate
214416512|NCT03728595|DIAGNOSTIC_TEST|Spirometry|All patients who have not had a spirometry in the 12 months prior to the HAST will undergo one on the day of the HAST.
214505576|NCT02540525|DEVICE|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
214505577|NCT03563690|OTHER|treatment1|"1. Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~2. operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes."
214505578|NCT03563690|OTHER|treatment2|"1. Acupoints：Needling points are the same to the above group~2. operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes."
214416513|NCT03728595|DIAGNOSTIC_TEST|Hypoxic altitude simulation test (HAST)|HAST will be performed as per clinical team request. No changes to this intervention will be made for research purposes.
214416514|NCT02228408|DRUG|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Target Dose:~Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day~Dose Titration:~ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects."
214416515|NCT02228408|DRUG|Placebo|Placebo titration will mimic titration of active study arm
214416516|NCT00000878|DRUG|Lamivudine|
214416517|NCT00000878|DRUG|Stavudine|
214416518|NCT00000878|DRUG|Zidovudine|
214416519|NCT01230619|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
214416520|NCT01230619|DRUG|Placebo|Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
214416521|NCT04747392|BIOLOGICAL|SAL001|administrated once by subcutaneous injection
214416522|NCT04747392|BIOLOGICAL|FORSTEO|administrated once by subcutaneous injection
214416523|NCT02327104|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
214416524|NCT02327104|OTHER|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
214416525|NCT02742896|OTHER|Erectile dysfunction|"The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.~The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm."
214416526|NCT02433795|DRUG|bendamustine plus rituximab|Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
214416527|NCT02454244|BEHAVIORAL|ART with Mindfulness|"1. Introduction of ART with Mindfulness. Visualization of 100% recovery~2. Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation~3. The ART. Breaking the negative thoughts related to the illness. Walking meditation~4. Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation~5. Mindfulness and self-compassion. Kindly awareness meditation~6. The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation~7. Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities~8. Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values~9. The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self~10. Return to regular life. Mindfulness practice"
214416528|NCT02454244|BEHAVIORAL|Mindfulness Compassion|"1. Introduction.Definition of Compassion~2. Self-Esteemed and Compassion~3. Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions~4. Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability~5. Love,affection and self-compassion.How participants connect with the suffering of others~6. Equanimity~7. Forgiveness~8. Interdependence. Gratitude.Affection to unknown people~9. Developing affection and empathy.Empathy and burn out~10. Review of the practices and meditations"
214416529|NCT02454244|BEHAVIORAL|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
214416530|NCT05162144|PROCEDURE|Proximal Medial Gastrocnemius Recession|Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
214416531|NCT00038714|DRUG|SGN-00101|
214416532|NCT04911049|DIAGNOSTIC_TEST|Blood Pressure measurement|Blood Pressure measurement
214416533|NCT01240941|DRUG|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
214416534|NCT01240941|DRUG|Exemestane|25 mg orally daily
214416535|NCT01240941|DRUG|Goserelin|3.6 mg orally monthly
214416536|NCT03896841|OTHER|Observation|Ocular Findings Observations
214416537|NCT05463354|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
214416538|NCT05463354|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
214416539|NCT01428895|PROCEDURE|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
214416540|NCT01428895|OTHER|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
214416541|NCT00906620|OTHER|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
214416542|NCT04533464|BIOLOGICAL|MultiStem|Intravenous Infusion
214416543|NCT04533464|BIOLOGICAL|Placebo|Intravenous Infusion
214416544|NCT03236064|DRUG|Polyethylene Glycols|Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
214416545|NCT05453955|DRUG|Propofol|Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
214416546|NCT05453955|DRUG|Remimazolam Besylate|Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
214416547|NCT00199108|DRUG|Depocyt|
214416548|NCT00199108|DRUG|Dexamethasone|
214416549|NCT00819884|DRUG|AZD1656|Oral suspension
214416550|NCT02490176|DRUG|liraglutide|Liraglutide were taken daily for 7 days
214416551|NCT02490176|DRUG|placebo|Placebo were taken daily for 7 days
215018098|NCT00917020|DRUG|Nasal CO2|As-Needed during the 14 day Treatment Period
215018099|NCT00917020|DRUG|Inactive Placebo Gas|Placebo
215018100|NCT02176525|DRUG|BI 207127 NA|
214416552|NCT00001934|DRUG|Zenapax|
214416553|NCT02378116|PROCEDURE|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
214505579|NCT03563690|OTHER|treatment3|"1. Acupoints：treating points are the same to the above group~2. Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes."
215018101|NCT02176525|DRUG|Placebo|
215018102|NCT00544726|BEHAVIORAL|Physical training|
215018103|NCT00544726|BEHAVIORAL|No training|
215018104|NCT00468546|DRUG|MabThera/Rituxan|1
215018105|NCT00468546|DRUG|Methotrexate|2
215018106|NCT00468546|OTHER|Placebo|3
215018107|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using the sheathless guiding approach
215018108|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using a conventional guiding approach
214416554|NCT04114383|OTHER|D3-Creatine|30mg D3-Creatine to measure muscle mass
214416555|NCT04114383|OTHER|Deuterium Oxide|D2O provided to measure muscle protein synthesis
214416556|NCT04114383|OTHER|D3-3-methylhistidine|D3-3-methylhistidine is provided to measure muscle protein breakdown
214416557|NCT06181318|DIAGNOSTIC_TEST|Multiparametric MRI scan of the liver|MRI scans will be performed at the Champalimaud Foundation using a 1.5T scanner after patients have fasted for 4 hours. Transverse abdominal T1 maps will be acquired to estimate extracellular fluid (which increases in cases of fibrosis and inflammation) and T2\* maps will be acquired to estimate liver iron levels. These quantitative MRI maps will be laid onto the volumetric images of Couinaud segments. Multi-slice quantitative maps will be generated using Liver MultiScan software (Perspectum, UK) with operators blinded to patient status. T1 measurements will be adjusted for the iron level to give iron-corrected T1 maps (cT1). Reference ranges for cT1 have been defined in the general population. PDFF maps of the liver will be calculated using MRI multi-echo and spoiled-gradient-echo acquisition. No intravenous contrast agents will be used in Liver MultiScan maps and the total scan duration will be approximately 30 minutes.
215018109|NCT05236465|BEHAVIORAL|A 3-day course|The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
215018110|NCT05236465|BEHAVIORAL|Waiting list|Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
215018111|NCT06081465|DRUG|VG290131|The study drug and matching placebo will be administered orally.
215018112|NCT02551107|DEVICE|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
215018113|NCT01151631|DEVICE|occipital nerve stimulation|Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60
215018114|NCT03849612|DEVICE|AID System|AID system
215018115|NCT03849612|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
215018116|NCT03997734|DRUG|AB001|single and repeated dosing
215018117|NCT03997734|DRUG|oral capsule|single dose
214416558|NCT03336450|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
214505580|NCT03563690|OTHER|treatment4|"1. Acupoints：Needling points are the same to the above group~2. Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes."
214505581|NCT03563690|OTHER|treatment5|"1. points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~2. Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 \* 25mm single-use needle with the depth of 1-2mm."
215018118|NCT03997734|DRUG|positive comparative patch|single and repeated dosing
215018119|NCT03997734|DRUG|Placebos|single and repeated dosing
215018120|NCT01216085|DRUG|high-dose imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
215018121|NCT00641212|DRUG|Budesonide|
215018122|NCT00641212|DRUG|Placebo|
215018123|NCT01311011|PROCEDURE|SCT|SCT
215018124|NCT04044248|DEVICE|TIPS-obliteration|Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
215101973|NCT05670509|DRUG|administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
214416559|NCT03336450|DRUG|MHOS/SHP615|MHOS/SHP615
214505582|NCT03563690|DRUG|Celebrex|Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
214505583|NCT04800042|DIAGNOSTIC_TEST|Diagnostic test|Blood iron status : ferritin and transferrin saturation factor
214505584|NCT03355534|DRUG|Intravenous dexmedetomidine|drug is intravenously infused to patients
214505585|NCT03355534|DRUG|nasal dexmedetomidine|drug is nasally given to patients
214505586|NCT03355534|DRUG|intravenous saline|saline is given to patients intravenously
214505587|NCT03355534|DRUG|nasal saline|normal saline is given to patients nasally
214505588|NCT02628106|DRUG|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
215018125|NCT05549882|OTHER|no intervention|no intervention
215018126|NCT03375164|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
215018127|NCT00484328|DRUG|Ribavirin|different dosing regimes of Ribavirin
215101974|NCT05670509|DRUG|administration of Nasal midazolam in ER group as a rescue medication for seizure control.|Children from the ER group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
215018128|NCT01440751|DEVICE|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
214416560|NCT04761237|DRUG|Goal-directed fluid therapy (GDET)|Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
214416561|NCT00192400|BIOLOGICAL|CAIV-T|
214505589|NCT00073255|DRUG|hokt3g1 (ALA-ALA)|
214505590|NCT06396975|PROCEDURE|robotic surgery|robotic surgery
215018129|NCT01440751|DRUG|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
214505591|NCT04185961|DEVICE|EVERA-RAPHA with 60mmHG|Apply EVERA-RAPHA with 60mmHG for 4weeks
214505592|NCT04185961|DEVICE|EVERA-RAPHA with 100mmHG|Apply EVERA-RAPHA with 100mmHG for 4weeks
215018130|NCT03016377|BIOLOGICAL|iC9-CAR19 cells|Three dose levels are being evaluated: dose level -1 (1 x 10\^5), dose level 1 (5 x 10\^5), and dose level 2 ( 1x 10\^6)
214505593|NCT04402736|BEHAVIORAL|The modified Barthel Index-based rehabilitation nursing program|The intervention with the program based on the MBI classified function of patients into five levels, with every 20 points as a level, Each level corresponds to different training items. Training items included self-care training and training in transfer activities, sitting balance, walking, and sit-to-stand, etc. Each training session lasting at least 30 minutes, two sessions per day, for seven continuous days. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
215018131|NCT03016377|DRUG|Rimiducid|Subjects with CRS and ICAN will assign one of two dose levels (DL)s of rimiducid with the standard treatment: 0.05 mg/kg or 0.1 mg/kg for subjects with CRS and 0.01mg/kg or 0.1mg/kg for subjects with ICAN. Subjects will first be enrolled on DL 1 and then enrolled on DL 2, and 0.4mg/kg rimiducid will be given to subjects who did not respond to the initial dose.
215018132|NCT03016377|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
215018133|NCT03016377|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
215018134|NCT05249348|DRUG|PC14586|An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
215018135|NCT06244199|BEHAVIORAL|T2CR Intervention|The T2CR intervention entails two phases. T2CR Phase 1 (Assess and Plan) is a program that occurs during or shortly after hospital discharge that includes completion of a comprehensive risk assessment, development of strategies to address identified risks while restoring function through education regarding living a healthy lifestyle and familiarization and practice of exercise training techniques. T2CR Phase 2 (Implementation and Support) entails a HBCR program that is based on the Promising Practices HBCR but further enriched by insights and strategies developed in T2CR Phase 1 and which also incorporates techniques that maximize the effectiveness and efficiency of exercise training.
215018136|NCT06244199|OTHER|Usual Care|Participants will receive usual care following an acute heart event that is recommended by their providers, which may include Promising Practices Home-Based Cardiac Rehabilitation (aka Usual HBCR) at both sites or site-based CR at VAPHS.
215018137|NCT02393469|OTHER|pulmonary rehabilitation|Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
214416562|NCT02278848|OTHER|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
214416563|NCT02372019|BEHAVIORAL|CBM With Active Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 10 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting."
214416564|NCT02372019|BEHAVIORAL|CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control."
214416565|NCT02372019|BEHAVIORAL|Inert CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions."
214416566|NCT00774436|PROCEDURE|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
214416567|NCT04009642|OTHER|Surely observational based on disease state|Metabolism in T2DM vs non diabetic
214416568|NCT02735486|DIETARY_SUPPLEMENT|Ginger drink|300 ml ginger drink
214416569|NCT02735486|DIETARY_SUPPLEMENT|Placebo: Super pure water|Placebo: Super pure water
214416570|NCT04241653|PROCEDURE|Pressure Support Ventilation|Ventilator will be adjusted to administer pressure at 10 cmH2O.
214416571|NCT04241653|PROCEDURE|Unparalyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.
214416572|NCT04241653|PROCEDURE|Paralyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.
214416573|NCT04241653|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.
214416574|NCT04241653|DRUG|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.
214416575|NCT01955694|DRUG|BAY94-8862|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
214416576|NCT01955694|DRUG|Eplerenone|INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
214416577|NCT01955694|DRUG|Placebo|matching placebo
214416578|NCT03020108|OTHER|Blood sample|2 cc blood samples will be drawn from antecubital vein
214416579|NCT01326715|DRUG|Mangafodipir (Teslascan)|gadolinium enhancement on contrast enhanced brain MRI.
215018138|NCT02393469|OTHER|Education and self-management for COPD|Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
214505594|NCT04402736|BEHAVIORAL|Usual care|Patients in the control group received clinical usual care including the activities of daily living assessment, early mobilization guide and health education. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
214505595|NCT02499601|DEVICE|CORolla™ TAA device|
214505596|NCT04773431|DRUG|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
215018139|NCT02970812|DEVICE|Electrical Muscle Stimulation|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
215018140|NCT02970812|DEVICE|Transcutaneous Electrical Nerve Stimulation|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
215018141|NCT00827307|DRUG|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
215018142|NCT00827307|DRUG|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
215018143|NCT02464358|BEHAVIORAL|IMB Intervention Group|Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
215018144|NCT02464358|BEHAVIORAL|Attention Control|Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
215101975|NCT05670509|DRUG|administration of Buccal midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
214416580|NCT04879082|OTHER|Professional course, occupational exposures|"The data collected are the following variables: age, sex, diploma, professional course coded in CITP (International Standard Classification of Professions) and NAF (French Nomenclature of Activities), occupational exposures, smoking, risk factors non-professionals, clinical elements of ILD and elements relating to an occupational disease certificate. This database is anonymized.~The precise diagnosis of ILD is retained during the multidisiciplinary meeting.~Occupational exposures are assessed in specialized consultation :~* a first professional interview phase: The professional history is traced, listing the training courses followed and the trades carried out. The questioning is precise and focuses on the different tasks performed, and the products used.~* a second step, where a questionnaire is completed by the doctor: A list of specific substances is offered to the patient, who responds whether or not he thinks he has been exposed to them in his professional past."
214416581|NCT01772420|DRUG|Eltrombopag Olamine|Given PO
215101976|NCT05670509|DRUG|administration of intramuscular midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
214416582|NCT01772420|OTHER|Laboratory Biomarker Analysis|Correlative studies
214416583|NCT01772420|DRUG|Lenalidomide|Given PO
214416584|NCT04293783|DIETARY_SUPPLEMENT|L.Reuteri|daily supplementation with two tablet for six months
215018145|NCT05562921|BEHAVIORAL|Controls-ususal care|Controls: patients who did not receive remote patient monitoring for blood pressure prescribed during routine care delivery, with multivariable matching to cases
215018146|NCT05562921|BEHAVIORAL|Cases-remote patient monitoring prescribed|Cases: patients prescribed remote patient monitoring for blood pressure during routing care delivery
214416585|NCT04293783|DIETARY_SUPPLEMENT|Placebo|daily supplementation with two tablet for six months
214416586|NCT05997654|DEVICE|MEDGEL ANTIAGE|The MEDGEL ANTIAGE is a medical grade silicone plate, biocompatible.
214416587|NCT02473120|BIOLOGICAL|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
214416588|NCT01928511|DRUG|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
214416589|NCT01928511|DRUG|Nucleos(t)ide analogue therapy|
214416590|NCT04596579|DIAGNOSTIC_TEST|SARS-CoV-2 Antibody Analysis|10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
214416591|NCT04596579|DIAGNOSTIC_TEST|Weck-cel Swab Collection|A Weck-cel swab will be used to collect secretions from the mucosal epithelium
214416592|NCT04596579|BEHAVIORAL|Web Based Questionnaire|A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
214416593|NCT04714450|BEHAVIORAL|Experimental: MMST+|The format of the MMST will remain the same; however, the white noise, images and math task will be modified to mitigate habituation effects.
214505597|NCT01237496|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
215018147|NCT01993758|PROCEDURE|Low tourniquet pressure|Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation
215018148|NCT01993758|PROCEDURE|Conventional tourniquet pressure|Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
215018149|NCT01596244|BEHAVIORAL|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
214505598|NCT01183598|DRUG|tocilizumab [RoActemra/Actemra]|maintenance dose
214505599|NCT04379869|DRUG|NNZ-2591|Single dose of NNZ-2591
214505600|NCT04379869|DRUG|Placebo|Comparator for double-blind MAD
214505601|NCT04931524|DRUG|carbon-14-[14C]-ANG-3777|Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
214505602|NCT05750043|DRUG|bi-annual CDTI|"bi-annual community directed treatment with ivermectin (CDTI) and community-based slash and clear vector control intervention"
214505603|NCT05194696|BEHAVIORAL|Questionnaire|Patients have to answer a questionnaire about their caffeine consumption habits during lifetime
215018150|NCT06301152|DEVICE|high intensive laser|high-intensity laser ,three times in a week, for three weeks, 9 session
215018151|NCT06301152|DEVICE|extracorporeal shock wave therapy|extracorporeal shock wave therapy, once a week, for three weeks ,3 times,
215018152|NCT04925440|DIETARY_SUPPLEMENT|Bifidobacterium longum 1714® strain|Probiotic capsules containing 5 x 10\^9 CFUs, corn-starch and magnesium stearate.
215018153|NCT04925440|DIETARY_SUPPLEMENT|Placebo|Capsules containing corn-starch and magnesium stearate only.
215018154|NCT00291226|DRUG|Glycine|Glycine 0.4 g/kg bid
215018155|NCT00291226|DRUG|Placebo|Placebo
215018156|NCT06293144|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
215018157|NCT03563612|DEVICE|cpap|application of cpap to the non-dependent lung, during one lung ventilation
215018158|NCT06285903|PROCEDURE|internal sinus lift surgery|surgery approach
215101977|NCT00454181|DRUG|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
215101978|NCT00454181|OTHER|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
215101979|NCT06506890|OTHER|Use of C-Polar coated HVAC Filter versus conventional HVAC Filter|comparing the difference in reduction of bioaerosols between HVAC filters.
215101980|NCT06287307|OTHER|Placebo|The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
214416594|NCT04292093|BEHAVIORAL|Home rehabilitation training|The rehabilitation training will be provided via Lumosity platform. Participants will be asked to play computer video-games aimed at strengthening specific sub-functions pertaining to the macro area of executive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. Specifically, 20 games out of a total of 64 available games provided by the platform have been selected. The selected games are aimed at training 4 cognitive skills: memory, attention, cognitive flexibility and problem solving. In particular, 5 different games were chosen for each cognitive ability.
214416595|NCT04292093|BEHAVIORAL|Home control activity|The control group will watch a series of animated / TV shows suitable for the sample age, again for 30 minutes a day, 5 days a week, for 8 weeks. The videos will be provided by the experimenter and participants will watch them on their personal computer. At the end of each videos, participants will answer a series of multiple-choice questions aimed at evaluating the attention deployed to the content of the videos.
214416596|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: Beef Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
215018159|NCT04845971|DIETARY_SUPPLEMENT|Saisei Maf capsules|Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan
215018160|NCT04726904|PROCEDURE|Sacral neuromodulation in conventional implantation technique|Sacral neuromodulation is implanted with the patients in a prone position, then the insert point of the needle is decided according to anatomical landmarks; afterwards, the lead will be inserted.
215018161|NCT06695897|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
214416597|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: whey Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
214416598|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: CHO|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
214416599|NCT00242853|PROCEDURE|Power doppler ultrasonography|
214416600|NCT00242853|PROCEDURE|High frequency ultrasonography|
214416601|NCT00242853|PROCEDURE|Exhaled nitric oxide assessment|
214416602|NCT03923387|DEVICE|MynxGrip|Vascular Closure
214416603|NCT03923387|OTHER|Manual compression|Manual compression is a commonly used method to achieve hemostasis of femoral artery
214416604|NCT05478902|PROCEDURE|Exercise Therapy|Exercise protocol for rotator cuff related shoulder pain
214416605|NCT05478902|PROCEDURE|Extracorporeal Shockwave Therapy|High Energy Extracorporeal Shockwave Therapy
214416606|NCT05478902|PROCEDURE|Ultrasound-Guided Percutaneous Irrigation|Two sessions of Ultrasound-Guided Percutaneous Irrigation
214416607|NCT05760690|PROCEDURE|Retro-Auricular Single-Site Endoscopic Thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
214416608|NCT05760690|PROCEDURE|Transoral Endoscopic Thyroidectomy Vestibular Approach|The patient was placed in a supine position with slight neck extension under nasotracheal intubation. The mouth was garbled with povidone iodine before surgery. Three laparoscopic ports (a 10- to 15-mm port at midline and two 5-mm ports at the lateral junction between the canine and first premolar teeth)were inserted under the lower lip at the oral vestibular area.The strap muscleswere separated in the midline to expose the thyroid and trachea. The recurrent laryngeal nerve (RLN) was identified at the insertion to the larynx, then followed downandparallel tothe trachea inferiorly.
214505604|NCT04851743|OTHER|Dry needling|The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
214505605|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
214505606|NCT05545306|DIETARY_SUPPLEMENT|fasting|Fasting for at least 24 hours
214505607|NCT05545306|DIETARY_SUPPLEMENT|-50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-50% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
214505608|NCT05545306|DIETARY_SUPPLEMENT|+150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
214505609|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+200% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
215101981|NCT06287307|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
215101982|NCT00001696|DRUG|Genistein|
215018162|NCT06874985|BEHAVIORAL|Lived experience video campaign|Participants in the selected villages will be shown a two-minute video developed specifically for the Lived Experience Communication Campaign in addition to usual awareness they receive for cancer screening mobilisation. The video will feature personal narratives from cancer survivors and local leaders emphasizing the importance of early detection and screening.
214416609|NCT05760690|PROCEDURE|Transareola Endoscopic Thyroidectomy|The patient was in supine position. Incision was made inside the right areola and a 10mm puncture device was placed, subcutaneous separation rod was used to separate the space, and a 30° endoscope was introduced, puncture device was placed in a 5mm incision on the left areola, ultrasonic knife free flap was used, subcutaneous separation space was placed in the upper sternal segment, and a 5mm puncture device was placed outside the right areola. The anterior cervical flap was further dissociated to establish a space. The median cervical line was cut to cut off the isthmus of the thyroid, and the tracheal fascia ligament of the thyroid was separated and the nerve was exposed to protect the nerves. Then remove the lobe of thyroid and central lymph nodes
214416610|NCT03670602|BEHAVIORAL|Episodic Future Thinking|Participants will practice using these cues when making decisions about health choices. Participants will implement EFT while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.
214416611|NCT03670602|BEHAVIORAL|Daily Check in|Participants will be asked to access the electronic app at the same rate as the experimental group (e.g. daily). Participants will receive behavioral weight loss treatment including The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, and finding behavioral substitutes for highly reinforcing food.
214416612|NCT01772056|DRUG|Fluticasone, cream|Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse
214416613|NCT01772056|DRUG|Placebo,|Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
214416614|NCT03828695|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
214416615|NCT01456936|DRUG|Placebo|Triple dummy placebo for each treatment arm
214416616|NCT01456936|DRUG|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
214416617|NCT01456936|DRUG|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
214416618|NCT01456936|DRUG|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
214416619|NCT04301674|DEVICE|Breath Biopsy|ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)
214416620|NCT01571778|BEHAVIORAL|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
214416621|NCT00543725|DRUG|TMC278|25 mg tablet once daily for 96 weeks
214416622|NCT00543725|DRUG|efavirenz|600 mg tablet once daily for 96 weeks
214416623|NCT00003790|GENETIC|polymerase chain reaction|
214416624|NCT00003790|OTHER|flow cytometry|
214416625|NCT04483843|OTHER|No intervention|No intervention will be performed while it is retrospective observational study.
214416626|NCT00906698|DRUG|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
214416627|NCT00906698|DRUG|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
214416628|NCT00906698|DRUG|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
214416629|NCT00906698|DRUG|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
214416630|NCT00906698|DRUG|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
214416631|NCT00906698|DRUG|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
214416632|NCT01526603|DRUG|Carboplatin|Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
214416633|NCT01526603|BIOLOGICAL|Autologous stem cell infusion|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
214416634|NCT01526603|BIOLOGICAL|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) \> 2000/μL for 3 consecutive days.
215101983|NCT04032080|COMBINATION_PRODUCT|Drug 1: LY3023414; Drug 2: Prexasertib|"Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses."
214416635|NCT01526603|RADIATION|Radiation therapy|It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring \>1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
214416636|NCT01526603|DRUG|Isotretinoin (13-cis-retinoic acid)|Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients \>12 kg isotretinoin (accutane) should be administered at 160 mg/m\^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
214416637|NCT01526603|DRUG|Melphalan|Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
214416638|NCT01526603|DRUG|Etoposide|Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
214416639|NCT02892799|OTHER|NICOM-Guided Diuresis|NICOM-based assessment of PLR-induced change in cardiac index
214416640|NCT02892799|OTHER|Standard of Care|
214416641|NCT05460936|OTHER|Lower Extremity Functional Training|motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
214416642|NCT05460936|OTHER|conventional physical therapy|Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
214416643|NCT01948960|DRUG|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
214416644|NCT04440943|DRUG|CDX-527|CDX-527 is administered by infusion every 2 weeks
214416645|NCT02377531|OTHER|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
214416646|NCT02377531|OTHER|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
214416647|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Standard Information-Only version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
214416648|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Enhanced Behavior Activation version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
214416649|NCT01249040|PROCEDURE|Physical therapy|
214416650|NCT01249040|PROCEDURE|steroid intraarticular injection|
214416651|NCT01271270|DRUG|Palomid 529|
214416652|NCT04735939|RADIATION|radiotherapy|Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
214416653|NCT00637676|PROCEDURE|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
214694022|NCT01773135|OTHER|collection of blood sample and tocolysis adminstration|"investigators will abtain a blood sample from all patient to measure the serum level of ACTH.~all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.~After delivery, investigators devide the pateints into 2 groups (full term delivery \& preterm delivery) and investigators compare between these 2 groups by level of hormone."
214416654|NCT00637676|PROCEDURE|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
214416655|NCT04215341|BEHAVIORAL|Physiotherapy|A course of breathing retraining delivered by a physiotherapist and practiced by the participant at home.
214416656|NCT00092560|DRUG|MK0653, ezetimibe|
214416657|NCT00092560|DRUG|Comparator: fenofibrate monotherapy|
214416658|NCT00000251|DRUG|30% N2O|
214416659|NCT00000251|DRUG|0.2% isoflurane|
214416660|NCT00000251|DRUG|0.4% isoflurane|
214416661|NCT00000251|OTHER|100% oxygen|Placebo
214416662|NCT03569683|PROCEDURE|External bevel gingivectomy|External bevel gingivectomy will be performed on 30 patients wherein the suprabony pockets will be eliminated with the help of a Bard parker blade no 15. The incision would be given 1mm apical to the pockets which would be marked by a Crane and Kaplan pocket marker, then the incision would be given and the tissue would be removed with the help of kirkland and orbans knives and the gingiva would be shaped. After the surgical procedure the patients would be treated either with the Diode laser(Group A), Hyaluronic acid gel (Group B), or Herbal gel(Group C).
214416663|NCT03569683|DEVICE|Diode laser Biostimulation|After gingivectomy, laser irradiation will be done using bio-stimulation tip in the anterior sextants of the mouth. (Group A)
214416664|NCT03569683|OTHER|Hyaluronic acid (Gengigel) topical application.|After gingivectomy, Hyaluronic acid gel(Gengigel) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group B)
214416665|NCT03569683|OTHER|Herbal gel (Hiora SG) topical application|After gingivectomy, Herbal gel(Hiora SG) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group C)
214416666|NCT02274402|BIOLOGICAL|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
214416667|NCT00459264|DRUG|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
214416668|NCT00459264|DRUG|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
214416669|NCT05403307|BIOLOGICAL|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
214416670|NCT05403307|BIOLOGICAL|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
214416671|NCT05566405|PROCEDURE|General Anaesthesia|All patients in the general anaesthesia group will be premedicated with intravenously administered (iv) midazolam (2mg) and fentanyl (100 mcg). Induction will be performed using intravenous propofol (2.5-3mg/kg) and lidocaine (40mg); dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg will also be administered. After successful tracheal intubation, total intravenous anaesthesia will be maintained by administering propofol (0.05 mg/kg/sec iv) and remifentanil (0.2 mcg/kg/sec iv). Pain management will be achieved by paracetamol (1g iv) and tramadol (100mg iv) whereas muscle relaxation by vecuronium (0.6 mg/kg iv).
214416672|NCT05566405|PROCEDURE|Combined (Epidural and Spinal) Anaesthesia|Combined (epidural and spinal) anaesthesia will be performed using an epidural 18G needle and a spinal 27G needle, in the L2-L3 or L3-L4 interspace. Induction will be carried out by spinal intrathecal administration of levobupivacaine (2.6-3ml of 0.5%) and mild sedation by midazolam (5mg iv in bolus). All patients will be administered dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg iv. Maintenance will be performed 75 minutes after induction and obtained using an epidural administration of levobupivacaine (4-5ml of 0.5%).
214416673|NCT05566405|PROCEDURE|Open Retropubic Radical Prostatectomy|All patients will undergo a nerve-sparing open retropubic radical prostatectomy
214416674|NCT05653089|PROCEDURE|Choice and adjustment of the wheelchair according to the patient's needs|"After a personalized analysis of the patient and his needs, the occupational therapists define the equipment necessary for the good positioning of the patient:~* Choice and adjustments of the wheelchair~* Choice and adjustments of the wheelchair/patient interface"
214689649|NCT05267353|BEHAVIORAL|Exercise intervention program|"It was developed, along with usual care, to prevent restricted ROM in both upper body and limited general physical functioning. Patients in exercise intervention group received verbal instructions about stretching major muscles and phsical activity recommendations from a trained nurse (intervenor), and then received the booklet plus DVD.~The physical therapist who developed and adjusted this program also trained the intervenor. After verifying the intervenor has performed exercise interventions were consistent with the physical therapist, he/she was responsible for all interventions. Therefore, if pain or discomfort persists for more than an hour, the patient should inform the intervenor. The intervention group patients also received telephone follow-up from the intervenor every two weeks until the end of the intervention."
214689650|NCT00528346|BEHAVIORAL|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies-allowing them to view their brain activity.
214689651|NCT00528346|BEHAVIORAL|placebo|Some participants will see simulated data that does not come from their own brains.
214689652|NCT01899404|BIOLOGICAL|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
214416675|NCT04223362|OTHER|Community-based physical activity programme|After completing a pulmonary rehabilitation programme, participants will enrol a 6-months personalised community-based physical activity programme, which will include 2 sessions/week, with the aerobic training being the cornerstone. Patients will receive the PICk UP manual and a diary to register their physical activities. During the 1st month the physiotherapist will guide patients through 4 types of outdoors and indoors physical activities. Patients will then be asked to choose and commit to 1 or 2 activities, according to their preferences, which they shall integrate for another 5 months. During this period, the support provided by physiotherapist will decrease over time.
214416676|NCT04223362|OTHER|Pulmonary Rehabilitation|Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
214416677|NCT02860260|BIOLOGICAL|Blood samples|
214416678|NCT02860260|OTHER|Cerebral MRI|
215018163|NCT06400745|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
215018164|NCT06400745|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
215018165|NCT06400745|PROCEDURE|Cataract surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
215018166|NCT03614780|BEHAVIORAL|30 minutes outdoors|Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
214416679|NCT06501079|PROCEDURE|ultrasound guided Erector Spinae Plane Block using 27ml bupivacaine 0.25%|"ESP block will be performed U/S at the level of T 10 paraspinal level. The ultrasound transducer should be placed in the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level.~Erector spinae muscle should be identified superficial to the transverse process. The needle inserted superior to the ultrasound probe in the cephalad to caudal direction. Once the needle tip is below the erector spinae muscle.~This separation from the transverse process confirms the proper needlemposition.~The local anesthetic should then be injected in 5 ml increments. The block will be performed preoperatively."
214416680|NCT01049620|DRUG|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
214416681|NCT01766167|DRUG|MP-424|Low
214416682|NCT01766167|DRUG|MP-424|Middle
214416683|NCT01766167|DRUG|MP-424|High
214416684|NCT01766167|DRUG|MP-424|Multiple
214416685|NCT02476773|BIOLOGICAL|Na-GST-1/Alhydrogel plus GLA-AF|
214416686|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
214416687|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel plus GLA-AF|
214416688|NCT02476773|BIOLOGICAL|Sterile Saline Placebo|
215018167|NCT02355470|BEHAVIORAL|GIFTSS|Universal education and brief counseling regarding sexual violence
215018168|NCT02355470|BEHAVIORAL|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
214416689|NCT02828605|DEVICE|Virtual Interactive Platform (VIP) Transplant|
214416690|NCT01813903|BEHAVIORAL|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
214416691|NCT01813903|BEHAVIORAL|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
214416692|NCT03035656|DRUG|Ropivacaine|Administration of Ropivaciane via epidural injection intra-operatively
214416693|NCT03035656|OTHER|Saline|Administration of saline via epidural injection intra-operatively
214416694|NCT03942822|DIETARY_SUPPLEMENT|Milled chia seeds|8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia
214416696|NCT04138862|BEHAVIORAL|Product Labelling and Sensory modifications|the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).
214416697|NCT03646331|DRUG|Imeglimin Reference product|Reference product
214416698|NCT03646331|DRUG|Imeglimin|Test product (new formulation tablet)
214416699|NCT02951117|DRUG|Venetoclax|Tablet
215018169|NCT01275937|DRUG|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
215018170|NCT01275937|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
214416700|NCT02951117|DRUG|ABBV-838|Intravenous infusion
214416701|NCT02951117|DRUG|Dexamethasone|Tablet or intravenous infusion
214416702|NCT04373187|DRUG|CC-93538|one injection of 2mL
214416703|NCT04373187|DRUG|CC-93538|two injections of 1.2mL
215018171|NCT07056413|PROCEDURE|BRILMA block|20 ml 0.25 % bupivacaine was injected into the fascial plane between the serratus anterior muscle and the external intercostal muscle at T4 level.
215018172|NCT07056413|OTHER|Standard intravenous analgesia.|Standard intravenous analgesia.
215018173|NCT06751992|DRUG|Conversion to extended-release tacrolimus|Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment
215018174|NCT06751992|DRUG|Maintenance of immediate-release tacrolimus|Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment
214416704|NCT05166174|PROCEDURE|Transvaginal ultrasound in the third trimester pregnancy|Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
214416705|NCT02824003|DRUG|ISIS-GCGRRx|once weekly dosing for 13 weeks
214416706|NCT02824003|DRUG|Placebo|once weekly dosing for 13 weeks
214416707|NCT03557333|COMBINATION_PRODUCT|INP104|No more than 2 doses within 24 hours, 3 doses within 7 days. 1.45 mg in a divided dose, one actuation per nostril.
214416708|NCT02393898|DRUG|Bevacizumab|Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.
214416709|NCT02393898|DRUG|Carboplatin|Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
214416710|NCT02393898|DRUG|Paclitaxel|Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
214416711|NCT03634189|DRUG|Cannabidiol|Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
214416712|NCT02272517|DRUG|Vortioxetine 10-20 mg|
214416713|NCT02272517|DRUG|Escitalopram 10-20 mg|
214416714|NCT04178395|DEVICE|bihemispheric transcranial direct stimulation|"tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA)."
214416715|NCT02846415|BEHAVIORAL|Play Intervention for Dementia|"1. 8 weekly session, 45-75 minutes each~2. Play with toys~3. Sessions will be facilitated by a play specialist, trained play assistants, and centre staff."
214416716|NCT01793740|BEHAVIORAL|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
214416717|NCT02293421|OTHER|Obstructive sleep apnea|
214416718|NCT02970461|OTHER|Gamified Group|See Gamified Group in Arms description.
214416719|NCT02970461|OTHER|Control Group|See Control Group in Arms description.
214416720|NCT06089629|PROCEDURE|Lingual frenuloplasty|Surgical release of ankyloglossia with suture reorientation of the wound to improve lingual mobility, done under local or general anesthesia
215018175|NCT06756165|BEHAVIORAL|Mental health screening|Participants in the intervention arm will receive a mental health screening, referral, and counselling program by trained LHWs and BHU staff. LHWs will screen 120-170 WRA using PHQ-2 and GAD-2. Screen-positive WRA will be referred to BHUs, where trained doctors will reassess them using PHQ-9 and GAD-7. Those with mild to moderate anxiety or mild to moderately severe depression will receive two counselling sessions (initial and follow-up), each lasting at least 20 minutes, covering psychoeducation, awareness, and coping strategies. Severe cases will be referred to tertiary care for specialized mental health services. Mild cases will be advised to join resilience-building sessions. All WRA will attend two of three monthly group sessions by LHWs (20-25 WRA, 2 hours each), focusing on mental health literacy and coping strategies, including those related to climate change stressors like floods.
214416721|NCT02934958|BEHAVIORAL|Colon Cancer Screening Navigation|Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
214416722|NCT02934958|BEHAVIORAL|Standard of Care|Patients will be tracked to compare how effective are usual care methods
214416723|NCT05933720|DRUG|Polypeptides|The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
215018176|NCT03042637|DRUG|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
214416724|NCT05933720|DEVICE|Femoral-popliteal bypass grafting with a synthetic graft above the knee|The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee
214416725|NCT05933720|OTHER|Routine conservative treatment|The patients will undergo routine conservative treatment as per clinical guidelines (acetylsalicylic acid 100mg daily, atorvastatin 20mg daily)
214416726|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the control arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
214416727|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the Lower Urinary Tract Symptoms ( LUTS) arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
214505610|NCT05545306|DIETARY_SUPPLEMENT|-25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
215018177|NCT04177199|OTHER|TRIAGE HF Pathway|A new care pathway (Triage-HF Plus) for the remote monitoring and management of heart failure stability in a cohort of device patients at 3 hospital sites in North West England.
214416728|NCT03383887|DRUG|Placebo oral capsule|Placebo before sleep
214416729|NCT03383887|DRUG|DAW1033D oral capsule|DAW1033D before sleep
214505611|NCT05545306|DIETARY_SUPPLEMENT|+150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
214505612|NCT02697305|DIETARY_SUPPLEMENT|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
214416730|NCT04455009|DIETARY_SUPPLEMENT|Fitness Drink Formula|Single drink provided following baseline assessments
214416731|NCT06118229|DEVICE|Wearable smart devices and PROs|Patients wearing wearable smart devices to monitor physiological data while regularly utilizing PROs to report subjective assessments of their own health status.
215018178|NCT05611736|OTHER|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
215018179|NCT05611736|OTHER|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
214416732|NCT00565708|OTHER|placebo|Placebo Comparator
214416733|NCT00565708|DRUG|Acetylsalicylic acid|Adjuvant Therapy
214416734|NCT00657280|DRUG|Sitagliptin|No one is blinded to the treatments.
214416735|NCT00698802|DRUG|EX1000|Treat-to-target titration scheme, s.c. injection
214416736|NCT00698802|DRUG|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
214416737|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.2%|
214416738|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.1%|
214416739|NCT02322216|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
214416740|NCT03096184|DRUG|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
214416741|NCT03096184|DRUG|Tegafur Gimeracil Oteracil Potassium Capsules|50mg bid p.o. every day for 14 days as a cycle
214416742|NCT01585038|DRUG|Efavirenz|600mg orally every evening
214505613|NCT02697305|DIETARY_SUPPLEMENT|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
214505614|NCT02697305|OTHER|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
215018180|NCT00450749|OTHER|placebo|Given PO
214416743|NCT01585038|DRUG|Rilpivirine|25mg orally once daily
214416744|NCT01304394|DRUG|Ped3CB|The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
214416745|NCT02909049|DRUG|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
214505615|NCT03440645|OTHER|Family-oriented primary cardiovascular prevention|An initial screening visit including a targeted history, physical exam, and investigations as per the Canadian Cardiovascular Society's recommendations for cardiovascular primary prevention. Counselling and informational handouts on improved cardiovascular risk factor and lifestyle habits. All family and household members, as well as the cardiovascular disease proband, are encouraged to attend and participate in all healthcare visits.
214505616|NCT05656066|BEHAVIORAL|The Vibration Intervention|The vibration frequency of the massager, which accelerates blood circulation, is 6000 / min, it works with a 1.5 volt battery. Can be used easily with one hand. The vibration simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
215018181|NCT00450749|PROCEDURE|therapeutic conventional surgery|Undergo radical prostatectomy
215018182|NCT00450749|OTHER|laboratory biomarker analysis|Correlative studies
214416746|NCT02909049|DRUG|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
214416747|NCT02909049|DRUG|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
214416748|NCT02909049|DRUG|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
214416749|NCT00061672|DRUG|ABT-510 - Thrombospondin-1 Mimetic|
215018183|NCT00450749|DRUG|lycopene|Given PO
215018184|NCT01245049|BIOLOGICAL|Boostrix PolioTM|Single dose, intramuscular administration.
215018185|NCT01245049|BIOLOGICAL|RepevaxTM|Single dose, intramuscular administration.
215018186|NCT01245049|BIOLOGICAL|PriorixTM|Single dose, intramuscular or subcutaneous administration.
215018187|NCT03600727|DRUG|Propofol|Propofol will be used to offer intraoperative sedation for patients in Propofol group.
215018188|NCT03600727|DRUG|Dexmedetomidine|Dexmedetomidine will be used to offer intraoperative sedation for patients in Dexmedetomidine group.
215018189|NCT05343429|DRUG|Benzydamine hydrochloride|In BN group,15 ml of 0.15 % Benzydamine hydrochloride (BN) will be dissolved in 15 ml plain water in a sterile container and given to participants before anesthesia for surgery
214416750|NCT01738802|DIETARY_SUPPLEMENT|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
214416751|NCT01738802|DRUG|Placebo|This group will take a placebo.
214416752|NCT00920296|DRUG|GSK1265744|GSK drug
214416753|NCT03965702|DEVICE|Use of a decision support system on the EV1000 monitoring (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
214416754|NCT03965702|OTHER|Manual application of the GDFT protocol (standard of care)|Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
214416755|NCT00235040|BEHAVIORAL|Smart Form|Computer Decision Support System
214416756|NCT03285191|OTHER|Numerical rating scale|Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
214505617|NCT05656066|BEHAVIORAL|The Pressure Intervention|Pressure was placed in the ıntramuscular area properly 30 seconds before injection. Then the injection process was completed.
214505618|NCT06046196|DRUG|Sarpogrelate SR|Sarpogrelate SR 300mg, once a daily, for 24weeks
214505619|NCT06046196|DRUG|Sarpogrelate|Sarpogrelate 100mg, 3 times a day, for 24weeks
215018190|NCT05343429|DRUG|Aspirin|In group AP, Aspirin (AP) 600 mg Aspirin tablets dissolved in 30 ml of plain water in a sterile container will be given to participants for gargling before anesthesia for surgery
215018191|NCT00877864|BEHAVIORAL|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
215018192|NCT00877864|BEHAVIORAL|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
215018193|NCT00877864|BEHAVIORAL|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
215018194|NCT00877864|BEHAVIORAL|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
215018195|NCT00877864|BEHAVIORAL|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
215018196|NCT00877864|BEHAVIORAL|Control|No exercise program provided by the study
215018197|NCT01572688|DRUG|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
215018198|NCT04405388|DRUG|Placebo|Placebo will be given orally as capsule (same size and weight as Spermidine capula)
215101984|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day."
215101985|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort."
214416757|NCT03285191|OTHER|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
214416758|NCT01082809|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
214416759|NCT06319664|PROCEDURE|retrosigmoid approach (RSA)|The skull base approach choice was fundamentally followed by the modified classification.
214416760|NCT06319664|PROCEDURE|subtemporal transtentorial transpetrosal approach (STTA)|The skull base approach choice was fundamentally followed by the modified classification.
214416761|NCT06319664|PROCEDURE|extended pterional transtentorial approach (EPTA)|The skull base approach choice was fundamentally followed by the modified classification.
215101986|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort."
214416762|NCT06319664|PROCEDURE|pretemporal trancavernous anterior transpetrosal approach (PTCA)|The skull base approach choice was fundamentally followed by the modified classification.
214416763|NCT06319664|PROCEDURE|presigmoid combined supra-infratentorial approach (PCA)|The skull base approach choice was fundamentally followed by the modified classification.
214416764|NCT06319664|PROCEDURE|inoperable|The skull base approach choice was fundamentally followed by the modified classification.
214416765|NCT02276508|DRUG|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
214416766|NCT00116623|DRUG|Indomethacin|
214416767|NCT00116623|DRUG|Magnesium sulfate|
214416768|NCT03956641|OTHER|Adaptated Physical Activity|Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
214416769|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition|a single dose of 1 mg AEF0117 in fed condition
214416770|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition|a single dose of 1 mg AEF0117 in fasting condition
214416771|NCT04327882|DIAGNOSTIC_TEST|Point-of-care ultrasound|performance of a POCUS: lung and cardiac ultrasound mainly
214416772|NCT05004272|PROCEDURE|Massage|20-minute manual full-body massage
214416773|NCT05004272|PROCEDURE|Gymnastics|20-minute moderate body workout
215018199|NCT04405388|DRUG|Spermidine|Spermidine will be given orally as capsule (4mg/day)
215018200|NCT02805348|DRUG|Bixalomer|Oral
215018201|NCT03812172|DRUG|99mTc-PYP or 99m Tc-HDP|10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
215018202|NCT00576745|PROCEDURE|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
215018203|NCT00576745|DEVICE|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
215018204|NCT05680636|DIAGNOSTIC_TEST|temperature measurement|Differential Leg Skin Temperature Measured With Handheld Low-cost Infrared Thermometers.
215018205|NCT04288531|DIETARY_SUPPLEMENT|Iodine supplementation|Recommendation, issued by the National Health Authorities, on supplementing with iodine (200 ug/day) women during preconception, pregnancy and lactation.
214416774|NCT05004272|OTHER|Lecture|20-minute lecture on medicinal herbs
214416775|NCT00365638|DRUG|simvastatin|
214416776|NCT04806256|BEHAVIORAL|Clinical Decision Support System|This project is based on the artificial intelligence (AI) algorithm to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the traditional Chinese medicine intervention Clinical Decision Support Systems (CDSS) for dry eye. At the same time, the CDSS is provided to clinicians for their selection.
214416777|NCT04806256|OTHER|Routine intervention|The routine intervention without CDSS is also the clinically common intervention at present.
214416778|NCT00545324|DRUG|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
214416779|NCT00545324|DRUG|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
214416780|NCT02209740|OTHER|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
214416781|NCT02717299|DEVICE|Verasense|Verasense will collect balancing data on all patients in this trial.
214416782|NCT03101618|OTHER|Animal allergy|Allergic symptom occurs during exposure to laboratory or pet animal
214505620|NCT06477679|PROCEDURE|• Furlow with buccinators myomucosal flap|• Furlow with buccinators myomucosal flap. Two opposing Z-plasties were designed on the oral and nasal mucosal surface. The posterior based flap on each surface was composed of muscle and mucosa, and the anterior surface was composed of mucosa only. BMFs were raised from the donor site, and immediately transferred to the recipient site to repair the defect. The flaps were sutured to the recipient site. The donor site was also closed primarily
214505621|NCT06477679|PROCEDURE|• Two flap palatoplasty as von langenbeck technique|• Two flap palatoplasty as von langenbeck technique, Upper left: Medial incisions design. Upper right: Lateral relaxing incisions and nasal mucosa closure using the anterior triangular flap and lateral nasal mucosa flaps. Release of the abnormal muscular insertion is performed. But two flap palatoplasty can lengthen the soft palate by push-back
214689653|NCT01831934|BIOLOGICAL|Fluzone®|This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
215018206|NCT04583553|DIAGNOSTIC_TEST|Vikor Scientific Urine-IDTM|Urine samples will be collected for both standard laboratory culture at KUMC Lab and expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will cover all costs associated with sample delivery. If insufficient urine volume is collected for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will be preferentially used for standard laboratory culture at KUMC Lab.
215018207|NCT04953169|OTHER|Biobank Video|The video describes the process of biobanking with visuals
215018208|NCT04953169|OTHER|Non-Video|The non-video group will receive a written informed consent
215018209|NCT06369545|OTHER|EXERCISE|All participants included in this group will receive Exercises
215018210|NCT06369545|OTHER|TENS|All participants included in this group will receive TENS
215018211|NCT06369545|OTHER|ESWT|All participants included in this group will receive ESWT
215018212|NCT02762890|DRUG|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
215101987|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
215101988|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
215101989|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
215101990|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
214416783|NCT03101618|OTHER|Non-animal allergy|Allergic symptom does not occur during exposure to laboratory or pet animal
214416784|NCT01191619|PROCEDURE|McIvor retractor|The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
214416785|NCT04361253|BIOLOGICAL|High-Titer COVID-19 Convalescent Plasma (HT-CCP)|250mL HT-CCP x2 doses given sequentially.
214416786|NCT04361253|BIOLOGICAL|Standard Plasma (FFP)|250mL FFP or FP24 x2 doses given sequentially.
214416787|NCT03163953|BEHAVIORAL|TPAG with long break|PA coaching based on Thai Physical Activity Guideline (TPAG) and long break or break 15 minutes for every 2 hours (TPAG with LB)
214416788|NCT03163953|BEHAVIORAL|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
214416789|NCT03163953|OTHER|Control|No intervention
214689654|NCT00436969|DEVICE|Orthovisc|Orthovisc injection
214689655|NCT00436969|DRUG|Control|Celestone (betamethasone sodium phosphate and acetate) - 2 mL
215018213|NCT02762890|DRUG|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
214416790|NCT05696977|DRUG|Cyclosporine Capsule|Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
214416791|NCT03552913|PROCEDURE|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
214416792|NCT03552913|PROCEDURE|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
214416793|NCT03552913|PROCEDURE|No specific program toward improving practices|No specific program toward improving practices
214416794|NCT01335932|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
214416795|NCT01335932|DRUG|Placebo|"For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications."
214416796|NCT01604447|PROCEDURE|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
214416797|NCT01604447|PROCEDURE|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
214689656|NCT05370599|DRUG|Anti-hypertensive agent: amlodipine|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
214416798|NCT02839369|OTHER|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
214416799|NCT02839369|OTHER|walking under varies conditions|walking on electronic walkway under different conditions
214416800|NCT02035735|PROCEDURE|WL and NBI|For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
214416801|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on breast cancer tissues|Total RNA is extracted from tissue sample and selected miRNA quantified by PCR based relative quantification method (QPCR) with a standard curve.
214416802|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on plasma samples|miRNAs extracted from plasma samples are analysed by QPCR and/or ddPCR .
214416803|NCT06555354|DIAGNOSTIC_TEST|miRNA profiling of breast cancer tissues|Selected samples from the retrospective cohort are profiled for miRNA expression by using GeneChip® miRNA 4.0 Array.
214416804|NCT01169363|GENETIC|proteomic profiling|
214416805|NCT01169363|OTHER|flow cytometry|
214416806|NCT01169363|OTHER|laboratory biomarker analysis|
214416807|NCT05490654|PROCEDURE|Abdominal Massage|Abdominal Massage delivered by manual method or by Mowoot device
214416808|NCT06233812|PROCEDURE|Simple interrupted suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
214689657|NCT05370599|DRUG|Anti-hypertensive agent: Chlorthalidone|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
214689658|NCT05370599|DRUG|Anti-hypertensive agent: Losartan|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
214416809|NCT06233812|PROCEDURE|Running suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
214416810|NCT04531137|DIETARY_SUPPLEMENT|CLA-fortified milk powder|3.4 gram of CLA-fortified milk powder one a day for 12 weeks
214416811|NCT04531137|OTHER|Placebo|Placebo milk powder one a day for 12 weeks
214689659|NCT05370599|DEVICE|Home BP monitoring with cuffed device|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
214689660|NCT05370599|DEVICE|Home BP monitoring with cuffed device + BP patch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
214689661|NCT05370599|DEVICE|Home BP monitoring with cuffed device + BP watch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
214689662|NCT05219617|DRUG|Carisbamate|"Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\])."
215018214|NCT05994534|DRUG|Cysteamine Bitartrate|Single dose, tablets at current therapeutic dose
215018215|NCT05994534|DRUG|N-Acetylcysteine Amide|Single dose, oral solution
215018216|NCT00495781|PROCEDURE|%-hypo (laboratory parameter, functional iron deficiency)|
215018217|NCT00495781|PROCEDURE|CHr (laboratory parameter, functional iron deficiency)|
215018218|NCT00495781|PROCEDURE|RET-HE (laboratory parameter, functional iron deficiency)|
215018219|NCT02576704|DEVICE|semi conductor gamma camera|we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.
215018220|NCT06119204|OTHER|Oviva programme|Total diet replacement for insulin-treated patients
215018221|NCT06119204|OTHER|Usual care|NHS 12 week weight loss programme
214416812|NCT04531137|OTHER|Nutrition Counseling|Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
214416813|NCT01998555|OTHER|CBT|
214416814|NCT02171663|DRUG|BIBW 2992|
214416815|NCT05158361|OTHER|Acupuncture|Participants will receive acupuncture, three times per week for eight weeks. The selected acupoints include bilateral BL33, BL35, SP6, and ST36. All acupoints areas have been sterilized before acupuncture. For BL33, a needle (Ф0.40×100mm) will be inserted with an angle of 60° in an inferomedial direction at a depth of 90-100mm. For BL35, the same needle will be inserted with a direction to the ischial rectal fossa at a depth of 60-70 mm deep. For SP6 and ST36, needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. After the needles are inserted, a portable electro-acupuncture machine will be connected to the handles of needles located in BL33 and BL35 to provide the electrical stimulation for 30 minutes with a disperse-dense wave (4/20Hz). All current intensities will be as high as can be tolerated.
214505622|NCT04378036|OTHER|Neurodevelopmental Therapy|The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.
214505623|NCT04378036|DEVICE|Hippotherapy Simulator|Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
214505624|NCT06569771|DIAGNOSTIC_TEST|Functional assessments|"* Computer Adaptive Test for Fugl-Meyer (CAT-FM)~* Action Research Arm Test (ARAT)~* Measurement of Functional Independence~* Star cancellation test~* Stroke Impact Scale~* ACTIVLIM (assesses the ability to perform activities of daily living requiring the use of the upper limbs)"
214505625|NCT01522014|DEVICE|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
214505626|NCT01522014|DEVICE|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
214505627|NCT05558683|OTHER|Randomized clinical trial.|Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.
214505628|NCT04336618|DEVICE|Liver MultiScan|The LiverMultiscan is a quick 15 minute, contrast free, non-invasive MRI scan that provides 3 liver metrics
214505629|NCT06100744|DRUG|Adalimumab|SC Injection
214505630|NCT06100744|DRUG|Risankizumab|Subcutaneous (SC) Injection
214505631|NCT01866800|DEVICE|Renal Guard|Renal Guard
214505632|NCT01866800|DRUG|Conventional Treatment|Saline and N-acetylcysteine
214505633|NCT05604547|DIAGNOSTIC_TEST|Non-Invasive Infrared Spectroscopy|NIRS is a non-Invasive optical technique for characterizing microvascular hemodynamics.
214505634|NCT00276276|DRUG|topotecan|
215018222|NCT04409769|OTHER|Description of use of ceftaroline and ceftobiprole|Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
215018223|NCT01213251|DEVICE|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
215018224|NCT01213251|DEVICE|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
214416816|NCT05158361|OTHER|Sham acupuncture|The sham acupoints will be located at 20 mm outward to BL33, BL35, SP6, and ST36, and the needless will be inserted with a depth of 2 mm. The BL33 and BL35 will not receive any electrical stimulation, though the handles of needles will be connected to the same machine as the acupuncture group, and the parameter setting and course are also the same.
214416817|NCT00952718|OTHER|Inspiratory muscle training|A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
214416818|NCT04589130|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).~Participants randomized to the control arm for the first 6 months will crossover and be administered 4 Contrave tablets a day during the second 6 months (2 tablets taken twice a day). All participants will be in the treatment group (Contrave) during the second 6 month phase of the study."
214416819|NCT04589130|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day (2 tablets, taken twice a day) during the first 6 months of the study. These participants will crossover to treatment with Contrave for the second 6 months of the study.
214416820|NCT00161018|DRUG|Quetiapine, Risperidone, Fluphenazine|
214416821|NCT02560519|DRUG|Albumin solution|"Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.~During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision."
214416822|NCT02560519|DRUG|Ringers acetate solution|"The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.~During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision."
214416823|NCT05056753|DEVICE|HWBV chair|vibration-actuated, saddle-seat type stool
214416824|NCT04308746|BEHAVIORAL|Online Individualistic Prime (statement writing)|Participants write 3 statements each about (1) themselves, (2) why they are not like others, and (3) why it is beneficial to stand out from others
214416825|NCT04308746|BEHAVIORAL|Online Collectivistic Prime (statement writing)|Participants think about a social group and write 3 statements each about (1) their social group, (2) why they are like others, and (3) why it is beneficial to blend in with others
214416826|NCT02370563|DRUG|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
214416827|NCT00754936|DRUG|Escitalopram|20 mg by mouth daily
214416828|NCT01992354|DEVICE|PET MR Device|GE PET/MRI system
214416829|NCT01387113|OTHER|Computed tomography perfusion imaging|As per standard of care at CPMC
214416830|NCT03665090|BEHAVIORAL|Diabetic eye disease screening|Community-based, prospective cohort study from three consecutive years (2016 to 2018) to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.
214416831|NCT06116812|OTHER|the laughter yoga group|"They will gather in five-person chemotherapy rooms, and laughter therapy will be applied to the women in the application group while they are receiving chemotherapy. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
214416832|NCT06116812|OTHER|the mindfulness based stress reduction group|"Mindfulnes therapy will be applied to the women in the application group while they are receiving chemotherapy, in five-person chemotherapy rooms. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
214416833|NCT01847651|PROCEDURE|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
214416834|NCT01847651|DRUG|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
214416835|NCT01847651|OTHER|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
215018225|NCT00666614|OTHER|Sleep Environment Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
215018226|NCT00666614|OTHER|Normal Hospital Environment|Normal Hospital Environment
214416836|NCT01847651|OTHER|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
214416837|NCT01847651|OTHER|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
214416838|NCT01847651|OTHER|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
214689663|NCT06526858|DEVICE|HyperQureTM Renal Denervation (RDN) System:|"The HyperQure RDN System consists of a Generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a extravascular(laparoscopic) approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the procedure by CTA."
214689664|NCT06172777|DIAGNOSTIC_TEST|suspected asthma|enrollment 200 asthma patients
215018227|NCT02529488|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
215018228|NCT00324857|BEHAVIORAL|Decision Aid Video|"The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
215018229|NCT00324857|BEHAVIORAL|Motivational Interviewing|The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
215101991|NCT05583994|OTHER|Optim Park Intervention|For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
215101992|NCT00147004|DRUG|hydrocortisone sodium succinate|50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
215101993|NCT00147004|DRUG|Placebo|
215101994|NCT04870918|BEHAVIORAL|self-care intervention|Health education will be carried out by the nurse.
215101995|NCT06083818|OTHER|Application of an anterior cruciate ligament injury prevention protocol for female football players with dynamic knee valgus for 12 weeks.|12-week ACL Injury Prevention Protocol
215101996|NCT06083818|OTHER|Placebo - Conventional fitness programme|Conventional training and physical preparation programme
215101997|NCT00307866|PROCEDURE|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
215101998|NCT03739515|OTHER|HSCP intervention|A team of HSCPs (physiotherapist, occupational therapist, medical social worker) will provide comprehensive functional assessment to older patients
215101999|NCT03739515|OTHER|ED routine care|ED staff including consultants and nurses will provide patients with routine ED medical care.
215102000|NCT03045341|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
215102001|NCT03045341|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|BWL counseling
215102002|NCT03045341|OTHER|Placebo|Placebo
215102003|NCT03689855|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
215102004|NCT03689855|DRUG|Atezolizumab|The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).
215102005|NCT03689855|PROCEDURE|Peripheral blood draw|-Baseline and Cycle 2 Day 1
215102006|NCT03689855|PROCEDURE|Biopsy|"* If archival biopsy tissue not available, participant will undergo biopsy at baseline~* When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan."
214416839|NCT01847651|OTHER|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
214416840|NCT01847651|OTHER|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
214416841|NCT01847651|OTHER|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
214416842|NCT00005786|DRUG|arsenic trioxide|Given IV
215102007|NCT02654938|DRUG|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
215102008|NCT02654938|DRUG|Placebo|5% infusion solution of dextrose
215102009|NCT02448290|DRUG|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
215102010|NCT02218944|BEHAVIORAL|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
214416843|NCT00005786|OTHER|laboratory biomarker analysis|Correlative studies
214416844|NCT01345838|PROCEDURE|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
214416845|NCT02460484|BIOLOGICAL|Autologous Cord Blood Infusion|Intravenous infusion
214416846|NCT04302519|BIOLOGICAL|Dental pulp mesenchymal stem cells|On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
214416847|NCT03206736|OTHER|Loop DS surgery|these patients will receive a loop DS bariatric procedure
214416848|NCT04033042|DEVICE|Prototype 0.5|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
214416849|NCT04964479|DRUG|TQB2450 injection|1200mg injection once every 3 week
215102011|NCT06195189|DRUG|Sunvozertinib|Sunvozertinib 200mg Quaquedie (QD)
215102012|NCT06195189|DRUG|Chemotherapy|Pemetrexed +platinum
215018230|NCT00324857|BEHAVIORAL|MI plus Decision aid|Patient viewed the video and then underwent MI.
214689665|NCT06172777|DIAGNOSTIC_TEST|suspected COPD|enrollment 200 COPD patients
214689666|NCT06172777|DIAGNOSTIC_TEST|confirmed asthma|enrollment 200 patients
214416850|NCT04964479|DRUG|Anlotinib Hydrochloride Capsules|12mg capsule once daily
214689667|NCT06172777|DIAGNOSTIC_TEST|confirmed COPD|enrollment 200 patients
214689668|NCT00142012|BEHAVIORAL|Nutrition Intervention|
214689669|NCT04472923|PROCEDURE|Traditional Treatment|"Patients belonging to the control group received conventional physical therapy program in the form of:~1. Dietetic Regulation: The diet was given in the form of the bulk-forming diet, fruits, vegetables, cereals, and bran.~2. Pelvic floor muscle exercises (Kegal exercises): The patient was instructed to lie crock lying position with knees bent. He/she was instructed to pull his/her pelvic muscles upward and inward and hold the contraction for 6 seconds as if to hold back a defecation movement, followed by relaxation for 6 seconds. The exercise was repeated 25 times. Gradually increase the time until reaching 10 seconds of contraction and relaxation for each with repetition up to 30 times. The exercises applied twice per week for 3 months."
214689670|NCT04472923|DEVICE|Biofeedback|"Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training.~Biofeedback was planned after full guardians' education. Local hygiene for perianal skin for soiling episodes and using zinc oxide cream to prevent excoriation. Biofeedback was done using two types of catheters; a 24-channel water-perfused catheter with latex balloon for sensory training and a double-lumen rectal PVC balloon clothed catheter (MMS U-72210) for strength training. Each biofeedback session took 30 minutes with two sessions per week for 3 months."
214689671|NCT04989829|DRUG|SHR6390、Omeprazole|SHR6390 tablet single dose、Omeprazol single dose.
214505635|NCT05328570|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
214689672|NCT04490265|BEHAVIORAL|Problem-solving treatment|included in arm descriptions
214689673|NCT04490265|BEHAVIORAL|Supportive Psychotherapy|included in arm descriptions
214689674|NCT06285552|BEHAVIORAL|Positive parenting PAIF program|Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences
214689675|NCT01864018|DRUG|Cyclophosphamide|Given PO
215018231|NCT00324857|OTHER|Attention control|patients received a booklet.
215018232|NCT02661347|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
215018233|NCT02661347|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
215018234|NCT04562805|DEVICE|DynamX Bioadaptor|DynamX Bioadaptor Treatment
215018235|NCT04562805|DEVICE|Resolute Onyx|Resolute Onyx Treatment
215018236|NCT05440565|DIAGNOSTIC_TEST|Fecal immunochemical test|Fecal immunochemical test can concentrate the high-risk population.
215018237|NCT05440565|DIAGNOSTIC_TEST|APCS score|APCS score can concentrate the high-risk population.
215018238|NCT00693511|BEHAVIORAL|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
215018239|NCT00693511|BEHAVIORAL|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
215018240|NCT01557244|DRUG|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
215018241|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
215018242|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
215018243|NCT01557244|DRUG|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
215018244|NCT01557244|DRUG|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
215018245|NCT01557244|DRUG|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
215018246|NCT01557244|DRUG|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
214416851|NCT04964479|DRUG|Pembrolizumab injection|200mg injection once every 3 week
214416852|NCT04964479|DRUG|Placebo|Placebo capsule once daily
214505636|NCT04740580|DIETARY_SUPPLEMENT|Glycine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
214505637|NCT04740580|DIETARY_SUPPLEMENT|N-acetylcysteine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
214505638|NCT04740580|DIETARY_SUPPLEMENT|Alanine|The placebo arm will supplement Alanine
214689676|NCT01864018|DRUG|Dexamethasone|Given PO
214689677|NCT01864018|DRUG|Ixazomib Citrate|Given PO
214689678|NCT01864018|OTHER|Laboratory Biomarker Analysis|Correlative studies
214689679|NCT01864018|OTHER|Pharmacological Study|Correlative studies
214689680|NCT01864018|OTHER|Quality-of-Life Assessment|Ancillary studies
214689681|NCT01864018|OTHER|Questionnaire Administration|Ancillary studies
214689682|NCT06300060|DIETARY_SUPPLEMENT|Synbiotic|Combination of a probiotic and prebiotic. Daily administration in a single dose in powder form.
214689683|NCT06300060|DIETARY_SUPPLEMENT|Placebo|Placebo. Daily administration in a single dose in powder form.
214689684|NCT03013777|BEHAVIORAL|8-week CBT Program|
214689685|NCT06822010|DRUG|Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)|"Drug: Gemcitabine (endoluminal administration)~Drug: Jelmyto (gel-based mitomycin, endoluminal administration)"
214689686|NCT06053268|DEVICE|Headspace|The intervention will be delivered via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control
215018247|NCT06325631|PROCEDURE|Intra-articular injection to lumbar facet joint|to treat low back pain caused by facet joint syndrome
214416853|NCT03936348|DEVICE|Exercise training program with and without FB|"Participants carried out a supervised RP for 8 weeks, 3 days per week. The training sessions lasted 60 minutes and included a warning up phase, the main phase and a recovery phase. After each session, Borg's perceived exertion was measured. The Rehabilitation Program (RP) included aerobic exercise on cycle ergometer and on treadmill (progressing since 10' to 30' and since 40 to 75% of the reserve heart rate (RHR) or 6-7 score based on Borg's perceived exertion), strengthening of lower and upper limb muscles groups, breathing exercises (pursed lip breathing, diaphragmatic and abdominal breathing and diaphragmatic mobility) and finally stretching exercises.~In the FB group, for restricted nasal breathing, at the beginning of the training program, the small size device was used (4 mm). The size of the device was progressively increasing according to the patient adaptation to the 5 or 6 mm device, depending on the score on Borg's perceived exertion scale."
214416854|NCT02491749|PROCEDURE|Ultra Fast-Track Anesthesia|early extubation at the end or within one hour post operatively
214416855|NCT02476890|DRUG|Gefapixant 100 mg|Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
214416856|NCT02476890|DRUG|Placebo|Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
214416857|NCT04908982|DRUG|Aspirin 81mg|81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
214416858|NCT00835380|BIOLOGICAL|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
214416859|NCT03614546|RADIATION|SBRT|Stereotactic Body Radiation Therapy (SBRT)
214416860|NCT03614546|RADIATION|IMRT|Intensity-modulated Radiation Therapy (IMRT)
214416861|NCT03614546|PROCEDURE|Hepatectomy|Hepatectomy
214416862|NCT03614546|PROCEDURE|TACE|transarterial chemoembolization (TACE)
214416863|NCT05735444|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) is one of the standard medical treatments for patients with OSAS. The mechanism of CPAP probably involves maintenance of a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure. CPAP also increases end-expiratory lung volume, which stabilises the upper airway through caudal traction.
214416864|NCT04610008|OTHER|No intervention. Purely observation|Retrospective image analysis of the shape of the optic nerve head in both groups
214416865|NCT02779608|DRUG|intraperitoneal docetaxel|One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
214416866|NCT02779608|DRUG|oral S-1|40mg/m² twice daily on day 1-14 every 3 weeks
215018248|NCT00438282|BEHAVIORAL|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
215018249|NCT02673060|DRUG|MBC-11|0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
215018250|NCT03635866|DIAGNOSTIC_TEST|Fluciclovine PET/MRI|It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.
215018251|NCT03752073|DEVICE|Trans-cervical cervical balloon|Insertion of Foley Catheter
215102013|NCT05325385|OTHER|There are no interventions - this is a database study only|There are no interventions - this is a database study only
215102014|NCT05548985|DRUG|Midodrine Oral Tablet|oral midodrine tablet (5 mg) 90 min before performing spinal block
215102015|NCT05548985|DRUG|Metoclopramide|oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
215102016|NCT00343707|DRUG|vestipitant|
215102017|NCT00343707|DRUG|paroxetine|
215102018|NCT02461082|DEVICE|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
214416867|NCT02892968|PROCEDURE|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
215102019|NCT02461082|OTHER|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
214416868|NCT02892968|PROCEDURE|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
214416869|NCT04883762|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Undergo FMT via colonoscopy.
214416870|NCT03247543|DRUG|Placebo|Placebo was administered once daily
214416871|NCT03247543|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
214416872|NCT03247543|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
214416873|NCT00491517|DRUG|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
214416874|NCT00491517|DRUG|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
214416875|NCT01377259|OTHER|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
214416876|NCT01097343|DRUG|clopidogrel 75 mg|75 mg once daily
214416877|NCT01097343|DRUG|Clopidogrel 150 mg|clopidogrel 150 mg
214416878|NCT02332369|DEVICE|Capsular Tension Ring|
215018252|NCT03752073|DEVICE|Hygroscopic cervical dilator|Insertion of Dilapan-s
215018253|NCT02224079|DRUG|BIIB 722 CL|
215018254|NCT02224079|DRUG|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
215018255|NCT00534586|DRUG|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
215018256|NCT00534586|DRUG|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
215018257|NCT00534586|DRUG|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
215018258|NCT00534586|DRUG|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
215018259|NCT03027050|PROCEDURE|T-PRF|Applied for treatment of periodontal bone loss.
214505639|NCT06975410|DRUG|YH32364|"Dose Escalation Part: In this part, 6 dose levels are planned and approximately 30 patients will be enrolled. After each dose level, Safety Review Committee (SRC) will evaluate the available safety, tolerability, PK of YH32364 to decide the next dose.~Dose Expansion Part: 50 participants with previously treated locally advanced or metastatic EGFR overexpressing HNSCC other than NPC will be randomized 1:1 ratio to each dose. (Cohort 1: Participants with locally advanced or metastatic EGFR overexpressing HNSCC other than NPC, whose disease progressed after or who are intolerable to all the available standard treatment)"
215018260|NCT03027050|PROCEDURE|Open Flap Debridement alone|
214689687|NCT00114972|DEVICE|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
215018261|NCT00670514|BEHAVIORAL|Nix Individual|Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
215018262|NCT00670514|BEHAVIORAL|Fimpa dig fri|"One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires."
215018263|NCT04989166|DIETARY_SUPPLEMENT|Nano-curcumin|Nano-curcumin soft gels
214505640|NCT06981195|DRUG|Placebo|Subjects who are randomized to placebo will receive identical capsules to the study drug. During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed
215102020|NCT05201950|OTHER|Virtual simulation|Virtual simulation using Full-Code, a virtual simulation software with a bank of emergency medicine cases
215102021|NCT05201950|OTHER|Team based in situ simulation|In situ simulation, using a high fidelity manikin in the critical care area of the emergency department, with team members consisting of multiple junior doctors and nurses, facilitated by senior emergency medicine doctors and nurses.
215102022|NCT01767623|DRUG|Vemurafenib|Vemurafenib orally BID 960 or 720 mg.
215102023|NCT02666612|PROCEDURE|Blood samples|
215102024|NCT03615014|OTHER|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
215102025|NCT00764673|DEVICE|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
215102026|NCT05392036|OTHER|baseline physical therapy treatment along with shockwave therapy|Group A, this group will receive conventional therapies along with shockwave therapy. Basic treatment includes icing (15-20 min) to control inflammation, rest, cessation of pain causing activity, anti-inflammatory (NSAIDs) and basic stretching and strengthening exercises. Shockwave therapy is a non-invasive therapeutic modality with convenience, effectiveness and safety. It is used to treat various musculoskeletal disorders without surgery. A session of 30-45 min will include icing 15 min and 5-10 min of shock wave therapy session will be commenced with strengthening and stretching exercises.
215102027|NCT05392036|OTHER|baseline physical therapy treatment along with therapeutic ultrasound|"This group will receive therapeutic ultrasound along with conventional treatment. Conventional therapy includes icing, rest, anti-inflammatory drugs, and basic strengthening and stretching exercises. A session of 30-45 min will include icing for 10-15 min therapeutic ultrasound 15min with a frequency 1-3MHz and the session will be ended with strengthening and stretching exercises.~Only eligible patients who have fulfilled the inclusion criteria will be included. A daily session of 30-45min for 2 consecutive weeks will be given. A baseline assessment will be done and the patient will be allocated randomly to both groups for two weeks. Re-assessment will be done after 2 weeks. For long term, effects re-assessment will be done after 6 weeks"
215102028|NCT01438177|DRUG|Velcade|
215102029|NCT01438177|DRUG|Cyclophosphamide|
215102030|NCT01438177|DRUG|Chloroquine|
215102031|NCT05945160|DRUG|Alpha Lipoic Acid 300mg|A naturally occuring mitochondrial antioxidant
215102032|NCT05945160|DRUG|Coenzyme Q10 200mg|A naturally occuring mitochondrial antioxidant
215102033|NCT03570346|DRUG|Hemay005|Subjects will be randomized into 3 dose groups orally twice daily.
215102034|NCT03570346|DRUG|Placebo|Subjects will be randomized into 3 dose groups orally twice daily.
215102035|NCT02974569|DEVICE|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
215102036|NCT02193412|PROCEDURE|noxious stimulus|standardized noxious stimulus with tetanic stimulation
215102037|NCT02193412|PROCEDURE|change in operating table slope: head-down tilt position|-30°
215102038|NCT02193412|PROCEDURE|change in operating table slope: head-up tilt position|+30°
215102039|NCT05457088|OTHER|1.5 protein|dietary plan having dietary protein of 1.5 gr/kg/day
215102040|NCT05457088|OTHER|0.8 protein|dietary plan having dietary protein of 0.8 gr/kg/day
215018264|NCT04989166|DRUG|Placebo|Placebo
215102041|NCT05380167|DIETARY_SUPPLEMENT|BRJ Nitrate|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink with nitrate.
215102042|NCT05380167|DIETARY_SUPPLEMENT|BRJ Placebo|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink without nitrate
215102043|NCT01727336|DRUG|Dalantercept and axitinib|
215102044|NCT01727336|DRUG|Placebo and axitinib|
214505641|NCT06981195|DRUG|Lemborexant 10 MG|During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed
214505642|NCT06980090|BEHAVIORAL|Session A: Positive Placebo + Active tTIS|Participants receive active tTIS, with two signals set at 2000 Hz and 2080 Hz, creating an 80 Hz interference beat targeting the anterior/mid-cingulate cortex (aMCC). Stimulation is delivered at 2 mA for 20 minutes. The stimulation is combined with a positive social placebo intervention delivered by the care provider. Participants complete three multimodal negative affect tasks (MNAT) before and after the stimulation.
214416879|NCT06000072|OTHER|Core Exercise Program|Core exercises
214416880|NCT02059980|BEHAVIORAL|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
214416881|NCT02059980|BEHAVIORAL|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
214416882|NCT04462107|OTHER|Surveys|All participants will complete surveys that range in time from baseline to 3 months post partum.
214416883|NCT01104415|DRUG|Telotristat etiprate|Telotristat etiprate capsules orally three times daily.
214416884|NCT01537003|DEVICE|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
214416885|NCT01537003|DEVICE|Coban 2 layer|Compression bandage
214416886|NCT04286529|DRUG|Calcitriol capsules|0.25micrograms, taken daily for eight weeks, orally
214416887|NCT04286529|DRUG|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
214416888|NCT00155363|DEVICE|conventional artificial kidney (AK) vs. high flux AK|
214416889|NCT04392713|DRUG|Ivermectin 6 MG Oral Tablet (2 tablets)|12 mg single dose of Ivermectin will be given to intervention arm
214416890|NCT05368025|DEVICE|Mobili-T/Noona|Use of two mobile health systems over a period of 6 months
214416891|NCT02026778|DRUG|ondansetron|"The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
214416892|NCT02026778|DRUG|ondansetron-betahistine|"The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
215018265|NCT01065805|BIOLOGICAL|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
215102045|NCT03590951|OTHER|Retrospective chart review|A retrospective chart review was conducted to evaluate the effect of body mass index on obstetric, anesthetic and neonatal complications in patients who underwent cesarean section at our institution
214416893|NCT02341625|DRUG|BMS-986148|
214416894|NCT02341625|BIOLOGICAL|Nivolumab|
215102046|NCT01014039|PROCEDURE|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
215102047|NCT02058394|PROCEDURE|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
215102048|NCT00908102|OTHER|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
214416895|NCT00165451|DRUG|Thalidomide|Oral administration once daily at night starting at 3mg/Kg for 6 months.
214416896|NCT00165451|DRUG|Celecoxib|Oral administration twice daily starting at 100mg/dose for 6 months.
215102049|NCT00908102|OTHER|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
215102050|NCT00908102|OTHER|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
214416897|NCT00165451|DRUG|Etoposide|Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
214416898|NCT00165451|DRUG|Cyclophosphamide|Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
214416899|NCT02748265|DRUG|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
214416900|NCT02748265|DRUG|Sevoflurane|Volatile maintenance anesthesia
214416901|NCT02748265|DRUG|Propofol|Intravenous maintenance anesthesia
214416902|NCT02616835|DEVICE|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
214416903|NCT02616835|DEVICE|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
214416904|NCT02275325|OTHER|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
214416905|NCT03551067|DRUG|Dexmedetomidine|Dexmedetomidine mixed with juice was given to the child orally preoperatively.
214416906|NCT03551067|COMBINATION_PRODUCT|Midazolam/Ketamine|Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
214416907|NCT06364150|BIOLOGICAL|Autologous Peripheral Blood Stem Cell injection|For peripheral blood stem cell mobilization, G-CSF and EPO will be injected for a total of 4 days, followed by collection of mobPBSC via apheresis. In ex-vivo setting, mobPBSC will be primed with Ang1 for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.
214416908|NCT06393244|BEHAVIORAL|a theory-based home-based multi-component exercise training|The participants in the intervention group will receive a 12-week theory-based home-based MCE program, which consists of three phases: exercise mobilization phase, exercise preparation phase (exercise instructions and exercise plan determination), and home-based autonomous exercise training. Structured guidelines have been developed for the intervention by the research team. This allowed interveners to deliver the intervention in a structured way with the same dosage.
214416909|NCT04055766|DEVICE|DeepDoc AI-based Decision Support System|Patients are diagnosed by the DeepDoc within 24 hours of admission.
214416910|NCT04307407|BEHAVIORAL|Aerobic Exercise|Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm
214416911|NCT02168751|DRUG|propofol|
214416912|NCT02168751|DRUG|Sevoflurane|
214416913|NCT04418323|PROCEDURE|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
214416914|NCT00917865|DRUG|anti [18F]FACBC|Anti\[18F\]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
214416915|NCT04628715|DEVICE|RSA biofeedback|Biofeedback intervention based on breathing at resonance frequency
214416916|NCT02040935|DRUG|Trastuzumab|600 mg SC Q3W by SID
214416917|NCT06512649|BEHAVIORAL|Early intervention|90-minute parent-coaching session once a week for 6 months with an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention. The intervention is individualized and tailored to each child's needs and identifies with caregivers the ways to embody objectives in daily life.
215018266|NCT01837953|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy (GPIP) condition, this intervention will consist of 16 weekly 90 minute sessions of GPIP. GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment. Examples of the patient's cyclical relational patterns (CRPs) that may underlie their symptoms are discussed and the patient will be encouraged to work on these in the groups. Therapists will be given a written summary of each patient's CRP.
214416918|NCT06512649|BEHAVIORAL|Active monitoring|90-minute session once a month for 6 months. Sessions will be performed by an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention.
214416919|NCT03907098|DRUG|Endostar|an anti-angiogenesis drug
214416920|NCT03907098|DRUG|Chemotherapy|Physician's choice
215102051|NCT00908102|OTHER|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
214416921|NCT03816124|PROCEDURE|radiofrequency ablation|radiofrequency ablation of the genicular nerves
214416922|NCT01263730|BEHAVIORAL|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
214416923|NCT05325853|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
214416924|NCT05325853|DRUG|Proparacaine Ophthalmic|0.5% Proparacaine Hydrochloride
214416925|NCT01669382|DEVICE|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
214416926|NCT04979988|DRUG|Lortlatinib|as provided in real world practice
214416927|NCT04678128|BEHAVIORAL|Dance4Healing Telehealth Live Zoom Sessions|"Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class."
214416928|NCT04678128|BEHAVIORAL|Dance Buddy|"Following randomization (beginning of intervention period) half of the participants will be assigned a dance buddy, and will be asked to dance with their buddies using the Dance4Healing TLVP at least 2 additional times/week. This group will have 24/7 access to Dance4Healing Platform during the intervention and post-intervention periods."
214416929|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from whole goat milk|Infant formula and follow-on formula made from whole goat milk
215102052|NCT04462939|DIETARY_SUPPLEMENT|Elevit Breastfeeding & Postnatal Care|Multi-micronutrients, lutein and DHA soft gel capsules; one capsule daily, oral
215102053|NCT04462939|DRUG|Placebo|No active ingredients except of 225 μg iodine; One capsule daily, oral
214416930|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from cow's milk ingredients|Infant formula and follow-on formula made from cow's milk ingredients
214416931|NCT04791124|OTHER|Electroencephalography|"EEG evaluation Composed by three consecutive tests~1. Resting state EEG, with either eyes open or closed~2. Auditory steady-state response (ASSR)~3. Auditory evoked potential"
214416932|NCT03072355|OTHER|Elastic Band|Localized muscle resistance test for shoulder
214416933|NCT03072355|OTHER|Isokinetic dynamometer|Localized muscle resistance test for shoulder
214416934|NCT01228513|DRUG|ZK245186|Daily topical application
214416935|NCT01228513|DRUG|Placebo (vehicle without active ingredient)|Daily topical application
214416936|NCT01749761|OTHER|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
215102054|NCT04377152|DRUG|68Gallium-PSMA-11|PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).
215102055|NCT04377152|PROCEDURE|Positron Emission Tomography (PET)|A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity
215102056|NCT04217213|PROCEDURE|Intercostal nerve block|In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.
215102057|NCT05701046|PROCEDURE|Interbody fusion surgery|Interbody fusion surgery
215102058|NCT01410188|DRUG|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
214416937|NCT01749761|OTHER|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
214416938|NCT02286765|DEVICE|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
214416939|NCT04329663|DEVICE|Indonesian computer-based game prototype|In order to improve the ADHD clinical symptoms and executive function of the player, this game should has challenge similar to memory game which is the player was given object to be memorized and then match the object in accordance to the task given inside the game. With some difficulty leves, this game was tried to trigger players in terms of accuracy and quickness in completing the mission.
215018267|NCT01837953|BEHAVIORAL|Unguided Self-Help|All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.
215102059|NCT01410188|DRUG|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
214689688|NCT00114972|PROCEDURE|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
215102060|NCT01410188|DRUG|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
214689689|NCT05092815|DRUG|HLX208|HLX208 450mg bid po
214689690|NCT02934412|DRUG|SHR-1314|Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
214689691|NCT02934412|DRUG|placebo|Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
214689692|NCT03878017|PROCEDURE|skin marking of clip axillary lymph node for localisation|to determine the feasibility of skin marking to localize clipped ln
214689693|NCT05429099|PROCEDURE|Virtual Surgical Planning (VSP)|The 3D reconstruction model, not requiring sterilization, will be sent directly to the SS. Prior to surgery, the SS will prebend a titanium fixation plate to the reconstruction model. Both the surgical cutting guides and titanium plate will be sterilized prior to use in surgery. If the planned resection cannot proceed (possibly due to tumour growth), the surgical team will note the reason for abandonment and conduct a standard FHS. Intraoperatively, the SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide is applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized by joining it to blood vessels in the neck.
214689694|NCT05429099|PROCEDURE|Free-Hand Surgery|The SS will adopt their standard procedure for the mandibular resection and reconstruction. This typically involves bending a titanium fixation plate, harvesting of the bony flap, and shaping of the segments all intraoperatively based on the SS's judgement.
214689695|NCT06432907|OTHER|motor tasks|"During the study session, the patient will sit at a table in front of a computer monitor. The stereoEEG electrodes will be connected to the Neurovisor-BMM52 electroencephalograph (Medical Computer Systems, Russia) and to a computer with a software for recording and decoding brain signals (BCI classifier). One microsensor (Ascension TrekStar, Ascension Technology, USA) and two disposable cutaneous electrodes (connected to the Neurovisor-BMM52 system) will be put on each patient's hand for electromyogram recording.~The session consists from 3 blocks (1-3). The participant is asked to:~1. execute simple motor tasks (thumbs up, open hand or clench hand into fist - 30 times with each hand with 5-second brakes), according to the instruction on the computer screen;~2. to imagine the same movements - 30 times with each hand with 5-second brakes;~3. to imagine the same movements with the feedback (brain-computer interface control).~The blocks are separated by 5-minute brakes."
214689696|NCT05750498|OTHER|No interventions|There are no interventions
214689697|NCT05413616|BEHAVIORAL|FITFOOD lifestyle intervention|Lifestyle intervention with a nutritional and exercise component.
214689698|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 1.0 mg/kg/week
214689699|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 2.0 mg/kg/week
215102061|NCT00619099|DRUG|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
215102062|NCT00619099|DRUG|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
215102063|NCT04506203|DIAGNOSTIC_TEST|Air test|Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
214416940|NCT00414206|DRUG|Mecamylamine|
214416941|NCT00414206|DRUG|Placebo|
214416942|NCT01227707|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
214416943|NCT01227707|DRUG|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
214416944|NCT01227707|RADIATION|Radiation therapy|Total dose of 45 Gy over 38 days
214416945|NCT01227707|PROCEDURE|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
214689700|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 4.0 mg/kg/week
214694023|NCT03533725|OTHER|Breastfeeding counseling and education services|Breastfeeding counseling and education by educated and trained peer counselors using mHealth tools
214694024|NCT02555566|PROCEDURE|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
214694025|NCT02555566|PROCEDURE|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
214694026|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via Optiflow THRIVE
214694027|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via non-rebreather
215018268|NCT01428713|DRUG|Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
215102064|NCT05701566|DEVICE|virtual reality headset|use of virtual reality headset during colonoscopy as a substitute to sedation.
214416946|NCT01227707|DRUG|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
214416947|NCT01227707|DRUG|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
214416948|NCT01227707|DRUG|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
214416949|NCT02900326|OTHER|Endurance exercise training|In each group, there will be a comparison of aerobic capacity, quality of life (with questionnaires), functional cerebral measurements (fRMI), and telomerase activity between before and after the 8 weeks program
214416950|NCT02900326|OTHER|Mindfulness-based-stress-reduction|
214416951|NCT02900326|OTHER|Both interventions together|
214416952|NCT02900326|OTHER|Vo2max measurements|
214416953|NCT02900326|GENETIC|Telomerase activity on a blood sample|
214416954|NCT02900326|OTHER|Quality of life (questionnaires)|
214689701|NCT03897920|OTHER|Doppler ultrasound assessment of renal arteria resistive index|A high frequency probe will be used together with the use of color or power Doppler to help vessel localization. As resistance to blood flow progressively increases from the hilar arteries toward the more peripheral parenchymal vessels, renal arteria resistive index (RRI) will be done at the level of the arcuate or interlobar arteries, adjacent to medullary pyramids. Measurements will be repeated in different parts of both organs (superior, median, and lower) when at least three reproducible waveforms have been obtained. An RRI will be calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and the mean value of three measurements at each kidney is usually considered. An RRI value 0.60 ± 0.01 (mean ± SD) is usually taken as normal with a value of 0.70 being considered the upper normal threshold
215018269|NCT01428713|DRUG|Oral Contraceptive Pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
214416955|NCT02900326|OTHER|Cerebral IRMf|
214416956|NCT03073499|PROCEDURE|Oncological Home Hospitalization|
214416957|NCT05663619|DEVICE|Virtual Reality Distraction during dental treatment of children.|One of the behavior management techniques used with children in dental clinics to allow for delivering quality dental treatment is the use of Virtual Reality distraction (VRD). Virtual reality distraction immerses the patient in an environment generated by a computer and works by simulating as many senses as possible: vision, hearing, and touch. In dentistry, VRD has exhibited great results in reducing anxiety and fear among children and adolescents compared to those who received no intervention or more conventional BMTs. VRD may allow the dentist to provide more efficient dental treatments, ranging from simple anesthesia to more advanced forms of dental treatment
214416958|NCT05663619|OTHER|Control: watching cartoon on screen as distraction during dental treatment of children.|"The American Academy of Pediatric Dentistry (AAPD) recommends a series of non-pharmacological behavior management techniques for managing children during dental care including distraction. Distraction is defined by AAPD as the technique of diverting the patient's attention from what may be perceived as an unpleasant procedure. It is widely used as it provides an effective and relaxing experience during treatment."
214416959|NCT04830722|DEVICE|Sculptra Aesthetic|One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume
214505643|NCT06980090|BEHAVIORAL|Session B: Positive Placebo + Sham tTIS|Participants receive sham tTIS, using two identical 2000 Hz signals that produce no low-frequency interference. The device mimics active parameters (2 mA, 20 minutes) without delivering effective stimulation. The sham stimulation is paired with a positive social placebo intervention. Participants complete three MNAT tasks before and after the session.
214505644|NCT06980090|BEHAVIORAL|Session C: Negative Placebo + Active tTIS|Participants receive active tTIS (2000 Hz and 2080 Hz signals, 2 mA, 20 minutes) combined with a negative social placebo intervention (neutral or skeptical messaging about treatment efficacy). Participants complete three MNAT tasks before and after the stimulation.
215018270|NCT02039206|DEVICE|Deep TMS|1Hz Stimulation
215018271|NCT01045239|DEVICE|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
215018272|NCT01045239|DEVICE|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
215018273|NCT05181696|DIAGNOSTIC_TEST|Chest X-ray|Retrospective analysis of chest x-rays of patients with COVID-19
215102065|NCT05701566|OTHER|colonoscopy with standard sedation.|use of standard sedation during colonoscopy.
215102066|NCT00885482|DRUG|Lamiduvine (Epivir)|Epivir 300 mg
215102067|NCT00885482|DRUG|Atazanavir (Reyataz)|Reyataz 300 mg
215102068|NCT00885482|DRUG|Ritonavir (Norvir)|Norvir 100 mg
215102069|NCT04911972|PROCEDURE|Functional muscle transfer|Muscle transfer to restore lower limb function
215102070|NCT01170078|DRUG|Epoetin Hospira|IV dose 3 times a week.
215102071|NCT01170078|DRUG|Epogen|IV dose 3 times a week
215102072|NCT00084656|BIOLOGICAL|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
214416960|NCT06553573|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Parasternal Block and Recto-Intercostal Fascial Plane Block:Superficial PSB is performed bilaterally with the patient in the supine position using a high-frequency linear USG probe. The probe is inserted longitudinally 2cm lateral to the sternal border to visualize the T2T4 intercostal space and identify the pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is administered between the pectoralis major and intercostal muscle. Additionally, a Recto-Intercostal Fascial Plane Block is performed bilaterally with a high-frequency linear USG probe. The probe is inserted 2-3cm lateral to the xiphoid to visualize the rectus abdominis muscle and the 6th-7th cartilages. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique, and 1-2ml of saline is injected. After spreading to the target plane is observed, 20ml of 0.25% bupivacaine is administered.
214416961|NCT06553573|OTHER|Parasternal Block and Erector Spinae Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2cm lateral to the sternal border to identify the T2T4 intercostal space, pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is applied between the pectoralis major and intercostal muscle. Additionally, an erector spinae plane block is performed with a high-frequency USG probe. Erector spinae plane block is performed under general anesthesia, in the lateral position, under USG guidance, after sterilization, by inserting a needle between the deep surface of the erector spinae muscle and the transverse process with an in-plane approach in the craniocaudal direction. If no air or blood is seen in the aspiration, a 2mL serum test dose is applied to this area and a total of 20mL of 0.25% bupivacaine is injected bilaterally to perform an erector spinae plane block.
214416962|NCT01115049|DRUG|chlorobutanol, hexetidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
214416963|NCT01115049|DRUG|Chlorhexidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
214416964|NCT02008253|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
214416965|NCT02744079|BEHAVIORAL|Low carbohydrate diet|45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal
214416966|NCT02744079|BEHAVIORAL|Low fat diet|20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
214416967|NCT03468920|DRUG|IV Acetaminophen|IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
214416968|NCT03468920|DRUG|PO Acetaminophen|Acetaminophen PO 1000mg once pre-operatively
214416969|NCT03468920|DRUG|PO Placebo|PO placebo capsule compounded to match PO Acetaminophen capsule
214416970|NCT03468920|DRUG|IV Solution Placebo|This will serve as the placebo for the IV Acetaminophen intervention
214416971|NCT03210727|BEHAVIORAL|Ready to CARE program|"The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion."
214416972|NCT05702710|OTHER|Surgery (PIRS)|"Laparoscopic procedure for repair of inguinal hernia as described in:~1\) Thomas DT, Göcmen KB, Tulgar S, Boga I. Percutaneous internal ring suturing is a safe and effective method for the minimal invasive treatment of pediatric inguinal hernia: Experience with 250 cases. J Pediatr Surg. 2016 Aug;51(8):1330-5. doi: 10.1016/j.jpedsurg.2015.11.024. Epub 2015 Dec 11. PMID: 26777889."
214416973|NCT04467463|PROCEDURE|peripheral nerve block by 0.25% levobupivacaine|SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.
214416974|NCT04810455|OTHER|Purrble|"The objective of this study is to evaluate the impact of having access to the Purrble intervention, compared to an active control in the form of a non-interactive plush toy, on child daily emotion regulation (primary outcome) as well as a range of secondary outcomes over a period of one month.~The investigators hypothesise that engagement with an in-situ, 'bottom-up' emotion regulation intervention which enables in-the-moment soothing for children, will lead to measurable changes in child self-regulatory behaviours over time."
214505645|NCT06980090|BEHAVIORAL|Session D: Negative Placebo + Sham tTIS|Participants receive sham tTIS (identical 2000 Hz signals, mimicking active stimulation) combined with a negative social placebo intervention. Participants complete three MNAT tasks before and after the session.
214505646|NCT06980090|BEHAVIORAL|Session E: On-Placebo + Sham tTIS|Participants receive sham tTIS (brief 15-second stimulation followed by no current) paired with a positive social placebo intervention. Participants complete three MNAT tasks before and after the session.
214505647|NCT06980090|BEHAVIORAL|Session F: Off-Placebo + Sham tTIS|Participants receive sham tTIS (brief 15-second stimulation, then no current) without any placebo intervention. Participants complete three MNAT tasks before and after the session.
214505648|NCT03988101|DRUG|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
214416975|NCT04810455|OTHER|Active control toy|The selected active control toy is the Wild Republic 8'' Hedgehog animal. The selection process was guided by: the plush toy needed to have analogous size, weight, quality of materials, and at least similar (if not higher) visual appeal. The investigators also made sure to include the design characteristics our prior work suggested were important for the narrative around the toy. These were selecting a similarly stylised animal (to enable emotion projection and feelings of care), as well as no visible mouth on the toy (to prevent setting an expectation about the toy's emotional state as a mouth would imply an emotional expression). Additionally, the investigators have adapted the one-page parent-facing descriptions of the narrative that come with Purrble also for the active control unit: as such, the active control families will receive the same general narrative-without the explicit mentions of the toy interactivity-and the same suggested activities for parents.
214416976|NCT04188028|DRUG|Dextromethorphan 5 MG|dextromethorphan 5 mg po
214416977|NCT04188028|DRUG|Paroxetine 10Mg Tablet|Paroxetine 10 mg po
214416978|NCT04188028|DRUG|Paroxetine 20Mg Tablet|Paroxetine 20 mg po
214416979|NCT06409195|DRUG|SM-020 1% Gel|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.
214416980|NCT05425836|DEVICE|Standard oxygen therapy|nasal cannula
214416981|NCT05425836|DEVICE|HFNC|High flow nasal cannula
214416982|NCT04966208|PROCEDURE|xenogeneic collagen matrix|xenogeneic collagen matrix called mucoderm used for root coverage for treatment of gingival recession instead of harvesting from the patients connective tissue
214416983|NCT01077245|DRUG|MIYA-BM Fine Granules (CBM588)|MIYA-BM Fine Granules (CBM588)
214416984|NCT01077245|DRUG|Placebo Fine Granules (without CBM588)|Placebo Fine Granules (without CBM588)
214416985|NCT04303182|PROCEDURE|Standard 3 port TEP|3 port TEP inguinal hernia repair with 10mm. port under the umbilicus and two 5mm. port in line under the 10mm. port
214416986|NCT04303182|PROCEDURE|LESS TEP|TEP inguinal hernia repair with one vertical skin incision under the umbilicus
214416987|NCT04461756|DRUG|PPP001|inhalation (vape)
214694028|NCT04171037|OTHER|Questionnaire Administration|Ancillary studies
214416988|NCT00155610|DEVICE|intravesical current perception test|
214416989|NCT01512966|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
214416990|NCT01532232|DRUG|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
214416991|NCT01532232|DRUG|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
214416992|NCT02501772|DEVICE|acupressure by ankle band|
214416993|NCT02785978|DRUG|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring"
214416994|NCT02785978|OTHER|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)"
214694029|NCT04171037|DEVICE|Optiflow THRIVE|Oxygen Administration
215018274|NCT05609058|DEVICE|dedicated treatment board with no degree|the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
214416995|NCT02785978|OTHER|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
214416996|NCT02785978|DEVICE|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
214416997|NCT02785978|OTHER|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
214505649|NCT03988101|DRUG|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
214505650|NCT06602089|DEVICE|Arterial pressure monitoring|We will record intraarterial arterial pressure, finger-sensor arterial pressure and oscillometric arterial pressure in all included patients.
214505651|NCT00281905|DRUG|carboplatin|
214505652|NCT00281905|DRUG|cisplatin|
214505653|NCT00281905|DRUG|cyclophosphamide|
214505654|NCT00281905|DRUG|methotrexate|
214505655|NCT00281905|DRUG|vincristine sulfate|
214505656|NCT00281905|RADIATION|radiation therapy|
214505657|NCT06595160|OTHER|Non-Interventional Study|Non-interventional study
215018275|NCT01345903|PROCEDURE|therapeutic conventional surgery|Undergo robotic-assisted surgery
215018276|NCT03709030|DIAGNOSTIC_TEST|magnetic resonance cholangiopancreatography (MRCP)|magnetic resonance imaging of liver, gall bladder, pancreas
214416998|NCT03896828|DIETARY_SUPPLEMENT|Mixed-macronutrient meal|"Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be \~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches."
214416999|NCT04005313|DEVICE|vibroacoustic device|the participants will receive the vibroacustic device or music therapy
214417000|NCT00284973|BIOLOGICAL|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
214417001|NCT01712594|DEVICE|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
214417002|NCT03028363|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
214417003|NCT03028363|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
214417004|NCT04729296|DRUG|Golimumab|For participants ≥45 kg, 50 mg of golimumab will be administered subcutaneously For participants \<45 kg, the dose of golimumab is 30 mg/m2 to maximum of 50 mg
214417005|NCT04729296|DRUG|Placebo|Inactive Drug
214417006|NCT04388488|DEVICE|CONNECT TF adaptable socket system|Prefabricated, adaptable socket system
214417007|NCT04388488|DEVICE|Any conventional handmade socket|Subjects current socket
214417008|NCT04204330|DEVICE|CardioQvark cardiac monitor and software, single-lead ECG|"Registration certificate for the medical device No. РЗН 2019/8124 dated February 15, 2019.~Product form: phone case.~Way of applying:~1. Download the CardioQVARK mobile application; create a profile.~2. Fill out the questionnaire:~   * age;~  * date of birth;~  * sex;~  * weight;~  * height;~  * blood type;~  * eye color;~  * hair color;~  * occupation;~  * town;~  * alcohol consumption;~  * tobacco use;~  * overeating;~  * insufficient sleep;~  * hypertension;~  * type 2 diabetes;~  * pacemaker;~  * the 10th revision of the International Classification of Diseases (ICD-10) code;~  * medicines.~3. Place index fingers on sensors that are on the case's backside and record 1-lead ECG of up to 3 minutes duration.~Recorded parameters:~* time parameters of the ECG intervals (RR, P, PR, QRS, QT, QTc);~* abnormal rhythms;~  * heart rate variability;~ * additional function - blood pressure and blood sugar diary. All recorded and calculated parameters are passed to the server."
214417009|NCT06457568|DIAGNOSTIC_TEST|Blood pressure measurement|The blood pressure measurement was taken simultaneously by two observers using mercury sphygmomanometer and by a supervisor using the tested device, CONTEC08C.
214417010|NCT01890889|DIETARY_SUPPLEMENT|Ad-Chol-Pre|
214417011|NCT01890889|DIETARY_SUPPLEMENT|Half-dose Ad-Chol-Pre|
214417012|NCT01890889|OTHER|Defatted egg yolk without the active ingredient of the other two interventions|
214417013|NCT02357784|DEVICE|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
214417014|NCT04003428|DEVICE|High Intensity Focused Ultrasound|HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
214417015|NCT03211325|PROCEDURE|Biopsy|
214417016|NCT02942056|DRUG|Cinnamon|Cinnamon tablets to treat type 2 DM
215018277|NCT02062346|DRUG|BQ123|Intravenous infusion of BQ123 ( selective ETA antagonist )
214417017|NCT02942056|DRUG|placebo|placebo
214689702|NCT02639793|PROCEDURE|catheter ablation|Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
215018278|NCT02062346|DRUG|BQ123/788|or BQ123/788 (mixed ETA/B antagonists)
215018279|NCT02062346|DRUG|Placebo|Intravenous infusion of saline
214417018|NCT04700007|DRUG|Capsaicin|A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.
214417019|NCT04700007|DRUG|Diphenhydramine|Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.
214417020|NCT04700007|DRUG|Morphine Chloride|Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.
214417021|NCT04700007|DRUG|Isotonic saline|injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
214417022|NCT04700007|DRUG|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
214417023|NCT01421654|DEVICE|S9 Elite with Acclimate|S9 Elite Flow Generator with Acclimate feature activated
214417024|NCT01421654|DEVICE|S9 Elite|S9 Elite Flow Generator
214694030|NCT03892330|DRUG|Vincristine|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
215018280|NCT05416632|DIAGNOSTIC_TEST|Athrometer|Arthrometer
215018281|NCT04121871|OTHER|No intervention|Not required
215018282|NCT00978185|OTHER|medical chart review|
215018283|NCT00978185|OTHER|questionnaire administration|
215018284|NCT00978185|PROCEDURE|acupressure therapy|
215018285|NCT00978185|PROCEDURE|quality-of-life assessment|
215018286|NCT00978185|PROCEDURE|sham intervention|
214417025|NCT01876654|DEVICE|TruMatch® patient specific cutting guide|
214417026|NCT01712113|DRUG|Irbesartan|
214417027|NCT01712113|DRUG|Avapro|
214417028|NCT00380627|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
214417029|NCT00640029|PROCEDURE|Arthrodesis|"* posterior,~* anterior,~* circumference approach"
214417030|NCT00640029|DEVICE|Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)|"* SYNTHES : PRODISC-C® , PRODISC-L®~* LDR : Mobi-C®, Mobidisc®~* MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~* SCIENT'X : DISCOCERV®"
214417031|NCT00572000|BIOLOGICAL|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
214417032|NCT02698241|DEVICE|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
214417033|NCT06409949|DIAGNOSTIC_TEST|Walking assessment|"Participating patients will undergo the following evaluations at baseline and after six months of treatment with MitoQ or placebo:~Assessment of walking impairment: Evaluation of treadmill maximum walking distances, six-minute walking distance, and daily physical activity (average steps taken daily)"
214417034|NCT06409949|OTHER|QOL Survey|Assessment of quality of life: Survey of Quality of life with the Walking Impairment Questionnaire and Short Form 36
214417035|NCT06409949|DIAGNOSTIC_TEST|Ankle pressure at rest and after stress|Assessment of leg hemodynamics: Evaluation of post-occlusive ankle pressure and ankle/brachial index
214417036|NCT06409949|DIAGNOSTIC_TEST|Muscle Oxygen|Evaluation of calf muscle heme oxygen saturation
214417037|NCT06409949|DIAGNOSTIC_TEST|Serum MitoQ Level|Evaluation of serum concentrations of MitoQ
215018287|NCT00978185|PROCEDURE|standard follow-up care|
214417038|NCT06409949|PROCEDURE|Needle Biopsy|Needle biopsy of the calf muscle
214417039|NCT01837641|BIOLOGICAL|LY3002813-IV|Administered IV
214417040|NCT01837641|BIOLOGICAL|LY3002813-SC|Administered SC
214417041|NCT01837641|DRUG|Placebo-IV|Administered IV
214694031|NCT03892330|DRUG|Oxytetracycline/ Cyclophosphamide|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
214417042|NCT04318444|DRUG|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
214417043|NCT04318444|DRUG|Placebo oral tablet|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
214417044|NCT05761080|DRUG|Amoxicillin clavulanic acid IV during hospitalization|Amoxicillin clavulanic acid IV 5 days during hospitalization. Application of discharge criteria at 5 postoperative days, according to guidelines current clinic.
214417045|NCT05761080|DRUG|Amoxicillin clavulanic acid IV 3 days and PO until day 5|"Amoxicillin clavulanic acid IV 3 days during hospitalization and at discharge Amoxicillin clavulanic acid PO until day 5.~Application of discharge criteria at 72 postoperative hours, administering oral antibiotic therapy with a spectrum similar to that of the control group total of 5 days and sending the patient home with oral analgesia."
214417046|NCT02819193|OTHER|raw mother's own milk|Infants receive mother's own milk before day 7.
214417047|NCT04217421|DRUG|Allopurinol|Allopurinol powder for solution for infusion (PFI) 20 mg/kg body weight per administration will be administered early postnatally (within 45 minutes and 12 hours after the first dose), preoperatively (12 hours before surgery), intraoperatively (during surgery) and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Allopurinol PFI will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
214417048|NCT04217421|DRUG|Mannitol|Mannitol powder for solution (PFI) placebo will be administered early postnatally (within 45 minutes and 12 hours after birth), preoperatively (12 hours before surgery), intraoperatively (during surgery), and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Mannitol PFI-placebo will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
214694032|NCT03892330|DRUG|Liposomal doxorubicin|The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
215018288|NCT01627912|OTHER|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink \[white wine or red wine or 12.5% ethanol or water\]/kg of individual, parallel with a standardized meal.
215018289|NCT00862277|BIOLOGICAL|Menactra®|0.5 mL, Intramuscular (from a previous study)
215018290|NCT00862277|BIOLOGICAL|Menomune®|0.5 mL, Intramuscular (from a previous study)
214417049|NCT04217785|DRUG|Optive, Ophthalmic Solution|6 drops per day, for 8 weeks
214417050|NCT04217785|BIOLOGICAL|Umbilical Cord Serum eye drops|UCS eye drops (6 drops per day, for 8 weeks)
214417051|NCT04217785|DRUG|Genteal lubricant gel|Genteal lubricant gel (2 drops per day, for 8 weeks)
214417052|NCT03286205|DRUG|IV iron|IV iron infusion based on weekly or every 3 week dosage.
214417053|NCT00708279|PROCEDURE|Osteopathic manipulation|Participant will be evaluated and treated for somatic dysfunction utilizing osteopathic manipulation once a week for 3 weeks, then once every 3 weeks for three more visits; a total of 6 interventions in 3 months.
214417054|NCT02181699|DRUG|KHK2823|single agent KHK2823
214417055|NCT03717987|DRUG|Botulinum toxin type A|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015)."
214417056|NCT03717987|DIETARY_SUPPLEMENT|Zinc supplementation|zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
214417057|NCT00906282|DRUG|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
214417058|NCT00906282|DRUG|Carboplatin|AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
214417059|NCT01930279|OTHER|Blood withdrawal|Blood withdrawal
214417060|NCT00071643|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
215018291|NCT06006221|BEHAVIORAL|Qi-gong relaxation exercise|Qi-gong relaxation exercise is a mindfulness-based exercise and is a type of exercise that consists of breathing-compatible body movements and relaxation used to relax the body and mind, reduce stress, distract attention from negative thoughts, accelerate blood flow, and improve emotions.
215018292|NCT04308993|PROCEDURE|percutaneous transhepatic choledochoscopy|percutaneous transhepatic choledochoscopy
215018293|NCT00871000|BIOLOGICAL|Boostrix Polio™ 711866|Single dose, intramuscular administration.
214417061|NCT00071643|DRUG|Escitalopram|Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
214417062|NCT00071643|OTHER|Placebo|Participants will receive a placebo pill.
214417063|NCT01792609|PROCEDURE|Maximum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
214417064|NCT01792609|PROCEDURE|Minimum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
214417065|NCT00395811|PROCEDURE|Bone Marrow Stem Cell Therapy combined CABG|Bone Marrow Stem Cell inject into myocardium
215018294|NCT00871000|BIOLOGICAL|Priorix Tetra TM 208136|Single dose, subcutaneously.
214417066|NCT02661646|DEVICE|Advanced Pneumatic Compression Device|Advanced Pneumatic Compression Device
214417067|NCT03944343|OTHER|Cereal based products|The cereal products are made from common Swedish cereals.
214417068|NCT06085950|DEVICE|Transcranial Ultrasonic Stimulation prototype|Transcranial Ultrasonic Stimulation prototype delivers personalized low-intensity ultrasound stimulation
214417069|NCT03515720|PROCEDURE|Prolotherapy|It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.
214417070|NCT01771900|BEHAVIORAL|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
214417071|NCT01771900|BEHAVIORAL|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
214417072|NCT04822129|BEHAVIORAL|Treatment as Usual|Treatment as usual will provide participants with basic information that is readily available as well as the encouragement to develop a brain health program that may be available from medical professionals.
214505658|NCT06586125|OTHER|Powered Mobility Training|The study procedure aims to observe the partecipants' behaviour while using the Virtual Reality - Power Mobility Program (VR-PMP) simulator applied during Power Mobility Training in clinical practice for 15 sessions. Participants use either semi-immersive mode (laptop screen with VR-PMP simulator) or immersive mode (head-mounted display with VR-PMP simulator). Five out of ten children unable to use conventional VR controllers or alternative access technologies available on the market, use brain-computer interface (BCI) developed specifically for these children to control the VR-PMP simulator.
214505659|NCT06141499|BEHAVIORAL|Provider educational materials|Dialysis providers will receive educational material about the kidney transplantation and waitlisting process.
214505660|NCT06141499|BEHAVIORAL|Patient letters|Dialysis patients will receive letters with information about their status within the kidney transplantation and waitlisting process. Letters will describe kidney waitlist status, living donor transplantation, Hepatitis C positive kidney transplants, and high Kidney Donor Profile Index (KDPI) transplants.
214505661|NCT05181618|DRUG|Emicizumab|The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
215018295|NCT00871000|BIOLOGICAL|Tetravac TM|Single dose, intramuscular administration.
215018296|NCT01052428|DRUG|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
214417073|NCT04822129|BEHAVIORAL|Cogtrastim Model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model.
214417074|NCT03553446|DRUG|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
214417075|NCT03949322|BEHAVIORAL|Adapted Physical Activity Program|The sessions in this program are similar to the adapted physical activity sessions already offered by sports therapy practitioners. This is an aerobic exercise session, with Nordic walking, and a combined session of muscle building and breathing exercises.
214505662|NCT06980766|DEVICE|Non Invasive Blood Pressure|"Manual blood pressure via sphygmomanometer~Or~Non invasive blood pressure via earlyvue VS30 Monitor"
215018297|NCT01052428|DRUG|Placebo|Placebo 100 mg once a day for 2 years
215018298|NCT00092742|DRUG|MK0663, etoricoxib|
215018299|NCT00092742|DRUG|Comparator: Diclofenac sodium|
215102073|NCT00084656|BIOLOGICAL|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
214417076|NCT00991744|DRUG|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
214417077|NCT00991744|DRUG|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
214417078|NCT01019577|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
214417079|NCT05541237|DIETARY_SUPPLEMENT|Food|Food
214417080|NCT04310059|DIETARY_SUPPLEMENT|Folic acid|women will be randomised into one of the three groups. Group A - Folic acid 5mg/day Group B - Folic acid 0.5mg/day Group C - Materna one tablet/day (a pregnancy supplement containing 0.6mg folic acid)
214417081|NCT04310059|DIETARY_SUPPLEMENT|Materna|Materna
214417082|NCT02540213|DEVICE|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
214417083|NCT02350595|OTHER|Lean fish|
214417084|NCT02350595|OTHER|Fatty fish|
214417085|NCT01506843|BIOLOGICAL|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
214417086|NCT01037933|OTHER|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
214417087|NCT01037933|OTHER|Non-humor intervention (distraction)|"A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player"
214417088|NCT00573703|PROCEDURE|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
214417089|NCT00573703|PROCEDURE|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
214417090|NCT02889822|DRUG|Alprostadil Liposomes for Injection|"1. Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~2. Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
214417091|NCT02289560|DEVICE|Transcranial ExAblate|Transcranial ExAblate
214417092|NCT04465578|PROCEDURE|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
214417093|NCT04465578|PROCEDURE|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
214417094|NCT01247558|OTHER|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for \>120 days
214417095|NCT01247558|OTHER|Not treated with Metanx®|Non-treated comparative cohort
214417096|NCT00035230|DRUG|Topiramate|
214417097|NCT03254329|OTHER|Assessment of human milk nutrient composition|Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.
214417098|NCT02696629|PROCEDURE|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
214417099|NCT02696629|DEVICE|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
214417100|NCT02696629|BEHAVIORAL|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
214417101|NCT02214251|DEVICE|PK-16CH EXG system|
214417102|NCT01286402|DRUG|Bupropion SR|"* 150mg, taken orally, taken daily for the 1st 3 days~* 300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment"
215018300|NCT06296030|BEHAVIORAL|POOF ACT program|The goal of this study is to test this culturally tailored intervention (POOF) against classic ACT, to discover if POOF does better at decreasing race-based trauma in African Americans.Guided by the cultural humility framework and social determinants of health model, we examine POOF, a culturally-tailored ACT model for use with anxious African Americans. The POOF approach builds on research on ACT for the general population, an evidence-based intervention, by tailoring the language of ACT while retaining the fidelity of the ACT model. Our hypotheses examine acceptability and attitudes toward treatment, treatment outcomes for psychological symptoms (i.e., anxiety) and an ACT-related outcome (i.e., psychological flexibility), and a possible underlying mechanism of change (i.e., race-based stress).
214417103|NCT01286402|OTHER|Placebo|-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
214417104|NCT03650322|BEHAVIORAL|Yoga|12 weeks, total of 150 minutes of exercise per week.
214417105|NCT03650322|BEHAVIORAL|Stretching and Toning|12 weeks, total of 150 minutes of exercise per week.
214417106|NCT03650322|BEHAVIORAL|Aerobic Walking|12 weeks, total of 150 minutes of exercise per week.
214417107|NCT02784327|DRUG|PRF110|
214417108|NCT06523855|PROCEDURE|bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation|bilateral alveolar cleft grafting using particulate iliac crest graft accompanied with fixation of graft and premaxilla using microplate
214694033|NCT03892330|DRUG|Doxorubicin|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
215018301|NCT06296030|BEHAVIORAL|Classic ACT program|This protocol is for a classic, non-adapted ACT intervention.
215018302|NCT00707369|DRUG|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
215018303|NCT00707369|DRUG|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
214417109|NCT05708066|OTHER|Lavender Aromatherapy|"Participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations.~After the lavender patch has been in place for 5 minutes, the same VAS anxiety questionnaire will be provided"
214417110|NCT05708066|OTHER|Non-scented Tab|A non-scented tab will be placed on the participant's chest, according to manufacturer recommendations. Participants in this group will only receive the initial VAS anxiety questionnaire.
214417111|NCT00290706|DRUG|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
215018304|NCT03400787|DEVICE|Latera Implant|Treatment with implant
214417112|NCT00290706|DRUG|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
214417113|NCT04884737|OTHER|Mepilex Border Flex® (MBF) dressing|A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
214417114|NCT02633189|DRUG|Erlotinib|given orally 150 mg daily
214417115|NCT02633189|DRUG|Bevacizumab|15 mg/kg intravenously every 21 days.
215018305|NCT03400787|DEVICE|Sham Procedure|Sham procedure where the Latera delivery device is inserted but no implant delivered.
214417116|NCT00770978|DRUG|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
214694034|NCT03892330|DRUG|Pharmorubicin|The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
214417117|NCT00770978|DRUG|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
214417118|NCT06141980|DRUG|DWP16001 0.3 mg|DWP16001 0.3mg, Tablets, Orally, Once daily
214417119|NCT01396291|DRUG|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
214417120|NCT01396291|DRUG|placebo|asenapine-matched placebo, sublingual tablets, BID
214417121|NCT00605033|DRUG|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
214417122|NCT00605033|DRUG|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
214417123|NCT03395353|DRUG|Duloxetine Hydrochloride|Administered orally
214417124|NCT02493933|DRUG|Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine|
214417125|NCT01719536|DRUG|Icotinib|Icotinib: 125 mg is administered orally three times per day.
214417126|NCT01719536|DRUG|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
214417127|NCT01196429|DRUG|Carboplatin|Given IV
214417128|NCT01196429|DRUG|Docetaxel|Given IV
214417129|NCT01196429|OTHER|Laboratory Biomarker Analysis|Correlative studies
214417130|NCT01196429|DRUG|Paclitaxel|Given IV
214417131|NCT01196429|DRUG|Temsirolimus|Given IV
214417132|NCT01260298|DEVICE|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
214417133|NCT05591001|DRUG|ketamine and dexmeditomidine combination|Dexmedetomidine( 0.4 -0.6 μg/.kg /.hr)) ketamine,( 1 -2m/.kg/.hr) infusion
214417134|NCT05591001|DRUG|Propofol|propofol (100 ug /kg/min) infusion
214417135|NCT04218669|PROCEDURE|Roux-en-Y Hepaticojejunostomy|The common hepatic duct was cut and the duodenal side is closed by suture. The small intestine was cut off 15 cm below the ligament of Treitz. The distal end was lifted, and a 1-2 cm incision was made at the jejunal wall 4-5 cm from the jejunal stump. The anastomosis is used a 5-0 PSD Ⅱ suture, with double needles, inside-out in the jejunum and outside-in in the hepatic duct. One side of needles was used to continuely penetrate and suture the whole layer of the posterior-lateral wall of the jejunum, the posterior-lateral wall of the biliary duct, and the other side of needles was used to continuely stuere the anterior part of the anastomosis. Mucosa-to-mucosa contact should be ensured with every stitch.The anastomotic stomas were then checked for leakage. Enteric-enteric anastomosis was performed 60 cm below the site of the hepatojejunal anastomosis.
214417136|NCT04218669|PROCEDURE|T-tube drainage|The T-tube was placed for biliary drainage and the common bile duct was intermittently sutured with 4-0 vicryl sutures.
214417137|NCT00111020|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
214417138|NCT03910517|OTHER|No intervention|No intervention
214417139|NCT06524700|PROCEDURE|pectopexy mesh|pectopexy with mesh
214417140|NCT06524700|PROCEDURE|pectopexy autologous|pectopexy using autologous graft
214417141|NCT03297112|DRUG|Perflutren Lipid Microspheres|Given IV
214417142|NCT03297112|PROCEDURE|Contrast-Enhanced Subharmonic Ultrasound Imaging|Undergo contrast-enhanced subharmonic ultrasound imaging
214417143|NCT05409664|BEHAVIORAL|Physical activity adoption|webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.
214417144|NCT05409664|BEHAVIORAL|Self monitoring|Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
214417145|NCT03047083|OTHER|Treatment patterns among AML patients|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
214417146|NCT03047083|OTHER|AML-related healthcare resources|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
214417147|NCT06461624|BIOLOGICAL|anti-GPC3 CAR-T|All subjects were intravenous administrated with CBG166.
214417148|NCT02101905|OTHER|Laboratory Biomarker Analysis|Correlative studies
214417149|NCT02101905|DRUG|Lapatinib|Given PO
214417150|NCT02101905|DRUG|Lapatinib Ditosylate|Given PO
214417151|NCT02101905|OTHER|Pharmacological Study|Correlative studies
214417152|NCT02101905|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
214417153|NCT03203525|BIOLOGICAL|Bevacizumab|Given IV
214417154|NCT03203525|DRUG|Fluorouracil|Given via pump
214417155|NCT03203525|DRUG|Leucovorin|Given via pump
214417156|NCT03203525|DRUG|Oxaliplatin|Given via pump
214417157|NCT03203525|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
214417158|NCT03203525|DRUG|Temsirolimus|Given IV
214417159|NCT03203525|PROCEDURE|Tumor Treating Fields Therapy|Use NovoTTF-100L(P) system
214417160|NCT05394779|DEVICE|DTXO APP|DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.
215018306|NCT02455726|DIETARY_SUPPLEMENT|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
214417161|NCT05394779|DEVICE|PLACEBO APP - Control group|The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
214417162|NCT01866969|OTHER|questionnaire administration|Ancillary studies
214417163|NCT01866969|PROCEDURE|quality-of-life assessment|Ancillary studies
214417164|NCT02960659|DRUG|Liraglutide|Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg.
214417165|NCT02960659|DRUG|Metformin|Metformin 500mg oral tablet
214417166|NCT06499584|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests. During the surgery, stimuli are delivered."
214417167|NCT02817282|OTHER|Hand hygiene implementation strategy|Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
214417168|NCT03640403|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
214417169|NCT03640403|DRUG|Artesunate-amodiaquine|Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
214417170|NCT05486312|DEVICE|CT-155 smartphone app|The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
214417171|NCT00121329|DRUG|Intrauterine lidocaine infusion 4%|
214417172|NCT05601830|DRUG|QN-030a|NK cell therapy
214417173|NCT05601830|DRUG|Cyclophosphamid|Lympho-conditioning Agent
214417174|NCT05601830|DRUG|Fludarabine|Lympho-conditioning Agent
214417175|NCT05601830|DRUG|Cytarabine|Lympho-conditioning Agent
214417176|NCT00821184|DRUG|Vesicare (solifenacin)|5mg po qd
215018307|NCT02455726|DIETARY_SUPPLEMENT|Fructose|Oral fructose 10 g twice a day
215018308|NCT02455726|DRUG|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
215018309|NCT02455726|DRUG|Pregabalin|Pregabalin 25 mg at 8 pm
215018310|NCT01889563|OTHER|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
215018311|NCT04469946|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
214417177|NCT00821184|BEHAVIORAL|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
214417178|NCT05348096|DRUG|Low-dose ibrutinib|Daily ibrutinib (140mg QD) and itraconazole (100mg BID) for six months.
215018312|NCT01745302|DRUG|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
215018313|NCT01745302|DRUG|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
215018314|NCT06569927|PROCEDURE|Utilization of a perioperative position management protocol for congenital microtia patients based on the ADDIE model.|Key elements included formation of a multidisciplinary team，perioperative postural management, preoperative sleeping posture adaptability training, neck movement training, standardization of head position angles and head suspension time during surgery, use of protective headrests, attention to transfer and handover procedures, and specially designed pillows.
214417179|NCT02342210|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
214417180|NCT05604885|DRUG|AP1189, 60 mg|AP1189 tablets for oral use
214417181|NCT05604885|DRUG|AP1189, 80 mg|AP1189 tablets for oral use
214417182|NCT05604885|DRUG|AP1189, 100 mg|AP1189 tablets for oral use
214417183|NCT05604885|DRUG|Placebo|Matching placebo tablets for oral use
214417184|NCT04618224|DIAGNOSTIC_TEST|DDART Testing|One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
214417185|NCT04618224|DIAGNOSTIC_TEST|wDDART Testing|One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
214417186|NCT02571816|DRUG|ASP2215|oral
214417187|NCT03286244|DRUG|CM082 plus paclitaxel|"CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles."
214417188|NCT04681079|DRUG|albuterol sulfate (MDI)|albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer
214417189|NCT04681079|DRUG|albuterol sulfate (nebulizer)|albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece
214417190|NCT04944446|OTHER|Treatment|Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint
214417191|NCT06188611|DRUG|Huazhi Rougan Granule Placebo granule|Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
214417192|NCT05991999|OTHER|Stretching|"Master swimmers will be taught iliopsoas, sternocleidomastoid and pectoralis major stretching exercises as stretching exercises. Participants will stretch daily for 3 repetitions, each stretching for 20 seconds.~Participants will continue their swimming training 2 days a week."
214417193|NCT05991999|OTHER|Training|Participants continued their swimming training 2 days a week.
214417194|NCT00502229|DRUG|Clomiphene citrate, metformin, highly purified urinary FSH|
214417195|NCT03167034|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
214417196|NCT03167034|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
214417197|NCT05800041|DRUG|WTX221|Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion
214417198|NCT00538213|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
214417199|NCT00538213|BIOLOGICAL|GSK Bio's Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
214417200|NCT02675088|RADIATION|high-dose TRT|every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
214417201|NCT02675088|RADIATION|standard-dose TRT|every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
214417202|NCT03181464|DRUG|Lidocaine 4%|lidocaine solution
214417203|NCT03181464|DRUG|Placebo|saline .9% injection
214417204|NCT05709873|BEHAVIORAL|Imagery rehearsal therapy|Therapy to reduce nightmares, delivered via videoconference sessions
214417205|NCT05709873|BEHAVIORAL|Targeted dream control|Therapy to reduce nightmares, delivered in videoconference sessions and lab session. Lab session will involve a sleep study during a daytime nap.
214417206|NCT01645423|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
214417207|NCT03140176|DRUG|Sunitinib|Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.
214417208|NCT04611360|OTHER|Anodal Transcranial Direct Current Stimulation Group|"Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used"
214417209|NCT04611360|OTHER|Conventional Training Exercises Group|Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
214417210|NCT04815616|RADIATION|Radiotherapy|Capecitabine with adjuvant radiotherapy in treatment of Early Stages Breast Cancer
214417211|NCT02452294|DRUG|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
214417212|NCT02242929|DRUG|Imiquimod 5% cream with prior curettage|
214417213|NCT02242929|PROCEDURE|Standard surgical excision|
214417214|NCT04075357|OTHER|Amniotic membrane transplantation|Amniotic membrane was located over median nerve during surgery of CTS, prior of closing.
214417215|NCT00773435|BIOLOGICAL|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
214417216|NCT00773435|OTHER|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
214417217|NCT04490252|DIETARY_SUPPLEMENT|Fasting mimetic diet|Fasting mimetic diet for 5 days, another cycle after 25 days
214417218|NCT04870060|DRUG|Curcumin Lozenges|Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
214417219|NCT02234778|DEVICE|TGI SVF material via intramuscular injection|Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
214417220|NCT03282526|DIAGNOSTIC_TEST|Whole body plethysmography|Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
214417221|NCT05318885|OTHER|A Randomized Controlled Study|For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
214689703|NCT02610400|COMBINATION_PRODUCT|RACD|"Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) \> 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop"
214694035|NCT03892330|DRUG|Pirarubicin|The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
214694036|NCT05415150|DRUG|Thrombolytic Agent|Subjects may receive one or more of the treatment options
215102074|NCT02555605|DRUG|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
215102075|NCT00875862|PROCEDURE|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
215102076|NCT05902481|OTHER|Education|education about breastfeeding with mixed reality technology.
215102077|NCT02772978|DRUG|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
215102078|NCT02772978|DRUG|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
215102079|NCT02178267|DIETARY_SUPPLEMENT|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
215102080|NCT02357589|PROCEDURE|2D laparoscopic cholecystectomy|
215102081|NCT02357589|PROCEDURE|3D laparoscopic cholecystectomy|
215102082|NCT06120894|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using Snellen optotype chart.
215102083|NCT06120894|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
215102084|NCT06120894|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
215102085|NCT06120894|DIAGNOSTIC_TEST|Refraction and keratometry|Measurement of refraction and keratometry using refractometer Nidek ARK-1a.
215102086|NCT06120894|DIAGNOSTIC_TEST|Optical biometry|Measurement of optical biometry using biometer Argos (Barrett or SRK/T formula).
215102087|NCT06120894|DIAGNOSTIC_TEST|Strip meniscometry (SM)|Strip meniscometry examination using strip meniscometry tube.
214417222|NCT01331824|DRUG|Amrubicin|Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
214417223|NCT02086370|PROCEDURE|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
215102088|NCT06120894|DIAGNOSTIC_TEST|Lid Parallel Conjunctival Folds test (LIPCOF)|Evaluation of lid parallel conjunctival folds using slit lamp examination.
215102089|NCT06120894|DIAGNOSTIC_TEST|Staining of the ocular surface with fluorescein|Evaluation of ocular surface fluorescein staining using Oxford scheme.
215102090|NCT06120894|DIAGNOSTIC_TEST|Tear break up time test (TBUT)|Evaluation of tear break up time using slit lamp examination.
215102091|NCT06120894|OTHER|Ocular Surface Disease Index questionnaire (OSDI)|Evaluation of Ocular Surface Disease Index using Ocular Surface Disease Index questionnaire.
215102092|NCT04123613|DRUG|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
214417224|NCT02086370|PROCEDURE|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
214417225|NCT00616733|DRUG|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
214417226|NCT00616733|DRUG|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
214417227|NCT00616733|DRUG|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
214417228|NCT05999864|OTHER|Rehabilitation|Proprioceptive neuromuscular facilitation exercise will be given to the study group as previously described (Gstoettner et al., 2011). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
214417229|NCT02669524|DRUG|LY2409021|
214417230|NCT02669524|DRUG|LY2409021 placebo|
214417231|NCT02669524|PROCEDURE|OGTT|
214417232|NCT02669524|PROCEDURE|IIGI|
214417233|NCT02669524|PROCEDURE|Standardised liquid meal|
214417234|NCT02892903|DEVICE|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow \<3 will not be examined but will be 'awarded' an FFR value of 0.5
214417235|NCT06242041|DRUG|sodium zirconium cyclic silicate|On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.
214417236|NCT05911256|BEHAVIORAL|Pharmacist Only|Clinical pharmacists conduct encounters with patients by videoconferencing or phone. Pharmacists conduct a broad range of activities including ongoing evaluation of medication and lifestyle adherence, setting therapeutic goals, formulating a provider-approved plan of care, and documenting the plan in the electronic health record. Pharmacists propose medication changes based on algorithms and protocols derived from national guidelines under physician guidance.
214417237|NCT05911256|DEVICE|Continuous Glucose Monitor (CGM)|Patients will receive the Continuous Glucose Monitoring (CGM) system. The instruction on use of device is the intervention being tested, not the effectiveness of the device itself. Participants will receive instruction and training on how to use the device and will wear the device for 14 days.
214417238|NCT05911256|BEHAVIORAL|Community Health Worker (CHW)|Patients are connected to a community health worker(CHW). CHWs conduct home visits and facilitate 3-way Telehealth visits (Patients, pharmacists, and CHWs) via an iPad with cellular plan. Additional CHW activities include social determinants of health screening, health behavior education, problem solving, goal setting, and medication adherence support.
214417239|NCT04265378|DEVICE|anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
214417240|NCT04265378|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
214505663|NCT06982677|BEHAVIORAL|Nurse Navigator Intervention|The intervention will integrate education, decision support, patient activation strategies, and cognitive-behavioral menopause symptom management skills. Participants will receive video and audio-recorded materials and a written manual.
215102093|NCT04183088|DRUG|Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.|"There will be no dose reduction for tislelizumab in this study. In the part 1(safety cohort), if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles (6 weeks) of treatment, the dosage of regorafenib may be escalated. For subjects who escalate the regorafenib dosage to Level 2, if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles of study drug treatment, the dosage of regorafenib may be further escalated to Level 3.~During study drug treatment, dose delay/ interruption of regorafenib will be done depending on the occurrence and severity of regorafenib-related adverse events. After dose reduction of regorafenib, if the subjects tolerate the reduced dose of regorafenib well, the investigators may consider re-escalation of regorafenib to the previous dose level, depending on the types and severity of adverse events that led to dose reduction."
215102094|NCT02678299|DRUG|PREBEN|
214505664|NCT06982677|OTHER|Education Control|"The control arm will receive the National Cancer Institute booklet, Facing Forward: Life After Cancer Treatment, which provides basic strategies for navigating cancer survivorship."
214505665|NCT06800989|BEHAVIORAL|sophrology sessions|Two sophrology sessions will be conducted in the experimental group. The first session (S1) should take place on Cycle 1 Day 1 or within a maximum of 3 weeks following Cycle 1 Day 1. The second session (S2) should be conducted within 3 to 4 weeks after the first session.
214417241|NCT00221208|BEHAVIORAL|Resistance Training|
214417242|NCT05371288|DRUG|NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)|Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
214417243|NCT00149630|DRUG|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
214417244|NCT00149630|DRUG|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
214417245|NCT00149630|BEHAVIORAL|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
214417246|NCT00149630|OTHER|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
214417247|NCT00427557|DRUG|Fludarabine|30 mg/m\^2 by vein for 4 Days (Day -10 through Day -7).
214417248|NCT00427557|DRUG|Melphalan|140 mg/m\^2 by vein for 1 Day (Day -7).
214417249|NCT00427557|PROCEDURE|Umbilical Cord Blood|1 UCB Unit by vein on Day -5.
214505666|NCT06800989|DEVICE|Morphee Device|Patients will be encouraged to perform at least one daily ambulatory sophrology session with the Morphée® device, according to a support plan defined with the sophrologist.
214505667|NCT06978920|DRUG|Allogeneic dopaminergic neural precursor cell(NCR201)|Bilateral implantation
214505671|NCT06116968|DRUG|Aficamten|5-20mg
214505672|NCT06027268|DRUG|Trilaciclib|IV infusion Day 1 and Day 8 every 21 days, at dose of 240 mg/m2
214505673|NCT06027268|DRUG|Pembrolizumab|IV infusion Day 1 every 21 days, at dose of 200 mg
215018315|NCT05781503|BEHAVIORAL|Identity Capital Intervention (Coach + Co-designed Leadership Guide)|Young people randomized to the intervention group will engage in a co-designed leadership guide with their assigned coach. The co-designed leadership guide contains 12 chapters with the overarching aim of enhancing identity capital along with providing strategies to achieve participant-identified goals. Each chapter contains four activities (e.g., self-reflection exercise or listening to a podcast). Ideally, youth will complete one chapter every month. Each young person in this group will meet individually with their coach every two weeks and with a larger group of 10 youth participants and their coach every month.
215102095|NCT00129467|DRUG|Methylphenidate|"Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.~If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.~Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is \> 10 at day 18, the dose may be increased to 15 mg bid."
215102096|NCT00129467|DRUG|Placebo|"Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention."
214417250|NCT00427557|DRUG|Rituximab|375 mg/m\^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
214417251|NCT00427557|OTHER|Peripheral Blood Stem Cell Infusion|Infusion of blood stem cells on Day 0.
214417252|NCT01174329|DEVICE|"Automatic neuro-electrostimulation by Saliwell Crown"|"Continuous stimulation of the lingual nerve by Saliwell Crown"
214417253|NCT01174329|DEVICE|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"On-demand stimulation of the lingual nerveby Saliwell Crown"
214417254|NCT03667547|DRUG|Raltegravir|Raltegravir 600 mg tablet
214417255|NCT05283460|BEHAVIORAL|mandala|The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
214417256|NCT04090320|DEVICE|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
214417257|NCT04689321|OTHER|No intervention|This is not an interventional study.
214417258|NCT02932293|DRUG|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
214417259|NCT00154648|PROCEDURE|CE-MRA|
214417260|NCT03683862|OTHER|orthodontic appliance|Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
215018316|NCT05781503|OTHER|Monthly Rent Subsidies|All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.
214417261|NCT00470795|OTHER|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
214417262|NCT00470795|PROCEDURE|placebo/sham acupuncture|acupuncture at sham points without skin penetration
214417263|NCT02491931|DIETARY_SUPPLEMENT|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
214417264|NCT03223883|DRUG|Curcumin|Oral supplement for 12 months
214417265|NCT03223883|OTHER|Placebo|Oral placebo for 12 months
214417266|NCT04769609|DEVICE|bioresorbable membrane|reconstructive surgical treatment of peri-implant bone defects
214417267|NCT03668327|OTHER||
214417268|NCT06063356|PROCEDURE|Intra-articular and extra-articular Dextrose Prolotherapy injection|In the prolotherapy group, 28 patients will receive intra-articular 5 cc 25% dextrose solution (4 cc 30% dextrose + 1 cc saline) and extra-articular 10 cc 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) in 3 sessions.Extra-articular Injection: Using a sterile syringe with a 27 gauge needle tip (Dental), the points previously found and marked with US (medial collateral ligament, lateral collateral ligament, patellar ligament and adhesion sites of coronary ligaments; pes anserine and superior patellar regions) perpendicular to the surface, using peppering technique, a total of 10 cc of 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) will be injected in small volumes (0.5cc-1cc) at each point.Injection applications will be done at weeks 0 - 3 - 6.
214505674|NCT06027268|DRUG|Gemcitabine|IV infusion Day 1 and Day 8 every 21 days, at dose 1000 mg/m2
214694037|NCT03670069|DRUG|Itacitinib|Given PO
215018317|NCT06570083|BEHAVIORAL|Mobile Exercise Support|Participants receive three months of personalized support via WeChat, including tailored exercise recommendations, motivational messages, and educational content.
214417269|NCT06063356|PROCEDURE|Intra-articular and extra-articular Saline injection|In the saline group, 28 patients are planned to receive 3 sessions of intra-articular 5 cc saline and extra-articular 10 cc lidocaine-serum physiologic solution (5 cc saline + 5 cc 1% lidocaine).Injection applications will be done at weeks 0 - 3 - 6.
215018318|NCT06570083|BEHAVIORAL|Self-help physical activity booklet|Participants receive a self-help booklet to promote physical activity among the elderly. The booklet will include guidelines for safe and effective exercises, tips for staying motivated, and information on the health benefits of regular physical activity.
214417270|NCT05298111|OTHER|Formulation 3|Respondents were consumed 36 g of Formulation 3 containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
214417271|NCT05298111|OTHER|Control|Respondents were consumed 4.5 g of control containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
215018319|NCT06258512|OTHER|Intervention with a narrative approach.|"Health social workers will carry out a intervention with a narrative approach, through its training profile based on transversal skills, which will consist of 10 sessions carried out over five months. The interval between sessions will be of two weeks with a specific duration of fifty minutes per session. This type of intervention, with the objective of reorienting and redefining the demand or the initial problems that motivated the consultation, gives space to the patient\&#39;s subjective complaint, as well as to locate the understanding of the discomfort and the symbolic meaning of the symptoms.~That is, recognizing the physical symptoms while listening to stories of chaos to legitimize both the user and his symptoms, an encounter that allows return the user to its context without feeling rejected or judged by the health system."
214417272|NCT04538820|DRUG|Dexamethasone 4 mg IV-control|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
214417273|NCT04538820|DRUG|Dexamethasone 4 mg IV|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
214417274|NCT04538820|DRUG|Dexamethasone 8 mg IV|dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
214417275|NCT02689349|DEVICE|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
214417276|NCT03518112|BIOLOGICAL|Blinatumomab|Given IV
214417277|NCT03518112|DRUG|Cyclophosphamide|Given IV
214417278|NCT03518112|DRUG|Cytarabine|Given IT or IV
214417279|NCT03518112|DRUG|Dexamethasone|PO or IV
214417280|NCT03518112|BIOLOGICAL|Filgrastim|Given SC
214417281|NCT03518112|OTHER|Laboratory Biomarker Analysis|Correlative studies
214417282|NCT03518112|DRUG|Leucovorin Calcium|Given IV
214417283|NCT03518112|DRUG|Mercaptopurine|Given PO
214417284|NCT03518112|DRUG|Methotrexate|Given IT or IV
214417285|NCT03518112|BIOLOGICAL|Pegfilgrastim|Given SC
214417286|NCT03518112|BIOLOGICAL|Rituximab|Given IV
214417287|NCT03518112|DRUG|Vincristine Sulfate|Given IV
214417288|NCT03723512|DEVICE|Non contrast-enhanced magnetic resonance imaging|Non contrast-enhanced magnetic resonance imaging
214417289|NCT06055595|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
214417290|NCT03094104|OTHER|News items with spin|Interpretation of news items with spin
214417291|NCT03094104|OTHER|News items without spin|Interpretation of news items without spin
214417292|NCT01087684|PROCEDURE|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
214417293|NCT01087684|PROCEDURE|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
214417294|NCT00449813|DRUG|Pantoprazole|40 mg Pantoprazole
214417295|NCT04621682|OTHER|Non technical skills and checklist training in simulation|using structured debrifing, in three random medical simulation crises, training in non-technical skills will be carried out
214417296|NCT04621682|OTHER|Checklist training simulation|using structured debrifing, in three random medical simulation crises, training in checklist will be carried out
214417297|NCT04665661|BEHAVIORAL|High-intensity aerobic training|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
214505675|NCT06027268|DRUG|Carboplatin|IV infusion Day 1 and Day 8 every 21 days, at dose area under curve (AUC) 2 (maximum of 300 mg)
214694038|NCT03670069|OTHER|Laboratory Biomarker Analysis|Correlative studies
214694039|NCT03160105|DRUG|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
214694040|NCT03160105|OTHER|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
214694041|NCT03995628|DRUG|Dexamethasone|One dose of dexamethasone (0.5 mg/kg) on post-operative day 3 after tonsillectomy
215018320|NCT03408808|PROCEDURE|Platelet rich plasma|Aspiration of ganglion and injection with platelet rich plasma.
214417298|NCT04665661|BEHAVIORAL|Wait-list control|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
214417299|NCT04612894|DRUG|Camrelizumab and Apatinib|All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
214417300|NCT04612894|PROCEDURE|surgery|Perform surgery if operable after neoadjuvant therapy
214417301|NCT04612894|PROCEDURE|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
214417302|NCT00143689|DRUG|lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine|See Detailed Description.
214417303|NCT02319122|OTHER|High Intensity Interval Training|See arm description
214694042|NCT03995628|DRUG|Placebo|One dose of placebo on post-operative day 3 after tonsillectomy
214694043|NCT05019040|DRUG|PA1010|TDF as control
215018321|NCT03408808|PROCEDURE|Aspiration alone|Aspiration of the ganglion
215018322|NCT00597792|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
215018323|NCT03090035|DRUG|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
215018324|NCT03090035|DRUG|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3
215102097|NCT00129467|DRUG|Selective Serotonin Uptake Inhibitor (SSRI)|"Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion"
215102098|NCT05047432|OTHER|Non-interventional trial|Non-interventional trial
215102099|NCT01532869|DRUG|Placebo|Subcutaneously weekly, Weeks 0-48
215102100|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Weeks 0-48
214417304|NCT02319122|OTHER|Progressive Resistance Training|See arm description
214417305|NCT04307199|PROCEDURE|Amniotic membrane sweep|Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.
214417306|NCT02313441|OTHER|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
214417307|NCT03392558|OTHER|Burt's Bees Skin Care Regimen|Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)
214417308|NCT03392558|OTHER|Control Regimen|Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
215102101|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Week 48-96
215018325|NCT01990352|DRUG|Pegylated liposomal doxorubicin|Doxil will be administered intravenously at 30mg/m2 on days 1 of a 21 day cycle.
214417309|NCT06321913|DRUG|IBI343 combined with IBI308|IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion
214417310|NCT06420713|PROCEDURE|Horizontal Bone Augmentation of Alveolar Ridge|Elevation of the flap in the anterior region of atrophic maxilla to receive particulate autogenous bone mixed with deproteinized bovine bone graft (Group A) or Leukocyte-and-Platelet-Rich Fibrin (L-PRF) mixed with deproteinized bovine bone graft (Group B). In both groups, bone augmentations were covered with a collagen membrane stabilized with pins.
214505676|NCT06986759|OTHER|Laser|The therapy system will be used the Thor DD Laser Therapy Unit. This will be a class 3B laser with an 810-nm, 100-mW infrared probe. Laser or placebo laser treatment protocols will be identical and will be delivered with the patients lying prone, with their foot over the end of the treatment plinth and the ankle plantar-grade. The contact method will be used to apply the laser treatment probe to 3 standardized points on both sides of the Achilles' tendon (6 in all: at the site of the lesion, 2cm proximal, and 2cm distal) for 30 seconds, giving a dose of 3J per point and 18J per session for the active probe(23). The treating physiotherapist, without any knowledge of which position on the switch will be the active laser, will select position 1 or 2 on the switch according to group allocation.
215018326|NCT01856660|BEHAVIORAL|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to \> 40 min per day, 5 times/week.
214505677|NCT06986759|OTHER|Extracorporeal shock wave therapy protocol|When treating Achilles tendinopathy, most researchers will be used 3 sessions of extracorporeal shock wave therapy (ESWT) with a one-week break in between. There will also be shorter breaks of 3 to 4 days or longer 2-week breaks. The number of pulses per session will range from 800 to 3000, and the pulse frequency will be between 4 and 50 Hz.
215018327|NCT01856660|BEHAVIORAL|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
215018328|NCT01257893|DRUG|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
215102102|NCT01700712|DIETARY_SUPPLEMENT|Probiotic Lactobacilli reuteri|
215018329|NCT01257893|DRUG|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
215018330|NCT04432298|DRUG|Pamrevlumab|Sterile liquid for injection
215018331|NCT04432298|DRUG|Placebo|Sterile liquid for injection
215018332|NCT00678574|DRUG|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
215102103|NCT01700712|DIETARY_SUPPLEMENT|Placebo|
215102104|NCT03322670|OTHER|Signs of CAP and a positive chest X-Ray|"* collection of clinical examination data~* biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~* self-reported questionnaires on duration of symptoms and restriction of activity~* telephone contact on day 28 and day 90 if hospitalized before day 28"
214417311|NCT06420713|PROCEDURE|Groups|"The patients underwent Guided Bone Regeneration (GBR) procedures for the reconstruction of atrophic edentulous alveolar ridges and were divided into two groups according to the proposed treatment:~Group A - GBR using a mixture of particulate autogenous bone graft and deproteinized bovine bone graft (Bio-Oss® Small; Geistlich AG, Wolhusen, Switzerland).~Group B - GBR using a mixture of deproteinized bovine bone graft (Bio-Oss® Small) and L-PRF + Liquid Fibrinogen."
214417312|NCT06420713|PROCEDURE|Dental Implants|"After 8 months of GBR healing, dental implants were placed in the grafted regions using guided surgery techniques.~Cone beam computed tomography (CBCT) scans were performed preoperatively, immediately after the surgical procedure, and after 8 months of follow-up to measure the linear and volumetric changes in the alveolar ridge. At the time of dental implant placement, after an 8-month period following the GBR procedures, bone biopsies were obtained from the grafted area for histological and micro-CT analysis.~The stability of the implants was assessed using resonance frequency analysis in the immediate postoperative period and at 6 months postoperatively.~After the 6-month period following dental implant placement, the patients were cleared for implant-supported prosthetic rehabilitation."
214417313|NCT05824377|OTHER|Continuous Feeds|Continuous feeds will be delivered via an indwelling nasogastric/orogastric tube with a continuous infusion pump.
214417314|NCT05824377|OTHER|Intermittent Bolus Feeds|Intermittent bolus feedings will be given by gravity every 3 hours over 15- 30 minutes.
214417315|NCT05218837|OTHER|Vaginal birth|Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
214417316|NCT04648436|OTHER|Early neurosurgical hematoma evacuation|Early neurosurgical hematoma evacuation (preferably within 2 hours)
214417317|NCT04648436|OTHER|Conservative treatment (best medical management)|Conservative treatment (best medical management) on the ICU or ward
214417318|NCT01830166|RADIATION|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
214417319|NCT04096144|DRUG|Neuromuscular Blocking Agents|Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
214417320|NCT06438406|DEVICE|Orthotic devices and therapeutic exercise (Group A)|Group A consisting of patients who were prescribed orthoses, to use gradually, and a 20-session rehabilitation programme, based on the Back School method
214417321|NCT06438406|DEVICE|Orthotic devices (Group B)|Group B consisting of patients who were only prescribed orthoses for the lower limbs
215018333|NCT04016428|BEHAVIORAL|OPTIMISM|Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.
214417322|NCT06126536|PROCEDURE|Crestal Maxillary Sinus Floor Elevation using Osseodensification|Patients will be prepared for surgery with local anesthesia and thorough oral cavity disinfection. A full thickness crestal incision will be made slightly towards the palate to enhance the possibility of achieving primary wound closure. A conservative flap will be raised, extending slightly beyond the alveolar crest, to minimize flap-related issues. After preparing the osteotomy site using Densah burs and elevating the sinus to the desired height, the implant will be inserted into the osteotomy site.
214417323|NCT06126536|PROCEDURE|Lateral Maxillary Sinus Floor Elevation|A crestal incision with an anterior vertical releasing incision exposes the sinus's lateral wall. A mucoperiosteal flap is carefully reflected, revealing the sinus. A bony window is created using a Piezoelectric device, and after elevation, the sinus floor is carefully lifted with various curettes. Implant osteotomies follow standard placement protocol, with precautions against sinus membrane perforation. Nanobone is used as graft material, mixed with saline and gently packed into the sinus. A resorbable membrane is placed on the window's outer surface, secured with circumferential resorbable sutures, and the flap is sutured for closure.
214417324|NCT01103219|DIETARY_SUPPLEMENT|Nutrition|The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
214417325|NCT03967886|DRUG|YYD601 20mg|Patients should take drugs an hour before breakfast.
214417326|NCT03967886|DRUG|Nexium 20mg|Patients should take drugs an hour before breakfast.
214417327|NCT03967886|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
214417328|NCT01181180|DIETARY_SUPPLEMENT|water consumption|The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
214417329|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). No Redon drainage system will be left in the subcutaneous tissue."
214417330|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique with an absorbable PP mesh"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). A partially absorbable low-density polypropylene suprapubic mesh (Ultrapro®, Ethicon) will be added. Mesh fixation will be done with absorbable staples (Ethicon SecurestrapTM) +/- slow-absorbing resorbable sutures at the discretion of the surgical team.~In the case of a diverting stoma, the prophylactic mesh will not encircle it. A Redon-type drainage will be left at the subcutaneous tissue level. One or two drains will be left at the discretion of the surgical team. Closure of the subcutaneous tissue will be performed with 2/0 or 3/0 absorbable, multifilament, interlocking sutures."
214417331|NCT03003988|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (6.0 g) + dextrose (0.5 g)
215018334|NCT04016428|BEHAVIORAL|Sleep Education|Six-week online program that provides education on sleep during pregnancy.
215018335|NCT04187690|DRUG|Jin-shui Huan-xian granule|Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
215018336|NCT04187690|DRUG|Jin-shui Huan-xian granule placebo|Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
215018337|NCT02365064|DEVICE|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
214417332|NCT03003988|DIETARY_SUPPLEMENT|Creatine nitrate|Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
214417333|NCT03003988|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
215018338|NCT01282138|DRUG|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
215018339|NCT01282138|OTHER|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
215018340|NCT02451007|DRUG|lurbinectedin (PM01183)|
215018341|NCT06532344|DRUG|ONO-7913|Specified dose on specified days
215018342|NCT06532344|DRUG|ONO-4538|Specified dose on specified days
215018343|NCT06532344|DRUG|Oxaliplatin|Specified dose on specified days
215018344|NCT06532344|DRUG|Levofolinate|Specified dose on specified days
215018345|NCT06532344|DRUG|Irinotecan|Specified dose on specified days
215018346|NCT06532344|DRUG|Fluorouracil|Specified dose on specified days
215018347|NCT03997591|OTHER|Ready2E.A.T. PROGRAM|"Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy."
215018348|NCT04718441|DRUG|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
215018349|NCT01118637|BEHAVIORAL|StopPulling.com|subsidized access to an interactive self-help website for TTM
215018350|NCT01688401|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
215018351|NCT00618566|BEHAVIORAL|WPD and Depression Treatment Group|Intervention selected will depend on Phase I data analysis.
215018352|NCT06243250|DIAGNOSTIC_TEST|Hyperpolarized 13C-MRI|Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.
214417334|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
215018353|NCT00348374|DRUG|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
215018354|NCT00348374|DRUG|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
215018355|NCT05298969|PROCEDURE|Temporalis Myofascial flap|Improvement of speech and feeding quality in patients with palatal defects by temporalis myofascial flap
214417335|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
214417336|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
214417337|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
215018356|NCT02241031|BIOLOGICAL|MPs|MPs are generated from cord blood using a combination of cytokines.
215018357|NCT02241031|DRUG|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
215018358|NCT04157582|OTHER|Pilates training|"1. Pilates warm-up training (5 minutes) consisted of Breathing, the Chest stretch, the Toy soldier, Upper extremity PNF patterns, and Roll down.~2. Pilates mat training performed in 5 different positions (30 minutes).~   1. One leg stretch, Hundreds, the Double leg stretch, Scissors, the Shoulder bridge, Oblique preparation, and the Hip twist were performed in the supine position(Fig.7).~  2. Clare, the Side kick, Arm openings, the Lower lift, Leg lifts, and the Side bend were performed in the side-lying position.~  3. Swan dive, the One leg kick, Swimming, the Breast stroke preparations, the Breast stroke performed in the prone position(Fig.8).~  4. Half roll back, Oblique roll up were performed in the sitting position.~  5. Swimming was performed in the kneeling position.~3. The Pilates cool down training (5 minutes) were the Spine stretch, Saw, Chest stretch, Toy soldier. (Cruz et al .,2011)"
215018359|NCT04157582|OTHER|Conventional physical therapy|"1. Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~2. Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~3. Balance training (Wobble board training) :~   * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~  * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times)."
215102105|NCT03322670|OTHER|Patients directly hospitalized|"* collection of clinical examination data~* telephone contact on day 28 and retrieval of hospitalization report~* telephone contact on day 90"
214417338|NCT05534100|DEVICE|Biostrap EVO Wristband|Participants in both groups will wear the Biostrap wearable device
214417339|NCT04481386|DEVICE|Vitargus, BFC-1401|A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.
214417340|NCT00596648|DRUG|XL184|Capsules administered orally daily
214417341|NCT00596648|DRUG|erlotinib|Tablets administered orally daily.
215018360|NCT03608007|DRUG|X-396 Capsule|225 mg once daily
215018361|NCT04952688|OTHER|OCT- Angiographie|Ophthalmological examinations
215018362|NCT03241160|OTHER|Chewing evaluation|Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
215018363|NCT01644331|DRUG|Tolvaptan|IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
215018364|NCT01644331|DRUG|Placebo|IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
215018365|NCT02801227|DRUG|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
214417342|NCT01036113|DRUG|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
214417343|NCT05722106|BEHAVIORAL|Persuasive Appeal|Persuasive appeals were manipulated using promotional flyers ostensibly distributed by the Public Health Agency of Canada.
214417344|NCT03738137|DEVICE|Narotrend|Narcotrend motoring
214417345|NCT03738137|DEVICE|BIS|Bispectral index monitoring
214417346|NCT03738137|DRUG|Sufentanil|sufentanil is applied.
214417347|NCT03738137|DRUG|Lidocaine|Topical Anesthesia
214417348|NCT03738137|DRUG|Midazolam|midazolam is applied.
214417349|NCT06002360|BEHAVIORAL|Reach Out and Read|Families will be provided with a book and ROR programming from trained study team members (either the principal investigator or a research assistant, both of whom are ROR trained). ROR programming will include discussion of current reading practices, anticipatory guidance on the importance and benefits of reading, modeling of active reading, discussion of how to incorporate reading into a daily routine and answering any questions parents/caregivers may have.
214417350|NCT02794064|DEVICE|Tri-modal imaging|This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
214417351|NCT02857491|DRUG|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
214417352|NCT02857491|DRUG|sham|sham intravitreal injection before vitrectomy
214417353|NCT02857491|PROCEDURE|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
215018366|NCT02801227|DRUG|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
215102106|NCT03322670|DIAGNOSTIC_TEST|Control patients|\- bacteriological examinations (urine)
214417354|NCT01809964|BIOLOGICAL|ANT-1401|
214417355|NCT01809964|BIOLOGICAL|Vehicle|
214417356|NCT00918957|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
214417357|NCT00918957|DRUG|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
214417358|NCT03313206|DRUG|Pembrolizumab|"Neo-adjuvant therapy :~* Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~* Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
214417359|NCT03313206|PROCEDURE|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
214417360|NCT03313206|RADIATION|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
214417361|NCT03313206|DRUG|Lenvatinib|up to 26 evaluable patients will be treated with pembrolizumab combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
214417362|NCT02169102|OTHER|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
214417363|NCT02169102|RADIATION|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
214417364|NCT02169102|RADIATION|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
214417365|NCT02169102|RADIATION|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
214417366|NCT04289610|DEVICE|Transcutaneous pulse radiofrequency therapy|Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality
214417367|NCT01803646|DRUG|AM-101|AM-101 gel for intratympanic injection
215018367|NCT02543385|DRUG|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
214417368|NCT01803646|DRUG|Placebo|Placebo gel for intratympanic injection
214417369|NCT03282786|OTHER|carbon dioxide insufflation during colonoscopy|Use of Carbon dioxide instead of air insufflation
214417370|NCT00773708|DRUG|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
215018368|NCT05684198|DEVICE|subcutaneous NPWT|Following fascia closure, NPWT system will be inserted into subcutaneous tissue, continuous negative pressure of 120 mmHg will be applied.
215018369|NCT02062008|DEVICE|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
215102107|NCT03322670|OTHER|Patients with partial participation|\- collection of clinical examination data
215102108|NCT03322670|OTHER|Signs of CAP and a negative chest X-Ray|"* collection of clinical examination data~* telephone contact on day 28"
214417371|NCT02864095|DRUG|Tranexamic acid (TXA)|IV and topical administration
214417372|NCT02864095|DRUG|Epinephrine|
214417373|NCT06225882|DRUG|Oxaluria evolution.|To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
215018370|NCT01631929|OTHER|One bag|Infusion of dextrose and electrolytes using one bag
215018371|NCT01631929|OTHER|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
215018372|NCT00000437|DRUG|Naltrexone Tablet and Nicotine Patch|
215102109|NCT05967949|DRUG|chidamide|This subset of patients received chidamide as first-line maintenance therapy.
214417374|NCT02260310|OTHER|Weizhong and Huantiao|
214417375|NCT02260310|OTHER|A-shi point|
214417376|NCT05983484|DEVICE|Skiin Underwear|All participants enrolled will wear simultaneously the PocketECG (Standard Holter) and the Skiin Underwear Chestband (wearable textile). Each participant will wear both systems for the duration prescribed by their physician (1 to 14 days).
214417377|NCT03996746|DIAGNOSTIC_TEST|No intervention|No intervention
214417378|NCT03008499|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
214417379|NCT03921450|DEVICE|1 Hz rTMS|1 Hz stimulation at 110% of resting motor threshold over supplementary motor area
214417380|NCT03921450|DEVICE|iTBS|50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area
214417381|NCT03921450|DRUG|Placebo|1 Hz stimulation with the placebo TMS coil without any magnetic emission
214417382|NCT04104698|DIAGNOSTIC_TEST|Quantitative EEG|"1. Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~2. Both groups will be assessed for psychological \& cognitive contributes respectively using:~   A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~3. Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~4. The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed."
214417383|NCT01131494|OTHER|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
214417384|NCT01691963|DEVICE|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
214417385|NCT02614560|DRUG|Fludarabine|30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)
214417386|NCT02614560|DRUG|Melphalan|Melphalan 140 mg/m2 intravenously, 2 days before the transplant
215018373|NCT00000437|DRUG|Naltrexone Tablet and Placebo Patch|
215018374|NCT00000437|DRUG|Placebo Tablet and Nicotine Patch|
215018375|NCT00000437|DRUG|Placebo Tablet and Placebo Patch|
215102110|NCT03860467|OTHER|collection of patient data|Patient data will be collected using the in-house digital patient record systems and the local digital electroencephalogram (EEG)-database
214417387|NCT02614560|DRUG|vadastuximab talirine|Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant
214417388|NCT02614560|DRUG|vadastuximab talirine|Post-allo (after stem cell transplant) given on Day 1 of each cycle
214417389|NCT03334019|OTHER|blood test|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
214417390|NCT04691778|PROCEDURE|CTO PCI with the first-choice Gladius guidewire|CTO PCI using antegrade wiring strategy with the first-choice Gladius guidewire
214417391|NCT04691778|PROCEDURE|CTO PCI without the first-choice Gladius guidewire|CTO PCI using standard antegrade wire escalation strategy
215018376|NCT04482920|DIAGNOSTIC_TEST|p-aminohippurate clearance study|To measure kidney blood flow, small doses of a substance called p-aminohippurate (PAH) are used.
215018377|NCT04482920|DIAGNOSTIC_TEST|Iohexol infusion|To measure glomerular filtration rate (GFR)
215102111|NCT00209898|PROCEDURE|Fast initiation procedure|
214417392|NCT04566042|BEHAVIORAL|Acceptance and commitment therapy video game|The intervention is a videogame which teaches the participant about acceptance and commitment therapy.
214417393|NCT03923491|BEHAVIORAL|Healthy Feeding, Healthy Eating|Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
215018378|NCT05398848|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
215018379|NCT05398848|BIOLOGICAL|Placebo|"Before reconstitution:~Lyophilized powder for reconstitution in single-use vials~After reconstitution with BFA03 adjuvant:~Milk-white solution with no visible foreign matter"
215018380|NCT06281002|DEVICE|conventional impression stone casts digitization|"Nine conventional physical open tray impressions will be poured into a hard dental stone to obtain nine definitive implant casts with conventional implant analogs to act as a reference comparator.~Impressions will be digitized to reference STL files."
215102112|NCT00072774|DRUG|DVS-233 SR|
214689704|NCT02610400|COMBINATION_PRODUCT|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
214417394|NCT03923491|BEHAVIORAL|Reading Readiness|Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
214417395|NCT02173444|OTHER|Blood test|
214417396|NCT03425630|DIETARY_SUPPLEMENT|Argicolina|8 weeks
214417397|NCT03425630|DIETARY_SUPPLEMENT|Normolip|8 weeks
214417398|NCT05257733|OTHER|None, pure observationnal study|pure observationnal study
214417399|NCT00426036|DRUG|Licarbazepine|
214417400|NCT05359913|BEHAVIORAL|Cervical cancer podcast for African American women|"The video podcast will deliver cervical cancer prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
214417401|NCT04041999|BEHAVIORAL|Daily Cognition Training Program|"Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc."
214417402|NCT05857306|DIETARY_SUPPLEMENT|Olvanil|"Nutritional recommendation along with 4 mg Olvanil (1 capsule daily)~Subects within the Intervention group will be provided with a nutritional recommendation along with Olvanil capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 4 mg Olvanil and 255 mg soy lecithin as excipient"
214417403|NCT05857306|DIETARY_SUPPLEMENT|Placebo|"Nutritional recommendation along with 255 mg soy lecithin (1 capsule daily)~Subects within the placebo group will be provided with a nutritional recommendation along with placebo capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 255 mg soy lecithin"
214417404|NCT02175043|PROCEDURE|atrial electrogram and liner ablation|"1. The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~2. The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation"
214689705|NCT02610400|COMBINATION_PRODUCT|rfMDA|"Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) \> 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop"
214689706|NCT01123278|DRUG|Testosterone|Testosterone transdermal gel 50 mg/day (5 gr)
214689707|NCT01123278|DRUG|Placebo|Placebo transdermal gel (5 gr)
214689708|NCT01716468|OTHER|Ketogenic Diet|modified ketogenic diet
214689709|NCT06189001|DRUG|Oxytocin|Intravenous oxytocin 0.2 IU/min during experimental days
214689710|NCT06189001|OTHER|Placebo (saline)|Intravenous saline during experimental days
215018381|NCT06281002|DEVICE|digital scanning with coupled scanning aiding device|Nine optical impressions will be obtained while additional geometric scanning aids are coupled with the scan bodies to get nine CAD/CAM 3D-printed polymer casts with digital implant analogs.
215018382|NCT06281002|DEVICE|Digital Implant Model assessment of accuracy|The nine STL files of optical scanning will serve as reference data for comparison with the digitized DIMs to evaluate the accuracy of representation of the actual position of implants in the software.
215018383|NCT02327143|DRUG|LY2835219|Administered orally
215018384|NCT02327143|DRUG|¹³C₈-LY2835219|Administered IV
215018385|NCT02447406|DRUG|AZD6094|
215018386|NCT02447406|DRUG|docetaxel|
215018387|NCT03426852|OTHER|No intervention|No intervention
214417405|NCT00692562|PROCEDURE|simultaneous islet-kidney transplantation|
214417406|NCT02174562|BEHAVIORAL|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
214417407|NCT02174562|BEHAVIORAL|Enhanced Usual Care|Usual care enhanced with education and attention
214417408|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
214417409|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
214417410|NCT00545376|OTHER|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
214505678|NCT06269003|OTHER|Expert, one-sided|Participants will view a brief description of an expert source and see one-sided e-cigarette education messages.
214505679|NCT06269003|OTHER|Expert, two-sided|Participants will view a brief description of an expert source and see two-sided e-cigarette education messages.
214505680|NCT06269003|OTHER|Peer, one-sided|Participants will view a brief description of a peer source and see one-sided e-cigarette education messages.
214505681|NCT06269003|OTHER|Peer, two-sided|Participants will view a brief description of a peer source and see two-sided e-cigarette education messages.
214417411|NCT03005249|PROCEDURE|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
214417412|NCT03005249|OTHER|the control group|The patients will be assigned to the control group for cerebral palsy.
214505682|NCT05563181|BEHAVIORAL|Control bar code label|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
214689711|NCT05345834|BEHAVIORAL|Patient Navigation|Participants in arm 2 will receive patient navigation provided by humans (rather than e-navigation) to provide personalized care to include support, resources, and referrals to address psychosocial issues that arise during the perinatal period. Patient navigation is available to participants through 12 months postpartum.
214689712|NCT05345834|BEHAVIORAL|Adapted Cognitive-Behavioral Therapy|Participants who do not meet diagnostic criteria (Group 2a) will participate in a prevention group which includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Participants who meet diagnostic criteria (Group 2b) will participate in individual treatment which includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations.
214417413|NCT00633854|PROCEDURE|Ultrasound examination|Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
214505683|NCT05563181|BEHAVIORAL|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
214505684|NCT05563181|BEHAVIORAL|Informational campaign poster about added-sugar warning labels|Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
214505685|NCT04961762|OTHER|Navigator Program|The main role of the Homeless Outreach Counsellor is to support continuity and comprehensiveness of care by helping participants follow their post-discharge plans and facilitating strong links with community-based health and social services. The Homeless Outreach Counsellor also helps address specific needs of participants, develop comprehensive care plans with members of patient's multidisciplinary circle of care, and facilitate the transition of clients to long-term community-based health and social services.
214505687|NCT06825715|OTHER|Multilevel intervention|3 components: patient education video, provider audit/feedback, and EMR ordering change
214505688|NCT06214923|DEVICE|RelieVRx|Participants will use RelieVRx daily for 20min/day for 3 weeks
214417414|NCT03252106|PROCEDURE|Contour augmentation with implant placement|Contour augmentation with implant placement
215018388|NCT01254539|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation"
215018389|NCT01254539|PROCEDURE|Intrathecal infusion of autologous bone marrow stem cells|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells."
214417415|NCT04559243|DIAGNOSTIC_TEST|Transthoracic Echocardiography|After the surgey, the tests data will be collected during 8 visits when the subjects go back to the hospital.
214417416|NCT05303155|DIAGNOSTIC_TEST|16S rRNA sequencing|Fecal microbiome analysis using 16S rRNA sequencing
214417417|NCT06554067|DEVICE|Active transcranial direct current stimulation|Ten minutes of active transcranial direct current stimulation
214417418|NCT06554067|DEVICE|Active vagus nerve stimulation|Ten minutes of active vagus nerve stimulation
214505689|NCT06214923|DEVICE|Sham-VR|"Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the sense of presence and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min/day for 3 weeks"
214505690|NCT06214923|OTHER|No-VR (natural history control)|Participants will continue regular/usual care without any VR devices (goggles or audiovisual input)
214505691|NCT00848289|BEHAVIORAL|Interviews|Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
215018390|NCT01254539|PROCEDURE|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
215018391|NCT00721890|DIETARY_SUPPLEMENT|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
214417419|NCT06554067|OTHER|Sham transcranial direct current stimulation|Ten minutes of sham tDCS
214417420|NCT06554067|OTHER|Sham vagus nerve stimulation|Ten minutes of sham VNS
214417421|NCT06545994|OTHER|Observation|It's a observational cohort study and no interventions are performed.
214417422|NCT02401633|PROCEDURE|CO-CPR|CPR provided by bystander with chest-compressions only
214417423|NCT02401633|PROCEDURE|S-CPR|CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
214417424|NCT05193318|DRUG|Ketamine-assisted psychotherapy|Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
214417425|NCT05675956|DEVICE|Experimental group with 100% intensity setting on Apollo Neuro device|The group will have the device set to 100% intensity at one of their two experimental visits.
214417426|NCT05675956|DEVICE|Active Comparator group with 10% intensity setting on the Apollo Neuro device|The group will have the device set to 10% intensity at one of their two experimental visits.
214417427|NCT00798096|DRUG|Fostamatinib Disodium|200 mg PO BID
214417428|NCT01291004|DRUG|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
214417429|NCT01291004|DRUG|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
214417430|NCT01291004|DRUG|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
214505692|NCT06605872|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. Insulin therapy prescription for the next 24 hours is suggested once daily by the GlucoTab system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the algorithm is to maintain fasting and premeal glucose concentrations between 100-140 mg/dl, (5.6 to 7.8 mmol/l).
214505693|NCT06605872|OTHER|Diabetes Treatment|Diabetes Standard Care
214505694|NCT04984213|DEVICE|Karma Posterior Fixation Device|Posterior Fixation
214689713|NCT03914820|PROCEDURE|HIPEC CO2 surgery|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
214417431|NCT05753917|DEVICE|Piezo-surgery insert OR Conventional Drills|piezo-surgery: Group A (piezoelectric device with IM1, IM2, IM2-3, or IM3 piezo-inserts according to the manufacturer's protocol (Piezosurgery, Mectron Medical Technology, Carasco, Italy) Conventional drill: Group B (conventional drills according to the manufacturer's protocol (Premium, Sweden \& Martina, Due Carrare, Padova, Italy)
215018392|NCT00742690|DRUG|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
214417432|NCT04911842|DEVICE|HydroMID|Hydrophilic biomaterial
214417433|NCT04911842|DEVICE|TPU|Thermoplastic polyurethane
215018393|NCT00742690|DRUG|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
214417434|NCT04460573|DEVICE|Boot|Smart boot in one of three configurations provided to participants
214417435|NCT04362215|DIAGNOSTIC_TEST|Subjective accomodation amplitude measurement|ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
214417436|NCT02054299|DRUG|Drug application Amitriptyline|Amitriptyline: 25 mg, single oral application
215018394|NCT01585207|DRUG|vigabatrin|3 tablets, bid for 8 weeks
214417437|NCT02054299|DRUG|Drug application Desvenlafaxine|Desvenlafaxine: 50 mg, single oral application
214417438|NCT02054299|DRUG|Drug application Sumatriptan|Sumatriptan: 50 mg, single oral application
214417439|NCT02054299|DRUG|Drug application Proguanil|Proguanil: 200mg, single oral application
214417440|NCT02054299|DRUG|Drug application Fenoterol|Fenoterol: 180 mcg, single intravenous application
214417441|NCT02054299|DRUG|Drug application Thiamine|Thiamine: 200mg, single oral application
214417442|NCT05154942|DEVICE|DOXO+electroacupuncture|DOXO+electroacupuncture
214417443|NCT01833065|DRUG|Elobixibat 10 mg/day|Elobixibat 10 mg/day
214417444|NCT01833065|DRUG|Elobixibat 5 mg/day|Elobixibat 5 mg/day
214417445|NCT01833065|DRUG|Placebo|Placebo
214417446|NCT03441763|DEVICE|Emed foot device|foot pressure will be measure by using emed foot pressure system
214417447|NCT02798718|DIETARY_SUPPLEMENT|full-fat milk|intake 250ml full-fat milk per day, do not intake any other dairy products
214417448|NCT02899585|OTHER|Questionnaires|
214417449|NCT02899585|OTHER|Score|
214689714|NCT03914820|PROCEDURE|Standard surgery|Standard surgery without HIPEC CO2
214689715|NCT03914820|DRUG|Mitomycin|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
215018395|NCT03489083|OTHER|Strength training|Strength training was performed three times per week for twelve weeks. Supervised (by qualified sport and exercise scientists) exercise was performed in a gym on three non-consecutive days of the week. Each session lasted \~60 min and consisted of a warm up, the resistance exercise training and a cool down. The training programme consisted of a combination of upper and lower body exercises using gym equipments, free weights and body weight as the primary resistance. The twelve weeks of strength training were divided into three mesocycles of four weeks each. The resistance training was performed using two to three sets per exercise at intensities between 12-15 repetition maximum-RM.
214417450|NCT06290544|OTHER|Standard of care plus additional examinations|The patient will undergo good clinical practice examinations according to guidelines plus The patient will undergo to the evaluation of endothelial dysfunction with ENDOPAT 2000 and whole blood sampling for future omics studies
214417451|NCT03794180|DRUG|TJ003234|Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
214417452|NCT03794180|DRUG|Placebo|Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
214417453|NCT00574743|DRUG|Enteric-coated Mycophenolate Sodium|
214417454|NCT05394896|DEVICE|ACUMEN (Edwards Lifesciences, Irvine, USA)|ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.
214417455|NCT05394896|DEVICE|Invasive Blood Pressure|Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)
214417456|NCT00762099|DRUG|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
214417457|NCT00762099|DRUG|Placebo|Placebo/sugar tabs will look identical to active drug.
214417458|NCT05541757|DRUG|In vitro heparin|In vitro heparin and in vitro LMWH
214417459|NCT01564875|DRUG|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
214417460|NCT01564875|DRUG|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
214417461|NCT02396056|OTHER|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
214417462|NCT02396056|OTHER|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
215018396|NCT03489083|OTHER|No Training|"Control group performed a placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks. To avoid any significant adaptation, all stretching exercises (for large muscle groups only) were performed at very low intensity without any significant discomfort."
215018397|NCT04714177|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
214417463|NCT02544282|DRUG|Levobupivacaine|Pecs II Block
214417464|NCT02544282|DRUG|NaCl 0.9%|Placebo Pecs II block
214417465|NCT02544282|DRUG|Sevoflurane|General Anesthesia
214417466|NCT02544282|DRUG|Propofol|General Anesthesia
214417467|NCT02544282|DRUG|Sufentanil|General Anesthesia
214417468|NCT02544282|DRUG|Atracurium|General Anesthesia
214505695|NCT06607146|BEHAVIORAL|Sound Success|Subjects will be instructed to perform auditory training with the Sound Success computer-based auditory training program. This is a free program that requires a brief account registration. Subjects will be instructed to perform auditory training on a personal device and will be recommended a target usage of at least 30 minutes 5 times per week.
214505696|NCT06607146|BEHAVIORAL|Standard of Care|Subjects will be provided a list of common exercises for auditory training. This is the current standard of care at our institution.
214505697|NCT06607549|DRUG|Loncastuximab tesirine and rituximab (Lonca-R)|Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 4 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).
214505698|NCT06692608|OTHER|strength training|Comparison between isometric and dynamic strength training in soccer players
214505699|NCT06706310|DRUG|Placebo|Placebo contains no active substance.
214505700|NCT06706310|DRUG|TQA3334 Tablet|Inhibit viral replication.
215018398|NCT04714177|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
214417469|NCT02544282|DRUG|Paracetamol|Pain Relief
214417470|NCT02544282|DRUG|Tramadol|Pain Relief
214417471|NCT02544282|DRUG|Piritramide|Pain Relief
214417472|NCT04683718|DEVICE|Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management|The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.
214417473|NCT00845611|BIOLOGICAL|peptide vaccine|peptides emulsified with Montanide ISA51
214417474|NCT05990569|OTHER|Ultrasound guided Pudendal nerve block|Ultrasound guided bilateral pudendal nerve block
214417475|NCT00241644|BIOLOGICAL|Rotarix™|Two or Three doses, oral administration
214417476|NCT00241644|BIOLOGICAL|Placebo|One or three doses, oral administration.
214505701|NCT06706310|DRUG|Nucleoside (acid) analogs (NAs)|Inhibit viral replication.
214689716|NCT01425190|DRUG|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
214417477|NCT04109690|DRUG|CPX-351|Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
214417478|NCT04584021|DEVICE|Xiaomi MiBand3|Recording of sleep, activity and heart rate data to study their association with stress.
214417479|NCT04584021|OTHER|Socio-demographic questionnaire|Self-made questionnaire to be filled by the participants at the beginning of the study with the following personal data: age, gender, marital status, residential environment, cohabitation unit, educational level, socio-economic level, contract, working hours, overtime or not, number of overtime hours in a day, overtime frequency and perceived stress level
214417480|NCT04584021|OTHER|EuroQol-5D-5L|Quality of life questionnaire to be filled by the participants at the beginning, mid-term and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
214417481|NCT04584021|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Questionnaire to be filled by the participants whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning, mid-term, and completion of the study.
214417482|NCT04584021|OTHER|State-Trait Anxiety Inventory (STAI)|Questionnaire to be filled by the participants which measures the anxiety level. To be given at the beginning, mid-term and completion of the study.
214417483|NCT04584021|OTHER|Perceived Stress Scale-10 (PSS-10)|Questionnaire to be filled by the participants which measures the stress level. To be given at the beginning, mid-term and completion of the study.
214417484|NCT04584021|OTHER|Stress questionnaire|Questionnaire designed by a work stress psychologist professional from the research group which is focused on stress and daily functioning. This questionnaire was given for the participants to fill. It is composed by 3 daily items and 4 weekly items.
214417485|NCT03095508|DRUG|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
214417486|NCT03095508|DRUG|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
214417487|NCT02830750|PROCEDURE|Ablation|
214417488|NCT01231113|DRUG|artesunate-amodiaquine|The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
214417489|NCT01231113|DRUG|Dihydroartemisinin-piperaquine|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
214417490|NCT02886741|OTHER|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
214417491|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
214417492|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
214417493|NCT00261547|DRUG|Rituximab|All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
214417494|NCT00361621|DRUG|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
214417495|NCT00361621|DRUG|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
214417496|NCT00361621|DRUG|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
214417497|NCT00361621|DRUG|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
214417498|NCT00361621|DRUG|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
215018399|NCT00780598|DRUG|Tosedostat|"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~* 120 mg for 6 months once daily, OR~* 240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
215018400|NCT03177070|DRUG|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
215018401|NCT03146793|DRUG|Sodium Thiosulfate|25g intravenously 3 times per week
215018402|NCT04105257|DIAGNOSTIC_TEST|All patients|Comparison of the results of the CTP with MRI
215018403|NCT02595437|DRUG|Triferic|
215018404|NCT02956564|PROCEDURE|intrauterine intervention|choose different surgeries according to different causes
215018405|NCT04477512|DRUG|Cabozantinib|Supplied by Exelixis
215018406|NCT04477512|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
215018407|NCT04477512|DRUG|Abiraterone acetate|Commercially available
214417499|NCT00361621|DRUG|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
214417500|NCT00361621|RADIATION|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
215018408|NCT04477512|DRUG|Prednisone|Commercially available
215018409|NCT04477512|PROCEDURE|Peripheral blood collection|Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment
215018410|NCT04658680|DRUG|BCG vaccination at first health facility contact|"Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region.~The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres."
215018411|NCT04226105|DRUG|GP40081|1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
215018412|NCT04226105|DRUG|NovoMix 30|1 ml of the NovoMix 30 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
214417501|NCT03767764|DIAGNOSTIC_TEST|Test Yliver|Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique
214417502|NCT03921684|DRUG|Capecitabine|Capecitabine 825 mg/m2 orally twice-daily, 5 days a week for a total of 28 days, given with radiation therapy
215018413|NCT04858347|DEVICE|Total knee replacement|Implantation of the GEMINI SL Fixed Bearing PS knee prosthesis. The operation technique of the GEMINI SL Fixed Bearing PS knee prosthesis will be followed.
215018414|NCT03355261|PROCEDURE|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
214417503|NCT03921684|RADIATION|Radiation therapy|1.8 Gy/day, 5 days a week for a total of 28 days, given with Capecitabine
214417504|NCT03921684|DRUG|mFOLFOX6|oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab
214417505|NCT03921684|DRUG|Nivolumab|Nivolumab 240mg IV, day 1 of each treatment cycle, every two weeks, given with mFOLFOX6
214417506|NCT02949570|DRUG|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
214417507|NCT05787444|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative and differential detection of nucleocapsid viral antigens from SARS-CoV-2, influenza A, and influenza B in an anterior nares sample (from both nostrils) collected by a healthcare professional for individuals aged 2 years and older. The test is authorized for individuals with symptoms of COVID-19, influenza A and B within the first 6 days of symptom onset.
214417508|NCT03983889|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
214417509|NCT03983889|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
214417510|NCT03983889|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
214417511|NCT03983889|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
214417512|NCT03983889|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
214417513|NCT03308487|DIETARY_SUPPLEMENT|vitamin D3 (1000 IU)|
214417514|NCT03308487|DIETARY_SUPPLEMENT|Vitamin D3 (2000 IU)|
214417515|NCT06494124|DEVICE|transcranial Alternating current stimulation (tACS)|It is a non-invasive brain stimulation technique that uses small, pulsed alternating current (1mA) to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
214417516|NCT06494124|DEVICE|transcranial Direct current stimulation (tDCS)|It is a non-invasive brain stimulation technique that uses constant, low direct current to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
214417517|NCT06494124|DEVICE|Sham controlled|1mA current will be applied for the first 30 seconds to provide the initial sensation of real stimulation, and then the current will be stopped, thus minimizing the stimulatory effects. It is known to have no effect on psychopathology/neuro-cognition and means to mimic the tDCS/tACS (in order to help blinding of the participants).
214417518|NCT02690103|DRUG|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
215018415|NCT03355261|PROCEDURE|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
214505702|NCT07039071|DEVICE|Laceback|"Lacebacks are a kind of orthodontic auxilliaries used during the initial phase of orthodontic fixed appliance treatment, especially in premolar extraction cases. They are 0.010 stainless steel ligatures tied in figure-of-8 fashion beneath the main archwires, from the canine bracket till the first molar hook of one quadrant. For this study, on the side that is randomly allocated to receive laceback, laceback will be put on both upper and lower arches (from canine bracket to 1st molar hook)."
215018416|NCT03355261|PROCEDURE|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
214505703|NCT07038694|OTHER|Qualitative semi structured interview|60 minute, virtually performed via Microsoft Teams, semi-structured interview
214505704|NCT06704009|DRUG|NT-101 0.05 mM|Low concentration of NT-101 (0.05 mM)
214505705|NCT06704009|DRUG|NT-101 0.2 mM|High concentration of NT-101 (0.2 mM)
214505706|NCT06883032|OTHER|AR Eyeglasses first, SR Eyeglasses second|First Eyeglasses based on Automated Refraction, Second Eyeglasses based on Subjective Refraction
215018417|NCT03355261|PROCEDURE|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
215018418|NCT04403893|OTHER|HANARO biliary stent placement|HANARO biliary stent placement
215018419|NCT02070380|DRUG|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
215018420|NCT02070380|DRUG|Dotarem|Dotarem administered at 0.1 mmol/kg
215018421|NCT02070380|DRUG|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
214689717|NCT04097756|DRUG|LX-039 tablets|orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
214689718|NCT04597034|PROCEDURE|AN69-Oxiris|To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.
214689719|NCT04597034|PROCEDURE|AN69-Standard|Standard treatment.
214689720|NCT01912729|BEHAVIORAL|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
214689721|NCT01912729|BEHAVIORAL|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
214689722|NCT04236206|BEHAVIORAL|Mobile Phone Short Message Service|"SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~* The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~* The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~* Patients will be encouraged to send messages/call the researcher for any queries encountered."
214689723|NCT00584220|DEVICE|senofilcon A toric|contact lens
214689724|NCT00584220|DEVICE|alphafilcon A toric|contact lens
214689725|NCT04972032|DEVICE|Estrogen Intrauterine Stent System|A Estrogen Intrauterine Stent System（E-IUS）will be introduced post-operatively. The E-IUS will be removed 60 days after surgery with continuous dydrogesterone administration for 5 days at 20 mg/d, and routine management.
214689726|NCT04972032|DEVICE|Foley balloon combined with self-cross-link sodium hyaluronate gel|Foley balloon combined with self-crosslinking sodium hyaluronate gel will be introduced post-operatively，2 cycles of estrogen-progestin sequential therapy comprised of continuous estrogen and progestin added in the second half of the cycle or continuous estradiol valerate for 60 days, followed by dydrogesterone for 10 days
214689727|NCT00042354|DRUG|clofarabine (IV formulation)|
214689728|NCT03359005|DRUG|Vincristine|vincristine 1.5mg/m2 iv D1,D8
214689729|NCT03359005|DRUG|Temozolomide|Temozolomide 100mg/m2/d iv on days 1-5.
214689730|NCT00782665|PROCEDURE|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
214689731|NCT01107756|DRUG|LENOGRASTIM (GRANOGYTE 34)|Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
214689732|NCT02853734|OTHER|SEVERE PERIODONTITIS|Patients exhibiting moderate to severe periodontitis
214689733|NCT02853734|OTHER|NO PERIODONTITIS|Patients without existing periodontitis or exhibiting mild periodontitis
214689734|NCT03262597|OTHER|enterade|Subjects will consume enterade, which is an amino acid-based oral rehydration solution.
214689735|NCT03262597|OTHER|Pedialyte|Subjects will consume Pedialyte
214689736|NCT03262597|OTHER|Gatorade|Subjects will consume Gatorade
214689737|NCT03262597|OTHER|Water|Subjects will consume water as the control beverage
214689738|NCT06452628|OTHER|Mulligan mobilizations|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Mulligan mobilizations.
214689739|NCT06452628|OTHER|Active Release Technique|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with the Active release technique.
215018422|NCT00130559|PROCEDURE|BNP guided diagnostics and initial therapy|BNP guided diagnostics and initial therapy
215018423|NCT06517511|DRUG|Selinexor Oral Tablet [Xpovio]|Selinexor (60mg po D1, 8) is added from the second cycle of R-CHOP regimen.
215018424|NCT06517511|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
214417519|NCT02690103|DIETARY_SUPPLEMENT|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
214417520|NCT02690103|DRUG|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
214417521|NCT01027286|DEVICE|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
214417522|NCT04722276|OTHER|positive end expiratory pressure|7cmH2O of positive end expiratory pressure with fraction of inspired oxygen 80% applied during induction of anesthesia
215018425|NCT03223805|OTHER|Respiratory Distress Symptom Intervention|"The RDSI comprises of four components~1. Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~2. Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~3. Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~4. Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required"
215018426|NCT01366014|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
215018427|NCT01366014|DRUG|Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral|multiple dose, single schedule
215018428|NCT01366014|DRUG|Placebo; oral|matching placebo
215018429|NCT02063438|PROCEDURE|Pericostal suture technique|
215018430|NCT02063438|PROCEDURE|Intracostal suture technique|
215018431|NCT02940119|DEVICE|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
215018432|NCT01507103|BIOLOGICAL|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
214417523|NCT04722276|OTHER|fraction of inspired oxygen 80%|fraction of inspired oxygen 80% applied during induction of anesthesia
214417524|NCT02890693|BEHAVIORAL|interdisciplinary lifestyle and psychosocial intervention|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
214417525|NCT00013143|BEHAVIORAL|Patient risk profiling (potential ADEs) w/provider feedback|
214417526|NCT04399525|DRUG|Desloratadine Single Dose|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
214417527|NCT04399525|DRUG|Levocetirizine Single Dose|Levocetirizine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
215018433|NCT01507103|DRUG|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
215018434|NCT01507103|OTHER|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
215018435|NCT06541080|DIAGNOSTIC_TEST|Shallow Whole Genome Sequencing (sWGS)-GIPXplore|GIPXplore will be used to mine shallow whole genome sequencing cell free DNA data for identification of signatures.
215018436|NCT06541080|DIAGNOSTIC_TEST|methylation-sensitive restriction enzymes (MSRE)-Single-molecule molecular inversion probes (smMIP)-seq assay|Aberrant methylation in ccfDNA will be analyzed using the novel, highly sensitive MSRE-smMIP-seq technology.
215018437|NCT03673982|BEHAVIORAL|iCASK|Materials and support to aid transitions
215018438|NCT06005636|DIAGNOSTIC_TEST|Test delirium state|use scale to test whether ischemic stroke patients have post-stroke delirium
215018439|NCT01408108|PROCEDURE|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique)."
215018440|NCT01408108|PROCEDURE|Laparoscopic primary posterior crural repair|"Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used)."
215018441|NCT02242903|DRUG|LY3079514|Administered SC
215018442|NCT02242903|DRUG|LY3079514|Administered IV
215018443|NCT02242903|DRUG|Placebo|Administered SC
215018444|NCT02242903|DRUG|Placebo|Administered IV
215018445|NCT03939494|BEHAVIORAL|Telehealth Encounter|Contact will be made with participants via Face Time or Skype.
214417528|NCT04399525|DRUG|Desloratadine Fourfold Dose|Desloratadine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively
214417529|NCT04399525|DRUG|Levocetirizine Fourfold Dose|Levocetirizine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively.
214417530|NCT06343584|OTHER|Study will conducted over a six-month period using a quasi-experimental Pre-test/Post-test design using Stamm's (2009) ProQOL Scale.|Group 1 will receive a list of suggested tools used to decrease the amount of smartphone interruptions after business hours (Appendix B) and Group 2 will receive a work-issued smartphone with instructions for use (Appendix C). Both groups will use a pre-post test format designed to compare the outcomes between the two groups. Post-study analysis will compare pre- and post-tests within each group and will compare Group 1 and Group 2 post-intervention outcomes.
214417531|NCT05242926|DRUG|ModraDoc006/r|One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
214417532|NCT03201809|DEVICE|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
214417533|NCT03201809|DRUG|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
214417534|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly
214417535|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly
214689740|NCT06452628|OTHER|Mulligan mobilizations with active release technique|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with mulligan mobilizations with active release technique.
214689741|NCT03559244|OTHER|Dynamic compression brace|custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
214689742|NCT03559244|OTHER|Exercises|posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
214689743|NCT01418664|DIETARY_SUPPLEMENT|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
214689744|NCT00427583|DRUG|imatinib mesylate|
214689745|NCT03206034|BEHAVIORAL|Stylistic Memory Enhancement|
214689746|NCT04276311|DEVICE|Percutaneous transluminal angioplasty|The purpose of this study is to evaluate the efficacy and the feasibility of atherectomy, using the Jetstream™ artery preparation associated to DCB treatment (Ranger™ Paclitaxel-Coated balloon), in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo femoropopliteal arterial lesions (TASC C).
214689747|NCT01952834|DIETARY_SUPPLEMENT|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
215018446|NCT01857115|DRUG|Carfilzomib|
215018447|NCT01857115|DRUG|Cyclophosphamide|
215018448|NCT01857115|DRUG|Dexamethasone|
214417536|NCT01816113|BIOLOGICAL|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
214417537|NCT01816113|BIOLOGICAL|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
214417538|NCT02228811|DRUG|DCC-2701 tablet|
214689748|NCT01952834|DRUG|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
214689749|NCT04285346|DRUG|Ganaxolone|titration followed by maintenance and extension period
214417539|NCT04527614|DIAGNOSTIC_TEST|qRT-PCR and serology|qRT-PCR and serology
215018449|NCT02258919|PROCEDURE|Decompressive craniectomy (DC) and best medical treatment|"Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively."
214417540|NCT02303769|DRUG|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
214417541|NCT02303769|DRUG|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
214417542|NCT05532813|DRUG|Treatment taken|Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
214417543|NCT00545844|DRUG|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
214417544|NCT03038503|DRUG|Methylene Blue|after defined refractory shock (need NE\>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr\*4 hr (intervention add on to standard care)
214417545|NCT03038503|DRUG|Terlipressin|after defined refractory shock (need NE\>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
214689750|NCT06269341|OTHER|No intervention|No intervention
214689751|NCT02432287|DRUG|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
214689752|NCT02432287|DRUG|Placebo|there is no other name we used for the placebo
214417546|NCT01588015|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given SC
214417547|NCT01588015|OTHER|laboratory biomarker analysis|Correlative studies
214417548|NCT00975806|DRUG|Lenalidomide|Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
214417549|NCT00975806|DRUG|Sunitinib|Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
214417550|NCT00409058|BEHAVIORAL|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
214417551|NCT02377362|DRUG|GLWL-01, Part A|Capsules administered orally, in 2 out of 3 periods
214417552|NCT02377362|DRUG|Placebo, Part A|Capsules administered orally in 1 out of 3 periods
214417553|NCT02377362|DRUG|GLWL-01, Part B|Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
214417554|NCT02377362|DRUG|Placebo, Part B|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
214417555|NCT02377362|DRUG|GLWL-01, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
215018450|NCT02258919|PROCEDURE|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
215018451|NCT05957094|DRUG|Pharmacological agent: Citalopram|Participants will be given 40 mg in capsule form, which is a normal clinical dose.
215018452|NCT05957094|OTHER|Placebo|Participants will ingest a placebo (sugar pill) that is identical in appearance to the drug condition.
214689753|NCT04874909|OTHER|Blood sample|"Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
214689754|NCT04874909|OTHER|Urine sample|Urine sample (500 ml) once time
214689755|NCT00610935|DRUG|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
214417556|NCT02377362|DRUG|Placebo, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
214417557|NCT00094809|DRUG|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
214417558|NCT00094809|DRUG|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
214417559|NCT05171998|PROCEDURE|venous blood sample|Phlebotomy procedure for a venous blood draw.
214417560|NCT04333069|PROCEDURE|cataract surgery|cataract surgery in form of phaco emulsification or irrigation aspiration
214417561|NCT01723436|OTHER|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
214689756|NCT00610935|DRUG|Placebo|Single intramuscular injection
215018453|NCT04029662|BEHAVIORAL|Valsalva Maneuver|Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
215018454|NCT02105012|DRUG|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
215018455|NCT02105012|DRUG|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
215018456|NCT02105012|DRUG|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
215018457|NCT02105012|DRUG|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
215018458|NCT02105012|DRUG|Placebo MDI|Placebo MDI administered as 2 inhalations BID
215018459|NCT00936039|BEHAVIORAL|unloading|2 weeks of unloading of a single leg
215018460|NCT03670433|OTHER|Cost analysis of medication reconciliation|"1. The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~2. The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS."
214417562|NCT03693443|BEHAVIORAL|early childhood caries|a questionnaire evaluates the oral health beliefs, knowledge, and behaviors of a sample representing Egyptian mothers toward early childhood caries
214417563|NCT02888431|DEVICE|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
214417564|NCT00990678|DRUG|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
215018461|NCT05674565|DRUG|Magnesium sulfate loading with maintenance dose|4 gm MgSo4 loading over 20 minutes followed by 1 gm per hour maintenance till delivery
215018462|NCT05674565|DRUG|Magnesium sulfate loading dose only|4 gm MgSo4 loading over 20 minutes within one hour before delivery
214417565|NCT00990678|DRUG|Vitamin D|tablets, vitamin D3, 30 microgram daily
215018463|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^4 TCID50
215018464|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 \^5 TCID50.
215018465|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^6 TCID50.
215018466|NCT05213221|DRUG|Envafolimab|300mg, subcutaneous injection, q3w
215018467|NCT05213221|PROCEDURE|TACE|The first TACE will be started on d1, and the subsequent TACE will be performed on demand.
215018468|NCT05213221|DRUG|Lenvatinib|8mg,QD (body weight \<60kg); 12mg, QD (body weight ≥ 60kg)
215018469|NCT04304248|DRUG|Albumin-bound paclitaxel, Carboplatin, Toripalimab|Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
215018470|NCT00324545|BEHAVIORAL|Medium-intensity Minimally-directive Counseling|
215018471|NCT03844035|DIAGNOSTIC_TEST|Periimplant crevicular fluid (PICF) collection|Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.
215018472|NCT03837535|PROCEDURE|Surgery|Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
214417566|NCT00990678|DRUG|Calcium|tablets, 400 mg calcium, 3 times daily
214417567|NCT03665701|PROCEDURE|Blood Sampling|Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
214417568|NCT02219906|DIETARY_SUPPLEMENT|Resveratrol|1000mg tid
214505707|NCT06883032|OTHER|SR Eyeglasses first, AR Eyeglasses second|First Eyeglasses based on Subjective Refraction, Second Eyeglasses based on Automated Refraction
214505708|NCT07038382|DRUG|HLX79 10mg/kg/Placebo+HLX01|Subjects with MN will receive HLX79 10mg/kg or placebo, combine with HLX01 375 mg/m2
214689757|NCT03369301|DRUG|Gammanorm|Gammanorm given per standard of care
214689758|NCT03369301|DRUG|Other Subcutaneous Immunoglobulins|Other Subcutaneous Immunoglobulins given per standard of care
214689759|NCT03886727|DEVICE|Rubber Dam Set|Rubber dam set is the generic name of an isolation device that consists of a rubber sheet that isolates the tooth from saliva, a clamp to hold the rubber sheet on the tooth to be isolated, and a metal frame to keep the rubber sheet in a stretched position during dental procedures.
214689760|NCT03886727|DEVICE|Dental Cotton Roll|Cotton roll is the generic name of a disposable isolation device made of cotton in a cylindrical form. Cotton rolls are used to isolate the teeth from saliva, by being placed in the cheek and tongue during placement of sealants or filings.
214689761|NCT05427825|OTHER|ERAS anesthetic care|The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
215018473|NCT03641677|DEVICE|Centralized Lung Evaluation System|Assessment of allograft lung for transplant suitability
215018474|NCT03641677|PROCEDURE|Lung Transplant|Orthotopic single or double lung transplantation.
215018475|NCT01390519|OTHER|everolimis|
214417569|NCT02219906|DIETARY_SUPPLEMENT|Placebo|1000mg tid placebo
214417570|NCT00457990|DRUG|Oral administration of ferrous sulphate|
214505709|NCT07038382|DRUG|HLX79 20mg/kg/Placebo + HLX01|Subjects with MN will receive HLX79 20mg/kg or placebo combined with HLX01 375 mg/m2
214505710|NCT07038382|DRUG|HLX79 30mg/kg/placebo+HLX01|Subjects with MN will receive HLX79 30mg/kg or placebo combined with HLX01 375 mg/m2
214689762|NCT05427825|OTHER|Standard anesthetic care|The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
214689763|NCT03792776|OTHER|cuff inflation with air|Endotracheal tube cuff inflation with air
214689764|NCT03792776|DRUG|cuff inflation with lidocaine 1%|Endotracheal tube cuff inflation with lidocaine 1%
214689765|NCT03792776|DRUG|cuff inflation with lidocaine 2%|Endotracheal tube cuff inflation with lidocaine 2%
215018476|NCT04535362|DRUG|Nicotine|session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.
215018477|NCT02419911|PROCEDURE|Laparoscopic surgery|gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
214417571|NCT02117843|DEVICE|AVI® Arsenic trioxide drug eluting stent|AVI® Arsenic trioxide drug eluting stent
215018478|NCT02419911|DEVICE|FloShield Defogging and Cleaning System|Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
215018479|NCT02419911|DEVICE|Clearify Defogging and Cleaning System|Single-use, ex vivo device to clean and defog the laparoscope camera lens
214417572|NCT04653714|PROCEDURE|Scaling and root planing|Patients with periodontitis in the test group will be treated by conventional non-surgical root debridement and in the control group by low-intensive supragingival plaque removal with mechanical brush and professional tooth paste only.
214417573|NCT04653714|DEVICE|Probiotic lozenges|Patients with gingivitis in the test group will be treated with supragingival debridement and with probiotic lozenges with strains of Lactobacillus brevis and Lactobacillus plantarum once a day for 3 months and in the control group by low-intensive supragingival plaque removal, as a placebo treatment, and placebo probiotics lozenges.
215018480|NCT05023889|DRUG|patisiran|"Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days)."
215018481|NCT06496971|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
214417574|NCT05328076|DRUG|Indocyanine green|Indocyanine green is used to perform intraoperative angiography.
214417575|NCT05328076|DEVICE|SPY Portable Handheld Imaging (SPY-PHI)|The device is used to perform intraoperative angiography.
214417576|NCT02205086|OTHER|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
214417577|NCT04889664|DRUG|Ketamine|Repeated intravenous Ketamine infusions.
214417578|NCT04889664|BEHAVIORAL|Written Exposure Therapy|WET is a brief, 5-session evidence-based written trauma-focused therapy
214417579|NCT04581837|DIAGNOSTIC_TEST|2D-speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography (2D-STE) allows for an angle-independent evaluation of myocardial strain, and provides comprehensive information on LV myocardial contractility. Thus, 2DSTE is superior in detecting subtle deteriorations of contractility. we will take 2D speckle tracking views for LV and RV strain (4ch, 2ch, 3ch, RV modified view).
214417580|NCT02313844|BIOLOGICAL|Viralym-B|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
214417581|NCT06175923|BIOLOGICAL|Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care|When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
214417582|NCT00461799|DRUG|orlistat|
214417583|NCT03608670|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
214417584|NCT04991233|PROCEDURE|Endoscopic surgery|The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
215018482|NCT06496971|DRUG|Microbubble|Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
215018483|NCT06496971|DEVICE|Low-Intensity Focused Ultrasound|Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
215018484|NCT03791060|DRUG|Secukinumab|Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
214417585|NCT04991233|PROCEDURE|Suboccipital craniotomy surgery|The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
215018485|NCT01604031|BIOLOGICAL|B-CLL Vaccine|Patients will receive a fixed dose (2X10\^7) of IL-2 secreting B-cells together with (2X10\^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
215018486|NCT01604031|DRUG|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
214417586|NCT02950779|OTHER|Handgrip Strength Measurement|
214689766|NCT03792776|OTHER|Induction of anesthesia|The induction of anesthesia will be made following a preoxygenation with a facial mask with 100% Oxygen. It consists on the intravenous injection of Sufentanil 5 mcg or Fentanyl 50mcg, Lidocaine 1mg/Kg, Propofol 2.5mg/kg, Rocuronium 0.6mg/kg or Cisatracurium 0.15mg/kg.
214689767|NCT03792776|OTHER|Maintenance of anesthesia|Maintenance of anesthesia will be done by sevoflurane + nitrous oxide, and reinjections of morphinomimetics and curare will be made as needed (the total doses will be noted at the end of the intervention).
215018487|NCT00092469|BIOLOGICAL|V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine|
215018488|NCT00554580|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
214417587|NCT03636451|DRUG|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
214417588|NCT03636451|DRUG|20cc 1% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
214417589|NCT02438800|BEHAVIORAL|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
214417590|NCT01784146|OTHER|Oxygen|"For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen."
214417591|NCT01784146|OTHER|Heliox|"For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al."
214417592|NCT01784146|OTHER|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
214417593|NCT01043406|DEVICE|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
214417594|NCT03012919|OTHER|active decision support system|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
214417595|NCT02755363|OTHER|osteopathic manual therapy|"* suboccipital decompression - atlanto-occipital joint relaxation technique.~* deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~* thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~* stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
214417596|NCT02755363|OTHER|control group|"* manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~* manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
214417597|NCT02834143|OTHER|No intervention|The is no intervention. This study is a descriptive one
214417598|NCT06228807|COMBINATION_PRODUCT|The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups.|Differences in clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic findings, coronary microvascular function using caIMR and clinical outcomes were assessed between the two groups to identify potential risk factors. Subsequently, the incidence of clinical outcomes and mortality was compared. Univariate logistic regression and multivariate logistic regression analyses, adjusted for significant risk factors, were conducted to identify independent predictive factors. Finally, a Receiver Operating Characteristic (ROC) curve was generated, and the area under the curve was evaluated to assess the predictive accuracy of the regression model.
214417599|NCT00470743|DRUG|Ibuprofen|
214417600|NCT00470743|DRUG|Indomethacin|
214417601|NCT02834689|BEHAVIORAL|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
214417602|NCT02834689|BEHAVIORAL|Seated Control|Sitting for 50 minutes
215018489|NCT00554580|PROCEDURE|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
215018490|NCT03061851|BEHAVIORAL|conventional treatment|the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
214417603|NCT00001421|DRUG|methimazole|
214417604|NCT01982019|BEHAVIORAL|Meal test taking and hormones measure including 26RFa|Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
214417605|NCT00768781|BEHAVIORAL|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
214417606|NCT00768781|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
214689768|NCT03792776|OTHER|Endotracheal intubation|The intubation is made by a N° 7.5 tube in men and a N° 7 tube in women. Cuff inflation will be done upon placement of the endotracheal tube. The cuff's pressure will be monitored at several intervals of the intervention and kept \< or = 20 centimeter of water (cmH2O).
214689769|NCT03792776|OTHER|Systematic post-operative analgesia|All patients will receive Paracetamol every 6 hours for the first 24 hours after the end of surgery.
214689770|NCT04651725|OTHER|Exercises|Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
215018491|NCT03061851|OTHER|Maltose app|"1. Weekly diabetes-related science articles.~2. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.~3. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.~4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.~5. Personalize the development of diet, exercise program.~6. different insulin and oral hypoglycemic drug medication time to remind.~7. hypoglycemic drug side effects query."
214417607|NCT00768781|BEHAVIORAL|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
214417608|NCT06394791|DRUG|Tislelizumab + IL-2 Combined with Capox|Tislelizumab + IL-2 Combined with Capox
214417609|NCT00368719|DRUG|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
214417610|NCT04061408|RADIATION|Fractionated stereotactic radiotherapy(FSRT)|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
214417611|NCT00232011|DRUG|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
214417612|NCT01884389|OTHER|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
214417613|NCT02057354|BEHAVIORAL|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
214417614|NCT02057354|BEHAVIORAL|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
214417615|NCT00680537|PROCEDURE|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
214417616|NCT02534441|OTHER|Skin patch test|
214417617|NCT03724370|BEHAVIORAL|Telehealth Monitoring System|TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
214417618|NCT03724370|OTHER|VHA-SRM|Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
214417619|NCT01947179|BEHAVIORAL|Anxiety Risk Reduction|Involves psychoeducation and interoceptive exposure exercises
214417620|NCT00272935|DRUG|Cenestin 0.3 mg Tablets|1 tablet daily
214417621|NCT00272935|OTHER|Placebo|1 tablet daily
214417622|NCT02952053|DEVICE|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
214417623|NCT02952053|DEVICE|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
214417624|NCT04107805|DRUG|BI 1323495|Tablet
215018492|NCT03709589|OTHER|Modified Early Warning Score|Modified Early Warning Score
215018493|NCT00943202|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
215018494|NCT00943202|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - \<36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
215018495|NCT03116087|DRUG|Testosterone patch|300 mcg testosterone patches or placebo applied twice weekly
215018496|NCT03116087|DRUG|Placebo|Placebo patch
215018497|NCT05942989|OTHER|Reiki implementation|Reiki is implied by putting hands on the patient and it is believed that energy is transferred to patients by hands.
215018498|NCT03286803|BIOLOGICAL|Inactivated Poliovirus vaccine|we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine
215018499|NCT04250974|OTHER|electroacupuncture|acupuncture with electricity
214417625|NCT04107805|DRUG|Placebo|Tablet
214417626|NCT04107805|DRUG|Midazolam|Oral administration
214417627|NCT00768131|DRUG|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
214417628|NCT00768131|DRUG|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
214417629|NCT00768131|DRUG|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
214417630|NCT04590651|PROCEDURE|Cataract surgery|Routine phacoemulsification cataract surgery using the Alcon Centurion® device.
214417631|NCT04590651|PROCEDURE|Cataract surgery with extra anterior chamber angle aspiration|Routine phacoemulsification cataract surgery using the Alcon Centurion® device. At the end of the case a one minute extra anterior chamber angle aspiration will be preformed after the removal of the viscoelastic agent.
214417632|NCT01450124|DRUG|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
215018500|NCT03675555|DRUG|Mirtazapine|Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
215018501|NCT03675555|DRUG|Dexamethasone phosphate|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
215018502|NCT03675555|DRUG|Placebo|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
215018503|NCT02567292|OTHER|Human Milk|Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants \<37 weeks PMA and/or or weight \<2,200g or PBCLN-002 for infants \>37 weeks PMA and/or weight \>2,200g)
214417633|NCT04820101|DRUG|Dexmedetomidine|administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure
215018504|NCT02988388|PROCEDURE|Lung biopsy/lobectomy|Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
215018505|NCT01911325|DRUG|Buparlisib|
214417634|NCT02869958|OTHER|Digital action plan for asthma exacerbations + Written action plan|Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
214417635|NCT02869958|OTHER|Written action plan|
214417636|NCT02286999|DRUG|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
214417637|NCT02286999|DRUG|Placebo|
214417638|NCT02563704|DRUG|Artesunate|
215018506|NCT01911325|DRUG|Buparlisib matching placebo|
215018507|NCT01911325|DRUG|Docetaxel|
215018508|NCT03276481|DIAGNOSTIC_TEST|Oral microbiota assessment|Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
215018509|NCT03276481|DIAGNOSTIC_TEST|Comprehensive chemical gustometry|Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
215018510|NCT03276481|DIAGNOSTIC_TEST|Measurement of salivary flow|Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
215018511|NCT03276481|BEHAVIORAL|Surveys assessing taste disturbances|Surveys will be administered and examine taste disturbances pre and post HCT.
215018512|NCT02619812|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)
215018513|NCT02619812|DRUG|Colesevelam|Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).
215018514|NCT02619812|OTHER|Double Placebo|Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
215018515|NCT00981175|BIOLOGICAL|Live attenuated Japanese encephalitis virus, then ChimeriVax diluent|ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28
215018516|NCT00981175|BIOLOGICAL|ChimeriVax diluent, then Live attenuated Japanese encephalitis virus|ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
215018517|NCT01242046|DIETARY_SUPPLEMENT|Caffeine|400 mg of caffeine in tablet form
215018518|NCT01242046|DIETARY_SUPPLEMENT|Placebo|Inert tablet
215018519|NCT02924116|DEVICE|Bioboosti|Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
215018520|NCT05961384|DRUG|baxdrostat|a blood pressure lowering drug, oral dose
214505711|NCT07035548|OTHER|Educative: Peer-learning|Peer learning, also known as peer-to-peer learning, is a collaborative educational strategy where students actively learn from one another. It involves interaction among peers to share knowledge, solve problems, and develop skills. This methodology can take various forms, from peer tutoring, where a more advanced student assists a less experienced one, to study groups where everyone contributes equally. The process fosters critical thinking, effective communication, and the co-construction of knowledge. By explaining concepts to others or discussing ideas, students solidify their own understanding and discover new perspectives. Moreover, it promotes individual and collective responsibility, as each participant plays an active role in their own learning and that of their peers. This approach not only improves academic performance but also develops crucial social and emotional skills, such as empathy, patience, and the ability to collaborate, preparing students for more cooperative work
214505712|NCT07033156|DIAGNOSTIC_TEST|This study does not require intervention trials|This study does not require intervention trials
214505713|NCT07039786|DIETARY_SUPPLEMENT|Placebo Control|Participants will use their Radicle Health Control Study Product as directed for a period of 6 weeks.
214505714|NCT07039786|DIETARY_SUPPLEMENT|Active Product|Participants will use their Radicle Health Active Study Product as directed for a period of 6 weeks.
214505715|NCT05562830|BIOLOGICAL|Zilovertamab vedotin|Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
215018521|NCT01197105|BIOLOGICAL|Use of natural product (Schinus terebinthifolius)|Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
215018522|NCT00000778|DRUG|Isoniazid|
215018523|NCT00000778|DRUG|Pyridoxine hydrochloride|
214417639|NCT02563704|DRUG|Quinine|
214417640|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet, 10mmoL of sodium per day, for 6 days
214417641|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet + IV normal saline|Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
214417642|NCT02261688|DIETARY_SUPPLEMENT|Liberal salt diet|Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
215018524|NCT00000778|DRUG|Levofloxacin|
215018525|NCT02559960|DRUG|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
215018526|NCT03444688|OTHER|Conventional Gait Training|Subjects allocated to the CT group will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. They will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. They will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.
215018527|NCT03444688|DEVICE|Gait rehabilitation with walker|For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes.
215018528|NCT02884960|PROCEDURE|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
214417643|NCT06055114|DIAGNOSTIC_TEST|Microscopic examination of vaginal discharge|Using gram-stained smears to detect vaginal secretions, and then the concentration and diversity of bacterial flora are observed using a microscope.
214417644|NCT06178822|OTHER|No intervention|There is no intervention
214417645|NCT02777632|PROCEDURE|Living donor liver transplantation|
214417646|NCT05196438|OTHER|Collecting statistics about congenital heart patterns and investigations done and interventions done to them|Collecting statistics about congenital heart patterns and investigations done and treatment given or interventions e.g. catheterization or surgical operations done to them
214417647|NCT03558204|PROCEDURE|Denervation of the thumb CMC joint|Removal/disconnection of the nerve branches to the joint from their attachments to the joint
214417648|NCT03558204|PROCEDURE|trapeziectomy with ligament reconstruction (LRTI)|excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
214417649|NCT01934829|DRUG|urea-based cream|"urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator."
214417650|NCT05787730|DEVICE|Transobturator tape|
214417651|NCT03098290|PROCEDURE|Catheter-based endovascular revascularization|(e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
214417652|NCT03098290|PROCEDURE|Bypass-Surgery|Venous or alloplastic or comparable Bypass
214505716|NCT05562830|BIOLOGICAL|Pembrolizumab|Administered via IV infusion on Day 1 of each 6 week cycle.
214505717|NCT05562830|BIOLOGICAL|MK-3120|Administered as an IV infusion on Day 1, Day 15, and Day 29 of each 6 week cycle.
214505718|NCT07043140|OTHER|mobile application|mobile application for lymphedema information and exercise
214505719|NCT07043257|BEHAVIORAL|Escape Room-Based Bladder Catheterization Training|This intervention involves an escape room-based educational strategy designed to teach bladder catheterization to nursing students. The method includes interactive puzzles, clinical problem-solving tasks, and scenario-based simulations. The training promotes engagement, teamwork, and application of theoretical knowledge in a gamified learning environment.
214417653|NCT03098290|PROCEDURE|Endarterectomy|Endarterectomy, Patchplasty
214417654|NCT05623384|PROCEDURE|Stellate ganglion block|A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）
214417655|NCT05623384|PROCEDURE|Facial and glossopharyngeal nerve blocks|The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. （mecobalamin injection 1mg；lidocaine 20mg； dexamethasone 10mg ；Physiological saline 2ml）
214505720|NCT07043257|BEHAVIORAL|Traditional Bladder Catheterization Training|This intervention includes standard bladder catheterization training based on traditional teaching methods. The students will receive theoretical instruction through lectures and demonstration-based simulation without interactive or gamified components.
214505721|NCT07042815|DEVICE|Epidural Stimulation Programs|Epidural stimulations will accompany stimulation programs that have been established during research visits in the prior study and have been recommended by the clinical research team for use in the home and community. Stimulation programs will be given for activities (such as standing or walking) and/or responses that were completed in the previous study. This will be continued until the device is removed or approved for commercial use.
214505722|NCT07042711|DIETARY_SUPPLEMENT|Placebo|Patients are given capsules that can contain either a placebo or Vitamin D.
214505723|NCT07042711|DIETARY_SUPPLEMENT|Vitamin D 5,000IU Oral Tablet|Patients are given capsules that can contain either a placebo or Vitamin D.
214417656|NCT05623384|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
215018529|NCT05813483|OTHER|Skinceuticals skin care product(CE)|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
215018530|NCT05813483|OTHER|fraxel laser therapy|fraxel laser therapy combined with routine moisturizing and sun protection
214417657|NCT01356225|DRUG|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
214417658|NCT01356225|DRUG|Placebo|IN placebo
214417659|NCT06256211|DRUG|Paracetamol|"All cases will be randomized simply by opaque closed envelop and treated with either rectal or intravenous paracetamol according to the following doses.~* Rectal dose~  * Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.11~ * The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total).11~* Intravenous dose~  * Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).12~ * After the 3-day follow up echocardiogram will be done.12 This will be the end of randomization for the purpose of the study."
214417660|NCT05753644|PROCEDURE|stellate ganglion blocks|At the level between C6 and C7, a 25-gauge needle is inserted laterally, and the needle tip is placed posterior to the carotid artery and anterior to the longus colli muscle using an in-plane approach.
214417661|NCT05753644|DRUG|Ropivacaine|5 mL of 0.5% ropivacaine injected in the plane of the right stellate ganglion
215018531|NCT00693108|DRUG|Transdermal testosterone|
214417662|NCT05753644|DRUG|Sham treatment|5 mL of saline injected in the plane of the right stellate ganglion
215018532|NCT04289272|BEHAVIORAL|Dove Confident Me|Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
214417663|NCT06064032|BEHAVIORAL|cognitive behavioral therapy|In control group there is 10 min session of PMR, 2 min deep breathing exercises,3 min training for life style modification which include use of planner, setting alarms breaking a task into parts positive reinforcement and communication.
215018533|NCT02011997|PROCEDURE|patients undergo cVATS segmentectomy|
215018534|NCT02011997|PROCEDURE|Patients undergo cVATS lobectomy|
215018535|NCT01681303|DRUG|AST-120|
215018536|NCT02303938|BEHAVIORAL|physical exercise|Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
215018537|NCT03578263|DRUG|Carbetocin|Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby.
215018538|NCT03578263|DRUG|oxytocin|Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and
215018539|NCT03578263|DRUG|ergometrine|intramuscular ergometrine 0.2 mg.
214417664|NCT06064032|BEHAVIORAL|Motor Learning Techniques|In experimental group, participants will be given a 10 min PMR ,2 min deep breathing exercises, 3 min training for life style modification which include the use of planners setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with 3 min session of drawing a specific pattern with installing pegs on pegboard, 2 min session of balance board training, 3 min session of jigsaw puzzle training, 1 min session of squeezing a ball with maximum repetition and 1 min session of finding beads in puttey.
214417665|NCT00422201|DRUG|Mifepristone|Singe dose
214417666|NCT04354610|PROCEDURE|Biological samples specific to research|Blood samples, saliva collection, and urine collection to carry out biomarker assays and for the constitution of a biological collection.
214417667|NCT04354610|PROCEDURE|Clinical examination|Clinical examination
214417668|NCT04354610|PROCEDURE|Telephone follow-up|Telephone follow-up at 3 months after discharge from hospital
214417669|NCT02000505|DEVICE|PocketCPR|5 minutes chest-compression-only CPR, using Zoll PocketCPR
214417670|NCT02000505|DEVICE|Metronome|5 minutes chest-compression-only CPR, using a metronome
214417671|NCT02000505|DEVICE|110bpm Song|5 minutes chest-compression-only CPR, using a song with 110bpm for support
214417672|NCT03408860|OTHER|Countering Emotional Behaviors Module from Unified Protocol|This is a 4-week behavioral treatment that teaches patients to counter problematic emotional avoidance by approaching behaviors and situations that may bring up strong emotions in the short-term, but prevent interfering emotional difficulties in the long-term.
215018540|NCT05986058|BEHAVIORAL|Golden Circle|The original Golden Circle project was deployed in response to the COVID-19 pandemic and the need to implement remote social services in South Korea. Golden Circle had the aim of building a case management model using a healthcare-oriented automation system based on wearable devices (smartwatches and mobile applications). Through innovative system expansions, the goals were to promote healthful CVH and physical function and cultivate self-care management skills in older Korean adults.
214417673|NCT03718793|DIAGNOSTIC_TEST|Peripheral exhaled nitric oxide|Small airway inflammation and dysfunction will be measured using the above mentioned tests.
214417674|NCT00744250|DRUG|Pancrelipase|PANCRECARB MS-16
214417675|NCT02716649|OTHER|No intervention|
214417676|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with occlusive or nonocclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
215018541|NCT05875610|DRUG|Venlafaxine 75 MG|Venlafaxine 75 mg extended release capsules for a 7-days duration
215018542|NCT05875610|DRUG|Gabapentin 400 mg|Gabapentin 400 mg capsules
214417677|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
214417678|NCT01596751|DRUG|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
214417679|NCT01596751|DRUG|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
214417680|NCT03168204|BEHAVIORAL|Tailored care and support|Offering tailored care and support whereby the competences, strengths and resources of the older person are taken into account.The intervention will be an enhancement of usual care and will depend on the availability of the municipality, and could be formal (i.e., home care) or informal (e.g. activities of an older adult's association).
214689771|NCT06819566|PROCEDURE|Endoscopic variceal ligation (EVL)|"1. EVL for high-risk varices will be performed by experienced endoscopists, certified in gastroenterological endoscopy, within two weeks prior to the initiation of the Atezo/Bev.~2. A follow-up EGD will be conducted one week after the Atezo/Bev #3. If any of the following criteria are met, additional EVL will not be performed, and anticancer treatment will proceed two weeks later. Otherwise, an additional on-demand EVL session will be conducted:~   * The esophageal varices have improved to F1 or less.~  * The red color sign has disappeared.~3. On-demand EVL will be considered after 5th, and 7th consecutive doses of Atezo/Bev, with EGD follow-up performed to assess eligibility. The maximum number of EVL sessions is limited to three sessions."
214417681|NCT01191086|DRUG|USL255|
214417682|NCT02205151|DRUG|Fimasartan|
215018543|NCT01141543|DRUG|Plerixafor (mozobil)|"Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN"
215018544|NCT02104011|DRUG|Propranolol|
215018545|NCT02985775|BIOLOGICAL|Donor-derived CMVpp65-specific T cells|About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
215018546|NCT04032327|DRUG|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed to be injected vaginally prior to the start of posterior colporrhaphy
215018547|NCT04032327|DRUG|Bupivacaine|20 mL of 0.25% plain bupivacaine to be injected vaginally prior to the start of posterior colporrhaphy
215018548|NCT01658735|DEVICE|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
214417683|NCT02205151|DRUG|Amlodipine|
214417684|NCT02205151|DRUG|Fimasartan/Amlodipine combination|
214689772|NCT06612034|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
215018549|NCT01658735|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
215018550|NCT01658735|DEVICE|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
215018551|NCT00216658|DRUG|fentanyl|
215018552|NCT06005831|OTHER|sandbag|The standard sandbag used in our clinic, 20 × 20 × 3 cm3 in dimensions and 3 kg in weight
215018553|NCT04065256|OTHER|Personalized music|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
215018554|NCT04065256|OTHER|Personalized music plus earplug|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
215018555|NCT02998125|PROCEDURE|Total knee arthroplasty|prospective assessments for the functional outcome before and after the total knee arthroplasty
215018556|NCT01436890|DRUG|Revamilast|Tablet. Low dose, Once daily for 12 weeks
214417685|NCT05460806|OTHER|Aerobic Exercise|Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
214417686|NCT01014858|DRUG|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
214417687|NCT03817736|PROCEDURE|TACE|Procedure of TACE will be standardized.
214417688|NCT03817736|RADIATION|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
215018557|NCT01436890|DRUG|Revamilast|Medium dose, Once daily for 12 weeks
214417689|NCT03817736|DRUG|Immune Checkpoint Inhibitor|An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.
214417690|NCT03248011|OTHER|Stretching|Lower extremity flexibility exercises will be performed
214417691|NCT03248011|OTHER|Strengthening|Eccentric hamstring strengthening exercises will be performed
214417692|NCT03248011|OTHER|Neuromuscular|Dynamic lower extremity balance and movement control exercises will be performed
215018558|NCT01436890|DRUG|Revamilast|High dose, Once daily for 12 weeks
214417693|NCT05097924|OTHER|NAN Supreme HypoAllergenic Starter Infant Formula in ready-to-feed format|Post-market observational study with formula feeding administered via standard of care
214417694|NCT00771849|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
214417695|NCT00771849|BIOLOGICAL|Haemophilus Influenzae Type b (Hib) vaccine|0.5 mL, Intramuscular
215018559|NCT01436890|DRUG|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
214689773|NCT06650176|BEHAVIORAL|Lifestyle Management|The Metrikamind intervention features a unique digital ecosystem designed to manage mental health specifically in workplace contexts, with a focus on aiding recovery and facilitating the return to work for employees on sick leave. This innovative tool employs bifactor models to enhance the accuracy of self-reported data, effectively countering potential faking behaviors. Through continuous, real-time data collection on a user-friendly platform, Metrikamind tracks and assesses various mental health conditions, including stress, anxiety, and depression. The intervention\&amp;#39;s advanced analytics enable personalized feedback and targeted interventions, improving the detection, management, and ultimately, the mitigation of mental health issues. By focusing on individuals currently unable to work due to mental health challenges, Metrikamind aims to support their recovery and accelerate their readiness to return to work, thus addressing both immediate and long-term recovery trajectories.
214689774|NCT05118958|DRUG|KVD824 Prototype 1 modified-release tablet|300 mg modified-release tablet
214689775|NCT05118958|DRUG|KVD824 Prototype 2 modified-release tablet|300 mg modified-release tablet
214417696|NCT01762072|DIETARY_SUPPLEMENT|Fish oil|
214417697|NCT01762072|DIETARY_SUPPLEMENT|vitaminB12|
214417698|NCT01636206|DRUG|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year
214417699|NCT01636206|DRUG|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: \~1 year
215018560|NCT01348906|PROCEDURE|intermittent normoxia|3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
215018561|NCT06366919|DIAGNOSTIC_TEST|Alexander Technique (AT)|The AT arm of study will involve participants receiving indivisual sessions. These sessions will typically focus on non specific neck pain management improving posture , movement coordination and body awareness through gentle hands on guidance
215018562|NCT06366919|DIAGNOSTIC_TEST|Feldenkrais Technique (FT)|The FT arm of study will involve participants recieving individual sessions. These sessions will typically focus on pain improvement, maintaining alignment, reducing muscle tension and promoting ease of movement.
214417700|NCT06234865|OTHER|Control Group|Patients in the control group will receive standard education plus a brochure education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The brochure education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
214417701|NCT06234865|OTHER|Video Education Group|Patients in the experimental group will receive standard education plus a video education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The video education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
214417702|NCT03748433|DEVICE|Dexcom G6 CGM|Commercially available Dexcom G6 Continuous Glucose Monitoring
214417703|NCT03748433|DEVICE|Tandem t:slim X2 Insulin Pump|sensor augmented insulin pump with predictive low glucose suspend
214417704|NCT02167243|BEHAVIORAL|Reinforcement for BG testing|Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
214689776|NCT05118958|DRUG|KVD824 Immediate-Release Capsule|300 mg immediate-release capsule
214689777|NCT05118958|DRUG|Placebo to KVD824 Prototype 1|Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
214689778|NCT05118958|DRUG|KVD824 Prototype 3 modified-release tablet|300 mg modified-release tablet
214689779|NCT03161769|PROCEDURE|Neurovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms using flow diverting stents
214417705|NCT02167243|OTHER|Standard of care|Subjects receive standard of care
214417706|NCT04216823|DEVICE|perfusion index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
214417707|NCT00893373|DRUG|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
214417708|NCT00893373|DRUG|placebo|Standard AML chemotherapy plus placebo
214417709|NCT04376385|BEHAVIORAL|GROw: An Internet based Self Applied Treatment Program for Prolonged Grief Disorder (PGD)|"It is a self-applied treatment through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is 8-10 weeks. A support call will be made a week (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided.~Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
214417710|NCT04425434|OTHER|OBSERVATIONAL|We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
214417711|NCT00913328|DRUG|Montelukast (Singulair)|10 mg tablet once daily
214417712|NCT00913328|DRUG|Placebo|Oral placebo once daily
214417713|NCT06326866|DIAGNOSTIC_TEST|Otoacoustic emissions (non-invasive)|There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
214417714|NCT02754011|DRUG|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
214417715|NCT02592837|DEVICE|Flexible 19G EBUS-TBNA needle|
214417716|NCT02592837|DEVICE|21G EBUS-TBNA needle|
214417717|NCT03591809|OTHER|combined exercise training|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
214417718|NCT02046616|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered subcutaneously QW.
214417719|NCT02046616|DRUG|Methotrexate|Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
214417720|NCT02046616|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
214417721|NCT05468606|BIOLOGICAL|GA2|GA2 sporozoites administered by 50 mosquito bites
214417722|NCT05468606|BIOLOGICAL|BCG|0.1 mL BCG vaccine intradermally
214417723|NCT05468606|BIOLOGICAL|YF-17D (fractional ID dose)|0.1 mL YF17D vaccine intradermally
214417724|NCT05468606|DRUG|Imiquimod|250mg imiquimod 5% cream topical
214417725|NCT05468606|OTHER|Mock immunization|50 bites by uninfected mosquitoes
214417726|NCT02736799|DEVICE|Sham vibrating capsule|Sham device without vibration
214417727|NCT02736799|DEVICE|Vibrant Capsule (1 vibration)|1 vibration/min
214417728|NCT02736799|DEVICE|Vibrant Capsule (3 vibration)|3 vibration/min
214417729|NCT02736799|DEVICE|Vibrant Capsule (5 vibration)|5 vibration/min
214417730|NCT04983745|DRUG|Combination drug|niraparib and dostarlimab combination
214417731|NCT03316794|DRUG|SC-005|intravenous
214417732|NCT05640596|DRUG|Betamethasone|
214417733|NCT01183533|DRUG|Alteplase (iv t-PA)|0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
214417734|NCT03684096|DIETARY_SUPPLEMENT|non-estrogenic pollen extract PCC-100|non-estrogenic pollen extract PCC-100
214417735|NCT03684096|OTHER|placebo|placebo -non-estrogenic pollen extract PCC-100
214417736|NCT02034149|BEHAVIORAL|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
214417737|NCT02034149|BEHAVIORAL|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
214417738|NCT02034149|BEHAVIORAL|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
214417739|NCT03036735|DEVICE|steroid eluting spacer|The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
214417740|NCT01156116|DEVICE|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_"
214417741|NCT01156116|DRUG|Placebo|oral placebo tablet
214417742|NCT05576051|OTHER|patterns of use of combination therapy and monotherapy|
214417743|NCT00344019|DRUG|Placebo Oral Tablet|placebo pre-PCI for ACS
214417744|NCT00344019|DRUG|Atorvastatin 80mg|atorvastatin 80 mg pre-angio/PCI
214417745|NCT00344019|OTHER|Screening|Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
214417746|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
214417747|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
214417748|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
214417749|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
214417750|NCT02057718|DRUG|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).
214417751|NCT01367548|DRUG|IV Methylnaltrexone (MNTX)|
214417752|NCT01367548|DRUG|Placebo|
214417753|NCT03857334|BIOLOGICAL|Injection of autologous platelet rich plasma|
214417754|NCT03857334|DRUG|Injection of cortivazol : Altim®|Corticosteroids
214417755|NCT03031756|DEVICE|glycine powder air-polishing (Air-Flows)Perio Powder|
214417756|NCT03031756|DEVICE|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
214417757|NCT05095558|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
214417758|NCT01952795|BEHAVIORAL|Diet and exercise|Total caloric intake aimed at maintaining a diet with\> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
214417759|NCT04008394|GENETIC|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
214417760|NCT00508963|DRUG|sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days
214417761|NCT03187782|DIAGNOSTIC_TEST|ANSWatch|
214417762|NCT02503202|BIOLOGICAL|V920 Consistency Lot A|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
214417763|NCT02503202|BIOLOGICAL|V920 Consistency Lot B|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
214417764|NCT02503202|BIOLOGICAL|V920 Consistency Lot C|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
214417765|NCT02503202|BIOLOGICAL|V920 High-dose Lot|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
214417766|NCT02503202|BIOLOGICAL|Placebo to V920|Sodium chloride 0.9%, sterile solution for intramuscular injection
214417767|NCT00320502|DRUG|BXT-51072|
214417768|NCT03114020|DRUG|Hyaluronic Acid Inhalation Solution|twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
214417769|NCT03114020|DRUG|Placebo Inhalation Solution|Twice a day 3 ml of placebo inhalation solution
214417770|NCT05689268|DIAGNOSTIC_TEST|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
215018563|NCT04483219|DRUG|TKI ± anti-PD-1 antibody|"After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~1. Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~2. Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years."
215018564|NCT02440529|BEHAVIORAL|Intervention|Discussion
214417771|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Relative Risk|Risk of T2D is presented in comparison to the rest of the Singapore population in a scale 1-10. Suggestions on different lifestyle changes and its potential to reduce the individual's relative risk is presented for user to observe impact of preventative behaviours.
214417772|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Metabolic Age|Risk of T2D is presented as an age, compared to their chronological age as a proxy for their current health status. Suggestions on different lifestyle changes and its potential to reduce the individual's metabolic age is presented for user to observe impact of preventative behaviours.
215018565|NCT02440529|BEHAVIORAL|Verbal Group|Detailed Discussion
214417773|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Traffic Light|Risk of T2D is presented as either High (Red) or Low (Green). Generic tips on how to reduce risk of diabetes are included. This imitates the tool that is currently available for residents of Singapore to use to assess their risk of T2D.
214417774|NCT00651378|DRUG|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
214417775|NCT00651378|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
214417776|NCT00651378|DRUG|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
214417777|NCT00209443|DRUG|Gadodiamide Injection|
214417778|NCT05187767|DIAGNOSTIC_TEST|cf DNA and ct DNA|Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA
214417779|NCT04454892|OTHER|Amyotrophic lateral sclerosis|AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3
214417780|NCT04577170|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
214417781|NCT01254591|OTHER|18F-fluoromisonidazole|
214417782|NCT01254591|OTHER|fluorescence angiography|
214417783|NCT01254591|OTHER|laboratory biomarker analysis|
214417784|NCT01254591|PROCEDURE|infrared thermography|
214417785|NCT01254591|PROCEDURE|magnetic resonance imaging|
214417786|NCT01254591|PROCEDURE|therapeutic conventional surgery|
214505724|NCT07042984|DIAGNOSTIC_TEST|AI-Ultrasound RET Prediction|Deep-learning algorithm that analyses thyroid ultrasound DICOM images and outputs a probability score for RET gene alteration and lateral-neck lymph-node metastasis; run offline, results blinded to treating surgeons.
214505725|NCT07044050|BIOLOGICAL|allogenic natural killer cells|OT-C001 will be administered by IV infusion weekly for at least 3 doses.
214417787|NCT01254591|RADIATION|[18F]-ML-10|
214505726|NCT07042555|BEHAVIORAL|CBT-cp|The participants in CBT-cp arm will receive weekly sessions of Cognitive Behavior Therapy for Chronic Pain.
214505727|NCT07042555|OTHER|Pelvic Floor Therapy|The participants in PFT arm will receive weekly sessions of pelvic floor therapy.
215018566|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
214505728|NCT07042555|DRUG|Pharmacotherapy|The participants in Pharmacotherapy arm will receive prescription and non prescription pain medication.
214505729|NCT07042555|COMBINATION_PRODUCT|CBT-cp+PFT|The participants in integrated arm will receive weekly sessions of both CBT-cp and PFT.
214505730|NCT07042555|OTHER|Placebo|The participants in placebo arm will receive sham drug.
214505731|NCT07042490|PROCEDURE|Plasma adsorption|Plasma adsorption was initiated after endovascular thrombectomy once daily for 3 days.
214505732|NCT07042490|PROCEDURE|Endovascular Thrombectomy|The patients will be treated with endovascular thrombectomy.
215018567|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
214417788|NCT01254591|RADIATION|fludeoxyglucose F 18|
214417789|NCT01254591|RADIATION|rubidium Rb-82|
214505733|NCT07042724|BEHAVIORAL|Physical exercise and nutrition intervention for the neoadjuvant setting|"* Physical exercise: 3 sessions/week. It will comprise high-intensity interval training consisting of 2 minutes of high-intensity intervals interspersed with 2 minutes of active recovery completed at mild intensity. The number of intervals will start with five and progress based on the patient's exercise response. Resistance training will include 3-4 exercises involving major muscle groups, performed with body weight or using elastic bands, at moderate to vigorous intensity.~* Nutrition: will be directed to achieve estimated protein-calorie requirements. Total daily energy requirements will be calculated using the data obtained in the baseline assessment, while daily protein requirements will be set at 1.5 g/kg of body weight. Oral nutritional supplements, particularly a high-calorie, high-protein nutritional blend containing arginine, nucleotides \[RNA\], and omega-3 fatty acids, will be proposed."
214689780|NCT03161769|DEVICE|AneurysmFlow image processing software|Software to process and display images of intracranial aneurysm treatment using flow diverting stents.
214417790|NCT05444179|BEHAVIORAL|Mommies can Eat & Exercise with No Stress (MomEENS)|This intervention involving behaviour modification, incorporates nutrition and physical activity modification. The intervention encourages participants to consume a healthy diet and active lifestyle during postpartum period. For nutrition modification, a general advice on healthy nutrition were given and several nutrients are highlighted which evidenced can reduce postpartum depression. While for physical activity, the mothers are encouraged to do exercise, targeting aerobic, flexibility, and strength type of exercise. The exercise protocol is progressive. During the first month, the participants will be advised to conduct flexibility and strength exercises for 8 repetitions (1 set), at least 3 days per week for both aerobic and flexibility exercise. While during the second month, participants are asked to increase repetitions and frequency of exercises, up to 16 repetitions (2 set) for each flexibility exercise, and conduct exercise at least 5 days per week.
214417791|NCT02521116|OTHER|Dynamic Vessel Analyzer|
214417792|NCT02521116|OTHER|Oxymap T1|
214417793|NCT02931851|OTHER|ICU Families Website|Professionally developed website for relatives of ICU patients
214417794|NCT02931851|OTHER|Placebo|Standard Information provided online
214417795|NCT04554823|BEHAVIORAL|Health Education|Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
214505734|NCT07042724|BEHAVIORAL|Physical exercise and nutrition for the adjuvant setting|"* Physical exercise: 2-3 sessions/week. Each session will be composed of: i) resistance training, including 6-8 exercises for major muscle groups performed in 2-4 sets of 8-12 repetitions; ii) aerobic component, starting at 10-20 minutes, based on the patient's baseline assessments, with monthly progressions up to 40-45 minutes at the end of the program. The insentisy will be set from moderate to vigorous.~* Nutrition: will be directed to achieve estimated protein-calorie requirements. Total daily energy requirements will be calculated using the data obtained in the baseline assessment, while daily protein requirements will be set at 1.5 g/kg of body weight. Oral nutritional supplements, particularly whey protein, will be proposed."
214689781|NCT00740779|DRUG|Silodosin 8 mg|Silodosin 8 mg daily
214689782|NCT00740779|DRUG|Placebo|Placebo
214689783|NCT00740779|DRUG|Silodosin 4 mg|Silodosin 4 mg daily
214689784|NCT00850460|DRUG|Statins|Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
214689785|NCT00850460|DRUG|Placebo|Placebo pills will consist of lactose and will be given one capsule once daily
214689786|NCT05099770|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Participants will have a kidney biopsy followed 14 weeks later with a REACT injection into the biopsied kidney, then, another 12 weeks (+28 days) later a REACT injection into their contralateral kidney.
215018568|NCT01379937|BIOLOGICAL|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
215018569|NCT01379937|BIOLOGICAL|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
215018570|NCT06430411|PROCEDURE|Radical prostatectomy|Removal of the prostate and seminal vesicles.
215018571|NCT06430411|RADIATION|Prostate irradiation|Radiation therapy of the prostate.
215018572|NCT06430411|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases.
215018573|NCT06430411|RADIATION|Irradiation of metastases|Radiation therapy of metastases.
215018574|NCT06430411|DRUG|Abiraterone acetate|Administered as part of multimodal treatment for oligometastatic prostate cancer
214417796|NCT04554823|BEHAVIORAL|Physical Exercise|Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
214417797|NCT00405951|DRUG|Obatoclax mesylate 250 ml|
214417798|NCT00405951|DRUG|Docetaxel|
214689787|NCT05099770|PROCEDURE|Sham Comparator|Participants will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 12 weeks (+28 days) after the first sham procedure.
214689788|NCT05882604|DRUG|Mesna Injection|1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.
215018575|NCT06430411|DRUG|Enzalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
215018576|NCT06430411|DRUG|Darolutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
215018577|NCT06430411|DRUG|Apalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
215018578|NCT06430411|DRUG|Docetaxel|Administered as part of multimodal treatment for oligometastatic prostate cancer
215018579|NCT06430411|DRUG|Lutetium-PSMA|Administered as part of multimodal treatment for oligometastatic prostate cancer
215018580|NCT06430411|DRUG|Androgen deprivation treatment|Administered as part of multimodal treatment for oligometastatic prostate cancer
215018581|NCT01104870|DRUG|UT-15C|oral
215018582|NCT00741221|DRUG|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
215018583|NCT00741221|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
215018584|NCT05020119|DRUG|Neoantigen-expanded cell therapy.|Infusion of personalized neoantigen-expanded T (CIK) cells
214689789|NCT05882604|DRUG|Arthrocentesis with ringer solution|Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid
214417799|NCT04875858|DRUG|ProDiax-23 (PPSV23)|diabetic old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed) and healthy old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed)
214417800|NCT01887041|PROCEDURE|Stent|Endoscopically inserted biliary tract drainage
214417801|NCT01887041|PROCEDURE|Biliodigestive anastomosis|Biliodigestive anastomosis
214417802|NCT03869918|OTHER|Exercise Program|Exercise at home or through a class as chosen by the subject.
214417803|NCT00518557|PROCEDURE|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
214417804|NCT05252871|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
214417805|NCT01245439|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
214417806|NCT06238154|DRUG|Flurbiprofen|The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen
214417807|NCT02488174|OTHER|PROOFcheck|
215018585|NCT06467058|DEVICE|DABQ questionnaire versus Actigraph as reference method|"In this study, participants will have one contact session with the researcher, which will be held either at Ghent University Hospital or at the participants' home. During this session, participants will be provided with an accelerometer device and two questionnaires (to be filled in after wearing the Actigraph), namely the Daily Activity Behavior Questionnaire (DABQ) and general information questionnaire.~The participants will receive an Actigraph wGT3X+BT accelerometer which will be worn for seven consecutive days. Instructions will be given on how to wear the accelerometer (e.g. during the day at the hip and during the night at the wrist). At the end of this week, the participants will fill in both questionnaires. After wearing the accelerometer for seven consecutive days and filling in both questionnaires, the researcher will visit the participants to collect the devices, or the participants will send them back by postal package."
215018586|NCT02006615|DEVICE|Functional near infrared spectroscopy|Using high-sensitivity infrared to detect the active brain areas
214417808|NCT02488174|OTHER|Standard Care|
214417809|NCT01050569|DRUG|Nicotine Patch|21 mg
214417810|NCT01050569|OTHER|VLNC Cigarette|Cigarette where the tobacco contains \<0.1 mg of nicotine yield.
215018587|NCT02006615|DEVICE|rTMS|To modulate brain cortex
215018588|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk + Lactobacillus plantarum IS-10506|125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
214417811|NCT01050569|OTHER|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing \<0.1 mg nicotine yield.
214417812|NCT05356312|BIOLOGICAL|Vaccination|Personalized neoantigen vaccination
214417813|NCT03673943|DRUG|64Cu-DOTATATE|Detection of somatostatin positive lesions in NET
214417814|NCT03525119|BIOLOGICAL|TDV|TDV SC injection
214417815|NCT03525119|BIOLOGICAL|HAV Vaccine|HAV Vaccine IM injection.
215018589|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk|125 ml UHT milk given to placebo group
214417816|NCT03525119|BIOLOGICAL|TDV Placebo|Placebo-matching (normal saline (0.9% NaCl) SC injection.
214417817|NCT03525119|BIOLOGICAL|HAV Vaccine Placebo|Placebo-matching (normal saline (0.9% NaCl) IM injection.
214417818|NCT01507948|BEHAVIORAL|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
214417819|NCT04249388|OTHER|No Intervention, just observation|No Intervention, just observation
214417820|NCT03178994|DRUG|2% ketoconazole cream|2% ketoconazole cream applies twice daily
215018590|NCT04287556|DIAGNOSTIC_TEST|In vitro contracture test (IVCT)|In vitro study of muscle contraction after exposure to different substances (caffeine and halothane).
215018591|NCT04287556|DIAGNOSTIC_TEST|In vitro test of hypermetabolism in B lymphocytes|In vitro study of the activation of lymphocytes B after being incubated with a cocktail of primary antibodies and measuring the acidification in response to the RyR1, 4-CmC agonist, using ryanodine as a positive control.
215018592|NCT04287556|DIAGNOSTIC_TEST|Genetic test|Analysis of genes related to MH (CACNA1S and RYR1).
215018593|NCT01515254|BEHAVIORAL|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
214417821|NCT03178994|DRUG|Hydrophilic Cream|Hydrophilic cream (in-house preparation) applies twice daily
214417822|NCT01955668|DRUG|Administration of AZD6738|An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
214417823|NCT02795650|DRUG|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
214417824|NCT02795650|DRUG|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
214417825|NCT02425254|DRUG|Intravenous paracetamol|1000mg intravenous solution for infusion
215018594|NCT00404300|DRUG|Optivate|Plasma-derived Factor VIII
214417826|NCT02425254|DRUG|Intravenous saline 0.9%|0.9% sodium chloride in order to ensure double-blinding
214417827|NCT05042193|OTHER|SARS-CoV-2|Observational
214417828|NCT01638949|BEHAVIORAL|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
214417829|NCT01638949|BIOLOGICAL|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
214417830|NCT01638949|GENETIC|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
214417831|NCT01638949|OTHER|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
214417832|NCT01959412|DRUG|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
214417833|NCT01959412|DRUG|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
214417834|NCT01959412|DRUG|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
214417835|NCT01959412|DRUG|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
214417836|NCT01959412|DRUG|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
214417837|NCT01959412|DRUG|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
214417838|NCT01130818|DRUG|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
214417839|NCT01130818|DRUG|placebo|single dose, oral solution
214417840|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), fasting
214417841|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast
214417842|NCT04159636|OTHER|Carbohydrate beverage|The participants in this group are allowed to drink carbohydrate until 2 hours before surgery
214417843|NCT05147389|DIAGNOSTIC_TEST|AI model classification|AIWorks is an artificial intelligence model for real-time cholangioscopic detection of neoplastic and non-neoplastic bile duct lesions. It allows you to choose using a video file or a USB camera input as the detection source. Once the input source has been selected, the software performs real-time detection by surrounding the area of interest (i.e., the area with malignancy features) inside a bounding box. All detections made are displayed on the right side of the screen and can also be reviewed afterwards.
214505735|NCT07042724|BEHAVIORAL|Health educational material|Health educational materials, including the benefits of exercise and nutrition during cancer care, the current recommendations and information on how to pursue them, as well as strategies to achieve and maintain a healthy psychological status
214505736|NCT07043036|DEVICE|GutyCare|Device : GutyCare The participants will use GutyCare remote patient monitoring.
214505737|NCT06577662|BEHAVIORAL|individual and family self-management (IFSM) fall prevention program|"The IFSM program will last for ten weeks, two weeks in the hospital, and follow up at eight weeks after patients discharge to home. It will include 11 sessions, including ten sessions developed in the inpatient department within two weeks and one online booster session developed in the first month (week 4) after discharge in home. There will be also one session just for caregivers.~Session 1 : PRST combined with GRI (one) Session 2 : Environment safety Session 3 : Assistant technology Session 4 : PRST combined with GRI (two) Session 5 : Medication review Session 6 : Safety in daily activities Session 7 : How to keep loved one safety Session 8 : Review of PRST combined with GRI Session 9 : Review of other five fall prevention skills Session 10 : Summary of the program and setting goals Session 11 : Booster session Week 10: Evaluation"
214505738|NCT07099235|DRUG|ketamine hydrochloride|Racemic ketamine is a 50/50 mixture of enantiomers (S)-ketamine and (R)-ketamine. The repeated administration of racemic ketamine intravenously at subanesthetic doses has emerged as an efficacious treatment for treatment-resistant depression.
214505739|NCT07099196|DEVICE|Headset-based Virtual Reality Simulation|The device used was a HEALTHY-MIND© PICO G2 Virtual Reality headset, which is medically graded and suited for distraction and relaxation in clinical settings.
214505740|NCT07099586|OTHER|No Interventions|This is an observational study. No intervention will be administered. Participants will provide blood samples for micronutrient analysis.
215018595|NCT05566054|DRUG|Chidamide|Chidamide 10mg orally daily for 7 days (d1-d7)
215018596|NCT05566054|DRUG|Azacitidine|azacytidine 75mg/m2 daily for 7 days (d1-d7)
215018597|NCT05566054|DRUG|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
215018598|NCT01694186|DRUG|FAI insert|
215018599|NCT01694186|DRUG|Sham injection|
215018600|NCT00501943|DRUG|Avonex (Interferon beta 1a)|
215018601|NCT00501943|DRUG|Riluzole|
215018602|NCT00501943|DRUG|Placebo|
215018603|NCT02134808|DRUG|Creatine|Creatine is a nutritional supplement.
215018604|NCT02134808|DRUG|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
214417844|NCT05147389|DIAGNOSTIC_TEST|DSOC endoscopist experts' classification|"Six endoscopists with high DSOC expertise will observe and classify a set of videos among neoplastic or non-neoplastic bile duct lesions following a Bernoulli distribution; blinded to clinical records and should have never attended said patients.~Gastroenterologists from each center, with non-DSOC responsibility, will select DSOC videos and corresponding baseline data. DSOC videos and data will be gathered in one set. Each video represents a full DSOC for a single patient. The patient will be the unit of this study.~The neoplastic bile duct criteria are in accordance with the Robles-Medranda et al and the Mendoza classifications (ie. Irregular mucosa surface, Tortuous and dilated vascularity, Irregular nodulations, Polyps, Ulceration, Honeycomb pattern, etc.). The experts will assess neoplastic bile duct by presence or absence of disaggregated criteria. Likewise, by Boolean logical operators, the statistical software will compute disaggregated answers."
215018605|NCT06537466|DIETARY_SUPPLEMENT|Mediterranean diet|This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
214417845|NCT04652817|DEVICE|MMI-22-04-2019|A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
214417846|NCT00702806|DRUG|Org 36286|Intra-abdominal injection of Org 36286
214417847|NCT00702806|DRUG|Puregon®|Subcutaneous Puregon® 150 IU
214417848|NCT00702806|DRUG|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
214417849|NCT00702806|DRUG|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
214417850|NCT01081340|BEHAVIORAL|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
214417851|NCT01081340|BEHAVIORAL|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
214417852|NCT00509769|DRUG|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
214417853|NCT05407142|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml."
214417854|NCT05407142|OTHER|The data from volunteers from the control group|Official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.
214417855|NCT04009356|PROCEDURE|bariatric surgical procedures|gastric bypass, sleeve, banding,biliopancreatic diversion
214417856|NCT04364269|DRUG|VIT-2763 once a day (QD)|Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
214417857|NCT04364269|DRUG|VIT-2763 twice a day (BID)|Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
214417858|NCT04364269|DRUG|Placebo|Participants will receive hard capsules of Placebo, twice a day.
214417859|NCT02466048|PROCEDURE|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
214417860|NCT02466048|DEVICE|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
214417861|NCT04480593|DRUG|Brazilian Green Propolis Extract (EPP-AF)|Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.
214417862|NCT04480593|OTHER|Standard care|Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).
214417863|NCT00383188|DRUG|placebo|Capsule, once daily (QD) for 12 weeks
214505741|NCT07098325|DEVICE|retainer with .5 mm thickness|direct 3d printed retainer with .5 mm thickness
214417864|NCT00383188|DRUG|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
214505742|NCT07098325|DEVICE|retainer with 1 mm thickness|direct 3d printed retainer with 1 mm thickness,
215018606|NCT06537466|DIETARY_SUPPLEMENT|Very Low Ketogenic Diet|The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
214417865|NCT00383188|DRUG|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
214417866|NCT00383188|DRUG|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
215018607|NCT04052126|OTHER|Individualized physical activity program|"Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment."
215018608|NCT06429085|DEVICE|Rex robotic assisted balance exercises|Individual is supported by a Rex robotic exoskeleton which enables assisted and supervised practise of balance exercises. This intervention took place as a supported and supervised series of 5 sessions over 5 weeks as an Out-patient.
215018609|NCT02317042|DEVICE|Juno|Juno device set to ST mode with participant's current therapy settings.
215018610|NCT02317042|DEVICE|Juno|Juno device set to AutoEPAP iVAPS mode.
214417867|NCT00383188|DRUG|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
214417868|NCT03773861|OTHER|errors made in one BLS session|BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
214417869|NCT01662180|DRUG|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
214417870|NCT03660917|DRUG|Riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
214417871|NCT03660917|DRUG|Placebo|Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
214417872|NCT06351787|BEHAVIORAL|Resting and movement-based focused awareness meditations|Resting and movement-based focused awareness meditations
214417873|NCT06511817|OTHER|No intervention will be performed|No intervention will be performed
214417874|NCT03501173|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
214417875|NCT00319566|DRUG|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
214417876|NCT05161403|DRUG|Hyaluronic acid|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
214417877|NCT05161403|DIETARY_SUPPLEMENT|honey|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~Use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
214417878|NCT05649098|DRUG|Dupilumab|The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
214417879|NCT01093534|DRUG|Placebo|Matching solifenacin placebo tablet
214417880|NCT01093534|DRUG|solifenacin|Tablet for oral administration
214417881|NCT01792648|OTHER|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
214417882|NCT01792648|OTHER|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
214417883|NCT01792648|OTHER|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
214417884|NCT00281918|DRUG|Rituximab|Intravenous repeating dose
214417885|NCT00281918|DRUG|Cyclophosphamide|Intravenous repeating dose
214417886|NCT00281918|DRUG|Fludarabine Phosphate|Intravenous repeating dose
214417887|NCT01137903|PROCEDURE|Conservative surgery|Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy
214417888|NCT01137903|DRUG|Ciprofloxacin|500 mg/ 12 hours during 90 days
214417889|NCT01137903|DRUG|Amoxicillin-Potassium Clavulanate Combination|875/125 mg/12 hours during 90 days
215018611|NCT02317042|DEVICE|Juno|Juno device set to Fixed EPAP iVAPS mode.
215018612|NCT03093246|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
215018613|NCT03093246|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
214417890|NCT01137903|DRUG|Sulfamethoxazole trimethoprim|Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
214417891|NCT05620303|OTHER|Exercise|Parents/guardians will receive three different contents weekly (i.e., infographics, video recipes, information pills, or videos) each week related to 24-h movement behaviors (i.e., PA, sedentary behavior, sleep duration) or Mediterranean Diet for 36 weeks.
214417892|NCT04026620|BEHAVIORAL|Informational Pamphlet|The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.
214417893|NCT04026620|BEHAVIORAL|Brief Motivational Enhancement Therapy (MET) Session|The case control trial/efficacy study will provide a one-session MET session in Afrikaans (the predominant language of the region). The face-to-face session will provide information to help people and pregnant women who want to change their drinking behavior, become 'dry' and stay motivated to change their drinking behaviors. Sessions will be approximately one (1) hour and 30 minutes.
214417894|NCT04511806|OTHER|Registry|This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
214417895|NCT06628635|BEHAVIORAL|Exercise|Exercise involving aerobics, isometrics, and stretching
215018614|NCT03093246|OTHER|Placebo|Placebo pills over a period of 180 days
215018615|NCT03093246|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
215018616|NCT05118438|OTHER|Health Promotion Nursing Intervention|A one-on-one program was conducted over six sessions, with each session ranging from 60 to 120 minutes. The caring program for health promotion included the following concepts: understanding the self; sharing traumatic events and negative emotions; re-framing the meaning of traumatic events; identifying thoughts and physical and emotional responses; developing health-promoting activities; and maintaining a positive attitude during the process of change .
214417896|NCT06628635|BEHAVIORAL|Resting|Resting
214417897|NCT06365554|DEVICE|Remedy Robot|A trained Neurointerventionalist will operate the Remedy Robot from a computer-based user interface in a room adjacent to the patient. An entire cerebral angiogram or cerebral embolization will be performed, excluding insertion and removal of the femoral sheath.
214417898|NCT03118752|BEHAVIORAL|Collaborative Care|The CC intervention will use a novel three-pronged approach to these high-risk patients. Care managers will provide centralized care coordination and specific interventions targeting: (1) the psychiatric disorders, (2) cardiac health behaviors, and (3) the cardiac illness.
214417899|NCT03770624|DRUG|QL-007 tablet|QL-007 will be administered orally daily over the 28 days under fasted state.
215018617|NCT03644446|BIOLOGICAL|Bisoprolol plasma residual concentration dosage|Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance \< 30mL/min, mild altered between 30-60mL/min, normal \> 60mL/min as estimated by the CKD-EPI formula)
215018618|NCT00043680|DRUG|Celecoxib|
215018619|NCT05338450|DRUG|Clemastine Fumarate|4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)
215018620|NCT05338450|DRUG|Placebo|Placebo equivalent to experimental arm
214417900|NCT03770624|DRUG|TDF|TDF will be administered orally daily over the 28 days e.
214417901|NCT06081855|DIAGNOSTIC_TEST|CT|Measuring aortic root diameter by CT
214417902|NCT05448755|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
214417903|NCT04173962|DRUG|Ketamine|administered 1 week prior to a laboratory-induced stress
214417904|NCT04173962|DRUG|Midazolam|administered 1 week prior to a laboratory-induced stress
215018621|NCT00005898|DRUG|anti-thymocyte globulin|
215018622|NCT00005898|DRUG|cyclophosphamide|
215018623|NCT00005898|DRUG|cyclosporine|
214417905|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.~No PK samples will be collected in this cohort."
214417906|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized."
215018624|NCT00005898|DRUG|filgrastim|
215018625|NCT00005898|DRUG|fludarabine|
215018626|NCT00005898|DRUG|methylprednisolone|
215018627|NCT06548620|DRUG|RD06-04 cell infusion|CAR T Cells
215018628|NCT06548295|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|"Restraint the involved extremity by using a mitten. Repetitive task practice i.e filling a glass, drinking a glass of water, and eating with a spoon , stacking cones and stacking blocks, grasping and releasing of an object, reaching forward and sideways, lifting and dropping of an object from the one end of table to the other end.~The shaping exercises included cube stacking, card turning, throwing balls into a box, grasping/holding and placing objects of different sizes, and drawing and painting exercises. Intervention: 5 sessions per week for 50 minutes for 6 weeks"
215018629|NCT06548295|COMBINATION_PRODUCT|conservative treatment|"The conservative rehabilitation program consisted of upper-limb range of motion exercises, positioning, stretching, and strengthening exercises, Passive mobilization of the shoulder ,elbow , wrist and small joints of hand Stretching of the affected arm including biceps, triceps and muscles of forearm and hand.~Strengthening exercises of upper arm and forearm muscles involved. Intervention: 5 sessions per week for six weeks and 50 mintues"
215018630|NCT01008046|DRUG|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
215018631|NCT01008046|DRUG|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
214417907|NCT04699669|DRUG|CBL-514|Both sides of the abdominal region will receive CBL-514.
214417908|NCT00345852|PROCEDURE|Fetoscopic Selective Laser Photocoagulation|
214417909|NCT03265873|OTHER|Systematic consideration of the advice of the ENT surgeon in the determination of the radiotherapy target volumes in head and neck cancers.|The contouring of the different target volumes will be first performed by the radiotherapists. During the Head and Neck Tumor Board, the volumes initially determined by the radiotherapists will be analyzed jointly by the radiotherapists and the patient's ENT surgeon to carry out, if necessary, modifications, taking into account clinical observations, intraoperative findings (if any) and endoscopy findings. Concordance parameters will be calculated in a second time with the determined volumes (in particular, index of concordance, coefficient of similarity).
214417910|NCT02987335|DRUG|Pancreatic Clamp|We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
214417911|NCT03842150|DIAGNOSTIC_TEST|biliary atresia screen score|The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.
214417912|NCT00684970|DRUG|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
214417913|NCT02759029|DRUG|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
214417914|NCT00431509|PROCEDURE|conventional vs. navigated total knee arthroplasty|
214417915|NCT01670110|DRUG|Pasireotide LAR|Injectible, 60mg per month
214417916|NCT01670110|DRUG|Placebo|To be injected once per month
215018632|NCT00079781|PROCEDURE|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
215018633|NCT00079781|DEVICE|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
215018634|NCT03386058|DEVICE|Temporary device deactivation|Patient-controlled, temporary deactivation of implanted device
215018635|NCT04641975|DRUG|Mirabegron|Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight \< 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
214417917|NCT02555631|BEHAVIORAL|lifestyle|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
214417918|NCT03418324|DRUG|TRC105|Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks
214417919|NCT03418324|DRUG|Abiraterone|Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.
214417920|NCT03418324|DRUG|Enzalutamide|Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
214417921|NCT01768676|DRUG|avanafil|100 mg
214417922|NCT01768676|DRUG|Placebo|
215018636|NCT04641975|DRUG|Placebo|Oral/ Oral Suspension
215018637|NCT02307435|BIOLOGICAL|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
215018638|NCT00124033|PROCEDURE|Transcystic Stenting (Facilitated ERCP)|
215018639|NCT01431573|BEHAVIORAL|Wake Therapy|Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.
215018640|NCT01431573|DEVICE|light box|use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire
214417923|NCT04248829|DRUG|Lazertinib 240 mg/160 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
215018641|NCT01431573|DRUG|Lithium|For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
214417924|NCT04248829|DRUG|Gefitinib 250 mg|The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
215018642|NCT04365881|OTHER|Cross-sectional observational study|Survey
215018643|NCT03543020|RADIATION|radiation therapy to brain|OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
214417925|NCT04248829|DRUG|Lazertinib-matching placebo 240 mg/160 mg|The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
215018644|NCT02631031|DRUG|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
215018645|NCT04693715|DRUG|RNS60|RNS60 injection solution
215018646|NCT04693715|DRUG|Placebo|Placebo injection solution
214417926|NCT04248829|DRUG|Gefitinib-matching placebo 250 mg|The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
214417927|NCT05799560|OTHER|THERAPEUTIC TOUCH|Therapeutic touch will be done. It will be applied twice a week for two weeks, each application for 20 minutes.
214417928|NCT05799560|OTHER|REİKİ|It will be applied twice a week for two weeks, each application for 20 minutes.
214417929|NCT02685033|DRUG|Dalbavancin|
214417930|NCT02685033|DRUG|Comparator|
214417931|NCT05722951|DRUG|Levetiracetam &/or sodium valproate|levetiracetam \&/or sodium valproate will be given to 30 patients and monitored for 6 months
214417932|NCT05722951|DRUG|Metformin|metformin + (levetiracetam \&/or sodium valproate) will be given to 30 patients and monitored for 6 months will be given to 30 patients and monitored for 6 months
214417933|NCT03824899|DIAGNOSTIC_TEST|Blood concentration check|Blood concentration check：the plasma concentration of SN-38 was detected by HPLC (high-performance liquid chromatography) at 1.5 h and 49.0 h after CPT-11 infusion
215018647|NCT03015779|OTHER|cultured autologous oral mucosal epithelial cell sheet|a prospective study,Before and after self control
215018648|NCT05900349|OTHER|Carbohydrate mouth rinsing|the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted to a 6.4% maltodextrin solution for the participants to rinse their mouths for 20 seconds
215018649|NCT05900349|OTHER|200 mg caffeine gum|Chewing caffeinated gum for 20 minutes
215018650|NCT05489458|PROCEDURE|Resection|Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.
215018651|NCT05489458|PROCEDURE|No Resection|Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.
215018652|NCT03477591|OTHER|Evidence-based information|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
215018653|NCT03477591|OTHER|Patient Decision Aid|Patient Decision Aid for prostate cancer screening decision
215018654|NCT03477591|OTHER|Sham information|Educational information not specific to PSA testing or cancer screening
215018655|NCT00087672|DRUG|CC-5013|10 mg orally (2 capsules) daily
215018656|NCT04993768|DRUG|TPN-101, 100 mg/day|100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
215018657|NCT04993768|DRUG|TPN-101, 200 mg/day|200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
215018658|NCT04993768|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
215018659|NCT04993768|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
214417934|NCT06214221|DEVICE|Signos System|The intervention involves the use of the Signos System, a combination of a proprietary software application with a continuous glucose monitor (CGM), to manage weight in overweight and obese adults.
214417935|NCT06214221|OTHER|Standard Lifestyle Education|"In the Standard Lifestyle Education arm, participants receive conventional advice on diet and exercise, focusing on general healthy lifestyle habits to manage weight."
214417936|NCT04774224|DRUG|Baricitinib|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
214417937|NCT04774224|DRUG|Placebo|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
214417938|NCT06614010|DRUG|Dexmedetomidine Injection|Before anesthesia induction, an iliac fascia block was administered using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, dexmedetomidine was infused intravenously at a rate of 0.5 µg/kg/h.
214417939|NCT06614010|DRUG|Ropivacaine and Dexmedetomidine|Before anesthesia induction, an iliac fascia block was administered using a mixture of 0.375% ropivacaine and 1ug/kg dexmedetomidine (30ml) under ultrasound guidance. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
214417940|NCT06614010|DRUG|Sodium Chloride Injection|Before anesthesia induction, an iliac fascia block was performed using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
214417941|NCT06711497|OTHER|global postural reeducation exercises|Subjects will be trained on global postural reeducation exercises (GPR) and active neck exercises. At each session, they will maintain two different lying postures to stretch anterior and posterior muscle chain and one standing posture to integrate the postural correction into activity of daily living (ADL.Initially, without gravity load, a lying posture was applied to the anterior muscle chain for approximately 15 min, then another lying posture to the posterior muscle chain for other 15 min, and finally the patients worked in a standing posture for postural integration under a gravity load for 5 min.
214417942|NCT06711497|OTHER|deep neck flexor activation exercise|"Subjects will be trained on deep neck flexor activation using pressure biofeedback and active neck exercises . The pressure sensor will be put under the neck and will be asked to de gentle nod as if saying yes so that the pressure sensor measures 2mmHg above baseline (20mmHg), then 4mmHg, followed by 6mmHg,8mmHg, and 10 mmHg without rests in between. the pressure sensor should read 30mmHg at the end of the movement sequence. Patient will hold each increment for 2 seconds, 10 seconds total after all 5 increments. Highest level achieved will be repeated with the correct form until a total of 10 reps with 10-second holds will be achieved in three series with 30 seconds of interval between the series plus active neck flexor exercise"
214417943|NCT04893421|DEVICE|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
214417944|NCT06009419|OTHER|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.
214417945|NCT01066923|DRUG|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
215018660|NCT03748472|PROCEDURE|Continuous gavage feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
215018661|NCT03748472|PROCEDURE|Bolus feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
214417946|NCT01066923|OTHER|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
214417947|NCT01066923|DRUG|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
214417948|NCT01066923|OTHER|Passive cooling|Removing protective garments for passive cooling following exercise
214417949|NCT01066923|DRUG|Daily placebo|Placebo comparator for daily aspirin therapy
214417950|NCT01066923|DRUG|Acute placebo|Placebo comparator for acute aspirin therapy
215018662|NCT04645030|DIAGNOSTIC_TEST|Ultra low-dose computer thermography|The ULD-CT scan will be executed according to a standardized predeveloped technical protocol. The technical protocol will differentiate between patients with BMI \<25 and \>25 to insure optimal ULD-CT image quality.
215018663|NCT04645030|DIAGNOSTIC_TEST|lung ultrasound|"LUS will be performed by trained researchers. Before inclusion researchers preforming LUS scans, will undergo a training program and will complete 25 supervised LUS scans to be certified in LUS. At the end of the training program, researchers will be tested to insure proficiency in LUS.~LUS will be performed according to LUS protocol with seven scanning's zones on each side; 2 anterior, 2 lateral and 3 posterior."
214417951|NCT06478992|PROCEDURE|A:hysteroscopic suture fixation of Mirena|A(the thickness of the thickest uterine myometrium ≥30mm ):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
214417952|NCT06478992|PROCEDURE|A: simple Mirena placement under hysteroscopy|A(the thickness of the thickest uterine myometrium ≥30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
214417953|NCT06478992|PROCEDURE|B: hysteroscopic suture fixation of Mirena|B(the thickness of the thickest uterine myometrium\<30mm):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
215018664|NCT00968045|DRUG|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
214417954|NCT06478992|PROCEDURE|B：simple Mirena placement under hysteroscopy|B(the thickness of the thickest uterine myometrium\<30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
214417955|NCT02312336|OTHER|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
214417956|NCT02312336|OTHER|Cohort B - Cooled coronary perfusate|"Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees."
214417957|NCT05819450|PROCEDURE|Volumetric rejuvenation|Volumetric Rejuvenation with FDA-approved fillers on the skin of the dorsal hands
214417958|NCT00003880|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
214417959|NCT00003880|DRUG|carboplatin|
214417960|NCT00003880|DRUG|paclitaxel|
214417961|NCT05571436|BEHAVIORAL|iCan Diabetes Self-management and Prevention Support Group|"Participants will be asked to attend six weekly sessions and complete pre-and post-assessments with an optional focus group.~The intervention will cover the following topics: 1) Yes, iCan! - Affirmations and Empowerment, 2) The Language of Diabetes - Diabetes Synopsis, 3) Diabetes and Me - Management Strategies, 4) Extraordinary Health - Dream Team, 5) Food for Thought - Food Conscious, and 6) Discussion - Stories/Goals.~Each session is composed of a Check-in, Affirmation/Empowerment Activity, Short Presentation, Q\&A and Discussion, Goal setting, and Testing Healthy Snacks."
214417962|NCT01748318|DRUG|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
214417963|NCT01748318|DRUG|Bactrim DS|Bactrim DS
214417964|NCT00666094|BEHAVIORAL|Endurance training|supervised endurance training. Three sessions per week in three months.
214417965|NCT00666094|BEHAVIORAL|strength training|Supervised strength training. Three sessions per week in three months.
214417966|NCT04722094|DIAGNOSTIC_TEST|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
214417967|NCT04722094|OTHER|Saliva sampling|Saliva samples for miRNAs detection will be taken before starting the visit.
214417968|NCT06211907|DEVICE|Postoperative intraocular tamponade|Flushing the eye cavity with a tamponade at the end of surgery
214417969|NCT04895007|BIOLOGICAL|Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine|Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.
214417970|NCT00218556|BEHAVIORAL|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
214417971|NCT01546155|RADIATION|PET imaging|Up to a 120 minute PET scan using \[11C\]diprenorphine as the radiotracer
214417972|NCT00752817|OTHER|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
214417973|NCT00752817|OTHER|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
214417974|NCT01182116|PROCEDURE|J Pouch|Comparing J pouch, side to end coloanal surgery
214417975|NCT02899000|DRUG|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
214417976|NCT02899000|DRUG|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
214417977|NCT04275193|DRUG|Zishenqing|Zishenqing Granule
214417978|NCT04275193|DRUG|Placebo|Granule manufactured to mimic Zishenqing(containing 10% composition)
214417979|NCT03712306|OTHER|Dietary advice|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d
214417980|NCT03712306|OTHER|Dietary advice and advice on timing|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d plus advice on consuming protein in close proximity of usual physical activity
214417981|NCT03407131|PROCEDURE|Joint replacement surgery|Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.
214417982|NCT03407131|PROCEDURE|Intramedullary nail fixation|Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
214417983|NCT05518201|BIOLOGICAL|Placebo among 18-45 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
215018665|NCT05398666|DEVICE|White LED light|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
215018666|NCT05398666|DEVICE|Green LED light|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
215018667|NCT02067156|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
214417984|NCT05518201|BIOLOGICAL|Placebo among 9-17 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
215018668|NCT02520362|DRUG|denosumab|subcutaneous injection
215018669|NCT02520362|DRUG|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate \[Fosamax®\], risedronate \[Actonel®\], ibandronate \[Boniva®/Bonviva®\] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate \[Reclast®/Aclasta®\].
214417985|NCT04182087|BEHAVIORAL|Cognitive tasks|Attention, language, memory, decision-making or executive functions
215018670|NCT06639815|OTHER|clinical and radiographic examination|clinical and radiographic examination
215018671|NCT06566365|OTHER|Subcostal Transversus Abdominis Plane Block|After ensuring airway safety under general anesthesia, a bilateral Transversus Abdominis Plane Block using 20 cc of 0.25% bupivacaine with a subcostal approach under ultrasound guidance will be administered
215018672|NCT06581692|OTHER|This is a routine procedure, no intervention will be provided.|This is a routine procedure, no intervention will be provided.
215018673|NCT03596983|BEHAVIORAL|Sleep Intervention|"* Sleep Diaries (Daily)~* Fitbit 24/7~* Phone/ video conference calls (weekly with study team)~* Epworth Sleepiness Scale (weekly)~* PROMIS fatigue scale-evening (weekly)"
214417986|NCT02469467|DIETARY_SUPPLEMENT|VS-505|VS-505 is orally administered with meal for 8 weeks
214417987|NCT03042520|OTHER|Observation only|
215018674|NCT03596983|BEHAVIORAL|Week 2 Intervention|"* Sleep Diaries (Daily)~* Phone Calls (weekly with study team)~* Wrist Accelerometry and fitbit 24/7 for 14 days~* SAFTEE Questionnaire~* ASA24~* Behavioral risk factor surveillance system (smoking and alcohol use questions)~* Psychological well-being (SF36)~* Index of Self Regulation~* PROMIS fatigue scale-morning (weekly)~* PROMIS fatigue scale-evening (weekly)~* Epworth Sleepiness Scale (weekly)"
214417988|NCT00917358|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
215018675|NCT03381651|RADIATION|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
214417989|NCT04815057|BEHAVIORAL|Wellness Education|The wellness education given to fifth grade students and the quality of life, its effect on physical activity status
214417990|NCT06392451|DIAGNOSTIC_TEST|LIAISON NES FLU A/B, RSV, & COVID-19|The LIAISON® NES FLU A/B, RSV \& COVID-19 real-time (RT) PCR assay is a Point of Care (POC) system that enables the extraction, amplification, detection and differentiation of influenza A, Influenza B, respiratory syncytial virus (RSV) and SARS-CoV-2 viral RNA from dry nasal swabs (NS). The system consists of the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, the LIAISON® NES system (with LIAISON® NES Software), and associated accessories. In the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, extraction reagents and lyophilized fluorescent probes are used together with corresponding forward and reverse primers to extract and amplify influenza A, influenza B, RSV, SARS-CoV-2 and internal control RNA targets.
214417991|NCT06392451|DIAGNOSTIC_TEST|LIAISON PLEX Respiratory Flex Assay|"The LIAISON PLEX® (also known as VERIGENE® II) RSP Flex Assay is an automated test for the detection and identification of common viruses and bacteria, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, from upper respiratory specimens. The VERIGENE® II Respiratory Flex (RSP Flex) Assay is performed on the VERIGENE® II System. The VERIGENE® II System is an automated platform that performs sample preparation and is capable of polymerase chain reaction (PCR) for the detection of target-specific nucleic acids. The VERIGENE® II System is a fully automated, bench-top sample-to-answer device. The test reagents are supplied in a single, disposable test cartridge."
214417992|NCT00771667|DRUG|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
215018676|NCT03381651|RADIATION|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
214417993|NCT00771667|DRUG|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
214417994|NCT00771667|DRUG|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
214505743|NCT07098065|BEHAVIORAL|Graphical health warnings|This group will receive only graphical health warnings (GHWs) featuring images proposed by the Bangladesh Tobacco Control Cell, explicitly illustrating smoking-related harms, such as mouth diseases, damaged teeth and gums, lung diseases and cancer, heart diseases and cardiovascular damage, and throat and oral cancer. Additionally, these warnings will clearly highlight the benefits of quitting smoking-including improved overall health, reduced disease risks, financial savings, and enhanced quality of life-as well as practical cessation techniques. Participants will receive these GHW materials at baseline and again at the six-month follow-up to reinforce these critical health messages; however, this intervention group will not receive any counselling services. Monthly SMS reminders will also be sent to participants, prompting them to review the GHW leaflet and reinforcing the negative health impacts of smoking and the benefits of quitting.
214505744|NCT07098065|BEHAVIORAL|Graphical health warnings plus pharmacist-led counselling|Participants in this group will receive graphical health warnings (GHWs) featuring Bangladesh Tobacco Control Cell-approved images clearly depicting smoking-related harms (e.g., mouth diseases, damaged teeth and gums, lung cancer, heart disease, and oral cancer). Additionally, they will receive personalized counselling from community pharmacists, focused on the specific health and financial benefits of quitting, practical cessation techniques, strategies for overcoming barriers, and relapse prevention. This combined intervention will be provided at baseline and reinforced at a six-month follow-up. Monthly SMS reminders will also be sent, reinforcing key messages on the harmful effects of smoking and benefits of cessation.
215018677|NCT02663570|DRUG|Melatonin|
214417995|NCT00771667|DRUG|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
214417996|NCT00771667|DRUG|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
214417997|NCT00771667|DRUG|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
214417998|NCT00771667|DRUG|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
214417999|NCT00771667|DRUG|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
214418000|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
214418001|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
214418002|NCT00109967|BIOLOGICAL|rituximab|375 mg/m\^2 Given IV
215018678|NCT03024671|OTHER|Patch test application|test patch with cosmetic product will be applied to the back
215018679|NCT06043765|DEVICE|real repetitive transcranial magnetic stimulation (rTMS)|real rTMS -- 3 sessions a week/7 weeks (21 sessions)
215018680|NCT06043765|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|sham rTMS - 3 sessions a week/7 weeks (21 sessions)
215018681|NCT06043765|BEHAVIORAL|cognitive strategy training|7 weekly sessions with a trained neuropsychologist.
215102113|NCT01993563|OTHER|Graded Motor Imagery|"GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).~IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.~EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.~MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror."
214418003|NCT00109967|DRUG|temsirolimus|25 mg given IV
214418004|NCT04313543|DIETARY_SUPPLEMENT|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes. Then, they take 50g of longan syrup in 250 ml of water in 5 minutes
214418005|NCT05745376|BEHAVIORAL|Farm to ECE programming|Students and parents at this center will receive program elements described in arm descriptions.
214418006|NCT06133452|PROCEDURE|skin reducing mastectomy|"The goal of mastectomy skin reducing is to create a breast reconstruction that appears natural and aesthetically harmonious by minimizing excess skin. Excess skin can be removed in two main ways: as a conventional ellipse around the nipple-areola complex or, preferably, as part of an inverted T-shaped incision, commonly used in reduction mammoplasty. This procedure adheres to oncological principles of skin-conserving mastectomy and also incorporates a lower dermal flap, used to create a dermo-muscular pocket that reinforces the coverage of the prosthetic implant.~This technique allows complete detachment of the pectoral muscle at the bottom while ensuring full coverage of the prosthetic implant with a dermo-muscular layer. By increasing the implant pocket and providing an additional tissue layer at the bottom of the breast, this technique can reduce the risk of complications and improve aesthetic outcomes."
214418007|NCT02076919|DRUG|LHA510 Ophthalmic Suspension|Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
214418008|NCT02076919|DRUG|LHA510 Vehicle|Inactive ingredients used for masking purposes
214505745|NCT07098065|OTHER|Routine pharmacy services (no intervention)|Participants in this group will receive only routine pharmacy services based on standard pharmacy practice guidelines applicable in each country. They will not receive any additional graphical health warnings or counselling interventions. Outcomes will be assessed at baseline, 6 months, and 12 months, consistent with the intervention groups.
214505746|NCT07099937|OTHER|Observational cross-sectional study with no intervention.|"This study does not involve any intervention. It is a cross-sectional observational study. The term intervention here refers to laboratory investigations and clinical assessments conducted as part of data collection only."
214505747|NCT03938792|DRUG|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
215018682|NCT05287685|BEHAVIORAL|Screen media adapted School Readiness Parenting Program|For the screen time adapted parenting intervention, screen time intervention components will be infused into the SRPP (described below) to address three primary areas shown in research to play an important role in healthy screen media use: (1) reducing and managing screen time use; (2) maximizing benefits of screen time content; and (3) promoting positive parent-child interactions during co-use of screen media. Psychoeducation and practice of these strategies will be incorporated into sessions of the SRPP in which relevant behavioral concepts are addressed.The screen time adapted parenting intervention will utilize the same format (large group, 8 weekly 1.5 hour sessions) as the SRPP.
215102114|NCT01993563|OTHER|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
215102115|NCT05893472|COMBINATION_PRODUCT|combination of venetoclax and HAA regimen|Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
214418009|NCT00105820|PROCEDURE|System level depression care quality improvement|
214418010|NCT00169780|RADIATION|High definition helical CT (64 head scanner)|"Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs."
214418011|NCT02590042|BIOLOGICAL|ADSC-SVF-002|"ADSC-SVF with the following identity:~Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10\^6 cells/g of liposuctioned (hydrated fat)"
214418012|NCT00628862|DRUG|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
214418013|NCT00628862|DRUG|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
214418014|NCT00628862|DRUG|Turbuhaler® placebo|placebo inhaled twice daily
214418015|NCT01063036|DRUG|Entecavir|Tablets, Oral, 1 mg, once daily, 96 weeks
214418016|NCT01063036|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily, 96 weeks
214418017|NCT05295134|DIETARY_SUPPLEMENT|Placebo|Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
214418018|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (225,000 FIP lipase units per day)|Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
214418019|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (450,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
215018683|NCT05287685|BEHAVIORAL|School Readiness Parenting Program|The SRPP is an 8-week parenting program for parents of preschool aged children with externalizing behavior problems. The SRPP targets child externalizing behavior problems specifically, as well as to help parents promote children's school readiness skills. The SRPP follows a group Parent-Child Interaction Therapy (PCIT) model and also uses motivational interviewing and modelling problem solving approaches. The SRPP utilizes a large group format (10-15 parents) with weekly sessions lasting 1.5 hours. The SRPP curriculum contains traditional aspects of behavioral management strategies (e.g., improving parenting skills and the parent-child relationship; discipline strategies such as time out). Specific sessions of the SRPP also directly target parental interactions during children's learning activities and setting up homework and household structure and routines. In its original form, SRPP does not address children's screen time.
215018684|NCT00920270|DRUG|nebulized colistin|nebulized colistin 75 mg every 12 hours
215018685|NCT00920270|DRUG|antibiotics|conventional parenteral antibiotics
215018686|NCT04541693|DEVICE|Full revision|Both cup and stem require revision
215018687|NCT04541693|DEVICE|Cup revision|Only the cup requires revision
214418020|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (675,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
214418021|NCT01819493|BEHAVIORAL|Lifestyle Intervention|Family-based group lifestyle intervention
214418022|NCT01819493|BEHAVIORAL|Standard Family-Based intervention|Comparison intervention
214505748|NCT04014387|DRUG|Suvorexant|Suvorexant (Belsomra) is an FDA approved, dual orexin receptor antagonist. It is prescribed for insomnia, reducing time to sleep onset, and to maintain nighttime sleep.
215018688|NCT04541693|DEVICE|Stem revision|Only the stem requires revision
215018689|NCT01345942|DRUG|RO5428029|Single oral dose
215102116|NCT01331291|DRUG|bosutinib|Taken orally
215102117|NCT01026220|BIOLOGICAL|bleomycin sulfate|Given IV or SC
214418023|NCT04779892|DRUG|Infliximab|100mg/vial
214418024|NCT00740415|BIOLOGICAL|rituximab|Rituximab, 375 mg/m2 Intraveinous
214418025|NCT00740415|DRUG|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
214418026|NCT00740415|DRUG|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
214418027|NCT00740415|DRUG|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
214418028|NCT02092077|DRUG|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
214418029|NCT02092077|DRUG|somatropin|Dose may be adjusted as required
214418030|NCT05860140|OTHER|Education video|Six minutes long education video focusing on protein and energy meals
214418031|NCT06422650|DRUG|Nigella Sativa capsule 500mg|Nigella Sativa capsule 500mg twice daily for 8 weeks
215102118|NCT01026220|DRUG|doxorubicin hydrochloride|Given IV
215102119|NCT01026220|DRUG|liposomal vincristine sulfate|Given IV
215102120|NCT01026220|DRUG|vinorelbine tartrate|Given IV
215102121|NCT01026220|DRUG|cyclophosphamide|Given IV
215102122|NCT01026220|DRUG|etoposide phosphate|Given IV
215102123|NCT01026220|DRUG|prednisone|Given IV
215102124|NCT01026220|BIOLOGICAL|filgrastim|Given IV or SC
215102125|NCT01026220|DRUG|ifosfamide|Given IV
215102126|NCT05547789|DRUG|non steroidal anti inflammatory drugs|effect of non steroidal anti inflammatory drugs on macular changes
215102127|NCT04170829|BIOLOGICAL|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
215102128|NCT05930236|DIAGNOSTIC_TEST|Lumbar medial branch block|The lumbar medial branch block on three lumbar levels (L3-L4, L4-L5 and L5-S1) will be performed by ultrasound-guidance in a longitudinal plane and the correct placement of the needle will be verified by radiography to show if the two modalities are equivalent.
215102129|NCT05930236|DRUG|Lidocain|Linisol infiltration with depomedrol and omnipaque
215102130|NCT05930236|DRUG|Methylprednisolone|infiltration with linisol and omnipaque
215102131|NCT05930236|DRUG|Omnipaque|infiltration with linisol and methylprednisolone
215102132|NCT04684992|DEVICE|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
214418032|NCT06422650|DRUG|Placebo|Oral placebo identical to astaxanthin
214418033|NCT05344014|PROCEDURE|Photobiomodulation|In experimental groups, before topical anesthesia, PBMT was applied by utilizing a diode laser (EpiX; Biolase technology, inc., USA) with a continuous wavelength of 940 nm on a 400-μm fiber with only biostimulation properties. In accordance with the recommendations of the device's manufacturer, it was applied using circular motions in a manner as slowly as possible (an average of 33-36 circular movements in 60 s)
214418034|NCT05344014|PROCEDURE|Placebo|In the control group (placebo), the laser probe was directed to the mucosa for (buccal and palatal area), but not activated, and the sound of the laser device previously recorded on the mobile telephone was played for the same time of experimental group in order to provide similar conditions
214418035|NCT04797416|DEVICE|FGM infiltration 1 hour group|The sensor is activated immediately after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
214418036|NCT04797416|DEVICE|FGM infiltration 6-hour group|Reactivate the sensor 5 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
214418037|NCT04797416|DEVICE|FGM infiltration 12-hour group|Reactivate the sensor 11 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
214418038|NCT05948358|OTHER|Menstrual Distress Questionnaire|The Menstrual Distress Questionnaire (MEDI-Q) is a new tool originally developed in Italian that comprehensively evaluates menstrual-related distress.
214418039|NCT01013441|BIOLOGICAL|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
214418040|NCT00565110|BEHAVIORAL|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
214418041|NCT00432588|DRUG|misoprostol|
214418042|NCT00432588|DRUG|dinoprostone|
214418043|NCT00703911|DRUG|eptacog alfa (activated)|Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
214689790|NCT06600165|PROCEDURE|Ex vivo confocal microscopy|The aim is to use AI to assist surgeons in analyzing CLSM tissue slide images obtained during BCC surgeries with the aim to integrate it in real time. We plan to use AI to analyze CLSM images of BCCs and distinguish between tumor tissue, inflammatory tissue, and non-tumor/non-inflammatory tissue. This approach would provide surgeons with real-time feedback and automated image analysis, leading to a more targeted and efficient approach to tissue analysis. By improving the accuracy and speed of tissue analysis, our proposal could ultimately improve operative patient outcomes and benefit healthcare professionals.
214418044|NCT00257348|DRUG|Capecitabine|
214418045|NCT00257348|DRUG|Docetaxel|
214418046|NCT06360744|BIOLOGICAL|Johnson & Johnson|Vaccination with the Johnson \& Johnson vaccine which is NOT part of the Danish National Government programme
214418047|NCT05712941|DRUG|Lerociclib|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice a day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
214418048|NCT05712941|DRUG|Letrozole 2.5mg|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
214418049|NCT05712941|DRUG|Placebo|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
214418050|NCT00596310|OTHER|CT|Screening CT
214418051|NCT05495477|DEVICE|EIT|Evaluation of ventilation distrinution during deep sedation through EIT
214689791|NCT02773914|OTHER|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessment intervention
215102133|NCT02257203|BEHAVIORAL|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
215102134|NCT02257203|BEHAVIORAL|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
214418052|NCT05287282|OTHER|TECAR application|Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
214418053|NCT01551056|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
214418054|NCT01551056|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
214418055|NCT00086892|BIOLOGICAL|cetuximab|
214418056|NCT00086892|DRUG|carboplatin|
214418057|NCT04386733|OTHER|no intervention, it was an observational study which looked at the reasons for surgical cancellations|the investigators observed how many patients had their surgeries cancelled and analysed the reasons of these cancellations
215018690|NCT04213339|BEHAVIORAL|Kegel Exercises|"Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~1. Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~2. Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~3. Squeeze the muscles in anus like holding a bowel movement focus penile area~4. Relax the pelvic floor muscles after each attempt.~5. Repeat this exercise 10 to 20 times.~6. While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises"
214418058|NCT06264648|OTHER|Pressure sensitivity education|Therapists were asked to apply pressure to the scale with estimated weights of 0.5 kg, 1 kg, 2 kg and 4 kg. In each measurement, the value shown on the scale was recorded without being shown to the participant.After the measurements, the participants were made to experiment when the digital screen can be seen, in order to teach the physiotherapists how much pressure they applied to reach the target weight. Participants were given a total of 10 minutes for the trials. Then, the digital screen was hidden again, and the therapist was asked to apply 0.5 kg, 1 kg, 2 kg and 4 kg weight in a randomized order and maintain this pressure for 5 seconds. The weight fixed by the therapist for 5 seconds was noted by the researcher; the participant was not informed about the values on the digital screen.
214418059|NCT00853827|DRUG|Placebo|Placebo
214418060|NCT00853827|DRUG|Aliskiren|300 mg
214418061|NCT01563991|PROCEDURE|Normal fluid volume|Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
214418062|NCT01563991|PROCEDURE|Reduced fluid volume|Subject receives 80 cc/ hr LR during the peri-operative period
215018691|NCT02145611|DRUG|Glibenclamide|Glibenclamide
215018692|NCT02145611|DRUG|Vildagliptin|Vildagliptin
215018693|NCT01235117|DRUG|azacitidine|
215018694|NCT01235117|OTHER|laboratory biomarker analysis|
215018695|NCT02983942|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
215018696|NCT02983942|DIETARY_SUPPLEMENT|Routine diet|Routine diet is given without blood ketone requirement
215018697|NCT02201628|DEVICE|Nasopharyngeal and oesophageal temperature probes|
215018698|NCT06278298|DEVICE|Shockwave|CDT and different dose of shockwave
215018699|NCT06278298|OTHER|CDT|CDT
214418063|NCT00864812|DRUG|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
214418064|NCT00864812|DRUG|tiotropium|COPD patients treated with tiotropium
214418065|NCT03183232|PROCEDURE|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
214418066|NCT03183232|BIOLOGICAL|γδ T cell|γδ T cells will be used against Lung Cancer
214418067|NCT03183232|OTHER|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
215102135|NCT00409344|DRUG|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
214418068|NCT02343744|DRUG|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
214418069|NCT04089618|BEHAVIORAL|MBLM|Complex 8 week Mind-Body program.
214418070|NCT00477100|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and stool
214418071|NCT00477100|OTHER|Interview|Participate in interview
214418072|NCT00477100|OTHER|Medical Chart Review|Undergo collection of medical data
215102136|NCT00409344|OTHER|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
214418073|NCT00477100|OTHER|Questionnaire Administration|Ancillary Studies
214418074|NCT04059237|BEHAVIORAL|Web based decision aid intervention|Decision aid tool (website) to assist young adult female cancer survivors in making decisions and preparing for family-building after cancer.
214418075|NCT00135135|DRUG|Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|See Detailed Description.
214505749|NCT04014387|DRUG|Zolpidem|Zolpidem (Ambien) is an FDA approved, Benzodiazepine Receptor agonist that has been extensively studied for the treatment of insomnia in older adults. It acts as a sedative and is typically prescribed to treat insomnia, reducing time to sleep onset, but may not alter the ability to maintain sleep.
214505750|NCT04014387|DRUG|Placebo oral capsule|Placebo (microcrystalline cellulose) capsules will be used.
214505751|NCT06827691|OTHER|Heat Therapy Intervention|Heat Therapy Intervention of shoulder depth submersion in a 40°C hot tub.
214505752|NCT04886960|BIOLOGICAL|Amniotic Fluid Injection|Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
214505753|NCT04886960|OTHER|Standard of Care|Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
214505754|NCT06832449|DEVICE|PNS|Retrospective study investigating PNS
214505755|NCT04779853|DIAGNOSTIC_TEST|Blood samples for pertussis antibody testing|Blood samples will be sent to the laboratories of the National Centers of Expertise within 24-48 hours of blood collection. The samples will be transferred to the reference laboratory of SPCSEEM in Almaty, Kazakhstan. Serum samples will be stored in the reference laboratory at a temperature of -20 C.
214505756|NCT06087406|DRUG|Imvotamab|Administered intravenously
214505757|NCT06087406|DRUG|Placebo|0.9% sodium chloride administered intravenously
214505758|NCT05935085|DRUG|ANB032|BTLA agonist antibody
214505759|NCT05935085|DRUG|Placebo|Placebo
214505760|NCT06917352|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of pulse rate.
214418076|NCT00135135|PROCEDURE|Radiation therapy, Surgery, Peripheral Stem cell transplant|See Detailed Description.
214418077|NCT04921423|BEHAVIORAL|Situational simulation teaching|The intervention included communication theory and skills, aging trend and knowledge, teaching plans for elderly nursing, activities for the elderly and visual experience, application and debriefing of empathy.
215018700|NCT01347957|OTHER|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
214418078|NCT00906035|DRUG|Dipyridamole 200mg and Aspirin 25mg bid:|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
214418079|NCT00906035|DRUG|Dipyridamole 200 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
214418080|NCT00906035|DRUG|Aspirin 25 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
214418081|NCT02050308|OTHER|Internet-All Nations Breath of Life (I-ANBL)|"* Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~* Weekly procedures will follow the same format as for the first session"
214418082|NCT02050308|OTHER|Honoring the Gift of Heart Health|"These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities."
214505761|NCT04186247|DRUG|Azithromycin|Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
214505762|NCT04186247|DRUG|Metronidazole|Weeks 4-12: 20 mg/kg/day of metronidazole (10 mg/kg twice daily to a maximum of 1000 mg/day) for 8 weeks
214505763|NCT04186247|OTHER|Standard of Care|SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
215018701|NCT01347957|OTHER|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
215018702|NCT01585701|BIOLOGICAL|AT13148|Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.
215018703|NCT06333158|DIETARY_SUPPLEMENT|Cholesfytol NG|3 capsules a day with dinner.
215018704|NCT06333158|OTHER|Placebo|3 capsules a day with dinner
214505764|NCT06299462|DRUG|ATG 5.0|ATG 2.5 mg/kg on days -3 and -2
214505765|NCT06299462|DRUG|Cyclophosphamide injection|Cyclophosphamide 50 mg/kg on days +3 and +4
214505766|NCT06299462|DRUG|ATG 4.0|ATG 2.5 mg/kg on day -2 + 1.5 mg/kg on day -3
215018705|NCT03115463|OTHER|Titration of oxygen during neonatal resuscitation|Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
215018706|NCT00338000|DRUG|Epoetin alfa|
215018707|NCT03656614|DRUG|Sugammadex|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)"
215018708|NCT03656614|DRUG|Neostigmine|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow."
215018709|NCT03656614|DRUG|Saline 0.9%|At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
215018710|NCT00666575|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
215018711|NCT00666575|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
215018712|NCT05377814|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
215018713|NCT01923974|DRUG|Melatonin 10 mg|
214505767|NCT04922307|PROCEDURE|Blood Sparing Protocol|Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass
214505768|NCT04922307|PROCEDURE|Standard Blood Replacement|Allogenic blood transfusion as determined intra-operatively
215018714|NCT01923974|DRUG|Melatonin 100 mg|
215018715|NCT01923974|DRUG|Placebo|
214418083|NCT02050308|DRUG|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
214418084|NCT05879588|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
214505769|NCT03508700|DRUG|TNX-102 SL 5.6 mg|cyclobenzaprine HCl sublingual tablets
214418085|NCT05879588|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 3 days of debonding
214418086|NCT03109704|PROCEDURE|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
214505770|NCT06132984|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Cardiac magnetic resonance protocols include cine, non-contrast T1-mapping and T2-mapping.
214505771|NCT04820088|OTHER|Computer based role play trianing|Participants will train with a computer-based role-play simulation. They will interact with a lifelike video character on screen. They will interact with the character in one of four scenarios (i.e., patient intake, traditional needs, high-risk needs,and social and physical transition). They will receive real-time and after-action feedback in a safe, non-stressful environment. Their usage of the system will be monitored and transcripts will be collected.
214505772|NCT06405451|OTHER|Conventional treatment|Conventional treatment to improve trunk control and stability for 30 minutes, twice a day, and six times per week.
214505773|NCT06405451|OTHER|Experimental treatment|"Respiratory muscle training will be conducted using the Threshold IMT-Philips inspiratory training device and the Threshold PEP expiratory training device, both from Respironics®. Participants will be comfortably seated in a chair with their feet on the ground, without back support, and with the trunk at a 90° angle to the hips. A conventional nasal clip will be used to prevent air leaks. During forced expiratory training, participants will use the ThresholdPEP® with a customized mouthpiece and perform forced expiration through the resistance device. Inspiratory muscle training will follow the same procedure using the Threshold IMT® (45).~Both inspiratory and expiratory trainings will be repeated 10-15 times, 5 sets for 20 minutes in one session, with a rest time of 30-60 seconds between each set."
214505774|NCT04458597|RADIATION|Image-guided adjuvant pelvic radiotherapy|Image-guided adjuvant pelvic radiotherapy delivered at an SBRT prescription dose of 30 Gy in 5 fractions if feasible, well-tolerated and effective for the adjuvant treatment of high-risk endometrial cancer.
214505775|NCT06341309|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
214505776|NCT06341309|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
214505777|NCT02776124|DIETARY_SUPPLEMENT|Healing Elements,Methuselah Medical Technology|ONS group will receive Healing Elements ONS everyday during CRT
215102137|NCT03843801|DEVICE|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of transmural anterior-posterior sutures in the stomach in order to achieve a gastric remodelling. Patient will be kept overnight after the procedure.
215102138|NCT01897090|OTHER|Elimination Diet|
215102139|NCT01897090|OTHER|Dietary Guidelines for Americans|
215102140|NCT05492981|BEHAVIORAL|Enhanced (intervention) education|See arm description
215102141|NCT06174909|DRUG|Calcium Hydroxide|After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
215102142|NCT06174909|DRUG|Triple Antibiotic paste|After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
215102143|NCT01389323|DRUG|Daclatasvir|Tablet, Oral, 60 mg, once daily, 24 weeks
215102144|NCT01389323|DRUG|Peg-Interferon Alfa-2a|Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
215102145|NCT01389323|DRUG|Ribavirin|Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
215102146|NCT05501951|OTHER|tDCS stimulation|The transcranial direct current stimulation (tDCS) method has emerged in the recent years as a non-invasive, safe, cheap, convenient and effective means to modulate brain functions and behaviours
215102147|NCT05501951|OTHER|Sham stimulation|For the sham group, the electrode positioning will be randomly allocated to be identical to either the DLPFC or the OFC group, and active stimulation will be delivered for the first 30 seconds only
215102148|NCT06335355|DRUG|Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin|Adebrelimab,1200mg; SHR-8068, 1.0 mg/kg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
215102149|NCT06335355|DRUG|Camrelizumab + Pemetrexed + Carboplatin|Camrelizumab,200mg;Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
215102150|NCT06335355|DRUG|Adebrelimab + Pemetrexed + Carboplatin|Adebrelimab,1200mg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
215102151|NCT03802903|DEVICE|Remo-Wax|topical treatment
214418087|NCT03109704|PROCEDURE|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
214418088|NCT03109704|PROCEDURE|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
215018716|NCT01946646|DRUG|S-1-CCRT|
215018717|NCT06010108|BEHAVIORAL|Heroes for Her|Market outreach intervention- daily awareness creation through public market announcements, and distribution of educational fliers in local dialects. Community women will also be involved in the spread awareness through door to door approach. Thee will be repeated radio jingles to promote awareness. Interested women and girls will be provided with screening and vaccination services at a designated community health facility. All samples will be returned to the facility by the women and sent to a designated laboratory for testing. Participants contact information will be collected for follow up
215018718|NCT06010108|BEHAVIORAL|The Reach Initiative|School based intervention-The Reach Initiative involves the organisation of the Mother-Daughter Day (MDD) by Mother-Daughter Planning Committee (MDPC) who are volunteer young school girls and their mothers and provision of a Key-Card which is a cervical cancer awareness card attached to a key chain for awareness creation. HPV vaccination and HPV -self sampling will be carried out in private rooms within the venue of the intervention and all samples will be sent to designated laboratory for testing. Participants contact information will be collected for follow up and communication of results
215018719|NCT06010108|BEHAVIORAL|W.H.I.T.E project|Community based intervention- This will involve the engagement of women's trade unions and organisations in the community to create awareness and women and girls interested in the uptake of HPV prevention services will be directed to receive these services at a designated community facility accessible to women and girls in the community. Participants contact details will be collected for follow uo and communication of results
215102152|NCT02526251|OTHER|observational|No intervention
214418089|NCT03058991|BEHAVIORAL|Distress Tolerance Intervention|See arm/group description.
214418090|NCT03058991|BEHAVIORAL|Working Memory Intervention|See arm/group description.
214418091|NCT03058991|BEHAVIORAL|Control Informational Intervention|See arm/group description.
214418092|NCT02533206|PROCEDURE|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
214418093|NCT02533206|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
214418094|NCT06051500|BEHAVIORAL|Nostril focus followed by belly focus|Focused breathing on the nostrils followed by focus breathing on the belly.
214418095|NCT06051500|BEHAVIORAL|Belly focus followed by nostril focus|Focused breathing on the bellyfollowed by focus breathing on the nostrils.
214418096|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
214418097|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
214418098|NCT00444613|DRUG|Placebo|Intramuscular injection, placebo twice a week for 3.5 years.
215102153|NCT01120925|BIOLOGICAL|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
215102154|NCT01120925|BIOLOGICAL|CD133|5-15 X 106 cells in 20ML suspension IPV
214505778|NCT00455104|OTHER|No intervention|This is an observational, voluntary registry.
214505779|NCT05817513|OTHER|Myofascial release.|Myofascial release (MFR) is a therapeutic treatment that uses gentle pressure and stretching to facilitate the release of fascial restrictions caused by accidents, injury, stress, repetitive use, and traumatic or surgical scarring. The fascial restrictions are palpated by the practitioner and the techniques are applied directly to the skin of the patient without lotions or oils. The pressure is applied into the direction of the restriction just until resistance is felt or the tissue is perceived to stop moving. The pressure is sustained at this point of resistance, without sliding over the skin or forcing the tissue, for a minimum of 90-120s. As the tissue begins to release, the practitioner maintains the same amount of pressure and follows the release three dimensionally through multiple releases.
214505780|NCT05817513|OTHER|Traditional exercises for scoliosis treatment.|"The exercises are:~1. Pelvic tilt.~2. Arm and leg raises.~3. Cat-cow.~4. Bird dog.~5. Latismus dorsi stretch.~6. Abdominal press.~7. Practice a good posture.~8. Stretching and scapular exercises."
214505781|NCT04323800|BIOLOGICAL|Anti- SARS-CoV-2 Plasma|SARS-CoV-2 convalescent plasma (1 unit; \~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
214505782|NCT04323800|BIOLOGICAL|SARS-CoV-2 non-immune Plasma|Normal human plasma collected prior to December 2019
214505783|NCT00489554|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
214505784|NCT00489554|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
215102155|NCT01120925|BIOLOGICAL|Control|Injection of 20 ml Normal saline via IPV
215102156|NCT04628949|DEVICE|aScope™ Duodeno endoscope and aBox™ Duodeno|"The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope."
215102157|NCT00158912|DEVICE|Implantable Cardioverter Defibrillator|
214418099|NCT00999843|DRUG|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
214418100|NCT00130637|DRUG|Daclizumab|
215018720|NCT06010108|BEHAVIORAL|Project Shield|Utilization of community based structures (pharmacy and health center)- The intervention will involve the creation of a branded self-sampling kit for HPV screening and a free vaccination voucher to encourage mother-daughter uptake of cervical cancer prevention measures. Awareness will be raised through banners at the points of access of the vaccines and kits, use of jingles, and the involvement of the Community Development Association (CDA) to help mobilize girls, women and the men. Women and girls will be referred to community health centers to receive the HPV vaccination and carry out the screening
215102158|NCT05764915|DRUG|RGT-264 phosphate tablets|RGT-264 phosphate tablets will be administered orally once daily (QD).
214418101|NCT02787941|BEHAVIORAL|Pharmacist-delivered multifaceted intervention|"First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.~Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding."
214418102|NCT03122704|PROCEDURE|GBS screening|Vaginal and anal swabs of patients will be screened for GBS screening
214418103|NCT05831917|RADIATION|Radiotherapy|"Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles.~chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles."
214418104|NCT02081898|DIETARY_SUPPLEMENT|LCD|approximate 100 kcal/d caloric deficit
214418105|NCT02881749|RADIATION|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
214418106|NCT02881749|DRUG|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
214418107|NCT02114749|DEVICE|a set of wearable respiration and cardiac monitoring devices|feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
214418108|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
214505785|NCT00489554|BIOLOGICAL|Rotarix|Oral, 2 doses.
214689792|NCT05299502|BEHAVIORAL|Nutritional Intervention|4 individual 1-hour in person (or virtual, according to potential public health restrictions and patients' preference) motivational interviews (12, 18, 24 and 30 weeks) with a registered dietitian will be conducted to elaborate S.M.A.R.T. (Specific,Measurable, Attainable, Relevant, Timely) goals regarding diet, based on the 2019 Canada's Food Guide. Between those individual follow-ups, 4 phone calls with the registered dietitian will be provided (15, 21, 27, 33 weeks). Throughout the study, 10 informative nutritional video clips will also be provided. Participants receiving the intervention will have access to an online Facebook private community to discuss and share experiences, thus maintaining motivation and providing social support.
215102159|NCT01230138|DRUG|Placebo|Placebo tablets
215102160|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 250mg TID
215102161|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 375mg BID
215102162|NCT01230138|DRUG|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
215102163|NCT01230138|DRUG|FP187|Oral tablets, up to 3 times daily for 20 weeks.
215102164|NCT04798209|DRUG|ACT-777991 (SAD)|ACT-777991 administered as hard capsules for oral use.
215102165|NCT04798209|DRUG|ACT-777991 (MAD)|ACT-777991 administered as hard capsules for oral use, once daily.
215102166|NCT04798209|DRUG|Placebo (SAD)|ACT-777991 matching placebo administered as hard capsules for oral use.
215102167|NCT04798209|DRUG|Placebo (MAD)|Matching placebo administered as hard capsules for oral use, once daily.
215102168|NCT04798209|DRUG|14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer, administered intravenously.
215102169|NCT04798209|DRUG|Microtracer matching placebo (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
215102170|NCT04798209|DRUG|14C-ACT-777991 microtracer (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer, oral solution..
215102171|NCT04798209|DRUG|Microtracer matching placebo (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
215102172|NCT00000713|DRUG|Ampligen|
215102173|NCT00372541|DRUG|ceftriaxone|
215102174|NCT00445276|DRUG|Diacerein|
215102175|NCT03201159|DRUG|VLX103|150mg tablets
215102176|NCT01424228|DRUG|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
215102177|NCT01424228|DRUG|prucalopride|"Prucalopride 2 mg daily before breakfast~1 mg for subjects \>65 years; in case of insufficient response 2 mg at week 2 or week 4"
215018721|NCT06010108|BEHAVIORAL|Project SHADE|"Community-based approach- health education of girls and women. The use of a uniquely designed bag Eno Iban to package and distribute the self-collection tool, vaccination of the adolescent girls. Screening and HPV will be provided at designated areas within the community for women and girls. A simple app (d-SHADE) will be used to collect data of the girls and women by the health professionals and volunteers, as well as send the reminders for next screening dates and test results"
215018722|NCT06010108|BEHAVIORAL|Operation Reach Her (ORH) program|"Faith based approach- Awareness programs would be conducted in the chosen religious centres to educate women and girls about their health, cervical cancer, its prevention, and the benefits of screening and HPV vaccination. This would be achieved by organizing a  Health Day  for free health check-ups for all members of the congregation. The self-sampling kit would be distributed to women aged 30-65 in mobile tents stationed in churches in Akoka and HPV vaccinations would be administered to girls aged 9-14 in mobile tents stationed at churches and mosques in Akoka, Lagos"
215018723|NCT06010108|BEHAVIORAL|Project Care|Community pharmacy intervention-Trained community volunteers will be involved in creating awareness of HPV prevention services and cervical cancer. There will be distribution of cervical cancer self-sampling kits to community pharmacies which will serve as service points for screening (self-collection point) and vaccination point for girls in the community,
214418109|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
214418110|NCT00740155|BIOLOGICAL|Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
214418111|NCT00740155|BIOLOGICAL|Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
214418112|NCT00740155|BIOLOGICAL|JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
214418113|NCT00942149|DRUG|Daptomycin|single dose of 6 mg/kg of daptomycin
214418114|NCT02999048|DRUG|Panax Notoginseng Saponins|Panax Notoginseng Saponins integrated with conventional therapy
214418115|NCT01701713|DEVICE|DKI ED2011|
214418116|NCT01701713|DEVICE|Sham-TDCS|
214418117|NCT06164249|OTHER|strength training|Strength training, three times a week, during nine weeks.
214418118|NCT01460342|DRUG|Tadalafil|5 mg (2 x 2.5-mg tablets), given once daily as oral tablet
214418119|NCT01460342|DRUG|Placebo|2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
214418120|NCT02139449|PROCEDURE|ICD/CRT|cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
214418121|NCT02170636|DRUG|BIBR 1048 MS Capsule E|50 mg BIBR 1048 MS
214418122|NCT02170636|DRUG|BIBR 1048 MS Capsule F|50 mg BIBR 1048 MS
214418123|NCT02170636|DRUG|BIBR 1048 MS Capsule G|50 mg BIBR 1048 MS
214418124|NCT02170636|DRUG|BIBR 1048 MS Tablet H|50 mg BIBR 1048 MS
214418125|NCT02170636|DRUG|BIBR 1048 MS Drinking solution|50 mg BIBR 1048 MS tartaric acid solution
214418126|NCT02170636|DRUG|Pantoprazole|40 mg Pantoprazole
214689793|NCT04857073|OTHER|Glucose Monitoring|Glucose monitoring consists of finger stick fasting and 2 hours post prandial
214689794|NCT02399813|DRUG|Axalimogene filolisbac|
214689795|NCT03833674|OTHER|Daily AIH Block|Daily sessions of AIH (dAIH) with use of short episodes of low oxygen (9% O2)
215018724|NCT02800746|DRUG|Ferric carboxymaltose|Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
215018725|NCT02800746|DRUG|Placebo|normal saline 100 ml is intravenously administered on 7-10 day before surgery
214418127|NCT01689519|DRUG|Placebo|Placebo supplied as tablets
214418128|NCT01689519|DRUG|Vemurafenib|Vemurafenib supplied as tablets
214418129|NCT01689519|DRUG|Cobimetinib|Cobimetinib supplied as tablets
214418130|NCT02777099|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.
214418131|NCT02777099|PROCEDURE|sham remote ischemic postconditioning|Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
214418132|NCT00744393|DRUG|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
214418133|NCT00744393|DRUG|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
214418134|NCT04555954|OTHER|surveys and questionnaires|The study practised the physical activity levels of healthy adults aged 18-65 years in Turkey during the novel type of coronavirus pandemic by the International Physical Activity Questionnaires-Short Form (IPAQ-SF). Communication with the participants of the study was conducted via online survey software (Google Forms) and social media communication application (WhatsApp).
214418135|NCT03140579|OTHER|APRV|Airway pressure release ventilation is a method of inverse ventilation, where high levels of positive end expiratory pressure are maintained to optimise oxygenation with brief releases of pressure to allow ventilation and release carbon dioxide. It is an approved and frequently used method of ventilation.
214418136|NCT04353830|DRUG|IBI939|Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
214689796|NCT03833674|OTHER|Sham dAIH Block|Daily sessions of sham dAIH which includes breathing room air (21% O2)
215018726|NCT04969107|PROCEDURE|taTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in a rendezvous procedure of an abdominal and a transanal approach.
215018727|NCT04969107|PROCEDURE|abdTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in an abdominal Approach.
215018728|NCT02448173|BIOLOGICAL|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
215018729|NCT02448173|PROCEDURE|Surgery|Surgical resection of Stage II colon cancer
214418137|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
214418138|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
214505786|NCT06571695|PROCEDURE|Anatomic Long Head of Biceps Tensioning Technique|The standard mini-open subpectoral approach will be made. The myotendinous junction of the long head of the biceps tendon and its location within the intertubercular groove will be marked using electrocautery. The surgeon will then turn to the glenohumeral joint and perform the biceps tenotomy.The long head of the biceps tendon will be retrieved.The tendon is tagged with a running, locking number 2 fiberwire suture at the mid substance of the myotendinous junction using the previously made electrocautery marks to set the tension. The tendon is shortened. The sutures from the biceps are passed through the Arthrex cortical button.The pectoralis major tendon is retracted and 2 centimeters proximal to the distal insertion a unicortical bone tunnel is drilled in the bicipital groove with a 3.2 millimeter drill.The wound is irrigated and the biceps button is threaded into this tunnel and then flipped.The suture is tensioned, securing the biceps against the groove
215018730|NCT03376412|DEVICE|Raindrop Near Vision Inlay|A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
215018731|NCT02187081|PROCEDURE|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
215018732|NCT02187081|PROCEDURE|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
215102178|NCT05768984|OTHER|Empowerment program|It is planned to conduct the empowerment program online (zoom session). For this, to protect each individual's privacy, a quiet, bright and ventilated, spacious physical environment and technological elements such as computers, headphones, microphones and internet connection are needed. The empowerment program was planned as a total of 10 sessions, one session per week. In the program, goals and objectives have been established for each session. These aims and objectives will be shared with the participants before each session. The application time of each session is planned as an average of 90 minutes.
215102179|NCT05173701|DIETARY_SUPPLEMENT|Probiotics|Selected probiotics mixture, in powder form, will be administered once daily for three months in the morning.
215102180|NCT05173701|DIETARY_SUPPLEMENT|Placebo|A placebo (2,7g maltodextrin) will be administered once daily for three months in the morning.
215018733|NCT00021359|DRUG|dexamethasone|
215102181|NCT02578329|BEHAVIORAL|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
215102182|NCT02578329|BEHAVIORAL|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
215102183|NCT00003552|DRUG|allogeneic lymphocytes|
215102184|NCT00003552|DRUG|anti-thymocyte globulin|
215102185|NCT00003552|DRUG|cyclophosphamide|
214418139|NCT00098280|DRUG|Eculizumab|
215018734|NCT00021359|DRUG|isotretinoin|
215018735|NCT02226783|DRUG|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
215102186|NCT00003552|DRUG|fludarabine|
215018736|NCT02226783|DRUG|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
215102187|NCT00180011|DRUG|Omalizumab|injectable medication
215102188|NCT02687087|DEVICE|Visco-ease|19.6 mg/mL of LMS-611
215102189|NCT02687087|DEVICE|Placebo|Physiological Saline
215102190|NCT01087216|DEVICE|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
215102191|NCT01087216|DRUG|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
215102192|NCT00844558|OTHER|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
215102193|NCT00844558|OTHER|Control|There is no intervention associated with this arm of the study
215102194|NCT03921333|DIETARY_SUPPLEMENT|Low dose response efficacy of plant extracts|300mg
215102195|NCT03921333|DIETARY_SUPPLEMENT|Middle dose response efficacy of plant extracts|500mg
215102196|NCT03921333|DIETARY_SUPPLEMENT|High Dose response efficacy of plant extracts|700mg
215102197|NCT03921333|DIETARY_SUPPLEMENT|Placebo|Cellulose microcrystalline
215102198|NCT06481085|DRUG|HDM1002 50 mg|HDM1002 tablets, 50 mg once daily, 12 weeks
215102199|NCT06481085|DRUG|HDM1002 100 mg|HDM1002 tablets, 100 mg once daily, 12 weeks
215102200|NCT06481085|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily, 12 weeks
215102201|NCT06481085|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily, 12 weeks
215018737|NCT02226783|DRUG|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
215018738|NCT03555097|PROCEDURE|incremental pressure support|Inspiratory positive airway pressure (IPAP) gradually increases from 10 to 24 cm water column (cmH2O) with 2 water column (cmH2O) increments. The expiratory positive airway pressure (EPAP) remains 4 water column (cmH2O), and each pressure level is maintained for 5 to 10 minutes.
214418140|NCT00869037|DRUG|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
214418141|NCT00869037|DRUG|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
214418142|NCT05422716|DEVICE|Epidural implant stimulation device|Individuals randomized to the Baclofen pump device group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments). The epidural implant group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity.
214418143|NCT01713530|DRUG|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
215018739|NCT02261532|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
214418144|NCT01713530|DRUG|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
214418145|NCT01713530|DRUG|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
214418146|NCT05796440|DRUG|LUM-201|Administered orally once daily
214418147|NCT03013348|DEVICE|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography \[EEG\] recordings) that are pathognomonic for PNES activity.
214418148|NCT00819819|DIETARY_SUPPLEMENT|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
214418149|NCT00819819|DIETARY_SUPPLEMENT|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
214505787|NCT06571695|PROCEDURE|Traditional Long Head of Biceps Tensioning Technique|Diagnostic arthroscopic shoulder scope will occur to assess the long head of the biceps for tendinopathy. Tenotomy will occur at the junction of the supraglenoid tubercle with arthroscopic scissors. Subsequent tensioning and tenodesis will be based on surgeon's preference
214689797|NCT03833674|OTHER|Respiratory Strength Training Block|Respiratory strength training using a hand-held device that resists inspiration or expiration.
214689798|NCT03833674|OTHER|AIH + Strength Training Block|AIH followed by respiratory strength training.
215018740|NCT05124236|RADIATION|preoperative radiosurgery|single fraction radiosurgery
215018741|NCT05124236|RADIATION|postoperative hypofractionated stereotactic radiotherapy|5 fraction stereotactic radiotherapy /fractionated radiosurgery
215018742|NCT03413449|DIAGNOSTIC_TEST|Frailty model|"1. Grip strength~2. 30 second chair sit stand test~3. Psoas muscle area~4. Six minute walk"
215018743|NCT06439706|BEHAVIORAL|HPV Self-Sampling|HPV self-sampling kit
215018744|NCT06439706|BEHAVIORAL|Group Education|Small-group education led by bilingual health educator
215018745|NCT03242070|OTHER|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
215018746|NCT02842281|OTHER|Fructan|Short-chain oligosaccharide primarily composed of fructose polymers
215018747|NCT02842281|OTHER|Maltodextrin|Polysaccharide produced from starch
215102202|NCT06481085|DRUG|HDM1002 200 mg BID|HDM1002 tablets, 200 mg twice daily, 12 weeks
215102203|NCT06481085|DRUG|Placebo|Matching placebo will be provided
215102204|NCT00685737|DRUG|1-MNA|Capsule
215102205|NCT00685737|DRUG|Placebo|Capsule
214418150|NCT03939819|DEVICE|ViSiGi® 3D suction calibration device|ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
215102206|NCT00028574|DRUG|gabapentin|
215102207|NCT00028574|OTHER|placebo|
215102208|NCT05900973|DRUG|Darolutamide Oral Tablet [Nubeqa]|Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
214418151|NCT03939819|DEVICE|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
214418152|NCT00006413|PROCEDURE|Stem cell transplantation|
214418153|NCT05921526|DIAGNOSTIC_TEST|Point-of-care lung ultrasound|Participants assigned to the intervention group will receive POCLUS which will be performed by one of the trained pediatricians. The procedure involves 12 views: two anterior views, two lateral views and two posterior views on both chest walls
214418154|NCT05921526|DIAGNOSTIC_TEST|Chest X-ray (digital images)|Participants assigned to the chest X--ray group will be sent to the Radiology department to get a CXR (digital) which will be performed by radio technicians like in routine care. Anteroposterior and/or posteroanterior chest images will be obtained. Reading/ reporting of the digital images will be done by both the radiologist and the enrolling pediatrician. The image/ clinical expert review panels (IERP/ CERP) will also have access to the images for review.
214418155|NCT00182936|BEHAVIORAL|Delirium Abatement Program|
215018748|NCT04739345|DRUG|Pentoxifylline|400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
214418156|NCT03522519|BEHAVIORAL|Real world performance of physical activity and arm use|Patients will be assessed by using movement sensors and standard clinical assessments
214505788|NCT01219153|DRUG|Extended high dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
215018749|NCT03159442|DRUG|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
215018750|NCT03159442|DRUG|Placebo|Powder for inhalation administered via single dose DPI
215018751|NCT06549868|BEHAVIORAL|Yoga-based bedtime routine|"Dyads in the yoga intervention group receive a picture book outlining a bedtime-themed yoga routine and are instructed to incorporate it into their bedtime routine at least four nights per week for four weeks. The routine guides children through a sequence of yoga poses, starting with the mountain pose and ending in child's pose, designed to calm them as the story progresses. Parents are given a bedtime diary to record the date, whether the child completed the yoga routine each evening, and any comments about their experience with the book.~At week 6, families return to the lab, complete anthropometric assessments and questionnaires, and are fitted with accelerometers to wear for the next week. The accelerometers are returned and data is downloaded a week later. Families are then encouraged to continue using the yoga routine as often as they wish for an additional four weeks, although the frequency of use is not tracked during this maintenance period."
215018752|NCT05725525|BEHAVIORAL|Remote PCIT augmented with wearable devices|Participants will be enrolled in remote PCIT and be asked to wear a Garmin watch throughout the course of the study in order to measure biometric fluctuations
215018753|NCT02777190|DRUG|Misoprostol|Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
214689799|NCT04111887|BEHAVIORAL|Group-based therapy|College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
215018754|NCT00707304|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
215018755|NCT00707304|DRUG|Placebo|Oral, twice per day
215018756|NCT04342546|DEVICE|NovaGray RILA Breast® test|The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
215102209|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (Booster)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine (Booster)
215102210|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (single dose)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine ( single dose)
215102211|NCT03401060|DRUG|Denosumab|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
215102212|NCT03401060|DRUG|Placebo|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
215102213|NCT03902119|DEVICE|INYBI tool|Patients will lie down in supine position so that the INYBI tool will contact the suboccipital muscles at the posterior arch of the atlas. The therapist will adapt the height of the tool for each individual. All patients will use the softest head of the device. A 50Hz vibration speed will be set sup during 5 minutes.
215102214|NCT03902119|OTHER|Manual suboccipital inhibition|Patients will lie down in supine position.The therapist will be seated at the head of the treatment table. The therapist will keep the metacarpophalangeal joints in a flexed position, while therapists fingertips of both hands will contact with the suboccipital muscles at the posterior arch of the atlas.
215102215|NCT02470884|DEVICE|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
214418157|NCT01229839|OTHER|Embolization|embolization with lipiodol and polyvinyl alcohol particles (PVA)
214418158|NCT01229839|OTHER|Infusion of anticancer agent|infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
214418159|NCT01229839|OTHER|Infusion of mixture of anticancer agent and lipiodol|infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
215018757|NCT00127543|BEHAVIORAL|Medication Education for Children|
215018758|NCT04562519|DEVICE|TENS|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
215102216|NCT02837042|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
214418160|NCT05292638|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
215018759|NCT06571071|OTHER|De-Stress and Chill Gummies-U001|Two gummies in sequence daily after meal for 60 days
215018760|NCT06571071|OTHER|De-Stress and Chill Gummies-I001|Two gummies in sequence daily after meal for 60 days
215018761|NCT06571071|OTHER|Placebo Gummies-001|Two gummies in sequence daily after meal for 60 days
214418161|NCT05292638|DRUG|Botox®|Intramuscular injection Botox®
214418162|NCT06112717|OTHER|Supportive-Educative Nursing Care|Adolescents in the intervention group were received Supportive-Educative Nursing Care based on Orem's Self Care Deficit Nursing Theory
214418163|NCT03298919|BEHAVIORAL|Exercise Video Games|12 weeks laboratory based exercise videogames
214418164|NCT03298919|BEHAVIORAL|Aerobic Exercise|Stationary bike and/or treadmill walking for 12 weeks
214418165|NCT03298919|BEHAVIORAL|Home exercise videogames|videogame console and active videogames
214418166|NCT03298919|BEHAVIORAL|Home Standard Exercise|Personalized physical activity promotion materials
214418167|NCT05981534|DRUG|Vitamin D|4000IU/day vitamin D supplement will be used for 6 months
214418168|NCT05981534|DRUG|Placebo|Placebo will be used for 6 months
214418169|NCT02276820|BIOLOGICAL|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
214418170|NCT03145935|DIAGNOSTIC_TEST|Abdominal compression (AC)|An echocardiography with stroke volume measurement coupled with an abdominal compression will be performed before and after ta diuretics induced diuresis of 10ml/kg in pediatric patients hospitalized in a pediatric intensive care unit (PICU) diagnosed with fluid overload
214418171|NCT03145935|DIAGNOSTIC_TEST|blood sample|proteinemia and hematocrit will be measured before and after a diuretics induced diuresis of 10ml/kg
214418172|NCT01826695|OTHER|Neurodynamic technique group|"Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.~The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks."
214418173|NCT01826695|OTHER|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
214505789|NCT01219153|DRUG|Short low dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
214505790|NCT06081985|DEVICE|Transcranial Magnetic Stimulation with double-cone coil|Deep Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with double-cone coil
215018762|NCT04801693|DRUG|BI 1819479|BI 1819479
214418174|NCT02573818|DEVICE|SEDASYS System|propofol sedation with the SEDASYS System
214418175|NCT00001384|DRUG|Adriamycin|
214418176|NCT00001384|DRUG|cyclophosphamide|
214418177|NCT00001384|DRUG|G-CSF|
214418178|NCT00001384|DRUG|paclitaxel|
215018763|NCT04801693|DRUG|Placebo|Placebo
215018764|NCT03237312|PROCEDURE|Laparoscopic ovarian drilling|The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
215018765|NCT03237312|BIOLOGICAL|Antimullerian hormone|"1. In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~2. In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed."
215018766|NCT03063164|DEVICE|Intralase IFS150|Intralase flap creation
215018767|NCT03063164|DEVICE|Visumax|Visumax flap creation
215018768|NCT04421001|DEVICE|I-port use|patient will use I-port device fo 2 months
215018769|NCT01340170|DEVICE|OsseoSpeed TX|OsseoSpeed TX dental implants, 6-17 mm
215018770|NCT05912725|PROCEDURE|Implant placement|"4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar"
215018771|NCT03186924|BEHAVIORAL|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
215018772|NCT02443129|DEVICE|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
215018773|NCT03901209|DEVICE|Mid-face osteotomy|The mid-face osteotomy - typically according to LeFort I - is performed using a pulsed erbium-doped yttrium aluminium garnet (Er:YAG) laser driven by the CARLO robot arm.
215018774|NCT00624078|DRUG|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
215102217|NCT00306709|BEHAVIORAL|culturally adapted behavior change|Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
215102218|NCT00006656|DRUG|carmustine in ethanol|
215102219|NCT00006656|PROCEDURE|conventional surgery|
215102220|NCT01862549|BEHAVIORAL|Dialectical Behavior Therapy for children|
215102221|NCT01862549|BEHAVIORAL|Treatment as Usual|
214418179|NCT02613364|BEHAVIORAL|Behavioral Intervention|Undergo yoga intervention
214418180|NCT02613364|OTHER|Cognitive Intervention|Undergo CBT-I intervention
214418181|NCT02613364|OTHER|Educational Intervention|Receive health education
214418182|NCT02613364|OTHER|Laboratory Biomarker Analysis|Correlative studies
214418183|NCT02613364|DEVICE|Monitoring Device|Correlative studies
214418184|NCT02613364|OTHER|Quality-of-Life Assessment|Ancillary studies
214418185|NCT01899872|BEHAVIORAL|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
214418186|NCT01899872|BEHAVIORAL|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
214418187|NCT02939469|OTHER|Physiologic maneuvers|"Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
214418188|NCT05539248|DRUG|CAN106 20 mg/kg|"Induction and maintenance dosing for cohort 1:~12 mg/kg on Day 1, 16 mg/kg on Day 8, and 20 mg/kg on Day 15 and every 4 weeks thereafter;"
214418189|NCT05539248|DRUG|CAN106 40 mg/kg|"Induction and maintenance dosing for cohort 2:~30 mg/kg on Day 1, and 40mg/kg on Day 8 and every 4 weeks thereafter；"
214418190|NCT05539248|DRUG|CAN106 80 mg/kg|"Induction and maintenance dosing for cohort 3:~60 mg/kg on day 1, and 80 mg/kg on day 15 and every 8 weeks thereafter."
214418191|NCT00215345|DRUG|Taxotere|
214418192|NCT00215345|DRUG|Celecoxib|
214418193|NCT05274334|OTHER|Assessment of de novo lipogenesis non-invasively in exhaled breath|"1. Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~2. They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~3. Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~4. Participants execute several exhalation sets over time.~5. Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~6. Participants execute several exhalation sets over time.~7. After around 4.5hours with regular exhalation sets taking place, the trial is concluded."
214418194|NCT05541393|BEHAVIORAL|Active Intervention Group|The intervention will involve meetings with the church health ministers to discuss COVID-19 vaccines and booster shots.
214418195|NCT06121830|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 4 weeks
214418196|NCT06121830|DRUG|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 4 weeks
214418197|NCT06121830|DRUG|Placebo|Placebo, tablet, orally, once daily for up to 4 weeks
214418198|NCT02309580|DRUG|Ibrutinib|Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
214418199|NCT00436644|DRUG|Lapatinib|1250 mg orally days 1 -28.
214418200|NCT00436644|DRUG|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 \& 15.
214418201|NCT00619645|DRUG|busulfan|
214505791|NCT06081985|DEVICE|Transcranial Magnetic Stimulation with sham coil|Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with sham coil
214418202|NCT00619645|DRUG|cyclosporine|
214418203|NCT00619645|DRUG|fludarabine phosphate|
214505792|NCT05739136|DRUG|Relugolix + Estradiol + Norethindrone Acetate|Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)
214418204|NCT00619645|DRUG|mycophenolate mofetil|
214418205|NCT00619645|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214418206|NCT00619645|PROCEDURE|peripheral blood stem cell transplantation|
214505793|NCT06092307|DIAGNOSTIC_TEST|Bioelectrical impedance|Resistance, reactance, phase angle,free-fat mass, body cell mass, body cell mass index and total body will be recorded
214505794|NCT06092307|DIAGNOSTIC_TEST|Handgrip strength test|Handgrip strength test using a hydraulic hand dynamometer and sit-to-stand test will be performed.
214418207|NCT03229707|DEVICE|Digital photography using software Photoshop|"When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).~* Images are then opened into Photoshop.~* The INFO panel must be open.~* Click on the small eyedropper in the Info panel window and click on ''Lab Color.~* Place the mouse over the center of the tooth to be measured for L value.~* Click on the HSB Color option, which stands for hue, saturation, and brightness."
214418208|NCT03229707|DEVICE|Vita 3D master shade guide|Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
214418209|NCT04683159|DRUG|Brimonidine Tartrate 0.15% Oph Soln|1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery
214418210|NCT04683159|DRUG|Brimonidine Tartrate 0.025% Oph Soln|1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery
214418211|NCT03326648|OTHER|Strength training|Heavy load strength training performed twice a week for 10 weeks.
214418212|NCT03326648|DIETARY_SUPPLEMENT|Protein supplementation|Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
214418213|NCT02526680|DEVICE|OrCam|The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
214418214|NCT01598948|DRUG|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
214418215|NCT03719391|OTHER|Virginia Tobacco flavored JUUL 5% ENDS|Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).
214418216|NCT03719391|OTHER|Cool Mint flavored JUUL 5% ENDS|Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).
214505795|NCT06092307|DIAGNOSTIC_TEST|muscle ultrasound.|The following ultrasound parameters will be evaluated: radial, ulnar, rectus femoris, rectus abdominis and medial gastrocnemius muscle thickness and echo intensity with gray-scale-index; rectus femoris muscle cross sectional area; gastrocnemius muscle fiber length and pennation angle.
214505796|NCT00895596|DRUG|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
214418217|NCT03719391|OTHER|Mango flavored JUUL 5% ENDS|Treatment with Mango flavored JUUL 5% ENDS (10 puffs).
214418218|NCT03719391|OTHER|Creme Brulee flavored JUUL 5% ENDS|Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).
214418219|NCT03719391|OTHER|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).
214418220|NCT03719391|OTHER|Nicorette White Ice Mint 4mg nicotine polacrilex gum|Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)
214418221|NCT03719391|OTHER|Usual Brand combustible cigarette|Treatment with usual brand cigarette (10 puffs).
214418222|NCT01846169|BEHAVIORAL|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
214418223|NCT03844854|OTHER|Stabilization occlusal splint and manual therapy|Providing stabilization occlusal splint and manual therapy
214418224|NCT04155151|OTHER|6 minute walk test|A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
214505797|NCT00773344|DRUG|Tanespimycin|"Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)"
215102222|NCT01776866|PROCEDURE|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
215102223|NCT01894022|DRUG|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
215102224|NCT05030480|DIAGNOSTIC_TEST|renal functions|urea, creatinine, GFR
215102225|NCT03173768|PROCEDURE|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
215102226|NCT04499222|DEVICE|Portex|nasotracheal intubation with PORTEX POLAR \[Smiths Medical International, Hythe, United Kingdom\] nasotracheal tube.
215102227|NCT04499222|DEVICE|Mallinckrodt|nasotracheal intubation with Mallinckrodt TaperGuard \[Covidien, Ireland\] nasotracheal tube.
215102228|NCT03134690|PROCEDURE|delayed start|In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
215102229|NCT03134690|PROCEDURE|Conventional|In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
215102230|NCT04994678|OTHER|Virtual Reality Training|The Virtual reality based training group will receive a game based virtual reality training via XBOX 360or wii fit balance games. Player will be required to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week or 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
215102231|NCT04994678|OTHER|Moderate Aerobic Exercise Training|Moderate intensity continuous Aerobic exercises (Recombinant/Stationary cycling for 10-15 min with progression followed by treadmill walking for 10-15 min with progression, as well as stepping and Jogging). The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
215102232|NCT00123045|BEHAVIORAL|health education|
215102233|NCT04965532|DRUG|sevoflurane anesthesia|Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
215102234|NCT04965532|DRUG|Propofol Injection|Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
215102235|NCT04608422|OTHER|Electrical stimulation|A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
215102236|NCT03256253|DRUG|Pregabalin|pregabalin up to 600 mg/day
215102237|NCT04496453|OTHER|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
215102238|NCT03712488|DEVICE|flowcytometry|four colour flowcytometry
215102239|NCT02447809|DRUG|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.
215102240|NCT02447809|DRUG|acetylsalicylic acid (ASA)|
215102241|NCT05505409|DRUG|Pirfenidone|Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
215102242|NCT05505409|DRUG|glucocorticoid and immunosuppressant|Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
215102243|NCT03578328|PROCEDURE|targeted temperature management|Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
214418225|NCT01056835|DRUG|prostaglandin I2 analogue|
214418226|NCT03547752|OTHER|observed action and motor imaginery|Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.
214418227|NCT00585455|DRUG|sertraline|open label 25-50 mg daily as tolerated
215102244|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
214418228|NCT04094155|DIAGNOSTIC_TEST|retinal vascular analysis|Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
214505798|NCT01850342|PROCEDURE|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
214505799|NCT05856682|PROCEDURE|Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block|Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee. • Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be anterior to the midaxillary line between the costal margin and iliac crest bilaterally.
214505800|NCT05996900|DEVICE|Intracranial electrodes|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
215018775|NCT05039385|OTHER|Exercise Program focused on resistance training|"The program will be carried out by a personal trainer. To ensure correct execution, given that the groups will be of a maximum of 5 people. Each session will include:~A) Warm up: movility exercises and coordination games B) Main part: 3 exercises will be included to strengthen different muscle groups (pull , bench press and back squat). Velocity based training (VBT) will be used to control load. 3 sets of 16-30 repetitions mantaining the speed between Light (estimated loss of speed of the series 5-10%).~C) Cool down: feedback with patients based on the work of Stiles-Shields (2015).~Specific training content will focus on safety, while re-educating patients on proper exercise methods, motivation-related attitudes, and transparency on health benefits and potential harms as a result of increased exercise."
215018776|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
215018777|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
215018778|NCT01554852|DRUG|Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1 \& 2, 8 \& 9, 15 \& 16 - carfilzomib 20\*/36 mg/m2\*\* IV (\*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; \*\*carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 \& 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
215102245|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection simulation|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
215102246|NCT03083223|OTHER|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
215102247|NCT05387057|BEHAVIORAL|Exergame training according to the 'Brain-IT' exergame-based training concept|For an overview, our 'Brain-IT' exergame-based training concept consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) visuospatial skills. According to the training concept, each participant is instructed to train 5x/week for 24 min per session resulting in a weekly exercise volume of 120 min. All training sessions are planned to take place at participant's homes using the exergame training system 'Senso Flex' (Dividat AG, Schindellegi, Switzerland). For a detailed description of the complete 'Brain-IT' exergame-based training concept with sufficient details to allow full replication, consider our methodological paper (doi: 10.3389/fnagi.2021.734012).
215102248|NCT05387057|BEHAVIORAL|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
215102249|NCT02728297|PROCEDURE|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
215102250|NCT00410605|BIOLOGICAL|bevacizumab|Given IV
215102251|NCT00410605|DRUG|lenalidomide|Given orally
215102252|NCT00410605|DRUG|dexamethasone|Given orally
214418229|NCT00972504|DRUG|GSK835726 10mg|GSK835726 10mg tablet
214418230|NCT00972504|DRUG|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
214418231|NCT00972504|DRUG|Cetirizine 10mg|Cetirizine 10mg active comparator
214418232|NCT00972504|DRUG|placebo|placebo to match actives
214418233|NCT00506181|DRUG|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
214418234|NCT00506181|DRUG|Placebo|
214418235|NCT00732368|DRUG|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
214418236|NCT06252727|DRUG|Aminolevulinic Acid|Given PO
214418237|NCT00234442|DRUG|Iressa (Gefitinib)|
214418238|NCT05112718|BIOLOGICAL|Platelet Rich Plasma Injections|"PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections."
214505801|NCT05996900|DEVICE|TMS|TMS will be used for the delivery of noninvasive brain stimulation both before and after implantation electrode surgery.
214505802|NCT04529928|DEVICE|Carillon Mitral Contour System|Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
214418239|NCT05112718|OTHER|Normal Saline Injections|"Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 injections at 4-6-week intervals."
214418240|NCT00597519|DRUG|Fludarabine, Cyclophosphamide|"Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery."
214418241|NCT00597519|PROCEDURE|Transplantation|The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
214418242|NCT00140972|DRUG|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
214418243|NCT00140972|DRUG|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
214418244|NCT04742842|BIOLOGICAL|COVIGEN C19 0.8 mg ID or Placebo ID|2 doses of COVIGEN C19 0.8 mg ID or Placebo ID will be given at Day 1 and Day 29.
214418245|NCT04742842|BIOLOGICAL|COVIGEN C19 2.0 mg IM or Placebo IM|2 doses of COVIGEN C19 2.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
214418246|NCT04742842|BIOLOGICAL|COVIGEN C19 4.0 mg IM or Placebo IM|2 doses of COVIGEN C19 4.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
214418247|NCT04742842|BIOLOGICAL|COVIGEN C20 1.0mg vaccine ID|COVIGEN C20 1.0mg ID vaccine will be given at Day 1
215018779|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
215018780|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
215018781|NCT01554852|DRUG|Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Days 1, 4, 8 \& 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 \& 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
215018782|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
215018783|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 \& 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
215018784|NCT01554852|DRUG|High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)|High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
215018785|NCT05223712|OTHER|Diagnostic Test: Chronic Kidney Diseases|The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.
214418248|NCT04246762|DRUG|Olokizumab|Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
214418249|NCT04246762|DRUG|Omeprazole|Tablets, 20 mg, oral
214418250|NCT04246762|DRUG|Caffeine|Tablets, 100 mg, oral
214418251|NCT04246762|DRUG|Warfarin+ Vitamin K|Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.
214418252|NCT04246762|DRUG|Midazolam|Syrup, 2 mg/mL, oral
214418253|NCT05679713|DIAGNOSTIC_TEST|Comprehensive risk assessment algorithm|Risk assessment algorithm including clinical and patient-centered information and a novel RNA-based biomarkers using next-generation sequencing technology.
214418254|NCT00410124|DRUG|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
214418255|NCT00410124|DRUG|Placebo|
214418256|NCT00212784|DRUG|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
214418257|NCT00212784|DRUG|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
214418258|NCT01006551|DRUG|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
214505803|NCT01349270|DRUG|Immunoglobulin perfusion|patient who received monthly 2g/kg intravenous cure of immunoglobulin
214505804|NCT01349270|DRUG|Prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
214505805|NCT02596061|BEHAVIORAL|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
214505806|NCT02596061|OTHER|Incentives|Patients receive incentives for completing smoking cessation activities.
214505807|NCT05075200|DRUG|Tranexamic acid|Participants in both groups will be given single intravenous bolus of TXA 20 mg/kg over 15 min after induction of spinal (or other regional technique) or general anesthesia as per standard of care.
214505808|NCT00989742|DRUG|Doxycycline|50mg od
214418259|NCT03908424|OTHER|Epidural Blood patch.|"An epidural blood patch is a surgical procedure that uses autologous blood in order to close one or many holes in the dura mater of the spinal cord, usually as a result of a previous lumbar puncture. A small amount of the patient's blood is injected into the epidural space near the site of the original puncture; the resulting blood clot then patches the meningeal leak. An epidural needle is inserted into the epidural space at the site of the cerebrospinal fluid leak and blood is injected. The clotting factors of the blood close the hole in the dura."
214418260|NCT00765492|DRUG|AZD8529|oral
214418261|NCT00765492|DRUG|Placebo|oral
214418262|NCT02953080|OTHER|Call for life mHealth adherence support|Daily/ weekly pill reminder support Health Info-tips Appointment visit reminders Self-reported symptom support
214418263|NCT04473586|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
214418264|NCT01377129|PROCEDURE|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
214418265|NCT01377129|PROCEDURE|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
214418266|NCT05404893|DIAGNOSTIC_TEST|Fecal calprotectin measurement|Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
214418267|NCT02206386|OTHER|MHTraining-Net|See Arm Description for more details.
214418268|NCT02206386|OTHER|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
214418269|NCT04848441|OTHER|The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1|The purpose of the study is to compare the effects of BNT162b2, mRNA-1273 and ChAdOx1 with respect to incident COVID-19 infection of different severities.
214418270|NCT04580199|PROCEDURE|thyroidectomy|to excise the thyroid gland
214418271|NCT02572024|DEVICE|BAT|Baroreflex activation therapy device ON
214418272|NCT02572024|OTHER|Placebo|Baroreflex activation therapy device OFF
214418273|NCT05353517|DEVICE|Device: focal muscle vibration and theta burst stimulation|non invasive techniques of neuromodulation for inducing plasticity in M1 and spinal cord
214418274|NCT04911933|BEHAVIORAL|Family Therapy|There will be systemic family psychotherapy sessions every two weeks. Families and individuals who require a more intensive service will be referred to a higher level of care.
214505809|NCT00989742|DRUG|Placebo|50mg od
214505810|NCT03030651|BEHAVIORAL|Breastfeeding Education and Support|Women Development Army (WDA) leaders will function as peers for mothers in intervention group. There will be two visits during pregnancy and 8 visits postnatally. During pregnancy, WDA leaders will cover in detail the importance of EBF, feeding colostrum first, and discouraging prelacteal foods and encourage the mother to deliver at the nearby health center. During Postnatal visits, mothers will be observed positioning, attaching, and feeding the new-born, with appropriate feedback provided, solving any BF problems, encourage the mothers to continue exclusive breastfeeding for 6 months, emphasize nutrition for sufficient breast milk to breastfeed successfully and hands-on guidance only when necessary.
214505811|NCT00237926|BEHAVIORAL|Exercise|aerobic or resistance training
214418275|NCT02979899|BIOLOGICAL|TRC105|TRC105 antibody
214418276|NCT02979899|DRUG|Votrient|pazopanib
214418277|NCT03636867|OTHER|data and specimen collection|to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient
214418278|NCT02533713|DEVICE|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
214418279|NCT04719377|DEVICE|catheter placement|catheter placement
214418280|NCT01816958|OTHER|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
214418281|NCT06468657|OTHER|mortality rates|mortality rates
214418282|NCT06629012|PROCEDURE|Breast reconstruction with neurotization|Patients received breast reconstruction with neurotization procedure
214418283|NCT06629012|PROCEDURE|Breast reconstruction without neurotization|Patients received breast reconstruction without neurotization
214418284|NCT02403024|BEHAVIORAL|InterWalk|Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
214418285|NCT02403024|BEHAVIORAL|Waiting list control|Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
214418286|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
214418287|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
214418288|NCT05585775|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.
214418289|NCT05585775|BEHAVIORAL|Wellness for Wellbeing|Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
214418290|NCT00683735|DRUG|Sitagliptin|100 mg once daily in the morning
214418291|NCT00683735|DRUG|Metformin|up to 2000 mg/day
214418292|NCT00683735|DRUG|Placebo|500mg 1-0-0-0
214418293|NCT00683735|DRUG|Placebo|100mg 1-0-0-0
214418294|NCT01545674|PROCEDURE|Blood Draw|Blood will be drawn from the mother and father
214418295|NCT03692520|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
214418296|NCT00780663|DRUG|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
214418297|NCT05117450|DEVICE|Decrease per-dialytic heparin therapy|Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
214418298|NCT04495634|DEVICE|Stationary Head CT (s-HCT)|The system consists of a total of three x-ray sources and nine x-ray detectors with an estimation of approximately 150 projection angles per slice, with less than a minute per slice reconstruction. Radiation dose will be configured as to not exceed that of a conventional head CT, or 2 mSv. The subjects will be positioned on a medical procedure table that will move the subject through the scanning system at the rate of roughly 1 cm per second, during which the necessary x-ray projections will be acquired. The head will be positioned in a carbon fiber head holder from a clinical CT scanner that is secured to the table.
214418299|NCT00133588|BIOLOGICAL|Trivalent split Inf|
214418300|NCT03030950|DRUG|Dexmedetomidine|to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
214418301|NCT03030950|DRUG|Normal saline|to give normal saline to the other group as a placebo
214505812|NCT06075641|PROCEDURE|Gingival depigmentation|Gingival depigmentation is the most widely used periodontal procedure to remove or reduce the melanotic areas. Various techniques can be employed to effectively carry out the depigmentation procedure, including surgical scraping, scalpel technique, bur abrasion, free gingival graft, gingivectomy, cryosurgery, electrosurgery, chemical therapies, and different types of lasers
214505813|NCT02118311|BIOLOGICAL|T Regulatory cells|Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
214505814|NCT02118311|DRUG|Fludarabine|Fludarabine 30mg/m\^2 IV over 1 hour on days -6 through -2 from transplant
214505815|NCT02118311|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
214418302|NCT02283255|OTHER|Aerobic Exercise Training|Supervised aerobic and light muscle resistance exercise training
214418303|NCT02283255|OTHER|Inspiratory Muscle Training|Inspiratory muscle training with POWERbreathe device
214418304|NCT02283255|OTHER|No Exercise Training|Usual care
214418305|NCT01720719|DRUG|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
214418306|NCT01720719|DRUG|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
214418307|NCT04589611|DRUG|amobarbital/Gel-One (one dose)|One dose of amobarbital/Gel-One during the initial surgical intervention
214418308|NCT04589611|DRUG|Placebo (single dose)|One dose of placebo during the initial surgical intervention
214418309|NCT04589611|DRUG|amobarbital/Gel-One (two doses)|One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
214418310|NCT04589611|DRUG|Placebo (two doses)|One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
214505816|NCT02118311|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
215018786|NCT03272893|BEHAVIORAL|Acceptance and Commitment Therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
215018787|NCT06300684|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|This intervention involves structured sessions aimed at addressing maladaptive sleep behaviors and promoting healthy sleep habits. Participants in this group will engage in cognitive restructuring, relaxation techniques, and sleep hygiene education to improve sleep quality and duration. The goal of CBTi is to modify behaviors and thoughts that contribute to insomnia, leading to more restful and consolidated sleep patterns.
215018788|NCT03733483|BEHAVIORAL|Sleep Deprivation|Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
215018789|NCT03435315|OTHER|Treadmill Exercise- behavioral approach|12-session, 6-week treadmill exercise program utilizing behavioral techniques while walking
215018790|NCT03435315|OTHER|Treadmill Exercise- traditional approach|12-session, 6-week traditional treadmill exercise program
214418311|NCT03955419|DIETARY_SUPPLEMENT|NO-NPO (Daesang WelLife Co., Ltd., Korea)|800 mL of carbohydrate beverage consists of 12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg.
214418312|NCT02050594|DRUG|Ipilimumab|
214418313|NCT04239339|DRUG|Escitalopram 20 mg|20mg daily for approximately 3 weeks.
214418314|NCT04239339|DRUG|Placebo|Placebo daily for approximately 3 weeks.
214418315|NCT02417311|OTHER|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
214418316|NCT03684733|DIAGNOSTIC_TEST|MRI|Clinical MRI breast screening examination
215018791|NCT00449800|DRUG|ceftriaxone|
215018792|NCT03125356|OTHER|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
215018793|NCT05136521|DRUG|Trazodone HCl - new polymer|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
215018794|NCT05136521|DRUG|Trazodone HCl - Contramid®|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
214418317|NCT02431143|DRUG|Miltefosine|
214418318|NCT00541697|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
214418319|NCT00541697|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
214418320|NCT05042271|DRUG|meropenem|each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
214418321|NCT00143650|BEHAVIORAL|House dust|
214418322|NCT00207532|DRUG|folic acid|
214418323|NCT05506098|OTHER|no intervention|no intervention
214418324|NCT00741988|DRUG|Ixabepilone|ixabepilone 30 mg/m2
214418325|NCT00741988|DRUG|Carboplatin|carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
214418326|NCT00741988|DRUG|Bevacizumab|bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
214418327|NCT03103412|DRUG|TD-3504|TD-3504
214418328|NCT03103412|DRUG|15N2-tofacitinib|15N2-tofacitinib
214418329|NCT03103412|DRUG|Placebo|Placebo
214418330|NCT02250716|PROCEDURE|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
214418331|NCT04397172|PROCEDURE|Study Arm|"First inpatient examination (within 24 hours after admission to ICU):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial function testing~* Neurophysiological examination (MVRC recording)~Follow-up inpatient examinations (day 2, 5 and 10 after admission):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial functions testing~* Neurophysiological examination (MVRC recording)~* Day 10 only: Extended neurophysiological examination according to diagnostic criteria~* Day 10 only: Grading of muscle strength (Medical Research Council (MRC) system)~Follow-up outpatient examination (after discharge from intensive care):~* Clinical examination~* Grading of muscle strength (MRC)~* Modified Rankin Scale (mRS)~* Barthel Scale~* Questionnaires (Short Form (36) Health Survey, Essener Questionnaire for Coping with a Disease and Beck's Depression Inventory II)"
214418332|NCT02621593|DEVICE|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
214505817|NCT01380145|BIOLOGICAL|recMAGE-A3 Protein + AS15 Adjuvant|recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
215018795|NCT03077308|PROCEDURE|Auditory and Visual Event-related Potentials and EEG|Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
215018796|NCT03954873|OTHER|Glucagon-like peptide 2|Human glucagon-like peptide 2
215018797|NCT03954873|OTHER|Saline|Placebo
215018798|NCT03954873|OTHER|Glucose|20% (w/v) glucose infusion for regulating plasma glucose
215018799|NCT03954873|OTHER|Insulin|Actrapid (insulin) for lowering plasma glucose
215018800|NCT05999851|DEVICE|Arterial applanation tonometry|Arterial applanation tonometry will be performed at the carotid and femoral level by the PulsePen device (Software WPulsePen version 2.3.1, DiaTecne, Milan, Italy), while the subject is lying in the horizontal position and after 5 minutes of rest.
215018801|NCT05999851|DEVICE|In vivo endothelial glycocalyx measurement|The in vivo microscopy (GlycoCheck system) is performed in the sublingual capillaries during the morning, with the participant sitting on a chair. The sublingual capillaries are visualized using an SDF video microscope (Capiscope handheld, KK Research technology Ltd).
215018802|NCT05999851|DIAGNOSTIC_TEST|Serum markers of angiogenesis and endothelial dysfunction|ELISA assays to measure serum circulating markers of angiogenesis and endothelial dysfunction (ANG-1, ANG-2, ET-1, ICAM-1 and VCAM-1).
215018803|NCT05999851|DIAGNOSTIC_TEST|Blood chemistry test|Immunochemistry analysis of serum levels of uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, Lipoprotein (a)
215018804|NCT05999851|DIAGNOSTIC_TEST|Serum xanthine oxidase activity|Serum xanthine oxidase (XO) activity will be assessed in blood samples measuring the ability of XO to produce uric acid
215018805|NCT04338620|DRUG|camrelizumab、albumin-bound paclitaxel and platinum|Experimental Group：camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
215018806|NCT04338620|DRUG|albumin-bound paclitaxel and platinum|"Control group：albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle.~Platinum included Cisplatin/carboplatin/Nedaplatin"
215018807|NCT00240773|DRUG|acetaminophen|4 grams daily for six months
215018808|NCT00240773|DRUG|naproxen|750 mg daily for 12 months
215018809|NCT00240773|DRUG|acetaminophen|4 grams daily for 12 months
215018810|NCT00240773|DRUG|naproxen|750 mg daily for six months
215018811|NCT00540761|DEVICE|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
215018812|NCT04088292|DRUG|Alteplase 20 Mg Powder for Solution for Injection Vial|Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
215018813|NCT04088292|DEVICE|Ultrasound assisted Thrombolysis|Ultrasound assisted thrombolysis (USAT)
215018814|NCT05732363|DEVICE|Ultrasonography|The US muscle measurement will be performed with the handheld portable Philips Lumify Sonography connected to a Samsung tablet. The measurement will take approximately 5-10 minutes. A seven-point measurement has to be performed based on the seven-site Jackson Pollock Generalized Prediction Equations for circumference and skinfold thickness measurements.6,7
215018815|NCT05732363|RADIATION|Dual-energy X-ray Absorptiometry|The brand of the DXA scanner is the Hologic Discovery A, which has a weight limit of 204 kilograms. During the DXA scan, patients will be exposed to radiation, which is approximately 0.2 micro Sievert (µSv) for measuring body composition. For comparison: the average amount of background radiation per hour is approximately 0.23 µSv. The DXA body composition scan will be performed according to standard protocol by a specialized technician.
215018816|NCT03776240|DRUG|HD201|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
214418333|NCT05172154|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test Kit|The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection
214418334|NCT04990219|DRUG|Lu AG06466|Lu AG06466 - capsule
214418335|NCT04990219|DRUG|Placebo|Placebo - capsule
214418336|NCT00811057|DRUG|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
215018817|NCT03776240|DRUG|EU-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
215018818|NCT03776240|DRUG|US-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
214418337|NCT00811057|DRUG|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
214418338|NCT00811057|DRUG|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
214418339|NCT04463524|DEVICE|Personal ECG digital sensor|Patients in test group will receive personal ECG sensor and in control gropu will not.
215018819|NCT01392196|PROCEDURE|Renal Denervation|Renal Denervation using the Symplicity Catheter in Heart Failure Population
215018820|NCT04352530|OTHER|Health Communication|Spoken word poems set to images performed by youth who wrote the poems. Videos were produced by The Bigger Project and were posted publicly to the Bigger Picture Project website and YouTube. Duration of videos ranges from 2 minutes to 6 minutes.
215018821|NCT03838705|PROCEDURE|hypoxia|It was accepted that hypoxia developed in patients with SpO2\< 92 or falling over 20% compared to preoperative values.
215018822|NCT03838705|PROCEDURE|normooxy|It was accepted that patients with SpO2 between 100-92 mmHg
214418340|NCT05365529|BEHAVIORAL|Time-Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
214418341|NCT05365529|BEHAVIORAL|Standard of Care|Participants in the Standard of Care group will continue to follow their physician's treatment plan for type II diabetes mellitus.
214418342|NCT06409988|OTHER|Safe discharge|There was no specific intervention, we only aimed to see if those admitted patients could have been safely dicharged from the emergency department.
215018823|NCT02214732|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
215018824|NCT00472641|DRUG|Ziprasidone/Geodon|Ziprasidone/Geodon
214418343|NCT02885311|BEHAVIORAL|Motivation Enhancement Therapy|Motivation Enhancement Therapy (MET) similarly allows for goal choice in treatment, and has been shown to be effective in treating a broad spectrum of drinking problems in both abstinent and non-abstinent goal conditions. The unique goals of MET (enhancing intrinsic motivation for change and facilitating development of a self-generated change plan).
214418344|NCT02885311|BEHAVIORAL|Modified Behavioral Self-Control Therapy|Motivational Interviewing was developed to increase self-efficacy and motivation for drinking, and Cognitive Behavioral Therapy allows for individuals to develop strategies for drinking reduction. Both are evidence-based interventions that have been combined in previous studies for drinking reduction in problem drinkers.
214418345|NCT02885311|DRUG|Naltrexone|Participants, who choose medication treatment, will be offered naltrexone (50 mg per day), which is an FDA-Approved medication for alcohol use disorder. According to the package insert for NTX, the medication has been associated with liver toxicity at very high doses (up to 300 mg/day); however, a number of clinical trials and published studies suggest there are few serious adverse effects, including minimal hepatotoxicity, associated with daily dose of 50 mg of naltrexone. Its most common side effects in opioid-free individuals are nausea, vomiting, anxiety, headache, abdominal discomfort, difficulty sleeping, fatigue, irritability, and decreased appetite. A rare serious adverse effect may include minimal liver toxicity, but is more likely to occur at very high doses (300 mg/day).
215018825|NCT00176215|PROCEDURE|survival failure of more than 20 %|
215018826|NCT01025895|PROCEDURE|acl reconstruction - double bundle technique|
215018827|NCT01025895|PROCEDURE|acle reconstruction - single bundle technique|
215018828|NCT04509011|DEVICE|Fluobeam® LX|Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
215018829|NCT02325895|OTHER|Dried Plum|Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
215018830|NCT04144764|OTHER|Workplace-based exercise|Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
215018831|NCT04144764|OTHER|Ergonomic advice and education|Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
215018832|NCT00239980|DRUG|dalteparin|50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
215018833|NCT05865249|OTHER|Spirometry decision support software (ArtiQ.Spiro)|ArtiQ.Spiro is a decision support software that combines two sub-components - one focussing on quality assessment (ArtiQ.QC), and one on spirometry interpretation (ArtiQ.PFT). It is intended to be used as an adjunct to spirometry to assist with the grading of spirometry quality and the interpretation of spirometry by providing the probability of six disease / or no disease categories.
215018834|NCT00377806|DRUG|Diclofenac gel|
215018835|NCT05907499|DRUG|Decitabine|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
215018836|NCT05907499|DRUG|Granulocyte Colony-Stimulating Factor|5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
214505818|NCT05080257|DEVICE|Lung Ultrasonography|"The ultrasonography will be done using the curved probe of the SONOACE R3 SAMSUNG ultrasonography machine, SN: S0GYM3HCC00016M, manufacture date: 12-2012.~Assessment of lung condition using the Lung Ultrasonography Score (total score calculated from the 12 standard examined areas, from 0 to 3 in each area, with a minimum of 0 up to 36)"
214505819|NCT04918394|OTHER|Questionnaire of Mold / moisture exposure|"Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home:~* Presence of visible mold~* Impression of dampness~* Apparent dampness~* Existence of recent water damage in the last year~* Presence of a moldy odor"
214505820|NCT02174146|PROCEDURE|non-surgical periodontal therapy|supra and subgingival debridement
215018837|NCT05907499|DRUG|Thrombopoietin Receptor Agonist|Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
215018838|NCT05907499|DRUG|Recombinant human erythropoietin|10000 U/day when hemoglobin ≤ 85 g/L
215018839|NCT04044287|DRUG|200 micrograms of misoprostol|200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
214418346|NCT02885311|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
215018840|NCT04044287|DRUG|Placebo Oral Tablet|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
215018841|NCT00451984|BIOLOGICAL|Twinrix|
215018842|NCT00451984|BIOLOGICAL|interleukin-2|
215018843|NCT00150527|DRUG|Citalopram|40 mg, pill, single dose
215018844|NCT00150527|DRUG|Escitalopram|20 mg, pill, single dose
215018845|NCT00150527|DRUG|Dexamethasone|1 mg, pill, single dose
215102253|NCT02600091|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
214418347|NCT02885311|OTHER|Referral to specialty substance use disorder treatment|Participants who present with complex drinking concerns will be referred to specialty substance use disorder treatment. This treatment will be provided in a separate treatment facility that focuses on substance use disorders and will potentially provide a combination of medication management and individual/group behavioral treatment for substance use disorders.
214418348|NCT04263545|BEHAVIORAL|Group session with smoking cessation counsellor|Group session with smoking cessation counsellor
215018846|NCT00150527|BEHAVIORAL|Cold Pressor Test|single test
215018847|NCT00139035|DRUG|cyclosporine A|
215018848|NCT02178189|OTHER|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
215018849|NCT02178189|OTHER|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
215018850|NCT02988557|PROCEDURE|walking on a treadmill with a sloped surface|walking on a treadmill with a sloped surface
215018851|NCT02988557|DEVICE|treadmill|walking on a treadmill with a sloped surface
215018852|NCT02979158|PROCEDURE|CPB Low Dose|Performing CPB with low dose heparin and coated equipment
215018853|NCT02979158|PROCEDURE|CPB High Dose|Performing CPB with high dose heparin and uncoated equipment
215018854|NCT03693508|DRUG|Genvoya®|Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
215018855|NCT04615988|OTHER|blood draw and questionnaire completion|questionaires provided to subjects during visits while on study and baseline one tube of blood drawn
214418349|NCT04263545|BEHAVIORAL|Standard Care|standard care arm will receive very brief advice (VBA) and signposting to local organisations to support a quit.
214418350|NCT03699488|BEHAVIORAL|psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
214418351|NCT00768651|DRUG|Pantoprazole|Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
214418352|NCT00768651|DRUG|Sitagliptin|Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
214418353|NCT00515450|BIOLOGICAL|GB-0998 (Intravenous immunoglobulin)|
214418354|NCT00515450|PROCEDURE|Plasmapheresis|
214418355|NCT02444013|DRUG|Folic acid|
214418356|NCT02444013|DRUG|Placebo|
214418357|NCT03766711|OTHER|Physical Therapy|Repetitive bimanual task training for upper limb motor function recovery.
214418358|NCT03799380|DIETARY_SUPPLEMENT|Gatorade G2|Gatorade (G2), 20 oz. bottle, daily through the entire course of radiation therapy (approximately 5-7 weeks)
214418359|NCT03799380|DIETARY_SUPPLEMENT|Standard of care nutritional support|Standard of care nutritional support
214418360|NCT05134025|OTHER|Pump settings|Alteration in the pump setting prior to exercise commencement
214418361|NCT06272162|RADIATION|MR guided radiotherapy|5 fractions of 10 Gray MRgRT in addition to standard of care
214418362|NCT04367376|OTHER|mobilization|central postroanterion mobilization on the most painful vertebral level at the lumbar spine
214418363|NCT04367376|OTHER|manual therapy|manual therapy
214418364|NCT04367376|OTHER|instrumental manual therapy|instrumental manual therapy
214418365|NCT02156609|DEVICE|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
214418366|NCT00193518|DRUG|Arsenic Trioxide|
214418367|NCT05027178|OTHER|Chiropractic Care|Chiropractic care on stroke participants
214418368|NCT02104765|DRUG|LY2951742|Administered subcutaneously.
214418369|NCT02104765|DRUG|Placebo|Administered subcutaneously.
214418370|NCT06113406|BEHAVIORAL|Classroom Training|Active Comparator
214418371|NCT06113406|BEHAVIORAL|Virtual Reality Training|Experimental
215018856|NCT04615988|OTHER|questionnaire completion, blood collection|questionnaire provided to subject during study visits. One tube blood collected for research purposes at baseline
215018857|NCT00103753|DRUG|deferiprone|
215018858|NCT05706675|PROCEDURE|Non surgical periodontal therapy|Manual root planning+Ultrasonic subgingival debridement
215018859|NCT03374904|BEHAVIORAL|Video Feedback|first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.
215018860|NCT03374904|BEHAVIORAL|Control Group|Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
215018861|NCT02622594|DRUG|Aminolevulinic Acid (ALA)|
215018862|NCT02622594|DEVICE|Environ Cosmetic Roller|
215018863|NCT02622594|DEVICE|BLU-U IIlluminator|
214418372|NCT01970618|DRUG|RV1162 single dose|Safety and tolerability of single escalating doses
214418373|NCT01970618|DRUG|RV1162 matching placebo single dose|Safety and tolerability of single escalating doses
214418374|NCT01970618|DRUG|RV1162: 7 day repeat dose|Safety and tolerability of a repeat dose
214418375|NCT01970618|DRUG|RV1162 matching placebo: 7 day repeat dose|Safety and tolerability of a repeat dose
214418376|NCT01970618|DRUG|RV1162: 14 day repeat dose|Safety and tolerability of repeat escalating doses
215018864|NCT00558207|DRUG|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
214418377|NCT01970618|DRUG|RV1162 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
214418378|NCT03201224|DEVICE|"After Group"|
215018865|NCT00558207|DRUG|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
214418379|NCT04204564|DEVICE|pactlitaxel PAD device|Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.
215018866|NCT03721107|BIOLOGICAL|Blautix|Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.
215018867|NCT03721107|OTHER|Placebo|Placebo control
214418380|NCT03990038|DRUG|Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h|Group C receive the intervention Group U receives the placebo See arm description
215018868|NCT03807167|OTHER|Mattis Dementia Rating Scale|This scale was developed to assess the cognitive status of patients with neurodegenerative diseases. There are 37 items that are presented in a fixed order and grouped into five sub-scales: attention, initiation, construction, conceptualization and memory. Patients and healthy subjects with a score below 125 are not included because of major cognitive impairment.
214505821|NCT01672684|PROCEDURE|support group therapy|Complete at-home group video calling support sessions
214505822|NCT01672684|OTHER|educational intervention|Receive an educational workbook journal
214505823|NCT06211998|DEVICE|Group 1|Salbutamol inhaler, Omron® CompAIR Pro NE-C900 Compressor Nebulizer (Omron Healthcare Co., Ltd., Kyoto, Japan) was used in Group 1
214505824|NCT06211998|DEVICE|Group 2|Salbutamol inhaler, Mesh nebulizer (Aerogen Solo®, Aerogen Ltd, Galway, Ireland) was used in Group 2
215018869|NCT03807167|OTHER|Unified Parkinson 's Disease Rating Scale-III|This scale is used to rate the severity of extra-pyramidal symptoms (akinesia, rigidity and tremors). These symptoms may be the cause of reduction of motor activity apart from any reduction in motivation, they onstitute a confounding factor that it should be controlled.
215102254|NCT00501865|DRUG|GW273225|GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
215102255|NCT04741763|DIETARY_SUPPLEMENT|EyePromise Visual Edge|A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
214505825|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
214505826|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an IV infusion.
214505827|NCT05139615|DRUG|Placebo|Participants will receive a single dose of APD418 matching placebo as an IV infusion.
215102256|NCT01289366|DEVICE|Endocytoscopy|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
215102257|NCT03579641|DEVICE|HeartLogic Sensors|HeartLogic Sensors
215102258|NCT01323140|DRUG|testosterone matrix transdermal system|
215102259|NCT01623739|PROCEDURE|Placement of a dental implant|Type 1 implant placement Type 2 implant placement
215102260|NCT06276166|OTHER|No intervention|No intervention
215102261|NCT03342092|OTHER|Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
214505828|NCT04997798|DRUG|Trastuzumab Pyrotinib Exemestane Dalpiciclib|Early triple positive breast cancer patients receive combination regimen of Dalpiciclib in Combination With Exemestane and Trastuzumab plus pyrotinib
214505829|NCT04746404|BEHAVIORAL|Emotional Skills Development Program|Emotional Skills Development Program (positive psychology)
215102262|NCT02013245|BIOLOGICAL|MTBVAC live vaccine|Live-attenuated Mycobacterium tuberculosis vaccine
215102263|NCT02013245|BIOLOGICAL|Commercially available BCG live vaccine|Live-attenuated Mycobacterium bovis vaccine
215102264|NCT00065845|PROCEDURE|Burch urethropexy at time of sacrocolpopexy|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
215102265|NCT03468647|OTHER|soles|Volunteer must walk this this connected seamless to measure different walking parameters
215102266|NCT03468647|OTHER|weighting machine|This weighting machine measure weight evolution and equilibrate of volunteers
215102267|NCT03468647|OTHER|gripping force|this machine measure the gripping force of volunteer
214418381|NCT03990038|DRUG|Extended Release Capsule|"Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description"
215018870|NCT03807167|OTHER|Mini Neuropsychiatric Investigation|This is a structured interview that allows rapid screening in about 20 minutes of troubles Psychiatric. It is based on short questions to which the patient must answer yes or no and on a decision tree. Patients must validate clinical diagnoses of depression.
214418382|NCT06189105|OTHER|miss alice face it you love me serum|Facial serum with niacinamide, plant-based collagen and peptides will be applied by each participant to the treatment site according to randomization protocol every evening
214418383|NCT06189105|OTHER|No treatment (usual skincare rutine)|No treatment (usual skincare rutine)
214418384|NCT04332757|OTHER|Training intervention.|The investigators have designed a phased 18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation. The rehabilitation element of the programme will specifically target pelvic floor function and core strength and stability (known collectively as Core Reconnection training) from weeks 6 to 24 postpartum, and the training element of the programme will contain resistance and high-intensity interval training (HIIT) from weeks 12 to 24 postpartum.
214418385|NCT03338218|DRUG|Volulyte 6%|Solution for infusion
214418386|NCT03338218|DRUG|Ionolyte|Solution for infusion
214418387|NCT05453682|RADIATION|hypo-IMRT|Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume.
214418388|NCT00281762|DRUG|NSAID|
214418389|NCT06554197|DIAGNOSTIC_TEST|CMV/EBV-CMI|The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90 days, 120 days, 180 days after transplantation.
214689800|NCT04009174|OTHER|Imaging Panel|"Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~* \[18F\]-FCH PET + Dynamic CT~* MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~* 3D-Transrectal ultrasound~* Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~* Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~* \[18-F\]-DCFPyL PET+Dynamic CT~* PET/MRI with endorectal coil~* 3D-Transrectal Ultrasound~* Optional Sodium (23Na) MRI"
214689801|NCT00136747|DRUG|Memantine|Two capsules of Memantine twice daily for 12 days.
214689802|NCT00136747|DRUG|bupropion|
215018871|NCT03807167|OTHER|Montgomery and Asberg depression Rating Scale|This scale is composed of 10 items from 0 to 6 from a semi-structured interview, to obtain a total depression score of 0 to 60 (0 no depression, 60 maximum intensity of depression).
215018872|NCT03807167|OTHER|Clinical Global Impression|heterosexual assessment that rates the severity of symptoms suicidal and changes in suicidal symptoms. Any subject with a score greater than 4 is not included.
215018873|NCT03807167|OTHER|Apathy diagnostic criteria|The clinical criteria make it possible to make a diagnosis of apathy with a functional repercussion. It is based on a lack of motivation felt by the patient, causing a functional or social impact that is not the consequence of a disturbance of consciousness or a disability engine. The cognitive, emotional and behavioral dimensions are affected.
215018874|NCT03807167|OTHER|walking speed test|The patient is timed to walk 10m. A speed \<1m / sec is a criterion exclusion because it shows severe sarcopenia and constitutes a bias.
214418390|NCT01024179|DEVICE|Polymer-based sirolimus-eluting stent (Partner stent )|Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
214689803|NCT00136747|DRUG|placebo|
214689804|NCT01193192|OTHER|Neevo®|"A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid"
214689805|NCT01193192|OTHER|Prenatal vitamins|for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
215018875|NCT03807167|OTHER|accelerometer presentation|accelerometer presentation and pose
215018876|NCT03807167|OTHER|data acquisition from the accelerometer|withdrawal of the accelerometer and data acquisition from the accelerometer
215018877|NCT03807167|OTHER|Apathy Evaluation Scale,|clinician version and near-helping version. It's a hetero rating scale from an interview semi structured by a trained clinician. It assesses cognitive, emotional and behavioral apathy than three items of various apathy. The total score ranges from 18 (total absence of apathy) to 72.
215018878|NCT03807167|OTHER|fatigue Visual Analog Scale|To date, there is no valid fatigue scale in the depression of the elderly subject, a fortiori in French. The fatigue scale in adult depression includes has been validated with an EVA (Visual Analogue Scale) (38). We therefore propose to use this type of evaluation to control this aspect.
215018879|NCT03807167|OTHER|executive function|"* Modified Card Sorting Test MCST(Modified Card Sorting Test) (Wisconsin Test): This test assesses conceptualization, attention and mental flexibility using a deck of cards.~* Trail Making Test (TMT): This test is used to assess mental flexibility.~* Fluences verbal: This test tests the capacities of setting up search strategies in memory semantics and oral language.~* Stroop Paradigm: This test is used to evaluate the resistance to interference, ie the patient's ability to inhibit some over-learned and automated responses."
215018880|NCT03807167|OTHER|MRI|An MRI lasting 30 minutes is programmed
215018881|NCT03807167|OTHER|Apathy Motivation Index|"This is a self-questionnaire of 18 items, each side on a 5-level Likert scale (0: not everything at 4: very often). It differentiates between behavioral apathy and social apathy.~Emotional."
215018882|NCT05285150|OTHER|Survey|It´s a survey
215018883|NCT01189227|PROCEDURE|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
215018884|NCT01189227|PROCEDURE|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
215102268|NCT03782922|OTHER|Exercise Training Program|10min of coordination and strength training (2-3x per week) during 2-6 weeks
215018885|NCT06269601|DIAGNOSTIC_TEST|Upper Limb Rotation Test|The athletes were instructed to perform a 90° abduction and 90° external rotation of the shoulder, accompanied by trunk rotation for a duration of 15 seconds. The number of repetitions was recorded. The tested side was the upper extremity in which the closed kinetic chain position was maintained. The test was repeated three times, and the average of the results was calculated.
215018886|NCT01977976|PROCEDURE|Endometrial aspiration by pipelle|Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
215018887|NCT00873886|DRUG|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
215018888|NCT00873886|PROCEDURE|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
215102269|NCT05618418|OTHER|No intervention|No intervention
215102270|NCT06474403|PROCEDURE|standard Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
215102271|NCT06474403|PROCEDURE|modified Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
215102272|NCT01879969|PROCEDURE|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
214418391|NCT02124460|BEHAVIORAL|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
214418392|NCT00331162|DRUG|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
214418393|NCT00331162|DRUG|Anti-Thymocyte Globulin|"1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr \< 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature \> 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours"
214418394|NCT05880238|BEHAVIORAL|Intervention group|The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.
214418395|NCT05880238|OTHER|Control group|The control group will continue their education according to the preschool education curriculum.
214418396|NCT04168814|OTHER|Observational test|Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site. Covid-19 diagnosis.
214418397|NCT05976854|OTHER|Pain neuroscience education|The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 Pain neuroscience education lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler \& Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.
214505830|NCT03531242|BIOLOGICAL|0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1|"administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (\< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
214689806|NCT01658696|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu heterologous prime-boost immunisation
215018889|NCT03000751|OTHER|Simple Audit Report|The simple audit provides comparison and feedback on radiation doses.
215018890|NCT03000751|OTHER|Multi-Component Intervention|The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
214418398|NCT05976854|OTHER|Prenatal education|The standard prenatal education is based on the Pregnancy and Postpartum Clinical Practice Guide, consisting of general information about pregnancy (visits and monitoring of pregnancy, diet, phases of delivery, lactation, etc.), as well as specific recommendations for lumbopelvic pain associated with pregnancy. These contents will be developed by midwives from the participating hospitals. Participants will receive 12 educational sessions, with an estimated duration of 10 minutes each.
215018891|NCT03000751|OTHER|In-Person Meeting|Collaborator meeting with an emphasis on quality improvement.
214418399|NCT06560840|OTHER|dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
215018892|NCT06097988|DEVICE|ABIO3419|Intra-articular injection
215018893|NCT01885234|OTHER|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
215018894|NCT01885234|OTHER|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
215102273|NCT01879969|PROCEDURE|computer assisted orthognathic planning and surgery of asymmetric patients|
214505831|NCT00724737|PROCEDURE|Presurgical MRI|"People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
214505832|NCT00724737|PROCEDURE|functional MRI (fMRI) of the brain|"Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
214505833|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Flexible Cystosocpy|Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
214505834|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Rigid Cystoscopy|Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
214505835|NCT03848975|OTHER|Simulation training for ECV|Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.
214505836|NCT03848975|OTHER|Simulation training for VE|Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
214505837|NCT05687214|OTHER|Osteopathic manipulative treatment|"Each participant in the experimental group will receive eight osteopathic manipulative treatments. Each treatment will include the following manipulations:~* Pompage Cv4;~* Occipital-sternal technique;~* Relaxining manipulation of the diaphragmatic domes;~* Pelvic and abdominal diaphragm synchronization;~* Dynamogenic technique;~* Mesenteric traction;~* Release of colic angles;~* Manipulation and mobilization of the sacrum."
214505838|NCT04552457|BEHAVIORAL|No activity restrictions|"Patients in the No activity restrictions group will be allowed to return to their normal activity immediately."
214689807|NCT01658696|BIOLOGICAL|Rabies vaccine|2 x 2.5IU Verorab
215018895|NCT05417386|DRUG|FOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
215018896|NCT05417386|DRUG|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
215018897|NCT05417386|DRUG|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
215018898|NCT05417386|DRUG|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
215018899|NCT05417386|DRUG|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
215018900|NCT05417386|DRUG|NIS793|Given by intravenous infusion
215018901|NCT05417386|RADIATION|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
215018902|NCT05417386|DRUG|Capecitabine|Taken Orally as part of Chemoradiation
215018903|NCT05417386|RADIATION|Radiation Therapy|Radiation Therapy as part of Chemoradiation
215018904|NCT05417386|PROCEDURE|Surgery|Surgical removal of tumor
215102274|NCT02760316|DRUG|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
215102275|NCT02760316|DRUG|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
215102276|NCT02760316|DRUG|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
215102277|NCT02760316|DRUG|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
215102278|NCT02760316|DRUG|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
215102279|NCT02760316|DRUG|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
215102280|NCT02760316|DRUG|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
214418400|NCT06107517|OTHER|DREAMS-OT|"Patients will receive the DREAMS-OT protocol 3 times per day, 20 minutes per therapy session.~Intervention frequency will be confirmed with a feasibility trial. If not feasible to maintain 3 times per day, the intervention will still be maintained at the same intensity of 1 hour per day, with a graded approach."
215018905|NCT01378273|DRUG|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
215018906|NCT01378273|OTHER|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
215018907|NCT05474716|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.
215018908|NCT03686722|DRUG|Metformin|Metformin is used primarly in treatment of diabetes type II
215018909|NCT03686722|DRUG|Daclatasvir|Daclatsvir is a direct acting antiviral drug
215018910|NCT06514729|PROCEDURE|Adopting different ventilation modes during the operation|The ventilation side adopts different ventilation modes combined with continuous positive pressure ventilation on the surgical side.
215018911|NCT06269666|DEVICE|P200TxE|SLO and OCT imaging
215018912|NCT01608308|DRUG|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
214418401|NCT01657318|OTHER|Olivamine containing wound care products|Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
214418402|NCT00926939|BEHAVIORAL|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
214418403|NCT00926939|BEHAVIORAL|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
214418404|NCT04840862|DRUG|Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]|Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
214418405|NCT04840862|DRUG|Rifabutin 300mg|After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
214418406|NCT03256682|BEHAVIORAL|Stress management counseling|stress management counseling based on CBT and relaxation
214418407|NCT00995709|DRUG|AIN457|
215018913|NCT01608308|DRUG|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
215018914|NCT06437366|BEHAVIORAL|Nurse-Led Heart Math Training Program|"he nurse-led HeartMath training program consists of several key components designed to enhance resilience, sense of coherence, and emotional adjustment:~Heart-Focused Breathing Techniques: Patients are taught specific breathing techniques that help synchronize heart and brain activity, leading to a state of physiological coherence.~Emotional Regulation Skills: The training includes exercises that help individuals recognize and shift from negative to positive emotional states, thereby improving emotional stability and reducing stress."
215018915|NCT06140238|DRUG|Parecoxib|Parecoxib administration 15 minutes before start surgical operation
215018916|NCT06140238|DRUG|Normal saline|Normal saline administration 15 minutes before start surgical operation
215018917|NCT04867590|DEVICE|Endorotor|"The treatment itself is preceded by a sub-mucosa saline and adrenalin solution injection administered by an endoscopic sclerotherapy needle lifting the submucosa and thus reducing the risk of perforation and hemorrhage.~The interventional tool is then applied tangentially to be brought into contact with the lifted mucosa, visual monitored by endoscope. The aspiration and sectioning system is activated by use of a pedal and a generator specially made for the system, used in every procedure. The entire surface area of the targeted mucosa must be covered by the probe. The residual tissue is then removed via the aspiration system and caught by a filter. The specimens are then easily retrievable at the end of the procedure and can be stored in formalin fixing solution for histological analysis."
214418408|NCT00995709|DRUG|AIN457|
214418409|NCT00995709|DRUG|Placebo|
214418410|NCT05123638|DEVICE|Virtual reality cycling exercise|Daily voluntary cycling for up to 30 minutes with the virtual reality technology
214418411|NCT05123638|BEHAVIORAL|Unsupervised stationary cycling exercise|Daily voluntary cycling for up to 30 minutes (WITHOUT the virtual reality technology)
214418412|NCT00421902|PROCEDURE|Acupuncture|Patients will be have acupuncture (with electro stimulation)
214418413|NCT04758897|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
214418414|NCT05998096|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Caffeine-based energy drink containing 200 mg caffeine
214418415|NCT05998096|DIETARY_SUPPLEMENT|Placebo|Placebo void of all active ingredients
214418416|NCT03317639|BEHAVIORAL|Behaviour Change Wheel model guided intervention|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
214418417|NCT03904199|DRUG|Insulin|Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
214418418|NCT04204837|DRUG|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
214418419|NCT04204837|DRUG|Nivolumab plus Relatlimab|Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
214418420|NCT02178917|OTHER|Neurofeedback therapy|
214418421|NCT02178917|OTHER|No neurofeedback therapy|
214689808|NCT06515652|DRUG|rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun|Comparing allopathic and herbal group of drugs for metabolic syndrome
214689809|NCT00988559|BIOLOGICAL|DNA vaccination|vaccination with pNGVL4a-CRT/E7(detox)
214418422|NCT00846313|OTHER|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
214418423|NCT01111903|DRUG|Lenalidomide|Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
214418424|NCT01697319|DRUG|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
214418425|NCT05391724|DRUG|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
214418426|NCT02984319|DIETARY_SUPPLEMENT|Cherry versus placebo concentrate|Acute cherry concentrate
214505839|NCT04552457|BEHAVIORAL|Activity restrictions|"Patients in the Activity restrictions group will not be allowed to perform strenuous exercise or lift anything greater than 10lbs. Strenuous exercise will be defined as is any activity that requires so much exertion that one cannot have a conversation comfortably while doing it."
214505840|NCT02038049|DRUG|VAY736|Single intravenous infusion of VAY736 (10 mg/kg)
214505841|NCT02038049|DRUG|Placebo|Placebo to VAY736
214505842|NCT01691716|DRUG|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
214505843|NCT01691716|BEHAVIORAL|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
214505844|NCT05364840|DRUG|STI-1558|Orally available protease inhibitor capsule
214505845|NCT05364840|DRUG|Placebo|Placebo product capsule
214505846|NCT02656147|BIOLOGICAL|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
214505847|NCT03540329|DEVICE|Internal Osteogenesis distractor|Internal distraction osteogenesis in mandible
214505848|NCT03540329|DEVICE|External Osteogenesis distractor|External distraction osteogenesis in mandible
214505849|NCT00586755|PROCEDURE|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
214505850|NCT01378884|DRUG|Domperidone|Patient to receive treatment with Domperidone
214505851|NCT02454556|DRUG|FOLITIME®|
214505852|NCT02454556|DRUG|Gonal-F®|
214505853|NCT02905292|OTHER|evaluation and treatment maneuver for BPPV|
214505854|NCT04540926|DRUG|Cyclosporin A|COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
214505855|NCT06499116|DRUG|Topiramate|Treatment will be prescribed for GPs and they will decide the specific dosage 25-100 mg/12h.
214505856|NCT06499116|DRUG|Flunarizine|Treatment will be prescribed for GPs and they will decide the specific dosage 2,5-10 mg mg/24h.
214505857|NCT06499116|DRUG|Amitriptyline|Treatment will be prescribed for GPs and they will decide the specific dosage 10-75 mg/24h.
214505858|NCT06499116|DRUG|Propranolol|Treatment will be prescribed for GPs and they will decide the specific dosage 20-120 mg/12h.
214505859|NCT01030315|DRUG|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
214505860|NCT05013398|BEHAVIORAL|The Together Webinar Programme|"The TTP-Webinar consists of six hour-long sessions. Each session focuses on psychoeducation and self-management strategies for supporting veteran mental health difficulties as well as self-management tools to enhance partners' own wellbeing.~The TTP-Webinar treatment protocol incorporates a range of techniques used in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Compassion Focused Therapy (CFT), and Acceptance and Commitment Therapy (ACT)."
215018918|NCT04867590|DEVICE|Radiofrequency|"Endoscopic treatment using the HALO® 360 or 90 system is a thermal method for destroying the superficial mucosa. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.~For circumferential BEs, a single-use 360 Express® probe is used to make it possible to size the diameter of the esophagus and the treatment used. The length of the treatment area is 5 cm and several points of impact can be achieved by overlapping the catheter at two consecutive heights, with the zone spanned measuring one centimeter, in order to cover the entire pathological area requiring treatment.~For non-circumferential lesions a palette applicator is used in a variety of sizes, and in this context no sizing of the esophagus is required."
215102281|NCT02760316|DRUG|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
215102282|NCT02760316|DRUG|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
214418427|NCT04222959|BEHAVIORAL|Girls Invest Intervention|"App-based trainings: The first 2 modules cover gender and cultural norms related to girls' social and economic empowerment, increasing girls' recognition of the importance of financial literacy and independence. The last 3 modules cover finance, educational loans, and employment.~Savings account: Participants receive $100 deposited into a savings account we set up for them, conditional upon completion of app-based trainings."
214418428|NCT03872869|OTHER|Hip school or Tai CHi for arthritis|Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group
214418429|NCT02183246|DRUG|Porfiromycin|
215102283|NCT01512992|PROCEDURE|Home telehealth|"Patients receive tailored intervention according to their clinical complexity.~All patients in the intervention group receive:~* Personalised care plan~* Education on self-management~* Access to a personalized online health folder~* Access to Call center~* Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).~Patients with LOW complexity additionally receive:~* Daily videoconferences for the 1st week after discharge~* Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.~Patients with HIGH complexity additionally receive:~* Videoconferences for at least 1 month after discharge, scheduled on an individual basis.~* Remote monitoring for respiratory parameters.~* One monthly phone call from the call centre to promote and assess patient self-management."
215102284|NCT05848362|OTHER|Blood Glucose Measurement Values Taken by Different Methods|"In total, blood samples will be collected from 3 different sites (central venous catheter, capillary, arterial catheterization) in the same patient. In total, with 5 different techniques from 3 different regions from the same patient;~ARTERIAL BLOOD SAMPLE i) Washing with 5 cc 1% Heparin fluid ii) Washing with 10 cc 1% Heparin fluid CAPILAR BLOOD SAMPLE iii) Right / Left Fingertip iv) Thumb base CENTRAL VENOUS CATHETERIZATION BLOOD SAMPLE will be collected."
215102285|NCT02340416|DEVICE|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
215102286|NCT06504186|DRUG|Blinatumomab|"* Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles."
214505861|NCT04119947|DRUG|SY-009|The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
214505862|NCT01890278|RADIATION|Whole Brain IMRT|
215102287|NCT04552106|DIETARY_SUPPLEMENT|3 caps x3/day|3 capsules 3 times daily for 28 days
215102288|NCT04552106|DIETARY_SUPPLEMENT|3 caps x2/day|3 capsules 2 times daily for 28 days
215102289|NCT04552106|DIETARY_SUPPLEMENT|2 caps x3/day|2 capsules 3 times daily for 28 days
215102290|NCT04552106|DIETARY_SUPPLEMENT|2 caps x2/day|2 capsules 2 times daily for 28 days
215102291|NCT04552106|DIETARY_SUPPLEMENT|3 caps x1/day|3 capsules 1 times daily for 28 days
215102292|NCT03235089|DEVICE|Test Lens|Daily disposable contact lens
215102293|NCT03235089|DEVICE|Control Lens|Focus Dailies All Day Comfort contact lens (nelfilcon A)
214418430|NCT02183246|DRUG|Placebo|
214418431|NCT02183246|RADIATION|Radiotherapy|
214418432|NCT01516788|OTHER|Phototesting|Single MED dose on Day 2
214418433|NCT01549730|PROCEDURE|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
214505863|NCT01890278|RADIATION|Conventional Whole Brain RT|
214505864|NCT01808534|DRUG|palifosfamide|Given IV
214505865|NCT05186402|PROCEDURE|Total or subtotal gastrectomy|Gastric resection with digestive continuity according Roux or Bilroth
214505866|NCT00002599|BIOLOGICAL|filgrastim|
214505867|NCT00002599|BIOLOGICAL|recombinant interferon alfa|
214505868|NCT00002599|BIOLOGICAL|sargramostim|
214505869|NCT00002599|DRUG|carmustine|
214505870|NCT00002599|DRUG|cyclophosphamide|
214505871|NCT00002599|DRUG|doxorubicin hydrochloride|
214505872|NCT00002599|DRUG|melphalan|
214505873|NCT00002599|DRUG|methylprednisolone|
214505874|NCT00002599|DRUG|prednisone|
214505875|NCT00002599|DRUG|vincristine sulfate|
214505876|NCT00002599|RADIATION|low-LET cobalt-60 gamma ray therapy|
214505877|NCT00002599|RADIATION|low-LET photon therapy|
215102294|NCT01595555|BEHAVIORAL|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
215102295|NCT05997706|PROCEDURE|Testicular biopsy|Testicular biopsy is a clinical procedure for extraction of testicular tissue
215102296|NCT00953563|DEVICE|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
214418434|NCT02401919|BEHAVIORAL|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
214418435|NCT01109095|BIOLOGICAL|HER.CAR CMV-specific CTLs|"HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:~* 1 x 10\^6/m\^2~* 3 x 10\^6/m\^2~* 1 x 10\^7/m\^2~* 3 x 10\^7/m\^2~* 1 x 10\^8/m\^2"
214418436|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
214418437|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft. The injectable PRF will be added to the particulate demineralized dentin graft forming sticky demineralized tooth graft then inserted in the extraction socket and covered then suturing
214418438|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
214418439|NCT00392678|DRUG|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
214418440|NCT00392678|DRUG|Placebo|Placebo to Salsalate
214418441|NCT04710225|PROCEDURE|Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting|"Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= \[SBP+10\]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure."
214418442|NCT02039713|DEVICE|DeSyne drug eluting stent group|
214418443|NCT06206330|OTHER|Platelet rich plasma|After application of platelet rich plasma after surgery, the patients have examined for infection, hematoma, pain, recurrence and the time of epithelialization of the wound.
214418444|NCT01322919|PROCEDURE|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
214418445|NCT01623349|DRUG|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
214418446|NCT01623349|DRUG|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
214418447|NCT01694628|BEHAVIORAL|CLIMB (COPD Lifestyle, Mood, and Behavior)|Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
214418448|NCT06555146|DRUG|Semaglutide, 0.5 mg/mL|1 subcutaneous injection on baseline day
214418449|NCT06555146|DRUG|Placebo, Saline|1 subcutaneous injection on baseline day
214418450|NCT02703740|DEVICE|Hyaluronic acid dermal filler with lidocaine 0.3%|injection in labial fold of a dermal filler
214418451|NCT05262803|GENETIC|CYP2C19*2/*3|"* Non-carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with clopidogrel and ASA~* Carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with prasugrel (or ticagrelor) and ASA"
214418452|NCT05262803|OTHER|Shorter DAPT duration|Duration of DAPT is shortened to 3 months
214418453|NCT02083991|DRUG|Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon|
214418454|NCT02519699|DRUG|norepinephrine|Increase in mean arterial pressure using norepinephrine
214418455|NCT03008915|DRUG|Aspirin|81mg aspirin taken once per day in the morning
214418456|NCT03008915|DRUG|Placebo|placebo taken once per day in the morning
214418457|NCT03008915|OTHER|Withdrawal from alpha1 antitrypsin replacement therapy|After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
215102297|NCT01032499|DRUG|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
215102298|NCT01032499|DRUG|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
215102299|NCT02747368|DEVICE|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
215102300|NCT03969017|DRUG|pegylated interferon (Peg IFN)α-2b|Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg \<0.05IU/ml, with a maximum duration of 48 weeks.
215102301|NCT03969017|DRUG|Nucleoside （acid）analogue (NAs)|Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
215102302|NCT03006224|OTHER|One Lung Ventilation|
215102303|NCT05061498|DIAGNOSTIC_TEST|Additional Pacing maneuvers|In order to determine the optimal setting for pacemapping in all participants additional pacing maneuvers (output and cycle length) are performed
215102304|NCT00002122|DRUG|Azithromycin|
215102305|NCT00002122|DRUG|Rifabutin|
215102306|NCT00002122|DRUG|Fluconazole|
215018919|NCT06054880|DRUG|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
214418458|NCT04411836|DRUG|Tafenoquine|patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
214418459|NCT04411836|DRUG|Primaquine|patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
214418460|NCT06554769|PROCEDURE|non rigid indirect anchorage connection|a nonrigid connection is placed between the miniscrews and the second premolar to prevent mesial tooth movement.
214418461|NCT06554769|PROCEDURE|rigid indirect anchorage connection|a rigid connection is placed between the miniscrews and the first molar to prevent mesial tooth movement.
214418462|NCT02098382|DEVICE|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
214418463|NCT01944319|DRUG|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
214418464|NCT01944319|DRUG|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
214418465|NCT01139398|DIETARY_SUPPLEMENT|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
215018920|NCT06054880|OTHER|Saline injection 0.9%|Placebo
215018921|NCT05330546|PROCEDURE|Densah burs|using Densah burs to prepare implant osteotomy
215018922|NCT05330546|PROCEDURE|Ridge expansion screws|using Ridge expansion screws to prepare implant osteotomy
215018923|NCT04648241|BIOLOGICAL|TBE vaccine 0.5 mL|TBE vaccine 0.5 mL (intramuscular injection).
215018924|NCT04648241|BIOLOGICAL|TBE vaccine 0.25 mL|TBE vaccine 0.25 mL (intramuscular injection).
214418466|NCT02994017|OTHER|cardiopulmonary exercise testing|The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
214418467|NCT06395311|OTHER|COPD psychological well-being assessment|Patients will complete the following questionnaires: Hospital Anxiety and Depression Scale (HADS), COPD Assessment Test (CAT), State Shame and Guilt Scale (SSGS), Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE), Brief Fear of Negative Evaluation Scale (BFNE), Self-Compassion Scale Short Form (SCS-SF). Dyspnea will be evaluated with the mMRC scale, and functional capacity will be assessed with the six-minute walking test (6MWT).
214418468|NCT05972694|DIETARY_SUPPLEMENT|Freeze dried grape powder|46g/d freeze-dried grape powder
214418469|NCT05450302|OTHER|PURE EP (Observational Study)|This is an observational study. No interventions involved in this study.
214505878|NCT00407732|BEHAVIORAL|psychosocial intervention|motivational enhancing case management intervention
214505879|NCT01355445|DRUG|Vincristine, Irinotecan|"* D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
214505880|NCT01355445|DRUG|Vincristine, Irinotecan, Temozolomide|"* D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience \> grade 3 toxicity of any kind)~* D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
214505881|NCT02660086|BEHAVIORAL|Personalized nutrition feedback|Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
214505882|NCT00063089|DRUG|S. aureus Immune Globulin Intravenous (Human) 5%|
214505883|NCT01653509|DEVICE|Acyclovir patch|Patch containing acyclovir
214505884|NCT01653509|DEVICE|Placebo patch|Patch without acyclovir
214505885|NCT05338567|DIAGNOSTIC_TEST|Small intestine length measurement method|Accuracy of digital 3D reconstruction for predicting small bowel length
214505886|NCT04089930|DIAGNOSTIC_TEST|Immunogenicity|anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)
214505887|NCT00667017|BIOLOGICAL|RFT5-dgA immunotoxin|
214505888|NCT00667017|OTHER|fluorescence activated cell sorting|
214505889|NCT00667017|OTHER|immunohistochemistry staining method|
214505890|NCT00188747|PROCEDURE|Thromboelastograph, Point of Care|
214505891|NCT00505986|PROCEDURE|endometrial biopsy|
214505892|NCT00038636|DRUG|Lopinavir/ritonavir|
214505893|NCT00038636|DRUG|Ritonavir|
214505894|NCT05174520|OTHER|Routine Physical Therapy|Routine physical therapy will be provided to group A for 25 minutes thrice a week for 4 weeks.
214689810|NCT00988559|DEVICE|Gene gun vaccine|8 micrograms (group 1) or 16 micrograms (group 2)
215018925|NCT05677126|DRUG|Tralement|Tralement with Manganese
215018926|NCT05677126|DRUG|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese
215018927|NCT05259722|DRUG|Delgocitinib|Cream for topical application 20 mg/g
215018928|NCT05259722|DRUG|Toctino|1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
215018929|NCT00962650|DEVICE|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
214418470|NCT03667248|DEVICE|Sorin Perceval ® Sutureless Valve (Sorin Group Italia Srl, 13040 Saluggia, Italy), available in different sizes (S 19-21mm, M 21-23mm, L 23-25mm, XL 25-27mm)|Sizing of the valve by preoperative CT scan of the heart and comparison of this measurement with the standard procedure (Sizing intraoperatively using the measuring devices provided by the product manufacturer)
214418471|NCT00712166|DRUG|AZLI 75 mg three times daily (TID)|
214418472|NCT00712166|DRUG|Placebo three times daily (TID)|
214418473|NCT04457141|COMBINATION_PRODUCT|Effect of pelvic floor for the use of minimalist shoes versus shod in woman.|Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.
214418474|NCT04995887|DEVICE|Jada® System|The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
214418475|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
214418476|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
214418477|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
214418478|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
214418479|NCT00378677|DRUG|Cyclosporine A dry powder inhalation (Drug)|
214418480|NCT00694811|BEHAVIORAL|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
214418481|NCT04374318|DRUG|Dexmedetomidine|INTRATHECAL AND INTRAVENOUS
214418482|NCT01773122|DRUG|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
214418483|NCT01773122|DRUG|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
214418484|NCT01773122|DRUG|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
214418485|NCT01773122|DRUG|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
215018930|NCT02402036|DRUG|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
214418486|NCT01264718|BEHAVIORAL|Parent Mentors|After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
214418487|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
214418488|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
214689811|NCT00988559|BIOLOGICAL|intramuscular vaccination|1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
215018931|NCT02624089|DRUG|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
215018932|NCT02624089|DRUG|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
215018933|NCT03026725|OTHER|Tri-calcium Phosphate|A paste contains Tri Calcium Phosphate \& Fluoride
215018934|NCT03026725|OTHER|Placebo|paste manufactured to mimic Clinpro, without Tri Calcium Phosphate
215018935|NCT02381327|DEVICE|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
214418489|NCT05543811|DIETARY_SUPPLEMENT|Food for special dietary use|Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner
214418490|NCT02712619|DRUG|Metformin|
214418491|NCT03317535|PROCEDURE|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
214418492|NCT03317535|PROCEDURE|Local anesthesia/concious sedation|Patients will be injected with propofol and remifentanil.
214418493|NCT03317535|PROCEDURE|Spontaneous breath|Patients will be kept spontaneous breath.
214418494|NCT03317535|PROCEDURE|Controlled ventilation|Patient will be kept with controlled ventilation.
214505895|NCT05174520|OTHER|Muscle Energy Technique|Muscle Energy technique along with Routine physical therapy will be provided to group B for40 minutes thrice a week for 4 weeks.
214505896|NCT03651934|DIETARY_SUPPLEMENT|Normal iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
214505897|NCT03651934|DIETARY_SUPPLEMENT|Weak iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
214689812|NCT00988559|BIOLOGICAL|intra-lesional vaccine administration|1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
215018936|NCT02466581|DRUG|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
214689813|NCT00988559|PROCEDURE|therapeutic resection of the lesion|at week 15, all residual lesions will be resected
214689814|NCT00988559|DRUG|imiquimod|imiquimod applied to the cervix by the physician
214689815|NCT02224846|DRUG|Tadalafil|Administered orally
214689816|NCT05788068|BEHAVIORAL|Cognitive behavior therapy|"Participants will receive CBT intervention for smoking cessation via wechat-based mini-program developed by a professional team."
214689817|NCT05942898|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
215018937|NCT02466581|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
215018938|NCT02466581|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
214418495|NCT04621708|DEVICE|Repetitive transcranial magnetic stimulation|Left DLPFC iTBS rTMS
214418496|NCT02646592|DRUG|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
214689818|NCT03115801|DRUG|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
214689819|NCT03115801|DRUG|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
214689820|NCT03115801|RADIATION|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
214689821|NCT03115801|DRUG|Pembrolizumab|Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
214689822|NCT01073748|DRUG|paracetamol|single dose of paracetamol 15mg/kg.
214689823|NCT01312792|OTHER|Amoxycilline, Cephradine followed by follow up on day 3|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
215018939|NCT02466581|BIOLOGICAL|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
215018940|NCT02667834|BEHAVIORAL|Social Cognition and Interaction Training (SCIT)|A randomized, controled trial of social cognition and interaction training ( SCIT) for patients with schizophrenia Spectrum disorders
214418497|NCT02646592|DRUG|sevoflurane or propofol|
214418498|NCT00598897|DRUG|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
214418499|NCT02664376|OTHER|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~* Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~* Walking speed measurement~* Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected."
214418500|NCT05273281|PROCEDURE|Transabdominal plane block|Peripheral nerve block
214418501|NCT05273281|PROCEDURE|Quadratus lumborum block|Peripheral nerve block
214418502|NCT04893135|OTHER|pratice physical activity|treadmill walking : walk at a speed of 2.7 km.h-1 in 3 stages of 3 mins with an incline of 0%, 5% and 10%
214418503|NCT04178343|RADIATION|tomotherapy|"1. the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;~2. WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.~d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF)."
214418504|NCT06049108|DRUG|[14C]-LY3871801|Administered orally
214418505|NCT02328820|OTHER|Percutaneous coronary intervention (PCI)|For lesions with both FFR\<=0.8 and CFR\<2.0
214418506|NCT02328820|OTHER|Optimal medical therapy (OMT)|For lesions with FFR\>0.8 or CFR\>=2.0 or both
214418507|NCT04349384|PROCEDURE|Colorectal resection|Colon or rectal resection for colorectal adenocarcinoma
214418508|NCT04376814|DRUG|Favipiravir|Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days
214418509|NCT04376814|DRUG|Hydroxychloroquine|200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
214418510|NCT04376814|DRUG|Lopinavir / Ritonavir|Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
214418511|NCT01895517|OTHER|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
214505898|NCT03651934|DIETARY_SUPPLEMENT|Normal selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
214505899|NCT03651934|DIETARY_SUPPLEMENT|Weak selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
214505900|NCT05353062|PROCEDURE|Hemostatic therapy|Bipolar hemostatic forceps
214505901|NCT05353062|PROCEDURE|Endoscopic therapy with hemoclip +/- injection of epinephrine solution|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
214418512|NCT01895517|OTHER|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
214418513|NCT04910347|DRUG|Nivolumab|"Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs."
214418514|NCT00999492|DEVICE|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
214418515|NCT03476109|DRUG|Randomisation to omalizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
214418516|NCT03476109|DRUG|Randomisation to mepolizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
214418517|NCT03812159|DEVICE|iCSPlan|"The Investigator will acquire a routine pre-operative CT-scan to help assess the synostosis severity. A week before the surgery a routine preoperative visit will be done. If the potential subject agrees to participate in the study, a presurgical plan will be built, and based on the CT scan, it will (1) quantify shape differences between pathological and healthy cranial shapes; (2) compensates for brain and cranial growth during the months between diagnosis, treatment and recovery; and (3) guides bone-cuts and bone-placement for the simplest and optimal surgical procedure.~Finally this plan will be recorded in a software, iCSPlan, which will be reviewed by the surgeon. If it is accepted, it will be available during the surgery as a rely-on tool which may or may not be followed."
214418518|NCT01045317|DRUG|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
214418519|NCT06479018|BIOLOGICAL|Blood sampling|Venous blood sampling will be carried out for each patient included in the study.
214689824|NCT01312792|OTHER|Injectable ampicillin followed by urgent referral|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
214689825|NCT05869344|DIETARY_SUPPLEMENT|Black bean protein hydrolysates (BPH)|Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.
214418520|NCT06479018|BIOLOGICAL|Liquid bubble sampling|Liquid bubble sampling will be carried out for each patients with Bullous Pemphigoid included in the study.
214505902|NCT06486610|BEHAVIORAL|Fish-shaped nebulizer and fish-shaped toy|In order to reduce the child's fear and anxiety, it is planned to apply inhalation therapy using a nebulizer with a red fish figure and an amigurumi toy with a red fish figure.
214505903|NCT06486610|DEVICE|Silent nebulizer|It is planned to apply inhalation therapy using a silent nebulizer to reduce the child's fear and anxiety.
215018941|NCT02667834|BEHAVIORAL|therapeutic education program (ETP)|usual treatment ,30 hours with therapist, only discussion between patients
215018942|NCT03727581|DIAGNOSTIC_TEST|Ultrasound guidance|Jugular vein is punctured with ultrasound guidance and guidewire is advanced. Right atrium and inferior vena cava junction is visualized by ultrasound using substernal view. Presence of guidewire in inferior vena cava or right atrium is confirmed. The procedure of catheter insertion is continued.
215102307|NCT05284916|BEHAVIORAL|liver diseases admissions|The different patterns of liver disease related admissions after the era of DAAS
214505904|NCT06436105|OTHER|FICB|FICB is applied to the patients after spinal anesthesia.
214505905|NCT06436105|OTHER|4 in 1 block|4 in 1 block is applied to the patients after spinal anesthesia.
214505906|NCT06436105|OTHER|Control|Peripheral nerve block will not be performed on Group Control patients.
214505907|NCT01419210|OTHER|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
214505908|NCT01419210|OTHER|Educational Presentations|Attend a two-hour presentation each week for four weeks
215018943|NCT01463345|OTHER|Blood transfusion|Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 7.5 g/dl. Blood products should be given to maintain Hgb levels \>7.5 g/dl.
215102308|NCT04397419|DIETARY_SUPPLEMENT|Red Bull Energy Drink|"The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
214505909|NCT01419210|OTHER|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
214505910|NCT01419210|OTHER|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
214689826|NCT05869344|OTHER|Commercial non-caloric beverage|Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.
214689827|NCT03223038|OTHER|No intervention|No intervention - exposure is mechanical ventilation in PICU
215018944|NCT01463345|OTHER|Blood transfusion|Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 9.0 g/dl. Blood products should be given to maintain Hgb levels \> 9.0 g/dl.
215102309|NCT04397419|OTHER|Still water|"The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
214689828|NCT03400670|DEVICE|ventilator NCPAP|infants will be randomized into two different NCPAP groups
215018945|NCT01848808|DIETARY_SUPPLEMENT|Wobenzym PS|
215018946|NCT01848808|DIETARY_SUPPLEMENT|Placebo|
215102310|NCT03238924|DRUG|Oxytocin|40 IU oxytocin nasal spray, self-administered
215102311|NCT03238924|DRUG|Placebos|Saline nasal spray, self-administered
214418521|NCT06479018|PROCEDURE|Cutaneous biopsy|At least the first cutaneous biopsy will be carried out for each patients with Bullous Pemphigoid included in the study.
215018947|NCT06034275|DRUG|VIP943 (QW)|VIP943 will be administered by IV Infusion weekly
214418522|NCT04945694|OTHER|Ultrasound-guided bilateral pecto-intercostal fascial block|\- PATIENT IN SUPINE POSITION, SKIN WILL BE DISINFECTED, A HIGH-FREQUENCY LINEAR PROBE WILL BE PLACED PARALLEL TO LONGITUDINAL AXIS OF STERNUM ON LATERAL BORDER AND SCANNED LATERALLY TO IDENTIFY 4TH AND 5TH COSTAL CARTILAGE. THE PECTORALIS MAJOR MUSCLE (PMM), INTERNAL INTERCOSTAL MUSCLE (IIM), TRANSVERSUS THORACIS MUSCLE (TTM), RIBS, AND PLEURA WILL BE IDENTIFIED. COLOR DOPPLER ULTRASONOGRAPHY WILL BE USED TO DETERMINE PERFORATING BRANCHES OF INTERNAL THORACIC ARTERY, WHICH TRAVEL ANTERIORLY THROUGH THE ANTERIOR CHEST WALL, PIERCING THE INTERCOSTAL MUSCLE AND PMM. A 22G NEEDLE WILL BE INSERTED IN PLANE WITH PROBE, IN CAUDAL-TO-CRANIAL DIRECTION UNTIL THE TIP IS POSITIONED IN INTER- FASCIAL PLANE BETWEEN THE PMM AND IIM. NORMAL SALINE WILL BE USED TO DETERMINE CORRECT PLACEMENT OF NEEDLE TIP IN INTER-FASCIAL PLANE, AS SHOWN BY SEPARATION OF FASCIAL LAYERS THEN LOCAL ANESTHETIC WILL BE INJECTED
214418523|NCT04945694|DRUG|Intravenous fentanyl|In this group, patients will receive only incremental doses of intravenous fentanyl
214418524|NCT04945694|DRUG|Propofol|Propofol anesthesia
214418525|NCT04945694|DRUG|Sevoflurane|Sevoflurane anesthesia
214418526|NCT04945694|DRUG|Atracurium|Intravenous atracurium
214418527|NCT04945694|DEVICE|ultrasound|ultrasound-guided block
214418528|NCT03261661|BEHAVIORAL|Reading|Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.
214505911|NCT03360513|OTHER|general group|The sample comprised maxillary and mandibular dental casts of 70 Caucasian Brazilian individuals (28 men and 42 women) with an average age of 16.4 years, all of which had natural normal occlusion with at least four of the six keys to normal occlusion. 14 The first item of the first key was considered essential for sample selection(Angle Class I molar relationship). Another inclusion criterion was that individuals should be at least 15 years of age with no odontogenic abnormalities and all permanent teeth in occlusion.
214505912|NCT01303796|DRUG|Sapacitabine|Oral sapacitabine capsules
214418529|NCT03261661|BEHAVIORAL|Mindset|Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.
214418530|NCT03261661|BEHAVIORAL|Reading Embedded with Mindset|Mindset training explicitly linked to the reading content through lesson openers, feedback prompts, and self-monitoring of mindset during reading work.
214505913|NCT01303796|DRUG|Decitabine|Decitabine intravenous
215018948|NCT06034275|DRUG|VIP943 (BIW)|VIP943 will be administered by IV Infusion bi-weekly
214505914|NCT00326196|DEVICE|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
214418531|NCT03261661|BEHAVIORAL|Business as Usual|Reading interventions already provided to students with reading difficulties as per typical procedures at the participating school
214418532|NCT05949203|DRUG|Cabotegravir Injection|Administration of HIV pre-exposure prophylaxis with cabotegravir 600 mg/3mL extended release injectable suspension every other month.
214418533|NCT01673113|DEVICE|Zeltiq CoolSculpting device|"This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles."
214418534|NCT02058914|DIETARY_SUPPLEMENT|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
214418535|NCT02058914|DIETARY_SUPPLEMENT|High Glucose sweetened beverage|HG-sweetened beverage
214418536|NCT06414980|BEHAVIORAL|Experimental|The effect of suggestion given to patients with the olfactory memory method before the surgical operation on vital signs and systemic evaluation scoring during awakening.
214505915|NCT00326196|PROCEDURE|Coronary artery bypass graft (CABG)|coronary bypass
214505916|NCT05040828|BEHAVIORAL|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
215018949|NCT00494156|DRUG|heparin|
215018950|NCT00494156|DRUG|aspirin and clopidogrel|
215018951|NCT04078399|DRUG|Azacitidine combined with interferon preemptive treatment|Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system
215018952|NCT03753477|DRUG|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)
215018953|NCT03753477|DRUG|Sevikar and Crestor|Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
215102312|NCT04855019|PROCEDURE|shoulder periarticular injection, suprascapular and axillary nerve block|"In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance."
215102313|NCT04607876|OTHER|Technological Facilitator|See Enhanced Intervention Arm for full description.
215102314|NCT04607876|OTHER|Standard of Care|Risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
215102315|NCT05564806|DRUG|YH004|All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
215102316|NCT03576716|DRUG|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
215102317|NCT03549715|DRUG|Durvalumab|1500 mg IV D1 every 28 days (2 doses for each patient)
214418537|NCT00329979|BEHAVIORAL|vascular access site|Randomized vascular access site
215018954|NCT04400955|DIAGNOSTIC_TEST|Audiometry tablet diagnostic tool and web-based test|as above
215018955|NCT05538468|OTHER|Assessment|Thirty stroke patients were included in the study. After the demographic information was obtained from all patients who accepted to participate in the study by complying with the inclusion criteria; The kinesiophobia scores of the patients were evaluated, depression severity, postural control and pain severity.
214418538|NCT02294643|DRUG|Sarpogrelate|
214418539|NCT02294643|DRUG|Aspirin|
214418540|NCT02294643|DRUG|Clopidogrel|
214418541|NCT02294643|DRUG|Placebo (for Sarpogrelate)|
214418542|NCT00371020|DRUG|low molecular weight heparin, 5-FU|
214418543|NCT01769391|DRUG|Necitumumab|Administered IV
214418544|NCT01769391|DRUG|Paclitaxel|Administered IV
214418545|NCT01769391|DRUG|Carboplatin|Administered IV
214418546|NCT04671108|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
214418547|NCT05872321|OTHER|Complication|whether or not complications occur
214418548|NCT00006391|DRUG|oxaliplatin|
214418549|NCT00006391|DRUG|topotecan hydrochloride|
214418550|NCT00345202|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
214418551|NCT04243343|DEVICE|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program for treatment of plantar fasciosis.
214418552|NCT04243343|OTHER|Standard of care|Standard of care prescribed home exercise program for treatment of plantar fasciosis.
214418553|NCT03386929|DRUG|Avelumab|A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
214418554|NCT03386929|DRUG|Axitinib|A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
214418555|NCT03386929|DRUG|Palbociclib|A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
214418556|NCT00000106|DEVICE|Whole body hyperthermia unit|
214418557|NCT05310929|DRUG|Labetalol and Glyceril trinitrate|for control of blood pressure
214689829|NCT02806778|OTHER|BIS Monitor-guided sedation|The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.
215018956|NCT04612621|DIAGNOSTIC_TEST|combination of diagnostic tests|capsule endoscopy, MRE , intestinal ultrasound, fecal microbiota, blood and serum biomarkers as described
214418558|NCT02837237|DRUG|KBP-5074|"In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session."
214418559|NCT00258518|PROCEDURE|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
214418560|NCT01975467|DEVICE|CRx|The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
214418561|NCT03425162|DRUG|Morphine Sulfate|patient-controlled analgesia (PCA) morphine
214418562|NCT03425162|PROCEDURE|Group P|Group P:patient-controlled analgesia (PCA) morphine
214418563|NCT03425162|PROCEDURE|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 Bupivacaine
214418564|NCT04181931|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
214418565|NCT04181931|PROCEDURE|Surgery alone|hepatic resection remove the liver tumor and portal vein tumor thrombus
214418566|NCT03100162|DIETARY_SUPPLEMENT|Probiotic|
214418567|NCT03100162|DIETARY_SUPPLEMENT|Placebo|
214418568|NCT06413303|BEHAVIORAL|Experiential Classroom|Experiential classroom emphasizes putting pregnant women at the center, based on their subjective willingness and previous knowledge and experience, creating an environment for free discussion, exchange, and reflection, and utilizing peer education to fully mobilize the subjective initiative of pregnant women. This approach allows them to explore, discuss, reflect, and learn autonomously, aiming to truly absorb, master, and apply theoretical knowledge.
215018957|NCT05142085|DIETARY_SUPPLEMENT|nano-PSO|This active treatment will be delivered to 3 out of 5 patients
215018958|NCT05142085|OTHER|placebo|This treatment will be assigned to 2 out of 5 patients
215018959|NCT05396781|DRUG|Proflavine|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
215018960|NCT05396781|DEVICE|Mobile, Augmented High Resolution Microendoscope|The marHRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
215018961|NCT02410174|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
215018962|NCT03483220|DIAGNOSTIC_TEST|MRI brain|"1\. Emotion Regulation Questionnaire (ERQ): A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale .~UPPS-P Impulsive Behavior Scale- Short form: The UPPS-P impulsivity scale is a 20-item scale designed to assess five distinct personality traits to impulsive behavior: Negative Urgency, Lack of Perseverance, Lack of Premeditation, Positive Urgency and Sensation Seeking .~Magnetic resonance imaging examination:~The MR examination of brain was done using 1.5T MR scanner (Achieva, Philips Medical Systems, The Netherlands) with a 16 channel head coil without using any sedation."
215018963|NCT06419309|OTHER|Dietary intervention|"Four different dietary interventions are planned.~* Gluten-free, lactose-free diet,~* Diet enriched with Aronia Melanocarpa,~* Gluten-free, lactose-free and enriched with Aronia Melanocarpa diet,~* Healthy diet"
214418569|NCT01338727|BEHAVIORAL|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
214418570|NCT04994743|DRUG|CORT113176|CORT113176 lipid capsule formulation for oral administration
214418571|NCT04994743|DRUG|Placebo matching CORT113176|Placebo matching CORT113176 lipid capsule formulation for oral administration
214418572|NCT00006204|DRUG|naltrexone (Revia)|
214418573|NCT00006204|DRUG|fluoxetine (Prozac)|
214418574|NCT03332134|BEHAVIORAL|Intimate Partner Violence (IPV) Prevention Intervention|The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
214418575|NCT00394381|PROCEDURE|Infusion of autologous CIK cells|Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
214418576|NCT00436137|BEHAVIORAL|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
214418577|NCT02575391|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
214418578|NCT01144182|BEHAVIORAL|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
214418579|NCT00841958|PROCEDURE|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
214418580|NCT04274751|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation
214418581|NCT06015594|DRUG|Metformin|Patients treated with metformin
214418582|NCT05781269|OTHER|VLCKD|VLCKD diet treatment with medical food
214418583|NCT05781269|OTHER|r-MedDiet|Mediterranean diet treatment
214418584|NCT00308958|DEVICE|High frequency chest wall oscillator|
214418585|NCT03772964|DRUG|MetFORMIN Hydrochloride ER|Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
214418586|NCT03772964|DRUG|Placebo|Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
214418587|NCT00662636|DRUG|dasatinib|Given orally
214418588|NCT00662636|DRUG|lapatinib ditosylate|Given orally
214418589|NCT00662636|OTHER|pharmacological study|Correlative study (cohort II only)
214418590|NCT00662636|OTHER|laboratory biomarker analysis|Correlative study (cohort II only)
214418591|NCT01624558|DEVICE|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
214418592|NCT01701609|BEHAVIORAL|Cognitive Remediation Therapy|
215018964|NCT02268851|DRUG|TGR-1202|Capsules taken whole daily with water and with food
215018965|NCT02268851|DRUG|Ibrutinib|Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
215102318|NCT03549715|DRUG|Tremelimumab|75 mg IV D1 every 28 days ((2 doses for each patient)
215102319|NCT03549715|DRUG|MVAC Protocol|"1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1"
215102320|NCT01835834|PROCEDURE|zirconia bridge restoration|
215102321|NCT00004275|DRUG|growth hormone|
215102322|NCT00004275|DRUG|oxandrolone|
215102323|NCT04346849|PROCEDURE|Pulpotomy|Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
215102324|NCT06024018|DEVICE|high intensity electromagnetic technology device, diet restriction, and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months
215018966|NCT00797901|OTHER|Collaborative Care|
214418593|NCT05547191|DEVICE|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
214418594|NCT05527483|DRUG|[68Ga]PSMA|Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
214418595|NCT05527483|DRUG|Flourine-18 [F-18] Sodium Fluoride (NaF)|Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
214418596|NCT05527483|DIAGNOSTIC_TEST|PET/CT|Patients will receive \[68Ga\]PSMA with a PET/CT and Flourine-18 \[F-18\] Sodium Fluoride (NaF) with a PET/CT
214418597|NCT00941356|DIETARY_SUPPLEMENT|Bio-K+ CL1285|2 capsules per day before breakfast
214418598|NCT00941356|DIETARY_SUPPLEMENT|Placebo|2 capsules per day before breakfast
214418599|NCT03264456|DIAGNOSTIC_TEST|[18F] Fluciclovine PET/MRI|\[18F\] fluciclovine PET/MRI
214418600|NCT03264456|DRUG|[18F] fluciclovine|\[18F\] fluciclovine
214418601|NCT03538054|DRUG|Dextromethorphan|(1)10 mg, by mouth, twice daily every 12 hours.
214418602|NCT03538054|DRUG|Placebo|1 capsule, by mouth, twice daily every 12 hours.
214418603|NCT05128305|DRUG|traditional Chinese medicine1 and traditional Chinese medicine 2|We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
214418604|NCT00798772|DIETARY_SUPPLEMENT|Micronutrients and antioxidants|8 capsules twice daily for two years
214418605|NCT00798772|DIETARY_SUPPLEMENT|Multivitamins and minerals|8 capsules twice daily for two years
214418606|NCT05835115|DIAGNOSTIC_TEST|A deep learning-based myopia and myopic maculopathy detection and prediction system|This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.
214418607|NCT02078934|PROCEDURE|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
214418608|NCT02200952|DRUG|recombinant LH|recombinant LH twice/day for 10 days from pick up
214418609|NCT03132324|DRUG|INCB059872|INCB059872 tablets
214418610|NCT04991974|BEHAVIORAL|Patient Navigation|A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
215018967|NCT03614988|OTHER|Evening Levothyroxine Administration|Bedtime levothyroxine intake, with 60-minute meal-free interval
214418611|NCT04991974|DRUG|Buprenorphine|"Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community."
214418612|NCT05602155|PROCEDURE|Group 1|Even numbered patients will partial weight bearing after treatment,
214418613|NCT05602155|PROCEDURE|Group 2|patients with odd numbers will walk with full weight bearing after treatment
214418614|NCT03279666|OTHER|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
214418615|NCT03543839|BIOLOGICAL|Belimumab|Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years
214418616|NCT03543839|BIOLOGICAL|Belimumab/Placebo|Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.
214418617|NCT03543839|OTHER|Placebo|Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
214418618|NCT03254394|DRUG|Lidocaine Hydrochloride|"Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study."
214689830|NCT02806778|OTHER|Jugular bulb catheter|Jugular bulb catheter will be implanted in the patients enrolled in the study.
214418619|NCT03254394|DRUG|Placebo|Dextrose 5% in water will be administered as active comparator.
214418620|NCT03254394|DRUG|FOLFOX regimen|"Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
214418621|NCT05341518|PROCEDURE|Subscapularis repair|To complete reverse total shoulder arthroplasty, the surgeon must cut through the subscapularis muscle. In this arm of the study, the muscle will be repaired, rather than left to heal itself.
214418622|NCT06069986|PROCEDURE|coronary artery bypass graft CABG|comparison between onpump and off pump CABG
214418623|NCT02672813|PROCEDURE|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
214418624|NCT03360396|DEVICE|Endobronchial Coils|Endobronchial Coil implants
214418625|NCT01991912|PROCEDURE|open lumbar decompression|A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
215018968|NCT03614988|OTHER|Morning Levothyroxine Administration|Morning levothyroxine intake, 60 minutes before breakfast.
215018969|NCT02539394|DRUG|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
215018970|NCT02539394|OTHER|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
215018971|NCT02595554|RADIATION|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
214418626|NCT00076180|BIOLOGICAL|Hu-MiK-Beta-1|Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
214418627|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
214418628|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
214418629|NCT05102266|DRUG|BR1016C|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
214418630|NCT05102266|DRUG|BR1016D|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
214418631|NCT00350831|DRUG|XL820|
214418632|NCT02351180|DRUG|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
214418633|NCT02351180|DRUG|Placebo|Placebo will serve as a control treatment
214418634|NCT02116855|OTHER|according to the efficacy of AJBRs|
215018972|NCT02595554|DRUG|Paclitaxel|New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
215018973|NCT02595554|PROCEDURE|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
215018974|NCT02595554|DRUG|Cisplatin|New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
215018975|NCT05431907|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
215018976|NCT03685240|BEHAVIORAL|SafelyYou Fall Prevention System|Technology + Quality Assurance Services Provided by SafelyYou
215018977|NCT05492903|BEHAVIORAL|COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)|A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.
215018978|NCT02495935|DEVICE|OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
215018979|NCT02495935|DEVICE|Sham-OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
215018980|NCT00017186|DRUG|epirubicin hydrochloride|
215018981|NCT00017186|DRUG|gemcitabine hydrochloride|
215018982|NCT05830643|BEHAVIORAL|Social skills group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
215018983|NCT05830643|BEHAVIORAL|Adult interest group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
215018984|NCT01250314|OTHER|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
214418635|NCT05288517|BEHAVIORAL|Lock to Live|Lock to Live is an anonymous web-based self-administered decision aid for safe firearm and medication storage (Public URL: http://lock2live.com/).
214418636|NCT04666337|PROCEDURE|ultrasound-guided supraclavicular brachial plexus blockade|Ultrasound-guided supraclavicular brachial plexus block was done using an ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe. The brachial plexus and its relation to the surrounding structures were viewed while the patient was supine and the head turned 45° to the contralateral side. In the supraclavicular fossa, the probe was placed in the coronal plane to visualize the subclavian artery and the brachial plexus in a transverse sectional view. After skin sterilization and local anesthetic administration, an insulated needle was then introduced lateral to the ultrasound probe and parallel to the long axis of the probe. Once the needle penetrated the brachial plexus cluster, the local anesthetic mixture was injected incrementally after negative aspiration for blood or air just next to the artery, then the needle was repositioned to inject on the upper pole of the artery.
214418637|NCT02686554|OTHER|Neuropsychological assessment|The patients perform tests to assess their cognitive abilities
214505917|NCT05040828|BEHAVIORAL|Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.|10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
214505918|NCT05040828|DRUG|No oral drug therapy throughout the pollen period|Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
214418638|NCT04872829|DEVICE|cataract surgery|"All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D."
214418639|NCT03545217|BEHAVIORAL|Lifestyle Intervention|a 6-month intensive lifestyle intervention program led by a multidisciplinary team of diabetes nurses and dieticians, and a follow up at 12 months for these participants. This will be a group-based activity adapted from the Diabetes Prevention Program -Thailand project
214418640|NCT01300858|DRUG|EGEN-001-301|Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
214418641|NCT01071967|OTHER|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
214418642|NCT01393912|DRUG|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
214418643|NCT00673296|DRUG|Intravitreal Bevacizumab|Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
214418644|NCT01556256|OTHER|Caregiver-Related Intervention or Procedure|Undergo TMV+P
214418645|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV
214418646|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV+P
215018985|NCT01250314|OTHER|Biological, biochemical and genetic samples|"\*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~\*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~* Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~* Homocysteine~* IGF1~  * Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way."
214418647|NCT01556256|OTHER|Quality-of-Life Assessment|Ancillary studies
214418648|NCT01556256|OTHER|Questionnaire Administration|Ancillary studies
214689831|NCT01904877|BEHAVIORAL|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
214505919|NCT01337141|OTHER|Control|7 face-to-face visits.
214505920|NCT01337141|DEVICE|Telecare system|5 telematic visits and 2 face-to-face visits.
214689832|NCT02831491|DRUG|Ramucirumab|Administered IV
214689833|NCT02831491|DRUG|Docetaxel|Administered IV
215018986|NCT03158779|COMBINATION_PRODUCT|SBRT and chemotherapy|Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.
215018987|NCT01084486|DRUG|Metformin|
215018988|NCT02205359|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled (AdaptivBiV and LV)
215018989|NCT02205359|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
215018990|NCT02820103|BEHAVIORAL|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
214505921|NCT00481572|DRUG|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
214505922|NCT00481572|DRUG|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
214505923|NCT00481572|DRUG|Norepinephrine|titrated norepinephrine over a period of 48 hrs
214418649|NCT02061332|BIOLOGICAL|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
214418650|NCT01751724|DRUG|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
215018991|NCT02820103|BEHAVIORAL|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
214418651|NCT01751724|OTHER|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
214418652|NCT05679037|OTHER|Placebo|Inactive capsules
215018992|NCT02820103|BEHAVIORAL|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
215018993|NCT00573820|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
214418653|NCT05679037|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Universal antioxidant
214418654|NCT00627874|DEVICE|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
214418655|NCT06315400|DRUG|Ingavirin®|60 mg/day for 5 days
214418656|NCT06315400|DRUG|Placebo|1 capsule/day for 5 days
214418657|NCT03488056|OTHER|ICCMS|"The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment~-Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.~After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The treatment is divided into Non-Operative Care and Tooth-Preserving Operative Care (restorations with minimal intervention to preserve maximum dental structure).~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
214418658|NCT03488056|OTHER|SESC standard care|Standard care related to: Caries Diagnosis, operative and non-operative treatments, Indication of recall interval according to the dentist opinion
214418659|NCT01025999|OTHER|No intervention|
215018994|NCT02112227|OTHER|PACT-HF Model|PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
215018995|NCT04595812|DRUG|Misoprostol 200mcg Tab vaginal|2 tablets vaginally 1 hour before surgery
215018996|NCT04595812|DRUG|Oxytocin|30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h
215018997|NCT04595812|DRUG|Carbetocin|100 μg IV Carbetocin (1ml) in 5 ml saline over 1 minute
215018998|NCT04595812|PROCEDURE|pericervical hemostatic tourniquet|a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision,The time of tourniquet administration will be recorded, and will be released not later than 45 minutes after its application. For those requiring multiple applications, the tourniquet will be reapplied after a period of at least 15 minutes.
214418660|NCT05969236|DRUG|MDI-1228_mesylate Ophthalmic Solution|"MDI-1228\_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)"
214418661|NCT05969236|DRUG|Placebo|The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228\_mesylate is absent.
214418662|NCT00095004|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
214418663|NCT00095004|DRUG|Comparator: placebo / Duration of Treatment: 1 day|
214418664|NCT03906968|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
214418665|NCT04841733|OTHER|Foam Roller (FR)|Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
214418666|NCT04841733|OTHER|Stretching (STR)|Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.
214418667|NCT04841733|OTHER|Cold-Water Immersion (CWI)|Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
215102325|NCT06024018|BEHAVIORAL|diet restriction and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
214689834|NCT01310595|PROCEDURE|Manual mobilization on cervical spine|Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
214689835|NCT01310595|PROCEDURE|Infra-red therapy with self exercise pamphlet|Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
214689836|NCT06302205|OTHER|Physical activity|The home-based training intervention consists of two phases of each three months in duration. It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.
214689837|NCT06302205|OTHER|Sham intervention|2 times a week, flexibility and balance training
214418668|NCT03121950|OTHER|Dance|The primary intervention is a dance class
214418669|NCT03121950|OTHER|Music|the secondary intervention is listening to live music
214418670|NCT04117191|DIETARY_SUPPLEMENT|Doctor's Best L-Tryptophan|2g tryptophan loading once
214418671|NCT02328352|PROCEDURE|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
215018999|NCT05900310|DIAGNOSTIC_TEST|Core Cognitive Evaluation (CCE)|The Linus Health Core Cognitive Evaluation (CCE) is an easy-to-use but powerful tool to augment and facilitate cognitive health assessment during a patient's visit to their PCP. As a digital assessment solution, the CCE combines objective insights into cognitive ability with patient-reported insights to detect early signs of cognitive impairment and reveal specific modifiable risk factors earlier than the existing status quo assessments. The CCE is an FDA-listed Class II 510k exempt software as a medical device. The CCE has two components: The Digital Clock and Recall (DCR™) test and the Life and Health Questionnaire (LHQ).
215019000|NCT00236197|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
214689838|NCT04965012|BEHAVIORAL|Online CBT with MET treatment|The CBT with MET treatment condition will begin with an MET-therapist guided introduction to the program and first module. After this guided introduction, they will have access to the remaining 7 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
215019001|NCT00236197|DRUG|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
215019002|NCT06539663|COMBINATION_PRODUCT|OmniLenz®|OmniLenz® applied for 1 week in all patients after development of corneal perforation
214418672|NCT02328352|PROCEDURE|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
215019003|NCT04330339|BEHAVIORAL|Fasting|Fasting
215019004|NCT05301231|DIAGNOSTIC_TEST|Genomics (DNA Extraction)|"Blood samples for detection of:~Genes for Dyslipidemia BY WES and NGS (4 GWA) (30 cases) Genes polymorphism for NAFLD/NASH BY TaqMan SNP Genotyping Assay on 10 GWAS"
215019005|NCT05301231|DIAGNOSTIC_TEST|Epi-genomics|"* blood samples for detection of Expression profiling of plasma microRNAs~* PCR array to determine the altered miRNAs for 168 plasma miRNAs (12 cases)~* Expression analysis of top 5 altered miRNAs (All)"
215019006|NCT05301231|DIAGNOSTIC_TEST|Proteomics (Glycoproteomics)|blood samples for Identifying glycosylation pattern of five glycoproteins linked with NAFLD/NASH (transferrin, apoC III, haptoglobin, Mac2 binding protein, IgG)
215019007|NCT05301231|DIAGNOSTIC_TEST|Salivary Metabolomics|"Salivary Samples for detecting Salivary Metabolomics~1. Genome analysis (Identification of microbial strains common among Egyptians BY apid RT-PCR (DNA sequencing: 16S rRNA gene amplicons)~2. Microbiome related Metabolites Identification using GC-MS Analysis (the top 5 identified microbial-related metabolites) as metabolomics~3. Meta-genomic assess of three microbiome-related metabolites; lactoferrin, (LPS), (IgA) BY Commercial ELISA kits"
215019008|NCT05301231|BEHAVIORAL|Individualized counselling for behavioural modification|"Individualized counselling for behavioral modification (3 sessions):~Nutritional education, Promotion of physical activities and Cognitive \& Psychological support"
215019009|NCT01893762|BIOLOGICAL|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
215019010|NCT01893762|BIOLOGICAL|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
215019011|NCT03072342|PROCEDURE|Intensive Periodontal Treatment|
215019012|NCT03072342|PROCEDURE|Control Periodontal Treatment|
214418673|NCT02328352|PROCEDURE|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
214418674|NCT02328352|PROCEDURE|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
214418675|NCT04803630|OTHER|Quality-of-Life Assessment|Ancillary studies
214418676|NCT04803630|OTHER|Questionnaire Administration|Ancillary studies
214418677|NCT04803630|PROCEDURE|Thermotherapy|Undergo thermal therapy
214418678|NCT02981706|PROCEDURE|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
214418679|NCT02981706|PROCEDURE|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
214418680|NCT04533139|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens"
214418681|NCT03902236|OTHER|Reaction Time and Postural Control|Reaction Time and Postural Control: With ''Fitlight TrainerTM'', 6 light emitting diode (LED) lights placed at certain points on the wall are randomly lit and expected to deactivate them as fast as possible. In the protocol, the leds will be placed according to the physical structure of the person, and the scores of 29 LED's will be kept in seconds. The scores will be compared cystic fibrosis, bronchiectasis and healthy groups.
214418682|NCT03902236|OTHER|Muscle oxygenation|Muscle oxygenation will be assessed with wearable lactate threshold predicting device in cystic fibrosis, bronchiectasis and healthy groups.
214418683|NCT03902236|OTHER|Exercise capacity|Exercise capacity will be assessed with incremental shuttle walk test in cystic fibrosis, bronchiectasis and healthy groups.The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases.The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends The number of shuttles is recorded. Each shuttle represents a distance of ten metres
215019013|NCT02713841|DRUG|inhaled human insulin (INH)|recombinant human insulin administered with Adagio-01 inhaler device
215019014|NCT02713841|DRUG|sc insulin lispro (LIS)|insulin lispro administered subcutaneously
215019015|NCT05250726|BIOLOGICAL|MENISC-T|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of meniscus used as interposition at the STT joint
215019016|NCT01903200|DRUG|FK949E|Oral
214418684|NCT03902236|OTHER|Balance|Balance will be assessed with functional reach test in cystic fibrosis, bronchiectasis and healthy groups Functional Reach measures the maximum distance a person can reach forward, the distance of the person standing at the edge of the wall with a 90-degree shoulder flexion and the maximum distance to the front of the thumb will be noted.
214505924|NCT05764057|DRUG|Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)|"Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines\* for 6 months (experimental group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
215019017|NCT04028960|DRUG|Regular insulin (Humulin-R), intranasal route|Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
215019018|NCT04028960|DEVICE|SipNose intranasal device|The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
215019019|NCT03188029|DIAGNOSTIC_TEST|adrenocortical function|"Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.~Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate."
215019020|NCT02032784|DRUG|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
215019021|NCT02032784|OTHER|No Octreotide|No drug
215019022|NCT02113215|PROCEDURE|Stable Isotope Infusion|9-hour infusion of stable isotope tracers
215102326|NCT02119390|BEHAVIORAL|Staff-delivered intervention sessions|In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
215102327|NCT02119390|OTHER|Demographic Questionnaire|Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
214418685|NCT05638204|BEHAVIORAL|Suicidal Crisis Intervention (SCI)|This study's experimental condition consisted of the Suicidal Crisis Intervention (SCI), developed by the Flemish Centre of Expertise of Suicide prevention. The SCI aims to provide tools for dealing with future suicidal crises for people after a suicidal crisis or suicide attempt. The intervention attempts to provide insight into the suicidal crisis by giving suicidality meaning within the life history. It aims to increase motivation for specialized care and therefore facilitate continuity of care. In addition, the method also wants to involve the close relative(s) of the suicidal person in the treatment. The SCI offers care providers a clear structure and handles to do this within a short period of time (4 sessions). Within the SCI are a number of crucial elements: the therapeutic relationship, involving loved ones, person-centred care, the Integrated Explanatory Model for Suicidal Behavior (Van Heeringen, 2007), the safety plan (Stanley \& Brown, 2012) and continuity of care.
214418686|NCT00028301|DRUG|Atazanavir|
215019023|NCT03164707|DIAGNOSTIC_TEST|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
214418687|NCT00028301|DRUG|Lopinavir/Ritonavir|
214418688|NCT03795077|OTHER|Experimental group|Experimental group followed the 3-months programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used.
215019024|NCT05399342|OTHER|No Intervention|Patients in the LAAOS III trial either had or did not have their left atrial appendage occluded at the time of surgery in that trial. No further intervention is required in this cohort, it is observational follow-up only.
214418689|NCT02043717|DIETARY_SUPPLEMENT|Vitamin D|"Supplementing oral cholecalciferol according to the new guidelines by:~Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism \[Internet\]. 2012 May \[cited 2012 Oct 31\];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505"
214418690|NCT01646775|DRUG|epidural fentanyl|withold epidural fentanyl
214418691|NCT06650930|DRUG|Oral calcium carbonate|All participants receive a single, open-label dose of oral calcium carbonate 3000mg
214418692|NCT01867580|DEVICE|V.A.C.Ulta with Prontosan instillation|NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
214418693|NCT01867580|DEVICE|V.A.C.Ulta without instillation|NPWT only
214418694|NCT05298384|OTHER|Compression stockings|Graduated compression stockings (GCS) are used to treat chronic venous diseases and edema. They help to improve blood flow and prevent blood pooling in the legs. The use of GCS will be in accordance with this indication. The greatest pressure is exerted at the ankle with gradually decreasing pressures up the length of the stockings. GCS are designed for use out of bed and are manufactured using strict medical and technical specifications.
214418695|NCT01303835|DRUG|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
214418696|NCT01303835|DRUG|Placebo|Randomized patients received placebo to be taken every night before bed.
214418697|NCT06614985|DRUG|Telitacicept|Subcutaneous injection of 160 mg is administered once a week.
214418698|NCT06614985|DRUG|Prednisone|Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.
215019025|NCT00992394|DRUG|etanercept|etanercept 50 mg once weekly as requested.
215019026|NCT00992394|DRUG|etanercept|etanercept 25 mg or 50 mg as requested.
215019027|NCT04345432|DRUG|Gabapentin|"Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study."
215019028|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA containing composite|Bonding materials of fixed lingual retainers applied with Bis-GMA containing composite
215019029|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA-free composite|Bonding materials of fixed lingual retainers applied with Bis-GMA-free composite
215019030|NCT05738889|DEVICE|Vacuum-formed retainers|vacuum-forming machine and vacuum formed plates
215019031|NCT05738889|DEVICE|Hawley retainers|Acrylic based hawley retainers
215019032|NCT01959971|DRUG|alirocumab|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
215019033|NCT01959971|DRUG|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
215019034|NCT00246207|DRUG|CONCERTA (OROS methylphenidate hydrochloride)|
215019035|NCT06138080|DIAGNOSTIC_TEST|Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography|We have no specific intervention. We investigate different diagnostic modalities of VUR.
215019036|NCT01420003|PROCEDURE|Bone Marrow Aspiration|3 per study
215019037|NCT01420003|PROCEDURE|Tonsil Biopsy|Optional upon completion of study
214418699|NCT06614985|DRUG|Cyclophosphamide|An intravenous injection of 0.4 g is administered twice a month.
214418700|NCT03397914|DRUG|Colistimethate Sodium|Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections
214418701|NCT06614348|DRUG|Prednisolone acetate eye drop group|Patients receive prednisolone acetate eye drops 4 times per 30min within 2 hours before cataract surgery
214418702|NCT06614348|DRUG|Sodium hyaluronate eye drops|Patients receive sodium hyaluronate eye drops 4 times per 30min within 2 hours before cataract surgery
214418703|NCT06619639|BEHAVIORAL|Social-emotional learning curriculum|EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context.
214418704|NCT06628583|OTHER|Magnetic Resonance Imaging with Contrast|The study was retrospective and did not set interventions
214418705|NCT05423587|PROCEDURE|Genicular Artery Embolisation|Transarterial catheter directed embolisation of hypervascularity in patients with mild to moderate knee osteoarthritis
214418706|NCT05423587|PROCEDURE|Genicular Artery Injection|Transarterial catheter directed injection of normal (0.9%) saline in patients with mild to moderate knee osteoarthritis
214418707|NCT06713096|BEHAVIORAL|Tempos Certos protocol|Improve the enhanced recovery by using the Tempos Certos Protocol by the multiprofissional team , using interventions known by science and recommended by scientists.
214418708|NCT03425643|BIOLOGICAL|Pembrolizumab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
214418709|NCT03425643|DRUG|Placebo|Normal saline by IV infusion Q3W, given on cycle day 1.
214418710|NCT03425643|DRUG|Cisplatin|75 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
214418711|NCT03425643|DRUG|Gemcitabine|1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
214418712|NCT03425643|DRUG|Pemetrexed|500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
214418713|NCT03141788|DEVICE|Clear Aligner|Clear Aligner used to straighten teeth to desired outcome
214418714|NCT05866016|BEHAVIORAL|Skill birth attendant training|It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.
214418715|NCT04419181|DRUG|Docetaxel|Dose: 75 mg/m2 q3w
214418716|NCT04419181|DRUG|Carboplatin|Dose: area under the concentration-time curve \[AUC\] 6 q3w
214418717|NCT04419181|DRUG|Trastuzumab|Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
214418718|NCT04419181|DRUG|Pertuzumab|Dose: 840-mg loading dose, 420-mg maintenance dose q3w
215019038|NCT01435915|DRUG|Ropinirole|"Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period."
215019039|NCT03983655|DEVICE|High Frequency Low Intensity TMS|125 hz, 10 gauss, 2 times daily for 6 monts
215019040|NCT00537082|DRUG|FTY720|Administered orally once daily for 6 months
215019041|NCT00537082|DRUG|Placebo|Administered orally once daily for 6 months
215019042|NCT04588363|OTHER|SARS-CoV-2 and/or MIS-C Exposure|This is an observational cohort study.
215019043|NCT00655746|DRUG|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
215019044|NCT03833089|COMBINATION_PRODUCT|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Mineralocorticoid receptor antagonists, 3) Potassium supplementation,
215019045|NCT06933875|BEHAVIORAL|Clinical Decision Support Tool|Deliver prognostic information and evidence-based decision support at the point of care
215019046|NCT03645681|DEVICE|InnAVasc arteriovenous graft surgical implant|An InnAVasc AVG will be surgically implanted into the upper arm or forearm of enrolled participants
214418719|NCT04419181|DRUG|Trastuzumab emtansine|Dose: 3.6mg/kg q3w
214418720|NCT00697411|OTHER|Syndrome cause identification|
214418721|NCT00644709|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
214418722|NCT03523702|DRUG|PembroRT|"Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.~Patients whose tumors are found to have low (\< 50%) PD-L1 will be treated with a standard-o-care regimen and not be a part of this clinical trial."
214418723|NCT05877638|DEVICE|SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel|(FDA) 510(k) cleared wound care medical devices formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn serves as a protective gel dressing.
215019047|NCT03755154|DRUG|S65487- initial scheme|S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
215019048|NCT03755154|DRUG|S65487 - alternative scheme|S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
214689839|NCT04965012|BEHAVIORAL|CBT without MET treatment|The CBT without MET treatment condition will begin with a brief non-MET trained research assistant welcome to the program, and will not include working through the first module together. After this welcome, they will have access to the 8 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
214418724|NCT05877638|DRUG|SILVADENE Cream 1% (silver sulfadiazine)|SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
214418725|NCT04956354|DEVICE|ANNE™ Monitoring System (2 sensors) - version B|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Chest and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - A chest unit (ANNE™ Chest) with embedded battery, sensors, and a three-axis accelerometer that captures the following signals: electrocardiography (ECG), temperature, seismocardiography (SCG) and the chest wall movements.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
214418726|NCT04956354|DEVICE|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
214418727|NCT04956354|DEVICE|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
214418728|NCT06195891|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214418729|NCT06195891|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214418730|NCT06195891|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214418731|NCT06195891|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT/MRI scan
214418732|NCT06195891|PROCEDURE|Echocardiography|Undergo echocardiography
214418733|NCT06195891|DRUG|Fludarabine|Given IV
214418734|NCT06195891|PROCEDURE|Magnetic Resonance Imaging|Undergo DECT/MRI scan
214689840|NCT02538666|BIOLOGICAL|Nivolumab|
215019049|NCT05229354|BIOLOGICAL|TV005|The TV005 admixture is comprised of four monovalent dengue vaccine candidates representing each of the four DENV serotypes: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30.
215019050|NCT05229354|BIOLOGICAL|rDEN2Δ30-7169 attenuated virus strain|based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified
215019051|NCT02958072|OTHER|LeucoPatch|LeucoPatch is an fully autologous growth factor-containing dressing
215019052|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single dose of AT-527 and digoxin will be co-administered."
215019053|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later)."
215019054|NCT04835597|BEHAVIORAL|Behavioral Assessment|Complete movement assessment
214418735|NCT06195891|DRUG|Melphalan|Given IV
214418736|NCT06195891|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214418737|NCT06195891|BIOLOGICAL|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Given IV
214418738|NCT06195891|DRUG|Tacrolimus|Given tacrolimus
214418739|NCT06195891|DRUG|Thiotepa|Given IV
214418740|NCT06195891|RADIATION|Total Marrow and Lymphoid Irradiation|Undergo TMLI
214689841|NCT02538666|BIOLOGICAL|Ipilimumab|
214689842|NCT02538666|OTHER|Placebo|
214689843|NCT02188121|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
214689844|NCT02188121|DRUG|Losartan|Angiotensin II receptor antagonist
214689845|NCT00002706|PROCEDURE|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
214418741|NCT04689061|DEVICE|Arthrex FastThread Interference Screw|The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
214418742|NCT02556034|OTHER|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
214418743|NCT03379740|OTHER|E-cigarette|Subject's own e-cigarette
214418744|NCT03379740|OTHER|P4M3-1.7%|P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
214418745|NCT03379740|OTHER|P4M3-1.7%LA|P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
214418746|NCT03379740|OTHER|P4M3-3%LA|P4M3 e-liquid concentration of 3% nicotine with lactic acid
214418747|NCT03379740|OTHER|P4M3-4%LA|P4M3 e-liquid concentration of 4% nicotine with lactic acid
214418748|NCT00505323|DEVICE|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :~Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
214418749|NCT00718848|PROCEDURE|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
214418750|NCT00718848|PROCEDURE|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
214418751|NCT05365633|BEHAVIORAL|Empowerment activity-enhanced tobacco cessation assistance|Participants will receive standard Tobacco Treatment Research Program (TTRP) tobacco cessation assistance either remotely or in-person: 6 weekly counseling sessions and 12 weeks of combination NRT (nicotine patches + nicotine gum or lozenges). During the 6 weeks of counseling, participants will also engage in at least 4 'empowerment activities' (i.e., SGM social change mobilization and community-building activities48) for a total of at least 8 hours. Activities will be tailored to each participant's comfort level and skills. Examples are compiling publicly-available information about school board meetings to support community members in participating in their school districts and making follow-up phone calls with a script to Freedom OK's name change clinic participants.
214418752|NCT01824030|DEVICE|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
214418753|NCT01824030|DEVICE|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
214418754|NCT03988036|DRUG|Pembrolizumab|Intravenous infusion; 200 mg; every 3 weeks
214418755|NCT03988036|DRUG|Trastuzumab Biosimilar ABP 980|Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks
214418756|NCT03988036|DRUG|Pertuzumab|Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks
214418757|NCT00318019|DIETARY_SUPPLEMENT|OPC Factor(TM)|Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
214418758|NCT00318019|OTHER|Placebo|Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
214418759|NCT02764645|DEVICE|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
214418760|NCT02764645|DEVICE|22Fr curved Cannula|arterial cannula for use in cardiac surgery
215019055|NCT04835597|OTHER|Electronic Health Record Review|SAE data is collected
215019056|NCT06027398|DIAGNOSTIC_TEST|SARS-CoV-2 RNA detection|SARS-CoV-2 RNA detection in used mask filters
215019057|NCT06501209|BEHAVIORAL|5A-5R-based counselling session|"The 5As (Ask, Advise, Assess, Assist, Arrange) summarize all the activities that a healthcare provider can do to help a tobacco user (both smoking within 3-5 minutes in a primary care setting. This model can guide you through the right process to talk to respondents who are ready to quit tobacco use and deliver advice.~The 5 R's - relevance, risks, rewards, roadblocks, and repetition - are the content areas that should be addressed in a motivational counseling intervention to help those who are not ready to quit."
215019058|NCT06501209|BEHAVIORAL|Counseling through mobile phone call and text message|Participants will get weekly a phone call and a text message
214418761|NCT05573191|DRUG|Lidocaine|The experimental group was injected with lidocaine 1.5mg/kg, and propofol was pumped intravenously at 90s after lidocaine injection.The dose of propofol was further set according to groups. The heart rate, mean arterial pressure, pulse oxygen saturation and NTI values of subjects were recorded in tne basic state,during the 90s after lidocaine administration, 60s after propofol administration and consciousness loss.The control group simply replaced lidocaine with equal volume normal saline
214418762|NCT05573191|DRUG|Normal saline|Normal saline
214689846|NCT00002706|OTHER|Quality-of-Life Assessment|Ancillary studies
215019059|NCT02602145|OTHER|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.
215019060|NCT05770973|OTHER|Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany|Compression dressing after ptosis surgery
215019061|NCT05845255|DEVICE|mjn-SERAS|Using of wearable, non-invasive device for EEG recording and forecasting of epileptic seizures
215019062|NCT03948789|PROCEDURE|Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy|Magnetic Resonance Imaging-controlled high-focussed ultrasound
215019063|NCT03948789|PROCEDURE|Myomectomy (laparoscopic or open surgical)|Myomectomy (laparoscopic or open surgical)
215019064|NCT01965483|RADIATION|once-weekly breast irradiation|
214418763|NCT06101992|DRUG|Mesoglycan|Mesoglycan capsules 50 mg are composed by heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine
214418764|NCT06101992|OTHER|Placebo|placebo capsules are composed by lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate
214418765|NCT04633980|DRUG|Mixture 3,6% H2 in N2 (96.4%)|Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
214418766|NCT00652301|DRUG|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
215019065|NCT01994005|BEHAVIORAL|Facebook|Facebook page with contraception information used for counseling
215019066|NCT01994005|BEHAVIORAL|Pamphlet|Contraceptive knowledge pamphlets
215019067|NCT03169374|DEVICE|Virtual Reality Technology|Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
215019068|NCT03943511|OTHER|Oral Antibiotics-Close Monitoring|To receive oral antibiotics and close monitoring, defined as twice weekly telephone calls by a member of the care team, of their chest tube and valve.
215019069|NCT03943511|OTHER|Standard of Care|No calls from the care team but waiting for the subject to contact the care team when the air leak has stopped.
215019070|NCT01793129|DEVICE|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
215019071|NCT01793129|PROCEDURE|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
215019072|NCT04128215|BEHAVIORAL|Control Period|Participants completed an 8-week control period of normal lifestyle.
215019073|NCT04128215|BEHAVIORAL|Exercise Period|Participants completed an 8-week exercise intervention period of remotely supervised home-based non-weight-bearing all-extremity high intensity interval training (NWA-HIIT). NWA-HIIT consisted of 4x4-min bouts at 90% of maximal heart rate (HRmax) interspersed by 3x3-min bouts at 70% of HRmax. A 10-min warm-up and 5-minute cool-down at 70% of HRmax were included.
215019074|NCT03487458|PROCEDURE|Rib Fixation Surgery|Rib Fixation Surgery
215019075|NCT06211868|BEHAVIORAL|Digital wearable and AI-human symbiotic lifestyle intervention|Digital wearable and AI-human symbiotic lifestyle intervention
214418767|NCT00652301|DRUG|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
214418768|NCT00652301|DRUG|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
214418769|NCT01841437|DEVICE|iStent|
214418770|NCT03751891|DEVICE|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
214418771|NCT03751891|DEVICE|HearingAid_A|HearingAid\_A is the most recent Receiver-in-the-canal Hearing aid from manufacturer\_A which will be fitted to the participants individual Hearing loss.
214418772|NCT03751891|DEVICE|HearingAid_B|HearingAid\_B is the most recent Receiver-in-the-canal Hearing aid from manufacturer\_B which will be fitted to the participants individual Hearing loss.
214418773|NCT02126878|DRUG|Kenalog|
214418774|NCT01984086|DRUG|Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
214418775|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
214418776|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
215019076|NCT03527979|PROCEDURE|IVF/ICSI|IVF/ICSI
215019077|NCT00839579|OTHER|1x4 min interval|Aerobic interval training
215019078|NCT01926509|DRUG|MK-8892|
215019079|NCT01926509|DRUG|Placebo for MK-8892|
215019080|NCT03004183|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
215019081|NCT03004183|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
215019082|NCT03004183|RADIATION|SBRT|Low-dose SBRT
215019083|NCT03004183|DRUG|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
215019084|NCT04964466|BIOLOGICAL|Amount of PDGF-BB in PRF preparation vs. GEM21|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
214418777|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
214689847|NCT00002706|PROCEDURE|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
214418778|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister|Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
215019085|NCT04964466|BIOLOGICAL|Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
215019086|NCT04964466|BIOLOGICAL|Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
215102328|NCT02119390|OTHER|Questionnaires|Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
215102329|NCT01020253|DRUG|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
215102330|NCT00255775|DIETARY_SUPPLEMENT|broccoli sprout extract|
215102331|NCT00255775|PROCEDURE|complementary or alternative medicine procedure|
215102332|NCT04356040|DEVICE|TactiFlex SE|Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
214418779|NCT01984086|DRUG|Salbutamol MDI 100mcg|Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
215102333|NCT04356040|DEVICE|TactiFlex SE - High Standard Power|Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the High Standard Power Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
214418780|NCT01984086|DRUG|Salbutamol Sulphate UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
214418781|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
214418782|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister without activated charcoal|Formulation will be determined depending on the outcome of Part A.
214418783|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister with activated charcoal|Formulation will be determined depending on the outcome of Part A.
214418784|NCT01984086|DRUG|Salbutamol MDI 100mcg without activated charcoal|Formulation will be determined depending on the outcome of Part A.
214418785|NCT01984086|DRUG|Salbutamol MDI 100mcg with activated charcoal|Formulation will be determined depending on the outcome of Part A.
214418786|NCT05178225|DIETARY_SUPPLEMENT|ubiquinol (reduced coenzyme Q10)|supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg. one morning after breakfast, and second dose after dinner.
214418787|NCT05178225|OTHER|mountain spa rehabilitation|special spa rehabilitation in the mountain High Tatras; Functional capacity of the lungs (6MWT) at before and after 16-18 days of rehabilitation, Borg scale for dyspnea and oxygen saturation SpO2 (%) were monitored.
214418788|NCT05178225|DIAGNOSTIC_TEST|2x14 ml of peripheral blood collected in a tube with anticoagulant|2x14 ml of peripheral blood collected in a tube with anticoagulant
214418789|NCT00846326|DRUG|oxymetazoline-fluticasone propionate|Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily
214418790|NCT00846326|DRUG|Oxymetazoline|oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily
214418791|NCT00319306|DRUG|Budesonide/formoterol|
214418792|NCT00319306|DEVICE|Symbicort® Turbohaler®|
214418793|NCT03084744|BEHAVIORAL|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
214418794|NCT03084744|BEHAVIORAL|Active monitoring|Active tele-monitoring by clinical psychologists.
214418795|NCT03357640|DRUG|combined oral contraceptive pills|one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
214418796|NCT02734056|OTHER|Music|Listening to music that the patient likes
214418797|NCT02734056|OTHER|Control|Control
214418798|NCT05068167|DIAGNOSTIC_TEST|Kidney function test|Creatinine twice the baseline and urine output of fewer than 0.5 ml/kg per hour for 12 hours
214505925|NCT05764057|DRUG|Placebo comparator|"Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
214418799|NCT03119363|DEVICE|AYO light glasses (Experimental)|The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
214418800|NCT03119363|DEVICE|AYO light glasses (Comparator)|The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
214418801|NCT01234610|BEHAVIORAL|Supervised exercise training|Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
214418802|NCT01576133|BEHAVIORAL|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
214418803|NCT01576133|BEHAVIORAL|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
214418804|NCT03789955|PROCEDURE|Fluoroscopic-guided TEB|When performing a fluoroscopic-guided thoracic epidural block (TEB), an 18-gauge Tuohy needle will be used for interlaminar epidural access. If the epidural space was accessed under fluoroscopic guidance and using the loss of resistance technique with air. All procedures will be performed with a paramedian approach under the true AP and lateral view at first, If the interlaminar space is not visible, the CLO view will be used. If the needle is deemed to be in the epidural space when the loss occurred, six fluoroscopic views will be obtained: true AP, CLO at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral. The CLO measured angle will be determined by measuring the angle between the superior lamina and spinous process on the midsagittal plane on thoracic MRI or CT.
214418805|NCT02220478|DEVICE|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
214418806|NCT00067691|PROCEDURE|Acupuncture|
214418807|NCT03980873|BEHAVIORAL|ESTEEM (Effective Sikills to Empower Effective Men)|"ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2010).~Is an individually-delivered cognitive behavioral treatment with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation abilities; reducing maladaptive cognitive, affective, and behavioral avoidance patterns; and improving motivation and self-efficacy for enacting behavior change"
214418808|NCT00189813|DRUG|YM060|
214418809|NCT06087549|DRUG|Pericapsular nerve group block using 0.2% ropivacaine|Unilateral ultrasound guided pericapsular nerve block using 0.5mL/kg 0.2% Ropimol (max 20mL)
214418810|NCT06087549|DRUG|Erector Spinae Plane Block using 0.2% ropivacaine|Unilateral ultrasound guided erector spinae block using 0.5mL/kg 0.2% Ropimol (max 20mL)
214418811|NCT06087549|OTHER|Standard care|No erector spinae block and no pericapsular nerve group block
214418812|NCT05099575|DRUG|Syntocinon, papal, misotac|Using different drugs to prevent atonic PPH during CD in high risk group
214418813|NCT01025843|DRUG|MK-5478|In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
214418814|NCT01025843|DRUG|Comparator: Candesartan cilexetil|Single dose administration of candesartan, 32 mg oral tablet
214418815|NCT01025843|DRUG|Comparator: Pbo|Placebo
214418816|NCT00382161|DRUG|Fluvastatin-sodium|
214418817|NCT03224299|DRUG|OCT - clear|Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
214418818|NCT03224299|DRUG|OCT- tinted|Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
214418819|NCT03224299|OTHER|ChloraPrep|Active Control: ChloraPrep® - Hi-Lite Orange® applicator
214418820|NCT03224299|OTHER|Saline|Negative Control: sterile 0.9% saline applied with single use applicator
214418821|NCT00479206|DRUG|Artesunate|
214418822|NCT00444990|DEVICE|Magnetic Flex Pad|
214505926|NCT02139241|DRUG|Ramosetron|0.3 mg IV as bolus before induction of general anesthesia
214505927|NCT02139241|DRUG|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
214505928|NCT02094534|BIOLOGICAL|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
214505929|NCT02094534|OTHER|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
214505930|NCT05543109|DRUG|Fentanyl|1 mic/kg during induction of anesthesia
214505931|NCT05543109|DRUG|Propofol|3mg/kg during induction of anesthesia
214505932|NCT05543109|DRUG|Rocuronium|0.9 mg/kg during induction of anesthesia
214418823|NCT03109886|DRUG|Milciclib maleate|100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
214418824|NCT02882230|DRUG|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|chemical dosage ARV
215019087|NCT04964466|BIOLOGICAL|Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
214418825|NCT01679262|DEVICE|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
214418826|NCT04928053|GENETIC|ocytocine dosage and genetic analyse|All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
214418827|NCT04378062|PROCEDURE|Digital nerve procedure|The type of procedure performed on the digital nerve at the time of amputation
214418828|NCT03702400|DRUG|Phenylephrine 100 mcg|Phenylephrine at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug, 5 mL each bolus
215019088|NCT05063136|DRUG|Capecitabine+endocrine therapy|Capecitabine (500mg, tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
214418829|NCT03702400|DRUG|Norepinephrine 5 mcg|Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
214418830|NCT02064660|DEVICE|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
214418831|NCT03200587|DRUG|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
214418832|NCT03200587|DRUG|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
214418833|NCT00377455|DRUG|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
214418834|NCT00377455|DRUG|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
214418835|NCT02846194|BEHAVIORAL|brief guided imagery|
214418836|NCT00019669|BIOLOGICAL|aldesleukin|
214418837|NCT00019669|BIOLOGICAL|fowlpox virus vaccine vector|
214418838|NCT00019669|BIOLOGICAL|gp100 antigen|
214418839|NCT00075972|BEHAVIORAL|Mood Tolearance|
215019089|NCT05063136|DRUG|Placebo+endocrine therapy|Placebo (tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
215019090|NCT04785352|DIETARY_SUPPLEMENT|Nutrition Intervention|One egg per day for six months
215019091|NCT04785352|BEHAVIORAL|Grandi Byen|Multicomponent intervention on responsive parenting, nutrition, hygiene + one egg per day for 6 months
215019092|NCT03681093|DRUG|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily administered orally as tablet
215019093|NCT03681093|DRUG|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily administered orally as tablet
215019094|NCT03681093|DRUG|Placebo|Placebo once daily administered orally as tablet
214418840|NCT00075972|BEHAVIORAL|Mood Management|
214418841|NCT00075972|DRUG|Nicotine Replacement therapy|
214418842|NCT04246619|DRUG|Pregabalin|"Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg.~Duration: 12 weeks"
214418843|NCT04246619|DRUG|Duloxetine|"Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.~Duration: 12 weeks"
214418844|NCT01070888|DRUG|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
214418845|NCT01070888|DRUG|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
214418846|NCT02421081|PROCEDURE|vessel microsurgery|That is a surgery ro repair artery laceration.
214418847|NCT02421081|PROCEDURE|tendon repair|That is a surgery ro repair tendon cut.
214418848|NCT02421081|PROCEDURE|nerve microsurgery|That is a surgery ro repair median/ ulnar/ radial nerve cut.
214505933|NCT05543109|DRUG|Sevoflurane|2-3% during maintanance of anesthesia
215019095|NCT06633549|OTHER|Home Accidents Prevention Training|Mothers in the education group who participated in the study were informed about the research and their written consent was obtained. Mothers filled out the 'Information Form' then completed the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6 Years'. Mothers were helped when filling out the form and their questions were answered. The training program was organized so that there would be a maximum of 5 mothers in each group. The trainings were conducted face-to-face with a PowerPoint presentation and lasted about 40-45 minutes. Question-answer and discussion methods were used during the training. After the training, the mothers were asked to fill out the same scale again one month later. One month after the training, the mothers were interviewed face-to-face and the scale was filled in again and the changes they made at home were recorded.
214418849|NCT03635294|OTHER|Blood sample|combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells
214689848|NCT04652687|OTHER|VIA Disc NP (HCT/P)|VIA Disc NP - Allograft tissue injection
214689849|NCT03312140|DRUG|Choline Chloride|
214418850|NCT04456543|PROCEDURE|pressure monitoring|garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.
214689850|NCT01892527|DRUG|Tivantinib (ARQ197)|Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
214689851|NCT04678167|DIAGNOSTIC_TEST|Caloric test|Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
214689852|NCT04678167|DIAGNOSTIC_TEST|Measurement of the speed of Nystagmus|A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
214689853|NCT04678167|DIAGNOSTIC_TEST|Angle of deviation at Fukuda|The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
214689854|NCT04678167|DIAGNOSTIC_TEST|Alexander's degree of nystagmus|"there are 3 degrees:~* Degree I: nystagmus that exists only when the eyes are turned to the right.~* Degree II: also exists when the eyes are to the right or to the front.~* Degree Ill: exists when the eyes are on the right, front, or left"
214689855|NCT04678167|OTHER|EHTEV questionnaire|Handicap Scale for Balance Disorders and Vertigo
214689856|NCT04678167|OTHER|EEV questionnaire|European Vertigo Assessment Questionnaire
215019096|NCT06633549|OTHER|Control Group|Mothers in the control group were informed about the research and the 'Informed Consent Form' was signed. The mothers filled out the 'Information Form' and this process took about 15-20 minutes. Mothers were helped when filling out the form and their questions were answered. In addition, mothers were asked to complete the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6' by introducing. A month later, they were informed that they had to fill out this scale again. A month later, the mothers were interviewed face-to-face and allowed to fill out the scale again. After the last test, the mothers in the control group were given 'Home Accidents and Prevention Training for Children in the 0-6 Age Group' and the output of the training presentation was distributed.
214689857|NCT04678167|OTHER|anxiety VAS|visual analog scale of anxiety
214689858|NCT03510663|DRUG|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
214689859|NCT03510663|DRUG|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
214689860|NCT03510663|DRUG|Moxifloxacin|400mg tablet will be administrated once a week.
214418851|NCT00959920|PROCEDURE|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
214689861|NCT03510663|DRUG|Placebos|Placebo will be intravenously administered once a week.
214689862|NCT05407298|OTHER|Non applicable|Non Applicable
214689863|NCT01924897|BEHAVIORAL|Exercise training|
214689864|NCT00843622|DRUG|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
214418852|NCT00959920|PROCEDURE|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
214418853|NCT02289625|OTHER|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
214418854|NCT05453864|BEHAVIORAL|CMAP Plus TFCBT|This will include 8 individual sessions of CMAP Plus TFCBT delivered by a trained therapist over a period of 12 weeks. Each session will last between 45 to 60 minutes.
214418855|NCT05804604|PROCEDURE|Surgical treatment of proximal femur fracture and blood sample test|Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB
214418856|NCT05804604|PROCEDURE|Blood sample test|Analysis of serum concentration of: SHBG, CTX - I, CK-MB
214418857|NCT06553287|DRUG|LNK01004 ointment 0.3%|LNK01004 ointment 0.3% for topical application
215019097|NCT01704573|DRUG|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|"The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA."
215019098|NCT05175378|OTHER|Lifestyle intervention|We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.
215019099|NCT03355092|DEVICE|vBloc Therapy|The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
214418858|NCT06553287|DRUG|LNK01004 ointment 1.0%|LNK01004 ointment 1.0% for topical application
214418859|NCT06553287|DRUG|LNK01004 ointment 1.5%|LNK01004 ointment 1.5% for topical application
214418860|NCT06553287|DRUG|Vehicle BID|Inactive vehicle matched to LNK01004 ointment for topical application.
214418861|NCT04484480|PROCEDURE|Balance training|Proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
214418862|NCT02628093|DEVICE|THUNDERBEAT|Tissue dissection and vessels ligation
214418863|NCT02628093|DEVICE|LIGASURE|Tissue dissection and vessels ligation
214418864|NCT01897233|DRUG|Lumacaftor|
214418865|NCT01897233|DRUG|Ivacaftor|
214418866|NCT02242162|PROCEDURE|phrenic nerves magnetic stimulations|
214418867|NCT06134466|DIETARY_SUPPLEMENT|Liquid Extensively hydrolyzed cow's milk protein infant formula|Liquid Investigational Formula (Extensively hydrolyzed cow's milk protein infant formula) 2.8 g protein/100 kcal
214418868|NCT02220491|RADIATION|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
214418869|NCT02220491|RADIATION|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
214418870|NCT02768272|DEVICE|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
214418871|NCT02768272|PROCEDURE|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
214418872|NCT00626418|DRUG|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
214418873|NCT00626418|DRUG|Placebo|Placebo tablets
214418874|NCT02049697|DRUG|14C-JNJ-39823277|Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
214418875|NCT00573339|OTHER|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
214505934|NCT05543109|DRUG|Ropivacaine|0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.
214505935|NCT03926702|DRUG|Radiopharmaceuticals|All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
214505936|NCT01673594|DRUG|SODAS MPH|Adults with ADHD will receive open-label SODAS MPH
214505937|NCT01673594|DRUG|Naltrexone|"Subjects randomized to the active double-blind group will receive Naltrexone HCl"
214505938|NCT04178213|DEVICE|Implantation of ADAPT 3D ALR|The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.
214505939|NCT03069391|BEHAVIORAL|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
214418876|NCT03586596|BEHAVIORAL|The Decídetext program|Decídetext participants will be directed to the tablet-based software. Participants will receive an interactive education session that will lead them through language-appropriate, culturally-relevant information about stopping smoking, collection of basic smoking history data, and choices/plans about preparing to quit. Quit plans include: 1) choice of quit date, 2) NRT preference, 3) plan to remove smoking cues, 4) identification of trigger situations and 5) choice of suggested coping strategies. Participant data and choices are used to generate a printed 1-page individualized treatment plan. Tablet components, assessment items, audio narrative, brief multimedia instructional video clips, and the printed treatment plan have been developed to address low-literacy levels.
214418877|NCT03586596|BEHAVIORAL|Standard Care Control|Educational Material provided as of suggested by American Cancer Society and, the National Cancer Institute
215019100|NCT01121029|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
214418878|NCT03899480|BIOLOGICAL|Haploidentical Natural Killer (NK) Cells|infusion with N-803 activated NK cells
214418879|NCT02491554|DEVICE|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
214418880|NCT02491554|DEVICE|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
214418881|NCT04459988|DRUG|Ocrelizumab|Description Needed
214418882|NCT01740570|DRUG|Cabazitaxel|"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I."
214418883|NCT04235283|DEVICE|Primary total knee replacement by pinless navigation (Orthomap Express,Stryker, Michigan)|The varus/valgus, extension/flexion, thickness of distal cut of femur was determined and done by pinless navigation system. After cutting, the instant information of resection level can show on the display screen. If the alignment is satisfying, the anterior/posterior femoral cut, chamfer cut and box resection were done by conventional jig
215019101|NCT03084900|OTHER|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
215019102|NCT02698787|DEVICE|Experimental sound coding strategy (FAST)|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
215019103|NCT02698787|DEVICE|Commercially available ACE sound coding strategy|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
215019104|NCT02459600|OTHER|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
215019105|NCT04245579|OTHER|Multifactorial Memory Training Program (UMAM method)|
214418884|NCT04235283|PROCEDURE|Primary total knee replacement by traditional jig and minimally invasive technique|The femoral alignment was determined by intramedullary guide. The femoral alignment jig was set to 5-7 degree valgus dependent on the preoperative radiograph. A bone plug is impacted into the entry hole of femoral medullary canal before prosthesis placement.
214418885|NCT02834871|DEVICE|Electromyogram|
214418886|NCT02715258|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
214418887|NCT02715258|DRUG|Placebo|tablets matching the appearance of bexagliflozin tablets
214418888|NCT03443037|DRUG|amantadine sulphate|
214418889|NCT03002246|OTHER|Ultrasound Examination|Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.
214418890|NCT05113355|DRUG|Chidamide|30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
214418891|NCT05113355|DRUG|Sintilimab|200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
214418892|NCT01944410|BIOLOGICAL|PRP injection|injection of PRP to traumatic bone cyst defect
214418893|NCT02814643|DRUG|Benralizumab|Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
214418894|NCT02814643|DRUG|Benralizumab Placebo|Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
214418895|NCT02814643|DRUG|Seasonal influenza virus vaccine|Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
214418896|NCT04215198|DIETARY_SUPPLEMENT|Move3™ (NEM® brand eggshell membrane + KD PUR® brand fish oil)|Dietary supplement combination for the support of joint health.
214418897|NCT04215198|DIETARY_SUPPLEMENT|Placebo|Placebo
214418898|NCT02263508|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec administered by intratumoral injection
214418899|NCT02263508|DRUG|Pembrolizumab|Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
214418900|NCT02263508|DRUG|Placebo|Administered by intratumoral injection
214505940|NCT03069391|DEVICE|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
215019106|NCT05686486|OTHER|Tai Chi inspired gymnastics|"The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance."
214418901|NCT05857358|PROCEDURE|lipoaspiration|"Adipose tissue harvest will be conducted by a surgeon under under local and intra-veinous sedation anesthesia. Once the patient is asleep and just before the laying of the operating drapes, the skin will be thoroughly disinfected, in order to avoid bacteriological contamination. Each entry point will be disinfected with betadine before and regularly during the procedure and will receive local anesthesia.~The lipoaspiration sites will be infiltrated using a closed system, thanks to a Khoury canula. Adipose tissue will be harvested after waiting at least 5 minutes, in order to limit hematoma and excessive blood harvesting. A 3mm incision will be made then the tissue collection will be performed using a canula, manually, by gentle aspirations into a syringe then directly transferred into a connected sterile bag.~The incision will be closed with 1 stitch of 6-0 absorbable and a paraffin gauze dressing. Then, patient will be awaken and transported to the recovery room."
214418902|NCT05857358|DRUG|Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)|"Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~* 2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~* 2 for the sublingual glands (0.5mL for each gland)~* 2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose."
214418903|NCT05573854|DIETARY_SUPPLEMENT|Gastric emptying after an oral supplement containing carbohydrates and whey protein|Ingestion of an oral supplement containing carbohydrates and whey protein
214418904|NCT05573854|DIETARY_SUPPLEMENT|Overnight Fast|Residual Gastric Volume assessed by MRI after overnight fast (8h)
214418905|NCT02008019|DRUG|Everolimus 2.5 mg/day|Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
214418906|NCT02008019|DRUG|Everolimus 10 mg/day|Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
214418907|NCT02241668|PROCEDURE|PET Scan|FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
214418908|NCT02241668|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
214418909|NCT03483519|OTHER|Rehabilitation|Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
214418910|NCT03483519|OTHER|Standard of Care|Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
214418911|NCT00531518|DRUG|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
214418912|NCT00531518|BEHAVIORAL|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
214418913|NCT00531518|BEHAVIORAL|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
215019107|NCT05033561|BIOLOGICAL|nOPV2|Novel Oral Poliomyelitis Type 2 Vaccine
214418914|NCT02783235|OTHER|cervical cancer screening|for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
214418915|NCT00873691|DEVICE|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
214418916|NCT00440973|DRUG|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
214418917|NCT00440973|DRUG|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T \& B lymphocyte proliferation
214418918|NCT06302491|DRUG|AND017 capsules|Administer AND017 capsules once per day (QD)
214418919|NCT06302491|DRUG|AND017 Placebo|Administer AND017 matching placebo capsules once per day (QD)
215019108|NCT02445365|DEVICE|AutoRIC device|
215019109|NCT03008473|DEVICE|video laryngoscope and chest CT iminge|
214418920|NCT00992238|DRUG|Flavoxate Hydrochloride Tablets, 100mg|
215019110|NCT03008473|DEVICE|Conventional intubation of uniblocker|
215019111|NCT01100580|DIETARY_SUPPLEMENT|low salt diet|Daily salt intake less than 4 g/day
215019112|NCT01100580|DIETARY_SUPPLEMENT|water therapy|abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
214418921|NCT00992238|DRUG|Urispas® Tablets, 100mg|
214505941|NCT03069391|DEVICE|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
214505942|NCT04627896|DEVICE|Katty focal therapy|Microwave ablation with TATO3 generator (Katty system) under guidance of ultrasound/mpMRI fusion image device Trinity
214505943|NCT00808834|DEVICE|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
214505944|NCT00808834|DEVICE|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
214418922|NCT00182845|DRUG|Donepezil|
214418923|NCT01833507|BEHAVIORAL|Self-Exercise|Behavioral Goal Setting
214418924|NCT01833507|BEHAVIORAL|Usual Care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
215019113|NCT01882829|DRUG|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
215019114|NCT06355141|OTHER|oral assessment|observational oral assessment
215019115|NCT03453515|BEHAVIORAL|HEART|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
215019116|NCT03453515|BEHAVIORAL|Growing Minds|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
215019117|NCT01245023|PROCEDURE|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
215019118|NCT01245023|PROCEDURE|Placebo-surgery|skin incisions without laparoscopy or related procedures
215019119|NCT05183984|DRUG|Chemotherapy|Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period
215019120|NCT05183984|DRUG|Bevacizumab-Awwb|"MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months."
215019121|NCT05183984|DRUG|Niraparib|niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.
215019122|NCT01313676|DRUG|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
215019123|NCT01313676|DRUG|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
215019124|NCT01313676|DRUG|vilanterol|25mcg given once daily via novel dry powder inhaler
215019125|NCT01313676|OTHER|Placebo|placebo comparator once daily via novel dry powder inhaler
215019126|NCT00800345|DRUG|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
215019127|NCT00800345|DRUG|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
214418925|NCT03265210|BEHAVIORAL|RELIEF|A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.
214418926|NCT05756140|OTHER|No intervention|No Control
215019128|NCT05280860|PROCEDURE|ultrasound-guided bilateral rectus sheath block|Bilateral RSB was guided by ultrasound before surgery after the completion of general anesthesia, First, the probe is placed transversely and perpendicular to reveal the anterior, hypoechoic, and posterior rectus sheath of the hyperechoic rectus abdominis. Moving the probe outward to reveal the sound images of the lateral margin of the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. After the scanning, the needle was inserted from any segment of the probe under the guidance of real-time ultrasound; the tip reached between the rectus abdominis muscle and the posterior sheath of the rectus abdominis muscle. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct, If the needle tip was correctly positioned, 0.5 % ropivacaine 10 mL of local anesthetic was injected on each side. The same anesthesiologist was performed bilateral RSB under ultrasound guidance.
215019129|NCT05901207|DIAGNOSTIC_TEST|blood test|blood test
215019130|NCT06794359|PROCEDURE|Minimally Invasive Coronary Artery Bypass Grafting|Minimally Invasive Coronary Artery Bypass Grafting will be accomplished by complete revascularization of all previous defined coronary targets through left anterior thoracotomy. On or off pump approach will be determined by the surgeon. For on pump cases, femoral canulation will be performed and aortic cross clamp will be used. Off Pump cases will be performed using Medtronic Octopus and Starfish NS. Intra operative Transit time flow measurement will be performed in all cases.
215019131|NCT06794359|PROCEDURE|Coronary artery bypass surgery|Procedure: Conventional Coronary Artery Bypass Grafting will be accomplished by complete revascularization of all previous defined coronary targets through classical total sternotomy. On or off pump approach will be determined by the surgeon. Intra operative Transit time flow measurement will be performed in all cases.
215019132|NCT02831335|OTHER|MRI|Perform MRI studies
215019133|NCT02831335|OTHER|MRI|Perform MRI studies
215019134|NCT02831335|OTHER|MRI|Perform MRI studies
215019135|NCT02831335|OTHER|Group 4|Perform MRI studies
215019136|NCT04878757|BEHAVIORAL|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
215019137|NCT05626777|DRUG|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
215019138|NCT05626777|DRUG|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
214418927|NCT00411996|DRUG|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
214418928|NCT00598208|DRUG|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
214418929|NCT00598208|DRUG|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
214418930|NCT03861741|GENETIC|WES|A peripheral venous blood sample will be processed internally, and externally subjected to WES. Only genetic material from relatives of probands in which a mutation has been identified will be sequenced.
215019139|NCT05119335|DRUG|Oral NKT2152|Oral HIF2α inhibitor
215019140|NCT06634862|OTHER|Normatec Air Compression|Intermittent pneumatic pressure has been used in other studies, usually for deep vein thrombosis and vascular disorders. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
214689865|NCT00843622|OTHER|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
214689866|NCT03491163|DIAGNOSTIC_TEST|Syndecan-1 concentration evaluation|Blood sample will be taken and analysed using ELISA method.
214689867|NCT02491658|BIOLOGICAL|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
214418931|NCT03861741|DIAGNOSTIC_TEST|MRI|A MRI of the thoracic aorta will be performed in all relatives able to attend the Glenfield Hospital and who have no contra-indications to this imaging modality; pulse-wave velocity will be recorded.
214418932|NCT03861741|DIAGNOSTIC_TEST|TTE|TTE screening will be performed by a trained physiologist. Aortic diameter will be measured from the parasternal long-axis view at the sinuses of Valsalva and at the widest level of the ascending aorta. All measurements will be made in end-diastole.
214418933|NCT03861741|OTHER|Questionnaire|Acceptability questionnaires will be submitted to assess a baseline score of depression/anxiety that will be compared with a follow up value at three months
214418934|NCT01567683|DRUG|Imiquimod (topical use)|
214418935|NCT01153451|OTHER|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
214418936|NCT00140088|DRUG|ALGRX 3268|
214689868|NCT04942483|DIAGNOSTIC_TEST|Blood eosinophil count|Peripheral blood eosinophil count will be measured from a finger prick blood sample, using the Haemocue machine, allowing a result in approximately 2 minutes. The test will allow to assess the presence or not of eosinophilia and if it can predict future wheezing exacerbations and response to inhaled corticosteroids (ICS).
214418937|NCT02065050|OTHER|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
214418938|NCT04962282|OTHER|Follow-up by telephone|Studies have shown that the compliance of patients at 8-12 weeks reaches a peak, so this time node is the most suitable time node to investigate compliance. Telephone follow-up is irreplaceable convenience, so the telephone follow-up survey of patient compliance with exercise prescriptions is The most feasible method The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.
214418939|NCT05936671|PROCEDURE|EEG-and-ANI-guided anesthesia|During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.
215019141|NCT06634862|OTHER|Soft Tissue Mobilization|The soft tissue mobilisation technique has been investigated in other studies in terms of its effect on soft tissue and its role recovery. In this way, there is no comparison with other recovery interventions for post-exercise recovery applications.
215019142|NCT06634862|OTHER|Percussive therapy|Percussive therapy has been investigated in device research and athlete health. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
214418940|NCT05936671|PROCEDURE|standard anesthesia|During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.
214418941|NCT05936671|DRUG|Sevoflurane and remifentanil|For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.
214689869|NCT04942483|DIAGNOSTIC_TEST|Atopic sensitization|Skin prick tests will be performed to: (a) house dust mite, (b) grass pollen, (c) tree pollen, (d) cat hair, (e) dog hair, as well as normal saline and histamine which will act as negative and positive controls respectively. In addition, skin prick tests will allow the assessment of which aeroallergen is the most useful predictor of outcomes in preschool children.
214689870|NCT04942483|DIAGNOSTIC_TEST|FeNO (offline method)|The child will breathe normally into a sample bag that will be collected for later analysis of FeNO levels. The test will be performed twice.
215019143|NCT06636422|DRUG|Motherwort injection|Patients will be given motherwort injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
215019144|NCT02469961|DRUG|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
215019145|NCT02469961|DRUG|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
215019146|NCT02469961|OTHER|Interscalene block|Interscalene block is used for the main anesthetic for the case
215019147|NCT02935036|DRUG|ADPS topical product|topical product
215019148|NCT02935036|DRUG|Placebo Control|topical product
215019149|NCT05298046|DRUG|Experimental: TAVO101|TAVO101 single ascending dose IV infusion.
215019150|NCT05298046|OTHER|Other: Placebo|Placebo single ascending dose IV infusion.
215019151|NCT03629717|PROCEDURE|Ultrasound-guided core needle biopsy|Tissue collection for this research proposal will be used for research purposes only and will not inform participant care
215019152|NCT03629717|DRUG|Denosumab|Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
215019153|NCT03629717|PROCEDURE|Blood draw|20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)
215019154|NCT03629717|DRUG|Calcium|1200mg daily
215019155|NCT03629717|DRUG|Vitamin D|800 IU daily
214418942|NCT05936671|DEVICE|EEG and ANI|EEG monitoring using SEDline (Masimo, Irvine, California, USA) and Analgesia Nociception Index (ANI; MetroDoloris Medical Systems, Lille, France) monitoring will be performed.
214418943|NCT06081231|DEVICE|open-source APS;|a continuous glucose monitoring system, an insulin pump, and an intelligent algorithm.
214418944|NCT03302546|PROCEDURE|Incremental hemodialysis|Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
214418945|NCT03302546|PROCEDURE|Conventional hemodialysis|Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
214418946|NCT04989725|OTHER|Standard arm|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
214418947|NCT04989725|RADIATION|Experimental arm|SABR to all oligoprogressive lesions + continuation of current systemic therapy
214418948|NCT01975311|OTHER|Lumbopelvic Manipulation|High-velocity low-amplitude non-specific lumbopelvic thrust manipulation
214418949|NCT01975311|OTHER|Passive lumbar spine flexion and extension|Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
214418950|NCT04020718|BEHAVIORAL|Brief telephone advice plus tailored text messages|All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
214418951|NCT04020718|DRUG|Mailed nicotine replacement therapy|Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
214418952|NCT04020718|BEHAVIORAL|Proactive telephone coaching|Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
214418953|NCT00566514|DIETARY_SUPPLEMENT|D-ribose|5 grams administered orally TID
214418954|NCT00566514|OTHER|dextrose|5 grams orally TID
214418955|NCT01885845|DEVICE|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
214418956|NCT01885845|OTHER|Indirect weight assesment of blood loss|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
214689871|NCT05886647|OTHER|Active non-invasive stimulation and inspiratory muscle training|Simultaneously with the current application, the patient will perform inspiratory muscle training (IMT) by KH2; PowerBreathe International Ltd. UK along with a feedback Breathelink, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI.
215019156|NCT06363981|DEVICE|Active rTMS over the left DLPFC and over the left DMPFC|Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.
215019157|NCT06363981|DEVICE|Active rTMS over the left DLPFC|Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.
215019158|NCT06363981|DEVICE|Sham rTMS|Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.
215019159|NCT03435107|DRUG|Durvalumab|"Study treatment consists of durvalumab 1500 mg Q4W for patients \> 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
215019160|NCT05130281|BEHAVIORAL|Maya mobile app|The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.
215019161|NCT05130281|BEHAVIORAL|Social Support|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message. Participants can identify a person they know to receive updates about their progress and support them throughout their time in the program. Participants will not be required to choose a person they know to receive updates about their use of the program; instead, they can choose to have a member of the study team serve as their social support if they are assigned to this condition.
214418957|NCT02835768|OTHER|Internet-based injury prevention program|"An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum."
215019162|NCT05130281|BEHAVIORAL|Gain Framed|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message.
214418958|NCT01261234|DRUG|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
214418959|NCT04077151|BEHAVIORAL|PrEP Demonstration Project|In phase 2, a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth will be developed by incorporates the PK data from phase 1 and data gathered from focus groups and in-depth interviews with young transgender women and transgender men. During phase 3, this intervention will be given to the experimental arm and tested versus a standard-of-care control group.
214418960|NCT01281813|DRUG|Darunavir|Participants will receive darunavir (per parent study) as oral suspension.
214418961|NCT01281813|DRUG|Ritonavir|Participants will receive ritonavir (per parent study) as oral solution/suspension.
214418962|NCT03546907|DRUG|SAR440340|Pharmaceutical form: Solution for injection; Route of administration: SC
214418963|NCT03546907|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: SC
214418964|NCT03546907|DRUG|Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
214418965|NCT03546907|DRUG|Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
214418966|NCT03546907|DRUG|Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
214418967|NCT03546907|DRUG|Any short-acting β agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
214418968|NCT01189006|DRUG|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
214418969|NCT01980069|DRUG|Sugammadex|In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
214418970|NCT01980069|DRUG|Neostigmine|In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
214689872|NCT05886647|OTHER|Sham compatorator and inspiratory muscle training|As for the patients allocated in the control group, they will receive the HD-tDCS sham for 20 minutes associated with IMT, following for the same training, duration and load increment used in the experimental group.
214689873|NCT03175744|DEVICE|Stellarex DCB|Intervention with the Stellarex DCB
214689874|NCT03175744|DEVICE|PTA Catheter|Intervention with an uncoated Standard PTA
214689875|NCT04652063|OTHER|Osteopathic Manipulative Medicine|Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
215019163|NCT05130281|BEHAVIORAL|Loss Framed|Participants lost points and badges for not completing sessions, homework, and skills on time and receive post session feedback via text message.
215019164|NCT06249672|OTHER|Local excision|Organ preservation after RCT (radiochemotherapy) of rectal cancer
215019165|NCT04481659|PROCEDURE|Lap partial ISR|A direct laparoscopic surgery with completely abdominal approach laparoscopic partial intersphincteric resection
214689876|NCT05162612|DIAGNOSTIC_TEST|abtominal CT|standard basic Abdominal Ct scan
215019166|NCT04481659|COMBINATION_PRODUCT|NCRT+Lap partial ISR|Preoperative radiation and chemotherapy + laparoscopic completely abdominal approach laparoscopic partial intersphincteric resection
214689877|NCT05628467|DRUG|Antidepressive Agents|Compare the signal obtained from the pharmacovigilance database study between adults over 65 who fall on antidepressants versus those who fall on other drugs
215019167|NCT06497088|DEVICE|Nasotrak System|"Device: The Nasotrak System~The Nasotrak Medical System is intended to aid, in conjunction with institutional protocols, qualified operators in the placement of the Nasotrak's 12 Fr feeding tube into the stomach of patients requiring enteral feeding after insertion and before every feed. The Nasotrak nasogastric tube(NGT) is designed for use with Nasotrak's handheld device (HHD) which is able to detect the tip of the NGT via piezoelectric sensor, which converts ultrasound waves to electronic signals, thus assisting to track its location as an indicator of placement in the stomach. Nasotrak's NGT is intended only to be used with Nasotrak's HHD.~The Nasotrak NGT is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition."
215019168|NCT06268717|OTHER|Ground pork containing alpha-gal|150 grams of cooked, ground pork meat containing alpha-gal sugar eaten once
215019169|NCT06268717|OTHER|Pork meat not containing alpha-gal|150 grams of cooked, ground pork meat not containing alpha-gal sugar
214418971|NCT04560855|DEVICE|Connected devices measurements|The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
214418972|NCT03510949|DEVICE|Nasopharyngeal airway or laryngeal mask airway|Comparing the incidence of postoperative soar throat with the use of nasopharyngeal airway versus laryngeal mask airway
214418973|NCT05432934|DRUG|Dexamethasone|Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
214418974|NCT06379711|DEVICE|Transcutaneous Spinal Cord Stimulation (tSCS)|Transcutaneous spinal cord stimulation (tSCS) will be delivered via a non-invasive central nervous system stimulator TESCoN or SCONE (SpineX Inc., CA - experimental type II medical devices) through self-adhesive electrode(s) placed on the skin between spinous processes over the midline of the vertebral column as the cathode(s) and two rectangular electrodes placed symmetrically on the skin over the iliac crests as anodes. Stimulation will be applied at various waveforms and frequencies (ranging between 1Hz and 90Hz) with and without a carrier frequency. Current amplitude will start at 10mA and proceed incrementally until tolerable or responses plateau. If spasticity occurs or is uncomfortable, the current will be decreased. Specific areas for electrode placement will be examined and prepared to reduce skin impedance. tSCS will be delivered under the supervision of a physician (Dr. Krassioukov/Dr. Berger) by trained doctoral/post-doctoral trainees.
214418975|NCT01446068|DIETARY_SUPPLEMENT|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
214418976|NCT02599142|DEVICE|Group A: Closed-face shell|As for arm description
214418977|NCT02599142|DEVICE|Group B: Open-face shell|As for arm description
214418978|NCT00816751|PROCEDURE|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
214418979|NCT00816751|PROCEDURE|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
214418980|NCT00816751|DRUG|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
214418981|NCT02620761|DRUG|Fenoldopam|Randomized to receive Fenoldopam or 0.9%NS
214418982|NCT02620761|DRUG|0.9%NS|Randomized to receive Fenoldopam or 0.9%NS
214418983|NCT03737097|OTHER|Online Spaced Education|Investigators created a set of fall prevention strategies for multiple sclerosis patients into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), spaced education has been shown in randomized trials to improve knowledge acquisition, boosts learning retention for up to two years, and durably improves changes in behavior.
214418984|NCT03737097|OTHER|Brochure Education|The investigators translated and validated the Minimizing Your Risk of Falls A GUIDE FOR PEOPLE WITH MS brochure developed by the National Multiple Sclerosis Society. The control cohort will receive the main education model for patients that has been used in the past few years.
214418985|NCT05110391|DRUG|Hormonal Therapy Agent|Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
214418986|NCT00044148|DRUG|LY333531|
214418987|NCT06242899|OTHER|Exercise|"Exercise with a cycle ergometer in three phases:~* Warm-up: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.~* Short exercise at moderate intensity for 8, 10 or 15 minutes according to group allocation. The exercise was cycling at 75% HRmax determined with an effort test.~* Cool down: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes."
214418988|NCT05054764|DEVICE|Promus PREMIER BTK DES|Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients
214418989|NCT04033432|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
214418990|NCT04693130|BEHAVIORAL|Mindfulness-based prenatal education|Mindfulness-based prenatal education involves mindfulness breathing and other skills with mindfulness meditations.
214418991|NCT04693130|BEHAVIORAL|Hospital-based antenatal care|Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
214418992|NCT02598596|BIOLOGICAL|Pegloticase|Pegloticase, IV
214418993|NCT02598596|DRUG|Azathioprine|Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
214418994|NCT02886221|PROCEDURE|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
214418995|NCT02965248|DRUG|Standard adjuvant systemic chemotherapy|"Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles."
214689878|NCT01158495|PROCEDURE|Intubation with a cuffed ET Tube|
214418996|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed|Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.
214418997|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin|Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
214418998|NCT06070324|PROCEDURE|Breast surgery|Any surgery involving incisions made along the nipple areolar complex. These would include transgender mastectomy, cisgender female breast reduction/augmentation/reconstruction, and cisgender male gynecomastia correction.
215019170|NCT06844812|OTHER|This is not an interventional study. Patients who are planned to start methylphenidate treatment have been invited to participate in the study.|This is not an interventional study. Patients diagnosed with Attention Deficit Hyperactivity Disorder (ADHD), for whom methylphenidate treatment is planned, have been invited to participate in the study. The patients have been enrolled in follow-up, and our contact information has been provided to them. As part of routine care, patients have been called in once a month. Necessary dosage adjustments have been made in accordance with medical guidelines, without any intervention for the study. Patients with complaints or those who needed to be seen earlier have been seen in between. As a result, the patients were followed for a total of 3 months for this study. Serum samples for oxidative stress markers were collected at baseline (before treatment started) and at the 3rd month (after treatment began).
215019171|NCT05018507|OTHER|Data collection only|No intervention, just data collection from system machines
215019172|NCT01446588|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
215019173|NCT04566510|OTHER|long lasting insecticidal nets with alpha-cypermethrin + pyriproxyfen (PPF LLIN, Royal Guard))|Next-generation bed net combining insecticides with different modes of action
215019174|NCT04566510|OTHER|long lasting insecticidal nets with deltamethrin + piperonyl butoxide (PBO LLIN, PermaNet 3.0))|Next-generation bed net combining an insecticide with a synergist
214418999|NCT06070324|DEVICE|Suturing of surgical incision|The closing of a surgical incision by using sutures so appose and maintain apposition of two skin edges. Suturing may or may not require knot-tying depending on the material of suture used.
214419000|NCT04790604|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
214419001|NCT05617586|OTHER|In-depth parental interview|A semi-structurerd interview will be conducted of parents with a child diagnosed with DCD. The interview will be audio-recorderded. The audiofile will be transcribed ad-verbatim and analyzed using narrative analysis methods.
214419002|NCT05617586|OTHER|Developmental Coordination Disorder Questionnaire (DCD-Q)|Parents will be asked to complete the DCD-Q. This will help us describe the sample.
214419003|NCT03173105|DEVICE|active tDCS|TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
214419004|NCT03173105|DEVICE|sham tDCS|Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
214505945|NCT04778670|DIAGNOSTIC_TEST|AI CAD|The Lunit INSIGHT MMG will be used as the AI CAD in our study. Initially, version 1.6.1.1 will be installed. The software version will be continuously updated with subsequent software releases, after confirming in a historic calibration dataset that the performance is improved. The operating point will be set based on a historic calibration dataset to attain a joint sensitivity of breast cancer detection of AI and first reader which is 2% higher than for first and second reader.
214505946|NCT04778670|DIAGNOSTIC_TEST|Radiologist reading|Standard of care, each radiologist will assess the mammography examination, making a binary flagging decision (flag the examination to continue to consensus discussion, or not)
214505947|NCT04681794|OTHER|exercise-based intervention|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, jumping/hopping, and movement-based mindfulness.
214505948|NCT01711294|DEVICE|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
214505949|NCT01711294|DEVICE|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
214505950|NCT01711294|DEVICE|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
214505951|NCT05973773|DRUG|TAS6417|oral tablets
214505952|NCT02605174|DRUG|Lasmiditan 50 mg|One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
214505953|NCT02605174|DRUG|Lasmiditan 100 mg|One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
214505954|NCT02605174|DRUG|Lasmiditan 200 mg|One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
214505955|NCT02605174|DRUG|Placebo|Two placebo tablets to match lasmiditan doses.
214505956|NCT00937014|OTHER|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
214505957|NCT00937014|OTHER|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
214689879|NCT01158495|PROCEDURE|CT scan Radiation|
215019175|NCT04566510|BEHAVIORAL|Social behaviour change communication|SBCC activities will use digital and other platforms, similar to those used for the COVID-19 response, including the following: (1) LLIN launch on television and radio; (2) regional advocacy meetings on Zoom; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about COVID-19, malaria, and use, care, repair and repurposing of LLINs.
214419005|NCT03173105|OTHER|Dynamic proprioceptive exercises|The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
215019176|NCT01442285|BEHAVIORAL|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
214419006|NCT03173105|OTHER|static proprioceptive exercises|The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
215019177|NCT01558414|PROCEDURE|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
215019178|NCT01558414|PROCEDURE|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
215019179|NCT01558414|PROCEDURE|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
215019180|NCT02347865|DRUG|AMG 162 - Prolia|500 patients
215019181|NCT02347865|DRUG|AMG 162 - Prolia|250 patients, one year later
215019182|NCT00464529|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
215019183|NCT00368849|DRUG|atomoxetine|This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.
214689880|NCT00993603|BEHAVIORAL|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
215019184|NCT00368849|DRUG|Matching Placebo|This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
215019185|NCT05462496|PROCEDURE|Biopsy|Pre-treatment tumor biopsy
215019186|NCT05462496|DRUG|FOLFIRINOX|"Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3"
215019187|NCT05462496|DRUG|Ciprofloxacin|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
215019188|NCT05462496|DRUG|Metronidazole|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
215019189|NCT05462496|DRUG|Pembrolizumab|Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
215019190|NCT05462496|PROCEDURE|Surgical Resection|Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
215019191|NCT02006836|DIETARY_SUPPLEMENT|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
215019192|NCT02006836|DIETARY_SUPPLEMENT|Glucose|We dissolved 50 g of glucose in 200 ml water.
215019193|NCT02006836|OTHER|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
214419007|NCT04581317|OTHER|meals|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.
214419008|NCT04581317|OTHER|AES 8 basic usage|For the second 6 weeks, participants will continue to have meal deliveries and will now have the AES 8 device which can be used by the cognitively impaired participant and their caregiver. AES 8 devices will be installed in participant's homes by the study team and participants will be given basic instructions on using the device as well as a one-page handout that will include instructions on how to use and maintain privacy with their device. The study staff will continue to call twice a week to ask the 5 questions. At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
214505958|NCT03768466|DRUG|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
214689881|NCT03318640|BEHAVIORAL|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
215019194|NCT02006836|DRUG|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
215019195|NCT02006836|DRUG|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
215019196|NCT06500897|DEVICE|VEST|External MEsh Support for safein vein
215019197|NCT05280314|DRUG|IO102-IO103|IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
215019198|NCT05280314|DRUG|Pembrolizumab KEYTRUDA®|Pembrolizumab KEYTRUDA® administered intravenously
215019199|NCT06309797|DEVICE|Interdental brush+HA|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm) +20 mL of 0.2% HA gel (Gengigel; Ricerfarma, Milan, Italy)
215019200|NCT06309797|DEVICE|Interdental brush|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm)
215019201|NCT02571543|DRUG|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
215019202|NCT04202211|BIOLOGICAL|FMT oral|lyophilized FMT given orally (10 capsules) twice weekly for total of 8 weeks
214505959|NCT00002801|DRUG|leucovorin calcium|
214505960|NCT00002801|DRUG|tegafur-uracil|
214505961|NCT00002801|RADIATION|radiation therapy|
214505962|NCT00666419|OTHER|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
214505963|NCT01010945|DRUG|erlotinib|administered orally
215019203|NCT04202211|BIOLOGICAL|FMT enema|lyophilized FMT given via enema (1) twice weekly for total of 8 weeks
215019204|NCT04202211|OTHER|Placebo oral|placebo given orally (10 capsules) twice weekly for total of 8 weeks
215019205|NCT04202211|OTHER|Placebo enema|placebo given via enema (1) twice weekly for total of 8 weeks
215019206|NCT01699685|DRUG|QAB149|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
215019207|NCT01699685|DRUG|Placebo|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
215019208|NCT01699685|DRUG|NVA237|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
214505964|NCT01010945|DRUG|gemcitabine|administered intravenously
214505965|NCT01010945|DRUG|nab-paclitaxel|administered intravenously
214505966|NCT04295642|DRUG|CVL-751|Oral tablet
214505967|NCT03081013|BEHAVIORAL|Social information|Social comparison information will be provided to the study participants weekly via SMS
215019209|NCT04950907|DIAGNOSTIC_TEST|vats|Use uniportal tubeless VATS to obtain the biopsy
215019210|NCT04950907|DIAGNOSTIC_TEST|CT-guided fine needle biopsy|Use CT-guided fine needle to obtain the biopsy
214505968|NCT03081013|DEVICE|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
214505969|NCT00005962|BIOLOGICAL|sargramostim|
214505970|NCT00005962|DRUG|cyclophosphamide|
214505971|NCT00005962|DRUG|cytarabine|
214505972|NCT00005962|DRUG|gemtuzumab ozogamicin|
214505973|NCT00005962|DRUG|liposomal daunorubicin citrate|
214505974|NCT00005962|DRUG|topotecan hydrochloride|
215019211|NCT02885922|DRUG|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
215019212|NCT03635996|DRUG|Etripamil NS 70 mg|All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
215019213|NCT03635996|DEVICE|Aptar Pharma Nasal Spray Bidose System|Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
215019214|NCT02797548|DRUG|Aspirin only|Aspirin only during surgery
215019215|NCT02797548|DRUG|No antiplatelet therapy|No antiplatelet therapy will be during surgery
214419009|NCT04581317|OTHER|AES 8 advanced usage|In the third 6 weeks, the participants will continue to have meal deliveries and the AES 8 will be upgraded to provide an active intervention by asking the twice a week 5 questions through the device. The questions should be answered by the cognitively impaired older adult using the device, though the caregiver can still use the device for other basic services. The participant will be able to answer the questions verbally or by touch screen options displayed on the device.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
214419010|NCT00919685|BIOLOGICAL|blood sample|from rest of blood sample collected for other measurements
214419011|NCT04226703|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|"Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge root.~Indirect Laryngoscopy: Grading of laryngoscopic view (I=Visible anterior commissure and vocal cords, II= visible posterior part of vocal cords and posterior commissure, III= Visible posterior commissure and epiglottis, IV= Visible only epiglottis tip and posterior pharyngeal wall)"
214419012|NCT00637936|DRUG|Oxygen|Inspiratory fraction during anaesthesia
214419013|NCT02589002|OTHER|Sucralose|
214419014|NCT04566458|OTHER|No intervention|retrospective chart review study
214419015|NCT02192606|DEVICE|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
214419016|NCT02192606|DEVICE|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
214419017|NCT01793441|DRUG|Placebo|Placebo will be administered in different stages of the study for 12 weeks.
214419018|NCT01793441|DRUG|RG7314|RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
214419019|NCT03110458|DRUG|SENS-111 100mg|SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
215019216|NCT04482803|DRUG|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes|Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
215019217|NCT06377748|OTHER|Facilitated tucking position|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will administer intramuscular vaccine injection into the vastus lateralis region of the left leg of the infant in the facilitated tucking position according to routine practice.
215019218|NCT06377748|DEVICE|ShotBlocker|Immediately prior to the vaccination procedure, the nurse will place the protruding surface of the ShotBlocker on the neonate's vaccination procedure site (left leg vastus lateralis muscle). The nurse will continue to hold the ShotBlocker at the injection site by pressing against the skin for 20 seconds. At the end of the time, she will grasp the tissue with the ShotBlocker and inject the vaccine through the opening in the center. After the procedure is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin.
214419020|NCT03110458|DRUG|SENS-111 200mg|SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
214419021|NCT03110458|DRUG|Placebo Oral Tablet|Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
214419022|NCT02212522|OTHER|Collect of environmental data on T1D patients before diagnosis|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
214419023|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
214419024|NCT02212522|OTHER|Collect of clinical data on the disease and its evolution|Collect of clinical data on the disease and its evolution every 6 months after enrollment
214419025|NCT02212522|OTHER|Collect of environmental data on French controls (age-matched for T1D patients)|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
214419026|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
214419027|NCT01443416|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
214419028|NCT01443416|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
215019219|NCT06377748|COMBINATION_PRODUCT|Combined facilitated tucking and ShotBlocker|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will place the ShotBlocker on the procedure site and apply pressure to the skin for 20 seconds. At the end of the time, the nurse will grasp the tissue with the ShotBlocker and inject the vaccine through the central opening. After the injection is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin. The newborn will continue to take facilitated tucking position until 1 minute after the ShotBlocker is removed.
215019220|NCT00582829|OTHER|Generic Print Intervention|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
215019221|NCT00582829|OTHER|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
215019222|NCT00582829|OTHER|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
215019223|NCT02834442|DRUG|MT-7117|
215019224|NCT02834442|DRUG|Placebo|
214419029|NCT05559281|OTHER|Botulinum|injection of Botulinum Toxin injection in lip muscles following cleft lip repair surgically.
214419030|NCT05559281|PROCEDURE|Fisher technique|The cleft lip will be treated surgically using the Fisher technique only.
214419031|NCT06404710|BEHAVIORAL|Exercise|Participants in this group will be given a gradual muscle relaxation exercise.
214419032|NCT00947817|OTHER|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
214419033|NCT03201549|DIETARY_SUPPLEMENT|oral fructose challenge|Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
214419034|NCT03903900|BEHAVIORAL|Lifestyle-oriented Occupational Therapy added to current treatment of chronic non-malignant pain|The participants are recruited from the outpatient cohort admitted at The Multidisciplinary Pain Center (MPC) at Naestved Hospital (Zealand Region, Denmark). The participants receive both, the current treatment based on Cognitive Behavioural Therapy (CBT) and delivered by physicians, nurses, physical therapists and a social worker as usual care, and a lifestyle-oriented Occupational Therapy intervention. The Occupational Therapy intervention targets meaningful daily occupations, physical activity, and eating habits and routines. The intervention is delivered by graduated occupational therapists once á week during the 15 weeks after the initial 5-weeks compulsory psychoeducation course at the MPC. The intervention contains in-person contacts with OTs every other week (e.g. two 1-hour individual sessions at the hospital and/ or at-home and five 2-hours group sessions) and seven phone consultations in the opposite weeks.
214419035|NCT04306705|DRUG|Tocilizumab|Administered as an intravenous infusion.
215019225|NCT03612414|DIETARY_SUPPLEMENT|Aqualief|Three tablets/day
215019226|NCT03612414|DIETARY_SUPPLEMENT|Placebo|Three tablets/day
215019227|NCT04885712|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
215019228|NCT04885712|DRUG|Pioglitazone 15mg|Subjects take the investigational products once a day for 24 weeks.
215019229|NCT04885712|DRUG|Pioglitazone 30 mg|Subjects take the investigational products once a day for 24 weeks.
215019230|NCT04885712|DRUG|Pioglitazone 15mg Placebo|Subjects take the investigational products once a day for 24 weeks.
215019231|NCT04885712|DRUG|Pioglitazone 30mg Placebo|Subjects take the investigational products once a day for 24 weeks.
215019232|NCT04885712|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
215019233|NCT06507644|PROCEDURE|light curettage|Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.
215019234|NCT06507644|OTHER|Pre irradiation of 1 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 1 hour.
214419036|NCT04306705|OTHER|Standard of care|Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
214419037|NCT04306705|PROCEDURE|Continuous renal replacement therapy|Catheter insertion site is femoral vein.
214419038|NCT01736098|OTHER|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
214419039|NCT00497991|DRUG|AZD1152|
214419040|NCT05030077|DRUG|Anlotinib|Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle
214419041|NCT05030077|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
214419042|NCT05030077|DRUG|Carboplatin|If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1
214419043|NCT05030077|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
214419044|NCT03278769|PROCEDURE|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
215019235|NCT06507644|OTHER|Pre irradiation of 3 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 3 hour.
215019236|NCT06507644|OTHER|topical application of 8% methyl aminolevulinate photosensitizer MAL|Participants will be treated with 8% topical MAL photosensitizer
215019237|NCT06507644|OTHER|topical application of 16% methyl aminolevulinate photosensitizer (MAL)|Participants will be treated with 16% topical MAL photosensitizer
214419045|NCT02351648|OTHER|a transitional care model|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
215019238|NCT06507644|DEVICE|Visible light source|Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm
215019239|NCT03876548|DEVICE|Cadexomer Iodine Gel|Subjects will apply gel product to keloid scar site every other day for 28 days following keloid scar revision surgery.
215019240|NCT02916914|OTHER|Q2 feeding|Infants are going to be fed every 2 hours
215019241|NCT03607136|OTHER|exercise training|Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
214419046|NCT02351648|OTHER|Control|Patients receive usual standard of care from the internal medicine team
214419047|NCT00239434|DRUG|tiotropium inhalation powder capsule|
214419048|NCT00239434|DRUG|ipratropium bromide Metered Dose Inhaler|
214419049|NCT03179722|BEHAVIORAL|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
214419050|NCT03179722|BEHAVIORAL|Additional data collection: questionnaires|"Pre-post study design.~At three timepoints, data is collected:~* before the medication review (T-1week)~* during the review (Tweek 3)~* after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
214419051|NCT00613782|DRUG|Reandron 1000|1000mg at 0,6,18,30 weeks
214419052|NCT00613782|DRUG|placebo|placebo injection 0,6.18.30 weeks
214419053|NCT05201261|DEVICE|ltrasonic measure|In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.
214419054|NCT04302246|GENETIC|Biological testing on sequential blood sample|Biological characterization of various immune function and blood circulating leukocytes phenotyping before liver transplantation and therafter at day-3, -7, -14 postoperatively and if septic complication occurs.
215019242|NCT02402231|DRUG|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
215019243|NCT05058456|DEVICE|Shockwave Medical Mini S Peripheral IVL Catheter|The Shockwave Medical Mini S Peripheral IVL Catheter is intended for lithotripsy-enhanced catheter dilatation of lesions, including calcified lesions found in the peripheral vasculature, such as the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. The Mini S IVL Catheter is not for use in the coronary or cerebral vasculature.
215019244|NCT02933151|DIETARY_SUPPLEMENT|Nutritional Supplement|Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
214419055|NCT04792554|OTHER|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, Brief Psychiatric Rating Scale, NuDESC, 3D-CAM. Blood taking.
214419056|NCT03185780|OTHER|Acupuncture|"Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas."
215019245|NCT00002482|BIOLOGICAL|antibody therapy|
215019246|NCT00002482|BIOLOGICAL|biological therapy|
214505975|NCT03622710|OTHER|Rehabilitation therapy|Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
214505976|NCT01792401|DRUG|Probiotics|
215019247|NCT00002482|BIOLOGICAL|muromonab-CD3|
215019248|NCT00002482|DRUG|cyclophosphamide|
215019249|NCT03153293|DRUG|rAAV2-ND4|a Single IVT Injection
215019250|NCT03849235|DIETARY_SUPPLEMENT|Standardised meal or glucagon|Standardised meal (Nutridrink, Nutricia, 300 kcal, 18.4 g carbohydrates, 5.8 g fat, 12 g protein) or 1mg glucagon
215019251|NCT04178863|DEVICE|CATS Tonometer|latanoprost vs. timolol
215019252|NCT04178863|DRUG|Latanoprost|latanoprost IOP reduction
215019253|NCT05142644|PROCEDURE|ultrasound|An extra ultrasound performed during pregnancy
214419057|NCT03195426|PROCEDURE|distal nerves blocks group|"* ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.~* SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.~* SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique."
214419058|NCT03195426|PROCEDURE|Diaphragmatic function assessment|"Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.~This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure."
214419059|NCT05975749|DRUG|Serplulimab|Serplulimab: 4.5mg/Kg on day 1
214419060|NCT05975749|DRUG|Trastuzuma|Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1
214419061|NCT05975749|DRUG|Chemotherapy|Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
214419062|NCT01184664|DRUG|Nicotine Patch|Varenicline + nicotine patch
214419063|NCT01184664|DRUG|Placebo|Varenicline + placebo patch
214419064|NCT01184664|DRUG|Varenicline|All participants will receive a standard dose of varenicline (12 weeks).
214419065|NCT00711126|DRUG|GW642444|2.5mcg IV
214419066|NCT00711126|DRUG|GW642444|5mcg IV
214419067|NCT00711126|DRUG|GW642444|10mcg IV
214419068|NCT00711126|DRUG|GW642444|100mcg inhaled
214419069|NCT00711126|DRUG|GW642444|20mcg IV
214419070|NCT00711126|DRUG|GW642444|500mcg oral
214419071|NCT00557206|DRUG|Oxaliplatin and Docetaxel|"Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."
214419072|NCT01458210|DRUG|Ortho-Cyclen|Administered orally
214419073|NCT01458210|BIOLOGICAL|Dulaglutide|Administered subcutaneously
214419074|NCT01562925|DIETARY_SUPPLEMENT|Red wine|Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
214419075|NCT01562925|DIETARY_SUPPLEMENT|White wine|White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
214419076|NCT01562925|DIETARY_SUPPLEMENT|Beer|Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
214419077|NCT01021865|DRUG|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|"GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"
214419078|NCT02921399|OTHER|eradication timing|patients who underwent ESD for gastric neoplasms were randomized to receive early (3-5 days) or late (8-9 weeks) H. pylori eradication therapy after ESD.
214419079|NCT04126239|OTHER|Online survey - questionnaire|Online survey - questionnaire
214419080|NCT05136092|DIETARY_SUPPLEMENT|Cohort 1: HFCS (fructose) fed|"Two to three hours before surgery. Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml"
214419081|NCT05136092|DIETARY_SUPPLEMENT|Cohort 2: D-Xylose (xylose-fed)|"Two to three hours before surgery.~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml"
214419082|NCT04748575|DIETARY_SUPPLEMENT|Acai smoothie|Smoothie containing 150g acai pulp
214505977|NCT01792401|DRUG|Placebo|
215019254|NCT04250389|OTHER|Hemodynamic assessment (micro and macrocirculatory)|"Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~* Mean, systolic, diastolic arterial, heart rate (HR)~* Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~* A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~* Cutaneous and gingival refill time~* Tissue oxygen saturation combined with vascular occlusion test (VOT)~* Video microscopy measurements of the sublingual microcirculation~* Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases."
215019255|NCT04534725|DRUG|Interferon alfa|intranasal spray
214419083|NCT04748575|DIETARY_SUPPLEMENT|Placebo smoothie|Control smoothie matched nutritionally (macronutrients) and sensorially to the acai smoothie.
214419084|NCT05906940|DEVICE|Transcutaneous Vagus Nerve Stimulation|As a vagus stimulation protocol, bilateral auricular stimulation and stimulation frequency of 10 Hz, pulse width of 300 µs, biphasic application for 20 minutes, each participant will be stimulated twice, with at least 48 hours between them.
214419085|NCT03753152|DEVICE|experimental|Neuramis® Deep Lidocaine
214419086|NCT03753152|DEVICE|comparator|YVOIRE® Volume Plus
214419087|NCT04008836|DEVICE|T-PLUS Meter|Blood Glucose Monitoring System (BGMS)
214419088|NCT00286741|OTHER|Diabetes Group Management Visits|Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.
214419089|NCT04038229|OTHER|Enhanced recovery pathway|The applied protocol include psychological screening for yellow flags, preoperative gabapentin, peroperative multimodal preemptive management and postoperative holistic evaluation short -and long term
214419090|NCT02093533|DRUG|Eculizumab|
214419091|NCT01810250|DEVICE|Endurant Stent Graft|
214419092|NCT00860353|DRUG|AZD2551|Single dose of oral solution.
214419093|NCT00860353|DRUG|Placebo|Single dose of oral solution
214419094|NCT00223548|DRUG|sodium 2-mercaptoethane sulfonate|
214419095|NCT01615432|DEVICE|V-PAP III ventilator|
214419096|NCT01615432|DEVICE|Stellar 150 ventilator|
214419097|NCT01615432|DEVICE|BiPAP vision ventilator|
214419098|NCT01615432|DEVICE|V60 ventilator|
214419099|NCT03107403|BEHAVIORAL|web form|The scale assessing the bereavement process is the one reported in Teissier 2010
214689882|NCT04016883|OTHER|Problem Solving Therapy offered through a web platform|Problem Solving Therapy offered through a web platform. There will be four sessions, during the first four weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; different ways to reach goals are discussed and evaluated; action plans are created, and its effectiveness is evaluated to achieve the objectives. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model.
214689883|NCT04016883|OTHER|Conventional web platform|The conventional web platform, which will contain the general content on stress coping techniques.
214689884|NCT03524677|DIAGNOSTIC_TEST|Liquid Biopsy|K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
214419100|NCT01406262|BIOLOGICAL|Albiglutide|once weekly subcutaneous injection
214419101|NCT01406262|DRUG|Moxifloxacin|oral tablet
214419102|NCT03484585|DRUG|Rogaratinib (BAY1163877)|Single dose, intake orally, 200 mg
214419103|NCT06251193|BEHAVIORAL|E-CBSST|E-CBSST is a blended intervention that combines Cognitive Behavioral Social Skills Training and Executive Function Training.
214419104|NCT05829096|OTHER|The COMBINED approach|"1. Patient-level intervention:~   * Assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~  * Brief intervention to support health behaviour change: smoking cessation, increasing physical activity levels and consuming a healthy diet~  * Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring.~2. Clinician-level implementation toolkit:~   * Training package including a face-to-face workshop, training manual, recorded role play simulations and an online follow-up training session~  * Additional supporting resources; a step-by-step guide to The COMBINED approach, scripts, patient signposting information to support services and a lay summary infographic to explain the links between the health behaviours and RC disorders to patients~  * Audit and feedback via observations of consultations to address any 'drift' from the intervention delivery as intended"
214419105|NCT02633358|DEVICE|Therapeutic hypothermia group|Therapeutic hypothermia
214419106|NCT02545062|OTHER|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
214419107|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
214419108|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
214689885|NCT05681741|PROCEDURE|current versus high pump flow|during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
214689886|NCT02027298|DRUG|Abatacept|by SC injection of 125 mg weekly for 6 months
214689887|NCT02487849|PROCEDURE|HIPEC|secondary cytoreductive operation
215019256|NCT04534725|DRUG|Selinexor|oral tablet
215019257|NCT04534725|DRUG|Lenzilumab|intravenous infusion
215019258|NCT00374985|DRUG|Docetaxel, Oxaliplatin|weekly doses
215019259|NCT00374985|PROCEDURE|Radiotherapy|regular fractions
214419109|NCT02559518|DEVICE|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
214419110|NCT02559518|DEVICE|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
214419111|NCT02559518|DEVICE|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
214419112|NCT02559518|DEVICE|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
214419113|NCT02559518|DEVICE|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
214505978|NCT02117310|DRUG|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
214505979|NCT01855165|BEHAVIORAL|Advice on DDIs|
214505980|NCT03733275|DRUG|Lidocaine|for experimental arm, lidocaine spray and lidocaine bupivacine mixture-soaked nasal packing vs. for placebo arm, normal saline spray and packing
215019260|NCT05227014|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
215019261|NCT02202265|DIETARY_SUPPLEMENT|Olive oil|30ml a day of olive oil
215019262|NCT02202265|DIETARY_SUPPLEMENT|Nuts|30g a day of nuts
215019263|NCT02202265|DIETARY_SUPPLEMENT|Control diet|Diet based on standard guidelines
215019264|NCT01395602|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly
215019265|NCT01395602|OTHER|placebo|1 pill twice weekly
215019266|NCT05527314|DRUG|Remimazolam|Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
215019267|NCT05527314|DRUG|Sevoflurane|Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.
215019268|NCT05527314|DRUG|Fentanyl|Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
215019269|NCT05527314|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
215019270|NCT05527314|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
215019271|NCT02267525|DRUG|Velusetrag|
214505981|NCT04338919|PROCEDURE|Percutaneous coronary intervention|PCI with stent implantation
214689888|NCT02487849|DRUG|Carboplatin|Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
214689889|NCT04806932|PROCEDURE|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
215019272|NCT02267525|DRUG|Placebo|
215019273|NCT01404065|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
214505982|NCT04338919|DRUG|Ticagrelor plus aspirin|Ticagrelor plus aspirin
214505983|NCT00864006|DRUG|Divalproex Sodium|
214505984|NCT00864006|DRUG|Depakote DR Tablets|
214505985|NCT03585400|OTHER|Observational Study|Observational Study: Not Applicable for Observational Studies
214505986|NCT03398668|DEVICE|Relievion device- Treatment stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
214689890|NCT04806932|PROCEDURE|The conventional approach|The conventional approach
215019274|NCT04882605|GENETIC|MHC typing|Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.
215019275|NCT04882605|GENETIC|KIR typing|Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.
215019276|NCT04882605|GENETIC|Assessment of KIR-based prediction scores|Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores
215029038|NCT06568575|BEHAVIORAL|experiment of exercise|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by music program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes. The music experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time, and a total experiment time of 1420 minutes. Examples of songs：Everytime We Touch- Cascada (115 bpm), Beat It - Michael Jackson (120 bpm), Viva La
214419114|NCT05246553|PROCEDURE|Electrical stimulation of the vestibular system|Patients are implanted with a modified cochlear implant (CI) which comprises one to three extracochlear electrodes that are placed in the proximity of vestibular afferents (i.e., vestibular nerves or the ampullae of each semicircular canal), and an intracochlear array. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the implanted electrodes (cochlear or vestibular) and modulated via computer-controlled signals, audio signals (captured with a microphone) or by signals captured by head-mounted motion sensors.
214419115|NCT05246553|PROCEDURE|Electrical stimulation of the auditory system|A cochlear implant (CI) is a device providing a sense of sound to a person who suffers from severe to profound sensorineural hearing loss. A CI comprises the following parts, a microphone (capturing the sound from the environment), a speech processor (receiving and encoding the sounds captured by the mircophone), a transmitter-receiver antenna pair (transmitting the information from the external to the implanted components), an implanted stimulator (converting the signal into a tonotopically arranged set of electrical pulses) and an electrode array inserted in the cochlea that will deliver the electrical pulses to different portions of the auditory nerve. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the electrodes in the cochlear array and modulated via computer-controlled signals or audio signals (captured with a microphone).
214419116|NCT05246553|DIAGNOSTIC_TEST|Bilateral vestibulopathy Patients (BV)|Diagnosis established on the basis of the consensus document of the Classification Committee of the Bárány Society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
214419117|NCT05246553|DIAGNOSTIC_TEST|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
214419118|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
214505987|NCT03398668|DEVICE|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
214689891|NCT00263302|DRUG|dexamethasone|
215019277|NCT01407133|DEVICE|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|"The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months."
215102334|NCT01700010|DRUG|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
214419119|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo R-LESS RP
214689892|NCT00409604|DEVICE|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
214419120|NCT02079155|OTHER|laboratory biomarker analysis|Correlative studies
214419121|NCT02079155|OTHER|quality-of-life assessment|Ancillary studies
214689893|NCT02292199|DEVICE|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
214505988|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
214689894|NCT02292199|DEVICE|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
214689895|NCT02292199|DEVICE|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
214505989|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks
214419122|NCT02079155|OTHER|questionnaire administration|Ancillary studies
215019278|NCT01407133|DEVICE|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
215019279|NCT00251654|PROCEDURE|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
215019280|NCT04484662|OTHER|Potted Mint Plants|We will measure 2 indoor environments (living room and bedroom) for placing potted plants.
215019281|NCT05517785|OTHER|Motor performance tests|Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance
215019282|NCT03492294|DIAGNOSTIC_TEST|functional magnetic resonance imaging|Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
215019283|NCT02072057|DRUG|Ruxolitinib|
215019284|NCT01125644|DRUG|SPK-843|SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
215019285|NCT04985110|DRUG|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
215019286|NCT04985110|DRUG|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
215019287|NCT00998959|BEHAVIORAL|Mindfulness Based Stress Reduction and Psychoeducation|Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
215019288|NCT00998959|BEHAVIORAL|Psychoeducation|Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
215019289|NCT02913573|DEVICE|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
215019290|NCT02913573|DRUG|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
215019291|NCT02976844|PROCEDURE|Positive end-expiratory Pressure|Positive end-expiratory pressure will be used during mechanical ventilation.
215019292|NCT06300632|OTHER|geriatric locomotive syndrome|Elderly individuals will be included in the study. Before each elderly person starts the study, they will be informed about the content of the study and they will read and sign the consent form stating that they participate in the study voluntarily. Socio-demographic data (age, body mass index, and family history, fall history, ) of all individuals participating in the study will be recorded.Within the scope of the evaluation, locomotive syndrome evaluation will be made through a survey. Fear of movement will be evaluated with the Tampa kinesiophobia scale, your physical activity level with the physical activity scale for the elderly, your physical performance with the short physical performance battery, your fatigue level with the fatigue severity scale, and your cognitive functions with the Montreal Cognitive Assessment Scale.
215019293|NCT02167126|DEVICE|Kinesio Taping|"using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity."
214419123|NCT03751150|OTHER|Exercise program|The runners will be asked to perform the training program twice a week. The intervention consist of muscle control and foam rolling exercises for the lower extremities.
214419124|NCT04146818|BEHAVIORAL|Adapted Tango Dancing|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months) consisting in music therapy, engagement in social activities, cognitive training and psycho-education.
214505990|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
214419125|NCT04146818|BEHAVIORAL|Control|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
214505991|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks
214419126|NCT00957658|DEVICE|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
214419127|NCT03662048|BEHAVIORAL|Safe|Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
214419128|NCT04189900|DRUG|Triptorelin|Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
214505992|NCT04090476|OTHER|Exercise|During each of the exercise sessions the LSVT Big daily exercises will be performed along with functional tasks and gait/balance tasks. The functional tasks and gait/balance tasks will change weekly to monthly and all activities will be modified to the participant's mobility level.
214505993|NCT00236652|DRUG|levofloxacin|
214419129|NCT03333655|PROCEDURE|Biopsy|Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.
214419130|NCT04604054|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
215019294|NCT02167126|DEVICE|Placebo Tape|"Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella."
214419131|NCT04604054|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
214419132|NCT03172208|BIOLOGICAL|Caplacizumab Dose 1 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 1
214419133|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 2
214419134|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (single-dose)|Single subcutaneous (sc) administration of Caplacizumab Dose 2
214419135|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (multiple-dose)|Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
214419136|NCT03172208|OTHER|Placebo iv (single-dose)|Single intravenous (iv) administration of Placebo
214419137|NCT03172208|OTHER|Placebo sc (single-dose)|Single subcutaneous (sc) administration of Placebo
214419138|NCT03172208|OTHER|Placebo sc (multiple-dose)|Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
214419139|NCT00199641|DEVICE|enteral nutrition|
214689896|NCT04371731|OTHER|Care4todayheart failure platform|Platform allowing patients to enter information about their health at home, namely weight and BP and medications
215019295|NCT03823482|DRUG|Lidocaine|Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
215019296|NCT06272929|DEVICE|doppler ultrasound|doppler US
215019297|NCT00456911|BEHAVIORAL|Fat and carbohydrate controlled diet|
215019298|NCT02755883|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
214419140|NCT02918916|OTHER|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
214419141|NCT02918916|OTHER|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
214419142|NCT04602052|PROCEDURE|Dilation and evacuation|Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
214419143|NCT02896894|OTHER|Big White Wall (BWW)|"The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe."
214419144|NCT05069935|DRUG|FT538|FT538 is an allogeneic natural killer (NK)-cell immunotherapy
214505994|NCT01580436|PROCEDURE|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
214505995|NCT05114993|DEVICE|wearing a disposable surgical mask|Physiologic vital signs will be monitored every minute for 5 minutes without a mask, followed by every minute for 15 minutes with a surgical mask.
214419145|NCT05069935|DRUG|Cyclophosphamide|Lympho-conditioning agent
214505996|NCT05372224|DRUG|Cholecalciferol|4000 IU were administrated once a day for 3 months.
214505997|NCT03540524|DRUG|GLPG2451 dose regimen A|GLPG2451 oral suspension, daily.
214505998|NCT03540524|DRUG|GLPG2451 dose regimen B|GLPG2451 oral suspension, daily.
214419146|NCT05069935|DRUG|Fludarabine|Lympho-conditioning agent
214419147|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Escalation|either avelumab, trastuzumab or cetuximab
214419148|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Expansion|either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab
214419149|NCT06116019|RADIATION|Online adaptive radiation therapy|Daily cone-beam CT based online adaptive radiation therapy
214505999|NCT03540524|DRUG|GLPG2222|GLPG2222 tablet for oral use, daily.
214506000|NCT03540524|DRUG|GLPG2737|GLPG2737 capsules for oral use, daily.
214506001|NCT00681941|DRUG|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
214506002|NCT05922124|DRUG|Cefiderocol|Test drug regimen
214506003|NCT05922124|DRUG|Ampicillin-sulbactam|Synergistic combination
214506004|NCT05922124|DRUG|Colistin|Historical comparator
214506005|NCT05922124|DRUG|Meropenem|Historical comparator synergistic combination
214506006|NCT03398980|RADIATION|survivors treated with CRT|Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).
214506007|NCT01849107|BIOLOGICAL|Plasma citrulline|
214689897|NCT00086658|DRUG|mepolizumab|
214689898|NCT01921257|DRUG|Cat-PAD|
214689899|NCT01921257|DRUG|Placebo|
215019299|NCT02755883|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
215019300|NCT05426681|DRUG|GlyBURIDE Oral Tablet|"Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide"
215019301|NCT05178654|DRUG|[14C]PF-07321332|Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
215019302|NCT04392362|DRUG|Adenosine|A vial of adenosine with 6mg
215019303|NCT00365820|DRUG|Tegaserod|
215019304|NCT05781750|DRUG|zetomipzomib|Subcutaneous injection of zetomipzomib
214419150|NCT02973919|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, \& Renssen, 1999; de Jongh, Holmshaw, Carswell, \& van Wijk, 2011; Lapsekili \& Yelboga, 2014; Muris, Merckelbach, van Haaften, \& Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
214419151|NCT02973919|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger \& Pauli, 2011).
215019305|NCT05781750|DRUG|placebo|Subcutaneous injection of placebo
215019306|NCT05552573|BIOLOGICAL|low-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
215019307|NCT05552573|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO Cell)|This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.
215019308|NCT05552573|BIOLOGICAL|high-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
215019309|NCT04919473|BIOLOGICAL|Gene Therapy product:vMCO-I|The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
215019310|NCT05226000|DRUG|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
215019311|NCT05411900|DRUG|BoNT-A|"A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
215019312|NCT05411900|DRUG|Placebo|"Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
215019313|NCT05468177|COMBINATION_PRODUCT|neoadjuvant chemotherapy|"Cetuximab: 500mg/m2,day1, every 2 weeks. mFOLFOX: oxaliplatin 85mg/m2, day 1;LV 400mg/m2, day 1;5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h) (every 2 weeks).~Anti-PD-1(Sintilimab Injection):200mg every 3 weeks. Surgery will be performed after 4 cycles for locally advanced or initially resectable metastatic right colon cancer.If the initial unresectable metastatic right colon cancer were converted into resectable metastases, and surgery will be performed. Patients who failed to convert after 6 cycles of treatment will be withdrawn from the study.Cetuximab +mFOLFOX was treat for 8 cycles, and Anti-PD-1 was treated for one year in the perioperation period unless disease progression, toxicity intolerance, initiation of new anti-tumor therapy."
215019314|NCT05450120|OTHER|Functional Rehabilitation|Functional rehabilitation protocol
215019315|NCT05450120|OTHER|Neuromuscular Electrical Stimulation|Neuromuscular electrical stimulation protocol
214689900|NCT04517617|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.he perinatal period.
215019316|NCT02156505|PROCEDURE|placement of double bare stent|
214419152|NCT06062706|PROCEDURE|Donor hepatectomy|"Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach."
214689901|NCT05158595|OTHER|Exergaming low intensity group|wobble board-based Exergame balance training, the game intensity will be low for this group (Size of goal will be kept small for 3 times a week, 30 minutes per day for 8 weeks.
214689902|NCT05158595|OTHER|Exergaming moderate intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept medium).for 3 times a week, 30 minutes per day for 8 weeks.
215019317|NCT02156505|DEVICE|DoubleBare stent|
215019318|NCT02925143|OTHER|E-learning course in neuromuscular monitoring|An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
215019319|NCT04524429|PROCEDURE|Bariatric Surgery|Bariatric surgery includes sleeve gastrectomy and gastric bypass.
215019320|NCT05127200|DEVICE|Starstim (Neuroelectrics)|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
215019321|NCT01234376|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy
215019322|NCT06292507|OTHER|MYOFASCIAL STRETCH|Group A 10 participants will receive Myofascial Stretching
214419153|NCT03080792|BEHAVIORAL|Experimental: moderate to high-intensity exercise|2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)
214419154|NCT05381701|PROCEDURE|Lung Ultrasound Score|Measuring the atelectasis area by ultrasound guidance from 12 different regions of the lung
214419155|NCT04194502|DIAGNOSTIC_TEST|Transesophageal echocardiogram (TEE)|All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
214419156|NCT00522756|DRUG|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
214419157|NCT00522756|DRUG|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
214419158|NCT01253499|DRUG|TRx0037|75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
214419159|NCT04437056|PROCEDURE|Cognitive nerve transfers to spastic upper extremity muscles in stroke patients|Based on the fact that upper motor neuron syndrome after stroke is presented with variable clinical features, usually without affecting in the same way the entire upper extremity, we aim to investigate the efficacy of nerve transfers to spastic muscles after stroke using as donor nerves that innervate unaffected ipsilateral volitionally controlled muscles.
214419160|NCT01805362|OTHER|Randomization that determine the time of treatment|
214419161|NCT01085279|DEVICE|Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)|1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
214419162|NCT01085279|DRUG|Modified Kligman's formula (Triple topical therapy)|Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
214419163|NCT01762241|BEHAVIORAL|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
215019323|NCT06292507|OTHER|CONTRACT-RELAX TECHNIQUE|group B 10 participants will receive Control-Relax Stretching Technique.
215019324|NCT03850431|BEHAVIORAL|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
215019325|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
215019326|NCT03850431|BEHAVIORAL|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
215102335|NCT03778463|OTHER|Synovectomy|Removal of the synovium during total knee arthroplasty
214419164|NCT01348191|PROCEDURE|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
215102336|NCT01868386|RADIATION|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
215102337|NCT01821482|BIOLOGICAL|Dendritic and Cytokine-induced Killer Cells|
214419165|NCT03775551|BEHAVIORAL|Improvement cycle|at least 6 workshops (sessions) will be held with the members of the care system, in order to identify opportunities for improvement oriented to the design and application of an innovative intervention based on best practices.
214419166|NCT01833832|DRUG|Cisplatin|Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
214419167|NCT01833832|PROCEDURE|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
214419168|NCT01833832|DRUG|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
214419169|NCT01558921|OTHER|M1 scheme|short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
215102338|NCT03100773|OTHER|Oral health educational strategy|Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).
215102339|NCT03100773|PROCEDURE|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.
215102340|NCT01717326|DRUG|Grazoprevir|100 mg tablet orally QD
215102341|NCT01717326|DRUG|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
215102342|NCT01717326|DRUG|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
215102343|NCT01717326|DRUG|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
215102344|NCT03409250|DRUG|Ranibizumab, Lucentis|Intravitreal injection with Lucentis (Ranibizumab)
214419170|NCT01558921|OTHER|standard long course chemoradiotherapy|long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
214419171|NCT00533013|OTHER|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
214419172|NCT00533013|OTHER|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
214419173|NCT01392872|OTHER|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
214419174|NCT01821586|OTHER|Modified ORS-1|
214419175|NCT01821586|OTHER|Modified ORS-2 (ReSoMal)|
214419176|NCT01821586|OTHER|Modified ORS-3 (Benefibre)|
214419177|NCT04586036|OTHER|ankle joint brace 1|The influence of ankle joint brace 1 on gait biomechanics
214419178|NCT04586036|OTHER|ankle joint brace 2|The influence of ankle joint brace 2 on gait biomechanics
214419179|NCT04586036|OTHER|ankle joint brace 3|The influence of ankle joint brace 3 on gait biomechanics
214419180|NCT04586036|OTHER|ankle joint brace 4|The influence of ankle joint brace 4 on gait biomechanics
214419181|NCT04586036|OTHER|ankle joint brace 5|The influence of ankle joint brace 5 on gait biomechanics
214419182|NCT01455051|DRUG|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
214419183|NCT01193153|DRUG|Placebo|monthly by i.m. injection for 15 months
214419184|NCT01193153|DRUG|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
214419185|NCT01988233|BEHAVIORAL|BAILAMOS© Dance Program|
214419186|NCT01988233|BEHAVIORAL|Health Education Control Group|
214419187|NCT01844141|DRUG|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
214419188|NCT01844141|DRUG|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
214419189|NCT04369534|DRUG|Clopidogrel|Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI
214419190|NCT04369534|DRUG|Ticagrelor|Administration of standard dose of ticagrelor during 12 months after PCI
215102345|NCT05407350|DIAGNOSTIC_TEST|Ultrasound, Colonoscopy, MRE|After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine \[DICOM\] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.
215102346|NCT01031862|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
215102347|NCT06124794|BIOLOGICAL|PROTOXIN|Clostridium botulinum toxin type A
214419191|NCT03621761|BEHAVIORAL|Telephone-based Cognitive Behavioral Therapy|"Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue."
214419192|NCT03621761|DRUG|Modafinil|Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
215102348|NCT00345722|PROCEDURE|strawberry dietary intervention|
215102349|NCT03485170|DIAGNOSTIC_TEST|18F-FDG PET/CT|glucose analogue fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography scan
215102350|NCT02572622|OTHER|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
215102351|NCT02572622|OTHER|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
214419193|NCT03259932|OTHER|no physical activity|no physical activity
214419194|NCT03259932|OTHER|physical activity|Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
214419195|NCT04033237|OTHER|Very low nicotine content cigarettes|Cigarettes containing 0.4 mg nicotine/g tobacco
214419196|NCT05156450|DRUG|TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone|Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
214419197|NCT02770196|BEHAVIORAL|CO-CSA plus Nutrition Education|Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
214419198|NCT05046132|DRUG|Setmelanotide|Administered once daily via SC injection.
214419199|NCT05046132|DRUG|Moxifloxacin|Moxifloxacin capsules via oral administration.
215019327|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions|A letter with all types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
215019328|NCT05479227|PROCEDURE|Management of bile duct injury|There are different options for BDI management, we analyzed their utilization and results
215019329|NCT02046876|OTHER|Multimodal Physiotherapy Program|Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
214419200|NCT05046132|DRUG|Oral Placebo|Placebo capsules via oral administration.
214419201|NCT05046132|DRUG|SC Placebo|Placebo via SC injection.
214419202|NCT05042024|PROCEDURE|Scaling and root planing|Conventional periodontal therapy, non-surgical periodontal therapy
214419203|NCT05042024|DRUG|Oral L-arginine aspartate administration|The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
214419204|NCT05042024|DRUG|Oral L-ornithine aspartate administration|The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
214419205|NCT00444769|DRUG|GW842166|
214419206|NCT00423254|BIOLOGICAL|PSMA/PRAME|Low dose
214419207|NCT00423254|BIOLOGICAL|PSMA/PRAME|high dose
214419208|NCT04857346|DRUG|Indocyanine green|Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.
214419209|NCT03413319|DRUG|ABBV-8E12|Solution for infusion
214419210|NCT00270426|DRUG|Benazepril|
214419211|NCT01852019|DRUG|Cangrelor|Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
214419212|NCT01852019|DRUG|Prasugrel|"Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8."
214419213|NCT04551794|BEHAVIORAL|Selfapy with therapeutic guidance|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.
214419214|NCT04551794|BEHAVIORAL|Selfapy with additional peer support|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
214506008|NCT04288388|BEHAVIORAL|massage group|In recent years, in the literature, it is known that many non-pharmacological techniques are applied to reduce the pain of birth in addition to local anesthesia. One of these nonpharmacological methods is the application of pressure to LI4 point on hand with ice.
214506009|NCT05119699|DEVICE|MagPro X100/R30 stimulator equipped with the B70 fluid-cooled coil|Subjects will receive 5 consecutive days (always Monday to Friday) of TBS rTMS, administered 8 times daily at 1 hour intervals. Patients will undergo cTBS of the R DLPFC at 110-120% RMT using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for a total of 600 pulses over 40 seconds, followed by iTBS of the L DLPFC at 110-120% resting motor threshold (RMT) using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz with a duty cycle of 2 s on, 8 s off for a total of 600 pulses over 3 min 9 s. Participants will be titrated to 110-120% RMT within the first four treatments to aid with tolerability. If patients tolerate the stimulation well, the target will be 120%. Assessments focused on depressive symptoms will be administered at baseline, after final treatment and four weeks post final treatment.
214506010|NCT00259116|DRUG|Relaxin|
214506011|NCT01707303|OTHER|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
214506012|NCT01707303|OTHER|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
215019330|NCT01034657|DRUG|LBH589|LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
215019331|NCT01034657|DRUG|Epoetin Alfa|Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
214419215|NCT00711919|DRUG|Pitavastatin|"comparison of different target levels of lipid lowering using Pitavastatin~Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months."
214419216|NCT00711919|DRUG|Pitavastatin|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
214419217|NCT04456348|OTHER|there is no intervention|There is no intervention
214419218|NCT01186848|DEVICE|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
214419219|NCT01186848|DEVICE|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
214419220|NCT00199589|DRUG|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
214689903|NCT05158595|OTHER|Exergaming high intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept high).for 3 times a week, 30 minutes per day for 8 weeks.
214419221|NCT02508844|DIETARY_SUPPLEMENT|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
214689904|NCT05158595|OTHER|control group exergaming|Exer games training with soccer heading and penguin slide games(Wii Fitt balance games) for 3 times a week, 30 minutes per day for 8 weeks.
214419222|NCT02508844|DIETARY_SUPPLEMENT|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
214689905|NCT02280967|BEHAVIORAL|Education about HPV by school nurse|Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
214419223|NCT04283825|BEHAVIORAL|Psychological and physical rehabilitation based humanistic care|This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.
214689906|NCT00777491|DRUG|induction cisplatin|15 mg/m\^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
214689907|NCT00777491|DRUG|induction 5-fluorouracil|400mg/m\^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
215019332|NCT02674256|DRUG|CRH|100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
215019333|NCT02674256|OTHER|Placebo|1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
214419224|NCT03966794|DEVICE|Epidural Electrical Stimulation|Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
214419225|NCT03966794|COMBINATION_PRODUCT|Functional scaffold & Epidural Electrical Stimulation|Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
214419226|NCT05322824|DRUG|standard medical treatment|standard medical treatment
214419227|NCT05322824|PROCEDURE|Interventional stenting|Interventional stenting
214419228|NCT04061902|OTHER|Participation with enhanced patient perioperative information|Improved information and dialogue about the care goals in the fast track protocol.
215019334|NCT01210599|DRUG|Pamidronate|The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
214419229|NCT04935749|DEVICE|Ultra wide-field retinal imaging|Diabetic patients will be imaged with an ultra wide-field retinal imaging device (Optos, California). Patients will be imaged either with or without mydriasis.
214419230|NCT00208507|DEVICE|28 mm ceramic head on ceramic acetabular liner.|Total hip replacement with 28 mm ceramic head on ceramic liner articulation
215019335|NCT04348058|BEHAVIORAL|Telephone recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation
215019336|NCT04348058|BEHAVIORAL|Combined methods recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation
215019337|NCT04295928|BEHAVIORAL|PPP|Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation
215019338|NCT00379379|DEVICE|electroacupuncture|
215019339|NCT02544087|DRUG|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
215019340|NCT02544087|DRUG|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
214419231|NCT00208507|DEVICE|28 mm ceramic head on polyethylene liner|Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
214419232|NCT02903836|DRUG|Nafithromycin 800 mg 3 days|
214419233|NCT02903836|DRUG|Nafithromycin 800 mg 5 days|
214419234|NCT02903836|DRUG|Moxifloxacin 400 mg|
214419235|NCT05421988|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.
214419236|NCT04213599|DIAGNOSTIC_TEST|Coronary intervention|Patients with STEMI undergo coronary intervention
214419237|NCT03465345|DRUG|Metformin|Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
214689908|NCT00777491|DRUG|induction gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
214689909|NCT00777491|RADIATION|Induction BID radiation therapy|Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
214689910|NCT00777491|RADIATION|Induction QD radiation therapy|Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
214689911|NCT00777491|RADIATION|Consolidation BID radiation therapy|Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
215019341|NCT02544087|DRUG|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
215019342|NCT05542901|DIAGNOSTIC_TEST|Joint Position Sense Analysis|The Xsens DOT Motion Capture System will be used to analyze joint position sense.
214419238|NCT03465345|DRUG|Oligomeric Procyanidin Complex|OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
214419239|NCT00756743|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
214419240|NCT00756743|DRUG|Placebo|Placebo capsules q12 hours for 10 days
214419241|NCT04593719|OTHER|Experiment|The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
214419242|NCT05329454|DRUG|Ibuprofen Tablets|"Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing)."
214419243|NCT02786602|GENETIC|pyrosequencing|
214419244|NCT00982033|DRUG|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
214506013|NCT00006350|BIOLOGICAL|daclizumab|
215019343|NCT01862965|DRUG|PredEver|Firstline treatment with prednisone and Everolimus
215019344|NCT06045286|RADIATION|Radiation: High- and Low-dose radiotherapy|High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.
215019345|NCT06045286|DRUG|PD-1 Inhibitors|Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
215019346|NCT05299957|DIAGNOSTIC_TEST|PETMRI|PET/MRI data will be acquired on the integrated PET/MRI scanner. After fast-view T1-weighted MR localizer sequence for scout imaging and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed to cover from the head to the proximal thigh, with an acquisition time of 4 min per bed position. Simultaneously, whole body MR image acquisition will be performed with the axial HASTE sequence and coronal STIR sequence as well as the sagittal T1-weighted Turbo spine echo and STIR sequence. Afterwards, regional PET and MRI images will be simultaneously performed. DWI will be performed using a single shot spin-echo echo-planar technique. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis imaging. DCE-PWI will be acquired by using a 3D T1-weighted spoiled gradient-echo sequence. Thereafter, dedicated regional MRI will be obtained. Finally, whole body axial VIBE with fat saturation will be performed.
215019347|NCT04504669|DRUG|AZD8701|FOXP3 antisense oligonucleotide
215019348|NCT04504669|BIOLOGICAL|Durvalumab|anti PDL-1 monoclonal antibody
215019349|NCT05315583|OTHER|Collection of biological samples|All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
215102352|NCT02572622|OTHER|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
214506014|NCT00006350|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214506015|NCT00006350|DRUG|mycophenolate mofetil|
214506016|NCT00006350|DRUG|tacrolimus|
214506017|NCT00006350|PROCEDURE|peripheral blood stem cell transplantation|
214689912|NCT00777491|RADIATION|Consolidation QD radiation therapy|Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
214689913|NCT00777491|DRUG|consolidation gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
215019350|NCT05823077|OTHER|Bergamot|The affected knee will be massaged with Bergamot oil for 4 weeks, 2 sessions per week.
215019351|NCT05823077|OTHER|Placebo|The affected knee will be massaged with sweet almond oil for 4 weeks, 2 sessions per week.
215102353|NCT02572622|OTHER|exercise|special lumbar stabilization exercises were applied in advanced protocol.
214506018|NCT02964793|OTHER|intervention group|"The intervention will include~1. clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements~2. the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document~3. the use of the EFW values mentioned on US report, to plot EFW on the customised chart~4. and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended."
215019352|NCT05102838|OTHER|Anti-virus treatment|Anti-virus treatment
215019353|NCT05365464|DRUG|Progesterone Pill|Orally active progesterone
215019354|NCT05365464|DRUG|hCG|Given by subcutaneous injection
215019355|NCT03250195|DIAGNOSTIC_TEST|PET/MRI|PET/MRI scan
215019356|NCT03932383|DEVICE|Custom CPAP mask|Modified CPAP mask based on 3D image capture
215019357|NCT02417480|BEHAVIORAL|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
215019358|NCT02417480|BEHAVIORAL|Follow habitual, usual diet|Participants will be asked to consume their habitual, usual diet.
215102354|NCT01369732|DRUG|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
215102355|NCT01369732|DRUG|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
214506019|NCT05704192|PROCEDURE|TACE ± Systemic therapy|TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
214419245|NCT00982033|DRUG|placebo|placebo qd for 24 weeks
214419246|NCT01669148|DEVICE|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
214419247|NCT01669148|DEVICE|Conventional|conventional (2D) imaging (standard mammography)
214419248|NCT00002995|BIOLOGICAL|dactinomycin|
215019359|NCT01433081|DRUG|Placebo infusion of .9 normal saline|administration of .9 normal saline
215019360|NCT01433081|DRUG|administration of magnesium sulfate|administration of magnesium sulfate
215019361|NCT06276075|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery|66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
215019362|NCT02589912|DEVICE|Nucleus Profile ABI541 Auditory Brainstem Implant|
215019363|NCT01205737|BIOLOGICAL|TL011|375 mg/m2 iv every 3 weeks for 8 cycles
215019364|NCT01205737|BIOLOGICAL|Rituximab|375 mg/m2 iv every 3 weeks for 8 cycles
214419249|NCT00002995|BIOLOGICAL|filgrastim|
214419250|NCT00002995|BIOLOGICAL|sargramostim|
215019365|NCT04985682|BIOLOGICAL|ADVATE|Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
215019366|NCT04206943|BIOLOGICAL|Car-T Cell Therapy|"Lymphodepletion Protocol:~* -6. Day: Cyclophosphamide 300 mg / m\^2 i.v.~* -5. -4. and -3. Days: Fludarabine 30 mg / m\^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements."
215019367|NCT00592527|DRUG|insulin detemir|
215019368|NCT04304196|OTHER|TEMPO|TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).
215102356|NCT03824093|BEHAVIORAL|AFIX Only|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates.
215102357|NCT03824093|BEHAVIORAL|AFIX+ Provider Communication Training|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates along with communication training for providers and poster and brochure displays.
215102358|NCT02653937|DRUG|Tsumura's shigyakusan|"Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne"
215102359|NCT04424693|DRUG|Tdap Vaccine Administration|Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
215102360|NCT05698953|OTHER|Reiki|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
215102361|NCT05698953|OTHER|Placebo|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days by an independent nurse during the same application period.
215102362|NCT02596945|DRUG|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
215102363|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
214419251|NCT00002995|DRUG|cyclophosphamide|
214419252|NCT00002995|DRUG|vincristine sulfate|
214419253|NCT00002995|RADIATION|radiation therapy|
214419254|NCT00092716|DRUG|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
214419255|NCT00092716|DRUG|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
215102364|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
214419256|NCT01183780|BIOLOGICAL|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
214419257|NCT01183780|BIOLOGICAL|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
214419258|NCT01183780|DRUG|Irinotecan|180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
214419259|NCT01183780|DRUG|Folinic Acid|400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
214689914|NCT00777491|DRUG|consolidation 5-fluorouracil|400 mg/m\^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
214419260|NCT01183780|DRUG|5-Fluorouracil|400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
214419261|NCT03259919|DRUG|Metformin|Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
214419262|NCT03259919|DRUG|Placebo|Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
214419263|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
214419264|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
214419265|NCT04760119|PROCEDURE|Vein bypass surgery first strategy|Vein bypass will be performed with standart anaesthetic and surgical techniques using reversed great saphenous vein conduit. Location of proximal and distal anastomosis will be recorded. Post surgery completion angiography imaging will be performed.
214419266|NCT04760119|PROCEDURE|Endovascular treatment first (drug coated balloon angioplasty) strategy|Endovascular treatment using drug-coated balloons will be performed under local anaesthetic via common femoral artery. Final angiography imaging will be demonstrated.
214419267|NCT04875130|DIAGNOSTIC_TEST|blood samples|Taking blood samples (plasma, serum) and measure the level of Adrenomedullin
214419268|NCT01492218|DRUG|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
215019369|NCT04304196|OTHER|Usual care|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
215019370|NCT00970177|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
215019371|NCT02220400|DRUG|Ketamine|
215019372|NCT03374956|DRUG|Phentermine-Topiramate|Extended Release at dose of 7.5/46 mg oral daily
215019373|NCT03374956|DRUG|Liraglutide|dose of 3 mg subcutaneous daily
215019374|NCT03374956|DRUG|Naltrexone/bupropion|Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
215019375|NCT03374956|DRUG|Phentermine|15-37.5 mg oral daily
214419269|NCT04379713|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
215019376|NCT06540495|BEHAVIORAL|Salaso Virtual Exercise Program|Salaso is a digital health technology company that has online, mobile and telehealth solutions enabling providers to 'prescribe' evidence-based exercise programs for patients to complete virtually.
215019377|NCT01546987|DRUG|GnRH agonist|LHRH agonists are administered with a variety of techniques. The manufacturer's instructions should be followed. Begins within 6 weeks after registration (if not started prior) at same time as anti-androgen and TAK-700 (if applicable).
215019378|NCT01546987|DRUG|Anti-androgen|Starts at same time as GnRH agonist, ends at end of radiation therapy. Either flutamide (orally 250 mg three times a day) or bicalutamide (orally 50 mg once a day).
215019379|NCT01546987|DRUG|TAK-700|300 mg twice daily (BID) (600 mg per day) orally, continuously for 2 years starting with ADT.
215019380|NCT01546987|RADIATION|Radiation therapy|Starts 8-10 weeks after initiation of ADT. Initially 45 Gy (1.8 Gy / fraction) to prostate and pelvic lymph nodes delivered with 3DCRT/IMRT, then a boost using intensity-modulated radiation therapy (IMRT), low dose rate (LDR) brachytherapy, or high dose rate (HDR) brachytherapy.
215019381|NCT03201380|OTHER|TEP scanner with choline|
215019382|NCT03401580|DRUG|Viena II 160/10|once daily
215019383|NCT03401580|DRUG|Viena II 190/10|once daily
215019384|NCT03401580|DRUG|Viena II 160/12|once daily
215019385|NCT03401580|DRUG|Viena II 190/12|once daily
214419270|NCT04379713|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
214419271|NCT01872819|OTHER|antitumor drug screening assay|Undergo high throughput drug sensitivity assay
214419272|NCT01872819|DRUG|chemotherapy|Patients receive 1 of 160 possible interventions
214419273|NCT01872819|BIOLOGICAL|biological therapy|Patients receive 1 of 160 possible interventions
214419274|NCT04089488|OTHER|Medical Chart Review|Correlative studies
214419275|NCT04089488|OTHER|Survey Administration|Respond to surveys
214419276|NCT05112861|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
214419277|NCT00001304|DRUG|Synthetic Human Parathyroid Hormone 1-34|twice daily subcutaneous injections
214419278|NCT00001304|DRUG|Calcitriol & Calcium|Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
214419279|NCT00258037|BEHAVIORAL|Pelvic Floor Muscle training|
215019386|NCT01019057|PROCEDURE|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
215019387|NCT03399747|DRUG|Abb-R-CHOP|"Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy"
215019388|NCT03692026|PROCEDURE|Immediate implant placement|implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.
215019389|NCT03692026|DRUG|Hyaluronic acid and Melatonin Mixture|a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
215102365|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
215102366|NCT01853605|DEVICE|Anatomically shaped silicone gel-filled breast implants|Surgical implant
215102367|NCT06124456|OTHER|Usual Care Control Group|Subjects in the usual care control group will receive health education as the attention control. The program will consist of eight 150-minute bi-weekly sessions covering major health issues relating to general health and NAFLD, to be obtained from publicly accessible resources from the Hong Kong Department of Health. Health education information on non-communicable diseases (e.g., cancers, diabetes, coronary heart diseases, obesity, and mental illness), infectious diseases (e.g., COVID-19), and a healthy lifestyle (e.g., balanced diet, physical activity, good sleep, tobacco use, alcohol cessation, and stress management) will also be distributed to the subjects in the exercise groups through recorded presentation videos and leaflets/pamphlets during the first 16 weeks.
215019390|NCT02197065|DRUG|Atorvastatin|Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45
214689915|NCT00777491|DRUG|consolidation cisplatin|15 mg/m\^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
214689916|NCT00777491|PROCEDURE|radical cystectomy|Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
214689917|NCT00777491|PROCEDURE|Post-Induction Chemoradiotherapy Endoscopic Response Evaluation|Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
215019391|NCT02197065|DRUG|Placebo|
215019392|NCT04975165|PROCEDURE|Total knee arthroplasty|Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
215019393|NCT03059888|DRUG|Abatacept Injection|Subcutaneous administration of abatacept
215019394|NCT01991886|DEVICE|Vapotherm Precision Flow|Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
214419280|NCT02762006|DRUG|Durvalumab|Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.
214419281|NCT02762006|DRUG|Tremelimumab|Tremelimumab is a CTLA-4 monoclonal antibody.
215019395|NCT02174445|DRUG|Imatinib|Imatinib, 400 to 800 mg p.o., daily
215019396|NCT02174445|DRUG|Nilotinib|300mg p.o., twice-daily
215019397|NCT00085020|BIOLOGICAL|trastuzumab|
215019398|NCT00085020|DRUG|lapatinib ditosylate|
215019399|NCT00000472|DRUG|tissue plasminogen activator|
215019400|NCT00000472|DRUG|heparin|
215019401|NCT03822819|DIETARY_SUPPLEMENT|probiotic cocktail capsules|Daily uptake of probiotic cocktail for three weeks
215019402|NCT03822819|DIETARY_SUPPLEMENT|placebo capsules|Daily uptake of placebo capsule for three weeks
215019403|NCT03469609|OTHER|mucous fistula refeeding|Transfer of infants' own stool
214419282|NCT04709796|DRUG|EmbryoGlue®, Vitrolife|The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.
214419283|NCT04709796|DRUG|Conventional Transfer|The control arm is the conventional embryo transfer without Embryo glue medium
214419284|NCT03335969|DEVICE|colon irrigation|Study is to compare bowel movement patterns before and after colon irrigation.
214419285|NCT02148133|DRUG|Eltrombopag 12.5 mg|White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
214419286|NCT02148133|DRUG|Eltrombopag 25 mg|White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
214419287|NCT05241119|PROCEDURE|SLNB|undergo fluorescence SLNB.
214419288|NCT05241119|PROCEDURE|pALND|undergo low axillary lymph node dissection with ICBN as the boundary
214419289|NCT05241119|PROCEDURE|ALND|undergo ALND
214419290|NCT02399696|BEHAVIORAL|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
214419291|NCT02399696|BEHAVIORAL|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
214419292|NCT03808883|BEHAVIORAL|TGNC Directed Advocacy Meetings|Series of 18 meetings with TGNC cohort, including 3 facilitated dialogues with the healthcare participants, to articulate barriers to access and to enter into dialogue with medical providers and staff.
214419293|NCT03808883|BEHAVIORAL|Facilitated Dialogues between TGNC Cohort and Healthcare Participants|Healthcare Participants attend a facilitated dialogue with the TGNC cohort. 3 total facilitated dialogues were held, but each healthcare participant attends only 1 session.
214419294|NCT06054867|DEVICE|Robotic Waterjet Treatment|"The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System.~During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real-time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan."
214419295|NCT05377346|OTHER|Placement of the i-gel|The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.
214419296|NCT04941924|PROCEDURE|Intraductal Radio-Frequency Ablation|"The electrode employed in this study is the STARmed ELRA™ (Endo Luminal Radiofrequency Ablation) electrode; this is a CE marked device. The selected electrode will be connected to the VIVA™ Combo generator (also a CE marked device) and advanced over the guide wire.~The power of the generator should be set at either 7 or 10 W depending on the electrode used per manufacturer instructions. An ablation should then be applied at a temperature of 70 to 80℃ for 2 minutes. For longer length strictures or stent occlusions, the RFA probe is withdrawn from proximal to distal in a step by step fashion in respect to the access method used."
214419297|NCT04941924|DEVICE|Biliary Stent Placement|Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
214419298|NCT06281431|PROCEDURE|Echogenic nerve block needle|A 22G 8-cm echogenic nerve block needle (LEAPMED, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The spread of the medication will be assessed through short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the incidence of punctures, and any associated complications are all meticulously appraised.
214689918|NCT00777491|DRUG|adjuvant gemcitabine|1000 mg/m\^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
214689919|NCT00777491|DRUG|adjuvant cisplatin|70 mg/m\^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
214689920|NCT04129684|OTHER|Probiotics|subgingival delivery and lozenges
214689921|NCT02514460|DEVICE|plaque excision system|
214419299|NCT06281431|PROCEDURE|Non-echogenic nerve block needle|A 22G 8-cm thin wall low bottom nerve block needle (KDL, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The distribution of the medication will be assessed using short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the number of punctures, and any associated complications are all meticulously appraised.
214689922|NCT02514460|DEVICE|Stent|
214689923|NCT05129813|BEHAVIORAL|Recovery Guide Counseling|Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
214689924|NCT03987620|DRUG|Ibrexafungerp|Ibrexafungerp 300mg BID for one day
214689925|NCT03987620|DRUG|Placebo|Matching Placebo
214689926|NCT05029544|OTHER|Dynamic taping|The intervention of this experimental study was therapeutic taping (dynamic tape) on the symptomatic shoulders of the participants.
214689927|NCT05029544|OTHER|Kinesio taping|The intervention of this experimental study was therapeutic taping (kinesio tape) on the symptomatic shoulders of the participants.
214689928|NCT05029544|OTHER|Physiotherapy and Rehabilitation|exercise, manuel therapy, mobilization, massage, sensorimotor control
214689929|NCT03003416|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
214689930|NCT03859986|DRUG|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle
214689931|NCT03859986|DRUG|ALX-101 Gel 5%|ALX-101 Gel 5%
214689932|NCT04523844|DRUG|Brinzolamide-brimonidine Fixed Combination|In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection
214689933|NCT02305901|DRUG|repaglinide|single dose on day 1 of visits 2 and 3
215019404|NCT05938816|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR consists of weekly two-hour sessions for eight weeks, and a 7.5 hour retreat between weeks 6 and 7. The MBSR intervention will be facilitated by an experienced and certified MBSR teacher. MBSR curriculum strongly encourages completion of home practice assignments (\~30 minutes daily) to help integration of concepts into daily life. Participants will receive audio CDs and a DVD to help guide home practice.
215029039|NCT06559241|DEVICE|14-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 14 days post-thrombectomy.
214689934|NCT02305901|DRUG|BI 187004 tablet|multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
214689935|NCT02305901|DRUG|bupropion extended release tablet|single dose on day 3 of visits 2 and 3
214689936|NCT03302416|DRUG|Hydrocortisone|
214689937|NCT03302416|RADIATION|[C-11]NOP-1A|
214689938|NCT03653702|DRUG|Lumason|Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
214689939|NCT00914836|DRUG|Betamethasone Sodium Phosphate|1cc:2cc
214689940|NCT00914836|DRUG|1 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
214689941|NCT00914836|DRUG|2 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
214689942|NCT03243513|OTHER|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
214689943|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Behavioral Counseling|
214689944|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Attention Control|
214689945|NCT04355156|DRUG|Axitinib|"* All patients randomised to this arm will receive 3mg BD, and increased at 2 weeks to 5mg BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)~* At 8 weeks, after tumour CT RECIST assessments, responders will continue monotherapy. In non-responders, those with disease progression, monotherapy can be continued if patient chooses to continue and if tolerated"
214689946|NCT04355156|DRUG|Placebo|"* All patients receiving placebo will receive tablets to take BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)"
214689947|NCT06336577|OTHER|lower respiratory tract disease|lower respiratory tract disease
214689948|NCT00471445|DRUG|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
214689949|NCT00471445|OTHER|placebo|Applied topically
215019405|NCT05938816|BEHAVIORAL|Health and Wellness Education (HWE)|HWE is a didactic-based group intervention designed as an active comparator for randomized-controlled trials of MBSR. HWE provides instruction to participants regarding improving their emotional and physical health. In contrast to MBSR, there are no attempts to train participants' breathing, movement, or meditation habits or practices. HWE is administered in 8 weekly 2.5-hour classes with home practice to be completed between sessions (matched to MBSR for amount and effort). HWE also features one extended 7.5-hour retreat, similar to MBSR.84 Dr. Autumn Gallegos (consultant) has conducted trials of MBSR among veterans with PTSD using a HWE control group, and will provide mentorship to the PI in administering the HWE intervention. Dr. Kaplan and a trained RA will facilitate HWE.
215019406|NCT05856461|PROCEDURE|Pulmonary vein isolation|Circumferential pulmonary vein isolation procedure using 3D navigation systems with entrance and exit block verification
215019407|NCT05856461|PROCEDURE|Sham pulmonary artery denervation|Sham pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries with creation of the false ablation points. No true ablation lesions will be performed in the pulmonary artery
214419300|NCT04524832|DRUG|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks
215019408|NCT05856461|PROCEDURE|Pulmonary artery denervation|Pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries and 3 circles of ablation lesions (bifurcation of the main pulmonary artery, left and right pulmonary arteries)
214419301|NCT05977933|DEVICE|Shape II CPET|Submaximal Cardiopulmonary exercise test equipment
214419302|NCT00325923|BEHAVIORAL|Decision aid|
214506020|NCT06270732|BEHAVIORAL|iMentalize Program (iMentalize)|"This is a 30-hour group training involving 30 sessions lasting 45 minutes and 7.5 hours of inter-sessions work.~Session 1: Program presentation; Session 2: Reflective Parenting; Session 3: Cartoon's session I (baseline); Session 3: What is Mentalization; Session 4: Fundamentals of Human Interaction; Session 5: Cartoon's session II (the beginnings); Session 6: Mentalization and Mental Health; Session 7: MISC context and cultural components; Session 8: Cartoon's session III (practice with MISC context comp.); Session 9: The importance of emotions in human interaction; Session 10: MISC emotional components; Session 11: Cartoon's session IV (practice with emotional comp.); Session 11: How mentalization is developed; Session 12: MISC cognitive components; Session 13: Cartoon's session V (practice with cognitive comp.); Session 14: How to foster children mentalization skills. Sessions 15 to 30: Cartoon's sessions using MISC components to foster children mentalization."
214506021|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 30-hour individual training involving 30-weekly online, individual, self-administered 45' sessions (22.5h) + 7.5h of between sessions work (readings, supervision, video- recordings for later video-feedback, reﬂection exercises). BLOCK I: Session 1: Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC; Sessions 9-18 (MISC practice and video-feedback); Summer break: Recording daily life interactions; BLOCK II: Session 19: Recap; Sessions 20-30: guided reﬂection and video-feedback.
214506022|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|"This is an equivalent 30-hour online self-administered training involving 30 x 45' individual online sessions (22.5h), mostly based on reﬂection exercises around brief readings, pills, and animated shorts, but not video- feedback and guided practice. This is complemented with 7.5h of between-sessions work based on looking for new information, adult-child (non-guided) activities (and not for later video- feedback) or out-of-line guided reﬂective exercises.~Session 1: Program presentation; Session 2-8: Theoretical bases of MISC and mentalization; Session 9-16: MISC and mentalization applied to mental health; 17-18: Benefits of MISC to improve children learning; 19-20: Benefits of MISC for self-esteem; 21-22: The importance of MISC to foster mentalization; 23-24: Mentalization and pro-social behavior; 25-26: The importance of MISC to promote secure attachment; 27: MISC impact in epistemic trust; 28-29: MISC and well-being; 30: MISC, mentalization and environmental enrichment."
215019409|NCT05875831|BEHAVIORAL|Active Cycle of Breathing|Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients
215019410|NCT05875831|DIAGNOSTIC_TEST|Coughing|Coughing to Improve Pulmonary Functions in Post-Surgical Patients
215102368|NCT06124456|OTHER|Moderate-intensity Exercise Intervention|The walking time in each session will be 50 minutes for the moderate-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
215102369|NCT06124456|OTHER|Vigorous-intensity Exercise Intervention|The walking time in each session will be 25 minutes for the vigorous-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
215102370|NCT03613467|PROCEDURE|VATS lobectomy|Patients who received lobectomy by video-assisted thoracoscopic surgery
214419303|NCT04107129|PROCEDURE|Endometrial Biopsy|An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers
214419304|NCT04107129|OTHER|Euploid embryo transfer|Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.
214419305|NCT04107129|DIAGNOSTIC_TEST|Blood sample|Estradiol and Progesterone levels in the blood will be checked
214419306|NCT01597154|BEHAVIORAL|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
214506023|NCT02290158|OTHER|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
215102371|NCT03613467|PROCEDURE|Thoracotomy lobectomy|Patients who received lobectomy by thoracotomy
215102372|NCT05629468|DRUG|Azithromycin|antibiotic
215102373|NCT05629468|DRUG|Probiotic Formula|probiotics
215102374|NCT05629468|DRUG|Benzoyl Peroxide 4 % Topical Cream|topical cream
214506024|NCT04989842|BEHAVIORAL|Curriculum Hannover|The methodology uses a natural variation design within the Dr. Becker Clinical Group. The interventions consist of a face-to-face or a digital psychosomatic aftercare basing upon the concept of the Curriculum Hanover. A control group is included that does not receive these two interventions (but receives a similar rehabilitation treatment to the intervention groups).
215019411|NCT01080547|PROCEDURE|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
215019412|NCT01080547|DRUG|XELOX Chemotherapy|XELOX chemotherapy
215019413|NCT01080547|DRUG|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
215019414|NCT01080547|OTHER|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
215019415|NCT01080547|OTHER|Conventional Perioperative Treatment|Conventional treatment during perioperation period
215019416|NCT01080547|PROCEDURE|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
215019417|NCT02355509|DRUG|Acarbose|"Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months"
215019418|NCT02355509|DRUG|Placebo|Placebo pills are given instead of acarbose in this group
215019419|NCT05984862|DEVICE|Bandage|To determine if using bandage versus no-bandage, plays a role in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure
215019420|NCT06523153|BIOLOGICAL|VYD2311|Monoclonal antibody
215019421|NCT06523153|OTHER|Placebo|Matching Placebo
215019422|NCT02338557|DEVICE|motor relearning programme|MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
215019423|NCT02338557|DEVICE|MIRROR THERAPY|Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
215019424|NCT00000603|PROCEDURE|stem cell transplantation|
215019425|NCT06571578|DEVICE|Threshold Inspiratory muscle trainer|threshold inspiratory muscle trainer device Each subject will breathe through a separate mouthpiece through attach the mouthpiece firmly While putting a nose clip and inhale deeply through the mouthpiece to generate an inspiratory pressure greater than the indicated presetting threshold pressure to compress the spring and open the valve. Using High - intensity interval training technique
215019426|NCT06571578|OTHER|posture correction exercises|"conventional exercise consists of~* Cervical isometric exercises will be performed in the sitting position by resisting at the forehead (cervical ﬂexion, extension, rotation and side bending) for 10 seconds with 15 seconds breaks between holds with 10-15 repetitions in a progressive manner 3time/week for 12 weeks.~* Postural correction exercise consists of gently rolling of pelvis forward to an upright neutral sitting position, followed by scapular correction and occipital lift. Also, for the sub-occipital muscles stretching~* stretching exercises for scalene and levator muscles"
215019427|NCT03818074|DEVICE|Boston Wavewriter 1000Hz Spinal cord Stimulation|High frequency spinal cord stimulation.
215019428|NCT03769948|OTHER|risk factors for diabetic retinopathy|Demographic variables: gender, race, marital status, urban rural status. Co-morbidity variable: neuropathy, nephropathy, peripheral circulatory, ketoacidosis, hyperosmolarity Lab tests variables: alanine aminotransferase (ALT), albumin serum, anion gap, aspartate aminotransferase, blood urea nitrogen, calcium serum, chloride serum, creatinine serum, glucose serum plasma, hematocrit, hemoglobin, mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MPV), potassium serum, protein total serum, red blood cell (RBC) count, sodium serum, white blood cell (WBC) count
215019429|NCT01755403|DRUG|Benznidazole|
215019430|NCT05984992|DRUG|SRN-001|siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized
215019431|NCT05984992|DRUG|Placebo|0.9% Sodium Chloride(Normal saline)
215019432|NCT03878602|PROCEDURE|Delayed umbilical cord clamping|Umbilical cord will be clamped after 1 min after the birth of the newborn
215019433|NCT03878602|PROCEDURE|Immediate umbilical cord clamping|Umbilical cord will be clamped immediately after the birth of the newborn
215019434|NCT02776176|PROCEDURE|Enhanced Recovery After Surgery Program|optimized peri-operative protocol
215019435|NCT02776176|PROCEDURE|Traditional Program|traditional standard protocol
215019436|NCT05456217|OTHER|admission to ICU|admission to an intensive care unit or high dependency unit in Kenya
215019437|NCT01289587|BEHAVIORAL|Physical activity intervention|36 sessions of physical activity offered at different frequencies
214506025|NCT00293761|DRUG|Travoprost, Investigational|One drop in study eye once daily for 13 days
214506026|NCT00293761|DRUG|Travoprost (TRAVATAN)|One drop in study eye once daily for 13 days
214506027|NCT00532350|DRUG|QAT370|
214506028|NCT00532350|DRUG|Placebo|
214506029|NCT00532350|DRUG|Tiotropium|
215019438|NCT03175588|OTHER|Virtual Rehabilitation|Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
214419307|NCT06278025|DIAGNOSTIC_TEST|assessment|"DCF Muscle Strength Evaluation~DCF muscle strength was determined using the 5-step Craniocervical Flexion Test (CCFT) performed with a Chattanooga Stabilizer ™ Pressure Biofeedback Unit which was developed by Jull et al. \[33, 34\]. The CCFT is based on the craniocervical flexion movement, which is provided by DCF muscle contraction. The CCFT includes 5 pressure increments starting with 20mmHg.Activation score ranges from 0 to 10. The performance index is determined by both the highest pressure level and the number of repetitions.~Evaluation of the DCF Endurance The DCF endurance test, which is a valid and reliable method, was used to measure DCF muscle endurance \[36\]. Conducted in supine, endurance is measured by calculating the time (in seconds) an individual can raise their head at minimal flexion angle."
214419308|NCT04352582|OTHER|Survey|Survey
214419309|NCT00202969|DRUG|S-1|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
214419310|NCT00202969|DRUG|S-1 plus CDDP|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
215019439|NCT02417337|PROCEDURE|Root Canal Treatment|A standardized endodontic procedures performed.
215019440|NCT02417337|DRUG|Paracetamol|
214419311|NCT00202969|DRUG|5-FU plus CDDP|5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
214419312|NCT00480766|DRUG|MK0217/Duration of Treatment : 12 Months|
214419313|NCT06544382|OTHER|The Long COVID Rehabilitation Intervention|The intervention is a structured rehabilitation intervention with a duration of minimum 3 months comprising 4-12 individual sessions and 1-4 group-based courses delivered by physiotherapists and occupational therapists.
214419314|NCT06544382|OTHER|Usual care|A less structured rehabilitation programme comprising individual session with a few group options with patients with long COVID or mixed diagnoses.
214419315|NCT02959658|DRUG|Dimethyl fumarate|
214419316|NCT02959658|DRUG|Placebo|Manufactured to mimic Dimethyl Fumarate capsules
214419317|NCT04701294|DEVICE|Giomer Beautifil flow plusF03 Shofu-Japan|A pair of permanent first molars will be used for each participant homologs The operator will apply in the upper / lower first molars the sealant material in the order assigned according to the previous randomization. For the intervention group, they will be sealed based on a fluid resin with s-prg glass ionomer filling (Giomer F03 Beautiful -Shofu) in association with a bottle of adhesive (Single Bond) . The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
214419318|NCT04701294|DEVICE|Tetric N flow ivoclar vivadent-Germany|And on the contralateral side (control) the first upper / lower molars will be sealed will be sealed with a fluid resin compound (Tetric N-Flow ivoclar vivadent) in association with a bottle of adhesive (Single Bond). Both materials have a similar color. The operator and the child will not be informed about the brand of the material used. The assistant will collect the data in the file. The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
214419319|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), incremental exercise protocol|The incremental work rate exercise test will be performed using a cycle-ergometer. The exercise protocol is initiated by a five-minute warm-up at 50 Watts (W). Subsequently, they will complete a stepwise protocol, which will begin at 100 W and increase by 2 W every 6th second, until exhaustion or until the patient is unable to continue exercise, for any reason.
214419320|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), continuous work rate protocol|"Within two weeks the participants will perform an additional CLE-test at various intensities. The new exercise protocol is designed to induce EILO at different exercise intensities. Using the participants' individually calculated exercise capacity, three different workloads (70 %, 80 % and 90 %) will be calculated.~The exercise protocol will be initiated with a five-minute warm-up at 50 W, then the workload will increase to the watt equivalent to 70 % of the participant's maximal exercise capacity. This workload will be fixed for ten minutes and only terminated if the participant feels the need to stop due to exhaustion or breathing difficulties. Next, the participant will have a five-minute resting phase with a set workload of 50 W. This protocol will be repeated at a workload equivalent to 80 % and 90 %"
214419321|NCT04567888|BEHAVIORAL|Happify Teens|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
214506030|NCT04460066|DRUG|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
214506031|NCT04460066|DRUG|albumin bound paclitaxel|Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
215019441|NCT02417337|DRUG|Ibuprofen|
215019442|NCT02417337|DRUG|Mefenamic acid|
215019443|NCT02417337|DRUG|Diclofenac|
215019444|NCT02305615|OTHER|Bevacizumab|Bevacizumab at a dose and schedule according to approved label and SmPC. The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 milligrams per kilogram (mg/kg) or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. Bevacizumab is always used in combination with chemotherapy for the treatment of participants with metastatic CRC. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.
215102375|NCT06217003|DRUG|Trilaciclib|Preoperative application of trilaciclib during perioperative chemotherapy
215019445|NCT02305615|COMBINATION_PRODUCT|Chemotherapy|Fluoropyrimidine-based doublet chemotherapy (5-Fluorouracil \[5-FU\] or capecitabine plus oxaliplatin or irinotecan) as first-line treatment; and continued fluoropyrimidine treatment with or without treatment modification for oxaliplatin or irinotecan, as per treating physician discretion.
215019446|NCT04296682|PROCEDURE|Alveolar Ridge Preservation With Gingival Graft|Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
215019447|NCT01895179|OTHER|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
215102376|NCT04072263|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
215019448|NCT01895179|OTHER|Grazing|Grazing involves eating meals spread out over the course of the day.
215019449|NCT00388141|BEHAVIORAL|NIDCAP|Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
215019450|NCT03258957|OTHER|Fresh Milk|Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk
215019451|NCT04588558|DEVICE|Flywheel exercise|Flywheel training is a strength training modality that offers the possibility of performing exercises with eccentric overload and variable resistance as compared to conventional gravity-based resistance training. Flywheel exercise applied three days a week for 8 weeks
215019452|NCT04588558|OTHER|Home exercise|The active ROM exercise was performed via knee in extension to full-flexion, then knee in flexion to full-extension exercises, repeated 10 times. The strengthening exercises consisted of quadriceps strengthening by holding maximal isometric contractions for 10 s and performing 10 repetitions. Stretching targeted the gastrocnemius- soleus and hamstring muscle and was performed by asking the patient to stretch the muscle for 30 s and to complete three repetitions for each muscle group.
214419322|NCT04643236|BEHAVIORAL|Periodontal health education session|This session comprised of a condensed version of motivational interviewing and a periodontal education view/point. First, patients were analysed in terms of expectations from periodontal treatment/oral hygiene practice, knowledge about periodontal diseases and its consequences, daily oral hygiene routine, awareness of the current periodontal status and the main reasons for not doing proper brushing and interproximal cleaning. The same researcher who did not included in the clinic process informed the patients about how periodontal diseases develops, its aetiology, symptoms, consequences and the relationship with the important systemic disorders verbally and via brochure as well. The importance of the patients' own efforts about daily cleaning of the mouth were emphasized. Finally oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
214419323|NCT04643236|BEHAVIORAL|Oral hygiene motivation session|Standard oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
214419324|NCT02817724|DEVICE|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
214419325|NCT02817724|OTHER|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
215019453|NCT04588558|DEVICE|Electrotherapy group|"The participants in the electrotherapy group received TENS (Intellect; Chattanooga Group, Hixson, TN), therapeutic ultrasound (Intellect 340 Combo) and exercise. TENS was applied via four electrodes around the knee joint: two on the medial and two on the lateral aspect on either side of the joint line for approximately 20 min. For pain relief, the devices were set to a continuous mode (110 Hz, 50 μ). Electrical pulses were asymmetric and biphasic.~Therapeutic pulsed ultrasound therapy was administered using a 1-MHz frequency, 0.8 W/cm power ultrasound device with a sound-head area of 5 cm2 and effective radiating area of 3.5-5 cm2 . Ultrasound was applied to the medial and lateral parts of the knee in circular movements for a duration of 5 min with the patient in a supine position.~All participants received the same standardized exercise program. The exercises included aerobic, active ROM, strength, and stretching exercises"
215019454|NCT02813512|DRUG|ADSCs|Autologous ADSCs
214419326|NCT03874650|BEHAVIORAL|Activity Planning Group|Participants in this group will receive 8 1-hour sessions of Behavioural Activation combined with select Goal Management Training strategies over the course of 8 weeks.
214419327|NCT03874650|BEHAVIORAL|Activity Engagement Group|Participants in this group will attend 8 1-hour sessions of various social activities such as board games and puzzles.
214419328|NCT03874650|BEHAVIORAL|Waitlist Group|Participants in this group will continue on their care as usual before being re-randomised into either the Activity Planning Group or Activity Engagement Group after 8 weeks.
214419329|NCT00993850|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
214419330|NCT00993850|OTHER|Bipolar education|Psychoeducation
214419331|NCT00273949|DRUG|lactulose|
214419332|NCT05001750|DRUG|long term prophylactic antibiotics (Nafcillin or Doxycycline)|VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
214419333|NCT04671719|BIOLOGICAL|blood sample|blood sample for circulating autotaxin measurement (5ml).
214419334|NCT00803933|DRUG|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
214419335|NCT00803933|DRUG|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
214419336|NCT04028635|BEHAVIORAL|Cognitive-behavioral therapy plus VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions.
214419337|NCT04028635|BEHAVIORAL|Cognitive behavioral therapy|Usual CBT
214506032|NCT04460066|DRUG|cisplatin|Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
215019455|NCT00134498|DRUG|torcetrapib/atorvastatin|
215019456|NCT00134498|DRUG|atorvastatin|
214419338|NCT05183906|DIAGNOSTIC_TEST|Next generation sequencing|Evaluation of microbiological culturing versus next generation sequencing for ribosomal DNA
214506033|NCT04460066|DRUG|placebo|Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
214506034|NCT04460066|PROCEDURE|radical resection of esophageal carcinoma|Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
214506035|NCT01058018|DRUG|RVX000222|RVX000222 twice a day for 12 weeks
214506036|NCT01058018|DRUG|Placebo|Placebo twice a day for 12 weeks
214506037|NCT06368999|DIAGNOSTIC_TEST|EEG|registration of 8 minutes of EEG
214506038|NCT03438409|OTHER|Robotic gait training|Robotic gait training
214689950|NCT05347498|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
214419339|NCT00199342|DRUG|KW-2871|potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma
214419340|NCT05300399|DEVICE|mHealth app|The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
214419341|NCT03870854|PROCEDURE|PEFA VT ablation technique|Catheter ablation guided by PEFA technique
214419342|NCT01687452|BIOLOGICAL|Blood samples|
214506039|NCT06509204|DIETARY_SUPPLEMENT|Glucotrojan|"Day 1: Start wearing the CGM sensor and let it self-calibrate for 24 h Day 2: Consume 1 serving of Test Meal for breakfast. Log the meal in the app. Day 3: Consume 1 serving of Test Meal with GlucoTrojan for breakfast. Log the meal in the app.~Days 4-8: Participants will be instructed to take GlucoTrojan twice per day. Once during their typical breakfast meal and once during their typical dinner meal. Each breakfast and dinner will be logged in the app.~Days 9-13: Participants will continue with their typical lives but continue to log meals - breakfast and dinner - in the app.~Day 14: end"
215019457|NCT00452530|DRUG|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
215019458|NCT00452530|DRUG|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
215019459|NCT00452530|DRUG|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
215019460|NCT00452530|DRUG|Apixaban-matching placebo|Oral tablet administered twice daily
215019461|NCT01988558|DRUG|DL - Lactic Acid|Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
215019462|NCT01988558|DIETARY_SUPPLEMENT|Raspberry flavored syrup|Placebo group to receive Raspberry flavored Syrup
215102377|NCT04072263|DRUG|Interferon Alfa 2A|Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
215102378|NCT04072263|DRUG|Carboplatin|chemotherapy i.v.
215102379|NCT04072263|DRUG|Paclitaxel|Chemotherapy i.v.
215102380|NCT00826670|DRUG|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
215102381|NCT00826670|DRUG|Placebo (Decolonization)|Placebo
215102382|NCT06402032|OTHER|Hesperidin|Hesperidin is a natural flavonoid with well-known of its anti-inflammatory properties in many disease. Hesperidin in previous studies has been documented to reduce inflammation as well as pain through suppression of cytokine production, NF-κB activity, and oxidative stress. Hesperidin, as a natural product, have been considered as a promising pulp capping material in several invitro and animal studies. However, the regenerative effect of hesperidin as pulp capping material in human teeth has not yet been reported.
215102383|NCT06402032|OTHER|Mineral Trioxide Aggregate (MTA)|Mineral trioxide aggregate is a cementitious material having various advantages as it is biocompatible, bioactive, osteo-inductive, non-resorbable material with exciting clinical applications, stimulating reparative continuous dentin formation along with maintaining the integrity of the pulp. Moreover, mineral trioxide aggregate provides seal to tooth structure and is of high strength. It is considered the gold standard material for direct pulp capping.
215102384|NCT00376896|DRUG|GW876008 200mcg|GW876008
215102385|NCT00376896|DRUG|GW876008 20mcg|GW876008 20mcg
215102386|NCT00376896|OTHER|Placebo|placebo
215102387|NCT02542787|DRUG|VSN16R|Small molecule
215102388|NCT02542787|OTHER|Placebo|dummy tablet
215102389|NCT04255641|OTHER|time lapse analysis|grading of the embryos before freezing using time lapse/
214419343|NCT04136496|DEVICE|Black-Eye Ink|There are two proposed studies utilizing the Ink during differing timepoints.Both will identify patients with breast cancer, with a biopsied metastatic axillary lymph node(LN) with a tissue marker clip placed, as is current practice. In Study A, 0.5mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy. In Study B, 0.5mL of Black Eye Ink will be placed before neoadjuvant therapy. In both studies, the LN containing the tissue marker clip will be the one to have the radioactive seed and Ink inserted. The seed will still be inserted, in the event the dye is not well-visualized. In both studies, the surgeon will attempt to find the LN by direct visualization and then confirm the appropriate LN has been removed by using the Gamma probe and intra-operative radiographs. If the seed is not within the tattooed node, the LN containing the seed will also be removed. All lymph nodes injected with Ink will be removed by the surgeon;no Ink-injected node remains in body.
214506040|NCT05376982|DIAGNOSTIC_TEST|Neurodevelopmental Treatment|Using Neurodevelopmental Treatment Method
215102390|NCT06017726|OTHER|treatment of insulin resistance with appropriate modality according to each patient|insulin resistance will be treated with either diet alone or combined diet and appropriate pharmacological treatment with the net result of normalization of HOMA IR index
215102391|NCT02305212|BEHAVIORAL|Cogmed|
215102392|NCT00002503|RADIATION|strontium chloride Sr 89|
215102393|NCT03738618|DRUG|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 15 μg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 μg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 μg, and the maximum daily dose was 24 μg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed"
215102394|NCT03738618|DRUG|Placebo|"Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed."
215102395|NCT00649428|BIOLOGICAL|Autologous Human Fibroblast (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
215102396|NCT00649428|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection visits administered 5 ± 1 weeks apart on each side of the face."
214419344|NCT02772653|OTHER|Blood Lactate|Analyzed at the 1rst, 8th and 24th hour from hospital admission
214419345|NCT02772653|OTHER|Blood Base Excess|Analyzed at the 1rst, 8th and 24th hour from hospital admission
214419346|NCT02772653|OTHER|Blood B-type Natriuretic Peptide|Analyzed at the 1rst, 8th and 24th hour from hospital admission
214419347|NCT02772653|OTHER|Blood Thromboelastometry (ROTEM)|Analyzed at the 1rst, 8th and 24th hour from hospital admission
214419348|NCT02772653|OTHER|Near-infrared spectroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
214419349|NCT02772653|OTHER|Sublingual videomicroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
214419350|NCT06552390|PROCEDURE|Cardiac Rehabilitation|"HRN4HTx is a phase 1 rehabilitation intervention protocol for post-heart transplant focused on the physical exercise component, and an educational plan regarding risk factors and safety criteria. The intervention protocol and its assessments are implemented by the team's rehabilitation nurses, always safeguarding the protective isolation required for these patients. The physical training protocol is divided into five stages of progressive levels of intervention. The protocol was defined following FITT parameters, international recommendations, and an integrated teaching program aimed at the therapeutic regimen exercise area. The frequency of intervention sessions is 7 days a week, twice a day (average of 13 sessions per week) throughout the hospitalization.~The intensity was defined according to Borg's modified scale of subjective perception of exertion (SPE), which must be maintained at less than 5."
214419351|NCT00750750|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
214419352|NCT00750750|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
214419353|NCT00750750|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
214419354|NCT00750750|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
214419355|NCT00595205|OTHER|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
214506041|NCT05376982|DIAGNOSTIC_TEST|Body weight supported treadmill training along with conventional therapy|Using Body weight supported treadmill training along with conventional therapy Method
214506042|NCT02409043|OTHER|Blood draw|Blood drawn for comparison with other groups
215019463|NCT02375256|BIOLOGICAL|AERAS-402|Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
215019464|NCT02375256|BIOLOGICAL|Placebo|Identical buffer solution in which AERAS-402 is formulated.
215019465|NCT02375256|BIOLOGICAL|BCG (1-8 x105 cfu ID)|BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
215019466|NCT02349828|DRUG|Acyclovir|
215019467|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
215019468|NCT01504542|BIOLOGICAL|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
215019469|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
215019470|NCT02003157|PROCEDURE|hypnosis during embryo transfer or usual transfer procedure|
215019471|NCT03955185|PROCEDURE|minimally invasive surgery|Laparoscopic or robotic assisted radical hysterectomy
215019472|NCT03955185|PROCEDURE|open abdominal surgery|Traditional open abdominal radical hysterectomy
215019473|NCT02191397|DRUG|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
215019474|NCT02191397|DRUG|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
215019475|NCT02191397|DRUG|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
215019476|NCT02191397|DRUG|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
215019477|NCT06237764|OTHER|No intervention|No intervention.
215019478|NCT05472181|DEVICE|rTMS (Repetitive TMS)|TMS stimulation produce electromagnetic pulses that can directly changes the neural firing in the brain. The rTMS applies the magnetic pulses in a repetitive manner, and can induce either an inhibitory or excitatory effect on cortical neurons. In this study we use high frequency rTMS (10 Hz) to provide the excitatory effect.
215019479|NCT05472181|BEHAVIORAL|Speech training|The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.
215019480|NCT04928131|OTHER|No intervention - retrospective observational cohort study|
215019481|NCT01113814|DEVICE|FibroScan|
215019482|NCT01113814|DEVICE|Acoustic Radiation Force Impulse (ARFI)- Imaging|
215019483|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.~In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units."
215019484|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat."
215019485|NCT00549211|DRUG|GSK557296|
215019486|NCT05085847|OTHER|Mindfulness meditation training|Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (\> 5 years each) experiences.
215019487|NCT05085847|OTHER|Active control|Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
215019488|NCT04629521|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
215019489|NCT04629521|PROCEDURE|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
215019490|NCT05554224|DIAGNOSTIC_TEST|To propose diagnostic tests for liver diseases before surgical decisions.|Observational although patients are candidates for metabolic surgery.
215019491|NCT02981160|OTHER|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
215019492|NCT06345703|DRUG|Placebo|NS-136 matching placebo
214419356|NCT02967588|BEHAVIORAL|Intervention group|"All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.~Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').~Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients."
214419357|NCT04946045|OTHER|Sensorimotor Interventions (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking)|"Sensorimotor interventions were applied to in preterm infants between 30-33 weeks of age for 10 days. After that, preterms were included in the Six-phase feeding progression protocol."
214419358|NCT04189107|DRUG|Dexamethasone|High-dose dexamethasone peroperative and postoperative on day 2 and 4
214419359|NCT04189107|DRUG|Placebo|low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4
214419360|NCT04994054|DIETARY_SUPPLEMENT|silkworms (Bombyx mori L.) pupae extracts group|silkworms (Bombyx mori L.) pupae extracts 2,400 mg/day for 12 weeks
214419361|NCT04994054|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,400 mg/day for 12 weeks
214419362|NCT05481333|DRUG|REGN7999|Ascending IV or SC dose administered per protocol
214419363|NCT05481333|DRUG|Placebo|Ascending IV or SC dose administered per protocol
214419364|NCT05309980|OTHER|standard of care|retrospective study : standard of care
214419365|NCT04347135|DRUG|F-18 FES|F-18 FES PET/MRI for detection of endometriosis.
214419366|NCT04615299|DEVICE|Auricular acupuncture|Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.
214419367|NCT03437642|BEHAVIORAL|Short Term Psychotherapy|Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
214419368|NCT00371566|DRUG|Lapatinib oral tablets|
215019493|NCT06345703|DRUG|NS-136 tablet|Investigational product NS-136
215019494|NCT06525454|BEHAVIORAL|Personalized coaching messages for blood glucose and emotions|For six weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on blood data from continuous glucose monitors and bi-weekly personalized coaching messages for depression management based on depression questionnaires.
214419369|NCT00371566|DRUG|Placebo|
214419370|NCT02029664|DEVICE|Visual distortion increment based on the gait pattern|
214419371|NCT03321344|DEVICE|Focused Ultrasound Thermal ablation|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
214419372|NCT02009735|DEVICE|virosensor|"virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
214419373|NCT00878722|DRUG|PXD101|
214419374|NCT00878722|DRUG|idarubicin|
214419375|NCT02961127|OTHER|Venous blood was collected|Venous blood was collected by standard vein puncture in fasting condition
215019495|NCT03240445|DRUG|ODM-203 (Period 1)|ODM-203 400mg as tablets taken 30 minutes after food
215019496|NCT03240445|DRUG|ODM-203 (Period 2)|ODM-203 400mg as tablets taken 1 hour before a light breakfast
215102397|NCT01542710|DRUG|Ganfort|Bimatoprost/Timolol fixed combination
214419376|NCT06444386|DEVICE|MPP + SyncAV|Cardiac resynchronization therapy (CRT) features of MultiPoint Pacing (MPP) and SyncAV (dynamic atrioventricular delay programming) enabled.
214419377|NCT02375048|RADIATION|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
214419378|NCT02375048|RADIATION|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
214419379|NCT01813825|OTHER|Registry|
214689951|NCT05347498|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
214419380|NCT00319436|BEHAVIORAL|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
214419381|NCT00319436|BEHAVIORAL|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
214419382|NCT04467788|OTHER|Computer-aided sessions|Changing participants' KAP of ergonomics in dentistry
214419383|NCT04467788|OTHER|Clinical simulation sessions|Changing participants' KAP of ergonomics in dentistry
214419384|NCT01787773|DEVICE|Veniti Inferior Vena Cava Filter|
214419385|NCT04275778|DRUG|Plaquenil 200Mg Tablet|Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery
214419386|NCT04275778|DRUG|Placebo oral tablet|placebo will be taken at a dosage of 400 mg / day until delivery
214419387|NCT04382365|OTHER|Sleep Health Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness|Cognitive-Behavioral Treatment for insomnia (CBT-I) is a non-pharmacological intervention that is effective in treating insomnia in older adults, even when present with comorbid medical and psychological conditions.25 CBT-I focuses on the maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems, and typically consists of five primary treatment components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
214506043|NCT02409043|OTHER|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
214506044|NCT03737110|DRUG|Rilonacept|Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly
215019497|NCT03240445|DRUG|ODM-203 (Periods 3-6)|ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food
214506045|NCT03737110|DRUG|Placebo|Placebo SC injections once weekly
214689952|NCT04761094|DEVICE|Insulin pump|Treatment with continuous subcutaneous insulin infusion
214689953|NCT00685620|BEHAVIORAL|Reinforcement Based Treatment|3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
214689954|NCT00434863|DRUG|botulinum toxin type A|
215019498|NCT02588534|DEVICE|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
215019499|NCT02588534|OTHER|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
215019500|NCT04551924|DRUG|HR18034|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
215019501|NCT04551924|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
215019502|NCT05264584|DRUG|Isotonic saline|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
215019503|NCT05264584|DRUG|N-acetyl cysteine|all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
215019504|NCT05264584|DRUG|Febuxostat 80 MG|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
215019505|NCT02893436|PROCEDURE|Surgery with tracheal intubation curarisation|
215019506|NCT01623284|DRUG|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of \[N-methyl-11C\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
215019507|NCT01623284|DRUG|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
215019508|NCT02831036|OTHER|training program|subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.
215019509|NCT02831036|OTHER|VO2max test|each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
215019510|NCT02831036|OTHER|spatial orientation test|each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
215019511|NCT00163852|DRUG|Normal saline IV, salt tablets|
215019512|NCT02239484|DRUG|Tadalafil|
215019513|NCT02239484|DRUG|Tamsulosin|
215019514|NCT02239484|DRUG|Tadalafil + Tamsulosin|
214419388|NCT01629186|OTHER|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) \<5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) \<80 beats/min or oxygen saturation (SpO2) \<85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
214419389|NCT05619016|DIAGNOSTIC_TEST|[68Ga]Ga-ABY-025 PET|\[68Ga\]Ga-ABY-025 PET: Each patient in Cohort 1 will be imaged with a PET/CT twice using the radiolabeled investigational product ABY-025 as a tracer. At the time of injection, a 45-minutes long dynamic scan will take place over a pre specified region of interest. Three hours after injection a full body PET scan followed by a CT scan will be performed.
214419390|NCT05619016|DIAGNOSTIC_TEST|Biopsy and analysis of HER2 expression|Biopsy: Within 3 days after the first ABY-025-PET a tissue sample from at least one metastasis \>10 mm available for biopsy, preferably shallow lymph nodes, will be analyzed for HER2 expression through immunohistochemistry- (IHC) and in situ hybridization- (ISH) analysis in patients with GEAC and HER2low mBC.
214419391|NCT00362726|DRUG|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
214419392|NCT00362726|DRUG|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
214419393|NCT00362726|DRUG|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
214419394|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
214419395|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
214419396|NCT01527253|OTHER|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
214419397|NCT03951207|DRUG|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
214419398|NCT03951207|DRUG|Rosuampin 20/5mg|Rosuampin 20/5mg qd for 8 weeks
214419399|NCT03951207|DRUG|Amlodipine/Atorvastatin 5/20mg|Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
215019515|NCT00492674|DEVICE|APOS biomechanical gait system|
214419400|NCT00064714|DRUG|AC2993 (exenatide)|Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
214419401|NCT00064714|DRUG|daclizumab (immunosuppressive)|2 mg/kg intravenously infused over 30 minutes every month for 12 months
214419402|NCT01161498|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection
214419403|NCT01161498|RADIATION|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
215019516|NCT00492674|PROCEDURE|Physical Therapy|
215019517|NCT01276418|DEVICE|CO2 laser|Ablation and coagulation of soft tissue
215019518|NCT01512173|DRUG|propranolol gel|Topical administration twice daily
215019519|NCT01512173|DRUG|Placebo|Topical administration twice daily
215019520|NCT03844412|DRUG|5% lidocaine/5 mg/ml 0.02% estradiol compound cream|Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
215019521|NCT03844412|DRUG|Nortriptyline|Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
215019522|NCT03844412|DRUG|Placebo cream|The comparison treatment will be an identical-appearing placebo Moisturel™ cream
215019523|NCT03844412|DRUG|Placebo pill|The comparison treatment will be an identical-appearing placebo pill
215102398|NCT01542710|DRUG|Duotrav|Fixed combination of Travoprost and Timolol
215019524|NCT01618708|DEVICE|Synvisc-One (hylan G-F 20)|6-mL IA injection
215019525|NCT01618708|DEVICE|Placebo|6 mL injection of phosphate buffered saline
215019526|NCT05686252|OTHER|Held Position|Change in angle of held position during kangaroo mother care to alternative angle
215019527|NCT05362136|PROCEDURE|perforation of the sinus floor|perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation
215019528|NCT05362136|PROCEDURE|no perforation of the sinus floor|standard procedure for sinus floor elevation
215019529|NCT03531567|BEHAVIORAL|Virtual Reality Mystic Isle Game|8 week virtual reality based exercise program
215019530|NCT03531567|BEHAVIORAL|Standard Home Exercise Program|8 week standard occupational therapy home exercise program
215019531|NCT02511158|PROCEDURE|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
214419404|NCT01161498|DRUG|Cisplatin|Administered by intravenous infusion
214419405|NCT04677322|DRUG|Adult patients diagnosed and treated for high blood pressure|Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.
214419406|NCT06271304|DEVICE|Blue blocking eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
214419407|NCT06271304|DEVICE|Low filtration eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
214419408|NCT06521892|BEHAVIORAL|social surveillance and health education interventions|"Social surveillance: In the intervention group retail pharmacies posted or hung signs antibiotics need to be purchased by prescription, if found without prescription sales, welcome to call 12315 hotline to report, to form social supervision intervention.~Health education: On-site training for retail pharmacy staff, inviting respiratory physicians and pediatricians to give health education lectures on disease diagnosis, treatment and medication."
214419409|NCT05095246|BIOLOGICAL|KB407 (Nebulization)|Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
214419410|NCT00812526|PROCEDURE|Suction cup application|
215019532|NCT04792970|DRUG|Talc|All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
215019533|NCT03702374|DRUG|Combined antioxidant therapy|It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
214419411|NCT00812526|PROCEDURE|Squatting|
214419412|NCT04476745|DIETARY_SUPPLEMENT|Vitamin D3|Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
214419413|NCT00188604|DRUG|sodium selenite|
214419414|NCT00967512|DRUG|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
214419415|NCT00967512|DRUG|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
214419416|NCT00967512|DRUG|idarubicin, cytarabine|idarubicin, cytarabine
214689955|NCT02330627|BEHAVIORAL|Positive Valence System Treatment|Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
214689956|NCT01794494|PROCEDURE|Bypass surgery|Patients are treated with femoro-popliteal bypass
215019534|NCT03702374|OTHER|Placebo|It consists in a capsule with 100mg of magnesium oxide.
215019535|NCT00449852|BEHAVIORAL|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
215019536|NCT02824549|DEVICE|FreeStyle Libre Flash Glucose Monitoring|
215019537|NCT02554474|BEHAVIORAL|Education, Fitbit/FitViz, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
215019538|NCT02554474|BEHAVIORAL|Same intervention with a 9-week delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 9-week delay.
215019539|NCT03211832|OTHER|Dissemination of public health knowledge|Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
215019540|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks
215019541|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Syrup Orofer (5 ml = 50 mg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral iron 25 mg from Emcure Pharmaceuticals Ltd. to be administered once daily for 24 weeks
214419417|NCT04010318|PROCEDURE|Spinal Anesthesia|The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
214419418|NCT01245452|DRUG|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
214419419|NCT01245452|DRUG|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
214419420|NCT06632132|OTHER|Antimicrobial resistance Training in Hemodialysis Units|"The educational program developed by the researcher is meticulously designed, drawing on extensive insights from the WHO curricula guide (nurses' education and training on antimicrobial resistance; 2019) and the literature review addressed the use of antibiotics and prevention of AMR in hemodialysis facilities. The curriculum, using simple English, provides a broad set of learning objectives tailored to the expected roles of nurses.~The education program includes four main modular outline:~1. Foundations that build awareness of antimicrobial resistance~2. Appropriate use of antimicrobial agents~3. Infection prevention and control~4. Diagnostic stewardship and surveillance~The educational material was sent by a study researcher (X) to the WhatsApp number for all members of the experimental group via Chatbot software, which was designed by software engineer. The educational materials were sent in the form of written materials, photos, and videos."
214689957|NCT01794494|PROCEDURE|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
214689958|NCT03591146|DRUG|TLC590|TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
214689959|NCT03591146|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
214689960|NCT02572830|BEHAVIORAL|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
214689961|NCT02572830|BEHAVIORAL|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
214689962|NCT02934048|OTHER|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
214419421|NCT01544062|DRUG|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
214419422|NCT01544062|DRUG|Placebo|Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
214419423|NCT01548846|RADIATION|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
214419424|NCT01304342|DRUG|Remifentanil|1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
214419425|NCT01304342|DRUG|Fentanyl|Intranasal fentanyl 200 micrograms 5 min before the ERCP
214419426|NCT01304342|DRUG|Normal saline|Normal saline intravenously and intranasally
214419427|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
214419428|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
214419429|NCT02807493|DEVICE|Occlusal Support Device|Bite plate
214506046|NCT05407051|BEHAVIORAL|Family Centered Treatment|In the Family-Centered Treatment Arm, parents would be given the same list of mental health referrals and crisis numbers, but in this condition, they would authorize researchers to share their contact information with the partner agency, Catholic Charities, and would then be linked directly to bilingual adult mental health services there with a behavioral health provider who would provide collateral therapy to parents via telehealth. Although parents will be referred to the community partner for therapy as a part of the research intervention, the behavioral health providers at the community partner will be providing therapy as they usually do for these participants in line with their usual job duties.
214689963|NCT02934048|OTHER|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
215019542|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Tablet Tayo (60000 IU)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral vitamin D3 (60000 IU) from Eris Lifesciences Ltd to be administered once in 3 months for 24 weeks
214689964|NCT02934048|OTHER|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
214689965|NCT06505057|OTHER|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation
215019543|NCT05675293|DEVICE|IONTOPHORESIS|The process of increasing the penetration of drugs into the skin by application of an electric current
215019544|NCT05675293|DRUG|ORAL ANTIBIOTIC|Oral Antibiotic
215019545|NCT01766089|DRUG|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
215019546|NCT01766089|DRUG|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
215019547|NCT04171869|OTHER|no intervention|observational study, no intervention
215019548|NCT03272165|DRUG|MEDI1341|Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
215019549|NCT03272165|DRUG|Placebo|Participants will receive IV infusion of placebo matched to MEDI1341.
215019550|NCT02770365|DRUG|estrace cream (Perrigo)|
215019551|NCT02770365|DRUG|estrace cream (Reference)|
215019552|NCT02770365|DRUG|Placebo cream|
214419430|NCT02807493|OTHER|Control|Control group
214419431|NCT00873899|DEVICE|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
214419432|NCT02590913|DIETARY_SUPPLEMENT|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
214419433|NCT02590913|DIETARY_SUPPLEMENT|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
214419434|NCT02729272|PROCEDURE|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
214419435|NCT02729272|PROCEDURE|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
214419436|NCT02729272|DEVICE|Monopolar ESD|
214419437|NCT02729272|DEVICE|Ultrasonic ESD|
214419438|NCT05928819|PROCEDURE|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
214419439|NCT05437783|DRUG|Azithromycin Dihydrate|exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
214419440|NCT00212056|DRUG|ANP(hANP)|0∙025 μg/kg per min for 3 days(intravenous)
214419441|NCT00212056|DRUG|Control|placebo
214419442|NCT03441048|BIOLOGICAL|Lintuzumab-Ac-225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of relapsed/refractory acute myeloid leukemia.
214419443|NCT03441048|DRUG|Cladribine|Cladribine is a purine antimetabolite.
214419444|NCT03441048|DRUG|Cytarabine|Cytarabine is an antineoplastic anti-metabolite.
214419445|NCT03441048|DRUG|Mitoxantrone|Mitoxantrone is an anthracenedione antineoplastic agent.
214419446|NCT03441048|DRUG|G-CSF|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.
214419447|NCT00005813|BIOLOGICAL|bispecific antibody MDX447|
214419448|NCT00005813|BIOLOGICAL|lymphokine-activated killer cells|
214419449|NCT00005813|PROCEDURE|conventional surgery|
214419450|NCT03417843|DEVICE|EUSRA RF electrode|"At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces"
214419451|NCT03873324|DRUG|CPL500036 compound|IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
214419452|NCT03873324|DRUG|Placebo|matching placebo capsules
214419453|NCT01343654|BEHAVIORAL|Text messaging plus EMA|Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
214419454|NCT01343654|BEHAVIORAL|Treatment as usual|usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
214419455|NCT03526120|OTHER|Pistachio|Dailly 44 g unsalted pistachios snack for 12 weeks
214419456|NCT01203553|PROCEDURE|Abdominal surgery|Intraoperative mesh implantation
214419457|NCT00387361|PROCEDURE|Osteopathic Manipulative Treatment|20 minute post-operative osteopathic manipulation as described in the protocol
214419458|NCT04083651|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
214419459|NCT04083651|DRUG|Placebo|Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
214419460|NCT02781584|DRUG|SEL|Administered orally once daily
214419461|NCT02781584|DRUG|FIR|Administered orally once daily
214419462|NCT02781584|DRUG|CILO|Administered orally once daily
214419463|NCT02781584|DRUG|FENO|Administered orally once daily
214419464|NCT02781584|DRUG|VAS|Administered orally two times daily
214419465|NCT01267409|OTHER|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
214419466|NCT04973852|DEVICE|Ekso|Exoskeleton walking
214419467|NCT05255718|DIETARY_SUPPLEMENT|Aronia juice|Once daily dose of 100 mL of aronia juice
214419468|NCT05255718|OTHER|Placebo|Once daily dose of 100 mL of placebo juice containing no polyphenols and matched to experimental Aronia juice in color, taste, and macronutrient content
214419469|NCT04842669|OTHER|low level laser therapy|Endo-laser 422 with interchangeable laser probes will be used for the purpose. It is a 2-channel unit and is software operated. For treatment of small surfaces with mono laser there are diodes of 25, 100 and 500 milliWatt.Frequency will be adjusted to 500 Hz, dose 0.1/cm2 with time duration of 1-5 minutes.
214419470|NCT04842669|OTHER|Conservative treatment|(Topical ibuprofen gel) for muscle soreness will be provided
214419471|NCT01400750|DRUG|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
214419472|NCT01400750|DRUG|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
214419473|NCT03103971|BIOLOGICAL|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
214419474|NCT03103971|DRUG|Cyclophosphamide|Given IV
214419475|NCT03103971|DRUG|Fludarabine|Given IV
214419476|NCT03103971|OTHER|Laboratory Biomarker Analysis|Correlative studies
214419477|NCT03103971|PROCEDURE|Leukapheresis|Undergo leukapheresis
214419478|NCT03103971|OTHER|Pharmacological Study|Correlative studies
214419479|NCT03611530|DEVICE|Coqun® ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Coqun® ophthalmic solution
214419480|NCT03611530|OTHER|Placebo ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Placebo ophthalmic solution
214419481|NCT05602909|DEVICE|Guided biaxial alveolar distraction device|A crestal incision will be done, a surgical guide will be placed to assist the correct position of osteotomy, an Extraosseous alveolar distractor will be placed on the ridge to mark screw sites and then will be removed, A distractor will be stabilized to the basal segment with a monocortical screw.
214419482|NCT00819442|PROCEDURE|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
214419483|NCT05061524|DRUG|YH35324|Subcutaneous injection of YH35324
214419484|NCT05061524|DRUG|Placebo|Subcutaneous injection of None of active ingredient
214419485|NCT05061524|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
214419486|NCT02930590|OTHER|Alternating low pressure mattress with air loss function|IsoAir, Stryker, USA
214419487|NCT02930590|OTHER|Gel mattress|IsoGel, Stryker, USA
215019553|NCT03339765|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
215019554|NCT04316650|BEHAVIORAL|Evaluation Scales|"* PATHOS / PEACCE : hypersexuality diagnostic scale~* PDQ-4+: Personality Diagnostic Questionnaire version 4~* AUDIT~* Life trajectory : THQ~* Cognitive function (MoCA, Stroop)~* ISDSS: and self report of sexual activity and desire~* BARS: Brief Adhesion Rating Scale (treatment observance)~* SF-36 scale : quality of life~* BDI-II : Beck Depression Inventory~* BSSI ; Beck suicidal Inventory~* Cognitive functioning evaluation : Molest and Rape Scale~* Empathy: EMPAT~* Evaluation of Cognitive functioning: denial evaluation and Mc Kibben minimization~* Baratt Impulsivity Scale~* CSBI~* Static 99 and Stable 2007"
215019555|NCT04316650|OTHER|osteodensitometry|Osteodensitometry
215019556|NCT04316650|BIOLOGICAL|blood samples|"* Lipid profile (total cholesterol, triglycerides, HDL cholesterol)~* Liver function (ASAT, ALAT, total bilirubin, transferase gamma-glutamyl et alcalin phosphatases~* Kydney function~* Blood count~* Biological Measurements and Measurement of Systematic Plasma Testosterone and TeBG Levels in Sex Offenders check for pathology of the Gonadotropin Axis~* Biological Measurements of Plasma Prolactin level"
215019557|NCT04316650|OTHER|ECG|ECG (heart rate, search for cardiac conduction disorders or cardiac arrhythmias)
215019558|NCT04316650|GENETIC|Blood and saliva samples|Blood and saliva samples
215019559|NCT02991859|DRUG|Fluticasone furoate (FF) Dry Powder Inhaler|Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
215019560|NCT02991859|DRUG|Fluticasone propionate (FP) Dry Powder Inhaler|Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
215019561|NCT02991859|DRUG|Budesonide (BUD) Turbuhaler|Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
215019562|NCT02991859|DRUG|Placebo (ELLIPTA or DISKUS)|Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
215102399|NCT04195217|BEHAVIORAL|Art therapy|"When the patient is placed in a treatment room, a nurse or the ARC proposes to complete the questionnaires corresponding to his visit in accordance with the diagram of the investigations, then retrieve the questionnaire and forward it to the art therapist Then, the art therapist intervenes ans propose different Artistic supports : paint, watercolor pencils, pastels, pencils, clay , origami, music in as an accompaniment to artistic creation.~The workshop runs from 30 minutes to 2:30. It can be cut by doctors and nurses interventions during medical care. The limit of care is set at 2:30 for reasons of concentration of the patient, organization of the service but the patient is an actor of his care, and chooses when the session ends.~At the end of intervention, the nurse or the ARC proposes at patient to complete the end questionnaire. Theses last are retrieve it and to forward it to the art therapist."
215102400|NCT00668837|DRUG|Paliperidone|
214419488|NCT02930590|OTHER|Basic foam|Standard hospital mattress
214419489|NCT05447013|BIOLOGICAL|Coronavirus-2-specific T cells|Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors
215102401|NCT03833219|BEHAVIORAL|Weekly feedback|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week.
215102402|NCT03833219|BEHAVIORAL|End of intervention period incentive|Notify participant about potential incentive at the end of the intervention period, but do not provide weekly feedback about performance.
214419490|NCT05447013|OTHER|standard of care (SOC)|standard of care (SOC)
214419491|NCT03764943|DIETARY_SUPPLEMENT|Impact Advanced Recovery|immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
214419492|NCT00001994|DRUG|Atovaquone|
214506047|NCT05407051|BEHAVIORAL|Treatment as Usual|"All participants (parents) would receive follow-up calls from a MetroHealth research personnel at 3 months and 6 months to measure changes in parent mental health outcomes, as well as satisfaction.~Children of parents in both conditions will receive treatment as usual which includes brief consultation for 3-5 sessions with an integrated MetroHealth behavioral health provider which is already standard practice in the clinic. Sessions typically occur monthly. Teens will be re-administered the Patient Health Questionnaire -9 by the integrated behavioral health provider as a part of clinical practice to measure treatment progress and this information will be obtained at the end of 6 months of treatment via chart review (see data sheet). Repeated measurement of patient's symptoms over the course of several months of treatment is common in clinical practice to measure patient's symptom improvement."
215019563|NCT05835596|DEVICE|Access to MumCare app|Education, push warning to book cardiovascular health follow-up at own general practitioner , registration of BP and lipids, HbAc
215019564|NCT03674450|BEHAVIORAL|Heart Rate Variability Biofeedback Training|The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
214506048|NCT05697536|OTHER|Pilates training|"It consists of patients who will receive pilates exercise training sessions 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercise programs follow the basic principles of pilates method but particularly movements with low and medium difficulty levels will be chosen to adapt the program to the physical capacity of the patients.~Protocol will be compromise of 9 modules: postural education, search for neutral position, sitting exercise, antalgic exercise, stretching exercises, proprioceptively improvement exercises and breathing exercises."
214506049|NCT05697536|OTHER|Aerobic Exercise|"It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 45 minutes.~It will include warm up phase, active phase and"
214689966|NCT04737031|OTHER|Clinician Nudge|"Investigators will use the Best Practice Alert functionality within the EMR as the conduit to the point of decision-making. Epic currently fires a BPA for each new patient presenting to ACC within the Medical Assistant check-in and vital sign workflow, requiring that medical assistants assess tobacco use status within the past 30 days and satisfy the alert with one of three possible answers. Upon opening the Epic Order tab at a patient's next visit after the screening encounter, clinicians will receive the implementation strategy, placed directly over the order interface. The clinician will be required to acknowledge or opt-out when presented with the order. Opting-out will require clinicians to acknowledge a reason for opt-out using a checklist or free text."
215019565|NCT03763266|OTHER|1 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
215019566|NCT03763266|OTHER|3 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
215019567|NCT03320083|BEHAVIORAL|Educational care derived from POSSUMS|Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
215019568|NCT05259540|DRUG|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
215019569|NCT01584297|DRUG|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
215102403|NCT03833219|BEHAVIORAL|Loss-framed weekly incentive|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week. Pay participant weekly according to where they fall on the distribution each week.
215019570|NCT06082817|DRUG|Oral Testosterone Undecanoate|50mg oral testosterone undecanoate daily
215102404|NCT00644488|DRUG|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
215102405|NCT01450098|DRUG|LY2484595 Reference Formulation (RF)|Administered orally
215102406|NCT01450098|DRUG|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
215102407|NCT01905878|DRUG|DLBS1033|
215102408|NCT02470481|OTHER|No Intervention|This is an obervational study
214506050|NCT01619319|OTHER|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
215102409|NCT02277925|OTHER|Polytetrafluoroethylene|Suture used to attach mesh during sacral colpopexy surgery
214506051|NCT01619319|OTHER|computer games|computer games that that consist of word puzzles
214506052|NCT04696016|PROCEDURE|Skin conductance guided antinociception|The value of skin conductance guides the titration of sufentanil
214506053|NCT04696016|PROCEDURE|Standard care antinociception|The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
214506054|NCT05967130|BIOLOGICAL|Phage|Inserting specific specimen of phages in to the bladder
214506055|NCT04397185|DEVICE|Breast Cancer Locator (BCL) guided partial mastectomy|The BCL is a patient-specific, plastic, bra-like form which is placed on the breast to localize the tumor during surgery.
214506056|NCT04397185|DEVICE|Wire Localized (WL) partial mastectomy|Standard of care procedure
214506057|NCT01179100|DRUG|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
214506058|NCT06435481|DRUG|3D printed chewable formulation of hydrocortisone|Administration of a novel hydrocortisone formulation provided as chewable tablets. Each tablet, manufactured with a volume dosing device (3D printer), contains a precise dosage of hydrocortisone.
215102410|NCT02277925|OTHER|Polydioxanone|Suture used to attach mesh during sacral colpopexy surgery
215102411|NCT00257361|DRUG|D-Cycloserine|
215102412|NCT01986608|DRUG|Lacosamide infusion|"Strength: 10 mg/mL for infusion~Form: solution for infusion~Dosage: 200 mg, single dose~Duration: 30-minute infusion or 60-minute infusion"
215102413|NCT01986608|DRUG|Lacosamide oral|"Strength: 200 mg~Form: film-coated tablet~Dosage: 200 mg, single dose~Duration: single oral intake"
215102414|NCT01272635|DRUG|Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
215102415|NCT01272635|DRUG|Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
215102416|NCT01272635|OTHER|Placebo Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
215102417|NCT01272635|DRUG|Placebo Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
214419493|NCT02095704|DRUG|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
214419494|NCT02095704|DRUG|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
214419495|NCT01123083|BIOLOGICAL|Otelixizumab|infusion
214419496|NCT01123083|BIOLOGICAL|Placebo|Infusion
214419497|NCT01117441|DRUG|PEG-L-asparaginase|see detailed protocol description
214419498|NCT01117441|DRUG|cyclophosphamide|see detailed protocol description
214419499|NCT01117441|DRUG|cytarabine|see detailed protocol description
214419500|NCT01117441|DRUG|daunorubicin hydrochloride|see detailed protocol description
214419501|NCT01117441|DRUG|dexamethasone|see detailed protocol description
214419502|NCT01117441|DRUG|doxorubicin hydrochloride|see detailed protocol description
214419503|NCT01117441|DRUG|etoposide|see detailed protocol description
214419504|NCT01117441|DRUG|ifosfamide|see detailed protocol description
214419505|NCT01117441|DRUG|mercaptopurine|see detailed protocol description
214689967|NCT04737031|OTHER|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status (at the screening encounter). In all cases, the message will include information specific to the upcoming appointment with the oncology clinician.
214689968|NCT04323748|DRUG|rituxan|"The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2"
214689969|NCT00236639|DRUG|topiramate|
214689970|NCT01433627|OTHER|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
214689971|NCT01433627|OTHER|trans-radial and long-term bivalirudin infusion|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
215029040|NCT06559241|DEVICE|30-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 30 days post-thrombectomy.
214419506|NCT01117441|DRUG|methotrexate|see detailed protocol description
214419507|NCT01117441|DRUG|prednisone|see detailed protocol description
214419508|NCT01117441|DRUG|thioguanine|see detailed protocol description
214419509|NCT01117441|DRUG|vincristine sulfate|see detailed protocol description
214419510|NCT01117441|DRUG|vindesine|see detailed protocol description
214419511|NCT01117441|DRUG|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
214419512|NCT01117441|DRUG|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
214419513|NCT01117441|RADIATION|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
214419514|NCT02347163|DRUG|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
214419515|NCT00159796|DRUG|Asenapine|Asenapine, 3 weeks
214419516|NCT00159796|DRUG|Olanzapine|Olanzapine, 3 weeks
214419517|NCT00159796|DRUG|Placebo|placebo, 3 weeks
214419518|NCT02584153|DRUG|Fibrin Sealant|TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
214419519|NCT02584153|DRUG|Silver Microparticles|Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
214419520|NCT00612391|PROCEDURE|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
214506059|NCT06435481|DRUG|Oral suspension of hydrocortisone|Administration of a standard hydrocortisone oral suspension. The solution, based on simple syrup, contains 1mg of hydrocortisone per milliliter.
214506060|NCT02431442|DRUG|RM-493|
214506061|NCT02431442|DRUG|Placebo|
214506062|NCT00669474|PROCEDURE|Suction curettage|Suction curettage
214506063|NCT00669474|DRUG|Treatment with Botox|Treatment with Botox
214506064|NCT03028805|OTHER|Automatic inclusion of COPD orders in admission orders|Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.
214506065|NCT03028805|OTHER|Dynamic, end-user order set design|Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
214506066|NCT03438565|DEVICE|Asahi Chikai Black 18 neurovascular guidewire|"The Asahi Chikai Black 18 microguidewire employs a reverse tapered shaft with 0.018 tip and 0.014 proximal shaft, which provides additional support and tactile feedback."
214506067|NCT05109598|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).
214419521|NCT00612391|PROCEDURE|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
214419522|NCT05097781|DRUG|PD-1 blocking antibody|All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
214419523|NCT02197299|DIETARY_SUPPLEMENT|L-carnitine|
214419524|NCT02197299|DIETARY_SUPPLEMENT|Placebo|
214419525|NCT02060019|DRUG|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
214419526|NCT00908336|DRUG|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
214419527|NCT00908336|DRUG|Erlotinib|150 mg/day po daily
214419528|NCT05923008|DRUG|IBI130|Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
214419529|NCT01970748|DRUG|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
214419530|NCT01970748|PROCEDURE|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
214419531|NCT03958513|DRUG|Bupivacaine|1.5 ml 0.25% bupivacaine for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
214419532|NCT03958513|DRUG|0.9% normal saline|1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
214419533|NCT04117724|OTHER|Survey|Patients will be asked to complete a 4 question survey assessing adherence. Follow up via patient's preferred method of contact will be conducted after the patient's intended antibiotic completion date and covariates for antibiotic regimens will be recorded including antibiotic type, number of doses, antibiotic duration, reason for non-adherence, pills remaining, and number of other medications.
214419534|NCT00861510|DRUG|ON01910 Na|
214419535|NCT00639015|DRUG|Phenylephrine|Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
214419536|NCT00639015|DRUG|Norepinephrine|Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
214419537|NCT00005890|DRUG|corticotropin|
214419538|NCT03922243|OTHER|retrospective|Retrospective study to assess treatment done by dental students
214419539|NCT04231474|DEVICE|Urodynamic testing|All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
214419540|NCT05852366|DRUG|Toothpaste Preparation|Dentifrice for management of dentinal hypersensitivity
214419541|NCT00366873|PROCEDURE|Calcium absorption|formula with or without prebiotics
214419542|NCT02729701|DRUG|Duavee|Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
214419543|NCT02888249|OTHER|Altered composition cigarette|This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.
214419544|NCT05433935|OTHER|Observation|This is an observational study.
214419545|NCT02385669|DRUG|Ipilimumab|Checkpoint blockade inhibitor
214419546|NCT02385669|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
214419547|NCT02875938|BEHAVIORAL|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
214419548|NCT02875938|BEHAVIORAL|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
214419549|NCT02875938|BEHAVIORAL|Control|control condition using reading materials without music.
214419550|NCT04330768|PROCEDURE|PRF pulp capping|PRF is injected in the site of exposure
214419551|NCT04330768|PROCEDURE|MTA pulp capping|conventional pulp capping procedure
214419552|NCT03973944|DEVICE|Cardiac resynchronization therapy|Atrio-biventricular pacing to shorten the prolonged PR interval
214419553|NCT02810080|DEVICE|Closed Loop Control Ventilation|Closed loop control ventilation using ZOLL 731 ventilator with physiologic closed-loop control software
214419554|NCT02810080|DEVICE|Manual Control Ventilation|Manual control ventilation using ZOLL 731 ventilator
215019571|NCT03607786|PROCEDURE|Retrograde Inferior Vena Caval Perfusion|Retrograde Inferior Vena Caval Perfusion is achieved by tethering the inferior vena cava with a band around the cannula and by clamping the distal end of the inferior vena cava drainage tube, which allowed a pump to drive oxygenated blood into the inferior vena cava. Pump pressure is maintained at 20-30 mmHg, and blood flow is maintained at 8-12 mL/min/kg. The aim of RIVP is to maintain the lower body perfusion during circulation arrest, and reduce the ischemia-associated vital organ injury.
215019572|NCT03607786|PROCEDURE|Select antegrade cerebral perfusion|Antegrade cerebral perfusion is achieved using a 12 F cannula inserted into the brachiocephalic artery or right axillary artery. The antegrade perfusion flow rate is maintained at 6-12 mL/min/kg
215019573|NCT00002461|BIOLOGICAL|filgrastim|
214506068|NCT01738698|DRUG|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
214506069|NCT01738698|DRUG|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
214506070|NCT01738698|DRUG|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
214506071|NCT01738698|DRUG|Placebo|Oral administration once-daily for 12 weeks
214506072|NCT02575365|DRUG|0,5 mg Fingolimod|0.5 mg p.o fingolimod daily
214506073|NCT03392194|BEHAVIORAL|Sleep hygiene intervention|The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.
215019574|NCT00002461|BIOLOGICAL|sargramostim|
215019575|NCT00002461|DRUG|carmustine|
215019576|NCT00002461|DRUG|cisplatin|
215019577|NCT00002461|DRUG|cyclophosphamide|
215019578|NCT00002461|DRUG|etoposide|
215019579|NCT00002461|PROCEDURE|autologous bone marrow transplantation|
215019580|NCT00002461|PROCEDURE|in vitro-treated bone marrow transplantation|
214506074|NCT03392194|BEHAVIORAL|Yoga intervention|Following the SH intervention, participants randomized to the SH+Y arm will participate in 8 weekly beginner level yoga classes. Classes will increase participants' skill and comfort with yoga postures and relaxing breathing exercises so that participants can adopt an evening yoga practice (10 weeks).
214506075|NCT03865732|DRUG|Ganaxolone|active drug
214506076|NCT03865732|DRUG|Placebo|inactive
214419555|NCT00588302|DRUG|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
214419556|NCT05964231|DIETARY_SUPPLEMENT|Heat-treated PS23|Lactobacillus paracasei PS23 heat-treated, 2caps daily use
214419557|NCT05964231|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, 2caps daily use
214419558|NCT00360386|DRUG|Clopidogrel|
214506077|NCT01928875|DEVICE|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
214506078|NCT01928875|DEVICE|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
214506079|NCT04661774|OTHER|reflexology massage|reflexology massage of the foot zone implicated in diaphragm stimulation
214506080|NCT04661774|OTHER|sham massage|traditional massage of the foot
214506081|NCT02345551|BEHAVIORAL|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
215019581|NCT00002461|PROCEDURE|peripheral blood stem cell transplantation|
215019582|NCT00002461|RADIATION|radiation therapy|
215019583|NCT03825666|OTHER|ProvideXtra® Fresenius Kabi|Improving wellbeeing
215019584|NCT06103799|BEHAVIORAL|IMB model-based continuity of care|The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.
215019585|NCT01065766|DRUG|Sitagliptin/metformin|Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
215019586|NCT00712075|BEHAVIORAL|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
215019587|NCT00712075|BEHAVIORAL|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
215029041|NCT06559241|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy procedures are performed according to the guidelines to recanalize the occluded large vessel safely.
214419559|NCT01790529|PROCEDURE|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)|
214689972|NCT01433627|OTHER|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
214419560|NCT01790529|PROCEDURE|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)|
214419561|NCT01365208|DRUG|Chemotherapy|platinum-based chemotherapy
214419562|NCT03248271|DRUG|Insulin Lispro|Insulin
214419563|NCT05061641|DRUG|Progesterone|The delivery outcomes of the three groups were compared, including the rate of premature delivery (\<37 weeks of gestation), the rate of early premature delivery (\<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (\<37 weeks), neonatal perinatal mortality and morbidity.
214419564|NCT03597100|DEVICE|Cala TWO|Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
214419565|NCT05257798|DRUG|IFN-β inhibitor treatment|PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
214419566|NCT05257798|OTHER|Placebo|Placebo for PF-06823859, 0 mg/mL solution for injection
214689973|NCT01433627|OTHER|Trans-femoral and Short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
214689974|NCT01433627|OTHER|trans-femoral and long-term bivalirudin infusion|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
215019588|NCT00712075|BEHAVIORAL|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
215019589|NCT02268305|DRUG|MSM 1000mg twice a day (6000 mgs)|MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
215019590|NCT02268305|OTHER|Placebo capsules twice a day|Placebo is a capsule filled with rice flour.
215019591|NCT00908908|DRUG|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m\^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
215019592|NCT04223687|OTHER|Sugar-Sweetened Beverage Warning Label|Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.
215019593|NCT04223687|OTHER|Neutral label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
215019594|NCT03004677|BEHAVIORAL|Continuous skin-to-skin contact|Infants will rest in skin-to-skin contact on parents' chest 24 hours a day alternating between the parents. The parents will note who provides the SSC and if and for how long they are off SSC for any reason.
214419567|NCT01685528|BEHAVIORAL|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
214419568|NCT05939063|PROCEDURE|LRAMPS|For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
214419569|NCT05939063|PROCEDURE|LDP|For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
214506082|NCT03863405|DRUG|Metformin|metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
214506083|NCT03863405|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
214506084|NCT03863405|DRUG|Placebo Oral Tablet|oral tablet
214506085|NCT02517385|DRUG|Phosphatidylcholine|Pharmaceutical form:Paste Route of administration: Oral
215019595|NCT03004677|OTHER|Standard Care|Infants will receive regular care in the NICU. Parents may practice SSC if they like. Parents will note if, with whom, and for how long they provide SSC.
215019596|NCT02787174|OTHER|Asthma Medication Adherence Education|
215019597|NCT05522829|BIOLOGICAL|SCTV01E-1 on D0|Day 0; intramuscular injection
215019598|NCT05522829|BIOLOGICAL|SCTV01E-1 on D28|Day 28; intramuscular injection
215019599|NCT05522829|BIOLOGICAL|SCTV01E-1 on D150|Day 150; intramuscular injection
215019600|NCT05522829|BIOLOGICAL|SCTV01E on D0|Day 0; intramuscular injection
215019601|NCT05522829|BIOLOGICAL|SCTV01E on D28|Day 28; intramuscular injection
215019602|NCT05522829|BIOLOGICAL|SCTV01E on D150|Day 150; intramuscular injection
215019603|NCT05522829|BIOLOGICAL|SCTV01E-1 on D120|Day 120; intramuscular injection
215019604|NCT05522829|BIOLOGICAL|SCTV01E on D120|Day 120; intramuscular injection
214419570|NCT02073123|DRUG|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~* If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~* If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~* If \> 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~* If \>1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If \>1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
214419571|NCT02073123|DRUG|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
214419572|NCT02073123|DRUG|Nivolumab|Nivolumab administered intravenously at 240 mg every 2 weeks.
214419573|NCT02073123|DRUG|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
214419574|NCT05414786|BIOLOGICAL|eOD-GT8 60mer mRNA Vaccine (100µg)|"* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~* No control group. There is no blinding and no randomization in this open label study"
214419575|NCT02550197|BIOLOGICAL|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
214419576|NCT02550197|BIOLOGICAL|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
214419577|NCT00131144|DRUG|Octreotide Acetate in Microspheres 20 mg|
214419578|NCT00131144|DRUG|Octreotide Acetate in Microspheres|
214419579|NCT00131144|DRUG|Placebo|
214419580|NCT04940117|DIETARY_SUPPLEMENT|Eefooton oral solution|Check eGFR value, liver and kidney function every month
214419581|NCT02504086|BEHAVIORAL|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
214419582|NCT00419094|DRUG|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
214419583|NCT00419094|DRUG|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
214419584|NCT06427486|OTHER|Parents Telecoaching Intervention|\- Synchronous (Zoom platform) and Asynchronous coaching sessions for parents of children with autism.
215019605|NCT02277366|PROCEDURE|Fluorescence Bronchoscopy/Narrow Band Bronchoscopy|Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
215019606|NCT00490412|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
215019607|NCT00490412|OTHER|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
215102418|NCT03853863|BEHAVIORAL|in-school walking training with minimalist shoes|Participants in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks. Similar to previous minimalist footwear studies, the intervention duration will be gradually increased over the 12-week training. In brief, subjects will wear the minimalist shoes for 1 out of 5 school days at the first week; 2 days at the second week, and so on until fully use of the minimalist shoes at the fifth week.
215102419|NCT03853863|BEHAVIORAL|in-school walking training with protective shoes|Participants in the TSW group will be given a pair of given a pair of protective shoes with arch support for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks,while follow the same wearing pattern as the MSW group.
215019608|NCT00425854|DRUG|BIBW 2992|high dose once daily
215102420|NCT06069947|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
215102421|NCT05359835|DRUG|Calcium DTPA and Zinc DTPA|Intravenous administration of 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by 900 mL of normal saline infusion over about 90 minutes, followed by 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by infusion of the remaining 100 mL of normal saline over about 10 minutes. Procedure repeated with Zn-DTPA the following day. Two-day procedure repeated at an interval of one week or more for a total of six 2-day treatment sessions.
215102422|NCT02751476|OTHER|Point of Use (PoU) water treatment flocculent disinfectant.|A household level point of use water treatment of a flocculent disinfectant will be tested.
215102423|NCT02751476|OTHER|Point of Use (PoU) water treatment chlorine disinfectant|A household level point of use water treatment of a chlorine disinfectant will be tested.
215102424|NCT02751476|DEVICE|Point of Use (PoU) ceramic water filter|A household level point of use water treatment of a ceramic water filter will be tested.
215102425|NCT02751476|OTHER|Standard Severe Acute Malnutrition Treatment|Standard CMAM treatment.
215102426|NCT05627024|DRUG|30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
214419585|NCT01551407|DRUG|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
214419586|NCT06131359|DIAGNOSTIC_TEST|Fine wire EMG and Force Frame muscle strength testing|Insertion of fine wires for EMG study of tibialis posterior and assessment of muscle strength using a force frame
214419587|NCT06222918|PROCEDURE|Deep Margin Elevation (G-ænial Universal Injectable)|Deep margin elevation (DME), or coronal margin relocation (CMR), is a procedure used to raise or reposition sub-gingival margins into supra-gingival margins using several materials to increase marginal integrity and bonding strength
214419588|NCT00989937|DRUG|Oxytocin|20 IU BID or 40 IU BID
214419589|NCT00989937|DRUG|Placebo|20 IU BID or 40 IU BID
214419590|NCT01965119|DRUG|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
214419591|NCT01900834|OTHER|No treatment given|The participants will not receive any treatment
214419592|NCT02937792|DRUG|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
214419593|NCT02034916|DRUG|talazoparib|
214419594|NCT06297135|BEHAVIORAL|Behavioral Parent Training|Teaches parents antecedent- and reinforcement-based behavior management techniques and provide support to manage their stress
214419595|NCT03131206|DRUG|Alectinib|"* Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."
214506086|NCT04973306|PROCEDURE|Neoadjuvant Chemoradiotherapy|"Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.~Radiotherapy: A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 days per week (Radiotherapy was performed on the 2nd, 3rd, 4th, 5th, and 6th day in each cycle, and only 3 times in the 5th cycle)"
214506087|NCT04973306|DRUG|Tislelizumab|"Tislelizumab (200mg/time) was administered intravenously on the 1st and 22nd day.~The intravenous injection lasts about 30 minutes (micropump is recommended, intravenous bolus is prohibited, duration should be not less than 20 minutes and not more than 60 minutes);"
215019609|NCT03535519|DRUG|Methotrexate|standard of care treatment with methotrexate
215019610|NCT00202852|OTHER|Placebo|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
215019611|NCT00202852|DRUG|MTX|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
215019612|NCT00202852|BIOLOGICAL|Infliximab|Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
215019613|NCT00202852|DRUG|MTX|3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
215019614|NCT01505803|DIETARY_SUPPLEMENT|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
215019615|NCT01505803|DIETARY_SUPPLEMENT|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
215019616|NCT01505803|DIETARY_SUPPLEMENT|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
215019617|NCT03814629|DRUG|Weifuchun|The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
215019618|NCT02042144|DRUG|Stivarga (Regorafenib, BAY73-4506)|Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
215019619|NCT03944876|DRUG|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
215019620|NCT03944876|DRUG|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
215019621|NCT06964516|PROCEDURE|The group using the whole-breast bandaging method|Use 1 to 2 pieces of sterile loose gauze to knead into a gauze ball, press it on the residual cavity. Then, continue to use 5 to 8 pieces of loose gauze to stack gauze balls within a diameter of 5 cm around the wound for bandaging. Finally, apply compression bandaging with an elastic bra. The time for compression bandaging with the elastic bra is 24 hours.
215029042|NCT06559241|DRUG|Best medical management|Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.
215029043|NCT03110510|DRUG|Fluorouracil|5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
214419596|NCT04019509|DIAGNOSTIC_TEST|blood test|blood test for thyroid antibodies and thyroid function (TSH, FT4)
214419597|NCT04019509|OTHER|follow up treatment outcome|questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery
214419598|NCT00189969|BIOLOGICAL|Elstree-BN|
214419599|NCT04946487|PROCEDURE|total laminectomy|Total laminectomy removes the posterior ligamentous complex (PLC) at the fusion and superior levels.
214419600|NCT02520856|OTHER|blood sample|
214419601|NCT01616654|DRUG|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
214419602|NCT01616654|DRUG|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
214419603|NCT01616654|DRUG|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
214419604|NCT01616654|DRUG|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
214419605|NCT01616654|DRUG|Vehicle cream|Vehicle cream applied once daily
214419606|NCT04750850|OTHER|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
215019622|NCT06964516|PROCEDURE|The group using the local bandaging method|Knead one or two pieces of loose gauze into a gauze ball to replace multiple gauze balls and place it in the residual cavity. Then, use elastic medical adhesive tape for local compression and sticking. Finally, place a pure cotton clean towel inside the elastic bra and wear the elastic bra for just one day.
214506088|NCT04973306|PROCEDURE|Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)|After neoadjuvant therapy, patients in groups receive Ivor-Lewis or Mckeown Esophagectomy (Mckeown Esophagectomy recommended)
215019623|NCT06964230|DRUG|T3D-959|"Experimental:~T3D-959 30 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength capsules contain 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest two size 0, 15mg capsules once per day in the morning."
215019624|NCT06964230|OTHER|Placebo Comparator|Placebo used to compare to T3D-959 drug
215019625|NCT06963892|BEHAVIORAL|Neuromuscular Exercise Programme (GLA:D®-based|Participants underwent supervised neuromuscular exercise sessions based on the Good Life with osteoArthritis in Denmark (GLA:D®) programme. Exercises targeted dynamic joint stability, balance, proprioception, functional movements, and muscle strengthening. Sessions were held once weekly, lasting approximately 60 minutes each, over six consecutive weeks. The intervention was tailored progressively to each participant's capabilities, symptoms, and pain tolerance.
214419607|NCT04750850|OTHER|Usual care|Usual routine as walking and activities of daily living.
214419608|NCT04369807|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to 3 visits to a partnering imaging facility - this will include measurement of height and weight (to calculate BMI), blood pressure measurement, 3 sets of blood tests, 3 Questionnaires and 3 MRI tests.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications."
214419609|NCT05894824|DRUG|T-Dxd(Trastuzmab deruxtecan), Ramucirumab|"Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4\~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~* Dosing Regimen~  * Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~ * Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle"
214506089|NCT05361356|RADIATION|Spectral CT scanning|Volunteer accept spectral CT scanning
214506090|NCT04069806|DIETARY_SUPPLEMENT|preoperative oral carbohydrate, preOp|Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
214506091|NCT01336842|DRUG|Panobinostat, Cisplatin, Pemetrexed|"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."
214419610|NCT02057692|DRUG|LUM001|LUM001 administered orally
214419611|NCT02057692|DRUG|Placebo|Placebo administered orally
214419612|NCT05347199|DRUG|Amisulpride Pill|Two single low doses amisulpride (100 mg); orally
214419613|NCT05347199|DRUG|Placebo|two doses, orally
214419614|NCT06306378|DIAGNOSTIC_TEST|social memory levels and spindle levels|Take a face recognition memory test, and a car recognition memory test as a control . Then record nighttime EEG recordings after the two tasks and performed subsequent spindle analysis.So conduct the correlation between social memory levels and the level of spindles in the EEG by using machine learning to model.
214506092|NCT02125292|DRUG|Mesalamine|
214506093|NCT00776139|DRUG|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
214419615|NCT00839046|BEHAVIORAL|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
214419616|NCT00839046|OTHER|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
214419617|NCT00839046|OTHER|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
214419618|NCT06467279|DEVICE|Target Controlled İnfusion|TCI (Target-Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
214419619|NCT06467279|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
214419620|NCT05025267|OTHER|Medical Food: Peptide-Based Enteral Formula|Will be fed exclusively the study peptide-based, high protein enteral formula via a feeding tube
214506094|NCT03068312|DRUG|Ivacaftor|IVA 150 mg tablet.
215019626|NCT06963892|BEHAVIORAL|Usual Physiotherapy Care (NHS Standard)|Participants received standard NHS physiotherapy care for hip or knee osteoarthritis. This included routine joint mobility exercises, strengthening activities, general education, and advice. Sessions were delivered in outpatient clinics following standard practice without specific emphasis on neuromuscular control training. Frequency and duration-matched usual clinical care.
214419621|NCT01091831|DRUG|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
214419622|NCT01091831|DRUG|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
214419623|NCT01091831|DRUG|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
214419624|NCT01091831|DRUG|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
214506095|NCT03068312|DRUG|Placebo|Placebo matched to IVA tablet.
214506096|NCT02551224|OTHER|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
214506097|NCT06140888|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract 8 pills three times per day is administrated.
215029044|NCT03110510|DRUG|Irinotecan Hydrochloride|Irinotecan 180 mg/m2
215029045|NCT03110510|DRUG|leucovorin calcium|Leucovorin 200 mg/m2
215029046|NCT02106546|DRUG|Carboplatin|Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
215029047|NCT02106546|DRUG|Veliparib|Capsules taken orally twice a day, 12 hours apart.
215029048|NCT02106546|DRUG|Paclitaxel|Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
215029049|NCT02106546|DRUG|Placebo to veliparib|Capsules taken orally twice a day, 12 hours apart.
215029050|NCT03204812|BIOLOGICAL|Durvalumab|Given IV
215029051|NCT03204812|BIOLOGICAL|Tremelimumab|Given IV
215029052|NCT03990987|OTHER|time of receiving operation|patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
215029053|NCT02399852|DRUG|Lomitapide|
214419625|NCT02376517|BEHAVIORAL|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
214419626|NCT04970810|BEHAVIORAL|My Diabetes Goal|Subjects enrolled in the MDG arm will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls.
214419627|NCT04970810|BEHAVIORAL|My Diabetes Goal + CommunityRx|"Subjects enrolled in the MDG arm + CRx will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. Participants will also receive a HealtheRx (personalized resource prescriptions) for community organizations."
214419628|NCT04983537|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
214419629|NCT05776680|OTHER|Psychological support|60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
214419630|NCT03300037|DEVICE|Kinesthetic stimulation|The kinesthetic actuator is placed on the skin near the ear and emits vibrations.
214419631|NCT06961110|DIETARY_SUPPLEMENT|Hydrogen-rich water|Hydrogen-rich water with molecular hydrogen concentration 1.2-1.6 ppm. No added sugar or preservatives.
215019627|NCT05534607|BEHAVIORAL|Ola Mau i ka Hula|"The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons.~These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network.~For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly."
214419632|NCT06961110|DIETARY_SUPPLEMENT|Placebo|Drinking water with molecular hydrogen concentration 0.0 ppm. No added sugar or preservatives.
214419633|NCT05277831|OTHER|Guided Imagery Intervention|Participants in the Guided Imagery Intervention receive 6 sessions of a Guided Imagery plus standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to create or revise guided imagery scripts. After the session, coaches record the script as a digital audio file and send to the participant. Participants listen to their audio file every day and practice behavioral skills between sessions.
214419634|NCT05277831|OTHER|Standard Behavioral Control|Participants in the Standard Behavioral Control condition receive 6 sessions of a standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to identify lifestyle changes to support tobacco cessation, and set a schedule for practicing new behavioral strategies. Participants complete exercises in a quit booklet every day and practice behavioral skills between sessions.
214419635|NCT05774587|BEHAVIORAL|mHealth control group|Cardiac rehab control group
214419636|NCT05774587|BEHAVIORAL|mHealth technology assisted exercise counselling (mHealth)|Exercise and counselling through mHealth technology
214419637|NCT04589000|OTHER|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
214419638|NCT05283616|DRUG|Pegfilgrastim|Pegfilgrastim 3mg per chemotherapy cycle
214419639|NCT01870479|OTHER|Live music|
214419640|NCT01870479|OTHER|Taped music|
214506098|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
214506099|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
215019628|NCT05308862|BEHAVIORAL|Care process for assessements of risks|Intervention aiming to reduce the risk of pressure ulcers, malnutrition, poor oral health and falls among older persons in nursing homes, workshops will be conducted in collaboration with nurse aides, registered nurses and managers. Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it .
215019629|NCT02738697|DRUG|Adjuvant chemotherapy|8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
215019630|NCT02738697|PROCEDURE|Follow-up|Patients received just follow-up instead of adjuvant chemotherapy
215019631|NCT06494371|BIOLOGICAL|LCAR-HL30 cells|Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
215019632|NCT05800002|PROCEDURE|Intravascular ultrasound|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.
215019633|NCT05800002|PROCEDURE|Angiography|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
215019634|NCT06525870|DRUG|85%TCA topical application|85%TCA topical application is done at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of TCA will be applied to cover the lesion and transformation zone.
215019635|NCT06525870|DRUG|3% acetic acid|3% acetic acid topical application is done at cervical lesion and transformation zone. Application will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of acetic acid will be applied to cover the lesion and transformation zone.
215019636|NCT00582452|OTHER|Telephone survey|Telephone survey
214419641|NCT02935218|BEHAVIORAL|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
215019637|NCT06122493|DRUG|Tirelizumab|immunotherapy, 200 mg on day 1 per 3 weeks
214506100|NCT00606216|PROCEDURE|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
214506101|NCT00608699|DRUG|GSK256073A tablets + IR niacin tablets|single dosing for 4 to 5 sessions
214506102|NCT01349998|DRUG|Product 33525|Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
214506103|NCT01070537|DEVICE|Bonfils fiberscope intubation|
214419642|NCT04023916|DRUG|Sintilimab-R-CHOP|"Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m\^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable."
214419643|NCT02536430|DRUG|Ketorolac Tromethamine|One group received a buccal infiltration of Ketorolac Tromethamine
214419644|NCT02536430|DRUG|Placebo|buccal infiltration of Normal Saline.
214419645|NCT01209546|OTHER|control group|In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
214419646|NCT01209546|OTHER|Flutter group|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
214419647|NCT01209546|OTHER|PEP group|Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
215019638|NCT06122493|DRUG|Nab paclitaxel|chemotherapy, 175 mg/m² on day 1 per 3 weeks
214419648|NCT01209546|OTHER|Group Sham|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
214419649|NCT00864682|DRUG|Saline|3.3 mL normal saline
214419650|NCT00864682|DRUG|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
214419651|NCT00864682|DRUG|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
214419652|NCT00714558|DRUG|Fentanyl citrate; Naltrexone; Naloxone|
215019639|NCT06122493|DRUG|Carboplatin|chemotherapy, AUC=5 on day 1 per 3 weeks
215019640|NCT06122493|RADIATION|Radiotherapy|Patients without disease progression after four cycles of chemoimmunotherapy receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy delivered over 28 fractions.
214419653|NCT03321539|DRUG|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
214419654|NCT03321539|DRUG|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.
214419655|NCT03495284|DIETARY_SUPPLEMENT|Potato-based side dish|Daily consumption of a potato-based side dish equivalent to one medium size potato for 4 weeks
214419656|NCT03495284|DIETARY_SUPPLEMENT|Refined grain-based|Daily consumption of an isocaloric refined grain-based side dish for 4 weeks
214419657|NCT05610696|OTHER|Low impact immersion|Consists of a sequence of shoulder, trunk and hip movements. In this modality, the aim will be to understand the physiological effects of immersion in heat water. Resisted movements (either by turbulence or by floats) or interventional maneuvers in the knee joints will not be performed. Considering the period of 5 minutes for acclimatization to the liquid environment, the program will last approximately 47 minutes.
214506104|NCT04455204|DIAGNOSTIC_TEST|Serum asymmetteric dimethyl arginine|Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay
214506105|NCT04455204|DIAGNOSTIC_TEST|serum lipid profiles|serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits
214506106|NCT04455204|DIAGNOSTIC_TEST|Serum vaspin|vaspin concentrations will be assayed using commercially available ELISA kits
214506107|NCT04455204|DIAGNOSTIC_TEST|Serum resistin|resistin concentrations will be assayed using commercially available ELISA kits
214506108|NCT01509183|DEVICE|Propeller Health System (formerly Asthmapolis System)|The Propeller (formerly Asthmapolis) system works through the provision of information to patients and their providers. With the Propeller (formerly Asthmapolis) device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Propeller (formerly Asthmapolis) where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
214506109|NCT02110407|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
214506110|NCT02110407|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
215019641|NCT00180453|DEVICE|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
215019642|NCT00180453|DEVICE|Coronary artery stent placement|Coronary artery stent placement
215019643|NCT00997815|DRUG|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
215019644|NCT00997815|DRUG|Normal saline injection|Using normal saline 2.5 ml injected in control side
215019645|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg
215019646|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg
215019647|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181|Group 3: TG-2349 200 mg + DAG181 100 mg
215019648|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181|Group 4: TG-2349 400 mg + DAG181 200 mg
214419658|NCT05610696|OTHER|Conventional aquatic physiotherapy|include warm-up, strengthening and calming down activities. Aquatic steppes will be used to ensure that all participants will maintain the waterline level approximately in the xiphoid appendix. For strengthening activities, the exercises must be performed at an adequate speed, which ensures a comfortable level for the activity. For this purpose, a subjective feedback will be extracted from the participants constantly. The warm-up sequence consists of six different active hip and knee movements performed at maximum range of motion and contributes to neuromuscular activation. For strengthening, each movement should be performed for 1 minute (30 seconds for each lower limb) followed by a period of 30 seconds of rest between each movement.
214419659|NCT05610696|OTHER|High intensity aquatic physiotherapy|In this modality subjects will perform the same sequence of exercises of the Conventional Aquatic Physiotherapy program will be respected. However the work load and speed will be adjusted to the maximum level. For strengthening, each movement should be performed for 2 minutes (1 minute for each lower limb) followed by a period of 30 seconds of rest between each movement. To guarantee the maximum effort of the participants, verbal stimuli will be constantly provided. The program will last approximately 68 minutes.
214419660|NCT01033058|DRUG|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
214419661|NCT01033058|DRUG|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
214419662|NCT00455754|DRUG|Esomeprazole|
214419663|NCT01535989|DRUG|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
214419664|NCT01535989|DRUG|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
214419665|NCT03022903|PROCEDURE|Aminolevulinic Acid (ALA)|Photosensitizing
214419666|NCT05719818|DRUG|biphosphonates|Initiation of bisphosphonate therapy
214419667|NCT05719818|PROCEDURE|Dental care|Surgical dental care
214419668|NCT05349097|DRUG|SAD IMG-004 30mg|Each participant will be randomized to receive a single oral dose of 30mg IMG-004
214419669|NCT05349097|DRUG|SAD IMG-004 100mg|Each participant will be randomized to receive a single oral dose of 100mg IMG-004
214419670|NCT05349097|DRUG|SAD IMG-004 200mg|Each participant will be randomized to receive a single oral dose of 200mg IMG-004
214419671|NCT05349097|DRUG|SAD IMG-004 400mg|Each participant will be randomized to receive a single oral dose of 400mg IMG-004
214419672|NCT05349097|DRUG|SAD IMG-004 600mg|Each participant will be randomized to receive a single oral dose of 600mg IMG-004
215019649|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg\_
215019650|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181|Group6: TG-2349 400 mg + DAG181 200 mg
215019651|NCT00135161|PROCEDURE|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
215029054|NCT06560736|BEHAVIORAL|Show Me FIRST coping skills intervention|Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change.
214419673|NCT05349097|DRUG|SAD Placebo 30mg|Each participant will be randomized to receive a single oral dose of 30mg matching placebo
214689975|NCT01433627|OTHER|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
214689976|NCT03922360|BEHAVIORAL|Smartphone-based Financial Incentives|"Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test."
214689977|NCT03922360|BEHAVIORAL|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
214689978|NCT00108927|BEHAVIORAL|TRANSLATE|
214689979|NCT06555926|OTHER|Acupressure|The pregnant women will receive acupressure on the (Pc-6/Lung-7 )acupoints one minute for each point with 3 repetitions on both side( about 30minutes /session),2 times per week in addition to advices for 12 weeks.
214689980|NCT06555926|OTHER|advices for relieving carpal tunnel syndrome|"The pregnant women will receive advices for 12 weeks as follows:~* Avoid heavy lifting.~* Avoid repetitive tasks.~* Sit on chairs with armrests and elevate affected hand on the armrest~* Avoid sleeping on the side of the affected hand.~* Keep the wrist in a neutral (straight) position.~* Avoid positions of full flexion and extension.~* Reduce general swelling by:~  * eating less salty food .~ * elevating legs when sitting .~ * wearing compression garments.~* Apply cold water over the wrist."
215019652|NCT03189433|DRUG|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
215019653|NCT00558493|DRUG|Clevudine|clevudine 30 mg qd for 24 seeks
215019654|NCT04642066|OTHER|Cold water immersion|Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.
215019655|NCT04642066|OTHER|No cold water immersion|People without cold water immersion
215102427|NCT05627024|DRUG|60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
215102428|NCT01832155|BEHAVIORAL|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
215102429|NCT01832155|BEHAVIORAL|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
214419674|NCT05349097|DRUG|SAD Placebo 100mg|Each participant will be randomized to receive a single oral dose of 100mg matching placebo
214419675|NCT05349097|DRUG|SAD Placebo 200mg|Each participant will be randomized to receive a single oral dose of 200mg matching placebo
214419676|NCT05349097|DRUG|SAD Placebo 400mg|Each participant will be randomized to receive a single oral dose of 400mg matching placebo
214419677|NCT05349097|DRUG|SAD Placebo 600mg|Each participant will be randomized to receive a single oral dose of 600mg matching placebo
214419678|NCT05349097|DRUG|MAD IMG-004 50mg|Each participant will be randomized to receive daily oral dose of 50mg IMG-004 for 10 days
214419679|NCT05349097|DRUG|MAD Placebo 50mg|Each participant will be randomized to receive daily oral dose of 50mg matching placebo for 10 days
214689981|NCT03535324|BEHAVIORAL|PROA for optimization|The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.
214689982|NCT03535324|OTHER|Control|There will be no intervention
214689983|NCT04018469|OTHER|No Interventions|No Interventions
214689984|NCT04507438|DRUG|Donepezil 5-10 Mg Oral Tablet|Donepezil 5mg or 10mg oral tablet administered daily for an 8 week period
214689985|NCT04507438|DRUG|Placebo Oral Tablet|Placebo oral tablet administered daily for an 8 week period
214689986|NCT03564171|COMBINATION_PRODUCT|Prehabilitation|stress counseling, exercise, nutritional counseling, smoking cessation counseling
214689987|NCT02738437|DEVICE|Kryptonite-bone cement|
214689988|NCT00169988|DRUG|risperidone|
215019656|NCT05652140|OTHER|Data collections|Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.
214419680|NCT05349097|DRUG|MAD IMG-004 150mg|Each participant will be randomized to receive daily oral dose of 150mg IMG-004 for 10 days
214419681|NCT05349097|DRUG|MAD Placebo 150mg|Each participant will be randomized to receive daily oral dose of 150mg matching placebo for 10 days
214419682|NCT05349097|DRUG|MAD IMG-004 300mg|Each participant will be randomized to receive daily oral dose of 300mg IMG-004 for 10 days
214689989|NCT00169988|DRUG|sertraline-primary|
214689990|NCT05837078|PROCEDURE|ridge splitting with implant placement|ridge splitting of mandibular denture followed by two implant placement
214689991|NCT01468909|OTHER|Laboratory Biomarker Analysis|Correlative studies
214689992|NCT01468909|DRUG|Paclitaxel|Given IV
214689993|NCT01468909|DRUG|Pazopanib Hydrochloride|Given PO
214689994|NCT01468909|OTHER|Placebo|Given PO
214689995|NCT05909215|DRUG|Normal saline|Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes
214689996|NCT05909215|DRUG|Dexmedetomidine 0.5 microgram/kg|Dexmedetomidine 0.5 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
214689997|NCT05909215|DRUG|Dexmedetomidine 0.75 microgram/kg|Dexmedetomidine 0.75 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
215019657|NCT01064284|DRUG|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
214419683|NCT05349097|DRUG|MAD Placebo 300mg|Each participant will be randomized to receive daily oral dose of 300mg matching placebo for 10 days
214419684|NCT05349097|DRUG|FE IMG-004 150mg|A single dose of IMG-004 at 150 mg dose level will be administered to the participants in fed and fasted states
214419685|NCT01027299|DEVICE|Biventricular pacing|Optimised temporary biventricular pacing.
214419686|NCT06373549|PROCEDURE|Patients with coronary artery bypass surgery routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
214419687|NCT06373549|PROCEDURE|Patients who underwent heart valve surgery without coronary artery disease routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
214419688|NCT04855513|DRUG|Metformin|Metformin is a medication used for treatment of diabetes. In this study it will be used to explore is potential role in prevention of preeclampsia. The drug will start before 12 week of pregnancy and continue till delivery
214419689|NCT00141830|DRUG|Methotrexate plus ERB-041 for 12 weeks|
214419690|NCT00141830|DRUG|Placebo for 12 weeks|
214419691|NCT04286256|BEHAVIORAL|Motivational Interviewing|Participants/caregivers will receive several telephone-based and in-person motivational interviewing sessions along with specific oral health recommendations.
214689998|NCT00849264|DRUG|chemotherapy with endostar|15mg/d×14d
214689999|NCT00849264|DRUG|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
214690000|NCT00849264|DRUG|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
214690001|NCT04217577|DIETARY_SUPPLEMENT|Dried plums|10-16 dried plums/day, approximately 100-120 g/day
214690002|NCT06064708|BEHAVIORAL|Mindfulness-based intervention|"The experimental group received 30 minutes of MBI according to Smith's (2005) MBI protocol, which is a standardized theory-based intervention.~Smith's (2005) MBI protocol comprises six components:~1. Being mindful of the breath (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of the thought (5 minutes)~4. Being mindful of the sound (5 minutes)~5. Being mindful during walking (5 minutes)~6. Full meditation (5 minutes)."
214690003|NCT03047863|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
214690004|NCT03047863|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
214690005|NCT06350344|DEVICE|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients with high-risk of VTE during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
214690006|NCT02592629|DRUG|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
214690007|NCT02592629|DRUG|ethyl chloride|topical spray
214690008|NCT02592629|DRUG|Kenalog|used with lidocaine in shoulder injection
214690009|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
214690010|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
214690011|NCT01204658|BIOLOGICAL|Synflorix|Intramuscular injection
215019658|NCT01064284|DRUG|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
215019659|NCT06471517|DEVICE|Somatosensory feedback|Performing different mobility tasks in 10 separate sessions while the device is providing or not somatotopic sensations through non-invasive electrical stimulation. Benefits connected to the stimulation of sensory nerves will be assessed.
214419692|NCT05372094|DEVICE|Phonak Hearing Aid|Commercially available hearing aid with various noise reduction strengths
214419693|NCT02393716|DEVICE|Endurant Evo AAA Stent Graft System|
214419694|NCT02393716|PROCEDURE|Endovascular aneurysm repair (EVAR)|
214419695|NCT02116829|OTHER|Danish butter|The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
214419696|NCT02116829|OTHER|Olive oil|
214419697|NCT00497562|DRUG|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
214419698|NCT00497562|DRUG|amitriptyline, fluoxetine and tramadol alone (control group)|
214419699|NCT00000634|DRUG|Nevirapine|
214419700|NCT01420718|DRUG|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
214419701|NCT01420718|DRUG|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
214419702|NCT04806919|DRUG|Progesteron TID|increasing the dose
215019660|NCT05782244|DRUG|Sildenafil Citrate low dose|Sildenafil citrate 20 mg, oral, TID
215019661|NCT05782244|DRUG|Placebo|Placebo, oral, TID
215019662|NCT05782244|DRUG|Sildenafil medium dose|Sildenafil 40 mg, oral, TID
215019663|NCT05782244|DRUG|Sildenafil high dose|Sildenafil 80 mg, oral, TID
215019664|NCT05783349|BIOLOGICAL|Unique blod sample|sampling of 4mL of blood on lithium heparin tube, the day of frozen embryo implantation
214419703|NCT01801293|DRUG|GS-5806|
215019665|NCT04787042|BIOLOGICAL|ST-067|ST-067 is an engineered variant of human interleukin-18.
215019666|NCT04787042|BIOLOGICAL|Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
214419704|NCT02897622|OTHER|Case management|Case management by Eira unit
214419705|NCT05165849|DRUG|GFS101A|GFS101A will be administrated intravenously Q3W.
215102430|NCT04811495|OTHER|Physiotherapy treatment|A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
215102431|NCT00189605|DEVICE|Perc-DLR/Perc-DLG|Device technique will be used per IFU
215102432|NCT00189605|DRUG|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
215102433|NCT03415438|DIAGNOSTIC_TEST|Visual Analogue Scale|intensity of pain perception patients feel
215102434|NCT03415438|DIAGNOSTIC_TEST|posterior capsule tightness|tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.
215102435|NCT03415438|DIAGNOSTIC_TEST|shortness tests for lumbar movements|tape measurement for lumbar movements
215102436|NCT03415438|DIAGNOSTIC_TEST|range of motion tests for lumbar movements|range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.
214419706|NCT05165849|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg Q3W administered intravenously.
214419707|NCT02153606|DRUG|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
214419708|NCT02153606|OTHER|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
214419709|NCT04420195|DRUG|Extended-Release Tacrolimus|Envarsus XR is an FDA-approved drug for the prophylaxis of organ rejection in de novo kidney transplant patients or in kidney transplant patients converted from IR tacrolimus when used with other immunosuppressants. Envarsus XR is a novel extended-release formulation of tacrolimus created using MeltDose technology. Envarsus XR is available in tablet form. It is available in 0.75, 1, and 4 mg tablets.
214419710|NCT04420195|DRUG|Immediate-Release Tacrolimus|Historical cohort of 20 subjects who will be maintained on IR tacrolimus following transplant. Dosing will be converted on an individual basis (Capsules: 0.5 mg, 1 mg and 5 mg or Injection: 5 mg) . All patients will be initiated on IR tacrolimus either under the tongue (sublingual) or as a solution given through a tube placed through the nose into the stomach, which is standard of care for all lung transplant recipients.
214419711|NCT04842604|DRUG|Glasdegib|25 mg or 100 mg tablet
214419712|NCT04842604|DRUG|Azacitidine|100 mg/vial powder for 25 mg/mL suspension for injection
214419713|NCT03126409|PROCEDURE|No-Touch vein harvesting technique|The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.
214419714|NCT03126409|PROCEDURE|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
214419715|NCT03094767|OTHER|Cardiovascular Rehabilitation|Aerobic and anaerobic exercises performed for 12 weeks, 3x/week, of 60 minutes each.
214419716|NCT03094767|OTHER|Initial and Final assessment|Measuring blood preassure, heart rate, Borg scale, respiratory rate, oxygen saturation and HbA1C in the first day of assessment and after 12 weeks.
215019667|NCT04787042|BIOLOGICAL|pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
215019668|NCT03121274|PROCEDURE|vaginal delivery|vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
215019669|NCT06048705|DRUG|GSK3901961|GSK3901961 was administered.
215019670|NCT06048705|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
215019671|NCT06048705|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
215102437|NCT03415438|DIAGNOSTIC_TEST|The thoracolumbar fascia length test|patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length
215102438|NCT03415438|DIAGNOSTIC_TEST|Modify Schober test|tape measurement of spinal flexion between designated regions
214419717|NCT02618317|DRUG|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
214419718|NCT02618317|DRUG|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
214419719|NCT02618317|DRUG|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
214419720|NCT05079061|DRUG|Misoprostol|sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
214419721|NCT04213560|DEVICE|weighted waist-hooping|weighted waist-hooping
214419722|NCT02706067|DRUG|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent \[%\] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
214419723|NCT01648140|DRUG|GSK2336805 40 mg|20 mg tablet, round, 10-mm diameter, white to off-white, no markings
214419724|NCT01648140|DRUG|GSK2336805 60 mg|30 mg tablet, round, 10-mm diameter, white to off-white, no markings
214419725|NCT01648140|DRUG|Pegylated interferon alpha-2a|180 microgram per 0.5 mL prefilled syringe for single use
214419726|NCT01648140|DRUG|Ribavirin|"200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side"
214419727|NCT01648140|DRUG|Telaprevir|375 mg film-coated tablet
214419728|NCT05566418|OTHER|mulligan mobilization|Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide.
214419729|NCT05566418|OTHER|myofascial release|Myofascial release will be performed on the patient, commencing at the common extensor origin and progressing all the way to the extensor retinaculum in the wrist. The periosteum will be engaged with the fingertips, with contact progressing inferiorly to the common extensor tendon and then to the wrist's extensor retinaculum
214419730|NCT03275077|DEVICE|Thromboelastography|A viscoelastic test of coagulation
214419731|NCT06288152|DRUG|Sodium Thiosulfate|0.15 mL administered
214419732|NCT05715151|OTHER|CQI intervention|Activity 1: Reflective sessions and problem prioritisation. Activity 2: PDSA cycles. Activity 3: Group mentoring.
214419733|NCT05715151|OTHER|Audit and Feedback|Audit and Feedback on six key AA indicators, patients reported experience about access and selected AA processes.
214419734|NCT03319017|PROCEDURE|Multiple-trauma patients|"The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.~A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed."
214419735|NCT05218733|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive bilateral ultrasound-guided ESPB by the an experienced anesthetist in US regional blocks, with each block 20 mL of bupivacaine 0.25%
214419736|NCT05218733|DRUG|Intra thecal morphine.|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive intra thecal morphine with spinal needle 25G, 3 ml containing 300 ug preservative free morphine
214419737|NCT05218733|DRUG|General anesthesia using intravenous fentanyl (1µgm/kg)|Patients will receive general anesthesia using intravenous fentanyl (1µgm/kg)
214419738|NCT00927667|PROCEDURE|No Drug|Patients have received primary FVIII prophylaxis (started \< 2 years of age)
215029055|NCT05682677|DEVICE|iTBS|iTBS over the left dorsolateral prefrontal cortex
215029056|NCT05682677|DEVICE|sham iTBS|sham iTBS over the left dorsolateral prefrontal cortex
215029057|NCT05682677|BEHAVIORAL|Personalized, Augmented Cognitive Training (PACT)|6 sessions of PACT
215029058|NCT05003700|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin and raltitrexed via the tumor feeding arteries every 3 weeks.
215029059|NCT05003700|DRUG|Lenvatinib|8 mg once daily (QD) oral dosing.
215029060|NCT05003700|DRUG|Camrelizumab|200mg intravenously every 3 weeks.
215029061|NCT05024786|OTHER|continuous quality improvements|We implement the continuous quality improvement strategy in CQI group, and observe the effect of the strategy on the mortality of patients supported with ECMO .
215029062|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
215029063|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
215029064|NCT03194529|BIOLOGICAL|FMT|Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
215029065|NCT01190371|DRUG|Artesunate|Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
215029066|NCT03340935|OTHER|Fasting mimicking diet|Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (600 Kcal on day 1, followed by 300 KCal/day on days 2 to 5), low-protein, low carbohydrate diet
215029067|NCT01432431|PROCEDURE|spiritual therapy|Undergo palliative spiritual care
215029068|NCT01432431|OTHER|questionnaire administration|Ancillary studies
215029069|NCT01432431|OTHER|survey administration|Ancillary studies
215029070|NCT01432431|OTHER|counseling intervention|Undergo palliative spiritual care
215029071|NCT01432431|OTHER|psychosocial support for caregiver|Undergo palliative spiritual care
215029072|NCT01432431|PROCEDURE|psychosocial assessment and care|Undergo palliative spiritual care
215019672|NCT06838988|DIAGNOSTIC_TEST|Transcutaneous ultrasound|"The ultrasonographic characteristics of the subcutaneous nodules were evaluated using an ultrasound machine (Venue Go™, wide-band linear array ultrasound probe (hockey stick shape), frequency range between 6.7 MHz and 18.0 MHz, from GE HealthCare Illinois, United States).~The procedure for capturing images at the location of the lesion of interest is as follows:~* Brightness mode (B-mode): Record at least 4 images using a depth of 2 cm.~* Color Doppler mode: Record images along the vertical axis (1 image) and along the horizontal axis (1 image). The two axes mentioned above must be perpendicular to each other.~* Video recording: Capture at least 10 seconds of video in both Brightness mode and Color Doppler mode."
215019673|NCT05478707|DRUG|Dulaglutide|GLP1-RA
215019674|NCT05478707|DRUG|Placebo|Saline placebo
215019675|NCT05478707|BEHAVIORAL|exercise training|supervised high intensity interval training
215019676|NCT05063383|OTHER|This study does not involve any interventions|This study does not involve any interventions
214419739|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 2 - \< 6 years of age)
214419740|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 6 - \< 12 years of age)
214419741|NCT00927667|PROCEDURE|No Drug|Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
214419742|NCT00927667|PROCEDURE|No Drug|Patients have received on-demand therapy
214419743|NCT05823181|DEVICE|laparoscopy|laparoscopic exploration of common bile duct
214419744|NCT02684565|DIETARY_SUPPLEMENT|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
214419745|NCT02684565|DIETARY_SUPPLEMENT|BCAA Low Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
214419746|NCT00478335|DRUG|sildenafil|25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
214419747|NCT00478335|DRUG|calcitonin|one nasal spray daily for 4 days
214419748|NCT00478335|DRUG|hydrochlorothiazide/amiloride|25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
214419749|NCT00478335|DRUG|indomethacin|50 mg QD or 50 mg BID x 8 days depending on subject weight
214419750|NCT00478335|DRUG|Placebo for sildenafil|one tablet daily for 4 days
214419751|NCT00478335|DRUG|placebo for calcitonin|one nasal spray daily
214419752|NCT00608907|DRUG|bortezomib|1.3 mg/m\^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
214419753|NCT00608907|DRUG|bortezomib, rifampicin|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
214419754|NCT00608907|DRUG|bortezomib, dexamethasone|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
215019677|NCT05940246|BEHAVIORAL|Motivational Interviewing|"MI was introduced by William Miller in 1983 as a strategy to promote behavioral changes that would make people drink less. It is well established that MI can be successfully applied to many areas across the medical disciplines. Although the aim of MI is behavioral changes toward a specific goal it is necessary to understand the essence of MI with the four key interrelated elements of the spirits of MI. These are partnership, acceptance, compassion, and evocation. Together they form an equal and respectful collaboration between the MI practitioner and the patient wherein empathy and acknowledgment are important pillars. Moreover, an important message derived from the spirit of MI is the belief that patients in themselves have and know what is needed and get support from the MI practitioner to find it."
215019678|NCT01209468|DEVICE|monobloc oral appliance|one piece oral appliance
215019679|NCT01209468|DEVICE|twinblock oral appliance|two-piece oral appliance
215019680|NCT03072849|PROCEDURE|Pulmonary function testing|Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
215019681|NCT03072849|DRUG|FAM Therapy|All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC \<0.8.
215019682|NCT03512158|OTHER|Non-invasive respiratory support mode|A mode of providing respiratory support via nasal masks or prongs
215029073|NCT04391608|DRUG|Switching to Tenofovir Alafenamide|Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
215029074|NCT01126398|PROCEDURE|ankle or distal tibia surgery|internal fixation for ankle or distal tibia fracture
215029075|NCT06011889|DRUG|Etanercept|treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
214419755|NCT02667535|DRUG|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
214419756|NCT05483335|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
214419757|NCT02458599|DIETARY_SUPPLEMENT|Test product|Whey protein hydrolysate (20 g)
214419758|NCT02458599|DIETARY_SUPPLEMENT|Reference product 1|Iso-energetic carbohydrate (20 g)
214419759|NCT02458599|DIETARY_SUPPLEMENT|Reference product 2|Negligible energy placebo (20 g)
214419760|NCT02710149|BIOLOGICAL|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
214419761|NCT04943380|DIAGNOSTIC_TEST|Cxbladder|The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
214690012|NCT01204658|BIOLOGICAL|Prevenar 13|Intramuscular injection
214690013|NCT01204658|BIOLOGICAL|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
214690014|NCT00905021|DRUG|Exemestane|Exemestane 25 mg by mouth every day.
214690015|NCT00905021|DRUG|Sutent|Sunitinib 37.5 mg by mouth every day.
214419762|NCT03990220|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus yoba 2012|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug."
214419763|NCT01986686|PROCEDURE|Colon resection|Elective robotic/laparoscopic/open colon resection for diverticular disease.
214419764|NCT01345604|PROCEDURE|transcruciate injection of 20cc of normal saline|Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
214419765|NCT01345604|PROCEDURE|transcruciate injection of 20 cc of 0.5% Ropivacaine|Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
214419766|NCT04767828|DRUG|PYRROTINI|CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .
214419767|NCT04767828|RADIATION|Brain radiation therapy|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.
214419768|NCT00034463|DRUG|ALIMTA|
214419769|NCT00034463|DRUG|folic acid|
214419770|NCT00034463|DRUG|multi-vitamins|
214419771|NCT02667249|OTHER|clinical pathway|implementation of a standardized clinical pathway
214419772|NCT02572219|DIETARY_SUPPLEMENT|Nutraceutical compound|
214419773|NCT02572219|DIETARY_SUPPLEMENT|Placebo|
214419774|NCT03264248|DEVICE|E-Scale|Daily bodyweight system used under legs of bed
214419775|NCT02435199|DRUG|EMA401 600mg|
215019683|NCT03954730|OTHER|Eccentric Training|First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
215019684|NCT03954730|OTHER|Active Release Technique|Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
214419776|NCT02435199|DRUG|Placebo|
214419777|NCT04915599|DEVICE|Cooral® mouth cooling device (MCD)|Cooral® mouth cooling device (MCD) to prevent oral mucositis (QM) in patients undergoing radiation therapy for head and neck malignancies
214419778|NCT00470106|BEHAVIORAL|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
215019685|NCT01016015|BIOLOGICAL|Cixutumumab|Given IV
215019686|NCT01016015|OTHER|Laboratory Biomarker Analysis|Correlative studies
215019687|NCT01016015|DRUG|Temsirolimus|Given IV
215019688|NCT03947021|RADIATION|Computed tomography (CT) scan|A CT scan of thorax and heart will be performed in the CT+BSPM group.
214419779|NCT00470106|BEHAVIORAL|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
214419780|NCT00470106|BEHAVIORAL|hybrid intervention|A combination of the two groups listed above.
214419781|NCT00470106|BEHAVIORAL|skills training|Skills training in how to identify symptoms of illness and medication side effects.
214419782|NCT01409512|PROCEDURE|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
214419783|NCT02178540|DRUG|Placebo|one dose (4 capsules) of placebo
214419784|NCT02178540|DEVICE|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
214690016|NCT04129749|PROCEDURE|Real-Time Analysis Interactive Lab|The Real-Time Analysis Interactive Lab uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment.
214419785|NCT04836624|DEVICE|Co-designing of personalised aids of daily living|"In the initial session the researcher will work with the participants to identify challenges in daily living for the device to overcome.~In between sessions the researcher will design and manufacture different solutions which will then be sent out for the participant to trial. The participant will then meet with the researcher to and feedback on the device provided. Feedback from the user is used to alter and improve the design of the device; new device(s) are then , enabling the design to be adapted to the participants needs. The process of design changes and feedback forms an iterative loop. This is expected to continue for 4-5 appointments over a period of serveral months until a final design is agreed upon.~After the device is issue, both qualitative and quantitative outcome measures are provided to participants to complete, including questionnaires and semi-structured interviews. ."
214419786|NCT02246816|DRUG|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
214419787|NCT03278288|DEVICE|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
214419788|NCT00758602|DRUG|mycophenolate mofetil|0.75-1 g PO BID from Day 0 through Month 12
214419789|NCT00758602|DRUG|tacrolimus, standard dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
214419790|NCT00758602|DRUG|tacrolimus, low dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
214419791|NCT00758602|DRUG|corticosteroids|According to center's practice
214419792|NCT06242964|BEHAVIORAL|Promoting Resilience in Stress Management - Social Needs (PRISM-SN)|The Promoting Resilience in Stress Management - Social Needs (PRISM-SN) intervention is a brief, skill-based psychosocial program. Five core sessions are delivered one-on-one, 1-2 weeks apart, in-person or via videoconference. Sessions teach evidence-based behavioral skills for managing stress, setting goals, reframing negative thoughts, meaning-making, and connecting with others. Each session lasts \<60 minutes and is supported by paper-and-pencil or mobile app-based worksheet(s) for learning and practice. A final review session may be completed individually or with a family member, caregiver, or significant other.
214419793|NCT04628572|DRUG|Ceftazidime-avibactam|Non-Interventional Study
214419794|NCT00158054|BEHAVIORAL|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
214419795|NCT00158054|BEHAVIORAL|Referred depression care|Physician notified of depression symptoms, usual care followed.
214419796|NCT05236491|BIOLOGICAL|COVID-19 vaccine|Participants are to receive a booster dose of a COVID-19 vaccine.
214419797|NCT00243399|DRUG|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
214419798|NCT04630080|DEVICE|Scalp cooling|Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
214419799|NCT02470949|BEHAVIORAL|Low Social Status|The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
214419800|NCT02470949|BEHAVIORAL|High Social Status|The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
214419801|NCT01219699|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
214419802|NCT01219699|DRUG|Fulvestrant|"In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection"
214419803|NCT04825652|DRUG|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles.
214419804|NCT04825652|DRUG|PSMA-11|Patients will receive a dose of gallium (68Ga) gozetotide that is 1.8-2.2 MBq/kg of body weight (0.049-0.059 mCi/kg), with a minimum dose of 111 MBq (3mCi) up to a maximum dose of 259 MBq (7 mCi).
214419805|NCT05434611|DIAGNOSTIC_TEST|S100A12|The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
214419806|NCT04460612|DEVICE|Active IR sock|Subjects will be wearing the infrared socks for 60 minutes
214419807|NCT04460612|OTHER|Placebo socks|Placebo Socks will be placed on participants feet first for 60 minute
214419808|NCT02727764|GENETIC|ART-I02|Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
214419809|NCT03045419|PROCEDURE|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
215019689|NCT03947021|DEVICE|Body-surface potential mapping|Measurement of 256-lead body-surface electrocardiogram
215019690|NCT05569889|PROCEDURE|Anterior Cruciate Ligament reconstruction (ACLR)|A comparison between the two groups were done regarding the three following stages: (a) the preparation time of the trolley, which is the time taken by the CNOR to recover from the reserves all the single-packed sterile instruments (SPSI) necessary for the intervention or to recover the CST (b) the opening time of the instruments by the circulating nurse who opens the packages and gives them to the surgical nurse while respecting the sterility of the items, and by the surgical nurse who prepares the table for the intervention, and (c) the sorting time of the waste between plastic and paper at the end of the intervention.
215019691|NCT03917836|DIAGNOSTIC_TEST|endoscopy and histology|diagnostic evaluation of chronic gastritis
215029076|NCT06011889|DRUG|Placebo|treatment with placebo in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
215102439|NCT06584526|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the experimental groups).
215019692|NCT03683199|PROCEDURE|Rhinoplasty|"The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts."
214419810|NCT03977116|DRUG|SLGT2|These patients will receive SLGT2 therapy after catheter ablation.
214419811|NCT03977116|DRUG|Placebo|These patients will receive placebo therapy after catheter ablation.
214419812|NCT03646006|DRUG|Bupivacaine|10 mL (5mg/mL)
214419813|NCT03646006|DRUG|Placebo|10 mL normal saline
214419814|NCT03038399|DRUG|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 months.
214419815|NCT03038399|DRUG|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 months.
214419816|NCT03038399|DRUG|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 months.
214419817|NCT03038399|DRUG|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 months.
214419818|NCT02219919|OTHER|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
214419819|NCT02219919|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
214419820|NCT05026034|DEVICE|non-invasive Cardiopulmonary Management (CPM) wearable device|non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure
214419821|NCT06335836|BEHAVIORAL|social isolation|social isolation (0≤LSNS-6≤12)
214419822|NCT00155558|DRUG|5-Fluorouracil, Leucovorin|
214419823|NCT03861169|DEVICE|Transluminal viscoelastic delivery and trabeculotomy|Ab-interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System
214419824|NCT03337568|PROCEDURE|allogeneic hematopoietic cell transplantation|perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin
214419825|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
214419826|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
214419827|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
214419828|NCT01595854|DRUG|dabigatran etexilate|low dose dabigatran
214419829|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
214419830|NCT01505946|OTHER|TGA (Thrombin generation Assay)|"TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period"
215019693|NCT02057666|DRUG|Tasquinimod|A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
214419831|NCT04848649|OTHER|Study arm|Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
214419832|NCT04126109|OTHER|questionaire|A questionaire will be offered to every parents
214419833|NCT04365400|DRUG|DS102|DS102 Epeleuton capsules
214419834|NCT04365400|DRUG|Placebo|Placebo capsules
215019694|NCT02057666|DRUG|Placebo|Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
215019695|NCT03101982|DRUG|HBO|Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
214419835|NCT03938428|OTHER|Survey|Patients who are eligible for this study will have been previously identified as part of the PREFACES project. The pharmacist who has conducted the clinical medication review will obtain verbal permission from the patient to be contacted by the research study team. This will be documented on the referral outcome document that is returned to the YAS clinical team. A member of YAS clinical staff from the PREFACES project will forward the name and residential address of patients who have agreed to be contacted to the research paramedic for this study. A covering letter, participant information sheet, questionnaire and consent form, will be posted to potential participants. A stamped addressed envelope will be included to enable return of the completed booklet at no costs to participants.
214419836|NCT03489317|DRUG|Metformin|Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
214419837|NCT03489317|BEHAVIORAL|lifestyle modification|Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
214419838|NCT03489317|DRUG|Simvastatin 10mg|Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
214419839|NCT03489317|DRUG|Amlodipine 5mg|Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
215019696|NCT05572216|PROCEDURE|Robot assisted partial nephrectomy with 3D image guidance|patient have a partial nephrectomy for renal complex tumor
214419840|NCT06226636|OTHER|salt|After ≥8 hr overnight fasting, participants will be required to ingest 780 mg of sodium (2 g salt) and BP measured every 10 minutes for 2 hours to determine IPROS. For SSBP, Participants are put on low salt (50 mmol Na/day) followed by seven days of high salt diet (250 mmol Na/day). Participants' mean arterial pressure (MAP) difference between low- and high-salt diet will be used to define salt sensitivity (MAP≥8 mmHg) and salt resistance (MAP≤5 mmHg).
214419841|NCT03829267|BEHAVIORAL|eFIT Intervention|eFIT: social network accountability partners, a psychosocial intervention to increase physical activity in persons with multiple sclerosis
214419842|NCT03829267|BEHAVIORAL|eJournal Intervention|1-hour online each week engaged in an active journaling activity
215102440|NCT06584526|OTHER|Physical Therapy and Aerobic Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a cycle ergometer.
214419843|NCT03829267|BEHAVIORAL|Treatment as usual|Participants in this condition will complete baseline and follow-up surveys with the same frequency as the active treatment groups, but will receive neither eFIT nor eJournal.
214419844|NCT00079183|DRUG|sirolimus|Given PO
215019697|NCT03811873|DIAGNOSTIC_TEST|Dual x-ray absorptiometry|DEXA is a means of measuring bone mineral density (BMD) using spectral imaging. Two X-ray beams, with different energy levels, are aimed at the bones. Soft tissue absorption is subtracted out, then the bone mineral density (BMD) can be determined from the absorption of each beam by bone.
215019698|NCT03811873|OTHER|Vertebral Fracture Assessment|Lumbar/thoracic spine x-ray and labs assessed for bone turnover markers.
215019699|NCT04871945|DIAGNOSTIC_TEST|Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)|The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.
215102441|NCT06584526|OTHER|Physical Therapy and Strength Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes strength exercise programme.
215102442|NCT02082704|BEHAVIORAL|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
214419845|NCT03068637|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
214419846|NCT01052233|PROCEDURE|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
214419847|NCT01052233|PROCEDURE|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
214419848|NCT01544569|GENETIC|DNA analysis|
214419849|NCT01544569|GENETIC|fluorescence in situ hybridization|
214419850|NCT01544569|GENETIC|gene expression analysis|
214419851|NCT01544569|GENETIC|gene mapping|
214419852|NCT01544569|GENETIC|microarray analysis|
214419853|NCT01544569|GENETIC|polymerase chain reaction|
214419854|NCT01544569|GENETIC|protein expression analysis|
214419855|NCT01544569|OTHER|laboratory biomarker analysis|
214419856|NCT01544569|OTHER|medical chart review|
214419857|NCT02371746|DRUG|ENV515-3 Travoprost XR|
214419858|NCT02371746|DRUG|ENV515-1 Travoprost XR|
214419859|NCT02371746|DRUG|ENV515-3-2 Travoprost XR|
214419860|NCT06367517|DRUG|Tocilizumab|Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks
214419861|NCT05128019|BEHAVIORAL|ICIT|Patients in the intervention group will receive a number of consultations with their GP based on the ICIT
214419862|NCT05516654|DIAGNOSTIC_TEST|Routine bacteriological cultures|culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI
215019700|NCT05486286|DEVICE|NCKU-NG system|A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes. This system consists of a camera and light source that can be inserted into the commercial NG tube to view live video during feeding tube placement. Manual air insufflation may aid feeding tube placement and improve visualization of anatomic landmarks. After the procedure, an abdominal X-ray is done to confirm the position of the feeding tube.
214419863|NCT05516654|DIAGNOSTIC_TEST|Identification of the organism and antibiotic sensitivity will be done by VITEK II|Automated identification of the organism and antibiotic sensitivity will be done by VITEK II
214419864|NCT05516654|DIAGNOSTIC_TEST|Detection of biofilm formation|Detection of Biofilm formation to the collected organism by tissue culture plate method.
214419865|NCT05516654|DIAGNOSTIC_TEST|Molecular detection by PCR|Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.
214419866|NCT02045719|DRUG|uncaria tomentosa (cat´s claw)|
214419867|NCT01137266|DEVICE|TENS|TENS
214419868|NCT01412034|DRUG|CER-001|Biweekly infusion
214690017|NCT05980832|OTHER|Peer practitioner training - Peer Education Supported Psychosocial Skills Education|"Psychosocial skills training-practitioner training will be given to 4 patients diagnosed with chronic mental disorder by the research psychiatry nurse.~Educational content~1. Getting acquainted - briefing about the study~2. The Importance, Aims and Objectives of Psychosocial Skills Education~3. The importance of peer support~4. The importance, aims and objectives of peer education supported psychosocial skills training~5. Management of the meeting game, warm-up games and role plays~6. 1st and 2nd session peer education supported psychosocial skills training~7. 3rd and 4th session peer education supported psychosocial skills training~8. The last 5th and 6th sessions of peer education are supported by psychosocial skills training.~9. Key points and termination in group management. The training will be planned to last 10-13 hours in total. Trainer's booklet prepared by the researcher psychiatric nurse."
214690018|NCT05980832|OTHER|Peer Education Supported Psychosocial Skills Education|"It is a psychosocial skills training that will be given to both experimental groups in 6 sessions within 6 weeks. 2 of the 4 peer trainers who received the practitioner training will conduct the training. During the training period, the research psychiatric nurse will support.~Session titles are as follows:~1. Session:Preparation Session~2. Session: Understanding Mental Disorders~3. Session: Developing Communication Skills~4. Session: Developing Emotion Recognition and Expression Skills~5. Session: Dealing with Daily Living Activities and Problems~6. Session: Understanding the Stigma Experience~The duration of each session is determined as 90 minutes. Taking into account the patient's opinions breaks not exceeding 15 minutes will be given as needed."
214690019|NCT00704509|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
214690020|NCT00704509|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
214690021|NCT00704509|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
214690022|NCT00916500|DRUG|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
214690023|NCT01918098|DRUG|Oxycodone/naloxone prolonged release tablets|
215019701|NCT02233088|BEHAVIORAL|ELM Group|"ELM participants are trained to portion their meals according to the Perfect Plate method, a modified version of the USDA's ChooseMyPlate.gov. The stress management focuses on mindful living, cognitive restructuring; the enhancement of positive emotions. The physical activity component focuses on reduction of sedentary activity (by increasing daily step counts) and moderate-to-vigorous physical activity."
215019702|NCT02233088|OTHER|ELM Classes|ELM classes will be administered through Rush Generations program and focus on health education.
215019703|NCT02233088|OTHER|ELM Individual|ELM Individual arm participants will receive education materials on metabolic syndrome and diet, exercise, stress reduction recommendations. The participants will be recommended to follow these guidelines and discuss/seek support from their health care provider (visits at baseline, 3 and 6 months will be recommended.
215019704|NCT02744547|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
215019705|NCT00362323|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
215019706|NCT00362323|DRUG|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
215019707|NCT06516848|OTHER|High Intensity Inspiratory Muscle Training Group (H-IMT)|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device. Initially, it will be worked out vigorously at 80% of the maximum inspiratory pressure determined by mouth pressure measurement. The load will be increased weekly.
215019708|NCT06516848|OTHER|Low Intensity Inspiratory Muscle Training Group (L-IMT)|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device. Initially, it will be worked out vigorously at 30% of the maximum inspiratory pressure determined by mouth pressure measurement. The load will be increased weekly.
215019709|NCT00313898|DRUG|sildenafil (viagra)|
214419869|NCT03414736|DRUG|SAR425899|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
214419870|NCT02376036|DRUG|MGD010|MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
214419871|NCT02376036|DRUG|Placebo|Placebo comparator.
214419872|NCT02376036|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine, inactivated
214419873|NCT01569919|BIOLOGICAL|TroVax®|Dose of 1 x 10\^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
214419874|NCT01569919|DRUG|Pemetrexed|500 mg/m\^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
214419875|NCT01569919|DRUG|Cisplatin|75mg/m\^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
214419876|NCT01569919|DIETARY_SUPPLEMENT|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
214419877|NCT01569919|DIETARY_SUPPLEMENT|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
214419878|NCT01569919|DRUG|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
214419879|NCT06440824|DRUG|Romiplostim N01|2.0 µg/kg, subcutaneous injection, once a week, up to a maximum of 8 weeks. Stop medication when platelet count increases by 50 × 109/L or more compared to before medication
214419880|NCT06440824|DRUG|Recombinant Human Thrombopoietin|30000 U/d, subcutaneously injected once a day, for a maximum of 8 weeks. Medication should be stopped when platelets increase by 50 × 109/L or more compared to before medication
214419881|NCT00435799|PROCEDURE|corneal cross-linking (CCL)|
214419882|NCT00435799|DRUG|Riboflavin/dextran eyedrops|
214419883|NCT00435799|DEVICE|UV-X system|
215019710|NCT05125432|DEVICE|Acupuncture group|Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
215019711|NCT06277726|OTHER|Emotional freedom technique group|Emotional freedom technique will be applied to women in this group before intrauterine device application.
215019712|NCT06277726|OTHER|Music group|Women in this group will wear headphones and listen to music throughout the intrauterine device application.
214419884|NCT00630188|OTHER|You Decide|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
214419885|NCT00630188|OTHER|Reducing Your Risks in the Crash|Publicly available video on highway safety and reducing individual risks in a crash
214419886|NCT03312335|DRUG|Low-dose Aldesleukin (Proleukin®)|Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
215019713|NCT06277726|OTHER|Control group|No intervention will be applied to women in the control group.
214419887|NCT00153309|BEHAVIORAL|People with Arthritis Can Exercise|
214419888|NCT01002768|DRUG|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
214419889|NCT01002768|DRUG|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
214419890|NCT03320096|DEVICE|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3\*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
214419891|NCT05456386|BEHAVIORAL|The Circadian Rhythm Approach to Weight Loss (CRAWL)|The Circadian Rhythm Approach to Weight Loss (CRAWL) is a behavioral intervention that is designed to provide support for behavioral change to improve sleep and feeding parameters that will lead to sustainable weight loss.
214419892|NCT04485156|DRUG|High-dose rifampicin|30mg/kg
214419893|NCT04485156|DRUG|Isoniazid|300mg
214419894|NCT04485156|DRUG|Pyrazinamide|20-30mg/kg
214419895|NCT04485156|DRUG|Ethambutol|15-20mg/kg
214419896|NCT04485156|DRUG|Rifampicin|10mg/kg
214419897|NCT04577625|DIETARY_SUPPLEMENT|Lactobacillus reuteri (L. reuteri)|L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
214419898|NCT03582618|DRUG|Sorafenib|Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period
214419899|NCT03582618|DRUG|CVM-1118|CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle
214419900|NCT03342872|BEHAVIORAL|Core Training: FBS System Mapping and MTFS-I Installation|Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.
215019714|NCT00308282|DRUG|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
215019715|NCT00308282|DRUG|Placebo|IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
215019716|NCT05372900|OTHER|Test Product|Whey Protein Isolate with Mulberry leaf extract
215102443|NCT02082704|BEHAVIORAL|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
215019717|NCT05372900|OTHER|Control Product|Wheat Protein Hydrolysate
215019718|NCT04268212|DIETARY_SUPPLEMENT|Bitter melon juice (100 ml)|Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.
215102444|NCT04787172|RADIATION|Multi Slice computed tomography|use of MSCT as a diagnostic tool in evaluation of patients with congenital cardiovascular anomalies
215102445|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
215102446|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
215102447|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
215102448|NCT02140749|DIETARY_SUPPLEMENT|Placebo|Chewing tablets without short-chain Fructooligosaccharides
215102449|NCT04566432|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
215102450|NCT02623582|BIOLOGICAL|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
215102451|NCT02623582|DRUG|Cyclophosphamide|Given IV
215019719|NCT04268212|BEHAVIORAL|Exercise|The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
215019720|NCT04663217|OTHER|Exercise|After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
215019721|NCT06265805|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
215019722|NCT06265805|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
215029077|NCT05566236|BEHAVIORAL|board game|A board game was designed based on situated learning theory and the results of relevant studies. This board game contains a summary, answer booklet, and multiple card game tasks including situations of interpersonal interaction. The participants must discuss, share personal experiences, and find the answer together.
214419901|NCT03342872|BEHAVIORAL|Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings|Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
215102452|NCT02545764|OTHER|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
214419902|NCT05818904|OTHER|Physical Therapy|All arthrosis participants will be treated as the traditional methods using physical therapy.
214419903|NCT01667354|BEHAVIORAL|Academic Detailing|"The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations."
214419904|NCT00709644|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid.|
214506111|NCT04305340|DEVICE|Myant SKIIN Device|"1. Supine position: Participant lays on a bed on their back for 5 minutes~2. Sitting position: Participant sits on a chair for 5 minutes~3. Standing position: Participant stands for 5 minutes.~4. Exercise measurement: treadmill exercise test - the protocol entails increases of 0.5 mph every minute with zero change in the incline. Starting point would 1.5 mph. The test will be interrupted if the target heart rate of 190 beats per minute is reached or if symptoms and/or arrhythmias and ST depression would be observed. Patient will be monitor during recovery for 5 minutes.~5. Cool-down: Participants cool-down for 5 minutes"
214506112|NCT03620955|OTHER|Justified risk stratification based on MRD after three course chemo therapy|All patients are routinely divided into different risk groups according to the NCCN guild based on cytogenetic and molecular abnormality. Then all patients are treated with anthracycline combined with cytarabine regimens for two courses . The patients without obtaining CR will go on one cycle of salvage therapy and then be bridged to allo-HSCT. Those acquiring CR will be given one more course of HDAC as consolidation treatment and then be detested MRD with flow cytometry after that. The patients with MRD positive would be moved to a higher risk class.The stratified therapy should be considered according to the new risk stratification.
214506113|NCT03075683|BEHAVIORAL|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
215102453|NCT03693547|DRUG|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
214506114|NCT03075683|BEHAVIORAL|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
214506115|NCT00343083|DRUG|Erbitux, Paclitaxel & Carboplatin|"Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)"
214506116|NCT00343083|RADIATION|Radiation|XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
214506117|NCT04187482|OTHER|Exercise training|All participants with DM1 will undergo a 12-week aerobic exercise training intervention on a cycle ergometer
214506118|NCT01951703|DEVICE|senofilcon A|Control, senfilcon A
214506119|NCT01951703|DEVICE|senofilcon A|Test, senofilcon A
214506120|NCT01009645|BEHAVIORAL|Fact Only Education Message|Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
214419905|NCT04852146|PROCEDURE|Electronic feedback|Feedbacks have been identified as one of the most effective interventions to improve practices and organisations in health care institutions. It is also a tool for facilitating and coordinating practice registers, improving the contribution of data producers and the quality of data.
214419906|NCT00261053|DRUG|i.v. recombinant human C1 inhibitor|
214419907|NCT04629118|DEVICE|Selution SLR™ 018 Drug Eluting Balloon|Target lesion will be pre-dilated with high pressure non-compliant balloon, then treated with SELUTION SLR™ 018 DEB Balloon.
214419908|NCT03163186|PROCEDURE|Transarterial embolization|Transarterial hepatic embolization of liver cancer
214419909|NCT01064804|DRUG|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
215019723|NCT06265805|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
215019724|NCT00548561|DRUG|Dexrazoxane|
215019725|NCT01713140|OTHER|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
215019726|NCT00498485|DRUG|Placebo|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
215019727|NCT00498485|DRUG|Sodium Oxybate|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
215019728|NCT04607382|DRUG|LEP|LEP dosage up to the discretion of the treating gynecologists.
215019729|NCT04607382|DRUG|NSAIDs and/or Chinese medicine (CM)|Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
215019730|NCT03832088|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale performed for balance disorder
215019731|NCT03832088|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test for walking speed
215019732|NCT03832088|DIAGNOSTIC_TEST|Jamar hand dynamometer|Jamar hand dynamometer for grip strength which correlates with muscle strength of patient
215019733|NCT03832088|DIAGNOSTIC_TEST|Calf circumference|Calf circumference for muscle mass evaluation. Calf circumference is an anthropometric measurement which correlates with muscle mass.
215019734|NCT01506375|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
215019735|NCT01506375|BIOLOGICAL|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
215019736|NCT01539525|BEHAVIORAL|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
215019737|NCT01539525|OTHER|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
215019738|NCT04356443|DEVICE|AirGo Respiratory Monitor|AirGo™ is composed of a wearable, miniaturized recorder unit and a medical grade Holter worn over the floating ribs of patients both at rest and during normal activity. The recorder measures live circumference changes.
215019739|NCT04086667|OTHER|Spinal manipulation|Spinal manipulation: The patient is placed in the side-position and a standard manipulation lumbar-roll technique will be applied at the indicated segment dependent on the subgroup indication.
215019740|NCT00190892|DRUG|olanzapine|
215019741|NCT00190892|DRUG|carbamazepine|
215019742|NCT06255587|OTHER|Screening|cross sectional
214419910|NCT00525850|OTHER|high fat diet|high saturated fat no starch diet
214419911|NCT00525850|OTHER|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
214419912|NCT04276402|PROCEDURE|Irradiation of implants with 808nm laser|Irradiation of implants with 808nm laser
214419913|NCT00908817|DRUG|triamcinolone acetonide|paste applied over tracheal tube for lubrication
214419914|NCT00908817|DRUG|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
214419915|NCT04505943|DRUG|Isonicotinic Acid Hydrazide|2 vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
214419916|NCT04505943|DRUG|dinoprostine|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
214419917|NCT04505943|DRUG|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion
214419918|NCT03743246|DRUG|JCAR017|JCAR017
214419919|NCT03743246|DRUG|Lymphodepleting|Lymphodepleting
214419920|NCT03743246|DRUG|Fludarabine|Fludarabine
214419921|NCT03743246|DRUG|Cyclophosphamide|Cyclophosphamide
214419922|NCT01490580|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
214419923|NCT01490580|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
214419924|NCT03400488|DRUG|AZD5718 oral suspension|In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
214506121|NCT01009645|BEHAVIORAL|Fact and Myth Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
214506122|NCT01009645|BEHAVIORAL|Fact, Myth, Why Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
215019743|NCT05415111|PROCEDURE|Subepithelial connective tissue|Study specific intervention is the placement of a soft tissue autogenous graft (SCTG) in addition to bone grafting of periimplantitis-affected implants.
215019744|NCT05415111|PROCEDURE|Volume stable Collagen Matrix|Study specific intervention is the placement of a soft tissue substitute (VCMX) in addition to bone grafting of periimplantitis-affected implants.
215019745|NCT05415111|PROCEDURE|No soft tissue augmentation|Study specific control intervention is the placement of a bone graft at periimplantitis-affected implants. No soft tissue grafts will be placed.
215019746|NCT01712074|DRUG|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
215019747|NCT01712074|OTHER|Placebo|Placebo QD
215019748|NCT05150288|OTHER|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
214506123|NCT01009645|BEHAVIORAL|Control Educational Message|Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
214506124|NCT03086226|DRUG|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
214506125|NCT03086226|DRUG|Itraconazole|This will be the active comparator
214506126|NCT05785325|DRUG|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
214506127|NCT06227988|PROCEDURE|patients with liver disease who undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
214506128|NCT06227988|PROCEDURE|patients with liver disease who do not undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
214506129|NCT02808832|BEHAVIORAL|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
214506130|NCT00396487|DRUG|Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat|
214506131|NCT05672485|DIAGNOSTIC_TEST|SPECT/CT imaging with 99mTc-P137 nuclide probe|inject the tracer 99mTc-P137 to subjects and perform SPECT/CT scans
214506132|NCT03946956|BEHAVIORAL|Prebooking|Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
214506133|NCT03946956|BEHAVIORAL|Pictured invitation|Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
214506134|NCT05400759|OTHER|IOP monitoring data|
214506135|NCT00141232|DRUG|Atorvastatin and Omega-3 fatty acids|
214506136|NCT01586416|BEHAVIORAL|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
214506137|NCT00620854|DRUG|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
214506138|NCT00620854|DRUG|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
214506139|NCT00620854|DRUG|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
214506140|NCT00620854|DRUG|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
214506141|NCT02407899|DRUG|Saxagliptin|Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.
214506142|NCT02407899|DRUG|Vitamin D3|Take vitamin D drops 2000 IU p.o. qd. for 104 weeks after randomization.
215019749|NCT00754286|OTHER|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
214419925|NCT03400488|OTHER|Placebo matching AZD5817 oral suspension|In all cohorts, randomized subjects will receive orally placebo matching AZD5718 oral suspension on Day 1 and from Days 3 to 10. On Day 2, no dose will be given.
214419926|NCT01159704|BEHAVIORAL|Peer Education Model|The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.
214419927|NCT01159704|BEHAVIORAL|HIV Counseling and Education Model|"The C \& E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
214419928|NCT04955119|DIAGNOSTIC_TEST|Fusion imaging contrast-enhanced ultrasound|"Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
214419929|NCT03662399|DEVICE|Insoles|Orthotic Insoles
215019750|NCT00754286|OTHER|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
215019751|NCT03123107|DRUG|Ascorbic Acid|Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
215019752|NCT02474901|BIOLOGICAL|Quadrivalent Live Attenuated Influenza Vaccine|
214419930|NCT03662399|OTHER|Standard shoe|Standard shoe
215019753|NCT01472835|DRUG|Midazolam|Used for anxiolysis
215019754|NCT01472835|DRUG|Fentanyl|Used for analgesia and as a sedative
215019755|NCT04180878|BEHAVIORAL|Intervention|Participants received a interactive physical activity monitoring system that allowed study personnel to monitor their activity level.
215019756|NCT04180878|BEHAVIORAL|Intervention 2|Participants received an interactive physical activity monitoring system, an electronic scale to report weekly body weight, weekly hour long conference calls with structured interactive educational lessons led by Health Educator, dietary recalls were completed at three different time points during their participation, and study personnel monitored physical activity levels weekly.
215102454|NCT02961491|DRUG|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
215102455|NCT00089947|DRUG|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
214419931|NCT01465243|DRUG|Icotinib|125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
214419932|NCT04302155|OTHER|balance-specific -games focusing on dynamic aspects of COP on Wii fit system.|"The participants were randomly assigned into two groups interventional and control. Total 18 minutes session was given to both groups wii fit group and traditional balance training group. All participants were given 3 sessions per week for 6.~Total 48 participants were initially accessed initially for eligibility , 13 participants were excluded because of having good balance and good balance age score on Wii fit assessment, 35 participants were recruited for balance training. These participants were randomly divided into Wii fit and traditional training group through sealed enveloped method 18 participants was recruited in Wii fit group and 17 in traditional balance training group. 3 participants drop out from Wii fit group and 2 from traditional balance training group.~Some examples include catching apples in a basket ,moving a golf ball around barriers towards a hole , popping rising balloons/bubbles and air hockey ."
214419933|NCT04302155|OTHER|mini trampoline and inflatable discs group|"High skipping and landing on a limb every time (2 repeats of 45 s each leg).Standing on one leg and try to catch the ball thrown at them in various directions by the researcher (2 repeats of 45 s each leg) Exercises in inFlated rubber hemisphere attached toa rigid platform (BOSU)~1. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance (2 repeats of 45 s each leg).~2. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance, while lifting the non-support leg forward and backward (2 repeats of 45 s each leg).~3. Standing on BOSU flat hard surface with both legs, in an attempt to maintain balance (3 minutes on both legs).~4. Standing on BOSUs flat hard surface with both feet, in an attempt to maintain balance, while trying to catch the ball thrown at them by the experimenter in various directions (3 minutes on both leg)"
214419934|NCT04630912|OTHER|Acceptance and Commitment Therapy|There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
214419935|NCT04534712|DIAGNOSTIC_TEST|LYMPHOCYTE MONOCYTE RATIO|Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
214419936|NCT04083833|DRUG|Tetrodotoxin|A single TTX dose in a dose ascending study
214419937|NCT04083833|DRUG|Placebos|matching placebo comparator
214419938|NCT02404337|DRUG|Betaine|
215019757|NCT04483232|BIOLOGICAL|Ear canal swab|Ear canal swab
215019758|NCT04545372|OTHER|aerobic exercise|
215019759|NCT00747071|DRUG|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
215019760|NCT03450135|BEHAVIORAL|Trier Social Stress Test|Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
215019761|NCT03450135|BEHAVIORAL|Emotional go/no-go task|Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
215019762|NCT03372915|BEHAVIORAL|Standard Exposure|Exposure therapy conducted according to standard clinical care practices
215102456|NCT00000572|PROCEDURE|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
215102457|NCT00000572|PROCEDURE|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
215102458|NCT01262664|DRUG|Prohibitin-TP01|Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
214419939|NCT04635488|PROCEDURE|lateral lymph node dissection|All participted would receive lateral lymph node dissection for rectal cancer.
214419940|NCT00949975|DRUG|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
214419941|NCT00949975|DRUG|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
214419942|NCT00949975|DRUG|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
214419943|NCT00949975|DRUG|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
214419944|NCT04302844|BEHAVIORAL|Imago Relationship Therapy|Imago relationship therapy (IRT) involves learning the Imago dialogue process, which helps couples understand more clearly why they and their partners react as they do. Couples practice communicating in a manner that helps them move from reactivity and blame to understanding and empathy. The dialogue is used to transform conflicts into opportunities for healing and growth, and to connect more deeply and effectively with one another. Specific topics of therapy are determined by the couple's needs and goals. In general, the therapist helps them use the Imago dialogue to promote understanding, heal painful emotions, and make requests of one another to change behaviors. In effort to minimize risk of exposure to the virus that causes COVID-19, since the spring of 2020, therapy sessions will be conducted via telehealth, with a HIPAA-compliant audio/visual platform, and with couples at home or in another private place during the therapy sessions and the therapist in his or her office.
214419945|NCT04302844|BEHAVIORAL|Waitlist with Bibliotherapy followed by Workshop|"Participants assigned to this group will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read, with exercises to practice, during that time. After 12 weeks and the 12-week assessment has been completed, couples will attend an educational workshop that provides the principles and communication skills of Imago Relationship Therapy, typically in a weekend format that is usually about 18-20 hours. The workshops, called Getting the Love You Want (GTLYW), are led by certified and experienced Imago workshop presenters, and are attended by a group of couples. The workshop includes presentations, discussions, and practice of communication exercises. Participation in the workshops will also be virtual or via telehealth, as described above."
214419946|NCT02457507|DIETARY_SUPPLEMENT|Vitamin B12|2 tablets
214419947|NCT02457507|DIETARY_SUPPLEMENT|Placebo|2 tablets
214419948|NCT04664049|DIETARY_SUPPLEMENT|NRICM101|"Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
214419949|NCT05452980|PROCEDURE|reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
214419950|NCT05452980|PROCEDURE|sleeve gastrectomy|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
215019763|NCT03372915|BEHAVIORAL|Exposure + Inhibitory Learning|Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction
215019764|NCT00430664|PROCEDURE|Pleurodesis with either talc or iodopovidone|
215019765|NCT01864096|DRUG|Metformin|One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
215019766|NCT01864096|DRUG|Placebo|One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
214419951|NCT00568542|DRUG|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
214419952|NCT00568542|DRUG|placebo|35 I.E. kg body weight placebo to erythropoetin beta
214419953|NCT02873754|BEHAVIORAL|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
214419954|NCT02873754|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
215019767|NCT04063904|DRUG|Mifepristone|One 200 mg pill (oral)
215019768|NCT04063904|DRUG|Misoprostol|Two 400 mcg pills (sublingual)
215019769|NCT01760980|DRUG|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
214419955|NCT02873754|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
215019770|NCT01760980|DRUG|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
215019771|NCT00620802|DRUG|CGT-2168|(CGT-2168, one capsule each daily)
215019772|NCT00620802|DRUG|Plavix|(clopidogrel, 75 mg)
215019773|NCT01968408|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10(9) CFU/daily
215019774|NCT01968408|DIETARY_SUPPLEMENT|Placebo|
215019775|NCT04455295|DEVICE|Transdermal Vagus Nerve Stimulation (tVNS)|Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.
215029078|NCT06673836|DEVICE|DYNAMIC CYCLING|"Balance Training: Exercises focused on improving coordination and balance, such as standing on one leg, walking on uneven surfaces, or using balance boards.~Core Strengthening: Strengthening core muscles helps children maintain stability during dynamic movements, such as walking or running.~Proprioceptive Training: Exercises that improve awareness of the body's position in space, such as obstacle courses or activities that challenge movement coordination."
215029079|NCT06673836|DEVICE|INCLINED TREAD MILL|Dynamic Cycling: Refers to the fluctuating nature of movement patterns, often used in therapies like stationary biking or recumbe.nt cycling, where the intensity and resistance vary. Dynamic cycling can also refer to training that involves alternating between high and low-intensity phases or cycling between different positions (sitting, standing) or speeds during the activity
215019776|NCT01248390|BEHAVIORAL|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
214419956|NCT02873754|DRUG|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
214419957|NCT02873754|DRUG|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
214419958|NCT02873754|DRUG|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
214419959|NCT00309088|DRUG|tacrolimus|oral
214419960|NCT00309088|DRUG|placebo|oral
214419961|NCT00576888|OTHER|no intervention|no intervention - observational only
214419962|NCT02578108|PROCEDURE|genicular nerve diagnostic block with lidocaine (local anesthetic)|sensory denervation of the knee joint
214419963|NCT02578108|PROCEDURE|genicular nerve radiofrequency ablation|Ablation of the genicular nerves of the knee by radiofrequency energy
214419964|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
214419965|NCT00128193|OTHER|MLSA-LAM|Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
215019777|NCT04941365|DIAGNOSTIC_TEST|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
215019778|NCT06499220|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulation (SCS) as an aid in the management of chronic, intractable pain of the trunk and/or limbs.
215019779|NCT00398242|DEVICE|above or below elbow cast for the last 3 weeks of treatment|
215019780|NCT06253728|DIETARY_SUPPLEMENT|High fiber and protein meal|In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.
215019781|NCT06253728|DIETARY_SUPPLEMENT|Control|The control meal is low fiber and low protein meal.
215019782|NCT02903381|DRUG|Nivolumab|Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
215019783|NCT02903381|DRUG|Lenalidomide|Oral, predetermined dosage, Days 1-21 of cycle 1-12
215019784|NCT02903381|DRUG|Dexamethasone|Oral, Days 1, 8, 15 of cycle 1-6
215019785|NCT05612607|DRUG|Immunoglobulin replacement therapy (IGRT)|IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
215019786|NCT03028922|DEVICE|creos xenogain|GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
215019787|NCT04113980|OTHER|music group|The children in the groups were distracted by music 2 minutes before venipuncture, until the process was over
215019788|NCT04113980|OTHER|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before venipuncture, until the process was over
215102459|NCT04783077|BEHAVIORAL|WhatsApp|Participants assigned to the WhatsApp group will receive weekly messages developed by communication specialists aimed to motivate blood donation, be encouraged to discuss their blood donation experiences, and share their own motivations for donating blood in a moderated, closed group over a six-month duration. The moderator will provide guidelines on acceptable use of WhatsApp in the group, including images they can or cannot share. Participants will also receive standard NBSG communications for first-time donors.
215102460|NCT04783077|BEHAVIORAL|Control|Participants in this group will receive the standard NBSG communications for first-time donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to the second blood donation eligibility. The second blood donation eligibility is four months after the first donation.
215102461|NCT04783077|BEHAVIORAL|Docudrama|Participants will be exposed to a document-drama related to blood donation.
215102462|NCT01141491|BIOLOGICAL|Trivalent ganglioside vaccine|Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
215019789|NCT04113980|OTHER|video group|The children in the groups were distracted by watching video 2 minutes before venipuncture, until the process was over
214419966|NCT00128193|OTHER|MLCwA|Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
214419967|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|Licensed TB reagent, 100 microliters, 5 TU dose.
214419968|NCT00128193|OTHER|Placebo|Saline (NaCl) serves as a diluent control in Stage A and B only.
214419969|NCT00197886|DRUG|Changing dose of norepinephrine and blood pressure|
214419970|NCT02010619|BEHAVIORAL|Cognitive behavior therapy|
214419971|NCT02010619|BEHAVIORAL|Supportive therapy|
214419972|NCT01184235|DRUG|Pharmacological Intervention|This study will include those anticipating or receiving any pharmacological intervention
214419973|NCT02955524|DRUG|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
214419974|NCT02955524|DRUG|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
214419975|NCT01800513|PROCEDURE|Endometrial Biopsy|
214419976|NCT01800513|PROCEDURE|Sham Procedure|
215019790|NCT01796444|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
215019791|NCT01796444|PROCEDURE|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
215019792|NCT01796444|PROCEDURE|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
215019793|NCT01796444|PROCEDURE|Pathological Evaluation|H\&E and IHC
215019794|NCT01796444|DRUG|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
215019795|NCT01796444|RADIATION|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
215019796|NCT04303403|DRUG|Trametinib|Taken orally once daily
214419977|NCT05998005|BEHAVIORAL|First Face Training Program|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
214419978|NCT03705299|DEVICE|Non-Invasive CVP vs Standard CVP|
214419979|NCT03390569|BEHAVIORAL|Exercise|The patients meet with a registered physiotherapist and receive individualized exercise programs starting the second week of treatment, and continuing up to 3 months later.
214690024|NCT01977053|OTHER|Clinical and psychosocial phone calls|"The standard medical supervision is defined as follows:~* Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.~* Nominative notebook containing details of chemotherapy administered and medical contacts.~* Consultations with psycho-oncologist or psychiatrist (if necessary).~The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported."
214690025|NCT00214851|DRUG|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
214690026|NCT04136353|DRUG|Darolutamide|2 x 300mg oral tablets twice daily for 96 weeks
214690027|NCT04136353|DRUG|Placebo oral tablet|2 oral tablets twice daily for 96 weeks
214690028|NCT04136353|DRUG|Luteinizing Hormone-Releasing Hormone Analog|All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.
215019797|NCT04303403|DRUG|Ruxolitinib|Taken orally twice daily
215019798|NCT00067873|BEHAVIORAL|Diet|
215019799|NCT00067873|BEHAVIORAL|Aerobic exercise|
214419980|NCT06345417|OTHER|Patient Blood Management (PBM)|PBM is a strategy to manage the participant's own blood. Its focus is on anemia, bleeding and coagulation management.
214419981|NCT06345417|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
214419982|NCT00082810|DRUG|fulvestrant|Given intramuscularly
214419983|NCT00082810|DRUG|tipifarnib|Given IV
214419984|NCT00354406|DRUG|abciximab|standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
214419985|NCT05053009|DRUG|Brufen Retard|800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
214419986|NCT02950558|DRUG|Ropivacaine|Single injection of ropivacaine immediately prior to surgery.
214419987|NCT02950558|PROCEDURE|Nerve block|insertion of catheter to deliver continuous 5 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
214419988|NCT06017167|DRUG|Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .|compare antiemetic effects between dexmedetomidine and ondansetron in the first group versus dexamethasone and ondansetron in the second group
214690029|NCT04136353|RADIATION|External Beam Radiotherapy|All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
215019800|NCT00067873|BEHAVIORAL|Resistance exercise|
215019801|NCT01570907|DRUG|Quetiapine Fumarate|25 mg tablet
215019802|NCT02405065|DRUG|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
215019803|NCT04779593|OTHER|Clinical examination|Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.
215019804|NCT04779593|OTHER|SF36 questionnaire|"At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.~Items are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).~Scoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life)."
215029080|NCT06688305|DRUG|68Ga-NI-FAPI|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-NI-FAPI.
215029081|NCT05365880|DRUG|Liquid Lidocaine|The investigational treatment is 2 mL of aqueous 2% lidocaine.
215029082|NCT05365880|DRUG|Placebo|The active placebo comparator will be provided to participant.
215029083|NCT04943341|PROCEDURE|Eco-guided Triamcinolone-Acetonide injection|"The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with in plane technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed."
215029084|NCT03648372|DRUG|TAK-981|Intravenous infusion.
215029085|NCT04211870|RADIATION|LED clusters|Each LED board contains six (6) LEDs with a wavelength of 660nm and a duration of seven (7) minutes in each muscle. The treatment was carried out in a total of four (4) sessions, one (1) session per week.
215029086|NCT06349304|DIETARY_SUPPLEMENT|Freeze-dried table grape powder|Consumption of grape powder as part of daily diet
215019805|NCT04779593|OTHER|AIMS2_SF questionnaire|At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.
215019806|NCT04779593|OTHER|WOMAC questionnaire|At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.
215019807|NCT04779593|OTHER|EQ-5D-5L questionnaire|At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.
215019808|NCT04779593|BIOLOGICAL|Blood Sample Complete blood count|Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit
215102463|NCT01141491|BIOLOGICAL|OPT-821|Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
215102464|NCT04130698|BEHAVIORAL|Distress Tolerance|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
215102465|NCT04130698|DRUG|transdermal nicotine patch|Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
215102466|NCT04130698|BEHAVIORAL|Active Health Control|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
215019809|NCT04779593|BIOLOGICAL|Blood Sample Iron panel|Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.
215019810|NCT04779593|BIOLOGICAL|Blood Sample Fasting Glucose|Blood Sample Fasting Glucose at D0 and M24/end follow-up visit
215102467|NCT02954666|DEVICE|radio-frequency ablation|"Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications \> 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
215102468|NCT05943782|PROCEDURE|onlay manufactured by milling|indirect restorations for treating mutilated molars manufactured by CAD/CAM subtractive technique
215102469|NCT05943782|PROCEDURE|Onlay manufactured by 3D printing|indirect restorations for treating mutilated molars manufactured by CAD/CAM additive technique
215102470|NCT02409719|OTHER|Schedule|Illustrative daily planner to point the day that the exercise was performed
215102471|NCT02409719|OTHER|Verbal Information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
215102472|NCT02479139|BIOLOGICAL|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
215102473|NCT02479139|BIOLOGICAL|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
215102474|NCT01391988|PROCEDURE|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
215102475|NCT01391988|PROCEDURE|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
215102476|NCT00849862|DRUG|Levetiracetam|750 mg Tablet
215102477|NCT00849862|DRUG|Keppra®|750 mg Tablet
215102478|NCT03505736|BIOLOGICAL|Adenosine|Given IV
215102479|NCT03505736|PROCEDURE|Magnetic Resonance Imaging|Undergo CMR imaging
215102480|NCT03505736|DRUG|Regadenoson|Given IV
215102481|NCT03505736|PROCEDURE|Stress Management Therapy|Undergo stress test
215102482|NCT05954767|DRUG|IS-001|IV injection of IS-001 drug substance with near infrared (NIR) imaging
215102483|NCT04314076|OTHER|Rhythmic auditory stimulation|RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.
214419989|NCT06017167|DRUG|Ondansetron 4mg + dexamethasone 8mg + normal saline.|Group II: Ondansetron 4mg + dexamethasone 8mg + normal saline.
214419990|NCT05078424|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a well-established, evidence-based intervention frequently used for easing depressive and anxiety symptoms. The intervention will be delivered for 6-7 sessions, each session lasts for 1.5 hours, in the format of a group for a period of 6-7 weeks by frontline social or youth workers trained by professional CBT clinicians. Core treatment components include mood monitoring, emotion education, behavioural activation, emotion cycle/ ABC model, identification of automatic thoughts, and cognitive restructuring. It is designed to improve youths' abilities/ skills in handling their moods to have better emotional management.
214419991|NCT06342063|DEVICE|Blood Flow Restriction Therapy|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is inflated.
214419992|NCT06342063|DEVICE|Blood Flow Restriction Therapy Sham|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is not inflated.
214419993|NCT05577611|COMBINATION_PRODUCT|Basic chemotherapy + UCB transplantation|"The basic chemotherapy regimen was the same as that of the control group~UCB micro transplantation scheme:~Aza 100mg, 75mg/m2/d, IVGTT, D-10 to D-4~Ara-C 1000mg/m2/q12h, IVGTT, D-3 to D-2~Single non consanguineous umbilical cord blood (NC \> 1.5 \* 10 \^ 7 / kg), IVGTT, D0~Bone marrow aspiration smear, MRD and bone marrow chimerism were detected on D14, d30 and D60 after transplantation."
214419994|NCT00004878|BIOLOGICAL|therapeutic allogeneic lymphocytes|
214419995|NCT00004878|DRUG|cytarabine|
214419996|NCT00004878|DRUG|fludarabine phosphate|
214419997|NCT00004878|DRUG|idarubicin|
214419998|NCT00004878|DRUG|methotrexate|
214419999|NCT00004878|DRUG|tacrolimus|
214420000|NCT00004878|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
214420001|NCT00004878|PROCEDURE|peripheral blood stem cell transplantation|
214420002|NCT01147380|BIOLOGICAL|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
214420003|NCT01321606|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10\^10 organisms
214420004|NCT01321606|DIETARY_SUPPLEMENT|sugar pill (placebo)|Placebo identical to the active product will be given
214420005|NCT06318104|DRUG|Tegoprazan|Tegoprazan 50 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
214420006|NCT06318104|DRUG|Esomeprazole 40mg|Esomeprazole 40 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
214420007|NCT00637234|DRUG|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
214420008|NCT00637234|DRUG|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
214420009|NCT03745001|DRUG|EHP-101 Liquid single dose|One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
214420010|NCT03745001|DRUG|EHP-101 Liquid multiple doses|One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
214420011|NCT03745001|DRUG|Matching placebo|Oral liquid administration daily
214420012|NCT05496816|DIAGNOSTIC_TEST|CAC in septic patients|"Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge."
214420013|NCT04747756|OTHER|Virtual Village|The purpose of this study is to create a virtual village for people aging with HIV, and to pilot test the virtual village intervention as a final step.
214420014|NCT00021008|DRUG|picoplatin|
214420015|NCT05739903|DRUG|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
214420016|NCT05739903|DRUG|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
214506143|NCT02407899|DRUG|Insulin|For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
215019811|NCT04779593|BIOLOGICAL|Blood sample lipid panel|Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit
215019812|NCT04779593|BIOLOGICAL|Blood sample liver panel|Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit
215019813|NCT04779593|BIOLOGICAL|Blood sample C reactive protein|Blood sample C reactive protein at D0 and M24/end follow-up visit
215029087|NCT06349304|DIETARY_SUPPLEMENT|Placebo grape powder|Consumption of placebo grape powder as part of daily diet
215102484|NCT04314076|OTHER|Gait Training|Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.
215102485|NCT02027753|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution Route of administration: subcutaneous
215102486|NCT02027753|DRUG|Metformin|Pharmaceutical form: tablet Route of administration: oral
215102487|NCT02027753|DRUG|DPP-4 inhibitor|Pharmaceutical form: tablet Route of administration: oral
215102488|NCT02027753|DRUG|Sulphonylurea|Pharmaceutical form: tablet Route of administration: oral
215019814|NCT04779593|PROCEDURE|Bloodletting - control group|Patients treated with bloodletting according to current guidelines (ferritin alone). Patient will undergo bloodletting with a goal of maintaining a serum ferritin equal or lower than 50 g/L according to current clinical practice guidelines (French and European).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.
214420017|NCT02387099|DRUG|3 weeks Dose Induction of Everolimus|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
214420018|NCT02387099|DRUG|3 weeks Conventional Everolimus Dosing|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
214420019|NCT02387099|DRUG|Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
214420020|NCT02387099|DRUG|Standard Care after 24 weeks|It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
214420021|NCT04039984|DEVICE|Prime Cup|Patients in this group will have the Prime cementless acetabular cup used during surgery.
214420022|NCT04876573|DRUG|Cyproheptadine Hydrochloride 4 MG|"Phase 1: Cyproheptadine 4 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~Phase 2: Cyproheptadine 8 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~The dose will be adjusted according to the renal function."
214420023|NCT02613676|DEVICE|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
214420024|NCT02613676|OTHER|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
214420025|NCT03311113|OTHER|Drug adherence questionnaire|Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
214420026|NCT00537563|DRUG|Telithromycin|
214420027|NCT00933088|OTHER|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.~Mothers will be asked to complete data form."
214420028|NCT01464736|OTHER|physical training|For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
214420029|NCT02271971|DIETARY_SUPPLEMENT|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
214420030|NCT02271971|DIETARY_SUPPLEMENT|Placebo|A daily placebo capsule during 6 weeks.
214420031|NCT02889237|DIETARY_SUPPLEMENT|Calcium|Immediate administration of daily calcium supplementation for 12 weeks
214420032|NCT02889237|DIETARY_SUPPLEMENT|Calcium + low dose vitamin D|Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
214420033|NCT02889237|DIETARY_SUPPLEMENT|Calcium + high dose vitamin D|Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
214420034|NCT02914522|DRUG|Filgotinib|Tablet(s) administered orally once daily
214420035|NCT02914522|DRUG|PTM filgotinib|Tablet(s) administered orally once daily
214420036|NCT04838158|DIAGNOSTIC_TEST|Isokinetic measurements|Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).
214506144|NCT02407899|DRUG|Metformin|Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
214506145|NCT05478096|BEHAVIORAL|GetStarted|Guided internet-based intervention for procrastination.
214506146|NCT02560961|OTHER|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
215019815|NCT04779593|BIOLOGICAL|BioBank|Blood sample will be collected for BioBank at D0, M12 and M24.
215019816|NCT04779593|OTHER|Medico-economical|Medico-economic data will be collected at each follow up visit.
215019817|NCT04779593|PROCEDURE|Bloodletting - experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin. Patients will undergo bloodletting with a goal of maintaining a serum transferrin saturation equal or lower than 50 % and a serum ferritin lower than the upper limit of the normal range (300 g/L for men and 200 g/L for women).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit."
214420037|NCT03276104|PROCEDURE|IOL repositioning|Intraocular lens repositioning by scleral suturing
214420038|NCT03276104|PROCEDURE|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
214420039|NCT06064357|OTHER|Transverese friction massage and tissue floss technique|"Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf of both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval.4 session / week for 6 weeks.~Tissue floss band will be applied on Rectus femoris, hip adductors, calf and hamstring of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap and then 10 Reps of rom will be performed the rest interval is 2 mint. 4 sessions / week for 6 weeks.~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf (10 repetitions with at least 8 seconds hold) 4 times / week for 6 weeks."
214420040|NCT04043364|BEHAVIORAL|LIVE|Learning, Innovation, Volunteers and Empowerment
214420041|NCT03949348|PROCEDURE|Mid-urethral sling placement using autologous rectus fascia|Mid-urethral sling placement using autologous rectus fascia
214420042|NCT03949348|PROCEDURE|Mid-urethral sling placement using synthetic mesh|Mid-urethral sling placement using synthetic mesh
214420043|NCT04825184|BEHAVIORAL|Body image chatbot|See arm/group description.
214420044|NCT01482013|DRUG|HPP854|Oral, once a day for 28 days.
214420045|NCT01482013|DRUG|Placebo|Oral, once a day for 28 days.
214420046|NCT02662530|DRUG|Botulinum Toxin Type A|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
214420047|NCT06024369|DEVICE|CPM Device|Wearable monitor used for 5 minutes per day.
214420048|NCT05356572|DEVICE|Investigational Skin Preparation Device|Removal of hyperkeratotic skin with Investigational Skin Preparation Device
214420049|NCT05356572|DEVICE|GMDN 47102 / Electrode Skin Abrasive Pad|Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation
214506147|NCT02560961|OTHER|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
215019818|NCT06549920|RADIATION|Internal mammary node irradiation|Irradiation of the internal mammary nodes in intercostal space 1-4.
214506148|NCT02773862|DEVICE|HS-1000|
214506149|NCT02318628|DEVICE|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|"CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.~CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability."
214506150|NCT02539576|DRUG|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
215019819|NCT02815254|OTHER|High intensity functional exercise|
215019820|NCT02815254|OTHER|Low intensity functional exercise|
215019821|NCT00667589|DRUG|urea 40% cream|urea 40% cream applied twice per day to affected areas
215019822|NCT00667589|DRUG|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
215019823|NCT00667589|DRUG|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
214420050|NCT05356572|DEVICE|UMDNS 13-230 / Biopsy punch (Dermal Curette)|Removal of hyperkeratotic skin with Disposable Dermal Curette
214506151|NCT04160559|OTHER|green tea|The investigators require patients to regularly drink green tea during the trial period.
214420051|NCT01802866|DRUG|ACU-4429|Take orally once daily for 24 months
214420052|NCT01802866|DRUG|Placebo|Take orally once daily for 24 months
214420053|NCT00413595|OTHER|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
214506152|NCT01958385|DEVICE|placement of g-Cath EZ suture anchors|
215019824|NCT00667589|DRUG|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
214420054|NCT04300426|DRUG|"ACHIM as solute (10^9 intestinal microbes/ml)"|Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
214420055|NCT02200159|DRUG|Sedation with dexmedetomidine|
214420056|NCT01130558|OTHER|Diabetes Management|Using electronic insulin order template for basal-bolus insulin and education
214420057|NCT04381273|OTHER|No intervention|questionnaire-based assessment
214420058|NCT03329066|BEHAVIORAL|MAST - Managing Asthma & Sleep in Teens|This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
214420059|NCT03329066|BEHAVIORAL|ASMA - Asthma Self-Management for Adol|This behavioral intervention focuses only on asthma care.
214420060|NCT03329066|BEHAVIORAL|Information & Referral Control Group|Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
214420061|NCT03330418|BIOLOGICAL|Placebo|Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
214420062|NCT03330418|BIOLOGICAL|RC18 160 mg|In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
214420063|NCT03572023|OTHER|Integrative characterization of MINOCA patients|"Characterization of MINOCA patients will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
214420064|NCT03572023|OTHER|Characterization of MI patients with coronary obstruction|"Characterization of patients with myocardial infarction and obstructive atherosclerosis will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
214506153|NCT01958385|PROCEDURE|Sham procedure|
214506154|NCT01958385|BEHAVIORAL|Diet and Exercise|A structured diet and exercise plan
214506155|NCT05494658|DIETARY_SUPPLEMENT|BCAA|600ml drink which contains 18g BCAA was consumed by patients 2-4h before surgery.
214506156|NCT05494658|DIETARY_SUPPLEMENT|water|600ml water was consumed by patients 2-4h before suegery.
214506157|NCT03755115|DRUG|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m\^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m\^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
214506158|NCT05907070|OTHER|Mandala group|Mandala group will participate in 2 sessions of individual mandala drawing art activity with the theme of 'Emotions' accompanied by classical or instrumental music. In each session, a mandala will be created.
215019825|NCT02382263|DRUG|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
214506159|NCT05907070|OTHER|Value clarification group|Value clarification groups will participate in the value clarification activity by writing 2 sessions individually with the theme of 'Emotions' accompanied by classical or instrumental music.
214506160|NCT05260866|OTHER|national population-based study|No intervention
214506161|NCT05073822|DRUG|Tacrolimus|reduction of both standard Tacrolimus \& Mycophenolate mofetil does in one arm
215019826|NCT02382263|DRUG|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
214420065|NCT00756730|DRUG|ATV/r|Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
215019827|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
215019828|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
214420066|NCT00756730|DRUG|DRV/r|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
214420067|NCT01872403|DRUG|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
214420068|NCT04320186|BEHAVIORAL|Entertainment education|
214420069|NCT04320186|OTHER|video|video
214420070|NCT02323529|DRUG|Nitisinone|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
214420071|NCT00375453|DRUG|SH U04722|
215019829|NCT02792257|DRUG|Dronabinol (Marinol®)|5mg - 10mg daily dose
215019830|NCT02792257|DRUG|Placebo|Daily dose
215019831|NCT00553475|DRUG|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
215019832|NCT00553475|DRUG|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
214420072|NCT00345761|DRUG|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
214420073|NCT00345761|DRUG|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
214420074|NCT00345761|DRUG|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
214420075|NCT01426178|DEVICE|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|"After written information and consent, patients are randomised in two groups: NAVA first or PSV first.~They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter."
214420076|NCT03857971|DEVICE|Coronary Optical Coherence tomography|Optical coherence tomography imaging is performed of non-obstructive, non-culprit coronary lesions to assess plaque morphology.
214420077|NCT03093467|BEHAVIORAL|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
214420078|NCT03093467|DRUG|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
214420079|NCT03093467|BEHAVIORAL|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
214420080|NCT02849535|BEHAVIORAL|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
214420081|NCT05271188|PROCEDURE|Infiltration of local anaesthetic between popliteal artery and posterior knee capsule|Adductor canal block (ACB) is a popular peripheral nerve block that has been shown to decrease pain significantly and thereby opioid consumption with minimal effect on quadriceps function \[8\]. Though ACB provides analgesia to the peripatellar and intra-articular aspect of knee joint, it does not relieve posterior knee pain which is moderate to severe in intensity \[9, 10\]. The recent technique of an ultrasound (US)-guided local anesthetic infiltration of the interspace between popliteal artery and the capsule of posterior knee (IPACK) has shown to provide significant posterior knee analgesia without affecting the common peroneal nerve (CPN) \[11\]. We postulated that IPACK will provide better pain relief and improve knee function in the immediate postoperative period compared to ACB
214420082|NCT01622075|DEVICE|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
214420083|NCT01622075|DEVICE|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
214420084|NCT04349150|DEVICE|Virtual reality|Intervention consists of providing virtual reality in place of standard sedatives and narcotics for a portion or the duration of the colonoscopy
214420085|NCT03293056|OTHER|High-intensity interval Hydrogynmastics|The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.
214420086|NCT03293056|OTHER|Hydrogynmastics Continuous Moderate|For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
214420087|NCT05698069|DIAGNOSTIC_TEST|Pain Modulation Index|A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.
214420088|NCT05698069|OTHER|Pain Detect|A questionnaire that was validated for the assessment of neuropathic pain
214420089|NCT05698069|OTHER|Central sensitization inventory|A questionnaire developed for the detection of central sensitization.
214420090|NCT02542852|DRUG|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
214420091|NCT03684213|DRUG|Control (Norepinephrine)|This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
214420092|NCT03684213|DRUG|Norepinephrine + Ascorbic Acid|This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.
214420093|NCT03684213|DRUG|Norepinephrine + L-NAME|This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.
214420094|NCT03684213|DRUG|Norepinephrine + L-NAME + Ascorbic Acid|This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
214420095|NCT00319397|BEHAVIORAL|Exercise-Training Program|
214506162|NCT03903978|BEHAVIORAL|Cognitive Behavioral Therapy|"The training protocol consists of 6 weekly modules:~0.Welcome:Introduction module to the program, with an explanation about the tools and the way to use CORE~1. Psychoeducation: Explanation of psychological wellbeing and the concept of resilience~2. Autonomy, building my way: Enhancement of autonomy~3. Mindfulness and self-compassion:Training in mindfulness, savoring, and an attitude of self-compassion~4. Overcoming obstacles: Development of coping strategies to deal with daily difficulties in life~5. Connecting to others:Acknowledge the relevance of relationships and how they can be helpful in the construction of well-being~6. Purpose in life and personal growth:Approach the future with a positive attitude, planning goals for the future."
214690030|NCT01762657|DRUG|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
214690031|NCT01762657|DRUG|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
214420096|NCT02499471|OTHER|Levothyroxine therapy (137.75 ± 23.75 μg/day)|This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
214690032|NCT00606762|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
214690033|NCT02893774|OTHER|quality of life assessment|"All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.~Those assessment will use standardized quality of life questionnaire :~* QLQ-C30~* SWLS (Satisfaction with Life Scale)~* PTGI (Post-Traumatic Growth Inventory)~* HADS (Hospital Anxiety and Depression Scale)~* Brief COPE~* MHLCS (Multidimensional Health Locus of Control Scale)"
214690034|NCT04983329|OTHER|Telemedicine intervention|Following education, the telemedicine center will subsequently monitor operating rooms included in this trial for protocol adherence for three-months. The telemedicine center is staffed by attending anesthesiologists, resident anesthesiologists, certified registered nurse anesthetists (CRNAs) and student registered nurse anesthetists (SRNAs) and is currently providing evidence-based support to clinicians in a subset of operating rooms and post-anesthesia care unit (PACU) beds at Barnes-Jewish Hospital.
214690035|NCT02750657|GENETIC|Molecular Profiling|Whole Genome Sequencing
214420097|NCT05382104|DRUG|Maribavir|Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.
214420098|NCT00639002|DRUG|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
214420099|NCT00639002|DRUG|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
214420100|NCT05907473|OTHER|Virtual Reality Therapy|Patients in this group will play balance-based games with the Virtual Reality System.
214420101|NCT05907473|OTHER|Conventional Rehabilitation|In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
214420102|NCT03506880|BEHAVIORAL|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
214420103|NCT03506880|BEHAVIORAL|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
214690036|NCT06023173|DIAGNOSTIC_TEST|Deep radiomics-based fusion model|This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
214690037|NCT04889534|PROCEDURE|Analgesia|Patients will be observed during postoperative period,
214420104|NCT00000217|DRUG|Carbamazepine|
214420105|NCT05074836|DIETARY_SUPPLEMENT|Formula milk|"Brand name: Yili (QQ star formula milk);~Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
214420106|NCT05074836|DIETARY_SUPPLEMENT|Regular milk|"Brand name: Yili；~Type: regular milk (pure milk);~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
214690038|NCT01511419|BIOLOGICAL|LAIV H7N3|2 doses of vaccine
214690039|NCT01511419|BIOLOGICAL|placebo|2 doses of placebo
214690040|NCT01532063|PROCEDURE|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
214690041|NCT02058134|DEVICE|cardioPAT cell saver|
215019833|NCT00553475|DRUG|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
215019834|NCT05975125|DRUG|Vitamin C 500 MG Oral Tablet|compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
215019835|NCT03842800|OTHER|MRI|Patients and volunteers will receive an MRI.
215019836|NCT03842800|DRUG|Ketamine|Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
215019837|NCT04921800|PROCEDURE|Anterior Cervical Discectomy & Fusion|Participants are undergoing previously scheduled anterior cervical discectomy \& fusion for single level or multiple level cervical disease
215019838|NCT04921800|DEVICE|Application of ADAM mechanoacoustic skin sensor|Applying the ADAM sensor to the suprasternal notch following surgery to allow for collection of the anatomical data
215019839|NCT05545488|DEVICE|Virtual reality|I had the women wear virtual reality glasses and watch the video they wanted for at least 5, maximum 15 minutes during the examination.
215019840|NCT06761612|BIOLOGICAL|FDA approved mRNA vaccines|This study is non-interventional as participants will have received an FDA approved mRNA COVID-19 vaccine prior to entering the study. The study protocol does not determine or allocate receipt of vaccine
214690042|NCT01160055|PROCEDURE|Middle ear fluid and urine.|Middle ear fluid and urine collection.
214690043|NCT00786838|DRUG|Trabectedin|Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
214690044|NCT00786838|DRUG|Placebo|Participants will receive 3-hour placebo intravenous infusion on Day 1.
214690045|NCT03064295|DEVICE|Myocardial Perfusion Cardiac MRI.|MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
214690046|NCT03064295|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
215019841|NCT01733693|DRUG|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
215019842|NCT01733693|DRUG|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
214420107|NCT05074836|OTHER|Control foods|"Brand: N/A;~Food type: grain foods (e.g., bread);~Dosage: 20-40g \* 2/d grain foods~Intervention duration: 12 months"
214420108|NCT03462589|DRUG|SY-008|The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
214420109|NCT03950869|BEHAVIORAL|Positive Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase positive expectations.
214420110|NCT03950869|BEHAVIORAL|Negative Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase negative expectations.
214420111|NCT00298597|DRUG|granulocyte - colony stimulating factor (G-CSF)|
214420112|NCT00298597|DRUG|erythropoetin (EPO)|
214420113|NCT02354885|DRUG|Tranexamic Acid|Coagulation Management / Efficiency
214420114|NCT06231277|DRUG|BH002|Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
214420115|NCT02052375|DRUG|ASP2408|subcutaneous injection
214420116|NCT02052375|DRUG|Placebo|subcutaneous injection
214420117|NCT05261997|PROCEDURE|extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct|In addition to drug administrated in the control group, patients in this group would be treated with ESWL and endoscopic drainage of the main pancreatic duct.
214420118|NCT05261997|DRUG|pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)|Patients will receive drugs to control pancreatic insufficiency
214420119|NCT02509585|DRUG|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
214420120|NCT00102258|DRUG|Growth Hormone Therapy|
214420121|NCT00848627|OTHER|Specimen and questionnaires only|Specimen and questionnaires only
214420122|NCT02010372|OTHER|Reminder Recall Report|Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
214420123|NCT02010372|OTHER|Audit-Feedback/Immunization Forecasting Reports|Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
214420124|NCT01052246|DRUG|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
214420125|NCT01052246|DEVICE|Pulsed dye laser|"Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~* Wavelength 585 nm~* Energy fluence 3 J/cm2~* Pulse duration 0.35 msec~* Spot size 7 mm"
214420126|NCT01148719|OTHER|Index group|Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
214420127|NCT02867566|DRUG|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
214420128|NCT02867566|DRUG|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
214420129|NCT00739765|BEHAVIORAL|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
214420130|NCT00739765|BEHAVIORAL|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
214506163|NCT03903978|BEHAVIORAL|Healthy lifestyle|"1. Beginning of a lifestyle change The patient will learn to identify healthy and risky behaviors and recognize obstacles that prevent them from adopting a healthy lifestyle.~2. Physical activity The importance of moving on and activating behavior will be taught through regular exercise information to improve mood.~3. Diet This module is dedicated to teaching the importance of diet for good physical and mental health. The Mediterranean diet will be taken as an example for a balanced and balanced diet, because it does not differ from the habits of other countries.~4. Sleep The importance of good sleep will be addressed with information and strategies for understanding the relationship between sleep and overall health."
214506164|NCT01229384|DEVICE|Positive Airway Pressure nebulization|Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
214506165|NCT01229384|DEVICE|Standard passive nebulization of respiratory medications|Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
214506166|NCT01255800|DRUG|IPI-926 and Cetuximab|"* Patients will receive Cetuximab IV every week.~* Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day."
214506167|NCT02263105|DRUG|CDDP|
214420131|NCT00739765|BEHAVIORAL|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
214420132|NCT06630377|DIETARY_SUPPLEMENT|GOS|During the study period, subjects are instructed to take one pocket of galactooligosaccharide per day during the first week, followed by two pockets of galactooligosaccharide per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
215019843|NCT05208320|BEHAVIORAL|Adherence|"Patients received interventions as follow:~* The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~* Home health education by Community Health Workers every month for 6 months"
215019844|NCT02043860|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
215019845|NCT02043860|PROCEDURE|Autologous Transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
215019846|NCT02043860|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant.
215019847|NCT02043860|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
215019848|NCT04264585|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend \~15 mins. per week/per client.
215019849|NCT04264585|BEHAVIORAL|Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive access to the Planning for Change lesson before accessing Lesson 1. They will be presented with five interactive online exercises based on motivational interviewing principles (i.e. values clarification, importance ruler, looking back, confidence ruler, and looking forward). As clients complete the exercises, they are prompted to answer open-ended questions and are provided with written feedback.
215102489|NCT00778895|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
214420133|NCT06630377|DIETARY_SUPPLEMENT|Placebo|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
214420134|NCT06628518|BEHAVIORAL|FAmily oriented Mindfulness informed Legal Education (FAMiLE)|The FAmily oriented Mindfulness informed Legal Education (FAMiLE) is a low-intensity intervention involving four sessions. The session will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The Family oriented component will include stress management, including coping techniques and problem-solving, positive communication, behaviour modification and parenting, and a session on consolidation including sustaining gains. The intervention will also incorporate positive parenting and interactions with children.
214420135|NCT05838495|OTHER|formulated liquid diet|will be fed exclusively the pediatric enteral study formula with a feeding tube
214420136|NCT05469802|BIOLOGICAL|Purified Inactivated Zika Virus Vaccine (PIZV)|PIZV vaccine with aluminium hydroxide adjuvant IM injection.
214420137|NCT05469802|OTHER|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
214420138|NCT00388661|DRUG|Melatonin tablet 3 mg once daily|Melatonin tablet 3 mg once daily
214420139|NCT00388661|DRUG|Placebo comparator|Placebo comparator
214420140|NCT00033163|DRUG|Adefovir dipivoxil|
214420141|NCT00033163|DRUG|Tenofovir disoproxil fumarate|
214420142|NCT05686421|DEVICE|OCT Imaging Using Device N|Standard conventional OCT imaging device equipped with extendable and comfortable chin and forehead rest.
214420143|NCT05686421|DEVICE|OCT Imaging Using Device C|Standard conventional OCT imaging device.
214420144|NCT02812459|OTHER|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
214420145|NCT02812459|OTHER|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
214420146|NCT03752385|BEHAVIORAL|reducing smartphone screen time|"Cutting average smartphone screen time in half. Sleeping without smartphone in bedroom. Establishing a bedtime to stop smartphone screen time."
214420147|NCT02196818|DEVICE|Mpact Acetabular Shell|Total Hip Replacement
214420148|NCT00718406|DRUG|Metoprolol|
214420149|NCT00718406|DRUG|metoprolol plus morphine|
214420150|NCT03312439|BEHAVIORAL|Given advice|Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
214420151|NCT01737008|DRUG|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
214420152|NCT01737008|RADIATION|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
214420153|NCT01737008|DRUG|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
215019850|NCT04264585|BEHAVIORAL|Booster Session|"Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered)."
214420154|NCT03649165|DRUG|Treatment A|During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
214420155|NCT03649165|DRUG|Treatment B|During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
214420156|NCT03649165|DRUG|Treatment C|During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
214420157|NCT03649165|DRUG|Treatment D|During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
214420158|NCT03649165|DRUG|Acetaminophen|Participants will receive a single 500mg dose of acetaminophen at the same time.
214420159|NCT04143555|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy|Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
214420160|NCT01026636|DRUG|Ceftobiprole|
214420161|NCT02847117|OTHER|Mastiha|The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
214420162|NCT01866566|BIOLOGICAL|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
214420163|NCT01866566|BIOLOGICAL|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
215019851|NCT01101048|DRUG|Placebo|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
215019852|NCT01101048|DRUG|AMG 167|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
215019853|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - IR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) immediate release gel capsule formulation for 90 days in total
215019854|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - GR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) gastro resistant gel capsule formulation for 90 days in total
215019855|NCT05791591|DIETARY_SUPPLEMENT|Placebo|Placebo containing starch Powder (1000 mg, daily in two administration orally for 90 days)
215019856|NCT01791296|DRUG|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
215019857|NCT01791296|OTHER|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
214420164|NCT01866566|BIOLOGICAL|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
214420165|NCT01866566|BIOLOGICAL|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
214420166|NCT00940992|DRUG|DER 45 EV|Topical application to face for 12 weeks
214420167|NCT00940992|DRUG|Vehicle|Topical application to face for 12 weeks
214420168|NCT04426045|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.
214420169|NCT04426045|PROCEDURE|Supra-inguinal fascia iliaca compartment block|"A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected."
215019858|NCT06094829|OTHER|Oral cytobrush|Oral epithelial cells will be collected during routine odontology appointments, upon documented non-opposition, via minimally invasive cytobrush sampling of the inner cheek
215019859|NCT02541487|DIETARY_SUPPLEMENT|Alli-nutritional supplement|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
215019860|NCT01905683|DRUG|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
215019861|NCT00588276|RADIATION|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three \*IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
215019862|NCT05476848|DIAGNOSTIC_TEST|ELISA test for Cytokines|ELISA tests specific for cytokines (IL-1, IL-6, IL-10) and immunoglobulins (IgA, IgG, IgM) will be performed by a biochemistry lab, both for blood samples and oral swap samples.
215019863|NCT01395537|DRUG|Carboplatin AUC|Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
215019864|NCT01395537|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
215019865|NCT01395537|DRUG|lapatinib|Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
215019866|NCT02568254|DEVICE|Lens 1 (etafilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
215019867|NCT02568254|DEVICE|Lens 2 (nelfilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
215019868|NCT02568254|DEVICE|Lens 3 (nesofilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
215019869|NCT03325257|OTHER|Routine care|This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.
215019870|NCT06929975|BEHAVIORAL|podcast training|In accordance with the established training program for participants, a four-phase podcast listening process aimed at reducing birth fear will be implemented. The first podcast will be launched at the 33rd week of pregnancy, with the goal of helping participants gain information about the childbirth process and reduce their anxiety. Following that, a second podcast will be played at the 34th week of pregnancy, focusing on supporting psychological preparation for childbirth. The third podcast, to be implemented at the 35th week, will address topics such as relaxation techniques and breathing exercises that can be used during labor. Finally, the fourth podcast, played at the 36th week, will emphasize the importance of positive thinking and partner support during labor. To evaluate the effectiveness of the podcast sessions, psychological status and partner support scales will be applied at specific weeks.
215019871|NCT00775515|PROCEDURE|laparoscopic prostatectomy|laparoscopic prostatectomy
214690047|NCT03064295|DRUG|Pharmacologic Stress Agent|The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
215019872|NCT05673291|OTHER|No intervention|Volunteers who will be included in the research will be informed about the research and an informed consent form will be signed. Questionnaire evaluating sociodemographic characteristics and working positions; The Extended Nordic Musculoskeletal Questionnaire (7) and measurements made with the Spinal Mouse device for posture analysis will be applied when individuals feel comfortable. Questionnaires and device and posture analysis will be carried out after the purpose of the research is explained to the individuals and their consent is obtained. The data will be analyzed in the SSPS program. Number, percentage, standard deviation and mean from descriptive statistics will be used in the evaluation of the data. The relationship between posture and musculoskeletal pain will be evaluated by correlation analysis. The confidence interval of the research will be 95% and the significance level will be considered as p\<0.05.
214690048|NCT00276978|DRUG|Aripiprazole|Addition of Aripiprazole 10 mg to concurrent medication
214420170|NCT06147245|BEHAVIORAL|Person-centred culturally sensitive course of treatment|12-month person-centred and culturally sensitive intervention: Participants will attend 6 visits at SDCC including visits with a diabetes nurse, physician and dietitian. The course of treatment is focusing on extended time in consultations, use of technology for diabetes monitoring, meeting the same healthcare professionals, awareness of language barriers and use of accurate communication and dialogue tools in participants native language.
214420171|NCT06023186|DRUG|mavacamten|Study participants will receive mavacamten under the standard of care
214420172|NCT01343342|DIETARY_SUPPLEMENT|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
214420173|NCT05062577|DRUG|ASP8062|oral
214420174|NCT05062577|DRUG|Placebo ASP8062|oral
214420175|NCT05062577|DRUG|buprenorphine/naloxone|sublingual
214420176|NCT04518930|OTHER|Peanuts or plain Greek yogurt|Two different types of dietary snacks
214420177|NCT04716803|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
214420178|NCT04716803|DEVICE|Angel Concentrated Platelet Rich Plasma (cPRP) System|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
214420179|NCT00869570|DRUG|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
214420180|NCT00869570|DRUG|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
214420181|NCT00869570|RADIATION|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
214420182|NCT00629200|DRUG|Sodium Stibogluconate|400 mg/m\^2 IV daily on days 1-5.
214420183|NCT00629200|DRUG|Interferon Alpha-2b|3x10\^6 units subcutaneously three times weekly
214420184|NCT04878341|OTHER|Erector Spinae Plane Block|The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
214420185|NCT05776706|DIAGNOSTIC_TEST|AR-based navigation|"The surgeon will perform all surgical planning and operations with reference to the existing navigation. In this process, the errors of the existing navigation and the newly developed navigation are measured and compared in 3D at several points, and the points are as follows.~1. Fiducial markers~2. Nasion~3. Tumor's margin (anterior, posterior, superior, inferior)"
214420186|NCT04135378|DRUG|ascorbic acid|Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
214420187|NCT04135378|OTHER|placebo|:- included 30 students given placebo for one week before presentation.
214420188|NCT05895760|OTHER|Multi-component physical exercise online intervention|"A multicomponent exercise program was implemented consisting of a combined program of endurance, strength, coordination, balance, and flexibility exercises depending on the level of functional capacity.~Three types of physical exercise programs were designed according to the physical performance level of each participant. The first type of exercise program training was performed for frail adults with an SPPB score of 4 to 6, the second was for the pre-frail adults with an SPPB score of 7 to 9 and the third for robust adults with an SPPB of 10 to 12."
214420189|NCT01928004|DEVICE|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
214420190|NCT01928004|PROCEDURE|Conventional reline|conventional reline of the existing mandibular complete denture
214420191|NCT01393470|PROCEDURE|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
214420192|NCT06430125|DRUG|Nicorandil 10 MG Oral Tablet|Nicorandil 10 MG oral tablet twice daily
214420193|NCT03955640|DRUG|Olaparib|Given PO
214420194|NCT03955640|PROCEDURE|Hyperthermia Treatment|Undergo hyperthermia treatment
214420195|NCT03955640|OTHER|Questionnaire Administration|Ancillary studies
214420196|NCT03955640|OTHER|Quality-of-Life Assessment|Ancillary studies
214420197|NCT02875665|DEVICE|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
214420198|NCT04008420|OTHER|monitoring of the oxygen reserve index|The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
214420199|NCT04025606|DRUG|Thoracic epidural|Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.
214420200|NCT04025606|DRUG|Paravertebral block|Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
214420201|NCT03161691|PROCEDURE|Percutaneous treatment of ischemic stroke|An additional C-arm CT imaging scan will be done during neurovascular treatment to evaluate perfusion and collateral vessels in ischemic stroke patients.
214420202|NCT01774994|OTHER|stable isotope infusion for measurement of metabolism|
214420203|NCT00413179|DRUG|Metformin|
214420204|NCT00413179|DRUG|Clomiphene citrate|
214420205|NCT00413179|DRUG|Placebo|
215019873|NCT03167710|OTHER|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
215019874|NCT03167710|OTHER|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
215019875|NCT03015948|DRUG|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
214420206|NCT03986424|DRUG|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
214420207|NCT03986424|DRUG|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg to be taken orally, twice daily
214420208|NCT03782558|PROCEDURE|Surgical transection of transverse ligament|Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
214420209|NCT04743128|BEHAVIORAL|Exercise|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
214420210|NCT06477302|BEHAVIORAL|Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer (STA-RR-LC)|Patients will be given a measurement instrument to determine the level of therapeutic adherence.
214420211|NCT02200341|BEHAVIORAL|MBCT|
214420212|NCT02200341|BEHAVIORAL|PRT-PsyEd|
214420213|NCT02767219|DRUG|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
214420214|NCT02767219|DRUG|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
214420215|NCT02767219|DRUG|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
214420216|NCT03776890|BEHAVIORAL|DeStress for Health Program|The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
214420217|NCT02006017|OTHER|Evidence summary alone plus a recommendation|
214420218|NCT02006017|OTHER|Evidence summary alone|
214420219|NCT04441242|OTHER|Ambient lighting|Use of ambient lighting (75-150 lux) in endoscopy room.
214506168|NCT02263105|DRUG|Temozolomide|If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
215019876|NCT03015948|DRUG|Placebo|a single dose of placebo (n=2) for each dose cohort .
214420220|NCT04441242|OTHER|Low lighting|Use of low lighting (\<75 lux) in endoscopy room.
214506169|NCT05579184|DRUG|[177Lu]Ludotadipep|"Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
214506170|NCT04301713|OTHER|Evaluation of rik of falls|An evaluation of the risk of falls will be carried out in the elderly in the province of Salamanca. This will attempt to identify the risk of falling as well as to be able to establish protocols for action of a preventive and rehabilitative nature.
214506171|NCT01482325|DEVICE|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
214506172|NCT02596737|BEHAVIORAL|wittyFit concept|
215019877|NCT00001789|DRUG|BG9588|
215019878|NCT01744366|DRUG|Degarelix|
215019879|NCT01744366|DRUG|Goserelin|
215019880|NCT01449994|DEVICE|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
215019881|NCT00165308|DRUG|Tamoxifen|Given orally, daily for one year.
215019882|NCT02376855|OTHER|eConsult|"An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit."
215019883|NCT05624957|DRUG|Lidocaine epinephrine|Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
215019884|NCT05624957|DRUG|Epinephrin|0.25 mg epinephrine mixed with one litre of fluid irrigation
215019885|NCT00000726|DRUG|Foscarnet sodium|
215019886|NCT04241432|DEVICE|vibrating platform|Use of two different types of vibrating platform
214420221|NCT03517579|DEVICE|Cervical Collar Therapy Indicator (COTI)|"Study Device; The CoTI has 3 components;~* A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~* A cable that connects the collar unit to the Control Unit~* A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~1. Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~2. Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131."
214420222|NCT00191035|DRUG|Atomoxetine|
214420223|NCT01761396|BEHAVIORAL|CBT|
214420224|NCT01761396|BEHAVIORAL|UC|
214420225|NCT06306365|BEHAVIORAL|Modern board game-based learning|Modern board game-based learning involves using contemporary board games as educational tools. It emphasizes active participation, critical thinking, and social interaction among participants. By integrating strategic thinking and problem-solving within a game context, this approach aims to enhance learning experiences in an engaging and enjoyable manner. In this study, board games have been selected to target and engage executive functions.
214420226|NCT01778712|BEHAVIORAL|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
214420227|NCT04561037|DEVICE|Pulsed Electromagnetic Field therapy (PEMFT)|PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication
214420228|NCT04561037|OTHER|TMJ physical therapy program|TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
214420229|NCT00180102|DRUG|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
214420230|NCT00180102|PROCEDURE|early allogeneic PBSCT within induction therapy|
214420231|NCT00180102|PROCEDURE|autologous PBSCT|
214420232|NCT00163085|DRUG|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
214420233|NCT03313128|OTHER|Sanitation|Improved sanitation facility
214420234|NCT02824094|DRUG|crizotinib|Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule
214420235|NCT00839540|DRUG|micafungin|100 mg qd by slow IV infusion for 24 h
214420236|NCT00839540|DRUG|Micafungin|200 mg qd by slow IV infusion for 24 h
214420237|NCT00839540|DRUG|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
214420238|NCT00032799|DRUG|natalizumab|
214420239|NCT06369090|DEVICE|Electrical impedance tomography (EIT)|Non-invasive, radiation-free bedside lung monitoring using small alternating currents with no known side effects.
214420240|NCT00299741|DRUG|Sunitinib|Sunitinib 50 mg daily, 4/2 schedule
214420241|NCT05311319|DRUG|HAIC+TQB2450+Anlotinib|HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
214420242|NCT06031350|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optovue, Inc., Fremont, CA, USA
214420243|NCT05016713|COMBINATION_PRODUCT|Chlorhexidine mouthwash|"Chlorhexidine mouthwash is added to the oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.~If any participant shows any signs of CHX hypersensitivity, the intervention will be discontinued."
214420244|NCT05016713|DEVICE|Interdental brush|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
214420245|NCT05016713|OTHER|Fluoride-based toothpaste|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
214420246|NCT04279171|DIAGNOSTIC_TEST|Greyson NDE scale|Questionnaire to detect occurence of NDE. A NDE is identified if score \> or = 7/32
214420247|NCT04279171|DIAGNOSTIC_TEST|DES dissociation scale|Screening for dissociative symptoms
214420248|NCT04279171|DIAGNOSTIC_TEST|WHOQOL-SRPB|WHOQOL-SRPB is an instrument developed to evaluate how spirituality, religiosity and personal beliefs (SRPB) are related to quality of life in health and health care.
214420249|NCT04279171|DIAGNOSTIC_TEST|cerebral magnetic resonance imaging|Types of images to be acquired: T1, T2, Diffusion Weighted Imaging-DWI, Fluid Attenuated Inversion Recovery and spectroscopy
214420250|NCT05969665|DEVICE|Fitbit Inspire 2|A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.
215019887|NCT01832038|DRUG|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 \[NCT01710657\], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
214420251|NCT05969665|DEVICE|Abbott Freestyle Libre 3|A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.
214420252|NCT04304859|DIAGNOSTIC_TEST|BASIC|Validation
215019888|NCT01267136|DRUG|Codeine with acetaminophen|Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg \[=0.3 mL/kg\] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
215019889|NCT01267136|DRUG|Tramadol suspension|Liquid tramadol 1.05 mg/kg \[=0.3 mL/kg\] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
215019890|NCT01893814|DIETARY_SUPPLEMENT|Probiotics|
214506173|NCT05124210|BIOLOGICAL|Sotrovimab|Sotrovimab will be administered.
215019891|NCT01893814|DIETARY_SUPPLEMENT|Control|
215019892|NCT02722330|DEVICE|Baha 5 SuperPower on Baha Attract System|The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
214506174|NCT05197452|BEHAVIORAL|COVID-19 Testing|"For in-person PCR testing, a nasal swab will be inserted shallowly into the participant's nose and rotated in each nostril. The swab will be broken off into a designated test tube and placed into a specimen bag along with a label. All specimens will be stored in a cooler until they are transported the Rush Laboratory for COVID-19 analysis.~For at home antigen testing, participants will download an app to their mobile phone and watch an informational video. The test will be self-administered by inserting a nasal swab into the nostril until a cap containing the swab touches the nose; rubbing the swab tip around the nose cavity 3 times; removing the swab and repeating in the other nostril. The nasal swab, a dropper, processing fluid, and a blue tooth connected analyzer are provided with the testing kit to analyze the sample for COVID-19. COVID-19 home test results are displayed on the participants smart phone after 15 minutes."
214506175|NCT01428583|DRUG|oxycodone HCl and naltrexone HCl extended-release capsules|Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
214506176|NCT02983721|PROCEDURE|transradial|transradial route for coronary angiography and PCI
214506177|NCT02983721|PROCEDURE|Transfemoral|transfemoral route for coronary angiography and PCI
214506178|NCT01817491|OTHER|American Heart Association Diet|
214506179|NCT01817491|OTHER|Reduced Fat Vegan Diet|
215019893|NCT02096380|DRUG|One cycle TPF induction chemotherapy for NPC|"One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
215019894|NCT02096380|DRUG|Three cycles TPF induction chemotherapy for NPC|"Three cycles TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
214420253|NCT01551433|DEVICE|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
214420254|NCT00361283|DRUG|Atorvastatin|atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
214420255|NCT03399968|DEVICE|ESWT|at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right
214420256|NCT03399968|DEVICE|Placebo ESWT|the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group
214420257|NCT04446689|BEHAVIORAL|Biofeedback|This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph.
214420258|NCT03201614|DEVICE|A-CP HA Kit|Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2
214420259|NCT03201614|DEVICE|ArthroVisc 40|Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2
214420260|NCT03201614|DRUG|Placebo|Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
214420261|NCT03232684|DIAGNOSTIC_TEST|Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA
214420262|NCT03031444|DRUG|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
214420263|NCT03031444|DRUG|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
214420264|NCT06388447|BIOLOGICAL|Umbilical cord-mesenchymal stem cells|One injection will be given at each papilla set with the volume of 0.1mL with 2.0 x 10⁶ cells per syringe at every visit. A total of 3 injections will be given at the interval of 6 weeks, with a total of 6.0 x 10⁶ cells for each interdental papilla at the end of the 3 injections. Every injection starts with locally application of local anesthetic. For the control group, participants will be injected with 0.9% sodium chloride after locally application of local anesthetic
214420265|NCT06041087|BEHAVIORAL|High-Intensity Exercise|A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
214420266|NCT06041087|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50g consumed immediately after exercise and 1h after exercise.
214420267|NCT06041087|DIETARY_SUPPLEMENT|Skim Milk|500ml consumed immediately after exercise and 1h after exercise.
214420268|NCT06041087|DIETARY_SUPPLEMENT|Greek yogurt|200g consumed immediately after exercise and 1h after exercise.
214420269|NCT06041087|DIETARY_SUPPLEMENT|Water|500ml consumed immediately after exercise and 1h after exercise.
214420270|NCT01569906|RADIATION|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
214420271|NCT03234816|DRUG|Norepinephrine 0.05 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
214420272|NCT03234816|DRUG|Norepinephrine 0.1 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
214420273|NCT03234816|DRUG|Norepinephrine 0.15 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
214506180|NCT00033748|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
214506181|NCT00033748|BIOLOGICAL|monoclonal antibody 3H1 Alu Gel|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
214506182|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po
214506183|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
215102490|NCT00778895|BIOLOGICAL|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
214420274|NCT03234816|DRUG|Bupivacaine|10 mg Bupivacaine intra-thecal for spinal anesthesia
214420275|NCT02765373|DRUG|Exemestane|
214420276|NCT02765373|DRUG|Letrozole|
214420277|NCT02765373|DRUG|Anastrozole|
214506184|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
214420278|NCT00719823|DRUG|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
214506185|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
214506186|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
214690049|NCT04897555|DEVICE|LLLT|This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
215102491|NCT03968185|OTHER|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
215019895|NCT01934231|DRUG|Amoxicillin-Potassium Clavulanate Combination|The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
214420279|NCT00208767|DRUG|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
214420280|NCT00208767|DRUG|Placebo|A matched placebo pill will be given orally daily.
214420281|NCT03503630|DRUG|COMPOUND 2055269|COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
214420282|NCT03503630|RADIATION|Radiation Therapy|Radiotherapy 25 Gy to be given on Days 1-5
214420283|NCT03503630|DRUG|mFOLFOX|Given every 2 weeks for 6 cycles
214420284|NCT03503630|PROCEDURE|Total Mesorectal Excision|Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
214420285|NCT05193630|DIETARY_SUPPLEMENT|Milnutri Sure™|"Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water."
214420286|NCT01735474|OTHER|Manual technique|"A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles."
214420287|NCT01735474|OTHER|Placebo|Usual care
214420288|NCT03658499|BEHAVIORAL|two day skills group plus treatment adjuncts|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.
214420289|NCT03658499|BEHAVIORAL|two day skills group control group|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
214506187|NCT02134782|BEHAVIORAL|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
215019896|NCT06424119|BEHAVIORAL|Traditional Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to TCR arm, they will attend 36 sessions of the program at one of three locations.
215019897|NCT06424119|BEHAVIORAL|Intensive Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm, they will attend 72 sessions of the program at one of three locations.
214420290|NCT04593797|DIAGNOSTIC_TEST|carotid blood flow measurement with ultrasound|carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
214420291|NCT00907218|DRUG|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
214420292|NCT02511639|DRUG|Everolimus|Everolimus is formulated as tablets of 10 mg strength for oral administration.
214420293|NCT02511639|DRUG|Aromatase Inhibitors|Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
214420294|NCT00006450|DRUG|Phenylbutyrate|
214420295|NCT04251143|PROCEDURE|corneal cross-linking|UV-A Irradiation and riboflavin
214690050|NCT03673241|DEVICE|Guardian System|The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
214690051|NCT01648543|PROCEDURE|lumbar sympathetic ganglion block|
214420296|NCT04251143|DIAGNOSTIC_TEST|corneal topography and tomography|Detailed Information about corneal tomography is used for diagnosis
214420297|NCT04296032|BEHAVIORAL|virtual reality game traning|The controllers were attached to upper extremity to control the game. The game could train the shoulder, elbow, and wrist control.
214420298|NCT04296032|BEHAVIORAL|standard treatment|The program included bilateral hand, grasp/release, and pinch activities.
214420299|NCT02308137|DRUG|Domperidone|Simon-2-stage design for domperidone futility
214420300|NCT04514419|DRUG|HS627|Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).
214420301|NCT04514419|DRUG|Pertuzumab|Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).
214420302|NCT01979354|DRUG|Spinal morphine|0.15 mg spinal morphine
214420303|NCT00600457|DEVICE|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
214420304|NCT03775369|OTHER|endurance training|physical activity and exercising (PAE)
214420305|NCT03775369|OTHER|social support and counseling|social support and counseling
214420306|NCT03775369|OTHER|resistance training|physical activity and exercising (PAE)
214420307|NCT01070056|BEHAVIORAL|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
214420308|NCT01070056|BEHAVIORAL|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
214420309|NCT06631404|DIAGNOSTIC_TEST|renal doppler|doppler srudy on renal arteries bilaterally , and detection of RI of renal artery
214420310|NCT06631560|DIAGNOSTIC_TEST|ELISA testing|Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
214420311|NCT06629116|DRUG|Patients with AIS receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).|Whether to administer albumin to AIS patients after intravascular thrombectomy and reperfusion.
214420312|NCT06629805|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
214420313|NCT06629805|DIETARY_SUPPLEMENT|Placebo|Placebo 1,000 mg/day for 12 weeks
214420314|NCT06714539|DEVICE|Patient Specific Virtual Reality Stimulation|A novel virtual reality (VR) simulator for spine procedures that will take patient specific medical imaging (3D scans) and create a virtual patient that surgical procedures can be performed on.
214506188|NCT02134782|OTHER|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
214506189|NCT00529009|DRUG|UDCA|
214506190|NCT00655213|DEVICE|Symphony D 2450|
214506191|NCT00655213|DEVICE|Symphony DR 2550|
214506192|NCT05193175|BEHAVIORAL|Prolonged sitting|Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping
214506193|NCT05837689|DRUG|Blinatumomab|IV
215019898|NCT06424119|OTHER|C2life® Food|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm with food, they will receive the food at the beginning of the second week of their respective program. Food will be delivered by mail weekly for a total of 11 weeks to the patient's home address.
215019899|NCT04733482|BEHAVIORAL|Cosmetic care|
215019900|NCT04921306|DRUG|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
214420315|NCT06709911|BEHAVIORAL|Basic Manipulation Stretching|This group received standard hand tenosynovitis stretching therapy, which focused on the flexor and extensor muscle groups of the wrist and hand for release. Muscle tension and tendon adhesions were relieved by basic stretching maneuvers, with each intervention lasting 20-30 minutes, twice a week, over a 4- to 8-week period.
214506194|NCT05107869|OTHER|High Saturated Fat|High saturated fat meal
214506195|NCT04874493|OTHER|Electronic Health Record Review|Review of medical records
214506196|NCT04874493|OTHER|Questionnaire Administration|Complete questionnaire
215019901|NCT04921306|DRUG|Placebo|Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
214506197|NCT04781322|DRUG|Alirocumab|Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.
214506198|NCT04781322|OTHER|Placebo|Heavy drinking healthy volunteers
214506199|NCT05414201|DRUG|Adalimumab|Subcutaneous Injection
214506200|NCT02054000|DRUG|Tirofiban|Intracoronary administering of Tirofiban
214506201|NCT02054000|OTHER|Placebo|Intracoronary serum physiologic
214506202|NCT04289571|DIAGNOSTIC_TEST|VR Mobility Tool|Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
214690052|NCT02746393|OTHER|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
214690053|NCT02746393|OTHER|211 Information Sheet|Receive a printed list of community resources to address social needs.
214690054|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, needle|Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles
215019902|NCT01314248|DEVICE|each child will receive both the LMA and ILA|each child will receive both the size 2 LMA and size 1.5 ILA
215019903|NCT00101400|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
214420316|NCT06709911|BEHAVIORAL|Massage and Tui Na Manipulation|The group received Tui Na manipulation interventions, including pointing, pressing and rolling techniques for the tendon sheath and thumb region, focusing on the stimulation of acupoints such as Hegu, Yangchi and Waiguan. The aim of Tui Na manipulation was to relieve the inflammatory reaction around the tendon sheath, promote blood circulation and improve local function. Each intervention lasts 20-30 minutes, twice a week for 4-8 weeks.
214420317|NCT06709911|BEHAVIORAL|Blood flow restriction training|This group used pressurized blood flow restriction training, in which the proximal part of the temporal joint was pressurized by a pressurized device to restrict blood flow. The training consisted of low-load wrist flexion and extension, fist clenching and unclenching, and wrist rotation. The training intensity was set at 20%-50% 1RM, and the frequency was 2 times per week for 4 to 8 weeks. Pressurization was performed before training and the pressure was set in the range of 20-50 mmHg, and the training period was supervised by a professional.
214506203|NCT02915432|BIOLOGICAL|3 mg/kg anti-PD-1 mAb JS001 Q2W|"This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment."
214506204|NCT02915432|BIOLOGICAL|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
214690055|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, cannula|Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas
214690056|NCT04594239|DEVICE|Untreated-control / delayed-treatment, needle|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)
214690057|NCT04594239|DEVICE|Untreated-control / delayed-treatment, cannulas|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
214690058|NCT06295081|OTHER|Exercise exposure|"Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational.~Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each).~The mass-participation exercise events have a sport-specific minimum distance of:~a mass-participation exercise event with a:~* Walking distance ≥20 km~* Cycling distance ≥100 km~* Running distance ≥15 km"
214690059|NCT04226859|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
214690060|NCT06672107|BEHAVIORAL|Active Driver Training Intervention|simulated driver training focusing on practice of 4 specific driving skills including lane positioning, speed management, collision avoidance, and dashboard attention
214690061|NCT06672107|BEHAVIORAL|Control Intervention|pre-scripted familiarization with driving simulator controls in the absence of any complex driving scenarios, decision making requirements, or feedback pertaining to driving skills
214690062|NCT02408146|PROCEDURE|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
214690063|NCT02408146|DRUG|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
215102492|NCT03968185|OTHER|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
214690064|NCT02408146|PROCEDURE|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
214690065|NCT02408146|DRUG|fentanyl citrate+ ondansetron hydrochloride + normal saline|
214690066|NCT02408146|DRUG|celecoxib|
214690067|NCT06692010|DRUG|Bupivacaine with Dexamethasone Solution|10 to 15 ml %0.25 bupivacaine \& 4 mg Dexamethazone
214690068|NCT04649528|BEHAVIORAL|Effective endurance 4x4 training - Supervised|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
214690069|NCT04649528|DEVICE|Effective endurance 4x4 training - APP|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
214420318|NCT06709911|BEHAVIORAL|Magnetic Bead Pressure Stimulation and Tui Na Manipulation Combined Intervention|This group received the combined intervention of magnetic bead pressure stimulation and Tui Na manipulation. Before treatment, the magnetic beads were applied to specific acupoints on the hand (e.g., Hegu, Ahshi, Waiguan, etc.), fixed by breathable patches, and combined with Tui Na manipulation. During Tui Na, the magnetic beads are pressed and kneaded to further enhance the stimulation effect of the acupoints. After Tui Na, the magnetic beads remain in the affected area and can be pressed and kneaded 2-3 times a day for 3 minutes each time to produce a slight sensation of soreness and distension. The aim of the massage is to relieve the inflammatory reaction around the tendon, loosen muscle tension and tendon sheath adhesions and promote blood circulation and joint mobility. The cycle of intervention is 4 to 8 weeks.
214420319|NCT04687085|OTHER|10 minute mindful meditation recording|10 minute mindful meditation recording
214420320|NCT06712160|DIAGNOSTIC_TEST|Artificial Intelligence|The number of canals detected by AI
214420321|NCT06711900|DRUG|SKB264|IV Infusion
214420322|NCT06711900|DRUG|Pembrolizumab|IV Infusion
214420323|NCT06711900|DRUG|pemetrexed|IV Infusion
215019904|NCT05679934|OTHER|Exercise Program|Stretching and strengthening exercises will be applied to the participants
214420324|NCT06711900|DRUG|carboplatin or cisplatin|IV Infusion
214420325|NCT06713876|DEVICE|VA-ECMO-assisted PCI|A total of 220 consecutive patients with VA-ECMO-assisted PCI will be enrolled. Data related to medical history, procedural characteristics, and outcomes were collected. Clinical follow-up will be conducted in the periprocedural and postoperative at 1 month, 1 year, 2 years, 3 years, 4 years, and 5 years.
214420326|NCT05052983|DRUG|Nemolizumab|Participants received either 1 \[30 milligram (mg)\] or 2 (2\*30 mg) subcutaneous (SC) injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
214420327|NCT05052983|DRUG|Placebo|Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
214420328|NCT06713395|OTHER|The control group received standard postoperative care|standard postoperative care
214420329|NCT06713395|OTHER|PERMA|"1. Establishment of the Integrated Psychological Intervention Team:~   The team consisted of 2 primary nurses, 4 specialist nurses, 1 psychologist, 2 physicians at the attending level or higher, and 2 researchers.~   Team Responsibilities: The primary and specialist nurses were responsible for implementing the intervention protocol. The physicians handled any adverse reactions experienced by the patients. The researchers were in charge of developing the intervention protocol and collecting data. All team members were required to undergo specialized training from the psychologist and pass an assessment before initiating the intervention.~2. Protocol Development:~   The intervention protocol, including specific content, team responsibilities, implementation process, and responses to adverse events, was carefully developed in written form by the researchers. The protocol was discussed and approved by all team members before implementation.~3. Protocol Implementation:~Emotional Support Intervention:"
214420330|NCT06713486|PROCEDURE|Fixed pressure obtained in the polysomnography for 28 days|home nocturnal therapy either at the fixed pressure obtained in the polysomnography for 28 days
214420331|NCT06713486|PROCEDURE|Dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode|dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode (program B) for 28 days, using the apnea threshold obtained in the titration as the maximum EPAP pressure and adjusting the support pressure for inferred Vt to 8 ml/kg of ideal body weight. After the first 28 days, a polysomnography will be performed under therapy with the device, and the next morning, cycle ergometry will be conducted.
214420332|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA layered technique|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
214420333|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
215102493|NCT05032885|OTHER|physiotherapy|"Patients in the intervention group will receive early physiotherapy treatment. This intervention will consist of exercises and physiotherapy techniques commonly used and aimed at improving the patient's respiratory and motor conditioning.~At the respiratory level: diaphragmatic and costal targeted ventilation, pursed-lip breathing and bronchial hygiene techniques if required.~At the motor level: passive, active-assisted kinesitherapy and analytical and global potentiation of the upper and lower limbs that will allow the maintenance and improvement of the articular pathway and will prevent muscle weakness; retraining of transfers and balance; gait reeducation."
214420334|NCT04133363|PROCEDURE|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF
214420335|NCT01125761|DRUG|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
214420336|NCT01125761|DRUG|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
214420337|NCT05144217|DRUG|Placebo|1 capsule per day of placebo
214420338|NCT05144217|DRUG|2x 140 mg per day|2 capsule per day of silimarit
214420339|NCT05144217|DRUG|3x 280 mg per day|3 capsule per day of silimarit
214420340|NCT05144217|DRUG|1x 1120 mg|8 capsule per day of silimarit
214420341|NCT03315507|DRUG|PB1046 Subcutaneous Injection|Eight weekly doses of PB1046.
215019905|NCT06088914|DEVICE|Anodal transcranial direct current stimulation|Anodal tDCS will be delivered for 5 consecutive days. Participants will receive 2 mA of stimulation for 20 minutes with the anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
215019906|NCT06088914|DEVICE|Sham transcranial direct current stimulation|Sham tDCS will be delivered for 5 consecutive days. Participants will receive sham stimulation for 20 minutes with the current intensity ramping down after 30 seconds of stimulation. The anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
214420342|NCT01254981|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent
214420343|NCT01473719|BEHAVIORAL|motivational intervention|7-session individual motivationally-based intervention
214420344|NCT01473719|BEHAVIORAL|health education|7 individual sessions focusing on health education
214420345|NCT00238446|DRUG|EC-MPS|
215019907|NCT03906955|BEHAVIORAL|Efficacy for Lifestyle PA|The intervention group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for engaging in lifestyle physical activity.
215019908|NCT03906955|BEHAVIORAL|Efficacy for Work-life Balance|The time-matched control group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for work-life balance.
215019909|NCT00032331|PROCEDURE|PET Imaging|
215019910|NCT00032331|PROCEDURE|CT scan|
215019911|NCT05546372|DEVICE|Endobiliary radiofrequency ablation (eRFA)|Intraductal radiofrequency ablation of tumor prior to stent placement
215019912|NCT05546372|DEVICE|uncovered self-expanding metal stent (uSEMS)|Intraductal placement of uncovered metal stent
215019913|NCT02082782|PROCEDURE|Irreversible electroporation (IRE)|Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
215019914|NCT01807741|DRUG|Asenapine|Available in 5 and 10 mg.
215019915|NCT01807741|DRUG|Placebo|
215102494|NCT03762798|DEVICE|The Bridge|The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
215102495|NCT04752345|OTHER|Pharmacoinvasive strategy|Pharmacoinvasive treatment \[full-dose fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI (3 to 24 hours, in case of successful fibrinolysis)
215102496|NCT04752345|OTHER|Reduced-dose facilitated PCI strategy|Reduced-dose facilitated PCI\[reduced-dose fibrinolysis,simultaneously transfer,immediate coronary angiography and andioplasty when arrived at PCI center(\<3 hours)\]
215102497|NCT03410342|OTHER|LFV|1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
214420346|NCT04415333|DRUG|Sodium Butyrate 5 mmol|Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
214420347|NCT04415333|DRUG|Sodium Butyrate 80 mmol|Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
214420348|NCT06220045|COMBINATION_PRODUCT|Polyvinylidene fluoride mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polyvinylidene fluoride mesh."
214420349|NCT06220045|COMBINATION_PRODUCT|Prophylactic polypropylene mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polypropylene mesh."
214420350|NCT04637750|BEHAVIORAL|Educational intervention|The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).
214420351|NCT00849147|BIOLOGICAL|Haploidentical Bone Marrow Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~* Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor."
214420352|NCT00849147|BIOLOGICAL|GVHD prophylaxis|"The GVHD prophylaxis regimen will consist of the following:~* Cy: 50 mg/kg IV on Days 3 and 4~* Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~* Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~* Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm\^3 for 3 consecutive days"
214420353|NCT03244436|PROCEDURE|Surgery following catheterization|Emergency surgery following pediatric cardiac catheterization
214420354|NCT05571722|DRUG|Vancomycin Injection|Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.
214420355|NCT05571722|DRUG|Linezolid Injection|Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
214420356|NCT05507749|PROCEDURE|cryoballoon ablation|Cryoballoon ablation for the treatment of atrial fibrillation
214420357|NCT05507749|DEVICE|implantable loop recorder insertion|The device called a implantable loop recorder, is placed just under the skin of one's chest during a minor surgery.
214420358|NCT06174220|DRUG|Tideglusib|Tideglusib 1g po daily
214420359|NCT06174220|DRUG|Placebo|Matching placebo 1g po daily
214420360|NCT04822753|PROCEDURE|Platelet Rich Plasma injection to the lumbar facet joint|Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.
214420361|NCT06788717|DEVICE|Comprehensive Primary Revision Stems|Comprehensive Primary Revision Stem (implants and instrumentation) when used for shoulder arthroplasty.
214420362|NCT05138601|OTHER|Virtual Collaborative Care Clinic|Trained clinical pharmacists will monitor BP, prescribe and adjust medications and monitor for side effects of medications under the license of, and in communication with, the patient's physician.
214420363|NCT01210820|DEVICE|iFS™ Femtosecond Laser System|intrastromal arcuate cuts made with iFS™ femtosecond laser
214420364|NCT02976532|OTHER|Electromagnetic tracking unit in femoral derotation surgery|Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
214420365|NCT00482729|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
214420366|NCT00482729|DRUG|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
214420367|NCT05721924|PROCEDURE|Pericapsular nerve group (PENG) block|In PENG group, the patient will be given PENG block 30mls of 0.2% ropivacaine
214420368|NCT05721924|PROCEDURE|Supra-inguinal fascia iliaca compartment (S-FICB) block|Patients in group B (S-FICB group) will be supra-inguinal fascia iliaca compartment block 30mls of 0.2% ropivacaine
214420369|NCT01675895|DRUG|Levobupivacaine lidocaine spinal anesthesia|Spinal anesthesia
214420370|NCT01675895|DRUG|levobupivacaine Spinal anesthesia|spinal anesthesia
214420371|NCT03357289|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
214420372|NCT01606124|DRUG|defined green tea catechin extract|Given PO
214420373|NCT01606124|OTHER|placebo|Given PO
214420374|NCT01606124|OTHER|questionnaire administration|Ancillary studies
215019916|NCT06199830|DIAGNOSTIC_TEST|positive bronchial provocation test|Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation. This test was stopped until a reducing in baseline FEV1 of 20%.
215019917|NCT04427111|DEVICE|Non-titratable-customized mandibular advancement device|The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.
214420375|NCT01606124|OTHER|laboratory biomarker analysis|Correlative studies
214420376|NCT04439747|OTHER|Ultrasound, DXA, hormonal tests|Diagnostic tests in selected groups with investigation of revealed hormonal disorders
214420379|NCT04036877|OTHER|Mood Disorder Assessment|Assess depression, anxiety, HRQOL, and financial toxicity in both bladder cancer patients and their caregivers via telephone survey
214420380|NCT05707871|DRUG|SPECTRUM cigarettes|SPECTRUM cigarettes have varying amount of nicotine content
214420381|NCT05707871|OTHER|usual brand of Cigarettes|Usual Brand of Cigarettes
214420382|NCT00042198|BEHAVIORAL|Cognitive behavior therapy|Up to 12 weekly, individual, hour-long sessions
214420383|NCT00042198|BEHAVIORAL|Supportive Stress Management|Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
214420384|NCT02515838|DRUG|Sevuparin|The Drug Product sevuparin solution for IV infusion
214506205|NCT02915432|BIOLOGICAL|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
214420385|NCT02515838|OTHER|Placebo|Placebo for IV infusion
214420386|NCT00460785|DRUG|Opioid|
214420387|NCT03692013|DRUG|Losartan|Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
214420388|NCT04074902|DEVICE|Ultrasonography|Mindray dp1100 plus.
214420389|NCT00669461|DRUG|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
214420390|NCT03391908|DIAGNOSTIC_TEST|cardiac imaging tests|Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
214420391|NCT06555276|DEVICE|Disposable endoscope linear cutting stapler and components|to use the study device for excision, transection and anastomosis of lung, bronchial tissue, stomach and intestine in open or endoscopic surgery.
214420392|NCT04628286|OTHER|Sham Laser|Sham Laser in plantar fascia
214420393|NCT04628286|OTHER|Myofascial Induction|Myofascial Induction in plantar fascia
214420394|NCT03865758|DEVICE|IN2L computer system|Therapists will use the IN2L computer system to choose videos, music, games and exercise specific to the rehabilitation needs and personal preferences of patients.
214420395|NCT00748150|BIOLOGICAL|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
214420396|NCT05918159|OTHER|Sarcopenia Assessment|The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.
214420397|NCT04672772|DRUG|Cetuximab|Weekly cetuximab at starting dose, that could be switched to biweekly
214420398|NCT04672772|DRUG|Paclitaxel|Paclitaxel at starting dose of 80 mg/m2
214420399|NCT03311568|DEVICE|ultrasound for microcirculatory assessment|"Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface."
214420400|NCT04505813|BIOLOGICAL|NEXI-002 T Cells|The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.
214420401|NCT06416202|DEVICE|Advanced hybrid closed loop insulin pump|All groups will receive comprehensive diabetes education and extensive carbohydrate counting training. Continuous glucose monitoring (CGM) will be conducted using the Guardian 4 sensor or Dexcom G6 for the intervention group depending on the type of pump used. fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
214420402|NCT06416202|OTHER|Open Loop Insulin Delivery system|the control group will continue using their current CGM device. Data on glycemic control, hypoglycemic events, and patient satisfaction will be collected before and throughout Ramadan. Additionally, fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
214420403|NCT04431934|DIETARY_SUPPLEMENT|PROBIOTIC|"Participants assigned to the probiotic arm will receive 2 sachets of Vivomixx® dissolved in 50 L of warm water (according to the manufacturer indications) every 12 h orally or through a nasogastric tube (in this case the tube will be flushed with 50 mL of water after the administration). The probiotic will be started 24 h after the last dose of NAA and will be administered for 14 consecutive days. Each sachet of Vivomixx® contains a combination of 4 Lactobacillus (L. paracasei 24733, L. acidophilus 24735, L. delbrueckii ssp bulgaricus 24734, L. plantarum 24730), 3 Bifidobacteria (B. brief 24732, B. longum 24736, B. infantis 24737), and Streptococcus thermophilus 24731 at a concentration of 450 billion (45x1010) live lyophilized bacteria per sachet."
214420404|NCT04431934|DIETARY_SUPPLEMENT|FMT REGIMEN|The FMT preparation will be administered as 2 doses, once a week, of 14-17 capsules per dose. Each dose (14-17 capsules) will contain the fecal microbiota equivalent to 50 gr of stools from a healthy donor. If the patient is carrying a nasogastric tube, the content of capsules will be decapsulized (\~27 gr of powder), diluted in 50 mL of water and passed through it, followed by the administration of 50 mL of water to flush the tube. The first dose will be administered 24 h after the last dose of NAA and the second dose one week later. Whenever possible, the two doses of FMT will be originated from the same donor. According to our data done by flow cytometry and bacterial culture in three replicates, each absorbate capsule contains approximately 1.12x1010 live bacteria.
214420405|NCT02631148|DRUG|Melatonin|2mg controlled release melatonin tablet
214420406|NCT02631148|DRUG|Placebo|placebo tablet identical to circadin
214420407|NCT04157855|PROCEDURE|Abdominal Plane Block(s) with depot Steroids|APB Steroids treatment: under real time ultrasound guidance, a 100 mm needle is introduced into the specified plane (subcostal TAP for upper abdomen pain, posterior TAP for lower abdomen pain or TQL for flank and lower abdominal pain). Normal saline (10 ml) is used to open the fascial plane (saline hydrodissection). Then 40 mg of depomedrone diluted in 10 ml of 0.25% levo-bupivacaine is injected into the plane. . A total of 80 mg of depomedrone (steroid) will be used.
214420408|NCT05752136|BIOLOGICAL|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
214420409|NCT04292054|DRUG|active intervention|The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
214420410|NCT04292054|OTHER|placebo intervention|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
214420411|NCT03503084|BEHAVIORAL|Classical Yang's TCC exercise|
215019918|NCT04787016|OTHER|Pilate training|Pilates is an exercise training program used to build core strength and flexibility.
214506206|NCT05342246|PROCEDURE|Endodontic retreatment|retreatment of the patent root canal only without attempt to retrieve the separated instrument
214506207|NCT02967861|BEHAVIORAL|Pranayama|Pranayama is the breathing exercise through the nostrils. It enhances the systemic immunity which in turn enhances the overall defense mechanism of an individual.
214506208|NCT02967861|PROCEDURE|Scaling and root planing|It is a mechanical debridement of dental plaque.
214506209|NCT01786876|DRUG|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
214506210|NCT00741650|BEHAVIORAL|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
215019919|NCT04565353|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
215019920|NCT03239054|BEHAVIORAL|Physical activity|pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
215019921|NCT03239054|BEHAVIORAL|Control group|Information will be given as part of standard care
214420412|NCT03657017|DIAGNOSTIC_TEST|PET/MR|Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.
214420413|NCT01256736|DRUG|Tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
214420414|NCT01256736|DRUG|DMARDs|DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
214420415|NCT03737682|DIAGNOSTIC_TEST|ENzyme linked immunity-sorbet assays|Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels
214420416|NCT02391207|PROCEDURE|Hepatic vein-sparing hepatectomy|HV detachment, partial resection and section on the basis of HV-CLM relationship
214420417|NCT02828423|PROCEDURE|EMD|Regenerative surgery with EMD
214420418|NCT02828423|PROCEDURE|BC|Regenerative surgery with BC
214420419|NCT05570188|BIOLOGICAL|anti-CD19 UCAR-NK cells|"Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells:~Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg."
215019922|NCT05428670|DRUG|Zanubrutinib+Rituximab+Lenalidomide|Zanubrutinib is a bruton' s tyrosine kinase inhibitor independently developed in China.
214420420|NCT06376357|OTHER|Foot Massage with roller|The intervention group is expected to apply roller massage to the soles of both feet in a sitting position on a chair (8 hours apart at 08.00, 16.00, 24.00 hours) every day for 6 weeks, 3x5 minutes a day. Video recording will be used as a reminder in the application.
214420421|NCT00168662|BIOLOGICAL|Measles and inactivated polio vaccine|
214420422|NCT02787694|OTHER|Factor Targeted Walking Training|Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches
214420423|NCT02787694|DEVICE|treadmill|
215019923|NCT05428670|DRUG|RCHOP/RCDOP|RCHOP/RCDOP is the classic treatment of diffuse large B cell lymphoma.
215019924|NCT00684294|BIOLOGICAL|TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine|Patients with solid tumors will receive TAG Vaccine 1 x 10\^7 cells/ injection or TAG Vaccine 2.5 X 10\^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
215019925|NCT04613089|OTHER|Natural History|Natural History and Clinical Follow Up.
214420424|NCT04860258|BIOLOGICAL|CVnCoV Vaccine|Intramuscular (IM) injection in the deltoid area, preferably in the non-dominant arm.
214420425|NCT01624844|OTHER|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
214420426|NCT05635604|DRUG|Eptinezumab|Eptinezumab or ALD403 is a humanized anti-calcitonin gene-related peptide IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). It selectively binds human CGRP ligand to prevent activation of the CGRP receptor and blocks its binding to the receptor for the prevention of migraine.
214420427|NCT05635604|DRUG|PACAP-38|PACAP-38 is a naturally occurring peptide diffusely expressed throughout the body. The Danish Headache Center has used infusion of PACAP-38 for several years and the first time in 2007 where infusion of PACAP-38 triggered headaches and migraines in migraine patients.
214420428|NCT02607384|BEHAVIORAL|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
214420429|NCT02607384|BEHAVIORAL|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
214420430|NCT02607384|OTHER|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
214420431|NCT02130128|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
214420432|NCT00001637|PROCEDURE|Blood cell transplantation|
214420433|NCT02416076|DEVICE|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
214420434|NCT02416076|DEVICE|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
214506211|NCT00741650|BEHAVIORAL|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,"
215019926|NCT01829763|DRUG|injection botox|
215019927|NCT06421441|OTHER|Self Management Skills Training|Nursing students will be given self-management skills training for a total of 12 hours, two days a week, two hours a day (60 min. + 60 min.) for three weeks.
215019928|NCT00216931|DRUG|iloprost|
215019929|NCT06202989|DRUG|Multiprofen-CC™ plus standard treatment|Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery
215019930|NCT06202989|OTHER|Placebo plus standard treatment|The placebo is the base cream with no medicinal ingredients to be applied 3 times per day for 6 weeks after surgery
215019931|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
215102498|NCT03410342|OTHER|HFV|4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
215102499|NCT03410342|OTHER|CC|4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
215102500|NCT03744520|PROCEDURE|Erector spinae plane block|Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
215102501|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
215102502|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
215102503|NCT02967601|BEHAVIORAL|STAI (State Trait Anxiety Inventory) questionaire|Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
215102504|NCT06186115|COMBINATION_PRODUCT|Gold|Intra articular
215102505|NCT00667667|DEVICE|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
215102506|NCT00667667|DEVICE|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
215102507|NCT00667667|BEHAVIORAL|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
214420435|NCT06533878|DRUG|HY-209|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
215019932|NCT06057103|DRUG|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
215019933|NCT06057103|DRUG|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
215019934|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
215019935|NCT06057103|DRUG|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
215019936|NCT06057103|DRUG|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
215019937|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
215019938|NCT04555733|DRUG|Lemborexant|Lemborexant oral tablets.
215019939|NCT05670340|DEVICE|Switched Prosthetic Profile|The implant will be rehabilitated with a switched emergence profile
215102508|NCT04797962|BEHAVIORAL|Case management|dedicated case management to address social support needs
215102509|NCT02540993|DRUG|Finerenone (BAY94-8862)|Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
215102510|NCT02540993|DRUG|Placebo|Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
215019940|NCT05670340|DEVICE|Matched Prosthetic Profile|The implant will be rehabilitated with a matched emergence profile
215019941|NCT05333965|DEVICE|Lens A (lehfilcon A lens)|Daily wear for 1 month.
214420436|NCT06533878|DRUG|HY-209 placebo|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg
214420437|NCT03919864|BEHAVIORAL|CONNECT Intervention|Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
214420438|NCT03919864|BEHAVIORAL|CONTROL Group|Participants will receive a generic printed list of hospital, community, and national supportive care resources.
214420439|NCT04045977|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
214420440|NCT04045977|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
214420441|NCT04045977|BEHAVIORAL|Standard therapeutic support|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
214506212|NCT06375759|PROCEDURE|Subarachnoid-Subarachnoid (S-S) Bypass|"The dura was widely exposed beyond the level of trauma, and then a midline dural opening was made under an operative microscope. When dura and arachnoid were adhered because of an expansion of arachnoiditis, they had to be released with great care to place the bypass tubes. During this procedure, S-S bypass was not usually needed to performed arachnoid lysis. This exposure had to reach the normal arachnoid mater free from arachnoiditis and adhesion, with normal CSF circulation.~After dissections of the normal arachnoid mater at the cephalic and caudal sites, 1 or 2 tubes made of medical grade silicone (ventricular drainage tube; internal diameter 1.5-2.0 mm, external diameter 2.5-3.3 mm) were inserted into the cephalic and caudal ends of the normal subarachnoid space. The part of the tube inserted into the subarachnoid space was approximately 2 cm long."
215019942|NCT05333965|DEVICE|Lens B (comfilcon A lens)|Daily wear for 1 month.
215019943|NCT05855278|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
215019944|NCT04922879|BEHAVIORAL|Individualized lung rehabilitation|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
215019945|NCT01975480|DRUG|Desvenlafaxine|
215019946|NCT02320552|OTHER|No intervention|no intervention
215019947|NCT02312128|OTHER|Questionnaire|DASH Score, PRWE Score, Mayo Wrist Score
215019948|NCT02312128|RADIATION|X- Ray|X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
215019949|NCT02312128|OTHER|Grip Strength|Grip strength measurement
215019950|NCT02312128|OTHER|VAS Score|Measurement pain according to the visual analogue scale (VAS)
215019951|NCT02312128|OTHER|Range of Motion measurement|Angle measurement of the active range of motion in the wrist
215019952|NCT04802785|DRUG|Citicoline|Citicoline 500 mg (Vitaae®) per os
215019953|NCT04802785|DRUG|Cytochrome C6|Cytochrome10 mg per os
215019954|NCT04802785|DRUG|Sodium Chloride Oral Product|Sodium Chloride (NaCl) 2.6 g. per os
215019955|NCT04802785|DRUG|Potassium Chloride Oral Product|Potassium Chloride 1.5 g per os
215019956|NCT04802785|DRUG|Sodium Citrate Oral Product|Sodium Citrate 2.90 g per os
215019957|NCT04802785|DRUG|Dextrose Oral Tablet, Chewable|Dextrose 13.5 g per os
214506213|NCT06375759|PROCEDURE|Intradural Adhesion Lysis|Intradural spinal cord Adhesion Lysis
214506214|NCT02895659|PROCEDURE|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
214506215|NCT04332094|DRUG|Tocilizumab|162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)
214506216|NCT04332094|DRUG|Hydroxychloroquine|400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
214506217|NCT04332094|DRUG|Azithromycin|500 mg / day v.o. for 3 days
214506218|NCT00476736|DRUG|Effect on small airways (N-Acetylcystein)|
214506219|NCT05879705|OTHER|Parent intervention|Family centered, strength-based, Occupational therapy intervention program
214506220|NCT04278755|DRUG|Drospirenone-Ethinyl Estradiol Oral Tablet|3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
214506221|NCT05925699|OTHER|Collection of clinical, radiological, and biological data from patients' medical records|Collection of clinical, radiological, and biological data from patients' medical records
214420442|NCT03746665|BIOLOGICAL|meningococcal serogroup A conjugate vaccine|Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
214420443|NCT03336424|DIAGNOSTIC_TEST|Non-invasive investigations|Ultrasound, blood tests, urine analysis and culture, uroflowmetry
214420444|NCT03336424|DIAGNOSTIC_TEST|Invasive investigations|Cystomanometry, pressure flow study, EMG
214420445|NCT01465724|PROCEDURE|Renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
214420446|NCT02120599|DIETARY_SUPPLEMENT|ready-to-use supplementary food|
214420447|NCT02120599|DIETARY_SUPPLEMENT|corn-soy blend|
214420448|NCT02120599|DIETARY_SUPPLEMENT|iron|
214420449|NCT02120599|DIETARY_SUPPLEMENT|folic acid|
214420450|NCT02120599|DIETARY_SUPPLEMENT|UNIMMAP|
214420451|NCT05731466|DEVICE|CardioMems HF System|"1. Implantation CardioMems device.~2. Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements."
214420452|NCT02576821|OTHER|Neurological examinations|
214420453|NCT02576821|OTHER|Neuropsychological examinations|
214506222|NCT00140725|DRUG|Lamivudine plus Polyethylene glyco-interferon alfa-2b|
214506223|NCT00140725|DRUG|Lamivudine|
214506224|NCT04257799|OTHER|Structured Light Imaging (SLI) System|Investigation of SLI and Tomographic Imaging to see if they will identify cancer cells at the edge of tissue specimens removed during the operation.
214506225|NCT03154736|OTHER|Interview|Individual interview and group interview Socio-economic questionnaire
215019958|NCT04802785|DRUG|Domperidone Oral Product|Domperidone 1 tablet per os
214420454|NCT02576821|OTHER|Clinical examinations|
214420455|NCT02576821|RADIATION|MRI 3T|
214506226|NCT06438237|PROCEDURE|Bowel preparation before colonoscopy|Patients use purgative for bowel cleansing before colonoscopy.
214420456|NCT02576821|RADIATION|MRI 7T|
214420457|NCT06555510|OTHER|InBody|Bioelectrical impedance analysis
214420458|NCT01976936|DRUG|Low Dose Lovastatin|80 mg daily for 3 days
214420459|NCT01976936|OTHER|Placebo|Placebo for 3 days
214420460|NCT01976936|DRUG|High Dose Lovastatin|640 mg daily for 3 days
214420461|NCT01191892|DRUG|carboplatin|
214420462|NCT01191892|DRUG|gemcitabine hydrochloride|
214420463|NCT01191892|DRUG|vandetanib|
214420464|NCT01191892|DRUG|Placebo|Placebo of vandetanib tablet
214420465|NCT00028769|DRUG|bicalutamide|
214420466|NCT00028769|DRUG|estramustine|
214420467|NCT00028769|DRUG|etoposide|
214420468|NCT00028769|DRUG|flutamide|
214420469|NCT00028769|DRUG|goserelin|
214420470|NCT00028769|DRUG|leuprolide|
214420471|NCT00028769|DRUG|nilutamide|
214420472|NCT00028769|DRUG|paclitaxel|
214420473|NCT01796782|DRUG|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
214506227|NCT00843050|DRUG|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
214506228|NCT03184987|DRUG|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
214506229|NCT03184987|DRUG|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
214506230|NCT03184987|DRUG|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
214506231|NCT03184987|OTHER|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
214506232|NCT04559074|DRUG|Amlodipine|Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
215019959|NCT04802785|DRUG|Simethicone|3-4 capsules per os
215019960|NCT04802785|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 150 mg per os
214420474|NCT01796782|DRUG|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
214420475|NCT03579368|DEVICE|Symfony implantation|Bilateral Symfony IOL Implantation
214420476|NCT04383730|DRUG|Intravenous sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
214420477|NCT04383730|DRUG|Inhaled sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
214420478|NCT05922215|OTHER|Dynamic Balance training|The Experimental group will be given the Baseline treatment comprising of Stretching \& Static balance training (i.e. heel and toe raises, alternate rising of the left and right foot above the floor and tandem standing.) alongside Dynamic Balance training which will include (weight shifting forward, backward, sideward, and diagonally with eyes opened and eyes closed, walking toe-to-heel barefoot, side walking, reverse walking and one-foot jumps), and Progressive activity training (such as stepping over/on obstacles, throwing and catching a ball, and kicking a ball.) for 40 minutes per day, twice each week for 8 weeks.
214420479|NCT05922215|OTHER|Static balance training|The Control group will continue their regular school schedule, which will include participation in physical education activities at the same frequency. Along with that Baseline treatment including Static balance training (i.e. alternate rising of the left and right foot above the floor and tandem standing.) only, at the same intervals and for the same length of time as the intervention group, with the exception of additional Dynamic balance training and progressive activity training.
214420480|NCT01134562|DRUG|Placebo|Single IV injection.
214420481|NCT01134562|DRUG|Etelcalcetide|Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
214420482|NCT01271517|DRUG|NPH insulin|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
214420483|NCT01271517|DRUG|Glargine|Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
214420484|NCT01271517|DRUG|Detemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
214506233|NCT02328144|DRUG|Metronidazole|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
214506234|NCT02328144|DRUG|Placebo|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
214506235|NCT03353961|BEHAVIORAL|Emotion regulation individual therapy|The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
214506236|NCT03353961|BEHAVIORAL|Treatment as usual|Treatment as usual as provided in the community.
214420485|NCT00357396|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
214420486|NCT00357396|DRUG|busulfan|
214690070|NCT04552873|DRUG|Urea|"the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered."
214690071|NCT04552873|OTHER|PLACEBO|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
215019961|NCT04802785|DRUG|Magnesium hydroxide|magnesium hydroxide 30 mg per os
214420487|NCT00357396|DRUG|melphalan|
214420488|NCT00357396|DRUG|thiotepa|
214420489|NCT00357396|PROCEDURE|allogeneic bone marrow transplantation|
214420490|NCT00357396|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
214420491|NCT00357396|PROCEDURE|peripheral blood stem cell transplantation|
214420492|NCT04002973|DEVICE|INVSENSOR00037|Noninvasive regional oximeter.
214420493|NCT02496702|DEVICE|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
214420494|NCT00487578|DRUG|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
214420495|NCT03458546|DRUG|Roflumilast|All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
214506237|NCT04826406|DRUG|Camrelizumab combined Apatinib regimen|Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day.
214506238|NCT05500352|OTHER|Hyperglycemia with slow decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
215019962|NCT04802785|DRUG|Probiotic Formula|1 capsule per os.
215019963|NCT04802785|DRUG|Melatonin 5 mg|Melatonin 5 mg per os.
215019964|NCT00382863|DEVICE|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
215019965|NCT00382863|DRUG|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
215019966|NCT01067911|DIETARY_SUPPLEMENT|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
214420496|NCT04663464|COMBINATION_PRODUCT|abaloparatide-sMTS|Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
214420497|NCT04663464|COMBINATION_PRODUCT|abaloparatide-SC|Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen
214420498|NCT04745663|DRUG|Povidone-Iodine 0.3%|Low concentration iodine
214420499|NCT04745663|DRUG|Povidone-Iodine 5%|Standard concentration iodine
214420500|NCT03233919|DEVICE|comprehensive remote ischaemic conditioning|"comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
214420501|NCT02378714|DRUG|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
214420502|NCT02378714|BEHAVIORAL|BASC|"The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions."
214420503|NCT02378714|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
214420504|NCT04775290|BEHAVIORAL|Yoga lessons|2 weekly yoga classes during the 5 weeks of radiotherapy
214420505|NCT02525796|DRUG|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
214420506|NCT02525796|DRUG|amiloride|amiloride, titrated up to a maximum of 10mg BID
214420507|NCT02525796|DRUG|Placebo|
214420508|NCT02525796|DRUG|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
214420509|NCT02152813|BEHAVIORAL|TENS and Task-orientated training|All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
214690072|NCT04283032|PROCEDURE|Multiparametric magnetic resonance|MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
214690073|NCT01996345|PROCEDURE|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
214690074|NCT06921772|BEHAVIORAL|PNF Stretching Exercise|Proprioceptive Neuromuscular Facilitation (PNF) stretching exercises were applied three times per week for six weeks. The intervention included contract-relax and hold-relax techniques targeting lower extremity muscle groups, conducted in addition to regular volleyball training.
214690075|NCT03662464|OTHER|No intervention|develop and validate a specific tool to score the risk of escaping in Nursing Homes residents
214690076|NCT07128121|BIOLOGICAL|Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)|Formulation for injection
214420510|NCT03185156|DRUG|Propofol|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
214420511|NCT03185156|DRUG|Normal saline|first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
214420512|NCT00552097|DRUG|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
214420513|NCT00552097|DRUG|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
214420514|NCT05538455|DEVICE|PC4L solutions|Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
214420515|NCT03565939|BIOLOGICAL|Trichuris suis ova|Eggs from the pig whipworm
214420516|NCT03565939|BIOLOGICAL|Placebo|Solution without TSO
214690077|NCT07128121|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
214690078|NCT01808703|DEVICE|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
214420517|NCT01517347|DRUG|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
214506239|NCT05500352|OTHER|Hyperglycemia with rapid decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
214420518|NCT03802032|DRUG|Lidocaine Gel|topical lidocaine gel
214420519|NCT03802032|DRUG|KY jelly|topical KY jelly
214420520|NCT00001318|DRUG|interferon gamma|
214506240|NCT05500352|OTHER|Rebound hyperglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L)
214506241|NCT05500352|OTHER|Rebound euglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in euglycemia (PG: 5-8 mmol/L).
214506242|NCT05500352|OTHER|Hypoglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L) or euglycemia (PG: 5-8 mmol/L)
214506243|NCT05500352|OTHER|Hypoglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
214506244|NCT05500352|OTHER|Hypoglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
214506245|NCT05500352|OTHER|Hyperglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
214506246|NCT05500352|OTHER|Hyperglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
214506247|NCT06177561|PROCEDURE|Lymphoplasma exchange|The LPE treatment regimen is: LPE\*2 times (20-30ml/kg, treatment interval of 2 days);CD20 monoclonal antibody 375mg/m2\*2 times, gamma globulin 0.4g/kg/d\*5d.
214506248|NCT00275444|DRUG|Tipranavir|
214506249|NCT02851498|OTHER|Food product: high-protein pasta and cereal|
214506250|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
214506251|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
214506252|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
214506253|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
214506254|NCT01727570|DIETARY_SUPPLEMENT|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
214506255|NCT06002035|DIETARY_SUPPLEMENT|Binom Vitamin D drops|Take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added
214506256|NCT05381090|DIAGNOSTIC_TEST|Venous blood collection|Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.
214506257|NCT03764020|DRUG|Placebo oral capsule/placebo comparator|3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline
214506258|NCT03764020|DRUG|Melatonin/experimental|Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
214506259|NCT03569774|PROCEDURE|One-lung ventilation with individualized PEEP|During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
214506260|NCT03569774|PROCEDURE|One-lung ventilation with low PEEP|Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
214420521|NCT02001818|DRUG|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
214420522|NCT01199783|DRUG|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
214420523|NCT01199783|DRUG|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
214420524|NCT00726999|DRUG|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
214420525|NCT00726999|DRUG|Placebo|
214420526|NCT00726999|DRUG|Morphine|Administered as needed
214420527|NCT00785863|OTHER|Placebo|Placebo IV before placebo infusion
214420528|NCT00785863|DRUG|Remifentanil|placebo IV and remifentanil infusion
214420529|NCT00785863|DRUG|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
214506261|NCT02286869|PROCEDURE|Three different mechanical ventilation modes|patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
214506262|NCT00861991|BEHAVIORAL|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
214506263|NCT01354288|OTHER|Educational tool|Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
214690079|NCT01808703|PROCEDURE|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
214420530|NCT00785863|DRUG|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
214420531|NCT05111483|OTHER|Tupler technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~1. Repositioning with diastasis rehab splint :~2. Protect the connective tissue~3. Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~4. Diastasis safe exercises program to maintain the gains"
214420532|NCT05111483|OTHER|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~1. Tie a scarf around abdomen while performing exercises~2. Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~3. Respiratory rehabilitation manoeuvre"
214420533|NCT00955825|DRUG|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
214420534|NCT00955825|DRUG|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
214420535|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
214420536|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
214420537|NCT00542113|BEHAVIORAL|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
214420538|NCT02227771|DEVICE|Percutaneous coronary intervention|
214690080|NCT06929585|PROCEDURE|Genicular artery embolization|The patient will receive GAE procedure and sham IA procedure.
214420539|NCT01499134|DRUG|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
214420540|NCT01499134|DRUG|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
214420544|NCT02488980|DRUG|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
214420545|NCT02488980|DRUG|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
214420546|NCT02488980|DRUG|Placebo|Placebo for three days followed by placebo once a week for 24 weeks
214506264|NCT05589415|DEVICE|High-definition Transcranial Direct Current Stimulation|"High-definition Transcranial Direct Current Stimulation (HD-tDCS) delivers current through five small electrodes (0.8 cm2) placed in an X-shaped configuration via a simple cap. This configuration leads to an 80% greater concentration or focusing of the electric field within the targeted region compared to conventional, non-focal Transcranial Direct Current Stimulation (tDCS). The participant will undergo 30 minutes of treatment at 2 milliamps."
214506265|NCT05589415|DEVICE|Conventional Transcranial Direct Current Stimulation|Surface electrodes will be placed in saline-soaked sponges (5 x 7 cm2) and applied to different regions of the scalp. The participant will undergo 30 minutes of treatment at 2 milliamps.
214506266|NCT02436070|BEHAVIORAL|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
214506267|NCT02436070|BEHAVIORAL|General text messages|Subjects received text messages generalized to children with asthma
214506268|NCT01220999|DRUG|CS-1008|CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).
214506269|NCT02253966|DRUG|Methylprednisoloneacetate|
214506270|NCT02253966|DRUG|Lidocaine|
214506271|NCT02253966|OTHER|sodium chloride|
214506272|NCT02652845|BEHAVIORAL|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
214506273|NCT02697656|BEHAVIORAL|IPS|Individualized job support provided by an employment specialist
214506274|NCT02697656|BEHAVIORAL|Self-help|Self-help resources on obtaining employment and coping with chronic pain
214506275|NCT02697656|BEHAVIORAL|Treatment as usual|Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
214506276|NCT01560429|PROCEDURE|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
214690081|NCT06929585|PROCEDURE|Intra-articular injection with corticosteroids.|The patient will receive IA procedure and sham GAE procedure.
214420547|NCT03003637|DRUG|Nivolumab|Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
214506277|NCT01560429|PROCEDURE|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
214506278|NCT00000892|DRUG|Ritonavir|
214420548|NCT03003637|DRUG|Ipilimumab|Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
214420549|NCT01820195|DRUG|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
214420550|NCT01820195|DRUG|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
214506279|NCT00000892|DRUG|Nelfinavir mesylate|
214506280|NCT00000892|DRUG|Levocarnitine|
214506281|NCT00000892|DRUG|Adefovir dipivoxil|
214506282|NCT00000892|DRUG|Saquinavir|
214506283|NCT00000892|DRUG|Delavirdine mesylate|
214506284|NCT00917098|BEHAVIORAL|Behavior Therapy|Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary
214506285|NCT00917098|BEHAVIORAL|Supportive Counseling|Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
214506286|NCT01302106|DRUG|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
214506287|NCT06425289|OTHER|Macrohemodynamic parameters|"Macrohemodynamic parameters will be estimated with transpulmonary thermodilution every 6 hours during the intervention period (5 days).~* Cardiac index~* Extravascular lung water index~* Pulmonary vascular permeability index~* Cardiac function index~* Global end-diastolic volume index~* Central venous pressure~* Fluid responsivness status (passive leg rising test)"
214506288|NCT05705245|OTHER|recruitment|Automated alveolar recruitment menouever applied during mechanical ventilation in the intraoperative period
214506289|NCT04188522|DIAGNOSTIC_TEST|Magnetoencephalography (MEG)|Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.
214420551|NCT01820195|DRUG|Placebo group|The patients in this group will be received both oral placebo and IV placebo
214420552|NCT04147910|DRUG|KW-6356|Single oral dose of KW-6356
214420553|NCT02546219|OTHER|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
214420554|NCT01091298|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
214420555|NCT01091298|OTHER|Placebo|Single dose (0.5 mL) of the placebo administered orally
214506290|NCT04127513|DRUG|Ammonium Lactate|12% ammonium lactate moisturizing cream
215102511|NCT02424045|DRUG|BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)|All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
215102512|NCT04731532|PROCEDURE|classical respiratory physiotherapy with thoracic vibration|Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .
214506291|NCT04127513|DRUG|Urea|10% urea moisturizing cream
214506292|NCT04058847|OTHER|Your Heart Forecast|1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.
214506293|NCT00461656|DRUG|Preoperative conjunctival irrigation with 5% or 1.25% PI|Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
214506294|NCT05732142|OTHER|Postpartum Integration of Vaccines and Contraception Through Gender-Transformative Programming(PIVoT)|The PIVoT intervention is a 30-minute focused information exchange that supports shared contraceptive decision making. The program includes a gender-equity and family planning curriculum covering basic family planning information as well as gender norms and son preference and interactive family planning method index cards (detailing method characteristics, use, duration of action, efficacy, side effects, and contraindications for each method). The program is designed to support person-centered contraceptive choice and encourages women to consider joint family planning decision-making with male partners. If a contraceptive method is desired, it will be provided by nurses who are trained to provide comprehensive family planning care.
214506295|NCT01028976|DIETARY_SUPPLEMENT|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
214506296|NCT01028976|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
214506297|NCT06111014|DRUG|Latozinemab|All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
214506298|NCT05353296|BEHAVIORAL|Digital cognitive behavioral therapy for insomnia (CBT-I) program|A self-guided digital program of CBT-I (Somryst) that has been culturally adapted for Spanish-language speakers. Somryst is an interactive and tailored mobile-based program modeled on the primary tenets of face-to-face CBT-I. Patients will be asked to complete six cores (main intervention content) during the 9-week intervention period. The cores provide key content across six domains including behavioral (sleep restriction, stimulus control), cognitive (cognitive restricting), educational (sleep hygiene), overview, and consolidation/relapse prevention.
214506299|NCT05353296|BEHAVIORAL|Minimally Enhanced Usual Care (mEUC)|A minimally enhanced usual care, which will include usual care by patients' Primary Care Provider and a sleep hygiene brochure.
214506300|NCT05353296|DEVICE|Somryst (culturally adapted)|FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) trains your brain for better sleep.
214420556|NCT01495936|PROCEDURE|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
214420557|NCT01495936|PROCEDURE|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
214420558|NCT01755897|PROCEDURE|radical hysterectomy + pelvic lymph node dissection|
214420559|NCT01755897|DRUG|Paclitaxel|135-175 mg/m(2) intravenously (IV) on day 1
214420560|NCT01755897|DRUG|Cisplatin|75 mg/m(2) IV on day 2 and 3
214420561|NCT01755897|DRUG|Cisplatin|35 mg/m(2) IV once a week
214420562|NCT01755897|RADIATION|Pelvic RT|IMRT
214420563|NCT01701453|DRUG|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
214420564|NCT03107962|DRUG|Pembrolizumab (PD-1 Blocking Antibody)|pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
214420565|NCT05967338|DEVICE|using McGrath Video Laryngoscope|glottis visualization in indirect and direct lifting methods by using McGrath Video Laryngoscope
214420566|NCT00649935|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fed
214420567|NCT00649935|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fed
214420568|NCT04529278|DRUG|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
214420569|NCT01198275|DRUG|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
214420570|NCT01198275|DRUG|Placebo|1.0 g of olive oil,one capsule twice a day
214420571|NCT01198275|DRUG|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
214506301|NCT06576167|BEHAVIORAL|IMPROVE|IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.
214420572|NCT01198275|DRUG|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
214420573|NCT04040530|PROCEDURE|CT-guided cryoablation|Percutaneous computed tomography guided cryoablation with the patient in sedation or general anaesthesia.
214506302|NCT05681351|DRUG|Olezarsen|Administered as SC injection.
214506303|NCT05586243|OTHER|No intervention|This is an observational study looking at brain chemicals related to oxidative stress and inflammation using magnetic resonance spectroscopy (MRS).
214506304|NCT04349436|BIOLOGICAL|RP1, intra-tumoral injection, oncolytic virus|Genetically modified herpes simplex type 1 virus
214506305|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. \[three video banks of RDE + Support\]).
214506306|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders.|Self-monitoring of pain, stress, and opioid use + alerts/reminders.
214420574|NCT04040530|PROCEDURE|Partial nephrectomy|Surgical removal of the renal cancer, leaving the healthy renal tissue. Surgery is either done laparoscopically, robot-assisted laparoscopically or as an open surgery. The patient is under general anaesthesia.
214420575|NCT00391846|DRUG|Captopril|
214420576|NCT00391846|DRUG|Enalapril|
214420577|NCT00391846|DRUG|Lisinopril|
214506307|NCT06302439|OTHER|No Intervention for this observational study|No Intervention for this observational study
215102513|NCT00120601|DRUG|Naltrexone|
214420578|NCT00391846|DRUG|Ramipril|
214420579|NCT00391846|DRUG|Trandolapril|
215102514|NCT00120601|DRUG|Acamprosate|
215102515|NCT03550404|BEHAVIORAL|Seasons of Care App|A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
215102516|NCT05435417|RADIATION|CBCT radiation|CBCT scanning
214420580|NCT00391846|DRUG|Bisoprolol|
214420581|NCT00391846|DRUG|Carvedilol|
214506308|NCT02345603|PROCEDURE|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
214506309|NCT02329639|GENETIC|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
214690082|NCT02279589|BIOLOGICAL|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
214420582|NCT00391846|DRUG|Metoprolol succinate|
214506310|NCT06159894|OTHER|DAY HOSPITAL ARM|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
214506311|NCT06159894|OTHER|Specialist-Care arm|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
215019967|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
215019968|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
215019969|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
215019970|NCT02157727|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
214420583|NCT00391846|DRUG|Candesartan|
214420584|NCT00391846|DRUG|Valsartan|
214420585|NCT00391846|DRUG|Eplerenone|
214420586|NCT00391846|DRUG|Spironolactone|
214420587|NCT00391846|DRUG|Diuretics|
214506312|NCT04539015|DEVICE|Prevena Plus|PREVENA Plus is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
214506313|NCT01053793|OTHER|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
215019971|NCT02168439|DRUG|Dexmedetomidine|
215019972|NCT02168439|DRUG|Midazolam|
215019973|NCT06569979|OTHER|Survey|"The survey was developed using the Google Forms platform. The first part of the questionnaire consisted of descriptive information such as age, gender, duration of academic experience. In addition to this informations, the questionnaire also included information related the status of use ICF in any fields.~In the other part of the questionnaire, a total of 59 questions (16 related to body functions, 3 related to body structures, 30 related to activity and participation, 10 related to environmental factors) were asked to the academicians whether these categories are present in the amputee rehabilitation course content. Academicians were asked to answer yes or no to each question."
215019974|NCT06569446|OTHER|There is no intervention. This a qualitative study to explore barriers to rectal irrigation|"This will involve semi-structured, open-ended questions about hypothesized barriers to rectal irrigation where the interviewer will ask a pre-determined number of questions and the participants will answer which will further initiate discussion allowing new themes to emerge. After the entire list of barriers is discussed, participants will be asked if they have any new barriers to add which have not been discussed. All new barriers identified will be added to the hypothesized barriers list for the next focused group sessions. Focused group sessions will continue until no new barriers are found in two consecutive sessions (thematic saturation).~9.2 Phase - 2 includes Cognitive Interviews This will involve semi-structured, open-ended questions about barriers to rectal irrigation identified during focused group sessions where the interviewer will ask pre-determined number of questions for individual participants to answer."
215102517|NCT01640262|OTHER|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
215102518|NCT00490048|PROCEDURE|Induced sputum (inhalation of 3.5% saline)|
214420588|NCT00391846|DRUG|HF treatment according to Swedish guidelines|
214420589|NCT00391846|PROCEDURE|Blood samples|
214420590|NCT00391846|PROCEDURE|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
214420591|NCT02217644|DRUG|BI 653048 H3PO4 solution|
214420592|NCT02217644|DRUG|BI 653048 H3PO4 low dose capsule|
214420593|NCT02217644|DRUG|BI 653048 H3PO4 high dose capsule|
214420594|NCT02217644|DRUG|Placebo|
214420595|NCT05019417|DRUG|Glycerol Phenylbutyrate 1100 MG/ML|Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
214420596|NCT04091425|DRUG|TAK-925|TAK-925 IV infusion
214420597|NCT04091425|DRUG|Placebo|TAK-925 placebo-matching IV infusion
214420598|NCT05598580|DRUG|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy.
214420599|NCT05598580|DRUG|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
214420600|NCT00041548|DRUG|nitric oxide for inhalation|given at 20 ppm for 1 hour then weaned off over 4 hours
214420601|NCT00041548|DRUG|Oxygen|given at 20 ppm for one hour, then weaned off over four hours
214420602|NCT00150176|DRUG|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
214506314|NCT04693741|PROCEDURE|secondary alveolar bone graft|"Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps."
214506315|NCT04693741|PROCEDURE|Harvesting of the autogenous bone graft|Under general anaesthesia ,the soft tissue in the superior iliac crest will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. The cancellous bone will harvested with an osteotome and then cut into small bone granules.
214506316|NCT04693741|PROCEDURE|Preparation of PRP|10 ml of blood will be collected in vacuum tubes without anticoagulants which are then immediately centrifuged at a rate of 3000 rpm for 10 min. After centrifugation, the resultant product consists of three layers. The topmost layer consisting of acellular PPP (platelet poor plasma), PRF clot in the middle and RBCs at the bottom of the test tube. The attached red blood cells scraped off from it and discarded. The discarded PRF is then mixed with xenograft and placed inside the alveolar defect.
215019975|NCT06571916|BEHAVIORAL|Brief-SfSL|"Brief-SfSL is a single 90-minute intervention that that:~1. helps clients understand their suicide narrative, which explores the origin and meaning of their suicidal thoughts~2. builds specific skills to keep oneself safe from suicide even if suicidal thoughts are present~3. includes enhanced safety planning by identifying the barriers to enacting a safety plan and solutions to overcome them"
215019976|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with no arthroscopy|The two procedures, with and without arthroscopy, only differ by the method of assessing cartilage removal. Cartilage removal will be assessed arthroscopically in the procedure with arthroscopy. In the procedure without arthroscopy, cartilage removal will be assessed via direct visualization through a mini arthrotomy procedure. After use of the cartilage burr the surgeon will make a small dorsal portal and use this opening to ensure that the cartilage is removed and all debris removed. The incision will be 2 cm long and centered over the dorsal medial aspect of the joint.
215019977|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with arthroscopy|After removal of the cartilage with the cartilage burr, a 3.0 arthroscope will be inserted to inspect the joint for all cartilage removal. Any residual cartilage pieces will be removed to ensure complete cartilage debridement from the subchondral bone and fragments removed from the joint.
215019978|NCT00237627|DRUG|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
215019979|NCT00237627|DRUG|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
215019980|NCT00237627|DRUG|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
215102519|NCT03776461|DEVICE|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
215102520|NCT00667290|BEHAVIORAL|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
214506317|NCT02276599|PROCEDURE|Volume expansion|Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
214506318|NCT02426255|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
214506319|NCT02494336|PROCEDURE|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
214506320|NCT02494336|PROCEDURE|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
215102521|NCT00073281|PROCEDURE|Islet transplantation|
215102522|NCT01207089|DRUG|AZD8329|AZD8329 Oral Solution 20mg/ml
215102523|NCT01207089|DRUG|Placebo|Placebo AZD8329 Oral Solution
215102524|NCT01009086|DRUG|Placebo|SC injections
215102525|NCT01009086|DRUG|Ustekinumab 45 mg|SC injections
215102526|NCT01009086|DRUG|Ustekinumab 90 mg|SC injections
215102527|NCT02190890|PROCEDURE|Dry needling|
215102528|NCT02190890|PROCEDURE|Control|
215102529|NCT03678233|DRUG|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
215102530|NCT01415492|BEHAVIORAL|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
214420603|NCT00150176|DRUG|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
214420604|NCT00150176|DRUG|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
214420605|NCT01291290|PROCEDURE|Platelet|2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
214420606|NCT01126112|BIOLOGICAL|Panitumumab|Panitumumab: 6 mg/Kg Q2W
215019981|NCT02685436|DRUG|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
215019982|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
215019983|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
215019984|NCT02040012|DRUG|AZP-531|
214420607|NCT01086917|BIOLOGICAL|PfSPZ Challenge|each volunteer to receive a single dose
214420608|NCT00184041|DRUG|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
214420609|NCT03636919|OTHER|e-BOOK|Patients will filled an e (carnet) included the questionnaire includes the Control of Allergic Rhinitis and Asthma Test (CARAT)
214420610|NCT02618018|PROCEDURE|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
214420611|NCT02494999|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
214420612|NCT02494999|BIOLOGICAL|Prevnar 13|0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
214420613|NCT05813899|DIETARY_SUPPLEMENT|PS23 heat-treated|PS23 heat-treated, 2 caps daily use
214420614|NCT06552676|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy is a widely used technique in intensive care. It involves creating a passage between the tracheal lumen and the outside, through which a cannula is placed.
214420615|NCT01162876|DRUG|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
214420616|NCT04442919|DRUG|Ticagrelor followed with Methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
214420617|NCT04442919|DRUG|Ticagrelor followed with Morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
215019985|NCT02040012|DRUG|Placebo|
215019986|NCT03570385|DEVICE|MRI|MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)
214506321|NCT02494336|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
214420618|NCT04442919|DRUG|Ticagrelor alone|patients who received ticagrelor without any analgesia due to unstable angina
214420619|NCT03624413|BEHAVIORAL|Social Media Intervention|The social media intervention is a behavioral intervention developed by the study investigators and is delivered via mobile phones. The intervention uses the Social-ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) model, highlighting modifiable targets of intervention that can be addressed through a social media platform. The SMART model incorporates modifiable factors such as knowledge, skills/self-efficacy, relationships and social support that can be targets of interventions to improve transition care. The SMART model emphasizes eight modifiable factors, three key stakeholders (adolescents, caregivers, and clinicians) and their interconnected relationship in influencing successful transition to adult care. The intervention is designed to overcome barriers and enhance facilitators to transitioning care among adolescents living with HIV who are transitioning to adult care in South Africa.
214420620|NCT03624413|OTHER|Standard of Care|Standard of care transition from pediatric to adult care for HIV.
214420621|NCT03329144|BEHAVIORAL|Cognitive Behavioural Therapy|The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
214420622|NCT02854319|DEVICE|LOTUS Edge Valve System|Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
214420623|NCT02825225|OTHER|20 core-biopsy fragments|Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.
214506322|NCT02911961|DRUG|Acetaminophen|1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
214506323|NCT02878616|DRUG|LFG316|LFG316 single dose
214506324|NCT02878616|DRUG|IVIG|IVIG single dose
215019987|NCT00605657|DRUG|Valproic Acid|Oral administration of valproic acid
215019988|NCT00605657|PROCEDURE|CT Scan|CT scans were done before and after treating the patient with valproic acid
215019989|NCT00605657|PROCEDURE|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
215029088|NCT06950606|DEVICE|Pneumatic leg compression|Patients assigned to the PLC group will receive a pneumatic leg compression sleeve encompassing the calf and thigh, with sleeve size adjusted according to thigh circumference and manufacturer recommendations. The compression pump will be activated before the start of surgery. After surgery, the responsible trial personnel will deactivate the pump and remove the compression sleeves in the PLC group. There will be no standardized anesthesia management protocol; all decisions regarding hemodynamic management will be made at the discretion of the treating anesthesiologist
215029089|NCT06188975|DRUG|DRUG: ABBV-CLS-484|
215029090|NCT06295471|DEVICE|DFG Laser|Laser treatment to the upper thigh
215029091|NCT06295471|DEVICE|CO2 Laser|Laser treatment to the upper thigh
215029092|NCT06295471|DEVICE|Optical coherence tomography (OCT)|Angiographic OCT imaging at areas of interest
214690083|NCT02279589|BIOLOGICAL|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
214690084|NCT02279589|BIOLOGICAL|Prevenar13® 0,5|"The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197)."
214690085|NCT07162987|BEHAVIORAL|Prehabilitation|Please refer to arm description
214690086|NCT07163650|DRUG|Efsubaglutide Alfa Injection|Efsubaglutide Alfa was injected daily in the morning before meals Subcutaneous injection at a dose of 1 mg/week in the first two weeks, increased to 3 mg/week in week 3, increased to 6 mg/week in week 5, up to 9 mg/2 week in week 13.
215019990|NCT03733782|DIETARY_SUPPLEMENT|Modular enteral protein - Prosource|Supplemental protein (2 gm/kg/day of Prosource; Medtrition, Lancaster, PA) was administered via the nasal/oral feeding tube in 60 - 180 ml bolus infusions 2 - 4 times per day, independently of the enteral formula received. That is, the daily target amount of protein was initially administered as the supplement boluses and only after the enteral formula infusion approached the target rate was the amount of supplement decreased. Supplemental protein was reduced by 50% once the patient received 75% of targeted caloric intake over the previous day (0700 - 0700). Once the patient reached the target caloric intake for 48 hours, the amount of supplemental protein was decreased in order that the total protein prescribed equaled 2 gm/kg/day.
215019991|NCT00658073|PROCEDURE|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
214420624|NCT02825225|PROCEDURE|Base and apex local anesthesia|Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
214420625|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
214420626|NCT01623336|DRUG|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
214420627|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
214420628|NCT00970307|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
214420629|NCT00970307|BIOLOGICAL|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
214420630|NCT00970307|BIOLOGICAL|Infanrix hexa™|Intramuscular, three doses
214506325|NCT01576796|RADIATION|Radiotherapy|"No additional dose (patients negative F-miso)~* Radiation therapy is conducted under standard conditions of conformal radiotherapy:~* The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week~With additional dose (patients positive for F-miso)~The dose in the PTVmiso increased until the maximum tolerable radiation by the lung."
215019992|NCT00658073|PROCEDURE|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
215019993|NCT01053065|DRUG|Atorvastatin - Cholestyramine - Sitosterol|
214420631|NCT00970307|BIOLOGICAL|Menjugate®|Intramuscular, two doses
214420632|NCT00332644|DRUG|nicotine patch|used according to FDA package label
215019994|NCT02180672|DRUG|Nasal Fluticasone|One spray per nostril, per day.
215019995|NCT02180672|DRUG|Placebo|One spray per nostril, per day.
214420633|NCT00332644|DRUG|nicotine lozenge|used according to FDA-approved package directions
214420634|NCT00332644|DRUG|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
214420635|NCT00332644|DRUG|bupropion|dosage according to FDA-approved instructions
214420636|NCT00332644|DRUG|bupropion + lozenge|dosage according to FDA approved standard instructions
214420637|NCT00332644|DRUG|placebo|dosage same as active drug conditions
214420638|NCT06376513|OTHER|Evaluation|Evaluation of the manipulation abilities of patients with penile prostheses Evaluation of the rigidity of erections with penile prosthesis, the patient and partner's sexual satisfaction, the satisfaction related to pump manipulation
214420639|NCT05308381|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
214420640|NCT05308381|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
214420641|NCT05308381|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
214506326|NCT06030817|DIAGNOSTIC_TEST|99mTc-CNDG SPECT/CT|Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
214506327|NCT02436694|DRUG|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
215019996|NCT06192797|PROCEDURE|HAIC|administration of gemcitabine and oxaliplatin via the tumor feeding arteries every 3 weeks.
214506328|NCT02436694|DRUG|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
214690087|NCT07163650|BEHAVIORAL|Diet and exercise guidelines|Participants followed a science-based diet and exercise program intervention.
215019997|NCT06192797|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
215029093|NCT03375437|GENETIC|Blood and tumor samples|"FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2\*10mL EDTA)"
214690088|NCT07163455|BEHAVIORAL|Balanced Diet|Participants will receive balanced dietary guidance informed by the Weight Management Manual (developed in line with the Dietary Guidelines for Chinese Residents) along with biweekly consultations with a nutritionist, with an emphasis on weight management education.
214420642|NCT04519671|DRUG|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)
214420643|NCT04519671|OTHER|Placebo|Normal saline
214506329|NCT01360918|DEVICE|Epicardial pulmonary vein isolation|After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
214506330|NCT01360918|OTHER|Usual care|Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
214506331|NCT00556478|DRUG|PSD502, contains a mixture of lidocaine and prilocaine|"PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
214506332|NCT00556478|DRUG|Placebo|"The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
214420644|NCT00281996|DRUG|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
214420645|NCT00281996|DRUG|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
214420646|NCT00393848|DRUG|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
214420647|NCT00393848|DRUG|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
214420648|NCT00393848|DRUG|Placebo|Placebo for Ketoconazole
215019998|NCT01218256|OTHER|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
214506333|NCT04924296|DRUG|SHR-1314|SHR-1314 s.c. + Steroids
215019999|NCT01963832|DRUG|Fluoxetine|
215020000|NCT01963832|DRUG|Placebo|
215020001|NCT01963832|PROCEDURE|eCMIT|
215020002|NCT01963832|PROCEDURE|Usual Care|
214420649|NCT03184623|OTHER|muscle mass measurement|measurement of muscle mass by echocardiography
214420650|NCT00920257|DRUG|GSK2141795|GSK2141795 is an oral AKT inhibitor.
214420651|NCT05417893|DEVICE|MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)|The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
214506334|NCT04924296|DRUG|Placebo|Placebo s.c. + Steroids
214506335|NCT02285218|OTHER|serum blood sampling|
214506336|NCT05032716|OTHER|Balance exrcises|the group (20 children) received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance. Tools of traditional physical therapy exercises were; special tools were used for traditional physical therapy exercises include vestibular board, rolls of different sizes, blocks and wedges of different heights
215020003|NCT05305703|OTHER|cervical stretching|Heating therapy for 10 minutes Passive stretching of neck muscles including Sub-occipital muscles, Trapezius upper boarder and Sternocleidomastoid muscle with 10 reps each
215020004|NCT05305703|OTHER|soft tissue mobilization|Heating therapy for 10 minutes Soft tissue mobilization for 8 minutes and trigger point release of sub-occiptal muscles with 5 repetitions each.
215020005|NCT05653011|OTHER|Endoscopic biopsy|"When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions."
215020006|NCT02837952|DRUG|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
215020007|NCT02837952|DRUG|Placebo|Placebo
215020008|NCT02718482|DRUG|Gemcitabine and Docetaxel|Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
215020009|NCT02718482|DRUG|Ifosfamide|Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
215020010|NCT05638217|COMBINATION_PRODUCT|Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%|"1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence."
215020011|NCT01362530|DRUG|Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
214506337|NCT05032716|OTHER|Balance exrcises and Treadmill training|the group (20 children) received the same traditional physical therapy program as the same applied in group of balance exercises, in addition to treadmill training (30 min). The child walked on the treadmill (motorized treadmill, ENTRED, Enraf-Nonius) at 75% of over-ground speed and individually prescribed low-endurance walking at 0% incline for 20 min, three times a week for 8 successive weeks. The walking area of the treadmill is made from heavy steel with a minimum 8-inch thickness and is available with cushioning in case of accidental impacts. Before the walking session, each child underwent 5 min of active stretching exercises that include prolonged and progressive stretching of the hamstrings, quadriceps muscles, and Achilles tendon.
214420652|NCT03485859|DEVICE|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
214420653|NCT03485859|DEVICE|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
214420654|NCT03239899|DRUG|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
214420655|NCT03087084|DEVICE|Cardiac Pacing and Impedance Measurement system|Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
214420656|NCT00075491|DRUG|fenretinide|Given orally
214420657|NCT00075491|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214420658|NCT00075491|OTHER|pharmacological study|Correlative studies
214506338|NCT04125901|OTHER|Pain Neuroscience Education and Exercise|The incorporation of the exercise in this group will be gradual, in order to decrease the education component and increase the exercise component (up to 45/60 minutes). The 1st session will be only PNE and will last approximately 45 minutes. In the 2nd session, there will be 30 minutes of PNE and the remaining 15 minutes of exercise. In the following 4th and 6th sessions, 15 minutes of each session will be used to clarify doubts and emphasize PNE concepts and strategies. The 8th session will include exercises only. In WhatsApp sessions, in addition to the video with the exercises, participants will receive activities about the PNE.
214506339|NCT04125901|OTHER|Exercise|The exercise group will perform exercises in all sessions (45 minutes of exercise in face-to-face sessions). In WhatsApp sessions, participants will receive a video with exercises to perform at home.
214506340|NCT02564536|DRUG|Pacritinib|-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
214506341|NCT02564536|DRUG|Decitabine|-From commercial stock
214506342|NCT00188305|BEHAVIORAL|General health counselling and risk information|General health counselling and risk information
214506343|NCT04864782|DRUG|QL1604|Intravenous Infusion
214506344|NCT04864782|DRUG|Paclitaxel injection|Intravenous Infusion
215020012|NCT01362530|DRUG|Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
215020013|NCT01362530|DRUG|Aprepitant powder for suspension (PFS)|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
214420659|NCT00075491|OTHER|laboratory biomarker analysis|Correlative studies
214506345|NCT04864782|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
214506346|NCT01570894|DRUG|Quetiapine Fumarate|25 mg tablet
214506347|NCT00065000|BEHAVIORAL|Water, Cafeteria and Staff Health Promotion|
214506348|NCT01190852|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
215020014|NCT01362530|DRUG|Ondansetron|Day 1: Administered according to product label for pediatric usage or local standard of care
215020015|NCT01362530|DRUG|Placebo for Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
215020016|NCT01362530|DRUG|Placebo for Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
215020017|NCT01362530|DRUG|Placebo for Aprepitant PFS|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
214420660|NCT05485402|DIETARY_SUPPLEMENT|Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
214420661|NCT05485402|DIETARY_SUPPLEMENT|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
214420662|NCT05485402|DIETARY_SUPPLEMENT|Maltodextrin|The dosage will be 7,5 g/day of maltodextrin.
214420663|NCT05485402|DIETARY_SUPPLEMENT|Prebiotic (FOS and inulin)|The dosage will be 7,5 g/day of prebiotic supplement (FOS and inulin).
214420664|NCT05485402|OTHER|Nutritional and physical activity recommendations|The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.
214420665|NCT05751499|DIAGNOSTIC_TEST|• Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN|"* Low Back Outcome Scale~* Center for Epidemiological Studies-Depression Scale (CES-D)~* International Physical Activity Questionnaire~* Roland-Morris Disability Questionnaire~* Force Platform~* Pain Self-Efficacy Questionnaire (PSEQ)~* Numeric Rating Scale~* Job Content Questionnaire~* Pits Burgh Sleep Quality Index (PSQI)~* Orebo Musculoskeletal Pain Screening Questionnaire~* Gait \& Balance App~* Keele STarT Back Screening Tool (SBST)~* Fear-Avoidance Beliefs Questionnaire (FABQ)~* Pain Catastrophizing Scale"
214420666|NCT02107339|DRUG|Methadone|Methadone 0.2 mg/kg administered at induction of anesthesia
214420667|NCT02107339|DRUG|Hydromorphone|Hydromorphone 2 mg administered at the conclusion of anesthesia
214420668|NCT02105064|DEVICE|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
215020018|NCT01362530|DRUG|Emetogenic chemotherapy|"Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
215020019|NCT03611361|DEVICE|SpectralMD DeepView Wound Imaging System 2.0|The DeepView is an imaging device which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a machine learning (ML) algorithm to categorize microvascular blood flow and provide a quantitative assessment for selection of tissue healing.
214420669|NCT02105064|DEVICE|SHAM rTMS|Sham rTMS, without brain stimulation
214420670|NCT03655626|OTHER|Sepsis Watch|The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
214420671|NCT00834951|RADIATION|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
214420672|NCT00002018|DRUG|Interferon alfa-n3|
214420673|NCT02082158|OTHER|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
214420674|NCT04723706|DIAGNOSTIC_TEST|COVID-19 serology IgG|patients with SCT or CART who decide to get their vaccines we will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days after vaccination; 1 month +/- 10 days (after the first dose), 2 months +/- 10 days (after the 2nd dose), 3 months +/- 10 days, 6 months +/- 10 days and 12 months +/- 10 days
214420675|NCT02464293|OTHER|Mindfulness-based cognitive therapy|An 8 week course of mindfulness-based cognitive therapy
214420676|NCT04781881|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
215020020|NCT06427642|BIOLOGICAL|Mononuclear cells|UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation
214420677|NCT02067026|DIETARY_SUPPLEMENT|Aleurone|
214420678|NCT02067026|DIETARY_SUPPLEMENT|Placebo|
214420679|NCT04807322|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|Implantation of a Reverse Total Shoulder Arthroplasty
214420680|NCT00738699|DRUG|MORAb-003 (farletuzumab)|Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
214420681|NCT00738699|DRUG|0.9% Saline|Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
214420682|NCT00738699|DRUG|Paclitaxel|
214420683|NCT04571606|PROCEDURE|Single injection peripheral nerve block with liposomal bupivacaine (Exparel)|10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine
214506349|NCT01190852|DRUG|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
214506350|NCT01190852|DRUG|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
214506351|NCT01896843|DRUG|STX107|
215020021|NCT06427642|DEVICE|Mild hypothermia therapy|Mild hypothermia therapy via hypothermia therapy apparatus
214506352|NCT05878106|DIETARY_SUPPLEMENT|Creatine supplementation|"5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention.~The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily."
214506353|NCT05878106|OTHER|Resistance training|They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.
214506354|NCT03224806|OTHER|Wholegrain bread|156.8g wholegrain bread
214506355|NCT03224806|OTHER|White bread|122.6g white bread
215020022|NCT06427642|DEVICE|Breathing support technique|Breathing support via ventilator
214420684|NCT04571606|PROCEDURE|Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump|20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
214420685|NCT00539799|DRUG|prednisolone|5 - 7.5 mg/day
214420686|NCT00539799|DRUG|Placebo|Matched placebo to prednisolone
214420687|NCT00160004|BEHAVIORAL|Intensive Controlled Exercise|
215020023|NCT06427642|PROCEDURE|Total parenteral nutrition|Liquid nutrition injected directly into the bloodstream
214420688|NCT03789786|DIAGNOSTIC_TEST|Gait and Motion Analysis|Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
214420689|NCT03789786|DIAGNOSTIC_TEST|Gross Motor Function Measure (GMFM)|Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
215020024|NCT03471286|DRUG|Epacadostat|Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
215020025|NCT00930800|OTHER|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
214420690|NCT03789786|BEHAVIORAL|Surveys|Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
214420691|NCT00596609|DRUG|Intrathecal Morphine|"* In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~* In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
214420692|NCT00554736|BIOLOGICAL|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
214420693|NCT03182959|DRUG|Avmacol®|Avmacol® tablets
214420694|NCT03426033|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
214420695|NCT03426033|DRUG|Warfarin|25mg tablet administered orally
214420696|NCT03005197|DEVICE|Laser Doppler Flowmetry|
214420697|NCT02389777|BIOLOGICAL|ST266 immediate|ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
214420698|NCT02389777|BIOLOGICAL|ST266 delayed|ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
214420699|NCT02830906|DRUG|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
214420700|NCT02830906|DRUG|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
214420701|NCT05819099|DIAGNOSTIC_TEST|An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning|This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
214420702|NCT01352533|PROCEDURE|Running polypropylene closure|Half of every wound will be closed with Standard of Care running polypropylene sutures
214420703|NCT01352533|PROCEDURE|Tissue Adhesive (Derma-Bond)|Approximately half of wounds will be randomized to be closed with tissue adhesive.
214420704|NCT01352533|PROCEDURE|Subcuticular polyglactin-910 combined with tissue adhesive|Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
214420705|NCT04825028|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
214420706|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive BBT-CI
214420707|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive HEAL
214420708|NCT04829539|OTHER|Quality-of-Life Assessment|Ancillary studies
214420709|NCT04829539|OTHER|Questionnaire Administration|Ancillary studies
214420710|NCT05231408|OTHER|High-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
214420711|NCT05231408|OTHER|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
215020026|NCT06014723|PROCEDURE|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
215020027|NCT05294146|DRUG|Clofazimine|"All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.~Blood samples will be taken at Day 28 (+/- 2 days), Day 29 (Day 28 +1) and after 4 months of treatment to assess the pharmacokinetics of CFZ, both with the loading dose and the standard dose. In addition, the safety/tolerability of CFZ will monitored."
215020028|NCT01941342|PROCEDURE|Pancreatoduodenectomy|
215020029|NCT01941342|PROCEDURE|ENBD and Pancreatoduodenectomy|
214420712|NCT03754218|DRUG|Amnion Membrane Powder|This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.
215020030|NCT01941342|PROCEDURE|EBD and Pancreatoduodenectomy|
215020031|NCT01941342|PROCEDURE|PTCD and Pancreatoduodenectomy|
215020032|NCT03291236|OTHER|Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.
215020033|NCT03757117|DRUG|Feminizing hormone therapy|"Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily"
215102531|NCT01415492|BEHAVIORAL|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
214420713|NCT03754218|PROCEDURE|SOC Wound Covering|Institutional standard of care wound covering.
214420714|NCT01456715|BIOLOGICAL|Gardasil vaccine, Immunogenicity, Booster dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
214420715|NCT01456715|BIOLOGICAL|Cervarix Vaccine, Immunogenicity, Booster Dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
214420716|NCT03196310|DRUG|Platelet Concentrate|Platelet Rich plasma
214420717|NCT03196310|DRUG|Corticosteroid injection|Kenalog
214506356|NCT03224806|OTHER|15% fiber-rich bread|139.2g bread made with 15% added wheat bran
214506357|NCT03224806|OTHER|30% fiber-rich bread|166.5g bread made with 30% added wheat bran
214506358|NCT00794300|DEVICE|second magnetic resonance imaging scan|
214506359|NCT01228500|DEVICE|PriMatrix|Dermal Repair Scaffold
214506360|NCT00262366|DEVICE|Comparison of automatic CPAP versus fixed CPAP|
214506361|NCT03897699|DEVICE|Transcranial Direct Current Stimulation|A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.
214506362|NCT03897699|BEHAVIORAL|Mindful Breathing|MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
214506363|NCT03897699|OTHER|Sham|Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
214506364|NCT03026166|DRUG|Ipilimumab|Administered by intravenous infusion
214506365|NCT03026166|DRUG|Nivolumab|Administered by intravenous infusion
214506366|NCT03026166|DRUG|Rovalpituzumab tesirine|Administered by intravenous infusion
214506367|NCT06082115|OTHER|Selected Physical and Occupational Therapy Program|"The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L \& L.L (U.L \& L.L approximation, U.L \& L.L weight bearing exercises), stretching exercises for U.L \& L.L muscles, strengthening exercises for antispastic group of U.L \& L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands."
214506368|NCT06082115|OTHER|Mirror Therapy|The mirror therapy program include tasks of manipulative and grasping skills that performed by the non-affected hand in-front of mirror while the affected hand behind the mirror. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
215020034|NCT03757117|BEHAVIORAL|Peer navigation|Transgender women community peer navigation
215020035|NCT04315961|DRUG|Blinded drug dose conditions|Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
215020036|NCT04214444|BIOLOGICAL|Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma|The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
215029094|NCT04847687|DRUG|methylprednisolone|Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
215029095|NCT01357681|DRUG|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
215029096|NCT01357681|DRUG|Placebo|Placebo
215102532|NCT04782947|DEVICE|Exoskeletal assisted walking|Exoskeletal assisted walking includes the use of robotic suit to train participant to walk with different level of assistance.
214420718|NCT03196310|OTHER|Normal Saline|Control Group - Placebo
214420719|NCT01244113|DRUG|propofol|optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
214420720|NCT00617331|BIOLOGICAL|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
214420721|NCT03145649|OTHER|Dietary therapy or insulin injection|
214420722|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; low temperature)|
214420723|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; low temperature)|
214420724|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; high temperature)|
214420725|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; high temperature)|
214420726|NCT03036644|OTHER|tobacco cigarette|
214420727|NCT06522880|DIAGNOSTIC_TEST|CMV PCR on saliva|Observational study to measure prevalence of CMV shedding by saliva PCR
214420728|NCT00801658|DEVICE|selective Laser Trabeculoplasty (SLT)|
214420729|NCT00203216|DRUG|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
214420730|NCT00203216|PROCEDURE|Transcranial Magnetic Stimulation|
214420731|NCT06522711|DEVICE|Virtual reality headset|A brief overview of all three virtual reality scenarios will be shown in a consolidated video prior to letting the participant select the preferred scenario. The participant's choice of scenario will then be documented. Once paravertebral blocks are completed and the participants are in supine position and the surgeon is ready to disinfect, the VR headset will be applied on the face of the participants in the intervention group and the chosen scenario will be started. If at any point the patient expresses a desire to stop using VR during the surgery, we will first offer them an alternate scenario. If they reiterate their willingness to stop, with or without having experienced the new scenario, the headset will be removed for the remainder of the surgery.
214420732|NCT06522711|OTHER|Standard of care|Standard of care in anesthesia with patient-controlled sedation.
214420733|NCT01709266|DIETARY_SUPPLEMENT|Probiotics|
214420734|NCT01709266|DIETARY_SUPPLEMENT|Placebo|
214420735|NCT05717218|DEVICE|Ultra-protective mechanical ventilation monitored by electrical impedance tomography|"A silicone EIT belt will be placed around the patient's thorax (sixth intercostal parasternal space). EIT data will be generated by application of a small alternating electrical current (5 mA at 50 kHz). Introduction of ultraprotective mechanical ventilation will be monitored."
214420736|NCT06070688|DIAGNOSTIC_TEST|MeMed BV® biomarker test|one purple top tube of whole blood (2-3 cc) to be used for the MeMed Key® device processing without the need for centrifuge. The MeMed BV® test takes approximately 15 minutes to process and result. After, the sample has been processed and the MeMed BV® test has resulted, the sample of blood will be discarded for each patient enrolled in the study.
214420737|NCT06070688|DIAGNOSTIC_TEST|Usual care|Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.
214420738|NCT01924975|PROCEDURE|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
214420739|NCT01924975|DEVICE|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
214420740|NCT01924975|DEVICE|A 22 or 24 G intravenous catheter|
214420741|NCT04874415|BEHAVIORAL|1RLD|1RLD=One text per day, ramped goal, loss incentive, daily goal time period
214420742|NCT04874415|BEHAVIORAL|1RLW|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
214420743|NCT04874415|BEHAVIORAL|1RGD|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
214420744|NCT04874415|BEHAVIORAL|1RGW|One text per day, ramped goal, gain incentive, weekly goal time period.
214420745|NCT04874415|BEHAVIORAL|2RLD|Two texts per day, ramped goal, loss incentive, daily goal time period.
214420746|NCT04874415|BEHAVIORAL|2RLW|Two texts per day, ramped goal, loss incentive, weekly goal time period.
214420747|NCT04874415|BEHAVIORAL|2RGD|Two texts per day, ramped goal, gain incentive, daily goal time period.
214420748|NCT04874415|BEHAVIORAL|2RGW|Two texts per day, ramped goal, gain incentive, weekly goal time period.
214506369|NCT06082115|OTHER|Task-Oriented Training|The task-oriented training program include tasks of manipulative and grasping skills that performed by the affected hand based on repetition practice. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
215029097|NCT00410579|OTHER|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
215102533|NCT04782947|DEVICE|Epidural Stimulation|lumbo-sacral epidural simulation at the beginning of the study.
214420749|NCT04874415|BEHAVIORAL|1FLD|One text per day, fixed goal, loss incentive, daily weekly goal time period.
214420750|NCT04874415|BEHAVIORAL|1FLW|One text per day, fixed goal, loss incentive, weekly goal time period.
214420751|NCT04874415|BEHAVIORAL|1FGD|One text per day, fixed goal, gain incentive, daily goal time period.
214420752|NCT04874415|BEHAVIORAL|1FGW|One text per day, fixed goal, gain incentive, weekly goal time period.
214420753|NCT04874415|BEHAVIORAL|2FLD|Two texts per day, fixed goal, loss incentive, daily goal time period.
214420754|NCT04874415|BEHAVIORAL|2FLW|Two texts per day, fixed goal, loss incentive, weekly goal time period.
214420755|NCT04874415|BEHAVIORAL|2FGD|Two texts per day, fixed goal, gain incentive, daily goal time period.
214420756|NCT04874415|BEHAVIORAL|2FGW|Two texts per day, fixed goal, gain incentive, weekly goal time period.
214420757|NCT06316206|DRUG|Ethinylestradiol/Dienogest 0.03mg/2mg|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
214420758|NCT06567119|BIOLOGICAL|SPOT-mRNA01|SPOT-mRNA01 (COL1A1 mRNA-loaded by EVs) ,single-dose subcutaneous injection
214420759|NCT06567119|OTHER|Placebo|Sterile isotonic solution, subcutaneous injection
214420760|NCT03629730|BEHAVIORAL|Coordination training|The intervention will consist of 8 weeks of exercises to decrease the variability of participants' body and gait coordination. The intervention will consist of 1 training session /week in the Mobility Research Laboratory and 4 days of home-based training. In each session participants will perform 6 trials of 4 body coordination exercises and 1 gait exercise. In the intervention sessions participants will perform interlimb coordination exercises, synchronizing body segments with auditory metronome tones. Participants also will perform a gait exercise by synchronizing steps with an auditory metronome during walking. The metronome will assist participants to retrain their movement timing to decrease coordination variability.
214420761|NCT04957485|DRUG|Tecovirimat|oral antiviral
214420762|NCT04957485|DRUG|Smallpox and Mpox Vaccine|vaccine
214420763|NCT04957485|OTHER|Placebo|TPOXX Placebo
214420764|NCT01192542|DEVICE|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
214420765|NCT01192542|DEVICE|enfilcon A lens|Marketed silicone hydrogel contact lens
214420766|NCT05142137|DIETARY_SUPPLEMENT|Drinkable solution|The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup
214420767|NCT00355914|PROCEDURE|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
214420768|NCT02797249|DRUG|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
214420769|NCT02797249|OTHER|Blank|Routine examination during pregnancy.
214420770|NCT04476095|DEVICE|Active PBMT|Active PBMT will be applied using a device with 152 emitters (wavelength - 808 nm; dose - 3000 J; treatment time - 600 s), in the low back region.
214420771|NCT04476095|DEVICE|Placebo PBMT|The placebo PBMT will be applied using the same device as that of active PBMT but without any emission of therapeutic dose. Moreover, the irradiated site and the irradiation time were the same as that of active PBMT. Patients received a total dose of 0 J in the placebo mode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
214420772|NCT01886625|PROCEDURE|unilateral single-port VATS sympathicotomy|
214420773|NCT01740063|DRUG|DAS181-F02 formulation|
214420774|NCT01740063|DRUG|DAS181-F04 formulation|
214420775|NCT01740063|DRUG|Placebo|
214420776|NCT03457246|OTHER|D-Pigment rich texture|
214420777|NCT03457246|OTHER|Hydrance optimale riche|
214420778|NCT02497092|OTHER|Technique of injection|
214420779|NCT04190342|OTHER|control group|A booklet on the self-management of cancer symptoms. After the pilot RCT is completed, if the participants allocated to the control group are interested in practising tai chi, the intervention will be provided
214420780|NCT04190342|BEHAVIORAL|tai chi group|Around 60 minutes practising easy tai chi movements/postures twice per week
214420781|NCT06369922|PROCEDURE|TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
214420782|NCT06369922|PROCEDURE|Control TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
214420783|NCT05058469|DEVICE|Tracheotomy|Tracheotomy in patients +/- antiplatelet therapy
215020037|NCT05882331|PROCEDURE|Extracorporeal photopheresis|ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes \~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.
215020038|NCT04250363|BIOLOGICAL|PfSPZ Challenge|Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
215020039|NCT04250363|DRUG|Palcebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
215020040|NCT04250363|DRUG|M5717 30 mg|Participants received 30 mg single oral dose of M5717 capsule on Day 1.
214420784|NCT05390736|BEHAVIORAL|Gait and balance assessment|Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).
214420785|NCT05390736|BEHAVIORAL|Medication review|Patients' medication history in the EHR is assessed for polypharmacy (using 5 or more medications concurrently) and use of medication in the following classes: tricyclic antidepressants, antihistamines, antiemetics, antipsychotics, antispasmotics, muscle relaxants, benzodiazepines, hypnotics, and opioids. The CRN confirms prescriptions with the patient. The CRN reports the medication risk in her provider report and provides medication management educational materials to the patient. At the patient's upcoming primary care visit, providers evaluated whether the medications associated with increased fall risk could be adjusted.
214420786|NCT05390736|BEHAVIORAL|Comorbidity review|The clinical research nurse reviews the patient's EHR problem list for diagnoses of comorbidities associated with increased fall risk including: cognition problems, Parkinson's disease, cardiac issues, depression, or incontinence. Comorbidities are shared with providers in the recommendation statement.
214420787|NCT05390736|BEHAVIORAL|Fall history|The CRN asks how many times the patient had fallen in the past 12 months, whether those with falls sought medical attention, and if they experienced blackouts, loss of consciousness, or a broken/fractured bone(s) resulting from a fall. Fall history information is added to the provider report to increase the salience of fall prevention information.
215020041|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 1.
215020042|NCT04250363|DRUG|M5717 80 mg|Participants received 80 mg single oral dose of M5717 capsule on Day 1.
215020043|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 1.
215020044|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 1.
214420788|NCT05390736|BEHAVIORAL|Assessment of feet/footwear|The CRN observes or asks about the patient's current footwear, asks about foot pain or loss of sensation, and notes a diabetes diagnosis when applicable. Patient reports of foot pain, loss of sensation or diabetes result in a CRN note to the provider to examine the patient's feet and the potential need for a referral to podiatry. The CRN also reviewed a safe footwear handout with all patients regardless of their responses and emailed it to patients with other patient information following the call.
214420789|NCT05390736|BEHAVIORAL|Assessment of visual acuity|The CRN projects a Banner eye chart on Zoom for the patient to read with their contacts or glasses from five feet away for both eyes together and each eye individually. Phone patients are asked to self-report any vision problems. If either the video screening or patient self-report indicated any vision problems, the CRN notes the result and recommendation for eye care referral for the patient's provider to review and order.
214420790|NCT05390736|BEHAVIORAL|Home safety risk assessment|"The CRN reviews the CDC brochure Check for Safety: A Home Fall Prevention Checklist for Older Adults with each patient. Check for Safety asks 17 questions about the home's floors, stairs and steps, kitchen, bathrooms, and bedrooms and suggests ideas for removing or reducing fall hazards. The CRN communicates home safety risks and a recommendation for occupational therapy to the provider for indicated patients."
214420791|NCT05390736|BEHAVIORAL|Vitamin D Deficiency|The CRN asks the patient if they usually take a Vitamin D supplement with their other medications. If the patient does not take a Vitamin D supplement, the CRN recommends the provider check Vitamin D levels and consider supplementation if Vitamin D levels are less than 20 ng/mL.
214420792|NCT06281704|BIOLOGICAL|AK101 IV|AK101 will be administered intravenously.
214420793|NCT06281704|BIOLOGICAL|AK101 SC|AK101 will be administered subcutaneously.
214420794|NCT06281704|BIOLOGICAL|Placebo|Placebo will be administered subcutaneously or intravenously.
214420795|NCT06281704|BIOLOGICAL|AK101 IV/AK101 SC|AK101 will be administered as intravenous infusion at Week8, then subcutaneously every 8 weeks thereafter .
214420796|NCT01169311|DEVICE|Hemorrhoidopexy|
214420797|NCT02306577|DRUG|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
214420798|NCT05565859|BEHAVIORAL|Planetary Health Plate signage|A Planetary Health Plate graphic was developed based on the healthy reference diet proposed by the Eat Lancet Commission. The graphic was designed to capture the food groups and proportions of food groups promoted by the Planetary Health diet.
214420799|NCT00208078|DEVICE|pressure support ventilator|Non invasive ventilation 4h/d 5 days a week
214420800|NCT01418118|DRUG|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
214420801|NCT01418118|DRUG|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
214420802|NCT01418118|DRUG|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
214420803|NCT01418118|DRUG|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
214420804|NCT02116543|DRUG|TD-6450|
214420805|NCT02116543|DRUG|Placebo|
214420806|NCT00590707|DEVICE|Deeper sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
214420807|NCT00590707|DEVICE|Moderate sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
214420808|NCT01982136|PROCEDURE|end-to-end urethroplasty|
214506370|NCT05522023|PROCEDURE|group treated with aromatic solution|The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
214420809|NCT01982136|PROCEDURE|substitution urethroplasty (buccal mucosa)|
214420810|NCT01982136|PROCEDURE|substitution urethroplasty (pedicled skin flap)|
214420811|NCT05647980|OTHER|TACTIC|Participants execute the three steps of TACTIC Participants fill in questionnaires Participants take laboratory and biometric tests to measure their cardiovascular risk
214420812|NCT04616053|BEHAVIORAL|IMPACT intervention|A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
214420813|NCT00366353|OTHER|Sedation during SBT|
214420814|NCT00366353|OTHER|No sedation|
214420815|NCT00793286|PROCEDURE|Mesh fixation by staples|Mesh fixation by staples
214420816|NCT00793286|PROCEDURE|Mesh fixation by glue|Mesh fixation by glue
214420817|NCT00012506|DRUG|TNFR:Fc|
214420818|NCT00943735|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
214420819|NCT00943735|BEHAVIORAL|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
214506371|NCT05522023|PROCEDURE|group treated with drinking water|In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
214506372|NCT03035942|DRUG|Dexamethasone|Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
214420820|NCT05502458|DRUG|Desﬂurane|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h. In the general anesthesia group with desflurane (group D), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane. The analgesic and muscle relaxant regimens were the same in both groups except for sedative drugs. All patients were treated with no medication before operation, and the operation was completed under endotracheal intubation and general anesthesia. The amount of propofol or desflurane was adjusted according to BIS or MAC values and hemodynamic changes during operation. Add 10mg of rocuronium every half hour. Vasoactive drugs can be used to maintain hemodynamic stability during the operation, and corresponding records should be made
214420821|NCT05502458|DRUG|Propofol|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h.
214420822|NCT00367692|DRUG|PSI-697|
214420823|NCT00521937|OTHER|Dermagen®|Weekly topical applications
214420824|NCT00003429|PROCEDURE|biopsy|
214420825|NCT00003429|PROCEDURE|computed tomography|
214420826|NCT00003429|PROCEDURE|positron emission tomography|
214420827|NCT00003429|RADIATION|fludeoxyglucose F 18|
214420828|NCT06476925|PROCEDURE|sonar guided stellate ganglion injection|using high frequency probe, sonar guided stellate ganglion block with 8 ml saline 0.9%
214420829|NCT06476925|PROCEDURE|sonar guided stellate ganglion block|using high frequency probe, sonar guided stellate ganglion block with 8 ml bupivacaine 0.25%
214420830|NCT02587130|DRUG|Ketamine|ketamine administered in bolus by subcutaneous injection
214420831|NCT03804918|OTHER|VitalTips mobile application|VitalTips is a mobile learning application with learning on breaking bad news. Participants were expected to spend at least three hours using the mobile learning resource, ensuring that the time did not impact on their clinical and academic commitments.
214420832|NCT00206258|DRUG|Pramlintide and glucagon|
214420833|NCT04132024|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
214420834|NCT05719038|DIAGNOSTIC_TEST|observational study|observational study
214420835|NCT06131047|OTHER|High intensity Traditional Resistance Traning without Blood Flow Restriction|Group A will undergo Traditional Resistance training without blood flow Restriction. A 30-minute progressive, weight training program will be initiated 8 weeks after the ACL-reconstruction and will be conducted subsequent to the individual based program. The resistance (training loads) will be increased when the individual could do more repetitions than the number specified in the weight training protocol. The exercises will be performed at a slow speed to ensure full control of the movement
214420836|NCT06131047|OTHER|High intensity Traditional Resistance Traning with Blood Flow Restriction|Group B will recieve low-load blood flow restriction (LL-BFR) training using external loads of 20-40% 1RM has been suggested as an alternative to traditional strength rehabilitation. Minimum of 2 -3 sets and maximum total 5 sets,20-30 repetitions of each exercise with 30 to 60 seconds rest period and 2-3 times per weekly for 4-6 weeks to During LL-BFR training, a pressurized cuff is applied to the proximal thigh that oc¬cludes venous outflow while maintaining arterial in¬flow. The combination of venous occlusion and resis¬tance training is believed to induce muscle hypertrophy secondary to elevated systematic hormone production, cell swelling, production of reactive oxygen species, intramus¬cular anabolic signaling and fast-twitch fiber recruit¬ment
214420837|NCT06043128|OTHER|Patients With Stroke With Different Trunk Impact Levels|"Before the study, written and verbal Informed Consent Form will be obtained from all participants who meet the inclusion criteria.Trunk Impairment Scale (TRS) will be used to measure trunk control, which is our independent variable. Scores close to 23 points on the TIS will constitute the group with high trunk control, and those with scores close to 0 will constitute the group with low trunk control. Spasticity of the participants, Modified Tardiue Scale (MTS), cervical proprioceptive awareness cervical joint error test, lower extremity proprioceptive awareness Proprioception test in Technobody Prokin 252 Isokinetic Balance Platform, balance skills Dynamic and static balance in Tecnobody Prokin 252 Isonkinetic Balance Platform will be evaluated by tests. The patients' quality of life will be evaluated with the stroke-specific quality of life scale. All data obtained will be noted on a prepared evaluation form."
214420838|NCT01329328|DEVICE|vibrating platform (Bioplate RF)|whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
214420839|NCT02562352|OTHER|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
214420840|NCT04035291|OTHER|exercise|exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
214420841|NCT04768361|BEHAVIORAL|Behavioral Activation without Mindfulness|"Behavioral Activation without Mindfulness includes functional analysis as key to defining out-of-session and activation strategies as central to mood change."
214420842|NCT04768361|BEHAVIORAL|Behavioral Activation with Mindfulness|"Behavioral Activation with Mindfulness includes functional analysis as key to defining out-of-session and activation strategies and mindfulness as central to mood change."
214420843|NCT01040741|OTHER|Non-intervention observational study|Non-intervention observational study
214420844|NCT04960176|PROCEDURE|Acupuncture|Acupuncture will be applied by using 0,25x25mm needles.
214420845|NCT04960176|PROCEDURE|Non-invasive Sham Acupuncture|Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
215102534|NCT04782947|PROCEDURE|Resistance Training|Using two forms of resistance training to increase muscle size. The first form includes seated leg extension exercise for 12 weeks followed by a second form that includes sit-to-stand exercise using participant's body weight.
214420846|NCT04201327|BEHAVIORAL|Project Jumpstart|PrEP focused intervention to improve PrEP related health outcomes
214420847|NCT02331043|DIETARY_SUPPLEMENT|Plant stanol ester|
214420848|NCT02331043|DIETARY_SUPPLEMENT|Placebo|
214420849|NCT00227682|DIETARY_SUPPLEMENT|ascorbic acid|
214420850|NCT00227682|DRUG|arsenic trioxide|
214506373|NCT03035942|DRUG|Ondansetron|Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
214506374|NCT03035942|DRUG|Saline|Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
214506375|NCT01911559|DEVICE|standing-frame|
214506376|NCT05022615|DIAGNOSTIC_TEST|Topcon Camera|Standard 7 field imaging
214506377|NCT05022615|DIAGNOSTIC_TEST|Optos Camera|Ultrawide field imaging
214506378|NCT05022615|DIAGNOSTIC_TEST|Clarus Camera|Ultrawide field imaging
214506379|NCT04987528|DIAGNOSTIC_TEST|Aminoterminal type III peptide of procollagen|Serial Measurement of PIIINP in serum and/or BAL
214506380|NCT04987528|DIAGNOSTIC_TEST|Lung computed tomography|Screening for the presence of reticulation or bronchiectasia within lung parenchyma
214506381|NCT05270460|DRUG|PCS12852|PCS12852 oral tablet administered once daily
214506382|NCT05270460|DRUG|Placebo|Placebo comparator oral tablet administered once daily
214506383|NCT05387863|OTHER|Decision Aid (DA) Web Tool|The DA web tool provides information on kidney masses and available treatment options. It uses risk communication, directed teaching, and interactive benefit-harm assessment to present information.
215020045|NCT04250363|DRUG|Placebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
214420851|NCT00227682|DRUG|dexamethasone|
214420852|NCT00227682|DRUG|thalidomide|
214420853|NCT04689568|BEHAVIORAL|Moodkit|"MoodKit is divided into four main sections: Activities, Thoughts, Mood and Journal. In the Thoughts section, the user is asked to briefly describe stressful situations and their reactions to the event and is later educated on a number of thought distortions. In the Mood section, the user is asked to give an overall rating of mood, which can be done several times per day. In the Journal section, the user can write freestanding journal entries. Additional areas of advice and goal setting are contained in a section called Thrive Tips."
214420854|NCT04689568|BEHAVIORAL|Moodgym|The program consists of five modules each taking 20- to 40-minutes to complete, which are completed in a prescribed order.
214506384|NCT05387863|OTHER|Institutional Pamphlet|The institutional pamphlet provides information on kidney masses, but does not use risk communication, directed teaching, or interactive benefit-harm assessment.
214506385|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD plus 0.5 g/kg alcohol
214506386|NCT01054859|OTHER|alcohol|0.5 g/kg alcohol
214506387|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD
214506388|NCT01595867|DRUG|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
214506389|NCT01595867|DRUG|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
214506390|NCT01595867|DRUG|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
214506391|NCT04338451|OTHER|Music during the first part of ESWL|Music listening during first part of ESWL
214506392|NCT04338451|OTHER|Music during the second part of ESWL|Music listening during second part of ESWL
214506393|NCT02231970|PROCEDURE|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
214506394|NCT05757674|OTHER|Sample examination|No intervention will be performed
215020046|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 5.
215020047|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 5.
215020048|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 5.
215020049|NCT01485198|PROCEDURE|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
215020050|NCT01485198|DRUG|Acetaminophen|Acetaminophen (750mg orally TID) administration
215029098|NCT01781988|DRUG|carboplatin, gemcitabine , pametrexed|"A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression."
215029099|NCT02875535|BEHAVIORAL|RLAS|"The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide)."
214506395|NCT06497920|DEVICE|Active rTMS to the motor cortex|Active bilateral repetitive transcranial magnetic stimulation to the motor cortex
214506396|NCT06497920|DEVICE|Sham rTMS to the motor cortex|Sham bilateral repetitive transcranial magnetic stimulation to the motor cortex
214506397|NCT02765126|BIOLOGICAL|Seasonal influenza vaccine|Intramuscular standard seasonal influenza vaccine
214506398|NCT02765126|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine|Intramuscular DTaP vaccine
214506399|NCT03673605|DRUG|Rivaroxaban 15 mg|Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
214506400|NCT03673605|DRUG|Warfarin|Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
215029100|NCT03637816|DRUG|Anamorelin Hydrochloride|Given PO
215029101|NCT03637816|OTHER|Placebo|Given PO
215029102|NCT03637816|OTHER|Questionnaire Administration|Ancillary studies
214420855|NCT04689568|BEHAVIORAL|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey.
214506401|NCT02091752|DRUG|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
214506402|NCT05406947|OTHER|Prospective observational study, no intervention|Prospective observational study, no intervention
214506403|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
215020051|NCT05518981|DEVICE|Respiratory Remote Patient Monitor (Spire Health Tag)|"The RPM service, tailored to chronic respiratory disease patients, utilizes a system that includes three components: undergarment-adhered cardiorespiratory sensors, in-home data transmission hub, and web-based clinical dashboard. The sensors are a set of six proprietary, skin-safe devices that include sensors for intermittent photoplethysmography, continuous respiratory force, and tri-axis accelerometers for activity. Clinical liaisons monitor deviations from patient-specific baselines and contact subjects for a risk assessment call, including questions about symptoms. If a subject fails the risk assessment, they are escalated to the site to be seen, and potentially treated, by their pulmonologist."
215020052|NCT03351959|RADIATION|neo-adjuvant treatment|long-course radio-chemoradiation; short-course radiation with immediate/delayed surgery
214420856|NCT04993963|OTHER|Cycle Ergometery Training (Prehabilitation)|Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion \<13 on Borg scale 20-30 min/session/day (intermittent of exercise 2-3 mint, followed by 1-2 min of active recovery) Cool down (5 minutes) AROM +Body stretch
214420857|NCT04993963|OTHER|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
214420858|NCT03359460|DRUG|Ibrutinib|Given PO
214420859|NCT03359460|DRUG|Lenalidomide|Given PO
214420860|NCT04920617|DRUG|DPX-Survivac|SC injection on D7 and D28, then every 8 weeks
214420861|NCT04920617|DRUG|Pembrolizumab|IV infusion every 3 weeks
214420862|NCT04920617|DRUG|CPA|50 mg twice daily, week on then week off
214420863|NCT00520208|DRUG|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
214420864|NCT00325858|DRUG|Tramadol HCl ER|
214420865|NCT04179227|OTHER|Questionnaire Administration|Ancillary studies
214420866|NCT04179227|OTHER|Survey Administration|Ancillary studies
214420867|NCT02023554|DRUG|Theophylline with azithromycin|"Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7."
214420868|NCT02023554|DRUG|Theophylline alone|Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
214420869|NCT04617717|PROCEDURE|Invasive cardiac electrophysiological study and ablation therapy|Invasive cardiac electrophysiological study with cathecholamine provocation and pacing procedures, as well as standard 3D mapping and PVC ablation
214420870|NCT04617717|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Standard ergometer bicycle test
214420871|NCT04617717|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with cine-imaging and late-gadolinium enhancement
214420872|NCT04617717|DIAGNOSTIC_TEST|Holter monitoring|24h 5 lead or 12 lead ECG recording
214420873|NCT04617717|DIAGNOSTIC_TEST|Transthoracic echocardiography|2D echocardiography
214420874|NCT04617717|DIAGNOSTIC_TEST|Coronary angiography|Conventional invasive coronary angiography or CT angiography as indicated
214420875|NCT06555380|BEHAVIORAL|The one-year intervention|A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
214420876|NCT06555380|BEHAVIORAL|The three-year intervention|A multifactorial family-centered lifestyle intervention extending up to three years, with clinical visits at local healthcare centers which included repeatedly visits (up to 8 times / year). The intervention was managed by specialized nurses.
214420877|NCT03009513|DRUG|Teneligliptin+Glimepiride|
214420878|NCT00964366|DRUG|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
214420879|NCT00964366|DRUG|Dapsone gel|Twice-daily applications of dapsone gel
214506404|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
214506405|NCT03719352|PROCEDURE|Experimental: Deep dry needling|Deep dry needling until achieving twitch response of the muscle
214506406|NCT03719352|PROCEDURE|Experimental: Superficial dry needling|Superficial dry needling to achieve sensitive pain with needle rotation
215020053|NCT05601063|BEHAVIORAL|Winterlight Speech Assessment|Digital assessment of speech and language abilities
215102535|NCT04782947|DEVICE|delayed-ES|lumbo-sacral epidural simulation starting 6 months after the beginning of the study.
214420880|NCT01370694|DRUG|MK-8808|
214420881|NCT01370694|DRUG|cyclophosphamide|
214420882|NCT01370694|DRUG|vincristine|
214420883|NCT01370694|DRUG|prednisolone|
214506407|NCT03719352|PROCEDURE|Placebo Comparator: Placebo Gastrocnemius dry needling|Simulate pain with de plastic needle guard in the gastrocnemius muscle
214420884|NCT00127829|DRUG|Gefitinib|Oral tablet
214420885|NCT02009358|OTHER|mental health promotion|
214420886|NCT03107286|DRUG|Tc-99M-MAG3|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
214420887|NCT03107286|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
214420888|NCT03014596|OTHER|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
214420889|NCT05633199|OTHER|cytoreductive surgery|Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
214420890|NCT00872417|DRUG|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
214420891|NCT00872417|DRUG|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
214420892|NCT00978237|DRUG|EFV|one pill QD VO.
214420893|NCT00978237|DRUG|LPV/r|2 pills QD VO
214420894|NCT02319785|BEHAVIORAL|RAT-NMES|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.
214420895|NCT02319785|BEHAVIORAL|RAT-MT|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.
214420896|NCT02319785|BEHAVIORAL|Mirror therapy|This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
214420897|NCT02319785|BEHAVIORAL|Unilateral RAT|"This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System."
214420898|NCT02319785|BEHAVIORAL|Bilateral RAT|"This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany)."
214420899|NCT02319785|BEHAVIORAL|Conventional rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
214506408|NCT05972252|DEVICE|Cerebrovascular Interventional Procedural Control System|The Cerebrovascular Interventional Procedural Control System is intended for use in the remote delivery and manipulation of guidewires and rapid deliver stent catheters, and remote manipulation of guide catheters during cerebrovascular intervention procedures.
214506409|NCT04703907|OTHER|Auricular stimulation|"Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)"
214506410|NCT03579407|PROCEDURE|BMA cell therapy injection|The bone marrow aspirate will be injected into the affected knee joint.
214506411|NCT03156738|DRUG|MT-2990|Subjects will receive a single IV dose of MT-2990
214506412|NCT03156738|DRUG|Placebo|Subjects will receive a single IV dose of placebo
214506413|NCT02180932|BIOLOGICAL|periodontal pocket samples|
214506414|NCT00729209|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
214506415|NCT00729209|DRUG|Placebo; oral|matching placebo
214506416|NCT01420757|PROCEDURE|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
214506417|NCT02390778|BEHAVIORAL|Group Debriefing|Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
215020054|NCT05698992|OTHER|evidence-based individualized rehabilitation|The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
215020055|NCT00636974|PROCEDURE|Combined spinal epidural anaesthesia|
215020056|NCT03021005|BEHAVIORAL|HIV Self-testing|
214506418|NCT02390778|BEHAVIORAL|leisure activity (film showing)|
215020057|NCT00276380|DRUG|EGb761|EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
215020058|NCT00276380|DRUG|Placebo|Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
215020059|NCT00276380|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
215020060|NCT02748174|BEHAVIORAL|Audio Files|Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
215020061|NCT03568123|DEVICE|MC polyethylene bearing|"Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
215020062|NCT03568123|DEVICE|CR polyethylene bearing|"Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
215020063|NCT03207087|DEVICE|WEB Aneurysm Embolization|Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
215020064|NCT06547359|DRUG|Obicetrapib 10mg|tablets
215020065|NCT06547359|DRUG|Ezetimibe 10mg|tablets
215020066|NCT02719730|BEHAVIORAL|Reimbursement for whole grain purchases|All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
215020067|NCT06564402|BEHAVIORAL|Positive Mental Rehearsal|After exposure trial, participants are asked about the positive aspects of their exposure experience (e.g., thoughts, feelings), based on which an imagination script is formulated and recounted
215020068|NCT06564402|BEHAVIORAL|Mental Rehearsal|After exposure, participants are asked about what happened during the exposure experience and whether their central concerns/expected outcome actually occurred during exposure
215020069|NCT06564402|BEHAVIORAL|Exposure|All participants complete exposure exercises (i.e., talking on the phone and talking with a stranger) before positive mental rehearsal is executed
215020070|NCT03411187|DEVICE|used of the Pressure adjustable foot-control method|Whether The Pressure adjustable foot-control method is used.
215020071|NCT03411187|DEVICE|direct exhaust|direct exhaust through the trocar.
215020072|NCT05350267|BEHAVIORAL|HALO|"Health and Lifestyle Behaviors in Offspring, or HALO is designed for mothers who recently had bariatric surgery who have a school-aged child. HALO focuses on providing each mother with education and parenting strategies to improve her child's healthy lifestyle behaviors, such as her child's eating and physical activity, while she is engaged in her own lifestyle behavior change after bariatric surgery."
215020073|NCT05350267|BEHAVIORAL|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
215020074|NCT05960435|OTHER|Proprioceptive Neuromuscular Facilitation|PNF, a method used to increase the range of motion of the joint and strengthen the muscles in the newly gained range, is a holistic approach and is based on motor learning principles. PNF stretching involves isometric contraction of the target muscle in addition to static stretching.
215020075|NCT05960435|OTHER|Control Group Exercise|The control group will include static stretching, capsule stretching, progressive ROM exercises and strengthening exercises.
215020076|NCT03184675|OTHER|Functional action observation training|the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
215020077|NCT03184675|OTHER|General action observation training|step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
215020078|NCT03473301|BIOLOGICAL|Infusion of allogeneic umbilical cord blood|Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.
215020079|NCT03473301|BIOLOGICAL|Infusion of MSCs|Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).
215020080|NCT04829214|DRUG|OTO-313|Single intratympanic injection
215020081|NCT04829214|DRUG|Placebo|Single intratympanic injection
215020082|NCT05313256|DRUG|Lidocaine epinephrine buffered with sodium bicarbonate|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.
215020083|NCT05313256|DRUG|Lidocaine epinephrine|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
215020084|NCT06002594|OTHER|group low-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 4 ml of 0.9% sodium chloride(NaCl) solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
215020085|NCT06002594|OTHER|group high-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 20 ml of 0.9% NaCl solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
215020086|NCT06640322|OTHER|Reliability and validity|Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Non-specific Neck Pain
215020087|NCT04559464|DEVICE|AeriSeal|The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.
215020088|NCT04559464|DEVICE|Zephyr Valves|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
215020089|NCT05882006|OTHER|gallstones|fellow up if the patients have gallstones
214420900|NCT02957539|BEHAVIORAL|Financial rewards|Veterans in the financial reward arm receive all of the services of the usual care arm, plus rewards that are earned in two ways: an assured portion, and a random portion. For the assured reward, they will receive compensation at the end of each month (defined as a four week period) that they are at or below their target weight. For the random portion, each week that a participant is at or below their target weight, the patient is entered into a drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning. Over the 17-32 week period, Veterans in this group will receive token incentives for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters their weight into the portal, s/he will have a 1-in-8 chance to earn the token incentive, such as a t-shirt or movie ticket. The participant will receive reminder text messages.
214420901|NCT02957539|BEHAVIORAL|Non-Financial rewards|Procedures for the non-financial rewards arm are identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each weekly random drawing will be for 20 points. Veterans will choose non-financial rewards associated with the number of points they earn.
214420902|NCT05752513|PROCEDURE|Late bladder dissection|The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection
215020090|NCT03254641|DRUG|human chorionic gonadotropin|5000 IE times one
214420903|NCT05752513|PROCEDURE|early bladder dissection|The bladder dissection is early as in classic cesarean hysterectomy
214420904|NCT04503356|PROCEDURE|OMNI as a standalone procedure|It uses a single, self-sealing clear corneal incision with ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System as a standalone procedure.
214420905|NCT04503356|PROCEDURE|OMNI combined with cataract surgery|Phacoemulsification with intraocular lens implantation is performed. Then, ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System.
214420906|NCT00947596|DRUG|atropine sulfate|dry powder for inhalation
214506419|NCT02268240|BEHAVIORAL|Stepped Care|Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
214506420|NCT05344742|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle)
214506421|NCT05344742|DRUG|Capecitabine|The fixed dose of oral capecitabine will be administered 1000mg/m\^2, twice daily, from day 1 to day 14.
214506422|NCT05344742|DRUG|Albumin-paclitaxel|The fixed dose of albumin-paclitaxel will be set as 260 mg/m\^2, once every three weeks.
214506423|NCT05101317|DRUG|HMI-115|HMI-115 is human monoclonal antibody
215020091|NCT06284798|DRUG|NNC0650-0013 A|NNC0650-0013 will be administered subcutaneously or intravenously.
215020092|NCT06284798|DRUG|Placebo|Subcutaneous administration.
215020093|NCT06446778|DEVICE|Pipeline embolization device with or without shield technique|The patients undenwent Pipeline embolization device implantation with or without shield technique due to market availability, choice and preferences of the surgeon.
215020094|NCT04869124|DRUG|Dapagliflozin|Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
214506424|NCT05101317|DRUG|Placebo|Placebo
214506425|NCT05647642|DRUG|Precedex and dormicum|Premedication
214506426|NCT04675268|DIAGNOSTIC_TEST|oximetry|A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
215020095|NCT04869124|DRUG|Placebo|Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
215020096|NCT04218682|BEHAVIORAL|Shadow's Edge Mobile Application Gameplay|6 weeks of individual, interactive game play of the Shadow's Edge mobile app.
215020097|NCT01122368|DRUG|micafungin|IV
215020098|NCT01122368|DRUG|placebo|IV
215020099|NCT05659251|COMBINATION_PRODUCT|Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy|Serplulimab 4.5mg/kg, IV, Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 3 cycles, one cycle every 21 days.
215020100|NCT05659251|PROCEDURE|Esophagectomy|"Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy.~The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon."
215020101|NCT05659251|OTHER|sample|"Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use.~5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery.~Tumour sample will be collected before neoadjuvant therapy and after surgery."
215020102|NCT05635409|BIOLOGICAL|STEM-PD|STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.
215020103|NCT06290011|DEVICE|Pain key group|mixed real pain treatment software, pain treatment scenarios in MR
215020104|NCT04592562|DEVICE|the Terumo Hydropearl® microspheres device|"Genicular artery embolization (GAE) is a new, minimally invasive investigational not yet approved therapy. In previous studies, this procedure has provided pain relief in patients with mild to moderate OA in the short to midterm. We will be utilizing the Terumo Hydropearl® microspheres particle beads during the GAE procedures. The procedure will take place utilizing fluoroscopic and ultrasound guidance. Following catheterization of the femoral artery, angiography of the affected limb will be performed to define the genicular arterial anatomy. Genicular arteries demonstrating abnormal vascularity and corresponding to the site of the patient's pain will be catheterized and embolized using microspheres. Prior to and after embolization, parametric imaging will be performed utilizing proprietary software to quantify changes in blood flow to the target area~The intended use of the Terumo Hydropearl® microspheres device is to embolize the geniculate artery branch."
214420907|NCT00947596|DRUG|atropine sulfate|intramuscular injection
214420908|NCT02931383|DRUG|Liraglutide 3 mg (Saxenda)|
214420909|NCT02931383|DRUG|Liraglutide 3 mg placebo|
214420910|NCT03889678|DIAGNOSTIC_TEST|Color flow doppler|Color flow doppler proximal to vein insertion site to document flow
214420911|NCT04154137|OTHER|Questionnaire|Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
214420912|NCT00596167|DRUG|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
214420913|NCT04270604|OTHER|Biological sample collection|Biological sample collection for biobanking and research
214420914|NCT01187576|BEHAVIORAL|Multi-professional team intervention with PAR, lifestyle brochure|Multi-professional team intervention with PAR, lifestyle brochure
214420915|NCT01187576|BEHAVIORAL|Ordinary recommendations on health behaviours, lifestyle brochure|Ordinary recommendations on health behaviours, lifestyle brochure
214420916|NCT04835987|DIAGNOSTIC_TEST|Holter ECG|Measurement of the modification of the sympathomimetic balance
214420917|NCT04835987|BEHAVIORAL|Questionary|Lifestyle questionary (time spent in front of television, physical activity)
214506427|NCT06398210|OTHER|Cognitive Exercise Therapy Approach (BETY)|Cognitive Exercise Therapy Approach (BETY) BETY includes mind-body interaction information management, pain management strategies, mood information management through dance therapy/authentic movement, and sexuality information management. BETY first session; After meeting the patient and completing the evaluations, it consists of the steps of analysis of the person's problem, selection of exercise for this problem, replacement of the exercise in function, pain management, and recovery agreement. The basic exercise model used in BETY is function-oriented trunk stabilization exercises. Patients are given information about the 5 features of trunk stabilization (neck, shoulder, rib cage, lumbopelvic region postures, and respiratory control), visual imagery, and their control.
214420918|NCT04835987|DIAGNOSTIC_TEST|Pupillometry|Monitoring of nociception and autonomic nervous system by pupillometry in intraoperative.
214420919|NCT02242773|DEVICE|Multi-Parametric MRI|Multi-Parametric MRI
215020105|NCT06225531|OTHER|Autobiographical Memory Based Intervention|"The intervention involves 6 sessions of therapeutic input based around autobiographical memories. Memory based activities will broadly follow the 5 stages outlines in the broad-minded affective coping (BMAC) procedure, but with a focus on specific memories. It will follow the following structure:~Session 1 - Introduction and Familiarisation Session 2 - Neutral Memories Session 3 - Positive Memories Session 4 - Memories of Moves Away from Suicidality Session 5 - Practice of Preferred Memory (from Sessions 2-4) Session 6 - Continued Practice and Post-Intervention Planning"
215020106|NCT05974111|DIAGNOSTIC_TEST|blood sampling|At 5 time points (D0 (T0),morning after (T0B),D3 (T1),D5 (T2),D7(T3)) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained as well as cell free DNA methylation
214420920|NCT02242773|DEVICE|MRI-Guided Biopsy|MRI-Guided Biopsy
214420921|NCT03683628|PROCEDURE|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
214420922|NCT03683628|DRUG|No PB-MNC therapy|Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
215102536|NCT04782947|PROCEDURE|no-Resistance training|The participants will perform 24 weeks of passive movement or passive stretching from seated position.
214420923|NCT03601351|OTHER|ELISA for MOR-1 expression|To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.
214506428|NCT00783952|DEVICE|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
215020111|NCT05821088|PROCEDURE|Biopsy|Undergo tissue biopsy
214506429|NCT00783952|DEVICE|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
214690089|NCT07163455|BEHAVIORAL|Artificial Intelligence-Assisted Time-Restricted Eating with Evening Caloric Restriction|"This intervention combines Artificial Intelligence-assisted Time-Restricted Eating (10-hour eating window) with Evening Caloric Restriction (\<20% of total daily energy intake at dinner). The recommended daily energy distribution is 40% for breakfast, 40% for lunch, and 20% for dinner. Al support will be provided via the Weight Manager app, which sends meal reminders ahead of each meal. Participants will log each meal by the app. If no log is recorded for seven consecutive days, the weight management AI will notify a study dietitian to contact the participant for follow-up and provide dietary counseling. Educational infographics and articles on the benefits of restricting the eating window and reducing dinner caloric intake will be pushed once a month via the Weight Manager app or WeChat. Dietary records collected during follow-up visits will be reviewed to reinforce education on lowering the proportion of daily energy consumed at dinner."
214690090|NCT05459077|BEHAVIORAL|Hypertension control through education and monitoring|Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..
215020112|NCT05821088|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215020113|NCT05821088|DRUG|Carboplatin|Given IV
215020114|NCT05821088|PROCEDURE|Computed Tomography|Undergo CT
215020115|NCT05821088|DRUG|Etoposide|Given IV
215020116|NCT05821088|DRUG|Ifosfamide|Given IV
215020117|NCT05821088|DRUG|Lenalidomide|Given PO
215020118|NCT05821088|PROCEDURE|Positron Emission Tomography|Undergo PET
215020119|NCT05821088|BIOLOGICAL|Tafasitamab|Given IV
214690091|NCT06185075|PROCEDURE|Implant crown delivery|Dental implant crown will be designed, fabricated by a dental lab, and delivered.
214690092|NCT06795438|DIETARY_SUPPLEMENT|Green tea|Green tea tablets 1000mg 1 x per day
215020120|NCT06199882|DRUG|SBRT Sequential Surufatinib Combined With Immunotherapy|"1. SBRT :~   Bioequivalent total dose \> 75Gy, completed within 2 weeks (once daily, 5 times a week).~2. Drug treatment (every 3 weeks is a treatment cycle) :~1\) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle."
215020121|NCT00940121|DRUG|mirabegron|oral tablet
215020122|NCT00940121|DRUG|mirabegron|IV solution
215020123|NCT05522972|BEHAVIORAL|Video Game Vision Training|A new approach for improving amblyopic vision using video games
214420924|NCT05471726|BEHAVIORAL|Prospective audit-and-feedback|The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge.
214420925|NCT02773160|OTHER|Sensor-based postural feedback|Motion tracking sensors will provide feedback to subjects during the learning phase of a motor control task
214690093|NCT06795438|OTHER|Placebo|Placebo control 1 x blinded placebo tablet per day
215020124|NCT05522972|BEHAVIORAL|Perceptual Learning|A new approach for improving amblyopic vision with perceptual learning
215020125|NCT05522972|BEHAVIORAL|Occlusion Therapy|Conventional treatment for amblyopia
215020126|NCT04635280|DEVICE|any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking|A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and an algorithm.
215020127|NCT06641050|DIAGNOSTIC_TEST|Triage+ Score|The TriAGE+ score is used to evaluate the risk of cerebrovascular disease in patients presenting with dizziness. The score assists in determining the necessity of advanced diagnostic evaluation for stroke, potentially improving diagnostic accuracy and patient outcomes.
215020128|NCT06640608|BEHAVIORAL|ICBT - Internet Based Cognitive Behavioral Therapy|The study (intervention) group received 6 consecutive sessions utilizing ICBT techniques to overcome Fear of childbirth
215020129|NCT06641505|BEHAVIORAL|Guiding rehydration|Preoperative fluid rehydration was performed according to 421 fluid rehydration principles
214420926|NCT02773160|OTHER|Mirror feedback|Subjects will receive feedback from a mirror during the learning phase of a motor control task
214420927|NCT02773160|OTHER|Control group|Subjects will receive no feedback during the learning phase of a motor control task
214420928|NCT01377519|PROCEDURE|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
214420929|NCT01377519|PROCEDURE|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
214420930|NCT03746418|DRUG|Ultrasound Guided Bilateral single shot Erector Spinae Plane Block|Under aseptic technique and after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle (visioplex® - vygon - France) was introduced in plane in a cephalad to caudad direction until (L3) transverse process was hit \[figure1(A)(B)(C)\] and the needle was slightly withdrawn. The confirmation of the correct position of the needle tip was done by injecting 0.5-1 ml of LA. Once confirmed, 20 ml of the drug was administered under vision after confirming negative aspiration of blood. LA distribution was observed in both cranial and caudal directions. This was repeated on the other side also. Twenty minutes later, sensory loss to cold was evident between (T10-T 12) and (L5-S1) vertebral level of the posterior dermatomes and dermatomes of the anterior roots of the spinal nerves (lumbar plexus, upper leg) on both sides without hemodynamic changes. Motor function of the legs was evaluated with a Bromage (0-3) score.
214506430|NCT01910194|DRUG|Luyxumia versus Lantus|
215020130|NCT04082273|DEVICE|Femtosecond Laser for Cataract Surgery|Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment
215020131|NCT04082273|OTHER|Conventional Cataract Surgery|Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
215029103|NCT04280783|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
215029104|NCT04280783|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
214420931|NCT03522558|BEHAVIORAL|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
214420932|NCT03522558|BEHAVIORAL|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
214420933|NCT01563354|DRUG|Pasireotide LAR|60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
214420934|NCT01563354|DRUG|Everolimus|10 mg tables administered orally once a day
214420935|NCT01563354|DRUG|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
214420936|NCT04390958|DRUG|nab-paclitaxel|125mg/m2 ivgtt d1、d8
214420937|NCT04390958|DRUG|Cisplatin|60mg/m2 ivgtt d1 or d1-2
214420938|NCT04390958|DRUG|Capecitabine|1750mg/m2 po bid d1-14
214420939|NCT00485940|DRUG|Prucalopride|2 mg o.d.
214420940|NCT00485940|OTHER|Placebo|Placebo o.d.
214420941|NCT00485940|DRUG|Prucalopride|4 mg o.d.
214420942|NCT02061930|PROCEDURE|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
214420943|NCT00316316|BEHAVIORAL|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
214420944|NCT00316316|BEHAVIORAL|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
214420945|NCT01565928|DRUG|MDV3100|4 x 40 mg capsules, orally, once per day
214420946|NCT03097016|DRUG|CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
214420947|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
214420948|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
214420949|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
214420950|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
214420951|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
214420952|NCT01596725|BIOLOGICAL|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
214420953|NCT01119950|DRUG|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
214506431|NCT03658603|PROCEDURE|thoracodorsal artery perforator flap|fascio-cutaneous flap used in cases of trauma or burns
214506432|NCT03658603|PROCEDURE|latissimus dorsi flap|musculo-cutaneous flap used in cases of trauma or burns
215029105|NCT05703126|DIAGNOSTIC_TEST|History taking|Careful history taking, including using questionnaires, to identify risk factors for the development of cardiovascular diseases using the SCORE scale.
215029106|NCT05703126|DIAGNOSTIC_TEST|Anthropometry|Anthropometry: measurement of body weight and height. Calculation of body surface area using the Du Bois formula.
214420954|NCT01119950|DRUG|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
214420955|NCT01119950|DRUG|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
214420956|NCT01119950|DRUG|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
214420957|NCT01119950|DRUG|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
214420958|NCT01119950|DRUG|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
214420959|NCT01119950|DRUG|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
214420960|NCT01119950|DRUG|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
214420961|NCT04256876|DEVICE|TTNS|See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
214506433|NCT04029090|DRUG|MCI-186|A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
214506434|NCT04029090|DRUG|MCI-186|A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
214506435|NCT04029090|DRUG|Placebo|A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
214506436|NCT03034278|OTHER|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
214506437|NCT02571868|DEVICE|Optimization CRT-D|
214506438|NCT02581904|DEVICE|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
214506439|NCT02581904|DEVICE|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
214506440|NCT03511144|DEVICE|Unity Knee™ TKR using measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
214420962|NCT04256876|DEVICE|TTNS Sham|See section 'arms'
214420963|NCT00048529|DRUG|T900607-sodium intravenous|
214506441|NCT03511144|DEVICE|Unity Knee™ TKR using ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
214506442|NCT00493688|OTHER|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
215020132|NCT06642233|DIAGNOSTIC_TEST|Socio-demographic survey|Socio-demographic survey includes: age, sex, time of symptoms, work activity, hours of work activity, work position, activities with loads, physical activity, household chores, missing teeth, dental splints, dentures, smoking, alcohol consumption, whether they can reproduce their symptoms, hours during which they perform focal distance tasks, whether they have visual problems, whether they take painkillers or anti-inflammatory drugs, presence of headaches and their frequency), whether you can reproduce your symptoms, hours during which you perform tasks at focal distance, whether you have visual problems, whether you take analgesics or anti-inflammatory drugs, presence and frequency of headaches.
214420964|NCT05399394|DRUG|Chemotherapy|The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
214420965|NCT05399394|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by the Clinical Target Volume (CTV) with a safety margin to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied through cone-beam computed tomography systems (CBCT) for all patients to evaluate the precision of the set-up.
214506443|NCT02397707|DRUG|Voxilaprevir|100 mg tablet administered orally
214506444|NCT01065779|DRUG|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
214506445|NCT01065779|DRUG|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
215020133|NCT06642233|DIAGNOSTIC_TEST|Visual Analogue Scale|VAS scale - The subject must indicate with a horizontal line their perception of pain on a scale (not numbered) of 100 millimetres, with 0 being the absence of pain and 100 the worst pain imaginable. The patient will complete the VAS scale, responding to the average, maximum and minimum pain experienced throughout its duration.
215102537|NCT06237556|OTHER|Placebo|Patients in the control group will receive placebo.
214506446|NCT02157948|DRUG|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
214506447|NCT02157948|DRUG|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
214506448|NCT06317623|DIAGNOSTIC_TEST|Prenatal and postnatal ultrasound examination|Prenatal ultrasound examination of fetus with urinary tract dilation in second trimester and next in third trimester and when the dilation is persist, the child is managed after birth by pediatric nephrologist.
214506449|NCT00142246|DRUG|Intermittent preventive treatment (SP and amodiaquine)|Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
214506450|NCT00142246|OTHER|Placebo|Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
214506451|NCT04123795|DRUG|Certolizumab pegol|"Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use"
214506452|NCT04123795|DRUG|Placebo|"Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use"
214420966|NCT00711542|BIOLOGICAL|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
214506453|NCT04942288|OTHER|The first group is acupressure and massage, the second group is massage|In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.
214506454|NCT06097260|DRUG|PLN-74809|PLN-74809
214506455|NCT06097260|DRUG|Placebo|Placebo
214506456|NCT05907720|BEHAVIORAL|Human-centered design prototype solutions for vulnerable pregnant women|The intervention package will include various social and behavior change programs derived from a human-centered design approach. The intervention will be tailored to vulnerable pregnant women's needs and contexts. It may include but is not limited to health communication campaigns, including radio and print media.
214506457|NCT04803799|OTHER|Training Programme|Cognitive-motor dual task exercises corresponding to associations between different motor tasks and different cognitive tasks.
215102538|NCT06237556|DRUG|Melatonin 5 MG|Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
214506458|NCT03559959|BEHAVIORAL|Vouchers for HIV self-testing kits|Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.
214690094|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
214690095|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
214694044|NCT06367790|OTHER|Experimental group|"The athletes included in the experimental group will undergo an intervention using a plyometric exercise protocol, 2 days a week, and dry needling of the gastrocnemius muscles will be applied in a weekly session.~To perform the dry needling intervention, 0.3x50mm disposable steel needles will be used, applying the quick in-and-out technique. To do this, first of all, the intervention area will be cleaned with alcohol and sterile gloves will be used to perform the manoeuvre in complete safety. The active or latent trigger point is then located within the taut band by inserting the needle deeper and deeper, and then moving the needle up and down in search of a local contraction response. A maximum of 8 insertions or up to the athlete's tolerance limit will be applied."
214420967|NCT00711542|BIOLOGICAL|placebo medium|intracoronary infusion of placebo medium
214420968|NCT00444431|PROCEDURE|Pyeloplasty|
215102539|NCT04226040|BEHAVIORAL|DOW and illness perception|Acutely ill patients are exposed to a survey regarding their degree of worry and illness perception
214420969|NCT01640678|PROCEDURE|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
214420970|NCT01640678|PROCEDURE|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
214420971|NCT01161563|DRUG|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
214420972|NCT01161563|DRUG|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
214506459|NCT01604824|DRUG|Alirocumab|SC injection in the abdomen
214506460|NCT01604824|DRUG|Placebo|SC injection in the abdomen
214506461|NCT04197791|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to core stabilization muscles will be applied using 8 electrodes. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
214506462|NCT04197791|OTHER|Core Stabilization Exercises|Warm-up and cool-down exercises will be performed before and after core stabilization exercises. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
214506463|NCT05173987|BIOLOGICAL|pembrolizumab|Intravenous (IV) infusion
214506464|NCT05173987|DRUG|carboplatin|IV infusion
214506465|NCT05173987|DRUG|paclitaxel|IV infusion
214506466|NCT05173987|DRUG|docetaxel|IV infusion
214506467|NCT05173987|DRUG|cisplatin|IV infusion
214420973|NCT02852863|OTHER|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
215020134|NCT06642233|DIAGNOSTIC_TEST|The World Health Organization Quality-of-Life Scale-BREF questionnaire|The WHOQOL-BREF questionnaire is used to assess domains quality of life: physical, mental, social functioning and functioning in the environment. Responses are on a 5-point scale (score range 1-5). In each field you can get maximum 20 points. The results of individual areas are positive (the higher the number of points, the higher the quality of life).
215020135|NCT06642233|DIAGNOSTIC_TEST|The International Physical Activity Questionnaire|The International Physical Activity Questionnaire (IPAQ) is a self-reported questionnaire for assessing physical activity and sedentary behavior for adults aged 15-69 years, across a range of socio-economic settings.
215020136|NCT06642233|DIAGNOSTIC_TEST|The Neck Disability Index questionnaire|The NDI evaluates the effect of neck pain on activities of daily living and social relationships. It consists of 10 items with 6 response options that are scored from 0 to 5 points each for a total possible score of 50. The classification of disability is based on the total score obtained, with higher number indicating greater disability.
214420974|NCT04731051|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
215020137|NCT06642233|DEVICE|Body composition analysis using TANITA device|"TANITA device - body composition analyzer, the proportion of muscle mass and fat in the upper limbs~* Body height will be determined using a SECA 217 stadimeter.~* General and segmental body composition using the eight-electrode body composition analyzer by TANITA."
215020138|NCT06642233|DIAGNOSTIC_TEST|Cervical spine AROM (Active range of motion)|"Measurement of cervical spine AROM can be performed using the CROM system (Performance Attainment Associates, Roseville, MN, USA). Flexion, extension, side bending to the right and left, and rotation to the right and left of the cervical spine are examined.~The CROM measuring equipment consists of a helmet-shaped structure with the shape of glasses. These glasses adjust to the nasal septum thanks to the velcro on the back to fit them on the head. Three inclinometers for measuring on 3 cardinal planes were placed in the plastic construction."
215102540|NCT05024136|DEVICE|Limon essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of Limon essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
215102541|NCT05024136|DEVICE|Vetiver essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of vetiver essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
215102542|NCT00351962|PROCEDURE|Fractionated Stereotactic Radiotherapy|
214420975|NCT04731051|DRUG|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
214420976|NCT03437746|DRUG|injection of methylprednisolone at anesthetic induction|intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
214420977|NCT03437746|BIOLOGICAL|Blood samples|Blood samples (D0, D1, D2, D3, D4)
214420978|NCT01591616|DRUG|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
214420979|NCT02865733|DRUG|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
214420980|NCT02865733|DRUG|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
214506468|NCT03938987|BIOLOGICAL|autologous CD19-directed chimeric antigen receptor (CAR) T-cells|Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
214694045|NCT06367790|OTHER|Control group|The athletes included in the control group will perform an intervention using a plyometric exercise protocol, 2 days a week, under the same conditions as the experimental group.
215020139|NCT06642233|DIAGNOSTIC_TEST|Sagittal plane UCS AROM (Upper cervical spine active range of motion)|Measurement of sagittal plane UCS AROM can be performed using the CROM system. Flexion and extension of the upper cervical spine are examined.
215020140|NCT06642233|DIAGNOSTIC_TEST|Flexion-Rotation Test|The flexion-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is flexed.
215020141|NCT06642233|DIAGNOSTIC_TEST|Sidebending-Rotation Test|The sidebending-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is in a lateral tilt.
215020142|NCT06642233|DIAGNOSTIC_TEST|Axial rotation test C0-C2|The Axial rotation test C0-C2 can be performed using the CROM system. Rotation of the C0-C2 is examined.
214420981|NCT04914936|DRUG|ACP-196|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.
214420982|NCT04914936|DRUG|Calcium carbonate|Participants will receive a single oral dose of calcium carbonate 1 g tablet on Day 1 of Period 2 in Part 1.
214420983|NCT04914936|DRUG|Omeprazole|Participants will receive multiple oral doses of omeprazole 40 mg capsules QD for 5 consecutive days in Period 2 of Part 2.
214420984|NCT04914936|DRUG|Rifampin|Participants will receive multiple oral doses of rifampin 600 mg capsule QD for 9 consecutive days in Period 2 of Part 3.
214420985|NCT04258358|OTHER|CASCADE ways of working|Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
214506469|NCT04899999|BEHAVIORAL|Financial reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.
214506470|NCT04899999|BEHAVIORAL|Health reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.
215020143|NCT06642233|DIAGNOSTIC_TEST|Tilting test C0-C1 and C2-C3|The Tilting test C0-C1 and C2-C3 can be performed using a goniometer. Lateral tilt of the C0-C1 and C2-C3 are examined.
215020144|NCT06642233|DIAGNOSTIC_TEST|Craniocervical flexion test|The test measures the level of activation of the deep neck flexors using a pressure biofeedback device, an air-filled manual pressure cuff (Stabilizer TM, Chattanooga Group, INC., USA).
215020145|NCT06642233|DIAGNOSTIC_TEST|Craniovertebral angle|The test measure the craniovertebral angle using a telephone placed on a tripod and a computer program. The CVA measurement is defined as the angle a horizontal line passing the neural spine of C7 in relation to the line connecting the tragus and the neural spine of C7.
215020146|NCT06643780|DRUG|Denosumab|60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
215020147|NCT06643780|DRUG|Zolendronic Acid|5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
215020148|NCT06402474|PROCEDURE|sunbed position|30° reverse trendelenburg legs together 30° hip flexion (sunbed position)
215020149|NCT06542341|DEVICE|decoLITE (TN2037)|Red/Near infra red light therapy
215020150|NCT02594956|DEVICE|no nasogastric tube|
215020151|NCT02594956|DEVICE|nasogastric tube|
214420986|NCT00571818|PROCEDURE|Oral glucose tolerance test|test done over 2 hours
214420987|NCT00571818|PROCEDURE|IV Glucose Tolerance Test|Done over 4 hours
214420988|NCT01726530|DRUG|transdermal fentanyl patch (50 mcg/hour)|
214506471|NCT04899999|BEHAVIORAL|Self-efficacy graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.
214506472|NCT04899999|BEHAVIORAL|Social norms graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
214506473|NCT04712539|DRUG|Baloxavir Marboxil|Given PO
214506474|NCT04712539|DRUG|Oseltamivir|Given PO
214506475|NCT06384573|DRUG|lecanemab|Administered intravenously
214506476|NCT05283512|OTHER|Preventive treatment with IV-hydration|IV hydration with isotonic 0.9% NaCl
214506477|NCT05283512|OTHER|Preventive treatment with oral hydration|Oral hydration with regular bottled water
215020152|NCT06563752|OTHER|Participants will use 3D glasses to view VR educational information|"Participants will use 3D glasses to view VR educational information, which includes:~1. Understanding of psychiatric symptoms, including symptoms, disease course, treatment, and prognosis.~2. Knowledge about medications, their relationship with symptom stabilization, and handling of side effects.~3. Schizophrenia as a chronic illness, with analogies to other chronic diseases.~4. Signs of disease relapse.~5. How to manage ongoing psychiatric symptoms of schizophrenia, including delusions, hallucinations, paranoia, and negative symptoms.~6. Strategies for interacting and communicating with patients.~7. Stress management and adjustment, as well as suicide prevention.~8. Available resources."
214420989|NCT01726530|DRUG|Placebo|
214420990|NCT04680260|OTHER|Standard of care|Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.
215020153|NCT06563752|OTHER|routine care|Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.
214420991|NCT04680260|OTHER|Circulating tumor DNA guided treatment approach|Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.
215020154|NCT05431179|DRUG|Zilovertamab|After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
215020155|NCT05431179|DRUG|Ibrutinib|All participants will receive oral Ibrutinib (560mg) daily.
214420992|NCT02187900|DRUG|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
214420993|NCT02187900|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
214420994|NCT02674646|RADIATION|Radiotherapy|Radiation as indicated by the cancer diagnosis
214420995|NCT02674646|DEVICE|Needle Acupuncture|Needle Acupuncture according to Traditional Chinese Medicine (TCM)
214420996|NCT00855465|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
215020156|NCT05431179|DRUG|Placebo|After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
215020157|NCT05383898|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
215020158|NCT00948207|BEHAVIORAL|My Living Story|"Components include:~1\. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2\) Edited transcript is delivered in a word format on...;~3\) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4\) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
214420997|NCT00855465|DRUG|Placebo|Matching Placebo tid orally for 16 weeks
214420998|NCT04676568|PROCEDURE|Extravesical VVF repair|Both standard transvesical and extravesical approach for VVF repair will be utilised
214420999|NCT01125319|OTHER|blood sample|
214421000|NCT00366171|DRUG|Bifeprunox|
214421001|NCT01610479|DRUG|TAS-114 + S-1|
214421002|NCT03219645|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
214421003|NCT03219645|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
214421004|NCT00755781|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
214421005|NCT05125133|OTHER|ITENs + ITWS|A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.
214421006|NCT02297880|OTHER|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
214506478|NCT03651973|OTHER|Standard follow-up|Patients enrolled into standard group will be followed in a standard way without any additional procedure except randomization that allocates to the standard group
214506479|NCT03651973|OTHER|Learning workshops|Patients enrolled into experimental arm will participate to educative workshops before and after surgery for breast cancer. The aim of these workshop is to educate patient to self massages and self stretching.
214506480|NCT05643430|DEVICE|BioFreedom Ultra|The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
214506481|NCT06613087|OTHER|Foot bath|In the foot bath application, the feet will be kept in water at a constant temperature of 38-40 °C for about 20 minutes. During this time, the water temperature will be checked with a thermometer at intervals. Foot bath applications will be performed for 3 days, on the 2nd, 3rd and 4th days of hospitalization.
214506482|NCT05847998|DEVICE|Standardized measurement of capillary refill time by second generation DICART prototype|"Capillary refill time is measured by two independent operators, each one blinded from the other, with second generation DICART prototype.~Each operator performs two series of three consecutive measurement on the finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax"
214421007|NCT02297880|OTHER|Still water|Still water (no flavour)
214421008|NCT02886754|BEHAVIORAL|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
214421009|NCT02886754|BEHAVIORAL|National e-learning programme only|National e-learning programme (COMPASS)
214694046|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
214694047|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
214694048|NCT01473251|DRUG|Lucentis|0.5 mg monthly for 4 months
215020159|NCT00948207|BEHAVIORAL|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
215020160|NCT01774539|OTHER|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
215020161|NCT00002011|DRUG|Methoxsalen|
215020162|NCT02431520|PROCEDURE|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
215020163|NCT02431520|PROCEDURE|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
215020164|NCT00004061|BIOLOGICAL|filgrastim|
215020165|NCT00004061|BIOLOGICAL|palifermin|
215020166|NCT00004061|DRUG|cyclophosphamide|
214421010|NCT02886754|BEHAVIORAL|Standard simulation|Paper based simulation cases
214421011|NCT01795144|DRUG|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
214421012|NCT01795144|DRUG|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
214421013|NCT02485236|DEVICE|Low flow oxygen via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of \> 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
214421014|NCT02485236|DEVICE|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen \> 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
214421015|NCT05843136|OTHER|physiotherapy treatment|this is an interventional study of the use of 3 physiotherapy treatment techniques in order to evaluate the effectiveness of interferential current in relieving chronic low back pain
215020167|NCT00004061|DRUG|etoposide|
215020168|NCT00004061|DRUG|ifosfamide|
215020169|NCT00004061|PROCEDURE|peripheral blood stem cell transplantation|
215020170|NCT00004061|PROCEDURE|quality-of-life assessment|
215020171|NCT00004061|RADIATION|radiation therapy|
215102543|NCT03886155|PROCEDURE|Biopsy|During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
214421016|NCT02845856|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
214421017|NCT02845856|BIOLOGICAL|NK immunotherapy|For each procedure, 10 billion cells will be infused in 4 times
215102544|NCT02564328|GENETIC|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
214421018|NCT02749318|GENETIC|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
214421019|NCT00001524|DRUG|Thalidomide|
214421020|NCT01114945|DEVICE|McGrath|Intubation with the McGrath device
214421021|NCT01114945|DEVICE|GlideScope|Intubation with the GlideScope device
214421022|NCT01114945|DEVICE|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
214506483|NCT05847998|DIAGNOSTIC_TEST|Clinical measurement of capillary refill time|"Capillary refill time is clinically measured by two independent operators, each one blinded from the other.~Each operator performs, two series of three consecutive measurement on the second finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax, inverted relative to DICART measurements."
214506484|NCT05835895|GENETIC|GNSC-001|intra-articular injection
214694049|NCT02951611|PROCEDURE|Acupuncture stimulation|Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4
214421023|NCT01114945|DEVICE|Video-Mac|Intubation with the Video-Mac device
214421024|NCT01157182|DRUG|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
214421025|NCT01157182|DRUG|Activella®|1/0.5 mg Tablets
214421026|NCT04658212|PROCEDURE|3D LCBDE|three-dimensional (3D) video system for LCBDE (laparoscopic cholecystectomy and laparoscopic common bile duct exploration )
214421027|NCT04658212|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
214421028|NCT05626504|DEVICE|Pipeline Embolization Device with Vantage Technology|Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.
214421029|NCT00716144|DRUG|Talarozole|Oral Capsule Once Daily
214421030|NCT05505279|DEVICE|THRIVE (High Flow Nasal Cannula)|2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen
214421031|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 500|Experimental arm
214421032|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 1000|Experimental arm
214421033|NCT03574844|DIETARY_SUPPLEMENT|Placebo|Placebo comparator arm
214421034|NCT04801836|DRUG|Estetrol monohydrate 15 mg|One Estetrol monohydrate (E4) 15 mg tablet once per day
214421035|NCT04801836|DRUG|Placebo|One placebo tablet once per day
214421036|NCT00866554|DRUG|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
214506485|NCT05835895|DRUG|transient immune-modulation|oral
214506486|NCT05835895|DRUG|transient immune-modulation|intra-articular injection
214506487|NCT05835895|DRUG|Placebo|intra-articular injection
214694050|NCT02951611|PROCEDURE|Sham stimulation|Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
214694051|NCT01201070|DRUG|antithrombin III|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
214694052|NCT02191241|DRUG|Red Vine Leaf Extract|
214694053|NCT04017533|PROCEDURE|GMK Sphere TKR|Se earlier
214694054|NCT05606679|GENETIC|Analysis combinations of maternal KIR and HLA-C genotypes|Analysis of combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients
214694055|NCT03398746|PROCEDURE|LOOP Technique|Placement of subcutaneous loop drain
214694056|NCT03398746|PROCEDURE|Standard incision and drainage|Incise and drain with placement of packing
215102545|NCT00303888|DRUG|docetaxel|Given IV
215102546|NCT00303888|DRUG|idronoxil|Given orally
215102547|NCT00303888|OTHER|placebo|Given orally
215102548|NCT06071156|DRUG|Anakinra|Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences
214694057|NCT06560645|DRUG|PRT7732|PRT7732 capsules will be self-administered once daily at the dose-level assigned
215102549|NCT05096312|DIETARY_SUPPLEMENT|Zinc gluconate|oral zinc gluconate 200mg
214694058|NCT06221722|DIAGNOSTIC_TEST|BOLD-fMRI|Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging
214694059|NCT06221722|DRUG|Regular treatment of functional constipation|at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
214694060|NCT06221722|DRUG|fluoxetine|Fluoxetine oral treatment for 4 weeks.
214694061|NCT04216927|DRUG|Nitric Oxide|gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
214694062|NCT04216927|DRUG|Oxygen|Oxygen alone will be entrained for placebo arm
214694063|NCT05972759|OTHER|Forced and voluntary exercise|Twenty-five participants with PD utilizing the Medtronic Percept PC DBS system will be enrolled for this project and complete a single bout of both FE and VE. The 150-minute experimental session will be completed in the OFF antiparkinsonian and Off-DBS state.
214694064|NCT04491786|DRUG|Gabapentin|Gabapentin plus nefopam
214694065|NCT06224829|PROCEDURE|Pain Inducing Massage|60 seconds of direct pressure to the neck resulting in 5/10 pain . This will be repeated four times for a total of 240 seconds
214694066|NCT06224829|PROCEDURE|Pain Free Massage|60 seconds of direct pressure to the neck resulting in 0/10 pain . This will be repeated four times for a total of 240 seconds
214694067|NCT06224829|PROCEDURE|Cold Water Bath|Participants will place their hand in a cold water bath maintained at 6 to 8 degrees Celsius for 60 seconds. This will be repeated four times for a total of 240 seconds.
215020172|NCT02384343|DRUG|Dexmedetomidine|An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
215020173|NCT02384343|DRUG|Normal saline|An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
214421037|NCT00866554|DRUG|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
215020174|NCT02571244|BEHAVIORAL|Motivational Interview plus text message|After discharge the experimental group has received extended care including a counseling session and text messages. The session provided basic information about smoking and successful quitting. The counselor has used motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The focus was to increase motivation to make quit attempt, including confidence building, medication use, and cessation planning. The session lasted approximately 30 minutes. Participants in the experimental arm were offered up to 30 text messages to help them to implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or those that had already quit have received 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages followed the self efficacy theory.
215020175|NCT02990143|PROCEDURE|Ologen|Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
215020176|NCT01593111|OTHER|Environmental Intervention|Home-based environmental intervention
214421038|NCT05214235|DRUG|Hypoglycemic Drugs|Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
214421039|NCT00909363|DRUG|Promacta|"WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment"
214421040|NCT00909363|DIAGNOSTIC_TEST|blood drawing in patients with WAS|blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
214421041|NCT00909363|DIAGNOSTIC_TEST|blood drawing in healthy controls|blood will be drawn once in healthy children as controls for platelet parameters
214421042|NCT05641311|DRUG|ALXN1840|Tablet for oral use.
214421043|NCT05483374|OTHER|observation|Not applicable, it is an observational registry
214421044|NCT05966389|OTHER|No interventions|No interventions
215020177|NCT03565588|BEHAVIORAL|Education session with fixed incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants assigned to receive fixed incentives will receive payment through mobile payments. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
215029107|NCT05703126|DIAGNOSTIC_TEST|Complete blood count|Before and after each course of chemotherapy: Complete blood count with counting the number of erythrocytes, leukocytes, leukocyte formula, platelets, erythrocyte sedimentation rate.
215029108|NCT05703126|DIAGNOSTIC_TEST|Biochemical blood test|Before and after each course of chemotherapy: Biochemical blood test with the determination of the amount of total protein, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, urea, AlAT, AsAT, LDH, glucose, C-reactive protein, troponin T, proBNP.
214421045|NCT06292182|DEVICE|Near-infrared light|daily application of near-infrared light
214421046|NCT02533167|OTHER|skin to skin|initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
214421047|NCT00367055|DRUG|rosiglitazone-metformin|
214421048|NCT00367055|DRUG|Metformin|
214421049|NCT00367055|DRUG|metformin+ gliclazide|
214421050|NCT05712018|DRUG|Hydroxyethyl starch coload - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214421051|NCT05712018|DRUG|Hydroxyethyl starch coload - 5 ml/kg|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214421052|NCT05712018|DRUG|Hydroxyethyl starch coload - 10 ml/kg|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
214421053|NCT02459899|DRUG|Placebo|Placebo, once daily, before the first meal of the day
214421054|NCT02459899|DRUG|Sotagliflozin|Sotagliflozin,once daily, before the first meal of the day
214421055|NCT06112119|DEVICE|MSCT|Using Semi-automatic MSCT Volumetry in assessment of brain atrophy associated with septic ICU patients
214421056|NCT05028712|BEHAVIORAL|Visual Information Training|Participants in this arm will receive training to improve the use of residual vision to enhance functional performance.
214421057|NCT05028712|BEHAVIORAL|Multimodal training|Participants in this arm will receive training in integrating input from different senses to enhance functional performance.
214421058|NCT01586780|DIETARY_SUPPLEMENT|Protein drink|Test drink providing 9g protein
214421059|NCT01586780|DIETARY_SUPPLEMENT|Reference meal|Control meal
214421060|NCT01118338|DEVICE|Redesigned Purevision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
214421061|NCT01118338|DEVICE|PureVision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
214421062|NCT01918644|RADIATION|stereotactic body radiation therapy|Undergo SBRT
214421063|NCT01918644|DRUG|capecitabine|Given PO
214421064|NCT01918644|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
214421065|NCT01918644|PROCEDURE|magnetic resonance imaging|Optional correlative studies
214421066|NCT01918644|OTHER|laboratory biomarker analysis|Optional correlative studies
214421067|NCT05384132|OTHER|SRP + Livfresh Dental Gel|SRP at baseline with use of LDG (test dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use LDG as their primary dentrifice (toothpaste) for the next 6 months. They're instructed to use LDG twice daily with toothbrushing for 2 minutes. LDG in previous studies have been reported to be superior to conventional over-the-counter toothpaste in terms of reducing bacterial plaque and gingival inflammation due to its EDTA (ethylenediaminetetraacetic acid) ingredient. EDTA prevents adhesion of bacterial plaque to teeth.
214421068|NCT05384132|OTHER|SRP + standard flouride dentifrice|SRP at baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use standard fluoride toothpaste (commercial over-the-counter toothpaste) as their primary dentrifice (toothpaste). They're instructed to use standard fluoride toothpaste twice daily with toothbrushing for 2 minutes.
214421069|NCT04222270|BEHAVIORAL|Champion Caregiver peer mentoring support to caregivers on child care and medication adherence to enhance achievement of viral suppression|Caregiver to caregiver peer support intervention through group/one-on-one education and counselling
214421070|NCT05638945|BEHAVIORAL|ED Delirium Screening and Detection Program (ED-DDP)|The intervention arm will have standardized delirium screening by nurses using the brief confusion assessment method (bCAM) in the EHR and will receive the ED-DDP. The ED-DDP will consist of: 1) a multicomponent 1-day delirium champion workshop; 2) real-time direct observation/training via telehealth (tele-training); and 3) training of nurses by champions. Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses.
214421071|NCT06538558|DRUG|Tezampanel|Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation
214506488|NCT04670640|DEVICE|Vibration|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. There will be no explicit tasks or direction given in this intervention. Participants will experience smooth slowly varying breath-like vibration on their sternum. They will receive their assigned intervention for approximately 18 minutes.
214421072|NCT06538558|DRUG|Placebo|Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
214694068|NCT03977285|PROCEDURE|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
215029109|NCT05703126|DIAGNOSTIC_TEST|Coagulogram|Before and after each course of chemotherapy: Coagulogram parameters (fibrinogen, APTT, INR).
215029110|NCT05703126|DIAGNOSTIC_TEST|Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine|Before the start of the treatment and after each course of chemotherapy: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine.
215029111|NCT05703126|DIAGNOSTIC_TEST|Stress echocardiography with the definition of global longitudinal deformation of the myocardium|Before the start of the treatment and after each course of chemotherapy: Stress echocardiography with the definition of global longitudinal deformation of the myocardium.
214421073|NCT05175248|BEHAVIORAL|Plant-based Intervention Group|Participants in the intervention group will be instructed in ways to adopt a plant-based diet, use appropriate methods of food preparation, and make meals enjoyable and appetizing. The plant-based diet primarily emphasizes whole grains, vegetables, beans and legumes, and fruits. Animal products and added oils will be proscribed and the use of ultra-processed foods, sugar, and sugar-sweetened beverages will be discouraged. Fat intake will be limited to 20-30 g/day.
214421074|NCT00391755|DRUG|ramelteon|"1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary"
214421075|NCT01312337|DRUG|salvage iressa|Iressa 250mg per day until progression
214421076|NCT00732953|DEVICE|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
214421077|NCT00732953|DEVICE|Genous stent implantation|Genous stent implantation
214421078|NCT03356132|DEVICE|Silimed® Textured Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® Textured Silicone Gel-Filled Breast Implant.
214421079|NCT03356132|DEVICE|Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® silicone gel-filled breast implants with polyurethane foam covered surface.
215029112|NCT05703126|DIAGNOSTIC_TEST|Triplex scanning of neck vessels|Before the start of the treatment and after each course of chemotherapy: Triplex scanning of neck vessels.
215029113|NCT05703126|DIAGNOSTIC_TEST|Electrocardiography|Before and after each course of chemotherapy: Electrocardiography.
214421080|NCT04470193|OTHER|MyChildCMC app|Patients/parents will self-monitor their symptoms daily using the MyChildCMC app completing the daily vitals form. After patient/parents complete the daily form, the app provides in-app alerts and graphs showing symptom data over time.
214421081|NCT03245541|DRUG|Durvalumab|Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q28 days up to 1 year or until progression (11 doses), unacceptable toxicity or other reason. If a patient undergoes resection, they will resume durvalumab once appropriately healed from surgery (approximately 4-8 weeks) at discretion of treating medical oncologist.
214421082|NCT03245541|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.
214421083|NCT04663802|BEHAVIORAL|Default order set|With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 milliliters per kilogram of predicted body weight (cc/kg PBW; as determined by each patient's height and gender). The physician will have the option to opt out of any of the specified LPV settings and select other values.
214421084|NCT04663802|BEHAVIORAL|Physician-targeted accountable justification|When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg PBW, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.
214421085|NCT04663802|BEHAVIORAL|Respiratory therapist (RT)-targeted accountable justification|If an RT enters a tidal volume in a flowsheet documentation field value greater than 6 cc/kg PBW, an alert will appear requiring them to enter a reason for entering a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The RT will not be able to save the documentation in the EHR until after a response is entered.
214421086|NCT05829681|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants will receive a 5-day course of 10x daily rTMS, with sessions delivered hourly. Each session will deliver up to 1800 pulses of theta-burst stimulation per target.
214421087|NCT04443153|DEVICE|Personalized Feedback|Provides tailored information to the user about what glycemic risk they may be facing as well as how glycemic control and system use looked in the past week. Treatment decision and therapy changes are entirely left to the decision of the user.
214421088|NCT04443153|DEVICE|Decision Support System|CGM-based system that includes Personalized Feedback (PF) and further assists with treatment recommendations for common metabolic challenges
214421089|NCT04443153|DEVICE|Sensor Augmented Mode|A mode in Diabetes Assistant (DiAs) that combines Diabetes Assistant, Insulin pump or Multiple Daily Injections, CGM, ketone meters, and glycemic treatment guidelines together to manage diabetes.
214421090|NCT04004000|DRUG|Losmapimod|"The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination."
214421091|NCT03035045|DRUG|Paracetamol|
214421092|NCT03035045|DRUG|Placebo Oral Tablet|
214421093|NCT03612804|BEHAVIORAL|Unsigned note to provider about cessation medication prescription|For patients of providers assigned to the proactive study group, a local coordinator will review the patient's cessation medication history. If the patient is not currently being provided cessation support medication, the coordinator will enter a note for the provider about the recommended medication indicated by VA formulary guidelines.
214421094|NCT03612804|BEHAVIORAL|Proactive Telephone Counseling from VA Quitline|Patients of providers assigned to the proactive study group will be contacted by specially trained counselors at the VA Quitline. Counselors will attempt to provide two sessions of proactive telephone support.
214421095|NCT06498453|DEVICE|Trak-Physio knee condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
214421096|NCT06498453|DEVICE|Trak-Physio in shoulder condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
214421097|NCT06498453|OTHER|Knee conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
214421098|NCT06498453|OTHER|Shoulder conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
214421099|NCT03316456|DIAGNOSTIC_TEST|Observational: Stool Sample Collection|"Observational: Stool Sample Collection~\- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
214421100|NCT03316456|DIAGNOSTIC_TEST|Observational: Blood Sample Collection|"Observational: Blood Sample Collection~\- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
214421101|NCT03316456|DIAGNOSTIC_TEST|Observational: Urine Sample Collection|"Observational: Urine Sample Collection~\- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
214421102|NCT03105128|DRUG|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
215029114|NCT05703126|DIAGNOSTIC_TEST|Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes|Before the start of the treatment and after each course of chemotherapy: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes.
214421103|NCT03105128|DRUG|risankizumab IV|Risankizumab administered by intravenous infusion
214421104|NCT03105128|DRUG|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
214421105|NCT04598529|OTHER|A2 milk|a variety of cow's milk that contains only A2 beta-casein (and therefore lacks of A1 beta-casein).
215020178|NCT03565588|BEHAVIORAL|Education session with lottery incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants will participate in a lottery with prizes equivalent in expected value to the fixed incentives. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
215020179|NCT06226415|BEHAVIORAL|Rehabilitation therapy|"The study lasted 14d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
215020180|NCT06226415|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
215020181|NCT06226415|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
215020182|NCT03997838|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
215020183|NCT03997838|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
215102550|NCT05096312|DRUG|Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]|Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening
215102551|NCT05096312|OTHER|Placebo|contains cornstarch
214421106|NCT04598529|OTHER|Conventional milk|cow's milk with a mixture of A1 and A2 beta-casein.
214421107|NCT04066751|DRUG|Ivacaftor|Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
214421108|NCT06414382|OTHER|Tape-stripping|22mm tapes x 40 will be attached and removed to skin of all for limbs (tape stripping). On left arm and leg skin will also be subject to micro needling.
214421109|NCT06258980|DRUG|Proph7|Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females
214421110|NCT05019729|DRUG|VRC-MALMAB0114-00-AB|VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.
215102552|NCT01760590|PROCEDURE|Manual Manipulation|A grade 5 thrust to the thoracic spine
214421111|NCT05019729|OTHER|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum
214421112|NCT00612001|BIOLOGICAL|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
214421113|NCT00241423|DRUG|exenatide|subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
214421114|NCT00241423|DRUG|Placebo|subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
214421115|NCT06028451|OTHER|Record the information data|Record the information data
214421116|NCT00185016|BEHAVIORAL|a training to improve recognition of partner abuse.|
214421117|NCT04402320|DRUG|Midazolam|reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
214421118|NCT04402320|DEVICE|ventilator|reconnected to mechanical ventilation before extubation for one hour with sedation
214421119|NCT01326988|PROCEDURE|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
214421120|NCT02885350|DRUG|Spinal analgesia for labour pain|Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
214421121|NCT02885350|DRUG|Epidural analgesia for labour pain|Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
215020184|NCT00483509|DRUG|NGR-hTNF|iv q3W 0.8 mcg/sqm NGR-hTNF
214421122|NCT05632731|PROCEDURE|double cleavage-stage or single blastocyst stage embryos transfer|Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
215020185|NCT00483509|DRUG|Doxorubicin|iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
215102553|NCT01760590|PROCEDURE|Mobilization|A grade 1-4 mobilization directed at thoracic spine
215102554|NCT04133714|DEVICE|multi-channel tDCS|multi-channel transcranial direct current stimulation, tDCS
214421123|NCT01638884|BEHAVIORAL|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
214421124|NCT01638884|OTHER|Structural MRI|to compare differences between each populations
214421125|NCT01638884|OTHER|Functional MRI|to compare differences between each populations
214421126|NCT01638884|OTHER|Virtual reality / Memory assessment|to compare differences between each populations
214421127|NCT03773120|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
214421128|NCT02770430|BIOLOGICAL|mesenchymal stem cells|MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg
214506489|NCT04670640|BEHAVIORAL|Breath Focus|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. The participant will be asked to focus on their breathing during this intervention. They will receive their assigned intervention for approximately 18 minutes.
214506490|NCT04670640|BEHAVIORAL|No Distractions|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. Participants will engage in a period of no-screen time; during this time there will be no outside visual or auditory distractions. There will be no explicit tasks or direction given in this intervention. They will receive their assigned intervention for approximately 18 minutes.
214506491|NCT05525455|DRUG|TT-816|TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors
214506492|NCT05525455|DRUG|A PD-1 inhibitor|Programmed death receptor-1 (PD 1)-blocking antibody
214506493|NCT05507723|OTHER|Treat-to-target|Treatment to achieve urate target using supported self-management approach
214506494|NCT05507723|OTHER|Usual Care|Treatment escalation by GP based on usual clinical practice
214506495|NCT06281496|BEHAVIORAL|AlloCare|Survivorship supportive care
214506496|NCT05541965|OTHER|Reflexology and kegel exercises|"Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence"
214506497|NCT06505122|BEHAVIORAL|Dyadic Life Review|DLR is an intervention that will promote relationship closeness, communication, and psychological distress in both older adults and caregivers.
214506498|NCT03901807|DEVICE|Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge|TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
214690096|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
215029115|NCT05703126|DIAGNOSTIC_TEST|Cytogenetic examination of the bone marrow to determine genetic abnormalities.|Before the start of the treatment: Cytogenetic examination of the bone marrow to determine genetic abnormalities.
215102555|NCT04133714|DEVICE|single-channel tDCS|single-channel transcranial direct current stimulation
214421129|NCT02770430|DRUG|conventional treatment|"1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
214421130|NCT02398565|OTHER|No intervention|
214421131|NCT03409263|OTHER|Observational study|Not applicable (observational registry study)
214421132|NCT01972763|DRUG|Ranibizumab|Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
214421133|NCT00459758|DEVICE|Hans unit|
214421134|NCT03356444|DRUG|Abiraterone Acetate|Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
214421135|NCT03356444|DRUG|Docetaxel|"Docetaxel: intravenously, 75 mg/m\^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment"
214421136|NCT05931107|OTHER|Stress ball practice group (Stress ball squeezing)|The stress ball is made of round, colorful, high-quality silicone. A stress ball of medium hardness and 6 cm in diameter (suitable for adult use) will be used in the research. When it is loosened, it returns to its original state. In the experimental group, the patients are required to squeeze the ball once after counting to three, inhale each time they squeeze the ball, exhale when they loosen their grip, and focus only on the ball. The experimental group has to squeeze the stress ball for 10-15 minutes every day for 4 weeks.
214506499|NCT05465109|OTHER|TBI-AD/ADRD Caregiver Support Intervention (TACSI)|The TBI-AD/ADRD Caregiver Support Intervention (TACSI) incorporates psychosocial and psychoeducational approaches with the objective of: a) identifying stressors associated with caregiving for family members who have the dual diagnosis of traumatic brain injury and dementia; and b) supporting caregivers in developing more effective coping and communication strategies as well as enhanced caregiving self-efficacy. This intervention offers individual and family coaching and knowledge and skills to help manage stress and reduce caregiver burden.
214506500|NCT06579092|DRUG|AZD5004|AZD5004 film-coated tablet once daily during 36 weeks
214506501|NCT06579092|DRUG|Placebo|Placebo matching AZD5004 film-coated tablet once daily during 36 weeks
214421137|NCT04479540|RADIATION|Angiography scanner|systematic thoracic angiography scanner to diagnose pulmonary embolism and additional blood sample (hemostasis exploration)
214421138|NCT00038103|DRUG|Exemestane|Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
214421139|NCT00038103|DRUG|Celecoxib + Exemestane|Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
214421140|NCT06426303|DRUG|Naltrexone|12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.
214421141|NCT01597128|DEVICE|Flex HD|Flex HD mesh for hernia repair
214421142|NCT01597128|DEVICE|Strattice|Strattice mesh for hernia repair
214421143|NCT00117364|DRUG|SACCHACHITIN patch|
214421144|NCT01805921|BIOLOGICAL|PanAd3-RSV given intra-nasally (high dose)|High dose = 5x10\^10 vp
214421145|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (high dose)|High dose = 1x10\^8 pfu
214506502|NCT04783038|OTHER|Distance Reiki|Reiki therapy session performed remotely over a Zoom® video conferencing platform led by Reiki Practitioners who are also Health Care Providers at the Mayo Clinic, and have at least 6 months of experience in Reiki.
214506503|NCT04783038|OTHER|Sham distance Reiki|Session performed remotely over a Zoom® video conferencing platform led by a Health Care Provider employed at the Mayo Clinic, but will have no experience in Reiki and will not be a certified Reiki Practitioner.
214506504|NCT05599191|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
214506505|NCT05599191|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
214506506|NCT05343741|OTHER|Psychological Intervention|The CPA provides outpatient psychological services to individuals: children, adolescents and adults, couples and families. At the CPA, care is carried out through the co-therapy model, which involves the participation of a professional clinical psychologist and a trainee. Psychotherapists with diverse theoretical and clinical backgrounds (mainly psychodynamic, cognitive, systemic and integrative), but a common constructivist approach, work in the center. The following elements are transversal in their practice: therapeutic alliance, healing environment, and a collaborative procedure between the client, the psychotherapist and the trainee co-therapist.
214506507|NCT06966401|DRUG|NBI-1065845|NBI-1065845 tablets
214506508|NCT05676346|GENETIC|LUTS|Patients included in this group are subjects with lower urinary tracto symptoms. An oral mucosa swab will be used to extract a genetic specimen
214506509|NCT03275961|BEHAVIORAL|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
214506510|NCT03340415|OTHER|Accelerated Rehabilitation plan|early weight bearing after surgery
215020186|NCT06235970|DEVICE|Transcranial electrical stimulation (tES) including SHAM|Transcranial electrical stimulation, known as tES, refers to a family of devices that utilize low-cost technologies and involve low-intensity currents which are safe for humans, and carry minimal risk of side effects or adverse events. Conventional approaches, which utilize fixed direct currents (tDCS) or alternating currents at a fixed oscillatory frequency (tACS), have been widely used as both a basic research tool and as a clinical intervention. In the current project, we use a custom-built device that enables near real-time current modulation triggered digitally, via software control, to allow for stimulation protocols guided by whole-brain individualized neural modeling.
214421146|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (high dose)|High dose = 5x10\^10 vp
214421147|NCT01805921|BIOLOGICAL|PanAd3-RSV given intranasally (low dose)|Low dose = 5x10\^9 vp
214421148|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (low dose)|Low dose = 1x10\^7 pfu
214421149|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (low dose)|Low dose = 5x10\^9 vp
214421150|NCT06266858|OTHER|rehydration|The fasting patients in anaesthetised receive saline rehydration to maintain central venous pressure of 6-8 cmH2O when undergoing UCG.
214421151|NCT06266858|DIAGNOSTIC_TEST|UCG|UCG is the most common imaging modality to assess the mitral regurgitation in clinical and also is the primary modality recommended by guidelines. At the beginning of the study, the fasting patients receive UCG in the different situation such as pre-anaesthetic, post-anaesthetic and post-rehydration.
214421152|NCT06266858|DIAGNOSTIC_TEST|CMR|CMR may be more accurate than UCG in assessing MR severity. In another time, the patients receive CMR.
214506511|NCT03775213|BEHAVIORAL|Decision Support Tool with Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including active monitoring and surgery options.
214506512|NCT03775213|BEHAVIORAL|Decision Support Tool without Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including surgery options only.
214421153|NCT06266858|OTHER|fasting|At the beginning of the study, the patients need to fast when receive UCG.
214421154|NCT03860220|DRUG|NEWSTATIN TS|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
215029116|NCT05703126|DIAGNOSTIC_TEST|Cytological examination of bone marrow cells with cytochemical examination|Before the start of the treatment and after each course of chemotherapy: Cytological examination of bone marrow cells with cytochemical examination.
215029117|NCT05703126|DIAGNOSTIC_TEST|Immunophenotypic examination of the bone marrow by flow cytometry|Before the start of the treatment: Immunophenotypic examination of the bone marrow by flow cytometry.
215029118|NCT05703126|DIAGNOSTIC_TEST|Determination of the presence of a FLT3 mutation using the PCR Method|Before the start of the treatment: Determination of the presence of a FLT3 mutation using the PCR Method.
214421155|NCT03860220|DRUG|CADUET|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
214421156|NCT03545984|OTHER|Simulation-based learning|Simulation-based teaching involves using done on a mannequin to simulate actual conditions
214421157|NCT03545984|OTHER|interactive problem based learning|Standard teaching (problem based learning discussion) during cardiac/vascular rotation
214421158|NCT00387465|DRUG|Azacitidine 30mg/m2|Azacitidine 30mg/m2 subcutaneously (SQ)
214421159|NCT00387465|DRUG|Entinostat|7mg by mouth (PO) on days 3 and 10 of each cycle
214421160|NCT00387465|DRUG|Azacitidine 40mg/m2|Azacitidine 40mg/m2 SQ
214506513|NCT06968351|BEHAVIORAL|Animal-Assisted Intervention|A brief animal-assisted intervention is offered on a group basis across four sessions. Each session lasts approximately 60 minutes and covers the same themes but through different exercises. These themes include effective communication, behavioral principles, problem-solving, and teamwork. The first part of a session involves learning to give effective single-component commands to a rehabilitative dog under the guidance of a professional dog handler. The second part of a session involves the applications of two or more of these single-component commands to an interactive group activity. Project staff are present at each session to facilitate discussions among participants on any challenges encountered, learning, and intra- as well as inter-personal experiences during the session.
214506514|NCT06458036|DRUG|Selpercatinib Monotherapy|Patients will receive selpercatinib monotherapy for 6 months at the FDA-approved dose.
214694069|NCT02568917|PROCEDURE|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
215020187|NCT04298333|DRUG|BP-C1|"BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days."
215020188|NCT01696214|DRUG|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
215020189|NCT01696214|DRUG|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
215020190|NCT01696214|DRUG|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
215020191|NCT01696214|DRUG|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
215020192|NCT01687205|DRUG|1% Tenofovir Gel|
215020193|NCT03600103|BEHAVIORAL|Tech2Check|The intervention uses behaviors to improve HIV adherence and self-care. Investigators will use the Center for Disease Control (CDC) Partnership for Health (PfH) Medication Adherence.The CHN will administer PfH at all home/venue-based encounters, using communication styles that are more receptive to adolescents and young adults. Resources will be provided. At the end of the session, the participant will be able to state/demonstrate: goals of HIV care and adherence, meaning of CD4 and Viral Load (VL) measurements and the significance of their own measurements,signs of complications or problems for which participants need to seek additional care,understanding of optimal self-care.Further, CHNs will also provide tips to stay on schedule with taking their ART and problem-solve adherence barriers.
214421161|NCT05678296|DIAGNOSTIC_TEST|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
214421162|NCT05678296|DRUG|Analgesic|Analgesics are prescribed for the patients for all groups.
215020194|NCT00007943|DRUG|gemcitabine hydrochloride|
214421163|NCT05678296|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
214421164|NCT05678296|BIOLOGICAL|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
214421165|NCT05678296|DRUG|Antibiotic|no systemic antibiotics are prescribed for the patients for all groups.
214421166|NCT00156117|DRUG|asenapine|5 mg BID or 10mg BID
214421167|NCT00156117|DRUG|Placebo|Placebo
214421168|NCT00156117|DRUG|olanzapine|olanzapine 15 mg QD
214421169|NCT01843491|BIOLOGICAL|Ad-PfCA|Vaccine
214421170|NCT01159249|DRUG|Vildagliptin|
214506515|NCT06458036|RADIATION|131I Therapy|Patients will receive 131I therapy after 6 months of selpercatinib.
214506516|NCT06305312|BEHAVIORAL|Community Service Navigation|Patients randomized to the intervention will be directly referred to the United Way of Salt Lake's 211 community referral service for additional outreach.
214506517|NCT06305312|OTHER|Usual Care|Standard referral to community resources.
214506518|NCT04821271|OTHER|Placebo|Participants received Placebo capsule orally once daily for three weeks.
214506519|NCT04821271|DRUG|TS-161|Participants received TS-161 50-100 mg capsule orally once daily for three weeks. TS-161 is a mGlu2/3 receptor antagonist prodrug.
214506520|NCT02414178|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
214506521|NCT05640167|BEHAVIORAL|Interdisciplinary Clinic|Interdisciplinary Clinic - assessment and recommendations by Nutrition, Pharmacy, Physical Therapy, and Speech Therapy and Educational Seminar - Parkinson's specific education and resources in group format
214694070|NCT02568917|PROCEDURE|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
215020195|NCT01775410|DEVICE|Wolverine System to perform atherectomy|
215020196|NCT03847012|OTHER|exercise|The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
215020197|NCT02768246|DEVICE|BVGA|The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation
215020198|NCT02768246|DEVICE|Face Mask|Classic face mask
215020199|NCT01642667|DRUG|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
215020200|NCT01642667|DRUG|Placebo|
215020201|NCT02572687|DRUG|Ramucirumab|Administered IV
215020202|NCT02572687|DRUG|MEDI4736|Administered IV
215020203|NCT01905267|BEHAVIORAL|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
215020204|NCT03888482|DEVICE|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
215020205|NCT03888482|DEVICE|Somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
215020206|NCT06436521|BEHAVIORAL|Positive Cognitive Behavioral Therapy|Positive CBT integrates brief Solution-Focused Brief Therapy with Positive Psychology techniques, within a cognitive-behavioral framework. It is considered a competency and strengths-based model.
215020207|NCT06436521|BEHAVIORAL|Traditional Cognitive Behavioral Therapy|Traditional cognitive behavioral therapy is a form of psychological treatment that emphasizes that psychological problems are based on faulty or unhelpful ways of thinking and the focus is to change thinking patterns.
215020208|NCT03907579|BEHAVIORAL|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
215020209|NCT00049946|DRUG|talnetant|
215020210|NCT00049946|DRUG|risperidone|
215020211|NCT03546257|DEVICE|magnifying endoscopy with narrow band imaging (ME-NBI)|A system consisting of a magnifying endoscope combined with narrow-band imaging (NBI), with the spectral band width narrowed by optical filters, was developed to enhance visualization of mucosal surface structure and vascular architecture. There were some reports that the magnifying endoscopy with narrow band imaging (ME-NBI) is superior to predict the histologic differentiation, depth of invasion and lesion margin than WLE.
215020212|NCT03509480|PROCEDURE|Surgical Curettage for benign bone lesion|Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
215020213|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS|20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
215020214|NCT04698447|DIETARY_SUPPLEMENT|Placebo (without any active ingredients)|20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
215020215|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS|20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
215020216|NCT01401205|OTHER|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
214506522|NCT06326996|DRUG|Thiamine|Participants will be given an infusion of thiamine.
214694071|NCT04145830|DEVICE|Ultrasound Cyclo Plasty (UCP)|Cyclocoagulation using High Intensity Focused Ultrasound
215020217|NCT00567229|BIOLOGICAL|rituximab|
215020218|NCT00567229|DRUG|lenalidomide|
215020219|NCT00567229|GENETIC|microarray analysis|
215020220|NCT00567229|OTHER|flow cytometry|
214506523|NCT06326996|DRUG|Placebo|Participants will be given an infusion of the placebo treatment.
215020221|NCT00567229|OTHER|laboratory biomarker analysis|
215020222|NCT03729141|DIETARY_SUPPLEMENT|Added Cholesterol|Participants assigned to the added cholesterol group will receive snacks containing added cholesterol (1g/day) for 3 weeks prior to surgery.
215020223|NCT03729141|OTHER|No Added Cholesterol|Participants assigned to the no added cholesterol group will receive snacks containing no added cholesterol for 3 weeks prior to surgery.
215020224|NCT01455090|DRUG|BMS-650032|
215020225|NCT01455090|DRUG|BMS-790052|
215020226|NCT01455090|DRUG|BMS-791325|
215020227|NCT01455090|DRUG|Ribavirin|
214421171|NCT04548011|OTHER|Acupuncture|The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
214421172|NCT00597350|DIETARY_SUPPLEMENT|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
214421173|NCT03655938|PROCEDURE|Piezocision combined minimally invasive alveolar bone regeneration|The piezocision surgery was performed two weeks after orthodontic appliance placement. The patients received local anesthesia in mandibular arch and vertical interproximal incisions were made below the interdental papillae in the midline, from the mesial aspect of each canine and in between each of the posterior lower teeth. The periostium was then released in order to create two subperiotal envelopes connecting the vertical incisions together. Thereafter, corticotomies were performed in the region of the incisions with a piezotome (Acteon, Merignac, France) and the envelopes were filled with a beta tricalcium phosphate, a resorbable biomaterial in order to thicken the buccal bone plate. Resorbable 5-0 sutures were used to close the flaps. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
214421174|NCT01941563|DRUG|Condoliase|1.25U, intradiscal injection, one time
214421175|NCT01941563|DRUG|placebo|
214421176|NCT00002527|DRUG|aspirin|
214421177|NCT00002527|OTHER|placebo|
214421178|NCT00964184|DRUG|Metformin|
214421179|NCT00964184|BEHAVIORAL|Lifestyle modification|
214421180|NCT04783181|BIOLOGICAL|AAV BBP-631|intravenous
214506524|NCT06698653|DEVICE|SAM device (experimental): a removable structure, fixed to the horizontal frame of the medical bed, equipped with a handle to assist the sitting-up process|The patients will use the experimental device during 7 days straight as well as the comparator during 7 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : - Groupe 1 : Experimental device during 7 days then control device during 7 days - Groupe 2 : Control device during 7 days then experimental device during 7 days
214690097|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
214694072|NCT05442463|DRUG|Captopril Tablets|Captorpril challenge to each participant
215020228|NCT06626997|DIETARY_SUPPLEMENT|Kombucha tea|"During Visit 1 (week 0), a fasting blood test must be performed at the IMDEA Alimentación facilities to obtain different markers: blood lipids, blood glucose, etc. Approximately 20 mL will be extracted (for comparison, keep in mind that a donation requires 450 mL). The blood sample will be extracted by qualified nursing staff from the UNILABS Laboratory. The blood tests based on the security and privacy requirements for handling samples will be carried out by the same laboratory.~You will also be asked to provide the stool sample that you must have collected at home prior to attending that visit with the material provided at the screening visit (V0) and at the intermediate visit (V2)."
215020229|NCT04637347|DEVICE|Catheterization approach|In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization
214694073|NCT05442463|DRUG|Iohexol|Iohexol infusion to evaluate measured GFR
215102556|NCT04556318|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
214421181|NCT05012644|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
214421182|NCT05012644|DRUG|Aromatase inhibitor|Aromatase inhibitor
215020230|NCT00195611|DRUG|Prevenar|
215102557|NCT03135210|OTHER|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
215102558|NCT03135210|DEVICE|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
215102559|NCT03369613|DEVICE|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
214421183|NCT06070415|DEVICE|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
214506525|NCT06698653|DEVICE|Over bed pole hoist (control device)|The patients will use the experimental device during 7 days straight as well as the comparator during 7 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : - Groupe 1 : Experimental device during 7 days then control device during 7 days - Groupe 2 : Control device during 7 days then experimental device during 7 days
214694074|NCT06600048|DRUG|Hyperbaric prilocaine|Patients will receive 1.5 ml (30 mg) 0.5% hyperbaric prilocaine.
214421184|NCT06070415|OTHER|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
214421185|NCT06070415|OTHER|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
214421186|NCT01910636|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
214421187|NCT01910636|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
214421188|NCT02251613|DRUG|Olopatadine HCl ophthalmic solution, 0.1%|
214421189|NCT02251613|DRUG|Epinastine HCl ophthalmic solution, 0.05%|
214421190|NCT02600442|OTHER|non interventional study|
214421191|NCT03644537|PROCEDURE|Orthodontic intrusion|"27 female patients coming to the Orthodontic department, Cairo University seeking orthodontic treatment, where their age ranges from 15 - 18 years, where their treatment plan include extraction of upper first premolars, and using the split-mouth technique, one side will be control group without application of force where the other side will receive intrusive mechanics for the same patient in the upper arch (one side will not receive any force and the same tooth on the other side of the arch will suffer intrusive mechanics, that's why named SPLIT MOUTH TECHNIQUE - as if the arch is split into two subjects, one control subject (tooth) and the other study subject (tooth) . According to the amount of force of the working side, the total number of patients will be divided into 3 groups.~Each of 9 subjects, the first group where a light force will be applied (10 gm), the second group where moderate force will be applied (25gm), the third group where heavy force will be applied(100 gram)."
214421192|NCT00283374|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
214421193|NCT02008734|DRUG|PD0332991|
214421194|NCT04851561|DIAGNOSTIC_TEST|Cardiopulmonary stress test (CPET)|Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.
214421195|NCT00255437|DRUG|ferumoxytol or oral iron|
214421196|NCT03119636|BIOLOGICAL|NPC transplantation|The cells are stereotactically implanted in the striatum.
214421197|NCT03119636|DRUG|Levodopa|Levodopa is used depending on the patient's condition
214421198|NCT02517411|OTHER|Standard care|The standard care of stable COPD is based on long-acting bronchodilators (LABD).
214421199|NCT02517411|OTHER|Physiotherapy added to standard care|The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
214506526|NCT07025850|DRUG|Digoxin|p.o. 0.5mg q.d.
215020231|NCT06535737|DRUG|Cabozantinib|Cabozantinib (Cabometyx) 60, 40 and 20 mg
214421200|NCT00423007|DRUG|Bromfenac|
214421201|NCT00423007|DRUG|Placebo|
214421202|NCT06269874|DIAGNOSTIC_TEST|microvascular function assessment|mircovascular function parameters will be measured by administering adenosine in two different pathways
214421203|NCT01946035|DRUG|Doxazosin XL|
214421204|NCT01946035|OTHER|Placebo|
214421205|NCT05358730|OTHER|Standard Exercise|Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).
214421206|NCT05358730|OTHER|Instrument Assisted Soft Tissue Mobilization (IASTM)|IASTM treatment was applied to the posterior-anterior-middle deltoid, latissimus dorsi, teres major, teres minor, supraspinatus and infraspinatus muscle fibers, superficial and deep fascia. IASTM was applied in parallel and vertical direction to the muscle fibers treated with the instrument at a 45° angle, each technique (SWEEP, BRUSH (straight short steps) techniques) for 20 seconds (Ikeda, Otsuka, Kawanishi, and Kawakami, 2019). It was performed two days per week for six weeks.
214421207|NCT05358730|OTHER|Home Exercise|"Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks."
214506527|NCT07025850|DRUG|Fuquinitinib|Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
214506528|NCT07025850|DRUG|Tislelizumab|Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
214506529|NCT07097896|DEVICE|ESV|This study arm will undergo ESV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
214506530|NCT07097896|DEVICE|EBV|This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
214506531|NCT07097935|DRUG|HS-10516 + Lenvatinib|Administered orally.
214694075|NCT06600048|DRUG|Hyperbaric bupivacaine|Patients will receive 1.5 ml (7.5 mg) 0.5% hyperbaric bupivacaine.
214694076|NCT00205725|DRUG|Ziprasidone, Olanzapine|
214694077|NCT01082718|DRUG|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
214694078|NCT05201586|OTHER|Conditional Cash Transfer|CCTs will be given to participants in the form of a pre-loaded debit card.
214694079|NCT05201586|OTHER|Semi-structured interviews|Research team will conduct semi-structured interviews exploring how social determinants of health and social needs impact health. Participants will be asked to set a health goal. 6 months after the initial interview, the team will interview the patients again and evaluate whether that health goal was achieved.
214694080|NCT05414617|DEVICE|Intra-articular single injection|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
215020232|NCT01630811|DRUG|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
215020233|NCT01630811|OTHER|Placebo|Placebo will be given once daily for 7 days.
215020234|NCT02438085|OTHER|prospective collection of data and follow-up|prospective collection of data and follow-up of all patients admitted to hospital for ACS
214421208|NCT06675994|DRUG|PCSK9 Antibody, PCSK9 Enzyme|In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.
214421209|NCT06676423|BIOLOGICAL|Lenzumestrocel|1.0 ⅹ 10\^6 cells/kg of Neuronata-R mixed with HTS-FRS suspension are administered twice in the cerebrospinal fluid at intervals of 26 days
214421210|NCT06676423|DRUG|Riluzole|In the case of a subject who is not taking Riluzole at the time of screening (visit 1), Riluzole should be taken except when discontinued due to Adverse events. The dose can be changed within the authorization according to the medical expert's judgement
214506532|NCT07099794|DRUG|Liposomal irinotecan+5-FU/LV+Lenvatinib|Liposomal irinotecan II: calculated as free base, 56.5 mg/m2, IV, d1q2w Renvastinib: ≥60kg, 12mg; \<60kg, 8mg, PO, once daily 5-FU: 1200 mg/ (m2·d) x2d continuous intravenous infusion for 46-48h, q2w LV: 400 mg/m2 intravenously, d1 q2w
214506533|NCT07099794|DRUG|NALIRI|Liposomal irinotecan II: calculated as free base, 56.5 mg/m2, IV, d1q2w 5-FU: 1200 mg/ (m2·d) x2d continuous intravenous infusion for 46-48h, q2w LV: 400 mg/m2 intravenously, d1 q2w
215020235|NCT02872688|OTHER|GanedenBC30|
215020236|NCT00979615|DRUG|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
215020237|NCT00979615|DRUG|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
215020238|NCT02501785|BEHAVIORAL|Caregiver Reaction Assessment (CRA)|
215020239|NCT02501785|BEHAVIORAL|The Caregiver Quality of Life - Cancer (CQOLC)|
215020240|NCT04518657|BEHAVIORAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
215020241|NCT04518657|BEHAVIORAL|Wellness for MS (WellMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing wellness in people with MS.
215020242|NCT04873856|DIETARY_SUPPLEMENT|Intervention|"The four dimensions of MINDNUT are described below:~Nutritional plan: is conducted in collaboration with the participant based on nutritional registration and information about routines and habits to reach a daily protein target of 1.5 g/kg/day. The nutritional plan is adjusted at the regular contact, and nutritional supplementation will be handed out to the participant.~Friendly reminder/informal caregiver: is a friendly reminder that encourage the participant to follow the nutritional plan and to ask for support (a note to hang on the refrigerator). The informal caregiver is a person with close contact to the participant.~Regular contacts: The participant will be contacted on regular basis (with an interval of 7-14 days) via phone and besides nutritional plan, this conversation will be used to talk about well-being, compliance and potential side-effects.~Weight diary: participants is instructed in keeping a weight diary which include registration of a daily weight."
215020243|NCT04146207|DRUG|SHR0302|SHR0302 po QD
215020244|NCT04146207|DRUG|Prednisone|Prednisone 1mg/kg/d po
215020245|NCT04292496|PROCEDURE|Introperative leak testing|After anastomosis was completed. We test the integrity of anastomosis intraoperatively.
215020246|NCT04276701|BIOLOGICAL|blood sample|35 ml whole blood for Peripheral blood mononuclear cell (PBMC), serum and plasma
214506534|NCT07098819|DEVICE|Vibrational Shear wave elastography algorithm|An algorithm that detects the propogation of shear waves in the head and neck.
214506535|NCT06831695|PROCEDURE|Craniotomy|Intervention: Bone flap replaced after dural closure Additional Information: This procedure involves creating a single free bone flap using high-speed drills. The bone is repositioned and secured using mini plates or sutures after the surgical intervention is completed. Post-operative monitoring will include assessment for CSF leakage, wound healing, and neurological recovery.
215020247|NCT04276701|OTHER|Ultrasonography assessment|assessment of atherosclerotic plaques and measurement of carotid intima-media thickness (cIMT)
215020248|NCT04276701|BEHAVIORAL|questionnaires|Food and exercise questionnaires validated by the American heart Association
214506536|NCT06831695|PROCEDURE|Craniectomy|Intervention: Bone permanently removed Additional Information: In this approach, the bone is removed in pieces using rongeurs, leaving an open dural surface without replacement of the bone. The dura is closed with sutures, and dural augmentation may be performed as needed. Post-operative assessment will focus on complications such as pseudomeningocele, CSF leakage, and extended hospital stays.
215020249|NCT05284513|BEHAVIORAL|FH diagnosis program|Uptake of screening, diagnosis, and initiation of care management for FH
215020250|NCT05284513|BEHAVIORAL|Implementation strategy package: Develop and implement tools for quality monitoring|EHR tools to order labs, record results, and document FH care
215020251|NCT05284513|BEHAVIORAL|Implementation strategy package: Develop educational materials|Education regarding guidelines for identification and treatment of FH
214421211|NCT04283409|OTHER|Graded activity|Exercise therapy using principles of cognitive behavioral therapy and education
214506537|NCT04256031|OTHER|Assessment|The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.
215020252|NCT05284513|BEHAVIORAL|Implementation strategy package: Conduct educational outreach visits|Continuing medical education (CME) material for FH that is presented to
215020253|NCT05284513|BEHAVIORAL|Implementation strategy package: Intervene with clinicians and patients to enhance|Notify patients simultaneously with clinicians about the need for screening
215020254|NCT05284513|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions|Clinical lipid champions
215102560|NCT03250572|DIAGNOSTIC_TEST|serum ferritin|serum samples and ferritin ELISA test
214421212|NCT04283409|OTHER|Motor Control Exercises|Exercise therapy using principles of motor control and motor learning and education
214421213|NCT06677333|OTHER|Whey Protein|This intervention will add 50 g of a whey or pea protein supplement to their usual dietary intake.
214421214|NCT06677333|OTHER|Pea protein|This intervention will add 50 g of a pea protein supplement to their usual dietary intake.
214421215|NCT06676462|DEVICE|Video laryngoscopy with visionPRO|Video laryngoscopy to be performed using the visionPRO (HEINE® Optotechnick, Gilching, Germany) during intubation.
214421216|NCT06676462|DEVICE|Video laryngoscopy with Glidescope|Video laryngoscopy to be performed using theGlideScope (Verathon Inc., Bothell, USA) during intubation.
214421217|NCT06620614|COMBINATION_PRODUCT|0.5% Heavy Bupivacaine|There are two groups.
214421218|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks|
214506538|NCT05440110|DEVICE|active and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
215020255|NCT05284513|BEHAVIORAL|Implementation strategy package: Audit and provide feedback|Provide aggregate level feedback to clinics on diagnosing FH
215020256|NCT05284513|BEHAVIORAL|Implementation strategy package: Stage implementation scale up|Develop the timeline for the stepped-wedge rollout to primary care
215020257|NCT04818086|DRUG|Lemborexant|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive 5 mg of lemborexant (first visit) and 10 mg of lemborexant (second visit).
215020258|NCT04818086|DRUG|Placebo|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which is encapsulated to look the same as the intervention drug.
215020259|NCT04818086|DRUG|Buprenorphine-naloxone|Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
214421219|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks, telephone counselling|
214421220|NCT06629324|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cell Transfusion|Bone marrow was collected under general anesthesia from both anterior superior iliac crests, taking 15-20 minutes, with a maximum volume of 350 mL for older children. Mononuclear cells were isolated using Ficoll density gradient centrifugation and prepared for infusion. The infusion, performed in the L4-L5 spinal space, lasted about 30 minutes at a rate of 20 mL per hour. Cerebrospinal fluid (CSF) was withdrawn before infusion, with the amount based on the child's weight. Patients received Rocephin for infection prevention and pain relief with alternating doses of Ibuprofen and Efferalgan for 2 days post-procedure. Seduxen was given once on the first night after bone marrow collection.
214421221|NCT06629324|OTHER|Rehabilitation|Rehabilitation methods involve various therapies tailored to the patient\&#39;s mobility level. (1) Physical therapy focuses on exercises to control the head, neck, and trunk, manage muscle tone, and reduce spasticity. Patients gradually practice essential movements like rolling, sitting, crawling, standing, and walking, aligned with developmental milestones. (2) Occupational therapy aims to enhance fine motor skills and daily activities. Through hand function exercises, patients improve upper limb functionality, strengthen their ability to grasp and hold objects and refine coordination between both hands and hand-eye coordination. (3) Speech therapy improves communication, cognitive abilities, and chewing and swallowing functions. Specific exercises target lip and mouth movements, helping patients express and understand language better. Additionally, there are activities to strengthen jaw and facial muscles, which are essential for improving chewing and swallowing abilities.
214421222|NCT06631716|DEVICE|CVT|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is CVT.
214421223|NCT06631716|DEVICE|HFCWO|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is HFCWO.
214421224|NCT06631716|DEVICE|MetaNeb|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is MetaNeb.
214421225|NCT06632067|DRUG|sugammadex|sugammadex used for neuromuscular reversal
214421226|NCT06632067|DRUG|Neostigmine + Atropine|Neostigmine and Atropine used for neuromuscular reversal
214421227|NCT06628661|PROCEDURE|Surgery for HCC larger than 6.5 cm|Surgery for HCC larger than 6.5 cm without mVI
214421228|NCT06628661|PROCEDURE|Surgery for HCC larger than 2 cm|Surgery for HCC larger than 2 cm with mVI
214421229|NCT06629051|DRUG|Berberine Hydrochloride|post-intervention of berberine
214421230|NCT06629051|DRUG|Placebo|Looks the same as berberine
214421231|NCT06711523|DRUG|PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)|This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.
214421232|NCT06711523|DRUG|PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)|This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.
215020260|NCT03319654|DIAGNOSTIC_TEST|DNA fragmentation by TUNEL assay|Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
215020261|NCT01725308|DRUG|FK949E|Taken by mouth (orally).
215020262|NCT01725308|DRUG|Placebo|Taken by mouth (orally).
215020263|NCT05950659|DEVICE|Orpyx Sensory Insole System|The Orpyx Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading
215020264|NCT03959904|PROCEDURE|Small stitch|Wound closure will be using small stiches or larger spaced stitches
215020265|NCT03959904|OTHER|Blood sample|A blood sample to look for biological markers of Hernia formation will be taken
215020266|NCT03959904|OTHER|Tissue Sample|A tissue sample will be taken to measure markers of wound healing.
215020267|NCT03959904|OTHER|Pain Score|A pain score will be recorded following the surgical procedure.
214421233|NCT06713941|OTHER|Study of the treatment|Intervention Description 1 \* (Limit: 1000 characters) Study of prescribed treatments, treatments taken by the patients, and treatment discontinuation
214421234|NCT06712043|BEHAVIORAL|Personalised Exercise|An individualized exercise program consisting of aerobic exercises, strength exercises and balance exercises. The exercises will be prescribed via the Physitrack app.
214421235|NCT06712043|BEHAVIORAL|Historical control group|Aerobic training (see study Voet 2024, Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD)
214421236|NCT01212757|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
214421237|NCT01212757|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
214506539|NCT05440110|DEVICE|sham and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min. Sham stimulation applies the same iTBS protocol with the sham coil.
214506540|NCT06830252|BEHAVIORAL|Exercise|Exercise.
214506541|NCT06830161|DIAGNOSTIC_TEST|Gingival Thermal Images|The degree of inflammation was evaluated using the Gingival Index
214506542|NCT03821623|DRUG|Nicotinamide riboside|Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.
214506543|NCT03821623|OTHER|Placebo|Subjects will take placebo pills twice a day for 3 months
214506544|NCT05867992|OTHER|Type of trauma|Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.
214506545|NCT03470597|OTHER|dietary iodine restriction on subjects with iodine overload|In this case registry study (observational study),all intervention will be performed not for research purposes, but only part of routine treatment, which will be recorded in database of the registry study.
215020268|NCT03959904|OTHER|Quality of Life Score|A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery
214506546|NCT05148949|BIOLOGICAL|Standard dosage inactivated vaccine|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
214506547|NCT05148949|BIOLOGICAL|Double dosage inactivated vaccine|This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
214506548|NCT05942664|BEHAVIORAL|Sleep|Sleep will be restricted to 60% normal sleep duration
215020269|NCT04128228|BEHAVIORAL|8-week outpatient treatment|Individuals with AUD participated in an 8-week treatment program integrating cognitive behavioral techniques focused on emotion regulation with breathing-based stress management.
215020270|NCT05453357|DEVICE|iGlucose|The patient will use the monitor as instructed by their healthcare team to monitor their blood glucose.
215020271|NCT00000738|DRUG|Nimodipine|
215020272|NCT00000738|DRUG|Zidovudine|
215020273|NCT05377671|DIAGNOSTIC_TEST|IRM multimodale a ultra-haute camp|The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
214421238|NCT01212757|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
214421239|NCT01212757|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
214421240|NCT06711393|OTHER|Exercise|Traditional home exercise including balance and muscle strength training 15 minutes at the time and three times over the week. In addition, game-based exercises 15 minutes at the time and three times over the week.
214421241|NCT06711393|OTHER|Exercise as usual|Traditional home exercise including balance and muscle strength training 15 minutes at the time and three times over the week without exergaming.
214421242|NCT04781595|DIETARY_SUPPLEMENT|Watermelon|A single dose of watermelon powder containing 3g of L-citrulline
214421243|NCT04781595|DIETARY_SUPPLEMENT|Beetroot|A single dose of beetroot powder containing 8 mmol of nitrate
214421244|NCT04781595|DIETARY_SUPPLEMENT|Watermelon + beetroot|A single dose of watermelon and beetroot powder containing 3g of L-citrulline and 8 mmol of nitrate
214421245|NCT04781595|DIETARY_SUPPLEMENT|Placebo|A single dose of maltodextrin
214421246|NCT06219642|BEHAVIORAL|Mindfulness using virtual reality|"In each session, participants will be led through the following mindfulness script while using the VR device here is an abbreviated version with excerpts:~Look around. Try to bring yourself to the moment you are in. Notice the presence of the scene around you. How does the air feel against your skin? How do your feet feel against the ground? Where are you? What do you see? Do you hear anything? What do you smell? What do you taste? While you stay seated, imagine you are walking. What body sensations are you experiencing? What thoughts are you having? What emotions are you feeling? At the end of the intervention, participants are asked questions like, What did you notice about your thoughts and mood before, during, and after the VR session? Did you notice a change in how your body felt or your emotions? Was there anything difficult or uncomfortable about the experience that you feel comfortable sharing?"
214421247|NCT02694835|DEVICE|Delefilcon A contact lenses with UV Absorber|
214421248|NCT02694835|DEVICE|Delefilcon A contact lenses|
214421249|NCT05315336|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
214421250|NCT02531568|DRUG|Warfarin|
214421251|NCT02531568|DRUG|MT-3995|
214421252|NCT00622531|DEVICE|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
215020274|NCT01637571|DRUG|Dexilant|60mg of Dexilant QD for 12 weeks
215020275|NCT01637571|DRUG|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
214506549|NCT00511316|DRUG|Montelukast/ Singulair|20 mg daily for six months
214421253|NCT00622531|OTHER|hidden BNP value|no intervention
214421254|NCT04753580|GENETIC|Stool collection|"The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g."
214421255|NCT04563156|DIAGNOSTIC_TEST|Lung Function Test|Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
214421256|NCT02541916|OTHER|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy \& LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
214506550|NCT00511316|DRUG|Placebo|Placebo 20 mg daily for 6 months
214506551|NCT04917185|OTHER|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
215020276|NCT05358912|DRUG|Vasopressor Agent|"Patients will receive vasopressor agents according to Surviving Sepsis Campaign Guidelines 2021"
215020277|NCT05358912|DRUG|Crystalloid Solutions|"Patients will receive crystalloid solutions according to Surviving Sepsis Campaign Guidelines 2021"
215020278|NCT05358912|PROCEDURE|Invasive Blood Pressure Monitoring|Invasive blood pressure monitoring will be performed through an intra-arterial cannula placed in the radial artery. Philips Intellivue mx 500 monitors will be used for bedside monitoring.
215020279|NCT05358912|PROCEDURE|Intra-Abdominal Pressure Monitoring|"IAP will be measured indirectly by monitoring the pressure in the bladder.~Bladder pressure will be measured through an indwelling Foley catheter every twelve hours. Twenty-five mL of sterile normal saline will be injected in each measurement and readings will be recorded with a pressure transducer."
215020280|NCT05358912|OTHER|Abdominal Perfusion Pressure|APP will be calculated with the following formula: (Mean arterial pressure) - (Intra-abdominal Pressure)
215020281|NCT03114644|OTHER|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
215020282|NCT06509074|DRUG|Beta blocker|Pragmatic design. Any beta-blocker with alpha or NO activity may be used
215020283|NCT01206270|DRUG|Testosterone undecanoate|Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
215020284|NCT01206270|DRUG|Castor Oil|4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
215020285|NCT02936271|OTHER|Vasculera|"Vasculera is a specially formulated prescription medical food product. This study compares Vasculera to placebo at reducing post procedural pain, bruising and edema for patients requiring an intervention for lower extremity venous disease.~Patient will be randomized to receive Active Vasculera or Vasculera Placebo. The study product will be taken for two weeks prior to the patient's planned procedure and continued for four weeks after their procedure. If multiple procedures are required the patient will be instructed to use the product throughout treatment."
215020286|NCT02936271|OTHER|Placebo|
215020287|NCT06466252|BEHAVIORAL|Psychometric Group|There are no interventions
215020288|NCT04056637|OTHER|Choice of follow-up option|Participant will be given the opportunity to choose from 3 follow-up options.
215020289|NCT04056637|DEVICE|Multi-level pregnancy test|The Multi-level pregnancy test (MLPT) strategy involves the use of the MLPT to estimate a pregnant person's baseline hCG range prior to beginning their abortion (i.e. prior to mifepristone administration). A follow-up test is then administered one week later to again estimate the woman's hCG range. A decline in hCG range reliably signifies absence of an ongoing pregnancy. Among clients ≤63 days' LMP at initiation of treatment, this strategy has shown to be highly effective: 100% of clients (n=1487/1487) with a decline in hCG range did not have an ongoing pregnancy and 100% of clients (n=21/21) with an ongoing pregnancy showed steady or increase in hCG range on their follow-up MLPT.
215020290|NCT05493345|BEHAVIORAL|Bridge-building between municipality-based lifestyle programs and community-based physical activities|Four co-created bridge-building activities has been implemented in the municipality of Odsherred, including (1) A digital portal for information and sharing of knowledge, (2) Visits between municipal rehabilitation programs and community-based physical activities, (3) Co-created teams for the target group, and (4) a 'Bridge builder' coordinator.
215020291|NCT03511209|BEHAVIORAL|CBTI plus taper method A|This intervention includes CBTI plus the novel hypnotic tapering method.
215020292|NCT03511209|BEHAVIORAL|CBTI plus taper method B|This intervention includes CBTI plus the usual hypnotic tapering method used by the VA.
215020293|NCT06069271|OTHER|Kettlebell swing|The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
215020294|NCT00725231|BIOLOGICAL|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
215020295|NCT00725231|DRUG|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
215020296|NCT01743703|OTHER|diagnostic whole body MRI|diagnostic whole body MRI, both STIR and diffusion weighted
215020297|NCT04011189|PROCEDURE|Videotaping|Before the videotaping, patients will be asked on their baseline pain scores. Their face and body pose from a frontal view will be videotaped via a mobile phone with no internet access. The collected videos will be further processed to extract key points, which will be the primary input for modelling algorithms and will further ensure anonymity of the patients in the video sequences.
215020298|NCT04011189|OTHER|Questionnaires|"Patients will be asked to fill in 1-2 questionnaires before surgery/procedure/consultation (Hospital Anxiety and Depression Scale (HADS) and/or EQ-5D-3L). After surgery/procedure/consultation, patients will be again asked to fill in HADS questionnaire (optional).~For pediatrics patient, only Child Pain Anxiety Symptoms Scale (CPASS) will be administered before the surgery."
215020299|NCT04011189|DEVICE|Empatica E4 wristband|A medical grade wearable device, Empatica E4 wristband, will be used in phase 3 for pediatrics patients to monitor real-time physiological data on heart rate and body temperature.
215020300|NCT05810311|DRUG|Roxadustat|"The group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight \<100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
215020301|NCT05810311|DRUG|Darbepoietin Alfa|"The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
215020302|NCT00068848|BEHAVIORAL|Quick start oral contraceptive initiation|
215020303|NCT06465602|DRUG|Nicotinamide|The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.
215020304|NCT06465602|DRUG|Placebo|The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.
215020305|NCT00829478|BEHAVIORAL|Decision Aid for Atrial Fibrillation|Single contact educational session
215020306|NCT00829478|OTHER|Usual Care|Usual Care
215020307|NCT06565936|RADIATION|PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG|Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.
215020308|NCT04947865|OTHER|Peripheral nerve stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
214421257|NCT04683263|OTHER|Placebo|topical cream with same composition as Intervention but without active ingredients
215020309|NCT04947865|DEVICE|Commercial knee brace|Knee brace used to limit knee mobility in healthy individuals to imitate stroke survivors and measure resulting gait kinematics and surface muscle activity.
215020310|NCT04755062|BEHAVIORAL|Micronutrient-dense plant-rich Intervention|"The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes."
215020311|NCT03163264|BEHAVIORAL|Peer Assisted Lifestyle|Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
215020312|NCT03163264|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
215020313|NCT00447369|DRUG|Pregabalin|
215020314|NCT00447369|DRUG|sodium valproate|
214421258|NCT04683263|OTHER|Fisiocrem|a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
214421259|NCT02482519|OTHER|High calorie diet|High calorie diet for 10 days
214421260|NCT02482519|OTHER|Fasting|10 day fast
214421261|NCT00561886|DRUG|Formoterol|One inhalation of 24µg Formoterol
214421262|NCT01808495|DRUG|Mitomycin C|
214421263|NCT04168619|DRUG|Discontinue methotrexate|According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
214421264|NCT04168619|OTHER|Medication depends on clinical judgement|Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
214421265|NCT00851240|DRUG|BTT-1023|intravenous
214421266|NCT00851240|DRUG|Placebo|Intravenous
214421267|NCT05486260|DIETARY_SUPPLEMENT|DMB lowest dose|Intake of 150 mg of DMB
214421268|NCT05486260|DIETARY_SUPPLEMENT|DMB highest dose|Intake of 300 mg of DMB
214421269|NCT05486260|DIETARY_SUPPLEMENT|Strawberry lyophilisate|Intake of 300 mg of strawberry lyophilisate
214421270|NCT03825133|PROCEDURE|Bone Marrow Aspirate Concentrate|Bone marrow ( 100 ml) is aspirated from proximal tibia, concentrated in Arthrex Angel Centrifuge, and after concentration 6 ml of BMAC is injected in the knee
214421271|NCT03825133|PROCEDURE|Leukocyte Rich Platelet Rich Plasma|Blood sample is taken ( 100 ml), centrifuged in Arthrex Angel Centrifuge and after double spinning process about 6 ml of PRP is injected in the knee
215020315|NCT06323473|DIETARY_SUPPLEMENT|Black Maitake Prothera|Mushroom extract; liquid
215020316|NCT06063031|DIETARY_SUPPLEMENT|Active|Active nutritional supplement plus telerehabilitation
215020317|NCT06063031|OTHER|Placebo|Placebo nutritional supplement plus telerehabilitation
215020318|NCT06003621|BIOLOGICAL|Tiragolumab|600mg IV every 21 days from Cycle 1 Day 1
214506552|NCT01567852|DRUG|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
214506553|NCT01567852|DRUG|Methohexital|Methohexital (1.5mg/kg) will be given for induction
214506554|NCT05606185|PROCEDURE|retraction method|Three dimensional evaluation of root resorption using cone beam computed tomography
214506555|NCT04004520|BEHAVIORAL|Virtual Reality with Meditation|The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
215020319|NCT06003621|BIOLOGICAL|Atezolizumab|1,200mg IV every 21 days from Cycle 2 Day 1
215020320|NCT06054815|DRUG|DA-1241|Route of Administration: Oral, with subjects in a fasting state
215020321|NCT06054815|DRUG|Sitagliptin|Route of Administration: Oral, with subjects in a fasting state
215020322|NCT06054815|DRUG|DA-1241 Placebo|Route of Administration: Oral, with subjects in a fasting state
215020323|NCT06054815|DRUG|Sitagliptin Placebo|Route of Administration: Oral, with subjects in a fasting state
215020324|NCT05685160|DIAGNOSTIC_TEST|MRI with contrast|MRI of the forefoot with contrast (Gadovist)
215020325|NCT05685160|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging of the forefoot
215020326|NCT06585423|DIAGNOSTIC_TEST|Sterile commercially available bandage contact lens|Medical grade acrylic tip covered by a sterile commercially available bandage contact lens
215020327|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness <100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \<100 µm
215020328|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness >100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \>100 µm
215020329|NCT05520762|PROCEDURE|A strategy of first choice supraglottic airway|See description in Arms section
214506556|NCT04004520|BEHAVIORAL|Audio Control|The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
214506557|NCT04004520|BEHAVIORAL|Virtual reality Control|The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
215020330|NCT05520762|PROCEDURE|A strategy of first choice endotracheal intubation|See description in Arms section
215020331|NCT06329336|BEHAVIORAL|Social Emotional Competence for Children and Parents|This preventive parenting intervention combines behavioral parenting and mindfulness-based well-being practices to support effective parenting.
215020332|NCT04453007|BEHAVIORAL|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
215020333|NCT04453007|BEHAVIORAL|Feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
215020334|NCT06157827|DRUG|LBL-024 for Injection|Initial dose-MTD; Q3W; intravenous infusion
215020335|NCT06157827|DRUG|Etoposide Injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
215102561|NCT02647346|DEVICE|Daily use of podimetrics smart-foot mat|
214506558|NCT03792061|BEHAVIORAL|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
214506559|NCT02976363|RADIATION|Radiotherapy breast cancer|
214506560|NCT02976363|OTHER|Evaluation Maximal Respiratory Pressures|
214506561|NCT04809623|DRUG|Edecesertib|Tablets administered orally
214506562|NCT04809623|DRUG|Placebo|Placebo to match edecesertib tablets administered orally
214506563|NCT04809623|DRUG|Standard of Care|Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)
214506564|NCT00217152|DRUG|CellCept|
215020336|NCT06157827|DRUG|Carboplatin Injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
215020337|NCT06157827|DRUG|Atezolizumab injection|Initial dose; Q3W; intravenous infusion
215020338|NCT06157827|DRUG|Cisplatin injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
215020339|NCT05849662|DRUG|Trametinib|"PO or NG QD Days 1-28~For patients age \< 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day"
215020340|NCT05849662|DRUG|Azacitidine|"IV over 30 minutes Days 1-5~Age \< 1 year or weight \<10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day"
215020341|NCT05849662|DRUG|Fludarabine|"IV over 30 minutes Days 6-10~30 mg/m2/day (1mg/kg if \<12 kg)"
215020342|NCT05849662|DRUG|Cytarabine|"IV over 3 hours Days 6-10~2000 mg/m2/day (67mg/kg if \<12 kg)"
215102562|NCT00438594|BEHAVIORAL|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
215102563|NCT04506801|DIETARY_SUPPLEMENT|Probalans senior|Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.
215102564|NCT04506801|OTHER|Placebo|Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention
214421272|NCT03825133|DRUG|Hyaluronic Acid|Three injections of Cartinorm (1% Sodium Hyaluronat (20mg/2 ml) by Goodwill Pharma) is injected in the knee weekly
214421273|NCT04407325|DEVICE|electronic nose device|electronic nose device will be tested as a triage instrument for tuberculosis in a high risk population
214421274|NCT04407325|DEVICE|dig chest Xray with automated readings|software for tuberculosis detection on digital Chest Xray providing a probability score from 0-100
214506565|NCT04012359|DIAGNOSTIC_TEST|Lung ultrasound|Non-invasive external ultrasonography of the chest wall
214506566|NCT04012359|DIAGNOSTIC_TEST|Chest radiography|Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
215020343|NCT02549638|GENETIC|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
215020344|NCT01602666|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
214421275|NCT00369733|DRUG|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
214690098|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
214421276|NCT04298788|OTHER|Blue dishware|blue dishware is used for plates and bowls
214690099|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
214690100|NCT01883934|OTHER|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
214690101|NCT01883934|OTHER|Control|
214690102|NCT05909254|OTHER|Palatally impacted canine exposure using a surgical guide|Under local anaesthesia the tissues covering the palatally impacted canine are removed with the help of a surgical guide to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction.
214690103|NCT05909254|OTHER|Palatally impacted canine exposure using the conventional free.hand method|Under local anaesthesia the tissues covering the palatally impacted canine are removed to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction. The surgeon relies on the surgical plan and their experience to localize the impacted canine.
214690104|NCT03363048|BEHAVIORAL|Restricted|Certain foods and beverages are not allowed to be purchased with food benefit dollars.
214690105|NCT03363048|BEHAVIORAL|Restriction plus Incentive|Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
215020345|NCT01602666|DRUG|Carboplatin|Given IV
214421277|NCT03356665|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT)|The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.
214421278|NCT03356665|DIAGNOSTIC_TEST|Serological and molecular tests on DBS|Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard
214506567|NCT04012359|DIAGNOSTIC_TEST|Pulmonary function tests|Pulmonary function evaluation as part of routine care for emphysematous patients
214506568|NCT04012359|OTHER|Clinical examination|Standard clinical examination performed by investigating physician
214421279|NCT00228007|DRUG|Antidepressant Medication|
214421280|NCT05254769|DEVICE|Neurofeedback Equipment (Cygnet) by BEE Medic GmbH Technologies, Baden-Wurttemberg, Germany.|The EEG NeuroAmp (Electroencephalogram Amplifier) is a user-friendly high-performance interface between client and clinician computer. It can be used in two different functionalities: In an EEG/ERP (Event related potential) measurement and in an EEG biofeedback (neurofeedback) and/or peripheral biofeedback setting.
214506569|NCT00907933|DRUG|SB-705498|0.5mg intranasal SB-705498
214506570|NCT00907933|DRUG|SB-705498|1.5mg intranasal SB-705498
214506571|NCT00907933|DRUG|SB-705498|3mg intranasal SB-705498
214506572|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498
214506573|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498
214506574|NCT00907933|DRUG|Placebo|Placebo '498
214421281|NCT02379299|DEVICE|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
214506575|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498 for 14 days bid
214506576|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498 14 days bid
215020346|NCT01602666|DRUG|Etoposide|Given IV
214421282|NCT02379299|DEVICE|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
214421283|NCT00118768|DRUG|valopicitabine|
214421284|NCT00118768|DRUG|Pegylated Interferon Alfa|
214421285|NCT02180763|BIOLOGICAL|Gammanorm|Sub-Q IgG
214421286|NCT01301716|DRUG|GDC-0980|Oral escalating dose
214506577|NCT00907933|DRUG|Placebo|Placebo
214506578|NCT01752816|BEHAVIORAL|exercise training|
214506579|NCT02027259|BEHAVIORAL|Behavioral activation (BA)|The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
214506580|NCT03863587|BIOLOGICAL|HLX12|healthy volunters receive HLX12 (8mg/kg) once
214506581|NCT03863587|BIOLOGICAL|Cyramza (Ramucirumab)|healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
215020347|NCT01602666|DRUG|Ifosfamide|Given IV
215102565|NCT05840588|DRUG|Antibiotic Treatment|Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid
214421287|NCT01301716|DRUG|bevacizumab|Intravenous repeating dose
214421288|NCT01301716|DRUG|carboplatin|Intravenous repeating dose
214421289|NCT01301716|DRUG|cisplatin|intravenous repeating dose
214421290|NCT01301716|DRUG|paclitaxel|Intravenous repeating dose
214421291|NCT01301716|DRUG|pemetrexed|intravenous repeating dose
214421292|NCT05344326|OTHER|Cognitive Analytic Therapy - Guided Self Help (CAT-GSH)|CAT-GSH is a novel intervention designed to help those with depression by focusing on the relationships within their life. GSH is used in step two of IAPT services and is typically six fortnightly sessions where the PWP helps the service user complete the self help manual.
214421293|NCT02983617|DRUG|Tirabrutinib|Administered orally once daily
214421294|NCT02983617|DRUG|Entospletinib|Administered orally once daily
214421295|NCT02983617|DRUG|Obinutuzumab|Administered intravenously
214506582|NCT00678925|DIETARY_SUPPLEMENT|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
214506583|NCT00678925|DIETARY_SUPPLEMENT|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
214506584|NCT06195449|OTHER|ALKASITE RESTORATIVE MATERIAL|Restorative material for primary teeth
214506585|NCT06195449|OTHER|Glass Ionomer Cement|Restorative material for primary teeth
214506586|NCT00539812|BEHAVIORAL|Standard Care|Standard 40 hour state mandated batterer intervention program
214506587|NCT00539812|BEHAVIORAL|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
214506588|NCT03155100|DRUG|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
214506589|NCT03155100|DRUG|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
214690106|NCT01107275|BIOLOGICAL|rabies vaccine|intradermal vaccination
214690107|NCT02955134|DRUG|Talcid®|Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
214506590|NCT03155100|DRUG|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
214506591|NCT02326506|DEVICE|VA-ELS pump speed variations|Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
214506592|NCT01292213|PROCEDURE|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
214506593|NCT01292213|PROCEDURE|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
215020348|NCT01602666|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214506594|NCT01292213|PROCEDURE|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
214506595|NCT01292213|PROCEDURE|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
214506596|NCT01292213|PROCEDURE|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
214506597|NCT01292213|OTHER|Data collection|Questionnaire completion.
214506598|NCT01782105|BEHAVIORAL|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
214506599|NCT01782105|BEHAVIORAL|Control group|Evaluation of nutritional and physcial activity habits
214506600|NCT01087437|DIETARY_SUPPLEMENT|gastrolith calcium|
215020349|NCT05186077|OTHER|Magnetic Resonance Imaging|Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
215020350|NCT05186077|OTHER|Psychiatric testing|Subjects will be evaluated using psychiatric assessments
215020351|NCT05186077|OTHER|Eye-Tracking|Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
215020352|NCT05186077|OTHER|Neuropsychology Evaluation|The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
215102566|NCT05840588|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium breve PRL2020 treatment|Probiotic Bifidobacterium breve PRL2020
215102567|NCT04494308|OTHER|biomarker identification|flow cytometric analysis of eosinophils membrane molecules
215102568|NCT04772781|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuflex®
215102569|NCT04772781|DRUG|Ibuflex®|Ibuflex® + placebo of S (+) - Ibuprofen
215102570|NCT06536556|OTHER|First Assessment|pre-treatment assessment
215102571|NCT06536556|OTHER|Second Assessment|4 days post-treatment assessment
215102572|NCT00892138|BEHAVIORAL|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
215020353|NCT04227522|DRUG|Rucaparib|A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
215020354|NCT04227522|DRUG|Placebos|Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
215020355|NCT03000166|BEHAVIORAL|Step-Up Intervention|Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
215020356|NCT01861275|DEVICE|Nasal CPAP|Nasal CPAP treatment for obstructive sleep apnoea
215020357|NCT00276003|DRUG|Gemcitabine, Irinotecan, Allopurinol.|Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle
215020358|NCT03923998|DRUG|Neoadjuvant chemotherapy|Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
215020359|NCT03923998|RADIATION|Neoadjuvant radiotherapy|Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
215020360|NCT03923998|PROCEDURE|Resection and reconstruction|Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
215020361|NCT01444924|DRUG|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
215020362|NCT01444924|DRUG|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
215020363|NCT04968600|PROCEDURE|total knee arthroplasty|Posterior-cruciate-ligament is retained in one arm and sacrificed in another arm during total knee arthroplasty
215020364|NCT05091450|BEHAVIORAL|Couple-based I-BMS intervention for infertility|It is based on the previous I-BMS intervention for women undergoing IVF treatment, and aims to improve fertility quality of life and couple flourishing by (1) increasing awareness of the interconnectedness between physical and psychosocial well-being, (2) practicing body-mind-spirit techniques, (3) facilitating personal growth and partner empathy and compassion, and (3) creating the shared meaning of life, family, children. As a strength-focused and meaning-oriented approach, it utilizes experiential and self-reflective exercises to help participants reconstruct the meaning behind their ordeal and rediscover the strengths that keep them going.
215020365|NCT06163807|DRUG|Antiasthmatic|real-life
215020366|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (20 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
215020367|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
215020368|NCT00215657|DRUG|Degarelix|Degarelix 160 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
215020369|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
215020370|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
215020371|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
215020372|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
215020373|NCT00215657|DRUG|Degarelix|Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
215102573|NCT01192828|DRUG|taurine|Take Taurine for 4 1/2 days, two doses per day
215020374|NCT05761496|DEVICE|Biliary stents insertion|Endoscopic placement of plastic and metal biliary stents
215020375|NCT05181735|DRUG|Luspatercept Injection [Reblozyl]|All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg
215020376|NCT05181735|DRUG|Eprex|Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
215020377|NCT03769467|BIOLOGICAL|Tabelecleucel|Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
215020378|NCT03769467|BIOLOGICAL|Pembrolizumab|pembrolizumab IV infusion
215020379|NCT04163315|OTHER|dMRI, fMRI and electrocorticography|Patients included in the study will perform the pre-operative MRI (fMRI and fMRI) with a specific High Resolution Angular Diffusion (HARDI) sequence and a functional rest sequence. The additional scan time for this specific sequence is approximately 25 minutes, with no foreseeable negative impact on the patient
215020380|NCT02614066|BIOLOGICAL|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
215020381|NCT02614066|DRUG|Cyclophosphamide|Administered intravenously.
215020382|NCT02614066|DRUG|Fludarabine|Administered intravenously.
215020383|NCT06029998|DRUG|Bortezomib|sub-cutaneous injection of bortezomib for 6-8 cycles of treatment.
215102574|NCT01867138|DRUG|Cefazolin|
215102575|NCT01867138|DRUG|Vancomycin|
215102576|NCT01867138|DRUG|Amikacin|
214421296|NCT04707729|DIAGNOSTIC_TEST|ROX index algorithm|"The thresholds of the ROX index for intubation are the following:~* After 2 hours of HFNC: ROX \<2.85.~* After 4 and 6 hours of HFNC: ROX \<3.47~* After 8, 10 and 12 hours of HFNC: ROX \<3.85 If the ROX index is between the abovementioned thresholds and 4.88, the NHF support will be also increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done and the ROX index will be recalculated after 30 minutes of full NHF support. The ROX index will be recalculated in 30 minutes: 1) if the ΔROX is \<0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 20 minutes; and 3) if the ΔROX is \>0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration."
215020384|NCT04565756|DRUG|EXN407|EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.
214421297|NCT00831272|DRUG|naltrexone|50mg/day
214506601|NCT02202317|DEVICE|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
214421298|NCT00831272|DRUG|Placebo|Placebo
214421299|NCT05380791|OTHER|Follow-up visits|Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
214421300|NCT02698891|DRUG|Paclitaxel|
215020385|NCT02096159|DRUG|trimethoprim-sulfamethoxazole|
215020386|NCT02096159|OTHER|placebo|
215020387|NCT03568058|DRUG|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
215020388|NCT03568058|DRUG|Pembrolizumab|200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
215020389|NCT04274218|OTHER|Perturbation|Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
215020390|NCT04943068|DRUG|Bremelanotide|Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
215020391|NCT04943068|DRUG|Placebo|Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
215020392|NCT06521736|DEVICE|AAC-BCI device|Participants without speech and severe movement disorders will be trained on the augmentative and alternative communication, brain-computer interface (AAC-BCI) system, using it for at least 10 hours per week in their homes for communication and other control functions. Participants will have daily support for using the AAC-BCI from trained caregivers along with intervention support from consultants and speech language pathologists.
215020393|NCT06017128|OTHER|sexual counseling based on the PLISSIT model|In the initial follow-up, the experimental group will receive information about total hip replacement surgery and its impact on sexual life based on the PLISSIT model. An educational booklet containing information about total hip replacement surgery, the rehabilitation process, and post-operative sexual life will also be prepared and distributed. In the second follow-up (5-7 days after surgery), the experimental group will be provided with information about home care before discharge and returning to sexual life.
214421301|NCT02698891|DRUG|Neulasta|
214421302|NCT00516386|DRUG|RhIGF-1|35-40 mcg/k/dose twice daily SC
214421303|NCT05245825|OTHER|Flaxseed|A total of 30 g of ground flaxseed per day divided into two portions of 15 grams each, subjects will be asked to take 15 g in the morning and 15 g in the night dissolved in 400 ml of water. They will receive a dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates.
214506602|NCT02718196|BEHAVIORAL|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
215020394|NCT01331330|DEVICE|Deep Brain Stimulation|Normal DBS Programming
215020395|NCT01331330|DEVICE|Deep Brain Stimulation|Low Programming
215020396|NCT05226884|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance and intermediate visual acuity at variety targeted correction.
215020397|NCT05226884|DIAGNOSTIC_TEST|Defocus Curve|Measurement of a defocus curve
215020398|NCT03069937|DRUG|Docetaxel|The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
215020399|NCT03069937|DRUG|Degarelix|Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.
215020400|NCT05026632|DRUG|NPI-002 Intravitreal Implant|Implant inserted during vitrectomy.
215020401|NCT05614336|BIOLOGICAL|Blood sample|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
215020402|NCT02370862|DRUG|Neostigmine and Glycopyrrolate|
215020403|NCT01205308|DIETARY_SUPPLEMENT|Vegetable oil based margarine with plant stanol ester enrichment|3 g plant stanols/ day
215020404|NCT06122545|PROCEDURE|Greater Occipital Nerve Block|"Patients will receive Greater Occipital Nerve Block (GONB) either with local anesthetic (bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.~Ultrasound-guided GONB will be performed to more accurately locate the nerve through searching for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process and injection will be done medial to the artery"
215020405|NCT06122545|OTHER|Medical Treatment|Patients who will receive medical treatment
215020406|NCT06122545|DRUG|bupivacaine or onabotulinum toxin A injection.|bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.
214421304|NCT05245825|OTHER|Dietary plan|Dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates, controlled consumption of alpha-linolenic acid (no more than 6.8 g/day, the amount provided by 30 g of flaxseed).
214421305|NCT05539755|PROCEDURE|Non surgical debridement of peri-implantitis|"The procedure was standardized as follows: the implants' prosthesis was checked for its cleansability, and retrieved when possible. Then, the prosthesis was modified following a previously described elsewhere (de Tapia et al., 2019). After local anaesthesia (articaine 4% and adrenaline 1:100,000), the implant surfaces were cleaned with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the steel alloy H3 dental ultrasonic scaler tip (H3, Satelec Acteon; Olliergues, France), curettage (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) of the bone defect was performed, and glycine air powder applied submucosally (Air-flow® powder subgingival PERIO, EMS; Nyon, France) with an air-flow piezon device (Air-flow master piezon®, EMS, Nyon; France).~Oral hygiene instructions were given and metronidazole 500 mg every 8 h for 7 days was prescribed. Patients were scheduled at 3 months for supragingival plaque control and supragingival debridement, if needed."
214421306|NCT00781378|DRUG|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
214421307|NCT00781378|DRUG|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
214421308|NCT01180088|PROCEDURE|RIGHT HEPATECTOMY WITH CLASSIC APPROACH|The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
214421309|NCT03231722|DRUG|Panitumumab|6 mg/kg iv over 60 minutes, day 1
214421310|NCT03231722|DRUG|Irinotecan|150 mg/sqm iv over 60 minutes day 1
214421311|NCT03231722|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
214421312|NCT03231722|DRUG|l-leucovorin|200 mg/sqm iv over 2 hours
214421313|NCT03231722|DRUG|5-fluorouracil|400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
214421314|NCT02560649|DRUG|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
214421315|NCT02560649|DRUG|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
214421316|NCT02560649|DRUG|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
214421317|NCT02560649|DRUG|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
214421318|NCT02560649|DRUG|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
214421319|NCT02560649|DRUG|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
214421320|NCT02560649|DRUG|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
214421321|NCT02560649|DRUG|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
214506603|NCT05374694|DIAGNOSTIC_TEST|Physiological invasive coronary evaluation|Performance of FFR, IMR and acetylcholine test (Only patients in groups 3 and 4 will undergo the acetylcholine test)
214506604|NCT04886466|PROCEDURE|core stability in a sitting position and while walking in one place|The intervention consisted of checking how the active tension of the multisection and transverse abdominal muscles affects the pattern of the trunk movement (in the sitting position) and the work of the lower limbs and the speed of movement while walking in a place.
214694081|NCT05414617|DEVICE|Intra-articular three injections|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15."
215020407|NCT03640624|COMBINATION_PRODUCT|Multidisciplinary treatment|"1. Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~2. Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~3. Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients."
215020408|NCT03640624|COMBINATION_PRODUCT|Treatment as usual|Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 - 6 months)
215020409|NCT03985995|DRUG|CBD 800 mg p.o|cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
215020410|NCT03985995|DRUG|Placebo p.o|single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
215020411|NCT00642265|PROCEDURE|osteosynthesis|operative treatment
215020412|NCT00642265|OTHER|sling|conservative treatment
215020413|NCT05248243|PROCEDURE|Recruitment assessment|"Intervention Details:~Construction of the P/V curve with subsequent measurement of HR and Vmax."
215020414|NCT02390388|PROCEDURE|pudendal nerve block|nerve stimulator-guided Pudendal block
215020415|NCT02390388|PROCEDURE|caudal block|caudal block
215020416|NCT03003897|OTHER|Soluble Fiber|Participants receiving soluble fiber.
215020417|NCT03003897|OTHER|Placebo|Participants receiving placebo.
215020418|NCT00968968|DRUG|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
215020419|NCT00968968|BIOLOGICAL|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
214421323|NCT00255281|DRUG|AZD7009, no generic name available|
214506605|NCT00764166|DRUG|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:~* To D1 of every cycle in the dose of 70 mg/m²,~* Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
214506606|NCT00764166|DRUG|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
214506607|NCT02522598|DRUG|VVZ-149 injections|Colorless, transparent liquid in water for injection
214694082|NCT04599205|DRUG|Tranexamic acid|fractional co2 laser, microneedling and topical tranexamic acid gel
215020420|NCT06150443|OTHER|Osteopathic manipulative treatment (OMT)|Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.
215020421|NCT06150443|OTHER|Conservative treatment|Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical therapy will be excluded from the conservative therapy regimen.
215020422|NCT04488094|DRUG|[18F]FSPG|A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of \[18F\]FSPG.
215020423|NCT02874352|DEVICE|high resolution impedance manometry with Automated Impedance Manometry analysis|
215020424|NCT04085003|PROCEDURE|Endovascular repair or Open surgery|The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
215020425|NCT00622063|DRUG|ARQ 501|Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received
215020426|NCT03409458|DRUG|PT-112|"The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15."
215020427|NCT03409458|BIOLOGICAL|avelumab|Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.
215020428|NCT03624036|BIOLOGICAL|brexucabtagene autoleucel|CAR-transduced autologous T cells administered intravenously
215020429|NCT03624036|DRUG|Fludarabine|Administered intravenously
215102577|NCT04515108|OTHER|Clinical assessment|Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.
215102578|NCT03822000|OTHER|Survival|Elderly patients with fall-induced femoral fracture who were survived.
215020430|NCT03624036|DRUG|Cyclophosphamide|Administered intravenously
215020431|NCT01185366|DRUG|Everolimus|10 mg by mouth once a day.
215020432|NCT01185366|DRUG|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
215020433|NCT03466164|BEHAVIORAL|Mindfulness Based Stress Reduction Program|8 week, 10-session course of mindfulness training
215020434|NCT02668419|DEVICE|Neuromuscular Electrical Stimulator|"Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min."
215020435|NCT02668419|OTHER|Physical Therapy Session|each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure \>15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as \>200 mmHg; 6) a rise in diastolic blood pressure during exercise \>110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
215102579|NCT03822000|OTHER|Death|Elderly patients with fall-induced femoral fracture who were dead.
215102580|NCT02103972|DIETARY_SUPPLEMENT|GM080|
214421324|NCT00818454|DRUG|Combivent CFC MDI|
214421325|NCT00818454|DRUG|Albuterol HFA MDI|
214421326|NCT00818454|DRUG|Respimat Combivent|
214421327|NCT03848910|DEVICE|Investigational device - Sound Processor|"At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator."
214421328|NCT04763044|DRUG|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
214421329|NCT04763044|DRUG|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
214506608|NCT02522598|DRUG|Placebo|water for injection
215102581|NCT02103972|DIETARY_SUPPLEMENT|Maltodextrin|
215102582|NCT00855972|DRUG|Low Dose Naltrexone|
215102583|NCT00820222|DRUG|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
215102584|NCT00820222|DRUG|lapatinib|oral medication; daily dose taken once a day
214421330|NCT04763044|DRUG|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
214421331|NCT04763044|DRUG|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
214421332|NCT04763044|DRUG|1100 ppm SnF2|Each subject will be assigned to this treatment during the fifth period for this crossover study.
214421333|NCT01171625|DEVICE|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
214506609|NCT06031818|OTHER|The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will fill in a questionnaire to evaluate the usability of the interpretable framework.
214506610|NCT06031818|OTHER|The model prediction|The radiologist and clinicians will be provided the model prediction results without the explanation of the model and they will be asked to give their own prediction.
214506611|NCT06031818|OTHER|The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will be asked to give their own prediction.
214506612|NCT01115036|DRUG|panobinostat|Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
214506613|NCT02808234|PROCEDURE|One or two level lumbar interbody fusion surgery|One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
214506614|NCT02808234|OTHER|Nucel|Allograft derived from human amnion and amniotic fluid
214690108|NCT02955134|DRUG|Chinese medicine prescription|"The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks."
214690109|NCT02955134|DRUG|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
214690110|NCT02955134|DRUG|Compound Azimtamide Entieric-coated Tablets|Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
214690111|NCT02648958|DRUG|Dexmedetomidine|The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
214506615|NCT02177825|DRUG|Imatinib Mesylate|oral administration
214506616|NCT00856687|DRUG|PF-03893787|Oral, two doses 12 hours apart
214506617|NCT00856687|DRUG|Placebo|Oral, two doses 12 hours apart
214506618|NCT00856687|DRUG|Montelukast|Oral, two doses 12 hours apart
214690112|NCT02648958|DRUG|normal saline|The control group received the normal saline infusion
214690113|NCT02622100|DEVICE|Bioresorbable Vascular Scaffold|
215020436|NCT02544724|BIOLOGICAL|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
215020437|NCT02708706|DRUG|hyaluronic acid (hyruan)|2cc hyaluronic acid
215020438|NCT02708706|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
215102585|NCT00820222|DRUG|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
214421334|NCT02218502|OTHER|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
214421335|NCT02218502|OTHER|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
214421336|NCT02218502|OTHER|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
214506619|NCT05610566|DEVICE|the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System|The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a subannular implant (SAI), and their delivery systems and accessories. The TMV is a 28mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI), comprising a ring (made of polycarbonate urethane (PCU), nitinol, gold markers and polyester (Dacron) to be placed around the mitral valve apparatus to stabilize the position of the mitral valve implant.
214506620|NCT02638506|DRUG|Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
214506621|NCT02638506|OTHER|Salinex|All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
214506622|NCT01888991|OTHER|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
214506623|NCT04714346|OTHER|no interventions|there is no intervention
214506624|NCT00495144|DRUG|TH-302|
214690114|NCT03484923|DRUG|PDR001|400 mg of PDR001 administered every 4 weeks intravenously
215020439|NCT01514175|DRUG|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
215020440|NCT01514175|DRUG|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
215102586|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
215020441|NCT03799120|DRUG|Tamsulosin BID|comparison of once daily versus twice daily tamsulosin
215020442|NCT03799120|OTHER|Placebo|Placebo
214421337|NCT02218502|OTHER|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
214421338|NCT00795054|OTHER|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
214421339|NCT03411278|DEVICE|Deep Oscillation (DO)|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2).The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
214421340|NCT02345018|PROCEDURE|Mechano-chemical ablation|Treatment with mechano-chemical ablation
214421341|NCT01149395|DRUG|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
214506625|NCT06234020|OTHER|To see the frequency of vertebrospinal anomalies in patients presenting with Anorectal Malformation|The patients presenting with anorectal malformation go through x-ray. We will get the reporting of x-ray done to see the vertebral anomalies and the patients presenting with fecal/urinary incontinence will go through MRI for spinal anomalies.
214506626|NCT03372252|DEVICE|Electroencephalography|Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
214506627|NCT01005615|DEVICE|Non-FES Upper Extremity Exercise|While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.
214506628|NCT01005615|DEVICE|RT300-SLSA, from Restorative Therapies, Inc.|They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
214506629|NCT01014299|OTHER|Recruitment maneuver|"Assigned interventions:~* No intervention after tracheal intubation (control group)~* Alveolar recruitment maneuver (RM group) immediately after intubation"
214690115|NCT03484923|DRUG|LAG525|600 mg of LAG525 administered every 4 weeks intravenously
215020443|NCT04049565|DIAGNOSTIC_TEST|Procalcitonin biomarker and CRP biomarker|collecting blood samples to measure serum CRP and Procalcitonin
214421342|NCT01376089|DRUG|Iodixanol|Iodixanol 320 mg I/mL as a single iv. administration.
214421343|NCT01376089|DRUG|Iopamidol|Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
214690116|NCT03484923|DRUG|INC280|400 mg of INC280 administered twice daily orally
215020444|NCT02774278|DRUG|Erlotinib|Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
214421344|NCT00549848|DRUG|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
214421345|NCT00549848|DRUG|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
214421346|NCT03854253|PROCEDURE|Long introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-25cm
214421347|NCT03854253|PROCEDURE|Short introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-10cm
214421348|NCT04827654|DIETARY_SUPPLEMENT|Weekly produce box and gift card|Weekly box of produce (5-10 lbs) and $10.00 gift card to a local grocery store to purchase preferred produce. If progress on self-goals completed, an additional $10.00 card provided, weekly, for 3 weeks.
214421349|NCT03262935|DRUG|(vic-)trastuzumab duocarmazine|Intravenous SYD985, Q3W
214421350|NCT03262935|DRUG|Physician's choice|See drug label
215020445|NCT01691313|DRUG|Vanoxerine|single oral dose
215020446|NCT01691313|DRUG|Placebo|single oral dose
215020447|NCT05644509|BIOLOGICAL|Oncolytic Virus Injection（Revottack）+PD-1|Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
215020448|NCT05662943|DRUG|Intravitreal aflibercept injection|Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
215020449|NCT05673850|DRUG|NET or NCT|In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
215020450|NCT00408447|DRUG|Busulfan|Busulfan 4 mg/kg/d x 4d
215020451|NCT00408447|DRUG|Fludarabine|Fludarabine 30 mg/m2/d x 6d
215020452|NCT00408447|DRUG|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
215020453|NCT00408447|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
215020454|NCT02122523|PROCEDURE|Near-Infrared (NIR) dye Indocyanin Green (ICG)|
215029119|NCT05703126|DIAGNOSTIC_TEST|laser Doppler flowmetry|Before the start of the treatment and after each course of chemotherapy: Examination of microcirculation by laser Doppler flowmetry using the LAKK-OP apparatus (NPP Lazma, Moscow, 2011) with respiratory and occlusion tests.
215029120|NCT04605276|OTHER|No intervention|No intervention
215029121|NCT01696565|DRUG|PG2|Injectable
215029122|NCT05284617|DRUG|HU6|HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).
215029123|NCT05284617|DRUG|Placebo|Placebo
215020455|NCT01538407|OTHER|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
214421351|NCT03621826|OTHER|Questionnaire/Interview|A convenience sample of patients/parents and stakeholders will be asked to participate in a survey and/or interview to evaluate barriers to care in sickle cell.
214506630|NCT02085512|PROCEDURE|Neurocognitive retraining Web Based Intervention|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
215020456|NCT01312675|DEVICE|S.A.F.E.BT|Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
215020457|NCT00065546|OTHER|Estrogen plus choline depletion diet|Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.
215020458|NCT00065546|OTHER|Placebo plus choline depletion diet|Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.
215020459|NCT00065546|OTHER|Pre-menopausal women with SNPs given a low choline diet|Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.
215020460|NCT02449577|OTHER|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
215020461|NCT02449577|OTHER|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
215020462|NCT02449577|OTHER|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
215020463|NCT02449577|OTHER|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
215102587|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
214421352|NCT00307463|PROCEDURE|strict volume control policy|strict volume control by UF and dietary salt restriction
214421353|NCT00307463|PROCEDURE|antihypertensive drugs administration|continue antihypertensive medications
214421354|NCT01060514|DRUG|Pazopanib|dose escalation, administered orally, daily
214421355|NCT01060514|DRUG|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
214421356|NCT01811706|DRUG|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
214421357|NCT01811706|DRUG|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
214506631|NCT02085512|OTHER|Control, web-based tasks|No training modules
214506632|NCT02976272|OTHER|bortezomib|
214506633|NCT05781932|PROCEDURE|Dermal barb suture combined with medical glue|In the experimental group, after tension reduction and suture were completed, the wound and surrounding skin were wiped clean with normal saline and clean gauze, and the blood accumulated in the wound was squeezed out. Histoacryl medical tissue glue (specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4\[(toluene)amino\]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)) were evenly spread on the surgical incision and kept in the butt state for 4 to 6 seconds. After it got solidify and dry, a sterile gauze covered the surgical incision. There was no need to disinfect and change the dressings after the operation. Patients can shower normally on the day after the operation by just avoiding rubbing the incision covered with glue. Patients can move normally 1-2 days after the operation, and the glue film falls off on its own within 5-10 days.
214506634|NCT00647075|DIETARY_SUPPLEMENT|Yunzhi extract|3.5 g/day
214506635|NCT00647075|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
214506636|NCT04638049|OTHER|Collection of human biofluids|Feces, blood and urine: (1) shortly before, (2) during and (3) shortly after RT treatment, as well as (4) one-month post-RT
214506637|NCT04638049|OTHER|Patient reported outcome measures|EORTC QLQ-C30, PR25: (1) shortly before and (2) shortly after RT treatment, as well as (3) one-month post-RT
214421358|NCT06068439|DRUG|Acetylsalicylic Acid|aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
214421359|NCT06068439|DRUG|Placebo|Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
214421360|NCT04674436|BEHAVIORAL|Walking|6 minute casual walk
214421361|NCT03901937|DRUG|ω-3 polyunsaturated fatty acid|CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
214421362|NCT03901937|PROCEDURE|Intestinal surgery for Crohn's Disease|Patients receive bowel resection due to complications of Crohn's Disease
214506638|NCT00706888|DIETARY_SUPPLEMENT|Vitamins B6, B9 and B12 and polyphenols|
214506639|NCT00706888|DIETARY_SUPPLEMENT|placebo|
215020464|NCT02449577|OTHER|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
215020465|NCT02449577|OTHER|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
215020466|NCT02449577|OTHER|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
215020467|NCT02449577|OTHER|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
215020468|NCT02449577|OTHER|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
215020469|NCT02449577|OTHER|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
215020470|NCT02449577|OTHER|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
215020471|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
215020472|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
214690117|NCT03484923|DRUG|ACZ885|200 mg of ACZ885 administered every 4 weeks subcutaneosuly
215020473|NCT00127933|DRUG|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
215020474|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
214421363|NCT05761834|OTHER|Sample blood and 2D-echocardiography with Doppler|Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.
214506640|NCT03510195|OTHER|MEDICORP HO PREPARATORY MODULE|3 DAY course module to prepare medical graduates to become house officers
214506641|NCT00927706|DEVICE|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
214690118|NCT03484923|DRUG|LEE011|600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
214690119|NCT03165357|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|
214506642|NCT05818852|DRUG|VX-548|Tablets for oral administration.
214506643|NCT05818852|DRUG|Moxifloxacin|Capsules for oral administration.
214690120|NCT03165357|DIETARY_SUPPLEMENT|Placebo treatment|
214690121|NCT06198049|OTHER|Pilates Training|This group will receive Pilates training General rehabilitation exercises. Balance and strengthening exercises. Stretching exercises will be performed.Each exercises will be performed with ten repetition for three sessions per week
214506644|NCT05818852|DRUG|Moxifloxacin Placebo|Capsules for oral administration.
214506645|NCT05818852|DRUG|VX-548 Placebo|Tablets for oral administration.
214506646|NCT03031509|BIOLOGICAL|Human Amniotic Epithelial Cells|Human Amniotic Epithelial Cells transplant after debridement
214690122|NCT06198049|OTHER|Balance Proprioception Exercises|This group will receive balance Proprioception exercises. The training program will consist of 14 basic exercises on and off the balance board, with variations on each exercise. Mat walking time per session increased from 6 to 12 min during the acclimation period of the first two sessions and progressed gradually but incrementally to a maximum of 20 min per session over the 12 ensuing sessions.
214506647|NCT03031509|PROCEDURE|debridement|debridement
214690123|NCT01337531|DRUG|Gonal-F, Fostimon|dosage form
214690124|NCT01337531|DRUG|Gonal-F, Fostimon|injection, daily, 10-15 days
214690125|NCT02123160|BEHAVIORAL|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
215020475|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
214421364|NCT00480662|DRUG|alendronate|Duration of Treatment : 6 Months
214421365|NCT00354640|DRUG|anastrozole|1 milligram tablet PO QD for 14 days
214421366|NCT00354640|DRUG|simvastatin|40 milligram tablet PO QD for 14 days
214421367|NCT00354640|OTHER|pharmacological study|laboratory analysis
214421368|NCT00354640|PROCEDURE|adjuvant therapy|laboratory analysis
214421369|NCT00316641|DRUG|Lipid-lowing Tea|
214421370|NCT02894151|DRUG|Depot medroxyprogesterone acetate|
214421371|NCT02894151|DEVICE|LNG-IUS|
214421372|NCT00753012|DRUG|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
214506648|NCT05701579|PROCEDURE|"ACL decompression"|"The technique of ACL decompression by the means of longitudinal incisions and evacuation of extrafibrous mucoid tissue."
215029124|NCT05253196|DEVICE|Use of the foley catheter assistive device|All participants will use the foley catheter assistive device when performing their daily enema
215029125|NCT01802346|DIETARY_SUPPLEMENT|dietary intervention|Consume a low-calorie diet
215029126|NCT01802346|PROCEDURE|nutritional support|Receive dietary advice
215029127|NCT01802346|OTHER|laboratory biomarker analysis|Correlative studies
215029128|NCT03037749|DRUG|Alcohol beverage|Alcohol beverage measured to have participant achieve a BAC of 0.08%
215029129|NCT03037749|DRUG|Placebo beverage|Placebo beverage measured to mimic the smell and taste of the alcohol beverage.
215029130|NCT01953159|OTHER|Blood Collection|
215029131|NCT01953159|OTHER|Patient Questionnaires|
215029132|NCT03314428|BEHAVIORAL|Gait retraining|Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
215029133|NCT05421494|BEHAVIORAL|written exposure therapy-revised version|WET-R is a manualized exposure-based therapy program consisting of 5-7 sequential individual sessions. The interval between every 2 consecutive sessions is 0-3 days. There will be 5-7 one to one online sessions in total (only one index trauma will be discussed), and 1-3 weeks to complete. Sessions are scheduled to last for 1 hour in the first session and 50 minutes in other sessions.
214421373|NCT06373744|DRUG|cyclophosphamide , methotrexate , vinorelbine ,capecitabine|The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
214421374|NCT01367483|DRUG|IV methylnaltrexone (MNTX)|
214421375|NCT05662891|OTHER|Blood Flow Restriction|After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.
214421376|NCT00221637|DRUG|Sodium Valproate|
214421377|NCT03060642|DEVICE|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
214421378|NCT03060642|DEVICE|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
214421379|NCT05603520|OTHER|Collection of Clinical Data|prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms
214421380|NCT02329613|OTHER|Standard evening meals.|Patients will receive usual evening meals.
214421381|NCT02329613|OTHER|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
214421382|NCT02383108|DRUG|DTG +DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
214421383|NCT02383108|DRUG|SOC|Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
215020476|NCT03580187|DRUG|Morphine (+)|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still\> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. After 30 minutes, if VAS still\> 4, we concluded to a failure of morphine nebulization.~The patients were divided into two groups:~morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization"
215020477|NCT01101555|DRUG|subcutanious administration|drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
215020478|NCT01101555|OTHER|Placebo|Placebo will be given to one member of each cohort.
215020479|NCT02422901|DRUG|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
215020480|NCT00881244|DRUG|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
215020481|NCT01339013|DEVICE|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
215102588|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
215102589|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
214421384|NCT04136639|OTHER|Miswak|sticks
214421385|NCT04136639|OTHER|Grape Seed Extract Mouthwash|Mouthwash
214421386|NCT04136639|OTHER|fluoride|mouthwash
214506649|NCT06293066|DIAGNOSTIC_TEST|Ultrasound|Usefulness of transvaginal ultrasound
214506650|NCT01235520|DRUG|Placebo|Oral doses, once a day for 52 weeks
214506651|NCT01235520|DRUG|RO4917838|Oral dose level 1, once a day for 52 weeks
214506652|NCT01235520|DRUG|RO4917838|Oral dose level 2, once a day for 52 weeks
214506653|NCT05647759|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will aim to complete 150 minutes of moderate-intensity exercise a week with the help of a virtual exercise coach
214421387|NCT05575869|OTHER|(online) PRONEtect educational material|This is a website containing educational material like short simulation videos on how to turn a patient from supine-to-prone and prone-to-supine positioning, how to protect the skin from incontinence, or before securing endotracheal-/nasogastric tubes, how to reposition the patient to prevent pressure injuries, a full protocol regarding prone positioning etc.
214421388|NCT05575869|OTHER|Classic (normal) one hour lesson/lecture|As per normal, a classroom lecture given by the nursing school by one of the nursing school lecturers.
214421389|NCT00242190|DRUG|oxaliplatin|
214421390|NCT00242190|DRUG|gemcitabine|
214421391|NCT00242190|PROCEDURE|radiation therapy|
214421392|NCT04277299|DEVICE|IcorySolution|The ICory-solution programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery. The healthcare professional have received face-to-face training on how to use the BuddyCare dashboard and BuddyCare has been in the hospital in earlier studies.The Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support, games and distraction to children and a virtual tour to the hospital before children´s operation.
214421393|NCT00002555|DRUG|cisplatin|
214421394|NCT00002555|RADIATION|low-LET cobalt-60 gamma ray therapy|
214506654|NCT02434276|BIOLOGICAL|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
214506655|NCT02434276|BIOLOGICAL|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
215020482|NCT01783938|BIOLOGICAL|Nivolumab|
215020483|NCT01783938|BIOLOGICAL|Ipilimumab|
215020484|NCT01872936|DRUG|Miravirsen|
215020485|NCT01872936|DRUG|Telaprevir|
215020486|NCT01872936|DRUG|Ribavirin|
215020487|NCT04324489|DRUG|DAS181|Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
215020488|NCT00211900|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine|single IM dose totalling 200 mcg of conjugate
215102590|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
214421395|NCT00002555|RADIATION|low-LET electron therapy|
215020489|NCT00066937|DRUG|Nortriptyline Oral Capsule|Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.
214421396|NCT00002555|RADIATION|low-LET photon therapy|
215102591|NCT01742689|DRUG|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
215102592|NCT01742689|DRUG|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
214506656|NCT03263117|DRUG|Sedation|"The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist."
214690126|NCT02123160|BEHAVIORAL|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
214421397|NCT03767257|DRUG|Colesevelam Pill|For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
214421398|NCT00298649|BEHAVIORAL|Lay Health Advisor|
214421399|NCT02507336|DRUG|Thalidomide|100-300 mg capsule taken by mouth once daily.
214421400|NCT00727038|DRUG|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
214421401|NCT02760381|DEVICE|NBI + Acetic Acid (AA)|Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
214690127|NCT04341675|DRUG|Sirolimus|Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.
214690128|NCT04341675|DRUG|Placebo|Matching placebo
215102593|NCT01742689|DRUG|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
214421402|NCT02562911|PROCEDURE|Data collection|"* Clinical examination~* Complete pelvic ultrasound abdominal ultrasound~* Bone age: X-ray~* biological examination~* Lung function assessed by the Maximum Volume Expired~* Brasfield radiological score (if available)"
214421403|NCT04353674|DEVICE|Control group|Patients randomized into this group will receive standard of care for COVID-19 infection
214421404|NCT04353674|DEVICE|SLEDD with a L-MOD|Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
214421405|NCT00319085|PROCEDURE|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
214421406|NCT03801551|DIAGNOSTIC_TEST|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
214421407|NCT05966779|OTHER|modified CDT physical therapy protocol, based on Godoy's Method|modified CDT physical therapy protocol
214421408|NCT03175913|DEVICE|vapocoolant spray|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
215020490|NCT00066937|DRUG|Benztropine Oral Product|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
215020491|NCT00066937|BEHAVIORAL|CBT|Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.
215102594|NCT00590577|DRUG|Paliperidone palmitate 25 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
215102595|NCT00590577|DRUG|Paliperidone palmitate 150 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
215102596|NCT00590577|DRUG|Placebo|Placebo i.m. Days 1, 8, 36, 64
215102597|NCT00590577|DRUG|Paliperidone palmitate 100 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
215102598|NCT01229449|DRUG|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
215102599|NCT01229449|DRUG|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
215102600|NCT01229449|DRUG|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
215102601|NCT01229449|DRUG|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
215102602|NCT01229449|DRUG|Placebo|Two placebo tablets, single dose taken orally with 300 ml water
215102603|NCT05105867|BIOLOGICAL|Anti-CD19 Universal CAR-T Cells injection|Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion.
215102604|NCT02307162|DRUG|RPL554|Phosphodiesterase 3 and 4 Inhibitor
215102605|NCT02307162|DRUG|Placebo|Dummy solution
215102606|NCT01784718|DRUG|Buphenyl|
214421409|NCT03175913|DRUG|local infiltration|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
214421410|NCT03009006|DRUG|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
214421411|NCT03009006|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
214506657|NCT03263117|DRUG|General Anesthesia (GA)|"The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)"
214506658|NCT03263117|PROCEDURE|Intra-arterial Thrombectomy|The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
214506659|NCT02867579|BEHAVIORAL|"evaluation of the child quality attachment (Strange situation)"|
214506660|NCT06462781|DRUG|Lidocaine hydrochloride|Intra-arterial injection of 40mg lidocaine per middle meningeal artery (total 2 arteries) administered one time
214506661|NCT06462781|DRUG|Methylprednisolone sodium succinate|Intra-arterial injection of 20mg methylprednisolone per middle meningeal artery (total 2 arteries) administered one time
214506662|NCT01450007|DRUG|Ropivacaine|25 ml ropivacaine 0.5%
214506663|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (perineural)
214506664|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
214506665|NCT01450007|DRUG|Normal saline|5 ml normal saline (intravenous)
214506666|NCT01450007|DRUG|Normal saline|0.8 ml normal saline (perineural)
214506667|NCT04039646|COMBINATION_PRODUCT|ERAS treatment|The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
215102607|NCT03327558|DRUG|Apriso 0.375G ER CAP|ER capsule
215102608|NCT03327558|DRUG|APRISO 375 mg extended-release capsules|375 mg extended-release capsules
215102609|NCT00212706|DRUG|ONO-8025 (KRP-197)|
215102610|NCT03070821|OTHER|rtfMRI neurofeedback training|Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
215102611|NCT03070821|DEVICE|3T MRI|A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
215102612|NCT00288262|DRUG|melatonin 0.5 mg|
215102613|NCT02722707|DEVICE|magnetic anal sphincter augmentation for fecal incontinence|Surgical placement of HUD called FENIX for female patients that have failed conservative therapy and less invasive therapies or who are not candidates for such therapies
215102614|NCT02555384|OTHER|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
215102615|NCT02555384|OTHER|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
214421412|NCT03900819|OTHER|dexterity measurement|4 non-invasive tests will be performed
214421413|NCT06167265|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
214421414|NCT06167265|DRUG|PMR Tablet 145 mg|Single oral dose (total daily dose of 290 mg)
214506668|NCT03851458|BEHAVIORAL|Initial in-person individual diet and exercise counseling (N vs. Y)|Individual counseling utilizing MI has been effective in promoting behavioral change.18 A SANOS interventionist (MRNY promotora) will deliver a 45-60 minute counseling session, utilizing MI techniques, on diet and exercise, and how to stretch one's food dollars (see description of 10 modules described above under COMIDA Pilot). The promotora will evaluate the participant's diet based on the 24-hour dietary recall132 conducted at intake (see below), will compare diet composition to the USDA's MyPlate guidelines, and will then personalize education to address identiﬁed knowledge gaps and unhealthy food choices. Promotoras will focus on goal-setting, problem solving, selfeﬃcacy enhancements, selfmonitoring skills (i.e., participants will be taught how to monitor their diet, weight, and physical activity (PA), with simple pencil-and-paper logs or with 'Self-monitoring tools' if randomized to also receive that component), and modeling of healthy behaviors.
214690129|NCT02391090|DEVICE|hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
214690130|NCT02391090|DEVICE|sham hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
214690131|NCT02391090|PROCEDURE|Pulse oximetry|Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.
214690132|NCT02391090|OTHER|Asthma and Quality of Life Questionnaires|Before every session in the hypoxic chamber as well as on the day after the last session will be completed.
215102616|NCT05593627|DRUG|Lithium Carbonate 250 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 250mg lithium carbonate
215102617|NCT05593627|DRUG|Calcium Carbonate 500 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 500mg calcium carbonate
215102618|NCT01802307|RADIATION|Brachytherapy|
215020492|NCT00066937|BEHAVIORAL|Disease MGT|Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
215102619|NCT02229526|DIETARY_SUPPLEMENT|Low dose fish oil|Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
215102620|NCT02229526|DIETARY_SUPPLEMENT|Low dose olive oil|Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
215102621|NCT02229526|DIETARY_SUPPLEMENT|High dose fish oil|Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
214421415|NCT03895788|DRUG|niraparib|Niraparib will be administered as a flat-fixed dose (100mg or 200 mg, daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
214421416|NCT03895788|DRUG|Brivanib|Brivanib will be administered as a flat-fixed dose (200mg, 400 mg, or 600 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area.
214421417|NCT01689272|PROCEDURE|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
214421418|NCT02925195|DIETARY_SUPPLEMENT|Vitamin D3|cholecalciferol (vitamin D3) 2000 IU capsules daily
214421419|NCT02925195|DRUG|Placebo|
214421420|NCT03618849|DEVICE|tDCS|Real and sham tDCS/Mozart piano sonata (K.448)
214421421|NCT00159354|DRUG|predisolone|
214421422|NCT05603767|OTHER|RMT+ VR|(RMT+ VR). The responsive music therapy session combined with virtual reality involves four stages: a) Background settings; b) VR video and music selection; c) Listening experience and VR; and e) Return to alert status. The therapist will help the patient to select the video to be used for the experience. Utilizing the application created by the research team, the patient will be provided with four possible scenarios. As for the music, patients are asked to choose music that relaxes them the most. Chosen music can be instrumental music (guitar, electric piano or violin) or sung music with harmonic accompaniment (piano or guitar). In both cases the music will be played live.
214421423|NCT04977128|DRUG|89Zr-KN035|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
214421424|NCT00183638|BEHAVIORAL|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
214421425|NCT00183638|BEHAVIORAL|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
214421426|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
214421427|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
214421428|NCT00217672|BIOLOGICAL|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
214421429|NCT00217672|DRUG|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
214421430|NCT04650048|DEVICE|Active HD-tDCS|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
214421431|NCT04650048|DEVICE|Sham HD-tDCS|"Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS."
214421432|NCT01296425|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
214421433|NCT01787240|DRUG|Escitalopram 10mg|
214421434|NCT01787240|DRUG|Placebo|
214421435|NCT03951649|DRUG|Occipital Nerve Block|This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
214690133|NCT02391090|PROCEDURE|Lung function testing|On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.
214690134|NCT02391090|PROCEDURE|Blood taking|On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.
214690135|NCT02391090|PROCEDURE|FeNO measurement|Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
214690136|NCT00948662|DRUG|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
214690137|NCT00948662|DRUG|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
214690138|NCT00948662|DRUG|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
214690139|NCT02152592|DRUG|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
215020493|NCT03306381|OTHER|Dietary intervention|Elimination of certain products.
215020494|NCT03072875|DEVICE|CAMS-RAS|
215020495|NCT03478787|DRUG|risankizumab|Subcutaneous (SC) injection
215020496|NCT03478787|DRUG|secukinumab|Subcutaneous (SC) injection
215020497|NCT01837095|DRUG|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
215020498|NCT04221152|DRUG|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
214421436|NCT03961152|BEHAVIORAL|PainCoach app|In response to the patient's input of the pain experienced (no pain, bearable pain, unbearable pain, or untenable pain), the app gave advice on pain medication use, exercises/rest and when to call the clinic from day 1 until day 14 after surgery.
214690140|NCT02152592|DRUG|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
214690141|NCT01693133|OTHER|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
214421437|NCT00878462|DRUG|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
214421438|NCT00878462|DRUG|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
214421439|NCT00878462|DRUG|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
214421440|NCT01596504|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection self-administered with a pen-like injector (OptiClik®).~Route of administration: subcutaneous"
214421441|NCT01596504|DRUG|Liraglutide|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
214421442|NCT01596504|DRUG|Insulin Glargine|Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)
214421443|NCT01596504|DRUG|Metformin|If previously taken metformin to be continued at stable dose throughout the study
214421444|NCT00002819|DRUG|carboplatin|
214421445|NCT00002819|DRUG|cyclophosphamide|
214421446|NCT00002819|DRUG|mitoxantrone hydrochloride|
214421447|NCT00002819|DRUG|paclitaxel|
214421448|NCT00002819|PROCEDURE|autologous bone marrow transplantation|
214421449|NCT00002819|PROCEDURE|peripheral blood stem cell transplantation|
214421450|NCT01901276|DRUG|Omeprazole 40 mg bid|As above.
214421451|NCT04000269|DEVICE|Soterix MxN Neuromodulation device|Up to 2 mA stimulation to primary motor cortex for 10 sessions at 20min per session
214421452|NCT04000269|DEVICE|Sham Stimulation|Uses slight stimulation initially then turns of and provides no stimulation after a few seconds.
214421453|NCT04666818|DEVICE|Use of Flash Glucose Monitoring|Participants in the intervention group were advised to monitor glucose levels by means of flash glucose system.
214421454|NCT02015741|DEVICE|EEG monitoring with Bispectral Index and NeuroSENSE|
214421455|NCT02015741|BEHAVIORAL|Clinical observation|Patients will be observed during awake periods and during natural sleep.
214421456|NCT03890640|PROCEDURE|Ultrasound-guided TECI|When performing an ultrasound-guided thoracic epidural catheter insertion (TECI), an 18-gauge Tuohy needle will be used for interlaminar epidural access. All procedures will be performed with a paramedian approach under ultrasound-guidance and using the loss of resistance technique with saline. If the needle is deemed to be in the epidural space when the loss of resistance occurred, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
214421457|NCT05045703|DIETARY_SUPPLEMENT|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
215020499|NCT04679818|DRUG|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
215020500|NCT04679818|DEVICE|PMD-200 Nol-guided opioid administration|PMD-200 Nociception level (NOL) values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
214421458|NCT00294905|BEHAVIORAL|Implementation of a combined smoking cessation strategy|
214421459|NCT02894749|RADIATION|3D rotational angiography (3DRA)|3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
214421460|NCT00703625|DRUG|Temsirolimus|
214421461|NCT00703625|DRUG|Docetaxel|
214421462|NCT00000313|DRUG|Fenfluramine|
214421463|NCT03629119|DIETARY_SUPPLEMENT|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
214421464|NCT00492791|DEVICE|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
214421465|NCT04090762|BEHAVIORAL|Conditional cash transfer|Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
214421466|NCT04090762|BEHAVIORAL|Risk information provision|Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
214690142|NCT01693133|OTHER|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
214690143|NCT02717065|OTHER|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
214690144|NCT02717065|OTHER|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
214690145|NCT03816410|PROCEDURE|LAA amputation|complete surgical amputation of the left atrial appendage
215020501|NCT04093284|DEVICE|The needle-free jet injector|Continuous insulin therapy for 9 days
215020502|NCT00971503|PROCEDURE|autologous bone marrow implantation|Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery
215020503|NCT00971503|OTHER|Saline injection|Injection of saline solution for 5 days
215020504|NCT02016508|DRUG|autologous bone marrow derived stem cells|intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
215020505|NCT04169659|DEVICE|Kyphoplasty with insertion of Sctructured Titanium Microspheres|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.
215020506|NCT04169659|DEVICE|Kyphoplasty with Polimethylmetacrilate (convetional surgery)|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
215020507|NCT04411407|DEVICE|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
215020508|NCT02655809|RADIATION|Fluoroscopic examination|
215020509|NCT05838040|OTHER|General exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
215020510|NCT05838040|OTHER|General exercises with tranversus abdmoinis contraction|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. In addition to these exercises, the Back to Fitness Program includes the activation of the transverse abdominis muscle, which is an important stabilizing muscle in the core. The activation of this muscle is done through specific exercises and techniques, and is intended to improve core stability and reduce the risk of further back injuries.
214421467|NCT04459819|OTHER|Respiratory physiotherapy|"Respiratory physiotherapy consists of:~* early mobilization (passive and active mobilization, muscle-strengthening exercises, mobilization out of bed, standing, walking, ADL)~* patients positioning~* non-invasive mechanical ventilation / CPAP~* tracheostomy management~* invasive mechanical ventilation weaning~* airway clearance~* oxygen titration"
214421468|NCT03502317|BEHAVIORAL|Physical Prehabilitation|Physical prehabilitation will comprise a personalized, home-based exercise program designed to meet the Cancer Care Ontario Exercise Guidelines for Cancer Survivors. A Registered Kinesiologist (RKin) will complete a baseline physical assessment and prescribe an individualized multi-modal exercise program consisting of 4-5 days of 30+ minutes of aerobic exercise (brisk walking or equivalent to target heart rate of 40-60% of max) and 2-3 days of moderate intensity resistance training of major muscle groups (8-10 repetitions). Participants will be provided with a Fitbit with a heart rate monitor, resistance bands, and a stability ball. Patients will be required to wear their Fitbit and record the number of steps at the end of each day from randomization to 90 days post-surgery.
214421469|NCT03502317|BEHAVIORAL|Psychological Prehabilitation|Psychological prehabilitation will consist of one in-person coaching session of a 'mindfulness' informed intervention conducted by a specially trained RKin. The 40 minute coaching session will include a guided mindfulness session and debriefing. Participants will be asked to practice for 20 minutes twice a day. The patients will be given access to an audio file that will walk them through the 20 minute sessions.
214421470|NCT05061342|OTHER|No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic therapy, radiotherapy, Chinese traditional medicine, or palliative/supportive care.|Any anticancer or palliative care
214421471|NCT04620018|DRUG|Amoxicillin|Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
215020511|NCT03024632|PROCEDURE|Trial of labor|trial of labor after 3 or more previous cesarean deliveries
215102622|NCT02229526|DIETARY_SUPPLEMENT|High dose olive oil|Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
215102623|NCT03134131|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
215102624|NCT02156336|DRUG|Ranolazine|Oral administration, BID; for a maximum of 51 days.
214421472|NCT06315049|OTHER|Music therapy|Music therapy sessions to reduce anxiety
214421473|NCT05967819|BEHAVIORAL|Exercise Stress|Increased exercise volume
214421474|NCT05967819|BEHAVIORAL|Psychosocial Stress|cognitive tasks
214421475|NCT05590273|BEHAVIORAL|CALM Therapy|"The CALM intervention includes 3 to 6 individual therapy Zoom teletherapy sessions, each approximately 50-60 minutes in length biweekly, delivered over 3 months. Participants (caregivers) will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy (baseline) and immediately after the program (post-intervention)~In addition, after each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components.~Lastly, participants will complete an exit interview immediately following the end of the intervention."
215102625|NCT02156336|DRUG|Placebo|Oral administration, BID; for a maximum of 51 days.
215102626|NCT04715698|OTHER|ICG-guided drug selection|anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience
215102627|NCT04715698|OTHER|empirical drug selection|anti-hypertensive drug selection based on physician's experience only
215102628|NCT02134678|BEHAVIORAL|self-system therapy|
215102629|NCT02134678|BEHAVIORAL|cognitive therapy|
215020512|NCT06203665|DIAGNOSTIC_TEST|Recruitment Maneuver|The surgery would be performed under general anaesthesia according to the common practice using protective lung ventilation ( Vt= 6 ml /Kg ideal body weight , RR to maintain end-expiratory CO2 35-45 cmH2O and PEEP= 6- 8 cm H20). An incremental and decremental positive end-expiratory pressure alveolar recruitment maneuver would be performed after release of pneumoperitoneum.
215020513|NCT02480361|DEVICE|acupuncture|Acupuncture treatment after gastric cancer surgery during 5 postoperative days
215020514|NCT05752331|BEHAVIORAL|Physical activity behavioural modification|8-week intervention consisting motivational interview, individualised action plan and weekly consultations regarding activities of daily living and symptom management.
215020515|NCT00689286|DEVICE|BION|"They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises."
215020516|NCT03688113|BEHAVIORAL|Tinnitus application|Use of tinnitus application
214421476|NCT06184854|OTHER|3D-Enhanced Training Models|3D-enhanced Jenga polo model for task 1 and 3D-enhanced suturing model for task 2
215020517|NCT02413346|DRUG|Sarecycline|Administered based on participant's body weight.
215020518|NCT01496703|OTHER|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
215020519|NCT02297035|BEHAVIORAL|Behavioural testing|
215020520|NCT02297035|OTHER|Brain imaging|MRI, PET
215020521|NCT02297035|GENETIC|Genetic screening|APOE, Progranulin
215020522|NCT04995926|PROCEDURE|Labial mucosal epithelium grafting for corneal limbus substitution|Labial mucosa epithelium grafting for corneal limbus substitution will be used to treat limbal stem cell deficiency by way of corneal surface re-epithelization
215020523|NCT02403778|DRUG|VESANOID|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
214690146|NCT04503928|DRUG|Euphorbia kansui Pill|1 g (10 pills) of Euphorbia kansui Pill taken by mouth, once a day for 7 consecutive days.
214690147|NCT02637791|DEVICE|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
215020524|NCT02403778|DRUG|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
215020525|NCT01044693|DRUG|Placebo|Placebo capsule
215020526|NCT01044693|DRUG|Nebivolol 5 mg|Nebivolol 5mg single oral dose
215020527|NCT01044693|DRUG|metoprolol tartrate 50 mg|metoprolol tartrate 50 mg single oral dose
215020528|NCT01044693|DRUG|Sildenafil25 mg|Sildenafil 25 mg single oral dose
215020529|NCT00320580|DRUG|norelgestromin/ethinyl estradiol|
215020530|NCT05318378|DIAGNOSTIC_TEST|BIXAM|Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
215020531|NCT00006215|BIOLOGICAL|filgrastim|
215020532|NCT00006215|DRUG|docetaxel|
215020533|NCT00006215|DRUG|vinorelbine tartrate|
215102630|NCT03141541|BEHAVIORAL|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
215102631|NCT01590654|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
214421477|NCT06184854|OTHER|Standard 3D LapPass Training Models|Standard 3D LapPass polo model for task 1 and standard 3D LapPass model for task 2
214421478|NCT03835390|BEHAVIORAL|SIMDiscovery|The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
214421479|NCT03016455|OTHER|Presence of DSA w/ cAMR|
214421480|NCT03016455|OTHER|Presence of DSA w/o cAMR|
214421481|NCT03016455|OTHER|No DSA No cAMR|
214421482|NCT03617406|DIAGNOSTIC_TEST|Volume Challenge|Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
214421483|NCT05988307|DEVICE|Percussion massage gun|Percussion massage gun on hamstrings flexibility in patients with knee Osteoarthritis.
214690150|NCT02260167|OTHER|A mix of natural treatments and medications|
214690151|NCT02773719|OTHER|True Biofield therapy|
214690152|NCT02773719|OTHER|Fake Biofield therapy|
214421484|NCT04347954|DRUG|Povidone-Iodine 2%|Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day
214421485|NCT04347954|DRUG|Povidone-Iodine 0.5%|Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day
214421486|NCT04347954|DRUG|Isotonic saline 0.9%|Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
214421487|NCT03906942|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content in the form of 152 BET I CAN challenges \[1\]. Behavior challenges are intended to increase a participant's capabilities to set a goal and to create positive habits. Emotion challenges are intended to increase a participant's capabilities to cope with negative emotions and to cultivate positive emotions. Thought challenges are intended to increase a participant's capabilities to challenge negative assumptions and to create a new narrative for their life. Interaction challenges are intended to increase a participant's capabilities to communicate and connect with others. Context challenges are intended to increase a participant's capabilities to read cues and to change cues in the environment. Awareness challenges are intended to increase a participant's capabilities to know herself/himself and to know the issue. Next steps challenges are intended to increase a participant's capabilities to make a plan and to stick with a plan.
215020534|NCT00991003|PROCEDURE|Colon capsule endoscopy|The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
215020535|NCT00991003|PROCEDURE|Conventional Colonoscopy|
215020536|NCT02446938|PROCEDURE|Esophagus balloon catheter insertion.|Esophagus balloon catheter will be inserted and the position of the balloon will be confirmed by a air injection test.A bolus of 30 ml of air was injected to the gastric lumen of the catheter just next to the distal edge of the balloon, during the onset of end-expiratory phase. The presence of a positive disturbing wave (PDW) in esophageal pressure waveform to this air injection will be the indicator of the right balloon position.
215020537|NCT01316900|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
215020538|NCT01316900|DRUG|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
215020539|NCT01316900|DRUG|GW642444|25 mcg once-daily
215020540|NCT01316900|DRUG|tiotropium bromide|18 mcg once-daily
215020541|NCT03109925|DEVICE|DC Lumi Bead, BTG|Embolic agent which is radio-opaque
215020542|NCT05047887|PROCEDURE|Modified socket shield technique with autogenous dentin graft material (in one side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then Tooth particles will be demineralized using 2% HNO3 (El-Gomhouria CO. Egypt) for 20 minutes to expose the dentin organic matrix.
215020543|NCT05047887|PROCEDURE|Modified socket shield technique with alloplast graft material (in contralateral side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then alloplast graft will be used
214421488|NCT04108754|OTHER|microangiopathic burden|to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
214421489|NCT05781555|DEVICE|Experimental: DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. The study objectives are to collect data on the general safety and efficacy of DaRT among patients who do not fit the entry criteria of existing investigational trials.
214421490|NCT00761930|DRUG|Fluoride|Brush twice daily
214421491|NCT00761930|DRUG|Triclosan and fluoride|Brush twice daily
214421492|NCT00761930|DRUG|Herbal Ingredient and fluoride|Brush twice daily
214690153|NCT02930798|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-116)"
214690154|NCT03633786|PROCEDURE|standard laparoscopic surgery|removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm
215020544|NCT05025371|OTHER|Systemic immune-inflammatory markers|Systemic immune-inflammatory markers used in this study: total neutrophil count, total lymphocyte count, total monocyte count, total platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI)
215020545|NCT03879577|DRUG|Docetaxel|Administered to all patients for a minimum of 4 cycles for 12 weeks.
215102632|NCT01590654|DRUG|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
215102633|NCT02048488|DRUG|TSR-011|Number of cycles until progression or unacceptable toxicity develops.
215102634|NCT01636128|DRUG|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
215102635|NCT01636128|DRUG|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
215102636|NCT06527534|DRUG|Filgotinib|Patients will receive pills of Filgotinib 200 mg qd for 12 weeks
215102637|NCT06527534|DRUG|Adalimumab|Patients will receive subcutaneous injections of Adalimumab 40 mg q2wk for 12 weeks
215102638|NCT03221361|DEVICE|thermoplastic complete denture|a device used ti substitute teeth for edentlous patient made of thermoplastic resin
215102639|NCT03221361|DEVICE|conventional acrylic resin complete denture|A device used to substitute the teeth for edentlous patient made of acrylic resin
215102640|NCT05378061|DRUG|Pituitary adenylate cyclase activating polypeptide-38|Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.
214421493|NCT03257813|DRUG|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
214421494|NCT03257813|DRUG|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
214421495|NCT02878330|DRUG|MEDI8897|A single IM dose of 50 mg on Day 1 of the study.
214421496|NCT02878330|DRUG|Placebo|A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
214421497|NCT02274896|DEVICE|PD Catheter group|PD catheter
214421498|NCT00092833|DRUG|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
214421499|NCT00578656|DIETARY_SUPPLEMENT|Baked Milk|Extensively heated milk
214421500|NCT02683811|BEHAVIORAL|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
214421501|NCT02698007|DEVICE|Laryngeal Mask Airway (LMA)|Fiberoptic bronchoscopy with the use of LMA
214421502|NCT02511197|DRUG|68Ga-NOTA-PRGD2|68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
214421503|NCT02511197|DEVICE|PET/CT|
215020546|NCT03879577|DRUG|Herceptin|Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.
215020547|NCT03879577|DRUG|FEC|Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
215020548|NCT03879577|DRUG|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
215020549|NCT03879577|DRUG|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
215020550|NCT03879577|DRUG|LHRH agonist|Administered to all premenopausal patients.
215020551|NCT02427672|DEVICE|Transcranial direct current stimulation|
215020552|NCT02427672|DEVICE|Sham transcranial direct current stimulation|
215020553|NCT05363215|DRUG|S-217622|Tablet for oral administration
215020554|NCT01684033|DEVICE|Opti-Free® PureMoist® MPDS|
215020555|NCT01684033|DEVICE|Biotrue™ MPS|
215020556|NCT01684033|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
214421504|NCT00107835|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
214421505|NCT00349583|DRUG|Topical Cyclosporine, Tears|
214421506|NCT06466564|DEVICE|Nufairy® Coil embolization system for intracranial aneurysm|Nufairy® Coil embolization system for intracranial aneurysm
214421507|NCT01424540|DRUG|GSK2336805 150mg|Single Dose
214421508|NCT01424540|OTHER|Placebo|Single Dose
214690155|NCT03633786|PROCEDURE|robot-assisted surgery|"removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console."
214690156|NCT03633786|DIAGNOSTIC_TEST|assessment of sexual function|assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery
215020557|NCT04612127|DIETARY_SUPPLEMENT|Dietary supplement consumption and physical exercise|"The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week."
214690157|NCT03633786|DIAGNOSTIC_TEST|assessment of bowel symptoms|assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery
214690158|NCT03633786|DIAGNOSTIC_TEST|assessment of urinary symptoms|assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
215020558|NCT04853537|DIETARY_SUPPLEMENT|intermittent fasting diet|intermittent fasting diet to obese pregnant women \>30 BMI and incidence of gestational diabetes
215020559|NCT05496738|DRUG|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously in single ascending doses
215020560|NCT05496738|DRUG|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously in multiple ascending doses
215020561|NCT05496738|OTHER|Intravenous placebo|Placebo will be administered intravenously in single ascending doses
215020562|NCT05496738|OTHER|subcutaneous placebo|Placebo will be administered subcutaneously in multiple ascending doses
215020563|NCT04465149|PROCEDURE|Third Molar Germectomy|Surgical extraction of Third Molars that exhibits at least a third of its root in formation, with a periodontal ligament discernible on panoramic x-ray (defined as germectomy).
215020564|NCT06494514|DRUG|nal-IRI+Oxaliplatin+5-FU/LV+PD-1|These drugs are given on d1, d15, 28 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
215020565|NCT06494514|DRUG|Gemcitabine + albumin-paclitaxel+PD-1|These drugs are given on d1, d8, 21 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
215020566|NCT05535088|DEVICE|Virtual reality|Virtual reality consists for about a minute and a half 6 times per session. During the first and the second session, subjects will experiment virtual reality while sited. Moreover, during the third and the fourth session subjects will be standing with a side by side stand. During the last two experimental sessions subjetcts will be standing with a semi tandem stand.
214421509|NCT04203264|DIAGNOSTIC_TEST|Real-time artificial intelligence identification system|The patients swallowed the MCE with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. The magnetic steering time for passing through the pylorus was not allowed more than 15 min. The real-time auxiliary system implemented real-time processing for the output image of MCE system. Professional operators guarantee the integrity of the examination and the diagnostic results of professional endoscopist was used as the gold standard. The system diagnosis results was recorded at the same time. The sensitivity, delay time, specificity of lesions and anatomical landmarks will be analyzed.
214421510|NCT02732678|DRUG|PROPRANOLOL|
214421511|NCT02805439|DRUG|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
214421512|NCT02805439|DRUG|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
214506669|NCT03851458|BEHAVIORAL|Thrice weekly diet and exercise text messages (N vs. Y)|Text message interventions have been demonstrated to be effective in increasing self-eﬃcacy, weight loss, and PA.65-67 Participants will receive thrice weekly healthy eating, PA, and health care access text message tips. Links to additional information and videos will also be sent via text (e.g. local farmers markets, healthy recipes, free exercise classes, workout videos, video demonstrations of how to prepare healthy meals, etc.). Texts were developed and piloted in the COMIDA Pilot, are designed to promote goal-setting, problem-solving, self-monitoring, modeling, and self-eﬃcacy, and will be further reﬁned during the formative research phase (see below). Texts will be sent via Mosio Text Messaging Solutions. Messages will be concise, as longer messages have shown no demonstrable impact. Based on each participant's status at intake, tailored text messages will also encourage regular follow-up with PCPs. Text messages will be interactive.
214506670|NCT03851458|BEHAVIORAL|Weekly telephone support (N vs. Y)|Several lifestyle interventions including Hispanics have successfully incorporated telephone support.134-138 Weekly telephone support (or more frequently if requested) will be delivered by the promotoras throughout the 6-month intervention. Frequent and prolonged contact in behavioral interventions is more effective than single sessions; most interventions leading to diet or PA changes persisting for \>12 months have follow-up contact sessions for at least 4 months.18 Greater numbers of follow-up sessions facilitate success of behavior change, and initial behavior change can decrease with decreased contact.18,139 Telephone sessions (10-15 minutes) will use MI principles, will focus on goal-setting, problem solving, reviewing/integrating new diet/PA knowledge/skills (including self-monitoring) into individuals' daily routines, self-eﬃcacy enhancements, encouraging participants to seek opportunities for modeling and encouraging regular follow-up with PCPs.
214506671|NCT03851458|BEHAVIORAL|Self-monitoring tools (N vs. Y) (for diet and weight)|Self-monitoring is an important component in achieving behavioral change.18 Participants will be given a SANOS food diary (adapted for and pilot-tested at the VDS in our pilot work) and a digital scale. As part of VDS Mobile usual care, all participants will receive a pedometer to assess exercise behavior (secondary outcome), so additional self-monitoring tools for PA will not be included in this component.
214506672|NCT05020028|DRUG|Cannabidiol (CBD)|Patients will be dispensed enough 25mg cannabidiol (CBD) Orally Disintegrating Tablets (ODT) to take a standard dose of 50mg three times daily for 84 days.
214506673|NCT05020028|DRUG|Placebo|25mg Placebo ODT looks like the cannabidiol (CBD) Orally Disintegrating Tablets (ODT), but contains no active ingredients.
215029134|NCT05421494|BEHAVIORAL|minimal contact control|Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.
214421513|NCT02805439|DRUG|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
214421514|NCT01315886|DRUG|SL fentanyl|SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
214421515|NCT03725371|OTHER|No intervention was administered for the purpose of this study.|No intervention was administered for the purpose of this study. Observations were carried out for all participants.
214506674|NCT00639418|BIOLOGICAL|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
214506675|NCT00204399|BEHAVIORAL|Telephone counseling support|
214506676|NCT00444743|DRUG|MM-093|60 mg, administered subcutaneously, weekly
214506677|NCT00444743|OTHER|Placebo|Placebo
214506678|NCT00005826|DRUG|rubitecan|
214690159|NCT06364228|DRUG|Placebo|Placebo intranasal spray liquid with no oxytocin will be delivered in 2 puffs to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).
215029135|NCT05550727|OTHER|PorchLight|The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
215029136|NCT06535100|BEHAVIORAL|Art therapy|artistic therapy, wood painting, lithography, jewelry design, mud free shaping, expression workshop and training workshops
214421516|NCT02215278|DIETARY_SUPPLEMENT|10 x 55 g/ bean per arm|
214421517|NCT04557488|OTHER|Music therapy|Each session will follow a similar structure with a hello song, musical activities, and a goodbye song. The musical activities will vary in each session and will be mixed in later sessions to revisit and practice social skills
214421518|NCT04557488|BEHAVIORAL|Behavioral-based social skill training|Each intervention session will follow a standard structure of opening greetings, social activities according to the theme of the session, and a closing activity. The activities and games will vary in each session and will be mixed in later session to revisit and practice social skills.
215020567|NCT02483910|BEHAVIORAL|Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)|"DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons."
214421519|NCT02939378|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
214421520|NCT02939378|DIETARY_SUPPLEMENT|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
214421521|NCT05146817|OTHER|Oral care|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
214421522|NCT06234644|OTHER|Standardized Walking Obstacle Course (SWOC)|The Standardized Walking Obstacle Course (SWOC) is a test that allows interaction of a child with environmental demands and obstructions while examining differences in functional ambulation performances. The Group A (experimental group) will receive the treatment with Standardized walking obstacle course (SWOC), the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of SWOC training and 5 minutes of cool down period.
214421523|NCT06234644|OTHER|Conventional Gait Training|Conventional gait training protocol including walking on a treadmill, parallel bar walk, seated marching. The Group B (Control group) will receive the treatment with conventional Gait training, the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of Conventional gait training and 5 minutes of cool down period.
214421524|NCT03070938|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
214421525|NCT06354283|BEHAVIORAL|Progressive Muscle Relaxation Exercises|Progressive muscle relaxation techniques were explained to the women from the couples assigned to the Intervention Group by a researcher. In addition to relaxation exercises, deep breathing movements were also explained to the women and progressive muscle relaxation exercises and breathing exercises were performed together. The importance of the exercises and how to do them were explained to the women by the researcher for about 30 minutes and then demonstrated practically for 30 minutes. Each progressive muscle relaxation exercise session lasted approximately 20-25 minutes. The women in the intervention group continued the exercises at home three times a week for four weeks.
214421526|NCT03899675|DIETARY_SUPPLEMENT|Placebo|On the first day of collection, the volunteers will not take placebo intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of placebo and will be advised to consume 1 hour before the procedure.
214506679|NCT03233152|DRUG|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
214506680|NCT03233152|DRUG|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
214506681|NCT06509867|PROCEDURE|DGG+PRF|de-epithelialized subepithelial connective tissue grafts+ L-Platelet Rich Fibrin + Coronally advanced flap
214690160|NCT06364228|DRUG|Oxytocin Intranasal Spray 12 International Unit (12IU)|Participants weighing less than 40 kg (88 pounds) will receive 12 IU of oxytocin delivered as 1 puff (6 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).
214690161|NCT06364228|DRUG|Oxytocin Intranasal Spray 24 International Unit (24IU)|Participants weighing more than 40 kg (880 pounds) will receive 24 IU of oxytocin delivered as 2 puffs (12 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).
215020568|NCT02483910|BEHAVIORAL|Standard of care delivered via telehealth (e.g., Zoom or WebEx)|Usual care including speech therapy in school, community or both
214421527|NCT03899675|OTHER|Caffeine|On the first day of collection, the volunteers will not take caffeine intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of caffeine and will be advised to consume 1 hour before the procedure.
214421528|NCT02618239|DIETARY_SUPPLEMENT|Bimuno Galacto-oligo-saccharide|
214421529|NCT01767259|DRUG|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
214421530|NCT01767259|DRUG|Valsartan|Valsartan alone
214421531|NCT01767259|DRUG|Hydrochlorothiazide|Hydrochlorothiazide alone
214421532|NCT01026233|DRUG|brentuximab vedotin|1.8 mg/kg IV every 21 days
214421533|NCT02886897|BIOLOGICAL|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
214421534|NCT01273844|DRUG|Bortezomib|Bortezomib
214690162|NCT06364228|PROCEDURE|Functional MRI|Functional MRI (fMRI) scan with affective Stroop and Empathy and Theory of Mind task (EmpaTom task will administered pre- and post-administration of oxytocin.
215020569|NCT03672981|BEHAVIORAL|Exercise Intervention|Undergo resistance training program and cardiovascular exercise
215020570|NCT03672981|OTHER|Quality-of-Life Assessment|Ancillary studies
215020571|NCT03672981|OTHER|Questionnaire Administration|Ancillary studies
215020572|NCT03672981|BEHAVIORAL|Telephone-Based Intervention|Participate in phone calls with exercise physiologist
215020573|NCT00257855|DRUG|Lamotrigine|
215020574|NCT01856829|DIETARY_SUPPLEMENT|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
215020575|NCT01856829|OTHER|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
215020576|NCT02687165|DRUG|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
214421535|NCT01311180|DRUG|Sensoril®|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
214421536|NCT01311180|DRUG|Placebo|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
214421537|NCT01989910|DRUG|Raltegravir|Raltegravir 400mg oral twice daily
214421538|NCT01989910|DRUG|Efavirenz|Efavirenz 600mg oral at bedtime
214421539|NCT02983370|PROCEDURE|Minicraniotomy|The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
214421540|NCT05826951|DRUG|Alcohol|Alcohol (0.8g/kg)
214421541|NCT05826951|DRUG|Placebo|Placebo
214421542|NCT03498170|DRUG|BCT197|Single dose of BCT197
214421543|NCT03498170|DRUG|Itraconazole 200 mg|Single dose of itraconazole
215020577|NCT01124266|PROCEDURE|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
215020578|NCT01124266|PROCEDURE|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
215020579|NCT02948075|DRUG|Quisinostat|
215020580|NCT02948075|DRUG|Paclitaxel|
214421544|NCT03747354|DIAGNOSTIC_TEST|blood samples|blood samples
214421545|NCT02467296|OTHER|Dietary plan with controlled amount of Sodium|Dietary plan with 1.5 gr vs 3 gr of Sodium
215020581|NCT02948075|DRUG|Carboplatin|
214421546|NCT01760837|OTHER|Baked milk products to cow's milk allergic patients|
214421547|NCT00974025|DIETARY_SUPPLEMENT|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
214421548|NCT00974025|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered twice daily for four weeks
214421549|NCT04060537|OTHER|Laboratory analysis of samples|RNA sequencing, immunohistochemistry, immunofluorescence, and cytometry of tumour tissues
214421550|NCT04060537|OTHER|Application of machine learning|Using machine learning to interrogate data generated from analysis of Renal Cell Cancer tumours using RNA sequencing, immunohistochemistry, immunofluorescence, cytometry, and MRI imaging of tumours.
214421551|NCT02747732|DRUG|Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
214690163|NCT04855565|DRUG|ALY688-SR|single dose subcutaneous injection
214690164|NCT01316601|DRUG|QAX567|
214690165|NCT01879670|DEVICE|CircuLite Synergy left ventricular assist device|
215020582|NCT04674904|OTHER|Dry Needling|Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min
215020583|NCT04674904|OTHER|Hot pack , TENS , Stretching|"Treatments are~1. Hot Pack for 15 minutes~2. TENS for 10 minutes~3. Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine"
215020584|NCT04147741|DIETARY_SUPPLEMENT|Pre-Workout Supplement|"One week familiarisation, one-week training, two weeks washout period and one-week training.~15 Minutes before every training, the Pre-Workout Arm (PRE-W) will take a Supplement shake, consisting of some ingredients (Multi-Ingredient, explained before) and the Placebo Comparator Arm (CHO) will drink a Placebo shake, consisting of Maltodextrin."
215029137|NCT05053555|DEVICE|high dose rate brachytherapy|diagnostic workup, staging, and treatment per the institution standard of care
215029138|NCT05053555|DEVICE|high dose rate brachytherapy|reviewing historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021
215029139|NCT06451497|BIOLOGICAL|ZM008|Intravenous delivery
214421552|NCT04948151|DRUG|Sildenafil|Patients will apply 2-gram applications up to 9 times per month.
214421553|NCT04948151|DRUG|Placebo|Patients will apply 2-gram applications up to 9 times per month
214421554|NCT02528591|DEVICE|oscillometric device (Arteriograph®, Medexpert)|Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
214421555|NCT04097210|DIAGNOSTIC_TEST|POC|
214421556|NCT00688948|DRUG|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
214506682|NCT06509867|PROCEDURE|DGG|de-epithelialized subepithelial connective tissue grafts+ Coronally advanced flap
214506683|NCT04541199|DEVICE|closed loop|RR and VT will be selected according to the respiratory mechanics by closed loop algorithm
215020585|NCT04147741|OTHER|Resistance Training|-Resistance Training days (Monday-Wednesday-Friday): Before training starts, Tensiomyography and Energy Feeling will be assessed (Energy Level, Fatigue Level, Feeling of Alertness, and Feeling of Focus on the task). Immediately after finishing, Tensiomyography and Performance (Vertical Jump, Overhead Medicine Ball Throw, and Maximal Mid-Tigh Pull Isometric Strength) will be assessed. Training Protocol: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Parallel Squat; Bench Press; Alternate Box Set-Ups; Shoulder Press; Alternate Lunges; Up-right Row; Hip-Thrust; Squat on Isoinertial Fly-Wheel or Drop Jump). The participants will have to perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2,5 to 5 kg will be added for the next set. Also, whole-body Perceptual Response will be assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
215020586|NCT04147741|OTHER|Endurance Training|\- Endurance Training days (Tuesday-Thursday): Energy Feeling Questionnaire will be implemented before training. The training will consist of 30 minutes cycling at their Fatmax Intensity (\~60% Vo2max) on a Cycloergometer (estimated during familiarisation week). Also, the Heart Rate will be recorded during the whole training. Besides, Perception of Effort will be assessed using the 6-20 version of the Borg Scale every 5 minutes during training and 15 minutes after it has been completed.
215020587|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
215020588|NCT00951873|DRUG|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
215020589|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
215020590|NCT02289014|OTHER|online stress Management program|Active treatment group
215020591|NCT01528852|DRUG|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
215020592|NCT01528852|DRUG|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
215020593|NCT01528852|OTHER|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
215020594|NCT01018771|PROCEDURE|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
214421557|NCT00166192|PROCEDURE|Jessner's solution chemical peel|
214421558|NCT00166192|PROCEDURE|Trichloroacetic acid chemical peel|
214421559|NCT06076382|PROCEDURE|endoscopic ultrasound guided colorectal ESD surgery|The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. After water injection, the lesion was scanned and (1) the direction of gravity was determined. (2) fibrosis/infiltration under the mucosa, and the fibrosis was divided into F0 (no fibrosis), F1 (cold fibrosis), or F2 (severe fibrosis). (3) The lesion was divided into nine compartments. Mark submucosal fibrosis/infiltration sites, according to nine compartments. (4) Based on the results of endoscopic ultrasound scanning of the lesion, the surgeon draw up surgical approach and perform injection and dissection.
214421560|NCT06076382|PROCEDURE|the traditional colorectal ESD surgery|The control group underwent injection and dissection directly.
214421561|NCT01949740|OTHER|questionnaire administration|Ancillary studies
214506684|NCT04541199|DEVICE|conventional|RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
214506685|NCT05593107|DRUG|[68Ga]N188|68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
214506686|NCT01453959|DRUG|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
214506687|NCT01453959|OTHER|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
214506688|NCT01459952|DIETARY_SUPPLEMENT|Rose hip Liquid|Rose hip Liquid, 20 ml BID
214506689|NCT02123953|DRUG|TAK-438|TAK-438 tablets
214506690|NCT02123953|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
214506691|NCT04233905|BEHAVIORAL|Psychometric questionnaire study|Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.
214506692|NCT01170845|DRUG|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
214421562|NCT01949740|PROCEDURE|quality-of-life assessment|Ancillary studies
214421563|NCT00809120|DEVICE|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
214421564|NCT02674451|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
214421565|NCT03145246|PROCEDURE|regeneration treated teeth loss|number of regeneration treated teeth loss
214690166|NCT01289626|DRUG|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
214690167|NCT01289626|DRUG|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
214421566|NCT03145246|PROCEDURE|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
215020595|NCT01018771|PROCEDURE|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
215020596|NCT04902482|DEVICE|iCycle Mark 3|The iCycle Mark 3 is a cycle ergometer, designed to be used by people with SCI while they are seated in their own wheelchairs. The purpose of iCycle is to stimulate the leg muscles in the correct phase for cycling while motivating the person with a Virtual Reality cycling event, perhaps a race, to try to use their muscles.
215020597|NCT03397719|BEHAVIORAL|Treatment Condition|This group will receive three hours of parent coaching per week, one hour per week will involve feedback on parent usage of coached strategies based on parent recorded interactions with their children.
215020598|NCT03397719|BEHAVIORAL|Control Group|This group will receive in-vivo parent coaching three hours per week.
215020599|NCT01290354|DRUG|Lapatinib|Unlabelled, administered orally
215020600|NCT01290354|DRUG|[11C] lapatinib|Radiolabelled, administered intravenously
215020601|NCT05157789|OTHER|SMS|In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
214421567|NCT01555684|PROCEDURE|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
214421568|NCT03448757|OTHER|measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure|"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.~Patients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma."
214421569|NCT02526641|PROCEDURE|Functional Hepatic Nitrogen Clearance (FHNC)|
214421570|NCT02526641|PROCEDURE|Galactose Elimination Capacity (GEC)|
214421571|NCT02526641|PROCEDURE|Liver vein catheterization|
214506693|NCT05329519|BEHAVIORAL|Listening music|Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
214506694|NCT04217252|DIAGNOSTIC_TEST|PMseqTM high-throughput sequencing technology|high throughput sequencing of infectious pathogens
214506695|NCT03166605|DRUG|Simethicone|Giving simethicone before and after capsule ingestion.
215020602|NCT05143515|BEHAVIORAL|PACE label|There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
214506696|NCT03160976|OTHER|Cryolipolysis|First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
215020603|NCT02956863|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
215020604|NCT02956863|PROCEDURE|Exercises|Exercise for stretching and strength for neck muscles
215020605|NCT01179620|DRUG|Certoparin|Certoparin
215020606|NCT02446288|DEVICE|TMJ Next Generation|
214506697|NCT02404844|DRUG|BKM120|daily oral
214506698|NCT02404844|DRUG|Tamoxifen|daily oral
215020607|NCT02446288|DEVICE|DSG Relaxer|
215020608|NCT06190379|OTHER|Essential oil blend|an aroma stick containing a blend of essential oils
215020609|NCT06190379|OTHER|Placebo|an aroma stick containing an inert blend of oils
215020610|NCT01005979|DRUG|Lenalidomide, Rituximab, and Cyclophosphamide|"COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~Patients will receive a total of 6-8 cycles."
215020611|NCT00089583|DRUG|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
215020612|NCT00089583|DRUG|Ritonavir|Ritonavir solution bid
215020613|NCT05918770|DIAGNOSTIC_TEST|systematic screening and early treatment|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition
215029140|NCT05654181|DRUG|PF-07328948|investigational drug administered orally
215029141|NCT05654181|DRUG|Placebo|Placebo matching active drug administered orally
215029142|NCT05918029|DRUG|Potassium Citrate Extended Release Oral Tablet|Oral potassium citrate extended-release tablet
215029143|NCT05918029|OTHER|Placebo|Placebo capsule identical to active ingredient
214421572|NCT04988048|BIOLOGICAL|COVID-19 vaccines|"Gam-COVID-Vac Gamaleya National Center for Epidemiology and Microbiology - Russia. Non-replicative viral vector. Multi-dose vial (5 doses in 3 mL) Single-dose vial (1 dose in 0.5 mL). Intramuscular T° less than -18 ° C~BBIBP-CorV Beijing Institute of Biological Products - People's Republic of China. Inactivated viruses. Single-dose vials (1 dose in 0.5 mL) or multi-dose vial (2 doses per vial). Intramuscular T° 2 to 8 ° C~ChAdOx1 nCoV-19 vaccine AZD1222 AstraZeneca-Oxford - United Kingdom. Non-replicative viral vector. Multi-dose vial (10 doses in 5 mL). Intramuscular T°: 2 to 8 ° C~mRNA-1273 or Spikevax Moderna Switzerland GmbH and the National Institute of Allergy and Infectious Diseases (NIAID) of the United States. mRNA. Multi-dose vial (maximum 15 doses per 0.5ml vial). Intramuscular. T°-15 ° to -50 °"
214421573|NCT05171218|BEHAVIORAL|Music & Auditory Beat Stimulation|Listening to calm music and auditory beat stimulation Participants listened to calm music with theta auditory beat stimulation for 24 minutes
214421574|NCT05171218|BEHAVIORAL|Music Alone|Listening to calm music Participants listened to calm music for 24 minutes
214421575|NCT05171218|BEHAVIORAL|Auditory Beat Stimulation|Listening to theta auditory beat stimulation Participants listened to theta auditory beat stimulation for 24 minutes
214421576|NCT05171218|BEHAVIORAL|Pink Noise|Listening to pink noise Participants listened to pink noise for 24 minutes
214421577|NCT01099891|DRUG|rhEGF|rhEGF 50 μg/ml, spray type, twice a day
214421578|NCT01099891|DRUG|Placebo|Placebo, Spray type, Twice a day
214421579|NCT03429062|OTHER|Personal training exercises|Personal training: strengthening, stretching, endurance, balance Whole body vibration: strengthening, balance, stretching, endurance, balance
214421580|NCT05705700|DRUG|Dutasteride|High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression
214421581|NCT05705700|DRUG|Abiraterone|1000 mg PO daily
214421582|NCT02954848|DRUG|Placebo|TAK-438 placebo-matching tablets
214421583|NCT02954848|DRUG|TAK-438 10 mg|TAK-438 tablets
214421584|NCT04224181|RADIATION|Cardiac PET|A scan examining blood flow to the heart
214421585|NCT04224181|RADIATION|99mTc-tilmanocept SPECT/CT|A scan to look at inflammation in the arteries
214421586|NCT04224181|RADIATION|Contrast Enhanced Coronary and Aortic Computed Tomography Angiography|A scan of the heart and surrounding blood vessels
214421587|NCT04126330|DIETARY_SUPPLEMENT|Probiotic, Omega-3, Vitamin D supplement|"The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards)."
214421588|NCT04126330|DIETARY_SUPPLEMENT|Placebo|Placebo generated for probiotic and omega-3/vitamin D supplements
214421589|NCT00968448|BEHAVIORAL|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
214421590|NCT00968448|BEHAVIORAL|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
214421591|NCT00025987|DEVICE|Head and Neck Cooling System|
214421592|NCT00025987|DEVICE|Thermometer Pill|
215020614|NCT06481072|OTHER|Digital patient education|This educative intervention includes both medical and psychological explanations, as well as basic strategies to manage pediatric FAPD. The medical information spans the topics of pain, functional abdominal pain and general advice in terms of child health, and the psychological information is based on cognitive-behavioural and pain management theoretical approaches. The intervention consists of six short, animated films with a total run-time of approximately 30 minutes. The films each cover one of the following topics; Why and how do we feel pain? What is functional abdominal pain? How to help: general advice, Thoughts, feelings and behaviour, Goals and strategies. The films are accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform that is recognised by the care provider as meeting current safety criteria and standards.
215029144|NCT05918029|DRUG|Potassium Citrate and Citric Acid Oral Solution|Oral potassium citrate and citric acid
214421593|NCT02713048|OTHER|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
214421594|NCT00226148|PROCEDURE|Use of a membrane to cover bonedefects around implant|
214421595|NCT00226148|DEVICE|Use of bonechips to fill up defects around implant|
214421596|NCT00226148|PROCEDURE|Use of membrane and bonechips to manage defects|
214421597|NCT01069341|DRUG|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
214421598|NCT01215019|DRUG|Mannitol|20% Mannitol, 1-5 doses as needed to control ICP
214421599|NCT01215019|DRUG|NaCl|3% sodium chloride injection, 1-5 doses, as needed to control ICP
214421600|NCT00269880|DRUG|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
214421601|NCT00269880|DRUG|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
214421602|NCT00269880|DRUG|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
214421603|NCT03471611|DRUG|Autologous CD34+ Cells|The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min
214421604|NCT03471611|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5mg/kg twice daily
214421605|NCT03631537|OTHER|NST group|Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
214421606|NCT00922207|DRUG|Adefovir|From week -4 to week 2
214421607|NCT00922207|DRUG|Entecavir|From week -4 to week 2
214421608|NCT00922207|DRUG|Placebo|From week -4 to week 2
214421609|NCT00922207|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
214421610|NCT01802632|DRUG|AZD9291|Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
214421611|NCT01765686|DEVICE|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
215020615|NCT06481072|OTHER|Digital patient education and iCBT|This includes the educative intervention and a fully digital, four session version of the Aim to Decrease Anxiety and Pain Treatment (ADAPT), a CBT treatment program for FAPD. The treatment focuses on pain-management through the following core elements; The Pain-Gate Theory, breathing and relaxation strategies, calming statements, activity pacing, problem solving and behavior activation. This intervention is also accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform.
215020616|NCT01229202|DRUG|Bevacizumab|single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
215020617|NCT03288831|DIETARY_SUPPLEMENT|Gluten|Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.
215020618|NCT03288831|DIETARY_SUPPLEMENT|Placebo|Subjects will drink a mixture of rice water and Tang flavoring one time.
215020619|NCT05538650|BEHAVIORAL|Mindfulness-Based Social Work and Self Care (MBSWSC)|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory. This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The programme has been the subject of an initial RCT, which has helped to inform the current programme content and structure. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
215020620|NCT05538650|BEHAVIORAL|Mindfulness-Based Self-Care (MBSC)|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion/self-care. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
215020621|NCT05287100|DRUG|Midodrine Oral Tablet|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
215020622|NCT05287100|OTHER|Standard Medical Treatment|"Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is \< 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to \< 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (\>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3"
215020623|NCT00507507|DRUG|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
215020624|NCT00507507|DRUG|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
215020625|NCT00507507|DRUG|Placebo|Placebo to match FTC taken once daily
215020626|NCT02916433|DRUG|Octreotide|
215020627|NCT04918797|BIOLOGICAL|COVAXIN|Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)
215020628|NCT05847335|BEHAVIORAL|Survey work|Childhood Trauma scale, Personality Beliefs questionnaire, Emotional Intelligence scale
215020629|NCT01412983|DEVICE|Bausch & Lomb Test lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
214421612|NCT01765686|DEVICE|Ligasure Small Jaw (Covidien, USA)|
214421613|NCT00427752|PROCEDURE|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
214421614|NCT02342119|OTHER|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
214506699|NCT05099562|DEVICE|Acupuncture|Patients received standardized acupuncture treatment. A blood sample of genomic DNA storage was taken from the back of the hand between the first and second metacarpals. Genotypes were obtained by oligonucleotide ligation/polymerase chain reaction and capillary electrophoresis of peripheral neuropathy-associated SNPs.
214506700|NCT05005351|DEVICE|Digital ACT|Participants in Digital ACT arm complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual.
214506701|NCT05005351|DEVICE|Digital Symptom Tracker|Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual.
215020630|NCT01412983|DEVICE|Ciba Vision soft contact lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
215020631|NCT01623154|OTHER|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
214506702|NCT01852045|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
214506703|NCT05085704|DEVICE|Magnetic resonance imaging|Medical imaging technique used in radiology to form pictures of the anatomy.
214506704|NCT00407706|PROCEDURE|blood test|
214506705|NCT01705366|PROCEDURE|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
214506706|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
214421615|NCT02342119|OTHER|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
214421616|NCT03890016|DIAGNOSTIC_TEST|20'Whole Blood ClottingTest (WBCT)|"1ml of blood drawn from snake bite victims in clean glass test tubes of 1 cm diameter Kept undisturbed for a period of 20 minutes (measured by a stop watch). At the end of 20 minutes the tube is tilted to see if the blood has clotted or not.~If a well formed clot is not formed, the test is recorded as 'abnormal'.~If the clot seems well formed, it is further observed for a period of 30 minutes to look for dissolution of the formed clot and would be termed clot lysis. Clot lysis indicates an unstable clot."
214421617|NCT03890016|DIAGNOSTIC_TEST|Modified Lee and White (MLW) Method Clotting Time|"The blood collected in three additional test tubes would be utilised for MLW.~The three test tubes would be kept on a rack at ambient temperature.~The blood sample would be drawn in a 5cc syringe and 1 ml would be added in the three test tubes consecutively.~The test tube would be left undisturbed for 5 minutes, after that the first tube would be tilted approximately to check for clot formation every 30 seconds while the other tubes are left undisturbed.~After the blood in the first tube has clotted, the time would be noted and the second tube would be tilted every 30 seconds and examined.~Following its clotting, the third tube would be examined. The time at which the third tube is recorded as the CT value.~Once clotted, then the sample in the all three test tube would be assessed at 20 minute and 30 min to look for breakup or lysis of the clot."
214421618|NCT05381571|OTHER|Motivating reminiscence physical therapy|The jDome BikeAround system involves participants using a stationary bike while their selected location is displayed in front of them on a domed projector screen using Google Street View. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
214690168|NCT00702156|DRUG|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
214421619|NCT00176813|DRUG|Gemcitabine|
214506707|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
214506708|NCT01705366|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
214690169|NCT00702156|DRUG|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
214690170|NCT04712656|DEVICE|CPAP therapy|CPAP treatment of obstructive sleep apnea.
215029145|NCT05714748|BIOLOGICAL|EBV mRNA vaccine|With 25ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval
214690171|NCT05377177|DEVICE|Accelerated Theta Burst Stimulation|B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
214690172|NCT03810209|DRUG|Magnesium Sulphate|adding magnesium sulphate to local anaesthetic in SAP Block
214690173|NCT03810209|DRUG|Normal saline|adding normal saline to local anaesthetic in SAP block
214690174|NCT05154266|BEHAVIORAL|Taking it Further|This programme is offered to individuals who have already completed a Mindfulness-Based Cognitive Therapy (MBCT) or Mindfulness-Based Stress Reduction Programme (MBSR). In this programme, participants explore weekly themes (i.e. 'Responding not reacting' and 'Taking care of ourselves, taking care of others'). These themes reinforce the learning from the eight-week MBCT/MBSR courses whilst also providing new learning opportunities. The programme makes some of the dimensions that are implicit in MBCT/MBSR more explicit; for example, the cultivation of attitudes of mindfulness (such as equanimity, joy, and kindness). These attitudes of mindfulness require a foundational mindfulness practice and thus this is an additive learning theme from traditional MBCT/MBSR programmes.
214690175|NCT00489840|DRUG|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
214690176|NCT00489840|DRUG|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
214690177|NCT00681538|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
214690178|NCT00681538|DRUG|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
214690179|NCT00630812|DRUG|inhaled mannitol|400 mg BD for 26 + 26 weeks
214690180|NCT00630812|DRUG|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
215102641|NCT05378061|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
214421620|NCT00176813|DRUG|Cisplatin|
214421621|NCT00176813|DRUG|Celecoxib|
214690181|NCT04604314|DEVICE|CEREC Tessera|Full ceramic endocrown restorations will be made from the high strength ceramic, CEREC Tessera
214690182|NCT04373642|DRUG|Pebrolizumab + QUADSHOT Radiotherapy|"Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab."
214690183|NCT05946395|DEVICE|Hearing aid|Fitting a hearing aid
214690184|NCT05946395|OTHER|Speech therapy session|As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
214690185|NCT06122675|DEVICE|DBS|Implanted in the cerebellum.
215020632|NCT00693732|DRUG|Escitalopram treatment|On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
215020633|NCT00693732|BEHAVIORAL|Quantitative sensory testing|Rectal Distention Stimulation
214506709|NCT01705366|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
215020634|NCT03286075|DEVICE|tDCS Anode session|"The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.~The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
215020635|NCT03286075|DEVICE|tDCS Cathode session|"The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.~This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
215102642|NCT05522595|DEVICE|S360|"In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care).~A first diagnosis is established according to the interpretation of the results by a first evaluator.~In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360.~A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator."
214421622|NCT02326649|DEVICE|Physioflow|impedance cardiography instrument that measures cardiac output non-invasively
214421623|NCT05702996|DRUG|Eculizumab administration|Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab
214506710|NCT01705366|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
214506711|NCT01962597|OTHER|aerobic exercise|
214690186|NCT06043700|OTHER|No Intervention|No treatment intervention will be administered.
214506712|NCT01962597|OTHER|resistance training|
214506713|NCT05533905|DIAGNOSTIC_TEST|Lumbar puncture|A thin needle is inserted between the bones in the spine.
214506714|NCT05533905|DIAGNOSTIC_TEST|MRI|A scan of the head.
214506715|NCT03918005|OTHER|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
214506716|NCT01487954|DIETARY_SUPPLEMENT|alkaline water|Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
214690187|NCT01728584|DRUG|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
214421624|NCT03814668|DIETARY_SUPPLEMENT|Probiotic|Intake of probiotic
214421625|NCT03814668|DIETARY_SUPPLEMENT|Lactase|Intake of lactase
214506717|NCT01487954|DIETARY_SUPPLEMENT|distilled water|Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
214506718|NCT01487954|RADIATION|external beam radiation therapy (EBRT)|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
214506719|NCT00487240|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
214421626|NCT03814668|OTHER|Placebo|Intake of placebo
214421627|NCT03781206|DEVICE|PICO™ 7|PICO™ system (Smith\&Nephew Healthcare, Hull, UK) is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips.
214421628|NCT03404154|DIAGNOSTIC_TEST|3D ultrasound|it describes the diagnostic test which is 3D us to diagnose the cause of postmenopausal bleeding
214421629|NCT03404154|PROCEDURE|Dilatation and curretage|it describes the surgical maneuver that will be made to diagnose cause of bleeding
214421630|NCT00541125|BIOLOGICAL|bevacizumab|
214421631|NCT00541125|BIOLOGICAL|filgrastim|
214506720|NCT00487240|DRUG|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
214506721|NCT05072002|OTHER|no intervention / observational study|no intervention / observational study
214506722|NCT04027985|OTHER|Kinesiotaping|inesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
214690188|NCT01728584|OTHER|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~* Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~* Low insufflation pressure - a starting pressure of 8 mmHg will be used."
214690189|NCT01728584|DRUG|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
214690190|NCT04699903|DIAGNOSTIC_TEST|POC SARS-Cov-2 IgG Antibody test|All patients will undergo a Point of care (POC) SARS-Cov-2 IgG Antibody test in fingerstick whole blood
214421632|NCT00541125|DRUG|fluorouracil|
214421633|NCT00541125|DRUG|irinotecan hydrochloride|
214421634|NCT00541125|DRUG|leucovorin calcium|
214506723|NCT04027985|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.
214690191|NCT02014935|OTHER|Low intensity laser|"The study wants to evaluate the use of low intensity laser on the spastic muscle.~Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate."
215020636|NCT03286075|DEVICE|tDCS Placebo session|"This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)"
215020637|NCT03256656|OTHER|electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials|
215020638|NCT05858151|BEHAVIORAL|Food system and demand generation|The Global Alliance for Improved Nutrition (GAIN) will implement the Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable program, which will use a market-based approach to improving diets through food systems. The set of interventions proposed is based on characteristics and challenges of the food environments of bottom of pyramid consumers in Mozambique. GAIN will focus on elements of the food environment related to accessibility, affordability, and desirability of animal source foods (ASFs) in Mozambique.
215020639|NCT00890097|DRUG|AL-8309B Ophthalmic Solution|
215020640|NCT00890097|DRUG|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
215020641|NCT04784871|BEHAVIORAL|5waysA Intervention|Web-based 10 week intervention, encouraging participants engaging in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
215020642|NCT04784871|BEHAVIORAL|5waysA Active wait-list control|Writing activity log in the waiting time. Then, after five months and the writing of activity log, the participants get the web-based intervention and SMS massages, which encourage the participants to engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
215020643|NCT04784871|BEHAVIORAL|5waysA Inactive wait-list control|No activity while the participants wait. After five months of waiting, the participants get the web-based intervention and SMS messages, which encourage participants engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
215020644|NCT01163877|DIETARY_SUPPLEMENT|Fe-57 orally, Fe-58 intravenously|Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
215020645|NCT05515263|DIETARY_SUPPLEMENT|Intervention snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
214421635|NCT05402735|DIAGNOSTIC_TEST|Serum uric acid level|Serum uric acid level
214421636|NCT02423135|BIOLOGICAL|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
214421637|NCT01983306|DRUG|SP-333 1 mg|Tablet
214421638|NCT01983306|DRUG|SP-333 3 mg|Tablet
214421639|NCT01983306|DRUG|SP-333 6 mg|Tablet
214421640|NCT01983306|DRUG|Placebo|Tablet
214421641|NCT02135172|BEHAVIORAL|Sitting|
214421642|NCT02135172|BEHAVIORAL|Standing|
214421643|NCT02135172|BEHAVIORAL|Walking|
214421644|NCT00243854|DRUG|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
214421645|NCT06333132|BEHAVIORAL|Weight loss-induced Diabetes Remission|Patients will undergo a dietary intervention plus drugs (if needed) with the purpose to obtain a 10% (or at least 10 kg) body weight reduction to achieve diabetes remission
214421646|NCT01052454|BEHAVIORAL|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
214506724|NCT04027985|OTHER|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
214421647|NCT01628237|DEVICE|comparison of spinal cord stimulation|
214506725|NCT04019067|DIAGNOSTIC_TEST|MCE first|"Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours."
214690192|NCT06511999|DEVICE|Continuous SjO2 monitoring with a PediaSat Oximetry Catheter|The PediaSat Oximetry Catheter is capable of continuous, indwelling measurement of venous oxygen saturation, which is displayed on a bedside monitor connected by an optical cable. Enrolled participants will undergo continuous SjO2 measurement for 72 hours. Clinical care will not be directed by the continuous SjO2 values.
214694083|NCT01054677|BEHAVIORAL|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
215020646|NCT05515263|DIETARY_SUPPLEMENT|Control snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
214421648|NCT02578615|OTHER|physiotherapy|physiotherapeutic intervention according to the principles of the Spiraldynamik® concept
214421649|NCT02418806|BEHAVIORAL|Psychotherapy groups|
214421650|NCT02418806|BEHAVIORAL|Self-help groups|
215020647|NCT02516111|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
215020648|NCT02516111|BIOLOGICAL|OFD with PRF|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
214690193|NCT06511999|DIAGNOSTIC_TEST|Intermittent SjO2 monitoring with a PediaSat Oximetry Catheter|The PediaSat Oximetry Catheter is also capable of intermittent blood sampling enabling measurement of SjO2 on a laboratory blood gas analyzer. Enrolled participants will undergo intermittent SjO2 measurement every 4-6 hours for 72 hours. Clinical care will be directly by the intermittent values.
214421651|NCT00109785|PROCEDURE|positron emission tomography|
214421652|NCT00109785|RADIATION|fludeoxyglucose F 18|
214421653|NCT00109785|RADIATION|iodine I 124 iododeoxyuridine|
214421654|NCT06554548|DRUG|HS-10518|Treatment A: Single oral dose of HS-10518 160 mg tablet under fasted conditions Treatment B: Single oral dose of HS-10518 160 mg tablet after a high-fat meal
214421655|NCT02770599|OTHER|IBD multidisciplinary team model including IBD nurse|IBD multidisciplinary team model including IBD nurse
214421656|NCT01953757|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
214421657|NCT01953757|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
214421658|NCT04558424|DIETARY_SUPPLEMENT|zinc gluconate and ascorbic acid|This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
214421659|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|5mg/day
214421660|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|10mg/day
214690194|NCT04821310|DRUG|Full dose Pantoprazole plus matching placebo|Full healing dose of pantoprazole plus matching placebo
214690195|NCT04821310|DRUG|Half Dose Pantoprazole plus matching placebo|Half healing dose of pantoprazole plus matching placebo
215020649|NCT02516111|DRUG|OFD with ALN|Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
215020650|NCT02516111|DRUG|OFD with ATV|Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
215020651|NCT06753903|PROCEDURE|PCD-CT|Photon-counting detector computed tomography
215020652|NCT02408770|DRUG|ulipristal acetate|selective progesterone receptor modulator
214421661|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|25mg/day
214421662|NCT00288691|DRUG|Placebo|Placebo
214421663|NCT01230840|DIETARY_SUPPLEMENT|wheat dextrin|5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
214421664|NCT01230840|DIETARY_SUPPLEMENT|placebo|cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
214421665|NCT02892162|PROCEDURE|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
214421666|NCT02061228|DEVICE|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
214421667|NCT03385967|DRUG|Dexmedetomidine|Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
214421668|NCT03385967|DRUG|ropivacaine|Standard of care 0.5%ropivacaine
214421669|NCT03969472|DRUG|probiotics|apply probiotic after operation
214421670|NCT03969472|DEVICE|Electrophysiologic Therapy|Pelvic floor electrophysiological therapy is used after surgery
214421671|NCT03630224|DRUG|Plasmalyte Viaflo|Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
214421672|NCT03630224|DRUG|NaCl 0.9%|Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
214421673|NCT01392313|DIETARY_SUPPLEMENT|Carnitine|Carnitine Ingestion
214421674|NCT01392313|DIETARY_SUPPLEMENT|Placebo|Carnitine placebo
214421675|NCT05769517|DIAGNOSTIC_TEST|Germinal BRCA|We will conduct a multicenter prospective observational study aimed at automatically implementing the predictive model and collecting US images of healthy ovaries from patients tested for germline BRCA pathogenetic variants according to current indications.
214421676|NCT03058965|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
214421677|NCT03058965|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-958.
214690196|NCT05815433|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
215020653|NCT00954538|DRUG|[18F]MK-3328|IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
215020654|NCT05924230|OTHER|RL 10ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area
215020655|NCT05924230|OTHER|RL 15ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
215020656|NCT01942512|DEVICE|Endovascular treatment of intracranial aneurysm|
215020657|NCT05362539|PROCEDURE|Cystoscopy|diagnostic cystoscopy for detection of any bladder lesions
215020658|NCT05362539|DIAGNOSTIC_TEST|Computed tomography|Computed tomography for patients to exclude bladder lesions
215020659|NCT05362539|GENETIC|DNA hypermethylation assay|DNA hypermethylation assay of six genes (GATA4, P16, P14, APC, CDH1 and CD99)
215020660|NCT05362539|DIAGNOSTIC_TEST|Urine cytology|voided urine cytology for all patients
215020661|NCT02148627|DRUG|LY3041658 (SC)|Administered SC
215020662|NCT02148627|DRUG|LY3041658 (IV)|Administered as slow IV infusion
215020663|NCT02148627|DRUG|Placebo|Administered as slow IV infusion
215020664|NCT01164969|DRUG|Antibiotics to which H. pylori can not develope resistance|Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
215020665|NCT01452217|DRUG|Secretin|Secretin 1 IU/kg over 3 min
215020666|NCT01801969|OTHER|Rehabilitation service|"* Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~* Size of the municipality responsible for providing rehabilitation services after discharge from hospital"
215020667|NCT03338686|PROCEDURE|Free Gingival Graft (FGG)|Free Gingival Graft (FGG) was performed on all study sites in this arm.
215020668|NCT03338686|PROCEDURE|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
215020669|NCT03555045|PROCEDURE|conducting the slanted recession technique on the superior and inferior poles|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
215020670|NCT03555045|PROCEDURE|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
215020671|NCT05042687|DRUG|Tc99m sestamibi|Given by IV
214421678|NCT03058965|DRUG|DaTscan|DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
214421679|NCT04424836|DEVICE|high flow nasal cannula device|device is supplying oxygen with heated and humidified air in a high flow rate
214421680|NCT00751075|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
215020672|NCT03178942|DRUG|Permethrin Cream, 5%|Permethrin Cream 5%
215020673|NCT03178942|DRUG|Elimite™ Cream (permethrin) 5%|Permethrin Cream 5%
215020674|NCT00490997|DRUG|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
215020675|NCT00490997|DRUG|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
215020676|NCT01657942|DEVICE|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
215020677|NCT02669108|DEVICE|PET/ MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
215020678|NCT06896734|DEVICE|Evaluation of the ECG signal in the nominal location and in three alternate positions|Evaluation of the ECG signal in the nominal location and in three alternate positions to determine if the three alternate positions are interpretable.
215020679|NCT06891222|DIAGNOSTIC_TEST|AI-ECG (artificial intelligence-enabled electrocardiogram)|Participants will undergo electrocardiogram analysis using AI-ECG during the baseline visit
215020680|NCT06891222|DIAGNOSTIC_TEST|Focus Screening (focused cardiac ultrasonography)|Participants will undergo a focused cardiac ultrasound if the AI-ECG reflects a positive value
214421681|NCT00751075|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
214421682|NCT00751075|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
214421683|NCT00751075|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
214421684|NCT03698708|BEHAVIORAL|CARES Intervention|A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
214421685|NCT00476255|BEHAVIORAL|Enhanced Standard Care (ESC)|Reading material
214421686|NCT00476255|BEHAVIORAL|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
214421687|NCT03922412|PROCEDURE|PLANTAR BLOCK|"1. Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of mepivacain 1% (200mg)~2. Plantar block 10 minutes later : patient in supine position. Medial midfoot injection of 5 ml of the mixture labelled  BLOC PLANTAIRE  containing 5 ml of Ropivacaine 0,5% (25mg) with 0,5 ml dexaméthasone (2mg)~3. Distal deep fibular block : patient in supine position, injection around the dorsal foot artery of 2 ml of the mixture labelled  BLOC FIBULAIRE  containing 2 ml of Ropivacaine 0,5% (10mg)."
214421688|NCT03922412|PROCEDURE|Sciatic popliteal block|"1-Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of ropivacaine 0,5% (100mg) with 2mg (0,5 ml) of dexamethasone"
214421689|NCT04635267|OTHER|Prone position in patients with ARDS|Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
214421690|NCT02806869|DRUG|Single dose of ibuprofen (800 mg tablet)|
214506726|NCT04148885|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
214421691|NCT02806869|DIETARY_SUPPLEMENT|Pulmocare, two 8.0 oz (236.6 mL) cans|
214421692|NCT00360451|BEHAVIORAL|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
215020681|NCT03023696|PROCEDURE|Bilateral Cervical Keyhole Foraminotomy|Under microscopic or loop magnification, a high-speed burr is used to perform the foraminotomy. The keyhole foraminotomy begins at the lamina-facet junction, with careful consideration of the amount of facet resection. Typically, only the medial one third is drilled. Then a 1- or 2-mm Kerrison punch can be carefully placed over the nerve root and then used to undercut the facet, ensuring that the spine is not destabilized by the foraminotomy. The amount of facet resection must not exceed 50% in order to preserve spine stability.
215020682|NCT03023696|PROCEDURE|Cervical Decompression|Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion
215020683|NCT06926361|BEHAVIORAL|Mindfulness for Life|Behavioral: Mindfulness for Life (MBCT-L) MBCT-L is an 8-week program consisting of mindfulness practices and cognitive-behavioral techniques with 8 sessions (2 hours and 15 minutes per session) and one-day retreat that can provide participants with an extended period to deepen their personal mindfulness practices.
215020684|NCT06926361|BEHAVIORAL|Positive education training|Positive Education program is an 8-week course consisting of theories and activities of positive psychology to enhance teachers' skills to support students' learning and wellbeing using a strength-based approach.
215020685|NCT04225819|DIETARY_SUPPLEMENT|Vitamin D3|Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
214421693|NCT00360451|BEHAVIORAL|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
214421694|NCT02652936|DRUG|AF-130|AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
214421695|NCT02652936|DRUG|Placebo comparator|AF-130 matching placebo capsule
214421696|NCT03495713|DRUG|Nivolumab|Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
214421697|NCT04001517|DRUG|Neflamapimod|Double-Blind, Placebo-Controlled
214421698|NCT05081310|DEVICE|superior vena cava isolation|SVC isolation by the means of cryoballoon
214506727|NCT04148885|DRUG|carboplatin|Patients secondly receive carboplatin AUC=5 (iv, 30 minutes) on days 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
214506728|NCT01698918|DRUG|Everolimus|Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
214506729|NCT01698918|DRUG|Letrozole|1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
214506730|NCT01698918|DRUG|Exemestane|2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
214506731|NCT01698918|DRUG|Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)|Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
214506732|NCT01698918|DRUG|Standard of care to treat stomatitis (Stomatitis sub-study)|Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
214506733|NCT05851157|DRUG|VX-548|Tablets for oral administration.
215020686|NCT04225819|OTHER|Placebo|Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
215020687|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
215020688|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
215020689|NCT05529953|DIETARY_SUPPLEMENT|Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)|Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects
214421699|NCT05081310|DEVICE|pulmonary vein isolation|conventional pulmonary vein isolation by the means of cryoballoon
214421700|NCT06356116|OTHER|Usual care|"During hospitalization, physical therapist visits the patient once or twice on day one or two post-operative (treatments including bedside standing, ambulation, stepping, active-assisted range of motion exercises).~Educational material will be given at discharge from hospital."
214506734|NCT03192501|DRUG|inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.|Choose appropriate targeted drugs according to NGS/IHC results.
215020690|NCT05529953|DIETARY_SUPPLEMENT|Control commercial olive oil|Postprandial study of Oleanolic acid bioavailability in healthy subjects
215020691|NCT04755725|DEVICE|Epidural catheter|epidural catheter inserted pre induction
215020692|NCT04755725|DEVICE|rectus sheath catheter|The surgeon will place one hand inside the abdomen and with the other hand inserted the Tuohy needle through the skin and fascia. The surgeon will feel when the needle tip is just superfacial to interface between the peritoneum and muscle layer and avoid penetration of inferior epigastric artery. The procedure will be repeated on the contralateral
214421701|NCT06356116|OTHER|Accelerated rehabilitation|"Physical therapist visits 5 times during hospitalization, including~1. Pre-operatively: instruction regarding range of motion exercises, use of assistive device.~2. Post-operative day zero: bedside standing, ambulation, stepping, active-assisted range of motion exercises.~3. Post-operative day one: visit #1 continuing the day-zero exercises;~4. Post-operative day one: visit #2 mini-squat against wall; stair negotiation training (1/2 flight).~5. Post-operative day two: continuing the day-zero exercises; stair negotiation (1 flight); discharge from hospital in the afternoon.~After discharge from hospital: post-operative day three \~ week 4: telerehabilitation"
215020693|NCT04938466|DRUG|Long-Acting Growth Hormone (LAGH)|Long-acting growth hormone (LAGH) treatment
215020694|NCT00851136|DRUG|bevacizumab|Intravenous repeating dose
215020695|NCT00851136|DRUG|FOLFOX|Intravenous repeating dose
215020696|NCT00851136|DRUG|PRO95780|Intravenous repeating dose
214421702|NCT02880241|DRUG|MMV390048|Tablets of 20mg each
214421703|NCT05516641|DIETARY_SUPPLEMENT|Soluble Corn Fiber|once daily additive to diet
214421704|NCT05516641|DIETARY_SUPPLEMENT|Maltodextrin|once daily additive to diet
214421705|NCT01131624|DRUG|ferrous sulphate|200 mg iron per day in a convenient dosage schedule.
214421706|NCT01131624|DRUG|Ferinject|1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
214421707|NCT04250285|OTHER|descriptive method|After obtaining relevant permissions from the university and organization of education and selecting participants, the study was explained for students and their satisfaction obtained. Then questionnaires were given to participants. To observe ethical considerations, questionnaires were anonymous and has been confided that the participants' responses was maintained in the study and is not given anyone
214421708|NCT03253913|DRUG|Sirolimus|Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
214421709|NCT03253913|DRUG|Resveratrol|Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
214421710|NCT05983107|DRUG|Everolimus|Everolimus combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
214421711|NCT05983107|DRUG|Chidamide|Chidamide combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
214506735|NCT01019135|BEHAVIORAL|Cardiac Rehabilitation|comparison of multiple cardiac rehabilitation program models
214506736|NCT03690466|DEVICE|Study device treatment|The ultrasound portable device comprises a tabletop control unit and a transducer connected to the control unit by a cord.
215020697|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
215020698|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
215020699|NCT06955962|OTHER|Mandala Art Therapy|Arm Description: The mandala art therapy for individuals in the intervention group is planned to be conducted in their home environments under suitable conditions. The therapy sessions will be accompanied by music of the participants' choosing and are scheduled to take place over a six-week period, at least three to four times per week, for a minimum of 30 minutes per session. Before the first mandala art therapy session, participants in the intervention group will receive a brief orientation by the researcher on the appropriate environment for the practice and an introduction to mandala art therapy. This orientation will include information on the definition and characteristics of mandala art therapy, the application setting and duration, and general guidelines to be followed during the sessions. At the end of the six-week mandala art therapy program, Post-tests ill be administered face-to-face, and the archived mandala folders will be collected
214506737|NCT03690466|DEVICE|Sham device treatment|A similar device as used for the study device treatment will be used, except that no energy will be delivered to the spleen.
214506738|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
214506739|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
214506740|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
215020700|NCT05812495|PROCEDURE|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
215020701|NCT05812495|PROCEDURE|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
215020702|NCT03756935|PROCEDURE|All monitoring|Dicpleth and PI are obtained a posteriori from the PPG waveform reconstruction and blindly from ABP values. Dicpleth is defined as the ratio of the height of the dicrotic notch (from nadir point of the complex to the notch) to the height of the systolic peak (from nadir point of the complex to the pic), measured at end-expiratory time (average of 3 consecutive complex). PI is calculated as the ratio of the pulsatile component of the PPG signal and the continuous component.
214421712|NCT05983107|DRUG|Endocrine therapy|Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.
214421713|NCT05983107|DRUG|Ovarian function suppression(OFS)|Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.
214421714|NCT02018224|PROCEDURE|End-to-end suturation without augmentation|End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
214421715|NCT02018224|PROCEDURE|End-to-end suturation with augmentation.|End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
214421716|NCT02110056|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
214421717|NCT02110056|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
214421718|NCT03332992|BEHAVIORAL|Viral changes|Telephone script language provided pre-questions regarding the fact that influenza viruses change each year
214421719|NCT03332992|BEHAVIORAL|Protect others|Telephone script language provided pre-questions emphasizing the need to protect vulnerable others
214421720|NCT03332992|BEHAVIORAL|General intentions|Question language asking about general interest in getting influenza vaccination
214421721|NCT03332992|BEHAVIORAL|Behavioral intentions|Question language asking individual to make specific plans to be vaccinated
214421722|NCT03332992|BEHAVIORAL|Accountability|Question language asking individual whether their care team can learn about their vaccination intentions
214421723|NCT04812951|DRUG|CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion|one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
214421724|NCT04812951|DEVICE|cationorm eye drops|one cationorm eye drop twice a day for 30 preoperative days
215020703|NCT03061214|DRUG|Semaglutide 0.5 mg|Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
215020704|NCT03061214|DRUG|Semaglutide 1.0 mg|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
214421725|NCT04014803|DRUG|Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin|"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~1. Prasugrel plus Aspirin arm~2. Clopidogrel plus Aspirin arm"
215020705|NCT03061214|DRUG|Sitagliptin placebo|Sitagliptin placebo tablets taken once-daily for 30 weeks
215020706|NCT03061214|DRUG|Sitagliptin|100 mg sitagliptin tablets taken once-daily for 30 weeks
215020707|NCT03061214|DRUG|Semaglutide placebo 0.5 mg|Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
215020708|NCT03061214|DRUG|Semaglutide placebo 1.0 mg|Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
215020709|NCT03971045|DRUG|Pembrolizumab|Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
215020710|NCT00485342|DRUG|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
215020711|NCT00485342|DRUG|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
215020712|NCT04356703|OTHER|Neuropsicomotor developmental test|Children will be evaluated trough Bayley III and PEDI scale. They also will be examined by pediatrician, neurosurgeon, orthopedics and phisiatry
215020713|NCT01729429|BEHAVIORAL|HPV brochure, recall, reminders|"* HPV-vaccine specific brochure mailed before clinic visit~* Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~* Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
215020714|NCT01729429|BEHAVIORAL|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
215020715|NCT02012777|DRUG|propranolol|Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
215020716|NCT05281653|BEHAVIORAL|Neuromuscular exercise Training|Progressive neuromuscular exercise training
215020717|NCT05281653|BEHAVIORAL|Routine training sessions|Routine training sessions
215020718|NCT04205825|OTHER|The New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
215020719|NCT04759404|OTHER|Deep Oscillation Treatment|Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
214506741|NCT00637858|DIETARY_SUPPLEMENT|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
214506742|NCT00637858|OTHER|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
215020720|NCT04759404|OTHER|Myofascial Release Treatment|Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
214506743|NCT06470386|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
214506744|NCT06470386|DRUG|Carvedilol|taken orally, starting dose of 6.25 mg once a day, gradually adjusted according to heart rate to 6.25 mg twice a day, 12.5 mg in the morning and 6.25 mg in the evening, 12.5 mg twice a day, or adjusted to the maximum tolerated dose (heart rate greater than 55 beats/min and systolic blood pressure greater than 90 mmHg), taken continuously for 24 weeks.
214506745|NCT05087407|PROCEDURE|Decomprssion and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
214506746|NCT05087407|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
214506747|NCT02353507|DEVICE|Opticell Ag+|
214506748|NCT02353507|DEVICE|Aquacel Ag+|
214506749|NCT05738785|OTHER|Document review and scanning|Osteoporosis risk and osteoporotic fracture risk will be calculated by examining the patients' files.
214506750|NCT00010959|DRUG|Cimicifuga racemosa|
214506751|NCT00010959|DRUG|Trifolium pratense|
214506752|NCT02558543|DRUG|Stromal Vascular fraction|
214506753|NCT02558543|DRUG|Ringer lactate|
214506754|NCT01244997|PROCEDURE|Dental Implant|This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
214506755|NCT02064283|PROCEDURE|Diffusion MRI|
214421726|NCT03189316|OTHER|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
214421727|NCT06467253|DEVICE|1. rTMS + CS|"In the first phase each participant will receive 15 sessions of rTMS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of rTMS and 1 session of CS per week for 12 weeks. Each session will consist of 10 trains of 10 stimuli, at a 5-Hz frequency and a stimulation intensity of 120% of the resting motor threshold.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The rTMS condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
214421728|NCT06467253|DEVICE|2. rTMS Sham + CS|"In the first phase each participant will receive 15 sessions of rTMS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham rTMS and 1 session of CS per week for 12 weeks.~In total, each participant will receive 27 sessions of Sham rTMS and 21 sessions of CS.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The sham condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
214421729|NCT06467253|DEVICE|3. tDCS + CS|"In the first phase each participant will receive 15 sessions of tDCS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of tDCS and 1 session of CS per week for 12 weeks. Each session will consist of the delivery of a weak direct current of 2mA for 30 minutes.~tDCS will be administered by the Sooma tDCS stimulator. The tDCS condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of tCDS and 21 sessions of CS."
215020721|NCT01625078|DEVICE|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
215020722|NCT01357746|PROCEDURE|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
215020723|NCT00600704|PROCEDURE|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
215020724|NCT00600704|PROCEDURE|Free fluid infusion|Free fluid infusion unless Hb\< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
214506756|NCT03971552|PROCEDURE|gadolinium-enhanced extracranial magnetic resonance angiogram|288 of the 912 acute ischemic stroke patients received gadolinium-enhanced extracranial MRA additionally to the standardized stroke MRI imaging protocol.
214506757|NCT02052167|DEVICE|methotrexate prefilled pen|
214506758|NCT05512299|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
214506759|NCT04037072|DRUG|Mitomycin C|Topical application of Mytomycin C (MMC)
214506760|NCT04037072|OTHER|Control|Topical application of Normal Saline
214506761|NCT02222506|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
214506762|NCT05864625|DRUG|Remimazolam besylate|During induction, patients allocated to the remimazolam group will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combied with remifetanil.
214506763|NCT05864625|DRUG|Propofol/ Sevoflurane|During induction, patients allocated to the P/S group will receive propofol 1% 1-2mg/kg with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with sevoflurane and remifentanil.
214506764|NCT06489353|BEHAVIORAL|Video-watching|Participants will watch age-appropriate and engaging videos.
214506765|NCT06489353|BEHAVIORAL|Blowing Pinwheels|Participants will blow pinwheels during the venipuncture procedure
214506766|NCT05990933|DRUG|Adrenaline|Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
214506767|NCT00262015|BIOLOGICAL|· Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|
214506768|NCT01105988|OTHER|Radiologic exams|FLT PET scan x 2 MRI scan x 2
214506769|NCT02304757|DRUG|99Tc-MDP|99Tc-MDP, H20000218
214506770|NCT02304757|DRUG|Fosamax|H20080172
215020725|NCT02795962|OTHER|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
215020726|NCT00107614|DRUG|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with \< 50% response to induction) OR MEL-DT PACE (Patients with \> 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
214421730|NCT06467253|DEVICE|4. tDCS Sham + CS|"In the first phase each participant will receive 15 sessions of tDCS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham tDCS and 1 session of CS per week for 12 weeks.~tDCS will be administered by the Sooma tDCS stimulator. The sham condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of Sham tDCS and 21 sessions of CS."
214421731|NCT02068430|DRUG|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
215020727|NCT04632381|DRUG|Zotatifin|Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).
215020728|NCT04632381|DRUG|Placebo|5% dextrose injection, USP
215020729|NCT01532219|BEHAVIORAL|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
215020730|NCT01532219|BEHAVIORAL|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
215020731|NCT04198337|PROCEDURE|Endoscopic Full Thickness Resection|Endoscopic full thickness resection achieved by resecting the submucosal tumor using retraction techniques and submucosal dissection, followed by closure
215020732|NCT02672605|OTHER|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
215020733|NCT03780062|BIOLOGICAL|S100B protein dosing|Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L
215020734|NCT00842465|BIOLOGICAL|blood collection for hormonal status analysis|for hormonal status analysis
215020735|NCT00842465|PROCEDURE|breast Biopsy or surgery|breast Biopsy or surgery
215020736|NCT00842465|GENETIC|blood collection|blood collection for prlR gene sequencing
215020737|NCT00842465|OTHER|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
215020738|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies!|Fruits and Vegetables
215020739|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
215020740|NCT02918630|DRUG|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
215020741|NCT02918630|DRUG|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
215020742|NCT04705233|OTHER|sputum colour chart|5-point Sputum Colour Chart plus best standard care
215020743|NCT04297735|OTHER|Standard of care group|Visits every 6 months is standard of care.
215020744|NCT04297735|BEHAVIORAL|Telemedicine group|Conduct monthly telemedicine 'skype' visit
215020745|NCT04297735|BEHAVIORAL|Telemedicine|Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
215020746|NCT02389738|DRUG|Regadenoson|Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
214506771|NCT04437043|OTHER|quality of life questionnaires|pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
214506772|NCT04758949|DRUG|FL-101|200 mg administered intravenously every 2 weeks prior to surgery.
214506773|NCT04758949|DRUG|Nivolumab|240 mg administered intravenously every 2 weeks prior to surgery.
215020747|NCT02389738|DRUG|Temozolomide|Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
215020748|NCT02389738|DEVICE|Microdialysis catheter|Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
215020749|NCT06421454|DRUG|Melatonin|Pressure Ulcer will be treated with a melatonin cream daily
215020750|NCT06421454|DRUG|Hydrogel|Pressure ulcer will be treated with hydrogel daily as a comparator
215020751|NCT04739215|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg / day oral
215020752|NCT04739215|DRUG|Placebo|One Placebo capsule daily oral
215020753|NCT00235625|DRUG|Curcuminoids C3 Complex®|
215020754|NCT05874011|OTHER|understanding of prosody|The inverse correlation test consists of having the same word heard twice, and asking which of the two sounds the most like a question. The exercise will be repeated several times, for a task that will take a total of about thirty minutes
215020755|NCT04332770|OTHER|levothyroxine withdrawal|All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
215020756|NCT05524792|OTHER|no interventional study|no interventional study
215020757|NCT05890573|DRUG|Bailing capsule|6 Bailing capsules,po,tid,12 weeks
214421732|NCT02068430|OTHER|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
215020758|NCT06117631|BEHAVIORAL|Centering Parenting|See Arm description.
215020759|NCT06117631|BEHAVIORAL|Bright by Text|See Arm description.
215020760|NCT02576197|DIETARY_SUPPLEMENT|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
215020761|NCT02576197|DIETARY_SUPPLEMENT|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
215020762|NCT02715856|OTHER|Monitoring Device|Undergo surgical wound and physical activity monitoring
215020763|NCT02715856|OTHER|Physical Activity Measurement|Undergo physical activity measurement
215020764|NCT02715856|OTHER|Quality-of-Life Assessment|Ancillary studies
215020765|NCT02715856|OTHER|Questionnaire Administration|Ancillary studies
215020766|NCT02715856|PROCEDURE|Standard Follow-Up Care|Undergo standard follow-up care
215020767|NCT02715856|OTHER|Survey Administration|Ancillary studies
215020768|NCT06244823|DRUG|Fremanezumab Prefilled Syringe|MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.
215020769|NCT01177306|DRUG|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
214690197|NCT04779229|BEHAVIORAL|Parent Activation|Parent Activation (PA) is comprised of concrete social learning theory steps (i.e., direct instruction, modeling, practice opportunities, and reinforcement) that aim to enhance a parent's confidence, knowledge, and ability to manage his/her child's health. PA is applicable across a range of conditions, including behavioral and psychiatric problems, and it can be delivered by varied providers, including paraprofessionals.
214690198|NCT04779229|BEHAVIORAL|Usual Services|This intervention refers to the typical techniques that JPOs employ to monitor the juveniles on their caseloads (e.g., regular meetings with youth and parents to ensure the youth is following conditions of probation and issuing swift sanctions \[community service; detention\] if conditions are not being followed).
214690199|NCT04493411|PROCEDURE|WBMRI|"WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
215020770|NCT03607669|OTHER|Mangafodipir trisodium|Manganese-based MRI contrast agent
215020771|NCT03390400|DEVICE|Femtosecondlaser-assisted|Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.
214506774|NCT04758949|DRUG|Placebo|200 mg administered intravenously every 2 weeks prior to surgery.
214421733|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of high fat diet
214421734|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of low fat diet
214421735|NCT04713371|DRUG|Keytruda Injectable Product|"Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected."
214506775|NCT05884567|OTHER|Isometric exercises|These exercises are used to increase muscle endurance, power and ROM
214506776|NCT05884567|OTHER|Mobilization|These exercises are used to increase ROM and used for pain reduction
214506777|NCT00826826|PROCEDURE|Catheter ablation|(Pulmonary vein isolation)
215020772|NCT03390400|PROCEDURE|Anterior Capsulotomy|Cataract Surgery
215020773|NCT03390400|PROCEDURE|Lens Fragmentation|Cataract Surgery
215020774|NCT02213991|DEVICE|Intraoperative radiotherapy using Intrabeam®|"Operation day~1. Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~2. Purse string suture pulles up tissues and wraps up the applicator.~3. Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~4. After IORT, applicator was out of the operative field, and usual wound closure will be done.~   * Postoperative period~     * Chemotherapy WBRT (46 Gy) for 4\~5 weeks~    * Endocrine therapy or target therapy"
215020775|NCT01548326|DRUG|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
215020776|NCT01548326|DRUG|placebo|one Placebo tablet orally per day for 10 days
214421736|NCT04713371|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected."
214421737|NCT04713371|DRUG|Cytoxan|Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.
214506778|NCT00826826|DRUG|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
214506779|NCT00826826|DRUG|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
214506780|NCT02003872|DEVICE|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
214506781|NCT02767674|DRUG|Rituximab|375 mg/m2 IVD day0
215020777|NCT03863301|RADIATION|MR-guided single dose preoperative PBI|A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.
215020778|NCT01772693|DEVICE|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
215020779|NCT01772693|DEVICE|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
215020780|NCT05722769|BEHAVIORAL|CSTOP Now!|Child sex trafficking stops with you. Implement and evaluate the effectiveness of a multi-level bystander-informed program (CSTOP Now!) aimed at Kentucky public middle school staff. Participants will be trained to use the See It To Stop It Indicator Tool (SITSII) by using tiers of concern (clear concern, possible concern, and monitor of emerging concern). The SITSII tool directs the bystander actions to Decide, Directly Intervene, Disrupt, Delegate, and Document.
215020781|NCT05722769|BEHAVIORAL|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed videos we invite active comparator schools to review which also include how to identify and report child sex trafficking.
215020782|NCT05513105|DIAGNOSTIC_TEST|Iron study of neonates|Blood sambles
215020783|NCT05134519|DRUG|Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)|Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles
215020784|NCT01783808|OTHER|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
215020785|NCT01893450|DRUG|Methimazole|
215020786|NCT01893450|DRUG|Bromocriptine|
215020787|NCT01893450|DRUG|Pentoxifylline|
215020788|NCT01160718|DRUG|fulvestrant|Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
215020789|NCT01160718|DRUG|selumetinib|AZD6244 75 mg p.o. bid
215020790|NCT02525432|BIOLOGICAL|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
215020791|NCT02525432|BIOLOGICAL|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
215020792|NCT05646693|DIETARY_SUPPLEMENT|Drusen Mega®|It consists of a dietary supplement composed of Vitamin C 60.0mg, Vitamin E 30.0mg, Zinc 12.5mg, Copper 1.0mg, Astaxanthin 4.0mg, Zeaxanthin 2.0mg, Lutein 10.0mg and Omega 3 Acids 500.0mg. It is suggested to consume one capsule per day, preferably with food. This supplement is indicated for nutritional deficiencies and in patients with ophthalmological pathologies.
215020793|NCT05646693|DRUG|Sertraline|It consists of a drug capsule composed of Sertraline Hydrochloride 50mg. In adults it is suggested to consume one to four capsule(s) per day, administering (preferably) the highest dose in the evening, before going to bed. This drug is indicated in the treatment of depressive states with anxiety or moderate to severe agitation, which are accompanied by tension, excitement, insomnia, obsessive and hypochondriac traits. It is also indicated in obsessive-compulsive disorder, panic attacks, stress disorder, post-traumatic disorder, social anxiety disorder and used to relieve the symptoms of premenstrual dysphoric disorder.
214421738|NCT04713371|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.
214421739|NCT04713371|DRUG|GM-CSF Injectable|Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
214421740|NCT02705586|BEHAVIORAL|Mindfulness|Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
215020794|NCT05646693|DRUG|Placebo|It consists of a placebo capsule composed of Magnesium Oxide 100mg. This component is inert in the dose at which it will be administered.
214506782|NCT02767674|DRUG|Gemcitabine|Gemcitabine 1 g/m2 IVD day 1
214506783|NCT02767674|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IVD day1
215020795|NCT05052892|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
215020796|NCT05167058|DEVICE|Cardiologs Platform|Smartwatch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
215020797|NCT05084885|OTHER|Online therapy|Standard counseling provided over the internet.
215020798|NCT02094885|BIOLOGICAL|Bioseal Fibrin Sealant|
215020799|NCT02094885|OTHER|Manual Compression|
214421741|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 1 month|temporary discontinuation of hormone replacement therapy for 1 month prior to screening mammogram.
214506784|NCT02767674|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2 IVD d1
214506785|NCT02767674|DRUG|Epirubicin Injectable Product|Epirubicin 35 mg/m2 IVD d1
214506786|NCT02767674|DRUG|Vindesine|Vindesine 2 mg IVP d1
214506787|NCT02767674|DRUG|Prednisone|Prednisone 40mg/m2 PO d1-5
214506788|NCT01750424|PROCEDURE|Autologous Fat Grafting|
214506789|NCT01750424|OTHER|No intervention|Subjects in this arm will only be followed up and have no procedure performed.
214506790|NCT01802424|BEHAVIORAL|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
214506791|NCT00853411|DRUG|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
214506792|NCT02095678|PROCEDURE|liver biopsy|patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results
215020800|NCT03917901|OTHER|Anxiety Sensitivity Training|Computerized Single-Session Anxiety Sensitivity Reduction Program
215020801|NCT03917901|OTHER|Health Control|Computerized Single-Session Health Information Control
215020802|NCT04498273|DRUG|Apixaban 2.5 MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
215020803|NCT04498273|DRUG|Apixaban 5MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
215020804|NCT04498273|DRUG|Aspirin|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
215020805|NCT04498273|DRUG|Placebo|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
215020806|NCT02124421|PROCEDURE|Cytoreductive Surgery (CRS)|Cytoreductive surgery
215020807|NCT02124421|DRUG|Adjuvant Chemotherapy|Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
215020808|NCT02124421|OTHER|Questionnaire|Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
215020809|NCT02124421|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
215020810|NCT02124421|DRUG|Carboplatin|AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
215020811|NCT02124421|DRUG|Paclitaxel|175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
215020812|NCT02124421|DRUG|Paclitaxel|Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
215020813|NCT02124421|DRUG|Cisplatin|Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
215020814|NCT01950494|OTHER|fiteBac Hand Sanitizer|Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
215020815|NCT05199038|DRUG|Octreotide|Octreotide infusion for 2 days in patients with bleeding esophageal varices.
215020816|NCT04228653|DEVICE|Renishaw Drug Delivery System|Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.
214421742|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 2 months|temporary discontinuation of hormone replacement therapy for 2 months prior to screening mammogram
214421743|NCT04209049|DRUG|NNC0174-0833|A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
214421744|NCT01785004|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
214421745|NCT01785004|DRUG|omega-3 fatty acids (fish oil)|
214421746|NCT05515042|DRUG|Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)|As included in arm/group descriptions
214506793|NCT02095678|DEVICE|free-breathing MRI|All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to \<8 seconds and validate quantifiable techniques which improve liver image quality
214506794|NCT01553266|BEHAVIORAL|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
214506795|NCT01629420|DRUG|KLH-2109|
214506796|NCT01629420|DRUG|KLH-2109|
215020817|NCT05929911|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in the ability to reflect and affective regulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
214421747|NCT05237921|BEHAVIORAL|Combined Exercise and Dietary Intervention (CEDI)|"Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status.~Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Forticare®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake."
214421748|NCT05237921|BEHAVIORAL|Standard Care|Standard Care
214421749|NCT02194933|DRUG|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
214421750|NCT02789917|OTHER|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
214421751|NCT02789917|OTHER|Triple Therapy|"HAS-BLED-Score \<3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
214421752|NCT03053388|DRUG|Nitric Oxide|Nitric Oxide given via inhalation in cycles
215020818|NCT05369156|OTHER|Chiropractic Care|The actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent and the duration of the thrust is always less than 200 milliseconds.
215020819|NCT05369156|OTHER|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
215020820|NCT04747626|DEVICE|B-SAFER|Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
215020821|NCT01704560|OTHER|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
214421753|NCT03053388|OTHER|Supportive treatment|Supportive treatment (including oxygen)
214506797|NCT01756599|BIOLOGICAL|blood samples|
214506798|NCT02203799|BIOLOGICAL|Peanut Oral Immunotherapy (POIT)|The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
214421754|NCT05254171|DRUG|SBP-101|small molecule polyamine metabolic inhibitor for subcutaneous injection
214421755|NCT05254171|DRUG|Nab-paclitaxel|paclitaxel protein-bound particles for injectable suspension
214421756|NCT05254171|DRUG|Gemcitabine|gemcitabine for injection
214421757|NCT05254171|OTHER|Placebo|Normal Saline
214421758|NCT03400462|DRUG|NSAID|Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.
214421759|NCT03400462|DEVICE|oral appliance|The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.
214421760|NCT03400462|OTHER|dry needling|Equipment: acupuncture needle 0,6\*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
214421761|NCT01454661|DIETARY_SUPPLEMENT|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
214421762|NCT01454661|DIETARY_SUPPLEMENT|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
214506799|NCT03655366|OTHER|Questionnaire for Dog owners|Questionnaire directed to epileptic patients, parents of epileptic children and legal representatives of epileptic patients with intellectual disabilities. It includes questions about demographics, epilepsy diagnosis, seizures, the behavior of their dogs around the time they have a seizure and a validates scale to measure dog personality traits.
214421763|NCT01454661|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is used as placebo.
214421764|NCT02747563|OTHER|Blood test (PSA)|Measurement of blood PSA levels
214421765|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
214421766|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
214421767|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml|0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
214421768|NCT01312441|DRUG|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
214421769|NCT01312441|DRUG|Placebo|Placebo by mouth once weekly for 6 months
214421770|NCT02447263|PROCEDURE|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
215020822|NCT04046952|DEVICE|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
215020823|NCT04046952|DEVICE|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
215020824|NCT05598307|DRUG|magnesium bolus followed by normal saline infusion|a bolus dose of magnesium will be followed by normal saline infusion
215020825|NCT05598307|DRUG|magnesium bolus followed by magnesium infusion|a bolus dose of magnesium will be followed by a magnesium infusion
215020826|NCT05598307|DRUG|normal saline bolus followed by normal saline infusion|a bolus of normal saline will be followed by normal saline infusion
215020827|NCT00215553|DRUG|A.1 Lucinactant|3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
215020828|NCT00215553|OTHER|B.3 SoC|Standard ARDS management and ICU care
215020829|NCT00215553|DRUG|A.2 Lucinactant|3 30 mL aliquots at a concentration of 10 mg/mL each
215020830|NCT00215553|DRUG|A.3 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
214421771|NCT02045836|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
214421772|NCT02045836|BIOLOGICAL|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
214506800|NCT03655366|OTHER|Questionnaire for Dog trainers|Questionnaire for seizure response and seizure alert dog trainers including information on number of active working dogs, dog demographic information and selection criteria, the type of patient inclusion criteria they use, training methods used.
214506801|NCT01433185|OTHER|Text message|Text messages sent to women before and after delivery
214506802|NCT00349232|BEHAVIORAL|lifestyle intervention (diet and physical activity)|
214506803|NCT01847768|BIOLOGICAL|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
215020831|NCT00215553|DRUG|A.4 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
215020832|NCT00215553|DRUG|B.1 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
215020833|NCT00215553|DRUG|B.2 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
215020834|NCT01450267|DRUG|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
214421773|NCT06513442|OTHER|Trabecular bone score software|To assess the clinical utility of trabecular bone score (TBS) on fracture risk prediction including the new version (TBS V4) and future TBS versions at the spine and hip.
214421774|NCT05561036|DRUG|Liposome doxorubicin|Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days
214421775|NCT05561036|DRUG|Saline Solution|saline solution
214506804|NCT01847768|PROCEDURE|Bronchoalveolar Lavage|
214506805|NCT01847768|DRUG|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
214506806|NCT01847768|PROCEDURE|Nasal Lavage|
215020835|NCT01450267|DRUG|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
215020836|NCT04720170|PROCEDURE|Revascularization|Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
215020837|NCT05960123|PROCEDURE|Tubularized Incised Plate (TIP) urethroplasty|tubularization of urethral plate with or without spongioplasty
214421776|NCT02582710|DIETARY_SUPPLEMENT|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
214421777|NCT02582710|DIETARY_SUPPLEMENT|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
214421778|NCT04930393|PROCEDURE|Nerve Block - either PECS II or axillary ring|In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
214421779|NCT02053363|DRUG|Tranexamic Acid (Cyklokapron)|
214421780|NCT05033509|OTHER|supervision the Kidney fonction on ECMO|patients who benefited from ECMO, and presented an acute kidney injury afterwards
214421781|NCT06240663|BEHAVIORAL|Exercise|Both groups complete the exercise intervention identically, but one is in the fasted state and one is in the fed state.
215020838|NCT00756314|BEHAVIORAL|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
215020839|NCT02944461|DRUG|Dapsone 7.5 % gel|Dapsone gel 7.5% applied once daily to truncal acne
214506807|NCT01847768|PROCEDURE|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
214506808|NCT01847768|PROCEDURE|Bronchial Brushings|
214506809|NCT01847768|PROCEDURE|Lung Mucosal Biopsy|
214506810|NCT01847768|PROCEDURE|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer \& glycerol negative control.
215020840|NCT03696667|DEVICE|BCI|As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
215020841|NCT05157763|DRUG|EscharEx 5% (EX-02 formulation)|EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
215020842|NCT02232932|PROCEDURE|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
215020843|NCT02232932|PROCEDURE|RESECTION|Intent-to-treat R0 liver resection
215020844|NCT02605967|DRUG|Spartalizumab|Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
215020845|NCT02605967|DRUG|Investigator choice of chemotherapy|Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
215020846|NCT05788354|PROCEDURE|IUD insertion during cesarean section|placement of IUD during cesarean section after placental delivery
215020847|NCT02193347|BIOLOGICAL|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
215020848|NCT02193347|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
215020849|NCT02193347|DRUG|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
215020850|NCT00109070|DRUG|Avastin (bevacizumab)|
215020851|NCT02957903|DRUG|Ropivacaine|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
215020852|NCT02957903|DRUG|Isotonic Saline|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
215020853|NCT01287429|OTHER|lung and pleural ultrasound|After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
215020854|NCT03002909|DEVICE|epidural catheter|
215020855|NCT03002909|DEVICE|preperitoneal catheter|
215020856|NCT01079390|DEVICE|acupuncture|patient will receive high dose, low dose or sham acupuncture treatment.
215020857|NCT05343650|DEVICE|NOVAPAK nasal packing applied to forearm|Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm.
215020858|NCT05343650|DEVICE|NOVAPAK nasal packing applied to nasal cavity|A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes
214506811|NCT01847768|PROCEDURE|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
214506812|NCT01847768|PROCEDURE|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
214506813|NCT01847768|PROCEDURE|Spirometry|
214694084|NCT02654106|RADIATION|Fractionated Stereotactic Radiotherapy|The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
214506814|NCT03658252|BEHAVIORAL|Targeted education|Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids
214421782|NCT05817968|DEVICE|intelligent Esophageal Pressure Catheter (iEPC)|"Placement of the iEPC nasogastric catheter with solid state sensor for esophageal manometry.~Comparator: Esophageal balloon catheter (NutriVent)."
214421783|NCT04878198|BEHAVIORAL|Jogging program|This intervention consists of 50 sessions of morning jogging sessions at moderate intensity level. Each intervention session will be administered by a trained research assistant assisted by student helpers. All the research staff (i.e. student helpers and research assistant) will be required to attend a workshop (see educational plan) to standardize the procedure on implementing the intervention, as well as handling and motivating their ASD partners. Motivation techniques in previous protocol will be used to enhance the compliance rate.
214421784|NCT04878198|DRUG|Melatonin supplement intervention|This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.
214421785|NCT05676190|COMBINATION_PRODUCT|CIK combined with chemotherapy group|Combination of chemotherapy and autologous cytokine induced killer cells
214421786|NCT05676190|COMBINATION_PRODUCT|CIK combined immunotherapy group|Combination of immunotherapy and autologous cytokine induced killer cells
214421787|NCT05676190|COMBINATION_PRODUCT|CIK combined targeted therapy group|Combination of targeted therapy and autologous cytokine induced killer cells
214421788|NCT05676190|COMBINATION_PRODUCT|CIK in combination with other therapies|CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
214421789|NCT01783977|BIOLOGICAL|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
214421790|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid
214421791|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid
214421792|NCT01783977|BIOLOGICAL|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
214421793|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
214421794|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
214421795|NCT04273412|BEHAVIORAL|moderate-intensity lifestyle intervention|standardized 12- week program and would be delivered in 4 sessions (2 individual, 2 telephonic). This lifestyle modification program is a combination of diet therapy (optimum calorie), increased daily physical activity and behavioral modification (self-monitoring, stimulus control, motivational interviewing)
214421796|NCT03305003|OTHER|Spiral notebook|
214421797|NCT03305003|OTHER|Mobile application|
214421798|NCT03391635|DEVICE|Electroacupuncture|Participants will receive electroacupuncture at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
214421799|NCT03391635|DEVICE|TranscutaneousElectricNerveStimulation|Participants will receive transcutaneous electric nerve stimulation at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
214421800|NCT01550666|BEHAVIORAL|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
214421801|NCT01794936|DEVICE|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
214421802|NCT02874326|DRUG|Octreotide LAR|
214421803|NCT03920215|DRUG|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray
214421804|NCT03920215|DRUG|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray
214421805|NCT03920215|DRUG|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray
214506815|NCT03658252|BEHAVIORAL|Online disease specific forum|An invitation to join an online moderated disease specific social forum
214421806|NCT03920215|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
214421807|NCT04866069|BIOLOGICAL|SARS-CoV-2 vaccine|Adjuvanted inactivated vaccine
214421808|NCT04866069|BIOLOGICAL|Placebo|0.9% NaCl
214421809|NCT05159297|OTHER|Reference values|Normative reference values of coordination tests will be obtained
214421810|NCT03255096|DRUG|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
214506816|NCT01581099|PROCEDURE|Digestive Adaptations III surgery|
214506817|NCT05467566|DEVICE|Transcranial direct current stimulation|Exercise protocol + application of active direct current stimulation for 30 minutes.
214506818|NCT05467566|DEVICE|Sham Transcranial direct current stimulation|Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
214506819|NCT04105751|DEVICE|Novel Communication System|Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
214694085|NCT02654106|DRUG|Temozolomide|concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2\*5d, q28d, 6cycles
214694086|NCT00748540|DEVICE|Vibrant Soundbridge|Mixed and conductive hearing loss using round window stimulation
214694087|NCT02464787|DIETARY_SUPPLEMENT|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
214421811|NCT03255096|DRUG|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
214421812|NCT03255096|DRUG|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
214421813|NCT02000817|BIOLOGICAL|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
214421814|NCT02000817|BIOLOGICAL|Placebo|Placebo is available 0.9% w/v sodium chloride
215020859|NCT06424535|OTHER|Chinese medicine for internal or external use、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application of traditional Chinese herbal medicinal cake|"The treatment project a Chinese medicine practitioner based individual needs of the patient, and will be followed by a four-week treatment.~1. Traditional Chinese medicine for internal or external use: prescribe Chinese medicine based on syndrome differentiation and treatment of the patient's condition.~2. Acupuncture or laser acupuncture treatment: Traditional Chinese medicine practitioners select acupuncture points to treat based on the patient's condition, and treat them twice a week for 20 minutes each time.~3. Acupoint massage: Select treatment acupoints and techniques according to the patient's condition, 20 minutes at a time.~4. Traditional Chinese Medicine Cake Acupoint Application: Warm Navel Cream to the CV-4 (Guanyuan) acupoint once a day~5. Nursing and health education and guidance~6. Dietary hygiene education: personalized western nutrition and TCM dietary guidance suggestions based on TCM constitution syndromes."
215020860|NCT06424535|OTHER|Western medicine|Patients will receive routine Western medicine treatments as per individual patient's needs. The medications and bandages can vary due to the depth and size of the burn and scald.
215020861|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight \>20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight \>45 kg: 80 mg 3 times a day (tid)
215020862|NCT00159874|DRUG|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight \>20 kg
215020863|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight \>20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight \>45 kg: 40 mg 3 times a day (tid)
215020864|NCT01234714|OTHER|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
215020865|NCT01234714|PROCEDURE|Major liver resection|Hepatectomy of \>= 3 liver segments
215020866|NCT05439863|DEVICE|transcatheter heart valve|patients with severe aortic valve disease underwent transcatheter heart valve
215020867|NCT04019704|DRUG|AXS-05|Oral AXS-05 tablets, taken daily for 6 weeks.
215020868|NCT04019704|DRUG|Placebo|Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
215020869|NCT01475825|DRUG|mipomersen sodium 200 mg|Subcutaneous mipomersen 200 mg once weekly
215020870|NCT01475825|DRUG|Placebo|Placebo vehicle for subcutaneous injection.
215020871|NCT01475825|DRUG|mipomersen sodium 70 mg|Subcutaneous mipomersen 70 mg thrice weekly
214421815|NCT01063686|DEVICE|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
214421816|NCT03094013|OTHER|Assessment|Assessment
214506820|NCT01663454|BEHAVIORAL|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
214506821|NCT00000418|PROCEDURE|Psychosocial intervention|
214506822|NCT02562612|DRUG|SM-88|Daily SM-88 in multiple ascending doses over 6 months
215020872|NCT01986023|BEHAVIORAL|SMS- Short Messaging Service|
214421817|NCT01038648|DRUG|Sitagliptin|100mg/day
214421818|NCT01038648|OTHER|life style modification at base line|Advice on physical activity, diet and drug adherence.
214421819|NCT01141322|DRUG|Ursodeoxycholic Acid|ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
214421820|NCT01141322|DRUG|Placebo|The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
214421821|NCT03731312|OTHER|No intervention|This is an observational study and no interventions will be administered.
214421822|NCT03292315|DRUG|Semaglutide 1MG Injection [Ozempic]|Once weekly injection of 1mg of Semaglutide.
214506823|NCT03556410|BEHAVIORAL|sleep|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
214421823|NCT03292315|OTHER|No Intervention|No injection will be administered
214421824|NCT02785380|PROCEDURE|laparoscopic surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
214506824|NCT03556410|BEHAVIORAL|exercise|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
214506825|NCT03346733|DIETARY_SUPPLEMENT|Psyllium Fibre|Viscous soluble psyllium fibre
214506826|NCT01178372|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
214506827|NCT01178372|DRUG|Probiotics(VSL#3)|will receive VSL#3 (110 billion CFU)three times a day
215020873|NCT03649087|OTHER|Vitrification|Vitrification of ovarian tissue
215020874|NCT02570425|DEVICE|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
215020875|NCT02570425|DEVICE|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
215020876|NCT00309946|DRUG|cediranib maleate|Given orally
215020877|NCT03622931|DRUG|Standard chemotherapy|Chemotherapy
215020878|NCT03622931|DRUG|Romiplostim|
215020879|NCT03622931|DRUG|Placebos|
215020880|NCT03840889|OTHER|Data collection|"he different modes of active data collection:~* Data collection by telephone~* Data collection by mail~* Collection from discharge database summaries (PMSI)"
215020881|NCT05686720|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 5.0×10\^7 and 2.0×10\^8 cells. The infusion is given every 2 weeks.
215020882|NCT00609349|DEVICE|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
215020883|NCT03631693|PROCEDURE|Simplified papilla preservation flap|The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
215020884|NCT03631693|PROCEDURE|Resective periodontal flap with osseous recontouring|The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
215020885|NCT04156100|DRUG|AGEN1223|AGEN1223 is a bispecific antibody.
215020886|NCT04156100|DRUG|AGEN1223 and balstilimab|AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.
215020887|NCT04398225|DRUG|Centanafadine|Extended release capsule
215020888|NCT05534490|OTHER|therapatic Foot massaje (sweden technic)|Everything is explained to the individuals on the day of surgery. After the surgery, when the individuals regains consciousness in the service, the Swedish massage technique is applied bilaterally for 10 minutes. In addition to the demographic data of the patient before the application and in the preoperative period; pain, mental level, delirium status, mobility, kinesiophobia, balance, and functional independence level measurement evaluations are made. Massage is continued for a total of 20 minutes, 10 minutes for each foot, once a day until the patient is discharged. The measurements are repeated on the day the individual will be discharged.
215020889|NCT02096926|DRUG|Placebo|
215020890|NCT02096926|DRUG|Ibuprofen|400 mg PO
215020891|NCT00964522|OTHER|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
215020892|NCT01918358|DRUG|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
215020893|NCT01918358|DRUG|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
215020894|NCT01918358|DRUG|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
215020895|NCT01918358|DRUG|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
215020896|NCT01918358|DRUG|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
215020897|NCT01918358|DRUG|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
215020898|NCT05757349|BEHAVIORAL|Face-down position time 1-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
215020899|NCT05757349|BEHAVIORAL|Face-down position time 3-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
215020900|NCT02096887|BEHAVIORAL|Patient Education|"Patient Education using the following two instruments:~1. Framingham Risk Score calculator:~2. Know your numbers patient booklet"
215020901|NCT03136094|BEHAVIORAL|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
215020902|NCT03136094|BEHAVIORAL|SBIRT+Usual Care|Patients receive usual SBIRT care
215020903|NCT00109668|DRUG|beclomethasone dipropionate (QVAR)|
215020904|NCT02934217|DRUG|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
215020905|NCT02934217|DRUG|Placebo|One single intravenous bolus injection of Placebo
215020906|NCT02934217|PROCEDURE|Echocardiography|3 years after AMI
215020907|NCT06549322|OTHER|The exercise in morning|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: AM 11:00-11:30"
215020908|NCT06549322|OTHER|The exercise in evening|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: PM 05:00-05:30"
214694088|NCT03765346|DRUG|Oxycodone IR ADF|Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
215020909|NCT04426513|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
214506828|NCT04377191|OTHER|exergame|Microsoft Xbox 360 Kinect The exercises were advanced from simple to complex. The program started with exercises in a sitting position. In the next stage, the games requiring weight transfer and use of upper limbs in standing position were continued. The program ended with games that require more complex movements such as lunge and mini squats.
214690200|NCT04493411|PROCEDURE|Positron Emission Tomography/Computed Tomography (PET/CT)|"PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
214690201|NCT05403944|BEHAVIORAL|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
214690202|NCT05403944|BEHAVIORAL|Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)|6 weeks of STRIPE rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
215020910|NCT06640803|BEHAVIORAL|Stepped-Care including Cognitive Behavioral Case Management|Step 1:assessment and feedback, general engagement strategies, assessment of needs and social determinants of health, begin case management, goal setting. Step 2: TAU. Initiation of team-based care at community clinics and 'enhanced monitoring'. Step 3: atheoretically-based stress management skills (stress thermometer, coping skills and coping plans), problem solving strategies. Step 4: targeted intervention for CHRp. Initiation of formulation-based CBT modules, therapy consultation groups with the UC Davis team (UCD), regular meetings between clinic leadership and UCD. Participants may switch providers to increase level of early psychosis specialization. Step 5: add prescriber consultation groups with UCD. Step 6: assessment of trauma and family conflict then Family-Focused Therapy, Trauma-Focused Cognitive Behavioral Therapy, or CBT for CHR at UCD. Termination: At 24 months, referral to UCD coordinated specialty care clinic or other appropriate service for those still CHRp+.
215020911|NCT03687671|OTHER|Animal-assisted therapy|Animal-assisted occupational therapy, animal-assisted physiotherapy and animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
215020912|NCT03687671|OTHER|Treatment as usual|Speech therapy, occupational therapy or physiotherapy
215020913|NCT05215561|OTHER|Cosentyx|There was no treatment allocation. Patients administered Cosentyx by prescription that had started before inclusion of the patient into the study were enrolled.
215020914|NCT05121090|BEHAVIORAL|Educational program|"The educational program is based on dietary, physical activity, psychology, and sophrology approaches dispensed by health care professionals. Evaluations will consist of anthropometric measurements (height, weight, body mass index), behavioural questionnaires, and basic physical tests (handgrip, squats, balance, …).~Optionally, a saliva collection will be proposed to obtain the DNA required for genetic analyses."
214421825|NCT02785380|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
214421826|NCT02644174|PROCEDURE|Bariatric Surgery|
214421827|NCT01405872|OTHER|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
214421828|NCT01752465|BEHAVIORAL|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
214421829|NCT01752465|BEHAVIORAL|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
214421830|NCT00166166|DRUG|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
214421831|NCT00166166|DRUG|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
214421832|NCT00166166|DRUG|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
214506829|NCT04377191|OTHER|exergame|ALDA In the training, games that could be controlled by balance swing, trunk movements and weight transfer in sitting or standing position were used.
214506830|NCT04377191|OTHER|exercise|Standard Exercise Program The program included warm-up, main exercise and cooling. Warm-up and cooling included neck, trunk, upper-lower extremity range of movement (ROM) exercises and stretching exercises. Main exercise included postural alignment, strengthening for trunk and lower extremity, balance and walking exercises.
214690203|NCT06075706|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
214421833|NCT00166166|DRUG|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
214690204|NCT06075706|BIOLOGICAL|BAT|BAT including ECP, ATG, etanercept, infliximab or RUX will be administered based on Investigator's decision.
214690205|NCT05701904|OTHER|Local mechanical vibration|Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.
214421834|NCT00166166|DRUG|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
214421835|NCT00166166|DRUG|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
215020915|NCT05292287|DEVICE|Polar Ignite Wearable Activity Monitor|A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
215020916|NCT05702489|DRUG|ZX-7101A|a drug to treatment influenza in Chinese adults
215020917|NCT05300607|OTHER|Cross-cultural adaptation, validity, and reliability|evaluation, translation, cultural adaption, validation, and investigation of the reliability of Arabic version of The Western Ontario Rotator Cuff Index (WORC) to be used in Arabic countries.
215020918|NCT06224153|OTHER|3-day dietary record|This is the conventional ingesta assessment. It will be performed twice during the study.
215020919|NCT06224153|OTHER|Food Frequency Questionnaire (FFQ)|This questionnaire is used to obtain information on the frequency of foods and drinks consumed over a period of time (1 week, 1 month...). It will be performed twice during the study.
215020920|NCT05071027|OTHER|Endovascular Neurosurgery|Custom Dual Antiplatelet Therapy reminders for patients receiving endovascular treatment of cerebral unruptured aneurysms. The app utilized to generate reminders is available on the Apple app store.
214421836|NCT00166166|DRUG|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
214421837|NCT00097188|DRUG|rituximab|
214421838|NCT02886637|OTHER|None intervention|
214421839|NCT05989646|DEVICE|Sacral TENS|Sacral TENS applied two hours daily for 10 weeks
214421840|NCT03812978|OTHER|Smart phone application|Smart phone application including exercise videos, push notifications for exercise, questions and answers, exercise diary.
214421841|NCT00177216|DRUG|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or \>). The dose was decreased to 5 mg if side effects occurred.
214506831|NCT00681109|DRUG|2.5% IL-1Ra|2.5% custom made topical IL-1Ra three times a day in both eyes for three months
215020921|NCT05818943|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
215102643|NCT05243589|OTHER|Proprioceptive training|"Proprioceptive training included exercises on different floor textures composed of 10 stations of exercises with the objective of stimulating the sole of the foot where participants had to coordinate gait by stepping with alternate feet on markers placed on the ground and the progression was manipulated through modifications of speed and direction.~Sequence of materials was 10 cm-thick foam, wood box with beans, two-cm thick mat with a density lower than the foam, wood box with cotton, two-cm thick mat volunteers sat on a bench and trained feet flexors by grasping with the toes a towel put on the floor, Two proprioception balls was used with an eight cm diameter with external projections resting on the floor a box with grains and sandpaper. After that joint Positional Sense Exercises were performed."
214421842|NCT00177216|DRUG|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
214421843|NCT00177216|DRUG|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
214421844|NCT00113971|DRUG|epratuzumab|
214421845|NCT04042545|DRUG|PPP001|1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
214421846|NCT04042545|DRUG|Placebo|1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
214421847|NCT04943770|PROCEDURE|Spinal cord stimulator implant|"Patients will undergo spinal cord implant procedures as per standard of care and be implanted with the WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system.~Implant Procedures will be followed by a healing period (4-6 weeks) during which patients will be offered therapy (up to one 1Khz). Patients will then be randomised to receive therapy at four different rates (A, B, C, D) in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit."
214506832|NCT00681109|DRUG|Placebo|custom eye drop to be applied three times a day in both eyes for three months
214506833|NCT00681109|DRUG|5% IL-1Ra|5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
214694089|NCT03765346|DRUG|Oxycodone API powder|Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
214694090|NCT03765346|DRUG|Placebo to match oxycodone API powder|Placebo to match oxycodone API powder (mass of 30 mg).
215020924|NCT03287349|OTHER|Blood draw|Two 12.5 mL blood draws
215020925|NCT03287349|OTHER|Photograph|Photograph of severe reaction, will be anonymized
215020926|NCT03287349|DIAGNOSTIC_TEST|Autoimmune testing|Autoimmune testing in patients without prior testing
215020927|NCT06551961|DIETARY_SUPPLEMENT|methylcellulose|2.5 and 5 gm Methylcelllose heated to create a gel
215020928|NCT06551961|DIETARY_SUPPLEMENT|inulin|2.5 and 5 gm inulin powder dissolved in water
215020929|NCT06551961|DIETARY_SUPPLEMENT|maltodextrin|2.5 and 5gm maltodextrin dissolved in water
214421848|NCT04943770|DIAGNOSTIC_TEST|Healing period|Acute opioid pain medications may be continued. No additional scheduled assessments will be completed during this period.
214421849|NCT04943770|DEVICE|WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|Patients will then be randomised to receive therapy (up to 1KHz) at four different rates in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit.
214421850|NCT05475405|OTHER|scapulothoracic mobilization|Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula.
214421851|NCT05475405|OTHER|IASTM|"Restrictions and myofascial adhesions should be assessed prior to treatment along both sides using IASTM tool and a lubricant.~Once restrictions are assessed, fanning strokes at 45 degree angles to skin should be applied using the tool. This technique should be performed for 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers for each muscle group in scapulothoracic region. Total time for IASTM application is 10 mints. Upon completing all this patient should be given a home plan consisting of 2 different self-stretches targeting levator scapulae and upper trapezius"
214421852|NCT03310112|BEHAVIORAL|4-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
214421853|NCT03310112|BEHAVIORAL|2-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
215020930|NCT06059248|OTHER|"the head in the sniffing position "|"Intubation was performed with the head in the  elevation  position"
215020931|NCT04135352|DRUG|200 mg of pembrolizumab|Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
215020932|NCT04135352|BIOLOGICAL|V938|Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
215020933|NCT06640400|DEVICE|Cardiovascular ultrasound|Participants in the intervention group will be treated with a medical LIPUS device (838C-M-L-I/II, Shenzhen, China) for 10 days in addition to conventional medical treatment. The ultrasound therapy instrument is equipped with a sound head comprising 5 transducer units, operating at an ultrasonic frequency of 0.84MHz with a sound intensity range of 1 W/cm2 -1.25 W/cm2. The therapeutic ultrasound sessions necessitate a controlled environmental temperature. Patients will assume the supine position, exposing the precordial region, with the five-pronged head positioned parallel to the heart\&amp;amp;amp;amp;#39;s long axis, covering the entire precordial region including the right and left coronary arterial trunks and the aortic root. The ultrasound therapy device operates in a pulsed mode, with each treatment session lasting 20 minutes, comprising 2 daily sessions for a total of 20 treatments.
215020934|NCT06639321|DEVICE|Percutaneous Ventricular Assist System|Percutaneous Ventricular Assist System provides intraoperative circulatory support during high-risk PCI.
215020935|NCT06639321|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO provides intraoperative circulatory support during high-risk PCI.
215020936|NCT06639945|DEVICE|transcranial MR-guided focused ultrasound|MRI-guided transcranial focused ultrasound (MRgFUS) combines magnetic resonance imaging (MRI) with focused ultrasound to target specific areas in the brain non-invasively. MRgFUS allows for treatment without surgical incisions, leading to fewer risks and a quicker recovery. MRI provides real-time imaging that helps precisely locate and treat affected brain regions, such as the thalamus or globus pallidus.The procedure allows for continuous monitoring of the treatment effects, enabling adjustments as needed.
215020937|NCT00511199|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year)."
214506842|NCT02599025|DEVICE|Innowalk cycling system|Innowalk is a unique, motorized medical device
215020938|NCT00511199|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
215020939|NCT02449447|BEHAVIORAL|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
215020940|NCT02449447|OTHER|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
215020941|NCT05671887|PROCEDURE|Double Lung Transplantation|To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.
215020942|NCT00048308|DRUG|pexelizumab|
215102644|NCT05243589|OTHER|routine physical therapy|Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).
215020943|NCT04601493|BEHAVIORAL|Choice Architecture Nudge|"During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic)."
215020944|NCT04601493|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
214421854|NCT03320434|DRUG|PRT-2761 0.5%|Six drops in each eye over a 17 day period.
214421855|NCT03320434|DRUG|PRT-2761 1%|Six drops in each eye over a 17 day period.
214421856|NCT03320434|DRUG|Patanol|Six drops in each eye over a 17 day period.
214421857|NCT03320434|DRUG|Pred-forte|Four drops in each eye over a 3 day period.
215020945|NCT03136302|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation
215020946|NCT06628960|BEHAVIORAL|Su Jok Therapy|Su Jok Therapy
215020947|NCT03255200|DEVICE|ReActiv8 Implantable Stimulation System|Implantable electrical stimulation system.
215020948|NCT00790660|DRUG|ASP1941|Oral
215020949|NCT00790660|DRUG|Placebo|Oral
215020950|NCT02522260|OTHER|Resistance and aerobic training|Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks
215020951|NCT02522260|OTHER|Aerobic training|Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
215020952|NCT02522260|OTHER|Standard supportive care|Standard supportive care
215020953|NCT04281576|DEVICE|NovoTTF-100L(P)|Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
215020954|NCT04281576|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 intravenous infusion will be administered once every 3 weeks
215020955|NCT04281576|DRUG|Capecitabine|Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
214421858|NCT03320434|DRUG|PRT-2761 0%|Six drops in each eye over a 17 day period.
214421859|NCT03383146|DRUG|Placebo|Placebo injected subcutaneously twice daily.
214421860|NCT03383146|DRUG|Relamorelin|Relamorelin 10 μg injected subcutaneously twice daily.
214421861|NCT00636064|DRUG|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
214421862|NCT00636064|DRUG|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
214506843|NCT02599025|DEVICE|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
214506844|NCT01758549|OTHER|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
214506845|NCT01758549|OTHER|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
214506846|NCT04016207|DRUG|Guanfacine|regular treatment
214506847|NCT05017909|BEHAVIORAL|Face to face education|Face to face education techniques on the acquisition of the mothering Role
214506848|NCT05017909|BEHAVIORAL|Web based education|web based education techniques on the acquisition of the mothering Role
214506849|NCT05017909|BEHAVIORAL|No education|Control group will not be educated
214506850|NCT02504801|DRUG|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
214506851|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m\^2 (milligram per square meter).
214506852|NCT04660799|DRUG|Rituximab SC|Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).
214506853|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m\^2.
214506854|NCT04660799|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2
214506855|NCT04660799|DRUG|Doxorubicin|Doxorubicin will be administered IV at a dose of 50 mg/m\^2
214421863|NCT00636064|OTHER|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
214421864|NCT03399370|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
214421865|NCT03399370|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
214421866|NCT03665298|BEHAVIORAL|Smartphone Application|App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
214421867|NCT04193215|BIOLOGICAL|V114|IM injection
215020956|NCT04281576|DRUG|Trastuzumab|Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
215020957|NCT04834388|DRUG|Anakinra|Anakinra treatment is started within 8 hours of symptom onset
214506856|NCT04660799|DRUG|Vincristine|Vincristine will be administered IV at a dose of 1.4 mg/m\^2
214506857|NCT04660799|DRUG|Prednisone|Prednisone will be administered orally at a dose of 100 mg/day
215020958|NCT06344923|PROCEDURE|Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. A support rod, made of a 24# silicone drainage tube with a 1ml syringe was passed through the mesentery of the small intestine. The support rod was removed two weeks after surgery. It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches.
215020959|NCT06344923|PROCEDURE|Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. The seromuscular layer of the ileum or the mesentery was intermittently sutured with peritoneum and the anterior sheath of the rectus abdominis circumferentially with 8-10 stitches (3-0 silk thread). It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches
215020960|NCT06510231|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) targets the inspiratory muscles and is used to improve inspiratory muscle strength.
215020961|NCT06576570|BEHAVIORAL|Education presentation of surgical ergonomics|During an individual meeting with participant, a brief presentation will be supplied for review.
215020962|NCT06576570|BEHAVIORAL|Summary of Ergonomic Measurement System|Participant will view a video of their movements with a visual guideline highlighting high-risk angles and movements.
215020963|NCT04656548|DEVICE|HydroPICC|PICC lines
215020964|NCT00005021|BIOLOGICAL|filgrastim|
215020965|NCT00005021|DRUG|carboplatin|
215020966|NCT00005021|DRUG|paclitaxel|
214421868|NCT04193215|OTHER|Pediatric vaccines|Standard of care vaccines administered according to the local recommended schedule.
214421869|NCT05342766|DIETARY_SUPPLEMENT|Nutrigenetic|"Each grup will receive two interventions (Nutrigenetic and Standard), in a cross-over design (3 months each), spaced by a wash-out period (3 months)."
214421870|NCT06628856|OTHER|Quality of life|The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being.
214506858|NCT04660799|DRUG|Paracetamol|All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab
214506859|NCT04660799|DRUG|Diphenhydramine hydrochloride or alternative antihistamine|All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab
214506860|NCT02764970|DRUG|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
215020967|NCT00005021|DRUG|topotecan hydrochloride|
215020968|NCT03081923|DRUG|Durvalumab|anti-PD-L1 mono therapy
215020969|NCT03081923|DRUG|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
215020970|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
215020971|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
215020972|NCT02739828|BIOLOGICAL|Adalimumab|Adalimumab
215020973|NCT03031730|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215020974|NCT03031730|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
215020975|NCT03031730|DRUG|Carfilzomib|Given IV
215020976|NCT03031730|DRUG|Dexamethasone|Given PO
215020977|NCT03031730|DRUG|Dexamethasone Sodium Phosphate|Given IV
215020978|NCT03031730|PROCEDURE|Echocardiography|Undergo echocardiography
215020979|NCT03031730|DRUG|Lenalidomide|Given PO
215020980|NCT03031730|DRUG|Navtemadlin|Given PO
215020981|NCT02314247|DRUG|Selinexor|"20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment."
215020982|NCT06082544|OTHER|mini-screw implant|JEIL SCREW 1.6\* 8 MM 16-G2-008 or JEIL SCREW 1.6\*10 MM 14-G2-010
214690206|NCT05701904|OTHER|Shotblocker group|It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injection (Tugrul, Celik, and Khorshid 2017). The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.
214690207|NCT05983003|PROCEDURE|endoscopic sinus surgery|Open the sinus ostium, improve anatomical issues and remove the diseased tissue.
215020983|NCT06082544|DEVICE|removable partial denture|Acrylic removable partial denture
215020984|NCT01953354|BIOLOGICAL|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
215020985|NCT01953354|BIOLOGICAL|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
214421871|NCT05639699|OTHER|motivational interview|Quitting smoking with motivational interviewing
214421872|NCT02498769|DRUG|Botulinum Toxin Type A|The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
214421873|NCT02498769|DRUG|Placebo|
214421874|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
215020986|NCT03951415|DRUG|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
215020987|NCT01392495|DRUG|Imatinib|200 mg or 400 mg qd
215020988|NCT02167685|DRUG|CMX001|
215020989|NCT03178890|DEVICE|OHMG|Device will be implanted in all enrolled patients.
215020990|NCT03263390|PROCEDURE|Bariatric Surgery|Sleeve gastrectomy or Roux-en-Y Gastric Bypass
215020991|NCT03263390|DRUG|Anti Obesity Drugs|Response to FDA approved anti obesity medications
215020992|NCT01570192|DRUG|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
215102645|NCT02427503|PROCEDURE|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
215102646|NCT02134730|BEHAVIORAL|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
215102647|NCT05257902|DRUG|choline alphoscerate|400mg bid/day
215102648|NCT05257902|DRUG|Placebo|Placebo 1T bid/day
215102649|NCT06041633|DIAGNOSTIC_TEST|Clinical|Questionnaire
215102650|NCT04015674|OTHER|Exercise group|Aerobic exercise on a stationary bicycle
215102651|NCT04015674|OTHER|Control group|In a rest
215102652|NCT05835583|BEHAVIORAL|The theory based integrated program|The theory-based integrated program is administered by a nurse trained in motivational interviewing.In the 12-hour intervention, this program uses motivational interviewing skills to increase the patient's attitude towards medication, enhance the support of significant others around them, and increase the patient's control over their own behavior.
215102653|NCT00418574|BIOLOGICAL|Abagovomab|2 mg/ml SC (subcutaneously)
215102654|NCT00418574|BIOLOGICAL|Placebo|2 mg/ml SC (subcutaneously)
214421875|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
214421876|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
214421877|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
214421878|NCT04465071|DRUG|AEONTM Repair and AEONTM Protect Plus lubricating eye drops|AEONTM Repair and AEONTM Protect Plus lubricating eye drops
214421879|NCT03557788|DRUG|Rifaximin Oral Tablet|PO 550mg TDS for 2 weeks
214421880|NCT00300040|DRUG|Hemoglobin glutamer 250 - bovine|intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
214421881|NCT00300040|DRUG|6% Hydroxyethylstarch|250ml for intravenous infusion
214421882|NCT03265717|BIOLOGICAL|INVAC-1|Patients are treated by INVAC-1 for 6 cycles at 4-week intervals
214421883|NCT00307307|DRUG|Niacin/simvastatin compared to simvastatin alone at 2 doses|
214421884|NCT06554080|PROCEDURE|Platform-switched implant placement|NobelParallel or NobelActive implants placed
214421885|NCT06554080|PROCEDURE|Platform-matched implant placement|Nobel Brånemark, NobelSpeedy Groovy implants placed
215020993|NCT01570192|DRUG|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
215020994|NCT01570192|DRUG|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
215020995|NCT01570192|DRUG|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
214421886|NCT02739035|DRUG|Dexamethasone|8 mg of IV dexamethasone immediately before MUA.
214421887|NCT02739035|DRUG|Celecoxib|2 weeks per mouth of celecoxib (200 mg daily)
214690208|NCT06129604|DRUG|TPST-1495|Eligible subjects will receive study treatment of 50mg TPST-1495 taken orally, once a day for 7 days prior and discontinued 3 days prior to scheduled surgery.
214694091|NCT03765346|DRUG|Placebo to match manipulated oxycodone IR ADF.|Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
214694092|NCT02824380|DRUG|DA-4001 H|5% minoxidil / high dose of finasteride
215020996|NCT01570192|DEVICE|tobramycin nebulization|tobramycin nebulization 600mg/day
215102655|NCT01807377|DRUG|PF-05175157|200 mg tablet administered twice per day for 14 days
214421888|NCT03384069|BEHAVIORAL|Group-based Cognitive Behavioral Therapy (CBT)|The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.
215020997|NCT02560792|BEHAVIORAL|Positive Affect Condition|"Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
215020998|NCT02560792|BEHAVIORAL|Negative Affect Condition|"Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
215020999|NCT02560792|BEHAVIORAL|Control Condition|Participants receive no information about affective response
215021000|NCT03156452|DRUG|Mycophenolate Mofetil|500 mg and 250mg tablets for oral administration
215021001|NCT03156452|DRUG|Prednisolone|5mg tablets for oral administration
215021002|NCT02965976|BIOLOGICAL|Botulinum Toxin Type A|Given IM
215021003|NCT02965976|PROCEDURE|Esophagectomy|Undergo esophagectomy
215021004|NCT02965976|OTHER|Quality-of-Life Assessment|Ancillary studies
215021005|NCT04420182|OTHER|Virtual Care at Home|Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
215021006|NCT00806026|DRUG|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
214421889|NCT03384069|BEHAVIORAL|Phone-based Cognitive Behavioral Therapy (CBT)|Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
214421890|NCT00293865|PROCEDURE|sentinel node|detection of the sentinel node in breast cancer
215021007|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
214421891|NCT00293865|PROCEDURE|GAS|
214421892|NCT00552942|PROCEDURE|laparoscopic gastric bypass plus omentectomy|
214421893|NCT01352611|DRUG|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
215102656|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
215102657|NCT01807377|OTHER|Placebo|Placebo administered twice per day for 14 days
214421894|NCT06258031|DRUG|Psilocybin (COMP360)|Up to 10mg on two occasions
214421895|NCT03210402|DEVICE|Elevated night pacing on|Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
214421896|NCT03210402|DEVICE|Elevated night pacing off|Device will be programmed to normal lower rates
215021008|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
215021009|NCT00806026|DRUG|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
215021010|NCT00806026|DRUG|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
215021011|NCT00806026|DRUG|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
215021012|NCT00653705|OTHER|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
215021013|NCT00653705|OTHER|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
215021014|NCT01899378|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10\^8 CFU
215021015|NCT01899378|DIETARY_SUPPLEMENT|Bifidobacterium longum infantis|10\^9 CFU
215021016|NCT01687595|DRUG|HerpV and QS-21|HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21
215021017|NCT01687595|DRUG|Placebo|phosphate buffered saline
215021018|NCT01307618|BIOLOGICAL|NA17.A2 Peptide Vaccine|Given SC or ID
215021019|NCT01307618|BIOLOGICAL|Recombinant MAGE-3.1 Antigen|Given SC or ID
215021020|NCT01307618|BIOLOGICAL|Recombinant Interleukin-12|Given SC or ID
215021021|NCT01307618|BIOLOGICAL|MART-1 Antigen|Given SC or ID
215021022|NCT01307618|OTHER|Laboratory Biomarker Analysis|Correlative studies
215021023|NCT06300905|DRUG|test product|toothpaste containing 0.45% stannous fluoride
215021024|NCT06300905|DRUG|Control product|toothpaste containing 0.76% sodium monofluorophosphate
215021025|NCT02858661|OTHER|Nasopharyngeal swab|
215021026|NCT00489359|DRUG|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
215102658|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
214421897|NCT05819190|DEVICE|Healsea Rescue*|Subjects will be administered with Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
214421898|NCT05819190|DEVICE|Placebo|Subjects will be administered with isotonic saline nasal spray indistinguishable from the Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
214421899|NCT05131919|DRUG|Pembrolizumab|Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.
214421900|NCT02517307|DRUG|Intralipid/Heparin|Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
215021027|NCT00489359|DRUG|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
215021028|NCT00489359|DRUG|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles
215021029|NCT00489359|DRUG|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles
214421901|NCT02517307|DRUG|Glycerol/Saline|Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
214421902|NCT02517307|DRUG|Hyperinsulinemic euglycemic clamp|Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
214421903|NCT00193297|DRUG|Topotecan|
214421904|NCT00193297|DRUG|Paclitaxel|
214506861|NCT04864834|BIOLOGICAL|SOK583A1 (40 mg/mL)|IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
215021030|NCT05919212|DIAGNOSTIC_TEST|HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment|We study the circulating changes associated with resistance to T-DXd, including changes in HER2 status,studied through a new approach called HER2-2D that simultaneously assesses HER2 amplification and overexpression in blood
215021031|NCT00635466|PROCEDURE|laparoscopic surgery for rectal carcinoma|Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (\<8 cm).
215021032|NCT03180138|BEHAVIORAL|Reminders alone|Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
215021033|NCT03180138|BEHAVIORAL|Compliance-linked incentives|Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
215021034|NCT04476485|OTHER|endocrine therapy|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy. 1. For postmenopausal patients: Extend treatment with aromatase inhibitors 10 years: letrozole or anastrozole or exemestane. 2. For premenopausal patients: An initial 5 years tamoxifen treatment followed by additional 5 years extended tamoxifen treatment. Postmenopausals are treated with aromatase inhibitors 5 years. 3. For patients have completed ovarian function suppression plus initial 5-year aromatase inhibitor treatment: Menopausals: Aromatase inhibitors; Non-menopausals: 5 years of tamoxifen treatment or ovarian function suppression plus 5 years of aromatase inhibitor treatment. 4. For patients have completed ovarian function suppression plus initial 5-year tamoxifen treatment: Menopausals: Aromatase inhibitors for additional 5 years; Non-menopausals: Tamoxifen for additional 5 years.
215021035|NCT03115515|DRUG|levothyroxine|To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
215021036|NCT04967001|DIAGNOSTIC_TEST|PSMA PET|68Ga-PSMA PET
215021037|NCT06492720|DEVICE|Focused ultrasound (FUS) treatment|The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.
215021038|NCT01872754|DRUG|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
215102659|NCT01506284|PROCEDURE|Forced oscillatory technique (FOT) and laser interferometry (LIR).|"FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient."
215102660|NCT00700505|DEVICE|FlowPants(R) Garment|"The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding."
214694093|NCT02824380|DRUG|DA-4001 L|5% minoxidil / low dose of finasteride
214421905|NCT00193297|DRUG|Carboplatin|
214421906|NCT04499131|DRUG|Progesterone|Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
214421907|NCT04499131|OTHER|Artificial Cycle (no intervention)|Control group of 19 subjects in the context of a natural cycle with only endogenous progesterone present
215021039|NCT01872754|DRUG|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
215021040|NCT03905174|DEVICE|custom made device|surgical intervention to place custom made orthopaedic device
215021041|NCT01026428|DRUG|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
215021042|NCT01026428|OTHER|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
215021043|NCT03719300|DRUG|inodiftagene vixteplasmid|"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
215021044|NCT02442531|DRUG|CriPec® docetaxel|-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
215021045|NCT05810116|DRUG|Levagen+|Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
215021046|NCT05810116|DRUG|Microcrystalline cellulose|Daily dose of 1-2 capsules (1 capsule containing 350mg)
215021047|NCT05587543|BEHAVIORAL|PK Blood Collection|All subjects were subjected to PK blood sampling as prescribed by the protocol.
215021048|NCT05587543|DRUG|CAR|Target A positive subjects will receive CAR-T cell therapy.
215021049|NCT05587543|DRUG|TCR|Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.
215021050|NCT02557919|OTHER|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
215021051|NCT02557919|OTHER|Usual Best Practice|.5 day training on tobacco control and emerging products.
215021052|NCT06542380|DEVICE|TAVI, pacemaker|Retrospective analysis of need for pacemaker implantation after TAVI
215021053|NCT05007860|BIOLOGICAL|PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.|Vaccines administered per standard of care
215021054|NCT00909688|DRUG|BLI-489|
215021055|NCT00909688|DRUG|placebo|
215021056|NCT06499181|DRUG|Liposomal bupivacaine|The primary objective is to examine differences in post-operative opioid consumption between the two groups.
215021057|NCT06499181|DRUG|Bupivacain|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
215021058|NCT06499181|DRUG|Epinephrin|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
215021059|NCT04411069|DRUG|Droperidol|Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
214506862|NCT04864834|BIOLOGICAL|Eylea EU (40 mg/mL)|IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
214506863|NCT05995691|DRUG|ABP 501|SC injection
214506864|NCT05995691|DRUG|Adalimumab|SC injection
214506865|NCT00944359|DIETARY_SUPPLEMENT|Daily preventive Zn; placebo treatment|7 mg zinc / day and placebo supplement during diarrhea episodes
215021060|NCT04090606|OTHER|FTC Method Smoking Regimen|cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes
215021061|NCT04090606|OTHER|Massachusetts Method Smoking Regimen|45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes
214506866|NCT00944359|DIETARY_SUPPLEMENT|Therapeutic Zn; daily placebo|20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
214506867|NCT00944359|DIETARY_SUPPLEMENT|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
214506868|NCT00944359|OTHER|Surveillance control group|Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
214506869|NCT04256395|OTHER|mobile internet survey on self-test|1\. make a questionnaire, the content of which refers to the new coronavirus diagnosis and treatment guidelines released by the National Health Commission; 2. develop the mobile applet and carry out internet propagation; 3. background data could be identified according to computer technology, de duplication and de privacy; 4. once registered, the applet can automatically remind the self-test twice a day, and encourage to adhere to 14 days; 5. automatically compare with the standards and highly suspected population could be given medical guidance and encouraged to go to the fever clinic of the designated hospital for definite diagnosis.
214506870|NCT00043589|DRUG|donepezil|
215021062|NCT04090606|OTHER|Health Canada Intense Smoking Regimen|55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes
214506871|NCT00043589|PROCEDURE|Memory-training class|
214506872|NCT03592407|DRUG|Epacadostat|Given PO
215021063|NCT00704834|OTHER|Blood Draw|35 cc of peripheral blood will be obtained by venipuncture from each subject.
215021064|NCT02587364|DRUG|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
215021065|NCT02587364|DRUG|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
215021066|NCT02587364|DRUG|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
215021067|NCT02587364|DRUG|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
215021068|NCT02587364|DRUG|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
215021069|NCT02587364|DRUG|Placebo|Placebo once daily (QD)
214421908|NCT02051439|PROCEDURE|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava 3 times before balloon assisted Valsava 3 times. The second group performed balloon assisted Valsava 3 times before conventional Valsava 3 times for venous reflux examination by duplex scan.
214421909|NCT05960162|DIAGNOSTIC_TEST|90K|Blood test
215021070|NCT02953964|OTHER|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
215021071|NCT02953964|OTHER|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
215102661|NCT02782026|DEVICE|Exhaled Breath Olfactory Signature (Artificial Nose)|
215102662|NCT03001778|OTHER|Usability Testing|"Usability testing of ready made workouts in a group format."
215102663|NCT00164411|BIOLOGICAL|Tetanus-diphtheria toxoids (Td)|
215102664|NCT00164411|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
215102665|NCT00164411|BIOLOGICAL|23-valent polysaccharide vaccine|
215102666|NCT04510103|DRUG|Moisturizer A, F#9155-005|OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
215102667|NCT04510103|OTHER|Moisturizer B, F#E1387-004|Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
215102668|NCT04510103|PROCEDURE|Regression|2 week regression period after 6 weeks of moisturizer use.
214421910|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by \[(3× birth weight (Kg) + 9)/2+1)\]
215102669|NCT04510103|PROCEDURE|Non-Regression|Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
215102670|NCT04836247|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
214506873|NCT03592407|OTHER|Laboratory Biomarker Analysis|Correlative studies
214506874|NCT03592407|BIOLOGICAL|Pembrolizumab|Given IV
214506875|NCT03592407|OTHER|Pharmacodynamic Study|Correlative studies
215102671|NCT04836247|BEHAVIORAL|Mindfulness|Participants will be able to choose from several guided meditations to promote mindfulness
215102672|NCT03589222|DRUG|Selinexor|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
215102673|NCT03589222|DRUG|Daratumumab|daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
215102674|NCT03589222|DRUG|Bortezomib|bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
215102675|NCT03589222|DRUG|Dexamethasone|dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
215102676|NCT03085745|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.
215102677|NCT00180583|DEVICE|Guidant GALILEO Intravascular Radiotherapy System|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
215102678|NCT03884647|DEVICE|DELPhI system|DELPhI software is acquiring and analyzing the TMS evoked response recorded with the EEG.
215102679|NCT00002812|DRUG|asparaginase|Given IV
214421911|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
214421912|NCT02939690|DEVICE|Ultrasound|
214421913|NCT03771885|DRUG|BI 705564|Film-coated Tablet
214421914|NCT03771885|DRUG|Placebo|Film-coated Tablet
214421915|NCT00823979|DRUG|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
214421916|NCT00823979|DRUG|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
214506876|NCT03941509|BEHAVIORAL|Antimicrobial stewardship|Education, guidelines, communication tools and audit and feedback
214506877|NCT01849523|BEHAVIORAL|Web-based information and support|
214506878|NCT04262115|BEHAVIORAL|AM-EX|AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
214506879|NCT04262115|BEHAVIORAL|PM-EX|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
214506880|NCT02858115|OTHER|Fluid challenge|100 ml of crystalloid was infused over 1-min
214506881|NCT02858115|OTHER|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
214694094|NCT03604471|DRUG|Atorvastatin|Blood sampling for atorvastatin quantification and pharmacogenetic analysis.
214421917|NCT00823979|DRUG|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
214421918|NCT04895566|BIOLOGICAL|Monoclonal antibody (Mab) sB24M|200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.
214421919|NCT03586544|DRUG|Albuterol Sulfate|Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
214421920|NCT03586544|BEHAVIORAL|Interval Warm-up exercise|Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
214421921|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 1|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
214421922|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 2|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
214421923|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 3|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
214421924|NCT03490851|OTHER|Cream of Rice|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
215102680|NCT00002812|DRUG|cyclophosphamide|Given IV
214421925|NCT03523091|DRUG|OnabotulinumtoxinA 100Unit Injection|Initial treatment with the option of repeat injections every 3 months
214421926|NCT01070251|BEHAVIORAL|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
214421927|NCT01070251|BEHAVIORAL|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
214421928|NCT03451435|DRUG|N acetyl cysteine|N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
214421929|NCT00984087|DEVICE|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
214421930|NCT01242150|DEVICE|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow \>40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
214421931|NCT01242150|DEVICE|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
214421932|NCT04639349|BEHAVIORAL|exercise group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
214421933|NCT04639349|OTHER|control group|the control group will not be trained
214421934|NCT05790941|COMBINATION_PRODUCT|Latanoprost and Minoxidil|Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
214690209|NCT05628181|BEHAVIORAL|Educational nudge intervention|This project will adapt the EMPOWER educational brochure for PLWD receiving CNS polyRx. The educational brochure will be mailed to intervention participants identified through EHR at Michigan Medicine and Henry Ford Health System. The brochure will describe what CNS polyRx is, present information about the associated risks, and suggest that participants speak with the prescribing clinician or pharmacist about ways to potentially simplify the medication regimen. The tool will be adapted through three successive rounds of focus groups (AIM one of this project) of PLWD.
214690210|NCT05415358|OTHER|Blood and tissue samples|Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of immune checkpoint inhibitor treatment discontinuation.
214690211|NCT02649387|DRUG|Ibrutinib|Given PO
214690212|NCT02649387|OTHER|Laboratory Biomarker Analysis|Correlative studies
214690213|NCT06580106|OTHER|Biospecimen samples|Buccal swabs and Blood samples will be collected throughout study.
214690214|NCT04937478|OTHER|Observation|Only observational study, no intervention.
214690215|NCT03207022|PROCEDURE|axillary brachial plexus block|ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
214690216|NCT02532361|DEVICE|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
215102681|NCT00002812|DRUG|cytarabine|Given IV
215102682|NCT00002812|DRUG|daunorubicin hydrochloride|Given IV
215102683|NCT00002812|DRUG|dexamethasone|Given IV
215102684|NCT00002812|DRUG|doxorubicin hydrochloride|Given IV
215102685|NCT00002812|DRUG|idarubicin|Given IV
215102686|NCT00002812|DRUG|mercaptopurine|Given IV
215102687|NCT00002812|DRUG|methotrexate|Given PO
215102688|NCT00002812|DRUG|pegaspargase|Given IV
215102689|NCT00002812|DRUG|prednisone|Given PO
215102690|NCT00002812|DRUG|thioguanine|Given IV
215102691|NCT00002812|DRUG|vincristine sulfate|Given IV
215102692|NCT00002812|RADIATION|radiation therapy|
215102693|NCT05295355|DRUG|Tiotropium Bromide Combined With Odaterol|2 puffs once daily at the same time of the day for 52 week
215021072|NCT02953964|OTHER|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
215021073|NCT04462250|DEVICE|Prescription Opioid Management App|Smartphone application that provides education and reinforcement of safe opioid use, storage, and disposal
215021074|NCT05615350|OTHER|Meals served during breakfast with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during breakfast at the eating behaviour lab
215021075|NCT05615350|OTHER|Meals served during lunch with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during lunch at the eating behaviour lab
215021076|NCT02281864|BEHAVIORAL|Smoking Cessation Intervention Bundle|Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
214421935|NCT04242732|DIAGNOSTIC_TEST|CT scan of the knee under weight-bearing with the Cone Beam Computed Tomography (CBCT) scanner system.|The patient will be evaluated under weight-bearing, with knee flexed at 30 ° and therefore with contracted thigh muscles. The measurement and maintenance of the 30 ° of flexion will be controlled by a goniometer applied laterally to the knee and fixed by means of an elastic band.
214421936|NCT04242732|DIAGNOSTIC_TEST|Conventional CT scan|The patient will be evaluated in supine position, with the muscles relaxed and the knee in full extension by conventional CT scan
214421937|NCT00471029|DRUG|esomeprazole|
214421938|NCT01832506|DRUG|MSC2156119J|Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
214421939|NCT02888002|BEHAVIORAL|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
214421940|NCT00820079|DRUG|ADX10059|oral administration
214421941|NCT00820079|DRUG|ADX10059 Matching Placebo|oral administration
214421942|NCT00670020|PROCEDURE|supplemental perioperative oxygen|increased perioperative oxygen verses non-interventional oxygen
214421943|NCT02563613|BEHAVIORAL|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
214690217|NCT02532361|PROCEDURE|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
214690218|NCT00610727|DRUG|Prochlorperazine 0.5 mg IV over 5 sec|IV Prochlorperazine for bioavailability
214690219|NCT00610727|DRUG|Inhaled prochlorperazine 0.625 mg|Inhaled Staccato Prochlorperazine 0.625 mg
214690220|NCT00610727|DRUG|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato Prochlorperazine 1.25 mg
214690221|NCT00610727|DRUG|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato Prochlorperazine 2.5 mg
214690222|NCT00610727|DRUG|Inhaled prochlorperazine 5 mg|InhaledStaccato Prochlorperazine 5 mg
215021077|NCT02281864|OTHER|Control Group: Quitline|Referral to the Quitline
215021078|NCT05250557|DIAGNOSTIC_TEST|Fractional flow reserve|Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
215021079|NCT00551993|PROCEDURE|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
215021080|NCT00551993|PROCEDURE|Laparoscopic Sacral Colpopexy|Standard laparoscopy
215021081|NCT02100644|DRUG|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG\&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
215021082|NCT00000853|BIOLOGICAL|rgp120/HIV-1MN|
215021083|NCT00728182|DRUG|NA-1|single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
215021084|NCT00728182|DRUG|Placebo|single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
215021085|NCT02236767|DEVICE|Neurostar Transcranial Magnetic Stimulation Therapy System|Treatment will entail daily (5 days/week) sessions of repetitive transcranial magnetic stimulation for 6 weeks employing right-sided, low frequency stimulation (1 Hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (DLPFC).
215021086|NCT01513928|DRUG|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
215021087|NCT01513928|DRUG|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
215021088|NCT01513928|DRUG|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
215021089|NCT01898091|DRUG|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
215021090|NCT01898091|DRUG|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
215021091|NCT05129384|DIETARY_SUPPLEMENT|B. infantis EVC001 or Lactose Placebo|Infant probiotic
215021092|NCT01187875|DIETARY_SUPPLEMENT|Placebo- Fiber free control|Dextrin control administered in a muffin treatment.
215021093|NCT01187875|DIETARY_SUPPLEMENT|Hi-maize resistant starch 9g|9g Hi-maize resistant starch administered in a muffin treatment.
215021094|NCT01187875|DIETARY_SUPPLEMENT|Novalose 330 resistant starch 9g|9g Novalose 330 resistant starch administered in a muffin treatment.
215021095|NCT01187875|DIETARY_SUPPLEMENT|4.5g Hi-maize resistant starch and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
215021096|NCT03830411|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
214421944|NCT02563613|BEHAVIORAL|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
214421945|NCT02563613|OTHER|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
215021097|NCT03830411|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
215021098|NCT03830411|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
215021099|NCT01573793|BEHAVIORAL|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
215021100|NCT01573793|BEHAVIORAL|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
215021101|NCT03368521|OTHER|Back pain screening test|The care giver use the screening tool in order to score the back patient to three levels of risk. For each level of risk, one suggested type of care is provided; 1) simple advise; 2) physiotherapy; 3) multimodal rehabilitation. highest risk level includes multimodal intervention.
215021102|NCT04381559|BEHAVIORAL|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
215021103|NCT04381559|BEHAVIORAL|Applied Relaxation|12 sessions of AR will serve as our second, control arm. In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response.86 AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety.87 This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition.88 Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety.87 However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
215021104|NCT05393908|PROCEDURE|TAP Block Group|Participants will receive a surgeon administered TAP block.
215021105|NCT03430973|BEHAVIORAL|Videos|Videos depicting various aggressive driving and road rage behaviors.
215021106|NCT03430973|BEHAVIORAL|Bumper stickers|Bumper stickers hypothesized to increase or decrease aggressive driving.
214690223|NCT00610727|DRUG|Inhaled prochlorperazine 10 mg|InhaledStaccato Prochlorperazine 10 mg
215021107|NCT03430973|BEHAVIORAL|Alcohol-related cues|Case of beer or water on passenger seat.
214421946|NCT01001078|DEVICE|I-Gel supraglottic airway device|2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.
214421947|NCT01001078|DEVICE|LMA Supreme supraglottic airway device|In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
215021108|NCT03430973|BEHAVIORAL|Music|Lyrics and tempo of music will be manipulated to increase or decrease aggressive driving.
214421948|NCT01001078|DEVICE|Standard endotracheal tube|In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
214421949|NCT00270803|DRUG|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
214421950|NCT03629444|RADIATION|ct scan|all patients will be subjected to CT scan and anthroprometric measurments
214690224|NCT00610727|DRUG|Inhaled placebo|Inhaled Staccato Placebo (0 mg)
214690225|NCT00610727|DRUG|Prochlorperazine 10 mg IV over 5 sec|Prochlorperazine 10 mg IV over 5 sec for patient qualification
214690226|NCT06493825|OTHER|Aurora Mindfulness app versus sham|It would either immersive virtual reality exposure for the experimental group or non-immersive virtual reality exposure for the placebo group.
214690227|NCT04150822|OTHER|Registry and Saliva sample|Non-interventional registry with saliva sample collected for DNA analysis
214690228|NCT06565338|DRUG|Dexmedetomidine|drug
214690229|NCT06565338|DRUG|Vitamin D3|drug
214690230|NCT05374174|DIAGNOSTIC_TEST|Tardieu Scale for Spasticity|The clinician will rotate the elbow joint at various speeds while the participant sits relaxed.
214690231|NCT05627622|BEHAVIORAL|WhatsApp health education message|stone-prevention information on a monthly basis, using personal WhatsApp messages
214690232|NCT03656926|DRUG|Liposomal Cyclosporine A|"This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm.~The L-CsA was administered as 10 mg/2.4 mL inhalation via the PARI eFlow device BID (morning/evening, approximately 12 hours apart) for 48 weeks. Nebulization time per inhalation dose was approximately 6 to 17 minutes.~Patients received training on the use of the device and the first dose of L-CsA was self-administered by each patient under the supervision of trained personnel. In addition, during all subsequent scheduled visits the L-CsA inhalation was self-administered by the patient and under the supervision of trained study personnel."
214421951|NCT03863834|DEVICE|InModeRF|InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
214421952|NCT05839938|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
215021109|NCT03430973|BEHAVIORAL|Roadside vegetation|The roadside will contain trash to increase aggressive driving, or vegetation to decrease aggressive driving. There is also a control group.
215021110|NCT03430973|BEHAVIORAL|Video game|Participants will play a racing or neutral video game before driving in the simulator.
215021111|NCT06432452|DRUG|Endothelin Receptor Antagonist|Oral capsules twice daily
215021112|NCT06432452|OTHER|Placebo control|Oral capsules twice daily
215021113|NCT06267508|PROCEDURE|Maternal HIV viral load testing at delivery for VHT risk assessment|Maternal HIV viral load testing will be performed for all mothers enrolled in the study at delivery. Results will be used along with WHO-defined clinical criteria to determine risk status for VHT. The intervention also includes personnel to support the additional testing volume and management of high-risk cases and eHealth solutions for communication of test results between health facilities.
215021114|NCT05157893|DEVICE|Virtual reality based analgesic therapy|The intervention is a single 15 min VR therapy. The VR therapy is consisted of VR device and software. The model of VR device used is Pico Neo 3 Pro. The software run on the VR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.
215021115|NCT01595815|OTHER|Calcium ionophore|Oocytes were activated with calcium ionophore after ICSI
215021116|NCT01595815|OTHER|Strontium chloride (SrCl2)|Oocytes were activated with strontium chloride after ICSI
214421953|NCT05839938|OTHER|Placebo|Placebo
214694095|NCT05715541|OTHER|"mobile applications with the name Set My INR"|"The relevant software company assisted in developing the phone application. The language of the application created with the name Set My INR is Turkish. The application provided an opportunity for patients to share and communicate with their physician after having the INR value measured in a health institution near their place of residence before coming to the hospital"
214421954|NCT02685488|DEVICE|Transcranial Ultrasound Power|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
214694096|NCT00308425|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS), valsartan|
214694097|NCT04208867|BEHAVIORAL|QI Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH services
214694098|NCT01814800|BIOLOGICAL|RI-002|Immune Globulin Intravenous (IGIV)
215021117|NCT06393985|DRUG|Decitabine, venetoclax and blinatumomab|"Cycle1 and cycle3： Decitabine monotherapy,20 mg/m2 qd, d1-5,intravenous infusion;~Cycle2 and cycle4:~Venetoclax 200mg qd, d1-14, orally; Blinatumomab d4-17(Weight ≥45 kg, 9ug d4-6, 28ug d7-17; Weight \<45 kg, 5ug/m2 d4-6, 15ug/m2 d7-17;continuous intravenous infusion)"
214421955|NCT02685488|DEVICE|Transcranial Ultrasound Sham|"Transcranial ultrasound will be used without power for a sham condition."
214421956|NCT04118374|OTHER|Standard Carb Diet|Approximately 50% of caloric intake will come from carbohydrate consumption.
215021118|NCT05358639|DRUG|Olaparib tablet|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
214421957|NCT04118374|OTHER|Low Carb Diet|Approximately 25% of caloric intake will come from carbohydrate consumption.
214421958|NCT05216120|DRUG|Pemigatinib 4.5 MG|"Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles~Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food."
214421959|NCT01126307|DRUG|Verapamil|80 mg tid
214421960|NCT01126307|DRUG|placebo|placebo tid
215021119|NCT05358639|DRUG|Navitoclax|For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
215021120|NCT05094102|DEVICE|OnLume Imaging System|for fluorescence-guided surgery with ICG dye
215021121|NCT05094102|DRUG|Indocyanine green|Indocyanine green is a cyanine dye used in medical diagnostics
215021122|NCT01340118|DRUG|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
215021123|NCT05269940|DRUG|ZX-101A|oral dosing, once daily
215021124|NCT06015165|DRUG|Analgesia plan for Anes. Group|For Anes. Group, hydromorphone intravenous pump (PCIA) with 0.04mg/hr and 0.2mg/hr bolus controlled administration. Rescue opioids will be given as sufentanil 5μg/hr, depending on the time of the last intraoperative administration. NSAIDs such as flurbiprofen axetil or ibuprofen will be administered as a complementary treatment option.
215021125|NCT06015165|DRUG|Analgesia plan for Surg. Group|For Surg. Group, hydromorphone intravenous pump is set with the same analgesic formula as in Anes. Group. Routine prescriptions for rescue opioids (tramadol) and NSAIDs according to pain level recommended by the pharmacy department will be administered.
214421961|NCT02964780|PROCEDURE|Gastric bypass surgery|
214421962|NCT02964780|BEHAVIORAL|Conservative weight loss program|
215021126|NCT06015165|PROCEDURE|Multi-modal analgesia during the surgery|Multi-modal analgesia, including intraoperative long-acting local anesthetics (ropivacaine and methylene blue), perioperative narcotic analgesics, and postoperative laxative and antibiotics. PCIA with the same analgesic formula will be applied in both groups.
215021127|NCT04870554|BEHAVIORAL|Enteric feeding|All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
215021128|NCT05811637|OTHER|Pilates Exercise|The program will be applied with the Pilates exercises every week. All patients were evaluated before and after the treatment (6 weeks).
214421963|NCT04481906|PROCEDURE|Vaginal mesh for female cystocele|Vaginal mesh procedures (e.g. Perigee) were susgested for women with POP-Q stage III or more cystocele
214421964|NCT01177852|DRUG|diphenhydramine + dropropizine + pseudoephedrine|"Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~\- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml"
215021129|NCT05811637|OTHER|Supervised Rehabilitation|The program will be applied with the progression of the supervised rehabilitation in the 4th week
215021130|NCT06483828|BEHAVIORAL|Dental Anxiety Coping Module|Dental tour where participants will be introduced to the dental clinic setting while Expressive Art Therapy, participants will engage with activity of making collage and finger painting.
215021131|NCT02364271|OTHER|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
215021132|NCT02364271|BIOLOGICAL|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
215021133|NCT02364271|OTHER|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
214421965|NCT01177852|DRUG|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|"Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml"
214694099|NCT02030145|PROCEDURE|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
214694100|NCT02030145|PROCEDURE|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
215021134|NCT04584320|OTHER|Stool sample|Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
215021135|NCT05867940|BEHAVIORAL|Physical activity on prescription|"Physical activity on prescription (PAP) is a well-established method to enhance physical activity in adults in primary care. The prescribed activity should lead to moderate increase of the pulse, such as walking, cycling, swimming, or gardening, and should be performed over a longer period of time in order to achieve a change towards a more active lifestyle. The activity may be prescribed by a physiotherapist, physician, nurse, or other health professional. PAP has shown to be feasible to increase participation in physical activity and to reduce sedentary behaviour in children with cerebral palsy.~Motivational interviewing is used for our PAP with participants with disabilities. During PAP-period, the participants are asked to fill in an activity logbook."
215021136|NCT06393426|DRUG|Chinese Herb|Chinese herbal medicine
215021137|NCT01505426|DRUG|ASP1941|oral
215021138|NCT01505426|DRUG|metformin|oral, concomitant use
215021139|NCT01505426|DRUG|Placebo|oral
215021140|NCT04257513|DIAGNOSTIC_TEST|Brain MRI|Neurological and Cognitive evaluation; Brain MRI
215021141|NCT06106984|DEVICE|Graded motor imagery mobile app|The Graded Motor Imagery mobile app is a mobile app designed for intervention in phantom limb pain.
215021142|NCT05532657|OTHER|Hearing intervention|The hearing intervention is best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist for 3 years and will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
215021143|NCT05532657|OTHER|Successful aging/delayed hearing intervention|The successful aging health education program follows the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator, with initial sessions spaced over the 2-3 months post-randomization and semi-annual sessions for 3 years. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
215021144|NCT05445323|GENETIC|Low dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
215021145|NCT05445323|GENETIC|Mid Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
215021146|NCT05445323|GENETIC|High Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
215021147|NCT06013800|OTHER|Measurement of sodium levels|Patients will get measurements of sodium levels daily in the first 48 hours, then daily or every other day until normal sodium levels (\>135mEq/L).
215021148|NCT00674843|RADIATION|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
215021149|NCT00694928|DRUG|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
215021150|NCT00694928|DRUG|butoconazole nitrate|semi-solid, single dose
215021151|NCT02743754|OTHER|Standard therapy|The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
215021152|NCT02743754|OTHER|Hyperbaric Oxygen|The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
215021153|NCT05118529|OTHER|Routine care|Mobilization to chair
215021154|NCT05591300|DIAGNOSTIC_TEST|Microparticles research|The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).
215021155|NCT03797326|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
215021156|NCT03797326|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle.
214690233|NCT03656926|DRUG|Standard of Care|"Standard of Care Therapy (SoC). The SoC included maintenance immunosuppressive medication including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent; but also a prophylaxis against common opportunistic infections, and all other necessary medications and therapies for the optimal care of the patient.~This also included vaccination against COVID-19 All changes in concurrent treatment or medication were administered according to site's SoC.~The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, should be on a stable regimen for a least 4-weeks prior to randomization and continued to receive azithromycin during the trial as deemed appropriate by the investigator."
214690234|NCT05472233|PROCEDURE|Suture removal after Coronally Positioned Flap|Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
214690235|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy and Identity Exploration (HIP+EYME)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME.
214690236|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy, Identity, and Geniotype Exploration (HIP+EYME+GENIOTYPE)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME. Also, participants will answer the Geniotype questionnaire and the results will be worked with the adolescents.
215021157|NCT05455658|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given IV
215021158|NCT05455658|BIOLOGICAL|Sargramostim|Given ID
215021159|NCT04754399|DRUG|Cannabidiol (CBD)|"week 1: 25 mg twice daily, approximately 12 hours apart, with food~week 2: 50 mg twice daily, approximately 12 hours apart, with food~week 3: 75 mg twice daily, approximately 12 hours apart, with food~week 4+: 100 mg twice daily, approximately 12 hours apart, with food"
215021160|NCT05555576|DIETARY_SUPPLEMENT|Vitamin C|1000 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
215021161|NCT05555576|OTHER|Placebo|Placebo taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
215021162|NCT04933422|DRUG|CM93|oral capsule of CM93 administered once daily
215021163|NCT04462393|OTHER|Admission to ICU for COVID-19|All patients admitted to Swedish ICUs with COVID-19 between 6 Mar - 6 May 2020
215021164|NCT05377216|DRUG|Stellate Ganglion Block|Left sided percutaneous stellate ganglion block
215021165|NCT03302429|OTHER|PRF/ BCP|Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)
215021166|NCT03302429|OTHER|Autogenous bone graft|Bone obtained from the same individual who receiving the graft
215021167|NCT00231465|DRUG|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
214421966|NCT02156635|DEVICE|Transcranial direct current stimulation|
214421967|NCT02156635|BEHAVIORAL|Constraint-Induced Movement Therapy|
214421968|NCT02156635|OTHER|Placebo|
214421969|NCT03433950|OTHER|No Intervention|Observational
214421970|NCT00253058|DRUG|Cetirizine Dry Syrup|
214421971|NCT01550978|DEVICE|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
214421972|NCT00595218|BEHAVIORAL|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
214421973|NCT00595218|OTHER|Patient Preference Results|Knowledge of Patient Preference Results
215021168|NCT00231465|DRUG|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
215021169|NCT04817579|DEVICE|Digital photography combined with eLABor_aid shade analyzing software|ELABor\_aid is a new approach to objective shade communication and shade reproduction in dentistry, based on numeric quantification obtained from standardized RGB (red-green-blue) images, and the formulation of a patient personal shade recipe using trichromatic subtractive color mixing laws, thus abandoning the use of visual assessment and shade guides entirely. This approach is currently enjoying increasing popularity for its ease of use, reliability as well as for its practically oriented features like its imaging ability or the digital try-in.
215021170|NCT04817579|DEVICE|Spectrophotometer|Spectrophotometric measurement methods employing computer calculations, based on color science and theories, allow quantitative evaluation which is objective and appears to be more accurate.
215021171|NCT04817579|DEVICE|Conventional visual shade matching|Visual shade matching is the most common method, in which a color standard from a commercially available dental shade guide is compared to and matched with the target tooth.
215021172|NCT05354258|DRUG|Albendazole|Anthelminthic drugs for the treatment of soil-transmitted helminths
215021173|NCT05354258|DRUG|Praziquantel|Anthelminthic drugs for the treatment of schistosomiasis
215021174|NCT05354258|DRUG|Amodiaquine|SMC partner drug
215021175|NCT05354258|DRUG|Sulfadoxine pyrimethamine|SMC partner drug
215021176|NCT03390491|BEHAVIORAL|OnTrack>TheGame (OTG)|OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack\>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.
215021177|NCT03390491|BEHAVIORAL|Recovery Videos (RV)|As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
215021178|NCT00600782|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
215021179|NCT02801773|DIETARY_SUPPLEMENT|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
215021180|NCT02801773|OTHER|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
215021181|NCT02380872|PROCEDURE|Connective tissue graft|gingival recession treated with connective tissue graft
215021182|NCT02380872|PROCEDURE|Platelet Rich Fibrin|gingival recession treated with platelet rich fibrin
215021183|NCT01321645|DRUG|Azadirachta Indica|To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
215021184|NCT01909401|DRUG|boceprevir|
214421974|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
214690237|NCT03789604|BIOLOGICAL|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
214694101|NCT05009823|DIETARY_SUPPLEMENT|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml.
215021185|NCT05802849|DRUG|Acetazolamide|Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.
215021186|NCT00949936|DEVICE|CAdisc™-L (Total Disc Replacement)|
214421975|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
214421976|NCT05060562|OTHER|COVID 19 positive|Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.
214421977|NCT05060562|OTHER|COVID 19 negative|Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.
214421978|NCT00324038|DRUG|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
214421979|NCT00324038|DRUG|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
214421980|NCT02770248|DRUG|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
214421981|NCT02770248|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
214421982|NCT00924534|DRUG|Placebo|Placebo
214421983|NCT00924534|DRUG|SLV337|SLV337 400 mg/day
214421984|NCT00924534|DRUG|SLV337|SLV337 800 mg/day
214421985|NCT00924534|DRUG|SLV337|SLV337 1400 mg/day
214421986|NCT00043082|DRUG|carboplatin|intravenous q 4 weeks
214421987|NCT00043082|DRUG|pegylated liposomal doxorubicin hydrochloride|intravenous q 4 weeks
215021187|NCT00996177|DRUG|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
214421988|NCT04709744|DRUG|Vitamin D|Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
214421989|NCT04709744|DIAGNOSTIC_TEST|ELISA|Measure vitamin D level
214421990|NCT02473562|DRUG|Varenicline|Tablet 1 mg BID
215021188|NCT00996177|DRUG|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
215021189|NCT01946100|GENETIC|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
215021190|NCT06438952|PROCEDURE|Transforaminal steroid injection combined with lumbar sympathetic blockade|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance Lumbar sympathetic blockade will be made with 5 ml 0.5% bupivacaine + 6 mg dexamethason + 10 ml NaCl
214421991|NCT02473562|DRUG|Placebo (for varenicline)|Tablet 1 mg BID
215021191|NCT06438952|PROCEDURE|Transforaminal steroid injection only|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance
215021192|NCT00025233|BIOLOGICAL|bevacizumab|Given IV
215021193|NCT00025233|OTHER|laboratory biomarker analysis|Correlative studies
215021194|NCT01522027|PROCEDURE|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
215021195|NCT06305546|DRUG|Chlorhexidine Gluconate|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
215021196|NCT06305546|DRUG|Metronidazole|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
215021197|NCT06305546|DRUG|combination gel (chlorhexidine and metronidazole)|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
215021198|NCT06305546|DRUG|Placebo|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
214421992|NCT00667745|DRUG|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
214421993|NCT00667745|DRUG|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
215021199|NCT01260415|DRUG|Panitumumab, Oxaliplatin, 5-FU|"* Panitumumab 6 mg / kg, given over 60 minutes~* Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~* Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~* 5FU 400 mg / m2, by bolus infusion~* 5FU 2400 mg / m2, given over 46 hours"
214421994|NCT05301556|OTHER|Experimental Product|"* Before the surgery: FSMP provides daily target energy needed by participants~* 1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. FSMP provides daily target energy needed by participants"
214690238|NCT03789604|BIOLOGICAL|CS1001 placebo|Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
214421995|NCT05301556|OTHER|Control Product|"* Before surgery: TPF-T provides daily target energy needed by participants~* 1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. TPF-T provides daily target energy needed by participants"
215021200|NCT06131463|DEVICE|Electrocardiogram (ECG) feature in smart watches|A study participant that is randomly assigned to the experimental group should enable the ECG function on his or her smart watch and make sure that there is synchronization with a corresponding application on his or her mobile phone. The ECG function must stay enabled, and the participant should wear the smartwatch every day for 30 days.
215021201|NCT03782103|DRUG|ZuraPrep Clear Solution|Apply topically.
215021202|NCT03782103|DRUG|ChloraPrep|Apply topically.
215021203|NCT03782103|DRUG|ZuraPrep Vehicle|Apply topically.
215021204|NCT00270569|DRUG|PhyxolTM, Cisplatin|
215021205|NCT02058277|DRUG|bosutinib or bosutinib + aprepitant|Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
215021206|NCT03087357|OTHER|SmartNIPT|A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
215021207|NCT02027194|DRUG|Cure-Allergic Rhinitis Syrup|Delivered one bottle for two weeks to the participants twice
215021208|NCT02027194|DRUG|Yu-ping-fung San|Delivered one bottle for 2-week usage to the participants twice
215021209|NCT02027194|DRUG|Placebo|Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
215021210|NCT02167360|DRUG|CTL019|A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
215021211|NCT00930176|BIOLOGICAL|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
215021212|NCT00440570|DEVICE|Low levels of amplitude-modulated electromagnetic fields|
214421996|NCT04850482|OTHER|MyJourney|MyJourney is an online self-help interactive program based on Contextual Cognitive Behavioural Therapy.
214421997|NCT03342651|OTHER|Vitamin D|Vitamin D, general anesthesia, respiratory complications
214421998|NCT04546997|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
214421999|NCT02160106|DRUG|TEW-7197|Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
214422000|NCT01606995|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
214422001|NCT01523249|DEVICE|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
214422002|NCT03768206|BEHAVIORAL|Standard Physical Therapy|Participants will receive standard outpatient physical therapy that is typical following knee replacement
214422003|NCT03768206|BEHAVIORAL|Physical therapist discuss aerobic physical activity|Physical therapists will provide recommendations to increase aerobic physical activity and set goals during standard physical therapy sessions after knee replacement.
214422004|NCT03768206|BEHAVIORAL|Physical activity session|Participants will receive a one hour coaching session on aerobic physical activity and goal setting after knee replacement.
215021213|NCT00440570|DEVICE|Emitter of low levels of amplitude-modulated electromagnetic fields|
215021214|NCT04006756|BEHAVIORAL|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
215021215|NCT04006756|BEHAVIORAL|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
215021216|NCT01363830|BEHAVIORAL|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
215021217|NCT01363830|BEHAVIORAL|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
214422005|NCT06345560|DRUG|Drospirenone|4 mg tablet once daily
214422006|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
214422007|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
214690239|NCT01194557|DEVICE|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
214690240|NCT01194557|DRUG|Lumartem|Presumptive treatment of malaria/fever
215021218|NCT01137760|DIETARY_SUPPLEMENT|Sucrose|5 g of sucrose daily for 8 weeks
215021219|NCT01137760|DIETARY_SUPPLEMENT|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
215021220|NCT01137760|DIETARY_SUPPLEMENT|Galactooligosaccharide|5.0 g galactooligosaccharide daily for 8 weeks
215021221|NCT03406975|DEVICE|Overstitch Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), an endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
215021222|NCT03406975|BEHAVIORAL|Lifestyle Intervention|Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
214422008|NCT03800667|DRUG|Ascorbic Acid 1000 MG|1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
214422009|NCT06553248|DRUG|GZR4|Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
214422010|NCT06553248|DRUG|Insulin Degludec|Administered once daily subcutaneously (s.c., under the skin) for 6 weeks
214422011|NCT02545751|RADIATION|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
214422012|NCT02545751|DRUG|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
214506882|NCT02446275|OTHER|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.
214506883|NCT02446275|OTHER|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
215021223|NCT04877639|DRUG|Esmketamine,Dexmedetomidine|Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
215021224|NCT00220714|DRUG|atypical antipsychotics:oral vs. long-acting route|
215021225|NCT00220714|BEHAVIORAL|Family Psychoeducation|
215021226|NCT03056430|BEHAVIORAL|Training|
214422013|NCT06713200|PROCEDURE|High intensity percutaneous electrolysis|A sterile, disposable stainless steel needle of different lengths depending on the area to be treated will be connected to the EP device; the gauge of these needles will be 0.25 mm. A current of 3 mA will be applied for 3 times with a duration of 3 seconds each. In order to avoid biases, the technique will be performed for 90 seconds as in the low intensity treatment group and in the last 20 seconds the current will be applied with the parameters previously described. Three sessions divided in three consecutive weeks will be applied.
214506884|NCT00946972|DRUG|JNJ-38431055; Placebo|
214506885|NCT01737749|DEVICE|Neurokeeper stroke detector|Electrophisoloigcal monitoring
214506886|NCT03616015|BIOLOGICAL|blood samples|20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
215021227|NCT03709095|OTHER|Sprint interval training|Participants utilized the arm ergometer for improving aerobic exercise capacity
214422014|NCT06713200|PROCEDURE|Low intensity Percutaneous Electrolysis|This technique will be performed with the same instrument as the high intensity technique. It differs from the previous treatment group in that the current intensity in this case will be of an amperage of 0.3mA during 90 seconds. In the same way, 3 sessions divided in 21 consecutive days will be applied.
214506887|NCT03616015|BIOLOGICAL|fecal samples|1 g of feces (D-8, D0, D15, D30, D90)
214506888|NCT03616015|BEHAVIORAL|Anxiety test|Test of Spielberger
214506889|NCT03616015|BEHAVIORAL|Stress test|Test of Cohen
214506890|NCT02106884|DRUG|Nab-paclitaxel|
214506891|NCT02106884|DRUG|Gemcitabine|
214506892|NCT04597931|DRUG|Romosozumab|SC Romosozumab 210 mg/monthly
214506893|NCT04597931|DRUG|Zoledronic Acid|IV Zoledronic acid 5 mg
214506894|NCT04317430|DRUG|Niclosamide|Niclosamide tablets 1 gram once daily
214506895|NCT04317430|DRUG|Placebo oral tablet|lactose tablets
214506896|NCT00105846|PROCEDURE|Home care telemedicine|
214506897|NCT05652907|DRUG|FSD201|Tablets for oral administration.
214506898|NCT05652907|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
215021228|NCT03709095|OTHER|moderate intensity continuous training|Participants utilized the arm ergometer for improving aerobic exercise capacity
215021229|NCT00401830|DRUG|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
215021230|NCT00401830|OTHER|Placebo|Matching placebo tablet administered twice daily
215021231|NCT02382900|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine|dose scheme (0 and 6 month)
215021232|NCT02623439|DRUG|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
215021233|NCT02425488|BEHAVIORAL|Nursing therapeutics education|"Educational intervention will focus on~1. Appropriate lifestyles~2. Early recognition of signs/prodromal symptoms of HF~3. Early recognition of signs of inflammation of the ICD-pocket~4. Good management of the device~1\) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI"
215021234|NCT03120923|DRUG|Lidocaine 3 cc|
215021235|NCT03120923|DRUG|Lidocaine 9 cc|9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide
215021236|NCT03120923|DRUG|Triamcinolone Acetonide|
214506899|NCT01593644|DRUG|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
214506900|NCT02449785|DEVICE|MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)|
214506901|NCT02449785|DEVICE|CT measurements of lung morphological changes in cystic fibrosis|
214506902|NCT02427191|OTHER|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
214506903|NCT02427191|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
214506904|NCT02733731|DRUG|Chinese Herbal Compound Ointment|
214506905|NCT02733731|DRUG|Estriol|
214690241|NCT02114333|BIOLOGICAL|Zostavax|0.65ml, subcutaneous
214690242|NCT02114333|BIOLOGICAL|HZ/su vaccine|0.5ml, intramuscular
215021237|NCT02423720|BEHAVIORAL|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
215021238|NCT01399086|DRUG|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
215021239|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
215021240|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
214422015|NCT06713200|PROCEDURE|Simulated Percutaneous Electrolysis|The needle and PD device will be connected in the same way as for the other treatment groups. The needle will be inserted without reaching the lesion area and the characteristic sound of turning on the PD machine will be made. It will last 90 seconds and at no time the galvanic current will be applied. The same aseptic precautions will be applied, in addition to performing the same final hemostasis guidelines and providing the same post-treatment guidelines as for all the other subjects in the study.
214422016|NCT06712199|DRUG|oxalidine|"Opioid anesthesia group (OBA group) Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and sufentanil 0.3μg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Anesthesia was maintained with propofol 4-12 mg·kg-1·h-1 and remifentanil 0.2-0.5 μg·kg-1·min-1. Sufentanil 10μg was bridaged 30min before the end of surgery. The PCA dosing regimen was sufentanil 2 µg/kg+ dexmedetomidine 2 µg/kg+ ondansetron 24mg.~Reduced-opioid anesthesia group (OFA group)~Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and esketamine 0.3mg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Propofol 4-12 mg·kg-1·h-1 and esketamine 0.3-0.5 mg·kg-1·h-1 were pumped to maintain anesthesia during operation. Oxalidine 1.5mg was given in two divided doses of 0.75mg each time with an interval of 10min 30min before the end of surgery. The PCA regimen was as follows:"
214690243|NCT02114333|BIOLOGICAL|Placebo|0.65ml, subcutaneous
214690244|NCT06205147|DEVICE|Elastic Band|Using the newly patented product, the Muscle Exercise and Falling Prevention Elastic Strap (Patent Certificate No. M585601), the procedure involves securing the elastic strap to a high-back chair to administer elastic band intervention exercises for patients.Guided by continuous contextual action demonstration videos, participants will engage in the elastic band resistance intervention twice a day, each session lasting 20 minutes, over a span of five days. These videos are designed to provide a continuous contextual demonstration, incorporating them within the video itself.
214690245|NCT05065801|COMBINATION_PRODUCT|GEMBRAX/FOLFIRINOX Arm A|Patients in the experimental arm received sequential treatment: A maximum of 6 cycles (12 months) of chemotherapy; One cycle = 3 administrations of GEMBRAX followed by 2 administrations of FOLFIRINOX
214690246|NCT05065801|COMBINATION_PRODUCT|FOLFIRINOX Arm B|Patients in this arm received : A maximum of 3 cycles (6 months) of chemotherapy. One cycle = 4 administrations of FOLFIRINOX
214422017|NCT06711237|OTHER|self-adhesive resin cement (RC)|Single-unit implant-supported single crowns were cemented to the abutments using a self-adhesive resin cement (RC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.
214422018|NCT06711237|OTHER|resin-modified glass-ionomer cement (RMGIC)|Single-unit implant-supported single crowns were cemented to the abutments using a resin-modified glass-ionomer cement (RMGIC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.
214422019|NCT04493242|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
214422020|NCT04493242|OTHER|Intravenous normal saline|Placebo
214422021|NCT03714750|PROCEDURE|DK crush|revascularization of true coronary bifurcation stenosis in DK crush technique
214422022|NCT03714750|PROCEDURE|Reverse TAP|revascularization of true coronary bifurcation stenosis in Reverse TAP technique
214690247|NCT05610176|DEVICE|Amvia Sky pacemaker or CRT-P device|Subjects with an indication for a pacemaker or CRT-P device will be implanted with an Amvia Sky device of the Amvia/Solvia pacemaker family according to standard pacemaker implantation procedures. Device programming will be done according to the medical needs of the subjects.
214690248|NCT05813431|OTHER|FRENCH grid (classification for emergency nurses in French hospitals)|Triage tool validated by the French Society of Emergency Medicine (SFMU) which is used to prioritize patients according to standardized criteria and to orient them within the emergency department.
214422023|NCT00284401|PROCEDURE|Evaluation of the placement of the Delta prosthesis|
215021241|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
215021242|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
214422024|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields
214422025|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields
214690249|NCT05813431|OTHER|QuickSOFA|Rapid score that consists of an evaluation based on 3 clinical criteria (blood pressure, respiratory rate and consciousness) to quickly establish a severity score.
214690250|NCT05813431|OTHER|Capillary lactate assessment|Collect a drop of blood from the fingertip (less than 1 ml)
214694102|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 With CMV|Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.
215021243|NCT01023464|OTHER|FID114657|artificial tears
215021244|NCT01023464|OTHER|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
215021245|NCT00452400|DRUG|BI 1744CL|
215021246|NCT01720602|DRUG|vorinostat|Given PO
215021247|NCT01720602|DRUG|anastrozole|Given PO
215021248|NCT01720602|DRUG|letrozole|Given PO
215021249|NCT01720602|DRUG|exemestane|Given PO
215021250|NCT01720602|PROCEDURE|positron emission tomography|Correlative studies
215021251|NCT01720602|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
215021252|NCT01720602|RADIATION|fludeoxyglucose F 18|Correlative studies
215021253|NCT01720602|OTHER|laboratory biomarker analysis|Correlative studies
214690251|NCT06349616|OTHER|Intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment. At 2 time points in the experiment, participants will place their hands and forearms in a bucket of cold tap water for 10 minutes.
214690252|NCT06349616|OTHER|No intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment.
214690253|NCT06247592|PROCEDURE|Greater occipital nerve block|Pulse Radiofrequency application to the greater occipital nerve will be applicated after radiofrequency cannula placed near the greater occipital nerve location at 42 degree, for 240 seconds.
214422026|NCT05632068|DRUG|Xian-Hua-Cha|Zizyphus jujuba Mill., Nelumbo nucifera Gaertn, Citrus reticulata Blanco, Rosa rugosa Thunb., Cassia obtusifolia L., Stevioside, resistant starch, and water
214690254|NCT06247592|PROCEDURE|Greater occipital nerve pulse radiofrequency|The greater occipital nerve will be blocked with 5 cc 2% prilocaine.
215021254|NCT02781701|DEVICE|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
215021255|NCT05156814|DRUG|Femoston® 1, Femoston® 2|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
215021256|NCT05156814|DRUG|Duphaston|Duphaston®, 10 mg
215021257|NCT05156814|DRUG|Klimadynon|Cimicifuga racemosa rhizomatum extract
215021258|NCT05156814|DRUG|Divigel|Divigel, 0.1%
215021259|NCT03315559|DRUG|[14C]-GSK2269557 IV infusion|The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
215021260|NCT03315559|DRUG|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
215021261|NCT03315559|DRUG|[14C]-GSK2269557 oral solution|The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
215102694|NCT00604045|BEHAVIORAL|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
215102695|NCT00604045|BEHAVIORAL|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
214422027|NCT02280161|OTHER|cytology specimen collection procedure|Correlative studies
214422028|NCT00647530|BIOLOGICAL|panitumumab|
214422029|NCT00647530|DRUG|capecitabine|
214422030|NCT00647530|DRUG|fluorouracil|
214422031|NCT00647530|DRUG|oxaliplatin|
214422032|NCT01029093|OTHER|no intervention, MRI and motor skill test|Two MR Investigations at two different times
214506906|NCT05178706|OTHER|upper extremity rehabilitation program|Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.
214506907|NCT05178706|DIAGNOSTIC_TEST|Results of assessment|The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.
214506908|NCT04129099|BIOLOGICAL|GC022F|GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.
214506909|NCT01714076|OTHER|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
214690255|NCT01375504|BEHAVIORAL|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
214690256|NCT01375504|BEHAVIORAL|Mindfulness Training Program|The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
214690257|NCT00978861|DRUG|Hydrogen Peroxide|Whitening product syringe type
214690258|NCT05397886|DRUG|Remimazolam Besylate|Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
214690259|NCT05397886|DRUG|Flumazenil|Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
214690260|NCT05397886|DRUG|Propofol|Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
214690261|NCT02353260|DEVICE|Ultrasound Hyperthermia|treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
215021262|NCT02767245|DRUG|Thiamine|Thiamine IV 100 mg/day
215021263|NCT02882984|DRUG|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|radiation given along with one of kind TKI
215021264|NCT02882984|RADIATION|WBRT|3750 cGy in 15 fractions given within 3 weeks time.
214422033|NCT02611427|BEHAVIORAL|Education/Self-efficacy|The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.
214422034|NCT02611427|BEHAVIORAL|Education|The education group will receive information about safe physical activity.
214422035|NCT01942707|PROCEDURE|abdominoplasty with Scarpa's Fascia|During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
215021265|NCT02882984|RADIATION|HFSRS|All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
215021266|NCT03802357|PROCEDURE|Exercise training|Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.
215021267|NCT03378635|DRUG|Dasiglucagon|Glucagon analog
215021268|NCT03378635|DRUG|GlucaGen|Native glucagon
215021269|NCT03378635|DRUG|Placebo|Placebo for dasiglucagon
214422036|NCT01942707|PROCEDURE|Abdominoplasty without Scarpa´s Facia|During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
214422037|NCT04045470|DEVICE|Microdevices|The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.
214422038|NCT04045470|OTHER|Standard of care therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
214422039|NCT04045470|OTHER|Standard of care systemic therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
214422040|NCT02812966|DEVICE|Lutonix|Drug Coated Balloons
214422041|NCT02812966|DEVICE|IN.PACT|Drug Coated Balloons
214422042|NCT06507657|DRUG|empagliflozin|"intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
214422043|NCT06507657|DRUG|Placebo tablet|"intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
215021270|NCT05004168|OTHER|Day Gel-0120|Two milligrams of test article applied to the test area. The test products are Day Gel-0120C and Day Gel-0120-D. The products are applied together on the test area with
215021271|NCT05004168|OTHER|P5 Reference Standard (SPF 35 reference)|The reference product is P5 according to ISO 24444:2019. The application of reference product is similar with test product.
215102696|NCT04492163|DEVICE|TTFields|"TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.~Other Names:~• TTFields"
214506910|NCT04406532|BEHAVIORAL|PT-Pal|"Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
214690262|NCT02353260|DRUG|Docetaxel,Cisplatin,Fluorouracil|Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
214690263|NCT00977327|DEVICE|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
214694103|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 Without CMV|Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.
215021272|NCT02849223|DEVICE|Anodal Transcranial Direct Current Stimulation|2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.
215021273|NCT02849223|DEVICE|Sham stimulation|30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
215021274|NCT01098578|DRUG|Floseal|Received 1 syringe of Floseal as treatment for posterior epistaxis.
215021275|NCT02580006|DRUG|EPORON|single dose administration subcutaneously
215021276|NCT02580006|DRUG|EPREX|single dose administration subcutaneously
215021277|NCT05013086|DRUG|1.48 GBq of 177Lu-AB-3PRGD2|accepted intravenous injection of 177Lu-AB-3PRGD2
215021278|NCT04633876|BEHAVIORAL|Individual coaching|Individual coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
215021279|NCT04633876|BEHAVIORAL|Group coaching|Group coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
215021280|NCT04633876|OTHER|Control group|Group receives no lifestyle coaching but did get baseline results from assessments which might motivate for lifestyle change.
215102697|NCT01984996|DEVICE|Freedom ProFlor Inguinal Hernia Implant|
215102698|NCT02804035|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
214422044|NCT04857944|BEHAVIORAL|IDEA program (Improving depressive symptoms through personalised exercise and activation)|The program will consist of six 90-minute group sessions composed of four to six participants. These short intervention sessions will be distributed in one month, with a frequency of once or twice a week depending on the week of the program. Of the six sessions, two will be exercise-oriented and will include on-site practice. The remaining four sessions will include definitions of depressive symptomatology, the relationship between depression and having an active lifestyle, motivation and barriers towards exercise, and maintenance strategies.
214422045|NCT04857944|DEVICE|IDEApp|An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.
214690264|NCT00977327|DEVICE|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
215021281|NCT02978508|DRUG|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
215021282|NCT02978508|DRUG|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
215021283|NCT02846727|DEVICE|skin perfusion image|Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
215021284|NCT01105832|DRUG|Teriparatide|Teriparatide (Forsteo) 20 micrograms daily during four weeks
215021285|NCT05383950|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory, cardiac, or geriatric diseases.
215021286|NCT06279403|DRUG|Toripalimab|Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.
215021287|NCT06279403|PROCEDURE|Cytoreductive Nephrectomy|"Radical Nephrectomy: Complete resection of the tumor and affected kidney within the renal fascia.~Partial Nephrectomy: Complete resection of the tumor while preserving maximal kidney function.~Lymph Node Dissection: For patients with evident enlargement of retroperitoneal lymph nodes preoperatively, perform lymph node dissection at the renal hilum, along the ipsilateral major vessels, and anterior to the ipsilateral major vessels. Lymph node dissection is not required for patients without evident enlargement of retroperitoneal lymph nodes preoperatively."
215021288|NCT06279403|DRUG|Axitinib|Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.
215021289|NCT01746069|BEHAVIORAL|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
215021290|NCT01746069|BEHAVIORAL|health advice|routine clinical practice
215021291|NCT00493558|DEVICE|Trabecular Metal Intervertebral Cage with RSA beads|Roentgen Stereophotogrammetric Analysis beads will be inserted at time of implant of the Trabecular Metal Intervertebral Cage.
215102699|NCT02781168|DEVICE|use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
215102700|NCT01887353|DRUG|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
214422046|NCT03180905|DEVICE|ImPACT Online/Paper Pencil Tests|Compare ImPACT Online versus Paper and Pencil Neurocognitive Tests
214422047|NCT03180905|DEVICE|ImPACT Online|ImPACT Online will be administered at 2 time points.
214422048|NCT05903027|DRUG|Rimegepant 75 MG Disintegrating Oral Tablet|Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
214422049|NCT00590382|DEVICE|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
214422050|NCT05709899|OTHER|nerve blocks|Comparison of ultrasound-guided erector spinae plane block and transmuscular quadratus lumborum block for postoperative analgesia in abdominal cancer surgeries.
214422051|NCT04257058|BEHAVIORAL|Electronic educational material|Electronic media via email
215021292|NCT00562861|DRUG|citalopram + mood stabilizer|Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
215021293|NCT00562861|DRUG|placebo + mood stabilizer|This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
215021294|NCT03409146|DEVICE|Monica Novii Wireless Patch System|The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
215021295|NCT03927755|OTHER|Education|Physicians will undergo training on how to rapidly obtain appropriate images.
215102701|NCT01887353|DRUG|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
214422052|NCT04969991|DRUG|Varespladib|250 mg immediate-release oblong, white, film-coated tablet for oral administration
214694104|NCT05009823|DIETARY_SUPPLEMENT|F100|100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
214694105|NCT05009823|DIETARY_SUPPLEMENT|Standard F75 + RUTF|Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive
215021296|NCT04129333|OTHER|Hypnosis|"The hypnosis session :~* Creation of the therapist-patient link~* Choice of a theme and the preferred sensory channel by the patient~* Collection of the theme chosen by the patient~* Orientation in the here and now.~* Induction~* Realization of the gesture and hypnosis~* At the end of the procedure, reassociation of the patient in the here and now"
215021297|NCT04129333|OTHER|No hypnosis|No hypnosis
215021298|NCT05152095|OTHER|Vaccaria seed (Wang Bu Liu Xing) pre-attached to adhesive tape used for auricular acupressure|Apply on auricular acupoints, Shenmen and Occiput, apply pressure for 3 minutes, 5 times per day, at the interval of 2 \~ 3 hours, for 5 days.
215021299|NCT05152095|OTHER|Plain ear adhesive tape|Apply on Shenmen and Occiput without applying pressure for 5 days.
214422053|NCT04969991|DRUG|Placebo|Oral formulation matched to the oral varespladib tablet
214422054|NCT03007589|DRUG|otc sunscreens|Sunscreens of various SPF levels and ingredients
214422055|NCT03007589|OTHER|sun protection fabrics|fabrics
214422056|NCT03007589|OTHER|Optical Filters|Optical band pass or long pass filters or surfaces/mirrors used in solar simulators
214422057|NCT03849716|OTHER|Blood sample|Blood samples obtained for biomarker analyses
214422058|NCT03849716|OTHER|Cheek swab|Cheek swab obtained for genetic analysis
214422059|NCT06362759|DRUG|TOUR006 - 50 MG|TOUR006 50 MG
214422060|NCT06362759|DRUG|TOUR006 - 25 MG|TOUR006 25 MG
214422061|NCT06362759|DRUG|TOUR006 - 15 MG|TOUR006 15 MG
214422062|NCT06362759|OTHER|Placebo|Placebo
214422063|NCT04482894|OTHER|Palliative Care Visits|Regular visits with a palliative (supportive) care specialist
214422064|NCT04167969|DRUG|(64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer, or (89Zr)-DFO-PSMAi-PEG-Cy5.5-C' dots|Patients will be injected with approximately 5 mCi (+/- 10%) of 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots or 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
214422065|NCT04167969|DIAGNOSTIC_TEST|PET/MRI/fluorescence imaging|Imaging will be performed using the GE Signa PET/MRI.
214422066|NCT04167969|OTHER|Blood and urine sampling|Staff will perform the IV blood draws and collect urine samples
214506911|NCT04406532|BEHAVIORAL|Self-guided exercises|"Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
214506912|NCT05307952|DIAGNOSTIC_TEST|Tone Audiometry|Evaluation of the participants' audiometrical thresholds
214506913|NCT05307952|DIAGNOSTIC_TEST|Spectrotemporal Assessment|Evaluation of the participants' promptness in detecting a modulation of a harmonic complex
214506914|NCT05307952|DIAGNOSTIC_TEST|Phoneme and Speech Perception|Evaluation of the participants' understanding of phonemes and short words, both in quiet and in noise
214506915|NCT05307952|DIAGNOSTIC_TEST|Digit Triplet Test|Evaluation of the participants' ability to discern speech in noise
214422067|NCT04167969|PROCEDURE|laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection|Surgery will be performed within 24 h of the third PET/MRI scan.
214422068|NCT03729011|DRUG|Volatile agent|Patients will receive volatile agent to provide general anaesthesia, including CPB period. Volatile agents will be administered from anesthesia induction to the end of surgery. Concentration (MAC) of volatile agent will be selected by anaesthesiologist according to clinical situation and patient features.
214422069|NCT03729011|DRUG|Propofol|Patients will receive propofol and no volatile agent. Propofol will be used for induction and maintenance of anesthesia.
214506916|NCT05307952|OTHER|Personalized fitting|Adjustment of the parameters of the participants' cochlear implants aimed at improving their speech perception
214506917|NCT05307952|BEHAVIORAL|Personalized training|Self-administered training exercises focused on the speech components the participants are experiencing difficulties into
215021300|NCT02783963|DEVICE|OCT and CMR imaging|"OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings."
215021301|NCT06497686|DIAGNOSTIC_TEST|mesoscale nonlinear optical gigascope|An nonlinear optical microscope with ultra-large field of view and ultra-high resolution.
215021302|NCT06497686|DIAGNOSTIC_TEST|Fluorescence microscope|An optical microscope used to examine the fluorescence signal from stained tissues.
215021303|NCT03778697|PROCEDURE|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness suture system to plicate the greater curvature of the stomach
215021304|NCT01694771|DRUG|Tiotropium|Marketed dose
215021305|NCT01694771|DRUG|Placebo matching Olodaterol|One dose
215021306|NCT01694771|DRUG|Olodaterol|One dose
215021307|NCT01694771|DRUG|Tiotropium|Marketed dose
215021308|NCT05672537|DRUG|Durvalumab|1500mg intravenous injection for 21d cycle
215021309|NCT05672537|PROCEDURE|Surgery|Surgery
215021310|NCT05672537|DRUG|Gemcitabine|gemcitabine 1000mg/m2, D1\&D8, 21d cycle.
215021311|NCT05672537|DRUG|Cisplatin|cisplatin 25mg/m2, D1\&D8, 21d cycle.
215021312|NCT05151419|PROCEDURE|bronchoscpe|bronchoscopic biopsy from lung mass using cryobiopsy and forceps
215021313|NCT03721367|OTHER|Diagnostic Ultrasound|All individuals will undergo a blood draw for measurement of biomarkers of liver disease and an ultrasound with shear-wave elastography.
215021314|NCT06105892|DEVICE|Virtual Eye Rotation Vision Exercise (VERVE)|VERVE utilizes a virtual reality (VR) headset with integrated eye-tracking where the patient makes specific vergence eye movements by playing a VR game controlled by eye movements. Participants will be making convergence and divergence eye movements as steps and ramps.
215021315|NCT06105892|DEVICE|Sham VR Therapy|VERVE game without changes in eye movement demands. Maximizing gameplay with no intervention.
215021316|NCT04056429|COMBINATION_PRODUCT|BHA|BHA active ingredients include beta-tricalcium phosphate and a blood-derived component. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
215021317|NCT01391871|DEVICE|OCT|Optical coherence tomography
215021318|NCT01391871|DEVICE|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
215021319|NCT03907956|OTHER|Dry Needling with Fascial Winding Technique|"For placement of Dry Needling (DN) needles with Fascial Winding Technique (FWT) according to the Four-pole Carpal Dry Needling (FCDN) approach model, only anatomical references are used, in all cases from a carpal ventral approach. The needles used are the Chinese type with silver handle and guide tube, measuring 25x0.30 mm., Agupunt® brand. Four needles are placed, at the level of the bones: scaphoid, pisiform, trapezius and hamate. The four needles follow an oblique direction, always on the back and looking for the midline of the center of the carpal tunnel, with an inclination of approximately 45º, both in the cranio-caudal and medial-lateral directions. In each of the needles, it deepens until it reaches a firm elastic stop, attributable to the Transverse Carpal Ligament. Next, the FWT is applied to each of the needles, consisting of rotating them in the same direction until you feel the final stop of the needle grasp."
215021320|NCT05792254|DRUG|Huaier granule|Oral Huai Er granules, 20 g once, 3 times a day, continued to progress or intolerance toxicity.
215021321|NCT02037880|PROCEDURE|Lumbar puncture|
215021322|NCT02037880|DEVICE|Magnetic Resonance Imaging (MRI) of the brain|
215021323|NCT00392509|PROCEDURE|ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Surgery
215021324|NCT03059342|PROCEDURE|single event multilevel surgery|
215021325|NCT00398450|BIOLOGICAL|recombinant interferon alfa-2b|
214422070|NCT06159127|BEHAVIORAL|SMART@Home|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
215021326|NCT00398450|DRUG|azacitidine|
215021327|NCT04249193|OTHER|Transfusion|pRBC and non-pRBC transfusions
215021328|NCT01941628|DRUG|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
215021329|NCT01941628|DRUG|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
215021330|NCT00859274|DRUG|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
215021331|NCT04920994|PROCEDURE|M-TAPA block|A high-frequency linear ultrasound probe will be used, probe will be placed on the costochondral angle in the sagittal plane and angled deeply to view the lower aspect of the chondrium in the midline, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced into the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
215021332|NCT04920994|PROCEDURE|SCTAP block|A high-frequency linear ultrasound probe will be placed obliquely on the upper abdominal wall, along the subcostal margin near the midline. After identifying the rectus abdominis muscle, the ultrasound probe will be gradually moved laterally along the subcostal margin until the transversus abdominis muscle will be identified lying posterior to the rectus muscle, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced medially and directed towards the transversus abdominis plane until its tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles on entering the neurofascial plane. The same procedure will be repeated on the contralateral side.
215021333|NCT04920994|DRUG|Bupivacaine Hydrochloride|20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
215021334|NCT05777278|DRUG|Savolitinib|Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)
215021335|NCT05777278|DRUG|Docetaxel|Docetaxel (60 mg/m2, ivgtt, q3w)
215021336|NCT03870971|OTHER|blood glucose measurement|After the patient has performed the manual reading, the investigator or staff member will obtain another capillary blood sample and a reference reading by means of the YSI 2300 Stat plus analyzer will be performed and recorded. If patients need more than one attempt to get a successful blood glucose reading, the number of attempts will be documented. A questionnaire needs to filled by the participant
215102702|NCT00699335|DRUG|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
215102703|NCT03363880|OTHER|trauma treatment team|Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.
214422071|NCT06487806|BEHAVIORAL|SmokefreeSGM|Participants will be asked to set a quit date within the next 15 days before being enrolled in the SmokefreeSGM Español text messaging program. They will be mailed a 6-week supply of nicotine patches. The participants will get daily text messages for 6 weeks that will encourage them to quit smoking.
215021337|NCT01783873|OTHER|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
215021338|NCT00289900|DRUG|MK-0524A|
215021339|NCT00289900|DRUG|Atorvastatin|
215021340|NCT00289900|DRUG|Simvastatin|
215021341|NCT06209125|DEVICE|hybrid aesthetic functional appliance|treatment of class II division one malocclusion
215021342|NCT01152385|DRUG|AZD1656|Oral tablet administered twice daily during 4 months
215021343|NCT01152385|DRUG|Placebo|administered twice daily during 4 months
215021344|NCT02999360|BEHAVIORAL|Language therapy|There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
215021345|NCT02999360|BEHAVIORAL|Background Music|30 minutes background music only
215021346|NCT02999360|BEHAVIORAL|Aerobic Exercise|There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
215021347|NCT06222736|OTHER|Rocabado Exercises|Patients trained by Rocabado Exercises
215021348|NCT06222736|OTHER|Servical Core Exercises|Servical Core Exercises
215021349|NCT06308926|DRUG|MRG-001 (Low-dose)|MRG-001 is subcutaneously administered.
215021350|NCT06308926|DRUG|MRG-001 (High-dose)|MRG-001 is subcutaneously administered.
215021351|NCT06308926|OTHER|Placebo|Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.
215021352|NCT04200209|OTHER|Implementation of a quality indicator feedback mechanism|"1. Audit and feedback: A summary of clinical performance and hospital safety culture over a specified period of time.~2. Benchmarking Achievable: benchmarks are calculated from the performance of all members of a peer group and represents a realistic standard of excellence attained by the top performers in that group (i.e. comparing to the top 10% of peers).~3. Educational outreach: A trained independent person or investigator will meet with health professionals or managers in their practice setting to provide information (e.g. feedback of quality indicators).~4. Action planning: The purpose of action planning is to support quality improvement efforts by identifying opportunities for improvement, strategies and steps to accomplish the work."
215021353|NCT02656173|DRUG|Mirabegron|Oral tablet
215021354|NCT02656173|DRUG|Placebo|Oral tablet
215021355|NCT02656173|DRUG|Tamsulosin|Oral tablet
215021356|NCT01064622|DRUG|Gemcitabine Hydrochloride|Given IV
215021357|NCT01064622|OTHER|Hydrocortisone/Placebo|Given PO
215102704|NCT03363880|OTHER|Basic experimental settings|Establishing the trauma management system without a trauma treatment team.
215021358|NCT01064622|DRUG|Vismodegib|Given PO
215021359|NCT06663293|OTHER|Conventional Nasal Cannula|The initial flow rate for nasal cannula oxygen was set at 3 L/min. In cases of hypoxia, the oxygen concentration was adjusted by increasing the flow rate by 1 to 2 L/min.
215102705|NCT00762541|DEVICE|MEL 80 Treatment of High Myopia|The reduction or elimination of myopia \> -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D.
215102706|NCT02622893|DRUG|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
215021360|NCT06663293|OTHER|High-flow nasal cannula|The high-flow nasal oxygenation device was set to a temperature of 36°C and an FiO2 of 0.4. The initial oxygen flow rate for the high flow group was determined according to the age and weight of the patients, based on our pediatric intensive care team's guidelines and the reference from the Slain study. When SpO2 fell below 94%, it was considered hypoxia, and the flow rate was increased by 2 to 4 L/min.
215021361|NCT06663293|DRUG|midazolam, ketamine, propofol|Sedation was done with IV midazolam 0.025 to 0.1 mg/kg, IV ketamine 0.25 to 0.5 mg/kg, and IV propofol (1%) 0.25 to 0.5 mg/kg
215102707|NCT02622893|DRUG|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
215102708|NCT02776254|OTHER|START|Point of care testing for rapid ART initiation
214422072|NCT06479889|BEHAVIORAL|Guardians receiving counseling + lock|Guardians of patients admitted to the Pediatric Hospital Medicine behavioral health team will be provided a brief lethal means educational session and offered up to 3 secure storage devices of their choosing (lock box and or cable locks)
214422073|NCT05208359|BEHAVIORAL|Supporting Transition Resilience Of Newcomer Groups (STRONG)|10 group sessions that offer skills, strengths, support, and affirmation for newcomer youth
214422074|NCT05147233|DRUG|OCS-01|Dexamethasone ophthalmic suspension, 1.5%
214422075|NCT05147233|DRUG|Vehicle|Vehicle
215021362|NCT06663293|DRUG|Propofol|Sedation maintenance was done by propofol 0.5 to 1 mg/kg/h
214422076|NCT03030495|DEVICE|Comprehensive physiologic evaluation|Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
214422077|NCT03030495|DEVICE|Intravascular imaging devices|Intravascular ultrasound or optical coherence tomography
214422078|NCT03645031|OTHER|Acute Intermittent Hypoxia|AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
214422079|NCT03645031|OTHER|Sham Acute Intermittent Hypoxia|Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
214422080|NCT05204446|BEHAVIORAL|GROW Project|"(GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week."
214506918|NCT03120026|DIETARY_SUPPLEMENT|Experimental product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
214506919|NCT03120026|DIETARY_SUPPLEMENT|Isocaloric placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
214506920|NCT01005693|OTHER|questionnaire administration|
215021363|NCT04132427|COMBINATION_PRODUCT|vancomycin, magnesium citrate, microbiota|10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota
214506921|NCT01005693|PROCEDURE|cognitive assessment|
214506922|NCT01005693|PROCEDURE|examination|
215021364|NCT04132427|COMBINATION_PRODUCT|placebo vancomycin, real magnesium citrate, placebo microbiota|10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota
215021365|NCT06208631|BEHAVIORAL|Gait retraining|Changing muscle coordination while walking
215021366|NCT01426555|OTHER|FES-Rowing|FES- Rowing Exercise
215021367|NCT01426555|DRUG|Zoledronic acid|5 mg IV single dose
214506923|NCT01005693|PROCEDURE|management of therapy complications|
214506924|NCT03192709|DRUG|Sildenafil vaginal suppositories|Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
215102709|NCT02776254|OTHER|CAG|Community Adherence Group
214506925|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
214506926|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
214506927|NCT05804825|BEHAVIORAL|Argument inoculation messages|Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
214506928|NCT05804825|BEHAVIORAL|Simple forewarning message|Participants will be presented with a simple forewarning message.
214506929|NCT02879942|OTHER|Ultrasound study of the placenta|The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
215021368|NCT03685435|OTHER|Bedside ultrasound|Checking for gastric content using bedside ultrasound
215102710|NCT02776254|OTHER|UAG|Urban Adherence Group
215102711|NCT02776254|OTHER|FAST-TRACK|Prescription refill only
215102712|NCT02258087|RADIATION|LDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.
214506930|NCT02879942|OTHER|Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test|
214506931|NCT01061580|DEVICE|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
214694106|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 with CMV + RUTF|Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase
215021369|NCT05530707|OTHER|Moisturizer containing saccharide isomerate and niacinamide|Moisturizer containing saccharide isomerate and niacinamide
215021370|NCT03103308|OTHER|Walk Training and Transplant|Subjects will receive free activity monitors and have three training sessions per week for the duration of their bone marrow transplant treatment
215102713|NCT02258087|RADIATION|HDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
215102714|NCT03262441|DRUG|Mycophenolate Mofetil 500Mg Tab|500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
215102715|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
215102716|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
214690265|NCT06331923|DEVICE|Continuous glucose monitoring (CGM) device|Continuous glucose monitoring (CGM) will be prescribed by the attending physician for at least 6 hours before surgery. The supervising nurse will educate the patient and their family on the correct wearing and connection of the CGM device. The calibration frequency and interval of glucose monitoring devices before and after surgery should be determined according to institutional treatment guidelines and the requirements of the monitoring device used. Intraoperative glucose calibration should be done immediately upon entering the operating room, immediately after skin incision, every 2 hours after skin incision, and at the end of wound closure. Glucose monitoring should be continued until the 7th day after surgery or discharge.
214422081|NCT05204446|BEHAVIORAL|GROW+ Project|"(GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention."
214422082|NCT06831669|OTHER|Collecting biospecimens|Collecting blood, urine, tissue, and faecal samples
214694107|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 without CMV + RUTF|Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
215021371|NCT03103308|OTHER|Activity Monitoring and Transplant|Subjects will receive free activity monitors for the duration of their bone marrow transplant treatment
215021372|NCT03073070|DRUG|biotin labeled RBCs|Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
215021373|NCT05177328|BIOLOGICAL|S. hominis A 9 Product|Commensal staph species, phosphate buffered saline, and glycerol.
215021374|NCT05177328|DRUG|Placebo|Phosphate buffered saline and glycerol
215021375|NCT06057337|BEHAVIORAL|"Families with Pride (Familias con Orgullo)"|Families with Pride (Familias con Orgullo) aims to prevent the co-occurring epidemics of drug use and depression in Hispanic sexual minority youth. It focuses on improving parent support for the adolescent, parent acceptance of the adolescent, family functioning (e.g., communication), and decreasing stress and sexual minority stress. The program consists of 11 weekly, in-person sessions: 7 parent group sessions, 3 concurrent adolescent group sessions, both lasting two hours, 4 family sessions lasting 1 hour in either Spanish or English, depending on participant language preference. In the parent group sessions, parents come together to foster social support, family functioning, and increase parental support and acceptance for the adolescent. In the adolescent sessions, adolescents build skills in confronting and managing stressors related to being a sexual minority.
215021376|NCT06600802|BIOLOGICAL|Blood samples|A total of 3 blood samples (2 tubes of 9mL each) are added. The first sample will be taken at the inclusion visit, the 2nd at the end of the 2nd treatment cycle and the last at the end of Lu-PSMA treatment.
215021377|NCT03927846|BEHAVIORAL|Nurse-guided Web-based Cognitive Behavioral Therapy|nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
215021378|NCT05706376|BEHAVIORAL|Promoting Positive Family Futures|Promoting Positive Family Futures is a group-based program that aims to help parents and their adolescent children (13-16 yrs) cope with chronic violence by developing emotional and cognitive awareness, learning constructive conflict resolution strategies, and developing family-wide emotional security and positive family relationships. Emotional Security Theory is the foundational conceptual model for the program, and as such, the PPFF focuses on promoting family-wide communication and establishing emotional security in both the family and community across multiple sessions.Firmly grounded the cultural context of Palestine, the intervention also incorporates intervention elements derived from social ecological theories of resilience, and cognitive behavioral approaches to coping. In total, the program includes 8 sessions lasting approximately 1.5 hours each.
215021379|NCT05706376|BEHAVIORAL|Treatment as Usual|Families assigned to the TAU condition will participate in a common service offered by both PCC and CRS - a weekly adolescent-only support group. Both CRS and PCC conduct extended group programs for children and adolescents (24 sessions at PCC; 25 sessions at CRS).
215102717|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
215102718|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
215102719|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
215102720|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
215102721|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
215102722|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
215102723|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
215102724|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
214422083|NCT05828550|DIAGNOSTIC_TEST|antibiotic sensitivity|"The resistance pattern of the isolates will be detected by disc diffusion method.~Detection of efflux pump genes responsible for the resistance ( norA , norB , norC ) by PCR"
214422084|NCT03608202|BEHAVIORAL|POCUS protocol group|"The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h."
214694108|NCT05522335|BIOLOGICAL|BBV154(Intranasal) & covaxin|Intervention Covaxin
214694109|NCT02938065|PROCEDURE|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
214422085|NCT03608202|OTHER|Control group|Routine protocol of the treating team is followed
214422086|NCT05900791|PROCEDURE|Primary knee arthroplasty|All patients surveyed have undergone primary knee arthroplasty approximately 1 year prior to survey distribution
214422087|NCT06964282|PROCEDURE|PENG Block|Also performed under ultrasound guidance with an 80 mm B-Braun X360 needle and a 3-5 MHz curved probe. The femoral nerve, femoral artery, iliopsoas muscle, and pubic ramus are identified. The needle is inserted in-plane, and 14 ml of ropivacaine 3.75 mg/ml is injected between the psoas tendon and pubic ramus.
214422088|NCT06964282|PROCEDURE|Iliopsoas nerve block|Performed under ultrasound guidance with a curvilinear probe (5-2 MHz). The transducer is positioned transversely below the anterior superior iliac spine (ASIS), then pivoted medially. After identifying the femoral head and acetabular rim, a 22G 80 mm needle is inserted in-plane to reach the iliopsoas plane, lateral to the iliopsoas tendon. 7 ml of ropivacaine 7.5 mg/ml is then injected.
215021380|NCT06671899|OTHER|Constraint-induced movement therapy (CIMT)|Clinically implemented modified CIMT. Including the three main components; intensive and repetitive task-oriented training of the affected limb, constraint of the non-affected limb and behavioural strategies known as the Transfer Package. In this model the training is supervised by therapist from several professions and some training sessions is performed in group settings with other inpatients and outpatients undergoing primary rehabilitation at the clinic.
215021381|NCT06521853|OTHER|PEEK With Autogenous Bone Graft|placement of PEEK With Autogenous Bone Graft
215021382|NCT06521853|OTHER|PEEK With Xenograft|placement of PEEK With xenograft
215021383|NCT04822558|OTHER|Plantar pressure measurement|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
215021384|NCT04822558|OTHER|Gait analysis|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
215021385|NCT04822558|PROCEDURE|Ankle and hindfoot reconstruction surgery|Ankle and hindfoot reconstruction surgery
215021386|NCT04167436|OTHER|Prehabilitation|A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
215021387|NCT04774146|PROCEDURE|pars plana vitrectomy|silicone oil active aspiration and isovolumetric BSS replacement followed by irrigation and /o gas fluid exchange
215021388|NCT06674759|DRUG|Tongren-Dahuoluo Bolus|0.72g,2 times a day, oral, for 24 weeks.
215021389|NCT06674759|DRUG|Tongren-Dahuoluo Bolus Placebo|0.72g,2 times a day, oral, for 12 weeks.
215021390|NCT06674512|BEHAVIORAL|Clinical Pharmacist-led Pharmaceutical Services|Pharmacists developed an intervention plan to reduce DRPs and improve patients' quality of life by assessing patients' medication knowledge, drug-related problems, and adherence problems in the intervention group in the order of urgency, importance, and priority to be addressed. The plan included a list of patients' medication or lifestyle-related problems, a list of programs based on the assessed problems, and other information.
215021391|NCT06673537|OTHER|Connective Tissue Massage (CTM)|"Connective Tissue Massage (CTM) was administered to the lumbar and abdominal regions by an experienced physiotherapist three times a week for 15 minutes over six weeks. The treatment started from the predicted day of ovulation (cycle length minus 14 days) until the onset of the next menstrual period. Both short and long strokes were utilized during CTM. Each stroke was repeated three times, first on the right side and then on the left side, across all manipulated areas. During the manipulation, the tip of the middle finger remained in contact with the patient's skin. The finger was positioned at a 45° angle, with the distal interphalangeal joint in flexion, and was moved to create traction.~During the lumbar region treatment, participants were instructed to sit upright with their hips, knees, and ankles flexed at 90°, ensuring that their thighs and feet were fully supported. For the abdominal region treatment, participants lay supine with pillows placed under their head and knees."
215021392|NCT06673537|OTHER|Spinal Manipulation|Spinal manipulation was performed by an experienced physiotherapist on the intervention group three times a week following Connective Tissue Massage (CTM). Participants in this group were positioned laterally, ensuring their lower leg remained straight and in contact with the treatment table. The contralateral or upper hip and knee were flexed and positioned so that they did not touch the table, allowing an unopposed force to be applied at the selected joint. Following CTM, manipulation was carried out with high-velocity, low-amplitude (HVLA) force applied bilaterally to all clinically relevant vertebral levels from T10 to L5 and the sacroiliac joints, accompanied by an audible sound from one or more joints.
214422089|NCT04670822|BEHAVIORAL|Breastfeeding promotion|The intervention group will receive multicomponent interventions consisting of 7 half-hour postnatal visits for lactation counseling, family/peer/employer support, contingent financial incentives, and early limited formula milk via syringe (optional for at-risk infants).
214422090|NCT04670822|BEHAVIORAL|Attention placebo control|The attention placebo control group will complete the same frequency and duration of study visits as the intervention group but focus on general infant care counseling and support.
214422091|NCT06154265|DEVICE|TEE probe|Transesophageal echocardiography, ultrasound probe
214422092|NCT04922606|DIAGNOSTIC_TEST|US ot the GSV|Ultrasound of the Great Saphenous Vein
214694110|NCT02938065|OTHER|2% milk|16 participants will drink 10 ounces of 2% milk
214694111|NCT02938065|OTHER|apple juice|16 participants will drink 10 ounces of apple juice
214694112|NCT02938065|OTHER|ensure clear|16 participants will drink 10 ounces of ensure clear
214694113|NCT00362063|DRUG|growth hormone (Nutropin)|growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
214694114|NCT03727321|COMBINATION_PRODUCT|Fecal Microbial Transplant|Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
215021393|NCT06673537|OTHER|Sham Spinal Manipulation|Sham spinal manipulation was administered by an experienced physiotherapist to the Sham Manipulation group three times a week following Connective Tissue Massage (CTM). In this group, participants were positioned laterally with their lower legs straight and in contact with the treatment table. The contralateral or upper hip and knee were flexed and positioned so that they did not touch the table, thereby allowing an unopposed force to be applied at the selected joint. Following CTM, low-amplitude force was applied bilaterally to all clinically relevant vertebral levels from T10 to L5 and the sacroiliac joints, without creating an audible sound.
215021394|NCT05787119|OTHER|Conventional therapy|The CT consists of 1 session of 30 minutes of physical therapy (type of re-education established according to the pain at rest and during movement assessed every day) and 1 session of 30 minutes of occupational therapy (type of re-education established according to the pain at rest and during movement assessed every day). CT is performed 5 days a week.
215021395|NCT05787119|OTHER|ARMT|The ARMT consists of 1 session of 30 minutes (type of rehabilitation established according to the pain at rest and during movement evaluated daily). ARMT is performed 5 days a week for 1 month.
215021396|NCT05787119|OTHER|cortical reactivity|An electroencephalogram was taken at the start and end of the study to study cortical reactivity during the performance of 3 different tasks repeated 30 times: a resting task (consisting of looking at a cross on a screen), a motor imagery task (consisting of imagining performing wrist flexions/extensions) and a motor execution task (consisting of performing wrist flexions/extensions).
215021397|NCT05787119|OTHER|Fluidity of movement|Motion capture at the start and end of the study to study the fluidity of movement during 3 different tasks repeated 30 times: a resting task (looking at a cross on a screen), a motor imagery task (imagining wrist flexions/extensions) and a motor execution task (performing wrist flexions/extensions).
215021398|NCT06689579|DEVICE|Unipolar hemiarthroplasty|
215021399|NCT06689579|DEVICE|Bipolar hemiarthroplasty|
215021400|NCT05414747|DEVICE|ABV-1701|ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)
214422093|NCT04225403|BEHAVIORAL|Telephone-based motivational interviewing for smoking cessation|"The motivational brief intervention is known by the acronym 5 R and lasts about 5-10 minutes. It is an approach based on the principles of motivational interviewing and develops the intervention in five short steps:~* Relevance. Help patients identify why personal reasons may be relevant to quitting smoking.~* Risks. Help identify what negative consequences tobacco use has.~* Rewards. Help identify potential benefits of quitting smoking.~* Resistors. Help patients identify barriers to smoking cessation, which can often include fear of withdrawal symptoms, failure, wainweight, face social situations, etc.~* Repeat. Repeat the intervention at 3 months if you do not advance at the stage of change."
214422094|NCT06953180|OTHER|Genetic: DNA analysis|Investigation of telomere length (TL) and DNA methylation level analysis
214506932|NCT01562964|BEHAVIORAL|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
215021401|NCT05414747|DEVICE|SF6 Gas|SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)
215021402|NCT02499536|DEVICE|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
215021403|NCT03289741|DRUG|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
215021404|NCT03289741|DRUG|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
215021405|NCT03289741|BEHAVIORAL|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
215021406|NCT06674369|DEVICE|Peli prism for hemianopia|Peli prism uses high-powered prisms (40 Dioptre) that expand a hemianopic patient's awareness of their blind side. This awareness enables patients to better detect obstacles and navigate around them. Effect of the prism considered as temporary We investigated whether the effect persists after the prism is removed.To understand the persistence of the effect, we examined the changes in the visual field with CVF (Computerized visual field examination)before the prism was applied, with the prism and 1 week after the prism was removed.
215021407|NCT06675305|DIETARY_SUPPLEMENT|Beetroot juice (James White, UK)|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
215021408|NCT06675305|DIETARY_SUPPLEMENT|Placebo acute supplementation (James White, UK)|One serving 140 mL of BJ (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
215021409|NCT06683924|PROCEDURE|Pulsed Radiofrequency Ablation|The area where the lateral femoral cutaneous nerve is seen with US will be anesthetized with 1 ml of 1% lidocaine and a 22 Gauge, 10 cm-5 mm RF cannula will be inserted. Sensory fibers will be stimulated with 0.3-0.5 V. Then, motor fibers will be stimulated up to 1.5 V. If no motor contraction is seen, LFCN will be ablated at 42 degrees Celsius for 240 seconds. The procedure will be completed with the injection of 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone through the RF cannula.
215021410|NCT06683924|DRUG|Steroid (dexamethasone) Injection|Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.
215021411|NCT06684678|OTHER|individualized automatic coaching message for glycemic management and depressive symptom|For 12 weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires, instead of non-face-to-face diabetes management.
214422095|NCT06789367|DRUG|perineural Dexamethasone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg perineural Dexamethasone
214422096|NCT06789367|DRUG|intravenous Dexamethsone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg intravenous Dexamethasone
214422097|NCT06434389|DIAGNOSTIC_TEST|the Electrochemical-based device|Electrochemical-based device for rapid detection of fibrinogen is a novel POC diagnostic method, which is suitable for operating theatres and emergency rooms.
214422098|NCT04517864|DRUG|PF-06651600|50 mg tablet, dosed as 200 mg QD or 50 mg QD 50 mg capsule, dosed as 50 mg QD
214422099|NCT04517864|DRUG|Placebo|tablet, dosed as 4 tablets QD or 1 tablet QD
214422100|NCT04662710|BIOLOGICAL|Pembrolizumab|400 mg Q6W by IV infusion
214422101|NCT04662710|BIOLOGICAL|Lenvatinib|Administered PO QD, 8 mg induction/20 mg consolidation.
214422102|NCT04662710|DRUG|Oxaliplatin|130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
215021412|NCT06682975|DRUG|ZP9830|Participants will receive 1 single dose of ZP9830 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
215021413|NCT06682975|DRUG|Placebo|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Volume will be matching the active treatment
215021414|NCT03289195|PROCEDURE|MRI Biopsy|Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
214422103|NCT04662710|DRUG|Capecitabine|1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.
214422104|NCT04662710|DRUG|Leucovorin (or Levoleucovorin)|Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
214506933|NCT01562964|BEHAVIORAL|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
214506934|NCT03491566|OTHER|Clinic Pilates Group|"Clinical Pilates exercises include Hundreds, One Leg Stretch, Shoulder Bridge, One Leg Kick, Swimming , Double Leg Stretch, Swan Dive Circle , Arm Opening , Spine Twist , Roll Down exercises."
214506935|NCT03491566|OTHER|Aerobic Exercise Group|Aerobic exercise with using an elliptical bike, or bike or treadmill under supervision of a physiotherapist.
215102725|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
214506936|NCT03567278|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
214506937|NCT03056378|BIOLOGICAL|Standard RBCs|Transfusion of standard pRBCs that are matched for C, E and K
214694115|NCT03727321|DIETARY_SUPPLEMENT|Fiber|A combination of soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)
214694116|NCT03727321|DIETARY_SUPPLEMENT|Cellulose|Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
214422105|NCT04662710|DRUG|5-FU|400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.
214422106|NCT02201043|DRUG|Thalidomide 150mg|
214422107|NCT02201043|DRUG|Thalidomide 100mg|
214422108|NCT02201043|DRUG|Placebo|
214694117|NCT01896037|DIETARY_SUPPLEMENT|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
214422110|NCT06013514|DEVICE|PERLE Sterile Smooth Opaque gel filled mammary implants|Sterile smooth opaque gel filled mammary implants will be implanted in adult women having breast surgery for either augmentation, reconstruction or revision surgery. Different ranges of implants will be used to suit patient needs
214422111|NCT04199728|DRUG|Liraglutide Pen Injector|Liraglutide will be provided using an injection pen provided by the manufacturer
214422112|NCT04199728|DRUG|Placebo|Placebo injection pen
214422113|NCT05260359|DRUG|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation|SU E 101413 85
214422114|NCT05260359|DRUG|6% Bemotrizinol (BEMT) dispersion in petrolatum|SU-E-101413-82
214422115|NCT05260359|OTHER|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT|SU E 101413 91
214422116|NCT05260359|OTHER|Petrolatum vehicle|SU-E-101413-83
214422117|NCT05260359|OTHER|0.9% Saline|low irritancy control
214422118|NCT05260359|OTHER|Sodium Lauryl Sulfate 0.1% (SLS)|positive control
214422119|NCT05260359|OTHER|Undosed patch|negative control
215021415|NCT06687551|DRUG|Baricitinib (LY3009104) 4 mg|"Treatment with baricitinib 4 mg daily~* Step 1 (after randomization): baricitinib 2mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day"
215102726|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
215102727|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
215102728|NCT02051634|DRUG|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
215102729|NCT02051634|DRUG|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
214422120|NCT04722003|BIOLOGICAL|Meningococcal Group B Vaccine|A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.
214694118|NCT02586636|DRUG|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
214422121|NCT04722003|OTHER|Placebo|0.9% Sodium Chloride, USP injection.
215021416|NCT06687551|DRUG|filgotinib 200mg/day|"Treatment with filgotinib 200 mg daily~* Step 1 (after randomisation): filgotinib 100 mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day"
215021417|NCT06687551|DRUG|Tofacitinib 5 mg twice daily|"Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily~* Step 1 (after randomisation): tofacitinib 5 mg once daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day"
215021418|NCT06687551|DRUG|Upadacitinib 15 MG|"Treatment with upadacitinib 15 mg daily~* Step 1 (after randomisation): upadacitinib 15 mg every other day~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days"
215021419|NCT06687551|DRUG|Baricitinib (LY3009104) 4 mg|use of JAK inhibitor at full dose until the end of the protocol
215021420|NCT06687551|DRUG|filgotinib 200mg/day|use of JAK inhibitor at full dose until the end of the protocol
215021421|NCT06687551|DRUG|Tofacitinib 5 mg twice daily|use of JAK inhibitor at full dose until the end of the protocol
215021422|NCT06687551|DRUG|Upadacitinib 15 MG|use of JAK inhibitor at full dose until the end of the protocol
215021423|NCT06691503|PROCEDURE|mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)|mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)
215102730|NCT01363115|DIETARY_SUPPLEMENT|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
215102731|NCT01363115|DIETARY_SUPPLEMENT|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
214422122|NCT03255928|DIAGNOSTIC_TEST|PAS assay, TGT|Evaluation of platelet function
214422123|NCT04246177|DRUG|Lenvatinib|Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) via oral capsules once a day during each 21-day cycle.
215102732|NCT01363115|BEHAVIORAL|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
215102733|NCT03337009|BEHAVIORAL|Naloxone Navigator (NN)|Patients prescribed chronic opioid therapy will be identified and recruited to enroll in the study. Patients randomized to receive the web-based animated video (Naloxone Navigator) will be sent a link to the video after enrollment. The web-based, animated video provides education on what is an opioid overdose, how to prevent it, how to recognize an overdose, and how to respond with naloxone. This video also encourages patients to pick up naloxone from a pharmacy under a standing order.
214422124|NCT04246177|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
214422125|NCT04246177|DRUG|Oral Placebo|Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
214422126|NCT04246177|DRUG|IV Placebo|Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
214422127|NCT04246177|PROCEDURE|TACE|Conducted as a background procedure of chemotherapeutic and embolic agent(s).
214422128|NCT06139315|DRUG|BI 765845|BI 765845
214422129|NCT06139315|DRUG|Placebo|Placebo
214422130|NCT05520658|DRUG|combined digoxin and furosemide|one session every 2 weeks for maximum 6 sessions
214422131|NCT05520658|DRUG|5 fluorouracil|5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
214422132|NCT03883542|GENETIC|genomic mutations study|"Sequencing of the DNA samples extracted from the subgroups~1. serous BOT tissue,~2. serous BOT tissue with non-invasive implants and~3. serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)"
214422133|NCT06108934|DEVICE|Hip stem prosthesis|The Insignia hip stem prosthesis will be used in cementless total hip replacement surgery (THA). The surgery typically takes approximately two hours. All study participants will receive the Insignia hip stem and compatible components. Experienced Orthopaedic Surgeons trained in THA will perform the surgeries as per the standard surgical technique guide for this prosthesis.
214422134|NCT02301559|BEHAVIORAL|Pilates exercises|Pilates exercises with emphasis on pelvic region
214422135|NCT05543057|RADIATION|3DCRT|Three-dimensional conformal radiotherapy (3DCRT)
214506938|NCT01092715|PROCEDURE|Spinal mobilization|Non thrust mobilization to the cervical spine
214506939|NCT01092715|PROCEDURE|Massage|Sedative massage to cervical paraspinal muscles
214506940|NCT01092715|PROCEDURE|Neck exercises|Range of motion exercises to include foraminal opening
215102734|NCT04654455|OTHER|Describe the evolution of dry eye between 1 month and 3 months post-LASIK|Dry eye will be assessed through the OSDI (Ocular Surface Disease Index) questionnaire. The questionnaire will be dispensed during consultations by an orthoptist or an intern/junior doctor, at 1 month and at 3 months post-LASIK.
215102735|NCT03546088|DEVICE|fiberoptic naso-tracheal intubation|The trachea will be intubated under direct fiberoptic view after a fiberoptic upper airway examination. The flexible nasolaryngoscope will be armed with an intubating tube and passed inside tracheal lumen trough one of the nostrils.
214506941|NCT02476929|DEVICE|Nasal nitrous oxide|Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
214506942|NCT02476929|DEVICE|Electronic nose|To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
214506943|NCT01385800|BIOLOGICAL|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
214506944|NCT01385800|BIOLOGICAL|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
214690266|NCT06536153|COMBINATION_PRODUCT|Amaranth grain flat bread|The recipe will be produced according to the recommended dietary allowance (RDA); based on RDA, 200 g of flat-bread (30% chickpea and 70% amaranth grain) comprised 30 mg of iron, which can satisfy 50% of RDA supposing 15-20% iron absorption (54). A prior study concluded that the acceptability was satisfactory in the community (55). Also, a study from the Hawassa University Department of Food Sciences reported that amaranth-grain flat-bread was safe for consumption for 48 hours after preparation and improved the nutritional values (56). To lower the phytate levels in the amaranth grain, home-level processing will be used. For 24 hours, amaranth grain will be soaked in water with 5 milliliters of lemon juice per 100 milliliters of water, and it will germinate for 72 hours. It will be sun-dried, roasted, and ground using a nearby electrical mill before fermented bread is made
214690267|NCT01368341|DRUG|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
214690268|NCT01368341|DRUG|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
214690269|NCT01368341|DRUG|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
214690270|NCT05653206|PROCEDURE|Nonsurgical treatment|Cervical collar, Halo ring, Halo vest, cervical braces, skeletal skull traction, MAP, steroids, observation or bedrest
214690271|NCT05653206|PROCEDURE|Surgical treatment|Anterior discectomy and instrumented fusion (single level), Anterior discectomy and instrumented fusion (multi-level), Posterior decompression-laminectomy, Posterior decompression-laminoplasty, Posterior decompression and instrumented fusion, Combined anterior and posterior decompression and instrumented fusion
214690272|NCT02197429|OTHER|Acupuncture|
215102736|NCT03546088|DRUG|Topical anaesthesia|Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.
215102737|NCT03546088|DRUG|Light sedation|The patient will be sedated with a combination of midazolam, fentanyl administered intravenously in small boluses until the desired level of sedation is achieved as expressed of The Observer's Assessment of Alertness/Sedation Scale (OAA/S) of 4 or 5.
215102738|NCT04735146|OTHER|Adapted physical activity|"Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity."
215102739|NCT04775264|PROCEDURE|Pulsed Electric Field Ablation|Catheter ablation of Ganglionated Plexi (GP) structures on the epicardial surface of the heart during cardiothoracic surgery
214422136|NCT01049503|OTHER|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
214690273|NCT00471536|DRUG|pazopanib hydrochloride|800 mg Given orally
214690274|NCT00679679|DRUG|Metformin|Metformin 750 mg BID for 4 months
214690275|NCT00679679|DRUG|Placebo|Diet counseling and exercise
214690276|NCT05060666|DRUG|Ivermectin|"2 doses of Ivermectin will be administered with 48 hours time interval.~The dosage is based on body weight calculated as follows:~* 15 mg for 40-60 kg = 5 tablets à 3 mg~* 18 mg for 60-80 kg = 6 tablets à 3 mg~* 24 mg for \> 80 kg = 8 tablets à 3 mg each~This corresponds to an ivermectin dose of about 300 µg / kg."
214690277|NCT05060666|DRUG|Placebo|"An analogous number of tablets is administered for placebo:~* 5 tablets for 40-60 kg~* 6 tablets for 60-80 kg~* 8 tablets for \> 80 kg~The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin."
214690278|NCT05520814|DRUG|PD-1 inhibitors|treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg \* q21d (until the disease progresses, intolerable toxicity or the investigator / subject decides to withdraw from the study, and the duration of PD-1 inhibitor is not more than 96 weeks)
214690279|NCT05520814|RADIATION|chemoradiotherapy|"Chemotherapy：~1. GP: gemcitabine 1g/m2 D1, 8 Cisplatin 80 mg/m2 d1~   \* Treatment courses every 3 weeks~2. Cisplatin 80mg/m2 d1 or carboplatin area under the curve 5mg/ml/min \* Treatment courses every 3 weeks~Radiotherapy： All the metastatic lesions received radiation dose from 30 to 60Gy according to different metastatic sites."
214690280|NCT02405234|DEVICE|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
214690281|NCT02405234|DEVICE|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
214422137|NCT06070207|PROCEDURE|TEP group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
214422138|NCT06070207|PROCEDURE|eTEP group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
214422139|NCT00726596|DRUG|hydroxychloroquine|Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
214422140|NCT02952209|DEVICE|Xenograft|
214422141|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 1|Search of positivity with anti-AGO antibodies test
214422142|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 2|Title of anti-AGO antibodies
214690282|NCT02555761|DRUG|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
214690283|NCT00966758|PROCEDURE|Computed Tomography|1 low dose CT scan is taken
214690284|NCT00966758|PROCEDURE|Single Photon Emission Computed Tomography|1 SPECT scan is taken
214422143|NCT05966350|OTHER|Comparison with Chi2 method|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a Chi2 method for qualitative data.
214422144|NCT05966350|OTHER|Comparison of data with parametric Test (T-test)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography, evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a parametric test (T-test).
215021424|NCT06691802|DRUG|Shu Fei Tie|Optimize the extraction process and matrix formulation, and combine the use of traditional Chinese medicine volatile oil and chemical transdermal enhancers to develop adermal patch（Shu Fei Tie）
214422145|NCT05966350|OTHER|Comparison of data with non-parametric test (ANNOVA)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a non-parametric (ANNOVA).
214422146|NCT04487600|OTHER|Active voiding trial|
214422147|NCT02328963|DRUG|Everolimus|"Everolimus : 0.75 bid, targeted to 3-8 ng/ml~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
214422148|NCT02328963|DRUG|mycophenolic acid|"Mycophenolic acid :~1080 mg bid for one month, then 720 mg bid~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
214422149|NCT01416558|DRUG|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks~Given until progression, unacceptable toxicity, patient's request or withdrawal from Study"
214422150|NCT02370758|DRUG|Valganciclovir or Ganciclovir|
214422151|NCT02948114|OTHER|Control: Cow milk-based infant formula|
214422152|NCT02948114|OTHER|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
214422153|NCT02948114|OTHER|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
214422154|NCT02948114|OTHER|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
214690285|NCT02065310|OTHER|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 \& 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
214690286|NCT01687738|OTHER|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
215021425|NCT06691802|DRUG|Shu Fei Tie placebo|Shu Fei Tie Placebos are made using substances without active drug ingredients, following the same preparation procedures
215021426|NCT06691295|OTHER|Questionnaires|"This study aims to explore transdiagnostic psychological processes (PP) via the administration of self-reported scales and questionnaires, in a population of newly diagnosed FND patients, prior to any therapeutic management.~The main objective is to describe the psychometric properties (scores on tools measuring psychological processes) of NFT patients (presenting the main phenotypes; sensitivo-motor; and seizures and discomfort)."
215021427|NCT06686004|DIETARY_SUPPLEMENT|Carrots|Detection of polyacetylene and carotenoids in human biofluids
215021428|NCT06689644|DIETARY_SUPPLEMENT|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Commercially available product: Mind lab pro
215021429|NCT06689644|DIETARY_SUPPLEMENT|Placebo|A cellulose commonly used as a bulking agent in supplement products
215021430|NCT06689644|BEHAVIORAL|Perceptual decision-making performance|A computerised cognitive task involving rapid visual categorisation of images
215021431|NCT06689644|DEVICE|Electroencephalography|Brain signals are recorded from a 64 channel EEG system during the cognitive task
215021432|NCT06690762|OTHER|Education|It consists of nutrition, physical activity, stress management, relaxation exercises and defecation training.
215021433|NCT06687629|PROCEDURE|Concha bullosa crushing|Concha bullosa crushing
215021434|NCT06687629|PROCEDURE|Concha bullosa resection|Concha bullosa resection
215021435|NCT06689865|DEVICE|HA-HCP|Prescription hearing aid fit by a hearing healthcare professional using audiology best practices.
215021436|NCT06689865|DEVICE|OTC-HCP|Over-the-counter hearing aids fit by a hearing care professional using audiology best practices.
215021437|NCT06689865|DEVICE|OTC-R|OTC fit to an individual using some best practices via remote consultation.
215021438|NCT06689865|DEVICE|OTC-SF|Self-fit OTC hearing aids without any clinical support from HCPs.
214422155|NCT02234128|DEVICE|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
214422156|NCT02036307|DIETARY_SUPPLEMENT|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
214422157|NCT02036307|DIETARY_SUPPLEMENT|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
215021439|NCT06691841|DRUG|Chlorhexidine Gluconate|oral wiping and oral care solution rinsing, oral care solution was 0.12% chlorhexidine gluconate, and the frequency of oral care was 3 times a day.
215021440|NCT06691841|OTHER|normal saline|oral wiping and oral care solution rinsing, oral care solution was 0.9% normal saline, and the frequency of oral care was 3 times a day.
215021441|NCT06687317|OTHER|Behavioral|KNAP
215021442|NCT06688500|PROCEDURE|Bowel function post Holmium Laser Enucleation of the Prostate|Observing post operative bowel functions among participants who have undergone a HoLEP procedure.
215021443|NCT06689683|DEVICE|Shock wave lithotripsy|SWL works on the principle of focusing on the calculus using fluoroscopy. There has yet to be a consensus on the optimal frequency of fluoroscopic monitoring in the literature.
215021444|NCT06691542|DRUG|platelet-rich plasma|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
215021445|NCT06691542|DRUG|Metformin|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
215021446|NCT06691542|OTHER|cryotherapy|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
215021447|NCT06164730|DRUG|VERVE-102|Intravenous (IV) infusion
215021448|NCT06695364|OTHER|survey study|Not all classes were included in the study
215021449|NCT06694961|OTHER|Online Educational Material|Online educational material will be an easy way to reach large number of physicians
215021450|NCT06695078|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
215021451|NCT06693947|OTHER|Alpine dairy products|The intervention group will be instructed to eat three portions of alpine dairy products daily. The proposed three portions represent an estimated mean consummation in the study population, taking into consideration the national statistics.
215021452|NCT06694298|DRUG|SYS6020|BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion
215021453|NCT06694324|DRUG|Liposomal Doxorubicin (Doxil)|30 mg/m2, d1, IV
215021454|NCT06694324|DRUG|Apatinib|250 mg, qd
215021455|NCT06694324|DRUG|Camrelizumab|200 mg, d1, IV
215021456|NCT06688838|DRUG|Tofacitinib|If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.
215021457|NCT06687902|DIAGNOSTIC_TEST|Digital breast tomosynthesis|In digital breast tomosynthesis (DBT), images are acquired using a specialized X-ray tube that moves in an arc around the breast. This technique captures multiple low-dose images from various angles, typically within a 15° to 60° range. These images are then reconstructed into 1-mm slices to create a 3D representation of the breast, allowing for detailed layer-by-layer evaluation. The number of images acquired varies depending on the size of the breast and the specifications of the equipment but generally ranges from 10 to 25 projections, captured within a few seconds.
215021458|NCT06687759|DRUG|[14C]MK-1084|Oral administration
215021459|NCT06689189|OTHER|Blood fluorescence metabolite analysis|This is an observational study and does not involve intervention. In both the early and late stages of sepsis, a significant increase in inflammatory free radicals changes the optical properties of the patient\&#39;s blood, distinguishing it from that of healthy individuals. To explore this phenomenon, 4 cc of fasting blood is drawn from patients who pass our screening criteria. This sample is then centrifuged in accordance with our detailed standard operating procedures to ready it for analysis. Subsequently, the fluorescence intensity of the blood is measured quantitatively using a precisely calibrated blood fluorometer, which is specifically designed to detect subtle variations indicative of both early and late sepsis. This entire process is executed under stringent quality control protocols to ensure the reliability and accuracy of the results, which are pivotal for the timely diagnosis and intervention in septic patients.
214422158|NCT04591067|OTHER|Testing of physical capacity|"This cross-sectional study will involve evaluation of physical capacity by assessment of:~1. Gait function~2. Muscle activity during walking~3. Endurance during walking~4. Hip muscle strength~5. Hip range of motion~6. Hip and muscle-tendon-related groin pain~7. Hip and groin related patient-reported outcome measures (PROMs)"
214690287|NCT01687738|OTHER|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
214690288|NCT04912037|DEVICE|artificial intelligence assistance system|the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
215021460|NCT06687499|DRUG|Bismuth-based susceptibility-guided treatment|The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori. A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.
215021461|NCT04448912|PROCEDURE|Damage control surgery|Surgery for non-traumatic abdominal emergencies using the damage control approach
215021462|NCT04448912|PROCEDURE|Conventional surgery|Conventional surgery for non-traumatic abdominal emergencies
215021463|NCT05289453|PROCEDURE|lens extraction by phacoemulsification|lens extraction by phacoemulsification
215021464|NCT06695260|DIAGNOSTIC_TEST|CT scan|CT will be performed when the wrist is under loading compared to normal conditions. scapholunate kinematics will be examines
215021465|NCT06687707|OTHER|Attitude Scale towards Physiotherapy Profession|It is a questionnaire that evaluates the attitudes of physiotherapists with 35 questions under 3 headings: professional satisfaction, qualifications required by the profession, and concerns about the profession. It was developed in 2018 by Begümhan Turhan. In this scale, which is a Likert-type questionnaire, each question is scored between 0 and 5 points. The minimum score that can be obtained from the scale is 35 and the maximum score is 175. A high score indicates that physiotherapists have a positive attitude towards their profession
214422159|NCT06093386|OTHER|Intensive Transition Support|Participants assigned to the intervention arm will transfer their transition support leadership to a transition team composed of a transition navigator (an advance practice nurse), a nurse navigator (a registered nurse) and a social worker over 2 years to support them through the multiple phases of CMC transitions including guidance, monitoring, planning, care transfer and transfer completion. CMC and their caregivers will be offered support in care planning, receiving funding, and connecting with a primary care provider and adult subspecialists.
215021466|NCT06687707|OTHER|Minnesota Job Satisfaction Scale|It is a 20-item Likert-type questionnaire. Scores less than 3 points indicate low job satisfaction. Turkish validity and reliability studies were conducted. The validity and reliability study in Turkey was conducted by Baycan and the Cronbach's alpha value of the scale was found to be 0.77. It is a tool consisting of 20 items with features that reveal internal and external job satisfaction factors. The neutral satisfaction score of the scale is 3. If the score obtained from the scale is less than 3, job satisfaction is considered low, and if it is greater than 3, job satisfaction is considered high.
215021467|NCT06687707|OTHER|Maslach Burnout Scale|The Burnout Inventory, which was developed by Maslach and Jackson (1981) and introduced to the literature under Maslach's name, is a seven-point Likert-type scale and consists of a total of 22 items and three subscales. Among these subscales, emotional exhaustion subscale consists of 9 items, depersonalisation subscale consists of 5 items and personal accomplishment subscale consists of 8 items. Scale items are scored as '1 never' and '7 always'. The Turkish validity and reliability of the questionnaire was conducted by Burhan Çapri. It is a 5-point Likert-type scale measured with 0: never 4: always options. High scores are expected
215021468|NCT06691763|BEHAVIORAL|Pythagorean Self-Awareness Intervention for stress management and health promotion|Pythagorean Self-Awareness is a holistic stress magement program that combines cognitive reconstruction and the implementation of the 6 pillars of life-style medicine depending on the targeted population.
215021469|NCT06689228|OTHER|Rational Drug Use Training|Rational Drug Use Training and Tele-monitoring will include information on drugs and their importance, rational drug use, rational drug use in haemodialysis patients, harms of irrational drug use, benefits of rational drug use, obstacles encountered in rational drug use, ways to overcome obstacles encountered in rational drug use, and increasing self-efficacy. The first training is planned to last approximately 30-35 minutes for each patient and the second training (summary training) is planned to last approximately 15-20 minutes. With telemonitoring, reminder messages will be sent to patients' phones at intervals.
215021470|NCT06887881|GENETIC|PIMS screening|Couples in the PIMS group will have up to 6 blastocysts screened with PIMS and a single euploid embryo with the optimal state of whole-genome DNA methylation and the highest morphologic score will be selected for the initial transfer
215021471|NCT06887881|GENETIC|PGT-A screening|Couples in the PGT-A group will have up to 6 blastocysts screened with PGT-A and a single euploid blastocyst with the highest morphologic score selected for the initial transfer.
215021472|NCT00468000|BIOLOGICAL|Ixmyelocel-T|IM injection
215021473|NCT00468000|BIOLOGICAL|Placebo|IM Injection
215102740|NCT03665688|DEVICE|Outpatient Dilapan-S|After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L\&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L\&D unit for standard protocol of labor induction.
214422160|NCT02646969|DIETARY_SUPPLEMENT|Formula regimen 1|
214422161|NCT02646969|DIETARY_SUPPLEMENT|Formula regimen 2|
214422162|NCT00092014|DRUG|Alendronate|Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
214422163|NCT00092014|DRUG|Risedronate 35 mg|Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
214422164|NCT00092014|DIETARY_SUPPLEMENT|Elemental Calcium|Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
214690289|NCT04332029|BEHAVIORAL|CBT + WGP + CM|The intervention will be implemented in 8-week group-based sessions and includes: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating, and 3) a Contingency Management procedure reinforcing smoking abstinence. This component will consist on providing vouchers to reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
214422165|NCT00092014|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
214422166|NCT00092014|DRUG|Risendronate placebo|Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
214422167|NCT00092014|DRUG|Alendronate placebo|Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
214422168|NCT04191954|DRUG|Fasudil eye drops (concentration 0.5 percent)|receive Fasudil eye drops (concentration 0.5 percent) twice daily
214422169|NCT04191954|DRUG|receive artificial tears drop|receive artificial tears drop with the same frequency
214422170|NCT05747313|DRUG|Chidamide|"Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal."
215021474|NCT02318979|DEVICE|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
215021475|NCT02318979|DEVICE|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
215021476|NCT02318979|DEVICE|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
215021477|NCT02369692|DEVICE|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
215021478|NCT05683626|DRUG|Humira|subcutaneous injection
215021479|NCT00383851|DRUG|ATN-224|
215021480|NCT00383851|DRUG|Temozolomide|
215021481|NCT05583058|OTHER|Hormone Overdose and Misuse|This is an observational study. Hormone Overdose and Misuse is an exposure.
215021482|NCT01639521|DRUG|cisplatin|Given IV
215021483|NCT01639521|DRUG|gemcitabine hydrochloride|Given IV
215021484|NCT01639521|DRUG|methotrexate|Given IV
215021485|NCT01639521|DRUG|vinblastine|Given IV
215021486|NCT01639521|DRUG|doxorubicin hydrochloride|Given IV
215021487|NCT01639521|BIOLOGICAL|pegfilgrastim|Given SC
215021488|NCT01639521|OTHER|laboratory biomarker analysis|Correlative studies
215021489|NCT02099591|DRUG|Naloxegol|Opioid Antagonist
215021490|NCT02286791|BEHAVIORAL|Mindful Awareness Program|For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
215021491|NCT02286791|BEHAVIORAL|Health Education Program|"For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.~Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support"
215021492|NCT01157429|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
215021493|NCT01157429|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
214690290|NCT04332029|BEHAVIORAL|CBT + WGP|The intervention will be implemented in 8-week group-based sessions and will include only the first two components of the experimental intervention: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating.
215021494|NCT01157429|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
215021495|NCT02571855|DRUG|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
214690291|NCT03796091|BEHAVIORAL|Educational Brochure|Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.
215021496|NCT02571855|DRUG|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
215021497|NCT02571855|DRUG|Placebo|Placebo capsules matching the ACT-541468 formulations
215021498|NCT02037984|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
215021499|NCT02037984|BIOLOGICAL|V114 1x:1x:1x|V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
215021500|NCT02037984|BIOLOGICAL|V114 2x:2x:2x|V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
215021501|NCT02037984|BIOLOGICAL|V114 2x:1x:2x|V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
215021502|NCT02037984|BIOLOGICAL|V114 1x:1x:2x|V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
215021503|NCT02037984|BIOLOGICAL|V114 0.5x:0.5x:2x|V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
215021504|NCT03305211|OTHER|sample|Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
214422171|NCT06203197|OTHER|Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)|intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS).
214422172|NCT05618236|DRUG|Group N; neostigmine+atropine|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
215021505|NCT01319461|DEVICE|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
215021506|NCT01319461|DEVICE|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
215021507|NCT03529149|COMBINATION_PRODUCT|Urapidil Hydrochloride Injection|"Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV\>37cm/s of （middle cerebral artery)MCA, PI \< 1.34cm/s, aMFV\>40cm/s of (basilar artery)BA, PI \< 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure."
215021508|NCT02842671|OTHER|Assigned Ambassador|If assigned to the intervention group, participants will be contacted by the assigned medical student ambassador at least 1 day prior to the procedure. A brief discussion will take place to review the child's history and survey results. The family will be met by the Ambassador at the hospital and stay with the family until the patient is in the post anesthesia recovery unit. The ambassador is expected to make accommodations for the child as determined by the accommodations survey results. The family will be required to allow the Ambassador to stay through check-in and the procedure.
215021509|NCT05877612|DEVICE|Implantable spinal cord stimulator|Spinal cord stimulation is possible thanks to implantable spinal cord neurostimulators. These are medical devices, which include a stimulation electrode and an implantable box, designed to deliver electrical stimulation for pain relief. The electrode is implanted in the epidural space in order to stimulate the posterior cords of the spinal cord through the dura mater, at the dorsal or cervical level.
215021510|NCT01932580|DRUG|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
215021511|NCT01981993|BIOLOGICAL|Urinary proteomic analysis|
215021512|NCT00974233|DRUG|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
215021513|NCT00974233|DRUG|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
215021514|NCT00974233|DRUG|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
215021515|NCT03396458|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg, anti-HBs and anti-HBc).
215021516|NCT03396458|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g. sharing toothbrushes, HBV infected family member) and HBV vaccination status.
215021517|NCT03586232|DIETARY_SUPPLEMENT|Arnica Montana|Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
215021518|NCT03586232|DIETARY_SUPPLEMENT|Bromelain|Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
215021519|NCT03586232|OTHER|Placebo|A pharmacologically inert preparation
215021520|NCT01580722|PROCEDURE|early reconstruction|patients underwent \< 8 weeks reconstruction after injury
215021521|NCT01580722|PROCEDURE|delay reconstruction|patients underwent \> 8 weeks reconstruction after injury
215021522|NCT01691092|DRUG|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
214422173|NCT05618236|DRUG|GROUP S; decurarized with sugammadex.|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
214422174|NCT02974634|OTHER|Ostomy self management training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
214422175|NCT01708499|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
215021523|NCT06932744|DRUG|MY008211A tablets|Participants will receive MY008211A at a dose of 400 mg orally b.i.d for 24 weeks
215021524|NCT06932744|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
215021525|NCT06214520|BEHAVIORAL|App-based Motivational Interviewing & Human health coaching|"Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.~App-based Motivational Interviewing \& Human health coaching:~The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call."
215021526|NCT06214520|BEHAVIORAL|Empower+ App & Smartwatch wearable tracker|Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.
214422176|NCT05603013|DRUG|Vinorelbine|Vinorelbine Tartrate Oral
214422177|NCT05603013|RADIATION|Radiotherapy|hypofractionated radiotherapy
214422178|NCT05603013|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
214422179|NCT05603013|DRUG|GM-CSF|GM-CSF subcutaneous injection
214422180|NCT05603013|DRUG|IL-2|IL-2 subcutaneous injection
214422181|NCT02067949|DRUG|Simvastatin|single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
214422182|NCT00881842|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
214506945|NCT05963802|OTHER|Artificial Intelligence (ChatGPT) Group|Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process.
214422183|NCT02645006|BEHAVIORAL|3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
214422184|NCT02645006|BEHAVIORAL|1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
215021527|NCT01529151|OTHER|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
214422185|NCT01263002|DRUG|clevudine, Adefovir|"Nucleoside-analogue naive patient : Clevudine 30mg qd~1. Assess the complete virological response(HBV DNA \< 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd~2. Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd~3. During medication of Clevudine, virological breakthrough : add adefovir 10mg qd~4. During treatment period, composite virological response : stop the medication and F/U for 2 years~5. Recurrence after stopping treatment(HBV DNA \> 2,000IU/ml) retreat medication at composite virological response.~   * complete virological response: HBV DNA \< 60 IU/ml~  * virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously."
214506946|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
214506947|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
215021528|NCT01529151|OTHER|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
215021529|NCT05837247|OTHER|Game-based telerehabilitation exercises|online Game-based home exercises are physiotherapy programs that include exercises transformed into game activities to increase the child's participation in the rehabilitation process. The exercises were planned such as; the dwarf camel game as squat exercises; the flamingo balance game as single leg balance exercises and weight-bearing activities etc. The exercise program will be conducted for 6 weeks and 3 sessions in a week.
215021530|NCT05837247|OTHER|Home exercises|The physiotherapist will evaluate the control group patients and monitor them using only a home exercise program.
214422186|NCT04233632|DEVICE|FC2 Condom|FC2: FC2 is composed of a synthetic nitrile rubber latex and 170mm in length. It has a flexible inner ring as the internal retention mechanism and a circular ring as the outer retention mechanism at the open end of the condom. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is available in clear and other colors/scents. It is manufactured by Female Health Company, USA and has USFDA, World Health Organisation (WHO)/United Nations Populations Fund (UNFPA) and South African Bureau of Standards (SABS) approval
214506948|NCT02037568|BEHAVIORAL|fPER|"Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal."
214506949|NCT00647465|DRUG|vaccine|IFNalpha 2b
214422187|NCT04233632|DEVICE|Cupid Condom|Cupid is composed of a Natural rubber latex and is 155mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in clear and red color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union (EU) and SABS approval
214422188|NCT04233632|DEVICE|Cupid 2 Condom|Cupid2 is composed of a Natural rubber latex and is 125mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in Clear and purple color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, CE Mark of the EU and SABS approval
214422189|NCT01399671|OTHER|vestibular stimulation|vestibular stimulation
214422190|NCT02743078|DRUG|Bevacizumab|10 mg/kg every 2 weeks intravenously over 30 minutes.
214422191|NCT02743078|DEVICE|TTFields Therapy|Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.
214422192|NCT01985269|OTHER|Home visits|The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
214422193|NCT02002052|DRUG|Concurrent platinum-based chemotherapy|Platinum-based concurrent chemotherapy in both arms
214422194|NCT02002052|RADIATION|Standard Radiotherapy, 60 Gy in 30 fractions.|
214422195|NCT02002052|RADIATION|Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions|
214422196|NCT05242653|PROCEDURE|pressure by a cotton swab|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.
214422197|NCT05242653|PROCEDURE|stromal hydration with the balanced salt solution（BSS）|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
214422198|NCT02444130|DEVICE|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
214422199|NCT05215925|DRUG|HLX07+carboplatin+pemetrexed|HLX07 1500mg q3w+carboplatin+pemetrexed
214422200|NCT05215925|DRUG|HLX07+docetaxel|HLX07 1500mg q3w+docetaxel
214422201|NCT05215925|DRUG|HLX07|HLX07 1500mg q3w
214422202|NCT04308330|DRUG|Vorinostat|This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.
214422203|NCT00661778|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
214422204|NCT00661778|DRUG|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
214422205|NCT00661778|DRUG|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
214422206|NCT00766298|BEHAVIORAL|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
214422207|NCT00766298|BEHAVIORAL|Weight Loss|The reduction of kcal/day through implementation of low fat diet
214422208|NCT00766298|BEHAVIORAL|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
214422209|NCT02468388|OTHER|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
215102741|NCT03665688|DEVICE|Inpatient Dilapan-S|"After Dilapan-S placement, subjects will be admitted to L\&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
214422210|NCT02468388|OTHER|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
214422211|NCT02468388|OTHER|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
214422212|NCT03156595|BEHAVIORAL|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
214422213|NCT03156595|BEHAVIORAL|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
215021531|NCT06184009|DRUG|ALL, High risk|"Intervention Description :~* Clinical and genetic factors consistent with High risk : Induction → Consolidation~  1. BM MRD \&lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~ 2. BM MRD ≥ 0.01% after Induction, \&lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~ 3. BM MRD ≥ 0.01% after Consolidation~  <!-- -->~  1. T cell ALL : Change to very high risk regimen~ 2. Pre-B ALL : IM #1 → Intensification~     1. BM MRD \&lt; 0.01% after IM #1 : Continue with \&#39;No. 2\&#39; of High risk regimen starting with DI #1~    2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~        * T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported."
214422214|NCT01573598|DRUG|Placebo|Matching placebo given orally, once per day
214422215|NCT01573598|DRUG|Vilazodone|Vilazodone, 20 mg per day, oral administration
214422216|NCT01573598|DRUG|Vilazodone|Vilazodone, 40 mg once per day, oral administration
214422217|NCT00455494|DRUG|AQ-13|
214422218|NCT03710057|DRUG|Ivabradine|A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
214506950|NCT00647465|DRUG|Placebo|Placebo
214506951|NCT03837015|DRUG|Estring Vaginal Ring|Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
214506952|NCT03837015|OTHER|RepHresh Pro-B|Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally
214506953|NCT05064072|DEVICE|Water-based barrier tape|"The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure."
214506954|NCT05064072|DEVICE|Hydrocolloid barrier tape|"As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the pain felt by the infants evaluated with Neonatal Infant Pain Scale and the score recorded in the chart. Since the hydrocolloid barrier tape can stay on the skin for 7 days and the assessment of the pain realized in 7th day and noted down to the chart. Pain score evaluated in 7th day 3 min. before procedure, during and 3 min after procedure"
214506955|NCT05064072|DEVICE|Silk tape|"The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape on the silk tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure"
214506956|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."
215021532|NCT05405166|DRUG|Isatuximab IV|Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
215021533|NCT05405166|DRUG|Isatuximab SC|Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
215021534|NCT05405166|DRUG|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
215021535|NCT05405166|DRUG|Pomalidomide|Pharmaceutical form: hard capsules; Route of administration: Oral
215021536|NCT05405166|DRUG|Dexamethasone|Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02
214422219|NCT01601041|OTHER|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
214422220|NCT05408559|DRUG|Sulforaphane|Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
214422221|NCT05791448|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
214422222|NCT05791448|PROCEDURE|Computed Tomography|Undergo CT scan
214422223|NCT05791448|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214422224|NCT05791448|DRUG|RNA Transcription Modulator AU-409|Given PO
214422225|NCT04123132|OTHER|Kinesiophobia|The presence of kinesiofobia in patients with metabolic syndrome
214422226|NCT04831385|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a first line therapy for insomnia
215021537|NCT05405166|DRUG|Montelukast|Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03
215021538|NCT05405166|DRUG|Paracetamol / Acetaminophen|Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
215021539|NCT05405166|DRUG|Diphenhydramine|Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02
214422227|NCT06442969|OTHER|Education and resources provided by community health workers|The intervention will consist of implementing existing tools provided by EPA's Design for the Environment program, CalOSHA and NIOSH sector-specific guidance for agricultural workers, the Imperial County Department of Public Health and materials from California Department of Toxics Substances Control. The investigators will utilize and adjust existing educational tools such as the Heat Illness Prevention plan developed by CalOSHA. In addition to the educational materials, the investigators will give each farmworker cooling working gear to be worn during their work-shift with (specialized clothes that has been used in other occupational settings). The investigators will provide all participants with a low-cost fan filter, known as Corsi-Rosenthal box built jointly by the community health/research team to reduce chemicals at home, and a small A/C unit to reduce heat stress.
214422228|NCT00002436|DRUG|Lamivudine|
214506957|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."
215102742|NCT06003088|DRUG|HSK7653(5mg)|Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
215102743|NCT06003088|DRUG|HSK7653(25mg)|Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
215102744|NCT00446082|DRUG|Pasireotide|
215102745|NCT04628988|DRUG|CC-90011|Capsule
215102746|NCT04628988|DRUG|Abiraterone|Tablet
215102747|NCT04628988|DRUG|Prednisone|Tablet
214422229|NCT00002436|DRUG|Zidovudine|
214422230|NCT00002436|DRUG|Zalcitabine|
215021540|NCT05405166|DRUG|Methylprednisolone|Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
215021541|NCT05693935|DRUG|TV-44749 - Dose level 1|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
214422231|NCT05304663|DRUG|Onfekafusp alfa|Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26
214422232|NCT05304663|DRUG|Lomustine|"Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles."
214690292|NCT03796091|BEHAVIORAL|Body Project Traditional|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice \& Shaw, 2001).
214690293|NCT03796091|BEHAVIORAL|Body Project Expanded|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
214690294|NCT01930812|PROCEDURE|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
215021542|NCT05693935|DRUG|TV-44749 - Dose level 2|In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections
215021543|NCT05693935|DRUG|TV-44749 - Dose level 3|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
215021544|NCT05693935|DRUG|Placebo|In Period 1, 2 monthly injections (Period 1 only)
215021545|NCT04857281|DEVICE|nVNS (gammaCore)|The treatment will be self-administered using nVNS and will be applied for 4 weeks; a member of the study will provide the proper training on the correct use of nVNS. The patient will be instructed to use the nVNS in place of the rescue medications. When the nauseas gets bad enough that they feel to use a rescue medication they will first use the device on one side of the neck for two 2-minute stimulations and wait fifteen minutes to check if the stimulation works. If this does not help either, they will stimulate with an additional 2 stimulations and wait for another fifteen minutes. If there is no improvement rescue medication will be used. nVNS can be used up to, but no more than, 8 times a day.
215021546|NCT01569763|DEVICE|Aurora Endometrial Ablation|Endometrial Ablation using the Aurora Endometrial Ablation system
215021547|NCT01569763|DEVICE|Rollerball Ablation/Resection|Hysteroscopic rollerball resection/ablation
215021548|NCT00148538|BEHAVIORAL|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
215021549|NCT02290574|RADIATION|Hyperthermia with concurrent chemo-radiation therapy|
215021550|NCT06114472|DRUG|aromatherapy blend containing Lavender|hree drops of aromatherapy blend containing Lavender essence 10% were poured on cotton in cast containers, and the patient was asked to inhale it for 5 minutes from a distance of 10 cm
215021551|NCT03211858|DRUG|Insulin aspart|SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 millimoles/liter \[mmol/L\] \[\<180 milligram/deciliter {mg/dL}\]) while avoiding hypoglycemia.
215021552|NCT03211858|DRUG|NovoLog/NovoRapid|NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia.
214422233|NCT02425449|DRUG|Succinylcholine|will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
215021553|NCT03211858|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
214422234|NCT02750072|PROCEDURE|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
215021554|NCT02973152|PROCEDURE|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
214422235|NCT02750072|PROCEDURE|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
214422236|NCT03430414|DIAGNOSTIC_TEST|Transcriptome Analysis|Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies
214422237|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
214422238|NCT04271449|BEHAVIORAL|Virtual reality device|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
214422239|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be either the cerebellum or the primary motor cortex, but the stimulation will be turned off after 15 seconds to insure a sham condition.~Prismatic googles will also be used in the same way in all groups during prism exposure."
214422240|NCT04961749|OTHER|Whole body vibration training|Whole-body vibration training applies a vibration stimulus to an individual as they are standing on a side-alternating platform. The vibration creates small muscle contractions in the lower extremity musculature which has been shown to improve function and ambulatory function.
214422241|NCT06174337|BEHAVIORAL|Use of Video Connection with Family via Robot|A remote family member is able to connect via video with a nursing home resident.
214422242|NCT01037530|DRUG|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
214422243|NCT04152616|OTHER|Instrumental evaluation of posture|"After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®)."
214422244|NCT05047341|DRUG|SHR0302、[14C]SHR0302|8 mg SHR0302/ 80 µCi \[14C\]SHR0302, once, D1
214422245|NCT00024466|BIOLOGICAL|GVAX|
214422246|NCT00024466|PROCEDURE|Autologous transplant|
214422247|NCT02947217|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
214506958|NCT04028518|DRUG|Alteplase for Injection|"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."
215102748|NCT05068219|PROCEDURE|Usual physical therapy|"Standard rehabilitation for diaphragmatic paresis~* EFA (Expiratory Flow Acceleration) at the upper thoracic level.~* PEP (Positive Expiratory Pressure).~* Expectoration if necessary (coughing up and spitting out)"
215102749|NCT05068219|PROCEDURE|Contract-Relax technique|"The diaphragmatic CR is done in a semi-sitting position.~The CR is composed of 4 steps :~* First maximum inspiration expiration with position of the hands of the physiotherapist on the last ribs and without resistance (Goal: taking rhythm).~* Second maximum inspiration expiration : Free inspiration, expiration with pressure on the last ribs to bring the diaphragm into internal stroke.~* Maximum inspiration against resistance, then maximum expiration with increased pressure.~* Maximum inspiration with dynamic release of resistance (Goal: hyperextension of the diaphragm) followed by maximum expiration with resistance to allow an increase in expiratory flow."
214422248|NCT02947217|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
214422249|NCT04455516|PROCEDURE|Meniscus repair; partial meniscectomy|69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
214422250|NCT02962674|DEVICE|prostaFix System|
214422251|NCT05013606|DIETARY_SUPPLEMENT|Hydrogen water|This is an over the counter pill supplement that is dissolved in water.
214422252|NCT02091336|DRUG|Metformin|patients treatment
214422253|NCT02091336|DRUG|Glyburide|patients treatment
214506959|NCT04001582|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
214506960|NCT03861234|DRUG|BI 836880|Solution for Intravitreal (IVT) injection
214506961|NCT05914896|DRUG|HighOsmo|This group received a priming solution with high osmolality
214422254|NCT05250336|OTHER|Observational Study|Assessment of Prognostic and Predictive value of Tumor-Infiltrating Lymphocytes and Programmed cell Death - Ligand 1 in Breast cancer
214422255|NCT04438668|DEVICE|Centaflow and Standard Care|The intervention is screening methods
214422256|NCT04438668|DIAGNOSTIC_TEST|Standard Care|The intervention is screening methods
214422257|NCT00092781|DRUG|MK0663, etoricoxib|
214422258|NCT00092781|DRUG|Comparator: celecoxib|
214422259|NCT00364286|DRUG|Dasatinib (BMS-354825)|50mg Orally twice daily
214422260|NCT01299753|DRUG|placebo|identically packed placebo
214422261|NCT01299753|DRUG|propranolol|20-40 mg q6-8h
214422262|NCT00091624|DRUG|CC-5013|
214422263|NCT03780816|OTHER|Observation of provider-patient interactions and interviews|Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
214422264|NCT03749590|DRUG|Magnesium Sulfate|Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
215021555|NCT02973152|PROCEDURE|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
214422265|NCT03749590|DRUG|Placebo (NaCl 0,9%)|Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
214422266|NCT02712411|DRUG|HCP1303|
214422267|NCT02712411|DRUG|HGP1201|
214422268|NCT02712411|DRUG|HIP1402|
214422269|NCT06030713|DRUG|Cefazolin|Cord clamping before or after antibiotic (cefazolin) prophylaxis
214422270|NCT01061424|BEHAVIORAL|community health worker|community health worker provides home visits for education
214422271|NCT01061424|BEHAVIORAL|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
214422272|NCT05875285|OTHER|Iontophoresis with methotrexate|"The methotrexate iontophoresis group the patient's hands are placed in direct contact with the conductive electrodes.~The patient will receive full explanation to the purpose of the treatment, the therapeutic and physiological benefits of this method of treatment. Before starting the treatment, all the previous measurements of each patient in this group is taken for a comparison.~Every patient will receive 12 sessions 3times/week every session consist of 30 minutes application of methotrexate iontophoresis using continuous direct current, the patient should feel mild tingling sensation (not painful), the polarity should be reversed halftime of treatment session, as the anodal current is more effective."
214422273|NCT05875285|OTHER|Iontophoresis with coal tar ointement|For coal tar ointement group the ointement is putted direct on the skin after describing the instruction and method of application and time of application and do alarm instead not to forget.
214422274|NCT00190008|DRUG|piracetam|
214422275|NCT04368858|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.|In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.
214422276|NCT06552702|OTHER|There is no intervention|There is no intervention.
214422277|NCT02740686|OTHER|Sample collection|Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.
214422278|NCT03556137|DRUG|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
214422279|NCT00003339|BIOLOGICAL|gp100 antigen|
214422280|NCT00003339|BIOLOGICAL|incomplete Freund's adjuvant|
214422281|NCT00003339|BIOLOGICAL|recombinant interleukin-12|
214422282|NCT00003339|BIOLOGICAL|tyrosinase peptide|
214422283|NCT00942058|OTHER|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
214422284|NCT02195713|DEVICE|Accuryn|Accuryn is a novel electronic urine output monitor
214422285|NCT03521037|DRUG|Rucaparib camsylate|In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
214422286|NCT04128436|OTHER|Taking blood samples for analyzing progesterone levels|As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
214422287|NCT06339489|DIAGNOSTIC_TEST|Testing the serum levels of bone metabolic markers|Testing serum levels of TRACP-5b and BALP, BMD values of lumbar spine L1-L4, left and right hip, left and right femoral neck et.al.
214422288|NCT02971176|RADIATION|Low-dose protocol computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
214422289|NCT02971176|RADIATION|Standard-dose protocol computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
214422290|NCT02574026|BEHAVIORAL|Psychomotor tasks|the acquisition of data will be performed in one unique session no drug administration no surgery
214422291|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution)|The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.
215021556|NCT04314206|DRUG|VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
215021557|NCT04314206|DRUG|Placebo for VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
215021558|NCT04501705|DRUG|Apatinib Mesylate|"Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator."
215021559|NCT03810365|BEHAVIORAL|Brief behavioral treatment for insomnia|Brief Behavioral Treatment for Insomnia includes content on sleep restriction, stimulus control, and sleep hygiene content with 1 month for primary outcome followed by 3 month 12 month follow-up visits.
215021560|NCT03810365|BEHAVIORAL|Healthy Eating Control|Healthy eating control involves healthy eating content with 1 month for primary outcome followed by 3 month and 12 month follow-up visits.
215021561|NCT00002431|DRUG|Chlorhexidine gluconate|
215021562|NCT03137407|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
215021563|NCT03137407|BIOLOGICAL|Placebo|Intramuscular injection
215021564|NCT05476731|DIAGNOSTIC_TEST|culture and antifungal sensitivity and molecular detection|"Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine"
215021565|NCT03629002|BIOLOGICAL|Study of the gene expression profile|qPCR analysis
215021566|NCT00963885|DRUG|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
215021567|NCT00963885|DRUG|Pegasys|180micrograms sc weekly for 24 or 48 weeks
215021568|NCT00963885|DRUG|Placebo|po for 12 weeks
214422292|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD|The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
214422293|NCT00269516|DRUG|pardoprunox|fixed dose 6 mg
215021569|NCT00963885|DRUG|Placebo|po for 24 weeks
215021570|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h for 12 weeks
215021571|NCT00963885|DRUG|RO5190591 (Danoprevir)|600mg po q12h for 12 weeks
215021572|NCT00963885|DRUG|RO5190591 (Danoprevir)|900mg po q12h for 12 weeks
215021573|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
215021574|NCT00555373|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
215021575|NCT01509404|DRUG|Valganciclovir|Valcyte per package insert guidelines for 200 days post transplant
215021576|NCT01509404|BIOLOGICAL|CMV hyperimmune globulin|100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
215021577|NCT01509404|DRUG|Valganciclovir|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
215021578|NCT02079285|PROCEDURE|EUS-FNA|
214422294|NCT00269516|DRUG|Pardoprunox|fixed dose 12 mg
214422295|NCT00269516|DRUG|Pardoprunox|12-42mg
214422296|NCT00269516|DRUG|Placebo|Placebo
214422297|NCT01305733|DRUG|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
214422298|NCT01305733|OTHER|saline injection|saline
214422299|NCT04065932|DRUG|BMS-986165-01|Participants will receive BMS- 986165 -01 in prototype formulation
214422300|NCT04065932|DRUG|BMS-986165 Tablet|Participants will receive BMS-986165 in tablet form.
215021579|NCT04917510|PROCEDURE|Erector spinae block|See experimental arm group description
215021580|NCT04917510|PROCEDURE|Local block|See control and study arm group descriptions for the local block
215021581|NCT05612295|BEHAVIORAL|MBPP|"MBPP program consist of three fundamental principles (i.e., attention monitoring, acceptance, sport-specific rationale) and six performance-related core mental attributes including three behavioral and three neurocognitive components.~Each session will start with a brief homework discussion and recap of the preceding session, and instructors will deliver a topic-related brief story or group activity to participants, followed by a theoretical introduction and practice of mindfulness. Finally, at the end of each session, instructors will guide participant to discuss mindfulness applications related to specific sports performances. At the end of the session, participants will be assigned homework to increase the effectiveness of MBPP, and participants will be encouraged to practice daily for at least 10-15 min between the sessions."
214690295|NCT01930812|PROCEDURE|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
214690296|NCT01930812|DRUG|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
215021582|NCT05612295|BEHAVIORAL|Self-talk|self-talk sessions include: Session 1 \& 2. The concepts, types, and the importance of self-talk will be introduced; Session 3. Researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific instructional scripts for specific sports performance (e.g., running); Session 4. practice of sport-specific instructional self-talk; Session 5. researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific motivational self-talk scripts for specific sports performances; Session 6. practice of sport-specific motivational self-talk; and Session 7 \& 8. general practice for learned self-talk techniques.
215021583|NCT04636580|BEHAVIORAL|parent accompanying the child during treatment|After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
214690297|NCT01253044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
215021584|NCT04038008|DRUG|Fluconazole|Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.
214690298|NCT01253044|BEHAVIORAL|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
215021585|NCT04038008|DRUG|Diflucan®|Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
215021586|NCT00506311|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected groin area.
215021587|NCT01978015|DRUG|travoprost and timolol maleate fixed combination|travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
215021588|NCT01978015|DRUG|latanoprost and maleate timolol fixed combination|Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
215021589|NCT01978015|DRUG|bimatoprost and timolol maleate fixed combination|bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
215021590|NCT01978015|DRUG|dextran and hypromellose|Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
215021591|NCT04854499|DRUG|Magrolimab|Administered intravenously
214690299|NCT05685368|BEHAVIORAL|ACT for Race Related Stress|This intervention will be guided by: Payne, J. S. (2022). Out of the Fire: Healing Black Trauma Caused by Systemic Racism Using Acceptance and commitment Therapy New Harbinger Publications, Inc.
214690300|NCT03116399|BEHAVIORAL|PRISM 2.0 Condition|Access to the PRISM 2.0 program
214690301|NCT03116399|BEHAVIORAL|Tablet Condition|Access to the tablet
214690302|NCT00320736|DRUG|galantamine|
214690303|NCT05873153|BEHAVIORAL|Health Education|Education materials on high blood pressure, lowering sodium, starting an exercise program, and weight management.
215021592|NCT04854499|DRUG|Pembrolizumab|Administered intravenously
215021593|NCT04854499|DRUG|Docetaxel|Administered intravenously
214690304|NCT05873153|OTHER|Home Blood Pressure Monitor|Blood pressure cuff for home use
214690305|NCT05749926|BIOLOGICAL|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
214690306|NCT05749926|BIOLOGICAL|VidPrevtyn® Beta vaccine (Sanofi/GSK)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
214690307|NCT01237808|DRUG|Cytarabine|in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).
215021594|NCT04854499|DRUG|5-FU|Administered intravenously
215021595|NCT04854499|DRUG|Cisplatin|Administered intravenously
214422301|NCT04065932|DRUG|Famotidine|Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
214506962|NCT00621842|DRUG|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
214690308|NCT01237808|DRUG|Etoposide|first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).
214690309|NCT01237808|DRUG|All-trans retinoic acid (ATRA)|in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
214690310|NCT00905307|DRUG|OPC-34712|oral, once daily
214690311|NCT00905307|DRUG|Placebo|Placebo
214690312|NCT00905307|DRUG|Aripiprazole|oral, once daily
214690313|NCT05556733|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4, week 8
214690314|NCT00005117|DRUG|pravastatin|
214690315|NCT03978819|DEVICE|ANI|"ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI\>80 + Remifentanil \>6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis."
214690316|NCT03860727|DIAGNOSTIC_TEST|Welch Allyn IExaminer|Fundus Examination
214690317|NCT02304536|DRUG|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
215021596|NCT04854499|DRUG|Carboplatin|Administered intravenously
215021597|NCT04854499|DRUG|Zimberelimab|Administered intravenously
215021598|NCT00185614|PROCEDURE|Autologous hematopoietic cell transplant (Auto-HCT)|The target cell dose is 2.6 x 10e6 CD34+ cells/kg
215021599|NCT00185614|PROCEDURE|Allogeneic hematopoietic cell transplant (Allo-HCT)|The target cell dose is 5 x 10e6 CD34 cells/kg
215021600|NCT00185614|DRUG|Cyclophosphamide|Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
215021601|NCT00185614|DRUG|Filgrastim|"* Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~* Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~* Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)"
215021602|NCT00185614|DRUG|Melphalan|Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
215021603|NCT00185614|RADIATION|Total body irradiation (TBI)|200 centigray (cGy) total body irradiation delivered on Day 0
215021604|NCT00185614|PROCEDURE|Cyclosporine (CSP)|Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
215021605|NCT00185614|DRUG|Mycophenolate Mofetil (MMF)|Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
215021606|NCT06243926|OTHER|Sperm selection for ICSI|Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.
215021607|NCT01048359|BEHAVIORAL|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
215021608|NCT01048359|BEHAVIORAL|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
215021609|NCT01048359|BEHAVIORAL|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
215021610|NCT00536705|DRUG|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
215021611|NCT05818007|DRUG|Hyaluronic acid|The main function of HA appears to be in tissue healing, by activating and modulating inflammatory responses, stimulating cellular proliferation, migration, and angiogenesis, inducing basal keratinocyte proliferation and re-epithelization by reducing collagen deposition and scarring
215021612|NCT05818007|DRUG|Sodium bicarbonate|sodium bicarbonate solution
215021613|NCT05856942|OTHER|Health service - home-based PrEP monitoring|Home-based PrEP care
215021614|NCT03160573|DRUG|ClōSYS® Unflavored Rinse|
215021615|NCT03160573|DRUG|ClōSYS® Flavored Rinse|
215021616|NCT03160573|OTHER|Placebo-Flavored Oral Rinse|Flavor-matched placebo rinse
215021617|NCT03160573|OTHER|Placebo-Unflavored Oral Rinse|Unflavored-matched placebo rinse
215021618|NCT05678127|PROCEDURE|Skin biopsy|"Two 3mm skin biopsies from the abdominal wall will be taken. One at the triggerpoint of the pain, the second one at the contralateral, non-affected side of the abdominal wall.~Lidocaine will be used for local anaesthesia of the skin, before the biopsies will be taken."
215021619|NCT05982379|OTHER|Technology Based Motivation Program|"A 10-week Technology Based Motivation Program was given to the intervention group. The website and four training modules were used with the children in the intervention group. Nine coaching interviews with each child (once a week) were conducted over WhatsApp. The children were encouraged to do progressive relaxation and breathing exercises at least twice a week, and eight therapeutic stories (once a week) were sent to the child's phone in the form of animation.~Three training modules were used with the primary caregivers, and coaching interviews were conducted on WhatsApp twice during the program. Primary caregivers practiced progressive relaxation and breathing exercises at least twice a week. In addition, eight motivation messages were sent to the child and primary caregiver, and 24/7 consultancy was provided."
215021620|NCT01620047|DRUG|Fentanyl|Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
215021621|NCT01620047|DRUG|Ropivacaine|Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
215021622|NCT01620047|DRUG|Fentanyl|0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
215021623|NCT04652999|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot). The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds. The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
215021624|NCT04652999|BEHAVIORAL|Neutral Guided Imagery|This placebo consists on neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, be it positive or negative, which occurred before patient has the current DFU. Then, questions are asked which allow a more detailed reconstruction of the event and the patient is asked to imagine according only to the instructions given. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered in each of the questions given.
215021625|NCT03638180|DRUG|BLU-5937|BLU-5937 oral tablet
215021626|NCT03638180|DRUG|Placebo|Matching placebo to BLU-5937
215021627|NCT01283945|DRUG|Lucitanib|"Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)"
215021628|NCT05522400|BEHAVIORAL|Virtual Reality (VR) and human computer interaction system|The experimental group used VR technology and human-computer interaction system for exercise, while the control group used traditional exercise program
215021629|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block
215021630|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation with Local Anesthetic infiltration|IV midazolam and propofol-based sedation with Local Anesthetic infiltration
215021631|NCT01872000|PROCEDURE|Cataract surgery|
215021632|NCT02163863|DEVICE|Femoropopliteal stenting|
215021633|NCT00968630|OTHER|Laboratory Biomarker Analysis|Correlative studies
215021634|NCT00968630|PROCEDURE|Leukapheresis|Undergo leukapheresis
215021635|NCT01728896|OTHER|Patient-controlled oral refeeding|
215021636|NCT03188380|DIAGNOSTIC_TEST|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
215021637|NCT03188380|DIAGNOSTIC_TEST|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
215021638|NCT01834378|BEHAVIORAL|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
215021639|NCT01834378|BEHAVIORAL|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
215021640|NCT06569966|BEHAVIORAL|preoperative prehabilitation treatment of ileostomy contents filtrate reinfusion through distal ileocolon or retention of enema colon|The contents of the ileostomy were collected and placed in a wide mouth container, mixed with 500mL normal temperature saline, and placed in a funnel with double layer medical gauze. The filtrate of the ileal contents was collected and placed into an enema for use. The catheter was placed into the ileal output end of the ostomy through anterograde enema or transanal retention enema, and slowly infused for 15-20 minutes, 2-3 times a day for 4 weeks. The adverse reactions such as abdominal pain, abdominal distension and fever were observed. The number, time, antegrade/retrograde prehabilitation operation, adverse reactions during the operation and other special conditions were recorded every day, and the weight of the patient was recorded
215021641|NCT06569888|DEVICE|LIPUS stimulation|Low Intensity Pulsed Ultrasound stimulation of the gut at the pre-clinically optimized conditions and energy dosage
215021642|NCT02155855|OTHER|Telemedicine|Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (\<70 mg/dL \> 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
215021643|NCT02155855|OTHER|Control|Routine care
215021644|NCT02402907|DEVICE|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
214422302|NCT05133063|BEHAVIORAL|Gratitude letter|"Participants are given the following instructions:~Think of someone in your life who you feel like you have never fully or properly thanked for something meaningful or important that they did for you. . . . In the space provided below, please write a note to this person that describes why you feel like you never properly thanked them and letting them know why you feel thankful for something important that they did for you. Though this letter will not actually be sent to this person and is simply an exercise for you, please use this as an opportunity to really explore those feelings surrounding how you feel about what they have done for you and write honestly and openly from your heart. You have ten minutes."
214422303|NCT05133063|BEHAVIORAL|Control intervention|"Participants receive the following instructions:~Think of the room you are in…. In the space below, please provide a description of the room you are in. Try to focus on the specific elements in the room, the colours of the wall or objects in the room. Use this writing session as an opportunity to paint a detailed picture of this room and include as much specific information as you can. You have ten minutes."
214422304|NCT01773980|OTHER|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
214422305|NCT01773980|OTHER|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
214422306|NCT02845063|BEHAVIORAL|concentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
214506963|NCT00621842|DRUG|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
214506964|NCT02926118|DIETARY_SUPPLEMENT|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
214506965|NCT02926118|DIETARY_SUPPLEMENT|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
214506966|NCT04810975|DEVICE|Muscle Strength Training|Strength training occurring specific exercise regimens using Exercise Equipment A or B
214506967|NCT02111551|DRUG|DMXB-A 150 mg|
214506968|NCT02111551|OTHER|placebo|
214506969|NCT02111551|DRUG|DMXB-A 75 mg|
214506970|NCT02066636|DRUG|Nivolumab|
214506971|NCT00857077|DRUG|Sulfadoxine-pyrimethamine|
214506972|NCT00857077|DRUG|Placebo|
214506973|NCT04806100|DEVICE|Malleo-Lok|The Malleo-Lok is a novel, low-profile carbon fiber device with two laterally positioned struts aligned in the sagittal plane.
215021645|NCT02402907|DEVICE|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
215021646|NCT00283569|OTHER|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
215021647|NCT04093882|DIAGNOSTIC_TEST|Contrast agent enhanced MRI using Gadovist|By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
214422307|NCT02845063|BEHAVIORAL|eccentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
214422308|NCT02845063|GENETIC|ACE genotyping|Subjects will be genotyped for the ACE-I/D gene polymorphism.
214422309|NCT04668742|DEVICE|DYNAtraq|Tracheostomy alignment with DYNAtraq
214422310|NCT00490685|DRUG|Sorafenib (BAY-43-9006)|
214422311|NCT00696280|BEHAVIORAL|Functional Living Index - Emesis|
214506974|NCT00391170|DRUG|Topical Dexamethasone|dexamethasone 0.01%
214506975|NCT00391170|DRUG|Placebo|Placebo
214506976|NCT04644887|OTHER|Dietary intervention: Healthy diet|Dietary guidance in the intervention group is based on the Nordic and Finnish nutrition recommendations with an emphasis on the quality of dietary fat. The aims for the intake of fatty acids will be SFA \< 10 % of energy intake (E%) and mono- and polyunsaturated fatty acids (UFA) \>2/3 of the total fat intake. The key food products such as vegetable oil-based spread, liquid margarine and canola oil are provided to the participants. The participants are recommended to use fat free (e.g. milk, sourdough milk and yogurt) and low fat (e.g. cheese ≤ 17%) dairy products and low-fat meat, poultry, and fish as well as natural nuts and seeds.
214422312|NCT04847219|DEVICE|Professional flash glucose mornitoring|Subjects will use Professional flash glucose mornitoring once a month for 3 months.
214422313|NCT04847219|DEVICE|Personal flash glucose mornitoring|Subjects will use Personal flash glucose mornitoring once a month for 3 months.
214422314|NCT02577419|OTHER|Target Fortification|
214422315|NCT02577419|OTHER|Higher Initial Concentration|
214422316|NCT02577419|OTHER|Portagen Formula|
214422317|NCT05339763|RADIATION|chemoradiotherapy|exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery
214506977|NCT04644887|OTHER|Dietary intervention: Control diet|The control diet corresponds to the average nutrient intake in the Nordic countries, i.e. the intake of SFA about 15 E% and the proportion of UFA about 50 % of total fat intake. The participants of the control group will get butter-based spread for bread and cooking. They are recommended to use semi-skimmed milk (1,5 %), normal fat yogurt (\~2%), normal fat cheese (\~24-35 %) and avoid consumption of vegetable oils. They are allowed to eat a portion of fish and nuts once a week.
214422318|NCT01566708|BEHAVIORAL|Neuro-Music Therapy immediately|20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
214422319|NCT01566708|BEHAVIORAL|Neuro-Music Therapy after waiting time|20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
214690318|NCT02304536|PROCEDURE|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
214690319|NCT05255705|OTHER|Observation only|Observation only
214690320|NCT02671695|DRUG|Spirulina|Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
214690321|NCT02671695|DRUG|Amlodipine|Amlodipine in a dose of 5 mg/day orally for 3 months
214694119|NCT02586636|DRUG|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
214694120|NCT02586636|DRUG|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
214694121|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 200 mL tap water via nasogastric tube|
214694122|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
214694123|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
214694124|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
214694125|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
214694126|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
214694127|NCT01403740|DRUG|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
214694128|NCT03190720|DEVICE|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
214694129|NCT05304182|DEVICE|EYESTAR 900|The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.
214694130|NCT05304182|DEVICE|LENSTAR LS 900|"The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'."
214694131|NCT00430625|BIOLOGICAL|VPRIV ®,|Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
214694132|NCT03649958|DEVICE|HIRREM-SOP or Cereset|HIRREM-SOP for ten 90 minute sessions
214694133|NCT03649958|DEVICE|Cereset 2x|Cereset 2x for five 90 minute sessions
214694134|NCT03605810|OTHER|No Intervention|This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
214694135|NCT00243230|DRUG|Vicriviroc 30 mg|Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).
214694136|NCT00243230|DRUG|Vicriviroc 20 mg|Two tablets of vicriviroc 10 mg once daily for 48 weeks.
214694137|NCT00243230|DRUG|Placebo|Three tablets of placebo once daily for 48 weeks.
215021648|NCT06569654|DEVICE|Saebo splint|"The SaeboFlex orthosis was fitted individually for each participant in the intervention group. The orthosis was adjusted to ensure proper alignment and comfort.~Participants were instructed on how to don and doff the orthosis correctly and safely.~The orthosis positions the wrist and fingers in extension in preparation for grasp and release activities, enabling participants to perform functional tasks despite limited voluntary movement.~Task-Oriented Repetitive Training:~The intervention consisted of 45-minute sessions, conducted twice a week, over a period of 12 weeks.~Each session focused on repetitive, task-oriented exercises designed to improve motor function and enhance neuroplasticity.~Training Activities:~* Moving the Ball~* Bringing the Ball to the Mouth~* Reaching Towards a Target~* Manipulating the Ball Around a Target~* Placing the Ball into Tubes~* Throwing the Ball~* Catching a Rolling Ball"
214690322|NCT01757782|DRUG|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be \<10% of previous value and SpO2 was not increasing \>5 of previous value) and blood pressure remained stable
214690323|NCT01757782|DRUG|Placebo (distilled water)|Distill water oral
215021649|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments
215021650|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 2|Fresh fermented dairy drink containing probiotic strain
215021651|NCT02920294|DIETARY_SUPPLEMENT|Placebo|Acidified dairy drink without ferments
215021652|NCT03379493|BIOLOGICAL|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion
215021653|NCT04845555|OTHER|Observation of the association between clotting factor level and risk of bleeding whilst physical activity|"The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit."
215021654|NCT00594997|BEHAVIORAL|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
215021655|NCT00594997|BEHAVIORAL|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
215021656|NCT03570515|BEHAVIORAL|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
215021657|NCT03570515|BEHAVIORAL|Educational film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
215021658|NCT00131742|DRUG|telbivudine|
215021659|NCT00131742|DRUG|lamivudine|
215021660|NCT00443014|DEVICE|Cognitive, physical and social stimulation|Sessions of 30 minutes daily five days a week for one year
214690324|NCT04898738|OTHER|Alcohol based hand sanitizer|Provision of ABHS to randomly selected households
214690325|NCT06039761|PROCEDURE|Digestive or gynecological surgery by laparoscopy|Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
215021661|NCT02852837|DRUG|Daratumumab|Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
215021662|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
215021663|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
215021664|NCT02317419|DRUG|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
215021665|NCT02317419|DRUG|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
214690326|NCT05465733|DRUG|Envafolimab;Pemetrexed|single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
214690327|NCT06157502|DRUG|Shuxuening Injection|Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
214690328|NCT06157502|OTHER|Placebo|Receiving 20 ml placebo Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days.
214690329|NCT03316391|OTHER|Dosage of urinary podocyturia|Dosage of urinary podocyturia at admission, delivery and post-partum visit
214694138|NCT00243230|DRUG|Placebo|Two tablets of placebo once daily for 48 weeks.
214694139|NCT00243230|DRUG|Background ART Regimen|"An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir."
215021666|NCT00130390|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily for 28 days
215021667|NCT00130390|OTHER|Placebo|One placebo tablet twice daily for 28 days
215021668|NCT03410745|BEHAVIORAL|Exercise.|Moderate to heavy intensity resistance exercise consisting of leg press.
215021669|NCT05074381|OTHER|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leadi
215021670|NCT05074381|OTHER|Sham Needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
215021671|NCT00019838|DRUG|7-hydroxystaurosporine|
215021672|NCT00019838|DRUG|fludarabine phosphate|
214506978|NCT06021613|BEHAVIORAL|Randomized instructions|"Behavioral: Start: On Cannabis- In this two-day block, participants will be instructed to consume cannabis for one day and avoid cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.~Behavioral: Start: Off Cannabis- In this two-day block, participants will be instructed to avoid cannabis for one day and consume cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis."
214506979|NCT03139331|DRUG|Pazopanib|Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
215021673|NCT02631785|OTHER|Cognitive Behavioral Therapy|"Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session."
215021674|NCT00656695|DRUG|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
215021675|NCT00656695|DRUG|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
215021676|NCT01423084|BIOLOGICAL|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
215021677|NCT02758028|BEHAVIORAL|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
215021678|NCT00396370|BIOLOGICAL|BCG strain Connaught|Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10\^5 CFU vaccine for intradermal administration.
215021679|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10\^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
215021680|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10\^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
215021681|NCT00396370|OTHER|Placebo|0.1 mL of sterile Sauton medium for intradermal administration.
215021682|NCT00396370|OTHER|Placebo|60 mL of sterile phosphate buffered saline (PBS) for oral administration.
215021683|NCT03582397|DEVICE|Virtual Reality Mirror Therapy|Virtual reality mirror therapy (WiseMind) developed by Realiteer and delivered via Oculus Rift virtual reality platform.
214690330|NCT02777775|PROCEDURE|Skin Biopsy|"The procedure to sample the cutaneous neurofibroma involves a skin incision and will take approximately 10 to 15 minutes. The tissue will be taken in the following way:~* The skin area will be cleaned~* The skin area will be numbed (by either a numbing cream or a tiny numbing shot)~* Cutaneous (skin) Neurofibroma: will be taken via a small incision and removal of the neurofibroma whenever possible.~* A small piece of normal (skin) tissue will be numbed as above and taken using a special skin biopsy device.~Afterward, the area will be cleaned and the skin put back together with medical super glue or 1 to 2 dissolvable stitches that will dissolve as the incision heals, they do not require removal. The purpose of taking this piece of skin is to compare normal skin with the skin of a cutaneous neurofibroma."
215021684|NCT03602495|DRUG|Donafenib|Donafenib 0.3g Bid orally, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
215021685|NCT03602495|DRUG|Placebo|Matching placebo Bid orally, continuously.
215021686|NCT00661687|DEVICE|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
215021687|NCT00661687|DEVICE|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
215021688|NCT05388968|BIOLOGICAL|Metatranscriptomic|Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling
215021689|NCT05388968|DIAGNOSTIC_TEST|Specific microbiologic diagnosis|If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
215021690|NCT04628052|PROCEDURE|Colonoscopy|Music vs. No-Music
215021691|NCT02013908|PROCEDURE|Acupuncture plus standard ED management|
215021692|NCT02013908|PROCEDURE|Standard ED management alone|
215021693|NCT00001476|DRUG|Gene Therapy Method for CGD|
215021694|NCT00001476|DEVICE|Isolex 300i Magnetic Cell Selector|
215021695|NCT02206438|DEVICE|Insertion of C-LMA|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
215021696|NCT02206438|DEVICE|Insertion of air-Q according|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
215021697|NCT03379584|DRUG|SGN-CD48A|Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
215021698|NCT02462057|OTHER|Email message regarding the HealthyFood benefit|
215021699|NCT04582487|OTHER|bone marrow and/or peripheral blood samples withdrawal|bone marrow and/or peripheral blood samples evaluation
215021700|NCT03382860|DIAGNOSTIC_TEST|Fundus videos|Recordings of fundus videos
215021701|NCT02336555|DRUG|MK-8291|MK-8291 oral tablets
215021702|NCT02336555|DRUG|Placebo|Placebo oral tablets
215021703|NCT02363426|DEVICE|INVOcell Culture Device|INVOcell is a vaginal culture device
215021704|NCT02363426|DEVICE|IVF Incubation|IVF Incubator
215021705|NCT06323083|OTHER|Emotional Freedom Technique|Emotional freedom techniques is a psychophysiological intervention that combines psychological methods from traditional therapies with somatic stimulation. EFT involves tapping acupuncture points to desensitize negative emotions by focusing on the emotion.
214506980|NCT03139331|DRUG|Irinotecan|"Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects."
215021706|NCT05752838|OTHER|No intervention|This is a survey study, and there were no intervention
215021707|NCT05384548|BEHAVIORAL|Problematic smart phone use course|A 6 session, online, group-based, psychological course targetting problematic smart phone use.
215021708|NCT01202357|BEHAVIORAL|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
214506981|NCT03139331|DRUG|Temozolomide|Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
215102750|NCT00961194|DRUG|Ketamine|"Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
214506982|NCT06032689|COMBINATION_PRODUCT|Xtra-fill|the material was placed in bulk.
214506983|NCT06032689|COMBINATION_PRODUCT|x-base|The x-base liner was placed and then veneered with Xtra-fill.
214506984|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-tra|bulk placement of the restoration Admira fusion -xtra.
214506985|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-base|Admira fusion x-base liner was used and then veneered by Admira fusion x-tra.
214506986|NCT02025504|DEVICE|ColoWrap|ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
214506987|NCT00849485|DRUG|Levetiracetam|750 mg Tablet
214506988|NCT00849485|DRUG|Keppra®|750 mg Tablet
214506989|NCT01849536|DEVICE|SENSIMED Triggerfish®|
214506990|NCT05215249|PROCEDURE|Transnasal humidified high-flow oxygen delivery|The Optiflow system consists of an apparatus that is capable of delivering humidified oxygen, room air, or a mixture of variable oxygen concentration. The oxygen concentration can be precisely varied from 21-100% (or 0.21 - 1.00 FiO2). The gas is warmed to 37°C with a 100% relative humidity. The humidified and warmed gas can be delivered to the patient at high-flows (up to 70 L/min) using various delivery mechanisms. The investigators will be using a nasal cannula to deliver high flow oxygen (2-3 L/kg/min) to the patient.
214690331|NCT05057702|OTHER|Specialized Tumor Board Treatment Plan|Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
214690332|NCT05057702|OTHER|Combinations|Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
214690333|NCT04906889|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
215021709|NCT00900042|GENETIC|DNA ploidy analysis|
215021710|NCT00900042|GENETIC|DNA stability analysis|
215021711|NCT00900042|GENETIC|chromosomal translocation analysis|
215021712|NCT00900042|GENETIC|cytogenetic analysis|
215021713|NCT00900042|OTHER|flow cytometry|
215021714|NCT00900042|OTHER|laboratory biomarker analysis|
215021715|NCT05308459|BEHAVIORAL|Data-driven health promotion at Vocational Education and Training schools (Data Health VET)|"The intervention consists of the following steps:~1. A local health profile is conducted among all students~2. Results are shortly hereafter presented and discussed with all student and staff, and the school decide what health problem they will work with during the next year~3. A participatory group model process based on a dynamic systems approach is conducted to develop sustainable and system changing activities to address the chosen health problem~4. The activities are implemented~5. A new health profile is conducted to a) evaluate the effects of the implemented activities and to b) determine if a new health problem warrant focus and new activities are needed (the process repeats itself)."
215021716|NCT04054180|OTHER|CPAP associated with connected devices: blood pressure monitor , scales and activity monitor|CPAP associated with connected devices: blood pressure monitor , PROMs and activity monitor Patients will use their connected devices for one year. Data from the connected devices will be transmitted to their smartphone application Sefam Access. At the beginning of the study, patients will have a dietary assessment and start a support program for nutrition counselling and physical activity. At each study visit the dietician and physical exercise coach will give the patient advices on diet and for adjusting physical activity.
215021717|NCT06143423|DRUG|AP026 (TQA2226) for injection|AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
215021718|NCT06143423|DRUG|AP026 (TQA2226) for injection matching placebo|AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.
214506991|NCT04572867|DEVICE|Aquapheresis|The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).
215021719|NCT04872946|DIETARY_SUPPLEMENT|Tea|Ashwagandha(Withania somnifera) root and leaf extract (32% Withania Oligosaccharides, 10% Withanolide Glycosides, 0.5% Withaferin A) 125 mg Saffron(Crocus Sativus) stigmas extract (3.48% Crocin and 0.03% Safranal) 28mg
215021720|NCT04872946|OTHER|Serum|Aqua/Water/Eau, Glycerin, Propanediol, Diheptyl Succinate, Caprylic/Capric Triglyceride, Lactococcus Ferment Lysate, Sorbitol, Dimethicone, Steareth-21, Octyldodecyl Neopentanoate, Sodium Polyacrylate, Steareth-2, Caprylyl Glycol, Hydrogenated Polydecene, Trideceth-6, Octyldodecanol, Panthenol, Sodium PCA, Azelaic Acid, Bisabolol, Capryloyl Glycerin/Sebacic Acid Copolymer, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Caprylhydroxamic Acid, Phytic Acid, Aminomethyl Propanol, Lactic Acid, Sodium Chloride, Phenoxyethanol, Sodium Benzoate.
215021721|NCT04872946|OTHER|Moisturizer|Aqua/Water/Eau, Glycerin, Diisopropyl Dimer Dilinoleate, Coco-Caprylate, Lactococcus Ferment Lysate, Myristyl Myristate, Dimethicone, Propanediol, Behenyl Alcohol, Glyceryl Stearate SE, Potassium Cetyl Phosphate, Palmitic Acid, Ammonium Acryloyldimethyltaurate/Beheneth-25 Methacrylate Crosspolymer, Myristyl Laurate, Caprylyl Glycol, Hydroxyethylcellulose, Myristic Acid, Tocopherol, Ethylhexylglycerin, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Helianthus Annuus (Sunflower) Seed Oil, Trisodium Ethylenediamine Disuccinate, Lactic Acid, Sodium Hydroxide, Sodium Phosphate, Disodium Phosphate, Sodium Chloride, t-Butyl Alcohol, Phenoxyethanol, Sodium Benzoate.
215021722|NCT04525469|BEHAVIORAL|Narrative Exposure Therapy|"NET involves: 1) diagnostic interview and psychoeducation, 2) laying out the Lifeline, 3) NET therapy sessions (constructing the trauma narrative in context of the life course), 4) final session rituals. Laying out the Lifeline (using rope or string) allows participants to take a bird's eye view of the events of their life using simple items such as flowers to represent positive events and stones to represent traumatic events. The focus of NET sessions is to encourage participants to describe the details of traumas and integrating the cold memories (i.e., facts) with the hot memories (e.g., cognitions, emotions, physiological feelings, and sensory information). The therapist makes notes after each session narrating the details of the traumas (stones) and reads this at the beginning of each subsequent session. Final session rituals involve re-reading the trauma narrative, hopes for the future, and laying out the final Lifeline placing flowers for hopes and wishes for the future."
214422320|NCT01566708|BEHAVIORAL|Music-therapeutical stress management coaching|20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
214506992|NCT04572867|DRUG|IV Diuretics|Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR\< 2.0, or 5mg PO if Cr \> 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
215021723|NCT01927848|DIETARY_SUPPLEMENT|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
215021724|NCT01927848|DIETARY_SUPPLEMENT|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
215021725|NCT03474601|OTHER|Dynamic hormone study and Magnetic resonance imaging|"1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue"
215021726|NCT02704377|OTHER|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
215021727|NCT02704377|PROCEDURE|Dual X-ray Absorptiometry|Undergo iDXA
215021728|NCT02704377|OTHER|Laboratory Biomarker Analysis|Correlative studies
215021729|NCT02704377|OTHER|Quality-of-Life Assessment|Ancillary studies
215021730|NCT02704377|OTHER|Questionnaire Administration|Ancillary studies
214422321|NCT02716220|DEVICE|Percutaneous Coronary Intervention|Implanttaion fo the DREAMS 2G Scaffold
214422322|NCT03703219|OTHER|Mothers Touch Program|Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
214422323|NCT04707430|OTHER|blood progesterone test|progesterone levels on blood sample
214422324|NCT06156319|OTHER|No intervention|No intervention
214506993|NCT02733484|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
214506994|NCT02733484|DIETARY_SUPPLEMENT|Placebo|the patients in this arm will receive placebo intervention
214690334|NCT04906889|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
214690335|NCT04906889|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
215021731|NCT01633112|DRUG|fingolimod|capsule
215021732|NCT01633112|DRUG|glatiramer acetate|subcutaneous injection
215021733|NCT01959919|DEVICE|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
215021734|NCT03934619|DEVICE|Dolores One|Dolores One, which is a will be applied personal sounds amplification device, will be used to determine if it improves the ability to communication and improves intelligibility
215021735|NCT00383032|DRUG|mifepristone|
215021736|NCT01908699|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
215021737|NCT01908699|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
215021738|NCT01697501|OTHER|Interleukin 28B testing|Blood sampling for IL28B genotyping
214422325|NCT02108106|DRUG|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
214422326|NCT02108106|DRUG|Placebo|
214422327|NCT06076980|DRUG|Paracetamol|compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
214422328|NCT06076980|DRUG|Normal saline|as placebo
214506995|NCT04002349|DRUG|Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
214506996|NCT04002349|DRUG|Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
214506997|NCT04002349|DRUG|0.9% natural saline|Detailed in arm descriptions
214690336|NCT01507610|DRUG|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
215021739|NCT04846946|BEHAVIORAL|Hey, Friend|"Intervention in development. However, we will use intervention mapping and the designing for dissemination approach, informed by self-reported qualitative data, to develop the Hey, Friend modules. The mHealth intervention will include three modules that include multiple sub-topics (e.g., What is HIV?; How do I protect myself from HIV?; What is PrEP?, etc.), deliver culturally appropriate counseling content in community settings, juvenile court system, clinics, and schools; will include Motivational Interviewing components that are effective in evoking behavior change while being acceptable to adolescents and parents, and will include ongoing support through a text reminder to maximize the likelihood of initiating HIV prevention through testing and PrEP."
215021740|NCT02944331|PROCEDURE|Endovenous steam ablation|
215021741|NCT06154525|OTHER|RO water|Aquafina's reverse osmosis (RO) water, produced by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively. The RO water ampoules are produced using a similar process as the LIVESPO Preg-Mom/ KIDS but contain 5ml of high-quality RO water from Aquafina (proper noun)
215021742|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo Preg-Mom|LiveSpo® Preg-Mom has a registration number 7695/2020/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
215021743|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo KIDS|LiveSpo® KIDS has a registration number 1537/2023/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
215021744|NCT02985944|PROCEDURE|Colonoscopy|Colonoscopy performed in adult consecutive patients for different indications
215021745|NCT03497702|DRUG|Doxorubicin|60mg/m2 IV every 3 weeks for 4 cycles
215021746|NCT03497702|DRUG|Cyclophosphamide|600mg/m2 IV every 3 weeks for 4 cycles
215102751|NCT02136628|PROCEDURE|Method RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
214422329|NCT00014248|DRUG|adenosine triphosphate|
215021747|NCT03497702|DRUG|Docetaxel|75mg/m2 IV every 3 weeks for 4 cycles
215021748|NCT03497702|DRUG|Letrozole|2.5 mg once daily preoperably
215021749|NCT03497702|DRUG|leuprorelin|3.75 mg SC every 4 weeks for premenopausal patients
214422330|NCT00014248|PROCEDURE|quality-of-life assessment|
214422331|NCT01124188|DRUG|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
215021750|NCT06232954|DEVICE|Mossie-Go containing treated transfluthrin disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with repellent discs impregnated with transfluthrin and a carrier oil. These discs sit above a fan that is powered by a small motor charged by solar energy. The device is expected to both prevent bites and cause some mortality to mosquitoes when switched on for 8-12 hours overnight for up to 1 calendar month. The discs then need to be replaced.
215021751|NCT06232954|DEVICE|Mossie-Go containing untreated blank disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with a blank untreated disc. These discs sit above a fan that is powered by a small motor charged by solar energy. The device containing the untreated disc is not expected to prevent mosquito bites. The discs will still be replaced monthly for blinding purposes.
214506998|NCT03606551|DEVICE|EXD-959 Bracket System|EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.
214506999|NCT03385759|PROCEDURE|Unicompartmental knee arthroplasty|Implant to replace the medial compartment of a patient with knee osteoarthritis
215021752|NCT00253955|DRUG|Levofloxacin|
215021753|NCT00253955|DRUG|Piperacillin/Tazobactam|
214422332|NCT01124188|BEHAVIORAL|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
214422333|NCT01124188|BEHAVIORAL|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
214422334|NCT04947072|PROCEDURE|Erector Spinae Plane Block|The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000
214422335|NCT04947072|PROCEDURE|Spinal anesthesia|Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
214422336|NCT01266265|DRUG|inhaled prostacyclin|Tyvaso
214422337|NCT01266265|DRUG|inhaled prostacyclin|As prescribed by the physician
214422338|NCT01266265|DRUG|prostacyclin|As prescribed by the physician
215021754|NCT01951729|DRUG|Control|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes."
214422339|NCT01266265|DRUG|subcutaneous and intravenous prostacyclin|As prescribed by physician
215102752|NCT05169411|DIAGNOSTIC_TEST|Blood pressure|The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
214422340|NCT01266265|DRUG|oral ERA|As prescribed by physician
214422341|NCT01266265|DRUG|oral PDE5 inhibitors|As prescribed by physician
214422342|NCT01580293|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
214422343|NCT05640869|BEHAVIORAL|Modified Diabetes Prevention Program Curriculum|The modified DPP curriculum will be an exact copy of the current DPP curriculum except that references to the prevention of diabetes will be modified to prevention of health outcomes associated with overweight/obesity and/or management of overweight/obesity.
214422344|NCT01750307|DIETARY_SUPPLEMENT|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
214422345|NCT01750307|DIETARY_SUPPLEMENT|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
214422346|NCT03816228|DRUG|F 18 T807 Flortaucipir|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
214422347|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Hita, Oita, Japan)|
214422348|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Aso-gun, Kumamoto, Japan)|
214422349|NCT02170324|DRUG|Exenatide|
214422350|NCT02170324|DRUG|Placebo|
214422351|NCT00719459|DRUG|Iron Sucrose|Venofer 20 mg/mL
214422352|NCT00719459|DRUG|Iron Sucrose|Iron sucrose 20 mg/mL
214422353|NCT01645098|DRUG|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
214422354|NCT01645098|DRUG|Dexmedetomidine|0.5 mcg/kg/hr IV
214422355|NCT00479648|BIOLOGICAL|CSL412|
215021755|NCT01951729|DRUG|Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes."
214422356|NCT00479648|BIOLOGICAL|Inactivated trivalent influenza vaccine|
214422357|NCT00009217|DRUG|Haloperidol-Haloperidol|Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
215021756|NCT01951729|DRUG|GIP without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes."
215021757|NCT01951729|DRUG|Placebo with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
215021758|NCT01951729|DRUG|Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
215021759|NCT01951729|DRUG|GIP with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
215021760|NCT01951729|DRUG|GIP plus Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes."
215021761|NCT01951729|DRUG|GIP plus Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
215021762|NCT04867629|DIETARY_SUPPLEMENT|Rapeseed oil|20mL of rapeseed oil to be consumed daily in replacement to habitual oil
215021763|NCT04867629|DIETARY_SUPPLEMENT|Sunflower oil|20mL of sunflower oil to be consumed daily in replacement to habitual oil
215021764|NCT05206045|OTHER|Standard of care|Standard of care for patients with Sezary Syndrome
215021765|NCT01212692|BEHAVIORAL|mentally stimulating activities|The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
215021766|NCT04248673|OTHER|carbohydrate reduced bread|Consumption of carbohydrate reduced bread for three months.
215021767|NCT04248673|OTHER|carbohydrate rich bread|Consumption of carbohydrate rich bread for three months.
215021768|NCT06222957|OTHER|None (Observational study)|Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
215021769|NCT03992872|BIOLOGICAL|Chikungunya|Virus Like Particle
214422358|NCT00009217|DRUG|Haloperidol-Placebo|Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
214422359|NCT04949607|DIETARY_SUPPLEMENT|Inulin fructooligosaccharide|Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.
214422360|NCT06513117|BEHAVIORAL|Behaviour change|healthy conversations to support behaviour change
214422361|NCT06513117|BEHAVIORAL|Dietary support|Guidance on healthy eating
214422362|NCT06513117|BEHAVIORAL|Breathing pattern retraining|guidance on breathing pattern in exercise
214422363|NCT06513117|BEHAVIORAL|Exercise training|Exercise intervention prescribed to participant fitness level
214507000|NCT03385759|PROCEDURE|Total knee arthroplasty|Implant to replace the knee joint of a patient with knee osteoarthritis
214507001|NCT00349206|DRUG|sorafenib tosylate|Given orally
214507002|NCT00349206|DRUG|temsirolimus|Given IV
214507003|NCT04275960|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
214507004|NCT02399241|DEVICE|Bluetooth enabled nebuliser device (I-neb)|
214507005|NCT03196869|DEVICE|Chrono-chemotherapy|Chrono-chemotherapy+concurrent radiochemotherapy
214507006|NCT03196869|DEVICE|Routine intravenous drip|Routine intravenous drip-chemotherap
214507007|NCT03196869|DRUG|induction Chrono-chemotherapy|Experimental group:docetaxel,cisplatin,5-FU
214507008|NCT03196869|DRUG|induction Routine-chemotherapy|control group:docetaxel,cisplatin,5-FU
214507009|NCT03196869|DRUG|cisplatin chrono-chemotherapy|Experimental group: cisplatin chrono-chemotherapy
214507010|NCT03196869|DRUG|cisplatin routine-chemotherapy|control group:cisplatin routine-chemotherapy
214507011|NCT03196869|RADIATION|intensity-modulated radiation therapy|control group is similar to Experimental group
214507012|NCT03816839|DRUG|Amcenestrant (SAR439859)|"Pharmaceutical form: Capsules~Route of administration: Oral"
214507013|NCT05369000|BIOLOGICAL|LAVA-1207|"In part 1 \& part 2~• LAVA-1207 will be administered via intravenous infusion."
214507014|NCT05369000|BIOLOGICAL|LAVA-1207 plus Pembrolizumab|Pembrolizumab will be administered via intravenous infusion
215021770|NCT01033669|DEVICE|CRC-749|There is no drug being used. This is a device.
215021771|NCT01033669|DEVICE|Diskus|There is no drug being used. This is a device.
215021772|NCT01033669|DEVICE|Twisthaler|There is no drug being used. This is a device.
215021773|NCT01033669|DEVICE|Miat Monohaler|There is no drug being used. This is a device.
215021774|NCT05580679|OTHER|Abdominal massage|"Application time of the massage: 30 minutes after meals, twice a day, at 10:00 in the morning and at 16:00 in the evening.~Application time of the massage: 15 minutes each Materials needed: Gloves, Liquid Vaseline, Paper Towel Massage methods used: Efflorage, Petrissage, Vibration"
215021775|NCT00889005|OTHER|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
215021776|NCT03452345|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
215021777|NCT03452345|DRUG|Placebo|Placebo (Normal saline)
215021778|NCT00003151|DIETARY_SUPPLEMENT|bismuth subcitrate|
215021779|NCT00003151|DRUG|amoxicillin|
215021780|NCT00003151|DRUG|clarithromycin|
215021781|NCT00003151|DRUG|metronidazole hydrochloride|
215021782|NCT00003151|DRUG|omeprazole|
215021783|NCT00003151|DRUG|tetracycline hydrochloride|
215021784|NCT00128492|DRUG|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
215021785|NCT00612768|BIOLOGICAL|TRUE Test allergens Fragrance Mix and Thimerosol|"* Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~* Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~* Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~* Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
215021786|NCT02166762|PROCEDURE|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
215021787|NCT02822690|OTHER|Hospice care at UMCG|introduction of hospice care facilities on the wards at the UMCG
215021788|NCT03476252|DIAGNOSTIC_TEST|pentraxin 3|serum pentraxin 3 level will be assessed using ELISA kits
215021789|NCT04629157|DEVICE|Innova Lateral Flow Device|The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
215021790|NCT04394000|OTHER|thromboprofylaxis protocol|This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
215021791|NCT04394000|OTHER|standard protocol|This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
215021792|NCT05209737|PROCEDURE|Trendelenburg position|A 10-degree head-down position will be used in this group
215021793|NCT05209737|PROCEDURE|Semirecumbent position|A 30-degree head-up position will be used in this group
215021794|NCT05657171|DRUG|cyproterone Acetate/Ethinyl Estradiol Combination|cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
215021795|NCT03956082|DEVICE|Ultravision™ Visual Field Clearing System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
215021796|NCT03956082|DEVICE|Ultravision Ionwand™|The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
215021797|NCT03823885|OTHER|e-cigarette|use e-cig for 30 minutes
215021798|NCT03823885|OTHER|empty (-cigarette sham control)|use empty e-cig (sham control)
214690337|NCT06257238|DEVICE|Fully immersive Head-Mounted Display Virtual Reality|patients are asked to wear the Oculus Quest VR on their heads and to hold the hand controllers by their hands and start the game exercises (Dance loop, Tennis ball and Boxing) with 10 min. for each game with 1 min. rest in between, plus the traditional PT program:(Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
214690338|NCT06257238|BEHAVIORAL|Traditional Physical Therapy Program|patients are treated with Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles, 2 sessions per week for 2 months.
214690339|NCT06316622|DEVICE|ultrasound|measured by ultrasound
214690340|NCT02379741|BIOLOGICAL|ADC-1013|Agonistic human monoclonal IgG1 anti-CD40 antibody
214422364|NCT03814265|BEHAVIORAL|Laughter yoga|440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
214422365|NCT05499039|DEVICE|High flow nasal cannula (HFNC)|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%"
214507015|NCT04250545|DRUG|Sapanisertib|Given PO
214690341|NCT02283606|DEVICE|Accuvix SnonAce UGEO|vaginal ultrasonography
214690342|NCT04757779|DRUG|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach.Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle),the dose of anlotinib can be adjusted as 12mg,10mg or 8mg according to adverse effects.On Day1 and Day8, subjects are required to inject irinotecan (65mg/m2)or docetaxel (60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
215102753|NCT05169411|DIAGNOSTIC_TEST|Urine protein|Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
215102754|NCT05913024|BIOLOGICAL|Enterovirus Type 71 Vaccine|Participants received two doses of the vaccine, 28 days apart
214507016|NCT04250545|DRUG|Telaglenastat Hydrochloride|Given PO
214507017|NCT05269394|DRUG|E2814|Administered intravenously in a blinded fashion
214507018|NCT05269394|DRUG|Lecanemab|Administered intravenously
214507019|NCT05269394|DRUG|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
214507020|NCT05658497|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
214507021|NCT05658497|DRUG|Avonex|Administered as specified in the treatment arm.
214507022|NCT05658497|BIOLOGICAL|Tysabri|Administered as specified in the treatment arm.
214507023|NCT05658497|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
214507024|NCT06133075|DRUG|Mirabegron 50 MG|10 patients will receive drug for 8 weeks
214507025|NCT06133075|DRUG|Mirabegron 25 MG|10 patients will receive drug for 8 weeks
214507026|NCT06772246|DRUG|Quizartinib|Participants will receive a single oral dose of 90 mg
214507027|NCT06772246|OTHER|Placebo|Participants will receive a single oral dose of 90 mg
214507028|NCT02678182|DRUG|Capecitabine|1250 mg/m2/day, 21 day cycle
214507029|NCT02678182|DRUG|MEDI4736 (Durvalumab)|IV treatment on days 1\&15 of 28 day cycle
214507030|NCT02678182|DRUG|Trastuzumab|6mg/kg on day 1 cycle every 21 days
214507031|NCT02678182|DRUG|Rucaparib|600mg PO twice daily
214507032|NCT02678182|DRUG|Ramucirumab|ramucirumab 8mg/kg IV day 1 and day 8
214507033|NCT03156816|DRUG|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
214507034|NCT03156816|DRUG|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
214507035|NCT05993754|OTHER|Non-pharmacological intervention|"The intervention consists of six main elements:~Correction of sensory deficits: Before surgery, the use of glasses, hearing aids and/or removable dental prostheses will be allowed, which will be removed before starting anesthesia in the emergency room. After surgery, they will be delivered back to the user.~Reorientation: In the postoperative period, the person will be informed where they are and the visit of the companion will be coordinated.~Early mobilization: A protocolized mobilization routine will be applied according to pain, state of consciousness, risk of thromboembolic disease and risk of falls.~Environmental management: You will be shown the time on a clock, it will reinforce the idea of the place where you are and that you can count on the team in case you need assistance.~Sleep protocol: The elderly person who does not want or cannot perform the mobilization routine, non-pharmacological sleep will be privileged.~Reduction of anticholinergic drugs"
214507036|NCT05452681|OTHER|Educational Intervention|Receive Y-AMBIENT
214507037|NCT05452681|OTHER|Quality-of-Life Assessment|Ancillary studies
214507038|NCT05452681|OTHER|Questionnaire Administration|Ancillary studies
214507039|NCT05452681|OTHER|Control Intervention|Receive cookbook and socialization calls
214507040|NCT05630807|DRUG|Bepirovirsen|Bepirovirsen will be administered.
214507041|NCT05630807|OTHER|Placebo|Matching placebo will be administered.
214507042|NCT06439329|BEHAVIORAL|Standard PN|Standard of care
214507043|NCT06439329|BEHAVIORAL|Patient Choice|Participants can select from a menu of options including brick and mortar services, Mobile Health Unit (MHU) or telehealth services.
214507044|NCT01690416|PROCEDURE|Traditional palpation technique|
214422366|NCT05499039|DEVICE|Non-Invasive Mechanical Ventilation (NIV)|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation"
214422367|NCT03932188|BEHAVIORAL|Mental Health Assessments and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
214422368|NCT03932188|DEVICE|MRI scan|Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
214422369|NCT01967186|PROCEDURE|Intraportal islet transplantation|
214422370|NCT01967186|PROCEDURE|Intramuscular islet transplantation|
214422371|NCT01967186|PROCEDURE|Intramuscular transpl with stemcells|
214422372|NCT01967186|PROCEDURE|Kidney transplantation|All patients will undergo kidney transplantation regardless of arm
214422373|NCT02048592|DIETARY_SUPPLEMENT|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support \|(Nutridrink) for another 8 weeks."
214422374|NCT02048592|DIETARY_SUPPLEMENT|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
214422375|NCT02806518|PROCEDURE|DIRT|An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
214507045|NCT01690416|PROCEDURE|Ultrasound DNTP|
214507046|NCT00741546|PROCEDURE|Cardiac Surgery|Cardiac Surgery
214507047|NCT02831816|DRUG|ZuraPrep|Apply topically.
214422376|NCT01522092|DRUG|escitalopram|5mg-20mg, tablet, od, 12 months
214422377|NCT01664871|DEVICE|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
214507048|NCT02831816|DRUG|ChloraPrep|Apply topically.
214507049|NCT02831816|DRUG|ZP Vehicle|Apply topically.
214507050|NCT06623669|BEHAVIORAL|MORPH|A remote behavioral intervention combining coaching and digital health tools to improve diet and activity behaviors.
214507051|NCT06623669|BEHAVIORAL|Measurement Only|This intervention entails receipt of a body weight scale and wearable activity monitor.
214507052|NCT04587648|OTHER|NA, observational study|NA, observational study
214507053|NCT05527613|OTHER|whatsapp application with oral hygiene reminder for orthodontic patients|Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
215021799|NCT01197274|DEVICE|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
215021800|NCT00460915|DRUG|Lacidipine & Amlodipine|
215021801|NCT03479684|OTHER|Gene-directed dosage of warfarin|the first day given model prediction dose \* 1.5 times（\<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
215021802|NCT03479684|OTHER|standard dosage of warfarin|the first day given 4.5mg; adjusted dose based on INR from the second day
215021803|NCT01201044|DRUG|Gemcitabine, Nedaplatin, iV|Gemcitabine, Injection, 1000mg/m2, D1 \& D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
215021804|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
215021805|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
215021806|NCT01201044|DRUG|Gemcitabine，Nedaplatin, BAI|"Drug: Gemcitabine, Nedaplatin, iV~Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI"
215021807|NCT06168006|BEHAVIORAL|Exercise|The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.
215021808|NCT06168006|BEHAVIORAL|Control|They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.
215021809|NCT00636337|BEHAVIORAL|Attention Training|Computer program training for attention difficulties.
215021810|NCT00636337|BEHAVIORAL|Placebo|Comparison computer program
215021811|NCT05186298|DEVICE|AcrySof® IQ PanOptix®|The AcrySof IQ PanOptix® (Alcon) mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL
215021812|NCT05186298|DEVICE|Synergy®|The TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing far vision comparable to an aspheric monofocal IOL. Compared to an aspheric monofocal IOL, the lens provides significantly improved intermediate and near vision, including in low-light conditions.
215021813|NCT05186298|PROCEDURE|Cataract Surgery|IOL implantation will be performed
215021814|NCT01313325|OTHER|Hippotherapy|Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
214422378|NCT02561871|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 in Group 2.
214422379|NCT02561871|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 85 in Group 2.
214422380|NCT02561871|DRUG|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
214422381|NCT01340261|BEHAVIORAL|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
214422382|NCT00768664|DRUG|PF-00299804|45 mg by continuous oral dosing
214422383|NCT00939419|OTHER|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
214422384|NCT00939419|OTHER|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
214422385|NCT00939419|OTHER|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
214422386|NCT03926884|DIETARY_SUPPLEMENT|Three-seeds mixture|mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
214422387|NCT03926884|DIETARY_SUPPLEMENT|Control|warm water with negligible amount of the three-seeds mixture
214422388|NCT00484614|PROCEDURE|Positron Emission Mammography|Molecular Imaging Device
214422389|NCT00484614|PROCEDURE|Magnetic Resonance Imaging|Imaging Device
214422390|NCT03656094|DRUG|Pembrolizumab plus chemotherapy|Pembrolizumab plus chemotherapy
214422391|NCT03656094|DRUG|Placebo plus chemotherapy|Placebo plus chemotherapy
214507054|NCT00951691|BEHAVIORAL|Enhanced acute medical rehabilitation|"Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data."
214507055|NCT00951691|BEHAVIORAL|Treatment as usual|Standard treatment with physical and occupational therapies
214507056|NCT03185052|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
214507057|NCT01194011|BEHAVIORAL|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
214507058|NCT00527267|DRUG|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
214507059|NCT00527267|DRUG|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
214422392|NCT01324453|PROCEDURE|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
214422393|NCT01324453|PROCEDURE|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
214422394|NCT00096967|DRUG|Avastin (bevacizumab)|
214422395|NCT02042898|OTHER|Restrictive Transfusion Strategy|
214422396|NCT02042898|OTHER|Liberal transfusion strategy|
214422397|NCT00015990|DRUG|thalidomide|Given orally
214422398|NCT00015990|OTHER|laboratory biomarker analysis|Correlative studies
214422399|NCT02675309|DRUG|MT-8554|
214422400|NCT02675309|DRUG|rosuvastatin|
214422401|NCT02675309|DRUG|simvastatin|
214507060|NCT02727205|DRUG|Rotigotine Transdermal System|
214507061|NCT00968903|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
214507062|NCT01218594|DRUG|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
214507063|NCT05895578|DIETARY_SUPPLEMENT|Probiotic|1 capsule of probiotic (Lactobacillus CECT 9422 + Bifidobacterium CECT 30257) every 12 hours for 6-months.
214507064|NCT05895578|DIETARY_SUPPLEMENT|Probiotic + placebo|1 capsule of probiotic + 1 capsule of placebo per day for 6-months.
215021815|NCT05073731|OTHER|Telerehabilitation-based Upper Extremity Training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training."
215021816|NCT05704699|BEHAVIORAL|eTRE|eating between 0800h and 1600h daily
215021817|NCT05704699|BEHAVIORAL|eTRE with BISC|eating between 0800h and 1600h daily and completing 3 sessions of BISC per week of study duration
215021818|NCT00692237|DRUG|Sildenafil|100 mg daily (3 capsules/day)
214422402|NCT04730999|DRUG|Etoposide|Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
214422403|NCT04730999|DRUG|Carboplatin|Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
214507065|NCT05895578|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo every 12 hours for 6-months.
214507066|NCT00708266|DEVICE|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
215021819|NCT00692237|DRUG|Placebo|Placebo 100 mg (3 capsules/day)
215021820|NCT03003065|DRUG|Temoporfin|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
215021821|NCT02969226|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
215021822|NCT02969226|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
215021823|NCT02969226|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS \>0 and =\< 8 cm H2O with PEEP\>0 and =\< 5 cm H2O
215021824|NCT02969226|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
215021825|NCT02475863|DEVICE|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
215021826|NCT02475863|OTHER|Standard Practice|Warfarin dose adjustments according to standard unit protocol
215021827|NCT04045145|DRUG|Crinecerfont|Crinecerfont administered orally for 14 consecutive days.
214507067|NCT00708266|DIETARY_SUPPLEMENT|Intralipid 20%|"Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits."
214507068|NCT00708266|OTHER|0.9% Saline Solution|"0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits."
214507069|NCT00452114|DEVICE|In-Exsufflator Cough Assist Device|
214507070|NCT00452114|DEVICE|Active Comparator: Flutter Valve Device|Active Comparator
215021828|NCT02594072|RADIATION|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
214422404|NCT04730999|DRUG|Bevacizumab|"Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal."
214422405|NCT04730999|DRUG|Atezolizumab|"Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit."
214422406|NCT05790096|BIOLOGICAL|Granulokine|Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
214422407|NCT05790096|BIOLOGICAL|Filgrastine|Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
214422408|NCT05505071|DEVICE|DANTE SPACE sequence|investigational MRI sequence less than 15 minutes
214690343|NCT03136757|OTHER|Transcriptomic analysis of GVHD biopsies|"The transcriptomic analysis of GVHD biopsies aims at:~* to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier~* to identify new intracellular signaling pathways that could lead to new therapeutic"
215021829|NCT02594072|RADIATION|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
215021830|NCT02594072|DRUG|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
215021831|NCT01358305|OTHER|Protein Blend|Single intake of approximately 20 grams of total protein
215021832|NCT04742023|DEVICE|Continuous Glucose Monitor Application|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied and values interpreted by nursing.
215021833|NCT04742023|DIAGNOSTIC_TEST|Finger Stick Glucose Measurement|Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.
215021834|NCT04742023|DRUG|Insulin|Insulin will be administered.
215021835|NCT04742023|DEVICE|Continuous Glucose Monitor Placebo Applied|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied however values will not be interpreted.
215021836|NCT02579057|DRUG|Furosemide Injection Solution (SCP-101)|
215021837|NCT02579057|DRUG|Furosemide Injection Solution, USP|
214690344|NCT03264482|PROCEDURE|M-TURP|endoscopic resection of the prostatic adenoma
214690345|NCT03264482|PROCEDURE|THUVAP|vaporization of prostatic adenoma via THULIUM laser
214690346|NCT05428358|DIAGNOSTIC_TEST|Preoperative MRI|Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
214690347|NCT06502964|DRUG|ALTO-101|ALTO-101 patches
214690348|NCT06502964|DEVICE|ALTO-101 Transdermal Delivery System|ALTO-101 transdermal delivery system
214422409|NCT06239948|OTHER|With Music|each subject was placed in a TMS laboratory with music for 20 minutes
214422410|NCT06239948|OTHER|Without Music|each subject was placed in a TMS laboratory without music for 20 minutes
214422411|NCT05263609|DRUG|Axitinib|If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
214422412|NCT05263609|DRUG|Pembrolizumab|If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
214507071|NCT06156176|OTHER|COVIDEx|The COVIDEx intervention was developed by triangulating patient preferences/needs, clinicians' expertise, and best current evidence specific to Long COVID and adapted from interventions for other complex fatigue disorders, which are consistent with evidence informed practice. The program is delivered by trained instructors and comprises of two 50-minute sessions each week for eight weeks. The intervention is designed to be delivered virtually in groups of 6 patients, to eliminate travel requirements for the study. The components of the program are: (i) warm-up (1 min), (ii) cardio training (5 min), (iii) rest (3 min), (iv) balance training (5 min), (v) breathing exercises (3 min), (vi) cognitive training (5 min), (vii) strengthening training (5 min), and (viii) stretching (10min). The COVIDEx program will be paced in order to prevent post-exertional malaise (PEM) in participants.
214507072|NCT06988774|PROCEDURE|chromopertubation|Pre- and post-myomectomy chromopertubation procedure using dilute methylene blue dye solution for evaluation of tubal occlusion
214507073|NCT06992076|DRUG|Marstacimab|the first visit (V1) is scheduled on the day of the first administration of marstacimab. The recommended dosing frequency for the patient should follow the instructions provided, which are as follows: On Day 1, administer 300 mg subcutaneously (divided into two injections, each 150 mg) (loading dose); starting from Day 8, administer 150 mg subcutaneously once a week. Record the patient's prescription recommendations, actual treatment records (administration time, dosage, frequency), and adherence rates. Visit 2 (V2) and visit 3 (V3) are defined as 30 days (±7 days) and 180 days (±30 days) after the initiation of marstacimab treatment, respectively.
214507074|NCT04060758|DRUG|PA5108 Latanoprost FA SR Ocular Implant|Ocular Implant
214690349|NCT06502964|DRUG|Placebo|Inactive placebo patches
214690350|NCT06502964|DEVICE|Placebo Transdermal Delivery System|Placebo transdermal delivery system
214690351|NCT05574647|DIAGNOSTIC_TEST|bpMRI|biparametric MRI takes 30-40 minutes and requires a contrast injection called gadolinium (like a dye). This is also called long MRI and is most commonly used in the NHS.
214690352|NCT05574647|DIAGNOSTIC_TEST|Image-Fusion targeted and systematic Biopsy|During image fusion targeted biopsy, the biopsy operator uses the MRI scans that were taken beforehand but laid on top of the live ultrasound images during the biopsy. This uses software and takes a few minutes longer to perform. Once the MRI images and ultrasound images are 'fused', the actual biopsies are taken as normal.
214690353|NCT04342715|DRUG|Sodium stibogluconate / paramomycin|Treatment with Sodium stibogluconate / paramomycin
214690354|NCT05735717|DRUG|Fludarabine|Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
214690355|NCT05735717|DRUG|Busulfan|Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5
214690356|NCT05735717|DRUG|Melphalan|Melphalan 50 mg/m2 IV on days -4 to -2
214690357|NCT05735717|DRUG|Rituximab|200 mg/m2 intravenous given once on day-1
214690358|NCT05735717|DRUG|Levetiracetam|As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
214690359|NCT05735717|BIOLOGICAL|Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells|Patients will be treated on the most medically appropriate regimen followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
214690360|NCT05735717|DRUG|Thymoglobulin|rabbit anti-thymocyte globulin (rATG). Used in conditioning regimens for in vivo depletion of T cells, and the use of fludarabine model-based dosing to optimize dosing.
214690361|NCT05735717|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV over 2 hours on days -3 and -2
214690362|NCT05619497|OTHER|Clinic-wide Trainings|The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.
214694140|NCT04188340|BEHAVIORAL|Su-Man formula massage oil|bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
214694141|NCT03003143|DRUG|Vigabatrin 500 MG|
214694142|NCT00333268|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
214694143|NCT00333268|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
214694144|NCT01137331|DRUG|K301|Liquid- applied once daily prior to bed
214694145|NCT01137331|DRUG|Placebo|Liquid- applied once daily prior to bed
215102755|NCT03054324|DIAGNOSTIC_TEST|Fractional Flow Reserve|Coronary fraction flow reserve (FFR), the ratio of the mean coronary pressure distal to a coronary stenosis to the mean aortic pressure during maximal coronary blood flow (hyperemia), defines the hemodynamic significance of coronary artery narrowing.
215102756|NCT03851055|DRUG|Zinc|One arm will receive Zinc Second arm will receive placebo
215102757|NCT00548899|DRUG|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
215021838|NCT00934388|PROCEDURE|Pre peritoneal mesh placement|
215021839|NCT00934388|PROCEDURE|Laparoscopy|
214690363|NCT05619497|OTHER|Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST)|"The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.~The DST is founded on principles of decision-science and will address barriers to PrEP delivery. The DST will present HIV prevention information through a tablet in the clinical setting. The tool provides information about vulnerabilities to HIV and core characteristics of different HIV prevention methods, and the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The tool emphasizes the highly variable and individual nature of baseline risk."
214690364|NCT05619497|OTHER|Standard Care with the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma informed care. These participants will view the decision support tool. These participants were recruited in Aim 1 of this study.
214690365|NCT05562037|OTHER|Stepped Care|Patients meeting a non-response criterion will be stepped up to the next step
214422413|NCT01012453|BEHAVIORAL|A randomised clinical trial of the effect of classification and individual counselling|The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
214422414|NCT00708032|DEVICE|spectacles|habitual spectacles
214507075|NCT06538090|BEHAVIORAL|Early Movers|The intervention includes: 1) an educational resource (i.e., hard-copy handout) developed for this study on the 24-Hour Movement Guidelines provided to parents at 2-month immunization appointments by public health nurses, who will answer any questions, followed by a discussion with research staff. 2) Follow-up support via access to a digital app with evidence-based information and support through an online toolkit, an anonymous forum, as well as weekly text messages that include tips and supportive messaging related to the guidelines.
214690366|NCT04188873|DRUG|Preparation Varenicline and Standard Duration Varenicline|16 weeks of varenicline starting 4 weeks pre-quit
214690367|NCT04188873|DRUG|Preparation Varenicline and Extended Duration Varenicline|28 weeks of varenicline starting 4 weeks pre-quit
215102758|NCT00559988|DRUG|Home Monitoring Guided OAC|"Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
214690368|NCT04188873|DRUG|Standard Duration Varenicline|12 weeks of varenicline
214690369|NCT04188873|DRUG|Extended Duration Varenicline|24 weeks of varenicline
214690370|NCT04188873|DRUG|Preparation Combination NRT and Standard Duration Combination NRT|16 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
214690371|NCT04188873|DRUG|Preparation Combination NRT and Extended Duration Combination NRT|28 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
214690372|NCT04188873|DRUG|Standard Duration Combination NRT|12 weeks of nicotine patch + nicotine mini-lozenge
214690373|NCT04188873|DRUG|Extended Duration Combination NRT|24 weeks of nicotine patch + nicotine mini-lozenge
215102759|NCT00559988|DRUG|Physician-Directed OAC|"Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
214422415|NCT00708032|DEVICE|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
214422416|NCT01400776|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
214690374|NCT04188873|BEHAVIORAL|Intensive Counseling|4 phone or video counseling sessions
214422417|NCT01400776|DRUG|Vehicle|Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
214422418|NCT01807546|DRUG|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
214422419|NCT02624219|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
214422420|NCT02624219|DRUG|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
214690375|NCT04188873|BEHAVIORAL|Minimal Counseling|2 brief phone or video counseling sessions
214694146|NCT01680094|DRUG|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
215021840|NCT03975179|PROCEDURE|Omission of intraoperative frozen section biopsy for margin status|Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
215021841|NCT03975179|PROCEDURE|Frozen section biopsy for margin status|Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
215021842|NCT01347086|DRUG|Matching placebo (low dose)|single dose of matching placebo
215021843|NCT01347086|DRUG|BI 207127 NA (medium dose)|Single does of BI 207127 NA
215021844|NCT01347086|DRUG|BI 207127 NA (low dose)|single dose of BI 207127 NA
215021845|NCT01347086|DRUG|Matching placebo (medium dose)|Single dose of matching placebo
215021846|NCT01347086|DRUG|BI 207127 NA (high dose)|Single dose of BI 207127 NA
214422421|NCT02624219|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
214422422|NCT00002450|DRUG|Tenofovir disoproxil fumarate|
214422423|NCT05783726|OTHER|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
214422424|NCT05783726|BEHAVIORAL|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
214422425|NCT05783726|BEHAVIORAL|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
214422426|NCT05783726|BEHAVIORAL|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
214422427|NCT05223205|PROCEDURE|Air|Test if air is sufficient for macular hole closure.
214422428|NCT05223205|PROCEDURE|10% SF6 and 90% air|Test if 10% SF6 and 90% air is sufficient for macular hole closure.
214422429|NCT03648346|DRUG|Cohort 1: HL217 Ophathalmic Solution BID|Two drops of 3 mg/mL of the treatment in one eye twice a day
214507076|NCT06860295|DIAGNOSTIC_TEST|Single Cell RNA Sequencing|"Reprocessing~Data normalization, dimensionality reduction, and clustering will be performed using the Seurat package (based on R).~Cell types will be identified based on canonical marker gene expression. Cell Subpopulation Identification~Clusters will be annotated based on signatures of known cell types (e.g., endothelial cells, smooth muscle cells, macrophages, etc.).~Differential gene expression analysis will be conducted to identify disease-associated genes.~Pathway and Function Enrichment~Gene Set Enrichment Analysis (GSEA) and pathway analyses (e.g., KEGG, Reactome) will be carried out to investigate the biological processes and pathways driving atherosclerosis.~Quality Control~Sequencing reads will be assessed for quality using FASTQC, and low-quality reads will be filtered out.~The Cell Ranger software (10x Genomics) will be used to align reads to the human genome and quantify gene expression at the single-cell level."
215021847|NCT01347086|DRUG|Matching placebo (high dose)|Single dose of matching placebo
215021848|NCT01366274|OTHER|Protective manual hyperinflation|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
214422430|NCT03648346|DRUG|Cohort 2: HL217 Ophathalmic Solution QID|Two drops of 3 mg/mL of the treatment in one eye 4 times a day
214422431|NCT03648346|DRUG|Placebo|Placebo eye drops
214422432|NCT00837746|DRUG|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
214422433|NCT02174393|DRUG|Universal Peel|Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
214422434|NCT02174393|PROCEDURE|Microneedling|"Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.~For this protocol, the needle depth will be increased over the 3 sessions:~Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.~Each Session: Microneedling procedure on Day 1, followed by skin care regimen"
214422435|NCT02174393|DRUG|Post-Microneedling Skin Care|"On Day 1 (after Microneedling procedure):~* Gentle Antioxidant Soothing Cleanser daily~* Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~* AM: Physical sheer sunscreen and recovery ointment~* PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~* AM: BD Hydrating Day/Night Cream~* PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)"
214422436|NCT02174393|DRUG|Post-Universal Peel Skin Care|"* Gentle Antioxidant Soothing Cleanser daily~* Physical Sunscreen daily~* Soothing recovery ointment fortified with silver only when peeling occurs~* After completely peeling, vitamin c product in the morning and the retinol in the evening"
214422437|NCT01314352|DRUG|Desloratadine|Desloratadine Tablets, 5 mg
214422438|NCT04399148|DRUG|Desloratadine 5 mg|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
215021849|NCT01366274|OTHER|Usual method of MHI|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
214422439|NCT04399148|DRUG|Aprepitant 125 mg|Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
214422440|NCT04399148|DRUG|Ketotifen 1 MG|Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
215021850|NCT03373669|BIOLOGICAL|Oral Cholera Vaccine|Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.
215021851|NCT03373669|BIOLOGICAL|Adjusted Dose Oral Cholera Vaccine|The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
215102760|NCT04741672|BEHAVIORAL|Providing guidance after discharge routine procedure and calling one week after discharge.|Guidance will be given to mothers after routine discharge. After one week, she will be called by phone and her questions about infant care will be answered.
215102761|NCT04741672|BEHAVIORAL|Discharge routine procedure.|Discharge routine procedure.
215102762|NCT04942782|OTHER|lumbopelvic stabilization exercises|the patients will receive lumbopelvic stabilization in the form of three parts: 1 Segmental control over primary stabilizers (mainly TrA, deep multifidus, pelvic floor and diaphragm) 2-Exercises in closed chain, with low velocity and low load 3-Exercises in open chain, with high velocity and load
214422441|NCT02797717|RADIATION|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
214422442|NCT02797717|DRUG|Vincristine|ARM A and ARM B
214422443|NCT02797717|DRUG|Etoposide|ARM B , 100mg/m2/day
214422444|NCT02797717|DRUG|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
214422445|NCT02797717|DRUG|Doxorubicin|ARM B , 25mg/m2
214422446|NCT02797717|DRUG|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
214422447|NCT02797717|DRUG|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
214422448|NCT00212745|BEHAVIORAL|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
214422449|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
214422450|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
214422451|NCT03315884|PROCEDURE|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)|"Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used."
214422452|NCT03315884|PROCEDURE|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch|Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
214507077|NCT06616779|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal insulin algorithm is to maintain blood glucose (BG) within acceptable targets according to the predefined health status. For a limited time period after therapy start, three BG measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status. Nurses and nursing assistants will be trained in the use of the GlucoTab system.
214507078|NCT06616779|OTHER|Diabetes Treatment|Diabetes Standard Care
214507079|NCT06993155|DRUG|Leflutrozole, Dose 1|Leflutrozole, Dose 1 once weekly for 16 weeks
214690376|NCT05112458|OTHER|Cope 360 mobile health application|Cope 360 is a mHealth (mobile health) app designed to support caregivers of children with cancer with symptom tracking, medication management, and emergency preparedness. We will evaluate Cope 360 via a pilot, randomized control trial in which some caregivers will receive the app and some will not. The purpose of this study is to assess: 1) feasibility of caregiver use over extended period of time, 2) acceptability of the mHealth tool by caregivers in a real-world setting, 3) impact of the mHealth tool on caregiver self-efficacy, mastery of caregiving skills/knowledge, and caregiver stress, and 4) effect on healthcare utilization of the child with cancer (i.e. preliminary data about sick visits and ED encounters).
214422453|NCT01227278|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
214422454|NCT01227278|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
214422455|NCT03109223|OTHER|sole source nutrition|Infant formula
214422456|NCT02468297|DEVICE|Electronic Acupunture Shoes|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy."
214507080|NCT06993155|DRUG|Leflutrozole, Dose 2|Leflutrozole, Dose 2 once weekly for 16 weeks
214507081|NCT06993155|DRUG|Leflutrozole, Dose 3|Leflutrozole, Dose 3 once weekly for 16 weeks
214507082|NCT06993155|DRUG|Placebo|Placebo once weekly for 16 weeks
214507083|NCT06861660|BEHAVIORAL|Digitally Prompted Parenting|Parents will receive an email invitation to sign up for Digitally Prompted Parenting, a text message-delivered PBI. Parents set up an account and input information about themselves and their student, which will customize the text messages they receive. Parents will receive at least two text prompts per week for the first 10 weeks of their student's first semester in college. These texts will (1) prompt parents to call their student to discuss the past week and week ahead, and (2) prompt parents to send an alcohol-specific risk reducing text to their student.
215102763|NCT04942782|OTHER|pilates exercise|the patient will receive pilates exercise in the form of Breast stroke prep, Side leg lift series, One leg circle, Hundreds, Shoulder bridge, and Spine stretch forward
215102764|NCT04942782|OTHER|conventional therapy|Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance
214422457|NCT02468297|DRUG|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
214422458|NCT00423098|DRUG|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
214690377|NCT05112458|OTHER|Usual care|Caregivers of children with cancer will receive the usual clinical care provided to our patient population.
214422459|NCT00423098|DRUG|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
214422460|NCT00423098|DRUG|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
214422461|NCT06020963|PROCEDURE|Low Intensity Shockwave Therapy (LiSWT)|Low Intensity Shockwave Therapy (LiSWT) has been used for many years. Its mechanism is to use shock wave energy to promote angiogenesis to achieve the functions of tissue repair and cell regeneration.
214422462|NCT06020963|DRUG|Tamsulosin|Tamsulosin is a selective alpha-1 blocker, its main function is to relax the smooth muscles of the base of the prostate, urethra, and bladder, and improve lower urinary tract symptoms.
214422463|NCT01639638|DRUG|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
214422464|NCT04184336|OTHER|surveillance|
214422465|NCT05747495|OTHER|Online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link \[https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/\]."
214422466|NCT01012388|DEVICE|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
214690378|NCT00660504|DRUG|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
214690379|NCT00660504|DRUG|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
214690380|NCT06286956|DEVICE|Treatment of rectal lesions with UNI-VEC|Polyp resections
214690381|NCT06524999|BEHAVIORAL|Progressive muscle relaxation|This intervention consists of two parts. The first part gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are relaxation exercises accompanied. Both the briefing and the intervention lasted 30 minutes for each patient.
214690382|NCT04819100|DRUG|Selpercatinib|Administered orally.
214690383|NCT04819100|DRUG|Placebo|Administered orally.
215021852|NCT05306015|COMBINATION_PRODUCT|Mindfulness meditation based on brain-computer interface|"Before surgery, The nurses will teach and explain the methods and significance of meditation training. Let the patient be familiar with the function and background of this method, and explain the use of the headband during the operation, so that the patient believes that meditation training can relieve pain.~In surgery, Wear a brain-computer interface headband for the patient to collect EEG, monitor the patient's psychological changes, and provide real-time feedback.~The patient wears a Bluetooth headset, according to the patient's preferences, different types of music are selected, and voice playback guides the patient to prepare, relax muscles and regulate breathing.~APP judges the patient's meditation state based on EEG signals, and adjusts music, voice guidance.~The nurse will give personalized guidance based on the patient's specific situation and the EEG displayed on the APP to help the patient achieve a state of meditation and relaxation."
215021853|NCT05306015|COMBINATION_PRODUCT|Routine care|Give routine treatment and care, and increase or decrease the dose or adjust according to the patient's condition in accordance with the doctor's advice. Before surgery, we will introduce the level of medical care involved in the surgery and the equipment of our hospital. Inform the patient of the surgical process and possible pain, and explain in detail the cause, location and characteristics of the pain, including the time when the pain will appear and last. Instruct patients to stabilize their emotions and maintain a calm state of mind. As far as possible to meet the patient's intraoperative care needs, give psychological care, wear a headband to collect EEG signals, but do not intervene in mindfulness meditation.
215021854|NCT03232892|DRUG|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
215021855|NCT05272605|BIOLOGICAL|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
215021856|NCT05272605|BIOLOGICAL|SARS-CoV-2 beta variant RBD mRNA vaccine|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
215021857|NCT05272605|OTHER|Normal Saline|Placebo comparator
215021858|NCT03161496|GENETIC|detection of genotype|detection of genotype by next generation sequencing
215021859|NCT01424137|DEVICE|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
215021860|NCT01424137|DEVICE|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
215021861|NCT01424137|DEVICE|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
215021862|NCT06003647|OTHER|Educational Intervention|Educational module and video
215021863|NCT00395447|PROCEDURE|Straight-forward Device Replacement|
215021864|NCT00395447|PROCEDURE|Device Replacement with Upgrade|
215021865|NCT03536858|BEHAVIORAL|COACH (Communicating about Choices in Transplantation)|COACH is a behavioral communication intervention designed specifically for ESRD patients pursuing kidney transplantation. The COACH program consists of four modules: 1) Kidney transplant options, 2) Discussing your transplant options, 3) Requesting living donation, and 4) Maintaining positive relationships. The content and teaching strategies were guided by the concepts of social cognitive theory as well as principles of adult learning and communication skill acquisition. We believe that patients will transfer these skills to other patients at the hemodialysis clinic who are on their shift.
215021866|NCT05293002|DEVICE|Restorer Iliac Stent System|Not applicable (only one intervention)
214422467|NCT04035668|DRUG|Remibrutinib|Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.
214422468|NCT04035668|DRUG|Placebo|Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
214422469|NCT05686434|DRUG|Osimertinib|This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
214422470|NCT04651881|DRUG|Reference drug|1 Cap., single oral administration under fed condition
215021867|NCT05818930|DIAGNOSTIC_TEST|REMI|Diagnostic monitoring
215102765|NCT00653081|PROCEDURE|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
215102766|NCT00653081|PROCEDURE|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
214422471|NCT04651881|DRUG|Test drug 1|1 Tab., single oral administration under fed condition
215102767|NCT02249182|DRUG|LDV/SOF|LDV/SOF FDC administered orally once daily
215102768|NCT02249182|DRUG|RBV|Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
215102769|NCT01455194|DRUG|Ciclesonide|During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
214422472|NCT04651881|DRUG|Test drug 2|1 Tab., single oral administration under fed condition
214422473|NCT05516004|DEVICE|PXL Platinum 330 system|to determine the efficacy of riboflavin solution and UV light to treat cornea thinning conditions
214422474|NCT00014794|DRUG|15-O labeled water|
214422475|NCT05673252|DIAGNOSTIC_TEST|Venous blood sample|Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
214422476|NCT05673252|PROCEDURE|biopsy|histopathology findings
214422477|NCT04528706|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
214422478|NCT06210334|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d3, q3w
214507084|NCT06861660|BEHAVIORAL|Active Control|Parents will receive an email that explains the Parent Handbook intervention and includes a link to a website where the Handbook is embedded. They will also receive three booster emails summarizing the key points of the intervention. Parents can review both the Parent Handbook and the booster emails at their own pace.
214690384|NCT02668237|OTHER|OptiPAC|Molecular and urinary tests.
215021868|NCT03851952|DEVICE|Optilume Drug Coated Balloon|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
215021869|NCT02090894|DEVICE|UV Light (Laser Genesis)|
215021870|NCT00111735|DRUG|Thyroxine|
214422479|NCT06210334|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg), po, qd
214422480|NCT04618757|BEHAVIORAL|Hedonic Reward|A reimbursement credit for hedonic expenses worth up to $50 will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
215021871|NCT06154850|OTHER|Immersive virtual reality|Oculus Quest 2 will be used with NatureTrek application for 10 minutes.
214422481|NCT04618757|BEHAVIORAL|Cash Reward|A reimbursement credit for $50 in cash will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
214422482|NCT04618757|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
214422483|NCT06552884|BEHAVIORAL|(Maternity Identity Development Training)|Monitoring the Effect of the Education Given to Parents According to Maternal Role Ability Theory on Maternal Role Mother-Baby and Father-Infant Attachment
214690385|NCT02668237|OTHER|Usual care|Antibiotics for prevention.
214690386|NCT04813042|BEHAVIORAL|Working Out Dads|"The WOD is a manualised group intervention underpinned by solution-focused therapy and social cognitive theories. Psychoeducation about the transition to fatherhood and its potential impacts on wellbeing and family relationships is provided. Fathers are encouraged to share practical ideas for managing stress, revisit previous strategies, validate what they are doing well, and explore solutions.~The group discussion is followed by a structured group fitness session provided by a personal trainer. This session focuses on body weight exercises, cardio-based activities, stretching, mobility and incidental activity.~Fathers in the WOD study arm receive 10 weeks of encouraging text messages - one each week during the intervention, and four in the weeks after. These will be sent via the WhatsApp group created for each WOD group. These text messages and the WhatsApp group are designed to facilitate fathers' active engagement with the intervention, and to maintain contact with each other."
215021872|NCT06154850|OTHER|Non-immersive virtual reality|Patients will watch a video including scenes from NatureTrek application on a screen.
215021873|NCT03111108|DRUG|EBR/GZR (50 mg/100 mg) FDC|One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
214422484|NCT03915340|DRUG|Propafenone|Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
214422485|NCT03915340|DRUG|Rytmonorm|Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
214422486|NCT00211913|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
214422487|NCT00211913|BIOLOGICAL|placebo|single IM dose
214422488|NCT00006505|DRUG|Islet Transplantation|Islet cell transplantation. This study will test whether a new islet transplant procedure will enable patients with type 1 diabetes mellitus to stop insulin therapy
214690387|NCT04813042|BEHAVIORAL|Usual care|The Usual Care arm, also known as 'Talking about being dad' comprises a telephone consultation with a qualified mental health professional. Topics including in this consultation include: (a) discuss family and fathering; (b) health and wellbeing; (c) mental health symptoms and conduct a risk assessment for suicidal ideation; (d) current supports and support needs; (e) provide referral options to telephone support services (PANDA; MensLine); and (f) encourage a general practitioner visit to discuss a mental health care plan.
215102770|NCT05553184|DRUG|Formoterol Fumarate 12 micrograms Inhalation Powder|At time 60 minutes, a total of 48 micrograms will be inhaled within 3 minutes: 4 inhalations of 12 micrograms of fumarate formoterol (Oxeze® Turbuhaler®).
215102771|NCT05553184|DRUG|Nicotinic Acid 50 MG Oral Tablet|a total dose of 1050 MG will be ingested. From time 0 to 180 minutes, doses of 150 MG will be repeated every 30 minutes.
215102772|NCT05553184|OTHER|Acute Cold Exposure|Participants will be fitted with a liquid-conditioned tube suit. The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
215102773|NCT05553184|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|PET imaging using C11-palmitate (time 90), C11-acetate (time 120) and F18-Fluorodeoxyglucose (FDG) (time 150)
214422489|NCT04544761|OTHER|Structured Interview|Structured interview with research staff about your experience living with spinal cord injury
214690388|NCT04117685|OTHER|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
214690389|NCT02572128|OTHER|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
214690390|NCT01245426|DRUG|GW870086 2mg|oral inhalation
214690391|NCT01245426|DRUG|GW870086 4mg|oral inhalation
215102774|NCT05553184|DIAGNOSTIC_TEST|Indirect calorimetry|will be repeated every hour, for 20 minutes, using Vmax29n.
215102775|NCT05553184|DIAGNOSTIC_TEST|dual-energy x-ray absorptiometry (DEXA scan)|Whole body scan
215102776|NCT05553184|PROCEDURE|Biopsy|After local anesthesia with 2% xylocaine without epinephrine, 100-200 mg of subcutaneous adipose tissue will be sampled by needle (14G) biopsy
215102777|NCT05553184|PROCEDURE|iv lines|for stable tracer perfusion and blood sampling
215102778|NCT05553184|PROCEDURE|Electromyogram (EMG)|Surface electrodes will be used to measure skeletal muscle activity and shivering intensity
215102779|NCT06292676|OTHER|skills retained for home birth delivery in emergency|skills on mannequin for home birth scenario in emergency
215102780|NCT06001619|DRUG|Prostate hyperplasia medication|The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.
215102781|NCT06001619|DRUG|LhRH-antagonist|The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
215102782|NCT02023047|DRUG|Nifedipine 12 mg coated suppositories|
214422490|NCT00168467|DRUG|Ramipril|
215021874|NCT00005038|BIOLOGICAL|aldesleukin|
215021875|NCT00005038|DRUG|histamine dihydrochloride|
215021876|NCT02035228|DEVICE|Abdominal Stimulation - low / early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the first half of exhalation"
215021877|NCT02035228|DEVICE|Abdominal stimulation - low/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the second half of exhalation"
215021878|NCT02035228|DEVICE|Abdominal Stimulation - low/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current throughout exhalation"
215021879|NCT02035228|DEVICE|Abdominal stimulation - med/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the first half of exhalation"
215021880|NCT02035228|DEVICE|Abdominal stimulation - med/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the second half of exhalation"
215102783|NCT00586976|DRUG|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
215102784|NCT00586976|DRUG|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
215102785|NCT00266682|DEVICE|Pacing Lead|
215102786|NCT01277484|DRUG|Decitabine|"1\. Dose finding study (cycle 1-cycle4)~* Indicated dose for 5 consecutive days every 28 days~* Cohort 1: 5mg/m2 of decitabine~* Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model"
215102787|NCT05856019|OTHER|J Stroke Myofascial Release|Group A will receive J stroke myofascial release on planter fascia (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
215102788|NCT05856019|OTHER|Ischemic Release on Gastrocnemius through Dry Cupping|Group B will ischemic release on gastrocnemius (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
214690392|NCT01245426|DRUG|GW870086 Placebo|oral inhalation
214690393|NCT01245426|DRUG|GW870086 1mg|oral inhalation
215021881|NCT02035228|DEVICE|Abdominal Stimulation - med/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current throughout exhalation"
214422491|NCT04666506|OTHER|Virtual reality|"The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog)."
214422492|NCT02284555|DRUG|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
214422493|NCT02320123|BEHAVIORAL|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
214422494|NCT04675944|DRUG|BIA 5-1058|200 mg (2 x 100 mg tablets), oral route
214422495|NCT04675944|DRUG|treprostinil|1 mg (1 extended-release tablet), oral route
214422496|NCT00422617|DRUG|Alefacept (Amevive)|
214422497|NCT01437358|OTHER|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
215021882|NCT02035228|DEVICE|Abdominal Stimulation - high/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current for the first half of exhalation"
215021883|NCT02035228|DEVICE|Abdominal Stimulation - high/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at hig stimulation current for the second half of exhalation"
215021884|NCT02035228|DEVICE|Abdominal Stimulation - high/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current throughout exhalation"
215021885|NCT06110195|DRUG|Xevinapant|Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.
215021886|NCT06110195|DRUG|Carboplatin|Given with radiation weekly for 7 doses.
214422498|NCT00432523|BIOLOGICAL|M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®|
214422499|NCT06048991|DIAGNOSTIC_TEST|Thermographic assessment|Patients will undergo a termographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
214422500|NCT06552325|BEHAVIORAL|Single Session Narrative Therapy|The proposed single session narrative therapy intervention has been widely implemented in walk-in therapy clinics in Ontario Province, Canada. In these clinics, 60-minute psychotherapy sessions, informed by narrative therapy, are available on a walk-in basis. The therapist collaborates with a patient to co-develop a useful and meaningful focus for the session and then engages the patient in conversation that is respectful but shifts their way of thinking about the presenting problem. The therapist highlights and documents the patient's values and skills and works with the patient to create an action plan. If the therapist identifies additional treatment needs, the patient is offered an external referral to specialty mental health services.
214422501|NCT06261372|BEHAVIORAL|The mindfulness meditation combined with progressive muscle relaxation training .|The first part is progressive muscle relaxation training. The second part is mindfulness meditation training.
214422502|NCT04480827|DRUG|Aramchol free acid tablet 600mg, single dose|Aramchol free acid tablet 600mg, single dose
214422503|NCT04480827|DRUG|Aramchol free acid tablet 300mg, bid|Aramchol acid tablet 300mg, bid for 12 days
214422504|NCT01767714|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
214422505|NCT01767714|DRUG|Plerixafor|0.24 mg/kg/day subcutaneous injection
214690394|NCT01245426|DRUG|GW870086 3mg|oral inhalation
214690395|NCT04161586|DRUG|Prilocaine Hydrochloride|Spinal Prilocaine for Ambulatory Surgery
215021887|NCT06110195|DRUG|Paclitaxel|Given with radiation weekly for 7 doses.
215021888|NCT06110195|RADIATION|Radiation Therapy|Radiation will be given together with paclitaxel and carboplatin for 7 weeks.
215021889|NCT02771145|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
215021890|NCT02771145|DEVICE|Soft contact lenses (SCL)|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.
215021891|NCT02771145|DEVICE|SCL preservative solution|Commercially available solution for rinsing soft contact lenses
215021892|NCT00879372|DRUG|tianeptine|tianeptine 12,5mg TID
215021893|NCT00879372|DRUG|Placebo|Placebo 12.5 mg TID
215021894|NCT01414647|DIETARY_SUPPLEMENT|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
214690396|NCT03834571|DRUG|Carboplatin|Given IV
214690397|NCT03834571|DRUG|Cisplatin|Given IV
214690398|NCT03834571|DRUG|Paclitaxel|Given IV
214690399|NCT03834571|PROCEDURE|Patient Monitoring|Undergo active monitoring
214690400|NCT03834571|RADIATION|Radiation Therapy|Undergo radiation
214422506|NCT01767714|DRUG|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
214422507|NCT06552663|DEVICE|CCTA|Coronary CT angiography
214422508|NCT01129232|DRUG|GAD-alum|20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
214422509|NCT01129232|OTHER|Placebo|Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
214690401|NCT05516901|PROCEDURE|The erector spinae plane block group|The probe should then slowly be moved laterally until the transverse process is visible. The 100 mm, 25-gauge needle should be inserted using an in-plane approach in the cephalad to caudal direction and advanced under ultrasound guidance towards the transverse process; once the needle tip is below the erector spinae muscle, a small bolus of local anesthetic should be given. The erector spinae muscle should be visualized, separating from the transverse process. After aspiration the local anesthetic (20 ml of 0.25% bupivacaine was injected. Technique was repeated on the other side.
214422510|NCT05572801|DIAGNOSTIC_TEST|AMR B: HPV positive ctDNA guided imaging in follow-up|Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure
215021895|NCT01414647|DIETARY_SUPPLEMENT|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
215021896|NCT01414647|OTHER|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
215021897|NCT05019963|BEHAVIORAL|NexJ Connected Wellness|NexJ Connected Wellness is an electronic case management platform with a patient-facing smart phone application and a clinician-facing web dashboard.
215021898|NCT05019963|OTHER|Usual Care|Participants will receive a treatment plan as decided on with their clinician(s).
215021899|NCT02264821|DRUG|ropivacaine infiltration|wound infiltration
215021900|NCT02264821|DRUG|intrathecal morphine|100 µg added to the spinal anaesthesia
215021901|NCT02264821|DRUG|placebo|placebo in spinal anaesthesia and in wound infiltration
215021902|NCT00160368|BEHAVIORAL|Potassium supplementation|
215021903|NCT05596812|OTHER|New Care Pathway|The New Care Pathway will include continuation of lifestyle and dietary modification, self-blood glucose monitoring, and routine prenatal care.
215021904|NCT00527631|RADIATION|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
215021905|NCT02956148|RADIATION|Radioligand [18F]MNI-659|The effective radiation dose for the injection of \[18F\]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
215021906|NCT05600517|OTHER|Fluoride|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
215021907|NCT01943084|DRUG|Norditropin® FlexPro® pen|Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
215021908|NCT01943084|DRUG|Genotropin Pen®|Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
215021909|NCT06036524|DIAGNOSTIC_TEST|Multi-modal, multi-parametric, multiscale imaging of the myofascial unit|Study Participants will undergo four study procedures at one visit, including magnetic resonance imaging (MRI), surface electromyography (sEMG), fiber-optic imaging and sensing, and questionnaires.
214690402|NCT05516901|PROCEDURE|Control group|Patients in this group will receive general anesthesia alone.
215021910|NCT06642038|PROCEDURE|Transbronchial Endoscopic Thermal Vapor Ablation|Transbronchial Endoscopic Thermal Vapor Ablation
214422511|NCT00465816|BIOLOGICAL|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
214690403|NCT03223324|DEVICE|abdominal fetal/maternal monitor|A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
214690404|NCT02797041|DRUG|Bortezomib|Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
214690405|NCT03280550|DRUG|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
214690406|NCT03280550|DRUG|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
214690407|NCT03438422|DIETARY_SUPPLEMENT|Pollen extract|1 tablet a day
214690408|NCT03345836|DRUG|Matching Placebo for Upadacitinib|Matching placebo tablets
214690409|NCT03345836|DRUG|Upadacitinib|Upadacitinib tablets
214690410|NCT02610088|DRUG|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.
215021911|NCT06638138|DEVICE|Flexband|Artelon FLEXBAND is a commercially available, polycaprolactone polyurethane urea (PCL/PUUR) multipolymer synthetic knitted mesh that is used for soft tissue reinforcement procedures. The device is biocompatible and degradable and has been used as an augmentation device in over 50,000 Orthopedic tendon and ligament reconstructive procedures. The FLEXBAND kits contain the device and all of the instrumentation needed to insert the device.
215021912|NCT02662582|DRUG|Reldesemtiv|Oral tablet
215021913|NCT02662582|DRUG|Placebo|Oral tablet
215021914|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
215021915|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
215021916|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
214422512|NCT00465816|BIOLOGICAL|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
215021917|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
214690411|NCT02610088|DRUG|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
214690412|NCT03321292|DRUG|L-arginine 1000 mg and Acetylesalicylic acid75mg|l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
214690413|NCT03321292|DRUG|acetylsalicylic acid 75 mg|acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
215021918|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
215021919|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
215021920|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
215021921|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
215021922|NCT06334211|DRUG|FP-020|MMP-12 inhibitor
215021923|NCT06334211|OTHER|placebo|placebo
215021924|NCT05804084|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
215021925|NCT05804084|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
215021926|NCT04194619|OTHER|Questionnaire|Interview of women with a rare vascular disease through a phone questionnaire about severe and specific obstetrical complications during and after pregnancy.
215021927|NCT01903733|DRUG|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
215021928|NCT00192478|BIOLOGICAL|Medi-524|IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
215021929|NCT03150641|PROCEDURE|Umbilical cord clamping|The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
215021930|NCT01340534|DEVICE|Supplemental oxygen 80% FIO2|Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
215021931|NCT01340534|PROCEDURE|Use of air (no oxygen during surgery)|No use of oxygen during surgery or in the 2 hours after the procedure.
215021932|NCT02645370|DRUG|Danzhen|
215021933|NCT02645370|DRUG|Topiramate|
215021934|NCT00043784|DRUG|enoxaparin|
215021935|NCT02688166|OTHER|Complete Cardiac Magnetic Resonance Imaging (MRI)|Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
215021936|NCT04147169|BEHAVIORAL|Focused end-of-life conversations to promote connections among patients, family members and clinicians.|All eligible patients and families who were invited to participate in wish elicitation and implementation. For family interviews, criterion sampling was used. For the clinician focus groups, criterion sampling was used, based on involvement in the care of a 3WP patient. For the manager/hospital administrator interviews, purposive sampling was used, based on relevant leadership positions. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data include characteristics of patients, families and clinicians, questionnaire responses from families who agree to interviews, and clinicians who agree to focus groups, respectively, types of wishes elicited and implemented, and their cost. Qualitative data was obtained through individual family interviews, inter-professional clinician focus groups, project team field notes, additional ideas about the costs and benefits of the project from manager interviews, and analysis of project documents.
215021937|NCT04878185|OTHER|Exercise|Preoperative exercise
215021938|NCT05495230|BEHAVIORAL|Person-centred integrated care intervention|See arm description.
215021939|NCT05495230|OTHER|Usual care|See arm description.
215021940|NCT00970710|BEHAVIORAL|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
215021941|NCT03660449|COMBINATION_PRODUCT|Moderately hypofractionated conformal radiation combined With S-1|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
215021942|NCT06446362|BEHAVIORAL|IMCHB-Based Breastfeeding Support Program|"This intervention includes a structured breastfeeding support program based on the Interaction Model of Client Health Behavior (IMCHB). It consists of:~Educational Sessions: Conducted during the last trimester of pregnancy to provide information and prepare mothers for breastfeeding.~Motivational Interviews: Conducted face-to-face at 1-3 days, 15 days, 30 days, 45 days, and 60 days postpartum to address individual challenges and provide personalized support.~Follow-Up Support: Two follow-up sessions via WhatsApp video calls at 4 and 5 months postpartum to reinforce the intervention and provide ongoing assistance."
215021943|NCT06446362|BEHAVIORAL|Standard Breastfeeding Education|Participants receive the standard care provided at Family Health Centers, which includes routine breastfeeding education and support typically offered to new mothers. This standard care does not include the additional structured support interventions provided in the IMCHB-Based Breastfeeding Support Program.
215021944|NCT04874961|DIETARY_SUPPLEMENT|Tensiofytol®|standardized olive extract
215021945|NCT04874961|OTHER|Placebo|contains excipients only
215021946|NCT00461318|PROCEDURE|Individual placement and support (vocational rehabilitation)|
215021947|NCT02395627|DRUG|Tamoxifen|
215021948|NCT02395627|DRUG|Vorinostat|
215021949|NCT02395627|DRUG|Pembrolizumab|
215021950|NCT06311513|BIOLOGICAL|Concentrated Bone Marrow Aspirate Injection|Intraoperatively, bone marrow will be harvested from the iliac crest with a commercial kit, it will then be prepared via centrifugation and an injection of the resulting concentrated product (cBMA) will be administered in the operative knee. cBMA is an autologous biologic product.
215021951|NCT06311513|PROCEDURE|Sham Incision|A 2 mm sham incision will be made in the anatomical site where bone marrow would be harvested.
215021952|NCT06311513|PROCEDURE|Revision Anterior Cruciate Ligament Reconstruction|This is the standard-of-care surgical procedure.
215021953|NCT02492776|DRUG|Omeprazole|20 mg oral capsules administered once daily for 8 days
214422513|NCT05457127|DEVICE|Automatic Positive Airway Pressure (APAP)|"If eligible, participants will be given a clinical Automatic Positive Airway Pressure (APAP) device for up to 3 months, while they are waiting for their clinical evaluation from a sleep physician. The APAP device will we will be using is the ResMed Airsense 11 Autoset. APAP is a smart positive airway pressure (PAP) device, where the pressure changes as needed to provide optimal pressure to splint the upper airway. Dr. Lee and Dr. Schmickl will oversee management of the device.~During the first month of APAP use, individuals will participate in weekly phone calls or in-person visits to ensure optimal adherence and troubleshoot any issues (improper mask fitting, discomfort, etc) that may arise."
214422514|NCT01500395|PROCEDURE|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
214422515|NCT00703950|PROCEDURE|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
214422516|NCT00703950|PROCEDURE|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
214422517|NCT01533870|DRUG|NKTR-118|Oral 25 mg
214690414|NCT05598996|BEHAVIORAL|COT-Based Intervention|The COT-based approach uses a controller that runs case-by-case dynamical systems simulations modeling based on answers to daily questions rooted in social cognitive theory to produce ambitious but achievable daily adaptive step goal recommendations. The process for the COT-based approach is as follows: Phase 1) 2-week measurement only; Phase 2) open-loop system identification experiment (meant to create individualized dynamical models for each participant); Phase 3) closed-loop experiment to optimize for PA initiation, and Phase 4) closed-loop experiment to optimize for PA maintenance.
214690415|NCT01555463|DRUG|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
214690416|NCT01555463|DRUG|Vehicle foam|twice daily topical application
214690417|NCT03586843|DRUG|JNJ-64565111|JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
214690418|NCT04618393|BIOLOGICAL|EMB-02|EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.
214690419|NCT03934593|BEHAVIORAL|Faith-Based (FB, BHT DSMS)|BHT DSMS Intervention components include Health Sermon and a 6-session Health Bible Study with cooking demonstrations, followed by the Stanford DSMP and a Diabetes Resource Seminar. All intervention activities are implemented by trained church lay leaders.
214690420|NCT03934593|OTHER|Faith-Placed (FP, Stanford DSMP)|Standard Stanford DSMP delivered by health professional
214690421|NCT04728971|DRUG|Micafungin Sodium 50 MG Injection|Give Micafungin 150 mg/d within 24 hours after liver transplantation.
215021954|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
214422518|NCT01533870|DRUG|Rifampin|Oral 600 mg
214422519|NCT05756335|BEHAVIORAL|(Un)predictable and (un)attended stimuli|Subjects will complete four task conditions in each scan session: (1) Visual Unpredictable, (2) Visual Predictable, (3) Auditory Unpredictable, and (4) Auditory Predictable. In visual and auditory conditions subjects attend to visual or auditory stimuli and ignore the other domain, pressing a button when they detect an infrequently occurring stimulus inversion in the target domain. In unpredictable and predictable conditions, the attended domain either presents random (unpredictable) stimuli, or the same face or word stimuli repeated (predictable).
214690422|NCT04728971|DRUG|Caspofungin Acetate|Give Caspofungin 35 mg/d lasts 1 week after liver transplantation.
214690423|NCT02154269|DRUG|Treatment with G-CSF (Granulocyte colony stimulating factor)|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
214690424|NCT02154269|DRUG|Placebo saline|Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
214690425|NCT04764123|DIAGNOSTIC_TEST|AVNRT mapping|AV annuli mapping during AVNRT
214690426|NCT01943864|DRUG|Trametinib (single tablet)|The drug substance is blended with inert
214690427|NCT01943864|DRUG|Trametinib (Multiple tablet)|The drug substance is blended with inert
214690428|NCT04005443|OTHER|radiopharmaceutical|his study will consist of a monthly intra-ocular injection of antiangiogenic and a follow-up ophthalmological consultation with OCT and visual acuity score
214690429|NCT04370028|DRUG|Divaza|Oral administration.
215021955|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
215021956|NCT02636335|DEVICE|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
215021957|NCT01992081|DEVICE|Automated telehealth system|The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
215021958|NCT01992081|OTHER|Usual care|Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
215021959|NCT00318136|DRUG|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
215021960|NCT00318136|DRUG|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
215021961|NCT00318136|DRUG|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
215021962|NCT02487329|OTHER|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
215021963|NCT02487329|OTHER|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
214690430|NCT00832754|DEVICE|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
214690431|NCT00832754|OTHER|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
214422520|NCT01521013|BEHAVIORAL|Supported self-care|"Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook."
214422521|NCT01521013|BEHAVIORAL|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
215021964|NCT02487329|OTHER|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
214690432|NCT04534426|DRUG|: Arnica montana|In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
214690433|NCT04534426|DRUG|Mucopolysaccharide polysulfate|In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
215021965|NCT02487329|OTHER|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
214422522|NCT04828642|DIETARY_SUPPLEMENT|Vitamin C and vitamin E|1000 mg 235 mg
214422523|NCT04828642|DIETARY_SUPPLEMENT|Placebo|Placebo
214422524|NCT04583046|DRUG|normal saline inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).
214690434|NCT04534426|OTHER|Control group|In Control group, only standard therapy was performed after surgery
214690435|NCT03415724|PROCEDURE|Inferior alveolar nerve block|Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars
214690436|NCT02965534|DEVICE|Spectacle/Glasses|
215102789|NCT03274518|DEVICE|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
215102790|NCT03274518|DEVICE|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
215102791|NCT02516228|DEVICE|GTEN 100|"Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.~During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days."
214690437|NCT00003019|DRUG|methotrexate|
214690438|NCT00003019|DRUG|vinblastine sulfate|
214690439|NCT06403384|DEVICE|Vibration|Local vibration was applied
214690440|NCT05203133|DIETARY_SUPPLEMENT|Energy Balance|Energy balance phase to elicit weight-maintenance
214690441|NCT05203133|DIETARY_SUPPLEMENT|Energy Deficit|Energy deficit phase to elicit weight-loss
214690442|NCT05203133|DIETARY_SUPPLEMENT|Baseline Assessment|Free-living assessment of energy status
214690443|NCT03304483|OTHER|246-km running|Spartathlon 2017
214690444|NCT00003859|DRUG|carboplatin|
214690445|NCT00003859|DRUG|cyclophosphamide|
214690446|NCT00003859|DRUG|etoposide|
215102792|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention|"AQ provides daily ART reminders and calendar; weekly tailored message; monthly appointment and refill reminders; social support via daily chat wall; daily challenge featuring skills-building and articles; education center; narrative collections; in app account rewards daily use by adding or subtracting small financial reward dependent on daily app use; personalized profile and avatar. Participants have 24-hour access to all features of the AQ app."
214690447|NCT00003859|DRUG|vincristine sulfate|
214690448|NCT00003859|PROCEDURE|surgical procedure|
214690449|NCT00003859|RADIATION|radiation therapy|
214690450|NCT05436938|COMBINATION_PRODUCT|Jing Si herbal tea liquid packets use|with or without Jing Si herbal tea liquid packets use
214690451|NCT03061123|OTHER|Questionnaire|
214690452|NCT02805218|DRUG|PEG-rhG-CSF|
215021966|NCT06125301|DEVICE|MS Sherpa|MS sherpa® is a medical device, intended to support monitoring of persons with MS in order to give patients and their professional healthcare team(s) insight into the presence and progress of symptoms related to MS. MS sherpa® is a system consisting of a smartphone app for data collection and data presentation, a cloud service for data storage, analysis algorithms, and a clinician or research dashboard for user management and data visualization. The device measures the course of symptoms related to MS with respect to walking speed (average walking speed derived from the distance walked during a 2-minute walk), cognitive processing speed, number of correct answers on a smartphone variant of the symbol digit modalities test (SDMT) and patient reported outcomes, through predefined questionnaires regarding fatigue, amongst others. MS sherpa® measures changes in these parameters over time and shows these on an insights screen in the app and on the clinician dashboard.
214690453|NCT02431585|DIETARY_SUPPLEMENT|gluten|
214690454|NCT02431585|DIETARY_SUPPLEMENT|placebo|
214690455|NCT02354170|DRUG|Mifepristone|
214690456|NCT02354170|DRUG|Placebo|
214690457|NCT02213198|BEHAVIORAL|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
215021967|NCT03599297|PROCEDURE|Bilateral synchronous simultaneous stone surgery|Patients undergoing Bilateral synchronous simultaneous stone surgery (one kidney undergoing percutaneous nephrolithotomy, other kidney undergoing ureteroscopy at the same time in a single patient)
215021968|NCT03948620|DRUG|Macrolides|Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
214690458|NCT02213198|BEHAVIORAL|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
214690459|NCT00606697|DRUG|GR205171|10 milligrams (mg)
214690460|NCT00606697|DRUG|GW597599|15 mg
214690461|NCT06472505|DEVICE|polyglycolic acid(Neoveil)|This study plans to enroll patients with pituitary tumors who need to undergo surgical treatment according to current routine medical standards. After the tumor tissue is removed, the integrity of the spider web or skull base will be thoroughly checked by endoscopy during the operation to confirm whether there is any cerebrospinal fluid leakage. At the end of the operation, use a 100\*50\*0.15mm, green sheet-like Navi tissue repair patch, cut it aseptically to fit the size of the defect for repair (the common case is 2\*3.5cm defect), and place it on the spider web or skull base Tissue repair at the surgical site to prevent cerebrospinal fluid leakage.
214690462|NCT02444897|DRUG|Epidural PCA Ropivacaine|"Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S"
215021969|NCT03948620|DRUG|Penicillins|The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
215021970|NCT02852005|BIOLOGICAL|MVA/HIV62B vaccine|1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
215021971|NCT02852005|BIOLOGICAL|AIDSVAX B/E vaccine|600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
215021972|NCT02852005|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
215021973|NCT06570057|BEHAVIORAL|Participatory, learning and Action (PLA) Based intervention|An PLA based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after completion of 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
215021974|NCT06113614|PROCEDURE|Physiotherapy|All participants will be treated with the standardized physiotherapy protocol suggested by Ratajczak et al. 2019. To receive physiotherapy treatment, participants will need to attend a 30-minute session, twice a week, for 12 weeks.
215021975|NCT06113614|DEVICE|Photobiomodulation|The PBM will be applied with LED devices in the form of a shoulder brace. The applications will occur every day starting 24 hours after the surgical procedure. The shoulder brace from the brand Cosmedical (Mauá, SP, Brazil) contains 70 red LEDs and 70 infrared LEDs. The area corresponding to the fixation plate will not be irradiated (no LEDs will be placed). PBM will be applied every day for 10 minutes using a device containing 318 light-emitting diodes (LEDs), including 159 LEDs at 660 nm (28.5 mW; 12 J/cm2 to 17 J) and 159 LEDs at 850 nm (23 mW; 10 J/cm2 to 14 J).
215021976|NCT06113614|DEVICE|Simulation of photobiomodulation|The simulation of PBM will use the same LED devices in the form of a shoulder brace but without active light. It will be applied following the same regimen of the Photobiomodulation group.
215021977|NCT03295786|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
215021978|NCT03295786|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
215021979|NCT05979818|DRUG|Propranolol hydrochloride|10 mg, PO, BID, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
215021980|NCT05979818|DRUG|Sintilimab|intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
215021981|NCT05979818|DRUG|Chemotherapy|"Platinum-based chemotherapy:~For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1-3, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4-6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent."
215021982|NCT04797884|DEVICE|TheraBionic Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at one of the recruiting site, all other treatments will be self-administered at the patient's home.
215021983|NCT04797884|DEVICE|Placebo Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at the recruiting site, all other treatments will be self-administered at the patient's home.
215021984|NCT04797884|DEVICE|Quality of Life Assessment|Ancillary services
215021985|NCT05370209|DEVICE|Otinova® Ear Spray|Ear spray
214690463|NCT02444897|DRUG|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
215021986|NCT05245175|OTHER|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
215021987|NCT05245175|OTHER|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
215021988|NCT05245175|OTHER|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
215021989|NCT05245175|OTHER|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
215102793|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention + NSC|In AQ+, participants receive all of AQ and have the added ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve ART adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. AQ+ includes unprompted check-in messages from the NSC counselor and scheduled in-app NSC sessions approximately every other week.
215102794|NCT02661074|OTHER|Questionnaire|"A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish."
215102795|NCT05116696|PROCEDURE|For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery|"For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy"
215021990|NCT05245175|OTHER|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
214422525|NCT04583046|DRUG|iloprost inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
214422526|NCT02384577|DRUG|Budesonide, Formoterol Fumarate Dihydrate|
214422527|NCT06357910|DRUG|HCP2303|Take 1 tablet once per period
214422528|NCT06357910|DRUG|RLD2302|Take 1 tablet once per period
214422529|NCT06357910|DRUG|RLD2102|Take 1 tablet once per period
214422530|NCT05118581|DEVICE|ultrasound guided vascular access|Arterial or venous catheterization guided by ultrasound
214422531|NCT00078572|DRUG|capecitabine|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
214422532|NCT00078572|DRUG|lapatinib (GW572016)|Lapatinib 1250 mg orally once daily
214422533|NCT04305574|BEHAVIORAL|Use of social media during COVID-19|Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
214422534|NCT00005137|OTHER|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
214422535|NCT02208258|DEVICE|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
214507085|NCT07004179|BEHAVIORAL|Implementation strategy developed using the Implementation Mapping model to enhance the effective integration of the Protocol for Assistance to People with Diabetic Foot|"The intervention will be based on the Implementation Mapping methodology (IM). This model is based on the Intervention Mapping. IM consists of several specific tasks:~1. Conduct an assessment of needs and identification of programme adopters and implementers through a review of qualitative or mixed studies assessing the perceptions of both patients and professionals regarding DF prevention as well as individual semi-structured interviews with patients, health professionals and management staff~2. Indicate adoption and implementation outcomes and action objectives, identifying determinants and create matrices of change; this process will allow for the identification of determinants, which are those factors that influence the actions will be implemented~3. Select theoretical methods and select or design implementation strategies using the ERIC model (Expert Recommendations for Implementing Change)~4. Produce implementation protocols and materials~5. Evaluate implementation results"
214507086|NCT07004179|OTHER|Sham Comparator|Usual care: No systematic implementation of the protocol based on the prevention of foot at risk, ulcer treatment and screening of the risk of diabetic foot ulcer for referral to hospital care.
214507087|NCT07006181|DRUG|cyproheptadine hydrochloride|Giving Cyproheptadine hydrochloride 0.25 mg/kg/day divided by 2 dose every 12 hours for 4 weeks.
214507088|NCT07006181|OTHER|Giving placebo divided by 2 dose every 12 hours for 4 weeks.|Giving placebo divided by 2 dose every 12 hours for 4 weeks.
215021991|NCT02449928|DRUG|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
215102796|NCT02492282|DEVICE|Closed-Loop propofol and remifentanil system by Bispectral Index|
215102797|NCT02492282|DEVICE|Open-Loop propofol and remifentanil by Target Controlled Infusion|
215102798|NCT02492282|DRUG|propofol|
215102799|NCT05500430|DEVICE|Air abrasion sandblasting aluminum oxide particles (Al2O3) AquaCare single (Velopex, Medivance Instruments Ltd., London, UK)|Air abrasion sandblasting aluminum oxide particles (Al2O3) Aqua Care single (London, UK) will be done for the defective area then repairing with bioactive injectable composite, Beautiful Flow Plus X F00 (Shofu, Japan).
215102800|NCT03050320|OTHER|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
215102801|NCT03050320|OTHER|No Exercise|A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
215102802|NCT01252979|DIETARY_SUPPLEMENT|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
215102803|NCT02262962|OTHER|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
215102804|NCT04904848|OTHER|Survey evaluation|examine the convergent validity and reliability of a Turkish version
215102805|NCT01596036|BEHAVIORAL|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
215102806|NCT01596036|OTHER|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
215102807|NCT01092663|DRUG|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
215102808|NCT01092663|DRUG|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
214422536|NCT00897546|OTHER|laboratory biomarker analysis|
214422537|NCT02278393|OTHER|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
215021992|NCT02449928|DRUG|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
215102809|NCT00085449|BIOLOGICAL|alemtuzumab|
215102810|NCT00085449|DRUG|cyclosporine|
215102811|NCT00085449|DRUG|fludarabine phosphate|
214422538|NCT02278393|OTHER|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
214507089|NCT07008014|OTHER|Magnetic Resonance Imaging|Participants will receive an additional MRI image in addition to standard of care to investigate if it was a useful imaging modality for their condition
215021993|NCT06195111|DRUG|Trifluridine/Tipiracil|This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription
215021994|NCT02631694|DRUG|Propranolol|Intake of propranolol pill (40 milligram)
215021995|NCT02631694|DRUG|Placebo|Intake of placebo pill (40 milligram)
215021996|NCT02631694|OTHER|Carbon dioxide|Inhalation of 35% carbon dioxide
215021997|NCT02631694|OTHER|Compressed air|Inhalation of air
215021998|NCT04151641|DIETARY_SUPPLEMENT|MNGDPF|Standardized mangosteen extract in dry powder form
215021999|NCT04151641|DIETARY_SUPPLEMENT|MNGEF|Standardized mangosteen extract in encapsulated form
215022000|NCT06455254|DRUG|Candonilimab (AK104)|Cadonilimab (AK104): 6mg/kg, i.v. q2w.
215022001|NCT06455254|DRUG|Regorafenib|Regorafenib: 80 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).
215022002|NCT04262427|DRUG|Cyclophosphamide 50mg|cytotoxic chemotherapy
215022003|NCT04262427|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
215022004|NCT05410795|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
215022005|NCT01391494|BIOLOGICAL|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
215022006|NCT01391494|BIOLOGICAL|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
215022007|NCT01391494|BIOLOGICAL|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
215022008|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
215022009|NCT01391494|BIOLOGICAL|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
215022010|NCT01391494|BIOLOGICAL|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
214422539|NCT02552186|OTHER|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
215022011|NCT01391494|BIOLOGICAL|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
215022012|NCT01391494|BIOLOGICAL|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
215022013|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
215022014|NCT01391494|BIOLOGICAL|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
215022015|NCT01391494|BIOLOGICAL|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
215022016|NCT01391494|BIOLOGICAL|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
215022017|NCT01391494|BIOLOGICAL|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
215102812|NCT00085449|DRUG|melphalan|
215102813|NCT00085449|DRUG|mycophenolate mofetil|
215102814|NCT00085449|PROCEDURE|peripheral blood stem cell transplantation|
215102815|NCT00085449|RADIATION|radiation therapy|
215102816|NCT03006692|OTHER|With arterial blood gas, parameters not being normal can be corrected|If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
214422540|NCT02712658|DRUG|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
214422541|NCT02712658|DRUG|Placebo|
214422542|NCT01328418|PROCEDURE|Lengthening over nail|External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
214422543|NCT04162119|BIOLOGICAL|BCMA-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.
214422544|NCT04931446|PROCEDURE|Biopsy/surgical tissue and peripheral blood|Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens
214422545|NCT03450278|PROCEDURE|micro-osteoperforation|Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
214422546|NCT02711839|DIETARY_SUPPLEMENT|Commercial diabetic formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
215102817|NCT05961137|OTHER|Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol|Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
215022018|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
215022019|NCT01391494|BIOLOGICAL|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
215022020|NCT03491085|DRUG|Amoxicillin/clavulanate|after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.
215022021|NCT02294019|DRUG|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
215022022|NCT03172559|RADIATION|Stereotactic body radiotherapy|The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
215022023|NCT02369159|DRUG|Peramivir|
215022024|NCT02369159|DRUG|Oseltamivir|
215022025|NCT05214027|OTHER|Treadmill-Based Exercise (60% VO2 Max for 60 minutes)|"Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max."
215102818|NCT05961137|OTHER|Conventional Prehospital Suspected Sepsis Protocol|Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
215102819|NCT05697796|PROCEDURE|Two different surgical methods|SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension
214422547|NCT02711839|DIETARY_SUPPLEMENT|White sweet potato formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
214422548|NCT00941655|DRUG|Oxaliplatin|"Oxaliplatin 460 mg/m\^2 diluted in 2.0 L/m\^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m\^2 over 120 minutes,"
214422549|NCT00941655|DRUG|Irinotecan|Irinotecan 165 mg/m\^2 IV over 90 minutes
214422550|NCT00941655|DRUG|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m\^2 continuous intravenous over 48 hours."
214422551|NCT00941655|DRUG|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes."
214422552|NCT00941655|PROCEDURE|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
215022026|NCT05214027|OTHER|Rest (60 minutes)|Each participant will undergo a 60-minute rest period in a randomised order.
215022027|NCT02975115|OTHER|RQ-PCR RNA Analysis|Conventional Q-RT-PCR every 3 months
215022028|NCT03969030|OTHER|PEBRA model|"The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~1. ART Refill~2. SMS notifications~3. Support"
215022029|NCT03038919|DRUG|Testosterone cypionate|Bi-weekly intramuscular injection of testosterone cypionate 200mg.
215022030|NCT03038919|OTHER|Standard nutrition and physical therapy at ICU|follow-up of the patient without use of testosterone cypionate
215022031|NCT04802005|OTHER|Aerobic Interval Training|The aerobic interval training group
215022032|NCT03288259|PROCEDURE|transnasal endoscopy|Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery
215022033|NCT03288259|DRUG|Local Anesthetics,Topical|Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
214422553|NCT02704741|DEVICE|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
214422554|NCT03192319|BIOLOGICAL|Zostavax|Zostavax will be administrated by subcutaneous injection
214422555|NCT02731339|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
214690464|NCT05828264|BEHAVIORAL|Quantum touch|this group by the nurse who is included in the study and who has a practice certificate before vascular access is established. In this process, the treatment process of the patient will continue and will not create an obstacle. While the child is in a comfortable position (lying or sitting position) during the application, the child's back/shoulder/head will be touched by the practitioner and guantum touch energy will be applied. Then, vascular access will be performed by the nurse included in the study. The child will be asked to rate the level of pain during the procedure with 'FPS-R', the level of fear with 'CDS', and the level of anxiety with 'ÇAS-D'.
214422556|NCT02731339|BEHAVIORAL|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
214422557|NCT02731339|BEHAVIORAL|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
214422558|NCT02731339|BEHAVIORAL|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
214422559|NCT02477670|DRUG|AVP-786|
214422560|NCT02477670|DRUG|Placebo|
214422561|NCT06456970|DEVICE|fibroscan|"Fibroscan examination with controlled attenuation parameterCAP (Echosens FibroScan ® Compact 530) for evaluation of steatosis and its degree (by CAP score) and fibrosis stage by liver stiffness measurement(LSM)"
215022034|NCT02635672|DRUG|VIP152 (BAY 1251152)|The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
215022035|NCT02635672|DRUG|VIP152 (BAY 1251152) 30 mg|30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.
215022036|NCT02635672|DRUG|Keytruda|200 mg IV fixed dose once every 3 weeks of a 21 day cycle
215022037|NCT02635672|DRUG|VIP152 (BAY 1251152) 15 mg|The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.
215022038|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).|Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
215022039|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the effectiveness of SABR.|Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
215022040|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test for Oligometastatic Cancer (OC).|Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
215022041|NCT02467881|BEHAVIORAL|Physical Activity Increase (GLB-MOD)|"The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.~The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
215022042|NCT02467881|BEHAVIORAL|Sedentary Time Decrease (GLB-SED)|"As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
215022043|NCT02467881|OTHER|6-month delayed (DELAYED)|Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
215022044|NCT01173926|DRUG|insulin degludec|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
215022045|NCT01173926|DRUG|insulin degludec/insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
215022046|NCT01173926|DRUG|insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
215022047|NCT03769116|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
215022048|NCT03769116|GENETIC|placebo|Single IV infusion of matching placebo
215022049|NCT00932503|DEVICE|Vicryl plus|triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
215022050|NCT06500871|DRUG|Diclofenac Potassium|NSAID
215022051|NCT04743206|DEVICE|Standard Airway Clearance device|Subjects will be using their home standard airway clearance device, VEST (High Frequency Chest Wall Oscillation VEST) for 2 weeks followed by PIAPD.
215022052|NCT04743206|DEVICE|Portable Internal Airway Percussion device|Subjects will be using the investigational device, PIAPD (Portable Internal Airway Percussion Device) for 2 weeks.
215022053|NCT01821872|DRUG|Administration of paracetamol|Administration of 1g intravenous paracetamol
215022054|NCT04094090|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
215022055|NCT03241420|DEVICE|lung clearance index (LCI)|Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
215022056|NCT06265610|PROCEDURE|TIVA/TCI|: The aim of this study was to evaluate the effects of total intravenous anesthesia with target-controlled infusion (TCI/TIVA) on intraoperative hemodynamic parameters and postoperative awakening criteria in pediatric endovascular intervention patients
215022057|NCT02844075|DRUG|MK-3475(pembrolizumab)|"Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery."
214690465|NCT03611959|OTHER|Non Applicable|
214690466|NCT03553329|DRUG|dabrafenib|Monthly biological assessment which included: blood count, a blood electrolytes, an creatininemia, a dosage of urea, a dosage of transaminases, of gammaGT, of phosphatases alkaline, of LDH and of albumin.
215102820|NCT05591716|PROCEDURE|Bilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis.The ureteroscope was extracted together with the case with the ureteral revision: there was no damage to the ureter.Next, this procedure is performed from the other side. Urine was excreted from the bladder using a Nelaton catheter.
215102821|NCT05591716|PROCEDURE|Unilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis. The ureteroscope was extracted together with the body with revision of the ureter: there was no damage to the ureter. Urine was excreted from the bladder using a Nelaton catheter.
215102822|NCT00697710|DRUG|50 mg S-777469|S-777469, 50 mg BID
214507093|NCT06831994|OTHER|gp-multitool.de|"The intervention is based on the digital tool gp-multitool.de. The GPs can send questionnaires by email to patients and patients can fill out questionnaires at their home or in the waiting room of the practice using any digital device with browser and access to the internet. The digital tool also includes instructions for conducting a medication review. Results will be available from the computers of attending GPs. Decisions from talks between GPs and patients can be documented in the tool. The tool includes ten questionnaires:~1. patient preferences (including a. treatment goals, and b. involvement of other persons in decision making);~2. social life (including a. activities and participation, and b. social support);~3. treatment situation (including a. problems with medication, and b. treatment burden);~4. health complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~5. resilience and protective behavior against heat."
214507094|NCT06067763|BEHAVIORAL|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
215022058|NCT05958225|BEHAVIORAL|SEE Change Business and Personal Agency Training|"A three day residential training based on SEE Change's Empowered Entrepreneur Training curriculum. This training will be led by a certified SEE Change trained facilitator. The workshop will include individual and group exercises that allow participants to increase their self-awareness, build mental tools for resiliency and adaptability in their life, create life visions and key tools to create behavior change. Additional exercises will include specific business related content including record keeping, financial planning and marketing strategies based on the Business Model Canvas tool.~After the 3 day training, the participants will receive a supportive message through an interactive voice recording, once a week for 6 weeks. In addition, they will be contacted once a month, for three months (either by phone or in person) by the trainer to see how they are doing on their goals."
215022059|NCT06332339|BIOLOGICAL|16055 NFL delta Gly4 trimer|200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each)
215022060|NCT06332339|BIOLOGICAL|Trimer 4571|100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each)
215022061|NCT06332339|BIOLOGICAL|Ad4-Env145NFL, 5 x 108 viral particles (vp)|to be administered intranasally (IN) (0.07 mL into 1 nostril)
215022062|NCT04530695|OTHER|Scaling and Root Planing|Periodontal treatment by scaling and root planing (SRP), deep cleaning
215022063|NCT00003008|DRUG|indinavir sulfate|
215022064|NCT00003008|DRUG|nelfinavir mesylate|
215022065|NCT00003008|DRUG|paclitaxel|
215102823|NCT00697710|DRUG|200 mg S-777469|S-777469, 200 mg BID
215102824|NCT00697710|DRUG|800 mg S-777469|S-777469, 800 mg BID
215102825|NCT00697710|DRUG|Placebo|Matching Placebo
215102826|NCT04328272|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|Hydroxychloroquine administered orally with water
214507095|NCT06067763|BEHAVIORAL|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
214507096|NCT06067763|OTHER|The Weight of the Nation|This 2012 documentary discusses the facts and myths about obesity and the impacts of obesity on individuals and the health care system in the United States.
214507097|NCT07012460|DEVICE|CTI ablation|CTI ablation will be performed with PFA. Before ablation, The RA geometry will be created with a multipolar catheter. Coronary angiogram will be performed at baseline in LAO 45 degree before and after each set of ablations. After ablation, a 15-minute waiting period will be mandated. The CTI block will be rechecked with 3D mapping system and multipolar catheter. If there is persistent CTI conduction, ablation will be repeated until CTI block is achieved. This will be followed by another 15 minutes of waiting period before rechecking the block across CTI, and so on. TNG will be prepared. It will be given via intracoronary route in 100-200mcg bolus if severe spasm is observed. If CTI block cannot be achieved with repeated PFA ablation, ablation with radiofrequency will be allowed to achieve block. Patient will come back for follow up at 3 months for a remapping procedure. During the remapping procedure, a RCA coronary angiogram will be performed to exclude late coronary damage.
214507098|NCT07012980|DRUG|Glofitamab|Glofitamab will be administered i.v. on a step-up dosing schedule starting on Day 8 of Cycle 1 (2.5 mg), Day 15 of Cycle 1 (10 mg), followed by 30 mg on Day 1 of Cycles 2-6, with each cycle being 21 days. A single dose of obinutuzumab 1000 mg will be administered intravenously on Day 1 of Cycle 1.
214507099|NCT07012980|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin (1.8 mg/kg) will be administered intravenously on Day 2 of Cycle 1 and on Day 1 of the subsequent Cycle 2-6 (each Q3W).
215102827|NCT04328272|DRUG|Azithromycin 500Mg Oral Tablet|Azithromycin administered orally with water
214507100|NCT07012980|DRUG|Zanubrutinib|Zanubrutinib (160mg bid p.o.) will be administered for 7 days as pretreatment and from D1 to D21 through all 12 cycles Q3W.
214690467|NCT05091060|DEVICE|Erchonia HLS|56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
215022066|NCT00003008|DRUG|ritonavir|
215022067|NCT00003008|DRUG|saquinavir mesylate|
215022068|NCT06566703|BEHAVIORAL|All Nations Snuff Out Smokeless|All Nations Snuff Out Smokeless is a culturally tailored smokeless tobacco cessation program that incorporates group-based and individual counseling.
214422562|NCT04307316|OTHER|ACBT group|"ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization"
214422563|NCT04307316|OTHER|Conventional Physical therapy|Chest percussion, deep breathing, Huff and cough. Early mobilization
214422564|NCT03290248|BIOLOGICAL|B244 suspension|B244 suspension in 30ml/bottle
214422565|NCT03290248|BIOLOGICAL|Vehicle|Vehicle, 30ml/bottle
214422566|NCT03273348|PROCEDURE|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
214422567|NCT01815008|DRUG|Clopidogrel|Clopidogrel 75 mg daily
214422568|NCT01815008|DRUG|Aspirin|Aspirin 81 mg daily
214422569|NCT03493269|DRUG|BAY1834845|Orally administered.
214422570|NCT03493269|OTHER|Matching Placebo|Orally administered.
214422571|NCT03493269|DRUG|Midazolam|Part 1: Orally administered 1mg as a single dose.
215022069|NCT06566703|BEHAVIORAL|Healthy Living|Healthy Living is an educational program that provides information about diet, exercise, stress, and general health. It uses group-based and individual discussion, along with educational materials.
215022070|NCT06125327|DRUG|SC1011|Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
215022071|NCT06125327|DRUG|Placebo comparator|Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
215022072|NCT06530303|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
215022073|NCT06530303|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
215022074|NCT06530303|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
214422572|NCT04848233|DIETARY_SUPPLEMENT|Drinks containing 5AA+CrPic and Placebo|Same diet will be repeated for 3 days in a row and the beverage switched every day. 3 periods of 3 days are included in the study.
214507101|NCT07012304|DRUG|Gecacitinib Hydrochloride Tablets|Gecacitinib hydrochloride tablets are taken orally on an empty stomach. The starting dose is 50 mg once daily (QD). The maximum dose is 100 mg twice daily (BID), and the minimum dose is 50 mg every other day (QOD). Dose adjustments should be made in 50-mg increments or decrements.
215022075|NCT06530303|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
215022076|NCT06530303|DRUG|Pembrolizumab|Intravenous (IV) infusion
215022077|NCT01908387|DRUG|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
215102828|NCT04328272|DIETARY_SUPPLEMENT|Glucose tablets|administered orally with water
215102829|NCT02014779|BEHAVIORAL|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
214422573|NCT00983593|BEHAVIORAL|Mind-Body Bridging|16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
214422574|NCT02026076|OTHER|mechanical lumbar traction|15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
214507102|NCT07013344|DIAGNOSTIC_TEST|BNP|Measurement of plasma NT-proBNP level.
214507103|NCT07013955|DRUG|Saline|Group I (Group C): (control group) Patients in this group will receive only 5 ml of intranasal saline.
214507104|NCT07013955|DRUG|Dexmedetomidine|Group II (Group D): Patients in this group will receive only intranasal Dexmedetomidine (1 mcg/kg) made up to 5 ml in normal saline.
215102830|NCT02014779|BEHAVIORAL|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
215102831|NCT03892135|OTHER|Interviews with parents of children with juvenile idiopathic arthritis|Interviews with parents of children with juvenile idiopathic arthritis
215102832|NCT03892135|OTHER|Interviews with children with juvenile idiopathic arthritis|Interviews with children with juvenile idiopathic arthritis
215102833|NCT03892135|OTHER|Interviews with Physicians|Interviews with Physicians
215102834|NCT01699074|DIETARY_SUPPLEMENT|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
214422575|NCT00018226|BEHAVIORAL|Case Management|
214422576|NCT06241989|OTHER|health education supported by motivational interviewing|The intervention group will receive health education supported by motivational interviewing consisting of 6 sessions. Within the scope of the intervention, the first two sessions will be health education and the last four sessions will be motivational interviewing.
214422577|NCT04080258|OTHER|Osteopathic manipulative therapy (OMTh)|"The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment."
214422578|NCT04080258|OTHER|Light Touch Therapy (LTT)|The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
215022078|NCT03540485|DRUG|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
215022079|NCT03540485|OTHER|Placebo|Daily administration of placebo orally, for 24 months between 10pm to 11pm
215022080|NCT03231735|DEVICE|Mid frequency ventilation|Mechanical ventilator used at rates \> 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
215022081|NCT03231735|DEVICE|Standard frequency ventilation|Mechanical ventilator used at rates \< 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
215102835|NCT01699074|DIETARY_SUPPLEMENT|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
214507105|NCT07013955|DRUG|Midazolam|Group III (Group M): Patients in this group will receive only intranasal midazolam (0.2 mg/kg) made up to 5 ml in normal saline.
215022082|NCT06461273|BEHAVIORAL|Lifestyle Medicine Program|"Participants will engage in culinary and nutrition education for 6 weeks curated by a professional chef working in conjunction with the project team from community partner Ethos Farm to Health. Lessons will be adapted from the American College of Lifestyle Medicine (ACLM) Culinary Medicine Curriculum~Participants will engage in exercise sessions on weeks without culinary and nutrition instruction for a total of 6 weeks. Exercise sessions will include a variety of activities to include calisthenics, weight training, walking, running, dance, and games delivered by the Rutgers physical therapy team.~Urban Agriculture lessons will occur longitudinally throughout the 12-week course. Participants will learn to cultivate a variety of crops in limited spaces, emphasizing sustainable practices and the importance of local food systems in urban communities.~Additionally, this arm will receive a supplemental food box weekly consistent with the dietary pattern set forth by ACLM."
215022083|NCT06461273|BEHAVIORAL|Medically Tailored Groceries|"Participants in the Food is Medicine arm will receive a supplemental food box weekly curated by a registered dietician and dietetics students. Each food box will contain seasonally available fruit and vegetables and other items including protein, dairy/cheese, and legumes that may be available at the time of the food box delivery. Each box will contain approximately 8 pounds of food and all participants in this group will receive the same food items. Classes and educational materials provided will be tailored to the specific foods contained in the weekly food box and will include simple preparation methods, recipes, nutrition information and grocery shopping tips."
215022084|NCT06006468|GENETIC|High genetic risk for type 1 diabetes|in individuals without diabetes comparison of prevalence of islet auto antibodies between individuals at high genetic risk of type 1 diabetes versus controls
215022085|NCT06006468|GENETIC|High gentic risk for Coeliac disease|in individuals without Coeliac disease comparison of prevalence of anti tissue transglutaminase antibodies between individuals at high genetic risk of coeliac disease versus controls
215022086|NCT06356350|OTHER|Conventional neuromuscular exercises|Conventional neuromuscular exercises represent a contemporary physiotherapeutic approach. These exercises aim to improve neuromuscular control, strength, and endurance in various muscles surrounding the included joint, contributing to the correction and maintenance of proper posture.
215022087|NCT06356350|OTHER|Core based exercises|Core based exercises increase overall mobility, relieve pain, improve posture, and support spinal alignment. Especially important for children who are still growing is to slow or stop the progression of deformities because of the asymmetrical loading pattern.
215022088|NCT04993911|OTHER|Experimental Group|"Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~* Walking forward~* Walking backward~* Side stepping~* Walk heel to toe~* Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
215022089|NCT04993911|OTHER|Control Group|"Participants of this group will receive only conventional therapy which will include; before beginning the program, each session will feature a 5-minute warm-up on a fitness bike or treadmill, followed by a 5-minute cool-down. Participants of this group will receive only conventional therapy which will include.~* CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
215022090|NCT02056951|PROCEDURE|Multidisciplinary rehabilitation|"Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:~* health education~* exercise therapy~* back school~* physical treatments~* psychological interventions in groups and individual counselling~* rehabilitation/social counselling."
215022091|NCT02056951|PROCEDURE|Interprofessional rehabilitation|"Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:~* education about low back pain~* behavioural exercise therapy~* coping with pain~* relaxation~* work related informations"
215102836|NCT01699074|DIETARY_SUPPLEMENT|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
215102837|NCT01699074|DIETARY_SUPPLEMENT|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
215102838|NCT01699074|DIETARY_SUPPLEMENT|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
215102839|NCT02670967|DIETARY_SUPPLEMENT|Soluble Fibre|
215102840|NCT05485324|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
214507106|NCT07013955|DRUG|Bupivacaine|Group IV (Group B): Patients in this group will receive only intranasal bupivacaine (0.5% solution) 5 ml.
214507107|NCT07013981|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
214507108|NCT07013981|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
214507109|NCT07012239|DRUG|Azathioprine (AZA)|"Patient fulfilled indication of AZA Maintenance of remission of lupus nephritis, Neuro-psychiatric lupus, vasculitis, intolerance to steroid, associate with Defuse Parenchymal Lung Disease (DPLD) Starting AZA at a dose of 1 mg/kg/ body weight~First follow-up at 2nd week and change dose of AZA 2 mg /kg/ BW/day~Then Follow-up 4 weekly for total 12 week~Not adverse effect of Azathioprine"
214507110|NCT07012239|DRUG|TPMT|Adverse effect of azathioprine in SLE
215022092|NCT04409418|DEVICE|Extended dwell catheters|EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.
215022093|NCT00310141|BEHAVIORAL|Smoking cessation intervention|6 weeks of computer delivered treatment for quitting smoking
215022094|NCT00310141|OTHER|Counseling intervention|In-person counseling (5 sessions)
214422579|NCT02667743|DRUG|Paclitaxel Micelles for Injection|
214422580|NCT02667743|DRUG|Paclitaxel Injection|
214422581|NCT02667743|DRUG|Cisplatin|
214422582|NCT00446550|DRUG|afegostat tartrate|
214507111|NCT07012278|OTHER|Caesarean section scar dressing with St. John's wort oil|Dressing the incision site with St. John's wort oil once a day every day
214507112|NCT07012837|DRUG|Placebo|Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Saline will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
215022095|NCT00310141|DRUG|Nicotine patch|6-week supply of the nicotine patch
215022096|NCT06456684|DIAGNOSTIC_TEST|Fluoro[18F]promethazine|It is the first F-18-labeled VMAT2 imaging agent for PET imaging that is currently being used in the clinic internationally. In the brains of Parkinson's disease (PD) patients, the target binding of fluoro\[18F\]promethazine was significantly reduced compared with that of normal controls, with an 81% reduction in the posterior region of the nucleus accumbens, a 70% reduction in the anterior region of the nucleus accumbens, and a 48% reduction in the caudate nucleus; the radioactivity uptake in the caudate nucleus of PD patients was correlated with the extent of their disease
215022097|NCT04980963|BEHAVIORAL|Cognitive Support Technology (CST)|Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment. CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).
215102841|NCT03688620|OTHER|Passive enhanced safety surveillance|Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card was returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card was returned by mail) for children aged \<9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects had up to 14 days post vaccination to return their ADR card (at the next study visit or by mail).
214507113|NCT07012837|DRUG|Desmopresin|Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Desmopressin 0.3 ug/kg of the patient's body weight will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
214507114|NCT07013370|BIOLOGICAL|Anti-CMV immunoglobulins [Megalotect (R)]|Children received an anti-CMV immunoglobulin to prevent viral infections
214507115|NCT07012681|OTHER|discharge training (oral and written brochure)|The group that received oral and written brochure training during discharge training
215022098|NCT01346917|DRUG|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
215022099|NCT01346917|DRUG|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
215102842|NCT01399710|PROCEDURE|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
215102843|NCT01399710|PROCEDURE|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
214507116|NCT07012681|OTHER|discharge education (oral education)|group receiving oral training in discharge training
214507117|NCT07025018|DRUG|HMPL-306|IDH small molecule inhibitor
214690468|NCT04841629|OTHER|PreBioGyn Gel|Cellulose-based prebiotic gel developed to optimize vaginal health and reduce the risk of cervical cancer in women.
214690469|NCT04841629|OTHER|Trimosan Gel|Carbomer-based gel
214690470|NCT04841629|OTHER|RepHresh Gel|Carbomer-based gel
215022100|NCT01166698|DRUG|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
214422583|NCT03396848|OTHER|SHAReClinic|Online clinic with educational modules
214422584|NCT02937831|BIOLOGICAL|RIXUBIS|
214422585|NCT05000944|OTHER|breakfast omission (BO)|this group will not be provided with a breakfast until lunch time (at 12:30).
214422586|NCT05000944|OTHER|early-morning breakfast consumption (EM-BC)|this group will be provided with an early morning breakfast (at 08:30).
214422587|NCT05000944|OTHER|mid-morning breakfast consumption (MM-BC)|this group will be provided with a mid (late) morning breakfast (at 10:30).
214422588|NCT02630719|DRUG|Timolol eye drops|eye drops
214422589|NCT02630719|DRUG|Artificial tears|Placebo drop
214422590|NCT00457769|DRUG|Donepezil and self-generated memory training|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
214422591|NCT00457769|DRUG|Donepezil and experimenter-administered memory training|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
214422592|NCT01552980|DRUG|S-1 and Oxaliplatin|"Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;~Efficacy will be evaluated every three cycles."
214422593|NCT04573803|DRUG|Phenytoin Sodium|Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
214422594|NCT04573803|DRUG|Levetiracetam|Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
214422595|NCT00502736|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3
215022101|NCT01166698|DRUG|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
215022102|NCT01166698|DRUG|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
215022103|NCT01217515|DRUG|Diltiazem hydrochloride 4% cream|3 times daily
215022104|NCT01217515|DRUG|Diltiazem hydrochloride 2% cream|3 times daily
215022105|NCT01217515|OTHER|Placebo|3 times daily
215022106|NCT06275958|DRUG|Doublet Chemotherapy, Standard Dose (100%)|Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
215022107|NCT06275958|DRUG|Doublet Chemotherapy, Dose-reduced (75%)|75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
215022108|NCT06275958|DRUG|Monotherapy, Standard Dose (100%)|\- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
215022109|NCT06275958|DRUG|Monotherapy, Dose-reduced (75%)|"75% of:~\- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)"
215022110|NCT05799625|BEHAVIORAL|StepOne Smartphone Application|This smartphone application provides a 14-day program that delivers the core components of smoking cessation (i.e., counseling, education) and takes advantage of pandemic-accelerated acceptance of virtual care, videoconferencing, remote monitoring, and social networking. The program seeks to move participants from the pre-action stage (not interested in quitting) to the action stage (intention to quit) and incorporates daily reminders, gamification, and models of habit formation to engage users.
215022111|NCT06259812|OTHER|Parameters of Early Warning Scores|Parameters of Early Warning Scores
215022112|NCT05930067|DEVICE|Pinnacle Gription Acetabular Cup|Pinnacle Gription cup with Corail/ACTIS stem
215022113|NCT05930067|DEVICE|Pinnacle Dual Mobility|Bi-Mentum AltrX liner
215022114|NCT03989674|DIETARY_SUPPLEMENT|Anthocyanin|25% w/w anthocyanin extract obtained from black rice
215022115|NCT02344498|DRUG|Tenofovir disoproxil|
215022116|NCT01887600|DRUG|Roxadustat|Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
215022117|NCT01887600|DRUG|Placebo|Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
215022118|NCT03688139|BEHAVIORAL|Engage Therapy|"Engage therapy is designed to help individuals with depression become involved in activities they previously enjoyed but have not been participating in since developing depression. In Engage therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding activities of their choice."
215022119|NCT03688139|BEHAVIORAL|Supportive Therapy|Supportive therapy is designed to provide a warm and supportive environment in which individuals with depression can feel comfortable expressing their thoughts and feelings. In supportive therapy, therapists help patients identify themes in their thinking, provide reassurance, emphasize coping skills, and provide guidance as needed.
214422596|NCT04133740|DRUG|Oxygen|Liberal versus conservative oxygen therapy.
214422597|NCT02888457|OTHER|Nasopharyngeal sampling with a swab|
214422598|NCT03997682|OTHER|Hands-Up Program|In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
214422599|NCT04700930|OTHER|CBD-Cigarettes|CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
215022120|NCT02137278|DRUG|Vasoactive drug therapies|Continue current vasoactive therapy
215022121|NCT02137278|OTHER|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
215022122|NCT02380235|BIOLOGICAL|PEG-somatropin|0.20mg/kg/w
215022123|NCT02380235|BIOLOGICAL|PEG-somatropin|0.12mg/kg/w
214422600|NCT03696862|PROCEDURE|free gingival graft|Use of free gingival graft to seal the socket after flapless atraumatic tooth extraction is performed, implant placement and filling the socket with bone graft.
215022124|NCT04545697|OTHER|Medcorder|Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
215022125|NCT02470377|DEVICE|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
214422601|NCT04310072|DEVICE|Neuromuscular electrical stimulation|NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.
215022126|NCT01907646|DEVICE|bladder training|vescical catheter
215022127|NCT01907646|PROCEDURE|No bladder training|
215022128|NCT03274089|DEVICE|Kiosk intervention group|"SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~* Collects patient information using patient-specific identification~* Prompts the user for answers to screening questions for acute conditions~* Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~* Triages patients based on responses to screening questions, physiological parameters and blood test results~* Provides recommendations to the patient on the care plan, self management and lifestyle choices"
215022129|NCT03274661|DRUG|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
214422602|NCT03646136|PROCEDURE|Retained fluid|Retained fluid
214422603|NCT03646136|PROCEDURE|Emptied fluid|Emptied fluid
214422604|NCT03426228|DIAGNOSTIC_TEST|HbA1C|"After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:~1. At baseline (second day of the menstrual period)~2. Triggering phase (post-egg retrieval procedure)~3. Embryo transfer phase (post-transfer procedure)~4. Week 4 (positive bHCG)~4\. Week 8 of pregnancy"
215022130|NCT02783859|DRUG|Amoxicillin-clavulanic Acid|
215022131|NCT02783859|DRUG|Placebo (for Amoxicillin-clavulanic Acid)|
215022132|NCT01083472|DEVICE|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
215022133|NCT01083472|PROCEDURE|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
215022134|NCT01280500|BEHAVIORAL|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
215022135|NCT01280500|OTHER|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
215022136|NCT01280500|OTHER|usual care|No EMR
215022137|NCT01280500|OTHER|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
215022138|NCT01280500|OTHER|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
215102844|NCT01399710|DEVICE|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
215102845|NCT03190616|DRUG|apatinib|apatinib 500mg/qd, 28d/cycle
214507118|NCT06699472|DRUG|Chemotherapy|Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration
214507119|NCT06699472|DRUG|Trilaciclib Injection [Cosela]|Trilaciclib, intravenous infusion, 240 mg/m2, administered following chemotherapy (2 hours after completion of vincristine administration and within 4 hours before administration of other chemotherapy drugs)
215102846|NCT01008904|DRUG|magnesium oxide|Given PO
214422605|NCT03791905|DRUG|Paclitaxel|chemotherapy drug
214422606|NCT03791905|DRUG|Cisplatin|chemotherapy drug
214422607|NCT03791905|DRUG|Oxaliplatin|chemotherapy drug
214422608|NCT03791905|DRUG|5-FU|chemotherapy drug
214422609|NCT03791905|DRUG|Leucovorin|chemotherapy drug
214422610|NCT03791905|RADIATION|Intensity-modulated radiotherapy|radiotherapy technique
214422611|NCT03791905|DEVICE|PET|Using PET to evaluate response to induction chemotherapy
214422612|NCT04676984|OTHER|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
214422613|NCT03720210|DEVICE|RFA|Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis
214422614|NCT00114244|DRUG|sorafenib tosylate|Given PO
214422615|NCT00114244|DRUG|gemcitabine hydrochloride|Given IV
214507120|NCT06698419|DEVICE|RADA16 gel application into mastoid cavity|A single application of RADA16 gel will be applied along the surface of the mastoid cavity intraoperatively prior to insertion of gelatin sponge packing. Application will involve a thin layer of gel just enough to cover the entire surface of the cavity.
214507121|NCT06632691|DEVICE|Virtual reality headset|Use of a virtual reality headset during rectosigmoidoscopy
214690471|NCT00870272|DRUG|Misoprostol|400mcg misoprostol taken sublingually or buccally
214690472|NCT03671759|BEHAVIORAL|Start: On Caffeine|In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
215022139|NCT02451475|DRUG|Amitriptyline|Amitriptyline 25 mg/day
214422616|NCT00114244|OTHER|laboratory biomarker analysis|Correlative studies
214422617|NCT01908296|DRUG|FK949E|Oral
214422618|NCT01908296|DRUG|fluvoxamine|Oral
214422619|NCT00003728|DRUG|asparaginase|
215022140|NCT02451475|DRUG|Venlafaxine|Venlafaxine 75 mg/day
215022141|NCT02451475|DRUG|Paroxetine|Paroxetine 25 mg/day
215022142|NCT03093168|BIOLOGICAL|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
215022143|NCT03093168|DRUG|Fludarabine|dose: 25mg/m2/d
215022144|NCT03093168|DRUG|Cyclophosphamide|Dose: 40mg/kg
215022145|NCT01390584|DRUG|Doxorubicin|IV
215022146|NCT01390584|DRUG|Bleomycin|IV
215022147|NCT01390584|DRUG|Vinblastine|IV
215022148|NCT01390584|DIAGNOSTIC_TEST|PET|fludeoxyglucose F 18 Imaging exam
215022149|NCT01390584|RADIATION|INRT|selective external radiation therapy
215022150|NCT01390584|DRUG|Dacarbazine|IV
215022151|NCT01390584|DRUG|Etoposide|IV
214422620|NCT00003728|DRUG|cyclophosphamide|
214422621|NCT00003728|DRUG|cytarabine|
214422622|NCT00003728|DRUG|daunorubicin hydrochloride|
214422623|NCT00003728|DRUG|dexamethasone|
215022152|NCT01390584|DRUG|Cyclophosphamide|May be given orally, IV push, or by IV infusion
215022153|NCT01390584|DRUG|Vincristine|IV
215022154|NCT01390584|DRUG|Procarbazine|PO
215022155|NCT01390584|DRUG|Prednisone|PO
215022156|NCT00121953|DRUG|Rosiglitazone|
214422624|NCT00003728|DRUG|doxorubicin hydrochloride|
214422625|NCT00003728|DRUG|etoposide|
214422626|NCT00003728|DRUG|leucovorin calcium|
214422627|NCT00003728|DRUG|mercaptopurine|
214422628|NCT00003728|DRUG|methotrexate|
214422629|NCT00003728|DRUG|methylprednisolone|
214422630|NCT00003728|DRUG|mitoxantrone hydrochloride|
214422631|NCT00003728|DRUG|prednisolone|
214422632|NCT00003728|DRUG|therapeutic hydrocortisone|
214422633|NCT00003728|DRUG|thioguanine|
214422634|NCT00003728|DRUG|vincristine sulfate|
214422635|NCT00003728|DRUG|vindesine|
214422636|NCT00003728|PROCEDURE|allogeneic bone marrow transplantation|
214422637|NCT00003728|PROCEDURE|peripheral blood stem cell transplantation|
214422638|NCT02817334|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
214422639|NCT05018325|PROCEDURE|Colonoscopy with 6 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
214422640|NCT05018325|PROCEDURE|Colonoscopy 9 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
214422641|NCT05018325|PROCEDURE|Colonoscopy 12 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
214422642|NCT00711958|DRUG|HX575, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
214422643|NCT00711958|DRUG|ERYPO®, Janssen-Cilag, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
214422644|NCT04627493|BEHAVIORAL|Online exercise|Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
214690473|NCT03671759|BEHAVIORAL|Start: Off Caffeine|In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
215022157|NCT05581888|DEVICE|trifocal intraocular lens|Binocular implantation of two different trifocal intraocular lens in high myopic cataracts
215022158|NCT05389800|OTHER|Upper Extremity Aerobic Exercise|Using a cycle-ergometer (Monark 881E)
215022159|NCT01714388|DRUG|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
215022160|NCT01835431|DRUG|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
215022161|NCT01835431|DRUG|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
215022162|NCT01835431|DRUG|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
215022163|NCT01835431|DRUG|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
215022164|NCT02609451|PROCEDURE|Ileostomy closure|Ileostomy closure at a different time point
215022165|NCT03977610|DRUG|Ga-68 PSMA ligand|For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
215022166|NCT03517293|BEHAVIORAL|Aerobic Exercise training|
215022167|NCT02080000|OTHER|Optimisation of V-V timing using R wave on surface ECG|
215022168|NCT02080000|OTHER|Standard V-V timing settings|
215022169|NCT01232582|DEVICE|Exablate treatment|MR guided Focused Ultrasound treatment
215022170|NCT00655356|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
215022171|NCT00655356|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
215022172|NCT05324787|DEVICE|Grency venous stent system|Venous stent implantation during the index procedure
215022173|NCT05995418|OTHER|There was no intervention as this was an observational study.|There was no intervention as this was an observational study.
215022174|NCT03996421|DIETARY_SUPPLEMENT|nutritional iron (14 mg) supplement in form of ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
215022175|NCT03996421|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
215022176|NCT04131894|BIOLOGICAL|autogenous dentin graft|
215022177|NCT04131894|BIOLOGICAL|platelet rich fibrin (PRF)|
215102847|NCT01008904|OTHER|questionnaire administration|Ancillary studies
214422645|NCT03881449|COMBINATION_PRODUCT|ABILIFY MYCITE|Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.
214422646|NCT00012935|BEHAVIORAL|Help with decision making on prostate cancer treatment|
215022178|NCT02601365|DRUG|Sargramostim 0.04 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
215022179|NCT02601365|DRUG|Sargramostim 0.2mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
215022180|NCT02601365|DRUG|Sargramostim 1 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
215022181|NCT04634331|BEHAVIORAL|Augmented Reality Multi-Modal Training|Training administered via an augmented reality headset.
215022182|NCT04634331|BEHAVIORAL|Traditional Multi-Modal Training|Training administered via a 1:1 physical therapy session
215022183|NCT01392066|BEHAVIORAL|questionnaire|"Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up."
215022184|NCT05705804|DRUG|Pitavastatin|Pitavastatin 4 mg will be given.
215022185|NCT05705804|DRUG|Pitavastatin plus Ezetemibe|Pitvastatin 4 mg plus ezetemibe 10 mg will be given.
215022186|NCT05705804|DRUG|Atorvastatin|Atorvastatin 40 mg will be given.
214422647|NCT01609517|DRUG|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
214422648|NCT02200523|DEVICE|SARA electrode|
214422649|NCT02200523|DEVICE|Gold cup|
214422650|NCT06448598|OTHER|Exercise|The exercise protocol involved twice-weekly sessions, with aerobic exercises performed at 70% of the maximum heart rate achieved during the step test, and resistance exercises at 60% of 1RM. Participants self-selected their exercise timing, either intradialytic (during HDF sessions) or interdialytic (on non-dialysis days). For the intradialytic group, exercise was seamlessly integrated into the HDF session, excluding the initial and final two hours of dialysis.
214690474|NCT01798706|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
214422651|NCT05177601|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.
214422652|NCT05177601|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
214422653|NCT05177601|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during TMS treatments (20 days).
214422654|NCT05177601|DRUG|Placebo oral capsule|Daily oral placebo during the TMS treatments (20 days).
214422655|NCT02319434|DEVICE|Ostom-i Alert Sensor|Sensor on ostomy bag.
214422656|NCT00006035|BIOLOGICAL|bleomycin sulfate|
215022187|NCT02496156|BEHAVIORAL|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
215022188|NCT02496156|BEHAVIORAL|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
215022189|NCT05023902|OTHER|Pilates|Pilates has been performed to all participants two times a week in order to compare the effects of NIA
215022190|NCT05023902|OTHER|Neuromuscular Integrative Action|NIA was the experimental group of this study.
215022191|NCT03760666|DRUG|Brequinar/Brequinar + Ribavirin|The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
215022192|NCT06644404|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
215022193|NCT06644404|DRUG|DWC202407 1,000mg|1 tablet, Orally, Twice daily
215022194|NCT06644404|DRUG|DWC202408 2mg|1 tablet, Orally, Once daily single dose
214422657|NCT00006035|DRUG|electroporation therapy|
214422658|NCT02176538|DRUG|Product 0405|Product 0405 will be administered topically twice daily for 28 days
214422659|NCT02176538|DRUG|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
214422660|NCT06007118|RADIATION|APBI|accelerated partial breast irradiation to the surgery bed (5 x 6,0 Gy; in 5 working days)
214690475|NCT01798706|DRUG|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
215022195|NCT04349098|DRUG|Selinexor|Participants will receive 20 mg of selinexor.
215022196|NCT04349098|OTHER|Placebo|Participants will receive 20 mg of placebo matched to selinexor.
215022197|NCT01950598|PROCEDURE|Boston KPro type I - fresh graft|Boston KPro mounted on fresh corneal carrier graft for implantation
215022198|NCT01950598|PROCEDURE|Boston KPro type I surgery - frozen graft|Boston KPro mounted on frozen corneal carrier graft for implantation
215022199|NCT05655988|DIAGNOSTIC_TEST|inguinal ultrasonography|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
215022200|NCT00705276|DRUG|Lactic acid (Dermacyd Femina Delicata)|
215102848|NCT01008904|PROCEDURE|quality-of-life assessment|Ancillary studies
214690476|NCT01798706|DRUG|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
214690477|NCT01284179|BEHAVIORAL|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
214690478|NCT01284179|BEHAVIORAL|Educational|Educational recordings regarding FCP and FGIDs.
215022201|NCT04576221|DEVICE|stacked breathing exercise|"• Breath stacking was done using a bag which is a simple device used to give artificial breaths..~* It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~* If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal."
215022202|NCT04576221|DEVICE|NIV by CPAP mask|provides pressurized air through a mask to help push air into your lungs and help you breathe
215022203|NCT04197323|DRUG|Alprostadil liposomes for injection|40ug,once a day,continuous administration for 2 weeks
215022204|NCT05740826|DEVICE|Algometer|The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
215022205|NCT01703221|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
215022206|NCT01703221|DRUG|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
215022207|NCT01703221|DRUG|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
215022208|NCT01703221|DRUG|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
215022209|NCT03505424|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
215022210|NCT03505424|OTHER|Group 2: NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
215022211|NCT03505424|OTHER|Group 3: SMART NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.
215022212|NCT04029051|OTHER|Focus thoracic ultrasound for dyspnea diagnosis|Focus thoracic ultrasound is composed by an advanced cardiac ultrasound with Doppler measures and a lung ultrasound.
215022213|NCT06608732|BIOLOGICAL|Inaticabtagene autoleucel|CNCT19 combined with autologous hematopoietic stem cell transplantation，Dose: （0.5 -2）x 10\^6/kg CNCT19 Cell Injection via intravenous infusion.
215102849|NCT02769169|DRUG|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
215102850|NCT02769169|DRUG|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
214422661|NCT06007118|RADIATION|WBI|accelerated whole breast irradiation with the boost to tumor bed (15x 2,67 Gy + 5x 2,0 Gy, every working day)
214422662|NCT06237751|DRUG|Sildenafil 100 MG|Sildenafil 100mg orally half an hour before surgery
214422663|NCT02363192|BEHAVIORAL|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
214422664|NCT05597280|DRUG|BE-PEP Bedaquiline|bedaquiline
215022214|NCT01312077|DRUG|Levobupivacaine|peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
215022215|NCT01312077|DRUG|Intrathecal morphine|intrathecal morphine bolus 200 micrograms
215022216|NCT03813251|DEVICE|ForConti Contix Fecal Incontinence Management System (FIMS)|Use the device for up to 12 hours per use for 4 weeks
215102851|NCT00128986|PROCEDURE|Tomotherapy|3T MRS scans (3T magnetic resonance spectroscopy)
214422665|NCT05597280|DRUG|SDR-PEP Rifampicin|SDR-PEP: rifampicin
214422666|NCT05597280|DRUG|BE-PEP Rifampicin|BE-PEP rifampicin
214690479|NCT05666011|DEVICE|M22 IPL|IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.
214507122|NCT06688539|DRUG|Varenicline Pill|In this study, all participants will be administered active medication for a 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
214507123|NCT06688539|BEHAVIORAL|Contingency management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on e-cigarette abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
214422667|NCT06112899|BEHAVIORAL|Nordic Hamstring Exercise|The NHE, also referred to as the nordic curl, is designed to improve eccentric strength of the hamstring muscles. Individuals start in a kneeling position, with the torso from the knees upward held rigid and straight. The training partner ensures that the individual's feet are in contact with the ground throughout the exercise by applying pressure to the player's heels/lower legs. The individual then lowers his upper body to the ground, as slowly as possible to maximize loading in the eccentric phase. Hands and arms are used to break his forward fall and to push him back up after the chest has touched the ground, to minimize loading in the concentric phase.The exercise protocol is planned as 5 sets of 8 repetitions and 2 minutes of rest between each set.
214422668|NCT04562636|OTHER|Environmental message|Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.
214507124|NCT06688539|BEHAVIORAL|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study.
214507125|NCT06698991|BIOLOGICAL|Plasma Exchange|"• Plasma exchange (1.5 times plasma exchange)~* Blood volume: 80ml/kg~* Plasma volume = Blood volume x (1 - Hematocrit/100)~* TPE volume = 1.5 x plasma volume~* Duration: 4 hours"
214507126|NCT06698991|OTHER|Standard Medical Treatment|Standard Medical Treatment
214507127|NCT06698952|OTHER|Intervention Group|The intervention group will engage with SPI-Bot, a conversational agent designed to deliver cognitive and behavioral strategies for managing psychological symptoms through fully automated interactions. SPI-Bot operates on a template-based platform with predefined dialogue options, utilizing natural language processing technology. The intervention spans eight weeks and includes key components such as psychoeducation, cognitive restructuring, relaxation training, activity scheduling, problem-solving skills training, and social skills training. Participants will complete one session per week over the eight-week period. Participants will receive weekly contact from the research team to report AIS symptoms, receive homework reminders, and address any intervention-related questions.
214507128|NCT06698952|OTHER|control group|Participants in the control group will interact with a different generative chatbot, engaging in casual conversations at a similar dosage to ensure balanced attention and interaction effects.
214507129|NCT06698341|PROCEDURE|Blood Draw|3X 6mL K2-EDTA tubes, 1X 3mL K2-EDTA tubes and 1X 3.5mL SST tube - 24.5ml of blood will be collected from patient
215022217|NCT05751811|DEVICE|Virtual reality|"The immersive video simulated a magical journey through a calming starry sky on a flying carpet. The headset will play the immersive video content throughout the hysteroscopic procedure; and will stop playing the content as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
215022218|NCT05751811|PROCEDURE|Music therapy|"Relaxing and light music will play throughout the hysteroscopic procedure; and will stop playing as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
215022219|NCT05486065|DRUG|Semaglutide|Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
215022220|NCT05486065|DRUG|Placebo|Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
215022221|NCT03878069|BIOLOGICAL|elapegademase-lvlr|Revcovi is administered intramuscularly (i.m.). Weekly dosage is calculated in mg/kg of body weight, and can be adjusted over the course of the trial based on ADA activity and dAXP concentration as well as on clinical assessment by the treating physician.
215022222|NCT06673199|DIETARY_SUPPLEMENT|Washoku diet|The Washoku diet will consist of following the principles of a healthy eating plate, which will be supplemented with elements of the Washoku diet (30g of roasted black soybeans and 5g of wakame). Food products will be given to women on the day of the first meeting. The Washoku diet will be used for 7 days a week for a period of 1 month (4 weeks).
215022223|NCT06212739|PROCEDURE|Laser|Diode laser used to effect closure of the anal fistula tract
215022224|NCT06212739|PROCEDURE|LIFT|The intersphincteric portion of the fistula is excised and ligated.
215022225|NCT06674772|DIAGNOSTIC_TEST|Saliva test|Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.
214507130|NCT06877429|PROCEDURE|Time of OPU|OPU procedure either at 8 am or 8 pm
214507131|NCT06691776|DEVICE|online CBCT-guided adaptive radiation therapy using a new software|Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.
214507132|NCT06879002|OTHER|Ovarian stimulation with menstruation or after ovulation|Ovarian stimulation with menstruation or after ovulation
214507133|NCT06712719|OTHER|LP then HP|"Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~LP then HP"
214507134|NCT06712719|OTHER|HP then LP|"Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~HP then LP"
214507135|NCT06887348|OTHER|Observational study with no interventions|This is an observational study and there will be no clinical interventions.
214507136|NCT07043153|DIAGNOSTIC_TEST|Albumin to globulin ratio and prognostic nutritional index model|Measurement of albumin to globulin ratio and prognostic nutritional index in participants to assess disease activity in systemic lupus erythematosus patients
214507137|NCT07042867|BIOLOGICAL|biobanking|blood draw at each time point
214507138|NCT07042867|RADIATION|low dose scan|low dose lung scan will be performed at each timepoint
215022226|NCT06673797|OTHER|Effects of Swiss Ball exercises|"Effects of Swiss ball exercises along with stretching as baseline treatment.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times.~2. Swiss ball exercises. a.Sitting on the Swiss ball with the trunk straight, arms by the sides, and eyes opened progressed towards eyes closed for 10 seconds, then rest. b.Sitting on the Swiss ball with trunk straight and arm by the sides. The therapist would assist the patient to engage the patient in shifting the body's weight to one side and the other side sideways as well as anterior and posterior and up and down alternatively. Start with 10 repetitions. c. Standing with gym ball in front. The therapist would stand behind the patient to provide support and ask the patient to lean forward on the gym ball with both hands via outstretched arms. Start with 10 repetitions d. One leg weight bearing on a gym ball with the therapist behind the patient, gripping the patient's pelvis to provide support. Start with 10 repetitions"
215022227|NCT06673797|OTHER|EFFECTS OF FRENKEL EXERCISES ON STATIC AND DYNAMIC BALANCE IN ATAXIC CHILDREN WITH CEREBRAL PALSY|"Frenkel Exercises along with stretching as baseline treatment. The second intervention group would participate in Frenkel Exercises along with stretching as baseline treatment. The exercises would be performed 3 times per week for four weeks.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times. (11)~   a. Calf stretching. b. Hamstring stretches. c. Quads stretching~2. Frenkel\&#39;s lower limb exercises are the exercises listed below. The time of each session was set to be 10 minutes in the first week and then raised by 5 minutes every week. The patients were given 5 minutes to relax after 10 minutes of practice. (12)~   1. Supine lying~  2. While sitting~  3. Stride standing"
215022228|NCT06673953|OTHER|Respiratory Muscle Training by (The Breather)|Patients are instructed to inhale deeply and forcefully (at non fatigable resistance) for 2-3 seconds, slight pause, and then exhale forcefully for 2-3 seconds for 10 repetitions with 2 sets.
215022229|NCT06673953|OTHER|Traditional physical therapy program|Traditional physical therapy program in form of: (TENS / Low-intensity continuous ultrasonic / Infrared radiation application / Cervical Stabilization exercise )
215102852|NCT01183065|DRUG|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
215102853|NCT02097654|OTHER|SENATOR software generated pharmacotherapy advice report.|
215102854|NCT02456857|BIOLOGICAL|Bevacizumab|Given IV
215102855|NCT02456857|DRUG|Everolimus|Given PO
215102856|NCT02456857|OTHER|Laboratory Biomarker Analysis|Correlative studies
215102857|NCT02456857|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
215102858|NCT00781859|DRUG|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
215102859|NCT00781859|DRUG|Placebo|Placebo intravitreal injection
214422669|NCT04562636|OTHER|Health message|Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.
214422670|NCT04562636|OTHER|Neutral Message|Participants will be randomized to view a set of four messages about checking their credit score.
214422671|NCT00553683|DRUG|cyclophosphamide|
214422672|NCT00553683|DRUG|poly ICLC|
214422673|NCT00553683|PROCEDURE|hepatic artery embolization|
214422674|NCT00553683|RADIATION|3-dimensional conformal radiation therapy|
214422675|NCT05632471|BEHAVIORAL|"web-based I know digital games training for intervation grup"|"I know digital games training consisting of 10 web-based videos"
214422676|NCT05632471|OTHER|The control group was not trained|The control group was not trained
214422677|NCT02694978|DRUG|Ferumoxytol|
214422678|NCT02694978|DRUG|FCM|
214422679|NCT03270124|BEHAVIORAL|Daily Activity Goal|Patients are given a tailored daily activity goal in terms of steps per day for which to aim.
214422680|NCT03270124|BEHAVIORAL|Resistance Exercises|Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
214422681|NCT03270124|BEHAVIORAL|Daily Activity Recording|A Fitbit will be worn by all participants to record daily activity.
214422682|NCT04997746|BEHAVIORAL|Multiprofessional educational interventions|Preventive educational interventions
214422683|NCT04997746|OTHER|Measurement of anthropometric measurements|Measurement of height (in meters), weight (in kilograms), knee height, arm circumference and calf circumference (in centimeters)
214422684|NCT00904852|DRUG|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
214507139|NCT07043712|DIETARY_SUPPLEMENT|High pulse consumption|Subjects are provided a high pulse diet for 4 weeks.collection, and anthropometrics measured.
214507140|NCT06716606|DRUG|Belimumab|Belimumab will be administered.
214507141|NCT07042828|DRUG|Bilastine oral dispersible tablets|Bilastine 20 mg oral dispersible tablets
214507142|NCT07042828|DRUG|Bilaxten oral dispersible tablets|Bilaxten 20 mg oral dispersible tablets
214422685|NCT01613716|DRUG|Ozurdex|Ozurdex .7 mg injected into the treated eye
214422686|NCT01580319|OTHER|physical exercise|150 minutes per week
214422687|NCT03489915|DEVICE|OCT|Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity
214422688|NCT00191412|DRUG|Pemetrexed|
214422689|NCT02759588|BIOLOGICAL|GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab|GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
214422690|NCT01689090|OTHER|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
214422691|NCT01689090|OTHER|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
214422692|NCT01689090|OTHER|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
214422693|NCT01377428|DRUG|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
214422694|NCT01377428|DRUG|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
214422695|NCT03417869|DEVICE|QuickVue Influenza A+B|Rapid diagnostic test with IVD, QuickVue Influenza A+B
214422696|NCT01763086|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10\^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
214507143|NCT06547515|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
214507144|NCT06736769|DRUG|Ketamine infusion|Ketamine will be delivered intravenously at 0.5 mg/kg over 40 minutes.
214507145|NCT07052370|DRUG|Thymoglobulin|IV
215022230|NCT06688552|OTHER|Proprioception Measurements|Laser cursor-assisted angle repetition test was used for proprioception assessment. A coordinate plane with different movement angles was fixed on a wall and the person was positioned 1 meter from this wall. The laser pointer was fixed on the person's arm for shoulder proprioception measurement, 5 cm above the elbow to avoid being affected by other joints, 5 cm above the person's wrist for elbow joint proprioception and fixed on the person's second metatarsal bone for wrist proprioception.
215022231|NCT06688552|OTHER|Fatigue Measurement|Myoton PRO® (Myoton AS, Tallinn, Estonia) muscle palpation device was used to assess fatigue, and the dynamic stiffness parameter was taken as the basis. The stiffness value is calculated as the maximum acceleration (N/m) of oscillation and deformation in the tissue sensed by the transducer (Chen et al., 2017). The increase in muscle dynamic stiffness has been associated with fatigue level (Klich et al., 2019; Shitova et al., 2020; Wang, 2017). Before the measurement, the athletes' pectoralis major, deltoideus and triceps brachii muscle reference points were determined and marked, and measurements were taken over these points. The athletes were asked to keep their muscles relaxed throughout the measurement in order not to affect the tissue stiffness and the application was performed at room temperature.
215022232|NCT06675981|OTHER|Real Acupuncture|Patients received 6 sessions of acupuncture (three sessions per week or every other day) for two consecutive weeks
214422697|NCT00328731|PROCEDURE|Procedure|
214422698|NCT01354795|PROCEDURE|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
215022233|NCT06675981|OTHER|Non-acupuncture at real-acupoint|The acupuncture simulation device will be used to perform acupuncture at the same acupoints as those of the real acupuncture group.
214422699|NCT01354795|PROCEDURE|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
214422700|NCT04484753|OTHER|Home Exercise Sheet|Received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
214422701|NCT04484753|OTHER|Ipelvis mobile application|Received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
214422702|NCT04484753|BEHAVIORAL|Home exercise sheet + Pelvic Physiotherapy|Performed 12 Pelvic Physiotherapy sessions, in group, once a week and received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
214422703|NCT04484753|BEHAVIORAL|Ipelvis mobile application + Pelvic Physiotherapy|Performed 12 pelvic physiotherapy sessions, in group, once a week and received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
214422704|NCT00404417|DRUG|Botulinum Toxin A / Placebo|Botulinum Toxin A at first injection / Placebo at second injection
214422705|NCT00404417|DRUG|Botulinum Toxin A / Botulinum Toxin A|Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
214507146|NCT07052370|DRUG|Cyclophosphamide|IV
214507147|NCT07052370|DRUG|Fludarabine|IV
214507148|NCT07052370|DRUG|Thiotepa|IV
214507149|NCT07052370|DRUG|Melphalan|IV
214507150|NCT07052370|DRUG|Mesna|IV
214507151|NCT07052370|DRUG|Filgrastim|IV
214507152|NCT07052370|DRUG|Blinatumomab|IV
214507153|NCT07052370|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
214507154|NCT07052812|BEHAVIORAL|MCT|Metacognitive Therapy (MCT) is a 12-week manualized treatment for OCD targeting maladaptive thought patterns. Clinicians deliver structured sessions including: (1) Attention Training to modify focus, (2) Detached Mindfulness to change responses to intrusive thoughts, and (3) behavioral experiments to reduce compulsions. Treatment progresses through psychoeducation, challenging perfectionism, addressing thought control, and relapse prevention. Primary outcome: Y-BOCS; secondary: MCQ-30 and TFI. Based on the evidence-based myMCT protocol.
215022234|NCT06675981|OTHER|Shallow acupuncture at real-acupoint|At the same acupoint in the acupuncture group, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
215102860|NCT01029847|DRUG|Adalimumab|Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
214422706|NCT00404417|DRUG|Placebo / Botulinum Toxin A|Placebo at first injection / Botulinum Toxin A at second injection
214422707|NCT00404417|DRUG|Placebo / Placebo|Placebo at first injection / Placebo at second injection
214422708|NCT01547546|DRUG|GDC-0084|Multiple doses
214422709|NCT04030767|DRUG|Botox Injectable Product|Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
214507155|NCT06829303|DEVICE|Emotional Facial Expression Paradigm (EFP)|The experimental intervention is a social cognition gamified training, through a software that implements communication between a participant and a computer, using a detection and classification algorithm based on EEG signal. The training consists of a visual stimulation model, specifically an emotional facial paradigm, where the subject is asked to observe the movements of a facial expression (referred to as cue image) expressing either happiness or sadness and to adapt the visual gaze according the cue image.
214507156|NCT06829303|DEVICE|Speller task|The control intervention is a executive function gamified training, through a software that implements communication between a participant and a computer, using a detection and classification algorithm based on the P300 EEG signal. The task consists of a speller, in which the participant is asked to write a word, by sequentially focusing the attention on the necessary letters.
214422710|NCT02224924|OTHER|ABPI|If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.
214690480|NCT00496873|DRUG|Cytoxan|600 mg/m\^2 on Day 1 of 21-day cycle.
214507157|NCT06754644|DRUG|QL2107|200mg on day 1 of each 21-day cycle of the study
214507158|NCT06754644|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 21-day cycle of the study
214507159|NCT06754644|DRUG|Carboplatin|Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles
214507160|NCT06754644|DRUG|Keytruda®|200mg on day 1 of each 21-day cycle of the study
214507161|NCT06897683|DRUG|PF-07220060|Single dose PF-07220060 tablet administered with a moderate-fat standard calorie meal
214507162|NCT06897683|DRUG|Carbamazepine ER Tablet|Carbamazepine dosing titration regimen in Period 2 from Day 1 to 18
214690481|NCT00496873|DRUG|Nipent|4 mg/m\^2 on Day 1 of 21 Day Cycle.
214690482|NCT00496873|DRUG|Rituxan|375 mg/m\^2 on Day 1 of 21 Day Cycle.
214690483|NCT02949765|DRUG|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
214690484|NCT02949765|DIETARY_SUPPLEMENT|Iron-rich diet|
215022235|NCT06675981|OTHER|Shallow acupuncture at non-meridian and non-acupoint|At non-meridian and non-acupoint, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
215102861|NCT01029847|DRUG|Placebo|"sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines."
214422711|NCT02224924|DEVICE|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
214422712|NCT03623997|OTHER|Iron stable isotope labeled iron(II) sulfate|Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
214422713|NCT03204968|DEVICE|Vagus nerve stimulation|transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
214422714|NCT03020745|DRUG|GSK3389404|GSK3389404 is available as Clear colorless to slightly yellow solution for injection.
214507163|NCT06808048|BEHAVIORAL|Cognitive testing|Participants will complete a cognitive testing battery that includes measures of attention, learning, memory, problem-solving and executive function.
214507164|NCT06808048|BEHAVIORAL|Task-based fMRI measure of inhibitory control|All participants will complete a task-based fMRI measure of inhibitory control. This Go/No-Go task provides a contrast of BOLD signals when response conflict is low (execution of motor responses on frequent Go trials) vs high (inhibiting the prepotent response on infrequent NoGo trials). It will provide an assessment of the effects of cannabis use on the frontostriatal implicit motor learning and cognitive control systems. Participants view shapes and press a button quickly (Go trials) to every shape except circles and squares (NoGo Trials). To increase response prepotency, Go trials are frequent (75%). Button presses must be rapid to be considered correct. The task uses an event-related design with each stimulus presented for 600 ms, followed by a 1.0-4.5 second jittered ISI during which a white fixation crosshair is displayed. Trial type is pseudo-randomized with the constraint of equal frequencies of consecutive Go trials (2, 3, or 4) between NoGo trials.
214690485|NCT00471367|DRUG|AZD4877|intravenous infusion administered twice a week for 2 weeks
214690486|NCT04201769|DRUG|Netupitant/Palonosetron|NEPA is adiministered 60 minutes before chemotherapy, on day 1
214690487|NCT04201769|DRUG|Dexamethasone|"Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm"
214690488|NCT03769740|DEVICE|Cerebral Oximetry|Non invasive, near infrared spectroscopy cerebral oximetry
214690489|NCT02484573|DRUG|Propanolol|
215022236|NCT06541301|DEVICE|PICC-port|Implantation of a PICC-port device by a dedicated PICC team member following predefined evidence-based international guidelines and protocols
215022237|NCT06541301|DEVICE|Chest-port|Implantation of a Chest-port device by expert physicians or certified expert nurses, following predefined evidence-based international guidelines and protocols
215022238|NCT02171208|DRUG|dimethyl fumarate - Reference form|single dose 240 mg
215022239|NCT02171208|DRUG|dimethyl fumarate - Test form|single dose 240 mg
214422715|NCT03020745|DRUG|Placebo|Placebo is available as a Clear colorless solution.
214507165|NCT06808048|BEHAVIORAL|Task-based fMRI measure of face-name learning|"This task is ideally suited to assess cannabis effects on explicit associative learning and memory as mediated by frontohippocampal networks. Participants memorize names corresponding to faces (encoding phase), and then recall the names after a short delay. The first encoding block begins with a 2-second cue (MEMORIZE) followed by 5 face-name pairs, each shown for 4 seconds; participants press a button when they encode each face-name pair. A distractor block follows. Next, a retrieval block begins with a cue to RECALL followed by presentations of each of the same 5 faces, now paired with ??? (i.e., prompting recall of previously paired names), with a 4 second stimulus duration and no ISI. On recall trials, participants press a button to indicate that they have recalled the name for the displayed face. Participants engage in silent uncued recall of face-name pairs. Immediately following the scan, participants are tested for accuracy of name retrieval."
214507166|NCT06842134|DRUG|Numeta G16%E|Numeta G16%E (1000mL) will be given intravenously via peripherally inserted central catheter and will provide an equimolar IV phosphate dose of 8.7 mmol over 9 h.
214690490|NCT04389476|OTHER|Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)|"Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors."
215022240|NCT00834587|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose non-fasting
215022241|NCT00834587|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose non-fasting
215022242|NCT00176254|RADIATION|Radiotherapy|80 centigray (cGy) on Day 1 \& 2 and 22 \& 23 of chemotherapy
215022243|NCT00176254|DRUG|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
215022244|NCT00176254|DRUG|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
215022245|NCT06679504|PROCEDURE|Fibrin glue fixation|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Fibrin Glue fixation
214422716|NCT05489536|BEHAVIORAL|A web/smartphone-based lifestyle program package|"There are two platforms for the lifestyle program, namely Health and Nutrition Education (HNE) website and HNE app. The participants are requested to download and register on the HNE website and the HNE app. The HNE app is Android and IOS compatible. Both the HNE website and app are designed to support self-directed learning and independently monitor their GWG and dietary intake during pregnancy. Both the HNE website and app will be passcode protected throughout the study period such that access is restricted to only participants in the intervention group.~The web/smartphone-based lifestyle program package consists of:~I. Health and Nutrition Education (HNE) resources II. Gestational Weight Gain (GWG) monitoring III. Dietary intake monitoring"
215022246|NCT06679504|PROCEDURE|Tack fixation|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Tack Mesh Fixation
215022247|NCT06678997|DEVICE|Zinc-L carnosine/Polaprezinc|This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
214422717|NCT05471635|BIOLOGICAL|COVID-19 Vaccine|All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
214422718|NCT05312021|DRUG|IMR-687|150 mg and 200 mg tablets
214422719|NCT05312021|OTHER|IMR-687 Placebo|Matching placebo to IMR-687
215022248|NCT06678997|OTHER|Thickened formula|This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
215022249|NCT06543758|DEVICE|Wearable exoskeletal robot|Participants will wear a wearable exoskeletal robot for gait training and undergo 10 sessions of 30-minute gait training over 4 weeks at home or in nearby indoor spaces. Participants will participate in physical function assessments, including the 10-meter walk test, Timed Up and Go (TUG) test, and Berg Balance Scale, both before and after the intervention. Additionally, participants will complete quality of life and depression inventories before and after the intervention.
215022250|NCT06546735|DRUG|N0728|1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®.
215022251|NCT06546735|DRUG|Vesomni®|1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
215022252|NCT06618534|DRUG|Azithromycin|A standard dose of azithromycin (500 mg) will be delivered by oral route.
214422720|NCT04583306|OTHER|Raman analysis of saliva, characterization of the Raman database and building of the classification model|Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
214422721|NCT03168048|OTHER|mobile application|Oncologic therapy support by means of a mobile application
215102862|NCT01211821|DRUG|metoprolol|Tablets, Oral, 200 mg, once, 1 day
215102863|NCT01211821|DRUG|BMS-914392|Tablets, Oral, 60 mg, once daily, 7 days
214422722|NCT02794194|OTHER|Proprioceptive training on a whole body vibration platform|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
214422723|NCT02794194|OTHER|Proprioceptive training with the BOSU® on the floor|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
215102864|NCT05546229|PROCEDURE|Microneedle based interstitial fluid collection|Interstitial fluid will be collected from the skin using microneedles and suction.
215102865|NCT01983774|DRUG|Esomeprazole|
214422724|NCT03002805|DRUG|CBT-1®|"CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:~Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 37.5 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed."
214422725|NCT06332040|DRUG|Gentamicin|random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
215022253|NCT06674057|PROCEDURE|KinesioTaping|"The experimental group will receive the following treatment for week 1-3 (3 days on alternate days):~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Kinesio tape 3 times per week. (Anchor opposed to effected compartment to provide facilitation and sustained stretch).~For week 3-6 the treatment will include:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Strengthening affected muscle groups by resistance training, 3 times per week (using a resistance band of mediu"
214422726|NCT01495663|DRUG|I-131-CLR1404|"Description:~* Dosimetry: IV, 5 mCi, single dose, 6-day duration~* Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"
214422727|NCT00317577|DRUG|brimonidine, timolol|
214507167|NCT06842134|DRUG|Sodium Glycerophosphate Injection|Organic phosphate (SGP) will be diluted 1000mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 8.7 mmol over 9 h.
214507168|NCT06762769|DRUG|Isatuximab|Subcutaneous isatuximab will be delivered using an unlicensed medical device (On Body Delivery System)
215022254|NCT06674057|PROCEDURE|Control|"The control group will receive the following treatment for week 1-3 on alternate days:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~For week 3-6 the treatment will include:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Strengthening affected muscle groups by resistance training, 3 times per week (using a resistance band of medium resistance)."
215022255|NCT06674876|BEHAVIORAL|Blog writing|Participants were asked to write 2blogs online for four weeks and attend a 4hours wellness workshop
215022256|NCT06673680|DEVICE|Do colposcopy and cervical punch biopsy then compare between findings|The aim of this study is to correlate colposcopy and histopathological findings in early screening of suspicious cervix and cervical cancer. And to do a colposcopic evaluation of all cervical lesions and the early detection of all cervical precancer and invasive lesions of the cervix in symptomatic women.
215022257|NCT06675877|OTHER|virtual reality camera|The virtual reality eyeglasses were placed on the child's head, the child watched 3 D VR kids' cartoons or videos to distract his/her attention during needle insertion. The video was displayed through a smart phone inserted inside the virtual reality headset.
214690491|NCT02839967|OTHER|Photobiomodulation|Intraoral photobiomodulation is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of photobiomodulation in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.
214690492|NCT02839967|OTHER|Photobiomodulation placebo|The volunteers will be subjected to the same Group intervention, Photobiomodulation and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
214690493|NCT04002440|COMBINATION_PRODUCT|AMIA with SHARESOURCE Connectivity Platform|The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
214422728|NCT02680457|DRUG|Insulin Degludec|Insulin Degludec 10 IU SC every 24 hours for 6 days
214507169|NCT06762769|DRUG|Iberdomide|Oral iberdomide
214507170|NCT06762769|DRUG|Dexamethasone|Oral dexamethasone
214422729|NCT02680457|DRUG|Insulin Glargine|Insulin Glargine 10 IU SC every 24 hours for 6 days
214422730|NCT00617812|BIOLOGICAL|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
214422731|NCT05948644|DRUG|TPN171H|TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
214422732|NCT02349503|DRUG|NBI-77860|
214422733|NCT02349503|DRUG|NBI-77860|
214422734|NCT02349503|DRUG|NBI-77860|
214422735|NCT03573258|DIETARY_SUPPLEMENT|Fiber or Placebo (depending on the randomization)|ingestion of dietary fibers prior to meal intake
214422736|NCT00541749|DRUG|rhuMAb IFNalpha|Intravenous repeating dose
214507171|NCT03407079|OTHER|Sucralose|Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.
214507172|NCT03407079|OTHER|Placebo|Placebo capsules will be taken orally for 28 days
214507173|NCT05004662|BEHAVIORAL|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
215022258|NCT06673459|BIOLOGICAL|TBICy|The TBI-Cy group was administered 250 mg/m2/d oral Me-CCNU on day -8. A total of 12 Gy TBI was for each patient and fractionated dose was 2 Gy twice daily or 4Gy once daily on days -8 to -6. Occluding of the lung fields during TBI, the corresponding irradiation dose reduced to a total of 8 Gy. On day -5, the schedule was intravenous 2 g/m2 Ara-C every 12 hours. Then intravenous 1.8 g/m2 CTX once per day from days -4 to -3.
215022259|NCT06673459|BIOLOGICAL|BuCy|The BuCy group received oral Me-CCNU 250 mg/m2/d twice daily on day -8, intravenous cytosine arabinoside (Ara-C) 2 g/m2 twice daily on day -7, intravenous Bu 3.2 mg/kg/d from days -6 to -4, and intravenous cyclophosphamide (CTX) 1.8 g/m2/d from days -3 to -2. There were no patients accepted oral Bu.
214690494|NCT04002440|DEVICE|HomeChoice PRO|Usual care
214422737|NCT03184558|DRUG|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor.
214422738|NCT04606251|OTHER|Exercise|The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
214422739|NCT04859595|OTHER|Telephone follow-up|"Monthly follow-up by telephone from M1 to M6. The interview will unroll in 2 stages, a first stage of discussion during which the speech therapist will take news of the patient. The second, more formal phase will be the opportunity to collect the data necessary for the validation of the primary and secondary outcomes. To do this, the speech therapist will use the Functional Oral Intake Scale (FOIS) score, the DHI and an interview grid.~The interview will be conducted using an interview sheet previously written by the project team. The following elements will be discussed: the description of oral food intakes (TIMES), the perceived swallowing handicap (DHI), the instructions related to the diet and their daily application, ongoing rehabilitation follow-ups, notable events as well, then his emotional and psychological experience in relation to the disorder."
214422740|NCT02506257|DRUG|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
214422741|NCT02506257|DRUG|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
214422742|NCT02506257|DRUG|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
214422743|NCT02506257|DRUG|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
214422744|NCT03081949|DRUG|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
214690495|NCT00271440|PROCEDURE|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
214690496|NCT05215392|BEHAVIORAL|Family Connections program|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
215029146|NCT05763849|BEHAVIORAL|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance in Anorexia Nervosa. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Early sessions include using exposure to foods and counterconditioning to pair a positive stimulus with a food that would typically produce food avoidance. Parents are trained to model this at home. Sessions mid-way through address the use of non-judgmental description of appearance during mirror exposure. Sessions at the end of the 20 weeks are focused on recognizing change, planning for future obstacles, and developing a relapse prevention plan to continue practicing distress tolerance, counter-conditioning, and food/body exposure.
215102866|NCT01983774|DRUG|Placebo|Sugar pill
214422745|NCT03123172|DIAGNOSTIC_TEST|arterial and central venous blood gases|withdrawal of arterial and central venous blood gases to measure Co2 gap
214422746|NCT01494246|OTHER|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
214422747|NCT00148291|DRUG|Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.|
214422748|NCT03760419|BEHAVIORAL|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
214422749|NCT04360057|OTHER|PMD|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance used on the initial visit.
214422750|NCT04360057|OTHER|PMDPlus|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance on follow up visits
214422751|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
214422752|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
214422753|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
214422754|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
214422755|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
214422756|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
214422757|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
214422758|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
214422759|NCT03514251|PROCEDURE|The suture marks the location of the parathyroid gland|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
214690497|NCT00096096|DRUG|mycophenolate mofetil|
214690498|NCT00096096|DRUG|tacrolimus|
214690499|NCT01276067|DRUG|Donepezil|10 mg Tablet
214690500|NCT02018614|OTHER|algoplus|
214690501|NCT00540969|PROCEDURE|cryosurgery|Patients undergo cryosurgery using guidance from CT scan or ultrasound
214690502|NCT00540969|RADIATION|radiation therapy|Patients undergo radiotherapy for 1 week
214422760|NCT00877435|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
214422761|NCT03829917|DRUG|Miltefosine and Paromomycin|28 days of miltefosine plus 28 days of Paromomycin cream
214422762|NCT03829917|DRUG|miltefosine|28 days of miltefosine
214422763|NCT03829917|DRUG|paromomycin|28 days of paromomycin creaam
214422764|NCT03052946|PROCEDURE|Bulking agent|Filling bulking agent in the anal canal
214422765|NCT03052946|PROCEDURE|Endoanal electrostimulation|The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
214422766|NCT01678196|BEHAVIORAL|VA-CRAFT|VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.
214422767|NCT01678196|OTHER|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
214422768|NCT03827512|OTHER|Doppler arterial waveforms analysis|terminology used when describing arterial Doppler waveforms
214422769|NCT02355535|DRUG|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
214422770|NCT04247204|BIOLOGICAL|Platelet-rich plasma intrauterine infusion|For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.
214507174|NCT05004662|DRUG|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
214507175|NCT05004662|BEHAVIORAL|Counceling|Phone counseling with the Florida Quitline
214507176|NCT05004662|DRUG|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
214690503|NCT05896761|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
214690504|NCT05896761|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
214690505|NCT03189576|DIAGNOSTIC_TEST|blood draw|
214690506|NCT02112162|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/MRI
214690507|NCT02112162|DEVICE|positron emission tomography|Undergo FDG PET/MRI
214422771|NCT01122420|OTHER|Goal-Setting Tool|Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
214422772|NCT01122420|OTHER|Health Web Sites|Access to publicly available health-related web sites
214422773|NCT01377623|DRUG|Dexmedetomidine group|Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
214507177|NCT06897046|DRUG|QL1706|PD-1/CTLA-4
214507178|NCT06897046|DRUG|QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed|PD-1/CTLA4 combined chemotherapy drugs
214507179|NCT07063056|DIETARY_SUPPLEMENT|Curcumin (Longvida™)|1 capsule per day at a usual curcumin dose for this particular product (80 mg curcumin)
214507180|NCT07063056|DIETARY_SUPPLEMENT|Half Dose Curcumin (Longvida™)|1 capsule per day at half the usual curcumin dose for this particular product (40 mg curcumin as the half dose)
214507181|NCT07063056|DIETARY_SUPPLEMENT|Astaxanthin|1 capsule per day at a usual astaxanthin dose (12 mg)
214507182|NCT07063056|OTHER|Placebo Control|Subject will get 1 capsule per day of a small amount of cellulose
214690508|NCT02112162|DEVICE|magnetic resonance imaging|Undergo FDG PET/MRI
214690509|NCT02112162|OTHER|laboratory biomarker analysis|Correlative studies
214690510|NCT03641989|OTHER|Plaque disclosing toothpaste|Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
214690511|NCT03641989|OTHER|Non-plaque disclosing toothpaste|Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
214690512|NCT03755531|DRUG|Carbetocin|"Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.~Drug was kept in cold storage (2 to 8°C)."
214690513|NCT03755531|DRUG|Oxytocin|"Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.~Drug was kept in cold storage (2 to 8°C)."
214690514|NCT00619684|DRUG|lenalidomide|Given PO
214690515|NCT02209233|OTHER|Massage Therapy|
215022260|NCT06675006|COMBINATION_PRODUCT|Medical Massage|This intervention refers to the application of therapeutic massage techniques aimed at alleviating pain and enhancing muscle relaxation in patients with nonspecific low back pain. The treatment focuses on manipulating soft tissues, including muscles, tendons, and fascia, to improve circulation, reduce muscle tension, and promote overall wellness. Medical massage is tailored to each patient's specific needs and can incorporate various techniques, including Swedish massage, Bowen Therapy, a gentle and non-invasive manual therapy, utilizes precise movements on specific points of the body to promote healing and restore balance. The therapist applies light pressure with the fingers, allowing the body to respond and relax. This technique aims to stimulate the body's innate healing mechanisms, encouraging improvements in pain levels and functional capacity. Sessions are typically structured to allow for periods of rest, giving the body time to process the treatment and enhancing its effects.
214422774|NCT01377623|DRUG|Placebo group|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
214422775|NCT05979324|DEVICE|ABAStroke Digital Therapeutics|The total time of the study is 30 weeks in total, i.e. 15 weeks of patient recruitment and then a maximum of another 15 weeks until the end of the observation of the last patient. Within 2 weeks from the last patient, the last Monitor's visit will be performed to close the study. The patient will use the ABAStroke application for a maximum of 91 days (the minimum time is 28 days) and standard therapy, including rehabilitation (as recommended by researchers or other physicians rehabilitating a patient after a stroke).
214422776|NCT04018508|OTHER|Massage|Massage intervention including effleurage, petrissage and energy work/Reiki at a pressure of 2 or less (Walton Pressure Scale)
214422777|NCT00401323|DRUG|docetaxel (XRP6976)|
214422778|NCT00401323|DRUG|cisplatin|
214422779|NCT00401323|DRUG|5-fluorouracil (5-FU)|
214422780|NCT01740817|DRUG|Intralipid 20%|30 ml/h for 48 h
214422781|NCT01740817|DRUG|Saline|30 ml/h for 48 h
214422782|NCT01320280|DRUG|BIBW 2992 (Afatinib)|50 mg BIBW 2992 (Afatinib) tablets daily continuously
214422783|NCT06186739|BEHAVIORAL|home-based motor rehabilitation training participated by caregivers|The knowledge provider was a multi-disciplinary home-based rehabilitation nursing team, which is composed of advanced practice nurse (APN) who engaged in professional rehabilitation of stroke, neurologists, rehabilitation doctors and physical therapists. Among them, APN mainly carry out and supervise family rehabilitation education and all members are collectively responsible for the adjustment and optimization of the program content. After the assessment is completed, the patient's current functional status will be confirmed. based on this, team members recommend home-exercise items that match the patient's motor function state . In this intervention programme, the content of the intervention was developed based on the recommendations of internationally published guidelines related to the rehabilitation of ischemic patients, with some adjustments to consider the cultural appropriateness of implementation in China.
214422784|NCT06186739|BEHAVIORAL|routine self-care|the patients in this group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
214422785|NCT05340244|DEVICE|Investigational ultrasound exam|"Eligible subjects will be enrolled into the study and positioned for their ultrasound exam. Standard clinical practice procedures will be followed using the standard of care device at the site to complete the clinically indicated exams.~After the clinically indicated exam, portions of the TTE and/or TEE exam will be repeated with the investigational ultrasound device."
214422786|NCT05493124|DRUG|Manpixiao|A traditional Chinese medicine composition
214422787|NCT05493124|DRUG|Active comparator|Other drugs that may have therapeutic effects
214422788|NCT00139737|DRUG|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
214422789|NCT05857319|BEHAVIORAL|Nutritional Psycho-Behavioral Reeducation Program|"The RNPC Program is based on a clinical protocol in three successive phases:~1. A weight loss phase during which food intake is restricted to 800-1000 kcal per day, with a nutrient distribution of 60% protein, 25% carbohydrates and 15% lipids. Patients eat two meals a day consisting of meat/fish/eggs/shellfish and vegetables, supplemented by products enriched in proteins, vitamins and minerals, and depleted in carbohydrates and lipids.~2. A stabilization phase specifically established for each patient according to their weight loss and their daily caloric needs, allowing them to gradually return to a balanced diet, with a nutrient distribution of 25% protein, 45% carbohydrates and 30% lipids. During this phase, the consumption of meal supplements gradually decreases.~3. A phase of return to dietary balance, unlimited in time, based on the precepts of the Mediterranean diet.~Each patient is followed every 14 days by a dietitian during the entire program."
214422790|NCT00391833|DRUG|Panax Ginseng|
214507183|NCT05735496|DRUG|TQB2102 injection|TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
214507184|NCT06776146|DIAGNOSTIC_TEST|proteomic profiling|proteomic profiling
214507185|NCT06758804|DEVICE|Winterized Pistacia Lentiscus Oil Nasal Drops (Bactorinol®)|Participants will receive winterized Pistacia lentiscus oil nasal drops (Bactorinol®), administered as 3 drops per nostril, three times daily for six consecutive days.
214507186|NCT06758804|DEVICE|Saline Solution (0.9% NaCl)|Participants will receive a saline solution (0.9% NaCl) administered as 3 drops per nostril, three times daily for six consecutive days.
214507187|NCT05831605|PROCEDURE|venipuncture with near-infrared light|with near-infrared light to locate the veins
214507188|NCT05501054|DRUG|Ipilimumab|Given by IV (vein)
214690516|NCT01044277|DRUG|Glutathione supplementation|500 mg, two times daily
214690517|NCT01044277|DRUG|Gluthathione peroxidases|125 mg, two times daily
214690518|NCT01044277|OTHER|Placebo|2 times daily
214422791|NCT04826055|OTHER|biliary limb as fixed length|n all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
215022261|NCT04840875|BIOLOGICAL|chimeric antigen receptor T cell treatment|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
215022262|NCT03810495|DRUG|naltrexone implant|1.8 g implant containing 60% naltrexone
215022263|NCT06623266|PROCEDURE|Neck management|"In the experimental arm: the neck management is neck observation, simultaneous elective neck dissection is not performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.~In the control arm: the neck management is elective neck dissection. Simultaneous elective neck dissection is performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions."
215022264|NCT06674668|OTHER|Vibrotactile stimulation|The intervention includes traditional physiotherapy and 20 minutes of vibrotactile device use. As traditional physiotherapy, 30 seconds of 8 repetitions of passive wrist stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Afterwards, the Intellinetix Elbow Wearable Vibration Device providing vibration will be worn on the affected tissue. The patient will remain in a comfortable position on the treatment table with the affected extremity for 20 minutes (10 minutes × 2).
215022265|NCT06674668|OTHER|Traditional physiotherapy|For traditional physiotherapy, passive stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Stretching exercises will be performed on the wrist flexor and extensor muscles for 30 seconds and 8 repetitions. Mill's manipulation, described by James Cyriax, will be applied once for radial head mobilization. The treatment will be completed with a 5-minute deep friction massage, affecting the wrist extensor muscle tendons and their ending points.
215022266|NCT06690203|COMBINATION_PRODUCT|NRICM102|A traditional Chinese medicine formula
215022267|NCT06688812|OTHER|Perceptual Motor Training|"8 set of exercises~1. Balance training and related exercises~2. Tones of awareness training, body parts' role and related exercises~3. Space awareness training and related exercises~4. Perception of shape training and related exercises~5. Visual perception training and related exercise.~6. Kinesthetic-tactile perception training and related exercises~7. Auditory perception training and related exercises~8. Eye and hand coordination, ﬁne motor movements and related Exercises"
215022268|NCT06688812|OTHER|Repetitive Facilitation Exercises|"Eight set of exercises:~1. Shoulder Flexion with 90° Elbow Flexion (Supine).~2. Shoulder Horizontal Extension/Flexion with Elbow flexion (supine).~3. Complex Shoulder and Upper Limb Movements (Supine)~4. Shoulder Flexion/Abduction/External Rotation with Elbow and Forearm Supination (Supine)~5. Forearm Supination/Pronation with 90° Elbow Flexion (Sitting)~6. Wrist Extension and Forearm Pronation with Finger Extension (Supine)~7. Finger Extension with Wrist Flexion (Supine)~8. Finger Extension/Flexion with Wrist Flexion (Sitting) • Therapist facilitate the movement by rubbing, tapping and gentle stretching."
215022269|NCT06691373|OTHER|Static Stretching|"Static stretching of the quadriceps and hamstrings which was performed in the dominant limb, and held in a position where the participants referred discomfort:~* Quadriceps - participants were in the standing position, with one hand holding the back of a chair to maintain the balance, and were instructed to pull the ankle of the lower limb to be stretched, pressing the heel towards the buttocks and, at the same time, extending the thigh;~* Hamstrings - participants were also in the standing position, with the heel resting on a chair. They were then instructed to lean the body forward keeping the spine erect and the pelvis in anteversion, to obtain a stretch over the knee and hip."
215022270|NCT06686589|DIAGNOSTIC_TEST|Intestinal ultrasound|Intestinal ultrasound performed by hand held ultrasound devices
215022271|NCT06691620|PROCEDURE|Nasal irrigation with isotonic saline|Infants were placed on the examination stretcher in the right or left lateral position. Then, 10 mL of isotonic saline solution was administered over 5 s into the upper nasal cavity of the infant. The secretion and irrigation solution from the lower nasal cavity were cleaned using gauze. The infant was placed on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
214507189|NCT05501054|DRUG|Nivolumab|Given by IV (vein)
214507190|NCT05501054|DRUG|Ciforadenant|Given by PO
214422792|NCT04826055|OTHER|biliary limb as a percentage from small intestine length|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
214422793|NCT00653341|DRUG|insulin glargine|
214422794|NCT00653341|DRUG|NPH human insulin|
214422795|NCT00939042|PROCEDURE|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
214507191|NCT07064226|OTHER|RICORDO|"During the RICORDO intervention, participants will engage in a multidomain cognitive telerehabilitation program using a digital platform (\[http://www.ricordo-dtx.com/\]), which allows for personalized interventions through an adaptive algorithm allowing an increment in task difficulties according to patients' needs. The treatment can be self-administered by the patient at home. The program lasts five weeks, with three treatment sessions per week, each lasting approximately 45 minutes.~The active control group (TAU) will undergo the same type of treatment with the following differences: the digital platform will not be used, as the treatment will consist solely of paper-and-pencil exercises; and there will be no personalization of the exercises, since automatic adaptation is not possible."
215022272|NCT06691620|PROCEDURE|Nasal irrigation with hypertonic saline|Infants were placed on the examination stretcher in the right or left lateral position. Then, 10 mL of hypertonic saline solution was administered over 5 s into the upper nasal cavity of the infant. The secretion and irrigation solution from the lower nasal cavity were cleaned using gauze. The infant was placed on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
215022273|NCT06691620|PROCEDURE|Nontraumatic nasopharyngeal aspiration|After nasal irrigation, the secretions and saline solution from the underlying nasal cavity were nontraumatically aspirated from the entrance of the nasal cavity after the irrigation. The infant was positioned on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
215022274|NCT06689982|DRUG|Tofacitinib tablets|All patients should be closely monitored for signs and symptoms of infection during and after treatment with tofacitinib tablets. If a patient develops a severe infection, opportunistic infection, or sepsis, medication should be discontinued. During treatment, patients with lymphocyte counts \< 500 cells/mm\^3 or ANC \< 500 cells/mm\^3 confirmed by repeated testing should be stopped. When 500≤ANC≤1000 cells/mm\^3, administration should be interrupted, and if ANC returns to more than 1000 cells/mm\^3, administration should be resumed. When hemoglobin \< 8 g/dL or decreases by more than 2 g/dL, administration should be interrupted until hemoglobin values return to normal.
215022275|NCT06687213|BEHAVIORAL|Smoking cessation counselling group|Case group will be counseled to cessate smoking and will be followed up with HbA1c
215022276|NCT06689137|OTHER|mini mental state assessment test|Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used. With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
215022277|NCT06689137|OTHER|mini-cog test|Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
215022278|NCT06689813|DIETARY_SUPPLEMENT|Vitamin D tablets|Vitamin D supplements is thought to reduce the severity of urinary incontinence.Vitamin D supplements were given to Group A
215022279|NCT06689813|OTHER|Ispaghula husk|Ispaghula husk tablets were given to Group B participants
215022280|NCT06689293|DIAGNOSTIC_TEST|Faecal Immunochemical Test|Self-collected sample from stool collected into testing kit
215022281|NCT06690580|OTHER|Motivational interviewing based on the knowledge motivation behavior skills model|Breastfeeding education that includes motivational interviews based on the knowledge motivation behavior skills model
215022282|NCT06685978|DRUG|Xiang Ju Ru Pi Ning capsule Placebo|Xiang Ju Ru Pi Ning capsule Placebo(0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
215022283|NCT06685978|DRUG|Xiang Ju Ru Pi Ning capsule|Xiang Ju Ru Pi Ning capsule (0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
215022284|NCT06688877|DEVICE|headphones with activated noise cancelling|noise cancelling is new
215022285|NCT06688877|DEVICE|headphones with activated noise cancelling and soft 60 bpm musc|noise cancelling is new
215022286|NCT06688877|DEVICE|heart rate measurement|three times (before, during and after surgery)
215022287|NCT06688877|OTHER|Questionnaire|two times (before and after surgery)
214507192|NCT07064226|OTHER|Treatment as Usual (TAU)|As described above, this type of intervention will consist in a multidomain cognitive rehabilitation treatment to be self administered by the participants at home with pencil paper excercises. Treatment will last 5 weeks, 3 sessions per week, each lasting approximately 45 minutes. The treatment will follow a predefined incremental difficulty structure since no personalization is available.
215022288|NCT06072261|OTHER|kinesio tape application|"Before the standard rehabilitation program, kinesio taping was applied to both upper extremities in the form of a Y tape from the medial epicondyle to the wrist flexors, with 15-20% tension, to the patients hospitalized in the orthopedic service after lower extremity surgery. The tape should remain on the patient's arm throughout the hospital stay"
215022289|NCT00941421|DEVICE|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
215022290|NCT06683495|OTHER|Mirror Therapy|For mirror therapy, a 50×40 cm mirror will be used
215022291|NCT06695793|PROCEDURE|Interrupted Sutures|The first layer of uterine incision will be closed using individual, separate sutures placed at regular intervals along the incision line. Each suture will be tied independently, ensuring adequate apposition of uterine tissue, followed by a second layer of running continuous sutures.
214507193|NCT05197998|BEHAVIORAL|ColorBRAVE|The intervention is a multi-module program delivered via a mobile app for parents of children in K-2nd grade. Each module in the program will take approximately 30 minutes to complete, with lessons facilitated through interactive storytelling, videos, and games.
214507194|NCT06841640|DRUG|AERO-001|Open-label
214507195|NCT06841640|DRUG|AERO-002|Open-label
214507196|NCT06841640|DRUG|AERO-007|Double-blind
215022292|NCT06695793|PROCEDURE|Locked Sutures|The first layer of uterine incision will be closed using continuous sutures placed along the uterine incision, incorporating a locking technique at specified intervals to prevent unraveling. The knots will be securely tied to maintain tissue approximation, followed by a second layer of running continuous sutures.
215022293|NCT06695793|BIOLOGICAL|Running Continuous Sutures|Double layer closure of uterine incision using running continuous suture used to close the uterine incision without interruption, providing seamless tissue approximation throughout the incision length.
215022294|NCT06685796|DRUG|BEBT-209 capsules|BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner or twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast.
215022295|NCT06685796|DRUG|Carboplatin injection|Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
214422796|NCT00939042|PROCEDURE|BMNC therapy|Injection of BMNC after common PCI
214422797|NCT01256034|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
214422798|NCT02655367|OTHER|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
214422799|NCT02655367|OTHER|Milled oats|Test meal consisting of 264g porridge made with milled oats
215022296|NCT06685796|DRUG|Gemcitabine hydrochloride for injection|Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
215022297|NCT06686823|BEHAVIORAL|Health Education Program|n informative leaflet will promote a healthy lifestyle with WHO guidelines to reduce cognitive decline, recommending a balanced diet, physical activity, social engagement, cognitive games, good sleep, stress management, hydration, and avoiding smoking and excessive alcohol.
215022298|NCT06686823|BEHAVIORAL|Cognitive Training Program|The cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
215022299|NCT06688760|PROCEDURE|Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Low Dose Radiotherapy|in experimental arm 1
215022300|NCT06688760|PROCEDURE|Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Double upper neck lymph node dissection|in experimental arm 2
215022301|NCT06687486|BEHAVIORAL|relaxin|caregivers relaxing and care burden
214422800|NCT05257785|BEHAVIORAL|Lymfit exercise intervention|Participants randomized to this arm will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed. Participants will be followed-up at 6 months and 12 months.
215022302|NCT06687486|OTHER|kontrol|no intervention
214422801|NCT05257785|BEHAVIORAL|Waitlist control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
214422802|NCT03781336|BEHAVIORAL|Mindfulness-based self care|Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
214422803|NCT02346006|BEHAVIORAL|More physical activity.|Subjects receiving more physical activity in school.
214422804|NCT00151606|PROCEDURE|Reinforced isolation + Muciprocine|
215022303|NCT06691399|OTHER|Oral care|Oral care done twice daily with chlorhexidine oral care solution (concentration 1.2%)
215022304|NCT06690619|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
215022305|NCT06690619|DIETARY_SUPPLEMENT|315 mg Alpha-GPC|350 mg of 90% pure alpha-GPC (315 mg)
214422805|NCT00773019|DEVICE|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
214422806|NCT03165071|DRUG|ACT-132577|Capsule
214422807|NCT03460756|DRUG|Ganaxolone|Oral
214422808|NCT03460756|DRUG|Placebo|Oral
215022306|NCT06690619|DIETARY_SUPPLEMENT|630 mg Alpha-GPC|700 mg of 90% pure alpha-GPC (630 mg)
215022307|NCT06689306|BEHAVIORAL|7E learning model|7E learning model7E learning cycle is a teaching model that encourages students to be active, to think about the findings they obtain, to interpret their findings according to their initial plans and to predict them in new situations. This model provides students with opportunities for discussion and interaction. The model is designed based on constructivist theory. The guiding concept of constructivism is that later learning is greatly influenced by previous knowledge; therefore, learning should be based on the interaction of old and new knowledge. 7E learning cycle model consists of seven steps: Reveal, Participate, Explore, Explain, Elaborate, Evaluate and Extend. According to past studies, 7E model is more effective in developing students than traditional learning models.
214422809|NCT02950948|DRUG|Progesterone|Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.
214422810|NCT02950948|DRUG|Placebo|A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
215022308|NCT06688617|OTHER|Swedish Hand Massage|Swedish technique hand massage: Effleurage-petrissage-friction-tapotement,-vibration-effleurage
215022309|NCT00879619|DRUG|sunitinib malate|Given PO
215022310|NCT00879619|DRUG|docetaxel|Given IV
215022311|NCT00879619|DRUG|prednisone|Given PO
215022312|NCT02536339|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
214422811|NCT05622786|OTHER|HIGT - physical rehab|High Intensity Gait Training using treadmill and overhead harness for fall prevention
214422812|NCT05622786|OTHER|Low intensity physical therapy|Low Intensity Gait Activities
214422813|NCT05509842|DEVICE|rTMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be used to apply rTMS to targeted locations marked on the structural MRI using a frameless infrared stereotactic neuronavigation system (Brainsight, Rogue Research).
214422814|NCT03987451|DRUG|Semaglutide|Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks
214422815|NCT03987451|DRUG|Placebo (semaglutide)|Semaglutide placebo s.c. given once-weekly for 48 weeks
214422816|NCT04372394|DRUG|surufatinib|Surufatinib: 300 mg as a single dose on Days 1 and 8 with or without food
214422817|NCT00786448|DRUG|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
215022313|NCT02536339|DRUG|Trastuzumab|Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
215022314|NCT06695182|BEHAVIORAL|physical activity|
214422818|NCT01491399|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
214422819|NCT01491399|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
214422820|NCT03888755|DRUG|Icatibant|Participants will receive icatibant 30 mg SC injection in the abdominal area.
214422821|NCT02441036|DEVICE|Ultherapy Treatment|Focused ultrasound energy delivered below the surface of the skin.
214422822|NCT00932022|DRUG|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
214422823|NCT00932022|OTHER|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
214422824|NCT05695833|DEVICE|Radiofrequency|Device emitting electric waves generating heat
214422825|NCT04314830|DEVICE|Gait training with perturbations|Changes in speed of one of the belt of the split belt treadmill during swing phase
214422826|NCT04314830|DEVICE|Gait training without perturbation|Walking on a treadmill with steady belt speed
214422827|NCT00764413|DRUG|methylprednisolone|1 gram intravenous a day for 3 days
214422828|NCT00764413|DRUG|Sodium chlorid|Sodium chlorid 9mg/ml 500 ml per day in 3 days
214422829|NCT03284086|DIAGNOSTIC_TEST|upper-body double-poling|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
214422830|NCT03284086|DIAGNOSTIC_TEST|arm crank ergometry|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
215022315|NCT06694506|OTHER|Biological Sample|Clinical examination and blood test. The clinical examination and blood test are considered standard-of-care as they could be performed annually or bi-annually as part of an adult GHD follow-up. Subsequently, the data will be collected directly from the patient's chosen physician.
215022316|NCT06694610|PROCEDURE|non-pulmonary vein ablation group|In the non-pulmonary vein ablation group, pulmonary vein isolation was not allowed, but the left atrial low-voltage area was treated first, and then the ablation route that terminated the reentry ring was treated.
215022317|NCT06694610|PROCEDURE|only pulmonary vein ablation group|In the group treated with only pulmonary vein ablation route, only potential isolation of pulmonary vein was performed, and bidirectional block was the end point.
215022318|NCT06695520|PROCEDURE|Caudal epidural block|Ultrasound Guidance: Using ultrasound improves the accuracy of the block by allowing real-time visualization of the anatomy and needle placement . injection: .5-1mg/kg of 25% bupivacaine according to the needed block level.
215022319|NCT06694870|DIAGNOSTIC_TEST|Transcutaneous CO2 monitoring|Transuctaneous CO2 monitoring
215022320|NCT06687720|OTHER|MetBroma|Mode of Usage: Take one slow-release capsule twice a day, after meal Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
215022321|NCT06687005|PROCEDURE|non-surgical periodontal therapy|non-surgical periodontal therapy
215022322|NCT06691633|DRUG|Preoperative Methadone|patient receives a one-time preoperative dose of 10 mg of methadone
215022323|NCT06691633|DRUG|Preoperative Oxycodone|patient receives a one-time preoperative dose of 10 mg of oral oxycodone
214422831|NCT00325013|DRUG|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
214422832|NCT04838886|OTHER|Telerehabilitation-based Pilates Exercise|The group that will receive telerehabilitation-based pilates training via telerehabilitation
215022324|NCT06686277|OTHER|Gong's Mobilization Technique|The therapist will push the scapula of the affected side in a posterior to anterior direction with one hand, and pushed the humeral head in an anterior to posterior direction parallel to joint plane with the other hand.
214422833|NCT01434134|DRUG|Metoprolol|Tablet, target dose 100 mg once daily
214422834|NCT01434134|DRUG|Placebo|Tablet, target dose 100 mg once daily
215022325|NCT06686277|OTHER|Mulligan Mobilization Technique|Mulligan Mobilization Technique
214422835|NCT01434134|DRUG|Candesartan|Tablet, target dose 32 mg once daily
214422836|NCT01434134|DRUG|Placebo|Tablet, 32 mg once daily
214422837|NCT02785718|OTHER|Global Haemostasis assays|
214422838|NCT04679519|OTHER|Drop Jumps|Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
214422839|NCT05570019|PROCEDURE|Revascularization|Open surgery (arterial endarterectomy with or without bypass surgery) and/or angioplasty (with or without stent placement)
214422840|NCT06020131|PROCEDURE|Thoracic Mobility Rehabilitation|Thoracic mobility exercises: Thoracic extension on foam roller, Sidelying thoracic rotation, Quadruped thoracic rotation, Squat with extension and rotation ( 10 reps x 3 set - 2 times x wk - 8 wk)
214422841|NCT06020131|PROCEDURE|Lumbopelvic Stability Rehabilitation|Lumbopelvic Stabilization Exercises : Bridge with alternate leg, Single leg bridge, Four point kneeling with arm and leg extension, Side plank on front arm with knee flexed (right, left), Sitting on a Swiss Ball and hip flexion (10 reps x 3 set - 2times/wk - 8 wk)
214422842|NCT06020131|PROCEDURE|Ankle Strengthening Home Exercises|Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)
214422843|NCT05573711|OTHER|assessments|Assessments, no specific intervention
214422844|NCT04925739|OTHER|Self-questionnaire on the comfort and general appreciation of a nasal mask|Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use
214422845|NCT04925739|OTHER|Self-questionnaire on the appearance of CPAP side effects related to the mask|Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use
215022326|NCT06689345|DEVICE|taVNS - transauricular vagal nerve stimulation|30 minutes of electrical stimulation on the afferent portion of the vagal nerve on the cymba conchae of the ear, in the following configuration: 30 seg ramp up, 30 seg on, 30 seg off in intensity on which the volunteer feels a light tingling.
215022327|NCT06689345|DEVICE|rPMS - repetitive peripheric magnetic stimulation|Magnetic stimulation on the efferent portion of the vagal nerve on the neck, on the following configuration: 20Hz, 25 pulses in the trein, in every inhalation, for 20 inhalations with 50% of machine capacity (500 pulses total).
215022328|NCT06689345|DEVICE|rTMS - repetitive transcranial magnetic stimulation|rTMS intermitent theta- burst on the left DLPFC, on the following configuration: 50 Hz in treins of 5Hz, with 110% of the resting motor limiar and 600 pulses in 3 minutes.
215022329|NCT06689345|DEVICE|taVNS sham|Simulated taVNS (SHAM) on helix left ear, that is the same as taVNS, but during only 1 minute
215022330|NCT04524130|DRUG|Lidocaine Hydrochloride|lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.
215022331|NCT04524130|DRUG|Ketamine|Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.
215022332|NCT04524130|DRUG|Placebo|Normal saline will be given with the same rate of lidocaine or ketamine.
215022333|NCT06695286|OTHER|Multimodal rehabilitation training at high intensity|"In High Intensive Training patients received 1800 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week.~Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise.~No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL."
215102867|NCT05747534|DRUG|Larazotide Acetate|AT1001 (Larazotide) is a locally acting, non-systemic, octapeptide inhibitor of the zonulin receptor that has shown efficacy in a large variety of animal models of inflammation. The effectiveness of AT1001 in controlling paracellular permeability as a tight junction regulator has been widely demonstrated in animal models both in vitro and in vivo. In MIS-C, prolonged presence of SARS-CoV-2 in the GI tract leads to release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation (Yonker, et. al. 2021). Five children treated with AT1001 (through an Emergency Investigational New Drug request authorized by the FDA) displayed a decrease in plasma SARS-CoV-2 Spike antigen levels, inflammatory markers, and symptom improvement superior to that achieved with the current standard of treatment for MIS-C (ie. immunoglobulin, systemic steroids) (Yonker, et. al. 2021) (Yonker, et. al. 2022)
214690519|NCT00782925|OTHER|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
215102868|NCT05747534|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
215102869|NCT06502834|DIETARY_SUPPLEMENT|D piger|Probiotic d piger
215102870|NCT06502834|DIETARY_SUPPLEMENT|Placebo|Placebo
215102871|NCT01008449|DEVICE|Surgical staples|Surgical staples will be used once for wound closure.
215102872|NCT01008449|DEVICE|Absorbable Surgical Suture|Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
214422846|NCT04925739|OTHER|Self-questionnaire on the patient's appreciation of the mask headgear,|Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.
214422847|NCT04925739|OTHER|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.
214422848|NCT04925739|OTHER|Self-questionnaire Epworth on the daytime sleepiness|"Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion.~To study the parameters of the CPAP treatment."
214422849|NCT04925739|OTHER|To study the CPAP compliance|To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
214422850|NCT04925739|OTHER|To study the unintentional leakage|To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.
214422851|NCT04925739|OTHER|To study the therapeutic pressures of CPAP|To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
214422852|NCT00676234|DRUG|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
214422853|NCT01132794|DRUG|Intranasal dexmedetomidine|1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
214422854|NCT01132794|DRUG|Placebo|Intranasal nasal saline
215022334|NCT06695286|OTHER|Multimodal rehabilitation training at low intensity|"In Low Intensive Training patients received less than 900 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week. Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise. No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL."
215022335|NCT06694376|OTHER|No intervention|No intervention.
215022336|NCT06695559|OTHER|Labrida Bioclean|Debridement on the active comparator group will be implemented on the implant surface with Labrida Bioclean (i.e. the chitosan brush).
215022337|NCT06695559|COMBINATION_PRODUCT|Labrida Bioclean and tetracycline slurry|On the experimental group debridement of the implant surface will be carried out with Labrida Bioclean and thereafter irrigation of the periimplant sulcus with tetracycline slurry will take place.
215022338|NCT06686498|BEHAVIORAL|Illness Management and Recovery adapted to suicidal behavior (IMR-ACS)|"Illness Management and Recovery adapted to suicidal behavior (IMR-ACS) is a protocolized clinical intervention in a brief group format aimed at people at risk of suicide. Specifically, people who have had more than two attempts in their lifetime are called repeaters. For its construction, we relied on the Spanish version of the Illness Management and Recovery IMR, developed by the Spanish Nursing Association, adapted to the field of suicidal behavior, taking as a reference the model of personal recovery from suicide attempt proposed by Sokol et al.~The goals of IMR-ACS are to 1) know the warning signs of a suicidal crisis, 2) implement strategies to manage the suicidal crisis, 3) foster social support among peers, 4) formulate goals for recovery from a suicidal crisis, and 5) seek help and make informed decisions in the event of a suicidal crisis.~IMR-ACS is a complementary intervention to the usual treatments."
215022339|NCT06690749|DEVICE|Negative pressure therapy, NPT|"We designed the experiment based on current clinical cases involving negative pressure therapy (NPT) for wounds and related animal studies. In this study, we applied three levels of negative pressure: -105 mmHg, -125 mmHg, and -145 mmHg, each for 10 minutes.~The -125 mmHg dosage was chosen based on findings from a previous study. Similar studies that utilized increments and decrements of 20 mmHg informed our research.~Moreover, to prevent any damage to new capillaries, we established a base dosage of -125 mmHg and refrained from using negative pressure levels exceeding -150 mmHg."
215022340|NCT04009135|BEHAVIORAL|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
215022341|NCT04009135|BEHAVIORAL|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind \& acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
215022342|NCT04009135|OTHER|Attention Control (AC)|1-module of psychoeducation about chronic pain and major depression. Weekly contact to complete measures of symptomatology and well-being.
215022343|NCT03449147|DRUG|Placebo|Placebo tablet administered orally BID
215022344|NCT03449147|DRUG|Gefapixant 15 mg BID|Gefapixant 15 mg tablet administered orally BID
215022345|NCT03449147|DRUG|Gefapixant 45 mg BID|Gefapixant 45 mg tablet administered orally BID
215022346|NCT04095936|DRUG|Romiplostim|Subcutaneous administration of 0 to 20ug/kg for 6 months
215022347|NCT00294567|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
215022348|NCT03556878|BEHAVIORAL|Fitted Transdiagnostic Sleep and Circadian intervention|Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
214422855|NCT01566513|BEHAVIORAL|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
214422856|NCT01566513|BEHAVIORAL|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
214422857|NCT01566513|BEHAVIORAL|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
214422858|NCT03179969|OTHER|paravalvular leak|Observational study on patients with paravalvular leak
215102873|NCT01220180|DRUG|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
214422859|NCT04323202|DRUG|Pembrolizumab|Post Fine-cut CT: 4 doses of pembrolizumab (200mg) IV q 3 weeks. Post standard resection and reconstruction: 1 year of pembrolizumab (200mg) q 3 weeks (another 13 doses, thus 17 doses total)
214422860|NCT04323202|OTHER|Tissue collection|Non-marginal tissue as well as pre-op biopsy tissue to be stored
214422861|NCT02703623|DRUG|Abiraterone Acetate|Given PO
214422862|NCT02703623|DRUG|Apalutamide|Given PO
214422863|NCT02703623|DRUG|Cabazitaxel|Given IV
215022349|NCT04064671|OTHER|Implantation of the Zephyr ZSI 475 FTM erectile implant|Until recently, all penile implants were manufactured for erectile dysfunction in biological males and thus presumed the presence of two corpora cavernosa. In 2016 however, the Swiss company, Zephyr Surgical Implants (ZSI), created a 3-piece inflatable erectile device specifically for female-to-male transsexuals: the Zephyr ZSI 475 FTM. This prosthesis has a realistic gland shape, only one cylinder, and a specific anchorage device made of titanium and silicone to anchor the system to the pubic bone of the patient. These specific features could potentially address the aforementioned issues with implanting erectile devices in the neophallus and hopefully lead to better surgical outcomes in these particular patients.
215022350|NCT04951063|RADIATION|Hypofractionated radiotherapy|"Split-course adaptive HRT-CHT is administered at the following three dose levels:~1. Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~2. Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~3. Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course."
215022351|NCT04951063|DRUG|Concurrent chemotherapy|weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT
215022352|NCT04951063|DRUG|Consolidation immunotherapy|Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
215022353|NCT00527878|DRUG|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
215102874|NCT01220180|DRUG|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
215102875|NCT01220180|DRUG|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
215102876|NCT05113992|OTHER|aromatherapy massage|In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm
215102877|NCT05113992|OTHER|classic massage|In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm.
214422864|NCT02703623|DRUG|Carboplatin|Given IV
215022354|NCT00527878|DRUG|Placebo|
215022355|NCT01177488|BEHAVIORAL|Behavioral Activation Therapeutic Exposure (BATE)|This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
215022356|NCT04917939|OTHER|RNA sequencing|Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.
215022357|NCT02931539|DRUG|Maribavir|Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
215022358|NCT02931539|DRUG|Ganciclovir|Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
215022359|NCT02931539|DRUG|Valganciclovir|Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
215022360|NCT02931539|DRUG|Foscarnet|Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
215022361|NCT02931539|DRUG|Cidofovir|Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
215022362|NCT02059642|DRUG|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
215022363|NCT02059642|DRUG|placebo|Placebo 1400 mg administered orally once daily
215102878|NCT00524615|DRUG|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
215102879|NCT00761202|DRUG|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
215102880|NCT00761202|DRUG|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
215102881|NCT02386826|DRUG|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
214422865|NCT02703623|BIOLOGICAL|Ipilimumab|Given IV
214422866|NCT02703623|OTHER|Laboratory Biomarker Analysis|Correlative studies
214422867|NCT02703623|DRUG|Prednisone|Given PO
214422868|NCT06795763|DEVICE|CTO-PCI Procedure with Acolyte Catheter System|Acolyte Catheter System is used to facilitate placement and positioning of guidewires and catheters within the coronary vasculature for the treatment of patients with coronary chronic total occlusions with persistent symptoms following medical therapy. The device provides real-time visualization of a coronary chronic total occlusion allowing for guidewire placement in the true lumen of the target vessel and subsequent revascularization.
214422869|NCT04891835|OTHER|Data extraction from medical files|Data extraction from medical files
214422870|NCT00309595|DEVICE|stent|Cordis SMART™ Nitinol Stent System
215022364|NCT01539889|RADIATION|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
215022365|NCT02736812|BIOLOGICAL|French Lyophilized Plasma|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of FLYP"
214422871|NCT00309595|DEVICE|balloon|balloon angioplasty
215022366|NCT02736812|BIOLOGICAL|Normale Saline Solution|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of Normale Saline Solution"
215022367|NCT01671774|DRUG|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
215022368|NCT01671774|DRUG|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
215022369|NCT01671774|DRUG|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
215022370|NCT01671774|DRUG|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
215022371|NCT05171205|DEVICE|Spinal cord stimulation|Spinal cord stimulation (SCS) is a very thin electrode implanted in the dorsal epidural space of the spinal cord to improve the patient's symptoms by stimulating the spinal nerves with pulsed electrical currents, which attenuate or enhance the flow of nerve impulses from the periphery to the central system, i.e., stimulating thick fibers to achieve therapeutic results. SCS system consists of three components: an electrode implanted in the epidural space of the patient's spinal cord, a stimulator implanted subcutaneously in the abdomen or buttocks that delivers electrical impulses, and an extension cord that connects the two.
215022372|NCT05626608|DEVICE|Classical ring stimulation|Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
215022373|NCT05626608|DEVICE|Stimulation in directional mode|Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
215022374|NCT04210115|BIOLOGICAL|pembrolizumab|IV infusion
215022375|NCT04210115|DRUG|placebo|IV infusion
215022376|NCT04210115|DRUG|cisplatin|IV infusion
215022377|NCT04210115|DRUG|5-FU|IV infusion
215022378|NCT04210115|RADIATION|radiotherapy|external radiation
215022379|NCT04210115|DRUG|leucovorin|IV infusion
215022380|NCT04210115|DRUG|levoleucovorin|IV infusion
215022381|NCT04210115|DRUG|oxaliplatin|IV infusion
214422872|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation|
214507197|NCT06743334|BIOLOGICAL|Tozinameran (BNT162b2)|"1. 12 years or older~   * Primary series: 2 doses, 30 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot~2. 5 to 11 years of age~   * Primary series: 2 doses, 10 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot~3. 6 months to 4 years of age~   * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)"
215022382|NCT06942780|BEHAVIORAL|Exercise intervention|"The multi-component exercise mode is adopted, and the three-stage structured design of warm-up preparation - main training - finishing and relaxation is adopted, and the participants' heart rate is monitored in real time with the exercise bracelet throughout the whole process to ensure that the training intensity is reached. The movement process is guided synchronously by the video music teaching system, and the specific process is as follows:~1. Warm-up preparation (3 minutes) : Warm up the head and neck, shoulder joints, arms and wrists, waist and abdomen, thighs and ankles in turn, and perform 30 seconds for each movement.~2. Main training stage (60min) : aerobic exercise adopts basic steps of square dance or advanced step training; The resistance training module carries out compound resistance exercises of sitting posture, leg lift and arms forward lift.~3. Finishing and relaxing stage (12min) : select the traditional health exercise eight Duan Jin."
214422873|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation|
214422874|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation|
214422875|NCT00680342|DRUG|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
215022383|NCT06942780|BEHAVIORAL|Social intervention|"The duration of each intervention was 40min, mainly group social interaction, guided by professionals (medical social workers). Divided into three stages:~The first stage (3min) : The facilitator will go through small jokes, soothing music, etc.Create a relaxed atmosphere and briefly introduce the theme of the week.~The second stage (35min) : During the activity, participants began to chat around the theme, and the host guided them timely.~The third stage (2min) : Summarize the intervention and praise the participants."
215102882|NCT02386826|BIOLOGICAL|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
215102883|NCT02713659|BEHAVIORAL|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
215102884|NCT02713659|BEHAVIORAL|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
214507198|NCT06743334|BIOLOGICAL|Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)|"1\. 12 years or older~\- Single booster dose, 15/15 μg, administered after ≥3 months after primary series"
214507199|NCT06743334|BIOLOGICAL|Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)|"1\. 12 years or older~\- Single booster dose, 15/15 μg administered after ≥3 months after primary series"
215022384|NCT06942780|BEHAVIORAL|Dietary intervention|The researcher distributed the health education manual of the cognitive disorder diagnosis and treatment center, and conducted a 5-minute MIND diet health education, explaining relevant dietary requirements and focusing on the collocation of one type of food every week. The participants were then given homework that asked them to strictly follow the MIND diet in their daily diet. At the same time, the participants' caregivers are required to upload photos of their daily meals to the wechat group for supervision and feedback.
215022385|NCT06942780|BEHAVIORAL|Cognitive intervention|Cognitive digital therapy was adopted, and participants were supervised by their caregivers for 5 days a week and 30min each time for cloud-based home training (avoiding 2 hospital intervention days) for 8 weeks. The training covers core cognitive functions such as attention, memory and logical reasoning.
215022386|NCT06942780|BEHAVIORAL|Health Education Manual|Distribute health education handbooks to guide patients to establish a good awareness of a healthy lifestyle. The manual can popularize health knowledge, covering various aspects such as diet, exercise, and rest, enabling patients to understand the importance of a healthy lifestyle, encouraging them to actively improve their living habits, slow down the progression of the disease, and enhance their quality of life.
214422876|NCT00680342|DRUG|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
214507200|NCT03173950|DRUG|Nivolumab|Individuals will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
214507201|NCT05656248|DRUG|CPX-351|Given Intraveneously (IV)
214507202|NCT05656248|DRUG|MHA|Given Intrathecal (IT)
214507203|NCT05656248|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
214507204|NCT06416436|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1680 mg IV route every 4 weeks (1680 mg on Day 1 of each 28-day cycle), which is an approved dosage for atezolizumab, as outlined in the prescribing information.
215022387|NCT01718106|DEVICE|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
215022388|NCT00188435|PROCEDURE|Minimum Dose CT|
215102885|NCT03601702|DEVICE|Mechanical thrombectomy with EmboTrap ® II Device|Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)
214507205|NCT06416436|RADIATION|Stereotactic Ablative Radiotherapy (SBRT)|"Ultra-High Doses of Ablative Radiosurgery~SBRT is delivered to metastases over 3-5 fractions within 1-2 weeks"
214422877|NCT00680342|OTHER|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
214422878|NCT00609908|PROCEDURE|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
214690520|NCT00782925|OTHER|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
214422879|NCT00609908|PROCEDURE|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
214422880|NCT00609908|PROCEDURE|serial excision|as much scar as possible is excised, whereafter the wound is closed
214422881|NCT00609908|PROCEDURE|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
214507206|NCT07094230|DIAGNOSTIC_TEST|biomarkers analyses|blood analyses
214690521|NCT00782925|OTHER|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
214690522|NCT00047281|DRUG|celecoxib|
214690523|NCT00047281|DRUG|cyclophosphamide|
214690524|NCT00047281|DRUG|etoposide|
214690525|NCT00047281|DRUG|thalidomide|
214690526|NCT05813210|DIAGNOSTIC_TEST|Exercise in combination with biomarkers and pharmacological stress CMR test|A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.
215022389|NCT05561985|DRUG|Itacitinib|
215022390|NCT04865887|DRUG|Pembrolizumab|200mg, every 3 weeks, IV infusion
215022391|NCT04865887|DRUG|Lenvatinib|20 mg (2 capsules x10mg), daily, orally
215022392|NCT06055569|OTHER|Rehabilitation protocol: AOT+NMES|Action observation and neuromuscular electrical stimulation followed by motor execution
215022393|NCT06055569|OTHER|Rehabilitation protocol: Action Observation Therapy (AOT)|Action observation followed by motor execution
215022394|NCT06055569|OTHER|Observation of motor-neutral stimuli (MNO)|Motor-neutral observation followed by motor execution
215102886|NCT00855049|DRUG|Acetaminophen|Intranasal acetaminophen administration
215102887|NCT00855049|DRUG|Acetaminophen|Oral acetaminophen administration
215102888|NCT00195156|DRUG|ATRA-IV|
215102889|NCT00195156|DRUG|Depakote|
215102890|NCT02211066|DRUG|Clopidogrel|
215102891|NCT02211066|DRUG|Ticagrelor|
215102892|NCT01242852|PROCEDURE|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS \& hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions \& endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
215102893|NCT04434014|DIETARY_SUPPLEMENT|proper diet|diet containing all essential vitamins
215102894|NCT01078844|DRUG|memantine|memantine 5-20 mg daily
214422882|NCT02064959|DEVICE|Temperature management Zoll Intravascular Temperature Management device|
214422883|NCT04369495|OTHER|BAFF serum levels|BAFF levels in serum in visit 0,1,2 during induction therapy
214422884|NCT03690037|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
214422885|NCT03690037|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid: Tranexamic Acid 500mg Tablets
214422886|NCT03802708|DIAGNOSTIC_TEST|Metabolomic analysis urine sample|a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
214422887|NCT00004124|DRUG|bicalutamide|
214422888|NCT00004124|DRUG|goserelin|
214507207|NCT07099144|DRUG|Inhaled nitric oxide (NO)|"The starting dose of INOmax is 20 ppm, which is controlled by the INOmax DSIR Plus delivery system in the respiratory circuit during mechanical ventilation. The dose will be maintained at 20 ppm for 4 hours after the start of administration, then the dose can be weaned to 5 ppm provided that the arterial oxygenation is adequate, as determined by the investigator within 4-24 hours of therapy, and the therapy should be maintained at 5 ppm until the fraction of inspired oxygen (FiO2) \< 0.60.~The treatment will be maintained until the potential hypoxia is resolved, or the investigator determines that the neonate no longer needs to use this drug. The maintenance treatment time is usually less than 4 days (96 hours). If the oxygenation level has not improved significantly after 4 days of maintenance treatment, the suitability of the treatment plan should be reassessed."
215022395|NCT05966051|BEHAVIORAL|Educational interventions|The educational interventions will consist in:
215022396|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET|Prostate specific membrane antigen positron emission tomography
215022397|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/MRI|Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging
215022398|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/CT|Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging
215022399|NCT05883748|DRUG|DISC-1459|DISC-1459 dose level 1
215022400|NCT05883748|DRUG|DISC-1459|DISC-1459 dose level 2
215022401|NCT06540118|OTHER|15 Medically Tailored Meals (MTM) per week|15 heart-healthy medically tailored meals delivered to participants each week. Meals include breakfast, lunch, dinner, and snack to consume Monday-Friday.
215022402|NCT06540118|OTHER|14 Medically Tailored Meals (MTM) per week|14 heart-healthy medically tailored meals delivered to participants each week. Meals include lunch and dinner to consume Monday-Sunday.
215022403|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Electrical stimulation (E-stim)|PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).
215022404|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Sham Stimulator|Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.
215022405|NCT06053320|OTHER|Gait Training|After PAT, participants will complete multiple 30-seconds to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts.
215022406|NCT04548050|OTHER|Nurses training|"* Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~* Presentation to all staff of a service protocol for early colostrum donation."
214422889|NCT00004124|DRUG|mitoxantrone hydrochloride|
214422890|NCT00004124|DRUG|prednisone|
214422891|NCT00787033|DRUG|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
214422892|NCT00018668|DRUG|Risperidone|
214422893|NCT00018668|DRUG|Olanzapine|
214422894|NCT00018668|DRUG|Quetiapine|
214422895|NCT05859542|DEVICE|Videolaryngoscope first|started the session with 3 intubations using the videolaryngoscope
214422896|NCT05859542|DEVICE|Direct laryngoscope first|started the session with 3 intubations using the Direct laryngoscope
214422897|NCT05319457|OTHER|The radon app|Participants will be asked to use the radon app.
214422898|NCT05319457|OTHER|Print brochure|Participants will receive print brochures.
214422899|NCT05222399|DRUG|LY3871801|Administered orally.
214422900|NCT04761146|RADIATION|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT is a brachytherapy treatment comprising stainless-steel 316LVM wires coated with radium-224 (Alpha DaRT seeds). The radioactive seeds are inserted directly into the tumour on the perineum and will be removed after 14 days.
214422901|NCT00651105|DRUG|Vildagliptin|
214422902|NCT00651105|DRUG|Placebo|
214422903|NCT06463054|BEHAVIORAL|Dialectical Behavior Therapy Skills Group Training|The investigators will employ Dialectical Behavior Therapy Skills Training in order to experimentally manipulate maternal emotion dysregulation, the targeted mechanism.
214422904|NCT06463054|BEHAVIORAL|Safety Planning Intervention|Safety Planning Intervention (SPI) or SPI only for 6 months, such that all mothers with history of suicidal behavior + ER difficulties will receive SPI.
214507208|NCT07099014|DRUG|Inahled Isoflurane|treatment administration
214507209|NCT07099014|DRUG|Propofol, midazolam|treatment administration
214507210|NCT07098780|DRUG|Tranexamic Acid|At the time of incision, 1000mg of the drug would be given intravenous, followed by two postoperative doses of 1000mg eight hours apart.
215102895|NCT01078844|DRUG|Placebo|Look-alike placebo
215102896|NCT01067469|DRUG|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
214422905|NCT02640781|PROCEDURE|self-expandable metal stent insertion(covered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
214422906|NCT02640781|PROCEDURE|self-expandable metal stent insertion(uncovered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
214422907|NCT03733522|PROCEDURE|Rubber dam isolation|Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration
214422908|NCT03733522|PROCEDURE|Relative isolation|No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
214422909|NCT05591040|DEVICE|Biofeedback|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
214507211|NCT07098780|OTHER|Normal Saline (Placebo)|At the time of incision, 10ml of the drug would be given intravenous, followed by two postoperative doses of 10ml eight hours apart.
214507212|NCT07098923|BEHAVIORAL|combination of aerobic and resistance exercise|"Aerobic exercise: The main form is walking(gait), which includes three parts: warm-up, walking, and relaxation. Exercise time and frequency: 30-60 minutes of exercise per day, 3-5 times per week.~Resistance exercise: Mainly uses elastic bands to enhance resistance exercise, since the risks of increased intra-abdominal pressure and fluid leakage in peritoneal dialysis patients is high, Investigator considered selective resistance exercise especially for limb and shoulder joint exercises. Patients can choose 3-5 muscle groups based on individual conditions, with each action 10-15 times and maintained for 10 seconds. Start with 2 sets of resistance exercise and then gradually increase to 3-5 sets, with 2-3 minutes of rest between each sets. Exercise frequency and duration: 2 times a week (non-consecutive days), 20 minutes each time."
214507213|NCT07098117|DRUG|SHR0302 Base Gel|Part I: once daily. Part 2:, twice daily.
215022407|NCT03508440|PROCEDURE|Intratympanic injection|Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
215022408|NCT03508440|DRUG|Prednisone|Oral Steroid
215022409|NCT03242031|PROCEDURE|monospot panretinal photocoagulation|panretinal photocoagulation with monospot laser
215022410|NCT03242031|PROCEDURE|multispot panretinal photocoagulation|panretinal photocoagulation with multispot laser
215022411|NCT04070040|DRUG|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
215022412|NCT02881216|DEVICE|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
215022413|NCT02881216|DEVICE|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
215022414|NCT04869527|DEVICE|BIOTRONIK ICDs with DX Technology|The BIOTRONIK DX system offers a single chamber ICD that enables sensing of atrial signals through floating atrial dipoles, using a single ventricular lead. This technology enables enhanced arrhythmia diagnosis based on atrial and ventricular electrograms and, in addition, early diagnosis and automatic transmission of AF and heart failure (HF) diagnostic data. The DX technology provides several features in a single chamber device that are usually only found in dual chamber devices, including atrial diagnostics and SVT discrimination - early detection of SAF, increased diagnostics accuracy, dual-chamber discrimination. Nevertheless, the benefits of a single chamber device are preserved: reduced lead complications, reduced procedure complexity, elimination of costs for atrial lead. The DX system also integrates with BIOTRONIK Home Monitoring, allowing physicians to remotely follow their patients' clinical and device statuses with daily updates.
215022415|NCT06371378|PROCEDURE|PEEP 0|PEEP 0 CMH20 will be used During Surgery
214507214|NCT07098117|DRUG|SHR0302 Base Gel Placebo|Part I: once daily. Part II: twice daily.
214507215|NCT07099599|DIAGNOSTIC_TEST|CT Perfusion|CT perfusion within 90 minutes of complete angiographic reperfusion
215022416|NCT06371378|PROCEDURE|PEEP 4|PEEP 4 CMH20 will be used During Surgery
214507216|NCT07098806|DRUG|186RNL|Multiple Doses of 186RNL
215022417|NCT06371378|PROCEDURE|PEEP 8|PEEP 8 CMH20 will be used During Surgery
215022418|NCT02730169|DRUG|BGS649|Capsules were taken weekly for a maximum of 24 weeks
215022419|NCT02730169|DRUG|Placebo|Capsules were taken weekly for a maximum of 24 weeks
215022420|NCT01821846|DRUG|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
215022421|NCT05066997|DRUG|Dexamethasone ophthalmic suspension (OCS-01)|"Stage 1: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
215022422|NCT05066997|DRUG|Vehicle|"Stage 1: Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Participant will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
214422910|NCT05591040|OTHER|Conventional|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
214422911|NCT01489982|DEVICE|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
214422912|NCT01489982|BEHAVIORAL|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
214422913|NCT01489982|DRUG|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
215022423|NCT03741374|PROCEDURE|Minimally-invasive non-surgical therapy (MINST)|A non-surgical minimally-invasive treatment protocol, named MINST, has been proposed (Ribeiro et al. 2011) for the treatment of periodontitis, in order to minimise patient discomfort and maximise the healing potential. This technique usually involve the use of magnification lenses or microscopes and small instruments which would reduce the risk of tissue trauma compared with traditional instruments.
215022424|NCT06273163|OTHER|Medically tailored meals|Medically tailored meals are nutritious meals formulated for weight wellness.
215022425|NCT06273163|BEHAVIORAL|Noom®|Noom® is a subscription-based mobile application used to support healthy eating and exercise behavior change.
215022426|NCT06273163|OTHER|Usual care|Care is provided at the discretion of the individual provider (e.g., usual care).
214422914|NCT01489982|DEVICE|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
215022427|NCT06358144|BEHAVIORAL|Packaging imagery|Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.
215022428|NCT06358144|BEHAVIORAL|No Imagery (Control)|Participants in the control condition will see the same four product packages, but without any added imagery.
214507217|NCT07100041|OTHER|Breathing Exercise Group|Before the dressing procedure, patients who volunteer to participate in the study will be given a patient information form, a burn-specific pain anxiety scale, and their pain level before dressing will be recorded using the GAS. After their vital signs are checked, they will be given a practical demonstration of breathing exercises. The breathing exercise will first be explained verbally by the project coordinator in the burn centre's training room, followed by a practical demonstration. The patient will then be asked to perform the exercise. Once the project coordinator is confident that the patient has learned how to perform the breathing exercise, the patient will be taken to the dressing room. During the standard dressing procedure, the patient will be instructed to continue performing the breathing exercise. Immediately before the dressing change, the patient will be positioned comfortably, and they will be instructed to use the breathing
214507218|NCT07100041|OTHER|Stress Ball Group|The stress ball is made of a medium-hard plastic material that can be easily held in the hand. Before the dressing procedure, patients who volunteer to participate in the study will be given information about the use of the stress ball after the patient information form, the burn-specific pain and anxiety scale, and the pain level before dressing have been recorded using the GAS, and their vital signs have been checked. During the standard dressing procedure, patients will be instructed to squeeze and release the stress ball periodically until the dressing procedure is complete, focusing solely on the stress ball during this time (Ozen et al., 2023) (Kasar et al., 2020). A separate stress ball will be used for each patient in the stress ball group to ensure that the effectiveness of the stress ball remains consistent. To support patients' relaxation during the dressing procedure, a stress ball usage guide prepared by the project team will be provided
215022429|NCT04804709|DRUG|Panobinostat 15 MG|After each instance of opening the BBB using specific parameters of focused ultrasound in the specific number of tumor sites (one, two, or three), the subjects will receive oral Panobinostat (15 mg/m\^2).
215102897|NCT01067469|DRUG|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
215102898|NCT01067469|DRUG|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
214422915|NCT05209230|PROCEDURE|Continuous renal replacement therapy|Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter
214422916|NCT05209230|OTHER|Control group|Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
214422917|NCT01751958|RADIATION|Epidural steroid injection|Epidural steroid injection
214422918|NCT02894463|OTHER|questionnaire|
214422919|NCT00459446|DRUG|MS-325 Injection (Gadofosveset Trisodium)|
214422920|NCT03778645|PROCEDURE|Adrenal Venous Sampling|Adrenal Venous Sampling via an Antecubital Approach
214422921|NCT06399029|DRUG|Ruxolitinib Topical Cream|Ruxolitinib cream will be applied topically twice daily on up to 20% of the body surface over 12 weeks in patients with lichenoid skin toxicity under anti PD1 treatment.
214422922|NCT02296424|DRUG|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
214422923|NCT02817984|BIOLOGICAL|Acellular Adipose Tissue (AAT)|The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
214422924|NCT05317572|DRUG|80 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
214422925|NCT05317572|DRUG|120 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
214422926|NCT05317572|DRUG|160 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
214422927|NCT05520294|OTHER|High-performance liquid chromatography-tandem mass spectrometry assays|Paraffin blocks will be requested for slide creation, and at least 12 mL of whole blood will be collected in 2 green top tubes, centrifuged, and plasma transferred for storage at -80 C until further processing
214422928|NCT05496777|PROCEDURE|Home-based prehabilitation program|The home-based prehabilitation program will consist of a four-week program, where patients are expected to perform a high-intensity interval training on a home-trainer combined with functional mobility training three times a week. The program is partly supervised by a trained physiotherapist.
214422929|NCT05972915|DIAGNOSTIC_TEST|Separation sign|The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta.
214422930|NCT02731885|DRUG|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
214422931|NCT02731885|DRUG|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
214422932|NCT04056039|DRUG|Atorvastatin|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
214422933|NCT04056039|DRUG|Colchicine|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
214422934|NCT00900211|GENETIC|microarray analysis|
214422935|NCT00900211|GENETIC|molecular diagnostic method|
214422936|NCT00900211|OTHER|biologic sample preservation procedure|
214422937|NCT06290297|DEVICE|Telerehabilitation VRRS|Telerehabilitation programs delivered at home, aiming to improve cognitive, motor and/or speech-language skills, through VRRS - Khymeia or Niurion devices. Such technologies are equipped with a wide library of activities to be performed also with the use of peripheral sensors. A one-shot assessment is also proposed to children admitted to institutes adhering to the project in order to understand the feasibility of the use of such devices. Ad hoc feasibility questionnaire are administered at the end of the one shot session and after the home training to the main stakeholders (children, families, clinicians)
214422938|NCT04523922|DRUG|40 IU Intranasal Oxytocin|40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
214422939|NCT04523922|DRUG|Placebo|Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
214422940|NCT04523922|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure|12 weekly sessions of COPE therapy for PTSD and AUD.
214422941|NCT00168519|DRUG|nitroprusside, pentalong, imdur, AICAR, isoptin|"Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)"
214422942|NCT06435819|OTHER|Embodied Conversational Agent (ECA)|A computer-animated character that can explain a medical illustration to laypersons.
214422943|NCT04525170|DEVICE|HPT treatment|
214422944|NCT04525170|DEVICE|untreated|
215022430|NCT04804709|DEVICE|Focused Ultrasound with neuro-navigator-controlled sonication|"The purpose of this study is to evaluate the feasibility of opening the BBB safely using specific parameters of focused ultrasound in progressive/recurrent diffuse midline gliomas in one, two, or three tumor sites. The trial will follow a 3+3 Number of Tumor Sites (NOTS) escalation scheme. The number of tumor sites in reference to here is the number of openings in the blood-brain barrier using Focused Ultrasound (FUS). Subjects will start the first cycle of the treatment arm with 1 tumor site and move on to incrementing NOTS levels if no dose-limiting toxicities (DLTs) are observed."
214422945|NCT06242379|BIOLOGICAL|GMP compliant-BM-MSC derived sEVs|The procedure will be performed under topical anesthesia (0.5% tetracaine hydrochloride ophthalmic solution). The intravitreal injection will be performed by the retina specialist. Topical antiseptic (5% povidone iodine solution) will be applied on the periorbital and ocular surface. Eyelid speculum will be inserted to expose the injection area. It will include an intravitreal injection at the superotemporal quadrant (right eye) and superonasal quadrant (left eye), 3.5 to 4 mm posterior to the limbus. A 30-gauge needle will be used to deliver a 0.05 to 0.1 ml sEV suspension into the vitreous cavity. Indirect ophthalmoscopy will be performed immediately after the procedure to ensure no occlusion of the central retinal artery. The eye will be rinsed thoroughly by normal saline to wash out remaining antiseptic. The total duration for an intravitreal injection will be approximately 30 minutes.
214422946|NCT05357482|RADIATION|TBI|300 cGy total body irradiation (TBI, day -2)
214507219|NCT07100041|OTHER|Control (Standard Treatment) Group|The standard dressing procedure in the control group is as follows: The protective covering over the wound is removed, and the wound is washed with an irrigation solution. Appropriate medications (decontamination and moisturising gel, debridement gel, alginate, antibiotics, and medications that promote cell regeneration) are applied based on the condition of the wound. A non-adhesive wound care dressing is then placed over the wound, and gauze is applied on top to cover it. Analgesia is not routinely administered in standard wound care. The dressing procedure takes an average of 5 minutes, depending on the size of the burn wound. In the control group, before the dressing procedure, the patient who volunteered to participate in the study will be given a patient information form, a burn-specific pain anxiety scale, and the pain level before dressing will be recorded using the Visual Analogue Scale (VAS) and vital signs will be checked,
214507220|NCT07099391|DRUG|Dara-RVd|This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy
214507221|NCT07099391|DRUG|Tec-RVd|This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy
214507222|NCT07098494|DIETARY_SUPPLEMENT|Saccharomyces Boulardii Probiotic Supplement|• Saccharomyces boulardii (strain CNCM I-745): 250 mg per day (5 billion colony-forming units (CFU)
215022431|NCT02500966|DEVICE|DUDA device|Insertion DUDA device
215022432|NCT02500966|PROCEDURE|LEEP|Loop Electrosurgical Excision Procedure
215102899|NCT06035848|PROCEDURE|Association of the components of metabolic derangement and paracentesis.|"In the intervention group were determined:~1. Components of metabolic derangement~2. Paracentesis. Determination of surgery: 3 positive points of the components of the metabolic derangement and a positive paracentesis.~The components of the metabolic derangement are the 7 parameters described by Tepas: positive blood culture, metabolic acidosis, neutropenia, bandemia, thrombocytopenia, hyponatremia and hypotension, being considered positive when 3 or more parameters are present.~Paracentesis was considered positive according to Kosloske's criteria: obtaining more than 0.5ml of serohematic fluid, Gram-positive fluid and obtaining fecal material.~Both groups had the same pre, trans and postoperative care."
215102900|NCT06035848|PROCEDURE|Bell's criteria: pneumoperitoneum|In the control group, the surgery was determined according to Bell's criteria, in the presence of radiographic pneumoperitoneum as an absolute indication for surgery.
215102901|NCT03931798|DIAGNOSTIC_TEST|Visual Scanning Test|The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
214422947|NCT05357482|DRUG|Hydroxyurea|Optimized 4-12 weeks prior to planned transplant date
214422948|NCT05357482|BIOLOGICAL|briquilimab|briquilimab, anti-CD117 monoclonal antibody at 0.6mg/kg at day -11 prior to infusion of allogeneic HSCs
214422949|NCT05357482|DRUG|Filgrastim (G-CSF)|May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.
214422950|NCT05357482|DRUG|Sirolimus|For immune suppression (day -1)
214422951|NCT05357482|BIOLOGICAL|Alemtuzumab|Alemtuzumab 1 mg/kg of alemtuzumab divided over 5 days (-7 through -3),
214422952|NCT05357482|DRUG|Plerixafor|For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
215022433|NCT03087149|DIETARY_SUPPLEMENT|monitored vit D supplementation|The vit D supplementation dose start from dose 500IU from 7th day of age and is modified based on vit D measurement at 4 week of age for infants born \<30 GA, at 8 week of age for infants born \<26 GA at 35+/-2 weeks PMA(postmenstrual age), +/-at 40+/-2 weeks PMA according to the protocol.
214507223|NCT07100002|DEVICE|Control Group|Patients in this group did not receive any treatment to improve pain and sleep quality during the study period. Routine postoperative care was applied in the clinic.
215022434|NCT03087149|DIETARY_SUPPLEMENT|standard vit D supplementation|The vitamin D supplementation dose is 500IU from 7th day of age.
215022435|NCT06002698|PROCEDURE|Root canal treatment (Control)|Root canal treatment - Removal of the inflamed pulp tissues from the whole root canals of the tooth.
215022436|NCT06002698|PROCEDURE|Full pulpotomy (Experimental)|Full pulpotomy - Removal of the inflamed coronal pulp tissues from the crown of the tooth.
215022437|NCT03024411|OTHER|iPod (Music/video games)|Experimental patients will be given an iPod to enjoy music/video games during induction of labor.
215022438|NCT04488887|DIAGNOSTIC_TEST|Optical coherence tomography angiography|patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test
215022439|NCT00949065|BIOLOGICAL|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
214422953|NCT06033287|DRUG|Different treatment regimens following progression on CDK4/6 inhibitors.|This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.
214422954|NCT02273544|DRUG|Asasantin ER (new formulation - low)|
214422955|NCT02273544|DRUG|Asasantin ER (new formulation - medium)|
215022440|NCT05533437|DEVICE|dry needling|the dry needle inserted to area of pain
215022441|NCT05533437|OTHER|kinesio taping|kinesio taping
215022442|NCT06313346|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
215022443|NCT06313346|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
215022444|NCT06501248|DRUG|Triticum Aestivum|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
215022445|NCT06501248|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
214422956|NCT02273544|DRUG|Asasantin ER (new formulation - high)|
214422957|NCT02273544|DRUG|Asasantin ER - commercial formulation|
214422958|NCT03667911|OTHER|virtual reality videos|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
214422959|NCT06520137|PROCEDURE|Tooth extraction|Extraction of maxillary third molars
214422960|NCT00252278|DRUG|atomoxetine|
214422961|NCT04956575|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
214422962|NCT04956575|BIOLOGICAL|Placebo|0.9% sodium chloride solution for injection
214422963|NCT04956575|BIOLOGICAL|Active Comparator|0.5 milliliter (mL) intramuscular (IM) injection
214422964|NCT03593876|BEHAVIORAL|Strategy Training|This study will use an adapted form of strategy training for people with communication impairments.
214507224|NCT07100002|DEVICE|Earplug Group|Patients who met the inclusion criteria were fitted with standard earplug of the same brand by the researcher at night. The researcher applied the earplug from 01:00 AM to 05:00 AM. The reason for this is that the procedures performed on the patients within the clinical routine ended at 01:00 AM and the patients' uninterrupted sleep hours coincided with these hours.
215022446|NCT04575298|DIETARY_SUPPLEMENT|Acceptability, tolerance study for an infant formula with human milk oligosaccharides|Prospective study
215022447|NCT01883375|BEHAVIORAL|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
215022448|NCT01883375|BEHAVIORAL|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
215022449|NCT06160778|DRUG|Ketorolac Tromethamine|Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
215102902|NCT00857519|DRUG|Melphalan, Carboplatin|Intra-arterial chemotherapy.
214422965|NCT00258635|BIOLOGICAL|RagweedMATAMPL|
214422966|NCT06516809|DEVICE|DormoTech Vlab SpO2 sensor|The Dormotech Vlab sensor was applied to one of the subject's forehead. Reference pulse oximeters were applied to the right fingers. Blood gas analysis to determine hemoglobin saturation (SaO2) was performed using an ABL-90 Flex Plus multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). The ABL90 Flex Plus contains factory calibration standards and automatically performs regular quality controls.
214422967|NCT03287622|BEHAVIORAL|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
214422968|NCT03287622|BEHAVIORAL|Nudge|Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
214422969|NCT00016250|DRUG|MKC-1|
214422970|NCT00432458|DRUG|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
214422971|NCT00432458|DRUG|zoledronic acid|4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
215022450|NCT06160778|DRUG|Morphine Sulfate|Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
215022451|NCT06160778|DRUG|normal saline|Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
215022452|NCT06160778|DRUG|Normal saline|Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
215022453|NCT06327165|OTHER|observation|The ANI monitor calculates heart rate variability mediated by changes in the parasympathetic nervous system.
215022454|NCT05390320|PROCEDURE|PAOO|Periodontally accelerated osteogenic orthodontics will be applied to treat patients with moderate crowding.
215022455|NCT05390320|OTHER|Fixed appliance|Fixed appliances will be applied to treat patients with moderate crowding without any acceleration methods.
215102903|NCT05236244|OTHER|İntervention group|Diaphragmatic Breathing Exercises
215102904|NCT04943432|BEHAVIORAL|Behavioral Activation|8 sessions of harm reduction-focused Behavioral Activation for Substance Use
215102905|NCT06086834|OTHER|McKenzie Retraction Exercises|McKenzie Retraction exercises 5 days a week and 10-15 times for active exercises and 5-6 repetitions of clinician assisted exercise for a period of 4 weeks and a rest interval of 2 minutes between exercises.
214422972|NCT05136807|OTHER|Quality-of-Life Assessment|Complete questionnaires
215022456|NCT01946269|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.~* The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.~* When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%.~* If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg."
215022457|NCT01946269|OTHER|Standard protocol|The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
215022458|NCT00000397|BEHAVIORAL|Behavioral insomnia therapy|
215022459|NCT02144337|BEHAVIORAL|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
215022460|NCT04973293|DRUG|sintilimab|Sintilimab 200 mg, 4 cycles of treatment before surgery
215022461|NCT04973293|DRUG|bevacizumab|bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
215022462|NCT01013337|PROCEDURE|acupuncture therapy|
215022463|NCT01013337|PROCEDURE|sham intervention|Placebo acupuncture
215022464|NCT03221335|DEVICE|EUS-guided RFA|All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
215022465|NCT03066180|DEVICE|Viveve SUI treatment|Non-ablative radiofrequency treatment with surface cooling
215022466|NCT01435642|OTHER|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
215022467|NCT04872647|BEHAVIORAL|Phone-Based Health Coaching Utilizing Lifestyle Action Plans|Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
215022468|NCT01730729|DRUG|cabergoline|Given orally
215022469|NCT03397641|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
215022470|NCT03397641|OTHER|Placebo|Normal Saline
215022471|NCT04127110|DRUG|Lorlatinib|Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
215022472|NCT02584738|DRUG|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
215022473|NCT02584738|DRUG|Nebulized isotonic saline|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
215022474|NCT02584738|DRUG|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
215022475|NCT02584738|DRUG|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
215022476|NCT02584738|DRUG|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
215022477|NCT06207019|DEVICE|Hyflex EDM , The XP-endo Shaper, Primary WaveOne Gold|rotary single files
214422973|NCT05136807|OTHER|Questionnaire Administration|Complete questionnaires
214422974|NCT03725059|BIOLOGICAL|Pembrolizumab (K)|IV infusion Q3W
214422975|NCT03725059|DRUG|Placebo (P)|Normal saline or dextrose IV infusion Q3W
215022478|NCT06569420|OTHER|Drug: Foritinib Succinate|SAF-189s: 160 mg QD, 21 days a cycle
215022479|NCT06569420|OTHER|Drug: Crizotinib|Crizotinib: 250 mg BID, 21 days a cycle
214422976|NCT03725059|DRUG|Paclitaxel (X)|IV infusion QW
214422977|NCT03725059|DRUG|Doxorubicin (A)|IV infusion either in Q2W or Q3W
214422978|NCT03725059|DRUG|Epirubicin (E)|IV infusion either in Q2W or Q3W
214422979|NCT03725059|DRUG|Cyclophosphamide (C)|IV infusion either in Q2W or Q3W
214422980|NCT03725059|DRUG|Endocrine therapy|Variable endocrine therapy for up 10 years
214422981|NCT03725059|RADIATION|Radiation therapy|Variable radiation therapy per local standard of care
214422982|NCT03725059|PROCEDURE|Surgery|Surgery for breast cancer
214422983|NCT02889341|DIETARY_SUPPLEMENT|DHA|
214422984|NCT02889341|OTHER|Placebo|
214422985|NCT00919594|BEHAVIORAL|Interpersonal Psychotherapy for Mothers (IPT-MOMS)|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
214507225|NCT07100002|DEVICE|Eye mask Group|Patients who met the inclusion criteria were fitted with standard eye masks of the same brand by the researcher at night. The researcher applied the eye mask from 01:00 AM to 05:00 AM. The reason for this is that the procedures performed on the patients within the clinical routine ended at 01:00 AM and the patients' uninterrupted sleep hours coincided with these hours.
214422986|NCT00919594|BEHAVIORAL|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
214422987|NCT01418794|DEVICE|High dose rapamycin stent|Concentration of rapamycin is 2.5%
215022480|NCT06571318|OTHER|Destress and Perform Capsule-U001|Two Capsules in sequence daily after meal for 60 days.
215022481|NCT06571318|OTHER|Destress and Perform Capsule-I001|Two Capsules in sequence daily after meal for 60 days.
215022482|NCT06571318|OTHER|Placebo capsules 002|Two Capsules in sequence daily after meal for 60 days
215022483|NCT06570421|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct transcutaneous, electrical stimulation of the peroneal nerve
215022484|NCT06571929|OTHER|INTERACT|INTERACT is an individualized, task-specific training program that includes environmental enrichment, natural and augmented realities, and active training.
215022485|NCT01435980|PROCEDURE|Gastric Bypass|basal treatment and Gastric Bypass
215022486|NCT01435980|DRUG|Exenatide|basal treatment and Exenatide
215022487|NCT06570668|DRUG|CDD-2101|All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
215022488|NCT06570837|DIETARY_SUPPLEMENT|Iron|observation effect of iron dificincy
215022489|NCT06570811|DRUG|Placebo|Placebo tablets is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
215022490|NCT06570811|DRUG|Coenzyme Q10 200mg twice daily|400 mg daily (200mg twice daily) of Coenzyme Q10 (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
215022491|NCT00449787|DRUG|Sumatriptan 100 mg|Sumatriptan 100mg tablet
215022492|NCT00449787|DRUG|Naproxen|Naproxen 500mg tablet
215022493|NCT03701074|DRUG|Ibuprofen and acetaminophen|Intravenous ibuprofen given concomitantly with oral acetaminophen
215022494|NCT03701074|DRUG|Ibuprofen and placebo|Intravenous ibuprofen given concomitantly with oral placebo
215022495|NCT03616093|OTHER|Test Beet Shot|Active supplement containing 6.2 mmol nitrate
215022496|NCT03616093|OTHER|Placebo Beverage|Placebo supplement containing negligible nitrate
215022497|NCT01141764|PROCEDURE|Positron Emission Tomography (PET) Scan|"The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.~This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days."
215022498|NCT01141764|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
215022499|NCT01141764|OTHER|Neuropsychological Testing|"On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on."
215022500|NCT02695771|DRUG|Mitomycin C|Cancer chemotherapeutic agent
214422988|NCT01418794|DEVICE|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
214422989|NCT05688761|DRUG|Proton pump inhibitor|Long-term use of medications, particularly proton pump inhibitors
214422990|NCT05193994|DRUG|Dolutegravir, Abacavir and Lamivudine|Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.
214422991|NCT05193994|DRUG|Placebo|Matching placebo.
214422992|NCT04131166|BEHAVIORAL|Mediterranean diet|A Mediterranean-type diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
214422993|NCT04131166|BEHAVIORAL|Low-carbohydrate, ketogenic diet|A low-carbohydrate, ketogenic diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
214422994|NCT04131166|BEHAVIORAL|Low-fat diet|A low-fat diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
214422995|NCT04131166|OTHER|Annual follow-up testing for 5 years|Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
215022501|NCT02695771|DRUG|Gemcitabine|Cancer chemotherapeutic agent
215022502|NCT05497245|OTHER|mobile app-based breastfeeding education|"The main screen of the application used to be six screens. These six screens; Breastfeeding, Expressing, Contingencies, Frequently asked questions and my Breastfeeding Log and Breastfeeding diary. Mothers could record the number and duration of breastfeeding, milking status, the baby's height and weight, if it was a measure, the breastfeeding problem and solutions they encountered, on the Breastfeeding Introduction tab, and they could follow their breastfeeding status in the Breastfeeding Diary tab."
215022503|NCT03574389|BIOLOGICAL|13vPnC|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
215022504|NCT03574389|BIOLOGICAL|Hib|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
215022505|NCT06316765|PROCEDURE|Intubation with stylet|The cohort of premature infants was intubated with stylet.
215022506|NCT00921544|OTHER|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
215022507|NCT00921544|OTHER|Sterile water|Sterile water administered 2 mins prior to eye exam
215102906|NCT06086834|OTHER|Bruegger's Exercise|Bruegger's Exercise will be started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time will be 30 seconds, 4 sets 12 times repetition, for duration of 30 mins per session, 5 days a week for a period of 4 weeks.
215102907|NCT02687698|OTHER|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
214422996|NCT03520673|DIAGNOSTIC_TEST|Urodynamics|All the men in the study will receive the urodynamics procedure as a reference test.
215022508|NCT05227365|DEVICE|Lenire|The sound stimulus of PS6 is comprised of sequences of tones and is spectrally modified according to the participant's hearing thresholds so that different components of the sound stimulus can be sufficiently heard by the participant irrespective of their hearing characteristics (audiological profile). The tongue stimulus of PS6 is delivered by an array of electrical signals via 32 transmucosal electrodes contacting the anterodorsal surface of the tongue. The sound and tongue stimulus parameters are presented with certain stimulus rates and timing relationships between modalities.
215022509|NCT02729012|DRUG|hypertonic saline solution (NACL 3%+NAHCO3)|Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
215022510|NCT02729012|OTHER|Saline Solution (NACL 0,9%)|Treatment with nebulized Saline Solution (NACL 0,9%)
215022511|NCT04551586|DRUG|ACH-0145228: Immediate Release|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
215022512|NCT04551586|DRUG|ACH-0145228: Powder-in-capsule|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
215022513|NCT01623427|PROCEDURE|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
215022514|NCT01623427|PROCEDURE|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
215022515|NCT01242384|DEVICE|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
215022516|NCT02944045|DRUG|Methylprednisolone|"Methylprednisolone intra veinous~* Day 1 to 5 : 30mg twice per day~* Day 6 to 10 : 30mg per day~* Day 11 to 21 : 20mg per day"
215022517|NCT02944045|DRUG|Placebo|saline serum
215022518|NCT01682603|DRUG|Botulinum toxin A|BoNT-A (BOTOX 300U)
214422997|NCT02028637|OTHER|TLRs|Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
214507226|NCT07099703|OTHER|Experimental|At Kırşehir Ahi Evran University, which is part of the Intervention Group, Ahilik education is a compulsory course within the current curriculum and will be taught over a period of 14 weeks. Ahilik education covers topics such as morality, etiquette, ethics, values, and professional ethics.
214507227|NCT07099703|OTHER|Routine education|They will continue with their current curriculum and will not receive any Ahilik training.
215022519|NCT00078195|BIOLOGICAL|omalizumab|A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
215022520|NCT00078195|BIOLOGICAL|Placebo omalizumab|The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
214422998|NCT01976910|DRUG|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
214507228|NCT07098208|BEHAVIORAL|Twin Heart Meditation|"Participants in this group receive the Twin Heart Meditation intervention, a guided meditative technique based on the principles of loving-kindness and spiritual energy. The intervention is designed to reduce exam-related anxiety by promoting inner peace and emotional regulation. The meditation protocol follows the steps conceptualized by Master Choa Kok Sui and includes the following components:~* Physical warm-up exercises~* Activation of the heart chakra~* Activation of the crown chakra~* Blessing the Earth with loving-kindness~* Silent meditation using the phrase Amen~* Expression of gratitude~* Closing exercises~Participants practice the meditation in three guided sessions over one week, each lasting 30 minutes, under the supervision of a trained instructor. Sessions are conducted in a quiet room with audio guidance and follow-up support."
215022521|NCT00078195|BIOLOGICAL|Ragweed rush immunotherapy (RIT)|RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
215022522|NCT00078195|BIOLOGICAL|Placebo rush immunotherapy (RIT)|The placebo for rush immunotherapy will contain the diluents and histamine.
215022523|NCT00078195|BIOLOGICAL|Ragweed immunotherapy (IT)|Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
215022524|NCT00078195|BIOLOGICAL|Placebo immunotherapy (IT)|The placebo for immunotherapy will contain the diluents and histamine.
215022525|NCT00993473|DRUG|Insulin glargine (HOE901)|"100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~* Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~* Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~* Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~* HbA1c \<7.5%."
215022526|NCT00993473|DRUG|Neutral Protamine Hagedorn (NPH) insulin|"NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine"
215022527|NCT00993473|DRUG|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
215022528|NCT03333889|OTHER|Vita Enamic hybrid crown|hybrid ceramic material in the form of mesoblocks where the ceramic block is attached to a ti base .The whole assembly is screw retained superstructure.
215022529|NCT03333889|OTHER|emax hybrid crown|high srength glass ceramic that can be milled in sections up to 1mm .
215022530|NCT03258229|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
214422999|NCT03590288|PROCEDURE|Transjugular intrahepatic portosystemic shunt|"Covered stents will be used, that will be dilated to 8 mm. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected."
214423000|NCT05845710|DEVICE|Neuroguard IEP Direct System|carotid artery stenting, direct access with blood flow redirection
214423001|NCT03823300|DRUG|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
214423002|NCT03823300|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
214423003|NCT03823300|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.
214423004|NCT02571387|BEHAVIORAL|Mindfulness-based intervention|
214423005|NCT02571387|BEHAVIORAL|Sham meditation|
214423006|NCT03703037|DIAGNOSTIC_TEST|Ultrasound and Doppler ultrasound|Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
214423007|NCT04017169|OTHER|No intervention as observational study|
215022531|NCT03258229|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 weeks
215022532|NCT01235637|DRUG|Alfentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
215022533|NCT01235637|DRUG|Sufentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
215022534|NCT03609944|PROCEDURE|ERCP with miES|Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy
215022535|NCT03609944|PROCEDURE|EUS|Endoscopic ultrasound
215022536|NCT05572632|BEHAVIORAL|COPD Wellness|COPD Wellness consists of 10 weekly sessions led by the COPD Wellness Coach. The intervention was designed to be portable, rely on little equipment, and require limited space (\~300sqft). The curriculum was iteratively developed with patient input and builds behavioral capability and self-efficacy through 30 minutes blocks of disease education and self-management skill building, exercise training, and social support.
215022537|NCT05572632|BEHAVIORAL|COPD Wellness Plus+|Couples COPD Wellness with the ZSFG Health Advocates Program. The HA will help the participant prioritize identified needs and, using an algorithm informed approach to connect the individual to the needed resource, this includes providing referrals to outside social or legal service agencies, help with applications for social benefits, or other services. The HA will use a checklist to track activities including review and prioritization of needs, referrals or resources provided, and contacts/contact attempts.
215022538|NCT05572632|BEHAVIORAL|Usual Care|Includes access to comprehensive primary care services that is standardized across the SFHN. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
214423008|NCT00003717|DRUG|estramustine phosphate sodium|
214423009|NCT00003717|DRUG|paclitaxel|
214423010|NCT05266599|OTHER|MTA Fillapex root canal sealer|Root canal treatments were performed with MTA Fillapex
214423011|NCT05266599|OTHER|AH Plus root canal sealer|Root canal treatments were performed with AH plus
214423012|NCT03477110|DRUG|Temozolomide|Given PO
214423013|NCT03477110|RADIATION|Radiation Therapy|Undergo radiation therapy
214423014|NCT03477110|DEVICE|NovoTTF-200A Device|Undergo tumor treatment fields therapy using NovoTTF-200A device
214423015|NCT03477110|PROCEDURE|Tumor Treating Fields Therapy|Undergo tumor treatment fields therapy using NovoTTF-200A device
214423016|NCT04352803|BIOLOGICAL|Autologous Adipose MSC's|Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV
215022539|NCT02115971|OTHER|Jumping exercise|Total 120min exercise
215022540|NCT02115971|OTHER|Strength exercise|Total 120 min exercise
215022541|NCT01816399|PROCEDURE|Routine coronary angiography|
214423017|NCT03368833|DIAGNOSTIC_TEST|Electrocardiogram|12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.
214423018|NCT04536441|BEHAVIORAL|Ultra Brief Online Mindfulness-based Intervention|We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley \& Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.
215022542|NCT04635774|DRUG|Insulin|40 IU via four activations of an intranasal spray
215022543|NCT04635774|DRUG|Saline|Four activations of an intranasal spray containing placebo (normal saline).
215022544|NCT05853939|DEVICE|repetitive transcranial magnetic stimulation|Repetitive TMS targeted by neuronavigation to left lower visual field of primary visual cortex. Randomized to 10 Hz or 1 Hz on different treatment days. Stimulation at 110% of phosphene threshold, or 110% resting motor threshold if phosphenes not detectable. 1 Hz: 1000 pulses total over 1000 seconds. 10 Hz: 1000 pulses over 10 10 second pulse trains, with 50 second intertrain intervals
215022545|NCT06136299|OTHER|Neuromuscular Training|This intervention uses the FIFA 11+ Kids program as a warm-up during soccer practice sessions.
215022546|NCT04907955|PROCEDURE|phacoemulsification with implantation of presbyopia correcting IOL|cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL
214423019|NCT04536441|BEHAVIORAL|Control|The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
214423020|NCT03612882|OTHER|Online questionnaire|Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
214423021|NCT00660478|DEVICE|Endeavor|Comparison of two different drug eluting coronary stents
214423022|NCT00660478|DEVICE|Cypher Select|Comparison of two different drug eluting coronary stents
214423023|NCT02402920|DRUG|Carboplatin|Given IV
214423024|NCT02402920|DRUG|Cisplatin|Given IV
214423025|NCT02402920|DRUG|Etoposide|Given IV
214423026|NCT02402920|OTHER|Laboratory Biomarker Analysis|Correlative studies
214423027|NCT02402920|BIOLOGICAL|Pembrolizumab|Given IV
214423028|NCT02402920|PROCEDURE|Radiation Therapy|Undergo radiation therapy
214423029|NCT04429230|DEVICE|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline soaked (0.9% NaCl) surface sponge electrodes. Anodal stimulation will be given to brain area based on qEEG findings
214423030|NCT04429230|DEVICE|Sham Transcranial pulsed current stimulation (tPCS)|Electrode placement will be the same as active stimulation but the electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
214423031|NCT00326924|BIOLOGICAL|Transfusion|PRBC blood transfusions.
214423032|NCT05650268|DRUG|Vitamin D3|Receiving 576000 international units in single oral dose of liquid vitamin D 3\~7 days prior to the surgery.
214423033|NCT05650268|OTHER|95% MCT|95% MCT supplement 3-7 day before surgery
214423034|NCT01373398|DRUG|EO9(Apaziquone)|immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
214423035|NCT02662855|OTHER|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
214423036|NCT02662855|DRUG|Favipiravir|oral administration of Favipiravir tablets
214423037|NCT02891278|DRUG|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM."
215022547|NCT01940744|PROCEDURE|Prescriptive Mobilization|"The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits."
215102908|NCT02272218|PROCEDURE|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
214423038|NCT02891278|DRUG|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
214423039|NCT02891278|PROCEDURE|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
214423040|NCT00507689|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
214423041|NCT00507689|DRUG|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
214423042|NCT05383313|DRUG|Psilocybin|Effect of psilocybin on treatment-resistant depression
214423043|NCT05383313|DRUG|Ketamine Hydrochloride|Effect of ketamine on treatment-resistant depression
214423044|NCT05383313|DRUG|Midazolam Ph. Eur 9.0|Effect of midazolam on treatment-resistant depression
214423045|NCT01927965|DRUG|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
215102909|NCT01299116|DRUG|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
214507232|NCT07098299|DRUG|Metformin|Metformin will be given for 14 days alone as a run in and then added to any standard of care chemotherapy or immunotherapy for solid tumors.
214423046|NCT03244579|BEHAVIORAL|Dietary Intervention|Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
214423047|NCT00486330|DRUG|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
214423048|NCT01290224|OTHER|scrambler therapy|Undergo MC5-A therapy
214423049|NCT01290224|PROCEDURE|sham intervention|Undergo sham procedure
214423050|NCT01290224|OTHER|questionnaire administration|Ancillary studies
214423051|NCT03531853|DEVICE|hand-held swept source optical coherence tomography|images the eye
214423052|NCT00346333|DRUG|Lutein|12mg/d
214423053|NCT00346333|DIETARY_SUPPLEMENT|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
214507233|NCT07099859|DRUG|Losartan 50 mg|Losartan 50 mg per day
214690527|NCT03332108|OTHER|EpxBreastfeeding|"We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past \[x\] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories."
214690528|NCT03332108|OTHER|Baby book survey|"We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe"
214690529|NCT04617613|DRUG|Omeprazole, Amoxicillin, Metronidazole and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
214423054|NCT04215406|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.
214423055|NCT03763721|DEVICE|intraoperative optical coherence tomography (iOCT)|"The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery."
214423056|NCT03023280|PROCEDURE|Radiofrequency ablation|
214423057|NCT00391547|DRUG|Frio Oral Rinse|
214423058|NCT00154791|DRUG|oxaliplatin|
214423059|NCT00154791|DRUG|gemcitabine|
214423060|NCT00154791|DRUG|5-FU/LV|
214507234|NCT07099859|DRUG|Placebo|Placebo 1 pill per day
214507235|NCT07098442|BEHAVIORAL|Control Group|On the first clinical day, students had a 30-45 minute meeting with the patient they were responsible for, which included the instructor.
214690530|NCT04617613|DRUG|Omeprazole, Amoxicillin and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
215102910|NCT01299116|DRUG|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
215102911|NCT01299116|DRUG|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
215102912|NCT01299116|DRUG|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
215102913|NCT01299116|DRUG|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
214423061|NCT05817630|OTHER|Silicone oil Tamponade for Retinal Detachment|eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed
214423062|NCT05501249|BEHAVIORAL|Aquatic Integrated Cognitive Motor Training|Aquatic exercise class with focus on cognitive and physical exercise
214423063|NCT00023725|DRUG|semaxanib|
214423064|NCT00023725|PROCEDURE|conventional surgery|
215102914|NCT00236756|DRUG|topiramate|
214423065|NCT00023725|RADIATION|radiation therapy|
214423066|NCT02212054|BEHAVIORAL|conservative|anal dilatation; colonic lavage; oral probiotic
214423067|NCT02212054|PROCEDURE|operative|one stage pull through radical colectomy
214423068|NCT02020824|BEHAVIORAL|Exposure to anxiogenous environments|"The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control)."
214423069|NCT02020824|OTHER|Imagery with functional MRI initial|Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
214423070|NCT02020824|OTHER|Imagery with PET-scanner initial|Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
214690531|NCT03552549|BIOLOGICAL|PEG-Intron|Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.
214690532|NCT03552549|BIOLOGICAL|INTRON A|Interferon alfa-2b, recombinant for intravenous injection.
214690533|NCT00363012|BIOLOGICAL|HER-2/neu intracellular domain protein|300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
214690534|NCT00363012|OTHER|flow cytometry|This is a laboratory test used to assess the antigen specific T cell population.
215102915|NCT02708420|DEVICE|Glidescope|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
215102916|NCT02708420|DEVICE|Macintosh Laryngoscope|This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
215102917|NCT04088591|DRUG|Ascorbic Acid 500Mg/Ml Inj|Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
215102918|NCT04088591|DRUG|Dextrose in Water|50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
214423071|NCT02020824|OTHER|Imagery with functional MRI final|Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
214423072|NCT02020824|OTHER|Imagery with PET-scanner final|Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
214423073|NCT03197337|PROCEDURE|Pressure-test|Pressure will be applied to the posterior fornix using a speculum.
214423074|NCT05586113|DRUG|10-day Tegoprazan bismuth-containing quadruple therapy|10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
214507236|NCT07098442|BEHAVIORAL|Online Interview Group|"Before the Interview~* Preliminary briefings were given by providing a scenario for the standard patient to be interviewed.~* Students were given the Interview Guide, Nursing Process Case Example, and Tips for Conducting a Successful Interview documents and were asked to read them before the interview.~Interview~• Students conducted a 30-45 minute interview with a pre-determined standard patient.~After the Interview~* The instructor, who monitored the interview, debriefed the students.~* On the first clinical day after the intervention, students conducted a 30-45 minute interview with the patient they were responsible for, which included the instructor."
214690535|NCT00363012|OTHER|immunohistochemistry staining method|This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
215022548|NCT01940744|PROCEDURE|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
215022549|NCT05299320|DIAGNOSTIC_TEST|Neuromuscular fatigue and postural sway evaluation|Neuromuscular fatigue will be established by using the Excalibur Sport Ergometer device and the Wingate Anaerobic Strength Test. Postural sway will be evaluated with Cyst Force Plate Balance device. This device is a precision device that provides objective measurable data.
215022550|NCT06438731|OTHER|BREAST MILK|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
215022551|NCT06438731|OTHER|KNITTED OCTOPUS|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
215022552|NCT03707821|DEVICE|senofilcon A TEST Lens|JJVC Investigational Contact Lens
215022553|NCT03707821|DEVICE|senofilcon A CONTROL Lens|Acuvue Oasys
215102919|NCT01338857|DRUG|Sorafenib (Nexavar)|"Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.~Children/adolescents (\< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily~Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily~NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily"
214507237|NCT07098442|BEHAVIORAL|Clinical Real Patient Group|"Before the Interview~* Patients who were willing to be interviewed in the clinic, stable, and physically and psychologically competent were selected, and the faculty member who would monitor the interview provided preliminary information about the interview.~* Students were provided with the Interview Guide, Nursing Process Case Example, and Tips for Conducting a Successful Interview documents and were asked to read them before the interview.~Interview~• Students conducted a 30-45 minute interview with a real patient in the pre-determined clinic.~After the Interview~* The faculty member who monitored the interview debriefed the students.~* On the first clinical day after the intervention, students had a 30-45 minute interview with the patient for whom they were responsible, which included the faculty member."
214507238|NCT07098975|DRUG|Pravastatin 40 mg|This study proposes administering a daily dose of 40 mg of pravastatin between 24 and 29.6 weeks of gestation to mothers diagnosed with preeclampsia and/or fetal growth restriction.
215102920|NCT02458183|BIOLOGICAL|DTaP-IPV combination vaccine|0.5-mL IM
215102921|NCT02458183|BIOLOGICAL|DTaP vaccine and IPV vaccine|0.5-mL IM
214690536|NCT00363012|PROCEDURE|biopsy|A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
214690537|NCT00363012|OTHER|Sterile water placement|100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
214690538|NCT00382889|DRUG|beclomethasone/salbutamol combination|
214690539|NCT00382889|DRUG|beclomethasone|
215022554|NCT00003455|DRUG|antineoplaston A10|
214690540|NCT00382889|DRUG|salbutamol|
214690541|NCT03403504|DRUG|Oxycodone Tamper Resistant|Orally administered Oxycodone Tamper Resistant 10mg
214690542|NCT03403504|DRUG|OXYCONTIN®|Orally administered OXYCONTIN® Tablet 10 mg
215022555|NCT00003455|DRUG|antineoplaston AS2-1|
215022556|NCT00003455|PROCEDURE|alternative product therapy|
215022557|NCT00003455|PROCEDURE|biological therapy|
215022558|NCT00003455|PROCEDURE|biologically based therapies|
215022559|NCT00003455|PROCEDURE|cancer prevention intervention|
215022560|NCT00003455|PROCEDURE|complementary and alternative therapy|
214423075|NCT01305434|DIETARY_SUPPLEMENT|Mulberry leaf extract effect on post prandial blood glucose|"Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications."
214423076|NCT01170299|DIETARY_SUPPLEMENT|dietary intervention|
215022561|NCT00003455|PROCEDURE|differentiation therapy|
215022562|NCT04585581|BEHAVIORAL|time-restricted eating|Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours.
215022563|NCT04585581|BEHAVIORAL|high intensity exercise|Participants will be encouraged to exercise with high intensity 2-3 times per week
214423077|NCT01170299|OTHER|laboratory biomarker analysis|
214423078|NCT01170299|PROCEDURE|gastrointestinal complications management/prevention|
214423079|NCT01170299|PROCEDURE|management of therapy complications|
214423080|NCT01170299|RADIATION|selective external radiation therapy|
214423081|NCT04645069|BIOLOGICAL|ADG126 Mono|ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.
214423082|NCT04645069|BIOLOGICAL|ADG126-anti PD1|ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion
214423083|NCT04645069|BIOLOGICAL|ADG126-ADG106|ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion
215022564|NCT04585581|OTHER|Standard Care|Standard clinical care
215022565|NCT04105283|BIOLOGICAL|Tc99m-MAA|Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
215022566|NCT04935593|OTHER|The RENEW Intervention|An game-based intervention that will provide lessons and activities in social-awareness, self-management, self-awareness, relationships and decision making in effort to strengthen social, emotional and behavioral competence. The intervention will be administered tri-weekly for 20 minutes each session.
215022567|NCT03482232|DRUG|Benzodiazepines|Benzodiazepines for insomnia, agitation or delirium in people older than 65
215022568|NCT03482232|DRUG|Non-steroidal anti-inflammatory drugs|Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
215022569|NCT03482232|DRUG|paracetamol|paracetamol 1g for more than 3 days
214423084|NCT01611467|DRUG|CC-223|20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution
214423085|NCT01611467|DRUG|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
214423086|NCT00002472|DRUG|cisplatin|
214423087|NCT00002472|DRUG|etoposide|
214423088|NCT00002472|PROCEDURE|conventional surgery|
214423089|NCT00002472|PROCEDURE|neoadjuvant therapy|
214423090|NCT00002472|RADIATION|radiation therapy|
214423091|NCT00723450|DRUG|lamictal|Flexible Dosing
214423092|NCT02033018|DRUG|Aflibercept Injection|Aflibercept intravitreal injection
214423093|NCT02158754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|
214423094|NCT01564199|DRUG|salmeterol / fluticasone propionate|100/1000 μg oral capsule
214423095|NCT04208802|OTHER|Use of fluoridated toothpaste|Use of fluoridated toothpaste
214423096|NCT04208802|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
215022570|NCT03482232|DRUG|Antimicrobial agent|antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
215022571|NCT03482232|DRUG|Lipid-lowering drug|Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
215022572|NCT03482232|DIAGNOSTIC_TEST|Prostate cancer|Screening for prostate cancer in asymptomatic patients
215022573|NCT03482232|RADIATION|Lumbago|image tests in non-specific lumbago
215022574|NCT03482232|DRUG|Antimicrobial agent|antibiotics for pharyngitis (infants)
215022575|NCT03482232|DRUG|Mucolytic|mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
215022576|NCT03482232|DRUG|Ibuprofen and paracetamol|treatment with ibuprofen and paracetamol (infants)
215022577|NCT06015334|PROCEDURE|cataract surgery with implantation of intraocular lens|Cataract surgery with implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.
214423097|NCT04208802|OTHER|Wearing of an intraoral device with resin samples|Wearing of an intraoral device with resin samples
214423098|NCT00487305|BIOLOGICAL|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
214423099|NCT02120313|OTHER|inpatient rehabilitation|
214423100|NCT02120313|OTHER|outpatient rehabilitation|
214423101|NCT00001182|PROCEDURE|current standard of care treatments|
214423102|NCT02523391|DRUG|TA-8995|Capsule
215022578|NCT02217007|DRUG|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
215022579|NCT05145894|DEVICE|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
215022580|NCT04334811|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SAbR) delivers of a potent, ablative or nearly ablative dose of radiation in oligofractions (ie, five or fewer fractions) primarily to create a compact dose delivered accurately to the intended target with steep gradients in all directions (geometric avoidance) and avoid damaging normal tissues.
215022581|NCT03148782|BEHAVIORAL|OST Intervention for participants with Organizational skill difficulties|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
215022582|NCT04774562|BEHAVIORAL|Video-Assisted Discharge Education (VADE)|Video-Assisted Discharge Education (VADE): Information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities.
214423103|NCT02523391|DRUG|TA-8995|Tablet
214423104|NCT00532220|DRUG|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
214423105|NCT00532220|DRUG|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
214423106|NCT00473811|BEHAVIORAL|Low GI|low-GI education
214423107|NCT00473811|BEHAVIORAL|ADA diet|ADA dietary education
214423108|NCT03920371|OTHER|gamma camera imaging|Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out
214423109|NCT01738308|PROCEDURE|Healing Touch|"When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
214423110|NCT01738308|PROCEDURE|Healing Touch Sham Treatment|"The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside"
214423111|NCT03309488|DIAGNOSTIC_TEST|Oral food challenge|Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.
214507239|NCT07098975|OTHER|Placebo|A visually identical but inactive pill (a placebo),
214690543|NCT04224740|DRUG|Pembrolizumab|Patients will receive pembrolizumab at the dose of 200mg IV Q3W with maximum duration of 2 years (34 cycles-counting the part combined with chemotherapy)
214690544|NCT04224740|DRUG|Standard of care therapy|Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
214690545|NCT03714113|DIAGNOSTIC_TEST|Anti-HLA donor-specific antibodies monitoring|Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
214690546|NCT04099316|DEVICE|Eccentric exercise|Eccentric exercise with Eccentron electronic device. Exercise intervention: The exercise intervention is performed to twice a week (Total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage),(5-8 weeks; 2nd stage).
215022583|NCT04774562|BEHAVIORAL|Physiotherapy (PT) Program|Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.
215022584|NCT04909411|OTHER|OPHTHALMOLOGICAL ASSESSMENT|assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination
215022585|NCT04909411|OTHER|NEUROPSYCHOLOGICAL ASSESSMENT|completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire
215022586|NCT00989443|DRUG|Cidofovir gel|topical gel applied once a week for 3 weeks
215022587|NCT05229367|OTHER|Eccentric isokinetic training|Eccentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
215022588|NCT05229367|OTHER|Concentric isokinetic training|Concentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
215022589|NCT00894010|DRUG|carbamazepine 400mg|
215022590|NCT00894010|DRUG|levetiracetam 1000mg|
215022591|NCT02577380|BEHAVIORAL|IPV/GBV HTC|Participants will be interviewed after receiving their services.
215022592|NCT03559686|DRUG|Certolizumab Pegol|The recommended maintenance dose of Cimzia® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .
215022593|NCT02977871|PROCEDURE|Bladder flap|Performing uterine incision and cesarean section with a bladder flap.
214690547|NCT04099316|DEVICE|Conventional resistance exercise|Leg press exercise with leg press machine. Exercise intervention: The exercise intervention is performed to twice a week (total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage), (5-8 weeks; 2nd stage).
215022594|NCT01258699|DRUG|Thiocacid HR Tab 600mg|600mg for 1 day
215022595|NCT01258699|DRUG|BK-C-0701 320mg|320mg for 1 day
215022596|NCT01258699|DRUG|BK-C-0701 480mg|480mg for 1 day
215022597|NCT02088411|DRUG|Diclofenac|
215022598|NCT02088411|DIETARY_SUPPLEMENT|Wobenzym|
215022599|NCT02088411|OTHER|Placebo|
215022600|NCT05122143|DEVICE|Treatment A|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril"
215022601|NCT05122143|DEVICE|Treatment B|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)"
215022602|NCT05122143|OTHER|Treatment C|No treatment
215022603|NCT00359398|PROCEDURE|Platelet rich plasma sequestration|Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
215022604|NCT03599726|DRUG|Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
215022605|NCT03599726|DRUG|Placebo|Placebo 5 mg per day for week 1-2 or 5-6
215022606|NCT01690325|DRUG|Docetaxel|
214423112|NCT03193619|DEVICE|PTA (UltraScore Focused Force PTA Balloon)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated."
214423113|NCT02770495|OTHER|blood sample|
214423114|NCT00765934|DRUG|Rapydan|lidocaine / tetracaine 70/70 mg patch
214423115|NCT00559286|DRUG|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
214423116|NCT01102049|DIETARY_SUPPLEMENT|fish, beef, fruit|
214423117|NCT03353116|PROCEDURE|the mandible first|the mandible osteotomy is going to be done and fixed first
214423118|NCT03353116|PROCEDURE|the maxilla first|the maxilla osteotomy is going to be done and fixed first
214423119|NCT04915885|OTHER|Routine care|Routine contraceptive counseling and routine method availability
215022607|NCT01690325|DRUG|Trastuzumab|
215022608|NCT01690325|DRUG|Bevacizumab|
215022609|NCT01690325|DRUG|Epirubicin|
215022610|NCT01690325|DRUG|Cyclophosphamid|
215022611|NCT03854981|BEHAVIORAL|Exercise|Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.
215022612|NCT03854981|PROCEDURE|Standard Care|Standard preoperative care of bariatric surgery
214423120|NCT04915885|OTHER|Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
214423121|NCT04915885|OTHER|Expanded methods|Expanded range of contraceptive methods as recommended by national policies
214423122|NCT05380869|DIAGNOSTIC_TEST|Point-of-care Test|to test Point-of-care procalcitonin in suspected pneumonia
215022613|NCT05855096|OTHER|Google Form Questionnaire|Google form questionnaire is performed by responders.
215022614|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
215022615|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
215022616|NCT01827189|OTHER|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
214423123|NCT03608618|BIOLOGICAL|MCY-M11|Intraperitoneal administration
214423124|NCT03608618|DRUG|Cyclophosphamide|Intravenous administration for preconditioning
214690548|NCT02796924|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
214690549|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
214690550|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
214690551|NCT01257217|DEVICE|Acri.LISA® 366D IOL|Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
215022617|NCT04740346|DIAGNOSTIC_TEST|Computed tomography, Chest X-ray, and blood test|CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
215022618|NCT06294899|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed to patients with suspected lower respiratory tract infections.
215022619|NCT06294899|DIAGNOSTIC_TEST|C-Reactive Protein Test|C-Reactive Protein Test will be performed to patients with suspected lower respiratory tract infections.
214690552|NCT01257217|DEVICE|Acri.LISA® 466TD Toric IOL|Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
214690553|NCT05663996|OTHER|locally applied to the skin|Applying St John's wort oil locally on the knee three times a day for three weeks.
214690554|NCT05663996|OTHER|locally applied to the skin|Applying olive oil locally on the knee three times a day for three weeks.
214690555|NCT01044173|DEVICE|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
214690556|NCT03778177|PROCEDURE|transcranial electrical brain stimulation|Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
214690557|NCT06298292|DIETARY_SUPPLEMENT|Zero minis (range of protein substitutes in tablet form)|Intervention: range of protein substitute tablets. Subjects who currently take a protein substitute for the dietary management of either tyrosinaemias or alkaptonuria, homocystinuria, or MSUD will be recruited. Subjects will take the study product for 7 days. Daily questionnaires will be completed (ease of preparation,administration; any problems or gastrointestinal effects). Subjects will replace some or their entire usual protein substitute with the new product suitable for their diagnosed rare metabolic disease. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Additional questions at the beginning and end of the study will record information on organoleptic properties, presentation and packaging of the product. Routine weekly blood samples will be collected and analysed for amino acids typically for the metabolic control of the individual specified metabolic disorders as is usual clinical practice.
214690558|NCT00817986|DRUG|Arbaclofen placarbil, 20 mg|tablets
215022620|NCT01601561|DRUG|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose."
214507240|NCT07098949|OTHER|Acupuncture|The patient takes a sitting or lateral position. The following acupoints are selected Baihui (GV20), Yintang (EX-HN3), Zhongwan (CV12), Bilateral Neiguan (PC6), Bilateral Zusanli (ST36), Bilateral Sanyinjiao (SP6), Bilateral Gongsun (SP4), Bilateral Pishu (BL20). Electroacupuncture is applied at bilateral Sanyinjiao (SP6) and bilateral Zusanli (ST36) by connecting them to an electroacupuncture device. The needles are retained for 30 minutes.
214690559|NCT00817986|DRUG|Placebo|tablets
214690560|NCT00817986|DRUG|Arbaclofen placarbil, 30 mg|tablets
214690561|NCT00817986|DRUG|Arbaclofen placarbil, 40 mg|tablets
214690562|NCT04249141|OTHER|Survey and concept mapping|ICU providers who participoated in SCCM ICU Liberation Collaborative will be invited to participate in surveys and a concept mapping excercise
215022621|NCT04544605|OTHER|Individualized-Chinese herbal medicine|"I. Lung and spleen qi deficiency syndrome Clinical manifestations: shortness of breath, fatigue, fatigue, anorexia, nausea, fullness, weak stool, and uneasiness. The tongue is pale and greasy. Recommended prescription: French Pinellia 9g, Chenpi 10g, Codonopsis 15g, Sunburn Astragalus 30g, Stir-fried Atractylodes 10g, Poria 15g, Huoxiang 10g, Amomum villosum 6g (later), and Licorice 6g~II. Qi and Yin deficiency syndrome Clinical manifestations: fatigue, shortness of breath, dry mouth, thirst, palpitations, sweating, poor appetite, low or no lever, dry cough and little sputum; dry tongue, fine or weak pulses. Recommended prescription: North and south radix salviae 10g, 15g ophiopogonis, 6g American ginseng, 6g schisandra, 6g gypsum l5g, 10g light bamboo leaves, 10g mulberry leaves, 15g reed root, 15g salviae miltiorrhiza, 6g raw liquorice."
214507241|NCT07098949|OTHER|Sham Acupuncture|sham acupuncture procedure that mirrors the acupuncture treatment in terms of acupoint selection and treatment schedule. However, instead of actual needle insertion, a blunt-tipped sham needle will be used to apply superficial pressure at the designated acupoints. The design of the sham needle includes a base that allows for simulated insertion, providing patients with a mild sensation of pressure and a visual cue as the needle appears to move toward the skin. This innovative approach ensures that while participants experience a similar tactile sensation, there is no penetration of the skin, distinguishing it clearly from the actual acupuncture treatment.
214507242|NCT07098949|DRUG|Chemotherapy|Adjuvant chemotherapy with either the XELOX (capecitabine + oxaliplatin) or SOX (S-1 + oxaliplatin) regimen
214507243|NCT07100054|GENETIC|Whole gene sequencing|Whole gene sequencing of CYP3A4 and PXR
214507244|NCT07100054|OTHER|Drug-drug interaction analysis|Evaluating potential drug interactions with CYP3A4 inhibitors and inducers
214507245|NCT07100054|OTHER|Biomarker analysis|Determination of circulating CYP3A4 mRNA, and 4b-hydroxycholesterol
214507246|NCT07097987|DIETARY_SUPPLEMENT|WM formula Group|Participants in the intervention group will consume a single dose of WM formula drink (50 mL) on the study day. The formula includes Bifidobacterium breve (probiotic), ClpB formula (prebiotic), and Rocket Apple extract. The ClpB formula consists of kombucha, soy peptide powder, L-arabinose and erythritol.
214507247|NCT07097987|OTHER|Control group|Participants in the control group will consume 50 mL water
214507248|NCT07098754|OTHER|Dry Needling|"will use dry needles of different recommended sizes to intercept the trigger points~will add on myofascial release technique manually."
214507249|NCT07098754|OTHER|Trigger point therapy|"will release trigger points by manual pressure using trigger point therapy technique protocols~will ad on stretching techniques"
214507250|NCT07098754|OTHER|Maitlands' Mobilizations|"Maitlands' Mobilizations Grade-1\& Grade-2 will be applied to upper thoracic and cervical regions~dry cupping therapy will be applied as ad on therapy"
214507251|NCT07098754|OTHER|Tens and ultrasound|TENS and ultrasound will be applied according to recommended dosages followed by stretching and Range of motion activities
214690563|NCT04210336|DEVICE|PAPILOCARE|"Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera."
214690564|NCT04210336|DEVICE|PLACEBO|The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.
215022622|NCT01006486|OTHER|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
215022623|NCT01006486|OTHER|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
215022624|NCT02219451|OTHER|exercise training|exercise training
215022625|NCT02236897|OTHER|PET Scanning|
215022626|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young men|"Participants in this intervention will be healthy young men. The information of nutritional supplements is below.~Hydrolyzed collagen: 30 grams unflavored hydrolysed collagen (HC) (Myprotein, Cheshire, UK) 30.5 grams unflavored maltodextrin (Myprotein, Cheshire, UK) 50 milligrams vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK) 3 grams non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
215022627|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young women|Participants in this intervention will be healthy young women. The same nutritional supplements in Arm 1 wil be used in Arm 2.
215022628|NCT03766906|BEHAVIORAL|Talk STEM Familia app|The Talk STEM Familia app will be used to improve access to sound instruction in scientific academic vocabulary through the development of a technology-enhanced, culturally responsive smart-speaker tool that engages Latino families in culturally responsive academic language acquisition and practice in the home setting.
215022629|NCT00019825|DRUG|decitabine|
215022630|NCT05703295|PROCEDURE|Biopsy|Sentinel lymph node biopsy
215022631|NCT04883749|BIOLOGICAL|Acalabrutinib|Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
215022632|NCT03226665|DIAGNOSTIC_TEST|ultrasound|"definition of prevalence of US detected obstruction in patients referred to an emergency facilities with symptoms potentially suggestive for such diagnosis.~Moreover, which clue, if any, could reinforce the need of US intestinal study, such as anaemia, CRP, NLR, hypotension.~This information is not yet available elsewhere. Moreover, in this context, sensitivity and specificity of ultrasound vs. confirm by CT and other procedures will make more sense and will be consequently assessed."
215022633|NCT03678857|DIETARY_SUPPLEMENT|Creatine|"Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes)."
215022634|NCT04582812|OTHER|Bilateral and simultaneous diaphragm ultrasonography reeducation plus inspiratory training|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
215022635|NCT04582812|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
215022636|NCT02624687|BEHAVIORAL|Intervention|Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
215022637|NCT02624687|OTHER|No intervention|No contact control
215022638|NCT03975946|PROCEDURE|Rheopheresis procedure|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
215022639|NCT03975946|BIOLOGICAL|Blood Sample|Biological analysis
214423125|NCT06223529|BEHAVIORAL|Therapeutic Instrumental Music Performance|Exercises using musical instruments to improve hemiparetic hand and arm function
214423126|NCT01957319|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|
214423127|NCT01957319|DRUG|sugar pill|
214423128|NCT02968472|GENETIC|prophylactic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
214690565|NCT05557890|BEHAVIORAL|System Constellation VR-Seminar|individual-centered intervention in a group VR-setting, duration 2 to 3 days
215022640|NCT03975946|PROCEDURE|Shamapheresis procedure|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
215022641|NCT06500585|OTHER|Mill's Manipulation|"Mill's Manipulation: The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5 min.~Stretching of Wrist Extensors: 15 sec hold, 10 stretches/session/day. Wrist extensors Isometric: resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
215022642|NCT06500585|OTHER|Mill's Manipulation and Muscle Energy Technique|"Mill's Manipulation:The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Muscle Energy Technique: Extensor carpi radialis stretch for 30 sec repeated 5 times during a single treatment session. Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5min.~Stretching of Wrist Extensors, 15 sec hold, 10 stretches/session/day. Wrist Extensors Isometric, resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
215102922|NCT02237261|DRUG|Bendamustine, Bortezomib, Prednisone|"Cycle 1 (d1-42) - Induction:~Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4~Cycle 2-9 (d1-28) - Consolidation:~Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4"
215102923|NCT04739878|PROCEDURE|Airway Ultrasound|Comparison between Airway ultrasound and CT cervical
215102924|NCT01123707|DRUG|Aripiprazole|Aripiprazole oral capsules
215102925|NCT01123707|DRUG|Escitalopram|Escitalopram oral capsules
215102926|NCT04519853|BEHAVIORAL|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks
214507253|NCT06668428|DEVICE|Virtual Reality Glasses|Pharmacological and non-pharmacological methods are applied in the management of pain and anxiety after cesarean section (Tetik \& Tekinemre, 2017). In addition to medical treatment during the post-cesarean care process, complementary and supportive non-pharmacological approaches can be used to address the woman holistically and provide multi-faceted contributions to the health of the mother and baby (Ali, 2022; Bayraktar, 2023). One of the non-pharmacological approaches, virtual reality glasses, is a device that provides two or three-dimensional environments to stimulate our senses by creating illusions of images (Appel et al., 2021). SGG creates a therapeutic effect by diverting attention, provides relaxation, and can thus be used in the management of pain and anxiety (Ayed et al., 2019). It has been determined that virtual reality glasses are an effective method in the management of pain and anxiety in the field of nursing (Akıncı \& Aydın Özkan, 2024).
214507254|NCT06247553|OTHER|Gait Training|The gait training in the experimental group will use a treadmill with a partial body-weight support system and our gait training device. A gait training session will include 2-minute warming up at the beginning and 2-minute cooling down at the end, at a treadmill speed of 0.6 mph. After the warming up, the treadmill speed will increase at every two minutes by an increment of 0.2 mph. Participant's heart rate will be monitored throughout the training session by using a Polar OH1 optical HR sensor placed in the participant's left forearm. Researchers will stop the increase and maintain the same treadmill speed after the HR reaching the target heart rate zone of 50% - 60% of age-predicted heart rate reserve.
214507255|NCT06247553|OTHER|Leg Cycling Exercise|The leg cycling exercise will use a stationary bicycle and the similar protocol as in the experimental group. The cycling exercise will include 2-minute warming up in the beginning and 2-minute cooling down at the end with a speed of 10 rpm and resistance of level 1 of 4. After warming up, the speed will increase at every two minutes by an increment of 5 rpm until reaching the target heart rate zone of 50% - 60% of age-predicted maximum heart rate. If the participant cannot tolerate any more increase in cycling speed before reaching the target heart rate, the resistance will be increased. The training duration will be individualized at the beginning and increase weekly by 5 minutes, depending on the tolerance of the participant, up to the maximum of 30 minutes. Both heart rate and blood pressure will be monitored before, during, and after each session to ensure safety. Each session including setting up will be about one hour.
214507256|NCT07092527|DRUG|Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution|Participants in the initiating group will receive weekly doses of testosterone for gender-affirming care.
214507257|NCT07098585|DRUG|Lisdexamfetamine capsule|Lisdexamfetamine 70 mg capsule
214507258|NCT07098585|DRUG|Elvanse® (Lisdexamfetamine dimesylate capsules, hard)|Elvanse® (Lisdexamfetamine dimesylate 70 mg capsules, hard)
214507259|NCT07100015|DEVICE|Control Group|in which patients did not receive any treatment and received routine postoperative care in the clinic
214507260|NCT07100015|DEVICE|therapeutic touch|Therapeutic touch applications
214507261|NCT07100015|DEVICE|Shoulder massage|shoulder massage was applied
214507262|NCT07099612|DEVICE|MEMS® Mobile smartphone application|The MEMS® Mobile app is a smartphone application that connects to the Cere®Pak smart blister pack via near-field communication (NFC). It allows participants to view their medication intake history, receive optional reminders, and manually edit or confirm recorded dosing events. The app is installed on the participant's own smartphone (iOS or Android) and used throughout the 8-week study period. Participants are encouraged to scan their blister at least once daily to synchronize data. This intervention is for the Arm 1 group only.
214507263|NCT07099612|DEVICE|Cere®Pak smart blister pack|The Cere®Pak is an electronic blister pack with 28 cavities containing placebo tablets. It automatically records the date and time when each cavity is opened, using embedded electronics. Participants are instructed to simulate a twice-daily medication schedule (morning and evening) for 8 weeks by pushing out tablets without ingesting them. The device functions independently in the control group and connects with the MEMS® Mobile app in the intervention group. Both arms work with this intervention.
214690566|NCT01958736|OTHER|Ballistic Strength Training|The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
214690567|NCT01958736|OTHER|Usual Care Physiotherapy|This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
214690568|NCT02739594|DRUG|Ibandronate|Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
214690569|NCT02739594|DRUG|Zoledronate|Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
215102927|NCT02474251|OTHER|Continuous positive airway pressure device|GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
215102928|NCT01299402|DIETARY_SUPPLEMENT|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
215102929|NCT01299402|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
215102930|NCT01727414|DRUG|OROS-Methylphenidate and placebo for inattentive type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
214690570|NCT03259542|DRUG|Mifepristone 300 MG|mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
214690571|NCT03259542|DRUG|Itraconazole 100 MG|itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
214690572|NCT05355090|DIETARY_SUPPLEMENT|PP|Protein Pacing three times per day
214690573|NCT00505700|DRUG|velcade|
214690574|NCT00505700|DRUG|Idarubicin|
214690575|NCT00505700|DRUG|Cytarabine|
214690576|NCT00199264|DRUG|Albaconazole oral solution|
214690577|NCT05323786|PROCEDURE|The combined topical anesthesia induction group|Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.
214690578|NCT05323786|PROCEDURE|The routine induction group|Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
214690579|NCT04339075|OTHER|Questionnaires|Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
214690580|NCT01350037|DRUG|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
214690581|NCT01350037|DRUG|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
214690582|NCT03774693|OTHER|General anesthesia with fentanyl boluses|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1
214690583|NCT03774693|PROCEDURE|Regional block|Patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block.
214690584|NCT03734107|BEHAVIORAL|Plan, Reflect, and Engage with Providers for Diabetes Care|Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care
214690585|NCT03088293|DRUG|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
214690586|NCT03088293|DRUG|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
214690587|NCT01465178|DIETARY_SUPPLEMENT|cholecalciferol|2000 IU cholecalciferol gelcaps by mouth daily
214690588|NCT01465178|DIETARY_SUPPLEMENT|Placebo|matching placebo
214690589|NCT00189007|DRUG|Allopurinol sodium|Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
214690590|NCT00189007|DRUG|Mannitol|Mannitol 500 mg/50 mL water for injection, intravenously, single dose
214690591|NCT06189677|OTHER|Observation of biological characteristics of fertile men|Sampling in outpatient settings, after biopsy or after surgery and collection of biological samples in fertile subjects
214690592|NCT02915861|OTHER|Non-invasive eschar samples + blood|EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).
214690593|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+blood|EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).
214690594|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
215022643|NCT04620980|DIAGNOSTIC_TEST|targeted resequencing|The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).
215022644|NCT06379620|DEVICE|Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)|Subjects will self-administer oxygen gas at 1to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with ventilation supplemented by the subject's rebreathed exhaled air. Total treatment is for 14 days
215022645|NCT03307824|DEVICE|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
215022646|NCT03307824|PROCEDURE|Glue-Free Suture Technique|Suture Technique
215022647|NCT00860769|BEHAVIORAL|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
215022648|NCT00860769|BEHAVIORAL|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
215022649|NCT04475380|DEVICE|Percutaneous coronary intervention|PCI for treatment of coronary or bypass graft lesions
215102931|NCT01727414|DRUG|OROS-Methylphenidate and placebo for combined type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
215102932|NCT05683002|DIETARY_SUPPLEMENT|Aronia supplementation|As described in experimental arm
214690595|NCT02915861|OTHER|Blood+Skin sample|Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
214690596|NCT06150105|OTHER|Exercise training|Intense endurance training
214690597|NCT01231633|DRUG|Ozurdex|Ozurdex, 0.7mg dexamethasone
214690598|NCT01231633|DRUG|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
214690599|NCT00527111|DRUG|Cetuximab|
214690600|NCT00527111|DRUG|5-fluorouracil|
214690601|NCT00527111|RADIATION|Pelvic irradiation|
214690602|NCT00148460|DRUG|TNK-tPA|
214690603|NCT00148460|DRUG|rt-PA|
214690604|NCT03732872|DIAGNOSTIC_TEST|Biopsy tissue analysis|biopsy samples for IHC staining and PCR
214690605|NCT03732872|DIAGNOSTIC_TEST|Saliva analysis|Saliva samples for miRNA 21 expression analysis
215022650|NCT04555239|PROCEDURE|Fascial Distortion Model (FDM)|"Only treatment of herniated trigger points, continuum distortions, and/or trigger bands will be performed.~* Herniated trigger points are single areas of sharp pain within soft tissue.~* Continuum distortions are single points of sharp pain overlying bony tissues.~* Trigger bands are lines of pain overlying either soft or bony tissues.~Treatment with FDM is performed using firm, direct pressure over the area of the patient's pain with the provider's thumb. This pressure is applied at a single point or area indicated by the patient for herniated trigger points and continuum distortions, and along the indicated line of pain for trigger bands."
215102933|NCT05683002|DIETARY_SUPPLEMENT|Cellulose supplementation|As described in placebo comparator arm
215102934|NCT03720002|DIETARY_SUPPLEMENT|HF2|placebo
215022651|NCT04555239|OTHER|Standard Care|"The usual standard of care for extremity pain varies from provider to provider and varies from patient to patient depending upon their comorbidities but often includes some combination of the following:~* X-rays, if suspicion for fracture exists~* Venous duplex ultrasound, if suspicion for DVT/SVT exists~* Computed tomography (CT) angiogram (CTA), if suspicion for arterial occlusion exists~* C-reactive Protein (CRP)/erythrocyte sedimentation rate (ESR)/arthrocentesis is suspicion if suspicion for septic arthritis exists~* Arthrocentesis if suspicion for gout exists~* Splinting/casting/immobilization~* NSAIDs, Tylenol, or opioids for pain control~* Possibly trigger point injections~* Possibly osteopathic manipulation~* Recommendations to use RICE (rest, ice, compression, elevation) at home~* Physical/occupational therapy referral~* Orthopedic referral"
215022652|NCT00168285|BEHAVIORAL|Pulmonary Rehabilitation|
215022653|NCT06328569|DEVICE|Virtual Reality Therapy|The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.
215022654|NCT06328569|BEHAVIORAL|Conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
215022655|NCT02369939|RADIATION|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
215022656|NCT02369939|DRUG|Mitomycin C|MMC w1, w5
215022657|NCT02369939|DRUG|5-Fluorouracil|5-FU w1, w5
215102935|NCT03807284|BEHAVIORAL|A group psychosocial course|A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
214690606|NCT04154267|PROCEDURE|Percutaneous renal biopsy.|The biopsy will be performed with a 16 Gauge semi-automatic needle gun for renal biopsy under real-time ultrasound control. After the procedure will be done ultrasound control
215022658|NCT02369939|PROCEDURE|Hyperthermia|6x deep regional hyperthermia
214690607|NCT02041546|DRUG|Lung lavage with surfactant|
214690608|NCT02041546|DRUG|Bolus surfactant|
214690609|NCT06672094|DIETARY_SUPPLEMENT|NeuroQ|Two (2) capsules of NeuroQ taken once a day for 60 days.
214690610|NCT06672094|OTHER|Placebo|Two (2) capsules of placebo taken once a day for 60 days.
214690611|NCT06050863|BIOLOGICAL|silk fibroin|silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films
214690612|NCT06050863|DRUG|Chlorhexidin|chlorhexidine is used
214690613|NCT06050863|BIOLOGICAL|combination of silk fibroin and chlorhexidine|combination of silk fibroin and chlorhexidine is used
214690614|NCT03684161|DIAGNOSTIC_TEST|Cardiopulmonary function|Body composition measurements; Pulmonary function tests; Cardiopulmonary exercise test; Force frequency releationship, ultrasound
214690615|NCT03689283|OTHER|Dry Needling|Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle
214690616|NCT03689283|OTHER|Sham Dry Needlling|Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
214690617|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
214690618|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).
214690619|NCT01135953|OTHER|Transcranial direct Stimulation (tDCS) and D-cycloserine|"Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).~D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session."
214690620|NCT00647777|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fed
215022659|NCT05816161|DIAGNOSTIC_TEST|Integrated Neuromuscular Inhibition Technique|Exercises
215022660|NCT05816161|DIAGNOSTIC_TEST|Myofascial Release|Exercises
215022661|NCT03903341|OTHER|fMRI|bold signal in visual pathway
215022662|NCT03789370|DRUG|Propofol|Maintanance of general anaesthesia with propofol
215022663|NCT03789370|DRUG|Sevoflurane|Maintainance of general anaesthesia with sevoflurane.
215022664|NCT01830465|DRUG|Bortezomib (VELCADE)|1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
215022665|NCT01830465|DRUG|Rituximab|375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
215022666|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
215022667|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
215022668|NCT00983801|DRUG|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m\^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
215022669|NCT02189967|RADIATION|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
215022670|NCT02189967|RADIATION|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
215022671|NCT01251055|DRUG|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1(500) 4# BID
215022672|NCT01251055|DRUG|Placebo|starch
215022673|NCT05545059|DRUG|Sacubitril/valsartan|In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
215102936|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when C sensor algorithm is used.
215102937|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when Zeus sensor algorithm is used.
215102938|NCT04378114|DRUG|Acetominophen|One time administration of acetaminophen.
215102939|NCT04793334|PROCEDURE|sleeve gastectomy|routine sleeve gastrectomy
215102940|NCT00629798|DRUG|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients \> or = to 4 years of age or 1.0 mg/kg IV for patients \< 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
214690621|NCT00647777|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fed
214690622|NCT02916498|DEVICE|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
215102941|NCT01801852|BIOLOGICAL|NKT cells|
215102942|NCT00048100|PROCEDURE|Apheresis|Apheresis for T-Cell collection
215102943|NCT00048100|BIOLOGICAL|Stem Cell Transplant|Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
215022674|NCT05545059|DRUG|valsartan|In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
215022675|NCT05880784|OTHER|Reinforcement of Peer coaching and clinical audit|The goal of the proposed research study is to test the effectiveness and feasibility of an intervention to enhance peer coaching and clinic audit activities to facilitate the implementation of the Package of Essential Non- Communicable Diseases (PEN) in Nepal.
215022676|NCT05880784|OTHER|Continuation of usual practice without intervention|No intervention will be carried out, instead usual practice will be evaluated at the start and the end of the study period.
215022677|NCT01748656|DEVICE|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
215022678|NCT01748656|DEVICE|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
215102944|NCT02389439|DRUG|Pyronaridine-artesunate|
215102945|NCT01973556|OTHER|Pharmacist-Physician Collaborative Medication Therapy Management|
215102946|NCT01975597|PROCEDURE|Bone marrow aspirates and biopsy|
215102947|NCT05236504|DIETARY_SUPPLEMENT|Melatonin and magnesium-containing pod|A 50-100mL hot water drink, obtained from a coffee pod machine, containing 1.9mg of melatonin and 200mg of magnesium in a powdered form, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
214690623|NCT03827473|DRUG|Abiraterone Acetate|Given PO
214690624|NCT03827473|DRUG|Antiandrogen Therapy|Given per standard of care
214690625|NCT03827473|DRUG|Docetaxel|Given IV
214690626|NCT03827473|DRUG|Prednisone|Given PO
214690627|NCT03827473|OTHER|Quality-of-Life Assessment|Ancillary studies
214690628|NCT03827473|OTHER|Questionnaire Administration|Ancillary studies
214690629|NCT01395589|DRUG|Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
214690630|NCT03241758|DIAGNOSTIC_TEST|Doppler ultrasound|Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
214690631|NCT02167568|GENETIC|Genetic|
214690632|NCT04081844|DRUG|HCP1306|Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
214690633|NCT04081844|DRUG|HGP0904|Amlodipine 5mg(Norvasc)
214690634|NCT04081844|DRUG|HGP0608|Losartan 100mg(Cozaar)
214690635|NCT00875017|DRUG|Lanthanum Carbonate|1 x 1000mg tablet
214690636|NCT00875017|DRUG|Sevelamer|3 x 800mg tablets
214690637|NCT00121355|DEVICE|safety glide|
214690638|NCT00121355|DEVICE|autocover needle|
214690639|NCT02674581|DRUG|Oral BMS-663068 (pro-drug)|Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
215022679|NCT01942369|DRUG|Triptorelin Acetate 3.75mg intramuscular injection|"Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks."
215102948|NCT05236504|OTHER|Placebo comparator|A 50-100mL hot water drink of identical taste, obtained from an identical pod with the same ingredients except melatonin and magnesium, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
215102949|NCT02670668|OTHER|Mutation analysis|
215102950|NCT06524622|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) measurements will be performed for all participants
215102951|NCT03582995|PROCEDURE|Flap Surgery for root coverage with Alloderm and xenograft|A coronally positioned FLAP technique with AlloDerm® GBR and osseous xenograft will be used for root coverage
215102952|NCT03582995|PROCEDURE|Tunnel Surgery for root coverage with Alloderm and xenograft|A coronally positioned TUNNEL technique with AlloDerm® GBR and osseous xenograft will be used for root coverage.
215102953|NCT06525233|OTHER|Physiotherapy and rehabilitation|The aerobic exercise is very crucial part of cardiac rehabilitation. This study compares the effects of interval and continuous training which are the two types of aerobic training on persons' life quality and exercise capacity diagnosed coronary artery disease patients.
215102954|NCT02568592|DIETARY_SUPPLEMENT|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
215102955|NCT02568592|DIETARY_SUPPLEMENT|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
215102956|NCT02568592|DIETARY_SUPPLEMENT|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
215102957|NCT03465267|DEVICE|Armeo power|"Intervention with Armeo power rehabilitation robot for upper extremity (made by Hocoma), which provide assistive force.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
214507264|NCT07099976|DIAGNOSTIC_TEST|The novel care pathway intervention|The pathway uses already-ascertained data, bioMérieux Spotfire testing, and POC CRP testing to stratify patients into risk categories. The first step in the pathway will be POC CRP testing; children with CRP \> 60 mg/L will be deemed 'appreciable risk', whereas those with CRP \< 20 mg/L will be deemed 'low risk'. The CRP cut-offs of 20mg/L (more sensitive) and 60mg/L (more specific) were selected after reviewing the literature, with particular emphasis on meta-analyses; other large recent studies have also used 60mg/L as an upper cut-off for bacterial infection. Participants with CRP between 20-60mg/L will be categorized further to identify children either more likely to have bacterial pneumonia or more intolerant of misclassification. 'If they have O2 saturation \<95% AND tachypnoea as per age-specific norms, they will be 'appreciable risk' (\>60 bpm for age \<1 y, \>50 bpm for 1-2 y, \>40 bpm for 2-4 y, and \>30 bpm for \>4 y).
214507265|NCT07099976|OTHER|Usual Care Alone|Participants will be recruited in the ED and will be managed as per the treating clinician; the study team will not influence management.
214507266|NCT07099781|DEVICE|handheld dynamometer and hand grip dynamometer|using handheld dynamometer and hand grip dynamometer to test the strength of the hand grip and lateral rotators of the shoulder
214507267|NCT07099807|BEHAVIORAL|Carbohydrate Mouth Rinse|A 6.4% maltodextrin solution (64 g/L) was prepared using Nutricost Maltodextrin Powder. Participants performed five mouth rinses per trial, each using 25 mL of the solution for 10 seconds before expectorating. Each rinse was followed by a 30-second rest. Participants were instructed not to swallow the solution. Rinsing procedure was standardized across all sessions.
214507268|NCT07099807|BEHAVIORAL|Placebo Mouth Rinse|A placebo solution containing 0.05 g/L of non-caloric sucralose in distilled water was used to match sweetness and viscosity of the CHO-MR. Participants performed five rinses of 25 mL for 10 seconds each, spitting out the solution after each rinse. 30-second rest intervals followed each rinse. Swallowing was not allowed. Rinse frequency, volume, and duration were standardized.
214507269|NCT07099807|BEHAVIORAL|Music Listening|"Participants listened to high-tempo music (120 bpm) for 15 minutes before exercise using standardized earbuds. Music was selected from a public YouTube playlist titled 120 BPM Best Dance Music for Running and Working Out. Volume was calibrated at 65 dB (50% of max device volume). Auditory conditions were standardized across all participants."
214507270|NCT07098078|DRUG|Domperidone (drug)|The primary exposure of interest will be oral domperidone at a dose of 30 mg or more per day, which represents the median dose found in high-throughput computing analyses. For the primary comparison, oral domperidone at doses below 30 mg per day will be chosen to reduce the influence of indication bias.
214507271|NCT07100028|OTHER|SSC crown with Hall technique|SSC crown placement using Hall technique
214507272|NCT07100028|OTHER|SSC with conventional technique|SSC placement using conventional technique
214690640|NCT02689219|DRUG|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
214690641|NCT04855123|OTHER|retinal imaging|OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer
215102958|NCT03465267|DEVICE|Armeo spring|"Intervention with Armeo spring rehabilitation robot for upper extremity (made by Hocoma), which is operated only by participants, without any assistive force from robot.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
215102959|NCT03757377|DEVICE|BackBeat Moderato System|Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
215102960|NCT03757377|DEVICE|BackBeat Moderato Sytsem|Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
215102961|NCT00002921|DRUG|suramin|
214690642|NCT04855123|OTHER|paraclinical surveillance|blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)
215022680|NCT01651208|BEHAVIORAL|Motivational Interviewing (MINT)|"We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment."
215102962|NCT00002921|DRUG|therapeutic hydrocortisone|
215102963|NCT04564677|DEVICE|Ifabond (Péters surgical)|Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
215022681|NCT01651208|BEHAVIORAL|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
215022682|NCT06636903|OTHER|Acupressure|Before pressing directly on the point for acupressure, a gentle warming, relaxing and preparatory process of approximately 15 seconds should be performed on the point area. In this case, manual pressure with the thumb, index finger and/or middle finger will be applied sequentially (in the rhythm of breathing) without lifting the finger for an average of 1.5 minutes on each point, at a frequency that does not disturb the person, does not cause pain and has a calming effect. Before the suturing procedure, acupressure will be applied to the HT7 and Li4 points by a researcher (EB) who has an acupressure certificate.
215022683|NCT06636903|OTHER|Acupressure|Before and after acupressure, vital signs and before acupressure, anxiety scores will be checked using the Spielger State Anxiety Scale. In addition, vital signs and anxiety scores will be checked again immediately after the stitching procedure.
215022684|NCT06640712|DIAGNOSTIC_TEST|Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria.|The same psychiatrist administered the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) to all participants. Oral health examinations were performed by a trained dental student and a specialist dentist using a portable dental chair, artificial light, and a dental mirror. Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria. This index included the number of decayed, missing (due to caries, excluding 3rd molars), and filled teeth in the permanent dentition. The oral health examiners were blinded to each participant's substance use type and sociodemographic information.
215102964|NCT00243984|DRUG|topiramate|
215102965|NCT01227005|BIOLOGICAL|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
215102966|NCT01959243|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
215102967|NCT01959243|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
215102968|NCT01959243|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
215102969|NCT01959243|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
215102970|NCT05502510|BEHAVIORAL|MyHealthyPregnancy|MyHealthyPregnancy is a mobile application prescribed to expectant mothers in conjunction with normal prenatal care. The application uses behavioral decision science principles to identify risks of preterm birth and alert the mother and care team of these risks.
215102971|NCT06192680|DRUG|Liposomal irinotecan|70 mg/m² IV
215102972|NCT06192680|DRUG|Capecitabine|1000 mg/m² PO BID
215102973|NCT06192680|DRUG|Bevacizumab|5mg/kg IV
215102974|NCT05417191|BEHAVIORAL|Conventional fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
214690643|NCT01477892|DRUG|low dose remifentanil|non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
214690644|NCT05075096|OTHER|No intervention.|No intervention observational study.
214690645|NCT03736746|BEHAVIORAL|Motivational Interviewing|An investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs)
215022685|NCT06640712|DIAGNOSTIC_TEST|Substance Use Disorder Diagnosis|This intervention involves a psychiatric evaluation conducted by a licensed psychiatrist to diagnose Substance Use Disorder according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The psychiatrist performs a comprehensive assessment of each participant's substance use history and related behaviors. This diagnosis step is essential for identifying participants with specific substance use disorders, such as Methamphetamine, Cannabis, or Polysubstance Use Disorders, before proceeding with the dental health examination.
215022686|NCT04709393|OTHER|FRAX+SARC-F questionnaire pre-screening|Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
215022687|NCT06442228|DIAGNOSTIC_TEST|spermiogram test|"Approximately 7 mL of blood sample will be taken by the health personnel in a vacuum gel tube for hormonal and biochemical analyses. The blood samples will be centrifuged at 1000xg for 20 minutes by the researchers. In the next step, the supernatant portion will be separated and transferred to 3 mL ependorfs. Serum samples will be stored in the -800C deep freezer of our hospital until the time of analysis.~Sperm samples from individuals will be collected in our hospital in accordance with the protocol and the results will be reported."
215022688|NCT04013854|DRUG|nivolumab|All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.
214507273|NCT07099261|OTHER|Crowns|"1. Tooth Preparation: Prepare the teeth to receive a zirconia crown.~2. Impression Taking: Obtain impressions using silicone.~3. Digital Conversion: Convert impressions into a digital model using a laboratory scanner.~4. Design Submission: Send the digital model to selected crown design program.~5. Crown Fabrication: crowns designed will be produced from PMMA using a milling unit.~6. Clinical Evaluation: Conduct a clinical assessment of the crowns~7. the best crown design will be milled from zirconia and delivered~Evaluation of Crowns designed by following metrics:~1. Marginal fit~2. proximal contact~3. Occlusion"
214507274|NCT07094542|DRUG|Temporo-masseteric Nerve Block Injection|The TMNB injection/placebo will be administered by the Principal Investigator. The injection will only be delivered on Day 2 on the side/s of significant jaw muscle pain. Following disinfection of skin overlying the suprazygomatic injection site, a single carpule of 1.8 ml 2% lidocaine with 1:100,000 epinephrine will be delivered using a 25- or 27- gauge 30 mm needle). The injection site will be approximately a centimeter above the zygomatic arch, and a centimeter behind the palpable posterior border of the frontal process of the zygomatic bone. The needle will be directed at a 45-degree downward angle, directed medially along the coronal plane. At the depth of insertion of the needle, the local anesthetic/placebo will be delivered.
214507275|NCT07094542|DRUG|Oral Pain Medications only|For participants with jaw muscle pain to palpation \<5 NRS score, no additional injection will be given. The participant will take the recommended pain medications as described.
215022689|NCT04013854|DRUG|Ipilimumab|Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )
215022690|NCT06636825|OTHER|Graded hypercapnia|Volunteers breathe 0%, 2%, 4%, 6%, and 8% CO2 (with 21% O2, balance nitrogen) for 12 minutes each
215022691|NCT06636825|DRUG|Caffeine|400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia
215022692|NCT06636825|DRUG|Placebo|Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
215022693|NCT06637735|OTHER|education|pregnant women will be given a 4-week training and the pre-test post-test will be analyzed
215022694|NCT00836901|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
215022695|NCT00836901|DRUG|Augmentin®|400 mg-57 mg chewable tablet
215022696|NCT06639932|BEHAVIORAL|We-INtervention|The We-INtervention focuses on the relationship dynamics of HIV-serodiscordant male couples. In developing the intervention, we reviewed relevant theories and frameworks, such as the cognitive transactional model, the systemic transactional model, the dyadic illness management model, and the intersectional framework of stigma. The three weekly 60-minute sessions are Session 1: We-disease appraisal. Despite stigma related to their dual minority identities, couples develop a perception of HIV as a shared disease, enhancing illness control. Session 2: Couple communication. Couples undertake skill-building exercises on effective communication techniques to strengthen their relationship. Session 3: Dyadic coping. Couples learn to optimize preference and value assessments in HIV management. A few skill-building exercises help them mobilize and maintain mutual support and develop joint problem-solving skills.
215022697|NCT06639932|BEHAVIORAL|Usual Care Group|The participants in the control condition will receive health information pamphlets. The HIV-seropositive partners will receive information on HIV-related knowledge (e.g., symptoms, comorbidity, stages, and opportunistic infection), treatment (e.g., ART and side effects), and management (e.g., nutrition and mental health). The HIV-seronegative partner will receive information on HIV transmission (e.g., risk factors), prevention (e.g., safe sex and PrEP), and testing.
215022698|NCT04002063|BEHAVIORAL|CBT MobileWork-V plus CBT|a smartphone app to assist with CBT homework skills practice plus CBT
215022699|NCT04002063|BEHAVIORAL|CBT alone|CBT therapy individual
215022700|NCT00221221|DEVICE|Pedometer|
215022701|NCT00221221|DEVICE|Exercise guidebook|
215102975|NCT05417191|BEHAVIORAL|Enriched fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
215102976|NCT04956653|OTHER|Without additional intervention|Only patients' information was collected
215102977|NCT03080363|DRUG|Bupivacaine|10 ml %0.5 bupivacaine
215102978|NCT03080363|DRUG|Lidocaine|10 ml %2 lidocaine
215102979|NCT06528912|OTHER|Radiotherapy|Follow-up
215022702|NCT06357377|DRUG|NEO100|"NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol.~NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol."
215022703|NCT04324944|BEHAVIORAL|Collaborative Decision Skills Training|An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.
215102980|NCT06529861|DIAGNOSTIC_TEST|[15O]H2O-PET Imaging|This imaging technique will be used to measure myocardial blood flow (MBF) and myocardial blood flow reserve (MBFR) in patients. The PET-CT scan involves the use of the radioactive tracer \[15O\]H2O to visualize blood flow in the heart, providing crucial data on coronary microvascular function.
215102981|NCT05801614|OTHER|Low carb diet|Low calori diet
215102982|NCT00428844|DRUG|daptomycin|6 mg/kg
215102983|NCT00428844|DRUG|daptomycin|8 mg/kg
215102984|NCT00428844|DRUG|vancomycin|1 gram
215102985|NCT00428844|DRUG|teicoplanin|6 mg/kg; used only at UK sites
215102986|NCT00428844|DRUG|nafcillin|1-2 gram
215102987|NCT00428844|DRUG|oxacillin|1-2 gram
215102988|NCT00428844|DRUG|flucloxacillin|1-2 mg
215102989|NCT00005859|DRUG|tipifarnib|
215102990|NCT03450265|DEVICE|Hemopatch|Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
215102991|NCT03450265|DEVICE|Tachosil|Applied according to the current instruction for use (IFU).
215102992|NCT02684188|BEHAVIORAL|Enhanced rural discharge and transition|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
215102993|NCT00488826|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
215102994|NCT00488826|BIOLOGICAL|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
215102995|NCT05700227|RADIATION|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
215102996|NCT03032549|DIETARY_SUPPLEMENT|RTD|Ready to Drink Supplement
215102997|NCT03032549|DIETARY_SUPPLEMENT|Placebo|Placebo
215102998|NCT00671606|PROCEDURE|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
215102999|NCT02303860|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
214423129|NCT03565796|BEHAVIORAL|Personalized active referral plus financial incentive|Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
214507276|NCT07099287|BEHAVIORAL|TRANSform your health|A culturally adapted smoking cessation intervention for transgender and gender diverse individuals living in Argentina
214507277|NCT07097974|DIETARY_SUPPLEMENT|WM formula liquid drink|One glass jar (50 g) of the WM formula liquid drink was administered once daily, 1 hour prior to the first meal of the day.
214507278|NCT07097974|DIETARY_SUPPLEMENT|Placebo|One glass jar (50 g) of the placebo liquid drink was administered once daily, 1 hour prior to the first meal of the day.
214507279|NCT07099924|DRUG|Ropivacaine 0.2%|2x30ml (bilateral) ropivacaine 0.2% every 8 hours via rectus sheath catheter
214507280|NCT07099924|DRUG|Saline 0.9%|2x30ml saline 0.9% every 8 hours via rectus sheath catheter
214507281|NCT07099547|DRUG|ZG005|ZG005 20 mg/kg IV Q3W
214507282|NCT07099547|DRUG|Tislelizumab|Tislelizumab 200mg IV Q3W
214507283|NCT07099547|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 Q3W. Gemcitabine will be administered on D1/D8 in every three weeks cycle.
214507284|NCT07099547|DRUG|Cisplatin|Cisplatin 25mg/m\^2 Q3W. Cisplatin will be administered on D1/D8 in every three weeks cycle.
214507285|NCT07099833|OTHER|Azita Sadeghzade|Azita Sadeghzade
214507286|NCT07098533|BEHAVIORAL|Cognicise Training|The Cognicise program included 16 sessions over 8 weeks (twice weekly, 60 minutes each). This dual-task training combined motor activities with cognitive exercises. During basic gymnastic movements, participants responded to real-time changes in live music and visual stimuli while also solving simple verbal and math tasks. Sessions were divided into 15 minutes of warm-up, 30 minutes of dual-task activity, and 15 minutes of breathing and relaxation exercises.
214507287|NCT07098533|BEHAVIORAL|Yoga Training|The yoga intervention consisted of 16 instructor-led sessions over 8 weeks (twice weekly, 60 minutes each). Each session included a warm-up (15 minutes), a main phase (30 minutes) focused on exercises targeting the spine, pelvis, and hips, and a relaxation period (15 minutes), including 10 minutes of deep relaxation techniques.
214507288|NCT07098936|DRUG|Momelotinib treatment|Patients included will receive momelotinib continuously until disease progression or loss of response, at physician's discretion.
214507289|NCT07098871|DIAGNOSTIC_TEST|Ultrasonography (Rectus and diaphragma muscle thickness measurement)|Rectus and diaphragma muscle thickness will be measured by ultrasonography preoperatively.
214507290|NCT07098520|OTHER|No intervention, just observation|no intervention, study investigates biomarkers associated with a disease
214690646|NCT01975766|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
214690647|NCT01975766|DEVICE|External beam radiation therapy|
214690648|NCT04559152|DIETARY_SUPPLEMENT|Zinc Supplementation Group|Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
215022704|NCT04324944|BEHAVIORAL|Leveling Up|An ten-session group intervention that focuses on psychoeducation around befriending. Each session is 60 minutes long.
215103000|NCT02303860|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
215103001|NCT02303860|DRUG|ORM-12741 IR|Immediately release formulation of ORM-12741
215022705|NCT06121284|DRUG|D-Cycloserine|Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
215022706|NCT06121284|DEVICE|intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
215022707|NCT06121284|DRUG|Placebo oral tablet|Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
215022708|NCT05336565|OTHER|Electronic medical record analysis|"Medical information system (MIS) BARS will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. Incidence rates and patterns of PIM prescription, polypharmacy, and PDDIs in the time of COVID-19 pandemic will be studied."
215022709|NCT04360681|DRUG|Lofexidine|BID dosing, and a max daily dose of 1.6 mg/day
215022710|NCT04360681|DRUG|Placebo oral tablet|Placebo
215022711|NCT05463952|DRUG|vepdegestrant|ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
215022712|NCT00771147|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
215022713|NCT01470820|OTHER|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
215022714|NCT01830387|DEVICE|Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.
214507291|NCT07099248|OTHER|Cervico-vestibular Home Exercise Program|Patients who consent to participate in this study will be given an informational handout by clinical athletic trainers that provides information about the study, the exercises in their cervico-vestibular home exercise program, and a detailed progression to higher HEP levels/intensities based on their symptoms. The handout will also provide the purpose of the program, definitions of unfamiliar terms, a planning section for frequency and success, how to monitor symptoms through program completion, and how to properly access their exercises, log their completion, and track their progression in the Medbridge Go app.
214507292|NCT07098156|OTHER|Single Research Visit 3T MRI Research Scan|Single research visit scan performed with a 3T magnetic resonance imaging scanner.
214507293|NCT07098156|OTHER|Demographic and Behavioural Questionnaires|A series of demographic and behavioural questionnaires to be completed by participants, either online or during the single study visit. Questionnaires include the Eating Disorder Examination Questionnaire, Autism Spectrum Quotient, Monotropism Questionnaire, Camouflaging Autistic Traits Questionnaire, Hospital Anxiety and Depression Scale, Adult Attention Deficit Hyperactivity Disorder Self-Report Scale, Work and Social Adjustment Scale, International Trauma Questionnaire and Leibowitz Social Anxiety Scale. These questionnaires will also include a demographic questionnaire to acquire measures such as age, BMI, co-occurring conditions, etc.
214507294|NCT06812975|OTHER|No intervention|This is an observational study
214507295|NCT07098013|BEHAVIORAL|Relaxation Self-Coach|This intervention is a fully automated, unguided internet-based relaxation program in English. Unlike many digital mental health programs, it required no therapist involvement or incentives and was structured for real-world use. It combined evidence-based techniques-mindfulness, deep breathing, progressive muscle relaxation, guided imagery, and acceptance practices-delivered via audio modules. The program was tested in two formats: a 4-week daily format (28 sessions) and a revised 3-week modular format (21 sessions) with enhanced usability and adherence features, such as a simplified multimedia interface, reminder emails, and optional reflection prompts.
214507296|NCT07099066|OTHER|sampling blood|3 types of sampling : urine, skin and blood.
214507298|NCT07099118|DRUG|HEC169584 capsule|Each dose of HEC83518 will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
214507299|NCT07099118|DRUG|placebo|The placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
214507300|NCT07099417|DIAGNOSTIC_TEST|No intervention (observational study)|No intervention (observational study)
215022715|NCT01830387|OTHER|Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
215022716|NCT04846699|PROCEDURE|per-cutaneous stone extraction|percutaneous nephrolithotripsy for renal stones by different renal access
215022717|NCT05261490|DRUG|maplirpacept (PF-07901801)|PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
215022718|NCT05261490|DRUG|Pegylated Liposomal Doxorubicin (PLD)|RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
215022719|NCT02732145|DIAGNOSTIC_TEST|"Three Rings Vulvoscopy (TRIV)"|"Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme."
215022720|NCT02732145|PROCEDURE|Histopathology|Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
215022721|NCT03979794|BEHAVIORAL|Behavioral Intervention for Wellness and Engaged Living (Be-WEL)|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
215022722|NCT03983070|OTHER|Seated Rowing Ergometer|Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures
215022723|NCT03983070|OTHER|Deadlift|Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.
215022724|NCT03983070|OTHER|Blood flow restriction|An occlusive cuff will be placed around each proximal thigh and inflated to 80% arterial occlusion during exercise sessions.
215022725|NCT03204747|OTHER|Observational study : gait speed|No intervention, only propose water and wait for need to void
215022726|NCT01722734|BEHAVIORAL|Text message reminders|Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
215103002|NCT02292706|DRUG|Sofosbuvir|Exposure of interest for participants who received sofosbuvir in a previous Gilead study for chronic HCV infection.
215103003|NCT02292706|DRUG|Ribavirin|
215103004|NCT02292706|DRUG|LDV/SOF|Exposure of interest for participants who received LDV/SOF in a previous Gilead study for chronic HCV infection.
215103005|NCT02292706|DRUG|SOF/VEL|Exposure of interest for participants who received SOF/VEL in a previous Gilead study for chronic HCV infection.
214423130|NCT03565796|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
215103006|NCT02292706|DRUG|SOF/VEL/VOX|Exposure of interest for participants who received SOF/VEL/VOX in a previous Gilead study for chronic HCV infection.
215103007|NCT02292706|DRUG|Other SOF-Based Regimen|"The other SOF-based regimens may have included the following:~* BMS-790052 (Daclatasvir) + GS-7977 (SOF) with or without RBV~* LDV/SOF + GS-9669, GS-7977 (SOF) + with or without RBV + TMC-435 (Simeprevir)~* LDV/SOF + Vedroprevir (VDV), LDV/SOF + GS-9669 (250 mg and 500 mg)~* LDV/SOF + VDV + RBV~* Simeprevir + SOF~* TMC-435 (Simeprevir) + VEL/SOF"
215103008|NCT02292706|OTHER|Ineligible parent treatment|Participants were enrolled from ineligible parent treatment group.
214423131|NCT03565796|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
214423132|NCT03565796|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
214423133|NCT03565796|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
214423134|NCT06068699|OTHER|Postcard|Participants received a postcard asking them to address non-adherence to remote monitoring.
214423135|NCT05038072|DRUG|suprachoroidal injection of Triamcinolone Acetonide.|4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
214423136|NCT00612586|DRUG|Enzastaurin|1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease
214423137|NCT00612586|DRUG|Placebo|oral, daily (up to 1 yr or until progressive disease)
214423138|NCT00612586|DRUG|Leucovorin (LV)|400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
214423139|NCT00612586|DRUG|5-fluorouracil (5-FU)|400 mg/m\^2 bolus then 2400 mg/m\^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
214423140|NCT00612586|DRUG|Bevacizumab (Bev)|5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
214423141|NCT05646745|PROCEDURE|Autologous Transobturator Fascia Lata Sling|"Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
214423142|NCT06410963|BEHAVIORAL|Reactivate|The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.
214423143|NCT05569837|OTHER|Regular meal pattern|6 meals every day
214423144|NCT05569837|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
214423145|NCT03504072|DRUG|Tofacitinib 5 mg,|tofacitinib 5 mg 12 hourly daily for 9 months
214423146|NCT03504072|DRUG|Etanercept|Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
214423147|NCT03922867|BEHAVIORAL|CBT|A web-based educational platform to deliver cognitive behavioral therapy (CBT) for insomnia
215103009|NCT01378468|OTHER|"oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)"|see Ebinger et al., IJS, 2010
215103010|NCT04358224|BIOLOGICAL|Dupilumab Prefilled Syringe|open-label
215022727|NCT01837550|BEHAVIORAL|Intervention group|The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.
215022728|NCT01837550|BEHAVIORAL|Control group|The control group only had access to reading material.
215022729|NCT03594656|DRUG|Ganoderma|0.8g twice daily
215022730|NCT03594656|DRUG|Placebos|0.8g twice daily
215022731|NCT04695626|PROCEDURE|The combination of bone marrow stimulation and modified suture bridge(Greenhouse tec)|According to the anteroposterior diameter of the injury, single or double high braided thread were used to suture the tendon in a modified Mason Allen way without knotting. Bone marrow stimulation was carried out in the footprint area of rotator cuff. A 2.0 mm diameter cone was created with a depth of 1 cm and a spacing of 5 mm. Six to eight holes were made due to the diameter of the tear of rotator cuff until blood and fat droplets exudate. Then the threads were passed through the locking eyelet of the lateral row anchor. After tightening the threads, the anchor was screwed in at the distal part of the gteater tuberosity. With this new technique, the rotator cuff was repaired by one lateral row anchor without medial row knotting.
215022732|NCT04425278|DEVICE|transcranial direct current stimulation with real current|transcranial direct current stimulation with real current is a noninvasive technique to activate and modify the activity of the neurons
215022733|NCT04425278|DEVICE|transcranial direct current stimulation with sham current|transcranial direct current stimulation with sham current is a placebo
215022734|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
215103011|NCT01229722|DEVICE|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
215103012|NCT01229722|DEVICE|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
215103013|NCT02422849|OTHER|hospital specialist|
215103014|NCT02422849|OTHER|General Practitioner|
215103015|NCT02725866|DRUG|Paritaprevir/ritonavir/ombitasvir|Co-formulated tablet
215103016|NCT02725866|DRUG|Dasabuvir|Tablet
214423148|NCT03192046|DEVICE|Carbon Fiber Ankle Foot Orthosis (AFO)|Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
214423149|NCT03192046|OTHER|Standardized walking/exercise program|standardized walking/exercise program without any brace or AFO
214423150|NCT04563559|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
214423151|NCT04563559|DRUG|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
214423152|NCT02916836|OTHER|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
214507301|NCT07099495|DEVICE|Low Frequency Neuromuscular Electrical Stimulation|The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or tape, and conductive gel will be used below the electrodes. Each electrically stimulated contraction will have a frequency of 10 Hz, duration of 10 seconds (ON time: 10s), interspersed with a 20-second rest period (OFF time: 20s), with a pulse width of 400 µs. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.
214507302|NCT07099495|DEVICE|Medium Frequency Neuromuscular Electrical Stimulation|The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or adhesive tape, and conductive gel will be used below the electrodes. Each electrically stimulated contraction will have a frequency of 50 Hz, duration of 10 seconds (ON time: 10s), interspersed by a period of 20 seconds of rest (OFF time: 20s), with a pulse width of 400 µs. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.
214507303|NCT07099495|DEVICE|Neuromuscular Electrical Stimulation without generating contractility|The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or adhesive tape, and conductive gel will be used below the electrodes. No muscle contractions will be generated. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.
214507304|NCT07099027|DIAGNOSTIC_TEST|Low dose CT|In this arm, participants will undergo a respiratory assessment, smoking cessation, low-dose CT and biospecimen for translational research.
214507305|NCT07099131|DRUG|Anesthetic spray|will be applied to back of the throat for 10 seconds; their chin will also be concealed from the GSI examiner using a small cup and masking tape.
214507306|NCT07099131|DEVICE|Acupuncture|"A 6C file (endodontic instrumentation file) will be placed on the patient's mentolabial fold (CV24). This file will be concealed by a small paper cup; A clean alcohol wipe will be used to clean the mentolabial area prior to placing the acupuncture needle (6 C-File)."
214507307|NCT07099131|GENETIC|Masking Tape|A piece of commercially available masking tape will be adhered to the patient's mentolabial fold and concealed by the small paper cup
214690649|NCT04559152|DIETARY_SUPPLEMENT|Placebo Group|Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
214690650|NCT05513703|BIOLOGICAL|Telisotuzumab Vedotin|Intravenous (IV) Infusion
214423153|NCT02916836|OTHER|No Use of therapeutic drug conciliation sheet (TDC)|
215103017|NCT02725866|DRUG|Ribavirin|Tablet
215022735|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|"Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD."
214507308|NCT07098104|DRUG|Immunotherapy|The nICT group received PD-1 inhibitors (sintilimab 200mg, tislelizumab 200mg, or nivolumab 240mg, all iv q3w) combined with two-drug chemotherapy (SOX: oxaliplatin 130mg/m² d1 + S-1 40-60mg bid d1-14; or XELOX: oxaliplatin 130mg/m² d1 + capecitabine 1000mg/m² bid d1-14, both q3w). The nCT group included two subgroups: nCT2 (SOX/XELOX) and nCT3 (FLOT: docetaxel 50mg/m² + oxaliplatin 85mg/m² + leucovorin 200mg/m² d1 + fluorouracil 2600mg/m² 48h CIV q2w; or DCF: docetaxel 75mg/m² + cisplatin 75mg/m² d1 + fluorouracil 750mg/m² d1-5 q3w).
214507309|NCT07097948|DRUG|Etoposide|Specified dose on specified days.
214507310|NCT07097948|DRUG|Platinum|Specified dose on specified days.
214507311|NCT07097948|DRUG|Toripalimab|Specified dose on specified days.
214507312|NCT07099573|RADIATION|Hyperthermia|Hyperthermia will be applied for a period of 15 to 20 minutes in the area to be treated, maintaining a thermal sensation of gentle heat for the patient and accompanied by active-assisted or passive mobilization of the structures adjacent to the bursa.
214507313|NCT07099573|OTHER|Physical Exercise|The therapeutic physical exercise will consist of 3 periods of isometric contraction of 30 seconds, with a rest period of 1 minute, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
214507314|NCT07099573|OTHER|Stretching|Stretching of the involved muscles will involve 3 periods of maximum tolerable stretching without pain, lasting 20 seconds and resting for 30 seconds.
214507315|NCT07098507|PROCEDURE|sentinel lymph node biopsy|As sentinel lymph node biopsy is still a standard of care in early-stage breast cancer surgery, it represents the intervention in the standard of care arm
214507316|NCT07098507|PROCEDURE|omission of sentinel lymph node biopsy|omission of sentinel lymph node biopsy is the intervention in the experimental arm
214507317|NCT07098702|OTHER|educational sessions and booklet|educational sessions and booklet about ergonomic practices during breastfeeding which include appropriate body mechanics , breastfeeding positions, and use of breastfeeding pillows.
214507318|NCT07098702|OTHER|No Interventions|In this group, the mothers will breastfeed their newborns according to the routine hospital postpartum instructions only.
214507321|NCT05318027|DEVICE|ChatBot|The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits. The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups. High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video. Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day. Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV). If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.
214507322|NCT06914492|BEHAVIORAL|AWARD advice|AWARD advice include Ask about smoking history, Warn about the high risk, Advise to quit, Refer smokers to smoking cessation services (with a referral card), and Do it again.
214507323|NCT06914492|BEHAVIORAL|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking.
214507324|NCT06914492|BEHAVIORAL|Referral card|The contents consist of brief information and a highlight of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.
214507325|NCT06914492|BEHAVIORAL|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
214507326|NCT06914492|BEHAVIORAL|Personalized active referral|Smokers will be introduced to various SC services in Hong Kong (using the referral card) and be motivated to use these services. Well-trained SC ambassadors will assist smoker to choose favourite/most convenient or preferred type of services. Research staff will assist participants in booking or re-booking the SC services at the 1- and 2-month follow-ups (after very brief questionnaire surveys). Participants' contact information will be forwarded to SC services providers within seven days, and providers are expected to contact the participants within 1-2 weeks. Research staff will also monitor SC services use of the participants at each follow-up (1-, 2-, 3- and 6- month) and assist participants to book or re-book the appointments if necessary at 1- and 2- month follow-up. We shall liaise with the existing service providers and seek their assistance in helping our smokers in helping our smokers in a timely manner.
215022736|NCT01971593|DRUG|Eplerenone|
215022737|NCT02917538|PROCEDURE|RFA|Both groups will receive radiofrequency ablation treatment
215022738|NCT02452593|OTHER|"Tibial stimulation and pelvic floor exercises"|A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
215022739|NCT00663195|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
215022740|NCT03374332|DRUG|Gemtuzumab Ozogamicin (GO)|Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
215022741|NCT03374332|OTHER|Donor Leukocytes|The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.
215022742|NCT02316132|DRUG|Stress|Corticotropin-Releasing Hormone
215022743|NCT02316132|DRUG|Control|Saline 0.9%
215103018|NCT02413047|DRUG|Azathioprine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
215103019|NCT02413047|DRUG|6 mercaptopurine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
215022744|NCT03139266|BEHAVIORAL|UPLIFT|Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
215022745|NCT03139266|BEHAVIORAL|Treatment as usual|The control group will receive the recommendation to consider maintaining mental health services
214690651|NCT02361203|BEHAVIORAL|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
215022746|NCT03497117|DEVICE|Lung Clearance Index|To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.
215022747|NCT03497117|DRUG|MRI with PFP|"* Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
215022748|NCT04667559|DEVICE|Conformis iTotal Identity Knee Replacement System|The iTotal® Identity KRS is a tri-compartmental semi-constrained knee prosthesis composed of three components: a Femoral Component, a Tibial Component, and a Patellar Component.Using patient imaging, a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. The treatment allows for the placement of a cemented metallic device designed from the patient's natural bone geometry. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation.
215022749|NCT04213274|BIOLOGICAL|80 mg RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
215022750|NCT04213274|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
215022751|NCT05596240|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
215022752|NCT05596240|OTHER|Sham Dry Needling|Streitberger Placebo-needles (Asia-med, Las Vegas, NV) will be used to perform the intervention for participants in the sham DN group. These needles have been reported to be indistinguishable from real needles. The device consists of a plastic tube with a blunted tip needle that allows for the sensation of a prick without penetrating the skin. The sham needle produces a sensation, which causes the participant to feel as if the needle enters the skin, while maintaining similar patient-therapist contact time and total intervention time.
215022753|NCT04191733|DEVICE|KINCISE(TM) Surgical Automated System|Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
215022754|NCT00928720|DEVICE|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
215022755|NCT00928720|DEVICE|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
215022756|NCT06137092|DRUG|Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)|rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
215022757|NCT00288561|DRUG|ranibizumab|
215022758|NCT03308331|OTHER|Tobacco smoking and nicotine patch|Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use
215022759|NCT04170075|BEHAVIORAL|Whole Body Vibration|Undergo WBV
214423154|NCT00762606|PROCEDURE|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
214690652|NCT00102505|DRUG|Motexafin Gadolinium Injection|
214690653|NCT01476176|DRUG|Experimental paracetamol|experimental paracetamol with caffeine
214690654|NCT01476176|DRUG|Paracetamol marketed formulation|marketed formulation containing caffeine
214690655|NCT02659683|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
214690656|NCT02659683|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
215022760|NCT05579288|DRUG|Nitrous oxide (N2O/O2)|Nitrous oxide (N2O/O2) for pain alleviation
215022761|NCT05579288|DRUG|Oxygen (O2)|Oxygen (O2) as placebo for control group
215022762|NCT02349477|DRUG|Gabapentin|gaba potentiating medication
215022763|NCT02349477|DRUG|Placebo|a pill that looks exactly like the active medication but does not contain medication
215022764|NCT06500156|OTHER|Fluid challenge|Rapid infusion (\< 15 minutes) of a fluid bolus of crystalloids (200 to 500cc)
215022765|NCT04938843|DIETARY_SUPPLEMENT|F. prausnitzii and D. piger|Dietary supplementation with capsules containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
215022766|NCT04938843|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo capsules identical to those containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
215022767|NCT02176759|OTHER|Administration of rice fortified with regular FePP|
215022768|NCT02176759|OTHER|Administration of rice fortified with regular FePP with citrate added during extrusion|
215022769|NCT02176759|OTHER|Administration of rice fortified with regular FePP and citrate added at consumption|
215022770|NCT02176759|OTHER|Administration of rice fortified with ferrous sulphate|
215022771|NCT02680496|DEVICE|Lokomat|A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
215022772|NCT02680496|OTHER|Treadmill|A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
214690657|NCT03477565|DEVICE|Kinesio tape lymphatic drainage technique application|Kinesio Tex Tape strips are applied following Dr.Kase draining techinique. The choice of tape's length and strips' number is based on the area of breast edema and/or presence of seroma, which must be completely covered. The patch is cut into fan strips. The major base is positioned near the functioning lymph node stations closest to the edema and/or seroma area. The bases and the tails of the fan must be applied with zero tension, while for the central part is reached 15-25% of tension. The first application takes place on the 1st post-operative day, while the second is performed on the 7th post-operative day. In case the tape is detached from one application to another, it is necessary that the patient resume in the clinic for a new application to ensure continuity of the therapeutic effect; otherwise the patient is eliminated from the study. The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and counselin.
214507327|NCT06914492|BEHAVIORAL|12 weeks of chatbot-based instant messaging support|Participants in the intervention group will receive 12 weeks of instant messaging support delivered by the LLM-based chatbot accessible via WhatsApp platform. The chatbot, powered by GPT-4o model (or more advanced model available) using prompt-engineering and agent-based techniques, will deliver brief theory-based, structured SC intervention alongside freeform, on-demand support. The structured intervention session deploys the 5As model (Ask, Advise, Assess, Assist, and Arrange follow-up) and 5Rs model (Relevance, Risks, Rewards, Roadblocks, Repetition), as used in our previous telephone-counselling trials and recommended by WHO for brief SC intervention.
214690658|NCT04969640|OTHER|Optical coherence tomography|Anterior segment optical coherence tomography examination of corneas with infective keratitis
214690659|NCT02843867|OTHER|blood sample|36 ml of blood sample at D0 and 1 year after transplantation
214690660|NCT02802059|DRUG|EcN-Suspension|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
214690661|NCT02802059|DRUG|Placebo|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
215022773|NCT02680496|OTHER|Overground|A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
214690662|NCT00473161|DEVICE|surface EMG biofeedback|
214690663|NCT02538588|DEVICE|Nebulizer 1|
214690664|NCT02538588|DEVICE|Nebulizer 2|
214690665|NCT00465153|DIETARY_SUPPLEMENT|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
214690666|NCT00465153|BEHAVIORAL|Resistance exercise training|Resistance training
215022774|NCT01714063|DEVICE|Pressurized Metered-Dose Inhaler|Pressurized Metered-Dose Inhaler
215022775|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 1|Sulindac (HLX-0201) Capsule
214690667|NCT06146712|OTHER|Asutra's 'Dream the night away' nighttime lotion|Product contains Water (Aqua), Magnesium Chloride, Dimethyl Sulfone (MSM), Prunus Amygdalus Dulcis (Sweet Almond) Oil, Butyrospermum Parkii (Shea Butter), Sodium Lactate, Cetearyl Alcohol, Glyceryl Stearate Citrate, Glycerin, Undecane, Cetyl Palmitate, Polyglyceryl-3 Diisostearate, Pentylene Glycol, Glyceryl Stearate, Magnesium Sulfate, Melatonin, Tridecane, Potassium Chloride, Sodium Chloride, Calcium Chloride, Tocopheryl Acetate, Xanthan Gum, Hydroxyacetophenone, Sodium Hydroxide, Cymbopogon Flexuosus (East-Indian Lemongrass) Oil, Citral, Geraniol, Linalool
214690668|NCT04008589|DEVICE|repetitive transorbital AC Stimulation|Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
214690669|NCT04008589|DEVICE|combination of transcranial direct current stimulaton and rtACS|Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
215022776|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 2|Sulindac (HLX-0201) Capsule
215022777|NCT04823052|DRUG|Placebo|Placebo Capsule
215022778|NCT04823052|DRUG|Gaboxadol (HLX-0206)|Gaboxadol (HLX-0206) Capsule
215022779|NCT02269774|PROCEDURE|Standard pulmonary vein isolation|The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
214507328|NCT06914492|BEHAVIORAL|Reminder messages|WhatsApp messages on follow-up survey reminders.
214507329|NCT07099872|OTHER|Control|Wear normal attire (shorts/t-shirt) during exercise sessions in a gym-like environment.
214507330|NCT07099872|OTHER|Overdressing|Wear standardized overdressing ensemble during exercise sessions in a gym-like environment.
214507331|NCT06130553|DRUG|AZD3470|AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.
214690670|NCT03462446|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
214690671|NCT03462446|DRUG|Vitamin K antagonists (VKAs)|As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
214690672|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
214690673|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
214690674|NCT01996735|DRUG|Ticagrelor 180 mg single dose|
214690675|NCT01996735|DRUG|Placebo|
215022780|NCT04964700|DRUG|Natalizumab|Monthly Infusions
215022781|NCT01646216|BEHAVIORAL|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
215103020|NCT02413047|DRUG|Methotrexate|Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
215103021|NCT01549977|DRUG|Febuxostat|Febuxostat tablets
215103022|NCT01549977|DRUG|Placebo|Febuxostat placebo-matching tablets
215022782|NCT00773591|DRUG|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
214423155|NCT00762606|PROCEDURE|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
214423156|NCT05379491|DRUG|3 L PEG + linaclotide|Participants take a linaclotide capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another linaclotide capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
215022783|NCT05112068|OTHER|traditional skin care method|Skin and hair care for critically ill patients will be carried out using traditional means: clean warm water, cotton diapers and napkins, liquid soap, 0.02% aqueous chlorhexidine solution, and regular shampoo.
215022784|NCT05112068|OTHER|method using specialized gloves|"Specialized hygienic gloves soaked in a washing lotion Aqua Total Hygiene (Cleanis, France) for skin care and Aqua Shampoo (Cleanis, France) for hair care will be used.~According to the manufacturer's recommendation, six hygienic gloves should be used for one skin care procedure, and two gloves should be used for hair care. The care method used in the experimental group will not require additional rinsing and drying."
214423157|NCT05379491|DRUG|3 L PEG + placebo|Participants take a placebo capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another placebo capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
214423158|NCT01045655|BEHAVIORAL|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
214423159|NCT02631343|BEHAVIORAL|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
214423160|NCT02631343|OTHER|Essential newborn care|
214423161|NCT02500654|DEVICE|Emdogain®|Surgery and Emdogain®
214423162|NCT02500654|DEVICE|Surgery alone|Surgery alone
214423163|NCT04421391|DIETARY_SUPPLEMENT|QuadraMune(TM)|QuadraMune(TM) is a commercially available nutritional supplement
214423164|NCT00781196|DRUG|folic acid|capsule 0.5 mg once a day
214423165|NCT00781196|DRUG|placebo|capsule, once a day
214423166|NCT03516604|DRUG|PF-04995274|PF-04995274 tablets
214423167|NCT03516604|DRUG|Citalopram|Citalopram capsule
214423168|NCT03516604|DRUG|Placebo Oral Tablet|Placebo tablet, identical to PF-04995274 tablet
214507332|NCT06472869|OTHER|NJOY ACE e-cigarette|Patients will be provided with NJOY ACE electronic cigarettes and 5% nicotine e-liquid cartridges in tobacco flavor for 4 weeks and asked to use the electronic cigarette as a substitute for smoking combustible cigarettes during the 4 weeks
214423169|NCT03516604|DRUG|Placebo oral capsule|Placebo capsule, identical to citalopram capsule
214423170|NCT05697081|OTHER|Medical doctors infected with COVID-19|web-based survey
214423171|NCT01335165|DRUG|ALXN1102|Single Ascending Dose IV
214423172|NCT01335165|DRUG|ALXN1103|Single Ascending Dose IV or SC
214507333|NCT06923839|BIOLOGICAL|Test bacterial peptide: RUCILP|The naturally occuring gut peptide RUCILP synthesized by the commensal gut bacterium Ruminococcus torques
214507334|NCT06923839|OTHER|Placebo|Placebo is identical to the active intervention except for the absence of the RUCILP molecule.
214507335|NCT04576689|DRUG|IBE-814 70ug|At least 10 and up to 33 participants will receive one (1) IBE-814. Route of administration: intravitreal injection.
214507336|NCT04576689|DRUG|IBE-814 140ug|Up to 27 participants will receive two (2) IBE-814. Route of administration: intravitreal injection.
214507337|NCT06934265|BEHAVIORAL|exuberant voice therapy|exuberant voice therapy validated for patients with age-related voice changes (i.e., vocal fold atrophy, presbyphonia)
214507338|NCT05119140|DRUG|Hydroxychloroquine|400mg of hydroxychloroquine per oral daily
214507339|NCT05119140|DRUG|Mesalamine|the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
214507340|NCT03649724|DRUG|Placebo|Placebo (0.25 ml normal saline) will be administered subcutaneously once every twelve weeks for 48 weeks.
214507341|NCT03649724|DRUG|Eligard 22.5Mg Suspension for Injection|Eligard 22.5Mg Suspension for Injection will be administered subcutaneously, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.
215022785|NCT06375772|DRUG|2-Deoxy-D-glucose|Intranasal administration
215022786|NCT06375772|OTHER|Placebo|Intranasal administration
215103023|NCT02161419|DRUG|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
215022787|NCT01903590|PROCEDURE|TVT surgery TOT surgery|
214423173|NCT01151839|PROCEDURE|Esophagectomy|Patient with squamous cell carcinoma of esophagus will be treated with surgery alone
215022788|NCT06305858|PROCEDURE|Prosthetic Surgical Procedure|"The population consists of 48 patients divided into two groups:~24 patients Group A experimental group: partial denture surgical procedure~24 patients Group B control group: total denture surgical procedure with patellar resurfacing"
214690676|NCT06276608|DIAGNOSTIC_TEST|Iron status|Iron status will be based on preoperative ferritin levels: a ferritin \< 10 mcg/L will be considered as iron deficiency, ferritin levels \> 10 mcg/L will be considered normal
215022789|NCT04768478|DRUG|CBD|25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management
215022790|NCT04768478|DRUG|Placebo|Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
215022791|NCT02633527|DRUG|Placebo|Placebo was administered once daily
215022792|NCT02633527|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
215022793|NCT02633527|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
215022794|NCT02633527|DRUG|300mg SPN-812|300mg SPN-812 was administered once daily and compared to placebo
215022795|NCT02633527|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
215022796|NCT01323543|DEVICE|Elaspine™|Implantation of device
215022797|NCT03615274|DEVICE|Executive function training|Home-based executive function training with adaptive difficulty, through Cogmed and Cognifit systems over 6 weeks (30-45 minuts/day, 5 days per week). Cognitive training will consist on working memory training (Cogmed, www.cogmed.com) and executive/inhibitory function training (Cognifit, www.cognifit.com).
215022798|NCT03615274|OTHER|Psychoeducation|Learning basic healthy habits through daily Prezi presentations that include healthy food recommendations, funny receipts to families, ideas for exercising, emotion and behavioral management strategies, etc.
215022799|NCT03615274|DEVICE|Placebo non-adaptive training|Executive function training with non-adaptive difficulty through Cognifit system over 6 weeks (30-45 minuts/day, 5 days per week). Exercices will be the same as the ones in the experimental group but minimizing the executive/working memory component and without incresing difficulty.
215022800|NCT06475495|DRUG|KYV101|an autologous fully-human anti-CD19 CAR T-cell immunotherapy
215022801|NCT06475495|DRUG|Rituximab (active comparator)|anti CD20 monoclonal antibody
215022802|NCT04254250|DIAGNOSTIC_TEST|Preoperative risk estimation of disc herniation recurrence|Risk estimation of disc herniation recurrence will be evaluated preoperatively, depend on the risk significance each patient will be assigned to one of two groups - with high risk and low risk. Then each patient will undergo conventional one-level microdiscectomy.
215022803|NCT04717479|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
215022804|NCT01681849|DRUG|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
215022805|NCT01681849|DRUG|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
215103024|NCT02161419|DRUG|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
215103025|NCT03595527|DIAGNOSTIC_TEST|HIV and HCV screening|HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott
215103026|NCT05556577|DRUG|investigational medicine product (IMP)|Investigational medicine product (IMP) received at SURMOUNT-CN trial
215103027|NCT05556577|OTHER|placebo|Placebo received at SURMOUNT-CN trial
215103028|NCT04147806|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
215103029|NCT04147806|RADIATION|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
215103030|NCT04147806|DRUG|Dexamethasone|4 mg by mouth on treatment days only
214423174|NCT01151839|PROCEDURE|Neoadjuvant chemoradiation followed by surgery|Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
214423175|NCT04794530|DRUG|cocoa flavanols|The cocoa flavanols intervention is manufactured by Mars Inc. Participants randomized to cocoa flavanols will take two capsules daily of cocoa flavanols. The two capsules of cocoa flavanols will contain approximately 500 mg of cocoa flavanols and appoximately 80 mg of (-)-epicatechin.
214690677|NCT03393364|DRUG|Oxycodone|Patients receive oxycodone for pain control after outpatient urologic surgery.
214690678|NCT03393364|DRUG|Ketorolac|Patients receive ketorolac for pain control after outpatient urologic surgery
214690679|NCT01259752|DEVICE|compression stockings|compression stockings
214690680|NCT01259752|OTHER|standard non compressive stockings|standard non compressive stockings
215022806|NCT01681849|OTHER|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
215022807|NCT02465112|DRUG|In111-Pentetréotide|
215022808|NCT02465112|OTHER|simple monitoring without active therapy|
215022809|NCT04074837|DRUG|NNI-362|NNI-362 small molecule in liquid suspension.
215022810|NCT04074837|DRUG|Placebo|Placebo liquid suspension
215103031|NCT04147806|DRUG|Tamsulosin|0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
215103032|NCT00379054|BEHAVIORAL|telephone based skills training intervention|
215103033|NCT05825976|DIETARY_SUPPLEMENT|Omega-3 Fatty ACids|Intervention consists of two different doses of omega-3: high concentration (Intervention group 1) and low concentration (Intervention group 2).
215103034|NCT05825976|OTHER|Control|Supplementation with extra virgin olive oil as a for of positive placebo control.
215103035|NCT04443166|COMBINATION_PRODUCT|A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program|a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
214690681|NCT00466999|DRUG|misoprostol|single dose of 400 mcg misoprostol administered sublingually
214690682|NCT00466999|PROCEDURE|surgery|standard surgical treatment (dilation and curettage or manual vacuum aspiration)
214690683|NCT02187094|DRUG|TC-6499|
214690684|NCT02187094|DRUG|Placebo|
214690685|NCT04398017|PROCEDURE|Transesophageal echography|Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
214690686|NCT00125658|OTHER|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
214690687|NCT00125658|OTHER|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
214690688|NCT03154723|DRUG|Vitamin A|Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.
214690689|NCT00363805|DIETARY_SUPPLEMENT|green tea|Given orally
215022811|NCT01974479|BIOLOGICAL|anti-CD19 redirected NK cells|Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
215022812|NCT06570239|PROCEDURE|intervention group|"Protocol A combines dry physiotherapy and psychological support. It will be organised on an outpatient basis. Weeks 1, 2 and 3: 8 sessions of dry physiotherapy and 3 sessions of psychotherapy. 5 psychotherapy sessions will be given over the following five weeks.~Protocol B combines hydro-physiotherapy and hydro-thermal treatments with psychological support. Protocol B begins with 3 weeks in a spa establishment - Care provided during weeks 1, 2 and 3: 8 hydrokinesitherapy sessions, 32 hydrothermal treatments, 3 psychotherapy sessions. 5 psychology sessions will be given over the following five weeks."
215022813|NCT02957019|DRUG|L19-IL2 - Ph I|Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
214690690|NCT00363805|DRUG|Polyphenon E|Given orally
214690691|NCT00363805|OTHER|placebo|Given orally
214690692|NCT05881551|DEVICE|eEgg|In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
214690693|NCT05881551|OTHER|NRS|Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
214690694|NCT02669550|DEVICE|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
214690695|NCT02669550|DEVICE|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
214690696|NCT05515601|DRUG|Mirikizumab|Administered SC.
214690697|NCT02476981|DRUG|Remifentanil|Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
214690698|NCT02476981|DRUG|Dexmedetomidine|Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
214690699|NCT02476981|DRUG|midazolam|All patients were premedicated with midazolam 0.02 mg/kg before induction.
214690700|NCT02476981|DRUG|propofol|All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
214690701|NCT02476981|DRUG|ephedrine|Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
214690702|NCT00398710|DRUG|Perifosine|150 mg daily (100 mg daily in case of dose reduction)
214690703|NCT01805232|DRUG|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
214690704|NCT01805232|DRUG|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
214690705|NCT04398849|BIOLOGICAL|Licenced 4CMenB Vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
214690706|NCT02353637|DIETARY_SUPPLEMENT|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
215022814|NCT02957019|DRUG|L19-IL2 at RD - Ph II|Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
215022815|NCT02957019|DRUG|Rituximab|Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
215022816|NCT00153790|DRUG|PhosphoLean|
215022817|NCT00962338|BEHAVIORAL|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
215022818|NCT06569849|OTHER|De-Stress and Focus capsule- U001|Two capsules in sequence daily after meal for 60 days.
215022819|NCT06569849|OTHER|De-Stress and Focus capsule - I001|Two capsules in sequence daily after meal for 60 days.
215022820|NCT06569849|OTHER|Placebo capsules 001|Two capsules in sequence daily after meal for 60 days.
215022821|NCT06569511|DIAGNOSTIC_TEST|N-terminal pro-B-type natriuretic peptide (NT-proBNP)|In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit
215022822|NCT06569511|DIAGNOSTIC_TEST|high sensitive cardiac troponin T (hs-cTnT)|In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.
215022823|NCT04135443|BEHAVIORAL|3T Tune in! Turn on! Turn up!|A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-19. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.
215022824|NCT04135443|BEHAVIORAL|General Health Materials Website|The control group will receive access to a website containing general health promotion materials.
215022825|NCT00070083|BIOLOGICAL|oblimersen sodium|
215022826|NCT00070083|BIOLOGICAL|rituximab|
215022827|NCT00070083|DRUG|cyclophosphamide|
215022828|NCT00070083|DRUG|doxorubicin hydrochloride|
215022829|NCT00070083|DRUG|prednisone|
215022830|NCT00070083|DRUG|vincristine sulfate|
215022831|NCT02420314|DRUG|Paclitaxel|"* Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
215022832|NCT02420314|DRUG|Carboplatin|"* Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
215022833|NCT02420314|DRUG|Ascorbic Acid|"* Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts"
215022834|NCT05584566|DEVICE|OSSIX Breeze|barrier membrane
215022835|NCT05584566|DEVICE|Jason membrane|barrier membrane
215022836|NCT03760068|DRUG|MYL-1601D Product|(100 U/mL)
215022837|NCT03760068|DRUG|FlexPen NovoLog®|(100 U/mL)
215022838|NCT01057940|PROCEDURE|DBE PEJ placement|One time procedure with follow-up telephone call.
215022839|NCT03856177|BEHAVIORAL|Emotion Induction|Described in arm
215022840|NCT05062772|DIAGNOSTIC_TEST|Ultrasound|Intraoperative ultrasound imaging
215022841|NCT00846482|DRUG|Oxaliplatin|Oxaliplatin will be administered once every 2 or 3 weeks
215022842|NCT05648279|OTHER|Personalized hemodynamic management|Personalized hemodynamic management: Intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index. Preoperative baseline cardiac index will be determined one day before surgery with the patient being awake and resting in the supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2). Intraoperative cardiac index will be measured using the Baxter Starling Fluid Management System.
215022843|NCT02088580|PROCEDURE|Triple Chronotherapy|
215022844|NCT04913090|DRUG|XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
215022845|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
215022846|NCT04913090|DRUG|XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
215022847|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
215022848|NCT04913090|DRUG|"XZP-5610 Tablet （for Part C1）"|Tablet(s) administered fasted orally once daily for 1 Day
215022849|NCT04913090|DRUG|"XZP-5610 Tablet for Part C2"|Tablet(s) administered after a high-fat meal orally once daily for 1 Day
215022850|NCT04037644|PROCEDURE|Fluid loading with Albumin|Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
215022851|NCT04037644|PROCEDURE|Fluid loading with Ringer Lactate|Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
215022852|NCT01906138|DEVICE|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
215103036|NCT01705106|DRUG|capecitabine|Given PO
215103037|NCT01705106|DRUG|celecoxib|Given PO
215103038|NCT01705106|OTHER|pharmacological study|Correlative studies
215103039|NCT01705106|OTHER|laboratory biomarker analysis|Correlative studies
215103040|NCT01705106|OTHER|pharmacogenomic studies|Correlative studies
215103041|NCT02401984|OTHER|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
215103042|NCT04667104|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.
215103043|NCT04667104|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
215103044|NCT04667104|DRUG|Tenofovir alafenamide (TAF)|TAF film-coated tablet will be administered orally once daily.
215103045|NCT04667104|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film-coated tablet will be administered orally once daily.
215103046|NCT04667104|DRUG|PegIFN-alpha2a|PegIFN-alpha2a injection will be administered subcutaneously once weekly.
215103047|NCT02943421|PROCEDURE|Transverse B-Lynch suture|
215103048|NCT03424603|DRUG|STRO-001|intravenous antibody drug conjugate
215103049|NCT01271374|DRUG|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
215022853|NCT03460704|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d. dosing).~The 1 MIU/ml CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (11 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d. (morning and evening) over aperiod of 12 month.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g. salbutamol/albuterol), supplied by the Sponsor, could be taken to improve tolerability."
215022854|NCT03460704|OTHER|Placebo|1 mL saline solution 0.45%. The placebo was made up of identical empty glass vials to which the same saline solution diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to mantain the blind.
215022855|NCT00760305|BEHAVIORAL|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
215022856|NCT02644057|DRUG|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
215022857|NCT02644057|DRUG|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
215022858|NCT05904379|DRUG|AK112|Subjects receive AK112 intravenously.
215022859|NCT05904379|DRUG|AK104|Subjects receive AK104 intravenously.
215022860|NCT05904379|DRUG|Carboplatin|Subjects receive carboplatin intravenously.
215022861|NCT05904379|DRUG|paclitaxel|Subjects receive paclitaxel intravenously.
215022862|NCT05904379|DRUG|pemetrexed|Subjects receive pemetrexed intravenously.
215022863|NCT05904379|DRUG|Docetaxel|Subjects receive docetaxel intravenously.
215022864|NCT01978301|DRUG|Triamcinolone acetonide|Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
215022865|NCT01978301|DRUG|Placebo|Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
215022866|NCT03888287|DEVICE|Watch Rx system|The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
215022867|NCT03888287|OTHER|Parkinson's Disease Inpatient Clinical Knowledge and Management Program|Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
215022868|NCT04160598|DRUG|IV infusion|Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
214423176|NCT04794530|DRUG|placebo|The placebo intervention will be manufactured by Mars Inc. and will appear identical to the cocoa flavanols intervention. Participants will take two capsules daily of placebo. The placebo will be a cellulose based capsule and will not contain cocoa flavanols or (-)-epicatechin.
214423177|NCT03279718|PROCEDURE|Periodontal Treatment|Scaling and root planing
214423178|NCT01418391|PROCEDURE|Transversus Abdominis Plane block|"TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12\~18 hours upon to the regional anesthetics choose"
214423179|NCT01080872|DEVICE|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
215022869|NCT04160598|DRUG|intrathecal fentanyl|10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
215022870|NCT05902975|DEVICE|Fiber reinforced composite resin space maintainer|Bonding of fiber reinforced with composite resin on primary second molar and primary canine under rubber dam isolation
215022871|NCT02913326|DRUG|Dabigatran etexilate|
215022872|NCT02913326|DRUG|Warfarin|
215022873|NCT05600257|DEVICE|DBT|Image with digital breast tomosynthesis
215022874|NCT05600257|DEVICE|DM|Image with digital mammography
215022875|NCT00002515|BIOLOGICAL|filgrastim|
215022876|NCT00002515|DRUG|carboplatin|
215022877|NCT00002515|DRUG|thiotepa|
215022878|NCT00002515|DRUG|topotecan hydrochloride|
215022879|NCT00002515|PROCEDURE|autologous bone marrow transplantation|
215022880|NCT00002515|PROCEDURE|bone marrow ablation with stem cell support|
215022881|NCT00002515|PROCEDURE|in vitro-treated bone marrow transplantation|
215022882|NCT00619398|DRUG|Prograf|Oral
215022883|NCT00619398|DRUG|FK506MR capsule|Oral
215022884|NCT02909257|DRUG|Same Bupivacaine Concentration|patient is exposed to the same concentration than previously successful one
215022885|NCT02909257|DRUG|Lower Bupivacaine Concentration|patient is exposed to a lower concentration than previously successful one
215022886|NCT01767857|DRUG|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
215022887|NCT01767857|DRUG|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
215022888|NCT00002985|DRUG|daunorubicin hydrochloride|
215022889|NCT00002985|DRUG|pegylated liposomal doxorubicin hydrochloride|
215022890|NCT03485885|DIETARY_SUPPLEMENT|Standardized maqui berry extract enriched in anthocyanins|Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water
215022891|NCT04795453|OTHER|score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
215022892|NCT04795453|OTHER|usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
214423180|NCT01282944|BEHAVIORAL|Financial Incentive|Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
214423181|NCT01282944|BEHAVIORAL|Peer Network|Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
214423182|NCT01194154|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
214423183|NCT01194154|DRUG|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
214423184|NCT01909336|DRUG|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
214423185|NCT01909336|DRUG|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
214423186|NCT01909336|DRUG|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
214423187|NCT01505881|DRUG|dabigatran etexilate low dose|active treatment (low)
214423188|NCT01505881|DRUG|warfarin 5mg|comparator warfarin
214423189|NCT01505881|DRUG|dabigatran etexilate intermediate dose|active treatment (medium)
214423190|NCT01505881|DRUG|warfarin 1mg|comparator warfarin
214423191|NCT01505881|DRUG|dabigatran etexilate high dose|active treatment (high)
214690707|NCT04176432|OTHER|No intervention|Retrospective observational study with no intervention
214423192|NCT01505881|DRUG|warfarin 3mg|comparator warfarin
214423193|NCT03884244|OTHER|chewing gum|The group who take chewing gum after operation
214423194|NCT00842257|DRUG|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
214423195|NCT05056051|DEVICE|WATS-3D tissue sampling prior to forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells.
214423196|NCT05056051|DEVICE|WATS-3D tissue sampling following forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells. This will be done after forceps biopsies in this arm.
214423197|NCT04956146|DRUG|Fruquintinib，Sintilimab，Pemetrexed，Carboplatin|Fruquintinib,fruquintinib at the dose determined in phase safety lead-in,5mg-intermittent (2 weeks on/ 1 week off) ，po，every 3 weeks(q3w) ; Sintilimab at the dose 200mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=4\~5，iv，d1；given every 3 weeks (q3w); Maintenance treatment：After 4\~6 cycles of carboplatin treatment, Sintilimab 200mg, iv, d1, q3w；Fruquintinib RP2D intermittent(2 weeks on/1 weeks off), po，q3w； pemetrexed 500mg/m2, d1,iv, q3w until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
214423198|NCT00979056|DRUG|Rifaximin|400 mg per day, oral use, maximum duration 28 days
214423199|NCT00979056|DRUG|Lactose|Coated Tablet, Oral Use
214690708|NCT01801137|DRUG|Everolimus (Afinitor®)|
214690709|NCT03870711|DRUG|lidocaine spray|10% lidocaine spray 4 puffs
215022893|NCT02792946|DRUG|Acebrophylline|
215022894|NCT00474357|BEHAVIORAL|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
215022895|NCT01942460|DRUG|Ferumoxytol|
215022896|NCT04126174|DEVICE|femtosecond laser system arcuate corneal incision|Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
215022897|NCT04126174|OTHER|Manual LRI|Manual LRI
215022898|NCT03138382|DEVICE|Vestibular Nerve Stimulator|Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.
215022899|NCT03138382|DEVICE|Sham stimulator|Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
215022900|NCT01514422|DRUG|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
214423200|NCT00395018|DRUG|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
214423201|NCT01306513|BIOLOGICAL|autologous bone marrow derived mesenchymal stromal cells|Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
214423202|NCT02245334|DRUG|Povidone-Iodine|1 pill per biopsy
214423203|NCT02314117|DRUG|Ramucirumab|Administered IV
214423204|NCT02314117|DRUG|Capecitabine|Administered orally
214423205|NCT02314117|DRUG|Cisplatin|Administered IV
214690710|NCT03870711|DRUG|Placebo|Sterile water 4 puffs
214690711|NCT00760227|OTHER|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
214690712|NCT00760227|OTHER|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
214690713|NCT00760227|OTHER|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
214690714|NCT00843297|DEVICE|Coolgard|invasive Cooling via femoral ICY-catheter
214690715|NCT00843297|DEVICE|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
214690716|NCT00843297|OTHER|Conventional treatment|Intensive care-treatment without cooling
214690717|NCT00364845|DRUG|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
214690718|NCT00364845|DRUG|Placebo|Prefilled syringe placebo, to match active arm
215022901|NCT06468553|BEHAVIORAL|Prediabetes Care Program|Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months
215022902|NCT03016702|OTHER|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
215022903|NCT03016702|OTHER|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
215022904|NCT04511741|OTHER|no intervention, it is an observational study.|no intervention, it is an observational study.
215022905|NCT00003680|DRUG|CMF regimen|
214690719|NCT01529476|DRUG|Levofloxacin|levofloxacin 500 mg,QD,7\~10 days
214690720|NCT01529476|DRUG|Nemonoxacin|Nemonoxacin 500mg,QD,7\~10 days
214690721|NCT00267280|DRUG|torcetrapib/atorvastatin|
214690722|NCT00267280|DRUG|simvastatin|
214690723|NCT02422927|DIETARY_SUPPLEMENT|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
215022906|NCT00003680|DRUG|cyclophosphamide|
215022907|NCT00003680|DRUG|fluorouracil|
215022908|NCT00003680|DRUG|methotrexate|
215022909|NCT00003680|DRUG|tamoxifen citrate|
214423206|NCT02314117|DRUG|Placebo|Administered IV
215022910|NCT00003680|DRUG|thiotepa|
215022911|NCT00003680|PROCEDURE|peripheral blood stem cell transplantation|
215022912|NCT00003680|RADIATION|radiation therapy|
215022913|NCT05208957|OTHER|No intervention|No intervention
214423207|NCT02314117|DRUG|Fluorouracil|Administered IV
214423208|NCT03988569|OTHER|audiovisual decision aid|Will view AVDA and then have opportunity for questions with physician before signing consent forms
214423209|NCT03795428|DRUG|Pemziviptadil (PB1046) Injection|Once-weekly subcutaneous injection
214423210|NCT01985906|PROCEDURE|Multiple overlapping uncovered stents|Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
214423211|NCT01985906|DEVICE|Uncovered stents|The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
214423212|NCT06556186|PROCEDURE|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
215022914|NCT03184025|OTHER|dentin adhesive|HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
215022915|NCT05438771|COMBINATION_PRODUCT|Ankaferd Blood Stopper|mouth wash
215022916|NCT05438771|OTHER|Bicarbonate|mouth wash
215022917|NCT03800901|OTHER|Continuing Medical Education|CME or ABIM MOC credits
215022918|NCT03800901|OTHER|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control."
215022919|NCT03008980|OTHER|Diagnostic Test|
215022920|NCT04526457|OTHER|Standard of Care|Randomized to standard of care with lipid testing only.
214690724|NCT02422927|OTHER|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
214690725|NCT02422927|OTHER|Placebo|placebo
214690726|NCT01187901|DRUG|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
214690727|NCT01187901|DRUG|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
214690728|NCT01187901|DRUG|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
214690729|NCT01187901|DRUG|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
215022921|NCT04526457|OTHER|Genetic Testing|Randomized to genetic testing.
215022922|NCT03908294|DIAGNOSTIC_TEST|Lab tests, non-invasive fibrosis (Fibroscan/ARFI)|Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
215103050|NCT01271374|DRUG|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
214423213|NCT06556186|DRUG|Bromocriptin 2.5mg, 2-3 times a day|Bromocriptin 2.5mg, 2-3 times a day
215022923|NCT04938531|OTHER|Exercise|Participants will perform an entry passive exercise test within 48 hours of onset of severe sepsis. Patients then will perform 30-60 min supine passive cycle ergometry exercise 5 days/week.
214423214|NCT00015236|BEHAVIORAL|Amantadine|
214423215|NCT05603338|PROCEDURE|LSG with omental band|LSG with omental band
215022924|NCT03635879|OTHER|MCTprocal medical food|32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
215022925|NCT03635879|OTHER|Milk/tricaprilin oil blend|154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
215022926|NCT03635879|OTHER|AC-1207|AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
215022927|NCT03635879|OTHER|AC-1205|AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
215022928|NCT03635879|OTHER|AC-1206|AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
215022929|NCT03635879|DRUG|AC-1202|AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
215022930|NCT00214526|PROCEDURE|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
214423216|NCT05603338|PROCEDURE|LSG|just to do sleeve gastrectomy
214690730|NCT04160468|DRUG|Exebacase|Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
214690731|NCT04160468|DRUG|Placebo|Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
214690732|NCT03505567|DEVICE|KOWA OCT Bi-µ|Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.
214690733|NCT03505567|DEVICE|Optovue iVue 100|U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
214690734|NCT01912768|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
214690735|NCT01912768|DEVICE|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
214690736|NCT01912768|DEVICE|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
214690737|NCT00088634|DRUG|Lurasidone|80 mg AM dosing once daily
214690738|NCT00088634|DRUG|Placebo|Matching Placebo to 40mg lurasidone tablets
214690739|NCT03152916|DEVICE|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
214690740|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily
214690741|NCT02150824|DRUG|Placebo|BI 187004 medium dose matching placebo once daily
214690742|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily add on to background metformin
214690743|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily add on to background metformin
214690744|NCT02150824|DRUG|Placebo|BI 187004 low dose matching placebo once daily
214690745|NCT02150824|DRUG|BI 187004|BI 187004 medium dose once daily
214690746|NCT02150824|DRUG|BI 187004|BI 187004 low dose once daily
214690747|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily
214690748|NCT01592279|DRUG|liraglutide|
214690749|NCT01592279|DRUG|Insulin injections|
214690750|NCT01803763|DRUG|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
215022931|NCT00214526|DRUG|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
215103051|NCT03043651|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
214690751|NCT01803763|DRUG|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
215022932|NCT04681313|PROCEDURE|High-risk percutaneous coronary intervention|Percutaneous coronary interventions (PCI) deemed high risk based on patient-related risk features, hemodynamic criteria, clinical presentation and complexity of coronary anatomy.
215022933|NCT03784300|DRUG|50 mg PTI-125|PTI-125 50 mg Oral Solution
215022934|NCT03784300|DRUG|100 mg PTI-125|PTI-125 100 mg Oral Solution
215022935|NCT03784300|DRUG|200 mg PTI-125|PTI-125 200 mg Oral Solution
215022936|NCT06523816|DIAGNOSTIC_TEST|dermoscopy|Dermoscopy is a fast imaging technique that allows an excellent visualization of non-melanocytic skin tumors to diagnose them without invasive interventon.
215022937|NCT05034887|DRUG|Trastuzumab Deruxtecan (T-DXd) monotherapy|T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.
215022938|NCT05034887|DRUG|T-DXd, Durvalumab and Capecitabine Combination|Administer each cycle over 21 days. T-DXd is administered by intravenous infusion at 5.4 mg/kg every 21 days (every 3 weeks). Capecitabine is given at 750 mg/m2 BID, taken orally for 14 days, followed by a drug holiday from the evening of Day 15 to the morning of Day 22 (Day 1 of the next cycle). Durvalumab is administered at 1500 mg by intravenous infusion over 60 minutes every 21 days (every 3 weeks). As neoadjuvant chemotherapy, administer T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles. As adjuvant chemotherapy consists of T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles, followed by Durvalumab monotherapy on a q4w schedule until 10 cycles are completed.
215022939|NCT05196724|BEHAVIORAL|Mentalization Based Therapy MBT|The focus is on improving the core components of secure attachment, particularly by developing the reflective functioning for all professionals working with children in out-of-home care, which is subsequently proposed to increase the psychosocial adjustment of the child and decrease emotional and behavioral problems. MBT treatment consists of up to 12 weekly sessions with the foster parents and child covering three core components: 1) psycho-education about mentalizing, trauma, and attachment for foster parents; 2) support for reflective practice in the professional network, and 3) mentalization-based therapy for the foster family \[41\].
215022940|NCT05196724|BEHAVIORAL|Usual care|The control group will receive the usual care offered to foster families such as supervision
215022941|NCT03978156|DRUG|Dronabinol 2.5 MG|Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.
215022942|NCT03978156|DRUG|Microcrystalline cellulose|Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
215022943|NCT06358703|DRUG|Caplacizumab|Early Caplacizumab use
214690752|NCT06227390|PROCEDURE|partial pulpotomy|2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
214690753|NCT04671914|DRUG|Hyaluronic Acid 20 MG/ML Injectable Solution|Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C
215022944|NCT05284747|DRUG|Evolocumab|Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.
215022945|NCT05284747|DRUG|Routine Lipid Management|Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
215022946|NCT02739880|DEVICE|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
215022947|NCT00378287|DRUG|rabeprazole sodium|
215022948|NCT05756556|COMBINATION_PRODUCT|T3011 + Cobimetinib|1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks \[Q2W\], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily \[QD\] for the first 21 days of each 28-day cycle)
215022949|NCT04467853|BIOLOGICAL|LCAR-C18S cells|Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen
215022950|NCT04722679|DRUG|Non-VKA Oral Anticoagulants (NOAC)|Follow clinical practice.
215022951|NCT01162785|DRUG|SCH 721015|Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
215022952|NCT06268678|OTHER|Phase of the menstrual cycle|Follicular or luteal phase
215103052|NCT04383054|BEHAVIORAL|'More minutes' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
214690754|NCT04671914|OTHER|Dilation and curretage|After abortion in II trimester we do D\&C.
214690755|NCT06674096|DRUG|RLC-CRCHOP|"Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:~rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.~Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.~maintenance treatment period: chidamide d1,4,8,11"
214690756|NCT00540436|DRUG|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
215022953|NCT06500000|DIAGNOSTIC_TEST|liquid chromatography-mass spectrometry (LC/MS)|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography- mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and reproducibility.
215022954|NCT02578537|DRUG|Ticagrelor|Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
215022955|NCT02578537|DRUG|Clopidogrel|Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
215022956|NCT01433861|PROCEDURE|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
215022957|NCT05392751|DRUG|EA-2353|EA-2353 Ophthalmic Suspension
215022958|NCT05930444|DIAGNOSTIC_TEST|Multimodal Machine Learning Program for Auxiliary Diagnosis of Eye Diseases|Patients presenting with eye-related chief complaints initially complete a mobile phone application. This application utilizes patient medical history and relevant images (such as selfies and photos from eye examinations) to provide intelligent diagnosis. The diagnosis remains undisclosed to the patients. Subsequently, patients seek medical attention and undergo clinical examination by a skilled clinician. The clinical diagnosis is subsequently reviewed by a second experienced clinician. If the diagnoses align, it is considered the gold standard. In cases of discrepancy, the consensus reached by the two clinicians becomes the gold standard.
215022959|NCT06563076|OTHER|Vestibular Rehabilitation|supervised vestibular rehabilitation program
215022960|NCT06563076|OTHER|Vestibular Electrical Stimulation|80 Hz high frequency transcutaneous vestibular electrical stimulation (VES)
215022961|NCT06144853|OTHER|scan|Fluorodeoxyglucose (FDG)-positron emission tomography/Computed tomography scan
215022962|NCT06132308|PROCEDURE|PENG Block with 0.25% bupivacaine|Peng block was performed.
215022963|NCT05544396|OTHER|probiotic|probiotic group give probiotics (2 packs per day) for 6 months.
215022964|NCT06315894|DEVICE|SuperCAP Program|"Distance program including tasks and exercises to improve cognitive, emotional, and functional status.~The intervention will be applied via cell phone and will have a duration of 3 months (12 weeks).~Tasks and exercises will be performed 5 days per week. Contents of the program will include daily exercises, daily games, daily videos, and weekly videos.~They will address cognitive functions, daily habits, and lifestyle factors in general.~Compliance will be monitored to control the adherence to the intervention. The program has been designed specifically for people with post-COVID syndrome."
215022965|NCT03995511|PROCEDURE|Bilateral Sagittal Split Osteotomy|Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
214507344|NCT06941337|BEHAVIORAL|HealthySteps (HS)|Evidence-based program that focuses on addressing Adverse Childhood Experiences (ACEs) and family stressors. The program provides parenting guidance, mental health support, and care coordination. The program is delivered during well-child visits by an HS specialist.
214507345|NCT06941337|BEHAVIORAL|PlayReadVIP|Evidence-based program that promotes Positive Childhood Experiences (PCEs) and strengthens parent-child interactions. The program involves recording and reviewing videos of parents engaging with their child to provide feedback and encourage positive practices. Families receive toys, books, and guides to extend activities at home.
214507346|NCT06147921|DRUG|Verasone|Administered by sinonasal irrigation.
214507347|NCT06943638|OTHER|Mild Exercise and stretches|For 15 minutes the patient received an individualized mild workout program intending to relax and relieve some of his stress. The workout includes deep breaths, easy-to-do exercises, and stretches from lying on the bed, sitting in a chair, or standing. I always followed the patient's tempo and provided him with as many breaks as he needed.
214507348|NCT04253457|DRUG|1ml of triamcinolone (40mg/1ml)|Single injection of 1ml of triamcinolone (40mg/1ml)
214507349|NCT06946433|DEVICE|Transcranial Direct Current Stimulation - Active|"This intervention involves non-invasive brain stimulation using transcranial direct current stimulation (tDCS) delivered via saline-soaked sponge electrodes. The anode is placed at F3 (left dorsolateral prefrontal cortex) and the cathode at Fp2 (right frontopolar cortex), according to the international 10-20 EEG system. A 2 mA current is applied for 20 minutes per session, administered once daily on 10 consecutive workdays.~During stimulation, participants engage in cognitive training using the NeuronUP platform, which provides structured, interactive tasks designed to train executive function, attention, and working memory. This combination aims to enhance neural plasticity by pairing neuromodulation with cognitive engagement."
214507350|NCT06946433|DEVICE|Transcranial Direct Current Stimulation - Sham|The sham condition mimics the active setup but delivers only brief ramp-up/down stimulation, producing the initial sensation without sustained current.
214690757|NCT00849979|BEHAVIORAL|Questionnaire|Day 1 MDASI-GI Questionnaire
214690758|NCT00849979|OTHER|Interview|Open-ended, audiotaped interviews
214690759|NCT03948659|PROCEDURE|Arterio ventricular coupling|We analyse ventriculo arterial coupling (VAC) among cirrhotic patients admitted in intensive care unit, with non-invasive echography method
214690760|NCT06100471|OTHER|Observational study|Observational study in different tissues in identifing new genetic markers related to endometriosis disease
215022966|NCT06517927|DIAGNOSTIC_TEST|Clinical and radiographic dental examination|complete clinical oral examination + intra-oral and panoramic x-rays
215022967|NCT05787483|BEHAVIORAL|MindUP group|MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.
214690761|NCT03758378|OTHER|Dietary intervention|Limiting dietary exposure to high intensity sweeteners and sugar alcohols; limiting eating out to a maximum of 2 days per week.
214690762|NCT03611933|OTHER|position change applied at different times|Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
215022968|NCT05787483|BEHAVIORAL|active control group|business as usual; regular wellness or SEL classes
215022969|NCT00141193|DRUG|Celecoxib|
215022970|NCT02617212|PROCEDURE|Implant surgery|The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.
215103053|NCT04383054|BEHAVIORAL|'one minute' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
215103054|NCT04196673|DEVICE|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
215103055|NCT04196673|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
215103056|NCT05281055|PROCEDURE|Endovascular thrombectomy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombosuction, others, or combination methods.
215103057|NCT00017407|BIOLOGICAL|ISIS 3521|
215103058|NCT00017407|DRUG|carboplatin|
214507351|NCT06946433|BEHAVIORAL|Cognitive Training|The cognitive training intervention in this study is delivered through NeuronUP, a digital platform offering evidence-based cognitive stimulation activities. This intervention targets core cognitive domains such as working memory, attention, and executive function through personalized, interactive tasks. What distinguishes this approach is NeuronUP's extensive library of over 10,000 activities, its ability to tailor difficulty levels in real time based on individual performance, and the inclusion of functional tasks that mirror real-life scenarios. Unlike other interventions, NeuronUP also enables therapist-guided customization, allowing for individualized treatment plans that evolve with participant progress, ensuring both relevance and ecological validity.
214507352|NCT06955286|DIAGNOSTIC_TEST|complete ACTH stimulation test the day after surgery|patients complete ACTH stimulation test on the one day after surgery
214507353|NCT06951984|DIAGNOSTIC_TEST|11C/18F-HED|Each subject receive a single intravenous injection of 11C/18F-HED and undergo PET/CT or MRI imaging within the specificed time.
214507354|NCT06952023|PROCEDURE|Modified Maze ablation with PFA|Modified Maze ablation with PFA
214507355|NCT06952023|PROCEDURE|PVI only with PFA|PVI only with PFA
214507356|NCT06951568|OTHER|Physical Exercise Program|The physiotherapy protocol has been developed using the GMFCS scale as a reference. Based on this assessment, each patient's level is determined according to their functional motor abilities, limitations, and use of assistive or mobility devices. Each protocol consists of a total of five exercises: two general exercises and three specific exercises focused on the phases of the corresponding transfer and on skills common to all transfers. Rest periods of 2 minutes and 30 seconds are provided between exercises to ensure adequate recovery and a safe progression. The somatosensory stimulation will consist of intermittent mechanical pressure applied to the skin over the neuromuscular motor points of the quadriceps and gastrocnemius muscles. T
214507357|NCT05552066|OTHER|Standard follow up|Patients enrolled into front phase will be followed in a standard way without any additional procedure except satisfaction questionnaire
214507358|NCT05552066|OTHER|short circuit|"Patients included in the post phase will have to complete the cem@santé application. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation)."
214690763|NCT00040833|PROCEDURE|complementary or alternative medicine procedure|
214690764|NCT00040833|PROCEDURE|pain therapy|
214507361|NCT05454124|BEHAVIORAL|Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
215103059|NCT00017407|DRUG|paclitaxel|
215103060|NCT00162812|DRUG|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
214690765|NCT00398151|DRUG|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
214690766|NCT01884454|BEHAVIORAL|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
214690767|NCT04292405|DEVICE|Wearable Cardioverter Defibrillator|Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.
214690768|NCT00470353|DIETARY_SUPPLEMENT|calcium carbonate|
214690769|NCT00470353|DIETARY_SUPPLEMENT|cholecalciferol|
214690770|NCT00470353|OTHER|immunohistochemistry staining method|
214690771|NCT00470353|OTHER|laboratory biomarker analysis|
214507362|NCT05454124|BEHAVIORAL|Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision, this condition combines elements of training visual sensitivity, spatial integration, and spatial attention.
214507363|NCT03895658|DEVICE|MRI|Structural and functional neuroimaging pre and post ECT treatment
214507364|NCT03895658|DEVICE|MagPro TMS stimulator and coil|Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment
215022971|NCT02617212|DEVICE|Three abutment dis-/reconnections.|At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
215022972|NCT02617212|DEVICE|No abutment dis-/reconnections.|Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
215022973|NCT00742742|BEHAVIORAL|healthy life style education|healthy life style education
215022974|NCT06147869|DEVICE|phonophoresis|Phonophoresis is a method of driving topically applied substances across tissues using ultrasound (US) to enhance percutaneous absorption of selected drugs such as corticosteroids, local anaesthetics, and salicylates
215022975|NCT06147869|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
215022976|NCT04824066|DEVICE|Device: Wearable Device|A Wearable Device will be placed on the wrist of the patient \~30 days prior to the patient's scheduled surgery, removed during the operation, and replaced for \~180 days post-operatively. The device will record activity in terms of steps, sleep quality, heart rate, etc.
215022977|NCT03192332|DEVICE|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
215103061|NCT03219684|DIAGNOSTIC_TEST|serum protein ,kidney function ,liver function.,serum cholesterol|monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients
215103062|NCT00006433|DRUG|Doxil|
215103063|NCT00006433|PROCEDURE|heat treatment|
215103064|NCT03605316|PROCEDURE|Deep brain stimulation (DBS)|Neurosurgical treatment by stereotactic implantation of electrodes in the brain that affects the functioning of subcortical neuronal circuits
214507365|NCT03895658|DEVICE|Thymatron (R) System IV paired with 4X1 HDECT|Multi-Channel Stimulation Interface (Model 4X1 HDECT)
214507366|NCT04313114|BEHAVIORAL|health literacy appropriate education and demonstration|If a patient chooses the Fecal Immunochemical Test (FIT), the Screening Coordinator (SC) will give the FIT kit, emphasize the necessity of annual completion, and distribute an additional plain language, literacy appropriate, actionable handout with simplified illustrated instructions on how to complete the test and mail to the central lab. The SC will review the handout and instructions with the patient and use the 'teach back' method to confirm understanding.
214690772|NCT00470353|OTHER|pharmacological study|
214690773|NCT00470353|PROCEDURE|biopsy|
214690774|NCT05362851|DRUG|YYC301-1 & YYC301-2 & YYC301-3|"YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day"
214690775|NCT05362851|DRUG|YYC301 placebo & Celecoxib 200mg|comparator medication
214690776|NCT03167086|BEHAVIORAL|"Empowered Relief (ER)"|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
215103065|NCT01630889|DRUG|Roxadustat|Oral capsule
215103066|NCT00235287|DRUG|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
215103067|NCT00235287|DRUG|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
215103068|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
215022978|NCT03192332|DRUG|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
214507367|NCT04313114|BEHAVIORAL|shared decision making|Screening Coordinator (SC) will give patients a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; using the low literacy handout as a teaching tool, the SC will briefly counsel patients on CRC screening options prior to seeing their healthcare provider, reviewing the benefits of each, as well as applicable costs. After reviewing the CRC screening pamphlets with a patient, the SC will use shared decision-making techniques using the study CRC materials to aid patients in selecting the test they prefer and that meets their needs - colonoscopy or FIT.
215022979|NCT02096965|DRUG|Tolvaptan|Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
215022980|NCT02096965|DRUG|Placebo|Patients will receive daily dose at 8 AM and at 4 PM.
215022981|NCT03657407|DRUG|Belladonna Opium|Belladonna Opium 16.2-60mg rectal suppository
215022982|NCT03657407|DRUG|Glycerin Suppository|Glycerine rectal suppository
214507368|NCT04313114|BEHAVIORAL|automated call reminders or automated texts|"Colonoscopy year 1: Will receive an automated call recording by PCP 48 hours after the clinic visit to remind them of their choice of colonoscopy; then, one week before the test reminding them to pick up the preparation kit. Those who chose SMS will receive a text message from their PCP with content similar to the voice call. A 3rd reminder call/text will be sent 2 days prior to the test. If no colonoscopy with 3 months, the clinical manager (CCM) will call to determine if they want to switch screening options. The CCM will discuss barriers and option of choosing FIT for 3 years. If they opt to change, they will be mailed a FIT with simplified instructions and then follow the FIT follow-up protocol.~FIT year 1: Motivational reminders recorded by their PCP will be sent by automated call or text within 48 hours after the visit and again at 4, 8 and 12 weeks for those who have NOT completed the test. FIT will be mailed year 2 \& 3 - follow-up will follow same procedure as year 1."
214507369|NCT06123143|OTHER|Standardized/structured CPAP weaning protocol|Standardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA.
214507370|NCT03124212|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
214507371|NCT02421679|DRUG|TNX-102 SL|1x 2.8mg TNX-102 SL Sublingual tablet
214507372|NCT05133700|OTHER|Interview or focus group discussion|There is no intervention. This is a qualitative piece of work only
214507373|NCT05133700|OTHER|Review of submitted medicines audit tools|There is no intervention. This is a qualitative piece of work only
214507374|NCT01458015|DRUG|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
214507375|NCT05972837|DEVICE|Surface electrical stimulation (SES)|Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.
214507376|NCT05972837|OTHER|Remote medical support|The remote medical support includes a session of video call with a rehabilitation doctor in the first week and weekly telehealth visits with a live physical therapist or physician. The contents of the video calls contain patient education, stretching exercises teaching and instructions of using SES for MPS.
214507377|NCT01953900|GENETIC|GD2 T cells|"On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.~Dose Level 1: 1x10\^6 cells/m\^2~Dose Level 2: 1x10\^7 cells/m\^2~The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:~Dose Level 7: 1 x 10\^7 cells/m2~Dose Level 8: 1 x 10\^8 cells/m\^2~Dose levels 9-11 will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to administration of the T cells.~Dose Level 9: 1 x 10\^8 cells/m\^2~Dose Level 10: 5 x 10\^8 cells/m\^2~Dose Level 11: 1 x 10\^9 cells/m\^2~The previously planned dose levels 3-6 will not be studied."
214507378|NCT01953900|BIOLOGICAL|VZV vaccine|Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
214690777|NCT03167086|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) \[1\& 2\], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner \[3\].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk \& Winter \[4\] for optional reading."
215022983|NCT06420076|BIOLOGICAL|CD5/CD7 CAR-T|"The intervention in this clinical trial involves a novel approach using CD5/CD7 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD5/CD7 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD5/CD7 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD5/CD7 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
215022984|NCT06087328|DRUG|Regular Nicotine patch and lozenge dose|1mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]
215103069|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
215103070|NCT03595488|DRUG|Dupilumab|dupilumab 300 mg subcutaneous injection every 2 weeks
215103071|NCT00486382|BIOLOGICAL|Leish-111f + MPL-SE Adjuvant|
215103072|NCT04814056|DRUG|Afatinib Dimaleate|Afatinib is the second-generation TKI drug, which can irreversibly bind to receptors of erbB family. Afatinib will be administered orally at a dose of 40 mg per time, Q.D. If a patient cannot tolerate a dose of 40mg due to adverse reactions, when the adverse reactions restore to level 1 (CTCAE 5.0) or below, the dosage could be adjusted to 30mg per day, Q.D.
215022985|NCT06087328|DRUG|Augmented Nicotine patch and lozenge dose|21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]
215022986|NCT05956535|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
215022987|NCT05956535|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
215022988|NCT05900830|OTHER|play therapy|A combined program based on physical and occupational therapy techniques within a play context
215022989|NCT05900830|OTHER|common educational methods|the child will receive his education in a passive manner
215022990|NCT02628145|BEHAVIORAL|Resistance Training Intervention|The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
214423217|NCT02026258|PROCEDURE|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
215022991|NCT02628145|BEHAVIORAL|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
215022992|NCT00153933|DRUG|Bortezomib|Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
215022993|NCT00153933|DRUG|CC-5013|Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
215022994|NCT05586685|OTHER|effect of diaphragmatic release on upper crossed syndrome|"The patients will be positioned in the supine position. The therapist stood at the head of the patient.therapist make manual contact of ribs and ask patient to inspire the move ribs laterally and then expire~conventional exercise Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position"
215022995|NCT05262673|BIOLOGICAL|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
215022996|NCT03186183|BEHAVIORAL|GPS program|GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
215022997|NCT02339675|OTHER|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
215022998|NCT00049283|DRUG|erlotinib hydrochloride|Given orally
215022999|NCT00049283|DRUG|docetaxel|Given IV
215023000|NCT00049283|RADIATION|radiation therapy|Undergo radiotherapy
215023001|NCT00049283|PROCEDURE|therapeutic conventional surgery|Undergo neck dissection
215023002|NCT00049283|OTHER|laboratory biomarker analysis|Correlative studies
215023003|NCT00049283|OTHER|pharmacological study|Correlative studies
214507379|NCT01953900|DRUG|Fludarabine|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
215103073|NCT03217214|DIAGNOSTIC_TEST|Thermography|Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
214507380|NCT01953900|DRUG|Cyclophosphamide|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
214507381|NCT01818063|DRUG|Paclitaxel|Given IV
214507382|NCT01818063|DRUG|Carboplatin|Given IV
214507383|NCT01818063|DRUG|Doxorubicin|Given IV
214507384|NCT01818063|DRUG|Cyclophosphamide|Given IV
214507385|NCT01818063|DRUG|Veliparib|Given PO
214507386|NCT04353778|DRUG|Pyridostigmine|Eight weeks of low-dose pyridostigmine
214507387|NCT04353778|DRUG|Placebos|matching placebo x 8 weeks
214507388|NCT04353778|PROCEDURE|non-invasive vagal nerve stimulation|stimulation of the vagus nerve
214507389|NCT03411421|DRUG|AL-794|AL-794 will be administered as tablets orally on Day 1 to Day 5.
214507390|NCT03411421|DRUG|Placebo|Matching placebo tablets will be administered.
215023004|NCT05668507|BEHAVIORAL|REACHOUT Virtual Mental Health Support|"REACHOUT is a mobile app which delivers peer-led mental health support to adults with type 1 diabetes. The mobile app has three support features:~1. One-on-one support delivered by a Peer Supporter. Participants will be able to review Peer Supporter profiles and connect with one of their choosing.~2. Group support delivered via a 24/7 chat room~3. Face to face support delivered via virtual happy hours"
214507391|NCT02589106|DEVICE|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
214507392|NCT05509569|DRUG|Icatibant|Icatibant, 10 to 30 mg, Subcutaneous injection
214507393|NCT06463860|DEVICE|DermDx|DermDx is a computer-aided diagnosis (CADx) software product that uses an AI-based algorithm to evaluate non-invasively captured images of skin lesions obtained from any commercially available dermoscopes. DermDx uses state-of-the-art deep neural network models that have been trained on a large database of dermoscopy images. DermDx analyzes the image of a new skin lesion and provides an output.
214507394|NCT04180904|OTHER|Diet 1|Diet 1 will focus on which foods are eaten and the impact on disease outcomes.
214507395|NCT04180904|OTHER|Diet 2|This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject's demographics (age, sex, weight, height).
214507396|NCT05230784|OTHER|AirOk Air Purifier|The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.
214507397|NCT05230784|OTHER|Placebo Air Filter|Participants in the placebo arm will receive an air purifier with only the EGAPA filter.
214507398|NCT06021457|DRUG|RBT-1|Intravenous administration
214507399|NCT06021457|DRUG|Placebo|Intravenous administration
214507400|NCT06434246|BEHAVIORAL|pulley system exercise regimen|The warm-up consists of gentle stretching and basic mobility exercises to prepare the muscles and joints for the activity. Following this, the main segment of the session involves specific exercises using the pulley system, designed to target and improve motor function, strength, and coordination of the upper limbs. The therapist will adjust the exercises according to each child's individual abilities and progression over time. The session concludes with a cool-down period involving light activities and relaxation techniques to ensure a gradual return to baseline physiological states.
214507401|NCT06434246|BIOLOGICAL|physical therapy program for CP|Participants in the control group will attend physical therapy sessions twice per week. These sessions aim to maintain or improve physical functioning and manage the symptoms of cerebral palsy. Each session lasts approximately 45 to 60 minutes, These sessions include a variety of therapeutic exercises tailored to each child's needs but do not include the use of the pulley system. Typical activities might involve stretching, strengthening exercises, and manual therapy techniques to enhance joint mobility and muscle function.
214507402|NCT01267188|DRUG|NBI-98854|powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
215023005|NCT05281458|PROCEDURE|Early drainage of peripancreatic fluid collections|Participants will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
215023006|NCT04098783|OTHER|Home visit, health education|
215023007|NCT06121635|COMBINATION_PRODUCT|Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation|At the robot-assisted gait training, 20-minute gait training for the patient at an appropriate speed with the Locohelp Woodway device. The aim is to re-teach proper walking, gait cycle timing, and create a near-normal gait pattern through multiple repetitions. Robot-assisted gait training will be performed immediately following the stimulation applied to the patients.
215023008|NCT06121635|COMBINATION_PRODUCT|Sham ts-DCS and sham t-DCS|Sham ts-DCS and sham t-DCS
215023009|NCT05530915|OTHER|Gel capsule|Single capsule per dose
215023010|NCT01460537|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
215023011|NCT01460537|DRUG|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
215023012|NCT01460537|DRUG|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
215023013|NCT01460537|DRUG|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
215023014|NCT01460537|DRUG|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
215023015|NCT00167531|BEHAVIORAL|treadmill walking with partial weight support|
215023016|NCT00167531|BEHAVIORAL|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
215023017|NCT05936138|DRUG|LY3502970|Administered orally.
215023018|NCT03976726|DEVICE|Comparison of physcial parameters|Increasement of weight, volume expansion and decrease of density are measured.
215023019|NCT02303483|DIETARY_SUPPLEMENT|Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )|
215023020|NCT02303483|DIETARY_SUPPLEMENT|Placebo|
215023021|NCT05701631|DIAGNOSTIC_TEST|Radiomic model|Radiomic model for PCP diagnosis
215023022|NCT04180423|DEVICE|Off-the-Shelf Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
214423218|NCT02026258|DEVICE|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
214507403|NCT04304378|BEHAVIORAL|Stabilization Techniques (ST)|The Stabilization Techniques intervention provides an opportunity to improve emotion/affect regulation and coping skills. The overarching goal of these sessions is to introduce different ways of managing emotional distress through imagery and stress reduction techniques. ST sessions focus on providing coping mechanisms for managing important symptoms of PTSD (i.e., hyperarousal, negative emotions, and physical symptoms).
214507404|NCT04304378|BEHAVIORAL|Stabilization Techniques with Behavioral Activation (ST+BA)|The Stabilization Techniques with Behavioral Activation intervention includes stabilization techniques as well as sessions targeted at increasing time engaged in physical activities during times outside of the intervention session. Preferred activities are selected by the participant. Strategies to foster engagement in the selected activities will include self-monitoring, structuring and scheduling daily activities, rating the degree of pleasure and accomplishment experienced during engagement in specific daily activities, exploring alternative behaviors related to achieving goals, and using role-play to address specific barriers. Establishing/maintaining routines and behavioral strategies to reduce avoidance and mange negative emotions are emphasized.
215023023|NCT04180423|DEVICE|Customized Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
215023024|NCT05625867|OTHER|Psychological and quality of life questionnaires|At 4/5 months and at 9 months
215023025|NCT05625867|OTHER|Interdisciplinary consultation at 4/5 months|About ten days after the questionnaires were administered
215023026|NCT03066518|DRUG|Melatonin 5 mg|
215023027|NCT03066518|OTHER|Placebo|
215023028|NCT00307580|DRUG|Cathflo Activase (Alteplase)|
215023029|NCT04887805|DRUG|Lenvatinib Mesylate|Given PO
215023030|NCT04887805|BIOLOGICAL|Pembrolizumab|Given IV
215023031|NCT06643962|DRUG|Venetoclax|Venetoclax in the EPBCRlow cohort will be added to the ongoing 3+7 regimen. In the first induction cycle: venetoclax needs to be ramped up: 100 mg on day 5, 200mg on day 6, and 400mg on days 7-14, orally once daily. In the second induction (if required), venetoclax 400mg will be administered orally once daily on days 5-14 without a dose ramp-up schedule. Venetoclax in the EPBCRlow cohort during consolidation therapy: 400mg on days 1-7, orally once daily, along with the consolidation chemotherapy.
215023032|NCT06643962|DRUG|Idarubincin|Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).
215023033|NCT06643962|DRUG|Cytarabine|During induction therapy: 100mg/m2/d on days 1-7, IV. During consolidation therapy: intermediate-dose cytarabine for age \>55 years old: 1.0g/m\^2 q12h on days 1-3, high-dose cytarabine for age ≦55 years old: 2g/m2 q12h on days 1-3.
215023034|NCT02926196|DRUG|MSB0010718C|MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
215023035|NCT05996068|DEVICE|arterial line|insert arterial line for patients who meet major trauma criteria
215023036|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White colored oval three-layer tablet
215023037|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White and pink colored oval two-layer tablet
215023038|NCT05510934|BEHAVIORAL|Shared-care model|A Shared care follow-up strategy involving patients, PCPs and specialists that uses an automated reminder system (TCARS).
215023039|NCT03153202|DRUG|Ibrutinib|once daily oral intake ibrutinib
215103074|NCT02372981|DEVICE|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
215103075|NCT02841462|DEVICE|Intra-bursal thermal ablation|A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
215103076|NCT01587235|DRUG|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
214423219|NCT04440046|OTHER|Manual therapy thoracic spine|Manual therapy mobilization directed to the costovertebral joint.
215023040|NCT03153202|DRUG|Pembrolizumab|200mg IV pembrolizumab on Day 1 of each cycle
215023041|NCT03201094|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular electrical stimulation twice daily during study period.
215023042|NCT03201094|DIETARY_SUPPLEMENT|High Protein Supplementation|High protein supplementation with whey protein shakes taken three times a day during study period.
215023043|NCT01540539|DRUG|REGN1154 or placebo|Participants will receive active drug or placebo
215023044|NCT03048825|DRUG|Colchicine|Colchicine 0.5 mg once daily
215023045|NCT03048825|DRUG|Spironolactone|Spironolactone 25 mg once daily
215023046|NCT03048825|DEVICE|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
215023047|NCT03048825|DRUG|Colchicine-Placebo|Matching Colchicine-placebo once daily
215023048|NCT03048825|DRUG|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
215023049|NCT00538265|DRUG|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
215103077|NCT01587235|DRUG|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
214423220|NCT04440046|OTHER|Manual therapy glenohumeral joint|Manual therapy mobilization directed to the glenohumeral joint.
214423221|NCT04440046|OTHER|Sham thoracic manual therapy|Sham manual therapy directed to the costovertebral joint.
214690778|NCT03167086|BEHAVIORAL|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
215023050|NCT00538265|DRUG|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)"
215023051|NCT00538265|DRUG|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
215103078|NCT00435851|DRUG|Thyrogen, thyroid hormone withdrawal, iode 131|
214507405|NCT04304378|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR is an exposure-based treatment that is the standard of care for PTSD delivered by the research team in Phnom Penh. EMDR utilizes sensory stimulation when participants are engaged in mental processing of traumatic material. EMDR follows a sequential framework targeting 1) past memories, 2) present symptoms, and 3) future actions.
214507406|NCT01372475|DEVICE|Hymovis Intra-articular Injection|Hymovis Intra-articular injection
214507407|NCT01372475|PROCEDURE|Phosphate Buffered Saline Injection|Placebo Intra-articular injection
214507408|NCT00949117|DIETARY_SUPPLEMENT|Ensure|Given orally
214507409|NCT00949117|DIETARY_SUPPLEMENT|PediaSure|Given orally
214507410|NCT00949117|DRUG|cyproheptadine hydrochloride|Given orally
214507411|NCT03926806|OTHER|Plain yoghurt|cups of 200 g yoghurt
214507412|NCT03926806|OTHER|Vitamin B yoghurt|cups of 200 g yoghurt
214507413|NCT04024982|OTHER|Sequence of teaching (Lecture first followed by Simulation)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
214507414|NCT04024982|OTHER|Sequence of teaching (Simulation first followed by Lecture)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
214507415|NCT02980432|OTHER|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
214507416|NCT03072745|DIAGNOSTIC_TEST|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
214507417|NCT00513123|PROCEDURE|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
214507418|NCT00620230|DRUG|NVP-VAK694|
214507419|NCT00620230|DRUG|NVP-VAK694|
214507420|NCT03306329|DRUG|DNS-7801 (low-dose)|DNS-7801 (low-dose) tablets administered once daily.
214507421|NCT03306329|DRUG|DNS-7801 (high dose)|DNS-7801 (high dose) tablets administered once daily.
214507422|NCT03306329|DRUG|Placebo|Placebo tablets administered once daily
214507423|NCT01505699|GENETIC|RNA analysis|
214690779|NCT01790737|DRUG|Cyclophosphamide|
214690780|NCT01790737|DRUG|Filgrastim|
214690781|NCT03255291|BEHAVIORAL|Risk Assessment App|The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.
214507424|NCT01505699|GENETIC|cytogenetic analysis|
214507425|NCT01505699|GENETIC|microarray analysis|
214507426|NCT01505699|OTHER|laboratory biomarker analysis|
214507427|NCT02211508|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
214507428|NCT00201045|OTHER|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
214507429|NCT00644501|DRUG|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
214690782|NCT03255291|BEHAVIORAL|Audio Recording - Sleep|-Participants imagine themselves improving sleep hygiene
214690783|NCT03255291|OTHER|Surveys|Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.
215023052|NCT00160875|DRUG|Irinotecan hydrochloride trihydrate|Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
215023053|NCT00160875|DRUG|Cisplatin|Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
215023054|NCT00420056|DRUG|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
215023055|NCT02069184|DRUG|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
215023056|NCT02069184|OTHER|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
215103079|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 1
214690784|NCT03255291|BEHAVIORAL|Audio Recording - Exercise|Participants imagine themselves improving exercise
215103080|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 2
215023057|NCT05848843|DRUG|Durvalumab|Given by vein (IV)
215023058|NCT05848843|DRUG|Adagrasib|Given by PO
215023059|NCT00870155|DRUG|dirucotide|500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
214507430|NCT01214200|DEVICE|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
214507431|NCT00721097|OTHER|spirometry, and blood taken|each month during one year
215023060|NCT01292538|DEVICE|Erchonia GLS|532 nm green diode low level laser light device
215023061|NCT01292538|DEVICE|Placebo laser|Sham light output with no therapeutic benefit
215023062|NCT00907088|OTHER|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
215023063|NCT00907088|OTHER|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
215023064|NCT00986895|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
215023065|NCT00029900|DRUG|ADI PEG|
215023066|NCT06254690|DRUG|Pyrotinib dose escalation|Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
215023067|NCT06254690|DRUG|Pyrotinib dose normal|Pyrotinib: 400mg per week, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
215023068|NCT03179709|BEHAVIORAL|Interview|The investigators will perform and analyze semi-structured interviews with enrolled participants.
214507432|NCT01719172|DEVICE|Veriset™ Hemostatic Patch|Topical Hemostat
214507433|NCT05944666|PROCEDURE|Multimodal technology (MT)|"Only fo the patients of the Main group. It will be different programms depending on severety of UL or LL paresis. Patients will receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, in moderate paresis of the upper limb, the neurointerface Exokist-2 with EEG registration will be used. The program for IS patients includes 10 sessions in inpatient stage every day 15-30 min for the method, 15 sessions with the MT in outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
214507434|NCT05944666|PROCEDURE|Conventional rehabilitation|It will be different programms depending on severety of UL or LL paresis. Conventional rehabilitation (CR) includes physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients consists of 10 sessions of every day trainings for inpatients stage, 15 sessions with the CR for outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
215023069|NCT03673722|OTHER|Foods consistent with a MDP|We aim to increase MDP by 3 points, according to a 14-point MEDAS score
215023070|NCT03673722|OTHER|Physical Activity|We aim to increase PA to 150 minutes moderate activity per week.
215023071|NCT03673722|OTHER|Control|Participants will be given generic healthy eating advice based
215023072|NCT02301793|BEHAVIORAL|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
215023073|NCT02301793|BEHAVIORAL|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
215103081|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Tes Lens 3
215103082|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 4
215103083|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Control Lens
215103084|NCT01854424|OTHER|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
214507435|NCT03100188|OTHER|modified PD prescription|For patients on CAPD, fewer daily exchanges or fewer total weekly exchanges are prescribed. Patients on CCPD are prescribed shorter cycler time or fewer total cycles during the week.
214507436|NCT05825274|DEVICE|Cathodal tDCS|We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
214507437|NCT00770874|DRUG|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
214507438|NCT00770874|DRUG|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
214507439|NCT04250636|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30mg/kg
214507440|NCT04250636|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 30mg/kg
215023074|NCT04281771|PROCEDURE|cardiac MRI|"Patients are studied on a clinical 1.5 Tesla scanner with cardiac radiofrequency receiver coil centered over the heart, and ECG monitoring. The following parameters are assessed:~Functional imaging: ECG-gated cine Steady-state free precession (SSFP) MRI images are obtained during repeated breath holds in long axis and short axis orientations covering the entire left ventricle. Global systolic and diastolic function are assessed, and left ventricular mass is calculated.~Flow imaging: ECG-gated 2D flow measurements are assessed above the prosthetic valve, and at the level of the pulmonary trunk."
214507441|NCT04062396|DEVICE|Eurosets REMOWELL 2 oxygenator|The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
214507442|NCT04062396|DEVICE|LivaNova INSPIRE oxygenator|INSPIRE oxygenator has no filtration system for extracavitary inlet
214507443|NCT02433587|DRUG|Aspirin|Patients will take Aspirin 81 mg
215023075|NCT00544687|DRUG|CRx-191|topical (mometasone furoate + nortriptyline HCl)
215023076|NCT00544687|DRUG|mometasone furoate|topical mometasone furoate
215023077|NCT00544687|DRUG|nortriptyline HCl|topical nortriptyline HCl
214423222|NCT04440046|OTHER|Sham glenohumeral manual therapy|Sham manual therapy directed to the glenohumeral joint.
214423223|NCT04440046|OTHER|Therapeutic exercise|Therapeutic exercise program consisting on isometric exercise with progressive load.
214423224|NCT04439799|DRUG|Testosterone Cypionate 200 Mg/ML|Participants in this group will receive intramuscular testosterone cypionate injections of 1 cc (200mg) once every 14 days for four months.
214423225|NCT04439799|DRUG|Intranasal Testosterone|Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
214423226|NCT05565391|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
214507444|NCT02433587|DRUG|Clopidogrel|Patients will take Clopidogrel 75 mg
214507445|NCT04024176|OTHER|Gait analysis|The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
214507446|NCT04598594|DRUG|Patch, Nicotine|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
214690785|NCT03255291|OTHER|Text message reminders|-Reminders to practice mental imagery
214690786|NCT03255291|OTHER|Text Message Survey|-Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.
214690787|NCT06085846|DEVICE|Vivally® System Wearable, Non-Invasive Neuromodulation System, and Mobile Application|Vivally® System Wearable, Non-Invasive Neuromodulation System and Mobile Application to treat patients with the conditions of urinary incontinence and urinary urgency.
215023078|NCT00544687|DRUG|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
215023079|NCT00544687|DRUG|Vehicle|topical (placebo)
215023080|NCT02477046|BIOLOGICAL|tOPV|administered per protocol
215023081|NCT02477046|BIOLOGICAL|bOPV|administered per protocol
215023082|NCT02477046|BIOLOGICAL|IPV|administered per protocol
215023083|NCT01435746|BEHAVIORAL|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
215023084|NCT04023474|PROCEDURE|Platelet Rich Fibrin (PRF) Application|Platelet Rich Fibrin application to flap defect.
215023085|NCT01885338|DRUG|N-acetylcysteine (NAC)|
215023086|NCT01885338|DRUG|Inactive placebo capsule|
215023087|NCT04978831|DEVICE|PEP Device|The breathing exercise device is a device that simulates pursed-lip breathing by creating positive expiratory pressure (PEP). Before starting to use the device, it will be explained that they need to put the mouthpiece on the device and put the nose clip on their nose, and the participants will be shown how it is done. The device will be used at 5 cmH2O pressure. A single exercise session consists of 3 exercise cycles, and a single exercise cycle consists of 15 breathing-exhalation activities. Participants will complete 3 cycles (a total of 45 inhales and exhales) in a single session. 1 loop lying on the left side, 1 loop lying on the right side, and 1 loop in sitting upright position. Participants held these sessions in the morning, afternoon, and evening. After completing each cycle, the participants will remove their nose clips and cough 2-3 times. Each participant will perform a total of 135 breathing exercises in one day.
214507447|NCT04598594|DRUG|Patch, Placebo|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
214690788|NCT06459531|BEHAVIORAL|Virtual Reality (VR) Therapy|"Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
214423227|NCT05565391|DRUG|Standard of care|Standard of care
214423228|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 20mg
214423229|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
214423230|NCT00362206|DRUG|Pravastatin|Pravastatin 40 mg
214423231|NCT02716324|BEHAVIORAL|Care Manager CM)|The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
215023088|NCT04978831|OTHER|Reading Aloud|"The patients in this group were given a book that they chose from among the book types within the scope of the study, according to their wishes. For the selection of books, opinions were taken from the experts in the education faculty of the same university and it was stated that any book separation was not important. The books that the participants wanted to read were provided by the researcher. They were asked to read this book aloud during the day, sitting upright on a chair or sofa, for 15 minutes, three times a day.~They were able to stop reading when the participant was tired or felt too short of breath to continue reading."
215023089|NCT01062295|DEVICE|Siesta-System|
215023090|NCT01062295|DEVICE|Standard headrest|
215103085|NCT00848224|BEHAVIORAL|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
215103086|NCT04599595|DEVICE|Peristeen (Coloplast)|"Patients with severe intestinal dysfunction impairment (PAC QoL score ≥ 32) will be offered the adoption of the TAI (Transanal Irrigation) with Peristeen Device as a way to manage their own evacuation, replacing any other measure used until that moment (suppositoires, clisms exceptionally cc) with the exception of the possible intake of macrogols and/or prebiotics and/or probiotics which instead patients can continue. This treatment will be proposed to all patients with severe impairment of intestinal function.~The TAI training with Peristeen will be carried out at the surgical clinic of the Surgical Department of the Ferrara University Hospital, Italy, by the health personnel involved in the study, usually in a single session, but more sessions may be necessary, with the continuation of the TAI for 4 weeks or with patient's exclusion from the study if the guarantees of appropriate use of the device will not be reached."
215103087|NCT05626127|OTHER|No interventions|As this is a observational study, there are no interventions.
215103088|NCT03905902|BIOLOGICAL|DCVAC/OvCa|activated autologous dendritic cells
215103089|NCT03905902|BIOLOGICAL|DCVAC/OvCa placebo|placebo for activated autologous cells
215103090|NCT05018104|OTHER|This is not an interventional study|This study utilizes data from the St. Paul's Hospital Peripheral Nerve Block Database.
215103091|NCT05073198|OTHER|Education brochure|In the content of the brochure about testicular cancer and CCTM prepared in line with the literature; It includes information such as the definition of testicular cancer, testicular cancer risk factors and symptoms, the importance of early diagnosis in testicular cancer, how CCTM is performed, and what to do in case of differences after the examination. Expert opinion was obtained from three faculty members (a professor from the Department of Urology, a professor in Public Health Nursing and a physician faculty member) regarding the content validity of the educational brochure created before the research.
215103092|NCT06128122|PROCEDURE|Intrarticular and subcutaneous dextrose injection with timed measurement of dextrose levels|"Step one: 30 mL of 12.5%/0.1% lidocaine will be injected into the knee using an inferomedial approach. Using ultrasound guidance, a 20-gauge 2-inch I.V. catheter will be placed in the suprapatellar pouch, by which samples of synovial fluid from the pouch will be withdrawn and analyzed for glucose level.~Step two: 3 mL of D5W will be injected into a marked spot on the back of the upper arm. A sensor/transmitter (Dexcom G7 Dexcom) is placed at the site of injection. The sensor/transmitter will begin providing dextrose levels at 5 minute intervals beginning one-half hour after placement of the sensor/transmitter, transmitted to a paired smart phone."
214507448|NCT01874964|BEHAVIORAL|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
214507449|NCT01874964|BEHAVIORAL|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
214507450|NCT02199626|DEVICE|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
214507451|NCT01730456|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
214507452|NCT03963466|DRUG|tranexamic acid|Oral tranexamic acid group(menstrual period\>2days) 250mg bid（exclude menstrual period ）
214507453|NCT03963466|RADIATION|1064-nm Q-Switched fractional laser|Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
214507454|NCT03963466|RADIATION|1064-nm Q-Switched laser|Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
214507455|NCT05582824|OTHER|Blood and urine test|Daily blood and urine samples
214507456|NCT03185936|PROCEDURE|pars plana vitrectomy with internal limiting membrane (ILM) peeling|pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
215023091|NCT02261142|DEVICE|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
215023092|NCT02472951|OTHER|Low carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%"
215023093|NCT02472951|OTHER|Standard carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%"
215023094|NCT06469580|OTHER|NPLUS (neonatologist performed lung ultrasound)|"NPLUS is conducted with an ultrasound scanner using a high-frequency (12-15 MHz) linear transducer probe (scanning depth approximately 4-5 cm). The neonate is placed in a supine position. The anterior, lateral and posterior chest areas are scanned using the presets lung or small parts. Landmarks are the anterior and posterior axillary line (longitudinal) on each hemithorax. A sequential scan from right to left, anterior to posterior is performed. (6 lung areas). In the study NPLUS is performed to quantify the lung ultrasound score at time points T0, T1 and T2. Sequences of 3-5 seconds are saved and assessed according to the lung ultrasound score adapted by Rodriguez-Fanjul et al. (0- to 3 point score for each area, resulting in a total score ranging from 0 to 18). To ensure inter-observer reliability the anonymous video sequences are then rated by two independent neonatologists."
215103093|NCT05669651|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from healthy people's feces into patients' intestines to rebuild new intestinal flora and achieve the treatment of intestinal and parenteral diseases. In this study, 100 patients with recurrent hepatic encephalopathy were randomly divided into 1:1 groups to receive FMT with different amounts of bacteria, observe the therapeutic effect and adverse reactions of hepatic encephalopathy, and evaluate the effectiveness and safety of the two groups of patients. At the same time, the blood and stool samples of patients with recurrent hepatic encephalopathy before and after FMT were collected clinically, the composition of bile acid and other metabolites in stool and serum samples was analyzed, and the effective core flora was identified to clarify the mechanism of intestinal bacteria transplantation for the treatment of recurrent hepatic encephalopathy.
215103094|NCT05660447|DRUG|Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]|One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
215103095|NCT05660447|DRUG|Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud|Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
215103096|NCT04427449|BIOLOGICAL|CD44v6-specific CAR gene-engineered T cells|4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10\^6 cells/kg body weight
214507457|NCT03041090|DEVICE|Lucerno ID (identification) System|The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
214507458|NCT00082966|DRUG|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|Given IV
214507459|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 200mg
214507460|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 300mg
214507461|NCT04880018|DEVICE|Capsular Tension Ring|Experimental group uses Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd;control group uses Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd
214507462|NCT00853528|OTHER|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
214507463|NCT00853528|PROCEDURE|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
214507464|NCT00853528|PROCEDURE|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
214507465|NCT00853528|RADIATION|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
214507466|NCT00853528|RADIATION|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
214507467|NCT04185818|OTHER|Reading a book|"Participants requested to specify usual genre of book they read.~1. Fiction~2. Non-Fiction~3. Other~4. Don't usually read a book in bed"
214507468|NCT01353274|DRUG|Micamlo|Telmisartan plus Amlodipine T40/A5
214507469|NCT04514562|DEVICE|NeVa Stent Retrievers|mechanical neurothrombectomy
214507470|NCT05075499|BIOLOGICAL|COVID-19 vaccination|Blood sample obtained before, 1 , 3 and 6 months after the intervention
214507471|NCT02431767|BIOLOGICAL|PENNVAX®-GP HIV-1 DNA vaccine|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
215023095|NCT05200780|DEVICE|ultrasound|All subjects will undergo the tests with the same machine. Transverse ultrasound images were obtained using the Philips HD with a 4-12 MHz probe. in neurosonology unit in neurology department.
215023096|NCT02473263|DRUG|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
215023097|NCT02473263|DRUG|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
215023098|NCT02473263|DRUG|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
214507472|NCT02431767|BIOLOGICAL|Interleukin-12 (IL-12) DNA adjuvant|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
214507473|NCT02431767|BIOLOGICAL|Placebo|Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
214507474|NCT00944541|DRUG|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
215023099|NCT02473263|DRUG|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
215023100|NCT01433003|PROCEDURE|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
215023101|NCT02838706|PROCEDURE|Surgery for hip fracture|
214507475|NCT03649191|OTHER|The BABEL Approach to Advance Care Planning in Nursing Homes|In intervention nursing homes, eligible residents will: (i) receive The BABEL Approach to Advance Care Planning (ACP), (ii) after these ACP discussions occur, the resident's primary care physician will be notified of the residents' ACP wishes, (iii) a brightly colored document will be placed in a standard location of the NH chart that identifies the resident's ACP wishes, (iv) paramedics will be educated to know about these sheets and where to find them, and that they should be taken with any resident transferred to another care setting.
215023102|NCT01292993|DRUG|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
215023103|NCT01292993|DRUG|1000 mg metformin|1000 mg metformin given as a solid oral dose form
215023104|NCT01446510|OTHER|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
215023105|NCT01044459|DRUG|Aclidinium Bromide 200 µg|aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
215023106|NCT01044459|DRUG|Aclidinium Bromide 400 µg|aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
215023107|NCT05154929|BEHAVIORAL|Dietary and physical activity JITAI delivered through the myBPmyLife app|A Fitbit smartwatch and home blood pressure monitor will be mailed to participants (in both the experimental and control arms). Participants in the intervention arm then will set up and utilize the myBPmyLife app. This app includes push notifications to promote increased physical activity and improve low-sodium food choices, establish goal setting for weekly step count and low sodium food choices, and deliver feedback on achieving the goals using a dashboard visualization within the mobile application.
215023108|NCT05154929|OTHER|Control Group|Participants will receive the myBPmyLife app, a smartwatch, and blood pressure cuff. The myBPmyLife app will not be fully activated (as they are in the control arm). They will be provided with the option of downloading and installing a mHealth app that is publicly available. In this arm they will also perform the blood pressure monitoring, but do not receive the intervention components through the myBPmyLife app.
215023109|NCT01029964|BEHAVIORAL|Individually and in groups|During three year in a clinical setting.
215023110|NCT05127785|PROCEDURE|LVAD or Heart Transplant|Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation
215023111|NCT02856373|PROCEDURE|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
215023112|NCT01095965|BEHAVIORAL|Nutrition education|Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
215023113|NCT04582643|BEHAVIORAL|6P intervention|6P assessment targeting on diet, activity and mentality, along with education provided based on the 6P components. The 6P tool serves the functions to help the women to self-monitor and be aware of their negative lifestyle choices.
214507476|NCT03649191|OTHER|Control group Advance Care Planning|Eligible residents in each control nursing homes will receive the prevalent approach to Advance Care Planning in that nursing home. No elements of The BABEL Approach to Advance Care Planning will be introduced in the control homes.
214507477|NCT00978159|DRUG|esomeprazole|esomeprazole 20 mg po for 4 weeks
214507478|NCT00978159|DRUG|Famotidine|Famotidine 40 mg po for 4 weeks
215023114|NCT04105725|BEHAVIORAL|Brief Motivational Intervention+Substance-Free Activity Session|A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.
215023115|NCT04105725|OTHER|Alcohol + Nutrition Education Session|Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
215103097|NCT02488993|OTHER|Prospective Phase Rifaximin-α 550mg|Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
215103098|NCT02488993|OTHER|Prospective Phase No Rifaximin-α 550mg|Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
215103099|NCT02488993|OTHER|Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
215103100|NCT05934864|GENETIC|84-gene penal|84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
214507479|NCT00237120|DRUG|Imatinib|
215103101|NCT00012168|DRUG|isosulfan blue|
215103102|NCT00012168|GENETIC|polymerase chain reaction|
215103103|NCT00012168|OTHER|immunohistochemistry staining method|
215103104|NCT00012168|PROCEDURE|lymphangiography|
215103105|NCT00012168|PROCEDURE|radionuclide imaging|
215103106|NCT00012168|PROCEDURE|sentinel lymph node biopsy|
215103107|NCT00012168|RADIATION|technetium Tc 99m sulfur colloid|
215103108|NCT02217917|DRUG|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
215103109|NCT02217917|DRUG|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
214423232|NCT02716324|OTHER|ADHD Portal|The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
214423233|NCT00099619|DRUG|exenatide/insulin glargine|Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
214423234|NCT00099619|DRUG|insulin glargine/exenatide|Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
214423235|NCT03753594|DEVICE|tissue oxygenation saturation|tissue oxygenation saturation
214423236|NCT03709719|DRUG|Blinatumomab Injection|Blinatumomab 28 μg/day : D1 to D28
214507480|NCT01409837|DRUG|Lisinopril|"The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis."
214507481|NCT03960645|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
214507482|NCT01481974|DRUG|Treprostinil|"The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design."
214507483|NCT01130298|DRUG|Testosterone Gel 1.62%|5 grams
214507484|NCT00130182|DRUG|denufosol tetrasodium (INS37217)|
214507485|NCT03739606|BIOLOGICAL|Anti-CD123/CD3 Monoclonal Antibody MGD006|Given IV
214507486|NCT04224415|DRUG|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
214507487|NCT06390449|OTHER|Kahoot intervention|Kahoot, one of the WEB-2.0 tools, will be applied to students who are second-year students of the nursing department and taking the basic principles and practices in nursing course after the course.
214507488|NCT05206058|PROCEDURE|venipuncture|Plan to enroll 240 health people who are 20-35 years of age. People with received veinpuncture. Blood will be collected at time and drawn into Heparin-coated tube.
214507489|NCT03292406|DRUG|Placebo|Non active ingredients of CD11301
214507490|NCT03292406|DRUG|CD11301 0.03%|Topical Gel
214507491|NCT03292406|DRUG|CD11301 0.06%|Topical Gel
214507492|NCT02605850|OTHER|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
214507493|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
214507494|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
214507495|NCT03720249|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.
214507496|NCT03720249|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.
214507497|NCT02056847|DRUG|Pitavastatin calcium 4mg|taking once a day
214507498|NCT02056847|DRUG|Pitavastatin calcium 2mg|Taking once a day
214507499|NCT01992965|OTHER|Different methods of blood glucose monitoring between groups|Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
214507500|NCT06050941|DRUG|idarubicin|Idarubicin 6mg/m2 d5-7
214507501|NCT06050941|DRUG|Cytarabine|Cytarabine 60mg/m2 d5-9
214507502|NCT00403494|OTHER|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
214507503|NCT00403494|DRUG|Sapropterin Dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
215103110|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
215103111|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
215103112|NCT02217917|DRUG|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
215103113|NCT00865319|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
215103114|NCT00865319|RADIATION|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
215103115|NCT04619355|DEVICE|NIRS-IVUS|Near-infrared spectroscopy-intravascular ultrasound can be implemented in parallel with intravascular ultrasound and provides important information for predicting prognosis by measuring the lipid component of atherosclerotic plaques.
215103116|NCT04411745|OTHER|No intervention, observational study|
214690789|NCT06459531|OTHER|Conservative Treatment|"Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
214690790|NCT04898426|OTHER|Enhanced bowel preparation instruction|Automated delivery of SMS, pre-recorded phone call, and link to an information website.
214690791|NCT00219765|DRUG|Imatinib mesylate 600 mg|
214690792|NCT00219765|DRUG|Cytarabine|
214690793|NCT00219765|DRUG|Daunorubicine|
214507504|NCT03744026|DEVICE|SonoCloud-9|Escalating numbers of ultrasound beams at constant acoustic pressure
214507505|NCT03744026|DRUG|Carboplatin|Dose of carboplatin infusion is AUC4-6
214507506|NCT02693288|PROCEDURE|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
214507507|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
214507508|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
215023116|NCT04195256|DRUG|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
215023117|NCT04195256|DRUG|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
215023118|NCT04195256|DRUG|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
215023119|NCT04195256|DRUG|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
215023120|NCT01498380|DRUG|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease \< 20% or blood pressure decrease/increase \< 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease \>/= 20% or SBP/DBP/MAP decrease or increase \>/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
215023121|NCT04879485|BIOLOGICAL|Blood products|Compare two different transfusion strategies against standard transfusion regimen
215023122|NCT06491576|DRUG|BGT-002|taking the study drug orally
215023123|NCT06491576|DRUG|Placebo|taking the placebo orally
215103117|NCT00852501|OTHER|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
215103118|NCT02501525|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
215103119|NCT02501525|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
214507509|NCT02731066|OTHER|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
215103120|NCT02604914|DRUG|ND0612|Subcutaneous solution
214507510|NCT02731066|OTHER|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
215103121|NCT02604914|DRUG|LCIG|Intrajejunal Gel
214507511|NCT02731066|OTHER|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.
215103122|NCT06066008|DRUG|ZM-01-L|rAAV-hRS1 intravitreal injection of low dose
215103123|NCT06066008|DRUG|ZM-01-H|rAAV-hRS1 intravitreal injection of high dose
215103124|NCT01506661|DRUG|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
215103125|NCT01221493|PROCEDURE|Cryo biopsy|Cryoprobe, Erbe Company
214507512|NCT02731066|OTHER|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
214507513|NCT00357019|DRUG|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
214507514|NCT02542332|OTHER|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
214690794|NCT05348265|OTHER|Low Intensity steady state training|Intervention will be provided for a period of 8 weeks. For the first 4 weeks the intervention will consist of 35-40 minutes of supervised slow paced treadmill walk, five days a week. From week 5 till 8 the intervention will consist of 50-60 minutes of supervised slow paced treadmill walk, five days a week.
215103126|NCT00793130|DIETARY_SUPPLEMENT|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
215023124|NCT05864716|BIOLOGICAL|Colonscopic probiotics spray|20g of multi-strain probiotics powder via colonoscopic spray. The probiotic used in this study is SynPro-15G, which has 15 probiotics, including Bacillus coagulans BC1031, Bifidobacterium bifidum BB14, Bifidobacterium breve BR18, Bifidobacterium animalis subsp. lactis BAL06, Bifidobacterium longum (B. longum) BL986, Lactobacillus acidophilus LA1063, Lactobacillus casei LC122, Lactobacillus delbrueckii subsp. lactis LDL114, Lactobacillus fermentum LF26, Lactobacillus helveticus LH43, Lactobacillus paracasei LPC12, Lactobacillus plantarum LP198, Lactobacillus reuteri LR21, Lactobacillus rhamnosus LRH10, and Streptococcus thermophilus ST37 at a concentration of 2x1010 CFU/g (Synbiotech Corp., Kaohsiung, Taiwan). SynPro-15G is made either as a vial of powder (2x1011 CFU /vial) for colonoscopic spray or as a capsule (2x1010 CFU/capsule) for oral intake.
215023125|NCT04190771|BEHAVIORAL|TAU + multicomponent treatment NAT-FM|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30 min.)~* Mindfulness techniques (30 min.)~* Physical exercise in a natural environment / nature exposure (30 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
215023126|NCT04190771|BEHAVIORAL|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
215103127|NCT00873184|BEHAVIORAL|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
214423237|NCT04962906|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.
214423238|NCT00530842|DRUG|Tiotropium plus Salmeterol|
214423239|NCT00530842|DRUG|Fluticasone/Salmeterol|
214423240|NCT00027820|DRUG|Fludarabine Phosphate|Given IV
214423241|NCT00027820|RADIATION|Total-Body Irradiation|Undergo TBI
214423242|NCT00027820|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
214423243|NCT00027820|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
214423244|NCT00027820|DRUG|Cyclosporine|Given PO
214423245|NCT00027820|DRUG|Mycophenolate Mofetil|Given PO
214423246|NCT04558437|OTHER|Questionnaire|"Questionnaire at M0 M3 M6:~PCL-5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) HAD (Hospital Anxiety and Depression Scale) SDS (Sheehan Disability Scales)"
214423247|NCT02533635|DIETARY_SUPPLEMENT|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
214423248|NCT03653013|BEHAVIORAL|Usual standard of care|Participants will receive treatment and diabetes management as usual standard of care from their diabetes care team. They will also complete as part of the study visit: a pediatric quality of life scale(PedsQL,GenericScale and Diabetes Module) and diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study.
214423249|NCT03653013|BEHAVIORAL|Neuropsychological Consultation|Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL,Generic Scale and Diabetes Module),diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
214423250|NCT02534350|DRUG|Presatovir|Tablets administered orally or via nasogastric (NG) tube once daily
214423251|NCT02534350|DRUG|Placebo|Tablets administered orally or via NG tube once daily
214423252|NCT01714193|DRUG|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
214507515|NCT03851094|BEHAVIORAL|Wellth app|The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
214507516|NCT00712413|DRUG|OBMT|Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
214423253|NCT01714193|DRUG|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
214507517|NCT01784809|BEHAVIORAL|Multimedia WORTH|"The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. \*\*\*To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation"
215023127|NCT03818971|OTHER|electroretinogram (flash, pattern and multifocal)|we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
215023128|NCT00480025|BIOLOGICAL|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
215023129|NCT00480025|BIOLOGICAL|Placebo Control|Intramuscular administration, 13 doses
215023130|NCT01310114|BIOLOGICAL|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
215103128|NCT04165629|DRUG|Aspirin 300mg and Clopidogrel 300mg|Aspirin 300mg and Clopidogrel 300mg on the day of the PTA
215103129|NCT01424033|DRUG|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
215103130|NCT00566254|DRUG|Zonisamide|8mg/kg per day for approximately 24 weeks.
215103131|NCT00566254|DRUG|Placebo|
215023131|NCT01310114|DRUG|Placebo|Thawed placebo
215023132|NCT04920825|DIETARY_SUPPLEMENT|Sacha Inchi Oil softgel supplement|A twice daily supplementation of Sacha Inchi Oil softgel for 12 weeks
214423254|NCT03215251|OTHER|Intervention bundle|Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
214423255|NCT05270551|PROCEDURE|ACL Reconstruction|All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program
214423256|NCT03758950|DRUG|Placebo|Once daily inhaled placebo for 48 weeks
214423257|NCT03758950|DRUG|Mometasone|Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
214507518|NCT01784809|BEHAVIORAL|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
214507519|NCT01784809|BEHAVIORAL|Wellness Promotion|
214507520|NCT06020300|DRUG|Oral Colchicine 0.6 mg|Anti-Inflammatory Effects
214507521|NCT06020300|DRUG|Oral Pyridoxine 10 mg|Colchicine look alike placebo
214507522|NCT05159271|DEVICE|Azeol spray nasal|Azeol Spray Nasal is a nasal spray intended to reduce the nasal congestion due to rhinitis, rhinosinusitis and colds which is marketed. The ID is conforming to the European Union (EU) legislation and is bearing the CE-mark. The ID is manufactured by PILEJE S.A.S (France).
214507523|NCT05159271|DEVICE|Placebo nasal spray|with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
214507524|NCT02022293|DRUG|Atorvastatin|Patients in this group will take 20mg per night.
214507525|NCT02022293|OTHER|Placebo|
214507526|NCT02196610|OTHER|Applanation tonometry|Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
215023133|NCT04920825|DIETARY_SUPPLEMENT|Corn oil softgel|A twice daily supplementation of Corn Oil softgel for 12 weeks (Placebo)
215023134|NCT05940649|PROCEDURE|Continuous norepinephrine administration|In patients randomized to continuous norepinephrine administration, hypotension (= mean arterial pressure \< 65mmHg) will be treated with continuous norepinephrine infusion. The norepinephrine perfusion line will be connected to the saline infusion line using a three-way valve. Treating anesthesiologists will be free to reduce or increase the norepinephrine infusion rate anytime.
214507527|NCT02734706|DIETARY_SUPPLEMENT|LRC™ capsule|Twice per day (BID), 9 weeks
215023135|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 50U|"Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline"
215023136|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 100U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
215023137|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 200U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
215103132|NCT00238238|BIOLOGICAL|rituximab|Given IV
215103133|NCT00238238|DRUG|lenalidomide|Given orally
215103134|NCT03458689|PROCEDURE|Left hemicolectomy, laparoscopic technique|Left hemicolectomy, Laparoscopic technique
214507528|NCT02734706|OTHER|Placebo capsule|Twice per day (BID), 9 weeks
214507529|NCT02086461|DEVICE|Pneumatic pyloric dilatation|
214507530|NCT02086461|OTHER|15 mm pyloric balloon dilatation|
215023138|NCT06480461|DRUG|VGN-R09b|This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
215023139|NCT00103701|DRUG|Dasatinib|Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
215023140|NCT00966446|DRUG|Unsupervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
215023141|NCT00966446|DRUG|Supervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
215023142|NCT02189629|DRUG|CD5789 (trifarotene)|
214423258|NCT01510041|OTHER|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
215023143|NCT01043029|DRUG|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
215023144|NCT01043029|DRUG|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
214423259|NCT01510041|OTHER|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
215023145|NCT03726879|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
215023146|NCT03726879|DRUG|Placebo|Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
215023147|NCT03726879|DRUG|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
214507531|NCT01536704|DRUG|Nicotine (2 mg)|2 mg nicotine lozenge in two formulations
215023148|NCT03726879|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
215023149|NCT03726879|DRUG|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
214507532|NCT01536704|DRUG|Nicotine (4 mg)|4 mg nicotine lozenge in two formulations
214507533|NCT02680015|BEHAVIORAL|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
214507534|NCT00986752|DEVICE|Stenting (Smart Stent)|Nitinol stent
214507535|NCT00986752|DEVICE|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
214507536|NCT00986752|PROCEDURE|Atherectomy (SilverHawk device)|Atherectomy
214507537|NCT00047385|DEVICE|low-dose helical computed tomography|A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.
214507538|NCT00047385|DEVICE|chest radiography|The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
214507539|NCT00057499|BIOLOGICAL|IBC-VS01|IBC-VS01
214507540|NCT00057499|BIOLOGICAL|IBC-VS01 placebo|IBC-VS01 placebo
214507541|NCT03490032|DRUG|[68Ga]-PSMA-R2|radio-labelled PSMA ligand
214507542|NCT02343666|BIOLOGICAL|C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs|Given IV
214507543|NCT02343666|DRUG|Carmustine|Given IV
214507544|NCT02343666|BIOLOGICAL|Filgrastim|Given SC
214507545|NCT02343666|OTHER|Laboratory Biomarker Analysis|Correlative studies
214507546|NCT02343666|DRUG|O6-Benzylguanine|Given IV
214507547|NCT02343666|DRUG|Plerixafor|Given SC
214507548|NCT01040312|DRUG|CPT-11|CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
214507549|NCT01040312|DRUG|Platinum analogues|Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
214507550|NCT00416975|OTHER|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
214507551|NCT00416975|OTHER|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
215023150|NCT03726879|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
214423260|NCT04330469|PROCEDURE|Periodontal therapy|"Treatment will be performed by a periodontist.~1. Intensive removal of subgingival and supragingival calculus and plaque biofilm by scaling, root-planing and polishing. The procedures will be carried out with the use of hand scalers and a piezoelectric ultrasonic scaler with universal tips. Disclosing solution will be used to visualize the plaque for the clinician.~2. One to four sessions of subgingival scaling and root planing by quadrant, under local anesthesia as may be deemed necessary during the study period.~3. Subgingival irrigation using an antiseptic mouth rinse (chlorhexidine 0.12%).~4. Polishing of the coronal and radicular surfaces of the teeth."
214423261|NCT04330469|PROCEDURE|Oral hygiene advice|Oral hygiene advised by Periodontist
215023151|NCT03726879|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
215023152|NCT03726879|DRUG|Trastuzumab Emtansine|Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
215023153|NCT02766478|DRUG|Genistein|Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
215023154|NCT02766478|DRUG|Placebo|A placebo pill will be taken orally for 12 weeks.
215023155|NCT05626686|DEVICE|CLINY catheter|Subjects using a single use catheter for bladder management at inclusion. During the study period, subjects will use the reusable CLINY catheter for 28 test-days
215023156|NCT00944840|DRUG|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
215023157|NCT00944840|DRUG|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
215023158|NCT01093573|DRUG|midostaurin|Given orally
215023159|NCT01093573|DRUG|azacitidine|Given IV
215023160|NCT01093573|OTHER|bone marrow aspiration|Correlative study: Pretreatment bone marrow aspirates or blood \[(3 ml in EDTA tube (purple top)\] will be analyzed according to local institution guidelines to determine whether blasts contain wild type Flt3, ITD, or Flt 3 mutations.
215023161|NCT01093573|OTHER|mutation analysis|Correlative study
215023162|NCT01093573|OTHER|Pharmacokinetic study|Correlative study: Concentrations of unchanged midostaurin and its major metabolites, CGP52421 and CGP62221 in plasma samples will be determined using a validated liquid chromatography / mass spectrometry method.
215023163|NCT06290037|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
215023164|NCT06290037|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
215023165|NCT06290037|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
214423262|NCT03068858|DIAGNOSTIC_TEST|real-time feedback of SYNTAX score category|
214423263|NCT00431431|DRUG|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
214423264|NCT00431431|DRUG|raloxifen|2 years treatment with raloxifene (60 mg)
215023166|NCT06290037|OTHER|Short Physical Performance Battery|Evaluation of functional capability and provide a measure of the biological age of an older individual by measuring lower extremity physical performance status(standing balance, walking speed, and chair stand tests).
215023167|NCT06290037|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
215023168|NCT00023972|DRUG|exatecan mesylate|
215023169|NCT00023972|DRUG|gemcitabine hydrochloride|
214423265|NCT05692947|DEVICE|Core body temperature device|This study is to verify the claims of CORE™ body temperature system to estimate core body temperature from skin temperature and heart rate during exercise under varying environmental conditions. Subjects will ingest a temperature sensing pill and be outfitted with skin temperature sensors, a chest strap heart rate monitor, and the CORE and CaleraResearch devices. Athletes will run or cycle in hot/dry and hot/humid conditions for 45 minutes at an absolute workload of 60% VO2 Max/Peak.
214423266|NCT04673851|DEVICE|Horyzons USA|Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.
215023170|NCT04107285|BEHAVIORAL|neurocognitive evaluations|The test battery consists of validated and reliable measures of attention, executive functions and memory.
215023171|NCT04107285|DIAGNOSTIC_TEST|brain MRIs|Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).
215023172|NCT04107285|OTHER|Blood samples|Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
215023173|NCT03708770|DEVICE|everlinQ endoAVF System|
215023174|NCT05253326|OTHER|Progressive Muscle Relaxation Exercises|It is among the relaxation techniques that require the active participation of the individual.
215023175|NCT04875845|BEHAVIORAL|Fasting for elective surgery|6-hours and 8-hours fasting before elective surgery
215023176|NCT04444297|OTHER|3D Telemedicine|A consultation performed with a 3D form of telemedicine
215023177|NCT04444297|OTHER|2D Telemedicine|A consultation performed with 2D (standard) telemedicine
215023178|NCT04924452|PROCEDURE|Laser conditioning and Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; laser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-tissue distance 1.5mm from the tooth surface; tip diameter 600 µm; laser energy 70 mJ; pulse frequency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm2; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
215023179|NCT04924452|PROCEDURE|Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
215103135|NCT03731078|OTHER|CBT Informed physical therapy Intervention|The 12 physical therapy sessions delivered in Massachusetts General Hospital outpatient physical therapy sites sessions include:1) evaluation and education; 2) strategy identification and goal setting; 3) functional strengthening part one; 4) functional strengthening part two; 5) pre-gait activities with distraction; 6) gait training with distraction and use of strategies; 7) minimizing tremor with use of strategies; 8) higher level balance training; 9) functional reintegration part one; 10) functional reintegration part two; 11) identification of strategies to limit recurrence; 12) education for relapse prevention.Patients will also be given and asked to complete the self-guided CBT workbookL Overcoming Functional Neurological Symptoms: A Five Area Approach. They will be asked to complete the first two chapters over the first 4 weeks and the remaining 8 chapters over the following 8 weeks.
214507552|NCT00416975|PROCEDURE|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
215103136|NCT00888485|BEHAVIORAL|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
215103137|NCT01345669|DRUG|Placebo|Once daily
215103138|NCT01345669|DRUG|Afatinib|Once daily
215103139|NCT01392209|OTHER|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
215103140|NCT01793883|DRUG|40 mg Laninamivir Octanoate|
215103141|NCT01793883|DRUG|80 mg Laninamivir Octanoate|
215103142|NCT01793883|DRUG|Placebo|
215103143|NCT00004113|DRUG|temozolomide|
215103144|NCT05448391|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
215103145|NCT02478255|DRUG|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
215103146|NCT02478255|DEVICE|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
215103147|NCT03484390|BEHAVIORAL|Mindfulness-based stress reduction|
215103148|NCT03484390|BEHAVIORAL|Wellness Group|
215103149|NCT02012712|BEHAVIORAL|Personal Health Record (PHR)|"Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.~Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE-3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login."
215103150|NCT01341028|PROCEDURE|Roux-en-Y gastric bypass (LRYGBP)|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
215103151|NCT01341028|PROCEDURE|LRYGBP+gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
215103152|NCT03223259|BEHAVIORAL|Injury Prevention Workshops|Each workshop will last 90 minutes and consist of approximately 20-30 minutes of lecture, 30 minutes of movement, no more than 20 minutes for a pre-test (workshop 1) or post-test (workshop 2), and remaining time for Q\&A.
215103153|NCT03222024|OTHER|routine medical care|This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
215103154|NCT04518488|OTHER|Exercises|Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.
214507553|NCT03950726|PROCEDURE|ileocolic resection|Ileocolic resection through McBurney incision
215023180|NCT04924452|DEVICE|Er:YAG laser therapy|Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for caries removal - parameters: enamel removal - energy 100-200mJ; density 9.84-13.03 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface. Restoration with compomer.
215023181|NCT04924452|PROCEDURE|Conventional therapy|Conventional rotary instruments will be used for caries removal - high-speed and low-speed dental handpieces. Restoration with compomer.
214690795|NCT05348265|OTHER|High intensity interval training|"Intervention will be provided for a period of 8 weeks, thrice a week. Intervention will start with a 5 minutes warm up period of jogging in place. For the first 4 weeks, 3 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.~Intervention will start with a 5 minutes warm up period of jogging in place. For weeks 5 to 8, 4 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches."
214690796|NCT01401816|OTHER|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
214690797|NCT01784406|BEHAVIORAL|Autonomy supportive counselling|
214690798|NCT05323903|OTHER|Telesimulation|Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.
214690799|NCT05323903|OTHER|Kahoot Game|Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.
215023182|NCT00098761|DRUG|laromustine|This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
215103155|NCT04518488|OTHER|Informational Support Group (Control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
215103156|NCT00525096|DRUG|placebo|2 tablets twice a day per os
215103157|NCT00525096|DRUG|Celecoxib|2\*200 mg tablets twice a day per os
214690800|NCT03531437|DRUG|1.5 mg estradiol and 2.5 mg nomegestrol acetate|
215023183|NCT06189872|DEVICE|Attune Cementless|"* Attune AFFIXIUM Cementless Tibial Baseplate, Fixed Bearing~* Attune POROCOAT Cementless Femoral Component, Cruciate Retaining~* Attune AOX Antioxidant Polyethylene Tibial Insert, Cruciate Retaining~* Attune AOX Patellar Button, Domed or Medialized Dome, Cemented or Cementless (surgeon preference for resurfacing)"
215023184|NCT03224377|DIAGNOSTIC_TEST|anti mutated citrullinated vimentin antibodies|Blood sampling using ELisa technique
215023185|NCT00072579|BIOLOGICAL|sargramostim|
215023186|NCT06660030|OTHER|No intervention|No intervention
215023187|NCT06590337|DIETARY_SUPPLEMENT|Spark Placebo Control Form 1|Participants will use their Radicle Spark Placebo Control Form 1 as directed for a period of 6 weeks.
215103158|NCT00525096|DRUG|Exemestane|Exemestane 25 mg per day per os
215103159|NCT00761527|DRUG|Desloratadine Syrup|"Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~* Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg \[milligrams\] of desloratadine)~* Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~* Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)"
215103160|NCT03412383|DRUG|Pyrotinib|Pyrotinib 400mg/day
214423267|NCT05127551|DEVICE|iStent Infinite|Implantation of the iStent Infinite
214423268|NCT05127551|DEVICE|Competitor Device|Implantation of competitor device
214423269|NCT00003900|DRUG|docetaxel|
214423270|NCT00003900|DRUG|irinotecan hydrochloride|
214423271|NCT01305291|OTHER|placebo|
214423272|NCT01305291|DIETARY_SUPPLEMENT|digestion-resistant maltodextrin|
214423273|NCT01685788|OTHER|No intervention|
214423274|NCT02602743|DRUG|Remifentanyl|0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
214423275|NCT02602743|DRUG|Propofol|1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
214423276|NCT02602743|DRUG|Ketamine|2 mg/kg ketamine will be administered for induction in 1 minute.
214423277|NCT02828254|DRUG|PRI-724|
214423278|NCT04642794|OTHER|observational study|patients admitted for AP with portosplenomesenteric vein thrombosis.
214423279|NCT01568918|DRUG|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
214423280|NCT01568918|OTHER|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
214423281|NCT01198340|PROCEDURE|PC-FNB with basal administration of local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
214423282|NCT01198340|PROCEDURE|PC-FNB without basal local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
214423283|NCT01285830|DIETARY_SUPPLEMENT|Lactobacillus reuteri|The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
214690801|NCT03531437|DRUG|15 µg ethinylestradiol and 60 µg gestodene|
214690802|NCT04019093|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
215023188|NCT06590337|DIETARY_SUPPLEMENT|Spark Active Study Product 1.1 Usage|Participants will use their Radicle Spark Active Study Product 1.1 as directed for a period of 6 weeks.
215023189|NCT06590337|DIETARY_SUPPLEMENT|Spark Placebo Control Form 2|Participants will use their Radicle Spark Placebo Control Form 2 as directed for a period of 6 weeks.
215023190|NCT06590337|DIETARY_SUPPLEMENT|Spark Active Study Product 2.1 Usage|Participants will use their Radicle Spark Active Study Product 2.1 as directed for a period of 6 weeks.
215023191|NCT04816292|PROCEDURE|Active Comparator: Hot Snare Polypectomy|Hot Snare Polypectomy with the use of electrocautery for the resection of polyps.
215023192|NCT04816292|PROCEDURE|Experimental: Cold Snare Polypectomy|Cold Snare Polypectomy without the use of electrocautery for the resection of polyps.
215023193|NCT05238220|DRUG|Valganciclovir|continuation of valganciclovir prophylaxis up to 12 months with absence of demonstrated anti-CMV immunity
215023194|NCT06535321|OTHER|vibration training|After modelling, when the vibration platform is closed, all participants of the control group completed the same action as vibration training.
215023195|NCT06535321|OTHER|vibration training|For the vibration group, vibration training was performed immediately after DOMS modelling.
215023196|NCT06535321|OTHER|Y-shaped kinesio taping|For the kinesio group, Y-shaped kinesio taping was performed 30 min before DOMS modelling.
215023197|NCT06535321|OTHER|Combined vibration training and Y-shaped kinesio taping|For the combined group, the vibration group and kinesio group interventions were performed simultaneously.
214507554|NCT05371951|DEVICE|Erchonia HLS|84 procedure administrations with the Erchonia® HLS™ administered by the subject at home: twice daily procedure administrations for 6 weeks.
215023198|NCT06678503|OTHER|balance exercise|Balance exercises are physical activities designed to improve stability, coordination, and posture by challenging the body's ability to maintain an upright position. These exercises target the muscles and systems involved in balance, particularly the core, legs, and the sensory systems (like vision and proprioception).
215023199|NCT06678503|OTHER|Core stability exercises|"Core stability exercises are physical activities designed to improve the strength, endurance, and coordination of the muscles that support and stabilize the spine, pelvis, and torso. These exercises specifically target the muscles of the abdomen, lower back, hips, and pelvis, collectively referred to as the core. The goal is to enhance overall posture, prevent injury, and improve performance in daily activities or sports by increasing the body's ability to stabilize itself during movement."
215103161|NCT03265782|DRUG|ibuprofen|drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
214507555|NCT05583656|PROCEDURE|Pulmonary valve replacement|Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.
215023200|NCT06679452|OTHER|Emotion-Focused Therapy|This feasibility protocol is a two-arm, parallel, double-blinded, RCT aimed at informing a future trial assessing the effectiveness of EFT in resolving emotional injuries in older adults in the context of interpersonal offenses.
215023201|NCT06691607|OTHER|Serum NGAL level|serum NGAL level
215023202|NCT06691074|PROCEDURE|Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter|catheter ablation
215023203|NCT06691074|PROCEDURE|Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter|Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter
215103162|NCT03265782|DRUG|paracetamol|drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
215103163|NCT04113525|DEVICE|MyoRegulator™ System|Paired transcutaneous spinal and peripheral nerve stimulation
214507556|NCT04336709|DRUG|Calcipex II|Water based intracanal medicament
214507557|NCT04336709|DRUG|Metapex|Oil based intracanal medicament
214690803|NCT04019093|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
214690804|NCT00697047|BEHAVIORAL|Automated Mailing|Usual Care plus Automated mailing
214690805|NCT00697047|BEHAVIORAL|Automated Mailing Plus Assisted|If not screened after automated mailing, MA assists with screening.
214690806|NCT00697047|BEHAVIORAL|Auto Plus Assisted Plus Navigation|If not screened after automated mailing and assistance by MA, RN begins navigation.
214690807|NCT00002333|DRUG|Saquinavir|
214690808|NCT00002333|DRUG|Zalcitabine|
214690809|NCT02061722|RADIATION|PET Imaging with [18F]MNI-659|"The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
215103164|NCT05503056|OTHER|art therapy|six sessions of art therapy with licensed therapists
215103165|NCT05503056|OTHER|nothing|no intervention to this group
215103166|NCT01730586|DRUG|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
215023204|NCT06686719|OTHER|Post Facilitation|"For hamstring muscle, the patient positioned in supine with hip and knee flexed to mid- range. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 30 % of the strength for 15 seconds by attempting to push the leg back toward the therapist and relax. The therapist then passively stretched the muscle until a mild stretch sensation was reported. The stretch was held for another 10 seconds. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand."
214690810|NCT04956822|OTHER|Basic information|Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.
214690811|NCT04956822|OTHER|Functional scores|depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores
214690812|NCT04956822|DEVICE|MINUX|MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.
214507558|NCT04648670|BEHAVIORAL|Cognitive stimulation|The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
215023205|NCT06686719|OTHER|Post Isometric Relaxation|"For hamstring muscle, the patient positioned in supine with hip and knee flexed. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 25 % of the strength for 7-10 seconds by attempting to push the leg back toward the therapist and relax.After relaxation, the therapist further extends the knee for 3 to 5 seconds.. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand."
215023206|NCT06686719|OTHER|Myofascial Release|"MFR for Hamstring muscle will be given with patient in prone position with 120 second hold. For giving the MFR, the thumb of the therapist will be allowed to sink in to the central portion of the hamstring. It will held for 120 seconds to allow the tissue to soften and then myofascial structures will spread in a lateral direction until feeling of first fascial barrier. MFR will be performed for 15 mins.~Stretching of the hip adductors, hip flexors and plantar flexors. Functional training includes kneeling, bridging and sit to stand."
215023207|NCT06691152|BIOLOGICAL|CD19 Universal CAR-T cells|Three dose groups (1×10\^7/kg, 3×10\^7/kg, 6×10\^7/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
214690813|NCT03361319|DRUG|Vargatef|small molecule triple kinase inhibitor
214690814|NCT03361319|DRUG|Abraxane|Paclitaxel formulated as albumin bound nanoparticles
215103167|NCT01477112|DIETARY_SUPPLEMENT|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
215103168|NCT01477112|DIETARY_SUPPLEMENT|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
215103169|NCT02904018|OTHER|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
215103170|NCT01431963|DRUG|Lamictal|No comparison.
215103171|NCT03706183|DIAGNOSTIC_TEST|Ischemia-modified albumin|The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
215103172|NCT03706183|DIAGNOSTIC_TEST|Hearing thresholds|The hearing levels will be determined for each group.
214507559|NCT03028285|DRUG|arginine sodium succinate|Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
214507560|NCT04689932|DRUG|Triferic AVNU|Ferric Pyrophosphate Citrate
214507561|NCT05785728|DRUG|DB-1202|Administered I.V.
214690815|NCT03361319|OTHER|placebo|Placebo in place of Ninedanib
215103173|NCT05845853|OTHER|scapular PNF technique|"PNF Technique is based on movement patterns to facilitate and correct sensory-motor function,then correct the impaired impulses emerging from proprioceptive receptors in the muscle. Therefore, it decreases pain and improve the strength of muscles.~PNF position renders a greater amount of sensory input coming from the periphery than that in the neutral position ."
215103174|NCT04356235|PROCEDURE|A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
215103175|NCT04356235|PROCEDURE|B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
214507562|NCT02584426|DEVICE|Ultrasonic Distribution of Cefazolin|
214507563|NCT04220983|RADIATION|MR-Guided Prostate SBRT|Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
214507564|NCT03274648|DIETARY_SUPPLEMENT|Oral butyrate|Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
215023208|NCT06687577|BEHAVIORAL|DBT-C|Tobacco cessation treatment adapted for high risk population.
215023209|NCT06687577|BEHAVIORAL|Treatment as usual|Standard behavioral tobacco cessation treatment.
215023210|NCT06633042|DRUG|Universal BCMA-CD19 CART|1.0-4.0×10\^6 CAR-T cells/kg
215023211|NCT06689904|DEVICE|Nanodropper|One eye is randomly selected to be dilated with the nanodropper
215023212|NCT06689904|DEVICE|Standard eye drop bottle|eye is dilated with the standard eye drop bottle
215023213|NCT06695234|BEHAVIORAL|Meditation Awareness Training|A second-generation mindfulness-based intervention that reincorporates Buddhist wisdom concepts into mindfulness-based intervention.
215023214|NCT06690047|BIOLOGICAL|Ruconest|recombinant human C1-esterase inhibitor
215023215|NCT06627595|DRUG|Immunotherapy|Patients will be treated in accordance with the guidelines for melanoma treatment.
215023216|NCT06695468|DRUG|Levobupivacaine|40-ml mixture of 20 ml of 0.5% levobupivacaine diluted with 20 ml of 0.9% N.S. (20 ml to be injected on each side
215023217|NCT06695468|DRUG|Levobupivacaine + Dexmedetomidine|60 ml mixture of 1.5 mic/kg dexmedetomidine added to 30 ml of 0.5% levobupivacaine diluted with 30 ml of 0.9% N.S. (30 ml to be administered on each side, divided into 15 ml for the upper segment and 15 ml for the lower segment).
215023218|NCT06694064|PROCEDURE|Pulpotomy|Pulpotomy will be done for mta group
215023219|NCT06694064|PROCEDURE|extraction for histologic examination|after pulp therapy the teeth exrtracted for histologic examination
215023220|NCT03557905|DEVICE|RM 0.5|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
215023221|NCT03557905|DEVICE|RM 0.3|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.3.
214690816|NCT03929588|DEVICE|Hand-held device supported by a mobile application|Hand-held device supported by a mobile application to obtain refractive error of the eye.
214690817|NCT03929588|DEVICE|Phoropter|Manual refraction and ETDRS chart
214690818|NCT03929588|DEVICE|Autorefractor|Automated refraction
214690819|NCT05155475|PROCEDURE|Ultrasound endoscopy|After identification of the lesion, the common bile duct will be identified and followed by the point of dilation due to the compression of the known lesion up to the hilum of the liver
215023222|NCT05522556|DRUG|Ritlecitinib|capsules
214423284|NCT01285830|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
214423285|NCT04788433|DIAGNOSTIC_TEST|glycomic analysis|Analysis of glycans on plasma samples
214690820|NCT04993950|OTHER|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
214690821|NCT04993950|OTHER|SNAGS with thoracic postural correction techniques|thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
214690822|NCT00002533|DRUG|fluconazole|
214690823|NCT00002533|RADIATION|radiation therapy|
214690824|NCT01968096|DEVICE|home-based ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
214690825|NCT03757481|OTHER|no intervention|SF-36 questionnaire , PembQoL, Villalta score ,PembQoL
215023223|NCT03578172|DRUG|human menopausal gonadotrophin|experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)\<100pg/ml，progesterone (P)\<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.
215023224|NCT03578172|DRUG|hormone replacement therapy|Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration \>60 days.
215023225|NCT05507333|DEVICE|Gedea pessary|Daily administration of the Gedea pessary during 6 days
215023226|NCT01387867|PROCEDURE|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
215023227|NCT01387867|PROCEDURE|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
215023228|NCT01387867|PROCEDURE|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
215023229|NCT03190421|DIAGNOSTIC_TEST|Expanded Urinary Culture|involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
215023230|NCT03190421|DIAGNOSTIC_TEST|Standard Urine Culture (SUC)|involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
215023231|NCT00273780|BEHAVIORAL|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
215023232|NCT00273780|DEVICE|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
215023233|NCT01215162|RADIATION|Intra-operative radiation to tumor bed|IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
215023234|NCT02457546|BIOLOGICAL|EVICEL Fibrin Sealant|
214690826|NCT06608511|OTHER|Blood draw for the laboratory assessment|Participants will have 50 milliliters (3.5 tablespoons) of blood drawn
214690827|NCT03934086|DRUG|rimegepant|rimegepant 75 mg
214690828|NCT04953650|BEHAVIORAL|Intermittent fasting|The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.
214690829|NCT04953650|OTHER|No intervention|The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
214690830|NCT02021526|DRUG|Triheptanoin|Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
214690831|NCT06376214|DRUG|Dratumumab / Hyaluronidase Injection [Darzalex Faspro]|Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.
214690832|NCT06376214|DRUG|Pomalidomide 4 MG|Patients received oral pomalidomide on days 1-21 of a 28-days cycle from cycle 1 to 6.
214690833|NCT06376214|PROCEDURE|autologous stem cell transplantation (ASCT)|"The ASCT protocol included mobilisation with colony-stimulating factor alone and conditioning with high-dose melphalan140-200 mg/m2~."
214690834|NCT04330755|DRUG|Saline Solution|Placebo
214690835|NCT04330755|DRUG|Levosimendan|Levosimendan
215023235|NCT02457546|DEVICE|Hydrogel sealant|
214423286|NCT04788433|OTHER|Phone interview|patients are followed up by phone up to 1 year
214423287|NCT02639013|PROCEDURE|transducer technique|the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
214423288|NCT04301986|DEVICE|Cytosponge|In a seated position, subjects will swallow the Cytosponge capsule with 150-250 mL of water. Seven minutes and 30 seconds to ten minutes after ingestion, the sponge is then withdrawn by gentle traction on the suture. After retrieval, the string is cut and the retrieved foam sphere containing the cytological specimen is immersed in fixative and stored refrigerated (1° to 12°C \[34° to 54°F\]).
214423289|NCT04301986|DEVICE|Transnasal Endoscopy (TNE)|In an upright position, the scope will be inserted via the nares to examine the posterior pharynx, esophagus and proximal stomach with the transnasal endoscopy approach. The scope will be withdrawn from the nares following completion of the exam.
214423290|NCT04301986|DEVICE|Esophagogastroduodenoscopy|Laying on the subjects' left side, the flexible endoscope is inserted through the mouth to allow visualization of the esophageal mucosa from the upper esophageal sphincter all the way to the esophagogastric junction (EGJ).
214423291|NCT01799148|OTHER|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
214507565|NCT03274648|DIETARY_SUPPLEMENT|Vegetarian diet|Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
214507566|NCT03274648|DIETARY_SUPPLEMENT|Habitual diet|Patients follow the habitual diet
214507567|NCT00012688|DRUG|Doxycycline HCI 10mg po for 2 weeks|
214507568|NCT00012688|PROCEDURE|Ultrasonic scaling with 0.12% chlorhexidine gluconate|
214507569|NCT00780793|DRUG|progressive spacing of TNF-blocker injections|"Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~* if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~* if DAS28 \> 2.6 and DAS28 change ≤ 0.6: continue at step N~* if DAS28 \> 2.6 and DAS28 change \> 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~* Adalimumab 40 mg / 14 days~* Etanercept 50 mg / 7 days~Step 1 :~* Adalimumab 40 mg / 21 days~* Etanercept 50 mg / 10 days~Step 2 :~* Adalimumab 40 mg / 28 days~* Etanercept 50 mg / 14 days~Step 3 :~* Adalimumab 40 mg / 42 days~* Etanercept 50 mg / 21 days~Step 4 :~* TNF-blocker stop"
214507570|NCT00780793|DRUG|DMARD maintenance|DMARD maintenance
214507571|NCT00310037|DRUG|bortezomib|Given IV
214507572|NCT02799537|OTHER|Randomized clinical study|Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
214690836|NCT04330755|DRUG|Magnesium Sulfate|Magnesium Sulfate
214690837|NCT03003780|BEHAVIORAL|Mindful Steps|Integrated website, activity tracker, and mind-body training
214690838|NCT05012319|DRUG|to be given as a treatment|"Nitric Oxide Nasal Spray Enovid"
214690839|NCT05397899|OTHER|Abdominal hypopressive Exercises (AHE)|Active and specific Therapeutic exercises will be used to treat postpartum low back pain in this study. AHE consisted of exhaling to their expiratory reserve volume, then holding their breath (apnea), and expanding their rib cage, to draw their abdominal wall inward and cranially without inhalation. Each exercise will have a specific frequency, intensity, and duration.
214690840|NCT05397899|OTHER|General exercises|General exercises are therapeutic exercises for core muscles for the treatment of postpartum low back pain.
214690841|NCT01996137|DEVICE|VASST II treadmill|Supervised treadmill training under physiotherapist
214690842|NCT06447025|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
214690843|NCT00962039|DRUG|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
214690844|NCT00962039|DRUG|Placebo|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
214690845|NCT01067508|OTHER|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
214690846|NCT03797040|BIOLOGICAL|Cell therapy|PLX-R18: Allogeneic ex vivo expanded placental stromal cells
214690847|NCT00526149|DRUG|BI 2536|
214690848|NCT00526149|OTHER|high performance liquid chromatography|
214423292|NCT00306449|BEHAVIORAL|Small group seminar-based educational intervention|
214423293|NCT06111937|OTHER|after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed within 2 hours|Patients received gastric ultrasound examination every 15 minutes 2 or 4 hours immediately after taking the last dose of MgSO4 solution in group A or B respectively.
214690849|NCT00526149|OTHER|mass spectrometry|
214423294|NCT01026064|OTHER|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
214423295|NCT01026064|DRUG|Azithromycin|Zithromax (250 mg oral capsule).
214690850|NCT00526149|OTHER|pharmacological study|
215023236|NCT04680208|PROCEDURE|Surgical procedure under anesthesia|Different varieties of surgical procedures done under anesthesia
214690851|NCT03578848|DEVICE|uAOBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
214690852|NCT03578848|DEVICE|Home BP|As for the home BP measurements, a validated device (WatchBP Home; Microlife AG, Widnau, Switzerland) will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning (within 2 hours after awakening) and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP (all BP reading and BP in the morning and in the afternoon) will be generated and provided for clinicians to guide their treatment.
214690853|NCT03578848|DEVICE|CBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
214690854|NCT02276157|DEVICE|Direct peroral cholangioscopy|"The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary."
214690855|NCT03650348|DRUG|PRS-343 in Combination with Atezolizumab|HER2/4-1BB Bispecific
215023237|NCT01931826|PROCEDURE|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
215023238|NCT01931826|PROCEDURE|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
215023239|NCT06413069|DIETARY_SUPPLEMENT|Raw whole almonds|Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks. Patients of the no-nut group will receive 6,7 kgs of almonds after finishing the study, supporting their compliance as untreated group.
215023240|NCT02019173|BEHAVIORAL|Boot Camp Balance Training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
215023241|NCT03348462|DRUG|ethosomal preparation of anthralin|once daily with short contact topical application
215023242|NCT03348462|DRUG|liposomal preparation of anthralin|once daily with short contact topical application
214423296|NCT01026064|DRUG|Placebo|Matching placebo
214423297|NCT03432780|DRUG|Docetaxel|
214423298|NCT03432780|BIOLOGICAL|Hormone and radiation therapy|
214423299|NCT03432780|RADIATION|Radiation therapy|
214423300|NCT01511471|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
215023243|NCT04713046|BIOLOGICAL|CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16|Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10\^6 CD4+ cells/kg; 2) 5 x 10\^6 CD4+ cells/kg; or 3) 10\^7 CD4+ cells/kg of recipient ideal body weight.
215023244|NCT04713046|BIOLOGICAL|Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16|Standard dosing for bone marrow graft (target dose of 4 x 10\^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).
215023245|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.
215023246|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
215023247|NCT01905085|DEVICE|No intervention|
215023248|NCT00926900|DRUG|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
215023249|NCT00926900|DRUG|Placebo|Placebo
215023250|NCT02667561|DRUG|Testosterone gel 1% 2.2 mg|Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
215023251|NCT02667561|DRUG|Testosterone gel 1% 4.4 mg|Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
215023252|NCT02667561|DRUG|Testosterone gel 1% 8.8 mg|Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
215103176|NCT04356235|PROCEDURE|C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
215103177|NCT04356235|PROCEDURE|D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
215023253|NCT02667561|DRUG|Placebo of Testosterone Gel 1%|Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
215023254|NCT03236805|DRUG|Ketamine|Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
215023255|NCT03236805|DRUG|Morphine|Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
215023256|NCT02056145|PROCEDURE|LFCNB|LFCNB - Normal Saline solution 10 cc
215023257|NCT02056145|PROCEDURE|FNB|FNB - Normal saline solution 10 cc
215103178|NCT04356235|PROCEDURE|E: unilateral simple mastectomy|unilateral simple mastectomy
215103179|NCT04356235|PROCEDURE|F: after bilateral SSM, ASM, NSM, expander-implant exchange|after bilateral SSM, ASM, NSM, expander-implant exchange
215103180|NCT01914653|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
215103181|NCT03036618|DIETARY_SUPPLEMENT|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
214423301|NCT04323358|DIAGNOSTIC_TEST|Biometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
214423302|NCT04323358|DIAGNOSTIC_TEST|Keratometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
214423303|NCT01174199|DRUG|vorinostat|Given orally
214423304|NCT01174199|DRUG|temsirolimus|Given IV
214423305|NCT01174199|OTHER|laboratory biomarker analysis|Correlative study
214423306|NCT01174199|PROCEDURE|positron emission tomography/computed tomography|PET scan
214507573|NCT04680598|DRUG|ICI|Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)
214507574|NCT04680598|DRUG|Antiviral Prophylaxis|Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir
215023258|NCT02056145|PROCEDURE|LFCNB|LFCNB - Chirocaine 0.25%, 20 cc
215103182|NCT03036618|DIETARY_SUPPLEMENT|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
214423307|NCT00880048|DRUG|orvepitant|neurokinin-1 antagonist
214423308|NCT00880048|OTHER|Placebo|Placebo to match orvepitant 30 mg and 60 mg
214507575|NCT02124044|DRUG|Asunaprevir and Daclatasvir|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
214507576|NCT02124044|DRUG|Asunaprevir and Daclatasvir with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
214507577|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 2 capsules
214507578|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 1 capsule
214507579|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch B Ultibro Breezhaler 85/43 μg 2 capsules
214507580|NCT04856098|DRUG|Ultibro Breezhaler with oral charcoal|Activated charcoal suspension, granules 50 g / bottle
214507581|NCT02487680|DIETARY_SUPPLEMENT|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
214507582|NCT02487680|DIETARY_SUPPLEMENT|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
214507583|NCT04081532|PROCEDURE|surgical removal of superficial peritoneal endometriosis|In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
214507584|NCT01835652|OTHER|Active Exercise|
214507585|NCT01835652|OTHER|Passive Exercise|
215023259|NCT02056145|PROCEDURE|FNB|FNB - Chirocaine 0.25%, 20 cc
214690856|NCT00444626|DEVICE|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
215023260|NCT03150888|DRUG|Antihypertensive Agents|Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
215023261|NCT03150888|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
215023262|NCT03614832|DRUG|Ticagrelor 90 mg|half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
215023263|NCT03614832|DRUG|Clopidogrel 150 mg|double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
214423309|NCT00964197|DEVICE|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
214423310|NCT06109831|DRUG|SHR-1918|SHR-1918
214690857|NCT00444626|DEVICE|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
215023264|NCT03167658|BEHAVIORAL|Workplace wellness program|Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
215023265|NCT01157494|OTHER|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
214423311|NCT06109831|DRUG|SHR-1918 placebo|SHR-1918 placebo
214423312|NCT03671525|DRUG|Nimodipine|Subject will receive two 30mg capsules of nimodipine during study visit.
214423313|NCT03671525|DRUG|Placebo oral capsule|Two coconut oil capsules that mimic the size and color of the nimodipine capsules
215023266|NCT05950997|DRUG|Acalabrutinib|100 mg capsules administered by mouth once daily (28-day cycles)
215023267|NCT05950997|DRUG|Obinutuzumab|100 mg administered intravenously on Day 1 and 900 mg administered intravenously on Day 2, 1000 mg administered intravenously on Day 8 and 15 of cycle 2 and 1000 mg on Day 1 of subsequent cycles for a total of 6 cycles (28-day cycles)
215023268|NCT04419987|GENETIC|draw blood|search for new genetic variations (when the diagnostic exploration will have been non informative) by sequencing exons.
215023269|NCT02743312|DEVICE|Torso Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
215023270|NCT02743312|DEVICE|Sham Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
215023271|NCT02743312|DEVICE|Fitbit Flex|Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
215103183|NCT03489928|DRUG|Oral Misoprostol|Prostaglandin E1 - 100ug tablet, divided in half by pharmacy staff to be administered by mouth.
214423314|NCT00480519|PROCEDURE|Meatotomy|
214423315|NCT06530264|OTHER|DCR|6\. An H shaped incision at the postero-inferior lacrimal sac is made, with a long anterior flap and shorter posterior flap. Similarly an H shaped incision at the nasal mucosa is made. The posterior flap of lacrimal sac is sutured with posterior flap of nasal mucosa in interrupted fashion using 6-0 vicryl sutures in Group A, while in Group B the posterior flap is trimmed without suturing.
214423316|NCT06002542|BEHAVIORAL|Information provided|get information at every stage of care in emergency room
214423317|NCT06002542|BEHAVIORAL|Control|Information is only provided when participants request it.
214423318|NCT03444506|DRUG|Molo 1 (also referred as GSP 301-2 NS)|
214423319|NCT03444506|DRUG|Molo 2 (also referred as GSP 301-1 NS)|
214423320|NCT03444506|DRUG|Placebo nasal spray|
214423321|NCT03444506|DRUG|DYMISTA nasal spray|
214423322|NCT03444506|DRUG|PATANASE nasal spray|
214423323|NCT04554628|DIAGNOSTIC_TEST|ELISA test in urine|enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
214423324|NCT03368937|DEVICE|Tandem t:slim X2 with Control-IQ Technology|Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
214423325|NCT03411239|DEVICE|Adult esophageal balloon catheter (obc)|Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
214423326|NCT02485444|DRUG|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
214423327|NCT00509639|DRUG|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
214423328|NCT00346151|DRUG|Belatacept|10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
215103184|NCT03489928|DRUG|Vaginal Misoprostol|Prostaglandin E1 - 100ug oral tablet, divided in quarters by pharmacy staff, vaginal placement of one or two quarters as needed every 6 hours
215103185|NCT03489928|DRUG|Dinoprostone|Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
215103186|NCT03951558|OTHER|Diet for calciuria prevention|Dietary recommendations for water, salt, calcium and proteins according to age and DIR
215103187|NCT03951558|DRUG|Hydrochlorothiazide|Hydroclorothiazide recommendations for hypercalciuria
215103188|NCT03903887|BIOLOGICAL|anti-PD1 antibody-activated TILs|Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
215023272|NCT03752372|PROCEDURE|hematopoietic stem cell transplantation|"1. Reduced intensity conditioning(RIC) chemotherapy regimen before transplantation~2. All patients were cared for in single rooms ventilated with a highly effective particulate air filtration system. All patients received intravenous immunoglobulin and antimicrobial prophylaxis, which included antiviral, antifungal, and Pneumocystis jirovecii prophylaxis with ganciclovir and micafungin, as per routine clinical practice before transplantation.~3. Umbilical cord blood transplantation"
214690858|NCT00444626|DRUG|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
215103189|NCT03387358|DEVICE|Nasal bridle securement device for small bore feeding tubes|A Nasal bridle securement device is an alternative method to securing small bore feeding tubes which are most commonly secured with adhesive tape to the nose. A nasal bridle securement device instead secures the feeding tube to a cloth ribbon that is inserted in one nostril, over then nasal bridle and out the other nostril.
215103190|NCT05583019|DEVICE|GENEActiv Accelerometry Device|a watch like wearable sensor
215103191|NCT05583019|DEVICE|Centrepoint Insights Watch (CPIW) Accelerometry Device|a watch like wearable sensor
214690859|NCT00462020|DRUG|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
215023273|NCT06310694|COMBINATION_PRODUCT|intervention group (Elastane circular dressing on sterile transparent dressing)|A circular dressing made of elastane material was placed on the patients in the intervention group on a sterile transparent dressing to provide additional fixation on the peripheral intravenous catheter.
215023274|NCT03345810|DRUG|Durvalumab|Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W
215023275|NCT03345810|DRUG|Vinorelbine|(30 mg/m2 D1 + D8 as infusion) cycle Q3W
215023276|NCT03345810|DRUG|Gemcitabine|(1000 mg/m2 D1 + D8 as infusion) cycle Q3W
215023277|NCT03345810|DRUG|nab-Paclitaxel|(100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W
215023278|NCT03345810|DRUG|Carboplatin|(AUC = 5 mg•min/mL on Day 1) cycle Q3W
215023279|NCT04053426|OTHER|Implementation of agitation care algorithm|Following the agitation care algorithm care professional adapt their behavior regarding agitation
215023280|NCT06569472|BIOLOGICAL|CD19-targetd CAR-T|Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion
214423329|NCT00346151|DRUG|Sirolimus|4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
214423330|NCT00346151|DRUG|Anti-thymocyte globulin|1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
214690860|NCT00462020|DRUG|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
214690861|NCT01822041|DRUG|ARN-509|Single oral dose of 240 mg ARN-509
214690862|NCT01665755|DEVICE|Upstroke Compression Defibrillation|
215023281|NCT06571877|OTHER|Dietary intervention with manipulation of the energy density|Dietary intervention with manipulation of the energy density either during breakfast or during lunch
215023282|NCT02532907|PROCEDURE|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
215023283|NCT06570330|DIETARY_SUPPLEMENT|SuperHMO|Super HMO Prebiotic Mix: five major types of human milk oligosaccharides including 2'-Fucosyllactose (2'-FL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 6'-Sialyllactose (6'SL), and 3'-Sialyllactose (3'SL)
215023284|NCT06570330|DIETARY_SUPPLEMENT|Non-GMO corn Maltodextrin, Rapid Absorption|he composition and absorption properties are similar to the investigational product and will be given in the same dosage (2.1g/day for days 1-5 and increasing to 4.2 g/day for days 6-30) and route of administration as the investigational product.
215023285|NCT02688231|OTHER|Task-oriented upper limb training|"Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks."
215023286|NCT02688231|OTHER|Control intervention|"The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).~The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks."
215103192|NCT05583019|DEVICE|Apple Watch Accelerometry Device|a watch like wearable sensor
215103193|NCT05583019|DEVICE|Polysomnography|Sleep monitor
215103194|NCT05583019|DEVICE|Videography|Thermal Camera
214423331|NCT00346151|DRUG|methylprednisolone|500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
214423332|NCT03354039|DRUG|Tamoxifen|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
214423333|NCT03354039|DRUG|Matching placebo|Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
214690863|NCT01665755|DEVICE|Precompression Defibrillation|
214690864|NCT01176097|DRUG|AZD5658|oral suspension, escalating single doses
214690865|NCT01176097|DRUG|Placebo|oral suspension,single doses
214690866|NCT06671756|DIETARY_SUPPLEMENT|Fructose Ingestion|Participants will consume a beverage containing 75g of fructose dissolved in 225ml of water.
214690867|NCT06671756|DIETARY_SUPPLEMENT|Glucose Ingestion|Participants will consume a beverage containing 75g of glucose dissolved in 225ml of water.
214690868|NCT06672731|DIAGNOSTIC_TEST|REMS: Radiofrequency Echographic Multi Spectrometry|it is a non invasive ultrasonographic evaluation of bone and muscle quality
214690869|NCT06693700|OTHER|Indoor Air Quality Monitor AirGradient ONE|Participants will be asked to set up an Indoor Air Quality Monitor AirGradient ONE (Model: I-9PSL) which is an award winning commercially available indoor air quality monitor designed to enable anyone to monitor their air quality in their home for about 60 days (8 weeks). Indoor air pollution levels within participating households will be measured using these AQMs.
214690870|NCT06693219|DIAGNOSTIC_TEST|ultrasonography to confirm the correct placement of a nasogastric tube in the stomach|The sonographic examination consisted of three parts: neck scan, epigastric scan, and injection test using a mixture of 25 mL NaCl 0.9% and 25 mL room air through the nasogastric tube to detect dynamic fogging
214690871|NCT00091390|RADIATION|High Dose brachytherapy boost|19 Gy in two fractions (on day of placement and 6-24 hours later) before or after external beam radiotherapy, such that all study treatment occurs within 8 weeks.
214690872|NCT00091390|RADIATION|External beam radiotherapy|45 Gy as 1.8 Gy five days a week for five weeks.
214690873|NCT06692790|OTHER|Venous Sinus Stenting Procedure|"Performed under general or local anesthesia. Targeted stenosis sites included the right transverse sinus, left transverse sinus, bilateral transverse sinuses, and right transverse and sigmoid sinuses.~Stents used included Venous Sinus Stent (CWS), CASPER, PRTCS, and multiple stents where necessary.~Post-procedure care included antiplatelet therapy and routine follow-up assessments"
214690874|NCT06693167|PROCEDURE|chirurgie canal carpien|study compares a group of patients who received a preoperative auriculotherapy session followed by standard analgesic treatment to a group who received only standard analgesic treatment, and this, during the three days following surgery (D1, D2, and D3).
214690875|NCT06692023|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
214690876|NCT06692023|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
215023287|NCT06571825|DRUG|Venetoclax|The consolidation therapy involves a regimen of intermediate-dose cytarabine (Ara-C) combined with Ven, specifically Ara-C at 1.0 g/m²/day for 3 days (days 1-3) and Ven at 400 mg/day for 10 to 14 days (days 1-10 to 14), with each cycle lasting 4 to 6 weeks, for a total of 3 consolidation cycles. This is followed by maintenance therapy with azacitidine (AZA) at 50 mg/m²/day for 5 days (days 1-5), with each cycle lasting 4 weeks, for a total of 6 maintenance cycles.
215023288|NCT06571825|DRUG|Allogeneic transplant|"The consolidation therapy involves allo-HSCT, with the choice of conditioning regimens typically using reduced-intensity conditioning such as the Fludarabine+Busulfan (FluBu) or Fludarabine+Melphalan (FluMel) regimens commonly used by centers, which can also include Ven.~FluBu regimen: Flu 30 mg/m²/day from day -10 to day -5, Bu 3.2 mg/kg/day from day -6 to day -5 or day -7 to day -5, antithymocyte globulin (ATG) (e.g., rabbit ATG at a total dose of 6-7.5 mg/kg, administered from day -4 to day -1), and Ven from day -10 to day -4.~FluMel regimen: Flu 30 mg/m²/day from day -10 to day -5, Mel 50-70 mg/m²/day from day -4 to day -3, ATG and Ven from day -10 to day -4.~12 weeks (±4 weeks) post-HSCT maintenance begins with AZA at 32 mg/m²/day for 5 days (days 1-5), with each lasting 6 weeks, for a total of 6 cycles. Donor lymphocyte infusion is allowed in cases of minimal residual disease (MRD) positivity."
215023289|NCT06571617|PROCEDURE|Mini PCNL (mini percutaneous nephrolithotomy)|half of the cases will be treated using mini PCNL
215023290|NCT06571617|PROCEDURE|RIRS (retrograde intrarenal surgery/ flexible URS)|THE OTHER HALF WILL BE TRAETED USING Flexible URS
215023291|NCT06289582|DRUG|[F-18]DPA714 administration IV|brain PET/MRI imaging after \[F-18\]DPA-714 administration
215023292|NCT06571097|DRUG|Levoﬂoxacin|0.5g/day for 2 weeks
214423334|NCT01018836|DRUG|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
214423335|NCT01018836|RADIATION|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
215023293|NCT03854435|OTHER|Heart rate assessment (stethoscope)|Immediately after birth heart rate will be evaluated by auscultation
215023294|NCT03854435|OTHER|Heart assessment (umbilical cord palpation)|Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
215023295|NCT03008096|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.
215023296|NCT01121354|DRUG|Cefazolin 2g for Injection USP and Dextrose Injection USP|Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
214423336|NCT00920725|DRUG|Insulin (Aspart Insulin [Novolog], Regular Insulin)|"Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous"
214423337|NCT01269736|BEHAVIORAL|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
215023297|NCT01121354|DRUG|Cefazolin 1.5g|Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
215023298|NCT01793571|PROCEDURE|TAP block|2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
215023299|NCT01830101|DRUG|TMZ plus concurrent re-irradiation|
215023300|NCT01830101|DRUG|Temozolomide|low-dose temozolomide daily for one year
215023301|NCT03240055|DRUG|spinal anesthesia|The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
215023302|NCT03240055|OTHER|etomidate|receive etomidate only
215023303|NCT02749461|PROCEDURE|heel stick|Consecutive routine blood sampling heel sticks
215023304|NCT02796482|DIETARY_SUPPLEMENT|EnergieShake 1.5kcal Complete|Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
215023305|NCT03841474|DRUG|Psychiatric treatment with sertraline|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
215023306|NCT03841474|DRUG|Psychiatric treatment with escitalopram|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
215103195|NCT03123991|BEHAVIORAL|UP-A adapted as a preventive intervention|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
215103196|NCT03123991|BEHAVIORAL|Same than experimental group (EG), after EG finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
215103197|NCT02412332|PROCEDURE|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
215103198|NCT02412332|PROCEDURE|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
214423338|NCT05566080|PROCEDURE|Carotid endarterectomy|Patients who have a significant carotid stenosis and who undergo surgical carotid endarterectomy
214423339|NCT01414842|DEVICE|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
214423340|NCT01414842|DEVICE|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
214423341|NCT04962074|DEVICE|Microfluidic sperm sorting chip|Fertile Ultimate® (Koek Biotechnology, Turkey) microfluidic sperm sorting chips
214423342|NCT04962074|DEVICE|Density gradient|Density gradient centrifugation
214423343|NCT02887768|DEVICE|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
214423344|NCT02887768|PROCEDURE|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
215023307|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from fillet|Intact cod protein from fillet 8 g protein daily for 8 weeks
214690877|NCT06693193|DEVICE|Immersive Virtual Reality|Individuals will participate in three VR sessions using Oculus headsets, experiencing virtual environments featuring realistic natural stimuli or custom settings tailored to their preferences and valued activities. Each environment allows for the adjustment of auditory elements (such as animal sounds, rustling wind, or specific music), visual elements (such as people, objects, or animals), and the time of day and weather conditions. The operator will use a user-friendly smartphone app to customize the environment, making real-time adjustments to settings and content. Throughout the VR experience, the operator can monitor the participant's visual focus in real-time.
214690878|NCT05549063|OTHER|Mobility and Stability Exercise|Mobility and stability exercises
214690879|NCT05549063|OTHER|Stretching Exercise|Balance and reaching exercise
215023308|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from residual material|Intact cod protein from residual material, 8 g protein daily for 8 weeks
215023309|NCT03538821|DIETARY_SUPPLEMENT|Control|Control group receive tablet containing fillers
215023310|NCT03796975|DRUG|Combination of Pioglitazone and Metformin Tablets|15mg/500mg, oral, 2/day
215023311|NCT03796975|DRUG|Metformin Hydrochloride Tablets|Oral metformin 850mg, 2/day in the control group
215023312|NCT00203242|DRUG|Depacon IV and Depakote ER|
215023313|NCT00526851|OTHER|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
214690880|NCT03238092|DRUG|Testosterone|testosterone gel daily during the late luteal phase.
214690881|NCT03238092|DRUG|Estradiol|oral estradiol during the late luteal phase.
215023314|NCT01668199|DRUG|TZP-101|
215023315|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 14 days before surgery|
214690882|NCT07044700|DRUG|Jardiance|Jardiance
215023316|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 72 hours before surgery|
215023317|NCT04304287|PROCEDURE|Without preoperative blood donation|
215023318|NCT02167347|BEHAVIORAL|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
214690883|NCT07044700|DRUG|non-SGLT2 inhibitors|non-SGLT2 inhibitors
214423345|NCT01229358|OTHER|Surgical dressing|Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
214423346|NCT02032329|DEVICE|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
214423347|NCT05790616|PROCEDURE|Arterial blood draw|"For the IN(Fast-Sitting) arm arterial blood will be collected to derive Gold-standard SaO2 reference values."
214423348|NCT05790616|OTHER|Oxygen reduction|Volunteers undergo an ambient oxygen decrease from 21% to 10%
214423349|NCT04014933|DIAGNOSTIC_TEST|LASER SPECKLE FLOWGRAPHY|Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
214423350|NCT05685095|BEHAVIORAL|Physical training|Supervised gait training program 3 times a week, 12 weeks
214690884|NCT06200116|OTHER|Non-Interventional Study|Non-interventional study
215023319|NCT03113188|DRUG|CBP501|CBP501, CDDP plus Nivolumab
215023320|NCT00434811|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
215023321|NCT00434811|BIOLOGICAL|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
215023322|NCT00434811|DRUG|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
215023323|NCT00434811|DRUG|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
215023324|NCT00434811|BIOLOGICAL|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
215023325|NCT00434811|PROCEDURE|Islet Transplantation|Transplantation of pancreatic islet cell
215023326|NCT00434811|BIOLOGICAL|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
215023327|NCT06437457|RADIATION|ceus|MRI was performed by using a superconducting magnet scanner operated at 3.0 T (GE discovery MR750w, USA) and the CEUS examination (Mindray, China), ultrasound was performed first in B-mode to identify the suspicious lesions and then switched to contrast mode prior to the injection of the contrast medium.
215023328|NCT05020808|DIETARY_SUPPLEMENT|NEAA|Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
215023329|NCT05020808|DIETARY_SUPPLEMENT|PPI|Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
215023330|NCT00866775|DRUG|Eslicarbazepine acetate|1600 mg QD
215023331|NCT00866775|DRUG|Eslicarbazepine acetate|1200 mg QD
215023332|NCT02149797|PROCEDURE|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
215023333|NCT02149797|PROCEDURE|SILC-Pick'n roll-Beginning (group I)|"SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided"
215023334|NCT02149797|PROCEDURE|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
215023335|NCT05075473|OTHER|Segmental stabilization|Physiotherapist will perform activation of multifidus in prone position. It also includes activation of transverse abdominas in crook lying position, in sitting as well as in point kneeling position to re-establish simultaneous contraction of deep muscles synergy.
215023336|NCT05075473|OTHER|Generalized Lumber stabilization exercsies|It can by performed by patient him or her self under physiotherapist's assistance. Lumber neutral position is maintained. Bridging in prone as well as supine position will be maintained.
215023337|NCT02051387|DRUG|Cannabidiol CR|
215023338|NCT02051387|DRUG|Cannabidiol|
215023339|NCT02051387|DRUG|Amisulpride|
215023340|NCT02051387|DRUG|Olanzapine|
215023341|NCT02051387|DRUG|Quetiapine|
215023342|NCT02051387|DRUG|Risperidone|
214423351|NCT03343938|OTHER|Embryo handling in a closed station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
214423352|NCT02861937|PROCEDURE|non surgical periodontal therapy|and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
214423353|NCT00002810|BIOLOGICAL|filgrastim|
214690885|NCT06742398|OTHER|Carbohydrate Dissolvable Strip|"Participants are provided with a carbohydrate dissolvable strip for every 12.5% of the time trial that is completed (calculated based on the distance covered).~The carbohydrate dissolvable strip (Innsol Health Corp.) is primarily composed of sucrose and glucose; however, the full ingredient list includes pullulan, mannitol, menthol, hydroxyl propyl methyl cellulose, eucalyptol, polysorbate 80, glyceryl oleate, purified water."
214690886|NCT06742398|OTHER|Carbohydrate Mouth Rinse|"Participants are provided with a carbohydrate mouth rinse for every 12.5% of the time trial that is completed (calculated based on the distance covered).~The sucrose solution will consist of 64g of sucrose dissolved in 1000 mL of water, with a bolus of 25 mL being used for each mouth rinse. Each mouth rinse solution will have 2mL of red food dye FD\&C Red No. 40 to ensure the same sensory response through appearance."
214690887|NCT06742398|OTHER|Water Mouth Rinse|"Participants are provided with a water mouth rinse for every 12.5% of the time trial that is completed (calculated based on the distance covered).~The water solution will consist of 1000 mL of water, with a bolus of 25 mL being used for each mouth rinse. Each mouth rinse solution will have 2mL of red food dye FD\&C Red No. 40 to ensure the same sensory response through appearance."
214690888|NCT06098261|DRUG|Test (T) Bilastine|Specification: Bilastine 20mg. Produced and supplied by Shandong Hubble Kisen Biological Technology Co., Ltd.
214690889|NCT06098261|DRUG|Reference (R) Bilastine|Specification: Bilastine 20mg. Produced by Menarini International Operations Luxembourg S.A.
215023343|NCT02051387|DRUG|Placebo|
215023344|NCT02973022|OTHER|CC&S|Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC\&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
215023345|NCT05454007|BEHAVIORAL|Step length asymmetry training|Participants will engage in four, five-minute periods of step symmetry training during session 2. This training uses established sensorimotor adaptation-based methods (e.g. split-belt treadmill walking, walking with unilateral leg weighting) to elicit motor aftereffects of more equal step lengths. Two minute sitting rest breaks will be given between training blocks or at the participant's request. A video recording will be taken of the first and final two minutes of training.
215023346|NCT01832298|DRUG|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
215023347|NCT00569998|DEVICE|NovoPen™ 4|
215023348|NCT00569998|DEVICE|NovoPen® 3|
215023349|NCT01500135|DRUG|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
214423354|NCT00002810|DRUG|melphalan|
214423355|NCT00002810|PROCEDURE|bone marrow ablation with stem cell support|
214423356|NCT00002810|PROCEDURE|peripheral blood stem cell transplantation|
214423357|NCT02955498|DRUG|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
214423358|NCT02955498|DRUG|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
214423359|NCT05131386|DRUG|Trabectedin|ET-743, Yondelis (vials of 1 mg). Route of administration: intravenous infusion
215023350|NCT01500135|DRUG|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
215023351|NCT01661595|DRUG|Sildenafil|50 mg/day for 4 weeks
215023352|NCT01661595|DRUG|tadalafil|10 mg/day for 4 weeks.
215023353|NCT01661595|DRUG|Placebo|Placebo 1 capsule per day for four weeks.
215023354|NCT00615160|DRUG|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
215023355|NCT00615160|DRUG|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
215023356|NCT03708510|DEVICE|Restorative materials- Filtek Silorane|Filtek Silorane
215023357|NCT03708510|DEVICE|Restorative materials-Kalore|Kalore
215023358|NCT03708510|DEVICE|Preparation-Er,Cr:YSGG Laser|Er,Cr:YSGG Laser
215023359|NCT03708510|DEVICE|Preparation- Diamond Bur|Bur
215023360|NCT02368873|PROCEDURE|Application of IPOM mesh|
215023361|NCT04578041|DEVICE|TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|"TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~* Modality: Excitatory stimulation~* Frequency: 5 Hz~* Interval between stimulus: 100 ms~* Duration of each stimulus: 25 ms~* Duration of stimulation: 40 minutes~* Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2"
215023362|NCT04578041|OTHER|Aerobic Exercise Program|Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
214507586|NCT03738592|OTHER|behavioral exploration of spatial hearing performances|"Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion."
214507587|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for cochlear implant children and their parents)|"For cochlear implant children and their parents, a SSQ questionnaire will be given and completed during the first visit (at the inclusion).~This questionnaire offers a version for parents of children with hearing loss (SSQ Parents CI) and a version for the children themselves (SSQ Children CI)."
214507588|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for parents of CI children)|"The SSQ questionnaire for Parents of CI children is composed of three distinct sections (A, B and C).~Each section will be filled separately by parents of CI children with one of the study collaborators during 3 telephone calls spaced 1 week apart. Thus, section A will be completed 7 days (+/- 2 days) after inclusion , section B 14 days (+/- 2 days) after inclusion, and section C 21 days (+/- 2 days) after inclusion."
214507589|NCT03019432|BEHAVIORAL|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
214690893|NCT03229759|DRUG|Octenidine Dihydrocloride in aqueous solution|application of investigational product
215023363|NCT04578041|OTHER|Computerized CT (Cognitive Training)|"Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session."
215023364|NCT01952262|OTHER|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
215023365|NCT04808011|DEVICE|Intelligent Dialysis Assistant (IDA)|The IDA is intended for home dialysis for subjects who are stage 5 kidney diease patients and who perform Peritoneal Dialysis. The system is used deveral times a day for approximately 20 minutes for each cycle. During the interventional period, subjects will use only the investigational IDA system for their in/out exchanges.
215023366|NCT01327729|DRUG|pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg|YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
215023367|NCT00364195|DRUG|Tesmilifene (YMB1002)|
215023368|NCT01872182|DRUG|ALS-L1023|daily twice for 12 weeks
215023369|NCT01872182|DRUG|placebo|daily twice for 12 weeks
215023370|NCT00781664|OTHER|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
215023371|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
215023372|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
215023373|NCT00781664|OTHER|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
215023374|NCT00781664|DRUG|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
215023375|NCT00781664|DRUG|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
215023376|NCT00781664|DRUG|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
215023377|NCT00781664|DRUG|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
215023378|NCT00781664|OTHER|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
215023379|NCT03497286|BEHAVIORAL|Text-based mentorship|The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.
215023380|NCT03497286|BEHAVIORAL|Control text messaging|Control participants will receive periodic texts from NurturePA with information about child safety and health.
214423360|NCT04810793|DRUG|Amoxicillin , Levofloxacin and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
214423361|NCT04810793|DRUG|Amoxicillin , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
214423362|NCT04810793|DRUG|Tetracycline , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
214423363|NCT04810793|DRUG|Amoxicillin,Levofloxacin and Vonoprazan fumarate|Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
214423364|NCT04810793|DRUG|Amoxicillin,Furazolidone and Vonoprazan fumarate|Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
214423365|NCT04810793|DRUG|Tetracycline,Furazolidone and Vonoprazan fumarate|Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
214423366|NCT01490112|DRUG|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
214423367|NCT03684265|DRUG|Meloxicam Capsule (Test)|single dose
214423368|NCT03684265|DRUG|Meloxicam Tablet (Reference)|single dose
214423369|NCT02724085|DRUG|TP-271|TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
214423370|NCT02009839|BEHAVIORAL|Meeky Mouse program|
214423371|NCT02009839|OTHER|Computer Games|
215023381|NCT00912509|DRUG|riboflavin|riboflavin 0.1% is applied every 2 minutes for 30 minutes
215023382|NCT00912509|DEVICE|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
214423372|NCT05692908|BIOLOGICAL|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
214423373|NCT05723510|DRUG|Tegoprazan 50mg|Oral administration of one tablet of tegoprazan 50 mg once daily
214423374|NCT05723510|DRUG|Edoxaban 60mg|Oral administration of one tablet of edoxaban 60 mg once daily
214423375|NCT05723510|DRUG|Apixaban 5mg|Oral administration of one tablet of apixaban 5 mg twice daily
214423376|NCT05723510|DRUG|Rivaroxaban 20mg|Oral administration of one tablet of rivaroxaban 20 mg once daily
214423377|NCT01518478|DRUG|Fluzone® Intradermal (Sanofi Pasteur Inc.)|"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."
214423378|NCT00790790|DRUG|Placebo|LY545694 placebo BID po for 5 weeks
214423379|NCT00790790|DRUG|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
214423380|NCT00790790|DRUG|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
214423381|NCT02570295|OTHER|Swiss Army Physical Fitness Training|2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
214423382|NCT02566707|DRUG|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
215023383|NCT05175001|DRUG|Diprospan|Diprospan combined with ropivacaine in ultrasound-guided thoracic paravertebral nerve block
215023384|NCT05175001|DRUG|Ropivacaine|Only ropivacaine in ultrasound-guided thoracic paravertebral nerve block
215023385|NCT01218321|BIOLOGICAL|antiepileptic treatment|White blood cells from peripheral blood samples
215023386|NCT03511287|OTHER|Inspiratory Muscle Training|Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
215023387|NCT02073201|OTHER|High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
215023388|NCT02073201|OTHER|Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
215023389|NCT02073201|OTHER|Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
215023390|NCT02399566|DRUG|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
215023391|NCT03346746|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
215023392|NCT03346746|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
215023393|NCT00310843|DRUG|Nevirapine|Patients with HIV-1 infection who have taken or are currently taking nevirapine
215023394|NCT03875443|OTHER|Instructional video|Video (produced by AO Trauma and Prof. Daniel Rikli) includes a stepwise and structured explanation of the different fluoroscopic views necessary to evaluate intraoperatively with the fluoroscope different aspects of the proximal femur. The video is publically available under: (https://www.aointeract.org/#/watch/video/L3YxL3ZpZGVvcy8xOTc=/intraoperative-imaging-of-femur).
215023395|NCT03875443|OTHER|Reduction algorithm|Intraoperative reduction algorithm (developed by PD Henrik Eckardt); each step in the algorithm will be checked and documented with the fluoroscope and archived using the store function of the fluoroscope.
215023396|NCT02115243|DRUG|Ipilimumab|
215023397|NCT01380132|PROCEDURE|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
215023398|NCT02674763|DRUG|IMGN779|
215023399|NCT03193138|DRUG|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
214423383|NCT02566707|DRUG|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
214423384|NCT02566707|DRUG|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
214423385|NCT01112644|DRUG|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
214423386|NCT01112644|OTHER|Placebo (PLA)|Different daily doses; intake every 12 hours
214423387|NCT05263115|OTHER|Resistance Exercise intervention|12-week progressive resistance exercise intervention
214423388|NCT05263115|OTHER|Functional stair climbing and stepping-based exercise intervention|12-week progressive stair climbing and stepping-based exercise intervention
214507590|NCT02815865|DEVICE|Foley catheter and pitocin|Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
214507591|NCT02815865|DEVICE|Foley catheter and Dinoprostone|Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
214507592|NCT02815865|DRUG|Dinoprostone|Dinoprostone 3 mg will be inserted to the posterior fornix
214507593|NCT02822599|DRUG|RiaStAP|To decrease post-operative bleeding volume.
214507594|NCT02822599|DRUG|Saline|Placebo consisting of normal saline 0.9%
214507595|NCT00851513|DRUG|Lidocaine|local anesthetics
214507596|NCT00851513|DRUG|Depmedrol|local steroids
214507597|NCT00851513|OTHER|physiological serum|important volumes of physiological serum
214507598|NCT01772199|DRUG|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
214507599|NCT01772199|DRUG|Placebo|White to almost white, round tablets. Once daily orally.
214507600|NCT02198898|DEVICE|GUARDIX-SG|
214507601|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
214507602|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
214423389|NCT04505982|OTHER|Data extraction from medical files|Data extraction from medical files
214423390|NCT06282744|OTHER|Outpatient physical therapy improvement in movement assessment log|The Outpatient Physical Therapy Improvement in Movement Assessment Log (OPTIMAL) is an instrument that measures difficulty and self-confidence in performing 22 movements that a patient needs to accomplish in order to do various functional activities.
214423391|NCT02841150|DRUG|IMBRUVICA (Treatment A)|IMBRUVICA (reference treatment), 4\*140 milligram (mg), capsules.
214507603|NCT02128269|BIOLOGICAL|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
214507604|NCT05352737|DIAGNOSTIC_TEST|methylmalonic acid testing|
214507605|NCT06026943|DEVICE|DaRT seeds insertion|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
214507606|NCT04753450|OTHER|No intervention|No intervention
214507607|NCT01623011|PROCEDURE|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
214690894|NCT03229759|OTHER|Vehicle Control|application of vehicle control
214690895|NCT03229759|OTHER|Saline Control|application of placebo
214690896|NCT07082790|OTHER|Music intervention|The music was provided to the pregnant women with wireless headphones worn over the head, an electronic acoustic device with sound-enhancing ear pads, and an adjustable headband. These headphones allowed the pregnant women to listen to music in isolation. The music played in the study was determined with the recommendation of the Research and Promotion of Turkish Music (TUMATA), which operates in Turkey and carries out treatment studies with Turkish music. Accordingly, pregnant women were made to listen to Acemashiran maqam, which is thought to have a positive effect on the uterus, the baby in the womb, and facilitate birth. According to TUMATA, Acemashiran Maqam has a fiery nature. It is a dry-hot makam. It is effective on bones and the brain. It helps balance fat in the body. It gives a sense of creativity and inspiration. Revitalizes stagnant thoughts and emotions. Facilitates childbirth in women. Helps to correct the wrong posture of the child in.
214690897|NCT07082790|OTHER|Virtual Reality Intervention|Pregnant women in the VR group were given adaptive three-dimensional (3D) glasses that fit snugly on their heads to optimize image quality and provide full distance adjustment. All pregnant women in the group were allowed to wear the glasses for a few minutes before the application in order to get used to the glasses. The image to be projected on the glasses was provided by placing a smartphone compatible with the glasses on the front of the glasses. Pregnant women in the VR group were shown an image of a green landscape with a relaxing sound accompanying the 3D images. Pregnant women in the VR group were shown an image of green nature due to the proven psychologically relaxing effect of green. Since the content in question is prepared in 360 degrees, the person wearing the glasses finds herself in the virtual world and experiences the feeling of being there, no matter which direction she looks.
215023400|NCT01063569|DRUG|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
215023401|NCT01063569|DRUG|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
214690898|NCT07084116|DRUG|Tretinoin 0.1% cream|Tretinoin 0.1% cream formulation.
214690899|NCT07084116|DRUG|Bland cream (non-drug)|Bland cream formulation.
215023402|NCT02095457|BEHAVIORAL|Frequent monitoring and feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
214690900|NCT07083713|BEHAVIORAL|Group Coaching|Group coaching using a protocol developed with Coaching in Context model
215023403|NCT05513170|PROCEDURE|Use of Densah Burs in closed sinus lift|Closed sinus will be performed using Densah Burs. Densah Burs enhance bone quality through osseodensification; a process through which bone is compacted and auto-graphted in the marrow spaces and apically to elevate the sinus floor and enhance bone density.
215023404|NCT05513170|PROCEDURE|Closed sinus lift using osteotomes|Closed sinus lift will be performed using osteotomes. Osteotomes elevate the sinus floor and enhance the bone quality.
214423392|NCT02841150|DRUG|Ibrutinib (Treatment B)|Ibrutinib (test treatment), 1\*560 mg, tablet.
214423393|NCT06469684|BEHAVIORAL|Health education session|1 hour health education session religious teaching promoting health-seeking behaviour, and question and answer session with healthcare professional.
214690901|NCT07084636|OTHER|Video Laryngeal Mask|Video laryngeal mask will be used in this group
215023405|NCT02542371|OTHER|Arterial Imaging|
214423394|NCT01420393|PROCEDURE|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
214423395|NCT01420393|OTHER|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR \< 80 bpm and 6-minute walk HR \< 110 bpm.
214423396|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
214423397|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
214423398|NCT03141333|BEHAVIORAL|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
214423399|NCT01301469|DRUG|6% HES 130/0.42 in plasma adapted Ringer's solution|60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
214423400|NCT01301469|DRUG|6% HES 130/0.4 in a saline solution|60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
214423401|NCT01895218|DRUG|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
214690902|NCT07084636|OTHER|Endotracheal intubation|Endotracheal intubation will be performed in this group.
214694147|NCT02029404|PROCEDURE|Tibial nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
215023406|NCT01582555|DRUG|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
214690903|NCT06929351|PROCEDURE|otago exercise|"Otago exercise program group 40 min/ thrice a week/ 8 weeks~1st week strengthening of knee flexors( prone lying), extensors ( in sitting) ,abductors( in standing) with 1-2 kg ankle cuff. Dorsi flexors, planter flexors(in standing on weight)/ hold 5-10 sec 5 reps/ 2 sets 2nd week Strengthening same as week 1 balance exercises.Knee bending( standing),tandem stance,sit to stand / with support/ 5-10 reps/2 sets 3rd week strengthening of all above Ms group with increase weight 2-3 kg ankle cuff or participant (The exercises are of moderate intensity; the person should not get unduly tired) balance exercise as 2nd week 4th week strengthening exs as in 3rd week balance exs: Knee bending, tandem stance( without support), forward walk,walking and turning around, side walk, one leg stand,sit to stand, stair climb( all with support)/5-10 reps 5th week strengthening exs of above ms group increase either weight 3-4 kg or repetitions 10-15 or hold time 10-15 sec 6th week strengthening same as 5"
214690904|NCT06929351|PROCEDURE|Dual task exercise|"Balance exercises and secondary cognitive task simultaneously 40 min/ thrice a week/ 8 weeks~1. st week Balance exercises: Narrow-base standing on the floor (firm surface) with eyes open and closed, Tandem standing on the floor with eyes open and closed, Single-leg standing on the floor with eyes open and closed, Wide-base walking on the floor, Chair sitting to standing transfer Cognitive tasks: Naming a group of cities; foodstuff; boy names; or girl names starting with A,I, S, and T sounds/ 3 trails~2. nd week Balance exercise: Narrow-base standing on the floor with open eyes while moving arms, Forward lunge standing on the floor with eyes open, Narrow-base walking on the floor, keeping balance while sitting on a ball and moving arms in different directions Cognitive task: Backward counting from 50,Count by multiple(3,6,9…….)/3trails Week 3 Balance exercises: Narrow-base standing on a foam with eyes open and closed, Tandem standing on a foam with eyes open and closed, Backward walking on"
215023407|NCT01582555|DRUG|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
215023408|NCT01933555|BEHAVIORAL|Empowerment Program|
215023409|NCT06564714|DRUG|Early baclofen Intervention|"Baclofen is initiated as soon as any sign of acute spasticity.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response, i.e. when spasticity is no longer problematic."
215023410|NCT06564714|DRUG|Usual routine care|"Baclofen is initiated only when acute spasticity is deemed problematic.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response."
215023411|NCT05665452|PROCEDURE|Patellar mobilization, retinacula release, deep friction message, stretch and strength|"All exercises will be performed for 30 to 45 minutes per session, 3 times per week for 4 weeks (12 sessions). Group (1): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise).~Group (2): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise). manual therapy consists from iliotibial band release, deep friction message for lateral retinacula and medial patella mobilization."
215023412|NCT02320071|OTHER|Examination of abdominal wall strength changes over time|
215023413|NCT05505786|BEHAVIORAL|Normal stance width|Normal self-selected stance width when performing squat exercises.
215023414|NCT05505786|BEHAVIORAL|Wide stance width|Increased stance with (by 20% over their own self-selected stance width) when performing squat exercises.
215023415|NCT04632862|DRUG|DWP16001|DWP16001 A mg
215023416|NCT02133872|DRUG|Minocycline dose escalation|Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.
215023417|NCT04085731|PROCEDURE|Catheter ablation|Driver-guided catheter ablation of persistent atrial fibrillation
215023418|NCT03439072|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
215023419|NCT03439072|DRUG|Lilly Glucagon|1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])
214423402|NCT01895218|OTHER|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
214423403|NCT01183871|PROCEDURE|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
215023420|NCT03594474|OTHER|Intravenous lipid emulsion|using higher dose of IV lipids after birth
215023421|NCT05299580|DRUG|dabrafenib|Dabrafenib 150 mg bid
215023422|NCT05299580|DRUG|Trametinib|Trametinib 2mg qd
215023423|NCT05001113|PROCEDURE|the subxiphoid approach thoracoscopic thymectomy|A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.
215023424|NCT05001113|PROCEDURE|the lateral intercostal approach thoracoscopic thymectomy|"Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces."
214690905|NCT06929208|DEVICE|Electrocardiogram (ECG) monitor|"A novel AI-based risk stratification algorithm incorporated into portable platform will be used to monitor and measure patient's ECG, blood pressure, SpO2, and HRV parameters. The platform comprises a tablet application that the clinicians interface with, and coupled with a patient monitoring device with the app that received the real-time patient vital signs to be processed. It requires only a 5-minute 12-lead ECG recording and provides a diagnostic report and risk score on major adverse cardiac events in patients with chest pain complaints. The device is approved as a Class C Medical device by Health Science Authority Singapore for clinical use in Singapore.~Three ECG samples for HRV data will be recorded before, during and after music listening, with a sampling rate of 1000Hz, 5-10-minute duration in the supine position and breathing spontaneously to minimise influence from external factors."
214690906|NCT06929208|OTHER|Music listening|Patients will be given a mobile phone to choose their preferred music to be played during surgery. The music list contains songs across pre-saved playlists spanning different music genres compiled by the institution's music therapist to ensure adequate coverage of the various music genres and to promote relaxation and serenity.
214690907|NCT07076251|OTHER|Family Box program|Boxes will include approximately five pounds of dry ingredients (e.g., whole grains, legumes, flour), which translates into about 40 servings of food for a family of four per month. Each ingredient box will include culturally relevant recipes and, six times out of the twelve boxes, include a culturally relevant book for the family's child/children.
214423404|NCT02940704|PROCEDURE|Reciproc|"* Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~* There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~* Reciproc file selection: R40 (40/0.06) is to be used."
214423405|NCT02940704|PROCEDURE|One Shape|"* Coronal preflaring will be performed using Gates Glidden drill.~* Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~* For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
214507608|NCT01623011|PROCEDURE|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
215023425|NCT01520103|DRUG|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
215023426|NCT01520103|DRUG|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
215023427|NCT02923167|DEVICE|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
215023428|NCT02154230|DIETARY_SUPPLEMENT|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
214423406|NCT06081686|DRUG|Phase I:[177Lu]Lu-XT033 Injection|Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of \[177Lu\] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .
214423407|NCT06081686|DRUG|Phase II:[177Lu]Lu-XT033 Injection|Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
214690908|NCT06817226|BEHAVIORAL|Assess decision making context.|Semistructured interviews will be conducted to understand the situations and settings in which breast reconstruction decisions occur for this population, including the role of digital tools and social media.
214690909|NCT06817226|BEHAVIORAL|Solicit input from the target population|Solicit input from the target population about the tool such as translation, website programming, and community feedback.
214690910|NCT06817226|BEHAVIORAL|Integration and refinemen of the decision aid|A final round of cognitive interviews with breast cancer survivors while they use the revised tool and a final round of website programming.
214690911|NCT07084376|OTHER|Enhanced Educational Program for Intermittent Catheterization|Participants in this group receive an enhanced educational program for intermittent catheterization (IC), including an informational booklet, a specifically designed video tutorial, and standard clinical practice training. The program aims to improve psychological acceptance, adherence, and self-efficacy by providing comprehensive and patient-centered educational materials in addition to standard care.
215023429|NCT02154230|DIETARY_SUPPLEMENT|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
214423408|NCT02570711|DRUG|ACP-196|ACP-196 capsule
214423409|NCT02570711|DRUG|Nab-paclitaxel|Nab-paclitaxel infusion
214423410|NCT02570711|DRUG|Gemcitabine|Gemcitabine infusion
214507609|NCT01623011|OTHER|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
215103199|NCT06312319|DEVICE|Respiratory training|Respiratory training using the EMST 150 device to increase inspiratory and expiratory muscle strength.
215103200|NCT06312319|OTHER|Orofacial exercises|The exercises will include activities to improve orofacial structures such as mobility, strength and coordination.
214690912|NCT07084376|OTHER|Standard Education Group|Participants in this group will receive standard clinical practice training for intermittent catheterization (IC), as routinely provided in participating healthcare centers. This training focuses on basic procedural skills and practical education necessary to perform IC independently, without additional enhanced educational materials such as booklets or video tutorials.
214690913|NCT07084519|RADIATION|hypofractionated radiotherapy|43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks)
214690914|NCT07084519|RADIATION|conventional fractionated radiotherapy|50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks
214690915|NCT04627428|BIOLOGICAL|RPESC-RPE-4W|RPESC-RPE-4W
214690916|NCT06923358|OTHER|Virtual Nature intervention (VN)|The intervention will consist of a 12-week virtual nature program in which participants will engage in two sessions per week. During each session, they will watch a 10-minute 360° video depicting a natural setting. Participants will select videos from a curated library of nature scenarios filmed by researchers in locations near or within the same region as their nursing homes. The videos will showcase various seasons in Norway (spring, summer, fall, and winter) and include popular activities such as hiking and cross-country skiing. The videos will be played using a Meta Quest 3 headset, with sessions conducted in participants' rooms by nursing home staff-except for the first session, which will be facilitated by the researchers.
214690917|NCT06931067|BEHAVIORAL|OTAGO Exercise Program with motivational interviewing|OTAGO exercise home visits will be offered 7 times with 2 phone-based check-ins during the 6-month period. As part of OTAGO home visits, participants will receive OTAGO exercise instruction and MI. Each home visit will be approximately an hour.
214690918|NCT06930482|BEHAVIORAL|Safe early intervention|The SAFE early intervention approach, an activity-focused, sensory intervention program, was applied to the babies in the intervention group in an enriched environment. As part of the intervention, coaching was provided in collaboration with the family on how to support the baby's development. For this purpose, family visits were made 15 days after the initial assessment and once a month. During these visits, the suggestions given to the family were repeated and all questions about the process were answered. It was discussed how the home environment should be structured in a way that is appropriate for the baby's development. The aims of the approaches applied were explained and information was provided about the follow-up process. In order to follow up on whether the family implemented the intervention, the family was interviewed by phone and the family was asked to keep an activity diary.
215023430|NCT04932772|OTHER|Kinesiotaping|Technique: Include Rectus Abdominas Muscles (RAM), Oblique Abdominal Muscles (OAM). Tape will be applied on RAM using muscles technique from origin to insertion of muscle with a tension between15-35%. Band will be start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xyphoid process. Finally will perform on the right and left external oblique muscles the procedure will be start with no tension from bottom and of 6-12 ribs and then the hip will be place in flexion and rotation to opposite direction and the band will tape on pubic bone with tension between 15-35% (Kase et al., 2003).
215023431|NCT04932772|OTHER|Abdominal Exercises|Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
215023432|NCT01537432|DRUG|secukinumab|secukinumab
215023433|NCT01537432|DRUG|placebo|placebo comparator
215023434|NCT04007679|OTHER|Pain neuroscience education|Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
215023435|NCT00370084|DRUG|Itopride|oral, three times daily
215023436|NCT00370084|OTHER|Placebo|oral, three times daily
215023437|NCT00916916|OTHER|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
215023438|NCT00314977|DRUG|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
214507610|NCT00878189|DRUG|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
214507611|NCT01750788|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
214507612|NCT02560155|DRUG|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
214507613|NCT02560155|DRUG|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
214507614|NCT04017364|DEVICE|PCB PTCA|Predilatation of coronary de-novo stenosis followed by a PCB
214507615|NCT04017364|DEVICE|SCB PTCA|Predilatation of coronary de-novo stenosis followed by a SCB
214507616|NCT05413993|RADIATION|photobiomodulation|Laser application intraorals and extraoral points in the region of the salivary glands bilaterally
214507617|NCT00643409|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
214507618|NCT00643409|OTHER|placebo|placebo
214507619|NCT00643409|DRUG|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
214690919|NCT06930482|BEHAVIORAL|early intervention approach based on neurodevelopmental treatment|Within the scope of the study, NGT-based applications were applied to the babies included in the control group by their families. After the first assessment, activities were planned to support skills appropriate to the child's developmental level. The treatment movements, how to facilitate the baby's movements, and how to provide hand contact were demonstrated to the families in practice. The applicability of the intervention program was monitored with weekly phone calls. The babies were called to the clinic environment for a check-up every month to revise the intervention program and teach new movements, and an evaluation was made. Two home visits were made to evaluate the families' home environments and parental attitudes (pre- and post-intervention).
214690920|NCT06928844|DRUG|Progesterone|Women will receive low dose progesterone 5 mg intramuscularly as a study group. (Letrozole 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).
214507620|NCT00643409|OTHER|placebo|placebo
215023439|NCT00314977|DRUG|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
214507621|NCT06244914|DEVICE|tDCS stimulation|tDCS 1mA will be applied for 20min. tDCS will be applied around the infract area. taVNS or sham taVNS wil be applied before tDCS. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
214507622|NCT06244914|DEVICE|taVNS stimulation|taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of taVNS will be adjusted under the patient's pain threshold. After taVNS, tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
214690921|NCT06928844|DRUG|Placebo|Women will receive placebo as a control group. (Placebo 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).
214690922|NCT06930261|DRUG|LBT-999|LBT-999 administration for PET imaging
214690923|NCT01686503|DRUG|IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose|Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
214690924|NCT00650429|DRUG|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
214507623|NCT06244914|DEVICE|sham tDCS stimulation|sham tDCS 1mA will be applied for 20min. sham tDCS will be applied around the infract area. The stimulation will be applied for only 10 seconds and no stimulation afterward. taVNS or sham taVNS wil be applied before sham tDCS.The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
214507624|NCT06244914|DEVICE|sham taVNS stimulation|sham taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of sham taVNS will be adjusted under the patient's pain threshold. The stimulation was only applied for 5 seconds and no stimulation afterward. After sham taVNS, tDCS or sham tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
214690925|NCT00523822|OTHER|Spinal Manipulative Therapy|
215023440|NCT00314977|DRUG|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
215023441|NCT01971918|BIOLOGICAL|anti drug antibodies dosage|anti drug antibodies dosage
215023442|NCT05507047|DRUG|Enamel Matrix Protein|Enamel matrix derivated is used with transcrestal sinus lifting treatment
215023443|NCT05166902|DEVICE|Lens A (comfilcon A lens)|1 month
215023444|NCT05166902|DEVICE|Lens B (lehfilcon A lens)|1 month
215023445|NCT05628571|COMBINATION_PRODUCT|Zinc toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).
215023446|NCT05628571|COMBINATION_PRODUCT|Fluoride Toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).
215023447|NCT03064009|OTHER|Infection|This is an observational trial
215023448|NCT01765413|BIOLOGICAL|Varicella-zoster virus|
215023449|NCT01765413|BIOLOGICAL|Yellow Fever Vaccine|
215023450|NCT01765413|BIOLOGICAL|Placebo|
215023451|NCT01998477|BIOLOGICAL|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain \[A/H1N1-like, A/H3N2-like, and B-like\]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
215023452|NCT01998477|BIOLOGICAL|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain \[A/ H1N1-like, A/H3N2-like, and B-like\]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
215023453|NCT01269775|OTHER|Teaching Methods|We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
215023454|NCT04843592|DEVICE|SOKARY Mobile|Effectiveness of using SOKARY Mobile Application on compliance of patient with Type II diabetes
215023455|NCT04984200|PROCEDURE|Retinal imaging|Subjects will undergo retinal imaging before and/or after administration of mydriatic agent
215023456|NCT04984200|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
215023457|NCT01532154|DRUG|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
215023458|NCT05044481|PROCEDURE|third molar surgical removal|ambulatory surgical intervention of the maxilla and / or mandible for third molar removal
215023459|NCT01210781|PROCEDURE|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
215023460|NCT00779909|DRUG|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
214690926|NCT07164144|BEHAVIORAL|Vaccine Communication Training|School personnel receive vaccine communication training + promotional materials
214690927|NCT07163247|BEHAVIORAL|Robotic pet (PARO) companionship|"The intervention is composed of the following components:~Duration: Robotic pet companionship lasting 30-120 minutes, depending on clinical goals during each spontaneous breathing trial (SBT).~Preparation and interaction: PARO is introduced 30 minutes before each SBT to establish emotional connection. Study staff will briefly introduce its interactive features, including responding to stroking, gentle tapping, head movements, and eye blinking. Participants may interact freely with PARO during the intervention.~Assessment: Outcome measurements are conducted during the intervention. If extubated successfully, a semi-structured interview is conducted three days later.~Early termination: The intervention is stopped if the participant becomes clinically unsuitable for further SBTs or experiences a serious adverse event (e.g., device dislodgement).~Additional information: After each SBT, PARO is sterilized and stored in a sealed container in the patient's room."
214690928|NCT07162701|DIAGNOSTIC_TEST|Bioimpedance analysis|Patients' body composition will be assessed using bioimpedance analysis (Akern)
214690929|NCT07163273|DRUG|NALIRIFOX|NALIRIFOX consists of 5-FU 2400 mg/m2 over 46 hours, liposomal irinotecan 50 mg/m2, and oxaliplatin 60 mg/m2, which would be given on Day 1 and Day 15
214690930|NCT07163273|DRUG|Gemcitabine plus nab-Paclitaxel (GnP)|GnP consists of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2, given on Days 1, 8, and 15.
214690931|NCT07161869|PROCEDURE|Registration of all findings during preoperative Endoscopic Ultrasound|Using the improved POELH-III EUS format
214690932|NCT01861938|BIOLOGICAL|Melanoma vaccine modified to express HLA A2/4-1BB ligand|
214690933|NCT05579912|PROCEDURE|Esophageal and gastric resections requiring an anastomosis|Distal gastrectomies, total gastrectomies, bariatric gastric bypasses, subtotal esophagectomies, proximal gastrectomies, palliative bypasses, and total esophagectomies.
214690934|NCT01556802|DRUG|Minocicline|Minocicline 100mg oral twice a day for 5 days
214690935|NCT01556802|DRUG|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
214507625|NCT05391867|DRUG|Lenvatinib|Tyrosine kinase inhibitor
214507626|NCT02007070|BIOLOGICAL|Pembrolizumab|Intravenous infusion
214690936|NCT06097767|DRUG|Caffeine citrate|It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
214690937|NCT06097767|DRUG|Amikacin|it includes preterm infants with respiratory distress syndrome who received amikacin in regular intervention therapy in control group
214690938|NCT01430572|DRUG|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
214690939|NCT01430572|DRUG|Everolimus|"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."
214690940|NCT01923233|BIOLOGICAL|AlloStim|allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
215023461|NCT00779909|OTHER|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
215023462|NCT03462602|PROCEDURE|NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was retained until the return of bowel function (passage of flatus or passage of stool) in the patients assigned to the NGT group.
215023463|NCT03462602|PROCEDURE|non-NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was removed in the operation room immediately after the surgery in those assigned to the non-NGT group.
215023464|NCT03523585|DRUG|Trastuzumab deruxtecan|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
215023465|NCT03523585|DRUG|Capecitabine|Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
215023466|NCT03523585|DRUG|Lapatinib|Investigator's choice Standard of Care when combined with capecitabine
215023467|NCT03523585|DRUG|Trastuzumab|Investigator's choice Standard of Care when combined with capecitabine
215023468|NCT02171728|DRUG|BIBW 2992|
215023469|NCT02386072|DRUG|mirabegron|oral
215023470|NCT02386072|DRUG|antimuscarinic medication|oral
214507627|NCT05350670|BEHAVIORAL|Perineal massage and cold compress|Using perineal massage and cold compress during the second stage of labor to observe the effect
214507628|NCT00703092|DRUG|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
214507629|NCT03773432|OTHER|Probe meal|The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).
214507630|NCT05774262|PROCEDURE|Pacemaker implantation|Elective pacemaker implantation (DDDR) for functional AVB according to the 2021 ESC Guidelines for Cardiac Pacing
214694148|NCT02029404|PROCEDURE|Tibial peroneal nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
215023471|NCT05277935|DEVICE|Use of the WeCancer app combined with the smartwatch.|To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy
215023472|NCT05454982|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
215023473|NCT04614779|DRUG|CN128 Tablets|Iron chelator, oral tablets
215023474|NCT01799902|DRUG|Solifenacin|Oral
215023475|NCT00000340|DRUG|Pemoline|
215023476|NCT05129306|OTHER|Observational|In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.
215103201|NCT05138887|DRUG|Tetrahydrobiopterin|The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
215103202|NCT04651608|BEHAVIORAL|manuel acupressure|Acupressure was applied once by the researcher 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child. 3 fingers were placed on the child's wrist with their fingers and the region (point P6) between the flexor carpi radians and palmaris longus 1 cm below. Acupressure was applied to the wrist of the child by press for 2 minutes. The same procedure was applied to the other wrist. Then, data were recorded in accordance with the data collection procedure.
214507631|NCT05774262|PROCEDURE|Cardioneuroablation (CNA)|"Experimental method; elective implantable loop recorder (ILR) and biatrial, binodal, atomically and electroanatomically guided CNA with extracardiac vagal nerve stimulation (ECVS) prior and after procedure monitoring (disappearance of ECVS-induced AVB with the goal of achieving post-procedure and maintaining a target heart rate \> 50 beats per minute). CNA procedure is performed with radio-frequency generators and irrigated catheters and with support of 3D-electroanatomic mapping system.~CNA group will receive external ECG recorders. The major reason for external ECG recorders is to provide documentation of clinical AVB, as well as monitoring of patients before and after CNA (or PM implantation, if accepted). In case of severe AVB symptoms always the emergency system will be called."
214507632|NCT03165305|OTHER|Sustained Inflation|Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
214507633|NCT06374407|BEHAVIORAL|Dietary intervention based on the MIND diet|A 12-week pilot randomized controlled trial (RCT) involving N=126 obese participants (1:1 gender ratio) to assess protocol feasibility, including recruitment, retention, compliance, physical examinations, and gut sample collection. Sample size, calculated by a statistician, expects a 5% body weight change at follow-up (std. dev. 10%). We chose a 12-week duration for this pilot study to allow sufficient time to observe significant changes in both body weight and mental health.
214507634|NCT02028390|DEVICE|Scout takes visual and thermal images of external wounds|All images are taken after the wound has acclimated.
214507635|NCT02028390|DEVICE|ImageReview's visual perimeter trace of the external wound|Trace is drawn by the study staff using the ImageReview software.
214507636|NCT02028390|DEVICE|ImageReview's External Wound Trace Overlay|Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
214507637|NCT02028390|DEVICE|ImageReview's unaffected reference area selected|Study Staff select an unaffected reference area of an adjacent body surface.
214507638|NCT02028390|DEVICE|Adjacent tissue trace of the wound trace overlay|Study staff select an adjacent tissue trace of the wound trace overlay
214507639|NCT04383392|DEVICE|Rate adaptive pacing|Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
214507640|NCT05255744|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
214507641|NCT05396365|DIAGNOSTIC_TEST|Dynamometry|Hand grip dynamometer measure of strength and anthropometric measurements
215023477|NCT00005940|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
214690941|NCT01303809|OTHER|Enhanced Recovery After Surgey for Sleeve Gastrectomy|"Intraoperative:~1. Pre-op carbohydrate loading~2. No pre-op GIK while NBM~3. Pre-medication~4. Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg~5. Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics~6. Fluid restriction~7. Standardised method of anaesthesia~8. Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites~9. 10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure~Postoperative:~1. Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively~2. Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1~3. Post operative oxygenation~4. Incentive spirometry~5. Drains (e.g. IDC) removed in recovery~6. Full mobilisation 4-8 hours post op)~7. Early Follow up"
214690942|NCT00536042|DRUG|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
214690943|NCT06129318|BEHAVIORAL|Clinical Pharmacist Led Pharmaceutical Care|Within the scope of pharmaceutical care, medication review services for past and current medication use were provided by the clinical pharmacist. The patients in the intervention group were given verbal information about the definition of stroke, symptoms, how to manage risk factors, and their medications by the clinical pharmacist on the day of discharge, in addition to the neurologist. Each patient in the intervention group had a scheduled meeting with the clinical pharmacist. During the 1-year follow-up the patient education given by the clinical pharmacist was repeated every 3 months.
215103203|NCT04651608|BEHAVIORAL|sea-band acupressure|30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child, sea-band acupress was applied by the researcher. The P6 point on the wrist was identified and marked with the child's own fingers. A sea band was attached to both wrists of the child by the researcher. The attached sea-band was allowed to remain for 15 minutes and was removed by the researcher at the end of the period. Separate sea-band was attached to each child. Acupress wrist bands, which are produced in separate sizes for adults and children, were used during the application, taking into account the physical development of the child, pediatric for the age range of 5-12, and adult size sea-band for the age of 12. Acupress application with sea-band was done once. Then, data were recorded in accordance with the data collection procedure
214423411|NCT03916835|DEVICE|Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.|"Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized."
214423412|NCT02798835|DRUG|Adductor canal block|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
214690944|NCT03172611|OTHER|Dietary Intervention|Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
214507642|NCT04155372|PROCEDURE|Different Fluid Ingestion Rate|The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.
214690945|NCT01711320|DRUG|Placebo|
214690946|NCT01711320|DRUG|Omeprazole|
215023478|NCT00005940|DRUG|busulfan|Given PO
215023479|NCT00005940|DRUG|cyclophosphamide|Given IV
214690947|NCT01116219|BIOLOGICAL|bevacizumab, erlotinib|"* Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~* Erlotinib 150 mg p.o. daily until progression."
214690948|NCT01116219|DRUG|bevacizumab, pemetrexed, cisplatin|"Induction chemotherapy with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. and~* Cisplatin\* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
214690949|NCT03779035|DRUG|Gemcitabine|1000mg/m2
214507643|NCT02803866|BEHAVIORAL|Training program CAP-PREM|1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
215023480|NCT00005940|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic PBSC or bone marrow transplant
215023481|NCT00005940|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
215023482|NCT00005940|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
215023483|NCT00005940|DRUG|cyclosporine|Given IV or PO
215023484|NCT00005940|DRUG|methotrexate|Given IV
215023485|NCT00005940|OTHER|laboratory biomarker analysis|Correlative studies
214507644|NCT02708498|BEHAVIORAL|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
214507645|NCT05173766|OTHER|ergonomic principls|Ergonomic principles for posture correction in office for computer users.
215023486|NCT04870866|DRUG|Nicotinamide ribonucleoside|Two year intervention
214690950|NCT03779035|DRUG|Capecitabine|1250mg/m2
215023487|NCT03878121|BIOLOGICAL|Ad4-Env145NFL|10\^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.
215023488|NCT03878121|BIOLOGICAL|Ad4-Env150KN|10\^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.
215023489|NCT03878121|BIOLOGICAL|VRC-HIVRGP096-00-VP (Trimer 4571) with alum|500-mcg dose of protein boost vaccine formulated for intramuscular administration.
215023490|NCT06546527|DRUG|[177Lu]Lu-PSMA-137|\[177Lu\]Lu-PSMA-137 500 MBq;50% optimal dosing;100% optimal dosing
215023491|NCT03940521|OTHER|Bioclinical evaluation|50-100ml blood extracted for flow cytometry and qPCR
215023492|NCT00003053|DRUG|cisplatin|
214507646|NCT06412432|OTHER|Exercise training (ET1+ET2)|Exercise training will consist of continuous aerobic training of moderate intensity on cycle ergometer/treadmill, with a frequency of 2-3 weekly sessions lasting 12 weeks, with exercise intensity of VO2 peak of 40% gradually increasing up to 50-60% of VO2 peak based on individual tolerability and improvement; 55-65% of heart rate at peak; 40-59% of heart rate reserve; 4-6 Metabolic equivalents (METS); the duration of the session will gradually increase from 15-30 min to 45-60 min.
215023493|NCT00003053|DRUG|etoposide|
215023494|NCT00003053|PROCEDURE|adjuvant therapy|
215023495|NCT05360225|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.
215023496|NCT05406726|DIETARY_SUPPLEMENT|palmitoylethanolamide|palmitoylethanolamide is an lipid based endocannabinoid naturally made by the body and is present in several common foods such as eggs
215023497|NCT05406726|DIETARY_SUPPLEMENT|Placebo|a capsule filled only with maltodextrin will be used as a placebo
215023498|NCT06401109|DEVICE|AquaPass|"The AquaPass system works by activating the body's natural sweating mechanism to remove excess fluid from the interstitial compartment. This process is achieved by wearing a garment that creates optimal microclimate conditions around the skin.~The system is controlled by a portable unit that delivers warm air to the wearable component while ensuring patient safety."
215023499|NCT03309475|BEHAVIORAL|SocialMIND|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
215023500|NCT03309475|BEHAVIORAL|Psychoeducational multicomponent intervention|The psychoeducational multicomponent intervention addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.
215023501|NCT03309475|BEHAVIORAL|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
215023502|NCT03309475|DRUG|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
215023503|NCT06142591|DRUG|Oxycodone 10mg|10mg of oxycodone was added to Octenisept in the wound dressing.
215023504|NCT06142591|DRUG|Oxycodone 20mg|20mg of oxycodone was added to Octenisept in the wound dressing.
215023505|NCT00744419|DRUG|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose \[0.4 mg/kg (\< 44 wks PMA) or 0.8 mg/kg (44 wks to \< 1 yr)\] and the last 6 subjects in each age group will receive high dose \[0.8 mg/kg(\< 44 wks PMA) or 1.6 mg/kg(44 wks to \< 1 yr)\]
215023506|NCT05345405|BEHAVIORAL|Dyadic CARE|Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
215023507|NCT05345405|BEHAVIORAL|Supporter-Only CARE|Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
215023508|NCT00635583|OTHER|Increased Dairy Consumption|"3 additional servings of dairy (two of which must be milk or yogurt)~* 8 oz milk~* 6 oz yogurt~* 1.5 oz cheese"
215023509|NCT03920020|OTHER|the concentric isokinetic exercise group|concentric isokinetic exercises
215023510|NCT03920020|OTHER|the eccentric isokinetic exercise group|eccentric isokinetic exercises
215103204|NCT04651608|BEHAVIORAL|placebo manuel acupressure|Placebo manual acupress was applied in the next protocol for the child who was administered manual acupressure.
215103205|NCT04651608|BEHAVIORAL|placebo sea-band|Placebo sea-band was applied in the next protocol for the child who was administered sea-band acupressure.
215103206|NCT06136611|DEVICE|TTFields|TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
215103207|NCT00619307|DRUG|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
214507647|NCT06412432|BEHAVIORAL|Optimal Medical Therapy (No-ET)|Patients will be handled according to optimal medical therapy
214507648|NCT00539955|BEHAVIORAL|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
214694149|NCT01064453|DRUG|E2/DRSP (Angeliq, BAY86-4891)|Take one tablet daily, continuously
215023511|NCT03920020|OTHER|the control group|conventional physiotherapy and standard therapeutic exercises predetermined by us
215023512|NCT03704922|BIOLOGICAL|Transfusion|Red cell units for transfusion
215023513|NCT01132690|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
215023514|NCT00003327|DRUG|paclitaxel|
215023515|NCT03380988|OTHER|Acute test meal with fiber-enriched buckwheat pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
215023516|NCT03380988|OTHER|Acute test meal with corn pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
215023517|NCT00825448|PROCEDURE|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
215023518|NCT00944021|DRUG|PA-824|50mg
215023519|NCT00944021|DRUG|PA-824|100mg
215023520|NCT00944021|DRUG|PA-824|150 mg
215023521|NCT00944021|DRUG|Rifafour e-275 mg|275 mg
215023522|NCT00944021|DRUG|PA-824|200 mg
215023523|NCT00170820|DRUG|Everolimus|
215023524|NCT03495895|BEHAVIORAL|Minding the Baby|Visits are carried out on an alternating basis by a team made up of a nurse practitioner (NP) and social worker.
215023525|NCT03495895|BEHAVIORAL|Usual Care|Usual care condition
215023526|NCT03568786|PROCEDURE|End-inspiratory pause 10%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 10% of the total inspiratory time
215023527|NCT03568786|PROCEDURE|End-inspiratory pause 30%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 30% of the total inspiratory time
215023528|NCT01795339|DRUG|AZD3293|Oral solution
215023529|NCT01795339|DRUG|Placebo|Oral solution
215023530|NCT02872142|BIOLOGICAL|Albutein 5%|Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
215023531|NCT02872142|PROCEDURE|Plasma Exchange|Plasma Exchange will be performed using albutein 5% as the replacement solution.
215023532|NCT05243316|PROCEDURE|Clamping|There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.
215023533|NCT05243316|PROCEDURE|Non Clampling|There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.
215023534|NCT06522932|DRUG|64Cu-GRIP B|Given IV
215023535|NCT06522932|PROCEDURE|Positron Emission Tomography (PET)|Undergo imaging procedure
215023536|NCT06522932|PROCEDURE|Optional tumor biopsy|Undergo optional tumor biopsy
215023537|NCT00204581|DRUG|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
215023538|NCT01903720|DRUG|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
215023539|NCT02002195|DRUG|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
215023540|NCT02002195|DRUG|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
215023541|NCT03199534|DRUG|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
215023542|NCT03199534|DRUG|Botulinum toxin A 100u|Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
215023543|NCT03199534|DRUG|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
215023544|NCT00952562|DIETARY_SUPPLEMENT|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
215023545|NCT00952562|DIETARY_SUPPLEMENT|placebo|Empty capsules, 3 capsules per day for 16 weeks
215023546|NCT03470883|OTHER|Evaluation of the long-term complete remission rate (> 12 months)|Evaluation of the long-term complete remission rate (\> 12 months)
215023547|NCT00002656|DRUG|pyrazoloacridine|"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
215023548|NCT01604798|OTHER|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
215023549|NCT02244957|DEVICE|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations \<88% while on stable bi-level settings.
214423413|NCT02798835|DRUG|Adductor canal block with dexamethasone|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
214423414|NCT02798835|DRUG|Adductor canal catheter|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
214423415|NCT02798835|DRUG|Bupivacaine|Used in spinal anesthetic
214423416|NCT02798835|DRUG|Fentanyl|May or may not be used in spinal anesthetic
214423417|NCT02798835|DRUG|Ropivacaine 0.5% Injectable Solution|Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
214423418|NCT02798835|DRUG|Dexamethasone|To be given intravenously at time of nerve block to one of the study arms.
214423419|NCT05767294|OTHER|Observation|clinical manifestation (body temperature, fever days before admission, cough, red throat/sore throat, runny nose, shortness of breath, wheezing, vomiting), physical signs (auscultation of lungs, X-ray results), length of stay, therapeutic measures (oxygen therapy, ICU admission, antibiotic therapy, etc.)
214423420|NCT00984737|DRUG|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
214423421|NCT03082846|RADIATION|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
214690951|NCT03785496|DRUG|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
214690952|NCT06017583|DRUG|Tislelizumab|Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed.
215023550|NCT02244957|DRUG|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
214507649|NCT00539955|BEHAVIORAL|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
215023551|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
215023552|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
215023553|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 24 weeks
215023554|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 48 weeks
215023555|NCT01482403|DRUG|boceprevir|800 mg three times a day for 24 weeks
215023556|NCT01482403|DRUG|boceprevir|800 mg three times a day for 48 weeks
215023557|NCT01482403|DRUG|mericitabine|1000 mg twice daily for 24 weeks
215103208|NCT00619307|DRUG|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
215103209|NCT00006026|DRUG|rubitecan|
215023558|NCT01482403|DRUG|mericitabine placebo|mericitabine placebo
215023559|NCT01482403|DRUG|boceprevir placebo|boceprevir placebo
215023560|NCT01482403|DRUG|boceprevir|800 mg three times a day for 44 weeks
214507652|NCT01558726|BEHAVIORAL|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
214507653|NCT01558726|BEHAVIORAL|Usual Treatment|The usual treatment used for regular patients of CAPSad
214507654|NCT00693836|GENETIC|genetic linkage analysis|
215023561|NCT02534155|DEVICE|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
215023562|NCT02534155|PROCEDURE|Mitral valve Surgery|Repair or replace mitral valve
215103210|NCT03226470|BIOLOGICAL|T512|T512 suppository contain 500 µg of T512 and suppocire.
215103211|NCT00420121|PROCEDURE|laboratory analysis|blood withdrawal for laboratory analysis
215103212|NCT00557453|DRUG|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
214423422|NCT03082846|DRUG|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
214423423|NCT05404906|DRUG|Azacitidine|Given SC
214423424|NCT05404906|DRUG|Venetoclax|Given PO
214423425|NCT05404906|OTHER|Supportive care|Patients will receive disease monitoring and supportive care for any complication.
214423426|NCT04558112|DRUG|L-DOPA|two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)
214423427|NCT04558112|DRUG|Placebo|two gel capsules of placebo
214507655|NCT00693836|GENETIC|loss of heterozygosity analysis|
214507656|NCT00693836|GENETIC|mutation analysis|
214507657|NCT00693836|GENETIC|polymerase chain reaction|
214507658|NCT00693836|GENETIC|polymorphism analysis|
214507659|NCT00693836|OTHER|biologic sample preservation procedure|
214507660|NCT00693836|OTHER|medical chart review|
214507661|NCT00693836|OTHER|questionnaire administration|
214507662|NCT00693836|PROCEDURE|evaluation of cancer risk factors|
214507663|NCT03748056|BEHAVIORAL|Targeted incentives|Participants receiving individually-targeted incentives will receive weekly coupons for healthier foods that are informed by their purchase history, responses to behavioral and health questions, food preferences, and need for improvement in different categories
214507664|NCT03748056|BEHAVIORAL|Nominal loyalty card discount and nutrition education|All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
214507665|NCT02520336|BEHAVIORAL|Reminder|
214507666|NCT06452121|OTHER|triglyceride glucose index|"The TyG index was calculated using the following equation: Ln \[TG (mg/dL)×FPG (mg/dL) / 2\].~CAD was referred to as at least one major coronary artery with≥50% stenosis evaluated by CAG"
215103213|NCT00557453|DRUG|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
214507667|NCT06215326|BEHAVIORAL|moderate-intensity continuous training|Participants in MICT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a warm-up of 5 minutes at 50% at peak WR, the patient start exercising at 60%-70% peak WR for 30-40 minutes (four 5-8 minutes sets, with a 2-min rest in between), and then the patients cooled down for 5 minutes at 50% peak WR. Moderate-intensity exercise training intensity control at 55-74% HRmax or 40-69% VO2peak or PRE12-13 as recommended by guidelines.
215023563|NCT02548819|OTHER|MRI|MR imaging of patients with implanted cardiac devices
215023564|NCT03194932|DRUG|Venetoclax|Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
215023565|NCT03194932|DRUG|Cytarabine|Given intravenously (IV) or intrathecally (IT).
214507668|NCT06215326|BEHAVIORAL|high-intensity interval training|Participants in HIIT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a 5-minute warm-up at 50% at peak WR, the patients complete 20 series of vigorous-intensity sprint (80%-100% peak WR for 30-60s) separated by a low-intensity recovery (30% peak WR or completely rest for 15s), and then the patients cooled down for 5 minutes at 50% peak WR. Participants will begin training at a relatively moderate intensity (60%-65% peak WR) for the first 3 sessions and gradually increase to the target intensity beginning on the 4th session. Intensity control of high-intensity exercise training at 75-90% HRmax or 70-85% VO2peak or PRE14-16 as recommended by guidelines.
214507669|NCT04312425|PROCEDURE|Modified rapid sequence induction|Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.
215023566|NCT03194932|DRUG|Idarubicin|Given IV.
215023567|NCT03194932|DRUG|Intrathecal Triple Therapy|Given IT.
215023568|NCT03194932|DRUG|Azacitidine|Given IV.
215023569|NCT05095441|BIOLOGICAL|C5252|A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.
215023570|NCT05207839|DIETARY_SUPPLEMENT|Milk powder|one sachet per day dissolved in 200 ml of water
215023571|NCT02150863|DEVICE|Ultrapulse Carbon Dioxide Laser|
215023572|NCT02150863|DEVICE|Cellutome epidermal harvesting system|
215023573|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
215023574|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
215103214|NCT05132777|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
215103215|NCT05132777|DRUG|Osimertinib Mesylate Tablets|Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).
215103216|NCT00547521|DRUG|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
215103217|NCT00547521|DRUG|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
215023575|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
215103218|NCT06448039|DRUG|Fibroblast Growth Factor 2|Randomized double-blinded placebo-controlled treatment of 20 patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with FGF2 or saline in a 3:1 ratio, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
215023576|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
215023577|NCT06791538|PROCEDURE|Robotic Gastrectomy|"The intervention measures for robotic gastrectomy include:~Preoperative Preparation: Comprehensive preoperative examinations, including imaging studies, laboratory tests, and tumor marker assessments, to confirm the diagnosis and staging.~Surgical Procedure: Utilizing the da Vinci Surgical System, which provides a high-definition 3D view and flexible robotic arms for enhanced surgical precision.~Lymphadenectomy: Systematic D2 lymph node dissection according to oncological standards to ensure thorough removal of regional lymph nodes.~Gastrectomy and Reconstruction: Performing subtotal or total gastrectomy based on tumor location and extent, with intracorporeal reconstruction assisted by the robotic system.~Postoperative Management: Close monitoring of vital signs, pain management, and early mobilization to facilitate recovery, along with prevention and management of postoperative complications."
215023578|NCT06791538|PROCEDURE|Laparoscopic Gastrectomy|"Preoperative Preparation: Confirm diagnosis and staging through imaging and laboratory tests.~Surgical Procedure: Use standard laparoscopic instruments and 2D HD camera. Lymphadenectomy: Perform systematic D2 lymph node dissection. Gastrectomy and Reconstruction: Conduct subtotal or total gastrectomy and intracorporeal reconstruction.~Postoperative Management: Monitor vital signs, manage pain, and promote early mobilization."
215023579|NCT06308211|OTHER|MOTOR IMAGERY+MIRROR THERAPY+ROUTINE PHYSICAL THERAPY|Subjects will be instructed to watch the video provided and recorded by investigator.In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.Participants will be than instructed to carry out the task in verbal commands given whenever necessary.The unaffected limb will be placed in front of the mirror so that the reflected illusion of the limb would be hallucinated to represent the affected limb and routine physical therapy includes passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions).
215103219|NCT06448039|DRUG|Saline control|Randomized double-blinded placebo-controlled treatment of patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with saline, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
215103220|NCT02035527|DRUG|sorafenib tosylate|Given daily PO in the a.m.
215103221|NCT02035527|DRUG|cisplatin|Given IV over 1 hour following Docetaxel administration
215103222|NCT02035527|DRUG|docetaxel|Given IV 1 hour prior to cisplatin administration
215023580|NCT06308211|OTHER|MOTOR RELEARNING PROGRAM+ROUTINE PHYSICAL THERAPY|"Motor relearning consists of five components including analysis of task, practice of missing components, practice of task and transference of training. Patient will be asked to practice task in both sitting and standing~* supine to side-lying to sitting~* looking up at ceiling (ensure that centre of body mass does not move back when head is tilted back)~* without moving one's feet, turning to gaze over each other's shoulders and scanning the surroundings for specific items, reaching motions in multiple directions while moving the head and trunk, scooting in bed, altering the base of support (standing with your feet together, in tandem, with one foot on a step, or on one leg)~* squatting to pick up an object and cross over stepping and routine physical therapy includes Passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions)."
215023581|NCT06108609|OTHER|Administration of the French version of the COSI and IOI-HA questionnaires|"Inclusion (D0):~* Audiometry (as part of treatment)~* Clinical evaluation (as part of treatment)~* Passing the French version of the COSI and IOI-HA questionnaires Visit 1 (D0 +3±1 week): only for 35 patients Second administration of the French version of the COSI and IOI-HA questionnaires either by telephone, or during a second consultation or hospitalization, if this occurs within a compatible time frame."
215023582|NCT06641492|BEHAVIORAL|Chatbot-delivered interventions tailored to one's stage of changes|The Chatbot will assess participants' physical activity level and stage of changes regarding physical activity and automatically deliver interventions tailor to their stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
215023583|NCT06641492|BEHAVIORAL|Chatbot-delivered standard interventions|The Chatbot will not assess participants' stage of changes. It will assess participants' physical activity level and provides a standard intervention covering general information about physical activity for older adults, which is not tailoring to participants' stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
215023584|NCT02249520|OTHER|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
215023585|NCT02249520|OTHER|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
215023586|NCT02249520|OTHER|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner
215023587|NCT04118920|DRUG|Topical insulin (4 units)|N=6: 100 U/ml; 4 units of insulin per application; 40 microliters per drop
215023588|NCT04118920|DRUG|Topical insulin (20 units)|N=6: 500 U/ml; 20 units of insulin per application; 40 microliters per drop
215023589|NCT04118920|DRUG|Artificial tears|N=3, 40 microliters per drop
215023590|NCT05599165|OTHER|signal processing on consonant recognition|Consonant recognition will be measured in noise without any signal processing.
215023591|NCT06638255|OTHER|Sequence A involves administering Low PEEP for 12 hours, followed by High PEEP for 12 hours.|"Patients will first receive the Low PEEP protocol for 12 hours, followed by the High PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies.~Description: Patients will first receive the High or LOW PEEP protocol for 12 hours, followed by the Low or HIGH PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies."
215023592|NCT06638255|OTHER|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.
215023593|NCT06637280|DEVICE|High - flow nasal cannula|"High flow nasal cannula (HFNC), a device first introduced in neonates and pediatric care, is currently used in a wide range of indications in adult respiratory and critical care medicine (5-7). It is a relatively new method in bronchoscopy with several notable theoretical advantages over low flow oxygen via conventional nasal cannula (CNC):~* High flow up to 60 liters per minute ensures a more stable FiO2 and better matches the increased patient's inspiratory flow~* High flow generates a small positive expiratory airway pressure (up to 5 cm H2O) which could stabilize the upper airways during sedation and have a beneficial effect in the lower airways~* High flow reduces dead space in the upper airways and increases alveolar ventilation."
215023594|NCT06637280|DEVICE|Standard nasal cannula|Standard method for supplementing oxygen during EBUS bronchoscopy
214507670|NCT04312425|PROCEDURE|Classic rapid sequence induction|In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
214507671|NCT01473069|DRUG|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
214507672|NCT01473069|DRUG|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
214507673|NCT02382172|BEHAVIORAL|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
214507674|NCT02382172|OTHER|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
214507675|NCT05501340|DRUG|Serplulimab|PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
214507676|NCT05501340|DRUG|Molgramostim|200ug qd subcutaneous injection for 7 days
214507677|NCT05501340|RADIATION|Hypofractionated radiotherapy/Sterotactic body radiotherapy|8Gy\*3f
215023595|NCT06642194|BEHAVIORAL|Education on sunnah of sleeping|The interventions had three session which conducted between 40-60 minutes per session. The session include: 1) introducing the research objectives, definition and benefits on sunnah of sleeping; 2) steps in sunnah of sleeping (early bedtime and early wake up time; perform ablution (wudoo) before going to bed and supplicate; dusting and cleaning the bed before sleeping; sleep position; turning off light before sleep; cover mouth when yawning and reciting some verses such as Ayat Kursi, Al-Ikhlas, Al-Falq and An-Nas); 3) providing mp3 and prayers beads to facilitate Qur'an recitation and zikr. These surat was chosen because the portion of surat concentrate on the absolute divinity of Allah and Allah's blessings to His creatures. The surat brings every Muslim the closeness to Allah, the calmness of the soul, and the cure for many physical and psychological diseases. The steps in sunnah of sleeping can be performed approximately about 10-15 minutes about 30 minutes prior to sleep.
215023596|NCT03424343|OTHER|Questionnaire bundle|Questionnaires on identity formation and psychosocial functioning, assessed and reported at baseline, one year later, two years later, and five years later.
215023597|NCT03424343|OTHER|Obtaining information from survivors' medical file|After obtaining informed consent, we will access the medical file of participants to obtain information on the diagnosis, time of diagnosis, treatment duration, type of treatment, and relapse (when applicable).
215023598|NCT06564103|COMBINATION_PRODUCT||
215023599|NCT06551909|RADIATION|Neoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost|Patients with Glioblastoma will receive neoadjuvant stereotactic radiotherapy to Planning Target Volume (PTV) to 30 Gy in 5 fractions, and a Simultaneous Integrated Boost delivering 35-50 GY to GTV. Patients will be divided into groups of 5 and will receive (in the absence of 2 G4 toxicities per group), the following dose levels: 35-40-42.5-45-47.5 and 50 Gy. Standard Temozolomide chemotherapy will be prescribed after surgery.
215023600|NCT06639152|DRUG|oil-based contrast medium|In oil group, ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml) was used as the contrast medium for hysterosalpingography.
215023601|NCT06639152|DRUG|water-based contrast medium|In water group, Ioversol (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 320 mg/ml) was used as the contrast medium for hysterosalpingography.
214507678|NCT04347005|DRUG|Cohort 1: AR882|Single dose of AR882 or matching placebo
214507679|NCT04347005|DRUG|Cohort 2: AR882|Single dose of AR882 or matching placebo
214507680|NCT04347005|DRUG|Cohort 3: AR882|Single dose of AR882 or matching placebo
214507681|NCT04347005|DRUG|Cohort 4: AR882|Single dose of AR882 or matching placebo
214507682|NCT04347005|DRUG|Cohort 5: AR882|Single dose of AR882 or matching placebo
214507683|NCT04347005|DRUG|Cohort 6: AR882 Food Effect|Single dose of AR882 or matching placebo in a fed state
214507684|NCT04347005|DRUG|Cohort 7: AR882 Solid Oral Formulation|Single dose of AR882 or matching placebo
214507685|NCT04347005|DRUG|Cohort 8: AR882 in combination with allopurinol|Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
214507686|NCT04347005|DRUG|Cohort 9: AR882 in combination with febuxostat|Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
214507687|NCT05121285|OTHER|Delivery of contrast fluid by lower GI endoscopy|Each participant will receive one delivery of 440 ml contrast fluid by lower GI endoscopy to the cecum of the colon. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. An colon X-ray is obtained within 10 minutes after the contrast fluid is delivered. The participants is in a supine position fram delivery and until the colon x-ray is obtained.
214507688|NCT05121285|OTHER|Delivery of contrast fluid by enema with and without positioning|"Each participant will receive one delivery of 440 ml contrast fluid by enema. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. The enema procedure includes:~1. The participant lies on his/her left side in neutral position when the enema is delivered~2. X-ray of the colon is obtained with the participant lying on his/her back.~3. The participant is positioned back to his/her left sided position and tilted in a Trendelenburg position. The position is held for two minutes~4. The participant is turned to an abdominal position while the bed remains tilted in Trendelenburg position.~5. Participant turne to the right side. When positioned the bed is tilted the opposite way (anti-Trendelenburg.) The position is held for two minutes.~6. A second colon X-ray is obtained after the participants has rested for ten minutes in a supine neutral position"
214507689|NCT01020097|DRUG|fluorine F18 EF5|Given IV
214507690|NCT01020097|PROCEDURE|immunohistochemistry staining method|Correlative study
214507691|NCT01020097|PROCEDURE|biopsy|Correlative study
214690953|NCT06017583|DRUG|Capecitabine|Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
215023602|NCT05694494|BEHAVIORAL|internet-based Lifestyle-integrated Functional Exercise (iLiFE)|receiving internet-based LiFE training and home safety assessment
214690954|NCT06017583|DRUG|Oxaliplatin|Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
214690955|NCT06017583|RADIATION|SIB-IMRT|The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy.
215023603|NCT05694494|BEHAVIORAL|upper limb exercise training|upper limb exercise training
215023604|NCT05888922|DRUG|Minoxidil Tablets|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
215023605|NCT05888922|DRUG|Minoxidil Topical|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
215023606|NCT05888922|DRUG|Placebo oral tablet|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
215023607|NCT05888922|DRUG|Vehicle solution|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
215023608|NCT00830336|DRUG|Azithromycin|Oral Suspension
215023609|NCT00830336|DRUG|Zithromax®|Oral Suspension
215023610|NCT01565759|DRUG|Lithium Carbonate|"The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg."
215023611|NCT03162211|OTHER|Feedback Report|There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
215023612|NCT06032923|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The dietary supplement Nicotinamide Riboside or a placebo capsule in subjects with SLE. Niagen(R) is a commercially available form of nicotinamide riboside (NR)
215023613|NCT06059001|DRUG|OMO-103|Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion
215023614|NCT06059001|DRUG|Nab-Paclitaxel|IV infusion - Standard of Care
215023615|NCT06059001|DRUG|Gemcitabine|IV infusion - Standard of Care
214690956|NCT06017583|RADIATION|IMRT|The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy.
214690957|NCT04574063|BEHAVIORAL|Lifestyle intervention to reduce breast cancer risk|Women will be educated about lifestyle factors which increase breast cancer risk. They will also be guided through an online goal setting process.
214690958|NCT00582062|OTHER|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
214690959|NCT03508765|DIAGNOSTIC_TEST|Structural Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
214690960|NCT03508765|DIAGNOSTIC_TEST|Functional Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
214690961|NCT03508765|BEHAVIORAL|Digit Span subtest|Evaluates auditory attention and working memory
214690962|NCT03508765|BEHAVIORAL|Brief Test of Attention|Assesses selective auditory attention
214690963|NCT03508765|BEHAVIORAL|Trail Making Test (Parts A & B)|Assesses visual scanning, graphomotor speed, and setshifting
215023616|NCT04406454|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.
215023617|NCT04138355|OTHER|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
214690964|NCT03508765|BEHAVIORAL|Auditory Consonant Trigrams Test|Assesses attention and susceptibility to interference
214690965|NCT03508765|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency.
214690966|NCT03508765|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall.
214690967|NCT03508765|BEHAVIORAL|The Center for Epidemiological Study-Depression|assesses perceived depression
215023618|NCT01127958|DEVICE|PCI with a drug-eluting balloon|PCI with a drug-eluting balloon for in-stent restenosis
215023619|NCT01127958|DEVICE|PCI with a drug-eluting stent|PCI with a drug-eluting stent for in-stent restenosis
215103223|NCT02035527|OTHER|Correlative Studies|Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
215103224|NCT02544659|DRUG|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
214690968|NCT03508765|BEHAVIORAL|The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4|A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue
214690969|NCT03508765|OTHER|Blood draw|Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
214690970|NCT04822857|DIAGNOSTIC_TEST|AMH|The group was divided according to the level of Anti-Müllerian Hormone
214690971|NCT05821153|DRUG|Aldesleukin|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
214507692|NCT01020097|PROCEDURE|Positron Emission tomography|Undergo scan
215103225|NCT05999266|DIAGNOSTIC_TEST|Ultrasonographic Measurements|In patients with or without knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. At the same time, Quadriceps and Hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest.
215103226|NCT05117190|PROCEDURE|Facial Allotransplantation|
214507693|NCT05015842|OTHER|Conventional Physical Therapy|This is a combine protocol of different therapeutic exercises and heat therapy.
214507694|NCT05015842|OTHER|Kinesio Tapping|Kinesio Tapping is an adhesive and elastic fiber used for different outcomes like pain and swelling reduction among physical therapists.
214507695|NCT06509594|OTHER|Protocol of Scapular Stabilization Exercises;|"Exercise for the middle trapezius and rhomboid muscles: Participants were instructed to stand with their arms hanging beside their bodies. Then, they were instructed to flex their elbows 90◦ holding an elastic band and performing an external rotation of the shoulder, pulling both scapula together. Subsequently, they returned to a neutral shoulder position with elbow flexion.~Exercise for the lower trapezius muscle: Participants were instructed to lie down in a prone position while holding an elastic band attached at one end under a mattress. They were then instructed to raise their shoulder 140◦.~Exercise for the serratus anterior muscle: Participants were instructed to stand and flex their elbows 90◦ while holding an elastic band fixed behind the participants. Next, they were instructed to move the arm forward with a protracted scapula."
214690972|NCT01814488|PROCEDURE|allogeneic transplant|"Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.~The conditioning regimen in standard use is:~Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;~Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;~Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.~Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if \<40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice."
214690973|NCT01814683|DRUG|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
214690974|NCT01814683|DRUG|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
214690975|NCT01814683|DRUG|Placebo|14 days placebo.
214690976|NCT03716817|DEVICE|Tetric CAD|Resilient ceramic crowns (Tetric CAD by Ivoclar Vivadent) are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
215103227|NCT01769196|DRUG|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
215103228|NCT01769196|DRUG|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
215103229|NCT05362760|DRUG|Abemaciclib + Aromatase Inhibitor|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
215103230|NCT05362760|DRUG|Abemaciclib + Fulvestrant|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
215103231|NCT03499314|DEVICE|Active RS-tDCS +At-Home Manual Dexterity Training|Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes
215103232|NCT03499314|DEVICE|Sham RS-tDCS +At-Home Manual Dexterity Training|"Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds"
215103233|NCT03499314|OTHER|Manual dexterity training|Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
215103234|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0 and Day 28)
215103235|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0)
214690977|NCT02476682|OTHER|blood or stool samples will be collected|blood or stool samples will be collected
215023620|NCT04873908|OTHER|modified constraint-induced therapy|Patients received conventional rehabilitation and modified constraint-induced therapy schedule
215023621|NCT04873908|OTHER|Proprioceptive Training|Patients received conventional rehabilitation and Proprioceptive Training schedule
215023622|NCT04873908|OTHER|conventional rehabilitation|Patients received conventional rehabilitation schedule
215103236|NCT00881348|DRUG|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
215103237|NCT04096287|BIOLOGICAL|PNT001|PNT001 diluted in 5% dextrose
215103238|NCT04096287|DRUG|Placebo|5% dextrose
215103239|NCT03813264|OTHER|Routine outcome measures (ROM)|The proposed study consists of two complementary processes: the first is the routine collection of clinical data using ROM; The second process is MATRIX-based intervention that is expected to improve the course of treatment.
215103240|NCT00239889|DRUG|Salmon calcitonin|
215103241|NCT05423964|DIAGNOSTIC_TEST|AI use in Endoscopy Room|The use of AI versus no AI in comparing the detection of adenomas during Endoscopy procedures.
215103242|NCT05423964|OTHER|Non-AI use Standard of Care endoscopy room|Non-AI use in comparing the detection of adenomas during Endoscopy procedures.
215103243|NCT06206460|OTHER|Online Assessment|"Online Assessment which consists of:~* Sociodemographic data (life changes, medical and gynaecological history)~* German PMS symptom diary retrospectively for last menstrual cycle~* Quality of Life Inventory (SF-12)~* Expectancy of relief"
215103244|NCT04788394|OTHER|data review|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
215103245|NCT04788394|OTHER|data comparing|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory-confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
215103246|NCT03478800|PROCEDURE|Acupuncture|Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
215103247|NCT01066728|OTHER|CO2 inhalation|Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
215103248|NCT01066728|DRUG|Theophylline|
215103249|NCT00655629|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
215103250|NCT00655629|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
215103251|NCT05810350|DRUG|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed|Patients receive Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
214507696|NCT06509594|OTHER|Protocol of Muscle Energy technique;|"During upper trapezius stretching, the participants were in seated position by holding the chair with one arm, and laterally tilted the head to the opposite side with the other hand pushing the head to increase lateral stretch.~For pectoralis muscle stretch, participants were asked to stand in front of the Doorframe with elbow bent at 90 degree and was asked to lean forward without Taking a step forward. The stretch is felt across the anterior chest, which is held for 15-30 seconds with 2-3 repetitions. For levator scapulae stretch, the subjects were asked to take the seated position while holding the chair with one hand in order to maintain shoulder depression, then To flex and rotate neck to the opposite side by placing the other hand at the back of their head and to slowly pull it down toward the armpit."
214507697|NCT03683641|DEVICE|Extracorporeal Shock Wave Therapy|Use ESWT on chronic insertional Achilles tendinopathy
214507698|NCT03683641|DEVICE|Sham Control group|Use sham ESWT on chronic insertional Achilles tendinopathy
214507699|NCT01218048|DRUG|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
214507700|NCT01218048|PROCEDURE|Surgery|Surgery for tumor
215103252|NCT02161991|DRUG|Aprepitant|aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
214507701|NCT01218048|RADIATION|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
214507702|NCT01218048|DRUG|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
214507703|NCT01273298|DRUG|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
214694150|NCT04044391|DIAGNOSTIC_TEST|CardioFlux Magnetocardiograph|CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
215103253|NCT02161991|DRUG|placebo|placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
214690978|NCT00833248|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
215103254|NCT05511571|DEVICE|Transcutaneous electrical neural stimulation (TENS)|The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.
214690979|NCT00833248|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
214690980|NCT00833248|DRUG|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
214690981|NCT05075148|OTHER|radiology|Interventional radiology for aneurysmal bone cyst ( percutaneous alcoholization, vascualr embolisation)
214690982|NCT00660036|DRUG|Gemtuzumab ozogamicin|On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
214690983|NCT00660036|DRUG|Mitoxantrone|On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
214690984|NCT00660036|DRUG|Etoposide|On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
215023623|NCT02599831|DEVICE|Electrical pudendal nerve stimulation|Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
215023624|NCT02599831|DEVICE|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
215023625|NCT02599831|DEVICE|Transanal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
215023626|NCT00601731|BIOLOGICAL|MenACWY-CRM197|Blood test, 40-months and 60-months children
215103255|NCT05511571|OTHER|Progressive relaxation exercises (PRE)|The PRE group: The PRE application was implemented in the patient room. A quiet and calm environment was prepared in the room for the intervention. The PRE application was implemented by the women under the researchers' instructions. Each session lasted 30 minutes. A total of five sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held. The PRE application includes exercises based on stretching and then the relaxation of different muscle groups, accompanied by deep breathing. The exercises were carried out in the following way: First doing a deep breathing exercise and then stretching all the muscles from feet to face accompanied by breathing in, keeping the breath, and finally relaxing the muscles by breathing out at the same time.
214507704|NCT01273298|DRUG|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
214507705|NCT00505024|BEHAVIORAL|Interactive Voice Response System|Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
214507706|NCT00505024|OTHER|Symptoms Report|A report of severe symptoms will be sent to your doctor or nurse.
214507707|NCT03556852|DRUG|Carbetocin|1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby
214507708|NCT03556852|DRUG|Misoprostol|2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
214507709|NCT01021748|DRUG|MK-2206|Oral tablets
214507710|NCT01021748|DRUG|AZD6244|Oral capsules
214690985|NCT01830361|DRUG|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
214690986|NCT02728440|DRUG|human chorionic gonadotropin, human menopausal gonadotropin|drug for the treatment of male hypogonadism
214690987|NCT00211588|DRUG|galantamine|
214690988|NCT03375359|DIAGNOSTIC_TEST|cfDNA screening|cfDNA screening test for aneuploidy risk assessment
214690989|NCT03545698|OTHER|Avizia Telehealth Platform|Avizia will be utilized as a communication tool between home-based caregivers (family members, formal caregivers, or informal caregivers) and the House Calls care management team.
215023627|NCT00601731|BIOLOGICAL|Blood test|Blood test, 40-months and 60-months children
215023628|NCT03376386|RADIATION|Adaptive dose-Escalated multi-modality image-guided radiotherapy|FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
215023629|NCT01383876|BEHAVIORAL|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
214690990|NCT03200873|DEVICE|repetitive transcranial magnetic stimulation|Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
214690991|NCT04185480|DEVICE|Hemopatch|Before closure of the wound this hemostatic sealant (Hemopatch), a pad of collagen derived from bovine dermis will be applied in the axilla
215023630|NCT01383876|BEHAVIORAL|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
215023631|NCT05205863|BIOLOGICAL|Cofact|Human prothrombin complex concentrate
215023632|NCT06529627|PROCEDURE|Long Gn-RH agonist protocol - Intracytoplasmic Sperm Injection|pituitary downregulation with GnRH agonist - ovarian stimulation with exogenous gonadotropin - hCG adminstration as trigger of oocyte maturation Oocyte retriveal via transvaginal ultrasound guided aspiration embryo transfer progesterone as luteal phase support
214690992|NCT00462098|DEVICE|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
215103256|NCT05511571|OTHER|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)|The TENS+PRE group: The PRE and TENS applications were carried out together in this group. The administration of the interventions was the same as in groups where only TENS and only PRE applications were carried out. In this group, first, a 30-minute PRE application was implemented, which was followed by a 30-minute-TENS application.
214690993|NCT00462098|DEVICE|non-treated control group|no change from routine care, no HBO
215023633|NCT06161181|DEVICE|Decision Support System|"TREAT (TREatment Adherence SupporT) is a web-based DSS that comprises four sections:~i) Metastatic Breast Cancer: contains information about MBC and its physical and psychological consequences;~ii) Adherence to Cancer Therapies: contains information about adherence in the cancer population;~iii) Promoting Adherence: contains information about resources, barriers, and available interventions used to foster adherence;~iv) My Adherence Diary."
215103257|NCT02585921|BEHAVIORAL|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
215023634|NCT02081703|DRUG|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
215103258|NCT02585921|BEHAVIORAL|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
215023635|NCT02081703|DRUG|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
214423428|NCT04761562|DRUG|Platelet- and extracellular vesicle-rich plasma|PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
214423429|NCT04761562|PROCEDURE|Control group|Edges of the tympanic membrane perforation will be refreshed and the tympanomeatal flap raised. Under the tympanic membrane perforation, a guide (fascia of the temporalis muscle, perichondrium, cartilage or fat) will be placed. An absorbent gelatin sponge will be placed under the guide and on the outer surface of the reconstructed tympanic membrane.
214507711|NCT04476524|OTHER|Quality improvement|All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
214507712|NCT05020067|RADIATION|superficial parotid lobe-sparing intensity-modulated radiotherapy|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
214690994|NCT02583802|DRUG|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
215023636|NCT02081703|DRUG|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
214690995|NCT02583802|DRUG|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
215023637|NCT02081703|DRUG|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
215103259|NCT05126836|DRUG|Cilostazol 100Mg Tab|Cilostazol Twice a Day
214690996|NCT02533518|PROCEDURE|Rigid bronchoscopy with ultraviolet transmission|
214690997|NCT02533518|OTHER|Biopsy|
215023638|NCT06501963|BIOLOGICAL|Live Attenuated Influenza Vaccine|The FDA-approved live attenuated seasonal influenza vaccine (LAIV) (FluMist®, AstraZeneca) is licensed in the US for people 2-49 years of age. The approved seasonal LAIV at the time of study enrollment will be obtained from the manufacturer. LAIV will be administered by a study nurse or health care provider at the Hope Clinic as a single 0.2 milliliter (mL) dose given as 0.1 mL spray in each nostril.
215023639|NCT04388631|OTHER|Coronavirus Disease 2019|male patients who have developed COVID-19
215103260|NCT05126836|DRUG|Placebo|Placebo
215103261|NCT06238804|PROCEDURE|KL, Iliofemoral, Ilioinguinal, Iliac fossa and combined approaches|A3.1, A3.2, A3.3
215023640|NCT01542944|DRUG|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
214423430|NCT00383513|BIOLOGICAL|Epratuzumab|360 mg/m\^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
214507713|NCT02743039|BEHAVIORAL|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
214507714|NCT00114452|BIOLOGICAL|Provacel|ex vivo cultured adult mesenchymal stem cells
215023641|NCT05218707|OTHER|GUEDEL Airway|GUEDEL Airway of size '000,00,0,' and '1' will be used.
215023642|NCT02772302|DEVICE|mindBEAGLE EEG-based brain-computer interface|
215023643|NCT01853280|DRUG|L-methylfolate|15mg/day L-methylfolate.
215023644|NCT01853280|DRUG|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
215023645|NCT01853280|DRUG|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
215023646|NCT05156112|DEVICE|Positive Airway Pressure Device|Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
215023647|NCT05821894|OTHER|Observational study|
215023648|NCT02735460|DEVICE|Andago V2.0|The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
215023649|NCT04702607|PROCEDURE|contrast enhanced 4DCT|Functional Lung Imaging with DECT and 4DCT
215103262|NCT06455501|PROCEDURE|Ventral mesh rectopexy|Ventral mesh rectopexy is performed with a superficial peritoneal incision from the right side of the sacral promontory, extended over the right outer border of the mesorectum, towards the deepest part of pouch of Douglas, sparing the right hypogastric nerve. In women, the vagina is retracted anteriorly and a dissection of the rectovaginal septum is performed down to the pelvic floor. A strip of mesh is attached to the ventral part of distal rectum and then fixed upon the sacral promontory.
215103263|NCT05669053|BEHAVIORAL|Super U Story intervention|Participants in this condition will be asked to play a Roblox adventure video game called 'Super U Story'. They will play the game once and have between 6 - 30 minutes to complete the game.
215103264|NCT05669053|BEHAVIORAL|Alternative Roblox game|Participants in this condition will be asked to play an alternative Roblox adventure video game called Rainbow Friends Story (colour story). They will play the game once and have between 6 - 30 minutes to complete the game.
215103265|NCT05669053|BEHAVIORAL|Online word search|Participants in this condition will have 20 minutes to complete a series of word searches online.
215103266|NCT05591391|OTHER|Mallya cap|After Mallya cap is correctly attached to the insulin pen, it will automatically record treatment information (dose, time and date of injection) and send in real time to the Health2Sync's platform by Bluetooth transmission. Suggestions regarding dose titration and glycemic control will be communicated on the Health2Sync's platform.
215103267|NCT05591391|OTHER|Standard care|Suggestions regarding dose titration and glycemic control will be communicated by weekly telephone calls.
215103268|NCT00889525|DRUG|Cabergoline|Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
215103269|NCT03255551|DRUG|Amosartan|amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
215103270|NCT06476353|OTHER|Analysis of Force and Pressure Requirements across Syringe Sizes for Pain Management Procedures|The investigators are analyzing the compression force required to plunge different syringe sizes to determine the operator's burden.
214507715|NCT00114452|BIOLOGICAL|Placebo|Placebo
214507716|NCT02330900|OTHER|Study group|Exposure to cell phone interference of the ICD
215023650|NCT00104884|DRUG|Depsipeptide|Given IV
215023651|NCT03032484|DRUG|Bevacizumab|Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
215023652|NCT03032484|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
215023653|NCT06170242|DRUG|EDP-323 Dose Regimen 1|EDP-323 capsule
215023654|NCT06170242|DRUG|EDP-323 Dose Regimen 2|EDP-323 capsule
215023655|NCT06170242|DRUG|Placebo|Placebo capsule
215023656|NCT05501522|BIOLOGICAL|GBP510 adjuvanted with AS03|injection volume of 0.5mL on Day 0
215023657|NCT05501522|OTHER|Placebo (Normal Saline)|injection volume of 0.5mL on Day 0
215103271|NCT05377138|OTHER|Online PEP/PrEP delivery|Delivery of PEP or PrEP after online consultation and HIVST image upload.
215103272|NCT01771159|DEVICE|TBC|"The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor \[bladder\] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.~After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder."
215103273|NCT00705367|DRUG|Placebo|Infusion, Intravenous, single dose, Day 1
215103274|NCT00705367|DRUG|Abatacept|Infusion, Intravenous, 30mg/kg, single dose, Day 1
215103275|NCT00705367|DRUG|Abatacept|Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
215103276|NCT03761238|DEVICE|Molecular Adsorbent Recirculating System|MARS therapy will start within 24-48 h after randomization and be given on 3 consecutive days in sessions of 8-12 h. The patients are observed for 2 days following the last session, with focus on bilirubin INR and signs of encephalopathy, and can thereafter receive 3 additional sessions in case of no or partial response to treatment.
215103277|NCT03761238|OTHER|Standard medical treatment (SMT)|Patient management and standard medical treatment (SMT) as specified in the study protocol.
214507717|NCT03945084|DRUG|Niraparib|"Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily \<77 kg or \<150,000 µL: 200 mg (2 X 100 mg capsules) daily\*~\* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy"
215023658|NCT04745806|DEVICE|ActiGraft|Whole blood clot (WBC) gel
215023659|NCT06184724|OTHER|Implementation Package for CGA|The Implementation Package will include a set of implementation strategies to improve the use of CGA before surgery. These strategies will be applied at the clinic-level to help increase the reach and adoption of the CGA.
215023660|NCT06184724|OTHER|Routine Clinical Care|Routine care may or may not include the use of the CGA before surgery. The use of CGA in clinical care is up to the medical and surgical healthcare providers.
215023661|NCT01229111|DRUG|cediranib maleate|Given PO
215023662|NCT01229111|DRUG|oxaliplatin|Given IV
215023663|NCT01229111|DRUG|leucovorin calcium|Given IV
215023664|NCT01229111|DRUG|fluorouracil|Given IV
215023665|NCT03989908|OTHER|Microfludic noodle|In this intervention arm, subjects will be served with noodles made using microfludic technology.
215023666|NCT03989908|OTHER|Control noodle|In this intervention arm, subjects will be served with normal noodle.
215023667|NCT05917964|DRUG|LP-168 tablet|LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
215023668|NCT05824728|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
215023669|NCT06160206|BIOLOGICAL|Bevacizumab|Given IV
215023670|NCT06160206|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215023671|NCT06160206|PROCEDURE|Computed Tomography|Undergo CT
215023672|NCT06160206|OTHER|Electronic Health Record Review|Ancillary studies
215023673|NCT06160206|RADIATION|Hypofractionated Radiation Therapy|Undergo radiation therapy
215023674|NCT06160206|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215023675|NCT06160206|BIOLOGICAL|Retifanlimab|Given IV
215023676|NCT03907891|BEHAVIORAL|Motivational social support from nurse|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
215023677|NCT03907891|BEHAVIORAL|Motivational social support from nurse with additional support from significant other|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
215023678|NCT03907891|BEHAVIORAL|Attention control|A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
215023679|NCT04503642|PROCEDURE|Changing the surgical team for wound closure|The intervention consists of the exchange of the primary surgical team with a second surgical team that consists of one surgeon and one student. The first surgical team then may leave the operation theatre but is continuously accessible for questions.
215023680|NCT03680508|DRUG|TSR-022 and TSR-042|immunotherapy
215023681|NCT06158477|DRUG|JYP0035 Experimental Drug Treatment|Single dose intervention
215023682|NCT05965323|BEHAVIORAL|Health Education|Health education with comic books and videos
215023683|NCT02383823|DRUG|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
215023684|NCT02383823|OTHER|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
215023685|NCT03942653|DRUG|Goserelin Acetate|Goserelin Acetate, SQ, Q4W
215023686|NCT03942653|DRUG|Pembrolizumab|Pembrolizumab, IV, Q3W
215023687|NCT01689649|DRUG|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
215023688|NCT03449485|DRUG|Chlorprothixene|Patients are tested for their normal prescription chlorprothixene medication
215023689|NCT05796193|OTHER|Alpha-cypermethrin and PBO LLIN|Veeralin Long lasting insecticidal net with Alpha-cypermethrin Pyrethroid insecticide and PBO
215023690|NCT05796193|OTHER|Alpha-cypermethrin and Clorfenapyr LLIN|Interceptor G2 dual active ingredient LLIN with with Alpha-cypermethrin Pyrethroid insecticide and Clorfenapyr
215023691|NCT05796193|OTHER|Alpha-cypermethrin only LLIN|reference: standard pyrethroid LLIN
215023692|NCT04831346|OTHER|Low level laser|940 nm wavelength with 0.2 W output power and 2 J energy applied for 10 seconds with an energy density of 2.5 J/cm2.
215023693|NCT04831346|DEVICE|Soft occlusive splint|"A vacuum-formed soft occlusal splint made from a 2-mm-thick elastic rubber sheets.~Participants are instructed to always wear the splint except during mealtimes and oral hygiene."
215023694|NCT04893811|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
215023695|NCT04906187|OTHER|Arm A : intraoperative ANI monitoring of nociception|For the experimental group (arm A), the sufentanil doses are adjusted to maintain an ANI between 50 and 70. Morphine doses are adjusted from 0.05 to 0.05 µg / ml. Intraoperative data will be collected for ANI, TIVA and hemodynamics.
215023696|NCT04906187|OTHER|Arm B : no specific monitoring of nociception|For the control group (arm B), adjustments to the opioid doses are made in relation to the hemodynamic reactions of the patient and the operating times. Intraoperative data will be collected for TIVA and hemodynamics.
215023697|NCT05059626|DRUG|simvastatin 10mg|Simvastation acts as a systemic LOX inhibitor.
215023698|NCT05059626|DRUG|Bazedoxifene 20/Estrogens,Con 0.45Mg Tb|Duavee is a selective estrogen receptor modulator.
215023699|NCT04140344|OTHER|Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
214690998|NCT00186745|DRUG|Tinzaparin|Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
215023700|NCT04970576|DRUG|Rivaroxaban|Dose of 20 mg once a day for three months followed by transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
214507718|NCT03945084|OTHER|Best supportive care|"In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment."
215023701|NCT04970576|DRUG|Warfarin|Dose as per the target INR of 2 to 3 with transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
215023702|NCT06463899|PROCEDURE|multi-perforated catheter|After skin closure, cardiac surgeons place multi-perforated catheters aseptically.
215023703|NCT06463899|PROCEDURE|Classic procedure|opioid analgesia (PCA morphine in bolus mode alone or morphine titration if PCA not available), nefopam, non-steroidal anti-inflammatory drugs, ketamine, pregabalin and paracetamol
215023704|NCT03268499|PROCEDURE|Lipiodol-based transarterial chemoembolization|Arterial catheterization to segmental, subsegmental, or sub-subsegmental level was achieved depending on the tumor size, to gain arterial access as close to the tumors as possible. The formulation was delivered under fluoroscopic control until the vasculature of all tumors was entirely filled, or until the maximum dose was reached.
215103278|NCT05979519|BEHAVIORAL|Fresh Funds for Mom's|"Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.~Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks."
215103279|NCT05979519|BEHAVIORAL|Standard Medical care|Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks or be provided the medically tailored meals for 12 weeks.
215103280|NCT05979519|BEHAVIORAL|Medically Tailored Frozen Meals|Participants will enroll in the MTM program. Once enrolled participants will receive 10 frozen meals delivered by Door Dash to their home each week for 12 weeks.
214507719|NCT05004909|DRUG|0.05% Tretinoin|Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
214507720|NCT00958048|DEVICE|non-invasive ventilation|CPAP, BiPAP
215103281|NCT03989362|DRUG|Vopratelimab|Specified dose on specified days
215103282|NCT03989362|DRUG|Ipilimumab|Specified dose on specified days
215103283|NCT05813704|DEVICE|Coronary Crossing System of Shanghai MicroPort Rhythm|The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
215103284|NCT04417231|DEVICE|CRP apheresis|"Selective CRP apheresis by use of the PentraSorb-CRP"
215103285|NCT01468350|DRUG|dalfampridine-ER 10mg|
215103286|NCT01468350|OTHER|Placebo|
215103287|NCT03149055|DRUG|Isavuconazole|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
215103288|NCT01554449|PROCEDURE|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
215103289|NCT01554449|PROCEDURE|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
215103290|NCT06432335|OTHER|E-Socket Monitoring|Limb-socket motion data is collected during participant take-home use. Bimonthly telephone interviews are conducted to assess participant residual limb health status. Analysis is conducted to determine if limb motions and activity changes precede limb health changes.
215103291|NCT04440813|BEHAVIORAL|Education and Training by Clinicians|Training in the use of PPE and education about the risks of blood exposure.
215103292|NCT04440813|BEHAVIORAL|Training and Education from Traditional Healers and Clinicians|Training in the use of PPE and education about the risks of blood exposure.
214507721|NCT03070548|DRUG|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
214507722|NCT01260883|DRUG|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
214507723|NCT01260883|DRUG|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
214507724|NCT01260883|DRUG|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
214507725|NCT02027350|DEVICE|CD Leycom/Millar Instruments conductance catheter|Conductance catheter-Pressure volume relationship
214507726|NCT03305705|DRUG|Iron Carboxymaltose|Single intravenous infusion within 20 min
214507727|NCT03305705|DRUG|Sodium chloride 0.9%|Single intravenous infusion of 250 ml within 20 min
214690999|NCT05220228|DRUG|Prucalopride|1mg prucalopride x 2d, 2mg prucalopride x 5-8d
214691000|NCT05220228|DRUG|Placebo|Lactose / sucrose placebo
214691001|NCT01087411|BEHAVIORAL|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
215103293|NCT02629822|DRUG|Doravirine/lamivudine/tenofovir disoproxil fumarate|FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
215023705|NCT05991466|DRUG|Dexmedetomidine|"All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications. The required laboratory work will be: complete blood count (CBC); prothrombin time and concentration (PT\&PC); partial thromboplastin time (PTT); bleeding time (BT); clotting time (CT); liver function tests and kidney function tests.~Before arrival to the operation room (OR), women will be premedicated by metoclopramide 10mg and ranitidine 50 mg intravenous. Intra operatively, hemodynamics will be recorded baseline before spinal anaesthesia , after its performance, every 3 minutes until delivery and then every 10 minutes till the end of the CS. Any change within 20% of baseline will be accepted and any changes more than 20% will be managed according to guidelines. All groups will be anaesthetized to preform CS with conventional spinal anaesthesia. The TAP block group will receive a landmark orientated Ultrasound guided bilateral TAP block."
215023706|NCT05041699|COMBINATION_PRODUCT|IPM Ring-105|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
215023707|NCT05041699|COMBINATION_PRODUCT|IPM Ring-106|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
215023708|NCT04526158|BEHAVIORAL|Mobile+Group LAMP Mindfulness-Based Intervention|The Mobile+Group LAMP Mindfulness-Based Intervention (MBI) condition consists of eight 90-minute weekly group sessions, delivered via secure video-conferencing. The first session is preceded by a 90-minute technical session introducing the video-conference system and other logistics. The program consists of educational and instructional videos presented by a trained mindfulness instructor interspersed with workbook reflections and group discussions, and daily practice exercises that participants do on their own. A trained facilitator (who is not required to be an expert in mindfulness) leads the group. Participants also have access to a mobile app and a study website, with the same educational and instructional videos that are presented in the group sessions, and the accompanying workbook.
215023709|NCT04526158|BEHAVIORAL|Mobile LAMP Mindfulness-Based Intervention|The Mobile LAMP MBI consists of 8 self-paced, 30- to 60-minute weekly sessions, delivered on a mobile app and available on the study website, with an accompanying workbook. The program consists of educational and instructional videos presented by a trained mindfulness instructor, with workbook reflections and daily practice exercises that participants do on their own (the same content used in Mobile+Group LAMP). Participants also participate in 3 engagement phone calls with a facilitator. The 1st call (45-60 minutes), held at the beginning of the program, includes technical and logistical information on engaging with mobile app, website, and workbook; and discussion of goals, challenges and plans for practice. The 2nd (middle of program) and 3rd call (end of program) are 25-45 minutes long and address technical/logistical issues and discussion of goals, progress, plans for practice and strategies to address challenges.
215023710|NCT03622905|DEVICE|DBS-f On|Deep Brain Stimulation of the fornix
215023711|NCT03622905|DEVICE|DBS Off|Deep Brain Stimulation of the fornix turned off
215023712|NCT05526157|DRUG|Finerenone (Kerendia, BAY 948862)|Retrospective analysis using secondary data collection from various sources
215023713|NCT05526157|DRUG|Sodium-glucose cotransporter 2 inhibitors (SGLT2i)|Retrospective analysis using secondary data collection from various sources
215023714|NCT05526157|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Retrospective analysis using secondary data collection from various sources
215023715|NCT05526157|DRUG|Steroidal mineral corticoid receptor antagonists (sMRA)|Retrospective analysis using secondary data collection from various sources
215023716|NCT05526157|DRUG|Non-steroidal mineral corticoid receptor antagonists (nsMRA)|Retrospective analysis using secondary data collection from various sources
215023717|NCT03760081|DRUG|ASP1650|Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
215023718|NCT03533491|BEHAVIORAL|Rewire App|A prototype Rewire app will be designed and created; the first four modules will be evaluated by 60 high-risk adolescents. The teens are asked to complete each module and spend a few minutes each day for two weeks using the practice exercises.
215023719|NCT06464913|RADIATION|With or without chest wall RT|Supraclavicular and infraclavicular lymphatic drainage area radiotherapy with or without chest wall RT
214507728|NCT01000207|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
214507729|NCT01315977|DIETARY_SUPPLEMENT|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
215023720|NCT02517918|DRUG|Sirolimus combined with CP, MT and ZA|"Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).~Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established."
215023721|NCT03164993|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
215023722|NCT03164993|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
215023723|NCT03164993|DRUG|Cyclophosphamide|Chemotherapy
215023724|NCT03164993|OTHER|Placebo|Placebo
215023725|NCT06397183|OTHER|Mulligan Strech with Traction (TSLR) Technique|The Mulligan traction straight leg raise (TSLR) technique is a mobilization technique that can increase hamstring flexibility and range of motion.
215023726|NCT06397183|OTHER|Post-Isometric Relaxation Technique|Post-Isometric Relaxation Technique is a Muscle Energy Technique which increases hamstring flexibility and range of motion.
214507730|NCT02718339|BEHAVIORAL|Intensive counseling|
214507731|NCT01890954|DEVICE|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
215023727|NCT05460169|DEVICE|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
215023728|NCT04508530|BIOLOGICAL|Panzyga|Panzyga 10% IVIG
215023729|NCT04508530|OTHER|Placebo|Placebo
215023730|NCT05702047|BEHAVIORAL|Nose-only breathing|Participants will breathe only through their nose (mouth closed) during rest and submaximal exercise.
215023731|NCT05702047|BEHAVIORAL|Mouth-only breathing|Participants will breathe only through their mouth (nose clips prevent nose breathing) during rest and submaximal exercise.
215023732|NCT06148948|DRUG|BI 1584862|BI 1584862
215023733|NCT06148948|DRUG|Placebo|Placebo matching BI 1584862
215023734|NCT06175533|PROCEDURE|ultrasound guided 60 degree CRF for plantar fasciitis|ultrasound guided plantar fascia CRF for chronic conditions not responding to treatment
215023735|NCT03315026|DRUG|Siltuximab|Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.
215023736|NCT03315026|BEHAVIORAL|The M.D. Anderson Symptom Inventory (MDASI)|assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
215023737|NCT04914273|DRUG|Inhalation Spray|400 mcg salbutamol administered per metered dose inhaler
215023738|NCT04914273|DRUG|Tablet|8 mg salbutamol administered per tablet for ingestion
215023739|NCT01725282|DRUG|quetiapine extended release (XR)|Extended release tablets
215023740|NCT01725282|DRUG|Placebo|matching tablets
215023741|NCT04064567|BEHAVIORAL|PrEP-LINK|CHW will assist with healthcare and social service navigation and will utilize adherence counseling techniques. As per the model our intervention is based upon (the national Transitions Clinic Network \[TCN\]), our CHW has a history of incarceration. Participants randomized to the intervention group, the CHW will assist individuals with employment, housing (if needed), referrals to mental health or substance use treatment, keeping track of medical appointments and medication adherence.
215023742|NCT04064567|OTHER|Enhanced Standard of Care|Participants will receive education about PrEP and referral to a community PrEP provider which exceeds the standards of care these individuals would otherwise receive.
215023743|NCT03984461|BIOLOGICAL|Autologous cell therapy|Biologic material is harvested from the participant and re-injected into an osteoarthritic joint
215023744|NCT05813093|DEVICE|rTMS|Accelerated iTBS treatment
215023745|NCT04624399|DRUG|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
215023746|NCT04576481|BEHAVIORAL|Texting|Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
215023747|NCT04576481|BEHAVIORAL|Regret|Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.
215023748|NCT04576481|BEHAVIORAL|Lottery|Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
214691002|NCT01087411|BEHAVIORAL|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
215023749|NCT05263791|DEVICE|Airmod|Both of the respiratory rate monitor (including experimental and reference device) are installed on the enrolled patients. The practitioners can clearly read the result of both devices.
215023750|NCT06402136|DRUG|83-0060|Oral MPro inhibitor
215023751|NCT06402136|DRUG|Placebo|Placebo
215023752|NCT06287853|DEVICE|Tapestry Biointegrative Implant|The Tapestry RC Biointegrative Implant System is an arthroscopic delivery and fixation system intended for tendon augmentation with Tapestry Biointegrative Implant during arthroscopic rotator cuff (RC) repair. The system combines the biointegrative collagen-based implant (Tapestry Biointegrative Implant) with bioabsorbable fixation ( Bioabsorbable Anchors). Tapestry Biointegrative Implant is a collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues.
215023753|NCT04879563|OTHER|ASCAPE-based follow-up strategy|"Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled.~The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues."
215023754|NCT05879302|BEHAVIORAL|Kidney Offer Shared Decision Making|The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
215023755|NCT06642714|PROCEDURE|weaning by early non-invasive ventilation and progressive high flow oxygen therapy|"Step 1 Clinical stability was confirmed:~(1)Without organ failure;(2)Without sepsis;(3)Stable heart rate and blood pressure without use of vascular active drugs.~Step2 Reduce the support parameters of the ventilator gradually. Step3 SBT when the ventilator mode is pressure support ventilation(PSV),P+PEEP≤16cmH2O for 2 hours.~Step4~①Success of SBT: titrate based HFOT time-------connected with tracheostomy tube ,flow rate and FiO2 able to maintain oxygen saturation as assessed by pulse oximetry monitoring of at least 95%.HFOT was interrupted in cases of sighs or symptoms of distress such as oxygen desaturation, RR\>30bpm, HR\>130bpm,SBP\>180mmHg or \<90mmHg.The time was based HFOT time. When any of these conditions were present the patient was connected again to the ventilator with the same parameters before titration. The duration of SBT was increased progressively over the following day according to patient tolerance. Then gradually extending HFOT time daily according patient condition. Wh"
215103294|NCT00741013|DRUG|placebo pill and placebo IV|"Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
214694151|NCT02249286|BEHAVIORAL|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
215023756|NCT06639243|DEVICE|QYM Technique|"The intervention in this study involves the application of the Quick Yielding Modified (QYM) technique for the treatment of complex aortic arch diseases. This procedure consists of two main components:~1. Thoracic Endovascular Aortic Repair (TEVAR): This minimally invasive procedure utilizes a covered stent graft to exclude the diseased segment of the thoracic aorta, providing immediate protection against rupture and controlling blood flow.~2. In Situ Fenestration and Revascularization of Supra-Aortic Branches: Following TEVAR, the QYM technique includes creating fenestrations in the stent graft to allow for the revascularization of the supra-aortic branches (such as the brachiocephalic, left common carotid, and left subclavian arteries). This is achieved through direct puncture and reconstruction of the branch vessels, ensuring adequate blood flow to these critical arteries while preserving their function.~The combination of these techniques aims to achieve effective treatment out"
215023757|NCT06637267|DIAGNOSTIC_TEST|Proclarix®|The aim of the study is the implementation of new biomarkers (Proclarix®) in order to increase the sensitivity and specificity of PSA-based Prostate cancer early detection avoiding unnecessary prostate biopsies thus decreasing the associated morbidity (infections, bleeding, urinary retention, etc.). PSA values, Proclarix and mpMRI findings will be correlated with the results of the prostate biopsy in order to improve patient selection for future biopsies in order to avoid unnecessary prostate biopsies, but still be able to detect relevant carcinomas at an early stage. The null hypothesis in our observational study is the lack of superiority in PCa early detection when using the Proclarix over PSA alone.
214423431|NCT03770507|OTHER|Exercise Training|Comparison of stationary bike and treadmill exercise among adolescents and adults
215023758|NCT06641544|DRUG|Inetetamab|Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.
215103295|NCT00741013|DRUG|Lovastatin pill and placebo IV|"lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
215103296|NCT00741013|DRUG|placebo pill and recombinant human activated protein C IV|"placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
215103297|NCT00741013|BIOLOGICAL|Endotoxin|Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
215103298|NCT02133781|BIOLOGICAL|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
215103299|NCT02133781|BIOLOGICAL|FluMist® 2009-2010 Formula|This vaccine is given intranasally
215103300|NCT02173171|OTHER|Information collection|Q3M Information collection
214423432|NCT02176096|DIETARY_SUPPLEMENT|Glycosade|
215103301|NCT00006195|DRUG|risperidone|
215103302|NCT00006195|DRUG|olanzapine|
214423433|NCT00145041|DRUG|Vincristine Sulfate Liposomes Injection|Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
214507732|NCT03799809|DRUG|Intrabronchial Voriconazole instillation|Efficacy of intrabronchial voriconazole instillation for inoperable pulmonary aspergilloma
214507733|NCT04089202|OTHER|eConsult|Completion of electronic consult utilizing data collected from flash glucose monitoring
214507734|NCT04089202|OTHER|Standard of care|Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
214507735|NCT02953756|RADIATION|Gamma Knife radiosurgery|Gamma Knife radiosurgery will be performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the tumor volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target
214507736|NCT06092177|PROCEDURE|Periodontal surgery with virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
215103303|NCT03322410|BIOLOGICAL|modified Peritoneal Equilibration test|"Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~*  High : D/P creatinine\>0,8; D/D0 glucose\<0,25~*  High average : 0,65\< D/P creatinine \<0,8; 0,25\< D/D0 glucose \<0,38~*  Low average : 0,5\< D/P creatinine \<0,65; 0,39\< D/D0 glucose \< 0,48~*  Low  : D/P creatinine\<0,5 ; D/D0 glucose\>0,49."
214423434|NCT05899335|DEVICE|SmartCP (mobile phone app)|As described
214423435|NCT04076202|DEVICE|Cementless Vanguard DD RP|Patients treated with the Cementless Vanguard DD RP knee implant
214423436|NCT02618278|OTHER|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
214507737|NCT06092177|PROCEDURE|Periodontal surgery without virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
214507738|NCT03279367|DIAGNOSTIC_TEST|Objective speech response detection|Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
214507739|NCT05549466|DRUG|Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W."
214507740|NCT05549466|DRUG|Apatinib, Camrelizumab|Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
214507741|NCT05549466|DRUG|Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W."
214507742|NCT05549466|DRUG|Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.
215023759|NCT06640062|OTHER|Erector spinae plane block|Patients received ultrasound-guided erector spinae plane block.
215023760|NCT06640062|OTHER|Oblique subcostal transversus abdominis plane block|Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.
215023761|NCT06637007|DRUG|Chidamide Tablets combined with AK112|Chidamide Tablets 30mg/day, po.Bid; AK112（10mg/kg or 20mg/kg）, ivgtt, Q3W.
215023762|NCT06638983|OTHER|Non-extraction Orthodontic Treatment of Angle Class I Malocclusion|Cephalometric radiographs, and extraoral and intraoral photographs, and cast impressions were collected before and after intervention. The weighted PAR Index (Peer Assessment Rating) employed to determine outcome of orthodontic treatment. Also the following soft tissue and bone indexes were assessed before and after intervention
215023763|NCT06637761|DRUG|NeoMTA2|Bio-active bio-ceramic mineral trioxide aggregate
215023764|NCT06637761|DRUG|WMTA|White Mineral trioxide aggregates
215023765|NCT06641947|PROCEDURE|Whipple procedure|Typically used for treating pancreatic cancer, particularly tumors located in the head of the pancreas.
215023766|NCT06637033|BEHAVIORAL|Chewing Food|Daily foods like candies and dumplings will be cut into small pieces. Patients will chew them before each feeding and then spit them out, with each training session lasting ten minutes.
215023767|NCT06637033|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
215023768|NCT06637033|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
215023769|NCT06639555|PROCEDURE|PRP( platelet rich plasma)|regenerative therapy with PRP for vertical bone defects
215023770|NCT06639555|PROCEDURE|EMD (Enamel Matrix Derivative)|regenerative therapy with EMD for vertical bone defects
215023771|NCT06639555|PROCEDURE|Guided Tissue Regeneration (barrier membrane)|guided tissue regeneration with barrier membrane alone for vertical bone defects
215023772|NCT06639555|PROCEDURE|Guided Tissue Regeneration(barrier membrane and PRP)|guided tissue regeneration with barrier membrane and PRP for vertical bone defects
215023773|NCT04652882|DRUG|Tasimelteon|oral capsule
215023774|NCT04652882|DRUG|Placebo|oral capsule
215103304|NCT02189291|PROCEDURE|Immediate catheter removal|The indwelling catheter will be removed prior to exiting the operating room.
215103305|NCT02189291|PROCEDURE|Post op day 1 catheter removal|For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
215103306|NCT01771237|BEHAVIORAL|MyPeeps Manualized Group Intervention|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
215103307|NCT01771237|BEHAVIORAL|Standard Sexual Health Education|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
215023775|NCT06643689|DRUG|Tranilast|Tranilast is an anti-allergic agent that is hypothesized to prevent stricture formation in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive 100 mg orally three times a day for 8 weeks.
215023776|NCT06643689|DRUG|Dexamethasone|Prednisone is a corticosteroid used to reduce inflammation and prevent stricture in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive an oral dose of 30 mg once daily for 8 weeks, with a gradual tapering of the dosage as follows: Weeks 1-2: 30 mg daily; Weeks 3-4: 25 mg daily; Weeks 5-6: 20 mg daily; Weeks 7-8: 15 mg daily; and then tapering to 10 mg daily in Week 7 and 5 mg daily in Week 8.
215023777|NCT06643819|DRUG|sacubitril/valsatran(dose maintenance)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
215023778|NCT06643819|DRUG|sacubitril/valsartan(dose increasing)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
215103308|NCT04750304|BEHAVIORAL|Application ARTHe|Patient will use ARTHe Application for 3 months
215103309|NCT02434419|DEVICE|PENS|The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
215103310|NCT02434419|OTHER|Specific training|Patients underwent specific training exercises to improve pectoral fitness.
215103311|NCT02431078|PROCEDURE|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
215103312|NCT00193180|DRUG|Imatinib|Imatinib
215023779|NCT06643819|DRUG|Valsartan|During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
214507743|NCT03316170|BEHAVIORAL|Social Support|A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.
214507744|NCT03316170|DRUG|NRT Sampling|"A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail."
215023780|NCT06643806|BEHAVIORAL|CHAI dyad study|In the CHAI (Cardiovascular Health among Asian Indian immigrants) Dyad study, we plan to Implement and pilot test a peer leader-facilitated 12-week dyadic intervention to decrease CVD risk among first generation AI immigrants;
215023781|NCT06645405|BEHAVIORAL|AI algorithm|Artificial intelligence algorithms in the automated reconstruction of intracranial large vessel occlusion (LVO)
215023782|NCT00595075|DRUG|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
215023783|NCT00595075|DRUG|placebo|placebo identical in appearance to active experimental drug x 1 dose
215023784|NCT03495635|BEHAVIORAL|Big Brothers Big Sisters Community-Based Mentoring Program|One-to-one mentoring provided by an adult volunteer with training and ongoing monitoring and support from program staff.
215023785|NCT01156467|DEVICE|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with Edi-catheter
215023786|NCT01156467|DEVICE|Control group, ventilation with i-Servo or Stephanie|Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
215023787|NCT04816903|DIAGNOSTIC_TEST|Gyni|Vaginal discharge collection
215023788|NCT01946880|DRUG|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
215023789|NCT01946880|DRUG|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
215103313|NCT00193180|DRUG|Docetaxel|Docetaxel
215103314|NCT05643950|DEVICE|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
214507745|NCT02039999|OTHER|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
214507746|NCT02039999|OTHER|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
214507747|NCT02039999|OTHER|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
214507748|NCT05160909|PROCEDURE|Beach Chair Position|Patients positioned in beach chair during arthroscopic shoulder stabilization
214507749|NCT05160909|PROCEDURE|Lateral Decubitus Position|Patients positioned in lateral decubitus position during arthroscopic shoulder stabilization
214507750|NCT02636114|PROCEDURE|scaling and root planing|Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
214507751|NCT05200286|DRUG|Olorofim|Single oral dose
214507752|NCT00188812|DRUG|donepezil hcl|
214507753|NCT02730091|DRUG|Letrozole|Letrozole 2.5 mg daily
214507754|NCT02730091|DRUG|Anastrozole|anastrozole 1 mg daily
214507755|NCT02730091|DRUG|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
214507756|NCT03052517|DRUG|QAW039 150 mg|One tablet of QAW039 150 mg once daily
214507757|NCT03052517|DRUG|QAW039 450 mg|One tablet of QAW039 450 mg once daily
214507758|NCT03052517|DRUG|Placebo|One tablet of Placebo once daily
215023790|NCT01946880|DRUG|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
215023791|NCT06225544|DRUG|Lumasiran|Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
215023792|NCT06225544|DRUG|0.9% Sodium Chloride (placebo)|Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
215023793|NCT04477837|DRUG|Apixaban 5 MG|frequency of heavy menstrual bleeding
215023794|NCT04477837|DRUG|Rivaroxaban 20 MG|frequency of heavy menstrual bleeding
215023795|NCT04477837|DRUG|Edoxaban 60 MG|frequency of heavy menstrual bleeding
215023796|NCT04477837|DRUG|Dabigatran 150 Mg Oral Capsule|frequency of heavy menstrual bleeding
215023797|NCT04543786|DEVICE|Transcutaneous spinal cord stimulation|Neuromodulation with transcutaneous spinal cord stimulation applied on lower back adjacent to spine for 30-60 minutes for 5 consecutive days.
215023798|NCT04880356|OTHER|collection of data|collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
215023799|NCT06063681|DRUG|SR-8541A|orally administered ENPP1 inhibitor
215023800|NCT06063681|DRUG|Immune checkpoint inhibitor (ICI)|The ICI will be either nivolumab or pembrolizumab.
215023801|NCT04850599|DRUG|Carfilzomib|Given IV
215023802|NCT04850599|BIOLOGICAL|Isatuximab|Given IV
215023803|NCT04850599|DRUG|Pomalidomide|Given PO
215023804|NCT05739162|DEVICE|Apollo Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), and endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 70-80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
215023805|NCT05739162|BEHAVIORAL|Lifestyle Intervention|Low-calorie healthy diet personalized by a dietician according to individual patients' needs and conducive to weight loss. Physical activity will be encourage and assessed.
215103315|NCT05643950|DEVICE|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
214423437|NCT03128658|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
215023806|NCT05960201|DRUG|[18F]fluoroestradiol (FES)|F-18 FES 111\~222 MBq(megabecquerel) injection
215023807|NCT04715022|DRUG|Ascorbic acid solution (American Regent Laboratories Inc.)|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
215023808|NCT04715022|DRUG|Saline|Placebo (saline) will be administered
215023809|NCT06484543|OTHER|Maslinic Acid|Consumption of Maslinic Acid for 12 weeks
215023810|NCT06484543|OTHER|Placebo|Consumption of Placebo for 12 weeks
215023811|NCT06547996|DEVICE|tES-tDCS group|2mA/20mins/session
215023812|NCT06547996|DEVICE|tES-tACS group|2mA/40Hz/20mins/session
215023813|NCT06547996|DEVICE|tES-sham group|0mA/20mins/session
215023814|NCT03403790|DRUG|Quetiapine|Oral (extended-release tablet)
215023815|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
215023816|NCT00720811|DRUG|amoxycillin|amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
215023817|NCT00720811|DRUG|paracetamol|paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
215023818|NCT00720811|DEVICE|malaria rapid diagnostic test, respiratory rate timer|malaria dipstick, and breath timer
215023819|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
215023820|NCT03197272|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
215023821|NCT01204281|OTHER|Mechanical ventilation mode (PAV+ vs. ACV)|Compare two ventilatory modes in the acute phase of illness
215023822|NCT04616235|DRUG|Tocilizumab Injectable Product|The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
215023823|NCT04616235|OTHER|Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour|The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
215023824|NCT04355689|DRUG|NPI-001|oral tablet
215023825|NCT04355689|OTHER|Placebo|Placebo tablets
214691003|NCT01087411|DIETARY_SUPPLEMENT|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
214507759|NCT06012409|DEVICE|Hall Technique Prefabricated Metal Crown|The Hall Technique is a type of minimally invasive dental treatment. Hall Technique involves sealing the carious lesion under a Prefabricated Metal Crown to stop its progression preventing pain and/or infection.This makes the technique less invasive and it can be more acceptable to children than a traditional filling involving injections and drilling.
214507760|NCT01640288|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
214507761|NCT01640288|OTHER|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
214507762|NCT05570227|OTHER|[U-13C]Glucose Infusion|Peri-operative infusion of \[U-13C\]glucose
214507763|NCT04803734|DRUG|Albuterol Sulfate inhalation aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
214507764|NCT04803734|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation|MDI, 2 puffs, single dose, fasting
214691004|NCT01087411|DIETARY_SUPPLEMENT|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
214691005|NCT03015922|DRUG|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
214691006|NCT03015922|BIOLOGICAL|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
214691007|NCT03994263|DEVICE|ITind device implant|device implanted for 5-7 days
214691008|NCT00107068|PROCEDURE|[A] Aerobic isokinetic cycling exercise|
214691009|NCT00107068|PROCEDURE|[B] Progressive Resistance Training|
214691010|NCT00107068|PROCEDURE|[A] + [B]|
214691011|NCT04467177|OTHER|30% glucose|Male neonates will receive 2 ml of 30% glucose two minutes prior to circumcision
214691012|NCT04467177|OTHER|Placebo|Male neonates will receive 2 ml of sterile water two minutes prior to circumcision
215023826|NCT06404554|OTHER|without any intervention|without any intervention
215023827|NCT05358782|DEVICE|Dental implant positioning|observational study of the effect of implant malposition
215023828|NCT01766843|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
215023829|NCT01766843|DRUG|Seretide Diskus|2 inhalations as a single dose
215023830|NCT01766843|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
215023831|NCT01766843|DRUG|SF Easyhaler|2 inhalations as a single dose
215023832|NCT06197516|OTHER|Integrated Neuromuscular Inhibition Technique|After palpating the trigger point ischemic compression were applied for 20-60 sec while strain Counterstain for 60-90 sec and MET is for 7-10 sec.
215023833|NCT06197516|OTHER|Neuromuscular Reeducation Technique|Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required
215023834|NCT05848232|DEVICE|coraFlex Catheter|The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
215023835|NCT05848232|DEVICE|coraForce Catheter|The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
215023836|NCT05848232|DEVICE|coraCross Catheter|The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
215023837|NCT05105971|DRUG|BAT6026|Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
215023838|NCT01682720|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
215023839|NCT01682720|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
215023840|NCT01682720|DRUG|Placebo to match SOF|Placebo to match SOF administered orally once daily
215023841|NCT01682720|DRUG|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
215023842|NCT02922712|DRUG|NISE|Nise 200mg Max per day in 2 divided doses
215023843|NCT01396785|DRUG|33525|Daily for 14 days
215023844|NCT01396785|DRUG|Placebo|Daily for 14 days
215023845|NCT01091532|DRUG|UK-396,082|"100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
215023846|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
215023847|NCT01091532|DRUG|UK-396,082|"300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
215023848|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
215023849|NCT01091532|DRUG|UK-396,082|"1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
215023850|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
215103316|NCT01400568|DRUG|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
214691013|NCT04606654|OTHER|Handgrip strength training without Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.
214691014|NCT04606654|OTHER|Handgrip strength training with Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
214691015|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
214691016|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
215023851|NCT01091532|DRUG|UK-396,082|"UK-396,082 given orally, once on Days 1 \& 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
215023852|NCT01091532|DRUG|placebo|given orally, once on Days 1 \& 14, and twice daily on Days 3-13.
215023853|NCT04476680|DIETARY_SUPPLEMENT|Vitamin D|Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
215023854|NCT03370835|DRUG|Metoprolol succinate ER|Cardioselective beta-blocker
215023855|NCT03370835|DRUG|Carvedilol|Non-cardioselective beta-blocker
215023856|NCT05541328|OTHER|Tisagenlecleucel|The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
215023857|NCT05103111|OTHER|No intervention|no intervention
215023858|NCT04204902|DRUG|Tepotinib 100 mg|Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in either treatment period 1 or 2.
215023859|NCT04204902|DRUG|Tepotinib 250 mg|Participants received a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in either treatment period 1 or 2.
215023860|NCT03791424|DRUG|Midazolam|Administering premedication with sedative drug to relieve anxiety
215023861|NCT03101670|DRUG|filgotinib|one filgotinib oral tablet q.d.
215023862|NCT03101670|DRUG|Placebo Oral Tablet|one placebo oral tablet q.d.
215023863|NCT04539431|GENETIC|validation of new technologies|Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
215023864|NCT05359562|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
215023865|NCT03876808|DEVICE|Bair Hugger™ Temperature Management Unit Model 750|Forced-air temperature management unit used for preoperative and intraoperative participant warming
215023866|NCT03876808|DEVICE|3M™ Bair Paws™ Flex Gown|Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
215023867|NCT03098706|PROCEDURE|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
215023868|NCT03098706|PROCEDURE|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
215023869|NCT05129735|DIETARY_SUPPLEMENT|Meal replacement shake|Each day for the study period (12 weeks), the participants will take one meal-replacement shake per day for breakfast. The breakfast will be replaced by the shake entirely.
215023870|NCT05938569|DEVICE|Hair restoration|The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
215023871|NCT00247039|DIETARY_SUPPLEMENT|Solgar Israel|Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
215023872|NCT00247039|OTHER|Placebo capsules|placebo capsules
215023873|NCT06047470|BEHAVIORAL|Kangaroo Care|Lactating parents will participate in kangaroo care (holding an infant upright, directly on the chest with skin-to-skin contact) prior to expressing a breast milk sample.
215023874|NCT06047470|BEHAVIORAL|No Kangaroo Care|Lactating parents will provide a breast milk sample after having no contact with their infant for at least 6 hours.
215023875|NCT01724307|PROCEDURE|Neurostimulation of stellate ganglion|An electrical nuerostimulation of the stellate ganglion up to 60 minutes
215023876|NCT02098486|DRUG|Moxifloxacin|
215023877|NCT02098486|DRUG|ceftriaxone|
215023878|NCT04873193|DEVICE|Leo device|Children's respiratory flow and volume measurements will be continuously recorded using the Leo device during oscillometry and pneumotach procedures.
215023879|NCT04797390|DEVICE|Advanced Pneumatic Compression Device (APCD)|Once daily treatment with Flexitouch Plus.
214691017|NCT03284294|DRUG|Cholecalciferol|cholecalciferol 2000 IU oral daily for 8 weeks
215023880|NCT04797390|OTHER|Usual Care|Usual care consists of a two-phase CDT. Phase 1 includes consultation with a lymphedema therapist, patient education, MLD, compression garments or bandages, skin care techniques, and a program of exercises and postural recommendations. Phase 2 consists of ongoing self-care, where patients conduct a life-long program of disease management that mimics the program in phase 1.
214691018|NCT03284294|DRUG|Placebo|Oral placebo daily for 8 weeks
215023881|NCT03060265|DRUG|Paracetamol|Administrating Paracetamol IV pre-cesarean section
215023882|NCT03060265|DRUG|PLACEBO|Administrating SALINE IV pre-cesarean section
215023883|NCT04167735|DEVICE|Hearing Aid without Reverberation Canceller (RevC).|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is without Reverberation Canceller principle enabled.
215023884|NCT04167735|DEVICE|Hearing Aid Reverberation Canceller enabled (RevC_1)|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The experimental condition applies the Reverberation Canceller and is predicted to provide a benefit in reverberant room simulations.
215023885|NCT06460662|OTHER|Routine Physical Therapy|"Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques"
215023886|NCT01254929|DEVICE|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
215023887|NCT01254929|DEVICE|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
215023888|NCT02136355|RADIATION|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
215023889|NCT00514397|DRUG|motexafin gadolinium|
215023890|NCT00514397|DRUG|temozolomide|
215023891|NCT00514397|PROCEDURE|adjuvant therapy|
215023892|NCT00514397|PROCEDURE|quality-of-life assessment|
215023893|NCT00514397|RADIATION|radiation therapy|
215023894|NCT00667979|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
214691019|NCT03863236|DIETARY_SUPPLEMENT|regular diet|The control group (group 1) will continue their regular diet.
214691020|NCT03863236|DIETARY_SUPPLEMENT|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
214691021|NCT03580382|DRUG|Trametinib daily Until PD|1.0 mg daily
214691022|NCT03580382|DRUG|CDX-3379 (ERBB3 antibody)|15mg/kg IV Q3W
214691023|NCT03913221|DRUG|Caffeine Citrate 5 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 5 mg/kg IV.
214691024|NCT03913221|DRUG|Caffeine Citrate 10 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 10 mg/kg IV.
214691025|NCT06457035|DRUG|immunosuppressant|No intervention was performed in this retrospective cohort study.
214691026|NCT04439370|DIAGNOSTIC_TEST|Microneurography to measure muscle sympathetic nerve activity (MSNA)|Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves
214691027|NCT04439370|DIAGNOSTIC_TEST|Baroreflex sensitivity testing|Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.
215023895|NCT00667979|DRUG|Placebo|Matching placebo
215023896|NCT01326897|BEHAVIORAL|Healthy Homes/Healthy Families|"Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings."
215023897|NCT01326897|BEHAVIORAL|Health Education|Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
215023898|NCT04142723|BIOLOGICAL|blood withdraw|venous blood sampling
215023899|NCT03981198|DEVICE|Soliton Rapid Acoustic Pulse (RAP)|Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
215023900|NCT01313533|DRUG|Polyarginine|Vein soak treated with polyarginine
215023901|NCT01313533|DRUG|Vein soak treated with Lactated Ringers Solution|Vein soak
215023902|NCT03796221|BEHAVIORAL|Parenting videos|Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
215023903|NCT03796221|BEHAVIORAL|Standard pediatric obesity treatment|Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
215023904|NCT01674361|DRUG|Bitopertin|Bitopertin once daily orally.
215023905|NCT01674361|DRUG|Placebo|Placebo matched to bitopertin once daily orally.
215023906|NCT01674361|DRUG|SSRI|Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
214691028|NCT04439370|DIAGNOSTIC_TEST|Sympathoexcitatory Maneuvers|Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed
215023907|NCT06091956|DRUG|Deucravacitinib|6 milligram (mg) orally administrated, twice daily
215023908|NCT05944393|DRUG|Ropivacaine 0.2% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.5% ropivacaine
215023909|NCT05944393|DRUG|Normal saline 0.9% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.9% normal saline
215023910|NCT02191995|BEHAVIORAL|yoga|
215023911|NCT01586897|DEVICE|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
215023912|NCT01586897|OTHER|Usual Care|
215023913|NCT04710303|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
215023914|NCT00801255|DRUG|RO5024048|500mg po bid/100mg po q8h for 7 days
215023915|NCT00801255|DRUG|danoprevir|500mg po bid/100mg po q8h for 14 days
215023916|NCT00801255|DRUG|danoprevir|1000mg po bid/100mg po q8h for 14 days\\n500mg po bid/200mg po q8h for 14 days
215103317|NCT01400568|DRUG|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
215103318|NCT02644785|DRUG|protamine|Protamine infusion exposures
215103319|NCT01506999|BIOLOGICAL|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
214423438|NCT03128658|DIAGNOSTIC_TEST|Computational model|The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
214423439|NCT02709863|DRUG|Sevoflurane|1-1.5 MAC, inhalation route, during operation
214507765|NCT03949478|DRUG|Ibuprofen|Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
214691029|NCT04439370|DIAGNOSTIC_TEST|Blood tests|Serum FSH, estrogen, progesterone, and testosterone will be measured
214691030|NCT06637865|DRUG|IMP761|intravenous
215023917|NCT00801255|DRUG|danoprevir|1000mg po bid/200mg po q8h for 14 days
215023918|NCT00801255|DRUG|danoprevir|1000mg/600mg po twice daily for 14 days
215023919|NCT00801255|DRUG|danoprevir|1000mg/900mg po twice daily for 14 days
215023920|NCT03813121|DRUG|midazolam intravenous infusion|Participants will receive a single drug infusion
214423440|NCT02709863|DRUG|Desflurane|1-1.5 MAC, inhalation route, during operation
214423441|NCT02709863|DRUG|Propofol|6-10 mg/kg/h, iv infusion, during operation
214507766|NCT03949478|DRUG|Nifedipine|Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
214691031|NCT06637865|DRUG|Placebo|intravenous
215023921|NCT03813121|DRUG|placebo intravenous infusion|Participants will receive a single placebo infusion
215023922|NCT03813121|DRUG|ketamine intravenous infusion|Participants will receive a single drug infusion
215023923|NCT06307366|OTHER|No intervention will be used|This is a qualitative study, no intervention will be used
214507767|NCT03949478|DRUG|Placebo|Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.
214507768|NCT01164176|DRUG|everolimus|
214507769|NCT01164176|OTHER|laboratory biomarker analysis|
214507770|NCT03180476|DRUG|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
214691032|NCT06637865|OTHER|keyhole limpet haemocyanin (KLH)|intramuscular immunization and intradermal challenge
215023924|NCT00003067|BIOLOGICAL|aldesleukin|
215023925|NCT00003067|BIOLOGICAL|lymphokine-activated killer cells|
215023926|NCT05200338|DRUG|Engerix-B|Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.
215023927|NCT04525183|BEHAVIORAL|Enhanced Usual Care (EOC)|Educational materials
215023928|NCT04525183|BEHAVIORAL|REVITALIZE ACT Intervention|Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks
215103320|NCT03090204|PROCEDURE|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle at 4 time points during a session of intermittent hemodialysis : before the intermittent hemodialysis connection, just after starting hemodialysis, after 1 hour of hemodialysis and 5 minutes before restitution
215103321|NCT03529981|OTHER|Tuned Vibroacoustic Stimulation (TVS)|TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance
215103322|NCT03529981|OTHER|no active intervention|No intervention will be administered
214691033|NCT05019456|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine (mRNA or J\&J)
215023929|NCT06401733|OTHER|Intensive Aerobic and Resistance Exercise Program (IAREP)|"IAREP is a combined aerobic exercise and resistance training program that developed by qualified exercise professionals. It encompasses a 12-week exercise intervention, conducted in a blended mode which consists of face-to-face exercise, Zoom exercise, and pre-recorded video exercise.~Frequency: 3 times exercise per week. Intensity: moderate to vigorous exercise. Time of the exercise: 45-60 mins. Type of exercise: combined aerobic and resistance training.~Warm-up: aerobic workout with dynamic stretch (for targeted muscles). Aerobic exercise: each session encompasses 5 exercise. Resistance training: each session encompasses 4 exercise, 2 upper body exercise and 2 lower body exercise.~Cool-down: relax targeted muscles."
215023930|NCT06571526|BEHAVIORAL|External focus|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to focus on a random series of digits ranging from 0 to 9 displayed on monitors placed at the immediate and future destinations of the walkway. Each number was displayed for at least 2 seconds to allow participants to have sufficient time to read them.
214691034|NCT02352116|OTHER|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
215023931|NCT06571526|BEHAVIORAL|Control|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to walk to the end of the walkway at your natural pace.
215023932|NCT00196612|DRUG|emtricitabine, FTC (drug)|
215023933|NCT00196612|DRUG|didanosine, ddI (drug)|
215023934|NCT00196612|DRUG|efavirenz (drug)|
214691035|NCT02352116|OTHER|Standard of care management|Current standard of care at a major U.S. teaching hospital.
214691036|NCT05217693|DRUG|BB-1705|BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
214691037|NCT01284322|DRUG|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
214691038|NCT06702501|DEVICE|PeriCut Catheter System performs minimally invasive pericardiotomy|The PeriCut Catheter System will incise the pericardium to reduce filling pressures of the heart.
214691039|NCT06467643|PROCEDURE|non-instrumented root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were irrigated with room temperature 5.25% sodium hypochlorite which was activated ultrasonically for 30 seconds and then intra-canal heated using a heat carrier to a temperature fixed at 150 degree celsius. Three consecutive cycles of PAU and intra-canal heating of sodium hypochlorite were performed. After the first and the last cycle, root canals were irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) and kept in the canal for 60 seconds and then flushed out with 5 mL of saline. Root canals of this group were kept un-instrumented.
214691040|NCT06467643|PROCEDURE|conventional root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were convetionally prepared using Reciproc Blue rotary files according to the manufacturer's instructions. Once the instrumentation was done, the canal was irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) kept for 60 seconds and then flushed with 5 mL of saline. NaOCl was placed in the canal and PUA followed by intracanal heating was performed three times as described for group 1 (IHAN).
214691041|NCT04813848|PROCEDURE|Application of varnish fluoride desensitizing agent on buccal surfaces of exposed dentin|"Varnish fluoride is a single dose transparent varnish with 5 % sodium fluoride (22.600 ppm fluoride) and 5 % calcium fluoride.~The application was performed according to the manufacturer's instructions. The varnish was applied on a clean and dry surface, then after 10-20 seconds to allow the fluoride varnish to be absorbed, was then dried with air."
214694152|NCT02249286|OTHER|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
214694153|NCT01470573|PROCEDURE|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
215023935|NCT05736887|DRUG|N-Acetylcysteine|N-Acetylcysteine in 600mg tablets
215023936|NCT05736887|DRUG|Placebo|Placebo in 600mg tablets
215023937|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
215023938|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
215023939|NCT00020007|DRUG|isolated perfusion|
215023940|NCT00020007|DRUG|paclitaxel|
215023941|NCT00020007|PROCEDURE|hyperthermia treatment|
215023942|NCT00178828|DRUG|sertraline|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
215023943|NCT00178828|DRUG|bupropion|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
215023944|NCT04499001|OTHER|Pharmacist's consultation|Information about bDMARDs management.
215023945|NCT01166646|DRUG|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
215023946|NCT01166646|DRUG|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
215023947|NCT05613946|DRUG|Lumason|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
215023948|NCT05613946|DRUG|Optison|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
215023949|NCT05613946|DRUG|Definity|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
215023950|NCT05996445|BIOLOGICAL|XmAb662|Intravenous (IV) administration
215023951|NCT05996445|BIOLOGICAL|Keytruda® (pembrolizumab)|Intravenous (IV) administration
214423442|NCT04052919|OTHER|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
214423443|NCT04584450|OTHER|Questionnaire|data collection using questionnaire
214423444|NCT03398837|DRUG|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
214507771|NCT06321094|DRUG|Vericiguat|Investigators divide our participants into two groups ;one group is required to take vericiguat,and the other isnot required to take vericiguat.Expect this,no intervention is used in the research.
214507772|NCT02605876|DEVICE|Whole body vibration|
214507773|NCT02605876|DEVICE|Local muscle vibration|
214507774|NCT00996242|DRUG|L-lysine|6 g/day for four weeks
214507775|NCT01903954|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
214507776|NCT01903954|DRUG|placebo|Orally b.i.d.
214507777|NCT01903954|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
214507778|NCT01903954|DRUG|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
214507779|NCT02399956|OTHER|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
214507780|NCT00162409|DRUG|Folic acid|
214507781|NCT06437158|DRUG|Bleomycin|To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
214507782|NCT06092905|OTHER|Endoscopic clearance of common bile duct stones|Under general anesthesia, in left lateral decubitus, endoscopic clearance of common bile duct stones was done. Ultrasonography was used to ensure right positioning of the guide wire in the common bile duct, and ensure stone clearance.
214507783|NCT05575687|OTHER|Water (reference)|Ingestion of 500 ml mineral water
214507784|NCT05575687|OTHER|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
214507785|NCT05575687|OTHER|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
214507786|NCT05575687|OTHER|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
214507787|NCT05575687|OTHER|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
214507788|NCT05575687|OTHER|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
214507789|NCT04236297|DEVICE|bite block|Physicians performing transesophageal echocardiogram in patients under sedation or general anesthesia will use either standard or modified bite block.
214507790|NCT00338325|BEHAVIORAL|Reading program|Reading of children's story/picture books preoperatively
214507791|NCT03775915|OTHER|Neurofeedback|A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.
214507792|NCT03775915|OTHER|Sham Neurofeedback|A visual representation of brain activity pre-recorded from a previous participant
215023952|NCT02890160|DEVICE|Firesorb|Sirolimus Target Eluting Bioresorbable Vascular Scaffold
215023953|NCT02890160|DEVICE|XIENCE|Everolimus Eluting Coronary Stent System
215023954|NCT04130971|OTHER|No intervention, just observation|No intervention, just observation of the differences between groups and within patients.
215023955|NCT02239042|PROCEDURE|LLLT|The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
215023956|NCT02511769|BEHAVIORAL|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
215023957|NCT02511769|BEHAVIORAL|WEB-MAP CBT|Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
215023958|NCT01406054|OTHER|neuromuscular exercises|neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
215023959|NCT03748212|DRUG|D935 Cap. 1T|single oral administration under fed condition
215023960|NCT03748212|DRUG|CKD-385 Tab. 1T|single oral administration under fed condition
215103323|NCT04082715|DRUG|carbidopa/levodopa and celecoxib|Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
215023961|NCT05814614|OTHER|pelvic physical therapy|Pelvic floor muscle exercises, biofeedback, bladder training
215023962|NCT00135876|DRUG|dalteparin|
215023963|NCT00274950|BIOLOGICAL|bleomycin sulfate|
215023964|NCT00274950|DRUG|carboplatin|
215023965|NCT00274950|DRUG|cisplatin|
215023966|NCT00274950|DRUG|etoposide|
215023967|NCT00274950|DRUG|ifosfamide|
215023968|NCT00274950|DRUG|vinblastine sulfate|
215023969|NCT00274950|PROCEDURE|adjuvant therapy|
215023970|NCT00274950|PROCEDURE|conventional surgery|
214423445|NCT03398837|DRUG|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
214423446|NCT03398837|OTHER|Placebo oral capsule|Subjects will receive placebo twice daily.
214423447|NCT04298086|OTHER|Exercise Treatment|Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.
214423448|NCT04298086|OTHER|Plant-Based Diet|Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
215023971|NCT02163356|DRUG|Fenretinide/LXS Oral Powder|Oral Powder
215023972|NCT02163356|DRUG|Ketoconazole|Oral Tablet
215023973|NCT02163356|DRUG|Vincristine|IV
215023974|NCT01813227|DRUG|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
215023975|NCT01813227|DRUG|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
215023976|NCT01813227|DRUG|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
215023977|NCT02858778|OTHER|Early order of palliative care consultation|
214423449|NCT04298086|OTHER|Physical activity|Treadmills and low-calorie recipes will be provided to patients in the counseling arm.
214423450|NCT04298086|OTHER|Nutrition counseling|Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).
214423451|NCT04298086|OTHER|Replication Exercise Test|Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
214423452|NCT01671124|OTHER|Soline capsule|
214423453|NCT00132119|DRUG|nalmefene HCl|Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
214423454|NCT00132119|OTHER|Placebo|Placebo tablet
215023978|NCT03804255|OTHER|Survey Administration|Complete surveys
215023979|NCT04672616|BEHAVIORAL|Group psychotherapy|The intervention is a group psychotherapeutic offer for mentally burdened adolescents and young adults to support their professional integration.
215023980|NCT06036264|OTHER|Collected of Datas|age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)
214691042|NCT04813848|PROCEDURE|Application of bonding agent desensitizing agent on buccal surfaces of exposed dentin|Bonding agent is a single dose dual curing universal adhesive and its application was performed according to the manufacturer's instruction for cases with hypersensitive tooth necks. The bonding was applied without etching, on a clean and dry surface. After 10 s any excess material was removed and then light cured for 30 s.
215103324|NCT04082715|DRUG|placebo1 and celecoxib|Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
215103325|NCT04082715|DRUG|placebo1 and placebo2|Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
215103326|NCT02490592|OTHER|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
215103327|NCT02490592|OTHER|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
215103328|NCT00539305|DRUG|testosterone gel|50-100mg applied topically daily for six months
215023981|NCT06036264|OTHER|semi-structured interview|Semi-structured interviews will be realized. The goal is to establish a qualitative analysis of the relevance and organization of pre-transplant assessments, of the reactivity in the adjustment of requests and assessments, and to identify the strong points or areas for improvement.
215023982|NCT06304896|DRUG|Carvedilol|Carvedilol 6.25 mg oral tablets. Prescribed: Twice daily PO with 200 mL of water.
215023983|NCT06304896|DRUG|Ramipril|Ramipril 2.5 mg oral capsules. Prescribed: Once daily PO with 200 mL of water.
215023984|NCT06304896|DRUG|Rosuvastatin|Rosuvastatin 20 mg oral tablets. Prescribed: Once daily PO with 200 mL of water.
215023985|NCT06304896|DRUG|Colchicine|Colchicine 0.6 mg oral tablets/capsules. Prescribed: Once daily PO with 200 mL of water.
215023986|NCT06304896|DRUG|Placebo|Placebo oral capsules. Prescribed: Once daily PO with 200 mL of water.
215103329|NCT00539305|DRUG|placebo gel|applied topically daily for six months
215103330|NCT00921843|DRUG|Methadone 0.1mg/kg|Subjects will receive methadone as their intraoperative opioid.
215103331|NCT00921843|DRUG|Methadone 0.2mg/kg|Subjects will receive methadone as their intraoperative opioid.
215103332|NCT00921843|DRUG|Methadone 0.3mg/kg|Subjects will receive methadone as their intraoperative opioid.
215103333|NCT00921843|DRUG|Control|Subjects will not receive methadone as their intraoperative opioid.
215103334|NCT05909384|OTHER|Survey|Multiple rounds of surveys collecting information on sepsis diagnosis and management in resource-limited settings.
215103335|NCT03979885|BEHAVIORAL|Smoking cessation counseling (Quitline)|Quitline offers community-based counseling session with a cessation counselor.
215103336|NCT03979885|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
215103337|NCT03979885|BEHAVIORAL|Financial incentives for smoking cessation|Participants will receive financial incentives for bioconfirmed smoking cessation.
214423455|NCT04575285|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.
214691043|NCT04348487|OTHER|Modified cephalica venous access|This modified technique prioritized the safety in TIVAPS by using several modified landmarks and techniques. The catheter was inserted through cephalic vein in deltopectoral groove regio and implanted the port in the anteromedial of thorax. Generally, the percutaneous and Seldinger technique was used to ensure safety and minimal tissue disruption. To connect the trimmed catheter to port pocket, the author anchored a special trocar from anteromedial of thorax to the deltopectoral groove for guidance.
215023987|NCT01335685|DRUG|Ixazomib|Ixazomib capsules
215023988|NCT01335685|DRUG|Melphalan|Melphalan tablets
215023989|NCT01335685|DRUG|Prednisone|Prednisone tablets
215023990|NCT01641055|DIETARY_SUPPLEMENT|Salmon protein hydrolysate|2.5g salmon protein hydrolysate per day for 8wk.
215023991|NCT01641055|DIETARY_SUPPLEMENT|Herring protein hydrolysate|2.5g herring protein hydrolysate per day for 8wk.
215023992|NCT01641055|DIETARY_SUPPLEMENT|Cod protein|2.5g cod protein per day for 8wk.
215023993|NCT01641055|DIETARY_SUPPLEMENT|Milk protein|2.5g milk protein per day for 8wk.
215023994|NCT01396876|BEHAVIORAL|clown|a distraction technique is performed by a clown during venipuncture
215023995|NCT02542280|PROCEDURE|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
215023996|NCT02542280|PROCEDURE|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
215023997|NCT02542280|DRUG|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
215023998|NCT00127478|DRUG|Atrasentan|
215023999|NCT04951843|DIETARY_SUPPLEMENT|Black soybean koji product|Black soybean koji product
215024000|NCT03116178|OTHER|Group G -PVI( Masimo co oximeter) guided fluid therapy|"goal directed fluid therapy maintaining pvi 4-11. when pvi\<4 fluid rate is 50-60ml/hr and pvi\>11 200ml colloid bolus transfusion till pvi value achieves normal range.~In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered"
215024001|NCT03116178|OTHER|Group B- Body weight guided intravenous fluid @6-8ml/kg|Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
214691044|NCT04549597|DRUG|Tenapanor|Use of tenapanor
215103338|NCT03979885|BEHAVIORAL|Financial incentives for use of evidence-based smoking cessation therapies|Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
214691045|NCT04109235|OTHER|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
214691046|NCT04109235|OTHER|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4\&5 from: http://csep.ca/CMFiles/Guidelines/CSEP\_PAGuidelines\_0-65plus\_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
214691047|NCT01173796|PROCEDURE|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
214691048|NCT01173796|PROCEDURE|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
214691049|NCT04592614|BEHAVIORAL|Choose to Move - Next Steps|Choose to Move - Next Steps consists of a series of group meetings delivered virtually for 2 years. Group meetings (1-hr each) of 6-11 older adults will be facilitated by a trained Activity Coach and delivered remotely via the Zoom or GoToMeeting platform (password protected; access through phone or internet). Each group meeting will provide information on a health-related topic of interest and will include time for goal setting, discussion and sharing among participants. Older adults will have the option to sign up for a bi-weekly CTM electronic newsletter containing health information and ideas and resources for older adults to be physically active and socially connected at home (and elsewhere as local restrictions permit). Activity Coaches will also facilitate social connections between participants to encourage contact (by phone or online) outside of group sessions (for interested participants only).
214691050|NCT05619172|DRUG|Nanrilkefusp alfa|Subcutaneous (SC) injection
214691051|NCT05619172|DRUG|Cetuximab|Intravenous (IV) infusion via peripheral or central venous line
214691052|NCT03664284|PROCEDURE|subcutaneous disinfection|The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
214691053|NCT04459702|DRUG|hydroxychloroquine|Treatment with the drug hydroxychloroquine
215103339|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 1 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
214691054|NCT04459702|DRUG|Azithromycin|Treatment with the drug azithromycin
215103340|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 2 for NG and CT|A combination test using target amplification to detect RNA from NG and CT.
215103341|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 3 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
215103342|NCT02481531|OTHER|Previously marketed infant formula|
215103343|NCT02481531|OTHER|Previously marketed formula using a similar protein|
215103344|NCT04899505|OTHER|Evaluation on appearance of unpleasant body odors|Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.
215103345|NCT03168178|DRUG|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
215103346|NCT03168178|OTHER|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
214691055|NCT04459702|DRUG|Ritonavir|Treatment with the drug ritonavir
214691056|NCT04459702|DRUG|Lopinavir|Treatment with the drug lopinavir
214691057|NCT03506321|DIAGNOSTIC_TEST|chromoendoscopy, high definition white light and narrow band imaging|Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
214691058|NCT00401622|BEHAVIORAL|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
214691059|NCT00401622|BEHAVIORAL|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
214694154|NCT01516164|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
215024002|NCT05198661|BIOLOGICAL|Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.|"Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7\*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection"
215024003|NCT04097665|DEVICE|indocyanine green angiography|All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1\*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
215024004|NCT02732496|BEHAVIORAL|Targeted Cognitive Training (TCT)|The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.
215024005|NCT02732496|OTHER|Youth Appropriate Online Games|Engaging games not designed to improve cognition.
215024006|NCT02214628|DRUG|Fovista® (anti-PDGF BB) plus anti-VEGF|
215024007|NCT01983670|OTHER|Temporal electrical stimulation|
215024008|NCT03777020|BEHAVIORAL|Service Dog Training Program|Participate in 8 weekly dog training sessions using a positive reinforcement method and curriculum under the direct supervision of trainer at the Warrior Canine Connection facility in Boyds (Montgomery County) MD.
215024009|NCT03777020|OTHER|Dog Training Education|Learn about training dogs by watching 8 weekly dog training online modules programs at the Warrior Canine Connection facility in Boyds (Montgomery County) MD. After completing this education the participants will participate in the service dog training program.
215024010|NCT01550887|OTHER|No intervention|No intervention will be performed on this study
215024011|NCT06474962|BEHAVIORAL|Pause|7 days of no e-cigarette consumption
215024012|NCT06020937|DIAGNOSTIC_TEST|TDI|Sniffin' Sticks Threshold and Identification Test
215024013|NCT06020937|DIAGNOSTIC_TEST|Trigeminal Test|Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response
215024014|NCT06020937|DIAGNOSTIC_TEST|Cognitive Evaluation by Montreal Cognitive Assessment|Montreal Cognitive assessment
215024015|NCT06020937|DIAGNOSTIC_TEST|Anxiety and Depression questionnaire|Specific test to evaluate patient's mood
215024016|NCT06020937|DIAGNOSTIC_TEST|Visual Analogue Scale Ratings|"* Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~* Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)"
215024017|NCT06020937|DIAGNOSTIC_TEST|Quality of smell Questionnaire|Patients will answer to a validated questionnaire
215024018|NCT00489476|DRUG|Staccato Loxapine|
215024019|NCT00489476|DRUG|Staccato Placebo|Placebo aerosol inhalation (0mg)
215024020|NCT03989479|BEHAVIORAL|Brushing demonstration using T shaped toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
215024021|NCT03989479|BEHAVIORAL|Brushing demonstration using conventional toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
215024022|NCT00005839|DRUG|capecitabine|
214423456|NCT03070483|DRUG|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
215024023|NCT00005839|DRUG|oxaliplatin|
215024024|NCT04418154|DRUG|epirubicin hydrochloride|Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
215024025|NCT04418154|DRUG|Cyclophosphamide|Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
215024026|NCT04418154|DRUG|Albumin bound paclitaxel|Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
215024027|NCT04418154|DRUG|Toripalimab|Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
215024028|NCT02098473|DRUG|RPC4046|
215024029|NCT02098473|DRUG|Placebo|
215024030|NCT01707446|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
215024031|NCT01707446|OTHER|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of \< 75% from baseline is reached for \> 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
215024032|NCT02423954|DRUG|Temsirolimus|
215024033|NCT02423954|DRUG|Irinotecan|
215024034|NCT02423954|DRUG|Irinotecan + capecitabine|
215024035|NCT02423954|DRUG|nivolumab|
215024036|NCT05045417|DIAGNOSTIC_TEST|Serum level of IL-17|"Measurement of serum level of IL-17 :~1. To explore the role of IL-17 in systemic lupus erythematosus~2. To determine the relation between IL-17 and lupus disease activity~3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)"
215024037|NCT02203279|OTHER|Rebase II Fast|It is going to be used a direct relining material
215024038|NCT02203279|OTHER|Flexacryl|This is going to be used as a second direct relining material
215024039|NCT02203279|OTHER|Vertex|This is going to be used as an indirect relining material
215024040|NCT01817946|OTHER|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
215024041|NCT00004665|DRUG|dehydroepiandrosterone|
215024042|NCT03563079|OTHER|Instrument Assisted Soft Tissue Mobilization|Soft Tissue Mobilization
215024043|NCT03563079|OTHER|Manual Myofascial Release|Myofascial Release Technique
215024044|NCT01373411|DRUG|ticagrelor|ticagrelor 90 mg BID for 90 days
215024045|NCT01373411|DRUG|Placebo|Placebo 1 pill BID for 90 days
215024046|NCT01055119|DIETARY_SUPPLEMENT|Omega-3 fatty acids|duration: 4 month
214691060|NCT05445297|DRUG|Pharmacological cardioversion with Amiodarone|"Patients in this group will receive intravenous amiodarone according to the following scheme:~1. administration of 5 mg/kg body weight of amiodarone diluted in 250 ml of 5% glucose solution intravenously for 20-60 minutes, depending on the tolerability of the drug.~2. if there is no effect (recovery of SR did not occur within 60 minutes from the start of the drug administration), continue the infusion of amiodarone intravenously at a dose of 100 mg/hour until a total dose of 1200 mg is reached."
214691061|NCT05445297|DRUG|Pharmacological cardioversion with Refralon|"Patients in this group will receive intravenous refralon according to the following scheme:~1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur), after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
214423457|NCT00628719|DRUG|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
214423458|NCT00628719|DRUG|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
214691062|NCT03555903|OTHER|Endometriosis cohort|"The investigator record data on risks factors, symptoms (pain), quality of life (using standardized quality of life questionnaires), infertility history, and management of the disease with a 5-years follow up.~Different surgical procedures exist to treat DIE and are they are described in the database, to allow comparison."
214691063|NCT02236546|DIAGNOSTIC_TEST|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
214423459|NCT01514903|DRUG|HIP0908|SINGLE DOSE , CROSS OVER
214423460|NCT01514903|DRUG|viagra|single dose, cross over
214423461|NCT00920244|PROCEDURE|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
214423462|NCT00920244|DRUG|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
214691064|NCT02236546|OTHER|Molecular assays on biopsied tissue|Correlative studies
214691065|NCT02236546|DEVICE|positron emission tomography|Undergo FDG-PET/CT
214691066|NCT02236546|DEVICE|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
214691067|NCT00475280|PROCEDURE|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
214691068|NCT00475280|PROCEDURE|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
214691069|NCT04030052|DRUG|Nuwiq (low dose protocol)|After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
214691070|NCT04030052|DRUG|HEMLIBRA|Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
214691071|NCT04030052|DRUG|Nuwiq (Atlanta protocol)|After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
215024047|NCT05812300|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
215024048|NCT03868280|PROCEDURE|Antegrade femoral nailing Supine Position|Antegrade femoral nailing in Supine Position using a Fracture Table
214423463|NCT00920244|DRUG|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency \< 60 beat/min.
214691072|NCT00520676|DRUG|pemetrexed|500 mg/m\^2, IV, q 21 days x 6 cycles maximum
214691073|NCT00520676|DRUG|docetaxel|75 mg/m\^2, IV, q 21 days x 6 cycles maximum
214691074|NCT00520676|DRUG|carboplatin|AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
214691075|NCT00928473|BEHAVIORAL|A family-centered, multidisciplinary obesity treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
214691076|NCT02179515|BIOLOGICAL|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
214691077|NCT05526170|DEVICE|Devices for long-term monitoring of objective and subjective parameters of the body|Patients will use a 1-lead Holter ECG (Bittium Faros) for heart rhythm and physical activity analysis, a wearable wrist-worn device with photoplethysmography and 6-lead ECG for heart rhythm analysis, a sleep tracking mat (Withings sleep analyser) for sleep analysis, a smartphone with triggers application for entering the subjective triggers (stress, coffee, alcohol intake and others), a 48-hour ambulatory blood pressure monitor for 2 days and a regular blood pressure monitor for up to 5 days. Patients will be monitored for up to 7 days with the described system of devices. In addition, patients will receive investigations of heart echocardiography, laboratory tests and surveys to evaluate the system and the use of acquired information.
214691078|NCT00000748|DRUG|Sulfamethoxazole-Trimethoprim|
215024049|NCT03868280|PROCEDURE|Antegrade Femoral Nailing Lateral Position|Antegrade femoral nailing in Lateral Position using a Free drape
215024050|NCT05700695|DRUG|Branch Chain Amino Acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
215024051|NCT05700695|DRUG|Lactulose|Oral lactulose will be given to patients in both arms
215024052|NCT06642688|OTHER|Sacroiliac Joint Manipulation|The patient was asked to tie his arms while he was in the side lying position. The patient's upper knee was flexed and positioned such that it was placed in the popliteal fossa of the lower knee, while the lower knee was in full extension. Pushing maneuver was performed with HVLA from posterior to anterior and from medial to lateral with pelvic rotation. The contact point of the sacroiliac joint was PSIS.
215024053|NCT06642688|OTHER|Cervical Spine Manipulation|Cervical SM was applied supine to restrictions found on motion palpation, according to the technique described by Bergmann and Peterson28 The participant's head and neck were simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7) -to the end of passive ROM. Thereafter, a high-velocity, low-amplitude thrust was delivered in the direction of restricted movement. Participants with more ROM restriction in the lateral plane were given more lateral-to-medial directed thrusts; participants with more restriction in rotation were given thrusts in the direction of restricted axial rotation; and participants with more restriction in extension were given more anteriorly directed thrusts.
215024054|NCT05117125|DIAGNOSTIC_TEST|Heparin-binding protein|Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
215024055|NCT05117125|DIAGNOSTIC_TEST|Interleukin-26|Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
215024056|NCT05117125|DIAGNOSTIC_TEST|Microbiome|Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
215024057|NCT05117125|DIAGNOSTIC_TEST|Bacterial transcriptome|Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
215024058|NCT05117125|DIAGNOSTIC_TEST|Proteome|Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
215024059|NCT02244788|DEVICE|SR™ PIP|SR™ PIP
215024060|NCT05457140|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
215024061|NCT05457140|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
215024062|NCT05019807|OTHER|WhatsApp group|Patients under intervention group will attend an education sessions by structured videos and images with the help of digital tool-WhatsApp group chat administered by the researcher. The group will have the objective interaction with patients and researchers to convey about their view of opinion on sight threatening diabetic retinopathy and management. The structured programme included definition of diabetes mellitus, symptoms, risk factors, awareness of DM and DR, importance of self-care about the disease (eye care and blood glucose monitoring), dietary management and importance of physical activity (Life style modification). The groups will be tracked frequently by WhatsApp/telephonic call and will be documented. Confidentiality of all participants will be maintained.
215103347|NCT04435275|OTHER|Virtual Assistant first, then Human Coach|Instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a VA (e-coach) in place of a safety officer (a human coach).
215103348|NCT04435275|OTHER|Human Coach first, then Virtual Assistant|instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a safety officer (a human coach).
215103349|NCT06530368|OTHER|Calisthenic home exercise programs|Participants in the second group were informed about calisthenic home exercise programs face to face and were asked to perform these exercises as home exercises for eight weeks.
215103350|NCT00208533|DRUG|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
215103351|NCT06584266|DIAGNOSTIC_TEST|Transoesophageal echocardiography|Imaging data obtained with transoesophageals echocardiography will be retained as well as data from transthoracic echocardiography and from other imaging modalities, if available
215103352|NCT06584266|PROCEDURE|Catheter ablation|Cathether ablation of atrial fibrillation substrate using one of available methods.
215103353|NCT02792153|DRUG|Estradiol|AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
215103354|NCT00651638|DRUG|Treatment with ARQ 197|Treatment with ARQ 197
215103355|NCT05244083|OTHER|Mirror Therapy|Therapy consisting of perfoming bimanual activities with a mirror placed on the patient's sagital plane, so it creates the brain illusion that the impaired limb moves the same way and quality that the unimpaired does.
215103356|NCT05244083|OTHER|Program without Mirror Therapy|Bimanual exercises performed with both upper limbs.
215103357|NCT00731146|OTHER|Ultrasound Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
214423464|NCT00920244|DRUG|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
214423465|NCT00920244|DEVICE|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
214423466|NCT04913779|DRUG|Anti-SARS-CoV-2|Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)
214423467|NCT04913779|DRUG|Placebo|Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
214691079|NCT02666092|OTHER|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
215103358|NCT00731146|OTHER|Nerve Stimulator Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
215024063|NCT05019807|OTHER|Control group|Patient under non-intervention group will not attend or take part in the education sessions or interaction with other patients. Will receive only the general instructions or advises from ophthalmologists about management and follow-up visit.
215024064|NCT05225012|OTHER|Acceptance and Commitment Therapy|Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
215024065|NCT04983238|DRUG|BYON5667 & SYD985|Ocular administration: BYON5667, Intravenous administration: SYD985
215024066|NCT04983238|DRUG|Placebo & SYD985|Ocular administration: Placebo, Intravenous administration: SYD985
215024067|NCT05815784|DRUG|Atropine|0.05% atropine. One drop per eye per day for 2 years.
215024068|NCT05815784|DEVICE|MiSight contact lenses|Daily wear for 2 years.
215024069|NCT02554838|OTHER|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
215024070|NCT02554838|OTHER|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
215024071|NCT02554838|BEHAVIORAL|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
215024072|NCT03324412|DRUG|Treatment of MTX|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
215024073|NCT03324412|DRUG|Treatment of MTX and TwHF|Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
215024074|NCT03668340|DRUG|AZD1775|AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
215024075|NCT04681885|DEVICE|Tapered bristles A|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .
215103359|NCT06256744|OTHER|exercise|Resistance exercise
215024076|NCT04681885|DEVICE|Tapered bristles B|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
215024077|NCT04681885|DEVICE|End rounded bristles|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
215024078|NCT06003790|DEVICE|MR-001|Use of device 3 times per week for 8 weeks - for a total of 24 sessions.
215024079|NCT02498795|OTHER|Group of Dry Needling|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
215024080|NCT02498795|OTHER|Group of Electrolysis|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
215024081|NCT02498795|OTHER|Control Group|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
215103360|NCT03522220|BEHAVIORAL|3D navigation video game intervention|Participants intensively train with a video game (Super Mario DS)
215103361|NCT03522220|BEHAVIORAL|video game intervention without 3D navigation|Participants train with a video game (Super Mario Bros)
215024082|NCT01726608|PROCEDURE|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
215024083|NCT04775979|DRUG|diphenylcyclopropenone (DPCP)|Depigmenting agent
215024084|NCT05770245|DEVICE|The novel electrolyzed water spray|The researcher used electrolyzed water or piped water to treat the diseased area two times a day for five days. The trial consists of 7 study visits (day 1-day 7). The reduction in the disease area of discomfort or itching scores and promoting healing of the damaged skin of patients with mild dermatophytosis event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
215024085|NCT02055339|DEVICE|Fisher & Paykel heated humidified high flow nasal cannula|
215024086|NCT02055339|DEVICE|InfantFlow/RAM nasal continuous positive airway pressure|
215024087|NCT06415240|OTHER|Facilitated Tucking|Facilitated Tucking is a position to be adopted for pain relief in neonates.
215024088|NCT06415240|OTHER|Gentle Human Touch|while gentle human touch is caressing on head for pain relief.
215103362|NCT03522220|BEHAVIORAL|No 3D navigation|Participants read on a kindle device (control group)
215103363|NCT01317901|DRUG|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
215103364|NCT01317901|DRUG|Bendamustine|Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
214423468|NCT01215695|DEVICE|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
215103365|NCT01317901|DRUG|Rituximab|Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.
215024089|NCT02531451|DRUG|Ibuprofen|
215024090|NCT02531451|DRUG|Acetylsalicylic acid|
215024091|NCT06060444|OTHER|Telemedicine Consult|Neurological consultation completed remotely
215024092|NCT06060444|OTHER|In-person Consult|Neurological consultation completed in-person
215024093|NCT00262613|DRUG|sodium pyruvate in 0.9% sodium chloride solution|
215024094|NCT03741855|DEVICE|Cloud Dx Kit with self-monitoring|Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.
215024095|NCT03741855|DEVICE|Cloud Dx Kit with remote-monitoring|"* Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~* A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~* The RT will also check on patients once a week irrespective of the value of the vitals."
215024096|NCT06303752|DRUG|ADRC injection|Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
215024097|NCT06303752|DRUG|ADRC001 injection|Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
215024098|NCT02999659|DEVICE|Pupilometer|Device to measure change in pupil diameter due to a defined light stimulus.
215024099|NCT06090799|DRUG|SHR-3032|Single dose at varying dosage levels depending on treatment assignment
215024100|NCT06090799|DRUG|SHR-3032 Placebo|Single dose at varying dosage levels depending on treatment assignment
215103366|NCT05574088|PROCEDURE|Apical patency with file|After an informed consent , One group will receive apical patency intervention with k file number 10 while the other will be control group
215103367|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
215103368|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
215103369|NCT00544791|DRUG|melatonin|5 mg, oral, daily dose for 6 months
214423469|NCT01215695|DEVICE|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
214423470|NCT02296619|PROCEDURE|TAP block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
215024101|NCT00581100|DRUG|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
215024102|NCT04744831|DRUG|DS-8201a 5.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)
215024103|NCT04744831|DRUG|DS-8201a 6.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)
215024104|NCT05142319|BIOLOGICAL|Homologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
215024105|NCT05142319|BIOLOGICAL|Heterologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
215024106|NCT05142319|BIOLOGICAL|COVAXIN|Single intradermal injection at 6ug (0.5ml) per dose.
215024107|NCT05142319|BIOLOGICAL|Nuvaxovid|Single intradermal injection at 5mcg (0.5mL) per dose.
215024108|NCT01627197|PROCEDURE|Surgery of percutaneous catheter system|Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
215024109|NCT05170061|DRUG|Nebivolol|Nebivolol 20 mg daily (1 week) followed by nebivolol 40 mg daily (3 weeks) followed by nebivolol 20 mg daily (1 week)
215024110|NCT05170061|DRUG|Valsartan|Valsartan 160 mg daily (1 week) followed by valsartan 320 mg daily (3 weeks) followed by valsartan 160 mg daily (1 week).
215103370|NCT00544791|DRUG|placebo like melatonin tablets|
215103371|NCT00000358|DRUG|Lofexidine|
215103372|NCT00098579|DRUG|alvocidib|Given IV
215103373|NCT00098579|DRUG|doxorubicin hydrochloride|Given IV
215103374|NCT03494582|PROCEDURE|Sacral Hysteropexy|Abdominal approach for uterine suspension
214423471|NCT02296619|PROCEDURE|Control|A sham band-aid will be applied to the abdomen of subjects
214694155|NCT01188382|PROCEDURE|CSF dynamic investigation|
215103375|NCT03494582|PROCEDURE|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
215103376|NCT01561742|DRUG|Minocycline|Minocycline will be given orally at 200 mg a day for 4 months
215103377|NCT01561742|DRUG|Placebo|EquivalentPlacebo will be given
215103378|NCT01059994|DRUG|Placebo sildenafil|Oral, daily, 1 week.
215103379|NCT01059994|DRUG|Sildenafil|oral, 25mg, daily for 1 week
215103380|NCT03914755|DRUG|Tucatinib|Administered via oral tablet
215103381|NCT02780544|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact with parent during eye examination.
215103382|NCT02780544|DEVICE|incubator|staying in incubator during eye examination.
215103383|NCT02780544|DRUG|Sucrose|oral sucrose before eye examination
215103384|NCT01331109|DRUG|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
215103385|NCT02992392|DRUG|Liposic|one eye of the participant recieved Lipoic
215024111|NCT05170061|DRUG|Nebivolol/valsartan combination|Valsartan/Nebivolol, 160/20 mg daily (1 week) followed by valsartan/nebivolol 320/40 mg daily (3 weeks) followed by valsartan/nebivolol 160/20 mg daily (1 week)
215024112|NCT04901975|DRUG|Spironolactone|Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every \~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg. Spironolactone, the aldosterone antagonist to be utilized in Specific Aim 2 of this study, is FDA approved, has been on the market for many years and is routinely administered to all types of children with congenital heart disease including SV patients. The choice of which patient this should be administered to is up to the clinician and their patients and therefore, not all SV patients are on this medication.
215024113|NCT04392570|DIAGNOSTIC_TEST|Fasting|blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
215024114|NCT05931965|DIETARY_SUPPLEMENT|L-methylfolate|Participants receive L-methylfolate 400µg orally twice daily for 4 weeks
215024115|NCT05931965|DIETARY_SUPPLEMENT|Vitamin B12|Participants receive mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
214691080|NCT02666092|BIOLOGICAL|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
214691081|NCT03439748|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
214691082|NCT03439748|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
214691083|NCT01532323|OTHER|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
215024116|NCT05931965|DIETARY_SUPPLEMENT|magnesium|Participants receive magnesium glycinate 400mg twice daily orally for 4 weeks (elemental 120mg approx.)
214691084|NCT05131451|DIAGNOSTIC_TEST|Point of Care Autonomous AI diabetic retinopathy exam|Participants will get a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
214691085|NCT00429065|DRUG|Rituximab|
214691086|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
214691087|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
215024117|NCT02344472|DRUG|pertuzumab|HER2 targeted Therapy
215024118|NCT02344472|DRUG|Trastuzumab|HER2 targeted Therapy
215024119|NCT02344472|DRUG|Capecitabine|Chemotherapy
215024120|NCT02344472|DRUG|Paclitaxel|Chemotherapy
215024121|NCT02344472|DRUG|Vinorelbine|Chemotherapy
215024122|NCT02344472|DRUG|Docetaxel|Chemotherapy
215024123|NCT02344472|DRUG|Exemestane|endocrine therapy
215103386|NCT02992392|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
215103387|NCT01389492|OTHER|frozen meat cutlets meal|250 g of meat cutlets
215103388|NCT01389492|OTHER|meat meals|250 g of meat meal for 4 days
214691088|NCT00782418|DRUG|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
214691089|NCT06347276|DEVICE|PFO occluder; ASD occluder|Transcatheter closure of atrial septal defect (ASD) and patent foramen ovale (PFO) All cases will be examined with DW-MRI preoperatively, and DW-MRI will be repeated 24 hours and 4 weeks after the transcatheter closure procedure.
214691090|NCT04393584|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
214691091|NCT04393584|DRUG|5-FU|d1-2 5-FU 2450 mg/m² every two weeks
214691092|NCT04393584|DRUG|Leucovorin|d1 Leucovorin 200 mg/m² every two weeks
214691093|NCT04393584|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
214691094|NCT04393584|DRUG|Docetaxel|d1 Docetaxel 50mg/m2 every two weeks
214691095|NCT02292303|DIETARY_SUPPLEMENT|zinc-enriched yeast|
214691096|NCT02292303|DIETARY_SUPPLEMENT|Zinc references|
214691097|NCT02805556|DRUG|BMS-663068|Single oral dose of BMS-663068
214691098|NCT02805556|DRUG|BMS-626529|Single intravenous dose of \[13C\]BMS 626529
214691099|NCT02804412|OTHER|Control group|This is the control group with 14 h treatment over 10 workdays.
214691100|NCT02804412|OTHER|CIAT-group|Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
214691101|NCT02804412|OTHER|communication treatment group (CTG)|Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
215024124|NCT02344472|DRUG|Letrozole|endocrine therapy
215024125|NCT02344472|DRUG|Anastrozole|endocrine therapy
215024126|NCT02344472|DRUG|Fulvestrant|endocrine therapy
215024127|NCT02344472|DRUG|Ribociclib|CDK 4/6 inhibitor
215024128|NCT02344472|DRUG|nab-Paclitaxel|chemotherapy
215024129|NCT02344472|DRUG|eribulin|chemotherapy
215024130|NCT02344472|DRUG|leuprorelin|endocrine therapy
215024131|NCT02344472|DRUG|goserelin|endocrine therapy
215024132|NCT03966118|DRUG|Avelumab|Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle
215024133|NCT03966118|DRUG|Ramucirumab|Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
215024134|NCT03966118|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
214691102|NCT01980108|OTHER|water|water
214691103|NCT01887899|DEVICE|transcranial direct current stimulation|
214691104|NCT01887899|DEVICE|sham stimulation|
214691105|NCT01718509|DRUG|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
214691106|NCT01718509|DRUG|Placebo|Administered once-daily, orally, for up to 12 weeks
214691107|NCT05263102|DEVICE|Vaginal Moisturizing Gel|All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
214691108|NCT04823208|DRUG|LY3437943|Administered SC
214691109|NCT04823208|DRUG|Placebo|Administered SC
215024135|NCT04775758|BEHAVIORAL|Self-evaluating questionnaires|Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
215024136|NCT04775758|BEHAVIORAL|iMotions analysis platform|While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
215024137|NCT00385515|DRUG|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
214691110|NCT05209932|BEHAVIORAL|Online New Beginnings Program (eNBP)|The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group-based NBP that can be used on a smart phone, tablet or computer. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations.
214691111|NCT03848221|DRUG|Systane Complete|Systane Complete is an artificial tear.
214691112|NCT03848221|DRUG|Sensitive Eyes Rewetting Drops|Sensitive Eyes Rewetting Drops is a rewetting drop.
214691113|NCT03505138|DEVICE|Group intervention|"GROUP 1 (telematic group):~These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day.~The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases.~The period of monitoring is 1 year."
214691114|NCT03505138|OTHER|health care system|"GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group).~The period of monitoring is 1 year."
214691115|NCT02103790|DEVICE|Home NIV installation|
214423472|NCT04935489|DEVICE|Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form|The intervention is used regularly for patients with treatment resistant depression, however, in this trial it will be given multiple times per day and over less days than the usual protocol
214423473|NCT01940003|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
214691116|NCT00318903|DRUG|Irinotecan (drug)|50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
214691117|NCT00318903|DRUG|Taxotere (drug)|Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
215024138|NCT00385515|DRUG|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
215103389|NCT04583332|OTHER|Rhymes|"Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
214423474|NCT05937919|DRUG|Intravenous injection of 68Ga-PMD22|68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
214423475|NCT04483063|DRUG|2% chlorhexidine gluconate skin cleanser|2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery
214423476|NCT00092755|DRUG|MK0663, etoricoxib|
214423477|NCT00092755|DRUG|Comparators: ibuprofen and placebo|
214423478|NCT06553521|OTHER|MyHEARTSMAP Youth Self-assessment Tool (At Admission)|MyHEARTSMAP is a validated self-assessment tool for pediatric populations, demonstrating high sensitivity and specificity for identifying psychosocial concerns. Adapted from HEARTSMAP, it allows self- and proxy-reporting across 10 well-being domains, providing personalized recommendations. Currently, the clinician-reported HEARTSMAP is the standard of care at BC Children's Hospital ED for the initial assessment of youth with primary psychiatric concerns
214691118|NCT00318903|PROCEDURE|Radiotherapy (procedure)|Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.
214691119|NCT00318903|PROCEDURE|Esophagectomy (procedure)|After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
214691120|NCT04281160|DEVICE|BeCare Mobile App|The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
215024139|NCT03676270|OTHER|Phase I|Chemotherapy, ITK, Hormotherapy, Immunotherapy
214691121|NCT05600192|OTHER|Aerobic or anaerobic exercise|Aerobic or anaerobic exercise in the morning or in the afternoon
215103390|NCT04583332|OTHER|Individual Items in Rhymes|"Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
215103391|NCT04583332|OTHER|Objects|Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
215103392|NCT03204370|DRUG|Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]|A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care
215103393|NCT06583564|PROCEDURE|ICG lymphangiography procedure|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
215103394|NCT04521985|PROCEDURE|thoracolumbar kyphosis surgery|patients receiving surgery or not
215103395|NCT03917914|DRUG|Bisoprolol|As in arm description
214691122|NCT01111201|BEHAVIORAL|questionnaires|The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
214694156|NCT00538876|DRUG|decitabine|"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."
214507793|NCT05076825|OTHER|Neurodynamic Sliding|Participants supine with their cervical and thoracic spine supported in a forward flexed position. Simultaneous hip and knee flexion will be alternated dynamically with simultaneous hip and knee extension. The therapist will change the arrangement of movement depending on the tissue resistance level.
214507794|NCT05076825|OTHER|Static Stretching|Participent lying supine, the therapist will passively position the subject into the straight leg raise position without discomfort or pain to the point where resistance to movement will be first felt.
214507795|NCT03883724|BEHAVIORAL|Brief behavioral treatment of insomnia (BBTI)|The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
214507796|NCT03883724|BEHAVIORAL|Information-only control (IC)|The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.
214507797|NCT02580227|DRUG|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
214507798|NCT02580227|OTHER|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
214507799|NCT00911391|DEVICE|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
214507800|NCT00911391|PROCEDURE|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
214507801|NCT03810300|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
214507802|NCT03810300|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
214507803|NCT03810300|OTHER|Food and cash transfer|15 kg of rice, 1 kg of lentils, and 1 kg of micronutrient-fortified cooking oil, and 750 taka cash per household, distributed monthly
214507804|NCT03810300|BEHAVIORAL|Nutrition behavior Communication Change (BCC)|Weekly, group-based, one-hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings
214507805|NCT03810300|OTHER|Control|No transfer, no behavior change communication
214507806|NCT01333449|DRUG|Decitabine|20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
214507807|NCT00195819|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
214507808|NCT00195819|BIOLOGICAL|placebo|Placebo every other week (eow)
214507809|NCT01964586|DRUG|Dexmedetomidine|2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
214507810|NCT01964586|DRUG|Lidocaine|10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
214507811|NCT01964586|DRUG|Adrenaline|12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
214691123|NCT00637364|PROCEDURE|High intensity focused ultrasound, HIFU|"The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).~The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue."
214691124|NCT03546179|OTHER|tidal volume challenge test|Tidal volume (VT) will be increased from 6 to 8 ml/kg of for one minute and hemodynamic variables, including PVI with 8 ml/kg tidal volume ventilation (PVI8) will be recorded.
214691125|NCT03546179|OTHER|Volume loading|After these two baseline hemodynamic measurements, volume expansion will be performed for 10 min using an infusion of balanced crystalloid solution (6ml/kg of predicted body weight).
214691126|NCT00643487|PROCEDURE|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
214691127|NCT01972009|PROCEDURE|Cardiac catheterisation|Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
214691128|NCT02985502|OTHER|pancreatogenic diabetes|pancreatogenic diabetes
214691129|NCT01970930|PROCEDURE|Blood specimen|4 green top tube 40 cc of blood draw
214691130|NCT04300491|OTHER|Suspension walking training|Physiotherapy session, objective wlaking with body weight support using a specific device
214691131|NCT04234126|PROCEDURE|ERCP|Routine ERCP for CBD stone with the gallbladder in situ, the chronic gallbladder status was defined as gallbladder wall thickness≥4mm, chronic cholecystitis, polyps,crudely or calculus .
214691132|NCT03102944|DIAGNOSTIC_TEST|Minicare BNP|no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
214507812|NCT04222205|DIAGNOSTIC_TEST|Spontaneous breathing trial (SBT) crossover sequence 1|SBTs with T-piece breathing for one hour during odd-numbered months and SBTs with inspiratory pressure augmentation for one hour during even-numbered months.
214691133|NCT00900250|OTHER|Cytology Specimen Collection Procedure|Correlative studies
214691134|NCT05920187|OTHER|Mediterranean diet and Anti-inflammatory diet|"Cases will be randomly allocated to two groups: Mediterranean diet group (following dietary intervention based on MD), and Anti\_inflammatory diet group(following dietary intervention based on IBD-AIF). Patients of the control group will not be instructed to follow a specific dietary intervention.~Evaluation of adherence of cases to dietary intervention will be at two points of time: after four weeks and after 12 weeks by using Mediterranean Diet Serving Score (MDSS) for MD adherence and Anti- Inflammatory Diet Serving Score for IBD- AID adherence. The AID Serving Score (AIDSS) is based on the latest update of the Anti-Inflammatory Diet Pyramid, using the recommended consumption frequency of foods and food group."
214691135|NCT06121700|RADIATION|Radiotherapy targeted to the primary lesion|5 to 7 fractions of short course hypofractionated radiotherapy (HFRT) targeted to the primary lesion.
214691136|NCT06121700|RADIATION|Radiotherapy targeted to the metastatic lesions|Hypofractionated radiotherapy (HFRT) or stereotactic body radiotherapy (SBRT) targeted to metastatic lesions. The target dose will be adjusted based on the lesion's site and diameter and organs at risk, with high-dose irradiation of 4-8 fractions. All metastatic lesions should be irradiated as much as possible, and partial lesion irradiation should be allowed when technically impractical.
214507813|NCT04222205|DIAGNOSTIC_TEST|Spontaneous breathing trial (SBT) crossover sequence 2|SBTs with inspiratory pressure augmentation for one hour during odd-numbered months and SBTs with T-piece breathing for one hour during even-numbered months.
214507814|NCT02124304|DEVICE|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
214507815|NCT04905004|PROCEDURE|Canine retraction|Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.
214507816|NCT02282254|OTHER|Overnight intervention|Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
214507817|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
214694157|NCT03765801|DRUG|GRTA9906 60 mg PR tablet|GRTA9906 60 mg PR tablet
214694158|NCT03765801|DRUG|GRTA9906 60 mg IR capsule|GRTA9906 60 mg IR capsule
214694159|NCT01438567|DRUG|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
215103396|NCT03917914|DRUG|Placebo Oral Tablet|As in arm description
214507818|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
214507819|NCT03781375|DRUG|Etanercept|Administered by subcutaneous injection twice a week
214507820|NCT03781375|DRUG|Placebo to Etanerceot|Administered by subcutaneous injection twice a week
214507821|NCT03781375|DRUG|Methotrexate|Administered orally or subcutaneously once a week at the same dose as prior to study entry
214507822|NCT03973515|DRUG|glucokinase activator|PB-201 is a kind of dual and partial GKA
214507823|NCT03973515|DRUG|Placebo|Placebo oral tablet
214507824|NCT02336958|DRUG|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
214507825|NCT02336958|DRUG|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
215024140|NCT03831776|DRUG|Bosutinib|Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (\> 300 mg/d \> 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.
215024141|NCT03831776|DRUG|Ropeginterferon|Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens. RoPegIFN will be given in an open-label fashion. Patients assigned to RoPegIFN will start with 50 μg injected subcutaneously every 14 days, in combination with Bosutinib.
215024142|NCT06570460|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 6 months
215024143|NCT06570460|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 6 months
215024144|NCT05670704|BIOLOGICAL|ARGX-119|Patients receiving ARGX-119 IV or SC
215024145|NCT05670704|OTHER|Placebo|Patients receiving Placebo IV or SC
215024146|NCT05603780|BEHAVIORAL|exploratory protocol|physiological and cognitive evaluations
215024147|NCT04616196|DRUG|NKTR-255|NKTR-255 IV every 21 days
215024148|NCT04616196|DRUG|Cetuximab|Cetuximab will be given at specified doses on specified days
215024149|NCT00467493|DRUG|Anastrozole|
215024150|NCT06062355|DRUG|HRS-9815 injection|HRS-9815 injection
215024151|NCT05463419|BIOLOGICAL|PIKA COVID-19 vaccine|"SARS-CoV-2 spike subunit protein (Also called Recombinant SARS-CoV-2 S-trimer protein), PIKA adjuvant."
215024152|NCT05463419|BIOLOGICAL|Inactivated Covid-19 vaccine|Inactivated SARS-CoV-2 virus
215024153|NCT06365502|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed.
215024154|NCT06365502|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
214507826|NCT02336958|DRUG|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
215024155|NCT05401409|DIETARY_SUPPLEMENT|Beetroot juice|70mls beetroot juice (400mg nitrate) given daily for 4 weeks
215024156|NCT05401409|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|70mls beetroot juice (nitrate-depleted) given daily for 4 weeks
215024157|NCT04252664|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
215024158|NCT04252664|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
215024159|NCT02371889|DRUG|Topiramate|Max therapeutic dose of 200mg/day
215024160|NCT02371889|BEHAVIORAL|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
215024161|NCT02371889|DRUG|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
215024162|NCT00571714|DRUG|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
215024163|NCT00571714|DRUG|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
215024164|NCT06959121|DEVICE|CellFX® nsPFA™ Cardiac Surgery System|Participants will receive cardiac ablation with the CellFX® nsPFA™ Cardiac Clamp
214507827|NCT02336958|DRUG|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
214507828|NCT01218841|DIETARY_SUPPLEMENT|Fish oil lipid emulsion|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
214507829|NCT01218841|DIETARY_SUPPLEMENT|MCT/LCT|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
214694160|NCT01438567|DRUG|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
215024165|NCT06630689|OTHER|Dry Full Body Massage|Applying massage after phototherapy
215024166|NCT06630689|OTHER|Oil Full Body Massage|Oil Full Body Massage
215024167|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
215024168|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
215024169|NCT04904549|BIOLOGICAL|Placebo|Pharmaceutical form: liquid. Route of administration: intramuscular administration.
215024170|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
215024171|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
215024172|NCT05359718|OTHER|Questionnaire|Questionnaire
215024173|NCT06284278|OTHER|Diaphragmatic breathing retraining|8 weeks diaphragmatic breathing training
215024174|NCT06284278|OTHER|Pelvic stabilization exercise|8 weeks pelvic stabilization exercise training
215024175|NCT06284278|OTHER|pelvic anatomy education|pelvic anatomy education
215024176|NCT01521741|OTHER|Breast Cancer-Related Lymphedema Screening|All patients enrolled in the trial will receive prospective BCRL screening from their pre-operative baseline throughout their breast cancer treatment process. All participants will be measured with perometry, bioimpedance spectroscopy, and patient-reported outcome measures.
215024177|NCT03495232|DEVICE|Zimmer Biomet Persona total knee system|Product manufactured by Zimmer Biomet used to replace the knee joint.
215024178|NCT04951505|DRUG|cefepime-taniborbactam|IV infusion
215024179|NCT05822817|DRUG|sevoflurane|Anesthesia is maintained with inhalation of sevoflurane. The concentration of sevoflurane was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
215024180|NCT05822817|DRUG|propofol|Anesthesia is maintained with an effect-site target-controlled infusion of propofol (2-6ug/ml) based on the Marsh mode. The concentration of propofol was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
214507830|NCT01303510|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
214507831|NCT03109080|DRUG|Olaparib|five levels of dose, per os administration, twice daily each day
214507832|NCT03109080|RADIATION|Radiation therapy|3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
214507833|NCT03770520|PROCEDURE|QFR-guided CABG|CABG surgery based on CAG and QFR
214507834|NCT03770520|PROCEDURE|Angio-guided CABG|CABG surgery based on heart team discussion of CAG
214507835|NCT06161259|DRUG|Leritrelvir(Ray1216)|Participants receive Leritrelvir orally.
214507836|NCT01753167|DRUG|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
214507837|NCT01753167|DRUG|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
214507838|NCT01753167|DRUG|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
214691137|NCT06121700|BIOLOGICAL|Anti-PD-1 monoclonal antibody|"The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status.~The commonly used anti-PD-1 mAb usages are as follows: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W."
214694161|NCT05118386|DRUG|RSM01|"Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM"
215024181|NCT05520333|BEHAVIORAL|BIPAS Alcohol|Weekly text messages for three months.
215024182|NCT00614341|DEVICE|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
215024183|NCT04343833|PROCEDURE|Immediate dental implants|At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
215024184|NCT04859686|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR program included weekly 2.5-hour sessions in a group format over eight weeks, plus a 1-day retreat. Formal practices included several types of meditation, such as mindful breathing, sitting meditation, walking meditation, gentle hatha yoga, body scan, and mindful awareness. Participants were asked to practice at home for 20 minutes daily, six days a week.
215103397|NCT04845178|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
215103398|NCT04845178|DRUG|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/PhEur
215103399|NCT05888753|PROCEDURE|Adrenalectomy|Scheduled adrenal surgery
215103400|NCT04047979|BIOLOGICAL|Shingrix®|A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
214507839|NCT02374736|DRUG|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL."
215103401|NCT02440243|DRUG|Purethal|prerseasonal course of SCIT - three years
215103402|NCT02440243|DRUG|Purethal -placebo|preseasonal course of SCIT - three years
214691138|NCT06121700|BIOLOGICAL|Trastuzumab|For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. The 3-weekly schedule of trastuzumab starts with a loading dose of trastuzumab of 8 mg/kg, followed by 6 mg/kg trastuzumab every 21 days.
214691139|NCT06121700|DRUG|Chemotherapy|"The investigator's choice of chemotherapy regimens included SOX, XELOX or FOLFOX. Their usages are as follows:~SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily; and oxaliplatin 130 mg/m2, day 1, every 3 weeks; XELOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks; FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks."
214691140|NCT06121700|PROCEDURE|R0 total/subtotal gastrectomy with D2 lymphadenectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For primary lesions, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper-third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle-third tumors, the gastric margin is recommended to be more than 5 cm, and total gastrectomy is performed. For lower-third tumors, a 2 cm duodenal margin is recommended, and subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
215103403|NCT05037019|PROCEDURE|Radiation therapy|Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
214691141|NCT06121700|PROCEDURE|Metastasectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For metastatic lesions, the surgical procedure and resection range are determined by the surgeon.
214691142|NCT06121700|PROCEDURE|Local ablative therapies|Local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) achieve high rates of complete tumor eradication of small metastases, and can be seen as alternatives if a widely invasive surgical approach is required or patient is inoperable.
214691143|NCT06116877|PROCEDURE|implant supported overdenture|mandibular 2-implant retained overdenture of non-modified printable acrylate resins base material with Zirconium oxide nanoparticles
214691144|NCT02843334|BIOLOGICAL|Dried blood spot (DBS) sampling|DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
214691145|NCT03783650|BEHAVIORAL|Control condition|Practices will submit control data and not receive centralized data feedback. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic.
214691146|NCT03783650|BEHAVIORAL|QIC with PCP and without subspecialist|During this phase, practice will begin working on improving HTN practices within their clinic via a QIC, while the other cohort will act as a control (usual care) with data collection. They will attend an initial 1-day interactive video webinar learning session where they will learn QI methodology, enhance and practice QI skills, identify local 30-60 day aims to improve local HTN practices and increase their understanding of pediatric HTN. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic. They will participate in QI coaching, monthly video conferences, and monthly mini-root cause analyses (Mini-RCAs).
214691147|NCT03783650|BEHAVIORAL|QIC with Subspecialist|Practices will integrate their HTN subspecialist into the QIC and focus on issues at the boundary of PCP and subspecialty care (e.g. pre-referral work-up, communication across providers, and time for next available appointment).
214694162|NCT05118386|OTHER|Placebo|"Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM"
215103404|NCT00661622|DRUG|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
215103405|NCT00661622|PROCEDURE|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
215103406|NCT03012711|OTHER|Neuromuscular exercise training|
215103407|NCT06976645|PROCEDURE|Levator muscle resection|Levator muscle resection
215103408|NCT04481217|OTHER|Self-questionnaires battery|"* Childhood trauma questionnaire (Bernstein, Ahluvalia, Pogge, \& Handelsman, 1997; Bernstein et al., 2003)~* The Young schema questionnaire short form (SQ-SF ; Cottraux \& Black, 2006; Young, 1998).~* Dissociative experiences scale (Laroi et al., 2013).~* Launay-Slade hallucination scale (Bentall \& Slade, 1985; Launay \& Slade, 1981)~* Cardiff Anomalous Perceptions Scale (Bell et al., 2006)"
215103409|NCT04481217|OTHER|Socio-demographic screening|age; gender; education; highest diploma; job; marital status; living place
214691148|NCT03783650|BEHAVIORAL|Hub and Spoke co-management|Practices will continue QIC components and implement a hub and spoke model, where the PCP diagnoses and provides definitive management for pediatric HTN with subspecialist support.
214691149|NCT03783650|BEHAVIORAL|Sustainability of changes|Practices will sustain their changes, illustrating the durability of these system changes even after QIC completion and without central feedback and regular meetings.
214691150|NCT02874404|DRUG|Ibrutinib|Given PO
214691151|NCT02874404|OTHER|Laboratory Biomarker Analysis|Correlative markers
214691152|NCT02874404|DRUG|PI3K-delta Inhibitor TGR-1202|Given PO
214691153|NCT04905381|BEHAVIORAL|Usual care|This arm receives usual care (control group)
214691154|NCT04905381|BEHAVIORAL|LENA Star Program sessions|LENA Start is an evidence-based community program designed to engage families and help them learn how to increase conversation with their children during the first few years of life.
214691155|NCT01332812|DRUG|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
214691156|NCT01332812|OTHER|control group|General anesthesia, without additional interventions
214691157|NCT06154031|BEHAVIORAL|Dyad learning|All participants will perform a gamified exercise using a dyad learning protocol. This means that all participants will practice the gamified exercise in pairs (dyads), for 60 minutes on two consecutive days.
214691158|NCT02311855|BIOLOGICAL|Influenza vaccine|"Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:~Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)~At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine."
215024185|NCT04859686|PROCEDURE|Acupuncture Treatment|"Participants received two treatments per week over eight weeks, 35-40 minutes each.~At each treatment, participants were treated with 10 body and two ear points: seven major points on either the front or back of the body. The treatment position alternated between sessions, such that the first session was on the back, with the next session on the front, unless a physical limitation prevented alternation."
215024186|NCT06548672|DRUG|BC3195|BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).
215024187|NCT05513573|DRUG|HLX07|1500 mg, D1，Q3W
215024188|NCT05513573|DRUG|HLX10|300 mg, D1, up to 2 years,Q3W
215024189|NCT05513573|DRUG|placebo|1500 mg, D1，Q3W
214423479|NCT01326130|BEHAVIORAL|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
214423480|NCT05132686|BEHAVIORAL|IER+MED|Over a 6 month period follow a euenergetic Mediterranean diet 5 days per week and a 20% energy restriction over 2 contiguous days as a 70% energy restriction using the same macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
214423481|NCT05132686|BEHAVIORAL|MED/DER|Over a 6 month period follow a Mediterranean diet 7 days per week with a 20% energy restriction 7 days a week using the macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
214691159|NCT01600183|DEVICE|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
214691160|NCT01600183|PROCEDURE|cast|casting of the infant legs
214691161|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
214691162|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
214691163|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
214691164|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
214691165|NCT01281852|DRUG|Cisplatin|Given IV
214691166|NCT01281852|OTHER|Laboratory Biomarker Analysis|Correlative studies
214691167|NCT01281852|DRUG|Paclitaxel|Given IV
214691168|NCT01281852|DRUG|Veliparib|Given PO
215024190|NCT05513573|DRUG|chemotherapy|gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
215024191|NCT02579759|DRUG|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
215024192|NCT02579759|DRUG|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
215024193|NCT02579759|DRUG|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
215024194|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
215024195|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
215024196|NCT02735642|BEHAVIORAL|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
215024197|NCT02735642|BEHAVIORAL|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
214423482|NCT00509535|DRUG|vitreoscilla filiformis cream|
214423483|NCT02701855|BEHAVIORAL|Cognitive tests|"Cognitive tests include:~* The MMSE (Mini Mental State Examination)~* Free and Cued Selective Recall Reminding Test (FCSRT).~* Executive functions (fluencies, TMT A and B, span).~* Tests of verbal fluency (literal and category)~* Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~* The Clinical Dementia Rating Scale~* The IADL scale evaluates autonomy.~* Geriatric Depression screening Scale (GDS)"
214423484|NCT02701855|BIOLOGICAL|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
214423485|NCT02701855|RADIATION|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
214423486|NCT02701855|OTHER|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
214423487|NCT06318624|OTHER|Mobilisation with Movement and Taping|For MWM for the talocrural joint, the hemiparetic side of the participant is positioned in a standing position on a stool. A non-elastic belt is passed behind the patient's distal tibia and secured around the therapist's pelvis. The patient is asked to perform active knee flexion and ankle dorsiflexion with weight on the hemiparetic side. Meanwhile, the therapist performs forward sliding of the tibia with the help of the belt. For 10 seconds active and painless sliding takes place and then return to the starting position. This application is applied as 10 repetitions, 6 sets, and 1 minute rest between sets. Following the MWM application, Mulligan talus stabilization taping is performed. For this taping, the participants' ankles are placed on a stool at a height of 30 cm and their feet are placed in the dorsiflexion position. The therapist starts taping from the plantar surface of the calcaneus using rigid tape and will wrap and stabilize the talus.
214507840|NCT03877354|OTHER|Data from anaesthesia records for ventilation setting screening|Data from anaesthesia records will be retrospectively screened for the ventilation settings
214507841|NCT03877354|OTHER|Data from intensive care records for ventilation setting screening|Data from paediatric intensive care charts will be retrospectively screened for the ventilation settings
214507842|NCT05127967|OTHER|Skin biopsy|A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.
214507843|NCT03372694|BEHAVIORAL|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.
214507844|NCT03372694|DRUG|TCM|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
214507845|NCT03372694|OTHER|Rehabilitation Education|General health education
214507846|NCT03372694|DRUG|placebo|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
214507847|NCT02322424|PROCEDURE|pancreaticoduodenectomy|
214507848|NCT02404441|BIOLOGICAL|PDR001|anti-PD1 antibody
214507849|NCT00822900|DRUG|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
214507850|NCT00822900|DRUG|Placebo|"Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours."
214507851|NCT04679675|OTHER|Usual Care|Subjects will receive Kaiser Permanente Washington standard of care.
214507852|NCT04679675|BEHAVIORAL|Education|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening.
214691169|NCT03258346|OTHER|Inertial Load Cycling Training|Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
214691170|NCT03258346|DIETARY_SUPPLEMENT|Pomegranate Juice|Subjects will consume 8oz of pomegranate juice daily for duration of study.
214691171|NCT03258346|DIETARY_SUPPLEMENT|Placebo|Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
214691172|NCT05625386|DEVICE|transcranial magnetic stimulation|TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).
214691173|NCT01596959|PROCEDURE|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
215024198|NCT02735642|BEHAVIORAL|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
215024199|NCT02735642|OTHER|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
215024200|NCT02410200|DRUG|dimethyl fumarate|
215024201|NCT01117662|DRUG|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
215024202|NCT01117662|DRUG|Placebo|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
215024203|NCT02674828|BEHAVIORAL|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
214691174|NCT01596959|PROCEDURE|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
215103410|NCT05393973|OTHER|Core stability exercises along with conventional physical therapy|"Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions"
214507853|NCT04679675|BEHAVIORAL|Direct Mail|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will also receive an insert describing the home-based cervical cancer screening option and that a kit will be sent within 1 week. An HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
214507854|NCT04679675|BEHAVIORAL|Opt-in|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
214507855|NCT00177619|DRUG|Alendronate|
214691175|NCT02251704|DIAGNOSTIC_TEST|Assessment of body temperature|Axillary body temperature of all participants recorded by a digital thermometer at the time of survey.
214691176|NCT02251704|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
214691177|NCT00390416|DRUG|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
214691178|NCT02940717|OTHER|Vita suprinity|New glass ceramic material
214691179|NCT02940717|OTHER|Emax CAD|standard etchable glass ceramic used for laminate venneers
215024204|NCT02674828|OTHER|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it \>2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
215024205|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
215024206|NCT02465814|DRUG|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
215024207|NCT02465814|DRUG|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
215024208|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
214507856|NCT02909205|OTHER|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
214507857|NCT02909205|OTHER|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
214507858|NCT05671445|BIOLOGICAL|CM326|CM326 injection
214507859|NCT04874649|OTHER|Balloon-blowing breathing|Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
214507860|NCT04874649|OTHER|Sustained maximal inspiration breathing|Participant sit on a chair. Inhale through their nose fully and hold for 3 seconds for a full breath, Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
214507861|NCT02541318|BEHAVIORAL|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
214507862|NCT05746741|BEHAVIORAL|Telehealth solution|Video conferencing
214507863|NCT02234141|DRUG|Placebo|Tablet administered orally once daily
214507864|NCT02234141|DRUG|Selonsertib|Tablets administered orally once daily
214507865|NCT05054270|OTHER|Chest examination with Ultrasound device|Chest examination with Ultrasound device
214507866|NCT03254472|DIAGNOSTIC_TEST|Measured concentrations of biomarkers|
214507867|NCT00259766|DRUG|Budesonide|
214507868|NCT00259766|DRUG|Formoterol|
214507869|NCT00259766|DRUG|Terbutaline|
214507870|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive
214507871|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive
214507872|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: BGM|measurement of blood glucose concentration using different BGM
214691180|NCT01219959|DRUG|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
214691181|NCT01219959|DRUG|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
215024209|NCT02465814|DRUG|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
215024210|NCT02465814|DRUG|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
215024211|NCT02465814|DRUG|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
214507873|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: reference method|measurement of blood glucose concentration using reference Method
214507874|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
214507875|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
214507876|NCT00134186|DRUG|motexafin gadolinium|
214507877|NCT05850624|OTHER|ice massage|active phase when cervical dilatation was 6-8 cm. Ice will apply to the huko point (LI4 area) which is located on the dorsum of the hand, between the first and second metacarpal bones, between the thumb and the index finger for 20 minutes with an ice pack
214507878|NCT05850624|OTHER|virtual reality animation|cervical dilatation was 6-8 cm. Immediately after the second VAS application, the women will be asked about the video they wanted to watch of the sound of waves in the Ocean, rain falling or blooming trees with virtual reality glass. animation will show for a total of 20 min.
214507879|NCT00774059|DEVICE|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
214507880|NCT01496339|BIOLOGICAL|MenSCs transplantation|1×10\^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
214507881|NCT01496339|DRUG|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
214691182|NCT05291871|BIOLOGICAL|HPV vaccine|One-fifth dose bivalent HPV Vaccine or One-fifth dose nonavalent HPV Vaccine
214691183|NCT06458439|DRUG|Epcoritamab|"* C1D1: fixed priming dose of 0.16 mg subcutaneous injection~* C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection~* C1D15 onward: fixed full dose of 48 mg subcutaneous injection"
214694163|NCT03566693|DEVICE|Dexcom G6 CGM System|continuous glucose monitor
214694164|NCT03566693|DEVICE|Blood glucose meter|Blue-tooth enabled blood glucose meter
214691184|NCT04544436|DRUG|Ocrelizumab|The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).
214691185|NCT04544436|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
214691186|NCT04544436|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
214691187|NCT04544436|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
214691188|NCT05961189|DRUG|Azithromycin|Standard of care, 5 days of drug per manufacturer's instructions.
214691189|NCT01874652|DEVICE|Light Weight Breast Implants|Light Weight Breast Implants
215024212|NCT03939065|DEVICE|Sensor Augmented Pump Therapy|Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
215103411|NCT05393973|OTHER|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
215103412|NCT06977061|DRUG|Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy|no other intervention
215103413|NCT02554578|OTHER|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
215103414|NCT01391936|PROCEDURE|Tension Band Wiring|AO technique of TBW for fixation of fracture.
215103415|NCT01391936|PROCEDURE|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
215103416|NCT02466009|DRUG|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
214691190|NCT02935634|BIOLOGICAL|Nivolumab|Specified dose on specified days
214691191|NCT02935634|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214691192|NCT02935634|BIOLOGICAL|Relatlimab|Specified dose on specified days
214691193|NCT02935634|BIOLOGICAL|BMS-986205|Specified dose on specified days
214691194|NCT02935634|DRUG|Rucaparib|Specified dose on specified days
214691195|NCT02730845|DRUG|Intra-articular dexmedetomidine|Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
214691196|NCT02730845|DRUG|Intravenous dexmedetomidine|Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
214691197|NCT02310802|DRUG|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
214691198|NCT02310802|DRUG|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
214691199|NCT02310802|DRUG|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
214691200|NCT02310802|DRUG|Placebo|Placebo dispersible tablets for single oral administration
214691201|NCT05906732|DRUG|LQT-1213|LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
214691202|NCT05906732|DRUG|Placebo|Matching Placebo
214691203|NCT05906732|DRUG|Dofetilide 250 μg Cap|Dofetilide is a potent, pure inward-rectifier potassium channels (IKr) blocker
214691204|NCT06095518|DIAGNOSTIC_TEST|DIC markers and Thrombin Generation Parameters|Observation of DIC markers and thrombin generation parameters in patients with and without thrombotic and hemorrhagic complications
214691205|NCT06677307|DRUG|KRRO-110|KRRO-110 drug product, IV
215024213|NCT03939065|DEVICE|Standard of Care with CGM|Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
214691206|NCT04851678|OTHER|None - observational study|None - observational study
214691207|NCT05761275|PROCEDURE|Elective cystectomy|Adnexal cyst removal for presumed benign adnexal pathology.
214691208|NCT05761275|PROCEDURE|Elective oophorectomy|Ovarian removal for presumed benign adnexal pathology.
214691209|NCT05761275|PROCEDURE|Elective salpingectomy|Tubal removal for presumed benign adnexal pathology.
214691210|NCT05761275|PROCEDURE|Elective tubal sterilization|Tubal obstruction as a definitive contraceptive method (tubal cauterization with or without sectioning, partial or total removal of both tubes, or obstruction with small clips/ligatures).
214691211|NCT01936285|DRUG|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
214691212|NCT01936285|DRUG|Placebo|
214691213|NCT06142422|PROCEDURE|stimulation device|"The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma.~The target is the left precuneus, which is defined by neuronavigation."
214691214|NCT05518305|DIAGNOSTIC_TEST|Medical Imaging|magnetic resonance imaging
215024214|NCT01534221|DEVICE|Biomatrix drug eluting stent|Biomatrix drug eluting stent
214691215|NCT04301843|DRUG|Eflornithine|DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.
214691216|NCT05583474|DRUG|OPC-1085EL|one drop for each eye, once per day
214691217|NCT05583474|DRUG|0.005% Latanoprost|one drop for each eye, once per day
214691218|NCT04860661|DRUG|Esketamine|After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump
214691219|NCT04860661|DRUG|Normal saline|10 ml normal saline
215024215|NCT04854473|DEVICE|Exero Medical Leak Detection System|"the Exero Leak Detection System components used in this study are:~* Smart drain - a surgical drain with added sensing electrodes~* Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~* Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes."
215024216|NCT04306120|OTHER|Traditional Rehabilitation Therapy|The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.
215024217|NCT01427673|PROCEDURE|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
215024218|NCT02126891|PROCEDURE|Tests|Individual parameters of echocardiography and heart rate variability
215024219|NCT04639791|OTHER|No intervention|Observation only, no intervention
215024220|NCT05131256|BEHAVIORAL|Neurofunctional characterization of emotional regulation (fMRI)|Investigation of neurofunctional characterization of emotional regulation and its links with the eating behaviours of patients suffering from obesity using a comprehensive, clinical, and cognitive assessment and task-based MRI exams.
215024221|NCT02192476|OTHER|conventional neuro rehabilitation programme|All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
215024222|NCT02192476|OTHER|California tri-pull taping (CTPT)|"Two types of tape was used, a self-adhesive 1.5 cotton undercover tape and a 1 rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape."
215024223|NCT03412591|DRUG|Suvorexant 20 mg|Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
215024224|NCT04952519|DRUG|Amantadine|Patients are treated with high doses of amantadine.
215024225|NCT03127163|DEVICE|Intraestromal corneal ring|The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
215024226|NCT03930511|PROCEDURE|Pulmonary Rehabilitation|According to patients' needs and physician referral, individually tailored treatments of respiratory physiotherapy, functional training, exercise training and patient education
215024227|NCT01486329|BIOLOGICAL|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
215103417|NCT02176161|DRUG|Metformin Hydrochloride Extended Release 750mg|Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
214691220|NCT03764202|OTHER|Detection of sufentanil concentration|"* Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point"
214691221|NCT03609528|DEVICE|CamPROBE|To be completed
214691222|NCT02558816|DRUG|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199
214691223|NCT01999855|OTHER|Phoniatric tests|
214691224|NCT04447989|DRUG|Sildenafil|Sildenafil citrate injection or powder for suspension
214691225|NCT04447989|DRUG|Placebo|dextrose 5%
214691226|NCT06214910|OTHER|Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP)|Participants randomized to this arm will receive the entire supply of TB preventive therapy (TPT) at enrollment.
214691227|NCT06214910|OTHER|Clinic-link TPT|Participants receive 2-week supply of TPT at initiation, then continue to receive remainder of TPT course at clinic (including refills).
214691228|NCT04995224|OTHER|Assessment of Psychophysiological factors|Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
214691229|NCT04995224|BIOLOGICAL|Assessment of Biological factors|Investigating autonomic nervous function using heart rate recording, colon biopsy samples, microbiota, and blood cytokines levels. (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons. Blood samples and stool samples will be taken when participants come to the hospital for colonoscopy)
214691230|NCT04995224|GENETIC|Assessment of Genetics|Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
215024228|NCT01486329|BIOLOGICAL|Placebo|Drink solution
215024229|NCT03590548|DIAGNOSTIC_TEST|gausher disease|lab investigation and radio logical
215024230|NCT00273585|DEVICE|Personally-tailored educational software program|
215024231|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/CT|Whole-body PET/CT (contrast enhanced CT or low-dose CT); from vertex to thighs.
215024232|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/MR|Pelvic PET/MR in addition to targeted PET/MR according to other findings from the PET/CT (e.g. columna)
215024233|NCT01484756|DIETARY_SUPPLEMENT|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
215024234|NCT01484756|DIETARY_SUPPLEMENT|Placebo|calcium carbonate 500 mg
215024235|NCT04949087|PROCEDURE|Glenohumeral Injection|Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
215024236|NCT04586751|OTHER|Pecs block|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed.
215024237|NCT04586751|OTHER|no Pecs block|no regional block will be performed in this arm
215024238|NCT01660373|DRUG|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
215024239|NCT01660373|DRUG|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
215024240|NCT05458531|OTHER|Questionnaire|A single questionnaire
215024241|NCT05458531|OTHER|Semi-structured interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
215024242|NCT01987999|DIETARY_SUPPLEMENT|Acetogenins|
215024243|NCT00663156|PROCEDURE|breast implants|patients will have breast augmentation using implants
215024244|NCT00663156|PROCEDURE|Liposuction, fat grafting|Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
215024245|NCT04787315|DEVICE|Conventional intensive functional rehabilitation + Workstations|Equipment will be provided to participants where they can do exercises to increase their motor abilities at the lower limbs, trunk and upper limbs, in addition to conventional intensive functional rehabilitation
215024246|NCT04787315|BEHAVIORAL|Conventional intensive functional rehabilitation|Includes rehabilitation interventions provided by professionnals (OT, PT, speech language therapy, neuropsychologists...)
215024247|NCT01266980|DRUG|Inhaled FF/ GW642444M (200/25mcg)|All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
215024248|NCT01751880|BEHAVIORAL|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
215024249|NCT05775939|OTHER|Fludeoxyglucose F-18|Given FDG
215024250|NCT05775939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
215024251|NCT05775939|PROCEDURE|Computed Tomography|Undergo PET-CT
215024252|NCT05775939|OTHER|Questionnaire Administration|Ancillary studies
215024253|NCT05941780|DIAGNOSTIC_TEST|Pain classification method|A current clinical algorithm will be used to determine the predominant type of pain in individuals with FMS. The classification to diagnose nociceptive, neuropathic and nociplastic pain will based on a recent method developed by Nijs et al. This method consists of seven steps in total. These steps question the following, respectively: duration of pain, pain distribution, presence of nociceptive pain, presence of neuropathic pain, phenomenon of hypersensitivity, presence of hypersensitization and presence of specific comorbidity. Besides, inter-rater and intra-rater reliability of pain classification algorithm will be determined by two independent researchers.
215024254|NCT02048007|DRUG|Azithromycin|Biannual mass oral azithromycin to children
215024255|NCT02048007|DRUG|Placebo|Biannual mass oral placebo to children
215024256|NCT02676037|DEVICE|foot pressure plate form|
215024257|NCT02998307|PROCEDURE|CPR Training|Brief CPR assessment and training done during working hours with real-time performance feedback
215024258|NCT05755581|DRUG|Hormonal Antineoplastics|the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.
215024259|NCT05755581|DRUG|Chemotherapy drug|the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.
215024260|NCT05815264|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.
215024261|NCT05815264|BIOLOGICAL|pneumococcal vaccine polyvalent|This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
215024262|NCT06490666|DEVICE|femoral artery doppler|femoral artery pulse wave doppler to measure both pulsatility and resistive indices
215024263|NCT01582581|BEHAVIORAL|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
214691231|NCT04995224|BEHAVIORAL|Assessment of Quality of Life|Investigating QOL by questionnaires.
214691232|NCT04995224|BIOLOGICAL|Assessment of Biological factors|Investigating colon biopsy samples (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons).
214694165|NCT06430047|DRUG|EsoDuo® Tablet|QD, PO
214694166|NCT01423617|DIETARY_SUPPLEMENT|Zenoctil|3 tablets 2 times daily
214694167|NCT01423617|OTHER|Placebo|3 tablets 2 times daily
214694168|NCT00004013|BIOLOGICAL|trastuzumab|
215103418|NCT00098306|DRUG|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
215103419|NCT00098306|DRUG|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
214694169|NCT00004013|DRUG|paclitaxel|
214694170|NCT00335946|DEVICE|HANS non-needle acupuncture|
215024264|NCT01582581|BEHAVIORAL|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
215024265|NCT04840511|DRUG|lidocaine group|lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)
214507882|NCT00898521|DRUG|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area."
215024266|NCT04840511|DRUG|control group|normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
215024267|NCT03395093|DRUG|Fentanyl|Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.
215024268|NCT03395093|DRUG|Midazolam|Five minutes before the patients is done the flexible bronchoscopy, midazolam will be intravenous injected.
215024269|NCT03395093|DRUG|Propofol|Propofol will be intravenous injected as soon as the flexible bronchoscopy begins.
215103420|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
215103421|NCT00098306|DRUG|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
215024270|NCT03395093|DEVICE|Bispectral Index monitoring|Bispectral Index monitoring will be used in the process of the flexible bronchoscopy.
215024271|NCT01577316|BIOLOGICAL|Seasonal influenza vaccination|"2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus;~* a B/Wisconsin/1/2010-like virus."
215024272|NCT04759287|DEVICE|C-MAC VS|The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS
215024273|NCT04759287|DEVICE|flexible fibreoptic bronchoscope|The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
215024274|NCT02494492|OTHER|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
214694171|NCT00335946|PROCEDURE|Stimulation of two acupuncture points bi-lateral|
214694172|NCT02523326|DEVICE|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
214694173|NCT03176940|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
214694174|NCT02837692|DRUG|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
214694175|NCT02837692|DRUG|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
215024275|NCT00814983|PROCEDURE|Naive T-cell Depleted Stem Cell Transplant|"The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant."
215024276|NCT00814983|PROCEDURE|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
215024277|NCT00814983|DEVICE|Isolex device from Baxter|
215024278|NCT02050399|OTHER|Isometric exercise|The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
215103422|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
215103423|NCT01177566|DRUG|pimecrolimus|pimecrolimus 1% cream twice daily
215103424|NCT01177566|DEVICE|topical medical device|Eletone cream three times daily
215103425|NCT04365933|DRUG|EYP001a|Oral tablets
215103426|NCT04365933|DRUG|Entecavir|Oral tablets
215103427|NCT04365933|DRUG|Pegylated interferon alpha2a|Subcutaneous
215024279|NCT02416544|OTHER|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
215024280|NCT00326014|DEVICE|iStent|Glaucoma Surgery
215024281|NCT00812539|OTHER|"Subject/Provider Portal Diabetes Connected Health tool - Deluxe"|"Subjects enrolled into the Deluxeintervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal (Diabetes Connected Health tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading."
215024282|NCT00812539|OTHER|"Subject only Portal Diabetes Connected Health Tool Basic"|"Patients enrolled in the Diabetes Connect Basic intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the Diabetes Connected Health tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system."
215024283|NCT04157738|DRUG|Rapid-Acting Insulin|Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
215024284|NCT04157738|DRUG|Long acting insulin|Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
215024285|NCT00160563|DRUG|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
215024286|NCT00160563|OTHER|Placebo|Oral drops, bid for 18 months
215103428|NCT05188495|DRUG|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
215103429|NCT00932165|DRUG|Exemestane|"Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."
215103430|NCT06005519|OTHER|low AGE diet education|Participants were divided into ten-person groups. Each group was individually invited for a face-to-face meeting where they were provided with a 50-minute low-AGE diet education prepared in accordance with the recommendations of the American Diabetes Association and the Turkish Society of Endocrinology and Metabolism. During the first 20 minutes of the education, a PowerPoint presentation highlighted the importance of choosing plant-based, low-AGE foods and emphasized cooking methods such as boiling, steaming, and preparing meals with added liquids. Participants were advised against frying, roasting, and grilling. Additionally, information was provided on marinade techniques and the use of spices or ingredients such as lemon or vinegar to lower pH in meals. Following the education, participants were given a dietary diary to record their food intake and were asked to self-assess their diet adherence on a scale of 1 to 10 on a weekly basis.
215103431|NCT03795090|COMBINATION_PRODUCT|Regular Patient privacy curtain|Laundered curtains, used in the hospital, coming from the hospital inventory.
215103432|NCT03795090|COMBINATION_PRODUCT|Antimicrobial Coated curtains|Antimicrobial coating consist of active polymers that are approved by USFDA and USEPA.
215103433|NCT00002140|DRUG|Ethambutol hydrochloride|
215103434|NCT00002140|DRUG|Clarithromycin|
215103435|NCT00002140|DRUG|Azithromycin|
215103436|NCT00242593|DRUG|Rosiglitazone|4 mg twice daily oral rosiglitazone or placebo pill for 18 months
215103437|NCT00005116|BEHAVIORAL|psychotherapy|
215103438|NCT04038762|PROCEDURE|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
214423488|NCT06318624|OTHER|Sham|During joint mobilization with movement, the therapist will stabilize the ankle while performing knee flexion and ankle dorsiflexion by actively moving the center of mass to the affected side, but the shear force required to slide the tibia forward with the belt will not be given. Placebo taping following the application will be applied in such a way that there is no stabilization effect without tension between the same start and end points.
214423489|NCT04776265|OTHER|Evaluation of therapeutical approach after ASCT|Evaluation of therapeutical approach after ASCT
214423490|NCT00694681|BEHAVIORAL|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
215103439|NCT01123824|DRUG|CLOPIDOGREL|"Pharmaceutical form: tablets~Route of administration: oral"
214691233|NCT05714098|BEHAVIORAL|Gerofit Exercise Program|The tele-Gerofit exercise intervention has training focused on meeting the physical activity guidelines and incorporating cardiovascular, strength, and balance training. Sessions will also include a mindfulness component, warm up, cool-down, and safety checks. Exercises are personalized to each person's functional status. Intensity of exercises will be determined by participants providing a rating of perceived exertion (RPE) on a scale of 0 (easy) to 10 (very hard) throughout the session. Initial exercise sessions will start at low-intensity and will gradually increase the duration and intensity to allow each person to reach recommended exercise levels at their own pace. Exercises are done virtually via Zoom. Each cohort will have 5-8 participants. The exercise program will be optimized after each cohort with modifications based on participant and exercise expert feedback.
214691234|NCT06266533|BEHAVIORAL|Conventional Ultra-processed Food Nutrition Education|The participants will receive a conventional nutrition education session with slides, flyers/handouts, and a lecture with discussion.
214691235|NCT06266533|BEHAVIORAL|Arts-based Ultra-processed Food Nutrition Education|The participants will receive an arts-based nutrition education session with video, animation, music, and discussion.
214691236|NCT02605421|DRUG|Thiotepa|Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
214691237|NCT02605421|DRUG|Cyclophosphamide|Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
214691238|NCT02605421|DRUG|Melphalan|Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
214691239|NCT02605421|DRUG|Etoposide|Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
214691240|NCT02605421|DRUG|Carboplatin|Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
214691241|NCT02605421|BIOLOGICAL|Autologous Stem Cell Infusion|On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
214691242|NCT02605421|BIOLOGICAL|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC \> 2000/μL for 3 consecutive days.
214691243|NCT05355350|DRUG|Piperacillin / Tazobactam Injection|4.5 grams QID
215024287|NCT00363363|BEHAVIORAL|Physical Activity|Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
215103440|NCT01123824|DRUG|placebo|"Pharmaceutical form: matching tablets~Route of administration: oral"
215103441|NCT06168266|DEVICE|Eccentric bike|Received eccentric cycling exercise
215103442|NCT06168266|OTHER|conventional group|Received conventional treatment
215103443|NCT05080374|OTHER|Spinal Manipulation + exercise program|high-speed, low-amplitude spinal manipulation plus a trunk exercise program
215103444|NCT05080374|OTHER|Spinal manipulation + Kinesiotaping|high-speed, low-amplitude spinal manipulation plus elastic bandage (Kinesiotaping) application to the trunk area
215103445|NCT05080374|OTHER|spinal manipulation + respiratory exercise|high-speed, low-amplitude spinal manipulation plus a breathing exercise program for the diaphragmatic muscles
215103446|NCT00588094|DRUG|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|"ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.~Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.~For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is \> 100kg. Leukapheresis will continue."
215103447|NCT06010134|OTHER|Physical Therapy Program|Physical Therapy Program plus Whole Body Vibration
215103448|NCT03672526|DEVICE|measure of injection pressure by compuflo|injection pressure mesured by Compuflo
214423491|NCT00476060|PROCEDURE|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
215103449|NCT01336023|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
214423492|NCT03644329|OTHER|Control group|The volunteers will not performed the interventions.
214423493|NCT03644329|OTHER|Lower-load resistance training (LL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
214691244|NCT05355350|DRUG|Meropenem|1 gram TID
214694176|NCT02837692|DRUG|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
214694177|NCT02837692|DRUG|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
214694178|NCT04640324|DRUG|Nutraceutical therapy|Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
215024288|NCT00363363|BEHAVIORAL|Education|Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
215024289|NCT05175729|DIAGNOSTIC_TEST|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
214507883|NCT03760653|OTHER|Physical Exercise and probiotic group|The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of \~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
214507884|NCT03760653|DIETARY_SUPPLEMENT|Probiotic group|Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
215024290|NCT04874597|DRUG|Ocrelizumab|Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.
215024291|NCT02302326|DRUG|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
215024292|NCT02302326|DIETARY_SUPPLEMENT|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
215024293|NCT04801901|PROCEDURE|dTRA|Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)
215024294|NCT04801901|PROCEDURE|fTRA|Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
215024295|NCT05770180|BIOLOGICAL|Recombinant COVID-19 variant vaccine (Sf9 cell)|WSK-V102
215024296|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (CHO cell)|control 1
215024297|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|control 2
215024298|NCT03177798|DRUG|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
215024299|NCT03177798|DRUG|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
215024300|NCT03905239|DIAGNOSTIC_TEST|algorithm|clinical examination and procalcitonin assessment
215024301|NCT05600751|PROCEDURE|Radiosurgery of ganglion stellatum|Patients will undergo radiosurgery of ganglion stellatum (left one or both)
215024302|NCT04072939|OTHER|Patients having had a lens surgery|Dilated fundus exam
215024303|NCT03662529|BEHAVIORAL|Four-Session Mind Freedom Plan|Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.
215024304|NCT03662529|BEHAVIORAL|Treatment as usual therapy|Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
215024305|NCT03713411|PROCEDURE|urethral catheter placement|urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
215024306|NCT04309266|DEVICE|Amadeo by Tyromotion|Distal upper extremity/hand robot for robot-assisted therapy
215103450|NCT01336023|DRUG|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
215103451|NCT01336023|DRUG|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
215103452|NCT00099866|DRUG|vildagliptin|
214423494|NCT03644329|OTHER|Higher-load resistance training (HL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
214423495|NCT03644329|OTHER|Higher-volume resistance training (HV)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
214423496|NCT06972563|OTHER|Psychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed with Generalized Anxiety Disorder|Psychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed with Generalized Anxiety Disorder
214423497|NCT06972563|OTHER|The initiative was not implemented.|The initiative was not implemented.
214423498|NCT06974409|DEVICE|foam roller|foam rollers with grids, knobs, and spikes
214423499|NCT04415086|BIOLOGICAL|convalescent plasma|The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
215103453|NCT00099866|DRUG|Metformin Comparator|
215024307|NCT04309266|BEHAVIORAL|Active Learning Protocol for Stroke|Metacognitive approach involving active problem solving for using the affected upper extremity in motoric activities. Also includes a home program.
215024308|NCT02695186|PROCEDURE|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
215024309|NCT00398879|DRUG|Perifosine|Perifosine 50 mg/d qd
215024310|NCT00398879|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
215024311|NCT00398879|OTHER|Perifosine Placebo|Placebo to Perifosine 50 mg/d qd
214423500|NCT01376336|DEVICE|Safe storage device|This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
215024312|NCT01720836|BIOLOGICAL|Vaccine + PolyICLC|The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
215024313|NCT01514279|BEHAVIORAL|HealthyCHANGE|"Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
215103454|NCT03951116|DRUG|FCN-437|FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
215103455|NCT04805710|DRUG|clopidogrel combined with rivaroxaban arm|Patients who have been selected will be randomized to the clopidogrel combined with rivaroxaban arm. clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily
214423501|NCT04183959|DEVICE|video stylet|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
214423502|NCT04183959|DEVICE|fiberoptic|intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
214423503|NCT01036412|DRUG|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
214423504|NCT01036412|BEHAVIORAL|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
214507885|NCT03760653|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks
214507886|NCT03315065|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, \< 1 hour
214507887|NCT03177226|DEVICE|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
215024314|NCT01514279|BEHAVIORAL|SystemCHANGE|"Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
214507888|NCT03177226|DEVICE|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
214507889|NCT06466616|OTHER|Real stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks stretching of plantar fascia, gastrocnemius and hamstring muscle.
214507890|NCT06466616|OTHER|Placebo stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks placebo stretching of plantar fascia, gastrocnemius and hamstring muscle.
214507891|NCT01594606|BEHAVIORAL|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
214507892|NCT05815420|DEVICE|Non invasive ventilation|Treatment by non invasive ventilation
214694179|NCT00294008|DRUG|Risperdal Consta|flexible dosage for 24 months
215103456|NCT03824600|DIAGNOSTIC_TEST|Fractional Flow Reserve Motorized Pullback|A pullback device (Volcano R 100, San Diego CA, USA), adapted to grip the coronary pressure wire (PressureWire X, St Jude Medical, Minneapolis, USA), set at a speed of 1 mm/sec to pullback the pressure-wire until the tip of the guiding catheter during continued pressure recording.
215103457|NCT01302197|OTHER|No intervention|longitudinal follow-up after stroke
215103458|NCT03837132|BEHAVIORAL|Palliative care assessment|Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
214423505|NCT02380209|OTHER|CEST MRI|CEST MRI will be performed on patients prior to surgical resection of their tumor
214423506|NCT01585558|DRUG|Ospemifene (Dose 1)|
214423507|NCT01585558|DRUG|Ospemifene (Dose 2)|
214423508|NCT01585558|DRUG|Placebo|
214423509|NCT01378065|DEVICE|Restorelle Direct Fix A&P|Restorelle Direct Fix A\&P is a permanently implantable synthetic mesh for reconstruction of the pelvic floor secondary to the prolapse or protrusion of the pelvic organs into or out of the vaginal canal.
214423510|NCT04561544|BEHAVIORAL|Knowing Who You Are (Becoming): Cultural Identity Intervention|8-week cultural identity development program led by Alaska Native Elders
214423511|NCT00476333|DEVICE|APOS biomechanical gait system|
214423512|NCT00566124|DRUG|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
214423513|NCT00566124|DRUG|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
215103459|NCT04597840|PROCEDURE|Incisional hernia repair with reinforcement of biosynthetic mesh|The biosynthetic mesh (Phasix or Bio-A meshes) will be placed as a sublay in the retromuscular position to reinforce midline fascial closure. All the surgical procedure (including placement and fixation of the mesh) will be performed according to a standardized protocol.
215103460|NCT04597840|PROCEDURE|Incisional hernia repair with simple suture or synthetic mesh reinforcement.|Based on the discretion of the surgeon, the incisional hernia repair will be done by simple suture or by synthetic mesh reinforcement. All the surgical procedure (including placement and fixation of the mesh if applicable) will be performed according to a standardized protocol.
215103461|NCT03369002|DRUG|seladelpar|Oral single dose 10 mg
215024315|NCT05139095|DRUG|Camrelizumab plus apatinib CohortA|Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.
215024316|NCT05139095|DRUG|Camrelizumab plus apatinib Cohort B|Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\]; or EMA/EP \[etoposide, methotrexate and actinomycin-D/etoposide, cisplatin\]; or FAEV \[floxuridine, actinomycin-D, etoposide, vincristine\]). The observation period is 21 days.
215024317|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
215024318|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
215024319|NCT06642961|OTHER|Placebo|The placebo will be administered SC.
215024320|NCT03407950|BEHAVIORAL|IPT+|Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
215024321|NCT03407950|BEHAVIORAL|Treatment as usual|no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
215024322|NCT00347269|BEHAVIORAL|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
215024323|NCT00347269|DRUG|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
215024324|NCT00347269|BEHAVIORAL|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
215024325|NCT06076213|DRUG|Artesunate-amodiaquine|Tablets
215024326|NCT06076213|DRUG|Artemether-lumefantrine|Tablets
215024327|NCT03415048|OTHER|No Intervention|
215103462|NCT03034902|DEVICE|Combined EEG and fNIRS|The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
215103463|NCT01343732|DEVICE|Deep TMS|deep transcranial magnetic stimulation
215024328|NCT04889950|DEVICE|Tixel C|Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
215103464|NCT02044861|DRUG|PFK-158|IV dose escalation
215103465|NCT00638976|DRUG|eptifibatide|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
215103466|NCT00638976|DRUG|placebo|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
215103467|NCT04373746|DEVICE|NICCI|Non-invasive beat-to-beat blood pressure monitor capable of producing a waveform similar to an invasive arterial line.
215024329|NCT04889950|DEVICE|LipiFlow|LipiFlow
215024330|NCT05389150|DRUG|Fixed dose combination Pregabalin 150 mg / Tramadol 50 mg|Pregabalin/Tramadol (Laboratorios Silanes S.A. de C.V.), Pharmaceutical Form: Tablet Dosage: 150 mg / 50 mg Administration way: oral
215024331|NCT05389150|DRUG|Pregabalin 150mg|From Pfizer S.a. de C.V. Pharmaceutical Form: Capsule Dosage: 150 mg Administration way: oral
215024332|NCT05389150|DRUG|Tramadol 50 mg|From Grünenthal de México, S.A. de C.V. Pharmaceutical Form: Capsule Dosage: 50 mg Administration way: oral
215024333|NCT06119321|OTHER|Pentacam, Corvis ST and Scansys|morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST
215024334|NCT06241014|OTHER|Mulligan Mobilization and Sling Exercises|Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times having two sessions per week for 3 weeks. For the sling exercise, the sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day. To perform the exercise, the subjects will be instructed with a demonstration and explanation.
215024335|NCT06241014|OTHER|Mulligan Mobilization|Mulligan Mobilization
215024336|NCT05662722|OTHER|percutaneous needle electrolysis|It´s an intervention of physiotherapy. It´s an invasive technique.
214423514|NCT00566124|DRUG|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
215024337|NCT05662722|OTHER|Dry needling|It´s an intervention of physiotherapy. It´s an invasive technique.
215024338|NCT05662722|OTHER|Sham needling|It´s an intervention of physiotherapy. It´s an invasive technique simulation.
215024339|NCT06215508|OTHER|Questionnaires|Questionnaires participants fill out at different study visits
215024340|NCT03702738|DRUG|N-acetyl cysteine|NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
215024341|NCT04724252|DRUG|Gabapentin|Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.
215024342|NCT04724252|OTHER|Placebo|Control Arm
215024343|NCT03945253|DRUG|ASP8374|Intravenous
215024344|NCT05158699|DRUG|Bromfenac|Bromfenac topical eye drops (Yellox)
215024345|NCT05158699|DRUG|Dexamethasone|Dexamethasone topical eye drops
215024346|NCT05158699|DRUG|Triamcinolone Acetonide|0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally
215024347|NCT05158699|DRUG|Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution|Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
215024348|NCT05531149|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
215024349|NCT05531149|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
214507893|NCT02161458|DRUG|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
215024350|NCT06451458|BEHAVIORAL|ECHO program for DMMC|For the intervention, an 18-month ECHO program of weekly videoconference sessions will mentor healthcare teams on complex care strategies for patients with DMMC, emphasizing evidence-based best practices related to common chronic conditions (e.g., diabetes, CKD, hypertension, hyperlipidemia and depression). Mentorship will be provided by a multidisciplinary team of experts including a patient representative, diabetes educator, endocrinologist, psychiatrist, a nephrologist/kidney disease and hypertension specialist, a clinical pharmacist, and a cardiology consultant. Each session will consist of a didactic presentation, de-identified patient case presentations, and questions and discussion.
215024351|NCT06451458|BEHAVIORAL|Usual care|The comparator will consist of 10 PMS FQHC clinics with healthcare teams practicing usual care according to PMS standard practices during the 18 months of the intervention arm.
215024352|NCT03100461|OTHER|I2|"A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.)."
214507894|NCT02161458|DRUG|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
214507895|NCT02161458|DRUG|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
215024353|NCT03100461|OTHER|Health Education|Standard of care approach that will provide basic information on CRC screening.
215024354|NCT06316999|DIAGNOSTIC_TEST|Intestinal Ultrasound|Transabdominal and trans perineal ultrasound of the pouch
215024355|NCT05632601|DIAGNOSTIC_TEST|PET scan|PET scan
215024356|NCT05931718|BIOLOGICAL|cytokine essays|evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples
215103468|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea containing L-arabinose and indigestible dextrin|
215103469|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea (Placebo)|
215103470|NCT01046214|DRUG|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
214507896|NCT02161458|DRUG|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
214507897|NCT02446106|DIETARY_SUPPLEMENT|Soup with MSG|0.5% MSG + 0.48% salt
214507898|NCT02446106|DIETARY_SUPPLEMENT|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
214507899|NCT01078272|OTHER|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
214507900|NCT01078272|OTHER|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
214507901|NCT04547660|BIOLOGICAL|Convalescent Plasma|Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.
214507902|NCT04547660|OTHER|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
214507903|NCT01933997|DRUG|Metadoxine (MG01CI )|
214507904|NCT04047407|DEVICE|Suprathreshold pain stimulation|"Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized."
214507905|NCT03046706|BEHAVIORAL|post operative voice rest|After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.
214691245|NCT04207619|OTHER|hyperinsulinemic-hypoglycemic clamp|An intravenous catheter will be placed in an antecubital vein for infusion of insulin and glucose. A second catheter will be placed retrograde in a dorsal vein of the contra-lateral hand for blood withdrawal. The hand will be placed in a heating box or pad at 70°C for arterialization of venous blood. A primed infusion of regular insulin (120 mU/min/m2) will be initiated and continued for approximately 2 hours. Beginning 20 minutes prior to the start of the insulin infusion, arterialized venous blood glucose will be measured at 5 minute intervals via a Hemocue or YSI analyzer. Following initiation of insulin infusion, blood glucose will be allowed to fall to 50 mg/dL and then maintained at this level using a variable infusion of exogenous dextrose (20% solution). Our goal is to achieve steady-state (blood glucose stabilized at 50 +/- 5 mg/dL) within the first 45 minutes following the start of insulin infusion.
214691246|NCT04207619|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples
214691247|NCT05618340|DEVICE|Pulsed electric field ablation device;Cardiac Pulsed Electric Field Ablation Catheter|"Routinely placing a coronary sinus electrode catheter, puncturing the interatrial septum, placing one sheath into the left atrium, confirming that the catheter is well in place, and setting the treatment time of the pulse ablation system in advance.~Pulmonary vein-by-pulmonary vein ablation using a circular pulse catheter, waiting for the end of the pulse ablation phase and immediate effect confirmation."
214691248|NCT05929755|DRUG|Depo-Medrol|steroid
214691249|NCT05929755|DRUG|Gel-Flow NT|hemostatic agent
214691250|NCT06549257|BIOLOGICAL|Pfs25-IMX313, Pfs48/45|Two soluble protein vaccines.
214691251|NCT06214455|OTHER|Low sugar diet and 10-12 hour eating window|Low sugar diet and 10-12 hour eating window for four weeks
214691252|NCT06214455|OTHER|Low sugar diet, 8 hour eating window and fasting|Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.
214691253|NCT06601712|OTHER|Adherence support strategy A|Community health worker (CHW) support through monthly home visits to remind the caregiver to administrate the PDMC drugs
214691254|NCT06601712|OTHER|Adherence support strategy B|SMS/phone reminders from the qualified community health officers (ASCQ) to the community health workers (CHW) to administrate the PDMC drugs
214691255|NCT06601712|OTHER|Control|No reminders
214691256|NCT06034938|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Switch previous therapy with DOR/TDF/3TC
214691257|NCT06235476|DIETARY_SUPPLEMENT|whey protein supplement|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
215024357|NCT05931718|BIOLOGICAL|NGS|evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples
215024358|NCT05931718|BIOLOGICAL|Fecal microbiome|evaluation of fecal microbiome on fecal samples
215024359|NCT05931718|DRUG|Erythropoietin|evaluation of recombinant erythropoietin use, safety and efficacy in patients with autoimmune hemolytic anemia according to clinical practice
215024360|NCT05931718|DRUG|Luspatercept|evaluation of cytokine levels, molecular profile and bone marrow microenvironment by single cell analysis in patients treated with luspatercept according to clinical practice
215024361|NCT05931718|DRUG|Thrombopoietin Receptor Agonist|evaluation of TPO-RA use, safety and efficacy in patients with ITP according to clinical practice
214423515|NCT06047522|DEVICE|Casque Lumeen|Participants will take part in virtual reality sessions via headset. They will benefit from a before/after evaluation, and a 3-week intervention where they will have 1 virtual reality session per week.
214691258|NCT06235476|DIETARY_SUPPLEMENT|mixed plant-based protein supplement|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
214691259|NCT06235476|OTHER|e-health application|Daily use of an e-health application with dietary intake counselling to increase protein intake. The overall goal of these advices is to increase protein intake from \<1.0g/kg/bw/d to \>1.2g/kg/bw/d which is approximately 30 grams of additional protein per day (similar to the other arms of the intervention).
214691260|NCT06235476|DIETARY_SUPPLEMENT|isocaloric carbohydrate control|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
214691261|NCT01014637|DRUG|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
214691262|NCT01014637|DRUG|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
214691263|NCT05888792|OTHER|Variant of Defocus Incorporated Spectacle lens (DG2)|DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously
214691264|NCT02267863|DRUG|APTO-253|APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.
214691265|NCT03893175|DRUG|Ibuprofen|400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
214691266|NCT03893175|DRUG|Acetaminophen|500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
215024362|NCT05931718|DRUG|G-CSF|evaluation of G-CSF use, safety and efficacy in patients with CIN/AIN according to clinical practice
215024363|NCT05201495|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
215103471|NCT01046214|DRUG|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
215103472|NCT06543342|BEHAVIORAL|Bystander Brief Motivational Intervention|Group-based interactive intervention, conducted in two sessions, including multiple tasks and exercises to identify different levels of risk behavior, different types of strategies, and practicing responding to different scenarios. Personal goals for helping friends stay safe, and identifying whether intervention as a bystander was successful are included.
215024364|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with CTG|"An epithelial-connective tissue graft of approximately 2-3 mm of thickness and adequate length will be taken from the palate or retromolar region of the patient and de-epithelialized with a scalpel (ideally a thickness of 1.5-2.0mm).~The connective tissue graft (CTG) obtained will then be positioned buccally to the dental implant and sutured to the internal side of the flap so to provide soft tissue bulk at the level of the neck of the implant and simulate a root prominence for the missing tooth."
215024365|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with Fibro-Gide|Fibro-Gide will be used to obtain buccal soft tissue augmentation. Fibro-Gide will be trimmed with a scalpel and adjusted in size and thickness to better adapt to the area buccal to the implant. In particular, the graft will be shaped in order to obtain a graft of approximately 2-3 mm of thickness and adequate length. Fibro-Gide will then be sutured to the inner side of the buccal flap, before repositioning the flap and suturing it in a tension-free way.
215024366|NCT04265768|PROCEDURE|No soft tissue augmentation|During implant placement surgery, no soft tissue augmentation will be performed
215024367|NCT05995600|DRUG|Antiplatelet Drug|Clopidogrel ± other antiplatelet drug
214507906|NCT03046706|BEHAVIORAL|No voice rest|No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
214691267|NCT03893175|DRUG|Placebo|By mouth
214691268|NCT03893175|DRUG|Oxycodone|5 mg by mouth every 6 hours as needed for pain
214691269|NCT02957058|PROCEDURE|SCAR technique|Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
215024368|NCT05995600|DRUG|Warfarin|Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
215024369|NCT05479981|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
214507907|NCT04249440|PROCEDURE|Preoperative systemic treatment|neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment
214507908|NCT04865744|DRUG|Semaglutide 7 MG Oral Tablet|Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
214507909|NCT04865744|DRUG|Placebo|Placebo tablet is taken after an overnight fast with up to120 ml of water.
214507910|NCT04865744|DRUG|Semaglutide 14 MG Oral Tablet|Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
215024370|NCT05479981|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
214507911|NCT03042767|BIOLOGICAL|IMM-124E|IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
214507912|NCT03042767|OTHER|Placebo|Matched Placebo
214507913|NCT04243772|OTHER|Data extraction|Data extraction from medical files
214507914|NCT02967822|GENETIC|Biological samples for patients|Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
214507915|NCT02967822|GENETIC|Biological samples for healthy relatives|Blood samples.
214507916|NCT03883217|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
214507917|NCT02798016|PROCEDURE|Platelet-Rich Plasma|This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
214507918|NCT02798016|PROCEDURE|Micro-needling|Micro-needling will be applied on the acne scars in one side of the face.
214507919|NCT02892591|DRUG|Cannabis|vaporized plant material
214507920|NCT02892591|DRUG|Oxycodone|oral capsule
214507921|NCT02892591|DRUG|Placebo for Cannabis|vaporized placebo plant material
214507922|NCT02892591|DRUG|Placebo for Oxycodone|oral placebo capsule
214691270|NCT00287326|DRUG|Bupivacaine, Clonidine, Morphine|
214691271|NCT06553313|DEVICE|Micro-Western Array|The subjects first took the energy measurement of the pulse sphygmograph and Ryodoraku, rested for 20 minutes, and then repeated the measurements again. In order to comply with the acupuncture treatment course was 5 weeks in the previous study, we have two blood draw point. Each subject's blood was drawn for the first time, and then for the second time in 5 weeks later. Each subject drew 10ml of blood each time. The blood samples are analyzed by Micro-Western Array (MWA) and Enzyme-linked immunosorbent assay (ELISA) to obtain the serum protein content value of healthy individuals.
214691272|NCT00506077|DRUG|MK0249|MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
214691273|NCT00506077|DRUG|Comparator: Placebo (unspecified)|MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
214691274|NCT04420416|OTHER|Survey|The investigators will use the Spanish language validated version of the Academic Self-Concept Scale (ASCS), the Patient Health Questionnaire-9 (PHQ-9) depression screening scale, and the General Anxiety Disorder-7 (GAD-7) screening scale. Additionally, the sample will be asked about their gender, age, preference of teaching modality, and finally, if the participants have perceived a change in their performance or any change in their grades.
214691275|NCT00279552|DRUG|Recombinant human intrinsic factor|
214691276|NCT04181567|OTHER|electroconvulsive therapy|electroconvulsive therapy 2 times weekly
214691277|NCT04181567|DRUG|agomelatine|agomelatine
214691278|NCT04181567|DRUG|Placebo|placebo
214691279|NCT01594632|DRUG|Jadelle|LNG containing subdermal contraceptive implant
215024371|NCT03042975|OTHER|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
215024372|NCT03042975|PROCEDURE|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies.
215024373|NCT05999383|DRUG|Cannabis|Participants will vape marijuana in varying doses from the PAX device
215024374|NCT05999383|DRUG|Nicotine|Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
215024375|NCT05999383|DEVICE|Pax Loose Leaf Vaporizer|In all arms, participants will be using the PAX Loose Leave Vaporizer.
215024376|NCT05999383|OTHER|Placebo Marijuana|Participants will vape placebo marijuana from the PAX device
215024377|NCT06449547|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
214691280|NCT01594632|DRUG|Sino-implant (II)|LNG containing subdermal contraceptive implant
215024380|NCT03689179|BEHAVIORAL|Time for Living and Caring (TLC)|"Time for Living \& Caring (TLC) is an online, self-administered intervention. It includes three types of modules: 1) virtual coaching module (defined as a series of prompts, reminders, and suggestions that guide caregivers through assessment, goal setting, and goal review activities) to monitor respite time-use and time-use goals, 2) an interactive calendar that can be used to schedule and track respite time, 3) resource pages (including links, printable forms, video guides) that provide education and resources such as What is Respite?, Why is Respite Important?, How do I Get (More) Respite?, How do I Use Respite?."
215024381|NCT03168529|DRUG|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
215024382|NCT03168529|DRUG|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
215024383|NCT04581629|DRUG|Encaleret|Tablets administered orally
215024384|NCT04522739|DRUG|Spironolactone|Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.
215024385|NCT04522739|DRUG|Placebo|A placebo to match spironolactone will be taken orally once per day for 12 months.
215024386|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
215024387|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app + EHR|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. The participant's primary care provider at MUSC will be provided access to a Moodivate provider portal that was developed by study team. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
215024388|NCT04463914|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
215024389|NCT03396861|DRUG|Aflibercept|Subconjunctival aflibercept
215024390|NCT06639308|PROCEDURE|Endoscopic Flexor Hallucis longus tendon transfer to tendon achilles|The endoscopic FHL tendon transfer is usually performed with the scope introduced through the posterolateral portal and instruments through the posteromedial portal. The FHL tendon must be identified during hindfoot working area creation. First, the calcaneoplasty is completed as described. Next, the FHL tendon is harvested. A tunnel was created into calcenous the tendon is introduced into the tunnel and the tendon is secured with an interference screw of same size than the tunnel
214423516|NCT02315469|OTHER|Comprehensive Geriatric Assessment|Complete pre-operative geriatric assessment
214423517|NCT02315469|OTHER|Questionnaire Administration|Ancillary studies
214423518|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours
214423519|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours
214423520|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours every 8 hours
214423521|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours every 8 hours
214423522|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.
214423523|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
214423524|NCT05905913|DRUG|Meropenem|Meropenem will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
214423525|NCT05905913|DRUG|Meropenem-placebo|Meropenem-placebo will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
214423526|NCT00891176|BIOLOGICAL|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
214423527|NCT00891176|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
214423528|NCT00891176|BIOLOGICAL|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
214423529|NCT00891176|BIOLOGICAL|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
214423530|NCT00891176|BIOLOGICAL|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
214507923|NCT00405184|DRUG|IntragamP|IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
214507924|NCT00405184|DRUG|Ig NextGen 10%|Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
214507925|NCT00528216|DRUG|Capsaicin Dermal Liquid|
214507926|NCT06157554|OTHER|Breathing Exercises|During the exercise sessions, participants will be seated in a chair. In the first five and last five minutes of the session, they will be instructed to focus on their breathing and the sensations produced in the body while sitting comfortably in a relaxed position with all joints in the chairs with their eyes closed. After the initial 5 minutes of relaxed breathing, participants will be instructed to perform diaphragmatic and costal breathing for 10 minutes. After 5 minutes of diaphragmatic breathing, the patient will be rested for 1 minute and then 5 minutes of costal breathing will be performed. While doing coastal breathing, patients will be asked to place their hands on their costas, take a deep breath and inflate the bottom of their hands; then they will be asked to exhale the breath they take in a longer (1:2) time.
214507927|NCT06157554|OTHER|Conventional treatment|Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
214507928|NCT00186446|DRUG|bupropion and smoking cessation behavioral intervention|
214507929|NCT00958321|PROCEDURE|computed tomography|
214507930|NCT00958321|RADIATION|3-dimensional conformal radiation therapy|
214507931|NCT00958321|RADIATION|fludeoxyglucose F 18|
214507932|NCT00958321|RADIATION|radiation therapy treatment planning/simulation|
214507933|NCT00158483|DRUG|Acyclovir (ACV)|
214507934|NCT03942575|DEVICE|Negative pressure wound therapy|Wound dressing with negative pressure on closed incisions
214507935|NCT00705159|DRUG|loteprednol etabonate and tobramycin|Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
214507936|NCT00705159|DRUG|loteprednol etabonate|Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
214507937|NCT00705159|DRUG|Tobramycin|Topical ocular administration of Tobramycin QID for 14 days.
214507938|NCT00705159|DRUG|Vehicle of Zylet|Topical ocular administration of the vehicle of Zylet QID for 14 days.
214507939|NCT04440800|DEVICE|Wearable activity tracker - FitBit|Participants will be given a wearable activity tracker and their daily step count recorded. If there is a reduction from baseline of over 1000 steps, the participant will be contacted and an ambulatory review organised if the reduction is not due to a device compliance issue
214507940|NCT03736980|DRUG|Placebo|100% lactose
214507941|NCT03736980|DRUG|Psilocybine|Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight
214507942|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
214507943|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
214507944|NCT01825720|DRUG|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
214507945|NCT01825720|DRUG|normal saline group|same rate of normal saline
214507946|NCT00526994|OTHER|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
214507947|NCT00526994|BEHAVIORAL|universal education|receives referral information
214507948|NCT03805243|DEVICE|test of sensors for somnonaute device|test of sensors
214507949|NCT03805243|DEVICE|test of sensors for uronaute device|test of sensors
214507950|NCT03805243|DEVICE|test of sensors for toconaute device|test of sensors
214507951|NCT03805243|DEVICE|test of sensors for neuronaute device|test of sensors
214507952|NCT03805243|DEVICE|test of sensors for cardioskin device|test of sensors
215024391|NCT06639308|PROCEDURE|Open Flexor Hallucis longus transfer to tendon achilles|The FHL tendon can be approached through the posterior longitudinal incision The FHL is confirmed by digital retraction of the tendon, watching for flexion of the hallux. Dissection of the FHL tendon is followed to the posterior talus and FHL tunnel, remaining lateral to avoid the neurovascular bundle. Release of the fibro-osseous tunnel along the posterior talus is necessary to gain length. With the hallux and ankle plantar flexed, the FHL tendon is transected as distally as possible. The tendon is fixed to the calcaneus just anterior to the Achilles stump insertion by an interference screw.
215024392|NCT06640504|DIAGNOSTIC_TEST|serum albumin|Serum albumin ratios were calculated as the ratio between the estimated blood lactate, and serum levels of CRP and PCT divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR), CRP-to-albumin ratio (CAR) and procalcitonin (PCT)-to-albumin ratio (PAR).
214507953|NCT04707820|DIAGNOSTIC_TEST|ELISPOT|"The evolution of the number of gamma interferon (IFN) producing T lymphocytes in response to Spike glycoprotein (Spike glycoprotein) will be assessed by enumeration in ELISPOT method at 4 measurement times: D0 (confirmation of infection by PCR), D+7, D+14 or at hospital departure (D+Departure) and D+56±14 days.~The ELISPOT method consists in stimulating peripheral blood mononuclear cells (isolated by density gradient and containing a known CD3+ T lymphocyte count) over a short period of time (16 to 20 hours) with a pool of 15 amino acid peptides (overlapping on 11 amino acids) representative of the S protein."
214507954|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
214507955|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
215024393|NCT06640504|DIAGNOSTIC_TEST|C-Reactive Protein|The serum levels of C-reactive protein (CRP) are divided by the estimated serum albumin level to get the CRP-to-albumin ratio (CAR).
215024394|NCT06640504|DIAGNOSTIC_TEST|Serum procalcitonin|The serum levels of procalcitonin (PCT) are divided by the estimated serum albumin level to get the PCT-to-albumin ratio (PAR).
214507956|NCT04466137|DRUG|rhG-CSF/PEG-rhG-CSF|rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10\^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.
214507957|NCT03482999|DEVICE|TissuGlu Surgical Adhesive|
214507958|NCT03062072|DRUG|Chemotherapy|Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
214507959|NCT04604652|DRUG|HTD1801 (BUDCA)|HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
214507960|NCT06510413|DRUG|Loxoprofen Sodium Patches(reference product)|Single dose of one patch in each period; Apply for 24 hours each time
214507961|NCT06510413|DRUG|Loxoprofen Sodium Patches(test product )|Single dose of one patch in each period; Apply for 24 hours each time
214507962|NCT04888052|DEVICE|Acute ACL injury|Quantification of the preoperative deficits, by an isokinetic dynamometer, in order to adapt the care management of patients found with a muscle deficiency. Patients with preoperative knee extensor deficits \> 15% will benefit from an additional preoperative rehabilitation protocol (8 weeks).
214507963|NCT03929198|OTHER|Healthy Lifestyle|6 week Diet, Exercise training, Behavioral modification
214507964|NCT05544305|OTHER|Digital Home Based Care pathway|The digital version of the pathway includes an integrated data platform with an automated patient flow management system, digitised patient-reported outcome on web-based patient portal, and AI-based automated reporting for clinical decision support.
214507965|NCT02906137|OTHER|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
214507966|NCT03393390|DIAGNOSTIC_TEST|Clinical Assessment Visit|Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
214507967|NCT03393390|OTHER|fMRI scan|Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
214507968|NCT03021616|OTHER|energy drink|32oz of commercially available energy drink
214507969|NCT03021616|OTHER|Moxifloxacin 400mg|400mg moxifloxacin active control drink
214507970|NCT03021616|OTHER|Placebo|Placebo drink
214507971|NCT05118100|DRUG|Clearfil Protect Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive containing an antibacterial monomer (MDPB)
214507972|NCT05118100|DRUG|Clearfil SE Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
214507973|NCT03794232|DIETARY_SUPPLEMENT|NIUCHANG|
214507974|NCT03794232|DIETARY_SUPPLEMENT|Placebo|
214507975|NCT01110096|BEHAVIORAL|Parent Management Training - Oregon (PMTO)|Method to help parents and caregivers manage the behavior of the children they are responsible for.
214507976|NCT01110096|BEHAVIORAL|Motivational interviewing|Communication method to facilitate behavioral change and empower the parents.
214507977|NCT01110096|BEHAVIORAL|Dynamic group therapy|Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
214507978|NCT01469585|DRUG|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
214507979|NCT03064906|DEVICE|Insulet AP (artificial pancreas) System|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
214507980|NCT02170532|DRUG|levalbuterol|0.5 ml. levalbuterol
214507981|NCT02170532|DRUG|saline|0.5ml saline
214507982|NCT02170532|OTHER|levalbuterol MDI|
214507983|NCT02170532|DEVICE|breath actuated nebulizer|
214507984|NCT02170532|DEVICE|aerochamber max|
214507985|NCT02170532|DRUG|ipratroprium|
214507986|NCT01042132|PROCEDURE|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
215024395|NCT06640504|DRUG|Blood Lactate|The serum levels of blood lactate are divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR).
215024396|NCT06642844|DRUG|Avastin, 25 Mg/mL Intravenous Solution|"Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity."
215024397|NCT06637982|PROCEDURE|ridge splitting with the use of allograft and pericardium membrane|ridge splitting with the use of allograft and pericardium membrane
215024398|NCT06637982|PROCEDURE|ridge splitting with the use of extended platelet rich fibrin|ridge splitting with the use of extended platelet rich fibrin
215024399|NCT06638086|DRUG|Acetaminophen Suppositories|Per rectal suppositories
215024400|NCT06638086|DRUG|Acetaminophen Injection|Intra-venous injection
215024401|NCT06643182|OTHER|Back Support|When the sandbag is to be left by the researcher together with the nurse caring for the patient, the patient will be placed in the left lateral position for a short time, a gel-filled orthopedic non-sweating viscose pillow will be placed in the patient's lumbar region and the patient will be placed in a supine position with the head supported.
215024402|NCT06527872|OTHER|None (Observational study)|Not Applicable since Observational Study
215024403|NCT05406453|OTHER|Whole Genome Sequencing testing|Whole Genome Sequencing testing, community-based contact tracing
215024404|NCT04577703|DRUG|CT053PTSA|CT053PTSA will be administered daily in fasting state
215024405|NCT06571331|OTHER|De-Stress & Snooze Gummies-U001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
215024406|NCT06571331|OTHER|De-Stress & Snooze Gummies-I001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
215024407|NCT06571331|OTHER|Placebo Gummies 002|Two gummies daily in sequence 30-45 minutes before bed for 60 days
215024408|NCT04246944|PROCEDURE|harvesting induced membrane|The induced membrane will be harvested during the second step of the bone reconstruction.
214691281|NCT03854643|OTHER|Pilates group|Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
215103473|NCT06213181|OTHER|Mindfulness intervention|It consists of 8 weekly sessions with a duration of 2 hours each. A variety of mindfulness practices including mindful movement will be introduced in all sessions. Participants will approach meditation as something natural and everyday, with the possibility of directing attention in all the moments and activities of daily life. Body scanning practices and conscious breathing will also be included. We will work in the group, with reflections and readings, as well as carrying out meditation and mindfulness practices, during the week, so that they can be carried out in the daily life of each participant. The intervention based on mindfulness will focus on the areas of well-being and personal skills such as attention, communication, emotional regulation and decision making.
215103474|NCT01408342|DRUG|Alemtuzumab and Rituximab|"* Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~* Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~* Cyclosporine 3 mg/kg starting day 21"
215103475|NCT00000382|BEHAVIORAL|Infant-Parent Psychotherapy|
215103476|NCT00000382|BEHAVIORAL|Child Protective Services|
215103477|NCT00000382|BEHAVIORAL|Psychoeducational Home Visitation|
215103478|NCT00000382|BEHAVIORAL|Parent Education|
215103479|NCT04842981|DRUG|Tocilizumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
215103480|NCT04842981|DRUG|Sarilumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
214507987|NCT01042132|PROCEDURE|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
214507988|NCT03400579|DEVICE|autoRIC® device|The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
214507989|NCT01381341|DRUG|linifanib|QD on Day 1 of Periods 1 and 2
214507990|NCT02833948|DRUG|Acetylsalicylic acid|"Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)"
214507991|NCT02833948|DRUG|Clopidogrel|Drug: Clopidogrel 75 mg OD for first 90 days
214507992|NCT02833948|DRUG|Rivaroxaban|"Drug: Rivaroxaban (Xarelto):~10 mg OD (once-daily)"
214507993|NCT05071677|PROCEDURE|Discussion|Participate in treatment planning meeting
214507994|NCT05071677|OTHER|Interview|Participate in interview
214507995|NCT05071677|OTHER|Survey Administration|Complete survey
214507996|NCT00162253|DRUG|BMS 587101|
214507997|NCT02644122|DRUG|SF1126|
214507998|NCT04901416|BIOLOGICAL|DVX201|"Based upon the occurrence of DLT (does limiting toxicity), the MTD will be estimated as the highest dose at which the toxicity probability is the closest to the target probability (denoted pT=0.30) following up to 2 doses of DVX201. The corresponding dose allocation methodology is a modified toxicity interval design based upon (Ji et al., 2010; Ji et al., 2013).~All patients who have at least one dose initiated will be included in the safety analysis. Patients who are enrolled but never exposed to investigational product will be replaced for all analyses. Patients who get exposed to lymphodepleting chemotherapy will be followed and reported for outcomes overall, but for determination of safety and efficacy, only those subjects who have been exposed to the investigational agent will be included."
214507999|NCT06178380|OTHER|rehabilitation|"For the experimental group:~Isokinetic training Antigravity treadmill Posturography~For the control group:~Patients will receive a standard rehabilitation prescription comprising:~Physiotherapy , muscle stretching and strengthening , proprioceptive exercises, and self-programmed"
214508000|NCT02450084|PROCEDURE|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
214508001|NCT02450084|DRUG|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
214508002|NCT02450084|OTHER|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
214508003|NCT02450084|DRUG|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
214508004|NCT04393571|OTHER|Mobile application|telemedicine is used to overcome distance when patients must travel to receive specialized care. We depend on the available, widely used smartphones via a mobile application to conduct follow up data as regard to patient quality of life and comparing this to conventional follow up visits and whether it help to obtain a complete follow up data
214691282|NCT03854643|OTHER|Control group|These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
214691283|NCT05544019|DRUG|SGR-1505|SGR-1505 will be administered orally.
215103481|NCT02935413|DEVICE|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
215024409|NCT05504746|DRUG|SHEN26 capsule|"Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used."
215024410|NCT05504746|DRUG|SHEN26 capsule|Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
215024411|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose."
214691284|NCT04536740|DEVICE|PDT treatment device|All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
214691285|NCT00818324|DRUG|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
214691286|NCT02426372|BIOLOGICAL|QBECO SSI|QBECO Site Specific Immunomodulators
214691287|NCT00636376|PROCEDURE|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
214691288|NCT00138034|PROCEDURE|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
214691289|NCT05509231|BEHAVIORAL|High-intensity exercise|Gross motor physical fitness activities to improve proprioceptive awareness, motor control, and coordination.
214691290|NCT05509231|DEVICE|Wearable glove and arm sleeve device to measure movement|Sign language and other fine motor skills activities using wearable technology.
214691291|NCT04709991|PROCEDURE|Endovascular procedure|Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
214691292|NCT06963775|DEVICE|Delphi-MD device (QuantalX Neuroscience Ltd., Saba Israel)|"Delphi-MD utilizes the use of transcranial magnetic stimulation evoked electroencephalography (TMS-EEG) for diagnostic purposes in a wide range of neurological disorders. Delphi-MD includes a magnetic stimulator and coil, an EEG amplifier and electrode cap and software for the acquisition and analysis of the data.~Delphi-MD stimulation protocol includes low intensities (sub motor thresholds) and frequencies over six stimulation sites (bilateral primary motor cortex, and bilateral dorsolateral prefrontal cortex)."
214691293|NCT05560841|DEVICE|topical treatment|Topical application of Nailner brush 2in1 for toenail onychomycosis
214691294|NCT03857763|COMBINATION_PRODUCT|Apatinib,Paclitaxel,Cisplatin,RT|Apatinib Mesylate Tablets 250mg qd p.o. d1-35; Paclitaxel：50mg/m2 iv d1，8，15，22，29; Cisplatin: 30mg/m2 iv d1，8，15，22，29; RT：41.4Gy/23f , 1.8Gy/f，5 f/w
214691295|NCT01727713|DRUG|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
214691296|NCT02351245|OTHER|observation|
214691297|NCT00330655|DRUG|memantine|
214691298|NCT00313599|DRUG|lapatinib|
214691299|NCT00313599|DRUG|paclitaxel|
214691300|NCT04652336|PROCEDURE|laparoscopic sleeve gastrectomy|Comparator arm - will receive standard laparoscopic sleeve gastrectomy
214691301|NCT04652336|PROCEDURE|ligamentum teres cardiopexy with sleeve gastrectomy|experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
215024412|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days."
215024413|NCT02928822|BEHAVIORAL|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
215024414|NCT02928822|BEHAVIORAL|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
215024415|NCT04025957|DRUG|SHR-1501|Administered subcutaneously
215024416|NCT04806399|OTHER|Educational Materials and Decision Counseling|Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.
215024417|NCT01142570|OTHER|Caloric Support (Group 1)|Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
215024418|NCT01142570|OTHER|Caloric Support (Group 2)|For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
215103482|NCT02935413|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
215103483|NCT03245983|BEHAVIORAL|Questionnaire and interview|Cancer patients will answer questionnaires and will be interviewed by a pshychologist to assess their spirituality and quality of life toward their disease
215103484|NCT05304897|PROCEDURE|PRP treatment|PRP treatment for bronchopleural fistula
215103485|NCT02861482|DEVICE|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
215103486|NCT02861482|DRUG|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
215103487|NCT02861482|DRUG|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
215024419|NCT01142570|DIETARY_SUPPLEMENT|Protein dose of 1.1 to 1.5 grams per kilogram weight.|Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
214508005|NCT00249405|DRUG|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
214508006|NCT00249405|BEHAVIORAL|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
214508007|NCT03182244|DRUG|Gilteritinib|Tablet administered orally once daily.
214508008|NCT03182244|DRUG|Cytarabine|Once/twice daily Intravenously (IV)/subcutaneously (SC).
214508009|NCT03182244|DRUG|Mitoxantrone|Once daily IV injection.
214508010|NCT03182244|DRUG|Etoposide|Once daily IV injection.
214508011|NCT03182244|DRUG|G-CSF|Once daily IV/SC injection.
214508012|NCT03182244|DRUG|Fludarabine|Once daily IV injection.
214508013|NCT02789488|DIETARY_SUPPLEMENT|Fenugreek seeds extract 500 mg|Furocyst one caps BID
214508014|NCT05816317|BEHAVIORAL|Single-Session Mechanism-Focused Intervention (SSMFI)|A brief intervention for patients hospitalized for suicide risk that directly targets hopelessness and perceptions of social relatedness.
215024420|NCT01142570|DIETARY_SUPPLEMENT|Protein at 1.1 grams per kilogram weight.|Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
215024421|NCT01142570|DIETARY_SUPPLEMENT|protein at a dose of 1.5 grams per kilogram weight.|Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
214508015|NCT05816317|BEHAVIORAL|Distress Tolerance Skills Review|Treatment as usual at the inpatient setting for this study.
214508016|NCT04810832|OTHER|Evoked related potentials|"Evoked related potentials are performed for each patient during each paradigm (neutral voice and expressive voices):~* with scalp electrodes in the department of neurophysiology~* with intracranial electrodes in the department of neurosurgery."
214508017|NCT04373772|OTHER|abdominal massage|the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
215024422|NCT03864328|DRUG|RVT-1601|Inhaled RVT-1601 administered TID via eFlow nebulizer
215024423|NCT03864328|DRUG|Placebo|Inhaled Placebo administered TID via eFlow nebulizer
215024424|NCT02626351|OTHER|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: \[1\] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; \[2\] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; \[3\] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; \[4\] Follow up.
215103488|NCT02861482|DRUG|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
215103489|NCT02861482|PROCEDURE|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
215103490|NCT02861482|PROCEDURE|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
215103491|NCT02861482|PROCEDURE|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
214508018|NCT05967845|PROCEDURE|cartilage tympanoplasty|cartilage tympanoplasty procedure entails repairing the tympanic membrane perforation by using a piece of cartilage harvested from the patient's auricle.
215103492|NCT02861482|PROCEDURE|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
215103493|NCT02861482|PROCEDURE|Hysterectomy|Hysterectomy with all the above measures not working
215103494|NCT02861482|DRUG|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
215103495|NCT01865383|BEHAVIORAL|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
214508019|NCT05967845|PROCEDURE|platelet rich fibrin augmented tympanoplasty|platelet rich fibrin augmented tympanoplasty entails performing the traditional tympanoplasty using the tempralis fascia as a grafting material. However, platelet rich fibrin clot is obtained from the patient's own blood, and applied to the graft to enhance healing process.
215103496|NCT01122849|DEVICE|Prototype Nasal Dilator|Prototype nasal dilator AB2R11
215103497|NCT01122849|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strip- Clear small/medium
215103498|NCT01122849|DEVICE|Placebo Nasal Strip|Placebo strip
215103499|NCT02447978|BIOLOGICAL|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
215103500|NCT02447978|BIOLOGICAL|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
215103501|NCT02447978|BIOLOGICAL|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
214691302|NCT05474508|OTHER|Diaphragmatic breathing|Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
214508020|NCT00365885|OTHER|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
215024425|NCT02626351|OTHER|Baseline data collection (active comparator)|Endpoint data collection only
215024426|NCT05900401|OTHER|Bone Marrow Transplant|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
215024427|NCT05900401|PROCEDURE|Peripheral Blood Stem Cell Collection|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.
215024428|NCT05900401|DRUG|Fludarabine|Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)
215024429|NCT05900401|DRUG|Cyclophosphamide|Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
215024430|NCT05900401|DRUG|Rituximab|Rituximab on study day -6
215024431|NCT05900401|DRUG|Siplizumab|Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.
215024432|NCT03165695|DRUG|Ramelteon|Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
215024433|NCT03165695|DRUG|Placebo|Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
215024434|NCT05187988|PROCEDURE|supraclavicular brachial plexus block|group will receive brachial plexus block above clavicle,Injection of anaesthetic will be done in brachial plexus around subclavian artery
215024435|NCT05187988|PROCEDURE|Retroclavicular brachial plexus block|group will receive brachial plexus block inferior to the clavicle,injection of anaesthetic will be done around axillary artery
215024436|NCT06253312|PROCEDURE|Open surgery|Patients with complex TASC C and D aortoiliac occlusive disease undergoing open surgery: aortobifemoral bypass, crossover bypass, axillobifemoral bypass, aortoiliac endarterectomy, iliofemoral bypass
215024437|NCT06253312|PROCEDURE|Hybrid repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing simultaneous open surgical femoral artery reconstruction (endarterectomy, bypass, profundoplasty) and stenting of the iliac axis
215024438|NCT06253312|PROCEDURE|Endovascular repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing total endovascular repair using different material: bare metal stents (self and balloon expandable), stent-grafts (self and balloon expandable), covered endovascular reconstruction of aortic bifurcation (CERAB), simple plain old balloon angioplasty (POBA)
215024439|NCT00408174|DRUG|Balsalazide disodium|
215024440|NCT01545310|DRUG|SLV354|One dose of ABT-354
215024441|NCT00154245|DRUG|Enteric-Coated Mycophenolate sodium (EC-MPS)|
214508021|NCT02266927|DRUG|Flovent HFA|
214508022|NCT02266927|DRUG|OPTINOSE™ FLUTICASONE|
214508023|NCT06553027|DRUG|CVN424 75 mg|Participants will receive 75 mg CVN424 tablet once daily.
214508024|NCT06553027|DRUG|CVN424 150 mg|Participants will receive 150 mg CVN424 tablet once daily.
214508025|NCT06553027|DRUG|Placebo|Participants will receive matching placebo tablet once daily.
214508026|NCT02721407|DRUG|Retroviral vector-transduced autologous T cells to express CD22-specific CARs|
214508027|NCT01652014|DRUG|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
215024442|NCT02868931|BEHAVIORAL|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators."
215024443|NCT00456365|DRUG|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
215024444|NCT00456365|DRUG|Placebo|Placebo daily
215024445|NCT00870324|DEVICE|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
215024446|NCT00870324|DEVICE|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
215024447|NCT02704000|BEHAVIORAL|Home visiting program (Jamaica curriculum)|Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
215024448|NCT00706537|DRUG|Active treatment|20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
215024449|NCT00706537|DRUG|Placebo|Placebo as two tablets once daily for three weeks
215103502|NCT02807688|BEHAVIORAL|Health Promotion Intervention|"The intervention package consists of the following elements:~i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer."
214508028|NCT01652014|DRUG|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
214508029|NCT01652014|DRUG|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
214508030|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
215024450|NCT02124005|DRUG|Bupivacaine|
215024451|NCT01930708|DRUG|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
215024452|NCT00347971|DRUG|recombinant human interleukin 21 and rituximab|rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
215024453|NCT04634136|DIAGNOSTIC_TEST|Lab tests|CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea \& creatinine, liver enzymes (AST, ALT, gGT)
215024454|NCT04634136|DIAGNOSTIC_TEST|ECG|Electrocardiogram
215024455|NCT04634136|DIAGNOSTIC_TEST|Cannabinoid Levels|Determination of levels of cannabidiol (CBD) and delta-9-tetrahydrocannbinol (THC) for determination of levels at following time(s) after ingestion: 0, 1, 2, 4, 8 and 24 hours.
215024456|NCT04634136|DRUG|Full-spectrum Medical Canabis Product (HemPhar)|Active substance
215024457|NCT04634136|DRUG|Placebo|Placebo
215024458|NCT04634136|DIAGNOSTIC_TEST|Spasticity level according to modified Ashworth scale (Bohannon)|"A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.~Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):~0 No increase in muscle tone~1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )~2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved~3. Considerable increase in muscle tone, passive movement difficult~4. Affected part(s) rigid in flexion or extension~Best score is 0 (no spasticity), worst score is 4 (severe spasticity)."
215024459|NCT04634136|DIAGNOSTIC_TEST|Gross Motor Function Measure|"A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy~The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.~Reference curves exist for GMFM-88 for each age group.~Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75."
215024460|NCT04634136|DIAGNOSTIC_TEST|Borg rating of perceived exertion scale|Borg rating of perceived exertion scale
215024461|NCT04634136|DIAGNOSTIC_TEST|Edmonton symptom assessment system|Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).
215103503|NCT03134339|DRUG|Nicotine saline 0.00mcg/kg/s|saline 0.00mcg/kg/s
215103504|NCT03134339|DRUG|Nicotine 0.24 mcg/kg/s|nicotine 0.24 mcg/kg/s
215103505|NCT03134339|DRUG|Nicotine 0.048 mcg/kg/s|nicotine 0.048 mcg/kg/s
215103506|NCT03134339|DRUG|Nicotine 0.024 mcg/kg/s|nicotine 0.024 mcg/kg/s
215103507|NCT00417430|DRUG|ICI 182,780 (Faslodex)|
215103508|NCT03054779|OTHER|Canola Oil|Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
215103509|NCT03054779|OTHER|High oleic acid canola oil|High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
214423531|NCT00891176|BIOLOGICAL|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
214423532|NCT00891176|BIOLOGICAL|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
214423533|NCT00891176|BIOLOGICAL|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
214423534|NCT00891176|BIOLOGICAL|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
214423535|NCT06164327|DRUG|BEBT-908 for Injection|BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
214423536|NCT06164327|DRUG|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.
214423537|NCT06164327|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
214423538|NCT06164327|DRUG|Oxaliplatin Injection|Oxaliplatin Injection，dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
214423539|NCT06164327|DRUG|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m\^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.
214423540|NCT06164327|DRUG|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m\^2,24 hours of continuous intravenous drip，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
214423541|NCT06164327|DRUG|Carboplatin Injection|Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
214423542|NCT00501618|DRUG|Fazaclo|single-arm
214423543|NCT05824546|PROCEDURE|Intervention Arm (uSINE-PAMS-technique)|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
214423544|NCT01270633|DEVICE|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
214423545|NCT01270633|OTHER|Standard of Care|Following sharp debridement, moist wound therapy
215024462|NCT02826785|BEHAVIORAL|Cognitive strategy training|The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
215024463|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.02%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
215024464|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.04%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
215024465|NCT05451329|DRUG|VVN539 Ophthalmic Solution Vehicle|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
215024466|NCT00832026|DEVICE|Trans Nasal Insufflation (TNI) [nasal canula]|"Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing."
215024467|NCT00133432|DRUG|Zinc|
215024468|NCT02714842|DRUG|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
215024469|NCT02714842|DRUG|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
215024470|NCT02714842|DRUG|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
215024471|NCT02714842|DRUG|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
215024472|NCT05152485|DRUG|BIIB104 Reference Formulation|Administered as specified in the treatment arm
215024473|NCT05152485|DRUG|BIIB104 Test Formulation|Administered as specified in the treatment arm
215024474|NCT00237159|DRUG|Zoledronic acid|
215024475|NCT00020176|BIOLOGICAL|filgrastim|
215103510|NCT03054779|OTHER|Western diet oil combination|"A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily"
214508031|NCT01652014|PROCEDURE|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
214508032|NCT01652014|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
215103511|NCT02522130|DRUG|Lidocaine|intracervical injection
215024476|NCT00020176|BIOLOGICAL|therapeutic allogeneic lymphocytes|
215024477|NCT00020176|DRUG|cyclophosphamide|
215103512|NCT02522130|DRUG|oral misoprostol|oral treatment
215024478|NCT00020176|DRUG|cyclosporine|
214508033|NCT01652014|RADIATION|total-body irradiation|Undergo TBI
214508034|NCT01652014|DRUG|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
215024479|NCT00020176|DRUG|fludarabine phosphate|
214508035|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
214508036|NCT01652014|PROCEDURE|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
214508037|NCT06204653|DEVICE|HFNO group|100% oxygen supplied in proportion to body weight using the Optiflow THRIVETM system while maintaining jaw thrust. (0-12 kg; 2 L/kg/min, 13-15 kg; 30 L/min, 16-30 kg; 35 L/min, 31-50 kg; 40 L/min)
214508038|NCT06204653|DEVICE|MV group|Mask ventilation using the one-hand E-C clamp technique and oropharyngeal airway (fresh gas flow 3 l/min, 100% O2, tidal volume 8-10 ml/kg, respiratory rate 20/min, I:E ratio 1:2, pop-off valve 13 cmH2O).
214508039|NCT00257894|DRUG|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
214508040|NCT00257894|DRUG|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
214508041|NCT01276275|DRUG|Risk of selected safety events|First time users of ticagrelor, clopidogrel and prasugrel, respectively
214508042|NCT02852824|DRUG|BI 655130 (spesolimab)|
214508043|NCT02852824|DRUG|Placebo|
214508044|NCT06452173|DIAGNOSTIC_TEST|Plasma|Plasma levels of metabolites and some proteins will be further determined
214508045|NCT06452173|DIAGNOSTIC_TEST|carotid high-resolution magnetic resonance imaging|Define plaque composition and morphological characteristics
214508046|NCT04564365|DRUG|beta-blocker|To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
214508047|NCT03791736|PROCEDURE|Injection of sandostatine|Intramuscular injection of sandostatin 30 mg 3 days before surgery
214508048|NCT04343898|OTHER|No intervention|Observational
214508049|NCT03267797|OTHER|Peripheral Blood Monouclear Cell|Blood samples (20 mL) were taken from individual patients at the time of ovulation induction. Then PBMC were isolated and cultured (20-30 million cells) 48 hour at the presence of hCG (10IU/ml daily). Afterward,15-20 million PBMCs in 500 microlitres PBS were injected into the uterine cavity two days before embryo transfer (ET) using ET catheter.
214508050|NCT03267797|OTHER|Phosphate Baffer Saline|Only 500 microlitres PBS will be injected into the uterine cavity, instead of PBMCs, two days before embryo transfer (ET) using ET catheter.
214508051|NCT00872248|PROCEDURE|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
214508052|NCT00872248|PROCEDURE|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
215103513|NCT02522130|DRUG|naproxen|oral treatment
215103514|NCT02522130|OTHER|placebo|oral treatment
215103515|NCT01678625|DEVICE|Train-of-four ratio calculation (T4-EMG)|TOF ratios will be compared between the EMG and AMG groups
215024480|NCT00020176|PROCEDURE|peripheral blood stem cell transplantation|
215024481|NCT02202577|DRUG|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
215024482|NCT02202577|DRUG|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
215024483|NCT03484195|DRUG|FOLFOXIRI|Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
215024484|NCT00069953|BIOLOGICAL|filgrastim|During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients \>70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
215024485|NCT00069953|BIOLOGICAL|pegfilgrastim|During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
215024486|NCT00069953|DRUG|cisplatin|During induction therapy, patients receive 15 mg/m\^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m\^2/day by IV over 1 hour beginning on days 57-61.
215024487|NCT00069953|DRUG|fluorouracil|During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
215024488|NCT00069953|DRUG|paclitaxel|During induction therapy, patients receive 200 mg/m\^2/day by IV over 2 hours on days 1 and 29.
215024489|NCT00069953|PROCEDURE|conventional surgery|Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
215024490|NCT00069953|RADIATION|radiation therapy|External beam radiotherapy with megavoltage linear accelerators (\> 6 MV) will be used to deliver multiple (\> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
215024491|NCT02034565|DRUG|Apixaban|
215024492|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
215024493|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
215024494|NCT00000373|DRUG|olanzapine + fluoxetine|
215024495|NCT00000373|DRUG|placebo + fluoxetine|
215024496|NCT05629572|DIAGNOSTIC_TEST|i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity|Paired whole blood and plasma samples collected at multiple time points.
215024497|NCT06416982|OTHER|Perineal massage|2 minutes of perineal massage as described in arm/group descriptions.
215024498|NCT06569641|DEVICE|Neoneur Feeding System|The Neoneur Feeding System is placed between a nipple and a bottle, and used to measure feeding skill patterns.
215024499|NCT06569628|COMBINATION_PRODUCT|Envita Stories Methodology in Long-term care Centres for old adults|Collaborative intervention program in long-term care Centres for old adults between professionals, old adults, families and volunteers that aims to foster person-centered care and promote meaningful relationships through the digitization of life stories and life project methodologies in a timeline.
215024500|NCT06569628|BEHAVIORAL|Contact Methodology in Long-term Care Centres for old adults|Professionals know and use Envita Stories Methodology but do not apply it directly with these people.
215103516|NCT02524873|DEVICE|Geneticure Collection Kit for Pharmaocogenetics of Hypertension|Buccal (cheek) swab kit for DNA collection for analysis of genes for hypertension
215103517|NCT01361178|DRUG|SQ IVIG|Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
215024501|NCT05211960|BEHAVIORAL|Mindfulness-based meditation|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness.
215024502|NCT02842346|OTHER|ultrasonography|
215024503|NCT03442972|DRUG|Teduglutide|Teduglutide
215024504|NCT03442972|DRUG|Placebo|Placebo
215024505|NCT02808884|GENETIC|Circulating tumor DNA assay|Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
215024506|NCT05860244|DRUG|Salbutamol|Salbutamol for 6 months
215024507|NCT05860244|DRUG|Placebo|Placebo Syrup for 6 months
215103518|NCT05407857|BEHAVIORAL|multi-modal non-pharmacological intervention|multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs
215103519|NCT05151757|OTHER|A standard image training set|The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
215103520|NCT00391625|DRUG|GA-GCB|15-60 U/kg every other week via intravenous infusion
214508053|NCT03973021|BIOLOGICAL|Very small embryonic-like stem cell(VSEL)|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
215024508|NCT00113373|DRUG|lapatinib ditosylate|Given orally
215024509|NCT00113373|OTHER|laboratory biomarker analysis|Correlative studies
215024510|NCT05957523|DEVICE|Remote ischaemic preconditioning|The participants rested in the supine position for 5 minutes, then turn on the ischaemic preconditioning apparatus and place the automatically programmed blood pressure cuff on both upper arms of the participant, pressurize to 200 mmHg, pressurize for 5 minutes, rest for 5 minutes, perform 4 cycles for a total of 40 minutes each time. The training for participants in group A will be performed once daily, while for participants in group B the training will be performed twice daily. And heart rate and blood pressure before and after each training will be recorded for 7 days.
215024511|NCT00829868|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg
215024512|NCT00829868|DRUG|SONATA® 10 mg capsules|1 x 10 mg
215024513|NCT00372320|GENETIC|Gene Transfer|
215024514|NCT00372320|DRUG|AdhAQP1|
215024515|NCT05902858|DEVICE|Conventional intubation with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo conventional intubation with hyperangulated videolaryngoscope
215024516|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope
215024517|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope
215024518|NCT04452370|DRUG|oral etoposide + anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
215024519|NCT04657692|PROCEDURE|Anesthesia; general or regional|General anesthesia: general anesthesia with endotracheal tube Regional anesthesia: spinal anesthesia, epidural anesthesia, combined spinal epidural anesthesia
215024520|NCT01548885|DEVICE|CONTOUR® NEXT EZ BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of CONTOUR® NEXT EZ BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
215024521|NCT01548885|DEVICE|FreeStyle Freedom Lite® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of FreeStyle Freedom Lite® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
215024522|NCT01548885|DEVICE|ACCU-CHEK® Aviva BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of ACCU-CHEK® Aviva BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
215024523|NCT01548885|DEVICE|TRUEtrack® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of TRUEtrack® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
215024524|NCT01548885|DEVICE|OneTouch® Ultra®2 BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® Ultra®2 BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
215024525|NCT04231851|DRUG|Glasdegib|Given PO
215024526|NCT04231851|DRUG|CPX-351|Given IV
215024527|NCT05547854|BEHAVIORAL|Behavior Therapy Training Institute|In-person therapist training will follow the Tourette Association of America's established Behavior Therapy Training Institute procedures and will consist of 12 hours of in-person training conducted over the course of 2 days. Day 1 will involve standardized didactic lectures on tic disorders and video demonstrations of therapeutic techniques. Day 2 will involve break-out groups and role-play practice of CBIT techniques. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a training instructor while providing CBIT to a study-enrolled patient.
215024528|NCT05547854|BEHAVIORAL|CBIT-Trainer|In the online therapist training condition participants will be provided with access to the CBIT-Trainer program and asked to complete the training over the course of 4 weeks. CBIT-Trainer is designed for the average user to complete in approximately 12 hours. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a CBIT expert while providing CBIT to a study-enrolled patient.
215024529|NCT05809154|DIAGNOSTIC_TEST|Video-Urodynamics|Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
214508054|NCT05729126|OTHER|Questionnare|A questionnaire form is emailed to radiologists to get their response of their practice with hemodialysis and chronic kidney disease patients
215103521|NCT03997825|DEVICE|Basivertebral Nerve (BVN) Ablation|Single follow-up visit of previously treated participants from the SMART trial.
215103522|NCT00876434|DRUG|Sirolimus|
215103523|NCT01528722|DRUG|Bupivacaine|0.25% 20ml administered intraperitoneal
215103524|NCT01528722|OTHER|Normal saline|sodium chloride 0.9% solution
214508055|NCT05716438|RADIATION|Forearm anteroposterior and lateral plain radiograph|2 view plain film of forearm after valving a short arm cast.
215103525|NCT00003066|DRUG|docetaxel|
215103526|NCT00003066|DRUG|estramustine phosphate sodium|
215103527|NCT01089205|DRUG|Metformin|
214691303|NCT05474508|OTHER|Aerobic exercises|Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks.
214691304|NCT00736710|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
214691305|NCT00736710|PROCEDURE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
215103528|NCT00383162|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
215103529|NCT00383162|DRUG|Placebo|Matching placebo tablet.
214508056|NCT02611869|PROCEDURE|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
214508057|NCT02611869|PROCEDURE|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
214508058|NCT00236509|DRUG|topiramate|
214508059|NCT00541996|DRUG|vabicaserin|
214508060|NCT06510985|DEVICE|transcutaneous vagus nerve stimulation|The study employs a CE-certified tVNS® E device, ensuring European safety standards (EU regulation 2017/745 on medical devices). This device features a stimulation cycle of 28 seconds on and 32 seconds off, with a 25 Hz impulse frequency. For the high-intensity group, the stimulation intensity will be individually adjusted in the session before starting the high-intensity tVNS stimulation at home. Recommended daily usage is max. 4 hours, after which it automatically shuts off.
215024530|NCT06222333|BEHAVIORAL|Respiratory physiotherapy|In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour.
215024531|NCT06222333|DRUG|Conservative Treatment|Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
215024532|NCT05042466|DRUG|Trauma|0.15g. thru 0.33g., M/W/F and monthly 1 time a dose of 1g. to 1.5g monthly. 8 week trial.
215024533|NCT00831155|DRUG|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
215029147|NCT05763849|BEHAVIORAL|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) includes parent-enforced contingencies to increase value of eating and decrease the value of food avoidance. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Sessions consist of checking in with the patient, discussion of the week's implementation of refeeding, and helping parents separate the illness from their child. In session 2, a family meal provides the therapist with an opportunity for direct observation of the familial interaction patterns around eating. The therapist makes careful and persistent requests for united parental action toward re-feeding and/or regulating eating habits, the primary concern at this point of the treatment, and the therapist tries to create and reinforce a strong parental alliance around efforts at feeding the child.
215103530|NCT00333918|DRUG|bromfenac ophthalmic solution|
215103531|NCT00333918|DRUG|placebo comparator|
215103532|NCT02082730|DEVICE|ASARM|The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
214508061|NCT06510985|BEHAVIORAL|Monitoring|Participants are monitored over 12 weeks using a combination of questionnaires and ecological momentary assessment. This approach allows for a comprehensive assessment of the patient's health and well-being.
214508062|NCT06510985|DEVICE|cardiowatch bracelet|The study employs the medically certified cardiowatch bracelet from Corsano (CE-MDR medical certification, FDA 510 (k) cleared) for continuous monitoring of vital signals, such as heart rate, heart rate variability, breathing rate, SpO2, physical activity and sleep.
214508063|NCT02102113|DRUG|Placebo|placebo
214508064|NCT02102113|DRUG|Very Low Dose THC|Subjects will receive 0.010mg/kg.
214508065|NCT02102113|DRUG|Low Dose THC|Subjects will receive 0.018 mg/kg over 20 minutes.
214508066|NCT04556773|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
215024534|NCT06289283|OTHER|Urine samples and tissue samples: Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigera|"Samples for microbiome analysis:~Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigerator until be analyzed at the microbiology laboratory of TBRI.~Urine samples (50 ml) for microbiome analysis will be collected during cystoscopy examination. Samples will be stored at -80 °C until processing.~Tissue and urine samples from patients with bladder cancer: Under standard procedure of diagnostic cystoscopy urine sample will be collected under complete aseptic conditions, patients who has bladder tumor will undergo transurethral resection of bladder tumor, a tissue sample 0.5x0.5 cm will be investigated for microbiome analysis. Samples will be stored at -80 °C until processing. Histopathological diagnosis with Hematoxylin and eosin stain will be done by an expert pathologist for tumor grade and stage according to WHO 22, and EAU guidelines 2023. This procedure will be applied for"
215024535|NCT00272805|DRUG|carvedilol|
215024536|NCT05102461|DIETARY_SUPPLEMENT|Florajen Digestion Supplementation|Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
215024537|NCT05102461|DIETARY_SUPPLEMENT|Placebo Supplementation|Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
215024538|NCT02029612|DRUG|Nicotine Patch|10 week supply of nicotine patches given to participants at baseline.
215024539|NCT02029612|BEHAVIORAL|Phone Counseling|Each participant counseled on quitting smoking at baseline.
215024540|NCT02029612|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3 months, and at 6 months.
215024541|NCT02029612|BEHAVIORAL|Breath Test|Breath test performed at 3 month and 6 month visit.
215024542|NCT02029612|BEHAVIORAL|Proactive Cell Phone Smoking Cessation Counseling|Participant receives 11 phone calls from study staff over a 6-month period.
215024543|NCT02029612|BEHAVIORAL|Text Message Smoking Cessation Support|Participants receive text messages for support about quitting smoking over a 6 month period.
215024544|NCT02799043|PROCEDURE|Standard PVI|Standard PVI procedure without FIRMap.
215024545|NCT02799043|PROCEDURE|FIRM-Guided Procedure and PVI|
215024546|NCT04591587|PROCEDURE|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery using VisuMax Femtosecond laser- Smile module surgery with primary objective to increase central corneal thickness and secondary objective to improve visual acuity and reduces K-values
215024547|NCT02665650|BIOLOGICAL|AFM13|
215024548|NCT02665650|BIOLOGICAL|Pembrolizumab|
215024549|NCT00896844|BEHAVIORAL|emotional disclosure|writing about emotional events from the past
215024550|NCT00896844|BEHAVIORAL|placebo writing|writing about how they spent their time the previous day
215024551|NCT02608086|BEHAVIORAL|Psychoeducation|"Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma."
215024552|NCT02608086|BEHAVIORAL|Psychological First Aid|"Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?."
215024553|NCT03154567|DRUG|Yohimbine|Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
215024554|NCT01414790|PROCEDURE|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
215024555|NCT00236795|DRUG|norelgestromin + ethinyl estradiol; triphasil.|
214508067|NCT04556773|DRUG|Durvalumab|Durvalumab: administered as an IV infusion
215024556|NCT06131112|DIAGNOSTIC_TEST|64Cu-DOTATATE PET/CT scan|Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.
215024557|NCT01950039|DRUG|Betaine|Betaine or placebo administered orally in divided doses over 12 weeks
215024558|NCT01950039|DRUG|Placebo|Placebo administered orally in divided doses over 3 months
215024559|NCT02408029|OTHER|Observational study - no intervention|
215024560|NCT06101485|DEVICE|Telerehabilitation|Telerehabilitation platform: Hjerteportalen, blood pressure monitor (iHealth(neo/BP5s), weight scale (iHealth Lina), Activity tracker (FitBit inspire 3), ECG monitor (AliveCor KardiaMobile), sleep sensor (Emfit QS), video consultation (VDX by MedCom)
215024561|NCT04939103|DEVICE|TRUS-FNA|Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
215024562|NCT01448304|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
215024563|NCT01782274|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
214508068|NCT04556773|DRUG|Paclitaxel|Paclitaxel: administered as an IV infusion
214508069|NCT04556773|DRUG|Capivasertib|Capivasertib: administered orally
214508070|NCT04556773|DRUG|Anastrozole|Anastrozole: administered orally
214508071|NCT04556773|DRUG|Fulvestrant|Fulvestrant: administered as an IM injection
214508072|NCT04556773|DRUG|Capecitabine|Capecitabine: administered orally
214508073|NCT04402073|DRUG|Sonidegib|Sonidegib is a selective smoothened inhibitor that inhibits the sonic hedgehog-signaling pathway. It is used in patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
214691306|NCT03683706|BEHAVIORAL|LTP in My Own Way Plus|LTP in My Own Way Plus is a 12-session integrated intervention-Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
214691307|NCT05977517|BEHAVIORAL|Sleep and well-being tracking|This study will track sleep, learning and wellbeing of 500 freshmen under free-living conditions for 20 weeks
214691308|NCT04758273|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
214691309|NCT04758273|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
214691310|NCT04758273|BIOLOGICAL|Placebo|placebo
214691311|NCT00455260|DRUG|hGH-ViaDerm™ System (hGH or somatropin)|transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
214691312|NCT00455260|DEVICE|hGH-ViaDerm™ System|"The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).~The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system."
214691313|NCT05282264|OTHER|device|closed-loop insulin
214691314|NCT03741894|DRUG|Iodoform|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
214691315|NCT03741894|OTHER|Wound closure using sutures|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
214691316|NCT03741894|DRUG|Chlorhexidine|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
214691317|NCT02028429|DRUG|Sildenafil.|Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
214691318|NCT06206668|OTHER|Action observation videos|The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
214691319|NCT02651194|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
214691320|NCT00652431|DRUG|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
214691321|NCT00652431|DRUG|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
215024564|NCT01782274|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
215024565|NCT01342042|BIOLOGICAL|rExenatide-4|This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 \[glucagon-like peptide-1\] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
215024566|NCT05216146|OTHER|Strength and Conditioning|A specially designed strength and conditioning program will be delivered for a period of 6 months from the experienced strength and conditioning coaches. The program will consist of the basic aerobic and anaerobic exercises that could be practiced without additional equipment and with own body weight.
215024567|NCT04265118|DEVICE|Sidewards Tilting Bed|Sidewards tilting of the bed is hypothesized to induce a body position change in sleeping subjects.
214691322|NCT00652431|DRUG|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
214691323|NCT02251054|OTHER|Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
215029148|NCT06429332|OTHER|Reversal of Oral anticoagulation within 30 minutes|In situations of either an elevated INR with the use of warfarin - treatment with either 3- or 4-factor prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) within 30 minutes of ICH diagnosis on NCCT to reach and maintain an INR target \<1.3; or where there has been recent use (\<48 hours) of a direct oral anticoagulant (DOAC), use of an appropriate reversal agent within 30 minutes, where available, and according to local approvals.
214691324|NCT02251054|OTHER|No Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
214691325|NCT01212172|DEVICE|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
214691326|NCT01212172|DEVICE|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
214691327|NCT06418672|BEHAVIORAL|Go Sun Smart Georgia (GSSG)|"Go Sun Smart Georgia (GSSG) is an educational, train-the-trainer, and technical assistance program for Georgia worksites that employ outdoor workers.~GSSG is delivered through personal contacts with senior worksite managers, employee training, and distribution of educational materials. In meetings with managers, trained coaches work to increase perceived need for workplace sun safety, cite advice from national authorities (e.g., CDC and NIOSH), plan for policy implementation, alter policies/education and/or workplace to improve fit, clarify changes to other managers/ employees, and bundle sun safety with worksite safety.~The intervention period will last 12-16 weeks in each of the groups."
214691328|NCT01426399|DRUG|LC15-0444|LC15-0444 50mg qd (8 days once daily)
214691329|NCT01426399|DRUG|Metformin|Metformin 1000 mg bid (8 days twice daily)
214691330|NCT01426399|DRUG|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
214691331|NCT02144454|DIETARY_SUPPLEMENT|Saturated fat|
214691332|NCT02144454|DIETARY_SUPPLEMENT|Monounsaturated fat|
214691333|NCT02144454|DIETARY_SUPPLEMENT|n-6 polyunsaturated fat|
214691334|NCT04462718|OTHER|Radiofrecuency|EXPERIMENTAL GROUP: After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.
214691335|NCT04462718|OTHER|Therapeutic Exercise|CONTROL GROUP: will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated at the end of that period and six moths later in order to have at least three timepoints to evaluate.
214423546|NCT04704739|DRUG|GLPG1205 film-coated tablets|Single oral dose of GLPG1205
214423547|NCT04704739|DRUG|[14C]-GLPG1205 solution for infusion|A 15-minute IV infusion of \[14C\]-GLPG1205
214423548|NCT04704739|DRUG|GLPG1205 capsules|Single oral dose of GLPG1205 as solid formulation
214423549|NCT03829813|OTHER|Music therapy|20 to 40 minute music therapy treatment session with a qualified music therapist.
214423550|NCT03749044|OTHER|Patient Educational Tool|This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
214423551|NCT05656846|DEVICE|PulseNmore ES™|The patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.
214423552|NCT05656846|DEVICE|Standard Ultrasound|These patients will not receive the additional intervention and will use the Standard Ultrasound. A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
215024568|NCT01130428|DEVICE|Juvent 1000 Vibration Platform|"As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (\~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading \[38\]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes."
215024569|NCT05168592|BEHAVIORAL|Threat conditioning|Day 1: The participant is repeatedly shown two stimulus (CS+,CS-), one at a time. CS+ is paired with an electric shock. CS- acts as a control stimulus. The stimuli consist of photos of two different objects. Stimuli will be counterbalanced between participants.
215024570|NCT05168592|BEHAVIORAL|Imaginal extinction|Day 1: Participants are repeatedly instructed to produce mental imagery of the two stimuli used during threat conditioning. Imagery is prompted through different written instructions presented in pseudo-randomized order on a screen. No shocks will be delivered.
215024571|NCT04043247|DEVICE|TEAS|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
215024572|NCT04043247|DEVICE|TEAS without electrical stimulation|Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
215024573|NCT05282407|DRUG|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
215024574|NCT05282407|DRUG|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
215024575|NCT03019653|DRUG|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
215024576|NCT03019653|DRUG|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
215024577|NCT04286776|DEVICE|Direct electrical stimulation|Stimulation will not exceed 0.75 mA and will be approved prior by study investigators. Each subject will have a safety threshold testing at the beginning of each session and if 'afterdischarges' occur the subject's stimulation threshold will be lowered.
215024578|NCT00003192|DRUG|aminocamptothecin|
215024579|NCT00967486|PROCEDURE|Carotid endarterectomy with routine shount|
215024580|NCT00967486|PROCEDURE|Carotid endarterectomy with selective shunt|
215024581|NCT02429167|DEVICE|Cranial nerve non-invasive neuromodulation via PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
215024582|NCT02429167|DEVICE|Sham PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
215024583|NCT00833729|DRUG|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
215024584|NCT01917370|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
215024585|NCT04063462|DRUG|Pyrotinib|pyrotinib, single agent, 400mg p.o once daily until disease progressed
215024586|NCT00389480|DRUG|AR-67 (formerly DB-67)|infusion daily x 5 days, every 21 days
215024587|NCT05769062|PROCEDURE|Single digit pelvic exam|The exam takes approximately 5 minutes and uses a single digit to palpate the pelvic floor muscles, during which patients will rate pain on a scale of 0-10 at 5 paired locations.
215024588|NCT03493893|DEVICE|Intermedullary nail|investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
215024589|NCT03282994|DEVICE|Dermal Cooling System|Cryotherapy
214691336|NCT05393817|DRUG|caffeine citrate|caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)
214691337|NCT03355287|OTHER|Traditionally Threshed Teff (TTT)|The intervention will take place for 7 months in Debre Zeit where the the arm will be fed injera based on teff that are threshed traditionally
214423553|NCT01852526|DEVICE|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
214423554|NCT01852526|DEVICE|Active Comparator: Plif|monosegmental PLIF
215024590|NCT02887794|OTHER|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
215024591|NCT01588925|DEVICE|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
214691338|NCT03355287|OTHER|Lab Threshed Teff (LTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher.
215024592|NCT01588925|DRUG|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
215024593|NCT01588925|DRUG|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
215024594|NCT04054882|BIOLOGICAL|Sabin-IPV and DTaP|simultaneously administration of Sabin-IPV and DTaP
215024595|NCT04054882|BIOLOGICAL|Sabin-IPV|administration of Sabin-IPV only
215024596|NCT04054882|BIOLOGICAL|DTaP|administration of DTaP only
215024597|NCT05391958|BEHAVIORAL|base on Lean Body Mass Pattern|PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC \> 2.
215024598|NCT05391958|BEHAVIORAL|base on Actual Body Weight|PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC \> 2.
215024599|NCT05391958|GENETIC|obese patients|obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
215103533|NCT06457698|PROCEDURE|Double-puncture TMJ arthrocentesis under local anaesthesia|The first puncture involved carefully palpating the lateral rim of the glenoid fossa. A 5-cc syringe was prepared with a mixture of 3 cc of Ringer lactate and 1.8 cc of lidocaine with epinephrine. A 21-G needle connected to the syringe was gently inserted into the TMJ skin area. Once the needle tip made contact with the posterior slope of the eminence of the upper joint compartment, it was oriented vertically to access the upper compartment, allowing the surgeon to perform a validation step. For the second puncture, the joint was maintained at maximum distention with continuous inflow through the first portal, while the surgeon felt insufflation/distention in the anterior joint area. The second portal was established using a 21-G needle with successful fluid outflow. After completing an effective circuit, joint washing was carried out using intra-articular hydraulic pressure with at least 150 ml of Ringer lactate solution.
214423555|NCT05834946|OTHER|Megagen implant placement|Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface
214691339|NCT03355287|OTHER|Fortified Lab Threshed Teff (FTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher. In addition, they will receive Ferrous sulfate drops
214691340|NCT05097053|BIOLOGICAL|MVC-COV1901(3 Months)|MVC-COV1901 vaccine after a 3-month Interval
214691341|NCT05097053|BIOLOGICAL|MVC-COV1901(6 Months)|MVC-COV1901 vaccine after a 6-month Interval
214691342|NCT03885726|DEVICE|Precision Flow Plus|High velocity nasal insufflation
214691343|NCT03885726|DEVICE|Treatment as Usual|Conventional therapy per institution
214691344|NCT01217190|DRUG|Ondansetron (ODFS)|Test Article
215024600|NCT05391958|GENETIC|normal patients|normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
215024601|NCT01848457|DRUG|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)
214691345|NCT01217190|DRUG|Zofran (ODT)|Comparator
214691346|NCT06291246|BEHAVIORAL|Virtual Family Navigation|Participants randomized to the Family Navigation condition will receive up to 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.
214691347|NCT06291246|BEHAVIORAL|Educational Materials|"The comparison condition (Educational Materials) consists of providing the participant's caregivers information about early intervention and community-based supports (i.e., infant-toddler programs, transition to school-based supports, family support groups, local organizations. Families in this condition will receive this information throughout 4 timepoints in the first 3 months after enrolling."
214691348|NCT02306993|OTHER|Healthy volunteers without SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
214691349|NCT02306993|OTHER|Healthy volunteers with SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
215024602|NCT01848457|DRUG|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
215103534|NCT02696239|DEVICE|V-lock suture|
214423556|NCT05834946|OTHER|Biomate-Swiss implant|Biomate-Swiss implant with precision dimension laser (PDL) surface
214423557|NCT00094575|PROCEDURE|Endovascular Repair|Endovascular Repair
214691350|NCT02306993|OTHER|Volunteers with SCD|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
215103535|NCT02696239|DEVICE|Vicryl Suture|
214423558|NCT00094575|PROCEDURE|Standard Open Repair|Standard Open Repair
214691351|NCT05966493|DRUG|lufepirsen high dose|Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
215024603|NCT04096235|OTHER|RAM Nasal Cannula|The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
215024604|NCT06391333|DEVICE|laryngeal mask airway and endotracheal tube|The two most commonly used devices for mechanical ventilation.
215024605|NCT05626335|DIAGNOSTIC_TEST|Intraoral scan|On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0), using 3Shape Trios 4 (3Shape, Copenhagen, Denmark). The scans were repeated after a month. The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3).
215024606|NCT02274233|DRUG|SP-420|
215024607|NCT01821014|OTHER|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
215024608|NCT01821014|OTHER|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
215024609|NCT00803049|DRUG|Teriflunomide (HMR1726)|Tablet, oral administration QD.
215024610|NCT01421459|DRUG|LY2963016|Administered subcutaneously
215024611|NCT01421459|DRUG|Lantus|Administered subcutaneously
215024612|NCT01421459|DRUG|OAMs|Administered orally
215024613|NCT04203771|DIETARY_SUPPLEMENT|Probiotic AB-DENTALAC|Orodispersible tablets containing Lactobacillus plantarum \[now Lactoplantibacillus plantarum\] KABP051 (CECT7481) and Lactobacillus brevis \[now Levilactobacillus brevis\] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10\^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.
215024614|NCT04203771|OTHER|Placebo|Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.
215024615|NCT04203771|PROCEDURE|Surgical removal of mandibular third molars at baseline|Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
215024616|NCT04203771|DRUG|Ibuprofen|Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
215024617|NCT05181085|DRUG|NST 6179|orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
215024618|NCT05181085|DRUG|Placebo|inactive analogue
215024619|NCT05214508|DIAGNOSTIC_TEST|interleukin 6|assessment of serum IL-6 by ELISA
215024620|NCT03897881|DRUG|mRNA-4157|Individualized Neoantigen Therapy
215024621|NCT03897881|BIOLOGICAL|Pembrolizumab|Intravenous infusion
215024622|NCT05980403|OTHER|no intervention|no intervention
215024623|NCT04115254|RADIATION|MR-guided Linac|Radiation will be delivered on an MR-guided Linear Accelerator
215024624|NCT05656274|DRUG|JS1-1-01|Oral tables
215024625|NCT05656274|DRUG|Placebo|Oral tables
215024626|NCT04439903|OTHER|Web-based Simulation Tool|Glucose, insulin and meal data from the participants' insulin pump will be collected and entered into the WST, which will generate personalized models of the participants' glucose metabolism to enable replay simulations.
215024627|NCT06522503|BEHAVIORAL|stress ball|The intervention group was provided with a stress ball to be held in both hands for a period of five minutes prior to the insertion of the port catheter needle. They were instructed to squeeze the ball in their hands at regular intervals until the conclusion of the procedure.
214691352|NCT05966493|DRUG|Vehicle|Matching vehicle without lufepirsen.
215024628|NCT06290323|PROCEDURE|Quadratus lumborum block|Posterior quadratus lumborum block
215024629|NCT06290323|PROCEDURE|Placebo|Patients in the first group are the control group and after spinal anesthesia, the sensory block is formed, the lithotomy position will be taken for the surgical procedure.
214691353|NCT05966493|DRUG|lufepirsen low dose|Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
214691354|NCT03212131|DRUG|Somapacitan|3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
214691355|NCT02868216|BEHAVIORAL|anger management training|
215024630|NCT04087655|BEHAVIORAL|Exercise|Eight weeks of interval exercise training
215024631|NCT05898334|DEVICE|Active Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the strong biophoton field so her/his entire body will be energized to promote self-healing.
215024632|NCT05898334|DEVICE|Inactive Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the normal hotel bed and the participant will not receive any biophotons.
215024633|NCT02901561|DRUG|misoprostol 200|
215024634|NCT02901561|DRUG|misoprostol 400|
215024635|NCT01188993|COMBINATION_PRODUCT|early septic shock|Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.
215024636|NCT05673902|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
215024637|NCT05128032|DEVICE|Standard microcatheter|Small device used for mapping as part of radioembolization procedure
215024638|NCT05128032|DEVICE|PEDD device|Pressure enabled small device used for mapping as part of radioembolization procedure
215024639|NCT01523431|DRUG|Irinotecan Injection [Camptosar]|CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
215024640|NCT01523431|DRUG|5-fluorouracil|The 5-FU dosage will remain the standard.
215024641|NCT01523431|DRUG|Leucovorin|The LV dosage will remain the standard.
214508074|NCT04402073|DRUG|Cisplatin|Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.
215024642|NCT05444088|DRUG|Adebrelimab|intravenous infusion
215024643|NCT05444088|DRUG|Bevacizumab|intravenous infusion
215024644|NCT05444088|DRUG|SHR-8068|intravenous infusion
215024645|NCT04130867|PROCEDURE|pHRM|Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.
215024646|NCT04130867|PROCEDURE|VFSS|Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.
215024647|NCT01512251|DRUG|BKM120 Combined with Vemurafenib (PLX4032)|"Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D"
215024648|NCT05065671|DRUG|Tolcapone 100 MG|Tolcapone 100 mg by mouth once
215024649|NCT05065671|DRUG|Duloxetine 20 MG|Duloxetine 20 mg by mouth once
215024650|NCT04356378|OTHER|Data record|Data record
215024651|NCT05540184|DRUG|Trimetazidine 35 mg|Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
215024652|NCT05540184|DRUG|Allopurinol 300 MG|allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
215024653|NCT05540184|DRUG|Normal saline|rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
215024654|NCT01878474|DRUG|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
215024655|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
215024656|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
215024657|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
215024658|NCT01878474|DRUG|Placebo|Single ascending dose in Caucasian men
214508075|NCT04402073|DRUG|Lomustine|Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.
214508076|NCT04402073|DRUG|Vincristine|Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.
214508077|NCT04402073|RADIATION|radiotherapy|Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
215024659|NCT01878474|DRUG|Placebo|Age-effect in Caucasian men
215024660|NCT01878474|DRUG|Placebo|Gender-effect in Caucasian women
215024661|NCT01878474|DRUG|Placebo|Single ascending dose in Japanese men
215024662|NCT06413875|OTHER|education|Education Specific to Menopause Symptoms
214508078|NCT06352619|OTHER|Conservative SBP Control|No or minimal treatment; if there is a need to treat a patient with a very-high (\>180 mmHg) baseline SBP, then the SBP reduction is 5-10mmHg or a target is 175-180 mmHg
214508079|NCT06352619|OTHER|Moderate SBP Control|If the patient has a very high (\>180 mmHg) or moderate high (160-180 mmHg) baseline SBP, SBP reduction is 10-20mmHg or a target of160±5 mmHg, which is higher; patients with low-high (150-160 mmHg) baseline SBP will not be treated
214508080|NCT06352619|OTHER|Intensive SBP Control|SBP reduction by 30-50mmHg or a target of 140±5 mmHg, which is higher
214508081|NCT06542562|PROCEDURE|guided implant placement|The key difference is that in Group 1, the guide is only used for the drilling sequence, while in Group 2 the guide is used for both the drilling and the actual implant placement.
214508082|NCT02732171|OTHER|Research Blood Collection|Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
215024663|NCT06302985|PROCEDURE|atomized inhalation ICG before thoracoscope pneumonectomy|"Preoperative preparation ICG solution dissolved in 5ml of normal saline (dose 0.5mg/kg) was inhaled 30 minutes before surgery.~Operation method After entering the chest cavity, the fluorescence endoscope was switched to the fluorescence display mode, and the fluorescence-stained normal lung tissue and non-stained lesion tissue could be clearly displayed through the display screen, and the external boundary of the lesion was marked with an electric hook. The mediastinal pleura and pulmonary pleura were opened along the boundary of the lesion, and the lung tissue was split along the gap between the lesion and the lung tissue with an electric coagulation hook and an ultrasonic knife, and the lesion arteries and bronchi were freed."
215024664|NCT01564030|OTHER|Empty|overnight fast
215024665|NCT01564030|OTHER|Fluid|250mL apple juice
215024666|NCT01564030|OTHER|Solid|breakfast
215024667|NCT06239753|BEHAVIORAL|Dynamic Neuromuscular Stabilization|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes. Application of Dynamic Neuromuscular Stabilization (DNS).
215024668|NCT06239753|BEHAVIORAL|Standard Prenatal Education Program Implementation|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes.
215024669|NCT04246749|DRUG|[14C]-CRN00808|Investigational drug
215024670|NCT04246749|DRUG|CRN00808|Investigational drug
215024671|NCT06252987|OTHER|routine treatment|Routine medical treatment, basic rehabilitation training and individualized cognitive training
215024672|NCT06252987|OTHER|Non-invasive brain stimulation|tDCS\&rTMS
215024673|NCT03564067|DEVICE|Soterix Medical tDCS mini-Clinical Trials system (mini-CT)|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.
214423559|NCT00111709|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
214423560|NCT00111709|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
214423561|NCT01632930|OTHER|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
215024674|NCT03564067|BEHAVIORAL|Computerized CBT (cCBT)|Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
215024675|NCT06644027|DEVICE|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
215024676|NCT06644027|DEVICE|Molicare Premium Bed Mat|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
215024677|NCT02598973|BEHAVIORAL|Exercise|Aerobic walking
215024678|NCT01790191|BEHAVIORAL|Repeated consumption of basic artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
215024679|NCT01790191|BEHAVIORAL|Repeated consumption of sweet artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
215103536|NCT02696239|DEVICE|Lapra-Ty II|
214423562|NCT06141577|DRUG|UI059|take UI059 1cap/day for 7 days
214508083|NCT06416397|DIAGNOSTIC_TEST|Proteomic profile|"Proteomic analysis of bile samples will be performed every 5 bile samples. Bile samples will be taken during endoscopy with retrograde papillary catheterization or radiological procedures in selected patients. In clinical practice, bile samples are taken for bacteriological purposes. An average of 10 mL is taken.~Five mL are required for bacteriological analysis. The remaining millilitres, which are usually discarded, will be kept for storage and to form the bile bank at the Biological Resources Centre before to be analyzed in proteomics."
214508084|NCT06849596|DEVICE|Ventilator derived positive pressure ventilation - V-PPV|The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. Ventilator delivered positive pressure ventilation (V-PPV) using a nasal interface will be delivered to the infant in the resuscitation room.
214508085|NCT06849596|DEVICE|T-piece resuscitator (TPR)|The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. PPV will be provided with a T-piece resuscitator (Neopuff, Fisher \& Paykel Healthcare) connected to an appropriately sized face-mask.
214508086|NCT06853054|PROCEDURE|Personalized patch template|The personalized, sterilizable patch template will be used as the surgeon's guide in fashioning the precise size and shape of the surgical patch.
214508087|NCT03954782|DRUG|Nintedanib 150 mg and 100 mg soft capsules|Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.
214508088|NCT03954782|DRUG|Oral treatment of placebo soft capsule|Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
214508089|NCT02502461|PROCEDURE|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
214508090|NCT04376775|OTHER|Transplant patient|Surveys will be distributed via an email sent by transplant centres or patient's associations. A link to a secure survey platform will be given. A questionnaire will completed by patients. Patients, who agreed to fill the survey, will be offered the possibility to be contacted for a second survey over a 6 months period.
214508091|NCT00892541|DRUG|ER OROS paliperidone|
214508092|NCT01401790|DEVICE|Telehomecare (Intelligent Distance Patient Monitoring)|"Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~* Automatic download of blood glucose levels~* Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~* Changes in treatment plan by the diabetes professionals~* E mail exchanges between families and health care professionals~* Reinforcement of teaching program"
214508093|NCT01401790|OTHER|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
214508094|NCT02089295|DRUG|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
214508095|NCT02089295|DRUG|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
214508096|NCT02089295|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
214508097|NCT03593785|DRUG|AZD8233|Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
214508098|NCT05913791|DIETARY_SUPPLEMENT|Nutrients-fortified egg|Consumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed)
214508099|NCT05913791|OTHER|Regular egg|Consumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison.
214508100|NCT00293410|DRUG|clofarabine|
214508101|NCT00293410|DRUG|cyclophosphamide|
215103537|NCT01819350|OTHER|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
214691356|NCT06084325|DEVICE|Respiration resistance sensitivity task (RRST)|The RRST measures interoception on the domain of the breath and thus allows its (non-invasive) manipulation. The RRST apparatus includes a step motor that moves a wedge piece back and forth to change the obstruction level in the breathing circuit. This fully automated apparatus will change the breathing obstruction level via a computer-controlled algorithm. The patient breath by the month though this device.
214691357|NCT06084325|BEHAVIORAL|Heartbeat Tracking (HBT)|The HBT measures interoception on the domain of the cardiovascular system, by assessing how accurate participants perceive their own heartbeat. After each time window participants will be asked how many heartbeats they counted, which will be compared to the actual heartbeat measured via electrocardiography (ECG).
214423563|NCT06141577|DRUG|UIC202201|take UIC202201 1cap/day for 7 days
214691358|NCT06084325|DEVICE|Heartbeat evoked potential (HEP)|The HEP is computed by averaging EEG signals time-locked to specific peaks of simultaneously measured ECG signals. Therefore both an ECG and an EEG will be set up for the participants. The task during the HEP is to simply focus on interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). A further condition of HEP measurement is the cardio-audio synchronization. Hereby, participants will be instructed to passively listen to sounds presented to them via in-ear phones while further fixating the cross.
214691359|NCT06084325|DEVICE|Libet task|Additionally we also link the interoceptive domain of the breath to a well-known and established agency task measuring conscious intention. Participants will do two versions of the Libet taks while simultaneously recording their EEG and breathing signals with a respiratory belt.
214691360|NCT02496585|DRUG|Nintedanib|
214691361|NCT02496585|DRUG|Prednisone|
214691362|NCT02496585|OTHER|Placebo|
215024680|NCT01790191|BEHAVIORAL|Repeated exposure to fat artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
215024681|NCT05810467|OTHER|Active Surveillance|"Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA \<10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, \>50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa."
215024682|NCT04222504|BEHAVIORAL|Provision of sexual health preventative services in the salon setting|"Participants at intervention salons will be offered a choice of receiving daily PrEP and/or contraceptives (oral and injectables). Participants that elect to receive at least PrEP or contraceptives will also be offered STI testing.~Follow-up visits will be planned for 3, 6, 9, and 12-months. Attendance at follow-up visits for monitoring and medication refill will be encouraged using text message reminders, WhatsApp support groups, and lottery-based incentives for free salon services."
215024683|NCT03707392|OTHER|Ostomy Education Video|Ostomy education video in addition to standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
215024684|NCT03707392|OTHER|Control - Standard ostomy education|Standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
215024685|NCT05607589|DRUG|DWP213388|immunosuppressant
215024686|NCT05607589|OTHER|Placebo|Placebo
215024687|NCT04003142|DRUG|Fezolinetant|Oral tablet
215024688|NCT04003142|DRUG|placebo|Oral Tablet
215024689|NCT05570318|DRUG|Polyethylene Glycols|To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
215024690|NCT05570318|DEVICE|Low volume trans anal irrigation|To be administered rectally on a daily basis throughout the study period (6 weeks) along with an adjusted dose of polyethylene glycols
215024691|NCT04042311|OTHER|High-intensity interval training|a high-intensity interval training programme completed 3 times a week for 6 weeks using a stationary Wattbike.
215024692|NCT06535646|OTHER|Home exercise program using Physitrack exercise program and a smart watch|Participants wear a smart watch to monitor activity levels while using a web based exercise program to follow along for 8 weeks.
215024693|NCT03434301|DEVICE|ReliaTack™|Absorbable tack (ReliaTack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
215024694|NCT03434301|DEVICE|Protack™|Non-absorbable tack (Protack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
215024695|NCT02725606|BIOLOGICAL|Pegylated Recombinant Human G-CSF|subcutaneous
215024696|NCT02725606|BIOLOGICAL|GW003|subcutaneous
215103538|NCT01819350|OTHER|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
215103539|NCT05727514|OTHER|music composition|4-session music composition program for participants lead by a composer-mentor, includes optional viewing of online string quartet performances of final musical scores
214423564|NCT05073718|DRUG|Low-dose acetylsalicylic acid|In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
214423565|NCT05073718|DRUG|Placebo|Placebo
214423566|NCT01705249|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
214423567|NCT02813252|GENETIC|JCAR015|No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
214691363|NCT01051375|BEHAVIORAL|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
214691364|NCT05743478|BEHAVIORAL|Forging Hopeful Futures|Forging Hopeful Futures is a 12 session curriculum for youth ages 13-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.
214691365|NCT05743478|BEHAVIORAL|Wellness Check-ins|Individual wellness checks will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
214691366|NCT04751435|OTHER|Cognitive interview|Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
214691367|NCT04751435|BEHAVIORAL|LCAM intervention|"Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic literacy screener and adapted clinical communication materials."
214691368|NCT04751435|BEHAVIORAL|Standard of care|Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics
214691369|NCT05955170|DRUG|Tucatinib in Combination of Oral VP16 and trastuzumab|Combination of tucatinib-Oral VP16-trastuzumab
214691370|NCT06802146|DRUG|Inqovi|Combination of a nucleoside metabolic inhibitor and cytidine deaminase inhibitor, 10mg DEC / 100mg CED tablet, taken orally per protocol.
214691371|NCT05965336|OTHER|Clinical Evaluation|"A clinical evaluation occurs at the first study session. The clinical evaluation assesses walking function and mobility, lower extremity, sensation, health-related quality of life (HRQoL) and foot function.~Session 2 will be a dynamometer-based evaluation of passive ankle stiffness and 3-dimensional gait analysis to evaluate baseline biomechanics. During Session 3, real-time biofeedback conditions will be used to measure the immediate effects on walking function."
214691372|NCT05965336|OTHER|Evaluation of Passive Ankle Stiffness|Participants will be seated in a dynamometer with their trunk and thigh stabilized to the dynamometer chair, ankle joint aligned with the rotational axis of the dynamometer, and foot stabilized to the foot plate. EMG activity will be recorded from lower limb muscles (gastrocnemius, soleus, tibialis anterior) during all isolated contractions. Participants will first perform three maximum voluntary isometric contractions (MVIC) while seated in a dynamometer. Participants will then perform three isokinetic dorsiflexion tasks while using electromyographic biofeedback at a prescribed level of 50% MVIC soleus activation. The slope of the linear best fit line from the ankle moment vs. angle plot will yield total ankle joint stiffness (i.e., active + passive) at a fixed activation. In three additional trials, the dynamometer will move the ankle joint through the same motion without active subject resistance and the same analytical procedures will derive passive ankle joint stiffness.
214691373|NCT05965336|OTHER|Gait Biomechanics|Three-dimensional gait analysis is performed as participants walk at a self-selected speed on an instrumented treadmill. Reflective markers are attached to lower extremity segments. Elastic bands are wrapped around the thighs, calves, and pelvis to which small, thermoplastic shells containing reflective markers are attached. Additional markers are taped to the participant's shoes and on the upper back, shoulder, hip, knee, and ankle joints with adhesive skin tape. Marker data is collected using a 7-camera motion analysis system (Vicon Inc., USA). Vicon motion analysis cameras will collect the location of the retroreflective markers in Vicon Nexus software.
214423568|NCT05032937|DRUG|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
214423569|NCT04814043|DRUG|PD-1 inhibitor|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
214423570|NCT05593042|BIOLOGICAL|CoronaVac®|The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.
215024697|NCT03182556|BEHAVIORAL|Electromyography-Biofeedback (EMG-BFB) training|The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
215024698|NCT03182556|BEHAVIORAL|Aquatic exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
215024699|NCT06567262|DEVICE|CAD/CAM metallic removable partial denture|"Make digital scans using an intraoral scanning device. Scan the maxillary (antagonistic scan) and mandibular (pre-preparation scan) arches, as well as an initial digital record of the inter-occlusal relation (occlusal scan).~Analyse the digital cast using CAD software. Primary electronic surveying will be carried out to ensure if the tooth preparations will be needed.~Make a definitive intraoral scan only of the prepared teeth and record the maxillary-mandibular relationship.~The virtual cast is digitally surveyed and the design of the framework is done using computer software. The wax pattern 3D framework information will be converted into a standard tessellation language (STL) file and transfer to a rapid prototyping (RP) system to be printed and finally cast using the conventional technique to produce RPD framework."
215029149|NCT06429332|OTHER|Early intensive blood pressure lowering|A systolic blood pressure (BP) target of 130-140 mmHg within 30 minutes of ICH diagnosis on NCCT is strived for, and to maintain this BP level for the first 7 days (for patients presenting with blood pressure \<200 mmHg). If blood pressure ≥200 and \<220, a target BP of 160 mmHg should be targeted at 30 minutes, and 130-140 mmHg should be achieved in 60 minutes. If BP ≥220, target BP of 160 mmHg and should be achieved in 60 minutes.
215029150|NCT06429332|OTHER|Treatment of pyrexia|To achieve a body temperature target \<37.5 °C within the first 24h following ICH diagnosis on NCCT
214691374|NCT05965336|OTHER|Gait Biofeedback|Audio-visual biofeedback will be provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map will represent the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target will be provided using the heat map colors of red and target line on the bar graph. For propulsion biofeedback, a visual display with a marker will represent the current propulsion (peak AGRF) and a target provided to modulate propulsion. The plantar pressure and AGRF measurements from the participant's baseline walking trials will be used to determine customized biofeedback targets.
214508102|NCT05113134|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder will undergo Transvaginal NOSE
214508103|NCT00912171|DRUG|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
214508104|NCT00912171|DRUG|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
214508105|NCT00451711|DRUG|Liposomal amphotericin B|
214508106|NCT01963598|DRUG|REGN1033 (SAR391786)|
214508107|NCT01963598|DRUG|placebo|
214508108|NCT06970249|BEHAVIORAL|Music intervention|Patient-preferred music (e.g., classical, jazz, ambient) will be selected preoperatively from a standardized list and delivered via headphones at 40-60 dB, verified by a sound meter.
214508109|NCT06452576|DEVICE|Vibration|Watch vibrates.
214508110|NCT06452576|BEHAVIORAL|constraint-induced movement therapy|A splint or mitt is placed on the stronger, unaffected hand to encourage use of the affected upper limb in therapy.
214508111|NCT03950427|BEHAVIORAL|Videogame-based physical activity|videogame-based physical activity
214508112|NCT03950427|BEHAVIORAL|Sedentary videogame|sedentary videogame
214508113|NCT03950427|DRUG|Bupropion|Bupropion
214508114|NCT03950427|BEHAVIORAL|Counseling|Counseling for smoking cessation
214508115|NCT02790281|PROCEDURE|Blood sampling|Blood sample collected at a single visit
214508116|NCT05123144|BEHAVIORAL|BHS+ORCHID|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
214508117|NCT03787628|DRUG|Cannabidiol (CBD) 600 mg|CBD (300 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc. (California, USA) under cGMP conditions.
214508118|NCT03787628|DRUG|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc. under cGMP conditions. The amount (number of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
214508119|NCT05288959|DEVICE|Session 2: Single-pulse TMS (spTMS)|Uni-focal TMS (MagVenture, Farum, Denmark) is delivered to one brain area while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The targeted brain areas and TMS intensities may vary across runs. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coil.
215024700|NCT06567262|DEVICE|Conventional metallic removable partial denture|"Primary impressions will be taken, the impressions will be poured to construct a study casts.~Maxillary Face-bow record and diagnostic bite will be taken. The study casts will be mounted on semi adjustable articulator to check inter-arch space.~Surveying of the study cast will be done. Required mouth preparation will be carried out then secondary impression will be taken using special tray.~Secondary impression will be poured to obtain master cast which will be surveyed to confirm proper mouth preparation, blocked out and then wax pattern will be designed and constructed.~A metallic framework will be obtained using the conventional lost wax technique and casting.~Intraoral try in of the framework will be done followed by bite registration record.~The next step will be teeth setting and try in. Heat cured acrylic resin denture base will be processed, finished and polished conventionally."
215024701|NCT06567301|COMBINATION_PRODUCT|Ultrasound therapy combined with Chitosan nanoparticles gel|Gymna - Belgian
215024702|NCT02370342|PROCEDURE|Robot-Assisted Laparoscopic Surgery|Undergo robot-assisted laparoscopic HIFU ablation
215024703|NCT02370342|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo robot-assisted laparoscopic HIFU ablation
215024704|NCT02370342|PROCEDURE|Therapeutic Laparoscopic Surgery|Undergo laparoscopic partial nephrectomy
215024705|NCT02370342|DEVICE|Sonatherm 600i Ultrasonic Lesion Generating System|Device used for high-intensity focused ultrasound ablation
215024706|NCT03382873|BEHAVIORAL|Group Lifestyle Balance (GLB)|The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.
215024707|NCT03382873|BEHAVIORAL|Group Lifestyle Balance Plus (GLB+)|The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.
215024708|NCT02592655|DEVICE|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
215024709|NCT02592655|DEVICE|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
215024710|NCT02592655|DEVICE|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
215024711|NCT02592655|DEVICE|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
215024712|NCT02592655|DEVICE|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
215024713|NCT00890656|DRUG|Cyclophosphamide (CTX)|300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
215024714|NCT00890656|DRUG|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
215024715|NCT00890656|DRUG|Doxorubicin|50 mg/m\^2 by vein (IV) over 24 hours
215024716|NCT00890656|DRUG|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
215024717|NCT00890656|DRUG|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
215024718|NCT00890656|DRUG|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
215024719|NCT00890656|DRUG|Ara-C|3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
215024720|NCT00890656|DRUG|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
215024721|NCT06308965|PROCEDURE|Vessel sparing technique|Vessel sparing
215024722|NCT06308965|PROCEDURE|Vessel ligation technique|Vessel ligation
215024723|NCT03436849|DRUG|ESN364|ESN364 will be administered orally.
215024724|NCT03436849|DRUG|Placebo|Placebo will be administered orally.
215024725|NCT03554330|OTHER|Radiofrequency catheter ablation|(1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).
215024726|NCT03554330|OTHER|Balloon atrial septostomy|Graded balloon atrial septostomy is performed in all patients.
215024727|NCT06094855|OTHER|20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest|2 bouts of 20 minutes of pedaling on a stationary recumbent bicycle, 1-2 weeks apart. Subjects will be cooled for one of the bouts and uncooled for the other.
215024728|NCT06468930|DEVICE|Low-level light therapy (LLLT)|LLLT therapy will be delivered using the Light Modulation® special facial mask (Espansione Marketing S.p.A., Bologna, Italy) which will be placed on the participant's face for 15 minutes. The mask has the shape of a half-face and will emit a red light in an LED system. The device has an emission power of 100 The mask has the shape of a half-face and will emit a red light in a light-emitting diode (LED) system. The device has an emission power of 100 milliwatts per square centimeter.
215029151|NCT06429332|OTHER|Hyperglycemia treatment|To maintain a blood glucose level 7-10 mmol/L within the first 24h following ICH diagnosis on NCCT
214694200|NCT03201198|BEHAVIORAL|Active Life|The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
215024729|NCT06468930|DEVICE|Intense pulsed light (IPL)|The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim
215024730|NCT05857878|DRUG|BI 1815368|BI 1815368
215024731|NCT05857878|DRUG|Matching placebo|Matching placebo
215024732|NCT05272579|OTHER|Fecal Filtrate Transfer|Treatment with donated fecal samples filtered to contain practically no bacteria and mainly viruses, including bacteriophages
215024733|NCT05272579|OTHER|Placebo|Saline solution
215024734|NCT05773352|DEVICE|Tornier Perform® Humeral System - Fracture|"A replacement of shoulder joints for anatomic and reverse shoulder arthroplasty.~A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains."
215024735|NCT03228043|DRUG|Apatinib|Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
215024736|NCT03228043|DRUG|CAPEOX|CAPEOX adjuvant chemotherapy for resectable colorectal
215024737|NCT05378529|OTHER|Lp(a) Screening|Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.
215024738|NCT05306574|BIOLOGICAL|Telitacicept|Subcutaneous injection weekly for 52 weeks
214423571|NCT05593042|BIOLOGICAL|Omicron Vaccine|"An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant."
215024739|NCT05306574|BIOLOGICAL|Placebo|Subcutaneous injection weekly for 52 weeks
215024740|NCT03717454|OTHER|Surgery|The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .
215024741|NCT03717454|DRUG|Drug treatment|The medication will continue if DA causes tumors to shrink.
215024742|NCT06439927|DEVICE|Polycaprolactone nasal mesh|a 3-dimensional fabricated Polycaprolactone nasal mesh
215024743|NCT01924065|PROCEDURE|Cardioversion|Electrical cardioversion
215024744|NCT01924065|DRUG|Oral Anticoagulant|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
215024745|NCT05838716|PROCEDURE|Biospecimen Collection|Undergo collection of blood
214423572|NCT05593042|BIOLOGICAL|Trivalent Vaccine|"An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant)."
214423573|NCT00622830|DRUG|SB-480848 (Darapladib)|
214423574|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Test Drug tablet|Investigational Medicinal Product
214423575|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Referent Product tablet|Sinemet (Savio Industrial S.R.L, Brazil)
214423576|NCT03037502|BEHAVIORAL|Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)|Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 80 African American and 40 Latino men; to compare changes in chronic disease risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 3-months.
214423577|NCT01390402|DRUG|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
214423578|NCT01390402|DRUG|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
214423579|NCT01390402|PROCEDURE|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
214423580|NCT01390402|DRUG|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
214423581|NCT01390402|DRUG|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
214423582|NCT01390402|PROCEDURE|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
214423583|NCT01390402|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
214423584|NCT01390402|DRUG|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
214423585|NCT01390402|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
214423586|NCT05647967|DIAGNOSTIC_TEST|Ultrasound|Each patient underwent ultrasound after admission of ICU.
214423587|NCT00332436|DRUG|brimonidine/timolol fixed combination|
214423588|NCT06073158|PROCEDURE|Esophageal biopsy collection during anastomosis|During the anastomosis, the surgeon will collect an esophageal mucosa biopsy
214423589|NCT02864628|BIOLOGICAL|MVA-BN-RSV|MVA-mBN294B
214423590|NCT02864628|OTHER|Placebo|Tris Buffered Saline
214423591|NCT05658198|BEHAVIORAL|Counseling|Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.
214423592|NCT04812938|DIAGNOSTIC_TEST|Patients with Ovarian cancer and pap test available|Define the possibility to detect through the pap test the presence of ovarian cancer cells in vaginal smear in patients with no evidence of ginecological malignancies.
215024746|NCT05838716|DIETARY_SUPPLEMENT|D Vitamin|Given PO
215024747|NCT05838716|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
215024748|NCT05838716|DRUG|Placebo Administration|Given PO
215024749|NCT05838716|OTHER|Quality-of-Life Assessment|Ancillary studies
215024750|NCT05838716|OTHER|Questionnaire Administration|Ancillary studies
215024751|NCT02061085|DRUG|Eribulin|
215024752|NCT03724097|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
215024753|NCT03724097|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
214423593|NCT00466414|DEVICE|Polycaprolactone Scaffold|
214423594|NCT01884636|DRUG|isavuconazole|oral
215024754|NCT03724097|DRUG|target drug with the score above 0,1|target drug with the score above 0,1
215024755|NCT03724097|DRUG|target drug with the score equal or below 0,1|target drug with the score equal or below 0,1
215024756|NCT03724097|DRUG|non-target drug|non-target drug
215024757|NCT03724097|DRUG|palliative care|palliative care
215024758|NCT00112307|PROCEDURE|Brachytherapy|
215024759|NCT04012710|PROCEDURE|Laparoscopy|Conventional abdominal laparoscopy
214423595|NCT01884636|DRUG|methotrexate|oral
214423596|NCT00127179|DRUG|MK0906, finasteride / Duration of Treatment: 48 weeks|
214423597|NCT00127179|DRUG|Comparator: placebo / Duration of Treatment: 48 weeks|
214423598|NCT00220350|DRUG|leuprolide acetate|
214423599|NCT00000635|DRUG|Trifluridine|
214423600|NCT00000635|DRUG|Bacitracin zinc/Polymyxin B sulfate|
214423601|NCT05393336|OTHER|V-sitting posture stabilization|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the V-sitting exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
214423602|NCT05393336|OTHER|Modified clamshell exercises|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the modified clamshell exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
214423603|NCT05861388|PROCEDURE|implant placement|2 implants were placed at position of lower 2nd premolar and 2nd molar
214423604|NCT05213715|OTHER|assessment|assessment of upper extremity functions, somatosensorial functions and proprioseption of upper extremity
214423605|NCT00430300|DRUG|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
215024760|NCT04012710|PROCEDURE|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
215024762|NCT06472791|DIETARY_SUPPLEMENT|Centella Asiatica|Centella Asiatica is a perennial, herbaceous plant that is sold as a dietary supplement in the United States under the name Gotu Kola. It has been used for centuries in Ayurvedic and Chinese medicine. Evidence suggests it may help with resilience to aging and cognitive decline. The product for this study will be produced by Arjuna Natural.
215024763|NCT06472791|DIETARY_SUPPLEMENT|Placebo Comparator|The comparator will contain microcystalline cellulose in matched capsules. The comparator product for this study will be produced by Arjuna Natural.
215024764|NCT04105634|DRUG|FNOS|The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
215024765|NCT04105634|DRUG|Florbetaben|The imaging drug used for this group is called Florbetaben, it is an FDA approved radioactive PET tracer used to image amyloid plaques in the body. Although not yet FDA approved for this purpose, it has already been used clinically to image amyloid in other parts of the body. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
215024766|NCT03247673|DRUG|CT-P16|CT-P16 is a biosimilar product for Avastin
215024767|NCT03247673|DRUG|EU-approved Avastin|EU-approved Avastin
215024768|NCT03247673|DRUG|US-licensed Avastin|US-licensed Avastin
215024769|NCT02097225|DRUG|Dabrafenib|Given PO
215024770|NCT02097225|OTHER|Laboratory Biomarker Analysis|Correlative studies
215024771|NCT02097225|DRUG|Onalespib|Given IV
215024772|NCT02097225|OTHER|Pharmacological Study|Correlative studies
215024773|NCT02097225|DRUG|Trametinib|Given PO
215024774|NCT06357078|OTHER|Art Therapy|Caregivers in the art therapy group will be given art therapy practices, lasting approximately 45 minutes-1 hour, twice a week for 4 weeks. Visual and handicraft practices (painting work, collage work, mandala work, painting with felt, clay work, painting and storytelling) are done in art therapy activities that will last for 4 weeks, and it is aimed to develop personal and emotional awareness, reduce stress and increase general well-being.
215024775|NCT02074839|DRUG|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
215024776|NCT04071535|DEVICE|sudoscan、nerve conduction tests|To evaluate sudomotor nerve and macrofibropathy.
215024777|NCT06037083|DEVICE|Oxygen saturation probe|The high-accuracy oxygen saturation signal will be continuously acquired for 168 hours post extubation from a separate pulse oximeter (Radical-7®, Masimo ROOT platform, MasimoCorp, Irvine, LA).
215029152|NCT06429332|OTHER|Do-not-resuscitate (DNR) or withdrawal of care|Refrain from the use of DNR or withdrawal of care orders for 48 hours
215103540|NCT01554995|DRUG|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
214694201|NCT03201198|BEHAVIORAL|Chair exercises|Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
214423606|NCT00430300|DRUG|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
214423607|NCT05826704|DIETARY_SUPPLEMENT|Probiotics|Participants will be taking 2 capsule a day for 6 weeks
215024778|NCT06037083|DEVICE|Near infrared spectroscopy sensors|The cerebral and splanchnic regional oxygen saturation signals will be acquired continuously for 168h post extubation using two near infrared spectroscopy sensors (Masimo ROOT platform, MasimoCorp, Irvine, LA), one placed on the forehead for cerebral oxygenation and one on the abdomen (for splanchnic oxygenation).
215024779|NCT06037083|DEVICE|Electrical impedance tomography|"The regional lung ventilation will be measured using Electrical Impedance Tomography (TIMPEL, USA) at three time points:~* From 1 hour pre-extubation to 2 hours post extubation (total 3 hours)~* Between 24 and 48 hours post extubation (total 3 hours)~* Between 72 and 96 hours post extubation (total 3 hours)"
215024780|NCT05135754|DEVICE|Heylo|Test of the supporting product (test product) for a 12 weeks period. No additional intervention will be conducted. A few follow up nurse calls to assess few endpoints together with subject. All remaining endpoints are captured via surveys send to the subjects every 14 days.
215024781|NCT02685852|DRUG|Exenatide|Exenatide at a dose of 5 mcg
215024782|NCT02685852|DRUG|Acarbose|Acarbose at a dose of 25 mg
215024783|NCT02685852|DRUG|Exenatide Placebo|Placebo for Exenatide
215024784|NCT02685852|DRUG|Acarbose Placebo|Placebo for Acarbose
215103541|NCT01554995|DRUG|Linezolid|Linezolid 600 mg (Cohort 9) none
215024785|NCT02993666|DEVICE|Bair Hugger|forced air warming with Bair Hugger air warmer
215024786|NCT01764932|PROCEDURE|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
215024787|NCT00181545|PROCEDURE|escalation of dose (radiotherapy treatment)|
215024788|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
215103542|NCT04193774|DIAGNOSTIC_TEST|Conjunctival swab|Swab of the conjunctival fornices of both eyes
214423608|NCT02754479|DEVICE|Nd:YAG laser|Treatment of lower extremity spider veins
214423609|NCT03012230|OTHER|Laboratory Biomarker Analysis|Correlative studies
214423610|NCT03012230|BIOLOGICAL|Pembrolizumab|Given IV
214423611|NCT03012230|DRUG|Ruxolitinib Phosphate|Given PO
214423612|NCT05559346|OTHER|Diaphragmatic exercises|Diaphragm exercises will be applied to the research group in addition to conventional rehabilitation.The content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control. In addition to conventional rehabilitation, manual diaphragmatic relaxation exercises and diaphragmatic breathing exercises will be applied to the children in the research group two days a week.
214423613|NCT05559346|OTHER|conventional physiotherapy|The control group will only be taken to the conventional rehabilitation program. e content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control.
214423614|NCT04656886|DRUG|Intravenous Infusion|
215024789|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
215024790|NCT00674063|DRUG|alefacept|IV
215024791|NCT00345280|PROCEDURE|impression cytology, obtain the tear fluid|Vitamin A
215024792|NCT05856760|DRUG|Sparsentan|Target dose of 400 mg daily
215024793|NCT01877057|DIETARY_SUPPLEMENT|Saturn|
215024794|NCT02757963|OTHER|Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool|The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score \>=3) and meet all other eligibility requirements will be enrolled in Part I of the study.
215103543|NCT04193774|DRUG|Oxybuprocaine Hydrochloride 0.4% Eye Drops|One drop of topical anesthesia in one eye
215103544|NCT04193774|DRUG|artificial tears|One drop of artificial tears in the other eye
215103545|NCT05091515|OTHER|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
215103546|NCT05392803|DEVICE|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy; then sham treatment after a 7-day washout period"
215103547|NCT05392803|DEVICE|Sham then Active Treatment|"Application of 30 days of sham treatment; then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy after a 7-day washout period"
215103548|NCT00642447|DRUG|helium:oxygen mixture|
214423615|NCT04028336|OTHER|TITRATION|PEP titration pulmonary opening (PEP-OP) was performed in all patients followed by new LUS and Peso measurement.
214423616|NCT04128423|BIOLOGICAL|AMV564|AMV564 will be administered daily
215103549|NCT01939639|DRUG|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
215103550|NCT01939639|DRUG|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
214691375|NCT05965336|OTHER|Plantar Pressure Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map represents the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target is provided using the heat map colors of red and target line on the bar graph. Participants are informed that the target is a measurement of the pressure under their foot, and their goal is to decrease pressure to achieve their target.
215024795|NCT02757963|OTHER|International Prostate Symptom Score (IPSS) screening tool|The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score \>=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
215024796|NCT03696693|DEVICE|acoustic vocal analysis|Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
215024797|NCT02971137|BEHAVIORAL|Smoking Cessation plus CBI|proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
215024798|NCT02971137|BEHAVIORAL|Smoking Cessation Standard|standard telephone-based smoking cessation intervention
215024799|NCT02505074|PROCEDURE|Valve replacement with the Melody valve|This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
215024800|NCT05259098|DRUG|Sufentanil Sublingual Tablet System|Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
215024801|NCT05259098|DRUG|Intravenous Patient-Controlled Analgesia with morfine|Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
214691376|NCT05965336|OTHER|Propulsion Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For propulsion biofeedback, a visual display with a marker represents the current propulsion (peak AGRF) and a target provided to modulate propulsion. Participants are informed that the marker is a measurement of how hard they are pushing the ground backward, and their goal is to push-off more to achieve their target.
214691377|NCT02196649|DEVICE|Endoscopic Clip|
215024802|NCT02088086|BEHAVIORAL|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
215024803|NCT02088086|BEHAVIORAL|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
215024804|NCT02088086|BEHAVIORAL|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
215024805|NCT03689088|DEVICE|Goldfish|Goldfish will be placed in the eye for 24h monitoring
215024806|NCT03689088|DEVICE|Tonometry|Fellow eye will be measured by tonometry
215024807|NCT00911157|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
215024808|NCT00911157|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
215024809|NCT04755231|DEVICE|AcrySof IQ PanOptix Presbyopia Correcting IOL|UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
214691378|NCT05178992|BEHAVIORAL|Socially Assistive Robot Activity|Participants will attend two weekly sessions with robot activities. Each session will last 30 minutes. Participants will attend robot sessions for 8 weeks.
215024810|NCT04755231|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
215024811|NCT06577948|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
215024812|NCT06577948|DEVICE|P.A.U.S.E. spectacle lens 1|P.A.U.S.E. spectacle lens 1
215024813|NCT06577948|DEVICE|P.A.U.S.E. spectacle lens 2|P.A.U.S.E. spectacle lens 2
215024814|NCT06554899|OTHER|Clinician-led intervention to address fear of cancer recurrence (CIFeR)|The intervention includes five components informed by theoretical models and existing interventions for FCR: 1) FCR normalization: reassurance that FCR is a common and normal phenomenon after treatment for cancer, 2) Providing prognostic information: asking patients whether they would like information about their risk of recurrence and, if yes,providing this information, 3) Providing education and take-home information on red-flag recurrence symptoms, 4) Brief advice on managing worry: distraction, meditation, mindfulness, reassurance, and links to online resources to manage FCR, and 5) referral to a psychologist if FCR is high (FCRI-SF \>= 22), or if deemed helpful by the patient or clinician. Access will be provided to ConquerFear-Group delivered online by trained psychologists.
215029153|NCT06429332|OTHER|Referral to Intensive Care|Immediate (\<30 min) referral to intensive care if airway, breathing and/or circulation are compromized
215029154|NCT06429332|OTHER|Referral to Neurosurgery|"Immediate (\<30 min) referral to neurosurgery if any of the following criteria are fulfilled:~* Large and/or rapidly evolving supratentorial ICH (\>20 ml volume)~* Any intraventricular extension~* Posterior fossa bleed, irrespective of volume~* Suspicion of a vascular malformation, independent of volume or location~* Reduction in reaction to sensory stimulation or drowsiness"
215029155|NCT06429332|DIAGNOSTIC_TEST|Repeat brain imaging|Repeat 6-12-hour brain imaging with the physicians choice of modality, preferably computed tomography (CT), if clinical deterioration or the patient received OAC reversal treatment
215024815|NCT06642948|OTHER|Motor rehabilitation based on ai visual recognition|Patients in the intervention group will engage in a home-based exercise program in addition to standard rehabilitation guidance. Initially, patients will be provided with exercise materials developed by the intervention team, one-on-one guidance via the AI rehabilitation platform, and a detailed explanation of the exercise intervention program (including its components, foundational knowledge, and benefits).The aerobic warm-up routine includes activities such as marching in place, full-body stretches, jumping jacks, side steps with arm circles, and squats with alternating punches. For the elderly, the warm-up routine is similar but also incorporates chest expansion exercises, abduction exercises, overhead reaches, lateral movements, hip extension exercises, calf raises, and additional full-body stretches.Functional training should be done 3 to 5 times per week at an intensity of RPE 3 to 4, with each session lasting 15 to 30 minutes.
215024816|NCT06637618|BEHAVIORAL|up front use of mineralocorticoid receptor antagonist|the sequence of which the four drug classes are prescribed will differ, where the intervention is early use of MRA, where the control group will receive standard care, where MRA are usually prescribed last
215024817|NCT06644885|PROCEDURE|TIVAD implantation complications|Follow up and post operative outcome of patients with devices implantation
214423617|NCT03026036|RADIATION|PET Scan with Raclopride|A subsample (21 per group) will complete the PET imaging.
214423618|NCT05338996|BEHAVIORAL|iENGAGE for PrEP|This intervention originally developed for people living with HIV (PLWH), is designed to promote engagement, retention, and adherence to treatment by addressing the social determinants of health that often act as barrier to remaining in care and achieving viral suppression. Based on our experience with this intervention we believe that it is well suited to similarly promote engagement, retention, and utilization of PrEP care among our proposed target population of WOC by a) removing barriers to care and b) addressing unmet needs by providing c) point-to-point linkage to care services delivered by multi-disciplinary teams of individuals within or outside of the health facility, and d) the use of telehealth visits to facilitate engagement in care and improve health visit attendance. The original iENGAGE is a 4-session, in-clinic behavioral intervention.
214423619|NCT04878081|BEHAVIORAL|hot flush|"Hot Flash Diaries to record the change of daily hot flush symptoms for 30 days. The Hot Flash Related Daily Interference Scale to record how much did hot flush effect daily life.~The Kupperman menopausal index to evaluate the severity of menopausal symptoms. The Pittsburgh Sleep Quality Index to evaluate sleep disorder. Wireless temperature monitor to record hot flush and body temperature during sleeping.~Classify patients' traditional Chinese constitution by using Physical classification and judgment self-test table."
214423620|NCT04013646|DRUG|Umbilical cord blood infusion|The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
214423621|NCT04013646|DRUG|Erythropoietin injection|Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
214691379|NCT03363828|DRUG|Estrofem|Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment
214691380|NCT05342584|DRUG|Venetoclax Oral Tablet|Given PO
214423622|NCT04013646|DRUG|Placebo umbilical cord blood infusion|Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
214691381|NCT05342584|DRUG|Daunorubicin|Given IV
214691382|NCT05342584|DRUG|Cytarabine|Given IV
215024818|NCT06643104|PROCEDURE|Tuina|X-ray mapping guides three days of tailored exercises, including 3D therapy, breathing techniques, and spinal manipulation.
215024819|NCT06535893|DRUG|TN|Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
215103551|NCT05512780|DRUG|Dalpiciclib|"An exploratory study of a single-arm, open design~All subjects enrolled will receive the following treatment:~Dalpiciclib combined with Letrozole, 28 days as one cycle."
215103552|NCT03492801|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215103553|NCT03492801|OTHER|Laboratory Biomarker Analysis|Correlative studies
215103554|NCT04581551|PROCEDURE|SWE assessor 1|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
215103555|NCT04581551|PROCEDURE|SWE assessor 2|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
215103556|NCT04581551|PROCEDURE|Stretch intervention|Transversal stretch of pectoralis major muscle on the hemiplegic side.
215103557|NCT04581551|PROCEDURE|No stretch intervention|Passive mobilisation of the hemiplegic hand.
215103558|NCT00083135|BIOLOGICAL|filgrastim|
214423623|NCT04013646|DRUG|Placebo erythropoietin injection|Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
214423624|NCT04013646|PROCEDURE|Active rehabilitation|Physical therapy and occupational therapy are performed daily.
214691383|NCT00500786|BIOLOGICAL|CYT006-AngQb|
214691384|NCT04315376|BEHAVIORAL|Exercise-Diet Intervention|The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
214691385|NCT04315376|BEHAVIORAL|Diet Intervention|This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
214691386|NCT04336397|DIAGNOSTIC_TEST|multi-target stool DNA test|Cluster randomized trial of high and medium intensity outreach with MT-sDNA compared with usual care
215024820|NCT06535893|DRUG|TN-1|Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
215024821|NCT06179004|DRUG|Liposomal bupivacaine|133mg Liposomal bupivacaine plus 10mL 0.5% bupivacaine administered in a supraclavicular single shot perineural injection
215024822|NCT06179004|DRUG|Bupivacaine Hydrochloride|20mL 0.25% bupivacaine administered in a supraclavicular single shot perineural injection
215024823|NCT06221813|BIOLOGICAL|PHV02|Nipah virus vaccine
215024824|NCT06221813|BIOLOGICAL|Lactated Ringer's|Placebo
215024825|NCT06019832|PROCEDURE|Total Knee Arthroplasty (TKA)|Both study arms will undergo TKA
215024826|NCT06019832|DEVICE|Stemmed Tibial Implant|A stemmed tibial implant
215103559|NCT00083135|PROCEDURE|autologous bone marrow transplantation|
215103560|NCT00083135|PROCEDURE|peripheral blood stem cell transplantation|
215103561|NCT00083135|RADIATION|iobenguane I 131|
215103562|NCT01069705|DRUG|Tobramycin inhalation powder|Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.
215103563|NCT00049660|DRUG|capecitabine|
215103564|NCT00049660|DRUG|vinorelbine tartrate|
215103565|NCT03485196|OTHER|Microsatellite instability|The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
215103566|NCT00441805|DEVICE|Radio Frequency|
215103567|NCT00002218|DRUG|CI-1012|
215103568|NCT00292539|DEVICE|Any pacemaker with right ventricular pacing option|
215103569|NCT02726022|DRUG|Peginterferon alfa-2a|As per treating physician discretion and according to summary of product characteristics.
214423625|NCT03824080|DRUG|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
215024827|NCT06019832|DEVICE|Non-stemmed tibial implant|non-stemmed tibial implants
215103570|NCT02726022|DRUG|Ribavirin|As per treating physician discretion and according to summary of product characteristics.
215103571|NCT01142427|OTHER|Cytology Specimen Collection Procedure|Correlative studies
215103572|NCT01142427|OTHER|Laboratory Biomarker Analysis|Correlative studies
215103573|NCT06190080|OTHER|Digestive endoscopy|Digestive endoscopies are performed in the operative room under general anaesthetic 3 months after the introduction or change of treatment. Biopsies of the upper, middle and lower thirds of the esophagus will be taken and analyzed for pathology.
215103574|NCT01781780|BEHAVIORAL|General Nutrition Recommendations|
215103575|NCT01781780|BEHAVIORAL|Breakfast Recommendation|
215103576|NCT01781780|BEHAVIORAL|No Breakfast Recommendation|
215024828|NCT02016599|OTHER|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
215103577|NCT03360058|BEHAVIORAL|Small Talk Big Difference Immediate access training|Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice
215103578|NCT03360058|BEHAVIORAL|Small Talk Big Difference delayed access training|Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
215103579|NCT01886703|BEHAVIORAL|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
215103580|NCT00451516|DRUG|Herbal medicine (St. John's wort and Kava)|
215103581|NCT05772013|DRUG|Azithromycin Pill|"Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September)."
215103582|NCT05772013|DRUG|Placebo|The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
214508120|NCT05288959|DEVICE|Sessions 3 - 5: Paired associative stimulation (PAS)|During each PAS run, bi-focal TMS (MagVenture, Farum, Denmark) is delivered to two brain areas while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The asynchronies between the two TMS coils are kept constant within each session but differ across sessions. Within each session, to observe PAS effects on connectivity, uni-focal spTMS is delivered to the stimulated areas before and after the PAS modulation while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. In addition, resting-state EEG/EMG and a behavioral measure (bimanual task coordination) are recorded before and after the PAS modulation. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coils.
214508121|NCT03784469|OTHER|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
214508122|NCT05962476|DEVICE|Transcutaneous vibro-acoustic device|Wearable device which sends low-frequency sound vibrations through the skin.
214508123|NCT00462475|DRUG|Recombinant Growth Hormone, Genotropin (Pfizer)|
214508124|NCT04634682|DIETARY_SUPPLEMENT|MYODM|Formulated composition containing Theobroma cacao supplemented with caffeine
214508125|NCT03936777|DRUG|ZX008 (Fenfluramine Hydrochloride)|Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.
214508126|NCT06510088|PROCEDURE|3-week multimodal prehabilitation program|"This program included four components:~Aerobic and Resistance Exercises A designated physical therapist supervises the resistance exercises and offers corrective guidance. Training intensity was continuously monitored and fine-tuned based on Borg scale assessments.~Respiratory Training Respiratory training was conducted using a respiratory trainer. Patients were instructed to engage in respiratory training at least three times daily, with each session lasting 10 minutes.~Nutrition Intervention Those in the multimodal prehabilitation group received daily whey protein powder to ensure a recommended protein intake of 1.5 g/kg/d. Protein supplements were to be consumed within one hour of exercise to promote muscle synthesis.~Psychological Intervention Anxiety-coping interventions included relaxation techniques and deep breathing exercises, administered in a one-to-one format by a nurse trained in psychological care."
214508127|NCT05402566|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
214508128|NCT04914702|DEVICE|Everion®|The Everion® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
214508129|NCT04914702|DEVICE|CORE®|The CORE® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
214508130|NCT03507179|OTHER|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional processing
214508131|NCT03507179|OTHER|conventional dentures|conventional dentures
214691387|NCT05226819|DRUG|PPI quadruple therapy|Among these outpatients, H. pylori-negative patients don't give any intervention. But H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed.
214508132|NCT04076059|DRUG|Enzalutamide|Oral
214508133|NCT04076059|DRUG|Placebo|Oral
214508134|NCT04076059|DRUG|Androgen deprivation therapy (ADT)|All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
214508135|NCT02124356|OTHER|Evaluation of functional performance|
215024829|NCT06479863|COMBINATION_PRODUCT|Pozelimab/Cemdisiran|Patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks
214508136|NCT02521493|DRUG|Asparaginase|Given IM or IV
214508137|NCT02521493|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
214508138|NCT02521493|DRUG|Cytarabine|Given IT and IV
214508139|NCT02521493|DRUG|Daunorubicin Hydrochloride|Given IV
214508140|NCT02521493|DRUG|Etoposide|Given IV
214508141|NCT02521493|OTHER|Laboratory Biomarker Analysis|Correlative studies
215024830|NCT04650893|DRUG|Intravenous Ketorolac|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
215024831|NCT04650893|DRUG|Intravenous Dexamethasone|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
215024832|NCT04650893|DRUG|Placebo|Control
215024833|NCT05919030|RADIATION|Intensity-modulated radiotherapy (IMRT)|Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy
215024834|NCT05919030|DRUG|Tislelizumab|200 mg IV Q3W
215024835|NCT05919030|DRUG|Cisplatin|During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
215024836|NCT05919030|DRUG|Nab paclitaxel|During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
214691388|NCT05948410|BEHAVIORAL|The State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) is a psychological inventory consisting of 40 self-report items on a 4-point Likert scale. The STAI measures two types of anxiety - state anxiety and trait anxiety. Higher scores are positively correlated with higher levels of anxiety.
214691389|NCT05948410|BEHAVIORAL|Perceived Stress Scale|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes a number of direct queries about current levels of experienced stress. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items. A short 4 item scale can be made from questions 2, 4, 5 and 10 of the PSS 10 item scale
214691390|NCT05948410|BEHAVIORAL|Visual Analog Scale|The visual analogue scale (VAS) is a psychometric response scale that can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end points.
215024837|NCT00298155|DRUG|goserelin with dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
215024838|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
215024839|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride and ketoconazole|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
215024840|NCT05487391|DRUG|QL1706 injection|QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
215024841|NCT05487391|DRUG|Vinorelbine Tartrate|Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
215024842|NCT05487391|DRUG|Paclitaxel|Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
215024843|NCT05487391|DRUG|Cisplatin|Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
214691391|NCT03272945|PROCEDURE|Linked-color imaging|Linked-color imaging colonoscopy
214691392|NCT01507584|DEVICE|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
214691393|NCT06036927|DRUG|TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
214691394|NCT06036927|DRUG|TQC2731 matching placebo|It'a a placebo injection without active substances.
214691395|NCT05540899|RADIATION|Hypofractionated Postoperative Radiotherapy|Hypofractionated Postoperative Radiation Therapy
214691396|NCT00837512|DEVICE|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
214691397|NCT00837512|DEVICE|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
214691398|NCT01401010|DRUG|Doripenem|500 mg every 8 hours
214691399|NCT01401010|DRUG|doripenem|1000 mg every 8 hours
215024844|NCT05487391|DRUG|Carboplatin|Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
215103583|NCT02772185|DEVICE|active tDCS|Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus
215103584|NCT02772185|DEVICE|sham tDCS|The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
215103585|NCT02772185|BEHAVIORAL|real CT|Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).
215103586|NCT02772185|BEHAVIORAL|placebo CT|Videos (short films) will be presented during the neurostimulation
214691400|NCT06060275|DIAGNOSTIC_TEST|serum sample and nerve conduction study and cerebrospinal fluid study|serum sample and cerebrospinal fluid study to detect Neurofilament light chain Nerve conduction study
214694202|NCT01588145|DRUG|HM61713|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
215024845|NCT05487391|DRUG|Pemetrexed|Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
215103587|NCT02258113|DEVICE|Ocusweep|A novel reaction-time based visual field device.
215103588|NCT02258113|DEVICE|Ocusweep OcuRT|Vision based choice reaction time test method
214423626|NCT03984617|OTHER|Emergency visit in a French tertiary Maternity hospital (Maternity of Nancy)|total number of visits (hospitalizations and consultations)
215024846|NCT05487391|DRUG|Placebo|Placebo
215024847|NCT00057577|BEHAVIORAL|Cognitive Therapy|CT sessions occur weekly during acute treatment and monthly during continuation. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue CT.
215024848|NCT00057577|DRUG|Medications|Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
215024849|NCT00250575|DRUG|Clozapine|
215024850|NCT05249400|PROCEDURE|Off-site assistance|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.
215103589|NCT05385250|OTHER|Bone sparring radiotherapy|Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
215024851|NCT00347087|DRUG|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
214423627|NCT04181307|BEHAVIORAL|BE-EHR module|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
214423628|NCT01257074|DRUG|Acyclovir 50mg/g|Cream, dose 5 times daily during 5 days
214423629|NCT01257074|DRUG|Penciclovir 10mg/g|Cream, dose 5 times daily during 5 days
214423630|NCT04063410|PROCEDURE|Angiography|Undergo standard of care CTA
214423631|NCT04063410|PROCEDURE|MRI-Based Angiogram|Undergo pPCA
214423632|NCT04063410|OTHER|Quality-of-Life Assessment|Ancillary studies
214423633|NCT01382030|DRUG|EIA chemotherapy|ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
214423634|NCT01682200|DRUG|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
214423635|NCT00617201|DRUG|atomoxetine|Once daily oral dosing
214423636|NCT00617201|DRUG|placebo|Once daily oral dosing - matched placebo
214423637|NCT04680871|DEVICE|In-Ear Sensor|The device will passively monitor participants' biometrics
214423638|NCT05619107|DEVICE|Active Transauricular nerve stimulation|The first allocated intervention will be undertaken for 30 minutes. The electrode placement and stimulation parameters are described in the arm/group section. After the 30-minute intervention, day 1 of the protocol will be complete. The investigator will remain present in the room with the participant to ensure compliance and adherence to the protocol. The allocated intervention will then be repeated by the participant at a similar time of day for 7 consecutive days. The investigator will arrange video-calls with the participant whilst off-site to ensure ongoing compliance and adherence to the protocol. On the seventh day, participants return to the clinical research facility to take the final first allocated intervention. A 14-day rest period will follow. Then the participants will perform the same 7-day protocol for the opposite intervention to their first treatment allocation.
214423639|NCT05619107|DEVICE|Sham transauricular nerve stimulation|Protocol as for active but sham ear leads are applied, unable to deliver current.
214423640|NCT03943459|DRUG|Quercetin|Quercetin 250 mg BID
214423641|NCT00003292|DRUG|ifosfamide|
214423642|NCT04220359|DEVICE|non-invasive monitoring|Prospective monitoring with retrospective big-data analysis
214423643|NCT00546871|DRUG|Immune Globulin Intravenous (Human), 10%|Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
214423644|NCT06060002|PROCEDURE|Group A - Stent exchange if cholecystectomy dated beyond 3 months|Stent removal and cholangiogram and stone clearance (if recurrent stone/s is/are found). Stent exchange if cholecystectomy dated beyond 3 months
214423645|NCT06060002|DIAGNOSTIC_TEST|Group B - Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months|Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months to see recurrence of CDL. ERC and stone clearance (if recurrent stone/s found on EUS/MRCP/USG abdomen)
214423646|NCT03688659|DRUG|Vancomycin and gentamycin|intravenous
214423647|NCT02206672|OTHER|Micro reinjection of autologus adipose tissue|
214423648|NCT03183518|OTHER|Facial micellar cleanser|Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.
214423649|NCT03183518|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
214423650|NCT04134143|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|A round patch of experimental skin tissue that the doctor applies over the ulcer
214423651|NCT02827617|DRUG|Ibrutinib|Treatment with ibrutinib 420 mg quaque die in the clinical practice
214423652|NCT05265559|PROCEDURE|Partial Indirect Restoration|Dental restorative treatment
214423653|NCT04049435|DEVICE|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
214423654|NCT03349736|OTHER|Pelvic Floor Muscle Training|All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
214423655|NCT03446482|OTHER|observation of differents tasks|Evaluation by an external observer (nurse student in research stage or clinical research technician) of the distribution of medical time for the performance of the different tasks of anesthesiologist (in minutes)
214423656|NCT05574452|DEVICE|ACL reconstruction using the SONAR Femoral Aimer PSI|ACL reconstruction using the SONAR Femoral Aimer PSI
214423657|NCT03328117|DRUG|Imatinib|Over-encapsulated 100 mg imatinib mesilate tablets
214423658|NCT03328117|DRUG|Placebo oral capsule|Matching placebo oral capsule
214423659|NCT03143309|BEHAVIORAL|Intervention|Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
214423660|NCT03143309|OTHER|Control|Non-health related messages delivered via WhatsApp 2-3 times per week.
215024852|NCT00804479|OTHER|No intervention.|
215024853|NCT00775086|DRUG|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
215024854|NCT02034266|DIETARY_SUPPLEMENT|Omega-3 supplementation|5 mL twice daily, administered under the tongue
215024855|NCT03109769|BEHAVIORAL|Mobile phone application|
215024856|NCT03109769|BEHAVIORAL|Verbal oral hygiene instructions|
215024857|NCT04918914|DRUG|Dapsone 100 MG|Dapsone 100-200 md orally daily, along with Cimetadine 400 mg PO TID
215024858|NCT02980185|PROCEDURE|Laparoscopic primary cytoreduction|Primary cytoreduction for ovarian cancer performed through a completely minimally-invasive approach
215024859|NCT06255340|DRUG|BI 3031185|BI 3031185
215024860|NCT06255340|DRUG|Placebo matching BI 3031185|Placebo
215024861|NCT00233961|BIOLOGICAL|filgrastim|
215024862|NCT00648713|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
215024863|NCT00648713|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fed
215024864|NCT05530538|BEHAVIORAL|BrainWeighve App|46 total adolescents (14-18 years old) with %BMIp95 will be recruited via various sources (e.g., clinic referrals, flyers, social media advertising) to participate in one of two stages of the study: the beta testing stage or the trial stage. Beta testing will enroll two successive groups of eight teens to test the app for three weeks; participants will be assessed in-person pre- and post-intervention. After each group, the app will be modified to incorporate their feedback in order to promote youth engagement. The trial stage will enroll 30 adolescents to participate in a four-month intervention; participants will complete three assessments, baseline, post-intervention (both in-person) and one-month post-intervention (either in-person or virtually).
215024865|NCT06151665|PROCEDURE|single file rotary|Kedo-S plus file is the fifth generation of pediatric files will be used in pulpectomy of primary molars
215024866|NCT06151665|PROCEDURE|Conventional Manual K files|Stainless-steel K files is the golden standard files used in pulpectomy of primary molars
215024867|NCT00185055|DRUG|Olmesartan medoxomil|
215024868|NCT00185055|DRUG|Irbesartan|
215024869|NCT00185055|DRUG|Valsartan|
215024870|NCT02322931|PROCEDURE|Intra-operative C-arm CT imaging|"1. Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.~2. Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.~3. One Cine loop C-arm scan in the sagittal plane while retracting the probe.~4. One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down)."
215024871|NCT00189878|DRUG|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
215024872|NCT00189878|DRUG|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
215024873|NCT04712227|OTHER|intubation|intubation
215024874|NCT04712227|OTHER|mask ventilation|mask ventilation
215024875|NCT02714543|DRUG|aloevera juice|aloevera juice to drink twice daily for 3 months.
215024876|NCT02714543|DRUG|Hydrocortisone|intralesional injection of hydrocortisone 100mg once a week for 6 weeks
215024877|NCT02714543|DRUG|Hyaluronic Acid|injection hyaluronic acid 1500IU once a week for 6 weeks
215024878|NCT02714543|DRUG|antioxidant|Capsules SM Fibro (antioxidants) once daily for 3 months.
215024879|NCT02714543|DRUG|aloevera gel|aloevera gel one scoop to be applied 3-4 times daily for 3 months
215024880|NCT00313521|DRUG|thiotepa|
215024881|NCT00313521|PROCEDURE|adjuvant therapy|
214423661|NCT02299336|DRUG|Aflibercept|pro re nata (PRN)
215024882|NCT00313521|RADIATION|radiation therapy|
215024883|NCT05346640|DEVICE|Cionic Neural Sleeve|Adaptive, functional electrical stimulation
215024884|NCT04365270|DRUG|Glass Ionomer|Glass ionomer filling material would be modified accordingly or used as is
215024885|NCT04365270|DRUG|Chitosan Low Molecular Weight (20-200 Mpa.S)|deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
215024886|NCT04365270|DRUG|Chlorhexidine Diacetate|Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
215024887|NCT04365270|DRUG|Titanium Dioxide|Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), \>99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
215024888|NCT04831619|DRUG|PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)|A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
215024889|NCT00761137|DRUG|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
215024890|NCT00761137|DRUG|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
214423662|NCT02299336|PROCEDURE|Focal Laser|Focal laser administered based on pre-specified criteria
214508142|NCT02521493|DRUG|Mitoxantrone Hydrochloride|Given IV
214508143|NCT02521493|DRUG|Thioguanine|Given PO
214508144|NCT06626919|BIOLOGICAL|anito-cel|Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain
214508145|NCT06626919|DRUG|Standard Lymphodepletion regimen|Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion
214508146|NCT03830788|RADIATION|Radiation by brachytherapy|Brachytherapy by Iodine 125 delivering 144 Gy to the prostate
214508147|NCT03830788|RADIATION|Radiation by SBRT|SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate.
215024891|NCT00761137|DRUG|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
215024892|NCT00761137|DRUG|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
215024893|NCT02577575|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
215024894|NCT02577575|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
215024895|NCT03468465|DRUG|Solifenacin Succinate|10 mg tablet daily during 75 days maximum
215024896|NCT03468465|DEVICE|Neuro-Muscular Stimulators (NMS)|Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
215024897|NCT01561612|BEHAVIORAL|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
215024898|NCT06354842|DIAGNOSTIC_TEST|pilocarpine iontopheresis|Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry
214423663|NCT00681252|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
214423664|NCT02940561|DRUG|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
214423665|NCT02940561|DRUG|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
214423666|NCT03203798|PROCEDURE|Training of pelvic floor muscles|The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
214508148|NCT03750981|BEHAVIORAL|12 week pilot intervention study.|Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
214508149|NCT06060353|BEHAVIORAL|Regulation Focused Psychotherapy (RFP-C)|Regulation-focused psychotherapy for children (RFP-C; Hoffman, Rice, \& Prout, 2016) is a manualized, psychodynamic play therapy. Through 20 sessions (16 with the child and four parent meetings), RFP-C allows the child to understand the ways distressing affects are avoided and to explore alternative ways of coping with unpleasant affect. The clinician works to increase the child's understanding that all behavior, especially oppositional and disruptive behavior, has meaning in the service of emotional and behavioral regulation. This work is also done with the parents to better support the child in achieving symptom reduction and increased emotion regulation.
214508150|NCT06060353|BEHAVIORAL|Parental Awareness and Child Social Skills Group|Parental awareness and child social skills group is a manualized group psychotherapy that involves twelve parallel sessions conducted separately with parents and children. The parent group involves modules related to psycho-education, role-play and awareness building activities on child needs \& rights, child temperament, praise \& acceptance, child play, limit setting, anger management, transmission of parenting styles through genograms and family trees. With children, the groups involve psycho-education and play based activities to build awareness on children's rights, temperament, feelings, play \& relationship skills, empathy \& praise, anger management.
214508151|NCT01470300|OTHER|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).
214508152|NCT00352599|DRUG|Lovastatin|
214508153|NCT00352599|DRUG|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
214508154|NCT00352599|DRUG|placebo pill|
214508155|NCT04334005|DIETARY_SUPPLEMENT|Vitamin D|The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
214508156|NCT05070559|OTHER|Active Release Technique|"Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone \& wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
214508157|NCT05070559|OTHER|Graston Technique Group|"Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
214508158|NCT03449771|OTHER|self-administered questionnaire|The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale).
214508159|NCT05734690|DRUG|SGLT2i, beta blocker, ARNI, MRA, MTD|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
214508160|NCT05734690|BEHAVIORAL|Education-First|For the first 3-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 3 months, be invited to participate in the remote heart failure clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for heart failure therapy. Provider education will also consist of the program's medical algorithm and a summary sheet on indications, outcomes, prescribing, and monitoring information
214508161|NCT00140400|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
214691401|NCT01542476|DRUG|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
215024899|NCT00901095|BEHAVIORAL|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
215024900|NCT04778709|DEVICE|Puros allograft|"Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone."
214508162|NCT04142255|BIOLOGICAL|FMT|FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
214508163|NCT00973999|DRUG|Botulinum Toxin|"Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle."
215024901|NCT00005931|DRUG|SU5416|
215024902|NCT06311331|DEVICE|Total Talus Replacement (TTR)|The restor3d patient-specific TTR Implant and Instrumentation System is designed to replace a native talus bone that has been affected by a disease state or injury. The implant is an additively manufactured Cobalt Chromium alloy (ASTM F3213) construct produced by laser powder bed fusion. The data-driven design of the implant enables the patient to salvage their joint while maintaining ankle range of motion, reducing pain and improving physical function.
215024903|NCT05290298|DIETARY_SUPPLEMENT|NITRATE|Multi-component nutritional formula
215024904|NCT05290298|DIETARY_SUPPLEMENT|PLACEBO|Placebo
215024905|NCT04604093|DEVICE|SMBG Meter|Self Monitoring Blood Glucose Meter
215024906|NCT04604093|DEVICE|FreeStyle Libre 2 System|The Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System
215024907|NCT03549507|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
215024908|NCT06679660|OTHER|inferior alveolar nerve block with 4% articaine|A single ampoule of 4% articaine was administered to a cohort of patients presenting with irreversible pulpitis in the first or second mandibular premolars, designated for Inferior Alveolar Block anesthesia via the mandibular foramen.
215024909|NCT06679660|OTHER|Mental/Incisive Nerve Block (%4 Articaine)|A single ampoule of 4% articaine was administered to a cohort of patients presenting with irreversible pulpitis in the first or second mandibular premolars, designated for Mental or Incisive Nerve Block anesthesia via the mental foramen.
215029156|NCT06429332|OTHER|Standard care|For patients in the usual-care group, decisions about the location of care delivery, investigations, monitoring, and all treatments are made by the treating clinical team. Data will be collected regarding the management of patients, including insertion of invasive monitoring devices, intravenous fluid resuscitation, BP lowering, vasoactive support, glycemic control, mechanical ventilation, neurosurgery, and other supportive therapy.
215029157|NCT04101331|DRUG|AFM13|weekly intravenous infusions of 200mg
215029158|NCT00214669|BEHAVIORAL|PACE (Professional Asthma Care Education)|Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
215029159|NCT00214669|BEHAVIORAL|Lay Led Expert Patient Programme|Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.
215029160|NCT00214669|BEHAVIORAL|Asthma self management education by a specialist nurse|asthma education and self management, asthma action plans
215029161|NCT04762368|DEVICE|Active anodal tDCS|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
215029162|NCT04762368|DEVICE|Sham anodal tDCS|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
215029163|NCT03208179|DRUG|dihydroartemisinin-piperaquine|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
214508164|NCT02337114|BEHAVIORAL|Acceptance and Commitment Therapy|A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
214508165|NCT02337114|BEHAVIORAL|Treatment as Usual|A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
215029164|NCT03208179|DRUG|sulphadoxine-pyrimethamine|Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
215029165|NCT03208179|DRUG|dihydroartemisinin-piperaquine plus azithromycin|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
215029166|NCT00195728|DRUG|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
215029167|NCT05706831|OTHER|Combinatory effect of music stimulation and neurostimulation|music
215029168|NCT04110145|DRUG|Linaclotide|Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.
215103590|NCT00915551|DRUG|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
214508166|NCT02101138|DRUG|Dexpramipexole|Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
215024910|NCT07009756|DIETARY_SUPPLEMENT|Cricket Powder|"The intervention product is each serving of cricket powder, which contains 21.5 grams of house cricket (Acheta domesticus) powder blended with pumpkin powder, packed in a sachet. The powder is prepared under sterile conditions and heat-treated to ensure microbiological safety, in compliance with Thai public health regulations.~Each serving of cricket powder will be consumed together with 32 grams of instant pork-flavored congee, serving as the food base.~This intervention is distinguished by its use of whole cricket powder as a natural, food-based source of protein, chitin, and bioactive compounds, rather than isolated nutrients or supplements. Unlike many clinical studies that use encapsulated insect protein, purified chitin, or insect extracts, this study utilizes a whole-food approach, incorporating cricket powder into a culturally relevant format, congee, to reflect real-life dietary practices."
215024911|NCT07009756|OTHER|Placebo|32 grams of instant pork-flavored congee that does not contain cricket powder
215024912|NCT06688669|OTHER|Fabrication of suitable complete or removable partial dentures for the patient|Fabrication of suitable complete and partial dentures for the patient. The study will not interfere with this treatment process; only follow-up assessments will be conducted at specific intervals after the dentures are fabricated, and surveys will be administered to the patient.
215024913|NCT06689111|DEVICE|Left bundle branch pacing lead|Use of LBBp Vs the standard method of BiVp in resynchronization therapy
215024914|NCT06689111|DEVICE|CRT with the standard method through cs|standard CRT procedure
215024915|NCT06690021|DRUG|Dexmedetomidine|Thoracolumbar Interfascial Plane Block using Bupivacaine and dexmedetomidine
215024916|NCT06686043|DRUG|HPV vaccine, Imiquimod, and metformin combination therapy|Participants in the treatment arm will have visits during the 2nd and 4th weeks of radiation, and then at weeks 8, 10, 12, and 16 after radiation. At each visit, a blood sample will be taken, and tumor cells collected using a cytobrush (or directly from the tumor for vulvar cancer). An HPV vaccine will be injected into the tumor, imiquimod cream will be applied topically, and participants will receive a subcutaneous vaccine shot. They will also take metformin tablets twice daily for two weeks and apply imiquimod cream at home three nights per week. Follow-up PET/CT scans will occur at week 20 and two years post-treatment, with exams every three months for two years.
215024917|NCT06686407|PROCEDURE|Open lumbar decompression ± fusion|"Open lumbar decompression by laminectomy and transpedicular screw fixation using screws and rods ± interbody cage device"
215024918|NCT06686407|PROCEDURE|"Minimally invasive lumbar foraminal decompression using unilateral biportal endoscopy device"|A new endoscopic technique that uses a Unilater Biportal Endoscopy for lumbar foraminal decompression
215024919|NCT06691347|BEHAVIORAL|Eye movement desensitization and reprocessing|Psychotherapy with EMDR. A therapist guides the client in recalling distressing events while simultaneously following a stimulus, like a moving light or tapping. The idea is that this bilateral stimulation helps reduce the intensity of the traumatic memory, allowing clients to gain perspective and lessen emotional distress associated with it. The standard treatment protocol includes up to 24 weekly sessions.
215024920|NCT06691347|BEHAVIORAL|Cognitive therapy for PTSD|"Psychotherapy with CT-PTSD. A therapist works with the client to understand how they interpret their trauma and identify distorted thinking patterns that fuel their PTSD symptoms. Through guided discussions, written exercises, and sometimes re-living the trauma in a controlled way, clients learn to reshape these beliefs, gain a more balanced perspective, and reduce symptoms like hypervigilance, flashbacks, and avoidance behaviors. The standard treatment protocol includes up to 24 weekly sessions."
215024921|NCT06694467|BEHAVIORAL|Education program|An official diabetes education program designed to provide people with diabetes and their families the information and abilities they need to manage their condition effectively. Diabetes kinds, blood sugar control, self-monitoring methods, nutrition, meal planning, physical activity recommendations, medication management, and problem-solving approaches are all included in these programs. Additionally, they offer psychological assistance to help people manage the emotional challenges of having diabetes.
215024922|NCT06694116|DIAGNOSTIC_TEST|sentinel lymph node biopsy using carbon dye|Sterile Charcoal carbon dye peritumoral injection will be performed around vulvar tumor and inguinofemoral lymph node dissection will be done 20 min later (unilateral or bilateral)
215024923|NCT06694909|DEVICE|tDCS + PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
215024924|NCT06694909|DEVICE|sham tDCS + sham PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
215024925|NCT06694909|DEVICE|tDCS + PNS without action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
215024926|NCT06694909|DEVICE|sham tDCS + PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
215024927|NCT06694909|DEVICE|tDCS + sham PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
215029169|NCT04110145|DRUG|Placebo|Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
215029170|NCT05205837|DRUG|Letrozole 2.5mg, hCG|Drug -Treatment Intramuscular injektion - Treatment
215029171|NCT05205837|DRUG|Placebo|Drug - Placebo Intramuscular injektion - placebo
215029172|NCT00963638|DIETARY_SUPPLEMENT|MagTabSR|MagTabSR/placebo 168 mgs BID for 6 six weeks
215029173|NCT00963638|DIETARY_SUPPLEMENT|Placebo|MagTabSR/placebo 168 mgs BID for 6 six weeks
215029174|NCT03453242|OTHER|Bone measurement by HR-pQCT and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites one measurement will be performed by HR-pQCT to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
214508167|NCT00968695|DRUG|Albumin|The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
214691402|NCT00551824|DRUG|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
215029175|NCT00488293|PROCEDURE|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
215103591|NCT00915551|DRUG|Vehicle Gel|once daily for 3 consecutive days
215103592|NCT00187525|DRUG|Memantine|
215103593|NCT02820025|DRUG|doxapram|
215024928|NCT06687512|OTHER|SaaTwae Bio-Natural Moisturizing Cream|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
215024929|NCT06687512|OTHER|Placebo|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
215024930|NCT06688591|OTHER|Intervention programme to optimise medication management and prevent MRPs|The intervention is based on a four-step patient empowerment process: 1) the patient understands their role; 2) the patient acquires sufficient knowledge to be able to engage with their healthcare professionals; 3) the patient improves their skills; and 4) there is a facilitating environment (30). Each older adult participant's plan will be unique and consider their preferences, medication literacy and treatment adherence.
214423667|NCT03203798|PROCEDURE|Hipopressive abdominal gymnastics|The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
214423668|NCT01359371|BEHAVIORAL|Peer telephone cessation counseling|For Veterans who received the inpatient Tobacco Tactics intervention, trained volunteers initiated follow-up telephone cessation counseling at 2, 14, 21 and 60 days after in-patient discharge; three attempts were made per time point.
215024931|NCT06688825|BEHAVIORAL|Education regarding Weight loss|Per American Association of Clinical Endocrinology (AACE) guidelines
215024932|NCT06688825|BEHAVIORAL|Lifestyle tools for weight loss|Calorie App, Continuous GlucosWe Monitor (CGM), Weight Scale, Food Scale
215024933|NCT06688825|BIOLOGICAL|Blood draw|Per American Association of Clinical Endocrinology (AACE) guidelines
215024934|NCT06690645|OTHER|Exposure: psychological stress status|The assessment of depressive, anxiety or perceived Stress was conducted using PHQ-9, GAD-7 or PSS scale. Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 or a PSS score ≥ 20 were categorized as the stressed group.
215024935|NCT06691711|BEHAVIORAL|ASPIRE support package|The ASPIRE support package has a modular structure with core modules that all participating families are encouraged to complete initially, followed by optional modules which the family is supported to select from according to their strengths and needs. Core modules provide psychoeducation for the caregiver and optional modules contain information on the selected positive psychology topic together with instructions for suggested activities to be completed by the caregiver with their child to implement evidence-based positive psychology strategies. All resources can be accessed both electronically via an online portal or via the printed resource pack. Each caregiver is supported through the programme by a trained practitioner who offers regular support sessions (up to 8 in total) to provide information, advice and encouragement. Support sessions can take place face-to-face, by video call or over the phone according to participant preference.
215024936|NCT05004987|DRUG|Escitalopram Oxalate|The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
215024937|NCT05004987|DRUG|Placebo|Daily dose of placebo will mimic that of ESC.
215024938|NCT06686069|DIETARY_SUPPLEMENT|bioarginina zero|treatment
215024939|NCT06686069|DIETARY_SUPPLEMENT|Placebo|absence of treatment
215029176|NCT02093273|BIOLOGICAL|tOPV pilot batch|the tOPV vaccine is given orally
215029177|NCT02093273|BIOLOGICAL|tOPV commercial batch|tOPV vaccine is given orally
215029178|NCT04179084|DRUG|fruquintinib|5mg qd, 2weeks on, 1week off
215103594|NCT02820025|OTHER|saline|
215103595|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
214423669|NCT01897298|BEHAVIORAL|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
215103596|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
214423670|NCT04948593|PROCEDURE|Native kidney biopsy|
215029179|NCT04179084|DRUG|Sintilimab|200mg q3w
214423671|NCT04204720|DEVICE|needle (Chiba)|intravascular injection using chiba needle during caudal epidural block
215029180|NCT05802134|DIETARY_SUPPLEMENT|Fruit and vegetable supplement|Weekly food kits including culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) and staple items to support DASH diet compliance
215029181|NCT05802134|BEHAVIORAL|Dietary and chronic disease management education|Intensive education for chronic disease management: participants will receive education on hypertension management, which will include an interprofessional health appointment with a medical professional to discuss medication compliance, and resources from an occupational therapist for chronic disease management strategies, and 2 nutrition appointments with a Registered Dietitian regarding the DASH Diet (initial education and follow-up at 2 weeks)
215103597|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
214691403|NCT03065634|BEHAVIORAL|Return to work and living healthy after head and neck cancer|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions. The individual sessions aim to improve work ability, quality of life and psychological well-being
214691404|NCT03065634|BEHAVIORAL|socio-legal counseling|"Non-manualized socio-legal counseling~two socio-legal counseling sessions delivered by a social worker"
215024940|NCT01851226|PROCEDURE|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
215024941|NCT02841631|GENETIC|HPV status and typing of tissue|HPV status and typing of tissue
215024942|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
214691405|NCT02422550|DEVICE|MRI or CT|Participants enrolled on this protocol may undergo multiple MRI or CT examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
214691406|NCT01064466|DRUG|ETOPOSIDE - Usual|Etoposide Capsule
214508168|NCT01670474|DRUG|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
214691407|NCT01064466|DRUG|ETOPOSIDE - Study|China Import Etoposide Capsule
215024943|NCT00280488|BEHAVIORAL|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
214691408|NCT06973642|DEVICE|Software as a Medical Device (WizeCare)|Telehealth services will be provided through a telerehabilitation platform with AI capabilities and markerless motion capture.
214691409|NCT03644277|OTHER|Acute Intermitted Hypoxia|Subjects will be fitted with a latex-free full non-rebreather mask with a custom neoprene head strap, mask and oxygen delivery system are commonly used for altitude training. The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask.
214691410|NCT03644277|PROCEDURE|Massed Practise|"Address gross upper extremity movements, grip and pinch strength, and coordination.~Tasks utilized may include, but are not limited to: lifting a weighted can, squeezing, cutting paper, popping bubble wrap, translating different resistance clothespins, etc. The ultimate goal of the session is to achieve a total of 300 repetitions during training. Task difficulty may be progressed (making it more difficult), if the participant is able to achieve \>100 repetitions in less than 15 minutes, on two different occasions. A task may be made easier if the participant is unable to achieve 50 repetitions of a task within 15minutes. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for a task to be deemed successful, increasing/decreasing the size of the object used. The number of total repetitions and any item progressions will be recorded."
214694203|NCT03076047|DEVICE|end-tidal CO2 (ETCO2) monitoring|monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2, Capnostream, and Massimo
215024944|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
215024945|NCT05723380|PROCEDURE|Erector spinae plane block|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
215024946|NCT05472987|PROCEDURE|Ventral Hernia Repair|Patients will undergo retromuscular ventral hernia repair
215024947|NCT04017455|DRUG|Atezolizumab|3 cycles of atezolizumab 840 mg
215024948|NCT04017455|DRUG|Bevacizumab|3 cycles of bevacizumab 5mg/kg
215024949|NCT05145387|BEHAVIORAL|Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)|Students randomized to TEAMSS will receive reading materials on transitioning to middle school and a a school tour with the middle school clinician (in 5th grade) and the TEAMSS group sessions (in 6th grade) delivered over 10 weeks. During the 10 weeks of TEAMSS, parents of students will attend two group meetings and clinicians will consult with at least one teacher (usually the advisory/homeroom teacher).
215103598|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
215103599|NCT00235716|DRUG|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
215103600|NCT05607862|OTHER|Home Physiotherapy Group|The intervention group will receive 2 sessions per week for 8 weeks supervised and assisted by a physiotherapist at the patient's home. Muscle strengthening exercises of the lower and upper limbs, stretching, coordination and balance exercises, gait re-education with the relevant technical aids, a pattern of exercises to be performed daily by the patient and health education guidelines will be carried out.
214694204|NCT05056467|PROCEDURE|Induction of Labor|Induction of Labor at 39 weeks of gestation
214694205|NCT00149604|DRUG|conjugated estrogens|
214694206|NCT00149604|DRUG|Raloxifene|
214694207|NCT00149604|BEHAVIORAL|exercise plus mild caloric restriction for weight loss|
214691411|NCT03644277|OTHER|Rapael Glove|The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement and hand function during a 45 minute session. Additional time may be required for device set up and activity selection/modification. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. Tasks will be modified based on participants' perceived fatigue and challenge levels, as determined by a rating from 0-10. The participant goal will be to maintain the task difficulty between a 5-8/10 range. This would depict a moderate to difficult task rating, but an ability to complete the task. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for task success, and increasing the duration of contraction. The number of total repetitions and activity outcomes will be recorded.
214691412|NCT06408025|OTHER|Syrenity App|"Currently, the Syrenity App has two active interventions. One is an exposure-based intervention called Face your fears. Another is an intervention based on behavioral activation called Get better. The app also provides self-report questionnaires for tracking mood along with psychoeducation on a variety of topics relevant to mental health."
214691413|NCT06180278|OTHER|Blood tests|Participants will have blood tests done at each scheduled visit (approximately every 6 months).
214691414|NCT06180278|DRUG|Inebilizumab|Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment at the discretion of their treating physician will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
214691415|NCT06552364|DRUG|LABA+LAMA|1 dose per day (AM)
214691416|NCT06552364|DRUG|LABA+LAMA+ICS|1 dose per day (AM)
215024950|NCT02836795|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
215024951|NCT04507581|OTHER|electrical impedance tomography during anaesthesia|Before induction of the anaesthesia, before the radiological procedure when the induction is terminated, after the termination of the radiological procedure, before transport to the Post anaesthesia Care Unite (PACU), and before the discharge from the PACU after 2 hours of monitoring ventilation distribution changes by thoracic electrical impedance tomography are measured (each measurement will last 1 min). For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated by an automated linearized Newton-Raphson reconstruction algorithm (9). Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity such as the global inhomogeneity index will be calculated as described previously, using customised software (Matlab R2013a, The MathWorks, Nattick, Massachusetts, USA)(10-12).
215024952|NCT06438003|BEHAVIORAL|Special Services|Community members will complete data collection at the extension office or community partner location. Extension cooking classes and helping to make raised bed gardens along with other area happenings will be offered to participants throughout the year with check-ins and reminders. Data will be collected from study participants (regardless of the intervention decided) , at two time points, to include survey, dietary recall, and carotenoid scanner.
215024953|NCT06438003|OTHER|Services as Usual|Community members will receive extension services as usual with Data collection on participants at two time points to assess changes in rates of food insecurity, dietary quality, and overall health conditions.
215024954|NCT05892393|DRUG|Zirconium Zr 89-DFO-YS5|Given IV
215024955|NCT05892393|PROCEDURE|Positron Emission Tomography / Computed Tomography (PET/CT)|Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image
215024956|NCT05892393|PROCEDURE|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)|Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.
215024957|NCT05892393|OTHER|Fludeoxyglucose F-18|Given IV
215103601|NCT05607862|OTHER|Control Group|The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment. All patients included in this study will receive physiotherapy treatment, and those in the control group will be treated once the intervention and the post-intervention assessment have been completed.
215103602|NCT01601262|DEVICE|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
215103603|NCT04390841|DEVICE|Cardiac Stimulator|The subjects will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
215103604|NCT01978223|PROCEDURE|Stool sample collection|Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
215103605|NCT02209896|DEVICE|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
214423672|NCT04204720|DEVICE|needle (Whitacre)|intravascular injection using whitacre needle during caudal epidural block
215024958|NCT06538012|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
215024959|NCT06538012|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
215024960|NCT06538012|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
215024961|NCT06538012|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
215024962|NCT06538012|DRUG|Pembrolizumab|Intravenous (IV) infusion
215024963|NCT05597397|DEVICE|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
215024964|NCT01197300|DRUG|Zoledronic acid|intravenous infusion
215024965|NCT05720091|DRUG|ZX-7101A 80mg|a drug to treatment influenza in Chinese adults
215024966|NCT05775042|BIOLOGICAL|CM338|CM338 injection
215024967|NCT05515575|DRUG|Niraparib|Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
215024968|NCT06479239|DRUG|EGFR FPBMC|Participants will receive 8 weekly infusions of EGFR FPBMC, then 8 additional infusions every 2 weeks.
214508169|NCT01670474|DRUG|rt-PA|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
214508170|NCT04841057|PROCEDURE|50 cm BP limb length|50 cm biliopancreatic limb length
214508171|NCT04841057|PROCEDURE|100 cm BP limb length|100 cm biliopancreatic limb length
214508172|NCT04841057|PROCEDURE|150 cm BP limb length|150 cm BP limb length
214508173|NCT00446368|DRUG|RAD001|Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
214508174|NCT03932214|DEVICE|ACCUVEIN|The nurse uses the Accuvein® device to identify the veins before puncture and then proceeds as usual, under illumination of the device.
214508175|NCT02955966|DEVICE|imaging 18F-FDG-PET/CT|18F-FDG PET Scan at Day 0, W6 and W12
214508176|NCT02955966|BIOLOGICAL|Blood collection|Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
214508177|NCT02562274|DIETARY_SUPPLEMENT|Placebo|Subjects are received placebo treatments once daily for 8 weeks
215024969|NCT04818177|DRUG|Institutional standard intravenous immune globulin treatment|No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.
215024970|NCT04021368|DRUG|RVU120(SEL120)|RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
215029182|NCT04775108|DEVICE|Epygon™ Transcatheter Mitral Valve System|"The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.~The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent."
215029183|NCT00500331|DRUG|GSK189075|Experimental Drug
215029184|NCT00500331|DRUG|pioglitazone|Active Control
215029185|NCT00500331|OTHER|Placebo|Placebo Comparator
215029186|NCT03919019|OTHER|Macuprev Group|oral supplementation (Macuprev) 2 capsules per day for 6 months
214508178|NCT02562274|DIETARY_SUPPLEMENT|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
214508179|NCT02562274|DIETARY_SUPPLEMENT|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
214691417|NCT06552364|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control
215029187|NCT03919019|OTHER|Placebo Group|oral placebo 2 capsules per day for 6 months
215029188|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Zidovudine|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
215029189|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
215029190|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Raltegravir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
215029191|NCT05192070|OTHER|Percussive Massage Group|Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
215029192|NCT05192070|OTHER|Dynamic stretching group|Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
215029193|NCT05192070|OTHER|Static stretching group|Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
215029194|NCT00057512|DRUG|M4N|Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
214691418|NCT06552364|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
214691419|NCT05071716|DRUG|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
214691420|NCT05071716|DRUG|Placebo|Placebo Twice Daily
214691421|NCT04641364|DRUG|recombinant human albumin injection|single dose or multiple doses of intravenous infusion
214691422|NCT04641364|DRUG|Placebo|Single dose intravenous infusion of 0.9% sodium chloride injection
214691423|NCT04641364|DRUG|human albumin injection|multiple doses of intravenous infusion
214691424|NCT06277154|BIOLOGICAL|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells.
214691425|NCT06277154|DRUG|Doxorubicin|Commercially approved for cancer treatment
214691426|NCT06277154|DRUG|Ifosfamide|Commercially approved for cancer treatment
214691427|NCT05674747|DEVICE|Swift Microwave treatment - weekly x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
214691428|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
214691429|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 24wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
214691430|NCT04481425|OTHER|SMS intervention|SMS intervention
214691431|NCT05610462|BEHAVIORAL|Guided Exercise Training Program|The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).
214691432|NCT05610462|BEHAVIORAL|Usual Care|Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
214691433|NCT06579833|RADIATION|Histotripsy|Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly expand and collapse, generating shock waves that disrupt the tissue. The technique is highly precise and can be targeted to specific areas of the liver, allowing for selective destruction of tumour cells while minimizing damage to healthy tissue.
214691434|NCT05954377|OTHER|Quarterly remote motivational interviews|Remote motivational interview will be in the form of quarterly telephone call (at 3, 6 and 9 months after the start of annual follow up; the patient is seen again at 12 months as part of the annual follow-up) and this for 4 years. It will be performed by medical staff trained in motivational interviewing and who have completed at least 40 hours training in therapeutic education
214691435|NCT00675974|DEVICE|Jobst Pressure Garment|Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.
214691436|NCT00675974|DEVICE|Medical Z pressure garment|Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
214691437|NCT04747483|OTHER|Extension Oriented Treatment Approach|"The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
214691438|NCT04747483|OTHER|EOTA+ Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
214691439|NCT00562003|PROCEDURE|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
215024971|NCT05385523|PROCEDURE|Rhomboid Intercostal and Sub-Serratus block technique (RISS)|The patient will be placed in lateral position. A linear ultrasound transducer of frequency 6-12 MHz will be placed medial to the lower border of the scapula in a sagittal plane. A 38-mm 22-gauge will be inserted under real-time in-plane from craniocaudal between the rhomboid major and intercostal muscles. After negative aspiration, single injection of 10 ml of the local anesthetic mixture will be administered at the T6 7 level. The spread of local anesthetic solution under the rhomboid muscle will be visualized by ultrasonography. Then the ultrasound probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscle for the sub-serratus block at T 8-9 level. The needle will be advanced from its previous position and a further of 10 ml of the local anesthetic mixture will be injected.
215029195|NCT03436732|DRUG|LMB-100|administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles
215029196|NCT03436732|DRUG|SEL-110|administered on day 1 of each cycle for up to 4 cycles
214691440|NCT00562003|DRUG|Ad5-delta24RGD|"Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.~The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'."
214508180|NCT01597674|DRUG|YF476|"There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.~Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments."
214508181|NCT06151340|OTHER|Data collection|Data collection
214508182|NCT02516709|RADIATION|Linear LDR Source|The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.
215024972|NCT05385523|PROCEDURE|General Anaesthesia|"Fentanyl (1 μg/kg), propofol (2-3mg/kg) and atracurium (0.3-0.5 mg/kg) will be injected intravenously 3-5 minutes after oxygenation. A single-lumen endotracheal tube will be used to complete ventilation. The ventilator ventilation mode is volume control mode, and the patient's end-expiratory carbon dioxide level is maintained at 35-40 mmHg throughout the anesthesia process. During the anesthesia maintenance phase, 2% sevoflurane mixed with 60% oxygen.~After general anaesthesia induction, all patients will receive RISS block with different local anesthetic drug mixture according to randomization."
215024973|NCT05385523|DRUG|dexamedatomidine|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
214691441|NCT06596369|DEVICE|Transcutaneous spinal cord stimulation|Continuous, sub motor threshold stimulation is delivered through surface electrodes placed over the cervical spine region.
214508183|NCT05594732|BEHAVIORAL|Weak outdoor light|Stay and stare far on the balcony or under the tree
214508184|NCT05594732|BEHAVIORAL|Strong outdoor light|Stay and stare far in the sunlight
214508185|NCT01959958|OTHER|Questionnaire/Interview|Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
214508186|NCT06287957|PROCEDURE|Labrida BioClean|Debriding the tissue around the implant with Labrida Bioclean
214508187|NCT06287957|PROCEDURE|EMS Handy 3.0 Perio Premium|Debriding the tissue around the implant with Air-Flow Device
214508188|NCT04748341|OTHER|Pedagogical Framework (Learn, See, Practice, Prove, Do, and Maintain)|"The Learn, See, Practice, Prove, Do, and Maintain (LSPPDM) pedagogy is acting as a guiding path for educators in teaching and learning procedural skills. It is synthesized after intensely reviewing the literature comprises steps. In the 1st step, learners learn through didactic lectures, further proceeding to see procedural videos. The 3rd step, Practice expose learners to perform the skill on a simulator. In the 4th step Prove the learner proves the skill. The 5th step Do comprise real-life exposure through the clinical rotation. Then, finally the 6th stepMaintain the learner maintains skill supplemented with simulation as needed."
214508189|NCT04748341|OTHER|Traditional Method|"The traditional method group learns through 2-step method.~1. didactic lectures on neonatal resuscitation were delivered.~2. Practice skill on mannequins"
214691442|NCT06596369|OTHER|Upper extremity rehabilitation|Using the ReJoyce system individuals will engage in upper extremity rehabilitation.
214691443|NCT06810843|DRUG|Remazolam combined with afentanil for non-intubated thoracoscopic surgery|Remazolam combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,
215024974|NCT05385523|DRUG|dexamethasone|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
215024975|NCT05385523|DRUG|saline|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
215024976|NCT04679987|DIAGNOSTIC_TEST|Holter ECG|all patients will be monitored for paroxysmal Af by holder ECG
215024977|NCT06334146|OTHER|Tap dance program|Participants will take part in a weekly adapted tap dance class, for one hour per week, for eight weeks.
215024978|NCT02811614|PROCEDURE|Endoscopic Evacuation|Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.
215024979|NCT02811614|PROCEDURE|Stereotactic Aspiration|Using image guidance to aspirate hematoma.
215103606|NCT03746041|DRUG|abaloparatide|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.
215103607|NCT03746041|DRUG|bevacizumab|In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
215103608|NCT02523573|PROCEDURE|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
215103609|NCT03036189|BEHAVIORAL|baa nnilah|7 meetings in the community led by a trained community facilitator
215103610|NCT00745433|DRUG|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
215103611|NCT00745433|DRUG|metformin|Start dose and frequency at the discretion of the physician following clinical practice
215103612|NCT03399955|DRUG|Paromomycin|Paromomycin (20 mg/kg/d) IM for 14 days
215103613|NCT03399955|DRUG|Ambisome|AmBisome® (20 mg/kg total dose) IV over 7 days
215103614|NCT03399955|DRUG|Miltefosine|Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)
215103615|NCT00006196|DRUG|Vitamin D|
214508190|NCT06131957|COMBINATION_PRODUCT|Fluoride varnish with SBGC|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA) mixed with 7.5% SBGC (Dencare (Chongqing) Oral Care Co., Ltd).
214508191|NCT06131957|DRUG|Fluoride varnish|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA)
214691444|NCT06810843|DRUG|Propofol combined with afentanil in non-intubated thoracoscopic surgery|Propofol combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,
214691445|NCT03523832|DRUG|Celecoxib and Pregabaline|Single dose versus repetition dose
214691446|NCT03523832|OTHER|Placebo|Placebo
215024980|NCT02811614|PROCEDURE|Craniotomy|Craniotomy with a big bone flap to evacuate intracerebral hematoma.
215024981|NCT02113878|DRUG|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
214691447|NCT06469762|OTHER|Dry Cupping|Dry cupping treatment session, using 4 regular plastic cups on the lumbar spine for 10 minutes.
215103616|NCT01501994|OTHER|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
214691448|NCT06469762|OTHER|Placebo Dry Cupping|Dry cupping treatment session, using 4 plastic cups with two 2 mm holes drilled in either side of them, on the lumbar spine for 10 minutes.
214691449|NCT03716232|DEVICE|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~\- Stent will be extracted endoscopically after 6 months."
215024982|NCT02113878|DRUG|Cisplatin|Cisplatin is a chemotherapy drug
214508192|NCT05591937|BEHAVIORAL|Self-Guided Online Prevention|An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
215024983|NCT02113878|RADIATION|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
215024984|NCT02988076|DEVICE|PEER Interactive Report|A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
215024985|NCT06402487|DIETARY_SUPPLEMENT|Propionic acid 1000 mg capsule|Patients will be assigned to propionic acid or placebo as add on MS treatment.
215024986|NCT06402487|DIETARY_SUPPLEMENT|Placebo|Patients will be assigned to propionic acid or placebo as add on MS treatment.
215024987|NCT02168699|OTHER|Ultrasound examination of the axilla|
215024988|NCT03461120|DRUG|Experimental continuous peripheral nerve blocks|Bupivacaine 0.3% \[or ropivacaine 0.5%\] infusions for 7 days via femoral and sciatic perineural catheters
214691450|NCT03716232|DEVICE|Multiple plastic stents|"Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
215024989|NCT03461120|DRUG|Control continuous peripheral nerve blocks|Bupivacaine 0.1% \[or ropivacaine 0.2%\] infusions for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
215024990|NCT00834574|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
215024991|NCT00834574|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
215024992|NCT00297791|PROCEDURE|surgery|randomized to open or laparoscopic technique
215024993|NCT03850067|DRUG|CC-90011|CC-90011
215024994|NCT03850067|DRUG|Cisplatin|Cisplatin
215024995|NCT03850067|DRUG|Carboplatin|Carboplatin
215024996|NCT03850067|DRUG|Etoposide|Etoposide
215024997|NCT03850067|DRUG|Nivolumab|Nivolumab
215024998|NCT05388487|DRUG|HF1K16 /Arm 45 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
215024999|NCT05388487|DRUG|HF1K16 /Arm 90 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
214508193|NCT05591937|BEHAVIORAL|Coach-Guided Online Cognitive Behavioral Therapy|An online digital therapy program that consists of online CBT modules supported by coaches through video chats. The modules are evidence-based and formatted into a unified approach for depression, anxiety and worry, panic, social anxiety, trauma and sleep dysregulation (developed as part of the University of California, Los Angeles (UCLA) Depression Grand Challenge). Lessons are designed to respond to participants' specific symptoms. Participants can access the system through any personal device (phone, tablet or computer) and speak to a certified student coach through remote video chat.
214691451|NCT00000271|DRUG|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
214691452|NCT00000271|DRUG|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
214691453|NCT03909191|DIAGNOSTIC_TEST|serum HBV RNA|serum HBV RNA level was determined by using HBV-SAT kit at different time point
214691454|NCT06420648|OTHER|Early passive mobilization|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
215025000|NCT05388487|DRUG|HF1K16 /Arm 120 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
215025001|NCT05388487|DRUG|HF1K16 /Arm 160 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
215025002|NCT05388487|DRUG|HF1K16 /Arm 120 mg or 180 mg|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
215025003|NCT04129398|DRUG|Letermovir tablet|A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks
215025004|NCT04129398|DRUG|Letermovir IV|IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks
215025005|NCT06274177|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment
215025006|NCT00198900|BEHAVIORAL|survey of information|
215025007|NCT03058952|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
215025008|NCT03058952|BEHAVIORAL|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
215025009|NCT06105255|DRUG|D-1553|D-1553 is a novel, targeted KRASG12C inhibitor.
215025010|NCT02256748|DRUG|BIRT 2584 XX|
215025011|NCT02256748|DRUG|Midazolam|
215025012|NCT01428635|DRUG|Eltrombopag Olamine|Given PO
215025013|NCT05210725|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
215025014|NCT03837509|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.
215025015|NCT03837509|BIOLOGICAL|Daratumumab SC|Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
215025016|NCT02150746|PROCEDURE|Peripheral/Central Venous Blood Draw|Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
215025017|NCT02150746|PROCEDURE|Peritoneal Wash|Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
215025018|NCT03490994|DRUG|Rivaroxaban|Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
215025019|NCT03490994|DRUG|Warfarin + LMWH|dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
215025020|NCT04473196|OTHER|weightbearing|immediate weightbearing
215025021|NCT01639690|GENETIC|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10\^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10\^6 untransduced CD34+ cells per kg will be preserved for every patient.
215025022|NCT05615883|OTHER|AEP Group Walking Sessions|The AEP Program consists in a single walking session on a treadmill lasting 80 minutes
215025023|NCT05615883|OTHER|CEP Group Walking Sessions|The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.
215025024|NCT05186233|BEHAVIORAL|Phototherapy|Light exposure recommendations provided by SHIFT mobile application
215025025|NCT05815199|OTHER|E-cigarette (EC)|Fixed dose. Participants are to use the EC as replacement for smoking combustible cigarettes. Participants will vape the EC.
215025026|NCT05815199|OTHER|Nicotine Replacement Therapy (NRT)|Includes nicotine patches and lozenges. NRT use recommendations will follow the guidelines of the product, e.g. one patch per day.
215103617|NCT01501994|OTHER|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
215025027|NCT05815199|BEHAVIORAL|Harm-Reduction Counseling|At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Up to five additional sessions will be delivered, 15\~20 minutes each.
215025028|NCT05815199|BEHAVIORAL|Ecological Momentary Intervention (EMI) Text Messaging|EMI can be defined as delivering tailored interventions via electronic messages (i.e., regular text messages) that include personalized feedback based on real-time assessment responses and other contextual factors. EMI will take place throughout the intervention period.
215025029|NCT05715320|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
215025030|NCT05584137|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
215025031|NCT05584137|DRUG|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
215025032|NCT04208256|DIETARY_SUPPLEMENT|Energy Stimulus|Energy stimulus (energy surplus v. energy neutral) will be randomly assigned at the first brain imaging visit. At the second brain imaging visit, the participant will receive the alternate stimulus from what they received at the first brain imaging visit.
214508194|NCT05591937|BEHAVIORAL|Clinician-Delivered Psychological and Psychiatric Care|Evidence-based clinician-delivered CBT modules. Participants are connected to a team of clinicians who will evaluate participants' specific symptoms and create an individualized and tailored treatment plan. Treatment will include weekly sessions delivered through telehealth, and if deemed appropriate, participants may also have medication appointments.
214508195|NCT06085989|BEHAVIORAL|Infant directed singing|In every known human culture and historical period, infant-directed singing exists as a natural feature of parental care for newborn infants. Infant-directed singing is effective in regulating infant affect and in capturing an infant's attention for a longer period than infant-directed speech. Parental stress significantly decreases when parents are encouraged to use their own voices to soothe their infants with a song or a lullaby of their choice.
214508196|NCT06085989|BEHAVIORAL|Standard care|Standard breastfeeding support to mothers with breastfeeding difficulties provided by health care professionals.
214508197|NCT00258609|DRUG|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
214508198|NCT05695469|DEVICE|Smart resuscitation glove (ResuGlove)|Participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). Participants in the ResuGlove group will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes.
215025033|NCT03755401|OTHER|TFPP|Trauma-Focused Psychodynamic Psychotherapy
215025034|NCT03755401|OTHER|TAU|treatment as usual at the VA for PTSD
215025035|NCT06062472|DIETARY_SUPPLEMENT|Probiotics|Lactobacillus paracasei PS23 will be used in this study
215025036|NCT06062472|DIETARY_SUPPLEMENT|heat-treated of Lactobacillus paracasei HT-PS23|heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use
215025037|NCT06062472|DIETARY_SUPPLEMENT|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use
215025038|NCT01251965|DRUG|Ruxolitinib|"Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I."
215025039|NCT04540380|DRUG|Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab|Conditioning regimen .Patients will receive Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Thymoglobulin
215025040|NCT04540380|PROCEDURE|Combined bone marrow and kidney transplant|Recipients will receive a conditioning regimen that includes rituximab on study days -7 and -2, fludarabine 10mg/m2/day on days -6 to -3 (4 doses), cyclophosphamide (22.5mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumabon days -1, 0, and +1. Combined kidney and bone marrow transplant will be performed on study day 0. Methylprednisolone will be started at 250 mg/day on day 0 and tapered to prednisone 20mg by day 10 after which it will be continued until day 20. Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 52 weeks following transplantation. The proportion of patients successfully weaned off immunosuppression without chimerism transition syndrome (CTS) will be assessed.
215025041|NCT06791044|DIETARY_SUPPLEMENT|DELTIUS|A treatment plan will be implemented, as applicable, consisting of 50,000 I.U of vitamin D weekly for 8 weeks
215025042|NCT06791044|DIETARY_SUPPLEMENT|DELTIUS|A treatment plan will be implemented, as applicable, consisting of 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks (totaling 8 weeks)
215025043|NCT02608385|RADIATION|Stereotactic body radiotherapy (SBRT)|Patients will receive 3 or 5 doses of SBRT to the chosen metastases.
215025044|NCT02608385|DRUG|Pembrolizumab|Pembrolizumab (200 mg) given every 3 weeks.
215025045|NCT06157983|OTHER|measurement of lipoprotein(a)|Plasma lipoprotein(a) will be measured in the biological relatives group as part of a clinical health care development project
215025046|NCT00945542|OTHER|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
215025047|NCT00945542|OTHER|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR\>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
215103618|NCT01501994|PROCEDURE|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
215103619|NCT04666194|PROCEDURE|Cold forceps|
214508199|NCT05695469|OTHER|Traditional CPR|Participants in the traditional CPR group will perform hand-only CPR without the ResuGlove and feedback guidance for 2 minutes.
214691455|NCT06420648|OTHER|Controlled active motion|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
215025048|NCT02531386|DEVICE|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
215103620|NCT04666194|PROCEDURE|Cold snare|
215025049|NCT06633991|PROCEDURE|verbal instructions|verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)
215103621|NCT04666194|PROCEDURE|Hot snare|
215025050|NCT06099366|DRUG|induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate|vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
214423673|NCT05035199|BEHAVIORAL|Spiritual Distress and Resources Questionnaire (SDRQ)|The SDRQ is a validated self-rating instrument to assess spiritual distress and resources. It focuses on beliefs, attitudes, experiences and practices of various kinds (every day and extraordinary), as well as on (dis-)connectedness. It consists of 22 items covering three subscales: spiritual resources, spiritual distress, and spiritual coping (Peng-Keller et. al., 2020, submitted). We constructed five additional questions to find out more why patients want to include spiritual aspects in their treatment.
215025051|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate
215025052|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
215025053|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate
215025054|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
215025055|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
215025056|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
215025057|NCT06099366|DRUG|Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
215029197|NCT00233168|BEHAVIORAL|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
214508200|NCT03307694|DIAGNOSTIC_TEST|Ultrasound|All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
214423674|NCT02106442|DRUG|Sodium risedronate|Sodium risedronate tablets
214423675|NCT06600685|OTHER|Functionally oriented music therapy (FMT)|There are different methods of music therapy and one of these is FMT. It is a body-based and music therapeutic treatment method that is used for health-promoting purposes. With the help of i.e. drums, cymbals, various custom-made drumsticks, flutes, chairs, balance balls and balance cushions. FMT strives to support, strengthen and develop the person's physical, mental and social abilities. FMT-sessions (20 minuets/1 time a week) are performed individuelly (a patient with a educated music therapist).
214423676|NCT05402891|DRUG|Lithium Carbonate|Patients will be administered lithiumcarbonate by an oral tablet of 300mg once a day for a duration of 6 months. Starting dose is 200mg for the first 5 days, dosage will be then increased to 300mg. To limit adverse events and side-effects, the lowest effective dose will be administered. The target serum level of lithium is 0.20 - 0.40 mmol/L and this will be maintained by regular lithium level testing.
214423677|NCT01181089|BIOLOGICAL|Placebo|
214423678|NCT01181089|BIOLOGICAL|Baminercept|
214423679|NCT06990984|DRUG|TTI-0102: cysteamine-pantetheine disulfide|TTI-0102: cysteamine-pantetheine disulfide, powder for dissolution in water for oral administration
214423680|NCT06990984|DRUG|D-Mannitol|D-Mannitol
214423681|NCT06604533|PROCEDURE|Intervention: MRI-Linac SABR|The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.
214423682|NCT06673602|DRUG|FCYC+Conventional treatment|Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment.
214508201|NCT03307694|DIAGNOSTIC_TEST|Shear wave elasticity imaging|"Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue."
214508202|NCT03307694|DIAGNOSTIC_TEST|Multi-angle compound shear wave elasticity imaging|The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
214508203|NCT00684242|DRUG|Lenalidomide|10 mg by mouth daily
214508204|NCT03085407|PROCEDURE|early cholecystectomy|cholecystectomy was done within 48 after admission
214508205|NCT03085407|PROCEDURE|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
214508206|NCT04823754|OTHER|Hospitalized patient with advanced hepatocellular carcinoma receiving systemic therapy.|"Administation of two surveys to included patients, about the perception of the disease and the expectations related to the treatment.~The physician will be asked to complete a survey on his or her perception of the prognosis and information received by the patient."
214508207|NCT00692185|DRUG|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
215025058|NCT03191734|DEVICE|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
215103622|NCT01860950|DEVICE|anodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder
215103623|NCT01860950|DEVICE|cathodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC.
214508208|NCT00692185|DRUG|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
215025059|NCT06439784|OTHER|whole body SPECT/CT|Patient will unergo a whole body SPECT/CT in treatment position
215025060|NCT02363283|DRUG|Glembatumumab Vedotin|Given IV
215025061|NCT02363283|OTHER|Laboratory Biomarker Analysis|Correlative studies
215025062|NCT02363283|OTHER|Pharmacological Study|Correlative studies
215025063|NCT04802590|DRUG|Ibrutinib 560 mg|560mg/d continuously from C1D2 to end C24
215025064|NCT04802590|DRUG|Venetoclax 10 MG Oral Tablet [Venclexta]|20mg/d from C2D1 to C2D7
215025065|NCT04802590|DRUG|Venetoclax 50 MG Oral Tablet [Venclexta]|50mg/d from C2D8 to C2D14
215025066|NCT04802590|DRUG|Venetoclax 100 MG Oral Tablet [Venclexta]|100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
215025067|NCT03261375|DEVICE|Renal Artery Radiofrequency Ablation System (Generator and Catheter )|A renal denervation system with a mesh 6-electrode radiofrequency ablation catheter and multi-channel radiofrequency generator
215025068|NCT03261375|DRUG|Antihypertensive Agents|Calcium channel blocker, Diuretic
215025069|NCT03261375|DEVICE|Sham Procedure|Catheterization without renal denervation
215025070|NCT02375711|BIOLOGICAL|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
215025071|NCT01460277|PROCEDURE|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
215025072|NCT01460277|PROCEDURE|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
214508209|NCT03510169|DEVICE|NeoVest|Negative pressure ventilation with NeoVest
214508210|NCT05407272|OTHER|Health Education Manual|A health education manual based on a shared model
214508211|NCT05407272|OTHER|manual|routine care
214508212|NCT07013942|PROCEDURE|Dry Needling Group|Group A, which will be considered the interventional group. This group will be receiving the dry needling along with the PNF techniques for spasticity and functional performance.
214508213|NCT07013942|PROCEDURE|Sham Needling Group|Group B, which will be considered the control group. This group will be receiving sham needling in addition to the PNF techniques for spasticity and the functional performance
214508214|NCT06866678|PROCEDURE|Observational Data Collection|No intervention will be performed as part of this study. This is an observational study; all patients will receive standard perioperative care according to current clinical practice. The study will only observe and record data related to frailty status and postoperative outcomes in patients undergoing elective colorectal cancer surgery. No experimental procedures, drugs, or additional interventions will be administered.
214508215|NCT06699992|DIAGNOSTIC_TEST|Blood biomarkers quantification|Blood biomarkers quantification
214508216|NCT06699368|PROCEDURE|The ultra-high-power ablation group|The ultra-high-power ablation group will use the QDOT ablation catheter with a power of 90W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g. The cold saline flow rate during ablation is 8ml/min, and the ablation device will adjust power and saline flow rate based on the electrode temperature at the tip of the QDOT ablation catheter. The target temperature is 60°C, and the cut-off temperature is 65°C, with an ablation endpoint of 4 seconds.
214508217|NCT06699368|PROCEDURE|The high-power ablation group|The high-power ablation group will use the STSF ablation catheter with a power of 50W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g, and a cold saline flow rate of 15ml/min during ablation. The ablation endpoint for the posterior wall of the left atrium is an Ablation Index (AI) value of 360-410, for the anterior wall 450-480, and for the bottom and top of the left atrium 420-450.
215025073|NCT02257138|DRUG|Decitabine|Given IV
215025074|NCT02257138|OTHER|Laboratory Biomarker Analysis|Correlative studies
215025075|NCT02257138|DRUG|Ruxolitinib Phosphate|Given PO
215025076|NCT00530257|DRUG|Placebo|Placebo (sugar pill)
215025077|NCT00530257|DRUG|OROS-methylphenidate|18 mg to 54 mg once a day for 1 week
215025078|NCT00216385|DRUG|Gatifloxacin combined regimen|
215025079|NCT06057025|BIOLOGICAL|"Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition"|"Single intramuscular injection of Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition."
215025080|NCT05867888|OTHER|conventional therapy|conventional therapy ( instructions, ice application, deep tissue massage, stretching exercises, joint mobilization and isometric exercises )
215025081|NCT05867888|OTHER|shock wave therapy|Acoustic waves (shock waves) that can carry energy and can propagate through tissues promote healing effects.
215025082|NCT05867888|OTHER|low level laser therapy|The application of light to a biologic system to promote tissue regeneration, reduce inflammation and relieve pain.
215103624|NCT01860950|DEVICE|sham tDCS|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session
215103625|NCT00467233|PROCEDURE|Laser Treatment|Laser treatment to half of the face at each study visit
214508218|NCT06410846|DEVICE|TopSpin360|Neck strength and conditioning device used during neck strengthening program.
215025083|NCT06184087|OTHER|Educational/Instructional|ICAP constructive-interactive engagement mode
215025084|NCT00000845|BIOLOGICAL|P3C541b Lipopeptide|
214508219|NCT06410846|OTHER|Neck Strengthening Exercise Plan|Physical therapist designed neck strengthening program.
214508220|NCT07052760|DRUG|111In-ABD147|Given intravenously (IV) prior to imaging
214508221|NCT07052760|PROCEDURE|Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)|Undergo imaging
214508222|NCT07052773|DEVICE|Lung Cancer Detection System (LCDS)|An AI-based decision support software designed to detect solid pulmonary nodules on LDCT chest scans. In this study, the LCDS is applied retrospectively to 100 previously acquired LDCT scans, and its performance is compared to a ground truth established by double-read radiologist reports with arbitration.
214508223|NCT07090447|BEHAVIORAL|Nutrition in Cirrhosis guide|"Patients in the intervention group received a paper copy of the Nutrition in Cirrhosis guide and were instructed to read and use it over the 6 months study period. The Nutrition in Cirrhosis guide consists 7 chapters, namely:~Chapter 1: Malnutrition - What is it and why is it so important?; Chapter 2: What should patients eat and what to avoid?; Chapter 3: Tips for when patients do not feel like eating; Chapter 4: Recipe list; Chapter 5: Using meal supplements; Chapter 6: Managing weight loss and cirrhosis; Chapter 7: What to expect in the hospital."
214508224|NCT07098221|DIETARY_SUPPLEMENT|Molecular Hydrogen|Participants in this arm will consume a single 250 mL dose of hydrogen-rich water containing approximately 1.6-2.0 ppm of dissolved molecular hydrogen (H₂), The HRW will be ingested following an overnight fast, and resting metabolism will be measured approximately 30-60 minutes post-consumption using indirect calorimetry.
214508225|NCT07098221|DIETARY_SUPPLEMENT|Placebo Comparator|Non-hydrogen-producing tablets, identical in appearance and taste to the active supplement
214508226|NCT07098364|BIOLOGICAL|Vevoctadekin|Given SC
214508227|NCT07098364|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
214508228|NCT07098364|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
214508229|NCT07098364|PROCEDURE|Computed Tomography|Undergo CT
214508230|NCT07098364|PROCEDURE|Echocardiography Test|Undergo ECHO
214508231|NCT07098364|PROCEDURE|Leukapheresis|Undergo leukapheresis
214508232|NCT07098364|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
214508233|NCT07098364|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
214508234|NCT07098364|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy
214508235|NCT07098364|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
214508236|NCT07098364|PROCEDURE|Positron Emission Tomography|Undergo PET scan
214508237|NCT07098364|PROCEDURE|X-Ray Imaging|Undergo x-ray
214508238|NCT07098364|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
214508239|NCT07098793|DEVICE|Cough monitoring|continuous recording of cough in patients sleeping area for 90-180 days
214508240|NCT06400732|DEVICE|Fitbone Transport and Lengthening System|Implantation of the intramedullary Fitbone Transport Nail and subsequent bone segment transport and, optionally, lengthening.
214691456|NCT00399984|BEHAVIORAL|Asthma Education Program|interactive seminars regarding daily inhaled corticosteroids
214691457|NCT02426411|DRUG|EMA401 200 mg|
214691458|NCT02426411|DRUG|EMA401 600 mg|
214691459|NCT02426411|DRUG|Placebo|
214691460|NCT01893190|DRUG|Nimodipine|Based upon Investigator Judgement
214691461|NCT01893190|DRUG|Nimodipine Microparticles|Based upon Investigator Judgement
215025085|NCT03428347|BIOLOGICAL|GamEMab|drug for emergency prevention of Ebola based on recombinant monoclonal antibodies
215025086|NCT03457662|COMBINATION_PRODUCT|OMC and pseudo-SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
215029198|NCT00233168|BEHAVIORAL|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
215029199|NCT03345550|DRUG|Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
215029200|NCT03345550|DRUG|Placebo - Cap|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
215029201|NCT05179577|DRUG|Arbaclofen|Arbaclofen Extended Release Tablets
215029202|NCT05179577|DRUG|Placebo|Placebo tablets
215029203|NCT04200963|DRUG|IK-175|Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
215029204|NCT04200963|DRUG|IK-175 and nivolumab|Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
215029205|NCT01760863|OTHER|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
215029206|NCT01631500|BEHAVIORAL|Conventional treatment|Conventional treatment
215029207|NCT01631500|OTHER|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
215029208|NCT01631500|OTHER|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
215025087|NCT03457662|COMBINATION_PRODUCT|OMC and SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
215025088|NCT06380907|DRUG|ZL-1102 1% w/w gel BID for 16 weeks|"ZL-1102~1% w/w gel BID for 16 weeks"
215025089|NCT06380907|DRUG|ZL-1102 3% w/w gel BID for 16 weeks|ZL-1102 3% w/w gel BID for 16 weeks
215025090|NCT06380907|DRUG|ZL-1102 3% w/w gel QD for 16 weeks|ZL-1102 3% w/w gel QD for 16 weeks
215025091|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel BID for 16 weeks|Vehicle 0% w/w gel BID for 16 weeks
215025092|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel QD for 16 weeks|Vehicle 0% w/w gel QD for 16 weeks
215025093|NCT05272488|OTHER|Manual therapy and vagus nerve stimulation|A neurodinamic intervention of vagus nerve through deep breaths involving diaphragm muscle and manual therapy techniques.
215025094|NCT05272488|OTHER|Manual therapy|Manual therapy techniques. Joint manipulation techniques for temporomandibular joints and Soft tissue techniques for the muscles
215025095|NCT00071994|DRUG|gefitinib|Given orally
214423683|NCT06673602|DRUG|conventional treatment|The control group will receive the current gold standard treatment for ICH according to the guidelines (AHA/ASA 2022). This involves blood pressure and care.
214423684|NCT06676956|PROCEDURE|Order of bronchoscopy procedures for peripheral nodule biopsy|Patient scheduled to undergo peripheral nodule biopsy of the lung under bronchoscopy typically get both a nodule biopsy as well as a linear EBUS of the lymph nodes to assess for any disease spread. This procedure will randomize patients to either getting the peripheral nodule first or linear EBUS of the lymph nodes first and assess overall diagnostic yield as the primary outcome.
214423685|NCT06676111|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)
214423686|NCT06676111|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)
215025096|NCT00071994|OTHER|laboratory biomarker analysis|Correlative studies
215025097|NCT02473302|OTHER|ham|160g per day during 4 days
215025098|NCT02473302|OTHER|ham + pomegranate extract|160g per day during 4 days
215025099|NCT02473302|OTHER|ham + tocopherol|160g per day during 4 days
215025100|NCT02473302|OTHER|rare sirloin steak|110g per day during 4 days
214423687|NCT03134235|OTHER|Dietary Intervention|Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
214423688|NCT00634452|BIOLOGICAL|MDX-1401|IV weekly for 4 weeks
214423689|NCT06628427|DIAGNOSTIC_TEST|MoCA Test|MoCA (Montreal Cognitive Assessment or The MoCA Test) was validated as a highly sensitive tool for early detection of mild cognitive impairment (MCI) in hundreds of peer-reviewed studies since 2000. MoCA has been widely adopted in clinical settings and used in academic and non-academic research around the world. The sensitivity of MoCA for detecting MCI is 90%, compared to 18% for the MMSE. Prospective participants meeting the eligibility criteria, as determined by the Montreal Cognitive Assessment (MoCA) test, will be invited to the Brain- Computer Interface (BCI) laboratory at the Kroto Research Centre on the University of Sheffield north campus to participate in the study.
214691462|NCT00880672|DRUG|dutasteride|5mg, oral, daily, 2-4 weeks
214691463|NCT06177782|DEVICE|Tooth modified scan bodies|Tooth modified scan bodies are used during scanning for full arch implant cases.
214691464|NCT06177782|DEVICE|Conventional scan bodies|Conventional scan bodies will be used for scanning the full arch implant cases.
214691465|NCT03472378|DRUG|DFN-15|Oral Solution of 4.8 mL containing 120 mg of DFN-15
214691466|NCT03472378|OTHER|Placebo|Oral Solution of 4.8 mL containing 0 mg of DFN-15
215025101|NCT02473302|OTHER|marinated rare sirloin steak|110g per day during 4 days
215025102|NCT02473302|OTHER|marinated cooked sirloin steak|110g per day during 4 days
215025103|NCT00569075|OTHER|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
215025104|NCT01897896|DRUG|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
215025105|NCT02002858|DRUG|Nicotine Patch|
215025106|NCT02002858|BEHAVIORAL|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
215025107|NCT02002858|BEHAVIORAL|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
215025108|NCT05708508|DRUG|ROVALCYTE|"Immuno-guided strategy arm"
215025109|NCT03517800|OTHER|Arterial embolization and/or surgical management.|Arterial embolization and/or surgical management.
215025110|NCT04519138|DEVICE|Endodrill Model X|The investigational device Endodrill Model X is used for biopsy sampling in the upper gastrointestinal tract
215025111|NCT04519138|DEVICE|Fine-needle aspiration/biopsy|The standard method is used for biopsy sampling in the upper gastrointestinal tract
215029209|NCT03464552|DRUG|Celecoxib 200mg|oral capsule 3 hours before procedure
215029210|NCT03464552|PROCEDURE|Colposcopic guided biopsy|Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
215029211|NCT03464552|DRUG|Placebo oral capsule|oral capsule 3 hours before procedure
215029212|NCT03158246|DRUG|Generic Zoledronic Acid|Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
215029213|NCT03158246|DRUG|Original Zoledronic Acid|Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
215029214|NCT03158246|DIETARY_SUPPLEMENT|calcium|600mg/d calcium for oral daily
215029215|NCT03158246|DIETARY_SUPPLEMENT|vitamin D|925IU/d vitamin D for oral daily
215029216|NCT06571643|OTHER|Lower Abdomen MRI|The patients will undergo a lower abdomen MRI to assess the size of the psoas muscle and derive the PMI
215025112|NCT02895984|BEHAVIORAL|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
215103626|NCT00467233|PROCEDURE|Acid Peel|Acid peel to half of the face at each study visit
214423690|NCT06628427|DEVICE|Random Dot Motion (RDM) task|Random Dot Motion task (RDM) has been widely used in research on spatial attention, and decision-making ability, etc., and its results (accuracy and reaction time) can be used as indicators to detect spatial attention. During the assessment, participants were required to monitor a series of dots in constant random motion on the screen. The dots sometimes moved coherently together to the left or right, and participants were required to press the left mouse button when they perceived them moving to the left and the right mouse button when they observed them moving to the right. We are going to use the motion coherence level of 50%. The higher the coherence level, the greater the number of dots moving together, and the combination of the moving direction and coherence level of the dots appear randomly during the task.
215025113|NCT06230913|DEVICE|Kinesiotape|To perform taping of the chest, the patient was asked to stand upright with the affected shoulder rotated externally. Five straps of the fan shaped tape were extended to the chest toward the affected axilla with 15% to 20% tension, and the anchor was positioned without tension in the anterior axilla on the sound side.
215025114|NCT06230913|DEVICE|Pressure garment|The skin was washed and dried before applying the PG. The Premium Lymphedema Gradient Garment (Jobskin, Long Eaton, England) was used to apply PGs. This garment has a pressure gradient built into it, applying between 20 and 60 mm Hg for at least 15 to 18 hours each day for three weeks. The gradient counter pressure is applied using a gram tension.
215025115|NCT00781898|DRUG|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
215025116|NCT00781898|OTHER|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
215025117|NCT02869009|DRUG|clopidogrel|
214508241|NCT06945796|OTHER|ACT based eating disorder prevention program|"This intervention protocol was developed specifically for women who have body dissatisfaction and disordered eating behaviors. Based on the psychological flexibility model (hexaflex), it is designed to improve people's body image flexibility using Acceptance and Commitment Therapy techniques.~Interventions related to the dimensions of the hexaflex were made during each session. The first session covers values and goal setting. The second session includes creative hopelessness, acceptance, and self-compassion. The third session covers defusion and mindfulness. The last session focuses on self-as-context exercises and the combined use of skills for committed action."
215025118|NCT02869009|DRUG|Aspirin|
215025119|NCT01791179|BEHAVIORAL|Comprehensive substance abuse services|
215025120|NCT05527769|PROCEDURE|mastectomy + immediate breast reconstruction|pre- or retro pectoral prosthesis
215025121|NCT03151668|DRUG|Dexmedetomidine|
215025122|NCT02090530|OTHER|Biospecimen collection|Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
215025123|NCT01266200|PROCEDURE|Mantis|percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
215025124|NCT01266200|PROCEDURE|XIA|Treatment of the fracture with Xia and conventional operation technique
215103627|NCT05316506|OTHER|Anticipated Discomfort Language|This language involves pain descriptors provided from physician to patient during procedure.
215103628|NCT05316506|OTHER|Objective Descriptive Language|This language involves neutral/objective descriptors provided from physician to patients during procedure.
214508242|NCT04476199|COMBINATION_PRODUCT|Venetoclax and Decitabine|The prognosis of acute myeloid leukemia (AML) patients aged over 60 years is poor and allogeneic stem cell transplantation (allo-SCT) is the only curative option.The association VEN-DEC is a promising combination therapy for AML elderly patients who are fit and eligible for allo-SCT.
214508243|NCT03616886|DRUG|Paclitaxel|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
214508244|NCT03616886|DRUG|Carboplatin|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
214508245|NCT03616886|DRUG|MEDI4736|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
214508246|NCT03616886|DRUG|MEDI9447|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
215025125|NCT01140932|DRUG|Prednisolone|12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
215025126|NCT01140932|BEHAVIORAL|Lifestyle change|High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
215025127|NCT00353119|DRUG|Placebo comparator|Patients received placebo subcutaneously twice weekly
215025128|NCT00353119|DRUG|Etanercept|Patients received etanercept 50 mg subcutaneously twice weekly
215025129|NCT04096677|PROCEDURE|hysteroscpy|
215103629|NCT04108806|PROCEDURE|Endovascular therapy|Ballon dialtation of the diseased artery
214508247|NCT05643534|DRUG|Tenapanor 50 MG|Participants will receive tenapanor 50 mg BID (total of 100 mg daily)
214508248|NCT05643534|DRUG|Tenapanor 25 mg bid|Participants will receive tenapanor 25 mg BID (total of 50 mg daily)
215025130|NCT01596023|DEVICE|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
215025131|NCT05315778|BIOLOGICAL|autologous anti-BCMA chimeric antigen receptor T cells|Lymphoadenodepletion chemotherapy with FC (fludarabine 30mg/ m2 for 3 consecutive days and cyclophosphamide 300mg/m2 for 3 consecutive days) will be given at day -5, -4 and -3 before CAR T-cells infusion. A total of 1.0-2.0×10e7/Kg autologous anti-BCMA CAR T-cells will be infused by dose-escalation after the lymphoadenodepletion chemotherapy. Dose of CAR T-cells are allowed to be adjusted according to the severity of cytokine release syndrome.
215025132|NCT02970058|OTHER|Platelet-rich Plasma|The active group will receive Platelet-rich Plasma following spinal injection
215025133|NCT02970058|OTHER|Control|The control group will receive saline as a placebo
215025134|NCT03318627|DEVICE|Sterile Spring Scale|Measuring intraoperative tension of tendon of rotator cuff tear
215025135|NCT00459550|DRUG|GSK933776|"Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg"
215025136|NCT00459550|DRUG|Placebo to match GSK933776|Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
215025137|NCT00698412|DEVICE|Cane|This group use the cane every day since the baseline
214423691|NCT06628427|DEVICE|P300-BCI task without feedback|Two different speller matrix sizes: 3×3 and 5×5, two inter-stimulus intervals (ISIs): 117ms (i.e., commonly used ISI for healthy adults) and 175ms (i.e., 50% longer than the widely used ISI) and two spelling words (QUICK and JUMP) are designed in this experiment to explore the calibration accuracy of these eight parameter combinations in the young and old groups and obtain the best parameter combination. The matrix contains letters and digits, and the target letters will be displayed below the matrix letter by letter. When the speller runs, the rows and columns in the matrix will flash 15 times each randomly. Each flash will last for 55ms, and the subsequent ISI will last for different times according to different parameter designs. Participants only need to focus on the target letter and silently count the number it flashes, as flashing target letters can generate P300 if well attended.
214423692|NCT06631664|OTHER|Traditional physical therapy|Participants received a traditional physical therapy program three times a week, for three successive months. Each session lasted for approximately 30 minutes and composed of the following: 1) Massage (spiral effleurage, longitudinal and transverse thumb effleurage for 5 minutes or until hyperemia), 2) Facilitation of muscle contraction through a variety of tactile and proprioceptive stimulation techniques - this was applied for the shoulder flexors, abductors, and external rotators, elbow flexors, and wrist/finger extensors. In patients whose lesion extend to involve C7, The facilitation techniques were also applied to elbow extensors. 3) Weight-bearing exercise, considering the developmental milestone (prone forearm support, prone full hand support). 4) Range of motion exercises - all joints of the affected side were moved through the full range of motion. 5) Sucking exercise.
214423693|NCT06631664|DEVICE|A computerized electrical stimulator (Vectra®2C; Chattanooga, TS, USA)|"The patient was positioned in supine lying position with the affected arm beside the body and elbow extended, the skin over the anterior and posterior comportment of the upper arm was cleaned using medical cotton sacked in alcohol before the application.~The first two stimulating electrodes for the biceps muscle were placed at the superior and inferior 1/3 of anterior surface of the upper arm with a distance in between the two electrodes at least the size of one of them, while the other two electrodes for the triceps muscle were placed at the superior and inferior 1/3 of the posterior surface of the upper arm.~One millisecond pulse duration and a frequency of 50Hz with a rectangular shaped pulse were utilized and stimulation was applied for 15 minutes. At first a low-intensity current is applied and gradually increased till a gentle contraction of the muscles appears and allow time for the child to become accustomed to the current and maintained sufficient and observable contraction."
214423694|NCT06630065|BEHAVIORAL|fMRI with emotional task and pupillometry|"Anatomical and functional magnetic resonance imaging (fMRI) imaging sequences with pupillometry (\~90 min)~A functional sequence - Task (\~20min):~* Emotional task in fMRI: Instructions: simply look images, then evaluate the emotions triggered at the end of each block; rating on a valence and intensity scale and intensity (arousal) scale.~* Experimental conditions: positive, negative and neutral~* Paradigm: block validated image banks: IAPS, GAPED, EMOPICS, OASIS, etc. Pupillometry: In order to collect objective data on emotional bias, we will use pupillometry (or eye-tracking) during functional MRI sequences."
214423695|NCT06630065|BEHAVIORAL|Behavioral task with emotional facial expressions|Description of the recognized emotion joy - sadness. Test to assess the hedonic value of an olfactory stimulus (10 min)
214423696|NCT06630065|GENETIC|Biological investigation|Standard biological assessment, immuno-inflammatory profile and the association of 8 mRNA editing variants
214423697|NCT06631014|DIAGNOSTIC_TEST|Early Rehab|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation.
214423698|NCT06631014|COMBINATION_PRODUCT|Delayed Rehab|The 2nd group of 25 patients that was fitted with Prosthesis after the time period of 6months after amputation. No physical rehab was done during this time period including physiotherapy and prosthetic treatment. Main aim was to check the significant impact of delayed rehabilitation.
214423699|NCT06632106|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
214423700|NCT06632106|DRUG|Tyrosine kinase inhibitor (TKIs)|TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab
214423701|NCT06632106|DRUG|Immune Checkpoint Inhibitors|ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab
214423702|NCT03911245|OTHER|Retrospective study. Analyze of data in medical records|Retrospective study. Analyze of data in medical records
215025138|NCT02771327|DEVICE|CPAP plus Gas|
215025139|NCT02771327|DEVICE|ventimask plus gas|
215025140|NCT05314387|DEVICE|SMR TT Hybrid Glenoid without Cementless Finned Short Stem|The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.
215029217|NCT06570538|DRUG|Ropivacaine|300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL/h of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.
215025141|NCT05314387|DEVICE|SMR TT Hybrid Glenoid with Cementless Finned Short Stem|"The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation."
214694208|NCT02499003|DRUG|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
215025142|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfate oral solution to 500ml and intake 12-14 hours before colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
215025143|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfates oral solution to 500ml and intake 16-18 hours before the colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
215025144|NCT04359329|DRUG|Estradiol patch|Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
215029218|NCT06570538|DRUG|Sufentanil|Sufentanil 2.0 μg/kg, 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
215029219|NCT06570564|DEVICE|The arm crank ergometer|Before starting the program, patients will perform an adaptation session for familiarization with the ergometer and also to identify the training load. For this, patients will perform 10 bouts of two minutes of exercising with a minimum load and two minute passive intervals between bouts. Patients will be instructed to maintain 50 revolutions per minute (RPM) during the exercise. Subsequently, to determine the training load for each session, patients will perform a progressive test where the load will be increased by 10 watts every minute of the test, following the protocol of two minutes of exercise with two minutes of interval
215029220|NCT06570564|DEVICE|bicycle ergometer|bicycle ergometer program will consist of a bicycling exercise 3 days per week. Exercise intensity was set at 70% of maximal load with 30 minutes per session. The exercise protocol also incorporated warm-up and cool-down sessions that involved stretches of the major lower limb muscle groups (total exercise time, 40-60 minutes)
215029221|NCT06570564|DEVICE|treadmill|Supervised treadmill exercise as routine physiotherapy program
215029222|NCT05380700|DEVICE|Virtual Reality Stimulation|Participants in the intervention group will be provided with up to 30 minutes of relaxing, 360-degree virtual reality (VR) stimulation and corresponding sounds, twice in 24 hours during their stay on the intermediate care unit.
215029223|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 1; small patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
214508249|NCT05643534|DRUG|Placebo|Participants will be randomized to receive matching placebo
214508250|NCT00768716|DRUG|Acetaminophen|2 x 500 mg by mouth once
214508251|NCT04528147|BEHAVIORAL|Yi Jin Jing Tiger Roaring Speech Rehabilitation|A traditional Chinese medicine treatment
214508252|NCT04528147|BEHAVIORAL|Conventional Speech Rehabilitation|A active speech rehabilitation method recommended by the Parkinson's Foundation of America
214508253|NCT06001593|DEVICE|YPS-201b|electrical stimulation device.
214508254|NCT06001593|DRUG|betahistine|Relieve symptoms of balance disorders or dizziness
214508255|NCT06001593|DEVICE|YPS-201b|sham electrical stimulation device.
214508256|NCT04560049|DRUG|Silver Nitrate|application of silver nitrate to sinus tract
214508257|NCT04560049|DRUG|Phenol|phenolisation of sinus tract
214508258|NCT06237465|DRUG|Normal saline|Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
214508259|NCT06237465|DRUG|Botulinum toxin type A|Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
214508260|NCT03753256|DEVICE|Transbond XT|"Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants."
214508261|NCT03753256|DEVICE|Protecto®CaF2Nano|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
214508262|NCT03753256|DEVICE|Pro Seal®|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
214508263|NCT03753256|DEVICE|Opal®Seal|"Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
214508264|NCT04614688|BEHAVIORAL|Patient Education Platform|The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
215025145|NCT01458457|OTHER|Individualized complementary medicine treatment|An individual treatment plan will be made for each patient that includes one to all of the following treatments: acupuncture, traditional Chinese herbal medicine, enzyme therapy, nutrition advise, Healing Touch, homoeopathy, hyperthermia treatment, infusions, laser therapy, lymphatic drainage, manual therapy, mistel therapy, neural therapy, orthomolecular therapy, osteopathy, phytotherapy, shiatsu
215025146|NCT01458457|OTHER|Individualized usual care|Patients get usual care from their general practitioners/specialized physicians
214691467|NCT03860311|DEVICE|Bladder Ultrasound|"Bladder fullness will be assessed upon enrollment and if not full, the patient will receive hydration, determined by treating physician, and the bladder ultrasound will be repeated every 30 minutes until the patient states that the bladder is full, or until bladder is deemed full based on a previously validated bladder fullness qualitative scale, at which point patients in this group will proceed to undergo pelvic ultrasound."
215025147|NCT00292903|BEHAVIORAL|Brief interpersonal psychotherapy|IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
214691468|NCT03860311|OTHER|Standard of Care|Per institution protocol, patients in the standard of care group will have urethral (bladder) catheter placed immediately after the order for pelvic ultrasound and will undergo retrograde bladder filling as determined by the radiologist/ultrasonographer to the point necessary to fully visualize pelvic structures.
215025148|NCT00292903|BEHAVIORAL|Facilitated referral for treatment as usual|F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
215025149|NCT01879826|DEVICE|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
215025150|NCT01879826|DEVICE|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
215025151|NCT03816579|OTHER|PRO-A|30 g of beef protein will be consumed at each meal
214691469|NCT03119116|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
215025152|NCT03816579|OTHER|PRO-B|30 g of complementary proteins will be consumed at each meal
215025153|NCT03816579|OTHER|PRO-C|30 g of complementary proteins will be consumed over 24 hours
215025154|NCT00057798|DRUG|gemcitabine hydrochloride|
215025155|NCT00057798|DRUG|vinorelbine ditartrate|
214423703|NCT06697873|OTHER|Experimental Group: A|21 participants will receive both Rhythmical stabilization and closed chain kinetic exercise followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes
215025156|NCT00057798|GENETIC|cytogenetic analysis|
215025157|NCT00057798|GENETIC|loss of heterozygosity analysis|
215025158|NCT00057798|GENETIC|microarray analysis|
215025159|NCT00057798|PROCEDURE|conventional surgery|
215025160|NCT00057798|PROCEDURE|neoadjuvant therapy|
215103630|NCT01204216|BIOLOGICAL|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
214423704|NCT06697873|OTHER|Experimental: Group B|21 participants will receive Rhythmical stabilization training program followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes.
214423705|NCT06714162|DIETARY_SUPPLEMENT|Longevity pill|vitamins and herbs
214423706|NCT01230047|BEHAVIORAL|Psychoeducational course|Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
214691470|NCT03119116|DRUG|Dabigatran|Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
214691471|NCT03119116|DRUG|Apixaban|Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
215025161|NCT02512939|PROCEDURE|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
215025162|NCT04431063|PROCEDURE|Distal Stump Suturing|in ACL Reconstruction case , Group A consist of subject with operation procedure suturing the distal stump peroneus longus against the peroneus brevis in ACL reconstruction using the peroneus longus autograft.
215025163|NCT04781842|OTHER|Boxing exercise program|Participants attended an hour long class once a week for 12 weeks. Included in class was a warm up, boxing activities including weight shifting, kicking, and punching bags, strengthening activities and a cool down.
214423707|NCT05756504|DRUG|Ketorolac|Injection ketorolac 30 mg IV x TDS will be given to each patient in each group.
214691472|NCT03118531|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)|The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
214691473|NCT03930953|DRUG|CC-99282|Specified dose on specified days
214691474|NCT03930953|DRUG|Rituximab|Specified dose on specified days
214691475|NCT03930953|DRUG|Obinutuzumab|Specified dose on specified days
215025164|NCT00977444|DRUG|kondrium|intraarticular injections once month
215025165|NCT00977444|DRUG|kondrium f|intraarticular injections once month
215025166|NCT00977444|DRUG|methyl prednisolone (corticosteroid)|intraarticular injections once month
215029224|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 2; large patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
215025167|NCT04714255|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of images attractive that need to be colored, created as a book called TICK-B. This book was created with the instructions and recommendations of a pediatric psychiatrist and a professional drawing teacher at a children's school.Distraction with TICK-B began 1-3 min. before the intravenous cannula procedure and lasted until the end of the procedure.
215103631|NCT01204216|BIOLOGICAL|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
215103632|NCT01204216|BEHAVIORAL|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
215025168|NCT03053232|DEVICE|Purse string suture device|Using purse string suture device to close gastrointestinal perforation under endoscopy.
215025169|NCT03053232|DEVICE|Endoclips|Using endoclips to close gastrointestinal perforation under endoscopy.
215025170|NCT01630109|DRUG|Metoclopramide|A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
215025171|NCT01630109|DRUG|Placebo|A placebo capsule made to look like the metoclopramide capsule.
215103633|NCT05301309|BEHAVIORAL|breastfeeding consultation|Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
215103634|NCT00001009|DRUG|Dextran sulfate|
215103635|NCT02992509|DEVICE|EMED detruset(TM) intravesical electrical stimulation|"There will be a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks. The electrical parameters utilized will be those previously determined to be appropriate for OAB and UUI. As the beneficial effect of electrical stimulation is dependent on a maximal level of stimulation, the stimulation voltage will be increased during the first minute of treatment until the maximum tolerated by the patient is established and then backed-off by 1-2 Volts. The therapy will continue for 15 minutes in total for each session. The VAS will be marked by the patient before each treatment session throughout the therapy period, and other questionnaires will be administered."
215103636|NCT04967339|DEVICE|Foot deformity correcting insoles|Foot deformity correcting insoles (e.g. insoles with medial arch support for plano-valgus deformity)
215103637|NCT04967339|DEVICE|Lateral wedge insoles|Lateral wedge insoles
215103638|NCT02348307|DRUG|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
214423708|NCT05756504|DRUG|Tramadol|Injection Tramadol 25-50 mg IV x TDs wil be given to each patient in this group. Maximum dose will be 400 mg/ day
214423709|NCT06814717|DRUG|cP12|cP12 is a novel fibronectin derived, 14-mer peptide
214423710|NCT04513522|BIOLOGICAL|Nivolumab|Specified dose on specified days
214423711|NCT04513522|BIOLOGICAL|Ipilimumab|Specified dose on specified days
214423712|NCT05218044|PROCEDURE|Cryoablation|The cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.
214508265|NCT05676541|OTHER|Complex intervention to enhance care for patients with multimorbidity in general practice consisting of an extended overview consultation and supporting elements|The intervention consists of 1) an extended overview consultation lasting 30-45 minutes in general practice, 2) access to cross-sectoral video conferences with secondary care specialists and 3) an instruction material for GPs on how to organize the intervention and 4) an adaptive toolbox to support elements in the intervention (not yet developed)
214691476|NCT03930953|DRUG|Tafasitamab|Specified dose on specified days
215025172|NCT02315950|OTHER|Botulinum toxin and cineMRI-UDS|The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
215025173|NCT04501822|DIAGNOSTIC_TEST|Evaluation of clinical, instrumental and laboratory diagnostics tests|During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
215025174|NCT04198649|DRUG|Non-surgical periodontal treatment and azithromycin treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions
215103639|NCT02348307|DRUG|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
215103640|NCT00751855|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
215103641|NCT00751855|DRUG|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
215103642|NCT00751855|DRUG|placebo|placebo
215103643|NCT00915291|OTHER|Web-based educational modules|Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
215103644|NCT03286816|DRUG|SodiumChloride|
215103645|NCT03286816|DRUG|Sodium Lactate|
215103646|NCT00723359|DRUG|BT062|biologic
215025175|NCT04198649|OTHER|Non-surgical periodontal treatment and placebo treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions
215103647|NCT00147303|DRUG|MCI-9042|
215103648|NCT03042884|BEHAVIORAL|Questionnaires|"Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete."
215025176|NCT05034081|PROCEDURE|body contouring|any post-bariatric body contouring surgery included
215103649|NCT03042884|DEVICE|Wearable Exercise Tracker Watch|"Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit."
215103650|NCT03505528|DRUG|Nanoparticle albumin-bound paclitaxel|Abraxane is administered intravenous at a constant dose of 100mg/m2
215025177|NCT06541132|OTHER|Observational study without human intervention|Observational study without human intervention
215025178|NCT04753359|OTHER|Med|Mediterranean diet
215025179|NCT04753359|OTHER|WL|Measuring change in weight
215025180|NCT05560113|OTHER|Continuous theta burst stimulation (cTBS)|cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
215025181|NCT05560113|OTHER|Sham continuous theta burst stimulation (cTBS)|This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
215103651|NCT03505528|DRUG|Phenelzine Sulfate|Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
215103652|NCT02188849|OTHER|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
215103653|NCT02188849|DRUG|Creatine|Creatine powder 5 g day
215103654|NCT05126849|OTHER|Allogenic transplantation|"1. Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~2. Stem cell source Bone Marrow~3. GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
215103655|NCT06405477|DIETARY_SUPPLEMENT|L-arginine|Capsules of 3 grams of L-arginine per Dose
215103656|NCT06405477|DIETARY_SUPPLEMENT|Placebo|Capsules of 3 grams of maize Starch per Dose
215103657|NCT06469528|DRUG|Colchicine 0.5 MG|Low dose daily colchicine
215103658|NCT00692419|BEHAVIORAL|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
215103659|NCT00692419|BEHAVIORAL|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
215103660|NCT05150210|DEVICE|Robotic-Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
215103661|NCT06430723|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty using short stem via an minimally invasive anterolateral approach
215103662|NCT03937960|OTHER|Carbohydrate restricted group|Prescribed low carbohydrate diet with set recipes
215103663|NCT03937960|OTHER|Standard low fat diet|Diet with less than 20% total calorie intake from dietary fats
215103664|NCT04450329|DRUG|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
215103665|NCT04450329|DRUG|Eylea (Aflibercept)|Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
215025182|NCT05286112|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
215025183|NCT05286112|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
215025184|NCT00839930|DRUG|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
215103666|NCT03515642|BEHAVIORAL|HIIT group|Physical Training
215025185|NCT00839930|DRUG|Pletal®|1 x 50 mg, single-dose tablet
215103667|NCT05709639|OTHER|Individualized counselling in nutrition|Individualized counselling in nutrition - collaborate on a nutrition plan
214508266|NCT01867879|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
214508267|NCT01867879|DRUG|Placebo|Placebo tablets, orally, single dose.
215025186|NCT05313373|OTHER|Virtual Reality|In addition to the routine procedure, virtual reality glasses will be applied to the women in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After being taken to the gynecological table for the HSG procedure, the women included in the experimental group will be made to watch a video lasting an average of 10 minutes with virtual reality glasses until the procedure is completed. While watching the video, the relaxing music of the video will be played.
214508268|NCT05052151|OTHER|Low dialysate temperature|35°C
215025187|NCT00809588|BIOLOGICAL|Autologous, lethally irradiated melanoma cells|Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
215025188|NCT03692169|PROCEDURE|Half-dose photodynamic therapy|Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
214508269|NCT05052151|OTHER|High dialysate temperature|37°C
214508270|NCT05052151|OTHER|Low dialysate bicarbonate concentration|30 mmol/L
214508271|NCT05052151|OTHER|High dialysate bicarbonate concentration|38 mmol/L
214691477|NCT03930953|DRUG|Valemetostat|Specified dose on specified days
215025189|NCT02500836|DRUG|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
215025190|NCT02500836|DRUG|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
214691478|NCT02973841|DEVICE|Sono-ease device|insertion of US guided IJV using sono-ease device
214691479|NCT02249234|DRUG|Botox|
214691480|NCT02249234|DRUG|Placebo|
214691481|NCT06652568|DEVICE|ThinkSono System|The ThinkSono Guidance System is a guidance software expected to help non-radiology specialist healthcare professionals produce compression ultrasound image data that meet or exceed the minimal image quality criteria for a remote diagnosis by an expert (e.g. radiologist).
214691482|NCT04229498|DRUG|Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)|In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
215103668|NCT05229029|DRUG|TCM Formula|TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.
215103669|NCT05229029|DRUG|Placebo|Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs
214423713|NCT04599764|OTHER|HD-tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.HD-tDCS was administered using the Soterix 1×1 tDCS Low-Intensity Stimulator and the Soterix 4×1 Adapter. The selection of the electrode montage was based on computational models generating simulated current topography using HD Explore, which demonstrated good current distribution in the left dorsolateral prefrontal cortex (DLPFC). For left DLPFC stimulation, the anodal electrode was placed at the F3 position (using the International 10-20 EEG system), and the 4 return electrodes (cathodes) were placed at positions AFz, FCz, F7, and C5 (4-6 cm from the anode). The center position CZ was aligned with the vertex of the head. During anodal DLPFC stimulation, participants received stimulation at 2 mA for 30 minutes, including a 30-second ramp-up period at the start and a 30-second ramp-down period at the end.
214423714|NCT04599764|OTHER|computer-based cognitive training|Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. This trial will employ a computerized multi-domain adaptive training program. This program and training model have been demonstrated to be effective and beneficial in patients with vascular cognitive impairment. In the CCT intervention group, participants will undergo 2 weeks of computerized, multi-domain, adaptive training. The training domains include processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Task rigor varies across domains and determines task grouping. Participants are required to complete 30 minutes of daily training(one session each of six 5-minute tasks).
214508272|NCT06720272|OTHER|School nurse program|The intervention consists in the introduction of a school-nurse program providing health care through education about rheumatic heart disease, assessment, intervention, and follow-up of group A beta-hemolytic streptococcal pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with rheumatic heart disease.
214691483|NCT05057273|DRUG|BT-11|Oral once daily tablet
214691484|NCT05057273|DRUG|Active comparator|Biologic
214691485|NCT03682510|PROCEDURE|stepwise devascularization|stepwise devascularization begins with suture the placenta bed through uterine artery ligation, internal iliac artery ligation etc
214694209|NCT04901065|DRUG|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle
214694210|NCT04901065|DRUG|Placebo|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
214694211|NCT02667990|OTHER|orthopaedic stilettoe|stilettos with orthopaedic in-sole buildt into the shoe
215103670|NCT00395421|DRUG|NM283 plus Peg-IFNα-2a|200 mg QD 180 µg QW
215025191|NCT02500836|DRUG|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
215025192|NCT00228956|DRUG|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
215025193|NCT02475356|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|The treatment of Mirena should comply with the local product information.
215025194|NCT03987685|DRUG|Oratopo|Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
215025195|NCT03822715|OTHER|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
215103671|NCT01675193|BEHAVIORAL|Disinvestment protocol|Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months
215103672|NCT02736981|BEHAVIORAL|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
215103673|NCT02736981|BEHAVIORAL|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
215103674|NCT02736981|BEHAVIORAL|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
214691486|NCT03682510|PROCEDURE|B-Lynch Transverse Compression Suture group|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side. After encircling the para-uterine vasculature, the needle then perforates the posterior side of the uterus behind the vascular bundle entering the uterine cavity."
214691487|NCT03682510|PROCEDURE|N&H sandwich technique|In the N\&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade.
214691488|NCT03823417|DRUG|Tranexamic Acid|Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
214691489|NCT03823417|DRUG|Normal saline|Normal saline infusion
215025196|NCT03822715|DRUG|standard of care aromatase inhibitors|standard of care aromatase inhibitors
215025197|NCT05777863|BEHAVIORAL|Multidomain lifestyle intervention|A multidomain lifestyle intervention including the following lifestyle domains: (1) diet, (2) physical activity, (3) sleep, (4) stress/mindfulness, and (5) cognitive training.
215025198|NCT00859885|DRUG|Antithrombotic treatment|antiplatelets, anticoagulants
215025199|NCT00859885|DEVICE|percutaneous device closure of PFO|umbrella device for PFO closure
215025200|NCT06440837|BEHAVIORAL|IMB stress self-management health education|The health education intervention program contains eight module topics: stress-related knowledge, the thinking and mentality under stress, social support, take care of your suffering, manage your difficult emotions, acceptance, embrace a better life, ending. One topic or session is delivered by weeks, each session lasting 30-40 minutes.
215025201|NCT04386239|DRUG|Sarilumab Prefilled Syringe|Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
215025202|NCT02125422|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
215025203|NCT02790736|DRUG|propranolol|active treatment
215025204|NCT02790736|DRUG|Placebo|inactive pill
215025205|NCT04545892|DRUG|Capsaicin|One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
215025206|NCT02273427|DRUG|BIIL 284 BS|
214691490|NCT04427787|DRUG|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day
214691491|NCT04427787|DRUG|Lanreotide|Lanreotide will be administrated 120 mg injection every 28 days
214691492|NCT01599468|DRUG|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
214691493|NCT01599468|DRUG|saline serum|The Placebo group received normal saline with the same volumes
214691494|NCT01778387|PROCEDURE|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
214691495|NCT02153450|DRUG|metformin hydrochloride|Given PO
215025207|NCT02273427|OTHER|high fat meal|
214691496|NCT02153450|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
214691497|NCT01975272|DRUG|Ferinject|
214691498|NCT01975272|DRUG|Ferrous fumarate|
214691499|NCT01975272|DRUG|Placebo for ferrous fumarate|
214691500|NCT01975272|DRUG|Placebo for ferinject|
214691501|NCT04661930|DRUG|TriCor® 145mg tablets|Fenofibrate; 145 mg daily (1/day); oral administration; 10 days
214691502|NCT04661930|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
214691503|NCT04661930|OTHER|Usual care|All participants will otherwise receive usual medical care
214691504|NCT06512467|DRUG|Donafenib|200 mg BID,oral administration will start before the first HAIC treatment .
214691505|NCT06512467|DRUG|Sintilimab|200 mg Q3W,Intravenous infusion will perform before HAIC treatment.
214691506|NCT06512467|OTHER|HAIC|HAIC,Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours).
215103675|NCT05368168|DEVICE|Posterior tibial nerve stimulation (PTNS)|"Posterior tibial nerve neurostimulation in postoperative patients treated for rectal neoplasms for 6 weeks at a rate of 2 sessions per week (12 sessions).~The sessions will be carried out by the nursing staff of the anorectal functional testing cabinet. The sessions will begin 3 weeks after hospital discharge for patients without lateral ileostomy and after ileostomy closure for patients with lateral ileostomy."
215103676|NCT02675530|DRUG|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"
214691507|NCT06553144|PROCEDURE|control|Canals were irrigated with only10 mL of 5% NaOCl
214691508|NCT06553144|PROCEDURE|methylene blue|0.1 mg/mL methylene blue solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
214691509|NCT06553144|PROCEDURE|erythrosine b|0.3 mg/mL eryrhtosine b solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
214691510|NCT06553144|PROCEDURE|curcumin|5.0 mg/mL curcumin solition delivered into the canal and irradiated with a 200mW diode laser at a wavelength of 450 nm
214691511|NCT03695432|BIOLOGICAL|Flubio|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
214691512|NCT03695432|DIETARY_SUPPLEMENT|Lacidofil|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
214691513|NCT03695432|OTHER|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
214691514|NCT03695432|OTHER|Placebo probiotic|Capsul
214691515|NCT03737968|DRUG|Durvalumab|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
214691516|NCT03737968|DRUG|durvalumab + tremelimumab|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
214691517|NCT00572806|DRUG|insulin aspart|
214691518|NCT04576637|PROCEDURE|Neurophysiological monitoring during intubation|In the operating room patients will be connected to the anesthesia monitor and an IV line as standard clinical practice. Participants will receive oxygen and an IV infusion of 1-3 ng/ml remifentanil via TCI infusion pump to achieve mild sedation. Patients will then be connected to the neurophysiological electrodes to monitor for EEG, EMG, SSEP and MEP signals. After preparing the videolaryngoscope, anesthesia induction will be achieved with the use of IV ketamine 2mg/kg. Then the anesthesiologist will perform a clinical and ECG reading assessment to ensure that the patient is anesthetized and will be able to titrate more ketamine as needed to achieve hypnosis. A biteblock will be located to prevent teeth damage. A neurophysiological baseline recordings will then be performed by a neurophysiologist. The videolaryngoscope will then be inserted, during which a second neurophysiological testing will be performed to ensure the patients safety. Then mechanical ventilation will be initiated.
214691519|NCT01234012|BIOLOGICAL|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
214691520|NCT02630082|PROCEDURE|Circumcision|
214691521|NCT02630082|PROCEDURE|Flexible sigmoidoscopy|
214694212|NCT02667990|OTHER|standard stiletto|standard stiletto without insole
215025208|NCT02273427|OTHER|low fat meal|
215025209|NCT05412979|DRUG|ST-1891|ST-1891
215025210|NCT05412979|DRUG|Levothyroxine|Levothyroxine
215025211|NCT04818710|PROCEDURE|skin incision with a scalpel|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 1 (skin incision with a scalpel)"
215025212|NCT04818710|PROCEDURE|skin incision with diathermy|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 2 (skin incision with diathermy)"
215025213|NCT02801578|DRUG|Ibrutinib|Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
215025214|NCT03484897|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study cream was applied once a day (at the morning or at the evening), preferentially always at the same hour, with a mild massage, for an uninterrupted period of 1 month
215103677|NCT00644111|DRUG|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
215103678|NCT00644111|DRUG|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
215103679|NCT00727155|BEHAVIORAL|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
215025215|NCT01030809|OTHER|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
215025216|NCT01839409|BEHAVIORAL|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
215025217|NCT00668642|DRUG|Dutasteride|0.5 mg capsule given orally on daily basis
215025218|NCT00668642|DRUG|Placebo|Identical placebo
215025219|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-40%)|HDV-Insulin Lispro and Insulin Degludec (-40%)
215025220|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-10%)|HDV-Insulin Lispro and Insulin Degludec (-10%)
215025221|NCT00589524|DEVICE|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
215025222|NCT01993680|DRUG|Pyridostigmine bromide|"Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days"
215025223|NCT01993680|DRUG|fludrocortisone|drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
215103680|NCT03555682|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
215025224|NCT01246518|DRUG|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
215025225|NCT02003898|DEVICE|Medtronic MiniMed 530G Insulin Pump|
215025226|NCT06054308|OTHER|MSLN CART|Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
215025227|NCT06015009|OTHER|Symptom management mobile health application with personalised support|"Other: Symptom management mobile health application with personalised support Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
215025228|NCT05053685|DIAGNOSTIC_TEST|Measurement of Urine and plasma metanephrines|Measurement of Urine and plasma metanephrines
215025229|NCT02108808|DRUG|Ticagrelor|
215025230|NCT02108808|DRUG|Prasugrel or Clopidogrel|
215103681|NCT03555682|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
215103682|NCT02561221|BEHAVIORAL|Lifestyle Counseling|"Trained health coaches delivered the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
215103683|NCT02592460|OTHER|poor-polyamines diet|Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
214691522|NCT06661291|OTHER|Pip Care Digital Health Platform|Pip Care Digital Health Platform is a smartphone application granting access to a health coach who will assist the patient in completing a health intake, creating personalized perioperative care plans, and meets regularly with the patient to encourage goal accomplishments and supports healthy surgical recovery.
214694213|NCT02667990|OTHER|comfy trainer|comfy trainer
214694214|NCT02912806|PROCEDURE|Total Knee Replacement|Primary total knee arthroplasty for knee osteoarthritis
215025231|NCT05403866|DRUG|LT3001 Drug Product|Administered by intravenous infusion
215025232|NCT05403866|DRUG|Placebo|Administered by intravenous infusion
215025233|NCT04166747|OTHER|Virtual Reality experience|Participants will receive virtual reality based experience and will be assessed for its influence on happiness, functional fitness components and quality of life of older age groups.
215025234|NCT02458027|DIETARY_SUPPLEMENT|Hemp Shake|Hemp Protein
215025235|NCT02458027|DIETARY_SUPPLEMENT|Hemp|Hemp Protein Shake
215025236|NCT02458027|DIETARY_SUPPLEMENT|Soybean Shake|Soybean Protein
215025237|NCT02458027|DIETARY_SUPPLEMENT|Soybean|Soybean Protein Shake
215025238|NCT02458027|DIETARY_SUPPLEMENT|Control|Non-Protein Shake
215025239|NCT02272985|OTHER|[15O]H2O PET-CT scan|All participants will undergo 3 \[15O\]H2O PET-CT scans during the hemodialysis study session
215025240|NCT02272985|OTHER|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
215025241|NCT00124358|DRUG|Buprenorphine|
215103684|NCT02592460|OTHER|high polyamines diet|Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
215103685|NCT05670418|DEVICE|Quantitative Electroencephalography|Each qEEG examination of one person lasted about 20 minutes and included two stages: the first-recording of brain waves with eyes closed (5 min), the other with eyes open (5 min)
215103686|NCT03673020|BIOLOGICAL|ASV® AGEN2017 + QS-21 Stimulon® adjuvant|Neoantigen Vaccine
215025242|NCT00124358|BEHAVIORAL|Integrated HIV care and office-based opioid dependence treatment|
215025243|NCT05115773|PROCEDURE|Intraligamentary anaesthesia|one tooth anaesthesia by 2 or 4 points intraligamentary injection
215025244|NCT05115773|PROCEDURE|Mandibular anaesthesia|Inferior alveolar nerve block by direct standart method
215025245|NCT00960245|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
215025246|NCT00960245|DRUG|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
215025247|NCT01539031|DRUG|E2020|"Subjects in the Group-10 mg:~Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg"
215025248|NCT01539031|DRUG|E2020|"Subjects in the Group-23 mg:~Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg"
215025249|NCT02921867|OTHER|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
215025250|NCT06240676|BEHAVIORAL|AWARENESS-BASED COGNITIVE THERAPY|A 6-week training program based on mindfulness practices will be applied to the experimental group determined by the single-blind method, after the 3rd month after birth. In order to observe the change in the experimental group, breast milk will be taken for pre-test (morning and evening) before training. After 6 weeks of training, a cortisol test will be performed by taking breast milk at 09:00 in the morning and 09:00 in the evening. Taken milk will be stored in the deep freezer for 1 week at -18 degrees. After the samples are prepared for testing under appropriate conditions (centrifuge), biochemical measurements will be made and recorded with the help of the SUNREDBIO brand human cortisol kit (the serial number is not known since we did not purchase the cortisol kit).A sleep diary will be used to measure newborn circadian rhythm.
215025251|NCT03446690|DRUG|MI Varnish|MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
215025252|NCT03446690|OTHER|Control group|Participants received routine treatment and oral hygiene regimes. No intervention for this group.
215025253|NCT00938626|BIOLOGICAL|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
215025254|NCT00938626|PROCEDURE|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
215025255|NCT00938626|PROCEDURE|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
215025256|NCT02738619|DRUG|Vitamin D3|1600 UI
215025257|NCT02738619|DRUG|placebo|placebo
215103687|NCT05090852|DEVICE|Hi-VNI|Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
215103688|NCT06293313|PROCEDURE|Mindfulness training|Before starting the study, an appointment will be made to meet with the students participating in the mindfulness group with randomization on the specified day and time. The students and the researcher will meet in a quiet, calm room of the school. Students will be informed about the practice of mindfulness and their written and verbal consents will be obtained before participating in the study. Then, a pre-test will be applied to the students who agree to participate in the study.
214508273|NCT06359574|OTHER|Core Competency Model for Corrections (CCM-C) Self-Directed Violence Prevention Training|The Core Competency Model (CCM; Cramer et al., 2013, 2019) is an evidence-based educational training program for BHCs in suicide prevention core suicide prevention skills. The ten core competencies are: (1) Manage personal attitudes and reactions to suicide; (2) Maintain a collaborative stance toward the client; (3) Elicit evidence-based risk and protective factors; (4) Focus on current suicide plan and intent of suicidal ideation; (5) Determine risk level; (6) Enact a collaborative evidence-based treatment plan; (7) Notify and involve other persons; (8) Document risk, plan, and reasoning for clinical decisions; (9) Know the law concerning suicide, and; (10) Engage in debriefing and self-care. The CCM will be adapted for this pilot trial. In light of the SDV problem in carceral settings, the CCM for Corrections (CCM-C; Cramer, Kaniuka, \& Peiper, 2022) was adapted to address both suicide and self-injury assessment, treatment, and prevention.
214508274|NCT03385291|DEVICE|music,name,and noise sound|A 5-minute baseline silence was followed by the presentation of three contrasting auditory stimuli(music,name,and noise), with a 2-minute washout silence separating each stimulus
214508275|NCT05460910|OTHER|core stability exercises with treadmill|swiss ball use patient is lying in supine position with 15 repitations and 3 sets.
214508276|NCT05460910|OTHER|core stability exercise without treadmill|technique used to improve stability
214508277|NCT04596488|DRUG|Efavirenz 400mg|HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
214508278|NCT03795688|OTHER|Pregnancy|Peripartum transition from pregnant to postpartum state
214508279|NCT05750719|GENETIC|BRCA1/2 genetic testing|All patients will undergo genetic testing for BRCA 1 and BRCA 2 germline mutations, employing next generation sequencing (NGS) techniques.
214508280|NCT04751097|OTHER|CUSH Health Digital platform|Remote mobility monitoring and physiotherapy video app
214691523|NCT06661291|OTHER|Standard of Care Protocol|Subjects in this intervention group will receive routine, standard of care throughout their surgery and hospital stay as determined by their acting clinical care team.
214691524|NCT05773716|BEHAVIORAL|Pelvic floor muscle training|Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2\~6-second and a 2\~6-second relaxation following each one.
214691525|NCT05773716|OTHER|Electroacupuncture|Participants will also receive electroacupuncture at bilateral Zhongliao (BL33), Huiyang (BL35), Zhongji (CV3), Guanyuan (CV4) and Dahe (KI12). During each therapy session, the electroacupuncture stimulation of acupoints in the abdomen and sacral regions will last for 30 minutes in total (15 minutes for each region) with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
214691526|NCT05773716|OTHER|Sham electroacupuncture|Sham electroacupuncture will be carried out with pragmatic placebo needles on the same acupoints in the experimental group. Procedures, electrode placements, and other treatment settings will also stay the same but with no electrical stimulation output.
215025258|NCT05954884|OTHER|Telemedicine-based WHO HEARTS package|"Interventions in this study will include-~1. Community- and team-based model of hypertension care delivery~2. Opportunistic hypertension screening at Community Clinic (CC) by Community Health Care Provider (CHCP)~3. Use of a hypertension treatment protocol with amlodipine and losartan and standardized approach to measuring and monitoring BP, retaining participants in care, and promoting adherence~4. Use of Simple App to document BP readings and medications/dosage and to monitor hypertension care delivery at the CC through utilities including dashboards~5. Establishment of telemedicine service between CC and Upazila Health Complex (UHC)~6. Community-based, multi-month prescription refills from CC~7. Training of clinic and research staff on BP measurement following standard techniques~8. Site monitoring and mentorship to ensure screening and patient enrollment/registration~9. Use of text messages to promote follow-up visits and medication adherence"
215025259|NCT02644304|DRUG|Clomiphene citrate|50 mg tablet twice daily from the second day of menses to the sixth day
215025260|NCT02644304|DRUG|Cabergoline|Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
215025261|NCT02644304|OTHER|Placebo|placebo(half tablet) every 3 days (4 doses).
215025262|NCT04199390|PROCEDURE|total hip arthroplasty|each patient is expected to undergo an anterior total hip arthroplasty procedure and some sort of physical therapy postoperatively
214423715|NCT04599764|OTHER|Sham tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.HD-tDCS was administered using the Soterix 1×1 tDCS Low-Intensity Stimulator and the Soterix 4×1 Adapter. The selection of the electrode montage was based on computational models generating simulated current topography using HD Explore, which demonstrated good current distribution in the left dorsolateral prefrontal cortex (DLPFC). For left DLPFC stimulation, the anodal electrode was placed at the F3 position (using the International 10-20 EEG system), and the 4 return electrodes (cathodes) were placed at positions AFz, FCz, F7, and C5 (4-6 cm from the anode). The center position CZ was aligned with the vertex of the head. For sham stimulation, participants received only the initial 30-second ramp-up to 2 mA, after which stimulation was immediately terminated.
215025263|NCT03682367|DRUG|Gabapentin|Use of Gabapentin peri- and post-operatively.
214423716|NCT04541303|DRUG|Tranexamic acid|tranexamic acid diluted to concentration of 25ml/mg
214423717|NCT04541303|DRUG|normal saline|0.9% sodium chloride
214423718|NCT00589667|DRUG|Pemetrexed plus Gemcitabine|"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist."
214423719|NCT04710771|OTHER|Prone Lying Position|patient lies on his/ her stomach facing floor.
214423720|NCT04710771|OTHER|alternate nostril breathing|patient inspires with one nostril at a time, right or left one by one and expires by mouth.
214423721|NCT05583526|DRUG|Ritlecitinib|50 mg capsule
214423722|NCT05583526|DRUG|Placebo|Matching capsule
214423723|NCT05967637|OTHER|Whole body vibration|The vibration will be applied for 10 minutes (30 seconds rest, 30 seconds training, 10 reps) in total with a low frequency (20 HZ) and low amplitude (2mm). Participants will be asked to stand in a squatting position by semi-flexing (30°) their knees during the 30-second vibration period.
214423724|NCT05967637|OTHER|Sham-Whole body vibration|The sham-whole body vibration treatment will follow the same procedures with the vibration machine off.
214423725|NCT03538041|DRUG|Parsaclisib|Parsaclisib administered orally.
214423726|NCT00343486|DRUG|Solabegron|
214423727|NCT06269055|OTHER|Interview|Telephone interview and questionnaires about the results and side effects experienced
214423728|NCT03759743|DIETARY_SUPPLEMENT|LMT1-48|capsules containing Probiotics
214423729|NCT03759743|DIETARY_SUPPLEMENT|Placebo|capsules that did not contain any probiotics
214423730|NCT03922880|DRUG|ADI PEG20|ADI-PEG 20 will be administered at a dose of 36mg/m2 intramuscularly once a week.
214423731|NCT03922880|DRUG|Nivolumab|Nivolumab 240mg + Ipilimumab 1mg/kg for up to 8 total doses of ipilimumab. One ipilimumab has completed, nivolumab 480mg will be given every 4 weeks.
214691527|NCT06054035|DRUG|Dapagliflozin (Forxiga®)|Dapagliflozin 10 mg once daily for 6 months. Route of administration: oral.
214691528|NCT06054035|DRUG|Placebo matching Dapaglifolzin|Placebo matching Dapaglifolzin once daily for 6 months. Route of administration: oral.
215025264|NCT03682367|DRUG|Placebo - Concentrate|Use of sugar-free Placebo peri- and post-operatively.
215025265|NCT06547320|BEHAVIORAL|Eat Less Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the amount of food eaten.
215025266|NCT06547320|BEHAVIORAL|Eat Slower Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the rate of eating.
215025267|NCT02567903|DEVICE|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
215025268|NCT02567903|PROCEDURE|Knee arthroscopy|Knee arthroscopy
215025269|NCT06044623|DRUG|CDK 4/6 inhibitors|Either Palbociclib, Ribociclib or Abemaciclib
215025270|NCT06044623|DRUG|Endocrine therapy|Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
215025271|NCT00615888|PROCEDURE|Fast track patient management|no bowel washout, patient controlled epidural anesthesia, early enteral feeding
215025272|NCT00615888|PROCEDURE|Traditional management|preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
215025273|NCT03295344|OTHER|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
215025274|NCT03295344|OTHER|Tissue Doppler|Determine the threshold value for diaphragm mobility
215025275|NCT04595292|OTHER|older adults, assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
215025276|NCT01069757|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
215025277|NCT02463435|BEHAVIORAL|Nutritional intervention|Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
215025278|NCT02463435|OTHER|Nutritional intervention plus olive oil|Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
214423732|NCT03922880|DRUG|Ipilimumab|Ipilimumab 1mg/kg with Nivolumab 240mg for up to 8 total doses of ipilimumab. The first four doses of ipilimumab will be scheduled once every 3 weeks. The 5th-8th doses of ipilimumab will be scheduled once every 6 weeks with nivoumab 240mg every 3 weeks.
214423733|NCT03827369|DIAGNOSTIC_TEST|ICU patient|Our study is to measure the coefficient of variation of the HCV of the radial arterial pulse among ICU patients with multiple organ failures (MOF). Patients admitted to Taoyuan General Hospital were recorded during the 6 months study.
214423734|NCT03310645|DRUG|BAY1817080|4 different doses over the course of study
214423735|NCT03310645|DRUG|Matching Placebo|Matching placebo for BAY1817080
215025279|NCT02463435|DIETARY_SUPPLEMENT|Olive oil|Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
214423736|NCT00131066|OTHER|Follow up from previous treatment with MEDI-507|There will be no investigational drugs administered under this protocol.
214423737|NCT02990754|BEHAVIORAL|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
214423738|NCT04737681|OTHER|body composition|This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
215025280|NCT05158010|OTHER|HELIX's follow-up|"* Visit 1 (Day 0): clinical examination (anthropometry, bioimpedance, blood pressure,spirometry), neurodevelopment computer testing, questionnaires (Physical activity,diet, psychological distress, tobacco exposure, pubertal development, sleeping patterns, light exposure before going to sleep, outdoor environment (green spaces, noise), address history, home environment, socio-economic status, noise, psychological distress, medical history, medication use) 7 consecutive days (minimum) of personal exposure monitoring including wearing an actigraph, a Smartphone (GPS data), carrying a NO2 diffusion tube, collection of hair, stool, urines (2 urines during 6 consecutive days) and filling a sleep and physical activity diary~* Visit 2 (Day 8): blood collection early in the morning and collection of all the 7- days personal monitoring material, and stools and urines samples."
215025281|NCT00770679|DRUG|lipitor|80 mg everyday (QD) for 3 weeks
214691529|NCT06054035|BEHAVIORAL|Lifestyle Intervention|Patients receive a conventional lifestyle intervention (one in depth individual session at the beginning and standard care information on a healthy lifestyle at every visit thereafter).
215103689|NCT06293313|OTHER|Will not be given any application|Before starting the research, the students in the control group determined by the randomization method will be informed about the research. Written and verbal consent will be obtained from the students that the students agree to participate in the research. Afterwards, students will meet in a quiet and calm room of the school on the specified day and time. Before starting the research, students will be given a pre-test. A mid-term test will be performed 8 weeks after the pre-test.
215103690|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cells|Single subtenon's injection for single eye
215103691|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes|Single subtenon's injection for single eye
214423739|NCT00867867|DRUG|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
214423740|NCT00867867|DRUG|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
214423741|NCT00867867|DRUG|Placebo|9.3 mg once per day, 6 days per week, for 9 months
214423742|NCT06242782|PROCEDURE|VRA + d-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced d-PTFE membrane
215025282|NCT05424588|DIAGNOSTIC_TEST|clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection|Total body dual-energy X-ray absorptiometry (DEXA) was taken BN and AN to measure total (FM) and segmental fat (truncal FM), visceral adipose tissue (VAT) and lean mass (LM). Tetra-polar dual frequency BIA (InBody 120; Cerritos, USA) was used BPP, BN and AN to measure weight and to estimate FM, FFM, and MM. Impedance measurements were performed. CPET was carried out on a cycle ergometer with clip-on pedals. Blood samples were collected in the morning BPP, BN, AN. Biochemical parameters considered in this study were: ALT, AST, creatinine, 25-hydroxy vitamin D, total cholesterol, HDL, LDL, triglycerides concentrations. We isolated CPCs from heparinized blood, as previously reported (14). After the collection of peripheral blood mononuclear cells (PBMCs) by a gradient centrifugation. (15). Differentiating Human Skeletal muscle cells were cultured with or without pooled sera of participants at 5% final concentration. 146b and 34a miRNAs were extracted from PBMCs.
215025283|NCT04940078|DRUG|Cagrilintide|Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
215025284|NCT04940078|DRUG|semaglutide|Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
215025285|NCT04940078|DRUG|Cagrilintide and semaglutide|Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
215025286|NCT06288893|DRUG|SHEN211 Tablets|SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.
215025287|NCT06288893|PROCEDURE|Placebo for SHEN211 Tablets|Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5
215103692|NCT05413148|OTHER|Placebo|Single Subtenon injection of saline for a single eye
215103693|NCT04869306|DEVICE|Hyaluronic acid gel|After lower third molar removal, the test group 1 will additionally receive hyaluronic acid gel prior to wound closure.
215103694|NCT04869306|DEVICE|Hyaluronic acid gel + carrier|After lower third molar removal, the test group 2 will additionally receive hyaluronic acid gel with a collagen carrier prior to wound closure.
215103695|NCT04851756|DEVICE|CRet|In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min F.M with CRet on capacitive mode (180-250VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (110-140W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (180-250VA) on the mentioned area. A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes.
214508281|NCT05277454|DRUG|HMPL-653|"Dose-escalation Stage:~Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment.~Dose-expansion Stage:~The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment."
214508282|NCT02393976|DIETARY_SUPPLEMENT|IMMUNONUTRITION|IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
214508283|NCT02393976|DIETARY_SUPPLEMENT|STANDART NUTRITION|STANDART NUTRITION PERIOPERATIVE
214508284|NCT00006200|DRUG|thalidomide|
214508285|NCT00006200|DRUG|dacarbazine|
214508286|NCT00749827|DRUG|Bicarbonate Hydration|"Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.~Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours."
214508287|NCT00749827|DRUG|Hypotonic hydration|Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
214508288|NCT04531007|DIAGNOSTIC_TEST|iFR/ FFR/ IVUS/ OCT|intermediate lesion evaluation with intracoronary physiology and imaging
214508289|NCT02930265|DRUG|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
214508290|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
214508291|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
214508292|NCT03769090|DRUG|Albuterol sulfate metered-dose inhaler 180 μg|Albuterol sulfate inhalation aerosol
214508293|NCT01246635|DEVICE|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
214508294|NCT01246635|PROCEDURE|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
214508295|NCT04711291|COMBINATION_PRODUCT|Conversion to Envarsus-XR and use of smart phone app, TransMedAx|"Convert to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours used in combination with the smart phone application, TransMedAx.~Patients in this arm will be trained to use the app along with conversion to Envarsus-XR. Once patient scan the code on medicine bottle and the app will remind them about the time and dose of the medication in their native language."
214508296|NCT04711291|DRUG|Convert to Envarsus XR once daily|Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours
215025288|NCT00296712|DRUG|escitalopram + bupropion|same dosing as for monotherapy arms
215025289|NCT06220110|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
215025290|NCT06220110|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
215025291|NCT00129974|DRUG|pemetrexed and gemcitabine|
215025292|NCT05096130|BEHAVIORAL|Lifestyle Medicine Strategies|"LM addresses health risk factors in primary, secondary, and tertiary prevention of developing disease rather than limiting resources and medical expenditures on acute care and reacting to illness, injury, and disease.~The intervention will target the four pillars of the LM approach including physical activity, diet, stress, and sleep. Certified in LM strategies professionals will consult participants from the LM group in a biweekly base in order to improve their lifestyle habits."
215025293|NCT01955551|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
215025294|NCT01955551|BEHAVIORAL|Anticipatory Guidance on Child Development|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
215025295|NCT00520338|DRUG|celecoxib|"1. placebo~2. celecoxib 400 mg oral single dose"
215025296|NCT01759641|DEVICE|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
215025297|NCT00319189|DRUG|Nateglinide|
215025298|NCT05848570|OTHER|Keeping it LITE|observational cohort only
215025299|NCT00266981|DEVICE|APOS - exercise component|
215025300|NCT04063202|OTHER|Observation|The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
215025301|NCT01494857|DRUG|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
215025302|NCT03591536|OTHER|Pentoxifylline|400 mg pentoxifylline oral tablet from 3 days before surgery and on the day of surgery
215025303|NCT03591536|OTHER|Placebo|oral placebo tablets from 3 days before surgery and on the day of surgery
215025304|NCT04734392|PROCEDURE|TAVR|TAVR implantation in cusp overlay technique
215025305|NCT04759170|OTHER|Music therapy|The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby
215025306|NCT04633720|OTHER|Changes in positive end-expiratory pressure and tidal volume|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
215025307|NCT00487630|DRUG|recombinant alpha-galactosidase A|
214423743|NCT06242782|PROCEDURE|VRA + e-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced e-PTFE membrane
215025308|NCT00414609|DRUG|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
215025309|NCT00414609|DRUG|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
214423744|NCT06242782|PROCEDURE|VRA + customised Ti-mesh|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + 3D printed Titanium mesh
214423745|NCT06242782|PROCEDURE|VRA + RPM|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Reinforced PTFE mesh
215025310|NCT01665794|DRUG|Pomalidomide|Pomalidomide taken orally at assigned dose.
215025311|NCT01665794|DRUG|Carfilzomib|Carfilzomib given by intravenous (IV) infusion at assigned dose.
215025312|NCT01665794|DRUG|dexamethasone|Dexamethasone taken orally of given by IV infusion.
215025313|NCT01665794|DRUG|Daratumumab|Daratumumab given by intravenous (IV) infusion at assigned dose.
215025314|NCT01819480|PROCEDURE|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
215025315|NCT04503421|OTHER|Blood Flow Restriction Therapy|Use of a tourniquet set to 50% of limb occlusion pressure while performing post operative physical therapy
215025316|NCT06110871|OTHER|inhaled lavender|They will be asked to inhale deeply 10 times. Then, a total of 30 minutes in the waiting room where aromastone is located and in the IA application room.
215025317|NCT06110871|OTHER|Working Group 2: Focusing|During IUD application
215025318|NCT06110871|OTHER|Working Group 3 music|for a total of 30 minutes
215025319|NCT03318393|DRUG|Bivalirudin|Continuous infusion
215025320|NCT03318393|DRUG|Unfractionated heparin|Continuous infusion
215025321|NCT00188032|PROCEDURE|Computer-Assisted diagnostic Decision Support|
215025322|NCT00188032|PROCEDURE|written diagnostic guidelines|
215025323|NCT00188032|PROCEDURE|electronic therapeutic reminders|
215025324|NCT03680521|DRUG|Sitravatinib|Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
215025325|NCT03680521|DRUG|Nivolumab|Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
215025326|NCT03627468|DRUG|Sofpironium Bromide Gel, 5%|Sofpironium Bromide Gel, 5%
215025327|NCT03627468|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
215025328|NCT04205916|DRUG|Dexamethasone|Drugs to be administer during cataract surgery to experimental group
215025329|NCT04205916|OTHER|Standard of care surgery|Standard method used for surgery and the use of post operative drops
215025330|NCT01730573|PROCEDURE|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
215025331|NCT01730573|PROCEDURE|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
214423746|NCT01566916|PROCEDURE|Total Hip Arthroplasty|
214423747|NCT06185738|OTHER|WCM app|WCM app evaluation at baseline, at completion of WCM program and 4 weeks after completion of WCM program, by completing PROMIS and Self Efficacy for managing disease scale questionnaires
215025332|NCT04325607|PROCEDURE|Excision of HS followed by NPWTi|The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
215025333|NCT04325607|PROCEDURE|Excision of HS followed by NPWT|The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
215025334|NCT03070834|DEVICE|Cook 'Celect' retrievable inferior vena cava filter|Cook 'Celect' device will be deployed If randomized to rIVCF insertion
215025335|NCT05737680|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg daily
215025336|NCT05737680|DRUG|Colchicine|Colchicine continued
214691530|NCT03392753|PROCEDURE|Mechanochemical ablation|Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)
215103696|NCT04851756|DEVICE|Sham CRet|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (0W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (0VA) on the mentioned area.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes."
215103697|NCT05492864|PROCEDURE|extrusion of the anterior teeth|sectional leveling and alignment of the teeth, then using of the extrusion arch as an overlay wire to treat the open bite
215103698|NCT01196416|DRUG|Cisplatin|Given IV
215025337|NCT03438032|DIAGNOSTIC_TEST|Bronchoscopy with lavage|During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
215025338|NCT00168376|DEVICE|Transcranial Magnetic Stimulation|
215025339|NCT03405350|PROCEDURE|Redon-sulfide baths|Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.
215025340|NCT03405350|PROCEDURE|Partial Mud Baths|duration: 20 minutes, temperature 40-42 degrees Celsius
215103699|NCT01196416|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
215103700|NCT01196416|OTHER|Laboratory Biomarker Analysis|Correlative studies
215103701|NCT01196416|OTHER|Pharmacological Study|Correlative studies
215103702|NCT01196416|DRUG|Temozolomide|Given PO
215025341|NCT03405350|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.
215025342|NCT03405350|PROCEDURE|Terrain Therapy|walking, outdoors physical activities,
215025343|NCT03405350|PROCEDURE|Dry Massage|Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).
215025344|NCT03405350|PROCEDURE|Laser Therapy|treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,
215025345|NCT03405350|PROCEDURE|Low-frequency Magnetic Field|duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,
215025346|NCT03405350|PROCEDURE|Ultrasonotherapy|treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,
215025347|NCT03405350|PROCEDURE|Cryotherapy|ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,
215103703|NCT01196416|DRUG|Vinblastine Sulfate|Given IV
215103704|NCT00504894|DRUG|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
215103705|NCT00504894|DRUG|Propofol|A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
215103706|NCT00504894|DRUG|Thiopental|A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
215103707|NCT01496820|DIETARY_SUPPLEMENT|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
215103708|NCT01496820|DIETARY_SUPPLEMENT|Placebo|placebo 1500mg/day for 12weeks
215103709|NCT04501796|DRUG|Double-Blind NT-I7|Administered by intramuscular (IM) injection
215103710|NCT04501796|DRUG|Double-Blind Placebo|Placebo
214508297|NCT00799409|DRUG|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
214508298|NCT00799409|DRUG|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
214508299|NCT00837291|DRUG|CF101|CF101 tablets 1 mg BID
214508300|NCT00837291|DRUG|Placebo|Placebo tablets BID
214508301|NCT05979766|OTHER|Manual lymphatic drainage versus marian clark drainage|Manual lymphatic drainage versus marian clark drainage
214508302|NCT02806752|DRUG|Triamcinolone Acetonide|Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
214508303|NCT02806752|DRUG|Ranibizumab|Intravitreal inject 0.5mg of Ranibizumab.
214508304|NCT00329914|DRUG|Progesterone|Vaginal pessaries, 200 mg/day
214508305|NCT00329914|DRUG|Placebo|Placebo pessaries containing peanut oil
214508306|NCT05861232|BEHAVIORAL|Behavioral|fear and anxiety during inhalation therapy
214508307|NCT04427124|OTHER|Multidisciplinary Team Based Care Model|All prospective patients admitted into the study will receive care based on multidisciplinary team collaboration and an institutional protocol for critical limb ischemia.
214508308|NCT05233904|DIAGNOSTIC_TEST|Diagnostic-CT-enabled Planning|Diagnostic-CT-enabled planning for patient receiving palliative radiation treatment to bone, soft tissue and lung disease
214508309|NCT05233904|DIAGNOSTIC_TEST|Standard of Care|Patients will be booked for CT simulation and treatment as per the local institution's standard practice
214691531|NCT03392753|PROCEDURE|Cyanoacrylate adhesive|Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)
214691532|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
215103711|NCT02736565|BIOLOGICAL|pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex|"Lipoplex is given intravenously as a single administration twice a week for 4 weeks for a total of 8 infusions per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met.~First dose started on Cycle 1 Week 1 Day 1 followed by observation and safety assessment for 13 days. If no toxicity was observed, then another single administration of study agent was given at Cycle 1 Week 3 Day 1 followed by observation and safety for 6 days. If no toxicity was observed, then study agent was given twice a week on Days 1 and 4 over 3 weeks, for a total of 8 infusions per cycle, followed by a 2-week washout before starting each subsequent cycle. Cycle 1 = 8 weeks. Each subsequent cycles = 6 weeks."
214691533|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
214691534|NCT00533637|DRUG|Placebo|Citrate buffer with preservatives
214691535|NCT01249183|BIOLOGICAL|Concomitant administration|1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
215103712|NCT00011622|DEVICE|Continuous ambulatory subcutaneous glucose monitor|
215103713|NCT01029041|OTHER|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
215103714|NCT01029041|OTHER|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
215103715|NCT02841241|DRUG|Esmolol|Esmolol infusion
215103716|NCT00148941|BIOLOGICAL|SB213503 lot 1|SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
214691536|NCT01249183|BIOLOGICAL|Separate administration|1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
214691537|NCT03737318|BEHAVIORAL|Biofeedback-ultrasound|In ultrasound biofeedback, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
214691538|NCT03737318|BEHAVIORAL|Biofeedback--visual-acoustic|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
214691539|NCT03737318|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
214691540|NCT01474330|DRUG|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
214423748|NCT04901312|BEHAVIORAL|Adolescent Community Reinforcement Approach|The Adolescent Community Reinforcement Approach (A-CRA) is a developmentally-appropriate behavioral treatment for youth and young adults ages 12 to 24 years old with substance use disorders. A-CRA seeks to increase the family, social, and educational/vocational reinforces to support recovery. This intervention has been implemented in outpatient, intensive outpatient, and residential treatment settings. A-CRA includes guidelines for three types of sessions: individuals alone, parents/caregivers alone, and individuals and parents/caregivers together. According to the individual's needs and self-assessment of happiness in multiple life areas, clinicians choose from a variety of A-CRA procedures that address, for example, problem-solving skills to cope with day-to-day stressors, communication skills, and active participation in positive social and recreational activities with the goal of improving life satisfaction and eliminating alcohol and substance use problems.
214691541|NCT01474330|DRUG|Placebo|Placebo capsule
214691542|NCT04374825|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|This intervention consists of 8, 90-minute online group sessions delivered via video conference. Content will be developed by tailoring an ACT intervention to the specific needs of women with MBC, by using qualitative data gathered in patient focus groups. The intervention will incorporate key concepts of ACT (i.e., creating meaning and purpose in life via coping skills, activities in line with patients' values, and mindfulness meditation).
214691543|NCT04374825|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|This intervention consists of 8, 90-minute online group sessions delivered via videoconference. Content is drawn from a standard published CBSM intervention previously tested in other studies. The intervention incorporates key concepts of CBSM (i.e., managing stress via deep breathing and relaxation, identifying distorted thoughts,cognitive restructuring, and effective interpersonal communication).
214691544|NCT06666426|DEVICE|PureWick System|The PureWick System consists of the PureWick Urine Collection System used with the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
215103717|NCT00148941|BIOLOGICAL|SB213503 lot 2|SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
215103718|NCT00148941|BIOLOGICAL|SB213503 lot 3|SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
215103719|NCT00148941|BIOLOGICAL|Infanrix|Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
215103720|NCT00148941|BIOLOGICAL|IPOL|IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
215103721|NCT00148941|BIOLOGICAL|M-M-R II|M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
215103722|NCT04241302|DIAGNOSTIC_TEST|Pure Tone Audiogram|A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).
214691545|NCT06666426|DEVICE|Hollister Female Urinary Pouch External Collection Device|The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence.
214691546|NCT02825264|DEVICE|STARflo Implant|All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
214691547|NCT06376604|OTHER|Fasting Mimicking Diet|Subject will consume 6 cycles of 5-day fasting mimicking diet: 3 days prior to, the day of, and 1 day following chemotherapy treatments.
214691548|NCT06376604|DRUG|Chemotherapy|6 cycles of standard chemotherapy for the gynecologic malignancy.
214691549|NCT05174312|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
214691550|NCT05174312|DRUG|Diuretic|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
214691551|NCT00110383|BEHAVIORAL|School-Based Supervised Asthma Therapy|Child's inhaled steroid use supervised daily at school
214691552|NCT00278265|DRUG|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
214691553|NCT00515008|BEHAVIORAL|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
214691554|NCT00515008|BEHAVIORAL|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
214691555|NCT04289103|BIOLOGICAL|Inolimomab (Leukotac)|"* Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~* Treatment phase - Leukotac will be given up to D28~* Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion."
214691556|NCT02151500|BEHAVIORAL|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
214691557|NCT01167595|OTHER|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
214691558|NCT01915849|DRUG|LIK066|LIK066 15 mg, 50 mg and 150 mg
214691559|NCT01915849|DRUG|Placebo|
214691560|NCT05823909|DEVICE|fabian Therapy evolution ventilators with PRICO (Predictive Intelligent Control of Oxygenation)|12 hours Automated PRICO FiO2 control
214423749|NCT04901312|BEHAVIORAL|Assertive Continuing Care|Assertive Continuing Care (ACC) uses Community Reinforcement Approach (CRA) procedures, home visits, and case management for individuals following an initial substance use treatment episode. It stresses rapid initiation of services after discharge from residential, intensive outpatient, or regular outpatient treatment in order to promote recovery and prevent relapse.
215103723|NCT03244826|OTHER|Shared Care|Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
215103724|NCT03244826|OTHER|Standard Care|The usual care provided by the transplant center at DFCI.
215103725|NCT03051919|OTHER|observation|
214423750|NCT04901312|BEHAVIORAL|Trauma Affect Regulation Guide for Education and Therapy|Trauma Affect Regulation: Guide for Education and Therapy is a psychosocial intervention for traumatized adolescents, adults, and families, and for workforce and organizational responses to secondary/vicarious traumatization. T4, the 4-session version, provides education about the impact of complex traumatic stress on the brain's stress response system, and strengths-based practical skills for re-setting the trauma-related alarm/survival reactions that occur in complex PTSD.
214423751|NCT04901312|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is a collaborative, person-centered form of guiding to elicit and strengthen motivation for change.
214423752|NCT04901312|OTHER|Opioid Education Workbook|A digital workbook designed to be completed on a computer in about 2 hours. Topics include opioid use, opioid use disorder, and prevention and treatment of opioid overdose.
214423753|NCT02549313|PROCEDURE|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
214423754|NCT04459169|PROCEDURE|diagnostic algorithm|Cardiac amyloidosis diagnosed according to Gillmore's algorithm
215025348|NCT03405350|PROCEDURE|Electrotherapy|Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,
215025349|NCT03405350|PROCEDURE|Light Therapy|blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
215025350|NCT03007433|OTHER|400ml of Liquid Nutrient Drink|12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
215025351|NCT00651287|DRUG|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
215025352|NCT00651287|DRUG|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
215025353|NCT00651287|DRUG|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
215025354|NCT06044792|OTHER|differences in CD4 reconstruction|Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.
215025355|NCT03893357|OTHER|Data extraction from medical files|Retrospective data extraction from the medical files
215025356|NCT00781261|DRUG|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
215025357|NCT00781261|DRUG|Placebo|Subjects in the control group will receive a placebo drug for a similar period
215025358|NCT05056857|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
215025359|NCT05056857|OTHER|Electronic Health Record Review|Medical charts are reviewed
215025360|NCT05212909|BEHAVIORAL|General Anxiety Disorder-7 scale|The General Anxiety Disorder-7 scale was used to evaluate the level of anxiety in anesthesiology providers.
215025361|NCT01047540|DRUG|AIC316|Oral administration
215025362|NCT01047540|DRUG|AIC316|Oral administration
215103726|NCT06143982|BEHAVIORAL|Brief Intensive Trauma Treatment|BITT is an outpatient, intensive, one-week individual trauma therapy program. BITT is based on well-established protocols, consisting of two 90-minutes trauma therapy sessions a day (trauma exposure in the morning and EMDR in the afternoon), two psychomotor therapy sessions a day (1x60 minutes, 1x45 minutes), one 90-minutes psycho-education and social support skill training for parents a day, and a 90-minutes family therapy session at the end of the week (sharing the trauma narrative).
215103727|NCT04764318|BEHAVIORAL|Remote patient monitoring for hypertension|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician.
214423755|NCT05653583|DEVICE|Wrist Device|peripheral nerve stimulation via wrist-worn device
214423756|NCT05653583|DEVICE|Ear Device|peripheral nerve stimulation via ear-worn device
214423757|NCT05653583|DEVICE|Sham Device|Wrist-worn device that does not actually deliver stimulation
214691561|NCT05823909|DEVICE|fabian Therapy evolution ventilators with manual FiO2 control|12 hours Manual PRICO FiO2 control
214423758|NCT06235294|DIETARY_SUPPLEMENT|Resveratrol|Daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene), by morning, every day during the 3 months preceding in vitro fertilization treatment.
214423759|NCT06235294|DIETARY_SUPPLEMENT|Folic acid|Daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), by morning, every day during the 3 months preceding in vitro fertilization treatment.
214423760|NCT06411834|BEHAVIORAL|Decision navigation tool|An electronic, interactive form that guides patients through the major factors that influence their decision-making in thyroid cancer
214691562|NCT01147315|PROCEDURE|Hybrid bone substitution|The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
214691563|NCT03634605|PROCEDURE|Chemical pleurodesis|
214691564|NCT03634605|DRUG|Tetracycline Topical Ointment|
214691565|NCT03634605|DRUG|Normal saline|
214691566|NCT03634605|DRUG|Lidocaine 2% Injectable Solution|
214691567|NCT01011881|OTHER|pleural level of procalcitonin|no intervention
214691568|NCT04961801|DRUG|Acalabrutinib, tacrolimus, methotrexate|For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
214691569|NCT03864172|DIETARY_SUPPLEMENT|Usual intake + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice
215025363|NCT01047540|DRUG|AIC316|Oral administration
215025364|NCT01047540|DRUG|AIC316|Oral administration
215025365|NCT01047540|DRUG|Placebo|Oral administration
215025366|NCT06320990|DRUG|Tamoxifen 20mg|Tamoxifen is a nonsteroidal antiestrogen for oral administration.
215025367|NCT06176586|OTHER|Mat Pilates Exercises|The intervention will consist of mat Pilates exercises performed twice a week over a duration of 12 weeks, as an adjunct to the routine medical treatment for the patients, under the guidance of a qualified physiotherapist. Each exercise session will last for approximately 60 minutes. The treatment protocol will encompass targeted mobility exercises for the thoracic and lumbar regions, along with strengthening exercises focusing on core activation. The exercise program will be progressed in every four weeks.
215025368|NCT00005980|DRUG|pegylated liposomal doxorubicin hydrochloride|
215025369|NCT04098588|BEHAVIORAL|BEAST|See Arm Description
215025370|NCT04098588|BEHAVIORAL|Descriptive Feedback|See Arm Description
215025371|NCT02344355|DRUG|Temozolomide|"oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days."
214691570|NCT03864172|DIETARY_SUPPLEMENT|Usual intake+SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
214691571|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
214691572|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium+ SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
214691573|NCT03222479|BEHAVIORAL|Stress guide|smartphone-based application that can evaluate stress level and teach how to manage their stress
214691574|NCT00668343|DRUG|simvastatin|40 mg/ day
214691575|NCT00668343|DRUG|placebo|80 mg /day
214691576|NCT04628559|DRUG|Dexmedetomidine|dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
214691577|NCT04628559|DRUG|Ketamine|In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
214691578|NCT04628559|DRUG|Saline|Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
214691579|NCT01809561|PROCEDURE|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
214691580|NCT04266860|OTHER|Experimental - Test Results and Education|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the DxTerity test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the DxTerity test at the clinically-appropriate point in each case."
214691581|NCT03817593|OTHER|Transcendental Meditation (TM)|Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
214691582|NCT05106660|PROCEDURE|Ambulatory Laparoscopic Sleeve Gastrectomy|Same-day discharge
214691583|NCT05106660|PROCEDURE|Conventional Laparoscopic Sleeve Gastrectomy|Next-day discharge
214691584|NCT02979795|PROCEDURE|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy. 2.5 Gray/fraction (Total in 45-54 Gray)
214691585|NCT01224912|BEHAVIORAL|Cognitive Behavioral Treatment|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
214691586|NCT00942773|DRUG|Voriconazole|
214691587|NCT04146584|DEVICE|Sofwave Treatments|The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.
215025372|NCT02344355|RADIATION|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
215025373|NCT02344355|DRUG|Ascorbic Acid|"Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide."
215025374|NCT04250207|DRUG|K-321 Solution|K-321 solution drops
215025375|NCT04250207|DRUG|Placebo Solution|Placebo solution drops for K-321
215025376|NCT01437189|DRUG|Sertraline|Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
214691588|NCT02775864|DRUG|Antipsychotic|New initiation of any antipsychotic medication
214691589|NCT02775864|DRUG|Antidepressant|New initiation of any antidepressant medications
214691590|NCT02775864|DRUG|Benzodiazepine|New initiation of any benzodiazepine
214691591|NCT02775864|DRUG|Mood stabilizer|New initiation of lithium or any mood stabilizing anti-epileptic drug
214691592|NCT00953550|DRUG|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
214691593|NCT00953550|DRUG|Succinylcholine|1 mg/kg
214691594|NCT03238235|DRUG|Givinostat|suspension of Givinostat (10 mg/mL)
214691595|NCT03238235|DRUG|Placebo|suspension manufactured to mimic Givinostat
214694215|NCT03816306|DRUG|LCZ 696|LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
215025377|NCT05603676|OTHER|Intermittent hypoxia-hyperoxia conditioning|The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
215025378|NCT05603676|OTHER|Placebo intervention|Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
215025379|NCT03308279|DIAGNOSTIC_TEST|Ultrasound|Ultrasound and Anthropometric meassures
215025380|NCT00376103|DRUG|temozolomide|75 mg/m2/day
215025381|NCT00376103|PROCEDURE|Brachytherapy|60 Gy to 1 cm
215025382|NCT00376103|PROCEDURE|External Beam Radiation Therapy|60 Gy
214691596|NCT03048240|DEVICE|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
215025383|NCT01878448|DRUG|Anlotinib|
215025384|NCT06518369|OTHER|Prehabilitation|"Prehabilitation program for 4-6 weeks before surgery will include:~* Review of the frailty risk analysis calculator score obtained in the frailty study (#2212-74)~* Review of lab results including complete blood count, creatinine, albumin, and prealbumin~* Review of chronic conditions.~* An office visit or telehealth visit to review instructions on instructions on nutrition, exercise, smoking cessation, and optimization of chronic disease.~* Drinking surgery immunonutrition drinks twice daily for 5 days before surgery.~* Educational information and video instruction~* Weekly phone calls to motivate, ensure adherence, and assess progress.~* Measurements of hand grip strength and body weight"
215025385|NCT06168968|BEHAVIORAL|Life and Medication Recommendations|Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
215025386|NCT03654326|DRUG|Gefapixant|Gefapixant tablet 45 mg taken orally
215025387|NCT03654326|DRUG|Placebo|Placebo matching gefapixant tablet taken orally
214691597|NCT03048240|DRUG|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
214691598|NCT02826044|DRUG|SP2086|The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
214691599|NCT04194658|DRUG|Letrozole 2.5mg|Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
214691600|NCT06149312|OTHER|Advance Care Planning Intervention|Standardized interview based on The letter Project (Stanford Medicine) and Questions Prompt List
214691601|NCT01506414|DRUG|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
214691602|NCT02146989|OTHER|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
214691603|NCT03868228|PROCEDURE|Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)|Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
214691604|NCT00177541|BEHAVIORAL|Biofeedback, pelvic floor muscle training, fMRI|Biofeedback, pelvic floor muscle training, fMRI
214691605|NCT01348282|DRUG|Lithium|lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
215025388|NCT03654326|DRUG|Naproxen|Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
215025389|NCT06399107|GENETIC|Drug Product is administered by IV infusion following myeloablative conditioning with busulfan|An autologous CD34+ cell-enriched population from patients with sickle cell disease (SCD), which includes hematopoietic stem cells (HSCs) that have been transduced with the BAH243 lentiviral vector (LVV) carrying the βA-T87Q-globin gene, is preserved in a cryopreservation solution.
215025390|NCT06404450|BEHAVIORAL|Digital CBT|The digital CBT program is called Daylight (Big Health, Ltd). The program employs a virtual therapist to guide individuals through interactive exercises and animations to facilitate the learning and implementation of CBT techniques. The program focuses on four modules (10-20 minutes each) which address specific CBT principles: stimulus control, applied relaxation, cognitive restructuring (decatastrophizing), and imaginal exposure. Daylight is designed to be self-paced, with the app encouraging users to practice techniques both within the app and in real-life situations on a daily basis. Users receive reminders and motivational messages via emails, push notifications, and text messages tailored to participant progress.
215025391|NCT05424315|DRUG|Dapagliflozin 10mg|10mg Tab once daily
215025392|NCT05424315|DRUG|Glucose Tab|Placebo Oral Tablet
214691606|NCT01348282|DRUG|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
214691607|NCT05041192|DIETARY_SUPPLEMENT|Synaquell|7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
214691608|NCT05041192|DIETARY_SUPPLEMENT|Placebo|7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
215025393|NCT05872516|DEVICE|Chang Gung Atrial Fibrillation Detecting Software|This software is expected to be used in clinical testing to interpret the static 12-lead ECG of adults who are over 20 years old and suspected of having atrial fibrillation, detect whether there is a signal of atrial fibrillation, and output the results for clinicians Near-instant auxiliary diagnostic use.
215025394|NCT01628770|DRUG|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
215025395|NCT01628770|DRUG|Ferrous sulphate|200mg twice daily
215025396|NCT04573478|DRUG|Atrasentan|Film-coated tablet
215025397|NCT04573478|DRUG|Placebo|Film-coated tablet
214691609|NCT00178360|BEHAVIORAL|Music Therapy|"During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.~Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:~* Group singing~* Group drumming~* Music assisted relaxation~* Group song writing~* Lyric analysis~* Improvisation~* Music with art"
215103728|NCT04764318|BEHAVIORAL|Remote patient monitoring with care management|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician and providing care management services to support the enrollment and active use of this service.
215103729|NCT00051896|DRUG|GBR 12909|
215103730|NCT02668913|OTHER|Diagnostic analysis|Molecular profiling
215103731|NCT05571020|OTHER|mat pilates|Both groups adapted for their rides by not participating in a different exercise and meal. In the study, they were not found in any store in the control groups. In the Mat-Pates Group, information about the 5 key elements of the study and pilates team, perspective (-neck-shoulder-waist-abdominal placement), lumbopel stabilization, scapular stabilization, review and information was covered. Then, in the study groups, it was purchased from groups of 5-6 people at most for one hour a day. In order to participate in all these application activities, he continues his life without participating in any evaluation.
214691610|NCT01011920|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
214691611|NCT01011920|DRUG|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
215025398|NCT04472468|DEVICE|Percutaneous Balloon Pericardiotomy|"* Subxiphoid approach under fluoroscopic guidance is used.~* An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space.~* Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections."
215025399|NCT00936650|DRUG|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
215025400|NCT00936650|DRUG|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
215025401|NCT04129021|DEVICE|High-resolution retinal imaging through adaptive optics|The protocol consists of performing retinal imaging using full-field optical coherence tomography. The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
215025402|NCT04129021|DEVICE|High-resolution retinal imaging through holographic systems|The protocol consists of performing retinal imaging using a laser Doppler holography. For each system, the participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
215025403|NCT05853406|DIAGNOSTIC_TEST|Functional Reach test|"The determination by statistical research is carried out during a usual physiotherapy assessment of the volunteers. Data patient demographics and standard tests (FRT, Tinetti test, Timed Up and Go test, unipodal station) will be noted.~A satisfaction questionnaire inspired by Patient rating of change will be sent to participants for the determination of the MCID by ANCHOR method.~Concerning the Delphi method, a questionnaire will be sent to physiotherapists with proven geriatric activity."
215025404|NCT05763303|OTHER|educational program|interventional program consists of educational part and training part in case of agreement of participants
215025405|NCT00281437|BEHAVIORAL|choice of exercise program|
215025406|NCT05181475|DRUG|Sodium Oligomannate Capsules (GV-971)|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
215103732|NCT02673684|DEVICE|Experimental NSS|5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
215103733|NCT02673684|DEVICE|Sham NSS|(5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
215103734|NCT03080636|OTHER|Aerobic exercise|30 minutes of treadmill exercise at 60-70% of heart rate reserve
215103735|NCT03080636|OTHER|Resistance exercise|30 minutes of circuit resistance session at 40% of 1 maximun repetition test
215103736|NCT03080636|OTHER|Control session|30 minutes seated resting
215103737|NCT02971553|DEVICE|Upright Resuscitator with PEEP|
215103738|NCT02971553|DEVICE|Upright Resuscitator|
215103739|NCT05938036|DRUG|ALT-100 mAb|Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.
215103740|NCT05938036|DRUG|ALT-100 (Placebo)|Normal saline solution via IV solution
215103741|NCT00166530|DRUG|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
214691612|NCT01011920|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 \& 0 every 3 weeks for a maximum of 4 cycles
214691613|NCT01011920|DRUG|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4
214691614|NCT01011920|RADIATION|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
214691615|NCT01011920|DRUG|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
214691616|NCT01011920|OTHER|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
215025407|NCT04157465|OTHER|Treatment strategy trial|"Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~1. Fungal Biomarkers positivity (Beta-D Glucan\>150 pg/ml, Galactomannan index\>1.0)~2. Mycological evidence of fungal infection on fungal cultures from a non-sterile site~3. Radiological evidence of fungal infection~4. Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures."
215025408|NCT05435859|BEHAVIORAL|Speech Tasks|Listen to 25-minutes of speech sounds in English.
215025409|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.4 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
215025410|NCT04424251|DRUG|Experimental: stage I：HSK21542 1 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
215025411|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
214691617|NCT04008862|BEHAVIORAL|Partnership-based nursing practice|Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
214691618|NCT05416229|DRUG|Psilocybin|Psilocybin-assisted therapy
214691619|NCT05416229|DRUG|Maltodextrin|Placebo-assisted therapy
214691620|NCT02740569|OTHER|No intervention|Observational study. Intervention according to the clinical routines (not included in this part)
214691621|NCT03638089|BEHAVIORAL|Fall-recovery training|Participants practice recovering from simulated, treadmill-induced slips and trips.
214691622|NCT01191294|OTHER|Simulation teaching session|Simulation-based, mastery learning educational intervention in visual screening for melanoma
214691623|NCT04498429|OTHER|Integrated Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. In addition to verbal cueing, the manual cueing group will receive hands-on tactile facilitation from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
214691624|NCT04498429|OTHER|Verbal Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. The verbal cueing protocol consists of verbal cueing from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
215025412|NCT04424251|DRUG|Experimental: stage I：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
215025413|NCT04424251|DRUG|Experimental: stage II：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
215025414|NCT04424251|DRUG|Experimental: stage II：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
215025415|NCT04424251|DRUG|Placebo|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
215025416|NCT04102514|BEHAVIORAL|Real-time Group Video|Dyads in the RGV arm will be asked to complete three 45 min sessions that include aerobic, resistance, and balance/coordination exercises delivered by a trained health coach via Zoom® software on an iPad during mos. 0-6, and 1 session/wk. during mos. 7-12 to groups of 5-8 dyads in their home along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
214691625|NCT04963712|DRUG|Zadaxin|1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.
214691626|NCT01868373|BIOLOGICAL|Microbiota Transplantation (FMT)|Active therapy
215025417|NCT04102514|BEHAVIORAL|Enhanced Usual Care|Dyads in the EUC arm, will be given a recommended exercise plan to follow on their own along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
215025418|NCT06432322|DRUG|Esketamine nasal spray|Nasal spray solution, 56mg (28mg per nostril), intranasal
214691627|NCT00000579|PROCEDURE|Low Tidal Volume Ventilation|
214691628|NCT00000579|PROCEDURE|Positive End-Expiratory Pressure|
214691629|NCT00000579|DRUG|Lysofylline|
215103742|NCT00166530|DRUG|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
215103743|NCT00166530|DRUG|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
214691630|NCT00000579|DRUG|Methylprednisolone|
214691631|NCT00000579|DRUG|Ketoconazole|
215025419|NCT06432322|OTHER|Placebo|Nasal spray solution, 0.9% NaCl, intranasal
215025420|NCT03761641|OTHER|Neurotriage|NeuroTriage binocular handset monitors pupil dynamics \& eye position with infrared cameras. Rubber non-allergenic ocular spacers contoured to eye sockets come in contact with the face \&cushion between the skin \& eyepiece. During pupil dilation tests, an LED briefly illuminates the pupil. The NeuroTriage system measures neurological pupil index, constriction velocity, \& dilation velocity. Total pupil dilation testing time is \< 1 minute. During saccade-tracking tests, patients direct their gaze towards dim LED targets selectable across the range of view. Visual targets involve center-out ocular motion or smooth pursuit following of illusory movement. The NeuroTriage system measures eye position \& movement velocity during these tests. Total saccade-tracking testing takes \< 3 minutes. Ocular measures are non-invasive, are done quickly and commonly used to measure neurological function.
215025421|NCT06035094|BEHAVIORAL|Exercise Intervention to improve overall Brain Health|"During each exercise session, the participant will be assigned to the HIIT or MIT exercise group and asked to ride the stationary bicycle for approximately 30-40 minutes, while wearing the heart rate monitor and recording the session on their smart phone application. For each exercise session, the Polar Beat application will record the time in each of four intensity zones. The participant will receive training on how to use the outlined schedule during the initial supervised training session."
215025422|NCT00835549|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
215025423|NCT00835549|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
214691632|NCT00000579|PROCEDURE|Fluid Management|
214691633|NCT00000579|PROCEDURE|Pulmonary Artery Catheter|
214691634|NCT02811133|DRUG|Inositol|Subjects will receive inositol
215025424|NCT03298334|BIOLOGICAL|Vaginal Seeding|A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
215025425|NCT03298334|OTHER|No Vaginal Seeding|A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
215025426|NCT05078710|DRUG|Telitacicept|160mg once a week for 24 weeks
214691635|NCT06175611|DEVICE|COVID-19/Flu A/Flu B/RSV Test Kit|"The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.~Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.~This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants."
214691636|NCT03654547|DRUG|TT-00420|"TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg."
214691637|NCT00843310|DRUG|Lenalidomide (Revlimid)|
214691638|NCT00843310|DRUG|Melphalan|
214691639|NCT00843310|DRUG|Dexamethasone|
214691640|NCT02028338|COMBINATION_PRODUCT|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
214691641|NCT02028338|COMBINATION_PRODUCT|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
214691642|NCT03273075|DRUG|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
214691643|NCT03273075|DRUG|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
214691644|NCT03273075|DRUG|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
215025427|NCT04360330|RADIATION|Stereotactic Ablative Breast Radiotherapy|"Preoperative SABER: Participants will be treated with an assigned dose level of preoperative SABER, delivered in once a day, 5 fractions given on non-consecutive days, over a period of 2 weeks. In this phase I study, starting with dose level II, a dose level of preoperative SABER will be assigned per study dose-escalation design, treating 2 to 6 patients per dose level. The tested doses are the following:~* Dose Level I: 35 Gy (5 fractions of 7 Gy)~* Dose Level II (Starting Dose): 40 Gy (5 fractions of 8 Gy)~* Dose Level III: 45 Gy (5 fractions of 9 Gy)~* Dose Level IV: 50 Gy (5 fractions of 10 Gy)"
215025428|NCT00835042|DRUG|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
215025429|NCT00835042|DRUG|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
215025430|NCT00619918|DRUG|Nebulized 3% saline|4 ml inhaled q8h
215103744|NCT06166108|DRUG|transversus abdominis plane (TAP) block in Abdominal hysterectomy|Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
215103745|NCT02744417|BEHAVIORAL|Smoking cessation counseling|Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
215103746|NCT02744417|PROCEDURE|Non-surgical periodontal therapy|Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
215025431|NCT00619918|DRUG|Nebulized 0.9% saline|normal saline
215025432|NCT06140420|DRUG|Naltrexone Oral Product|Generic, oral tablet.
215025433|NCT06140420|DRUG|Placebo|Oral Placebo
215025434|NCT04169009|BIOLOGICAL|Zostavax|Intradermal injection of Zostavax
215025435|NCT04169009|BIOLOGICAL|Shingrix|Given to subjects in Arm 4 who've never had a herpes zoster vaccine
215025436|NCT03492385|DRUG|PB2452 Infusion|30 minute - 12 hour infusion
215025437|NCT03492385|DRUG|Placebo - Sodium Chloride|30 minute - 12 hour infusion
215025438|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo
215025439|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo
215025440|NCT03617939|PROCEDURE|Biospeciman Collection|Collection of blood, tissue, and other biological samples.
215025441|NCT03617939|OTHER|Survey Assessments|Data taken from patient surveys and assessments, including quality of life.
215025442|NCT03617939|OTHER|Medical Chart Reviews|Data taken directly from the patients' medical charts.
215025443|NCT06138158|PROCEDURE|Exercise and Education Group|Physical exercise and pain education
215025444|NCT03118505|DEVICE|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
215025445|NCT03118505|DEVICE|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
214691645|NCT03273075|DRUG|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
214691646|NCT04165343|RADIATION|Positron Emission Tomography (PET) on EXPLORER|"Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive tracer (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you."
214691647|NCT04165343|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
215025446|NCT02891954|DRUG|Canagliflozin|Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
215025447|NCT05700721|DRUG|Niraparib|Given by PO
215025448|NCT05700721|DRUG|Dostarlimab|Given by IV (vein)
215025449|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF5993 pMDI
215025450|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF1535 pMDI or CHF5993 pMDI
215025451|NCT03920982|DIAGNOSTIC_TEST|Determination of the blood concentration of indoxyl sulfate (IS)|IS concentration will be determined in blood of patients with septic shock and acute kidney injury. IS blood concentration will be done every day during 7 first days after patient will be admitted in intensive care unit. Relation between IS peak serum concentration and mortality at day 28 will be determined.
215025452|NCT05829330|OTHER|Outpatient|Outpatient Initiation of noninvasive mechanical ventilation
215025453|NCT05829330|OTHER|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
215025454|NCT04989218|DRUG|Novel combination of chemotherapy and immunotherapy|This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
215025455|NCT05524948|OTHER|Experimental Dentifrice|Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.
215025456|NCT05524948|OTHER|Reference Dentifrice|Standard fluoride dentifrice containing 0.243% sodium fluoride.
215025457|NCT06637644|DEVICE|Right-sided ventricular assist device|Percutaneous device for right heart support
215025458|NCT05155085|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
215025459|NCT05155085|OTHER|Placebo|Placebo
215025460|NCT06639373|OTHER|Specialized clinical service access|A new model of addiction care that will offer comprehensive and coordinated service delivery
215025461|NCT06640348|OTHER|No intervention|No intervention
215025462|NCT06640686|OTHER|Exercise training|Inspiratory muscle training for increase strength of inspiratory muscle.
215025463|NCT06644313|DRUG|Vebreltinib|Neoadjuvant treatment stage: Vebreltinib 200mg, bid, po, 2-4 months in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Vebreltinib 200mg, bid, po, up to 2 years/until the disease progressed. PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
215025464|NCT06560346|OTHER|Geneticlly confirmed disease causing FXN mutatuion|No intervention in this observational Natural History Study
215025465|NCT06560346|OTHER|Healthy Control|No intervention in this observational Natural History Study
215025466|NCT03060707|DRUG|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
215025467|NCT03318874|DEVICE|Blephasteam|Steam delivery goggles, once daily
215025468|NCT03318874|DEVICE|THERA°PEARL Eye Mask|Heat delivery device, delivering heat to the eyelids, once daily
215025469|NCT03318874|DRUG|Hylo-comod|Tear substitute containing hyaluronic acid, four times daily
215025470|NCT00607477|DRUG|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
215025471|NCT00607477|DRUG|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
215025472|NCT03884920|DIETARY_SUPPLEMENT|Polyherbal formulation|Test candidate will be administered per oral before / with meal in two divided doses
215025473|NCT04067622|DEVICE|Exersides|A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
215025474|NCT02219100|DRUG|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
215025475|NCT03288857|DEVICE|NeilMed Naspira|NeilMed Naspira is a nasal-oral aspirator
215025476|NCT04661839|BIOLOGICAL|COVID-HIGIV|COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.
215025477|NCT04661839|OTHER|Placebo (saline)|The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.
215025478|NCT00248235|BEHAVIORAL|Exercise|
215025479|NCT03329131|DEVICE|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
215025480|NCT01462747|DEVICE|KULIST|Twice daily dosing for 8 weeks
215025481|NCT02758626|DRUG|ataluren|Powder formulation
215025482|NCT02758626|DRUG|Placebo|Powder formulation
215025483|NCT05429411|OTHER|Silicone gel|At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach \>21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
215025484|NCT02489487|DRUG|VM-1500|VM-1500 40 mg
215025485|NCT02489487|DRUG|Darunavir|Darunavir 600 mg
215025486|NCT02489487|DRUG|Ritonavir|Ritonavir 100 mg
215025487|NCT02489487|DRUG|Raltegravir|400 mg Raltegravir
215025488|NCT00610220|DEVICE|Fiberglass short arm cast|Cast will be applied for a 4-week period
215025489|NCT00610220|DEVICE|Prefabricated wrist splint|Splint will be applied for a 4-week period
215025490|NCT05617196|BEHAVIORAL|Virtual PREHAB|The Virtual PREHAB program begins with a virtual health care team assessment. The physiotherapist will support patients in identifying ways to safely engage in home-based physical activities and in their neighborhoods. Additional weekly 30-minute telephone consultations with the physiotherapist, nurse, and dietitian are provided as well as three 30-minute online consultations are provided; telephone calls will replace these online consults if the patient does not have internet access. Telephone and/or online consults with participants will monitor the progression of the individual through the program, review patient materials, review medication changes, as well as provide recommendations to adopting a physically active lifestyle, diet, well-being, smoking, or other supports available to the patient. Medication changes are monitored by a nurse and any necessary medication recommendations involve the program's medical director, the patient's family physician, and TAVI team.
215103747|NCT02744417|DRUG|Nicotine replacement therapy|Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
215103748|NCT02744417|DRUG|bupropion hydrochloride|bupropion hydrochloride 150mg
215025491|NCT05617196|BEHAVIORAL|Standard care|In Nova Scotia, patients are referred to the TAVI program. The TAVI health care team, consisting of a cardiac surgeon, cardiologist, nurse, and geriatric team conduct patient assessments and provide guidance and resources on self management.Once patient assessments are completed, patients are discussed at a multidisciplinary team meeting. When a patient is accepted for TAVI, they are placed on a waiting list which lasts for 3-6 months depending on urgency.
215025492|NCT05830097|DRUG|CBP-1019|Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.
215025493|NCT03277872|DEVICE|Laryngoscopy with GlideScope (GVL) Blade|"1. st Laryngoscopy with GVL Blade~2. nd Laryngoscopy with MAC Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
215025494|NCT03277872|DEVICE|Laryngoscopy with MacIntosh (MAC) Blade|"1. st Laryngoscopy with MAC Blade~2. nd Laryngoscopy with GVL Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
215025495|NCT00529815|DEVICE|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
215025496|NCT00529815|DEVICE|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
215025497|NCT03352180|PROCEDURE|arthroscopic reapir of subscapularis tendon|arthroscopic reapir of massive rotator cuff tears involving the subscapularis.
215025498|NCT03352180|PROCEDURE|arthroscopic debridement of subscapularis tendon|arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
215025499|NCT05313958|DRUG|Cladribine|5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
215025500|NCT05313958|DRUG|G-CSF|5ug/kg/day d0-5,if Peripheral blood leukocytes\<20,000/ul
215025501|NCT05313958|DRUG|Cytarabine|2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
215025502|NCT05313958|DRUG|Idarubicin|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
215025503|NCT05313958|DRUG|Mitoxantrone|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
215103749|NCT02744417|DRUG|Varenicline|Varenicline 0,5mg
215103750|NCT02387008|DEVICE|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
215103751|NCT02387008|DEVICE|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
215103752|NCT02387008|DEVICE|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
215103753|NCT03959917|PROCEDURE|transurethral resection of the prostate|Surgical removal of benign prostatic tissue
215103754|NCT04369157|PROCEDURE|Elective surgery|Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.
214691648|NCT04165343|DIAGNOSTIC_TEST|Echocardiogram and Electrocardiogram|You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
215025504|NCT05313958|DRUG|Sorafenib|200mg/m2/day was taken orally until molecular biology remission for 2 years
215025505|NCT05459779|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance.
215103755|NCT04294836|DRUG|Curcumin|BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice
215103756|NCT04294836|DRUG|Placebo oral tablet|PLACEBO Capsules 500mg
215103757|NCT00094848|DRUG|TRAIL-R1 mAb (TRM-1; HGS-ETR1)|
215025506|NCT05459779|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activating assistance.
215025507|NCT05720351|PROCEDURE|Lachmann maneuver|Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)
214508310|NCT03878394|OTHER|aerobic exercise and balance exercises|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
214508311|NCT03878394|OTHER|aerobic exercise and balance exercises with cognitive exercises|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
215025508|NCT05720351|PROCEDURE|Staircase maneuver|Patients undergone Undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
215025509|NCT05249660|OTHER|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
215025510|NCT05249660|OTHER|Comparator: Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
215103758|NCT01423266|PROCEDURE|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
215103759|NCT03368235|DRUG|AZD9567|oral OD SGRM administered as suspension
215103760|NCT03368235|DRUG|Prednisolone|oral capsules of 20 mg prednisolone administered OD for two weeks
215103761|NCT01112748|DRUG|Topical lidocaine patch|Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
215103762|NCT04770948|DEVICE|19 gauge needle|EBUS-TBNA performed using 19G needle
215103763|NCT04770948|DEVICE|22 gauge needle|EBUS-TBNA performed using 22G needle
215103764|NCT05414552|DRUG|ECP|Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
215103765|NCT03932630|OTHER|Low carbohydrate diet|The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.
215103766|NCT03932630|OTHER|balanced diet|The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
215103767|NCT04571996|DRUG|ODM-104|Capsule
215103768|NCT04571996|DRUG|Paracetamol|Rapidly dissolving tablet
215103769|NCT05167591|DIAGNOSTIC_TEST|Drug concentration measurement|Measurement of paracetamol concentration in capillary, venous plasma and saliva samples after standard premedication with paracetamol
215103770|NCT05650853|OTHER|Transrectal ultrasound|Examinations for observation of the pre, per and post-ejaculatory phases
215025511|NCT01215331|DRUG|Insulin|Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
215025512|NCT01215331|DRUG|Metformin, glyburide and insulin|"Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents."
215025513|NCT04652297|DRUG|HS-10356|Single dose of HS-10356
215025514|NCT04652297|DRUG|Placebo|Single dose of Placebo
215025515|NCT04652297|DRUG|HS-10356|Multiple doses of HS-10356
215025516|NCT04652297|DRUG|Placebo|Multiple doses of Placebo
215025517|NCT06414031|DRUG|Tranexamic Acid|Intravenous administration
214508312|NCT03964974|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
215025518|NCT06414031|DRUG|Placebo|Intravenous administration
214691649|NCT04165343|DIAGNOSTIC_TEST|Blood test|We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
215103771|NCT05650853|OTHER|Urethroscopy|Examinations for observation of the pre, per and post-ejaculatory phases
215103772|NCT04095091|DEVICE|4D Planar US Transducer|This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
215103773|NCT00772681|DRUG|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
215103774|NCT02846701|DRUG|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
215103775|NCT01873625|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
215103776|NCT01873625|BIOLOGICAL|placebo|
215103777|NCT00416455|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT
215103778|NCT00416455|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
215103779|NCT00416455|PROCEDURE|computed tomography|Undergo FDG PET/CT
215103780|NCT00416455|DRUG|ferumoxtran-10|Undergo femoxtran-10 MRI
215103781|NCT00416455|PROCEDURE|magnetic resonance imaging|Undergo femoxtran-10 MRI
215103782|NCT00416455|PROCEDURE|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
215103783|NCT00416455|PROCEDURE|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
215103784|NCT01515046|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
214423761|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
214423762|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
214691650|NCT02094586|BIOLOGICAL|PXVX0200 Lot A|Lot P700-1CA03
214691651|NCT02094586|BIOLOGICAL|PXVX0200 Lot B|Lot P700-3CA03
214691652|NCT02094586|BIOLOGICAL|PXVX0200 Lot C|Lot P700-6BA03
215103785|NCT03402828|DRUG|Any topical drug treatment|Any treatment strategy used to prevent relapse of psoriasis symptoms
214423763|NCT03143842|DEVICE|Vagus Nerve Stimulation|Delivering electrical pulses to the Vagus Nerve
214423764|NCT03090776|DRUG|Ketamine|low dose bolus and infusion ketamine, administered under general anesthesia
214691653|NCT02094586|BIOLOGICAL|Placebo|Placebo
215025519|NCT03071302|OTHER|EVALUATION OF VSX1, SOD1, and TIMP3 genes|Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
214691654|NCT03242278|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
215025520|NCT01071785|DIETARY_SUPPLEMENT|guar gum|guar gum 10g/day for six weeks
215025521|NCT00855166|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
215025522|NCT00855166|DRUG|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
215025523|NCT00855166|DRUG|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
215025524|NCT00855166|DRUG|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
215025525|NCT03320993|OTHER|Mixed meal with different macronutrient composition|A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
215025526|NCT02407938|OTHER|Rice meal|
215025527|NCT02478749|PROCEDURE|arm retraction|gently pulling through the ipsilateral arm to the knee
215025528|NCT02702999|DEVICE|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
215025529|NCT02702999|DEVICE|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
215025530|NCT04314973|DEVICE|Active Pelvis Orthosis|Walking with the robotic device providing the assistive protocol.
215025531|NCT04314973|OTHER|Walking exercises|Walking exercises without wearing the robotic device.
215025532|NCT06501352|DRUG|Dexmedetomidine|Additive to Local anesthetic mixture
215025533|NCT06501352|DRUG|Neostigmine|Additive to Local anesthetic mixture
215025534|NCT06501352|DRUG|Saline|Control
215025535|NCT01271231|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
215025536|NCT01271231|DRUG|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
215025537|NCT01271231|DRUG|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
215025538|NCT01272219|DRUG|liraglutide|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
215025539|NCT01272219|DRUG|placebo|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
215025540|NCT01272219|DRUG|liraglutide|Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
215025541|NCT01272219|DRUG|placebo|Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
215025542|NCT03131479|DRUG|LIK066|LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
215025543|NCT01906320|BEHAVIORAL|High-Intensity Resistance training|"Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).~The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.~Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program."
215025544|NCT02009449|DRUG|Pegilodecakin|Daily subcutaneous injections of pegilodecakin up to 12 months
215103786|NCT00668538|DRUG|Brentan (miconazole)|Vaginal suppository 1200 mg at day 6
215025545|NCT02009449|DRUG|Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Day 1 of every 21 day cycle
215025546|NCT02009449|DRUG|FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Intravenous administration on Day 1 and 2 of every 14 day cycle
215025547|NCT02009449|DRUG|gemcitabine/nab-paclitaxel|Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.
215025548|NCT02009449|DRUG|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
215025549|NCT02009449|DRUG|Pazopanib|Pazopanib will be administered orally daily continuously
215025550|NCT02009449|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
215025551|NCT02009449|DRUG|Paclitaxel|"Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV"
215025552|NCT02009449|DRUG|nivolumab|Nivolumab on Day 1 of each cycle (14 days = 1 cycle)
215025553|NCT02009449|DRUG|Gemcitabine/carboplatin|gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)
215025554|NCT04243863|DRUG|VNRX-7145|Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
215103787|NCT05688020|DRUG|Tranexamic acid|Tranexamic acid will be injected as part of the injectate during endoscopic resection.
215103788|NCT05688020|DRUG|Epinephrine injection|Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
215103789|NCT02549131|PROCEDURE|Randomizing to Suture or Staple closure of Cesarean section|Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
214691655|NCT00467909|BEHAVIORAL|micronutrients|
214691656|NCT02761993|BIOLOGICAL|ST266|1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
215025555|NCT04243863|DRUG|Placebo|Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
215025556|NCT06087289|DRUG|KAND567|"KAND567 is a drug in capsule and is intended to be orally administered approximately every 12 hours (±1 hour) with an initial loading dose on Day 2 of two times the dose specified for that dose group (e.g., 2 x 250, 2 x 375, 2 x 500, or 2 x 625 mg KAND567, depending on the dose group; in Part 2, this is the RPIID), followed by a KAND567 dose (Day 2, evening dose) that corresponds to the given dose level. On Days 3 to 7, the subjects will be orally administered the specified KAND567 dose (e.g., 250, 375, 500, or 625 mg BID, depending on the dose group; in Part 2, this is the RPIID).~During the second week of dosing (Days 8 to 14) in Part 1 and Part 2, the subjects will be orally administered KAND567 at a dose of 250 mg BID. One treatment cycle is defined as a 21-day period, and each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression)."
215025557|NCT06087289|DRUG|Carboplatin|Carboplatin will be administered i.v. according to standard of care at a dose of AUC 5. One cycle is defined as a 21-day period with chemotherapy given on Day 1. Each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression). The carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC 5 × (GFR + 25). GFR should be calculated using the Cockcroft-Gault formula. The maximum carboplatin dose is based on a calculated GFR that is capped at 125 mL/min for subjects with normal renal function.
215025558|NCT05408260|PROCEDURE|Ultrasonography|Undergo HHUS
215025559|NCT05408260|PROCEDURE|Automated Breast Ultrasound|Undergo ABUS
215025560|NCT04379271|DRUG|IMU-838|"Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable).~If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube."
215025561|NCT04379271|OTHER|Placebo|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838
215025562|NCT03917498|RADIATION|Single Pre-Operative Radiation Therapy - with Delayed Surgery|Single Pre-Operative Radiation Therapy - with Delayed Surgery
215025563|NCT03286569|DEVICE|Upper arch Wilson quadhelex appliance|Upper arch Wilson quadhelex appliance
215025564|NCT02899754|BEHAVIORAL|Lung Cancer Screening Decision Tool|This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
215025565|NCT02899754|BEHAVIORAL|Control Intervention|This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
215025566|NCT04818229|DRUG|CBP-307|CBP-307 capsules oral administration.
215025567|NCT04818229|DRUG|Placebo-matched CBP-307|Placebo-matched CBP-307 capsules oral administration.
215025568|NCT04818229|DRUG|Moxifloxacin (Avelox)|Moxifloxacin tablets oral administration。
215025569|NCT04818229|DRUG|Placebo-matched Moxifloxacin|Placebo-matched Moxifloxacin tablets oral administration.
215025570|NCT02486770|BIOLOGICAL|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
215025571|NCT02486770|BIOLOGICAL|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
215025572|NCT02486770|BIOLOGICAL|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
215025573|NCT03186378|COMBINATION_PRODUCT|VP-102 with applicator|Subjects will receive treatment to their molluscum contagiosum with VP-102.
215025574|NCT00265642|DRUG|Irbesartan|one tablet of 150 mg/d during 2 years
215025575|NCT00265642|DRUG|placebo|one tablet per day during 2 years
215025576|NCT06229873|DEVICE|App-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by a smartphone application. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. All training sessions will be guided by the smartphone application.
215025577|NCT06229873|DEVICE|Clinic-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by researchers. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. One training session each week will be performed in the research clinic.
215025578|NCT02514746|BIOLOGICAL|Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine|0.5 mL subcutaneous injection
215025579|NCT02181413|DRUG|Ixazomib Citrate|Ixazomib citrate capsules
215025580|NCT02181413|DRUG|Placebo|Ixazomib citrate placebo-matching capsules
215025581|NCT00045331|GENETIC|proteomic profiling|
215025582|NCT06048497|DEVICE|Corrected carotid flow time measurement guided fluid preload|Preoperative FTcs of pregnant women who underwent C/S operation were measured, and those below the cut-off value (327 ms) determined in previous studies were preloaded with Ringer Lactate until FTc was \> 327 ms.
215025583|NCT04669093|BEHAVIORAL|"Placebo cream- promotion suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a promotion approach (promoting good feelings)."
215025584|NCT04669093|BEHAVIORAL|"Placebo cream- prevention suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a prevention approach (preventing pain)."
215025585|NCT04669093|BEHAVIORAL|Control cream|In a control condition, with the same cream as in the placebo interventions, participants will be instructed that the cream is a control cream with no effects.
215025586|NCT02365688|PROCEDURE|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
215025587|NCT04487821|OTHER|Cawthorne Cooksey Exercises|"Activity sitting on the Exercise Ball swing (eye movements, first slow and then fast)~Swing sitting activity (head movements, first slow then fast - eyes open and eyes closed)~Trunk activities focusing on balance~Dynamic balance activity focusing on standing"
215025588|NCT00050011|DRUG|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
215025589|NCT00050011|DRUG|Letrozole|Participants received Letrozole 2.5 mg daily.
215025590|NCT05607472|OTHER|blood sampling|blood samples for bio collection
214508313|NCT03964974|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
214691657|NCT02761993|DRUG|Saline (0.9% NaCl)|Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
215025591|NCT05607472|OTHER|questionnary of health estate during 18 month|clinical exam Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation) during 18 months
215025592|NCT05513508|PROCEDURE|Protocolized rotational use of interfaces|The NIV mask will be changed every 6 hours, alternating two different interfaces between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask.
215025593|NCT05513508|PROCEDURE|Standard of care|Mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
215025594|NCT06568796|OTHER|randomize controlled study|eswt treatment
215025595|NCT02866331|DRUG|G-CSF (Leucostim)|
215025596|NCT02866331|BIOLOGICAL|CB (autologous cord blood)|
215025597|NCT02866331|DRUG|Placebo (Normal saline)|
215025598|NCT02214212|DEVICE|Bright White Light (BWL)|The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
215025599|NCT02214212|DEVICE|Red Light (RL)|The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
215025600|NCT00772525|DRUG|Nerispirdine|"form: tablet~Route: oral"
215025601|NCT00772525|DRUG|Placebo|"form: tablet~Route: oral"
215025602|NCT06362889|COMBINATION_PRODUCT|Microneedling with CBD|Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil Organic Hemp Seed Oil- used as carrier oil for CBD isolate in Combination with Microneedling Device
215025603|NCT05944237|DRUG|HTL0039732 Capsules|HTL0039732 Capsules will be administered orally to fasted participants, although an exploration of food effects may be performed as a single dose at Cycle 0. A single dose will be administered between 3 and 9 days prior to commencement of Cycle 1. From Cycle 1 Day 1, HTL0039732 will be administered on a once daily (QD) schedule. Each administration cycle will consist of 21 days with no break between cycles. Participants may initially receive up to 18 cycles but may continue for a further 18 cycles if they are deemed to be benefitting.
215025604|NCT05944237|DRUG|HTL0039732 Capsules and atezolizumab infusion|HTL0039732 Capsules will be administered orally on a QD schedule to participants starting on Cycle 1 Day 1. Each administration cycle will consist of 21 days with no break between cycles. Participants will also receive 1200 mg atezolizumab as an IV infusion on Day1 of each cycle (i.e. every 3 weeks). Participants may initially receive up to 18 cycles of HTL0039732 but may continue for a further 18 cycles if they are deemed to be benefitting, and they may receive up to 36 cycles of atezolizumab.
215025605|NCT06468865|DEVICE|Continuous glucose monitor (Dexcom® G7)|Continuous glucose monitors measures glucose levels in the interstitial fluid every 5 minutes
215025606|NCT03223987|DIETARY_SUPPLEMENT|Strath® Kräuterhefe Original (liquid)|"The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study."
215025607|NCT06047717|OTHER|Virtual Reality Driving Task|"Participants will steer a virtual car with the goal of staying in the center of a single-lane roadway while traveling at a constant speed of 26.6 m/s (approximately 60 miles/hr). The roadway alternates between a series of straights and turns of different radii to both the left and the right. This allows for careful control of task difficulty, and for the repeated presentation of specific conditions across multiple trials (i.e. turns in the road) in a randomized order. In addition, the density of the visual texture elements in the virtual environment that provide optic flow (OF) signal is also varied. The low-density OF condition has no road texture or foliage, and only the solid road edges on a flat-black ground plane. The medium-density OF condition has sparse textural elements distributed on the ground plane, and the high-density OF condition has high density road texture and a canopy of road-side trees that provide texture extending far above the horizon."
215025608|NCT05861752|BEHAVIORAL|Treatment as usual|both groups will undergo a psychiatric assessment including interviews, impulsivity tests and fill out questionnaires and leave blood samples. The clinical population will be followed regarding treatment as usual
215025609|NCT06289062|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
215025610|NCT06289062|DRUG|Cisplatin|75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
214508314|NCT01702103|DRUG|Mometasone furoate|
215025611|NCT06289062|DRUG|Nab paclitaxel|260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
215025612|NCT06289062|PROCEDURE|biopsy|cone biopsy + pelvic lymphadenectomy or Cervical biopsy + pelvic lymphadenectomy
215025613|NCT06645600|DIAGNOSTIC_TEST|Fracture risk|To calculate fracture risk, the percentages for major and hip fracture risks will be calculated using the Fracture Risk Assessment Tool (FRAX®). The one-leg stance test, used to assess static posture and balance, and the 30-second sit-to-stand test, used to evaluate endurance and lower extremity strength, will be applied to the patients.
215025614|NCT03984578|DRUG|CAPEOX|Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1
215025615|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 and Day 22
215103790|NCT04313478|BEHAVIORAL|Low Birth Weight and Normal Weight infants|This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
215103791|NCT06478303|OTHER|Motor imagery|Participants were asked to imagine arm or foot movements.
214691658|NCT03694574|BEHAVIORAL|instruction to suppress|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, \& Hoffmann, 2011)"
215103792|NCT06478303|OTHER|Action reading|Participants were asked to read sentences involving arm or foot movements
215103793|NCT06478303|OTHER|Motor localizer|Participants were asked to perform arm or foot movements
215103794|NCT00406679|DRUG|Paracetamol (acetaminophen) solution experimental|1 gm IV
215103795|NCT00406679|DRUG|paracetamol (acetaminophen) solution commercial|1 gm IV
215103796|NCT00406679|DRUG|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
215103797|NCT00232856|DEVICE|drug-eluting stent|PCI
215025616|NCT03984578|DRUG|Capecitabine/ 5-FU|Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation
215025617|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 of each cycle
215025618|NCT03984578|DRUG|CAPEOX/Pembrolizumab|"* Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle.~* IV Oxaliplatin: 130mg/m2 on Day 1 of a 3-week cycle.~* Pembrolizumab: IV infusion of 200mg on Day 1 of a 3-week cycle."
215025619|NCT03984578|DRUG|Pembrolizumab alone|IV infusion of 200mg 21 days from the last CAPEOX/Pembrolizumab combination dose.
215025620|NCT03984578|PROCEDURE|Surgical resection|Performed after all medical intervention.
215025621|NCT02118246|DEVICE|Dry Needling|Dry needling was performed for one week, three times a week.
215025622|NCT02118246|DEVICE|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
215025623|NCT03538808|DRUG|Varenicline|Participants will be provided varenicline medication
215025624|NCT03538808|OTHER|Placebo|Participants will be provided placebo medication
215025625|NCT04903093|DRUG|Abrocitinib tablet|Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
215025626|NCT04903093|DRUG|Abrocitinib Suspension F1|Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
215103798|NCT00284310|PROCEDURE|Anamnesis and clinical examination|Anamnesis and clinical examination to follow.
215103799|NCT01710098|DRUG|Degarelix|subcutaneous injection
215103800|NCT01081743|OTHER|Intervention of the social worker|Systematic home visits and regular follow-ups by phone from a social worker
215103801|NCT01876693|PROCEDURE|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
215103802|NCT05862090|DRUG|RLD2301|Take it once a day per period.
215025627|NCT04903093|DRUG|Abrocitinib Suspension F2|Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
215025628|NCT04903093|DRUG|Abrocitinib Suspension F3|Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
215103803|NCT05862090|DRUG|RLD2007|Take it once a day per period.
215103804|NCT04079114|DEVICE|Patients who received the Stafit Acetabular System|Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.
215103805|NCT04119011|BIOLOGICAL|Probiotic|(Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
214423765|NCT03090776|OTHER|Placebo saline|bolus and infusion saline, administered under general anesthesia
214508315|NCT01643122|OTHER|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
214508316|NCT01643122|OTHER|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
214423766|NCT05646004|DEVICE|Cataract surgery|Implantation of 621 lens
215025629|NCT04903093|DRUG|Abrocitinib Suspension F4|Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
215025630|NCT04903093|DRUG|Abrocitinib Suspension F5|Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
215025631|NCT04903093|DRUG|Abrocitinib Suspension F6|Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
215025632|NCT04903093|DRUG|Famotidine|Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
215103806|NCT04119011|OTHER|Placebo|lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
215103807|NCT04368793|BEHAVIORAL|Remote pulmonary rehabilitation|The pulmonary rehabilitation intervention includes respiratory exercise, barehanded aerobic training, exercise prescription of elastic band impedance training, respiratory muscle strength training, etc.
215103808|NCT06356389|DRUG|JX11502MA|Oral capsule
215103809|NCT06356389|DRUG|Placebo|Oral capsule
214508317|NCT06236204|PROCEDURE|Arthroscopic Scapholunate Ligament Reconstruction|reconstruction of the SL ligament with palmaris tendon graft tunneled through the scaphoid and lunate as described by Corella et al.
215103810|NCT02868047|PROCEDURE|Endoscopic Ultrasound|Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
215103811|NCT01796821|DRUG|Vehicle gel|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
215103812|NCT01796821|DRUG|SR-T100 gel with 1.0 % SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
214508318|NCT04214093|DRUG|AZD0466|"In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort."
214508319|NCT01729793|DIETARY_SUPPLEMENT|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
214508320|NCT01729793|OTHER|Placebo|Capsule containing microcrystalline cellulose
214508321|NCT01698567|DRUG|Antithrombin III|"ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)"
214508322|NCT01698567|DRUG|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
214508323|NCT04737993|DRUG|licocain|pulsed radiofrequency stimulation
215025633|NCT03555994|DRUG|MEDI0382|MEDI0382 administered subcutaneously
215025634|NCT03555994|DRUG|Placebo|Placebo administered subcutaneously
215025635|NCT03555994|DRUG|Liraglutide|Liraglutide administered subcutaneously
215025636|NCT05035628|OTHER|Cardiopulmonary exercise training|"Participants will follow a 2-month exercise training program, thrice-weekly trainings. The training sessions will start with a 5-min warmup, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with respiratory exercises and cool down period (10 min). Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test.~A certified kinesiologist will supervise trainings. Heart rate, oxygen saturation and rating of perceived exertion (Borg Scale, 6-20) will be measured during training sessions."
215025637|NCT06123468|DRUG|Sacituzumab govitecan|10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)
215025638|NCT01097681|DRUG|ASP1941|oral
215025639|NCT05399433|OTHER|Biopsy and venous blood|"A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis"
215103813|NCT01796821|DRUG|SR-T100 gel with 2.3% SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
215103814|NCT00996255|DRUG|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
215103815|NCT05474222|OTHER|Horizon Eagle Fatherhood Program - classroom instruction|The intervention group (the Horizon Eagle Fatherhood Programming) receives 40 hours of classroom instruction
215103816|NCT04797546|PROCEDURE|Adductor Canal Block|Continous peripheral nerve block
214508324|NCT04737993|OTHER|pulsed radiofrequency stimulation|pulsed radiofrequency stimulation of joint capsel
214508325|NCT00001895|DRUG|FDG|
214508326|NCT00001895|DRUG|NH(3)|
214508327|NCT04634994|DRUG|[F-18]SDM-8|PET radiopharmaceutical. Subjects will undergo \[F-18\]SDM-8 PET Scanning to measure synaptic density.
214508328|NCT03188978|DRUG|Atorvastatin 40mg|one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
214508329|NCT03188978|OTHER|Placebo|one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
214508330|NCT05024396|DIAGNOSTIC_TEST|maximum jump height|Three single leg countermovement jumps were performed. The maximum jump height is measured with a sensor that is adapted at the subjects'leg and with a force plate.
215025640|NCT06541249|DRUG|Methotrexate (MTX)|MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.
215025641|NCT05346809|DRUG|Isatuximab|Isatuximab in IV form 10 mg/kg doses
215103817|NCT04797546|DEVICE|Morphine Patient Controlled Analgesia|Morphine Patient Controlled Analgesia Delivery System
215103818|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
214508331|NCT05010499|DRUG|Levobupivacaine|femoral nerve block receives 20 ml of levobupivacaine 0.25%
214508332|NCT05010499|DRUG|Levobupivacaine|Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
214508333|NCT03462771|DRUG|Fish oil|4g of fish oil daily for 14 weeks
214508334|NCT03462771|DRUG|sunflower oil|4g of sunflower oil daily for 14 weeks
214508335|NCT04582994|BEHAVIORAL|Beta tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)
214508336|NCT04582994|BEHAVIORAL|Alfa tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)
214508337|NCT04582994|BEHAVIORAL|Sham|participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
214508338|NCT00705172|DRUG|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
214508339|NCT03337022|DRUG|CC-90006|CC-90006
214508340|NCT03337022|OTHER|Placebo|Placebo
214508341|NCT01452867|DEVICE|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
214508342|NCT01452867|DEVICE|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
214508343|NCT01452867|DEVICE|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
214508344|NCT01415206|BEHAVIORAL|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
214508345|NCT01415206|BEHAVIORAL|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
214508346|NCT05770115|PROCEDURE|Vicryl 1|Double layer closure with split thickness with vicryl 1, in continuous, non-locked, 1 cm apart sutures.
214508347|NCT05770115|PROCEDURE|Vicryl 2/0|Double layer closure with split thickness with vicryl 2/0, in continuous, non-locked, 1 cm apart sutures.
214508348|NCT02068157|OTHER|Laboratory Biomarker Analysis|Correlative studies
214508349|NCT02068157|DRUG|Photodynamic Therapy|Undergo image-guided I-PDT
214508350|NCT02068157|DRUG|Porfimer Sodium|Given IV
214508351|NCT02144883|BEHAVIORAL|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
214508352|NCT02144883|BEHAVIORAL|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
214508353|NCT01363128|DRUG|Cyclophosphamide|Given IV
215025642|NCT05346809|OTHER|Standard Procedures|Standard procedures (standard of care) for transplant
215025643|NCT05967455|BIOLOGICAL|Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
215025644|NCT05967455|BIOLOGICAL|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489
215025645|NCT04236154|OTHER|Pedometer|Participants will wear a pedometer for 4 days at baseline, and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
215025646|NCT04236154|OTHER|Actigraph|Participants will wear a Actigraph for 4 days at baseline and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
215025647|NCT04236154|OTHER|Perturbation Treadmill|Participants will walk on an instrumented treadmill while wearing a safety harness at baseline and 4-6 weeks later. The perturbation treadmill will assess an individual's risk for falling. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
214508354|NCT01363128|DRUG|Cytarabine|Given IV
215025648|NCT03973489|BEHAVIORAL|Magnetic resonance imaging (MRI)|On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
215025649|NCT03973489|DRUG|Methamphetamine Hydrochloride Tablets|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
215025650|NCT03973489|DRUG|Placebo oral tablet|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
215103819|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
214508355|NCT01363128|DRUG|Dexamethasone|Given IV or PO
214508356|NCT01363128|DRUG|Doxorubicin Hydrochloride|Given IV
214508357|NCT01363128|OTHER|Laboratory Biomarker Analysis|Correlative studies
214508358|NCT01363128|DRUG|Methotrexate|Given IV
214508359|NCT01363128|BIOLOGICAL|Ofatumumab|Given IV
214508360|NCT01363128|DRUG|Vincristine Sulfate|Given IV
214508361|NCT06500546|PROCEDURE|Treatment of cervical lesions|"Four non-carious cervical lesions from patients will be separated into four groups according to according to the adhesion trategies described below:~1. adhesive material will be applied in total-etch mode,~2. adhesive material will be applied in self-etch,~3. universal adhesive material will be applied for 10 sec. in total-etch mode, which includes rubbing,~4. universal adhesive material will be applied for 10 sec. in self-etch mode, which includes rubbing,"
214508362|NCT03266432|OTHER|blood samples|three blood samples : first one pre intervention and the other two blood samples post-intervention
214508363|NCT02008214|DRUG|Pentoxifylline|Addition of pentoxifylline to current HCV treatment
214508364|NCT02008214|DRUG|Placebo|Placebo matching pentoxifylline dosage
214508365|NCT00470756|OTHER|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
214508366|NCT04809701|PROCEDURE|Temporary implantation of defibrillation coils and pulse generator|Each subject will undergo temporary implantation of defibrillation coils and pulse generator according to the NV-ICD electrode configurations.
214508367|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration A first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration A. Then up to two defibrillation energies will be tested for Configuration B.
214508368|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration B first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration B. Then up to two defibrillation energies will be tested for Configuration A.
214508369|NCT04809701|PROCEDURE|Removal of defibrillation coils and pulse generator|Defibrillation coils and pulse generator will be removed from the subject after the defibrillation tests are completed.
215025651|NCT06308237|OTHER|RESISTED EXERCISES|"Patients will perform Chest plank for 30 seconds with 4 repetitions.~Then the Participants will perform these exercises for 1 minute each with 4 repetitions:~Wide grip lateral pull down , Lying triceps press, Sit up squats, Barbell curl each.~And will perform Thigh adduction for1 minute with 2 repititions."
215025652|NCT06308237|OTHER|BALANCE EXERCISES|"Static and dynamic balance exercises will include:~Patients will perform Arm abduction holding a half-kg dumbbell, Opposite arm and leg in a quadruped position, Walking in a tandem stance(forward and backward), Turning and bending to the sides in a standing position, Pass through obstacles in a spiral, for 2 minutes each.~Then they will perform throwing a medicine ball to investigator and back while trying to maintain balance, Tandem stance, Walking backwards, Two-leg bridge as well as single (2 repetitions), Leg bridge (raising the other leg), walking on the heel, performing rhythmic movements while stepping on a circular environment and balance board exercises, for 1 minute each.~And will Walk up and down the stairs for 3 minutes."
215025653|NCT05135260|BEHAVIORAL|Virtual reality therapy|Participants will watch a video allowing them to view nature, dinosaurs, animals, and human interactions in three dimensions during a session lasting 11 minutes.
215025654|NCT05135260|BEHAVIORAL|Questionnaires|Questionnaires will be completed regarding stress, pain and affect
214508370|NCT01256242|DEVICE|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
214508371|NCT01256242|PROCEDURE|Standard Suture Repair|standard suture repair
214508372|NCT06173622|BEHAVIORAL|Fetal Positioning|In the study, venipuncture was applied to the intervention and control groups. While the procedure was performed by an experienced neonatal nurse, the neonates' pain score, crying duration and physiological parameters were monitored by another researcher (observer).
214508373|NCT03015753|BEHAVIORAL|Tai Chi training|The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
214691659|NCT03694574|BEHAVIORAL|instruction to reappraise|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning. (Szasz et al., 2011)"
214691660|NCT03694574|BEHAVIORAL|control|No instruction
215025655|NCT05135260|PROCEDURE|Measure heart rate|To be measured prior to starting treatment and halfway through the 11 minute Video
215025656|NCT05135260|BEHAVIORAL|Cyber sickness measurement|To be measured using the fast motion sickness scale
215025657|NCT05936736|RADIATION|prostate SBRT|Patients with prostate cancer will be treated with high-dose SBRT to prostate and seminal vesicles, delivered in one fraction, sparing the urethra and generating a dose distribution similar to HDR brachytherapy
215025658|NCT03774121|DEVICE|Cryoneurolysis|A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve \& anterior femoral cutaneous nerve) guided by ultrasound visualization.
215025659|NCT03774121|OTHER|Neuromuscular exercise (GLA:D)|The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
215025660|NCT03774121|DEVICE|Sham|The sham intervention includes a similar procedure but without freezing temperatures.
215025661|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
215025662|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
215025663|NCT00392288|DRUG|Placebo|Placebo MDI over twelve weeks
215025664|NCT02544763|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
214508374|NCT03015753|OTHER|Waiting list control group|At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
214508375|NCT01605448|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
214508376|NCT05292066|DRUG|Duloxetine Tablets,|"Duloxetine is an FDA-approved medication used to treat the major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. It is taken by mouth. It is a serotonin-norepinephrine reuptake inhibitor.~Pregabalin is an FDA approved, sold under the brand name Lyrica. it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,"
214508377|NCT05292066|DRUG|Pregabalin Tablets|Pregabalin is an FDA approved, it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
214508378|NCT05658094|DEVICE|Exosome|Each patients will receive 4 injection with an interval of 14 days during two months
214508379|NCT00163501|DRUG|Ciclesonide|
214508380|NCT04012242|DIAGNOSTIC_TEST|Ultrasound application|Shear wave elastography, shear wave dispersion, attenuation imaging, and intensity analysis
214508381|NCT05085418|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
214508382|NCT01779050|DRUG|Doxorubicin|
214508383|NCT01779050|BIOLOGICAL|Trastuzumab|
215025665|NCT02544763|DRUG|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
214508384|NCT01779050|DRUG|Cyclophosphamide|
214508385|NCT01779050|DRUG|Paclitaxel|
214508386|NCT01779050|DRUG|Epirubicin|
214508387|NCT01779050|DRUG|Docetaxel|
214508388|NCT01779050|DRUG|Carboplatin|
214691661|NCT03173820|GENETIC|Genotype guided|Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5\*1/\*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5\*1/\*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5\*3/\*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.
214691662|NCT03173820|GENETIC|Conventional|Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
215025666|NCT06026696|OTHER|follow-up|Long term follow-up
215025667|NCT02113280|PROCEDURE|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
215025668|NCT02113280|PROCEDURE|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
215025669|NCT00919360|PROCEDURE|collection of maternal blood specimen prior to delivery|approximately 5 cc. of maternal blood will be drawn prior to delivery
215025670|NCT00919360|PROCEDURE|collection of placental cord blood after delivery|approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
215025671|NCT00919360|PROCEDURE|collection of placental tissue|within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
215025672|NCT00919360|PROCEDURE|collection of strip of decidua from uterine lining from cesarean section deliveries|A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
215025673|NCT01337310|DRUG|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
215025674|NCT01205412|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations
214508389|NCT01779050|DRUG|Fluorouracil|
214508390|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
215025675|NCT01887197|OTHER|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
214508391|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
214508392|NCT02666404|OTHER|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
214508393|NCT05820763|DRUG|Selinexor|Selinexor is administered by mouth on Days 1, 8, 15, and 22 at a dose of 60 mg during the four cycles of consolidation. Selinexor is then decreased to 40 mg and administered by mouth on Days 1, 8, 15, and 22 for up to 8 cycles of maintenance therapy.
214508394|NCT05820763|DRUG|Lenalidomide|"Lenalidomide is administered by mouth daily on Days 1 to 21 at a dose of 10 mg during the first three cycles of consolidation, and then titrated up to 15 mg on Days 1 to 21 for the fourth cycle of consolidation. Lenalidomide 15 mg by mouth daily on Days 1 to 21 can be continued for up to 8 cycles of maintenance therapy.~For patients with baseline renal dysfunction, the starting dose of lenalidomide will be 2.5 mg or 5 mg by mouth daily on Days 1 to 21. Patients may titrate up per physician discretion."
214508395|NCT05820763|DRUG|Dexamethasone|Dexamethasone is administered by mouth on Days 1, 8, 15, and 22 at a dose of 20 mg during all four cycles of consolidation only.
215025676|NCT01887197|DRUG|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
215025677|NCT01887197|DRUG|mannitol inhalation powder|mannitol inhalation powder
215025678|NCT03940157|BEHAVIORAL|Oh Happy Day Class - Still I Rise|one-time, 4-hour class focused on awareness of depression and healthy self-management strategies
215025679|NCT05270031|DEVICE|Balloon dilation of the eustachian tube|Balloon dilation of the eustachian tube
215103820|NCT04929080|BIOLOGICAL|JS001 and JS004|Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001
215103821|NCT01108380|PROCEDURE|Plasma pheresis, Right portal vein embolization|"Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam."
215103822|NCT06319859|DRUG|Morphine|The patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
215025680|NCT05584631|DRUG|Intravenous immune globulin G|Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
215025681|NCT05584631|DRUG|Subcutaneous immune globulin G|Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
215025682|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
214423767|NCT01275287|DRUG|Standard of care treatment|"induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m\^2 for patients \> than 70 or with estimated Glomerular Filtration Rate (eGFR) \< 20 ml/min) to be titrated up to 1 gm/m\^2 depending on the 2 week white blood count (WBC) nadir \> 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study."
215025683|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
215025684|NCT03233971|OTHER|rPATD Questionnaire|A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
215025685|NCT03434886|OTHER|CFView|Registry patient portal
214423768|NCT01275287|DRUG|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
215025686|NCT03434886|OTHER|CF educational videos|CF educational videos
215025687|NCT00299715|DRUG|Paliperidone extended-release|
214423769|NCT05162391|BEHAVIORAL|Contingency Management|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
214508396|NCT04390516|DEVICE|COViage|The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
215025688|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 440 micrograms sirolimus each.
215025689|NCT00656643|DRUG|Placebo|Two subconjunctival injections of placebo.
215025690|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 220 micrograms sirolimus each.
215025691|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 880 micrograms sirolimus each.
215025692|NCT02462629|DRUG|BLZ-100|
215103823|NCT06319859|DRUG|Placebo|The patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
215025693|NCT06083571|DRUG|Ketorolac|Non-inferiority
215025694|NCT06083571|DRUG|Prochlorperazine|Adjunct
215103824|NCT00562146|PROCEDURE|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
215103825|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1|packet containing 10\^9 cells of Bifidobacteria adolescentis BD1
215103826|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10\^9 cells of Bifidobacteria animalis subsp. lactis BB-12
215103827|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10\^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
215025695|NCT06083571|DRUG|Diphenhydramine|Adjunct
215025696|NCT04670315|DIAGNOSTIC_TEST|Telematic evaluation of motor function|Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
215103828|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10\^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
215103829|NCT02355210|DIETARY_SUPPLEMENT|galactooligosaccharide|5 g galactooligosaccharide
215103830|NCT02355210|DIETARY_SUPPLEMENT|Placebo|lactose powder, 5 grams
215025697|NCT01336699|OTHER|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
215025698|NCT01336699|BIOLOGICAL|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
215103831|NCT05755659|DRUG|Fosaprepitant Dimeglumine for Injection|The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
215103832|NCT04309058|DRUG|Vitamin D drops|Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
215103833|NCT04621487|DRUG|Amoxicillin|14 days 1 gr bid
215103834|NCT04621487|DRUG|Metronidazole|14 days 500 mg bid
215103835|NCT04621487|DRUG|Clarithromycin|14 days 500 mg bid
215025699|NCT01336699|BIOLOGICAL|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
215025700|NCT06641258|OTHER|Control Group (Standard Procedure)|"Application in Control Group: After the theoretical lesson, the nurses in the control group determined and classified the pressure injuries in their patients using the  Braden Risk Assessment Scale, which has been accepted as valid and reliable. The nurses in the control group, who determined the pressure injuries using the scale, were given training on the determination and classification of pressure injuries using written material, the content of which was prepared by the researchers. After the training, the Satisfaction with the Training Method Survey was applied to the nurses. One week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied. After the completion of the application, volunteer nurses from the control group were subjected to pressure injury detection and classification with the deep learning model and trained with the mobile application."
215025701|NCT06641258|OTHER|Experimental Group|"Application in the Experimental Group: After the theoretical course, the nurses in the experimental group detected and classified pressure injuries in their patients with the Deep Learning Model. In the experimental group, a mobile application developed by the researchers was installed on the phones of the nurses who detected pressure injuries using the deep learning model and training was applied. Thus, the nurses were provided with the patient's care and treatment according to the developed mobile application according to the pressure injury stage detected by the deep learning model. After the training, the Satisfaction Survey with the Training Method was applied to the nurses. 1 week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied"
215025702|NCT06085638|DRUG|Azacitidine|Given by SC (under the skin) or IV (vein)
215025703|NCT06085638|DRUG|Tamibarotene|Given by PO
215025704|NCT06085638|DRUG|Venetoclax|"Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax"
215103836|NCT04621487|DRUG|Pantoprazole 40mg|40 mg bid 14 days
215103837|NCT04621487|DRUG|according to antibiogram|according to antibiogram
215103838|NCT00244491|BEHAVIORAL|Care Transitions Intervention|
214423770|NCT03406936|DRUG|Daily interruption of midazolam|daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
215025705|NCT04548219|DRUG|Mirikizumab|Reference and test formulations of mirikizumab administered as a SC injection.
215025706|NCT00400088|DRUG|paroxetine|Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
215025707|NCT00400088|DRUG|lithium|start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
215025708|NCT03680131|DRUG|EB01 Cream Placebo|Vehicle Cream containing 0% EB w/w applied BID
215025709|NCT03680131|DRUG|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
215025710|NCT03680131|DRUG|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
215025711|NCT03680131|DRUG|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
215025712|NCT06673641|DRUG|Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
215103839|NCT02861859|DRUG|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
215103840|NCT02861859|DRUG|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
215103841|NCT04699461|DRUG|Loncastuximab Tesirine|IV infusion
215103842|NCT04699461|DRUG|Idelalisib|Oral tablet
215103843|NCT04933461|DEVICE|Safety lancet|There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
215103844|NCT00516165|DRUG|RAD001|Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
215103845|NCT05330091|DIETARY_SUPPLEMENT|Once Daily Women's Probiotic|Active product
215103846|NCT05330091|OTHER|Placebo|Placebo product
215103847|NCT01412385|BIOLOGICAL|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
215103848|NCT01412385|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
215103849|NCT01412385|BIOLOGICAL|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
215103850|NCT01226576|DEVICE|MRgFUS Treatment|Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
215103851|NCT00064051|DRUG|gemcitabine hydrochloride|
215103852|NCT00064051|DRUG|triapine|
215103853|NCT03068767|DIETARY_SUPPLEMENT|Vitamin D|
215103854|NCT00001644|DRUG|Indinavir|
215103855|NCT00001644|DRUG|Zidovudine|
215103856|NCT00001644|DRUG|Lamivudine|
215103857|NCT00001644|DRUG|Nevirapine|
215103858|NCT00001644|PROCEDURE|Blood testing|
215103859|NCT00001644|PROCEDURE|Lymph node biospy|
215103860|NCT00001644|PROCEDURE|Leukapheresis|
215025713|NCT06673641|DRUG|CABTREO Topical Gel|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
215025714|NCT06673641|DRUG|Placebo Control|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
215025715|NCT02613507|DRUG|Nivolumab|
215025716|NCT02613507|DRUG|Docetaxel|
215025717|NCT03941093|DRUG|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX|"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
215025718|NCT03941093|DRUG|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX|"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
215025719|NCT06690944|OTHER|Proprioceptive Neuromuscular Facilitation|The following basic principles and procedures were emphasized when applying the techniques: manual contact, resistance, approximation, verbal commands, and therapist's body mechanics. During stages 1 and 2 of the intervention, the amount of PNF optimal resistance used was necessary to maintain a stable and safe position, with good body alignment, in a manner that produced coordinated movements to generate appropriate motor learning.
215025720|NCT06690944|OTHER|Physical exercise without proprioceptive neuromuscular facilitation control group|The physical exercise without proprioceptive neuromuscular facilitation control group (CG) intervention consisted of the same activities carried out in the proprioceptive neuromuscular facilitation (PNF) group during Stages 1 and 2, during the same amount of minutes, sessions, and weeks; however, CG intervention did not include specific techniques and basic principles (i.e. approximation and optimal resistance) and procedures of the PNF concept. The activities were instructed and supervised by a trained professional through verbal command. The professional was at stand-by assistant position to prevent accidents.
215025721|NCT06141460|DRUG|RRG001|Administered via Subretinal injection. Dosage form: injection solution.
215025722|NCT06693141|OTHER|ESP block|ESP block was applied to the patients.
215025723|NCT06693141|OTHER|ITM|ITM was applied to the patients.
215025724|NCT06695962|DRUG|Domperidone 10mg|30 mg per day for 21 days
215025725|NCT06695962|DRUG|Placebo|3 per day for 21 days
215025726|NCT06695962|DIAGNOSTIC_TEST|gastric emptying test|gastric emptying test
215025727|NCT06695000|DEVICE|digital CBT-I|The intervention is a digital Cognitive Behavioral Therapy for Insomnia (CBT-I) program, delivered via a mobile application. The program includes structured, self-guided modules focusing on sleep hygiene education, cognitive restructuring, stimulus control, bed time restriction, and relaxation techniques. Each module offers interactive exercises and weekly assignments designed to support behavior change and improve sleep. Participants will receive app-based reminders to encourage regular engagement, with features for tracking progress and adherence throughout the 6 week program.
215025728|NCT06688110|DEVICE|Gixam System|Jubaan's Gixam System is designed to predict the likelihood of colorectal adenomas or SSL by using white light in the 400 to 720 nm range to capture ultra-high-definition images of the of the tongue and analyzing the spectral signature of the oral microbiome to predict the presence of colorectal adenomas or SSL with help of artificial intelligence (AI).
215025729|NCT06685926|PROCEDURE|Supermicrosurgical LVA, Groin Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)|
215025730|NCT06685926|PROCEDURE|Supermicrosurgical LVA, Conventional Multiple Access Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)|
215025731|NCT06689358|DRUG|0.4 ml/kg of 0.5% bupivacaine|0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space
215025732|NCT06689709|OTHER|Serum Alkaline Phosphatase Levels|Venous blood was drawn from the patients
215025733|NCT06686095|PROCEDURE|Group Adductor canal block|Adductor canal block procedure: The patient will be informed about the technique and consent will be obtained. The patient's hip will be slightly externally rotated, and an ultrasonography linear probe will be placed on the medial thigh, at the midpoint of the patella and vastus medialis. After locating the femoral artery at approximately 3-4 cm depth, if not visible, the artery can be traced distally from the inguinal region using Doppler mode. Once the vastus medialis and sartorius muscles are identified, the superficial femoral artery is centered at the midpoint of the sartorius muscle. The adductor canal roof, along with the saphenous and vastus medialis nerves, appears as hyperechoic structures. A needle is inserted in-plane, advancing toward the anterolateral femoral artery aspect, and 5-20 mL of LA is injected.
215025734|NCT06686095|PROCEDURE|Group Genicular Nerve Block|Genicular Nerve Block: The patient is informed and consent is obtained. With a pillow in the popliteal fossa, the knee is slightly flexed. For the superior lateral genicular nerve, a linear USG probe is positioned on the lateral femoral epicondyle, moving proximally to visualize the bone metaphysis. The superolateral artery is seen between the vastus lateralis fascia and the femur. Using in-plane or out-of-plane technique, the needle is guided to the bone, and 4-5 mL of LA is injected. For the superior medial nerve, the probe is placed on the medial epicondyle and moved proximally to visualize the bone near the adductor tubercle. The artery lies between the femur and vastus medialis fascia. For the inferomedial artery, the probe is placed on the tibial medial condyle, moving distally. A negative aspiration test is conducted before each LA injection.
215103861|NCT04112394|OTHER|local anesthetic injection|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
215025735|NCT06686095|PROCEDURE|Group IPACK Block|IPACK Block: Before the procedure, the patient is informed about the technique and written consent is obtained from the patient. The patient lies in the prone position. The linear USG probe is placed approximately 2-3 cm above the popliteal fossa and scanned distally to identify the femoral shaft and popliteal artery. If the femoral condyles are initially visualized, the probe is moved until the condyles disappear and the femoral shaft is identified as a straight line and hyperechoic. Color doppler can be used to identify the popliteal vessels. The peripheral block needle is advanced between the femoral shaft and the popliteal artery. After negative aspiration control, 15-20 mL of LA medication is injected here.
215103862|NCT04112394|OTHER|Standard perioperative and postoperative analgesia protocol.|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
214508397|NCT05868304|DEVICE|BFR|Exercises may involve warm up on a stationary bike for 5 minutes, application of a BFR cuff (a cuff that often uses air to inflate around a limb) on the selected extremity, and exercise sets (e.g. banded squats, step ups, Romanian dead lifts). We will record metrics on an iPad. Testing will be done with ForceDecks and ForceFrames (system for measuring muscle strength and imbalance).
214508398|NCT05868304|OTHER|Stanard strengthening program.|"The exercise program will be completed 3 times per week Participants will warm up on a stationary bike for 5 minutes~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
214508399|NCT00386685|DRUG|larotaxel (XRP9881)|intravenous administration
214508400|NCT00386685|DRUG|trastuzumab|intravenous administration
214508401|NCT01603108|DRUG|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
215025736|NCT06688773|BEHAVIORAL|Progressive relaxation exercise|In this study, the relaxation exercises CD, which is a material created by the Turkish Psychological Association, was used. This CD consists of three parts. The first part consists of 10 minutes and this part explains the definition and purpose of deep relaxation exercise and the points to be considered during the exercise. The second part of the CD consists of 30 minutes of verbal explanation of the items of relaxation exercises accompanied by the sound of a stream. The third part consists of 30 minutes and includes only relaxation music.
215025737|NCT06688773|OTHER|Control group: Standart nursing care group|Routine postoperative patient care in the clinic was applied.
215025738|NCT06685991|DRUG|Dexamethasone|Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.
215025739|NCT06688682|OTHER|PRP joint injection combined with acupoint injection|PRP acupoint injection
215025740|NCT06691139|PROCEDURE|Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia graft in patients ages from 12 years to 40 years|Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia
215025741|NCT06691139|OTHER|Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft|Group (A) Myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft
215103863|NCT03736876|BEHAVIORAL|About Us|Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
215103864|NCT02123368|DRUG|Hyaluronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
214508402|NCT01603108|DRUG|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
215025742|NCT06691139|PROCEDURE|Myringoplasty operation using periosteal graft and myringoplasty using Temporalis fascia graft|Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft in age from 12years to 40 years
214508403|NCT02430454|BEHAVIORAL|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
214508404|NCT05569343|OTHER|No intervention|This is an observational study without any intervention
214508405|NCT02459860|BEHAVIORAL|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
214508406|NCT02459860|BEHAVIORAL|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
214691663|NCT06531382|OTHER|Nurses attitudes toward adressing sexual health in patients with cancer|"Health professionals, within the field of cancer, attitude towards addressing sexual health with patients is unknown.~The aim is to investigate the attitudes of Danish cancer nurses towards addressing sexual health in their clinical work, as well as to assess differences in perceived competences and knowledge.~Method: The questionnaire Health professionals Attitudes towards Sexual Health-Danish version (PA-SH-D) is sent out to Danish cancer nurses via the Professional Society for Cancer Nurses. The questionnaire is sent out via a link via the RedCap database.~The questionnaire link is sent out to members of the Professional Association for Cancer Nurses under the Danish Nursing Council, and it is sent out via their membership register."
214691664|NCT02421328|DEVICE|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
214691665|NCT02421328|DEVICE|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
214691666|NCT03756974|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
215103865|NCT02123368|BIOLOGICAL|10 million Bone marrow mesenchimal stem cells|10 million of Bone marrow mesenchimal stem cells
214508407|NCT05501652|DEVICE|ALV1System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
215025743|NCT06691139|PROCEDURE|Group (A) myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft|Myringoplasty operation using Temporalis fascia graft and Myringoplasty using periosteal graft in patients from 12 years to 40 years
215025744|NCT06687083|DEVICE|nasal high frequency oscillatory ventilation mode|"Preterm neonates who will be allocated will start nHFOV: (CNO, Medin, Germany). nHFOV will be provided via binasal prongs (Size: small, medium, large; Diameter according to its chart; Medin, Germany).~The initial parameters will be mean airway pressure (MAP) of 6 cm H2O (range 6-10), frequency of 8 Hz (range 8-12) and amplitude will be adjusted until infant's chest showed slight oscillations and amplitude will be 7 (range 7-10).~The fraction of inspired oxygen (FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter."
215025745|NCT06687083|DRUG|nasal continuous positive pressure ventilation mode|Preterm neonates who will be allocated to this group to the nCPAP will be started on a pressure of 6-8 cm H2O, FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter
215025746|NCT06690697|DRUG|JS004|200 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
215025747|NCT06690697|DRUG|Toripalimab|240 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
215025748|NCT06690697|DRUG|Axitinib|5 mg, po, bid, each 21 days as a treatment cycle
215025749|NCT06690697|DRUG|Sorafenib|0.4 g, po, bid, each 21 days as a treatment cycle
215103866|NCT02123368|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million of Bone marrow mesenchimal stem cells
215025750|NCT03227575|BEHAVIORAL|Exercise Intervention|The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
215103867|NCT03100175|BEHAVIORAL|physiotherapy|strength training for upper and lower limbs fitness and balance work out
214508408|NCT05563571|DRUG|Methylprednisolon, Lidocaine|Intra-articular cortisone injection
214508409|NCT05563571|OTHER|Pulsed radiofrequency, Lidocaine|pulsed radiofrequency of shoulder joint and suprascapular nerve
214508410|NCT01052974|DRUG|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
214508411|NCT01318850|BEHAVIORAL|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
214691667|NCT03756974|DRUG|Placebo|Placebo of BX-1, oral solution
214691668|NCT01842620|DRUG|Metformin|Oral antidiabetic agent
215025751|NCT03454347|DIETARY_SUPPLEMENT|Profile Perform|The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.
215025752|NCT03454347|OTHER|Lower Limb Suspension|This group will complete two weeks of lower limb suspension.
215025753|NCT01260831|OTHER|Implementation of Bedside Paediatric Early Warning System|The Bedside Paediatric Early Warning System (Bedside PEWS) is a documentation-based system of care that will replace existing documentation systems for vital signs in inpatient ward areas in hospitals randomized to implement Bedside-PEWS. Frontline staff education within each hospital will occur over a period of three months preceding a 5 week run-in implementation phase, which will be followed by hospital-wide implementation. The Bedside-PEWS documentation record will become the primary method of documentation for vital signs and related data.
215103868|NCT00223249|DRUG|Quetiapine|
215103869|NCT02380040|DEVICE|PPG|A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
215103870|NCT04720300|OTHER|MaaS app|The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app.
215103871|NCT04720300|OTHER|No app|students receive no app or housing information
215103872|NCT01507480|DRUG|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
215103873|NCT00731471|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
214508412|NCT01318850|BEHAVIORAL|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
214508413|NCT01318850|OTHER|Healthy controls|No intervention
214508414|NCT05927259|DRUG|n acetyl cysteine|A patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/KgIV infusion every 4 hours up to 17 doses
214508415|NCT05927259|DRUG|standard treatment|stabilization and antidotes
214508416|NCT00315848|DRUG|Buprenorphine transdermal delivery system|
214508417|NCT02808403|OTHER|No intervention|No intervention; observation of routine medical care
214508418|NCT03087318|BEHAVIORAL|Physical activity|"Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~* during 3 months."
214508419|NCT02151084|DRUG|Selumetinib|
215025754|NCT01260831|OTHER|Hospital Standard of Care|Hospitals randomized to standard care will continue with established methods of care. This will include the use of calling criteria and/or the expert model to identify children at risk. As in intervention hospitals, existing MET-RRT practices, established staffing and documentation practices will continue.
215025755|NCT06695403|PROCEDURE|Pilates Exercise|"1. Pilates Exercise: The Pilates method is a low-intensity form of movement based on body control, which works the body in a complete way, promoting physical and mental health. PET is different when compared to traditional exercises, which, in turn, tend to isolate the working muscles and have specific training approaches using repetitive motions.~2. Telerehabilitation: Telehealth is emerging as a key method for delivering essential healthcare. Primary care research suggests that telehealth is acceptable and has potential to overcome geographical barriers for individuals needing many times rehabilitation by eliminating the need for extensive and costly travel~3. Diet approach: A customized low-carbohydrate high-fat (LCHF) restricted caloric diet in women with lipedema will be used for 12 weeks. The LCHF diet may be a valuable nutritional strategy for lipedema and overweight/obese women, reducing inflammatory status with a beneficial effect on weight, glucose profile the concentration of"
215025756|NCT06694818|BEHAVIORAL|trauma film paradigm|Use the trauma films as stressors to induce stress and evaluate how it affects sleep reactivity in healthy subjects with insomnia symptoms compared to healthy subjects without insomnia symptoms
215025757|NCT06694519|DEVICE|manometry through the PHENIX series device (model: PHENIX LIBERTY; manufacturer: ELECTRONIC CONCEPT LIGNON INNOVATION, Montpelier, France).|For this manometry the air probe, connected to the Phenix biofeedback system, covered by a latex probe cover lubricated with gel, will be used. In the procedure, the labia majora are opened with one hand and slowly rotated into the vagina while holding the back of the manometric probe with the other hand. Basal tone in g will be measured prior to pelvic floor muscles force measurements. The manometry probe will extract pelvic floor pressure signals by measuring both your basal tone and the maximum pressure held for 10 seconds in three measurements, the average of the three being calculated at the command, 'contract as hard as you can for as long as possible'.
214508420|NCT02151084|DRUG|Cisplatin|
214508421|NCT02151084|DRUG|Gemcitabine|
214508422|NCT04053699|DRUG|Von Willebrand Factor-Containing Product|Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
214508423|NCT01293292|DRUG|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
214508424|NCT02746107|OTHER|decision aid|decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
214508425|NCT04951791|DRUG|SMOFlipid|will receive intravenous infusion of 2ml\\kg of smoflipid 20%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed
214508426|NCT04951791|OTHER|Normal saline 0.9%|will receive intravenous infusion of 2ml\\kg of normal saline 0.9%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed.
214508427|NCT00022672|DRUG|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
214508428|NCT00022672|DRUG|anastrazole (Arimidex®)|1 mg tablet taken orally daily
214508429|NCT05474950|DRUG|minocycline|minocycline capsule (100mg) per day orally
214508430|NCT05545800|DRUG|metformin+empagliflozin+insulin glargine|Randomization was performed with the use of a computer-generated system provided by the sponsor. The dose of metformin will be initiated at 0.5 grams three times a day (the maximum dose is 2g/day); the dose of empagliflozin will be 10 milligrams once a day; insulin glargine will be received once daily at bedtime and the dose will be initiated at the 50% of 0.4-0.5 units/kg/day. All groups received counseling on lifestyle modification.
214508431|NCT05545800|DRUG|IDegLira|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will be initiated on 16 units (16 units degludec/0.58 mg liraglutide) and titrated twice weekly. The maximum dose of IDegLira was 50 units (50 units degludec/1.8 mg liraglutide). All groups received counseling on lifestyle modification.
214508432|NCT05545800|DRUG|premixed insulin analogues|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will received twice a day. The total daily insulin dose will be initiated at 0.4-0.5 units/kg/day and adjusted according to the plasma glucose. All groups received counseling on lifestyle modification.
215025758|NCT06694519|DIAGNOSTIC_TEST|PFIQ-20 questionnaire (Pelvic Floor Impact Questionnaire Short Form)|This questionnaire allows assessment of the impact of urinary symptoms, colo-rectal-anal symptoms and genital prolapse symptoms. This questionnaire will also be used as an inclusion criterion, to homogenise the characteristics of the population in terms of pelvic dysfunction prior to the intervention, as indicated above.
215103874|NCT04597073|PROCEDURE|Initial Periodontal Therapy|Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
215103875|NCT03281083|DRUG|Levothyroxine Sodium|
215025759|NCT06694519|DIAGNOSTIC_TEST|ICIQ-SF (International Consultation on Incontinence Questionnaire - Short Form)|a four-question self-administered questionnaire that identifies individuals with urinary incontinence by assessing frequency, severity and impact on quality of life. It is composed of five questions assessing frequency, severity and impact of UI, plus a set of eight self-diagnostic items related to UI situations experienced by patients. The maximum sum of the response values indicates a score of 21 points, referring to the high impact of UI on an individual's life.
215025760|NCT06694519|DIAGNOSTIC_TEST|Sandvik's test|It provides information on the severity of the UI by means of two questions. The interpretation based on the score is classified as: 1-2 mild UI, 3-6 moderate UI, 8-9 severe UI, 12 very severe UI.
215103876|NCT03212456|DRUG|opioid-free group|We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
215025761|NCT06694519|DIAGNOSTIC_TEST|vaginal health index (VHI)|this index consists of a graduated scale from 1 to 5 for each item (vaginal elasticity, fluid volume, pH, epithelial integrity and moisture).Vaginal elasticity ranges from 1 (no elasticity) to 5 (excellent elasticity), assessed by distension of the mucosa on palpation and speculum placement. The volume of fluid, assessed during inspection, varies between 1 (no discharge) and 5 (normal discharge) (white flocculent). The integrity of the epithelium varies between 1 (petechiae already detected on inspection) and 5 (non-friable tissue and normal mucosa). Moisture ranges from 1 (no moisture detected on inspection and presence of inflamed mucosa) to 5 (normal moisture). The pH will be quantified using a pH indicator strip between 0 and 14 (MColorpHast™-PH indicator strips) to be placed directly on the right lateral vaginal wall for one minute, giving 1 point for pH 6.1, 2 for pH 5.6-6.0, 3 for pH 5.1-5.5, 4 for pH 4.7-5.0 and 5 for pH ≤ 4.6. The sum of all items represents the vaginal health
215103877|NCT03212456|DRUG|Opioid Group|This group will receive fentanyl in the induction of anesthesia.
215103878|NCT03212456|PROCEDURE|transversus abdominal plane block with ropivacaine|The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
215103879|NCT03212456|PROCEDURE|transversus abdominal plane block with placebo|the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
215103880|NCT00432770|DRUG|ARC1779|
215103881|NCT00051922|BIOLOGICAL|PolyEnv1|Recombinant vaccinia virus vaccine
215103882|NCT01129661|BIOLOGICAL|CSL112 (reconstituted HDL)|Single escalating intravenous doses of CSL112
215103883|NCT01129661|BIOLOGICAL|normal saline (0.9%)|Single intravenous dose of normal saline (0.9%)
215103884|NCT02160691|DEVICE|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
215103885|NCT00934674|DRUG|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
215103886|NCT02020317|BEHAVIORAL|decision support in potassium-inc. drug-drug-interactions|display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
214508433|NCT04171674|DRUG|Treatment with high-dose ceftobiprole (500mg loading dose followed by 2.5g under continuos infusion).|High-dose ceftobiprole (500mg loading dose) will be administered to patients for 30 minutes followed by 2.5g under continuous infusion for 24 hours.
214508434|NCT02614157|PROCEDURE|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
214508435|NCT02614157|DEVICE|labeled line|
214508436|NCT00269815|DRUG|methylphenidate HCl|
214691669|NCT01647594|BEHAVIORAL|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
215103887|NCT01706783|DRUG|somapacitan|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 (somapacitan) in an escalating order
215103888|NCT01706783|DRUG|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
214508437|NCT02501369|BEHAVIORAL|Self-directed Teen Triple P|Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
214508438|NCT04648215|OTHER|lavender oil|aromatherapy--two drops applied to a 2x2 gauze and pinned to subject's gown
214508439|NCT04648215|OTHER|Grapeseed Oil|aromatherapy--two drops applied to a 2 X 2 gauze and pinned to subject's gown
214508440|NCT01332266|DRUG|E7050|E7050 given orally at 200, 300, or 400 mg once daily.
214508441|NCT01332266|DRUG|Cetuximab|Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
214691670|NCT01647594|BEHAVIORAL|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
215025762|NCT06694519|DIAGNOSTIC_TEST|Visual analogue scale (VAS)|This scale allows the intensity of pain described by the patient to be measured with maximum reproducibility between observers. It consists of a horizontal line of 10 centimetres, at the ends of which are the extreme expressions of a symptom. At the left end is the absence or lowest intensity and at the right end the highest intensity. The patient is asked to mark on the line the point that indicates the intensity of the pain during sexual intercourse and it is measured with a millimetres ruler. The intensity is expressed in centimetres or millimetres. The rating will be: 1 Mild pain if the patient scores the pain as less than 3; 2 Moderate pain if the rating is between 4 and 7; 3 Severe pain if the rating is equal to or greater than 8.
215025763|NCT06694519|DIAGNOSTIC_TEST|Body Image Scale (S-BIS)|It consists of 10 items assessing various dimensions of body image in cancer patients, evaluating: affective, behavioural and cognitive. The items are scored on a four-point scale (0: not at all; 1: a little; 2: quite a lot; 3: a lot) with a maximum possible score of 3 points. The higher the score, the higher the body image problem. Its brevity facilitates rapid assessment in both clinical and research settings. It shows a stable factor structure between samples, and good psychometric properties with high reliability (Cronbach's alpha=0.93), suggesting that it is a suitable and useful measure for assessing body image in breast cancer patients.
215025764|NCT06694519|DIAGNOSTIC_TEST|Likert's scale questionnaire|five-point Likert scale for satisfaction with treatment to be classified as: 1 (very dissatisfied), 2 (dissatisfied), 3 (no change), 4 (satisfied), 5 (very satisfied). Women who miss any of the RF sessions and/or whose attendance at the face-to-face physiotherapy sessions (RF and/or PFMT) does not reach 80% will be considered as not complying with the study protocol and their participation will be terminated, although they will be included in the analysis (by intention to treat).
215025765|NCT06694519|DIAGNOSTIC_TEST|Oxford's Scale|It allows the contractile capacity of the pelvic floor muscles to be assessed. It scores from 0 to 5, as follows: if there is no contraction it is 0, if the contraction is very weak it is 1, if the contraction is weak it is 2, if the contraction is moderate/with tension/and maintained it is 3, if the contraction is good and maintains tension with resistance it is 4, and if the contraction is strong and maintains tension against a resistant force it is 5.
215025766|NCT06694519|DIAGNOSTIC_TEST|Sexual function and self-esteem|The Female Sexual Function Index (FSFI) questionnaire consists of 19 items that assess sexual function over the past 4 weeks and performance in six domains: sexual desire, arousal, lubrication, orgasm, satisfaction and pain. A cut-off point ≤ 26.5 is considered sexual dysfunction and an increase in score is considered an improvement.
215025767|NCT06695455|BEHAVIORAL|Swallowing rehabilitation by rhythmic auditory cue|"Three assessments, each spread over two days, will be administered at three different time points during the study: before the experiment (T0), after 7 weeks of the experiment (T1), and 3 months after the intervention (T2). The evaluation will include a pharyngography as well as a clinical assessment of swallowing and rhythmic abilities.~Each subject will be invited to participate in 3 individual rehabilitation sessions per week for 7 weeks, conducted by a speech therapist at La Musse Hospital. Each session will be structured similarly: the subject will be asked to swallow their saliva, followed by a nectar-like texture (IDDSI 2) and a pudding-like texture (IDDSI 4), timed to the rhythm of a metronome. The rhythm will vary throughout the sessions. The goal will be to get as close as possible to the rhythm of a healthy swallow."
215025768|NCT06686225|OTHER|Bowen's technique.|"This group will receive 20 mint per session for 6 weeks of bowen's technique.~* Frequency: 3-5 days per week for 6 days~* Intensity: moderate to high intensity of soft tissue mobilization~* Time: 20 mints~* Type: Bowen's technique"
215025769|NCT06686225|OTHER|Mulligan bent leg raise technique|"This group will receive 15 mints per session for 6 weeks of mulligan's bent leg raise technique.~* Frequency: 3-5 days per week for 6 days~* Intensity: moderate to high intensity of soft tissue mobilization~* Time: 15 mints~* Type: Mulligan bent leg raise technique"
215025770|NCT06686160|OTHER|Plyometrics Training|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise, Plyometrics are primarily used by athletes to improve performance and are used in the fitness field to a much lesser degree. This training focuses on learning to move from a muscle extension to a contraction in a explosive way, for example repeated jumping.
215103889|NCT02211430|BEHAVIORAL|Cognitive-Behavioral Counseling (CBC)|Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.
215025771|NCT06686160|OTHER|Theraband Resistance Exercise|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise Therabands is a Set of bands which are primarily use for resistance Training for strength and Power.
215025772|NCT06686212|OTHER|Sensory re-education+ strengthening exercises+ kinesio taping|"Sensory re-education. Splinting: as constant maintained touch with wrist holding in neutral position for 15 minutes.~Topical anesthesia spray on affected area for 10 minutes. Massage: apply massage over sensitive areas with same speed and pressure, then the light pressure with cotton, velvet, terry cloth, polyester and wool over sensitive area for 10 minutes.~PNF using upper extremity (D2) pattern including shoulder extension, adduction, internal rotation, wrist and fingers flexed and wrist ulnar deviated. 10-15 repetitions for 5 minutes.~Strengthening exercises: wrist flexion and extension, supination and pronation, opposition, gripping, ball squeeze and fingers pinching against resistance. 10-15 repetitions of each exercise for 20 minutes.~Kinesio taping: Taping will be applied twice a week for 12 weeks."
215025773|NCT06686212|OTHER|Neural mobilization+ Strengthening exercises+ Kinesio taping.|"The median nerve is mobilized through wrist flexion and extension with elbow straight and palm facing up.~Wrist flexion and extension with elbow flexed to 90 degrees with palm facing up 10-15 repetitions.~Wrist flexors stretch with extended arm and palm facing down 10-15 repetitions. Straight fist: hold your hand up with fingers straight. Full fist: bend your fingers to form a full fist. Median nerve stretch and wrist extension exercises for 30 minutes. Free the bird exercises, busy bee flexion shape of Z exercises and wall stretch exercise. (10-15 repetitions) for 10 minutes.~Strengthening exercises: wrist flexion and extension, supination and pronation, opposition, gripping, ball squeeze and fingers pinching against resistance. 10-15 repetitions each for 20 minutes.~Kinesio taping: The taping will be applied twice a week for 12 weeks."
215103890|NCT02211430|BEHAVIORAL|Best Practice (BC) Control|"For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current best practice guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4)."
215103891|NCT00061633|DRUG|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
215103892|NCT00061633|DRUG|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
215103893|NCT02050087|DEVICE|Simple sling.|
215103894|NCT02050087|DEVICE|Neutral brace|
215103895|NCT00941122|DEVICE|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
215103896|NCT02599233|OTHER|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
215103897|NCT02599233|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
215103898|NCT02599233|OTHER|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
215103899|NCT05037058|OTHER|Quality improvement activities|Quality improvement activities
214691671|NCT01414816|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
214691672|NCT02995681|OTHER|Balance training|Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.
214691673|NCT02995681|OTHER|Pulmonary rehab|Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
214691674|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
214691675|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
214691676|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
214691677|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
215025774|NCT06686966|DIAGNOSTIC_TEST|gastric cancer|be diagnosed as gastric cancer
215025775|NCT00152958|DRUG|Pramipexole|
215025776|NCT04231565|DRUG|Tenofovir alafenamide Fumarate|Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
215103900|NCT00554372|GENETIC|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
215103901|NCT06470646|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body.By employing specialized catheters and devices,endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the targetsite,without the need for conventional open surgery.
215025777|NCT00908661|DEVICE|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
215025778|NCT02946411|PROCEDURE|Cardiac surgery|Glucose level will be measured after cardiac surgery.
215103902|NCT03326622|OTHER|standard care|A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
215103903|NCT03326622|OTHER|moderate exercise|A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
215103904|NCT05713435|DEVICE|intravaginal laser|application of intravaginal laser
214508442|NCT03306498|DRUG|Aminoleban (8% amino acids infusion)|Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
214508443|NCT03302091|DRUG|BI 1467335|28 day treatment period
214508444|NCT02792855|DEVICE|snifﬁng Position(place a 7-cm cushion under head )|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
214508445|NCT02792855|DEVICE|Simple Head Extension(without cushion)|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
214508446|NCT04301999|PROCEDURE|Photodynamic therapy|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visualradiography. The dilation catheter was then withdrawn to leavethe PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.
214508447|NCT04301999|PROCEDURE|radiofrequency ablation|an RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
214508448|NCT00994851|DRUG|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
214508449|NCT00994851|DRUG|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
214508450|NCT03139526|OTHER|observational study so no intervention|observational study, so no intervention
214508451|NCT05581251|BEHAVIORAL|Food and cooking skills|The researchers collected the study data using the face-to-face interview method through a questionnaire including the Descriptive Information Form, Cooking Skills and Food Skills Scale, and Three-Factor Eating Questionnaire-R21.
214508452|NCT05904652|DEVICE|"Fisher and Paykel HealthCare Airvo™ 3 high flow system"|High Flow Nasal Oxygen Delivery Device
214508453|NCT05904652|DEVICE|Conventional Oxygen Therapy|Low flow oxygen delivery device (Flow rate between 2 litres per minute and 15 litres per minute)
214508454|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
214508455|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
214691678|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
214691679|NCT00701740|DRUG|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
215025779|NCT03189953|RADIATION|68Ga-NODAGA-exendin 4 PET/CT|68Ga-NODAGA-exendin 4 PET/CT
215025780|NCT03033693|OTHER|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
215025781|NCT03033693|OTHER|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
215025782|NCT05339659|DEVICE|mHealth Intervention|Mobile health (mHealth) app to motivate and support quitting smoking.
215025783|NCT01306994|OTHER|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
215025784|NCT01306994|PROCEDURE|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
215025785|NCT01306994|OTHER|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
214508456|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
214508457|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
214508458|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
214508459|NCT01208506|DRUG|placebo|A single dose of NNC0114-0000-0005 placebo.
214508460|NCT03765385|OTHER|High-intensity training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
214508461|NCT03765385|OTHER|Moderate-intensity continuous training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
214508462|NCT01539252|PROCEDURE|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
214508463|NCT01539252|PROCEDURE|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
214508464|NCT03105960|DRUG|garlic with lime mouth wash|garlic with lime juice is herbal antimicrobial 10 ml (undiluted) for 30s and then expectorate for 14 days.o prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract.
214508465|NCT03105960|DRUG|chlorhexidine|hlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days.
214508466|NCT05556200|DRUG|Anti-PD-1 monoclonal antibody|Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight \<50 kg)
214508467|NCT05556200|DRUG|VEGFR2 Tyrosine Kinase Inhibitor|Apatinib 250 mg, po, qd
214508468|NCT02941744|DRUG|nivolumab|low fixed dose ipilimumab in combination with nivolumab
214508469|NCT02941744|DRUG|ipilimumab|low fixed dose ipilimumab in combination with nivolumab
214508470|NCT00286039|PROCEDURE|Blood sampling|Blood sampling is used.
214508471|NCT02392507|DRUG|Necitumumab|Administered IV
214508472|NCT02392507|DRUG|Nab-Paclitaxel|Administered IV
214508473|NCT02392507|DRUG|Carboplatin|Administered IV
214508474|NCT02224755|DEVICE|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
214508475|NCT02224755|DEVICE|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
214508476|NCT06323369|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214508477|NCT06323369|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214508478|NCT06323369|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214508479|NCT06323369|PROCEDURE|Surgical resection|Standard of care
214508480|NCT06323369|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214508481|NCT06323369|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214508482|NCT06323369|RADIATION|Radiation|Recommended, standard of care
214508483|NCT06323369|DRUG|Carboplatin（neoadjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214508484|NCT06323369|DRUG|Carboplatin（adjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
214508485|NCT06269068|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
214508486|NCT06269068|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
214508487|NCT06269068|OTHER|Oswestry Low Back Pain Disability Questionnaire|With this scale, it is questioned to what extent the patient is affected by low back pain in selected daily living activities under certain ten headings. In total scoring, disability is expressed as a percentage, and high scores are interpreted in favor of an increase in disability.
214508488|NCT06269068|OTHER|Douleur Neuropathique 4|The questionnaire consists of 10 items; while the nature of pain is questioned in 7 items, the other 3 items include brief sensory examination. Patients with a score of 4 or more out of 10 are considered to have neuropathic pain.
214508489|NCT06269068|OTHER|Visual analogue scale|global pain score on a 0 to 10
214508490|NCT04686617|DIAGNOSTIC_TEST|Mechanical Vibration|Oral B HummingBird device (Procter\&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
214508491|NCT02504411|DEVICE|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
214508492|NCT02504411|DEVICE|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
214508493|NCT01404637|DRUG|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
214508494|NCT01404637|DRUG|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
214508495|NCT05582226|PROCEDURE|ACL reconstruction|"Orthopedic surgical operation in which a ruptured anterior cruciate ligament is repaired and reattached to the muscle connection points with a graft, a fashioned ligament that is meant to serve as a replacement for the ruptured muscle tissue."
215025786|NCT01306994|OTHER|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
215025787|NCT01306994|OTHER|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
215025788|NCT01306994|OTHER|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
215025789|NCT01306994|OTHER|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
215025790|NCT01724385|DRUG|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
215025791|NCT00100477|DRUG|Topotecan|
215025792|NCT00100477|DRUG|Mitozantrone|
215025793|NCT00100477|DRUG|Etoposide|
215025794|NCT06690437|DEVICE|Galaxy Fixation System and Orthofix implantable devices|"It is planned to include 118 patients in 3 sites in Italy treated with GALAXY FIXATION™ System and Orthofix implantable devices for the following indications:~* fractures of the long bones or;~* Vertically stable pelvic fractures or vertically unstable pelvic fractures as a treatment adjunct Clinical data will be collected only from patients with a regular indication for GALAXY FIXATION™ System and Orthofix implantable devices as per IFUs (no off-label use will be included) and who underwent surgery performed with the specific devices."
215025795|NCT06686524|DRUG|Anti-CD19 UCAR-T cells|A single infusion of CD19 UCAR-T cells will be administered intravenously after lymphodepletion chemotherapy.
214508496|NCT05582226|PROCEDURE|Mesenchymal stem cell implantation|Stem cells are to be extracted from tissue at the stump of the ACL attachment point and inserted on the graft in the hopes of improving healing response
214508497|NCT04907383|OTHER|quality of life|QoL assessment
214508498|NCT02319707|DRUG|Oxytocin|"The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor."
214508499|NCT02319707|DRUG|Oxytocin in 100 ml NaCl 0.9%|"The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department)."
214691680|NCT00701740|DRUG|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
215025796|NCT04695119|OTHER|Exposure is septic shock (defined according to Sepsis-III) and standard treatment according to departmental protocols.|Collection of data, biomarker and echocardiography analysis will be centralized and blinded. Assessment of endpoints will be blinded.
215025797|NCT00335426|PROCEDURE|Spinal manipulative therapy|
215025798|NCT01258985|BEHAVIORAL|Tai Chi|12 weeks of Tai Chi
215025799|NCT01258985|BEHAVIORAL|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
215025800|NCT06438250|DRUG|68Ga-JH04|The dose will be 148-222 MBq given intravenously.
215025801|NCT05996653|DIAGNOSTIC_TEST|Saturation Transfer (ST)-MRI|"Non-contrast magnetic resonance imaging Saturation Transfer scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)"
215025802|NCT05550428|OTHER|home-based-exercise|"All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.~sessions."
215025803|NCT05550428|DEVICE|active pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 PEMF sessions per participant, each leg receiving 8 exposures.
215025804|NCT05550428|DEVICE|shame pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 sham PEMF sessions per participant, each leg receiving 8 exposures.
215025805|NCT06124924|DRUG|SGLT2 inhibitor|a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
215025806|NCT05581511|OTHER|Evaluation of the natural history of cutaneous neurofibromas|Cutaneous neurofibromas (cNFs) are the most common tumors in people with neurofibromatosis type 1 (NF1). Despite their benign histology, they can significantly impact patients' quality of life (QoL). In this project, the natural history of cNFs will be prospectively and systematically studied. To accomplish this, the reproducibility and efficiency of using 3D whole-body photography was evaluated in a small cohort of patients. The study is enrolling patients of all ages with cNFs into groups by epochs of life to characterize the baseline tumor burden and the change in number and morphology of cNFs over five years. In addition, the study will perform next generation sequencing to describe the genetic variations in the NF1 gene and evaluate potential relations between genotype and phenotype. Lastly, the study will validate clinician- and patient-reported severity scales of cNFs developed for this patient population.
215025807|NCT06640153|DIAGNOSTIC_TEST|mpMRI|Gastroesophageal junction or upper gastric adenocarcinoma patients undergo mpMRI at siewert classification, length of esophageal involvement, primary staging and restaging
215025808|NCT02686775|BEHAVIORAL|Patient coach|
215025809|NCT02686775|BEHAVIORAL|Standard care|
215025810|NCT06160167|DRUG|IMiD treatment|Participants with MM treated with IMiDs
215103905|NCT03477058|OTHER|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
215025811|NCT06160167|DRUG|No IMiD treatment|Participants with MM not treated with IMiDs
215103906|NCT03718858|PROCEDURE|Interscalene Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
215103907|NCT03718858|PROCEDURE|Superior Trunk Nerve Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.
214508500|NCT01566383|PROCEDURE|24-hr pH monitoring|"Visit 1~The following will be done:~* A medical history including review of your current drugs;~* Collection of demographic information;~* A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~* 24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~* The catheter will be removed from your nose; and~* You will return the recording device"
214508501|NCT01829711|DRUG|Moxetumomab pasudotox|
214508502|NCT01829711|DRUG|IV Bag Protectant for Moxetumomab pasudotox|
214508503|NCT01482091|DRUG|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
214508504|NCT01482091|DRUG|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
215025812|NCT06160167|DRUG|Systemic therapy|Participants with MM treated with systemic therapy
215025813|NCT06813378|BEHAVIORAL|(Neuro)Cognitive Remediation|(Neuro)Cognitive remediation is an intervention for people experiencing cognitive impairments that interfere with their daily functioning. Attention, memory, abstract reasoning, and processing speed are all examples of cognitive skills. By focusing on improving these underlying skills, the overall aim of cognitive remediation is to improve the client's daily satisfaction and success. Although cognitive remediation programs and strategies have been studied with other populations, it has not been sufficiently evaluated from a mental health trans-diagnostic perspective for military Veterans and police officers and retirees who this research will study.
215025814|NCT05633927|BIOLOGICAL|SARS-CoV-2 Vaccine|Analyse humoral and cellular response to SARS-CoV-2 Vaccine.
215025815|NCT00431379|DRUG|Tenecteplase|
215025816|NCT00817609|DRUG|Angongniuhuang Pill|7 days of Angongniuhuang Pill
214508505|NCT01214070|OTHER|Vision Restoration Therapy|Therapy that enhances the neuronal plasticity of the visual system
214508506|NCT01214070|BEHAVIORAL|NVT Eye Scanning Therapy|Therapy that trains eye and head scanning into the blind hemianoptic visual field
214508507|NCT01214070|BEHAVIORAL|Eccentric Viewing Training|Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
214508508|NCT01214070|BEHAVIORAL|Sham|Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
214508509|NCT01480258|BIOLOGICAL|PR5I|DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis \[acellular, component\], hepatitis B \[recombinant DNA\], polio virus \[inactivated\], and Haemophilus influenza type b conjugate vaccine \[adsorbed\]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
214508510|NCT01480258|BIOLOGICAL|Rotavirus vaccine|Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
214508511|NCT01480258|BIOLOGICAL|Prevenar 13™|Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
214691681|NCT04583566|GENETIC|COVID-19 Diagnostic and Assessment Tests|Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
215025817|NCT00817609|DRUG|placebo|7 days of placebo
215025818|NCT05711797|DRUG|ZX-7101A 80mg|ZX-7101A a drug to treatment influenza in Chinese adults
215025819|NCT02376010|DRUG|rivaroxaban|
215025820|NCT02376010|DRUG|Warfarin|
215025821|NCT00590317|DRUG|Prochlorperazine|Patients receiving Prochlorperazine
215103908|NCT02400541|BEHAVIORAL|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
215103909|NCT02400541|OTHER|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
215025822|NCT00590317|DRUG|Ondansetron|Patients receiving Ondansetron
215103910|NCT02725541|DRUG|Trastuzumab emtansine|HER2-targeted antibody drug conjugate of trastuzumab and DM1
215103911|NCT02476292|OTHER|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
215103912|NCT03599323|DRUG|Clotrimazole 1% (Empecid L Cream, BAYB5097)|Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
215103913|NCT02541734|DRUG|Gelofusine|Infusion of gelofusine
215103914|NCT02541734|RADIATION|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
215103915|NCT02541734|DRUG|Placebo|
215103916|NCT02567994|DRUG|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
215103917|NCT03913494|DEVICE|Transoral Neurostimulation Device (Snoozeal)|Use of the Transoral Neurostimulation Device for 20 minutes, morning and night, every day for at least 4 weeks.
215103918|NCT02133807|PROCEDURE|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
215103919|NCT05211817|BEHAVIORAL|Complex lifestyle intervention|Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.
215103920|NCT05211817|DIETARY_SUPPLEMENT|Carnosine|3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.
215103921|NCT03639506|PROCEDURE|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
215103922|NCT03639506|COMBINATION_PRODUCT|autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|autologous mitochondria transplantation
215103923|NCT03639506|DRUG|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
215103924|NCT00900367|OTHER|high performance liquid chromatography|
215103925|NCT00900367|OTHER|laboratory biomarker analysis|
215103926|NCT00900367|PROCEDURE|spectroscopy|
215103927|NCT02430987|DIAGNOSTIC_TEST|Female sexual function index questionnaire|"Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese with 19 items measuring female sexual function. Cut-off points of \>23 and \> 26.5 were adopted to define a diagnosis of Female Sexual Function based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM -IV- TR) by the American Psychiatric Association, duration criteria \> 24 weeks.~A score of 5 or less on the combination of items comprising the desire domain of the FSFI questionnaire was used to define the diagnosis of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women We consider that a score of 6 or more the woman does not present with HSDD."
215103928|NCT02430987|DIAGNOSTIC_TEST|Evaluation of presence of metabolic syndrome|The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol \< 50mg/dL; (3) triglycerides \> 150mg/dL; (4) arterial blood pressure (SAH) \> 130/85mmHg; and (5) fasting glucose \> 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.
214508512|NCT01480258|BIOLOGICAL|INFANRIX™ hexa|Combined Diphtheria-Tetanus-acellular Pertussis \[DTaP\], Hepatitis B \[HepB\], Poliovirus \[IPV\] and Haemophilus influenzae type b \[Hib\] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
214508513|NCT03477084|BIOLOGICAL|ESBL-producing enterobacteriaceae carriage|Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
214508514|NCT02169414|DRUG|BIA 9-1067 5 mg|OPC, Opicapone
214508515|NCT02169414|DRUG|BIA 9-1067 25 mg|OPC, Opicapone
215025823|NCT04732806|BEHAVIORAL|Mightier video games|Biofeedback video game play in home
215025824|NCT02741050|BEHAVIORAL|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
214508516|NCT02169414|DRUG|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
214508517|NCT02169414|DRUG|Placebo|PLC, Placebo
214508518|NCT02169414|DRUG|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
215025825|NCT02741050|BEHAVIORAL|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
215103929|NCT02430987|DIAGNOSTIC_TEST|Evaluation of the body mass index|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group
214508519|NCT00368602|DRUG|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
214691682|NCT01442129|BIOLOGICAL|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
215103930|NCT01597024|OTHER|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
214423771|NCT00550394|DRUG|quetiapine and placebo|"Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
214423772|NCT00550394|DRUG|Quetiapine and Topiramate|"Dosing Schedule and Titration of Quetiapine:~open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
214423773|NCT06208397|DIAGNOSTIC_TEST|Magnetic Resonance Elastography and routine MRI|Assessed boundary conditions through MRE-base SII before surgery and recorded HGP of tumor after surgery.
214508520|NCT00368602|OTHER|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
214508521|NCT03874949|DEVICE|SEALITE Regular|Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
214508522|NCT03874949|DEVICE|SEALITE Ultra|"Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control."
214508523|NCT03374254|BIOLOGICAL|Pembrolizumab|200 mg Pembrolizumab solution for IV infusion Q3W
215025826|NCT05269797|BEHAVIORAL|Nurse-led health coaching re: heart failure self-care management|A focus group meeting will be arranged with the nurse participants to provide training on the study intervention specific to the Nurse-led health coaching intervention. The intervention involves identifying barriers and finding strategies and solutions to self-care management, while employing a self-care HF management tool of adjusting diuretic dosing (ADD) according to the congestive cardiac calendar (designed in collaboration with nurses in Phase 1). It will be essential for the nurses to document key information pertaining to the rationale for these decision-making strategies or solutions. This is in comparison to the standard of care in primary health care of nurses not taking a standardize approach towards health coaching and the patient being instructed by the practitioner to take a set diuretic dosing (SDD).
214508524|NCT03374254|DRUG|Binimetinib|tablet orally BID at 30 or 45 mg depending upon DLT profile
215025827|NCT06228937|OTHER|analysis of a sample of stool|typing of the gut microbiota from a stool sample
215025828|NCT05645887|DRUG|Human albumin|Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.
215025829|NCT05645887|OTHER|Saline solution|Saline solution from day 0 to day 7.
215025830|NCT03999073|OTHER|Ultrasound measurement|Ultrasound measurement
215025831|NCT06548516|PROCEDURE|Control group (conventional scalpel surgery)|The patients in the control group will undergo frenectomy using conventional scalpel surgery.
215025832|NCT06548516|PROCEDURE|Diode laser group|The patients in the laser group will undergo frenectomy using a diode laser.
214508525|NCT03374254|DRUG|Oxaliplatin|85 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m\^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
214508526|NCT03374254|DRUG|Leucovorin|400 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
214508527|NCT03374254|DRUG|5-Fluorouracil [5-FU]|2400 mg/m\^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m\^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
215025833|NCT04804436|GENETIC|Genetic analysis|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
214508528|NCT03374254|DRUG|Irinotecan|180 mg/m\^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m\^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
215025834|NCT01965951|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
215025835|NCT01965951|OTHER|Commercially available computerized training|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
215025836|NCT02117271|DEVICE|continuous positive airway pressure|device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
215025837|NCT02117271|OTHER|Breathe Right ®|Nasal dilator strip treatment used during sleep to open the nasal airway
215103931|NCT01597024|OTHER|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
215103932|NCT02921087|DEVICE|Test Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
215025838|NCT04850963|DEVICE|Transcranial direct current stimulation (Anodal tDCS) + dual-task training|"anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
215025839|NCT04850963|DEVICE|Transcranial direct current stimulation (tDCS dualsite) + dual-task traning|"tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
215025840|NCT04850963|DEVICE|Transcranial direct current stimulation sham + dual-task training|"tDCS sham 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
215025841|NCT00461890|DRUG|Injectable Naltrexone|
215025842|NCT04883203|DRUG|Vit-D 0.2 MG/ML Oral Solution [Calcidol]|ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
215025843|NCT04883203|DRUG|Physiological Irrigating Solution|ARM 2 : placebo
215025844|NCT05708690|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
215025845|NCT05708690|DRUG|normal saline|Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
215025846|NCT02264756|OTHER|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
215025847|NCT04279769|DRUG|CB-280|CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
215025848|NCT04279769|DRUG|Placebos|Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
215025849|NCT03743519|DIETARY_SUPPLEMENT|Cherry juice|30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
215025850|NCT03743519|DIETARY_SUPPLEMENT|Placebo|Identical in taste and colour to the Cherry juice, but with no anthocyanin content
215025851|NCT04802109|DEVICE|wearing level D personal protective equipment|rubber gloves + surgical face mask + general isolation clothing
215025852|NCT04802109|DEVICE|wearing Level C personal protective equipment with N-95|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing"
215025853|NCT04802109|DEVICE|wearing Level C personal protective equipment with Powered Air-Purifying Respiratory|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory"
215025854|NCT03362632|DRUG|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment.
215025855|NCT04622267|DEVICE|Barbed suture|to close a C-section incision
215103933|NCT02921087|DEVICE|Control Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
214508529|NCT04288869|OTHER|Continuous monitoring of arterial blood pressure|For all patients, mean arterial pressure (unit mmHg) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.
214508530|NCT04288869|OTHER|Transcranial Doppler|"Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography.~For all patients, CFV (unit cm/s) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
215025856|NCT04622267|PROCEDURE|Standard antimicrobial suture|to close a C-section incision
215025857|NCT02510742|DEVICE|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
215025858|NCT02510742|DEVICE|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
215025859|NCT04722809|DRUG|Botulinum toxin injection|Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
215025860|NCT04722809|OTHER|QOL-Brux|Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
215025861|NCT04722809|OTHER|Muscular strength of the jaw|"Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.~At inclusion and 1 month post-injection."
215025862|NCT04722809|OTHER|Intensity and frequency of episodes of nocturnal bruxism|Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
215025863|NCT04722809|OTHER|visual analogue pain scale|Evaluation of jaw pain. At inclusion and 3 months post-injection
215025864|NCT04722809|OTHER|Endobuccal and linea alba photographs|"anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).~At inclusion"
215025865|NCT06571604|DIAGNOSTIC_TEST|Dislocation|One episode of total hip dislocation diagnozied on Xray within 2 years of surgery
215025866|NCT06571604|DIAGNOSTIC_TEST|No dislocation|No experience of dislocation within two years post-surgery
215025867|NCT06570876|PROCEDURE|Surgery|The decision between RS and CS depended on the patient's performance status; on the cyst's main characteristics and contact with liver structures; and on intraoperative findings.
215025868|NCT06569225|DRUG|Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig|: Patients will receive prior to surgery: 2 cycles of combinational therapy with Gemcitabine (800mg) /Cisplatin (25mg) /Nab-Paclitaxel (100mg) and Rilvegostomig (Q3W). Post-surgical resection, adjuvant therapy will consist of 4 cycles of Gemcitabine (1000mg) /Cisplatin (25mg) and Rilvegostomig (Q3W). Rilvegostomig (Q3W) will be continued for a total of 12 months in the adjuvant phase
215025869|NCT06570226|DIETARY_SUPPLEMENT|hibiscus tea|Some cell and animal experiments have pointed out that drinking tea may be related to hypotension, body composition and vision problems, and there are more and more related advertisements, especially for hibiscus tea, which is rich in anthocyanins.
215025870|NCT06569732|OTHER|Homemade oral nutrition supplements|The homemade oral nutrition supplement is made of soy milk, whey protein powder, vegetable oil, and fruit juices
215025871|NCT06569732|OTHER|Commercial oral nutrition supplements|The commercial oral nutrition supplement is kidney-specific oral nutrition supplement that is high in energy and protein, but low in electrolytes and fluid
214508531|NCT04288869|OTHER|Bispectral Index (BIS)|"Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS).~For all patients, BS will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation"
214691683|NCT01442129|BIOLOGICAL|Control Solution|Injection of control solution during the LVAD implantation.
215025872|NCT06565676|DIETARY_SUPPLEMENT|Bread with whey protein powder added|Volunteer participants will consume bread with and without whey powder added and its effect on blood sugar will be examined.
215025873|NCT02174237|DRUG|LNP1892|Tablets of two strengths (5 and 25 mg)
215025874|NCT02174237|DRUG|Placebo|Matching placebo
215025875|NCT03829514|DRUG|Fenofibrate|40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides \>150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.
215103934|NCT04680819|DIETARY_SUPPLEMENT|Anatolian Propolis|Health workers who agree to participate in the study will be accepted as the study group, and healthcare professionals who do not agree to participate in the study will be considered as the control group. The study group will be asked to take 20 drops of Propolis drop form twice a day in the morning / evening, and the control group will not receive any treatment and both groups will be followed. In this process, patients diagnosed with COVID-19 will be determined. PCR test positivity taken from the throat for the diagnosis of COVID-19 will be accepted. The research will cover a period of 1 month. At the end of 1 month, patients diagnosed with COVID-19 in the study and control groups will be compared. Thus, the protective properties of Anatolian propolis will be determined.
215103935|NCT01566487|DRUG|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
215103936|NCT00687531|DRUG|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
215025876|NCT04174482|PROCEDURE|morphological and functional evaluation of adult flat foot|Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
215025877|NCT03942744|DEVICE|on-line hemodiafiltration|on-line postdilutional hemodiafiltration with high convective transport above 21 liters
215025878|NCT01339091|DRUG|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
215025879|NCT01339091|DRUG|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
215025880|NCT00661180|DRUG|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
214508532|NCT04288869|OTHER|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
214508533|NCT05637944|PROCEDURE|oro tracheal intubation|chest trauma requiring oro tracheal intubation
214508534|NCT04226118|DEVICE|Vein Illumintion System device|Spotting veins of a patient by use of a Vein Illumintion System device
214508535|NCT04755907|PROCEDURE|surgical resection|Surgical resection will be performed for locoregional lesions or liver metastases.
214508536|NCT04755907|OTHER|adjuvant chemotherapy|Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
215025881|NCT03923088|BEHAVIORAL|jacobson's progressive muscle relaxation technique|This involves tensing specific muscle groups for 5-7 seconds, followed by 20 seconds of relaxation. The method can be demonstrated chairside, and should be practiced and rehearsed by the patient at home. Four major muscle groups are commonly tensed and relaxed. These are: 1) feet, calves, thighs, and buttocks; 2) hands, forearms, and biceps; 3) chest, stomach, and lower back; and 4) head, face, throat, and shoulders
215025882|NCT03923088|BEHAVIORAL|audio-visual distraction technique|audiovisual distraction not only leads to full involvement of scenes (visual and auditory), but it also induces a positive emotional reaction resulting in a relaxed experience.
215025883|NCT02788292|DRUG|Acetylcysteine|See arm description
215025884|NCT00844220|PROCEDURE|CT/MR|CT/MRI-directed clinical management strategy
215025885|NCT00844220|PROCEDURE|Catheterization|Standard clinical management directed by conventional coronary angiography
215025886|NCT03607110|DRUG|Ketamine|sedation drugs
215025887|NCT03607110|DRUG|fentanyl|sedation drugs
215025888|NCT03607110|DEVICE|patient control analgesia|patient control analgesia
215025889|NCT06304012|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
215025890|NCT06304012|DEVICE|Intermittent Oro-esophageal Tube Feeding|The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
215025891|NCT06304012|BEHAVIORAL|Rehabilitation therapy|"Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers."
214508537|NCT04755907|OTHER|neoadjuvant therapy|Regimens of neoadjuvant chemotherapy are directed by clinical guidance and experience.
214508538|NCT04502459|PROCEDURE|Tourniquet|A tourniquet is often used in total knee arthroplasty to achieve better visualization, reduce intra-operative bleeding and facilitate cement interdigitation
214508539|NCT03040453|DEVICE|Microwave ablation|
215025892|NCT00108563|DRUG|Citalopram or Placebo|
215025893|NCT05051410|PROCEDURE|intracanal cryotherapy using needle irrigation and EndoVac system|a cold saline will be used as final irrigant in two groups but with different irrigation systems.
215103937|NCT01612208|DEVICE|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
215103938|NCT01612208|DEVICE|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
215103939|NCT03143764|BEHAVIORAL|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
214508540|NCT03040453|DEVICE|Irreversible electroporation|
214508541|NCT05409170|PROCEDURE|COVID|Each surgical procedure was considered an independent event. Moreover, the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
214508542|NCT05210985|BEHAVIORAL|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
214691684|NCT04883385|OTHER|medical data collection|collection of medical data from patients' medical records
214691685|NCT01675219|PROCEDURE|white light TUR-BT|traditional transurethral bladder tumor resection
215025894|NCT05646173|DEVICE|vagus stimülation device|Vagustim is a wearable medical technology device that focuses on non-invasive bilateral auricular vagus nerve stimulation (VNS). VNS is a clinically approved, safe and effective neuromodulation method.
215025895|NCT05646173|DEVICE|Electrophysical agents|Electrophysical agents (EPAs) are those modalities that administer thermal, mechanical, electrical or light energy to the patient to provide physiological effects and therapeutic benefits.
215025896|NCT05646173|OTHER|home exercise program|The home exercise program will be explained to the patients by the physiotherapist and will also be given to the patient in the form of a brochure. Patients will be instructed to do the exercises regularly, three times a day for ten repetitions each day. The content of the exercises is updated weekly.
214691686|NCT01675219|PROCEDURE|blue light TUR-BT|photodynamic transurethral bladder tumor resection
214691687|NCT01675219|DRUG|optimized MMC|six weekly optimized mitomycin-C instillations
215025897|NCT01775345|PROCEDURE|Isotonic exercises|"20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
215025898|NCT01775345|PROCEDURE|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
215025899|NCT01775345|PROCEDURE|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
215025900|NCT01775345|PROCEDURE|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
215025901|NCT04414943|DRUG|S-ketamine|For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
215025902|NCT04414943|DRUG|Placebo|For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
215025903|NCT05273736|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
215025904|NCT02779231|OTHER|Bi-directional texting|
215025905|NCT02593630|DEVICE|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
215025906|NCT01321684|OTHER|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
215025907|NCT01321684|OTHER|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
215025908|NCT00625105|BEHAVIORAL|Biofeedback|
215025909|NCT00003907|DRUG|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
215025910|NCT00003907|DRUG|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
215025911|NCT00003907|DRUG|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
215025912|NCT00003907|PROCEDURE|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
215025913|NCT04437745|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
214691688|NCT01675219|DRUG|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
215025914|NCT01517178|DEVICE|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
215025915|NCT01517178|DEVICE|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
215025916|NCT04520230|DRUG|Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid|inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).
215025917|NCT04520230|DRUG|Tiotropium 18 mcg capsule inhaled once daily + Budesonide|inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).
215025918|NCT04520230|DRUG|Formoterol/Tiotropium|long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).
215025919|NCT06502028|DEVICE|Video laryngeal mask airway|The airway is secured with a video laryngeal mask airway.
215025920|NCT06502028|DEVICE|Endotracheal tube|The participant is intubated with an endotracheal tube via direct laryngoscopy.
215025921|NCT01573429|OTHER|deuterated-Bisphenol A (d-BPA)|The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
215025922|NCT05249855|BEHAVIORAL|Psychological measurement|Psychological assessment
214423774|NCT06572163|DEVICE|Eximis CS (Contained Segmentation) System|The Eximis CS System is an integrated system consisting of a 900 mL Capture Bag, Inflation Mechanism, two Eximis Segmenters, and the Eximis RF Generator.
215025923|NCT02553473|DRUG|Doxycycline|
214423775|NCT06333990|DRUG|Quetiapine Fumarate|Quetiapine is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia, bipolar disorder, and as an adjunct to treat major depression. It has a broad spectrum of actions at dopaminergic (D1, D2, D3 and D4), serotonergic (5-HT2A, 5-HT2C and 5-HT7), adrenergic (α1), histaminic (H1) and muscarinic (mACh), and partial agonist at 5-HT1A receptors.
214423776|NCT06333990|DRUG|TAU|Standard of care psychotropic medications for treatment of patients with mTBI.
214423777|NCT06399679|DRUG|Rivastigmine|Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
214423778|NCT06399679|DRUG|Placebo|Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
214423779|NCT06140303|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
214423780|NCT06140303|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen dressing~* Local offloading~* Foam~* Multi-layer compression dressing~* Off-loading device such as a controlled ankle motion (CAM) boot"
214508543|NCT05210985|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years."
214508544|NCT05210985|BEHAVIORAL|Test Of Sensory Functions In Infants (Tsfı)|This test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
214508545|NCT06506357|DIETARY_SUPPLEMENT|Good Girl Probiotics|Participants will take one capsule of the Good Girl Probiotics supplement daily in the morning for eight weeks.
214508546|NCT04555057|PROCEDURE|Music therapy|Music selected according to the patient's individual preferences.
214508547|NCT02176694|BEHAVIORAL|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
214508548|NCT03790098|BEHAVIORAL|Restorative-Flow Yoga|Restorative yoga consists of a series of gentle poses, supported by props, with an emphasis on breathing and relaxing; as opposed to stretching or contracting muscles, it is designed to support muscles. Flow yoga consists of a series of linked poses synchronized with the breath.
214508549|NCT02309515|OTHER|Laboratory Biomarker Analysis|Correlative studies
214508550|NCT02309515|DRUG|Lenalidomide|Given PO
214508551|NCT02309515|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
214508552|NCT02174978|BIOLOGICAL|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
214508553|NCT02174978|OTHER|P falciparum Controlled Human Malaria Infection (CHMI)|
215025924|NCT02553473|DRUG|Placebo|
215025925|NCT05663554|BEHAVIORAL|WW Intervention|The core of the WW food program is the SmartPoints® system. Briefly, the SmartPoints® system assigns each food and beverage a SmartPoints® value per volume based on four components: calories, sugar, saturated fat, and protein. Certain foods have a SmartPoints® value of zero (ZeroPoint foods). These foods (e.g., lean sources of protein such as skinless chicken breast and vegetables) form the basis of a healthy eating pattern, are at low risk for overconsumption and do not have to be weighed, measured or tracked. Participants were assigned a personalized SmartPoints® Budget, based on reported food and lifestyle preferences, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure.
214508554|NCT01124552|DRUG|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
215025926|NCT05663554|OTHER|Usual Care|The Usual Care group will continue to receive routine medical care by their provider, in addition to receiving one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments.
214508555|NCT01124552|DRUG|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
214508556|NCT01124552|OTHER|Vehicle|Vehicle Control
215025927|NCT02999997|BEHAVIORAL|Ronnie Gardiner Method (RGM)|RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
215025928|NCT05305573|BIOLOGICAL|COVID-19 Vaccine HIPRA 40 ug/dose|Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)
215025929|NCT05305573|BIOLOGICAL|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|Subjects will receive one injection of Comirnaty Vaccine
215025930|NCT05490056|OTHER|no intervention|the study will not apply on intervention
215025931|NCT00234793|BEHAVIORAL|Problem-Solving Skills Training|
215025932|NCT04628208|DIAGNOSTIC_TEST|Spartan COVID-19 v2 System|A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
215025933|NCT00055887|DRUG|carboplatin|
215025934|NCT00055887|DRUG|cisplatin|
215025935|NCT00055887|DRUG|efaproxiral|
215025936|NCT00055887|DRUG|gemcitabine hydrochloride|
215025937|NCT00055887|DRUG|paclitaxel|
215025938|NCT00055887|DRUG|vinorelbine ditartrate|
215025939|NCT00055887|PROCEDURE|radiation therapy|
215025940|NCT04245605|PROCEDURE|Coronary angiography|Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
215025941|NCT02256033|DRUG|Istradefylline|One 40 mg-tablet administered on Day 1
215025942|NCT03895476|DIAGNOSTIC_TEST|palatal wound will be cover with collagen and sutures|after harvesting the graft from the palate, a collagen sponge will be sutured to cover the harvested site
215025943|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with platelet rich fibrin|after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
215025944|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a collagen sponge and cyanoacrylate|after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
215025945|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a stent|after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
215025946|NCT06029166|DEVICE|Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)|Implantation of a subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®) before beginning the Bruton's tyrosine kinase inhibitor treatment.
214423781|NCT06415448|DRUG|Donidalorsen|Donidalorsen administered once monthly or every other month by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
214423782|NCT06324201|DEVICE|Ablation Procedure|Ablation Procedure for paroxysmal atrial fibrillation
215025947|NCT05559385|DEVICE|Robot-Assissted Therapy|Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.
215025948|NCT05559385|PROCEDURE|Conventional Rehabilitation|It is an upper extremity rehabilitation program prepared in line with individual needs.
215025949|NCT04883047|OTHER|holistic birth support strategies|"Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy."
215025950|NCT01050218|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
215025951|NCT06498180|OTHER|Periodontal initial treatment under local anesthesia|Removal of plaque retention factors, supragingival scaling and subgingival scraping under local anesthesia with articaine (combined with manual and ultrasound methods), and polishing
215025952|NCT06498180|DRUG|Glucocorticoid Therapy|Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
215025953|NCT06498180|BEHAVIORAL|oral hygiene instruction|Instructions and demonstrations for using manual toothbrushes Instructions and demonstrations for using dental floss or interdental brushes
215025954|NCT04369612|PROCEDURE|Standard follow-up|Standard post-transplant follow-up
215025955|NCT04369612|PROCEDURE|Home-based monitoring|Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
215025956|NCT05510167|BEHAVIORAL|Study arm|Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
215025957|NCT01149460|DRUG|Valacyclovir|Test 1000 mg Tablet
215025958|NCT01149460|DRUG|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
214423783|NCT05319626|OTHER|compression socks|The compression socks have a clinical pressure of 23-30 mm Hg. The socks are dressed to the participants based on the manufacturer's sizing guidelines.
214423784|NCT05319626|OTHER|textured insoles|The textured insoles have small, pyramidal peaks with centre-to-centre distances of approximately 2.5 mm (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
215025959|NCT05231252|PROCEDURE|Cyclophotocoagulation|Transcleral cyclophotocoagulation is used to treat glaucoma secondary to silicone oil.
215025960|NCT00077285|BIOLOGICAL|filgrastim|
215025961|NCT00077285|DRUG|carboplatin|
215025962|NCT00077285|DRUG|cyclophosphamide|
215025963|NCT00077285|DRUG|dexrazoxane hydrochloride|
215025964|NCT00077285|DRUG|doxorubicin hydrochloride|
215025965|NCT00077285|DRUG|etoposide|
215025966|NCT00077285|DRUG|ifosfamide|
215025967|NCT00077285|DRUG|irinotecan hydrochloride|
215025968|NCT00077285|DRUG|vincristine sulfate|
215025969|NCT00077285|PROCEDURE|conventional surgery|
215025970|NCT00077285|RADIATION|radiation therapy|
215025971|NCT00433186|DRUG|Mycophenolate Mofetil|Mycophenolate 3000 mg each day
215025972|NCT02772120|DRUG|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
215025973|NCT02772120|DRUG|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
215025974|NCT05845892|OTHER|stress ball|The use of the stress ball by the experimental group patients will be reminded by a hemodialysis nurse who was not involved in the study.
215025975|NCT04377776|OTHER|Practice details|Questionnaire
215025976|NCT04098913|BEHAVIORAL|Reduced screen-based media use|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
215025977|NCT01655446|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
215025978|NCT01655446|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
215025979|NCT01655446|BEHAVIORAL|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
215025980|NCT01655446|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
215025981|NCT01655446|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
215025982|NCT05388825|DRUG|TPN171H 2.5mg|TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
215025983|NCT05388825|DRUG|TPN171H 5mg|TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
215025984|NCT05388825|DRUG|TPN171H 10mg|TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
215025985|NCT05388825|DRUG|Placebo 5mg|Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
215025986|NCT05388825|DRUG|Placebo 10mg|Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
214508557|NCT01124552|DRUG|Placebo|Placebo Comparator
214508558|NCT02102698|DRUG|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1 receptor family.
214508559|NCT02369328|DEVICE|MULTIMODAL MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
214508560|NCT03481153|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS is a safe, non-invasive neurostimulation technique that can modulate neural excitability in the brain to positively impact cognition, behaviour and mood, particularly when combined with a behavioural intervention
214508561|NCT00091728|DRUG|Depo Medroxyprogesterone acetate|
214508562|NCT00091728|DRUG|Combined oral contraceptives|
214508563|NCT04277494|OTHER|Clorethyl cold spray® (Vapocoolant spray)|From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application.
214508564|NCT03880981|DRUG|Ibuprofen 600 mg|ibuprofen 600mg Po q 6 hours prn pain
214508565|NCT03880981|DRUG|Acetaminophen|acetaminophen 600mg po q6 hours prn pain
214508566|NCT02205255|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
214508567|NCT02205255|DRUG|Placebo|
214508568|NCT05205083|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (BBIBP-CorV), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
214508569|NCT04717687|PROCEDURE|Irreversible electroporation|Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
214508570|NCT03794388|DRUG|Capsaicin|Application of capsaicin patches at 8% on painful area
214508571|NCT03794388|DRUG|Pregabalin|Taking Pregabalin tablets
215025987|NCT01985282|BEHAVIORAL|Nutrition Status Questionnaires and Physicial Function Test|Nutrition status questionnaires will be administered, Physical functional status will be tested
215025988|NCT03673930|DIETARY_SUPPLEMENT|Zanthozylum armatum|Zanthozylum armatum MCT oil extract
215025989|NCT03673930|DIETARY_SUPPLEMENT|Placebo|sunflower oil matched for appearance
215025990|NCT05059665|DIAGNOSTIC_TEST|Helio Liver Test|De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).
215025991|NCT03020316|BEHAVIORAL|Peer Mentor|A volunteer with a similar disease as the subject
215025992|NCT03020316|BEHAVIORAL|Transcendental Meditation|A meditation technique
215025993|NCT03412552|DRUG|MgSO4|Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
215025994|NCT06540014|OTHER|No intervention|No intervention is made, groups are formed just due to the races.
215025995|NCT05226052|DIETARY_SUPPLEMENT|Saccharomyces boulardii (Floratil 600mg)|PGIC and PGIS assessment
215025996|NCT05226052|DIETARY_SUPPLEMENT|3 capsules of placebo|PGIC and PGIS assessment
215025997|NCT03119129|BEHAVIORAL|Ho'ouna Pono Drug Prevention Curriculum|Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
215025998|NCT00497497|DRUG|bevacizumab|(Only for patients not previously treated with bevacizumab) Intravenous repeating dose
215025999|NCT00497497|DRUG|cetuximab|Intravenous repeating dose
215026000|NCT00497497|DRUG|FOLFIRI regimen|Intravenous repeating dose
215026001|NCT00497497|DRUG|irinotecan|Intravenous repeating dose
215026002|NCT00497497|DRUG|PRO95780|Intravenous repeating dose
215026003|NCT00441324|PROCEDURE|recombinant human LH|
215026004|NCT03709667|BEHAVIORAL|EX|An individualized aerobic and resistance-exercise program will be developed for each participant on the basis of a maximal incremental exercise test and strength assessments performed at baseline. This test will measure aerobic capacity (VO2 max) and the metabolic or lactate threshold (VO2θ) (i.e., the level of O2 uptake that defines one's ability to perform prolonged work), using indirect calorimetry with an automated metabolic-measurement system. The intervention will comprise 24 sessions over 8 wk (3x/wk), supervised by a credentialed exercise specialist. Each session will consist of a 5-min warm-up, 30-40 min of aerobic activity on a treadmill, 15-20 min of resistance training, and a 5-min cool-down.
215026005|NCT03709667|BEHAVIORAL|CON|Participants attend 50-min sessions 3x/wk matched to EX for staff contact. A counselor will facilitate integrative group discussions, and will conduct a multimedia program addressing various health, wellness and lifestyle topics, such as nutrition, dental care, stress relief, sleep hygiene, relationships, immunizations, health screening, smoking, environmental health, and time management.
215026006|NCT00380926|DRUG|polyunsatturated fatty acids (fish oil)|
215026007|NCT01988077|BIOLOGICAL|Adoptive cell transfer|Adoptive cell transfer
215026008|NCT01988077|DRUG|Ipilimumab 5 MG/ML Injection [Yervoy]|2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
215026009|NCT03538847|OTHER|Numerical rating scale|Measure of postoperative pain
215026010|NCT00610038|DRUG|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
215026011|NCT03735914|OTHER|MRI|Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.
215026012|NCT04877379|DRUG|VNRX-7145|β-lactamase inhibitor
215026013|NCT04877379|DRUG|VNRX-5024 (ceftibuten)|β-lactam antibiotic
215026014|NCT04877379|DRUG|Placebo|Placebo
214423785|NCT05319626|OTHER|smooth socks|The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.
215026015|NCT06264544|DIETARY_SUPPLEMENT|zinc, selenium, and L-tyrosine in SEPP1|zinc, selenium, and L-tyrosine in SEPP1 polymorphism
215026016|NCT06264544|OTHER|Placebo|placebo comparator in SEPP1 polymorphism group
215026017|NCT06216262|OTHER|Control group|Brushing teeth twice a day for 8 weeks
215026018|NCT06216262|OTHER|Arginine|Brushing teeth twice a day for 8 weeks
215026019|NCT06216262|OTHER|Novamin|Brushing teeth twice a day for 8 weeks
215026020|NCT06216262|OTHER|Propolis|Brushing teeth twice a day for 8 weeks
215026021|NCT06216262|OTHER|Casein Phosphopeptide Amorphous Calcium Phosphate|Following the procedure in the control group, it is applied to the tooth surface once a day for 3 minutes before going to bed at night for 8 weeks
215026022|NCT06216262|OTHER|Potassium Nitrate|Following the procedure in the control group, mouthwash twice a day in the morning and evening for 8 weeks
215026023|NCT04250792|DRUG|Naltrexone Pill|role of low dose naltrexone in patients affected with psoriasis
215026024|NCT00002480|RADIATION|radiation therapy|
215026025|NCT00320320|DRUG|Irinotecan|
215026026|NCT00266032|DRUG|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
215026027|NCT00266032|DRUG|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
215026028|NCT00266032|DRUG|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
215026029|NCT05736913|BIOLOGICAL|ID BNT162b2 vaccine|intradermal BNT162b2 vaccine
215026030|NCT05736913|BIOLOGICAL|IM BNT162b2 vaccine|intramuscular BNT162b2 vaccine
214508572|NCT05689177|BIOLOGICAL|Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)|Booster dose administration
215026031|NCT02796456|OTHER|blood sample|
215026032|NCT01991873|DRUG|Maintenance Chemotherapy|
214508573|NCT02820506|PROCEDURE|SLN mapping and removal of PET-positive lymph nodes|Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes
214508574|NCT04191863|OTHER|Clinical, EEG and laboratory assessment at presentation|"* The patients' history, clinical, demographic, and laboratory data were acquired.~* The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate.~* Urinary tract ultrasonography (with full and void bladder).~* CT brain and EEG."
214508575|NCT04191863|DRUG|Valproate|valproate monotherapy
214508576|NCT04026256|DRUG|Teriparatide|teriparatide daily subcutaneous injection
214508577|NCT04026256|DRUG|Denosumab|denosumab subcutaneous injection
214508578|NCT01864590|DEVICE|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
214508579|NCT01864590|DEVICE|Double Sylo Bag - Mesh Protocol|"double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure"
215026033|NCT01991873|DRUG|Panitumumab (Within maintenance phase)|
215026034|NCT01991873|DRUG|mFOLFOX6 (Within re-induction phase)|
215026035|NCT01991873|DRUG|Panitumumab (Within re-induction phase)|
214423786|NCT05319626|OTHER|smooth insoles|The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
214423787|NCT01689844|BEHAVIORAL|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
214423788|NCT01689844|BEHAVIORAL|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
214423789|NCT00203372|DRUG|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
214423790|NCT00203372|DRUG|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
214423791|NCT00203372|DRUG|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
214423792|NCT00203372|DRUG|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
214423793|NCT02296463|BIOLOGICAL|RSV F Vaccine with adjuvant (0.5mL injection)|
214423794|NCT02296463|BIOLOGICAL|RSV F Vaccine (0.5mL injection)|
214423795|NCT02296463|BIOLOGICAL|Hepatitis A Vaccine (0.5mL injection)|
214423796|NCT02296463|BIOLOGICAL|Placebo (0.5mL injection)|
214423797|NCT02719600|BEHAVIORAL|Virtual reality|Evaluation of observational motor learning using virtual reality
214423798|NCT06436690|BEHAVIORAL|Diagnosis Mandate and Feedback|The intervention consists of: a) a Refresher Training on AMR, (b) a Diagnosis Mandate, and (c) an Individualized Feedback.
214423799|NCT03022123|DRUG|PL-doxorubicin and epirubicin|PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
214423800|NCT03981042|DEVICE|Monitoring|"After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~\- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed"
214423801|NCT04014114|OTHER|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
214508580|NCT04293718|OTHER|papillary gum biopsies|1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
214508581|NCT02892318|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
214508582|NCT02892318|DRUG|Guadecitabine|Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.
214508583|NCT04235920|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
214508584|NCT00000617|DRUG|azithromycin|
215026036|NCT03721458|OTHER|Sequence|Potentially identifying genetic defects that could have clinical significance
215026037|NCT01740518|DRUG|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
215026038|NCT04695366|OTHER|No intervention|No intervention
215026039|NCT02118831|BIOLOGICAL|Blood Sample Collection|Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
215026040|NCT02118831|DRUG|Aflibercept|an intravitreal injection of Aflibercept administered three times on a monthly basis.
215026041|NCT02118831|DRUG|Bevacizumab|an intravitreal injection of Bevacizumab administered three times on a monthly basis.
215026042|NCT02118831|DRUG|Ranibizumab|an intravitreal injection of Ranibizumab administered three times on a monthly basis.
215026043|NCT04491110|OTHER|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.
215026044|NCT04491110|OTHER|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
214508585|NCT03152214|OTHER|Vigorous Intensity Aerobic Exercise and Community Engagement|"Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at \> 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.~Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap."
214508586|NCT03152214|OTHER|Community Engagement|Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
214508587|NCT02400528|BEHAVIORAL|quality of life questionnaires|
214508588|NCT00000250|DRUG|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
215026045|NCT03587090|DIAGNOSTIC_TEST|echocardiography|echocardiography by subcostal and transhepatic views
215026046|NCT03190876|PROCEDURE|Variable drain usage|Influence of drain usage on seroma formation rate
215026047|NCT03070067|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
215026048|NCT04280380|DIAGNOSTIC_TEST|Real time PCR|At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with \>500 copies/mL of plasma will be considered positive.
215026049|NCT01514357|DRUG|Nesiritide (BNP)|NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
215026050|NCT01514357|DRUG|Placebo|Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
215026051|NCT00752219|DRUG|ceftazidime/NXL104 + metronidazole|IV TID
215026052|NCT00752219|DRUG|meropenem|IV TID
215026053|NCT05730660|DIETARY_SUPPLEMENT|Quercetin group|2 capsules a day of Quercetin Fitosoma® of 250 mg each
215026054|NCT05730660|DIETARY_SUPPLEMENT|Placebo group|2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
215026055|NCT04642209|DEVICE|Aggregometry|"After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS \<4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation."
215026056|NCT03576651|BIOLOGICAL|JHL1149|Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
215026057|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
215026058|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
215026059|NCT03751982|DEVICE|Transcranial Electrical Neuromodulation (TES)|TES phase-aligned with slow waves or not
214508589|NCT00000250|DRUG|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
214508590|NCT03046394|DEVICE|C-SACH|Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
215026060|NCT02811419|DEVICE|i-scan|examination will be performed with i-scan digital enhancement
215026061|NCT02811419|DEVICE|standard high-definition white light|examination will be performed with high-definition white light
215026062|NCT05598515|BEHAVIORAL|Time-Restricted Feeding|Participants will be asked to eat for only 8 hours out of 24 hours in a day.
215026063|NCT03604744|DRUG|LSD|LSD 0.1 mg per os, single dose
215026064|NCT03604744|DRUG|LSD|LSD 0.2 mg per os, single dose
215026065|NCT03604744|DRUG|Psilocybin|Psilocybin 15 mg per os, single dose
215026066|NCT03604744|DRUG|Psilocybin|Psilocybin 30 mg per os, single dose
215026067|NCT04211948|PROCEDURE|robotic surgery|Pancreatectomy with robotic assisted system
215026068|NCT04211948|PROCEDURE|open surgery|Traditional open pancreatectomy
215026069|NCT05263167|DRUG|Sodium Aescinate|sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
215026070|NCT05263167|DRUG|Placebo|250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
215026071|NCT03058887|OTHER|Exercise intervention - Cycling|The patients that will be randomly allocated to the exercise group - cycling will be requested to perform an exercise session on a cycle ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
215026072|NCT03058887|OTHER|Exercise intervention - arm cranking|The patients that will be randomly allocated to the exercise group - arm cranking will be requested to perform an exercise session on an arm crank ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
215026073|NCT04691115|DRUG|AM1476|AM1476 Capsules
215026074|NCT04691115|DRUG|Placebo|Placebo Capsules
215026075|NCT06020079|OTHER|laughter yoga|"According to the literature and the training received on laughter yoga, the time required for the treatment of depression is 50 minutes. The first 10 minutes includes relaxation, stretching and warm-up exercises. The next 30 minutes includes laughing exercises, and finally, the last 10 minutes includes relaxation exercises.~Steps of laughter yoga sessions:~1. Clapping hands and warm-up exercises: Participants clap their hands, fingers and palms. Then, sounds like ho-ho and ha-ha are added to the clapping exercises along with the rhythm.~2. Deep breathing exercises: Breathing exercises should be repeated 3-4 times while standing~3. Childlike games: Arms are raised, imitating the funny and clumsy behavior of a child.~4. Laughter exercises: The researcher names the exercise, explains how to do it, and the group performs the exercise together.~Dance and Relaxation"
215026076|NCT00323245|BEHAVIORAL|Physiotherapy for urinary incontinence|See Detailed Description.
215026077|NCT04383639|OTHER|No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)|The subjects will receive, after overnight fasting, a high-fat high-sugar breakfast. In treatment A, they will not receive any additional product; in treatment B, they will receive at the same time a mixture of coca and carob; in treatment C, they will receive the mixture of coca and carob 10 h before breakfast. A total of 6 blood samples will be collected during each visit: 0-30-60-120-180-240-270 min. Urine samples will be collected during the permanence of the subjects in the Unit of Human Nutrition. Feces will be collected the first time they are generated after treatments A and C. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
215026078|NCT05149768|DRUG|Brentuximab vedotin|Dose 0.6mg/kg will be given every 3 weeks for 16 cycles (48 weeks), in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil (MMF, cellcept) and mycophenolic acid (myfortic)
215026079|NCT05801887|DEVICE|Extracorporeal shockwave device|"Extracorporeal shockwave device generates true shock waves which are characterized by a sudden rise in pressure followed by an exponential decay.~This is different from the commercially available shockwave devices in which they use piezoelectric based mechanisms which generate high frequency waves."
215026080|NCT05801887|DEVICE|No ESWT|the osteoblast like cells are not exposed to shockwaves
215026081|NCT06641674|DRUG|18F-LF13|18F-LF13 PET/CT: after intravenous injection of 1.85 - 3.7 MBq/kg body weight of quality-controlled 18F-LF13, a Siemens Biograph PET/CT scan will be applied within 0.5 h, and the scan range will be from the top of the head to 1/3 of the upper thigh, 2 h to 4 h delayed scanning can be added if necessary.
215026082|NCT05898178|OTHER|Experimental intervention: 8-5-2% oxygen gradient concentration in the incubator|After oocyte retrieval and insemination, half of a given patient's embryos will be randomly allocated in an incubator set at a gradient of oxygen tension (8-5-2%). The embryos will remain in the incubator until their developmental assessments on day 5.
215026083|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed|"Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
215026084|NCT05849246|DRUG|Sintilimab+Carboplatin or Cisplatin+Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
215103940|NCT00613093|DRUG|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
214423802|NCT04128358|DIAGNOSTIC_TEST|Serological assay for blood born viral hepatitis|Qualitative PCR for patients with hepatitis C antibody positive
215026085|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab|"Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
214508591|NCT03046394|DEVICE|B-DER|Dynamic Motion by Otto Bock, advertised for activity category 2-3
214508592|NCT03046394|DEVICE|A-DER|Triton by Otto Bock, advertised for activity category 3-4
214508593|NCT06500195|PROCEDURE|implantation of the hybrid instrumentation system|Surgery corrections were performed using the hybrid instrumentation system (screws and bands).
214508594|NCT05667909|DRUG|Rituximab|375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
214508595|NCT00624377|DRUG|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
214508596|NCT03958266|DEVICE|MyIBD Care|Novel mobile phone application
214508597|NCT06022653|OTHER|Treatment|EVAR,TEVAR,PTA
214508598|NCT04669119|DIETARY_SUPPLEMENT|Bromelain/Boswellia Serrata Casperome|Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
214508599|NCT04669119|DIETARY_SUPPLEMENT|Centella Asiatica/Vitamins|Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
214508600|NCT04669119|DIETARY_SUPPLEMENT|Placebo|Placebo
214508601|NCT05064566|DEVICE|caries assessment|clinical visual examination (ICDAS II), digital io radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), and micro-CT images.
214508602|NCT02400645|PROCEDURE|Pre-incisional wound infiltration|Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
214508603|NCT02400645|PROCEDURE|Laparoscope to place TAP block with liposomal bupivacaine|Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%
214508604|NCT02400645|DRUG|Liposomal bupivacaine|Use of Liposomal bupivacaine in laparoscopic TAP block
214508605|NCT02400645|DRUG|Bupivacaine|20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.
214508606|NCT02400645|DRUG|Ketorolac|Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
214508607|NCT02979678|OTHER|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
214508608|NCT01622049|DEVICE|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
214508609|NCT05260437|BIOLOGICAL|CV2CoV (2 µg)|Study vaccine was administered as a single intramuscular injection.
214508610|NCT05260437|BIOLOGICAL|CV2CoV (4 µg)|Study vaccine was administered as a single intramuscular injection.
214508611|NCT05260437|BIOLOGICAL|CV2CoV (8 µg)|Study vaccine was administered as a single intramuscular injection.
214508612|NCT05260437|BIOLOGICAL|CV2CoV (12 µg)|Study vaccine was administered as a single intramuscular injection.
214508613|NCT05260437|BIOLOGICAL|CV2CoV (16 µg)|Study vaccine was administered as a single intramuscular injection.
214508614|NCT05260437|BIOLOGICAL|CV2CoV (20 µg)|Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it.
214508615|NCT03966456|DRUG|Chemotherapy|compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
214508616|NCT03779945|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
214508617|NCT03779945|PROCEDURE|posteriolateral lumbar fusion only|performing posteriolateral lumbar fusion without using platelet rich plasma
214508618|NCT00910962|DRUG|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
214508619|NCT00910962|DRUG|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
214508620|NCT00910962|DRUG|Placebo|Placebo
214508621|NCT03936725|OTHER|1 year phone call : data collection|"Included patients are contacted by telephone at 12 months after discharge. The investigators explain to the patient that this call is in the same context as a regular follow-up rehabilitation consultation and that the data collected will also be part of a study to evaluate and improve the program in which they participated. The interview will be transcribed in writing in their computerized and secure medical file. During this 20-minute telephone conversation, the patient answers a number of questions via a standardized questionnaire, in order to gather the various criteria for judgment.~If patients do not answer the first call, a phone message will be left and they will be contacted again up to 2 times. Patients who do not respond to 3 calls will be considered lost to follow-up."
214508622|NCT02525185|OTHER|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
214508623|NCT03043339|OTHER|Stool Specimen Collection|Participants will provide a stool sample at baseline (pre-operation) and 30 days after the transplant operation. Stool specimens will be self-collected by the participant.
214508624|NCT03043339|OTHER|Anal Swab Sampling|Anal swabs will be collected prior to surgery (baseline) and at post-operation days 2, 15, and 30. Participants whose planned hospitalization duration is extended from the pre-surgical plan will have an additional, optional, anal swab collected 2 days prior to their anticipated hospital discharge date. Anal swabs will be collected by the study team, except for the standard of care post-operative appointment (30 days after the operation) for the living donors who will collect their own samples.
215026086|NCT06451146|PROCEDURE|PCI Facilitated with Orbital Atherectomy Device|Percutaneous coronary intervention for coronary artery disease supported by the Orbital Atherectomy Device
215103941|NCT02484482|DRUG|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
215026087|NCT06126172|DIAGNOSTIC_TEST|Multiparametric magnetic resonance imaging (mpMRI)|Detecting and localizing prostate cancers and using radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.
215026088|NCT06638593|PROCEDURE|MIRRORS-FROZEN Protocol.|Initial laparoscopic phase and thorough inspection of the abdomino-pelvic cavity to determine the feasibility of proceeding robotically, followed by robotic excision of the mass(es) and its retrieval in a bag if deemed suitable to proceed robotically. The mass or cyst will be sent for frozen section to determine the extent of the surgery. The surgery will continue robotically, with conversion to laparotomy considered at any point at the discretion of the individual surgeon.
215026089|NCT06638593|PROCEDURE|Standard open surgery|A midline abdominal incision will be made from the outset, with intraoperative frozen section assessment to determine the extent of the surgery.
215026090|NCT06637228|BEHAVIORAL|Move Your Hands, Feet, and Brain: Integrated Exercise Intervention Based on Taipei City Elderly Physical Activity Guidelines|"This video is tailored for fitness exercises for both healthy and sub-healthy elderly individuals and features various physical activity themes, including warm-up routines, balance and coordination drills, aerobic coordination exercises, strength training using chairs and water bottles, and cool-down routines. We selected a 3-month duration with sessions held three times a week to align with established effective intervention periods and to ensure participant adherence.~Integrated exercise sessions were conducted by the staff at the dementia care centers/service bases and lasted 50 minutes. Considering the impact of dementia and aging on the ability of older adults to engage in physical activities, the staff provided simple instructions, and participants performed the exercises while seated to prevent falls. Meanwhile, the control group continued with their usual treatment and daily activities."
215026091|NCT06565039|DEVICE|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
215026092|NCT06565013|DRUG|Cabenuva 600/900|Participants will switch to Cabenuva at baseline. The visit schedule, the product administration and the clinical follow-up will be done according to standard of care.
215026093|NCT06565013|OTHER|Self administered questionnaires|Questionnaires on treatment satisfaction (HIVTSQs), quality of life (WHOQoL-HIV-BREF) and drug use assessment (DEBA-D) will be administered at baseline, M5 and M11
215026094|NCT06565013|OTHER|Semi-directed interview|At baseline and M11, participants will conduct a semi-directed interview about the perception of their HIV treatment and the global care they receive as a person living with HIV who is practicing chemsex.
215026095|NCT02331303|OTHER|Radium-223 dichloride (Xofigo, BAY88-8223)|Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
215026096|NCT01220687|DRUG|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
215026097|NCT01220687|OTHER|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
215026098|NCT04694287|DIAGNOSTIC_TEST|Percutaneous DUS volume flow measurements|Volume flow measurements of the AFV will be obtained using intraprocedural DUS just prior to sheath insertion and at the end of the final balloon dilation, before sheath removal.
215026099|NCT06643078|DRUG|HL231 Solution for Inhalation|HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg, treatment period; 52-weeks fixed dose.
215026100|NCT06643078|DRUG|Ultibro 110μg/50 μg|Ultibro capsule for inhalation once per day via Breezhaler, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, treatment period; 52-weeks fixed dose.
215026101|NCT06640205|PROCEDURE|pulpotomy|Removal of coronal pulp tissue and then placing pulpotomy agent
215026102|NCT06640777|DRUG|LEAF-4L6715|LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).
215026103|NCT06640777|DRUG|Supportive Care|Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
215026104|NCT06638554|BEHAVIORAL|Active Choice|The participant will be send a letter inviting them to complete a SDM visit either in-person or via telehealth.
215026105|NCT06638554|BEHAVIORAL|Telehealth Only|The participant will be send a letter inviting them to complete a SDM visit via telehealth only.
214508625|NCT03043339|OTHER|Short Diet Assessment (SDA)|The study coordinator will administer the Short Diet Assessment (SDA) to participants prior to surgery at baseline and post-operation days 2, 15, and 30. Participants whose planned hospital length of stay is extended from the pre-surgical plan will complete the questionnaire 2 days prior to their anticipated hospital discharge date.
215026106|NCT06638554|BEHAVIORAL|Low Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging.
215026107|NCT06638554|BEHAVIORAL|High Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging in combination with synchronous telephone-based digital care coordination.
215026108|NCT06645392|DEVICE|visual transparent bladed trocar of|visual transparent bladed trocar of diameter 10 mm and Ternamian bladeless trocar of diameter 10 mm
215026109|NCT06645392|DEVICE|Ternamian bladeless trocar|Ternamian bladeless trocar of diameter 10 mm
215026110|NCT06644105|DRUG|cefditoren pivoxil tablets|took cefditoren pivoxil tablets 200mg after
215026111|NCT06643221|BEHAVIORAL|Exercise|After an initial maximal graded exercise test to determine maximal oxygen uptake and peak cycling power, healthy participants will undergo a 20-minute graded exercise test at intensities corresponding to 50, 60, 70 and 80% VO2max (5-minutes per stage)
215103942|NCT04088526|COMBINATION_PRODUCT|intervention group|Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.
215103943|NCT03848949|DEVICE|Evenup|Orthotic which increases effective leg length.
215103944|NCT02103413|DEVICE|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
215026112|NCT06643221|DRUG|Isoproterenol|To determine if pharmacological activation of beta-adrenergic receptors evokes an immune respponse akin to exercise, healthy participants will receive an intravenous infusion of isoproterenol (50ng/kg/min)
215026113|NCT06643221|DRUG|Placebo|Healthy participants will consume the placebo 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
215026114|NCT06643221|DRUG|Bisoprolol Fumarate Tablet 10 mg|Healthy participants will consume a 10mg Bisoprolol Fumerate tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
215026115|NCT06643221|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|Healthy participants will consume a 80mg Nadolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
215026116|NCT06643221|DRUG|Carvedilol 50 mg|Healthy participants will consume a 50mg Carvedilol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
215026117|NCT06643221|DRUG|Roflumilast 500 Mcg Oral Tablet|Healthy participants will consume a 500mcg Roflumilast tablet and a 10mg Bisoprolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
215026118|NCT04878471|DRUG|Pudexacianinium chloride|Intravenous
215026119|NCT04878471|DRUG|Placebo|Intravenous
215026120|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
215026121|NCT05109559|BIOLOGICAL|Half dose of Ad26.COV2. 2.5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
215026122|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
215026123|NCT02518698|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
215026124|NCT02228330|PROCEDURE|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
215103945|NCT02103413|DEVICE|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
214508626|NCT03043339|OTHER|NHANES Dietary Screener Questionnaire (DSQ)|The National Health and Nutrition Examination Survey (NHANES) 2009-2010 Dietary Screener Questionnaire will be completed on Post-Operative Day 2. The questionnaire asks about foods consumed during the past 30 days. There are 25 items on the questionnaire and additional questions may be asked depending on responses provided. The questionnaire will be self-administered or administered by a study team member.
215026125|NCT04833738|DRUG|Hyaluronic acid|
215026126|NCT04833738|DRUG|Corticosteroids Triamcinolone Acetonide|triamcinolone acetonide, 40 mg/ml, single dose
215026127|NCT04833738|OTHER|Electrotherapy|electrotherapy
214508627|NCT03979937|PROCEDURE|Arthrocentesis|Arthrocentesis to determine the nature of the effusion (septic or aseptic).
215026128|NCT04025320|OTHER|Intraneural Facilitation|Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
215103946|NCT05670613|OTHER|CDSS Canceling|The use of Clinical Decision Support System in Parenteral Nutrition
215103947|NCT03309930|BEHAVIORAL|Comprehension Acquired Brain Injury|For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
215103948|NCT03470753|OTHER|Number of Exercises|Subjects will receive either 2 or 4 exercises to evaluate the short-term recall and performance.
215103949|NCT03470753|OTHER|Type of Instruction|The type of instruction in phase 1 will be compared: Instruction by providing a handout only vs being instructed by a provider and practiced by the patient with provider feedback.
215103950|NCT03470753|OTHER|Delivery Type|In phase 2 subjects will be provided 4 exercises using only a handout vs delivered to them electronically with the addition of a video.
215103951|NCT03470753|OTHER|Mobile Reminder|A text-message based mobile reminder tool will be utilized to engage with subjects via texting on a daily basis to provide reminders and encouragement to perform their home exercises.
215026129|NCT04025320|OTHER|Sham|A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
215026130|NCT04373551|BEHAVIORAL|Cultural adaptation of a patient-provider communication tool|Adaptation of a patient-provider communication tool for PrEP uptake utilized among AA women and their providers in a pilot pre/post-intervention design.
215026131|NCT04660682|OTHER|Modified static cross-body posterior shoulder stretching|For the modified cross-body position patient will be positioned in the side-lying position to limit the scapular abduction, and the patient aligned his/her forearms to limit the ER of the humerus while moving into horizontal adduction (HAdd). First, we will ask the patient to pull his/her arm into HAdd to the physiological barrier of the ROM, and then the patient will perform active-assistive static stretching with the help of the other hand for 30 seconds. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
215026132|NCT04660682|OTHER|Traditional static cross-body posterior shoulder stretching|For the traditional static cross-body posterior shoulder stretching, in the standing position, the patient will perform cross-body stretch alone by active-assistive pulling the humerus across the body into HAdd with the opposite arm, without concern for scapular stabilization for 30 sec. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
215026133|NCT04660682|OTHER|Control Group|In sham stretching, the patient will be positioned in the traditional static cross body posterior shoulder stretching position, and then the patient will perform active-assistive HAdd ROM without enough stretching of the relevant tissue. Active assistive ROM will be stopped before reaching the individual PST measurement result (in this way, sham stretching will be performed without proper stretching of the relevant tissue). The HAdd ROM exercise will be performed 5 times. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
215026134|NCT06042491|BEHAVIORAL|Prehabilitation intervention|The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions \>= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.
215026135|NCT00718731|DRUG|GSI-136|
215026136|NCT00718731|OTHER|Placebo|
215026137|NCT00413712|DRUG|Calcium Channel Blocker & Adenosine|
215026138|NCT01171079|DEVICE|application of oxidized regenerated cellulose|
215026139|NCT02524899|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
215026140|NCT02524899|DRUG|Guanfacine|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
215026141|NCT02524899|DRUG|Placebo|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
215026142|NCT02096354|DRUG|RRx-001|
215026143|NCT02096354|DRUG|Regorafenib|
215026144|NCT02096354|DRUG|Irinotecan|To be dosed after RRx-001 or regorafenib
215026145|NCT00332566|BIOLOGICAL|DTPw-HBV/Hib Kft vaccine GSK323527A|Intramuscular injection, 1 dose
215026146|NCT00332566|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|Intramuscular injection, 1 dose
215026147|NCT03715829|DRUG|PF-06651600|Induction dose 1. Oral tablet taken QD
215026148|NCT03715829|DRUG|PF-06651600|Induction dose 2. Oral tablet taken QD
215026149|NCT03715829|DRUG|PF-06651600|Maintenance dose A. Oral tablet taken QD
215026150|NCT03715829|DRUG|PF-06651600|Maintenance Dose B. Oral tablet taken QD
215026151|NCT03715829|DRUG|PF-06651600|Maintenance Dose C. Oral tablet taken QD
214423803|NCT04128358|DIAGNOSTIC_TEST|Quantitative microbiological test for HCV|Quantitative PCR in those with proven HCV infection
214423804|NCT02807467|DRUG|Dexmedetomidine|Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
214508628|NCT02677688|BIOLOGICAL|Autologous EBV specific CTL infusion|
214508629|NCT04434872|PROCEDURE|Colonoscopy|Fecal microbiota transplantation through colonoscopy
214508630|NCT04434872|PROCEDURE|Gastroscopy|Fecal microbiota transplantation through gastroscopy
215026152|NCT03715829|DRUG|placebo|placebo
215026153|NCT03715829|DRUG|PF06700841|Oral tablet taken QD
215026154|NCT03715829|DEVICE|narrow-band UVB phototherapy|Phototherapy will be combined with PF-06651600
215026155|NCT06538350|OTHER|Telemedicine Consultation|Telemedicine intervention will be delivered via Zoom and Video WhatsApp platforms via a secure internet connection.
215026156|NCT06538350|OTHER|Face-to-Face Consultation|Face-to-Face consultation according to the standard of care.
215026157|NCT00764426|DRUG|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
215026158|NCT00764426|DRUG|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
215026159|NCT04106635|PROCEDURE|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
215026160|NCT04106635|PROCEDURE|Cricoid pressure|To apply cricoid pressure, the cricoid cartilage is compressed by 30N force with a single-handed three finger maneuvre towards the vertebral bodies.
215026161|NCT01338597|PROCEDURE|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
215026162|NCT00001784|DRUG|Mexiletine|
215026163|NCT03422887|DRUG|Nalbuphine|Nalbuphine administration during surgery
215026164|NCT03422887|DRUG|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
215026165|NCT03422887|DRUG|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
215026166|NCT04903769|BEHAVIORAL|Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)|SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
215026167|NCT02105480|DEVICE|Computer aided auscultation (CAA)|
215026168|NCT04593745|DEVICE|Intraocular pressure measurment|Intraocular pressure measurmentt using iCare devise: TONOPEN
215026169|NCT03579719|DRUG|Balovaptan|"In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20."
215026170|NCT03579719|DRUG|Itraconazole|In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
215026171|NCT03747237|OTHER|Edema measurement methods|A correlation between the results of the first and second methods will be examined.
214508631|NCT04434872|DRUG|Fecal Microbiota|
215026172|NCT00202241|PROCEDURE|testosterone injection|
215026173|NCT01173003|DRUG|Mifepristone, misoprostol|
215026174|NCT05295953|DEVICE|TBS|Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.
215026175|NCT05295953|DEVICE|Sham TMS|Four sessions of sham TMS delivered using MagVenture B65 A/P coil.
215026176|NCT06569940|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 42 minutes.
214508632|NCT04434872|PROCEDURE|Enema|Fecal microbiota transplantation through enema
214508633|NCT00923078|BEHAVIORAL|Auditory Cognitive Training|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.
215026177|NCT01000116|PROCEDURE|Fibrin glue|Tissucol 2 ml
215026178|NCT01000116|PROCEDURE|Tacks|Protacks
215026179|NCT04957472|DEVICE|fabian HFO, fabian +nCPAP evolution and fabian Therapy evolution with PRICO function|24 hours of automated control of FiO2
215026180|NCT04957472|OTHER|Manual Control|24 hours of manual control of FiO2
215026181|NCT04598087|BEHAVIORAL|Prehabilitation|The multi-phasic prehabilitation intervention involves three phases: Phase 1: Before surgery (typically \~25 days); Phase 2: The in-hospital phase (typically 10-14 days); Phase 3: Discharge to 6-weeks after surgery.
215026182|NCT00517114|DRUG|Rabeprazole 20mg twice daily|
215026183|NCT02615613|OTHER|Low Acceptability Meal|
215026184|NCT02615613|OTHER|High acceptability meal|
215026185|NCT02800785|DRUG|Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin|Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
215026186|NCT02800785|PROCEDURE|Appendectomy|Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
215026187|NCT01974947|OTHER|Blood sample, sperm sample and clinical examens|Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
215026188|NCT00002759|DRUG|cyclosporine|
215026189|NCT00002759|DRUG|irinotecan hydrochloride|
215026190|NCT00002759|DRUG|phenobarbital|
215026191|NCT04753567|DEVICE|nCap pain relief patch|Each participant will be randomly assigned to sham or actual patch. Patches will be worn for 3 weeks. Pain and quality of life will be assessed and compared between groups
215026192|NCT04753567|DEVICE|Sham Patch|Sham patch will be worn for 3 weeks exactly like actual pain patch
215026193|NCT02446509|BEHAVIORAL|Psychoeducation|Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
215026194|NCT02446509|BEHAVIORAL|Psychoeducation - Delayed|The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
214423805|NCT02807467|DRUG|Propofol|Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
214423806|NCT01374893|BEHAVIORAL|Exercise|The intervention group will perform the multi-session per day training program
214423807|NCT01374893|BEHAVIORAL|Control|Usual care
215103952|NCT00533624|DRUG|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
215103953|NCT00533624|DRUG|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
215103954|NCT03565835|DRUG|Abiraterone Acetate|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
214423808|NCT00000152|DRUG|Aspirin|
214694216|NCT02142179|BEHAVIORAL|Knowledge about Asthma and Respiratory Education (KARE)|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
215026195|NCT06198777|DEVICE|Magnetometer|Inspection equipment for magnetocardiography
214423809|NCT00000152|DRUG|Beta-Carotene|
215026196|NCT02261610|PROCEDURE|Procalcitonin algorithm|Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
215026197|NCT03253627|BEHAVIORAL|Health Enhancement Program|The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition-without mindfulness instruction-using similar modalities to MBSR training for a matched schedule.
214423810|NCT00743444|DRUG|AZD3355|65 mg capsules, oral, 3 single doses
214423811|NCT00743444|DRUG|Placebo|capsules, oral, 3 single doses
214423812|NCT01525446|RADIATION|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of \> 3 cm)
214423813|NCT06367816|PROCEDURE|INTELLiVENT|Closed-loop mode of ventilation
214423814|NCT06367816|PROCEDURE|Conventional ventilation|Mode of ventilation
214423815|NCT02452918|DRUG|Oritavancin|Administered intravenously
214423816|NCT02452918|DRUG|Warfarin|Administered as a concomitant medication at a standard dose and dosing schedule
214508634|NCT00923078|BEHAVIORAL|Visual Cognitive Training|The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.
214508635|NCT01950689|DRUG|Nimorazole|
214508636|NCT01950689|RADIATION|Radiotherapy|
214508637|NCT00637559|DRUG|Esomeprazole Magnesium|
214508638|NCT03788707|OTHER|Passive leg raising|After 30 seconds of lying flat, volunteers will have passive leg raising to 45 degrees. Expired CO2 will be measured via a face mask before and after leg raising.
214423817|NCT00016471|PROCEDURE|Audiogram|
214423818|NCT00016471|PROCEDURE|Electroretinogram|
214423819|NCT00807144|DRUG|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
214423820|NCT00807144|DRUG|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
214423821|NCT06131385|DRUG|intravenous thrombolysis|Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.
214423822|NCT02784132|OTHER|Video diversion|The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.
214423823|NCT00394615|PROCEDURE|Metabolic Imaging|
214423824|NCT01536834|DEVICE|Medical Device|
214423825|NCT05774119|OTHER|breakfast with coffee|breakfast with coffee with 6 mg/caffeine/kg body weight
214508639|NCT06300294|OTHER|acupressure|After the CAG procedure, acupressure will be applied to individuals whose vital signs are within the normal range.
215026198|NCT03253627|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
215026199|NCT03079778|PROCEDURE|transarterial chemoembolization|Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
215026200|NCT03079778|RADIATION|TACE plus RT|radiobiologically guided radiation
215026201|NCT00394225|DRUG|Oxygen|
215026202|NCT00394225|DRUG|Helium|
215026203|NCT06124300|DIETARY_SUPPLEMENT|Female Hormone Balance Supplement|The product contains: Myo-Inositol D-Chiro Inositol Folic Acid Vitamin D Vitamin B12
214423826|NCT05774119|OTHER|breakfast with water|breakfast with 250 mL of water
214423827|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
215026204|NCT05187910|BEHAVIORAL|Speech Therapy|Training with a Speech Language Pathologists for voice disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
215026205|NCT05187910|BEHAVIORAL|Swallowing Therapy|Training with a Speech Language Pathologists for swallowing disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
215103955|NCT03565835|DRUG|Prednisone|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
214423828|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
214423829|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
214423830|NCT03352596|OTHER|low frutose diet|
214423831|NCT05704920|OTHER|IA|The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
214423832|NCT05704920|OTHER|Not IA|The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
214423833|NCT06118827|DRUG|HS-10518|QD, orally for 7 days
214423834|NCT06118827|DRUG|Placebo|QD, orally for 7 days
214423835|NCT02759913|PROCEDURE|Lumbar puncture|Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
214423836|NCT03567941|DRUG|Placebo|Tablet orally administered under fasting
214423837|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 1|Tablet orally administered under fasted conditions
214423838|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 2|Tablet orally administered under fed conditions
214423839|NCT03567941|DRUG|Reference|Tablet orally administered under fasted conditions
214423840|NCT01307267|DRUG|PF-05082566|Intravenous, Dose escalation, once per month
214423841|NCT01307267|DRUG|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
214423842|NCT01307267|DRUG|PF-05082566|IV, Dose escalation, once per month
214423843|NCT02135042|DRUG|Cisplatin|Given IV
214423844|NCT02135042|OTHER|Clinical Observation|Undergo clinical observation
214423845|NCT02135042|DRUG|Fluorouracil|Given IV
214508640|NCT03222232|BEHAVIORAL|catheter salvage|In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
214508641|NCT06019715|BEHAVIORAL|Postpartum Remote Physical Activity Intervention|Includes 8 remote health coaching session to promote physical activity, use of a Fitbit device, and use of a home based blood pressure monitor.
214508642|NCT01858688|DEVICE|Multiparametric MRI|an MRI of the prostate will be performed
214508643|NCT01858688|PROCEDURE|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
214508644|NCT04123119|BIOLOGICAL|Rotavirus vaccine|An exploratory and observational cohort study following infants receiving two standard doses of live, attenuated, oral Rotarix™ administered at 6 \& 10 weeks.
214508645|NCT02973932|BEHAVIORAL|Cognitive-bahavioral psychotherapy|
214508646|NCT00001998|DRUG|Nystatin|
214508647|NCT02593552|DEVICE|DriveCam|Video event monitoring device
214508648|NCT05612009|COMBINATION_PRODUCT|Toothpastes|"Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride)."
214508649|NCT00833599|DRUG|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
214508650|NCT04372706|DRUG|RTX-240|Engineered red cells co-expressing 4-1BBL and IL-15TP
214508651|NCT04372706|DRUG|Pembrolizumab|Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
214508652|NCT04883515|DIETARY_SUPPLEMENT|Oral glutamine supplementation|patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
214508653|NCT04883515|DIETARY_SUPPLEMENT|Oral protein powder supplementation|patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
214508654|NCT04883515|PROCEDURE|Insulin-resistance evaluation|Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
214508655|NCT04883515|PROCEDURE|Functional intestinal disorders evaluation|Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
214508656|NCT02013804|DRUG|MEDI0680 (AMP-514)|Study has planned dose escalation cohorts
214508657|NCT01999335|DRUG|Oprozomib|Extended release (ER) tablets administered orally
214508658|NCT01999335|DRUG|Pomalidomide|Capsules for oral administration
214508659|NCT01999335|DRUG|Dexamethasone|Tablets for oral administration
215026206|NCT05187910|BEHAVIORAL|Upper Airway Therapy|Training with a Speech Language Pathologists for upper airway disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
214691689|NCT06207500|PROCEDURE|Pharmacist-led Medication Reconciliation|The best possible medication history (BPMH) at hospital admission was obtained from medical and pharmacy records and by interviewing the patient or carers. The BPMH - an accurate and complete (or as close as possible) list of medications the patient is currently taking - was documented in the medication information system. At hospital admission the BPMH was compared with the therapy in hospital to identify discrepancies. All discrepancies were discussed with the treating physician, unintentional discrepancies were reconciled. Intentional discrepancies were documented in the medical records. Prior to discharge from hospital, the BPMH and the medications planned in the discharge therapy were compared again to ensure that all unintentional discrepancies were corrected. Intentional discrepancies were explained in the discharge letter. Individual patient counselling on discharge medications and pharmacotherapy changes was conducted and coupled with written instructions in lay language.
214691690|NCT00041717|DRUG|Fampridine-SR|25mg bid (twice daily)
214691691|NCT00041717|OTHER|Placebo|Placebo
214691692|NCT04307147|DRUG|Capecitabine|Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
214508660|NCT00787176|DRUG|Group A Intravenous bolus of 1000 ml lactated ringers solution|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
214508661|NCT00787176|DRUG|Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
214691693|NCT04307147|DRUG|Vinorelbine|Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
214691694|NCT06864754|OTHER|WashU DIEP Flap Video|Video uses visual cues and graphics to help explain complex procedures in a simplified, comprehensible fashion to patients.
215026207|NCT00498966|DRUG|Perifosine|"Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food."
215026208|NCT01082458|DRUG|remifentanil / lidocaine|"Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.~Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery."
215026209|NCT00606099|DRUG|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
215026210|NCT00606099|DRUG|adefovir dipivoxil|Active Comparator
215026211|NCT05116644|OTHER|NONE - this is a cross-sectional survey design|NONE - this is a cross-sectional survey design
215026212|NCT03576820|DRUG|Lidocaine|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive intranasal lidocaine via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
215026213|NCT03576820|DRUG|Placebo|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
215026214|NCT00742157|DRUG|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
215026215|NCT05630365|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs
214423846|NCT02135042|DRUG|Gemcitabine Hydrochloride|Given IV
215026216|NCT03539640|OTHER|PEEP: 5 cmH2O|During second part of the study (MRI)
215026217|NCT03539640|OTHER|PEEP: 10 cmH2O|During second part of the study (MRI)
214508662|NCT00787176|DRUG|Group C 125 mL/hr of lactated ringers|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
214508663|NCT00787176|DRUG|Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
215026218|NCT03539640|OTHER|PEEP: 15 cmH2O|During second part of the study (MRI)
215026219|NCT06214325|BEHAVIORAL|Music Therapy|Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, a minimum of 24 hours apart, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
215026220|NCT01455844|DRUG|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
215026221|NCT01455844|OTHER|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
215026222|NCT01455844|DRUG|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
215026223|NCT05807945|DRUG|Ropivacaine 0.75% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.75%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
214423847|NCT02135042|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214423848|NCT02135042|OTHER|Laboratory Biomarker Analysis|Correlative studies
214423849|NCT02135042|DRUG|Paclitaxel|Given IV
214423850|NCT02135042|OTHER|Quality-of-Life Assessment|Ancillary studies
214423851|NCT03804580|DRUG|osimertinib|Non-randomized trial, all patients receive therapy
214423852|NCT05728008|DRUG|Ustekinumab|a human monoclonal antibody to interleukin IL 12/23 p40. It is indicated in the treatment of adult patients with moderately to severely active UC. The induction phase consists of approximately 6 mg/kg intravenous dose administration. After the induction, the maintenance phase consists of a 90mg subcutaneous dose every 8 weeks.
215026224|NCT05807945|DRUG|Ropivacaine 0.2% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
215026225|NCT06468943|DRUG|Polatuzumab Vedotin|1.8mg/kg/21d（d0） Intravenous infusion
215026226|NCT06468943|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
215026227|NCT06468943|DRUG|Rituximab|375mg/㎡/21d（d0） Intravenous infusion
215026228|NCT06468943|DRUG|Cyclophosphamide|750mg/㎡/21d（d1） Intravenous infusion
215026229|NCT06468943|DRUG|Doxorubicin|50mg/㎡/21d（d1） Intravenous infusion
215026230|NCT06468943|DRUG|Prednisone|100mg PO （d1-d5）/21d
215026231|NCT05043831|DEVICE|DSLT|Direct-SLT is applied via the limbus to the trabecular meshwork
215026232|NCT04348630|OTHER|Simulated heatwave exposure|Older adults are exposed to a 8-hour simulated exposure
215026233|NCT05952375|DRUG|Chimeric antigen receptor T cell preparation targeting Claudin18.2|Chimeric antigen receptor T cell preparation targeting Claudin18.2
215026234|NCT02980458|DRUG|Deferiprone 500Mg Tablet|
215026235|NCT02980458|DRUG|Deferiprone 500 MG Oral Tablet [Ferriprox]|
215026236|NCT06570317|DRUG|Nintedanib|For patients with unresectable NSCLC, nidanib is administered during sequential radiotherapy
215026237|NCT01922895|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
215026238|NCT01922895|DRUG|Placebo for Probiotic|Capsule manufactured without active ingredients.
215026239|NCT01916226|DRUG|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
215026240|NCT01916226|DRUG|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
215026241|NCT01916226|DRUG|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
215026242|NCT01916226|DRUG|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
215026243|NCT03163667|DRUG|Placebo|oral tablets
214508664|NCT03732456|PROCEDURE|Shoulder surgery and post-op pharmacological treatment|Usual care surgery (shoulder arthroscopy) and post-operative pain management protocol
215026244|NCT03163667|DRUG|CB-839|oral tablets
215026245|NCT03163667|DRUG|everolimus|oral tablets
215026246|NCT04005326|PROCEDURE|quadratus lumborum block; (Anterior QLB or QLB III)|The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
215026247|NCT04005326|PROCEDURE|suprainguinal fascia iliaca block|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
215026248|NCT04005326|PROCEDURE|Subarachnoid block|"Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study."
215026249|NCT01686321|DRUG|Bendamustine and subcutaneous rituximab|
214508665|NCT03037736|DRUG|5-Fluorouracil|5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
215026250|NCT05102448|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12 months;~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
215026251|NCT05102448|DRUG|Methotrexate|"1. Methotrexate (15mg each week) for 12 months~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
215026252|NCT01257750|DRUG|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
215026253|NCT00400322|DRUG|Valganciclovir (Valcyte)|
215026254|NCT00400322|OTHER|Placebo|
215026255|NCT01013259|DRUG|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
215026256|NCT01013259|DRUG|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
215026257|NCT03098927|BEHAVIORAL|Motor imagery training|Motor imagery training
215026258|NCT02594579|DRUG|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
215026259|NCT02594579|DRUG|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
215026260|NCT03445442|PROCEDURE|SCP|Sacrocolpopexy (SCP) aims to secure the anterior vaginal wall, the uterus more or less the posterior vaginal wall using polypropylene prostheses and to secure them to the presacral ligament to restore the patient's anatomical features and improve pelvic symptoms
215026261|NCT03445442|PROCEDURE|NTR|Native tissue repair surgery (NTR) consist of site-specific surgical repair of the existing defect (anterior and/or posterior) using non-absorbable sutures. Specifically, anterior and/or posterior colporrhaphy for cystocele and rectocele respectively after adequate hydrodissection of the vesicovaginal or rectovaginal space.
215026262|NCT03445442|PROCEDURE|VMR|Vaginal mesh repair surgery (VMR) is performed using a single-incision mesh system. A single vertical incision is made in the anterior and/or posterior vaginal wall. A full-thickness dissection is performed laterally and apically to the ischial spine.
215026263|NCT05627986|OTHER|No intervention|No intervention
215026264|NCT02644070|DEVICE|alveolar bone preservation with mp3|graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
215026265|NCT02644070|DEVICE|alveolar bone preservation with apatos|graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
215026266|NCT02644070|DEVICE|stabilization with membrane|socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
215026267|NCT05721729|DRUG|Mizagliflozin|Encapsulated
215026268|NCT05721729|DRUG|Placebo|Encapsulated
215026269|NCT03663023|PROCEDURE|Intestinal obstruction|
215026270|NCT02594943|DEVICE|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
215103956|NCT06198335|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
214508666|NCT03037736|DRUG|Bevacizumab|Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
215026271|NCT02594943|DEVICE|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
215026272|NCT04104477|OTHER|Range of Motion Tasks|Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.
215026273|NCT04104477|OTHER|Strength Tasks|Participants will perform strength (pinch and grip) tests to evaluate fine and gross motor function.
215026274|NCT04910165|DRUG|Exparel|Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
215026275|NCT04910165|DRUG|Ropivacaine|Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
215026276|NCT01566565|DRUG|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
215026277|NCT01269437|DRUG|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
215026278|NCT06395766|DIAGNOSTIC_TEST|BREF,MSPSS|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL )~2. the Zimet Multidimensional Scale of Perceived Social Support -. The original version on the MSPSS"
215026279|NCT04942327|BEHAVIORAL|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
215026280|NCT00104403|DRUG|GW679769|
215026281|NCT00104403|DRUG|Dexamethasone|
215026282|NCT00104403|DRUG|Ondansetron Hydrochloride|
215026283|NCT01586715|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
215026284|NCT02940223|DRUG|Ethyl Icosapentate|Given by mouth 2 gm orally daily plus physical activity
215026285|NCT02940223|BEHAVIORAL|Exercise Intervention|Complete resistance exercises and undergo walking program
215026286|NCT02940223|BEHAVIORAL|Exercise Intervention|Meet with exercise specialist and complete stretching exercises
215026287|NCT02940223|OTHER|Laboratory Biomarker Analysis|Correlative studies
214508667|NCT03037736|DRUG|Normal saline|Normal saline will be used as the placebo.
214508668|NCT04463654|DEVICE|Zero Self-Harm app|Safety plan app for smartphones
214508669|NCT04518865|DEVICE|Herbst appliance|The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.
214508670|NCT01775657|DEVICE|Thopaz (Digital drainage)|
214508671|NCT01775657|DEVICE|Pleur Evac (Analogue drainage)|
214508672|NCT00992745|DRUG|123-I-MIP-1072|Single 10 mCi intravenous injection
214508673|NCT00992745|DRUG|111-In capromab pendetide|Single 5 mCi intravenous injection
215026288|NCT02940223|OTHER|Placebo|Given PO
214423853|NCT05728008|DRUG|Tofacitinib|Jak inhibitor. It is indicated in the treatment of adult patients with moderately to severely active UC who have experienced inadequate response or have lost the response or who are intolerant to conventional therapy or to a biological agent. The induction phase consists of 10mg twice daily for 8 to 16 weeks. After the induction, the maintenance phase consists of 5mg x twice daily.
215026289|NCT02940223|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
215026290|NCT02940223|OTHER|Questionnaire Administration|Ancillary studies
215026291|NCT05531942|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.
215026292|NCT05531942|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
215026293|NCT05937802|DIETARY_SUPPLEMENT|Osmotin|Oral administration for 6 months of 7 capsules per day (4 in the morning and 3 in the evening) for a daily dosage of 5 grams.
215026294|NCT00143845|PROCEDURE|Reduced intensity conditioning|Busulfan and Fludarabine regimen
215026295|NCT00143845|PROCEDURE|Rapid immunosuppressive taper|Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
215026296|NCT00143845|PROCEDURE|Prophylactic donor leukocyte infusions|If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
215026297|NCT04846998|DRUG|BR9003|"Treatment group B:~Once-daily oral administration of one BR9003 2mg tablet in the fasting state.~Treatment group C:~Once-daily oral administration of one BR9003 2mg tablet after a meal(high-fat meal) 30 minutes before the scheduled time of administration and finishing it."
215026298|NCT04846998|DRUG|BR9003A|"Treatment group A:~Twice-daily oral administration of one BR9003A 1mg tablet in the fasting state"
215026299|NCT06497673|OTHER|sample collection|New collected samples, as well as surplus surgical and diagnostic samples.
215026300|NCT03758846|BEHAVIORAL|Cognitive-motor exergaming|Participants undergo 6 weeks of cognitive-motor exergaming using Wii-fit Nintendo. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
215026301|NCT03758846|BEHAVIORAL|Conventional balance Training|Participants undergo 6 weeks of conventional exercise training. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
215026302|NCT03758846|BEHAVIORAL|Dance Therapy for Stroke|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
215026303|NCT03758846|BEHAVIORAL|Dance Therapy for Older adults|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two therapists."
215026304|NCT03758846|BEHAVIORAL|Home education for Older adults|Participants will receive a one-hour education on conventional physical exercises.
215026305|NCT00245154|DRUG|carboplatin|Given IV
215026306|NCT00245154|DRUG|cediranib maleate|Given orally
215026307|NCT00245154|DRUG|paclitaxel|Given IV
215026308|NCT00245154|OTHER|placebo|Given orally
215026309|NCT00521352|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
215026310|NCT00521352|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
215026311|NCT01422382|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
214423854|NCT01956552|OTHER|biopsy or cytopuncture|
214423855|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, single dose
214423856|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
214423857|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, single dose
215026312|NCT01422382|DRUG|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
215026313|NCT05032352|DRUG|Adjuvant|Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
215026314|NCT05032352|OTHER|Observation|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
215026315|NCT01485367|DRUG|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.
215026316|NCT01813357|DRUG|Rosuvastatin|encapsulated tablet 20mg daily
214423858|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
214423859|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
214508674|NCT00992745|DRUG|123-I-MIP-1072|Single 5 mCi intravenous injection
215026317|NCT01813357|OTHER|Placebo|Placebo arm included to maintain blinding
215026318|NCT00240019|DRUG|Addition of furosemide 20 mg oral bid to baseline regimen|
215026319|NCT01962753|DRUG|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
215026320|NCT06192966|DIETARY_SUPPLEMENT|Food supplement|Probiotic formulation containing Lactobacillus plantarum, cranberry and vitamine C for 6 months 1 capsule/day
215026321|NCT06192966|DIETARY_SUPPLEMENT|Placebo|Placebo composed of maltodextrin for 6 months 1 capsule/day
214423860|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, single dose
214423861|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, single dose
214423862|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, single dose
214423863|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, single-dose
214423864|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
214423865|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
214423866|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
214423867|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
214423868|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
214423869|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
214423870|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
214423871|NCT01134237|DRUG|urokinase|intrapleural urokinase injection
214423872|NCT01134237|DRUG|placebo|Normal saline as a placebo for control arm
214423873|NCT02887898|DEVICE|Automated bolus calculator|
214423874|NCT02887898|OTHER|Education|
214423875|NCT02568644|DIETARY_SUPPLEMENT|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).
214423876|NCT02568644|OTHER|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
214423877|NCT02568644|DRUG|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
214423878|NCT05174013|DRUG|GSK3858279|GSK3858279 will be administered
214694217|NCT03649100|PROCEDURE|Implant placement|Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
214423879|NCT05174013|DRUG|Placebo|Placebo will be administered
215026322|NCT05560880|BEHAVIORAL|High Intensity Interval Gait training|Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.
214423880|NCT04536519|OTHER|osteoarthritis management|"The conventional physical therapy will be consisted of an array of protocols being deployed in parallel. This will consist of~* Patient education regarding deforming forces, strategies of prevention and home exercise program~* Decreasing stiffness by controlled active range of motion and mobilization techniques involving join play.~* Mechanical stresses will be controlled in form of support provided by foot wear modification~* Range of motion will be increased muscle stretches and manual mobilization techniques~* Muscle performance and neuromuscular control will be addressed by gentle exercises of low intensity and repetitive exercises.~* Balance improvement by employing balance training activities as part of treatment~* Physical conditioning low impact or non-impact aerobics This conventional exercise will be given as baseline treatment to both of groups."
214423881|NCT04456218|DEVICE|NCKU-scope-01 (a custom-made biliary endoscope system)|The NCKU-scope-01 is a custom-made endoscope system for this study and it will be applied to help biliary disorders diagnosis
214423882|NCT00281424|DEVICE|pedometer|gave pedometer and info
214423883|NCT05882812|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
214423884|NCT05882812|DEVICE|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
214508675|NCT01274156|DEVICE|"MEDISPEC treatment probe"|300 shocks in 5 different anatomical locations of the penis.
214508676|NCT01274156|DEVICE|"MEDISPEC Sham Probe"|Sham probe applied same as treatment probe without energy
214508677|NCT01274156|DEVICE|"MEDISPEC Low intensity shock waves"|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
214508678|NCT01274156|DEVICE|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
214508679|NCT05220813|DRUG|Lidocaine|local infiltration by lidocaine in the surgical site
214508680|NCT05220813|DRUG|Bupivacain|44patients will receive bupivacaine in ilioinguinal \& iliohypogastric nerve blocks
214508681|NCT02028650|BIOLOGICAL|the first donor's stem cell|HLA-matched stem cell infusion
215026323|NCT05560880|BEHAVIORAL|Moderate Intensity Interval gait training|subjects will walk for 20 minutes at theri best comfortable pace
215026324|NCT03773562|DRUG|Erenumab|Erenumab will be used per label instructions.
215026325|NCT02825563|DRUG|Anlotinib|in the fasting state
215026326|NCT02825563|DRUG|Anlotinib|in the high fat diet
215026327|NCT03317873|DIETARY_SUPPLEMENT|Testmeal A|The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
215026328|NCT03317873|DIETARY_SUPPLEMENT|Testmeal B|The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
215026329|NCT06284122|DRUG|Mosunetuzumab|5 mg (step-up dosing) Day 1 of C1 45 mg Day 8 and Day 15 of C1, 45 mg Day 1 from C2 to C12, 45 mg Day 1 from C13 to C21
214691695|NCT00683358|BIOLOGICAL|VEGFR1-A24-1084 (SYGVLLWEI)|HLA-A\*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
214691696|NCT05122663|BEHAVIORAL|Vestibular Rehabilitation|Vestibular Rehabilitation refers to the specific interventions that physical therapists provide to patients with dizziness and vertigo symptoms. These interventions can involve repositioning maneuvers, habituation exercises, gaze stabilization, and/or balance training exercises, depending on the specific etiology of dizziness and vertigo per an established clinical protocol utilizing a patient's history and exam findings. Physical therapists instruct patients in how to perform these exercises at home and provide instructions and referral for patients to follow-up with an outpatient physical therapist for further care.
214691697|NCT05122663|OTHER|Usual Care|Usual Care refers to any combination of diagnostic testing, medications, and patient education or counseling provided by a patient's treating ED physician.
215026330|NCT06284122|DRUG|Lenalidomide|20 mg/day Day 1 to Day 21 from C2 to C12
215026331|NCT06284122|DRUG|Rituximab|when associated to CHOP IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C20
215026332|NCT06284122|DRUG|Obinutuzumab|when associated to CHOP 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C18
215026333|NCT06284122|DRUG|Cyclophosphamide|750 mg/m2 Day 1 from C1 to C6
215026334|NCT06284122|DRUG|Doxorubicin|50 mg/m2 Day 1 from C1 to C6
215026335|NCT06284122|DRUG|Vincristin|1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6
214691698|NCT01270581|OTHER|High Flow Nasal Cannula|Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
214691699|NCT01270581|OTHER|Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
214691700|NCT04353622|DEVICE|Exoskeleton robot for upper extremity|"Robot-assisted Treatment Program:~* 10 minutes elbow flexion/extension~* 10 minutes forearm supination/pronation~* 10 minutes wrist flexion/extension~* 10 minutes ulnar/radial deviation~Frequency: 2/week Duration: 12 sessions (6 weeks)"
214691701|NCT04353622|OTHER|Conventional physiotherapy|Ferquency: 2/week Duration: 12 sessions (6weeks) Each session: 50 minutes
214691702|NCT03468192|OTHER|Non-precaution group|Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed
215026336|NCT06284122|DRUG|Prednisone|100 mg/day Day 1 to Day 5 from C1 to C6
215026337|NCT06284122|DRUG|Rituximab|when associated to bendamustin IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C18
214423885|NCT05882812|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
214691703|NCT02142192|DRUG|natalizumab|Administered as specified in the treatment arm
214691704|NCT03342469|OTHER|Artificial Food Coloring|225mg mixed powdered Artificial Food Coloring (AFC)
214691705|NCT03342469|OTHER|Placebo|Placebo chocolate cookies
214691706|NCT01449357|DRUG|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
214691707|NCT04937582|DIAGNOSTIC_TEST|Cognitive assessment|Complete cognitive and psychological assessment
214423886|NCT03195075|PROCEDURE|Endoscopic ultrasonography guided biliary drainage|Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1
214691708|NCT04937582|DIAGNOSTIC_TEST|Imaging|"Brain MRI~Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)"
215026338|NCT06284122|DRUG|Obinutuzumab|when associated to bendamustin 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C20
215026339|NCT06284122|DRUG|Bendamustin|90 mg/m2 Day 1 and Day 2 from C1 to C6
215026340|NCT06190236|BEHAVIORAL|Stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder|CBT4CBT is a 7-module web-delivered program based on CBT, an evidence-based behavioral treatment for alcohol use disorder (AUD).
215026341|NCT01854762|DRUG|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
215026342|NCT01854762|DRUG|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
215026343|NCT04082364|BIOLOGICAL|margetuximab|margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
215026344|NCT04082364|BIOLOGICAL|Retifanlimab|Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.
215026345|NCT04082364|BIOLOGICAL|Tebotelimab|Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.
215026346|NCT04082364|BIOLOGICAL|Trastuzumab|Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle
215026347|NCT04082364|OTHER|Chemotherapy|"Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6~Chemotherapy~XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion~mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion."
215026348|NCT06199999|PROCEDURE|Erector Spinae Block|General anesthesia with Erector Spinae Plane Block
215026349|NCT06199999|PROCEDURE|Local infiltration with local anesthetic|General anesthesia with local infiltration of local anesthetic:
215026350|NCT03035097|OTHER|Biorepository|One-time blood draw for blood to be stored in a biorepositoy
215026351|NCT01375140|DRUG|Ruxolitinib|15 mg by mouth twice daily (BID), continuously in 28-day cycles.
215026352|NCT01375140|DRUG|Lenalidomide|5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.
215026353|NCT01375140|DRUG|Prednisone|"Prednisone will be added for patients who have not responded after 3 cycles of therapy.~30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued."
215026354|NCT05939544|DIETARY_SUPPLEMENT|Experimental: Milk Fat Globule Membrane-enriched Powdered Ingredient|Milk Fat Globule Membrane-enriched Powdered Ingredient
215026355|NCT05939544|DIETARY_SUPPLEMENT|Placebo Comparator: Control (Placebo) Powdered Ingredient|Placebo Comparator: Control (Placebo) Powdered Ingredient
215026356|NCT06362629|BEHAVIORAL|Artificial Intelligence assistant decision-making system (AIADMS) App|Participants will be assisted to use the Artificial Intelligence assistant decision-making system (AIADMS) app during the process of management of AD, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up.
214423887|NCT03195075|PROCEDURE|Percutaneous trans-hepatic biliary drainage|Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
214423888|NCT02682446|DRUG|H pylori eradication|The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]
214423889|NCT01204346|OTHER|MBT|The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
214423890|NCT01204346|OTHER|treatment as usual|less intensive and structured psychotherapeutic program
214691709|NCT04937582|DIAGNOSTIC_TEST|Routine care|"Electroencephalogram (EEG)~Optional: polysomnography, lumbar puncture"
214691710|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary
214691711|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary (before the end of their participation in the study)
214691712|NCT00240630|DRUG|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
215026357|NCT04806373|DRUG|Cathflo Activase|Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
215026358|NCT04806373|DRUG|Talc Slurry Pleurodesis|Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
215026359|NCT05449873|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Triple Cooled-Wet electrodes|Radiofrequency ablation will be performed by using triple cooled-wet electrodes. Two or three electrodes will be places around the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C.
215026360|NCT00423865|DRUG|cisplatin|cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
215026361|NCT00423865|DRUG|everolimus|escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
215026362|NCT00423865|GENETIC|gene expression analysis|Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
215026363|NCT00423865|OTHER|immunohistochemistry staining method|After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
214691713|NCT00240630|DRUG|placebo|placebo to match
214691714|NCT01763476|PROCEDURE|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
214691715|NCT01763476|PROCEDURE|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
214694218|NCT03855137|DRUG|Atogepant 30 mg|Tablets containing 30 mg atogepant
214694219|NCT03855137|DRUG|Atogepant 60 mg|Tablets containing 60 mg atogepant
214694220|NCT03855137|DRUG|Placebo|30 mg/60 mg tablets containing atogepant-matching placebo
214423891|NCT03409913|RADIATION|FDG PET/CT|Conventional FDG PET/CT including head in order to asses cranial arteries.
214423892|NCT03704350|DIETARY_SUPPLEMENT|controlled diet|Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
214508682|NCT02028650|BIOLOGICAL|the second donor's stem cell|HLA-mismatched, the second donor's stem cell infusion
214508683|NCT02556697|DEVICE|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
214508684|NCT01190995|DRUG|24% Sucrose|The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
214508685|NCT01190995|DRUG|Placebo|The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
214508686|NCT00884806|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
214508687|NCT00884806|DEVICE|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
214508688|NCT00884806|DEVICE|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
214508689|NCT00884806|DEVICE|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
214508690|NCT00884806|DEVICE|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
214508691|NCT00559572|BEHAVIORAL|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
214508692|NCT00559572|OTHER|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
214508693|NCT01817894|DRUG|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
214508694|NCT06469931|OTHER|range of motion exercises|In addition to range of motion exercises for wrist and hand and splinting, 3 sessions of ozone therapy will be applied once a week.
214508695|NCT06469931|DEVICE|Extracorporeal shock wave therapy|Patients in this group will receive ESWT once a week for 3 consecutive weeks in addition to range of motion exercises for wrist and hand and splinting.
214508696|NCT06469931|OTHER|ozone therapy|ozone therapy
214508697|NCT04044885|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
214508698|NCT02936401|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
214508699|NCT00059527|BEHAVIORAL|Healthy Youth Places: a behavior change model|
214508700|NCT02486939|DRUG|CHS-0214|Open label
214508701|NCT03431649|DRUG|Beraprost Sodium|1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
214508702|NCT03431649|DRUG|Sildenafil Citrate|0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
214508703|NCT00006084|BIOLOGICAL|lintuzumab|
214508704|NCT00825318|PROCEDURE|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
214508705|NCT01948557|BEHAVIORAL|Infant feeding counselling and support|"Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.~Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice."
214508706|NCT01631409|OTHER|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
214508707|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
214508708|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
214508709|NCT01631409|PROCEDURE|PCA|Percutaneous coronary angioplasty
214508710|NCT01631409|PROCEDURE|CABG|Coronary artery bypass grafting
214508711|NCT01631409|DEVICE|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
215026364|NCT00423865|OTHER|laboratory biomarker analysis|Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
215026365|NCT00423865|OTHER|pharmacological study|For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
215026366|NCT00423865|PROCEDURE|biopsy|"Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day."
215026367|NCT06566300|PROCEDURE|injection of autologous nanofat grafting|Injection of nanfat graft
215026368|NCT06566300|PROCEDURE|microneedling with autologus nanofat graft|delivery of nanofat graft with microneedling
215026369|NCT01285232|DRUG|Anakinra|150 mg sc once daily during four weeks
215026370|NCT06171737|BEHAVIORAL|Decision Aid|The American College of Cardiology decision aid: Treatment Options for Severe Aortic Stenosis for patients deciding between Tavi and Surgery
215026371|NCT06171737|BEHAVIORAL|Shared Decision Making Skills Training|60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies
215026372|NCT03503331|DRUG|[C-11]PiB-PET/MRI|All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
215026373|NCT06308770|BEHAVIORAL|Standard Care|Participants receive fatigue booklets from two charitable organisations providing information on fatigue, sleep, energy conservation, exercise and stress to help manage fatigue.
215026374|NCT06308770|BEHAVIORAL|4 week FMP|Participants attend 3 once weekly live online group interventions with a final intervention 8 weeks later.
215026375|NCT06308770|BEHAVIORAL|7 week FMP|Participants attend 6 once weekly live online group interventions with a final intervention 8 weeks later.
215026376|NCT01417988|DRUG|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
214691716|NCT06692946|BEHAVIORAL|Cooperative Parent-Mediated therapy|Parent-mediated therapy is an intervention where parents are trained to use therapeutic techniques to support their child's development and manage symptoms, often used for conditions like autism spectrum disorder (ASD).
215026377|NCT01417988|DRUG|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
215026378|NCT02113813|DRUG|naquotinib|oral
215026379|NCT02113813|DRUG|midazolam|oral
215026380|NCT06168734|DRUG|Cefepime-taniborbactam|Cefepime-taniborbactam administered 2.5g q8h intravenously (IV) over a 4-hour period for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
215026381|NCT06168734|DRUG|Meropenem|Meropenem will be administered 2g q8h IV over 4 hours for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
215026382|NCT06137807|DEVICE|TricValve® Transcatheter Bicaval Valve System|The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The system is a single use, sterile device compatible with all the valve sizes. The valves are premounted in the TricValve® Delivery System. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system available in sizes 25 and 29 for superior vena cava and 31 and 35 for inferior vena cava. The valve is implanted percutaneously by the transfemoral approach. The valves are supplied already premounted into the TricValve® Delivery System.
215026383|NCT06381791|DRUG|Epidiolex|150mg of Epidiolex
215026384|NCT06381791|DRUG|Placebo oral solution|150mg of Placebo oral solution
215026385|NCT04046419|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants.~4. Second application of the scales to the participants.~5. Statistical analysis and scaling"
215026386|NCT03301415|DRUG|Valganciclovir|Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
215026387|NCT01635530|DRUG|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
215026388|NCT01635530|DRUG|Ceftriaxone|2 g intravenous once a day, three weeks
215026389|NCT04912518|DRUG|Dexmedetomidine (DEX)|The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
215026390|NCT04912518|DRUG|Placebo (Saline)|The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
214691717|NCT06692946|BEHAVIORAL|Treatement as Usual|"Cognitive Behavioral Therapy (CBT) is a structured, short-term psychological treatment that focuses on identifying and changing negative thought patterns and behaviors. It aims to help individuals develop healthier ways of thinking and coping with challenges by addressing both cognitive (thought) and behavioral components.~Parent training is an educational intervention where parents learn strategies and techniques to effectively manage their child's behavior and support their development, often used to address challenges associated with conditions like autism or ADHD."
215026391|NCT01127204|DRUG|AZT-3TC-LPV/r twice a day|AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
214691718|NCT06696001|BEHAVIORAL|Psychoeducation|For the psychoeducation session, the focus is for the therapist to engage with the client regarding mental health broadly without a targeted effort to reinforce therapeutic alliance or to offer individualized guidance or techniques. The session will provide educational information on depression, depression symptoms and known causes, and strategies to reduce depression symptoms. The content will be delivered in a fashion to avoid individualization and psychotherapeutic exchange. The elements will focus on components of Cognitive Behavioral Therapy (CBT), differentiating between thoughts and feelings, common cognitive shortcuts, and the connection between behavior and emotion.
214691719|NCT06696001|BEHAVIORAL|Behavioral Activation|Behavioral Activation (BA) is a psychotherapy treatment modality used for depression and focuses on replacing maladaptive coping mechanism that reinforce depressive symptoms with adaptive coping mechanisms to increase exposure to positive reinforcement. The treatment will consist of the following elements: Introduction to establish concept of positive reinforcement and build rapport, identification of client-centered values, individualized values-based activity planning and scheduling, and developing adaptive coping strategies for the future.
214691720|NCT06375811|DRUG|Elagolix 200 MG|Elagolix tablet
214691721|NCT06375811|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
215103957|NCT06198335|OTHER|Transversus Abdominal Plane block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
214691722|NCT07026734|PROCEDURE|Deep brain stimulation surgery - GPi|Deep brain stimulation (DBS) surgery will be performed as normal clinical care. People with PD who are approved for GPi DBS will be enrolled in the study prior to their surgery.
214691723|NCT07026734|PROCEDURE|Deep Brain Stimulation Surgery - STN|Deep brain stimulation (DBS) surgery will be performed as normal clinical care. People with PD who are approved for STN DBS will be enrolled in the study prior to their surgery.
214691724|NCT04681573|DIAGNOSTIC_TEST|blood tests|"Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day."
214691725|NCT06699966|DRUG|Celecoxib|The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.
214691726|NCT06699966|DRUG|Minocycline|Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
215026392|NCT01127204|DRUG|ABC-3TC-EFV once a day|ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
215026393|NCT00622843|BIOLOGICAL|pneumococcal conjugate vaccine|"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."
215026394|NCT00622843|BIOLOGICAL|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
215103958|NCT06446791|PROCEDURE|Mehri Turki Surgical Technique of the Webbed Neck|The incision was made at the junction of the hairless skin and the hairy skin from the mastoid up to the acromion. A subcutaneous undermining allows direct visual control to excise the fibrotic band. Then the hairy skin with a triangular shape was excised. The closure of the defect was done after undermining an anterior cervical flap which was translated in a posterosuperior direction. Z plasty was performed in front of the acromion to prevent scar contracture. Surgical scars are concealed in the hairline which was well placed. The same procedure is done at the same surgical field on the other side to achieve perfect symmetry.
215103959|NCT03834935|DRUG|Elidel (pimecrolimus 1%)|topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
215103960|NCT03834935|DRUG|Cold Cream|Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
215103961|NCT03750643|DRUG|LY3454738|Administered IV
215103962|NCT03750643|DRUG|LY3454738|Administered SC
215103963|NCT03750643|DRUG|Placebo|Administered IV
214423893|NCT06129149|BEHAVIORAL|Trauma-Informed Care-adapted and Checklist-guided ACP intervention|The intervention will consist of a single one- to two-hour visit wherein the PI (Kimpel) will facilitate a flexible conversational approach with the resident (and, optionally, a healthcare decision-maker) in a quiet, private location in the resiliency hub. Using a conversation checklist adapted from a narrative synthesis of advance care planning (ACP) guides (Fahner et al., 2019), the PI will explore ACP with participants and use each visit to continually adapt the checklist and approach with trauma-informed care (TIC) principles: safety, trustworthiness and transparency, peer support, collaboration and mutuality, empowerment, and choice, and cultural, historical, and gender issues. Adverse Childhood Experiences and previous death-related experiences assessed during baseline data collection will be used to tailor the discussion to carefully explore relevant history to assess resident ACP values, preferences, and goals.
214508712|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
214508713|NCT01762397|DRUG|PMK-S005|
215026395|NCT05107271|DIAGNOSTIC_TEST|COVID-19 serosurvey|COVID-19 related antibody testing to assess immunogenicity of COVID-19 vaccines or post natural infection acquired immunity
215026396|NCT01812941|OTHER|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
215026397|NCT01812941|OTHER|healthy volunteers: blood collection|blood collected at designated time intervals
215026398|NCT01812941|OTHER|Burn: blood collection|blood collected at designated time intervals
215026399|NCT04418505|DEVICE|Vielight RX Plus|The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
215026400|NCT00842803|DRUG|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
215026401|NCT00586937|BEHAVIORAL|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
215026402|NCT02120248|OTHER|Telephone-based breastfeeding peer counseling|
215026403|NCT04504136|PROCEDURE|Serial Biopsy|"During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach."
215026404|NCT06487286|OTHER|observational study|observational study
215026405|NCT04825262|DRUG|Tacrolimus|Starting dose based on CYP3A5 genotype
215026406|NCT00410436|BEHAVIORAL|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
214508714|NCT06495463|DRUG|Trifluridine/tipiracil|"Trifluridine/tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~(choose one combination) : oxalipatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days."
214508715|NCT06962969|DRUG|Ibrance|Patients who received at least one initial prescription of Ibrance following a diagnosis of advanced/metastatic breast cancer
214508716|NCT04719026|OTHER|Full-mouth periodontal examination using computerised Florida probe|It is an observational study to investigate the prevalence of periodontitis in cases and controls.
214508717|NCT04241952|OTHER|Exercise|Bedcycling
214508718|NCT04751799|DEVICE|Virtual reality headset before colposcopy|Patients wear a virtual headset presenting 360° 3D views of relaxing environments
214508719|NCT04751799|DEVICE|Virtual reality headset during colposcopy|Patients wear a virtual headset presenting 360° 3D views of distracting environments
215026407|NCT05333588|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|The autologous TILs will be intravenous infused into patients.
215103964|NCT01686282|DIETARY_SUPPLEMENT|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
215103965|NCT01686282|DIETARY_SUPPLEMENT|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
215103966|NCT02744651|DEVICE|EUS-FNA|"Please note the text in section Arm description"
215103967|NCT02744651|DEVICE|EUS-Endodrill biopsy|"Please note the text in section Arm description"
215103968|NCT05331794|BEHAVIORAL|Training on BIOFIT-Park|"Participant will perform one strength training session on the new line of outdoor fitness equipment BIOFIT-Park. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series."
215103969|NCT05331794|BEHAVIORAL|Training on gym park equipament|Participant will perform one strength training session on a gym park equipment. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.
215103970|NCT06153472|DEVICE|VR-based intervention|The Virtual Reality-based sensory stimulation intervention will last for up to fourteen days, with all interventions administered by a research team. The primary outcomes will include delirium incidence, duration, and severity. The secondary outcomes will encompass patients' psychological well-being (post-traumatic stress disorder, sleep quality, and ICU memory), patients' clinical outcomes, and other outcomes (quality of life, independence, and cognitive function).
215103971|NCT03125772|DEVICE|TAXUS Element™ Paclitaxel-Eluting Stent System|Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
215103972|NCT03125772|DEVICE|Xience PRIME Everolimus-Eluting Stent System|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
215103973|NCT02353728|DRUG|Nilotinib|
214694221|NCT02467387|DRUG|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
215026408|NCT03094221|DEVICE|Rhythmia Mapping System|Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
215026409|NCT03915756|PROCEDURE|Drainage of surgical wound|Introduction of a drain before full fascial closure
215026410|NCT02577302|DEVICE|CAN-Stim - Protect CAN-Stim System|CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will continue therapy and followed for a total of 12 months.
215026411|NCT02577302|DEVICE|SNS - InterStim® System|"Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study.Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will receive a full implant and followed for a total of 12 months."
215026412|NCT03424980|COMBINATION_PRODUCT|Tyrosine kinase inhibitors|Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
215026413|NCT03361007|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Patients who were disqualified from surgical cortical valve replacement by decision of the Heart Team.
214423894|NCT06025019|BEHAVIORAL|parent-based Electronic Health intervention|"The eHealth intervention comprises 12 modules on three interaction modules related to physical activity, dietary behavior, and sleep. The intervention groups will be invited to a WeChat group. A 3-minute video (made on the TikTok APP) will be sent to each WeChat group. Based upon the social media studies recommendation, five to nine members in a group will produce the desirable group interactive effect. Therefore, the present study allocates eight parents to one WeChat group. In total, there will be 26 groups (206 parents) according to the sample size calculation. Consistent with Social Cognitive THeory, the content of each module will follow the four steps: 1. Attention (Read educational material and watch TikTok/Douyin video (less than 3 minutes). 2.Retention (parental interaction). 3.Reproduction (Set goals and conduct behaviors). 4.Motivation (feedback and making changes)."
214423895|NCT06191978|DRUG|ASTX727|Given by PO
214423896|NCT06191978|DRUG|Venetoclax|Given by PO
214423897|NCT06352541|DRUG|PRO-232|Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%
214423898|NCT06352541|OTHER|Placebo|Vehicle Control, ophthalmic solution
214423899|NCT05955898|BEHAVIORAL|Parents THRIVE|Parents THRIVE is a digital, one-time intervention that will give parents strategies to cope with their emotions and improve their distress tolerance. Parents will learn how to increase their emotion awareness to better tolerate strong emotions, such as anxiety, sadness, anger, and frustration.
214423900|NCT05955898|BEHAVIORAL|Sharing Feelings Project|Sharing Feelings Project is a digital, one-time program that focuses on the benefit of sharing emotions with others and will be used as a control. Parents will read about how sharing their emotions can be helpful and anecdotes from others' experiences sharing emotions.
214423901|NCT04151472|DRUG|Placebo|Placebo oral tablet, three times a day
214423902|NCT04151472|DRUG|90mg Idebenone|Idebenone 30 MG Oral Tablet, three times a day
214423903|NCT04151472|DRUG|270mg Idebenone|Idebenone 90 MG Oral Tablet, three times a day
214423904|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
214423905|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
214423906|NCT03568799|RADIATION|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
214423907|NCT02960269|OTHER|interprofessional back pain assessment|team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
214423908|NCT00271700|BEHAVIORAL|Order Set, Education, Feedback|
214508720|NCT05380089|OTHER|Increasing water intake|Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
214508721|NCT05723666|OTHER|Group watching virtual reality glasses|A nature video will be watched with virtual reality glasses.
214508722|NCT03807596|PROCEDURE|Periodontal treatment with Hyaluronic acid associated with SRP|In addition to SRP, patients in the test group received adjunct subgingival application of hyaluronic acid in all selected periodontal pockets.
214508723|NCT03807596|PROCEDURE|Scaling & root planning alone|Patients received full-mouth supra- \& sub-gingival SRP with the use of ultrasonic device \& periodontal universal \& Gracey curettes under local anesthesia.
214508724|NCT01837602|BIOLOGICAL|cMet RNA CAR T cells|
214508725|NCT01141972|DIETARY_SUPPLEMENT|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml \[≥75 nmol/L\]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
214423909|NCT04726813|BEHAVIORAL|MyADHD|The main goals of the intervention are to help participants with better functioning in daily life; offer strategies that will lead to stress reduction and reduce inattention and improve quality of life.The intervention includes: a short introductory chapter (open to everyone), followed by a start module (goal setting), followed by 6 different themed optional modules. Module content is based on GMT, DBT and CBT techniques and is tailored towards key concerns and difficulties experienced adults with ADHD as informed by previous research (focus-groups, lived experience groups) and experiences from group GMT and DBT.
214508726|NCT01141972|OTHER|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
215026414|NCT02416388|DRUG|Idarubicin|"Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~\+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
214508727|NCT03597087|PROCEDURE|Anesthesia before transurethral resection of the bladder tumor|"General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle"
214508728|NCT03597087|DRUG|Anesthesia|"General anaesthesia : propopol~Spinal anaesthesia : bupibacaine"
215026415|NCT02416388|DRUG|Daunorubicin|"Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~\+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
215026416|NCT02416388|DRUG|HD Cytarabine|"Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
215026417|NCT02416388|DRUG|Cyclosporine|"GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100"
215026418|NCT02416388|DRUG|Methotrexate|"GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11"
215026419|NCT02416388|DRUG|Mycophenolic acid (MPA)|"GvHD prophylaxis post allogeneic SCT :~* 720 mg BID from D0 to D+28 for HLA-identical siblings~* 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors"
214508729|NCT01769716|PROCEDURE|Umbilical cord blood transplantation|
214508730|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
214508731|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
214508732|NCT01835639|DIETARY_SUPPLEMENT|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
214508733|NCT00328666|BEHAVIORAL|Iyengar yoga|
214508734|NCT00328666|BEHAVIORAL|Enhanced nutritional care classes|
214508735|NCT03421249|OTHER|Exercises|Muscle strengthening exercises of the hip and knee muscles
214508736|NCT03421249|OTHER|Electromagnetic field therapy|Electromagnetic field therapy with Magnetron®
214508737|NCT02470169|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
214508738|NCT02470169|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
214508739|NCT02470169|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
214508740|NCT02470169|DEVICE|shepherd catheter|
214508741|NCT02470169|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
214508742|NCT04694066|BEHAVIORAL|Qigong|Qigong Baduanjin, comprising eight standardized movements, will be adopted in the study. It is practiced as a combination of body movements, breath control, and mindful meditation.
214691727|NCT06692491|DRUG|Albumin-Bound Paclitaxel|Albumin-Bound Paclitaxel 260mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with albumin-bound paclitaxel if PDOs show the highest response to this drug under the guidance of MTB.
215026420|NCT02416388|DRUG|vosaroxin|"Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4"
215026421|NCT02416388|DRUG|ID cytarabine|"Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
215026422|NCT02416388|DRUG|Dexamethasone|"Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5"
214508743|NCT04694066|BEHAVIORAL|Light flexibility exercise|The supervised sessions will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
214508744|NCT02725138|DIETARY_SUPPLEMENT|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
214508745|NCT02725138|OTHER|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
214508746|NCT01788605|DRUG|ramosetron|
214508747|NCT01717066|DRUG|the ginsenoside Rg3|
214508748|NCT01717066|DRUG|Placebo|
214691728|NCT06692491|DRUG|Epirubicin|Epirubicin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with epirubicin if PDOs show the highest response to this drug under the guidance of MTB.
214694222|NCT02467387|DRUG|Lactated Ringer's Solution|One time infusion 1.5mL/kg
214691729|NCT06692491|DRUG|Gemcitabine|Gemcitabine 1000mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with gemcitabine if PDOs show the highest response to this drug under the guidance of MTB.
214691730|NCT06692491|DRUG|Vinorelbine|Vinorelbine 25-30mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with vinorelbine if PDOs show the highest response to this drug under the guidance of MTB.
214691731|NCT06692491|DRUG|Cisplatin|Cisplatin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with cisplatin if PDOs show the highest response to this drug under the guidance of MTB.
214691732|NCT06692491|DRUG|Irinotecan|Irinotecan 125mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with irinotecan if PDOs show the highest response to this drug under the guidance of MTB.
214691733|NCT06692491|DRUG|Fluorouracil|Fluorouracil 600mg/m2,D1-5,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with fluorouracil if PDOs show the highest response to this drug under the guidance of MTB.
214691734|NCT06692491|DRUG|Nivolumab|Nivolumab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with nivolumab under the guidance of MTB.
214691735|NCT06692491|DRUG|Pembrolizumab|Pembrolizumab 200mg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with pembrolizumab under the guidance of MTB.
214691736|NCT06692491|DRUG|Durvalumab|Durvalumab 10mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with durvalumab under the guidance of MTB.
214691737|NCT06692491|DRUG|Atezolizumab|Atezolizumab 1200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with atezolizumab under the guidance of MTB.
214691738|NCT06692491|DRUG|Sintilimab|Sintilimab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with sintilimab under the guidance of MTB.
214691739|NCT06692491|DRUG|Tislelizumab|Tislelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with tislelizumab under the guidance of MTB.
214691740|NCT06692491|DRUG|Camrelizumab|Camrelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with camrelizumab under the guidance of MTB.
214691741|NCT06692491|DRUG|Toripalimab|Toripalimab 240kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with toripalimab under the guidance of MTB.
214691742|NCT06692491|DRUG|Serplulimab|Serplulimab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with serplulimab under the guidance of MTB.
214691743|NCT06692491|DRUG|Adebrelimab|Adebrelimab 20mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with adebrelimab under the guidance of MTB.
214691744|NCT06692491|DRUG|Envafolimab|Envafolimab 150mg,qw Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with envafolimab under the guidance of MTB.
214691745|NCT06692491|DRUG|Osimertinib|Osimertinib 80mg,qd Patients with advanced rare tumours who failed to standard treatment carrying EGFR mutations will be administrated with osimertinib under the guidance of MTB.
214691746|NCT06692491|DRUG|Alectinib|Alectinib 600mg,bid Patients with advanced rare tumours who failed to standard treatment carrying ALK fusion will be administrated with alectinib under the guidance of MTB.
214691747|NCT06692491|DRUG|Vemurafenib|Vemurafenib 960mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRAF V600E mutation will be administrated with vemurafenib under the guidance of MTB.
214691748|NCT06692491|DRUG|Pamiparib|Pamiparib 60mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRCA1/2 mutation will be administrated with pamiparib under the guidance of MTB.
214691749|NCT06692491|DRUG|Pyrotinib|Pyrotinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib under the guidance of MTB.
215026423|NCT02416388|DRUG|Venetoclax|"Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~* 100 mg/d on D1 to D8 (selection phase dose level 1)~* or 200 mg/d on D1 to D8 (selection phase dose level 2)~* or 400 mg/d on D1 to D8 (selection phase dose level 3)~* or 400 mg/d on D1 to D14 (selection phase dose level 4)"
215026424|NCT03765021|DRUG|Tranexamic Acid|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
215026425|NCT03765021|DEVICE|Fractional CO2 laser|The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
215026426|NCT03307590|DRUG|Dexmedetomidine|Caudal block by dexmedetomidine and bupivavaine
215026427|NCT03307590|DRUG|Bupivacaine|Caudal block by bupivavaine alone
215026428|NCT03644758|DIAGNOSTIC_TEST|socio-demographic data and personal medical history|Socio-demographic data and personal medical history is a self-administered questionnaire.
215026429|NCT03644758|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire. This score evaluates sleep disturbances.
215026430|NCT03644758|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale is a self-administered questionnaire. This score evaluates excessive drowsiness.
215026431|NCT03644758|DIAGNOSTIC_TEST|Insomnia Severity Index (ISI)|Insomnia Severity Index (ISI) is a self-administered questionnaire. This score evaluates insomnia severity.
215026432|NCT03644758|DIAGNOSTIC_TEST|stop-BANG questionnaire|Stop-BANG is a self-administered questionnaire. This score evaluates Obstructive Sleep Apnea (OSA).
215026433|NCT03177915|DRUG|Hylase|median nerve hydro-dissection using Hyalase + 10 cc saline injection
215026434|NCT03177915|DRUG|Saline|median nerve hydro-dissection using 10 cc saline injection
215026435|NCT00421408|DIETARY_SUPPLEMENT|Whey protein supplement|40-g whey protein supplement daily for 18 months
215026436|NCT00421408|DIETARY_SUPPLEMENT|Placebo|Placebo supplement daily for 18 months
215026437|NCT04091438|DRUG|TAK-925|TAK-925 IV infusion.
215026438|NCT04091438|DRUG|TAK-925 Placebo|TAK-925 placebo-matching IV infusion.
215026439|NCT03643588|DEVICE|HYAJOINT Plus|Single-injection, 60 mg / 3 ml (2%) cross-linked hyaluronan
215026440|NCT03643588|DEVICE|Hyalgan|Three-injection, 20 mg / 2 ml (1%) linear hyaluronan
215026441|NCT05510973|OTHER|Enhanced package for AHD care|The enhanced package of AHD care includes CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis \[TPT and CPT\], offered through a hub-and-spoke facility system, with continuous quality improvement (QI)
215026442|NCT03405753|DIETARY_SUPPLEMENT|Aronia, washout and then placebo|Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
215026443|NCT03405753|DIETARY_SUPPLEMENT|Placebo, washout and then aronia|Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
215026444|NCT02370693|DRUG|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
215026445|NCT02370693|DRUG|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
215026446|NCT02370693|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
215026447|NCT01954511|OTHER|Manual therapy|The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes
215026448|NCT01954511|OTHER|Manual therapy|The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes
215026449|NCT01954511|DEVICE|Pressure biofeedback device|Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
215026450|NCT00872287|PROCEDURE|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
215026451|NCT00872287|PROCEDURE|SILS|Single transumbilical incision laparoscopic cholecystectomy
215026452|NCT02142829|DRUG|EXPAREL|
215026453|NCT02142829|DRUG|On-Q Pain Ball|bupivacaine HCl 0.25%
215026454|NCT04168411|PROCEDURE|Symptomatic Treatment|Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
215026455|NCT02438397|DRUG|premix insulin|Premix-insulin(human insulin or analog) treatment will continue
215026456|NCT02438397|DRUG|metformin|500 mg tid by Merck
215026457|NCT02438397|DRUG|Acarbose|100mg tid by Bayer
215026458|NCT03075436|BEHAVIORAL|Enhanced demand-side sanitation, hygiene|The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
215026459|NCT03075436|BEHAVIORAL|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
215026460|NCT02627638|OTHER|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
215026461|NCT02976688|OTHER|Sodium Propionate|Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
215026462|NCT06234475|BEHAVIORAL|Mobile health support|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months"
215026463|NCT06234475|BEHAVIORAL|Financial incentive|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
215026464|NCT06234475|BEHAVIORAL|Combine intervention|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months~7. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
214423910|NCT04726813|BEHAVIORAL|Psychoeducation|Participants in the control condition will be assigned to psychoeducation modules (see Table 2) and will receive restricted access to the platform. They can contact or be contacted if their symptoms levels increases.
215026465|NCT06234475|BEHAVIORAL|Control group|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months for those without abstinence at 12-month follow-up after follow-ups ending~6. Acceptance and Commitment Therapy based rear-time Chat-based support for 3 months for those without abstinence at 12-month follow-up after follow-ups ending"
215026466|NCT00005880|DRUG|budesonide|
215026467|NCT03956108|DIAGNOSTIC_TEST|MRI+targeted biopsies+Stockholm3-test|MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.
215026468|NCT03956108|DIAGNOSTIC_TEST|PSA + systematic biopsies|Systematic biopsies and PSA test
215026469|NCT05420337|PROCEDURE|Group ıntramuscular|Group I will be applied 20 ml of % 0.25 bupivacain internal oblique and transversus abdominis muscle and 0.1 mg/kg morphine ıntramuscular. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
215026470|NCT05420337|PROCEDURE|Group TAP|Group T will be applied 20 ml of % 0.25 bupivacain and 0.1 mg/kg morphine internal oblique and transversus abdominis muscle. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
215026471|NCT00441935|DEVICE|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
215026472|NCT02390999|PROCEDURE|48 hours of therapeutic hypothermia|
215026473|NCT03737890|OTHER|Inspiratory Muscle Training|"Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
215026474|NCT03737890|OTHER|Hold Relax Pectoral Stretch|"In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
215026475|NCT05394051|BEHAVIORAL|Positive Affect Regulation sKills (PARK)|"The goal of the PARK program is to reduce feelings of anxiety, depression, and social isolation, as well as increase well-being and a sense of meaning and purpose through the practice of positive emotion skills via a self-guided online platform.~The total time involved from the beginning to the end of the intervention portion of the study is approximately 6 months (includes 6-week PARK course, baseline and follow-up assessments. Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up."
215026476|NCT02557165|PROCEDURE|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
215026477|NCT01955265|BEHAVIORAL|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
215026478|NCT01955265|BEHAVIORAL|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
215026479|NCT00677300|DRUG|Raltegravir|400mg P.O. (orally) twice daily for 48 weeks
214423911|NCT06037824|OTHER|cryotherapy|"cryotherapy was added to rehabilitation\*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~\* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
214423912|NCT01727128|DRUG|BKM120|
214423913|NCT00657943|DRUG|metformin|metformin tablets 2 g x 2
214423914|NCT00657943|DRUG|insulin detemir|insulin as requested
214423915|NCT00657943|DRUG|insulin aspart + insulin aspart protamin|insulin as requested
214423916|NCT00657943|DRUG|Insulin aspart|insulin as requested
214423917|NCT00783133|DRUG|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
214423918|NCT00783133|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
214423919|NCT00813449|DRUG|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
215026480|NCT00677300|DRUG|Darunavir|800 mg P.O. (orally) once daily
215026481|NCT00677300|DRUG|Ritonavir|100mg once daily
215026482|NCT00677300|DRUG|Tenofovir/Emtricitabine|300 mg/200 mg P.O. (orally) once daily
215026483|NCT00373360|DRUG|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
215026484|NCT00787800|DEVICE|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
215103974|NCT04522479|OTHER|Change the injection time of long acting GnRH-a|The whole dose of long acting GnRH-a drug was changed to be injected on day 21st-23rd day of menstruation
215103975|NCT03253328|DRUG|Active Arm N-acetyl cysteine (NAC)|N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
215103976|NCT03253328|DRUG|Placebo Arm|Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
215103977|NCT00044902|DRUG|epratuzumab|
214423920|NCT00813449|DRUG|dacarbazine plus placebo (control group)|dacarbazine plus placebo
214423921|NCT02178111|OTHER|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
214423922|NCT02178111|PROCEDURE|episiotomy|
214423923|NCT01721434|DRUG|Levosimendan|
214423924|NCT01721434|DRUG|Placebo|Similar coloured placebo
214508749|NCT05657821|DIETARY_SUPPLEMENT|Pumpkin seeds extract capsules|the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks
214508750|NCT00655109|DRUG|Olopatadine|Ophthalmic solution
214508751|NCT00655109|DRUG|Fluticasone|Nasal spray
215026485|NCT00787800|DEVICE|Single Chamber ICD|"Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.~VT/VF detection and therapies with discrimination criteria for single chamber device."
214423925|NCT05951218|OTHER|inhibition technique|Inhibition treatment consists of applying progressive pressure with the finger until resistance is felt. The patient should feel discomfort but not pain. They should stop when they consider that the trigger point has been sufficiently relaxed. All the techniques should last less than 5 minutes. Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator
215026486|NCT01431547|DRUG|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m\^2, and escalated for successive cohorts of participants until MTD is found
215026487|NCT01431547|DRUG|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
215026488|NCT01431547|DRUG|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
215026489|NCT02157337|DRUG|Atorvastatin|80 mg (PO) once daily for 6 days
215026490|NCT02157337|DRUG|placebo|80 mg (PO) once daily for 6 days
215026491|NCT00090675|DRUG|ZD1839|
215026492|NCT05297019|PROCEDURE|Hyperbaric Oxygen Therapy|hyperbaric oxygen therapy
215026493|NCT04228003|DIETARY_SUPPLEMENT|Pendulum Glucose Control formulation for T2D|"All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
215026494|NCT02481141|DRUG|5-ALA-SFC|Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
215026495|NCT02481141|DRUG|Placebo|
215026496|NCT00027300|DRUG|Natalizumab|Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
215026497|NCT00027300|DRUG|Placebo|Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
214423926|NCT05951218|OTHER|placebo|"The osteopath will perform a light touch on 4 areas for 30 seconds each time. The trigger point area must be lightly touched, followed by the upper part of the pectoralis major, the elbow and finally the anterior part of the opposite glenohumeral region.~Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator with a palpatory pressure measurement tool. A proposition of 1N will be proposed to have a very light touch, without activating the C-tactile sensors."
214423927|NCT06340646|OTHER|Return of Genetic Results: Biomarker information from cancer cells|Participants will receive a novel return of results report that is tailored to their choices.
214423928|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to cancer|Participants will receive a novel return of results report that is tailored to their choices.
215026498|NCT04309500|BEHAVIORAL|Personalized DAT Risk Disclosure Protocol|Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
215026499|NCT04743063|DRUG|sacubitril/valsartan|Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims
215026500|NCT04743063|DRUG|Angiotensin II Receptor Blockers|Initiation of ARBs, identified using prescription fill in pharmacy claims
214423929|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to other medical issues|Participants will receive a novel return of results report that is tailored to their choices.
214423930|NCT00006369|DRUG|ERA-923|
214508752|NCT00655109|DRUG|Saline|Nasal spray
214508753|NCT00655109|DRUG|Artificial tears|Ophthalmic Solution
215026501|NCT00047580|DRUG|tizanidine hydrochloride capsule|
215026502|NCT00498407|DRUG|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
215026503|NCT00913835|BIOLOGICAL|Olaratumab|20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
215026504|NCT00913835|DRUG|liposomal doxorubicin|40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
215026505|NCT06127901|PROCEDURE|Any surgery under any type of anaesthesia.|Any surgery under any type of anaesthesia.
215026506|NCT05930535|BEHAVIORAL|Parenting for Lifelong Health for Parents and Teens|"PLH will be delivered over 6 sessions as a group-based family program with both adolescents and caregivers attending, with joint and separate core sessions framed by joint introductions and endings. It will include activities such as: building positive parent-child relationships; developing problem-solving skills; stress-management and stress-reduction skills; improving effective limit-setting and discipline by parents; talking about feelings and regulating emotions.~The PLH program will also include a peer support component and incentive boosters. The Helping Adolescents Thrive comic chapters will be provided as homework activities. The comics, developed by UNICEF, cover adaptation to new situations, stress management, problem-solving, communication skills, risky choices and being there for each other."
215026507|NCT06366165|PROCEDURE|seemingly irrelevant funny videos and memes in teaching|linking funny videos and memes to special care dentistry curriculum lectures
215026508|NCT00000501|BEHAVIORAL|diet, sodium-restricted|
215026509|NCT00000501|BEHAVIORAL|diet, reducing|
215026510|NCT00000501|DRUG|potassium|
215026511|NCT05648747|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.
215026512|NCT03757663|BEHAVIORAL|UV Counseling|Participants will self-report their knowledge and attitudes related to UV exposure. They will then wear a dosimeter for 3 weeks. After, the study team will counsel the participants on their UV levels and exposure, creating a personal plan and advice for avoiding sun exposure before letting the participants wear the dosimeter for an additional 3 weeks.
215026513|NCT00557739|DRUG|mometasone furoate|Topical 0.1% mometasone furoate
215026514|NCT00557739|DRUG|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
215026515|NCT00557739|DRUG|Vehicle (placebo)|Topical placebo
215026516|NCT05914129|OTHER|Diaphragm, Stomach and Liver techniques|"Diaphragm Stretching:~The participant is seating down and the researcher will be behind, placing their hands on the inferior costal border. Cephalic traction is performed during inhalation, remaining during exhalation. Procedure is repeated 2 times, for 10 respiratory cycles, with 1-minute intervals.~Inferior Mobilization of the Stomach:~The participant is seating down with slight flexion of the torso, while the investigator stands behind them, placing the thumbs on the epigastric region. The volunteer will extend their body while the researcher performs a caudal traction. This procedure lasts 5 minutes.~Liver Pump:~Participant is laying on their back, and the investigator is standing on the participants side. The researcher places one hand on the right side inferior costal border posteriorly and the other one bellow the costal border anteriorly. Researcher compresses during exhalation and releases their hands abruptly during inhalation. This procedure lasts 5 minutes."
215026517|NCT05914129|OTHER|Stomach and Liver techniques|In this group, techniques are the exact same as described previously but only liver and stomach ones will be performed.
215026518|NCT05914129|OTHER|Sham technique|In the sham group, manual contact without any therapeutic intention will be performed in the same regions as the experimental groups. This contact will be maintained during the same amount of time as for the experimental group A.
215026519|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through single incision|Group I: experimental - single incision The surgical technique chosen for thumb basal join was trapeziectomy with ligamentous reconstruction and tendon interposition (LRTI), using flexor carpi radialis (FCR). Through a dorsal approach over trapeziometacarpal joint, the entire trapezium was excised. Volar traction of FCR allowed us to longitudinally incise the deep leaflet of FCR tendon until flexor pollicis longus (FPL) tendon was clearly visualized. Then, ulnar half of FCR tendon was harvested proximally through a second transverse incision in middle third of the forearm and split all the way to its insertion on the index metacarpal. A hole was placed in the base of the first metacarpal and FCR tendon was routed through the bone canal and then fixed with non-reabsorbable sutures. Finally, the tendon remanent was rolled up and placed into the trapezial void to act as a spacer.
215026520|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through double incision|Group II: active comparator - double incision Trapezial excision and ligament reconstruction were performed in the same way as in group I, except that FCR deep leaflet was not incised. After radial incision wound closure, carpal tunnel release was performed through a second separate longitudinal palmar incision.
215026521|NCT01014312|BEHAVIORAL|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
215026522|NCT01014312|BEHAVIORAL|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
215026523|NCT02067598|OTHER|scapular exercise|
215026524|NCT04868357|BEHAVIORAL|Hypnosis|Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.
214691750|NCT06692491|DRUG|Imatinib|Imatinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying CKIT mutation will be administrated with imatinib under the guidance of MTB.
214691751|NCT06692491|DRUG|Palbociclib|Palbociclib 125mg, 21/7 dosing schedule Patients with advanced rare tumours who failed to standard treatment following HR(+)/HER-2(-) will be administrated with palbociclib under the guidance of MTB.
214691752|NCT06692491|DRUG|Savolitinib|Savolitinib 300mg, qd Patients with advanced rare tumours who failed to standard treatment carrying C-MET mutation will be administrated with savolitinib under the guidance of MTB.
214508754|NCT05928754|DIAGNOSTIC_TEST|care strategy|"Uveitis patients:~* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7."
214508755|NCT03328637|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
214508756|NCT01217866|PROCEDURE|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
214691753|NCT06692491|DRUG|Entrectinib|Entrectinib 600mg, qd Patients with advanced rare tumours who failed to standard treatment carrying ROS-1 fusion or NTRK fusion will be administrated with entrectinib under the guidance of MTB.
214691754|NCT06692491|DRUG|Other|"Patients with advanced rare tumours who failed to standard treatment in RWS ICF Group will be administrated with empirical chemotherapy(e.g., Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine, Vinorelbine, Cisplatin, Irinotecan, Fluorouracil), immunological(e.g., Nivolumab, Pembrolizumab, Durvalumab, Atezolizumab, Sintilimab, Tislelizumab, Camrelizumab, Toripalimab, Serplulimab,Adebrelimab,Envafolimab) or targeted drugsl(e.g., Osimertinib, Alectinib, Vemurafenib, Vemurafenib, Pyrotinib, Imatinib, Palbociclib, Savolitinib, Entrectinib)treatments."
214691755|NCT06693583|DEVICE|Virtual Reality Headsets|Virtual reality (VR) headsets are used as a form of distraction technique widely throughout healthcare. Women will be assisted to apply the VR prior to their colposcopy examination beginning. They will be shown an immersive video of walking through a forest that reminds them to breath deeply. The aim is that this will relax them during the colposcopy examination.
214691756|NCT06692933|DRUG|Cannabidiol in the form of hemp|Cannabidiol (30 mg) in the form of an orally administered hemp oil softgel
215026525|NCT04868357|BEHAVIORAL|Relaxation|Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
215026526|NCT05039489|DRUG|Antipsychotic drugs|Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
215026527|NCT05039489|DEVICE|cTBS（the left temporoparietal cortex as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
214423931|NCT05319041|DRUG|Wei's Qi Ju Gan Lu Formula|"The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
214423932|NCT05319041|DRUG|Placebo|0.5g maltodextrin without any herbs medicine
214508757|NCT04641715|PROCEDURE|OAGB-MGB|One Anastomosis Gastric Bypass - Mini Gastric Bypass as both restrictive and malabsorptive bariatric procedure
214691757|NCT06692933|DRUG|Clopidogrel|75 mg oral clopidogrel
214694223|NCT01105416|BEHAVIORAL|Brief Prevention Intervention (BPI)|Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.
215026528|NCT05039489|DEVICE|cTBS （the left cerebellum Crus II as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
215026529|NCT05348122|DRUG|TG103,Q2W|TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
215026530|NCT05348122|DRUG|TG103,QW|TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
215026531|NCT05348122|DRUG|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
215026532|NCT05348122|DRUG|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
214508758|NCT02216084|DRUG|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
214508759|NCT00330785|DRUG|Amlodipine/Atorvastatin|
214508760|NCT03020433|DEVICE|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
214691758|NCT07023783|BEHAVIORAL|Transdiagnostic Sleep Health Intervention (TSHI)|"A transdiagnostic sleep health intervention (TSHI) will be delivered across six weekly 50-minute one-on-one sessions with a sleep expert via a HIPAA-compliant videoconference link. The six weekly TSHI sessions are outlined as:~Week 1: Consists of discussing sleep physiology and discussing appropriate bed and wake up times.~Week 2: Consists of discussing how to set/importance of setting, a bedtime routine Week 3: Consists of discussing how to improve daytime function through energy management for daily and weekly tasks.~Week 4: Consists of discussing the sleep beliefs the participant holds and possible corrections of any unhelpful sleep beliefs.~Week 5: Consists of educating participants on sleep hygiene and how it is influenced by environmental, social, and physical factors.~Week 6: Consists of discussing sleep behavior changes observed during the TSHI and collaborating with the participant on plans to maintain their new sleep pattern."
214691759|NCT06876220|BEHAVIORAL|Mindfulness-based Cognitive Therapy for Life (MBCT-L)|MBCT-L is an 8-week group intervention where participants are guided to practice mindfulness and cognitive exercise. The course covers themes such as anchoring, acceptance, and decentering. The course will be provided by mindfulness teachers who have completed the training offered by Oxford Mindfulness Foundation (OMF). Throughout the eight weeks, the course guides the participants through various themes such as anchoring, acceptance, and decentering. The sessions involve guided mindfulness practices, reflection, discussion, inquiry, and weekly home practice. The language of instruction is Cantonese.
214691760|NCT04946916|DIAGNOSTIC_TEST|blood sample taken|Comparaison of Neurofilament light chain serum concentration between the arms
215026533|NCT05348122|DRUG|Dulaglutide,QW|Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
215026534|NCT06563830|OTHER|educational application|The content of the training to be applied to nurses will include: definition of MDRPI, etiology, prevalence and cost, staging, risk factors, nursing initiatives to be implemented to prevent MDRPI.
215026535|NCT04083079|DRUG|PEG-rhG-CSF|Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
215026536|NCT04083079|DRUG|rhG-CSF|Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
215026537|NCT03918408|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
215026538|NCT01778621|DEVICE|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
215026539|NCT04948268|BEHAVIORAL|Adaptive messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.
215026540|NCT04948268|BEHAVIORAL|Non-personalized messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.
215026541|NCT04948268|BEHAVIORAL|Coaching|Human coaching to support intervention use and engagement via telephone calls, text or email
215026542|NCT04948268|BEHAVIORAL|Psychoeducational links|SMS messages with URLs containing brief psychoeducational information.
215026543|NCT02414841|DRUG|Vonapanitase|
215026544|NCT02414841|DRUG|Placebo|
215026545|NCT02197988|DRUG|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
214691761|NCT06692816|OTHER|Rehabilitation|As a therapeutic exercise program, it was planned to apply joint range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises by a trained physiotherapist with at least 5 years of experience and that the patients would do these exercises three times a day, in 3 sets, with 10 repetitions.
214691762|NCT00484250|DRUG|metronidazole,doxycycline|
214691763|NCT06168864|DIAGNOSTIC_TEST|Artificial intelligence models for segmentation and characterization of prostate cancer|rtificial intelligence algorithms for the automatic segmentation of prostate cancer lesions on medical images.
214691764|NCT04355091|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage forms, rather than using acupuncture needles.
214691765|NCT02674607|DIETARY_SUPPLEMENT|Spirulina|
215026546|NCT02197988|DRUG|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
215026547|NCT06569433|PROCEDURE|THERAPEUTIC EXERCISE AND MOBILISATION OF THE FEMORAL NERVE|"the control group that will perform only therapeutic exercise will perform a specific exercise programme for knee tendinitis under the supervision of a physiotherapist, while the intervention group that will perform therapeutic exercise plus femoral nerve mobilisation will receive therapeutic exercise sessions and femoral nerve mobilisations performed by a trained physiotherapist.~The intervention will last for 6 weeks, during which 60-minute sessions will be held at the centre, measurements will be taken during the six weeks, using standardised questionnaires to evaluate the variables (set out below) and always measuring the range of movement and femoral nerve mobility with the Slump Test on the same day of the week and at the same time of treatment."
215026548|NCT06656221|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 2000mg on Cycle 1 Days 1-2
215026549|NCT06656221|DRUG|Glofitamab|Glofitamab is given intravenously at a dose of 2.5mg on Cycle 1 Day 8. Glofitamab is given intravenously at a dose of 10mg on Cycle 1 Day 15. Glofitamab is given intravenously at a dose of 30mg on Day 1 of Cycles 2-6
215026550|NCT06656221|DRUG|Bortezomib|Bortezomib is given intravenously at a dose of 1.6 mg/m² on Days 1, 8, and 15 of Cycles 1-12.
215026551|NCT06656221|DRUG|Orelabrutinib|Orelabrutinib is given orally at a dose of 150 mg daily on Days 1-21 of Cycles 1-12.
215026552|NCT04846868|DRUG|Iclepertin|Iclepertin
214691766|NCT05507944|DIAGNOSTIC_TEST|FeNO measurement|Diurnal measurements before work and at 3 hours after work start.
215026553|NCT04846868|DRUG|Placebo|Placebo
215026554|NCT02842242|DRUG|MYK-461|
215026555|NCT00982579|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
215026556|NCT06609057|OTHER|Nutritional Intervention|Receive Cooking for Your Health in Southern New Mexico intervention
215026557|NCT06609057|OTHER|Questionnaire Administration|Ancillary studies
215026558|NCT06609057|OTHER|Survey Administration|Ancillary studies
215026559|NCT06609057|OTHER|Discussion|Ancillary studies
215026560|NCT03249558|DRUG|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
215026561|NCT03249558|DRUG|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
215026562|NCT03249558|DRUG|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
215026563|NCT06670521|DRUG|Methylprednisolone|50 mg methylprednisolone IV every 6 hours for 4 doses to reduce laryngeal edema
215026564|NCT06670521|DRUG|Normal Saline|Normal Saline placebo IV every 6 hours for 4 doses
215026565|NCT06670586|PROCEDURE|conventional in vitro fertilization|Fertilization via conventional In Vitro Fertilization
215026566|NCT06670586|PROCEDURE|intracytoplasmic sperm injection (ICSI)|Fertilization via intracytoplasmic sperm injection
215026567|NCT05032911|DIAGNOSTIC_TEST|sensorimotor control analysis using inertial sensor technology|Inertial Measurement Unit (IMU) sensors will measure sensorimotor control variables including active range of motion, movement speed, acceleration, smoothness of motion, head repositioning accuracy and motion coupling patterns
215026568|NCT06407401|DRUG|Duloxetine 60 MG|"Patients randomized to the duloxetine arm will take duloxetine orally daily, with or without food, on a continuous dosing schedule.~Initial dose is 30 mg daily for 1 week, followed by 60 mg daily for a total of 6 months of treatment, followed by a taper off the medication of 30 mg daily for 1 additional week."
215026569|NCT06407401|DRUG|Furosemide 40 mg|Patients randomized to the furosemide arm will take furosemide 40 mg orally daily, on an empty stomach with plenty of liquid, on a continuous dosing schedule.
215026570|NCT06407401|BEHAVIORAL|Booklet for healthy behaviors|All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.
215026571|NCT06613139|DRUG|YHP2305|Test drug: YHP2305 Comparator: YHR2404
215026572|NCT06613139|DRUG|YHR2404|Test drug: YHP2305 comparator: YHR2404
215026573|NCT06673914|BEHAVIORAL|Control Group: Diet Group|"Patient in Diet Group and Oleuropein and Diet Group will be given a personalized diet and be followed up by a dietician."
215026574|NCT06673914|DIETARY_SUPPLEMENT|Oleuropein and Diet Group|"Dietary Supplement: Oleuropein (Olive Leaf Extract) Patients in Oleuropein and Diet Group will receive 200 mg/day oleuropein supplement and personalized diet followed up by a dietician."
215026575|NCT06675448|DEVICE|MitraClip|Participants will undergo the Mitraclip procedure according to current standards of practice
215026576|NCT06675448|OTHER|Moderate MR|Patients who present with moderate MR (Mitral regurgitation) will serve also as an internal control against which the outcomes of Mitraclip treated patients)
215026577|NCT07010757|BEHAVIORAL|HARPP|In HARPP, MOVE! and CPT are delivered in up to 16 individual psychotherapy sessions. While all CPT content is included, it is slightly tailored to address factors that interfere with health behavior change (e.g., hypervigilance that hinders community-based physical activity). All MOVE! materials are included; MOVE! uses cognitive-behavioral techniques and autonomy-supporting counseling to promote physical activity and healthy eating. HARPP targets other PTSD-related barriers to recovery and healthy lifestyles by promoting sleep and relationship quality, and community engagement. HARPP participants receive at least one medication management consultation (review by clinician and telephone session) focused on currently may cause weight gain and AOM options. When relevant and based upon Veteran interest, medications are changed or prescribed, in coordination with the Veteran's psychiatric and primary care teams.
214691767|NCT01427569|DRUG|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
215026578|NCT07010757|BEHAVIORAL|control arm for HARPP trial|"Participants in the control condition will receive the following:~1. Referral to MOVE!; they will select a MOVE! that fits their schedule (at VAPS MOVE! is a 12-week group).~2. Standard CPT in 60-minute individual sessions, delivered by 4 CPT-trained psychotherapists (different therapists than intervention arm therapists to avoid contamination).~3. One non-visit consult medication review using the same procedures and template outlined above. After the non-visit consult, the Dr. will alert the Veteran's relevant usual care team member(s) via the non-visit consult template in the medical record. They will not have direct contact with control participants, but the study team will monitor for safety following any medication changes."
215103978|NCT03214042|DEVICE|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
215103979|NCT05407779|BIOLOGICAL|BCD-180, dose 1|anti-TRBV9 monoclonal antibody single infusion at dose 1
215103980|NCT05407779|BIOLOGICAL|BCD-180, dose 2|anti-TRBV9 monoclonal antibody, single infusion at dose 2
215103981|NCT05407779|BIOLOGICAL|BCD-180, dose 3|anti-TRBV9 monoclonal antibody, single infusion at dose 3
215103982|NCT05407779|BIOLOGICAL|BCD-180, dose 4|anti-TRBV9 monoclonal antibody, single infusion at dose 4
215103983|NCT05407779|BIOLOGICAL|BCD-180, dose 5|anti-TRBV9 monoclonal antibody, single infusion at dose 5
215103984|NCT05407779|BIOLOGICAL|BCD-180, dose 6|anti-TRBV9 monoclonal antibody, single infusion at dose 6
214691768|NCT01427569|OTHER|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
214694224|NCT01105416|BEHAVIORAL|ESC|Enhanced standard care
214694225|NCT01579981|PROCEDURE|Roux-en-Y Gastric Bypass|On two separate experimental days before, 1 wk, and 3 months after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized. At end of study day an ad libitum meal is served.
214694226|NCT02406547|DEVICE|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
214691769|NCT06726018|BEHAVIORAL|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion.
214691770|NCT07046403|DEVICE|High Purity Type-I Collagen-based Skin Substitute and SOC|The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
214691771|NCT07046403|DEVICE|Dehydrated Human Amnion / Chorion Membrane and SOC|The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
214691772|NCT07046793|DIAGNOSTIC_TEST|POCUS|Ultrasound screening of the distal forearm.
214691773|NCT04105556|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
214691774|NCT04604106|DIAGNOSTIC_TEST|Eyetracker|Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
214691775|NCT04604106|DIAGNOSTIC_TEST|Ages & Stages questionnaire|The Ages \& Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.
214691776|NCT04604106|DIAGNOSTIC_TEST|Bayley Scale of Infant Development|The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
214691777|NCT06765707|BEHAVIORAL|Pharmacist delivered symptom monitoring and management|Patients in the intervention phase will receive PRO-based symptom monitoring once a month and pharmacist-led management for problematic symptoms based on routine clinical care recommendations.
214691778|NCT06894017|DRUG|Ozurdex (dexamethasone)|Intravitreal dexamethasone implant (Ozurdex) given according to the recommendations by the manufacturer.
214691779|NCT07063589|OTHER|Mobile application|Cannabis use patterns and their resulting subjective experiences, along with social and health-related correlates will be collected in real time using a mobile application specifically designed for this study by a local custom software development company (Osedea, Montreal).
214691780|NCT07082569|OTHER|Volume Control Ventilation|Standard mode of mechanical ventilation delivering a preset tidal volume. Commonly used in ICU patients requiring controlled ventilation.
214691781|NCT07082569|OTHER|Pressure Control Ventilation|Pressure-targeted ventilation mode that delivers breaths at a fixed pressure. Commonly used in critically ill patients.
215103985|NCT05407779|BIOLOGICAL|BCD-180, dose 7|anti-TRBV9 monoclonal antibody, single infusion at dose 7
215103986|NCT02872272|DRUG|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
215103987|NCT06330337|DRUG|Temozolomide（TMZ） injection or oral administration|Oral administration of TMZ150-200mg/m2/ day, continuous use for 5 days, discontinued for 23 days, for a treatment cycle, a total of 6 cycles.
214423933|NCT06568536|OTHER|Repeated behavioral assessments, functional electroencephalography and brain imagery, TMS-EEG|The presence of consciousness will be classified considering the highest level of consciousness revealed by repeated behavioral examinations, functional electroencephalography (task-based EEG), and functional brain imagery (task-based fMRI). Based on the results of this composite standard reference, we will evaluate the diagnostic and prognostic accuracy of TMS-EEG measurements of brain complexity
214423934|NCT05502900|DRUG|Melatonin|White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
214423935|NCT05837806|DRUG|tislelizumab+disitamab-vedotin|Patients enrolled will receive 3 cycles of tislelizumab 200 mg in combination with disitamab-vedotin (RC48) 2.0mg/kg intravenously.
214423936|NCT06622083|OTHER|Education|Students in both groups will be given 40 minutes of both theoretical and practical training on the anatomy of the pelvic floor, its contraction mechanism, function and dysfunctions, evaluation and physiotherapy and rehabilitation. Theoretical training will be given through presentation and question-answer techniques containing this information, and practical training will be given through a pelvic model and gynecological examination simulator.
214691782|NCT07082569|OTHER|Pressure-Regulated Volume Control (PRVC)|Hybrid ventilation mode that automatically adjusts inspiratory pressure to achieve a preset tidal volume.
214691783|NCT07082504|BEHAVIORAL|Physical Exercise Program|Participants will complete supervised moderate-intensity physical exercise sessions three times per week for 12 weeks (totaling 150 minutes per week). The program includes balance, flexibility, strength, and mobility exercises designed according to WHO and ACSM guidelines for older adults. Sessions are delivered in small groups by trained physiotherapists.
214691784|NCT07082504|BEHAVIORAL|Cognitive Stimulation Program|Participants will attend cognitive stimulation sessions three times per week for 12 weeks. Activities include memory games, attention tasks, puzzles, orientation exercises, and problem-solving strategies. The sessions are led by a psychologist and a trained social educator, in small groups.
214694227|NCT02406547|DEVICE|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
214694228|NCT01672996|DRUG|Ioforminol 160 mgI/mL|Given as s single administration to the subject
214694229|NCT01672996|DRUG|Ioforminol 200 mgI/mL|Given as a single administration to the subject
215103988|NCT06330337|DRUG|Albumin-Bound Paclitaxel(ABX) intravenous drip|ABX was administered intravenously at a dose of 110mg/m2 on days 1 and 8 of a 28-day treatment cycle
215026579|NCT07010536|BEHAVIORAL|VR-Based Music Therapy|"VR-Based Music Therapy Protocol:~Participants undergo immersive VR sessions twice weekly for 6 weeks, each lasting 30 minutes, supervised by a physiotherapist. Each session includes three 10-minute activities with 2-minute breaks:~Rhythm Exercises: Participants follow tempo by clapping on a table while watching Brooklyn Music Factory YouTube videos played within the VR headset (levels 1-4), progressing weekly.~Ocean Rift: Exploration of calming underwater environments with marine life to enhance relaxation, attention, and cognition.~PianoVision: Virtual piano exercises using hand tracking with the unaffected hand; difficulty increases from levels 0 to 4."
215026580|NCT07010536|BEHAVIORAL|Conventional Physiotherapy and Rehabilitation|"Participants will receive conventional physiotherapy and rehabilitation exercises as follows:~Upper and lower extremity strengthening exercises~Resistance training exercises~Aerobic exercises~Basic and assisted parallel bar walking~Skill courses on various surfaces~Training on stable and unstable surfaces~Static and dynamic balance exercises~Fine motor skill exercises~Weight transfer exercises to improve postural stability~Exercises will be performed according to the patient's condition in standing, sitting, four-point kneeling, supine, and prone positions.~Exercise difficulty will be adjusted based on the patient's performance and functional level.~Sessions will be 60 minutes long, 5 days per week, for 6 weeks."
215026581|NCT06088563|OTHER|Vaccine injection|Injection of the vaccine in renal transplant patients.
215026582|NCT06685016|DIAGNOSTIC_TEST|Evaluation of Dentin hypersensitivity with VAS scale|Dentin hypersensitivity and periodontal indices evaluation are performed after and before IPR, at 1 week, 1 month and 3 months
214423937|NCT06622083|OTHER|Education and Aerobic exercise|Participants in the exercise group will undergo an aerobic exercise program using the Monark 938E Nova Ergometer and software before the training session. The bike operates with its computer software integrated with the ECG system. The aerobic exercise program will consist of 3-5 minutes of warm-up, 20 minutes of exercise, and 3-5 minutes of cool-down, performed at a moderate intensity. During the exercise session, heart rate will be recorded every 5 minutes using a Polar ECG sensor connected via Bluetooth to the 938E Nova Ergometer, while perceived exertion will be measured using Borg's 6-20 rating scale
214423938|NCT05978037|BIOLOGICAL|RH5.1 and/or RH5.2-VLP with Matrix-M|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial."
214423939|NCT05390099|DRUG|Moringa oleifera leaf|Moringa toothpaste
214691785|NCT07082504|BEHAVIORAL|Combined Physical Exercise and Cognitive Stimulation|Participants will receive both the physical exercise and cognitive stimulation interventions, conducted in parallel, over a 12-week period with three sessions per week. The combined program aims to improve physical and cognitive functions simultaneously and is delivered by a multidisciplinary team.
214694230|NCT01672996|DRUG|Iopamidol 300 mgI/mL|Given as a single administration to the subject
214423940|NCT05767099|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
215026583|NCT06685380|OTHER|Not applicable- observational study|For observational studies, participants are not assigned an intervention as part of the study
214423941|NCT06960590|OTHER|Training - static streching|The intervention group performed one training session per week. Each training session consisted of 2 series of static stretching of the back band. The rest time between series was 45 s. The intervention lasted 6 weeks.
214423942|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
214423943|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
214423944|NCT06504368|DRUG|DCR-PDL1|Solution for IV Infusion
214423945|NCT00502372|DIETARY_SUPPLEMENT|Nutritional Supplement/Amino acids and HMB|Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
214423946|NCT00502372|DIETARY_SUPPLEMENT|Juven|comparison of Juven with arginine only product in wound healing
214423947|NCT04063826|DEVICE|PET MRI|All participants will have a liver scan
214423948|NCT00814346|DRUG|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
214423949|NCT00814346|DRUG|Placebo|Placebo 1 tablet BID
214423950|NCT04800016|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV and blue-light filtering extended depth of focus foldable IOL intended to provide a full range of vision from distance to functional near.
214423951|NCT04800016|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ Vivity Extended Vision IOL
214423952|NCT03382080|OTHER|Dream School Program|The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
214423953|NCT03382080|OTHER|Mental Health Support Team|"MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~1. Co-location of services and staff working in services~2. One open door to increase accessibility to the services and staff for students~3. Focus on the transition from lower to upper secondary school~4. Close follow-up of students at risk to ensure tailored help to each student~5. Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools."
214423954|NCT04551781|DRUG|20 Mg Prednisone for 14 days|20 Mg Prednisone for 14 days
214423955|NCT04551781|DRUG|control|symptomatic ttt
215026584|NCT07010679|OTHER|Patient Centered CRS Treatment Decision Support|"The intervention is a web-based tool that includes:~* Educational content and Frequently Asked Questions (FAQ) about CRS and treatment options~* Patient stories from CRS patient interviews with artificial intelligence-assisted narrative writing~* A communication tool to support discussions between patients and their doctors~* Culturally tailored components, including Chinese language options and culturally relevant narratives Participants will be introduced to the PC CDS during a routine clinic visit or through a scheduled virtual meeting. They will use the tool before making treatment decisions. The tool is designed to be user-friendly and accessible across devices."
215026585|NCT06687239|DIAGNOSTIC_TEST|Blinded estimation of fetal weight|Blinded ultrasound-based estimation of fetal weight
215026586|NCT06687239|DIAGNOSTIC_TEST|Non blinded estimation of fetal weight|Non-blinded ultrasound-based estimation of fetal weight
215026587|NCT06690723|DRUG|Dapagliflozin (Forxiga)|Dapagliflozin plus lifestyle modification
215026588|NCT06690723|DRUG|Vitamin D3 ( Colecalciferol)|Vitamin D3 plus lifestyle modification
215026589|NCT06690723|DRUG|Vitamin D3 plus Dapagliflozin|Vitamin D3 plus Dapagliflozin plus lifestyle modification
215026590|NCT06690723|BEHAVIORAL|Lifestyle modification|Lifestyle modification alone
215026591|NCT06689319|BEHAVIORAL|Assessment of Artificial Intelligence Literacy|The Artificial Intelligence Literacy Scale will be used to determine the level of AI literacy.. The scale is a 12-item instrument designed to measure individuals' knowledge and skills in AI awareness, usage, evaluation, and ethical considerations. Items are rated on a Likert scale from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree), with some items reverse-coded (items 2, 5, and 11). The minimum possible score on the scale is 12, and the maximum score is 84; a higher score indicates a higher level of AI literacy. The Turkish version of the scale will be used in this study.
215026592|NCT06686732|OTHER|Multimodal physiotherapy|Experimental group included cold pack over lateral epicondyle. Passive stretching exercises in trapezius and levator scapulae and upper ECRB,ECRL,ECU,Extensor Digitorum, Extensor Digiti Minimi. Eccentric exercise of the extensor muscles associated with mobilization with movement. Neuromusclar Rehabilitation Excersise. In the region of origin of the tendons of the extensor muscles of the wrist and fingers for 2 min and inhibition of points of tension in the belly of the extensor region. Early mobilization with movement with the wrist in extension. Lateral sustained glide will be give at humeroradial joint during movement.
215026593|NCT06686732|OTHER|Conventional physiotherapy|Control group included Cold pack for 10 mins on the lateral epicondylitis, Extensor carpi radialis brevis stretching (hold for 15 seconds x 4 reps) Active ROM of wrist flexion and extension (10 reps x 3 sets) Active ROM of elbow flexion, extension, supination and pronation (10 reps x 3 sets) . Manually resisting wrist extensors (10 second hold x 5 reps x 3 sets) 4 sets of Maitland elbow joint mobilization with 1 min of rest between sets. Baseline Dynamometer for grip strength and VAS for pain. These pre and post intervention values were mentioned in questionnaire. The participants were administered with the protocol and data was collected again immediately after the interventions without any delay.
215026594|NCT07011498|OTHER|Dementia choir|Music therapy informed dementia choirs will be delivered once a week. Rehearsals last app. 2 hours, including a social break. Each choir will be led by 1 conductor and 1 accompanist. The choir leaders will have relevant professional qualifications that supplement each other, such as a music therapist, music pedagogue, conductor, singer, singing teacher, or health care professional with additional music competence. They will be trained by the research team to deliver the choirs in a dementia friendly and music therapy informed way. In addition, the choir leaders will receive supervision from the research team throughout the intervention periods. The choirs will involve volunteers to assist during rehearsals and breaks. The volunteers will also receive training on how to support the choir participants in a dementia friendly way.
215026595|NCT06681727|OTHER|Accessible Video Mental Healthcare Triage and Assessment (IP)|Patients aged 18 years and older who were registered at participating primary care centers were eligible to access the IP through a regional healthcare app. IP comprised a brief digital screening followed by a 45-minute video consultation with a mental health professional. Eligible patients could thereafter schedule appointments at cooperating healthcare centers and clinics through the app used for video consultations.
215026596|NCT05612750|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.
215026597|NCT05612750|BEHAVIORAL|Empowered Relief|A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.
215026598|NCT05965479|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
215026599|NCT05520736|BEHAVIORAL|Appointment reminders, motivational interviewing and targeted vaccine drives|Automated and real time phone call reminders, motivational interviewing and targeted vaccine drives applied in sequence
215026600|NCT06695143|DRUG|Fusidic Acid|Fusidic acid 2% cream
215026601|NCT06695143|OTHER|Vehicle cream|Cetomacrogol cream
214508761|NCT03020433|DEVICE|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
214508762|NCT03020433|DEVICE|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
214508763|NCT03020433|DEVICE|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
214508764|NCT00412178|DEVICE|telecommunication based glucose monitoring system|
214508765|NCT01501721|BEHAVIORAL|Exercise|Home-based exercise program
214508766|NCT01501721|BEHAVIORAL|Diet|Nutritional counseling aiming to reduce suggar intake
214508767|NCT01854866|OTHER|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
214508768|NCT05856409|DIAGNOSTIC_TEST|68Ga-FAPI|\[68Ga\]-FAPI is tumor imaging agent for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF)
214508769|NCT02322645|DRUG|Eszopiclone Tablets 3 mg|
214508770|NCT02449902|DRUG|Estradiol|1 10 µg capsule inserted vaginally for 14 days.
215026602|NCT06695715|BEHAVIORAL|Mindfulness Training Program|This mindfulness training program is based on the Mindfulness-Based Stress Reduction (MBSR) model developed by Jon Kabat-Zinn, incorporating elements of self-compassion and acceptance. What sets this program apart is its integration of both formal and informal practices. Participants engage in 45-minute guided sessions focused on breath awareness and the observation of thoughts, emotions, and physical sensations. Additionally, informal practices include brief daily moments of present-moment awareness. Participants will also receive 10 audio recordings for at-home practice, enhancing the program's accessibility and supporting consistency.
215026603|NCT06695715|BEHAVIORAL|HRV Biofeedback|This HRV biofeedback training program is distinguished by its combination of advanced technology and a novel at-home methodology. Participants will engage in five weekly sessions, with four conducted at home using a heart rate sensor and the EliteHRV mobile app, which provides real-time feedback on heart rate variability. One session per week will take place in the lab, utilizing the Procomp Infiniti biofeedback system. The at-home approach is based on recent research (Schumann et al., 2021), offering participants a flexible yet structured method to practice biofeedback and improve heart rate variability over the six-week program.
215026604|NCT06695715|BEHAVIORAL|Interoception Training|The interoception training program stands out by its focus on developing internal body awareness through structured guided sessions. Participants will engage in weekly 45-minute formal sessions at the university, where they will learn to focus on internal sensations like breath and muscle tension using specific techniques. Additionally, participants will receive 10 guided interoceptive exercises to practice at home, four times a week. This program not only focuses on the physical sensations but also integrates these practices into daily life, aiming to improve self-care and self-regulation over the six weeks, with personalized feedback provided.
215026605|NCT06694207|DRUG|Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl|Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients
215026606|NCT06695091|PROCEDURE|Monolithic zirconia crown|All-ceramic crown
215026607|NCT06695091|PROCEDURE|Monolithic lithium disilicate crown|All-ceramic crown
215026608|NCT06695039|DIAGNOSTIC_TEST|Fluoroestradiol (18F)|images for 90 minutes after F-18 FES injection
215026609|NCT06694220|OTHER|Tailored preventive exercises|Players in the experimental group will be asked to perform the tailored preventive program 2-3 times per week for 1 hour for at least 6 weeks preseason which includes warming up for 10 mins, flexibility exercises, strengthening exercises, core and lower body stability and balance exercises and drills all these exercises for 1-4 sets x 10-20 reps and cooling down stretches for the last 10 mins.
215026610|NCT06694220|OTHER|Traditional exercises|The players will be warmed up as usual, with jogging and ball-based exercises following FIFA 11+ warming up program which consist of three steps with 15 specific exercises running exercises for 8 mins, starting warming up in pairs; Path consists of 6-10 pairs of parallel cones: (Running Straight Ahead, Running Hip Out, Running Hip In, Running Circling Partner, Running Shoulder Contact, Running Quick Forwards and Backwards, Rep. x2). Strength, plyometric, balance for 10 minutes (The Bench, Sideways Bench, Single-leg Stance, Squats, Jumping Rep. 2x 30 sec each side). Running Exercises for 2 minutes (End of heating): (running across the pitch, running bounding, running plant, and cut. Rep x 2). Techniques need to be performed correctly and with an emphasis on maintaining the correct posture of the body. This exercise program should be done at least twice a week
215026611|NCT06689254|DRUG|Mifepristone 1200 mg daily|Oral tablets
215026612|NCT06689254|DRUG|Placebo|Oral tablet
214423956|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"Establishing optimal temperature and pressure for limb cryocompression therapy. Healthy subjects will undergo 3 hours of limb cryocompression.~The cryocompression device used in this study consists of a control unit, and limb wraps. The control unit contains the coolant reservoir and pump to circulate the coolant and air for compression. It is able to thermoregulate (control the temperature of the circulating coolant) and offer cyclic air pressure in the wraps. The wraps cover the limbs from the elbow/knee to the fingers/toes."
214423957|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Limb cryocompression sessions comprised of a pre-cooling period (up to one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, limb cryocompression will be administered for no longer than four hours."
214423958|NCT01443117|BIOLOGICAL|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
214423959|NCT01443117|BIOLOGICAL|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
214423960|NCT01443117|BIOLOGICAL|Placebo Vaccine|Administered as a 0.5 mL IM dose
214423961|NCT03419156|OTHER|Text Message Arm Intervention|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
214423962|NCT04143126|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
214423963|NCT04143126|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
214423964|NCT02513238|DRUG|Mesenchymal stem cell|Stemcells injected into submandibularis
214423965|NCT02513238|DRUG|Isotonic NaCl|
214508771|NCT02449902|DRUG|placebo|1 placebo capsule inserted vaginally for 14 days.
215103989|NCT06330337|DEVICE|Specific mode electroacupuncture stimulation(SMES) intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off).The 28-day treatment cycle was followed by simultaneous intervention with ABX on days 1 and 8."
215026613|NCT06688643|DEVICE|ITM group|Patients in the ITM group underwent intrathecal injection with 0.2 mg morphine after admission to the operating room.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.
215026614|NCT06688643|DEVICE|EA group|Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.
215103990|NCT03167528|BEHAVIORAL|Relaxation|Relaxation
215103991|NCT03167528|BEHAVIORAL|Hypnosis|Hypnosis
215103992|NCT03167528|BEHAVIORAL|Holistic gymnastics|holistic gymnastics
215103993|NCT03167528|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS
215026615|NCT06690684|BIOLOGICAL|Hematological indicators|This project is a retrospective clinical cohort study. STEMI patients undergoing PCI were selected to explore whether hematological indicators such as PIV, SHR, and Lp(a) can improve the accuracy of predicting short-term MACE events in STEMI patients.
215103994|NCT03167528|BEHAVIORAL|Sophrology|Sophrology
215103995|NCT03147989|DRUG|MultiHance|gadolinium contrast agent
214508772|NCT04515550|DIAGNOSTIC_TEST|lumbar puncture|Some participants will have an optional lumbar puncture
214508773|NCT02362789|BIOLOGICAL|Secukinumab|150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
214508774|NCT02362789|BIOLOGICAL|Placebo|Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
214508775|NCT03033056|BEHAVIORAL|Test of fear conditioning|Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
214508776|NCT03326856|BIOLOGICAL|botulinum toxin, Type A|topical liniment
214508777|NCT03326856|BIOLOGICAL|Vehicle|Vehicle Formulation
214508778|NCT03655704|DRUG|Apabetalone|A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.
214508779|NCT06311266|DEVICE|Robotic endoscopic neurosurgical intervention|Robotic guidance device for intraoperative trajectory alignment in endoscopic neurosurgical procedures
214508780|NCT00004831|DRUG|cysteine hydrochloride|
214508781|NCT04580433|BEHAVIORAL|Time-Restricted Feeding|"The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day."
214508782|NCT02136641|DRUG|Midazolam|Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
214508783|NCT02136641|DRUG|Midazolam+Fentanyl Combination|Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
215026616|NCT06690684|BIOLOGICAL|Serological indicators in patients with myocardial infarction|This study selected STEMI patients who underwent PCI and collected their hematological indicators to explore the value of PIV, SHR, Lp(a) and other indicators in improving the accuracy of predicting MACE in STEMI patients in the short term.
215026617|NCT06690684|BIOLOGICAL|Levels of biomarkers in blood of patients with acute myocardial infarction|Hemoglobin, neutrophil count, lymphocyte count, monocyte count and platelet count values, N-terminal pro-B type natriuretic peptide (NT-proBNP), peak creatine kinase isoenzymes (CK-MB), peak troponin T levels, total cholesterol (TC), fasting blood glucose (FBG), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and blood urine nitrogen, blood creatinine (Cr) and other indicators
215026618|NCT06691646|BEHAVIORAL|Gaze-control training game|An eyetracker-controlled computer game designed to improve attentional control by training inhibitory control over direction of gaze. It includes six mini-games, each designed to train different aspects of oculomotor control, including selective attention, motor inhibition, motor timing, and spatial working memory.
215026619|NCT06688149|DIAGNOSTIC_TEST|Derivation algorithms|Derivation algorithm based on non-invasive methods, to standardise the continuum of care for diabetic patients with NAFLD from primary care and endocrinology settings to NAFLD specialised units (NSU)
215103996|NCT02301624|BIOLOGICAL|Eculizumab|Intravenous administration of eculizumab.
215103997|NCT02301624|DRUG|Placebo|Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
215103998|NCT04790071|OTHER|Conventional physical therapy|Conventional physical therapy: The patients received physical therapy to the shoulder, transcutaneous electrical nerve stimulation, and stretching and strengthening exercises (5 days per week for three weeks in a total of 15 sessions).
215103999|NCT04790071|OTHER|Conventional physical therapy plus dry needling|Conventional physical therapy plus dry needling: The patients received physical therapy to the shoulder, including transcutaneous electrical nerve stimulation, stretching, and strengthening exercise (5 days per week for three weeks in a total of 15 sessions). And also, a total of 3 dry needling sessions were applied at 7-day intervals.
215026620|NCT06686199|DIETARY_SUPPLEMENT|steamed potato|135 g per day 4-5 times per week for 8 weeks
215104000|NCT05420649|PROCEDURE|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow (HFNO).
215104001|NCT00895310|DRUG|Ketoconazole|Ketoconazole is taken three times a day by mouth.
215104002|NCT00895310|DRUG|Hydrocortisone|Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
215104003|NCT02772627|DRUG|Nebicapone|Nebicapone 100 mg tablets; oral route.
215104004|NCT02772627|DRUG|Placebo|Placebo tablets; oral route.
215104005|NCT00654459|DIETARY_SUPPLEMENT|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
215026621|NCT06686199|DIETARY_SUPPLEMENT|fried potato|135 g per day 4-5 times per week for 8 weeks
215026622|NCT06689020|PROCEDURE|Continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP) therapy|During application of CPEP and CHFO, EIT is monitored.
215026623|NCT06688526|OTHER|Quiet Sounds|Quiet sounds are played during sleep
215026624|NCT06688526|OTHER|Sham sounds|No sounds are played during sleep
215026625|NCT06689930|OTHER|PDSA Cycles|Conduct PDSA cycle and follow-up interviews and surveys for patients (5 per cycle, 10 total) and CBO staff (no less than 2)
215026626|NCT06690541|DRUG|Lorlatinib 100 mg|Patients received continuous daily PO dosing of lorlatinib 100mg QD from the date of first dosing (per the current protocol) or until one of the following criteria were met (whichever occurred first): disease progression; initiation of a new anticancer therapy; unacceptable toxicities; global deterioration of health-related symptoms; pregnancy; withdrawal of consent; loss to follow-up; death; investigator decision dictated by protocol non-compliance; or study termination.
215026627|NCT06694740|DRUG|Interferon Gamma 1-b|interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
215026628|NCT06694740|DRUG|Placebo|Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
215026629|NCT06690073|OTHER|Motor Relearning Program|"Total duration of the intervention is 45 minutes per session (30 minutes of CPT treatment followed by 15 minutes MRP), three sessions per week.~MRP of sitting and standing activities: The physical therapist will instruct the participant, who will be seated in an armrest-equipped chair, to keep their feet back and position their trunk forward.. The participant will then be guided to press down through the affected foot, stand up quickly, and move their hips forward. The therapist will suggest pressing down through the participant's knee along the leg while moving it forward through the affected foot.~MRP of standing to sitting: The participant will stand while the physiotherapist assists with anterior shoulder movement and knee bending at the start of the transition. The therapist will then help maintain weight on the affected leg while sitting. The participant will progress by standing and sitting at different seat heights, stopping at various points in the ROM, and changing speed."
215026630|NCT06690073|OTHER|Conventional Physical Therapy|Conventional Physical Therapy (CPT) will be administered to the control group three times per week for six weeks (45 minutes per session). CPT treatments such as mat activities, assisted movements, weight-bearing strategies, and gymnasium training will be given to the control group.
215026631|NCT06695871|OTHER|Patient navigation-based health management|A patient navigation-based health management model for individuals with cervical lesions post-LEEP procedure, encompassing healthcare consultation services, personalized health guidance, and routine follow-up assessments.
215026632|NCT06689332|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is performed by a geriatrician and a geriatric nurse. CGA in this study includes: Assessment of coexisting diseases and treatments. Review of medications and adjustments as needed. Assessment of symptoms and health related issues including screening for depression, dementia, delirium, nutritional problems, falls, polypharmacy and fatigue. Objective examination including blood tests and electrocardiogram. Assessment of activities of daily living and instrumental activities of daily living through standardized questionnaires. Assessment of domestic conditions, including need for assistance from community-based health care services. Assessment of physical function through history and physical tests. Based on the CGA findings, the geriatrician will initiate relevant interventions (including investigations or treatments) and follow-up as required.
215026633|NCT06689787|OTHER|Self-Guided STAIR Coach with Real-Time Assessment|Two mobile apps to be used as one intervention package to support participants in their progress through STAIR (Skills Training in Affective and Interpersonal Regulation) with self-monitoring of symptoms and functioning
215104006|NCT03956524|BIOLOGICAL|EuTCV|Single 0.5 mL dose of TCV of EuBiologics co., Ltd.
215104007|NCT03956524|BIOLOGICAL|Typbar-TCV™|Single 0.5 mL dose of TCV of Bharat Biotech
215104008|NCT03956524|BIOLOGICAL|Typhim Vi®|Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur
215104009|NCT03109184|BEHAVIORAL|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
215104010|NCT03208634|DEVICE|Robotic intervention|One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
215104011|NCT05897606|COMBINATION_PRODUCT|Multiviamins and minerals|The intervention group received one capsule of multivitamin and minerals supplements every day, one hour after breakfast, for 12 weeks.
215104012|NCT05897606|COMBINATION_PRODUCT|Placebo|Placebo
215104013|NCT00561288|DRUG|acetaminophen|2 x 1000 mg doses per day
215104014|NCT00561288|OTHER|cornstarch|2 x 1000 mg cornstarch per day
215104015|NCT02106871|DRUG|Sildenafil|50mg of Sildenafil daily for 4 weeks
215104016|NCT00602420|DRUG|naproxen|Oral naproxen twice daily for 5-8 days.
215104017|NCT00602420|OTHER|placebo|Oral placebo twice daily for 5-8 days.
215104018|NCT04781686|DRUG|Camrelizumab|Camrelizumab (200mg) will be given i.v. on day 1 of each 3-week cycle
215104019|NCT04781686|DRUG|Apatinib Mesylate|Apatinib (250mg) will be administered orally once a day .
215104020|NCT04781686|DRUG|S1|S1 (BSA\<1.25 40mg, BSA \>=1.25-\<1.5 50mg, BSA \>=1.5 60mg) will be administered orally twice daily on days 1-7 of each 3-week cycle
215026634|NCT06689787|OTHER|Real-Time Assessment|One mobile app to support participants in self-monitoring of symptoms and functioning
215026635|NCT06686290|OTHER|Post-Isometric Relaxation Technique|Post isometric relaxation will be performed with the frequency of 5 times, such that it includes 30 isometric contraction of the muscle to be stretched for 10 seconds, followed by rest period of 5 seconds and then a stretch of 10 seconds hold.
215026636|NCT06686290|OTHER|Static Stretching|Static Stretching
215026637|NCT06695273|DIAGNOSTIC_TEST|AI-derived probability of coronary heart disease.|Physician readers will be assisted with AI-derived probability of coronary heart disease. The AI tool provides individualized obstructive CHD probabilities and diagnosis, leveraging retinal biomarkers associated with cardiovascular risk.
215026638|NCT06695273|DIAGNOSTIC_TEST|PCEs derived ASCVD risk|Physicians use a PCEs to calculate the probability of 10 year ASCVD risk. This approach aligns with current clinical guidelines to assist in decision-making.
215026639|NCT06695884|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized. Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
215104021|NCT04781686|DRUG|Docetaxel injection|Docetaxel (75mg/m2 IV.drop) will be administered on day 1 of each 3-week cycle, for six cycles.
215104022|NCT01926990|DEVICE|perfusion computed tomography|Undergo perfusion CT
215104023|NCT04803149|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
215104024|NCT04803149|DEVICE|Conventional Radiofrequency|Delivery of energy to ablate sensory nerves via standard or conventional radiofrequency probe
215104025|NCT00657982|DRUG|RAD001|10mg BID
215104026|NCT02842164|OTHER|Tension group|
214423966|NCT05599256|DRUG|Ruxolitinib|"Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens."
214423967|NCT05136443|DRUG|loteprednol etabonate 0.25% ophthalmic suspension|tapering dose
214423968|NCT03097744|DEVICE|Ceterix NovoStitch|The device allows the physician to place a circumferential compression stitch around meniscal tears. This stitch is placed by passing suture from the tibial side to the femoral side of the meniscus and across the tear. This allows compression across the entire tear surface.
214423969|NCT01486550|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
214423970|NCT01486550|DRUG|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
214423971|NCT04181255|DRUG|Curosurf|This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
214423972|NCT04181255|DRUG|Sham|This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
214423973|NCT06000748|DRUG|MAP-Target Algorithm|This is a clinical treatment algorithm that will determine the escalation and deescalation of vasoconstrictor utilization based on a target MAP, either high (≥80 mmHg) in the treatment group and low (\< 80 mmHg) in the comparator group.
214423974|NCT00910754|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
214423975|NCT00910754|DRUG|Prednisone|Prednisone 5 mg tablets administered orally twice daily.
214423976|NCT01806454|DRUG|calcium|
214423977|NCT03007836|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
214423978|NCT04559555|DRUG|Nilotinib|The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
214423979|NCT01203618|DRUG|Farletuzumab|Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
214423980|NCT06155071|OTHER|Plyometric Training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
214423981|NCT06155071|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
214423982|NCT02613871|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
214423983|NCT06555653|OTHER|Video based multimedia information|The intervention group was shown a 5 minute informational video before amniocentesis including definition of amniocentesis, its indications, the setup of amniocentesis room, the purpose and steps of the procedure, potential complications and how to manage them
214423984|NCT03794193|PROCEDURE|Radical resection of colon cancer|The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.
214423985|NCT02783755|BEHAVIORAL|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
215026640|NCT06688019|DEVICE|conventional oxygenation (nasal cannula)|conventional oxygenation arm will receive oxygen at 2 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
215104027|NCT02842164|OTHER|No tension group|
215104028|NCT02842164|OTHER|Foley catheter Balloon|
215104029|NCT06206993|BEHAVIORAL|Resistance training including the Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Experimental group will additionally train with Kieser A5 pelvic floor trainer.
215104030|NCT06206993|BEHAVIORAL|Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Active Comparator trains without the pelvic floor biofeedback device A5 and undergo conventional pelvic floor muscle training with a physiotherapist once a week before the resistance training unit starts.
215026641|NCT06688019|DEVICE|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|conventional oxygenation arm will receive oxygen at 2 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
215026642|NCT06687109|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
214691786|NCT07083102|OTHER|Experimental|"* Eligible participants will be randomly assigned to one of the following groups using a computer-generated sequence with allocation concealment via sealed opaque envelopes:~  * Group A: Control group~ * Group B: Full-coverage PFM crowns~ * Group C: Full-coverage Zirconia crowns~* Baseline gingival samples will be collected with the help of sterile swab from the target tooth region prior to prosthesis placement and at the follow-up visits i.e. 1, and 3 months; both for experimental groups and control group.~* Microbial analysis will be conducted through culture techniques to quantify CFUs and identify species.~* Alongside, the same sample from sterile swabs will be smeared by fixating it on a microscopic slide and then Candida albicans will be stained by Periodic Acid Schiff technique, and the bacterial species using Gram staining."
215104031|NCT01178268|DEVICE|XIENCE V EECSS|Patients who will receive this stent.
215104032|NCT01178268|DEVICE|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
215104033|NCT04017091|DIAGNOSTIC_TEST|Virtual Reality Cognitive Training|Bimodal VR-Stroop (ClinicaVR: Apartment Stroop) Patient find themselves seated with a virtual apartment, where they see a living room, in front of a flat-screen TV set, a kitchen and a window. This intervention consisted of two Stroop conditions across all 8 sessions. In Condition 1 (Inhibition), Patients indicated when the color named (audio stimulus) matched the color shown (visual stimulus). Participants were to withhold their response in mismatched trials. In Condition 2 (Interference), Participants clicked the mouse when the color heard was the same as the ink color; not the word printed.
215104034|NCT02729441|DRUG|ramipril|Comparison of two renin angiotensin aldosterone inhibitors
215104035|NCT02729441|DRUG|perindopril|Comparison of two renin angiotensin aldosterone inhibitors
215104036|NCT00592124|DRUG|Tenofovir disoproxil fumarate|300 mg tablet daily
215104037|NCT00592124|DRUG|Tenofovir gel|1 gm/100 ml of 1% gel vaginally daily
215104038|NCT00703924|DRUG|WR 279,396|A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
215104039|NCT00703924|DRUG|Placebo|Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
215104040|NCT05856981|DRUG|ADU-1805|anti-SIRPα monoclonal antibody
215104041|NCT05856981|DRUG|Pembrolizumab|Keytruda
215104042|NCT00002868|BIOLOGICAL|filgrastim|
215104043|NCT00002868|BIOLOGICAL|recombinant interferon alfa|
214691787|NCT07083596|OTHER|Experimental: Probiotic with LcS|Probiotic drink with LcS will be consumed once per day for four weeks
214691788|NCT07083596|OTHER|Control|Brochure containing recommendations to improve constipation will be provided at end of study.
215026643|NCT06687109|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty
215104044|NCT00002868|DRUG|busulfan|
215104045|NCT00002868|DRUG|cytarabine|
215104046|NCT00002868|DRUG|etoposide|
215104047|NCT00002868|DRUG|hydroxyurea|
215104048|NCT00002868|DRUG|idarubicin|
215104049|NCT00002868|PROCEDURE|peripheral blood stem cell transplantation|
215104050|NCT01131910|BIOLOGICAL|TBE-vaccine|Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
215104051|NCT01131910|BIOLOGICAL|TBE-vaccine|Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
215104052|NCT01131910|BIOLOGICAL|Vaccination against TBE|0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
215104053|NCT00323648|DRUG|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
215104054|NCT01606969|DRUG|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
215104055|NCT01606969|DRUG|scalp infiltration solution|1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
215104056|NCT05314465|OTHER|Median nerve mobilization|Median nerve mobilization was given 20 oscillations per minute for 3 times \& repeated 3 times with a pause of 1 minute between each sets for 5times/week for 4weeks.
214691789|NCT07083986|PROCEDURE|Carotid Artery Stent Placement|Carotid Artery Stent Placement was performed according to the standard technique.
214691790|NCT07083986|PROCEDURE|carotid endarterectomy|Carotid endarterectomy with stenting was performed according to the standard technique. For the purpose of the greatest comparability in the volume of anesthesia, it was decided to use regional anesthesia in all cases, including adequate dynamic observation of neurological status.
214691791|NCT07084649|DEVICE|TMS|accelerated intermittent theta burst stimulation
214691792|NCT07083778|PROCEDURE|Laser Fistula Surgery (FiLaC - Fistula-tract Laser Closure)|A minimally invasive procedure using a radial fiber diode laser probe to ablate the fistula tract. Laser energy (10W in pulsed mode) is applied circumferentially as the probe is slowly withdrawn, leading to shrinkage and closure of the fistula tract. The internal opening is closed with absorbable sutures. The procedure is done under spinal or general anesthesia.
215026644|NCT04912531|DEVICE|Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG|The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.
215104057|NCT00253123|DRUG|risperidone|
215104058|NCT03712683|DRUG|Thyroxine|Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed
215104059|NCT06344429|DEVICE|Stellest Lenses|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~A Group：Stellest Lenses spectacle (ST)"
215026645|NCT04912531|DEVICE|Essence Olfactory Necklace|The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, \>97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.
215026646|NCT04912531|DEVICE|Bedside Olfaction Device|The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
215026647|NCT06688318|BIOLOGICAL|Intra-articular secretome injection therapy|Intra-articular secretome injection therapy from hypoxic umbilical cord mesenchymal stem cell conditioned media
215026648|NCT05943990|DRUG|GSK3845097|GSK3845097 was administered.
215026649|NCT05943990|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
215026650|NCT05943990|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
215026651|NCT03407833|OTHER|Endoscopy biopsy|Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.
215026652|NCT03407833|OTHER|Surgical biopsy|Biopsy of the liver is standard of care for diagnosing NAFLD. Biopsy of omentum, skeletal muscle and subcutaneous adipose (the latter two tissues taken at the site of trocar placement) will be collected intraoperatively at the time of Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
215026653|NCT03407833|OTHER|Mixed-meal tolerance test|The mixed meal tolerance test (MMTT) shows how much insulin your body is making after drinking a liquid meal beverage that contains fats, protein and carbohydrates (sugar). Glucose, C-peptide, free fatty acids, triglycerides, incretins, pancreatic polypertide, bile aceis, and fatty acid amides can also be measured. A total of 9 tablespoons of blood is taken over a 255 minute period.
215026654|NCT03407833|OTHER|Excised Liver Tissue Sampling|Tissue will be collected from the excised liver for research after the diseased liver has been removed as part of the standard of care procedure.
215026655|NCT06470919|OTHER|SMS reminders for upcoming vaccination(s)|All parents/caregivers of children in participating villages will receive access to a digital vaccine card. This will be used for record-keeping application (digital vaccine registry). Selected parents/caregivers of children will receive SMS messages and reminders related to vaccination.
214694231|NCT03880240|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
215026656|NCT05972681|DRUG|Bupivacaine|10 milliliters (ml) of bupivacaine 0.50% injected to the vaginal laceration site.
215026657|NCT05972681|DRUG|Epinephrine|Epinephrine (1:200,000) injected to the vaginal laceration site.
215026658|NCT05972681|OTHER|Sham normal saline arm|10 milliliter (ml) of normal saline injected to the vaginal laceration site.
215026659|NCT02657356|DRUG|Placebo capsules|
215026660|NCT02657356|DRUG|Bardoxolone methyl capsules|
215026661|NCT06018519|OTHER|Clinical endpoints|"1. Number of epileptic seizures~2. Change in antiepileptic treatment (increase or decrease)~3. Visual analogical scale on a target symptom defined with the parents,~4. CGI,~5. Actimetry data over 24 hours,~6. Podometry data over 24 hours,~7. 6 minutes' walk test,~8. Clinical examination~9. Feasibility of performing an MRI without any anesthesia on a mock scanner"
215026662|NCT06018519|OTHER|Parental questionnaires|"10- Adaptive assessment with Vineland Adaptive Behavior scale II,~11- Mac Arthur questionnaire regarding language,~12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),~13- Dunn sensory profile,~14- Aberrant Behavior Checklist,~15- Nisonger Child Behavior Rating form,~16- Social Responsiveness Scale 2,~17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)"
215026663|NCT06018519|OTHER|Quality of life scale|18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
215026664|NCT06018519|OTHER|Cognitive assessments|"19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible~20- CPM-BF~21- Simple reasoning task on tablet (match-to-sample task)~22- Implicit rules learning (modified Brixton),~23- 4 sub-tests from the WPPSI-IV (zoo location to assess spatial memory, block design to assess visuo-constructive abilities, bug search , cancellation),~24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),~25- Elementary visuo-spatial perception (on tablets)"
215026665|NCT06018519|OTHER|Language assessments|"26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),~27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),~28- Automatic language analysis (during a 10 minutes interaction, play)."
215104060|NCT06344429|COMBINATION_PRODUCT|Stellest Lenses+0.05% atropine|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~B Group：Combined Treatment"
214423986|NCT03954015|DIAGNOSTIC_TEST|Contrast Enhanced imaging|Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.
215026666|NCT06018519|OTHER|Motor assessments|"29- Kinematic task (specifically designed),~30- Purdue-Pegboard test,~31- Renzi test"
215104061|NCT06344429|DRUG|Single vision Lenses+0.05% atropine|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~C Group：0.05% Atropine with single vision"
215104062|NCT03077919|DRUG|Ropivacaine|0.5% ropivacaine
214691793|NCT07083778|PROCEDURE|Open Fistula Surgery (Fistulotomy, Fistulectomy, or LIFT Procedure)|"Patients in this group will undergo standard open surgical treatment for fistula-in-ano. Based on the type and location of the fistula (intersphincteric or transsphincteric), the surgical procedure may be:~* Fistulotomy: Laying open the fistula tract.~* Fistulectomy: Excision of the entire fistulous tract.~* LIFT Procedure: Ligation of the intersphincteric fistula tract, preserving the sphincter complex. This sphincter-sparing technique is chosen for transsphincteric fistulas when appropriate.~All procedures are performed under spinal anesthesia. The choice of technique is individualized based on MR fistulogram findings and intraoperative assessment. Wounds are managed with regular dressings and allowed to heal by secondary intention. Standard postoperative care includes antibiotics, analgesia, and sitz baths. Follow-up is done at 1 week, 1 month, 3 months, and 6 months."
215104063|NCT03077919|DRUG|Sham treatment|preservative-free normal saline
215104064|NCT05737251|BEHAVIORAL|PoET|PoET consists of two online-sessions, each 3.5 hours within groups of 30 people. The following lessons regarding positive psychology constructs were conducted (including short information on each construct and specific exercises): happiness, hope, humour, optimism, gratitude, self-efficacy, flow, meaningfulness, forgiveness, spirituality and resilience.
215104065|NCT04533321|DRUG|Afatinib|Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
215104066|NCT00934219|DRUG|Omega-3-Acid Ethyl Esters|LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
215104067|NCT05388617|DEVICE|Brera|The applicators will be placed in contact with the skin. The entire defined treatment area will then be treated by delivering energy to the skin. Temperature may be continuously monitored and recorded during treatment. Parameters may be adjusted throughout the treatment to increase subject comfort.
215104068|NCT01018485|DRUG|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
215104069|NCT01031979|DRUG|Yohimbine|alpha-2 adrenergic receptor antagonist
215104070|NCT01031979|DRUG|Placebo|Placebo
215104071|NCT02809339|OTHER|Questionnaires|
215104072|NCT03808012|OTHER|Braking performance in a brake simulator|Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
214691794|NCT06931041|DRUG|insulin lispro|1 UI/ml of insulin added to the autologous serum formulation.
215104073|NCT00301418|DRUG|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
215104074|NCT03592368|DEVICE|IBT|Interpretation bias training
215104075|NCT03831100|BEHAVIORAL|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
215104076|NCT03831100|BEHAVIORAL|Active Control|AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session (Table 5) is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
215104077|NCT04005599|DRUG|Remifentanil group|Venous general anesthesia with propofol and remifentanil.
214691795|NCT06931041|OTHER|Autologous serum|Autologous Serum
215104078|NCT04005599|DRUG|Magnesium sulfate group|Venous general anesthesia with propofol and magnesium sulfate
215104079|NCT03430934|COMBINATION_PRODUCT|NAVI mapping with Indocyanine green|Moh's tumor imaging with Indocyanine green
215104080|NCT00772265|BIOLOGICAL|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
214691796|NCT07084454|OTHER|GAIN-S Multidisciplinary Telehealth Intervention|This intervention delivers a comprehensive geriatric assessment (GA) via telehealth to older adults with cancer. Based on the GA results, a multidisciplinary team including oncologists, geriatricians, psychiatrists, psychologists, nutritionists, and certified fitness trainers provide personalized supportive care recommendations and consultations remotely. The goal is to improve physical function, reduce depressive symptoms, and enhance quality of life during cancer treatment.
215104081|NCT00772265|BIOLOGICAL|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
215104082|NCT04459377|DRUG|S-Ketamine|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
215104083|NCT04459377|DRUG|Sodium Chloride 0.9% Inj|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
215026667|NCT06018519|OTHER|Social assessments|"32- Eye-tracking analysis of social visual scenes and social preference index (movies),~33- theory of mind assessment,~34- ADOS scale (Autism Spectrum Disorder),~35- sensitivity to inequality,~36- pro-social behaviors (help of the psychologist)"
215026668|NCT06018519|OTHER|3T MRI|37- Structural, metabolic and functional data
215026669|NCT06018519|OTHER|Cardiac assessments|"38- ECG~39- Ultrasound"
215026670|NCT06018519|OTHER|Biological collection|"40- Blood sample~41- Urinary sample~42- Superficial skin biopsy"
215026671|NCT06095037|BEHAVIORAL|Mindful yoga|12 week mindful yoga intervention
215026672|NCT06095037|BEHAVIORAL|Psychoeducation|12 week psychoeducation sessions
215026673|NCT02965313|PROCEDURE|SSLS Procedure|Synthetic suture repair
215026674|NCT02965313|PROCEDURE|BSSVF-M Procedure|Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
215026675|NCT00410657|BIOLOGICAL|alemtuzumab|
215026676|NCT00410657|DRUG|methylprednisolone|
215104084|NCT04010877|BIOLOGICAL|CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells|Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
215104085|NCT02175979|DIETARY_SUPPLEMENT|enriched enteral nutrition|enriched enteral tube feeding perioperative
215104086|NCT02175979|DIETARY_SUPPLEMENT|standard|standard of care
215026677|NCT00410657|DRUG|prednisone|
215104087|NCT01107665|DRUG|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
215104088|NCT05632302|DEVICE|nICP|The nICP probe contains infrared light sources that illuminate the deep brain tissue of the frontal lobe. Photodetectors in the probe detect the backscattered light, which is modulated by pulsation of the cerebral arteries.
215104089|NCT04131062|BEHAVIORAL|Electronic Consent (iPad)|Participants who receive the intervention will be consented using an electronic app presented via iPad and developed according to the Sage eConsent framework.
215026678|NCT00410657|OTHER|flow cytometry|
215026679|NCT00410657|OTHER|immunologic technique|
215026680|NCT00410657|OTHER|pharmacological study|
215026681|NCT05193383|BEHAVIORAL|Imaginal exposure|Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
215026682|NCT05193383|BEHAVIORAL|Exposure|Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
215026683|NCT05193383|BEHAVIORAL|Approach-avoidance conflict|Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).
214508784|NCT02136641|DRUG|Midazolam+Ketamine Combination|Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
215026684|NCT05193383|BEHAVIORAL|In vivo exposure|Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
215026685|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using Memsorb|Sevoflurane administration at 0.2L.min-1 (minimal gas flow)
215026686|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using classical Dräegersorb|Sevoflurane administration at 2L.min-1 (classical gas flow)
215026687|NCT03682744|BIOLOGICAL|anti-CEA CAR-T cells|Intraperitoneal delivery of anti-CEA CAR-T cells
215026688|NCT05299190|OTHER|Yoga intervention plus TAU|The yoga intervention consists of 8 weekly group sessions. The intervention is based on hatha yoga system. TAU is usual care participants receive from their health care provider
215026689|NCT05299190|OTHER|Clinical Monitoring plus TAU|clinical monitoring includes bi-weekly 15-20 minute telephone contact with participants. TAU is usual care participants receive from their health care provider.
215026690|NCT03849144|BEHAVIORAL|Therapy dog activity|Visiting therapy dogs and their owners, evaluated and registered as therapy dog teams with Pet Partners will be spread around a large room on the Aetna campus. Employees will arrive at scheduled times to visit with the dogs for 15 minutes, talking to the dogs and owners and petting the dogs
215026691|NCT03849144|BEHAVIORAL|Low impact exercise|The low impact exercise will consist of stretching exercises conducted by a member of Aetna's wellness team in the same room for 15 minutes.
215026692|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Electric-acoustic stimulation fitting|Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
215026693|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Full-electric stimulation fitting|Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
215026694|NCT00667043|DRUG|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
215026695|NCT00667043|DRUG|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
215026696|NCT04164186|OTHER|Automatic detection and segmentation of NSCLC tumors|an automated deep learning detection and segmentation software for non-small cell lung cancer (NSCLC) that can automatically detect and segment tumors on CT scans and thus reduce the human variation.
215026697|NCT01204385|PROCEDURE|Sample collection|Middle ear fluid and urine
215026698|NCT04215458|OTHER|sample collection (swap or tape strip)|collection of swap or tape strip to determine yeast colonization in skin
215026699|NCT02562703|DEVICE|Transcutaneous Vagus Nerve Stimulation|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
215026700|NCT05988281|PROCEDURE|Type I Dental implant placement.|Placement of dental implant.
215026701|NCT05988281|PROCEDURE|Type II Dental implant placement.|Placement of dental implant.
215026702|NCT05988281|PROCEDURE|Type III/IV dental implant placement.|Placement of dental implant.
215026703|NCT05157997|DRUG|Casirivimab and Imdevimab Antibody Cocktail|The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
215026704|NCT05281575|BEHAVIORAL|Baby Friendly Spaces (BFS)|Designed to meet the unique needs of populations living in humanitarian contexts, BFS focus on two domains: psychosocial support that targets maternal wellbeing and childcare practices that target caregiver functioning to also address child wellbeing and development. In so doing, BFS strengthens mothers' internal resources and skills in caring for their children both in quantity (time spent caring for the child) and quality (responsiveness), to positively impact the health status and wellbeing of their children. In BFS, the following activities are delivered by trained psychosocial workers: counselling for infant and young child feeding practices; hygiene education and promotion; mother-child bonding activities that provide psychosocial stimulation essential for children at risk of, or experiencing, malnutrition; and provision of maternal psychosocial support (i.e. psychoeducation, stress management).
215026705|NCT04229017|PROCEDURE|Anterior Cervical Discectomy and Fusion|Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
215026706|NCT04229017|DEVICE|Posterior Cervical Stabilization System (PCSS)|Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.
215026707|NCT00991978|OTHER|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
215026708|NCT00153231|DEVICE|IVS|Infracoccygeal sacropexy
215026709|NCT00153231|PROCEDURE|Sacrospinofixation|
215026710|NCT06168344|OTHER|Web-Based Education Program|This study was assessed the impact of a web-based education program provided to mothers of infants with congenital heart diseases on their quality of life and self-efficacy levels
215026711|NCT06461494|OTHER|baseline treatment|hot pack will be applied for 10 minutes
215026712|NCT04347109|DIAGNOSTIC_TEST|Non invasive epicardial mapping|Non invasive mapping using Cardio Insight system is performed in all included patients.
215026713|NCT04874194|DRUG|Omacetaxine Mepesuccinate|Given SC
215026714|NCT04874194|DRUG|Venetoclax|Given PO
215026715|NCT04083027|DEVICE|MRI|Breast MRI
215026716|NCT03858868|BEHAVIORAL|Church and park-based intervention|Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.
215026717|NCT03858868|BEHAVIORAL|Standard health education on physical activity|Participants will receive publicly available brochures, tip sheets, etc. about physical activity
215026718|NCT06135090|BEHAVIORAL|Trauma Recovery Program (official title TBD)|See arm description
214423987|NCT03954015|DRUG|Lumason|FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
215026719|NCT01394185|DRUG|Dronabinol 120mg/day|Participants receive 40mg dronabinol 3 times daily
215026720|NCT01394185|DRUG|Placebo|Participants receive placebo
215026721|NCT01394185|DRUG|Dronabinol 240mg/day|Participants receive 80mg dronabinol 3 times daily
215026722|NCT00633958|DRUG|18F-FLT|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
215026723|NCT00633958|RADIATION|PET Imaging|
215026724|NCT01823055|PROCEDURE|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
215026725|NCT00953628|DRUG|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
215026726|NCT00953628|DRUG|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
215026727|NCT02875418|DEVICE|EUM|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
215026728|NCT02875418|DEVICE|Tocodynamometry|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
215026729|NCT05040386|BEHAVIORAL|EPIC|Participants randomized to the intervention arm receive usual COPD care + EPIC. EPIC is informed by the ENABLE model or early palliative care. ENABLE (Educate, Nurture, Advise, Before Life Ends) is a theory-based, rigorously tested, and multicomponent early palliative care model that improved quality of life and emotional symptoms in patients with advanced cancer. The PI adapted ENABLE to meet the specific needs of patients with COPD and their care partners through EPIC. EPIC includes a series of weekly telephone-based, nurse coach-led sessions for patients (six) and their care partners (four) aided by a manualized curriculum. Participants also complete activities geared to solving problems and making difficult decisions, attend a Supportive Care clinic visit, and complete advance directives.
215026730|NCT05040386|OTHER|Usual COPD Care|Participants randomized to this arm receive standard of care for COPD. This includes routine clinic visits with their clinician, medications, inhalers, vaccinations, tobacco cessation counseling, illness education, cardiopulmonary rehabilitation, specialist referrals, and other COPD therapies deemed appropriate by their clinician.
215026731|NCT04287959|DEVICE|High flow nasal cannula support|airvo2 highflow devices will be used.
215026732|NCT04050839|OTHER|Pain neuroscience education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
215026733|NCT04050839|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
215026734|NCT05781308|DRUG|Paclitaxel|Paclitaxel 200 mg/m² every 3 weeks
215026735|NCT05781308|DRUG|Bevacizumab|Bevacizumab 15 mg/kg every 3 weeks
215026736|NCT05781308|DRUG|Atezolizumab|1200 mg every 3 weeks
215026737|NCT06635863|DRUG|Prednisone 40mg|Prednisone 40mg x 8weeks
215026738|NCT05544487|PROCEDURE|Colorectal Anastomosis|Differences in intra-operative techniques and surgeon grades
215026739|NCT05976633|OTHER|Whole white rice (control)|One serving size (140g cooked on stovetop) of whole white rice will be provided. Cooking time will be consistently maintained throughout.
215026740|NCT05976633|OTHER|Whole brown rice|One serving size (140g cooked on stovetop) of whole brown rice will be provided. Cooking time will be consistently maintained throughout.
215026741|NCT05976633|OTHER|Whole wild rice|One serving size (140g cooked on stovetop) of whole wild rice will be provided. Cooking time will be consistently maintained throughout.
214508785|NCT02506270|DEVICE|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
214508786|NCT02506270|DEVICE|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
215026742|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Stovetop|One serving size (140g cooked on stovetop) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
215026743|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Microwaved|One serving size (140g cooked in microwave) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
215026744|NCT05817175|PROCEDURE|pre-pectoral breast reconstruction|to prospectively evaluate the utilization of the pre-pectoral approach, and evaluate oncological and aesthetic outcomes related to each type of surgical technique and the use of postmastectomy radiation therapy
214508787|NCT03901781|COMBINATION_PRODUCT|ST266 via Intranasal Delivery|ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
214508788|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet and exercise advice
214508789|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
214508790|NCT03692871|BIOLOGICAL|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
214691797|NCT07084454|OTHER|Standard Oncology Care|Participants receive the usual oncology care provided by their treating physicians without a structured geriatric assessment-driven intervention. Geriatric assessment results are shared with the treating oncologist, who may refer patients to supportive care services based on clinical judgment. No coordinated multidisciplinary telehealth intervention is provided.
214691798|NCT06926140|DEVICE|Acupuncture|Both groups have a standard anti-tumor Western medical treatment regimen (PD-1/PD-L1 inhibitor combined with chemotherapy); the acupuncture group is combined with acupuncture treatment. The day of starting antitumor treatment for each cycle was D1; D1-D5 was performed by the investigator on the patient for 2 times of acupuncture treatment, once a day; D8-D13 and D15-D20 were operated by patients or family members, and the investigator remotely assisted via video to complete the press needle treatment 4 times each, once a day, for four consecutive synergistic cycles, for a total of 24 times. The main acupuncture points are Guanyuan (Ren Mai 4), Shangyintang (EX-HN3), Taiyang (EX-HN5), Taichong (Liv-3), Zusanli (ST-36), and Xin (CO-15).
214691799|NCT06926140|DEVICE|Sham Comparator|Both groups have a standard anti-tumor Western medical treatment regimen (PD-1/PD-L1 inhibitor combined with chemotherapy); the sham acupuncture group is combined with sham acupuncture treatment. The day of starting antitumor treatment for each cycle was D1; D1-D5 was performed by the investigator on the patient for 2 times of sham acupuncture treatment, once a day; D8-D13 and D15-D20 were operated by patients or family members, and the investigator remotely assisted via video to complete the sham press needle treatment 4 times each, once a day, for four consecutive synergistic cycles, for a total of 24 times. The main acupuncture points are Guanyuan (Ren Mai 4), Shangyintang (EX-HN3), Taiyang (EX-HN5), Taichong (Liv-3), Zusanli (ST-36), and Xin (CO-15).
214691800|NCT04924985|OTHER|Non-Physiological Feedback CPR|Non-physiologically guided CPR using AV feedback (integrated into defibrillators)
215026745|NCT04868032|BEHAVIORAL|Positive Psychology-Motivational Interviewing|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
215026746|NCT04868032|BEHAVIORAL|Physical Activity Education Control|Participants randomized to this condition will be provided with a Fitbit, and will be mailed educational materials about physical activity at 4 time points throughout the intervention period. They will not receive a manual or phone calls with an interventionist.
215104090|NCT04280796|BEHAVIORAL|psychophysical tasks|"All participants perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other.~In addition, in Substudy 1 an operant learning paradigm will be implement to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement or vice versa.~In Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients."
215104091|NCT04280796|BEHAVIORAL|cognitive task|In Substudy 3 participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component.
215026747|NCT05338320|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia and Ultrasound Guided Erector Spinae Plane Block
215104092|NCT02035917|DEVICE|Locking plate|
215104093|NCT02035917|DEVICE|Non-Locking plate|
215104094|NCT03565016|OTHER|no interventional study|no interventional study
215104095|NCT02211612|DIETARY_SUPPLEMENT|PUFA-group|
215104096|NCT02211612|DIETARY_SUPPLEMENT|SFA-group|
215104097|NCT03282513|DRUG|AG-120 (Ivosidenib)|Single 500 mg dose of AG-120 (Ivosidenib).
215104098|NCT02008227|DRUG|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
215104099|NCT02008227|DRUG|Docetaxel|75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle
215104100|NCT03811314|DEVICE|Strength training|Using dumbbells, butterfly machine and vertical leg press machine for strength training, 12 repetition maximum weight for 12 repetition, three times a day, five days a week, for a total of four weeks
214691801|NCT04924985|OTHER|Physiological Feedback CPR|Physiological feedback CPR using an optimal regional O2 Saturation (rSO2), End-tidal CO2 (ETCO2) or combined (rSO2/ETCO2) target
214691802|NCT06389383|OTHER|Nasal Swab|"* Nasal swab once a week for the duration of the stay in intensive care unit/intensive care (procedure already carried out routinely to detect nasal staphylococcus once a week).~* Nasal swab every 14 days when the newborn is hospitalized in routine care/kangaroo unit/hospitalization at home"
214691803|NCT05310227|DEVICE|Nerivio|The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
215026748|NCT05338320|DRUG|Intrathecal morphine|General anesthesia and intrathecal morphine
215026749|NCT05338320|OTHER|General anesthesia using intravenous fentanyl (1µg/kg)|General anesthesia using intravenous fentanyl (1µg/kg)
215026750|NCT05670184|DRUG|LSD|Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.
215026751|NCT05670184|DRUG|Ethanol|Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
215026752|NCT05250934|DEVICE|Robotic rehabilitation|The upper limb rehabilitation will be carried out with the planar rehabilitation robot Icone (a CE Class IIA medical device manufactured by Heaxel). The proposed exercises require the patient to move a cursor on the screen using the end-effector of the robot to reach specific points (planar reaching exercises). When the patient is able to perform these exercises independently, the robot assists the movement by minimizing the interaction force applied to the hand and limiting itself to acquiring the kinematic and dynamic parameters of the exercise, which are useful in determining the state of motor skills. Icone assist the subject by applying a force to his hand that helps him complete the task in the phases where the patient plans the movement correctly but is unable to complete it. As a result, the system will enable you to perform planar elbow and shoulder movements in active, passive, or active-assisted modes, with visual and acoustic feedback.
215026753|NCT05067842|DIAGNOSTIC_TEST|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
215104101|NCT03811314|DEVICE|Aerobic training|Using stationary bicycle to perform cardiopulmonary endurance training in 50-70 heart rate reserve for 20 minutes, five days per week, for a total of four weeks
215104102|NCT03811314|DEVICE|Isokinetic trinaing|Using Biodex isokinetic dynanometer and set it in isokinetic mode in 60 degree per second
215104103|NCT03811314|DEVICE|Isotonic training|Using Biodex isokinetic dynanometer and set it in isotonic mode at 60% of the maximal peak torque
215104104|NCT03261453|DEVICE|Active Elipse Device|Intervention Device
215104105|NCT03261453|DEVICE|Elipse Sham Device|Control Device
215104106|NCT03727932|DEVICE|VioOne HIV Profile Supplemental Assay|The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M \& Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
215104107|NCT01806909|BIOLOGICAL|Ad4-H5-Vtn|
215104108|NCT00534963|PROCEDURE|cervical vs. uterine placement of balloon catheter|
215104109|NCT00978146|DRUG|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
215104110|NCT02347306|OTHER|Telephone interview|
215104111|NCT01332253|DRUG|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
215104112|NCT01332253|OTHER|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
215104113|NCT03420274|BEHAVIORAL|NEST|This is a point-of-care shared decision-making instrument.
215104114|NCT03420274|BEHAVIORAL|Usual care|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
215104115|NCT03127176|OTHER|Genome sequencing of fecal samples|Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
215104116|NCT04995211|DEVICE|Assessment of resting energy expenditure|We will assess the resting metabolic rate and respiratory exchange ratio of twenty healthy adults, with every metabolic cart on two days in the morning. The assessment will last 30 minutes on each metabolic cart, with 15-minute breaks between measurements. The order of the metabolic carts will be randomly selected and replicated the second day.
215104117|NCT04311125|PROCEDURE|Mini posterior approach Total Hip Replacement|Total hip replacement in patients suffering from hip osteoarthritis using the mini posterior approach
215104118|NCT04311125|PROCEDURE|Anterior approach total hip replacement without a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis without the aid of a traction table
215104119|NCT04311125|PROCEDURE|Anterior approach total hip replacement with a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis with the aid of a traction table
215104120|NCT02184858|DRUG|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
215104121|NCT06078436|DEVICE|Pulmonary artery catheter|Pulmonary artery catheter monitoring or not
215104122|NCT02944786|BEHAVIORAL|HOPE-model|There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
215104123|NCT02039284|DEVICE|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
215104124|NCT02039284|DEVICE|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
215104125|NCT02039284|DEVICE|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
215104126|NCT02039284|DEVICE|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
215026754|NCT05363930|DEVICE|Novel motorized spiral enteroscopy|Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
215104127|NCT02583295|BEHAVIORAL|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
215104128|NCT02583295|BEHAVIORAL|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
215104129|NCT02625844|OTHER|No intervention|No intervention administered in this study.
215104130|NCT03291717|BEHAVIORAL|Bridging Community Gaps Photovoice (BCGP)|Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
215026755|NCT05363930|DEVICE|Single balloon enteroscopy|Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
215026756|NCT02904265|DRUG|Diazepam|
215026757|NCT02904265|DRUG|Acetazolamide|
215026758|NCT00592280|DRUG|Two-Layer Method pancreas preservation system drug|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
215026759|NCT00592280|DEVICE|Two-Layer Method pancreas preservation system device|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
215026760|NCT00100893|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
215026761|NCT02364895|OTHER|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
215026762|NCT02364895|OTHER|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
215026763|NCT02364895|OTHER|Males Group 2: New letter with neutral gender content|Unisex letter
215026764|NCT02364895|OTHER|Males Group 3: New letter with male-specific content|New letter tailored for men
214423988|NCT02876471|OTHER|CPAP|OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
214423989|NCT06849778|DRUG|TS-172|oral administration of TS-172 20 mg
214423990|NCT03600935|OTHER|Vancouver Clinical Pathway|Vancouver Clinical Pathway
214423991|NCT02169154|DRUG|1% Diclofenac Sodium|1% diclofenac sodium
214423992|NCT02169154|DRUG|3% Menthol|3% Menthol
214423993|NCT02169154|DRUG|0.09% Menthol|0.09% Menthol
214423994|NCT02169154|DRUG|0.2% Sodium Lauryl Sulfate|0.2% Sodium Lauryl Sulfate
214423995|NCT02169154|DRUG|0.9% Saline|0.9% Saline
214423996|NCT01845428|DRUG|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
214423997|NCT01197807|PROCEDURE|Bulb Suctioning|Bulb suctioning of the mouth then the nose immediately following delivery
215026765|NCT02364895|OTHER|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
215026766|NCT02364895|OTHER|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
215026767|NCT02364895|OTHER|Females Group 2: New letter with neutral gender content|Unisex letter
215026768|NCT05267600|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
215026769|NCT05267600|OTHER|placebo|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
215026770|NCT05267600|DRUG|Prednisone|Oral Prednisone
215026771|NCT06472024|PROCEDURE|Verum Acupuncture|Acupuncture therapy uses filiform needles at a perpendicular angle at acupuncture points to produce a therapeutic effect.
215104131|NCT01618695|DRUG|Perampanel|"Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.~Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day."
215104132|NCT01618695|DRUG|Placebo|"Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day."
215104133|NCT04692519|BEHAVIORAL|Duet Language Intervention Modules|The Duet 2.0 intervention modules promote the following guiding principles that help build effective communication. Below are the 5 principles covered in the six Duet modules: 1) General Awareness: Awareness and knowledge of child development 2) Creating Opportunities: Opportunities for communication during everyday activities 3) Conversational Duets: Rhythmic and reciprocal early language interactions 4) Scaffolding: Providing just enough help to support child independence 5) Harmonizing: Using the strategies together. These modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. The modules were informed and narrated by community members and carefully designed to address specific needs of high-risk communities. The modules have also been translated into Spanish, making sure to encompass specific cultural and dialect needs. Translation accuracy was verified by a qualified Spanish translator.
215104134|NCT03046576|DIAGNOSTIC_TEST|plasma DPP4 activity|DPP4a was determined by enzymatic assays.
215104135|NCT00079716|DRUG|SGN-40 (anti-huCD40 mAb)|0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
215026772|NCT06472024|PROCEDURE|Sham Acupuncture|Sham Acupuncture therapy uses filiform needles but is only attached with tape to acupuncture points
214423998|NCT01197807|PROCEDURE|Wiping|Gentle wiping of mouth then nose with a soft cloth immediately following delivery
215026773|NCT02832531|DRUG|Rivaroxaban (15 mg)|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
215026774|NCT02832531|DRUG|Aspirin|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
215026775|NCT04255381|DEVICE|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Zone-Model Predictive Control Artificial Pancreas (ZMPC\_AP)
215104136|NCT04492501|PROCEDURE|Therapeutic Plasma exchange|1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
214423999|NCT04824443|OTHER|Aerobic Exercise Therapy|Aerobic Exercise Therapy/AT will consist of 30 weeks of treadmill walking sessions. AT will consist of supervised, individualized walking delivered up to 6 times weekly (over a 7-day period) to achieve a cumulative total duration ranging from 90 mins/wk up to 375 mins/wk following a non-linear dosing schedule. The planned dose and scheduling of AT will be continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period (i.e., non-linear periodized schedule).
214424000|NCT03558893|BEHAVIORAL|Forced Desynchrony|All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
214424001|NCT06479668|BEHAVIORAL|Trier Social Stress Task|Specify details not covered in associated Arm Description.
214424002|NCT00232895|DRUG|lipuro propofol|
214424003|NCT00232895|DRUG|standard formulation propofol|
215026776|NCT00601445|BEHAVIORAL|Amount of sleep and wake|4 groups with different patterns of sleep and wake
215026777|NCT06004583|DIAGNOSTIC_TEST|Biochemical blood analysis|Serum CRP and albumin levels
215026778|NCT01254214|BEHAVIORAL|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
215026779|NCT01254214|BEHAVIORAL|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
215026780|NCT00205322|DRUG|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
215026781|NCT06151418|DRUG|Novel hormonal therapy|As provided in real-world setting
215026782|NCT05704803|DIAGNOSTIC_TEST|Diagnostic Test: IN Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
215026783|NCT01917032|DIETARY_SUPPLEMENT|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
215026784|NCT01917032|DIETARY_SUPPLEMENT|placebo|
215026785|NCT04822883|DRUG|RL-007|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
215026786|NCT04822883|DRUG|RL-007 Matching Placebo|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
215026787|NCT00302822|DRUG|enfuvirtide|from week 0 to 24
215026788|NCT00302822|DRUG|emtricitabine/tenofovir|1 pill/day
215104137|NCT04492501|BIOLOGICAL|Convalescent Plasma|"Convalescent plasma as part of replacement therapy (200-400ml) if reported within 14 days of illness. An IgG titer of \> 1.320 will be considered suitable for use. It will be Collected from person previously infected with Covid-19 and meet following criteria;~1. After 28 day of illness till 3 months~2. Symptom free 2 weeks prior to donation~3. Negative two consecutive PCRs any time between initial positivity and before donation~4. Anti SARS-CoV2 IgG positive, IgM negative~5. Fulfills healthy donor criteria as per WHO/AABB guidelines~6. Volume of plasma to be collected: 900-1200 ml through Apheresis OR plasma separated from phlebotomy donation"
215104138|NCT04492501|DRUG|Tocilizumab|A predefined number of patients having evidence of cytokine release storm with normal procalcitonin level for three consecutive days, a normal blood culture and IL-6 level \> 3 times ULN will be given 1-2 doses of Tocilizumab (80mg IV) . Following contraindications to Tocilizumab will be considered (Allergy to any monoclonal Ab, ANC \< 1000, Platelets \< 50, ALT or AST \> 5 times ULN, Pregnancy and breast feeding, Post TB lung). Some patients will receive it alone in addition to standard treatment whereas in few patients where indicated it will be given in combination with MSC or Remdesivir or both
214424004|NCT05590650|DRUG|SZKJT(San-Zhong-Kui-Jian-Tang)|The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
215026789|NCT00302822|DRUG|lopinavir or efavirenz|investigator choice
215026790|NCT06062485|DRUG|Surufatinib+Toripalimab+AG|"This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）"
215026791|NCT01108874|DRUG|Metaraminol|Patients will be given metaraminol every time SBP falls below baseline value.
215026792|NCT02649309|PROCEDURE|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
215026793|NCT02649309|PROCEDURE|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
215026794|NCT02649309|PROCEDURE|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
215026795|NCT02649309|PROCEDURE|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
215026796|NCT00974597|DEVICE|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
215026797|NCT00273663|DEVICE|TCES|
215026798|NCT05529602|OTHER|conventional physical therapy|"core stability exercises~A total of 3 sessions per week were given for 15-20 minutes"
214424005|NCT05345119|DRUG|Sirolimus|2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
214424006|NCT05345119|DRUG|Methylprednisolone|500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
214424007|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
214424008|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
214424009|NCT04163081|BEHAVIORAL|Quit Card Intervention (QCI)|"The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a Quit Card (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist."
214424010|NCT00604019|DRUG|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
214424011|NCT00604019|DRUG|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
214424012|NCT00831415|DRUG|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
215026799|NCT05529602|OTHER|relaxation exercise|"the experimental group was given Post-isometric relaxation exercise along with core stability~A total of 3 sessions per week were given for 15-20 minutes"
215026800|NCT05327569|OTHER|Myofascial Chain Release Techniques|Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.
215026801|NCT00267488|DRUG|topotecan|
215026802|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
215026803|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
215026804|NCT00803374|DRUG|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
215026805|NCT00803374|DRUG|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
215026806|NCT00803374|DRUG|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
215026807|NCT00803374|DRUG|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
215104139|NCT04492501|DRUG|Remdesivir|It will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. For adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on Day 1 followed by once daily maintenance doses of 100 mg IV for 9 days (days 2 through 10). For adults not requiring invasive mechanical ventilation 5 standard doses will be used. However, patients with known hypersensitivity to Remdesivir, multi organ failure, ALT \> 5 times ULN and GFR \< 30ml/minute will not be given Remdesivir. In some patients, where indicated other novel treatments including MSC therapy, Tocilizumab and therapeutic plasma exchange will be given.
214691804|NCT04961190|BEHAVIORAL|Prolonged Exposure Therapy|A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
214691805|NCT04961190|DRUG|Pharmacotherapy with paroxetine or venlafaxine XR|Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
214691806|NCT04909736|OTHER|Music Exposure|Music will be played for participants.
214691807|NCT05922878|DRUG|ALTO-300|ALTO-300 capsule QD
214691808|NCT05922878|DRUG|Placebo|Placebo capsule QD
215026808|NCT01557569|DRUG|Atomoxetine|During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
215026809|NCT01557569|DRUG|placebo|participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
215026810|NCT02695888|BEHAVIORAL|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
215026811|NCT02695888|BEHAVIORAL|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
215026812|NCT02254460|DIETARY_SUPPLEMENT|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
214424013|NCT05347108|PROCEDURE|laser-assisted neural decompression (LAND) procedure|"The LAND procedure is a minimally invasive spinal decompression procedure that uses a focused laser beam to reduce and remove disc herniations that are causing nerve compressions and impingements within the spinal canal. It is performed in an outpatient setting and the patient receives local anesthesia.~The LAND procedure has been performed extensively over the past 2-years on hundreds of patients, so including patients that have previously had the surgery allows for additional data points and improved reporting."
214691809|NCT06062823|DRUG|Afatinib 40 MG|Afatinib 40mg administered orally daily.
215026813|NCT02254460|OTHER|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
215026814|NCT05222711|DEVICE|Use of the PICO(TM) monitoring device|The aim is to record if the outcome (referral or not) is influenced by the results of the parameters and/or the ECG.
215026815|NCT00002171|DRUG|Nelfinavir mesylate|
215026816|NCT03706066|DEVICE|Acrysof IQ PanOptix IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
214424014|NCT04271410|BIOLOGICAL|CD19 CAR-T cells|CD19 CAR-T cell therapy
214424015|NCT06449300|OTHER|Resistance exercise-LVT|(low volume training - 3 sessions of 12 exercises per week)
214424016|NCT06449300|OTHER|Resistance exercise-MVT|(moderate volume training - 4 sessions of 12 exercises per week)
214424017|NCT06449300|OTHER|Resistance exercise-HVT|(high volume training - 5 sessions of 12 exercises per week)
214424018|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
214424019|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
214424020|NCT00779545|DRUG|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
214424021|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
214691810|NCT06781983|DRUG|IPH4502|Part 1 (dose escalation) and Part 2 (dose optimization)
214691811|NCT06811233|DRUG|DMSA|Given PO
214691812|NCT06811233|DRUG|Ca-EDTA|Given by IV
214691813|NCT06811233|DRUG|Magnesium Sulfate|Given by infusion
215026817|NCT03706066|PROCEDURE|Cataract surgery|Per investigator's standard of care
215026818|NCT03308773|OTHER|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
215026819|NCT00583531|DRUG|AST-120|Oral, 2 grams TID in sachets for 4 weeks
215026820|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab, Carboplatin, albumin-bound paclitaxel:4 cycles"
215026821|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab , Carboplatin, albumin-bound paclitaxel:2 cycles"
215026822|NCT04649749|DIAGNOSTIC_TEST|MRI|MRI scan
215026823|NCT04861701|BEHAVIORAL|Static stretching exercise|The intervention of this study is home-based stretching exercise. The experimental group will receive 6 stretching exercises which stretch 60 seconds for each side (left or right) of each movement, and relax for 10-20 seconds between the movements. It will take 10-15 minutes every day for continuous 4 weeks. The 6 stretching exercises include : (1) pectoral muscles + calf muscles ; (2) quadriceps ; (3) levator scapulae ; (4) gluteal muscles ; (5) hamstrings ; (6) trunk side-flexors.
215026824|NCT06238973|OTHER|Group Low|In order to maintain arterial blood pressure within the range of 50-57 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
215026825|NCT06238973|OTHER|Group Middle|In order to maintain arterial blood pressure within the range of 58-65 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
215026826|NCT03269266|DIAGNOSTIC_TEST|Scrub Typhus RDT Test|"A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid.~In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi."
215026827|NCT05634200|PROCEDURE|Bronchoscopy|During bronchoscopy endobronchial biopsy, transbronchial biopsy, transbronchial needle aspiration, bronchial washing, bronchoalveolar lavage, EBUS-TBNA and EUS-B-FNA may be performed
215026828|NCT02640131|BEHAVIORAL|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
215104140|NCT04492501|BIOLOGICAL|Mesenchymal stem cell therapy|Single Dose of 2 x 106 cells/kg will be administered either alone or in combination with other novel therapies. At Armed Forces Bone Marrow Transplant Centre (AFBMTC), MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37Oc in 5% CO2. Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- EDTA solution.
214424022|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
214691814|NCT06811233|DRUG|Multivitamin|Given PO
214691815|NCT05243290|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.
214424023|NCT00779545|DRUG|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
214508791|NCT03692871|BIOLOGICAL|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 ml dose
214508792|NCT05923788|DIAGNOSTIC_TEST|T1 mapping measurement|T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
214508793|NCT04658888|DEVICE|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cancer cells for screening purposes.
214508794|NCT03690557|BEHAVIORAL|IncentaHealth|IncentaHealth is a comprehensive, behavioral weight management program designed to help individuals initiate and maintain weight loss. Individuals participate in the IncentaHealth program from their homes, receive program information electronically through daily emails and through a smartphone app for the duration of the study, and have the option to receive text messages and speak with health coaches over the telephone. Participants in this study will be enrolled in the IncentaHealth program for 12 months, and will engage with health coaching, tracking of body weight, and are provided a number of resources for healthy living throughout the 12 months.
214508795|NCT00539084|DEVICE|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
214508796|NCT00399685|DRUG|Ortho Tri-Cyclen LO|Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
214691816|NCT05243290|DIETARY_SUPPLEMENT|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.
215026829|NCT02640131|BEHAVIORAL|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
215104141|NCT01481337|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR)|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
215104142|NCT01684319|DIETARY_SUPPLEMENT|Formula milk free of cow's milk protein|
215104143|NCT01684319|DIETARY_SUPPLEMENT|Placebo|Infant formula milk
214691817|NCT06017765|BEHAVIORAL|Meditation Training|"The Meditation Training consists of 8 weekly sessions of Mindfulness Training and is adapted from the group-based Stress Management and Resiliency Training - Relaxation Response Resiliency Program, SMART-3RP. This training is structured around the following four goals:~1. Education about stress response~2. Elicitation of the Relaxation Response through Mindfulness Training~3. Creating adaptive perspectives~4. Coping strategiest."
214691818|NCT06017765|BEHAVIORAL|Waitlist|The waitlist consists of a waiting time of 12 weeks during which participants will nog receive any type of intervention.
215026830|NCT02640131|BEHAVIORAL|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
215026831|NCT02572648|OTHER|Brain Imaging (Neuroimaging)|"Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes."
215104144|NCT04346446|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion
215104145|NCT04346446|OTHER|Supportive Care|Supportive Care
215104146|NCT04346446|DRUG|Random Donor Plasma|Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement
214508797|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
214508798|NCT00399685|DRUG|Ortho Cyclen + Efavirenz|Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
214508799|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
214508800|NCT04738214|OTHER|Neoadjuvant CCRT+operation +/- adjuvant treatment|Patients receive neoadjuvant CCRT and operation. Adjuvant treatment after operation is performed depending on pathologic response. The patients showing pathologic complete response after neoadjuvant CCRT are not treated with any adjuvant treatment.
214508801|NCT04269044|DIAGNOSTIC_TEST|non-contact EKG|ultra-sensitive, non-contact EKG pad will be placed beneath the infant
214508802|NCT02135315|DRUG|Isosorbide Dinitrate|administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used
214508803|NCT04243915|OTHER|Percutaneous neuromuscular electrical stimulation (PNMES) plus motor control exercise program|The technique consists of a muscular stimulation of the deep lumbar multifidus by means of a TENS current applied through four dry needling or acupuncture needles introduced by ultrasound guidance in said muscle 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
214508804|NCT04243915|OTHER|Sham PNMES (introducing the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
214508805|NCT04243915|OTHER|TENS plus motor control exercise program|Transcutaneous electrical nerve stimulation will be applied through 4 patches / adhesives placed in your lower back for 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
214508806|NCT04243915|OTHER|Sham PNMES (without inserting the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the needle will not be inserted and the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
214508807|NCT01316913|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
214508808|NCT01316913|DRUG|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
214508809|NCT01316913|DRUG|GSK573719|125 mcg once-daily
214508810|NCT01316913|DRUG|tiotropium bromide|18 mcg once-daily
214508811|NCT03564106|DRUG|intraarticular radiofrequency + intraarticular methylprednisolone|intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)
214508812|NCT03564106|DRUG|intraarticular methylprednisolone|intraarticular methylprednisolone (30 mg)
214508813|NCT06052722|OTHER|Correlation assessment|The relationship between the Premenstrual Syndrome Impact Scale and the Fonseca Anamnestic Index will be examined for individuals with premenstrual syndrome. The relationship between Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea Score and Fonseca Anamnestic Index will be examined for individuals with primary dysmenorrhea.
214508814|NCT02516085|DRUG|Metformin|
214508815|NCT02516085|DRUG|L-Arginine|
214508816|NCT04896567|DIAGNOSTIC_TEST|Cell isolation|Tissue from kidney biopsy will be used to isolate Cluster Differentiation 34+ cells.
214508817|NCT00911638|BEHAVIORAL|Patient decision aid|"Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
214508818|NCT00911638|BEHAVIORAL|Usual care|"Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only"
214508819|NCT00002086|DRUG|Zidovudine|
214508820|NCT00002086|DRUG|Zalcitabine|
214508821|NCT00002086|DRUG|Interferon alfa-n1|
215104147|NCT02376179|DEVICE|Cuffed ETT|
215104148|NCT05062135|DRUG|Progesterone 400 Mg Vaginal Suppository on PCOS|The same drug will be used in control group
215104149|NCT04077853|DRUG|17 Hydroxyprogesterone Capronate|Intramuscular injection 250 mg
215104150|NCT03716219|OTHER|Exercise Training|Physical activity in children and adults with asthma.
215104151|NCT02454478|DRUG|Lenvatinib|
215104152|NCT02454478|DRUG|Everolimus|
215104153|NCT04243993|OTHER|Calcium silicate cement|Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
215026832|NCT02572648|OTHER|Cognitive Function Assessment|Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 \& 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
214691819|NCT06352372|DEVICE|noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM)|The proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills.
215104154|NCT04701190|DRUG|Noradrenalin 10 microgram bolus|The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
214691820|NCT05367063|DRUG|Canagliflozin 100mg or Sitagliptin 100mg|Eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.
214691821|NCT06827704|BEHAVIORAL|Enhanced physical activity monitor which is Fitbit watch with mobile App|Participants will receive an enhanced physical activity monitor treatment for 6 months which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor (Fitbit watch). Edit
214691822|NCT06827704|BEHAVIORAL|Bollywood-style group dance|Participants will participate in 60-minute, moderate-intensity Bollywood-style culturally tailored group dance virtual sessions, 2x/week for 6 months
214691823|NCT06827704|BEHAVIORAL|PAMDance|Participants will receive an enhanced physical activity monitor treatment for 6 months which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor (Fitbit watch). In addition, Participants will participate in 60-minute, moderate-intensity Bollywood-style culturally tailored group dance virtual sessions, 2x/week for 6 months
215104155|NCT04701190|DRUG|Noradrenaline 5 microgram bolus|The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
214691824|NCT05786599|DRUG|methadone|"The treatment arm will take methadone 2 mg PO q8h and a placebo called placeboD PO qdaily. PlaceboD and duloxetine will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
214694232|NCT03880240|OTHER|Sham Transcranial Alternating Current Stimulation|Placebo Control, simulation of transcranial alternating current stimulation without receiving any stimulation
214694233|NCT03661268|OTHER|fluid chanllenge|A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
215026833|NCT03345082|BIOLOGICAL|OPT-302|Intravitreal injection
215026834|NCT03345082|BIOLOGICAL|ranibizumab|Intravitreal injection
215026835|NCT03345082|OTHER|sham intravitreal injection|Sham (mock) intravitreal injection
215104156|NCT04701190|DRUG|Noradrenaline 0.1 microgram/kg/minute infusion|"Infusion dosage: 0.1 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
215104157|NCT04701190|DRUG|Noradrenaline 0.05 microgram/kg/minute infusion|"Infusion dosage: 0.05 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
215104158|NCT04701190|DRUG|Infusion dosage: 0.075 microgram/kg/minute infusion|"nfusion dosage: 0.075 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
215104159|NCT04701190|PROCEDURE|Spinal anesthesia|Spinal anesthesia using 0.5% 10 milligram heavy bupivacaine plus 12.5 microgram fentanyl
214424024|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
214424025|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
215026836|NCT04133038|OTHER|Questionnaire|Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.
215026837|NCT02943499|BEHAVIORAL|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
215104160|NCT06136013|BEHAVIORAL|HIIT|1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.
215104161|NCT01874080|DRUG|Saxagliptin/Metformin|
215104162|NCT05760768|BEHAVIORAL|Individualized exercise guidance|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
215104163|NCT04141540|GENETIC|Molecular analyses|Comparaison of the molecular profil between two monozygotic twins carrying a deletion 22q11.2
215104164|NCT01128192|DRUG|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
215104165|NCT02312297|DRUG|Minocycline hydrochloride|extended release tablets 135 mg
215104166|NCT01271725|DRUG|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
214694234|NCT01924910|DIETARY_SUPPLEMENT|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
214694235|NCT01924910|DIETARY_SUPPLEMENT|Placebo|
215026838|NCT02943499|BEHAVIORAL|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
214694236|NCT05177952|OTHER|Blood Flow Restriction|Resistance training with BFR
215026839|NCT02943499|DEVICE|Smartphone|
215026840|NCT00583154|DRUG|BLI-801|Dose 1
215026841|NCT00583154|DRUG|BLI-801|Dose 2
215026842|NCT00583154|DRUG|BLI-801|Dose 3
215026843|NCT00583154|DRUG|BLI-801|Dose 4
215104167|NCT01271725|DRUG|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
215104168|NCT01271725|DRUG|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
215104169|NCT03354273|DRUG|PET MPI|Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.
215104170|NCT03354273|DRUG|SPECT MPI|SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.
215104171|NCT03354273|DRUG|Pharmacological stress agents|Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
215104172|NCT03590353|DEVICE|Dual Chamber Pacemaker|1\. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
214424026|NCT03145480|DRUG|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
214424027|NCT03145480|DRUG|Ibrutinib|560mg po daily
214424028|NCT03145480|OTHER|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
214424029|NCT05018754|DEVICE|TREATMENT OF ORAL MUCOSITIS USING PLATELET-RICH-FIBRIN (PRF)|All patients were affected by oral mucositis (9 RIOM, 6 chemotherapy-related oral mucositis). They were treated with almost 2 different systemic therapies before and during platelets gel applications. Median of time before the lesions were treated with platelets gel were 7 days. Lesions affected buccal mucosa, tongue, labial commissure and lower lip. Preliminar parameters were the microbiological contamination of lesions and presence of pain. Patients refer spontaneous widespread pain worsened by swallowing and feeding. Response to treatment has been evaluated in relation to the reduction of lesions dimensions, to the involution of pain and presence of granulation tissue after every application of platelet gel.
214424030|NCT04668391|PROCEDURE|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament|Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.
214424031|NCT04668391|PROCEDURE|Thoracic epidural analgesia|A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
214424032|NCT04800302|PROCEDURE|Continous Quadratum Lumborum Block III|Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum \& psoas major muscles with ultrasound guidance.
214424033|NCT04800302|PROCEDURE|Single dose Quadratum Lumborum Block III|Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
214424034|NCT04800302|PROCEDURE|Intra-venous Morphine|Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
214424035|NCT03034915|DRUG|UMEC/VI 62.5/25 mcg via ELLIPTA|ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
214424036|NCT03034915|DRUG|UMEC 62.5 mcg via ELLIPTA|The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
214424037|NCT03034915|DRUG|Salmeterol 50 mcg via DISKUS|The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
214508822|NCT04565717|DRUG|ALN-HSD|ALN-HSD will be administered by subcutaneous (SC) injection.
214508823|NCT04565717|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
214508824|NCT05149963|OTHER|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of Cognitive Behavioural Therapy (CBT) aiming to reduce their feelings of loneliness
215026844|NCT00853684|DRUG|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
215026845|NCT00853684|DRUG|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
215026846|NCT01076699|DRUG|0.075 mg RVX-100|This group is taking the lowest dose of RVX-100
215026847|NCT01076699|DRUG|0.125 mg RVX-100|This group is taking an average dose of RVX-100
215026848|NCT01076699|DRUG|0.250 mg RVX-100|This group is taking the highest dose of RVX-100
215026849|NCT01076699|DRUG|placebo|This group is taking a placebo
215026850|NCT03889379|DRUG|Administration of albuterol|Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
215026851|NCT02510924|DEVICE|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
215026852|NCT03947463|PROCEDURE|PECS block|After the induction of general anesthesia, PECS block was administered patients via ultrasound guided technique. We used Mindray M7 Portable ultrasound system using linear probe with (5-10 MHz) frequency. After cleaning the infra clavicular and axillary region with 2% chlorhexidine in 70% Alcohol solution, ultrasound probe was placed in the infraclavicular region and pectoral major and minor were identified. After identification of the landmarks, 20 gauge 50mm Visoplex needle was inserted in-plane direction. 20ml of 0.25% bupivacaine (within the safe limit of its dose) was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualized on the ultrasound screen.
215026853|NCT02538796|OTHER|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
215026854|NCT02538796|OTHER|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
215026855|NCT02538796|OTHER|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
215026856|NCT02538796|OTHER|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
214424038|NCT03034915|DRUG|Placebo via ELLIPTA|Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
214424039|NCT03034915|DRUG|Placebo via DISKUS|Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
214424040|NCT04986683|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate the presence, type, and severity of brain abnormalities in enrolled subjects.
214424041|NCT04986683|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language, and other neurocognitive functions potentially affected by drug-resistant epilepsy.
214424042|NCT00629941|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
214424043|NCT00243256|DRUG|Cholecalciferol|
214424044|NCT03861767|DRUG|Metformin ER|tablet
214424045|NCT03861767|DRUG|Placebo|Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
214424046|NCT06400394|DEVICE|Hydrocyn Aqua®|The study solution comes in a liquid form containing hypochlorous acid (HOCl) in a concentration of 0.003%. It is used as a topical agent for wound and peritoneal lavage before wound closure
214424047|NCT06400394|DEVICE|Normal Saline|aqueous solution of electrolytes and other hydrophilic molecules
214424048|NCT01087762|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
214424049|NCT01087762|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
214424050|NCT01087762|OTHER|Placebo|Matching Placebo to CZP injection.
214424051|NCT00813904|BIOLOGICAL|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
214424052|NCT01829386|OTHER|MRI scans with non heme iron levels|"MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research."
214424053|NCT01188499|DRUG|Birinapant|
214691825|NCT05786599|DRUG|duloxetine|"The control arm will receive duloxetine 30 mg PO qdaily, and a placebo called placeboM PO q8h. PlaceboM and methadone will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
214691826|NCT04294810|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
214691827|NCT04294810|DRUG|Tiragolumab|Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
214691828|NCT04294810|DRUG|Matching Placebo|Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
214508825|NCT03942094|DRUG|Nilotinib|"Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily"
214691829|NCT05205954|BEHAVIORAL|Hepatology Home Hospital|The Hepatology Home Hospital intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with hepatology clinicians regarding care delivered at home to ensure continuity of care.
214508826|NCT05141409|DEVICE|Artificial Intelligence|Artificial Intelligence
214508827|NCT02691702|DRUG|BIIB118|Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
214508828|NCT02691702|DRUG|Melatonin|Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
214508829|NCT02567591|OTHER|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
214508830|NCT01694147|DEVICE|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
215026857|NCT01737905|DRUG|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
214508831|NCT04876846|DEVICE|GEN 3 Monitoring of Fetus|"Measurement of tissue light scatter in the body in body during late term pregnancy and evaluation of signal integrity"
214691830|NCT05317429|OTHER|A meal delivering 75 g of carbohydrate|"The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity."
215026858|NCT01737905|DRUG|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
215026859|NCT04893525|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.
215026860|NCT03409198|DRUG|Ipilimumab|Ipilimumab blocks CTLA-4 and may deplete regulatory T cells
215026861|NCT03409198|DRUG|Nivolumab|Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.
214508832|NCT06389877|DRUG|BEAM-302|BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD
214691831|NCT04966351|BEHAVIORAL|Time-restricted feeding|Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.
214691832|NCT04966351|BEHAVIORAL|Circadian Misalignment|Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.
214691833|NCT06030206|BEHAVIORAL|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After three months, participants will gain access to the publicly available website (attention control) and will have an additional three months of access to both of these resources.
214691834|NCT06030206|BEHAVIORAL|Publicly available transplant education resource (Attention-control)|Participants will access the publicly available education resource via their login to a secure website. After three months, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional three months of access to both of these resources.
214691835|NCT04696159|PROCEDURE|Pyloromyotomy|Endoscopic Per-Oral Pyloromyotomy (POP)
214691836|NCT06795373|DRUG|Ritlecitinib|Once daily dose of 100mg of ritlecitinib taken orally for 12 weeks
214694237|NCT05177952|OTHER|Standard of Care|Resistance Training with no BFR
215026862|NCT03409198|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
215026863|NCT03409198|DRUG|Cyclophosphamide|Chemotherapy
215026864|NCT01817777|DRUG|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
215026865|NCT01817777|DRUG|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
215026866|NCT00756340|DRUG|Bevacizumab|"* Bevacizumab IV every 2 weeks~* Dose Level 0- 8 mg/kg~* Dose Level 1 (starting dose)- 10 mg/kg~* Dose Level 2- 10 mg/kg"
215026867|NCT00756340|DRUG|Everolimus|"* Everolimus~* Dose Level 0- 4 mg/m2~* Dose level 1 (starting dose)- 4 mg/m2~* Dose Level 2- 5 mg/m2"
215026868|NCT00557440|DRUG|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
215026869|NCT00557440|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
215026870|NCT00557440|DRUG|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
215026871|NCT00557440|DRUG|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
214424054|NCT05302713|DIETARY_SUPPLEMENT|Ionic Calcium|Ionic calcium (IC), a calcium in a free ionic state (i.e., non-protein bound), is purported to improve calcium uptake and homeostasis leading to improved cellular signaling that may have been disrupted through environmental and lifestyle stressors.
215026872|NCT01309061|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
215026873|NCT03524157|DRUG|PRO-087|The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
215026874|NCT03524157|DRUG|Systane Ultra|The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.
214424055|NCT05302713|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate supplementation in a solution identical in appearance, consistency, and taste to the intervention supplement.
214424056|NCT00424762|DRUG|rosiglitazone|6 months of treatment of blinded study drug
214424057|NCT00424762|DRUG|placebo|blinded treatment with matching placebo
214424058|NCT05490277|DEVICE|Active Vibrotactile coordinated reset|Participants will receive active vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
214424059|NCT05490277|DEVICE|Sham vibrotactile coordinated reset|Participants will receive sham vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
214424060|NCT02311972|DEVICE|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
214424061|NCT02311972|DEVICE|Standard of care feeding tube|
214508833|NCT05440760|DEVICE|The Oculus Quest 2 Virtual Reality Headset|"The hardware includes the wireless headset with integrated headphones which will block the sight and sounds of the clinical setting as well as the hand controllers for the interactive VR experience, which will be delivered through any of three VR software options (subject may choose one or more from the following options):~* Titans of Space® PLUS developed by Drash VR, LLC (Murrieta, CA, USA)~* TRIPP® developed by TRIPP, Inc. (Los Angeles, CA, USA)~* Nature Treks VR published by Greener Games (Ironbridge, England, UK)"
214508834|NCT05169684|BIOLOGICAL|BMS-986218|Specified dose on specified days
214508835|NCT05169684|DRUG|Docetaxel|Specified dose on specified days
214508836|NCT05169684|BIOLOGICAL|Nivolumab|Specified dose on specified days
214508837|NCT01668719|DRUG|Bortezomib|Given SC or IV
214508838|NCT01668719|DRUG|Dexamethasone|Given PO or IV
214508839|NCT01668719|BIOLOGICAL|Elotuzumab|Given IV
214508840|NCT01668719|OTHER|Laboratory Biomarker Analysis|Correlative studies
214508841|NCT01668719|DRUG|Lenalidomide|Given PO
214508842|NCT03539055|DRUG|Dabigatran Etexilate Oral Capsule|Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.
214508843|NCT05147675|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
214508844|NCT04922242|BEHAVIORAL|Welch Emotional Connection Screen for Neonatal Intensive Care Unit|The Welch Emotional Connection Screen (WECS) is an investigational developmental screening tool, developed to rate the quality of the emotional connection that formed between mother and child. The screen is administered in 2-3 minutes by observing a mother and child interact, and requires the rater to critically assess 4 sub-domains of emotional connection. The NICU WECS is a clinical tool adapted for use with neonates in the NICU. Reliability of NICU staff WECS scoring will be calculated via intra-class correlations with key scores. The WECS is scored on intervals of 0.5, with a minimum of 1 (rarely--low level of connection) and maximum of 3 (mostly--high connection). Scores are used to determine the level of need for intervention.
214508845|NCT04922242|OTHER|NICU WECS Training|"WECS Training is an educational module consisting of an introduction of the concepts of emotional connection and autonomic co-regulation as studied by The Nurture Science Program, as well as an illustration of how these experiential constructs differ from traditional care plans that focus on educating parents to encourage bonding as opposed to autonomic emotional connection within the NICU. An introduction to the domains of the WECS screen as well as illustrations of these domains through video will augment the training designed for NICU staff."
214508846|NCT04489355|PROCEDURE|coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)|
214508847|NCT05148988|DIAGNOSTIC_TEST|EchoPIV|All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.
214694238|NCT01341431|DRUG|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
214694239|NCT02435277|DRUG|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
214424062|NCT05949749|DIAGNOSTIC_TEST|Epitope exploration|Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.
214424063|NCT02401646|DIETARY_SUPPLEMENT|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
214424064|NCT02401646|DIETARY_SUPPLEMENT|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
215026875|NCT03524157|DRUG|Xyel Ofteno|The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
215026876|NCT05913167|PROCEDURE|laparoscopic nephrectomy|laparoscopic nephrectomy
215026877|NCT05648708|PROCEDURE|Combine Adductor Canal & Sciatic Nerve Block|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia
215026878|NCT05648708|PROCEDURE|Combine Femoral & Sciatic Nerve Block|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia
215026879|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
215026880|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
215026881|NCT03066375|DEVICE|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
215026882|NCT04826614|OTHER|optimized treatment|early adjust dose or change drug
215026883|NCT00850187|BIOLOGICAL|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
214424065|NCT03652207|OTHER|isomaltulose (Palatinose(TM)|isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
214424066|NCT03652207|OTHER|Sucrose|sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
214424067|NCT04965987|DRUG|Oxaloacetate|Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase. In this reaction, the hydrogen atoms from malate are transferred to NAD+, forming NADH, H+ and oxaloacetate. Oxaloacetate can be converted to citrate with the addition of acetyl-CoA by the enzyme citrate synthase. Oxaloacetate is a critical component in the production of ATP and must be constantly regenerated in order for the citric acid cycle and the electron transport chain to continue
214424068|NCT04965987|DRUG|Placebo|Placebo
214424069|NCT01405924|DRUG|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
214508848|NCT05148988|DIAGNOSTIC_TEST|4D flow MRI|A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
215026884|NCT02998099|DRUG|Rivipansel|A single dose of IV rivipansel over 20 minutes.
215026885|NCT02256878|DRUG|BIRT 2584 XX|
214424070|NCT01405924|DRUG|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
214424071|NCT01405924|DRUG|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
214424072|NCT01405924|DRUG|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
214424073|NCT05513300|OTHER|Exercise intervention|12 weeks of exercise training, 3 times per week, \~1h long
214424074|NCT06194734|DRUG|KC1036|KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle
214424075|NCT06194734|DRUG|Irinotecan|Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks
214424076|NCT06194734|DRUG|Docetaxel|Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks；
214424077|NCT06194734|DRUG|S-1|S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle
214424078|NCT04709055|OTHER|Co-management|Personalized and intensive geriatric peri-operative care
215026886|NCT02256878|DRUG|Amitriptyline|
215026887|NCT03235492|DEVICE|SmartAlbu|"Plan:~1. Consent an individual~2. Measure and record temperature, blood pressure, heart rate, height and weight~3. Obtain two samples of saliva for the SmartAlbu portable salivary sensor~4. Take a venous blood sample for HbA1c and~5. Glycated albumin~6. Obtain blood sample from a finger stick for point of care HbA1c device"
214424079|NCT04709055|OTHER|Usual care|Pre-operative and post-operative geriatric care as per usual practice
214424080|NCT05314400|DIAGNOSTIC_TEST|Full Gadoxetate-enhanced liver MRI|Standard pulse sequences
214424081|NCT05314400|DIAGNOSTIC_TEST|Shortened Gadoxetate-enhanced liver MRI|Fewer pulse sequences
215026888|NCT02118415|OTHER|Hsp70-peptide TKD/IL-2 activated, autologous NK cells|Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
215026889|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3-15mg/day; administered orally
215026890|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3mg every other day to 6mg/day; administered orally.
215026891|NCT01592747|DRUG|Placebo capsules|Once daily, oral administration.
214424082|NCT01028118|OTHER|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
214424083|NCT04364789|DRUG|TT-00920|Tablets
214424084|NCT04364789|DRUG|Placebos|Tablets
214424085|NCT03148990|BIOLOGICAL|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
214424086|NCT03148990|BIOLOGICAL|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
214508849|NCT06186960|DEVICE|Tandem Virtual Reality|Hospice patients and their primary caregiver will each wear virtual reality headsets and will experience a customized and synchronized 5-15min virtual reality experience.
214508850|NCT03237780|DRUG|Atezolizumab|Given IV
215026892|NCT01496859|DEVICE|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
215026893|NCT01275378|BEHAVIORAL|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
215026894|NCT01275378|BEHAVIORAL|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
215026895|NCT00832013|DRUG|Propofol|See detailed description
215026896|NCT00832013|DRUG|Propofol|See detailed description
214508851|NCT03237780|PROCEDURE|Biopsy Procedure|Undergo biopsy
214508852|NCT03237780|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
214508853|NCT03237780|PROCEDURE|Computed Tomography with Contrast|Undergo CT scan
214508854|NCT03237780|DRUG|Eribulin Mesylate|Given IV
214508855|NCT06533722|DRUG|Gemcitabine, Vinorelbine, or Eribulin|Gemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days
214508856|NCT04923256|BEHAVIORAL|AAT-APP: A novel smart-phone approach-avoidance bias modification intervention|Participants allocated to the intervention group will be required to upload photos of drinks they wish to avoid, as well as activities they wish to engage in more, and be trained to avoid and approach by repeatedly 'swiping' images away from and towards themselves, respectively.
214508857|NCT04923256|BEHAVIORAL|Sham training control|Complete an AAT on a weekly basis for four weeks
214508858|NCT03497052|OTHER|In vitro culture in medium 1|Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
214508859|NCT03497052|OTHER|In vitro culture in medium 2|Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
214508860|NCT02646774|DRUG|Micafungin|Injection
214508861|NCT02278627|OTHER|manual lymphatic drainage|
214508862|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
214508863|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
214508864|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
214508865|NCT06498609|BIOLOGICAL|iprf|i-PRF with leveling and alignment
214508866|NCT06498609|PROCEDURE|MOPs with leveling and alignment|mop
214508867|NCT03307044|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
214508868|NCT03307044|OTHER|Questionnaire Administration|Ancillary studies
214508869|NCT05484661|DIETARY_SUPPLEMENT|BCAA|Participants will participate in high-volume, moderate-intensity exercise 3x/week and consume either a placebo or BCAA (\~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
214508870|NCT00552253|DRUG|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1\~0.3 mU/L. It will be discontinued for 3 months. Then
214508871|NCT06152900|DEVICE|Accufit|"Magnet-based and Direct muscle stimulation devices are commonly used to generate current flow through the muscles in order to activate the muscle. The Accufit Electrical Muscle Stimulation device is an FDA cleared device having a two-channel stimulator that provides up to 8 electrodes with waveforms of interferential and biphasic for muscle stimulation. The Accufit system is indicated for relaxation of muscles, muscle re-education, reduction of pain and increased local blood circulation.~Muscle stimulation technology has been around for many decades and has been shown to be safe and effective for a variety of clinical applications. The foundational basis for the technology revolves around electrical current flowing through the muscle can be used to activate the muscle."
215026897|NCT06639893|PROCEDURE|Telescopic overdenture|Telescopic overdenture with two dental implants in intraforaminal area for mandible.
214508872|NCT03670121|DEVICE|Bronchoscopic Thermal Vapor Ablation (BTVA)|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
214508873|NCT04786275|DRUG|Fentanyl|Standard dose of 2 ug/kg after tetanic stimulation.
214508874|NCT04786275|OTHER|Tetanic stimulation|Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
214508875|NCT00152672|DEVICE|nCPAP vs oral appliance|
214508876|NCT03789357|DIAGNOSTIC_TEST|Aldosterone renin ratio|Aldosterone Renin Ratio to screen for Primary Aldosteronism
214508877|NCT02804256|OTHER|Blood Sample Collection|10 patients with ICCs to provide a second blood sample (20mls - 2 tablespoons) on top of the samples that will be collected for the biorepository.
214508878|NCT03615833|DRUG|Cholecalciferol|Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
214508879|NCT01828671|OTHER|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
214508880|NCT01828671|OTHER|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
214508881|NCT01828671|OTHER|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
214508882|NCT01828671|OTHER|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
214508883|NCT01828671|OTHER|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
214508884|NCT01904097|DRUG|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
214508885|NCT01904097|OTHER|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
214694240|NCT02435277|DRUG|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
214691837|NCT05361122|DIETARY_SUPPLEMENT|Maternal Use of Xylitol Chewing Gum During Pregnancy|There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at \<20 weeks gestation).
214691838|NCT05361122|DIETARY_SUPPLEMENT|No Maternal Xylitol Chewing Gum Use During Pregnancy|There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group
214691839|NCT06397690|BEHAVIORAL|My Choice for HIV Prevention (MyChoice)|My Choice for HIV Prevention (MyChoice) is a counselor-delivered shared decision-making approach for pregnant women considering PrEP
214691840|NCT06397690|BEHAVIORAL|Standard of care (control arm)|Standard of care (control arm) participants will receive comprehensive education on both the advantages and limitations of each PrEP method, including guidance on potential side effects.
214691841|NCT03890952|DRUG|Nivolumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
214691842|NCT03890952|DRUG|Bevacizumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
214691843|NCT06076499|DEVICE|NTX100|NTX100 Tonic Motor Activation (TOMAC) System - a non-invasive peripheral nerve stimulation device programmed to deliver active stimulation.
214691844|NCT06797375|DRUG|RLYB116 for Injection|RLYB116 is a small protein composed of an Affibody® Z-domain that binds with high affinity to C5, inhibiting terminal complement activation, and an albumin binding domain (ABD) that extends the effective plasma half-life of the protein by targeting serum albumin.
214691845|NCT03050359|DRUG|TAK-438|TAK-438 tablets
215026898|NCT06638684|OTHER|Exercise|Subjects in the two groups preformed 90-100 minutes of exercise at different intensities.
214691846|NCT03050359|DRUG|Lansoprazole|Lansoprazole capsules
214691847|NCT03050359|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets.
214691848|NCT03050359|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
214691849|NCT03050359|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
214691850|NCT01127126|DRUG|Bryophyllum pinnatum, Placebo in form of Lactose|"Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d."
214691851|NCT01671969|OTHER|very low calorie diet|medically supervised diet
214691852|NCT00793676|OTHER|spirometry|
214691853|NCT00793676|OTHER|blood test|
214691854|NCT01360944|DRUG|LAS41004|once daily, topical, 100 microgram
214691855|NCT01360944|DRUG|reference|once daily, 100 microgram
214691856|NCT06512948|PROCEDURE|High tibial osteotomy|Surgical treatment for patients with osteoarthritis and indications for high tibial osteotomy
214691857|NCT01136668|PROCEDURE|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
214691858|NCT01136668|PROCEDURE|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
214691859|NCT02614287|DRUG|Galcanezumab|Administered SC
214691860|NCT05898750|DIETARY_SUPPLEMENT|MorDom|oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)
214691861|NCT03571841|BEHAVIORAL|Group Session|The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
214691862|NCT03571841|BEHAVIORAL|Telephone Booster|One month following the group session, women will receive a telephone booster session (\<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
214691863|NCT05388162|DEVICE|Mobile colposcope|It is a comparison trial - Comparing a standard colposcpoe with a smart-phone based colpsocpe.
214691864|NCT01156597|DRUG|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
214691865|NCT05141773|DEVICE|Computed adenoma detection system (CADe) plus endocuff|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps. An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
214691866|NCT05141773|DEVICE|Endocuff|An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
214691867|NCT05268315|BEHAVIORAL|Brief Psychoeducational Intervention|The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
215026899|NCT02853136|DRUG|Fluvoxamine|Fluvoxamine
215026900|NCT02853136|DRUG|BI 409306 - Powder for oral solution (PfOS)|BI 409306 - Powder for oral solution (PfOS)
215026901|NCT02853136|DRUG|BI 409306 - film coated tablet|BI 409306 - film coated tablet
215026902|NCT05210543|OTHER|not applicable, observational study|Patients do not receive intervention; observational study
215026903|NCT06560788|OTHER|collection of cerebrospinal fluid|CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis
214691868|NCT01392989|DRUG|CIK cells|Standard of care
214691869|NCT01392989|DRUG|Cyclosporine|5 mg/kg, po
214691870|NCT01392989|DRUG|Mycophenolate Mofetil|15 mg/kg, oral
215026904|NCT00867334|DRUG|Imatinib mesylate and panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
214691871|NCT01392989|DRUG|Thymoglobulin|7.5 mg/kg, IV
214691872|NCT01392989|RADIATION|Total Lymphoid Irradiation (TLI)|
214691873|NCT02417870|BIOLOGICAL|aldesleukin|
215026905|NCT00867334|DRUG|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
215026906|NCT01847014|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
215026907|NCT03563001|DRUG|Budesonide(160ug) and Formoterol(4.5ug) bid|For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
215104173|NCT03590353|DEVICE|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
215104174|NCT04709445|DIAGNOSTIC_TEST|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) before and after anastomosis formation, postoperative analysis of ingress and egress for specific regions of interest
214691874|NCT00255684|BIOLOGICAL|graft-versus-tumor induction therapy|
215026908|NCT03730350|BEHAVIORAL|Clinical Hypnosis|Hypnosis guidance and audio tracks aimed at promoting pain relief, reducing distress and anxiety, and facilitating sleep will be provided for independent use, with daily practice recommended. Each hypnosis session will be 20-25 minutes long. The scripts for these sessions have been developed based on the clinical literature (e.g., Elkins, 2014) and are already in use with patients of the pain service.
215104175|NCT05693350|DIAGNOSTIC_TEST|DUS|Duplex ultrasound
214424087|NCT01051583|PROCEDURE|Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin|The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
214424088|NCT00620217|GENETIC|intramyocardial injection of VEGF-A165/bFGF:placebo plasmid|The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
214424089|NCT04878991|DIAGNOSTIC_TEST|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
214424090|NCT02083029|PROCEDURE|Simulated dive reflex|All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
214691875|NCT00255684|DRUG|cyclophosphamide|
214691876|NCT00255684|DRUG|cyclosporine|
214691877|NCT00255684|DRUG|fludarabine phosphate|
214691878|NCT00255684|DRUG|mycophenolate mofetil|
214691879|NCT00255684|PROCEDURE|umbilical cord blood transplantation|
214691880|NCT00255684|RADIATION|radiation therapy|
214691881|NCT05366972|DEVICE|Ultrasonographic measurements|"Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles"
214691882|NCT05394740|DRUG|Regorafenib|"90 mg administered orally, once daily for 21 consecutive days followed by 7 days off~\*Repeat every 4 weeks as Regorafenib therapy"
214691883|NCT05394740|DRUG|Nivolumab|CohotA:360 mg administered intravenously, every 3 weeks \*Administered on the same day as CapeOX therapy Cohort B: 240 mg administered intravenously, every 2 weeks \*Administered on the same day as FOLFOX therapy
214694241|NCT02435277|DRUG|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
215026909|NCT03242447|BEHAVIORAL|e-Practice Self-Regulation|e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
215026910|NCT03242447|BEHAVIORAL|Video Health Group|The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
215026911|NCT03586921|BEHAVIORAL|Psychosocial Group Intervention|The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party.
215026912|NCT03586921|OTHER|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
215026913|NCT03622983|OTHER|collection of sample and data|Recovery of surgical waste during surgery planned in the current care and clinical data collection
215026914|NCT05597124|BEHAVIORAL|Cardio-Dance Fitness|This is an aerobic cardio-dance fitness exercise class in a social context with aerobic intensity assessed by heart rate monitoring throughout the class. Participants will meet three times a week for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
215026915|NCT05597124|BEHAVIORAL|Strength, Flexibility & Balance|This intervention will serve as a stringent, structurally equivalent, active comparator to the CDF intervention, identical in duration, frequency, and social contact except for the content of this non-aerobic intervention. SFB will involve non-aerobic activity with strength, flexibility, and balance training.
215026916|NCT04204616|DRUG|Nemolizumab|Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
215026917|NCT03031626|BIOLOGICAL|Medical Air vs Oxygen|Medical Air/Oxygen will be given
215026918|NCT06352463|OTHER|Denken + Doen = Durven|DDD is an evidence based cognitive behavioural therapy (CBT)-treatment protocol for children with anxiety. This research will use the modular version of DDD, which means that the therapist will decide which modules she will use based on the specific symptoms and needs of the child. DDD consists of four parts. First, there will be psycho education in which the child learns about how anxiety can arise, when anxiety is normal, and how thoughts, emotions, and behaviour are linked. Second, the child will learn coping strategies for dealing with anxiety. Third, there will be cognitive restructuring by which that the child will learn skills to deal with anxious and negative thoughts, through challenging and experimenting. Finally, there will be exposure. In the exposure sessions, the child will face their fears step by step.
215104176|NCT01721226|DEVICE|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
215104177|NCT01721226|OTHER|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
214508886|NCT01904097|OTHER|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
214508887|NCT00110669|DRUG|Prednisone|"Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding."
214508888|NCT03516032|BEHAVIORAL|exercises|
214508889|NCT06439992|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.
214508890|NCT01856569|OTHER|no intervention|in real life of drug,dosage,frequency and duration
214508891|NCT03515369|DRUG|Babaodan oral capsule|On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
214508892|NCT03515369|DRUG|Placebo oral capsule|On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
214691884|NCT05394740|DRUG|CapeOX|"For Cohort A only~* Capecitabine 1,000 mg/m\^2 administered orally, twice daily (Days 1 to 14 continuous dosing of CapeOX therapy)~* Oxaliplatin 130 mg/m\^2 administered intravenously (Day 1 of CapeOX therapy) \*Repeat every 3 weeks as CapeOX therapy"
214691885|NCT05394740|DRUG|FOLFOX regimen|"For Cohort B only~* Leucovorin 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy)~* Fluorouracil 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)~* Oxaliplatin 85 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) \*Repeat every 2 weeks as FOLFOX therapy"
214691886|NCT06177795|BEHAVIORAL|Post-visit patient text messaging|Patients will be sent text message reminders 4 days and 14 days after their primary care visit. The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling. The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.
215026919|NCT06352463|OTHER|Supportive Parenting for Anxious Childhood Emotions|Parents will follow the SPACE program. SPACE is a theory driven, evidence-based treatment program of 12 sessions. In a structured way, parents are trained to change their own behaviour as a reaction to the symptoms of their child. First, they are trained to recognise family accommodation and slowly reduce this. Second, this program focuses on the increase in supportive reactions from parents. They are taught to accept the child's feelings, fears, and problems and to trust in the ability of the child to cope with and tolerate anxiety-related problems. These two goals are attained via a sequence of steps in the SPACE manual. Furthermore, SPACE includes additional modules that can be implemented if needed. These provide tools for conquering communal challenges that can arise during the treatment process, including dealing with extremely disruptive behaviour of children and improving parental collaboration.
214691887|NCT06177795|BEHAVIORAL|Default pended order|A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
214691888|NCT06177795|BEHAVIORAL|High risk bidirectional post-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component after their visit. This intervention will query the patient about common questions or concerns about breast cancer screening. The bi-directional text messaging intervention will provide additional educational materials based on patient response as well as information about resources to help navigate to screening.
214691889|NCT00472472|DEVICE|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
214691890|NCT02006667|DRUG|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
214691891|NCT02006667|DRUG|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
215026920|NCT04049214|OTHER|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
215026921|NCT03228732|DRUG|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
215104178|NCT01484535|PROCEDURE|Ankle Aspiration|Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.
215104179|NCT01484535|PROCEDURE|Ankle aspiration Standard Anterolateral|Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
214424091|NCT02655380|DRUG|Ketamine 1|Anesthesia induction is performed with 1 mg ketamine.
214424092|NCT02655380|DRUG|Ketamine 2|Anesthesia induction is performed with 2 mg ketamine.
214424093|NCT02655380|DRUG|Remifentanil|After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
214691892|NCT02006667|DRUG|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
214691893|NCT02037802|DEVICE|B-Braun, Perifix® ONE Paed, Germany|caudal epidural catheterization bupivacaine fentanyl
214691894|NCT02037802|DRUG|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
214691895|NCT02037802|DRUG|Propofol|fentanyl propofol atracurium besylate
214424094|NCT03914170|DRUG|Folfirinox + cetuximab|Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
214424095|NCT02272959|BEHAVIORAL|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
214424096|NCT02272959|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
214691896|NCT02037802|DRUG|Bupivacaine|
215026922|NCT03228732|DRUG|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
215104180|NCT02292563|PROCEDURE|Colonoscopist only|Only Colonosopist Observe during Colonoscopy (single observer)
215026923|NCT03228732|DRUG|Fluoxetine|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
214691897|NCT02037802|DRUG|Fentanyl|
215026924|NCT03228732|DRUG|DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
215026925|NCT03228732|DRUG|Fluoxetine and DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
215026926|NCT04616781|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|nutritional ketone ester
215026927|NCT04616781|DRUG|Isocaloric dextrose placebo|Drink indistinguishable from ketone ester
215026928|NCT04616781|OTHER|Alcohol drinks|drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
215104181|NCT02292563|PROCEDURE|Experienced Endoscopy Nurse Participation|Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
215104182|NCT03053947|DRUG|Intranasal Ketamine|Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
214508893|NCT00090415|BEHAVIORAL|Intensive behavioral therapy|Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
214508894|NCT02958566|DRUG|Acetaminophen|
214508895|NCT02958566|DRUG|Gabapentin|
214508896|NCT02958566|DRUG|Orphenadrine|
214508897|NCT02958566|DRUG|Lidocaine|
214508898|NCT02958566|DRUG|Marcaine|
214508899|NCT02958566|DRUG|Ketamine|
214508900|NCT02958566|DRUG|Methadone|
214508901|NCT02958566|DRUG|Tramadol|
214508902|NCT02958566|DRUG|Ketorolac|
214508903|NCT02958566|DRUG|Morphine Sulfate|
214508904|NCT02958566|DRUG|Fentanyl|
214508905|NCT02958566|DRUG|Dilaudid|
214508906|NCT02958566|DRUG|Hydrocodone-Acetaminophen Tab 5-325 MG|
214508907|NCT02958566|DRUG|Morphine Sulfate|PCA
214508908|NCT02958566|DRUG|Fentanyl|PCA
214508909|NCT02958566|DRUG|Dilaudid|PCA
214508910|NCT02958566|DRUG|HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET|Breakthrough
214508911|NCT05244967|OTHER|vaginal swab|self-sampling, vaginal swab
214508912|NCT01719874|BIOLOGICAL|TCN-032|
214508913|NCT01719874|BIOLOGICAL|Placebo (saline)|
214508914|NCT04841096|DRUG|A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
214508915|NCT04841096|DRUG|B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
214508916|NCT04841096|DRUG|(A2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
214508917|NCT04841096|DRUG|(B2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
214508918|NCT03315338|DRUG|CORT118335, 25 mg|CORT118335 is supplied as capsules for oral dosing
214508919|NCT03315338|DRUG|Prednisone Oral Tablet|"Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered."
214508920|NCT03315338|DRUG|Glucose|75 g in 300 mL solution, orally administered
214508921|NCT03315338|DRUG|Placebo oral suspension|"Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered."
214508922|NCT03315338|DRUG|CORT118335, 75mg|CORT118335 is supplied as capsules for oral dosing
214508923|NCT03315338|DRUG|CORT118335, 225mg|CORT118335 is supplied as capsules for oral dosing
214508924|NCT03315338|DRUG|CORT118335, 675mg|CORT118335 is supplied as capsules for oral dosing
214508925|NCT03315338|DRUG|CORT118335, 600mg|CORT118335 is supplied as capsules for oral dosing
214508926|NCT03315338|DRUG|CORT118335, 630mg|CORT118335 is supplied as capsules for oral dosing
214508927|NCT03315338|DRUG|CORT118335, 375mg|CORT118335 is supplied as capsules for oral dosing
214508928|NCT03315338|DRUG|CORT118335, 100mg|CORT118335 is supplied as a suspension for oral dosing
214508929|NCT03315338|DRUG|CORT118335, 300mg|CORT118335 is supplied as a suspension for oral dosing
214508930|NCT03315338|DRUG|CORT118335, 900mg|CORT118335 is supplied as a suspension for oral dosing
214508931|NCT03315338|DRUG|CORT118335, 150mg|CORT118335 is supplied as a suspension for oral dosing
214508932|NCT03315338|DRUG|CORT118335, 1500mg|CORT118335 is supplied as a suspension for oral dosing
214508933|NCT03315338|DRUG|Placebo oral capsule|Placebo capsules, orally administered
214508934|NCT03315338|DRUG|CORT118335, dose to be determined|CORT118335 is supplied as suspension for oral dosing
214508935|NCT04693169|DRUG|11C-Choline|1、PSMA137 labeled with \[Al18F\] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the \[Al18F\]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
214508936|NCT06122025|DEVICE|Patient Access|A 6-month pilot prospective interventional study with an independent groups design.
214508937|NCT03744052|OTHER|Motivational Messages|Messages regarding physical activity will be texted to participants.
215104183|NCT05148806|DIAGNOSTIC_TEST|self-administered lateral flow assays|The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.
214691898|NCT00000513|BEHAVIORAL|diet, reducing|
214691899|NCT00000513|BEHAVIORAL|diet, sodium-restricted|
214691900|NCT00000513|DRUG|chlorthalidone|
214691901|NCT00000513|DRUG|atenolol|
214691902|NCT02939937|DRUG|Phenytoin|100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
214691903|NCT02939937|DRUG|placebo|100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
214691904|NCT03458676|PROCEDURE|Advanced Magnetic Resonance Imaging Scan|"AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete"
214508938|NCT01860079|PROCEDURE|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
214691905|NCT03458676|PROCEDURE|Standard of Care Brain Biopsy and Tumor Removal|"During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed."
214691906|NCT00856479|DEVICE|Infuse Bone Morphogenic Protein (BMP) 2|"Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention."
215104184|NCT04522349|DEVICE|Greifer then Axon-Hook|Each participant is fitted with a Greifer and assessed after two weeks home-trial. Then he is fitted with Axon-Hook and assessed after two weeks home trial.
214691907|NCT00856479|PROCEDURE|iliac crest autograft|A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
214691908|NCT01895816|DIETARY_SUPPLEMENT|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus \& ZINGIBER OFFICINALE \& Onion \& Ocimum basilicum \& Cinnamomum zelanicum \& Citrullus lanatus \& Citrullus vulgaris \& Daucus carota
214691909|NCT01702662|DEVICE|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
214691910|NCT05598294|PROCEDURE|Mobilization recommendations|Standard mobilization recommendations will be given to all patients, and feedback will be given to the intervention group to increase the number of steps 4 times a day according to the daily targeted number of steps.
214691911|NCT04865250|DRUG|Atezolizumab 1200 mg abs day 1 q22 (iv)|Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)
215104185|NCT04522349|DEVICE|Axon-Hook then Greifer|Each participant is fitted with a Axon-Hook and assessed after two weeks home-trial. Then he is fitted with Greifer and assessed after two weeks home trial.
215104186|NCT02615340|DRUG|Melatonin|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
215104187|NCT02615340|DRUG|Placebo|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
214508939|NCT00434694|PROCEDURE|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
214508940|NCT05383989|BEHAVIORAL|UniVenture Hopelessness manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Hopelessness (HOP) personality traits on the Substance Use Risk Profile Scale (SURPS).
214508941|NCT05383989|BEHAVIORAL|UniVenture Anxiety Sensitivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Anxiety Sensitivity (AS) personality traits on the Substance Use Risk Profile Scale (SURPS).
214691912|NCT05142514|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
214691913|NCT05142514|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive 2 injections of Cominarty administered 21 days apart
214691914|NCT04961814|OTHER|liberal fasting|preoperative fasting according to 6-4-0 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
214691915|NCT04961814|OTHER|standard fasting|preoperative fasting according to 6-4-2 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
214691916|NCT03503682|RADIATION|standard treatment|3000 cGy in 10 daily fractions
214691917|NCT03503682|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
214691918|NCT01695850|DRUG|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
215026929|NCT06038214|OTHER|core exercises|"1.5 minutes walking 2. Stretching exercise~* hallowing in supine and side lying position~* Bracing in supine and side lying position~* Bracing on the prone and forearms~* Bracing in the crawling position~* Bracing in laptop, half-lap and standing position~* Heel slide exercise~* Bridge building exercise~* Unilateral limb flexion exercise in crawling position~* Reciprocal heel slide exercise in supine position~* Bilateral lower extremity lifting exercise~* Unilateral lower extremity flexion in bridging position~* Side bridging exercise with knees extended~* Unilateral lower extremity extension in crawling position~* Contralateral lower and upper extremity lift in the crawling position~* Straight and oblique trunk flexion~* Straight and oblique trunk flexion with hip and knee flexed to 90°~* bracing on the ball~* squat~* bracing while walking"
214508942|NCT05383989|BEHAVIORAL|UniVenture Sensation Seeking manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Sensation Seeking (SS) personality traits on the Substance Use Risk Profile Scale (SURPS)
215026930|NCT06038214|OTHER|home exercises|"Right and left rotation of the head~* lateral flexion of the head~* Flexion and extension of the head~* Stretching the neck extensors~* pectoral stretch~* Stretching the hip extensors~* Hamstrig stretching~* Stretching the lumbar extensors~* Abdominal strengthening~* bridging~* Hip abduction strengthening~* hip extension strengthening~* Upper extremity resistant flexion~* Upper extremity resistant abduction~* Upper extremity relaxation exercise~* Capsule stretching~* Stretching the hip flexors~* Stretching the lower extremity adductors~* relaxation exercise"
215026931|NCT05035927|DRUG|TRYP-0082|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
215026932|NCT05035927|BEHAVIORAL|Psychotherapy|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
215026933|NCT04375826|DEVICE|Epidural patient controlled analgesia|The device is connected to the epidural catheter prior to surgery and drug administration is started during surgery. The continuous infusion rate is 4 ml / hr. When the button is pressed, 2 ml is additionally administered and the lock time is 20 minutes.
215026934|NCT04375826|DEVICE|Preperitoneal analgesia and IV-PCA|During surgery, the preperitoneal analgesia catheters are inserted into the preperitoneal space and these catheters are connected to the pump with ropivacaine.
215026935|NCT06644794|DRUG|Progesterone-modified natural cycle preparation for frozen embryo transfer|A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.
215026936|NCT06644794|DRUG|Hormone replacement therapy cycle preparation for frozen embryo transfer|A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.
215026937|NCT04606290|DEVICE|O2matic HOT|Automated oxygen titration with O2matic HOT
215026938|NCT04606290|DEVICE|Oxygen concentrator|Fixed dose oxygen flow from concentrator
215026939|NCT06641167|PROCEDURE|Shoulder surgery|shoulder surgery by arthroscopic approach under locoregional anesthesia combining an interscalene block and a superficial cervical plexus block
215026940|NCT06641726|OTHER|Not applicable- observational study|This is non-interventional, cross-sectional observational study and thus there is no intervention.
215026941|NCT06642857|OTHER|Peripheral blood, tougue coating, saliva, and feces|Peripheral blood, coating, saliva, and feces on the tongue and clinical data of patients with advanced gastric cancer patients who received chemotherapy combined with immunotherapy will be collected.
215026942|NCT06641206|DRUG|Triamcinolone Acetonide|1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain
215026943|NCT06641206|DRUG|Bupivacaine Hydrochloride|20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain
215026944|NCT06641206|DRUG|Dexmedetomidine|Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
215026945|NCT06636799|DEVICE|Microneedling only|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left.
214508943|NCT05383989|BEHAVIORAL|UniVenture Impulsivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Impulsivity (IMP) personality traits on the Substance Use Risk Profile Scale (SURPS).
214508944|NCT05383989|BEHAVIORAL|Service as usual provided by the University|It is the regular university-provided well-being services.
214691919|NCT01695850|DRUG|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
214694242|NCT02435277|DRUG|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
215026946|NCT06636799|OTHER|Microneedling and actives|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left. Group G3 received microneedling associated with active ingredients. This manipulated active ingredient was composed of growth factors (EGF Factor, TGFß3 Factor, and IDP-2 Peptide), Hydroxyprolisilane, and hyaluronic acid.
215026947|NCT06638047|PROCEDURE|robotic-assisted TKA|Robotic-assisted TKA means that TKA surgery is operated with the guidance of robotic system.
215026948|NCT06638047|PROCEDURE|CI-TKA|TKA operated with conventional instruments
215026949|NCT06645067|BEHAVIORAL|Measuring energy balance|"The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.~Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. We will measure the resting ED at the start of the programme and the ED during moderate aerobic exercise in the 5th week of APA."
215026950|NCT05014126|BEHAVIORAL|Pain, Stress and Emotions|2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.
215026951|NCT06643520|DEVICE|19-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 19 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
214508945|NCT01088841|DIETARY_SUPPLEMENT|lactisole|lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
214508946|NCT00718120|BIOLOGICAL|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
214508947|NCT03292692|BEHAVIORAL|OurRelationship|Online intervention with coach support
214508948|NCT00040105|DRUG|Zarnestra (R115777)|"Starting Dose:~300 mg by mouth (PO) Twice daily"
214508949|NCT00040105|DRUG|Gleevec (Imatinib mesylate)|"Starting Dose:~300 mg By Mouth (PO) daily"
214508950|NCT02110381|DEVICE|Device guided breathing RESPeRATE|"Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.~Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit."
214508951|NCT02110381|DEVICE|Isometric hand grip Zona Plus|"Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.~Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit."
214508952|NCT02695004|DRUG|DKF-310|
214508953|NCT02695004|DRUG|Placebo|
214508954|NCT01915888|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
214508955|NCT06584734|OTHER|Not exercise|Patients were withdrawn from the exercise they had previously been doing during their hemodiafiltration sessions.
214508956|NCT06584734|OTHER|Exercise during hemodiafiltration session|Exercise with cycle ergometers during hemodiafiltration session, intensity was measure with power meters in Watts units.
214508957|NCT01189929|DRUG|Demcizumab|Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.
214508958|NCT01189929|DRUG|Abraxane®|Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
214508959|NCT01189929|DRUG|Gemcitabine|Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.
214508960|NCT02848105|DRUG|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
214508961|NCT03483649|DRUG|HLX04|HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
214508962|NCT03483649|DRUG|US-Avastin®|US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
214508963|NCT03483649|DRUG|EU-Avastin®|EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
214691920|NCT01695850|DRUG|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
214691921|NCT05216848|OTHER|Wijma Delivery Expectancy Questionnaire|Simple questionaire identifying the level of fear of childbirth in pregnancy
214691922|NCT05216848|OTHER|Clinical data collection|Collection of the standard clinical data during hospitalization
214691923|NCT03007485|OTHER|Telehealth Pulmonary Rehabilitation|Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
214691924|NCT01848054|DRUG|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
214691925|NCT01848054|DRUG|Buprenorphine|Buprenorphine sublingual tablets
214691926|NCT00792233|OTHER|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
215026952|NCT06643520|DEVICE|22-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely.~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 22 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
214691927|NCT02634099|DEVICE|blood measurement|Hemoglobin measurement
215026953|NCT06643559|OTHER|cognitive rehabilitation|Cognitive rehabilitation started to one group at the beginning of the antiseizure medicine. Participants underwent computer-based cognitive rehabilitation for 3 sessions per week, with each session lasting an average of 60 minutes. Before the sessions, all participants were given detailed information about the programme and its use. The rehabilitation process was carried out in three areas of cognitive functions: memory, executive functions, and language skills.
215104188|NCT02950480|DRUG|zafirlukast|Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.
215104189|NCT02950480|OTHER|Standard of Care (no intervention)|Standard of Care (no intervention)
215104190|NCT01913002|DRUG|LX4211 800 mg|
215104191|NCT01913002|DRUG|LX4211 2000 mg|
215104192|NCT01913002|DRUG|moxifloxacin 400 mg|
215104193|NCT01913002|DRUG|LX4211 Placebo|
215104194|NCT03121365|BEHAVIORAL|Digital/E-Book Arm|Promotion of early reader digital e-book reading
215104195|NCT03121365|BEHAVIORAL|Standard/Board Book Arm|Promotion of early reader board book reading
215104196|NCT04022863|DIAGNOSTIC_TEST|TEP|Tumor Educated Platelets
215104197|NCT04022863|DIAGNOSTIC_TEST|ctDNA|circulating tumor DNA
215104198|NCT00746863|DRUG|0.125% Marcaine|Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
215104199|NCT05494437|COMBINATION_PRODUCT|PP-01 High Dose|Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
215104200|NCT05494437|COMBINATION_PRODUCT|PP-01 Low Dose|CB1 partial agonist / GABAergic modulator
215104201|NCT05494437|DRUG|Placebo|Placebo comparator
215104202|NCT05494437|DRUG|Nabilone|CB1 receptor
215104203|NCT05494437|DRUG|Gabapentin|GABAergic modulator
214691928|NCT02634099|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
214691929|NCT02634099|DEVICE|hemoCue|non invasive method of hemoglobin measurement
214694243|NCT01915004|OTHER|Educational Intervention|Bladder Training Video
214694244|NCT00008138|DRUG|carboplatin|pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
214694245|NCT00008138|DRUG|paclitaxel|pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
215104204|NCT03229109|DEVICE|Spectrophon dehydration body monitor|Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
215104205|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories|
215104206|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme|
215104207|NCT06442488|DEVICE|Respiratory Monitoring System|Comparing the SNR and accuracy of measurement (RR, TV, MV, apnea duration) in a noisy external environment when the RMS has adaptive filtering and active noise cancellation turned on versus turned off.
215104208|NCT00370916|BEHAVIORAL|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
215104209|NCT00370916|BEHAVIORAL|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
215104210|NCT00406172|DRUG|Bevacizumab|
215104211|NCT02262702|DRUG|Paracetamol 665 mg|Paracetamol 665 mg tablet
215104212|NCT02262702|DRUG|Paracetamol 500 mg|Paracetamol 500 mg tablet
215104213|NCT00656864|DRUG|Pioglitazone|Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
214508964|NCT03483649|DRUG|CN-Avastin®|CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
214508965|NCT03347851|OTHER|MRI|Enrolled patients will complete a non-contrast cardiac MRI
215026954|NCT06645288|OTHER|Emergency Reflex Action Drill|Emergency Reflex Action Drill in performing Emergency Surgical Airway
215026955|NCT06644001|DIETARY_SUPPLEMENT|Bacillus coagulans GBI-30,6086 (BC GBI-30)|2g powder/sachet, consists of bacillus coagulans at a dose of 1x10\^9 CFU, taken once daily before a meal.
215026956|NCT06644001|DIETARY_SUPPLEMENT|Placebo|2g powder/sachet, consists of maltodextrin only, taken once daily before a meal.
215026957|NCT06460155|DEVICE|3 methods intervention|Stu All participants will undergo all three methods being studied: epidurogram (gold standard), CompuFlo CathCheck, and physical exam in PACU following epidural placement.
215104214|NCT00656864|DRUG|Placebo|placebo
215104215|NCT00668668|DRUG|Lactic acid (Dermacid)|
215104216|NCT03260296|OTHER|self-administered structured questionnaire|"Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences"
215104217|NCT02641301|DRUG|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
215104218|NCT02075788|OTHER|Commercial white bread|
215104219|NCT02075788|OTHER|Corn based products (porridge etc.)|
214508966|NCT03347851|OTHER|Transthoracic echocardiography exam|Enrolled patients will complete a transthoracic echocardiography exam.
214508967|NCT04114019|DIAGNOSTIC_TEST|Vaginal tactile imager|Vaginal elasticity evaluation using a vaginal tactile imager
214508968|NCT04802681|DEVICE|FFR-measurement with different pressure guidewires|Measuring FFR with different pressure guidewires
214508969|NCT01943669|DEVICE|ReWalk™ device|Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
214508970|NCT05063006|OTHER|Cardiopulmonary exercise tests with maintained baseline optimal pump speed settings.|Optimal resting LVAD speed settings is defined as periodic aortic valve opening while maintaining the central position of the intraventricular septum, minimizing mitral regurgitation, and preserving the mean systemic blood pressure above 65 mmHg. The aim is to achieve an aortic valve opening ratio of around 25-33% by changing the pump speed at resting conditions.
214694246|NCT00008138|PROCEDURE|debulking surgery|exploratory laparotomy, interval cytoreduction (to \< 1 cm residual)
214694247|NCT06503861|BEHAVIORAL|Food Is Medicine intervention|The intervention provides regular meal kits as well as cooking and nutritional education.
215026958|NCT06643624|OTHER|Vision Training Program|Vision training (experimental) group; vision training program was applied in addition to routine training programs. For 8 weeks, 5 sessions per week for a total of 40 sessions of vision training were applied by a physiotherapist. In the first 2 weeks, each movement was applied for 1 minute for a total of 10 minutes. In the 3rd week, each movement was practiced for 1.5 minutes for a total of 15 minutes. In weeks 4-8, each movement was performed for 2 minutes each for a total of 20 minutes.
215026959|NCT06643624|OTHER|Routine Training Program|All athletes performed their routine training for wrestling 6 days a week.
215104220|NCT02075788|OTHER|Millet based products (porridge etc.)|
215104221|NCT05813691|DIAGNOSTIC_TEST|Meridan Bioscience Point of Care test against HCV antibodies|Point of care evaluation of antibodies against HCV obtaining a drop of capillary blood via puncture of the fingertip. If antibodies were detected, HCV RNA assay will be performed.
215104222|NCT01835223|DRUG|Tivozanib (1mg)|Given PO
215104223|NCT01835223|DRUG|Tivozanib (1.5mg)|Given PO
215104224|NCT05767112|OTHER|Supplement administation|HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.
214508971|NCT05063006|OTHER|Cardiopulmonary exercise test with gradually increased pump speed depending on live echocardiographic imaging.|During the modified speed exercise, when the aortic valve opening ratio rises above 50%, the pump speed is increased by 100 revolutions per minute (RPM). As the aortic valve remains closed the RPM is lowered by 100. Speed increment is not greater than 100 RPM per 45 seconds to enable an echocardiographic analysis of resulting changes and prevent suction events. There is no determined target speed, neither per time period nor maximal.
214508972|NCT05912049|DRUG|9MW3811 Injection|Single dose intravenously infused on day 1
214508973|NCT05912049|DRUG|Placebo|Single dose of matching placebo intravenously infused on day 1
214508974|NCT06145191|DRUG|Tranexamic acid|Prophylactic topical application (1x) of tranexamic acid (100mg, 2ml, room temperature) before sampling
214508975|NCT06145191|DRUG|Adrenaline|Prophylactic topical application (1x) of adrenaline (1:10.000, 2ml, room temperature) before sampling
214508976|NCT06145191|DRUG|Placebo|Prophylactic topical application (1x) of placebo (0.9% NaCl, 2ml, room temperature) applied before sampling
214508977|NCT01412606|PROCEDURE|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
214694248|NCT03114982|BIOLOGICAL|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
215026960|NCT06643533|OTHER|Fecal Microbiota Transplantation|The FMT capsules will be prepared by matching the gut microbiome profiles of healthy donors with those of patients who achieved a complete response to the triple therapy. The FMT capsules will be taken orally at a dosage of 30 capsules per day for the first 3 days of each treatment cycle. The FMT intervention will be administered in 6 cycles, with each cycle lasting for 21 days (Q3W). The duration of the treatment will be determined by the response to therapy, with a maximum of 6 cycles or until disease progression, intolerable toxicity, or participant withdrawal of consent. The FMT capsules are intended to modify the gut microbiome to reverse the resistance to the triple therapy and enhance the therapeutic response.
214508978|NCT03295409|BEHAVIORAL|Self-affirmation|Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.
214508979|NCT05605132|OTHER|Proprioceptive Training Exercise|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~* head relocation~* gaze stability~* eye follow~* saccadic eye movement~* head and eye coordination"
214508980|NCT05605132|OTHER|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
214508981|NCT05605132|OTHER|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
214508982|NCT02305498|OTHER|Vigorous yoga practice|
214508983|NCT02305498|OTHER|Restorative (gentle) yoga practice|
214508984|NCT03576092|DIAGNOSTIC_TEST|Lung Ultrasound|Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
214508985|NCT02959385|RADIATION|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
214508986|NCT02959385|PROCEDURE|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
214508987|NCT01324076|DRUG|doxorubicin-eluting beads|
214508988|NCT01324076|DRUG|sorafenib tosylate|
214508989|NCT01324076|OTHER|laboratory biomarker analysis|
214508990|NCT01324076|OTHER|pharmacogenomic studies|
214508991|NCT01324076|OTHER|pharmacological study|
214508992|NCT01324076|PROCEDURE|quality-of-life assessment|
214508993|NCT00640588|DRUG|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
214508994|NCT00640588|DRUG|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
214508995|NCT05088200|PROCEDURE|surgery|Our study is observational and we use secondary data
214508996|NCT04063124|DRUG|Dasatinib + Quercetin|Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
214694249|NCT03114982|BIOLOGICAL|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
215104225|NCT01504841|DRUG|Etravirine (ETR)|ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
214508997|NCT00524797|DIETARY_SUPPLEMENT|Profonycia|
214508998|NCT02709200|DRUG|Dexmedetomidine|
214508999|NCT02950961|BEHAVIORAL|Collaborative Care for Women Veterans|This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators offered in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators trained appropriate MH providers in CALM and studied the ways in which the intervention needs to be tailored to women Veterans.
214509000|NCT04158206|OTHER|Maternal voice|Recording in the intensive care unit quiet and separate consultation room. For infants in the 'maternal voice group,' mothers were asked to tape what the mother wants to say to their babies and read of a child book from the independent publish, 'Xiao Qi's yellow persimmon' which talk about the mother who has a premature infants how to take caring of their baby. After reviewing the quality of the recording, the mother's voice recordings are compiled for 13 minutes with Sound Organizer. 2 , and the volume of the sound standard according to the American Academy of Pediatrics guidelines is 60 decibels in the incubator.
214509001|NCT02241785|DRUG|natalizumab|Administered as specified in the treatment arm
214509002|NCT01640340|DRUG|aprepitant|Given by mouth
214509003|NCT01640340|DRUG|palonosetron hydrochloride|Given IV(intervenous infusion)
214509004|NCT01640340|DRUG|ondansetron|Given PO
214509005|NCT01640340|DRUG|dexamethasone|Given PO
214509006|NCT03055988|DRUG|Tiotropium|Fixed Dose Combination
214509007|NCT03055988|DRUG|Olodaterol|Fixed Dose Combination
214509008|NCT03055988|DRUG|Fluticasone propionate|Fixed Dose Combination
214509009|NCT03055988|DRUG|Salmeterol|Fixed Dose Combination
214694250|NCT05931523|BEHAVIORAL|Stress First Aid|The focus of the model is ongoing monitoring of stress in personnel, wide spread training to help personnel recognize peers or subordinates who may need additional assistance, a spectrum of one-on-one interventions, and the ability to provide personnel higher levels of care when indicated.
214509010|NCT01733862|OTHER|Data collection|"Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016."
214509011|NCT03389919|BIOLOGICAL|MSC administration (intraosseal)|MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.
214509012|NCT05089487|PROCEDURE|Nocturnal rest (sleep study)|Proportion of patients free of severe hypoxemia without oxygen therapy during nocturnal rest .
214509013|NCT00845520|DEVICE|Lens implantation +1.00 D postop target|Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
214509014|NCT00845520|DEVICE|Lens implantation -1.00 D postop target|Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
214509015|NCT00845520|DEVICE|Lens implantation 0.00 D postop target|Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
214509016|NCT02507869|BEHAVIORAL|Positive affective response|Participants adjust the intensity of their exercise to maintain a pleasant affective response.
214509017|NCT02507869|BEHAVIORAL|Moderate-intensity heart rate|Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
214691930|NCT05738499|OTHER|Character strengths-based structured treatment and education programme (CSSTEP)|This CSSTEP intervention included both psychological and educational contents, and the intervention type was psycho-educational intervention. The implementation process lasted for three weeks. CSSTEP mainly includes two main components. The first part is character strengths-based intervention. The second part is educational intervention, which is structured treatment and education programme for stroke patients. The two components were combined and optimized on the basis of theoritical and empirical evidences, and then this kind of complex intervention suitable for Chinese clinical stroke patients was obtained.
214691931|NCT05738499|OTHER|Structured treatment and education programme (STEP)|The STEP programme is aimed at the treatment needs of stroke patients, considering the education level and cultural background of patients, screening important health education content, and planning and grading of patients' education. The intervention consisted of three educational sessions, focusing on patients' daily life, post-stroke rehabilitation and secondary prevention.
214691932|NCT06285929|OTHER|ACS CARES Student Navigation|Student volunteers providing navigation support to patients, families and caregivers with a cancer diagnosis through an SDOH assessment.
215104226|NCT02317848|OTHER|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
214509018|NCT01357694|BEHAVIORAL|psychotherapeutic contacts|psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
214509019|NCT00860236|OTHER|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
214509020|NCT00860236|BEHAVIORAL|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
214509021|NCT01181232|DRUG|Zolpidem MR|oral
214509022|NCT01181232|DRUG|Zolpidem IR|oral
214691933|NCT04626193|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
214691934|NCT04626193|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
214691935|NCT02704494|DRUG|Resveratrol|Resveratrol 500mg daily
214691936|NCT02704494|DRUG|Placebo|Placebo 1 capsule daily
214691937|NCT02704494|DRUG|Losartan|Losartan 12.5mg daily
214691938|NCT05249231|DRUG|Silver diamine fluoride|Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
215026961|NCT06644547|BEHAVIORAL|Gezond en goed met elkaar|"The intervention 'Gezond en goed met elkaar' focuses on improving (positive) health literacy and literacy. The six domains of positive health are the focus of the intervention meetings. This intervention has been made available for citizens of Almere, Zwolle, Gouda, Nunspeet and Leusden through collaboration with these municipalities. Lifestyle coaches working in these municipalities implement the intervention."
215026962|NCT02914886|DRUG|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
215026963|NCT02914886|DRUG|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
215026964|NCT04287829|DRUG|Pembrolizumab|Infusion
215026965|NCT04287829|DRUG|Lenvatinib|Capsule
215026966|NCT04981145|DRUG|Iguratimod Tablets|Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
215026967|NCT04981145|DRUG|Hydroxychloroquine Sulfate Tablets|Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
215026968|NCT05418426|DEVICE|IVR Dose 1|Estradiol 80 ug/progesterone 4 mg
215026969|NCT05418426|DEVICE|IVR Dose 2|Estradiol 160ug/progesterone 8 mg
214509023|NCT01736475|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
215026970|NCT05418426|DRUG|Oral Reference|estradiol 1mg/progesterone 100 mg
215026971|NCT01713829|OTHER|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
215026972|NCT01713829|OTHER|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
215026973|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
215104227|NCT03679624|DRUG|Ibrutinib|Ibrutinib, 420mg orally, once daily
214509024|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
214509025|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
214509026|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|On-demand treatment
215026974|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
215026975|NCT06276335|OTHER|Immediate implant placement and guided bone regeneration (Test)|In this group, immediately after tooth extraction, a tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. A prefabricated surgical template based on 3D pre-extraction planning will be used to place the implant. The jumping distance between the implant and the residual buccal bone will be measured and filled with slow resorption bone graft material (Bio-Oss®, Geistlich, Wolhusen, Switzerland) as per standard of practice.
214509028|NCT00127582|PROCEDURE|Electrophysiological study|
214509029|NCT00127582|DEVICE|pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant|
214509030|NCT02807857|PROCEDURE|Standard care|Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
214509031|NCT01876966|DRUG|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
214509032|NCT01876966|DRUG|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
214509033|NCT01876966|DRUG|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets \[20/120 mg\] at 0, 8, 24, 36, 48, and 60 hours)
214509034|NCT02509858|DRUG|thyroxine|treatment with 50μg of thyroxine once daily for two months.
214509035|NCT02509858|DRUG|Placebo|treatment with 50μg of placebo, once daily, for two months.
214509036|NCT02509858|OTHER|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
214509037|NCT00482742|DEVICE|CiTop(TM) Guidewire|
214509038|NCT03632876|DIETARY_SUPPLEMENT|retinyl palmitate|The intervention is a daily vitamin A supplement.
214509039|NCT01137916|DRUG|Imatinib|800 mg
214509040|NCT02515123|DEVICE|E-Motion System|"E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.~E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.~By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding."
214509041|NCT02515123|DEVICE|Sham E-Motion System|The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
214509042|NCT05001126|BEHAVIORAL|HIFT 1x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 1x/week represents a dose of one HIFT workout per week.
214509043|NCT05001126|BEHAVIORAL|HIFT 2x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 2x/week represents a dose of two HIFT workouts per week.
214509044|NCT05001126|BEHAVIORAL|HIFT 3x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 3x/week represents a dose of three HIFT workouts per week.
214509045|NCT04237909|BIOLOGICAL|PRP injection into at least one ovary|The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
214509046|NCT06143007|DRUG|BB3008 tablet|BB3008 tablets will be administered orally once daily (QD).
214509047|NCT00746759|DEVICE|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
214509048|NCT00056654|DRUG|Leuprolide acetate|45 mg Intramuscular injection 6 month depot formulation
214509049|NCT05554549|OTHER|Dietary pattern observed|Dietary pattern: regular meat-eater, occasional meat-eater, pescatarian, and vegetarian. There are no interventions in this observational cohort.
214509050|NCT03530631|DRUG|Adderall|Participants will be administered Adderall
214509051|NCT03530631|DRUG|Placebo|Participants will be administered placebo
214509052|NCT05137600|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
214509053|NCT05137600|DRUG|Midazolam|Midazolam is a sensitive CYP3A index substrate
214509054|NCT05137600|DRUG|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
214509055|NCT04205799|DRUG|Cabozantinib|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
214509056|NCT01827982|DRUG|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
214509057|NCT01827982|DRUG|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
214509058|NCT01827982|DRUG|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
214509059|NCT01827982|DRUG|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
214509060|NCT01827982|DRUG|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
214509061|NCT01827982|DRUG|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
214509062|NCT01827982|DRUG|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
215104228|NCT03679624|DRUG|Daratumumab|Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.
215104229|NCT01610336|DRUG|INC280|During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
214691939|NCT05249231|DEVICE|Hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method
215104230|NCT01610336|DRUG|Gefitinib|Gefitinib 250 mg taken once daily
215104231|NCT05030350|DRUG|PH94B|Nasal spray
215104232|NCT05882149|DIETARY_SUPPLEMENT|Single strain probiotic|"Sugar-free chewing gum with single strain probiotic and zinc.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
215104233|NCT05882149|DIETARY_SUPPLEMENT|Placebo|"Sugar-free chewing gum.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
215104234|NCT02139865|BEHAVIORAL|30% 1RM|Participant exercises using a protocol tailored at 30% of their 1RM
215104235|NCT02139865|BEHAVIORAL|80% 1RM|Participant exercises using a protocol tailored at 80% of their 1RM
214424097|NCT03387319|BEHAVIORAL|Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
214424098|NCT03387319|BEHAVIORAL|Non-Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
214424099|NCT04010955|DRUG|Edoxaban Monotherapy|when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
214424100|NCT03396692|PROCEDURE|Intravenous morphine patient-controlled analgesia (PCA)|"Group 1 control:~* Morphine titration at 0.1 mg/kg~* Establishment of PCA morphine:~* concentration 1mg/ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg"
214691940|NCT05973643|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (bitemporal) or unilaterally (or fronto-temporal) on the frontotemporal region under anesthesia.~The stimulation dose is determined by titration method, during the first ECT session. An ECT cure corresponding from 12 to 20 sessions of ECT. Patients will receive 2 sessions a week.~Blood samples will be done during the anesthesia process."
214691941|NCT00903747|DRUG|prucalopride|2-10 mg prucalopride
214691942|NCT00903747|DRUG|moxifloxacin|400 mg moxifloxacin (Group 2a)
214691943|NCT00903747|DRUG|placebo|placebo (Group 2b)
214691944|NCT01870219|DRUG|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
214691945|NCT01870219|DRUG|Ketamine|ketamine was given to 1mg/kg ıv bolus
214691946|NCT00243113|DRUG|docetaxel|
214691947|NCT00243113|RADIATION|radiation therapy|
214691948|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
214691949|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
214691950|NCT03406286|DRUG|Tolvaptan|
214691951|NCT06026254|DRUG|IMSA101|Intra-tumoral administration on Days 1 and 15 of every 28-day cycle
214691952|NCT06026254|DRUG|Immune Checkpoint Inhibitor|Administered according to product label
215026976|NCT06276335|OTHER|Late implant placement and guided bone regeneration (Control)|A tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed after complete bone healing (4 - 6 months after tooth extraction) in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. Guided bone regeneration (GBR) will be performed simultaneously with the aim to re-establish the bone contour and treat any fenestration/dehiscence if needed. A bovine osteoconductive graft (Bio-Oss®, Geistlich, Wolhusen, Switzerland) will be loosely compacted on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland).
215026977|NCT04620668|DEVICE|Wysa|Wysa is an AI-based mental health chatbot. It uses evidence-based techniques to help users build mental resilience skills and improve their mental health.
215026978|NCT01397591|BIOLOGICAL|Ofatumumab|Given intravenously
215026979|NCT01397591|DRUG|Bortezomib|Given intravenously
215026980|NCT02826187|OTHER|Early complications data|"Early complications of interest are :~* New arthroplasty for any reason~* Related to the implant :~  * Wrong position of the implant~ * Early displacement of the implant~* Related to the intervention :~  * Hematoma~ * Dislocation (or not causing the resumption of joint replacement)~ * Deep vein thrombosis~ * Pulmonary embolism~ * Acute Infection"
215026981|NCT02826187|OTHER|Late stage complications data|"Late complications taken into account are:~* New arthroplasty for any reason~* Aseptic loosening~* Delayed hypersensitivity reaction type IV~* Solid Tumors~* Recurrent dislocation (causing or not the resumption of joint replacement)~* Allergic reactions of any kind~* Chronic infection"
215026982|NCT02826187|OTHER|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
215026983|NCT02826187|OTHER|Efficacity|Efficacity as evaluated by Harris HIP score
215026984|NCT02826187|OTHER|Radiographic evaluation|Bone reaction visible in radiography
215026985|NCT06634771|DEVICE|10 Hz transcranial alternating current stimulation (tACS)|10 Hz bi-frontal tACS: Alternating current stimulation is delivered by an XCSITE 100 device (Pulvinar Neuro, Chapel Hill, NC), through three conductive carbon-rubber electrodes. Electrodes are placed over the apex of the head (Cz) and the prefrontal cortex bilaterally (F3 and F4). Stimulation is delivered during the second half of the HABIT Test session. Stimulation parameters: 2mA peak-to-peak 10Hz sine-wave flanked by 10 second linear envelope ramps in and out for a total duration of 30 min and 20 seconds.
215026986|NCT06634771|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham tACS: The procedure for sham stimulation will be identical, but it will last for 2 minutes instead of 30 minutes.
215026987|NCT06628986|BEHAVIORAL|MBSR|20 minutes once a week for 8 weeks
215026988|NCT06628986|BEHAVIORAL|NLP|NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks
215026989|NCT06628986|BEHAVIORAL|control|control group, no practice,
215026990|NCT06630130|DRUG|Trastuzumab deruxtecan|"* Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W for 3 cycles~* Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W 16 cycles (up to 12 months)"
215026991|NCT06630130|DRUG|Capecitabine|"* Neoadjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~* Adjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)"
215026992|NCT06630130|DRUG|Rilvegostomig|"(Only Cohort B)~* Neoadjuvant; Rilvegostomig 750mg IV on D1, Q3W for 3 cycles~* Adjuvant; Rilvegostomig 750mg IV on D1, Q3W for 16 cycles (up to 12 months)"
215026993|NCT04103814|DRUG|magnesium-cannabidiolic acid cream|Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
215026994|NCT04103814|DRUG|Placebo cream|Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
215026995|NCT04812483|DRUG|Eltrombopag (Revolade®)|Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
215026996|NCT04812483|DRUG|standard therapy (without eltrombopag): HD-DXM|standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
215026997|NCT06301815|DIAGNOSTIC_TEST|Scale for Contraversive Pushing|Lateropulsion will be assessed using the Scale for Contraversive Pushing (SCP). It involves observation of the posture of the participant in sitting and standing. Scores are assessed in sitting and standing giving a maximum score of 6.
215026998|NCT06301815|DIAGNOSTIC_TEST|Catherine Bergego Scale|Neglect will be assessed using the Catherine Bergego Scale. The scale is a 10-point scale with each item scored between 0 (no neglect) and 3 (severe neglect). It involves observation of a participant completing daily activities such as eating, dressing and walking.
215026999|NCT06301815|DIAGNOSTIC_TEST|Bucket Test|"The bucket test involves the patient being sat upright and looking into a translucent bucket with the bucket covering their complete field of vision. On the inside of the bucket on the bottom is a dark straight line. On the outside of the bottom of the bucket is a matching dark line, the bottom of the bucket is divided into degrees with the zero-degree line being equivalent to the line inside the bucket. For measurement the bucket will be randomly rotated right or left by the examiner to 45 degrees and then slowly rotated back to the zero-degree position. Patients will signal when they estimate the inside bottom line to be truly vertical by saying stop or by raising their non-paretic hand."
215027000|NCT01384045|OTHER|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
215027001|NCT04677361|COMBINATION_PRODUCT|MILs™ in Combination with Pembrolizumab|Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC
215027002|NCT02372357|DRUG|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
215027003|NCT02372357|PROCEDURE|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
214691953|NCT04281030|BEHAVIORAL|PMR (Progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
214691954|NCT04281030|BEHAVIORAL|Monitored Usual Care (MUC)|Subjects will be given basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
214691955|NCT03442894|PROCEDURE|Standard Physical Therapy Treatment|All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
214694251|NCT04158713|DRUG|Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine|Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
215027004|NCT01893099|DRUG|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
215027005|NCT01893099|DEVICE|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
215027006|NCT02315976|DRUG|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
214694252|NCT01264250|DRUG|AZD2927|Single dose of AZD2927
214694253|NCT01264250|DRUG|Placebo|Single dose of placebo
214694254|NCT05924776|BIOLOGICAL|Plasmodium immunotherapy|Inoculation 1-5 × 10\^6 Plasmodium vivax once
214691956|NCT03442894|PROCEDURE|Dry Needling|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits (they will occur at the same time). In 6 of the scheduled 10 visits, dry-needling intervention will be performed. They will have one DN session per week, which is consistent with typical clinical practice. After they complete their standard PT treatment, and while still in the clinic, the rotator cuff and periscapular muscles will be evaluated for the presence of MTrPs. Once located, the MTrPs will be treated with DN technique, as this is consistent with routine clinical practice. Potential muscles to receive TPDN treatment include the following: suprapsinatus, teres minor, infraspinatus, deltoid, upper trapezius, middle trapezius, levator scapula, pec major and pec minor.
214691957|NCT03442894|PROCEDURE|Sham Dry Needling|In addition to the standard PT treatment, patients in the sham DN group will receive what appears to be a DN treatment, but it will not be done with the acupuncture needles and the skin will not be punctured. The Sham DN procedure will be performed over the site of identified MTrPs using a guide tube and a toothpick. A guide tube is positioned firmly over the area to be treated and a toothpick is inserted in the guide tube. The clinician taps the toothpick to mimic the skin prick from a needle and the guide tube is removed. The clinician maintains pressure on the end of the toothpick and moves the end furthest from the skin in different directions to mimic the pistoning and changes in needle angle that occur in actual dry needling. Care will be taken to treat from 1-3 muscle groups for 5-10 seconds per MrTP identified.
214509063|NCT01827982|DRUG|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
214691958|NCT05421832|DEVICE|Digital Speech Application|A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.
214691959|NCT04813653|DRUG|cyclosporine in combination with carfilzomib and dexamethasone|patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
214691960|NCT04240665|BEHAVIORAL|Digital Memory Notebook (DMN) Application|Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
214691961|NCT02693483|DRUG|10% povidone iodine|Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
214691962|NCT01361009|DRUG|pramipexole|as prescibed by the investigator
214509064|NCT01827982|DRUG|Placebo|Matching placebo will be given as a single oral dose.
214509065|NCT01042184|DRUG|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
214691963|NCT05603702|DRUG|Lacosamide|Study Visit 1: Baseline study assessments will be made and questionnaires completed in person, on day 0. Drug treatment days will then occur on days 1-7. Study Visit 2: Following completion of the 7-day drug treatment period, participants will have a face-to-face clinic visit on day 8 (with a 3 day grace period), where similar assessments and questionnaires will again be completed. Participants will return all unused drug at this visit, for disposal and to monitor compliance. A follow-up phone visit will occur on day 21 (with a 3 day window) to assess for adverse events and medication changes
214691964|NCT04446793|DRUG|Onvansertib|15 mg/m\^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
214691965|NCT04446793|BIOLOGICAL|Bevacizumab|5 mg/kg will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
214691966|NCT04446793|DRUG|FOLFIRI|FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
214691967|NCT01826422|DIETARY_SUPPLEMENT|EPA and DHA|Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
214691968|NCT01826422|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
214691969|NCT02467803|OTHER|Scapula mobilization|
214691970|NCT02467803|OTHER|Shoulder ROM exercises|
214509066|NCT01042184|DRUG|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
214691971|NCT00266019|BEHAVIORAL|Weight Management (diet, exercise, and behavior modification)|
214509067|NCT01042184|DRUG|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
214509068|NCT01472406|DEVICE|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
214691972|NCT05913960|DEVICE|sham stimulation|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
214509069|NCT01472406|DEVICE|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
214509070|NCT01472406|DEVICE|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
214509071|NCT01472406|DEVICE|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
214509072|NCT01472406|DEVICE|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
214509073|NCT02457806|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
214509074|NCT02457806|DRUG|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
214691973|NCT05913960|DEVICE|accelerated intermittent theta burst stimulation|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
214691974|NCT05913960|DEVICE|high frequency stimulation|"Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
214691975|NCT03140930|DIETARY_SUPPLEMENT|Tastants duodenal|Duodenal infusion of combination of tastants (sweet, bitter and umami)
214691976|NCT03140930|DIETARY_SUPPLEMENT|Tastants ileal|Ileal infusion of combination of tastants (sweet, bitter and umami)
214691977|NCT03140930|DIETARY_SUPPLEMENT|Placebo duodenal|Duodenal infusion of placebo (tap water)
214691978|NCT03140930|DIETARY_SUPPLEMENT|Placebo ileal|Ileal infusion of placebo (tap water)
214691979|NCT01569425|OTHER|Dietary intervention|High Calorie breakfast and high calorie dinner
214691980|NCT03159377|DEVICE|Ultra low dose chest CT|Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
214691981|NCT06297850|DEVICE|Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)|A CGM device placed on the posterior aspect of the upper arm in which a sensor placed in the skin registers glucose values. Via Bluetooth, these readings are sent to a receiver near the patient every 5 minutes. The CGM system can alert when deviating glucose levels, but will for this observational study be blinding to patients and clinical staff. Thus, the patients' diabetic care will rely on standard practice.
214424101|NCT03396692|PROCEDURE|Block of the posterior exo-thoracic fascia with Ropivacaine|"Group 2 PEF block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia."
215104236|NCT05805046|DEVICE|Negative Pressure Wound Therapy System|The study device combines a sterile dressing comprising gelling fibre technology to absorb wound exudate with negative pressure applied to the wound via a vacuum pump.
215104237|NCT00572208|DRUG|Gabapentin group|"Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~1. st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~2. nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~3. rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~4. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~5. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
214424102|NCT03396692|PROCEDURE|Block of paravertebral space with Ropivacaine|"Group 3 paravertebral block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours.~Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.~In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse."
214424103|NCT03692117|DEVICE|Extracorporeal Carbon Dioxide Removal|Place a double lumen catheter in jugular vein, drainage the venous blood in vitro tube, after blood-gas exchange and remove CO2, then return back to the Superior vena cava
214424104|NCT02863900|OTHER|cohort of BC of each subtypes|
214424105|NCT01899027|DRUG|Rosuvastatin|Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
214424106|NCT01899027|DRUG|Placebo|Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
214424107|NCT06389071|DEVICE|Fractional 2940 nm Laser|Fractional 2940 nm Laser
214691982|NCT05329987|OTHER|Rehabilitation|Intervention focused on balance, gait and postural transfers rehabilitation. 20 session of 90 minutes (60 minutes of physiotherapy and 30 minutes of occupational therapy), 2 times a week, for 10 weeks.
214691983|NCT05632458|DEVICE|Thrombectomy|Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.
214691984|NCT05847244|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner)
214691985|NCT03832920|OTHER|Analgesia Nociception Index|A monitor of nociception for patients under general anesthesia
214694255|NCT01301560|RADIATION|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
215104238|NCT05637788|DIAGNOSTIC_TEST|CT Scan Radiomics Features Extraction|Extraction of CT radiomics data through AI
215104239|NCT04556279|PROCEDURE|adrenalectomy|Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.
215104240|NCT04556279|DRUG|Aldosterone Antagonist|Medical treatment of primary hyperaldosteronism.
215104241|NCT01928901|DRUG|administration of Sinupret|
215104242|NCT01928901|DRUG|administration of Bronchipret|
215104243|NCT01928901|DRUG|administration of Sinupret Placebo|
215104244|NCT01928901|DRUG|administration of Bronchipret Placebo|
215104245|NCT01193114|BEHAVIORAL|Ecologically Based Treatment (EBT)|Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
215104246|NCT01193114|BEHAVIORAL|Treatment as Usual (TAU)|Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
215104247|NCT05099796|PROCEDURE|Transforaminal epidural steroid injection|
214509075|NCT05913349|BEHAVIORAL|Group Cognitive Behavioral Therapy (GCBT)|Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
214694256|NCT01301560|RADIATION|Observation|No local treatment
214694257|NCT02349334|DEVICE|Percutaneous Tibial Nerve Stimulation|
215027007|NCT05318443|DRUG|SIBP04|SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
215027008|NCT05318443|DRUG|Avastin|Avastin, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
215027009|NCT05318443|DRUG|Paclitaxel|Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.
215027010|NCT05318443|DRUG|Carboplatin|Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
215027011|NCT02395328|BEHAVIORAL|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
215027012|NCT02951819|DRUG|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
215027013|NCT02951819|DRUG|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.
215027014|NCT02951819|DRUG|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
215027015|NCT02951819|DRUG|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
215027016|NCT05273437|BEHAVIORAL|System identification experiment for physical activity|The system identification experiment in Just Walk JITAI study has two key components that are the focus of the system identification experiment: daily adaptive step goal recommendations and within-day suggestions to either plan a bout of walking or to inspire reflection and, by extension, an increased urge to go for a walk.
215027017|NCT03173378|OTHER|Questionnaires|Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
214424108|NCT01387334|BEHAVIORAL|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
215027018|NCT02440165|BEHAVIORAL|Nursing nutrition intervention|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~* Information and advice;~* Examples of energy and protein rich meals;~* patients will be asked to register their nutritional intake for two days at home;~* after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
215027019|NCT01800110|DIETARY_SUPPLEMENT|pomegranate juice|
215027020|NCT04877366|DIETARY_SUPPLEMENT|Dietary Supplement: Sprinkled Format REDUCOSE.|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
215027021|NCT04877366|OTHER|Reference control|A placebo matching to the test product will be used as control
215027022|NCT04877366|OTHER|Active comparator|Acarbose 100 mg tablet (provided in open-label format)
214424109|NCT01128530|DRUG|JNJ-32729463|250 mg tablet twice daily
214424110|NCT01128530|DRUG|linezolid|600 mg tablet twice daily
214424111|NCT01128530|DRUG|JNJ-32729463 placebo|1 placebo tablet twice daily
214424112|NCT01128530|DRUG|linezolid placebo|1 placebo tablet, twice daily
214424113|NCT02488252|DRUG|Semi-individualised Chinese Medicine treatment|"A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb"
214424114|NCT02488252|DRUG|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
214424115|NCT04501276|DRUG|ADG116|For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
214424116|NCT04501276|DRUG|ADG106|For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
214424117|NCT04501276|DRUG|anti PD1 drug|For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
214424118|NCT01700400|DRUG|Everolimus|
214424119|NCT01700400|DRUG|Pemetrexed|
214424120|NCT01700400|DRUG|Carboplatin|
214424121|NCT01700400|DRUG|Bevacizumab|
214424122|NCT00079482|DRUG|CEP-701|
214424123|NCT00079482|DRUG|high-dose cytarabine|Chemotherapy
214691986|NCT00598195|DRUG|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
214691987|NCT03201510|OTHER|Observational|HPTN 075 is an observational study in sub-Saharan MSM
214424124|NCT00079482|DRUG|Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)|Chemotherapy
214691988|NCT04991454|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.
214691989|NCT02561416|BEHAVIORAL|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
215027023|NCT05032222|OTHER|Uroflowmetry|Diagnostic test
215027024|NCT01176500|DRUG|(18)Fluciclatide|
215027025|NCT05274698|BEHAVIORAL|muscle energy technique|It is a manual treatment in which a patient produces a contraction in a precisely controlled position and direction against a counterforce applied by a manual therapist .Muscle energy techniques (MET) were originally developed to treat soft tissue, mobilize joints, stretch tight muscles and fascia, reduce pain and to improve circulation and lymphatic drainage.
215027026|NCT05274698|BEHAVIORAL|conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.|"Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel"
215027027|NCT05116345|DRUG|DEXTENZA|Intracanalicular Dexamethasone ophthalmic insert (0.4mg)
215027028|NCT05116345|DRUG|Topical Dexamethasone|topical dexamethasone drops
215027029|NCT03116022|DRUG|Estriol|Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
215027030|NCT03116022|DRUG|Distal estriol|Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
215104248|NCT05099796|PROCEDURE|Caudal epidural steroid injection|
214424125|NCT05983068|DRUG|dupilumab|solution for injection; by subcutaneous (SC) injection
214424126|NCT03030248|DRUG|Vancomycin Oral Capsule|We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.
214424127|NCT03030248|DRUG|Placebo Oral Capsule|A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
214424128|NCT04333758|DEVICE|Jintronix Virtual Reality Telerehabilitation System|"System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training."
214424129|NCT00188461|DEVICE|CT Thorax|
214424130|NCT03851549|DEVICE|New BGMS (US)|New blood glucose monitoring system / In vitro diagnostic device (IVDD)
214424131|NCT00770965|BIOLOGICAL|AIN457|
214424132|NCT00770965|BIOLOGICAL|Placebo|
214424133|NCT00731523|DRUG|fingolimod (FTY720)|
214424134|NCT03768843|PROCEDURE|Harms technique|Atlantoaxial fusion
214424135|NCT05925686|DRUG|Tramadol.|Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.
214424136|NCT05339256|DRUG|Buprenorphine SL|Up to 24 mg per day
214424137|NCT05339256|OTHER|Telehealth|Telehealth MOUD, utilizing a standardized protocol for each healthcare provider session
214424138|NCT05339256|OTHER|In-person treatment as usual|in-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.
214424139|NCT03175432|DRUG|Atezolizumab|Given IV
214424140|NCT03175432|BIOLOGICAL|Bevacizumab|Given IV
214424141|NCT03175432|DRUG|Cobimetinib|Given PO
214424142|NCT03175432|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
214424143|NCT02228356|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy with either Dynamic Tumor Tracking/Internal Target Volume approach on the Vero machine, and/or Internal Target Volume approach on the Tomotherapy machine.
214424144|NCT04296227|DEVICE|The Vital Detect blood pressure monitor|The end goal is to provide Non-invasive Blood Pressure (NIBP) accuracy data to support validation of the Vital Detect blood pressure monitor.
215027031|NCT03116022|DRUG|Vaginal Gel|Women using a base water gel lubricant during intercourse
215027032|NCT06417788|DEVICE|Dental implant placement|Dental implant placement guided by Navident® (ClaroNav Inc., Toronto, Canada)
215027033|NCT06417788|PROCEDURE|Static guided implant placement|Dental implant placement guided by a stereolithographic pilot drill guide.
215027034|NCT02103179|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
215027035|NCT01390103|OTHER|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
215104249|NCT03594136|DEVICE|Raumedic Neurovent-P-tel|Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
215027036|NCT06046378|OTHER|Digital Story Group Prepared With Digital Audio File (Podcast)|"The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to. At the end of the subject on the date planned according to the academic calendar, the students will be interviewed again and a questionnaire will be applied to evaluate the effectiveness of the digital stories prepared with the post-test and digital audio file (podcast). The retention test will be applied 21 days after the last test application."
215027037|NCT06046378|OTHER|Control Group|After the students in the control group are determined, a pre-test will be conducted before the subject receives education. The same knowledge test will be repeated as a post-test after the students receive the classical course education and after the end of the subject. Students will be given a retention test 21 days after the last test. After the retention test application, digital stories prepared with a digital audio file (podcast) will be sent to the students in the control group. In this way, all students participating in the study will have access to the training material used in addition.
215027038|NCT03220256|DRUG|Lamotrigine|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
215027039|NCT06220253|PROCEDURE|vaginal hysterectomy by bipolar vessels sealing|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be coagulated and cut by a bipolar vessel sealing instrument
215027040|NCT06220253|PROCEDURE|vaginal hysterectomy by traditional technique|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be sutured by absorbable threads
215027041|NCT01518179|DEVICE|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
215027042|NCT01518179|OTHER|Routine follow up and treatment|Control
215027043|NCT06099639|DRUG|HER3-DXd|5.6 mg/kg Q3W \[on Day 1 of each 21-day cycle\]) infused IV over approximately 90 minutes
215027044|NCT04407117|BEHAVIORAL|Lock-down and social distancing|Lock-down and social distancing during COVID-19 pandemic
215027045|NCT02511743|OTHER|physicians|physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
214424145|NCT01426750|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
214424146|NCT06373107|BEHAVIORAL|High intensity gait training|Participants will practice walking that is vigorous enough to keep their heart rate over a certain level during their physical therapy sessions. During the sessions, participants will walk and step vigorously enough to keep the heart rate between 60-80% of their maximum heart rate. Maintaining this heart rate during exercise helps to improve heart health and walking, which can affect people after a stroke.
215027046|NCT03615768|COMBINATION_PRODUCT|Adapalene-Clindamycin Combination Gel|5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
215027047|NCT03615768|DRUG|Adapalene Gel|Differin 0.1% Gel, applied nightly for 12 weeks
214509076|NCT06272032|PROCEDURE|High-intensity focused ultrasound (HIFU)|Ultrasound is a type of mechanical vibrational wave capable of penetrating living tissues without causing harm to the tissue. As a non-invasive physical modality, ultrasound boasts advantages such as non-invasive safety, excellent directional propagation, strong penetration capability, and optimal focusing effects. It can induce a series of structural and functional changes in tissue cells through actions like cavitation, mechanical force vibration, and heat generation, leading to corresponding clinical effects. Clinical studies have demonstrated that focused ultrasound not only improves symptoms of allergic rhinitis (AR) but also holds certain advantages in preserving the structural and functional integrity of the nasal mucosa.
215027048|NCT03615768|DRUG|Clindamycin Gel|Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
215027049|NCT05810597|DRUG|Tirzepatide|Administered SC
215027050|NCT05810597|DEVICE|Single Dose Pen|Used to administer tirzepatide SC
215027051|NCT05810597|DEVICE|Multi-use Prefilled Pen|Used to administer tirzepatide SC
215027052|NCT05899959|DEVICE|Corsano CardioWatch 287-2|Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.
215027053|NCT03845166|DRUG|XL092|oral doses of XL092
215027054|NCT03845166|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
215027055|NCT03845166|DRUG|Avelumab|Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
215027056|NCT02913846|OTHER|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
214424147|NCT00888979|DRUG|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
214424148|NCT05827393|PROCEDURE|muscle transplantation|the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique
214424149|NCT00662480|PROCEDURE|Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm|Invited to vascular screening
214424150|NCT01391130|DRUG|LY2510924|Administered subcutaneously
214424151|NCT01391130|DRUG|Sunitinib|Administered orally
214424152|NCT00510601|DEVICE|Kaneka Liposorber|LDL-apheresis on a bi-weekly basis
215027057|NCT02913846|OTHER|Muscular assessment|An assessment of muscular force will be performed once a week.
214424153|NCT01113333|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
214424154|NCT01113333|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
214509077|NCT06272032|DRUG|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines and other therapies.
214509078|NCT03186248|PROCEDURE|Per oral endoscopic myotomy|General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
214509079|NCT04851665|OTHER|No Intervention - this was a qualitative analysis|No Intervention - this was a qualitative analysis
214509080|NCT01409772|DRUG|Ethanol Lock|Ethanol Lock
214509081|NCT00703391|DRUG|AZD9668|30mg oral tablets twice daily (bid) for 14 days
214509082|NCT00703391|DRUG|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
214509083|NCT07014124|BEHAVIORAL|Nicotine Replacement Therapy (NRT) Sampling|Participants will be advised to choose the NRT according to their preferences and daily cigarette consumption. Cigarette consumption of ≤20 daily will receive the 14mg patch or 2mg gum and participants consume \>20 cigarettes daily will receive the 21mg patch. An NRT use card (Appendix 6 draft) containing the instructions and potential side effects were given with a brief oral explanation. Full course of pharmacological treatment for 12-week are available in smoking cessation services. Participants requesting for additional or full course of NRT will be actively refer to the respective services as part of the Referral step in the AWARD model (Ask, Warn, Advise, Refer, and Do-it-again).
214691990|NCT02561416|BEHAVIORAL|FibroQol|"Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.~Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.~Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).~Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV."
215027058|NCT02913846|OTHER|Pre-albumine dosage|Dosage performed once a month.
215027059|NCT03376529|DRUG|SPR741|400 mg IV over 1 hour
215027060|NCT03376529|DRUG|Ceftazidime|1.0 gram IV over 1 hour
215027061|NCT03376529|DRUG|Piperacillin/tazobactam|4.5 grams IV over 1 hour
215027062|NCT03376529|DRUG|Aztreonam|1.0 gram IV over 1 hour
215027063|NCT06025708|DEVICE|Diagnostic Test: Quantra QStat Cartridge|Whole blood coagulation testing system
215027064|NCT03096431|BEHAVIORAL|Physical Activity|"* Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~* One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching."
215027065|NCT03096431|BEHAVIORAL|Cognitive rehabilitation|One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
215027066|NCT04354857|OTHER|olfactory and gustatory tests|"Participants rate quality of sense of smell and taste.~Olfaction test: Sniff 10ml test tube containing 1.5ml air freshner (Mifleur Citron, Coldis, Entraigues sur Sorgues, France) and rate perception of odor.~Gustatory test: Taste a pinch and sugar and salt and rate perception of sweet or salty taste"
215027067|NCT06309719|COMBINATION_PRODUCT|Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)|A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). A PNHA gel will be placed on the root surfaces and supra-bony defects, followed by a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture
215027068|NCT06309719|PROCEDURE|Periodontal Access Flap (AF)|A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). No gel will be placed before suturing the flap by tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture
215027069|NCT04065334|BEHAVIORAL|High dose training|4 x 4 minutes of high intensity workload on treadmill and 4 repetitions x 4 sets of high intensity workload in hack squat
215027070|NCT04065334|BEHAVIORAL|low dose training|1 x 4 minutes of high intensity workload on treadmill and 2 repetitions x 4 sets of high intensity workload in hack squat
215027071|NCT05021224|BEHAVIORAL|Caring Contacts|Non-demanding message sent from the care team
215027072|NCT05021224|BEHAVIORAL|Reminders|Appointment reminders sent electronically
215027073|NCT05021224|BEHAVIORAL|Informational Poster|An informational poster linking to an infographic
215027074|NCT05021224|BEHAVIORAL|Motivational Interviewing|Motivational interviewing training for intake coordinators
215027075|NCT03535987|DEVICE|myocardial PET imaging|using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
215027076|NCT05966675|DEVICE|conduction system pacing|Implantation of cardiac implantable electronic device (CIED) with conduction system pacing (left bundle branch area pacing or his bundle pacing).
215027077|NCT05966675|DEVICE|right ventricular or biventricular pacing|Implantation of cardiac implantable electronic device with right ventricular or biventricular pacing according to left ventricular ejection fraction and current ESC guidelines.
215027078|NCT02392728|BEHAVIORAL|Immersive Virtual Reality (VR)|Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
215104250|NCT01618825|DRUG|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
215104251|NCT01618825|DRUG|Lamotrigine|2 x 25 mg tablet once a day
215027079|NCT02392728|BEHAVIORAL|Guided Imagery|Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
215027080|NCT00515229|DRUG|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch"
215027081|NCT02412436|DRUG|Depot medroxyprogesterone acetate|Depot medroxyprogesterone acetate intramuscular injection
215027082|NCT06077279|BEHAVIORAL|Horticultural Therapy Program|Horticultural Therapy Program Is selected plant therapy
215027083|NCT06549647|OTHER|low caloric diet|A low caloric diet of 1200 Kcal will be followed by participant for 3 months. The dietary intervention follows a macronutrient ratio of 15% protein, 30% fat, and 55% carbohydrates. Participants are advised to consume 170-240g of complex carbohydrates, 60-100g of fat, and 55-93g of protein per day, with 20-35g of fiber. Patients are also advised to limit salt, tea, and caffeine intake, and receive supplemental vitamins to prevent deficiencies.
215027084|NCT06549647|OTHER|Placebo laser acupoint stimulation|Placebo laser acupoint stimulation will be used for all participants in group (A).
214509084|NCT07014124|BEHAVIORAL|mHealth-based motivational counselling|The mHealth intervention will be delivered via the most popular instant messaging app in Hong Kong (WhatsApp). A total of 24 messages with contents including the harms of smoking and smoke exposure for children, encouragement, benefits of quitting for children, methods of quitting, dealing with craving, and measures to reduce cigarette smoke exposure at home will be provided. The messages will be scheduled in a tapering schedule that participants will receive 5 messages in the first week, then cut down to 3 messages/week for the next 4 weeks and 1 message/week for the last 7 weeks. Using a more personalized approach, the messages will be tailored to the participants' motivation, intention to quit and other quitting patterns collected at baseline. Real-time conversations could be initiated by participants themselves, triggered by regular messages, or through prompt inquires (e.g., asking about the quitting progress).
214509085|NCT07014124|BEHAVIORAL|Brief cessation advice and self-help material|At baseline, participants will receive brief face-to-face advice on quitting smoking for the health of the children using the validated AWARD model (Ask, Warn, Advise, Refer, Do-it-again) with a print-based self-help material providing detailed information on health hazards of SHS exposure on children, methods to deal with craving and withdrawal symptoms, and measures on preventing SHS exposure for children at home.
215027085|NCT06549647|OTHER|Laser Acupuncture|Eazyone EZ1 level laser will be used for the treatment procedures for all participants in group (B) only. Every participant in group (B) will be instructed briefly about the effect of laser acupoints therapy to gain her confidence and co-operation. It will be applied with infrared laser with 830 nm wavelength, 5 W power output and 0.5 J energy on the following acupoints while the patient lie in supine lying position. The head of the machine will be applied perpendicularly on each point for 1 min (17 min total), 3 times/ week for 4 weeks.
215027086|NCT01111552|DRUG|Escitalopram|Escitalopram oral capsules.
215027087|NCT01111552|DRUG|Aripiprazole|Aripiprazole oral capsules.
215027088|NCT01111552|DRUG|Placebo|Study drug matching placebo capsule.
215027089|NCT06230341|OTHER|Health Services Research|MSPs benefit from a learning system. The learning system combines an individualised support programme provided by a regional support structure for quality and safety in health care (QualiREL Santé) and the provision of a web platform. Based on the 4 dimensions of the Shortell model, the support programme includes initial training (6 months) and personalised methodological support (18 months) for each MSP. A web platform is provided to MSPs to enable them to implement the full approach of the Risk Management Support Programme. It provides support for reporting, analysis and management of PSIs.
215027090|NCT00323986|DRUG|azithromycin (drug)|
215027091|NCT02658188|DRUG|ASP8825|Oral
215027092|NCT04990947|OTHER|lifestyle / RYGB|No intervention, just 2 different groups will be included
215027093|NCT06481813|OTHER|Blood Sampling (2*8mL Tubes)|Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)
215027094|NCT06481813|OTHER|PBMC Sampling (1*8mL Tubes)|Patients will be sampled from 1 x 8 mL PBMC
214509086|NCT07013773|DRUG|Y-4 tablet|The enrolled subjects will be randomly divided into group AB and group BA, with a total of 10 subjects in each group, all subjects will take one Y-4 tablet (pregabalin 112.5 mg, riluzole 28.125 mg) at each period. Subjects of group AB will take Y-4 tablet under fasted condition in period 1, and take Y-4 tablet under fed condition in period 2. In contrast, subjects of group BA will take Y-4 tablet under fed condition in period 1, and take Y-4 tablet under fasted condition in period 2. There will be 7 days of wash-out between the two periods.
214509087|NCT07013552|DRUG|Administration of a single or repeated dose of a long half-life antibiotic - oritavancin|"Intravenous administration of a single or repeated dose of lipoglycopeptide antibiotic - oritavancin.~In superficial ABSSSI or PI: Single dose of 1,200 mg (3 vials) administered as a 3-hour intravenous infusion in 5% glucose solution.~In LRIE: First dose of 1,200 mg (3 vials) administered as a 3-hour intravenous infusion in 5% glucose solution, subsequent doses of 800 mg (2 vials) administered as a 2-3 hour intravenous infusion at 7-day intervals, to achieve the required duration of drug therapy of 2-6 weeks (counted from the day of transvenous lead extraction)."
214691991|NCT02561416|DRUG|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
215027095|NCT06481813|OTHER|Paxgene Sampling|Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube
215027096|NCT06481813|PROCEDURE|Extended biopsies of tumor lesions|"Regarding the ancillary study, as part of the care, patients are biopsied at diagnosis and during relapse(s). For metastatic patients with multiple sites, one site (the most accessible) is chosen and biopsied in interventional radiology or pulmonology.~The material used is: 17-18G biopsy needle / Sampling chamber volume of 0.01 cm³ to 0.02 cm³.~For a standard biopsy as part of the care, 3 samples are taken (total volume of 0.03 cm³ to 0.06 cm³). Inclusion in the ancillary study would add one sample using the same biopsy path, resulting in an additional volume of 0.01 cm³ to 0.02 cm³.~In the case of a complex biopsy, no additional sampling related to the research will be performed."
215027097|NCT04002934|DRUG|Bazedoxifene Acetate|40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
215027098|NCT02102802|DRUG|Midomafetamine|125, 75, or 30 mg midomafetamine HCl followed 1.5 to 2 hours later by a supplemental dose of midomafetamine HCl half the initial dose
214691992|NCT00450372|BIOLOGICAL|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
214691993|NCT00450372|OTHER|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
214691994|NCT03874598|PROCEDURE|Ear acupuncture|Patients in the intervention group are treated twice a week for five weeks using semi-standardized ear acupuncture.
214691995|NCT03874598|BEHAVIORAL|Psychoeducation|Patients of the control group receive a 1,5 h psychoeducation group concerning sleep improving behaviour.
214691996|NCT05157672|DIETARY_SUPPLEMENT|Cinnamon (2 g)|oral capsules, 2 g
214509088|NCT07013552|DRUG|Administration of a repeated dose of a short half-life antibiotic - vancomycin|"Intravenous administration of repeated doses of glycopeptide antibiotic - vancomycin.~Repeated doses of 15-20 mg/kg body weight every 8-12 hours administered as an hourly intravenous infusion in 0.9% sodium chloride solution, under monitoring the drug concentration in serum, for 7-10 days in ABSSSI, for 10-14 days in PI, and for 2-6 weeks in LRIE (counted from the day of transvenous lead extraction)."
215027099|NCT02102802|BEHAVIORAL|Therapy|Manualized therapy
215027100|NCT04926285|DRUG|Omacetaxine|Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h
215027101|NCT04926285|DRUG|Venetoclax|Venetoclax at 400mg
215027102|NCT05649540|DRUG|Vonoprazan|Potassium-competitive acid blocker
215027103|NCT05649540|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
215027104|NCT04233385|OTHER|Myofascial Massage|The myofascial protocol outlines techniques, areas of the body, as well as time to be spent for each technique for a total of 25 minutes. The remaining 5 minutes of the massage are for the massage therapist to tailor myofascial massage to the needs and circumstances of each participant. In order to provide some level of customization, the therapist will determine the impact of massage on the participant's pre-existing pain and/or mobility limitations. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will use effleurage and petrissage techniques to gently massage the identified locations to soften and release the tissues. Techniques used will include deep friction of muscles, sustained compression, and fascial stretch.
215027105|NCT04233385|OTHER|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed light touch protocol for each of the 16 sessions. In addition, the therapist will inquire about the participant's response to the previous light touch treatment. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will place both hands on the participant for 3 minutes at each identified location. Pressure will be very light and consistent, with no side-to-side movement.
215027106|NCT04516213|OTHER|Enteral Formula With (PHGG)|Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)
215027107|NCT00306098|DRUG|islets|Intraportal infusion of islets
215027108|NCT00608790|DRUG|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
215027109|NCT00608790|DRUG|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
215027110|NCT02017834|PROCEDURE|surgical resection|neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
214509089|NCT07014228|PROCEDURE|single visit re-endo|In this group, a single visit re-endodontic treatment will be performed and completed in the same visit, including all the steps.
214509090|NCT07014228|PROCEDURE|multi visit re-endo|In this group, a multi-visit re-endodontic treatment will be performed and completed over different visits, including all the steps.
214509091|NCT06875362|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
214691997|NCT05157672|DRUG|Nicotine gum (2.5 mg)|gum, 2.5 mg
214691998|NCT05157672|DRUG|Letrozole (2.5 mg)|tablet, 2.5 mg
214691999|NCT05927389|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities
214692000|NCT00781781|DRUG|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
214692001|NCT02793167|DEVICE|AKI alert|
215027111|NCT06375863|DIAGNOSTIC_TEST|QT and QTc interval|measuring of QT and QTc on ECG
215027112|NCT05558085|BEHAVIORAL|Expanded Food and Nutrition Education Program (EFNEP)|Subjects will participate in nine hands-on EFNEP lessons to teach nutrition, healthy lifestyle choices, physical activity, food preparation, food safety, and food resource management.
215027113|NCT01515215|DEVICE|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
215027114|NCT01407341|PROCEDURE|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
215027115|NCT01407341|PROCEDURE|bone graft|Receive beta tricalcium-phosphate bone graft
215027116|NCT01407341|PROCEDURE|quality-of-life assessment|Ancillary studies
215027117|NCT01407341|OTHER|questionnaire administration|Ancillary studies
215027118|NCT05718531|DRUG|Rivaroxaban 2.5 Mg Oral Tablet twice daily|effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.
215027119|NCT05718531|DRUG|Clopidogrel 75 Mg Oral Tablet|Used as control group in 2nd arm and 5th arm
215027120|NCT05718531|DRUG|Aspirin tablet 75 mg|Used as control group in 2nd arm and 5th arm
215027121|NCT01323374|DRUG|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
215027122|NCT01323374|DRUG|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
215027123|NCT01323374|DRUG|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
214424155|NCT03961633|BEHAVIORAL|AWARE intervention|"will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes."
214424156|NCT00549536|DIETARY_SUPPLEMENT|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
214509092|NCT06875362|DIETARY_SUPPLEMENT|Placebo|The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
214509093|NCT06869915|DIAGNOSTIC_TEST|Prevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers).|This study is an observational prospective multi-centric non interventional study. The focus of the study is a homeless population sheltered in accommodation and social rehabilitation centres. The prevalence of neurodevelopmental disorders in this population will be studied.
214509094|NCT06874504|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of pulse rate.
214509095|NCT03731221|DRUG|Bupi HCI and lipo bupi|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
214509096|NCT03731221|DRUG|Bupi HCI|The LA used for the blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Control patients will have preservative free normal saline mixed with 0.5% bupivacaine HCL and all patients will have a total block solution volume of 60 ml.
214509097|NCT03778554|DRUG|Metoprolol Succinate|Eligible patients randomized to receive long-term therapy with oral beta-blockade
214509098|NCT03778554|DRUG|Bisoprolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
214509099|NCT03778554|DRUG|Carvedilol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
214509100|NCT03778554|DRUG|Nebivolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
214509101|NCT07014306|DIAGNOSTIC_TEST|MRI|Cohort 2
214509102|NCT07014306|DIAGNOSTIC_TEST|Computed tomography|Quantitative computed tomography
214509103|NCT03905642|DRUG|Arikayce™|Amikacin (aminoglycoside) in a liposomal formulation.
214509104|NCT06223633|DEVICE|PK Papyrus Covered Coronary Stent System|PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
214509105|NCT06164743|DRUG|VVN461 Ophthalmic Solution 1.0%|Topical ocular drug
215027124|NCT01323374|DRUG|Placebo|Oral, placebo TID
215027125|NCT05179915|OTHER|Therapeutic Touch focused on sacral region|In the latent phase of labor, the field energy of the sacral region will be cleared for an average of 15 minutes.
215104252|NCT03783299|DIAGNOSTIC_TEST|Standard RDT and HS-RDT|All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)
214509106|NCT06164743|DRUG|VVN461 Ophthalmic Solution 0.5%|Topical ocular drug
214509107|NCT06164743|DRUG|Vehicle|Topical ocular drug
214509108|NCT06698354|DEVICE|Virtual Reality-Assisted Hypnotherapy|Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic low back pain.
214692002|NCT02152865|DRUG|Lupeol|Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
215027126|NCT00236665|DRUG|topiramate|
215027127|NCT03487510|OTHER|NO interventions apply|does not apply
215027128|NCT00666341|DRUG|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
215027129|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
215027130|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
215027131|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
214424157|NCT00355940|DEVICE|Technological Methods|"Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images"
214424158|NCT00355940|DEVICE|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
214424159|NCT06391619|OTHER|No intervention|Study is observational
214424160|NCT03478696|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
214424161|NCT03478696|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
214424162|NCT03478696|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
214424163|NCT03478696|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
214424164|NCT03478696|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
214424165|NCT03478696|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
215027132|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
214424166|NCT03478696|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
214424167|NCT03478696|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
214424168|NCT03478696|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
214424169|NCT03478696|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
214424170|NCT06343103|OTHER|Workers exposed|Workers exposed to cytotoxic agents
214424171|NCT06343103|OTHER|Workers not exposed|Workers not exposed to cytotoxic agents
215027133|NCT04090749|BEHAVIORAL|Caregiver-Support|intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
215027134|NCT04351672|BEHAVIORAL|Early Time-Restricted Feeding|Eat between 8 am and 4 pm for two weeks
215027135|NCT04351672|BEHAVIORAL|Late Time-Restricted Feeding|Eat between 1 pm and 9 pm for two weeks
215027136|NCT05004298|OTHER|Animal Assited therapy|The intervention will be structured in 10 group sessions, with a weekly frequency and one hour duration.
215027137|NCT05389371|BEHAVIORAL|Alberta Healthy Living Program|Weight management services
215027138|NCT05389371|BEHAVIORAL|Alberta Obesity Centre Program|Multi-disciplinary obesity management
215027139|NCT05389371|BEHAVIORAL|Osteoarthritis advice|Living Your Best Life with Osteoarthritis Handbook
215027140|NCT05389371|BEHAVIORAL|Physiotherapy|GLA:D physiotherapy programs.
215027141|NCT02528305|OTHER|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5\&6, 8 sprints in sessions 7\&8, 9 sprints in sessions 9\&10 and 10 sprints in sessions 11\&12.
215027142|NCT01044043|PROCEDURE|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
215027143|NCT02272010|OTHER|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
215027144|NCT02272010|OTHER|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
215027145|NCT05983900|PROCEDURE|BRIX3000|chemo-mechanical caries removal agent
215027146|NCT05983900|PROCEDURE|papacarie|chemo-mechanical caries removal agent
215027147|NCT05983900|PROCEDURE|hand excavation|mechanical caries removal
214424172|NCT00653276|DRUG|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
215027148|NCT01299532|DEVICE|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
215027149|NCT02184442|DEVICE|TAVR Implantation with SAPIEN XT|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
215027150|NCT02184442|DEVICE|TAVR Implantation with SAPIEN|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
214424173|NCT00653276|DRUG|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
214424174|NCT01771588|DIETARY_SUPPLEMENT|Human milk fortifier|
214424175|NCT03491696|DRUG|Metyrapone|Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
214424176|NCT03782350|DRUG|Tranexamic Acid Dosage 1|Tranexamic Acid Dosage 1
214424177|NCT03782350|DRUG|Tranexamic Acid Dosage 2|Tranexamic Acid Dosage 2
214424178|NCT03615924|DRUG|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~* \>48 kg: Ticagrelor 45 mg, twice a day."
215027151|NCT05318560|DRUG|Lidocaine 2% Injectable Solution|for MPS
215027152|NCT05318560|DRUG|Ozone|for MPS
215027153|NCT05318560|OTHER|stretching exercise|for MPS
215027154|NCT00010907|DRUG|NPI-028|
215027155|NCT02285959|DRUG|Bevacizumab|
215027156|NCT04256837|DEVICE|Transcutaneous electrical auricular vagus nerve stimulation (VNS)|Electrical auricular stimulation is accomplished using a Roscoe Medical TENS 7000 that delivers a programmable electrical current density, frequency, and pulse width. The TENS 7000 will be connected to ear clip (or hand held) electrodes to transcutaneously stimulate the cymba conchae of the ear to activate the auricular branch of the vagus nerve (diagram above), also known as Arnold's nerve, which provides sensory innervation to the skin surrounding the ear canal. Through a neural reflex arc, activation of this sensory nerve sends a neural signal to the brainstem that then activates the efferent vagus nerve through the nucleus of the solitary tract (NTS). This is a well-described and clinically accepted neuromodulatory pathway, as transcutaneous electrical auricular stimulation has been studied to treat seizures, similarly to how invasive electrical vagus nerve stimulation has been approved by the FDA for the past two decades for the same indication.
215027157|NCT01789502|DEVICE|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
215027158|NCT01789502|DEVICE|Plastic stents|Plastic stents were inserted by ERCP
215027159|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks
215027160|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks
215027161|NCT02853773|OTHER|ingestion of a test meal with water|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
215027162|NCT01852214|DRUG|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
215027163|NCT01852214|DRUG|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
214692003|NCT02152865|DRUG|Control vehicle|Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
214692004|NCT04705025|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBSM using the BNT001 app
214692005|NCT04705025|OTHER|Interview|Complete interview
214692006|NCT04705025|OTHER|Quality-of-Life Assessment|Ancillary studies
215027164|NCT03088111|OTHER|Collection of samples|To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).
214692007|NCT04705025|OTHER|Questionnaire Administration|Ancillary studies
214692008|NCT03568539|DRUG|IBI308|IBI308 200mg IV infusion, every 3 weeks.
214692009|NCT06554314|DIETARY_SUPPLEMENT|probiotics|Eat a capsule for once, and once a day
214692010|NCT05978830|DEVICE|Transcranial ultrasound stimulation|In each active/sham-ultrasound stimulation experiment, subjects first underwent two baseline motor evoked potential (MEP) tests, with an interval of 15 minutes between the two baseline tests. After 15 minutes of true/pseudo-transcranial ultrasound stimulation, subjects immediately underwent a MEP test, and then 15 minutes later, subjects underwent another MEP test. The MEP was tested again 15 minutes later.
214692011|NCT03537339|OTHER|Record general information|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
215027165|NCT03088111|BIOLOGICAL|Obiltoxaximab|Obiltoxaximab standard of care
215027166|NCT00912873|DRUG|0.1% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
214692012|NCT00115349|DRUG|Deferoxamine|Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
214692013|NCT00115349|DRUG|Deferiprone (L1)|The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
214692014|NCT03374514|DRUG|Dexamethasone|instilation of the solution in the middle ear
214692015|NCT03374514|DRUG|Sterile isotonic saline solution|Sterile isotonic saline solution
214692016|NCT02116660|DRUG|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
215027167|NCT00912873|DRUG|0.4% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
214692017|NCT02116660|DRUG|Nevirapine|Nevirapine (NVP) 200 mg tablets
214692018|NCT02116660|DRUG|Lamivudine|Lamivudine (3TC) 150 mg tablets
215027168|NCT02691494|DRUG|Elagolix|Film-coated tablets
215104253|NCT03783299|DIAGNOSTIC_TEST|Standard RDT and HS-RDT|All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.
215104254|NCT03783299|DRUG|Artemether-lumefantrine|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
214692019|NCT02116660|DRUG|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
214692020|NCT02116660|DRUG|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
215104255|NCT03783299|DRUG|Primaquine Phosphate|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
215104256|NCT03536234|DRUG|Triptorelin acetate depot|3.75 mg triptorelin depot (monthly injections). 3 doses in total
215104257|NCT00852787|DRUG|Digoxin immune fab|Intravenously one time
215104258|NCT00852787|DRUG|Placebo|Intravenously one time
214692021|NCT02116660|DRUG|Lopinavir|Lopinavir (LPV) 200 mg tablets
214692022|NCT02116660|DRUG|Ritonavir|Ritonavir (r) 100 mg tablets
214692023|NCT02116660|DRUG|Atazanavir|Atazanavir (ATV) 300 mg tablets
214692024|NCT02116660|DRUG|Darunavir|Darunavir (DAR) 400 mg tablets
214692025|NCT04705727|DRUG|Budesonide Formoterol Drug Combination|This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).
214692026|NCT04705727|DRUG|nebulisation of terbutaline|Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
214692027|NCT01325480|DEVICE|Cardiac Pacing|
214692028|NCT02191787|DRUG|Seresis®|
214692029|NCT02191787|DRUG|Placebo|
214692030|NCT02750800|BIOLOGICAL|Adalimumab|Pre-filled syringe or pen, administered by subcutaneous injection
214692031|NCT02750800|BEHAVIORAL|AbbVie Care 2.0|Supportive services provided to participants included reminder calls, emails, text messages, nursing services, dietician, and psychological support. An adalimumab starter pack, injection guide, digital and print educational materials were also provided.
215027169|NCT02691494|DRUG|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
215027170|NCT02691494|DRUG|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
215027171|NCT02691494|DRUG|Placebo for Elagolix|Film-coated placebo tablets
215027172|NCT02522221|DRUG|Warfarin|Warfarin is an oral vitamin K antagonist anticoagulant.
215027173|NCT02522221|DRUG|tecarfarin|Tecarfarin is an oral vitamin K antagonist anticoagulant
215027174|NCT03357497|OTHER|Very early mobilization|The patient will be mobilized by a physiotherapist in our postoperative care unit. The intervention uses the SOMS protocol.
215027175|NCT01961180|DRUG|Cipralex|the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
215027176|NCT01961180|DRUG|Placebo|Placebo
215104259|NCT03282929|DEVICE|Part 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order
215104260|NCT03282929|DEVICE|Part 2 Group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
214424179|NCT03615924|DRUG|Placebo|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
214424180|NCT05103748|BEHAVIORAL|Traditional vestibular rehabilitation|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
214424181|NCT05103748|BEHAVIORAL|Cognitive and vestibular dual task training|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
214509109|NCT06698354|OTHER|Standard Physical Therapy|Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
214509110|NCT06698523|BEHAVIORAL|Breathing exercise|bubble blower used as play toys to facilitate the breathing exercise
214509111|NCT06698523|BEHAVIORAL|Deep breathing|pin wheel used as a play toy for achievement of breathing exercise
214424182|NCT00783354|DRUG|desloratadine|"Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (Placebo) in case of symptoms for 2 months."
214509112|NCT06699108|DRUG|VGR-R01|Subretinal injection of VGR-R01 (0.1 mL)
214509113|NCT06699160|DEVICE|Revision arthroplasty|Hip or knee revision surgery resulting from aseptic loosening of the prosthesis and/or infection of the prosthesis by gentamicin and/or clindamycin sensitive strains.
215027177|NCT02397369|OTHER|Tobacco users: Self Help|This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
215027178|NCT02397369|BEHAVIORAL|Tobacco users:Telephonic counseling|This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
215027179|NCT02397369|BEHAVIORAL|Tobacco users:Behavioural therapy Only|"1. Focus Group discussion:~   This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.~2. Individual tobacco cessation counseling sessions:~Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant."
215027180|NCT02397369|OTHER|Tobacco users:Pharmacologic|"Pharmaco Therapy will consist of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc"
215027181|NCT01081574|DRUG|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
215027182|NCT01568229|DRUG|AMG 747|Three dose levels once-daily oral administration
215027183|NCT01568229|DRUG|Placebo|Once-daily oral administration
215027184|NCT00637156|DEVICE|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
215027185|NCT00637156|DEVICE|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
215027186|NCT02340546|DEVICE|cardiac resynchronization therapy|cardiac resynchronization by means of biventricular pacing via left ventricular pace from coronary sinus veins combined with conventional any-site right ventricular pace
214692032|NCT06400836|OTHER|Carbohydrate timing - carbohydrate intake before or after exercise|The study aims to investigate how pre- or post evening exercise carbohydrate ingestion influences glucose metabolism and substrate oxidation (fat/CHO) during exercise and after exercise in athletes during the nocturnal period (21:00-06:00) and the morning after during an 120 minute oral glucose tolerance test (OGTT).
214692033|NCT04281745|BIOLOGICAL|CORETOX Inj|Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.
214692034|NCT03298412|DRUG|Blinatumomab|Blinatumomab is administered as a continuous IV infusion.
214692035|NCT00804258|DRUG|intraperitoneal chemotherapy|
214509114|NCT07034365|OTHER|No intervention|No intervention
214692036|NCT00804258|OTHER|educational intervention|
214692037|NCT00804258|OTHER|medical chart review|
214509115|NCT07032350|OTHER|Web-based pain management support tool|The Pain Control Enhancement App (PACE-app) is a web-based tool designed to help family caregivers manage pain in persons with dementia. The app provides a brief screening to identify caregiver challenges and delivers tailored strategies, communication prompts for providers, and an educational resource library. It includes a digital pain diary for tracking daily pain, treatments, and urgent care use, with weekly reports that can be shared with healthcare providers. The app is accessible on any internet-connected device and designed for caregivers with varying levels of digital literacy.
214509116|NCT07032350|BEHAVIORAL|Usual Pain Management Care|Caregivers receive no new intervention; they manage their care recipient's pain according to standard practices. No access to the PACE-app is given during the study period.
214692038|NCT00804258|OTHER|questionnaire administration|
214692039|NCT00804258|PROCEDURE|assessment of therapy complications|
215027187|NCT02431026|DEVICE|Cooling pack activated Excel Cryo Cooling Collar|Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
215027188|NCT00461812|DRUG|Mometasone|
215027189|NCT00461812|DRUG|Advair|
215027190|NCT01503177|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
215027191|NCT01503177|OTHER|laboratory biomarker analysis|Correlative studies
215027192|NCT01503177|PROCEDURE|single photon emission computed tomography|Correlative studies
215027193|NCT01503177|PROCEDURE|computed tomography|Correlative studies
215027194|NCT06105398|OTHER|clinical evaluation|clinical evaluation tests
214509117|NCT07044193|DRUG|pipecuronium bromide|Investigation of muscle relaxation with pipecuronium bromide
214509118|NCT07044193|DRUG|Rocuronium bromide|Muscle relaxation with rocuronium as a control
214692040|NCT00804258|PROCEDURE|end-of-life treatment/management|
214692041|NCT00804258|PROCEDURE|psychosocial assessment and care|
214692042|NCT00804258|PROCEDURE|quality-of-life assessment|
214692043|NCT04360616|DIAGNOSTIC_TEST|imaging|perform US and mammography examination
214692044|NCT05960019|DIETARY_SUPPLEMENT|Fermented milk product|This is a type of cultured bovine milk, that is prepared through mesophilic fermentation of milk, that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
214692045|NCT05960019|DIETARY_SUPPLEMENT|Fermented cereal based product|This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
214692046|NCT05960019|BEHAVIORAL|Behavioural modification counselling|Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the patients prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
214692047|NCT02464397|DEVICE|Stent|In the study, either OPTIMAX or SYNERGY stent will be implanted in coronary artery lesion
214692048|NCT05471245|DEVICE|Magic Touch SCB by Concept Medical Inc.|PCI with drug-coated balloon
214692049|NCT04776811|DEVICE|Continuous glucose monitoring system|Medtronic Guardian Connect with Guardian Sensor 3
215027195|NCT03193437|DRUG|Open Label Selinexor|Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.
215027196|NCT03856918|PROCEDURE|PEEP 3 cm of water|PEEP of 3 cm of water will be applied during one-lung ventilation.
215027197|NCT03856918|PROCEDURE|PEEP 6 cm of water|PEEP of 6 cm of water will be applied during one-lung ventilation.
215027198|NCT03856918|PROCEDURE|PEEP 9 cm of water|PEEP of 9 cm of water will be applied during one-lung ventilation.
215027199|NCT05487378|DIETARY_SUPPLEMENT|PKU GOLIKE|AA protein Substitute for the dietary management of PKU, PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
215027200|NCT04907084|DIETARY_SUPPLEMENT|Serine|Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)
215027201|NCT04907084|DRUG|Fenofibrate|Fenofibrate 160mg pill, taken orally
215027202|NCT06644352|PROCEDURE|different thoracic surgical approaches|Right Versus Left Thoracic Surgical Approaches
215027203|NCT03486470|DIAGNOSTIC_TEST|Ultrasound examination of radial arteries|Measuring the diameter and the depth of two radial segments on both arms
215027204|NCT01509456|DIETARY_SUPPLEMENT|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
215027205|NCT05003336|DRUG|Xiangshao Granules|dissolve 1 sachet (4 g) in water to be drank 3 times a day after meal for 8 weeks
215027206|NCT05003336|DRUG|Xiangshao Granules Placebo|Xiangshao Granules Placebo
215027207|NCT05212337|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
215027208|NCT05212337|DRUG|Sodium chloride|Subcutaneous injection with NaCl once
215027209|NCT06602817|OTHER|Exposure: prone position|Exposure: surgery in prone position
215027210|NCT06602817|OTHER|Exposure: Supine position|Exposure: Surgery in supine position
215027211|NCT04658368|PROCEDURE|Primary TMR|TMR procedure as part of the primary major limb amputation surgery
214509119|NCT07043244|BEHAVIORAL|virtual reality simulation|no description, work attempt completed
214509120|NCT07044141|DRUG|Azathioprine|azathioprine 50mg twice daily will be given
214509121|NCT07044141|DRUG|Tofacitinib|It is a janus kinase inhibitor
214509122|NCT06500988|COMBINATION_PRODUCT|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement a comprehensive digital atrial fibrilation guideline-recommended toolkit
214509123|NCT07098767|DIAGNOSTIC_TEST|ultrasound evaluation|Use high-frequency ultrasonography to assess the swallowing function in patients with dysphagia. The ultrasound examination focuses on visualization of the pharyngeal region to measure vocal cord movement, swallowing reflex, pharyngeal contraction, and the presence and location of pharyngeal residue.
215027212|NCT04658368|PROCEDURE|Secondary TMR|TMR procedure subsequent to major limb amputation surgery
215027213|NCT03053362|DRUG|Vortioxetine|Observing change in cognition using THINC-it tool in patients with MDD.
215027214|NCT03053362|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
215027215|NCT05553210|BEHAVIORAL|FOREST+|The intervention will be delivered as an internet-based stress recovery intervention consisting of six weekly modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. Each module consists of a psychoeducational and an exercise component. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.
215027216|NCT06603311|OTHER|Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection|Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection who have been treated for at least 48 weeks and reached HDV RNA below 100 IU/ml for at least 24 weeks.
215027217|NCT05251805|PROCEDURE|Blood, bone marrow and lung tumor tissue collection|"Blood sampling: 12ml of blood will be collected during the routine pre-operative blood collection~Bone marrow aspiration during thoracic surgery: following the surgical intervention, bone marrow aspiration will be performed through the incisions made for the thoracic procedure. The ribs lying directly above and below the trocar incision will be exposed. A bone marrow needle will be advanced into the periost until the needle tip reaches the bone marrow. After removing the stylet a 2ml syringe will be attached to the aspiration needle and 0.5ml to 2ml of bone marrow will be aspirated before removing the needle. This procedure will be repeated twice for every trocar site, for a maximum of 3 trocar sites, or until 5ml of bone marrow aspirate is obtained.~Lung tumor collection: all surgical samples will be analyzed by our anatomopathological department. Viable and fresh material, not used for the diagnostic purposes, will be sent to the LMCT."
215104261|NCT03282929|DRUG|Part 2 group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
215104262|NCT03282929|DEVICE|Part 2 group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
215104263|NCT03282929|DEVICE|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
215104264|NCT05529836|DEVICE|electroacupunture|The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.
215104265|NCT05529836|DEVICE|sham electroacupuncture|Participants in the SEA group will receive sham electroacupuncture with PSD, but not energizing the electropuncture device. Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no electricity output only.
215104266|NCT05529836|DEVICE|sham acupuncture|Participants in the SAC group will receive sham acupuncture with PSD and PSN on sham acupoints (the non-meridian and non-acupuncture points). Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no skin penetration, electricity output, or needle manipulation for achieving qi.
215104267|NCT01946737|RADIATION|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)|
215104268|NCT01946737|RADIATION|Active Comparator: Invasive coronary angiography (ICA)|
215104269|NCT06025981|OTHER|Preliminary Phase|In the preliminary phase, the characterization of the functionality of the SWalker robotic system, as well as the functionality of the Virtual Reality system, will be carried out. All descriptive usability questionnaires completed by the participants and electro-biomechanical parameters will be collected using the robot's measurement systems to analyze the functionality.
214509124|NCT07098767|DIAGNOSTIC_TEST|Fiberoptic endoscopic evaluation of swallowing (FEES)|FEES involves the use of a flexible endoscope inserted through the nasal passage to observe the pharyngeal phase of swallowing directly. This procedure allows for the real-time assessment of key aspects of swallowing, including vocal cord function, swallowing reflex, pharyngeal contraction, and the detection of aspiration or penetration.
214509125|NCT07098741|OTHER|Core stability exercises with electrotherapy|electrotherapy modalities for pain control will be used and exercises strengthening abdominal core muscles will be applied in two phases.
214509126|NCT07098741|OTHER|Soft tissue release with manual therapy and stretching|Manual soft tissue release will be performed and then stretching of back muscles and thigh muscles will be added to treatemnet.
214509127|NCT07098741|OTHER|Postural correction exercises with contrast therapy|Hot and cold packs will be used one after other for 10-15mins and specific exercises which are designed to improve posture will be taught and performed
214509128|NCT07098741|OTHER|combination of electrotherapy with stretching and flexibility exercises|some pain reducing electrotherapy modality like TENS will be used and general stretching and flexibility exercises will be performed
214692050|NCT05387252|DIETARY_SUPPLEMENT|Mulberry juice|Mulberry is a common macrophanerophyte that can be found in fields or farms. Mulberry fruits contain a large amount of anthocyanins and a relatively small amount of pro-anthocyanins. The plant is easy to grow and the fruit price is low compared with other types of plants producing anthocyanins, and thus a reliable source for anthocyanin supplements. Current laboratory evidence has shown that specific anthocyanins can reduce inflammation status, and potentially thrombosis. One of the enzymes inhibited by specific anthocyanins is cyclooxygenase which catalyzes the synthesis of prostanoids, including thromboxane and prostaglandins. Moreover, a critical study has shown that cyanidin 3-O-glucoside, the main anthocyanin in mulberry fruit, is an allosteric regulator of interleukin-17A.
214692051|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
214509129|NCT07098689|OTHER|The BEM (Body Emotional Maps) program|"The BEM method involves an intervention with the parents of children with diabetes, conducted in group settings, aimed at facilitating parents' adaptation to their child's diabetes condition. The BEM method involves an intervention with the parents of children with diabetes, conducted in group settings, aimed at facilitating parents' adaptation to their child's diabetes condition. The intervention is organized into three sessions.~The first session consists of an introduction and group formation. The second session involves sharing the onset of diabetes, identifying the most critical daily challenges, and the primary change the participants wish to implement. The third session features the BEM pathway, which includes guided visualization and the creation of a map with spatial anchors."
214509130|NCT07098689|OTHER|Control group|The control group will receive the same diabetes management information, accompanied by parent discussion sessions and recreational activities guided by the diabetes team staff. As with the BEM group, activities will take place over three days in an off-hospital location, in contact with nature.
214509131|NCT07098195|DEVICE|Coronary Stent|RisoR Crest Everolimus Eluting Coronary Stent System
214509132|NCT05586178|BEHAVIORAL|Reminder that facilitates action|Patients will receive a text message reminding them that they can now get the bivalent COVID-19 booster and facilitating action. The message will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find local pharmacies that carry the bivalent booster).
214509133|NCT05586178|BEHAVIORAL|Consistency framing|The message will leverage the psychological principle of consistency. It will highlight to patients that based on medical records, they have completed a COVID-19 vaccine primary series, have done a great job protecting their health, and can now get the bivalent booster.
214509134|NCT05586178|BEHAVIORAL|Information provision about the uniqueness of the bivalent booster|The message will contain information about how the bivalent booster differs from previous doses patients have received and why it is valuable.
214509135|NCT05586178|BEHAVIORAL|Information provision about bivalent booster eligibility|The message will clarify to patients that regardless of whether they are at high risk, received the original boosters, or previously got COVID-19, they are eligible for the bivalent booster based on their medical records, and the updated booster will be valuable for them.
214509136|NCT05586178|BEHAVIORAL|Information provision about the severity of COVID-19 symptoms|The message will contain information about the often underestimated chances of people developing severe or long-lasting COVID-19 symptoms. The message will also mention that the bivalent booster can reduce such chances.
214509137|NCT06358599|DRUG|Cisplatin|Neoadjuvant cisplatin-containing combination chemotherapy was defined as the receipt of multiagent systemic chemotherapy initiated within 6 months prior to the date of radical cystectomy
214509138|NCT03560271|DRUG|Cyclo-Z|Cyclo (His-Pro) and zinc
214509139|NCT03560271|OTHER|Placebo|Matching placebo
214509140|NCT01160159|OTHER|Tests|Arterial parameters
214509141|NCT01160159|OTHER|Healthy volunteers|Arterial parameters and blood test
214509142|NCT03030365|DEVICE|"Siemens Biograph mMR PET-MR (3T)"|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
214509143|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 1|Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
214509144|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 2|Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)
214509145|NCT05488990|DRUG|AKVANO vehicle formulation 1|Novel lipid based formulation (AKVANO) vehicle 1
214509146|NCT05488990|DRUG|AKVANO vehicle formulation 2|Novel lipid based formulation (AKVANO) vehicle 2
214509147|NCT05488990|DRUG|Daivonex solution|Daivonex solution containing Calcipotriol (50 μg/g)
214509148|NCT05488990|DRUG|Daivonex cream|Daivonex cream containing Calcipotriol (50 μg/g)
214509149|NCT05825105|BIOLOGICAL|Platelet-Rich Plasma|The PRP will be prepared using a single centrifugation process. Approximately 30 ml of peripheral blood will be drawn and collected into a vacutainer tubes with sodium citrate anticoagulant 0.129 mol/l (3.8%). The tubes will then be centrifuged at 900 RPM for 12 minutes at room temperature in a benchtop centrifuge. We will separate the lower third of the plasma fraction from all tubes with a syringe and needle, taking care to avoid the leukocyte layer. The PRP will be refrigerated at 4°C for no less than 1 hour. We will not use any exogenous factors to stimulate the platelet activation process. The periauricular skin surface will be disinfected with a povidone iodine solution, and an intra-articular local anesthetic with 1% lidocaine will be applied. A 21-gauge needle will be placed at the point of application. Finally, PRP will be injected into the joint, and the needle will be removed.
214509150|NCT01921985|DRUG|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
214509151|NCT01921985|DRUG|Placebo|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
214509152|NCT04808024|PROCEDURE|SelfMyofascial Release|Myofascial auto-release consisted of rolling the roller on a group of knee flexors for 3.5 minutes between the sciatic tumor and the knee joint in both directions, omitting the popliteal fossa. Before and after the intervention, sEMG of the biceps and gluteal muscles will be performed.
214692052|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
214692053|NCT05631548|DEVICE|iTBS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. Approximately 25% of the nasion-inion distance, or Talairah coordinates X 0 Y+60 Z+60 will be measured.The first session will begin with the acquisition of the resting motor threshold (rMT; lowest stimulus intensity that elicits a visible twitch on 50% of the trials) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last about 3 minutes. Each participant will receive 2 sessions with a 15-20 minute interval between sessions.
214509153|NCT00864188|DIETARY_SUPPLEMENT|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
214509154|NCT00864188|DIETARY_SUPPLEMENT|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
214509155|NCT00864188|DIETARY_SUPPLEMENT|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
215027218|NCT05444439|GENETIC|detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent H.Pylori genotypes by polymerase chain reaction amplification(PCR) in gastric biopsies :|Extraction of DNA, using Wizard® Genomic DNA Purification Kit (Promega-USA), will be done following the manufacturer instructions. For detection of vacuolating cytotoxin A and cytotoxin-associated gene A gene, polymerase chain reaction amplification will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 60˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. For detection of vacuolating cytotoxin A (S1/S2, m1, m2), PCR will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 56˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. Amplified DNA will be analyzed by agarose gel electrophoresis. A positive sample will give bands at DNA fragment 138-bp for cytotoxin-associated gene A, at 259/286-bp for vacuolating cytotoxin A s1/s2, and 290-bp and 352-bp for m1 \& m2, respectively
215027219|NCT05444439|DIAGNOSTIC_TEST|Culture and sensitivity of endoscopic gastric biopsies:|During endoscopy, three biopsies will be taken from antrum and/or corpus of and will be examined by rapid urease test also known as Campylobacter-like organism test (Kimberly-Clark,USA). Culture of the bacterium on Columbia agar plus 5-7% defibrinated horse or sheep blood and selective Dent supplement under microaerophilic condition at 37degree Celsius for 3-5days.
215027220|NCT05444439|OTHER|Histopathological examination endoscopic gastric biopsies:|Histological sections from the antrum and body regions will be stained with Giemsa stain. Giemsa stain working solution was prepared as follows: 40 ml Giemsa stock solution with 60 ml of distilled water. Giemsa stock solution will be prepared as follows: Giemsa powder 4 g, glycerol 250 ml and methanol 250 ml. Histological sections will be examined by a gastrointestinal pathologist to standardize the classification of gastritis. Histopathological classification will be recorded as following (acute gastritis, mild-moderate- severe chronic gastritis, Glandular atrophy or Intestinal metaplasia).
215027221|NCT05444439|PROCEDURE|Upper endoscopy|it will be done patient before start empirical therapy and multiple antrum and/or corpus biopsies will be taken . Patient will be fasting at least 8 hours.Upper and findings will be recorded in the report as presence of gastroesophageal reflux disease, diffuse or localised gastric and/or duodenal redness, mucosal swelling, atrophy of mucosa, nodularity, intestinal metaplasia, erosions or ulcers.
215104270|NCT06025981|OTHER|Phase I - Early gait rehabilitation|In the first phase, the participants will carry out the rehabilitation program for hip fracture in acute phase that will last 6 weeks. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the usual rehabilitation guidelines that integrate exercises aimed at improving strength, gait, functional mobility and balance. In the case of the experimental group, a robotic walker will be used to practice walking.
215104271|NCT06025981|OTHER|Phase II - Maintenance gait function ( with VR)|In the second phase, participants will carry out a 6-week program to consolidate walking function. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the use of the robotic system for gait exercise. In the case of the experimental group, the use of virtual reality will also be integrated.
215104272|NCT01559675|DRUG|Hydrocortisone High Dose|Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
214692054|NCT05631548|DEVICE|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 2 sessions with a 15-20 min interval between sessions.
214692055|NCT03875326|DEVICE|1 mA HD-tDCS|Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
214692056|NCT03875326|DEVICE|2 mA HD-tDCS|Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
214509156|NCT00864188|DIETARY_SUPPLEMENT|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
214509157|NCT00055068|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
214509158|NCT00055068|BEHAVIORAL|Relaxation Training|
214509159|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
214509160|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 48 weeks
214509161|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
214509162|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 24 weeks
214692057|NCT03875326|DEVICE|3 mA HD-tDCS|Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
214692058|NCT03875326|DEVICE|Sham|Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
214424183|NCT00783354|DRUG|desloratadine|"Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (desloratadine 5 mg) in case of symptoms for 2 months."
215027222|NCT05444439|DRUG|empirical H.pylori regimens|Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool
215027223|NCT05444439|DIAGNOSTIC_TEST|H.Pylori Ag in stool|"Any symptomatic patient is above 18 years old with H pylori infection patients diagnosed by positive H pylori Ag in stool will be included.~assessment of laboratory response, 2 weeks after finishing empirical therapy."
215027224|NCT06671301|BEHAVIORAL|PSAI|Holistic stress management program implementing the pillars of Lifestyle Medicine
215027225|NCT06671301|OTHER|Usual Care|Usual care without specific treatment
215027226|NCT06673771|OTHER|Vestibular Rehabiliation Therapy|"Moving the eye horizontally between two stationary target while keeping the head still Moving the eye vertically between two stationary target while keeping the head still Moving the target horizontally and tracking it with the eye while keeping the head still Moving the target vertically and tracking it with the eye while keeping the head still Moving the head horizontally while a keeping a look on stationary target Moving the head vertically while a keeping a look on stationary target Moving the head and target in opposite direction horizontally while tracking the target with eyes Moving the head and target in opposite direction vertically while tracking the target with eyes.~Sit down and stand up, sit down and stand up with eye open and eye close Stand up, but turn to the right while standing Stand up, but turn to the left while standing Place an object on the floor. Take it and bring it above your head and place it on the floor again"
215027227|NCT06673771|OTHER|Conventional treatment|Standing balance training, weight shifting training, walking training, muscle strength training, step-up-and-down training.
215027228|NCT03535701|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo ketogenic diet
215027229|NCT03535701|OTHER|Laboratory Biomarker Analysis|Correlative studies
214509163|NCT04633200|OTHER|DOT mobile app|DOT is a mobile phone app that has daily pill reminders and supportive texts, as well as various features designed to support PrEP medication adherence.
215027230|NCT03535701|DRUG|Paclitaxel|Given standard of care therapy with paclitaxel
215027231|NCT03535701|OTHER|Quality-of-Life Assessment|Ancillary studies
215027232|NCT03535701|OTHER|Questionnaire Administration|Ancillary studies
215027233|NCT06998927|OTHER|Application of Proportional Assist Ventilation Plus (PAV+) at three support levels (20%, 50%, 70%) to assess ventilator-displayed work of breathing and its correlation with physiologic measures.|This intervention is distinguished by applying Proportional Assist Ventilation Plus (PAV+) at three support levels (20%, 50%, 70%) within the same patient, allowing a stepwise analysis of its effect on work of breathing. It uses real-time ventilator-displayed work of breathing, a noninvasive and underexplored tool, correlated with multiple physiological parameters such as esophageal pressure, Pocc, and P0.1. This within-subject design controls for interindividual variability, improving the precision of the analysis. Focusing on patients with spontaneous respiratory effort facilitates clinical application to optimize personalized ventilatory support. Thus, the study provides novel data to adjust support levels according to the patient's actual effort and to validate ventilator measurements against reference physiological indicators.
215027234|NCT05483140|OTHER|Option 1|Partial meal replacement to achieve 900-1000 kcal/day (4 meal replacement products per day combined with 150-200 kcal from vegetable meals (recipes provided))
215027235|NCT05483140|OTHER|Option 2|Partial meal replacement to achieve 900-1000 kcal/day (2 meal replacement products per day combined with one balanced meal (recipes provided))
215027236|NCT05483140|OTHER|Option 3|A real food low energy diet to achieve 800-1000 kcal/day (recipes provided)
215104273|NCT01559675|DRUG|Hydrocortisone Low Dose|1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
215104274|NCT05240365|DEVICE|SDF modified Hall technique|"* Preparation for Hall technique and selection of the crown.~* Clinical application of SDF.~* Cementation of the selected crown."
214424184|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions)|
214424185|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting|
214424186|NCT02612818|DEVICE|Coelioscopy|
214424187|NCT02794350|DEVICE|Cochlear implant|
214424188|NCT05800639|PROCEDURE|Ophthalmic surgery|Ophthalmic surgery will be performed as standard practice of our institution.
214424189|NCT05800639|PROCEDURE|General anesthesia|General anesthesia will be performed as standard practice of our institution.
214424190|NCT00420654|DRUG|Growth Hormone|1.25 mg, 6 months
214509164|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 7 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
214509165|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 8 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
214509166|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 10 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
215027237|NCT06673849|OTHER|Rhythmic Stabilization|"Rhythmic Stabilization Program for Children with Cerebral Palsy Objective: Enhance upper extremity strength and stability through rhythmic stabilization exercises.~Program Overview:~Duration: 30-minute sessions Frequency: Once per week for 6 weeks~Exercise Steps:~Positioning: The child positions their upper extremity within their available range of motion.~Isometric Contraction: The child holds an isometric contraction, maintaining the position without movement.~Therapist's Role: Apply resistance that is sufficient to elicit a reaction but not enough to disrupt the isometric contraction.~Progression: Gradually increase the duration of the isometric hold. Increase the amount of resistance applied. Decrease the contact area between the therapist's hands and the child's upper extremity to enhance stability challenges. Monitoring and Adjustments: Assess the child's ability to maintain the contraction and adapt the resistance and support as needed. Encourage the child's engagement."
214424191|NCT00420654|DRUG|Placebo|Equivalent to 1.25 mg, 6 months
214424192|NCT00420654|OTHER|Healthy controls|Healthy controls
214424193|NCT03580798|PROCEDURE|Delayed graft|8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
214424194|NCT03580798|PROCEDURE|Simultaneous graft|At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
214424195|NCT04484415|COMBINATION_PRODUCT|Cevira®|The device is a single-use, disposable, LED-based red light source. The device will automatically switch on the light 5 hours after administration, and provide continuous photoactivation of 125 J/cm2 over 4.6 hours before automatically shutting down.
214424196|NCT04484415|COMBINATION_PRODUCT|Placebo|The placebo device is identical in appearance as the Cevira® device, but does not provide light.
214424197|NCT03958500|PROCEDURE|Indocyanine green fluorescent angiography intraluminally and intraperitoneally|The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis
214424198|NCT05076318|OTHER|Aminoacid, alanine-infusion|During 3 hours, patient will receive alanine-infusion, while amino-acid and urea will be monitored by blood samples.
214424199|NCT05790928|DEVICE|Lotrafilcon A spherical contact lenses|CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity
214424200|NCT00877513|BEHAVIORAL|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
214424201|NCT01679951|DRUG|Placebo|Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
214424202|NCT01679951|DRUG|JNJ-38518168 (3 mg)|Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
214424203|NCT01679951|DRUG|JNJ-38518168 (10 mg)|Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
214424204|NCT01679951|DRUG|JNJ-38518168 (30 mg)|Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
214424205|NCT01679951|DRUG|Methotrexate|Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
214424206|NCT04176367|DRUG|Nicergoline from China|This is the test arm of China local manufactured Nicergoline
214424207|NCT04176367|DRUG|Nicergoline from Italy|This is the reference arm of Italy originator Nicergoline.
214424208|NCT01891968|DRUG|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
214424209|NCT03183999|DIETARY_SUPPLEMENT|fermented ginseng (GINST)|Intervention group should take fermented ginseng (GINST) capsule 3 times a day, 2 capsules at one time for 12 weeks
214424210|NCT03183999|DIETARY_SUPPLEMENT|Placebo|Control group should take placebo capsule 3 times a day, 2 capsules at one time for 12 weeks
214424211|NCT04925648|DRUG|Dasatinib|Dasatinib 100mg once daily orally for 14 Days
214424212|NCT04925648|DRUG|Darolutamide|Darolumatide 600 mg twice daily orally for 14 Days
214424213|NCT01234844|BEHAVIORAL|care of guinea pigs|twice weekly sessions of care with guinea pigs
214424214|NCT01234844|BEHAVIORAL|guinea pigs|"twice weekly pet therapy and twice weekly usual  occupational therapy"
214424215|NCT04233931|BEHAVIORAL|PrEP medication adherence mobile app|Participants use a PrEP medication adherence mobile app for six weeks.
214424216|NCT03778099|DRUG|Cinnamon Cap 500 MG|The Cinnamomum cassia (C. aromaticum) capsules will be purchase from Spring Valley company (distributed by Wal-Mart Stores, Inc. USA) by the investigator.
214424217|NCT03778099|DRUG|Placebo|450 mg of starch and 50 mg of cinnamon powder
214424218|NCT03731936|OTHER|No intervention|No intervention
214692059|NCT05805423|PROCEDURE|bilateral superficial cervical plexus blocks and local wound infiltration|10mL bupivacaine at Erb's point bilaterally and 10mL 0.25% Bupicacaine at incision
214692060|NCT05805423|PROCEDURE|placebo injection and local wound infiltration|10mL normal saline at Erb's point bilaterally and 10mL 0.25% Bupicacaine at incision
214692061|NCT03172221|DIAGNOSTIC_TEST|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
214692062|NCT00718757|DRUG|Dexamethasone|5 doses given on Days 6-10
214692063|NCT00718757|DRUG|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
214692064|NCT00718757|DRUG|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~\* Patients \< 1 year of age or \< 10kg in weight: Vincristine 0.05 mg/kg"
215027238|NCT06673849|OTHER|Ball Balancing|"Ball Balancing Program Objective: Improve balance and stability. Equipment: 48-inch gymnastic ball~Program Details:~* Duration: 6 weeks~* Frequency: As needed~Steps:~1. Initial Balance:~   * Eyes Open: Balance on hands for 10 seconds.~  * Progression: Increase to 3-5 repetitions of 60 seconds.~2. Eyes Closed: Repeat the above exercise with eyes closed.~3. Variations:~   * Both Hands on One Ball~  * Each Hand on Separate Balls~  * Weaker Arm on One Ball~4. Body Positions: Progress through four body positions with eyes open, then closed.~5. Correction: If the child misses a position, they open their eyes and reposition actively."
214424219|NCT04141917|COMBINATION_PRODUCT|Point-of-care molecular testing and treatment of influenza|Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged \<12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
214509167|NCT02643368|BIOLOGICAL|IPV at 6 weeks of age|Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
215027239|NCT06675058|PROCEDURE|Indirect Pulp Treatment|Indirect pulp treatment is considered one of the most conservative pulp therapies, which preserves the pulp's vitality in teeth with reversible pulpitis. It has been chosen to be the intervention in both groups as the aim of this study is to assess the impact of caries location (proximal vs. occlusal caries) in influencing the success rate of IPT.
215104275|NCT05240365|DEVICE|Conventional pulpotomy and stainless steel crown|"* Teeth will be anesthetized .~* Rubber dam will be used and high suction in pulpotomy procedure.~* Cavity outline will be performed by sterile #330 high speed bur using water spray.~* Caries will be removed by large spoon excavator.~* pulpal exposure will be occurred then the roof of pulp chamber will be removed by low speed round bur. Hemostasis will be obtained by applying pressure with moist cotton pellet with saline.~* Teeth will be treated by using sterile cotton pellet with formcresol for three to five min then, remove it.~* Pulp stumps of will be dressed with reinforced zinc oxide eugenol, IRM®\*~* Tooth Preparation will be done followed by placement of stainless-steel crown"
215104276|NCT00730080|DRUG|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
215104277|NCT01496469|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
215104278|NCT01496469|DRUG|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
214509168|NCT04870905|DRUG|Tis-U-Sol|Tislelizumab 200mg will be given every 3 weeks for 12 cycles
214509169|NCT04421534|DRUG|Lactoferrin|adding lactoferrin to standard of care treatment regimens
214509170|NCT02713594|BEHAVIORAL|Counseling from WTQL|Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
214509171|NCT02713594|OTHER|Financial incentive to participate|Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
214509172|NCT02125409|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily for 7 days.
214509173|NCT02125409|PROCEDURE|Screening colonoscopy|
214509174|NCT05459974|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg once daily for 30 days after the atrial fibrillation ablation
214509175|NCT05459974|DRUG|Placebo|Placebo pill once daily for 30 days after the atrial fibrillation ablation
214509176|NCT02734784|PROCEDURE|Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
214692065|NCT00216099|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
214692066|NCT00216099|DIETARY_SUPPLEMENT|Folic Acid|All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
214692067|NCT00216099|DIETARY_SUPPLEMENT|Vitamin B12|All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
214692068|NCT02544971|BEHAVIORAL|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
214692069|NCT02544971|OTHER|Control|Treatment as usual
214692070|NCT05495074|OTHER|ATP III dietary intervention|The dietary intervention will consist of an approximate decrease of 500 kcal from the calories participants habitually consume, with the following macronutrient distribution 15-20% protein, 50-60% carbohydrates, 25-35% fat. Participants will receive recipes with menus for two weeks.
214692071|NCT02902172|DRUG|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
214692072|NCT02902172|DRUG|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
214692073|NCT05932511|DRUG|30% ascorbic acid in DMSO|see above
214692074|NCT03419767|DRUG|Melatonin|Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
214692075|NCT03419767|OTHER|blank|Patients under carotid revascularization surgery without taking melatonin
215027240|NCT07004712|DRUG|Adebelizumab combined with irinotecan liposome as second-line therapy|Adebellizumab: intravenous drip, 1200mg, the infusion time is controlled between 30-60 minutes, and the infusion is completed within 2 hours at most. It is administered on the first day of each cycle and repeated once every 3 weeks.Irinotecan liposome: intravenous drip, 80mg/m2, infusion time of 30 minutes, the first dose of each cycle, repeated once every 3 weeks.After 4-6 cycles of adebelizumab combined with irinotecan liposome treatment, the subjects who did not develop the disease continued to use adebelizumab (1200mg, D1, Q3W) for maintenance treatment until the disease progressed, the toxicity was intolerable, the subjects voluntarily asked to withdraw and the researchers judged that the subjects needed to withdraw from the study.
215104279|NCT03953469|DIETARY_SUPPLEMENT|Passiflora incarnata|One-time administration of 1/8 tsp solid extract Passiflora incarnata providing 900mg of Passiflora incarnata
215104280|NCT00291018|DEVICE|Total Disc Replacement|Total Disc Replacement using ProDisc-C
215027241|NCT05893732|DEVICE|High-Intensity Laser Therapy (HILT)|Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
214424220|NCT04021615|OTHER|Comprehensive physical therapy rehabilitation program combined with inspiratory muscle training|A threshold inspiratory muscle trainer will be connected to the artificial airway with 15 mm and 22 mm adaptors. Training bouts consist of three to five sets of six repetitions breathing through the trainer. Training will be conducted with the patient in bed with an approximately 30° head-up tilt and with intensity about 40 %- 50 % of maximal inspiratory pressure. Patients will be returned to mechanical ventilation for rest between training sets as needed. Three to five sets of six training breaths will be completed for a total of 18 to 30 training breaths per session. Following each training set, the patient indicated a rating of perceived inspiratory exertion on modified Borg scale . The study group will also receive comprehensive rehabilitation program consist of upper-extremity exercises, lower extremity exercises, pedaling exercises, trunk control exercises and bedside functional training
215027242|NCT05893732|DEVICE|Sham High-Intensity Laser Therapy (Sham HILT)|Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
215027243|NCT04331769|DEVICE|AccuCinch Ventricular Restoration System|AccuCinch Ventricular Restoration System
215027244|NCT04331769|DRUG|Guideline-Directed Medical Therapy|Guideline-Directed Medical Therapy
215104281|NCT00291018|DEVICE|ACDF|Anterior Cervical Discectomy and Fusion
215104282|NCT05219682|OTHER|electroencephalographic measurement|recording brain activity in mirror therapy, haptic and tactile stimulation and in mirror therapy using virtual reality
215104283|NCT01873040|BEHAVIORAL|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
214692076|NCT03277950|OTHER|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
214692077|NCT03277950|OTHER|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
214692078|NCT03277950|OTHER|Healthy|Healthy do not play game
214692079|NCT00048594|DRUG|aprepitant|
214692080|NCT00048594|DRUG|Comparator: placebo (unspecified)|
214692081|NCT01412645|DIETARY_SUPPLEMENT|Resveratrol|"500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months"
214692082|NCT01434472|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
214692083|NCT01434472|DRUG|Cyclosporine|Given PO
214692084|NCT01434472|DRUG|Fludarabine Phosphate|Given IV
214692085|NCT01434472|RADIATION|Indium In-111 Ibritumomab Tiuxetan|Given IV
214692086|NCT01434472|DRUG|Mycophenolate Mofetil|Given PO
214692087|NCT01434472|OTHER|Pharmacological Study|Correlative studies
215104284|NCT01873040|BEHAVIORAL|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
215104285|NCT02356718|BEHAVIORAL|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
215104286|NCT02356718|BEHAVIORAL|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
215027245|NCT07010367|PROCEDURE|Acupuncture|Patients will be instructed to lie in the supine position. After strict disinfection of the acupoints area, acupuncture needles will be inserted into the Baliao points (inserted at the surface projections of the first, second, and third pairs of sacral foramina, with a depth of 3-4 cm). The treatment will be administered five times per week, with each session lasting 30 minutes, for a total of two weeks.
214692088|NCT01434472|BIOLOGICAL|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
214692089|NCT01434472|RADIATION|Total-Body Irradiation|Undergo TBI
214692090|NCT01434472|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
214692091|NCT01434472|DRUG|Fludarabine|Given IV
214692092|NCT00947570|BEHAVIORAL|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
215027246|NCT07010367|PROCEDURE|Sham acupuncture|Patients will be instructed to lie in the supine position. After strict disinfection of the sham acupoints area, acupuncture needles will be inserted lateral to the surface projections of the first, second, and third pairs of sacral foramina, with a depth of 1 cm.The treatment will be administered five times per week, with each session lasting 30 minutes, for a total of two weeks.
215027247|NCT07009938|DEVICE|Drug-Coated Balloon (DCB)|Following lesion preparation (usually with a standard balloon), a drug-coated balloon is advanced to the target lesion. The balloon is inflated and maintained to allow effective drug transfer to the vessel wall.
215027248|NCT07009938|DEVICE|Drug-Eluting Stent (DES) implantation|After coronary angiography identifies the target lesion, a DES is selected based on the vessel size. Post-deployment angiography is performed to confirm the result and check for complications.
215027250|NCT07010328|PROCEDURE|Neurorehabilitation|4-8 weeks of inhospital Neurorehabilitation
215027251|NCT07010328|DEVICE|AI-based home rehabilitation for postural disorders|AI-based home rehabilitation for postural disorders by means of the Kemtai platform.
215027252|NCT07011238|DIAGNOSTIC_TEST|Patients meeting HLA immunization criteria|At enrollment visit, a single sample of a volume of 50 ml of blood will be taken as part of routine care in order to directly and simultaneously explore the clonality (BCR repertoire), the phenotype of membrane markers and the transcriptome of Bmem alloreactive with respect to a restricted panel of HLA alleles chosen according to the HLA antibody reactivity profile of the patients analyzed
214692093|NCT01240044|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
214692094|NCT01240044|PROCEDURE|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
214692095|NCT06391073|BEHAVIORAL|Self-Measured Blood Pressure Monitoring|Prompted SMBP with tailored feedback
214692096|NCT06391073|BEHAVIORAL|Physician appointment and transportation scheduling|Physician appointment and transportation scheduling or none dependent on current BP control
215027253|NCT07011251|BEHAVIORAL|Food as Medicine Program|Grocery Prescription - participants will receive a card loaded with $100 per month to be used on the Instacart Fresh Funds program website/app or a SodaHealth grocery prescription card to be used inside a Kroger or Food City stores. Patients who select grocery delivery where Instacart is not available will receive Food City meals for the same value. or 2) Medically Tailored Meals (MTM) - participants receive approximately 5 frozen meals per week from Mom's Meals that follow an approved diet for those with hypertension. Participants will complete screening questions (screening decision tree attached) after informed consent to determine which food package the participant will receive. The screening decision tree is a tool that asks about kitchen availability for preparing foods, skills, and access to transportation. Depending on how the patient answers they will receive either grocery prescription or MTM for 3-months or 12-weeks.
215027254|NCT07011251|OTHER|Survey|"Participants answering no to assistance but agreeing to the 20-30 minute survey will receive a direct link to a survey related to reasons for not wanting assistance to answer questions at one time point."
215027255|NCT07010016|DEVICE|NaviFus Model101|FUS Neuromodulation
215104287|NCT05502354|DEVICE|removal of transanal drainage tube|removal of transanal drainage tube after laparoscopic anterior resection for rectal carcinoma according to postoperative CRP trajectory
215104288|NCT00467129|GENETIC|microarray analysis|
215104289|NCT00467129|GENETIC|mutation analysis|
214692097|NCT05362643|OTHER|Acupuncture|Manual acupuncture on acupoint Tai Xi(KI3), bilateral;Sanyinjiao (SP6), bilateral; Zusanli (ST36), bilateral; Shenmen (HT7) unilateral, in the arm without arteriovenous fistula;Guan Yuan (CV4), unilateral, attempt to achieve De qi sensation. After generating needling sensation, needles were manipulated for one minute, every ten minutes during needle retention (20 minutes), using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
214692098|NCT05362643|OTHER|Sham Acupuncture|Manual acupuncture performed as superficial needling (5mm depth) on non-acupuncture points without an attempt to achieve De qi sensation and without stimulation, lasting 20 minutes, using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
214424221|NCT04021615|OTHER|Traditional chest physical therapy rehabilitation program combined with inspiratory muscle training|The same inspiratory muscle training for the study group combined with the traditional physical therapy program consist of positioning , modified postural drainage , percussion , vibration.
215027256|NCT06626347|OTHER|TREAT-ED Virtual Group Diabetes Self-Management Education and Support|TREAT-ED is an innovative group telehealth delivery model designed to engage emerging adults in DSMES services. TREAT-ED sessions are facilitated by a Diabetes Care and Education Specialist and include content centered around the ADCES7 Self-Care Behaviors and applied learning strategies, e.g., case scenarios integrating glucose monitoring, and group discussions to drive knowledge transfer and skill development for diabetes self-care behaviors within the context of issues that are salient to the target population.
215027257|NCT07010926|BIOLOGICAL|L2-01 adipose-derived mesenchymal stem cells (MSC)|L2-01 is a biological product consisting of human mesenchymal stem cells isolated from adipose tissue of the patient or a first-degree relative. The MSCs are expanded under Good Manufacturing Practice (GMP) conditions and suspended in 10 ml of lactated Ringer's solution. The product is administered as a single intravenous infusion at a dose of 1 × 10\^6 cells per kilogram of body weight, diluted in 100 ml of saline, infused over approximately 30 minutes. The infusion is closely monitored for safety.
215027258|NCT07010926|OTHER|Placebo saline solution|Placebo consists of 10 ml of lactated Ringer's solution mixed with 100 ml of saline. It is administered as a single intravenous infusion over approximately 30 minutes. The placebo is packaged identically to the active product to maintain study blinding.
215027259|NCT07011095|DRUG|VKA|Warfarin
215027260|NCT07011095|DRUG|Direct Oral Anticoagulant (DOAC)|Locally approved DOACs
215027261|NCT06683898|OTHER|External Focused Pilates|Pilates training was implemented with an external focus (EF).
215027262|NCT06683898|OTHER|Internal Focused Pilates|Pilates training was implemented with an internal focus (IF).
215027263|NCT06689176|DEVICE|Irrisept® Antimicrobial Wound Lavage|Irrisept® Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device comprised of a 450mL bottle of 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United States Pharmacopeia (USP) and an applicator (labeled Irriprobe®). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle. The CHG acts as a preservative to inhibit microbial growth in the solution.
215027264|NCT06690268|DIAGNOSTIC_TEST|Multimodal AI-driven predictive model|This intervention involves a multimodal artificial intelligence (AI) model that integrates clinical data, imaging results, and pathology findings to predict the risk of postoperative recurrence in patients with locally advanced gastric cancer. Unlike traditional methods that may rely on single data sources, this AI-driven model synthesizes multiple types of patient information, offering a comprehensive and personalized prediction of recurrence risk. This approach aims to improve accuracy in identifying high-risk patients, allowing for more tailored follow-up and treatment planning to enhance patient outcomes.
215027265|NCT06691789|OTHER|Social support|This intervention includes a social support given to the students during COVID-19 pandemic
215027266|NCT06690853|OTHER|Experimental Coordinative training|The warm-up protocols of the Experimental Group included four types of upper and lower limb coordination exercises using different-sized balls, with intensity increasing week by week.
215027267|NCT06690853|OTHER|Traditional training (control group)|The Control Group warm-up protocol only involved joint mobility exercises and muscle activation, as used in their regular training activities.
215027268|NCT06687811|OTHER|preoperative carbohydrate loading|Patients receive 200 ml drink containing Maltodextrin 12.5%, 2 hours prior to surgery
215027269|NCT06687811|OTHER|Placebo|Patients receive 200 ml regular drinking water with zero-calorie sweetener, 2 hours prior to surgery
215027270|NCT06688487|OTHER|early extubation of hypoxemic patients|patient extubated after the spontaneous ventilation trial despite the presence of hypoxemia defined by SpO2 ≤ 90% either in T-piece under 6 L/min, or under FiO2 = 40% if SBT is performed in spontaneous ventilation with minimal inspiratory assistance.
215027271|NCT06688565|DEVICE|Hativ® electrocardiogram monitoring|Using Hativ®, a currently commercially available class II medical device, ECGs are measured every day at home and before and after dialysis
215027272|NCT06694129|DRUG|Entrectinib|Patients in each cohort were treated with Entrectinib.
215027273|NCT06695052|DEVICE|multi modal Us|Greyscale US: grey scale ultrasound Color Doppler US: Color Doppler ultrasound Elastography US: Elastography ultrasound
215027274|NCT06694636|PROCEDURE|endovascular radiofrequency ablation and desympathetic nerve surgery|endovascular radiofrequency ablation and desympathetic nerve surgery
214424222|NCT06257693|DRUG|enzalutamide|Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy
214424223|NCT04481373|BEHAVIORAL|THRIVE|"The ACT components (3-3.5 hours) will focus on clarifying patient values and goals and identifying obstacles that may be getting in the way of living a rich life. Short-and long-term effects of avoidance will be discussed (e.g., avoidance reduces immediate contact with distressing experiences and provides short-term relief but leads to greater dysfunction in long run). Patients will be taught acceptance, mindfulness, and perspective taking to help patient cope with difficult emotions and thoughts that may interfere with living a values-driven life. Individuals will also be encouraged to examine the costs of stigmatization on their life (e.g. avoidance of medical care, sense of isolation).~Education will include medical information about HIV, services available at the clinic, and health needs related to comorbidities. This content to be delivered in 30 minutes."
214424224|NCT04481373|OTHER|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
214424225|NCT04048018|DIAGNOSTIC_TEST|Blood draw and IGRA test|One to two blood samples will be obtained from participants in all arms in order to conduct testing.
214424226|NCT00861458|DRUG|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
214424227|NCT00367991|DRUG|Recombinant human erythropoietin alfa (drug)|200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
215104290|NCT00467129|GENETIC|polymerase chain reaction|
215104291|NCT00467129|GENETIC|polymorphism analysis|
215104292|NCT00467129|OTHER|laboratory biomarker analysis|
215104293|NCT00467129|OTHER|questionnaire administration|
215027275|NCT06694532|DRUG|Hyaluronic acid|Comparative study between Hyalgan and Hyorth injectable products in TMJ Disorders by arthrocentesis of 2 syringes device
215027276|NCT06694532|DEVICE|Syringes|Whilst you are asleep, two small needles will be inserted into the TMJ / Jaw Joint. One of these needles allows sterile saline to be pumped into the joint under pressure whilst the other needle allows the saline to drain out of the joint then injection of the HA injectiable products .
215027277|NCT06695624|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganglion block group 4cc (80mg) 2% lidocaine + 1cc (4mg) dexamethasone in total 5cc volume will be prepared under sterile conditions before the procedure, 2.5 cc will be given to both nostrils. Sphenopalatine ganglion block will be applied by transnasal endoscopic method.
215027278|NCT06689384|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 4 different intraoral scanners (IOS) (Trios 3, 3Shape; Primescan, Dentsply; Element 5D, iTero; Lumina, iTero) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
215104294|NCT02843503|DEVICE|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
215104295|NCT02843503|DEVICE|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
215104296|NCT02843503|DEVICE|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
215104297|NCT01009606|OTHER|Usual strategy|Usual strategy
215104298|NCT01009606|OTHER|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
214424228|NCT00367991|DRUG|Placebo|Normal saline to match active drug (rHuEpo)
215104299|NCT00630344|DRUG|RAD001|
215104300|NCT00630344|DRUG|Bicalutamide|
215104301|NCT03045718|BEHAVIORAL|Horticultural Therapy|The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
215104302|NCT04368715|DEVICE|Laser-assisted frenectomy with 2780 nm Er:Cr;YSGG and 940 nm diode laser|
215104303|NCT03454607|DEVICE|FREE robot|FREE robot to hold endoscope
214424229|NCT06556160|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests to search synaptopathie. During the surgery, stimuli are delivered."
215104304|NCT01939327|DRUG|Lenalidomide/Rituximab|
215104305|NCT01930838|PROCEDURE|Gastric bypass operation|
215104306|NCT05345275|OTHER|The facial expressions analyzed|The facial expressions associated with pain were analyzed by the researchers in the OpenFace program. The patient's pain scores were estimated in the Python program by combining the numerical outputs of facial expression analyses with machine learning algorithms.
214424230|NCT06212167|BEHAVIORAL|Nursing Interventions for Stroke Patient Care|In the first phase of the research, the relatives of the patients who are in the hospital every day for a week during the routine and discharge process will be included in a training program. These trainings will be explained didactically to the caregiver at the bedside by the research supervisor and the intensive care nurse, the practices will be demonstrated with demonstrations, and the caregiver will be asked to apply them themselves. Then, the researchers will call the caregivers and make an appointment for an online meeting twice a week (7 weeks - 14 times). During these meetings, the training the caregivers need will be explained again and any questions they have will be answered. The researcher will also conduct motivational interviews with the caregivers.
214424231|NCT01184508|DRUG|Placebo|Administered orally, once daily, for 12 weeks
214424232|NCT01184508|DRUG|LY2300559|300 milligrams (mg) administered orally, once daily, for 12 weeks
214424233|NCT00980135|DEVICE|Sinecort cream|Application over 29 days
214424234|NCT00980135|DRUG|Hydrocortison cream|Application over 29 days
214424235|NCT00980135|OTHER|Untreated skin|
214424236|NCT03870607|DIETARY_SUPPLEMENT|prebiotics in combination with probiotics|Administration of prebiotics in combination with probiotics before the start of Ch-RT
214424237|NCT03441204|DRUG|LTOT 24 h/day|LTOT prescribed for 24 h/day.
214424238|NCT03441204|DRUG|LTOT 15h/day|: LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
214424239|NCT04778917|DRUG|Low-Molecular-Weight Heparins Calcium Injection|We use different dose of low-molecular-weight heparins calcium injection to different interventions
214424240|NCT01356758|DRUG|biological treatment|patients treated with anti-psoriatic biological agents
214424241|NCT04353102|DRUG|YH002|YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
214424242|NCT05727202|DIAGNOSTIC_TEST|The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel|A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).
215104307|NCT01357551|BEHAVIORAL|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
215104308|NCT04587310|DIAGNOSTIC_TEST|Laparoscopic Sleeve Gastrectomy|bariatric surgery
215027279|NCT06689384|PROCEDURE|Clamp placement on canine and 2nd molar teeth and rubberdam rubber band insertion|"The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. It was aimed to facilitate the second scanning process by expanding the isolation area to include 3 teeth.~A flowable composite was applied by placing Teflon tape on the occlusal surface of the 1st molar to create a difference in its morphology."
215104309|NCT04522167|DRUG|FYB203 (Proposed aflibercept biosimilar)|Patients will receive 1 IVT injection of FYB203 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
215027280|NCT05954494|BIOLOGICAL|BPAN Patients|Patients, children or adults with a neurological impairment (epilepsy, dystonia, cognitive impairment...) related to a pathogenic variant of the WDR45 gene
215027281|NCT06690827|DRUG|Anti-CD123 CAR NK cells|Each patient will receive two CAR-NK cell infusions at D0 and D7, and CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion.
215027282|NCT06685939|PROCEDURE|LPD|The patients who received the LPD
215029380|NCT00876941|BEHAVIORAL|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
215104310|NCT04522167|DRUG|Eylea® (Aflibercept)|Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
215104311|NCT03698552|BIOLOGICAL|ADCT-602|Starting dose of ADCT-602: 30 μg/kg given by vein.
215104312|NCT04044339|DRUG|TD-5202|Study Drug to be administered orally
215104313|NCT04044339|DRUG|Placebo|Placebo to be administered orally
215104314|NCT00668603|DRUG|17-b-estradiol|2mg oral daily for 6 months
214424243|NCT05496907|BEHAVIORAL|Diabetes specialist nurse-led collaborative care intervention|10 sessions with a diabetes nurse to help improve physical and mental health outcomes
214424244|NCT03385824|BEHAVIORAL|Self-Advocacy for Independent Life (SAIL)|SAIL program is based on an interactive workshop model. In -person sessions will focus on: enhancement of self-efficacy beliefs; enhancement of knowledge of TBI self-advocacy information; group process to instill hope and universality; and practice of self-advocacy behaviors in a supportive neuro-rehabilitation structured group environment.
215104315|NCT00668603|DRUG|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
215104316|NCT00668603|DRUG|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
214424245|NCT02905812|OTHER|RGI & Massage|A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
214424246|NCT03646435|DEVICE|Fitbit Charge 2|The Fitbit Charge 2 is the electronic wearable chosen for this pilot study. This particular Fitbit is capable of measuring patient heart rate, sleep and physical activity. The data collected will then be analyzed with respect to the outcomes of this study. To determine the accuracy of the Fitbit, data collected will be compared to the nurses' standard patient assessment (for HR and physical activity) and to patient responses on the Richards-Campbell Sleep Questionnaire (for sleep).
215104317|NCT00668603|DRUG|placebo pill + gel|placebo daily for 6 months
215104318|NCT02801565|DRUG|Conventional controlled ovarian stimulation proctol|Conventional controlled ovarian stimulation proctol without rhGH.
215104319|NCT01565681|DRUG|ASP1240|infusion
215104320|NCT01565681|DRUG|Placebo|infusion
215104321|NCT04800848|DEVICE|Mask|Physical Fitness is evaluated with the use of a face mask
215104322|NCT06474637|DEVICE|AEON Endoscopic Powered Stapler Handle and Reload|The AEON™ Endoscopic Stapler places two triple-staggered rows of titanium staples while simultaneously transecting between the two triple-staggered rows of staples. The size of the staples and staple line length are based on the selection of the Stapler Reload (2.0mm, 2.5mm, 3.25mm, 4.0mm, 5.0mm and 5.5mm).
214692099|NCT04659226|GENETIC|Blood sampling for microRNA testing|Blood samples will be collected and analyzed for the microRNA profile by means of microfluidic cards
214424247|NCT04178226|OTHER|Manual Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
214424248|NCT04178226|DEVICE|Laser Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
214424249|NCT01315314|DRUG|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
214424250|NCT00168922|DRUG|Bendamustin/Ribomustin|
214424251|NCT02534311|DRUG|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
214424252|NCT06461871|OTHER|BALANCE TRAINING WITH MODERATE INTESITY AEROBIC VERSUS RESISTED TRAINING (RT)|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP A: Baseline treatment + Moderate intensity aerobic exercises in combination with balance training
214424253|NCT06461871|OTHER|Moderate intensity resistance exercises in combination with balance training|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP B: Baseline treatment + Moderate intensity resistance exercises in combination with balance training
215104323|NCT04346836|BEHAVIORAL|Low-intensity, general-fitness exercises|"24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination."
214692100|NCT05024123|DIETARY_SUPPLEMENT|Placebo|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
215027283|NCT06690463|DIAGNOSTIC_TEST|sacroiliac joint injection|"The procedure involves the administration of a 2.5 cc injection of 2% lidocaine to the sacroiliac joint, targeting the articular or periarticular areas. The injection is performed under real-time ultrasound guidance to ensure accurate placement of the needle.~The 2% lidocaine solution is injected into both the joint space (articular area) and the surrounding soft tissues (periarticular area), which may include ligaments, capsules, and adjacent muscles. The goal is to temporarily anesthetize the joint and surrounding structures to assess the contribution of the sacroiliac joint in the patient's pain, as well as to provide therapeutic pain relief. The use of ultrasound ensures minimal risk of injury to surrounding structures and enhances the accuracy of the injection.~This intervention is commonly used in both diagnostic and therapeutic settings, helping to confirm the role of the sacroiliac joint in a patient's symptoms and providing relief in cases of sacroiliac joint dysfunction."
215027284|NCT06689657|BEHAVIORAL|Cognitive behavioral group therapy for adolescents and non violent resistance group for parents|"In the adolescents group, this cognitive-behavioral group therapy will include emotion regulation skills, distress tolerance skills, cognitive strategies, work on values and problem-solving strategies~Those sessions will include psychoeducation about adolescents, about suicidal ideation and suicidal behavior, coping with adolescent emotional distress, support on how to be a parent today (screen regulation...) and manage daily life"
215027285|NCT06689657|OTHER|Adolescent group therapy (CARES) and parent group therapy (RNV)|"In the adolescent group, they will attend 8 group sessions during 1 month (2 sessions/week). There also will be a boost session 3 month after the last session. Parents will attend 4 group sessions during 1 month too (1 session/week). There will be 2 boost sessions : 1 month and 3 month after the last session Patients will be randomized in each group with blinded assessment"
215104324|NCT04346836|BEHAVIORAL|Psychoeducation|A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
215104325|NCT01258023|BIOLOGICAL|Fluad 1x|"15 µg antigen/strain:~* A/California/07/2009 (H1N1) - like strain~* A/Perth/16/2009 (H3N2) - like strain~* B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml"
214424254|NCT00099086|DRUG|Bicalutamide|Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
214424255|NCT00099086|DRUG|docetaxel|Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
215027286|NCT06690866|BEHAVIORAL|Stress|Montreal Imaging Stress Task is a stress paradigm in the scanner to examine neuronal correlates of acute psychosocial stress.
214424256|NCT00099086|DRUG|GnRh analog|"A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)"
215027287|NCT06689124|DRUG|Nebulized fentanyl|After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.
215027288|NCT06690515|BIOLOGICAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A|0,5 ml DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A injected three-dose regimen with 28 days interval between doses. Vaccine is injected intramuscularly in left anterolateral thigh.
215104326|NCT03734003|DEVICE|liquid nitrogen|As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
215104327|NCT03734003|DEVICE|controllable infrared bioeffect system|As an experimental arm, for patients with cutaneous warts
214424257|NCT00099086|RADIATION|radiotherapy|External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
214424258|NCT03834792|OTHER|No intervention but exposure|Different sleep disorders will be considered as an exposure. The data elements included in the database: demographics, date of the sleep study, study type, all available polysomnography indices, symptoms, sleep schedule, comorbidities, medications, social history, electrocardiography, positive airway pressure treatment related variables.
215027289|NCT06690515|BIOLOGICAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B|0,5 ml injected of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B three-dose regimen with 28 days interval between doses. Injected intramuscularly in left anterolateral thigh.
214424259|NCT03900637|DRUG|Leuprorelin acetate|In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
215027290|NCT06690515|BIOLOGICAL|Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)®|The control group will receive 0,5 ml of Registered DTwP-Hepatitis B-Hib vaccine and 0,5 ml IPV (Sinovac)® injected in three-dose regimen with 28 days interval between doses. Registered DTwP-Hepatitis B-Hib Vaccine are injected intramuscularly into the left antero-lateral thigh region. IPV (Sinovac)® vaccine are injected intramuscularly into the right mid-lateral thigh region
215027291|NCT06687200|OTHER|Setup with neutral pelvic positioning technique|Setup with neutral pelvic positioning technique (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT Mega Voltage Computed Tomography)
214424260|NCT03900637|DRUG|Letrozole|2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
214424261|NCT03900637|GENETIC|MammaPrint|In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
214424262|NCT00003375|DRUG|lomustine|
214424263|NCT00003375|DRUG|procarbazine hydrochloride|
214424264|NCT00003375|DRUG|vincristine sulfate|
214424265|NCT00003375|RADIATION|radiation therapy|
214424266|NCT01015404|DRUG|Trafermin|Administered to the bone defect during flap operation
214424267|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
214424268|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
214424269|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
214424270|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
214424271|NCT03023800|PROCEDURE|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
214424272|NCT03023800|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
214424273|NCT03385681|OTHER|Tailored Educational Intervention|The intervention will be a one-day seminar for nurses working at the units, with lectures and workshops with main focus on the subjects showing the lowest pediatric pain management competence. In addition, there will be clinical supervision in pediatric postoperative pain management (two or three days per unit). The intervention will be conducted by two experts (nurse and physician) in pediatric postoperative pain management. After the intervention there will be different reminders every week for the first month, and then every month (in different forms) about pediatric pain management during six months of time.
214424274|NCT03573063|OTHER|Androgen metabolism after starvation|"The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant."
214424275|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
214424276|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
214424277|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
214424278|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
214424279|NCT03309579|OTHER|Liberal RBC Transfusion Strategy|RBC transfusion is triggered by a Hemoglobin value of ≤100g/L
214424280|NCT03309579|OTHER|Restrictive RBC Transfusion Strategy|Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
214424281|NCT06359327|DIETARY_SUPPLEMENT|Placebo|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given placebo for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
214509177|NCT02734784|PROCEDURE|Sham Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
214509178|NCT00670449|DRUG|Fingolimod|Fingolimod was supplied in capsules.
214509179|NCT02572986|DRUG|Permethrin|
214509180|NCT04728191|OTHER|Physiotherapy|physiotherapeutical instructions and training as described.
214509181|NCT04728191|OTHER|standard care|Standard care as described.
214509182|NCT00709605|DRUG|VRC-HIVADV014-00-VP|
214509183|NCT01058694|BEHAVIORAL|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
214509184|NCT01685476|DEVICE|Echodia® hand-held equipment|
214509185|NCT00495066|DRUG|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
215027292|NCT06687200|OTHER|Standard setup|Standard setup (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT)
215027293|NCT06689670|DEVICE|Needle based delivery of INT001 into liver tumors under real-time image guidance|Using ultrasound or CT imaging, the liver tumor is located. Under local anesthesia or, if necessary, intravenous sedation, the needle is inserted through the skin and the needle tip is brought to the center of the liver tumor using image guidance. 1-2 ml of the INT-001 is injected. The needle is removed and a bandaid is applied to the skin entry site. Right after, or as soon as MRI becomes available, MRI is performed to show that the entire tumor has been treated.
215027294|NCT06690177|DRUG|EscharEx (EX-03)|a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
215027295|NCT06690177|DRUG|Placebo (Gel vehicle)|A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
215027296|NCT06691009|PROCEDURE|Group 1 (mechanical pleurodesis)|pleural abrasions will be done by scrubbing the parietal and visceral pleura until a uniform aspect of bloody pleura by a piece of gauze attached to the end of a holding forceps , intercostal tube will then placed and monitoring of lung expansion will be done through serial CXR and chest ultrasound follow up and when the lung is fully expanded the tube will be clamped for two hours and follow up CXR will be done for follow up and then the tube removed
214424282|NCT06359327|DIETARY_SUPPLEMENT|Pep19 2 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 2 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
215027297|NCT06691009|PROCEDURE|Group 2 chemical pleurodesis by bleomycin)|Those Patients will have indwelling pleural catheter through which pleural fluid will be drained until dryness and then pleurodesis will be done by 60 mg bleomycin dissolved in 50 ml 0.9% saline and 10 ml 2% xylocaine solution then the catheter will be clamped for 6 hours
215027298|NCT06691477|OTHER|No Interventions|No intervention required. Subjects accepted regular medical treatment
214424283|NCT06359327|DIETARY_SUPPLEMENT|Pep19 5 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 5 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
214424284|NCT04716855|OTHER|Quality of life and daily living activities assessment tests|
214509186|NCT05995730|OTHER|Lavender oil inhalation|Lavender inhalation will be administered to this group. Participants will be asked to drop three drops of lavender oil solution on a small piece of cotton on the 1st, 2nd, and 3rd days of their first menstrual bleeding after enrollment in the study, hold it 7-10 cm from their noses, and sniff for 5 minutes. Participants will be asked to apply this application immediately after the onset of dysmenorrhea pain on the first day of their menstruation and to continue regularly every 8 hours for the first three days of menstrual bleeding. Participants will be asked to apply this application in the same way in two consecutive menstrual cycles and the participants will be followed in this process.
214509187|NCT05995730|OTHER|Placebo|Olive oil will be administered to the placebo group. The application will be similar to the experimental group.
214509188|NCT05213182|BEHAVIORAL|Young Women of Today|Adolescent mothers engaged in the development and implementation of the intervention which also involved key community stakeholders to address stigma related to mental illness and adolescent motherhood. Community health workers and peer educators in the intervention arm were recruited and trained on co-facilitating peer support groups. The intervention arm (n=104 adolescent mothers) participated in the peer support groups and completed sociodemographic, base-, mid-, and end-line surveys. The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys. Peer support groups (12 groups with 6-12 participants in each group) met in-person twice a month and completed 12 peer-group sessions from May-August 2019 addressing participant identified topics such as depression. WhatsApp Messenger was used for training and implementation support. Key community stakeholders met to discuss project progress and recommendations to improve adolescent mothers' health.
214509189|NCT01181115|DRUG|Avonex|Interferon treatment for MS
214509190|NCT05082688|BIOLOGICAL|Herpes zoster vaccination (Shingrix, GSK)|Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations
214509191|NCT05082688|BIOLOGICAL|Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)|Fluarix Tetra is a quadrivalent inactivated influenza vaccine
214509192|NCT05082688|BIOLOGICAL|Placebo|0.9% NaCl
214509193|NCT05559697|DEVICE|Sponsor incisional negative pressure wound therapy device and dressing|A sponsor incisional dressing placed on the knee and connected to a sponsor disposable negative pressure therapy device
214509194|NCT05559697|DEVICE|Standard of Care incisional negative pressure wound therapy system|The control incisional negative pressure wound therapy system represents the standard of care system and market leader. It consists of a disposable negative pressure therapy device and incisional dressing.
214509195|NCT03482102|DRUG|Tremelimumab|Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
214509196|NCT03482102|DRUG|Durvalumab|Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
214509197|NCT03482102|RADIATION|Radiation|Radiation therapy is used to shrink cancer cells.
214509198|NCT01503450|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
214509199|NCT04518397|BEHAVIORAL|Theatre|6-week participatory arts culturally-informed theatre program
214509200|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
214509201|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
214509202|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
214509203|NCT02443909|DEVICE|Holmium laser device|
214509204|NCT02771366|DRUG|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
214509205|NCT02771366|OTHER|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
214692101|NCT05024123|DIETARY_SUPPLEMENT|AstraGin|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
214692102|NCT01892033|BEHAVIORAL|Aerobic Exercise|12 weeks of brisk walking
214692103|NCT06165484|PROCEDURE|laparoscopy and hysteroscopy|laparoscopy and hysteroscopy for patient with failed IVF
214692104|NCT00000741|DRUG|Methylprednisolone|
214692105|NCT02990637|DIETARY_SUPPLEMENT|OLECOL|Olive leaf extract
214692106|NCT02990637|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214692107|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
214692108|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
214692109|NCT03270696|DRUG|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
214692110|NCT02555644|DRUG|Prexasertib|Administered IV
214692111|NCT02555644|DRUG|Cisplatin|Administered IV
215027299|NCT06687187|DRUG|Neostigmine|two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively
215027300|NCT06686550|OTHER|This is a observational study and there is no intervention.|This is a observational study and there is no intervention.
215027301|NCT06686186|OTHER|No Intervention: Observational Cohort|There were no interventions in our cohort. The subjects of our cohort were and will be followed up at the regular intervals.
215027302|NCT06690476|DRUG|Dose escalation(IPM514 monotherapy)|Drug：IPM514 Intramuscular Injection A total of 7 administrations, including 2 cycles of vaccination with each cycle at QW × 3 doses; there is a 2-weeks interval between the two cycles, then followed by a boost dose 3 weeks after the 2'nd cycle.
215027303|NCT06690476|DRUG|Dose expansion (IPM514 combined with tislelizumab)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration The usage and dosage of the tislelizumab will be based on the drug instructions. IPM514 administration is planned to be concomitant with PD-1 antibody and to be stopped after 9 doses of treatment, while the PD-1 antibody will be continuously administered for a maximum of 1 year.
215027304|NCT06690476|DRUG|Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration Drug：cisplatin intravenous administration Drug：paclitaxel intravenous administration In this stage, subjects will receive the treatment of IPM514 combined with Tislelizumab, cisplatin and paclitaxel. All four drugs will be administered once every 3 weeks (± 1 day). IPM514 will be administered for the first time on D0, and Tislelizumab, cisplatin and paclitaxel will be administered for the first time on D3 (the administration order: Tislelizumab - paclitaxel - cisplatin). IPM514 will be administered a total of 3 times, and PD-1 antibody, cisplatin and paclitaxel will all be administered a total of 2 times (that is, IPM514 is administered on D0/D21/D42, and Tislelizumab, paclitaxel and cisplatin are administered on D3/D24).
215027305|NCT06689280|BEHAVIORAL|Video-supervised home-based exercise training|12 weeks of patient-centered video-supervised home-based exercise training that will be kick-started during hospitalization and continued for 12 weeks after discharge, followed by 12 weeks of self-directed maintenance exercise.
215027306|NCT06688513|DEVICE|Carealth Phone App|The goal for this study is to assess Carealth app's ability to connect patients to resources to meet patient's identified SDH needs, with the end goal of assessing reduction in 30-day readmission and missed visits by connecting patients to resources to meet their social needs in a way that enables them to receive care earlier or avoid complications.
215027307|NCT06688513|BEHAVIORAL|Let's Talk: Sharing information about Family Cancer Risk|An interactive tool that patients can use to learn about how to talk with their family members about the family member's cancer risk
215027308|NCT06686836|PROCEDURE|Sinus lift augmentation with bone substitute (Bio-Oss)|A maxillary sinus lift augmentation was performed with a lateral window approach that was filled with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®).At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically.
215104328|NCT02930304|OTHER|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
215104329|NCT02930304|OTHER|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
215104330|NCT02930304|OTHER|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
215104331|NCT05281198|DIETARY_SUPPLEMENT|tart cherry juice|2, 8oz bottles of Montmorency tart cherry juice daily; 8oz taken in AM, 8oz taken in PM
215104332|NCT05281198|DIETARY_SUPPLEMENT|Placebo|2, 8oz bottles of placebo juice daily; 8oz taken in AM, 8oz taken in PM
214692112|NCT02555644|DRUG|Cetuximab|Administered IV
214692113|NCT02555644|RADIATION|Intensity Modulated Radiation Therapy|
214692114|NCT02515864|DRUG|FYU-981|
214692115|NCT02515864|DRUG|Placebo|
214692116|NCT02515864|DRUG|Moxifloxacin|
214692117|NCT02515864|DRUG|Moxifloxacin Placebo|
214692118|NCT01123122|OTHER|Strict glucose control|Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
215027309|NCT06686836|PROCEDURE|Open sinus lift surgery lift using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®(Geistlich AG, Wolhusen, Switzerland)) - L-PRF Block|"A maxillary sinus lift augmentation was performed with a lateral window approach that was filled using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®) (L-PRF block).~L-PRF block will be performed as described by Cortellini et al. 2018. L-PRF membranes are cut into small pieces and mixed with Bio-Oss® at a ratio of 2 membranes / 0.5 g biomaterial. Pieces of the block will be removed and compacted in the sinus cavity until it is filled.~At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically."
215027310|NCT06687993|DRUG|Donepezil 2.5 mg|2.5 mg daily oral intake for 90 days
215027311|NCT06687993|DRUG|Donepezil 5 mg|5 mg daily oral intake for 90 days
215027312|NCT06687993|DRUG|Placebo Comparator|daily oral intake for 90 days
215027313|NCT06688656|DRUG|Pemetrexed 500 mg/m2|1\. Pemetrexed: 500mg/m² on Day 1, Q3W, administered via intravenous infusion for a total of 3 cycles.
215027314|NCT06688656|DRUG|carboplatin|AUC=5 on Day 1, Q3W，administered via intravenous infusion for a total of 3 cycles.
215027315|NCT06688656|DRUG|Sintilimab|Sintilimab, 200mg, administered via intravenous infusion on the 3rd day of each cycle, Q3W, for a total of 3 cycles.
215027316|NCT06501339|PROCEDURE|maintenance ECT|Frequency of weekly sessions for 1 month, then fortnightly for 5 months
215027317|NCT06501339|DRUG|Aripiprazole tablet|Aripiprazole 10 mg in the morning throughout the study period
215027318|NCT06355284|OTHER|Functional MRI|While in the MRI scanner, participants will complete several classic experimental tasks designed to capture brain activity related to core cognitive features of overcontrol that impact social functioning. Tasks include the Stop Signal Task (error monitoring), Delay Discounting Task (valuation, impulsivity), and Reversal Learning (cognitive flexibility).
215027319|NCT06632873|DRUG|177Lu-TATE-RGD|accepted intravenous injection of 177Lu-TATE-RGD
215027320|NCT02251470|OTHER|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
215027321|NCT02251470|OTHER|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
215027322|NCT06694896|DIAGNOSTIC_TEST|Microarray Application|Microarray studies were performed on patients who met the inclusion criteria. CNVs identified were examined in relevant databases, and pathogenicity was assessed. Detected alterations were compared with the clinical findings in the patient database.
215027323|NCT06694597|DRUG|Astragalus Membranaceus Root|Astragalus tablets 15g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
215027324|NCT06687863|OTHER|Exercise training|Includes aerobic exercise, strength training, streching
215027325|NCT06686940|DEVICE|intervention group|The monitoring effect of a smart electrocardiogram watch based on the PPG algorithm on atrial fibrillation burden.
214424285|NCT04707313|DRUG|Placebo (Cohorts 1 and 2)|4 matching placebo tablets taken twice daily
214424286|NCT04707313|DRUG|PF-06882961 (Cohorts 1 and 2)|Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
214424287|NCT04707313|DRUG|Placebo (Cohort 3)|2 matching placebo tablets taken twice daily
214509206|NCT02155868|OTHER|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (\< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood \< 35 mmHg; mean arterial pressure \< 60 mmHg; central venous pressure \> 10 mmHg; cardiac index \< 2.0 l/min/m2; mixed venous oxygen saturation \< 60%; hemoglobin \< 65 g/L during cardiopulmonary bypass or hemoglobin \< 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
215027326|NCT06689514|DRUG|alpha receptor antagonist|Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)
215027327|NCT06689514|DRUG|Low dose Tranilast|Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 100mg TID
214509207|NCT02155868|OTHER|Standard treatment|Standard treatment
215027328|NCT06689514|DRUG|High dose Tranilast|Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 200mg TID
215104333|NCT02403401|DRUG|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
214509208|NCT00778609|DRUG|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
214509209|NCT00778609|DRUG|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
214509210|NCT01868555|DRUG|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
215104334|NCT05660317|OTHER|Tip control score|Scoring of endoscopist's tip control performing snare tip soft coagulation to the margins of a endoscopic mucosal resection (EMR) defect
214424288|NCT04707313|DRUG|PF-06882961 (Cohort 3)|Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
214509211|NCT01868555|DRUG|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
214509212|NCT01868555|DRUG|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
214509213|NCT01868555|DRUG|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
215027329|NCT06686706|OTHER|IASTM|"Graston therapy-8 min per session~Procedure:~The patient will be lying down with their knee bent 30 degrees. After a 5-minute ultrasound treatment and static stretching exercises.Treatment will be administered using the Graston tool (using the sweep approach). Applying a moderate amount of effort from the medial side of the heel to the metatarsals and from the metatarsals to the medial side of the heel, to-and-fro stroking at a 60° angle will be done on the sole of the foot for approximately eight minutes (60-70 strokes per minute with a 5- to 10-second rest interval. A cold pack will be used for five minutes after therapy. The GT session will last approximately 30 minutes.~Conventional Therapy:~Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min Functional status and Quality of Life (QOL) will be assessed before and after treatment of 4 weeks using using tools.~Intervention will be conducted once a week for 4 weeks."
215027330|NCT06686706|OTHER|KT group|"Kinesio tapping (left there for 3 days)~Procedure:~We will use a standard 2 (5 cm) kinesiology tape. Fascia tape will be applied to the plantar fascia, and it will be left there for three days. For four weeks, it will be applied once a week. The patient will be in a prone position, lying with the ankle joints in a neutral position while applying tape. With the toes extended against the bed or ground. The tape will be marked on the Achilles tendon. It will be cut longitudinally into five slices of equal width. It will be applied to the forefoot by stretching it by 25%. The last strap will be applied with gentle compression across the bases of the five slices beneath the foot and wrapped around the rear foot.(5) Conventional Therapy Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min"
215027331|NCT06697951|DEVICE|bilevel ventilation with the Neovent|Newborn infants with respiratory distress will be placed on the Neovent and we will see if study staff set up, use, and trouble shoot the Neovent correctly and see if study staff can monitor for safety problems in lower-resourced nurseries and to determine if the infants have any more problems than seen with bubble CPAP or Neovent in a higher resourced nursery including any more nasal irritation, abdominal distention, or clinically important amount of air around the lung (pneumothorax)
215027332|NCT05720936|PROCEDURE|Percutaneous stellate ganglion block (PSGB)|"Both the two approaches present in literature and commonly used for this technique are allowed for the study:~* The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~* The echo-guided approach"
215027333|NCT06694038|PROCEDURE|Needle Knife Fistulotomy|Biliary access using needle knife fistulotomy technique
215027334|NCT06694038|PROCEDURE|standard biliary cannulation|standard biliary cannulation
215027335|NCT06695481|PROCEDURE|Conventional RF|The conventional RF group consists of patients who received medial branch RF with a duration of 2 minutes, at 80̊ C temperature, and 7 Volts.
215027336|NCT06695481|PROCEDURE|Combined RF|In the combined RF group, treatment was initiated first with a conventional RF duration of 2 minutes at a temperature of 80̊ C at 7 Volts. Then, pulsed RF duration was applied for 6 minutes at a temperature of 42 C at 45 Volts, with a pulse frequency of 2 Hz and a width of 20 ms.
215027337|NCT06693973|DRUG|AcNK-Sup003 cell injection solution|The AcNK technology has successfully achieved the direct, covalent, and directional conjugation of intact antibodies which includes the Fc domain to the surface of NK cells via a one-step enzymatic reaction. This novel approach yields a non-genetically modified NK cell that is conjugated with dual-targeting antibodies, referred to as AcNK. Specifically, AcNK-Sup003 cells are cryopreserved NK cells that have been conjugated with bispecific antibodies target both CD20 and CD19.
215027338|NCT06688604|BEHAVIORAL|skin contact|Ensuring mother-infant skin-to-skin contact by the researcher within the first 5 minutes after birth
215027339|NCT06688045|DRUG|Nemtabrutinib|Oral administration
215027340|NCT06688045|DRUG|Itraconazole|Oral administration
215027341|NCT06691061|DRUG|Vedolizumab|UC patients treated with vedolizumab
215027342|NCT06691061|DRUG|Ustekinumab - Standard Dosage|UC patients treated with ustekinumab
215027343|NCT06691061|DRUG|JAK Inhibitor|UC patients treated with JAK inhibitors
215104335|NCT06075407|DEVICE|Assessment of fluid responsiveness by electrical cardiometry|"Electrical cardiometry (EC) measurements: by the ICON\_ hemodynamic monitor (ICON Cardiotropic, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3).~Transthoracic echocardiography (TTE) measurements will be performed equipped with echo probe. SV of the left ventricle will be calculated using LVOT diameter (D) just below the aortic valve from parasternal long-axis view and VTI measured in LVOT from apical 5 chamber view (by pulsed wave Doppler)."
215104336|NCT01957813|BEHAVIORAL|Lifestyle Counseling|"Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.~Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation"
215104337|NCT01957813|OTHER|Standard Health Services|Peer education and health services
215104338|NCT03190434|DEVICE|AL-SENSE|The AL-SENSE reacts differently when in contact with amniotic fluid than it does with urine. The indicator changes color to blue-green and fades back to yellow in case of urine and changes to stable blue-green in case of amniotic fluid.
215104339|NCT05137028|OTHER|Otago Exercise|"Otago exercise protocol~Strengthening exercise:~Resistance exercise for knee flexors, knee extensors, hip abductor, ankle dorsiflexors, ankle planterflexors~Balance exercise:~knee bending, backward walking, walking and turning around, sideway walking, tendem stance, tendem walking, one leg stand, heel walking, toe walking, heel to toe walking, sit to stand, stair walking"
215104340|NCT03806686|BIOLOGICAL|Placebo|Sterile normal saline
215104341|NCT03806686|BIOLOGICAL|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
214692119|NCT06330662|PROCEDURE|Testing the effectiveness of hyaluronic acid in experimental group using a coronally advanced flap compared to a control group using a coronally advanced flap only|The potential benefit of adding hyaluronic acid (HA) to the coronally advanced flap (CAF) operative technique to cover multiple adjacent recessions has not been sufficiently investigated. Improving aesthetics is one of the primary goals of root recession coverage periodontal surgery, and little is known about the same in multiple adjacent gingival recession coverage therapy. In patients with a sufficient amount (≥2 mm) of keratinized tissue, the coronally advanced flap (CAF) has been shown to be very effective in the treatment of multiple recessions, especially in terms of aesthetic results. The researchers concluded from a database search (Epistemonikos, Cochrane, Medline) that there is no evidence to support the use of HA + CAF to achieve greater root coverage in the treatment of multiple gingival recessions.
214692120|NCT03420131|DIAGNOSTIC_TEST|QFR and iFR|"iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option.~QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland"
214692121|NCT05357352|OTHER|NAFLD/NASH|the characteristics of patients with advanced fibrosis in a community-based referral center.
214692122|NCT00995345|DRUG|KRP-104|Tablet
214692123|NCT00995345|DRUG|Placebo|Tablet
215027344|NCT06694103|OTHER|Reverse Kangaroo Care Position|"* Babies will be taken to the examination table and their clothes other than diapers will be removed.~* Mothers will take off their upper clothes and lie on the examination table and position their babies in the reverse kangaroo care position, with the baby's back against the mother's bare chest.~* Babies will be monitored with disposable probes from their right feet.~* Video recording will be started. -While the position applied to the babies is maintained, the speculum will be placed in the eye by the ophthalmologist and the examination will be recorded on video from the beginning to end.~* After the completion of both eye examinations, the position of the babies whose monitoring continues will be maintained while the video recording will be taken for another 1 minute. The SPO2, HR, PIPP-R score at the end of the 15th second before the examination, the first minute during the examination and the 30th second after the examination will be evaluated."
215027345|NCT06694103|OTHER|ROP Position|"* Babies will be taken to the examination table and monitored with disposable probes from their right feet.~* The nurse will place the infant's own palms on the temporal region and hold them with her hands to support their head, while the mother will also support the infant by holding their legs.~* The video recording will be started.~* SPO2, HR, PIPP-R values will be recorded on video for one minute.~* While the ROP position applied to the babies is maintained, the speculum is placed in the eye by the ophthalmologist and the examination begins.~* SPO2, HR, PIPP-R evaluation at the 1st minute of the examination.~* After the completion of both eye examinations, the babies whose monitoring continues will be kept in their positions and a video recording will be taken for another 1 minute.~* The SPO2, HR values and PIPP-R pain score at the end of the 30 seconds after the examination will be evaluated."
215027346|NCT06691412|DRUG|Obeticholic Acid 5 mg|\- Patients will be randomly divided into two groups , the first will receive obeticholic acid at a dose of 5 mg once daily and antiviral drug ,and the other will receive the antiviral drug only for six months
215027347|NCT06689150|DRUG|Drospinetta|To evaluate the three different types of POPs, the new POPs Drosperinon 4 mg, Desogestrel 75 pg, and Levonorgestrel 30 pg in healthy female subjects as regard to the contraceptive efficacy, bleeding pattern, acceptability and safety
215027348|NCT06691048|OTHER|Description of an adult population diagnosed late with a neurodevelopmental disorder|Clinical description during diagnostic interview
214692124|NCT05337813|DEVICE|"Storz Medical Extracoporeeal Shock Wave Therapy System"|A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)
214692125|NCT02336594|DRUG|RDEA3170 10 mg|
214692126|NCT02336594|DRUG|RDEA3170 2.5 mg|
214692127|NCT00301782|BIOLOGICAL|bleomycin sulfate|
214692128|NCT00301782|DRUG|carboplatin|
215027349|NCT06686810|PROCEDURE|Endoscopic Retrogradade CholangioPancreatography (ERCP)|ERCP is an endoscopic therapeutic procedure to drain the bile ducts in case of stones or biliary strictures that can be treated by balloon dilatation or stents (plastic or metal) insertion
215027350|NCT06690528|PROCEDURE|Surgical resection of both the primary tumor and liver metastases|Surgical resection of both the primary tumor and liver metastases. The surgical approach, extent of resection, and perioperative management will follow the standard protocols at each participating center. Venous vascular resections might be performed to reach radicality. Either standard or parenchyma sparing liver resections might be performed for resection of the liver metastases. Alternatively, needle ablation/microwave on the liver lesions is possible for lesions \<20 mm if technically feasible. Post-operative chemotherapy and/or radiotherapy could be administered as per multi-disciplinary decision based on case-by-case evaluation.
215027351|NCT06689969|PROCEDURE|conventional implant placement method|Site marking was the first step in preparing the place for implantation. Subsequently, using a high speed surgical handpiece and a surgical motor, a pilot drill was revolved at 1200 RPM in a clockwise rotation to the desired depth, creating a 1.5 mm first pilot osteotomy. An X-ray was obtained using paralleling pins to validate the angle between the surrounding teeth and the implants. Eventually the implant's precise placement was established. To prepare the osteotomy site to the desired diameter, drills are used sequentially at 1200 RPM in a clockwise motion. Gradually bigger drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes were utilized in ascending order
214692129|NCT00301782|DRUG|cisplatin|
214692130|NCT00301782|DRUG|etoposide phosphate|
214692131|NCT00301782|DRUG|vincristine sulfate|
214692132|NCT03634358|PROCEDURE|Bipolar scissors|
214692133|NCT03634358|PROCEDURE|classic scalpel|
215104342|NCT06166199|BEHAVIORAL|HIIT combined with resistance training|"Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week."
214509214|NCT03917732|BEHAVIORAL|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
214509215|NCT03917732|BEHAVIORAL|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
215027352|NCT06689969|PROCEDURE|Osseodensification to implant placement using densah bur kit|"Beginning with site marking, the area was prepared for implantation. A high speed surgical handpiece and a surgical motor (surgic pro® NSK, Japan) were then used to construct a 1.5 mm initial pilot osteotomy using a pilot drill spun at 1200 RPM in a clockwise rotation to the desired depth. In order to verify the angle between the surrounding teeth and the implants, paralleling pins were used to capture an X-ray.~After it was determined that the implant was in the proper location, OD was used to extend the osteotomy using a Densah® Bur VT1525 2.0-mm (VersahTM, LLC, USA) in non-cutting anticlockwise rotation at 1200 RPM (Densifying Mode). The osteotomy was expanded to the desired diameter by repeatedly using a DensahTM Bur operating in a non-cutting anticlockwise (CCW) direction at 1200 RPM (Densifying Mode). Gradually increasing drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes (diameters) were utilised in ascending order"
215027353|NCT06688097|BEHAVIORAL|Compression of esophageal|Before the start of FMV, ultrasound is used to locate the esophagus, and pressure is applied to the esophagus at the cricoid level to collapse the esophageal lumen. Esophageal pressure is released just before tracheal intubation following 4 minutes of ventilation.
215027354|NCT06689371|OTHER|Group A (Dry Needling)|The patient will receive dry needling on suboccipital, upper trapezius and SCM muscles with conventional therapy 3 sessions per week for 4 weeks.
215027355|NCT06689371|OTHER|Group B (Dry cupping)|Patients will receive dry cupping on suboccipital, upper trapezius and SCM muscles weeks with conventional therapy 3 sessions per week for 4 weeks.
215027356|NCT06689371|OTHER|Group C (control)|will receive standard exercise three sessions per week for four weeks. This standard regimen consists of the same exercises as group A and B.
215027357|NCT06686563|OTHER|Intervention Group: Gamma stimulation|Participants in this group be stimulated with gamma frequency (39-42 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.
215027358|NCT06686563|OTHER|Control Group: Theta stimulation|Participants in this group will be stimulated with theta frequency (4-7 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.
214509216|NCT00671853|DRUG|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
215027359|NCT00690352|BEHAVIORAL|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
215027360|NCT06720259|DRUG|Oxantel Pamoate|Tablets containing 250 mg oxantel pamoate
215027361|NCT06720259|DRUG|Mebendazole|Tablets containing 500 mg mebendazole
215027362|NCT06694844|PROCEDURE|Socket preservation with M1|Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M1 membrane (peramem membrane).
215104343|NCT00534547|PROCEDURE|Duodenal Exclusion|duodenal-jejunal bypass
214509217|NCT00671853|DRUG|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
214509218|NCT00016042|BIOLOGICAL|lymphokine-activated killer cells|
214509219|NCT00016042|BIOLOGICAL|recombinant interferon alfa|
214509220|NCT00016042|BIOLOGICAL|sargramostim|
215027363|NCT06694844|PROCEDURE|Socket preservation with M2|Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M2 membrane (Cytoplast membrane).
214509221|NCT00016042|DRUG|fluorouracil|
214509222|NCT05726097|DRUG|polyethylene glycol|colonic preparation
214509223|NCT05726097|DRUG|sodium phosphate|colonic preparation
214509224|NCT05726097|DRUG|polyethylene glycol + ascorbic acid|colonic preparation
214509225|NCT05726097|DRUG|gastrografin|colonic preparation
214509226|NCT05726097|DRUG|magnesiumoxid + sodium picosulfate|colonic preparation
214509227|NCT05726097|DRUG|prucalopride|colonic preparation
214509228|NCT01000935|OTHER|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
214509229|NCT05516745|DEVICE|AioCare spirometer|In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.
214509230|NCT05516745|OTHER|telerehabiliation of the respiratory system|A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.
214509231|NCT00785798|DRUG|Vorinostat|200mg to 400 mg twice daily on days 1-7
214509232|NCT00785798|DRUG|Pegylated Liposomal Doxorubicin (PLD), Doxil|IV 30mg/m2 on day 3 of a 21-day cycle
215027364|NCT06729996|DRUG|Pioglitazone (PIO)|Subjects will take 30 mg tablet, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 45 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food till 24 weeks.
215027365|NCT06729996|DRUG|Empagliflozin (EMPA)|Subjects will start with 10 mg dose, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 25 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food.
215027366|NCT00028288|DRUG|Daclizumab|
215027367|NCT05103735|DRUG|Propofol|awake neurosurgery under propofol-remifentanil sedation
215027368|NCT06359626|DRUG|YHP2205|Test drug: YHP2205
215027369|NCT06359626|DRUG|YHR2401|comparator: YHR2401
215027370|NCT06113302|DRUG|Luspatercept|Given by SC or (Injection)
215027371|NCT06742684|PROCEDURE|PCI with following SSO2 Therapy|SSO2 Therapy
215027372|NCT06687473|DRUG|Bismuth-based susceptibility-guided treatment|"The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori.~A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens."
215027373|NCT00972257|DRUG|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
215027374|NCT00972257|DRUG|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
215027375|NCT03607058|OTHER|Kinect + Exercise Training|Kinect + Exercise Training : Patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will take the treatment 1-hour, 3 days in a week for 8 weeks.
215027376|NCT03607058|OTHER|Exercise Training|Exercise Training: Patients will take the treatment 1-hour, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks.
215027377|NCT01511237|DRUG|Nevirapine, zidovudine, lamivudine|"* Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~* Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:~  * NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake~ * AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).~ * 3TC syrup 2 mg/kg every 12 hours for four weeks."
215027378|NCT03595722|DEVICE|High Intensity Focused Ultrasound|High intensity focused ultrasound to rectal/pelvic cancer
215027379|NCT02620865|BIOLOGICAL|Aldesleukin|Given SC
215027380|NCT02620865|BIOLOGICAL|Antibody Therapy|Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
214509233|NCT03252210|PROCEDURE|Preoperative Stereoscopic Localization|1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
215027381|NCT02620865|DRUG|Fluorouracil|Given IV
215027382|NCT02620865|DRUG|Gemcitabine Hydrochloride|Given IV
215027383|NCT02620865|DRUG|Irinotecan Hydrochloride|Given IV
215027384|NCT02620865|OTHER|Laboratory Biomarker Analysis|Correlative studies
215027385|NCT02620865|DRUG|Leucovorin Calcium|Given IV
215027386|NCT02620865|DRUG|Oxaliplatin|Given IV
215027387|NCT02620865|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
215027388|NCT02620865|BIOLOGICAL|Sargramostim|Given SC
215027389|NCT03838328|DRUG|Tranexamic Acid|Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
214692134|NCT01860534|BEHAVIORAL|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
214692135|NCT05477342|BEHAVIORAL|Board Game|The BG group that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player) GP1- GP 2- GP 3- GP 4.
215104344|NCT06418490|DEVICE|Three-dimensional visualization technology|Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step. The software is called Abdominal Medical Image 3D Visualization Software (MI-3DVS, software copyright registration number: 2008SR18798).The AR-ANS (Software Copyright No.: 2018SR840555) is an intraoperative navigation system that integrates three-dimensional visualization technology.This modification provides visual guidance for surgeons when ligating or protecting critical vascular tissues during surgery.
215104345|NCT00392730|DIETARY_SUPPLEMENT|Remove Mn from PN if evidence of increased brain Mn on MRI|Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
214692136|NCT05477342|BEHAVIORAL|Tobacco Cesseation Education|The TCE group were divided three group that E1 (Precontemplation) -E2 (Contemplation)-E3 (Preparation) according to the thinking stages scale.
215104346|NCT02166619|DEVICE|tDCS + physical therapy|"Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy"
215104347|NCT05454657|DEVICE|Heart rate variability biofeedback + treatment as usual|"Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability.~Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation."
215104348|NCT05454657|BEHAVIORAL|Treatment as usual only|Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
214692137|NCT05477342|BEHAVIORAL|Combined İntervention|"The CI group was divided into five groups for play that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player)GP 5- GP 6- GP 7- GP 8- GP 9).~The CI group was divided into three groups for education that E4 (Precontemplation) -E5 (Contemplation)-E6 (Preparation) according to the thinking stages scale."
215027390|NCT05459714|DEVICE|MCE for obese patients|Sequence of stomach examination: The stomach examination is performed sequentially according to the order of fundus, cardia, gastric body, angulus, antrum, and pylorus, which should ensure the integrity of the observation of each part of the stomach and achieve the purpose of comprehensive observation by means of different observation distances such as distant view and close view, and different observation angles such as front and side.
215027391|NCT02194686|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
215027392|NCT02194686|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
215027393|NCT06070532|BIOLOGICAL|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
215027394|NCT03800628|OTHER|qualitative study|semi-structured interviews
215104349|NCT05532202|BEHAVIORAL|NICU Mom and Baby Net|See arm descriptions.
215104350|NCT05532202|OTHER|NICU Developmental Awareness System|See arm description.
215104351|NCT03993522|OTHER|Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test|Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
215104352|NCT00774800|DRUG|Humalog|
214692138|NCT01504854|DRUG|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
214692139|NCT01504854|DRUG|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
215027395|NCT03621215|DIETARY_SUPPLEMENT|Tart cherry juice|30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.
215027396|NCT03621215|OTHER|Fruit-flavoured placebo drink|Consumed daily by participants, with breakfast, for 12 months.
215027397|NCT00821821|DRUG|MCI-186|"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion"
215027398|NCT00821821|DRUG|Placebo|"Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo"
215027399|NCT04632030|BEHAVIORAL|Tobacco power wall size and tobacco products displayed|The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
215027400|NCT03220555|DEVICE|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
215027401|NCT03220555|DRUG|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
215027402|NCT00964678|DRUG|Carvedilol|twice daily oral treatment in escalating dose
215104353|NCT00774800|DRUG|Humulin-R|
215104354|NCT00774800|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
215104355|NCT00774800|OTHER|Liquid meal|
215104356|NCT04548804|DIAGNOSTIC_TEST|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan
215104357|NCT02779790|OTHER|Liquid Meal Replacements|An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.
215104358|NCT05527821|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
215104359|NCT05527821|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
215104360|NCT05527821|RADIATION|Short course radiotherapy|5Gy\*5F short course radiotherapy will be delivered
215104361|NCT01578577|BEHAVIORAL|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
215104362|NCT01578577|BEHAVIORAL|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
215104363|NCT00139555|DRUG|amlodipine/benazepril|
215104364|NCT02293603|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002 or placebo
215104365|NCT05326867|DEVICE|Infiltration of 2% Lidocaine with Needle|Infiltration of 2% Lidocaine with Needle
215104366|NCT05326867|DEVICE|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
215104367|NCT06975007|DEVICE|Paro Robotic Companion Seal|Paro is an interactive robotic companion designed to simulate the behaviour of a baby harp seal. It responds to touch, light, sound, posture and temperature, providing tactile and social interaction for stress relief.
215104368|NCT06975007|DEVICE|Weighted Sensory Toy|A soft, weighted animal-shaped toy (dog) designed to provide deep pressure stimulation. Participants hold or interact with the toy for 15 minutes following a stress induction task to promote relaxation and stress reduction.
215104369|NCT00773773|OTHER|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
215104371|NCT04360876|DRUG|Dexamethasone injection|Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days
215104372|NCT04360876|DRUG|Placebos|Placebo delivered intravenously on the same dosing schedule as dexamethasone
215104373|NCT04016259|DEVICE|Cranial Electrical Stimulation (CES)|CES will be applied for 60 minutes per session daily for 2 weeks (Monday to Friday) via the Alpha-Stim M Electromedical Products International, Inc., Mineral Wells, TX).
215104374|NCT04016259|DEVICE|Sham-CES|For sham CES, the electrodes will be identical look and be placed in the same positions as for active stimulation, but the stimulator will not deliver electrical current.
215104375|NCT02205528|DRUG|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
215104376|NCT02205528|DRUG|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
214509234|NCT01648049|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein \& Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, \& Dick, 1995).
215104377|NCT02205528|DRUG|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
215104378|NCT02205528|DRUG|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
215104379|NCT03694431|OTHER|Tech-supported HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
215104380|NCT03694431|OTHER|Standard HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
215104381|NCT06468020|OTHER|The Gather.town gaming intervention|The online game-based learning intervention (oGBL): The investigator will develop the oGBL intervention based on Rational Emotive Behavior Therapy (REBT), which consists of 8 sessions and plays a game through the Gather.Town platform.
215104382|NCT03068754|DRUG|Acthar|Repository corticotropin for subcutaneous injection
215104383|NCT03068754|DRUG|Placebo|Matching placebo for subcutaneous injection
215104384|NCT01093872|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Upon recruitment, all patients will undergo a 1 week treatment consisting of 5 rTMS sessions~Repetitive TMS consists of 1000 stimulations/ day at 1 Hz and 110% of the motor threshold, for five consecutive days over the left AC."
215104385|NCT04046978|OTHER|ConM SOSIP 50 ug and ConS UFO 50 ug|Intramuscular injection of synthetic viral immunogens ConM SOSIP and ConS UFO
215104386|NCT04046978|OTHER|Mos3.1 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.1
215104387|NCT04046978|OTHER|Mos3.2 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.2
215104388|NCT04046978|OTHER|Mos3.3 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.3
215104389|NCT04046978|OTHER|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug|Intramuscular injection of synthetic viral immunogens Mos3.1, Mos3.2 and Mos3.3
215104390|NCT03317782|DEVICE|NoL index|The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index \<20 indicates adequate analgesia.
215104391|NCT03137329|BEHAVIORAL|Exercise program|Physical therapy for aerobic and resistance training exercises
215104392|NCT03137329|DIETARY_SUPPLEMENT|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
215104393|NCT03137329|PROCEDURE|WLS|Weight loss surgery as planned
215104394|NCT02036008|OTHER|Liver MRI with Gdfos|"Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.~This study will be performed within 4 weeks of the MRI study with EcGd."
215104395|NCT02036008|OTHER|Liver MRI with EcGd|"Participants will receive a liver MRI with EcGd as per clinical institutional protocol.~Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging."
215104396|NCT05437432|PROCEDURE|VITA AMBRIA|25 onlay restroations will be fabricated from Vita-ambria glass ceramic press system.
215104397|NCT05437432|PROCEDURE|IPS e.max press|25 onlay restroations will be fabricated from IPS e.max glass ceramic press system.
215104398|NCT00504374|BEHAVIORAL|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
215104399|NCT02283203|DRUG|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
215104400|NCT02283203|DRUG|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
215104401|NCT00783458|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
215104402|NCT00783458|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
215104403|NCT04510896|OTHER|InheRET|Primary Appropriate Referral Rates 6-months pre-intervention vs post-intervention Compare appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention vs post- intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
215104404|NCT04510896|OTHER|Patient Acceptance|Acceptance by Patients Over the course of the study Acceptance measures will include completion rates and levels of ease of use of InheRET by the patient. Impact measures will include uptake of advised risk management interventions. We will qualitatively describe why patients do not follow up with their referral. We will explore patterns of acceptance and impact levels by demographic and clinical data using correlation, t- tests, ANOVA, or their non-parametric equivalents.
214424289|NCT03165175|BEHAVIORAL|prescription drug-abuse education smartphone application|As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
215027403|NCT05202171|OTHER|Cervical Stabilization Exercise|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
215027404|NCT05202171|OTHER|Standard treatment|standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
215027405|NCT04081012|DRUG|N-acetyl cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
214424290|NCT03525951|BEHAVIORAL|Enhanced Milieu Teaching|The parent training will incorporate the EMT strategies of responsive interaction, matched turns, language modeling, and expansions. There will be three, hour-long parent training sessions following the teach-model-coach-review format (TMCR). The TMCR framework teaching component will involve 10 minutes of verbal and visual instruction on the language stimulation target of interest. The teaching component will be followed by 15 minutes of clinician modeling of the target strategies with the child while the parent watches. The parent will then have the opportunity to practice using the strategy during naturalistic interaction with their child. The clinician will provide individualized coaching on the use of the target strategy during this 20-minute, parent-child interaction. Finally, the clinician will review the target strategies and set goals.
214424291|NCT03525951|OTHER|no intervention comparison group|No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.
214424292|NCT02709174|PROCEDURE|blood draw|blood draw
214424293|NCT06192394|OTHER|Chewing Gum|Patients will be asked to chew xylitol gum for 20 minutes every 2 hours (17.00-19.00, 19.00-21.00, 21.00-23.00) after drinking the X-M Diet syrup prescribed the day before the colonoscopy procedure. After the enema is given on the day of the colonoscopy, they will be asked to chew gum for 20 minutes every 2 hours until one hour before the scheduled procedure time. Xylitol is a naturally occurring five-carbon sugar alcohol (C5H12O5) found in fruits and vegetables such as plums, strawberries, cauliflower, and pumpkin. It is similar in taste to sucrose but contains 40% fewer calories than other carbohydrates (1 gram of xylitol = 2.4 calories). Xylitol has positive effects on dental health and may also have beneficial impacts on other systems such as immunity, respiratory, and digestive systems. Since xylitol is not digested by human enzymes, it has a laxative effect. In the study, sugar-free gum with xylitol will be used.
214424294|NCT06192394|OTHER|Walking Exercise|Patients will be given a pedometer to count their steps and will be asked to walk at least 3000 steps before the colonoscopy procedure.
214424295|NCT06192394|OTHER|Control|Patients will undergo standard bowel preparation determined by the hospital.
214424296|NCT06237842|DIAGNOSTIC_TEST|Diagnostic Test: EEG headband+Ring oximeter (RO)+Actigraphy (ACT)|Combination of ACT+RO+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
214424297|NCT02491723|DRUG|Azithromycin|Patients with bronchiectasis treated with Azithromycin for three to five days.
214424298|NCT05885126|OTHER|MANDALA TECHNIQUE|The ambient light and the position of the laptop table were adjusted appropriately during the intervention to help the participants move freely and eliminate the environmental stimulus. In addition, there was no communication between the patient and the practitioner during the application.
214424299|NCT04010448|BIOLOGICAL|TV P2-VP8|90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
214424300|NCT04010448|BIOLOGICAL|Rotarix|Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
214424301|NCT00834834|DRUG|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
214424302|NCT00834834|BEHAVIORAL|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
214424303|NCT00834834|DRUG|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
214424304|NCT03400124|PROCEDURE|ISBCS|The intervention group will undergo cataract surgery in both eyes on the same day (ISBCS)
214424305|NCT03400124|PROCEDURE|DSBCS|The usual care / control group will undergo cataract surgery in both eyes on separate days, with a time period of at least two weeks between surgeries.
214424306|NCT00001992|BIOLOGICAL|rgp120/HIV-1IIIB|
214424307|NCT04016025|BEHAVIORAL|Adherence to topical standard therapy assessed|Adherence defined as percentage of patients applying at least aimed daily dose
214424308|NCT02008084|DRUG|TRIA-662|Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
214424309|NCT02008084|DRUG|Placebo|Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
214424310|NCT04528264|DEVICE|Intraoperative ultrasound guided|Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.
214424311|NCT04528264|OTHER|Conventional blind reduction technique|Conventional blind reduction technique
214424312|NCT03207568|DEVICE|Thoracic Endovascular Aortic Repair (TEVAR)|thoracic endovascular repair (TEVAR) with a thoracic stent-graft
214424313|NCT00539292|PROCEDURE|Primary placement of a spring-loaded silo|
214424314|NCT00539292|PROCEDURE|Primary Closure|primary closure of abdomen
214509235|NCT01648049|BEHAVIORAL|Treatment as usual|Standard Care - Treatment as usual
214692140|NCT05927727|DIAGNOSTIC_TEST|Ultrasound and biyopsy|Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region
214692141|NCT00001019|BIOLOGICAL|rgp120/HIV-1 SF-2|
214692142|NCT00001019|BIOLOGICAL|MTP-PE/MF59|
215104405|NCT04510896|OTHER|Physician Acceptance Survey|Secondary Acceptance by Physicians Over the course of the study Acceptance by physicians will measure the physician effort required to deploy and use InheRET in their respective clinics, and overall satisfaction. Impact measures will include appropriate referral rates and rates of genetic testing. We will qualitatively describe why patients are not referred for genetic counseling if indicated. We will explore patterns in acceptance and impact levels by demographic and clinical data using correlations, t-tests, ANOVA, or their non-parametric equivalents.
215104406|NCT06547073|OTHER|Virtual reality exercise training|Beat saber
215104407|NCT06547073|OTHER|Traditional exercise training|Bench slides, supine active assisted flexion, pendulum exercise, seated active assisted external rotation
215104408|NCT04194125|DRUG|177Lu-DOTATOC|Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.
215104409|NCT03867942|DRUG|Monolayer group|Monolayered combination of gemigliptin and rosuvastatin
215104410|NCT03867942|DRUG|Bilayer group|Bilayered combination of gemigliptin and rosuvastatin
214509236|NCT02876653|OTHER|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
215104411|NCT00304863|DRUG|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
215104412|NCT00656435|DRUG|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
215104413|NCT03813992|DRUG|MED2005|Topical Product
215104414|NCT01377870|BIOLOGICAL|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
215104415|NCT01377870|BIOLOGICAL|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
215104416|NCT03869879|OTHER|Feedback-assisted physical therapy|The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.
215027406|NCT04081012|DRUG|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
215027407|NCT02292355|OTHER|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
215027408|NCT04380025|DIETARY_SUPPLEMENT|Experimental: Oral Mirtogenol|The experimental arm is Oral Mirtogenol dietary supplement, one capsule daily in addition to bimatoprost ophthalmic drops with primary open angle glaucoma
215027409|NCT04380025|DIETARY_SUPPLEMENT|Placebo of oral Dietary supplement|This is the oral placebo of the supplement (control) un daily capsule in addition to the bimatoprost ophtalmic drops
215027410|NCT02169258|PROCEDURE|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis \> 70% of the major epicardial vessels and bypass graft vessel or their major branches (\> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (\<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
215027411|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
215104417|NCT03869879|OTHER|Traditional physical therapy|Therapists will treat these patients with traditional therapeutic modalities and practices.
215104418|NCT02547584|PROCEDURE|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
215104419|NCT02788058|DRUG|EGFR-TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
215104420|NCT02788058|RADIATION|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
215104421|NCT00666965|DRUG|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
215104422|NCT03752658|DRUG|Tenofovir Alafenamide|The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
215104423|NCT01653236|DRUG|Boceprevir|
214424315|NCT05717114|PROCEDURE|Pecs block|(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.
214424316|NCT00866866|DRUG|N-Acetyl Cysteine|600 mg PO BID
214424317|NCT00866866|DRUG|Placebo|1 tab PO BID
214424318|NCT00488657|DEVICE|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
214509237|NCT04617145|OTHER|Aerobic exercise|resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.
214509238|NCT04122820|DIAGNOSTIC_TEST|Diagnostic of specific learning disabilities or of Developmental Coordination Disorder|Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
215104424|NCT01653236|DRUG|Peginterferon alfa-2b|
215104425|NCT01653236|DRUG|ribavirin|
215104426|NCT01340599|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given PO
215104427|NCT01340599|OTHER|placebo|Given PO
215104428|NCT01340599|OTHER|immunohistochemistry staining method|Correlative studies
215104429|NCT01340599|OTHER|immunoenzyme technique|Correlative studies
215027412|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
215027413|NCT05153486|PROCEDURE|Surgical ablation|Patients receive surgical ablation.
215027414|NCT02605616|DRUG|AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
215027415|NCT02605616|OTHER|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
215027416|NCT03359395|DRUG|Alfentanil|Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
215104430|NCT01340599|OTHER|questionnaire administration|Ancillary studies
215104431|NCT01340599|PROCEDURE|therapeutic conventional surgery|Undergo radical prostatectomy
215104432|NCT01340599|OTHER|high performance liquid chromatography|Correlative studies
215027417|NCT03359395|DRUG|Placebos|Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
215027418|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold."
215027419|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks."
215027420|NCT03164356|DEVICE|Bioimpedance monitor|Participant in aim 1 will be monitored using the bioimpedance monitor. Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
214424319|NCT02234739|DRUG|Voriconazole|2-week long intravenous instillation of voriconazole
214424320|NCT05503212|OTHER|Conservative treatment (CT)|Best medical treatment without intravenous thrombolysis nor endovascular thrombectomy
214424321|NCT05503212|OTHER|Intravenous thrombolysis (IVT)|Best medical treatment with intravenous thrombolysis but without endovascular thrombectomy
214424322|NCT05503212|OTHER|Endovascular thrombectomy (EVT) ± intravenous thrombolysis (IVT)|Best medical treatment with endovascular thrombectomy with or without intravenous thrombolysis
215027421|NCT03151603|DRUG|Arctuvan|application of a herbal drug
215104433|NCT01340599|OTHER|mass spectrometry|Correlative studies
215104434|NCT02207959|DRUG|Proflavine Hemisulphate salt|The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
214424323|NCT05323838|BEHAVIORAL|Subjective quality of live|The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.
214424324|NCT05323838|PROCEDURE|Blood extraction|Blood collection by qualified personnel.
214424325|NCT05323838|BEHAVIORAL|Accelerometry|To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique
215027422|NCT03151603|DRUG|Fosfomycin|application of an antibiotic drug
215104435|NCT02207959|PROCEDURE|White-light examination|standard white light examination
215104436|NCT02207959|PROCEDURE|Imaging with High Resolution Microendoscope|HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
215104437|NCT02533895|BIOLOGICAL|AV0113 DC-CIT|Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
214509239|NCT03937089|OTHER|Data collection|Data collection from medical file
215104438|NCT02533895|OTHER|Data evaluation|"For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc"
215104439|NCT05551884|PROCEDURE|Metabolites and HVPG|"HVPG measurement are performed by well-trained interventional radiologists in accordance with standard operating procedures.~All enrolled patients were analyzed for potential differential metabolites using metabolomics."
215104440|NCT04569357|DRUG|Prospekta|Oral administration.
215104441|NCT04569357|DRUG|Placebo|Oral administration.
215104442|NCT03698656|BEHAVIORAL|Spiritual Interview|Three patient interviews (45 to 60 minutes) will be conducted by the study nurse at the beginning of the study and approximately 2 and 4 month later, according to the program of the medical care. Each interview will be conducted according the active listening method of Carl Rogers.
215104443|NCT03845959|DRUG|TD0019 oral capsule|TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
215104444|NCT03845959|DRUG|Placebo oral capsule|Placebo
215104445|NCT01754571|BEHAVIORAL|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
215104446|NCT03854383|DRUG|Isosorbide mononitrate|Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women
215104447|NCT03854383|DRUG|Misoprostol|Used intravaginally to ripe the cevix in induction of labor
215027423|NCT03151603|DRUG|Placebo to Arctuvan|application of Placebo to Arctuvan
215027424|NCT03151603|DRUG|Placebo to Fosfomycin|application of Placebo to Fosfomycin
215027425|NCT03189927|DEVICE|BD-Covered esophageal stent|a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
215027426|NCT00561821|DRUG|Esmirtazapine|one tablet daily
215027427|NCT00561821|DRUG|Placebo|one tablet daily
215027428|NCT01415453|PROCEDURE|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
215027429|NCT02520154|DRUG|Carboplatin|Given IV
215027430|NCT02520154|OTHER|Laboratory Biomarker Analysis|Correlative studies
215027431|NCT02520154|DRUG|Paclitaxel|Given IV
215027432|NCT02520154|BIOLOGICAL|Pembrolizumab|Given IV
215027433|NCT02520154|OTHER|Pharmacological Study|Correlative studies
214424326|NCT05323838|DIETARY_SUPPLEMENT|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
214424327|NCT02020616|DRUG|LY3053102|Administered SC
214424328|NCT02020616|DRUG|Exenatide ER|Administered SC
214424329|NCT02020616|DRUG|Placebo|Administered SC
214424330|NCT02020616|DRUG|Metformin|Administered orally (PO)
215027434|NCT02288962|DRUG|cabergoline|
215027435|NCT05448313|BEHAVIORAL|Dyadic intervention|Dyads comprising a Veteran and cohabitating support person will participate in the 16-week VA MOVE! weight loss program delivered by video platform. They will then participate in 6 group sessions focused on weight maintenance skills. Communication skills will be taught throughout the intervention.
215104448|NCT00952900|BEHAVIORAL|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
215104449|NCT00952900|BEHAVIORAL|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
215104450|NCT01554800|DRUG|ACP-501|A single dose infusion
215104451|NCT05333380|DEVICE|ECG/PPG monitoring|"The enrolled patients will wear an ECG patch and watch at the same time to collect ECG and PPG data respectively. The data collection time is from the day of hospitalization to before the ablation operation, and from 2 hours after the removal of ECG monitoring equipment to before leaving the hospital. The monitoring duration of each patient shall not be less than 18 hours."
215104452|NCT01267526|DEVICE|Easypod™|Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph
215104453|NCT02939768|OTHER|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit \~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed \~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
214424331|NCT00006276|DRUG|Micellar Paclitaxel|
214509240|NCT05168345|OTHER|Course and web information|"The interventional phase of the study will be conducted on IBD patients only. Patients will undergo two interventional periods which will include:~1. Self-selected information from the internet - patients will be asked to independently search the web for information regarding the categories of information which are discussed in the online course.~2. An online, interactive IBD course. Lectures will be passed by the multidisciplinary team of the IBD Center which includes IBD gastroenterologists, an IBD nurse, an IBD dietitian, and a social worker."
214509241|NCT03723902|OTHER|Heavy-load strength training|Three weekly sessions of heavy-load strength training for 10 weeks
215027436|NCT05448313|BEHAVIORAL|Veteran-only intervention|Veterans will participate in a 72-week weight management program delivered by video platform. 16 sessions will address weight loss, with 6 additional ones addressing weight loss maintenance.
215027437|NCT06380686|OTHER|data collection|Demography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.
215104454|NCT02939768|OTHER|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
215104455|NCT02939768|OTHER|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
215027438|NCT04250766|PROCEDURE|Echo-guided uterine biopsy|"Echo-guided uterine biopsy will be performed by a specialized radiologist by transvaginal and exclusive transuterine approach. 4 to 5 samples will be made.~Local anesthesia will be performed. A pain assessment will be performed during the biopsy (visual or verbal scale)."
215027439|NCT03927079|BIOLOGICAL|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
215027440|NCT03927079|PROCEDURE|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
215104456|NCT00665964|DEVICE|X-3 polyethylene|highly cross-linked polyethylene for knee arthroplasty
215104457|NCT00665964|DEVICE|N2Vac polethylene|conventional polyethylene
215104458|NCT02828332|OTHER|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
215104459|NCT02828332|OTHER|Quality of life|Evaluation of the quality of life and comorbidities
215104460|NCT02697188|DRUG|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
215104461|NCT02697188|DRUG|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
215104462|NCT05406102|DRUG|Remimazolam|Patients received an initial dose of 0.1mg/kg of remimazolam (add to 0.05 mg/kg top-ups doses to a total of up to five times within 15minutes).
215104463|NCT05406102|DRUG|Propofol group|Patients received an initial dose of 1.5mg/kg of propofol(add to 0.5 mg/kg top-ups doses to a total of up to five times within 15minutes).
215104464|NCT01623388|PROCEDURE|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
215104465|NCT01195480|GENETIC|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10\^8/m2
215104466|NCT01195480|BIOLOGICAL|Irradiated donor-derived Lymphoblastoid Cell Line|"The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in \> 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10\^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion."
215104467|NCT04379778|OTHER|Aerobic exercise|Progressive moderate to high intensity aerobic exercise.
215104468|NCT02202538|DEVICE|Indego|Indego
215104469|NCT00618878|PROCEDURE|Electroacupuncture|twice a week for 26 treatments in total
215104470|NCT00618878|PROCEDURE|Laser Therapy|twice a week for a total of 26 treatments
215104471|NCT01453907|DRUG|"ETI-204, Anthim"|intravenously, single dose
215104472|NCT01453907|DRUG|placebo|intravenously, single dose
215027441|NCT03927079|BIOLOGICAL|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
215027442|NCT02441400|DEVICE|EndoStim LES Stimulation System|
215027443|NCT04946123|DIETARY_SUPPLEMENT|L-carnitine+Selenium|Supplementation with L-carnitine and Selenium
215027444|NCT06047587|BEHAVIORAL|VR-TrAC|Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each.
215027445|NCT06047587|OTHER|Care as Usual|Care as usual as provided in prison.
215027446|NCT04410796|DRUG|Osimertinib|80mg orally daily
214424332|NCT05235789|OTHER|Rational-Emotive-Behavioral Therapy|"The structure of the REBT sessions includes the following points:~1. Determine specific goals that explain what the participant want to achieve through the content of the session.~2. Explain the level of skills to be achieved in each session.~3. Development of the session, reminder of the previous session, review of homework (from the second session to the 8th). Irrational beliefs and disruptive thoughts will be worked on together with the participant in order to achieve an improvement in their emotional state. Key messages with healthier alternatives that make your daily life easier.~4. Establishing homework. Using the REBT Toolbox with Key Messages.~5. Individual psychosocial work will be recorded in the computerized medical history."
214424333|NCT05235789|OTHER|Control Group usual care|In the control group, for each center , the depression is treated as usual with the conventional treatment, according to national and international guidelines.
214424334|NCT02980718|BEHAVIORAL|intensive olfactory training|
214424335|NCT02980718|BEHAVIORAL|ordinary olfactory training|
214424336|NCT00748410|DRUG|SB-656933|7 days repeat dose
215027447|NCT04410796|DRUG|Carboplatin|Carboplatin (AUC 5 IV q 3 weeks)
215027448|NCT04410796|DRUG|Pemetrexed|Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles
215104473|NCT06289309|DEVICE|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
215104474|NCT01810497|PROCEDURE|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
215104475|NCT03760679|DEVICE|Laryngeal mask Supreme evaluation|Device: Laryngeal mask Supreme evaluation
215104476|NCT03760679|DEVICE|i-gel evaluation|Device: i-gel evaluation
215104477|NCT05556694|DIAGNOSTIC_TEST|calculation of cumulative fluid balance|\- We will calculate cumulative fluid balance as daily fluid balance within four days of the event of interest. Cumulative fluid balance will be computed as the sum of daily fluid balances over the previous 24 hours, calculated by total fluid input minus total fluid output on a specific day of ICU admission over the first four calendar days of mechanical ventilation. Insensible fluid loss, such as perspiration or evaporative water loss related to respiration will not be routinely assessed and will not be included in the calculation of cumulative fluid balance. The cumulative fluid balance from day 0 to day 1 will be labelled as day 1, and the following days as day 2 and day 3. Cumulative fluid balance at day 3 refers to the cumulative fluid balance during the first four calendar days.
215104478|NCT03902834|OTHER|Fitbit|Use the wearable technology (Fitbit) and proven behavioural change techniques to precondition patients prior to lung cancer surgery
215027449|NCT00826293|PROCEDURE|Stabilization belt|Patients receive true stabilization.
215027450|NCT00826293|PROCEDURE|Stabilization belt|Patients receive sham stabilization.
215027451|NCT05381753|DRUG|Avapritinib|Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.
215027452|NCT05381753|DRUG|Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )|Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
215027453|NCT04619147|OTHER|No intervention|This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.
215027454|NCT00385489|DRUG|LXR-623|
214424337|NCT05632432|PROCEDURE|Epicardial AAMs-patch transplantation|Perioperative assembly of an AAMs-patch with epicardial transplantation onto the epicardium of the scarred myocardium at the end of CABG surgery
214509242|NCT03723902|DIETARY_SUPPLEMENT|Protein supplementation|Daily supplementation of 2 x 17 grams of milk protein
215027455|NCT05301972|DRUG|BET Inhibitor|Bromodomain and Extra-Terminal Inhibitor
215027456|NCT04097860|BEHAVIORAL|Text message including biomarker of breast pumping adequacy|The intervention group will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the participant is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
215104479|NCT01180010|PROCEDURE|Low Dose CT|"A chest CT uses special radiographic equipment using x-rays to capture images of the chest, and with the aid of a computer, processes the images to create cross-sectional pictures or slices of the areas of interest. The images can then be printed out or examined on a monitor. The CT scanner is a large unit with a hole running directly through its center, giving the appearance of a doughnut. During the scanning, patients will lie flat on their back on a table, and they are periodically asked to hold their breath. The table will first move through the scanner to determine the correct starting position. The rest of the scans are made as the table moves more slowly through the cavity in the scanner."
215104480|NCT04020497|BEHAVIORAL|Ensemble programme|Ensemble is a individualized programme to address informal caregiver's specific unmet needs, emotions and social resources, in order to offer a targeted support in five sessions.
215104481|NCT04020497|OTHER|SAU|"Informal caregivers have often to manage the situation in usual different ways. Support as usual (SAU) alone consists of an informal support by patient's clinical team. Specific psychoeducational programs depending on patient's illnes (like Profamille for schizophrenia) or peer-support depending to the voluntary work of families' associations. Some general professional services focused on informal caregivers or relatives in order to inform and orient them if they are avaible in the study area. No attempts have been made to standardize this treatement as SAU depend to informal caregiver's need and knowledge of the health system, also her/his capacity or possibility to be in contact with patient's clinical team."
214509243|NCT05390515|DRUG|Tildrakizumab Prefilled Syringe|IL-23 inhibitor
215027457|NCT05964166|DEVICE|TetraGraph NMT Monitor|TetraGraph is a unique, EMG=based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
215027458|NCT03571633|DRUG|Trastuzumab + Paclitaxel|During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)
215027459|NCT03571633|DRUG|Pegfilgrastim|During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
215027460|NCT05712538|DRUG|ARCT-032|ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
215027461|NCT05712538|OTHER|Placebo|Normal saline
215027462|NCT05998564|DEVICE|Connecting patients to both non-invasive monitors to observe and compare the monitor's capabilities.|All patients will be connected to the NOL monitor and the SCA monitor during general anesthesia.
215027463|NCT01720563|DRUG|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
215027464|NCT01720563|DRUG|Placebo|500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
215027465|NCT01720563|PROCEDURE|Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks|
215027466|NCT04634617|OTHER|Questionnaire Administration|Complete questionnaires
215027467|NCT05670756|OTHER|Survey|Parents/guardians will complete a survey about when the medication allergy was identified and the exact symptomatology that resulted in determination of the allergy.
215027468|NCT06423794|DRUG|BHV-7000|BHV-7000 75 mg taken once daily
215027469|NCT03263533|DRUG|Vorinostat Oral Capsule Group 1|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
215027470|NCT03263533|DRUG|Vorinostat Oral Capsule Group 2|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
214509244|NCT02122484|DRUG|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
214509245|NCT04566276|BIOLOGICAL|ChulaCov19 vaccine|SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
214509246|NCT04566276|OTHER|Placebo|Saline
215027471|NCT06154824|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
215027472|NCT06154824|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
215027473|NCT04684862|DEVICE|Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)|This infusion system is composed of a Medtronic SynchroMed II programmable pump connected to a Intera tapered catheter. Specifically, the Medtronic pump comes with a small connector that ends in a metal flange. During the operation, under sterile conditions, the distal 1 cm of the flange is severed using a scissor. Then, using a Intera connector pin, the end of the Medtronic catheter is connected to the Intera catheter . Two 2-0 silk ties secure the catheters to the pin. The pump and catheter are then inserted into the patient into the abdominal wall or into the chest wall. The catheter is inserted into an artery within the abdomen (usually the gastroduodenal artery but it depends on the exact arterial branching in the individual patient) that feeds the liver.
214424338|NCT05632432|DIAGNOSTIC_TEST|RNA-stabilized whole blood sampling|Collection (preoperative and at 6-month-follow-up) of TEMPUS(TM) stabilizing whole blood for epitranscriptomics-oriented measurements
214424339|NCT05632432|DIAGNOSTIC_TEST|Plasma sampling|Collection (preoperative and at 6-month follow-up) of blood-derived both RNA-stabilized and non-stabilized plasma aliquots for epitranscriptomic-oriented and other CVD biomarker oriented measurements, respectively
214424340|NCT05632432|DIAGNOSTIC_TEST|Transthoracic echocardiography|To assess cardiac structure and function both pre- and postoperatively (at both hospital discharge and 3-month follow-up)
215027474|NCT04526925|DEVICE|Respiratory filter in-line placed with the standard mouthpiece|The respiratory filter is a device that removes solid/large particles from gas
215027475|NCT04526925|OTHER|Standard mouthpiece|The mouthpiece is the interface that is placed on participant's face in order to measure all the breathing physilogic responses
215027476|NCT05187650|DEVICE|Ekso (EksoNR, Ekso Bionics)|The EksoNR is a powered exoskeleton designed to be used in a rehabilitation setting. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices and is used for gait training in neurorehabilitation.
215027477|NCT05187650|DEVICE|FES (RehaMove2, Hasomed)|RehaMove 2 sends electrical impulses via electrodes to nerves to evoke muscle contraction. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices.
215027478|NCT04876287|DRUG|Radioiodine|cancer therapy
215027479|NCT00214565|DRUG|Galida|
215027481|NCT04745780|DIETARY_SUPPLEMENT|Myo-inositol, D-chiro-inositol, Gymnema sylvestre, Zinc and Alpha-lactalbumin|Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months
215027482|NCT04745780|DIETARY_SUPPLEMENT|Placebo|Placebo - Two-times daily on an empty stomach, for 6 months
215027483|NCT01558258|BEHAVIORAL|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
215027484|NCT02569008|DRUG|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
215027485|NCT05553236|DIAGNOSTIC_TEST|Targeted next-generation sequencing|During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.
215027486|NCT03795519|DRUG|[14C]-olinciguat|oral capsule
215027487|NCT00088699|DRUG|Ketamine|
215027488|NCT00088699|DRUG|Placebo|
215027489|NCT01756742|OTHER|Respiratory physiotherapy|"The respiratory physiotherapy intervention included:~* Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~* Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry."
215027490|NCT01756742|OTHER|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
215027491|NCT02244398|OTHER|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
215027492|NCT02244398|OTHER|FP services|VHTs in the control arm only provide family planning services
215027493|NCT01524744|DRUG|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
215027494|NCT01524744|DRUG|Adcortyl|triamcinolone acetonide 0.1% in orabase
215027495|NCT02326584|DRUG|Standard dose cytarabine for induction|100 mg/m2/day Days 1-7
215104482|NCT01853878|BIOLOGICAL|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
215104483|NCT01853878|BIOLOGICAL|Placebo|Intramuscular administration
215104484|NCT02161757|BIOLOGICAL|Tralokinumab|Subcutaneous injection
215104485|NCT02161757|OTHER|Placebo|Subcutaneous injection
215104486|NCT04314011|BIOLOGICAL|Human umbilical cord mesenchymal stem cells（HUC-MSCs）|Human umbilical cord mesenchymal stem cells（HUC-MSCs）
214424341|NCT05632432|DIAGNOSTIC_TEST|Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI)|To assess detailed cardiac structure (i.e. interstitial fibrosis) and function both preoperatively and at 6-month follow-up postoperatively.
214424342|NCT05632432|OTHER|Symptom-scaling|Standardised evaluation of IHD and HF-related angina pectoris (CCS) and dyspnea (NYHA) and life quality (RAND36) pre- and postoperatively (at both 3- and 6-month follow-up).
215027496|NCT02326584|DRUG|SGN-CD33A|Given intravenously Day 1 or Days 1 and 4 of each cycle
214424343|NCT05632432|OTHER|6-minute walking test (6MWT)|Standardised assessment of physcial capacity pre- and postoperatively (at 6-month follow-up)
215027497|NCT02326584|DRUG|Daunorubicin|60 mg/m2/day Days 1-3
215027498|NCT02326584|DRUG|High dose cytarabine for consolidation|3g/m2 on Days 1, 3, and 5 of each cycle
215027499|NCT03416816|DRUG|DSP-0337|DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.
215027500|NCT01556334|DRUG|Azithromycin|Azithromycin 1g po
215027501|NCT01556334|DRUG|Erythromycin|Erythromycin IV then PO
215027502|NCT06515613|DRUG|CTIM-76|Claudin 6 bispecific Antibody administered weekly (Day 1, 8, 15 and 22) of a 28 day treatment cycle until disease progression.
215027503|NCT06145711|OTHER|hiPSC-DAP|Using hiPSC-DAP for the treatment of the patients of Parkinson's diease
215104487|NCT04314011|BIOLOGICAL|Placebo|Placebo
215104488|NCT01399866|DRUG|D-cycloserine|2 single weekly doses, 50 mg capsule
215104489|NCT01399866|DRUG|Placebo|
215104490|NCT00767819|DRUG|Everolimus|2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
215104491|NCT01452503|DEVICE|Path Women's Condom|comparison between 3 types of female condoms
215104492|NCT01452503|DEVICE|FC2 female condom|comparison between 3 types of female condoms
215104493|NCT01452503|DEVICE|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
215027504|NCT05679622|OTHER|Fecal Microbiota Transplantation|In the induction stage of UC, FMT group received FMT and PEN intervention, and FMT group are given for at least one course of FMT treatment. If repeated FMTs are received, it is usually at a 2 month interval. All the participants received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention to help induce and maintain clinical remission.
215027505|NCT06132204|DRUG|HRS-7535 Tablets|HRS-7535 Tablets
215027506|NCT02615275|PROCEDURE|Bioelectric Impedance Analysis|Undergo BIA with seca mBCA
215027507|NCT02615275|PROCEDURE|Computed Tomography|Undergo CT
215027508|NCT02615275|PROCEDURE|Positron Emission Tomography|Undergo PET
215027509|NCT02615275|OTHER|Quality-of-Life Assessment|Ancillary studies
215027510|NCT02615275|OTHER|Questionnaire Administration|Ancillary studies
215027511|NCT02615275|RADIATION|Radiation Therapy|Undergo RT
215027512|NCT03443401|PROCEDURE|Standard physical therapy care|standard plan of care delivered to patient with chronic low back within scope of licensure
215027513|NCT03753516|PROCEDURE|Laparoscopic - Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close laparoscopically using an 0-Barbed suture.
215027514|NCT03753516|PROCEDURE|Vaginal- Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close vaginally using an 0-Vicryl suture in a vertical fashion.
215027515|NCT06060509|DIETARY_SUPPLEMENT|Phytosterol-rich Wheat and Corn Germ Blended Oil|Blending of corn germ oil and wheat germ oil supplied by Yihai Kerry to obtain germ blended oil with high phytosterol content.
215027516|NCT06060509|DIETARY_SUPPLEMENT|Peanut oil|Participants in the control group consumed peanut oil daily for cooking.
215027517|NCT04272034|DRUG|INCB099318|INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
215104494|NCT02443818|DRUG|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
215104495|NCT04271033|DEVICE|Carotid Artery Stenting|"Carotid artery stenting according to local clinical experience and ESC/ESVS guidelines using exclusively CGuard™, MicroNet covered stent under proximal or distal intraprocedural cerebral protection according to tailored CAS algorithm."
215104496|NCT02566733|DRUG|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
215104497|NCT02566733|DRUG|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
215104498|NCT03029091|DRUG|Losartan Potassium|Losartan potassium
215104499|NCT05071014|DRUG|Pembrolizumab|Pembrolizumab: 200mg/dose delivered by IV infusion
215104500|NCT05071014|PROCEDURE|Image-guided cryoablation|Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
215104501|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
215104502|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
215104503|NCT00881647|OTHER|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
215104504|NCT00794885|DRUG|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
215027518|NCT06446037|DEVICE|Non-invasive EMG band instrumentation|The sensed EMG signals from the subjects will be decoded by Phantom X algorithm and used to drive various gestures in a desk-mounted hand prosthesis
215027519|NCT05572736|DEVICE|Conduction system pacing|Pacing from the His-Purkinje system (His-bundle pacing, left bundle branch area pacing, or deep septal pacing).
215027520|NCT05572736|DEVICE|Biventricular pacing|Pacing from the coronary sinus and right ventricular leads.
215027521|NCT06844916|OTHER|AI-Assisted PEEP Optimization|"In this study, three artificial intelligence (AI) models (ChatGPT, DeepSeek, and Gemini) will analyze mechanical ventilation data, including compliance, elastance, auto-PEEP, time constant, and pressure-volume (P-V) curves, to generate patient-specific PEEP recommendations.~These AI-generated recommendations will be compared with manual PEEP titration performed by experienced ICU specialists. The AI models will also provide abnormal ventilation parameter detection, diagnostic suggestions, and treatment recommendations. The study aims to evaluate the reliability, accuracy, and clinical applicability of AI-generated outputs in optimizing PEEP settings for mechanically ventilated ICU patients."
215027522|NCT05799092|DIAGNOSTIC_TEST|Invasive coronary angiography|As alternative to non-invasive functional testing, invasive coronary angiography will be performed.
215027523|NCT05799092|DIAGNOSTIC_TEST|Non-invasive functional test|Standard non-invasive functional testing will be performed.
215027524|NCT04878718|BIOLOGICAL|Fecal Microbiota Transplant; Vancomycin|Subject will be treated with vancomycin followed by fecal microbiota transplant
215027525|NCT02466997|DRUG|tacrolimus|tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
215027526|NCT02466997|DRUG|Placebo|
215104505|NCT00794885|DRUG|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
215104506|NCT00465647|DRUG|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
215027527|NCT03615131|DIAGNOSTIC_TEST|MRI-TRUS fusion prostate biopsy|First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
215027528|NCT06549907|OTHER|Multi-omics testing|Samples include tissue, blood, urine and stool, and multi-omics approaches include single-cell sequencing, spatial transcriptome sequencing, macro transcriptome sequencing, whole exome sequencing, microproteomics, immunohistochemistry, and multiplex fluorescence immunohistochemistry.
215027529|NCT06549907|OTHER|MRI|MRI will be conducted to investigate image characteristics during treatment
215104507|NCT03225703|BEHAVIORAL|Hopping|A unilateral, hopping based exercise programme lasting six months.
215104508|NCT03916081|DRUG|Roflumilast Cream 0.05%|Roflumilast 0.05% cream for topical application
215027530|NCT06286072|OTHER|Education and message|COPD general education content and fatigue-specific coping strategies. Messages sent to phones
215104509|NCT03916081|DRUG|Roflumilast Cream 0.15%|Roflumilast 0.15% cream for topical application
215104510|NCT03916081|DRUG|Vehicle Cream|Inactive vehicle cream matched to roflumilast cream for topical application.
215104511|NCT05018663|OTHER|Artificial Intelligence software ROSE|Rapid on-site evaluation (ROSE) of Endoscopic Ultrasound (EUS) guided FNA/FNB (Fine Needle Aspirate/Fine Needle Biopsy) of pancreatic solid lesions (PSLs) has been shown in improve diagnostic yield. The availability and performance of ROSE at EUS performing centers is variable. With strides in Artificial Intelligence (AI) capabilities over the years, the University of Texas at Health Sciences Center at Houston in collaboration with Haystac is developing an artificial intelligence based proprietary system to analyze slides from EUS FNA/FNB samples at bedside.
215104512|NCT02272166|DRUG|propofol|
215104513|NCT02272166|DRUG|Sevoflurane|
215104514|NCT05655013|DRUG|Zoledronate|zoledronate 5 mg
215104515|NCT05655013|DRUG|Placebo|isotonic saline 100 mL
215104516|NCT00230503|DRUG|pradefovir mesylate|
215104517|NCT00230503|DRUG|adefovir dipivoxyl|
215104518|NCT06006403|BIOLOGICAL|CD123 targeted CAR-NK cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
215027531|NCT06296355|BEHAVIORAL|Health Warning Label|"Message displayed on warning label is: WARNING: Consuming ultra-processed food and drinks can cause weight gain, which increases the risk of obesity and type 2 diabetes."
215027532|NCT06296355|BEHAVIORAL|Identity Warning Label|"Message displayed on warning label is: WARNING: Ultra-processed food."
215027533|NCT06296355|OTHER|Barcode Label|Barcode is displayed.
215027534|NCT05802836|OTHER|no interventions|no intervention, only 3 different patients groups
215104519|NCT02168608|OTHER|Remote ischemia precondition|Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
215104520|NCT02168608|OTHER|None remote ischemia precondition|Placed an uninflated cuff on the right upper arm for 30 min.
215104521|NCT06432504|OTHER|Caffeine content|Participants will drink the same volume of coffee with different amounts of caffeine.
215104522|NCT01339897|DRUG|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
215104523|NCT01339897|DRUG|Placebo|Same administration procedures as active
215104524|NCT01339897|DRUG|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
215027535|NCT06405529|OTHER|Early and intensive mobilization protocol at the ICU and Rehabilitation post-hospital discharge|"During hospitalization in the ICU and ward, you will perform 30 to 60 minutes of exercises per day, according to the IMS scale.~After hospital discharge, participation in a supervised exercise program twice a week for 8 weeks at the Rehabilitation Center - CER of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto."
215104525|NCT01339897|DRUG|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
215104526|NCT04534881|DRUG|Progesterone 200 MG|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
215104527|NCT04534881|DRUG|Placebo|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
215104528|NCT00847197|DRUG|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
215104529|NCT00847197|DRUG|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
215104530|NCT01506011|DRUG|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
215104531|NCT01791101|DRUG|Eltrombopag|
215104532|NCT00013013|PROCEDURE|Systems Support|
215104533|NCT05532605|OTHER|cardiac rehabilitation phase I protocols|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own.
215104534|NCT05532605|OTHER|Cardiac rehab phase I protocols + Mindfullness base therapy|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own. Plus Mindfullness base therapy
215104535|NCT01660503|DIETARY_SUPPLEMENT|0 grams SCF|Given in snack foods (muffins and flavored beverage)
215104536|NCT01660503|DIETARY_SUPPLEMENT|10 grams SCF|Given in snack foods (muffins and flavored beverage)
215104537|NCT01660503|DIETARY_SUPPLEMENT|20 grams SCF|Given in snack foods (muffins and flavored beverage)
215104538|NCT02551029|OTHER|Capsaicin|
215104539|NCT02551029|OTHER|Placebo|
215104540|NCT01906528|DRUG|Mivacurium|Effect of Mivacurium in males vs females
215104541|NCT03776591|PROCEDURE|Open surgery|
215104542|NCT03776591|PROCEDURE|Right colectomy|
215104543|NCT03776591|PROCEDURE|Laparoscopic surgery|
215104544|NCT03776591|PROCEDURE|Central lymphadenectomy and vascular ligation|
215104545|NCT01124591|BEHAVIORAL|Brief motivational intervention|two session delivered two weeks apart
215104546|NCT03395951|DRUG|Diuretics|Observation of hemodynamics during diuretics treatment within clinical indication.
215104547|NCT00875290|DEVICE|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
215104548|NCT04617015|DRUG|Ipratropium Bromide|All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
215104549|NCT01098526|DRUG|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
215104550|NCT01098526|DRUG|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
215104551|NCT04939792|DRUG|Vitamin D|Capsules ingested orally
215104552|NCT04939792|DRUG|Placebo|Capsule ingested orally
215104553|NCT04939792|DRUG|Vitamin D + L-cysteine|Capsule ingested orally
215104554|NCT04939792|DRUG|L-cysteine|Capsule ingested orally
215104555|NCT04569981|OTHER|Climbing|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
215027536|NCT04502108|BEHAVIORAL|Covid19|Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.
215027537|NCT04505787|DRUG|Esflurbiprofen hydrogel patch 165 mg (EFHP)|patch application with PK blood sampling
215027538|NCT04505787|DRUG|Froben 100 mg comprimidos revestidos|tablet administration with PK blood sampling
215027539|NCT00814736|DRUG|UK369,003|oral tablet, once a day
215027540|NCT00814736|DRUG|sildenafil|single oral dose on day 14 or day 17
215027541|NCT00814736|DRUG|sildenafil matching placebo|single oral dose on day 14 or day 17
215027542|NCT03193580|DEVICE|Anodal Conventional tDCS|tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
215104556|NCT04569981|OTHER|Unsupervised activity group|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
215104557|NCT06226584|DIETARY_SUPPLEMENT|multiple-strain probiotics|Juice HA capsule which contains more than one strain of probiotics
215104558|NCT02105675|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa is the experimental therapy added on to Docetaxel
215104559|NCT02105675|DRUG|Docetaxel|Docetaxel is Standard of Care First Line Chemotherapy
215104560|NCT05325840|OTHER|music terapy|The aim of this study was to examine the effects of the music concert applied during the nonstress test procedure on the health of the fetus, the anxiety level of the pregnant woman and blood pressure.
215104561|NCT00444340|DRUG|Enbrel (Etanercept)|
215104562|NCT04306653|DRUG|ACTH|patients with acute gout will receive 100 IU ACTH IM
215104563|NCT04306653|DRUG|Betamethasone|patients with acute gout will receive 6 mg of betamethasone
215104564|NCT03985371|DRUG|EDTA Eye Drops|One drop in the Band Keratopathy affected eye only, two times per day for six months.
215104565|NCT00622388|DRUG|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
215104566|NCT03659071|OTHER|questionnaire VSP-A|VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
215104567|NCT03462381|DIETARY_SUPPLEMENT|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
215104568|NCT00348309|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
215104569|NCT00348309|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
215104570|NCT00348309|OTHER|Placebo|Placebo
215104571|NCT00348309|OTHER|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
215104572|NCT04477655|PROCEDURE|Awake prone positioning|Patients will be asked to remain in prone position or lateral decubitus throughout the day as long as possible.
215104573|NCT04477655|PROCEDURE|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%
215104574|NCT04374955|DIETARY_SUPPLEMENT|Activia Probiotics Shot|The product contains Actiregularis - at least 2x106 cfu / g.
215104575|NCT04374955|OTHER|Routine care|Routine care of the hospital will be provided.
215104576|NCT06384755|BEHAVIORAL|Honest Open Proud program|The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.
215104577|NCT04518683|DEVICE|Perineal rehabilitation with mobile applications for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. the sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home Program: The home program will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes. The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
215104578|NCT04518683|DEVICE|Classic perineal rehabilitation for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. The sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home program: The home program will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist."
215104579|NCT01894243|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
215104580|NCT02458443|OTHER|Isometric resistance training|Isometric handgrip exercise using a hand dynamometer
215104581|NCT02439034|DRUG|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
215104582|NCT02439034|DRUG|Ketoprofen|Ketoprofen\* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
215027543|NCT03193580|DEVICE|Anodal High Definition tDCS|HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
215027544|NCT03193580|DEVICE|Sham tDCS|tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
215027545|NCT00675233|DRUG|HPPH|Given IV
215027546|NCT00675233|PROCEDURE|laser therapy|Escalating light doses with 665 nm light
215027547|NCT05536791|DRUG|Dabigatran Etexilate (DE)|Dabigatran Etexilate (DE)
215027548|NCT04535115|PROCEDURE|Starting LRM (Lung Recruitment Maneuver)|The LRM is performed first for 30 seconds (an insufflation pressure of 30 cmH2O for 30 seconds is applied). After a free interval of 3 minutes, the VtC is done during 1 minute. For VtC, tidal volume is increased from 6 to 8 ml.kg-1 of predicted body weight. Finally, after a new free interval of 3 minutes, the fluid challenge (consisting in fluid administration of 250 ml of Ringer Lactate) is started for 10 minutes (in aim to determine which patients are responders). This sequence is repeated every 30 minutes (maximum four times).
215104583|NCT01640899|DEVICE|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
215104584|NCT03194113|BEHAVIORAL|Trauma-focused treatment|Weekly sessions
215104585|NCT03194113|BEHAVIORAL|Emotion regulation training|Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
214509247|NCT05940805|PROCEDURE|Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|"1. Low-frequency transcranial electrical stimulation (2/100 Hz) applied through 0.3-mm-diameter and 40-mm-long needles placed subcutaneously on the scalp at the projection of Penfield's motor homunculus and sensory and frontal supplementary motor associative areas.~2. Paraspinous block at the levels of the C5, C6 and C7 vertebrae concordant with spasticity laterality.~3. Dry needling of spastic upper limb muscles, as identified through a thorough physical examination, using 0.3-mm-diameter and 40-mm-long needles.~4. Muscular functional electrical stimulation (FES) in the antagonists of the upper limb muscles with spasticity with the following parameters: 20-Hz frequency, 300-µs pulse width, zero-second ramp time, 5-second stimulation time, and 5-second resting time."
215104586|NCT03194113|BEHAVIORAL|Intensive Trauma-focused treatment|Intensive version (3 sessions per week) of Trauma-focused treatment
215104587|NCT03686475|OTHER|Biodentine|pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
215104588|NCT03686475|OTHER|MTA pulpotomy|MTA pulpotomy
215027549|NCT04535115|PROCEDURE|Starting VtC (Tidal Volume Challenge)|The VtC is performed first for 1 minute. After a free interval of 3 minutes, the LRM is done for 30 seconds. Finally, after another free interval of 3 minutes, the fluid challenge is started for 10 minutes. This sequence is repe-tead every 30 minutes (maximum four times).
215027550|NCT04162158|BIOLOGICAL|allogeneic NK cells therapy|PBMC was isolated from the peripheral blood of the donors and infused to the patient after 14 days incubation. In each cycle, patients will be infused 4.0-5.0×10'9 allogeneic NK cells. All patients in the experimental group received a total of three cycles of treatment with one month interval between each treatment.
215027551|NCT04046744|PROCEDURE|Axillary brachial plexus block with a long-acting local anesthetic|axillary block with 15-30 ml Ropivacaine 0,5%.
215027552|NCT04046744|PROCEDURE|Axillary brachial plexus block with a short-acting local anesthetic + Analgesic block at the elbow with a long-acting local anesthetic|axillary block with 15-30 ml Lidocaine 1,5% + radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%.
215027553|NCT04046744|DRUG|Ropivacaine|axillary block with 15-30 ml Ropivacaine 0,5%
215027554|NCT04046744|DRUG|Ropivacaine|radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%
215027555|NCT04046744|DRUG|Lidocaine|axillary block with 15-30 ml Lidocaine 1,5%
215027556|NCT05006040|DEVICE|Hybrid Closed Loop System|Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system \[25, 26\]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days \[30\].
215027557|NCT05196529|OTHER|Inspiratory muscle training|All participants will undergo inspiratory muscle training.
215027558|NCT01808170|PROCEDURE|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
215104589|NCT05800912|OTHER|Narrative photography|"Students were shown real-life written stories, audio, and videos using a private online platform. The training activity included four modules: i) heart transplantation waiting list; ii) life expectancy, fear of death, and organ rejection; iii) post-transplant physical and functional limitations; and iv) lack of knowledge of physical exercise patients can perform.~The students were encouraged to think about how they would feel if they had undergone heart transplantation. Afterward, they had to communicate these feelings using up to three photographs and reflective explanatory text.~Two weeks later, the students met a heart transplantation expert patient followed by an educator-guided debate. Students' images were shared and discussed. Moreover, students were encouraged to explain their feelings and their acquired skills (two hours)."
215104590|NCT05800912|OTHER|Traditional learning|"A participatory lecture was carried out, in which cardiac rehabilitation in heart transplantation patients was explained. Then, there was an educator-guided debate about protocols and actions (one hour).~Second, the students autonomously prepared clinical cases on physical limitations, physical exercise, risk factors, and life after transplantation (two hours).~Two weeks later, the clinical session was held among students (2 hours). They adopted the roles of physical therapists or transplant patients to work on: i) post-transplant physical and functional limitations; ii) lack of knowledge of the physical exercise the patient can perform; iii) control of cardiovascular risk factors; iv) life post-transplant."
215104591|NCT00223704|DRUG|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
215104592|NCT00223704|DRUG|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
215104593|NCT00223704|DRUG|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
215104594|NCT04189029|OTHER|Extensive phenotyping|Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
215104595|NCT03392623|DRUG|Retinoic acid|topical administration in melasma lesions
215104596|NCT03392623|DEVICE|colorimetry measurement|Measurement of erythema and luminosity through a colorimeter
215104597|NCT03392623|DRUG|sunscreen|topical administration in melasma lesions
215104598|NCT03392623|DRUG|Niacinamide|topical administration in melasma lesions
215104599|NCT03530501|OTHER|Diet|Very low calorie ketogenic diet followed by low calorie diet
215104600|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic1|B. lactis, Lactobacillus rhamnosus, B. longum ES1 and prebiotics fiber
215104601|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic2|B. animalis subsp. lactis and prebiotics fiber
215104602|NCT04548518|BIOLOGICAL|GPO Tri Fluvac vaccine|Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).
215104603|NCT04548518|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020
215104604|NCT05293236|DRUG|ApTOLL|ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)
215104605|NCT05293236|OTHER|Saline|Saline for intravenous infusion
215104606|NCT04228432|OTHER|Dedicated and coordinated monitoring|"* Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~* Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6."
215104607|NCT00119171|DRUG|Ispinesib|
215027559|NCT01808170|PROCEDURE|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
215027560|NCT02758730|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
215027561|NCT02758730|BIOLOGICAL|Adjuvant without active component|s.c. injection
214424344|NCT05632432|DIAGNOSTIC_TEST|Blood sampling (NT-proBNP)|Collection of a blood sample measurement of NT-proBNP by an accredited hospital laboratory pre- and postoperatively (at both 3- and 6-month follow-up).
215027562|NCT00137449|DRUG|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
215027563|NCT06478524|BEHAVIORAL|Live music|Patients will have baseline data collection in the first week, followed by live music sessions and data collection during dialysis in the second week. The live music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
215027564|NCT06478524|BEHAVIORAL|Pre-recorded music|Patients will have baseline data collection in the first week, followed by pre-recorded music sessions and data collection during dialysis in the second week. The pre-recorded music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
215027565|NCT01356940|DRUG|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
215027566|NCT01356940|DRUG|placebo|identical placebo tablet administered bid for four weeks
215027567|NCT06367101|OTHER|AR training with gait and HRV feedback|Use projection-based AR system to train gait and HRV. To give gait and HRV feedback for subjects after AR training.
215027568|NCT03683979|BEHAVIORAL|Interpretation Bias Modification|A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.
215027569|NCT03683979|BEHAVIORAL|Control Training Program|A sham training program that is similar in design and delivery to the experimental training condition.
215027570|NCT05323344|OTHER|Neuro-physiotherapy|Neuro-Physiotherapy will be done in Intervention group I
215027571|NCT05323344|OTHER|Combination of metacognitive behavioral therapy and Neuro-physiotherapy|Combination of metacognitive behavioral therapy and Neuro-physiotherapy will be done in intervention group II
215027572|NCT00685295|DRUG|Fentanyl|Fentanyl rapid dissolving tablet 100mcg
215027573|NCT00685295|DRUG|Lansoprazole|lansoprazole 15mg rapidly dissolving tablet
215027574|NCT00685295|DRUG|Oxycodone|Oxycodone 5/325 mg tablet
215027575|NCT05409794|BIOLOGICAL|Blood sample|Blood sample for the determination of plasma lithium levels
215027576|NCT01900184|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
214509248|NCT05940805|PROCEDURE|SHAM Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used.
214509249|NCT04125342|DEVICE|Preventive Conditioned NIV Therapy after planned extubation|Conditioned NIV during 48 hours following extubation.
214509250|NCT04125342|DEVICE|Preventive HFOT after planned extubation|HFOT set according to patients tolerance during 48 hours following extubation
214509251|NCT00587171|DEVICE|Patching|2 hours daily patching
214509252|NCT00587171|PROCEDURE|Near activities|30 minutes daily near activities at home
214509253|NCT00587171|PROCEDURE|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
214509254|NCT00587171|PROCEDURE|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
214509255|NCT04246905|DRUG|sulforaphane|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
214424345|NCT05632432|DIAGNOSTIC_TEST|Transesophageal echocardiography|Performed by the perfusion-anesthesiologist at the beginning of the CABG surgery to evaluate both LAA and RAA for blood flow velocities, anatomy, possible sludge and thrombus.
214424346|NCT05632432|PROCEDURE|Epicardial collagen-based patch transplantation|Epicardial transplantation of the collaged-based patch material without the AAMs onto the epicardium of the scarred myocardium at the end of CABG surgery.
215104608|NCT00119171|DRUG|Capecitabine|
215104609|NCT02889445|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
215104610|NCT06351722|DIAGNOSTIC_TEST|Before non-surgical periodontal treatment|"Clinical Measurements and Laboratory Measurement Saliva and serum samples will be collected from all patients initially. Clinical parameters will also be recorded initially. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing.~Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time PCR."
214509256|NCT04246905|OTHER|placedo|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
215027577|NCT01900184|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
215027578|NCT00973128|DRUG|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
215027579|NCT00973128|DRUG|Meglumine antimoniate|20mg/daily for 20 days
215027580|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
215027581|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
215027582|NCT03235804|DIETARY_SUPPLEMENT|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
215027583|NCT00772057|DRUG|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
215027584|NCT00772057|DRUG|Placebo|Placebo tablets given two times daily.
215027585|NCT04729439|BEHAVIORAL|Homework Organization and Planning Skills (HOPS) Intervention|A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills
215027586|NCT04729439|DEVICE|Digital Health Application (Online Platform) for Encouraging Skills Practice|This online platform can be used on participants' personal devices including laptops, phones, tablets, or other computers and is designed to encourage adolescent's skills practice, monitor and reward treatment progress, and optimize motivation in treatment
215027587|NCT04408612|DIAGNOSTIC_TEST|Scales for assessment of symptoms|"Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale."
215027588|NCT00642291|DRUG|Emtricitabine|emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if \<30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if \>=7 to \<15kg; 10/2.5 mg/kg BID if \>=15 to \<=40 kg)
215027589|NCT00642291|DRUG|Emtricitabine|emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
215027590|NCT06192420|DRUG|Traumeel®|3g of gel three times daily for 7days (+1 day visit window)
215027591|NCT06192420|DRUG|Diclofenac sodium gel 1%|3g of gel three times daily for 7days (+1 day visit window)
215027592|NCT06192420|DRUG|Placebo|3g of gel three times daily for 7days (+1 day visit window)
215027593|NCT04908228|DRUG|Ibrutinib and obinutuzumab|Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
215027594|NCT06340867|DEVICE|CEREC primescan intra-oral scanner|intra-oral scanner
215027595|NCT04305210|DRUG|F-18 PMPBB3|In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
215027596|NCT04305210|DRUG|18F-florbetapir|18F-florbetapir
215027597|NCT01290991|DEVICE|Augment Bone Graft|Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
214509257|NCT04246905|DRUG|selective 5 - HT reuptake inhibitors (SSRI)|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
214509258|NCT06102538|BEHAVIORAL|# The importance of service in the IDF # Physical activity # Healthy nutrition # Psychological support|\# Education for the importance of service in the IDF # Education and training for physical activity adapted to abilities # Training for a healthy diet # Psychological support
214509259|NCT04389554|OTHER|Blood D-dimer assay|Blood samples will be taken from the patients and will be examined by the ELISA method.
214509260|NCT00865033|DRUG|Metformin HCL Tablets, 1000 mg Sandoz|
214509261|NCT00865033|DRUG|Glucophage 1000 mg|
215027598|NCT00505687|DRUG|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours."
215027599|NCT05598788|OTHER|Measurement of drug concentrations|Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample
215027600|NCT04608708|OTHER|The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions|lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
215104611|NCT06351722|PROCEDURE|non-surgical periodontal treatment|Treatment will be performed using ultrasonic devices followed by root planing with gracey curettes. SRP will be completed in two visits, each consisting of quadrants every 2 days. Oral hygiene instructions will include demonstrating proper brushing techniques and the use of interdental cleaning aids as needed. Saliva and serum samples will be collected again at the 3-month follow-up visit, all clinical parameter records will be repeated by the same clinician (ZTE), and oral hygiene instructions will be reconfirmed as needed. After the collection of 3-month records and samples, all patients with persistent pockets will be subjected to a standard periodontitis treatment protocol.
215104612|NCT06351722|DIAGNOSTIC_TEST|3rd month after non-surgical periodontal treatment|"All clinical and laboratory evaluations described under the heading Before non-surgical periodontal treatment will be repeated in the 3rd month after NSPT."
215104613|NCT06418451|PROCEDURE|sacrospinous ligament fixation (SLFF)|SSLF is a surgical procedure used to treat vaginal apex prolapse by fixing the vaginal apex to the right sacrospinous ligament. The procedure involves marking and incising the posterior vaginal wall, dissecting the vaginal rectal space, and placing sutures on the outer one-third of the ligament. These sutures connect the vaginal apex to the attachment point of the right uterosacral ligament. Anterior/posterior vaginal wall repair procedures can be performed if needed, without using implant materials. SSLF provides enhanced support for the vaginal apex.
215104614|NCT06418451|PROCEDURE|modified ischial spinous fascia fixation (modified ISFF)|The modified ISFF procedure involves making a midline incision along the posterior fornix of the vagina, exposing the ischial spine fascia. Two sutures are placed around the ischial spine and passed through the mucosa of the anterior and posterior vaginal walls, lifting the vaginal apex and anterior wall towards the spine. The procedure also allows for additional anterior/posterior vaginal wall repair if necessary, without using implant materials.
215104615|NCT06259539|BEHAVIORAL|YouTube nutrition education|For those in the intervention group, the YouTube training modules had step-by-step recipe demonstrations, strategies on how to get your child to eat more new foods, social stories, First-Then visual chart, and other nutrition education materials. All the videos were less than 5 minutes long, and parents were assigned 2 videos per week for 8 consecutive weeks. Parents answered 2 open-ended questions each week related to the educational materials they reviewed.
215104616|NCT01620944|DRUG|Atazanavir|Capsule, oral, 300 mg, Once daily (QD), 96 weeks
215104617|NCT01620944|DRUG|Ritonavir|Tablets, oral, 100 mg, QD, 96 Weeks
215104618|NCT01620944|DRUG|Lamivudine|Tablet, oral, 300 mg, QD, 96 Weeks
215104619|NCT01620944|DRUG|Tenofovir/Emtricitabine|Tablets, oral, 300/200 mg, QD, 48 Weeks
215027601|NCT00654602|DRUG|Rosuvastatin|
215104620|NCT04611451|OTHER|classic lumbar home exercise|classic lumbar home exercise
215104621|NCT04611451|DEVICE|Whole body vibration|Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point
215104622|NCT04611451|OTHER|Whole body vibration exercise|Whole body vibration exercise
215104623|NCT03852095|OTHER|minor trauma|following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
215104624|NCT04088110|DRUG|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
215104625|NCT04088110|DRUG|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
215104626|NCT04088110|DRUG|Aromatase Inhibitors|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
215104627|NCT02950844|OTHER|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
215027602|NCT00654602|BEHAVIORAL|Maintenance of specific diet|
215027603|NCT00000600|DRUG|Vitamin E|
215027604|NCT00000600|DRUG|Vitamin C|
215104628|NCT04016844|DEVICE|transcranial direct current stimulation or SHAM|"A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.~In the sham condition, the participants will receive the initial 30 seconds of stimulation, after which the current will be set to 0. The same tDCS device (Soterix) will be used."
215104629|NCT01364389|DRUG|AIN457|3 mg/kg
215104630|NCT01364389|DRUG|ACZ885|3 mg/kg
215104631|NCT01364389|DRUG|Prednisone|20 mg
215104632|NCT01364389|DRUG|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
215104633|NCT06027450|OTHER|NHIg prescription|Analysis of NHIg prescription
215104634|NCT03018977|OTHER|The sedative weaning protocol group|After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.
215104635|NCT03018977|OTHER|The usual group|After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
215104636|NCT00851461|DRUG|Goserelin|Goserelin 10.8 mg SC every 3 months
215104637|NCT00851461|PROCEDURE|Electrophysiologic study|Nerve conduction study Electromyogram
215104638|NCT00851461|PROCEDURE|tissue biopsy|skin and muscle biopsy before and after treatment every year
215104639|NCT02172404|DEVICE|Placebo capsule administered via the HandiHaler®|
215104640|NCT02172404|DEVICE|Ipratropium metered dose inhaler (MDI)|
215104641|NCT05278832|DRUG|QLS31905|QLS31905 injection
215027605|NCT03626233|OTHER|collect of placenta, blood and urinary samples at delivery|collect of placenta, blood and urinary samples at delivery
215027606|NCT03116126|DRUG|Guanfacine|2mg oral daily tablet
215027607|NCT03116126|DRUG|Placebo|inactive oral daily tablet
214509262|NCT01848483|BEHAVIORAL|AIDS EPC Package plus MI|"1. Motivational Interviewing: In MI session #1, the nurse will set the agenda \& ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 \& 4, the nurse will also introduce advance care planning.~2. EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic \& conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation \& coordination of care."
214509263|NCT01848483|OTHER|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
214509264|NCT01599078|DRUG|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
215104642|NCT05797597|DRUG|Aspirin 300 Mg Oral Tablet|8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks
215104643|NCT05797597|DRUG|Placebo|8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks
215104644|NCT02687581|DEVICE|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
214509265|NCT01599078|DRUG|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
214509266|NCT01148017|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
214509267|NCT02813954|DEVICE|Blood Gas Sampling|analyzing amniotic fluid by blood gas device
214509268|NCT06304051|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
214509269|NCT06304051|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, the investigators made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
215027608|NCT03205267|DRUG|Bosulif|Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to \<G2.
215027609|NCT01712373|DRUG|Ginseng|it is kind of drug
215027610|NCT01712373|DRUG|Placebo|it is placebo
215027611|NCT02177162|OTHER|Education to physiotherapists|
215027612|NCT01027676|DRUG|Study treatment|Gefitinib 250mg/QD plus vorinostat D1\~7 \& D15-21 / QD q 4weeks
215027613|NCT01631266|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
215027614|NCT01631266|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
215027615|NCT05997901|OTHER|Varenicline healthbot|The intervention is a healthbot that will provide information, reminders, answers to questions, and support to participants using varenicline for smoking cessation.
215027616|NCT03171948|BEHAVIORAL|Almond Group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
215027617|NCT03171948|BEHAVIORAL|Nut Free group|continue their diet without any nut consumption.
215027618|NCT06022640|BEHAVIORAL|Educational and supportive care|The trial had a total of 75 participants assigned to the intervention group, whereby they were provided with an educative and supporting program specifically developed by a clinical pharmacist. The intervention group was provided with assistance via a series of five visits, which included an initial visit upon admission, subsequent visits for monitoring medication, ovulation, and negative effects, as well as visits dedicated to giving emotional support. Additionally, a follow-up visit was conducted after the egg collecting process and embryo transfer.
215027619|NCT04509388|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
215027620|NCT02001792|PROCEDURE|Position the patient during colonoscopy|Position the patient either in a left lateral position during colonoscopy
215104645|NCT02687581|DEVICE|patch|6-hour of eye patch on the fellow eye
215104646|NCT05347303|OTHER|Finding-oriented orthopedic manual therapy treatment combined with foam roller|Blind randomized controlled clinical trial, where a total of 87 people, men and women, of legal age, university athletes of collective disciplines will be evaluated. The experimental group will receive foam roller therapy and manual therapy guided by findings (n = 44) for 8 weeks.
215104647|NCT05347303|OTHER|Foam roller treatment|Subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
215104648|NCT04514211|DRUG|Propofol|General anesthesia using propofol infusion
215104649|NCT04514211|DRUG|Sevoflurane|General anesthesia using sevoflurane
215104650|NCT01431391|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
214509270|NCT03758391|OTHER|Flipped Classroom education|Fellows will receive GI/Bilirubin education in a flipped classroom format.
215027621|NCT02001792|DEVICE|pulse oximeter|
215027622|NCT02974192|OTHER|Neopterin|Neopterin will be measured by using standard laboratory methods on the first day of admission.
215104651|NCT01431391|DRUG|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
215104652|NCT04849715|DRUG|parsaclisib|parsaclisib will be administered orally once daily.
215104653|NCT04849715|DRUG|rituximab|rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.
215104654|NCT04849715|DRUG|bendamustine|bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.
215104655|NCT04849715|DRUG|Placebo|placebo will be administered orally once daily
214509271|NCT01765699|DEVICE|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
214509272|NCT05673616|OTHER|Mckenzie Extension Exercises|"After two weeks of initial consultation, the patient will be taught to perform slouch-overcorrect on day 1 followed by flexion on day 2 in lying position and accompanied by flexion for 5 days in sitting position and finally flexion in standing will be performed.~The exercises will be repeated for 10 times and followed by extension in standing exercises."
214509273|NCT03185143|DRUG|Naltrexone and Acetaminophen Combination|Treat a single Qualified Migraine attack.
214509274|NCT03185143|DRUG|Sumatriptan 100 mg|One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
215027623|NCT00740675|OTHER|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:~1. Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~2. Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~3. Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
215027624|NCT06528080|GENETIC|LY-M001|LY-M001 Injection by Single Intravenous Infusion
214509275|NCT03185143|DRUG|Placebo|One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
215027625|NCT04826302|OTHER|Myofascial treatment|"40 minutes of myofascial intervention: 10 min in each of the following regions with the patient face up:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
215104656|NCT02554981|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
215104657|NCT01114438|DEVICE|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
215104658|NCT06526910|BEHAVIORAL|Swallowing exercises|Standard-of-care swallowing exercises include tongue exercise. The experimental part added in Phase 3 includes some participants completed standard-of-care exercises again and others completing standard-of-care exercises and motor imagery practice of those exercises.
215104659|NCT01734759|DRUG|Taste Test|"Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~* Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg"
215104660|NCT00753363|OTHER|Weight Loss|6 months of weight loss
215104661|NCT00753363|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training
215104662|NCT03875352|PROCEDURE|CHG technique|The CHG technique includes treatment using dressing with chlorhexidine.
215104663|NCT03875352|PROCEDURE|HMG technique|The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.
215104664|NCT01694836|BIOLOGICAL|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
215104665|NCT02508324|BIOLOGICAL|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10\^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
215104666|NCT02508324|BIOLOGICAL|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 nucleated blood cells/kg
215104667|NCT04794881|OTHER|24 hours|Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
215104668|NCT04794881|OTHER|48 hours|Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
215104669|NCT04246632|DEVICE|CapsoCam Colon Capsule Endoscopy|CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.
215104670|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
215104671|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
215104672|NCT03625999|BEHAVIORAL|video game training exercise|"The game, called The Silent Service and developed by our collaborators, is an online game with an underwater theme, and is comprised of 5 distinct mini-games, each of which demands auditory attention. The mission is to navigate an underwater scene, listening and responding to 'sonar' (e.g., an oddball in a stream of sounds). For example, participants may have to respond to an oddball sound stream to protect their submarine from a looming sea monster, while successfully ignoring a distractor sound stream (responses to the distractor sound stream allow the sea monster to damage the submarine). The five games share the same underlying framework of detecting oddballs while ignoring distractors but have unique artwork and 'backstories' to keep players interested. There is a hierarchical reward structure for 'leveling up' across the game that helps players to stay engaged and interested while playing."
215104673|NCT00000470|PROCEDURE|cardiac surgical procedures|
215104674|NCT00000470|PROCEDURE|cardiopulmonary bypass|
215104675|NCT00991406|DEVICE|FES|Surface stimulation to contract the muscles in the lower extremity
215104676|NCT02620488|BEHAVIORAL|Guided Imagery|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
215104677|NCT01955538|OTHER|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
215104678|NCT01955538|OTHER|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
215104679|NCT01955538|OTHER|Mixed physical activity|20 weeks, 1 hour/week.
215104680|NCT03295019|DEVICE|Test Oral Spray|HA formulation of FDA listed ingredients
215104681|NCT03295019|DEVICE|Placebo Oral Spray|Placebo formulation without the active ingredients
215104682|NCT03395002|DRUG|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.
215104683|NCT03395002|DRUG|Tiotropium 18 mcg Inhalation Powder|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.
214509276|NCT06086067|OTHER|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
215104684|NCT03395002|DRUG|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days
215104685|NCT04723680|OTHER|Qualitative interview|Qualitative semi structured interview
215104686|NCT03597061|BEHAVIORAL|Healthy Start to Feeding|The intervention provides parent education and skills training on a responsive feeding approach to introduction of healthy foods in infancy. Session content is manualized and administered by interventionists with expertise in child development and behavioral strategies for managing child eating behaviors under the supervision of a licensed clinical child psychologist and pediatric occupational therapist. Sessions are conducted individually with participants and primary caregivers and include educational content, handouts and instructions, modeling of skills by the interventionist, caregiver practicing of skills in session, establishment of behavioral goals, and problem solving barriers to implementation of treatment content. Content will include topics such as allowing infants' own hunger and satiety cues to guide the feeding experience, introducing healthy foods, parental attunement to infant satiety cues, and promoting infants' own self-feeding.
215104687|NCT03485521|PROCEDURE|The tracheobronchial aspiration|"Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure"
215104688|NCT02160145|DRUG|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
215104689|NCT02160145|DRUG|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
215104690|NCT00164515|BEHAVIORAL|Personalized exercise programme (PEP)|Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
215104691|NCT05021575|OTHER|Data collection on outpatient care|"Outpatient data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Outpatient data related to cardiovascular diseases (CVD) were collected as described:~1. data on visits were collected using ICD-10 codes I00-I99 and other CVD related codes (e.g., certain Z, Q codes, J81.0, R57.0)~2. data were collected from CVD prevention program~3. data on interventional cardiology were collected from day care facility regardless of the diagnosis.~Date of the visit, patient age, sex and municipality, service level (primary, secondary or tertiary), type of service and main diagnosis were recorded."
215027626|NCT04826302|OTHER|Sham myofascial treatment|"40 minutes of sham myofascial intervention: 10 min in each of the following regions with the patient face up and with the contact of the physiotherapist through a towel and without any intention:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
215027627|NCT03009292|DRUG|lenvatinib|once daily continuous dosing
215104692|NCT05021575|OTHER|Data collection on hospitalisation|"Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code."
215027628|NCT00448513|DIETARY_SUPPLEMENT|catechin extracts|comparison with placebo
215027629|NCT00278161|BIOLOGICAL|Pegfilgrastim|6 mg SQ 24-48 hours after last dose of cyclophosphamide.
215027630|NCT00278161|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52.
215027631|NCT00278161|DRUG|Cyclophosphamide|50 mg/kg/day on Days 15, 16, 17, and 18.
215027632|NCT01993082|BEHAVIORAL|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
215027633|NCT04382092|DIAGNOSTIC_TEST|FilmArray Pneumonia|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
215104693|NCT05021575|OTHER|Data collection on cardiovascular mortality|Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.
215104694|NCT05021575|OTHER|Data collection of patients presenting to the tertiary care centre with acute coronary syndrome|Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
215104695|NCT00375518|DRUG|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
215104696|NCT00375518|DRUG|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
215104697|NCT01700153|OTHER|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
215104698|NCT01700153|OTHER|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
215104699|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
215104700|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
215104701|NCT04558372|OTHER|exhaled breath sampling|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
215104702|NCT01674205|BIOLOGICAL|A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)|
215104703|NCT01674205|BIOLOGICAL|A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)|
215027634|NCT03223675|RADIATION|hippocampal-sparing WBRT|
215104704|NCT01674205|BIOLOGICAL|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)|
215104705|NCT01674205|BIOLOGICAL|Vaccine placebo (Leibovitz-15 [L-15])|
214424347|NCT02620618|DRUG|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
214424348|NCT04215471|DRUG|PD-L1 Antibody SHR-1316|Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
215027635|NCT00443456|DRUG|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
215027636|NCT04768244|OTHER|maternal SARS-CoV-2 infection|positive PCR in nasopharinx and/or presence of antibodies in serum
215027637|NCT05517408|DRUG|ciprofol|The first patient received Ciprofol 0.3mg/kg (actual body weight) at a rate of 1 mg/s. If the desired depth of sedation/anesthesia reached, then it was judged as negative, and the dose of Ciprofol in next patient would be decreased by one concentration gradient (the difference between two adjacent drugs was 1:1.1); If the desired sedation/anesthesia depth was not achieved, then it was judged as positive. And the dose of Ciprofol in next patient would be increased by one concentration gradient. Patients were enrolled consecutively until the trial was terminated at the eighth crossing point (positive to negative or negative to positive).
215027638|NCT02587455|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
215027639|NCT02587455|RADIATION|Radiotherapy|Radiotherapy - Standard Treatment
215027640|NCT03733327|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
215027641|NCT03733327|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
215027642|NCT03733327|DRUG|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
215027643|NCT00664222|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
215027644|NCT05333926|DEVICE|MHNA-001|3-month digital therapy program designed to reduce the severity of IBS symptoms
215104706|NCT01674205|BIOLOGICAL|Vaccine placebo (FluMist®)|
215104707|NCT00854841|DRUG|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
215104708|NCT02359513|DRUG|Antidepressants|bulimic patients are treated during 3 months
215027645|NCT03057184|BEHAVIORAL|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
215027646|NCT05724030|DEVICE|integrated pulmonary index|integarted pumobary index monitoring
215027647|NCT05724030|DEVICE|saturation|saturation monitorization
215027648|NCT04774666|BEHAVIORAL|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening|Oral fluid-based HIV test
215027649|NCT06187389|OTHER|1 Grups|This methodological study was conducted using a cross-sectional observational approach at a leading teaching and research hospital. The study duration was from March to June 2023
215027650|NCT04629430|OTHER|Pre-biotic foods/drinks|2 servings per day
215027651|NCT04815863|DIAGNOSTIC_TEST|Assessment of somatic symptom disorder with SSS-CN|SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms
215027652|NCT04815863|DIAGNOSTIC_TEST|Assessment of depressive symptoms disorder with PHQ-9|PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms
215027653|NCT04815863|DIAGNOSTIC_TEST|Assessment of anxiety disorder with GAD-7|GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
215027654|NCT00490711|DRUG|gemcitabine|
215104709|NCT02359513|DRUG|Positron Emission Tomography (PET)|PET scan using \[18F\]MPPF is performed before and after (3 months)antidepressant treatment
215027655|NCT00490711|DRUG|carboplatin|
215027656|NCT00490711|DRUG|paclitaxel|
215027657|NCT02695654|DRUG|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
215027658|NCT02695654|DRUG|Clonidine|Clonidine 100 mcg
215027659|NCT05904483|OTHER|PFA|PFA
215027660|NCT02644551|DRUG|CELEXT07|
215027661|NCT02644551|DRUG|Penlac|
215027662|NCT02644551|OTHER|vehicle solution|
215027663|NCT01769027|DRUG|Sertraline+Antibiotic (penicillin/azithromycin)|"12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.~Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)"
215027664|NCT01769027|DRUG|Sertraline+placebo|12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
215027665|NCT01769027|BIOLOGICAL|IVIG|Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
215027666|NCT02477748|DRUG|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
215027667|NCT02477748|DRUG|Placebo|Tablet PO, taken once daily for 10 weeks.
215027668|NCT01596426|DRUG|Sancuso|granisetron transdermal system
215027669|NCT01596426|DRUG|IV granisetron|IV granisetron
215027670|NCT01912235|OTHER|2-15N glutamine|Glutamine with N15 isotope tracer
215027671|NCT01912235|OTHER|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
215027672|NCT01912235|OTHER|1-13C glutamine|Glutamine carbon isotope tracer
215027673|NCT05321602|DRUG|LY03010 156 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
215027674|NCT05321602|DRUG|LY03010 156 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
215104710|NCT02006849|DRUG|Acthar|FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.
215104711|NCT05850338|DEVICE|cold pad pillow|cold pad pillow application when women have vasomotor symptoms for 8 weeks
215104712|NCT05850338|BEHAVIORAL|autogenic training|Autogenic relaxation for three times a day for eight weeks
215104713|NCT04919096|DRUG|SCB-420|Subjects randomised to SCB-420 arm will receive a total of 3 doses of SCB-420 as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
215104714|NCT04919096|DRUG|Aflibercept|Subjects randomised to Aflibercept arm will receive a total of 3 doses of Aflibercept as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
215104715|NCT03249987|OTHER|bladder diary|electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
214424349|NCT00028678|DRUG|dalteparin|
214424350|NCT00028678|RADIATION|radiation therapy|
214424351|NCT06969534|DRUG|Pucotenlimab combined with GP regimen|A total of 33 cases are planned to be enrolled. All the subjects will receive Pucotenlimab (3mg/kg, on day 1, with a maximum dose not exceeding 200mg), administered once every 3 weeks (Q3W), and combined with the GP regimen. The chemotherapy is a fixed regimen, with Gemcitabine at a dose of 1g/m² on day 1 and day 8, and cisplatin at a dose of 80mg/m² on day 1. The chemotherapy will be given for 3 to 6 cycles, once every 3 weeks (Q3W).
214424352|NCT01071993|DRUG|placebo|pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
214424353|NCT01071993|DRUG|atorvastatin|pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
214424354|NCT00296907|BEHAVIORAL|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
214424355|NCT03467555|DEVICE|Class II correction using miniplates in zygomatic region|
214424356|NCT01967654|OTHER|Technical Assistance, training and clinical reminders|
214424357|NCT01967654|OTHER|Referral to Community Health Worker|
214424358|NCT00128596|DRUG|arsenic trioxide|
214424359|NCT00305695|OTHER|Laboratory Biomarker Analysis|Correlative studies
215027675|NCT05321602|DRUG|LY03010 351 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
215027676|NCT05321602|DRUG|LY03010 351 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
215027677|NCT05775250|DRUG|giomer varnish|Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
215027678|NCT02157610|BEHAVIORAL|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
215104716|NCT00634062|DRUG|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
215104717|NCT00634062|DRUG|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
215104718|NCT02238860|DRUG|Entacavir|Entacavir-0.5 mg ,OD,for
215104719|NCT02238860|DRUG|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
215104720|NCT04338737|OTHER|timming of feeding|post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
215104721|NCT02098278|DRUG|CAT-2003|
215104722|NCT02098278|DRUG|Placebo|
215104723|NCT01108523|DEVICE|HP828-101|
214509277|NCT01281436|OTHER|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
214509278|NCT01281436|OTHER|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
215027679|NCT02157610|DRUG|Nicotine Patch|Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke \>10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke \<10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
215104724|NCT04978818|DRUG|Vaxelis|Eligible infants will be block randomized to one of two study arms.
215104725|NCT04978818|DRUG|PedvaxHIB|Eligible infants will be block randomized to one of two study arms.
215104726|NCT04186338|DEVICE|Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)|All participants were instructed to wear monitors for five consecutive days except during water-based activities. Data for each participant was collected to ensure included three valid weekdays. Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.
215104727|NCT03855683|BEHAVIORAL|Unified Protocol for The Treatment of Emotional Disorders|Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
214509279|NCT01052935|BIOLOGICAL|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
214509280|NCT00143806|DRUG|Transitioning patients from cyclosporine to alefacept|
214509281|NCT03928743|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
215027680|NCT02157610|BEHAVIORAL|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
215027681|NCT02157610|PROCEDURE|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
215027682|NCT02157610|BEHAVIORAL|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
215027683|NCT02157610|DRUG|Nicotine lozenge|Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
215027684|NCT03862417|OTHER|Schroth exercises|An exercise program begun individually and then continued in groups.
215027685|NCT01705392|DRUG|Bevacizumab|Bevacizumab 10 mg/kg q3w
215027686|NCT01705392|DRUG|Propranolol|Propranolol 80 mg x 1
215027687|NCT01705392|DRUG|Enalapril|Enalapril 5 mg x 1
215027688|NCT01705392|DRUG|Dacarbazine|dacarbazine 1000 mg/m2 q3w
215104728|NCT01085292|DRUG|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
214424360|NCT00305695|DRUG|Zoledronic Acid|Given IV
214509282|NCT03928743|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
214509283|NCT00239512|DRUG|Indomethacin and Ibuprofen|
215027689|NCT04785209|OTHER|Mean platelet volume, lymphocyte number, STEMI clinical risk scores|Lab parameters
215027690|NCT00855361|DRUG|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
215027691|NCT05732870|PROCEDURE|Relevant orthopaedic surgery|Inclusion criteria is purposefully broad to examine a range of discarded bone waste. Therefore, a large number of surgical interventions are relevant.
215027692|NCT00124657|DRUG|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
215027693|NCT06276140|DIAGNOSTIC_TEST|Laboratory analyses for the detection of iron deficiency anaemia|"Erythrocyte indices based on the preoperative complete blood count results will be calculated for each patient one day prior to surgical treatment.~Overall morbidity of each patient during hospital stay will be scored using the Comprehensive Complication Index (CCI). Intraoperative complications will be graded according to the ClassIntra classification of intraoperative adverse events. The quality of postoperative recovery of each observed patient will be scored on the first, second and fifth postoperative day, using the 15-item quality of recovery scale (QoR-15).~Data about red blood cell transfusion rate, all-cause infection rate, number of days when antibiotics were administered and the number of different antibiotics administered during hospital-stay will be collected."
215027694|NCT00205959|DEVICE|Locking proximal humerus plate|
215027695|NCT00205959|DEVICE|Proximal Humerus Internal Locking System|
215027696|NCT00205959|DEVICE|Proximal Humerus Nail|
215027697|NCT03410771|DRUG|Monitor antibiotic exposure (PK profile)|several plasma samples to measure drug exposure
215027698|NCT03410771|DEVICE|Bioelectrical impedance analysis to measure body composition|non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.
215027699|NCT02576626|DRUG|indacaterol/glycopyrronium 110/50 Breezhaler®|
215027700|NCT02576626|DEVICE|Placebo by Breezhaler®|
215027701|NCT02576626|DRUG|ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation|
215027702|NCT02576626|DEVICE|Placebo by nebulisation|
215027703|NCT00681070|OTHER|Arm 2: Absorbable sutures|use of absorbable catgut sutures in pediatric facial lacerations
215027704|NCT00681070|OTHER|Arm 1: non-absorbable sutures|Use of non-absorbing sutures
215027705|NCT01935947|DRUG|Azacitidine|Given SC
215027706|NCT01935947|DRUG|Azacitidine|Given PO
215027707|NCT01935947|DRUG|Docetaxel|Given IV
215027708|NCT01935947|DRUG|Entinostat|Given PO
215027709|NCT01935947|DRUG|Gemcitabine Hydrochloride|Given IV
215027710|NCT01935947|DRUG|Irinotecan Hydrochloride|Given IV
215027711|NCT01935947|OTHER|Laboratory Biomarker Analysis|Correlative studies
215027712|NCT01935947|DRUG|Pemetrexed Disodium|Given IV
215027713|NCT04696003|COMBINATION_PRODUCT|Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter|The amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intraamniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. and the amnioinfusion (about 100 ml/h, 2400 ml/day) with artificial amniotic fluid (Amnion Flush Solution, CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h under periodic ultrasound using the standard i.v. pump.
215027714|NCT00156195|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 months
215027715|NCT00156195|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 months
215027716|NCT04507763|DRUG|Etanercept|Patients with ankylosing spondylitis as provided in real world practice
215027717|NCT00626951|DEVICE|LMA Supreme|Extraglottic airway devices
215027718|NCT00626951|DEVICE|LMA ProSeal|
215027719|NCT05059275|PROCEDURE|modified ostium obstruction surgery|An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
215027720|NCT01146002|DRUG|Guanfacine (sustained release)|Treated with study drug once screening and initial testing is completed (see protocol above)
214424361|NCT00147277|DEVICE|Implantable Cardiac Defibrillator|Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
214509284|NCT03999788|PROCEDURE|lumbar puncture and blood withdrawal|lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening
215027721|NCT04183686|DRUG|ACT-1014-6470 (SAD)|Single dose of ACT-1014-6470; soft capsules for oral use.
215027722|NCT04183686|DRUG|ACT-1014-6470 (MAD)|Multiple doses of ACT-1014-6470; soft capsules for oral use.
215027723|NCT04183686|DRUG|Placebo (SAD)|Single dose of matching placebo; soft capsules for oral use.
215027724|NCT04183686|DRUG|Placebo (MAD)|Multiple doses of matching placebo; soft capsules for oral use.
215104729|NCT01085292|DRUG|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
215104730|NCT03248089|DIAGNOSTIC_TEST|Guardant360|Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.
215104731|NCT06128746|DEVICE|Repetitive Transcranial Magnetic Stimulation|1 Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
215104732|NCT06128746|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
215104733|NCT00004689|DRUG|amithiozone|
215104734|NCT00004689|DRUG|clarithromycin|
215104735|NCT00004689|DRUG|ethambutol|
215027725|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer|Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.
215027726|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer placebo|Single dose of matching placebo; soft capsules for oral use.
215027727|NCT04619849|DIAGNOSTIC_TEST|EMG|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
215027728|NCT04619849|DIAGNOSTIC_TEST|Palmaris Longus Test|Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
215027729|NCT00710619|DRUG|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
215104736|NCT00004689|DRUG|rifampin|
215104737|NCT00004689|DRUG|streptomycin|
215104738|NCT01616251|OTHER|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
215104739|NCT05574842|BEHAVIORAL|Double duty interventions using nutrition behavior change communication approach|The packages of the double-duty interventions were modified and adapted from the 2017 WHO policy brief report and Hawkes et al., 2020. These interventions are optimized strong education and nutrition behavior change communication focused on promotion of healthy diets (adequate adolescent nutrition, dietary diversity), physical activity (doing moderate intensity physical exercise, avoiding sitting for log time), prevent undue harm from energy-dense foods (avoiding Junk processed foods, avoiding fizzy sweetened drinks, street fast foods, chips, salt, sugar, fats etc.), and regulations on marketing foods from the customer side (e.g., buying of packed foods frequently).
215104740|NCT03897595|DEVICE|MPact Cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
215104741|NCT05118334|DRUG|Sintilimab|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
215104742|NCT05118334|DRUG|IBI310|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
215104743|NCT04456374|OTHER|Performance testing|Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.
215104744|NCT01211340|BEHAVIORAL|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
215104745|NCT00004274|DRUG|Estrogen|
215104746|NCT03755661|BEHAVIORAL|MI&TXT4MSM|brief in-person intervention followed by text messaging
215027730|NCT00710619|DRUG|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
215104747|NCT05614648|DRUG|Clonidine Micropellets|0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
215104748|NCT05614648|DEVICE|Tuohy epidural needle|18-gauge Tuohy epidural needle using a custom-built injector
215027731|NCT01021527|OTHER|Comparator: Treatment A|No Treatment
215027732|NCT01021527|DRUG|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
215027733|NCT01021527|DRUG|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
215027734|NCT01021527|PROCEDURE|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
215027735|NCT02174770|OTHER|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
215104749|NCT05047848|DRUG|Chidamide|chidamide 30mg orally，Biw
215104750|NCT05047848|DRUG|Fulvestrant|Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
215104751|NCT05612425|BEHAVIORAL|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
215104752|NCT05612425|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
215104753|NCT05659472|BEHAVIORAL|Combination mindfulness spiritual-based cognitive therapy plus hypnosis|The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis.
215027736|NCT02174770|OTHER|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
215027737|NCT03209765|OTHER|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
215027738|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
215027739|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
215027740|NCT03427619|DRUG|OK432|OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
215027741|NCT02196974|PROCEDURE|cryobiopsy|
215027742|NCT03113344|DRUG|cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
215027743|NCT03868696|PROCEDURE|MUA with sham ultrasound|Standard MUA with sham ultrasound
215027744|NCT03868696|PROCEDURE|MUA with active ultrasound|Standard MUA guided by ultrasound
215027745|NCT02003703|BIOLOGICAL|Recombinant Hepatitis B Virus Vaccine|
215027746|NCT02500108|DRUG|Domperidone|"Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.~Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).~Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date)."
215027747|NCT00425555|DRUG|Panobinostat|
215027748|NCT00684684|DEVICE|Chartis System|Assessment of airway flow and pressure
215027749|NCT03988218|BEHAVIORAL|perceptive tests|many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
215027750|NCT03208790|DRUG|Nigella sativa buccal tablets 10mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
215027751|NCT03208790|DRUG|Nigella sativa buccal tablets 5mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
215027752|NCT03208790|DRUG|Placebo buccal tablets|capsules with the same color and form as the active ones but without active ingredient will be given to the patients
215104754|NCT05659472|BEHAVIORAL|Mindfulness-based cognitive therapy|The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning.
215027753|NCT03064607|OTHER|Fluid collection|Fluids tested for biomarker S100beta
215027754|NCT04709523|PROCEDURE|bovine-derived xenograft with i-PRF|Bovine-derived xenograft was mixed with i-PRF and was placed in the augmentation site.
215027755|NCT04709523|PROCEDURE|bovine-derived xenograft alone|Bovine-derived xenograft was placed in the augmentation site.
215027756|NCT02150707|DRUG|Dipeptidyl-Peptidase IV Inhibitors|Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
215027757|NCT02150707|DRUG|Glucagon-Like Peptide 1|Glucagon-Like Peptide 1 to treat hyperglycaemia
215027758|NCT06167148|DEVICE|Biolase Epic X 940nm wavelength Diode laser|Participants were treated with Biolase Epic X 940nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (P3).
215027759|NCT06167148|DEVICE|Doctor smile simpler 980nm wavelength Diode laser|Participants were treated with doctor smile simpler 980nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (SP).
215027760|NCT06638749|DRUG|Tranexamic Acid|Administration of tranexamic acid
215027761|NCT06638749|DRUG|Normal Saline|Administration of normal saline
215027762|NCT05763381|DEVICE|Photobiomodulation Therapy (PBMT)|Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.
215027763|NCT05763381|DEVICE|Sham-Photobiomodualtion Therapy (Sham-PBMT)|Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
215027764|NCT06638359|BEHAVIORAL|moderate exercise|moderate exercise for 47 minutes
215027765|NCT06638359|BEHAVIORAL|interval exercise|interval exercise for 28 minutes
215027766|NCT06638359|BEHAVIORAL|Control (placebo) group|without exercise
215027767|NCT06564350|DEVICE|IMU (Inertial Measurement Unit) sensors|IMU sensors track an object's acceleration and angular velocity over time and do not emit any electromagnetic fields or radiation. They use tiny masses and springs to measure the acceleration, as well as Hall effect materials to measure the magnetic fields. The force sensor changes its electric resistor value based on the force applied to the sensor surface.
214509285|NCT03999788|PROCEDURE|Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity|iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
214509286|NCT04910204|OTHER|FES Therapy combined with task-specific training (FEST+TST)|The FEST+TST protocol consists of a 1-hour session, 3 to 5 days a week, for up to 12 weeks (40 sessions total) in addition to conventional occupational and physical therapies according to the standard of care.
214509287|NCT00977249|BEHAVIORAL|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
214509288|NCT00977249|DRUG|varenicline|
214509289|NCT00977249|DRUG|placebo|
214509290|NCT00808496|OTHER|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
214509291|NCT00808496|OTHER|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
214509292|NCT00808496|OTHER|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
214509293|NCT05193799|DEVICE|Investigational devices must be used 8 hours per day|During 3 consecutive days
214509294|NCT00002235|DRUG|Indinavir sulfate|
214509295|NCT00002235|DRUG|Nelfinavir mesylate|
214509296|NCT00002235|DRUG|Efavirenz|
214509297|NCT01128959|DRUG|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
214509298|NCT03830320|DRUG|[64Cu]FBP8|Injection of Copper-64 radiopeptide to detect thrombosis
214509299|NCT03830320|DEVICE|PET/MR|Whole body imaging using Siemens mMR PET/MR scanner
214509300|NCT03830320|PROCEDURE|Blood Collection|A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
214509301|NCT03830320|PROCEDURE|Electrocardiogram|A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
214509302|NCT02338999|RADIATION|PET/CT|The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.
214509303|NCT02338999|DRUG|Pioglitazone|Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.
214509304|NCT02338999|DRUG|Placebo|
214509305|NCT05077670|PROCEDURE|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy.
215027768|NCT06001255|DRUG|HS-20093|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
215027769|NCT06639802|OTHER|Hand Arm Bimanual Intensive therapy including lower extremity (HABIT-ILE)|HABIT-ILE is continuous intervention applied for 50-90 hours over two weeks. We will design the activities based on the findings of the initial assessments (T0) and the customized functional goals that were previously discussed with the parents (e.g., drinking on one\&#39;s own without spilling, using one hand to hold a book while turning pages with the other, removing a t-shirt, etc.). HABIT-ILE activities are presented as games and the whole environment is arranged in such a way that children perceive the therapy as fun. Progression of difficulty depend upon success in performance of current level. Specific bi-manual activities are selected on basis of child's motor abilities, age and interest.
215027770|NCT06637202|RADIATION|postoperative radiotherapy|50 Gy in 25 fractions
215027771|NCT06640621|DRUG|Different concentration of ropivacaine for single brachial plexus block|40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.
215027772|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Microencapsulated Magnesium|Volunteers will be provided with the product Microencapsulated Magnesium. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
215027773|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Oxide|Volunteers will be provided with the product Magnesium Oxide. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
215104755|NCT02277119|DEVICE|Maestro|OCT machines used for diagnostic purposes
215104756|NCT02277119|DEVICE|iVue|OCT machines used for diagnostic purposes
214509306|NCT05077670|DEVICE|Atrial substrate mapping|Electro-anatomical maps will be performed with CARTO navigation system with multi-electrode catheters.
214509307|NCT03142867|OTHER|non-applicable|non-applicable
214509308|NCT01683669|OTHER|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
215104757|NCT03144986|DEVICE|Deep Insula-coil rTMS|Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
215104758|NCT02193308|DRUG|Telmisartan/Amlodipine FDC|
215104759|NCT02193308|DRUG|Telmisartan|
215104760|NCT02193308|DRUG|Amlodipine|
215104761|NCT02469519|DRUG|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
215104762|NCT02469519|OTHER|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
215104763|NCT01494597|DRUG|isavuconazole|oral
215104764|NCT01494597|DRUG|cyclosporine|oral
215104765|NCT01631097|DRUG|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
215104766|NCT00028236|DRUG|Gene-Transduced Autologous CD34+ Stem Cells|
215104767|NCT05597553|OTHER|Premixed MTA|The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal
215027774|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Citrate|Volunteers will be provided with the product Magnesium Citrate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
215104768|NCT05597553|OTHER|Powder/liquid MTA|Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.
215027775|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Bisglycinate|Volunteers will be provided with the product Magnesium Bisglycinate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
215027776|NCT06197581|RADIATION|Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)|Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.
215104769|NCT06145958|DRUG|Luteinising Hormone-Releasing Factor Analogue|Androgen Deprivation Therapy
215104770|NCT02381340|DEVICE|ACE stapling procedure|Endoscopic trans-oral gastroplication
215104771|NCT00829959|BEHAVIORAL|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
215104772|NCT01750905|DRUG|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
215104773|NCT01750905|DRUG|Placebo|Vehicle (D5W) SQ
215104774|NCT02215005|DRUG|Telmisartan|
215104775|NCT02215005|DRUG|Ramipril|
215104776|NCT03662516|DRUG|PF-04965842|Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
215104777|NCT03662516|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
215104778|NCT00532506|DRUG|SK-0403|
215104779|NCT00562991|DEVICE|measurement of exhaled NO is used to guide treatment|exhaled NO
215104780|NCT00683839|BEHAVIORAL|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
215104781|NCT01108198|DRUG|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
215104782|NCT01108198|DRUG|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
215104783|NCT02242383|DRUG|Telmisartan|
215104784|NCT02242383|DRUG|Telmisartan in combination with hydrochlorothiazide|
215104785|NCT03588936|DRUG|Nivolumab (.25 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
215104786|NCT03588936|DRUG|Tocilizumab|Participants will receive 2 doses of tocilizumab
215104787|NCT03588936|DRUG|Nivolumab (.5 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
215104788|NCT05894811|DIAGNOSTIC_TEST|oral glucose tolerance test|Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.
215104789|NCT05894811|DIAGNOSTIC_TEST|MRI|Using MRI to quantify of fat content in the liver and pancreas of the subjects
215104790|NCT02331017|BEHAVIORAL|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
215104791|NCT04071418|RADIATION|3D-printing Template-assisted CT-guided I-125 Seeds Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seeds implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume; Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc. Regular follow-up was conducted after treatment.
215104792|NCT00219778|DRUG|mifepristone|
215104793|NCT05084092|RADIATION|Intraoperative Radiotherapy (IORT)|If biopsy is positive, local treatment with IORT will be performed. After IORT (15,40 Gray at 2 mm dept), the applicator will be removed and surgery will be continued in a standard fashion.
215104794|NCT05084092|PROCEDURE|Brain surgery|Surgery should be performed according to the local standard of care, preferentially as image-(neuronavigation) guided surgery. To establish the diagnosis of a metastasis and to exclude primary CNS tumors, lymphomas, SCLCs or germinomas it will be performed a peroperative biopsy
215104795|NCT02072369|OTHER|VAEDA Glove|Voice And EMG-Driven Actuated glove used during training
215104796|NCT02072369|OTHER|Occupational Therapy|novel upper extremity occupational therapy focused on the hand
215104797|NCT04478448|DRUG|Flupirava|1 tablet contains 200 mg Favipiravir
215104798|NCT04478448|DRUG|Avigan|1 tablet contains 200 mg Favipiravir
215104799|NCT06031363|DRUG|Indomethacin Suppository|Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
215027777|NCT04632654|BEHAVIORAL|A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)|A total of 7 weekly intervention sessions will occur in a period of 6 weeks. Week 0 is a setup session conducted at the participant's home, including equipment set up, safety instruction, personalized exergame prescription development, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 1 and 2 are coaching sessions delivered by the interventionist using the FaceTime application in iPad, including exergame minutes and prescription review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Week 3 is a progress session conducted at the participant's home. The personalized exergame prescription will be adjusted. This session also will include exergame minutes review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 4 and 5 are the same as weeks 1 and 2. Week 6 is the final session. Exergame platform will be picked up at the participant's home.
215027778|NCT06636695|DEVICE|Cellular Matrix|Group 1 (Cellular Matrix): Patients randomized to this group will be treated with two intra-articular injections of Cellular Matrix at D0 and M1.
215027779|NCT06636695|DEVICE|Orthovisc|Group 2 (HA): Patients randomized to this group will be treated with two intra-articular injections of HA alone provided by ORTHOVISC at D0 and M1
215104800|NCT00258323|DRUG|cisplatin|20mg/m2d/IV continuous infusion x days
215104801|NCT00258323|DRUG|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
215104802|NCT00258323|DRUG|Iressa|250mg po qd days 1-28 then x 2 years
215104803|NCT00258323|PROCEDURE|conventional surgery|conventional surgery
215104804|NCT00258323|RADIATION|radiation therapy|150 cGy bid
215104805|NCT05399290|DRUG|Doxycycline Hyclate|100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
215104806|NCT05940818|BEHAVIORAL|the intensive oral care|the intensive oral care
215104807|NCT00000643|DRUG|Pyrimethamine|
215104808|NCT00000643|DRUG|Leucovorin calcium|
215104809|NCT03665272|PROCEDURE|deepithelialized gingival graft fixation|one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.
215104810|NCT02607111|DRUG|Dalteparin|
215104811|NCT00771888|DRUG|lanreotide|lanreotide
215104812|NCT06330480|OTHER|Intervention group|Subjects will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2), that includes collection of physical data, blood, and urine for the assessment of parameters that are indicative of cardiovascular disease, chronic kidney disease, diabetes type 2 or their risk factors. Participants will also receive a questionnaire. Based on the results of the diagnostic screening, participants may be referred to their GP for appropriate treatment according to the prevailing guidelines (phase 3)
215104813|NCT04299035|PROCEDURE|Erector spinae plane block|Erector spinae plane block
215104814|NCT05687162|BEHAVIORAL|Overcoming Loneliness three-week intervention|A self-guided online loneliness intervention with three 10-20 minute sessions. The intervention content draws heavily from Internet Cognitive Behavioral Therapy for Loneliness and follows the form of single-session mental health interventions.
215104815|NCT05687162|BEHAVIORAL|Overcoming Loneliness single-session intervention|The Overcoming Loneliness Three-Week Intervention condensed into a single-session intervention lasting 20-30 minutes.
215104816|NCT05687162|BEHAVIORAL|"Single-session Sharing Feelings program"|"A self-guided online supportive therapy intervention with a single 20-30 minute session intended to encourage users to share feelings with close others. Slightly modified from the Sharing Feelings intervention"
215104817|NCT05687162|BEHAVIORAL|The Blu Surfer program: a popular online content-based intervention for psychological distress|The Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to mental health. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
214509309|NCT01683669|OTHER|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
214509310|NCT05044416|DEVICE|VieScope|intubation with VieScope laryngoscope
214509311|NCT05044416|DEVICE|Videolaryngoscopy|intubation with videolaryngoscope
214509312|NCT01044446|DRUG|Icodextrin|one exchange daily
215027780|NCT06638827|PROCEDURE|Thoracic Sympathectomy|"Bilateral thoracoscopic sympathectomy will be performed with general anesthesia, using single lung ventilation and monopolar cautery for transection of the sympathetic chain.~Persons with PFH who underwent the BTS were classified into three groups, depending the level of transaction of sympathetic chain:~1. transection at the level from the second to the forth thoracic sympathetic ganglion (T2- T4);~2. transection at the level from the third to the forth thoracic sympathetic ganglion (T3-T4)~3. transection at the level from the second to the third thoracic sympathetic ganglion (T2-T3).."
215104818|NCT05687162|BEHAVIORAL|The Action Brings Change (ABC) Program (TEAM Lab version)|The ABC project is a 20-30-minute SSI for teens based on behavioral activation. It was found to be efficacious for reducing depression, anxiety, hopelessness, and self-hate and increasing perceived control and agency in youth (link to SSI: https://osf.io/ch2tg/, license: http://creativecommons.org/licenses/by-nc-sa/4.0/). The researchers modified the phrasing in the intervention to make it more relevant to both teens and adults, as the original was designed for only teens.
215104819|NCT05687162|BEHAVIORAL|Online help-seeking as usual|"This intervention, created by the present research team, aims to emulate how one might find support on their own using the internet. In this condition, participants are asked to browse the internet for 25 minutes to find popular online content relevant to their personal struggles and create an annotated list of links to the content they find useful. The intervention is similar to a self-study condition, which found self-study and a video intervention equally increased mental health knowledge. The survey platform provides text entry boxes to help each participant create their guide and then provides a text version of their guide for them to keep."
215104820|NCT05687162|BEHAVIORAL|The Lonely Blu Surfer program: a popular online content-based intervention for loneliness|The Lonely Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to loneliness. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
215104821|NCT05687162|BEHAVIORAL|Overcoming loneliness SSI 8-minute version|A shortened version of an online self-guided intervention based on principles of CBT for loneliness. The research team created this intervention by cutting lengthy didactic material and exercises from the 23-minute version, while maintaining its core concepts.
215104822|NCT00962325|BEHAVIORAL|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
215104823|NCT02453503|DRUG|Licorice|licorice mucoadhesive films evey 6 hours for two weeks
214509313|NCT01044446|DRUG|glucose-based peritoneal dialysate|original exchange frequency
214509314|NCT02441374|DEVICE|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
215104824|NCT02453503|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
215104825|NCT05987696|DRUG|CD33/CLL1 dual CAR-NK cell|NK cell therapy
214509315|NCT02441374|OTHER|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
215104826|NCT05987696|DRUG|Cyclophosphamid|Lympho-conditioning Agent
215104827|NCT05987696|DRUG|Fludarabine|Lympho-conditioning Agent
215104828|NCT05987696|DRUG|Cytarabine|Lympho-conditioning Agent
215104829|NCT05987696|DRUG|CD33 CAR-NK cell|NK cell therapy
215104830|NCT05987696|DRUG|super NK cell|NK cell therapy
215104831|NCT01992835|OTHER|Grass pollen allergen extract|Each subject will be challenged with a grass pollen allergen extract and with placebo.
215104832|NCT01992835|OTHER|placebo|
215104833|NCT05349786|OTHER|Physical activity program|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. After the data obtained in the pre-test, the pedometers, which were calibrated and checked by the researchers, were delivered to the patients. At the end of each day of walking with pedometer monitoring, they were asked to record data such as the number of steps, walking hour, walking time, distance and complaints encountered during walking on the walking monitoring chart given to the patient by the researchers. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
215104834|NCT06271889|DEVICE|Non-stress test|It will be performed with the HUNTLEIGH brand BD4000XS-2 model NST device located at the maternity clinic to listen to the fetal heart sound, approximately min 3 max 5 min will be listened to. According to the studies conducted in the literature, the half-life of adrenaline in plasma is 3 minutes when an invasive/noninvasive intervention is performed on an adult individual. Therefore, the fetal heart rate will be listened to for 3 minutes (Dalal \& Grujic; 2021; https://www.medicines.org.uk/emc/product/6284/smpc#gref https://www.ncbi.nlm.nih.gov/books/NBK482160 / )
214509316|NCT04334252|OTHER|Questionnaire|Questionnaire
214509317|NCT05848856|BEHAVIORAL|Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up|Study of different types of risk-informed screening approaches and the measurement of patient compliance with screening recommendations based on different approaches to patient engagement
214509318|NCT03360617|DEVICE|Syringe IV Push over 2-3 minutes|IV antibiotics will be administered by Syringe IV Push over 2-3 minutes
214509319|NCT03360617|DEVICE|Piggyback over 30 minutes|IV antibiotics will be administered by IV Piggyback over 30 minutes.
214509320|NCT06260059|DRUG|Empagliflozin 10 MG|Patient will be given 10 mg of Empagliflozin if randomized to the drug arm or will receive placebo drug for 1 year
214509321|NCT06260059|DRUG|Placebo|To patients randomized to the placebo group, a placebo pill will be given
214509322|NCT06169566|DIETARY_SUPPLEMENT|synbiotics|synbiotics
214509323|NCT06169566|COMBINATION_PRODUCT|placebo|placebo
215104835|NCT05921565|BEHAVIORAL|Interventional Behavioral Arm|All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
215104836|NCT06335316|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
215104837|NCT06335316|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)
215104838|NCT06335316|BEHAVIORAL|Comprehensive therapy|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
214509324|NCT05491291|OTHER|Patients with chronic wound of the lower limbs|The rating scale will be passed at three different times, day 1, day 15 and day 75.
214509325|NCT04778813|DRUG|Artemether-lumefantrine|In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
214509326|NCT04437004|DRUG|Fenfluramine|The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.
214509327|NCT02748200|RADIATION|external beam radiotherapy (EBRT)|EBRT: 3 dose escalation levels
214509328|NCT06200090|OTHER|No intervention|No intervention
215104839|NCT06335316|BEHAVIORAL|placebo|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Only normal saline was used
215104840|NCT01248741|RADIATION|HDR prostate brachytherapy|"HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a boost combined with external beam radiotherapy"
215104841|NCT02243735|DRUG|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
215104842|NCT02243735|DRUG|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
215104843|NCT04066478|DRUG|Dehydroepiandrosterone|75mg Dehydroepiandrosterone daily
215104844|NCT04066478|DRUG|Placebo|Placebo
215104845|NCT03949608|OTHER|E-learning|"The intervention consists of the presentation and installation of an internet tool to educate the patient about his heart condition and about his medications in addition to usual care. The tool is an interactive web-hosting video called Mon Coeur, mon BASIC adaptable to smartphones and tablets. The total length of the video is around 15 minutes. The e-learning is interactive because of the possibility to click in the video to have more details about a particular point. The tool includes a part about the heart and particularly about the ACS (physiopathology, diagnosis, coronarography, angioplasty). A second part includes an education about the medications prescribed. The patient will select the medication being prescribed and receive information about it."
215104846|NCT01564147|OTHER|immediate therapeutic education|Access to the course of immediate therapeutic education
215104847|NCT01564147|OTHER|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
215104848|NCT04878965|DEVICE|Smartwatch|Smartwatch apparatus to measure strong emotions (e.g., anxiety)
214509329|NCT04082598|DRUG|Amoxicillin Clavulanate|tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
214509330|NCT04082598|DIETARY_SUPPLEMENT|Bifidobacterium longum and Lactoferrin|
214509331|NCT01883063|DEVICE|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
214509332|NCT01883063|DEVICE|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
214509333|NCT01535898|OTHER|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
214509334|NCT00644306|DRUG|Thalidomide|100 mg/day continuously for 18 months
214509335|NCT00644306|DRUG|melphalan, prednisone|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
214509336|NCT00644306|DRUG|melphalan, prednisone, thalidomide|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
214509337|NCT06510959|OTHER|Digital course|The course aims to enhance participants' digital skills concerning the use of smartphones, specifically focusing on daily utility apps such as email apps, eGov apps, mobility apps, etc. The course is structured into the following ten 90-minute weekly lessons.
214509338|NCT05731206|OTHER|Hydrolyzed protein infant formula|Hydrolyzed protein infant formula
215027781|NCT06644677|DIAGNOSTIC_TEST|HPV integration|Collect late-stage cervical cancer (Stage IIIB and beyond) and post-treatment recurrence and metastasis specimens (TCT, tissue) associated with HPV infection. Utilize third-generation nanopore technology to detect the integration sites of HPV DNA based on the principle of probe hybridization capture. Obtain information on HPV integration and hot spot genes in the samples. By analyzing the integration of HPV in primary and recurrent/metastatic tissues, identify insertions and gene alterations associated with recurrence/metastasis, and develop a predictive formula.
215027782|NCT01674062|DRUG|Pertuzumab|Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
215027783|NCT01674062|DRUG|Trastuzumab|2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
215027784|NCT01881932|DEVICE|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
215027785|NCT01881932|DEVICE|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
215027786|NCT01248819|DRUG|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
215027787|NCT01248819|DRUG|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
215027788|NCT04569825|DRUG|Ophtamesone|local application intranasally as drops
215027789|NCT01443026|DRUG|Lycopene 30mg|Lycopene 30 mg.
215027790|NCT01443026|DRUG|Placebo|Placebo
215027791|NCT00738660|DRUG|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
215027792|NCT00581919|DRUG|Bort, Dex, and Dox with ALCAR|Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
215027793|NCT06569745|OTHER|Verbal Explanation|In the verbal explanation group, a researcher wearing white coat provided oral and dental health education for 3 minutes using a jaw model
215027794|NCT06569745|OTHER|Animation Video Display|"In the animation group, oral and dental health education was presented to the children in the form of a cartoon lasting 1 minute and 17seconds. The animation video was created by the researcher using the test version of www.vyond.com. The animation featured a character voiced by one of the researchers, informative texts, and background music. The character conveyed information about oral and dental health education, using both voice and text content."
215027795|NCT06569745|OTHER|Peer-Led Reels Video Display|In the peer-led reels group, oral and dental health information was presented for 1 minute using a video created on the Instagram platform. The video showed oral hygiene information being provided to a child of a similar age to the target audience with the child then demonstrating the behaviour with music in the background. The video included some text, but did not feature the child's voice or information.
215027796|NCT05651490|BEHAVIORAL|Problem Solving Treatment for Diabetes|"In the introductory session, the structure of and rationale behind PST-D will be explained. The specialist will work with the participant to develop a problem list related to diabetes self-management and smoking cessation, if applicable.~During the weekly sessions, the participant will be taught and guided through the seven steps of problem solving:~1. Clarifying and defining the problem~2. Setting a realistic goal~3. Brainstorming multiple solutions~4. Generating pros and cons for each solution~5. Evaluating and choosing a preferred solution~6. Developing a specific action plan to implement the solution~7. Evaluating outcomes from the previous session.~Participants will also plan to engage in at least 1 enjoyable activity daily during the week.~The number of sessions will differ based on the specialist's assessment of the participant's problem-solving skills.~Maintenance sessions will be delivered monthly across 3 months in order to follow-up with participants."
215027797|NCT05651490|BEHAVIORAL|Attention Control Group|During the sessions, the healthcare practitioners will provide general information and recommendations on general health topics such as oral health, hearing loss, sleep, dementia, adult vaccination, influenza, and dengue fever. Participants will also be given handouts adapted from government agencies and/or public bodies, such as HealthHub, National Health Service, National Addictions Management Service, and National Environmental Agency, on these topics. The healthcare practitioners will avoid discussing topics related to diabetes, diet, physical activity, and medication.
215104849|NCT00003712|DRUG|temsirolimus|"•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.~The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.~•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II."
215104850|NCT02227667|DRUG|MEDI4736|Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
215104851|NCT00924768|BIOLOGICAL|20K EU CCRE|Inhalation of CCRE
215104852|NCT00791089|DRUG|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
215104853|NCT00791089|DRUG|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
215104854|NCT00791089|OTHER|placebo|Control group will receive placebo before \& after ablation.
215104855|NCT02815592|DRUG|BMS-986012|
215104856|NCT02815592|DRUG|Cisplatin|
215104857|NCT02815592|DRUG|Etoposide|
215104858|NCT02815592|DRUG|Platinum|
215104859|NCT02815592|DRUG|Carboplatin|
215104860|NCT04596748|DIETARY_SUPPLEMENT|Probiotic|Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
215104861|NCT04596748|DIETARY_SUPPLEMENT|Placebo|Placebo caps
215104862|NCT02474602|DEVICE|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
215104863|NCT04832191|DEVICE|CE-SM|contrast enhanced spectral mammography \&contrast enhanced magnetic resonance imaging
215104864|NCT03234413|DRUG|Botulinum toxin type A|Botulinum toxin type A
215104865|NCT05099835|DRUG|Botox|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
215104866|NCT05099835|DRUG|triamcinolonacetonide|triamcinolonacetonide stellate ganglion injection
215104867|NCT04340544|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
215104868|NCT04340544|DRUG|Placebo|Placebo capsules
215104869|NCT05344586|OTHER|Hamstring stretching program with neural load|Participants will perform a hamstring stretch with neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, different tension parameters will be added in the following order (the next parameter shall not be introduced until the previous one has been exhausted): ankle dorsiflexion, cervical and craniocervical flexion, and hip flexion.
215104870|NCT05344586|OTHER|Hamstring stretching program without neural load|Participants will perform a hamstring stretch without neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, tension will be added by flexing their hip, keeping their ankle relaxed and their spine neutral.
215104871|NCT00325117|DRUG|Vildagliptin|
215104872|NCT05253885|DEVICE|Smartphone use|"* Smartphone addiction scale (short version) higher than 33~* Smartphone users of 4-5 inches screen size smartphones, weighing 140-160 grams and dimensions less than 159\*79\*9 mm."
215104873|NCT01768364|DRUG|Trimetoprim-Sulfa (Bactrim)|
215104874|NCT01768364|OTHER|No antibiotics|
215104875|NCT02032498|DRUG|Indocyanine Green|Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
215104876|NCT03521141|DRUG|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
215104877|NCT03521141|DRUG|Varenicline|FDA-approved smoking cessation pharmacotherapy
215104878|NCT03521141|GENETIC|Nicotine metabolism|Information on nicotine metabolism will be used to inform selection of medication.
215104879|NCT03521141|GENETIC|Genetically-informed lung cancer risk score|This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
215104880|NCT03521141|BEHAVIORAL|"NCI Clearing the Air"|A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
215104881|NCT04379492|DRUG|Hydroxychloroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
215104882|NCT04379492|OTHER|Placebo|Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.
215104883|NCT03851159|DIETARY_SUPPLEMENT|Nyaditum resae®|Heat-killed Mycobacterium manresensis
215104884|NCT03851159|OTHER|Mannitol|Placebo
214509339|NCT05731206|OTHER|commercially available hypoallergenic infant formula|commercially available hypoallergenic infant formula
214509340|NCT04865718|DIAGNOSTIC_TEST|ICGA imaging|subjects undergoing intraoperative ICGA imaging
214509341|NCT03451461|OTHER|No intervention|Observational study. Clinical data recorded
215104885|NCT03335774|DRUG|Hydrocortisone Acetate Suppository, 25 mg (Nivagen)|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
215104886|NCT03335774|DRUG|Placebo (Vehicle) Suppository (Nivagen)|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
214509342|NCT01596686|DRUG|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
214509343|NCT01337752|DRUG|BHQ880|
214509344|NCT01337752|DRUG|BHQ880 Placebo|Intravenous infusion
214509345|NCT01337752|DRUG|bortezomib|intravenous injection
214509346|NCT01337752|DRUG|dexamethasone|Oral
214694258|NCT01693458|BEHAVIORAL|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
215027798|NCT02655601|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
215027799|NCT02655601|RADIATION|Radiation Therapy|RT will be delivered in daily fractions of 1.8-2 Gy given 5 days a week for 6 weeks for a total of 59.4-60 Gy.
215027800|NCT02655601|DRUG|Temozolomide|Initially, temozolomide (TMZ) will be dosed at 75 mg/m2 orally daily for 42 days. Two weeks after the completion of chemoradiation, patients will transition to adjuvant chemotherapy with TMZ dosed at 150-200 mg/m2 orally for 5 days of a 28-day cycle for a total of 12 cycles.
215027801|NCT00916526|PROCEDURE|bronchial provocation test with mannitol|"Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~1. Apply nose clip and subject should be directed to breathe through the mouth~2. Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~3. The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~4. At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~5. At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~6. Insert 5 mg capsule into inhalation device, and proceed as above~7. Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered."
215027802|NCT03523663|OTHER|no intervention. measure eye movement data|
215027803|NCT01600651|OTHER|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
215027804|NCT01600651|OTHER|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
215027805|NCT02398799|BEHAVIORAL|Psychoeducational support|"The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.~Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort."
215027806|NCT00778401|DRUG|Gabapentin tablets 800 mg|
215104887|NCT04561258|BIOLOGICAL|AGT103-T|An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells
215104888|NCT04936815|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography for the detection of congenital or acquired structural heart disease.
215104889|NCT04685265|DRUG|anle138b|capsule containing excipient and anle138b
215104890|NCT04685265|DRUG|Placebo|matching placebo capsule containing excipient
214509347|NCT02958553|DEVICE|emPOWER Ankle|The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
214509348|NCT02958553|DEVICE|Subject's own passive prosthesis|Devices will vary. Data gathered will form a baseline.
214509349|NCT03014791|OTHER|Brief lifestyle/medical history questionnaire|Core Measurement
214509350|NCT03014791|OTHER|Anthropometric measures|Core Measurement
214509351|NCT03014791|OTHER|Blood pressure and arterial stiffness|Core Measurement
214509352|NCT03014791|OTHER|Cardiac output and lung function|Core Measurement
214509353|NCT03014791|OTHER|Heart rate variability|Core Measurement
214509354|NCT03014791|OTHER|Blood sample & spot urine sample|Core Measurement
214509355|NCT03014791|OTHER|24 hour ambulatory blood pressure monitor|Detailed Measurement (Optional for participants).
214509356|NCT03014791|OTHER|24 hour urine collection|Detailed Measurement (Optional for participants).
214509357|NCT03014791|OTHER|Echocardiograph: Left ventricular mass|Detailed Measurement (Optional for participants).
214509358|NCT03014791|OTHER|Large artery structure: Carotid intima-media thickness|Detailed Measurement (Optional for participants).
214509359|NCT03014791|OTHER|Small artery structure: Minimum forearm vascular resistance|Detailed Measurement (Optional for participants).
214509360|NCT03014791|OTHER|Large artery endothelial function|Flow- and salbutamol-mediated vasodilatation Detailed Measurement (Optional for participants).
215027807|NCT02209675|OTHER|liver biopsy|C4d assessment by immunohistchemistry in liver biopsy
215104891|NCT04206371|DIAGNOSTIC_TEST|Defibrillator threshold testing|Under general or local anesthesia. Induction of Ventricular Fibrillation or R-wave synchronized shock
215027808|NCT00200746|DRUG|Arginine|Amino Acid Arginine
215027809|NCT00802503|DIETARY_SUPPLEMENT|SPN|SPN : in the treated group, SPN is started if at day 4 energy input by EN is \< 60% of energy target in order to reach 100% of energy target by peripheral or central line.
215027810|NCT01177358|DRUG|Botulinum Toxin Type A|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy."
215027811|NCT01177358|DRUG|Normal Saline|0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
215027812|NCT05029388|OTHER|Aerobic Exercise|The participants will complete three training sessions per week over 10 weeks. The aerobic training program will last for one hour. The session will include a 10-minute warm-up period, followed by a 45-minute aerobic workout, wherein the participants can choose to use either a treadmill, a cycle ergometer, or a rowing ergometer. After the workout, a five-minute period of stretching will be provided for cooling down. The intensity during the workout will be set at 40%-55% of the individual's maximum heart rate.
215027813|NCT05029388|OTHER|High Intensity Interval Training|The intervention will be conducted over a period of 10 weeks, while the participants will complete three training sessions per week. The HIIT training program will last for 30 minutes. The session will include a 10-minute warm-up period, followed by a 15-minute HIIT workout, and a 5-minute period of stretching to cool down. The exercises will include repeated, high-intensity intermittent bursts of vigorous activity at maximal effort. The HIIT will mainly include bodyweight exercises (e.g., push-ups, squats, lunges) that disregards equipment usage. The intensity during the workout will be set to 85%-95% of the individual's maximum heart rate. A half-day training workshop will be provided to the personal trainer to ensure that he/she knows the exercises and can demonstrate them to the participants.
215104892|NCT01994265|DRUG|Warfarin|Warfarin once daily, at fast, targeting INR between 2 and 3
215104893|NCT01994265|DRUG|Dabigatran|
215104894|NCT02089074|BEHAVIORAL|Drug use counselling|
215104895|NCT00003505|DRUG|antineoplaston A10|
215104896|NCT00003505|DRUG|antineoplaston AS2-1|
215104897|NCT00003505|PROCEDURE|alternative product therapy|
214509361|NCT03014791|OTHER|Small artery endothelial function: Forearm blood flow|Detailed Measurement (Optional for participants).
214509362|NCT03014791|OTHER|Dundee step test|Systolic blood pressure response to submaximal exercise Detailed Measurement (Optional for participants).
214509363|NCT03014791|OTHER|Detailed haemodynamic response to submaximal exercise|Detailed Measurement (Optional for participants).
214509364|NCT03014791|OTHER|Cardiopulmonary fitness: Maximum oxygen consumption|Detailed Measurement (Optional for participants).
214509365|NCT03014791|OTHER|Haemodynamic response to mental stress|Detailed Measurement (Optional for participants).
214509366|NCT03014791|OTHER|Small artery dilatory function: Forearm blood flow|Detailed Measurement (Optional for participants).
215027814|NCT05197374|DRUG|Estradiol Valerate 4mg|Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
215104898|NCT00003505|PROCEDURE|biological therapy|
215104899|NCT00003505|PROCEDURE|biologically based therapies|
215104900|NCT00003505|PROCEDURE|cancer prevention intervention|
215104901|NCT00003505|PROCEDURE|complementary and alternative therapy|
215104902|NCT00003505|PROCEDURE|differentiation therapy|
215104903|NCT01598909|DRUG|Arnica|Application of Arnica ointment periorbitally
215104904|NCT01598909|DRUG|Placebo ointment|Application of Arnica ointment, twice a day, for the period of one week.
215104905|NCT04804163|DEVICE|telesurgery by domestic robot|telesurgery of the upper urinary disease by domestic robot
215104906|NCT02915042|DRUG|Dexmedetomidine|Analgesic Efficacy
215104907|NCT02915042|DRUG|Placebo|Saline placebo
215104908|NCT03719742|OTHER|Sponsor Test Products|Baby Bee Foaming Cleanser(at least once daily but not more than twice daily), BB Baby Ultra Gentle Lotion (Once immediately after cleansing and again approximately 10-12 hours after cleansing)
214509367|NCT03111368|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
214509368|NCT01247077|OTHER|selenium|200 ug selenium once daily
214509369|NCT01247077|OTHER|placebo|
214509370|NCT03004989|BEHAVIORAL|Programme|The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important
214509371|NCT04009772|DRUG|Cefepime|Antibiotic prophylaxis
215027815|NCT06152926|OTHER|Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions|"People diagnosed with a urological cancer receiving Immune checkpoint inhibitor treatment at a single centre trust will be invited to either face to face or online video-conference individual interviews (Microsoft teams) according to participant preference.~Consenting participants will be interviewed via semi-structured interview methods round a topic guide and audio-recorded. Inductive thematic analysis will be conducted to explore participant experiences and perceptions of physical activity and exercise."
215027816|NCT01603368|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
215027817|NCT01603368|DIETARY_SUPPLEMENT|Placebo|Oil drops without Lactobacillus reuteri
215027818|NCT01873508|DRUG|RO4917523|Fast release MR capsule, single dose
215027819|NCT01873508|DRUG|RO4917523|Target release MR capsule, single dose
215027820|NCT01873508|DRUG|RO4917523|Slow release MR capsule, single dose
215027821|NCT01873508|DRUG|RO4917523|\[13C\]-labeled tracer dose i.v.
215104909|NCT00852865|DRUG|Lactobacillus farciminis|1 capsule per day. Each capsule containing 4\*109 CFU
214509372|NCT04009772|DRUG|Cefuroxime plus Metronidazole|Antibiotic prophylaxis
214509373|NCT03090698|DRUG|Hylan G-F 20|intra-articular administration
214509374|NCT03090698|DRUG|Triamcinolone|Intra-articular administration
214509375|NCT00308308|DRUG|Technosphere Insulin|Inhalation, 15U/30U
214509376|NCT00308308|DRUG|Active comparator|sc injectable insulin
214509377|NCT00120549|PROCEDURE|Assisted embryo hatching|
214509378|NCT01319032|OTHER|Extraction of whole blood|Extraction of DNA from whole blood
214509379|NCT03682614|DRUG|HCG|we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.
214509380|NCT03682614|OTHER|culture medium|The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
214509381|NCT05659394|OTHER|Standard Wound Care Alone|gold standard compression therapy
214509382|NCT05659394|DEVICE|Stand Wound Care plus IPC|gold standard compression therapy plus IPC (WoundExpress)
214509383|NCT01686152|DRUG|Imiquimod Cream, 3.75%|
214509384|NCT01686152|DRUG|Zyclara®|
215027822|NCT05725434|BIOLOGICAL|CT-P47 AI (tocilizumab)|CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2
214509385|NCT01686152|OTHER|Vehicle of Test Product|
214509386|NCT02194907|BEHAVIORAL|Brain activity training - anterior insula|training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain
215027823|NCT05725434|BIOLOGICAL|CT-P47 PFS (tocilizumab)|CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
215027824|NCT03829683|DRUG|Vitamin C|200mg/kg/24hours
215104910|NCT00852865|DRUG|Placebo|1 capsule per day
214509387|NCT02194907|BEHAVIORAL|Brain activity training - medial prefrontal cortex|training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain
214509388|NCT04784988|DRUG|EHL-FVIII|prophylaxis with EHL-FVIII targeting a 12% FVIII through level based on PK assessment with WAPPS-Hemo
214509389|NCT04784988|DRUG|FVIII concentrate|standard prophylaxis with FVIII concentrate according to current guidelines
214509390|NCT00332852|DRUG|Letrozole|2.5 mg/day - oraly
214509391|NCT05093894|DEVICE|Group 1|Microlyte will be cut into strips and placed on the subcutaneous space
214509392|NCT01095848|BIOLOGICAL|DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG|Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
214509393|NCT01802333|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
215027825|NCT03829683|DRUG|Dextrose 5% in water|50mL intravenously every 6 hours
215027826|NCT04450212|GENETIC|Phase I, Buccal Swab Collection for DNA Isolation|Buccal swab will be taken from study participants for DNA isolation.
215027827|NCT04450212|DIETARY_SUPPLEMENT|Phase II, Vitamin K (Vitacost) Supplementation|1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (\~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
215027828|NCT04546243|PROCEDURE|resection group|patients received VATS
215027829|NCT04546243|RADIATION|radiotherapy group|patients received radiotherapy
214509394|NCT01802333|DRUG|Cytarabine|Given IV
214509395|NCT01802333|DRUG|Daunorubicin Hydrochloride|Given IV
214509396|NCT01802333|DRUG|Idarubicin|Given IV
214509397|NCT01802333|OTHER|Laboratory Biomarker Analysis|Correlative studies
214509398|NCT01802333|DRUG|Vorinostat|Given PO
214509399|NCT03709797|PROCEDURE|Dry needling in infraspinatus muscle|Dry needling technique with multiple rapid needle insertion.
214509400|NCT00154609|DRUG|Gu-Sui-Bu (Davallia Divaricata)|
214509401|NCT00861874|DRUG|Decitabine|20 mg/m2 IV, Days 1-5
214509402|NCT00861874|DRUG|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
214509403|NCT01755559|DRUG|Artesunate-amodiaquine|antimalarial ACT
214509404|NCT01755559|DRUG|Dihydroartemisinin-piperaquine|antimalarial ACT
214509405|NCT01755559|DRUG|Artemether-lumefantrine|antimalarial ACT
214694259|NCT05422352|DIETARY_SUPPLEMENT|Carnosine|Patients who will receive carnosine supplementation 500mg capsules (Now foods) in combination with Vitamin B complex (B1+B6+B12, 150 mg+100 mg+1 mg, respectively, Neurovit, European Egyptian Pharm. Ind., Egypt), two tablets per day
215104911|NCT01702025|DRUG|Placebo|Yellow corn meal in gel capsules
215104912|NCT01702025|DRUG|Aminophylline|National Drug Code (NDC) 0143-1020-01
215104913|NCT01702025|DRUG|Methazolamide|NDC 0781-1072-01
215104914|NCT01702025|DRUG|Aminophylline+Methazolamide|NDC 0143-1020-01 and NDC 0781-1072-01
215104915|NCT03325374|OTHER|Questionnaires and examination|Patients with in the BLB patients study will have interview and questionnaire carried out.
215104916|NCT02551263|DRUG|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
215104917|NCT04200118|OTHER|Observational|non intervention
215104918|NCT05399563|OTHER||
215104919|NCT02975050|OTHER|Location|
215104920|NCT06832280|OTHER|Educational Website Developed by Study Team|This website was developed by the study team in previous research studies.
215104921|NCT06832280|OTHER|Basic Educational Website|This website is a basic education website about hypospadias.
215104922|NCT04949594|DEVICE|TENS|application on muscles where pain is situated (cervical)
215104923|NCT03325959|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 HBOT sessions at 2 ATA 100% oxygen
214509406|NCT00724009|DRUG|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
214509407|NCT02488798|PROCEDURE|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
214509408|NCT02488798|PROCEDURE|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
214509409|NCT02488798|PROCEDURE|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
214509410|NCT01947491|DRUG|DFD01 Spray|
214509411|NCT01947491|DRUG|Comp01 Lotion|
215027830|NCT01251757|OTHER|Interactive Voice Recognition (IVR) phone calls|"The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population."
215027831|NCT01251757|OTHER|Educational mailings and follow-up for nonadherence|Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
215027832|NCT03890107|DEVICE|OtoSight Middle Ear Scope|OtoSight imaging using a near-infrared laser
215027833|NCT06019494|PROCEDURE|Oocyte retrieval with low aspiration flow rate|All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.42 ml/sec.
215027834|NCT06019494|PROCEDURE|Oocyte retrieval with high aspiration flow rate|High aspiration flow rate All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.62 ml/sec.
215027835|NCT04010838|PROCEDURE|spinal cord stimulation|The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
215027836|NCT03419624|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg tablet once daily
215027837|NCT03419624|DRUG|Exenatide 2 mg [Bydureon]|Exenatide 2 mg injection once weekly
215027838|NCT03419624|DRUG|Placebo Oral Tablet|Placebo oral tablet once daily
215027839|NCT03419624|DRUG|Placebo injection|Placebo injection once weekly
215027840|NCT03419624|DRUG|Insulin|daily Insulin injections
214509412|NCT01947491|DRUG|Vehicle Lotion|
215027841|NCT03419624|DRUG|Metformin, if taken before|If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
215027842|NCT05395312|OTHER|Online blended stepped-care mental well-being platform|"Participants in experimental group will be stratified according to their level of anxiety and/or depressive symptoms.~Level 2 (normal range)~* Topic-based personal growth articles, exercises, and chatbots~* Webinars and talks on varied mental health related topics~* Virtual support community~Level 3 (mild to moderate)~* Online self-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online skills-based workshops, questions-and-answers sessions, retreats~Level 4 (severe)~* Online coach-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online group therapy, 4-week group cognitive behavioural therapy or 8-week group mindfulness-based cognitive therapy"
215027843|NCT00260338|BIOLOGICAL|stem cell|mesenchymal stromal cell
215027844|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
215027845|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
215027846|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers earned independent of cocaine use
215027847|NCT01743144|DRUG|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
215104924|NCT03325959|DRUG|Cymbalta / Lyrica treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
215104925|NCT03325959|DEVICE|Crossover Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen after crossover
215104926|NCT05875298|OTHER|physical therapy protocol|the patients will receive physical therapy protocol in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus.
214509413|NCT01947491|DRUG|Vehicle Spray|
214509414|NCT04598646|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
215104927|NCT05875298|OTHER|physical therapy protocol and medical drugs|the patients will receive physical therapy protocol and medical drugs in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus. The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
215104928|NCT05875298|OTHER|medical drugs|The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
215104929|NCT01576497|PROCEDURE|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
215104930|NCT01576497|DEVICE|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
215104931|NCT01576497|DEVICE|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
215027848|NCT01743144|DRUG|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
215027849|NCT02709707|DEVICE|Blood glucose monitor|
215104932|NCT03653988|PROCEDURE|PEC I/II blocks by anesthesiologist - pre-operative|PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
215027850|NCT02121639|DRUG|Placebo|
215104933|NCT03653988|PROCEDURE|PEC I/II blocks by surgeon - intra-operative|PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
215104934|NCT04207749|DEVICE|LID015385 contact lenses|Investigational soft contact lenses
215104935|NCT04207749|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses
215104936|NCT04207749|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
215027851|NCT02121639|DRUG|AZD5363|
215027852|NCT05753228|OTHER|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.
215027853|NCT05753228|OTHER|Chalder Fatigue Scale|The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.
215104937|NCT03226496|BEHAVIORAL|motivational interviewing|
215104938|NCT00004932|DRUG|imatinib mesylate|
215104939|NCT00636285|DRUG|Placebo|Placebo
215104940|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
215104941|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
214509415|NCT04598646|BEHAVIORAL|Support|Behavioural support via professionals and peer support and recommended physical activity guidelines for cancer survivors, to encourage physical activity.
214509416|NCT00606788|DEVICE|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
215027854|NCT05753228|OTHER|Health Questionnaire (EQ-5D-5L)|"The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems."
215027855|NCT05753228|OTHER|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
215027856|NCT06196034|GENETIC|No intervention|No intervention
214509417|NCT00606788|PROCEDURE|Conventional weaning|Patients received physician-directed non-protocolized weaning
215027857|NCT04448847|DIETARY_SUPPLEMENT|Bif195|Active trial product with minimum 100 billion CFU daily dose
215027858|NCT04448847|OTHER|Placebo|Placebo similar to trial product but without Bif195
215027859|NCT06558435|OTHER|FEES|Single group
215027860|NCT00691509|GENETIC|gene expression analysis|
215027861|NCT00691509|GENETIC|polymorphism analysis|
215104942|NCT06141447|DRUG|Oxytocin + normal saline|40 units IV oxytocin once in a 1000 mL bag of normal saline
215104943|NCT06141447|DRUG|Normal saline|1000 mL bag of normal saline alone
215104944|NCT01107314|OTHER|Phlebotomy|Blood draws (total 48 cc blood)
215104945|NCT05529069|DRUG|Pirtobrutinib|Given by PO
215104946|NCT05529069|DRUG|Venetoclax|Given by PO
215104947|NCT05362058|DRUG|Insulin Efsitora Alfa|Administered SC
215104948|NCT05362058|DRUG|Insulin Degludec|Administered SC
215104949|NCT05968807|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric solid organ transplant (SOT) recipients who are trained to offer vital peer support and mentorship.
214509418|NCT03879265|DIAGNOSTIC_TEST|Noninvasive chromosome screening|Screening based on MALBAC-NGS technology
214509419|NCT05158426|DRUG|Propofol|anesthesia induction is initiated with intravenous infusion propofol at 1.5µg/ml, and increased 0.5µg/ml every 3min until OAA/S score 0.
214509420|NCT02067663|DEVICE|Paragard|The IUD will be placed as part of standard clinical care.
214509421|NCT02067663|DRUG|Mirena|The IUD will be placed as part of standard clinical care.
215027862|NCT00691509|OTHER|high performance liquid chromatography|
215027863|NCT00691509|OTHER|laboratory biomarker analysis|
215027864|NCT00691509|OTHER|mass spectrometry|
215027865|NCT00691509|OTHER|questionnaire administration|
215027866|NCT06014801|DRUG|Dialysate fluid, Filtration replacement fluid|Dose of continuous hemodialysis and/or hemofiltration
215104950|NCT04219592|DIAGNOSTIC_TEST|IgG4 measurement (non-interventional, just obtaining data from medical records)|IgG4 measurement in mg/dL
215104951|NCT05484245|DEVICE|Sonography|Surgeon detects brain mass lesion and assesses extent of it's resection with sonography
215104952|NCT05283421|DIAGNOSTIC_TEST|Estrogen|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
214509422|NCT04130932|OTHER|Ergonomic flooring|Specially designed flooring system to optimize ergonomics of participants
214509423|NCT04103164|DEVICE|Cutera excel V™ Laser|The Cutera® excel V laser is manufactured by Cutera, Inc. This laser with 532 nm KTP and 1064 nm Nd:YAG wavelengths has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the device for use in surgical and aesthetic applications requiring selective photothermolysis of target chromophores in soft tissue 510(k) number 022226. The 532 nm wavelength is indicated for the coagulation and hemostasis of benign vascular and cutaneous lesions in dermatology including, but not limited to, benign vascular lesions like angiomas, hemangiomas, port wine stains, venous anomalies and telangiectasia; benign pigmented lesions like nevi, lentigines, chloasma, café-au-lait; verrucae; skin tags; keratoses; plaques. The Cutera® excel V laser has also obtained the European CE Mark. The system was tested to ensure compliance with federal laser performance standards as applicable.
215027867|NCT05105620|DIAGNOSTIC_TEST|Fluorescein Angiography|Fluorescein Angiography for pateints with diabetes using fundus camera (TRC-NW8F retinal camera; Topcon Corporation, Tokyo, Japan).
215027868|NCT05105620|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography for pateints with diabetes using • Topcon DRI OCT Triton device (ver.10.13; Topcon Corporation, Tokyo, Japan).
215027869|NCT02796651|DRUG|Formoterol fumarate (6 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
215027870|NCT02796651|DRUG|Formoterol furmarate (20 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
215027871|NCT02796651|DRUG|Placebo for formoterol fumarate|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
215027872|NCT02796651|DRUG|Formoterol fumarate (12 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
215104953|NCT05283421|DIAGNOSTIC_TEST|Placebo|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
215104954|NCT05081206|DRUG|Propofol infusion via manually controlled pump.|Patients will receive propofol bolus 2.5-3 mg/kg, for anesthesia induction and anesthesia maintenance was continued according to the Mc Farlan scheme, meaning continuous propofol infusion is used, with gradual reduction of the infusion speed in timely manner, depending on the duration of surgery: 15mg/kg/h...13mg/kg/h...11mg/kg/h...9mg/kg/h...6mg/kg/h.
215104955|NCT05081206|DRUG|Propofol infusion via target controlled pump.|Pedfusor model was used for delivering target controlled plasma concentration, with target concentration for anesthesia induction of 4 mcg/kg body weight and then 3 mcg/kg.
215027873|NCT02796651|DRUG|Formoterol fumarate (40 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
215027874|NCT05701345|DEVICE|OMNIFIT DTx-MDD|This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session
215104956|NCT02117180|OTHER|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
215104957|NCT06583525|OTHER|Intensive Transition Support|A multidisciplinary transition team (nurse practitioner and social worker) will coordinate the transition process for each patient across multiple settings, focused on the youth's highest priority needs while also supporting the caregivers. Participants will receive case management and care navigation using an intensive transition support model provided through the partnership of a transition team. The transition team will collaborate with the participants existing care team to help coordinate care, provide consultation, and support adult and primary care accepting these youth for 1 year following the transfer. This Intervention is modelled on best practices by Health Quality Ontario's Quality Standards for Transition from Youth to Adult Health Care Services to support youth at high risk of having poor transitional outcomes as they move from pediatric to adult care.
215027875|NCT05701345|OTHER|standard treatment|"It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines."
215027876|NCT04248153|DRUG|BR55|BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
215027877|NCT06211218|DIAGNOSTIC_TEST|Cornea diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose cornea diseases from slit-lamp images.
215027878|NCT03741842|BEHAVIORAL|COMBO-KEY|The intervention will last for eight weeks with four home visits and five phone coaching sessions. It will also consist of a 4-item resource package for stroke survivors (including a stroke self-management and self-discovery workbook, a health and life planning toolkit, and videos on sharing of experience by survivors who managed their post-stroke challenges successfully, and a stroke self-management quick reference guide). A telephone hotline for survivors and caregivers to seek information and support related to stroke self-management will also be established. A programme protocol will be developed to ensure the consistent delivery of the programme.
215027879|NCT05430919|DRUG|REGN5713|Administered subcutaneously (SC)
215027880|NCT05430919|DRUG|REGN5714|Administered SC
215027881|NCT05430919|DRUG|REGN5715|Administered SC
215027882|NCT05430919|OTHER|Placebo|Administered SC
215027883|NCT05014919|DRUG|Vortioxetine|Tablets
215027884|NCT05014919|DRUG|Placebo|Tablets
215027885|NCT04684212|DEVICE|LAmbre PlusTM Left Atrial Appendage Closure System|The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
215027886|NCT04684212|DRUG|Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)|Continuation of market approved OAC drug.
215027887|NCT01469156|DRUG|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
215027888|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 1|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
215104958|NCT05639530|BIOLOGICAL|IBI333|Intravitreal injection of IBI333
215104959|NCT06583356|BEHAVIORAL|Motivational interviewing|Participants will receive motivational interviewing intervention previously, delivered face-to-face at participants' home, 1 session, followed by 2 brief follow-up sessions. Each session is expected to last approximately 30 to 45 minutes.
215104960|NCT05695885|BEHAVIORAL|STEPS|behavioral counseling
215104961|NCT05695885|BEHAVIORAL|Services as usual (SAU)|behavioral counseling normally provided
215027889|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 2|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
215104962|NCT04090463|RADIATION|Intraoperative radiotherapy|"IORT will be delivered as follows:~1. Radical resection --\> delivery of 10-15 Gy to the tumor bed~2. Non radical resection --\> delivery of 15-20 Gy to the tumor in situ"
215104963|NCT06216210|DRUG|opioid-FREE anesthesia.|"They received opioid-free anesthesia. These patients were provided a multimodal combination infusion. The administration of this infusion commenced at a dosage of 0.2 micrograms per kilogram per hour of dexmedetomidine. The Modified Mulimix cocktail, consisting of dexmedetomidine at a concentration of 10 ug/ml, Ketamine at a concentration of 2.5 mg/ml, and Lignocaine at a concentration of 20 mg/ml, was administered to a patient weighing 100 kg and if the weight is 110 Kg the rate will be increased by 10 percent, etc.,"
214509424|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
214509425|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
215104964|NCT06216210|DRUG|opioid-CONTAINING anesthesia.|The process of inducing anesthesia included the injection of fentanyl at a dosage of 2 micrograms per kilogram during the induction phase. Additionally, morphine was administered at a dose of 0.03 milligrams per kilogram at the time of port insertion.
215104965|NCT03258775|OTHER|water intake|After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized
215104966|NCT05073926|OTHER|No intervention is part of the study protocol|No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
215104967|NCT03415945|DEVICE|Cardiac resynchronization therapy (CRT)|All study participants have a clinical indication for CRT and will receive CRT implantation as part of their routine medical care. Additionally, participants will receive temporary left and right ventricular septal pacing electrodes and a temporary PressureWire to investigate the acute hemodynamic effect of left ventricular septal pacing, using patients as their own controls.
215027890|NCT03851666|OTHER|12 weeks daily administration Placebo|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of placebo.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation."
215104968|NCT00904488|DRUG|Addition of oral Metolazone|Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
215104969|NCT00904488|DRUG|Furosemide dose escalation|Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
215104970|NCT01599013|DRUG|Vinflunine, Gemcitabine|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
215104971|NCT01599013|DRUG|Vinflunine, Carboplatin|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
215104972|NCT00818051|RADIATION|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
215027891|NCT02971163|BEHAVIORAL|SynDA|SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
215104973|NCT04954768|OTHER||This is a observational study, and there is no interventions.
215104974|NCT00380731|BEHAVIORAL|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
215104975|NCT00930553|BIOLOGICAL|alemtuzumab|Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
215104976|NCT02183766|DIETARY_SUPPLEMENT|Galactooligosaccharide prebiotic|6 mL once a day
215104977|NCT02183766|DRUG|Maltodextrin|6 mL once a day
215104978|NCT05668286|DRUG|A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%)|patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance. A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) were injected to all patients.
215104979|NCT01691157|OTHER|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
215104980|NCT01691157|OTHER|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
215104981|NCT00051909|DRUG|LY451395|
215104982|NCT05696756|BEHAVIORAL|Personalized Web-based training for EMMA app|Participants will complete six sessions of training to support uptake and habit formation of EMMA app use with a personalized web-based training platform.
214509426|NCT01061658|OTHER|Placebo|Placebo
215104983|NCT05696756|BEHAVIORAL|Motivational Interviewing: Clinician Support|Participants will receive weekly brief check-ins with clinicians to motivate and support the problem-solving and habit formation aspects of the web-based training.
215104984|NCT06018623|OTHER|It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients|"It is an observational study and no non-routine procedures will be performed on patients.~Routine anesthesia procedure will be applied to the patients"
215104985|NCT05405335|OTHER|Prone Positioning Maneuver|intermittent prone positioning for eight hours per day for seven days. each cycle should not be less than 30 minutes or more than 3 hours.
215027892|NCT05698498|OTHER|Guaranteed Income|Guaranteed income payments will be disbursed monthly for a total of 24 months to participants who are randomized to the guaranteed income intervention group. Participants will be given the choice to select from one of two different payment strategies (equal monthly payments of $1,000/month vs hybrid payment schedule with initial amount of $6,500 the first month followed by $500/month x 11 months); payment strategy preferences will be re-assessed after 12 months. The choice of payment strategy will be strictly left to participants to specify.
215027893|NCT05698498|OTHER|Public Benefits Information Session|All participants (both the control and intervention groups) will be offered the option of attending a Public Benefits Information Session during which they will receive a comprehensive resource directory of public benefit, assistance, and social service programs available to residents of Santa Clara County, have the opportunity to ask questions about enrolling in those programs, and also have the opportunity to seek additional benefits navigation assistance from our community partner, Sacred Heart Community Service. This session is intended to be optional, with the decision to attend and participant to be left to the discretion of each study participant. Attendance is not required for study participation.
215027894|NCT02959346|PROCEDURE|Sham Acupuncture|"Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
215027895|NCT02959346|PROCEDURE|Acupuncture|"Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
215027896|NCT04868071|BEHAVIORAL|Physical Exercise|Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).
215027897|NCT01855503|PROCEDURE|Core Biopsy|
215027898|NCT03828526|OTHER|High Fidelity Simulation|Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.
215027899|NCT03828526|OTHER|Traditional teaching strategy|Classroom-based strategy
215027900|NCT03073512|OTHER|Ultrasound examination|Participants will undergo ultrasound examination at 32 weeks gestation
215027901|NCT02082379|BEHAVIORAL|inhaled normal saline using different interfaces.|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
215104986|NCT04578184|DIAGNOSTIC_TEST|Corneal epithelial thickness measurements|Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.
215104987|NCT05844241|OTHER|Music and Theta Auditory Beat Stimulation|Listening to music and ABS for 30 minutes.
215104988|NCT05844241|OTHER|Audiobooks|Listening to audiobooks for 30 minutes
215104989|NCT03222297|DEVICE|early skull repair|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
215104990|NCT03222297|DEVICE|late-stage skull repair|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
215104991|NCT04256681|OTHER|SNAP questionnaire|The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
215104992|NCT02870634|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
215104993|NCT01431053|DRUG|aspirin|Aspirin 50mg po daily
215104994|NCT01431053|DRUG|Exemestane|Exemestane 25mg po daily
215104995|NCT04331470|DRUG|Levamisole Pill + Budesonide+Formoterol inhaler|Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours
215104996|NCT04331470|DRUG|Lopinavir/Ritonavir + hydoxychloroquine|Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
215027902|NCT02054728|OTHER|RHC and IMT|"Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).~The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters."
215027903|NCT04007731|DIETARY_SUPPLEMENT|DrRip - high protein, high fibre and creatine load|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
215027904|NCT04007731|DIETARY_SUPPLEMENT|Voltage energy bar|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
215104997|NCT00387634|BIOLOGICAL|TBE vaccine for adults|Serology blood draw.
215104998|NCT02330692|OTHER|No intervention|
215104999|NCT00413036|DRUG|lenalidomide|once daily oral capsule
215105000|NCT00066404|BIOLOGICAL|recombinant adenovirus-hIFN-beta|
215105001|NCT04042909|BEHAVIORAL|Counter Attitudinal Advocacy|same as Counter Attitudinal Advocacy arm
215105002|NCT04042909|BEHAVIORAL|Personalized Normative Feedback|same as Personalized Normative Feedback arm
215105003|NCT01369641|PROCEDURE|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
215105004|NCT01369641|DRUG|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
215105005|NCT01369641|OTHER|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
215105006|NCT01369641|DRUG|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
215105007|NCT04151433|PROCEDURE|Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).|cf. different arms
215105008|NCT03575611|PROCEDURE|Biopsy|Undergo tumor biopsy
215105009|NCT03575611|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215105010|NCT03575611|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
215105011|NCT03575611|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
215105012|NCT03575611|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
215105013|NCT03575611|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
215027905|NCT02392169|DRUG|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
215105014|NCT06002945|OTHER|Blood sample|Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
215027906|NCT00559039|OTHER|questionnaire administration|
215027907|NCT00559039|PROCEDURE|evaluation of cancer risk factors|
215105015|NCT00842543|DIETARY_SUPPLEMENT|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
215105016|NCT00842543|DIETARY_SUPPLEMENT|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
215105017|NCT05476172|DRUG|Dienogest Pill|The effect of dienogest on endometriosis pain symptoms.
215027908|NCT04905641|PROCEDURE|Bilateral intermediate cervical plexus block|Bilateral intermediate cervical plexus block was performed under ultrasound guidance.
215027909|NCT01491919|DRUG|Lisinopril|Subjects will be randomized to Low, Medium, or High dose of Lisinopril
215027910|NCT01352455|PROCEDURE|Hemodialysis|5 days per week hemodialysis
215027911|NCT04986189|DIAGNOSTIC_TEST|Low dose CT thorax|A low dose CT scan of the thorax to screen for lung cancer
215105018|NCT05476172|DRUG|Norethindrone Acetate|The effect of Norethindrone Acetateon endometriosis pain symptoms.
215105019|NCT04904874|DEVICE|intense pulsed light|treatment with 3 sessions of intense pulsed light, the second one after 2 weeks, the third one after 6 weeks
215105020|NCT01838915|DIETARY_SUPPLEMENT|Prebiotics+Glutamine|"Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function."
215105021|NCT01838915|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, 20 g.
215105022|NCT03265340|DEVICE|dTMS|
215105023|NCT06007820|PROCEDURE|Large Volume Thoracocentesis|Large Volume Thoracocentesis
215105024|NCT06007820|PROCEDURE|Pigtail Catheter|Pigtail Catheter
215105025|NCT05301010|DRUG|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
215105026|NCT05301010|DRUG|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
215105027|NCT05301010|DRUG|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
215105028|NCT01486342|RADIATION|PET-CT scan|"PET-CT imaging with \[18F\]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.~A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames."
215105029|NCT03738891|DEVICE|Zeltiq CoolSculpting System alone|The CoolSculpting System will be used to perform the treatments in Cohort 3.
215027912|NCT03833583|DEVICE|Soterix Medical mini-CT tDCS stimulator|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
215027913|NCT06536972|OTHER|knowledge|"Develop an instrument to evaluate knowledge about humidification systems among different health professionals in intensive care units (ICU).~Describe the knowledge about humidification systems among different health professionals in intensive care units (ICU)."
215027914|NCT06064162|DRUG|ketamine|60mg (.5mg/kg over 40 minutes intravenously)
215027915|NCT05377723|DEVICE|Neodyne Device|See Arm Description: Neodyne Device
215027916|NCT02871219|DRUG|Lenalidomide|Given PO
215027917|NCT02871219|BIOLOGICAL|Obinutuzumab|Given IV
215027918|NCT06042608|PROCEDURE|intercostobrachial nerve block|injection of local anesthetic to target the intercostobrachial nerve in the axilla
215027919|NCT04255043|DEVICE|IVUS guidance|IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment
214692143|NCT05138185|DEVICE|Exoskeleton assisted gait on a treadmill|Subjects were instructed to walk on a treadmill at a constant speed during trials of 5 minutes. All subjects carried out four trials: (1) NoExo: subjects only wore the sensors to acquire their basal motion; (2) Free: subjects wore the exoskeleton although the actuator was mechanically decoupled, so it enabled the free movement of the knee; (3) Echo: the device provided gait assistance following the Echo-control strategy; and (4) Pattern: the device provided gait assistance following the Pattern strategy. During trials, patients wore a safety harness that did not support any weight. Previously to the execution of the trials, the gait velocity was self-selected by the subjects to a comfortable level. Subjects rested between trials for five minutes. Healthy subjects also performed a previous trial under variable gait speed. They walked over the treadmill as in the NoExo condition, although the gait speed randomly varies from 1km/h to 3km/h in 0.2km/h steps for 15 seconds at least.
214692144|NCT02207699|DRUG|Benzonatate 200 mg|2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
214692145|NCT02207699|DRUG|Benzonatate 800 mg|8 benzonatate 100 mg perles given by mouth once
215105030|NCT03738891|DEVICE|Electromagnetic Muscle Stimulation alone|The EMS device(s) alone are used in Cohort 1.
215105031|NCT03738891|DEVICE|EMS followed by CoolSculping|Cohort 2 group will be treated with EMS followed by CoolSculpting
215105032|NCT03738891|DEVICE|CoolSculpting followed by EMS|Cohort 4 will be treated first with CoolSculpting, followed by EMS.
215105033|NCT00003411|DRUG|motexafin gadolinium|
215105034|NCT00003411|RADIATION|radiation therapy|
215105035|NCT00003202|DRUG|cisplatin|
215105036|NCT00003202|DRUG|gemcitabine hydrochloride|
215105037|NCT00003202|RADIATION|radiation therapy|
215105038|NCT05168020|BEHAVIORAL|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress
214509427|NCT00704340|DEVICE|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
215105039|NCT05168020|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress
215105040|NCT01749878|DRUG|REGN1500|
215105041|NCT01749878|DRUG|placebo|
215105042|NCT00398840|DRUG|ARQ 171|
215105043|NCT01483183|DRUG|OPC-108459|"Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1"
215105044|NCT01483183|DRUG|Placebo|Placebo dose, 10-minute constant rate IV infusion
214692146|NCT02207699|DRUG|Moxifloxacin 400 mg|1 moxifloxacin 400 mg tablet given by mouth once
214692147|NCT02207699|DRUG|Placebo|8 placebo perles given by mouth once
214692148|NCT03811678|DRUG|Kangdaprevir Sodium Tablet|Tablet，administered orally once daily
214692149|NCT03811678|DRUG|placebo|Tablet，administered orally once daily
214692150|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
214692151|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
215027920|NCT04255043|DEVICE|Angiography guidance|DCB (Sequent® Please) treatment
215027921|NCT06324695|BEHAVIORAL|HautKompass|The HautKompass program is a structured self-guided online psychosocial intervention designed to reduce self-stigma in people with visible chronic skin diseases. It combines educational content and practical exercises based on cognitive-behavioral therapy (CBT), namely cognitive restructuring of negative automatic thoughts and cultivating self-compassionate thinking and behavior. The program consists of eight skin-generic modules (on average, 15-20 minutes per module, one module per week).
215027922|NCT02081768|RADIATION|90yttrium colloid|90yttrium colloid will be inserted into a sellar/parasellar cyst
215027923|NCT06296706|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks
215027924|NCT06296706|DRUG|Taxotere (docetaxel)|Taxotere, by intravenous infusion, every 3 weeks.
215027925|NCT03004807|DIETARY_SUPPLEMENT|Centrum Silver Mens' Formula|Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.
215027926|NCT03004807|OTHER|Control|A matching tablet to the dietary supplement, but without any active ingredients
215105045|NCT00239928|DRUG|pegaptanib sodium|1 drop per dosed eye per protocol.
215105046|NCT03971565|BIOLOGICAL|Blood sample 5 milliliter|The blood of the patients will be collected during their hospitalization of the hematology department participating in the research
215105047|NCT03491514|OTHER|Test Granola|51 g Test Granola
215105048|NCT03491514|OTHER|Control Granola|54.1 Control Granola
215105049|NCT05893719|DEVICE|iNedit, iNdeep, iNtercept|Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept
215105050|NCT00286494|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
215105051|NCT00286494|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
215105052|NCT00286494|DRUG|Pioglitazone|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
214509428|NCT00704340|OTHER|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
214509429|NCT02586467|BEHAVIORAL|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
214509430|NCT02586467|BEHAVIORAL|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
214509431|NCT02586467|BEHAVIORAL|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
214509432|NCT02586467|BEHAVIORAL|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
214509433|NCT02586467|BEHAVIORAL|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
214509434|NCT01154504|OTHER|clinical treatment|The clinical treatment will be optimized to gold standard international heart failure treatment
214509435|NCT01154504|PROCEDURE|ultrafiltration|The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
214692152|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
214692153|NCT00004993|DRUG|Parathyroid hormone (hPTH 1-34)|
214692154|NCT04891770|DRUG|Tenofovir Alafenamide|Administered as film-coated oral tablets
214692155|NCT04891770|DRUG|VIR-2218|Administered as a sub-cutaneous (SC) injection
215105053|NCT05418088|BIOLOGICAL|Anti-CD19/CD20/CD22 CAR T-Cells|Given IV
215105054|NCT05418088|DRUG|Cyclophosphamide|Given IV
215105055|NCT05418088|DRUG|Fludarabine Phosphate|Given IV
215105056|NCT05418088|PROCEDURE|Echocardiography|Undergo echocardiography
215105057|NCT05418088|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
214692156|NCT04891770|DRUG|Nivolumab|Administered intravenously
214692157|NCT04891770|DRUG|Selgantolimod|Administered as film-coated oral tablets
214692158|NCT04571710|DRUG|SHR1258|Drug: SHR1258 400mg
214692159|NCT00284778|DRUG|Alimta®|
214692160|NCT00284778|DRUG|Taxotere®|
214692161|NCT06622694|BIOLOGICAL|RD13-02|"Before cell infusion (Day 0), subjects will undergo a lymphodepleting chemotherapy based on the Fludarabine + Cyclophosphamide (FC regimen). Prior to the lymphodepleting chemotherapy, subjects must undergo an assessment, and only those meeting the criteria will be eligible for the lymphodepleting chemotherapy. The CAR T infusion should be performed at least 48 hours after the completion of the lymphodepleting chemotherapy. The infusion will be administered intravenously as a single dose. It should be completed within 30 minutes, with continuous cardiac monitoring during the infusion to observe heart rate (HR), blood pressure (BP), respiratory rate (R), and peripheral oxygen saturation (SpO2) for up to 2 hours post-infusion."
214692162|NCT04026412|BIOLOGICAL|nivolumab|Specified dose on specified days
215105058|NCT05418088|PROCEDURE|Biopsy|Undergo tissue biopsy
215105059|NCT05418088|PROCEDURE|Pheresis|Undergo apheresis
215105060|NCT05418088|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
215105061|NCT05418088|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
215105062|NCT02098265|DEVICE|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
215105063|NCT02098265|BEHAVIORAL|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
215105064|NCT02098265|OTHER|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
215105065|NCT02098265|OTHER|EEG|EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
215105066|NCT02098265|OTHER|RecoveriX|RecoveriX is a brain driven rehabilitation system for stroke patients that pairs mental activities with motor functions.
215105067|NCT02098265|OTHER|Delay|10 week delay before intervention
214509436|NCT01154504|PROCEDURE|isovolumetric hemofiltration|The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
215105068|NCT02098265|DEVICE|BCI-FES|
214509437|NCT03124472|PROCEDURE|uterine artery ligation|Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
214692163|NCT04026412|BIOLOGICAL|ipilimumab|Specified dose on specified days
214692164|NCT04026412|BIOLOGICAL|durvalumab|Specified dose on specified days
215105069|NCT04375059|OTHER|using interactive attention training system|using the interactive attention training system to children with Attention Deficit Hyperactivity Disorder
214692165|NCT06169592|PROCEDURE|Liver transplantation|Related transplantation of the right lobe of the liver
214692166|NCT04372576|DIAGNOSTIC_TEST|Assessment of ventilator-associated pneumonia criteria|Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.
214692167|NCT06397924|DIETARY_SUPPLEMENT|Chitin Fiber|Dietary fiber isolated from an edible insect (chitin)
214692168|NCT06397924|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
214692169|NCT05107206|DEVICE|Mechanical Thrombectomy using the Envi™-SR Thrombectomy device|Clot removal using the Envi™-SR Thrombectomy device
214692170|NCT05107206|DEVICE|Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device|Clot removal using the Solitaire or Trevo Revascularization Device
214692171|NCT03340181|OTHER|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
214692172|NCT03716986|DIAGNOSTIC_TEST|MRI Oxygen Saturation Map|Calculation of the oxygen saturation map of gliomas cases
214692173|NCT06973096|DRUG|CART-EGFR-IL13Ra2 cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR epitope 806 and a humanized scFv targeting IL13Ra2; both scFvs are fused to the 4-1BB and CD3ζ signaling domains.
215027927|NCT06642623|DRUG|Enavogliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
215027928|NCT06642623|DRUG|Dapagliflozin or Empagliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
215027929|NCT06643013|DRUG|XBD173|4 weeks treatment
215027930|NCT06638580|DIAGNOSTIC_TEST|Clinical Periodontal Measurements (plaque index, gingival index, bleeding index, clinical attachment level), Optical Coherence Tomographic Measurements, Serum IL1-β, TNF-α, IL-10, TAS, TOS, OSİ levels|"Probing pocket depth (PPD) was measured as the distance between the deepest point of the sulcus (or pocket) and the gingival margin, and clinical attachment level (CAL) was measured as the distance between the base of the pocket and the cementoenamel junction. PPD and CAL were measured at six different points (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) in each tooth, and other index scores were taken at four different points (mesial, distal, vestibular and palatinal).~Serum IL1-β, TNF-α, and IL-10 levels were measured via immunosorbent assay method using human-specific kits according to the kit manufacturer's instructions.~Serum total antioxidant status (TAS) and total oxidant status (TOS) levels were mea-sured by a spectrophotometric method using specific kits.~Retinal and choroidal imaging and measurements were performed with optical coherence tomography (SS-OCT) with swept-source (SS) technology and non-invasive OCT angiography."
215027931|NCT06642805|PROCEDURE|duodenal atresia|surgery for duodenal atresia
215027932|NCT03248661|BEHAVIORAL|Now I'm Telling You|Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
215027933|NCT03975660|DEVICE|Pain Measurement Device|When participants request labor analgesia, the sensors of the pain measurement device (ROPA System \[CereVu Medical, Inc. San Francisco, CA\] and Edwards Foresight device) will be applied to the forehead and connected to the device. Data recording is then started.
215027934|NCT05494073|PROCEDURE|ACL Reconstruction with Hybrid Remnant Repair|The intervention includes the incorporation of the host ACL remnant into the graft. The intervention hopefully
215027935|NCT05494073|PROCEDURE|ACL Reconstruction without Hybrid Remnant Repair|ACL reconstruction without preservation or incorporation of host ACL remnant
215027936|NCT04678544|DEVICE|Scalp cooling system 2|"The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.~After the RCT, 34 patients who were expected to receive 4, 6, or 8 cycles of chemotherapy with an anthracycline regimen were further enrolled in the intervention group as a single-arm trial."
215027937|NCT04511468|DIETARY_SUPPLEMENT|Zinc, Chromium, Vitamin C, and Copper Supplementation|Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper
215027938|NCT04511468|BEHAVIORAL|Standard healthy lifestyle intervention|Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
215027939|NCT04511468|OTHER|Placebo|Placebo with inactive ingredients
215027940|NCT06477094|DEVICE|Stratus Nimbus Electrosurgical RF Multi-Tined Expandable Electrode|Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stratus Nimbus Electrode
215027941|NCT06477094|DEVICE|Stryker Venom Radiofrequency Cannula|Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stryker Venom Cannula
215027942|NCT02389517|DRUG|Ixazomib Citrate|Given PO
215027943|NCT02389517|DRUG|Lenalidomide|Given PO
215027944|NCT02389517|DRUG|Dexamethasone|Given PO
215027945|NCT04499534|BIOLOGICAL|Seasonal influenza vaccine|To evaluate immune function in BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination
215105070|NCT04776317|BIOLOGICAL|ChAdV68-S|Chimpanzee Adenovirus serotype 68 - Spike (ChAdV68-S) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5 mL intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
215105071|NCT04776317|BIOLOGICAL|ChAdV68-S-TCE|Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
215105072|NCT04776317|BIOLOGICAL|SAM-LNP-S|Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
215105073|NCT04776317|BIOLOGICAL|SAM-LNP-S-TCE|Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
215105074|NCT04776317|OTHER|Sodium Chloride, 0.9%|The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
215105075|NCT05257824|DRUG|Aspirin 100mg|"1. short-term dual antiplatelet: dual antiplatelet agents for 6 months~2. long-term dual antiplatelet: dual antiplatelet agents for 12 months"
215105076|NCT05257824|DRUG|Clopidogrel 75mg|"1. short-term dual antiplatelet: dual antiplatelet agents for 6 months~2. long-term dual antiplatelet: dual antiplatelet agents for 12 months"
215105077|NCT06025032|GENETIC|HG205|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
215105078|NCT02794233|OTHER|Impedance measurements|Refer to study description
215105079|NCT00001894|PROCEDURE|pacemaker implantation|
215105080|NCT00001894|PROCEDURE|percutaneous transluminal septal ablation (PTSA)|
215105081|NCT04942405|BIOLOGICAL|TURCOVAC|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28
215105082|NCT04942405|BIOLOGICAL|CoronaVac|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
215105083|NCT04085757|DRUG|long interval dinoprostone|A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
215105084|NCT04085757|DRUG|short interval dinoprostone|A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
215105085|NCT06583265|DRUG|Observational|To observe if endometrial compaction ≥ 5% in down regulated FET cycles increases clinical pregnancy rate.
215027946|NCT04283279|OTHER|Virtual reality exercise|"Participants will do exercises in a virtual environment, solving tasks that require cognitive efforts and motor/balance efforts. The virtual environment/tasks will be delivered through a head-mounted display (goggles). Difficulty will progress from standing/sitting, to walking on a treadmill. The environments that will be used will be both over-the-counter environments, as well as in-house designed environments."
215027947|NCT04283279|OTHER|Vestibular rehabilitation exercise|Vestibular rehabilitation exercises focus on head and eyes movements, as well as whole-body movements. The aim is to facilitate the use of other sensory organs than the vestibular organs, which will also be relevant to persons who are not receiving sufficient sensory information from the auditory system. The exercises will progress as tolerated, under careful supervision of trained therapists.
215027948|NCT04283279|OTHER|Control|Participants will not be randomised to either of the exercise interventions, but will be adviced to stay active
215027949|NCT04437823|BIOLOGICAL|Intravenous Infusions of Stem Cells|Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
215105086|NCT06583746|OTHER|Group1|30 children with DCP were included. The lower extremity evaluations of these cases were made according to ICF. Modified Ashworth Scale (MAS) was used for body structure and functions, Gillette Functional Assessment Questionnaire (FAQ) was used for activity and Pediatric Functional Independence Measure (WeeFIM) was used for participation.
215105087|NCT06583967|OTHER|Physical Training|Group 1 - Elliptical Trainer Group 2 - Treadmill
215105088|NCT00661817|BEHAVIORAL|Lifestyle Modification Program|"Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support."
215105089|NCT00661817|BEHAVIORAL|Usual Care and Reading Materials|"Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2."
215105090|NCT01847976|DRUG|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
215105091|NCT03082092|DRUG|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
215105092|NCT03082092|DRUG|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
215105093|NCT00896025|DRUG|N-acetylcysteine|"Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.~NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.~i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour~ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours~iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours~iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours~v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours"
215105094|NCT05602701|OTHER|Preoperative assessment|Preoperative assessment of physical fitness
215105095|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 3:1
215105096|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 9:1
214509438|NCT03124472|PROCEDURE|Lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~\- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~* Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~* Closure of the anterior abdominal wall in layers"
214509439|NCT00163358|DRUG|Ciclesonide|
214509440|NCT00905294|OTHER|Blood draws|Observational: blood draws only
214509441|NCT05814809|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet
215027950|NCT05309746|PROCEDURE|Laparoscopic surgery|Surgery used to remove the child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into the child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of the child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
215027951|NCT03105765|DRUG|Placebo|Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
215027952|NCT03105765|DRUG|Ketamine|Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
215027953|NCT00117442|DRUG|carboplatin|Chemotherapy
215027954|NCT00117442|DRUG|paclitaxel|chemotherapy
215027955|NCT00117442|DRUG|pegfilgrastim|Growth factor for mobilization
215027956|NCT03622515|COMBINATION_PRODUCT|Anesthesia level and cerebral perfusion pressure|Anesthetic dose and blood pressure
215027957|NCT00257933|DRUG|Prednisolone high dose|4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
215027958|NCT00257933|DRUG|Prednisolone lower dose|2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
215027959|NCT06127771|OTHER|Programming DBS using Percept PC neurostimulator's full potential|This study aims to enroll patients who previously had Activa PC neurostimulator and underwent a battery change to Medtronic PerceptTM PC as standard-of-care. However, in this study, the investigators intent to fully utilize the programming potential of Medtronic PerceptTM PC to optimize treatment outcome.
215105097|NCT03238625|DRUG|Lidocaine|Lidocaine injection
215105098|NCT03238625|DRUG|Sodium cloride 0.9%|Placebo
214509442|NCT05814809|DRUG|JP-1366 20mg capsule|R : JP-1366 20mg capsule
215027960|NCT00532415|DRUG|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
215027961|NCT01627106|DRUG|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
215027962|NCT01627106|DRUG|Amiodarone|Administered IV as per product label
215027963|NCT02821650|OTHER|TEJ (Traditional stove to Efficient stove in Jhuggi)|TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
215105099|NCT02524158|BEHAVIORAL|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
214509443|NCT03137784|DRUG|NVA237 (glycopyrronium bromide)|In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
214509444|NCT03137784|DRUG|Placebo|In each treatment arm, patient will receive placebo
214509445|NCT00410748|DRUG|OROS hydromorphone HCI CR|
215027964|NCT02298946|DRUG|AMP-224|10mg/kg on day 1 then every 14 days for a total of 6 doses.
215027965|NCT02298946|RADIATION|Stereotactic Body Radiation Therapy(SBRT)|Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days
215027966|NCT02298946|DRUG|Cyclophosphamide|200mg/m(2) IV on day 0.
215027967|NCT01514578|DRUG|TRV130A|Intravenous infusion of 1 hour duration
215105100|NCT05122091|DRUG|Fruquintinib + SOX|Fruquintinib：5mg qd for 2 weeks on and 1 week off, q3w； SOX: Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area），d1-14，q3w； Oxaliplatin：130mg/m2，intravenous (IV) ，d1，q3w.
215105101|NCT03887234|PROCEDURE|Coracoclavicular ligament reconstruction|Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
215105102|NCT00642161|DRUG|budesonide|
215105103|NCT00196144|DEVICE|Individualized Programming of PVAB|Performance of a test to detect far-field R-wave sensing
214509446|NCT04613284|DRUG|Recombinant human endostatin (Endostar)|Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
214509447|NCT04613284|RADIATION|Thoracic irradiation of 50 Gy with 3DCRT or IMRT|Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.
214509448|NCT05999448|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
214509449|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Individual|CICBT-Individual will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
214509450|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Group|CICBT-Group will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
214509451|NCT05999448|BEHAVIORAL|Dialectical Behavioral Therapy (DBT)|DBT will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
214509452|NCT05999448|BEHAVIORAL|Durand Sleep Intervention|Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.
214509453|NCT05999448|BEHAVIORAL|RUBI Intervention|RUBI will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
214509454|NCT05999448|BEHAVIORAL|Naturalistic Communication Intervention (NCI)|NCI will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
214509455|NCT05999448|BEHAVIORAL|Self-Guided Resources|Participants will be provided a self-guided resource notebook that includes 12 weeks of content that parallels the topics examined in other support programs (child behavior management, child sleep, child communication, caregiver mental health, caregiver health behaviors, community connection)
214509456|NCT05999448|BEHAVIORAL|Participation Enhancement Intervention (PEI)|"A standardized PEI intervention will be conducted by trained peer coaches who are also rare disorder caregivers. Each peer coach will work with their clients to complete a Change Plan Worksheet and will complete two booster sessions at midpoint and end of treatment. Coaches will also meet with their clients after follow-up data are complete to support connection back to community resources and patient-specific rare disorder communities."
214509457|NCT04210830|DIAGNOSTIC_TEST|Quantra-Device|Point of Care Coagulation Monitoring System
214509458|NCT04630119|OTHER|Questionnaires on quality of life, emotional health and presenteeism|After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
214509459|NCT05578807|PROCEDURE|without reverse ureteral catheter insertion|In contrast to conventional total tubeless percutaneous nephrolithotomy, there was no reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, no change in position, and no repeated disinfection.
215027968|NCT01514578|DRUG|Dextrose in Water|Intravenous infusion of 1 hour duration
215027969|NCT03847818|DRUG|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|"Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles"
215105104|NCT00196144|DEVICE|Nominal PVAB|nominal pacemaker settings
215105105|NCT03100058|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
214509460|NCT01157195|BEHAVIORAL|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
215105106|NCT03100058|DRUG|Placebo|Placebo
215105107|NCT04357808|DRUG|Sarilumab|Single dose treatment with sarilumab 2 x 200 mg subcutaneously
215105108|NCT04357808|OTHER|Standar of care|Usual clinical care
215105109|NCT03276546|BEHAVIORAL|shared decision-making tool (SHARE-D)|questionnaire
215105110|NCT03671304|DEVICE|Fitbit Versa|"Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days."
215105111|NCT00136045|DRUG|Rotigotine|
215105112|NCT05962892|OTHER|No Intervention|No Intervention
215105113|NCT05302271|BIOLOGICAL|AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN|AAVrh.10hFXN will be administered intravenously.
215105114|NCT05302271|DRUG|Prednisone|All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.
215105115|NCT00626444|DRUG|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
215105116|NCT02805855|DRUG|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
215105117|NCT05385055|OTHER|THS use|N/A: No intervention was assigned.
215105118|NCT05385055|OTHER|Cigarette smoking|N/A: No intervention was assigned.
215105119|NCT05385055|OTHER|Smoking abstinence|N/A: No intervention was assigned.
214509461|NCT01157195|BEHAVIORAL|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
215027970|NCT04600414|OTHER|Collaborative Care for Mental Health Disorders|CoCM is based on six key principles: 1) evidence-based, 2) measurement-based, 3) team-based, 4) population-based, 5) patient-centered, and 6) accountable. CoCM supports the delivery of evidence-based pharmacological and psychosocial treatments. CoCM is measurement-based with screening and monitoring of patient-reported outcomes over time to assess treatment response and facilitate treatment adjustments. CoCM is team-based led by a primary care provider with support from a care manager in consultation with a psychiatrist who provides treatment recommendations for patients who are not responding. CoCM is population-based whereby a registry is used to monitor treatment engagement and facilitate the identification of patients falling through the cracks. CoCM is patient-centered with proactive outreach to engage and activate patients. Collaborative care is accountable with continuous quality improvement to meet clinic performance benchmarks.
215027971|NCT04600414|OTHER|Collaborative Care for Opioid Use Disorder|"Pharmacologic treatment of OUD will rely mainly on transmucosal buprenorphine/naloxone prescribed by primary care providers with DATA 2000 waivers. Measurement-based care and treat to target are fundamental principles of CoCM and will be incorporated into the intervention. Care managers will ask four yes/no questions about: 1) opioid withdrawal symptoms, 2) illicit opioid craving, 3) illicit opioid use, 4) medication side effects. If necessary, consulting psychiatrists will then recommend a change to the treatment plan to the primary care provider. In the case of buprenorphine/naloxone, options for changing the treatment plan include: 1) increasing the dosage (max dose 32mg), 2) augmenting with clonidine, 3) switching to injectable buprenorphine, and/or 4) intensifying psychosocial interventions. If the patient is experiencing medication side effects, but not opioid withdrawal symptoms or illicit opioid craving, consideration will be given to lowering the medication dosage."
215027972|NCT03044899|PROCEDURE|All surgeries in adult patients|All surgeries in adult patients
215027973|NCT05933603|DRUG|Atomoxetine and Oxybutynin (ato-oxy)|0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly
215027974|NCT02019836|OTHER|Determining maternal and neonatal vitamin D levels|
215105120|NCT05536687|DEVICE|FeetMe|"Healthy volunteers will wear the insoles at 2 visits in hospitals (D0 and D8) and 2 visits at home (D1 and D7). The visits at the hospital will be composed of 3 tests of 6 min. in various conditions in a hospital environment :~* In degraded conditions, i.e. a 10m corridor, evaluated simultaneously by the FeetMe® system and an evaluator~* In degraded condition, a 10m corridor, evaluated simultaneously by the FeetMe® system and an odometer and evaluator~* Under the conditions recommended for the 6-minute test (ref), i.e. a 30m corridor, evaluated simultaneously by the FeetMe® system and the evaluator A rest time of 15 min minimum will be respected between each test. The visits at home will be composed of a 6-minute test at home or outdoors (quiet place, flat, hard surface, few or no passages, ideally no obstacles, covered if weather conditions are not suitable) with a 10-meter track that you can define simply with equipment provided by the promoter."
215105121|NCT05389176|DRUG|Esmolol|a continuous esmolol infusion titrated to maintain heart rate between 70/min and 100/min
215105122|NCT03694704|DEVICE|FineHearing strategy|Cochlear implant with FineHearing strategy
214509462|NCT02265107|OTHER|exercise training|The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
214509463|NCT02736188|DRUG|Aceneuramic Acid Extended-Release Tablets|
214509464|NCT03443206|OTHER|anonymous social support|Participants randomized to the intervention condition will be able to communicate with one another and offer social media-based forms of support (e.g., post music, photos, etc).
214509465|NCT03443206|OTHER|psychoeducation|educational materials related to mental health
214509466|NCT03443206|OTHER|online resources|links to online mental health resources
214509467|NCT04070105|DEVICE|Compliant Adaptive Energy Storage and Return Foot|The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button
214509468|NCT04070105|DEVICE|AllPro|Participants will be fit with a high activity foot designed to be used for walking and running
215027975|NCT00140920|DRUG|MK0966; rofecoxib|
215105123|NCT01435135|BIOLOGICAL|ALVAC-HIV|1 mL per injection containing 10\^6 CCID50/dose administered
215105124|NCT01435135|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
215105125|NCT01435135|BIOLOGICAL|ALVAC-HIV Placebo|1 ml per injection
215105126|NCT01435135|BIOLOGICAL|AIDSVAX B/E Placebo|1 ml per injection
215105127|NCT06363539|DRUG|Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION|steroid used for umblical granuloma
215105128|NCT06363539|DRUG|Silver Nitrate|silver nitrate used for treatment
215105129|NCT01558453|DRUG|Oxaliplatin|"Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30)."
215105130|NCT01882699|DEVICE|Cereve Sleep System|cerebral hypothermia
214509469|NCT03054506|DEVICE|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
215027976|NCT00140920|DRUG|Comparator: diclofenac 2x 75 mg|
215027977|NCT06215157|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
215027978|NCT06215157|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
215027979|NCT05767086|DRUG|Gonadotropin releasing hormone antagonist (Cetrotide)|clinical pregnancy rates
215027980|NCT05767086|DRUG|Medroxyprogesterone Acetate (Tarlusal)|clinical pregnancy rates
215027981|NCT05767086|DRUG|Dydrogesterone|clinical pregnancy rates
215027982|NCT06641661|DRUG|Hybutimibe 10mg QD|Hybutimibe was added to the conventional treatment
215027983|NCT04102566|DRUG|Ibuprofen 600 mg|We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
215027984|NCT04102566|BEHAVIORAL|Education|We'll be adding education to patient's post-operative instructions to aid in their pain control management.
215027985|NCT01549015|OTHER|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
215027986|NCT04476147|OTHER|Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.|This is an observational study. All the patients evaluate with CHA2DS2-VASc, HAS-BLED and Fried Scale, and observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with NVAF.
215027987|NCT03589833|DRUG|Tripterygium Wilfordii|Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
215027988|NCT03589833|DRUG|Methotrexate|Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
215027989|NCT03589833|DRUG|Yisaipu|Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
215027990|NCT05467098|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
215027991|NCT05144737|BEHAVIORAL|The Diabetes Prevention Program|The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
215027992|NCT06239285|DEVICE|Brief Violence Intervention VR (BVI-VR)|BVI-VR is being developed as a hospital-based brief gun violence intervention program founded on the principles of positive psychology, motivational goal setting (via gameplay), psychoeducation, cognitive-behavioral therapy, and dialectical behavioral therapy. All steps of the BVI-VR emphasize being in control of making positive choices, and how to locate and leverage opportunities within their communities to improve their well-being. BVI-VR empowers patients to be the driver of their well-being
215027993|NCT06239285|OTHER|Treatment as Usual (TAU)|group will receive a community resource brochure (the same one that is provided at the end of BVI-VR). This brochure provides contact detail for services in the local area. These include organizations that provide mental health counseling, mentorship services, career development programs, organized community activities and sports, educational support, financial support, substance abuse programs, and resource assistance (e.g., food, housing, etc.).
215027994|NCT04769986|BEHAVIORAL|Mobile Mindfulness-Relapse Prevention (mMBRP)|Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).
215027995|NCT04769986|BEHAVIORAL|Exercise/healthy eating mobile app|Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
215027996|NCT03285893|OTHER|oral cell DNA adducts|oral cells will be collected, DNA isolated, and analyzed for adducts
215027997|NCT06384625|OTHER|AIRWISE|AIRWISE (Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education) utilizes personal air cleaners (PACs) to filter indoor air, while enhanced aspects focus on improving compliance to PAC use. Key components include low-cost sensors (PurpleAir, Inc, USA) that change color according to air quality index (AQI) and behavioral recommendations that correspond to varying AQI levels.
215027998|NCT05299424|DRUG|CM336_group 1|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215105131|NCT00479856|DRUG|Lapatinib|Small molecule tyrosine kinase inhibitor
215105132|NCT00479856|DRUG|Capecitabine|Chemotherapy
215105133|NCT00479856|DRUG|Docetaxel|Chemotherapy
215105134|NCT00479856|DRUG|nab-Paclitaxel|Chemotherapy
215105135|NCT06115590|DIETARY_SUPPLEMENT|Nutritional supplement|Nutritional intervention hypothesized to have an acute anxiolytic effect
214509470|NCT03054506|DEVICE|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
214509471|NCT03054506|DEVICE|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
215105136|NCT00160836|DEVICE|"Tissue sampling (G.I.U.M. catheter)"|
215105137|NCT06965894|DEVICE|Johnston Pressure Splint|Application of a Johnston pressure splint to the lower extremity.
215105138|NCT06965894|OTHER|Rehabilitation Program|Rehabilitation program including neurodevelopmental therapy and proprioceptive neuromuscular facilitation (PNF) techniques.
215105139|NCT06584305|PROCEDURE|AI-Powered Body Dysmorphic Disorder Screening Procedure|The AI-Powered Body Dysmorphic Disorder Screening Procedure involves using an AI tool to evaluate patients for Body Dysmorphic Disorder (BDD) before undergoing elective cosmetic surgery. The screening integrates the Body Dysmorphic Disorder Questionnaire (BDDQ) with additional psychological assessments. The AI system processes the collected data to produce a risk score, guiding surgeons in making informed decisions about the need for psychological evaluation or intervention, and determining the suitability of patients for surgery.
215105140|NCT06443983|OTHER|AI-supported case|In the artificial intelligence-supported case lesson, students will listen to audio and visual content prepared by artificial intelligence.
215105141|NCT01597713|DRUG|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
215027999|NCT05299424|DRUG|CM336_group 2a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215028000|NCT05299424|DRUG|CM336_group 2b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215105142|NCT01597713|DRUG|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
215105143|NCT01597713|DRUG|placebo|Subjects will receive a single dose of oral placebo within each dose group
215105144|NCT01597713|DRUG|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
215028001|NCT05299424|DRUG|CM336_group 3a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215105145|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
215105146|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
215105147|NCT04091243|DRUG|Romosozumab|Experimental drug for the treatment of glucocorticoid induced osteoporosis
215105148|NCT02898298|BEHAVIORAL|Positive Emotion Regulation Training|Participants will receive a 3-session psycho-educative training on emotion regulation.
215105149|NCT01423734|OTHER|magnetic resonance imaging (MRI)|"Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.~During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center."
215105150|NCT03383380|DRUG|Rapamycin|Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.
214509472|NCT05228834|DRUG|Voxelotor Only Product in Oral Dose Form|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
214509473|NCT05228834|DRUG|Placebo|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
214509474|NCT02649725|BEHAVIORAL|patient's satisfaction|Questionnaire based measurement.
214509475|NCT00564447|DRUG|Azithromycin|azithromycin topical solution 1% given as a single drop in a single eye
214509476|NCT00564447|DRUG|Moxifloxacin|Moxifloxacin topical solution given as a single drop in a single eye
214509477|NCT00502359|DEVICE|capillary blood glucose measurement|
214509478|NCT00988845|DIETARY_SUPPLEMENT|Indole-3-carbinol|200 mg bid po X 8 weeks
214509479|NCT01291810|BIOLOGICAL|TNF Kinoid|TNF Kinoid
214509480|NCT01291810|BIOLOGICAL|WFI|WFI
214509481|NCT03547154|BIOLOGICAL|Pegylated interferon alfa-2b|Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg
214509482|NCT03547154|BIOLOGICAL|Interferon alfa-2b|Daily SC injection of interferon alfa-2b, 5 MIU/m\^2
214509483|NCT05584748|DEVICE|transcranial direct current stimulation|tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).
214509484|NCT05049941|DIAGNOSTIC_TEST|lactat and blood gases|observational
214509485|NCT03849482|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging|Multiparametric MRI evaluation includes Conventional MRI, Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI
215028002|NCT05299424|DRUG|CM336_group 3b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215105151|NCT04311931|OTHER|Active Dance Program|All Creative Dance sessions comprised five phases: 1) opening ritual (5 min), in which participants will be welcomed and will be informed about the objectives and structure of the session; 2) warm-up (15 min), in which body muscle groups will be activated through the introduction of basics elements of movement; 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives described above. This phase will end with a choreography composition; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience and they will fill a sheet with attendance, exercise intensity perception (Borg Scale) and satisfaction's (Caregiver Treatment Satisfaction questionnaire).
215105152|NCT04945109|OTHER|Mankai beverage|Recommended background healthy diet with Mankai supplementation after main meal (300 ml)
215028003|NCT05299424|DRUG|CM336_group 4a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215028004|NCT05299424|DRUG|CM336_group 4b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215028005|NCT05299424|DRUG|CM336_group 5|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215028006|NCT05299424|DRUG|CM336_group 6a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215105153|NCT04945109|OTHER|Water (control)|Recommended background healthy diet with water supplementation after main meal (300 ml)
215105154|NCT02760810|DEVICE|Marketed Contact Lens|Narafilcon A
215105155|NCT02690714|BIOLOGICAL|Plasminogen (Human) intravenous|Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
215105156|NCT06531317|DEVICE|transcranial Direct Current Stimulation|The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).
214509486|NCT03849482|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology|Ultrasound-Guided Fine Needle Aspiration Cytology
214509487|NCT03849482|DIAGNOSTIC_TEST|Clinical Evaluation|Patient's history and physical examination, reporting signs and symptoms suggestive of malignancy (pain, facial nerve weakness, fixation to skin and surrounding tissues, trismus, skin ulceration, lymphadenopathy, numbness, weight loss)
214509488|NCT03849482|DIAGNOSTIC_TEST|Final Histopathological Diagnosis|Final Diagnosis of the Disease from the Pathology Report after Surgical Resection of the Lesion
214509489|NCT02861456|OTHER|Standard Model of Care|
214509490|NCT02861456|OTHER|Alternative Model of Care|
214509491|NCT04471441|DRUG|Everolimus Tab.|After first dose 1mg BID(total 2mg daily PO), check the blood concentration of everolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/mL.
214509492|NCT04471441|DRUG|Mycophenolate mofetil Tab./Cap.|Up to 1.5g BID(total 3g daily), PO
214509493|NCT01488084|PROCEDURE|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
214509494|NCT01488084|PROCEDURE|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
214509495|NCT00895245|DRUG|fosaprepitant dimeglumine|Given IV
214509496|NCT00895245|DRUG|cisplatin|Given IV
214509497|NCT00895245|DRUG|palonosetron hydrochloride|Given IV
214509498|NCT00895245|DRUG|dexamethasone|Given IV and orally
214509499|NCT00895245|OTHER|Functional Living Index-Emesis Questionnaire|Ancillary studies
214509500|NCT00895245|BEHAVIORAL|Emesis Diary|Ancillary studies
214509501|NCT00895245|RADIATION|Radiotherapy|Undergo radiotherapy
214509502|NCT04653688|DEVICE|The FeetMe® Evaluation|The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.
215028007|NCT05299424|DRUG|CM336_group 6b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215105157|NCT06531317|DIAGNOSTIC_TEST|Electroencephalography|64-channel active-electrode EEG with impedances kept \~5KOhm
215105158|NCT02588209|BEHAVIORAL|Strategic Memory Advanced Reasoning Training|SMART teaches strategies to improve the ability to process information.
215105159|NCT02588209|BEHAVIORAL|Brain Health Workshop|Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
215105160|NCT05185414|DIAGNOSTIC_TEST|Venipuncture and skin biopsy for RNA extraction|"* Blood sampling (standard venipuncture)~* Skin biopsy (fibroblasts)"
215105161|NCT04294147|DRUG|Galcanezumab|Administered SC
215105162|NCT04294147|DRUG|Erenumab|Administered SC
215105163|NCT04602247|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin, whose bioavailability is to be studied
215105164|NCT04602247|DIETARY_SUPPLEMENT|SIC + AA combined|Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
215105165|NCT04602247|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate serves as a positive control, whose iron bioavailability is known
215105166|NCT04602247|DIETARY_SUPPLEMENT|FeSO4 + AA combined|Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
215105167|NCT04602247|OTHER|EP + FeSO4 combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
215028008|NCT05299424|DRUG|CM336_group 7|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215028009|NCT05299424|DRUG|CM336_group 8a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215028010|NCT05299424|DRUG|CM336_group 8b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215028011|NCT05299424|DRUG|CM336_group 9|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
215028012|NCT05299424|DRUG|CM336_RP2D|CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
215028013|NCT04046991|DEVICE|high-definition transcranial direct current stimulation|High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
215105168|NCT04602247|OTHER|EP + FeSO4 + AA combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
215105169|NCT03872856|DEVICE|BP-ICAN|"One of two home blood pressure monitor devices will be used.~1. Omron 7 Series Wrist cuff~2. Omron 10 Series Upper Arm cuff"
215105170|NCT00516867|RADIATION|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
215105171|NCT00516867|RADIATION|UV radiation|UVB 1.4 % and UVA 98.6
215105172|NCT05753163|COMBINATION_PRODUCT|HAIC-FOLFOX combined with Sintilimab and Regorafenib|HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2) was given every 4-6 weeks for 2-4 cycles depending on pts' health status, in combination with Sintilimab (200mg, iv, d1) and regorafenib (80mg, po, d1-21) every 3 weeks for up to 6 months .
215105173|NCT02205242|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
215105174|NCT02205242|DEVICE|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
215105175|NCT02205242|DRUG|Placebo|
215105176|NCT05621993|DRUG|Azvudine|Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in the Diagnostic and therapeutic protocol for COVID-9 in China.
215105177|NCT05862311|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
215105178|NCT00487292|BEHAVIORAL|naps and pulses of bright light|
215105179|NCT01708135|BEHAVIORAL|Use of smartphone app|
215105180|NCT06485388|DRUG|Propofol|Venous blood samples will be taken from the patients included in the study and incubated with propofol (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
215105181|NCT06485388|DRUG|Thiopental|Venous blood samples will be taken from the patients included in the study and incubated with thiopental (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
215105182|NCT00002148|DRUG|OPC 14117|
215105183|NCT01240135|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
215105184|NCT01240135|DEVICE|renu fresh Multi-Purpose Solution (MPS)|Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
215105185|NCT01240135|DEVICE|Galyfilcon A contact lenses (Acuvue Advance)|A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
215105186|NCT01371305|DRUG|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
215105187|NCT01371305|DRUG|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
215105188|NCT03682913|BEHAVIORAL|P-CIT protocol|Personalized inhibitory control training for one week.
215105189|NCT03682913|BEHAVIORAL|Placebo|without personalized inhibitory control training for one week.
215105190|NCT03825016|DRUG|Lidocaine Hydrochloride|Lidocaine infusion on hystroscopic media during office hystroscopy
215105191|NCT03825016|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium
215105192|NCT01247194|DRUG|PPI-461|capsule, oral, once daily for 3 days
215105193|NCT01247194|DRUG|Placebo|capsules, oral, once daily for 3 days
215105194|NCT01124955|OTHER|Acupuncture|The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)
215105195|NCT01124955|OTHER|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
215105196|NCT02891382|BEHAVIORAL|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
215105197|NCT02891382|BEHAVIORAL|Goal setting|Goals for weight loss and change in levels of HbA1c
215105198|NCT02891382|BEHAVIORAL|Companion Support|Patient has a companion/team support partner to support achieving goals.
215105199|NCT02891382|BEHAVIORAL|Individual Reward|The cash reward is given to the patient with diabetes.
214509503|NCT04653688|DEVICE|the PKG® Watch,|The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® system consists of a wrist-worn movement recording device known as the PKG® Watch,
214509504|NCT04653688|RADIATION|MRI|"* an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~* anatomical registration~* automated segmentation~* volumetric~* texture analysis"
214509505|NCT04653688|RADIATION|DaTSCAN|"* quantify nigrostriatal dopaminergic depletion~* correlate its impact on the type and severity of gait disorders in Parkinson's disease."
214509506|NCT02764905|BEHAVIORAL|intensive cognitive physical rehabilitation program|include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
214509507|NCT00989755|OTHER|Fax to Quit (F2Q)|Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
214509508|NCT05028465|PROCEDURE|Endoscopic Papillectomy|A snare devicewas inserted via the working channel, and the endoscopist adjusted the snare to securely grasp the lesion, which was then excised by using standard electrocautery.
214509509|NCT05028465|PROCEDURE|Endobiliary Radiofrequency Ablation|The RFA catheter was then placed under fluoroscopic guidance across the distal common bile duct. An ERBE VIO200D generator (ERBE Elktromedizin, Tubingen, Germany) was connected for RFA at 10 W for 90 seconds.
214509510|NCT04976556|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
214509511|NCT02706483|DRUG|Plecanatide|
214509512|NCT02587052|DRUG|Generic tacrolimus|Generic tacrolimus
214509513|NCT02587052|DRUG|Prograf|Prograf, the original tacrolimus
215105200|NCT02891382|BEHAVIORAL|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
215105201|NCT01618149|RADIATION|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
215105202|NCT05583084|OTHER|Investigation|
215105203|NCT01839149|DRUG|TI-001|TI-001 is intranasal oxytocin
215105204|NCT01839149|DRUG|Placebo|
215105205|NCT04233619|DIAGNOSTIC_TEST|optical coherence tomography|non-invasive test performed by an Ophthalmologist that allows three-dimensional imaging of the retinal vasculature
215105206|NCT01628965|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
215105207|NCT02677857|BEHAVIORAL|Common intervention components for Lifestyle|Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
215105208|NCT00025246|DRUG|imatinib mesylate|Given orally
215105209|NCT00025246|OTHER|laboratory biomarker analysis|Correlative studies
215105210|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
215105211|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
214509514|NCT01972776|DRUG|QBM076|Supplied in 25 mg and 75 mg capsules
214509515|NCT01972776|DRUG|Placebo|Matching placebo capsules
215105212|NCT00311259|DRUG|Melatonin (drug)|
215105213|NCT00311259|DRUG|Laktose|
215105214|NCT05262283|OTHER|No intervention|No intervention was made.
215105215|NCT00075738|DRUG|cisplatin|
215105216|NCT00075738|DRUG|fluorouracil|
215105217|NCT00075738|DRUG|irinotecan hydrochloride|
215105218|NCT00075738|DRUG|leucovorin calcium|
215028014|NCT04046991|BEHAVIORAL|modified constraint-induced language therapy|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
215028015|NCT04235062|DRUG|Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution|A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
215028016|NCT04235062|DRUG|Intravenous Bolus Furosemide|Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
215028017|NCT05302609|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in reinforcement of scleral thinning.
214509516|NCT02969200|DRUG|Enzyme replacement therapy|All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
215028018|NCT02456883|DRUG|gilteritinib|oral
215105219|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Granules for oral suspension, 10 mg, oral, single dose
215105220|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 10 mg, oral, single dose
215105221|NCT06212830|DRUG|Gabapentin|Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
214509517|NCT01388413|DRUG|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
214509518|NCT03763968|OTHER|treatment and outcome|
214509519|NCT03032757|DIETARY_SUPPLEMENT|Essential amino acids|240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.
214509520|NCT05565898|DEVICE|positron emission tomography for exclusion of bone marrow infiltration in lymphoma|compare the diagnostic accuracy of PET/CT scan against Bone Marrow Biopsy in detection of bone marrow involvement for staging of lymphoma
214509521|NCT02782260|DRUG|Dipyridamole|
214509522|NCT02782260|DRUG|Placebo|
214509523|NCT01774240|OTHER|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
215028019|NCT02456883|DRUG|14C-labeled gilteritinib|oral
215028020|NCT00059267|DRUG|HBIG, Epivir, Hepsera|
215028021|NCT06565663|BEHAVIORAL|MaPGAS Decision Aid|This intervention involves a novel, web-based decision aid tool specifically designed to support transgender and non-binary individuals assigned female at birth in making informed decisions about Metoidioplasty and Phalloplasty Gender Affirming Surgeries (MaPGAS). The tool includes comprehensive information on surgical options, risks, benefits, and medical illustrations to aid in aligning surgical decisions with the individual's personal values and goals.
215028022|NCT05644132|DEVICE|InDx Implant for the carpometacarpal joint|Treatment of thumb base joint arthritis with the InDx Implant
215105222|NCT06212830|DRUG|Targin|Targin 5 mg twice a day after the procedure for 48 hours
215105223|NCT06212830|DRUG|NSAID|Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
215105224|NCT06212830|DRUG|Paracetamol|Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
215105225|NCT05315089|OTHER|Virtual reality games +conventional exercises|Virtual reality games +conventional exercises
215105226|NCT05315089|OTHER|Conventional exercises|Conventional exercises
215105227|NCT06347263|OTHER|Entire papilla preservation technique|Minimally invasive periodontal surgery
215105228|NCT01799551|BEHAVIORAL|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
215105229|NCT05944627|BIOLOGICAL|FURESTEM-OA Kit Inj.|FURESTEM-OA Kit Inj. is a combination medical product in which FURESTEM-OA Inj. (solution 1) is the primary mode of action and CAM Inj. (solution 2) acts as an auxiliary. The product is administered after mixing solution 1 and solution 2.
215105230|NCT05944627|BIOLOGICAL|Placebo|placebo administration in Phase 2a clinical trial
215105231|NCT02828020|DRUG|Ubrogepant|50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
214509524|NCT01984099|DRUG|Methotrexate|Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
214509525|NCT01984099|DRUG|Vitamin B Complex|Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
214509526|NCT01543204|DRUG|Etanercept|Administered by subcutaneous injection
214509527|NCT00995683|DRUG|half molar sodium lactate|intravenous infusion of 0.5 ml/kg during 48 hours
214509528|NCT00995683|DRUG|isotonic sodium chloride|intravenous infusion of 0.5 ml/kg during 48 hours
215105232|NCT02828020|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
214509529|NCT00458185|DRUG|etanercept|
215028023|NCT06568393|OTHER|Calisthenic exercise|Calisthenic exercise program was included: jumping jack, burpee, mountain climber, squat thrust, squat, squat jump, split and alternate exercises.
215105233|NCT03691363|BEHAVIORAL|M-STEP|Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes \> MVPA at baseline with 2) HR\>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR\>140 (low end of MVPA). The intervention will be 6 weeks in duration.
215105234|NCT00391924|DRUG|Dehydroepiandrosterone|
215105235|NCT04717817|DEVICE|Inspiratory muscle training (IMT) using an IMT Threshold device (Philips)|Inspiratory muscle training on a daily basis prior to surgery during 2-3 weeks
214509530|NCT00603018|DRUG|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
215028024|NCT06541964|OTHER|Parent-Provide Distraction|The children will be asked riddles by their parents for 5 seconds before and during the blood collection procedure.
215028025|NCT06541964|OTHER|Windmill Toy Blowing|The children will blow on the windmill toy for 5 seconds before and during the blood collection procedure.
215028026|NCT06541964|OTHER|Control|No intervention will make on the children.
215028027|NCT05572073|OTHER|Natural History Study|Natural History Study
215028028|NCT02333292|DRUG|Telaprevir|Initiation of a regimen containing TVR
215028029|NCT02333292|DRUG|Boceprevir|Initiation of a regimen containing BOC
215028030|NCT02333292|DRUG|Sofosbuvir|Initiation of a regimen containing SOF
215028031|NCT02333292|DRUG|Simeprevir|Initiation of a regimen containing SMV
215028032|NCT02333292|DRUG|Daclatasvir|Initiation of a regimen containing DCV
215028033|NCT02333292|DRUG|Ledipasvir|Initiation of a regimen containing LDV
215028034|NCT02333292|DRUG|ritonavir-boosted Paritaprevir/ Ombitasvir|Initiation of a drug combination of PTV/OTV
215028035|NCT02333292|DRUG|Dasabuvir|Initiation of a regimen containing DBV
215028036|NCT02333292|DRUG|Velpatasvir|Initiation of a regimen containing VPV
215028037|NCT02333292|DRUG|Elbasvir|Initiation of a regimen containing EBV
215028038|NCT02333292|DRUG|Grazoprevir|Initiation of a regimen containing GZR
215028039|NCT05478265|DEVICE|RS-4i Plus|RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.
215028040|NCT06496659|PROCEDURE|Segmentectomy|A segmentectomy is a surgical procedure to remove a segment of the lung. This surgery will be done on patients who have completed neoadjuvant therapy for diagnosis of Non-Small Cell Lung Cancer.
215028041|NCT05114018|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Daily oral dose
215028042|NCT05114018|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
215028043|NCT06035510|DIETARY_SUPPLEMENT|whey protein supplement|Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative care on postoperative outcomes after gynecological cancer surgery
215028044|NCT04809714|DEVICE|Blood Flow Restriction with Delfi Tourniquet System Cuff|Postoperative rehabilitation will occur up to twice a day for 5 days a week for 2 weeks using a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of 60-100%. For each physical therapy session, participants will undergo therapy following a standardized protocol of 3-5 difference exercises each with 4 sets total in addition to NMES.
215028045|NCT04809714|OTHER|Routine Post-operative Physical Therapy|The control group with undergo a post-op therapy protocol that mirrors that of the intervention group except that they will use a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of only 10%. Participants will use a neuromuscular electrical stimulation device operating at a sub-therapeutic level.
215028046|NCT06431919|DRUG|Simvastatin 20mg|Simvastatin fixed dose of 20 mg per day
215028047|NCT06431919|DRUG|Carvedilol 3.125 mg|Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate
215028048|NCT05286619|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered on Day 1 every 3 weeks for up to 24months
215028049|NCT05286619|DRUG|Cisplatin|Cisplatin at 35 mg/m2 IV using a split dose regimen on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles.
215028050|NCT05286619|DRUG|Carboplatin|Carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles.
215028051|NCT05286619|DRUG|Gemcitabine|Gemcitabine 1250mg/m2 IV on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles
215028052|NCT05250583|BIOLOGICAL|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
215028053|NCT05824702|BEHAVIORAL|Peer education & communications|The intervention trains peer educators to promote medication-assisted drug treatment among peer who inject drugs and are living with HIV.
215028054|NCT05824702|BEHAVIORAL|Standard of care educational|This is an educational equal attention control group
215105236|NCT04717817|OTHER|Standard physiotherapy|Standard instructions and physiotherapy prior to surgery during 2-3 weeks
215105237|NCT04330027|BIOLOGICAL|Growth factors|A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
215105238|NCT04330027|OTHER|Saline|0.9% Sodium Chloride
215105239|NCT00216489|DRUG|rabeprazole sodium|
215105240|NCT00085891|DRUG|Quetiapine Fumarate|
215028055|NCT04737603|DRUG|ED-Initiated treatment with buprenorphine / naloxone|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores \>=8. Participants who weigh \> 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh \<= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
215028056|NCT06477016|DEVICE|OsciPulse|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
215105241|NCT00615173|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
215105242|NCT00615173|DRUG|cyclophosphamide or azathioprine|Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
215105243|NCT00682955|DRUG|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
215105244|NCT00682955|DRUG|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
215105245|NCT06039618|OTHER|Referral to Centre of Higher Organizational Level|Referral to Centre of Higher Organizational Level. This means referral from a primary neonatal care center to a secondary one, or from the secondary to the tertiary center.
215105246|NCT05122429|BEHAVIORAL|e-Health Treatment|Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
215105247|NCT03991429|DIAGNOSTIC_TEST|Simultaneous functional MRI and urodynamic studies|"Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure."
215028057|NCT06477016|DEVICE|Intermittent Pneumatic Compression|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
215028058|NCT06585384|COMBINATION_PRODUCT|etanercept and repeated contrast ultrasound|Strategy combining 9 weeks of etanercept administration (50mg/week) with 5 weeks of repeated contrast ultrasound of 2 sessions per day, 5 days per week (from the fifth week of etanercept treatment)
215105248|NCT03991429|BEHAVIORAL|Questionnaires|Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
215105249|NCT03991429|OTHER|Post Void Residual (PVR), Uroflow and Bladder Diary|Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.
215105250|NCT03991429|DIAGNOSTIC_TEST|Urinalysis|Urine sample
215105251|NCT03366467|OTHER|SADE|The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.
215105252|NCT03366467|OTHER|RDE|The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
215105253|NCT02645630|OTHER|Right Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
215028059|NCT01597700|DRUG|10mg Ezetimibe|1 tablet taken by mouth
215028060|NCT01597700|DRUG|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
215105254|NCT02645630|OTHER|Left Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
215105255|NCT02645630|OTHER|Sham Cervical Manipulation|The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
215028061|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/100|5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
215028062|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/10|5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
215105256|NCT02355444|DIETARY_SUPPLEMENT|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
215105257|NCT02355444|DIETARY_SUPPLEMENT|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
215105258|NCT00336557|PROCEDURE|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
215105259|NCT01517386|PROCEDURE|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
215105260|NCT00357825|DRUG|[S,S]-Reboxetine|
215105261|NCT00483795|DRUG|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
215105262|NCT06395532|OTHER|Observetional|After admission to the ICU, patients will be continuously monitored with ICU standard monitoring in addition to IPI using (Capnostream™ Medtronic). IPI will be recorded after transfer to the ICU, as well as at 2, 6, 12, 18 and 24 hours.
215105263|NCT02239952|DRUG|Sunitinib|50 mg once daily, oral use for 14 days
215105264|NCT02239952|DRUG|vandetanib|300 mg, once daily, oral use for 14 days
215105265|NCT02239952|DRUG|Erlotinib|150 mg, once daily, oral use for 14 days
215105266|NCT05230849|DEVICE|dry needling|is a physiotherapy treatment for neurological patients and studies the efficacy of dry needling by studying several pre-treatment and post-treatment variables after the experimental treatment.
215105267|NCT05230849|OTHER|convencional treatment|is a physiotherapy treatment for neurological patients
215028063|NCT03213405|BIOLOGICAL|rBCG-N-hRSV full dose|1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
215105268|NCT04238169|DRUG|Bevacizumab|7.5mg/kg once every three weeks
215105269|NCT04238169|DRUG|Toripalimab|240 mg once every three weeks
215105270|NCT04238169|RADIATION|SBRT|30-50Gy/5F（2-4 lesions）
215105271|NCT01249547|DRUG|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
215105272|NCT05150522|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cells infusion
215105273|NCT01402739|OTHER|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
215105274|NCT01402739|OTHER|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
215105275|NCT05006950|DEVICE|Stryker1688 Fluorescence imaging system|The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool to determine the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.
214509531|NCT01470209|DRUG|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
214509532|NCT01470209|DRUG|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
214509533|NCT05713136|DEVICE|Diagnostic Test: Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
215028064|NCT03213405|BIOLOGICAL|Conventional BCG full dose|2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
215028065|NCT04426591|DRUG|Biotin Labeled Red Blood Cells|On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of \~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion hemoglobin (Hb), sickle cell hemoglobin (HbS), and body weight, per clinical protocol.
215028066|NCT04426591|DEVICE|INTERCEPT Blood System|In addition to the blood drawn for the main study, individuals participating in this optional intervention will have additional tubes of peripheral venous blood will be drawn for evaluating treatment-emergent antibodies specific to INTERCEPT RBCs and acridine surface label monitoring. Tests for treatment-emergent antibodies specific to INTERCEPT RBCs will be performed according to procedures developed by Cerus Corporation.
215028067|NCT05375929|DRUG|Abrocitinib 100 mg|Orally administered, abrocitinib 100 mg tablets QD
215028068|NCT05375929|DRUG|Abrocitinib 200 mg|Orally administered, abrocitinib 200 mg tablets QD.
215105276|NCT04771676|DRUG|Oncorine (H101)|A modified human recombinant type 5 adenovirus with genetic modifications.
215105277|NCT04233450|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
215105278|NCT06311422|OTHER|resin nanoceramic block|Resin-based CAD/CAM materials
215105279|NCT06311422|OTHER|zirconia-reinforced lithium silicate|zirconia reinforced lithium silicate ceramic
215105280|NCT00966550|OTHER|Tomato|Tomato with high carb/fat meal
215105281|NCT00966550|OTHER|Non-tomato|Non-tomato with high carb/fat meal
215105282|NCT03999840|DRUG|cemdisiran|Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
215105283|NCT03999840|DRUG|Placebos|The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
215105284|NCT03012204|DEVICE|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
215105285|NCT03012204|DEVICE|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
215105286|NCT03012204|DEVICE|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
215105287|NCT03012204|DEVICE|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
215105288|NCT05374629|BEHAVIORAL|Use different methods of teaching|Both groups will receive a smoking cessation education guideline and post-test three months after the intervention.
215105289|NCT06085014|OTHER|Standard of care|All patients will undergo, as clinically indicated, AF ablation by pulmonary vein isolation achievable by radiofrequency, cryoenergy, or electroporation. All patients will preliminarily undergo electroanatomic mapping of the atrium by CARTO/Navx/Rhythmia system indifferently. Patients will be given follow-up visits at 3-6-12 months, during which any arrhythmic recurrences will be assessed
215105290|NCT06085014|OTHER|Data collection|There's no patient involvement. Data of patients who underwent ablative procedures two years before the start of the study will be retrospectively analyzed
215105291|NCT00379912|DRUG|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
215105292|NCT00379912|DRUG|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
215105293|NCT00379912|DRUG|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
215105294|NCT01128946|DRUG|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
215105295|NCT01128946|DRUG|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
215105296|NCT01128946|DRUG|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
215105297|NCT00621140|DRUG|linagliptin|active
215028069|NCT06054893|DRUG|Omaveloxolone|Administered as specified in the treatment arm
215028070|NCT02873962|DRUG|Bevacizumab|"* Bevacizumab will be given intravenously at a pre-determined dosage~* One dose reduction will be allowed for Bevacizumab"
215105298|NCT00621140|DRUG|placebo|placebo
215105299|NCT03422666|DRUG|Teduglutide|Teduglutide
215105300|NCT03422666|DRUG|Placebo|Placebo
215105301|NCT03057782|DEVICE|Waveguard (TM) EEG cap|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
215105302|NCT03057782|DEVICE|Micro Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
215105303|NCT03057782|DEVICE|Pico Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
215105304|NCT03057782|DEVICE|QS Piezostimulator|This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
215028071|NCT02873962|DRUG|Nivolumab|"* Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage.~* No dose reductions or escalations will be allowed for Nivolumab"
215028072|NCT02873962|DRUG|Rucaparib|"* Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage.~* Up to three dose reductions will be allowed for Rucaparib (depending on cohort)."
215028073|NCT06172257|DRUG|Dexamethasone ophthalmic suspension (OCS-01)|Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
215105305|NCT03057782|DEVICE|tactileTM sensory evaluator|This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
215105306|NCT05322369|OTHER|periodontal charting only|Periodontal charting only
215105307|NCT05041972|DRUG|ARX788|ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).
215105308|NCT04983420|OTHER|non-alcoholic Pilsner|intake of 1 L non-alcoholic Pilsner per day for 2 weeks
215105309|NCT04983420|OTHER|non-alcoholic wheat beer|intake of 1 L non-alcoholic wheat beer per day for 2 weeks
215105310|NCT04983420|OTHER|apple spritzer|intake of 1 L apple spritzer per day for 2 weeks
215105311|NCT04983420|OTHER|lemonade|intake of 1 L lemonade per day for 2 weeks
215105312|NCT01504685|PROCEDURE|Banded Laparoscopic Roux-en-Y gastric bypass|"A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
215105313|NCT01504685|PROCEDURE|Unbanded Laparoscopic Roux- en-Y gastric bypass|"A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
215105314|NCT02481778|OTHER|Blood sampling|
215105315|NCT01138501|DRUG|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
215105316|NCT01138501|DRUG|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
215105317|NCT01884272|DRUG|lesinurad 400 mg|
215105318|NCT01884272|DRUG|naproxen 250 mg|
215105319|NCT01884272|DRUG|indomethacin 25 mg|
215105320|NCT01656668|DRUG|BC1036|
215105321|NCT05226312|OTHER|Local Warm Compress|The warm application will be made by the researcher for 15 minutes three times a day according to the local warm application process steps.
215105322|NCT00365274|DRUG|Cyclophosphamide|Given IV 750 mg/m\^2 day 1
215105323|NCT00365274|DRUG|Doxorubicin hydrochloride|Given 50 mg/m\^2 IV day 1
215105324|NCT00365274|DRUG|vincristine sulfate|Given 1.4 mg/m\^2 IV
215105325|NCT00365274|DRUG|prednisone|100 mg orally daily days 1 - 5
215105326|NCT00365274|DRUG|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
215028074|NCT06172257|DRUG|Vehicle|Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
215028075|NCT06106568|PROCEDURE|EOB-MRI|Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan
215028076|NCT06106568|PROCEDURE|Surgery|Retrospective analysis for pancreatic cancer patients who had a record of any surgery for the pancreatic cancer in the Medical Data Vision (MDV) database in Japan
215028077|NCT06106568|PROCEDURE|Open-close Laparotomy|Retrospective analysis for pancreatic cancer patients who had a record of an open-close laparotomy in the Medical Data Vision (MDV) database in Japan
215028078|NCT03916419|DEVICE|ViewRay MR-Linear Accelerator|-Radiation will be delivered by this machine
215105327|NCT04807257|COMBINATION_PRODUCT|Auger Molecular Therapy (AMT)|The AMT consists of intratumorally delivered IUdR and local irradiation via AUTRON Therapy System.
215105328|NCT03809819|PROCEDURE|laparoscopic Vecchietti vaginoplasty|Patients who underwent laparoscopic Vecchietti vaginoplasty
215028079|NCT03916419|RADIATION|Radiation therapy|-60Gy in 15 fractions
215028080|NCT03916419|DRUG|Paclitaxel|-50 mg/m\^2 intravenous
215105329|NCT03809819|DIAGNOSTIC_TEST|FSFI questionnaire|Completion of FSFI questionnaire
215028081|NCT03916419|DRUG|Carboplatin AUC|-2 mg/mL/min intravenous over 30 minutes
215105330|NCT03809819|DIAGNOSTIC_TEST|UDI-6 questionnaire|Completion of UDI-6 questionnaire
215105331|NCT03809819|DIAGNOSTIC_TEST|IIQ-7 questionnaire|Completion of IIQ-7 questionnaire
215105332|NCT02343198|DEVICE|Custom-built research muscle stimulator|Muscle stimulator
215105333|NCT03063268|BEHAVIORAL|Trust-Enhanced Messaging on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
215105334|NCT03063268|BEHAVIORAL|Interactive features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
215105335|NCT03063268|BEHAVIORAL|Standard E-Consent|Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
215105336|NCT04471324|DEVICE|EBUS cryo probe|patients receive a transbronchial cryo biopsy with the EBUS cryo probe from ERBE and an ultra thin bronchoskope
215105337|NCT04887896|DEVICE|GS500|Device: GS500
215105338|NCT04887896|DEVICE|Placebo|Device: Placebo
215105339|NCT00196508|DEVICE|High Viscosity DERMABOND|
215028082|NCT03916419|BIOLOGICAL|Durvalumab|-10 mg/kg
215028083|NCT02941055|OTHER|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
215028084|NCT02941055|OTHER|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
215028085|NCT06636916|PROCEDURE|Short Intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
215028086|NCT06636916|PROCEDURE|Long intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
215028087|NCT03926247|BEHAVIORAL|Immigrant Well-Being Project|The IWP intervention emphasizes a sustainable and replicable partnership model between community-based organizations and universities that involves Mexican immigrants and undergraduate advocates working together to: a) increase immigrants' abilities to navigate their communities; b) improve immigrants' access to community resources; c) enhance meaningful social roles by valuing immigrants' culture, experiences, and knowledge; d) reduce immigrants' social isolation; and e) increase communities' responsiveness to immigrants through changes in policy and practice. The IWP is administered by university students enrolled in a service learning course, and has two elements: 1) Learning Circles, which involve cultural exchange and one-on-one learning opportunities, and; 2) Advocacy, which involves collaborative efforts to mobilize community resources related to health, housing, employment, education, and legal issues.
215105340|NCT03296449|PROCEDURE|CPAP|A recruitment maneuver will be applied to the ventilated lung. Immediately continuous positive airway pressure, at a pressure of 2-3cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP).
215105341|NCT03296449|PROCEDURE|HFJV|A recruitment maneuver will be applied to the ventilated lung. Immediately, high-frequency jet ventilation, with a driving pressure of 0.5 atm and a respiratory rate of 100 cycles per minute will applied to the non-ventilated lung for 20 minutes using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland). Monsoone III is a recognised ventilator design for HFJV.
215105342|NCT00360568|DRUG|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
215105343|NCT00360568|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
215105344|NCT00360568|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
215105345|NCT00360568|DEVICE|J-tube|jejunal tube
215105346|NCT02277808|DRUG|500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|
215105347|NCT02277808|DEVICE|Respirgard II|
215105348|NCT02277808|DEVICE|Isoneb®|
215105349|NCT02467842|BIOLOGICAL|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
215105350|NCT02467842|BIOLOGICAL|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
215105351|NCT02467842|BIOLOGICAL|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
215105352|NCT03696589|BEHAVIORAL|Physical Activity Coaching|Based in the self-determination theory, participants will be coached on beneficial exercises, how to utilize supports and overcome barriers to PA engagement. Emphasis of exercise coaching will be on increasing aerobic exercise engagement and will include us of Fitbit devices to facilitate uptake and monitor aerobic exercise. Intervention will be delivered by a physical or occupational therapist, who will work with the participant to develop a plan, set goals and targets, and track changes. Additional resources that will support exercise engagement will be provided. Participants will have the choice to receive their face-to-face session either in person or remotely via secure video-based service.
215105353|NCT05412628|DIAGNOSTIC_TEST|Oral swab test|In this study, we will perform tissue biopsy at esophageal tumor site in esophageal cancer patients and perform random biopsy at middle esophagus in patients without esophageal cancer. Besides, we will take oral swab in all participants.
214509534|NCT05052398|DRUG|PSP NEURO SERUM|PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3. Each patient will apply 1 g of PSP NEURO SERUM in their hands, three times a day.
214509535|NCT05052398|DRUG|Placebo PSP NEURO SERUM|Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
214509536|NCT02333565|DRUG|Everolimus|
214509537|NCT02333565|DRUG|Octreotide|
215028088|NCT01603251|DRUG|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
215028089|NCT01603251|DRUG|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
215028090|NCT01603251|DRUG|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
215105354|NCT02873338|DRUG|Dociparstat sodium|Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.
215105355|NCT02873338|DRUG|Idarubicin|Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
215105356|NCT02873338|DRUG|Cytarabine|Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
215105357|NCT04564872|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
215105358|NCT04564872|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
215105359|NCT04564872|DRUG|Linagliptin 5 mg QD|Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
215105360|NCT04506333|DEVICE|A&D UA-651 Blood Pressure Monitor|Test device to be validated.
215105361|NCT04506333|DEVICE|ADC 740-N Manual Sphygmomanometer|Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
215105362|NCT03657095|DRUG|Esuberaprost|Sodium tablets
215105363|NCT03657095|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
215028091|NCT03708809|DEVICE|Intrauterine system|13.5 mg levonorgestrel-releasing intrauterine system
215028092|NCT03708809|OTHER|Alternative contraception to intrauterine system|Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
215028093|NCT05142293|OTHER|Ambulatory procedure|In the same-day hospitalization group, some patients will be hospitalized on an ambulatory process
215028094|NCT01348581|DEVICE|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
215105364|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
215105365|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
215105366|NCT01399320|PROCEDURE|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
215105367|NCT05443711|OTHER|No intervention, observational study|No intervention, observational study
215105368|NCT00627055|DRUG|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
215105369|NCT00627055|DRUG|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
215105370|NCT05606055|DRUG|BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato|This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
215105371|NCT04499287|OTHER|15-minute walk at preferred walking speed.|
215105372|NCT04499287|DIETARY_SUPPLEMENT|Fiber|9 grams soluble fiber
215105373|NCT04499287|OTHER|control|control
215105374|NCT03507738|BIOLOGICAL|MT-5625 low dose|Intramuscular injection
215105375|NCT03507738|BIOLOGICAL|MT-5625 middle dose|Intramuscular injection
215028095|NCT03767387|OTHER|Trimodal Prehabilitation|Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.
215028096|NCT00178139|BEHAVIORAL|Music Therapy|Music Therapy
215105376|NCT03507738|BIOLOGICAL|MT-5625 high dose|Intramuscular injection
215105377|NCT03507738|BIOLOGICAL|Rotarix|Oral administration
215105378|NCT03507738|BIOLOGICAL|Placebo|Intramuscular injection
215105379|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 1|
215105380|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 2|
215105381|NCT02929459|OTHER|Placebo|
215105382|NCT00951652|BEHAVIORAL|CBT|
215105383|NCT00951652|OTHER|Interpersonal and emotional processing therapy|
215105384|NCT00951652|BEHAVIORAL|supportive listening|
215105385|NCT00001088|BIOLOGICAL|APL 400-047|
215105386|NCT00001088|DRUG|Bupivacaine hydrochloride|
215105387|NCT02634502|PROCEDURE|radiofrequency ablation|
215105388|NCT02634502|DRUG|S-1|
215105389|NCT00830180|BIOLOGICAL|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
215105390|NCT04305561|PROCEDURE|Contrast-enhanced ultrasound|"Ultrasound contrast agent: Stabilized sulfur hexafluoride microbubbles (SonoVue®, Bracco).~An 18 G needle will be placed in an antecubital vein and directly attached to a three-way stopcock with an extension tube.~The SonoVue® will be prepared and shaken shortly before injection in accordance with the instructions provided in the product information leaflet.~The patient will be injected with 1.2 ml SonoVue® at a pace of 1-2 ml/s using the 180 degree straight-flow channel of the three-way stopcock, directly followed by a 10 ml bolus of sodium chloride 9 mg/mL (0.9%) injected into the 90 degree channel of the three-way stopcock at a pace of approximately 2 ml/s.~A full examination will typically require one to two injections of 1.2 ml of SonoVue® (one injection per suspected parathyroid adenoma)."
215105391|NCT02920515|DRUG|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
215028097|NCT03191032|OTHER|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
215105392|NCT02920515|DRUG|Zhibo dihuang pills|Traditional Chinese Medicine
215105393|NCT02920515|DRUG|Dabu ying pills|Traditional Chinese Medicine
215028098|NCT05081271|BIOLOGICAL|Homologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
215028099|NCT05081271|BIOLOGICAL|Heterologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
215028100|NCT04691492|BEHAVIORAL|Friend-Based Motivational Interview|The intervention will use Motivational Interviewing's (MI) collaborative conversation style for strengthening commitment to change, to motivate and prepare women to work together to reduce Sexual Assault (SA) risk. This intervention will target ways that the friend dyad may support, encourage, and share responsibility with one another in protecting against SA. The Friend-based MI (FMI) will then use the responsibility and relationship of friends as a framework to foster collaborative efforts to increase readiness and decrease barriers to helping behavior. As part of this, the FMI will focus on the identification and implementation of skills friends can use to help one another prevent sexual assault. FMI will include a focused discussion of the ways drinking may impede helping efforts. Moreover, the FMI will encourage women to identify personal, specific strategies for reducing the effects of alcohol on helping.
214509538|NCT04749329|DEVICE|Mesh Group|"All MG patients underwent the procedure with ante rectus positioned prophylactic mesh according to the following standardized technique. A BIO-A circular-shaped mesh measuring 8X10 cm in diameter is prepared with an internal 2 cm hole to let the bowel pass.~An at least 8x8 cm space is created between the anterior rectus sheath and the rectus abdominis muscle and, then, the mesh is positioned. The bowel is passed through the rectus muscle via the circular incision in the middle of the mesh. Single absorbable monofilament sutures anchored the mesh laterally in the ante rectus pocket, while medially the mesh is fixed with four stitches to the colon and to both the anterior rectal sheet. The stoma is attached to the skin similarly to CG patients."
215028101|NCT02268487|DRUG|Sertraline|Treatment
215028102|NCT04310774|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug)|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
215028103|NCT01724814|DRUG|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
215028104|NCT01724814|DRUG|Placebo|Singe dose SC administration of Placebo
214509539|NCT01820702|OTHER|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at \~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against \~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
215028105|NCT01788774|DRUG|Risperidone ISM 50 mg|
215028106|NCT01788774|DRUG|Risperidone ISM 75 mg|
215028107|NCT01788774|DRUG|Risperidone ISM 100 mg|
215028108|NCT04192838|PROCEDURE|Laparoscopic incisional ventral hernia repair|Laparoscopic repair of incisional ventral hernias (5-15 cm) with adouble-layer polypropylene- expanded polytetrafluoroethylene (ePTFE) mesh.
215028109|NCT04192838|PROCEDURE|Open incisional ventral hernia repair|Standard polypropylene mesh was positioned as an inlay, or as an onlay over the external oblique fascia (i.e., subcutaneously), as preferred by the operating team. The mesh was fixed with absorbable stitches. Drains were usually placed.
215028110|NCT00337597|OTHER|Glucose 5%|
215028111|NCT00337597|OTHER|NaCl 0.9%|
215028112|NCT01270555|DRUG|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
215028113|NCT00773461|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
215028114|NCT00773461|DRUG|Placebo|iv every 4 weeks for 24 weeks
215105394|NCT01683578|OTHER|Variable Ventilation|
215105395|NCT03512392|OTHER|Conservative fluid and deresuscitation strategy|Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
215105396|NCT03512392|OTHER|Usual care strategy|Usual care at the discretion of the clinical team
215105397|NCT06328309|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
215105398|NCT06328309|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
215105399|NCT03993041|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Study therapists will deliver cognitive-behavioral therapy (CBT) based on an emotion-focused, transdiagnostic protocol. CBT targets problematic thoughts, feelings, and behaviors through goal-oriented, systematic procedures. The intervention used in this study is designed to target emotional processing with an emphasis on present-focused awareness, cognitive flexibility, emotional avoidance, awareness and tolerance of physical sensations, and situation-based emotion exposure. The intervention is designed to help individuals better understand emotional experiences in order to respond to intense emotions in a more adaptive way.
215105400|NCT01960153|DRUG|Tadalafil|Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
214509540|NCT02527694|DEVICE|Flexible EMS stretcher cart|The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
214509541|NCT02527694|DEVICE|mechanical CPR|
215028115|NCT04674319|BEHAVIORAL|external cues and cogntive movement strategies|"external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section."
215028116|NCT01754740|DRUG|Uréia|"The subjects were randomly divided into two groups:~1\. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months."
215028117|NCT01754740|DRUG|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
215028118|NCT06548347|DRUG|Linperlisib|Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles
215028119|NCT01827306|DRUG|Biofreeze|
215028120|NCT00833274|BEHAVIORAL|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
215028121|NCT02018679|PROCEDURE|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
215105401|NCT01960153|DRUG|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
215105402|NCT00187447|DRUG|indomethacin (two different dosing regimens)|
215105403|NCT02913378|PROCEDURE|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
215105404|NCT02913378|PROCEDURE|Sling|Conservative treatment with sling and rehabilitation
214509542|NCT05197088|DRUG|Tamsulosin|1 week of tamsulosin
214509543|NCT03742297|DRUG|Lenalidomide.|Lenalidomide
215105405|NCT01990612|PROCEDURE|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score \< 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
214509544|NCT03742297|DRUG|Carfilzomib|Carfilzomib
215105406|NCT04458415|OTHER|Traxi Panniculus Retractor (TPR)|Surgeon uses the Traxi Panniculus Retractor (TPR) surgical retraction device to retract the panniculus during C-Section.
214509545|NCT03742297|DRUG|Bortezomib|Bortezomib
214509546|NCT03742297|DRUG|Daratumumab|Daratumumab
214509547|NCT03742297|DRUG|Dexamethasone|Dexamethasone
214509548|NCT03742297|DRUG|Prednisone|Prednisone
214509549|NCT03742297|DRUG|Melphalan|Melphalan
214424362|NCT06372912|PROCEDURE|Sleeve gastrectomy, Roux-en-Y gastric bypass, mini-gastric bypass, SADIS, intragastric balloon insertion, and gastric band placement are bariatric surgeries.|Sleeve gastrectomy: reduces stomach size. Roux-en-Y gastric bypass: limits calorie absorption. Mini gastric bypass: achieves weight loss with fewer incisions. SADIS: combines sleeve gastrectomy with small bowel bypass. Intragastric balloon: reduces stomach volume. Gastric banding: restricts food intake.
214424363|NCT04324242|OTHER|abdominal hallowing maneuver|abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
214424364|NCT05817409|DRUG|Intrathecal Baclofen Pump|intrathecal baclofen treatment
214509550|NCT01896609|BIOLOGICAL|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
214509551|NCT01896609|DRUG|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
215028122|NCT02018679|PROCEDURE|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
215028123|NCT01407887|DRUG|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
215028124|NCT01793233|OTHER|Laboratory Biomarker Analysis|Correlative studies
215028125|NCT01793233|OTHER|Questionnaire Administration|Ancillary studies
215028126|NCT01407614|PROCEDURE|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
215028127|NCT00322218|DRUG|Zevalin|"Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one \[90Y\]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m\^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m\^2 immediately followed by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes."
215028128|NCT03238547|DIAGNOSTIC_TEST|semi-quantitative urine albumin-to-creatinine ratio test|measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
215028129|NCT03238547|DIAGNOSTIC_TEST|standard quantitative spot urine albumin-to-creatinine ratio|measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
215028130|NCT00000709|DRUG|Zidovudine|
215028131|NCT06326541|BEHAVIORAL|music therapy|Listening to the Holy Quran.
215028132|NCT03928015|DRUG|Adjunctive dronabinol|5mg BID and adjusting within the range of 2.5mg - 10mg BID, minimum of 48 hours, as an adjunct to systemic analgesics
215028133|NCT03928015|DRUG|Systemic analgesics|multimodal analgesia including opioid and non-opioid analgesics
215028134|NCT00190528|DRUG|neoadjuvant chemotherapy + radical hysterectomy|
215028135|NCT00190528|PROCEDURE|radical hysterectomy|
215028136|NCT06209450|PROCEDURE|Ventral hernia repair with mesh fixation|Sutured versus suturless mesh fixation
215105407|NCT04458415|OTHER|Silk Tape|Surgeon uses silk tape to retract the panniculus during C-Section.
215105408|NCT05258916|PROCEDURE|Nurse consultation|nurse consultation carried out within two weeks after maternity discharged
215105409|NCT06236490|DIAGNOSTIC_TEST|Blood Oxygen Level Test|The study participants rested for 15 minutes before measuring the BOLT score. During this time they were carefully instructed on how to perform the measurement. It was underlined that we do not measure how long one can hold their breath, but the time it takes for the body to react to lack of air and feel the desire to breathe. After a few normal breaths through the nose, after the exhalation, the participants held their breath until they felt the first definite desire to breathe or felt the first involuntary contractions of the respiratory muscles. The first was assessed by the participants, the latter was also visually assessed by the researchers. The nose was closed with the fingers to prevent any gas exchange. The researchers measured the time with a Finis 3x300M stopwatch (FINIS USA, Livermore, CA, USA). Time in seconds, to one decimal place, was noted as a BOLT score. The visualisation of BOLT is presented in Figure 2.
215105410|NCT06236490|DIAGNOSTIC_TEST|Wingate Anaerobic Test|WAnT was conducted with Monark 874E Cycle Ergometer (Monark Exercise AB, Sweden). Before WAnT, the participants performed a 5-minute warm-up with resistance ranging from 0.8 to 1.2 W/kg. Next, the participants performed a maximal 6-second sprint, with the resistance adjusted to 7.5% of the individual body mass. After a rest interval of 2 to 5 minutes, the participants underwent a 30-second WAnT with resistance set at 7.5% of the individual body mass. They were instructed to attain the highest peak power output as quickly as possible and maintain the highest power output throughout the entire duration of the test. The participants received motivating and enthusiastic verbal support. The following indices were measured and included in the further analysis: peak power (Ppeak), total work (TW), WSSR. All the indices were calculated with the dedicated software (MCE 6.0, JBA Z. Staniak, Poland) linked to the cycle ergometer.
215105411|NCT06236490|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|CPET was performed with the Cortex Metamax B3 (Cortex Biophysik GmbH, Leipzig, Germany), breath-by-breath method, and Cyclus II Ergometer (RBM, Leipzig, Germany). Participants underwent an incremental ramp test, commencing at 55-70W and incrementally increasing the load by 0.17-0.28 W·sec-1, individually adjusted for body mass. The participants were instructed to continue the effort until total exhaustion. All the participants fulfilled the maximum effort criteria (Wiecha et al. 2023): 1) respiratory exchange ratio ≥ 1.10, (2) present VO2 plateau (growth \< 100 mL·min-1 in VO2 despite increased cycling power), (3) respiratory frequency ≥ 45 breaths·min-1, (4) declared subjective exertion intensity during CPET ≥ 18 according to the Borg Scale (Borg 1998), (5) blood lactate concentration ≥8 mmol·L-1, (6) peak heart rate ≥ 15 beats·min-1 below predicted maximal heart rate (HRmax) (Lach et al. 2021).
215105412|NCT03968848|DRUG|acalabrutinib|A 50-mg single oral dose of acalabrutinib will be administered.
215105413|NCT04450095|DRUG|Ambrisentan 10 MG|be given once a day for 5 days, starting 48 hours before surgery
215105414|NCT01000324|PROCEDURE|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
215105415|NCT01000324|BIOLOGICAL|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
215105416|NCT01000324|BIOLOGICAL|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
215105417|NCT00360724|DRUG|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
215105418|NCT02316886|DEVICE|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) + Optimal Medical Treatment
215105419|NCT02316886|DRUG|Optimal Medical treatment|
215105420|NCT00123604|DRUG|Carvedilol|25 mg twice daily for five months.
215105421|NCT00123604|DRUG|Metoprolol|200 mg twice daily for five months.
215105422|NCT01068158|DRUG|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
215105423|NCT01068158|DRUG|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
215105424|NCT03633812|OTHER|Observational study, Beta blocker medication history|Observational study, Beta blocker medication history
215105425|NCT02300181|DIETARY_SUPPLEMENT|Placebo|
215105426|NCT02300181|DIETARY_SUPPLEMENT|Bacillus subtilis var natto DC-15|
215105427|NCT04969692|PROCEDURE|warming to increase local skin (puncture site) temperature|According to the group of participants, investigator applies the warmer to the hands and wrists of the participants, makes a local temperature of 40℃ gradually, and maintains it for about 10 minutes in warming group (which is divided in to warming-palpation (WP) and warming-US (WU) group).
215105428|NCT02847104|OTHER|dynamic insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
215105429|NCT02847104|OTHER|static insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
215105430|NCT03450733|DEVICE|Wright Medical Technology Metal-on-Metal Total Hip System|Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and \> 8 years.
215028137|NCT03631511|PROCEDURE|direct pulp capping with RetroMTA|The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
215028138|NCT00958425|DEVICE|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
215028139|NCT00958425|DEVICE|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
215105431|NCT00151502|DRUG|Atorvastatin|
215105432|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (ascending dose), daily for 14 days
215105433|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (optimized dose), daily for 28 days
215105434|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (20 mg), daily for 14 days
215105435|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational innovator formulation
215105436|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation a
215105437|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation b
215105438|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation c
215105439|NCT06267664|DRUG|Patients with migraine treated with triptans, Lasmiditan or Gepants|Patients will complete the study information in their smartphones, tablets or computers, using a QR code or a link that will redirect hem to the study questionnaires. RedCap will be used in the study.
215105440|NCT01300572|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
215105441|NCT01300572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
215105442|NCT01300572|DRUG|Cyclosporine|Given PO or IV
215105443|NCT01300572|DRUG|Fludarabine Phosphate|Given IV
215105444|NCT01300572|BIOLOGICAL|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
215105445|NCT01300572|OTHER|Laboratory Biomarker Analysis|Correlative studies
215105446|NCT01300572|DRUG|Mycophenolate Mofetil|Given PO or IV
215105447|NCT01300572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
215105448|NCT01300572|OTHER|Pharmacological Study|Correlative studies
215105449|NCT01300572|RADIATION|Total-Body Irradiation|Undergo TBI
215105450|NCT01300572|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
215105451|NCT03845738|DEVICE|OsseoSpeed EV implant|The investigational product (OsseoSpeed EV implant) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
215105452|NCT02715986|DEVICE|3T MRI|Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
215105453|NCT01835002|DEVICE|Transcorneal electrostimulation|Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
215105454|NCT03021772|DRUG|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
215105455|NCT03021772|DRUG|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
215105456|NCT02673502|DIETARY_SUPPLEMENT|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
215105457|NCT02673502|DIETARY_SUPPLEMENT|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
215105458|NCT06320314|OTHER|tested product (2039125 03)|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
215105459|NCT01086943|DEVICE|LT2420|
215105460|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 6th day of progesterone supplementation
215105461|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
215105462|NCT02556060|DRUG|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
215105463|NCT02556060|DRUG|Placebo|Same dosing schedule as study drug
215105464|NCT02239315|OTHER|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
215105465|NCT03887858|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration under fasting
215105466|NCT03887858|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
215105467|NCT04959305|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
215105468|NCT04959305|DRUG|RLD2003|Take it once daily for 8 weeks orally.
215105469|NCT04959305|DRUG|RLD2004|Take it once daily for 8 weeks orally.
215105470|NCT04959305|DRUG|RLD2005|Take it once daily for 8 weeks orally.
215105471|NCT04959305|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
215105472|NCT04959305|DRUG|HPP2005|Placebo drug. Take it once daily for 8 weeks orally.
215105473|NCT04166617|OTHER|Conventional therapy|conventional physcial therapy rehabilitation for the upper limb
215105474|NCT04166617|OTHER|Leap motion plus conventional therapya|leap motion plus conventional physcial therapy rehabilitation for the upper limb
215105475|NCT03273309|OTHER|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
215105476|NCT03273309|OTHER|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
215105477|NCT02197650|DRUG|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
215105478|NCT03335280|DRUG|68Ga-citrate PET/MR|Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
215105479|NCT00003336|BIOLOGICAL|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
215105480|NCT00003336|DRUG|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
215105481|NCT00003336|DRUG|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
215105482|NCT00003336|DRUG|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
215105483|NCT00003336|DRUG|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
215105484|NCT00003336|PROCEDURE|bone marrow ablation with stem cell support|
215105485|NCT00003336|PROCEDURE|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
215105486|NCT00003336|RADIATION|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
215105487|NCT00411632|DRUG|Bexarotene|400 mg/m\^2 by mouth daily x 28 Days
215105488|NCT00411632|DRUG|Erlotinib|150 mg by mouth daily x 28 Days
215105489|NCT02421289|DRUG|Efavirenz|There will be adjusted dose of efavirenz in CYP2B6 guide group
215105490|NCT02421289|DRUG|Efavirenz|If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
215105491|NCT02421289|OTHER|CYP450 2B6|All patients will be monitored drug level which should be in therapeutic level.
215105492|NCT06037408|DRUG|20mM sodium pyruvate nasal spray|The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2 (N115). Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
215105493|NCT06037408|OTHER|Saline Placebo control nasal spray|The placebo is 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2. Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
215105494|NCT04492761|BEHAVIORAL|qualitative study|The qualitative approach will be based on content analysis of - Isemi-structured nterviews of families
215105495|NCT04517643|OTHER|Therasphere Therapy|TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
215105496|NCT02992535|DEVICE|Intense Pulse Light Energy delivery (IPL)|
215105497|NCT04697732|OTHER|General anesthesia|Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
215105498|NCT05252663|PROCEDURE|Quake device training|In Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds. The patient had the mouthpiece firmly sealed to the lips and were asked to inhale and exhale completely
215105499|NCT05252663|PROCEDURE|Traditional chest physiotherapy|postural drainage - percussion
215105500|NCT00911339|DRUG|Atorvastatin|Atorvastatin 10 mg associated with stent genous
215105501|NCT00911339|DRUG|Atorvastatin|Atorvastatin 80 mg associated with stent genous
214509552|NCT01896609|DRUG|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
215105502|NCT03800511|DIAGNOSTIC_TEST|sliding test|ultrasound detected sliding test before doing repeated caesarean section
215105503|NCT05964543|DRUG|Q-1802 Injection,Oxaliplatin Injection,Capecitabine|Q-1802：A dose Q-1802 will be administered intravenously Q2W. XELOX（oxaliplatin，capecitabin）: 21 days as a cycle Oxaliplatin will be administered 130mg/m2 as a 2-hour IV infusion,administer once on the first day, with 21 days as a cycle Capecitabine will be administered 1000mg/m2 orally twice daily (D1-D14),21ds is one cycle.
215105504|NCT04277039|OTHER|osteopathic treatment + cognitive training|This intervention is a combination of manipulative osteopathic treatment and cognitive training to be administered each week for a 12-week study period
215105505|NCT04277039|OTHER|osteopathic treatment|manual treatment using osteopathic procedure. 8 sessions for a 12 week study period
215105506|NCT04277039|OTHER|usual care|administration of non-steroid inflammatory drug according to international guidelines
215105507|NCT04797806|DRUG|Anlotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.
215105508|NCT04797806|DRUG|Icotinib|Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
215105509|NCT04557046|DIAGNOSTIC_TEST|Nasal Swab|Collection of one more nasal swabs
215105510|NCT04557046|DIAGNOSTIC_TEST|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
215105511|NCT04557046|DIAGNOSTIC_TEST|Throat swab|Collection of one more throat swabs
214509553|NCT01896609|DRUG|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
214509554|NCT01688388|PROCEDURE|Intraoperative Radiotherapy|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
215105512|NCT04557046|DIAGNOSTIC_TEST|Fingerstick|Collection of capillary blood from one or more fingersticks
215105513|NCT04557046|DIAGNOSTIC_TEST|Saliva specimen|Collection of free drool
215105514|NCT06115356|DIAGNOSTIC_TEST|Vitamin D Plasma Level|Blood test measured in ng/ml
215105515|NCT06115356|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA) technique|Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded.
215105516|NCT06115356|DIAGNOSTIC_TEST|Ferritin|Ferritin plasma levels were measured in μg/L
215105517|NCT06115356|DIAGNOSTIC_TEST|C reactive protein (CRP)|CRP plasma levels were measured in mg/L
215105518|NCT06115356|DIAGNOSTIC_TEST|Inflammation-based prognostic scores|Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune-inflammation index (SII) were calculated using blood test results
215105519|NCT06115356|OTHER|Liver biopsy|A liver biopsy was used to study nonalcoholic steatohepatitis (NASH) and fibrosis according to the Kleiner-Brunt classification
215105520|NCT03669237|PROCEDURE|different reconstruction methods|Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
215105521|NCT03483298|OTHER|ICSI|The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI
215105522|NCT00004245|DRUG|sodium salicylate|
215105523|NCT02574689|BEHAVIORAL|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
215105524|NCT02574689|BEHAVIORAL|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
215105525|NCT05043389|OTHER|myofunctional therapy program|Exercise oral cavity muscle
215105526|NCT04185389|OTHER|HPV and cytology co-testing (via Liquid based collection device)|Liquid-based cytology co-testing is a procedure in which that a cervical sample is taken, and can be co-tested for HPV and standard cytology at the same time. It is collected in the same way that a traditional Pap is collected
215105527|NCT03147534|DEVICE|InstaTemp MD|The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.
215105528|NCT03147534|DEVICE|"Welch Allyn, rectal"|"The Welch Allyn rectal thermometer is intended to measure human body temperature."
215105529|NCT03147534|DEVICE|"Welch Allyn, oral"|"The Welch Allyn oral thermometer is intended to measure human body temperature."
215105530|NCT03147534|DEVICE|Covidien, tympanic|The Covidien tympanic thermometer is intended to measure human body temperature.
215105531|NCT01609881|DRUG|Acuvail|Dosing of drug 3 days prior to surgery
215105532|NCT01609881|OTHER|Placebo|Artificial tears qid for 3 days preoperatively
215105533|NCT01735370|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
215105534|NCT01735370|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
215105535|NCT05895240|DRUG|Ulinastatin|Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
215105536|NCT00695422|GENETIC|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
215105537|NCT00695422|OTHER|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
215105538|NCT00695422|OTHER|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
215105539|NCT00695422|PROCEDURE|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
215028140|NCT05278715|DRUG|Carboplatin|Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
215105540|NCT06396624|RADIATION|Intervention Group photobiomodulation|Seven spots on child's thorax and two spots on the face will be irradiated with 40s per point of photobiomodulation.
215105541|NCT06396624|OTHER|Control Group|The photobiomodulation device will positioned in seven spots on thorax and two in child's face, but it will not emit any time of radiation, since the device will be turned off.
215105542|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
215105543|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
215105544|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
215105545|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
215028141|NCT05278715|DRUG|Vincristine|Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.
215028142|NCT05278715|DRUG|Recombinant human endostatin|Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
215105546|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
215105547|NCT05694299|DEVICE|Nasal bridle|Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)
215105548|NCT05694299|OTHER|Nasal patch|Regular adhesive tape for medical use.
215105549|NCT05137977|PROCEDURE|Intensive Care|Invasive ventilation more than 24hs.
215105550|NCT00116116|DRUG|efavirenz, stavudine extended release, lamivudine|
215105551|NCT00002517|DRUG|cytarabine|
215105552|NCT00002517|DRUG|daunorubicin hydrochloride|
215105553|NCT00002517|DRUG|dexamethasone|
215105554|NCT00002517|DRUG|etoposide|
215105555|NCT00002517|DRUG|idarubicin|
215105556|NCT00002517|DRUG|mitoxantrone hydrochloride|
215105557|NCT00002517|DRUG|thioguanine|
215105558|NCT00002517|PROCEDURE|allogeneic bone marrow transplantation|
215105559|NCT00002517|RADIATION|radiation therapy|
215105560|NCT05329064|BIOLOGICAL|BNT162b2 Pfizer-BioNTech/Comirnaty|"The study will use 10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose.~Two doses will be given at 2 months apart between doses."
215105561|NCT00996983|DRUG|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
215105562|NCT02207218|DRUG|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
215105563|NCT01183455|DRUG|Aralast NP|Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
215105564|NCT01183455|DRUG|Placebo|Participants will receive IV infusions of placebo once a week for 12 weeks.
215105565|NCT00767767|DRUG|Placebos|IV Saline infusion for 2 hours.
215105566|NCT00767767|DRUG|Propofol 0.45mcg/mL|IV Propofol infusion for 2 hours.
215105567|NCT00767767|DRUG|Propofol 0.90mcg/mL|IV Propofol infusion for 2 hours.
215105568|NCT00767767|DRUG|Thiopental 1.5mcg/mL|IV Thiopental 1.5mcg/mL infusion for 2 hours
215105569|NCT00767767|DRUG|Thiopental 3mcg/mL|IV Thiopental 3mcg/mL infusion for 2 hours
215105570|NCT02724527|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
215105571|NCT02724527|DRUG|Placebo|Matched Placebo capsule
215105572|NCT05261009|DRUG|Peri-capsular Nerve Group (PENG)|PENG block for postoperative pain management
215105573|NCT05261009|OTHER|Lumbar Plexus Block (LPB)|LPB for postoperative pain management
215105574|NCT01805557|DRUG|R-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy"
215105575|NCT01805557|DRUG|BR-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Bortezomib SC 1.5 mg/sqm day 1, day 4~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days."
215105576|NCT05400304|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
215105577|NCT02762331|DRUG|Ascorbic Acid|Comparing safety and efficacy of IV Vitamin C in CABG patients
215105578|NCT02762331|DRUG|Placebo|Placebo intervention
215105579|NCT01549925|OTHER|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
215105580|NCT01549925|DEVICE|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
215105581|NCT00837850|DEVICE|Bone cement 1|Bone cement SmartSet® HV
215105582|NCT00837850|DEVICE|Bone cement 2|Bone cement Palacos R
215105583|NCT01942070|DEVICE|Bioresorbable vascular scaffold|
215105584|NCT01942070|DEVICE|Durable polymer everolimus-eluting metallic stent|
215105585|NCT02728466|DIETARY_SUPPLEMENT|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
215105586|NCT02728466|DIETARY_SUPPLEMENT|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
215105587|NCT02728466|DIETARY_SUPPLEMENT|control supplement deprived of flavanols and procyanidins|Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
215105588|NCT01748825|DRUG|MK-1775 (AZD1775)|MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
215105589|NCT01849419|DRUG|Within-subjects (MDMA)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).
215105590|NCT01849419|DRUG|Within-subjects (oxytocin)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).
215105591|NCT01849419|DRUG|Within-subjects (placebo)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
215105592|NCT02819687|DRUG|RDX5791|
215105593|NCT02819687|DRUG|Placebo|
215105594|NCT01116973|OTHER|PICC|Peripheral inserted catheter placement to take the reading
215105595|NCT03665311|BIOLOGICAL|25% Albumin fluid|25% Albumin fluid (100 mL)
215105596|NCT03665311|OTHER|Normal Saline|0.9% Normal Saline (100 mL)
214509555|NCT06451107|OTHER|specific strength training with static neck stretching|The intervention will consist of specific strength training composed of 5 exercises performed with dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. In addition to the following static stretches: stretching towards lateral flexion of the upper part of the trapezius muscle, the scalene muscles, and the sternocleidomastoid muscle on both sides; extension of the extensor muscles; flexion of the flexor muscles; and contralateral flexion and rotation combined with scapular depression of the scalene muscles and elevation of the scapula on both sides, holding each stretch for 10 seconds. This sequence of stretches will constitute one set, with 6 sets performed with a 30-second rest between sets, lasting 8 minutes. Therefore, the intervention will have a total duration of 28 minutes per session, conducting 3 sessions per week.
215028143|NCT05472870|DEVICE|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
215028144|NCT03094377|OTHER|Multisensory therapy|Sensory stimulation, motor training and ADL training
215105597|NCT03882645|OTHER|CHH-diet|"This study took the DASH Diet as the basic model and developed the Chinese Heart Healthy Diet ( CHH-diet) according to the principles in the 2016 Dietary Guidelines for Chinese Residents. The nutrients targets in CHH-diet are set as following: fat % of total kcal: 25-27% (saturated: 6%; monounsaturated: 12%; polyunsaturated: 8%); carbohydrate % of total kcal: 55-60%; protein % of total kcal: 17-19%; dietary fiber: 30 g/day; sodium: 3000 mg/day; potassium: 3700 mg/day; magnesium: 500 mg/day; calcium: 1200 mg/day. The total energy will be set according to how much participants are eating in run-in period."
215028145|NCT03094377|OTHER|Conventional training|Motor training and ADL training
215028146|NCT05730478|DEVICE|ASOCT&UBM|glaucoma assesment by ASOCT \&UBM
215028147|NCT05730478|DRUG|Glaucoma therapy|ASOCT and UBM parameters Comparison
215028148|NCT05730478|DRUG|Glaucoma therapy|Comparison
215028149|NCT05414942|BEHAVIORAL|Opioid Reduction Program|Subjects will engage in a brief, educational session which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
215028150|NCT03118895|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
215028151|NCT05162794|OTHER|Laparoscopy with excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. Then, the relevant tissue will be excised and a histology will be performed.
215028152|NCT05162794|OTHER|Laparoscopy without excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. However, no tissue will be excised and histology will not be performed.
215028153|NCT05162794|OTHER|Medical treatment-as-usual|Patients continue their hormonal and analgesic treatment-as-usual.
215028154|NCT01385995|DEVICE|Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
215028155|NCT01385995|DEVICE|Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
215028156|NCT04881097|BEHAVIORAL|no intervention|no intervention
215028157|NCT00112385|DRUG|Etanercept|Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
215028158|NCT00112385|DRUG|Placebo|Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
215028159|NCT02361697|OTHER|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
215028160|NCT03686189|DEVICE|Iliac Bifurcation Stent Graft System|Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
215028161|NCT04136288|DEVICE|MoreNova|Shockwave therapy delivered to the genital area with low dose shocks
215028162|NCT06003829|DRUG|Sinsunatovir|Single dose, to be spit out after tasting
215028163|NCT06003829|OTHER|Bitrex|Single dose, to be spit out after tasting
215028164|NCT06677086|DEVICE|Treatment with BTL-899|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 device will be applied over the designated area. Each treatment session will last 30 minutes.
215028165|NCT03682146|PROCEDURE|Prostatectomy|Comparison of robotic-assisted and conventional laparoscopic radical prostatectomy
215028166|NCT02006290|DRUG|PF-06412562|single oral split dose 30+20 mg QD
215028167|NCT02006290|DRUG|Placebo|tablet, matching placebo, QD
215028168|NCT06602180|OTHER|Scapular PNF technique, (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT).|"Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments.~Scapular PNF:~Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~TAPA involves an intervention protocol composed of:~10-min neuro dynamics oriented to the activity 10-min proprioceptive neuromuscular facilitation activities. 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,"
215028169|NCT06602180|OTHER|Scapular PNF technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT))|"Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
214509556|NCT06451107|OTHER|Specific Strength Training|The intervention will consist of specific strength training comprised of 5 exercises using dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. Four sets will be performed, with a 1-minute rest between sets. Each exercise will be executed for 30 seconds, followed by a 25-second rest between exercises. Three 20-minute sessions will be conducted per week.
215105598|NCT03882645|OTHER|local usual diet|The nutrients targets and total energy in usual diet are set according to how much participants are eating in run-in period.
215105599|NCT01392287|DRUG|Memantine|"Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
215105600|NCT04487652|OTHER|Gingival recession coverage|The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.
215105601|NCT04487652|DRUG|with CoQ10 spray application|After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.
215105602|NCT04487652|DRUG|with placebo spray application|After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
215105603|NCT04927572|DRUG|FMX114|Active Comparator
215105604|NCT04927572|OTHER|Vehicle|Placebo Comparator
215105605|NCT04841772|DIETARY_SUPPLEMENT|Recover Vegan Protein Supplement|Post exercise protein supplement (26g pea protein)
215105606|NCT04841772|DIETARY_SUPPLEMENT|Placebo|Post exercise placebo supplement (32g maltodextrin)
215105607|NCT05595772|DRUG|Drug: Growth Factors (CGF)|Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
215105608|NCT05595772|DRUG|Drug: Growth Factors (PRGF)|Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
215105609|NCT05595772|PROCEDURE|Surgery: Dental Implant surgery|Immediate implant following extraction
215105610|NCT05595772|PROCEDURE|Tooth extraction|A Traumatic tooth extraction
215105611|NCT05595772|PROCEDURE|Xenogenic bone grafting|Application of bovine bone grafting over area of dehiscence around immediate implant
215105612|NCT05785936|PROCEDURE|Desensitization|Patients that received apheresis and anti-cluster of differentiation antigen 20 for desensitization priori to kidney transplantation
215105613|NCT05964036|DEVICE|active TMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized target in the DMPFC will be generated using the pBFS method
215105614|NCT05964036|DEVICE|sham TMS|The parameters in the sham arm are the same as in the active stimulation group. Stimulation was delivered by the same device as the active group fitted with a sham coil
215105615|NCT00852241|DRUG|Restalyne|one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
215105616|NCT00852241|DRUG|Perlane|One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
215105617|NCT02339792|OTHER|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
215105618|NCT02524418|PROCEDURE|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
215105619|NCT03342118|DRUG|Phloroglucin(Flospan®)|The experimental group was taken with Phloroglucin(Flospan®) before endoscopy.
215105620|NCT03342118|DRUG|Normal saline|The control group was treated with normal saline before endoscopy
215105621|NCT06440551|BEHAVIORAL|TeleSalud Healthy Eating- Physical Activity/Sedentary Behavior (HE-PA/SB)|Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud HE-PA/SB Class, after which they will attend one maintenance meeting per month for 4 months. Weekly, Day 1 (Healthy Eating \& PA-SB Class): Participants will receive a 50-min. healthy eating class. Physical Activity- Sedentary Behavior (PA-SB) Class: By discussing barriers and strategies to overcome barriers, this will help to increase self-efficacy. We will engage in Latino-centered moderate impact (increasing to vigorous) aerobics with Latino or salsa movements and music for 45-50 minutes. Aspects of kickboxing aerobics will be integrated. Goal: Exercise a minimum of 150-250 min./ week of moderate intensity. Weekly, Day 2: PA-SB identical PA-SB to Day 1. Maintenance (Months 5-8): Meetings once/ month for 70 min. for HE/PA-SB class, including 25 min. to discuss diet and PA-SB barriers. Goal: Exercise a minimum of 150-250 min./week.
214509557|NCT01697826|DRUG|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
214509558|NCT01697826|DRUG|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
215105622|NCT06440551|BEHAVIORAL|TeleSalud General Health Intervention|Weekly: Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud General Heath Class, after which they will attend one maintenance meeting per month for 4 months. Participants will meet and discuss general health topics (not diet or PA). Examples of the general health topics are: Back Pain, Muscle Strains, Alcohol Use, Stress \& Coping, Oral and Dental Health, Safety Tips, Emergency Preparedness. The content is relevant to Latinos, and information is focused on Latino men. Maintenance (Months 5-8): Participants will meet via telehealth once/ month for 70 min. to discuss general health topics. To enhance motivation to complete the study and assessments, this group will receive a copy of the TeleSalud HE-PA/SB intervention manual and related materials after the maintenance period ends.
215105623|NCT00118430|BEHAVIORAL|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
215105624|NCT00118430|DRUG|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
215105625|NCT00118430|DRUG|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
215105626|NCT00659230|DRUG|Nepicastat|100-800mg
215105627|NCT00659230|DRUG|Placebo|100-800mg placebo
215105628|NCT00171847|DRUG|Letrozole|
215105629|NCT00171847|DRUG|Trastuzumab plus Letrozole|
215105630|NCT00171847|DRUG|Letrozole|
215105631|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
215105632|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
215105633|NCT00901121|DEVICE|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
215105634|NCT00901121|DEVICE|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
215105635|NCT00744107|DEVICE|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
215105636|NCT00033891|DRUG|Infliximab|
215105637|NCT02240264|DIETARY_SUPPLEMENT|Krill oil capsules|1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
215105638|NCT02240264|DIETARY_SUPPLEMENT|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
215105639|NCT00669383|DRUG|betamethasone|12 mg IM q 24 hours x 2 doses
215105640|NCT00669383|DRUG|placebo|Placebo IM q 24 hours x 2 doses
215105641|NCT05535829|OTHER|Laboratory analysis of samples|Laboratory analysis of samples
215105642|NCT04217044|DIAGNOSTIC_TEST|Histopathology images based prediction of molecular pathology|Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
215105643|NCT02948738|BEHAVIORAL|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
215105644|NCT02948738|BEHAVIORAL|Standard Asthma Education|Basic review of asthma action plan and inhaler use
215105645|NCT03960892|BEHAVIORAL|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialists, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
215105646|NCT02173587|DIETARY_SUPPLEMENT|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
215105647|NCT02173587|DIETARY_SUPPLEMENT|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
215105648|NCT02427776|BIOLOGICAL|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
215105649|NCT02069392|BEHAVIORAL|Cognitive remediation training|
215105650|NCT02069392|DRUG|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
215105651|NCT02997982|DRUG|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
214509559|NCT02203656|DRUG|Placebo|placebo supplement
214509560|NCT02203656|DIETARY_SUPPLEMENT|Nutritional Supplement|protein supplement
214509561|NCT02203656|BEHAVIORAL|In-home exercise|In-home exercise program
214509562|NCT02203656|DRUG|Testosterone|Testosterone injection
214509563|NCT02990494|BEHAVIORAL|STANDARD|Standard Internet-delivered behavioral weight loss
215105652|NCT00317382|DEVICE|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
215105653|NCT00269633|DEVICE|Blue Light Box 467 nm|467 nm Blue LED Light
215105654|NCT00269633|DEVICE|Red Light Box 657 nm|657 nm Red LED Light
215105655|NCT04412707|DRUG|Melphalan|Peripheral versus central administration
215105656|NCT04412707|DRUG|Dexamethasone|Oral tablets
215105657|NCT05532280|DRUG|Etoricoxib 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
215105658|NCT05532280|DRUG|Arcoxia 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
215105659|NCT03586115|DEVICE|Critical flicker frequency assessment|All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.
214424365|NCT03960619|BEHAVIORAL|coping skills training|We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
215105660|NCT06486415|DIAGNOSTIC_TEST|serum BHCG testing|Taking 5ml blood samples every 2 hours for 5 times for measurement of BHCG. Blood samples will be taken from the median cubital and cephalic veins which is located inner side of the elbow.
215105661|NCT02275442|OTHER|EPICES scale|
215105662|NCT02386501|DRUG|ADXS31-164|
215105663|NCT02476006|DRUG|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
215105664|NCT02476006|DRUG|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
215105665|NCT02476006|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
215105666|NCT02476006|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
215105667|NCT02476006|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
215105668|NCT02476006|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
215105669|NCT02335593|DIETARY_SUPPLEMENT|Zinc Sulphate|Zinc Sulphate Hard Gel capsules 110mg
215105670|NCT02335593|OTHER|Corn Starch filled Hard Gel Capsules|Corn Starch filled Hard Gel Capsules
215105671|NCT02335593|DRUG|Epoetin alfa 2000-4000 IU solution for injection|Epoetin alfa 2000-4000 IU solution for injection
215105672|NCT02335593|DRUG|Iron Hydroxide Saccharate Complex Solution for injection|Iron Hydroxide Saccharate Complex Solution for injection
214424366|NCT02031471|DRUG|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
214424367|NCT04050631|BEHAVIORAL|maternal arrest simulation on L&D floor|AFE on L\&D
214509564|NCT02990494|BEHAVIORAL|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
214509565|NCT02990494|BEHAVIORAL|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
214509566|NCT00465114|PROCEDURE|Hemodynamic Monitoring|
214509567|NCT05234489|BIOLOGICAL|Signature Cord Prime|"Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate."
215105673|NCT03872791|BIOLOGICAL|KN046|KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
215105674|NCT03872791|DRUG|Nab-paclitaxel|Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
215105675|NCT03831035|OTHER|Genetic analyse by whole exome sequencing|Exome sequencing requires analytic, bio informatic and interpretation steps.
215105676|NCT00240669|DEVICE|Resorbable device PLLA/PGA|
215105677|NCT00240669|DEVICE|Titanium device|
215105678|NCT03064919|BEHAVIORAL|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
215105679|NCT03210961|DRUG|PF-06826647 tablet|PF-06826647 tablet for oral administration
215105680|NCT03210961|DRUG|PF-06826647 oral suspension|PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
215105681|NCT03210961|OTHER|Placebo oral solution/suspension|placebo oral solution for the single ascending dose, first cohort only
215105682|NCT03210961|OTHER|Placebo tablet|Matching placebo tablet
215105683|NCT06280508|DRUG|Adebrelimab, Apatinib, Gemcitabine, cisplatin|Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery
215105684|NCT05187819|DIAGNOSTIC_TEST|predictive value of a blood test|Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.
215105685|NCT03088527|DRUG|RAD140|RAD140 will be supplied as formulated drug-in-capsules for oral administration.
215105686|NCT04974801|DEVICE|Provox Life|Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)
215105687|NCT04974801|DEVICE|Usual Care|Continued Usual Care routines.
215105688|NCT03857100|OTHER|Audit and feedback - letter and report|letter describing project and report of participants' outlier status and how participants compare to peers
215105689|NCT00940758|DRUG|PEP02|Dose escalation: 50-100 mg/m2 biweekly
215105690|NCT03609411|PROCEDURE|Splenectomy|Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
215105691|NCT03161106|DIETARY_SUPPLEMENT|Nutrition|Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements
215105692|NCT03161106|DRUG|Lactulose|Lactulose plus diet consumed by patient
215105693|NCT03161106|DIETARY_SUPPLEMENT|Diet|Protein Powder 15 to 20 gm/meal/day
215105694|NCT01277874|DEVICE|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
215028170|NCT06602180|OTHER|Activity-Oriented Antiedema Proprioceptive Therapy (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT)|"Activity-Oriented Proprioceptive Antiedema Therapy TAPA:~TAPA involves an intervention protocol composed of:~* 10-min neuro dynamics oriented to the activity~* 10-min proprioceptive neuromuscular facilitation activities.~* 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
215028171|NCT05148663|DIAGNOSTIC_TEST|CCM Hemorrhagic Panel|Biomarker
215105695|NCT01277874|DEVICE|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
215105696|NCT01487265|DRUG|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
215105697|NCT01040442|OTHER|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
215105698|NCT04160858|OTHER|Exercise|Spinal Cord Injury Exercise Guidelines: Participants will begin at the Starting Level which is 20 mins of moderate to vigorous aerobic activity 2x/week \& 3 sets of 10 repeats of strength training 2x/week. They will progress to Advanced Level which is 30 mins of moderate to vigorous aerobic activity 3x/week and 3 sets of 10 repetitions of strength training 2x/week. The intervention duration is 6 months.
215105699|NCT04160858|OTHER|Control|Wait-list control
215028172|NCT06593665|DRUG|Inrathecal Morphine|Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)
215028173|NCT06593665|DRUG|Intravenous Methadone|Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
215028174|NCT05947890|BIOLOGICAL|MTBVAC|The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.
215028175|NCT05947890|BIOLOGICAL|BCG|The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.
215028176|NCT06658756|BEHAVIORAL|internet-CBT|10 modules on line of I-CBT for OCD
215028177|NCT05669027|DEVICE|Neurofeedback|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.
215105700|NCT01822418|DRUG|agomelatine|Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day
215105701|NCT03875742|DEVICE|Ultraplex 360(Braun)|"This group will use as first needle the ultraplex 360 (Braun)"
215105702|NCT03875742|DEVICE|STIMUPLEX D SH, 30°(Braun)|"This group will use as first needle the  STIMUPLEX D SH, 30° (Braun)"
215105703|NCT00068757|BIOLOGICAL|trastuzumab|
215105704|NCT00068757|DRUG|lonafarnib|
215105705|NCT00068757|DRUG|paclitaxel|
215105706|NCT00068757|OTHER|pharmacological study|
215105707|NCT02342899|DEVICE|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
215105708|NCT02342899|DEVICE|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
215105709|NCT02466984|DRUG|metoclopramide intravenous|Administration route
215105710|NCT03917095|DEVICE|The Colonic Transendoscopic enteral Tubing.|The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).
215105711|NCT03917095|DRUG|Glutamine|The medications were infused into the colon
215105712|NCT03917095|DRUG|Mesalazine|The medications were infused into the colon
215105713|NCT00255541|DRUG|Tesaglitazar|
215105714|NCT00255541|DRUG|Glibenclamide|
215105715|NCT00866073|DRUG|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
215105716|NCT04683367|PROCEDURE|laparoscopic surgery|laparoscopic repair of hernia
215028178|NCT05669027|DEVICE|Sham (Placebo Control)|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).
215028179|NCT06612281|DEVICE|colorectal cancer (CRC) screening|Gixam test
215028180|NCT06612281|DIAGNOSTIC_TEST|colorectal cancer screening|Fecal Immunochemistry Test (FIT)
215028181|NCT06612281|PROCEDURE|Colonoscopy after bowel cleansing|Standard of care optical colonoscopy for colorectal cancer screening
215028182|NCT01688791|DRUG|Vintafolide|
215028183|NCT01688791|DRUG|Carboplatin|
215028184|NCT01688791|DRUG|Paclitaxel|
215028185|NCT03422731|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow and blood samples
215028186|NCT03422731|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT
215028187|NCT03422731|DRUG|Fluorothymidine F-18|Undergo FLT PET
215105717|NCT02291419|DRUG|ticagrelor|ticagrelor 90 mg bid
215105718|NCT02291419|DRUG|aspirin|aspirin 81 mg daily
215105719|NCT04102527|OTHER|Questionnaires|"Patients have to complete the study questionnaires every 2 months :~* Digestive Functional Score of Neurological Patients~* Bowel Function Index~* Severity score for constipation~* Bristol Scale~* Constipation assessment scale~* Estimate scale of risk of constipation"
215105720|NCT05523050|PROCEDURE|active surgical intervention|two kinds: one is colostomy, and the other one is colonic exclusion
215105721|NCT01115673|DRUG|Acetaminophen|Acetaminophen Caplet - single dose
215105722|NCT01115673|DRUG|Placebo Control|0 mg Caplet - single dose
215105723|NCT00965575|DRUG|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
215105724|NCT00965575|DRUG|Placebos|Placebo. Taken 30 minutes prior to bedtime for four weeks.
215028188|NCT03422731|OTHER|Laboratory Biomarker Analysis|Correlative studies
215028189|NCT03422731|PROCEDURE|Magnetic Resonance Imaging|Undergo water-fat MRI
215028190|NCT03422731|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
215028191|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
215028192|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
215028193|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
215028194|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
215105725|NCT00771966|PROCEDURE|Standard therapy|Standard therapy
214424368|NCT05112354|DRUG|systemic and intratympanic injection of steoid|"-If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator."
214424369|NCT03301454|DRUG|pursuit of chemotherapy|Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
214424370|NCT00002415|DRUG|Tenofovir disoproxil fumarate|
214424371|NCT03505619|BEHAVIORAL|ASSIST 1.0|10 weeks intervention applying a person-centred approach by using goal setting and smart products.
214424372|NCT05059730|OTHER|Zero Degrees Cold Environment|Participants will be exposed to zero degrees celsius environment.
214424373|NCT05059730|OTHER|Eight Degrees Cold Environment|Participants will be exposed to eight degrees celsius environment.
214424374|NCT05059730|OTHER|Ten Degrees Cold Environment|Participants will be exposed to Ten degrees celsius environment.
214424375|NCT05059730|OTHER|40 degrees Hot Environment|Participants will be exposed to 40 degrees celsius hot environment.
215028195|NCT06992089|DEVICE|Dual-chamber cardiac pacemaker (Essentio MRI L111 Boston Scientific®), Single-chamber cardiac pacemaker (Essentio MRI L110 Boston Scientific®)|"Dual-chamber cardiac pacemaker (Essentio MRI L111 Boston Scientific®), with rate-adaptive pacing of the right atrium. There will be an associated right atrial lead (INGEVITY™ MRI Pacing Lead Boston®) and right ventricular lead (INGEVITY™ MRI Pacing Lead Boston®).~Single-chamber cardiac pacemaker (Essentio MRI L110 Boston Scientific®), with rate-adaptive pacing of the ventricles. There will be a right ventricular lead (INGEVITY™ MRI P Boston®)."
215028196|NCT05700422|DRUG|Varenicline Nasal Spray|OC-01 (varenicline solution) 0.03 mg nasal spray
215105726|NCT00771966|PROCEDURE|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
215105727|NCT03043391|BIOLOGICAL|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
215105728|NCT05001204|DRUG|68Ga-NOTA-RM26|68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
215028197|NCT06671665|DRUG|calcium supplementation|Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.
215028198|NCT06671665|OTHER|Manual therapy|Manual therapy treatment will be in the form of craniosacral techniques and visceral manipulation techniques for 8 sessions in 12 weeks. Sessions will be divided into one session per week for the first 4 weeks then one session every two week for the next 8 weeks. Each session lasts for 45 minutes.
215105729|NCT02529163|OTHER|Late-life Schizophrenia ICP|"The ICP medication algorithms first trial begins with:~* Risperidone titrated to a max dose~Failure to Risperidone will lead to a second trial with either:~* Quetiapine OR Aripiprazole~If subject refuses or if this trial does not work, then offer:~* Ziprasidone or Loxapine~Failure of 2 anti-psychotic trials results in:~* Clozapine trial~If subject refuses a Clozapine trial then:~* Olanzapine offered~titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E~If compliance is an issue then a depot preparation:~* Paliperidone~* Risperidone~* Flupentixol~* Aripiprazole~Physicians will be prompted for non-pharmacological interventions"
214424376|NCT02657200|OTHER|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
214424377|NCT01291563|DRUG|Moxifloxacin|1 capsule of moxifloxacin (400 mg/capsule) on Day 2
214424378|NCT01291563|DRUG|TMC207|8 tablets of TMC207 (100 mg/tablet) on Day 1
214424379|NCT01291563|DRUG|TMC207 placebo|8 tablets of TMC207 placebo on Day 1
214424380|NCT01291563|DRUG|Moxifloxacin placebo|1 capsule of moxifloxacin placebo on Day 2
215028199|NCT06672133|DRUG|Adebrelimab|Given：IV
215028200|NCT06672133|RADIATION|Radiation Therapy|Undergo radiation therapy
215028201|NCT06673940|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS is applied on the acupuncture points Intervention arm
215028202|NCT06673940|OTHER|Physical Therapy program|Physical therapy methods
215028203|NCT06675279|OTHER|Survey-based study|The demographic information of individuals with migraines, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
215028204|NCT06674798|OTHER|School-based eHealth NCD Prevention Program|Students will participate in health-promoting sessions delivered by trained facilitators, with each session lasting 30 to 40 minutes. There will be a total of six health-promoting sessions conducted in the classroom for the intervention group, spanning two months with three sessions per month. The health-promoting videos from the school-based eHealth NCD prevention program will be shown in the classroom using multimedia. The drama-based videos will be developed in Urdu Language with English subtitles and will be based on based on contextually relevant content for the Pakistani secondary and higher secondary school students of age 13 to 18 years old. The content of these six sessions will be focused on the leading risk factors associated with NCDs as reported by different studies such as physical inactivity, unhealthy diet and overweight, obesity, harmful alcohol consumption and tobacco use.
215028205|NCT06543589|DEVICE|High-flow-nasal-cannula|Respiratory support will be provided by devices that deliver a blend of heated and humidified gas mixture of air and oxygen at gas flows exceeding 8 L/ min via binasal cannula.
215028206|NCT06675474|OTHER|Clinical periodontal measurements|Clinical periodontal measurements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.
215028207|NCT06675474|OTHER|Saliva sampling|The whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 2 minutes, wait for 10 minutes. Then the participants were requested to let the saliva pool in their floor of the mouth and to allow the saliva to drain passively into a falcon tube, 5 minutes.
215028208|NCT06675474|OTHER|Serum Sampling|5 ml of venous blood were taken from the antecubital vein by a standard venipuncture method.
215028209|NCT06675474|OTHER|GCF sampling|GCF was collected from the six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars, via steril paper strips.
215028210|NCT06675474|OTHER|Subgingival plaque sampling|Subgingival plaque was collected by inserting two standardized paper points (no:30) at six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars.
215028211|NCT06675682|DIETARY_SUPPLEMENT|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|Player randomization was performed using an online tool (https://www.randomizer.org/). An independent researcher assigned alphanumeric codes to each sequence to ensure blinding of both sprint athletes and researchers during the trials. Each player participated in two identical experimental trials separated by one week to allow physical recovery between testing occasions and washout from the beetroot juice treatment.
215028212|NCT06674070|GENETIC|Valproic Acid|syrup/ tablet EPIVAL (250mg
215028213|NCT06674941|DRUG|Teprotumumab|Administered as an SC injection.
215028214|NCT06675396|OTHER|Antidepressants|control
215028215|NCT06674200|PROCEDURE|Mesenteric Molding Suturing Group|"During the stoma surgery, the mesentery is shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Separate the mesentery around the stoma and shape it into a sturdy support structure.~Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
215028216|NCT06674200|PROCEDURE|Regular|"The stoma surgery is performed using conventional non-molding suturing techniques. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Perform routine suturing around the stoma without additional mesentery shaping. Form the stoma, ensuring a tight fit of the surrounding tissues."
215105730|NCT02529163|OTHER|Treatment as Usual|"The TAU group will be offered non-pharmacological interventions such as (but not limited to):~* metabolic monitoring~* skin hygiene~* pain management~* nutritional counseling~* family counselling~* Financial/housing support~* Group CBT (Cognitive Behavioral Therapy)~Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.~Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:~* Risperidone~* Aripiprazole~* Quetiapine~* Olanzapine~* Paliperidone~* Clozapine~* Ziprasidone~Max dosing and the time to reach the target dose is done at the discretion of the treating physician."
215105731|NCT02388334|OTHER|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).~The development of this standardized tool will also :~* identify the specific support needs of the caregivers~* study the links between the quality of care as perceived by the professionals, patients and caregivers~* identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
215105732|NCT00488735|BEHAVIORAL|Cognitive-behavioral rehabilitation|
215105733|NCT00488735|BEHAVIORAL|Traditional primary care|
215105734|NCT05257291|DRUG|Melatonin|Supplementation with 1 mg/day of melatonin for 1 year
215105735|NCT03443804|DRUG|Test(DW1401)|DW1401+Placebo of Stillen tab.
215105736|NCT03443804|DRUG|Reference(Stillen tab.)|Stillen tab.+Placebo of DW1401
215105737|NCT03295760|DRUG|Q10 Coenzyme|
215105738|NCT01593592|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
215105739|NCT01593592|DIETARY_SUPPLEMENT|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
215105740|NCT01593592|DRUG|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
215105741|NCT01593592|DRUG|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
215105742|NCT01593592|DRUG|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
215105743|NCT03319823|DRUG|Thiazide Treatment Group|"Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure \<160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment"
215105744|NCT03319823|DRUG|Intensified Thiazide Treatment Group|At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure \>120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure \>120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is \<120.
215105745|NCT03319823|DRUG|Combination Medication Treatment Group|"Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~* Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~* After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~  * If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~ * If sleep systolic blood pressure is \> 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy."
214424381|NCT06460688|OTHER|Mother Rehabilitative Aid Education Program|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. A class will be organized to educate Mothers/ Caregivers through PPT presentation, video and pictures. This class will contain 3 domains (Counseling, Educating, Practicing). Feedback will be taken on daily basis through video recordings. Mothers will take part in treatment session, 45 minutes for 5 days a week for 8 weeks.
215105746|NCT00389493|DRUG|Risperidone|Dosage of 0.5 mg to 4.0 mg per day as tolerated
215105747|NCT00389493|BEHAVIORAL|Exposure/ritual prevention therapy (EX/RP)|EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
215105748|NCT00389493|DRUG|Placebo|Placebo capsules will be identical in appearance to those of risperidone.
215105749|NCT01732770|BIOLOGICAL|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
215105750|NCT01732770|DRUG|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
215105751|NCT01732770|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
215105752|NCT01732770|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
215105753|NCT04332874|PROCEDURE|Isolated Limb Infusion|ILI will be performed within 18 days of initiation of pembrolizumab. ILI (infusion of melphalan and dactinomycin into the affected limb via arterial catheter) will be performed in the interventional radiology suite under anesthesia. In pediatric patients, the pediatric pharmacist w ill be consulted prior to the procedure, and an appropriate prophylactic anti-emetic therapy and dose will be selected for the individual patient.
215105754|NCT04332874|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.
215105755|NCT04332874|DRUG|infusion of melphalan and dactinomycin|infusion of melphalan and dactinomycin
215105756|NCT02449161|DRUG|MPA|
215105757|NCT02449161|DRUG|placebo|
215105758|NCT03047031|DRUG|Nintedanib|Nintedanib
215105759|NCT03047031|DRUG|Pirfenidone|Pirfenidone
215105760|NCT02451020|OTHER|Altitude exposure|Participants will stay for 3 weeks at an altitude of 3200 m
215105761|NCT00089531|DRUG|VRC-HIVDNA016-00-VP|
215105762|NCT01959841|DRUG|ASP2151|200 mg once daily or 400 mg once daily
215105763|NCT01959841|DRUG|valaciclovir|1000 mg three times daily
215105764|NCT02474420|DRUG|Amlodipine|amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
215105765|NCT02474420|DRUG|Deferasirox|Deferasirox administered per standard of care by the treating physician
215105766|NCT04579159|DEVICE|Preventicus heartbeat app in combination with wearables|CE certified devices
215105767|NCT04270084|BEHAVIORAL|Alive-Family|All participants receive lifestyle modification through use of m-health app
215105768|NCT00646360|DIETARY_SUPPLEMENT|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
215105769|NCT00646360|DIETARY_SUPPLEMENT|Placebo|2 tablets daily during pregnancy
215105770|NCT00780416|DRUG|MP-424|750 mg every 8 hours for 12 weeks
215105771|NCT00780416|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
215105772|NCT00780416|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
215105773|NCT00780416|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 48 weeks
215105774|NCT00780416|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 48 weeks
215105775|NCT03849222|PROCEDURE|Apexification|
215105776|NCT03849222|DRUG|MTA|
215105777|NCT03849222|DRUG|Ca(OH)2|
215105778|NCT03849222|DRUG|Apical matrix|collagen membrane (Biocollagen; Bioteck:Turin, Italy)
215105779|NCT04116125|PROCEDURE|Radiotherapy|Adjuvant radiotherapy on axillary region
215105780|NCT01096693|DRUG|Urocortin 2, Urocortin 3|"After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3."
215105781|NCT01096693|DRUG|Saline placebo|"After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
215105782|NCT04768543|DEVICE|Upper airway stimulation (Inspire Medical Systems, Inc.)|phasic hypoglossal nerve stimulation device
215028217|NCT03048682|DEVICE|Foley catheter - Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator."
215028218|NCT03048682|DEVICE|Foley catheter - Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice"
215028219|NCT03918031|BEHAVIORAL|PFI for Smoking & Distress Tolerance|Personalized Feedback Intervention for smoking and distress tolerance.
215028220|NCT03918031|BEHAVIORAL|PFI for Smoking Only|Personalized Feedback Intervention for smoking only (no distress tolerance component)
215028221|NCT06158438|DEVICE|BTL-754-4 Treatment|Treatment with the BTL-754 device with the BTL-754-4 applicator for reduction of facial wrinkles.
215028222|NCT07010744|DRUG|Triple drug regimen|Amoxicillin 1000mg at 12 hourly for 14 days Clarithromycin 500mg at 12 hourly for 14 days Esomeprazole 20 mg at 12 hourly for 14 days
215028223|NCT07010744|DRUG|Quadruple therapy|Bismuth subsalicylate 300mg at 6 hourly 14 days Metronidazole 400mg at 8 hourly 14 days Tetracycline 500mg at 6 hourly 14 days Esomeprazole 20 mg 12 hourly for 14 days
215028224|NCT07009873|OTHER|This study is designed to assess the non-inferiority of a novel ultrasound imaging technique, rather than to evaluate a therapeutic intervention.|This study is designed to assess the non-inferiority of a novel ultrasound imaging technique, rather than to evaluate a therapeutic intervention.
215028225|NCT07011186|DRUG|TQB3909 Tablets + Azacitidine|TQB3909 is a protein inhibitor; Azacitidine is a cytidine nucleoside analogue
215028226|NCT07011485|DRUG|Minoxidil 5% Topical Solution|Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.
215028227|NCT07011485|DRUG|PDFE-2304 Topical Solution|Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.
215028228|NCT07010003|PROCEDURE|Acupressure|Ear acupressure following the NADA Protocol is carried out using special acupuncture patches that press a small bead onto defined points on the ear: Shen Men, kidney, lung, liver, and vegetative. NADA ear acupressure is a non-invasive and low-risk intervention. In addition, the protocol is carried out exclusively by NADA-certified doctors, medical assistants, or nursing staff.
215105783|NCT02005588|DRUG|amino acid chelated iron|the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
215105784|NCT02005588|DRUG|iron salt (ferrous fumarate)|this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
215028229|NCT07011303|PROCEDURE|H-PRF|Blood will be taken from the patient before the surgical procedure is started. The blood sample will be placed in the H-TZF device for centrifugation and the sample will be horizontally centrifuged (2200 RPMx8 min, 700g). After the blood is processed for centrifugation, the surgery will begin. Surgery will be performed under local anesthesia with articaine 2 ml 4% and epinephrine 1:100,000. All patients will be operated by the same surgeon. After local anesthesia is achieved, tooth extraction will be started. After tooth extraction, the surgical field will be washed with sterile 0.9% saline, and H-PRF material will be placed in the area and primarily sutured with a 3.0 silk suture. All patients will be given postoperative instructions by the surgeon. Patients will be prescribed mouthwash (0.12% chlorhexidine mouthwash twice daily for 7 days).
215105785|NCT02255084|BEHAVIORAL|Group 1 remove self sample kit at gp consulting room or perform pap smear|"Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.~Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
215105786|NCT02255084|BEHAVIORAL|Group 2 perform self sample at home or pap smear|"Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
215105787|NCT02602119|DRUG|OTL38|Infusion of OTL38 prior to surgery
215105788|NCT04653194|DRUG|Biktarvy|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
215105789|NCT04653194|DRUG|Symtuza|Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg
215105790|NCT03648957|BEHAVIORAL|Lifestyle counselling|First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.
215105791|NCT03648957|BEHAVIORAL|Usual care|Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.
215105792|NCT03648957|DEVICE|Activity tracker|Participants are encouraged to wear a activity tracker to monitor their physical activity
215105793|NCT02411435|DRUG|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
215105794|NCT02411435|DRUG|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
215105795|NCT00666224|DRUG|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
215105796|NCT00666224|DRUG|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
215105797|NCT00666224|DRUG|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
215105798|NCT05498519|DRUG|SY-4798|FGFR4 selective inhibitor
215105799|NCT02678507|OTHER|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
214424382|NCT06460688|OTHER|Neuro physical Therapy|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. for 45 minutes, 5 days a week for 8 weeks. Participants in group B will not be educated about treatment plan. Routine home plan was given in this group once in a week, for 8 weeks.
215105800|NCT03466853|DIAGNOSTIC_TEST|Clinical assessment of nutritional status (CANS) score|Systematized inspection and estimation of loss of SC tissues and muscles of nine superficial physical parameters including hair and buccal fat in the cheeks, chin and neck, arms, back, inter or subscapular skin, buttocks, legs, chest, and abdominal wall skin. These signs will be rated from 1 (worst, severe FM) to 4 (best, well nourished), and the highest and lowest total scores are 36 and 9, 3respectively. A total score of \<25 is considered as fetal malnutrition.
215105801|NCT03466853|DIAGNOSTIC_TEST|Anthropometric indices|weight, length and head circumference
215105802|NCT03466853|DIAGNOSTIC_TEST|Proportionality indices|MAC/HC ratio (Calculation for each infant and value will be plotted on and compared with a standard curve). Ponderal index . A PI \<2.2 is considered as malnutrition). Body mass index (BMI= weight (kg) / length2 (m). A BMI \<11.2 kg/m2 is considered as malnutrition)
215105803|NCT00654979|DEVICE|SafeFlo IVC Filter|SafeFlo IVC Filter
215105804|NCT02091765|BEHAVIORAL|Internet-based cognitive behavioral therapy.|
215105805|NCT01126944|DEVICE|heart mate II|left ventricular assist device
215105806|NCT03084601|DRUG|Calcium Hydroxide, Iodoform, paste|mixture of calcium hydroxide and iodoform
215105807|NCT03084601|DRUG|3-mixtatin|3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
215105808|NCT05443256|DEVICE|Transcranial Magnetic Stimulation|Figure 8 coil stimulation
215105809|NCT03574883|DEVICE|tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
215105810|NCT03574883|DEVICE|tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
215105811|NCT06087575|DEVICE|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist device (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a HRPCI procedure. The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
215105812|NCT04591158|DEVICE|Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
215105813|NCT05095259|DRUG|insulin human|Hyperinsulinemic glucose clamp studies require that insulin is administered at a steady continuous rate to achieve stable levels of hyperinsulinemia. To reach this, insulin needs to be infused intravenously using a standard intravenous pump system. The insulin dose will be adjusted according to the body surface area, aiming for insulin levels of \~170 mIU/l, which is within the physiological range. Thus, for a subject with a bodyweight of 70 kg, body length of 180 cm and - consequently - a body surface area of 1.936 m2, the required insulin infusion can be calculated as: 1.936 x 60 x 60 ÷ 1000 = 7.0 units per hour
215105814|NCT05095259|DRUG|Epinephrin|Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50 ng∙kg-1∙min-1, for 20 minutes each. After each adrenaline infusion, substrate response will be measured by blood samples of glucose, lactate, free fatty acids, alanine, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
215105815|NCT05095259|PROCEDURE|Muscle biopsy|With the study subject resting in the supine position, the skin is disinfected on the lateral side of the thigh around 15 cm above the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the muscle with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the muscle. A small piece (around 150 mg) of the muscle is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some muscular tenderness for 2-3 days corresponding to minor muscular trauma.
215105816|NCT05095259|PROCEDURE|Adipose tissue biopsy|With the study subject resting in the supine position, the skin is disinfected on one side of the abdomen around 5-10 cm lateral from the umbilicus to the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the adipose tissue with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the adipose tissue. A small piece (around 1 gram) of the adipose tissue is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some tenderness for 2-3 days corresponding to minor trauma.
215105817|NCT05095259|DRUG|Glucagon|Glucagon is prepared in doses of 10 µg, 25 µg, and 50 µg and intravenously injected with intervals of 2 hours. After each glucagon injection, blood samples will be drawn to measure plasma glucose, glucagon, lactate, free fatty acids, alanine, amino-acids, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
215105818|NCT05095259|DEVICE|IPRO 2 Medtronic Minimed|All potential subjects will receive a blinded continuous glucose sensor at Visit 1. At the following visits, the continuous glucose monitor (CGM) will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A blinded CGM will be installed a week before every visit.
215105819|NCT05095259|PROCEDURE|7 Tesla (7T) Magnetic Resonance Imaging|Subjects will undergo a hyperinsulinemic euglycaemic glucose clamp, as mentioned above, in the MRI scanning room. After 30 minutes of stable normoglycaemia, subjects are taken into the MRI scanner (Philips Achieva 7.0 T) where brain, liver, thigh and calf muscle are scanned. After every anatomically different area, the subjects must be taken out of the scanner, while scanning coils are replaced. All subjects are advised to lie still and press the alarm button if necessary.
215105820|NCT05095259|PROCEDURE|Indirect Calorimetry using Jaeger Oxycon Champion|Resting metabolic rate will be estimated, after reaching stable plasma glucose level, via a hyperinsulinemic euglycaemic clamp, as mentioned above. This will be done by indirect calorimetry, using a ventilated hood system (Jaeger Oxycon Champion, software version 4.3, Jaeger, Mijnhardt). Subjects are instructed to lie down and rest for a period of 30 minutes. Subjects are also instructed not to move, talk or sleep unless necessary during the period of measurement. The recorded measurement after 5 minutes to 30 minutes will be used for analysis.
215105821|NCT05095259|PROCEDURE|Core temperature and thermography using Thermovision SC645|Thermography (Thermovision SC645, FLIR Systems, Wilsonville, OR, USA) is used to determine cutaneous vascular perfusion. Data is analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA).
215105822|NCT05095259|DEVICE|Freestyle Libre 2|All potential subjects will receive a continuous glucose sensor at Visit 1. At the following visits, the CGM will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A CGM will be installed a week before every visit.
215105823|NCT05860231|DEVICE|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
215105824|NCT05860231|DEVICE|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
215105825|NCT00482625|DRUG|erlotinib hydrochloride|Given PO
215105826|NCT00482625|PROCEDURE|conventional surgery|Undergo pancreatectomy
215105827|NCT00482625|OTHER|immunohistochemistry staining method|Correlative studies
215105828|NCT00482625|GENETIC|protein expression analysis|Correlative studies
215105829|NCT00482625|PROCEDURE|biopsy|Correlative studies
214424383|NCT03199781|DEVICE|Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics|Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
215105830|NCT00482625|OTHER|pharmacological study|Correlative studies
215105831|NCT00482625|OTHER|laboratory biomarker analysis|Correlative studies
215105832|NCT02016079|DIETARY_SUPPLEMENT|omega-3|200 ml fruit drink containing omega-3
215105833|NCT06243640|DRUG|Buagafuran capsules, 15mg/ capsule|Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;
215105834|NCT06243640|DRUG|Buagafuran capsules mimic, 0mg/ capsule|Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
215105835|NCT00871338|BIOLOGICAL|GSK2197870A|3 doses given at 2, 3 and 4 months of age
215105836|NCT00871338|BIOLOGICAL|Prevenar™|3 co-administered doses, intramuscular into right thigh
215105837|NCT00871338|BIOLOGICAL|Menitorix™|1 booster dose at 12 months of age
215105838|NCT00871338|BIOLOGICAL|Pediacel™|3 doses given at 2, 3 and 4 months of age
214424384|NCT00997386|DRUG|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
214424385|NCT03105505|DRUG|Permethrin 5%|Facial skin application once a night for 3 months.
215105839|NCT00871338|BIOLOGICAL|Menjugate™|2 doses given at 3 and 4 months of age
215105840|NCT04971356|DRUG|Aspirin 100mg for 1-month (immediately after PCI)|Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm
215105841|NCT04971356|DRUG|Ticagrelor 90mg for 6-month (immediately after PCI)|Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm
215105842|NCT04971356|DRUG|Aspirin 100mg for 6-month (6-month post PCI)|Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm
215105843|NCT04971356|DRUG|Aspirin 100mg for 12-month (immediately after PCI)|Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
215105844|NCT04971356|DRUG|Ticagrelor 90mg for 12-month (immediately after PCI)|Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
215105845|NCT01078363|DRUG|ramipril|Use of a ACE ( angiotension converting enzyme) inhibitors post heart Transplant for Blood pressure control.
215105846|NCT01078363|DRUG|Placebo|Use of a placebo post heart Transplant for Blood pressure control.
215105847|NCT00282659|DRUG|magnesium L-lactate|
215105848|NCT00001870|DRUG|Acetylcholine|
215105849|NCT04597385|OTHER|Long-term Follow-Up|No intervention
215105850|NCT03832335|DIAGNOSTIC_TEST|Measurement of aniseikonia tolerance|Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
215105851|NCT00557635|PROCEDURE|Chirurgical procedure|Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.
215105852|NCT05173909|DEVICE|BIS closed-loop target controlled infusion|BIS was monitored by connecting the BIS monitor (BISXP, Aspects Medical Systems, USA). The corresponding value was set on the BIS detector and connected to the targy-controlled infusion pump to automatically adjust the plasma drug concentration of propofol
215105853|NCT00044772|DRUG|Venlafaxine ER|
215105854|NCT03251937|DEVICE|Spectra WaveWriter SCS System|Multiple modalities of stimulation therapy
215105855|NCT06072417|OTHER|Assessment without intervention at High altitude|Assessments at High altitude corresponding to Baseline measures
215105856|NCT06072417|OTHER|Relocation to sea level for 2 days|Participants will be relocated to sea level and intervention and have assessements there.
215105857|NCT03828331|OTHER|Prosthetic/Bicycle Configuration|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
215105858|NCT04286815|DEVICE|Lentiviral Vector Gene Therapy|Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells
215105859|NCT01651325|DRUG|Isavuconazole|oral
215105860|NCT01651325|DRUG|dextromethorphan|oral
215105861|NCT06256341|OTHER|Cell cultivation, Antigen testing|"day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity.~No more interventions in human except blood sampling, only basic research."
215105862|NCT00244101|DRUG|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
215105863|NCT00244101|DEVICE|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
215105864|NCT00244101|DRUG|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
215105865|NCT05908903|COMBINATION_PRODUCT|Drinks with active ingredients such as poria and GABA|Take drinks half an hour before bedtime, 10ml/bag/day, daily. Subjects are uniformly using skin care products provided by the sponsor during the test.
215105866|NCT01959139|DRUG|PEGPH20|3 ug/kg on Day 1, IV over 15 minutes
215105867|NCT01959139|DRUG|Oxaliplatin|85 mg/m\^2, on Day 2, IV over 2 hours
215105868|NCT01959139|DRUG|Leucovorin|400 mg/m\^2, on Day 2, IV over 2 hours
215105869|NCT01959139|DRUG|Irinotecan|180 mg/m\^2, on Day 2, IV over 1.5 hours
215105870|NCT01959139|DRUG|5-fluorouracil|2,400 mg/m\^2, Days 2-4, IV over 46 hours
215105871|NCT04756804|DRUG|70% v/v Isopropyl Alcohol Surgical Solution|Patient preoperative skin preparation
215105872|NCT04756804|DRUG|2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol|Patient preoperative skin preparation
215105873|NCT01819896|DRUG|Pacemaker and defibrillator|
215105874|NCT04553900|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Placement of a transesophageal probe and performance of a diagnostic Transesophageal echocardiography examination.
215105875|NCT03996031|DEVICE|Plan to Thrive smartphone application|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests.
215105876|NCT02561442|DRUG|ceftriaxone|
215105877|NCT02181283|BEHAVIORAL|W+W|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps."
215105878|NCT02181283|BEHAVIORAL|W+P|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support."
215105879|NCT00005773|DRUG|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had \<=20 mm Hg increase in PaO2 (less than full response).
215105880|NCT00005773|DRUG|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).
215105881|NCT01964963|DRUG|Alogliptin|Alogliptin tablets
215105882|NCT03470207|PROCEDURE|Post-pulmonary embolism follow up protocol|Structured post-pulmonary embolism follow up protocol (outlined in Aim 1)
215105883|NCT03648515|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
215105884|NCT03648515|DIAGNOSTIC_TEST|Digital Images of the dental arches|The dental arches will be captured using a dedicated camera in order to be used for measuring the outcomes.
215105885|NCT03648515|DIAGNOSTIC_TEST|Digital images of models|The poured dental models will be captured using a dedicated camera in order to be used for measuring the outcomes.
215105886|NCT01415141|DRUG|Peginterferon alfa-2a|180ug subcutaneously, weekly
215105887|NCT01415141|DRUG|Ribavirin|"Administered orally twice a day as follows:~weight \< 75kg - 1000mg weight ≥ 75kg - 1200mg"
215105888|NCT01415141|DRUG|telaprevir|750mg every 8 hours, orally
215105889|NCT04879966|DRUG|Infliximab|Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
215105890|NCT04879966|DRUG|Corticosteroid|Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
215105891|NCT06117865|BEHAVIORAL|Module 1|Module 1: Introduction to IBS by a gastroenterologist.
215105892|NCT06117865|BEHAVIORAL|Module 2|Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.
215105893|NCT06117865|BEHAVIORAL|Module 3|Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.
215105894|NCT06117865|BEHAVIORAL|Module 4|Module 4: Intervention: behavioral therapy (exposure therapy and cognitive behavioral therapy).
215105895|NCT06117865|BEHAVIORAL|Module 5|Module 5: Intervention: The low FODMAP diet.
214424386|NCT03105505|DRUG|Synthomycine 5%|Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
214424387|NCT03105505|DRUG|Fusidic Acid 1% M/R Eye Drops|viscous eye drops application once a night for 3 months.
215105896|NCT01109355|OTHER|lung mechanics ventilatory|To perform the evaluation of lung mechanics ventilatory mode was changed to control volume with the following parameters: tidal volume (Vt) = 8ml/kg weight, peak flow (PF) = 6 x minute volume, fraction of inspired O2 (FiO2) = 40%, respiratory rate (RR) = 16 bpm, sensitivity = 1 cmH2O. The following variables were monitored: PIC, Blood Pressure (BP), heart rate (HR), peak pressure in the airways (pp.) and plateau pressure of the respiratory system (Ppl.), these values were monitored with PEEP = 5 cmH2O. PEEP employed ranged from 0 to 14 cmH2O. To eliminate a possible physiological accommodation by the progressive increase of PEEP, the range of values was determined by drawing a sealed envelope for each patient, ranging from 2 to 2 cmH2O.
215105897|NCT01109355|OTHER|Hemodynamic and intracranial pressure|At each value of PEEP the patient was ventilated for a period of five minutes to carry out monitoring of ICP, BP, HR, PPC and peripheral oxygen saturation (SpO2). The ICP monitoring catheter was kept closed for drainage and open for monitoring, since the arrival of the surgical block, was only open for drainage if there was an increase in ICP above 20 mmHg.
215105898|NCT00005608|DRUG|leucovorin calcium|
215105899|NCT00005608|DRUG|tegafur-uracil|
214424388|NCT04970342|DRUG|Placebo (Lactose) Capsule|Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
215105900|NCT00241345|DRUG|Valganciclovir|
215105901|NCT00241345|DRUG|Ganciclovir|
215105902|NCT01235234|DRUG|CF101|orally q12h
215105903|NCT00497406|PROCEDURE|Salivary gland transfer|Retrograde flow method
215105904|NCT00497406|PROCEDURE|Helical Tomotherapy treatment|total of 30 fractions
215105905|NCT00534859|DEVICE|High Risk PCI|High Risk Percutaneous Coronary Intervention
215105906|NCT02636530|BEHAVIORAL|Ground Reaction Forces|6 month exercise program that loads the body via gravitational forces.
215105907|NCT02636530|BEHAVIORAL|Joint Reaction Forces|6 month exercise program that loads the body via loading the joints.
214424389|NCT04970342|DRUG|0.75 mg Alprazolam Capsule|Single dose on one of the three study visits, orally administered 40 minutes prior to cannabis dose
214424390|NCT04970342|DRUG|Cannabis (6.18% THC / <0.025% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (6.18% THC / \<0.025% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose on one of the three study visits.
215105908|NCT01184924|BEHAVIORAL|Evaluation of the Arthritis Foundation Tai Chi Program|The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
215105909|NCT04085497|OTHER|Treatment|KT application: KT application includes 2 stages. The banding in the first step is directed to the patellar tendon in order to absorb the load of the knee. The second step is directed directly on the medial plica to benefit from its analgesic effect. For the first step, an I-band is measured from the top of the patella to the tuberositas tibia. I-band is 6 cm wide and 5 mm thick. This I-band is cut into Y-band. First, the part of the band above the patella is pasted with 10% tension. Then the patient's knee is flexed to maximum flexion and the tails of the band are pasted around the patella with 0% tension. The tails of the band are combined together on the tuberositas and completed. For the second step, 4 I-bands 8 cm long and 1.5 cm wide are prepared. The middle of the I-bands is attached to the medial plica with a 0% tension, giving a star shape.
215105910|NCT02352753|DRUG|Denosumab|Subcutaneous (SC) injection.
215105911|NCT05672706|PROCEDURE|CFR and IMR group|Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement
215105912|NCT04755036|OTHER|Survey and case vignette|We sent a survey and case vignette cases to every responsible in each center
215105913|NCT03406013|BEHAVIORAL|Written Information|Receive written information on diet and exercise relevant to older men with prostate cancer
215105914|NCT03406013|BEHAVIORAL|Prescription|Participants receive tailored exercise prescription and tailored diet recommendations
215105915|NCT03406013|BEHAVIORAL|Technology|Participants receive motivational text messages and can electronically log and track their exercise and diet habits
215105916|NCT03406013|BEHAVIORAL|Coaching|Participants receive access to an exercise and diet coach to provide advice by phone and/or email
215105917|NCT03058055|BEHAVIORAL|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
215105918|NCT03058055|BEHAVIORAL|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
215105919|NCT03058055|BEHAVIORAL|Reading|Book club that includes weekly one hour meetings and daily reading assignments
215105920|NCT05200676|DEVICE|ePatch|ePatch registers the heart rate continuously when attached to the chest of the participant.
215105921|NCT05200676|DEVICE|SmartPill|SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
215105922|NCT05300789|OTHER|Follow-up|There is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded.
215105923|NCT01247168|DRUG|AZD2461|oral capsules, continuous dosing and intermittent dosing
215105924|NCT05750576|DEVICE|Chlorhexidine-impregnated dressings|Sterile adhesive transparent dressings impregnated with Chlorhexidine Gluconate gel applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
215105925|NCT05750576|DEVICE|Non impregnated dressings|Single transparent adhesive dressings not impregnated with Chlorhexidine Gluconate applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
215105926|NCT04345679|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~200 mL over 4 hours
215105927|NCT05615207|OTHER|Motor Imagery as compared to physical practice for balance tasks|We will investigate if using motor imagery (mentally imagining and practicing a task) as a means of balance training is as effective as physical practice
215105928|NCT03874572|BIOLOGICAL|Allogeneic adipose derived stem/stromal cells|Culture expanded allogeneic adipose derived stem/stromal cells
215105929|NCT04425382|DRUG|Darunavir/Cobicistat|Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily
215105930|NCT04425382|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily
215105931|NCT02268825|DRUG|MK-3475|"MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose"
215105932|NCT04417153|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.
214692174|NCT06663956|BEHAVIORAL|a patient self-reporting applet|"We propose to develop a patient self-reporting applet that is easy to use and simple to operate. The program is embedded with questionnaires related to cancer pain and quality of life assessment, so that patients can fill out the questionnaires to report their symptoms and changes in their conditions to primary care doctors in a timely manner. At the same time, the background of the program will monitor the patient's indicators in real time. When the patient's pain reaches moderate-to-severe level, or when the patient experiences side effects of drugs, or when the patient's adherence to medication is poor, the primary care doctor can immediately receive relevant alerts through the app, so as to intervene in the patient's cancer pain treatment. When the patient has an alarm value, primary care doctors can provide feedback to doctors in higher-level hospitals and implement comprehensive and standardized treatment for cancer pain patients."
215105933|NCT00607867|OTHER|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
215105934|NCT00607867|OTHER|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
215105935|NCT04350996|OTHER|Wearable alcohol sensor|BACtrack Skyn, is a novel transdermal blood alcohol sensor developed by BACtrack, a company established for police-grade breathalyzers, and winner of the Wearable Alcohol Biosensor Challenge sponsored National Institute on Alcohol Abuse and Alcoholism.
215105936|NCT00711971|DRUG|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
214424391|NCT04970342|DRUG|Cannabis (0%/ THC / 0% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
214424392|NCT00188136|DRUG|Melphalan, ATG, Fludarabine|allo Tx during aplasia
215105937|NCT00711971|DRUG|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
214424393|NCT05625334|DRUG|ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
215105938|NCT00711971|DRUG|placebo|control arm
215105939|NCT01909089|DRUG|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~* effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~* Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
215105940|NCT01199809|DRUG|Placebo|multiple doses
214509568|NCT01289834|DEVICE|Hi-Fatigue Bone Cement|"Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH \& Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement."
215105941|NCT01199809|DRUG|RO5310074|multiple ascending doses
215105942|NCT02967510|DRUG|Estriol|
215105943|NCT02967510|DRUG|Placebo|
215105944|NCT03079596|PROCEDURE|ERAS perioperative cares|Patient's preoperative counseling \& education before surgery No Bowel preparation Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Fluid restriction \& Management by pulse contour analysis or transesophageal doppler Early mobilization Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD)) Epidural patient controlled analgesics (no opioids analgesics) Postoperative Nausea Active Control Thromboembolism prophylaxis by low molecular weighted heparin (LMWH) Perioperative High content Oxygen therapy No drain insertion No Levin tube Patients will be discharged at POD#4 if there's no problem.
215105945|NCT03079596|PROCEDURE|Conventional perioperative cares|No Patient's preoperative counseling \& education before surgery Bowel preparation No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Conventional Fluid Management by clinical signs (Urine output, heart rate etc.) Conventional Mobilization Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD) IV PCA Postoperative Nausea Control if needed No Thromboembolism prophylaxis No or Low Content Oxygen therapy Routine drain insertion Levin tube insertion if needed
215105946|NCT01584739|DRUG|AZD8683|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
215105947|NCT01584739|DRUG|Placebo|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
215105948|NCT05587192|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT based on diagnostic model|All enrolled patients will receive 18F-PSMA-1007 PET/CT based USTC diagnostic model before gaining the final pathological diagnosis to be used as experimental arm.
215105949|NCT05022966|OTHER|No intervention|Individuals did not received any intervention.
215105950|NCT03005548|DEVICE|Transcranial direct current stimulation|"Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins."
215105951|NCT03005548|DRUG|Morphine|"In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning."
214424394|NCT05625334|DRUG|non-enteric-coated chewable aspirin|Orally administered
214424395|NCT04077632|DEVICE|Transcranial direct current stimulation|tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
214424396|NCT01625013|DEVICE|Synvisc-One (G-F 20)|Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years.
214424397|NCT03958734|OTHER|High-fat meal|Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
214424398|NCT01398124|BIOLOGICAL|Cyclin B1 Peptide|vaccine
214424399|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 1|Oat based beverage with added different concentration of extracted oat component.
214424400|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 2|Oat based beverage with added different concentration of extracted oat component.
214424401|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 3|Oat based beverage with added different concentration of extracted oat component.
214424402|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 4|Oat based beverage with added different concentration of extracted oat component.
214424403|NCT03830736|COMBINATION_PRODUCT|Control product|Glucose based beverage without added test components is used as control product
214424404|NCT02869022|DRUG|Custodiol-N|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
214424405|NCT02869022|DRUG|Custodiol|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
214424406|NCT02869022|PROCEDURE|organ perfusion for heart transplantation|
215105952|NCT02746640|PROCEDURE|Cardiopulmonary resuscitation (CPR)|If there is a cardiopulmonary arrest, investigators observe the working processes of cardiopulmonary resuscitation.
215105953|NCT02768519|DRUG|OTS167IV|diluted to final concentration with cherry syrup
215105954|NCT02768519|OTHER|Cherry syrup|
215105955|NCT04246658|OTHER|conventional physical therapy program|traditional physical therapy program
215105956|NCT04246658|OTHER|gait training on platform swing walkway|gait training on platform swing walkway for 30 minute.
215105957|NCT04720521|DIAGNOSTIC_TEST|OE+white light|Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus
215105958|NCT01848119|DRUG|Gabapentin|
215105959|NCT01848119|DRUG|lactose|
215105960|NCT04280627|OTHER|Sample Collection|This study will involve the collection of oral swabs, saliva, urine and faeces samples, blood and skin scrapings from patients before and after kidney and pancreas transplantation at day 0, day 1, week 1 and at 3, 6 and 12 months post-transplant.
215105961|NCT04152915|DRUG|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks
215105962|NCT03237715|OTHER|Assessment of unbound bilirubin levels|Collection of residual blood for measurement of unbound bilirubin
215105963|NCT02210858|OTHER|Laboratory Biomarker Analysis|Correlative studies
215105964|NCT02210858|DRUG|Tipifarnib|Given PO
215105965|NCT01423292|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
215105966|NCT01423292|DRUG|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
215105967|NCT01423292|DRUG|Placebo|placebo
215105968|NCT00536471|DRUG|Duloxetine hydrochloride|
215105969|NCT00536471|DRUG|Placebo|
215105970|NCT00394550|PROCEDURE|supraglottoplasty with laser|"Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children"
215105971|NCT00394550|PROCEDURE|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
215105972|NCT00456287|DEVICE|CPAP (Continuous Positive Airway Pressure)|
215105973|NCT02551822|DEVICE|sacral neuromodulator|The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
215105974|NCT04239742|DIAGNOSTIC_TEST|F18-fluciclovine PET/CT|370 MBq ±10% 18F-Fluciclovin + low-dose CT scan, from skull base to pelvis.
215105975|NCT04239742|DIAGNOSTIC_TEST|F18-PSMA-1007 PET/CT|4 MBq/kg ±10% F18-PSMA + low-dose CT scan, from skull base to pelvis
215105976|NCT03962075|PROCEDURE|laparoscopic paravaginal repair|Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique
215105977|NCT03647644|DIAGNOSTIC_TEST|Coagulation Laboratory Testing|Standard coagulation testing (Platelet count, Fibrinogen, PT/INR, aPTT), and Thromboelastogram as is routine and per institutional protocol in this population.
215105978|NCT03450954|PROCEDURE|Amniotic membrane transplant|Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
215105979|NCT02668887|BEHAVIORAL|Quality of Life, status of employment|
215105980|NCT06459479|OTHER|Conversational Artificial Intelligence Simulations|Use of Conversational Artificial Intelligence Simulations generate medical scenario.
214424407|NCT05035004|DEVICE|Post exercise hot water immersion|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max), followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
214424408|NCT05035004|DEVICE|Exercise|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max).
214424409|NCT05035004|DEVICE|Hot water immersion|Participants will complete 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C), followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
215105981|NCT05906121|DRUG|lidocaine-ketamine infusions|Lidocaine and ketamine are infused over a period of 30 minutes. The dosage of lidocaine is 4mg/kg is maintained throughout the infusions, and the dosage of ketamine is increased within the first three infusions from 0.15mg/kg at the first, to 0.25mg/kg at the second and 0.5mg/kg at the third infusion. In case patients already experiencing sufficient analgesic effect and/or improvement in quality of life after the 1st or 2nd infusion or if side effects do not allow a further dose increase, no further step up of ketamine dosage is made. As a part of this study, at the end of the first, second and third infusion, side effects will be screened using customized questionnaires (SF - MPQ, BDI-II)
215105982|NCT04803227|DRUG|Emricasan|Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.
215105983|NCT04803227|OTHER|Placebo|Placebo BID \*days 1-14). Oral (capsule) administration.
215105984|NCT01336413|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
215105985|NCT01336413|DRUG|Placebo|Same as active comparator, except placebo dispensed.
215105986|NCT01440816|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
215105987|NCT01440816|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
215105988|NCT04430504|BEHAVIORAL|multidisciplinary telerehabilitation|weekly video meetings to instruct and monitor self-exercises at home
215105989|NCT01687101|DRUG|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
215105990|NCT05743361|DIAGNOSTIC_TEST|Blood sampling|Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
215105991|NCT02181764|DRUG|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
215105992|NCT01426022|OTHER|Nutrition|Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
215105993|NCT01426022|BEHAVIORAL|mood manipulation|Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
215105994|NCT02489383|OTHER|Continuous Exercise Training|The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
215105995|NCT02489383|OTHER|Interval Exercise Training|The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
215105996|NCT02489383|BEHAVIORAL|Education Program|The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
215105997|NCT03619772|OTHER|Bilateral|Participants will control game using EMG from both upper limbs.
215105998|NCT03619772|OTHER|Unilateral|Participants will control game using EMG from the more impaired upper limb.
215105999|NCT05156957|OTHER|physiotherapeutic intervention|The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.
215106000|NCT05179148|BEHAVIORAL|Motivational Interviewing|MI is a client-centered counselling style for strengthening a person's own motivation and commitment to change. MI helps evoke the person's own motivation for changes through reflective listening, engaging, evoking, and planning
215106001|NCT04574401|DRUG|IS-002|Intravenous injection of IS-002 Investigational Drug
215106002|NCT01402713|BIOLOGICAL|GC1107|GC1107-T5.0: low dose, GC1107-T7.5: high dose
214509569|NCT01289834|DEVICE|Palacos Bone Cement|"Palacos Bone Cement has been used for 48 years and has a good reputation as the gold standard among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing"
214509570|NCT01498614|BEHAVIORAL|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
214509571|NCT02589613|DIETARY_SUPPLEMENT|tap water|300ml tap water via nasogastric tube
214509572|NCT02589613|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g Glucose via nasogastric tube
214509573|NCT02589613|DIETARY_SUPPLEMENT|Fructose|300ml tap water with 25g Fructose via nasogastric tube
215106003|NCT01402713|BIOLOGICAL|TD_PUR INJ / SK Td vaccine|step 1(phase 2)-TD\_PUR INJ step 2(phase 3)-SK Td vaccine
215106004|NCT04991675|BEHAVIORAL|pelvic floor muscle exercises|During the first visit, the anatomy of the pelvic floor and the purpose of the program were explained. Exercises were taught in the supine position, as described by Kegel (1948), it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
215106005|NCT04991675|BEHAVIORAL|diaphragmatic breathing exercises|During the first visit, the anatomy of the diaphragm and abdominal wall and the purpose of the program were explained. Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
215106006|NCT01053494|PROCEDURE|massage therapy|Undergo massage therapy
215106007|NCT01053494|OTHER|questionnaire administration|Ancillary studies
215106008|NCT01053494|PROCEDURE|quality-of-life assessment|Ancillary studies
215106009|NCT01053494|OTHER|intervention by caregiver|Undergo massage by caregiver
215106010|NCT01053494|PROCEDURE|standard follow-up care|Undergo standard follow-up care
214509574|NCT06455072|DRUG|Nituzumab|EGFR monoclonal antibody
214509575|NCT06455072|DRUG|Serplulimab|PD-1 (programmed death receptor 1) monoclonal antibody
214509576|NCT02594267|DRUG|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone"
214509577|NCT06418919|PROCEDURE|Radiofrequency ablation treatment|RFA is used to ablate the entire thyroid gland
215106011|NCT02076282|OTHER|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast"
215106012|NCT03397342|DEVICE|CPAP machine|Use of CPAP machine during MRI
215106013|NCT05492097|BEHAVIORAL|Exercise Therapy|Traditional exercise therapy and NMES
215106014|NCT05492097|BEHAVIORAL|Exercise Therapy and Robotic Walking Training|Traditional exercise therapy and Robotic Walking Training
215106015|NCT03250182|DRUG|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
215106016|NCT01427426|DIETARY_SUPPLEMENT|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
215106017|NCT01427426|OTHER|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
215106018|NCT03355066|DRUG|SM08502|SM08502 tablets to be administered orally.
215106019|NCT02718209|DEVICE|Mid-Infrared Spectroscopy with ATR|
215106020|NCT04375111|PROCEDURE|Serratus anterior plane block|•Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.
215106021|NCT04375111|PROCEDURE|Transversus thoracic plane block|•Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of isobaric bupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
215106022|NCT05243082|DEVICE|Radio frequency ablation|Radio frequency ablation of pancreatic neuroendocrine tumors
215106023|NCT05211206|OTHER|IV fluids|Amount of intravenous fluids delivered
215106024|NCT05917418|DIETARY_SUPPLEMENT|nutritional support|nutritional support
215106025|NCT01621711|BEHAVIORAL|Linkage patient activation intervention|"Usual Care plus Linkage encompassed Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.~The patient activation intervention components -- 1) six 45-min Linkage sessions on activation regarding overall health behaviors and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and PC physician -- were delivered by a clinical psychologist."
215106026|NCT03067389|DIAGNOSTIC_TEST|Diagnostic test|Genetic diagnostic test
215106027|NCT02055378|DRUG|Atropine|topical 0.125% atropine eye drops
215106028|NCT02055378|DEVICE|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
215106029|NCT05816434|BEHAVIORAL|Sleep extension|\>1 hour additional time in bed per night for 1 week.
215106030|NCT05216341|DRUG|OLP-1002|"Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection."
215106031|NCT04289961|DIAGNOSTIC_TEST|Portal vein sampling|During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
215106032|NCT05159115|OTHER|Low-FODMAP diet|4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)
214509578|NCT02684136|DRUG|suvorexant|suvorexant 20 mg taken before sleep
215106033|NCT05159115|OTHER|Starch- and Sucrose Reduced Diet (SSRD)|4 weeks of a diet low in starch and sucrose
215106034|NCT06507696|OTHER|Ice Application|Drinking water was placed in a syringe and filled in the refrigerator
215106035|NCT06507696|OTHER|Wetted Gauze Application|Sterile gauze soaked with drinking water
215106036|NCT03369912|BIOLOGICAL|CSJ148|Active
215106037|NCT03369912|OTHER|Placebo|No Drug
215106038|NCT01255995|DEVICE|Capsular Tension Ring|Capsular Tension Ring
215106039|NCT06960668|BEHAVIORAL|Nature for Body Image|The intervention will include a range of activities in nature (e.g., in a public park), such as meditation, body scans, and grounding exercises.
215106040|NCT06960668|BEHAVIORAL|Simple nature exposure|The intervention will simply involve spending time in nature (e.g., in a public park), without specific guidelines.
215106041|NCT06960668|BEHAVIORAL|Structured Built Environment Exposure|The intervention will mirror the activities of the structured nature exposure intervention (e.g., meditation, body scans, and grounding exercises), but without any exposure to nature.
215106042|NCT01858740|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
215106043|NCT01858740|DRUG|Fludarabine Phosphate|Given IV
215106044|NCT01858740|OTHER|Laboratory Biomarker Analysis|Correlative studies
215106045|NCT01858740|DRUG|Methotrexate|Given IV
215106046|NCT01858740|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
215106047|NCT01858740|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
215106048|NCT01858740|DRUG|Tacrolimus|Given IV or PO
215106049|NCT01858740|DRUG|Thiotepa|Given IV
215106050|NCT01858740|RADIATION|Total-Body Irradiation|Undergo TBI
215106051|NCT03719911|BEHAVIORAL|Live diabetes coaching program|Live diabetes coaching program
215106052|NCT01080846|DRUG|Misoprostol|600 mcg of sublingual misoprostol
215106053|NCT02994875|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
215106054|NCT02994875|OTHER|Placebo|Sugar pill
215106055|NCT01035281|DRUG|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
215106056|NCT00410007|BEHAVIORAL|High Sodium Diet|250-350 mmol
215106057|NCT00410007|BEHAVIORAL|Low Sodium Diet|25-35 mmol
215106058|NCT00410007|BEHAVIORAL|Hypertonic saline infusion|7 ml/ kg of 3% saline were given over 30 minutes.
215106059|NCT00413790|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
215106060|NCT00413790|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
214509579|NCT02684136|DRUG|placebo|placebo taken before sleep
215106061|NCT00413790|DRUG|Placebo|Placebo tablet once daily
215106062|NCT01625546|DEVICE|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
215106063|NCT04102072|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
215106064|NCT04102072|DIAGNOSTIC_TEST|dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
215106065|NCT06960720|OTHER|Resistance Exercises|Twice-weekly resistance exercises completed in 45 minutes using resistance bands and a physical therapy workout plan.
215106066|NCT04996485|DRUG|Secukinumab Injection|Pathogenetic therapy with biologic drugs
215106067|NCT04996485|DRUG|Ustekinumab Injection|Pathogenetic therapy with biologic drugs
215106068|NCT04996485|DRUG|Dupilumab Injection|Pathogenetic therapy with biologic drugs
215106069|NCT04996485|OTHER|Symptomatic therapy|Active external agents, Emollients, systemic retinoids if needed
215106070|NCT04370353|DIETARY_SUPPLEMENT|Cocoa flavanols|Flavonoid-rich cocoa powder, containing 100mg total flavanols per 316mg.
215106071|NCT04370353|DIETARY_SUPPLEMENT|Placebo supplement|Microcrystalline filler, containing 0mg total flavanols.
215106072|NCT02540070|PROCEDURE|Periarticular|
215106073|NCT02540070|PROCEDURE|Motor free|
215106074|NCT02540070|PROCEDURE|Motor free with dex|
215106075|NCT02540070|DRUG|Ropivacaine|
215106076|NCT02540070|DRUG|epinephrine|
214509580|NCT00407485|BIOLOGICAL|ziv-aflibercept|Given IV
214509581|NCT00407485|OTHER|pharmacological study|Correlative studies
214509582|NCT01274000|DRUG|YM060|oral
214509583|NCT01274000|DRUG|placebo|oral
214509584|NCT05786768|DRUG|single infusion of Rituximab|single infusion of Rituximab 375 mg/m2
214509585|NCT05786768|DRUG|single infusion of Obinutuzumab|single infusion of Obinutuzumab 300mg/1.73 m2
214509586|NCT02762786|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
214509587|NCT05196958|OTHER|GLP1 analogues|This cohort study has 2 phases: an observation phase to collect all initial clinical and biological parameters and an intervention phase (prescription of GLP1 analogues) of 6 months including a visit at 3 and 6 months.
214509588|NCT00432445|RADIATION|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
214509589|NCT00432445|PROCEDURE|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
214509590|NCT02570100|PROCEDURE|Biological collection|"Collection of blood samples and tumor specimens :~Biological collection before treatment :~* 1 tumor specimen (under echographic control)~* 4 blood collections~Biological collection during treatment :~* 1 tumor specimen after 3 cycles~* 4 blood collections after 3 and 6 cycles"
214509591|NCT02148575|BEHAVIORAL|Self-Management Group|
214509592|NCT02148575|BEHAVIORAL|Symptom Management Group|
214509593|NCT04913506|OTHER|Group Mirror|For 30 minutes, ROM exercises will be applied to the solid upper extremity in all directions in front of a real mirror by the practitioner. (3 weeks, 5 days a week, 15 sessions in total)
215106077|NCT02540070|DRUG|morphine|
215106078|NCT02540070|DRUG|Ketorolac|
215106079|NCT02540070|DRUG|Dexmedetomidine|
215106080|NCT02540070|DRUG|saline|
215106081|NCT01362829|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
215106082|NCT05314907|DEVICE|Explanation on how to use self-sampling device and training in the screening visit.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is collected for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn Brush and after the woman collects an HPV sample by self-sampling in the same medical center as a trainning.~Finally, a new cervibrush (Evalyn brush) is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
215106083|NCT05314907|OTHER|Only explanation on how to use self-sampling device.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is taken for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn.~Finally, a Evalyn brush is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
215106084|NCT00709072|BEHAVIORAL|SMS (Short Message Service) reminders|SMS reminders sent every 2 weeks
215106085|NCT04570631|DRUG|Eftozanermin alfa|Intravenous (IV) infusion
215106086|NCT04570631|DRUG|Bortezomib|Intravenous (IV) or Subcutaneous (SC) injection
215106087|NCT04570631|DRUG|Dexamethasone|Oral Tablet
215106088|NCT04441580|DEVICE|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a FIT-positive screening population.
215106089|NCT06269939|BEHAVIORAL|STEM|Memory technique training
215106090|NCT04600934|DEVICE|Shockwave|Shockwave Medical, Inc. Peripheral Lithoplasty® System
215106091|NCT04600934|DEVICE|Plain old balloon angioplasty|POBA
215106092|NCT06028009|PROCEDURE|Injection of platelet-rich plasma|Injection of autologous platelet-rich plasma into anterior vaginal wall
214509594|NCT04913506|DEVICE|Group NMES|NMES will be applied to the hemiplegic arm(deltoid, elbow extensors and forearm) for 30 minutes by the practitioner (3 weeks, 5 days a week, 15 sessions in total)
214509595|NCT04913506|OTHER|Group Mirror+NMES|The practitioner will be synchronized with visual or auditory stimuli, and ROM exercises in all directions in front of the real mirror for 30 minutes, and NMES therapy for 30 minutes on the paretic upper extremity will be applied together. (3 weeks, 5 days a week, 15 sessions in total)
214509596|NCT01051869|PROCEDURE|Simple decompression|"Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken."
214509597|NCT01051869|PROCEDURE|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
214509598|NCT06009666|DIAGNOSTIC_TEST|Shear Wave Elastography and B Mode Ultrasonography|We evaluated the both upper extremities of the patient and control group with elastography and B mode ultrasonography. Shear wave elastography evaluates tissue deformation caused by acoustic radiation force. A highly focused ultrasound radiation is produced; The propagation speed of the shear wave depends on the stiffness of the tissue. It is a simple, inexpensive, bedside, widely available, non-invasive technique. B mode USG can be used to assess skin and subcutaneous tissue thickness and echogenicity. Skin and subcutaneous thickness were measured with b mode ultrasound. Skin and subcutaneous tissue stiffness was measured by shear wave ultrasonography
214509599|NCT06009666|DIAGNOSTIC_TEST|Quick Dash Questionnare|Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. In the questionnaire, the difficulties of the patients during their daily living activities are questioned with 11 questions. Each answer is scored from 1 to 5 on a Likert scale, from best to worst.
214509600|NCT06009666|DIAGNOSTIC_TEST|The Lymphedema Life Impact Scale|The Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 functional subgroups. Each question is scored from 1 to 5, with higher scores indicating increased seriousness.
214509601|NCT06009666|DIAGNOSTIC_TEST|Questioning lymphedema-related symptoms|Arm pain and feeling of tension, heaviness and stiffness in the arm were evaluated separately by numerical scale. This scale is a 10 cm ruler that writes no pain, no tension, no heaviness, no stiffness on one side, and unbearable pain, tension and heaviness on the other side. Patients were asked to rate their associated symptoms on this scale between 0 and 10.
214509602|NCT06009666|OTHER|Extremity circumference and volume measurement|For the diagnosis of lymphedema, a detailed physical examination and extremity circumference were measured. This measurement was taken from both wrists to arm height with 4 cm intervals. Those with a circumference difference greater than 2 cm and/or no 10% volume difference were considered preclinical (latent) and those with clinical lymphedema.
214509603|NCT01331772|OTHER|Control arm|Dietetic follow-up only
214509604|NCT01331772|OTHER|Intervention arm|Dietetic follow up + adapted physical activity
214509605|NCT04402476|DEVICE|Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
214509606|NCT02673866|DRUG|DS-1971a|
214509607|NCT02673866|DRUG|placebo|
214509608|NCT02673866|DRUG|pregabalin|pregabalin
214509609|NCT03964779|DIAGNOSTIC_TEST|Hormonal assay|Measurement of Thyroid stimulating hormone
214509610|NCT03964779|DIAGNOSTIC_TEST|Antibody assay|antithyroglobulin and antithyroid peroxidase
214509611|NCT04201314|DIETARY_SUPPLEMENT|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
214509612|NCT04201314|DIETARY_SUPPLEMENT|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
214509613|NCT03938272|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes Strain HC-1|Live, commensal bacteria
214509614|NCT06142838|BEHAVIORAL|community pharmacist intervention|The community pharmacist intervention comprises 2 parts: (1) first prescription counseling (oral and written information), and (2) a follow-up consultation (by telephone or in person) 7-14 days later, to identify problems with adherence/treatment
215106093|NCT06028009|PROCEDURE|Injection of saline|Injection of sterile normal saline into anterior vaginal wall
214509615|NCT05935839|DEVICE|Multispectral optoacoustic tomography|Molecular Imaging of tissue changes using MSOT in macroangiopathy in diabetes. Dual imaging before and after physical stress.
215106094|NCT04878913|DRUG|C21|C21 was administered in the VP-C21-006 trial
215106095|NCT04878913|DRUG|Placebo|Placebo was administered in the VP-C21-006 trial
215106096|NCT03019718|OTHER|GSA-Online plus|A 12-week online writing intervention based on the Core Conflictual Relationship Theme Method (CCRT) with feedback provided by online therapists.
215106097|NCT04734145|DIAGNOSTIC_TEST|Breathprinting test|Consented, enrolled participants will undergo a breathprinting test (e-nose) during the presurgical visit and at the same facility as their presurgical or prebiopsy visit, before any attempt is made to obtain cytohistological diagnosis of the pulmonary nodule.
215106098|NCT06464536|OTHER|Compression|conventional surgical gloves that are commonly used in hospitals will be used for compression therapy of both hands
215106099|NCT05345717|DRUG|Belatacept Injection|Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy
215106100|NCT01009008|DEVICE|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
214509616|NCT05935839|DIAGNOSTIC_TEST|Ankle Brachial Index|Dual measurement of ABI index before and after physical exercise.
214509617|NCT05935839|DIAGNOSTIC_TEST|Neuropathy Disability Score|Single measurement of the NSS
214509618|NCT02875704|OTHER|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
215106101|NCT01458418|DRUG|Montelukast|Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
215106102|NCT01458418|OTHER|placebo|Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.
214509619|NCT00069706|DRUG|AL-12182 0.003% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
215106103|NCT01458418|DRUG|5 mg Montelukast|Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
215106104|NCT03492541|OTHER|Propylene glycol-based eye drops|Nano-emulsion ocular lubricant
215106105|NCT00500994|DEVICE|MRI|The imaging study will use a block design to (i) optimize amygdala activation to emotionally valenced images, (ii) to optimize analysis of PPI and (iii) to optimize the go/no-task design. G. T2-sensitive functional images will be obtained on a MRI system with a 1.5 Tesla superconducting magnet and a standard head coil. An echo planar image sequence (TR=2500msec, TE=33 msec, 90 flip angle) with 30 contiguous 2mm thick coronal oblique slices with 1 mm interslice gap centered over the amygdala, tilted 30 to the anterior, to improve susceptibility artifact. Three-dimensional anatomical images will be taken for the co-registration of the functional images.
215106106|NCT05471089|DEVICE|Diathermy by emission of Radiofrequency|Applied only to experimental group
215106107|NCT05471089|OTHER|Therapeutic exercise|Applied to both arms/groups
215106108|NCT00734968|DRUG|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
214509620|NCT00069706|OTHER|AL-12182 Ophthalmic Solution Vehicle|Placebo
214509621|NCT00069706|DRUG|Latanoprost 0.005% Ophthalmic Solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
214509622|NCT00069706|DRUG|AL-12182 0.01% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
214509623|NCT00069706|DRUG|AL-12182 0.03% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
214509624|NCT05156606|DRUG|AndroGel|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
214509625|NCT02053506|DIETARY_SUPPLEMENT|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
214509626|NCT02053506|DIETARY_SUPPLEMENT|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
214509627|NCT02053506|DIETARY_SUPPLEMENT|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
214509628|NCT04085952|PROCEDURE|dermal graft (ARCUS repliform) for anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation
215106109|NCT00734968|OTHER|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
215106110|NCT00005084|PROCEDURE|conventional surgery|
215106111|NCT00005084|PROCEDURE|magnetic resonance spectroscopic imaging|
215106112|NCT00005084|RADIATION|radiation therapy|
215106113|NCT00894361|PROCEDURE|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
215106114|NCT00894361|PROCEDURE|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
215106115|NCT03124576|DEVICE|Implantable loop recorder|Continuous rhythm monitoring Medtronic
215106116|NCT06406023|OTHER|Conventional treatment|"Hot pack will be applied for 10 minutes. AROM's of Hip (5 reps x 2 sets each). Piriformis stretch 3 reps x 20 sec hold x 2 sets. SLR (5reps x 10 sec hold x 2 sets). Sciatic nerve stretch (5 reps x 10 sec hold x 2 sets) for 3 days/ week for 2 weeks.~Strengthening exercises will be performed after 2 weeks of previous intervention of Hip abductors (Hip abduction with band in sitting, standing, side-lying hip raise), and hip extensors (Gluteal bridges, Prone hip extension, Prone hams curl). (5 reps x 2 sets each).~SLR (5 reps x 10 sec hold x 2 sets) each exercise will be performed 3 days/ week for 2 weeks.~Total treatment protocol will be followed for 4 weeks. Each session will be of 30 minutes."
215106117|NCT06406023|OTHER|Instrument assisted soft tissue mobilization|Instrument assisted soft tissue mobilization IASTM with Graston tool along with conventional treatment in first 6 sessions. Apply hot pack for 10 mins on low back as passive warm up then AROM's of Hip (5 reps x 2 sets each) will be performed. Apply Graston tool at 30-60 degrees angle along the length of following muscles Piriformis, Gluteus medius and Hamstrings after applying emollient for 40-120 seconds.
215106118|NCT01848327|DIETARY_SUPPLEMENT|Caprylic Triglyceride|Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
215106119|NCT01848327|DIETARY_SUPPLEMENT|Placebo|Placebo (40 gram packet orally once a day for 90 days)
215106120|NCT02389036|DRUG|SDD Oral Paste|A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
215106121|NCT02389036|DRUG|SDD Gastric Suspension|2\. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
215106122|NCT02389036|DRUG|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
215106123|NCT02920749|DRUG|Sevoflurane group A|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was adjusted for the same MAP range.
215106124|NCT02920749|DRUG|Sevoflurane group B|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
215106125|NCT02920749|DRUG|Propofol group C|In this group anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol dosing was adjusted for the same MAP range.
215106126|NCT02920749|DRUG|Propofol group D|In this group anaesthesia was maintained with propofol. Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
215106127|NCT04207060|DRUG|Indomethacin|One capsule of 50 mg of indomethacin will be taken orally twice a day for a total of 28 days.
215106128|NCT04207060|DRUG|Placebo|One capsule of lactose not containing active study drug will be taken orally twice a day for a total of 28 days.
215106129|NCT04207060|PROCEDURE|Endoscopy for Pancreatic Function Testing|All subjects in the study (regardless of which treatment arm they are randomized to) will undergo an upper endoscopy during which they will receive an endoscopic pancreatic function test. An upper endoscopy will be performed during the baseline visit and at the follow-up visit at day 28 of the treatment (2 endoscopies total per each subject). Specifically, during the upper endoscopy, secretin will be administered intravenously at a weight-based dose of 0.2 mcg/kg over 1 minute. Fluid will be aspirated from the duodenum through the endoscope from 0-10 minutes and 10-20 minutes following secretin administration. The collected fluid will then be sent to the laboratory for analysis.
214509629|NCT04085952|PROCEDURE|suture based anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
215106130|NCT05612256|DIAGNOSTIC_TEST|Electrical impedance tomography (EIT)|EIT is the measurement of impedance changes of the lung against the flow of alternating electrical currents applied to the thorax. The signal of the electrodes is transmitted to a monitor, which enables real-time assessment of lung aeration and changes in lung volume. EIT is able to reconstruct impedance changes with a high temporal resolution and allows calculation of tidal volumes, relative stretch of lung tissue and areas of poor ventilation. Areas with impedance changes of \< 10 % of the maximum impedance changes are called 'Silent Spaces'.
215106131|NCT05612256|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|FOT enables non-invasive assessment of lung mechanics using sound waves to inform about the respiratory impedance of the respiratory system (Zrs). Reactance of the respiratory system (Xrs) as part of Zrs is a surrogate measure of compliance of the respiratory system. Xrs was previously used to identify optimal PEEP level, i.e., the PEEP at highest compliance equivalent, in newborn infants using a setup requiring research-specific hardware and software. The FOT module integrated in the commercially available neonatal ventilator is routinely used. FOT measurements are performed twice at each PEEP level to assess the reproducibility of the measurements.
215106132|NCT05612256|DIAGNOSTIC_TEST|Saturation oxygenation pressure index (SOPI)|SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
215106133|NCT04386954|PROCEDURE|observational study|observation study
215106134|NCT06549426|DRUG|anti-seizure medication + sedative agent(s)|"Stepwise approach:~1. a single dose of a parenteral benzodiazepine (lorazepam, midazolam, or diazepam) and a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)~2. a second parenteral anti-seizure medication plus a first continuous parenteral sedative agent (midazolam or propofol)~3. a second continuous parenteral sedative agent (midazolam, propofol, or ketamine)"
215106135|NCT06485323|DEVICE|MRI pelvimetry|MRI of the pelvis
215106136|NCT01871441|RADIATION|Total-body irradiation|Undergo TBI
215106137|NCT01871441|BIOLOGICAL|Donor lymphocytes infusion (DLI)|Undergo DLI
214509630|NCT03052998|DRUG|Ivermectin|Effect of Ivermectin on frequency of seizures
214509631|NCT01494766|DIETARY_SUPPLEMENT|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
215106138|NCT01871441|DRUG|Cyclophosphamide|Given IV
215106139|NCT01871441|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo haploidentical allogeneic HSCT
214509632|NCT01874366|DRUG|P11187|"* Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~* Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~* Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval."
214509633|NCT01874366|DRUG|Placebo|"Placebo capsules will be matching in appearance with the active drug capsules of P11187.~* In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~* In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo"
215106140|NCT01871441|DRUG|Tacrolimus|Given IV
215106141|NCT01871441|DRUG|Mycophenolate mofetil|Given IV
215106142|NCT01024842|BIOLOGICAL|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10\^8 pfu at week 0, 4 and 12.
215106143|NCT01024842|OTHER|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
215106144|NCT01024842|BIOLOGICAL|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10\^8 pfu at week 0, 4 and 12.
214509634|NCT03936699|DEVICE|Transcutaneous Nerve Stimulator (TENS)|"The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet \& Exercise Subjects to be instructed on a healthy 1200 calorie diet."
214509635|NCT03936699|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
215106145|NCT01024842|OTHER|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
215106146|NCT02718716|DRUG|UCB7665|"* Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion"
215106147|NCT03536832|PROCEDURE|Cesarean Section with Vicryl|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.
215106148|NCT03536832|PROCEDURE|Cesarean Section with Prolen|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
214509636|NCT03269500|OTHER|use of nutrition education tools|"Use of different nutrition education tools :~* General advice: feeding seniors~* Oral supplementation: instructions for use~* Information about enriched food~* Food modified in texture: chopped masticatory disorders, chopped swallowing disorders, co-mingled~* How should I drink? : With stimulus, texture syrup / nectar, velvety texture, texture compote / cream~* Recipe booklets for people to easily eat (chewing disorders) or recipe with molded texture (swallowing disorders)"
215106149|NCT05541679|DEVICE|Right ventricular septal pacing followed by left bundle branch area pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
215106150|NCT05541679|DEVICE|Left bundle branch area pacing followed by right ventricular septal pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
215106151|NCT05775731|DIAGNOSTIC_TEST|Tests for markers of inflammation and activated hemostasis|Volunteers who do not have exclusion criteria, are invited to complete the three questionnaires and to choose a date for blood drawing based on whether they are shift workers or not. Blood is immediately processed for platelet markers, and stored for inflammation and coagulation markers
215106152|NCT04316637|DRUG|Arimoclomol|Participants receive prescribed arimoclomol by oral administration
215106153|NCT00933465|DRUG|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
215106154|NCT00933465|DRUG|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
215106155|NCT02707328|DRUG|Gemcitabine|
215106156|NCT02707328|DRUG|nab-paclitaxel|
215106157|NCT02707328|RADIATION|CyberKnife|
215106158|NCT05606276|OTHER|Eccentric Exercise|Individuals will do a randomized crossover intervention involving maximal eccentric contractions (2 sets of 6 per leg; experimental condition)
215106159|NCT05606276|OTHER|Cycle ergometer|Individuals will do a randomized crossover intervention involving cycling (active control) exercise
215106160|NCT03111953|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|"In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately \~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum."
215106161|NCT03111953|PROCEDURE|Biliopancreatic Diversion Surgery|In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, \~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, \~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
215106162|NCT00033553|DRUG|carboplatin|Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
215106163|NCT00033553|DRUG|gemcitabine hydrochloride|1000 mg/sq m IV over 30 min days 1 \& 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
215106164|NCT00033553|DRUG|paclitaxel|225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
215106165|NCT00033553|RADIATION|radiation therapy|3-D XRT 7400 cGy total after induction (during cycles 3-9)
215106166|NCT00243711|DRUG|Carboxymethylcellulose sodium and Glycerin|
215106167|NCT00418327|DRUG|Tarceva (Erlotinib Hydrochloride)|tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
215106168|NCT03969927|DEVICE|Low-Fidelity PDS|"The principal investigator recently developed a low cost ($10,000) low fidelity portable driving simulator (PDS) in the University of Kansas Laboratory for Advanced Rehabilitation Research in Simulation (LARRS) that measures 25.5 Wide, 32.5 High, and 25 Deep and requires only approximately 4 square feet of space.~This intervention uses the PDS to retrain study participants and improve their driving related skills."
215106169|NCT03969927|DEVICE|High Fidelity Fixed-Base Simulator|This intervention uses the large high-fidelity fixed-base driving simulator to retrain study participants and improve their driving related skills.
215106170|NCT05160376|OTHER|Self-help CBT with email reminder and text message|"An online transdiagnostic self-help intervention that is delivered through an online mental health platform.~Email reminder and text message will be sent to remind participant to complete the module"
215106171|NCT05160376|OTHER|Feedback calls on participants' progress|Feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor
215106172|NCT03935243|BEHAVIORAL|equine assisted therapy|The equine assisted group therapy is carried out by a riding therapist (nurse psychiatry HF, certified riding therapist SG-TR). There is a detailed plan for the PT.
215106173|NCT03935243|BEHAVIORAL|activating control phase|The control phase includes a generally activating employment offer, such as board games, light physical activations, roundtables and artistic design.
215106174|NCT01894932|BEHAVIORAL|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams \& Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
215106175|NCT01894932|BEHAVIORAL|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
215106176|NCT00296140|BEHAVIORAL|self management of PSD symptoms|
215106177|NCT00296140|PROCEDURE|screening and treatment of PSD|
215106178|NCT01683825|DRUG|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
215106179|NCT03124082|DRUG|Remifentanil|continuous infusion intraop
215106180|NCT03124082|DRUG|Ketamine|bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
215106181|NCT03124082|DRUG|Lidocaine|lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
215106182|NCT03124082|DRUG|Clonidine|clonidine 4 mcg/kg
215106183|NCT03612765|BEHAVIORAL|Push-Pull-Hold Program|Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
215106184|NCT01651871|DRUG|S-555739 Dose 1|
215106185|NCT01651871|DRUG|S-555739 Dose 2|
215106186|NCT01651871|DRUG|Cetirizine HCl Dose 1|
214509637|NCT05143125|BIOLOGICAL|Decitabine combined with NK cell infusion|Decitabine combined with NK cell infusion
215106187|NCT01651871|DRUG|S-555739 placebo|
215106188|NCT01651871|DRUG|Cetirizine HCl placebo|
215106189|NCT02794519|DRUG|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
215106190|NCT02794519|DRUG|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
214509638|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance relaxometry|Spin-lattice relaxation (T1) relaxometry acquisition consisting of fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
215106191|NCT02794519|DRUG|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
215106192|NCT04165603|PROCEDURE|Preoperative Infusion of Indocyanine Green|preoperatively infuse indocyanine green through peripheral vein
215106193|NCT01856582|BIOLOGICAL|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
215106194|NCT03144375|OTHER|Medical optimization and education|Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling
215106195|NCT03144375|PROCEDURE|Standard of Care sinus surgery|
215106196|NCT02338050|BIOLOGICAL|Moxetumomab Pasudotox|
215106197|NCT02596789|DEVICE|"TMS Magpro®, Magventure Inc device"|
215106198|NCT03041896|DEVICE|coflex® Interlaminar Technology|Interlaminer Technology
215106199|NCT05318872|DEVICE|ENDOSWIR|Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
215106200|NCT05512416|DRUG|dalpiciclib plus letrozole|Six 4-week cycles of dalpiciclib orally, 150mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28
215106201|NCT03245398|DRUG|Treatment with one of the two regimens of mebendazole|Once in the morning and once in the evening for 3 consecutive days
215106202|NCT04871958|DEVICE|Continuous glucose monitoring (CGM, Dexcom G6)|"The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station.~In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers.~The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated.~V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h).~On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments."
215106203|NCT04362423|DEVICE|fNIRS|Near infrared spectroscopy (NIRS) is a non-invasive, portable, relatively inexpensive optical technology similar to pulse oximetry except that it measures total hemoglobin, oxy-hemoglobin, and deoxyhemoglobin in brain tissue (capillaries) rather than arteries.
215106204|NCT03359252|PROCEDURE|non-stent assisted coiling|non-stent assisted coiling of unruptured intracranial aneurysm
215106205|NCT03359252|PROCEDURE|stent assisted coiling|stent assisted coiling of unruptured intracranial aneurysm
215106206|NCT00596830|DRUG|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
215106207|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
215106208|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
215106209|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
215106210|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
215106211|NCT02638168|DRUG|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
215106212|NCT02638168|DRUG|Placebo|inert placebo ingredient
215106213|NCT06224179|PROCEDURE|ultrasound guided subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group A received ultrasound guided subcostal TAP block,"
215106214|NCT06224179|PROCEDURE|ultrasound guided combined posterior and subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group B received ultrasound guided combined posterior and subcostal TAP block,"
215106215|NCT00887926|BIOLOGICAL|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
215106216|NCT00964821|BIOLOGICAL|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
215106217|NCT00964821|OTHER|Immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
215106218|NCT00964821|OTHER|Laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
215106219|NCT02461940|BEHAVIORAL|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
215106220|NCT00880191|DRUG|dexamethasone|Given orally
215106221|NCT00880191|DRUG|gabapentin|Given orally
214424410|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-DP plus MTZ to assess whether DP is superior to SP in preventing adverse birth outcomes. This intervention arm will also be compared to the IPTp-SP plus MTZ placebo arm to assess whether the combination of MTZ with IPTp-SP is superior to IPTp-SP alone in reducing adverse pregnancy outcomes.
215106222|NCT00880191|OTHER|placebo|Given orally
215106223|NCT00236236|DEVICE|Cardiac Resynchronization Therapy|
215106224|NCT04903054|BIOLOGICAL|Lulizumab|Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.
215106225|NCT04903054|DRUG|Tacrolimus|Standard of Care: Renal transplant rejection prophylaxis.
215106226|NCT04903054|BIOLOGICAL|Thymoglobulin®|Standard of Care: Renal transplant rejection prophylaxis.
215106227|NCT04903054|DRUG|Methylprednisolone|Standard of Care: Renal transplant rejection prophylaxis.
215106228|NCT04903054|DRUG|Mycophenolate Mofetil|Standard of Care: Renal transplant rejection prophylaxis.
215106229|NCT04903054|DRUG|Prednisone|Standard of Care: Renal transplant rejection prophylaxis.
215106230|NCT04617730|DEVICE|Mepitel® film|This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.
215106231|NCT04617730|OTHER|Flamigel®|The control arm will be treated according to the standard of care.
215106232|NCT04619732|DIAGNOSTIC_TEST|Monitoring biochemical concentrations during cold machine perfusion|Three microdialysis probes will be introduced into the kidney tissues, the vein and ureter in order to measure creatinine, glucose and lactate while the organ is undergoing cold perfusion prior to transplantation.
215106233|NCT02097030|DEVICE|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
215106234|NCT02097030|DEVICE|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
215106235|NCT02097030|DEVICE|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
215106236|NCT05538676|DIAGNOSTIC_TEST|BPA-PET imaging|PET imaging
215106237|NCT01645410|DRUG|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
215106238|NCT01428739|DEVICE|MRS|Procedure
215106239|NCT00034827|DRUG|CI-1040|
215106240|NCT05539313|DEVICE|High-density mapping|Patients will undergo magnetic resonance imaging of both atria, and interventional high-density mapping of both atria.
215106241|NCT01919801|DRUG|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
214509639|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at multiple echo times. Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
215106242|NCT01919801|DRUG|Placebo|
215106243|NCT01843062|DRUG|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
215106244|NCT01843062|DRUG|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
215106245|NCT01843062|DRUG|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
215106246|NCT01090440|DRUG|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
215106247|NCT04569227|DRUG|EC-18|2000 mg PO daily
215106248|NCT04569227|DRUG|Placebo|PO daily
215106249|NCT05289479|PROCEDURE|Pre-heating of resin composite before application|the effect of preheating of resin composite before application in class II cavities
215106250|NCT05289479|PROCEDURE|no pre-heating of resin composite before application|The control group
215106251|NCT01677858|DRUG|Carfilzomib|Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
215106252|NCT01677858|DRUG|Dexamethasone|Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
215106253|NCT00481923|DRUG|rimonabant (SR141716)|
215106254|NCT06210230|DIETARY_SUPPLEMENT|MLCT supplementation|MLCT 25g/d for 6 months
215106255|NCT06210230|DIETARY_SUPPLEMENT|Olive oil|Matching placebo (olive oil) 25g/d for 6 months
215106256|NCT04343456|PROCEDURE|Salvage surgery with massive debulking|For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.
215106257|NCT03547895|DRUG|Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)|sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months
215106258|NCT03547895|DRUG|vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion|symptomatic therapy for liver support, control of ascites and bleeding tendency.
215106259|NCT00773747|DRUG|Vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
215106260|NCT00773747|DRUG|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
215106261|NCT00773747|DRUG|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
215106262|NCT03761901|DRUG|1L treatment|chemotherapy, EGFR TKI, immunotherapy, other
215106263|NCT03761901|DRUG|2L Treatment|Chemotherapy, EGFR TKI, immunotherapy, other
215106264|NCT03761901|DRUG|3L treatment|chemotherapy, EGFR TKI, immunotherapy, other
215106265|NCT04260347|DRUG|Alteplase|Intravenous injection
215106266|NCT02893696|OTHER|Various sitting time|Various sitting time
215106267|NCT01472068|DEVICE|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
215106268|NCT02669212|BEHAVIORAL|Cardiopulmonary Exercise Test (CPET)|All participants will undergo an exercise stress test
215106269|NCT06240949|DEVICE|Positional Release Technique|Positional Release Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
215106270|NCT06240949|DEVICE|Manual Pressure Technique|Manual Pressure Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
215106271|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using CIMBI-36 tracer|This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
215106272|NCT05516732|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
215106273|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using DASB tracer|To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
215106274|NCT05516732|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
215106275|NCT05516732|OTHER|Lumbar puncture|A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
215106276|NCT00828763|DRUG|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
215106277|NCT02113033|DEVICE|Equilia® Vagal Nerve Stimulation|Vagal Nerve Stimulation synchronized with cardiac activity
215106278|NCT00513942|OTHER|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
214509640|NCT06216704|DIAGNOSTIC_TEST|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and inflammation. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). Additionally, in participants with CF, we will assess inflammation, with a c-reactive protein (CRP), and dysglycemia, with a continuous glucose monitor.
214509641|NCT06216704|DIAGNOSTIC_TEST|DXA|DXA will be utilized to obtain BMD of the total body, lumbar spine, and hip using a Hologic Horizon densitometer (Hologic Inc, Bedford, MA). Body composition will be obtained from total body scans.
214509642|NCT06216704|DIAGNOSTIC_TEST|pQCT|pQCT will be utilized to obtain volumetric BMD (mg/cm3) of the left tibia. Measurements using a Stratec XCT 3000 device (Orthometrix, White Plains, NY) will be obtained at multiple locations, in relation to distal growth plate.
214509643|NCT00068107|DRUG|Replagal|enzyme replacement therapy
214509644|NCT03673618|DRUG|Soluble Corn Fiber|Fiber or placebo
214509645|NCT02500082|DRUG|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
215106279|NCT01661894|DEVICE|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
215106280|NCT04099784|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
215106281|NCT04099784|OTHER|Physical development and General Health|Physical development and General health examination
215106282|NCT04099784|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
215106283|NCT00275067|DRUG|arsenic trioxide|Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
215106284|NCT00275067|DRUG|temozolomide|Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
215106285|NCT00275067|RADIATION|radiation therapy|All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
215106286|NCT05034601|PROCEDURE|ESPB group|A 21-gauge 100-mm needle will be inserted into the fascial layer beneath the iliocostalis, longissimus, and spinalis muscles. A bolus of 0.25% ropivacaine 0.5 ml/kg will be injected into the fascial layer. Contralateral ESPB will be performed similarly.
215106287|NCT05034601|PROCEDURE|TPVB group|A 21-gauge 100-mm insulated needle will be inserted into the paravertebral space via an in-plane parasagittal approach. After perforating the costotransverse ligament, 0.25% ropivacaine 0.5 ml/kg will be injected. Anterior movement of the pleura indicated the appropriate spread of the local anesthetics in the paravertebral space. The process will be repeated on the contralateral side.
215106288|NCT02470325|DRUG|Avidekel oil|Avidekel cannabis oil 6:1 CBD:THC
215106289|NCT02470325|DRUG|Enriched Avidekel oil|Enriched Avidekel cannabis oil 20:1 CBD:THC
215106290|NCT03549104|BEHAVIORAL|Fear Reduction Intervention|FREE
215106291|NCT03549104|BEHAVIORAL|Attention Control|DSMES
215106292|NCT06196346|BEHAVIORAL|Psychotherapy|see group description
215106293|NCT00281346|PROCEDURE|Doppler echocardiography|Echocardiography
215106294|NCT05343377|DIAGNOSTIC_TEST|circulate free methylated EBV DNA|Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS
215106295|NCT04869358|DRUG|Ofatumumab|Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
215106296|NCT04164732|DRUG|LCZ696|LCZ696 orally twice daily
215106297|NCT04164732|DRUG|Placebo|placebo
215106298|NCT06168617|DIAGNOSTIC_TEST|Performance tasks in daily life|Evaluation of performance tests executed by patients in real-life situations.
215106299|NCT01537822|PROCEDURE|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith \& Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
215106300|NCT01537822|PROCEDURE|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
215106301|NCT00002822|DRUG|carboplatin|
215106302|NCT00002822|DRUG|cisplatin|
215106303|NCT00002822|DRUG|cyclophosphamide|
215106304|NCT00002822|DRUG|doxorubicin hydrochloride|
215106305|NCT00002822|DRUG|etoposide|
215106306|NCT00002822|DRUG|ifosfamide|
215106307|NCT00002822|DRUG|mesna|
215106308|NCT00002822|DRUG|vincristine sulfate|
215106309|NCT00002822|RADIATION|radiation therapy|
215106310|NCT02643342|DEVICE|Orthokeratology|
215106311|NCT05170178|BEHAVIORAL|inclusion and familiarization|"* presentation of the study purpose and the protocol to the volunteer~* clinical examination to check inclusion and exclusion criteria~* Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby"
215106312|NCT05170178|BEHAVIORAL|fMRI acquisition and closure|"* Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~* MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~* debriefing~* Protocol ending"
215106313|NCT03197922|BEHAVIORAL|MIE Treatment|"Appointments consist of a series of sitting routines (i.e., sits). Each sit consists of 10 min on the toilet, followed by 1 min of standing, then repeating the 10 min on the toilet 1 min off, for up to 32 cumulative minutes of sitting. The first sit occurs prior to the administration of any medication providing an opportunity for an independent continent bowel movement."
215106314|NCT03197922|DRUG|Glycerin Suppository|If no continent bowel movement occurs with the first sit, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely.
215106315|NCT03197922|COMBINATION_PRODUCT|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
215106316|NCT02263261|OTHER|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
215106317|NCT00979225|OTHER|Medication Management report|Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.
215106318|NCT00979225|OTHER|Care manager email notices|Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
215106319|NCT03459638|OTHER|Screening for DM, ASCVD, MetS and OSAS|Finger stick analysis, questionnaires and clinical measurements
215106320|NCT01575925|DRUG|4 mg Oral POM + 40 mg Oral DEX|
215106321|NCT01575925|DRUG|2 mg Oral POM + 40 mg Oral DEX|
215106322|NCT00610389|BIOLOGICAL|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
215106323|NCT03489512|DRUG|A (Chloraprep)|Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
215106324|NCT03489512|DRUG|B (Clorhexidine 2%)|Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
215106325|NCT01987583|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
215106326|NCT01987583|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
215106327|NCT03481140|DEVICE|TissuGlu Surgical Adhesive|lysine-derived urethane adhesive
215106328|NCT05807685|BEHAVIORAL|laughter therapy|Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researchers who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
215106329|NCT00285168|BEHAVIORAL|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
215106330|NCT01844778|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
215106331|NCT01844778|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
215106332|NCT01844778|DRUG|Colistimethate|Colistimethate was administered via nebuliser.
214509646|NCT02025712|DRUG|Exemestane|Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
214509647|NCT02025712|DRUG|Everolimus|Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.
214509648|NCT02321956|DIAGNOSTIC_TEST|Ultrasound|Using ultrasound to determine the size of endotracheal tube
214509649|NCT03543904|PROCEDURE|Pre-operative physiotherapy education|"Pre-operative education regarding post-operative physiotherapy intervention in children with abdominal surgery which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
214509650|NCT03543904|PROCEDURE|Post-operative physiotherapy intervention|"Post-operative physiotherapy intervention which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
214509651|NCT01838603|OTHER|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
214509652|NCT03288506|BEHAVIORAL|Google Hangout (VC) group|Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
214509653|NCT00695188|DRUG|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
214509654|NCT00695188|DRUG|methotrexate|25 mg oral administration
214509655|NCT06075030|DRUG|AND017|Oral administration of AND017 capsules three times per week
215106333|NCT04830488|BEHAVIORAL|e-learning didactic module|Participants utilize e-learning
215106334|NCT04830488|BEHAVIORAL|Personal reflection activities|Participants complete questionnaires
215106335|NCT02681315|DEVICE|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
215106336|NCT02681315|DEVICE|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
215106337|NCT05024903|OTHER|Serious illness medical planning plus the novel e-health platform (PWG 2.0)|"PWG 2.0 consists of the following components:~1. A diagnostic questionnaire, Preparedness for the Future Questionnaire and bench-marked report that helps users assess their strengths, weaknesses and opportunities for improvement.~2. A comprehensive e-workbook that helps users understand the science behind personal behavior change.~3. Links to webpages with additional e-workbooks and curated content aimed to help users progress on the 30 different attitudes, behaviors, and activities that portend for a better future (topics listed in Appendix A).~4. E-messages delivered via emails (via text an option for those that prefer) with tailored content designed to provide multiple nudges to guide the user to progress through our content.~5. Monthly newsletter with current topics and issues related to the 30 topics and behavior change in general.~6. A virtual consultation with Dr. Heyland, creator of PWG and principal investigator."
215106338|NCT05024903|OTHER|Standard of care|Participants are not planning for their future (PWG 2.0) or using the e-health platform
215106339|NCT05131191|DIAGNOSTIC_TEST|CT-FFR measurement|Patients were scanned with ≥ 64 row CT according to standard operating specifications. The software obtains the coronary CT angiography image file through the data communication interface. Based on the image processing algorithm, the centerline and contour of the target vessel can be extracted, and then the target vessel can be reconstructed to obtain the three-dimensional size information of the vessel; Based on hydrodynamics calculation and analysis, the fractional flow reserve (FFR) of each position of the target vessel is measured.
215106340|NCT05131191|PROCEDURE|invasive FFR|Insert the pressure guide wire into the finger guide tube and push the pressure guide wire until the pressure sensor just comes out of the orifice of guiding catheter; Equalize PD and PA values;Push the pressure guide wire to the distal end of the lesion, and record the measured blood vessel and position;Record the resting Pd / PA of the pressure guide wire;Nitroglycerin and adenosine triphosphate were administered intravenously according to standard catheter laboratory specifications to achieve maximum hyperemia;Record the FFR value of the in-stent lesions.
215106341|NCT00326248|DRUG|GW679769 (casopitant)|
215106342|NCT03794154|DRUG|Cymbalta capsule|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
215106343|NCT03794154|DRUG|Duloxetine hydrochloride capsule|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
215106344|NCT05740865|PROCEDURE|open posterior instrumented thoracolumbar surgery|Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
215106345|NCT01623869|OTHER|Laboratory Biomarker Analysis|Correlative studies
215106346|NCT01623869|BIOLOGICAL|Trebananib|Given IV
215106347|NCT05453045|DRUG|Albendazole|tablet administration after a meal contaning approximate 15 g of fat
215106348|NCT01868334|BEHAVIORAL|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
215106349|NCT01868334|BEHAVIORAL|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
215106350|NCT01868334|BEHAVIORAL|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
215106351|NCT01868334|BEHAVIORAL|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
215106352|NCT04607369|DEVICE|EyeCTester|Smartphone app that allows vision testing
215106353|NCT01356199|DIETARY_SUPPLEMENT|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
215106354|NCT01356199|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO. 6 per day for 8 months.
215106355|NCT05974319|OTHER|Dry heat application|Dry heat application: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. The researcher will heat the thermoregulated electric pad and set it to 42°C. After making sure that there are no contraindications in the application of the electric pad device, a dry heat of 42°C will be applied to the determined area with the electric pad for 5 minutes.
215106356|NCT05974319|OTHER|Dry cold application|Dry cold applicaiton: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. After the researcher is sure that there are no contraindications in the application of the gel pad, dry cold will be applied to the determined area with the gel pad for 3 minutes.
215106357|NCT02951429|DRUG|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
215106358|NCT02951429|DRUG|Placebo|Placebo matched with sildenafil.
215106359|NCT02951429|DRUG|Sildenafil|Sildenafil will be given as 20 mg, TID.
215106360|NCT04975100|DRUG|Sarcosine and SSRI|Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
215106361|NCT04975100|DRUG|Placebo and SSRI|Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
215106362|NCT05733078|DRUG|Vitamin C|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
214509656|NCT00487045|DEVICE|Hem-Avert Perianal Stabilizer|Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
215106363|NCT05733078|DRUG|Oral Rehydration Salt Formulations|The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
215106364|NCT01620528|DRUG|elagolix|oral tablet
215106365|NCT01620528|OTHER|placebo|oral tablet
215106366|NCT01254825|PROCEDURE|Adductor-Canal-Block, Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
215106367|NCT01254825|PROCEDURE|Adductor Canal Block, Placebo (saline)|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
215106368|NCT00597415|DRUG|celecoxib|celecoxib 200mg
215106369|NCT00597415|DRUG|placebo|placebo
215106370|NCT06546852|BEHAVIORAL|education|Patient education will be provide
215106371|NCT01714999|PROCEDURE|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
215106372|NCT01714999|PROCEDURE|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
215106373|NCT00859157|PROCEDURE|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
215106374|NCT01457846|DRUG|AZD4547|Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
215106375|NCT01457846|DRUG|paclitaxel|Infusion administered once a week, 3 weeks on and 1 week off
215106376|NCT02899702|DRUG|PRIVIGEN (CSL Behring)|"Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
215106377|NCT02899702|DRUG|Albumin|"4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
214509657|NCT01419184|DRUG|Daptomycin|
214509658|NCT01419184|DRUG|Vancomycin|
215106378|NCT01224080|DEVICE|Adiana placement|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
215106379|NCT02376803|DRUG|Warfarin|Morning vs Evening administration
215106380|NCT03796351|DRUG|MT10107|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
215106381|NCT03796351|DRUG|Botox|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
215106382|NCT01915979|BIOLOGICAL|Plasma rich in growth factors (PRGF)|
215106383|NCT01915979|DRUG|Celestone cronodose (Bethametasone)|
215106384|NCT00393614|DRUG|levetiracetam|20 mg pr. kg a day
215106385|NCT01642108|DRUG|Sitagliptin|50 mg once per day
215106386|NCT03992443|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
215106387|NCT02068287|DRUG|Esmolol|After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
215106388|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
215106389|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
215106390|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
215106391|NCT00973245|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
215106392|NCT01743040|DIAGNOSTIC_TEST|CADence|"Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.~CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report."
215106393|NCT04439981|DIETARY_SUPPLEMENT|Ice cream|Curcumin extract was added into ice cream
215106394|NCT03432559|DIAGNOSTIC_TEST|endoscopy|endoscopy of pharynx, upper esophagus, mid esophagus, cardia, gastric fundus, und gastric body
215106395|NCT05077293|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
215106396|NCT05077293|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
215106397|NCT05508893|RADIATION|CT Angiography|A CTA will be performed on asymptomatic individuals
215106398|NCT05508893|DIAGNOSTIC_TEST|Exercise stress test|A routine exercise stress test will be performed on a bicycle
215106399|NCT05717023|BEHAVIORAL|Online guided self-help intervention for sexual distress following sexual assault|4 Sessions of guided self-help will be shared with the participants. These will be in the form of handout and video recordings that participant access through Qualtrics. The intervention is based on research on sexual trauma, psychosexual difficulties and materials developed by Bart's NHS Foundation Trust Sexual Wellbeing Service. It has been made in collaboration with clinicians within the service, experts by experience and the chief investigator.Within the document there are scripts for each session which are read out in the video recordings. The handouts depict the visual images for the video and the materials provided to participant.
215106400|NCT00321633|DRUG|carboplatin|
215106401|NCT00321633|DRUG|docetaxel|
215106402|NCT00002961|DRUG|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
215106403|NCT00002961|DRUG|cyclosporine|"graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy."
215106404|NCT00002961|DRUG|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
214509659|NCT04242797|DEVICE|Calmare|Skin is stimulated with an electrical voltage via electrode pads, variably distorted sine wave at \~47 Hz.
215106405|NCT00002961|DRUG|methotrexate|"methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is \>2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted."
215106406|NCT00002961|PROCEDURE|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
215106407|NCT00002961|RADIATION|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) \[200 cGy twice a day (BID)\].
215106408|NCT00002961|DRUG|Busulfan|"Conditioning Regimen Arm B:~Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.~Patients \</= 20kg to receive busulfan 1.0 mg/kg/dose IV\*\*Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients \>20kg and 1.25 mg/kg/dose by mouth (po) for patients \</= 20 kg."
215106409|NCT00002961|DRUG|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
214509660|NCT04242797|DEVICE|TENS|Skin is stimulated with an electrical voltage via electrode pads, 300 micro-second rectangle pulse at 47 Hz.
214509661|NCT05751733|DRUG|Apatinib Mesylate|Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.
214509662|NCT05751733|DRUG|Sunitinib, Imatinib dosage, Dasatinib, Reveratinib|Second-line TKI drugs
215106410|NCT00002961|RADIATION|Radiation|"Central Nervous System (CNS) therapy:~a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) \>/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses \>3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.~Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-"
215106411|NCT02878837|DRUG|Dexmedetomidine|
215106412|NCT02878837|DRUG|Midazolam|
215106413|NCT01158391|DEVICE|NTrainer® Intervention|
215106414|NCT01158391|DEVICE|Control Intervention|
215106415|NCT03302637|OTHER|16S rRNA gene sequencing assay|extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
215106416|NCT04379076|DRUG|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
215106417|NCT04379076|DRUG|Placebos|Intramuscular (IM) placebo (normal saline) at the same frequency
215106418|NCT02274545|BIOLOGICAL|H7N9 Anhui 2013/AA ca|10\^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
215106419|NCT02274545|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|30 mcg
215106420|NCT02794545|PROCEDURE|cART course|The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
215106421|NCT04919837|OTHER|Low vision aids|the assisting devices fitting for low-vision patients
215106422|NCT03934853|DEVICE|Dynamic Dental Navigation|Aid in dental implant placement in humans
215106423|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
215106424|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
215106425|NCT06379269|DEVICE|App healthcare|Self-developed app: includes home stretching and strengthening exercises, muscle release technique instruction.
215106426|NCT06379269|OTHER|Control|general education and home rehab program
215106427|NCT02974842|DEVICE|MAKO 7|Hysteroscopic cell sampling
214509663|NCT00821288|BEHAVIORAL|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
214509664|NCT00821288|BEHAVIORAL|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
214509665|NCT01286636|OTHER|computer model|Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
215106428|NCT00879528|OTHER|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET:~PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
215106429|NCT00879528|OTHER|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET~PET positive, the consolidation therapy consists of 2 phases:~* phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells~* phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.~If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
215106430|NCT02122224|OTHER|High fiber breakfast|Breakfast will contain 10-11g fiber.
215106431|NCT02122224|OTHER|High Protein Breakfast|Breakfast will contain 19-20g of protein.
215106432|NCT02122224|OTHER|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
215106433|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
215106434|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
215106435|NCT05387668|DRUG|BGB-23339|Administered orally as a tablet.
215106436|NCT05387668|DRUG|Placebo|Administered orally as a tablet.
215106437|NCT01985568|BEHAVIORAL|Sequential BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.
215106438|NCT01985568|BEHAVIORAL|Standard BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
215106439|NCT01940081|OTHER|Transthoracic echocardiography|
215106440|NCT01940081|OTHER|Exercise test|
215106441|NCT01940081|OTHER|24-hour Holter electrocardiogram|
215106442|NCT01940081|OTHER|Contrast-enhanced magnetic resonance imaging|
215106443|NCT01940081|OTHER|123-iodine metaiodobenzylguanidine imaging|
215106444|NCT01940081|OTHER|Blood samples|
215106445|NCT01940081|GENETIC|Genetic analysis|
215106446|NCT01940081|PROCEDURE|Invasive electrophysiological study|
215106447|NCT01940081|PROCEDURE|Endomyocardial biopsy|
215106448|NCT01940081|PROCEDURE|Intraoperative biopsy|
215106449|NCT01940081|PROCEDURE|Intraoperative mapping and/or ablation|
215106450|NCT03824587|DRUG|Tenapanor|Active Drug
215106451|NCT03824587|DRUG|Placebo|Inactive Drug
215106452|NCT03824587|DRUG|Phosphate Binder Agents|standard of care phosphate binder use at study entry was maintained throughout the entire study
215106453|NCT02338700|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
215106454|NCT02338700|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
214509666|NCT01286636|OTHER|Polysomnogram|Diagnosis of sleep apnea will rely on polysomnogram
214509667|NCT00875706|BEHAVIORAL|Educational Intervention|The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
215106455|NCT03331523|DRUG|Calcipotriene/Betamethasone Dipropionate|Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
215106456|NCT03331523|DRUG|Taclonex®|Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
215106457|NCT03331523|DRUG|Placebo|Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
215106458|NCT02407782|DRUG|Ivermectin|oral ivermectin, 200μg/kg given at baseline and at day 10.
215106459|NCT02407782|DRUG|Permethrin|topical permethrin 5% cream applied at baseline and at day 10.
215106460|NCT00986362|DRUG|Ocriplasmin|175µg ocriplasmin intravitreal injection
215106461|NCT00986362|DRUG|Placebo|Placebo intravitreal injection
215106462|NCT02919514|OTHER|Physical training on hard surface.|Physical training on hard surface.
215106463|NCT02919514|OTHER|Physical training on sand surface.|Physical training on sand surface.
215106464|NCT02919514|OTHER|Physical training on soft surface.|Physical training on soft surface.
215106465|NCT01791478|DRUG|PI3K inhibitor BYL719|Given PO
215106466|NCT01791478|DRUG|letrozole|Given PO
215106467|NCT01791478|OTHER|laboratory biomarker analysis|Correlative studies
215106468|NCT01791478|OTHER|pharmacological studies|Correlative studies
215106469|NCT01954108|DEVICE|hyaluronic acid sodium salt|
215106470|NCT01954108|DEVICE|ESWT|
215106471|NCT00260416|PROCEDURE|Primary angioplasty with stent and abciximab|
215106472|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 1|Caffeine content: 200 mg
215106473|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 2|Caffeine content: 400 mg
215106474|NCT02255201|DIETARY_SUPPLEMENT|Performance Energy Blend|Caffeine content: 175 mg
215106475|NCT02255201|DIETARY_SUPPLEMENT|Energy Blend|Caffeine content: 200 mg
215106476|NCT02255201|DIETARY_SUPPLEMENT|Placebo|Caffeine content: 0 mg
215106477|NCT01969032|DRUG|Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
215106478|NCT00384332|DRUG|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
215106479|NCT00384332|DRUG|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
215106480|NCT02006979|OTHER|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
215106481|NCT03170193|DRUG|AMG 529|Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
215106482|NCT03170193|DRUG|Placebo|Single doses of matching placebo by SC or IV injection
215106483|NCT01347996|DRUG|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg \[16,400 IU/kg\] body weight twice daily for 10, 21 day cycles
215106484|NCT01301859|BEHAVIORAL|TIP|Treatment visits as usual with MD
215106485|NCT02560012|DRUG|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
215106486|NCT02560012|DRUG|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
215106487|NCT02560012|DRUG|Sorafenib|400 mg (2 tablets) orally twice daily without food
215106488|NCT02560012|DRUG|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
215106489|NCT02560012|DRUG|Everolimus|10 mg orally once daily with or without food
215106490|NCT02560012|DRUG|Axitinib|5 mg orally twice daily
215106491|NCT02861638|DEVICE|Experimental group|Video of the exercises
215106492|NCT02861638|DEVICE|Control group|video of nature scenes
215106493|NCT02861638|DEVICE|Conventional physiotherapy|Mobilization, exercises and transfer practice.
215106494|NCT01007838|OTHER|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
215106495|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
215106496|NCT01007838|OTHER|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
215106497|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
215106498|NCT06392269|DIAGNOSTIC_TEST|Tasso+SST|Clinical evaluation of capillary blood samples collected using the Tasso+SST device for downstream analyte testing.
215106499|NCT04225793|DRUG|Eziklen®|"The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure."
215106500|NCT04225793|DRUG|MoviPrep|"The Moviprep® solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Moviprep® solution should be completed at least 2 hours and no later than 4 hours before the procedure."
215106501|NCT04348006|DRUG|Bortezomib 3.5 MG|"VCD protocol~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)~* D, Dexamethasone oral: 40mg (days 1 to 4)~VRD protocol:~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* R, Lenalid® cap 25 mg po (day 1 to 21)~* D, Dexamethasone oral: 40mg (days 1 to 4)"
215106502|NCT05191875|DRUG|Saccharomyces Boulardii 250 MG|"Saccharomyces Boulardii:~0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory"
215106503|NCT05191875|DRUG|Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate|"Ilaprazole:~5mg\*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g \* 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD"
214424411|NCT04189744|DRUG|IPTp-dihydroartemisinin-piperaquine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-SP plus MTZ to assess whether DP is superior to SP in in reducing adverse pregnancy outcomes.
214424412|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine|The World Health Organization (WHO) recommends providing intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) to pregnant women during the second and third trimesters of pregnancy to clear placental infection.
214424413|NCT05516927|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
215106504|NCT02725229|PROCEDURE|parasternal block|parasternal block and PCA for sternotomy pain
215106505|NCT02725229|DEVICE|TENS group|TENS and PCA for sternotomy pain
215106506|NCT02725229|DEVICE|control group|PCA for sternotomy pain
215106507|NCT00351325|DRUG|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
215106508|NCT04888013|OTHER|Positive Birth Environment|The intent is to surround the woman and her caregivers with specific types of auditory, visual, and tactile stim uli. One key feature of the ambient room is what is missing-the standard hospital bed. As an alternative, a portable double-sized mattress with several large pillows is set up in a corner of the room. The intent is to allow the woman freedom in positioning and to permit close contact with support people, and to limit the routine use of continuous elec tronic fetal heart rate monitoring and other technologies during normal labor. Lighting is dimmed. A wide variety of music selections are also available.
215106509|NCT03238833|OTHER|luteal ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.
215106510|NCT03238833|OTHER|follicular ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
215106511|NCT00478686|PROCEDURE|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
215106512|NCT00003775|DRUG|leflunomide|
215106513|NCT02561559|RADIATION|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
215106514|NCT04794127|DRUG|Trabectedin|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
215106515|NCT04794127|DRUG|Pioglitazone Oral Product|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
215106516|NCT04167137|DRUG|SYNB1891|SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.
215106517|NCT04167137|DRUG|Atezolizumab|Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W).
215106518|NCT02483117|OTHER|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
215106519|NCT02147288|DEVICE|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
215106520|NCT01874444|DEVICE|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
215106521|NCT01874444|DEVICE|2|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
215106522|NCT01874444|DEVICE|3|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
215106523|NCT01874444|DEVICE|4|"Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
215106524|NCT04415411|OTHER|Nursing care based on the Theory of Human Caring|Planned nursing care based on 10 caritas processes of Theory of Human Caring.
215106525|NCT00997594|PROCEDURE|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
215106526|NCT05072730|DEVICE|Super High Pressure Balloon (OPN NC)|"Strategy of super high-pressure balloon angioplasty after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with OPN balloon. Optional additional pre-dilatation with OPN/standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with OPN balloon or standard NC balloon is permitted at the operator´s discretion."
215106527|NCT05072730|DEVICE|Intravascular lithotripsy (IVL)|"Strategy of IVL after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with IVL balloon. Optional additional pre-dilatation with standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with standard NC balloon is permitted at the operator´s discretion."
215106528|NCT02467582|DRUG|Aspirin|Aspirin 100 mg daily
215106529|NCT02467582|DRUG|Placebo|Placebo
215106530|NCT05192460|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1/L1.
215106531|NCT02008344|DRUG|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
215106532|NCT02008344|DRUG|placebo|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
215106533|NCT02959359|DRUG|Ledipasvir 90mg/Sofosbuvir 400 mg|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
215106534|NCT02959359|DRUG|Ribavirin|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
215106535|NCT01370265|DRUG|Regadenoson|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
215106536|NCT01370265|DRUG|Adenosine|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
215106537|NCT01370265|DRUG|N-13 ammonia|Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
215106538|NCT00674674|DRUG|Topotecan|"Induction (4 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 3.~The Induction period is the first 4 weeks of therapy."
215106539|NCT00674674|DRUG|Topotecan|Consolidation (6 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 4. The Consolidation period is 6 weeks in duration. Consolidation begins immediately after completion of the 4th week of Induction.
215106540|NCT00674674|DRUG|Topotecan|Maintenance (4 weeks for 11 courses): Patients will receive IT topotecan for 5 consecutive days during week 1. Each course of Maintenance is 4 weeks in duration. Maintenance begins immediately after completion of the 6th week of Consolidation.
215106541|NCT00735722|DEVICE|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
215106542|NCT03068702|DEVICE|Optical Coherence Tomography Angiography|
215106543|NCT05958797|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance
215106544|NCT05958797|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
215106545|NCT03063463|PROCEDURE|pneumatic dilation|Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.
215106546|NCT03063463|PROCEDURE|surgical myotomy|This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.
215106547|NCT02469350|OTHER|Serious game|Rehabilitation with serious game
215106548|NCT04608604|OTHER|Physiotherapy|Patients will be randomized in either physiotherapy 1 or physiotherapy 2. Physiotherapy programs are individually tailored based on a structured standardized series. In order to not unblind potential participants, detailed description of both interventions will be provided after recruitment has been finished.
215106549|NCT02611817|DRUG|Vedolizumab SC 108 mg|Vedolizumab SC Injection.
215106550|NCT02611817|DRUG|Placebo|Vedolizumab placebo-matching SC injection.
215106551|NCT02611817|DRUG|Vedolizumab IV 300 mg|Vedolizumab IV Injection.
215106552|NCT01748838|DRUG|CTX-4430|Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
215106553|NCT01748838|OTHER|Mannitol|excipient blended with CTX-4430 in capsules
215106554|NCT01748838|DRUG|Placebo|Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
215106555|NCT01748838|DRUG|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
215106556|NCT01748838|DRUG|Placebo|Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
215106557|NCT01748838|OTHER|Mannitol|excipient blended with CTX-4430
215106558|NCT02919254|DIETARY_SUPPLEMENT|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
215106559|NCT02919254|OTHER|Placebo|Fruit juice cordial containing negligible nitrate
215106560|NCT03683342|PROCEDURE|Ankle Block|Ankle block will be performed prior to surgery under ultrasound guidance
215106561|NCT03683342|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed prior to surgery under ultrasound guidance
215106562|NCT02454777|BEHAVIORAL|Exercise Intervention|Undergo HIT
215106563|NCT02454777|OTHER|Laboratory Biomarker Analysis|Correlative studies
215106564|NCT02454777|OTHER|Quality-of-Life Assessment|Ancillary studies
215106565|NCT02454777|OTHER|Questionnaire Administration|Ancillary studies
215106566|NCT01429701|DRUG|polymyxin B sulphate + prednisolone + benzocaine + clioquinol|applied 3 times / day at lesion
215106567|NCT01429701|DRUG|betamethasone + gentamicin + tolnaftato + cleoquinol|applied 3 times / day at lesion
215106568|NCT04499560|DIETARY_SUPPLEMENT|Supplement Drink|Superfoods based nutritional supplement
215106569|NCT00866255|DEVICE|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
215106570|NCT03850028|OTHER|89Zr-atezolizumab PET scans|"The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning.~These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151)."
215106571|NCT05579808|PROCEDURE|Epidural Analgesia|Using an aseptic technique while the patient is in sitting position, an epidural catheter was placed at the L2-L3 or L3-L4 interspace. Analgesia was established with the epidural administration of a low dose of local anaesthetic, plus a lipid-soluble opioid (ropivacaine 0.1% and sufentanyl 0.5%, 20 mL). Analgesia was maintained with a top-up regimen, using intermittent manual epidural boluses of increasing concentrations of ropivacaine, with up to 0.15% at full dilation, according to specific needs of individual participants.
215106572|NCT00837070|PROCEDURE|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
215106573|NCT06140173|PROCEDURE|Low osmolar contrast|100 mL of 350 mg omnipaque will be administered via nasogastric tube
215106574|NCT06140173|PROCEDURE|Sterile water|100 mL of sterile water will be administered via nasogastric tube
215106575|NCT03130920|PROCEDURE|Preconditioning|"Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ."
215106576|NCT05263414|DEVICE|tVNS|tVNS allows the non-invasive activation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to promote GABA release. tVNS will be performed by using a CE marked tVNS device. It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
215106577|NCT01054482|DRUG|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op \& Post-Op (total 4 cycles)
215106578|NCT01054482|OTHER|Pre-operative concurrent chemoradiation therapy|"Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op \& Post-Op: 2 cycles (total 4 cycles).~Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx"
215106579|NCT03178604|OTHER|Classic massage|It involves applying the classic massage techniques: effleurage (gliding or sliding movement over the skin with a smooth continuous motion following the direction of the muscle fibers of the superficial muscles in a distal to proximal direction); petrissage (lifting, wringing, or squeezing of soft tissues in a kneading motion, or pressing or rolling of the tissues under or between the hands); tapotement (various parts of the hand striking the tissues at a fairly rapid rate). The general objective is to improve extensibility of muscle, tendon, fascia, joint capsule, and ligamentous structures.
215106580|NCT03178604|OTHER|Sham massage|This group received a placebo intervention at the same time as the other group, maintaining only soft touch with the participant without exerting any mechanical pressure.
215106581|NCT01559272|DRUG|Paliperidone IR (Period 1)|Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
215106582|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel A: treatment group 1)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
215106583|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel A: treatment group 2)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
215106584|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 1)|Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
215106585|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 2)|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
215106586|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 3)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
215106587|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 4)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
215106588|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 5)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
215106589|NCT01559272|DRUG|Paliperidone palmitate F016|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
215106590|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 1)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
215106591|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 2)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
215106592|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 3)|Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
215106593|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 4)|Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
215106594|NCT00844012|DRUG|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
215106595|NCT00844012|DRUG|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
215106596|NCT02485132|OTHER|Observational|Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
215106597|NCT04311489|DRUG|Ularitide|Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.
215106598|NCT04311489|DRUG|Placebo|Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
215106599|NCT00265317|DRUG|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
215106600|NCT00265317|DRUG|sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
215106601|NCT00265317|DRUG|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
215106602|NCT00265317|DRUG|placebo|Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
215106603|NCT02472301|DIETARY_SUPPLEMENT|cowpeas complementary food|cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
215106604|NCT02472301|DIETARY_SUPPLEMENT|corn-soy flour|Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
215106605|NCT02472301|DIETARY_SUPPLEMENT|common bean complementary food|common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
215106606|NCT05027867|DRUG|KRT-232|Administered by mouth
215106607|NCT02037516|DEVICE|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
215106608|NCT02037516|DRUG|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
215106609|NCT02037516|DEVICE|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
215106610|NCT05727735|DEVICE|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
215106611|NCT05727735|DRUG|Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
215106612|NCT04803695|DIAGNOSTIC_TEST|Microbial biofilm diagnose|Usage of new microbiological methods for biofilm detection
215106613|NCT04091880|BIOLOGICAL|EV71 vaccine and influenza vaccine|simultaneously administrated with EV71 vaccine and influenza vaccine
215106614|NCT04091880|BIOLOGICAL|EV71 vaccine|administrated with EV71 vaccine only
215106615|NCT04091880|BIOLOGICAL|influenza vaccine|administrated with influenza vaccine only
215106616|NCT02510001|DRUG|PF-02341066|PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
215106617|NCT02510001|DRUG|PD-0325901|PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
215106618|NCT02510001|DRUG|Binimetinib|Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
215106619|NCT00830492|DRUG|clomiphene citrate|100 mg from cycle day 3 through 7
215106620|NCT00830492|PROCEDURE|Ultrasound|cycle day 8
215106621|NCT00830492|DRUG|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
215106622|NCT00830492|DRUG|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
215106623|NCT00830492|DRUG|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
215106624|NCT00830492|DRUG|rFSH|150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
215106625|NCT04042324|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
215106626|NCT04042324|DRUG|Heparin|Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
215106627|NCT03765892|OTHER|Questionnaire (Adult)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the distribution of socio-professional categories.~Answering the questionnaires will take 45 minutes."
215106628|NCT03765892|OTHER|Questionnaire (Children)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the proportion of subjects having repeated grades.~Answering the questionnaires will take 45 minutes."
215106629|NCT02816801|OTHER|Butler-Program 2.0|Internet based intervention for elderly, in which they learn how to use e-mail, video conferencing and a blog, in addition to virtual relaxation exercises.
215106630|NCT05904067|BIOLOGICAL|COVID Convalescent Plasma|200 ml of COVID Convalescent Plasma at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.
215106631|NCT00704704|DRUG|5-aza-cytidine and Thalidomide|5-AZA-Cytidine 75mg/m2 5 days a month. 12 months. Thalidomide 50mg orally daily for 6 months.
215106632|NCT02737124|DRUG|Acetaminophen|Acetaminophen will be given 24 hours before scheduled surgery.
215106633|NCT02737124|OTHER|Placebo|Placebo will be given to subjects 24 hours before scheduled surgery.
215106634|NCT03333629|BEHAVIORAL|Enhanced early detection|standardized screening
215106635|NCT02249611|DEVICE|Mobile physical activity promotion tool|"1. Mobile activity sensor~2. Smartphone with APP~3. Interactional webpage of internet~4. Evidence based health information~5. Individualized reminding messages according to the data from activity recording system~6. Personal counseling from professional personnel"
215106636|NCT02249611|OTHER|Standard care|Counseling on lifestyles with health education material
215106637|NCT02511886|DRUG|Arbaclofen Placarbil|Arbaclofen Placarbil
215106638|NCT02511886|DRUG|Placebo|Placebo matched tablets
215106639|NCT01183949|DRUG|AT7519M|"Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m\^2/dose and will be increased to 27mg/m\^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose."
215106640|NCT01183949|DRUG|Bortezomib|Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
215106641|NCT02744196|BIOLOGICAL|Acellbia|Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
215106642|NCT02744196|DRUG|Placebo|Placebo solution will look identical to the Acellbia solution.
215106643|NCT02744196|DRUG|Methotrexate|
215106644|NCT03567746|PROCEDURE|Underwater EMR|Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
215106645|NCT03567746|PROCEDURE|Conventional EMR|It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
215106646|NCT01822262|PROCEDURE|minimally invasive cholecystolithotomy with gallbladder reservation|
215106647|NCT01822262|PROCEDURE|laparoscopic cholecystectomy|
215106648|NCT00000422|BEHAVIORAL|Cognitive-behavioral psychotherapy and physical exercise|
215106649|NCT00303485|DRUG|Placebo|po monthly for 6 months
215106650|NCT00303485|DRUG|Vitamin D and calcium supplementation|As prescribed
215106651|NCT00303485|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
215106652|NCT02683434|DEVICE|Kinesio Taping application|Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
215106653|NCT00385138|DRUG|Cangrelor|cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
215106654|NCT00385138|DRUG|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
215106655|NCT00385138|DRUG|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
215106656|NCT00385138|DRUG|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
215106657|NCT00385138|DRUG|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
215106658|NCT02759250|DRUG|ARGX-110|
215106659|NCT00491582|DRUG|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
215106660|NCT04064762|DEVICE|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with Prolonged Exposure Therapy.
215106661|NCT05121948|DRUG|HC-7366|HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration. Each capsule contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Capsules are supplied in 3 strengths: 10, 25, and 100 mg HC-7366 free acid equivalent.
215106662|NCT02199925|DRUG|Gammaplex 5%|
215106663|NCT04196465|DRUG|IMC-001|IMC-001 is a fully human anti-programmed cell death ligand 1 (PD-L1) recombinant monoclonal antibody that strongly binds to PD-L1 to inhibit its binding to programmed cell death protein 1 (PD-1) or B7-1 (CD80). IMC-001 showed robust dose-dependent efficacy in animal models and no evidence of toxicity in cynomolgus monkeys
215106664|NCT04649463|DIAGNOSTIC_TEST|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
215106665|NCT06239103|DEVICE|Pulsed electromagnetic field therapy|Pulsed electromagnetic field therapy for 10 minutes, using a PEMF device, at 1 mT, 15 Hz.
215106666|NCT06239103|DEVICE|Sham treatment|Sham treatment, using the same PEMF device
215106667|NCT00648362|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fasting
215106668|NCT00648362|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fasting
215106669|NCT04120402|DRUG|EP-104IAR 25 mg|Single 5 mL intra-articular injection
215106670|NCT04120402|DRUG|Vehicle|Single 5 mL intra-articular injection
215106671|NCT01362894|DEVICE|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
215106672|NCT01362894|DEVICE|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
215106673|NCT02289807|DRUG|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
215106674|NCT02289807|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
215106675|NCT02709811|DRUG|Electrochemotherapy|
215106676|NCT02445326|DRUG|Dexamethasone|
215106677|NCT02445326|OTHER|Placebo Vehicle|
215106678|NCT03629522|DRUG|Ondansetron 8Mg/4mL Injection|investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
215106679|NCT02386163|BIOLOGICAL|MSC from synovial membrane and infrapatellar Fat Pad|
215106680|NCT02135237|BEHAVIORAL|Prize Contingency Management for Alcohol Abstinence|The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors
215106681|NCT02135237|BEHAVIORAL|Standard Care|
215106682|NCT06361017|PROCEDURE|endovascular thrombectomy|All individuals were anesthetized, with local or general anesthesia dependent on the cooperation level of the patient. During the procedure, it was mandatory to administer intravenous heparin to maintain the activated clotting time between 250 and 300 s, except for subjects who received intravenous alteplase. The procedures were performed through the femoral artery. The selection of stent retriever type and size, along with any required devices, such as guide wires and catheters, as well as the intervention strategy, was at the interventionists' discretion.
215106683|NCT05414630|DRUG|Envafolimab|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. The duration of treatment with Envafolimab should not exceed 2 years.
215028230|NCT07011303|PROCEDURE|L-PRF|Blood will be taken from the patient before the surgical procedure is started. The blood sample will be placed in the L-PRF device for centrifugation and the sample will be centrifuged. (2700M x 12 min, 700g) After the blood is processed for centrifugation, the surgery will begin. Surgery will be performed under local anaesthesia with articaine 2 ml 4% and epinephrine 1:100,000. All patients will be operated by the same surgeon. After local anaesthesia is achieved, tooth extraction will be started. After tooth extraction, the surgical field will be washed with sterile 0.9% saline, and L-PRF material will be placed in the area and primarily sutured with a 3.0 silk suture. All patients will be given postoperative instructions by the surgeon. Patients will be prescribed mouthwash (0.12% chlorhexidine mouthwash twice daily for 7 days).
215028231|NCT06689631|PROCEDURE|Respiratory Physiotherapy|Mucociliary clearance techniques (prolonged slow expiration and provoked cough), bronchodilator when prescribed and nebulisation with 3% hypertonic saline.
215028232|NCT03907566|OTHER|The Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals|Swallowing function will be evaluated by the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
215028233|NCT05970939|OTHER|Development of the Telerehabilitation Usability Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Usability Questionnaire in patients with MS.
215028234|NCT04037397|DRUG|Anti Arrhythmics|Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
215028235|NCT04037397|PROCEDURE|Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation|Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
215028236|NCT01594372|PROCEDURE|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
215028237|NCT01594372|PROCEDURE|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
215028238|NCT06694987|OTHER|Non-Physician Health Worker|"NPHW will aid participants in accessing a family doctor if required. The family doctor will receive a letter from the study, with suggested medication, based on the HOPE-4 algorithm. The family doctor may decide not to prescribe the recommended treatment or give another treatment (medication). In such case, the participant will still be part of the study and family physician's decision and reason why will be recorded. Follow-up will occur as per the visit schedule. All participants will attend a 20-minute follow-up visits in person at 0, 6 and 12 months, and via telephone at 3 and 9 months.~Participants will be assessed to determine if: i. the patient was assessed by their family physician, ii. the family doctor initiated recommended medication treatment(s), iii. they are adhering to the medications as prescribed, iv. they implemented what the NPHW has recommended about dietary and lifestyle changes, using the specific, measurable, achivable, relevant, time-bound (SMART) for goals."
215028239|NCT06699134|DEVICE|Total knee arthroplasty|Primary total knee replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
215028240|NCT06699134|DEVICE|Total Hip arthroplasty|Primary total hip replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
215028241|NCT05362799|DRUG|Letrozol (Femara, Novartis)|Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
215028242|NCT05362799|DRUG|Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)|Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
215028243|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
215106684|NCT04482582|RADIATION|Cryoneurolysis|Patients will be offered a minimally invasive solution known as cryoneurolysis. By directly applying a cold cryoneurolysis probe to the nerves the axon is destroyed, resulting in Wallerian degeneration of the distal nerve without distorting epineurial or perineurial tissue. Application of cryoneurolysis will help reduce the amount of narcotics the patient would need to take and instead provide them longer term pain control with minimal risk.
215106685|NCT04482582|OTHER|Standard of Care|Patients will be provided regular standard of care at the Stanford Hospital with long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.
215106686|NCT01363908|DRUG|SPD602|
215106687|NCT02644343|DEVICE|Custom Sound|Custom Sound is the programming software used to program Nucleus cochlear implants.
215106688|NCT01198639|DEVICE|manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method
215106689|NCT01198639|DEVICE|closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|an algorithm is used to maintain automatically the BIS values between 40 and 60
215106690|NCT05076890|DIETARY_SUPPLEMENT|15 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
215106691|NCT05076890|DIETARY_SUPPLEMENT|50 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
215106692|NCT00437424|DRUG|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
215106693|NCT03437577|DRUG|immediate-release tacrolimus|Standard of care for transplant patients
215106694|NCT03437577|DRUG|extended release tacrolimus|Experimental care
215106695|NCT04880655|DEVICE|WSD|Post debridement and within 24 hours of injury, wound care and WSD applied daily
215106696|NCT04880655|DEVICE|Dressed with bacitracin and petrolatum gauze|Post debridement and within 24 hours of injury, wound care and dressing applied daily
215106697|NCT02265250|OTHER|MRI|Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
215106698|NCT02265250|OTHER|PET/MRI|Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
215106699|NCT02265250|OTHER|Laboratory blood test|Cardiovascular biomarkers
215106700|NCT00328614|DRUG|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
215106701|NCT00328614|DRUG|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
215106702|NCT00328614|DRUG|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
215106703|NCT00328614|DEVICE|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
215106704|NCT04774926|DRUG|Brolucizumab|120 mg/ml solution for intravitreal injection
215106705|NCT01711450|PROCEDURE|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
215106706|NCT01711450|PROCEDURE|Control sham procedure|Injection of Normal saline into the paravertebral space
215106707|NCT04264364|PROCEDURE|Laparoscopic sleeve gastrectomy|Bariatric surgical intervention
215106708|NCT04264364|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic bariatric procedure
215106709|NCT03776201|OTHER|Balance Training|We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
215106710|NCT00391313|DRUG|Chloroquine|
215106711|NCT00123175|DEVICE|Intrauterine Device|Mirena and Provera
215106712|NCT05285540|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
215106713|NCT05285540|DRUG|DT-216 matching Placebo|Placebo will be administered by intravenous (IV) injection
215106714|NCT00336297|PROCEDURE|Woman Abuse Screening Tool|
215106715|NCT00336297|PROCEDURE|Partner Violence Screen|
215106716|NCT00336297|PROCEDURE|Computerized screening|
215106717|NCT00336297|PROCEDURE|Face to face screening|
215106718|NCT00336297|PROCEDURE|Written screening on forms|
215106719|NCT05144711|PROCEDURE|Selective caries excavation|Selective caries excavation leaving stained but leathery dentine towards the pulp
215106720|NCT05144711|PROCEDURE|Non selective caries excavation|Complete excavation of caries regardless of the risk of pulp exposure
215106721|NCT00108316|DRUG|Fluoxetine (Liquid Prozac)|
215106722|NCT01672424|OTHER|Ice Chips|11 ounces of ice chips given to the laboring parturient
215106723|NCT01672424|OTHER|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
215106724|NCT01877213|BEHAVIORAL|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
215106725|NCT01020552|OTHER|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
215106726|NCT05240625|DEVICE|"aetherAI Computer-aided Polyp Detection (CADe) Systems for Colonoscopy"|"The investigational medical device is intended to automatically detect potential polyps via colonoscopy in real-time during colonoscopy examinations.~The subject device contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic mucosal lesions and the detected polyps will be highlighted to the endoscopists during the real-time colonoscopy procedures."
215106727|NCT05240625|PROCEDURE|Standard colonoscopy|Standard colonoscopy procedure.
215106728|NCT02764658|DEVICE|Pulmonary recovery on the AECOPD|The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
215106729|NCT02764658|OTHER|Routine care on the AECOPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
215106730|NCT02764658|OTHER|Routine care on the stable COPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
215106731|NCT03856827|DRUG|IW-6463|IW-6463 Tablet
215106732|NCT03856827|DRUG|Matching Placebo|Matching Placebo Tablet
215106733|NCT03642496|BIOLOGICAL|Low dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 0.75×10\*6/kg.
215106734|NCT03642496|BIOLOGICAL|Middle dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 1.5×10\*6/kg.
215106735|NCT03642496|BIOLOGICAL|High dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 3.0×10\*6/kg.
215106736|NCT06121089|PROCEDURE|ileocecal resection with extended D3 lymphadenectomy.|Laparoscopy ileocecal resectionith extended D3 lymphadenectomy including 201, 202, 203 and 213 groups of lymph nodes. Manual double-row ileo-ascendo-anastomosis.
215106737|NCT06121089|PROCEDURE|Right hemicolectomy with D3 lymphadenectomy.|Laparoscopy right hemicolectomy with D3 lymphadenectomy including 201, 202, 203, 213, 211, 212, 221, 222-rt groups of lymph nodes. Manual double-row ileo-transverse-anastomosis.
215106738|NCT06309589|DRUG|Vitamin D|experimental group received UDCA combined with vitamin D3 (1200 IU per day) treatment
215106739|NCT00133861|DRUG|Botulinum toxin|
215106740|NCT03831217|PROCEDURE|mid urethral sling surgery|patients with clinically and/or urodynamically proven stress urinary incontinence underwent mid urethral sling surgery under general anesthesia.
215106741|NCT00550966|BEHAVIORAL|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
215106742|NCT00002201|DRUG|Ritonavir|
215106743|NCT00002201|DRUG|Nelfinavir mesylate|
215106744|NCT01406197|DRUG|Experimental: Vaginal progesterone|Vaginal progesterone formulation (150 mg micronized progesterone daily)
215106745|NCT01406197|DRUG|Experimental: Topical progesterone|Progesterone will be applied daily (150 mg micronized progesterone)by topical application
215106746|NCT01406197|DRUG|Experimental: Intramuscular progesterone|Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
215106747|NCT05499468|OTHER|Popular-Opinion Leader-led encouragement during training meetings and informal conversation|Investigators adapted evidence-based principles from the Popular Opinion Leader framework to increase utilizations of existing one-on-one emotional support resources for physicians-in-training at Stanford (an effective HIV prevention intervention developed by the CDC for changing social norms and reducing behavioral risk factors led by influential members of a community, trained to promote behavior change). All intervention activities designed to encourage utilization were delivered as part of health promotion during pre-existing clinical training meetings and no data was collected during these workshops. Identified POLs were recruited and trained to encourage their colleagues to use existing support resources and engage in two 30-60 minute workshops scheduled to occur during training meetings.
215106748|NCT01633164|BEHAVIORAL|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
215106749|NCT01633164|OTHER|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
215106750|NCT03078855|DIETARY_SUPPLEMENT|Vitamin D|vitamin D3 2,000 IU daily
215106751|NCT03078855|BIOLOGICAL|Rituximab|Administered weekly x 4
215106752|NCT03078855|OTHER|Placebo|methylcellulose
215106753|NCT01938833|DRUG|Romidepsin|
215106754|NCT01938833|DRUG|Abraxane|
215106755|NCT01770171|DRUG|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
215106756|NCT01770171|DRUG|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
215106757|NCT03765450|DRUG|Infliximab|Patients will receive infliximab at the discretion of their physician as part of standard of care.
215106758|NCT00391027|DRUG|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
215106759|NCT00391027|DRUG|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
215106760|NCT02816489|DEVICE|Clarity SL MBT brackets; 3M Unitek, Monrovia, CA, USA|(passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner)
215106761|NCT02816489|DEVICE|Gemini MBT brackets; 3M Unitek, Monrovia, CA, USA|(conventional stainless steel orthodontic brackets ligated with elastomeric ligature)
215106762|NCT01916434|OTHER|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (\~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
215106763|NCT01916434|OTHER|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (\~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
215106764|NCT01916434|OTHER|No salmon|The placebo group will continue to consume their habitual diet.
215106765|NCT02186665|DRUG|calcitriol ointment|
215106766|NCT02186665|DRUG|placebo comparator|
215106767|NCT03570541|DRUG|Ropivacaine|30 mL ropivacaine 0,375% administered on each side as bilateral TQL blocks
215106768|NCT03570541|DRUG|Acetaminophen|Every six hours postoperative, all patients are administered 1 g of acetaminophen.
215106769|NCT03570541|DEVICE|Patient controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
215106770|NCT03570541|DRUG|Morphine|intravenously administered morphine via PCA-pump
215106771|NCT03570541|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
215106772|NCT03570541|DIAGNOSTIC_TEST|Blood samples|On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis
215106773|NCT03570541|BEHAVIORAL|Quality of recovery-15 questionaire|On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a short questionaire.
215106774|NCT03570541|DIAGNOSTIC_TEST|Orthostatic hypotension|Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension.
215106775|NCT04124705|DRUG|Armour® Thyroid|Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
215106776|NCT04124705|DRUG|Levothyroxine|Administered orally once a day; the daily dose could range from 25- 200 µg.
215106777|NCT03343834|BIOLOGICAL|biological collection|"At D0:~* blood samples~* saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation"
215106778|NCT03618316|DRUG|Imeglimin|2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)
215106779|NCT03618316|DRUG|Cimetidine|400 mg of cimetidine bid from Day 5 to Day 10
215106780|NCT06016868|PROCEDURE|Tumor tissue|Each newly diagnosed patient with LACC who meets the inclusion criteria will undergo cervical cancer biopsy either during the outpatient clinical examination or during examination during anesthetic. Part of the biopsy will be sent for histopathological analysis, while the remaining tissue will be embedded in OCT compound and immediately frozen at -80°C prior to transfer to biobank for subsequent analysis.
215106781|NCT06016868|PROCEDURE|Blood sample|Every patient will undergo a peripheral venous blood sample which will be processed to analyze the presence of the proteins codified by three RNA species (ANXA2-NDRG1-STAT1). This blood sample will be performed before starting the treatment with exclusive CTRT.
215106782|NCT01711125|DRUG|Baclofen 30mg/day|30mg/day 10 mg t.i.d
215106783|NCT01711125|DRUG|Baclofen 75mg/day|75mg/day 25 mg t.i.d
215106784|NCT01711125|DRUG|Placebo|Placebo 3 matched tabs/day
215106785|NCT03010280|DIETARY_SUPPLEMENT|Immunonutrition|Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
215106786|NCT03010280|DIETARY_SUPPLEMENT|Balanced high-protein formula|Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
215106787|NCT06393179|OTHER|pressure-volume curve with a low-flow insufflation of 5 L/min|The patient undergoes a pressure-volume curve with a low-flow insufflation of 5 L/min while in a state of analgesia, sedation, and absence of spontaneous breathing.
215106788|NCT00663754|BEHAVIORAL|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
215106789|NCT00663754|BEHAVIORAL|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
215106790|NCT04123145|DIAGNOSTIC_TEST|Iron status testing|Iron status testing
215106791|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd|Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.
215106792|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w|The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).
215106793|NCT01111344|DIETARY_SUPPLEMENT|Glizigen + Viusid|"Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_3 daily applications~* 4 to 6.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_4 daily applications~* 7 to 10 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
215106794|NCT01111344|DIETARY_SUPPLEMENT|Placebo|"Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_3 daily applications~* 4 to 6.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_4 daily applications~* 7 to 10 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
215106795|NCT02056093|DEVICE|PSV mode|Application of PSV in all patients
215106796|NCT02056093|DEVICE|PAV mode|Application of PAV mode in all patients
215106797|NCT02056093|DEVICE|NAVA|
215106798|NCT00230841|DEVICE|nebulized humidity|
215106799|NCT03843983|DEVICE|Lipiflow® application|"Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment."
215106800|NCT06251583|DEVICE|duramesh suture|Duramesh-suture will be used for trocar closure in the experimental group
215106801|NCT02443168|DRUG|AG-221|Part 1: oral solution containing 100 mg \[14C\]-AG-221
215106802|NCT02443168|RADIATION|14C AG-221|5 mL of 100 micrograms \[14C\] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
215106803|NCT00349869|BEHAVIORAL|yoga|8-week yoga program.
215106804|NCT01771523|PROCEDURE|Thyroidectomy|total thyroidectomy or lobectomy
215106805|NCT01771523|DEVICE|use of drain|drain will be used
215028244|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
215028245|NCT06144658|DEVICE|Augmented Reality Headset / Hololens 2 or Varjo XR3|Augmented Reality Headset
215028246|NCT04635982|OTHER|Kinesiotape of the physical performance|It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique
215028247|NCT02712216|PROCEDURE|Laparoscopy|Determine best port sites to insert bariatric trocars
215028248|NCT03377998|OTHER|skin biopsy|Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
215028249|NCT00969085|DRUG|Curcumin (Turmeric)|"Chew then swallow 2 sticks per day for up to 6 months.~2 sticks = 1 packet of curcumin = 8 grams"
215028250|NCT00969085|BEHAVIORAL|Questionnaires|Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
215028251|NCT00969085|OTHER|Photos|Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
215028252|NCT02868879|OTHER|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2\*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
215028253|NCT00223379|PROCEDURE|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
215028254|NCT02144818|DRUG|Ovitrel|Triggering of ovulation with Ovitrel
215028255|NCT02144818|DRUG|Decapeptyl|Triggering with GnRH agonist
215028256|NCT05528445|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
215028257|NCT00908141|BIOLOGICAL|sargramostim|Given subcutaneously on varying schedule
215028258|NCT02207101|DIETARY_SUPPLEMENT|E-OJ-01 (OXYJUN)|
215028259|NCT02207101|DIETARY_SUPPLEMENT|Placebo|
215028260|NCT05902442|DEVICE|3DxSPLINT|Routine immobilization procedure with a patient-specific 3D printed splint instead of the use of a conventional forearm splint after one week of conventional immobilization.
215028261|NCT06752499|DEVICE|Online stimulation|5 Hz rTMS is applied to the primary motor cortex on the affected hemisphere when the patients are performing motor tasks.
215028262|NCT06752499|DEVICE|Offline stimulation|After 5 Hz rTMS is applied to the primary motor cortex on the affected hemisphere, the patients perform motor tasks.
215028263|NCT06752499|DEVICE|Sham stimulation|Sham rTMS is applied to the primary motor cortex on the affected hemisphere when the patients are performing motor tasks.
215028264|NCT06928454|BEHAVIORAL|Text messages over 8 weeks|Learn about ADRD/Prepare as a care partner/Care for yourself/Get support
215028265|NCT06687135|OTHER|KOKU|"KOKU is a digital strength and balance programme designed to prevent physical decline and frailty KOKU provides access to personalised, progressive strength and balance exercises.~More information can be found at: https://kokuhealth.com/"
215028266|NCT06687135|OTHER|FaME / OTAGO leaflet and AGE UK Stay Steady Leaflet|"A leaflet with information on a combination of strength and balance exercises and walking programs, performed on a weekly basis by older adults at home, or community settings. The exercises can be done individually or in a group setting and are aimed at reducing falls in older adults.~More information can be found at: https://fameexercise.com/ and https://www.livestronger.org.nz/assets/Uploads/acc1162-otago-exercise-manual.pdf https://www.ageuk.org.uk/information-advice/health-wellbeing/exercise/staying-steady-download-page/#:\~:text=This%20guide%20outlines%20things%20you%20can"
215028267|NCT06929936|DRUG|Trilaciclib combined with Docetaxel|"Trilaciclib: 240 mg/m2 as a 30-min iv. infusion, completed ≤4h prior to chemotherapy.~Docetaxel: 75mg/m2, iv. infusion for 1 hour on days 1 of each 21-day cycle, totaling 4 cycles of medication."
215028268|NCT01812746|DRUG|BIND-014|
215028269|NCT06686901|BEHAVIORAL|Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S)|Therapeutic Evaluative Conditioning for Suicide (active TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair suicidal behavior stimuli (pictures, words) with other negative stimuli and self-related stimuli with positive stimuli.
215028270|NCT06686901|BEHAVIORAL|Smartphone-delivered inactive Therapeutic Evaluative Conditioning|Therapeutic Evaluative Conditioning (inactive TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair positive and negative stimuli (pictures, words) with each other.
215028271|NCT06686368|DEVICE|I-DROP MGD|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
215028272|NCT06686368|DEVICE|Theloze Duo|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
215028273|NCT06686368|DEVICE|Systane Complete PF|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
215028274|NCT05833945|DEVICE|Large Vessel Occlusion Biomarkers Test|Duplex Point of Care test to measure the concentration of biomarkers associated to Large Vessel Occlusion in blood samples used in combination with an APP.
215028275|NCT05978128|BEHAVIORAL|Health Education|Access electronic patient portal with educational material
215028276|NCT05978128|OTHER|Health Promotion and Education|Receive materials on breast/lung cancer screening
215028277|NCT05978128|BEHAVIORAL|Patient Navigation|Interact with a patient navigator
215028278|NCT05978128|OTHER|Survey Administration|Ancillary studies
215028279|NCT02546232|DRUG|Carboplatin|Chemotherapy
215028280|NCT02546232|DRUG|Paclitaxel|Chemotherapy
215028281|NCT04089111|OTHER|Minute volume target of 100%|Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).
215028282|NCT04089111|OTHER|Minute volume target to reach PaCO2 less than 45% (high tidal volume)|Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
215028283|NCT04464733|DRUG|HRS9950|HRS9950
215028284|NCT04464733|DRUG|Placebo|Placebo
215028285|NCT04354233|DEVICE|Physical activity intervention with connected devices|"Participants randomized in the intervention arm will receive recommandations in physical activity. They will also receive an activity tracker Withings Steel to wear during 6 months. The tracker will be connected to the Withings Health Mate application and the ABLE02 application. Participants will be encouraged to practice at least three walking sessions weekly of more than 10 consecutive minutes. Concerning the number of steps per day, the first objective will be determined according to the 6-min walking distance and to participants' preferences and capacities. The objective will be recalculated monthly according to the number of steps performed the previous week and will be adapted by the physical activity (PA) instructor and participants. Phone calls with the participants are regularly planned. Weekly quizzes on PA and nutrition will be proposed through the ABLE02 application. A messaging system and a phone line will be available for participants to contact the study team."
215028286|NCT03864848|DEVICE|Mitral Touch Implant|The study population for this study will be comprised of patients who are to undergo cardiac surgery with a sternotomy (e.g. CABG) and who present moderate to severe ischemic or functional MR. In order to be considered eligible for the study, each patient must meet the conditions listed in the inclusion and none of the exclusion criteria.
215028287|NCT02041793|PROCEDURE|Laparoscopic cystogastrostomy|Patients undergo drainage of pseudocyst by laparoscopic technique
215028288|NCT02041793|PROCEDURE|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
215028289|NCT04580550|OTHER|Axial length variability|Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
215028290|NCT04744103|DRUG|TCA|Patients will receive a TCA peel as a treatment for their actinic cheilitis.
215028291|NCT04943757|DRUG|Bendamustine Hydrochloride|50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
215028292|NCT04943757|DRUG|Cyclophosphamid|25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
215028293|NCT05811949|DRUG|Dimethyl Fumarate 240 MG [Tecfidera]|DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
215028294|NCT01189851|DEVICE|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
215028295|NCT06448351|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
215028296|NCT06448351|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
215028297|NCT06448351|OTHER|Vaping session|Sample study e-liquids in vaping sessions at research lab with e-cig study device
215028298|NCT06448351|OTHER|Survey Administration|Ancillary studies
215028299|NCT03889015|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotics are found in different dairy products including yoghurt, that are known as carriers of probiotics. These products can be easily integrated in daily meals to reduce cariogenic streptococcus mutans bacteria in dental biofilm
215028300|NCT03889015|DIETARY_SUPPLEMENT|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
215028301|NCT03302663|DIAGNOSTIC_TEST|MRI scan|Addition of advanced imaging sequences for fetal MRI
215028302|NCT05494619|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
215028303|NCT05494619|DRUG|Placebo|Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
215028304|NCT05494619|DRUG|Intravenous immunoglobulin therapy|All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
215028305|NCT06342609|DRUG|Colchicine 0.5 MG|0.5mg per day of Colchicine orally administered
215028306|NCT00499447|PROCEDURE|radiofrequency ablation|
215028307|NCT00499447|RADIATION|radiation therapy|
215028308|NCT02209987|DRUG|GS-5745 SC|GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
215028309|NCT02209987|DRUG|GS-5745 IV|GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
215028310|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor+Regorafenib|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
215106806|NCT06116006|OTHER|Upper limb pointing movements in 3 experimental conditions|Recording of cerebral hemodynamic with fNIRS during upper limb pointing movements with a robotic device in three conditions: movements with robot assistance, movements without robot assistance and movements with robot resistance. Each subject are recorded during 6 trials for each condition (18 trials). The order is counterbalanced among the subjects.
215106807|NCT01973998|DRUG|Roflumilast|PDE4 inhibitor
215106808|NCT01973998|DRUG|Placebo|Inactive substance.
215106809|NCT01763606|DRUG|Enoxaparin|Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
215106810|NCT01763606|DRUG|Aspirin|Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
215106811|NCT06079021|DEVICE|CytoSorb|Application of CytoSorb treatment for 72 hours in patients with ACLF
215106812|NCT06970873|OTHER|Evaluation of Knowledge, Attitude, and Practice of Pediatric Dentists|Evaluation of Knowledge, Attitude, and Practice of pediatric dentists toward Obstructive Sleep Apnea among Children
215106813|NCT04700826|DRUG|Direct Oral Anticoagulants|choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
215106814|NCT06348797|DRUG|α-PD-L1/4-1BB DLL3 CAR-T (BHP01)|Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses; Bridge radiotherapy with 15 Gray (Gy)/5 fractions; α-PD-L1/4-1BB DLL3 CAR-T (BHP01): the first dose was 5x10\^5/kg.
215106815|NCT06974435|BEHAVIORAL|Interval training and electromagnetic therapy|Combined application of moderate intensity interval training and low frequency pulsed electromagnetic field therapy, in addition to pharmacotherapy.
215106816|NCT06974435|BEHAVIORAL|Interval exercise training|Application of moderate intensity interval training, in addition to pharmacotherapy.
215106817|NCT06974435|BEHAVIORAL|Electromagnetic therapy|Application of low-frequency pulsed electromagnetic field therapy, in addition to pharmacotherapy.
215106818|NCT06974435|OTHER|Control group (No intervention group)|Only Pharmacotherapy.
215106819|NCT04302545|PROCEDURE|Cystoinflation|Bladder retrofill with 300cc saline to distend the bladder to recognize bladder outline
215106820|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus 1x10^1 TCID50|SARS-CoV-2, intranasally, (1x10\^1 TCID50)
215106821|NCT04865237|DRUG|Remdesivir|VEKLURY™
215106822|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus 1x10^2 TCID50|SARS-CoV-2, intranasally, (1x10\^2 TCID50)
215106823|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus 1x10^3 TCID50|SARS-CoV-2, intranasally, (1x10\^3 TCID50)
215106824|NCT03821467|DEVICE|Dual beam Doppler Fourier-domain OCT (DOCT)|Retinal blood flow will be assessed using DOCT.
215106825|NCT03821467|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
215106826|NCT03821467|DEVICE|Optical coherence tomography (OCT)|Retinal morphology will be imaged using OCT.
215106827|NCT06975657|BEHAVIORAL|Wellbeing skills for reentry|A 6-week, in-person meditation training program for formerly incarcerated adults, with practices and concepts grounded in the four pillars of the Healthy Minds Program (awareness, connection, insight, and purpose)
215106828|NCT06974630|OTHER|Cervical erector spinae plane block|Patients will receive bilateral ultrasound-guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% on each side.
215106829|NCT06974630|OTHER|Cervical plexus block|Patients will receive bilateral ultrasound-guided superficial cervical block using 15 mL of 0.25% plain bupivacaine on each side of the neck.
215106830|NCT06974617|DRUG|Sphenopalatine block|Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.
215106831|NCT06974617|DRUG|Botulinum Toxin Type A|Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.
215106832|NCT06975449|BEHAVIORAL|Multicomponent Physical Exercise Program (Vivifrail)|Vivifrail physical training, 5 times/week, 50-60 minutes/session for 12 weeks
215106833|NCT06976632|BEHAVIORAL|Helfer Skin Tap Tecnique|"In the first phase of the study, pregnant women who agree to participate and meet the sampling criteria will be informed about the study, and their written and verbal consents will be obtained. Then, the Individual Identification Form will be completed.~In the second phase, the vital signs of the pregnant women will be measured by the nurse involved in the study. Following this, tetanus vaccination will be administered to the pregnant women in the intervention group using the Helfer Skin Tap technique in accordance with the Helfer Skin Tap IM Injection Procedure Guideline.~In the third phase of the study, pain will be assessed using the Numerical Pain Scale immediately after the procedure and 15 minutes later by the nurse, and the vital signs of the pregnant women will be measured again. To evaluate the long-term effects of pain, participants will be contacted via a link, and pain assessments will be conducted at the 24th and 48th hours following the vaccination."
215106834|NCT06976632|BEHAVIORAL|Local Cold Application|"In the first phase of the study, pregnant women who agree to participate and meet the sampling criteria will be informed about the study, and their written and verbal consents will be obtained. Then, the Individual Identification Form will be completed.~In the second phase, the vital signs of the pregnant women will be measured by the nurse involved in the study. Subsequently, tetanus vaccination will be administered to the pregnant women in the intervention group using a cold compress gel, based on the Cold Compress Gel IM Injection Procedure Guideline developed in line with the relevant literature.~In the third phase of the study, pain will be assessed using the Numerical Pain Scale immediately after the procedure and 15 minutes later by nurse, and the vital signs of the pregnant women will be measured again. Pain assessment will be repeated at the 24th and 48th hours following the vaccination."
215106835|NCT06976827|OTHER|Dietary and physical activity monitoring during the 3-months post-hospitalization period|Three consultations with a private dietician, one consultation with the general practitioner, three months of APA monitoring
215106836|NCT06976580|PROCEDURE|conventional local anesthetic injection|A conventional infiltration anesthesia will be conducted on the lumbar area of the patient, targeting the epidermis and subcutaneous tissue. A 25G syringe will be used, with the needle angle set between 30° and 45°. 1cc of 1% lidocaine will be injected. The target size of the wheal is 5-10 mm.
215106837|NCT06976580|PROCEDURE|skin stetching technique for local anesthetic injection|Skin stretching techinique will be applied to the local anesthetic injection site by stretching the skin around the needle entry point.
215106838|NCT06975020|DRUG|Participants will prepare their cannabis product ad libitum and inhale the prepared product as usual for a maximum of 15 minutes.|Participants will prepare and inhale their cannabis product ad libitum for a maximum of 15 minutes. Prior to inhaling cannabis (the baseline), and for three hours thereafter, biological samples (e.g., blood) will be collected. Participants will be asked to complete a series of questionnaires addressing their (subjective) neurocognitive function and well-being, as well as their self-rated driving ability and subjective cannabis effects.
215106839|NCT06975904|PROCEDURE|m-CIMT with VR exer-games by Kinect Xbox 360|Virtual reality workout session will be for about 30 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For week 1-3: Soccer and Space Bubble Pop games will be used For week 4-6: 20,000 Leaks and Rally Ball games will be used 5 minutes will be given for cool down.
215106840|NCT06975904|PROCEDURE|m-CIMT with Task-Specific Functional Training|Begin with low-intensity exercises and progress to moderate to high intensity; session will be for about 30 minutes Warm-up for 5 minutes;one minute of rest for every five minutes of exercise For week 1-3: Assisted standing and weight shifting, Heel raises, Toe taps, Supported stepping, Unassisted standing and balance tasks will be used For week 4-6: Progressive stepping exercises, Heel-to-toe standing,
215106841|NCT06976346|DRUG|HRG2010 Capsule, Sinemet®, Madopar®|In each period under fasting conditions, subjects received oral administration of either HRG2010 Capsule dose 1, HRG2010 Capsule dose 2, Sinemet®, or Madopar®.
215106842|NCT06975579|DEVICE|Ultrasound image processing|The COSIE study examines the coherence of ultrasound to improve the estimation of the backscatter coefficient.
215106843|NCT06976684|PROCEDURE|Extended Reality (XR)-Assisted CT-Guided Localization|This study plans to collect approximately 20 localization cases from multiple centers within our hospital. Initially, two sets of preoperative simulated CT scans (at end-inhalation and end-exhalation) will be performed in the CT suite to construct a usable model of the surgical posture and the lesion. Subsequently, in the hybrid operating room, a digital twin model will be applied to the patient using a metaverse platform. Guided by virtual localization lines, percutaneous injection of Patent Blue dye will be carried out at end-exhalation for accurate marking of the lesion. Immediately after the injection, intraoperative CT within the hybrid operating room will be used to verify the localization. If the accuracy is suboptimal (with a deviation greater than 2 cm), standard CT-guided Patent Blue dye localization will be performed as a supplementary measure to complete the localization and proceed with surgery.
215106844|NCT06977009|PROCEDURE|Occlusal Reduction|"patients will be allocated to either undergo occlusal reduction (Intervention group) where all occlusal contacts on the functional and non-functional cusps as well as on the marginal ridges will be reduced using a diamond bur, or not undergo occlusal reduction (Control group) where all occlusal contacts will remain intact.~The presence or absence of contact will be confirmed using articulating paper where occlusal surfaces will be dried and articulating paper will be held between the teeth with the mandible guided to the centric position. Intact occlusion will be assessed by examining the marks on the teeth.~A high-speed handpiece with copious coolant will be used to remove occlusal contacts (Intervention group) or just moved above the surface of the tooth without contacting the occlusal surface (Control group) to facilitate patient blinding."
215106845|NCT06138990|DIAGNOSTIC_TEST|Pharmacoscopy|Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
215106846|NCT06138990|DRUG|Clinical standard-of-care (physician's choice)|Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
215106847|NCT05985967|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
215106848|NCT05985967|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
215106849|NCT05985967|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
215106850|NCT05985967|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
215106851|NCT06576206|OTHER|Bin therapy and finger gnosia|Schedule bin therapy sessions 2-3 times per week at first, increasing the frequency as participants get used to it. Data will be collected twice i.e., at the start of the study and after completion of 6 weeks of treatment by using outcome measure tools
215106852|NCT06576206|OTHER|conventional therapy|schedule conventional therapy with 20-50 minutes of each session with each set comprises of 10-12 repetitions of each exercise
215106853|NCT02482467|OTHER|Hormonal analysis, pelvic US|
215106854|NCT03330639|OTHER|Capsaicin|Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.
215106855|NCT03330639|OTHER|Placebo|This group will receive the saline placebo solution.
215106856|NCT06493903|BEHAVIORAL|Positive Minds, Strong Joints|In this10-week physical and mental health intervention, participants will receive recommended exercise intervention and evidence-based mental health intervention for pain, depression and anxiety.
215106857|NCT05427240|OTHER|Pre-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
215106858|NCT05427240|OTHER|Standard of Care|Standard of Care with a Genetic Counselor by Remote Services
215106859|NCT05427240|OTHER|Post-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
215106860|NCT03938506|OTHER|cuff pressure of the endotracheal tube|The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
215106861|NCT04153916|DEVICE|Neurotrigger eye blinking stimulator|"Phase 1 - The first stage is composed of a one-time participation for about three hours and involves:~1. Verifying compliance of the patients with the research inclusion and exclusion criteria~2. Completion of the study clinical report form (CRF) for this stage~3. Placement of the single use mini-electrodes that will be adhered to the facial skin near the non-blinking eye and coupled to the Neurotrigger stimulator to elicit eyelid closure.~Participants may be enrolled to the second phase up to one year from the first phase visit In the second stage the duration of the participation is about three weeks (six days a week) and includes daily use of the device for up to 10 hours a day. During nights the patient will continue is standard pattern of either eye closure or leaving the eye open, as the patient used to do prior to the study.~This stage will involve a patient with a partner that is designated to support the patient closely during the placement and adjustment of the system"
215106862|NCT04211129|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
215106863|NCT04211129|OTHER|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
215106864|NCT06975826|PROCEDURE|Laparscopic percutaneous internal ring suturing (PIRS) technique in Management of inguinal hernia|Laparscopic percutaneous internal ring suturing (PIRS) technique
215106865|NCT06975826|PROCEDURE|Laparscopic inguinal herniotomy in pediatrics|Laparoscopic intraperitoneal purse string suture sac closure technique in pediatrics.
215106866|NCT06975384|OTHER|Exposure: sleep disturbance status|"The assessment of sleep disturbance was conducted using Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI). Patients with a PSQI score \> 5 or an ISI score \> 7 were categorized as sleep disturbance patients.~The assessment of chronotype was conducted using reduced Morningness-Eveningness Questionnaire (rMEQ). Patients with an rMEQ score 18-25 were categorized as the morning type, those with an rMEQ score 12-17 as the intermediate type, and those with an rMEQ score 4-11 as the evening type."
215106867|NCT06976294|OTHER|Cognitive Behavioral Approach-Based Psychoeducation|The 'Socio-Demographic Characteristics Form', the 'Post-Traumatic Growth Inventory', the 'Psychological Resilience Scale for Adults', and the 'Event-Related Rumination Inventory' will be administered to individuals in both the intervention and control groups. No intervention will be applied to the control group. For the intervention group, psychoeducation groups based on the cognitive behavioral approach will be formed for the primary caregivers. Eight face-to-face sessions, each lasting 60 to 90 minutes, will be conducted
215106868|NCT06974994|DIETARY_SUPPLEMENT|Synbiotic Supplement|Bifidobacterium bifidum and human milk oligosaccharides (HMOs)
215106869|NCT06974994|OTHER|Placebo|Maltodextrin
215106870|NCT06975475|DRUG|SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel|SHR-A1811:4.8mg/kg tratuzumab:Initial 8mg/kg followed by 6mg/kg pyrotinib:320mg Nab-Paclitaxel:100-150mg/m2
215106871|NCT02450292|PROCEDURE|Bioabsorbable screw fixation|
215106872|NCT01636986|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
215106873|NCT01636986|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
215106874|NCT05107570|OTHER|Cold exposure|Cold air exposure (\~ 9°C, maximum 1 hour duration)
215106875|NCT05118373|BEHAVIORAL|BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA|The intervention is a mass media campaign using TV, radio, billboard and posters to disseminate the message. The content are well-produced videos and pictures emphasising the need to wash hands, wear a mask, maintain social distance and clean surfaces. The English version of the video can be viewed at this link: https://youtu.be/tcjaLAxy4Ms.
215106876|NCT05777135|DRUG|Ringer Lactate prior to surgery and Propofol|Ringer Lactate prior to surgery and Propofol dose requirement for induction of anaesthesia will be noted
215106877|NCT02328534|BEHAVIORAL|Blastocyst Formation Rate|"Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
215106878|NCT02328534|PROCEDURE|Blastocyst Rate|"Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam."
215106879|NCT02328534|PROCEDURE|Pregnancy Rate|"All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
215106880|NCT04867733|OTHER|Micropatch (microneedle patch)|Each micropatch contains an array of 50 microneedles.
215106881|NCT05876845|OTHER|Combined pre-, pro-, and post-biotic supplement|Participants will take 2 capsules daily with water, with their first meal of the day.
215106882|NCT03700437|OTHER|Fasting-Mimicking Diet|Chemo-immunotherapy + FMD (fast-mimicking diet)
214509668|NCT04037033|BEHAVIORAL|Everyday Meaningful Activities (EMA) intervention|"The EMA intervention will include 6 intervention sessions. At session 1, the interventionist and participant will identify 2 meaningful active lifestyle behavior goals using COPM. Last, an action plan will be created for behavior 1. Participants will be asked to implement the action plan everyday.~At session 2, the interventionist and participants will review the daily activity log and the action plan.~At session 3, the interventionist and the participants will review the daily activity log and the action plan.~At session 4, an action plan will be created for behavior 2. Participants will be asked to implement the action plan for behavior 2 everyday.~At session 5, the participants and interventionists will discuss the participant's daily activity log and action plan.~At session 6, the participants and interventionists will discuss the participant's daily activity log and action plan."
214509669|NCT04872296|DEVICE|Controlled Ankle Motion (CAM) boot|A CAM boot will be worn on the affected ankle to allow weight bearing
214509670|NCT04872296|PROCEDURE|Physical Therapy|Standard physical therapy protocol will be started at 6 weeks after surgery
215106883|NCT03187808|OTHER|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
215106884|NCT03187808|OTHER|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
215106885|NCT05675228|OTHER|data collection|Knowledge about genital herpes
215106886|NCT03706300|DRUG|Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg|
215106887|NCT00644436|DEVICE|Tetrix|single topical application
215106888|NCT00644436|DEVICE|Tetrix|Single topical application
215106889|NCT02093338|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|
215106890|NCT02093338|OTHER|Placebo Comparator: maltodextrin|Placebo
215106891|NCT02291588|DRUG|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
215106892|NCT02291588|DRUG|Placebo|contains no active drug
215106893|NCT02210416|PROCEDURE|inguinal hernia surgery|
215106894|NCT02880917|DEVICE|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
215106895|NCT02880917|DEVICE|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
215106896|NCT02880917|OTHER|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
214509671|NCT02525822|DRUG|IDP-123 Lotion|Investigational Product: IDP-123 Lotion
214509672|NCT02525822|DRUG|Tazorac Cream, 0.1%,|Comparator Product: Tazorac Cream, 0.1%
214509673|NCT02525822|DRUG|Vehicle Cream|Comparator Product: Vehicle Cream
214509674|NCT02525822|DRUG|Vehicle Lotion|Comparator Product: Vehicle Lotion
214509675|NCT04290741|PROCEDURE|Auricular (Battlefield) Acupuncture|Placement of needles based on battlefield acupuncture protocol which includes up to 5 sites on each ear to treat pain.
214509676|NCT04290741|PROCEDURE|Peripheral Acupuncture|Placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
215106897|NCT02251210|DRUG|BIIL 284 BS low dose|
215106898|NCT02251210|DRUG|BIIL 284 BS medium dose|
215106899|NCT02251210|DRUG|BIIL 284 BS high dose|
215106900|NCT02251210|DRUG|Placebo|
215106901|NCT01812265|DRUG|PF-06305591|single Dose
215106902|NCT01812265|DRUG|PF-06305591|single Dose
215106903|NCT01812265|DRUG|Placebo|Single Dose
215106904|NCT00696839|BEHAVIORAL|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
215106905|NCT02793791|PROCEDURE|minimally invasive ablation therapies|Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
215106906|NCT02152319|DEVICE|KHV reporting|Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.
215106907|NCT02152319|PROCEDURE|Standard care|Subjects will receive the same disease management as if they were not participating in this study.
215106908|NCT05564585|OTHER|Kinesio Taping|Kinesio tape was applied over the calf muscle of either leg.
215106909|NCT05564585|OTHER|Sham Taping|The sham tape was applied over the calf muscle of either leg.
215106910|NCT00500825|PROCEDURE|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
215106911|NCT05942547|DRUG|Diosmin|diosmin 600mg twice daily
215106912|NCT05942547|DRUG|Placebo|twice daily
215106913|NCT02602418|OTHER|Adaptive WM CogMed Training|"12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects."
215106914|NCT02602418|OTHER|Nonadaptive WM CogMed Training|"The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions)."
215106915|NCT03929640|DRUG|Acetaminophen|Acetaminophen 650 mg tablet every 6 hours
215106916|NCT03929640|DRUG|Placebo|Placebo oral tablet every 6 hours
215106917|NCT03929640|DRUG|Ibuprofen|Ibuprofen 600 mg tablet every 6 hours
215106918|NCT01005758|DRUG|cyclophosphamide|
215106919|NCT01005758|DRUG|cytarabine|
215106920|NCT01005758|DRUG|dexamethasone|
215106921|NCT01005758|DRUG|doxorubicin hydrochloride|
215106922|NCT01005758|DRUG|etoposide phosphate|
215106923|NCT01005758|DRUG|hydrocortisone sodium succinate|
215106924|NCT01005758|DRUG|imatinib mesylate|
215106925|NCT01005758|DRUG|mercaptopurine|
215106926|NCT01005758|DRUG|methotrexate|
215106927|NCT01005758|DRUG|methylprednisolone|
215106928|NCT01005758|DRUG|pegaspargase|
215106929|NCT01005758|DRUG|prednisolone|
215106930|NCT01005758|DRUG|prednisone|
215106931|NCT01005758|DRUG|vincristine sulfate|
215106932|NCT01005758|OTHER|laboratory biomarker analysis|
215106933|NCT01005758|RADIATION|radiation therapy|
215106934|NCT03940391|DRUG|Chlorpheniramine and midazolam|Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.
215106935|NCT03940391|DRUG|Midazolam|Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.
215106936|NCT03261791|DRUG|Apatinib|Apatinib mesylate tablets 500 mg po qd.
215106937|NCT01922791|DIETARY_SUPPLEMENT|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
215106938|NCT04584957|DEVICE|VAC therapy|Prophylactic ciNPWT therapy (Prevena® KCI) entails placement of the device over a closed incision immediately post-operatively. Prevena® KCI may be left in place with no additional intervention for up to 7 days.
215106939|NCT03640221|DRUG|Ertugliflozin|The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
215106940|NCT03640221|DRUG|Hydrochlorothiazide 12.5mg|comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
215106941|NCT03640221|DEVICE|Microneurography|"Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are \<10% and \< 5%, respectively."
215106942|NCT03640221|OTHER|SKNA recordings|SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
215106943|NCT03640221|OTHER|Static Handgrip|Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
215106944|NCT03640221|OTHER|Post-handgrip forearm vascular occlusion|This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
215106945|NCT03640221|OTHER|Testing of the Arterial Baroreflex Function|We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
215106946|NCT04899453|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
215106947|NCT04899453|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
215106948|NCT04899453|DRUG|Zanubrutinib|160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
215106949|NCT06131138|OTHER|Aquatic exercises|This include aquatic exercises thrice as week for 6 weeks.
215106950|NCT06131138|OTHER|Core strengthening|This include core strengthening exercises thrice a week for 6 weeks
215106951|NCT02106403|OTHER|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
215106952|NCT02106403|OTHER|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
215106953|NCT02106403|OTHER|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
215106954|NCT04146935|DRUG|Burosumab Injection [Crysvita]|Burosumab/Crysvita SC injection monthly
215106955|NCT05189028|DRUG|gemcitabine and cisplatin|Neoadjuvant chemotherapy:gemcitabine and cisplatin
215106956|NCT02683863|DRUG|BG00012 (DMF) (Tecfidera®.)|Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
215106957|NCT05642299|DEVICE|MBCI-SR|Participants will be asked to wear and EEG+NIRS cap and a soft robotic glove on their stroke-impaired hand. The participant will be instructed to ask to imagine to picture moving the stroke-imparied hand in the mind. The brain signal (EEG and NIRS data) will be recorded as a reference. When the participant pictures this move again, upon detection of such imagined move by MBCI-SR system, the glove will be activated and assists the participants to perform a specific upper limb task based on individual ability. There are six different activities of daily living (ADL)-oriented tasks enacted through a virtual arm and virtual objects, which formed the visual feedback for the participants. These tasks include scanning goods, moving an object upward to a cabinet, using two hands to move a towel, pouring of water into a cup, eating action and fine motor movement of picking up a small block using two fingers. Training intensity is 1.5 hours for 3 times a week for 6 weeks, a total of 18 sessions.
215106958|NCT01303601|DRUG|olanzapine|"Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks"
215106959|NCT01303601|DRUG|Starch|
215106960|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on DLPFC|Repetitive trans-magnetic stimulation (rTMS) on DLPFC
215106961|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on OFC|Repetitive trans-magnetic stimulation (rTMS) on OFC
215106962|NCT03207633|PROCEDURE|Sham repetitive trans-magnetic stimulation (rTMS)|Sham repetitive trans-magnetic stimulation (rTMS)
215106963|NCT06332105|DIETARY_SUPPLEMENT|Glytactin|Glycomacropeptide based protein substitute for dietary treatment of PKU
215106964|NCT06332105|DIETARY_SUPPLEMENT|L-AA|Amino acid based protein substitute for dietary treatment of PKU
215106965|NCT03653728|DEVICE|Near infrared spectroscopy|"All patients would be receiving the same treatment including application of non-invasive monitoring with near-infrared spectroscopy (NIRS) together with the standard of care with interval CT Brain scan for all patients.~Non-invasive monitoring with near-infrared spectroscopy (NIRS) is very safe and is in current daily routine clinical use for intraoperative patients."
215106966|NCT04038567|BEHAVIORAL|Mobile mindfulness-based training|The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
215106967|NCT05846555|PROCEDURE|urologic surgery|surgery
214509677|NCT05077475|DRUG|C52R1H Tab. and C52R2 Tab.|Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
215106968|NCT01822392|BEHAVIORAL|Online Parent Management Training (Interactive)|
215106969|NCT01822392|BEHAVIORAL|Online Parent Management Training (Recorded)|
215106970|NCT03828851|OTHER|Domiciliary care - Activities of Daily Living|Home-based ADL training.
215106971|NCT03533244|DRUG|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
215106972|NCT03533244|DRUG|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
215106973|NCT03533244|DRUG|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
215106974|NCT04917913|DIETARY_SUPPLEMENT|Digestive enzyme blend|Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.
215106975|NCT04917913|DIETARY_SUPPLEMENT|Placebo|Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
215106976|NCT03799276|OTHER|Opticare study|"Each patient will be evaluated by~* An HIV physician~* A nurse~* A social worker~* A psychological therapist~* A cultural mediator/member of patients community if needed for migrants~Following these interviews and visits, a multisciplinary team will define for each patient an individualized OPTICARE program based on the following items: clinical, psychological/psychiatric, social status and follow up visits will be planned with the patient.~Regular (Day 15 and monthly) phone calls will be set up during the first six months of the OPTICARE program, to assess the clinical status and ART adherence.~Patients will have their medical, biological and social status assessed through visits at W4, W12, W24, W36 (medical and social status only) and W 48 with all members of the OPTICARE team."
215106977|NCT00473538|BEHAVIORAL|Structured exercise training|
215106978|NCT00473538|BEHAVIORAL|Hypocaloric hyperproteic diet|
214509678|NCT05077475|DRUG|AJU-C52L|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
214509679|NCT05611385|OTHER|Difference in development of Acute Lung Injury in Amphetamine positive and negative patients|No Intervention
215106979|NCT00995995|DRUG|Rosiglitazone|Rosiglitazone
215106980|NCT01496846|DRUG|IANB Articaine|IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.
215106981|NCT01496846|DRUG|SUP Articaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
215106982|NCT01496846|DRUG|SUP Lidocaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
215106983|NCT05196685|DIAGNOSTIC_TEST|Carotid Doppler USG|All Doppler ultrasonography measurements will be made in a dimly lit room at room temperature, with the patient in the supine position, the head slightly hyperextended, the patient looking to the left when measuring the right side, and the patient looking to the right when measuring the left side. In all patients, common carotid artery (CCA), internal carotid artery (ICA) and vertebral artery (VA) gray scale and color Doppler ultrasonography wşll be performed using the GE 9L Linear Probe. Color Doppler examination will be performed with a frequency of 4.0/8.0 MHz.
215106984|NCT02128880|BEHAVIORAL|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
215106985|NCT02128880|BEHAVIORAL|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
215106986|NCT01881568|DRUG|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
215106987|NCT01881568|DRUG|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
215106988|NCT00488696|DEVICE|Endovascular Bifurcated Stent-Graft|Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
215106989|NCT00612196|DRUG|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
215106990|NCT00612196|DRUG|Placebo|
214424414|NCT05220215|OTHER|Nordic Hamstring Exercise|To perform Nordic Hamstring Exercise, the subject was in kneeling position on the mat, arms by the side or in front of the chest, knee in 90-degree flexion and ankles well stabilized with the help of a therapist which is positioned behind the subject. Then subject was asked to lean forward by using the hamstring muscles by extending while trying to resist the forward fall, he should lean forward from the knee and not from the hip. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and them repeat the procedure again.
214424415|NCT05220215|OTHER|Hamstring Curl with Resistance band|"Traditional Hamstring Curl by using Resistance band.~Resistance Band: Thera-band Green, 4.6 kg resistance at 100% elongation"
214424416|NCT03809299|OTHER|Ad libitum meal timing|Research participants will eat meals provided by the study throughout the day, ad libitum
214424417|NCT03809299|OTHER|Twice a day meals|Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
214424418|NCT00922675|PROCEDURE|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
214424419|NCT00922675|PROCEDURE|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
214424420|NCT04133974|BEHAVIORAL|methadone induced memory retrieval-extinction procedure|Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
214424421|NCT03855709|DIAGNOSTIC_TEST|microbiological culture and sensetivity|microbioloical culture will be used to detect microbiological profile in hepatic patients with infections, drug sensitivity to detect resistent bacteria which will be confirmed using PCR detection of resistent gene
214424422|NCT06208696|OTHER|"Tomando control de su salud (Spanish Chronic Disease Self-Management)"|"Tomando control de su salud (Spanish Chronic Disease Self-Management) is a culturally appropriate program developed in Spanish to support Hispanics patients to build confidence in their ability to manage their health. This intervention was developed by Lorig et al. at Stanford University and has been widely used by the Puerto Rico Department of Health since it is recommended by the CDC as an evidenced-based intervention for chronic disease management."
214509680|NCT02590094|DRUG|Intravitreal bevacizumab or intravitreal ziv-aflibercept|Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
214509681|NCT01567007|BEHAVIORAL|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
214509682|NCT01567007|BEHAVIORAL|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
214509683|NCT01567007|BEHAVIORAL|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
214509684|NCT00258115|DRUG|salsalate|
214509685|NCT04377542|PROCEDURE|LIFT|Ligation of the fistula tract in the intersphincteric plane
214509686|NCT04377542|PROCEDURE|Parks|Modified Parks fistulotomy with complete internal anal sphincterotomy
214509687|NCT04377542|PROCEDURE|Seton|Excision of the superficial part of fistula tract and tying loose seton around the remaining part and anal sphincter muscles
214509688|NCT00786188|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
214509689|NCT00786188|DRUG|Sugar pill|Subjects will receive a sugar pill.
214509690|NCT00655785|BIOLOGICAL|VEGFR1-1084, VEGFR2-169|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
215106991|NCT05290116|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD."
215106992|NCT05138315|DEVICE|Metamorphopsia quantification|Alleye App and M.chart examinations will be performed pre- and postsurgically.
215106993|NCT04590716|OTHER|Data Collection|This is a non-interventional study conducted on the participant's smartphones to record MG related symptoms and conditions.
215106994|NCT04429724|DIAGNOSTIC_TEST|Diagnostic test Covid-19|Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
215106995|NCT02452450|DRUG|Ibuprofen Acid|
215106996|NCT02452450|DRUG|Ibuprofen Lysine|
215106997|NCT02452450|DRUG|Ibuprofen Sodium|
215106998|NCT02452450|DRUG|Ibuprofen Liquid Capsules|
215106999|NCT02452450|DRUG|Paracetamol|
215107000|NCT01772576|DEVICE|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
215107001|NCT02024724|DRUG|Bupivacaine|4 mL of 0.25% bupivacaine
215107002|NCT02024724|DRUG|Triamcinolone|40 mg of Triamcinolone
215107003|NCT02024724|DRUG|Dexamethasone|4 mg of Dexamethasone
215107004|NCT04955327|DRUG|A. Paniculata|Extract from A. Paniculata
215107005|NCT04955327|DRUG|A. Chilensis|Extract from A. Chilensis
215107006|NCT04955327|DRUG|A. Paniculata and A. Chilensis|Combination of A. Paniculata and A. Chilensis
215107007|NCT04955327|DRUG|Microcrystalline cellulose|Placebo comparator
215107008|NCT04854382|BEHAVIORAL|Tailored information|Tailored information about coronavirus for patients with chronic kidney disease by information videos followed by a teach back procedure
215107009|NCT00923845|DRUG|Pentostatin|Pentostatin: 2- 4mg/m\^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
215107010|NCT00923845|DRUG|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
215107011|NCT00923845|DRUG|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
215107012|NCT00923845|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
215107013|NCT00923845|PROCEDURE|Th2 rapa cells|Th2 rapa cell Transplantation
215107014|NCT00923845|PROCEDURE|Donor Lymphocyte Harvest|Apheresis
215107015|NCT00923845|PROCEDURE|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
215107016|NCT00923845|PROCEDURE|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
215107017|NCT00923845|PROCEDURE|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
215107018|NCT04077515|DRUG|Sirolimus(0.8mg/m2)|The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
215107019|NCT04077515|DRUG|Sirolimus(0.7mg/m2)|The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
214509691|NCT00655785|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
214509692|NCT01436214|DRUG|APC-100|Daily oral, dose escalation, 28-day cycle(s)
215107020|NCT05930184|PROCEDURE|peri-wound Transversus Abdominis Plane Block|0.25% bupivacaine 20ml was injected using no24 needle into a plane between internal oblique muscle and transversus abdominis muscle around every wound 2 cm. from wound opening. The procedure was confirmed by laparoscopic vision and the injection was done before removal of laparoscopic port.
214509693|NCT00336882|DRUG|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
214509694|NCT00336882|DRUG|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
215107021|NCT05930184|PROCEDURE|Local wound infiltration|0.25% bupivacaine 20ml was injected using no24 needle into subcutaneous tissue after the abdominal sheet was sutured.
215107022|NCT06469606|DEVICE|AI tool|"Both the arms will undergo the use of AI tool developed in the group. The tool will be trained to detect outcomes."
215107023|NCT02019875|DRUG|Rifampin|P450 inducer
215107024|NCT02019875|DRUG|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
215107025|NCT02019875|OTHER|Grapefruit Juice|CYP3A4 inhibitor in intestine
215107026|NCT02019875|OTHER|Placebo|
215107027|NCT02945514|OTHER|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
215107028|NCT03405428|OTHER|Allen test|Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.
215107029|NCT03405428|OTHER|Radial artery diameter measurement by ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.
215107030|NCT03405428|OTHER|Ulnar artery doppler ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
215107031|NCT00317096|PROCEDURE|FCM|Active comparator: Chemotherapy
215107032|NCT00317096|PROCEDURE|R-FCM|experimental: Chemotherapy with additional rituximab
215107033|NCT00317096|DRUG|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
215107034|NCT00317096|OTHER|observation only|no Intervention after completion of FCM or R-FCM
215107035|NCT03312426|DRUG|BMS-986205|Single dose, 100 mg administered at Day 1 and at Day 15.
215107036|NCT01651663|DRUG|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
215107037|NCT01651663|OTHER|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
215107038|NCT01651663|DRUG|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
215107039|NCT01651663|OTHER|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
215107040|NCT05998382|BEHAVIORAL|Online group-based parent-mediated intervention program|The program is an online group-based parent-mediated intervention program implemented in 2 sessions of 2 hours once a week for 6 weeks. In the first part of the weekly sessions, the topic of that week is explained to the parents. In the second part, videos recorded by the parents are watched and feedback is given to the parents. At the end of the session, written materials about that week's practices and homework are sent to the parents
215107041|NCT02823379|BEHAVIORAL|Physical Activity|A Smartphone delivered physical activity program
215107042|NCT02823379|BEHAVIORAL|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
214509695|NCT04329585|DRUG|flumazenil|EEG is observed in both groups to compare the difference between two groups.
215107043|NCT01304537|DRUG|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
214509696|NCT04329585|DRUG|Placebos|Placebo is the normal saline, which is given in the controlled group.
214509697|NCT04890626|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]|Main randomization
215107044|NCT01304537|DRUG|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
215107045|NCT01304537|DRUG|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
215107046|NCT05374330|OTHER|Electroacupuncture|Acupuncture needles are inserted into the body at standardized acupuncture points. An electrical current is then applied to 4 needles through 2 channels of electrical current. The sham group receives the same protocol with sham needles and sham electrical current.
215107047|NCT05176834|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
215107048|NCT04356352|DRUG|Lidocaine|1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
215107049|NCT04356352|DRUG|Esmolol|0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
215107050|NCT04356352|OTHER|Placebo|saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
214509698|NCT04890626|DRUG|Baricitinib + dexamethasone|Rescue randomization
214509699|NCT04890626|DRUG|Dexamethasone|Rescue randomization
215107051|NCT03298763|GENETIC|MSCTRAIL|"3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).~After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL."
215107052|NCT03298763|DRUG|Placebo|Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
215107053|NCT03202134|OTHER|opioid free anesthesia|general anesthesia blocking reflexes without using an opioid
215107054|NCT04519697|DRUG|Mesenchymal Stem Cells|Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.
215107055|NCT04519697|OTHER|Placebo|Normal Saline
215107056|NCT03404297|OTHER|Locally sourced compression therapy|The dressing is made up of a zinc oxide impregnated compression wrapping
215107057|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
215107058|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
215107059|NCT01371734|DRUG|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
215107060|NCT02052401|OTHER|Domiciliary Intervention|Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
215107061|NCT02073019|DRUG|BL-8040|
215107062|NCT02073019|DRUG|Placebo|
215107063|NCT03565237|BIOLOGICAL|RIXUBIS: On-Demand|RIXUBIS used under standard clinical practice in India: On-Demand treatment.
215107064|NCT03565237|BIOLOGICAL|RIXUBIS: Prophylaxis|RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
215107065|NCT00245843|BEHAVIORAL|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
215107066|NCT04292314|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
215107067|NCT04292314|DRUG|Nigella Sativa Oil|Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
215107068|NCT04292314|DRUG|Hydroxyurea|hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
215107069|NCT04292314|DRUG|Honey|Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
215107070|NCT04292314|DRUG|Deferoxamine|deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
215107071|NCT04292314|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
215107072|NCT02497690|BEHAVIORAL|Telemedicine|Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
215107073|NCT02497690|BEHAVIORAL|In-person ART|Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
215107074|NCT03534375|OTHER|The study is an observational cross sectional study|An intervention will not be performed
215107075|NCT04831177|PROCEDURE|Laser in situ keratomileusis|Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
215107076|NCT01401608|DEVICE|RF Ablation|Ablation of arrhythmogenic ventricular tissue
215107077|NCT03905850|DRUG|somapacitan|5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)
215107078|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 8 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 8 mmHg
215107079|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 12 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 12 mmHg
215107080|NCT00828750|DRUG|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
215107081|NCT03821610|DRUG|Fludarabine|IV
215107082|NCT03821610|DRUG|Melphalan|IV
215107083|NCT03821610|DRUG|Alemtuzumab|IV
215107084|NCT03821610|DRUG|Cyclophosphamide|IV
215107085|NCT03821610|DRUG|Mesna|IV
215107086|NCT03821610|RADIATION|Total Body Irradiation (8Gy)|TBI (8Gy)
215107087|NCT04006392|DEVICE|Erchonia FX-635|The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.
215107088|NCT04006392|DEVICE|Placebo Laser|Non-therapeutic output.
215107089|NCT01303926|DRUG|cisplatin pemetrexed|Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
215107090|NCT01303926|DRUG|carboplatin paclitaxel bevacizumab|Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
215107091|NCT02816229|DEVICE|Insertion of endobronchial valve|One or more endobronchial one- way valves will be inserted into the appropriate lung regions
215107092|NCT00302913|DRUG|Adjustment of clopidogrel dose|
215107093|NCT04087135|OTHER|direct laryngoscopy|Participants will intubate the hemoptysis cadaver model in simulation with direct laryngoscopy MacIntosh blade.
215107094|NCT04087135|OTHER|videolaryngoscopy McGrath|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade)
214424423|NCT01927952|PROCEDURE|Kirschner wire|Surgical fixation utiliziing Kirschner wire
215107095|NCT04087135|OTHER|videolaryngoscopy McGrath with suction|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade) and a suction they will advanced directly before the optic of the camera.
215107096|NCT03585049|OTHER|Vaginal swabs|The protocol includes the secondary use of vaginal swabs that are primarily used for routine diagnostic assessment in a vulvovaginal clinic
215107097|NCT05282420|PROCEDURE|intravitreal injection of Ranibizumab|intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
215107098|NCT05282420|PROCEDURE|intravitreal injection of Aflipercept|intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
215107099|NCT05282420|DRUG|Ranibizumab|Ranibizumab
215107100|NCT05282420|DRUG|Aflibercept|Aflipercept
215107101|NCT05677009|DEVICE|BUFEO system|In the BUFEO Condition, the subject will receive oxygen through the BUFEO system.
215107102|NCT05677009|OTHER|Standard of Care|Standard Condition is the baseline apparatus utilized by the subject at the time of enrollment in the study. In the hospital setting, the supplemental oxygen delivery may come from compressed oxygen cylinders or liquid oxygen and is often delivered through a port in the facility wall at the bedside.
215107103|NCT00336414|DRUG|cyclophosphamide-prednisone-azathioprine|
215107104|NCT03704714|DRUG|Cyclophosphamide|Given IV
215107105|NCT03704714|DRUG|Doxorubicin Hydrochloride|Given IV
215107106|NCT03704714|BIOLOGICAL|Nivolumab|Given IV
215107107|NCT03704714|DRUG|Prednisone|Given PO
215107108|NCT03704714|OTHER|Quality-of-Life Assessment|Ancillary studies
215107109|NCT03704714|BIOLOGICAL|Rituximab|Given IV
215107110|NCT03704714|DRUG|Vincristine Sulfate|Given IV
215107111|NCT03610373|BEHAVIORAL|Modular Approach to Therapy for Children (MATCH)|MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
215107112|NCT06514833|BEHAVIORAL|lifestyle recommendations to nap regularly|Participants will receive lifestyle recommendations to nap regularly for 15-30 minutes between 12:00 and 15:00
215107113|NCT06514833|OTHER|No recommendations to nap regularly|No lifestyle recommendations to nap regularly
215107114|NCT03057652|DEVICE|ReWalk|"ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
215107115|NCT03057652|DEVICE|EKSO|"EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
215107116|NCT03057652|DEVICE|REX|"REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
215107117|NCT01832532|DRUG|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
215107118|NCT02425514|DEVICE|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
215107119|NCT02425514|DEVICE|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
215107120|NCT05191108|BEHAVIORAL|mindfulness stres reduction programe|Complaints about PMS and sharing information about these complaints, Practice of breathing focused meditation, mplementation of mindful eating exercises,Raising awareness in daily activities,Teaching the body scanning exercise and repeating this practice during the week with the audio recordings given.Ensuring environmental awareness Ensuring that you live by being aware of the moments experienced during the week, 20 minutes of sitting breathing focused sitting meditation Coping with stress Sharing the experiences of the previous week Implementation of mindful vision practices Explaining the relationship between stress and experienced events.Eating exercises Mindful breathing Ensuring environmental awareness Explaining the importance of thinking about the relationship between stress and their reactions and accepting them without judgment, and sharing the experiences at the end of the day of silence.
215107121|NCT02464514|OTHER|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
215107122|NCT02464514|OTHER|High fat meal|58% fat, 17% protein, and 25% carbohydrate
215107123|NCT06506825|DIAGNOSTIC_TEST|Gastric Cancer AI-driven Data Integration Genomic Analysis Biomarker|Enter the clinical and related test, examination and treatment information of all gastric cancer patients, and find risk factors that affect the prognosis
215107124|NCT01534195|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 8 days.
215107125|NCT01534195|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 8 days
215107126|NCT06507826|BEHAVIORAL|Self-Compassionate Writing for Caregivers of Older Adults|Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).
215107127|NCT02628561|DEVICE|Transcranial direct current stimulation|
215107128|NCT02628561|BEHAVIORAL|Constraint-Induced Movement Therapy|
215107129|NCT03813914|DIETARY_SUPPLEMENT|Sineos|glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
215107130|NCT06393023|DEVICE|Continuous Positive Airway Pressure|Although this study is designed as an observational cohort study, where patients were not assigned to intervention or non-intervention groups, there is still an intervention project indicator present in the observational cohort. The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
215107131|NCT06524323|DRUG|5-fluorouracil Injection|The mixture contains 2mL of triamcinolone acetonide injection and 4mL of 5-fluorouracil injection, which is diluted with saline to 10mL.
215107132|NCT06524323|DRUG|Triamcinolone Acetonide|The mixture contains 2mL of triamcinolone acetonide injection which is diluted with saline to 10mL.
215107133|NCT03846284|DRUG|Bupivacaine|caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
215107134|NCT03846284|DRUG|Magnesium sulfate 50mg|caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.
215107135|NCT03846284|DRUG|Magnesium sulfate 30 mg|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~\+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
215107136|NCT06262243|OTHER|electric blankets|"While the patient is in surgery; An electric blanket will be placed under the bed mattress, and the bed will be placed on the electric blanket.~The bed sheet will be laid, and the blanket used in the clinic will be laid on top of the bed sheet.~-The electric blanket will be turned on at hot setting 20 minutes before the patient leaves the surgery. After the mother is placed in a heated bed, the electric blanket will be unplugged when the temperature reaches 36.5."
215107137|NCT01794676|GENETIC|Blood draw|Blood draw
215107138|NCT02564224|PROCEDURE|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
215107139|NCT02564224|PROCEDURE|Conventional Wound Closure|Procedure: Conventional Wound Closure
215107140|NCT02564224|DEVICE|prolene|
215107141|NCT03764683|DRUG|Suvorexant (Belsomra)|Suvorexant (Belsomra) is approved by the U.S. Food and Drug Administration (FDA) to treat insomnia. It has not yet been studied in people with bipolar disorder who have problems sleeping.
215107142|NCT03764683|DRUG|Placebo|Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
215107143|NCT01802190|GENETIC|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
215107144|NCT00308971|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 4 months
215107145|NCT00308971|DRUG|alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 4 months
215107146|NCT00308971|DRUG|placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
215107147|NCT00308971|DRUG|placebo|placebo for alpha lipoic acid; 2 pills daily for 4 months
215107148|NCT03441230|DEVICE|Balloon characteristics|Different size balloon
215107149|NCT05809362|DEVICE|WHOOP 4.0 Strap|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
215107150|NCT05809362|DEVICE|BioTel ePatch|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
215107151|NCT02253784|DRUG|Dexamethasone|
215107152|NCT02253784|DRUG|Bupivacaine|
215107153|NCT02027948|OTHER|nutritional and functional assessments|"Patients will undergo nutritional \& functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, \& baseline weight loss. Patients will receive chemotherapy \& radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) \& radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, \& post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, \& Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished \& receive the appropriate intervention."
215107154|NCT00486668|DRUG|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
215107155|NCT00486668|DRUG|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
215107156|NCT00486668|DRUG|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
215107157|NCT00486668|DRUG|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
215107158|NCT00486668|DRUG|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
215107159|NCT03075709|OTHER|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
215107160|NCT03455816|DEVICE|Social Diabetes App|"Social diabetes is an app for diabetes, free with CE mark, that by means of the incorporation of a glucometer (glucomen Areo) allows through NFC technology the automatic introduction of data in the application"
215107161|NCT03455816|DEVICE|Usual clinical monitoring group (Control group)|Active Comparator: Usual clinical monitoring group (control group) This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
214424424|NCT01927952|PROCEDURE|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
215107162|NCT03012867|OTHER|Diben, Fresenius Kabi|Patients receive Diben continously for 7 days
214424425|NCT01927952|PROCEDURE|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
215107163|NCT03012867|OTHER|Fresubin original fibre, Fresenius Kabi|Patients receive Fresubin original fibre continously for 7 days
215107164|NCT02391519|PROCEDURE|Collection of myometrial, cord blood, and placental tissue samples|We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
215107165|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
215107166|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
215107167|NCT03851432|DEVICE|Placebo plus metformin|Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
215107168|NCT04382222|PROCEDURE|prenatal ultrasound|prenatal cardiac ultrasound
214509700|NCT03742622|BEHAVIORAL|CON . control condition without exercise / rest condition|CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214509701|NCT03742622|BEHAVIORAL|EX. Condition with an acute exercise set in the middle of the morning|EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals
214509702|NCT03742622|BEHAVIORAL|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
214509703|NCT05116098|COMBINATION_PRODUCT|zinc 50 mg + Epigallocatechin gallate|ZINC 50 MG and EGCG 200mg oral daily for 1 month
214509704|NCT02279732|BIOLOGICAL|Paclitaxel|
214509705|NCT02279732|BIOLOGICAL|Carboplatin|
214509706|NCT02279732|BIOLOGICAL|Ipilimumab|
215107169|NCT06371521|DIETARY_SUPPLEMENT|Sportlegs|Sportlegs contains lactate (from calcium lactate pentahydrate and magnesium lactate dihydrate), magnesium (from magnesium lactate dihydrate), calcium (from calcium lactate pentahydrate), and vitamin D (as cholecalciferol).
215107170|NCT06371521|DIETARY_SUPPLEMENT|Placebo|Empty Capsules to serve as a placebo control
215107171|NCT01368081|DRUG|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
215107172|NCT01368081|DRUG|BI 10773|BI 10773 low dose tablet once daily
215107173|NCT01368081|DRUG|Placebo (low dose)|Placebo tablets once daily
215107174|NCT01368081|DRUG|BI 10773|BI 10773 high dose tablet once daily
215107175|NCT01368081|DRUG|Placebo (high dose)|Placebo tablets once daily
215107176|NCT04429698|DIAGNOSTIC_TEST|Point of care ultrasonography|Point-of-care Ultrasonography is an imaging method performed with ultrasound aid to facilitate rapid diagnosis and interventions during emergency intervention.
215107177|NCT05708339|OTHER|virtually fabricated ear prosthesis|virtually designed ear prosthesis
214509707|NCT02279732|OTHER|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
214509708|NCT05966480|DRUG|ESK-001|Oral tablet
214509709|NCT05966480|DRUG|Placebo|Oral tablet
214509710|NCT03230981|DEVICE|Optical imaging of the cornea in healthy subjects|OCT vibrography and Brillouin microscopy
214509711|NCT01578629|OTHER|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
214509712|NCT01578629|OTHER|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
214509713|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
214509714|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
214509715|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
215107178|NCT05708339|OTHER|conventionally fabricated ear prosthesis|conventionally fabricated ear prosthesis
215107179|NCT03731247|DEVICE|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
215107180|NCT03731247|DEVICE|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
215107181|NCT03368846|DRUG|Varlitinib|\[14C\]-Varlitinib
214509716|NCT01537497|DRUG|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
214509717|NCT05167318|OTHER|frequent standardized oral care|Standardized oral care will be provided every 3-4 hours
214509718|NCT00002840|DRUG|lomustine|
214509719|NCT00002840|DRUG|procarbazine hydrochloride|
215107182|NCT00714311|BEHAVIORAL|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
215107183|NCT00714311|BEHAVIORAL|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
215107184|NCT01533142|PROCEDURE|Bariatric surgery|"Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass"
215107185|NCT01533142|PROCEDURE|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
215107186|NCT00820716|OTHER|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
215107187|NCT06049030|DRUG|HS-10516|Oral HIF-2α inhibitor
215107188|NCT03803436|PROCEDURE|Liver transplant|Liver transplant from cadaveric donors
215107189|NCT03803436|DRUG|Chemotherapy|mFOLFOX
215107190|NCT03803436|DRUG|Chemotherapy|Panitumumab
215107191|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound in В-mode|A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.
215107192|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound examination using three-dimensional image reconstruction.|A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
215107193|NCT02259894|DRUG|BIRT 2584 XX|
215107194|NCT02259894|DRUG|Placebo|
215107195|NCT06180707|DRUG|pregabalin gel|10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
215107196|NCT06180707|DRUG|gel with 5% potassium nitrate and 2% sodium fluoride|gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
215107197|NCT06180707|OTHER|Placebo gel|placebo gel (carbopol-based gel 1%) for topical application to teeth before bleaching with hydrogen peroxide
215107198|NCT02071069|DRUG|Cetuximab|400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
215107199|NCT02071069|DRUG|irinotecan|180 mg/m2 IV every 2 weeks
215107200|NCT02071069|DRUG|fluorouracil|400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
215107204|NCT01940627|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
215107205|NCT01940627|DIETARY_SUPPLEMENT|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
215107206|NCT05367323|DEVICE|Pressure algometry (Baseline 2.2-Pound Dolorimeter) and Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|Both instruments are used for the assessment of the L4-5 interspinous space pain pressure threshold and the biomechanical-viscoelastic properties of L4-5 supraspinous ligament respectively
215107207|NCT02146625|DRUG|CJ-40002|
215107208|NCT00208351|DEVICE|Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.
215107209|NCT00208351|DEVICE|Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
215107210|NCT00208351|DEVICE|Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
215107211|NCT00208351|DEVICE|Ultima LX Collarless Stem - Polished finished|A collarless polished finished cementless femoral component for use in total hip replacement.
215107212|NCT02215824|DRUG|BIWH 3|
215107213|NCT02215824|DRUG|Placebo|
215107214|NCT01778101|DRUG|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
215107215|NCT01736618|DEVICE|S-ICD System|
215107216|NCT02634827|DRUG|Decitabine|Given IV
215107217|NCT02634827|OTHER|Laboratory Biomarker Analysis|Correlative studies
215107218|NCT02634827|DRUG|Midostaurin|Given PO
215107219|NCT04046731|DIAGNOSTIC_TEST|Skin Testing|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
215107220|NCT03291860|PROCEDURE|Ovum retrievum|assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles
215107221|NCT00252616|BEHAVIORAL|trophic enteral feeds|10cc/hr
215107222|NCT05922241|OTHER|Costophrenic assisted cough|Therapist places the hands on the costophrenic angles of the patient's rib cage. During the patient's inspiration, the therapist applies a series of three repeated quick-stretch contractions down and in to encourage maximal inspiration. At the end of expiration, the therapist applies a quick stretch down and in on the patient's lower chest to facilitate a stronger diaphragmatic and intercostal muscle contraction. While instructing the patient to cough, the therapist applies strong pressure through the hands in toward the central tendon of the patient's diaphragm
215107223|NCT05922241|OTHER|Anterior chest compression|The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process
215107224|NCT00819117|DEVICE|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
215107225|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fasted|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
214509720|NCT00002840|DRUG|vincristine sulfate|
215107226|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fed|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
215107227|NCT03637517|DRUG|DSM265 25% SDD, 400 mg fasted|Reference formulation used in early clinical trials.
215107228|NCT03409341|OTHER|Blood and tumor tissue analysis, Clinical response.|DNA sequencing and functional testing of peripheral blood mononuclear cells. DNA and RNA sequencing and immune cell analysis of tumor. Clinical response at 12 months.
215107229|NCT03975569|OTHER|Probiotic vaginal gel|Total daily administration of 2.5 ml of probiotic gel, containing three lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus pentosus KCA1 and Lactobacillus plantarum WCFS1). Final dosage per gram of gel: 10\^9-10\^10 colony forming units of lactobacilli.
215107230|NCT00400569|DRUG|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
215107231|NCT06152549|BEHAVIORAL|Maltreatment and Abuse Chronology of Exposure Scale as a stress challenge|The first group (N=250) will receive the Maltreatment and Abuse Chronology of Exposure (MACE) scale first, to assess early life adversity, followed by the standardized test questions. A POMS will be administered before each challenge.
215107232|NCT06152549|BEHAVIORAL|Standardized Maths and Verbal Questions such as the ones used in SATs|The second group (N=250) will be presented with the standardized test questions (Math/Verbal) to assess their stress level, measured through POMS, followed by the Maltreatment and Abuse Chronology of Exposure (MACE) scale.
215107233|NCT06152549|BEHAVIORAL|Chronology of Perceived Discrimination Scale (CPDS)|The group will also receive the Chronology of Perceived Discrimination Scale (CPDS) to assess type and timing of perceived discrimination during the first 18 years of life. A POMS will be administered before and after the intervention/challenge.
215107234|NCT06152549|BEHAVIORAL|International Personality Item Pool (IPIP-NEO)|Participants in both groups will be presented with the abbreviated version of the IPIP-NEO a personality questionnaire that provides ratings on the Five Factor Personality Model. The research team sees this task as non-stressful and even potentially soothing and envisions that it will help to restore an individual's mood before taking the next stressful test and again at the completion of the online session.
215107235|NCT03028779|PROCEDURE|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
215107236|NCT02474953|DIETARY_SUPPLEMENT|Proprietary Curcumin Formulation|
215107237|NCT02474953|DIETARY_SUPPLEMENT|Unformulated Comparator Curcumin Product|
215107238|NCT02919527|OTHER|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
215107239|NCT02919527|OTHER|Stretching|Static Stretching performed at the anterior thigh
215107240|NCT05002179|DRUG|Echinaforce Chewable tablets|"Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution."
215107241|NCT02113358|DRUG|Intravenous colloid bolus with Voluven|
215107242|NCT02714283|DRUG|inhaled corticosteroid therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
215107243|NCT02714283|DRUG|macrolide therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
214509721|NCT00002840|RADIATION|radiation therapy|
214509722|NCT04711200|DRUG|Adipose derived stromal cells intravenously injected|2×10\^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).
214509723|NCT06580275|DEVICE|CLAAS|All eligible subjects will have an LAA closure attempt using the CLAAS device guided by ICE technology.
214509724|NCT02970318|DRUG|Acalabrutinib (ACP-196)|Acalabrutinib monotherapy
215107244|NCT05192655|OTHER|Observation|Observation Study
215107245|NCT02790424|DEVICE|Imaging devices|technological adjustment tests
215107246|NCT03408964|OTHER|biological samples collection and analysis|Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
215107247|NCT00264264|PROCEDURE|Closure Device|
215107248|NCT00264264|PROCEDURE|Direct Compression|
215107249|NCT00006158|DRUG|Testosterone|
215107250|NCT01072253|PROCEDURE|eye amputation|
215107251|NCT02171741|DRUG|BIBW 2992|continuous daily dosing for 20 or 13 days
215107252|NCT02171741|DRUG|Docetaxel|single infusion on day 1
215107253|NCT05586841|DRUG|Dalpiciclib|Dalpiciclib: 100 mg/d or 125 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
215107254|NCT05586841|DRUG|Chidamide|Chidamide: 25 mg/BIW or 20 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
215107255|NCT00620113|DRUG|Odanacatib|Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.
215107256|NCT00620113|DIETARY_SUPPLEMENT|Vitamin D3|Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.
215107257|NCT00620113|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.
215107258|NCT00620113|DRUG|Placebo|Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
215107259|NCT05906355|DEVICE|the wearable filtrating artificial Kidney Device|the wearable filtrating artificial kidney device rapidly for rapid relief of fluid overload in patients
215107260|NCT05906355|DEVICE|traditional hemodialysis machine|the hemodialysis machine currently used in clinical practice to reduce fluid overload in patients
214509725|NCT02970318|DRUG|Rituximab|Rituximab in combination with idelalisib or bendamustine
214509726|NCT02970318|DRUG|Idelalisib|Idelalisib in combination with rituximab
214509727|NCT02970318|DRUG|Bendamustine|Bendamustine in combination with rituximab
214509728|NCT05498155|DRUG|Neoadjuvant Olaparib monotherapy group|Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.
214509729|NCT05498155|COMBINATION_PRODUCT|Neoadjuvant combination therapy with olaparib plus durvalumab|Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.
215107261|NCT02929940|OTHER|No intervention|No Intervention, observational
215107262|NCT02065505|OTHER|Mat Pilates|
215107263|NCT02065505|OTHER|Water Pilates|
215107264|NCT02973516|DRUG|P03277 at 0.1 mmol/kg|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
215107265|NCT02973516|DRUG|P03277 at 0.05 mmol/kg|P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
215107266|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
215107267|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
215107268|NCT02268994|DRUG|ferric citrate|1 g ferric citrate containing approximately 210 mg of ferric iron
215107269|NCT02268994|DRUG|Placebo|Matching placebo
215107270|NCT03968263|DEVICE|Hycon device(Routine protocol)|Hycon device will be activated half a turn every 3 days.
215107271|NCT03968263|DEVICE|Hycon device(Modified protocol)|The activation period of the hycon device will be modified.
215107272|NCT03968263|DEVICE|Hycon device(Routine protocol) and Vibration(Acceledent)|Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
215107273|NCT03968263|DEVICE|Hycon device(Modified protocol) and Vibration(Acceledent)|The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
215107274|NCT00211887|DRUG|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
215107275|NCT00211887|DRUG|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
215107276|NCT00211887|OTHER|placebo|an inactive substance
215107277|NCT05526339|DEVICE|High-flow nasal oxygenation combined with nasopharyngeal airway|The patients receive an oxygen flow of 30 L/min for preoxygenation with a high-flow oxygenation device before losing of conscious. At the time of the abolition of the eyelash reflex, the gas flow was increased to 60 L/min with an inspired oxygen fraction 100% and the nasopharyngeal airway was placed.
215107278|NCT05526339|DEVICE|Regular nasal cannula combined with nasopharyngeal airway|The patients receive an oxygen flow of 6 L/min for preoxygenation with a regular nasal cannula until the end of procedure. At the time of abolition of the eyelash reflex, the nasopharyngeal airway was placed.
215107279|NCT00679874|OTHER|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
215107280|NCT06071481|DRUG|Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution|2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol
215107281|NCT00541853|DRUG|Candesartan|Candesartan upto 8mg
215107282|NCT00541853|DRUG|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
215107283|NCT00541853|DRUG|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
215107284|NCT00005030|DRUG|SCH 66336|
215107285|NCT00005030|PROCEDURE|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
215107286|NCT05784519|DRUG|MSCs eye drops|MSCs were used to prepare single-cell suspension, and 0.9% sodium chloride was added to balance PH value to prepare the effective, safe and stable eye drops. Giving the patient with 5×10\^5 /50μl in each eye, twice a day for 2 weeks.
215107287|NCT03438136|BEHAVIORAL|Adult Broad Learning Experiment (ABLE)|"This intervention implements six factors from early childhood experiences: individualized scaffolding (having a responsive teacher), forgiving environment (allowing the learner to make and learn from mistakes), growth mindset (believing that abilities can develop with effort), open-minded learning (exploring new experiences), serious commitment to learning (adopting a learning lifestyle), and learning multiple skills simultaneously."
215107288|NCT04594928|DRUG|GLPG3667|GLPG3667 capsules
215107289|NCT04594928|DRUG|Placebo|Matching placebo capsules
215107290|NCT02078128|DIETARY_SUPPLEMENT|oral beta-glucans|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
215107291|NCT02078128|DRUG|oral sugar powder|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
215107292|NCT01106235|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
215107293|NCT01106235|BIOLOGICAL|aldesleukin|Given SC
215107294|NCT01106235|DRUG|cyclophosphamide|Given IV
215107295|NCT01106235|PROCEDURE|biopsy|Optional correlative studies
215107296|NCT01979133|DRUG|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
215107297|NCT00486824|DRUG|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
215107298|NCT00486824|DRUG|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
215107299|NCT00285402|DRUG|AST-726 Low dose|
215107300|NCT00285402|DRUG|AST-726 High dose|
215107301|NCT00285402|DRUG|AST-726 Placebo|
215107302|NCT04534270|DRUG|Dapagliflozin|Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks
215107303|NCT02650102|DRUG|Risperidone|a kind of antipsychotics
215107304|NCT02650102|DRUG|Olanzapine|a kind of antipsychotics
215107305|NCT02650102|DRUG|Quetiapine|a kind of antipsychotics
215107306|NCT02650102|DRUG|Aripiprazole|a kind of antipsychotics
215107307|NCT02650102|DRUG|Ziprasidone|a kind of antipsychotics
215107308|NCT00595010|BEHAVIORAL|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
215107309|NCT01893775|BIOLOGICAL|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
215107310|NCT00284362|PROCEDURE|Arthroscopic or open surgery for hallux rigidus|
215107311|NCT00715767|BEHAVIORAL|Assessment|"Cognitive Assessment:~Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:~Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).~Survey Instrument for Barriers to Acute Medicine Education:~A survey tool will be used to identify barriers to acute medicine education implementation and efficacy."
214509730|NCT00221559|PROCEDURE|Blood sampling for determination of serum Zn|
214509731|NCT02563119|PROCEDURE|Gastric Bypass or Sleeve gastrectomy|
214509732|NCT00982917|BEHAVIORAL|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
214509733|NCT00982917|BEHAVIORAL|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
215107312|NCT00980759|RADIATION|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
215107313|NCT00980759|RADIATION|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
215107314|NCT04241263|DEVICE|Wireless vital sign monitoring - comparative|Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.
215107315|NCT04241263|DEVICE|Wireless vital sign monitoring - usability|Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
215107316|NCT02036866|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.
215107317|NCT02036866|OTHER|Physical Therapy Exercises|Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.
215107318|NCT02036866|OTHER|No Intervention|Patients will be instructed to maintain their usual activity level.
215107319|NCT00913926|DRUG|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
215107320|NCT04316026|DEVICE|shock wave therapy|Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium
215107321|NCT04085913|DRUG|Lidocaine Epinephrine|Preincision injection, as is current practice
215107322|NCT04085913|DRUG|Bupivacaine Hydrochloride-EPINEPHrine|Preincision injection
215107323|NCT04085913|DRUG|Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine|Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
215107324|NCT04866901|BEHAVIORAL|Slow-Paced Breathing (SPB)|see arm description
215107325|NCT04866901|BEHAVIORAL|Mindfulness (M)|see arm description
215107326|NCT04866901|BEHAVIORAL|Yogic Breathing (SPB+M)|see arm description
215107327|NCT01467830|PROCEDURE|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
214509734|NCT01658241|DRUG|panobinostat|40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
215028311|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) ."
215028312|NCT06558773|DRUG|Regorafenib+Immune checkpoint inhibitor|"Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
214424426|NCT03985150|OTHER|Biomechanical analysis of femoralis superficialis atherosclerotic tissue|Tissue collection during above-knee amputation; mechanical testing of tissue; microstructural testing of tissue
214424427|NCT03985150|RADIATION|CT or MR angiogram|Obtaining in vivo geometry of diseased artery
214424428|NCT05356819|DEVICE|Smart Capnography™, Microstream®|patients monitored by capnograph
214424429|NCT00762619|DRUG|Fluoride|Brush twice daily
214424430|NCT00762619|DRUG|Triclosan, fluoride|Brush twice daily
214424431|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
215028313|NCT02016521|OTHER|Cooling Fabric|Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.
215028314|NCT02016521|OTHER|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser
215028315|NCT01657981|DRUG|YM150|14C-labeled YM150, oral solution
215028316|NCT04767321|DRUG|LTX-109 gel, 3% w/w|LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
215107328|NCT01012778|BEHAVIORAL|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
215107329|NCT03521245|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
215107330|NCT03521245|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
215107331|NCT03521245|DRUG|Trastuzumab|Standard Trastuzumab treatment regimen recommended for breast cancer
215107332|NCT03521245|DRUG|Chemotherapy|Standard chemotherapy regimen recommended for breast cancer
215107333|NCT01072994|DIETARY_SUPPLEMENT|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
215107334|NCT05293158|DRUG|Hepatect CP 50 I.E./ml infusion solution|"Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection."
215107335|NCT05340790|DRUG|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
215107336|NCT05340790|DRUG|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
215107337|NCT04546542|OTHER|Parallel Assignment|We will evaluate 75 patients with pSS (Consenso Americano-europeu de 2002 / EULAR/ACR Classification Criteria, 2016) of both sexes at baseline and 6-months
215107338|NCT01447953|OTHER|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
215107339|NCT01447953|OTHER|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
215107340|NCT00968877|DRUG|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
215107341|NCT04560153|OTHER|karate kata|sessions of karate kata every week during 4 months
215107342|NCT02990676|BEHAVIORAL|Computerised cognitive training|Computerised cognitive training regime
215107343|NCT02955342|OTHER|no intervention|no intervention
215107344|NCT02922426|DRUG|ALKS 3831|Daily dosing for 21 consecutive days
215107345|NCT02922426|DRUG|Olanzapine|Daily dosing for 21 consecutive days
215107346|NCT02922426|DRUG|Placebo|Daily dosing for 21 consecutive days
215107347|NCT06445816|DRUG|chemotherapy|"* Parents whose consent was obtained will be asked to fill out the Mother and Child Information Collection Form and Psychological Resilience Scale, respectively.~* Immediately after receiving chemotherapy, the pain levels of the children will be measured with the Facial Expressions Pain Scale - Faces Pain Scale-Revised (FPS-R).~* The psychological resilience scale will be applied to mothers."
215107348|NCT02536222|OTHER|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
215107349|NCT00305630|DRUG|Periocular injection of triamcinolone acetonide 40mg|
214424432|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
214424433|NCT00961636|DRUG|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
214424434|NCT00961636|DRUG|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
215107350|NCT04635514|PROCEDURE|Lateral colporrhaphy|
215107351|NCT02419820|DRUG|APD791|Temanogrel
215107352|NCT02419820|DRUG|Clopidogrel|Clopidogrel
215107353|NCT02419820|DRUG|Aspirin|Aspirin
215107354|NCT02419820|DRUG|Placebo for APD791|Placebo for APD791
215107355|NCT04932642|BEHAVIORAL|HIIT+RT experimental group|Each experimental group will be compared with their another contrast order session group
215107356|NCT04932642|BEHAVIORAL|RT+HIIT experimental group|Each experimental group will be compared with their another contrast order session group
215107357|NCT00965419|DRUG|Edivoxetine|0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
215107358|NCT03536507|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
215107359|NCT03536507|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
215107360|NCT00386321|DRUG|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
215107361|NCT04937283|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
215107362|NCT04937283|PROCEDURE|Lobectomy with hilar and mediastinal lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
215107363|NCT00500396|PROCEDURE|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
215107364|NCT00545896|PROCEDURE|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
215107365|NCT04833595|BEHAVIORAL|Mindfulness practice|Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
215107366|NCT03044808|DRUG|Lidocaine|
215107367|NCT03044808|DRUG|Saline|
215107368|NCT02927938|PROCEDURE|Allogeneic HCT|Allogeneic HCT
215107369|NCT02927938|DRUG|Consolidation chemotherapy|Cytarabine-based consolidation chemotherapy
214509735|NCT04246281|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
214509736|NCT04246281|PROCEDURE|Standard interventional management of low back pain|Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
214509737|NCT05470231|DIETARY_SUPPLEMENT|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
214509738|NCT03476772|DRUG|Nalbuphine|Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
214509739|NCT03584074|DRUG|Pregabalin 75mg|Orally taken twice daily for 8 weeks
215107370|NCT04598412|OTHER|No intervention|Cross-sectional
215107371|NCT03156374|DEVICE|Test use|Use of home ovulation test to predict ovulation
215107372|NCT01332747|DRUG|safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily"
215107373|NCT01332747|DRUG|compressed tablet of safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily"
215107374|NCT01332747|DRUG|Atorvastatin|atorvastatin 10 mgs once daily
215107375|NCT06094400|OTHER|Meditation|Participants in the intervention group will be furnished with a tablet incorporating a pre-installed Muse Meditation App and a set of headphones. They can choose their preferred immersive soundscape for the meditation session.
215107376|NCT06094400|OTHER|Control|Participants allocated to the control group will similarly wear the portable EEG headband, but they will receive a rest session without any additional intervention
215107377|NCT05084898|OTHER|Far-UVC light as an additional method of disinfection|Far-UVC light is a form of ultraviolet light with an extremely short wavelength (222 nm)
215107378|NCT05084898|OTHER|Placebo fluorescent light|"Inactive fluorescent light (no additional disinfection)"
215107379|NCT01900808|DEVICE|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
215107380|NCT01900808|DEVICE|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
215107381|NCT01900808|DEVICE|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
215107382|NCT03322150|DRUG|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
215107383|NCT03322150|DRUG|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
215107384|NCT04129892|BEHAVIORAL|"In Favor of My Resilient Self Academic course"|Assessing the effect of an academic course on student's emotional resilience.
215107385|NCT05273541|BIOLOGICAL|Coronavirus vaccination|Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
215107386|NCT02653547|OTHER|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
214509740|NCT03584074|DRUG|Celebrex 200Mg Capsule|Orally taken once daily for 8 weeks
214509741|NCT02589457|DRUG|CKD-390|Tenofovir Disoproxil Aspartate 1T PO
215107387|NCT02653547|OTHER|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
215107388|NCT02653547|OTHER|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
215107389|NCT02653547|OTHER|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
215107390|NCT01704404|DRUG|TD-4208|
215107391|NCT01704404|DRUG|Placebo|
215107392|NCT04522596|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day
215107393|NCT04522596|OTHER|Placebo|Placebo inhaled once a day
215107394|NCT04355819|BEHAVIORAL|Disclosure timing|When patients are told that a hernia was present on the CT scan
215107395|NCT04099615|PROCEDURE|Somatosensory Evoked Potentials|We stimulate both median nerves at wrist by means of surface adhesive electrodes. We apply square wave electrical pulses of 0.2 ms duration at a frequency of 5.7Hz. SEPs are recorded in a referential fashion from the C3' and C4' positions and from a reference electrode at Fpz or Cz' electrodes(international 10-20 system) with needle electrodes. The target signal is the presence of N20 response ipsilateral to the stroke site and, if present, measure amplitude and latency comparing with the contralateral if present. SEPs are registered during the whole procedure.
215107396|NCT05320172|DRUG|Autologous platelet rich plasma eye drops|Fifty milliliters of patient's own whole blood will be placed in five 10-ml vacutainer tubes containing anticoagulant-citrate-dextrose solution (1.4 ml) and centrifuged at 200g for 11 min. The upper two layers of the centrifuged blood, the plasma and buffy coat layer will be separated in a sterile manner and diluted to 20 % (v/v) with a sterile saline solution. The final preparation is divided into 5-ml bottles wrapped in aluminum foil for protection from ultraviolet light. The patients are instructed to store these bottles at -20 °C until required. The bottles being used will be maintained under refrigerated conditions at 4 °C.
215107397|NCT00897468|OTHER|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
215107398|NCT00897468|OTHER|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
215107399|NCT06040164|OTHER|Observational study|No intervention will be performed
215107400|NCT00082407|DRUG|exenatide|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
215107401|NCT00082407|DRUG|biphasic insulin aspart|subcutaneous injection, twice daily; titration to target blood glucose level
215107402|NCT04629651|DRUG|Captopril|Oral, to be administered per the dose escalation scheme.
215107403|NCT02586948|DEVICE|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
215107404|NCT02253953|DRUG|BILR 355 BS, D1|
214509742|NCT02589457|DRUG|Viread® tablet|Tenofovir Disoproxil Fumarate 1T PO
215107405|NCT02253953|DRUG|BILR 355 BS, D2|
215107406|NCT02253953|DRUG|BILR 355 BS, D3|
215107407|NCT02253953|DRUG|BILR 355 BS, D4|
215107408|NCT02253953|DRUG|BILR 355 BS, D5|
215107409|NCT02253953|DRUG|BILR 355 BS, D6|
215107410|NCT02253953|DRUG|BILR 355 BS, D7|
215107411|NCT02253953|DRUG|BILR 355 BS, D8|
215107412|NCT02253953|DRUG|BILR 355 BS, D10|
215107413|NCT02253953|DRUG|Placebo|
215107414|NCT02253953|OTHER|high-fat breakfast|
215107415|NCT02253953|DRUG|Ritonavir|
215107416|NCT02611843|BEHAVIORAL|Peer-Supported Web CBT|
215107417|NCT02611843|BEHAVIORAL|Self-Managed Web CBT|
215107418|NCT04190901|BEHAVIORAL|Simulated Black Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
215107419|NCT04190901|BEHAVIORAL|Simulated Black Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
215107420|NCT04190901|BEHAVIORAL|Simulated White Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
215107421|NCT04190901|BEHAVIORAL|Simulated White Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
215107422|NCT01626092|DRUG|Campath-1H|A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
214509743|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
214509744|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
214509745|NCT00824408|DRUG|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
215107423|NCT01626092|DRUG|Clofarabine|"A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,~-8, -7, -6, and -5."
215107424|NCT01626092|DRUG|Melphalan|A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.
215107425|NCT01626092|RADIATION|Total Body Irradiation with Marrow Boosting|"1. Dose to total body 200 cGy in single dose~2. Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border."
215107426|NCT01626092|BIOLOGICAL|Hematopoietic stem cell transplantation|Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
215107427|NCT01626092|DRUG|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.
215107428|NCT01626092|DRUG|Mycophenolate mofetil|Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
215107429|NCT06788119|BEHAVIORAL|Cognitive behavioral therapy with in vivo exposure|CBT will be used as the chosen approach for ADs. The main components will be psychoeducation and to help patients to challenge and change unhelpful cognitive distortions (e.g., thoughts, beliefs, and attitudes) and behaviors (e.g., avoidance), develop emotion regulation strategies (e.g., cognitive reappraisal), and learn coping strategies that target problem-solving. The practice is developed in several sessions that usually last between 10 and 20 sessions. Specifically, the exposure component will be considered as the first-line treatment. During the exposure component, patients will confront themselves over a long period of time, repetitively, with a feared stimulus until distress has decreased significantly by the exposure.In this condition participants will receive CBT treatment and be exposed to in vivo situations.
215107430|NCT06788119|BEHAVIORAL|Cognitive behavorial therapy with in vivo exposure plus SYMPTOMS-JIT|CBT will be used as the chosen approach for ADs. The main components will be psychoeducation and to help patients to challenge and change unhelpful cognitive distortions (e.g., thoughts, beliefs, and attitudes) and behaviors (e.g., avoidance), develop emotion regulation strategies (e.g., cognitive reappraisal), and learn coping strategies that target problem-solving. The practice is developed in several sessions that usually last between 10 and 20 sessions. Specifically, the exposure component will be considered as the first-line treatment. During the exposure component, patients will confront themselves over a long period of time, repetitively, with a feared stimulus until distress has decreased significantly by the exposure. In this condition participants will receive CBT treatment and be exposed to in vivo situations with the support of SYMPTOMS-JIT.
215107431|NCT06166667|PROCEDURE|Fecal Microbiota Transplant（FMT）|Patients involved in the trial received 20 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.
215107432|NCT01358058|RADIATION|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
215107433|NCT00891228|DRUG|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
215107434|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
215107435|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
215107436|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
215107437|NCT04647123|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
215107438|NCT02088489|DEVICE|Atrial flutter irrigated catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
215107439|NCT02088489|DEVICE|Atrial flutter porous tip catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
215107440|NCT02014168|BIOLOGICAL|Viroflu® and MVA-NP+M1|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu."
214509746|NCT01179802|OTHER|Strenuous Endurance exercise|"Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters."
214509747|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
215107441|NCT02014168|BIOLOGICAL|Viroflu® and saline placebo|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~0.9% saline placebo."
215107442|NCT03694834|DRUG|Pembrolizumab|"A single dose of Pembrolizumab (200 mg) will be administered IV over 30 min (-5 /+10 min) approximately 3 weeks prior to the scheduled hysterectomy.~Pembrolizumab (200 mg) will be administered IV over 30 min (-5/+10 min) every three weeks in combination with paclitaxel and carboplatin as adjuvant therapy over 6 cycles. Pembrolizumab should be given on D1 of each cycle after the infusion of cytotoxics."
215107443|NCT03694834|PROCEDURE|Hysterectomy|Hysterectomy/Surgical Staging per institutional standard of care.
215107444|NCT00118742|DRUG|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
215107445|NCT00118742|DRUG|Tacrolimus|As prescribed, for 12 months
215107446|NCT00118742|DRUG|Cyclosporine|As prescribed, for 12 months
215107447|NCT00118742|DRUG|Sirolimus|2-4 mg orally once daily for 9-11 months
215107448|NCT02688985|DRUG|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
215107449|NCT02688985|PROCEDURE|Lumbar Puncture|Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
215107450|NCT02688985|DRUG|Methyloprednisolone|Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
215107451|NCT02688985|DRUG|Antihistamine|Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
215107452|NCT03434158|DRUG|Olaparib|300 mg twice a day
215107453|NCT00081055|BIOLOGICAL|autologous expanded mesenchymal stem cells OTI-010|
215107454|NCT00081055|DRUG|busulfan|
215107455|NCT00081055|DRUG|cyclophosphamide|
215107456|NCT00081055|DRUG|cyclosporine|
215107457|NCT00081055|DRUG|methotrexate|
215107458|NCT00081055|PROCEDURE|peripheral blood stem cell transplantation|
215107459|NCT00081055|RADIATION|radiation therapy|
215107460|NCT06233006|OTHER|Assessment|upper extremity functions (hand skills, hand and finger grip strength, reaction time, position sense, upper extremity strength and endurance) and health-related quality of life
215107461|NCT02665572|BEHAVIORAL|bladder recycling|Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.
215107462|NCT02061514|PROCEDURE|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
215107463|NCT02061514|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
215107464|NCT01726582|DRUG|Milestone 1: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
214424435|NCT00890786|DRUG|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
214509748|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
214509749|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
214509750|NCT00780806|BIOLOGICAL|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
214509751|NCT00780806|PROCEDURE|Blood draw|Blood draw
214509752|NCT00046475|DRUG|Midodrine Hydrochloride|
215107465|NCT01726582|RADIATION|Milestone 2: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
215107466|NCT01726582|DRUG|Milestone 3: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
215107467|NCT01726582|RADIATION|Milestone 3: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
215107468|NCT01726582|DRUG|Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
215107469|NCT01726582|RADIATION|Milestone 4: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
215107470|NCT01726582|DRUG|Milestone 5: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
215107471|NCT01726582|RADIATION|Milestone 5: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
215107472|NCT01726582|DRUG|Milestone 6: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
215107473|NCT01726582|RADIATION|Milestone 6: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
215107474|NCT01726582|RADIATION|Milestone 7: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
215107475|NCT01726582|DRUG|Milestone 8: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
215107476|NCT01726582|DRUG|Milestone 9: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
214509753|NCT02070809|PROCEDURE|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
215107477|NCT01726582|OTHER|Milestone 10: No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
215107478|NCT01181817|OTHER|fMRI and MRS|fMRI and MRS
215107479|NCT01121432|PROCEDURE|endobronchial ultrasound-guided transbronchial needle aspiration|One time for aspiration/biopsy. The duration about 1-2 hour.
215107480|NCT05181644|DEVICE|EmoLED treatment|Treatment with the EmoLED device consists of irradiating each area of 5 cm in diameter of the lesion for 60 seconds; if the lesion is larger than 5 cm in diameter, the applications will be repeated up to cover the entire area of interest. EmoLED treatment is additional to the standard therapy for the patient.
215107481|NCT05181644|PROCEDURE|current Standard of Care|The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
215107482|NCT04086199|PROCEDURE|Lumbar discectomy|Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.
215107483|NCT03912779|BEHAVIORAL|C2Hear RLOs|Freely available online RLOs
214509754|NCT02070809|PROCEDURE|split-thickness skin graft method|This method is traditional split-thickness skin graft
214509755|NCT02441569|BEHAVIORAL|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
214509756|NCT02441569|BEHAVIORAL|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
215107484|NCT03912779|BEHAVIORAL|Printed hearing aid booklet|Departmental printed hearing aid booklet (standard care)
215107485|NCT03274544|OTHER|PROLUNG|"Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~* Huang Qi (Radix Astragali Membranaceus): 2 g~* Dan Shen (Radix Salviae Miltiorrhizae): 1 g~* Jiang Huang (Rhizoma Curcumae Longae): 1 g~* Yin Xing (Semen Gingko Bilobae): 1 g~* Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~* Bai He (Bulbus Lilii): 1g~* Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~* Zi Su Ye (Folium Perillae Frutescentis): 1 g~* Yin Yang Huo (Herba Epimedii): 1g"
215107486|NCT01224717|DRUG|PTH134|
215107487|NCT01224717|DRUG|Placebo|
215107488|NCT01224717|DRUG|Forsteo|
215107489|NCT02906397|DRUG|Galunisertib 150mg by mouth twice a day|on days 1-14 of 28 day cycles
215107490|NCT02906397|RADIATION|Stereotactic Body Radiotherapy (SBRT)|18GY delivered in one fraction between C1D15 and C1D28
215107491|NCT04789369|BEHAVIORAL|Questionnaires|Assessing the behavioral metrics (quality of life, functionality and fear of movement) with appropriate measurement tools
215107492|NCT06393972|DRUG|Tofacitinib 5 MG BID|Tofacitinib 5 MG BID
214509757|NCT01406106|DIETARY_SUPPLEMENT|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
214509758|NCT03704519|DRUG|Darolutamide (BAY1841788)|300 mg tablet darolutamide, once orally
215107493|NCT05097443|DRUG|Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies|"Orelabrutinib+R-CHOP： Orelabrutinib 150mg qd; R-CHOP：Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5.~Orelabrutinib+R-DA-EPOCH： Orelabrutinib 150mg qd； R-DA-EPOCH：Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5.~Orelabrutinib+R-HD-MTX: Orelabrutinib 150mg qd; R-HD-MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/ｍ2 d1.~Orelabrutinib+ R+other regimens: Orelabrutinib 150mg qd； R+other regimens: Rituximab 375mg/m2 d0. The dose of other drugs depends on the regimen.~All regimens follow every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance.~Dose adjustments of Orelabrutinib are allowed. The initial dose is 150 mg, QD, while the first adjustment is 100 mg, QD and the second adjustment is 50 mg, QD."
215107494|NCT03100591|DRUG|14C-radiolabeled ACT-132577|Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie \[μCi\]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
215107495|NCT00328367|DRUG|aripiprazole|aripiprazole augmentation of clozapine
215107496|NCT00328367|DRUG|placebo|placebo
215107497|NCT00043732|DRUG|SCIO-469|
215107498|NCT01961622|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
215107499|NCT01961622|DEVICE|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
215107500|NCT01104727|PROCEDURE|4-Ports Cholecystectomy (4PC)|a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
215107501|NCT01104727|PROCEDURE|Single-Port Cholecystectomy (SPC)|"a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
215107502|NCT05769205|DEVICE|MRI|MRI with contrast
215107503|NCT00738751|DRUG|Panobinostat (LBH589)|Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
215107504|NCT00738751|DRUG|erlotinib|Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
215107505|NCT04843761|BIOLOGICAL|Remdesivir|Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
215107506|NCT04843761|DRUG|Remdesivir Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
215107507|NCT04843761|BIOLOGICAL|Aviptadil|Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.
215107508|NCT04843761|DRUG|Aviptadil Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
215107509|NCT04843761|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
214509759|NCT03704519|DRUG|Enzalutamide|4 x 40 mg capsules, once orally
214509760|NCT03704519|OTHER|Placebo|4 placebo tablets, once orally
215107510|NCT02868411|OTHER|Rectal Swab|
215107511|NCT03683017|DEVICE|OrthoPulse 2.0|Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
215107512|NCT03683017|DEVICE|OrthoPulse 2.1|Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
215107513|NCT03683017|DEVICE|Invisalign 3.5 Day Wear|Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.
215107514|NCT03683017|DEVICE|Fixed Orthodontic Appliances (Braces)|Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
215107515|NCT01177189|DIETARY_SUPPLEMENT|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
215107516|NCT01984502|RADIATION|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
215107517|NCT00458458|DRUG|Norethindrone Acetate (NA)|52 weeks of treatment with Norethindrone Acetate
215107518|NCT00458458|DRUG|GnRH Agonist (Lupron Depot)|24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
215107519|NCT00513149|DRUG|Clopidogrel|Clopidogrel 600 mg loading
214509761|NCT00266656|DRUG|Humatrope|According to investigator's clinical practice and guided by the approved package insert
214509762|NCT03701906|DIETARY_SUPPLEMENT|Lactobacillus PS11603 & Bifidobacterium PS10402|Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L.salivarius PS11603 and 1\*10E8 CFU of B.longum PS10402.
215107520|NCT04328220|DIAGNOSTIC_TEST|chest ultrasound|"A point-of-care lung ultrasound exam will be performed within 24h of admission to PICU and serial follow up according to each case.~chest x-ray will be performed for comparison with ultrasound findings."
215107521|NCT02238158|DRUG|Atrovent® inhalets|
215107522|NCT03606187|DEVICE|Stimgenics SCS Programming Approach|Stimgenics SCS Programming approach Using Intellis(TM) SCS system
215107523|NCT03606187|DEVICE|Standard SCS Programming Approach|Standard SCS Programming approach using Intellis(TM) SCS system
215107524|NCT06231368|BIOLOGICAL|CNCT19 CAR-T cell therapy|CNCT19 was a second-generation CAR T-cell with scFv derived from clone HI19α and 4-1BB/CD3-ζ costimulatory domain.
214509763|NCT03701906|DIETARY_SUPPLEMENT|Placebo|8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
215107525|NCT03871244|PROCEDURE|Less red blood cell transfusions|The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.
215107526|NCT03871244|PROCEDURE|More red blood cell transfusion (standard transfusion strategy in PICU)|The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice
215107527|NCT04656743|PROCEDURE|intra-articular injection|The injection will be performed under ultrasound guidance by placing the patient's knee in approximately 90° of flexion with the leg hanging off the side of the bed (left). A high-frequency linear transducer ultrasound probe is placed in the superolateral corner of the patella, directed medially toward the patellofemoral joint space. In the extended leg, from anterior to posterior, the right image shows the quadriceps femoris tendon (QF), suprapatellar fat pad (SF), suprapatellar bursa (SB), prefemoral fat pad (PF), and femur (F). When the knee is flexed to 90°, the size of the suprapatellar bursa image is increased. Using an in-plane approach, the needle will be directed into the suprapatellar joint space, and 20 ml of bupivacaine 0.25% will be injected.
215107528|NCT04656743|PROCEDURE|genicular nerve block|The transducer will be first placed parallel to the long bone shaft and moved up or down to identify the epicondyle of the long bone. The genicular arteries will be identified near the periosteal areas, confirmed by color Doppler ultrasound. Accordingly, genicular nerve block target points should be next to each genicular artery. After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view. a gentle aspiration will be performed and a 2 mL injection volume will be administered.
215107529|NCT00811616|DEVICE|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
215107530|NCT00811616|DEVICE|Supralimus™ Core™ Sirolimus eluting stent|Supralimus™ Core™ Sirolimus eluting stent intended to treat coronary artery disease.
215107531|NCT03704688|DRUG|Trametinib 0.5 mg|0.5mg PO q daily
215107532|NCT03704688|DRUG|Trametinib 1 MG|1.0 mg PO q daily
215107533|NCT03704688|DRUG|Trametinib 1.5 MG|1.5mg PO q daily
215107534|NCT03704688|DRUG|Trametinib 2 mg|2 mg PO q daily
215107535|NCT03704688|DRUG|Ponatinib 15 MG|15mg PO q daily
215107536|NCT03704688|DRUG|Ponatinib 30 MG|30mg PO q daily
215107537|NCT01985750|DRUG|d-cycloserine|250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
215107538|NCT01985750|DRUG|placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
215107539|NCT02675608|BIOLOGICAL|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
215107540|NCT04847934|BEHAVIORAL|distraction methods|distraction methods
215107541|NCT05482230|PROCEDURE|Intubation and bronchial blocker placement performed in lateral position|In the lateral position group, patients were positioned laterally (as required for surgery) before anesthesia induction. After anesthesia induction, both endotracheal intubation and bronchial blocker placement were performed while the patient remained in the lateral position.
215107542|NCT03954821|DEVICE|prefabricated insoles|
214509764|NCT05932303|DRUG|BMS-986278|Specified dose on specified days
214509765|NCT05932303|DRUG|Itraconazole|Specified dose on specified days
215107543|NCT05981027|OTHER|Mulligan bent leg raise technique|In this study, while the participant was lying on his back on a high bed, the physiotherapist sat on the lateral side of the leg to be treated, placing the popliteal fossa of the participant's knee on his shoulder. The hip and knee of the leg to be stretched were placed in 90° flexion. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with his leg and then relax. At this relaxation point, the physiotherapist pushed the flexed knee as far as possible in the direction of the ipsilateral shoulder in a painless range.
215107544|NCT05981027|OTHER|Static stretching exercise|The participant lay on a stretcher in the supine position with his back straight. The physiotherapist placed the participant's leg on his shoulder with the knee in full extension and supported by the ankle and flexed the hip as much as possible until a tension was felt in the posterior thigh. This position was maintained for 30 seconds.
215107545|NCT06088719|PROCEDURE|axillary surgery|one group undergoes axillary surgery
215107546|NCT01359202|BIOLOGICAL|rfVIIa|80ug/kg IV bolus
215107547|NCT01359202|OTHER|Standard saline solution|Saline
215107548|NCT03908359|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
215107549|NCT03908359|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
215107550|NCT06488105|DRUG|Statin (rosuvastatin 10 or 40 mg daily, depending on risk)|moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)
215107551|NCT06488105|BEHAVIORAL|Healthy Lifestyle Counseling|Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework
215107552|NCT06488105|OTHER|Outpatient Followup|Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral
215107553|NCT06214546|OTHER|Regular walking|Participants perform 6 overground walking trials (12.5 m) without support system. Participants perform all measurements (regular walking, Myosuit, ZeroG) on one single measurement day.
215107554|NCT06214546|DEVICE|Myosuit|Participants perform 6 overground walking trials (12.5 m) while wearing the Myosuit. ZeroG and Myosuit intervention will be performed in random order.
215107555|NCT06214546|DEVICE|ZeroG|Participants perform 6 overground walking trials (12.5 m) while walking in the ZeroG. ZeroG and Myosuit intervention will be performed in random order.
215107556|NCT04878211|DRUG|Ofatumumab|3 loading doses followed by monthly administrations
215107557|NCT04878211|BIOLOGICAL|mRNA COVID-19 vaccine|Pfizer or Moderna mRNA Vaccine
215107558|NCT04878211|DRUG|interferon or glatiramer acetate|iDMT
215107559|NCT03997370|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215107560|NCT03997370|DRUG|Carboplatin|Given IV
215107561|NCT03997370|DRUG|Iohexol|Given IV
215107562|NCT01473628|OTHER|Clinical Observation|Undergo observation
215107563|NCT01473628|RADIATION|Radiation Therapy|Undergo radiation therapy
215107564|NCT01473628|BIOLOGICAL|Rituximab|Given IV
215107565|NCT05550194|DRUG|ValACYclovir 1000 MG|Valacyclcovir is a targeted anti-viral for varicella zoster virus (VZV).
215107566|NCT05550194|BIOLOGICAL|Shingrix|Vaccine indicated for prevention of herpes zoster
214509766|NCT05932303|DRUG|Gemfibrozil|Specified dose on specified days
214509767|NCT05932303|DRUG|Carbamazepine|Specified dose on specified days
214509768|NCT06152718|OTHER|Karisma|Use of regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen
215107567|NCT05467228|DEVICE|vibro-tactile stimulation (VTS)|To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
215107568|NCT05870878|OTHER|Standard care|Individual lifestyle consultation
215107569|NCT05870878|OTHER|Lifestyle program|Lifestyle program focusing on lifestyle advice, coping with stress and adherence to a healthy(er) lifestyle. This program consists of 3 group sessions and an online platform.
215107570|NCT05623241|DIAGNOSTIC_TEST|Liquid Biopsy|Venous blood sampling for liquid biopsy in breast cancer patients after segmentation of the lesion on mammography
215107571|NCT00477646|BEHAVIORAL|Prevention Care Management|Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
215107572|NCT02783599|DRUG|Olaratumab|Administered IV
215107573|NCT02783599|DRUG|Doxorubicin|Administered IV
215107574|NCT02783599|RADIATION|External Beam Radiotherapy|
215107575|NCT06210100|DEVICE|Active iTBS|Mag-TD stimulator
215107576|NCT06210100|DEVICE|Sham iTBS|Mag-TD stimulator
215107577|NCT04760405|OTHER|Tai Chi Easy|Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
215107578|NCT05643339|DIAGNOSTIC_TEST|microvascular flow imaging|microvascular flow imaging
215107579|NCT04954924|OTHER|standardized physiotherapy program and Kinesio tape|
215107580|NCT00856544|DRUG|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
215107581|NCT00856544|DRUG|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
215107582|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
215107583|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
215107584|NCT03453580|RADIATION|multislice computed tomography portography|imaging modality
215107585|NCT05133765|DEVICE|Insulin pump|Alterations in insulin pump therapy or carbohydrate consumption
215107586|NCT00633529|DRUG|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
215107587|NCT03536559|DRUG|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
215107588|NCT03536559|DRUG|Placebo|Placebo is liquid with identical color and taste
215107589|NCT01770236|DRUG|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
215107590|NCT02858947|PROCEDURE|Aelite Flo|Microhybrid flowable composite
215107591|NCT02858947|PROCEDURE|x-tra base|Bulk-fill flowable composite
215107592|NCT00787189|DEVICE|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
215107593|NCT00787189|DEVICE|Placebo Laser|inactive low level laser light therapy with no therapeutic output
215107594|NCT03630757|OTHER|Treatment|In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
214424436|NCT00890786|DRUG|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
214424437|NCT00890786|DRUG|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
214424438|NCT04891887|BEHAVIORAL|Health education program|"Seven face to face sessions and group discussion health education sessions. Two prepared booklets were distributed to all attendants titled Diabetes mellitus and how to control its complications and Mild cognitive impairment and how to prevent it.~Lab results were discussed individually with each participant to discuss his adherence to the lifestyle modification program.~Clinical follow-up and management with endocrinology and neurology specialists. Individualized Medical Nutrition. Participants were then counselled on healthy eating habits.~Individualized biweekly follow-up scheme through mobile phone. A WhatsApp group was created for all participants to contact the research team whenever they have any inquiry concerning life style modifications. Through this group, 12 HE audio electronic messages were shared with participants.~Final reassessment of clinical status and laboratory profile was carried out with participants who continued till the end of the study."
214424439|NCT02310295|DEVICE|Laser|focal macular laser therapy
214424440|NCT02310295|DRUG|Bevacizumab|Intravitreal injection of Bevacizumab
214424441|NCT02310295|DRUG|Triamcinolone Acetonide|Intravitreal injection of Triamcinolone Acetonide
214424442|NCT02341924|OTHER|Portfolio of functional foods|
214424443|NCT02341924|OTHER|Control foods|
214424444|NCT00227032|DRUG|erlotinib hydrochloride|"300 mg, per day for subjects taking EIAEDs~150 mg, per day for those NOT taking EIAEDs"
214424445|NCT04158999|DEVICE|milk analyzer|Human Milk Sample
214424446|NCT04158999|BEHAVIORAL|Mother's nutrition values|evaluation of nutritional elements of maternal onset with Bebis Program
214424447|NCT00202748|BEHAVIORAL|Increase in activity to control weight|
214424448|NCT00202748|BEHAVIORAL|Increase in activity to control weight.|
214509769|NCT01141257|DRUG|Angiocal® (PRS-050-PEG40)|Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
215028317|NCT04767321|DRUG|Placebo|Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
215028318|NCT00861887|DRUG|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
215028319|NCT00861887|DRUG|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
215028320|NCT04500145|RADIATION|SIB-IMRT|60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time
215028321|NCT04500145|RADIATION|routine IMRT|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
215028322|NCT06959537|DRUG|Cyclophosphamide|Given by mouth
215028323|NCT06959537|DRUG|Axatilimab (SNDX-6352)|Given by IV
215028324|NCT06959537|DRUG|Retifanlimab|Given by IV
215028325|NCT05967754|DIAGNOSTIC_TEST|polysomnography|polysomnography and serum uric acid measurement
215028326|NCT01128478|PROCEDURE|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
215028327|NCT00980044|DRUG|Tramadol|Oral Medication
215028328|NCT00980044|DRUG|Placebo|Oral Medication
215028329|NCT00175279|BEHAVIORAL|Opinion leader generated and endorsed evidence summaries|
215028330|NCT00000305|DRUG|Dextroamphetamine|
215028331|NCT02254291|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
215028332|NCT02254291|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
215028333|NCT02254291|DRUG|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
215028334|NCT02172729|DRUG|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
215028335|NCT02078869|DRUG|Progesterone in oil|Daily administration of 50 mg of IM Progesterone
215028336|NCT02078869|DRUG|vaginal progesterone suppositories|Vaginal Promterium 200 mg , 3 times a day
215028337|NCT06419348|DRUG|99mTc-QULIC-5-P1|Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.
215028338|NCT05813418|BIOLOGICAL|blood retriewal|blood retriewal for cytokine concentration measurement
215028339|NCT05576064|DIAGNOSTIC_TEST|Gait analysis|Analysis of gait profile and measures by gait laboratory on patients with suspected lower limb rotational deformities and anterior knee pain
215028340|NCT04518501|DRUG|Arsenic trioxide Tablet +Fuzuloparib Capsules|Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
215028341|NCT06298058|DRUG|SIBP-A13 formulation for injection|"SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion). Starting from the lowest dose, when the former does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD). The study adopts a 3+3 dose increasing design. Administration period: divided into single administration and multiple administration. Single dose administration: The participants are administered a single dose on the first day for a total of 21 days of observation, and complete the examinations and evaluations specify in the protocol. If dose-limiting toxicity (DLT) does not occur, the participant enters a multiple dosing period. Multiple administration: administration every 3 weeks."
215107595|NCT01458262|OTHER|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
215107596|NCT00252408|DRUG|Hormone replacement therapy|
215107597|NCT00847886|DRUG|LX3305|Daily oral intake of LX3305 for 14 days.
215107598|NCT00847886|DRUG|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
215107599|NCT00847886|DRUG|Methotrexate|Once weekly stable-dose methotrexate.
215107600|NCT00313105|DRUG|Smokeless tobacco (Oliver Twist pellets)|individual visits with counseling
215107601|NCT00313105|BEHAVIORAL|smoking cessation counseling|individual visits
215107602|NCT06353282|DRUG|MDMA|MDMA will be dosed in pre-filled capsules and administered orally to participants in two fixed doses - an 80mg dose following the fourth session and a 120mg dose following the ninth session of MDMA to each participant. MDMA experimental medication administration session 1 (8 hours); MDMA experimental medication session 2 (8 hours). Participants will be required to remain in the therapy room for the duration of the experimental medication sessions without the youths' parent/guardian present. The parent/guardian will be invited to attend integration sessions and must be available to drop off and pick up the participant.
215107603|NCT06353282|BEHAVIORAL|Psychotherapy|Treatment session order: Four weekly 90-minute experimental medication preparation psychotherapy sessions; four weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session; and Five weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session.
215107604|NCT05356780|DEVICE|Aligner|A method of straightening teeth without fixed braces
215107605|NCT03492606|PROCEDURE|Samples|lumbar puncture, blood and CSF samples, SNPs analysis
215107606|NCT00811681|DRUG|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
215107607|NCT00811681|DRUG|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
215107608|NCT05322434|OTHER|The Effect Of Online Breastfeeding Counseling Given At The Post-Birth Period On Breastfeeding Behavior|The aim of the study is to investigate breastfeeding behavior and initiation of solid food by giving breastfeeding counseling to women within the framework of the Health Belief Model for 6 months from birth.
215107609|NCT01401517|DRUG|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
215107610|NCT00356967|DRUG|dianicline|
214424449|NCT01370707|DRUG|Metformin|1000\~1500mg/day, 24weeks
215107611|NCT04202237|OTHER|Speckle Doppler imaging|Speckle Doppler Laser imaging
215107612|NCT04202237|OTHER|Blood sample|Blood sampling
215107613|NCT04486014|PROCEDURE|Erector spinae plane block|Erector Spinae Group (Group E) will receive bilateral ultrasound-guided erector spinae plane block using 30 ml hyperbaric bupivacaine 0.25% will be injected between erector spinae muscle and transverse process of T4
215107614|NCT04486014|PROCEDURE|Serratus anterior plane block|Serratus anterior Group (Group S) will undergo bilateral ultrasound-guided serratus anterior plane block with 30 ml hyperbaric bupivacaine 0.25% will be injected above or below serratus anterior muscle at the level of 4th and 5th rib on the midaxillary line
215107615|NCT01000259|OTHER|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
215107616|NCT00728091|DRUG|Satavaptan|tablets
215107617|NCT00728091|DRUG|placebo|tablets
215107618|NCT05899400|DIAGNOSTIC_TEST|Diascopic iON Image Analysis System|A scanning digital optical train that images sputum slides for automated analysis by a tuberculosis detecting algorithm
215107619|NCT06524193|BEHAVIORAL|Telepractice group voice therapy|"* Voice therapy delivered in group basis via telepractice.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
215107620|NCT06524193|BEHAVIORAL|Face-to-face group voice therapy|"* Voice therapy that will be delivered in group basis in-person with patients.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
215107621|NCT04909866|COMBINATION_PRODUCT|TACE+Lenvatininb+Camrelizumab|Patients included in the trial were treated with TACE, lenvatinib combined with Camrelizumab.
215107622|NCT00288678|PROCEDURE|Health Education|
215107623|NCT00627250|DRUG|Amantadine|Amantadine 100 mg every morning and 12 noon
214424450|NCT01370707|DRUG|CJ-30001/CJ-30002|0.6/1500mg\~0.9/1500mg/day, 24weeks
214424451|NCT06027372|DEVICE|"LARGAN ECG Holter"|"wear LARGAN ECG Holter during sleep once after completion of pulmonary function test"
214424452|NCT01964469|BEHAVIORAL|mobile & web-based action plan|Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
214424453|NCT00862680|PROCEDURE|4-Dimensional Computed Tomography|Undergo 4D PET/CT
214424454|NCT00862680|PROCEDURE|4D PET Scan|Undergo 4D PET/CT scan
214424455|NCT03598972|OTHER|intervention|elementary analysis
215107624|NCT01766180|DRUG|Fruitflow-II|150 mg/day for 3 months, orally
215107625|NCT01766180|DRUG|resVida|150 mg/day for 3 months, orally
215107626|NCT02953574|PROCEDURE|daily sleep enhancement nursing protocol|
215107627|NCT06371846|OTHER|Selected signals from Pacing System Analyzers|Comparative observational, prospective, multicenter study between the signals obtained by PSA vs MPS of consecutive patients who underwent a LBBAP strategy as first intention.
215107628|NCT04220944|DRUG|Sintilimab|Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
215107629|NCT04220944|PROCEDURE|Microwave Ablation|The ablation area should covered at least two thirds the size of the nodules.
215107630|NCT04220944|PROCEDURE|TACE|Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
215107631|NCT05881954|PROCEDURE|Groin infection|Femoral artery reconstruction with tubulized pericardium patch
215107632|NCT02677272|OTHER|Appropriateness of NH resident's transfer to ED|
215107633|NCT03958357|DEVICE|Advanced Gynecological Applicator configuration|The Advanced Gynecological Applicator Venezia configuration is a gynaecological applicator for intracavitary and interstitial brachytherapy. The applicator consists of tubes, caps and templates to place needles, which can be combined to reach a wide range of target areas. The tubes and possibly used needles, guide the radioactive source of the afterloader to the target volume. Dose optimization and dose fractionation is performed with the goal of adapting the dose to the target volume without exceeding the dose volume constraints for the surrounding normal tissues according to the standard cervical cancer treatment of the centre.
215107634|NCT04370106|OTHER|Social leg program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
215107635|NCT02289794|BIOLOGICAL|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
215107636|NCT02289794|BIOLOGICAL|Placebo|Single dose, intramuscular injection (0.5 mL)
215107637|NCT03863431|OTHER|High-fat diet|"Participants will consume a high fat diet for 14 days with approximately 65% of energy from fat. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
215107638|NCT03863431|OTHER|High-carbohydrate diet|"Participants will consume a high fat diet for 14 days with approximately 70% of energy from carbohydrate. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
215107639|NCT02172378|DRUG|Tiotropium inhalation capsules|
215107640|NCT02172378|DRUG|Placebo inhalation capsules|
215107641|NCT03499834|BIOLOGICAL|Immune Killer Cells (IKC)|Autologous cells of the immune system. Intravenous Injection (I.V.) frequency: One injection per week, twenty-four injections on-treatment
215107642|NCT04131179|BEHAVIORAL|Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP)|"Y-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the self-harm attempt, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking,relapse prevention strategies and training on anger management and assertiveness."
215107643|NCT02982421|BEHAVIORAL|Group art therapy|Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
215107644|NCT02982421|BEHAVIORAL|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
215107645|NCT04094857|DRUG|HBN-1|Intravenous infusion
215107646|NCT01032720|PROCEDURE|Ultrasound|Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
215107647|NCT01032720|PROCEDURE|Sham ultrasound|Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
215107648|NCT05501834|OTHER|Supracondylar Pin Removal Before Imaging|Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider. The order of these steps differs from our current standard of care, during which patients' pins are removed following cast removal and x-ray imaging.
215107649|NCT01602289|BIOLOGICAL|LY2875358|Administered IV
215107650|NCT01602289|DRUG|Erlotinib|Administered orally
215107651|NCT01602289|DRUG|Gefitinib|Administered orally
215107652|NCT01356459|DEVICE|Mepilex Border Dressing|Soft silicone self adherent dressing
215107653|NCT03205683|OTHER|Intraneural facilitation (INF)|INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.
214424456|NCT04954040|DRUG|Hydroxychloroquine Pill + Azithromycin Pill|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0"
214424457|NCT04954040|DRUG|SOC|Acetaminophen or Metamizole. Antitussives if needed.
215107654|NCT03205683|OTHER|Sham INF|Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.
215107655|NCT00064961|BEHAVIORAL|Individualized dietary-control and exercise program|
215107656|NCT00064961|BEHAVIORAL|Weight-management and smoking cessation maintenance|
215107657|NCT00064961|BEHAVIORAL|Smoking Cessation program|
215107658|NCT05375721|PROCEDURE|ST36 acupoint injection|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
215107659|NCT01849094|DRUG|Milrinone 6mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
215107660|NCT01849094|DRUG|milrinone 10mg ER|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
215107661|NCT01849094|DRUG|milrinone 14mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
215107662|NCT05838157|BIOLOGICAL|prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)|at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)
215107663|NCT04236362|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
215107664|NCT04236362|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
215107665|NCT04417335|BIOLOGICAL|BCG vaccine|Bacille Calmette-Guérin is a live attenuated strain of Mycobacterium bovis developed in 1921 to prevent tuberculosis and other mycobacterial related infections.
215107666|NCT04417335|BIOLOGICAL|Placebo|0.9% NaCl
215107667|NCT02546492|DRUG|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
215107668|NCT03920254|DRUG|TD-1473 Dose A|See Arm description
215107669|NCT03920254|DRUG|TD-1473 Dose B|See Arm description
215107670|NCT03920254|DRUG|TD-1473 Dose C|See Arm description
215107671|NCT03979859|DRUG|WCK 4873|
214509770|NCT01836159|OTHER|iPad Intervention|"Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total dose received. Patients may receive outpatient rehabilitation as required as part of usual care.~The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:~1. Popping a stationary balloon~2. Popping a moving balloon~3. Popping a pair of stationary balloons~4. Popping a pair of moving balloons~5. Stretching a balloon to pop~6. Balloon/Text distraction test"
215107672|NCT03979859|DRUG|Placebo Oral Tablet|
215107673|NCT03968835|OTHER|Bacitracin|For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.
215107674|NCT03968835|OTHER|Skin Graft|For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.
215107675|NCT00823667|OTHER|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
215107676|NCT00823667|OTHER|medical chart review|Occurs at 1 year post study enrollment
214509771|NCT01836159|OTHER|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
215107677|NCT00823667|OTHER|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
214509772|NCT00532766|DRUG|Jusline|
214509773|NCT02915783|DRUG|lenvatinib|4 mg and 10 mg capsules
215107678|NCT00823667|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
215107679|NCT00823667|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
214509774|NCT02915783|DRUG|everolimus|5 mg tablets
214509775|NCT06360224|DEVICE|MiraQ systems with Transit Time Flow Measurement (TTFM) and High Frequency Ultrasound (HFUS) probes|The objective of this study is to harvest a wide dataset of high quality to allow exploratory analysis and training of machine learning
214509776|NCT03507244|DRUG|Pemetrexed|Pemetrexed, 10 mg,intrathecal injection, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks in total.
215107680|NCT00823667|PROCEDURE|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
215107681|NCT04090333|OTHER|Standard withdrawal therapy|All painkillers are abruptly stopped for a 2 months period.
215107682|NCT04896281|DIETARY_SUPPLEMENT|Phenylalanine-free milk|Once a plasma PHE level of ≥ 95 μM is noted, phenylalanine-free diet (Phenex-2®, Abbott Nutrition, Ohio, USA; or Phenyl-Free 2®, Mead Johnson Nutrition, Minnesota, USA) is started as the only nutrition source for enteral feeding, as per the recommendation of dieticians, in the following 4 days. The phenylalanine-free diet is free of PHE but is enriched with protein, potassium, tyrosine, and antioxidant micronutrients. After the completion of the study, diet will be back to normal diet for all patients.
215107683|NCT00402467|DRUG|Rivaroxaban (BAY59-7939)|2.5mg bid
215107684|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|5mg bid
215107685|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|10 mg bid
215107686|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|20mg bid
215107687|NCT00402467|DRUG|Enoxaparine|30mg bid
215107688|NCT00402467|DRUG|Enoxaparine|30mg bid
215107689|NCT05274269|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
215107690|NCT05274269|DRUG|IVA|Tablet for oral administration.
215107691|NCT05274269|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
215107692|NCT05274269|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
215107693|NCT00473200|DIETARY_SUPPLEMENT|S-adenosylmethionine|1200 mg daily
215107694|NCT02255227|BIOLOGICAL|Prevenar 13|one dose for arm 1 and 2 doses for arm 2
215107695|NCT02255227|BIOLOGICAL|Pneumo 23|one dose
215107696|NCT04067258|DIAGNOSTIC_TEST|EDI-OCT|"EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged."
215107697|NCT04612257|OTHER|Insulin-alone closed-loop|40-hour intervention period using the insulin-alone closed-loop system.
215107698|NCT05614349|DRUG|Paxlovid|This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
215107699|NCT05614349|DRUG|Antioxidant|Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)
215107700|NCT05711823|DRUG|Aprepitant in combination with granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
215107701|NCT05711823|DRUG|Granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
215107702|NCT03930602|DRUG|BMS-986165|Participants will receive BMS-986165.
215107703|NCT03930602|DRUG|Fluvoxamine|Participants will receive fluvoxamine.
215107704|NCT00104624|DRUG|docetaxel|
215107705|NCT00104624|PROCEDURE|quality-of-life assessment|
215107706|NCT02115763|DRUG|Caffeine|
215107707|NCT02115763|DRUG|Placebo|
214509777|NCT03507244|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection, simultaneously with pemetrexed, once per week, 5 to 8 times, 4 to 7 weeks in total.
215107708|NCT02369393|BEHAVIORAL|Behavioral Activation|Behavioral Activation intervention promotes the involvement in meaningful activities close to personal values.
215107709|NCT02369393|BEHAVIORAL|Physical Activity|Physical Activity intervention promotes the gradual increase of the frequency and intensity of PA levels, with special attention to motivational strategies.
215107710|NCT05871099|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Experimental group receive HIPEC two times after laproscopic gastrectomy
215107711|NCT00398034|DRUG|Testosterone Gel|
215107712|NCT03362749|OTHER|RFA, MWA, cryo and IRE|local tumor ablation
215107713|NCT02047214|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
215107714|NCT02047214|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
215107715|NCT02206035|DRUG|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
214509778|NCT03507244|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
215107716|NCT02206035|DRUG|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.
215107717|NCT02206035|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
215107718|NCT04240574|DEVICE|Debritom|hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
215107719|NCT05904574|OTHER|Autologous blood patch|Approximately 3-4 pieces were taken with the 18 G core biopsy needle until sufficient tissue was obtained. In the autologous blood patch technique, approximately 6-7 ml of blood was taken from the patient with a 10 ml syringe before the procedure. By attaching a 3-way tap to the injector from which the blood is drawn, blood is drawn into a second injector to ensure that the clotted blood is dispersed and homogenized. The prepared autologous blood patch was given through the coaxial needle (approximately 1 ml of autologous blood patch was applied for every 1 cm when the coaxial needle was withdrawn) and the tract formed by the biopsy needle in the parenchyma, pleura, and under the skin was closed with the patient's autologous blood.
214509779|NCT02203032|DRUG|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
214509780|NCT02203032|DRUG|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
215107720|NCT05904574|OTHER|Percutaneous transthoracic biopsy|After determining the lung lobe where the lesion was observed, axial CT images of 5 mm cross-section thickness were obtained so that the upper and lower parts of it could be visualized. After ruling the entry site in the skin, antisepsis and local anesthesia were performed. The coaxial system (17 G) was cautiously advanced and CT images were continuously evaluated to confirm entrance into the lesion. Biopsy was taken and after sufficient tissue samples were taken at the last stage of the biopsy procedure, control CT imaging, including the whole lung, was performed to evaluate complications. The presences of pneumothorax were noted.
215107721|NCT05173012|DRUG|SAGE-324|SAGE-324 oral tablets.
215107722|NCT05173012|DRUG|SAGE-324 Matched Placebo|SAGE-324 matched placebo oral tablets.
215107723|NCT06552936|OTHER|Diode Laser 980 nm.|A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.
215107724|NCT03668613|DRUG|secukinumab low dose|dose depends on the weight group
215107725|NCT03668613|DRUG|secukinumab high dose|dose depends on the weight group
215107726|NCT02106494|DRUG|APF530|
215107727|NCT02106494|DRUG|Ondansetron|
215107728|NCT02106494|DRUG|Ondansetron placebo|
215107729|NCT02106494|DRUG|APF530 placebo|
215107730|NCT02106494|DRUG|Fosaprepitant|
215107731|NCT02106494|DRUG|Dexamethasone|
215107732|NCT05034250|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, the iron status is determined.
215107733|NCT03503760|DEVICE|LIMFA Therapy®|It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
215107734|NCT04282707|PROCEDURE|Endoscopic closure of ESD defect|Closure of ESD defect would be performed with clip loop purse string technique
215107735|NCT04282707|OTHER|Gastric ESD without closure of ESD defect|Historical control with patients undergoing ESD without closure of ESD defect
215107736|NCT01068769|DRUG|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
215107737|NCT06959758|DIETARY_SUPPLEMENT|Probiotic Arm|It is administered daily to children with functional constipation, alongside standard laxative treatment (PEG 3350) for the first 12 weeks, and then continued alone for the remainder of the 52-week study period. The study evaluates whether BioKid LR® helps maintain normal bowel movements after stopping PEG.
215107738|NCT06959758|DRUG|Placebo|A placebo maltodextrin powder is administered daily to children with functional constipation, alongside standard laxative treatment (PEG 3350) for the first 12 weeks, and then continued alone for the remainder of the 52-week study period.
215107739|NCT04040920|DEVICE|Ozone|One minute of pretreatment with ozone by using the OzoneDTA device
215107740|NCT04040920|OTHER|Pits and fissure sealants|cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';
215107741|NCT03371784|DRUG|Hydrocortisone|I.V. administration
215107742|NCT03371784|DRUG|Placebo|I.V. administration
215107743|NCT03239444|DEVICE|Intracardiac echocardiography imaging|Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
215107744|NCT02463682|DEVICE|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
215107745|NCT02463682|DEVICE|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
215107746|NCT00709618|DRUG|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
215107747|NCT02116452|DIETARY_SUPPLEMENT|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
215107748|NCT01578655|DRUG|cabazitaxel|Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
215107749|NCT01578655|DRUG|prednisone|Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles
215107750|NCT01578655|DRUG|custirsen sodium|Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
215107751|NCT05842252|PROCEDURE|greater trochanter transfer, subtrochanteric valgus osteotomy|greater trochanter transfer, subtrochanteric valgus osteotomy fixation by wagner TB and locked plate
215107752|NCT04428619|DEVICE|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial PENFS device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial PENFS device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
215107753|NCT04428619|DEVICE|Sham Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial sham device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial sham device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
215107754|NCT05620888|BEHAVIORAL|Walk behavior change: Tailored messages (TM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days."
215107755|NCT05620888|BEHAVIORAL|Walk behavior change: Non tailored messages (NTM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days."
215107756|NCT05319158|OTHER|MIT-PB, movement imitation therapy for preterm.|The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement
215107757|NCT06800820|DIETARY_SUPPLEMENT|Chondractiv™ Plus (Hydrolyzed chicken cartilage)|One oral dose
215107758|NCT04909164|DRUG|Immunnotherapy group|Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.
215107759|NCT01948063|DRUG|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
215107760|NCT01948063|DIETARY_SUPPLEMENT|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
215107761|NCT05844358|DEVICE|MySpine MC|Spinal stabilization throught the support of patient specific guide, MySpine MC according to cortical bone trajectory technique
215107762|NCT01110356|DRUG|Ferinject|Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
215107763|NCT01110356|OTHER|Saline|Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
215107764|NCT03387774|DRUG|Cisplatin|"Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy."
215107765|NCT03387774|RADIATION|Intensity Modulated Radiation Therapy|"Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225)."
215107766|NCT03387774|DRUG|Ulinastatin|"Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy."
215107767|NCT06160011|OTHER|Electrical dry needling + Conventional physiotherapy|Electrical dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
215107768|NCT06160011|OTHER|Dry needling + Conventional physiotherapy|Dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
215107769|NCT06160011|OTHER|Conventional physiotherapy|Conventional physiotherapy treatment (massage, pressure release): 2 sessions
215107770|NCT04204811|OTHER|Prehabilitation|A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.
215107771|NCT00887510|DRUG|Hydrochlorothiazide|"25 mg tablet once daily for 6 weeks~Other Names:~HCTZ"
215107772|NCT00887510|DRUG|Trandolapril|4 mg tablet once daily for 6 weeks
215107773|NCT04063163|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
215107774|NCT04063163|DRUG|carboplatin and etoposide|chemotherapeutics
215107775|NCT04063163|DRUG|placebo|placebo
215107776|NCT04728607|DEVICE|Compression device.|A compression device is a device that uses circumferential compression to reduce swelling around a stuck ring. The device is used by placing it near, but not overtop, the offending ring, and then is inflated compressing the finger. The device is applied, and the hand elevated, for approximately five minutes. The device is then removed, and with a small amount of lubricant, the ring is removed.
215107777|NCT00955539|DEVICE|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
215107778|NCT00955539|DEVICE|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
215107779|NCT00757055|DRUG|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate \< 60 bpm.
215107780|NCT00757055|DRUG|Placebo|No active treatment given
215107781|NCT06802835|DRUG|EGFR Antibody|6 cycles for combined therapy. Maintenance for 1 year.
215107782|NCT06802835|DRUG|PD-1 antibody|6 cycles for combined therapy. Maintenance for 1 year.
215107783|NCT06802835|DRUG|Gemcitabine, Cisplatin|6 cycles for combined therapy.
215107784|NCT06802835|RADIATION|IMRT|IMRT for primary lesion
215107785|NCT04951583|COMBINATION_PRODUCT|FMT + ICI|"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."
215107786|NCT02595905|DRUG|Cisplatin|Given IV
215107787|NCT02595905|OTHER|Laboratory Biomarker Analysis|Correlative studies
215107788|NCT02595905|OTHER|Placebo Administration|Given PO
215107789|NCT02595905|DRUG|Veliparib|Given PO
215107790|NCT03781414|BIOLOGICAL|CFZ533|Comparison with standard of care immunosuppression
215107791|NCT03781414|DRUG|Tacrolimus - MMF - corticosteroids|Standard of care immunosuppresive regimen
215107792|NCT06584461|DRUG|Lidocaine (drug)|IV lidocaine, administered once during the induction of anesthesia.
215107793|NCT06584461|DRUG|Saline (NaCl 0,9 %) (placebo)|IV placebo (normal saline), administered once during the induction of anesthesia.
215107794|NCT02644577|DRUG|Metformin|
215107795|NCT02644577|OTHER|Starch|
215107796|NCT02742376|OTHER|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
215107797|NCT02742376|OTHER|Floor|A marked path on the floor where the subject is instructed to walk.
215107798|NCT02742376|OTHER|Kyboot shoes|Special shoes will be worn by the subject.
215107799|NCT06451081|BEHAVIORAL|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
215107800|NCT06451081|BEHAVIORAL|Opt-out active referral|Participants will be automatically referred to a smoking cessation service upon joining the trial, unless they choose to opt out. Contacts of participants will be delivered to a service provider of their choice or based on their living district and preferred treatment modality
215107801|NCT06451081|BEHAVIORAL|Behavioral economic mobile messaging|Participants will receive behavioural economics-informed messages via mobile instant messaging for 3 months
215107802|NCT06451081|BEHAVIORAL|Opt-in active referral|Participants will be offered a referral to a smoking cessation service. Contacts of participants who opt-in will be delivered to a service provider of their choice
215107803|NCT04752358|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
215107804|NCT01049529|DIETARY_SUPPLEMENT|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
215107805|NCT01049529|DIETARY_SUPPLEMENT|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
215107806|NCT06549660|DEVICE|Active PBMT|Active with a dose of 165 J per site, resulting in a total dose of 495J.
215107807|NCT06549660|DEVICE|Placebo PBMT|Placebo, without therapeutic dose.
215107808|NCT00719355|BEHAVIORAL|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
215107809|NCT00719355|BEHAVIORAL|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
215107810|NCT03623568|DRUG|glecaprevir/pibrentasvir tablets|12 weeks of treatment with Mavyret
215107811|NCT06152588|OTHER|Time restricted eating|"3 months (12 weeks) strict TRE intervention: Participants will be instructed to reduce their eating window by minimum 3 hours compared to habitual eating, with an eating window below 10 hours. The timing of the eating window is self-selected but should be placed between 6 am and 8 pm. Diet during the eating window is ad libitum with no further dietary restrictions.~9 months (40 weeks) individually adjusted TRE intervention: An individual plan will be made based on participants' experiences during the strict TRE. Different choices of individual adjustment and support will be provided, including 1) eating window adjustments and the possibility of 'days off', 2) provision of a list of allowed calorie and caffeine free beverages that can be consumed outside the window, 3) continued opportunity to participate in peer-support group meetings, 4) extra phone calls with a project worker to discuss challenges or strategies to continue with TRE etc., and 5) further involvement of relatives."
215107812|NCT04054375|DRUG|Prednisone|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
215107813|NCT03364738|BIOLOGICAL|rhPTH(1-84)|Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.
214424458|NCT00329732|DRUG|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
214424459|NCT00329732|DRUG|Saline placebo|matching volume of saline (placebo)
214424460|NCT00664911|OTHER|chemotherapy|
214424461|NCT01125306|DEVICE|Xal-Ease|Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
214424462|NCT00411099|DRUG|agomelatine|
214424463|NCT00411099|DRUG|placebo|
215107814|NCT00766714|DEVICE|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
215107815|NCT00766714|DEVICE|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
215107816|NCT02932748|DIETARY_SUPPLEMENT|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
215107817|NCT02932748|BEHAVIORAL|Group Phone (GP)|Weight management program delivered via group conference call.
215107818|NCT02932748|DIETARY_SUPPLEMENT|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
215107819|NCT02932748|BEHAVIORAL|Individual Phone (IP)|Weight management program delivered via individual phone call.
215107820|NCT02932748|BEHAVIORAL|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
215107821|NCT03009734|DRUG|ATx201 dermal formulations 2%|Topical application of ATx201 dermal formulations 2%
215107822|NCT03579043|OTHER|Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
215107823|NCT03579043|OTHER|Non-Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
214509781|NCT02203032|DRUG|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
215107824|NCT03579043|OTHER|Carbonated Water|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
215107825|NCT05716360|DIAGNOSTIC_TEST|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
215107826|NCT05716360|PROCEDURE|Aneurysm Treatment with Flow-Diversion Therapy|Aneurysm Treatment with Flow-Diversion Therapy
215107827|NCT05716360|PROCEDURE|Aneurysm Treatment with Metalic Bare Stent|Aneurysm Treatment with Metalic Bare Stent
215107828|NCT02750319|DRUG|Amiodarone|
214509782|NCT02203032|DRUG|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
214509783|NCT04958837|OTHER|FIFA 11+ protocol with additional Core training exercises|Slow paced running exercises of 8 minutes' duration (2 rounds each), followed by Strength, plyometric and balance exercises including 3 sets of 20-30 sec of The Bench, Sideways Bench each side, Nordic Hamstring strengthening, single leg stance balance training, squatting and high speed running. The protocol will end with additional core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge. Each exercise plan will be progressively increased. Core training will be followed by 30 sec stretch of major muscle groups.
215107829|NCT02750319|DRUG|N-Acetylcysteine|
215107830|NCT02750319|DRUG|Placebo|
215107831|NCT02523781|OTHER|information pamphlet|The intervention group receives the information pamphlet
215107832|NCT01147354|DIETARY_SUPPLEMENT|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
215107833|NCT01147354|OTHER|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
215107834|NCT01847989|DRUG|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
215107835|NCT01847989|DRUG|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
215107836|NCT02156414|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
215107837|NCT02156414|PROCEDURE|Extended Lymphadenectomy|Extended Lymphadenectomy
215107838|NCT02663830|DRUG|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
214509784|NCT04958837|OTHER|FIFA 11+ protocol|Slow paced running exercises of 8 minutes' duration including running straight, running with hip out, running hip in, running circling partner, running shoulder contact and running quickly forward and backwards (2 rounds each), followed by Strength, plyometric and balance exercises including The Bench, Sideways Bench each side, Nordic Hamstring strengthening and single leg stance balance training, squatting and jumping. All exercises will be progressively increased as per established protocol. The final phase of the study includes fast running for 2 minutes.
214509785|NCT02258178|BIOLOGICAL|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
215107839|NCT02663830|DRUG|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
215107840|NCT00066963|DEVICE|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
215107841|NCT03377153|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
215107842|NCT03377153|OTHER|control|no supplementation
215107843|NCT00988091|DEVICE|1.2% Sodium Hyaluronate|IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).
215107844|NCT00988091|DEVICE|Buffered Saline|IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
215107845|NCT03023293|OTHER|n-3 PUFAs consumption and irisin|The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
215107846|NCT00994422|DRUG|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
215107847|NCT00994422|DRUG|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
215107848|NCT01520376|BEHAVIORAL|Counselling|Visit by a psychiatrist at day-30 and day-180 after discarge
215107849|NCT05118698|DRUG|Gynostemma|Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
215107850|NCT05118698|OTHER|Spinach|For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
215107851|NCT02087111|DRUG|Telaprevir|375 mg film coated tablets
215107852|NCT02087111|DRUG|40 Kd Pegylated interferon alfa 2a|180 µg in pre-filled syringe for sub-cutaneous injection
215107853|NCT02087111|DRUG|Ribavirin|200 mg tablets
215107854|NCT00276809|BIOLOGICAL|alemtuzumab|
215107855|NCT00276809|BIOLOGICAL|filgrastim|
215107856|NCT00276809|DRUG|carmustine|
215107857|NCT00276809|DRUG|cyclophosphamide|
215107858|NCT00276809|DRUG|cytarabine|
215107859|NCT00276809|DRUG|dexamethasone|
215107860|NCT00276809|DRUG|etoposide|
215107861|NCT00276809|DRUG|fludarabine phosphate|
215107862|NCT00276809|DRUG|melphalan|
215107863|NCT00276809|PROCEDURE|autologous bone marrow transplantation|
215107864|NCT00276809|PROCEDURE|peripheral blood stem cell transplantation|
215107865|NCT00276809|RADIATION|radiation therapy|
215107866|NCT00765180|DEVICE|TRE vs. NBI|TRE NBI
214509786|NCT06269497|PROCEDURE|Scaffold placement|The scaffold is placed in the alveola following extraction
214509787|NCT06269497|RADIATION|CBCT|A Cone Beam Computer Tomography (CBCT) is taken of the area of interest after surgery
214509788|NCT03371316|BIOLOGICAL|ViaShield|Anti-adhesion scores using amnion patch
214509789|NCT01192555|BIOLOGICAL|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|"1x10\^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
214509790|NCT01192555|DRUG|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
214692175|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.~Pleasant odorants will be delivered using passive diffusers placed in the room dedicated to the iTBS protocol, during the all-treatment duration. During the inclusion phase, 10 odors known to be pleasant will be presented to the subject. The 3 best rated by the subject will be chosen for olfactory stimulations. During the iTBS session, a randomly selected odor from the 3 will be presented at the same time as the iTBS treatment."
215028342|NCT05937048|BIOLOGICAL|Albumin|20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
215028343|NCT05937048|OTHER|Standard of Care|Standard treatment that the patient would receive had they not been included in the trial.
215028344|NCT05811013|DEVICE|Transcranial static magnetic field stimulation (tSMS)|Patients will be randomly assigned to either real or sham tSMS. Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Patients will choose whether to undergo stimulation at home or in the hospital on an outpatient setting. Real tSMS will be delivered with two cylindrical neodymium magnets (grade N45) of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), applied with south polarity, each pointing toward the motor cortex. To discharge the weight of the helmet from the head during the sessions, patients will be instructed to rest the back of head and helmet on an inclined surface in a comfortable position. They will be also instructed to rest, minimizing movement, and not to watch audiovisuals during the stimulation sessions.
215028345|NCT05811013|DEVICE|Sham Transcranial static magnetic field stimulation (tSMS)|Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain).
215028346|NCT04717258|OTHER|Fire and Rescue Service Safe and Well Visit|Safe and Well Visits by the Fire and Rescue Service to prevent falls and improve quality of life in an older population
215028347|NCT04717258|OTHER|Self-Determination Theory informed trial invitation letter|Invitation letter to take part in the FIREFLI study informed by Self-Determination Theory
215028348|NCT04717258|OTHER|Pen included with reminder questionaire|A pen will be included with the four-month reminder questionnaire.
215028349|NCT05146778|PROCEDURE|Opioid-free anesthesia|OFA group will be sedated using dexmedetomidine and lidocaine.
215028350|NCT05146778|PROCEDURE|Conventional opioid-based anesthesia|Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
215028351|NCT03988933|DRUG|Rifampin double dose|Double dose of rifampin for 2 months.
215028352|NCT03988933|DRUG|Rifampin triple dose|Triple dose of rifampin for 2 months.
215028353|NCT03988933|DRUG|Rifampin standard dose|Standard dose of rifampin for 4 months.
215028354|NCT04636073|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
215028355|NCT03705234|DRUG|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
215028356|NCT03705234|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
215028357|NCT05044871|DRUG|Pamiparib|40mg PO. bid.
215028358|NCT05044871|DRUG|Bevacizumab|7.5mg/kg IV. D1 (q3w.)
215028359|NCT05044871|DRUG|Tislelizumab|200mg IV. D1
215028360|NCT05044871|DRUG|Nab paclitaxel|125mg / m2 IV. D1, 8 (q3w).
215028361|NCT05044871|DRUG|Bevacizumab + Nab paclitaxel (intense dose-dense)|Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
215028362|NCT06277115|DEVICE|Continuous positive airway pressure (CPAP)|Nocturnal continuous positive airway pressure therapy is the gold standard treatment for symptomatic OSA. It provides positive pressure via a nasal or oronasal mask to prevent upper airway collapse during sleep.
215028363|NCT02759809|OTHER|Pasteurized donor human breastmilk|
215028364|NCT02759809|OTHER|Preterm formula|
215028365|NCT01257243|DRUG|Syrup of oxomemazine, guaifenesin and potassium iodate|5ml each 4 hours
215028366|NCT01257243|DRUG|Syrup of guaifenesin|5ml each 4 hours
215028367|NCT06311734|DRUG|LW231 tablets|P.O.
215028368|NCT06311734|DRUG|Placebo|P.O.
215028369|NCT04105361|PROCEDURE|Posterior neurectomy|Cut of posterior nasal nerve
215028370|NCT04839926|DRUG|0.5mg CY150112|single oral CY150112 while fasting on day 1.
215107867|NCT01162902|DRUG|Diltiazem treated group|Diltiazem 180mg for 9 months
215107868|NCT01162902|DRUG|Bisoprolol treated group|Bisoprolol 5mg for 9 months
214509791|NCT01915914|DRUG|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
214509792|NCT05038202|DRUG|Bencycloquidium Bromide Nasal Spray|"The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist.~This product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis."
214509793|NCT05038202|DRUG|Mometasone Furoate Aqueous Nasal Spray|"Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension.~This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment."
215107869|NCT01162902|DRUG|Candesartan treated group|Candesartan 32mg for 9 months
214509794|NCT04700202|OTHER|Observational|Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP
214509795|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
214509796|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
214509797|NCT03278977|BIOLOGICAL|Blood sample for specific analyzes|"Standard management of ALTE~* Hospitalization in pediatric intensive care unit or pediatric emergencies~* Etiologic research~* Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)"
215028371|NCT04839926|DRUG|1.5mg CY150112|single oral CY150112 while fasting on day 1.
215028372|NCT04839926|DRUG|4.5mg CY150112|single oral CY150112 while fasting on day 1.
215028373|NCT04839926|DRUG|10mg CY150112|single oral CY150112 while fasting on day 1.
215028374|NCT04839926|DRUG|18mg CY150112|single oral CY150112 while fasting on day 1.
215028375|NCT04839926|DRUG|24mg CY150112|single oral CY150112 while fasting on day 1.
215028376|NCT01337505|DRUG|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
215028377|NCT02346812|OTHER|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
215028378|NCT02346812|OTHER|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
215028379|NCT04384497|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
215028380|NCT03448835|DRUG|Atezolizumab|atezolizumab 1200 mg 5 cycles
215028381|NCT03448835|DRUG|Capecitabine|capecitabine 850 mg /m2 4 cycles
215028382|NCT03448835|DRUG|Oxaliplatin|oxaliplatin 100 mg/m2 4 cycles
215028383|NCT03448835|DRUG|Docetaxel|docetaxel 50 mg/m2 4 cycles
215028384|NCT02115672|DRUG|BL-8040|BL-8040 will be added to imatinib to improve CML response.
215028385|NCT04898309|DRUG|GNR-038, 50 МЕ/ kg|A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
215028386|NCT04898309|DRUG|GNR-038, 100 МЕ/ kg|A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
215028387|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
215028388|NCT04898309|DRUG|Placebo|A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
215028389|NCT04898309|DRUG|GNR-038. The dose will be selected according to results of stage 1 clinical trial.|A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
215028390|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
215028391|NCT05787782|DEVICE|Masimo INVSENSOR00063|Masimo INVSENSOR00063 will be used to measure temperature
215028392|NCT01713244|PROCEDURE|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
215028393|NCT01713244|PROCEDURE|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
215028394|NCT06193239|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
215028395|NCT05841667|DRUG|Remimazolam besylate|"This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam."
215028396|NCT03026777|DRUG|intravenous crystalloid fluid, 500 mL|
215028397|NCT04804345|OTHER|standard of care|retrospective study: standard of care
215028398|NCT05030389|BEHAVIORAL|Adapted Physical Activity (APA)|The APA program lasts 12 weeks and consists in three one-hour at-home sessions a week (total of 36 sessions), including two aerobic dominant web-based sessions and one muscle strengthening self-guided session.
215028399|NCT05030389|BEHAVIORAL|Bright Light Exposure (BLE)|Bright light exposure (BLE) consists in using lamps for light therapy during 12 weeks, at the rate of five one-hour at-home sessions a week.
214509798|NCT05058157|DIETARY_SUPPLEMENT|different ketogenic formulae|The research product may be in a form of powder to reconstitute or in a ready-to-drink format.
214509799|NCT03450811|PROCEDURE|Inguinal hernia repair|Lichtenstein procedure or laparoscopic method (Total extraperitoneal) inguinal hernia repair
214509800|NCT00454922|BEHAVIORAL|standard of care|no intervention
214509801|NCT00454922|OTHER|education|meet with trained glaucoma educator 6 times over life of study
214509802|NCT02541292|OTHER|No intervention, observational|
214509803|NCT00519935|BEHAVIORAL|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
214509804|NCT02918045|DEVICE|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
214509805|NCT02918045|DEVICE|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
214509806|NCT04890457|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
214509807|NCT04890457|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
214509808|NCT01615770|BEHAVIORAL|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
214509809|NCT00116649|DRUG|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
214509810|NCT03869970|BEHAVIORAL|REST|The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals
214509811|NCT03869970|BEHAVIORAL|ACTIVITY|ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.
214509812|NCT03869970|BEHAVIORAL|mHEALTH|mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
215107870|NCT04423692|OTHER|labs|A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy
215107871|NCT06364462|OTHER|lifestyle intervention|Dietary recommendations should consider energy restriction and exclusion of MAFLD-mediating components (processed food, food and beverages high in added fructose). A Mediterranean type diet is advisable. Both aerobic exercise and resistance training effectively reduce liver fat and should be tailored based on patient preferences to ensure long-term adherence.
215107872|NCT03637478|BEHAVIORAL|Enhanced Systems of Care Team|E-SOC team will be increasing connections between clinical care and community partners, such as schools, juvenile justice and child-serving state agencies, to reduce disparities in access to mental health/substance use evaluation and treatment. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning. Overall goals are: earlier identification of mental health needs including child trauma; increased treatment access and adherence; care delivered in least restrictive settings; care experience reflecting active youth and family engagement; program sustainability and replicability.
215107873|NCT03405519|PROCEDURE|Radiotherapy planning using both CT and MRI scans|Patients' radiotherapy will be planned using CT and MRI scans in order to establish the best methodology for planning of radiotherapy for nodal disease
215107874|NCT02333019|BEHAVIORAL|Let's Talk About Sex|Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
215107875|NCT02333019|BEHAVIORAL|Websites; preventing teen pregnancy|Two general web sites with information about preventing teen pregnancy
215107876|NCT03106467|PROCEDURE|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
214509813|NCT00297466|DRUG|transdermal nicotine patches|
214509814|NCT00297466|BEHAVIORAL|Motivational interview|
215107877|NCT03106467|PROCEDURE|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
215107878|NCT00820872|BIOLOGICAL|trastuzumab|
215107879|NCT00820872|DRUG|carboplatin|
215107880|NCT00820872|DRUG|docetaxel|
215107881|NCT00820872|DRUG|lapatinib ditosylate|
215107882|NCT05788913|BIOLOGICAL|Heparin|subcutaneous Heparin
215107883|NCT03574402|DRUG|Avitinib Maleate|300mg orally (PO) twice daily (BID) on day 1-28.
214509815|NCT02114515|BEHAVIORAL|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
215107884|NCT03574402|DRUG|Afatinib|40mg orally once a day, 28 days as one cycle.
215107885|NCT03574402|DRUG|Crizotinib|250mg PO QD on days 1-28. 28 days as one cycle.
215107886|NCT03574402|DRUG|X-396|225mg PO QD on days 1-28. 28 days as one cycle.
215107887|NCT03574402|DRUG|Chidamide|30mg orally twice weekly, 28 days as one cycle.
215107888|NCT03574402|DRUG|Pyrotinib Maleate|400mg PO QD on days 1-28. 28 days as one cycle.
215107889|NCT03574402|DRUG|AZD3759|200mg PO BID on days 1-28. 28 days as one cycle.
215107890|NCT03574402|DRUG|Pirotinib|60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
215107891|NCT03574402|DRUG|Nimotuzumab|400mg, iv gtt. on day 1,8,15. 21 days as one cycle.
214509816|NCT02114515|BEHAVIORAL|Navigator intervention|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
214509817|NCT02114515|BEHAVIORAL|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
214509818|NCT01177449|PROCEDURE|Prolotherapy|inject normal saline and 50% glugose water with 1:1 ratial in volumn
215107892|NCT03574402|DRUG|Pemetrexed|500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.
214509819|NCT02994004|OTHER|no intervention|
214509820|NCT01213940|BEHAVIORAL|pre-bariatric weight loss program|standard 6 month physician directed pre-bariatric weight loss program
214509821|NCT01213940|PROCEDURE|bariatric surgery|bariatric surgery for weight loss
215107893|NCT03574402|DRUG|Cisplatin|75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.
215107894|NCT03574402|DRUG|Sintilimab|200mg iv gtt. Q3W on day1. 21 days as one cycle.
215107895|NCT03574402|DRUG|Gemcitabine|1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
215107896|NCT03574402|DRUG|Gemcitabine|1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
215107897|NCT03574402|DRUG|Carboplatin|AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
215107898|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
215107899|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
215107900|NCT01354366|OTHER|Infant formula|
215107901|NCT05533970|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.
215107902|NCT05120141|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
215107903|NCT05120141|OTHER|American Dental Association (ADA) Ref Toothbrush|Participants will use soft bristled Toothbrush for brushing teeth twice daily.
215107904|NCT05120141|OTHER|Prototype 1 Mouth Rinse|Participants will use 20 mL of Prototype 1 Mouth Rinse for 30 seconds after brushing twice daily.
215107905|NCT05120141|OTHER|Prototype 2 Mouth Rinse|Participants will use 20 mL of Prototype 2 Mouth Rinse for 30 seconds after brushing twice daily.
215107906|NCT05120141|OTHER|Prototype 3 Mouth Rinse|Participants will use 20 mL of Prototype 3 Mouth Rinse for 30 seconds after brushing twice daily.
215107907|NCT05120141|OTHER|Listerine Cool Mint Mouth Rinse|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
215107908|NCT05120141|OTHER|Hydroalcohol Mouth Rinse|Participants will use 20 mL of Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
215107909|NCT02692378|DRUG|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
215107910|NCT05178485|DRUG|Bupivacain|FDA approved drug
215107911|NCT05178485|OTHER|Normal Saline|FDA approved
215107912|NCT05111028|BIOLOGICAL|Autologous Room Temperature stored Platelet transfusion|An autologous transfusion of platelets stored at 22°C for 7 days.
215107913|NCT05111028|BIOLOGICAL|Autologous Cold Stored Platelet transfusion|An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
215107914|NCT06527417|DEVICE|Neuro Trac Myo Plus Pro|Electrical stimulation parameters; stimuli were monophasic, rectangular, stimulus duration 300 µs, frequency 25 Hertz, amplitude was increased up to a maximum of 100 milliampere until contraction was seen.
215107915|NCT06527417|OTHER|Trunk eccentric exercises|The control group performed back eccentric exercises for 4 weeks, 3 times a week, 3 times in each session
215107916|NCT05199961|BEHAVIORAL|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
215107917|NCT06526559|DEVICE|Barbed suture|Use of two absorbable barbed sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
215107918|NCT06526559|DEVICE|PGA suture|Use of two absorbable polyglactin sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
215107919|NCT02077400|DRUG|Cephazolin|Cephazolin
214509822|NCT02659540|DRUG|Nivolumab|Nivolumab was administered as an intravenous (IV) infusion over approximately 30 or 90 minutes, with dosing calculated using body weight.
214509823|NCT02659540|DRUG|Ipilimumab|Ipilimumab was administered as an IV infusion over approximately 30 or 90 minutes, with dosing calculated using body weight. The ipilimumab infusion was initiated approximately 30 minutes after the end of the nivolumab infusion on applicable dosing days.
214509824|NCT02659540|RADIATION|Radiotherapy|RT was delivered in accordance with cohort assignment and institutional practices.
214509825|NCT02725372|DRUG|Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
215107920|NCT01238328|DRUG|Conditioning regimen|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
215107921|NCT01238328|DRUG|Graft-versus-host disease (GVHD) prophylaxis|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
214509826|NCT02725372|DRUG|Placebo|Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
214509827|NCT06369844|OTHER|Pressure injury education|Pressure injury education will be provided to participants in the intervention group in three separate sessions covering the topics of Pressure Injury Definition and Classification, Risk Assessment, Prevention, and Care.
215107922|NCT01238328|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
215107923|NCT00225095|DRUG|Mesenchymal Stem Cells|
215107924|NCT00225095|DRUG|Hyaluronan|
215107925|NCT04354883|PROCEDURE|External Chest Compressions on Manikin in Underwater Setting|Two different methods of CPR in an analogue model of mircogravity
215107926|NCT05656482|OTHER|Cats fed with PRO PLAN® LIVECLEAT®|Patient with domestic cats fed with an egg product containing anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®)
215107927|NCT05095168|DRUG|CAN106|CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.
215107928|NCT05095168|DRUG|Placebo|placebo
215107929|NCT03845595|DEVICE|(LF-rTMS) group|"The (LF-rTMS) (low frequency repetitive transcranial magnetic stimulation) group received 1-hertz (HZ) stimulation at 90% of motor threshold to the hot spot of the primary cerebral cortex, using a 70-mm figure- 8 coil and Magstim Rapid2 stimulator (Magstim Company, USA). Contralesional 1 HZ \*rTMS\* applied over the primary motor area hot spot at 90% of Active motor threshold . Each rTMS session consisted of 1,200pulses; lasting 20 minutes The optimal site of stimulation on the skull are known as the hot spot . Hot spots were found by searching for loci that triggered maximum visible contraction in the contralateral first dorsal interosseous \*FDI\* muscle, while the patient is contracting his whole limb as much as possible ."
215107930|NCT03845595|OTHER|Control group|neurodevelopmental technique (NDT) ( including Bobath and Brunnstrom approaches , proprioceptor and exteroceptor stimulation for the weak and inhibition for the hyperactive muscle groups, proprioceptive neuromuscular facilitation (PNF) specific techniques, Approximation and weight bearing, placing technique). Task-oriented training (moving, grasping and releasing bottles ,cups , small toys). Active participation of the whole hemiparetic upper extremity in different motor task training with coordination and Bilateral arm training exercise.
215107931|NCT00558181|DRUG|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
215107932|NCT01622777|DRUG|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
215107933|NCT01622777|DRUG|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
215107934|NCT05040074|DEVICE|SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System|Transesophageal echocardiography-guided, implantable mitral valve clip repair system
215107935|NCT00742755|BEHAVIORAL|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
215107936|NCT02416895|OTHER|In vivo immunity model|A measure of in vivo immune function.
215107937|NCT00808548|OTHER|counseling, emotional support|
215107938|NCT00808548|OTHER|emotional support|emotional support during the interview
214509828|NCT04216641|DIETARY_SUPPLEMENT|Adapted food intervention|Adapted food intervention
214509829|NCT00147667|DRUG|Erythromycin|
214509830|NCT01583959|DRUG|Folic Acid|Folic acid tablets 5 mg
214509831|NCT01583959|DRUG|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
214509832|NCT05290090|DRUG|Rituximab, Lenalidomide, Zanubrutinib and RCHOP|"chemo free period (21 days as a cycle, a total of 2 cycles): rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~Immunochemotherapy period: RCHOP regimen (21 days as 1 cycle, a total of 4 cycles): rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
214509833|NCT03305172|BEHAVIORAL|Financial Incentive|Giving different structures of long term (36 weeks) financial incentives to increase physical activity
214509834|NCT02118922|PROCEDURE|Brillouin imaging|
214509835|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
215107939|NCT00808548|OTHER|emotional support|emotional supporting during the interview
215107940|NCT04007419|BEHAVIORAL|Health Promoters and Organ Donation|Promotoras de Donación is a highly engaging and interactive online learning experience, that accommodates multiple learning styles by incorporating a variety of pedagogic approaches. The module consists of two components: a didactic educational component and a skills-based communication component. The didactic component provides basic information about organ donation and transplantation and the need for donors in the Hispanic community, and addresses concerns about donation commonly held by older Latina. The skills-based component provides instruction on the key communication skills needed to effectively engage small groups in discussions about organ donation. This component is intended to build communication self-efficacy or confidence opening the discussion about donation, addressing concerns raised by mature and older women participating in the small group sessions, and promoting the act of donor registration using persuasive, but non-coercive language.
215107941|NCT01569048|DRUG|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
215107942|NCT01569048|DRUG|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
215107943|NCT01846741|DEVICE|M106 VNS Therapy System|
214509836|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
214509837|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
214692176|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session."
215107944|NCT03664765|OTHER|UA and RMT|daily oropharyngeal and respiratory muscle exercises
215107945|NCT03664765|OTHER|Sham exercise|Daily sham exercises
215107946|NCT04260945|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
215107947|NCT01153698|DRUG|dabigatran|anticoagulation
215107948|NCT01090063|DRUG|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
215107949|NCT00088894|DRUG|gemcitabine hydrochloride|Given IV
215107950|NCT00088894|BIOLOGICAL|bevacizumab|Given IV
215107951|NCT00088894|OTHER|placebo|Given IV
215107952|NCT00088894|OTHER|laboratory biomarker analysis|Correlative studies
215107953|NCT00088894|OTHER|pharmacogenomic studies|Correlative studies
214424464|NCT01038349|OTHER|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
215107954|NCT00088894|OTHER|pharmacological study|Correlative studies
215107955|NCT01093391|DEVICE|DRUG ELUTING STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
214424465|NCT01948804|DRUG|GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)|
214424466|NCT01948804|DRUG|microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)|
214424467|NCT01948804|DRUG|Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)|
214424468|NCT01948804|DRUG|GnRH antagonist protocol (Cetrotide, Serono)|
214424469|NCT02551055|DRUG|MLN1117|MLN1117 Tablets
214424470|NCT02551055|DRUG|TAK-659|TAK-659 Tablets
214509838|NCT01412736|DRUG|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
214509839|NCT05563948|DRUG|Cannabis|Vaporized cannabis will be administered 3x/day for 15 days.
214509840|NCT01075152|DRUG|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
214509841|NCT01075152|BIOLOGICAL|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
215028400|NCT05030389|BEHAVIORAL|Galvanic Vestibular Stimulation (GVS)|The GVS program lasts 2 weeks and consists in five 20-minutes at-home sessions a week (total of 10 sessions), using a portable galvanic stimulator.
215028401|NCT05030389|BEHAVIORAL|Health Education program (HE)|The HE program lasts 14 weeks and consists in one one-hour at-home session a week (total of 14 sessions). This web-based intervention includes courses on general health (sleep habits, diet, physical activity, cardiovascular diseases, etc.).
215028402|NCT01881958|DRUG|DiaPep277®|
215028403|NCT03871504|OTHER|Submaximal isometric exercise|The exercise is a submaximal isometric contraction
214424471|NCT02551055|DRUG|Alisertib|Alisertib Tablets
214424472|NCT02551055|DRUG|Paclitaxel|Paclitaxel intravenous infusion
214424473|NCT02551055|DRUG|Docetaxel|Docetaxel intravenous infusion
214424474|NCT02023125|DRUG|Alectinib|A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
215107956|NCT01093391|DEVICE|BARE METAL STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
215107957|NCT04844853|DEVICE|electroencephalography|128-channel electroencephalography
215107958|NCT04844853|DEVICE|Tactile stimulation|Vibrotactile sequence on the forearm
215107959|NCT04844853|BEHAVIORAL|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
215107960|NCT04844853|BEHAVIORAL|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
215107961|NCT04844853|BEHAVIORAL|Laby 5-12|Test of motor planning using labyrinths
215107962|NCT04844853|BEHAVIORAL|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
215107963|NCT04844853|BEHAVIORAL|Stroop animals|Stroop test for preK children using animals instead of words
215107964|NCT03676907|PROCEDURE|double layer suturation technique|in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
215107965|NCT01478724|DIETARY_SUPPLEMENT|Milk proteins fraction|capsules, one per day, 24 months
215107966|NCT05758350|BEHAVIORAL|home based IOPI swallow training|Use IOPI for tongue and labial muscle resistance training. Conventional training was the same as controlled group.
214424475|NCT02023125|DRUG|Esomeprazole|Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
214424476|NCT02023125|OTHER|High Fat and Calorie Meal|High fat and calorie meal served prior to alectinib administration
214424477|NCT02023125|OTHER|Standard Meal|Standard meal served prior to alectinib administration
214424478|NCT02969954|OTHER|Self-efficacy for diabetes management|Participants at both sites will watch a 12 minute video featuring the digital stories on diabetes. Following the video, participants will engage in a brief facilitated discussion regarding motivations and barriers to diabetes management, led by a trained Spanish-speaking facilitator.
214424479|NCT01597752|BIOLOGICAL|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
215107967|NCT01817959|DRUG|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.
215107968|NCT01817959|DRUG|Placebo|Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
215107969|NCT04043650|BEHAVIORAL|HeartSteps|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
215107970|NCT05494034|DEVICE|Reveal LINQTM|"implantable cardiac monitoring device (Reveal LINQTM)"
215107971|NCT02326233|BIOLOGICAL|Pen of SB5|
215107972|NCT02326233|BIOLOGICAL|PFS of SB5|
215107973|NCT03440489|DIAGNOSTIC_TEST|Six-minute walking test|physical performance of the muscle measured by these tests
215107974|NCT03440489|DIAGNOSTIC_TEST|30 seconds chair stand test|physical performance of the muscle measured by these tests
215107975|NCT06260306|OTHER|Hip activation home exercise program|The hip activation HEP group will receive a combination of hip musculature activation exercises used by previous researchers that show an increase in hip muscle recruitment. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
215107976|NCT06260306|OTHER|Hip activation plus core stabilization home exercise program|The hip activation plus core stabilization HEP group will receive the same hip exercises, plus core stabilization exercises used by previous researchers. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
215107977|NCT02632487|BEHAVIORAL|Exercise|Center-based walking + balance, stretching, and light resistance
215107978|NCT02632487|BEHAVIORAL|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
215107979|NCT00748319|OTHER|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
215107980|NCT00917488|OTHER|Standardization of allergenic extract (Gly. domesticus)|Allergenic extract for cutaneous prick-test
215107981|NCT01810315|DRUG|TFV 1% gel|
215107982|NCT01810315|DRUG|Estradiol vaginal cream|
215107983|NCT02356848|BEHAVIORAL|Tailored Intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
215107984|NCT02356848|BEHAVIORAL|Current Practice (CP)|this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
215107985|NCT05026216|DRUG|Qwo|Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids. Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids.
215107986|NCT00961714|DEVICE|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
215107987|NCT04807049|OTHER|Observational|Observational
215107988|NCT03470402|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
215107989|NCT03470402|OTHER|BNAV|BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.
214509842|NCT03700034|OTHER|mHealth Integrated Model of Antenatal Care|"In the intervention facilities, antenatal care (ANC) will be provided to all pregnant women using the mIRA electronic decision support system (EDSS) by ANMs (Auxiliary Nurse Midwife), Staff nurses, or Medical Officers (MOs). These frontline healthcare workers (FHWs) will be trained to use the EDSS and will also be provided refresher training on the guideline-recommended processes of ANC. This training will enable them to use the mIRA EDSS in the provision of ANC. Non-physician FHWs (ANMs and staff nurses) will screen, detect, and refer PIH, GDM, and severe anemia cases. They will not prescribe treatments, but will carry out all other duties including diagnosis, referral to the MO to prescribe drugs, provide lifestyle advice, follow-up, and subsequently support adherence to management plans."
215107990|NCT03470402|OTHER|iNYP|Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
214509843|NCT03681366|DEVICE|DISC3.5 plus|The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
214692177|NCT01217281|PROCEDURE|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
215107991|NCT03470402|OTHER|Standard Educational Material|Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
215107992|NCT03470402|OTHER|High-Risk Message|Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
215107993|NCT02537184|PROCEDURE|Oral Clinical conditions|caries incidence assessment dental anxiety assessment
215107994|NCT04503824|DIAGNOSTIC_TEST|saliva samples|Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.
215107995|NCT00016991|DRUG|gefitinib|
215107996|NCT02457949|OTHER|Non-synchronized social assistance receipt|Social assistance disbursement outside government cheque issue week
215107997|NCT02457949|OTHER|cheque divided into two equal disbursements|Social assistance disbursement divided into two equal payments
215107998|NCT03684382|OTHER|NeW-I group|A 5-week intervention offered to parents of children with chronic life-threatening illness using an internet-based narrative approach with life review elements. After completion of the first four weeks of the intervention, participants will receive a 'legacy' document which is a compiled and edited document of their narrative expression during the first four weeks. This legacy document is structured in a manner that enables participants to find a sense of spiritual well-being and hope in their experience of caring for their child through examination of past experiences and achievements as well as future aspirations.
215107999|NCT04787991|DRUG|Nivolumab (Cohort A)|Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.
215108000|NCT04787991|DRUG|Ipilimumab (Cohort A, B and C)|For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.
215108001|NCT04787991|DRUG|Hydroxychloroquine (HCQ) (Cohort B)|Hydroxychloroquine will be administered orally daily for up to 2 years.
215108002|NCT04787991|DRUG|Nab-paclitaxel (nP) (Cohort A, B and C)|Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
215108003|NCT04787991|DRUG|Gemcitabine (gem) (Cohort A, B and C)|Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
215108004|NCT04787991|DRUG|NG350A (Cohort C)|NG-350A will be administered intravenously on Cycle 1 Days 15 (1e12 viral particles), 17 (3e12 viral particles), and 19 (3e12 viral particles).
215108005|NCT04770792|OTHER|2% chlorhexidine gluconate with mineral trioxide aggregate.|2% chlorhexidine gluconate with mineral trioxide aggregate.
215108006|NCT04770792|OTHER|Mineral trioxide aggregate.|Mineral trioxide aggregate.
214692178|NCT04827238|DIAGNOSTIC_TEST|Standardized Invasive Hemodynamics|The SIH technique is a standardized, reproducible and efficient way of obtaining hemodynamic measurements.
215108007|NCT05266391|OTHER|subacromial corticosteroid injections|Patients with SAIS whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate).
215108008|NCT02484222|DRUG|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
215108009|NCT02065817|OTHER|stable isotope of cholesterol|
215108010|NCT05861661|OTHER|The study do not include an intervention|The study do not include an intervention
215108011|NCT04715971|DIAGNOSTIC_TEST|portable ultrasound bladder scan|A post-void residual volume was measured using a Verathon BladdersScan BVI 3000.
215108012|NCT00153465|BEHAVIORAL|Motivational intervention, parent training|
215108013|NCT04001283|DRUG|Sodium Nitrite|Intravenous drug infusion
215108014|NCT04001283|DRUG|0.9% Sodium-chloride|Matched placebo
215108015|NCT00234169|DRUG|VTP195183|"VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.~Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first."
215108016|NCT04218591|OTHER|PRP|Platelet rich plasma
215108017|NCT04218591|OTHER|Placebo|Saline
215108018|NCT06134843|COMBINATION_PRODUCT|DERMASEAL|plasma film containing metallic silver microparticles and fibrin
215108019|NCT04132596|DEVICE|Transcutaneous spinal cord stimulation|Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes
215108020|NCT04132596|OTHER|Activity Based Therapy|Physical therapy
215108021|NCT05239767|DRUG|NSAID|We will administer oral NSAIDs
215108022|NCT00709410|BIOLOGICAL|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
215108023|NCT04479124|DIAGNOSTIC_TEST|COVID-19 PCR|Nasopharyngeal samples were analyzed by PCR for the detection of Novel Coronavirus 2019 DNA
215108024|NCT05735535|DRUG|Antiviral Agents|two-drug one-pill once day
215108025|NCT04398550|OTHER|Specific Carbohydrate Diet|Diet restricts all but simple carbohydrates and allows for inclusion of fresh fruits, vegetables, unprocessed meats, and homemade lactose-free cheese and yogurt.
215108026|NCT04398550|OTHER|Mediterranean Diet|Diet rich in whole vegetables, fruit, plant-based protein, and olive oil, with moderate amounts of seafood and dairy, and limited in sugar-sweetened goods, red meat, and nutrients like heme and sodium.
215108027|NCT01452581|OTHER|Red blood cell transfusion|Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.
215108028|NCT01452581|DRUG|Voluven|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
215108029|NCT00177255|DRUG|Docetaxel|"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
215108030|NCT00177255|DRUG|Capecitabine|"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
215108031|NCT01500304|PROCEDURE|Minimally invasive inguinal lymph node dissection|Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
215108032|NCT00330681|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
215108033|NCT00330681|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
214424480|NCT03463135|DRUG|Glucopyranosyl Lipid A (GLA)|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
214424481|NCT03463135|DRUG|Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Pharmaceutical form:Solution Route of administration: Sublingual
214424482|NCT03463135|DRUG|Placebo for GLA|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
214424483|NCT03463135|DRUG|Placebo for SLIT PE|Pharmaceutical form:Solution Route of administration: Sublingual
215108034|NCT03976206|BIOLOGICAL|Very small embryonic-like stem cell|We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
215108035|NCT04038450|OTHER|No intervention|No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
215108036|NCT05248139|DRUG|Intraoperative delivery of medication, Kenalog (Triamcinolone)|Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
215108037|NCT05248139|DRUG|Topical post-operative eyedrops, Prednisolone acetate|Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
215108038|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
215108039|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
215108040|NCT02578186|DRUG|Diphenhydramine Hydrochloride|30 mL at bedtime
215108041|NCT02578186|DRUG|Placebo|30 mL at bedtime
215108042|NCT01140061|DRUG|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
215108043|NCT01140061|DRUG|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
215108044|NCT01140061|DRUG|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
215108045|NCT01140061|DRUG|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
215108046|NCT01140061|DRUG|Plain patch|Plain patch containing no MK-0873 or placebo
215108047|NCT00959556|OTHER|laboratory biomarker analysis|
215108048|NCT00003354|PROCEDURE|conventional surgery|
215108049|NCT00003354|PROCEDURE|laparoscopic surgery|
215108050|NCT05284344|DRUG|Anti-Diabetics|The anti-diabetic treatments include insulin glargine, insulin aspart, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, metformin, sulfonylureas and/or gliclazide. Therapeutic dose of each drug follows recommendation by the treating doctor.
215108051|NCT00428389|DRUG|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm\^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
215108052|NCT00428389|DRUG|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm\^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
215108053|NCT05864937|OTHER|infertily evaluation|All couples had undergone a standard infertility evaluation, which included medical history, physical examination, and assessment of tubal patency by either hysterosalpingography or laparoscopy and hormonal analysis on cycle day 3. A transvaginal ultrasound scan was performed on the second day of the cycle. On the same day, ovarian stimulation was carried out with recombinant FSH follitropin);rFSH;Gonal-F,MerckSerono,France,orfollitropin ; Puregon, MSD, France), urinary FSH (urofollitropin, Fostimon, France),orhMG(menotropin,Menopur,France)atastarting dose of 75 IU/day from the second day of the cycle.
215108054|NCT03671915|DEVICE|Continuous Glucose Monitoring|collection of glucose data
215108055|NCT03671915|DEVICE|External Insulin Pump|Insulin delivery
215108056|NCT03671915|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
215108057|NCT03671915|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
215108058|NCT00075556|DRUG|capecitabine|
215108059|NCT00075556|PROCEDURE|conventional surgery|
215108060|NCT00075556|PROCEDURE|neoadjuvant therapy|
215108061|NCT00075556|RADIATION|radiation therapy|
215108062|NCT06137651|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215108063|NCT06137651|PROCEDURE|Computed Tomography|Undergo CT scan
215108064|NCT06137651|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
214424484|NCT02044588|BIOLOGICAL|HBsAg positive kidney allograft donor|
214424485|NCT04408937|DRUG|triopifexor|Tropifexor as a dry blend in hard gelatin capsules for oral administration
214424486|NCT04408937|DRUG|Placebo|Placebo capsules for oral administration
214424487|NCT03911479|PROCEDURE|Bariatric Surgery|Bariatric Surgery - convencionals Roux-en-Y gastric bypass (RYGB) and vertical gastrectomy (Sleeve; SG)
214424488|NCT01535144|DEVICE|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
214424489|NCT01535144|DEVICE|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
214424490|NCT00002972|DRUG|paclitaxel|
214424491|NCT02666742|DRUG|DOAC|DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
214424492|NCT02666742|DRUG|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
214424493|NCT01277796|DEVICE|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
214424494|NCT02205307|DEVICE|PINPOINT|
214424495|NCT02205307|DEVICE|SPY Elite|
214424496|NCT02041104|DIETARY_SUPPLEMENT|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
215108065|NCT06137651|RADIATION|Radiation Therapy|Undergo radiation therapy
215108066|NCT06137651|PROCEDURE|Resection|Undergo surgery
215108067|NCT06137651|DRUG|Trotabresib|Given PO
215108068|NCT06137651|DRUG|Vinorelbine|Given IV
215108069|NCT01306383|OTHER|SODIS Bottle|SODIS Bottles used by SODIS group to treat their drinking water
215108070|NCT03937492|OTHER|GMI protocol|"This group follow GMI program split in 3 step:~1. left/right descrimination~2. visual motor imagery~3. mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
215108071|NCT03937492|OTHER|Standard Rehabilitation Protocol|"This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
215108072|NCT03296150|BEHAVIORAL|PRESTAGE|PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
215108073|NCT05029739|DEVICE|A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease|See description of the e-intervention group as above.
215108074|NCT03216746|BEHAVIORAL|Oral orientation and App for smartphone|66 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
214424497|NCT02041104|DIETARY_SUPPLEMENT|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
215108075|NCT03216746|BEHAVIORAL|Oral orientation|71 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes.
215108076|NCT03216746|BEHAVIORAL|Video orientation and App for smartphone|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
215108077|NCT03216746|BEHAVIORAL|Video orientation|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes.
215108078|NCT04384523|DRUG|OsrHSA 20 mg/kg IV|A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
215108079|NCT04384523|DRUG|OsrHSA 40 mg/kg IV|A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
215108080|NCT04384523|DRUG|OsrHSA 80 mg/kg IV|A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
215108081|NCT04384523|DRUG|OsrHSA 140 mg/kg IV|A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
215108082|NCT04384523|DRUG|OsrHSA 200 mg/kg IV|A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
215108083|NCT04384523|OTHER|Placebo|Normal Saline (0.9% Sodium Chloride)
215108084|NCT02558777|OTHER|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
215108085|NCT02113332|DRUG|Liraglutide|
215108086|NCT02113332|DRUG|Placebo|
214424498|NCT01063517|DRUG|olaparib|100mg BID oral tablet continuous
215108087|NCT06293768|DEVICE|continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients)|Patients randomized to the experimental group on discharge or with transfer to the subacute ward will be connected to the system continuous monitoring of Vital Signs(Win@Hospital) continuous system for the continuous monitoring of blood sugar(Dexcom G6)(only for diabetic patients). The system, once applied, does not require the presence of a dedicated person and continuous monitoring in real time. It is set with alerts that are triggered both when the parameters they leave the normal ranges both if the data is not recorded due to technical problems. the data is transmitted in real time on mobile devices in the possession of a doctor and a nurse available 24 hours a day who guarantee the remote control system. Devices. Mobiles also contain the clinical information of each patient.
215108088|NCT00461279|BEHAVIORAL|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
215108089|NCT00461279|BEHAVIORAL|Interpersonal Psychotherapy|Established psychotherapy for depression
215108090|NCT06468670|DRUG|sintilimab，programmed death 1 monoclonal antibody|"short-course radiotherapy~+sintilimab (200mg, iv, D1, Q3W)"
215108091|NCT01153360|DRUG|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
215108092|NCT01153360|DRUG|placebo|vitamin B12
215108093|NCT04405076|BIOLOGICAL|Biological: mRNA-1273|Sterile liquid for injection
215108094|NCT04405076|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
215108095|NCT04405076|BIOLOGICAL|mRNA-1273.351|Sterile liquid for injection
215108096|NCT00500955|DRUG|Rosiglitazone|
215108097|NCT00392990|DRUG|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
215108098|NCT00392990|DRUG|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
215108099|NCT02381275|DRUG|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
215108100|NCT01947764|BEHAVIORAL|HADITHI Intervention|"The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.~In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:~Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.~Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.~Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure."
215108101|NCT03633266|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
215108102|NCT03633266|PROCEDURE|PRP|vitreoretinal surgery combined with intraoperative PRP
215108103|NCT03576911|DIETARY_SUPPLEMENT|Coenzyme Q10|
215108104|NCT03576911|OTHER|Placebo|
215108105|NCT01337544|OTHER|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
215108106|NCT06393166|DRUG|Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection|Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle Gemcitabine hydrochloride: 1g/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle 5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle Oxaliplatin: 85 mg/m2 ,ivgtt, D29, every 6 weeks for a treatment cycle LV: 400 mg/m2 ,ivgtt over 2h, D29, every 6 weeks for a treatment cycle Serplulimab Injection: 3mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle. Bevacizumab Injection: 5mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle.
215108107|NCT02639520|DRUG|Canephron® N|2 tablets 3 times a day for 7 days
215108108|NCT02639520|DRUG|Fosfomycin trometamol|1 sachet of 8 g of granules; one single dose on Day 1
215108109|NCT02639520|DRUG|Canephron® N-placebo|2 tablets 3 times a day for 7 days
215108110|NCT02639520|DRUG|Fosfomycin trometamol-placebo|1 sachet of 8 g of granules; one single dose on Day 1
215108111|NCT01107847|PROCEDURE|low flow pressure volume manoeuvre|In all patients a standard low flow pressure volume manoeuvre is applied by a respirator with a constant gas flow of 4 l/min starting at a zero end-expiratory pressure up to a tidal volume of 2 l or until a maximum airway pressure of 35 cm H2O was reached.
215108112|NCT01150565|DRUG|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
215108113|NCT02685904|BIOLOGICAL|ENIA11|
215108114|NCT02685904|BIOLOGICAL|Placebo|
215108115|NCT06183333|BEHAVIORAL|Heidelberg Emotion Regulation Training|The four-week intervention program is specifically designed to enhance the participants' emotion regulation. It focuses on developing their skills in accurately recognizing various emotions and effectively applying diverse emotion regulation strategies. To achieve this, the program includes video-based psychoeducation sessions. Alongside these sessions, the program incorporates daily short exercises, each lasting approximately five minutes. These exercises are crafted to help participants practically integrate the concepts and strategies learned from the psychoeducation sessions into their everyday lives. All components of the intervention are accessible through an online platform, ensuring ease of access and flexibility for participants.
215108116|NCT05608551|BEHAVIORAL|Animal-assisted trauma-focused therapy|Animal-assisted trauma-focused therapy (AA TF-CBT) is a specific form of trauma treatment, in which one or more animals are integrated into the therapy. AA TF-CBT follows a structured, standardized therapy manual.
215108117|NCT05608551|BEHAVIORAL|Standard trauma-focused therapy|Standard trauma-focused therapy (AA TF-CBT) is a standardized trauma therapy following a structured manual.
214424499|NCT01063517|DRUG|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
215108118|NCT02128412|DEVICE|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
215108119|NCT02128412|DEVICE|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
215108120|NCT01870310|PROCEDURE|Catheterised renal denervation|
215108121|NCT02980133|DRUG|Fluticasone Propionate|Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.
215108122|NCT02980133|DRUG|Fluticasone Propionate/Salmeterol|Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.
215108123|NCT02980133|DRUG|Placebo MDPI|Matching placebo was administered via MDPI per the schedule specified in the arm.
215108124|NCT04200144|DEVICE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)
215108125|NCT04420403|OTHER|Manual Therapy|Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.
215108126|NCT04420403|OTHER|Cervical Stabilazation Exercise (CSE)|The CSE program aims to maintain a neutral spine position and activate deep cervical muscles during exercises. It is performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program will start with postural training and then the cervical bracing technique with the activation of deep neck flexors for CSE was performed. The patients will be asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises will be increased weekly. It will be carried out 2 days a week for 6 weeks (12 sessions) by the supervisor physiotherapist.
215108127|NCT01509911|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
215108128|NCT01509911|DRUG|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
214692179|NCT03946423|PROCEDURE|Bariatric Surgery with Sleeve Gastrectomy|Standard of care bariatric surgery with sleeve gastrectomy
214692180|NCT03946423|BEHAVIORAL|Lifestyle Intervention|All participants receive lifestyle intervention. The lifestyle intervention program is modeled closely after that used in the Diabetes Primary Prevention Trial and the LookAHEAD diabetes treatment studies. Intervention includes counseling sessions weekly for the first six months, twice a month during months 7-9, and monthly during months 10-12, and energy intake and exercise goal monitoring and guidance.
214692181|NCT00619411|BEHAVIORAL|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
214692182|NCT04207957|DRUG|Olorofim|150 mg
215108129|NCT05141084|OTHER|Education, lifestyle|The weight loss program itself is the intervention, which will involve lifestyle modifications and intervention.
215108130|NCT02572765|OTHER|PET/CT scan|PET/CT scan
215108131|NCT04282525|OTHER|ECMO for hemodynamic or respiratory indication|ECMO for hemodynamic or respiratory indication
215108132|NCT01997671|OTHER|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
215108133|NCT03797300|DEVICE|Spry Loop Band|Loop band measures pulse oximetry and respiration rate
215108134|NCT01631396|DRUG|Sugammadex vs. Neostigmine|"* Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~* Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body."
215108135|NCT05100446|DRUG|Amoxicillin - high dose dual therapy|Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.
215108136|NCT05100446|DRUG|Pylera|Eradication with Pylera, for 10 days.
215108137|NCT05100446|DRUG|Esomeprazole 40mg|Esomeprazole 40mg, twice a day.
215108138|NCT02371031|DRUG|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
215108139|NCT02371031|DEVICE|PET/MRI|
215108140|NCT02371031|PROCEDURE|Surgical resection (standard of care)|
215108141|NCT05545839|BEHAVIORAL|Transition coaching|Transition coaching sessions (8 sessions), covering paediatric to adult care, self-advocacy, medication management, general health, lifestyle and behaviours, future planning, screening for mood disorders and coping skills.
215108142|NCT04223414|DEVICE|Analgesia Nociception Index (ANI)|"ANI will be used to analyse the autonomic nervous system's response to volume expansion.~ANI will be assessed during surgery, before during and after the volume expansion"
215108143|NCT00364741|DRUG|Oxygen|During and 2 hours after surgery
215108144|NCT02606058|PROCEDURE|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
215108145|NCT05229250|OTHER|Cycling test|RAMP and MULTI-STAGE test
215108146|NCT05229250|OTHER|Occlusion tests|Occlusion test before and after exercise
215108147|NCT05229250|DEVICE|NIRS during cycling|NIRS devices measuring oxygenation during exercise
215108148|NCT05229250|DEVICE|CPET|Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise
215108149|NCT05229250|DEVICE|Echo-Doppler examination|Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract
215108150|NCT05002491|OTHER|High protein diet|Normal vs high protein dietary feeding
215108151|NCT05244551|DRUG|ABSK061|In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
215108152|NCT02741206|BEHAVIORAL|Bellevue ROSE Intervention|
215108153|NCT02741206|BEHAVIORAL|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
215108154|NCT02741206|BEHAVIORAL|One Psycho-education session and usual, standard of care Control|
215108155|NCT01925248|DIETARY_SUPPLEMENT|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
215108156|NCT01925248|DIETARY_SUPPLEMENT|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
215108157|NCT02514148|BEHAVIORAL|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
215108158|NCT02514148|OTHER|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
215108159|NCT02514148|OTHER|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
215108160|NCT02514148|OTHER|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
215108161|NCT03287427|DRUG|TetMYB Vaccine|Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.
215108162|NCT03287427|DRUG|BGB-A317|3 weekly IV injections of 200mg commencing from Week 4.
215108163|NCT02112864|DRUG|Dexamethasone|10 mg (2.5 ml)
215108164|NCT02112864|DRUG|Normal Saline|2.5 mL normal saline
215108165|NCT03370666|OTHER|HFNT|High flow nasal therapy
214424500|NCT01063517|DRUG|Placebo|100mg BID oral tablet to match olaparib tablet
215108166|NCT03370666|OTHER|NIV|Noninvasive ventilation
215108167|NCT03504631|OTHER|No intervention|no intervention
215108168|NCT05144867|RADIATION|Stereotactic Radiosurgery|All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
215108169|NCT04410406|DRUG|Ivermectin|Ivermectin (IVM) 200 µg/kg
215108170|NCT04410406|DRUG|Diethylcarbamazine|Diethylcarbamazine (DEC) 6mg/kg
215108171|NCT04410406|DRUG|Albendazole|Albendazole (ABZ) 400 mg
215108172|NCT04410406|DRUG|Moxidectin|Moxidectin (Mox) 8 mg
215108173|NCT04607811|BEHAVIORAL|Gamification with social incentives|Participants will select a step goal that is 33%, 40%, or 50% above their baseline step value. Participants in this group will participate in a game with points and levels to help motivate participants to meet their daily step goal. Additionally, all participants will identify a support partner to receive weekly updates on their performance and offer positive encouragement to help the participant meet their step goal.
215108174|NCT01224743|DIETARY_SUPPLEMENT|Blend 1|Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
215108175|NCT01224743|DIETARY_SUPPLEMENT|Blend 2|Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
215108176|NCT01224743|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
215108177|NCT00898833|OTHER|laboratory biomarker analysis|
215108178|NCT02502825|OTHER|methacholine|methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
215108179|NCT02502825|DEVICE|Wright Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
215108180|NCT02502825|DEVICE|Devilbiss646 Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
215108181|NCT02913495|DRUG|Vaginal Progesterone|
215108182|NCT02913495|DRUG|Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)|
215108183|NCT00439062|DRUG|Roxithromycin|
215108184|NCT00172042|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
215108185|NCT02567019|OTHER|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
215108186|NCT03779581|OTHER|Self Correction exercises|Active self-correction exercises to restore movements in different planes as close to physiologically normal as possible.
214424501|NCT03799536|DRUG|Sotalol|Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
214424502|NCT03799536|DRUG|Sotalex|Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH \& Co. KGaA, Germany
215108187|NCT03779581|DEVICE|orthotic devices|the orthotic devices designed to correct the scoliosis curve
215108188|NCT00888953|OTHER|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
215108189|NCT00888953|OTHER|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
215108190|NCT04115137|DEVICE|pelvic varicose veins plug embolization|pelvic varicose veins plug embolization
215108191|NCT02493231|DRUG|Nefopam|
215108192|NCT02493231|DRUG|Ketamine|
215108193|NCT02493231|DRUG|Saline|
215108194|NCT05456620|OTHER|Exercise therapy|"The intervention treatment consists of a progressive 4-stage, criteria-based exercise protocol, in which the amount of tendon compression is limited. This includes:~1. Education: Specific information on the importance of limiting tendon compression during rehabilitation, as well as general information on load management, the importance of active exercise therapy and setting expectations.~2. Orthotic treatment: heel inserts to reduce ankle dorsiflexion during daily activities and sports~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) restricting the amount of tendon compression by limiting dorsiflexion of the ankle and prohibiting stretching"
215108195|NCT05456620|OTHER|Exercise therapy (usual care)|"The control treatment consists of a progressive 4-phase, criteria-based exercise protocol, in which the amount of tendon compression is not limited. This includes:~1. Education: general information on load management, the importance of active exercise therapy and setting expectations.~2. No orthotic treatment.~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) without any restriction around tendon compression and encouraging stretching"
215108196|NCT03581838|BEHAVIORAL|Observed eating session|Eating a Jimmy Johns turkey or vegetarian sandwich
215108197|NCT01959438|DRUG|Sodium selenite (Introselen)|Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
215108198|NCT01959438|DRUG|Sodium selenite|Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
215108199|NCT03052816|DRUG|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
214424503|NCT06512714|OTHER|A diagnosis of mycetoma in a medical, radiologic, or laboratory record.|For each patient, data will be extracted for each clinical, laboratory or radiologic visit related to the condition that may meet this study's case definition.
214424504|NCT04423328|BEHAVIORAL|acupressure|self-acupressure
214424505|NCT00333658|BEHAVIORAL|Goal setting and work feedback group|Goal setting and feedback using WBI
214424506|NCT00184925|PROCEDURE|Tracheostomy|trachesotomy with subglottic drainage
214424507|NCT00184925|DEVICE|cannula with subglottic drainage|
214424508|NCT00396851|DRUG|Gurmar|
214424509|NCT00396851|DRUG|Metformin|
214424510|NCT01350804|BIOLOGICAL|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
214424511|NCT01350804|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
214424512|NCT01350804|BIOLOGICAL|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
214424513|NCT01713946|DRUG|RAD001|Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
214424514|NCT01713946|DRUG|Placebo|Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
214424515|NCT01713946|DRUG|Antiepileptic drug (1 to 3 only)|no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
214424516|NCT01713946|DRUG|open label RAD001 (only used for post-extension phase)|everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
214424517|NCT00158639|BEHAVIORAL|Home BP;secure messaging;pharmaceutical care;|
214424518|NCT02464852|BEHAVIORAL|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
214424519|NCT02464852|BEHAVIORAL|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
214424520|NCT02464852|DEVICE|Sheffield Support Snood|
214424521|NCT02464852|DEVICE|sEMG|
214424522|NCT05535491|OTHER|Educational and Research Hospital|breathing exercise
215108200|NCT03052816|DRUG|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
215108201|NCT00058682|DRUG|Anidulafungin|
215108202|NCT00820417|DRUG|Cetuximab/Gefitinib combination and/or monotherapy|
215108203|NCT00408434|DRUG|CS-7017|CS-7017 0.05mg and 1.0mg tablets
215108204|NCT05817032|BEHAVIORAL|Telerehabilitation|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have a hybrid approach (10-12 in person, 24-26 virtual) or fully virtual.
215108205|NCT05817032|BEHAVIORAL|Standard rehabilitation care|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have 10-12 in person exercise.
215108206|NCT01278797|DRUG|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
214509844|NCT04015505|BEHAVIORAL|Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'|The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
214509845|NCT04820491|DIAGNOSTIC_TEST|X-Ray|Shoulder x-rays as felt necessary for standard of care of diagnosis of shoulder dislocation and reduction
214509846|NCT04820491|DIAGNOSTIC_TEST|Ultrasound|Initial evaluation with ultrasound; may also evaluate nearby areas for concern of fracture. Order x- rays after ultrasound as seen fit for other injuries of diagnostic uncertainty.
215108207|NCT01278797|DRUG|Amlodipine Monocomponent|Active Comparator
215108208|NCT02724709|PROCEDURE|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
215108209|NCT02724709|PROCEDURE|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
215108210|NCT04283591|PROCEDURE|Acupuncture Treatment|Acupuncture Treatment Group will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points of the hemiplegic side and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week.
214509847|NCT03280511|DRUG|PIPAC|PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
215108211|NCT04283591|OTHER|Conventional Rehabilitation Programme|They will continue to receive the conventional rehabilitation programme.
215108212|NCT00963794|OTHER|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
215108213|NCT03073993|PROCEDURE|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
215108214|NCT00895453|DRUG|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
215108215|NCT00895453|DRUG|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
215108216|NCT00895453|DRUG|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
215108217|NCT04219644|DEVICE|Breatheasy device|
215108218|NCT02982941|DRUG|Enoblituzumab|enoblituzumab administered IV weekly for up to 96 weeks
215108219|NCT02389400|DRUG|methotrexate|Single Group Assignment
215108220|NCT05185050|DIAGNOSTIC_TEST|physical examination and measurement of spinal alignment|physical examination for scoliosis and myofascial pain syndrome, measurement of spinal coronal and sagittal alignment in X-ray, and pain intensity (with Visual analog scale) if necessary (for MPS group)
215108221|NCT03918525|OTHER|Sindhi families|It is an observational study and no intervention is involved
214509848|NCT04263740|PROCEDURE|Kinesio Taping|Taping for 3 days every week and two sessions of PT twice a week. The PI also instructed the patient to inform him if the tape gets off or become loose. KT was removed after 72 hours, and then reapplied after a few days rest to allow the skin to recover and to avoid skin irritation. The patient was instructed to refrain from getting the tape wet for 30 to 45 minutes after application to allow for better adherence. Patients were also instructed to be careful during dressing and undressing so the tape does not get caught with their clothes if the edges of the tape get slightly loose. No physical therapy treatment or taping was provided during the rest period except for the prescribed home exercise program. Patients in both groups received the same traditional physical therapy treatment two times a week.
214509849|NCT04263740|PROCEDURE|Traditional Physical therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
214509850|NCT05696405|PROCEDURE|VATS resection of MEPA|VATS resection of mediastinal parathyroid adenoma
214509851|NCT00937287|OTHER|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
215108222|NCT03817268|DRUG|Capecitabine monotherapy|Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
215108223|NCT01931163|DRUG|Everolimus|
215108224|NCT02464722|DRUG|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
215108225|NCT02464722|DRUG|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
215108226|NCT02464722|DRUG|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
215108227|NCT02464722|DRUG|Propofol|Anesthesia was induced with propofol 2 mg kg-1
215108228|NCT02464722|DRUG|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
215108229|NCT04678388|DRUG|Reference drug|1 Cap., single oral administration under fasting condition
215108230|NCT04678388|DRUG|Test drug 1|1 Tab., single oral administration under fasting condition
215108231|NCT04678388|DRUG|Test drug 2|1 Tab., single oral administration under fasting condition
215108232|NCT04028141|DRUG|Procedural sedation with ketofol in a 1 on 4 ratio|"The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years."
215108233|NCT04794023|DEVICE|Corneal Ablation|Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
215108234|NCT00206713|DRUG|Sargramostim (Leukine)|6 μg/kg sargramostim administered SC once daily for 8 weeks
215108235|NCT00206713|DRUG|Placebo|Placebo administered SC once daily during the randomized retreatment phase.
215108236|NCT01441323|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
215108237|NCT01441323|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
215108238|NCT06383468|DRUG|AK120|300mg Q2W subcutaneous injection thereafter until week 50.
215108239|NCT01726985|OTHER|Parameter Based Clinical Disposition|"Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~* NT-ProBNP reduction of \> 23% from peak value during admission~* Fluid Reduction of \> 1.3L (orders for I/O q8h required)~* Serum Sodium of \> 135 mmol/L the day of planned discharge"
215108240|NCT04371692|OTHER|self-administered questionnaire|Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
215108241|NCT04371692|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
215108242|NCT00197925|BIOLOGICAL|Onco-peptide loaded autologous dendritic cells|
215108243|NCT04465292|DRUG|Tildrakizumab Prefilled Syringe|Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
215108244|NCT04375514|DRUG|ARO-ENaC|single or multiple doses of ARO-ENaC by inhalation of nebulized solution
215108245|NCT04375514|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
215108246|NCT03188510|BIOLOGICAL|LY3074828|Administered SC
215108247|NCT01477489|DRUG|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
215108248|NCT01477489|RADIATION|Standard radiation treatment|Limited to 60 Gy.
215108249|NCT04193592|DRUG|Pirfenidone|Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
215108250|NCT03869606|DEVICE|NICOM by Cheetah Medical|Observational measurement, Cardiac Output, Pre- and Post Anesthesia
215108251|NCT01989806|DEVICE|Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)|
215108252|NCT01989806|DEVICE|Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)|
215108253|NCT04254094|OTHER|Neuropsychological scales|Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
215108254|NCT02261766|DEVICE|Holter monitoring and Thumb ECG|5 days holtermonitoring and 30 days 30 seconds twice daily thumb ECG recording
215108255|NCT03300063|OTHER|Low flow nocturnal oxygen|Nocturnal low-flow oxygen via nasal cannula
215108256|NCT04182672|DRUG|FX006|Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
215108257|NCT03150420|DRUG|Sodium Thiosulfate|Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks
215108258|NCT03150420|DRUG|Placebo-Normal Saline|Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks
215108259|NCT02975258|PROCEDURE|Blood draw|Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
215108260|NCT02975258|OTHER|Questionnaires|The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
215108261|NCT02975258|PROCEDURE|Spirometry|Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
215108262|NCT02975258|PROCEDURE|Methacholine challenge test|A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
215108263|NCT02975258|RADIATION|Quantitative CT scans|There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
215108264|NCT02975258|PROCEDURE|Urine pregnancy test|All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
215108265|NCT02975258|PROCEDURE|Adipose biopsy|The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin \& into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
215108266|NCT02975258|PROCEDURE|Exhaled nitric oxide measurement|The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
215108267|NCT01755728|DRUG|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
215108268|NCT01755728|DRUG|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
215108269|NCT01755728|PROCEDURE|Closure of PDA|Open surgery for closure of PDA
215108270|NCT02564809|BEHAVIORAL|Fit Brains Training|These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
215108271|NCT02564809|BEHAVIORAL|Exercise + Fit Brains Training|These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
215108272|NCT02564809|BEHAVIORAL|Balanced And Tone|These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
215108273|NCT00005120|DRUG|Calanolide A|
215108274|NCT03025243|DEVICE|computer aided surgical guide|comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
215108275|NCT03361982|OTHER|Slow Freezing and Thawing|half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
215108276|NCT03052049|DEVICE|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
215108277|NCT05271760|PROCEDURE|Single-shot spinal analgesia|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml
215108278|NCT05271760|PROCEDURE|Continuous epidural analgesia|Epidural analgesia is performed using a 16-gauge Tuohy epidural needle using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid a test dose of 3 ml lidocaine 1.5% with epinephrine 1:200000 will be given via inserted catheter, 10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse in a rate of 6 -14 ml/h.
215108279|NCT05271760|PROCEDURE|Combined spinal-epidural analgesia|"Epidural analgesia is performed using a combined spinal-epidural set. using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance, once epidural space will be detected, 27 G Whitacre spinal needle inserted through Touhy epidural needle, intrathecal injection of 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml. Then an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid.~10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse at a rate of 6 -14 ml/h if needed."
215108280|NCT01918059|PROCEDURE|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
215108281|NCT01918059|PROCEDURE|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
215108282|NCT01918059|PROCEDURE|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
215108283|NCT03556709|DEVICE|Treadmill Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system, during treadmill walking, over a 6-week intervention period.
215108284|NCT03626961|OTHER|readmission|Readmission after 48 hours
215108285|NCT03626961|OTHER|discharge|Discharge
215108286|NCT04254666|BEHAVIORAL|Physical Literacy & Food Literacy Intervention.|A 12-week intervention designed to expose adolescents with ID to a variety of sports skills and healthy eating concepts to equip them with skills and confidence to participate in sports and make healthy food choices. The program will follow a protocol adapted to meet the needs of a diverse group of children with ID. Sessions will be held 1 time/week for 75 minutes virtually; 35 minutes will focus on sport skills activities with 35 minutes devoted to healthy eating.
215108287|NCT01695434|OTHER|MRI|All subjects will undergo a MRI.
214509852|NCT04033250|DRUG|Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure|Bowel preparation
215108288|NCT00025558|BIOLOGICAL|filgrastim|
215108289|NCT00025558|DRUG|carboplatin|
215108290|NCT00025558|DRUG|temozolomide|
215108291|NCT00025558|DRUG|thiotepa|
215108292|NCT00025558|PROCEDURE|autologous bone marrow transplantation|
215108293|NCT00025558|PROCEDURE|peripheral blood stem cell transplantation|
215108294|NCT01574066|PROCEDURE|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
215108295|NCT00114855|DRUG|HYPOCOL®|
214509853|NCT03846037|OTHER|Proprioceptive exercise on the vibratory platform|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the vibratory platform
214509854|NCT03846037|OTHER|Proprioceptive exercise on the ground (stable surface)|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the ground
214509855|NCT03080350|DRUG|Fentanyl sublingual|Fentanyl sublingual
214509856|NCT03080350|DRUG|Fentanyl ev|Fentanyl ev
214509857|NCT03080350|DRUG|Placebo sublingual|Placebo sublingual
214692183|NCT00904826|DRUG|Eculizumab|"The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months."
215108296|NCT01921504|DEVICE|Acupuncture|"Acupuncture treatment~1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 \~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
215108297|NCT03018613|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.
215108298|NCT03018613|OTHER|Normal Saline|Normal saline and the traditional treatments for chronic functional constipation in part 2
215108299|NCT00623870|DRUG|RO5045337|Multiple ascending doses
215108300|NCT02509845|DRUG|C16G2|Antimicrobial peptide
215108301|NCT02509845|OTHER|Placebo|Placebo
215108302|NCT05741398|DEVICE|VR system by Demaod|non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
215108303|NCT03343626|DRUG|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
215108304|NCT03343626|BIOLOGICAL|PIZV|Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.
215108305|NCT02856048|DRUG|Triptorelin (GnRHa) + Chemotherapy|During her chemotherapy, the patient in the experimental arm will have regular injections of Triptorelin (DECAPEPTYL LP 3 mg, IPSEN) in order to preserve her fertility
215108306|NCT00673335|DRUG|letrozole|
215108307|NCT00673335|DRUG|Placebo|
215108308|NCT01694056|OTHER|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
215108309|NCT01694056|OTHER|Control diet|4 weeks high mixed protein diet (20 en%)
215108310|NCT03919357|BEHAVIORAL|BMT-i|Passing the BMT-i test
215108311|NCT04051853|DRUG|Sorafenib|Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.
215108312|NCT04051853|OTHER|Midazolam clearance test|Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
215108313|NCT04051853|OTHER|CYP cocktail clearance test|In a subgroup of 15 patients (in the Academic Medical Center Amsterdam), this test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
215108314|NCT05968768|DRUG|Naxitamab|Naxitamab will be used only in a hospital setting and must be administered under the supervision of a doctor with experience in the use of oncological therapies. The medicinal product must be administered by a healthcare professional prepared to deal appropriately with severe allergic reactions, including anaphylaxis, in an environment that provides immediate, full access to resuscitation. The patient should have 2 well-functioning IV accesses before any naxitamab treatment is initiated. The solution should be administered through a peripheral or central intravenous catheter. Other concomitant intravenous medicinal products should be administered through separate intravenous access. Before the start of each infusion, premedication will be carried out.
215108315|NCT04978584|DRUG|Acalabrutinib|Given PO
214509858|NCT03080350|DRUG|Placebo ev|Placebo - NaCL 0,9% ev
214509859|NCT00035048|DRUG|aprepitant|
214509860|NCT00035048|DRUG|Comparator: placebo (unspecified)|
214509861|NCT02339519|DEVICE|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
214509862|NCT02339519|DEVICE|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
214509863|NCT02339519|DEVICE|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
215108316|NCT04978584|DRUG|Cyclophosphamide|Given IV
215108317|NCT04978584|DRUG|Doxorubicin Hydrochloride|Given IV
215108318|NCT04978584|DRUG|Lenalidomide|Given PO
215108319|NCT04978584|DRUG|Prednisone|Given PO
215108320|NCT04978584|BIOLOGICAL|Rituximab|Given IV
215108321|NCT04978584|BIOLOGICAL|Tafasitamab|Given IV
215108322|NCT04978584|DRUG|Vincristine|Given IV
215108323|NCT05924347|DIAGNOSTIC_TEST|MRI|Longitudinal MRI examination of the thoracic and lumbar spine (T2, T2w, sCT)
215108324|NCT05924347|DIAGNOSTIC_TEST|Scolioscan|3D ultrasound of the spine
215108325|NCT05924347|DIAGNOSTIC_TEST|Skeletal maturity assessment|At one timepoint, a Hand radiograph is taken for digital skeletal maturity assessment
215108326|NCT01563263|BIOLOGICAL|IC43|100 mcg
215108327|NCT01563263|DRUG|Placebo|phosphate buffered saline (PBS) solution containing 0,9 % NaCl
215108328|NCT02231619|BEHAVIORAL|Baseline verbal instruction on LSUPT|
215108329|NCT02798978|DRUG|GSK1795091|GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
215108330|NCT02798978|DRUG|Placebo|Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
215108331|NCT02475278|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
215108332|NCT00826618|DRUG|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
215108333|NCT01416948|DRUG|Methylphenidate Hydrochloride 20 mg|For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.
215108334|NCT01416948|DRUG|Placebo Capsule|For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
215108335|NCT01416948|DRUG|Galantamine 12 mg|For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
215108336|NCT01557088|OTHER|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
215108337|NCT01557088|PROCEDURE|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
215108338|NCT00003346|DRUG|acetaminophen|
215108339|NCT00003346|DRUG|acetylcysteine|
215108340|NCT00003346|DRUG|carmustine|
215108341|NCT03712787|DRUG|Tilavonemab|solution for IV infusion
215108342|NCT04197180|PROCEDURE|Hybrid Argon Plasma Coagulation|Argon Plasma Coagulation after water injection for local ablation
215108343|NCT00363623|DEVICE|Silicone hydrogel contact lens|
215108344|NCT02836405|DEVICE|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
215108345|NCT04205682|DRUG|Cannabidiol|CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
214424523|NCT03043638|PROCEDURE|CAF+ADM+PRP|CAF+ADM+PRP group treated with coronally advanced flap technique including ADM placement, In CAF+ADM+PRP group, ADM was hydrated in the platelet-poor plasma (PPP) and the PRP was applied to surgical sites prior to final suturing.
214424524|NCT03043638|PROCEDURE|CAF+ADM|CAF+ADM group treated with coronally advanced flap technique including ADM placement without PRP application
214424525|NCT05545891|DRUG|Placebo|A drug that contains no medicine
214424526|NCT05545891|DRUG|Aripiprazole|Atypical antipsychotic medication
214424527|NCT06382649|DRUG|Rivastigmine|Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
214424528|NCT06382649|DRUG|Placebo|Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
214424529|NCT04516135|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
214424530|NCT04516135|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
214424531|NCT04516135|OTHER|Quality-of-Life Assessment|Ancillary studies
214424532|NCT04516135|OTHER|Questionnaire Administration|Ancillary studies
214424533|NCT04516135|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
214424534|NCT05564533|BEHAVIORAL|Heart-Smile Training Intensive Introduction Program (HST-IIP)|"Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation."
214424535|NCT05300308|OTHER|usual care|The information about lymphoedema and its prevention is given during the hospital stay by the physical therapist of the department of urology. Skincare consists of daily skin moisturizer of feet and legs and prevention and care of wounds. Active exercises are performed to gain endurance and muscle strength after surgery and to stimulate the blood and lymph circulation. The exercises are supervised by the home physical therapist. Frequency of the supervised exercises is gradually decreased. If a patient develops lymphoedema, he/she receives compression stockings.
214692184|NCT06982937|OTHER|High-Intensity Half-Squat|Participants in the conditioning arm perform a single set of two to three half-squats with a free-weight barbell set at 90% of their one-rep max (1RM). Each squat is taken down until the thigh is parallel to the floor (knee at \~90°) and then driven upward as explosively as possible.
215108346|NCT04205682|DRUG|Placebo|Placebo capsules administered BD for 5 days
215108347|NCT01199224|DRUG|veliparib|veliparib formulation A
215108348|NCT01199224|DRUG|veliparib|veliparib formulation B
215108349|NCT01199224|DRUG|veliparib|veliparib formulation C
215108350|NCT01199224|DRUG|veliparib|veliparib formulation C
215108351|NCT00952081|DRUG|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
215108352|NCT00931606|BIOLOGICAL|Sotatercept|up to 4 subcutaneous doses of sotatercept given once every 28 days
215108353|NCT00931606|DRUG|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
214424536|NCT05909683|DIAGNOSTIC_TEST|Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.|After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.
215108354|NCT02549547|BEHAVIORAL|Group Medical Visits|"Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:~* Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes~* Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes~* Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity."
214424537|NCT05909683|OTHER|Standard of Care|Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
214424538|NCT06337526|DEVICE|Apple Watch v8|Apple Watch used for data collection only
214424539|NCT04411082|DRUG|IMR-687|Oral administration of once daily IMR-687
214424540|NCT04411082|DRUG|Placebo|Oral administration of once daily Placebo
214424541|NCT02804594|DRUG|N-acetyl cysteine|1250 mg of N- acetyl cysteine taken three times daily
214424542|NCT02804594|DRUG|Placebo|placebo taken three times daily
214424543|NCT01850836|PROCEDURE|repetitive transcranial magnetic stimulation|
215108355|NCT00432406|DRUG|Infliximab|Infliximab 5 mg/kg given at day 1, week 2, week 6
215108356|NCT00432406|DRUG|Etanercept|Etanercept 25 mg twice weekly
215108357|NCT05542758|OTHER|Total Body HIIT Program|One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
215108358|NCT00860171|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Autologous stem cells given via central catheter
215108359|NCT00860171|RADIATION|Iodine I 131 Monoclonal Antibody BC8|Given IV
215108360|NCT00860171|OTHER|Laboratory Biomarker Analysis|Correlative studies
215108361|NCT06529913|DIAGNOSTIC_TEST|Collection of environmental, biological, and clinical data|"All enrolled patients/healthy volunteers will undergo:~* measurement of serum and urine concentration of metals (nickel, cobalt, chromium, palladium, molybdenum, aluminium, and copper).~* Patch test to metals.~* Within-breath analysis of oscillometry parameters.~* Measurement of serum zonulin.~* Measurement of serum levels of protein oxidation products."
215108362|NCT02560272|BIOLOGICAL|Minhai-HIB|0.5ml, intramuscular
215108363|NCT02560272|BIOLOGICAL|Act-HIB®|0.5ml, intramuscular
215108364|NCT02170870|DRUG|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
215108365|NCT02170870|DRUG|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
215108366|NCT02170870|DRUG|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
215108367|NCT06413238|DRUG|curcumin, saffron, Combination of saffron and curcumin and placebo|This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.
215108368|NCT03412812|RADIATION|6 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
215108369|NCT03412812|RADIATION|7 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
215108370|NCT03412812|RADIATION|8 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
215108371|NCT03412812|RADIATION|9 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
215108372|NCT04142177|OTHER|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
215108373|NCT04142177|PROCEDURE|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
215108374|NCT04142177|OTHER|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
215108375|NCT04142177|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
215108376|NCT04142177|PROCEDURE|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
215108377|NCT04142177|PROCEDURE|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
215108378|NCT03069157|PROCEDURE|lung recruitment maneuver|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
215108379|NCT05487261|DRUG|Sacubitril-valsartan|level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday
215108380|NCT05487261|DRUG|Enalapril|level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day
215108381|NCT05487261|DRUG|placebo|placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan
215108382|NCT05487261|DRUG|Placebo|placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
215108383|NCT00491491|DRUG|ibritumomab tiuxetan|0.4 mCi/kg
215108384|NCT00491491|PROCEDURE|BEAM chemotherapy and autologous stem-cell transplantation|
215108385|NCT01350232|DRUG|Fludarabine|Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
215108386|NCT01350232|DRUG|Cytarabine|Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
215108387|NCT01350232|DEVICE|Cellular Infusions|"Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
215108388|NCT01350232|RADIATION|Total Body Irradiation|All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
215108389|NCT01350232|DRUG|Cyclophosphamide|All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
215108390|NCT01350232|DRUG|Bortezomib|Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
215108391|NCT01350232|DRUG|Rituximab|Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
215108392|NCT01350232|PROCEDURE|Plasmapheresis|Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
215108393|NCT00557999|OTHER|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
215108394|NCT00125957|DRUG|Wellbutrin|
215108395|NCT00125957|DRUG|Placebo|
214424544|NCT05897996|DEVICE|creation of vascular access for hemodialysis|endo-AVfs created with Wavelinq
214424545|NCT03877159|OTHER|There is no intervention.|There is no intervention. This is a retrospective study analysing archived tumour samples.
215108396|NCT03565380|OTHER|12-week community-based multi-model Tai Chi rehabilitation program|Participants will receive 12 x 90 minute sessions of supervised exercises over 12 weeks. In addition to usual care, supervised exercise will be held at the Center of Sports Training and Rehabilitation inside the University and each class will be restricted to no more than 8 participants to ensure sufficient personalized attention. Each training session involves warm-up together with stretching of lower extremity muscles, strengthening exercises of the major lower extremity muscle groups by Theraband, balancing exercise, Tai Chi training, and rest/ cool-down. All lower-extremity exercises will be performed bilaterally.
215108397|NCT03565380|OTHER|Usual post-operative care|No intervention will be provided
215108398|NCT03565380|OTHER|Untreated asymptomatic controls|No intervention will be provided
215108399|NCT02391363|BEHAVIORAL|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
215108400|NCT02391363|BEHAVIORAL|Information and referral|Resource counseling and follow-up for mental health and basic needs
215108401|NCT00305435|DRUG|Romiplostim (AMG-531)|Romiplostim (AMG-531)
215108402|NCT02673463|DRUG|Spironolactone|25 mg once daily
215108403|NCT02673463|DRUG|Placebo|Visually identical to spironolactone, once daily
215108404|NCT04744922|DIETARY_SUPPLEMENT|Extracts of citrus peels standardized in AUR and NAR (phytocomplex).|One capsule a day for 9 months
215108405|NCT05159466|PROCEDURE|Kidney transplant|Participants will be recruited at the Tulane Abdominal Transplant Institute site where they are evaluated and followed for organ transplantation as part of standard of care. HIV-positive adult candidates on the wait list or referred for organ transplantation evaluation willing to accept an HIV positive organ will be recruited.
215108406|NCT04329910|OTHER|no intervention|no intervention - observational only
215108407|NCT02934724|PROCEDURE|Self sample from vagina|Self sample using The Rover's Evalyn Brush
215108408|NCT02934724|PROCEDURE|Self sample from the oral cavity|Self sample using COPAN FloqSwab
215108409|NCT02934724|OTHER|Questionnaire|Questionnaire about vaccination status and sexual behaviour
215108410|NCT02744885|DIETARY_SUPPLEMENT|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
215108411|NCT02744885|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
215108412|NCT05210387|OTHER|Duration of therapy|"In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1)."
215108413|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
215108414|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
215108415|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
215108416|NCT03828617|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
215108417|NCT05605106|DIAGNOSTIC_TEST|speckle tracking echocardiography|"Speckle tracking is a recent development in image processing that uses proprietary software to automatically determine the movements of these points, which appear sonographically as speckles, within the myocardium over time. Tracking the movements of these speckles throughout the cardiac cycle yields positive values when the two points are moving away from one another, as in diastole, and negative values when they are moving towards one another, as in systole"
214424546|NCT04620902|OTHER|Tear sampling|Tear sampling using Schirmer's strips
214424547|NCT02077426|OTHER|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
214424548|NCT04435236|PROCEDURE|Cervical ESP block|Cervical ESP block will be performed as described by Elsharkawy at al. (7). ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
214424549|NCT00071253|DRUG|Divalproex Sodium (Delayed-Release Tablets)|
214424550|NCT00071253|DRUG|Divalproex Sodium (Extended-Release Tablets)|
214424551|NCT00071253|DRUG|Olanzapine|
215108418|NCT05605106|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.
215108419|NCT00126360|DRUG|Timing of Anastrozole in respect to radiotherapy|
215108420|NCT04886908|OTHER|Data extraction from medical files|Data extraction from medical files
215108421|NCT03315312|DRUG|Fluoride Varnishes|Fluoride varnish is randomly applied on randomly selected first permanent molar. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
215108422|NCT03315312|DRUG|Fissure Sealants|Resin-based fissure sealant is applied on contra-lateral first permanent molar and each child serves as its own control. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
215108423|NCT05013359|OTHER|No treatment given|No treatment given
215108424|NCT04344275|OTHER|-Scapular endurance test|The resistance of the trapezius and serratus anterior muscles to fatigue was assessed using the scapular muscle endurance test.
215108425|NCT04344275|OTHER|-Muscle strength test|Upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) muscle strengths were tested using a hand-held digital dynamometer (Lafayette Manual Muscle Tester, Model 01165).
215108426|NCT06099431|PROCEDURE|Mandibular marginal resection and reconstruction|Intraoral buccal and lingual incisions 2-3 mm away from the free gingival margins were carried out around the teeth to be included in the resection. The osteotomy lines were marked using a long shank surgical tapered fissure bur. The osteotomies completed and the resected segment was removed.
215108427|NCT06099431|DEVICE|mandibular osteosynthesis a 2.3mm reconstruction bone plate|a 2.3 mm reconstruction bone plate was then fit in place and fixed to both the proximal and distal segments
215108428|NCT02470598|OTHER|Treatment with Adapted Automated Peritoneal Dialysis (aAPD)|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists
215108429|NCT03940729|DRUG|Chlorhexidine Topical|In the Malmö needle exchange program, people who inject drugs (PWID) are repeatedly screened for S aureus colonization during one year. Those colonized will repeatedly shower with chlorhexidine during the following year. The infection frequency will be compared between the two periods.
215108430|NCT01156766|DEVICE|- locking anterior plate|"The number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. Several surgical techniques are described in particular locking plates and intrafocal pinning techniques.~The aim of the study is to compare (X-ray assessments and functional outcome) these two types of treatment by using a prospective, randomised multicentric analysis."
215108431|NCT00797849|DEVICE|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
215108432|NCT00797849|DEVICE|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
215108433|NCT02311114|OTHER|In Depth interview|In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.
215108434|NCT02311114|OTHER|Observational fieldwork|Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.
215108435|NCT02311114|OTHER|Survey|Surveys with participants will be conducted using validated survey tools.
215108436|NCT00431015|DRUG|IPI-504|IV Hsp90 inhibitor
215108437|NCT00997282|DRUG|OPC-262 2.5 mg|orally administered once daily for 24 weeks
215108438|NCT00997282|DRUG|OPC-262 5 mg|orally administered once daily for 24 weeks
215108439|NCT00997282|DRUG|Placebo|orally administered once daily for 24 weeks
215108440|NCT02688686|BIOLOGICAL|genetically modified dendritic cells + cytokine-induced killer|This Phase I/II Study to evaluate clinical efficacy, safety of genetically modified dendritic cells in combination with cytokine-induced killer cell treament in NSCLC with bone metastases.
215108441|NCT04449627|OTHER|Feeling Good Digital App|Audio based tracks using Jacobson relaxation and mindfullness based cognitive therapy (MBCT) techniques including positive visualisation.
215108442|NCT04794270|DEVICE|ACUVUE OASYS® 1-Day for Astigmatism - TAM 24|TEST
215108443|NCT04794270|DEVICE|ACUVUE OASYS® 1-Day for Astigmatism|CONTROL
215108444|NCT01937260|DRUG|Brodalumab|Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
215108445|NCT00441246|DRUG|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
215108446|NCT03652935|BEHAVIORAL|Mindfulness Based Stress Reduction|
215108447|NCT03652935|OTHER|Health Education Series|This is an active comparator condition that consists of 8 weekly classes related to health.
215108448|NCT00704938|BIOLOGICAL|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
215108449|NCT00704938|BIOLOGICAL|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10\^8 cells to 5 x 10\^10 cells.
215108450|NCT00704938|BIOLOGICAL|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10\^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
215108451|NCT00704938|BIOLOGICAL|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
215108452|NCT00704938|DRUG|cyclophosphamide|60mg/kg/day (Days-7,-6)
215108453|NCT00704938|DRUG|fludarabine phosphate|25mg/m\^2 (Days -5, -4, -3, -2, and -1)
215108454|NCT02103491|DIETARY_SUPPLEMENT|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
215108455|NCT02103491|DIETARY_SUPPLEMENT|Placebo administration|
215108456|NCT03410563|BEHAVIORAL|Auditory inputs|Three different auditory inputs
215108457|NCT01262859|DRUG|bevacizumab|Bevacizumab, 15 mg/kg IV over 30 minutes (if this infusion rate was well tolerated), every 3 weeks until completion of radiation The initial dose will be delivered over 90+/-15 minutes. If the first infusion is tolerated without infusion associated adverse events (fever and/or chills), the second infusion may be delivered over 60+/-10 minutes. If the 60 minute infusion is well tolerated, all subsequent infusions may be delivered over 30+/-10 minutes.
214424552|NCT03868397|DIAGNOSTIC_TEST|Liver MRI|"Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique."
214424553|NCT03720236|PROCEDURE|Implant bed preparation protocol|This is the first surgical phase, we prepare the implant bed by using different increasing size drills.
214424554|NCT03720236|PROCEDURE|Implant loading|This is the second phase, based on prosthetic procedures, to design the crown over the dental implant
214424555|NCT04498624|PROCEDURE|inverted flap|full thickness macular hole surgery
214424556|NCT04498624|PROCEDURE|peeling internal limiting membrane (ILM)|full thickness macular hole surgery
214424557|NCT06108375|OTHER|music therapy|music played live by a music therapist
214424558|NCT06108375|OTHER|recording|a recording of the same music played by the music therapist
214424559|NCT02014142|DRUG|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
214424560|NCT00084045|PROCEDURE|Intrapartum HIV counseling/testing|
214424561|NCT00084045|PROCEDURE|Postpartum HIV counseling/testing|
214424562|NCT05723133|DEVICE|Electric toothbrush|Patients will receive oral hygiene instructions and an electric toothbrush with or without daily personal feedback using the brushing app (Oral-B app).
214424563|NCT05723133|BEHAVIORAL|Oral hygiene instructions|The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.
214424564|NCT05910918|BEHAVIORAL|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
215108458|NCT06825832|DEVICE|high power laser therapy|The MLS® Laser Therapy device used in this study is M6 (ASA srl -Arcugnano, Italy), equipped with both a robotized multidiode head (up to 3,3W), able to perform automatic scanning treatments, and an MLS® handpiece (up to 1,1W), aimed to perform manual point to point or scanning treatments. Each treatment includes two stages: the scanning of the frontal and dorsal shoulder area of 93 cm2 each with a robotized multidiode head and a point-by-point process with the manual handpiece with 7 points of 3,14 cm2 area.
215108459|NCT06825832|DEVICE|pulsed electromagnetic field therapy|the PEMF application, with application of low intensity and frequency pulsed electromagnetic fields (PEMF), the portable device PMT QS (ASA Srl, Arcugnano) is used, equipped with Flexa applicators (36 x 21 x 2 cm (L x P x H) - 1.2 kg), programmable frequency from 0.5 to 100 Hz and variable magnetic field intensity from 5% to 100% (from \~2.5 to \~40 Gauss)), two solenoid applicators are placed at the anterior and posterior positions in the patient's shoulders and applied for 25 min at 25 G intensity at a frequency of 50 Hz.
215108460|NCT06825832|OTHER|Exercise|The conventional exercise program for hemiplegic shoulder pain (HSP) is stretching exercise therapy, joint stabilization exercise therapy.
215108461|NCT00732875|BIOLOGICAL|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
215108462|NCT03826186|DEVICE|Traditional (loss-of-resistance technique) thoracic epidural placement|Thoracic epidurals will be administered using the traditional loss-of resistance technique.
215108463|NCT03826186|DEVICE|CompuFlo thoracic epidural placement|Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
215108464|NCT00051376|DRUG|L-Arginine|
215108465|NCT06831513|DEVICE|Serkel 3D CRO|Serkel 3D CRO is intervention for those with deformational plagiocephaly and already qualified for a cranial remolding orthosis
215108466|NCT05658588|DEVICE|Cytosorb|Cytosorb cartridge It is composed of polystyrene divinylbenzene and polyvinylpyrrolidone copolymers and targets molecules in the 5-50 kDa range, which includes the molecular mass of several cytokines
215108467|NCT03470090|BEHAVIORAL|Neuromuscular Exercises|In the experimental group, the subjects who were taken into the study were taken to the neuromuscular exercise (NME) program after the pre-treatment evaluations. The subjects in this group were given classical physiotherapy and NME performed 6 days a week, 1 set of 10 times physiotherapist control. NME was including warming, neuromuscular exercises (balance, muscle strengthening, proprioception, sensorimotor system training, joint stabilization and postural control exercises) and cooling periods.
215108468|NCT03470090|BEHAVIORAL|Conventional Group|In the control group, the subjects who were taken into the study were taken to the classical physiotherapy (hotpack (HP), ultrasound (US), transcutaneous electrical stimulation (TENS)) and conventional exercises program after the pre-treatment evaluations.
215108469|NCT04628429|DRUG|Erenumab|anti-CGRP-receptor monoclonal anti-body
215108470|NCT04628429|DRUG|Galcanezumab|anti-CGRP-ligand monoclonal anti-body
215108471|NCT04628429|DRUG|Fremanezumab|anti-CGRP-ligand monoclonal anti-body
215108472|NCT04637425|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
215108473|NCT04637425|DRUG|Placebo|Matched tablets without any active substance.
215108474|NCT04561908|DEVICE|Transseptal puncture with Brockenbrough-needle|Conventional transseptal puncture with Brockenbrough-needle
215108475|NCT04561908|DEVICE|Microguidewire-assisted transseptal puncture|Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
215108476|NCT04428957|OTHER|Telemonitoring|Daily telemonitoring of heart rate (HR), blood pressure (BP), pulse oximetry (SpO2), spirometry (FVC), activity (accelerometry) and severity of cough and dyspnea
215108477|NCT06370013|DRUG|Tinengotinib|Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study. Dose may be decreased by one dose level from the previously-received dose upon study entry, based on physician discretion.
215108478|NCT03688074|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
215108479|NCT03688074|OTHER|Placebo|Placebo subcutaneous injection
215108480|NCT03306719|BIOLOGICAL|Blood sampling|Serial blood sampling
215108481|NCT04327726|DRUG|Dexmedetomidine Nebulization|ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment
215108482|NCT04327726|OTHER|0.9% Saline Nebulization|nebulization of 4mL 0.9% saline
215108483|NCT00724984|DRUG|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
215108484|NCT00721188|DRUG|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
215108485|NCT04814121|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
215108486|NCT04814121|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
215108487|NCT03928717|BEHAVIORAL|Text-Based Adherence Game|A mobile health intervention facilitated by a cloud-hosted web application and designed to promote adherence to HIV care through text message-delivered gamification strategies including peer comparison, point reinforcement, feedback on adherence outcomes, facilitation of social support, and use of an engaging and culturally-relevant story-line.
215108488|NCT03928717|BEHAVIORAL|Standard of Care (SOC)|A 10- to 20-minute in-person intervention led by a trained HIV treatment adherence counselor focused on providing basic knowledge of HIV and HIV treatment, motivating participants to engage in HIV treatment, and problem-solving barriers to adherence.
215108489|NCT00584259|OTHER|Coffee|3 cups of coffee over a 24 hour period
215108490|NCT03161080|DEVICE|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
215108491|NCT03161080|DEVICE|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
215108492|NCT03161080|DEVICE|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
215108493|NCT02110667|DEVICE|Transperineal Ultrasound|
215108494|NCT01304004|OTHER|Satiety|"Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~1. Experimental drinkable yogurt enriched in proteins and fibres~2. Placebo drinkable yogurt (isocaloric and isovolumetric)"
215108495|NCT00730808|DIETARY_SUPPLEMENT|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
215108496|NCT02013297|RADIATION|SBRT treatment|"For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy."
215108497|NCT04648683|BEHAVIORAL|Individual telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a one-on-one telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 75 minutes each (except the first session which lasts 90 minutes).
215108498|NCT04648683|BEHAVIORAL|Group telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a group-delivered telehealth (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 90 minutes each.
215108499|NCT03432169|OTHER|Yoga (stretching plus mindfulness)|Stretching plus mindfulness
215108500|NCT03432169|OTHER|Stretching|Stretching alone
215108501|NCT01736670|DRUG|Triamcinolone Acetonide spray|
215108502|NCT01736670|DRUG|Triamcinolone acetonide cream|
215108503|NCT01736670|DRUG|Alcohol spray|
215108504|NCT03154996|DRUG|Topotecan|"Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)"
215108505|NCT03154996|DRUG|Gadolinium|Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
215108506|NCT03154996|DEVICE|Synchromed II infusion pumps|Implanted subcutaneously to facilitate chronic infusion.
215108507|NCT02780284|BEHAVIORAL|Physical activity intervention|150 minutes per week of moderate intensity cardiovascular exercise. The exercise sessions will include a minimum of 30 minutes of exercise each day, 3 to 5 times per week for a total of 150 minutes of exercise per week.
215108508|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
215108509|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
215108510|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
215108511|NCT03790059|DRUG|H101|Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
215108512|NCT03790059|PROCEDURE|RFA|Treat the samll HCC with the RFA.
215108513|NCT03056339|DRUG|Fludarabine|30 mg/m2 by vein on Days -5 to -3.
215108514|NCT03056339|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days -5 to -3.
215108515|NCT03056339|DRUG|Mesna|300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
215108516|NCT03056339|BIOLOGICAL|iC9/CAR.19/IL15-Transduced CB-NK Cells|"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.~Starting dose: 10E5"
215108517|NCT03056339|DRUG|AP1903|If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
215108518|NCT00635167|DRUG|Contrast Enhanced-Transrectal Ultrasound|Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline \[Visit 2\]); week 5 (middle of treatment \[Visit 3\]); week 10 (end of treatment \[Visit 4\]); week 18 (2 months after end of EBRT \[Visit 5\]); week 26 (4 months after end of EBRT \[Visit 6\]); and week 36 (6 months after end of EBRT \[Visit 7\]).
215108519|NCT01048658|DRUG|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
215108520|NCT01048658|OTHER|No Sevoflurane|Subject only standard of care drug regimens for anesthesia with this procedure.
215108521|NCT02901418|BIOLOGICAL|200 IU HBIG|additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
215108522|NCT00917618|OTHER|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
215108523|NCT00917618|OTHER|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
215108524|NCT03529968|PROCEDURE|esophagectomy|Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
215108525|NCT03982680|DRUG|Toripalimab|3mg/kg on d1 and d15 q4W\*4cycles，then 3mg/kg q3w for 1 year in total
215108526|NCT03982680|DRUG|Gemcitabine|1250mg/m2 on d1 and d15 q4W\*4cycles
215108527|NCT03982680|DRUG|5- fluorine pyrimidine|400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W\*4cycles
215108528|NCT05224453|OTHER|Physical training and high protein diet|In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d)
215108529|NCT05224453|OTHER|Physical training and low protein diet|In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (\<1 g/kg aBW/d)
215108530|NCT02544919|DRUG|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
215108531|NCT05945446|DIAGNOSTIC_TEST|Galectin 3|Women diagnosed with Placenta Accreta Spectrum (PAS) were invited to join the study, providing they had no known systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. They also did not have cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection.
215108532|NCT05164627|DRUG|Dexmedetomidine|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
215108533|NCT05164627|DRUG|Magnesium Sulphate|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
215108534|NCT05164627|DRUG|Normal saline|After patient arrival at the PACU, Paediatric Anaesthesia Emergence Delirium (PAED) scale ,Ramsay sedation scores (RSS), emergence agitation, HR, and mean arterial blood pressure (MAP) were recorded every 5 min during the first 30 min, then every 10 min for the remaining 30 min of the recovery room stay. Patients were then transferred to the ward. All postoperative observations and scores were performed by the same anesthesiologist who was blinded to the group assignment
215108535|NCT05580939|OTHER|Intervention group|They use Web-based Simulation Application for 4 weeks
215108536|NCT03374371|DIAGNOSTIC_TEST|high-throughput sequencing|technique of high-throughput sequencing of the markers present in the genome of the S. epidermidis strains responsible for infection in order to help to discriminate the true infections of the contaminations
215108537|NCT02775448|DRUG|Carduus marianus 6cH|
215108538|NCT02775448|DRUG|Carduus marianus 12cH|
215108539|NCT02775448|DRUG|Carduus marianus 30cH|
215108540|NCT02775448|DRUG|Placebo|
215108541|NCT02775448|BEHAVIORAL|Exercise|aerobic exercise, 30 minutes, daily
215108542|NCT02775448|OTHER|Diet|1600 calories
215108543|NCT03833063|DRUG|botulinum toxin A|glabellar injections with botulinum toxin A
215108544|NCT03833063|DRUG|Placebos|glabellar injections with sodium chloride
215108545|NCT02580461|BEHAVIORAL|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
215108546|NCT05260827|OTHER|Heated tobacco product|Sham heated tobacco product
215108547|NCT04693286|BIOLOGICAL|novel oral polio type 2 vaccine (nOPV2)|• nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
215108548|NCT04693286|OTHER|Placebo|Placebo contains no active ingradients, only sucrose in buffer
215108549|NCT01128244|DIETARY_SUPPLEMENT|Vitamin B6|Subjects will receive vitamin B6 supplementation.
215108550|NCT01128244|PROCEDURE|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
215108551|NCT05217394|OTHER|OTHIG|Occupational Therapy Handwriting Intervention Guideline
215108552|NCT00031759|DRUG|imiquimod|
215108553|NCT00031759|PROCEDURE|Ablative or excisional therapy|
215108554|NCT00101985|DRUG|talnetant|
215108555|NCT02774369|BEHAVIORAL|Physical exercise|Individualized aerobic intervention program
215108556|NCT02774369|BEHAVIORAL|Cognitive-behavioral therapy|Psychological intervention combining behavioral, cognitive, and educational strategies
215108557|NCT01983085|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
215108558|NCT01983085|DEVICE|Standard of Care|Dressing changed as per normal clinical practice
215108559|NCT03654508|GENETIC|ADRB2-genotype guided treatment|This intervention assesses whether ADRB2 genotype-guided treatment leads to better asthma control after 3 months compared to usual care in children who are uncontrolled despite adherent and adequate use of ICS.
215108560|NCT03654508|OTHER|Randomisation|In the control arm, children will be randomised over double dose ICS or ICS+LABA instead of treatment according to their genotype.
214424565|NCT02735291|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
214424566|NCT05977179|OTHER|Dietary intervention to mitigate Post-Acute COVID-19 Syndrome|As it was described in the arm/group descriptions.
214424567|NCT05977179|OTHER|Attention Control|As it was described in the arm/group descriptions.
214424568|NCT02713334|BEHAVIORAL|survey|
214424569|NCT02713334|BEHAVIORAL|semi-structured interview|
215108561|NCT00939536|DRUG|Zolpidem Tartrate Tablets 10 mg|
214424571|NCT00816049|DRUG|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
214424572|NCT00816049|DRUG|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
214424573|NCT03941912|DEVICE|Erchonia EVRL|Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
214424574|NCT02692742|DRUG|Myelo001|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
214424575|NCT02692742|DRUG|Placebo|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
214424576|NCT06395870|BIOLOGICAL|LUCAR-G39D cells product|Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
214424577|NCT04483856|DEVICE|DermoRelizema cream|Fingertip units (FTU) depending from the extent of the affected skin to treat, two times per day for 7 (±3) days prior RT until about 14 (±3) days post RT end. The product can be used for further 2 weeks (from V3 to V4) in case of need, according to the investigator's judgment
214424578|NCT04483856|DEVICE|Dexeryl|FTUs depending on the extent of the affected skin to treat, two times per day. The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
215108562|NCT02219334|DEVICE|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
215108563|NCT00334243|DRUG|Microflare protocol for IVF|
215108564|NCT00334243|DRUG|Antagonist protocol for IVF|
215108565|NCT00334243|DRUG|Demi-halt protocol for IVF|
215108566|NCT03261219|DEVICE|Intrapulmonary Percussive ventilation|mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway
215108567|NCT03261219|DEVICE|Chest Physiotherapy Vest (Incourage)|mode of airway clearance using external vibratory vest
215108568|NCT04406675|OTHER|neuropsychological test|neuropsychological test
215108569|NCT06109064|BIOLOGICAL|Unrelated Umbilical Cord Blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
215108570|NCT06109064|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
215108571|NCT06109064|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
215108572|NCT06109064|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
215108573|NCT00589771|DRUG|Saccharomyces boulardii|"1. Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
215108574|NCT00589771|DRUG|Placebo|"1. Cap Placebo TDS for six weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
215108575|NCT04003740|DEVICE|Home-based transcranial direct current stimulation|The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
215108576|NCT01692977|OTHER|neuropsychological assessment|
215108577|NCT02891395|DRUG|Imatinib Mesylate and Nilotinib|"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
215108578|NCT05729932|DRUG|Inhaled vaporized cannabis|Double-blind cannabis and placebo doses, administered through vaporizer
215108579|NCT05729932|DRUG|Intransal opioid|Double-blind opioid and placebo doses, administered intranasal route
215108580|NCT04293185|GENETIC|bb1111|Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
215108581|NCT01108913|DRUG|Bimosiamose|
215108582|NCT01108913|DRUG|Placebo|
215108583|NCT06489951|DRUG|Solifenacin|The outpatient physician prescribed Solinaxine (up to 0.5mg daily) to the participant orally
215108584|NCT06489951|DIETARY_SUPPLEMENT|vitamin D|The outpatient physician prescribed vitamin d drops (2400iu daily) for the participants, which were taken orally by the participants
215108585|NCT06489951|BEHAVIORAL|Standard behavioral therapy|Participants will receive an initial behavioral therapy session at enrollment and a second behavioral therapy session six weeks later. Education including information about dry OAB, lifestyle adjustments, bladder and pelvic floor training, bowel management, and how to use a bladder diary to record urination
215108586|NCT06765590|DRUG|T, 260 mg/m2, paclitaxel for injection (albumin-bound)|T, 260 mg/m2, paclitaxel for injection (albumin-bound)
215108587|NCT06765590|DRUG|R, 260 mg/m2, paclitaxel for injection (albumin bound).|R, 260 mg/m2, paclitaxel for injection (albumin bound).
215108588|NCT05873842|DEVICE|Trans-femoral TAVI|Trans-femoral TAVI (Trans-catheter Aortic Valve Implantation) with calcified ilio-femoral arteries via PTA (Percutaneous transluminal angioplasty ) or IVL (Intra-vascular Lithotripsy)
215108589|NCT02397200|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
215108590|NCT02397200|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals
215108591|NCT04171219|BIOLOGICAL|Pembrolizumab|Given IV
215108592|NCT04171219|DRUG|Talabostat Mesylate|Given PO
215108593|NCT06234254|BEHAVIORAL|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
215108594|NCT06501703|OTHER|Instruments|instruments used as different techniques in final irrigation after root canal preparation
215108595|NCT05811169|GENETIC|Next generation sequencing|Next generation sequencing
215108596|NCT04276519|PROCEDURE|Physiotherapeutic, non-invasive position-induced opening of the intervertebral foramen|Opening of the mechanical interface of the nerve root, neurodynamics
215108597|NCT04166916|OTHER|Acoustic stimulation|Acoustic stimulation to modulate slow waves.
215108598|NCT04166916|OTHER|SHAM acoustic stimulation|This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
215108599|NCT02837185|PROCEDURE|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
214424579|NCT03622580|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
214424580|NCT03622580|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
214424581|NCT03622580|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
215108600|NCT02837185|OTHER|Physiological measures|These include TMS and EMG measurements
215108601|NCT06284668|DRUG|normal Saline|Patients undergoing oocyte retrieval were given 5ml 0.9% saline before anesthesia and surgery
215108602|NCT06284668|DRUG|Esketamine|Patients undergoing oocyte retrieval were given esketamine 0.2mg/kg before anesthesia and surgery
215108603|NCT06284668|DRUG|Remimazolam|Patients undergoing oocyte retrieval were given remimazolam 0.2mg/kg before anesthesia and surgery
215108604|NCT04694560|OTHER|Treatment Free Observation|Participants without evidence of clinical relapse will remain off therapy and continue serial monitoring through end of study at 24 cycles. Participants with clinical relapse will continue to be monitored off therapy through 24 cycles or until meeting criteria for treatment per iwCLL criteria. If participants experience clinical relapse requiring treatment, radiology assessment, disease assessment, and testing for resistance mutations will be performed. Participants will be observed for an additional 12 cycles following start of reintroduction of therapy.
214424582|NCT01441453|PROCEDURE|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
215108605|NCT06774378|BEHAVIORAL|Minds@Work-ADHD-Quality of Life|Minds@Work-ADHD-Quality of Life
215108606|NCT06774378|BEHAVIORAL|Minimal contact|Weekly 15-minute scripted phone calls made individually by a member of the research team to offer minimal support, without any active intervention.
215108607|NCT05707208|DRUG|ST-01|A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.
215108608|NCT05707208|DRUG|1% Lidocaine HCL|Currently approved lidocaine
215108609|NCT05477680|DEVICE|Navigation-guided surgery|Surgeon removes brain lesions and assesses brain shift with neuronavigation
215108610|NCT04838626|DRUG|[18F]CTT1057|PET/CT imaging with \[18F\]CTT1057
215108611|NCT06583707|PROCEDURE|Dry needling with and without ultrasound guidance|The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.
215108612|NCT05036317|DRUG|Empagliflozin (Jardiance®;|Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
215108613|NCT05036317|OTHER|Placebo Control Intervention|Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.
215108614|NCT04150094|OTHER|Pelvic floor muscle training (PFMT)|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.
215108615|NCT04150094|OTHER|Pelvic floor muscle training + intravaginal vibratory stimulus|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
215108616|NCT04543227|BEHAVIORAL|Opioid Use 90-Days Post Treatment|Survey conducted 90-days post treatment to determine use of opioid medications in relation to burn or knee arthroscopy pain
215108617|NCT05097495|PROCEDURE|Only NNS|"Before the procedure, the Premature Infant Comfort Scale shall be filled out.~Procedure steps for the control group:~* Materials shall be prepared (napkins, non-sterile gloves, pacifier)~* Hands shall be washed; gloves shall be worn.~* The infant shall be given a NNS just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
215108618|NCT05097495|PROCEDURE|NNS Combined with Breast Milk|"* Before the procedure, the Premature Infant Comfort Scale shall be filled out.~* Materials shall be prepared (napkins, non-sterile gloves, pacifier, breast milk, cup)~* Hands shall be washed; gloves shall be worn.~* The cylindrical part of a pacifier shall be in touch with breast milk for 5 seconds. The infant shall be given the pacifier, combined with breast milk, just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
215108619|NCT03029923|BEHAVIORAL|Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
215108620|NCT03029923|BEHAVIORAL|Smoking cessation plus Health and Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
215108621|NCT02381015|GENETIC|Genetic Risk Score: Number Format|Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
215108622|NCT02381015|GENETIC|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
215108623|NCT02381015|BEHAVIORAL|Family History: Number Format|Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
215108624|NCT02381015|BEHAVIORAL|Family History: Number + Pictograph|Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
215108625|NCT06011837|DEVICE|Altered Auditory Feedback|Mumble Melody is an application that leverages Altered Auditory Feedback (AAF). During AAF, a person's speech is altered in near-real time. Mumble Melody modulates the user's voice and plays it back to them while they are speaking. Included are Unaltered (raw voice), Whisper (voiceless sound), Reverb (cathedral sound), and Harmonized (robotic sound) voice transformations.
215108626|NCT02761343|OTHER|MRI scan|Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
215108627|NCT04985461|DEVICE|dental occlusion ties maxillo-mandibular fixation|"This research study is being done to determine if dental occlusion ties can adequately align and stabilize jaw fractures. The chief goal of jaw fracture repair is to ensure that the teeth align normally. Traditionally, alignment has been accomplished by using steel wires and bars (having the jaw wired). Dental occlusion ties are newer devices similar to cable ties or zip ties that are wrapped around and/or between some of the teeth and secured. This procedure is intended to hold the teeth in similar alignment as wires, yet with less application time and less damage to the gums."
215108628|NCT04174690|DEVICE|Force platform|In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
214509864|NCT06604481|BEHAVIORAL|eCoaching for Caregivers of Older Adults|The experimental group receives an online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills. This program is designed to operate individually on an e-platform. It consists of 6 weekly sessions, each lasting for less than 90 minutes. The content of the sessions focuses on teaching caregivers CBT techniques, lifestyle modifications to improve caregiving experiences, and effective communication strategies. In between each session, participants are assigned home practices to reinforce the skills learned further. All content will be included.
214509865|NCT06604481|BEHAVIORAL|eCoaching (need specific) for Caregivers of Older Adults|The experimental group receives an online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills as in eCoaching I. However, eCoaching II will include content specified to carer's specific need.
214509866|NCT06604481|BEHAVIORAL|Control Intervention for Caregivers of Older Adults|The control group attends 6 weekly online sessions that primarily provide educational information about lifestyle factors and communication. These sessions aim to enhance the control group's knowledge and understanding of the factors that impact caregiving. Each session in the control group also lasts for 90 minutes. The focus of these activities will be on building practical caregiving skills and promoting overall well-being, rather than targeting any particular psychological or mental health-related factors directly.
214509867|NCT02334215|DRUG|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
214509868|NCT02334215|BEHAVIORAL|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
214509869|NCT02334215|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
214509870|NCT06990269|DRUG|ADX-038|siRNA duplex oligonucleotide
214509871|NCT06990269|DRUG|Placebo|Saline
214509872|NCT05324085|BEHAVIORAL|High-intensity interval training|Supervised exercise intervention, three times a week for eight weeks.
215108629|NCT01934010|DRUG|AM-101|AM-101 gel for intratympanic injection
215108630|NCT02936024|PROCEDURE|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
215108631|NCT02936024|PROCEDURE|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
215108632|NCT06521372|OTHER|Magenta AI image analysis tool|MagentaTM is a non-invasive image analysis tool that utilizes artificial intelligence to evaluate 2-dimensional images of denuded mature MII oocytes. The MagentaTM software has been analyzed retrospectively, by Future Fertility. This data displays that a higher MagentaTM score is associated with a higher chance of blastocyst development. Additionally, the MagentaTM software has been validated in a prospective multi-center study, displaying that a higher MagentaTM score correlates to a higher chance of blastocyst development.
215108633|NCT00992355|DRUG|Tobramycin 0.3% - Dexamethasone 0.1%|
214509873|NCT05324085|BEHAVIORAL|Treatment as usual|The content of TAU is broadly individualized but most often includes various forms of group therapy, psychotherapy, psychoeducation and physical activity. The physical activity schedule for the patients typically includes gym-based exercises, individualized by preference of each patient, and various outdoors activities, four times per week all together.
214509874|NCT06999577|DRUG|Omeprazole 40 MG|8 week double dose therapy of proton pump inhibitor or placebo.
215108634|NCT00992355|DRUG|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
215108635|NCT03061435|PROCEDURE|Screening anal Pap smear - No high-resolution anoscopy|75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy
215108636|NCT03061435|PROCEDURE|Screening anal Pap smear - High-resolution anoscopy|25% of patients with negative cytology on their anal Pap smear will receive high-resolution anoscopy. All patients with positive (abnormal) cytology on their anal Pap smear will receive high-resolution anoscopy.
215108637|NCT05943249|PROCEDURE|magnetic resonance|
215108638|NCT00870181|BIOLOGICAL|ADV-TK/GCV|gene therapy
215108639|NCT00870181|PROCEDURE|Surgery|
215108640|NCT00870181|DRUG|systemic chemotherapy|
215108641|NCT01548027|PROCEDURE|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
215108642|NCT01548027|PROCEDURE|TAP block|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months
214424583|NCT03105219|DRUG|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
214424584|NCT03105219|OTHER|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
214424585|NCT02279017|BEHAVIORAL|mHealth Texting for Weight Loss|
215108643|NCT01548027|OTHER|No intervention|No intervention
215108644|NCT06419088|OTHER|Preoperative individualized education|Based on the identified individual education needs, the researcher implemented audio-visual education to the intervention group in the ward.
215108645|NCT03945461|OTHER|Chewing gum|xylitol based, peppermint flavored gum
215108646|NCT06411431|PROCEDURE|Early Chest Tube Removal|"Subjects within the Early Removal group will have their chest tube removed if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
215108647|NCT06411431|PROCEDURE|Standard Chest Tube Removal|"Subjects within the Standard Removal group will have their chest tube removal on POD#2 if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
215108648|NCT06411431|DEVICE|Apical Chest Tube|A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.
214509875|NCT06999577|BEHAVIORAL|Laryngeal Recalibration Therapy|LRT utilizes therapies that SLPs standardly utilize (mechanical and cognitive guidance) in combination specifically designed to treat laryngeal symptoms. Each session with the SLP will guide subjects through these therapies. The existing script-based LRT protocol consists of the following: 1) mechanical guidance (laryngeal suppression, voice production, breath coordination), 2) cognitive guidance (identification of thinking patterns, recalibration of thoughts about laryngeal sensations).
214509876|NCT06999577|BEHAVIORAL|GERD Lifestyle Recommendations|This is the typical lifestyle recommendations for GERD used clinically.
215108649|NCT05186740|DEVICE|ProVee Urethral Expander System|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
215108650|NCT05186740|PROCEDURE|Urethral Access Sheath|The Urethral Access Sheath is introduced into the prostatic urethra to simulate the placement of the ProVee Expander.
215108651|NCT01393821|DRUG|menadione topical lotion|Given topically
215108652|NCT01393821|OTHER|placebo|Given topically
215108653|NCT01393821|OTHER|questionnaire administration|Ancillary studies
215108654|NCT01393821|PROCEDURE|management of therapy complications|Given menadione topical lotion
215108655|NCT04339621|DEVICE|LiverMultiscan|The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores
215108656|NCT05004220|PROCEDURE|Plasmapheresis|Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.
215108657|NCT03515096|DRUG|Eltrombopag|Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
215108658|NCT03515096|DRUG|rhTPO|rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
215108659|NCT02211248|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
215108660|NCT02211248|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
215108661|NCT00657579|DRUG|DE-104 ophthalmic solution, low concentration|
215108662|NCT00657579|DRUG|DE-104 ophthalmic solution, medium concentration|
215108663|NCT00657579|DRUG|DE-104 ophthalmic solution, high concentration|
215108664|NCT00657579|DRUG|DE-104 vehicle|
215108665|NCT01189695|DRUG|Ritonavir-boosted lopinavir|Lopinavir/ritonavir 200/50 mg every 12 hours
215108666|NCT01189695|DRUG|optimized background regimens (OBRs)|Optimized background regimens such as NRTIs, etravirine or raltegravir
215108667|NCT00105690|BEHAVIORAL|Telemedicine intervention|
215108668|NCT03991455|DEVICE|Apyx device|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
215108669|NCT05299008|DRUG|Bethanechol|Infants whom will be treated with bethanechol for tracheobronchomalacia in level IV center Neonatal Intensive Care Unit.
215108670|NCT06451991|OTHER|Use of concept map in clinical practice in nursing students|Concept map will be used in clinical practice in nursing students.
215108671|NCT02336672|DEVICE|Cryothermal ablation|Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
215108672|NCT00760318|DRUG|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
215108673|NCT01204021|BEHAVIORAL|Tai Chi Chih|12 weeks of weekly classes of Tai Chi Chih
215108674|NCT01204021|BEHAVIORAL|Stress Education Control|Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
215108675|NCT01652339|DRUG|Exforge tab. 10/160mg|
215108676|NCT01652339|DRUG|Lodivixx tab. 5/160mg|
215108677|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Bicruciate retaining|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
215108678|NCT04334304|PROCEDURE|Robot-assisted Total Knee Arthroplasty|A total knee arthroplasty will be performed with robot-assistance (NAVIO).
215108679|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Posterior Stabilized|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
215108680|NCT05473871|BEHAVIORAL|Faith in Action|"Interpersonal level: Group exercise classes offered 6 days/week (walking, cardio dance, strength training), Kickoff event~Individual level: Motivational Interviewing calls every 6 months, Health handouts on 14 topics distributed at PA classes"
215108681|NCT05473871|BEHAVIORAL|Faith in Action+|Standard Faith in Action Intervention plus: 1) Health Behavior Change Workshop for FBO leaders; 2) Targeted Messaging; and 3) Empowerment Training for Promotoras
215108682|NCT05473871|BEHAVIORAL|Faith in Action++|Enhanced Condition plus: 1) Foster community collaborations and 2) Provide maintenance support
215108683|NCT04381663|PROCEDURE|conservative treatment|conservative treatment for patients with cervical spine stenosis without myelopathy
215108684|NCT04381663|PROCEDURE|surgical treatment|surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
215108685|NCT05248659|DRUG|Sibeprenlimab 400 mg s.c. Q4weeks|Sibeprenlimab 400 mg s.c. q 4 weeks
215108686|NCT05501080|OTHER|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
215108687|NCT05501080|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
215108688|NCT04678635|OTHER|Chronic transcranial direct current stimulation|Chronic transcranial direct current stimulation
215108689|NCT03970941|OTHER|Cost evaluation|The cost for the hospital of the strategy of management will be evaluated.
215108690|NCT03970941|OTHER|Questionnaire|The quality of life of patients will be measured.
215108691|NCT03422536|BIOLOGICAL|Cetuximab|Given IV
215108692|NCT03422536|DRUG|Ficlatuzumab|Given IV
215108693|NCT00087659|DRUG|zoledronic acid|
215108694|NCT06975917|DRUG|Chemotherapy|Any chemotherapy regimen that is used in the adjuvant setting
215108695|NCT06974500|PROCEDURE|Daily efferent limb stimulation for at least two weeks prior to surgery using saline solution and a thickering agent|"Participants in the intervention group will undergo daily stimulation of the efferent limb for a minimum of two weeks prior to ileostomy closure. The procedure involves the instillation of a solution composed of saline and a thickening agent through the efferent limb of the ileostomy via the inactive orifice. This is performed by the patient at home following specific training and instructions provided during a preoperative consultation.~The stimulation begins the day after the pre-anaesthesia consultation and is carried out once per day. Patients are supported with a structured follow-up, including one physical consultation in the stoma clinic, telephone contact with the research team every 48 hours, and access to an email address for queries. The objective of the intervention is to recondition the excluded colon before the restoration of intestinal continuity in order to reduce postoperative complications."
214424586|NCT00587925|OTHER|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
214424587|NCT03071848|OTHER|No Intervention|This was an observational study.
214424588|NCT03575819|DRUG|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
214424589|NCT02221219|DRUG|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
214424590|NCT02221219|PROCEDURE|delay in umbilical cord clamp at birth|provision of a \~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
214424591|NCT02221219|DRUG|placebo infusion|saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
214424592|NCT02221219|PROCEDURE|immediate cord clamp at birth|no delay in umbilical cord clamp; \<10sec (recorded in delivery note)
214424593|NCT01240837|OTHER|Arenga Pinnata Sugar|50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
214424594|NCT01240837|OTHER|Glucose|50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
214424595|NCT01240837|OTHER|Sucrose|50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
214424596|NCT02873312|DEVICE|StimRouter|"The StimRouter System is a neuromodulation system consisting of the following components and accessories:~* An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~* An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~* A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories."
214424597|NCT01483248|BIOLOGICAL|conventional therapy plus MenSC transplantation|"patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1\*10E6 MSC/kg body for 2 weeks."
214424598|NCT01483248|DRUG|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
214424599|NCT01930045|DRUG|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
214424600|NCT01930045|DRUG|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
215108696|NCT06976190|DRUG|MRG003 + Pucotenlimab|MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.
215108697|NCT06976190|DRUG|Gemcitabine, Docetaxel, or Capecitabine|"Gemcitabine will be administrated via intravenous infusion at 1000 mg/m2 once on Day 1 and 8 of every 3 weeks (21-day cycle).~Docetaxel will be administrated via intravenous infusion at 75 mg/m2 once on Day 1 of every 3 weeks (21-day cycle).~Capecitabine will be administrated orally at 1000 mg/m2 twice a day for Day 1 to 14 of every 3 weeks (21-day cycle)."
215108698|NCT06650267|BEHAVIORAL|Fathers for Change (F4C)|Defining features of F4C delivered over 18 sessions: 1) focus on the fathers model of fatherhood as a motivator for change, 2) focus on understanding and identifying feelings, teaching skills to identify and change emotional dysregulation that lead to both SU and FV, 3) co-parent communication skills to reduce stress and improve problem solving, 4) restorative parenting (see Table 1 and figure 1)127. F4C focuses on reflective understanding of emotional experiences, how that impacts thoughts and behaviors related to SU, FV, co-parenting/parenting each session. Through greater self-awareness, the father is better able to apply coping, communication and parenting skills introduced to reduce SU and FV.
215108699|NCT06650267|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC is an individual evidence-based SU treatment84 that incorporates two elements: endorsement of the disease model and the spiritual dimensions of recovery. These elements differentiate the approach from F4C. IDC is influenced by 12-step recovery philosophy and participation in 12-step groups like NA are encouraged. The model places focus on the individual in recovery without a focus on fatherhood or co-parenting. IDC will be offered in an 18-session format.
215108700|NCT06511349|DRUG|YOLT-203|The IP is administered intravenously at the predetermined dose.
214509877|NCT06820177|DRUG|Tranexamic Acid|1g tranexamic acid
215108701|NCT05696795|DRUG|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of sarcoidosis.
215108702|NCT06975397|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|This training and research project was conducted over eight weeks and started 6 - 8 weeks after natural childbirth. All study participants were included in the exercise program designed for postpartum females. Exercises included four sets that changed every two weeks and were held individually with a physiotherapist three times a week, every two to three days, for 45 minutes each unit. All participants performed breathing exercises, body posture correction, abdominal muscle strengthening exercises (transverse, oblique, and rectus abdominis muscles), and engaged other muscles to improve overall physical fitness.
215108703|NCT06975397|OTHER|kinesio taping|The Kinesiology Tape used in this study has a European quality certificate (CE). Before the exercise program, on the day of the first ultrasound, participants had tapes placed on their abdomens. The tape length for each participant was 20 cm to ensure the ends were located on the lateral edges of the rectus abdominis muscles. Both ends of the tape were simultaneously attached to the abdomen, with two attached from the navel line upwards and one below it Each participant in the tape group was asked to breathe in using the abdominal muscles, and after a maximal stretch of the abdominal integuments, three tapes were attached at 50% tension or without tension. The taping procedure was repeated once per week, with the tapes attached for six days and removed at the end of the 6th day. The placebo and tape groups had a break on the 7th day
215108704|NCT06975813|DRUG|masseter muscle|masseter muscle trigger points injection by magnesium sulphate
215108705|NCT06975813|DRUG|masseter and sternocleidomastoid muscle|masseter and sternocleidomastoid muscle trigger points injection by magnesium sulphate
215108706|NCT04766775|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
215108707|NCT04929249|DRUG|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
215108708|NCT06976281|OTHER|conventional exercise Program|Exercises include shoulder flexion, shoulder abduction, leg extension, and hand grip. Start with 1-3 sets of 12 reps at 30% of 1-repetition maximum, increasing by 10% according to patient endurance. Cycling is a 30-minute chair or bedside cycle ergometer exercise 2 time/weak for 2 consecutive months
215108709|NCT06976281|OTHER|blood flow restriction training|Patients received the same conventional exercise program, which included isometric, aerobic, and resisted exercise individualized for every patient with blood flow restriction by 50% of limb occlusion pressure. Training will be conducted for 2 time/weak for 2 consecutive month
214424601|NCT01018524|PROCEDURE|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
214424602|NCT04971447|DRUG|gender affirming hormonal treatment in transgender men|testosterone enanthate
214424603|NCT04971447|DRUG|gender affirming hormonal treatment in transgender women|GnRH agonists + estrogen
214424604|NCT02616237|BEHAVIORAL|Lifestyle Intervention|East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
214424605|NCT02997917|BEHAVIORAL|Education|
215108710|NCT06974526|DRUG|Oxandrolone|Absorbable oxandrolone implant (subdermal insertion) Men: 400 mg oxandrolone (two 200 mg oxandrolone implants each) Women: 200 mg oxandrolone (one 200 mg oxandrolone implant)
215108711|NCT06974526|DRUG|Placebo|Absorbable placebo implant (excipients; subdermal insertion) Men: 400 mg placebo (two 200 mg placebo implants each) Women: 200 mg placebo (one 200 mg placebo implant)
215108712|NCT06975527|OTHER|Breastfeeding guidelines|"All participants will be instructed by the following guidelines:~* Hold the breast so the nipple brushes the center of the infant's lips and wait for the infant to open the mouth.~* Infant's mouth should be opened wide, as with a yawn and should cover the entire areola, or a large amount of the areola.~* Both breasts are used in each feeding, usually 10 to 15 minutes on the first side, followed by burping before beginning the second side.~* Break suction by placing finger in the corner of infant's mouth and quickly remove breast.~* Apply breast massage before breastfeeding.~* The neonate is nursed shortly after birth and approximately every 2 to 3 hours thereafter for a total of 8 to 12 feedings a day.~* Lactating women needs about 8 to 10 glasses of fluids per day while breastfeeding.~* Caffeine consumption should be limited to 2 cups of coffee, tea or cola per day.~* Lactating mother should consume a healthy diet which is varied, balanced, and natural."
214424606|NCT02997917|BEHAVIORAL|Sham|
214509878|NCT06820177|DRUG|Placebo|10 mL 0.9% normal saline
214509879|NCT04557176|DEVICE|CRP, point-of-care assay|CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
215108713|NCT06975527|OTHER|Aerobic exercise|The participants will be engaged in a supervised moderate aerobic exercise in the form of walking on a treadmill for 40 minutes/ day, 3 days/ week, for 6 weeks beginning 6:8 weeks postpartum. Each exercise session will be divided into 3 phases. The warm-up phase begins with walking at low speed (within resting heart rate) on a treadmill for 5 minutes. The active phase continues for 30 minutes at a moderate intensity of 60 to 70% of maximal heart rate (HRmax). Gradual increase and adjustment of speed will be applied for each woman according to her prescribed intensity based on HRmax. HRmax is calculated by subtracting the age from 220. The program will be terminated with 5 minutes cool-down phase, during which the treadmill speed will be gradually decreased until the heart rate resumes its resting level.
215108714|NCT06974461|PROCEDURE|Blood Flow Restriction (BFR) Walking|Participants in this group will undergo a supervised treadmill walking program with blood flow restriction (BFR) applied using BFR pressure cuffs. The cuffs are applied to the proximal thighs, and the training pressure starts at 50% of the participant's arterial occlusion pressure (AOP), increasing every two weeks up to 200 mmHg. Walking is performed at 60% of the maximum walking speed, 20 minutes per session, 3 sessions per week for 6 weeks.
215108715|NCT06974461|PROCEDURE|Sham Blood Flow Restriction (Sham-BFR) Walking|Participants in this group will follow the same supervised treadmill walking protocol as the BFR group but with minimal cuff pressure (20 mmHg), which does not restrict blood flow. This simulates the sensation of BFR without physiological impact. The purpose is to serve as a placebo comparator. Walking is performed at 60% of maximum walking speed, 20 minutes per session, 3 sessions per week for 6 weeks.
215108716|NCT06974474|DRUG|Guselkumab|Guselkumab
215108717|NCT02208375|DRUG|Capivasertib|Given PO
215108718|NCT02208375|OTHER|Laboratory Biomarker Analysis|Correlative studies
215108719|NCT02208375|DRUG|Olaparib|Given PO
215108720|NCT02208375|OTHER|Pharmacological Study|Correlative studies
215108721|NCT02208375|DRUG|Vistusertib|Given PO
215108722|NCT04529343|OTHER|Virtual reality mediated upper extremity rehabilitation|"Game-based exercise will be applied for different range of motion of the upper extremity. Gamified exercise program consisting of 4 different scenarios will be applied 3 days a week for 6 weeks to the patients in the virtual reality group. A session takes an average of 45 minutes.~Games to be applied;~1. Finger flexion-extension (10 minutes / session)~2. Wrist flexion, extension, ulnar and radial deviation (10 minutes / session)~3. Forearm pronation and supination (10 minutes / session)~4. Elbow flexion-extension-shoulder internal and external rotation (15 minutes / session) will have scenarios controlled with. All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes."
215108723|NCT04529343|OTHER|Classical exercise therapy for upper extremities|All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
215108724|NCT02613585|OTHER|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
215108725|NCT06842888|DEVICE|Miraπ|"This device has tiny sensors that measure the movement of the healthy fingers and tiny motors that move the affected fingers of the patient.~The device is connected to a specially designed finger mechanism that moves the affected fingers of the patient. This opening mechanism is designed in a way that it prevents the fingers from being forced into any hurting position. If the patient moves the healthy fingers during training, also the fingers of the affected hand are moved by the device at the same time. This creates the effect of mirror therapy for the brain as the patient can see both hands moving."
215108726|NCT06842888|BEHAVIORAL|Mirror Therapy|Current standard of care using MT.
215108727|NCT05795985|DIAGNOSTIC_TEST|calprotectin levels|dosage of calprotectin levels in patients with abdominal pain
215108728|NCT04099121|DEVICE|Ultrasound Imaging|3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.
215108729|NCT03565146|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of pigmented lesions
215108730|NCT06524427|PROCEDURE|Robot-assisted lobectomy|Patients will receive robot-assisted lobectomy using Da Vinci surgical system
215108731|NCT06524427|PROCEDURE|Video-assisted lobectomy|Patients will receive video-assisted lobectomy
214424607|NCT04368403|DRUG|KHK4827|210 mg every 2 weeks (Q2W), subcutaneous (SC) injection
215108732|NCT06622512|DEVICE|Radial Pressure Wave Therapy|Radial pressure wave therapy (RPWT) is a non-invasive treatment used for musculoskeletal disorders, including knee OA. (Schroeder AN) It involves the application of mechanical energy to stimulate biological responses, RPWT differs fundamentally from focal shock wave therapy (FSWT) in several physical properties, in its point of maximum energy flux density (EFD), and in some clinical applications. RPWT activates cellular pathways involved in tissue regeneration and generates mechanical energy that spreads radially from the point of application, primarily affecting superficial tissues and leading to pain relief and improved function through a process known as mechano-transduction, by enhancing blood flow and stimulating cellular repair processes . (Simplicio CL, Wang CJ)
215108733|NCT06702410|BEHAVIORAL|mental health gap action program intervention guide (mhGAP-IG)|The mhGAP-IG is an evidence-based intervention developed by WHO. It was designed for non-specialists to scale up high quality mental health services. Although more than 90 countries worldwide have implemented mhGAP-IG, this study is the first to evaluated if it works for scaling up CMBDs services in China. Investigators have cultrually adapted the mhGAP-IG according Chinese context.
215108734|NCT06800963|BIOLOGICAL|Intravesical Recombinant Mycobacterium (rMBCG)|19.2e8 Colony-forming unit(s) CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration)
215108735|NCT04580693|OTHER|PET Scan|PET scan using a tracer that is under a physician sponsored IND.
215108736|NCT05730972|DEVICE|Transcutaneous electrical acupoint stimulation|The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.
215108737|NCT05730972|DEVICE|Sham transcutaneous electrical acupoint stimulation|The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, but could not output current normally.
215108738|NCT05730972|DRUG|Routine palliative treatment|The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
215108739|NCT01349764|DRUG|Vitamin D3|
215108740|NCT01561053|BIOLOGICAL|Albumin 5%|Therapeutic plasma exchange with human albumin 5%
215108741|NCT01561053|BIOLOGICAL|Albumin 20%|Low volume plasma exchange with human albumin 5%
215108742|NCT01561053|BIOLOGICAL|Immunoglobulin|Intravenous human immunoglobulin 5%
215108743|NCT03921177|DIETARY_SUPPLEMENT|Multiple micronutrient supplement|Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).
215108744|NCT03921177|DRUG|Placebo Oral Tablet|Preconception to 12-weeks gestation: identical tablet
215108745|NCT02130505|DIETARY_SUPPLEMENT|OGTT|Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
215108746|NCT01716455|DRUG|SSP-004184|
215108747|NCT04412447|DEVICE|Functional Electrical Stimulation|Electrical stimulation of motor-nerves innervating the musculature of the lower limb.
215108748|NCT06077890|OTHER|Digital Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be able to access home-based rehabilitation strategies through dynamic content provided by SIMPLI.REHAB digital tool.
215108749|NCT06077890|OTHER|Conventional Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be given home-based strategies in a printed paper brochure.
214424608|NCT02749578|DRUG|Atorvastatin|
215108750|NCT00395850|DRUG|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
215108751|NCT02816619|BEHAVIORAL|Personalized Physical Activity coaching program|
214424609|NCT02749578|DRUG|MGL-3196|
214424610|NCT03895268|DEVICE|ALiA Analyser|NPS specimens shall be tested with the investigational device
214424611|NCT03895268|DEVICE|Influenza A+B Test Kit|NPS specimens shall be tested with the investigational device
214424612|NCT03852836|OTHER|ultra-rapid acquisition of bile ducts images|On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.
214424613|NCT04555265|DEVICE|Radiofrequency ablation or microwave ablation|Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
214424614|NCT04299360|DEVICE|Cardiac Resynchronization Therapy device programming|Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
214424615|NCT05222087|RADIATION|Radiotherapy|35Gy/5# Central 40Gy/5# Large Tumours \>5cm (non-central) 36Gy/12# or 40Gy/15# Ultracentral lesions 50Gy/5# Peripheral Tumours ≤5cm
215108752|NCT02816619|BEHAVIORAL|Free practice of physical activity|
215108753|NCT03973762|DEVICE|DR Grading with CAD|A CAD system is used to make DR grading.
215108754|NCT03973762|OTHER|DR Grading by expert panel|DR Grading by expert panel
215108755|NCT06194071|OTHER|Completion of questionnaires and on-site visits during an 18 months follow-up after TBI|"We will evaluate the same outcomes and use the same questionnaires at 6, 12 and 18 months post-TBI.~For patients we will evaluate:~* Functional Outcome (GOS-Extended)~* Health-related Quality of Life (QOLIBRI)~* Neurocognitive tests (MoCA)~* Independence (Barthel Index)~* Daily issues (BICOQ)~* Anxiety and depression symptoms (HADS)~* Medico-economic evaluation (EQ5D-5L)~For Relatives we will evaluate:~* Symptoms of anxiety and depression (HADS)~* The appreciation of the patient's daily issues from their point of view (dedicated Bicoq for relatives)~* Burden of care (ZARIT)~Throughout the follow-up we will nest a qualitative research programs which will focus on several aspects:~* feasibility of such follow-up (6 months is the primary endpoint) defined as the drop-out rate, complete or incomplete completion of scales and their reasons~* factors that may lead to drop-out or the contrary that solidifies the follow-up"
215108756|NCT02141139|DRUG|NSAIDS (ketorolac and ibuprofen)|
215108757|NCT05529329|PROCEDURE|overlay|Lithium Disilicate partial coverage of hypo-mineralized defected enamel
215108758|NCT06321939|DIAGNOSTIC_TEST|EBV-DNA next generation sequencing|EBV-DNA next generation sequencing
215108759|NCT03311347|OTHER|+Gz accelerations and positive pressure breathing|
215108760|NCT05296031|DEVICE|Treatment with Zilver PTX Drug Eluting Stent (DES) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
215108761|NCT05296031|DEVICE|Treatment with Zilver Flex Bare Metal Stent (BMS) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
215108762|NCT00428870|PROCEDURE|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
215108763|NCT00351507|DRUG|Vildagliptin|
215108764|NCT04098861|DRUG|Latanoprost/Timolol|Latanoprost/Timolol Fixed Combination
215108765|NCT01241071|OTHER|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
215108766|NCT01241071|OTHER|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
215108767|NCT03784807|DIAGNOSTIC_TEST|synovial calprotectin, confocal laser microscopy|Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
215108768|NCT06144047|DEVICE|EEG SubQ subcutaneous EEG device|2-channel subcutaneous EEG device
215108769|NCT01973504|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
215108770|NCT01973504|DRUG|Control|Crystalloid solution IV infusion drip to keep vein open
215108771|NCT01297205|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
215108772|NCT03937414|DEVICE|The OSNA assay|SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
215108773|NCT02353390|OTHER|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
215108774|NCT00964561|DRUG|Ciprofloxacin and Valortim|Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
214424616|NCT05222087|DRUG|SoC systemic therapy|Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
215108775|NCT00964561|DRUG|Placebo Antibiotic and Valortim|Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
214424617|NCT02128607|DEVICE|SNAG|sustained natural apophyseal glide: SNAG / Mulligan technique
214424618|NCT02128607|DEVICE|Sham|
214509880|NCT07006493|DEVICE|Transcatheter Intramyocardial Septal Radiofrequency Ablation System|The device system includes a single-use RF ablation catheter, sheath, RF generator, and irrigation pump. Ablation is guided by intracardiac echocardiography (ICE).
215108776|NCT00964561|OTHER|Placebo Antibiotic and Placebo Valortim|Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
215108777|NCT04780464|DRUG|Doxorubicin|60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
215108778|NCT04780464|DRUG|Doxorubicin|12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
215108779|NCT04780464|DRUG|Cyclophosphamide Oral Product|100 mg BD on day 1 to day 7 of each 14 day cycle until PD
215108780|NCT04780464|DRUG|Prednisolone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD
215108781|NCT04780464|DRUG|Prednisone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
215108782|NCT00982202|DRUG|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for \~18months
215108783|NCT00982202|DRUG|Placebo|1 to 3 tablets daily for \~18 months
214424619|NCT03416842|DEVICE|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
215108784|NCT03355677|PROCEDURE|Case finding Clinic|Case finding clinic - participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 3 quality of life and functionality questionnaires the MRC dyspnoea score and the COPD diagnostic questionnaire. They will then be asked to perform FeNO CO and spirometry measurements.
215108785|NCT03355677|PROCEDURE|At Risk Case Clinics|Complex Case Clinic participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 6 quality of life and functionality questionnaires . They will then be asked to perform FeNO CO and spirometry measurements. Participants inhaler technique will be checked and any errors corrected. Smoking cessation advice and support will be given if necessary. Each participant will be given an individualised self management plan.
215108786|NCT03355677|OTHER|Usual Care|The control surgeries selected by the HHRA will continue with usual care.
215108787|NCT01435967|OTHER|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
214424620|NCT06259058|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14-day cycle
214424621|NCT06259058|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14-day cycle
214424622|NCT06259058|DRUG|5-Fluorouracil|2400 mg/m² continuous IV infusion in 46 h
214424623|NCT06259058|DRUG|Leucovorin|400 mg/m² on Day 1 of a 14-day cycle
214424624|NCT06259058|RADIATION|SBRT|30Gy/5Fx
214424625|NCT02076958|BEHAVIORAL|Community Health Advisor education|
214424626|NCT05758727|OTHER|Exercise intervention|The exercise programme is progressive and has three levels. Each bout of exercise and Tai-chi snacking consists of 5 exercises. Each exercise is performed for one minute with one minute rest in between. For exercise snacking movements (including leg exercise, shoulder exercise, single leg exercise, arm exercise, and ankle exercise), participants are encouraged to complete as many repetitions as possible of that exercise in that minute. For Tai-chi snacking movements (including single leg squat, trunk rotation, single leg stand, hip and knee exercise, and ankle mobility exercise), participants are encouraged to complete repetitions of each exercise at a self-selected pace that is comfortable for them to maintain for the full minute, with the aim being to complete the movements as accurately and smoothly as possible (based on correct posture and proper alignment).
214424627|NCT03949686|DRUG|Saline Solution|0.5 ml/kg saline
214424628|NCT03949686|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
214424629|NCT05890521|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|"Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person.~Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person."
214424630|NCT05493462|DRUG|Human FGF-1|Intranasal administration of human FGF-1
214424631|NCT04255888|PROCEDURE|Laterally positioned flap in thick periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
214424632|NCT04255888|PROCEDURE|Laterally positioned flap in thin periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
214424633|NCT06117683|DEVICE|ADULT Sotair Device|Sotair® device employs a flow limiting and pressure control valve mechanism.
214424634|NCT00447733|BEHAVIORAL|Integrated mental health and substance use treatment|Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
214424635|NCT00447733|BEHAVIORAL|Treatment as usual|Non-standardized psychiatric outpatient treatment
214424636|NCT02138006|DRUG|Intensive insulin treatment|Mealtime insulin (Actrapid) Basal insulin (Monotard)
215108788|NCT02461888|DRUG|Ixazomib|Chemotherapy
215108789|NCT02461888|DRUG|Cyclophosphamide|Chemotherapy
215108790|NCT02461888|DRUG|Dexamethasone|Chemotherapy
214424637|NCT02138006|DRUG|Standard insulin treatment|Insulin Mixtard
214424638|NCT05935319|OTHER|Vivifrail|Assess the physical activity status of the elderly, use the Vivifrail grade, provide exercise intervention, and improve physical activity function.
214424639|NCT00162331|DRUG|Technetium Tc99m Sestamibi|
214424640|NCT03624140|DEVICE|blood measurement|Hemoglobin measurement
214424641|NCT03624140|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
214424642|NCT03624140|DEVICE|hemoCue|non invasive method of hemoglobin measurement
214424643|NCT04893980|DRUG|Recombinant human interleukin-2 (rhIL-2)|During Day 0-14, patients in this group will receive treatment with antihistamines at the same dosage as pre-recruitment, together with a low-dose recombinant human Interleukin-2 (rhIL-2) at a dosage of 1 million international units every other day by intramuscular injection (rhIL-2, 1 MIU, im, Qod). During Day 15-28, the injections of rhIL-2 will be continued at the same dosage and the dose of antihistamines may be adjusted according to the control of symptoms.
215108791|NCT02295605|OTHER|water-based exercises|water-based exercise strengthening protocol for lower limb muscles
215108792|NCT02295605|OTHER|land-based exercises|land-based exercise strengthening protocol for lower limb muscles
215108793|NCT05575908|PROCEDURE|Digital expert team|A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
215108794|NCT04876612|PROCEDURE|Transforaminal epidural steroid injection (TFESI)|Well trained pain physician performs all the fluoroscopy-guided transforaminal epidural steroid injection (TFESI), who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For TFESI, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under fluoroscopy guidance at the patient's symptom complaining level. After confirming with a contrast medium, 3 ml of 0.1875% ropivacaine and 5 mg of dexamethasone are administered.
215108795|NCT02652468|DRUG|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
215108796|NCT02652468|DRUG|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
215108797|NCT02652468|DRUG|Cyclophosphamide|Given IV for 2 days
215108798|NCT02652468|RADIATION|Total nodal irradiation|Undergo total lymphoid irradiation
215108799|NCT02652468|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
215108800|NCT02652468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
215108801|NCT02652468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
215108802|NCT02652468|DRUG|Mycophenolate Mofetil|Given PO
215108803|NCT02652468|DRUG|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10\^5 cells/kg ideal BW of the patient
215108804|NCT02652468|BIOLOGICAL|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the patient
215108805|NCT02274740|DRUG|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
215108806|NCT02274740|DRUG|metformin|Pharmaceutical form:tablet Route of administration: oral
215108807|NCT01620762|DRUG|Cat-PAD|1 dose every 4 weeks
215108808|NCT01620762|DRUG|Placebo|1 dose every 4 weeks
215108809|NCT01298271|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
215108810|NCT02836431|DRUG|Dexmedetomidine 1mcg/kg Intranasal|DEX 1 mcg/kg Intranasal
215108811|NCT02836431|DRUG|Dexmedetomidine 2mcg/kg Intranasal|DEX 2 mcg/kg Intranasal
215108812|NCT02836431|DRUG|Dexmedetomidine 1mcg Intravenous|DEX 1 mcg/kg Intravenously
215108813|NCT00057408|DRUG|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
215108814|NCT00057408|DRUG|Placebo|Matching Placebo
215108815|NCT03521479|DRUG|Squaric Acid Dibutyl Ester|Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
215108816|NCT00705146|DEVICE|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
215108817|NCT00705146|DEVICE|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
215108818|NCT02910102|DRUG|RVT-101 35 mg|RVT-101 once daily, oral, 35-mg tablets
215108819|NCT02910102|DRUG|Placebo|Placebo once daily, oral
215108820|NCT04585607|DEVICE|A medium cut-off dialyzer (Theranova) will be used for HDx.|"A medium cut-off dialyzer used for HDx (Theranova) must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription.~HD with MCO dialyzer (Theranova 400®, Baxter) vs. high-flux dialyzer (eg. Polyflux H, Baxter)"
215108821|NCT04585607|DEVICE|A synthetic high-flux dialyzer (Polyflux)|A synthetic high-flux dialyzer (Polyflux) used for hemodialysis must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required.
215108822|NCT02658773|DRUG|lidocaine-Prilocaine cream|
215108823|NCT02658773|DRUG|placebo cream|
215108824|NCT02669121|BIOLOGICAL|NoV Placebo-matching Saline|NoV placebo-matching saline (0.9% sodium chloride).
215108825|NCT02669121|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.
215108826|NCT02782221|DRUG|Growth Hormone|Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
215108827|NCT02782221|DRUG|Pegisomant|One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
215108828|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
215108829|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
215108830|NCT02629003|DRUG|[11C]Cimbi-36|
215108831|NCT02629003|DRUG|[11C]Cimbi-36-5|
215108832|NCT06526091|OTHER|Cerebral NIRS monitoring at delivery|Application of cerebral NIRS monitoring immediately after delivery and during optimum cord management
215108833|NCT05411939|OTHER|Shared Decision-Making Tool|The Shared Decision-Making Tool (SDMT) is designed to provide a personalized, patient- centered framework for clinical discussions regarding treatment options for knee osteoarthritis. The tool functions through patient input of information such as pain severity and current symptoms, alongside other demographic information such as age, race, and comorbidities, to offer a series of outcomes to better illustrate how the patient's specific disease presentation will progress. Ultimately, using the SDMT may impact patient behavior if patients change their treatment preferences after utilizing the tool. This can empower them to seek additional support over time and maintain communication with their orthopedist to ensure they are on a healthier path.
215108834|NCT05411939|OTHER|Video|Short video that describes knee osteoarthritis and possible treatment options.
215108835|NCT05411939|OTHER|Standard of Care|Standard of care counseling for a patient presenting with knee osteoarthritis.
215108836|NCT06315127|DIETARY_SUPPLEMENT|Human donor milk|The intervention will involve providing donor milk as required as a supplement to parent milk and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. All donor milk will be aliquoted into individualized syringes in the Rogers Hixon Ontario Human Milk Bank which is located in Sinai Health. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad. As this study follows a pragmatic approach, the clinical team will assess the need for supplementation based on the mother-infant dyad's condition.
215108837|NCT06315127|DIETARY_SUPPLEMENT|Formula|The intervention will involve providing formula as required as a supplement to parent milk and as a standard of care, and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. The formula will be supplied from the hospital's inventory in accordance with the standard procedure followed by the well-baby unit to supplement infants. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad.
215108838|NCT00492336|DRUG|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
215108839|NCT00492336|DRUG|Placebo|Placebo 1 tablet each day
215108840|NCT02661867|BEHAVIORAL|delivery|delivery either vaginal or by cesarean section
215108841|NCT00241904|BEHAVIORAL|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
215108842|NCT00241904|DRUG|Antiplatelet Agents|Aspirin 81 mg q day
215108843|NCT00241904|DRUG|Beta Blocker|Oral medication
215108844|NCT00241904|DRUG|ACE Inhibitors|Oral medications, received 1-2 times per day
215108845|NCT02116088|BEHAVIORAL|Teacher Coaching|
215108846|NCT01467921|DRUG|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
215108847|NCT04331002|DRUG|Zilretta|ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.
215108848|NCT04331002|OTHER|Placebo|5 mL normal saline
215108849|NCT00825812|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
215108850|NCT00825812|DRUG|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
215108851|NCT03865784|OTHER|Experimental|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done, proceed to ask the subject to lean forward applying the rest of the strip, except the distal edge, with a tension of between 15 and 25%, finally requesting the subject to rejoin straining the distal base without tension, on the twelfth dorsal spinous process.
215108852|NCT03865784|OTHER|Control|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. The objective of the application of the technique based on this type of exercise is to improve muscle strength, endurance and neuromuscular control. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done the tape will be placed without tension and sn movement of the subject.
215108853|NCT05567926|DIETARY_SUPPLEMENT|Beetroot juice concentrate (140 ml)|A beetroot juice concentrate (140 ml) will be administered to participants in experimental conditions.
215108854|NCT05567926|DIETARY_SUPPLEMENT|Blackcurrant juice (placebo)|140 ml of blackcurrant juice with added appropriate amount of sugar to equalize the carbohydrate value and lemon juice fort the taste.
215108855|NCT06325865|OTHER|Interview|Interview with ALS patient in which the experiences of unpleasant sensations or pain during study procedures are assessed in a qualitative manner.
215108856|NCT00082199|DRUG|Aripiprazole|Tablets, Oral, 2-30mg, Once daily, 12 weeks.
215108857|NCT00082199|DRUG|Placebo|Tablets, Oral, Once daily, 12 weeks.
215108858|NCT05620264|DIAGNOSTIC_TEST|Tear Sample Probe|Samples will be collected by conjunctival lavage of the affected eye without topical anesthesia. Sterile normal saline will be infused at room temperature into the lower conjunctival sac by gently pulling down the lower eyelid and with a needle-free insulin syringe. After few seconds, the lavage fluid will be aspirated back into the same syringe without the syringe touching the conjunctiva.
215108859|NCT02779413|DRUG|insulin degludec|Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
215108860|NCT00894946|PROCEDURE|Lipiodol + IVF|IVF preceded by lipiodol
215108861|NCT00894946|PROCEDURE|IVF|IVF alone
215108862|NCT00483938|DRUG|Pegylated-interferon Alfa-2a|Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
215108863|NCT00483938|DRUG|Ribavirin|Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
215108864|NCT02534246|DEVICE|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic \[Beacon\] 25 gauge) from single lesion.
215108865|NCT02534246|DEVICE|Ultrasound biopsy needle SharkCore|
215108866|NCT06128603|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy was performed for periampullary benign and malignant diseases. Besides, the surgical video was recorded.
215108867|NCT04382378|DEVICE|neuromuscular electrical stimulation|application of an electric current through electrodes placed on the skin over the targeted musclesto induce skeletal muscle contractions
215108868|NCT05357508|BEHAVIORAL|Intervention brochure|Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.
215108869|NCT05357508|BEHAVIORAL|Control brochure|Provide participants with general information about options for colorectal cancer screening.
215108870|NCT02373644|OTHER|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
215108871|NCT02373644|OTHER|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
215108872|NCT01973725|DRUG|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
215108873|NCT04573608|DRUG|Papacarie|Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
215108874|NCT04573608|DRUG|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
215108875|NCT02218008|DRUG|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
215108876|NCT02218008|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
215108877|NCT03009968|OTHER|Post-void residual free voiding trial|Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
215108878|NCT01488201|DRUG|Placebo|
215108879|NCT01488201|DRUG|KHK4827|
215108880|NCT00106353|DRUG|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
215108881|NCT02038075|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|
215108882|NCT02038075|BEHAVIORAL|Treatment As Usual (TAU)|
215108883|NCT02346617|BIOLOGICAL|IFN-γ positive selected T-cells|No intervention
215108884|NCT00681928|DRUG|anastrozole|As determined by the subject's physician
215108885|NCT00681928|DRUG|letrozole|As determined by the subject's physician
215108886|NCT00681928|OTHER|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
214424644|NCT04893980|DRUG|Control group|During Day 0-14, patients in the control group receive treatment with only antihistamines at the same dosage as pre-recruitment, but no injection of rhIL-2. During Day 15-28, treatment with low dose recombinant human Interleukin-2 (rhIL-2), i.e., 1 million international units every other day by subcutaneous or intramuscular injection (rhIL-2, 1MIU, im, Qod), will be added.
214424645|NCT01436838|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
214424646|NCT06554262|OTHER|No intervention|No intervention was involved in this study
214424647|NCT00971711|BIOLOGICAL|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
214424648|NCT02054455|DIETARY_SUPPLEMENT|Lactobacillus paracasei F19|25x10E9 live bacterial cells for 3 days/week for 6 months
215108887|NCT00681928|PROCEDURE|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
215108888|NCT00681928|PROCEDURE|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
215108889|NCT04000581|OTHER|Best Practice|Receive standard of care
215108890|NCT04000581|OTHER|Physical Activity|Walk for minimum 30 minutes per day
215108891|NCT04000581|OTHER|Questionnaire Administration|Ancillary studies
215108892|NCT00588354|DRUG|Clonidine|200 or 400 micrograms clonidine
215108893|NCT00588354|DRUG|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
215108894|NCT00588354|DRUG|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
215108895|NCT00032357|PROCEDURE|Ferritin reduction to 25 ng/ml by phlebotomy|
215108896|NCT00141128|DRUG|SS-RBX|
215108897|NCT03477838|DEVICE|FreeStyle LibrePro CGM|a professional CGM device will be worn by the participant for up to 14 days
215108898|NCT00713895|BEHAVIORAL|Expert System|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
215108899|NCT00713895|BEHAVIORAL|Standard Self-Help|standard smoking cessation self-help manual
215108900|NCT04649684|DEVICE|Conventional robot-assisted gait training|They got conventional robot-assisted gait training, guidance force given equally to both limbs, and then gradually reduce the degree of guidance force to the extent that the patient is tolerable equally .during 4- week treatment session
215108901|NCT04649684|DEVICE|Lower CIMT robot-assisted gait training group|They got robot-assisted gait training based on CIMT concept; 100% guidance force is given on the unaffected side and then verbal ques are given not to contract unaffected muscle voluntarily as much as possible are provided, automatically according to the predetermined joint trajectory. In contrast at the affected side, gradually reduce the degree of guidance force to the extent that the patient is tolerable.
215108902|NCT02409771|DEVICE|PRECIZON Presbyopic|Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
215108903|NCT00839761|DIETARY_SUPPLEMENT|iron fortified rice|
215108904|NCT00839761|DIETARY_SUPPLEMENT|iron drops|
215108905|NCT00856804|DRUG|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
215108906|NCT05186168|DEVICE|MiniHip Stem|The MiniHip stem is a titanium femoral stem (Ti-6Al-4V) coated with a layer of hydroxyapatite applied over a layer of pure titanium
215108907|NCT05186168|DEVICE|Trinity Acetabular Cup System|The Trinity Acetabular System is a modular acetabular cup system consisting of a press fit, titanium alloy shell
215108908|NCT00015808|DRUG|Idebenone|
215108909|NCT02519595|DRUG|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
214424649|NCT02054455|DIETARY_SUPPLEMENT|Placebo|Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
214424650|NCT02087644|BIOLOGICAL|CYT003|Injections
214424651|NCT02087644|BIOLOGICAL|Placebo|Injections
214424652|NCT06184308|BEHAVIORAL|Home-based Physical Rehabilitation|Six out of seven days a week, gentle flexibility practice (upper arm and shoulder movements) that can be done seated or standing and two slow walking sessions focused on balance. In addition, complete a breathing practice focused on breathing in through the nose and exhaling through the mouth.
214424653|NCT06184308|BEHAVIORAL|Health Coaching|Study-trained nurse whom utilizes participant data to guide interactions in weekly calls.
214424654|NCT04686942|DIAGNOSTIC_TEST|After sonazoid|0.015ml/mg sonazoid enhanced US to detection of liver metastases.
214424655|NCT01596946|BEHAVIORAL|Contact tracing mode test at clinic|
214424656|NCT01596946|BEHAVIORAL|Self-sampling at home - Sent Test Kit|
214424657|NCT02847312|OTHER|High avenanthramide, phenolic acid|High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
214424658|NCT02847312|OTHER|Low avenanthramide, medium phenolic acid|Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
215108910|NCT02519595|DRUG|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
215108911|NCT02519595|DRUG|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
215108912|NCT02191813|DRUG|Seresis®|
215108913|NCT02191813|DRUG|Placebo|
215108914|NCT02846441|PROCEDURE|hepatobiliary scintigraphy|99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)
214424659|NCT02847312|OTHER|Control|Control are matched with energy and insoluable fibre.
214424660|NCT04148417|DEVICE|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure
214424661|NCT03308461|DRUG|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
214424662|NCT01122901|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
214424663|NCT01122901|PROCEDURE|therapeutic conventional surgery|Undergo surgery
214424664|NCT01122901|OTHER|pharmacological study|Correlative studies
214424665|NCT01122901|OTHER|laboratory biomarker analysis|Correlative studies
215108915|NCT06439303|DRUG|Cytisine 1,5 mg|Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
215108916|NCT03382808|BEHAVIORAL|SEE Training|Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.
215108917|NCT03382808|BEHAVIORAL|GAZE Training|Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
215108918|NCT00387036|DRUG|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
215108919|NCT00387036|DRUG|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
215108920|NCT00850538|RADIATION|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
215108921|NCT00850538|PROCEDURE|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
215108922|NCT02969460|BEHAVIORAL|Neurotrack Virtual Cognitive Health Program|
215108923|NCT06258408|DRUG|BB102 tablet|BB102 tablets will be administered orally once daily(QD).
215108924|NCT01760772|DRUG|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
215108925|NCT01760772|DRUG|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
215108926|NCT01760772|OTHER|saline|Constant infusion
215108927|NCT03113981|DEVICE|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
214424666|NCT01140113|PROCEDURE|Modified Ultrafiltration|After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
215108928|NCT03139344|OTHER|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.
215108929|NCT03139344|OTHER|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
215108930|NCT01031173|BIOLOGICAL|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
215108931|NCT04414566|DRUG|gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil|Patients receive GP gemcitabine (1000 mg/m\^2 d1,8) and cisplatin (80mg/m\^2 d1) or TPF docetaxel (60mg/m\^2 on day 1), cisplatin (60mg/m\^2 on day 1) and fluorouracil (600mg/m\^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
215108932|NCT04414566|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
215108933|NCT04414566|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m\^2 every 3 weeks for 3 cycles.
215108934|NCT02624531|DRUG|Taxane|NACT and Fertility-sparing Treatment Strategy
215108935|NCT02624531|PROCEDURE|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
215108936|NCT06407531|OTHER|VR-G|Patients watched videos with virtual glasses before undergoing colonoscopy
214424667|NCT02458911|DEVICE|Paclitaxel-eluting balloon|
214424668|NCT05023512|BEHAVIORAL|Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health|Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.
214424669|NCT05987969|OTHER|"Alena mobile application"|This mobile application primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.
214424670|NCT01842724|PROCEDURE|Motec total wrist arthroplasty|
214424671|NCT01842724|PROCEDURE|Remotion total wrist arthroplasty|
214424672|NCT01807663|DEVICE|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
215108937|NCT06496165|DRUG|Remimazolam|Intravenous pump injection. The loading dose will be 0.1mg/kg, the maintenance dose will be 0.1-0.5mg/kg/h, with the target RASS be -2-0
214424673|NCT01807663|DEVICE|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
214424674|NCT01696578|BEHAVIORAL|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
214424675|NCT02537769|DEVICE|Left ventricular assist device (LVAD)|Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
214424676|NCT02537769|PROCEDURE|Tricuspid Valve Repair (TVR)|Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
214424677|NCT05247749|DEVICE|CONVIVO Confocal Endomicroscopy System|Confocal Laser Endomicroscopy (CEM) system intended for viewing intra-operative blood flow in the cerebral vascular area. Manufacturer - Zeiss
214424678|NCT04891458|DRUG|Patients received lighter sedation with propofol after spinal anesthesia.|MOAA/S 0-2.
214509881|NCT03182816|BIOLOGICAL|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
214424679|NCT04891458|DRUG|Patients received heavier sedation with propofol after spinal anesthesia|MOAA/S 3-5.
215108938|NCT06496165|DRUG|Propofol|Intravenous pump injection. The loading dose will be 0.5mg/kg, the maintenance dose will be 1-4mg/kg/h, with the target RASS be -2-0
215108939|NCT02083497|OTHER|rigid bandage|
215108940|NCT02083497|OTHER|elastic bands|
215108941|NCT02083497|OTHER|without the use of banding|
215108942|NCT02343809|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
215108943|NCT02343809|OTHER|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
215108944|NCT02343809|OTHER|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
215108945|NCT04107207|DIETARY_SUPPLEMENT|Ginger Kombucha|Craft Ginger Kombucha, a fermented black tea
215108946|NCT04107207|DIETARY_SUPPLEMENT|Ginger Water|Placebo
215108947|NCT01366729|DEVICE|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
215108948|NCT01366729|DEVICE|Cane walking|All walking activities must take place with cane from waking until sleeping
215108949|NCT01418742|DRUG|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
215108950|NCT01418742|DRUG|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
215108951|NCT01291407|DRUG|S-1|S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
215108952|NCT01291407|DRUG|S-1|S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
215108953|NCT01291407|DRUG|S-1|S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
215108954|NCT01291407|DRUG|S-1|S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
215108955|NCT01291407|DRUG|S-1|S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
215108956|NCT01291407|DRUG|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
215108957|NCT02328027|DRUG|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
215108958|NCT02913716|DRUG|defactinib|Single oral dose of 400 mg \[14C\]-defactinib
215108959|NCT00003569|DRUG|cisplatin|
215108960|NCT00003569|DRUG|dimesna|
215108961|NCT00003569|DRUG|paclitaxel|
215108962|NCT00122369|BEHAVIORAL|Self-hypnotic Relaxation|A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.
215108963|NCT00122369|BEHAVIORAL|Empathic Attention|A research assistant displayed defined behaviors of empathic attention.
215108964|NCT01357252|DRUG|vildagliptin|
215108965|NCT01357252|DRUG|Placebo|
215108966|NCT01189591|DEVICE|Slow-wave deprivation|Using acoustic tones to suppress slow-wave sleep
215108967|NCT04995549|DEVICE|Cutiscan® CS 100|Repeated measures on healthy volunteers skin (forearm) are performed using Cutiscan® CS 100 device
215108968|NCT02146391|DRUG|Androxal 25 mg Capsules|
215108969|NCT00999518|BIOLOGICAL|Tanezumab|1 mg dose given subcutaneously twice at an 8-week interval.
215108970|NCT00999518|BIOLOGICAL|Tanezumab|2.5 mg dose given subcutaneously twice at an 8-week interval.
215108971|NCT00999518|BIOLOGICAL|Tanezumab|10 mg dose given subcutaneously twice at an 8-week interval.
215108972|NCT00999518|BIOLOGICAL|Tanezumab|20 mg dose given subcutaneously twice at an 8-week interval.
215108973|NCT00999518|OTHER|Placebo|Placebo dose given subcutaneously twice at an 8-week interval.
215108974|NCT05003596|DRUG|Methylprednisolone Tablet|Subjects will take a quantity 21 4mg tablets over a 6 week taper.
215108975|NCT05003596|OTHER|Standard Mobilization Treatment|standard treatment of hand injuries with focus on mobilization. No anti-inflammatory medications. Pain management via Tylenol or narcotics if deemed necessary.
215108976|NCT02922179|DRUG|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
215108977|NCT00496639|PROCEDURE|angioplasty|Balloonplasty of the stenotic lesion at the venous anastomosis of the thrombosed AV graft.
215108978|NCT00496639|PROCEDURE|stent placement|Balloonplasty plus stent deployment at the stenotic lesion at the venous anastomosis of the thrombosed AV graft
215108979|NCT00930228|DRUG|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
215108980|NCT00930228|DRUG|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
215108981|NCT01679886|RADIATION|Rubidium PET|Rubidium PET
215108982|NCT05905731|BIOLOGICAL|TCR-T|"Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment."
215108983|NCT02055300|DRUG|LY03005|
215108984|NCT02055300|DRUG|Placebo|
215108985|NCT02055300|OTHER|Meal|
215108986|NCT02055300|DRUG|Pristiq|
215108987|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS)|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress.
215108988|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress. The movements to be performed by the patient are automatically decided by the exoskeleton.
215108989|NCT03319212|DEVICE|senofilcon A contact lenses|Senofilcon A Daily Disposable Contact Lenses
214424680|NCT04891458|DRUG|Patients received lighter sedation with dexmedetomidine after spinal anesthesia|MOAA/S 0-2.
215108990|NCT00544427|DEVICE|Optical coherence tomography|Optical coherence tomography imaging
215108991|NCT03617146|BEHAVIORAL|Health coaching|The intervention will seek to help participants express their diabetes emotional needs and to work with them to figure out what can be done to meet those needs. Depending on the unique needs of each participant, the coaching approach for this study will include: improving motivation and self-efficacy for diabetes management using motivational interviewing and appreciative inquiry; building trust and rapport through mindful listening, open-ended inquiry, and perceptive reflections; and expressing empathy through nonviolent communication. Each participant will receive eight individual coaching sessions over a five month period. All coaching sessions will be delivered over the phone (i.e. telecoaching). The coaching intervention will be done by a certified health and wellness coach.
215108992|NCT03617146|OTHER|Diabetes Distress-specific Education|A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.
215108993|NCT00250276|BIOLOGICAL|Cervarix™|GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
215108994|NCT00332228|DRUG|depot naltrexone|long-acting depot parenteral formulation of naltrexone
215108995|NCT00332228|BEHAVIORAL|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
215108996|NCT00332228|DRUG|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
215108997|NCT04891484|DRUG|Ondansetron group|patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
215108998|NCT04891484|DRUG|Saline group|patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
215108999|NCT02825199|DIETARY_SUPPLEMENT|Caffeine|capsule: 300mg caffeine
215109000|NCT02825199|DIETARY_SUPPLEMENT|Non caffeine|capsule: placebo (maize starch)
214424681|NCT04891458|DRUG|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|MOAA/S 3-5.
214424682|NCT02678091|DEVICE|Ultrasound exam with Doppler|Ultrasound exam of the orbit
214424683|NCT00318253|PROCEDURE|cranberry juice|
214424684|NCT05168553|OTHER|Revascualrization|Regain pulp vascularity for mature permenant teeth
214424685|NCT05168553|OTHER|Conventional endodontic treatment|Root canal treatment of permenant mature teeth with mechanical preparation and cleaning followed by canal obturation by inert material ( gutta percha)
214424686|NCT02952768|BEHAVIORAL|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
214424687|NCT04412018|DRUG|Icosapent ethyl|Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
214424688|NCT02230358|PROCEDURE|Regional anesthesia|Regional anesthesia
214424689|NCT02230358|PROCEDURE|General anesthesia|General anesthesia
214424690|NCT02230358|DEVICE|Transcranial Doppler ultrasonography|6x for 4 hours
214424691|NCT02230358|PROCEDURE|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
214424692|NCT02230358|PROCEDURE|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
214424693|NCT02230358|PROCEDURE|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
214424694|NCT02230358|BEHAVIORAL|Neurological Control|perioperative, 2-3 days, as done in clinical routine
214424695|NCT02230358|BEHAVIORAL|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
214424696|NCT02230358|DEVICE|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
214424697|NCT00232635|DRUG|A-60444|
214424698|NCT05998525|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria and after catheterization will be randomized to receive Dapagliflozin 10 mg every 24 hours and upon dischargetreatment will continue for 12 months
214424699|NCT05998525|DRUG|Placebo|patients who meet the inclusion criteria and after catheterization will be randomized to receive a placebo pill 24 hours and upon discharge treatment will continue for 12 months
214424700|NCT00031512|OTHER|Placebo|Placebo.
214424701|NCT00031512|DRUG|Pleconaril|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
214424702|NCT05206266|OTHER|Turmeric|Three amounts of dietary turmeric will be tested: 1) turmeric 300 mg/day, 2) turmeric 1 g/day, 3) turmeric 3 g/day.
214424703|NCT05206266|OTHER|Turmeric+Black Pepper|Three amounts of dietary turmeric (300mg/day, 1g/day or 3g/day) with black pepper (300 mg) added to the turmeric.
214424704|NCT04738903|PROCEDURE|Femtosecond laser assisted LASIK eye surgery|FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.
214424705|NCT03450096|OTHER|LPB|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
215109001|NCT04832880|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg die (2 mg for patients aged \> 75 years) for 10 days.
215109002|NCT04832880|DRUG|Remdesivir|Intravenous remdesivir 200 mg on day 1, followed by remdesivir 100 mg die until day 10
215109003|NCT04832880|DRUG|Dexamethasone|Intravenous dexamethasone 6 mg for 10 days
215109004|NCT03186417|BIOLOGICAL|2 million hMSC/kg|2 million hMSCs/kg infusion
215109005|NCT03186417|BIOLOGICAL|4 million hMSC/kg|4 million hMSC/kg infusion
215109006|NCT03186417|BIOLOGICAL|6 million hMSC/kg|6 million hMSC/kg infusion
215109007|NCT03186417|BIOLOGICAL|placebo|placebo infusion
215109008|NCT00201942|PROCEDURE|PET scan|
215109009|NCT06156241|BIOLOGICAL|Stem Cell|Stem cells derived from human cord tissue.
215109010|NCT01088399|DRUG|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
215109011|NCT02861599|OTHER|proprioceptive therapy|
215109012|NCT02861599|OTHER|speech therapy|
215109013|NCT00286871|DRUG|Neoral|
215109014|NCT00286871|DRUG|Tacrolimus|
215109015|NCT00465777|BEHAVIORAL|Guideline adherence and financial incentive|
215109016|NCT06141265|DRUG|Niraparib|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
215109017|NCT04591847|DRUG|Vitamin D 2|Vitamin D2 20000IU 1 tab oral weekly
215109018|NCT04591847|DRUG|Placebo drug|Placebo drugs 1 tab oral weekly
215109019|NCT06333366|DEVICE|Intra-gastrointestinal monitoring device (PDT)|The PressureDOT(PDT) is an active intra-gastrointestinal device, that is intended to be introduced in the gastrointestinal tract, approximately along whole. The device is battery powered. The signal is wirelessly transmitted through outside the body and received by waist receiver, using an antenna array applied to the skin with a protection guard at the level of the abdomen.
215109020|NCT03752749|OTHER|Prednisolone + Acute Intermittent Hypoxia|Administration of oral prednisolone followed by 15, 60-second bouts of mild hypoxia
214424706|NCT03557658|DRUG|Bexagliflozin|Single oral dose of bexagliflozin tablet, 20 mg
214424707|NCT03197246|DEVICE|IVECG|Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
214424708|NCT03197246|DEVICE|Chest X-ray|Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
214424709|NCT02361437|DIETARY_SUPPLEMENT|Vasculera|Vasculera 630 mg b.i.d.
215109021|NCT03752749|OTHER|Placebo + Acute Intermittent Hypoxia|Administration of oral matching placebo followed by 15, 60-second bouts of mild hypoxia
215109022|NCT03120715|DRUG|estrogen|The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.
215109023|NCT03120715|DRUG|Low Molecular Weight Heparin|If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
215109024|NCT03120715|DRUG|hCG|If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
215109025|NCT03120715|DRUG|progesterone|on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
215109026|NCT00782483|DEVICE|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
215109027|NCT00782483|DEVICE|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
214424710|NCT05261568|BEHAVIORAL|PROGRESSIVE RELAXATION EXERCISE|Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
214424711|NCT04267744|OTHER|Myia Health® remote patient monitoring unblinded treatment arm|"After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)"
214424712|NCT01147341|DRUG|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
214424713|NCT01147341|DRUG|Placebo|prefilled saline syringe
214424714|NCT03879811|DRUG|TMZ|Oral TMZ at 150mg/m2
214424715|NCT03879811|DRUG|Nivolumab|Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
215109028|NCT00782483|DEVICE|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
215109029|NCT00774683|DRUG|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
215109030|NCT05313737|OTHER|Automated message|Automated message via phone call (audiocare)
215109031|NCT05313737|OTHER|Opt-out scheduling|Scheduling via non-automated phone call
215109032|NCT00349778|DRUG|Cyclophosphamide|Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours
215109033|NCT00349778|DRUG|Etoposide|100 mg etoposide as 5 mL solution in clear ampules for injection.
215109034|NCT00349778|DRUG|Melphalan|Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
215109035|NCT00349778|DRUG|Carmustine|Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
215109036|NCT00349778|DRUG|Filgrastim|Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
214424716|NCT04164680|DIAGNOSTIC_TEST|Multimodal Neuroimaging|fludeoxyglucose (FDG-)PET/MR imaging
214424717|NCT00398606|DRUG|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
214424718|NCT00398606|DRUG|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
214424719|NCT05676736|OTHER|No intervention|No intervention to be done for the group
214424720|NCT04771234|BEHAVIORAL|Digital self-guided CBT-i|A brief version of CBT-i consisting of brief psychoeducation, and the core components sleep restricion and stimulus control, where sleep restriction is based on a simplified sleep diary.
215109037|NCT04057846|DEVICE|EUS guided transgastric drainage|Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
215109038|NCT02313974|PROCEDURE|Renal Biopsy|
215109039|NCT04949074|OTHER|saliva sampling|when the patient goes to the laboratory for a covid 19 diagnostic from a routine nasopharingeal sample, an additionnal sample of saliva is asked
215109040|NCT01811186|DRUG|Oxycodone/naloxone|Oxycodone/naloxone titration
215109041|NCT03372174|DEVICE|Maintaining mechanical ventilation during surgery|dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
215109042|NCT03372174|DEVICE|Absence of mechanical ventilation during surgery|absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
215109043|NCT01092052|DRUG|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
215109044|NCT06130462|DIAGNOSTIC_TEST|Aluminum|Different concentrations of aluminium added to the blood test in vitro
215109045|NCT06130462|DIAGNOSTIC_TEST|Tetanus toxoid|Used as control substance
215109046|NCT05065853|DIAGNOSTIC_TEST|urine self-sampling group|collection of urine and vaginal samples
215109047|NCT05065853|DIAGNOSTIC_TEST|clinician-collected cervical sample group|A clinician takes a smear from cervix according to standard routine
214424721|NCT06269822|DIAGNOSTIC_TEST|Sympathetic skin response, heart rate variability test, quantitative EEG|Sympathetic skin test (electrodermal activity) to test for sympathetic function Heart rate variability test to assess cardiovagal function Quantitative EEG to quantitatively assessing the brain function using fast fourier transform technique
214424722|NCT03694288|PROCEDURE|Implant removal|Surgical Implant removal
214424723|NCT03126812|DRUG|Carboplatin|Carboplatin AUC=6
215109048|NCT01979458|DEVICE|PSE|
215109049|NCT04213716|COMBINATION_PRODUCT|silver nano particulate solution mixed with calcium hydroxide powder|1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
215109050|NCT04213716|COMBINATION_PRODUCT|conventional calcium hydroxide|1ml of distilled water mixed with 100 mg of calcium hydroxide powder and used as intracanal medication after root canal retreatment
215109051|NCT00378261|PROCEDURE|Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.|
215109052|NCT05623657|OTHER|Trunk Stabilization Exercise Training Group|The adolescents in this group who are involved in archery sports will be given 40 minutes of exercise training 2 days a week for 8 weeks. Exercise training will be applied as 5-10 minutes warm-up, 15-30 minutes trunk stabilization exercises, 5-10 minutes cooling down, and stretching exercises. The number of repetitions and difficulty levels of the exercises will gradually increase in the 3rd and 6th weeks.
215109053|NCT05623657|OTHER|Game Based Exercise Program Group|At least 4 different games selected from Xbox 360 Kinect® games will be applied to adolescents practicing archery sports in this group for a total of 40 minutes with the physiotherapist. The games will be selected from games that include movement patterns similar to the exercises of the trunk stabilization exercise group. Game-based exercise training is planned to be performed twice a week for a total of 8 weeks.
215109054|NCT01448499|DRUG|Clozapine|escalating dose of clozapine up to 900 mg/day
215109055|NCT01448499|DRUG|Amisulpride|escalating dose of amisulpride up to 800 mg/day
215109056|NCT01448499|DRUG|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
214424724|NCT03126812|DRUG|Paclitaxel|paclitaxel 80 mg/m2
214424725|NCT03126812|DRUG|Pembrolizumab|200 mg flat dose, starting cycle 2
214424726|NCT00958386|DRUG|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days."
214424727|NCT03769233|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 90 minutes per week, for 5 consecutive weeks with 6-15 participants per group.
215109057|NCT02300740|DIETARY_SUPPLEMENT|Nicotinamide riboside|NIAGEN, ChromaDex
215109058|NCT01670773|DRUG|CAT-1004|
215109059|NCT01670773|DRUG|Salsalate + DHA|
215109060|NCT01670773|DRUG|Placebo|
215109061|NCT03669289|OTHER|enhanced model of primary care|The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
215109062|NCT00688272|DRUG|Ciprofloxacin|Given 500mg BID x 6 days
215109063|NCT00688272|DRUG|Eltrombopag|Given QD x 6 days
215109064|NCT00688272|DRUG|Placebo|Given QD x 6 days
215109065|NCT05852236|OTHER|Assigned Interventions|Pressure ulcer care package application.
215109066|NCT05416736|PROCEDURE|The bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins. Maneuvers will be performed by the researcher. Infants in both groups will be held under the armpit by a parent, male infants will be held in the drooping legs, and female infants will be held in the hip flexion position.
215109067|NCT05416736|PROCEDURE|Steril urine bag|Steril urine bag are attached to the genital area to collect urine samples
215109068|NCT06420180|PROCEDURE|hip arthroscopy|"CT rotational profile Will be used for measurement of LL rotational abnormality.~MRI will be evaluated for the presence of labral tears, chondral lesions, ligamentum teres pathology, and other soft-tissue disorders."
215109069|NCT01800136|DEVICE|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
215109070|NCT01879943|DEVICE|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
215109071|NCT01879943|PROCEDURE|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
215109072|NCT05969340|DIAGNOSTIC_TEST|ultra-high-resolution CT-scan|Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
215109073|NCT02248636|DRUG|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
215109074|NCT02248636|DRUG|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
215109075|NCT04741490|DRUG|Camrelizumab|PD-1antibodies，200mg ivgtt Q3W
215109076|NCT04741490|RADIATION|radiotherapy|45-55Gy/1.8～2.0Gy
215109077|NCT03369236|DRUG|Danicopan|Danicopan was administered as an oral tablet.
215109078|NCT03369236|DRUG|Placebo|Matching placebo was administered as an oral tablet.
215109079|NCT02022436|DRUG|Contrast Ultrasound|Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
215109080|NCT01219062|DRUG|morphine|periarticular infiltration with 0.25% Bupivacaine for 20 ml.
215109081|NCT01219062|OTHER|control|the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)
215109082|NCT01219062|DRUG|Bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
215109083|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
215109084|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
215109085|NCT05293925|BEHAVIORAL|announcement of cessation of treatment|"The first 40 outpatients for whom an announcement to stop anti-tumour treatments is made at the Institut Curie Paris, in a conventional oncology consultation or in Palliative Care Day Hospital.~Categorical variables will be described by numbers and percentages. Quantitative variables will be described by the mean, standard deviation, median of the distribution as well as the minimum, maximum and interquartile range and compared by a Student's t test or a Wilcoxon test according to the normality of the variables."
215109086|NCT03334812|BIOLOGICAL|LNA043|LNA043 Single dose
214424728|NCT04832542|OTHER|outpatient follow-up|The patients were evaluated every six months in order to assess the incidence of traumatic syncope recurrence during follow-up after implantable loop recorder implantation.
214424729|NCT04696341|PROCEDURE|Matrix Rhythm Therapy|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.
214424730|NCT04696341|PROCEDURE|Control|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
215109087|NCT03334812|BIOLOGICAL|placebo to LNA043|placebo to LNA043 single dose
215109088|NCT00039663|DRUG|Pravastatin|
215109089|NCT00039663|DRUG|Gemfibrozil|
215109090|NCT00039663|DRUG|Rosiglitazone|
215109091|NCT03969186|BEHAVIORAL|Intervention|Telehealth intervention monitoring weight and medication adherence accompanied by a weekly phone call to monitor symptoms.
215109092|NCT01364311|DIETARY_SUPPLEMENT|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.~Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
215109093|NCT01600989|OTHER|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
215109094|NCT01600989|OTHER|blood sampling|Blood samples will be taken twice at a 7 day interval
215109095|NCT00426543|DRUG|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
215109096|NCT00426543|DRUG|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
215109097|NCT04966520|OTHER|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)|"Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients.~Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be \~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days."
215109098|NCT02566317|DEVICE|Sit-Stand workstation|Installation of a sit-stand desk at work
215109099|NCT02566317|BEHAVIORAL|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
215109100|NCT05831488|OTHER|Non-Interventional|Non Interventional
215109101|NCT03005132|OTHER|Normal brain tissue|The investigators will extract total protein, DNA and RNA from the samples.
215109102|NCT01740024|BIOLOGICAL|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
215109103|NCT03402724|OTHER|echographic|Patients are called for an echographic evaluation in the implanting center in case of the usual care
215109104|NCT02618902|BIOLOGICAL|tolerogenic dendritic cells (tolDC)|dose-escalation
215109105|NCT02880098|BIOLOGICAL|Troponin T blood level|assess Troponin T blood level for every child born from the same sample of blood (after clamping the umbilical cord) used for assessment of pH and lactate.
215109106|NCT00600210|DRUG|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
215109107|NCT00600210|DRUG|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
215109108|NCT00600210|RADIATION|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
215109109|NCT01865448|DIETARY_SUPPLEMENT|Omega-3 DHA|Patients take daily 2 tablets of Docosahexaenoic Acid
215109110|NCT01865448|OTHER|Placebo|Patients in control group take daily 2 placebo capsule
215109111|NCT04141423|DRUG|Tregopil|Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
215109112|NCT00227409|DRUG|calcium disodium EDTA (edetate calcium disodium)|
215109113|NCT06442384|OTHER|Tobacco and non-tobacco e-cigarettes|Participants with no e-cigarette restrictions.
215109114|NCT06442384|OTHER|Tobacco only e-cigarettes|Participants restricted to tobacco flavored e-cigarettes only.
215109115|NCT00620724|DRUG|Placebo|Placebo three times daily
215109116|NCT00620724|DRUG|Nifedipine|20 mg of slow-release Nifedipine three times daily
215109117|NCT03257839|DEVICE|Routine Full-Field Digital Mammography|Routine screening mammography exam, CC + MLO views.
215109118|NCT03257839|DEVICE|Routine Digital Breast Tomosynthesis|Routine screening tomosynthesis exam, CC + MLO views.
215109119|NCT03257839|DEVICE|Automated Whole Breast Ultrasound|Bilateral breast ultrasound performed as an adjunct to mammography.
215109120|NCT01043211|DRUG|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
215109121|NCT01043211|DRUG|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
215109122|NCT01043211|DRUG|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
214692185|NCT06982937|OTHER|Treadmill running|Participants engaged in a standardized 5-minute treadmill warm-up. Participants were instructed to walk at a moderate, self-selected pace of approximately 7-9 km/h, maintaining an incline of 0%. Heart rate and perceived exertion were monitored to ensure that the activity remained within a light-intensity range (Borg scale: 6-11).
215109123|NCT02756676|PROCEDURE|Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle- stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in daily living activities. The last session includes one hour of speech therapy.
215109124|NCT04627363|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
215109125|NCT04627363|DRUG|Bevacizumab|15mg/kg intravenously every 3 weeks
215109126|NCT04627363|DRUG|Toripalimab|240mg intravenously every 3 weeks
215109127|NCT04338308|DEVICE|new-DES|with ot without embolic protection device
215109128|NCT04338308|DEVICE|BMS|with ot without embolic protection device
215109129|NCT04005157|PROCEDURE|MWA|Patients diagnosed with early-stage NSCLC and signing the informed consent will undergo MWA with the guidance of ENB.
215109130|NCT04005157|DEVICE|ENB|ENB (LungCare Medical Technologies Ltd., Inc, Suzhou, China)will be used to guide bronchoscope into the accurate location of the lesion during MWA.
215109131|NCT02259465|BEHAVIORAL|low FODMAP diet|Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
214424731|NCT04707417|OTHER|Home care|Advanced home care
215109132|NCT02259465|DIETARY_SUPPLEMENT|Oligofructose|Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
215109133|NCT02259465|DIETARY_SUPPLEMENT|Maltodextrin|Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
215109134|NCT02924493|OTHER|Diet low in fermentable carbohydrates (low FODMAP diet)|The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
215109135|NCT04526223|OTHER|comprehensive treatment regimen|"1. Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF)~2. With at least two month Ruxolitinib treatment prior to transplantation~3. DAC+BF as myeloablative conditioning regimen~4. received Rux at +5d in ASCT and continued to +60d"
215109136|NCT04889508|BEHAVIORAL|Socio-emotional mental training|Core practice: Affect Dyad. In the Affect Dyad (AD), participants perform a 12-minute partner-based exercise which involves contemplating over one difficult situation and one situation which incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation. The goal of the exercise is to enhance coping with difficult emotions, empathic listening, social sharing, acceptance, and gratitude.
215109137|NCT04889508|BEHAVIORAL|Mindfulness-based mental training|Core practice: Breathing Meditation. In this intervention, participants will practice 12-minute basic attention-based mindfulness meditation such as the Breathing Meditation (BM). BM is a 12-minute individual exercise that requires participants to focus their attention on the sensations of breathing. Participants have to sustain their attention to breath for long stretches of time, and have to return their attention to their breath when their mind wanders. The key focus is on training attention and interoceptive body awareness. Other practices participants will be taught is mindfulness on sounds (here the object of attention is not the breath but sounds in the environment).
215109138|NCT03128242|DRUG|Oxytocin|intranasal administration of oxytocin (24IU)
215109139|NCT03128242|DRUG|placebo|intranasal administration of placebo (24IU)
215109140|NCT00941915|RADIATION|SBRT Prostate|Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
215109141|NCT00014079|GENETIC|DNA stability analysis|
215109142|NCT00014079|GENETIC|loss of heterozygosity analysis|
215109143|NCT00014079|GENETIC|microsatellite instability analysis|
215109144|NCT01051336|DEVICE|TARIS Placebo|
215109145|NCT01051336|PROCEDURE|Sham Procedure|
215109146|NCT00872599|DRUG|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
215109147|NCT00872599|DRUG|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
215109148|NCT00659932|BEHAVIORAL|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
215109149|NCT00659932|BEHAVIORAL|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
215109150|NCT00801229|DRUG|Vyvanse|Vyvanse 30, 50, or 70 mg daily
215109151|NCT00801229|DRUG|Placebo|Placebo 30, 50, 70 mg daily
215109152|NCT01512095|DRUG|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
215109153|NCT01512095|DRUG|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
214692186|NCT01308320|DRUG|fentanyl citrate|According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
214692187|NCT01308320|DRUG|saline|According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
215109154|NCT00654082|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
214509882|NCT07011862|BEHAVIORAL|Cancer, Older adults, Balance and Resistance Activities|The COBRA intervention is delivered as a web-based application through an iPad configured to allow access only to the study application and Zoom videoconferencing icons during the trial.
214509883|NCT07013994|PROCEDURE|peripheral venous cannulation with ultrasound-guided technique|Peripheral venous cannulation with short peripheral vascular access device, performed by ultrasound technique.
214509884|NCT07013994|PROCEDURE|Arterial gas puncture using ultrasound-guided technique|Arterial puncture using a needle and heparinised syringe to extract a sample for arterial blood gas analysis, using the ultrasound-guided technique.
214509885|NCT07013994|PROCEDURE|Peripheral venous cannulation with traditional technique|Cannulation of a short peripheral vascular access device using the traditional visualisation and palpation technique.
214509886|NCT07013994|PROCEDURE|Arterial puncture by traditional technique|Arterial puncture using a needle and heparinised syringe to extract an arterial blood sample for arterial gamosetry analysis, performed using the traditional arterial pulse palpation technique.
215109155|NCT00654082|DRUG|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
215109156|NCT05263557|DIETARY_SUPPLEMENT|Dehydroepiandrosterone (DHEA)|Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.
215109157|NCT05263557|DIETARY_SUPPLEMENT|11-ketoandrostenedione (11KA4)|11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.
215109158|NCT05213520|OTHER|Alternate Day Intermittent Energy Restriction|It is a dietary intervention designed to alternate between full energy consumption on one day and 40% of daily energy requirement on the following day.
215109159|NCT05213520|OTHER|Reduced Calorie Diet|It is a dietary intervention designed to reduce daily calorie intake by 500-1000 kcal below an individual's daily calorie needs.
215109160|NCT02255461|DRUG|palbociclib isethionate|Given PO
215109161|NCT02255461|OTHER|pharmacological study|Correlative studies
215109162|NCT02255461|OTHER|laboratory biomarker analysis|Correlative studies
215109163|NCT05236673|DRUG|JARDIANCE®|JARDIANCE® film-coated tablets 10mg
215109164|NCT00195533|DRUG|piperacillin-tazobactam|
215109165|NCT00195533|DRUG|glycopeptide|
215109166|NCT02075151|PROCEDURE|Bronchial Thermoplasty|Bronchial thermoplasty
214509887|NCT07013448|OTHER|Foot scan|This does not constitute a intervention but all participants will undergo image scans of their ulcer
214692188|NCT00195260|DRUG|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
215109167|NCT03770221|BEHAVIORAL|CATCH|Brief, intensive case management service.
215109168|NCT03770221|OTHER|Financial Incentive|Financial incentive for maintaining contact with CATCH service providers.
215109169|NCT00999440|DRUG|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
215109170|NCT03975686|OTHER|neuromuscual realigning exercise|neuromuscular realigning exercise
214509888|NCT07014189|DRUG|Neviparine (NVP)/ Lamivudine (3TC)|Treatment with nevirapine (400mg retard) and lamivudine (300mg) once daily
214509889|NCT07013786|DIAGNOSTIC_TEST|Pressure biofeedback assessment|Participants will be assessed for lumbar motor control using a pressure biofeedback unit (PBU) during the Abdominal Draw-In Maneuver (ADIM) in both crock lying and prone positions. This is a non-invasive test to evaluate deep core muscle function (TrA and MF) in patients with NSCLBP. No therapeutic intervention will be administered.
215109171|NCT05314335|OTHER|Reflexology socks+walking|Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)
215109172|NCT05314335|OTHER|Just walking|Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
215109173|NCT02148055|OTHER|Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.|
215109174|NCT01805479|OTHER|aerobic exercise|the active arm will be asked to perform 60% of maximum heart rate
215109175|NCT01805479|OTHER|stretching and flexibility program|stretching and flexibility program for the Placebo Comparator Arm
215109176|NCT05935332|DRUG|RPT193|RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
215109177|NCT05935332|OTHER|Placebo|placebo
215109178|NCT02527785|DRUG|Oxaliplatin, Irinotecan, S-1(OIS)|"Treatment will be delivered every 2 weeks~1. oxaliplatin 65 mg/m2 iv on day 1~2. irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day po on day 1-7"
215109179|NCT05403671|OTHER|Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer|Intervention includes exercising and relaxation in a group
215109180|NCT03231007|OTHER|Questionnaire|A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
215109181|NCT01120106|DRUG|levosimendan|patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
215109182|NCT01120106|DRUG|placebo|saline continuous infusion
215109183|NCT04157803|DIAGNOSTIC_TEST|Acetic acid % spray|"If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly."
215109184|NCT06172179|OTHER|No interventions|All procedures are observation. No intervention in this study.
215109185|NCT00644150|BEHAVIORAL|Physician Ai Shi Zi training|This training uses a curriculum developed specifically for Project Ai Shi Zi and includes training in stigma; risk-reduction counseling; and quality HIV/STI diagnosis, treatment, and management. Physician training will consist of multiple components: an orientation workshop on fundamental knowledge and skills of HIV/STI treatment and prevention, a 3-month practice period, a 3-month post-practice seminar on preventive counseling, another 3-month practice period, and a 6-month post-practice seminar on clinical HIV and STI management. The practice periods will promote learning-by-doing to further enhance physicians' abilities to deliver high quality, integrated HIV/STI prevention and treatment. Post-practice seminars will allow participants to share experiences gained during the previous 3-month practice period.
215109186|NCT00644150|DRUG|Standard care|If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
215109187|NCT00644150|BEHAVIORAL|Patient risk-reduction counseling|On the initial visit, participants will receive HIV/STI risk-behavior counseling from the physician trained in Ai Shi Zi. The process is based on motivational interviewing techniques and will include discussing topics such as partner notification, HIV/STI prevention, and expected difficulties in changing behaviors. This risk-reduction model encourages the HIV/STI-infected or -uninfected person to develop a risk-reduction plan. The objective is to decrease the chance of infection for that individual and for others, too. Patients will develop a list of risk-reduction strategies to follow.
215109188|NCT02926989|DRUG|Plasmalyte Glucos 50 mg/mL|Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
215109189|NCT02926989|DRUG|0.45% saline in 5% dextrose|Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
215109190|NCT05043753|OTHER|Point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)|"Midwives perform a POC-US to measure the fetal abdominal circumference (AC) and evaluate the quantity of amniotic fluid.~In order to identify the appropriate sonographic plane the following markers need to be identified on POC-US~* Fluid filled fetal stomach on the left.~* Umbilical vein~* Umbilical portion of left portal vein within liver, as it meets the pars transversa (horizontal portion of left portal vein) seen as a right sided  L  or  C  shape.~* Fetal spine seen in cross section Amniotic fluid volume will be evaluated determining the deepest vertical pocket (DVP). Measurement is performed by assessing a pocket of maximal depth of amniotic fluid free of umbilical cord and fetal parts. The transducer is held perpendicularly to the patient's abdomen. The absence of a pocket measuring at least 2 cm in depth and 1 cm in width is indicative of oligohydramnios, while detection of a pocket measuring 8 cm or larger is suggestive of polyhydramnios (ACOG bulletin 175, 2016)."
215109191|NCT06251297|OTHER|Foot reflexology|30 minutes reflexology session
215109192|NCT05357521|OTHER|stress test|TSST- psychosocial stress test
215109193|NCT05485038|PROCEDURE|Tumor resection in awake patient|Surgeon performs critical steps of tumor removal in awake patient and controls his/her motor functions by brain mapping and assessing of voluntary movements
215109194|NCT05485038|PROCEDURE|Tumor resection in asleep patient|Surgeon removes tumor in asleep patient and controls his/her motor functions by brain mapping
215109195|NCT05294445|PROCEDURE|Ablation of atrial fibrillation (AF)|Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)
215109196|NCT05182697|DRUG|SCI-210|Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily
215109197|NCT05182697|DRUG|Oral CBD oil|CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
215109198|NCT03886714|DIAGNOSTIC_TEST|Screening for Fabry disease|Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.
215109199|NCT03886714|DIAGNOSTIC_TEST|Screen for α-galactosidase mutation|If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).
215109200|NCT04730791|DIAGNOSTIC_TEST|Algo(s)rithm/ IASP clinical criteria|IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.
215109201|NCT04730791|DIAGNOSTIC_TEST|Pressure Pain Threshold|The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.
214509890|NCT04281017|DRUG|TIVA|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)
215109202|NCT02380443|BIOLOGICAL|AlloStim|AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.
215109203|NCT02380443|PROCEDURE|Cryoablation|Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
215109204|NCT05430113|DEVICE|Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)|2-4 leads FDA-approved for treatment of symptoms of refractory pain
215109205|NCT03988764|OTHER|None AHT|No further intervention planned for either group as part of the current study.
215109206|NCT04809285|DEVICE|Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app|Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
215109207|NCT06291480|BEHAVIORAL|Neurologic Music Therapy|Music therapy focused on cognitive and motor rehabilitation after stroke (subacute phase).
215109208|NCT06292130|BEHAVIORAL|refresh|A theoretically-grounded, highly individualized tobacco cessation Health-Kit enabled app. Unlike existing tobacco cessation apps, refresh: 1) implements a full range of best practices in tailored health behavior change communications; 2) individualizes messaging based on the patient's clinical context using Health app data obtained through Fast Healthcare Interoperability Resources (FHIR) standard Application Programming Interfaces (API) and behavior change constructs; and 3) provides data and key insights back to the EHR.
215109209|NCT06474312|BEHAVIORAL|Nae Disha|"Nae Disha for Life is a brief, multi-component, psychosocial promotion and resilience tool developed by Emmanuel Hospital Association, New Delhi. The purpose of this research work is to evaluate the feasibility, acceptance, and effectiveness of Nae Disha for Life tool in reducing suicide ideation among youth in Bundelkhand region. This will be implemented among the targeted schools of Nowgong block, Chhatarpur district."
215109210|NCT05637398|DRUG|Colchicine|The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
215109211|NCT02444052|DEVICE|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
215109212|NCT02444052|DEVICE|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
215109213|NCT06374706|BEHAVIORAL|Morning Walk training for stroke|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Symmetrical Walking on the Ground.
215109214|NCT06374706|BEHAVIORAL|Morning Walk training for healthy|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Asymmetrical Walking on the Ground.
215109215|NCT05495867|PROCEDURE|implant placement|implant placement in edentulous area
215109216|NCT03409783|DEVICE|ENSO Device|An active ENSO device that delivers neuromodulation therapy.
215109217|NCT03409783|DEVICE|Sham Device|Sham Device
215109218|NCT04966507|DRUG|Listerine Antiseptic Mouthwash Product|COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
215109219|NCT04966507|DRUG|Biotene Mouthwash|Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
215109220|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
214692189|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
214692190|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
215109221|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
215109222|NCT01038167|DRUG|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
215109223|NCT01038167|DRUG|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
215109224|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
215109225|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
215109226|NCT00004223|DRUG|docetaxel|
215109227|NCT00004223|DRUG|gemcitabine hydrochloride|
215109228|NCT02779049|OTHER|Blood examination|blood sampling
214509891|NCT04281017|DRUG|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg
215109229|NCT02084550|DIETARY_SUPPLEMENT|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
215109230|NCT02084550|OTHER|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
215109231|NCT00002203|DRUG|Lamivudine/Zidovudine|
215109232|NCT00002203|DRUG|Lamivudine|
215109233|NCT00002203|DRUG|Zidovudine|
215109234|NCT03350815|DRUG|150 mg open-label secukinumab|All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.
215109235|NCT03350815|DRUG|150 mg double-blinded secukinumab|Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)
215109236|NCT03350815|DRUG|300 mg double-blinded secukinumab|Treatment Period 2 300 mg (2 s.c. injections of the 150 mg dose)
215109237|NCT00863499|DRUG|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
215109238|NCT00863499|DRUG|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
215109239|NCT00000355|DRUG|Buprenorphine|
215109240|NCT03994874|DRUG|PolyCore (Polydextrin, L-Carnitine, D-xylitol)|A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
215109241|NCT04548856|PROCEDURE|Microsurgical clipping|Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.
215109242|NCT04548856|PROCEDURE|Endovascular embolization|Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.
215109243|NCT02630472|DRUG|Quinine Sulfate|Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.
215109244|NCT02630472|DRUG|Placebo|In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
215109245|NCT05766826|OTHER|Coupons for safe water program: Treatment|Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.
215109246|NCT05766826|OTHER|Coupons for safe water program: Control|Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
215109247|NCT00350688|RADIATION|Helical tomotherapy IMRT|Helical tomotherapy IMRT
215109248|NCT04515901|DRUG|2% lidocaine|Viscous lidocaine
215109249|NCT04515901|OTHER|Placebo|Methylcellulose and cherry flavouring
215109250|NCT04698603|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
215109251|NCT01015781|PROCEDURE|Progressive Tinnitus Management|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support"
215109252|NCT01015781|PROCEDURE|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
215109253|NCT05021770|DRUG|Orelabrutinib|150mg or 200mg orally daily
215109254|NCT05021770|DRUG|Orelabrutinib|RP2D
215109255|NCT05021770|DRUG|Thiotepa|30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
215109256|NCT03132701|DRUG|Magnesium|Mg is administered during anesthesia until 5 minutes before surgery ends
215109257|NCT03132701|DRUG|Saline|Same volume of saline is infused until 5 minutes before surgery ends
215109258|NCT05659927|DRUG|MG-ZG122 Humanized Monoclonal Antibody Injection|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
215109259|NCT05659927|DRUG|Placebo|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
215109260|NCT03484247|OTHER|Infraclavicular brachial plexus block|Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
215109261|NCT03484247|OTHER|axillary brachial plexus block|Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
215109262|NCT02023957|BEHAVIORAL|Interactive computer-assisted screening (iCAS)|
215109263|NCT04947241|DRUG|PD-1 inhibitor+ Gemcitabine + Cisplatin|"Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles"
215109264|NCT05472922|DEVICE|Placement of MiniMizer Gastric Ring|Insertion of MiniMizer Gastric Ring in addition to the normal MGB-OAGB
215109265|NCT05472922|PROCEDURE|Normal MGB-OAGB|No insertion of Minimizer Gastric Ring in addition to the normal MGB-OAGB
215109266|NCT02154919|PROCEDURE|Percutaneous coronary intervention|
215109267|NCT06571266|DRUG|Risankizumab|• Subcutaneous Injection via prefilled syringe
215109268|NCT03600441|DRUG|Abexinostat|Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
215109269|NCT05367791|OTHER|POSTUR|Training sessions without any stimulation
215109270|NCT05367791|OTHER|Localised Vibration|Training sessions with localized vibration
215109271|NCT05367791|OTHER|Somatosensory Electrical Stimulation|Training sessions with somatosensory electrical stimulation
215109272|NCT02094092|OTHER|ProTectis drops (five drops per day) for 21 days|
215109273|NCT02094092|OTHER|Placebo drops (five drops per day) for 21 days|
215109274|NCT02458573|OTHER|continuous epidural analgesia|the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.
215109275|NCT02458573|OTHER|continuous intravenous analgesia|the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
215109276|NCT03525691|DEVICE|Low flow Extracorporeal CO2 removal|Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)
215109277|NCT03040674|PROCEDURE|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
215109278|NCT00519272|BEHAVIORAL|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
215109279|NCT00036634|DRUG|Tenofovir DF|Tenofovir DF tablet administered orally once daily
215109280|NCT00036634|DRUG|Tenofovir alafenamide|Tenofovir alafenamide tablet(s) administered orally once daily
214692191|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
214692192|NCT00226681|BEHAVIORAL|Nursing Telephone Support Protocol|
215109281|NCT06342518|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT group received radial ESWT each session with a total of 2000 pulses at a frequency of 10 Hz. A gel was used at the interface, and the air pressure was set at 1.8 bar per session.
215109282|NCT06342518|DEVICE|Sham ESWT|The Sham-ESWT group received Sham radial ESWT each session, but without actual contact of the applicator. To enhance the illusion of treatment, gel was applied, and the device emitted sound at every shock
215109283|NCT06342518|BEHAVIORAL|Resting Splint , Exercises and ice|Ensuring proper usage of the wrist resting splint by the patient was confirmed during follow-up visits. The physician instructed the patients on stretching and strengthening exercises for wrist extensors, which they were asked to perform three times a day. Application of ice for 20 minutes every 3-4 hours during painful periods was recommended. During follow-up visits patients confirmed that they adherence to exercises and recommendations.
215109284|NCT02059304|DEVICE|Measurement of cervical length with embryo transfer catheter|
215109285|NCT04609631|BEHAVIORAL|Tai Chi|24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).
215109286|NCT04609631|BEHAVIORAL|CBT|CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.
215109287|NCT01709370|DRUG|Letrozole, PD 0332991|
215109288|NCT04625439|BEHAVIORAL|Personality Feedback Self-Management Intervention|The intervention is a personality feedback report that will tell participants whether they scored low (bottom third), average (middle third), or high (top third) on each of the five factor personality characteristics based on gender-matched norms. In addition to a description of general tendencies based on their level of each personality trait, the feedback will include information about how scoring in a given category may relate to an individual's cancer self-management or healthcare decision making. The feedback for each personality trait will include recommendations for how to improve key outcomes.
215109289|NCT01342588|PROCEDURE|Electric pulse train stimulation|Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
215109290|NCT02936843|DRUG|Salsalate|1 gram, 3 times daily by mouth (total of 3 grams daily)
215109291|NCT02936843|DRUG|PLACEBO|Placebo for Salsalate; 2 Tablets, 3 times daily by mouth (total of 3 grams daily)
215109292|NCT04336033|OTHER|Counseling|Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
215109293|NCT04336033|OTHER|Renal Diet App|Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
215109294|NCT04336033|OTHER|Printed Nutrition Pamphlet|"After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose.~Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions."
214509892|NCT07013695|DEVICE|Virtual reality headset|Patients in the intervention group receive a virtual reality session with a hypnotic purpose during surgery under regional anesthesia. The device consists of a virtual reality headset providing visual and auditory immersion in a calming environment, freely chosen by the patient. The session begins before the regional anesthesia is administered and may continue throughout the entire surgical procedure
214509893|NCT07013695|OTHER|Standard Care (in control arm)|Participants in this group receive standard anesthetic and surgical care without the use of virtual reality
215109295|NCT05777395|PROCEDURE|Maitland Oscillatory Mobilization|Maitland Posteroanterior unilateral vertebral pressure and Maitland cervical rotation technique will be used.3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given for 2 seconds.
215109296|NCT05777395|PROCEDURE|Kaltenborn Sustained Stretch Mobilization|"Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~* Kaltenborn technique used will be atlas-axis rotation"
215109297|NCT05777395|PROCEDURE|Conventional therapy|Moist heat, TENS, Neck Muscle Stretching, Neck muscle isometrics
215109298|NCT03218436|PROCEDURE|CAP treatment|Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
215109299|NCT02338089|DRUG|Oxytocin|Oxytocin, 100 micromolar solution
215109300|NCT03151330|OTHER|Screened Arm|Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking.
215109301|NCT05624073|DEVICE|Air-QTM Blocker|The Air-QTM Blocker (Cookgas LLC, Mercury Medical, Clearwater, FL, USA) is a SAD that is intended for use as a primary airway seal and an aid for tracheal intubation in situations of anticipated or unanticipated difficult airways. Its design includes a large airway tube inner diameter, a short airway tube length, and a tethered, removable standard 15mm circuit adapter. These features enable direct insertion of larger tracheal tubes up to 7.5 and 8.5mm inner diameters for Air-Q sizes 3.5 and 4.5 respectively (according to body weight; size 3.5: 50-70Kg, size 4.5:70-100Kg). In addition to the soft blocker channel (guide tube) that acts as a conduit for placing medical devices such as NG (Nasogastric) or Blocker tubes. NG tubes are used to decompress and suction the stomach. Standard NG tubes up to 18 Fr. are suitable for all Air-Q Blocker sizes
214692193|NCT00226681|BEHAVIORAL|Usual Care|
215109302|NCT05624073|DEVICE|LarySealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in: sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr. Both devices accommodated standard conventional endotracheal tubes for intubation.
215109303|NCT03386487|DRUG|PF 04457845|Study medication will be administered at 4mg by mouth daily for eight weeks.
215109304|NCT03386487|DRUG|Placebo Oral Tablet|Placebo comparator will be administered by mouth daily for eight weeks.
215109305|NCT03081871|OTHER|Pharmacist-led cardiovascular risk service (CVRS)|CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
215109306|NCT03081871|OTHER|Mobile access to study Personal Health Record|Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.
215109307|NCT03081871|OTHER|Web access to study Personal Health Record|Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
215109308|NCT04852198|PROCEDURE|OAGB|Simplified gastric bypass procedure
215109309|NCT04852198|PROCEDURE|RYGB|Roux-en-Y gastric bypass. Standard procedure in the Netherlands
215109310|NCT00273065|DRUG|Neosaxitoxin|
215109311|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg tablet|Cross-over study: Ursodeoxycholic Acid 300mg tablet and after Ursodeoxycholic Acid 300mg capsule
215109312|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg capsule|Cross-over study: Ursodeoxycholic Acid 300mg capsule and after Ursodeoxycholic Acid 300mg tablet
215109313|NCT05050461|OTHER|Immunological analyses|Immunological analyses will be performed at inclusion in both arms
215109314|NCT02694900|OTHER|Manually chest compressions|Chest compressions performed manually without any device
215109315|NCT02694900|DEVICE|Cardiopump|Chest compressions performed with Cardiopump
215109316|NCT02694900|DEVICE|LifeLine ARM|Chest compressions performed using mechanical chest compressions system LifeLine ARM
215109317|NCT02703324|DRUG|LY900014|Administered subcutaneously (SC)
215109318|NCT02703324|DRUG|Insulin Lispro|Administered SC
215109319|NCT01883544|DRUG|ALXN1007|
215109320|NCT00606619|OTHER|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
215109321|NCT00606619|OTHER|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
215109322|NCT04303572|DRUG|Eloctate ITI|This is a factor VIII-Fc infusion protein.
215109323|NCT04303572|DRUG|Emicizumab|This is a bispecific monoclonal antibody FVIII mimic.
215109324|NCT06312592|BEHAVIORAL|Entrepreneurship School with Gender Lens|"The Entrepreneurship School with Gender Lens (ESGL) is an approach that targets gender based violence survivors and women at-risk to help them develop business ideas, access needed support for the prevention of and response to GBV, exploitation and trafficking, and improve participants' overall self-reliance. Participants will go through a general business curriculum, work on business plans and learn gender issues and ways to mitigate GBV risks. Upon training completion, participants are eligible to pitch their business idea to a panel of experts and receive $800 of seed capital. They will also receive follow-up business advisory support for at least six months, focusing on access to markets and finance and building support networks, in order to continue building self-reliance.~The ESGL will also include a mental health and psychosocial support module."
215109325|NCT05533164|DRUG|Rituximab|1000mg rituximab in 250ml NaCl 0.9% intravenously
215109326|NCT05533164|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously
215109327|NCT05889377|PROCEDURE|Socket preservation|Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.
215109328|NCT00274963|DRUG|bendamustine hydrochloride|
215109329|NCT00274963|DRUG|mitoxantrone hydrochloride|
215109330|NCT01858766|DRUG|SOF|400 mg tablet administered orally once daily
215109331|NCT01858766|DRUG|VEL|Tablet administered orally once daily
215109332|NCT01858766|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
215109333|NCT03266406|DRUG|Hyaluronidase|4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
215109334|NCT00498589|DRUG|methotrexate|25 mg per week IM or SC during 24 weeks
215109335|NCT00498589|DRUG|placebo|one intramuscular injection per week
215109336|NCT03544255|PROCEDURE|Biopsy|Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.
214509894|NCT07012720|DIAGNOSTIC_TEST|Single-cell sequencing and spatial transcriptome|Tumor tissue samples of all enrolled patients before and after neoadjuvant therapy were collected. Based on single-cell sequencing and spatial transcriptome technology, the transcriptomic differences in neoadjuvant therapy response or treatment resistance under the same treatment regimen, as well as the transcriptomic changes of tumor tissues before and after treatment were explored.
214509895|NCT06683209|DIAGNOSTIC_TEST|Schocket scleral depressor|Use of this instrument to examine one eye
215109337|NCT05952206|DEVICE|Angiolite: Sirolimus-eluting stent|The angiolite stent (iVascular, Barcelona, Spain) is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design containing a durable biostable coating composed of three layers - acrylate to ensure adhesion to the metal surface, fluoroacrylate that carries the sirolimus, and a top layer of fluoroacrylate to control drug release.
215109338|NCT05952206|DEVICE|Xience: Everolimus-eluting stent|The Xience stent family (Abbott vascular, California, United States of America), characterized by an L-605 cobalt-chromium (CoCr) is a thin-strut cobalt-chromium everolimus-eluting stent with an open-cell design containing a nonerodable polymer made of PBMA, a reservoir made of a fluorinated copolymer of vinylidene fluoride and hexafluoropropylene monomers. Xience™ stent family includes XIENCE Skypoint™ and XIENCE Sierra™
215109339|NCT05952206|DRUG|1-month DAPT|"DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month. Then, only the same oral P2Y12 inhibitor (clopidogrel, prasugrel, and ticagrelor) up to 12 months.~The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC"
215109340|NCT05952206|DRUG|12-month DAPT (Standard of care)|DAPT with acetylsalicylic acid and prasugrel or ticagrelor up to 12 months. The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC
215109341|NCT05715307|OTHER|Intensive training for endocrinologists in T2DM management|"One-week intensive experiential training for endocrinologists includes a 1-week hospitalization experience at Ruijin Hospital, involving health examinations, results interpretation, and integrated training courses for T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and participate in regular training sessions, including experience-sharing meetings."
215109342|NCT05715307|OTHER|Regular training for endocrinologists in T2DM management|"Regular training and communication are implemented by Ruijin Hospital under the guidance of T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and receive regular routine training."
215109343|NCT03517228|DEVICE|BAUM device|The robotic manipulator will be placed at the start of each case. The manipulator will be cleaned and sanitized using the same process as other reusable OR devices. Feasibility will be determined by the rate of successful robotic manipulator docking and if the manipulation of the uterus was successful for the duration of the procedure. The V-Care is an FDA approved uterine manipulator which will attach to the investigational BAUM. Placement of a BAUM will be noted on the operative note.
215109344|NCT04400565|BEHAVIORAL|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
215109345|NCT03832751|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
215109346|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 1|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22
215109347|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 2|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22
215109348|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 3|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15
215109349|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 4|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
215109350|NCT01340053|DRUG|RDX5791|Capsule, QD
215109351|NCT05518357|BIOLOGICAL|LILRB4 STAR-T|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg。
215109352|NCT04696679|OTHER|Patient Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France
215109353|NCT04696679|OTHER|Control group Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)
215109354|NCT02813239|OTHER|hCG|Oocyte maturation with hCG
215109355|NCT02813239|OTHER|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
215109356|NCT05366634|BIOLOGICAL|MDK-703 or Placebo|Injection
215109357|NCT06361914|BEHAVIORAL|Digital CBT-I|"Sleep restriction includes behavioral instructions to limit the time spent in bed to increase sleep drive and further reduce time awake in bed.~Stimulus control therapy entails behavioral instructions to strengthen the association between bed and sleep and to eliminate conditioning of non-sleep behavior and bed.~Deactivation/relaxation training involves methods to reduce somatic tension and limit intrusive thought processes that interfere with sleep.~Cognitive therapy helps to identify, challenge, and modify dysfunctional beliefs about sleep.~Sleep hygiene education entails specific information relating to lifestyle and environmental factors that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake."
215109358|NCT06361914|BEHAVIORAL|Digital Sleep hygiene education|Sleep hygiene education entails specific information relating to lifestyle (diet, exercise, substance use) and environmental factors (light, noise, temperature) that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake.
215109359|NCT02882828|DRUG|switched from Prograf® to Envarsus®|
215109360|NCT04615650|PROCEDURE|Surgical treatment|Surgical treatment of suprasyndesmotic ankle fractures
215109361|NCT04615650|DEVICE|Ankle orthosis|Non-surgical treatment of suprasyndesmotic ankle fractures
215109362|NCT06213454|DRUG|TAP Anesthesia|ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections
215109363|NCT06213454|DRUG|Surgeon-Initiated Local Anesthetic|266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in 130 mL of normal saline (160 mL of solution), 40 mL fascial injection and 40 mL skin injection on either side of the wound
215109364|NCT05782322|BEHAVIORAL|Upper-limb training involving RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
215109365|NCT05782322|BEHAVIORAL|Upper-limb training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
215109366|NCT00156390|DEVICE|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
215109367|NCT00156390|OTHER|LV lead placement as per standard of care (without echo guidance)|
215109368|NCT06583863|DRUG|Echinacea Extract|175 mg of Echinacea extract was provided as an immunlant therapy twice daily.
215109369|NCT06583863|DRUG|MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]|500 mg of metronidazole was provided as an oral tablets twice daily
215109370|NCT06584162|DRUG|Vedolizumab Injection|"Based on therapeutic drug monitoring, patients could be de-escalated based on a pharmacokinetic model:~Dosing interval Trough Target 20 mg/L~Adjust dosing interval to:~2 weeks \< 33 mg/L 2 weeks 2 weeks 33 - 46 mg/L 3 weeks 2 weeks ≥ 46 mg/L 4 weeks 3 weeks \< 20 mg/L 2 weeks 3 weeks 20 - 29 mg/L 3 weeks 3 weeks ≥ 29 mg/L 4 weeks 4 weeks \< 13 mg/L 2 weeks 4 weeks 13 - 20 mg/L 3 weeks Version number: 6.1, 24-06-2024 22 of 44 4 weeks ≥ 20 mg/L 4 week"
214509896|NCT06683209|DIAGNOSTIC_TEST|Josephberg-Besser|Use of this instrument to examine one eye
214509897|NCT06683209|DIAGNOSTIC_TEST|Cotton tip applicator|Use of this instrument to examine one eye
214509898|NCT07012733|OTHER|Thoracic mobilization|Participants in this group will receive thoracic mobilization techniques in addition to conventional respiratory therapy. Thoracic mobilization will be delivered by a licensed physical therapist using passive manual techniques targeting the thoracic spine and rib cage to improve chest wall mobility and respiratory function.
215109371|NCT06584370|PROCEDURE|Pericardial insufflation with carbon dioxide through a transatrial microcatheter|Separate the walls of the pericardium by insufflating the pericardial space with carbon dioide.
215109372|NCT02960464|DEVICE|Transcranial direct current stimulation|
215109373|NCT02960464|DEVICE|Sham Transcranial direct current stimulation|
215109374|NCT05159570|DIETARY_SUPPLEMENT|Ketone ester|Commercially available ketone supplement
215109375|NCT05159570|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
215109376|NCT03941717|OTHER|Mindfulness-Based Condition|Each script for the mindfulness-based intervention was slightly modified to fit the context of a venipuncture, and begins with instructions to take deep breaths. Both scripts aim to cultivate present moment awareness of experiences, curiosity, nonjudgement, and acceptance of experiences as they unfold. In particular, the scripts ask that the participant visualize their worries and feelings as a cloud in the sky, and probes for curious thoughts about these experiences. The temporary nature of sensations is described, and the participant is asked to keep this openness and curiosity during the venipuncture.
215109377|NCT03941717|OTHER|Unfocused attention Condition|Each script for the unfocused attention task instructs participants to allow their mind and thoughts to roam. The aim is to encourage the participant to continue thinking and mind wandering as they typically would.
215109378|NCT01439594|DEVICE|MGH OFDI Imaging|Imaging of Esophagus with OFDI system
215109379|NCT00235144|DEVICE|sirolimus-coated Bx Velocity stent|drug-eluting stent
215109380|NCT00235144|DEVICE|uncoated Bx Velocity stent|bare-metal stent
215109381|NCT06165042|OTHER|glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply glass hybrid restorative system (Equia Forte, GC Europe, Leuven, Belgium)
215109382|NCT06165042|OTHER|Fluoride varnish + Glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
215109383|NCT00475709|DEVICE|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
215109384|NCT04583527|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
215109385|NCT01732315|BEHAVIORAL|Email Notification|This study will use a targeted email reminder/recall intervention that addresses specific aspects of adolescent under-immunization.
215109386|NCT00274508|DRUG|tiotropium bromide|
215109387|NCT03632772|DRUG|Solifenacin 5Mg|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
215109388|NCT03632772|DRUG|Mirabegron 50 MG|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
215109391|NCT05380440|BEHAVIORAL|Families Actively Improving Relationships (FAIR)|FAIR is a behavioral intervention for the treatment of parental substance abuse and child neglect for families involved in the child welfare system. This project will adapt the existing FAIR intervention for prevention. FAIR involves four major treatment components, supported by ongoing purposeful engagement : (1) Substance use treatment including contingency management and positive reinforcement, frequent urinalysis, relationship building, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; and (4) Resource building and provision of ancillary supports including assistance with housing and employment.
215109392|NCT05380440|BEHAVIORAL|Standard Case Management and Referral|Parents will be referred for a substance abuse and mental health assessment with possible resulting treatment. Child Welfare treatment plans typically include a series of recommendations, including parenting classes, securing safe housing, psychosocial treatment (e.g., domestic violence), accessing self-sufficiency services (e.g., food stamps, WIC), securing employment or education, and meeting court dates and requirements.
215109393|NCT01479361|DRUG|Atovaquone 750 mg twice daily|
215109394|NCT01479361|DRUG|Atovaquone 1500 mg twice daily|
215109395|NCT04132505|DRUG|Binimetinib|Given PO
215109396|NCT04132505|DRUG|Hydroxychloroquine|Given PO
215109397|NCT05536570|DRUG|IncobotulinumtoxinA 100 UNT|Scalene injection
215109398|NCT05679739|OTHER|Individualized blood pressure strategy|An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.
214509899|NCT07012733|OTHER|conventional therapy|Participants in this group will receive conventional respiratory therapy, including diaphragmatic breathing, pursed-lip breathing, and chest expansion exercises. The therapy will be administered by a licensed physical therapist following standard pulmonary rehabilitation protocols.
214509900|NCT07012109|DRUG|BEBT-507 Injection|The initial dose of BEBT-507 injection is 1.25mg/kg, administered subcutaneously at 1.25mg/kg, 2.5mg/kg, 5mg/kg, 10mg/kg or 15mg/kg every 12 weeks for two doses in total.
214509901|NCT02359565|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
214509902|NCT02359565|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo standard MRI
214509903|NCT02359565|PROCEDURE|Diffusion Tensor Imaging|Undergo DTI
214509904|NCT02359565|PROCEDURE|Diffusion Weighted Imaging|Undergo MR diffusion imaging
214509905|NCT02359565|PROCEDURE|Dynamic Contrast-enhanced MR Perfusion|Undergo DCE permeability MRI
214509906|NCT02359565|PROCEDURE|Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging|Undergo DSC perfusion MRI
214509907|NCT02359565|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
214509908|NCT02359565|BIOLOGICAL|Pembrolizumab|Given IV
214509909|NCT07012642|DRUG|GLP-1 Receptor Agonists|GLP-1 RAs in lymphedema
214509910|NCT07012473|BEHAVIORAL|Nutrition education on green leafy vegetables and legumes|The nutrition education intervention will be based on the Theory of Reasoned Action, Social Cognitive Theory, and the Health Belief Model to influence key behaviour change factors such as knowledge, attitudes, practices, and beliefs. Educational materials will include stickers featuring indigenous green leafy vegetables, legumes, and vitamin C-rich fruits, with information on their benefits, storage, preparation, and the importance of combining them for enhanced iron absorption. Other materials include videos, messages, and affirmative words on iron deficiency and its prevention. The intervention will be delivered to selected households in the intervention community through biweekly meetings and phone calls over six months. The control community will not receive any intervention from the researcher.
214509911|NCT07011693|DRUG|Sertraline|Commonly used oral antipsychotics intervention therapy.
214509912|NCT07011693|DRUG|Agomelatine|Commonly used oral antipsychotics intervention therapy.
214509913|NCT07011693|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
214509914|NCT06625515|DRUG|ATX-559|DHX9 tablets will be taken orally
214509915|NCT07012538|DRUG|Renin-angiotensin system inhibitors (RASi)|Using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or inappropriate use of RASi.
214509916|NCT07012538|DRUG|No renin-angiotensin system inhibitors (No RASi)|Not using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or needing RASi.
214509917|NCT07012499|DEVICE|Automated peritoneal dialysis with Sharesource device|Patients receive APD with an FMC device that contains sharesource software which can communicate with the medical team.
214509918|NCT07012499|DEVICE|APD without sharesource|Patients received APD with Same machine but this patients dose not using sharesource software
214509919|NCT07012551|PROCEDURE|Common iliac artery stenting|Stenting of common iliac artery by balloon mounted stent
214509920|NCT07013097|DRUG|PG-033|Oral tablets (2mg， 10mg)
214509921|NCT07013097|DRUG|PG-033 placebo comparator|Oral tablets (2 mg, 10 mg) (matching corresponding study medication)
214509922|NCT07013123|DRUG|Tezepelumab|"Patients will take Tezepelumab for 3 to 6 months (M-3/-6) to control asthma symptoms.~Once asthma symptoms are controlled (D0), patients will take an additionnal of 18 months of Tezepelumab"
214509923|NCT07013123|DRUG|Acarizax|Once asthma symptoms are controlled (D0), patients will take 18 months of Acarizax.
214509924|NCT07013123|DRUG|Placebo|Once asthma symptoms are controlled (D0), patients will take 18 months of Placebo.
215109399|NCT04491539|BEHAVIORAL|Finding Respect and Ending Stigma around HIV (FRESH)|The Finding Respect and Ending Stigma around HIV (FRESH) intervention is theoretically informed by Social Cognitive Theory (SCT) and Interpersonal Contact theory (ICT) and was specifically designed for delivery in high-stigma settings, such as Dominican Republic. FRESH was originally developed in Africa to address HIV-related stigma, and later was adapted to address intersectional stigmas experienced by sexual and gender minorities (SGM) living with HIV in the United States Deep South. To our knowledge, FRESH will be the first intervention to address intersectional stigmas experienced by men who have sex with men, transgender women, and people living with HIV in clinical settings in the Spanish-speaking Caribbean.
215109400|NCT06360848|OTHER|surgery|SURGICAL TREATMENT OF PSEUDARTHROSIS OF THE HUMERUS
215109401|NCT01835158|DRUG|Cabozantinib S-malate|Given PO
215109402|NCT01835158|OTHER|Laboratory Biomarker Analysis|Correlative studies
215109403|NCT01835158|DRUG|Sunitinib Malate|Given PO
214509925|NCT05430841|DIAGNOSTIC_TEST|18F-FDG, 18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
214509926|NCT06699082|OTHER|KinesioTaping and Keltonborn Mobilization|Experimental group was treated with kinesiotape and kaltenborn mobilization while the non experimental group was treated with conventional therapy along with kaltenborn mobilization.
214509927|NCT06699238|OTHER|Home Exercise|Standard conventional exercise for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.
214509928|NCT06699238|OTHER|Aerobic exercise|The aerobic exercise group performed the following training: warm-up for 5 min, walking for 20 min at an intensity that would use 60-70% of the HR reserve, and cool down for 5 min. Additionally, they performed standard conventional exercises at home for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.The aerobic exercise group performed on a treadmill under the supervision of a physician.
215109404|NCT04322617|DRUG|Anlotinib plus the same Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
215109405|NCT04322617|DRUG|Anlotinib plus the new Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
215109406|NCT04322617|DRUG|Anlotinib|Anlotinib, 8mg po qd, D1-D14 every 21days.
215109407|NCT06347679|OTHER|Aroma diffuser with single-note sweet orange essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note sweet orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
215109408|NCT06347679|OTHER|Aroma diffuser with single-note tea tree essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note tea tree essential oil into the aroma diffuser reservoir containing 120 ml of water.
214509929|NCT06711640|DRUG|LUCEMYRA (lofexidine) tablets|Tablets. Participants weighing ≥45 kg: three 0.18 mg tablets (0.54 mg) four times per day (QID). Participants weighing ≥30 to \<45 kg: two 0.18 mg tablets (0.36 mg) QID.
214509930|NCT06716632|DEVICE|Using Ligasure for heamostasis|Ligasure is a bipolar vascular sealing system utilized to achieve effective control of bleeding and create a bloodless surgical environment. It operates by utilizing an electrical current within the frequency range of 2-4 MHz It induces denaturation of collagen and elastin within the vessels and surrounding tissues. The localized tissue temperatures typically range between 60-100°C, facilitating the fusion of collagen and elastin in the vessel walls. This fusion process creates a durable sealed zone without any carbonization and enables hemostasis in vessels with diameters of up to 7 mm.
215109409|NCT06347679|OTHER|Aroma diffuser with water|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of water.
215109410|NCT03256201|BEHAVIORAL|Nutritional Counseling|Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.
215109411|NCT03256201|BEHAVIORAL|Standard Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
215109412|NCT03256201|BEHAVIORAL|Enhanced Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
215109413|NCT04259008|OTHER|Manganese omission|Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.
215109414|NCT04259008|OTHER|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."
215109415|NCT01415401|DRUG|Brinzolamide 1% / timolol 0.5% maleate fixed combination|
215109416|NCT04543695|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy|"Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
215109417|NCT04543695|DRUG|XELOX|"Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course"
215109418|NCT04543695|DRUG|mFOLFOX|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
215109419|NCT04543695|PROCEDURE|TME|Total mesorectal excision
215109420|NCT02130596|BEHAVIORAL|Acceptance-Based Behavioral Intervention|
215109421|NCT02130596|OTHER|Nutritional Counselling|
215109422|NCT03700489|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
215109423|NCT00475904|DRUG|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
215109424|NCT00475904|DRUG|Gabapentin Capsules|1800mg/day capsules for 4 weeks
215109425|NCT00475904|DRUG|placebo|placebo cream and caps
215109426|NCT02899091|BIOLOGICAL|CB-AC-02|"Stage1:~① Group1: CB-AC-02 administration on day 0~② Group2: CB-AC-02 administration on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20\~26 CB-AC-02 administration on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10\~19 CB-AC-02 administration on day 0 and on week 4 (repeated injection)"
215109427|NCT02899091|BIOLOGICAL|Placebo|"Stage2:~Placebo administration on day 0 and on week 4 (repeated injection)"
215109428|NCT06473792|OTHER|Probiotic Toothpaste|"Composition: Main - Water, calcium carbonate, calcium glycerophosphate, glycerin, xylitol, sodium bicarbonate, sweet fennel oil (Foeniculum vulgare), carrageenan, maltodextrin, Dental-Lac (Lactobacillus paracasei), potassium sorbate, yucca (Y. filamentosa) powder, stevia leaf extract (Eupatorium rebaudiana bertoni), zinc chloride.~Usage: This is mint flavored toothpaste containing Lactobacillus paracasei which has demonstrated the ability to help address harmful strains of oral flora, and promotes the maintenance of a healthy teeth and gums. The participant will be instructed to brush with it twice daily."
215109429|NCT00939562|DRUG|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
215109430|NCT00939562|DRUG|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
215109431|NCT00152308|DEVICE|2% rapamycin-eluting YUKONdes PEARL-stent|
215109432|NCT00152308|DEVICE|1% rapamycin-eluting YUKONdes PEARL-stent|
215109433|NCT00152308|DEVICE|YUKONdes PEARL-stent coated with placebo (ethanol)|
215109434|NCT05370872|DIAGNOSTIC_TEST|Remote functional testing protocol|Clients in the remote functional testing protocol group will be asked to describe their functional capacity limits using a clinician guided motivational interviewing approach and will also be asked to complete a mobility screening protocol to provide the clinician with the opportunity to observe the clients natural movements.
214509931|NCT06716632|PROCEDURE|Use of conventional knot tying technique for heamostasis|Conventional methods of vessel ligation, which involve the use of ties and suture ligatures, have long been employed in most medical centers. While these techniques effectively control bleeding from vessels, they are time-consuming and carry the risk of harming adjacent structures like the recurrent and superior laryngeal nerves.
215109435|NCT01023360|DRUG|Clopidogrel and proton pump inhibitors|"baseline detection --\> clopidogrel 75 mg PO QD for 1 week --\> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week --\>~1 week washout --\> aspirin 100mg PO QD for 1 week"
215109436|NCT04118049|OTHER|BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel.|BiopHreshTM is a vaginal probiotic supplement that is offered over the counter and contains four different lactobacilli strains (L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus). RestoreTM is a moisturizing personal lubricant that has been on the market for three years. Participants will use 1 probiotic capsule with RestoreTM gel nightly three times weekly.
215109437|NCT04118049|OTHER|Standard Care|Standard care arm is standard care for pessary use. Pessary maintenance will be performed standardly by their provider.
215109438|NCT03629353|PROCEDURE|endotracheal intubation|After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
215109439|NCT03629353|PROCEDURE|high flow nasal cannula|After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
215109440|NCT04543292|DEVICE|MATFILL (PTFE)|Filling of the prosthetic chimney with the compressed material
215109441|NCT02397148|RADIATION|Computed Tomography|imagery with ionizing radiation
215109442|NCT02397148|RADIATION|Cone Beam Computed Tomography|imagery with ionizing radiation
215109443|NCT03746717|DEVICE|occlusive wound closure|skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
215109444|NCT03746717|DEVICE|conventional wound closure|wound closure with surgical staples
214509932|NCT06699173|OTHER|Heat ped|The hot ped was used during ricig cystoscopy
214509933|NCT06883110|DRUG|Z11020076|Beijing Tongrentang Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days.
214509934|NCT06883110|DRUG|Z20063878|Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days.
214509935|NCT06717165|COMBINATION_PRODUCT|ERP combined with high-definition active tACS|The active tACS +ERP referred to a period of tACS applied in the first 20 minutes of the ERP treatment (the tACS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tACS+ERP treatment. Based on the EEG parameters, individualized modeling was conducted to determine specific stimulation parameter schemes (stimulation frequency). Anode electrode will be localized in front of the mPFC on the Fz point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AFz, Fcz, F1, F2).
214692194|NCT05841134|DRUG|Tislelizumab|"Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months."
215109445|NCT00093652|DRUG|gefitinib|
215109446|NCT00093652|DRUG|oxaliplatin|
215109447|NCT00093652|PROCEDURE|conventional surgery|
215109448|NCT00093652|PROCEDURE|neoadjuvant therapy|
215109449|NCT00093652|RADIATION|radiation therapy|
215109450|NCT05999500|BEHAVIORAL|Temple stay experience|Temple stay experience includes diet and behavior changes, such as vegetarian meals (ex. Balwoo Gongyang), mindful eating, no overeating, meditation, participation in daily monastic tasks.
215109451|NCT06207526|BEHAVIORAL|Blended face-to-face and smartphone intervention|The intervention comprises two phases: an initial stage involves baseline assessment, in-depth app training, psychoeducation, and EMA monitoring for functional analysis. The subsequent phase focuses on identifying and implementing individual coping strategies, forming the basis for daily personalized EMI reminders. Over six days, participants receive ten daily surveys to gauge fluctuations in paranoia and delusional ideation. EMA-derived feedback, considering antecedents and coping responses, shapes a personalized EMI. Four sessions with a psychologist involve discussing app feedback, emphasizing functional analysis, coding coping strategies into the app, assessing utility, and adapting as needed. Post-session two, five coping reminders and an eight-item evening survey are sent daily for two blocks of ten days to monitor delusional ideations and coping strategy effectiveness.
215109452|NCT06109207|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery
215109453|NCT06109207|DRUG|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
215109454|NCT06109207|DRUG|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
214509936|NCT06717165|COMBINATION_PRODUCT|ERP combined with sham tACS|Patients will get the same CBT setting as the active tACS group and they were applied the sham tACS cocurrently with ERP. The sham tACS device is the same as the active comparator's except that the sham tACS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tACS.
214509937|NCT06728982|DRUG|Metformin|1000mg of metformin twice daily by mouth
214509938|NCT07045909|DRUG|Daratumumab|Daratumumab will be administered by subcutaneous (SC) injection.
214509939|NCT07045909|DRUG|Isatuximab|Isatuximab will be administered IV.
214509940|NCT07045909|DRUG|Bortezomib|Bortezomib dose will be calculated using the patient's actual body surface area at baseline and will be administered by SC injection.
215109455|NCT05698602|DEVICE|NivolisMonitor|"NivolisMonitor comprises a sensing element and controller to measure respiratory values, such as pressure and flow optionnally temperature, relative humidity and oxygen concentration, of a patient being treated with a respiratory therapy devices NIV, CPAP or HDN.~NivolisMonitor is inserted between the respiratory assistance device and the mask or cannula inline with the standard patient circuit used routinely with the respiratory assistance device.~NivolisMonitor functions are:~* measure the respiratory values from the builtin sensor (Pressure, Flow, Temperature, Humidity, Oxygen fraction),~* store the measurements in the embedded memory~* extract from the measurement basic respiratory markers:~* detect if and when a patient is using the respiratory assist device,~* calculate leakage~* calculate respiratory frequency~* transmit the measured values via the NivolisBox component to NivolisPortal"
215109456|NCT05698602|DEVICE|NivolisAnton|"NivolisAnton device enables wireless and remote communication from tcPCO2 monitors which measure transcuteanously CO2 and O2 partial pressures in the blood (tcPCO2 \& tcPO2) .~NivolisAnton device connects to the serial port of tcPCO2 monitor, detects if the monitor is actively measuring blood gas values, collects the measurements from the monitor by following manufacturer's communication protocol and stores the collected values in its internal memory. When applicable per the manufacturer recommendations, NivolisAnton collects the values to apply the drift correction as per the manufacturer recommendations.~NivolisAnton transmits the collected data to external receiving devices, such as Medical Devices (NivolisMonitor or another Medical Device that is granted approved data access by Vivardis) via Bluetooth or data servers (NivolisBox as an example) via WIFI. This data is thereafter transmitted by previously mentioned devices to the NivolisPortal server for archiving."
215109457|NCT02465372|BEHAVIORAL|CSPAP|Comprehensive School Physical Activity Program.
215109458|NCT00300313|DRUG|Escitalopram|10 to 20 mg / day
215109459|NCT00300313|DRUG|Placebo|1-2 capsules
215109460|NCT04526041|OTHER|Nasofibroscopy|Laryngeal exploration performed using a flexible fibrescope while singing.
215109461|NCT04526041|OTHER|Electroglottography|Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.
215109462|NCT04526041|OTHER|Air flow measurement + acoustic signal recording|Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)
215109463|NCT04526041|OTHER|Questionnaire|Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
215109464|NCT00119470|PROCEDURE|EUS-FNA|
215109465|NCT00119470|PROCEDURE|Conventional Surgical Technique|
215109466|NCT03100604|DRUG|desflurane,|Patients were divided into two groups according to inhalation agent administered for the surgery; Sevofluran, Group S (n=25) and Desfluran, Group D (N=25).
215109467|NCT03100604|DRUG|Sevoflurane|For a drug, use generic name if established. Use the same name as in the associated Arm/Group Description(s).
215109468|NCT05564312|DEVICE|Transabdominal ultrasonographic guidance at embryo transfer.|During embryo transfer in each patient, endometrial thickness, uterine cavity dimensions, distance of transfer catheter to the fundus, distance of released air bubble to the fundus, and distance of air bubble to side walls will be systematically measured and recorded under the guidance of transabdominal ultrasonography.
215109469|NCT03084835|BEHAVIORAL|Usual Care|Brief cessation counseling
215109470|NCT03084835|BEHAVIORAL|WEB+TXT|Access to Become an Ex website plus text messaging
215109471|NCT03084835|BEHAVIORAL|WEB+TXT+TTS|Access to Become an Ex website plus text messaging plus consult with a trained tobacco treatment specialist
215109472|NCT01806675|DRUG|18F-fludeoxyglucose (18F-FDG)|18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan
215109473|NCT01806675|DRUG|18F-FPPRGD2|18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.
215109474|NCT00587704|PROCEDURE|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
215109475|NCT00587704|PROCEDURE|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
215109476|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
214509941|NCT07045909|DRUG|Lenalidomide|Lenalidomide will be administered by oral route (all cohorts at induction, and cohorts A and B at maintenance).
215109477|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
215109478|NCT00532298|BIOLOGICAL|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
215109479|NCT00532298|BIOLOGICAL|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
215109480|NCT00209703|DRUG|Oxaliplatin|
215109481|NCT00209703|DRUG|l-Leucovorin|
215109482|NCT00209703|DRUG|5-Fluorouracil|
215109483|NCT00761696|DRUG|IPI-926|Oral daily dosing
215109484|NCT06970340|BEHAVIORAL|Online MedEd Intern Bootcamp|6 months of online access plus biweekly live sessions
215109485|NCT05711524|BIOLOGICAL|Traditional Cryoprecipitate|This is the cryoprecipitate already currently being given to patients with a cryo order.
215109486|NCT05711524|BIOLOGICAL|Pathogen-Reduced Cryoprecipitate|This is the pathogen-reduced cryoprecipitate that is intended to be compared to the standard cryoprecipitate.
215109487|NCT06975566|PROCEDURE|radial artery catheterization|
215109488|NCT06977048|OTHER|Mobile Application-Based Educational Program|"Week 0:~Participants are informed about the study and trained in the use of the mobile application.~The mobile app is installed on their smartphones.~Educational animation videos and modules are watched with the researcher in a predefined order.~Questions about animations are answered.~Videos are downloaded to the participant's phone.~DFU photographs are recorded.~Weeks 1-12:~Participants are instructed to use the app regularly between weeks 5-12.~Video watching days and durations are logged using a tracking form.~Weekly push notifications remind participants to use the app.~Weekly phone calls are made to assess engagement using a structured checklist.~DFU photographs are taken at weeks 8 and 12.~At week 12, data are collected in person, including:~DFU size (length × width) with disposable paper ruler~Metabolic parameters from blood tests~Wagner-Meggitt classification~Re-ulceration assessment"
215109489|NCT06977048|OTHER|Standard care|"Participants provide consent and receive baseline information.~DFU photographs are taken at baseline, week 8, and week 12.~At week 12, the same outcome measures as the intervention group are collected.~After the study ends, participants are provided with access to the mobile application."
215109490|NCT06975254|OTHER|"On the basis of routine nursing, the Internet + nursing program based on the FLS model is implemented"|1\) During hospitalization: After the patient is admitted to hospital, the coordinator will establish wechat contact with the patient face to face and establish a good trust relationship with the patient; The coordinator and the doctor will collect the patients' cases together, and then according to the patients' conditions and wishes, the diagnosis and treatment plan will be formulated jointly by multiple disciplines, including medicine, rehabilitation and nutrition management. 2) Before discharge: the coordinator helps the patient to make an appointment for return visit; Issue business cards of the team's online and offline services to patients and guide them to use wechat and online service application procedures (such as Zheli Care and Dr. Nari); 3) After discharge: patients keep in touch with the liaison staff at any time, and any abnormal situation will be contacted by the liaison staff; Team members supervised the patient's medication situation by punching in the mini program
215109491|NCT06975033|OTHER|Video|Participants will watch video.
215109492|NCT05592379|DRUG|Psilocybin|The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).
215109493|NCT05592379|DRUG|Clonidine|Clonidine will be administered orally in a 0.2mg dose
215109494|NCT05592379|OTHER|Saline|The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.
215109495|NCT06325462|DEVICE|sensors of regional cerebral oxygen saturation (O3 regional oximeter, Masimo Corp, Irvine, CA) FDA Reg No. 3011353843|O3 regional oximetry monitors the regional hemoglobin oxygen saturation of the blood (rSO2) in adult patients, placed on the forehead by noninvasive and continuous combining arterial and venous oxygen saturation signals from near-infrared spectroscopy (NIRS)
215109496|NCT06576401|DRUG|[14C] HDM1002|Administered orally
215109497|NCT05931276|DRUG|Metoprolol Succinate|a dialyzable, beta-1 selective beta blocker
215109498|NCT05931276|DRUG|Carvedilol|a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
215109499|NCT02023996|RADIATION|89Zr-DFO-trastuzumab|
215109500|NCT02023996|DEVICE|PET imaging|
215109501|NCT06976658|DRUG|Dorzagliatin|Dorzagliatin 50mg bd
215109502|NCT06976658|DRUG|matched placebo|matched placebo
215109503|NCT06109714|OTHER|Goal Directed Fluid Therapy|Fluid administration and hemodynamic management guided with the assistance of Edwards Lifesciences ACUMEN monitor
215109504|NCT06974487|DRUG|GZR102 injection|Participants will get a single dose of GZR102 injection （fixed-ratio combination of GZR4 and GZR18）.
215109505|NCT06974487|DRUG|GZR4 injection|Participants will get a single dose of GZR4 injection
215109506|NCT06974487|DRUG|GZR18 injection|Participants will get a single dose of GZR18 injection
215109507|NCT05758402|DIAGNOSTIC_TEST|Routine practice group|Routine practice group
215109508|NCT05758402|DIAGNOSTIC_TEST|EARP group|EARP group
215109509|NCT01325688|DRUG|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
215109510|NCT01325688|DEVICE|Aluminium disk|
215109511|NCT01325688|DEVICE|OpSite(TM) disk|
214509942|NCT07045909|DRUG|Cyclophosphamide|As part of lymphodepleting therapy before CAR-T manufacture, administered IV.
214509943|NCT07045909|DRUG|Fludarabine|As part of lymphodepleting therapy before CAR-T manufacture, administered IV
215109512|NCT06866041|PROCEDURE|mpMRI-targeted confirmatory biopsy|mpMRI-targeted confirmatory biopsy after one year from the diagnosis, according to the international guidelines
214509944|NCT07045909|DRUG|Anitocabtagene Autoleucel|Single infusion IV
215109513|NCT04788316|BEHAVIORAL|CBI and Text messaging|A computerized brief intervention (2 sessions) followed by six months of personalized text messaging
215109514|NCT06626022|DEVICE|MRI|Standard prostate mpMRI.
215109515|NCT06626022|DEVICE|ExactVu|microUltrasound
215109516|NCT06816524|DIETARY_SUPPLEMENT|Iron syrup|Iron syrup administered daily from 6 to 10 months of age.
215109517|NCT06816524|DIETARY_SUPPLEMENT|Multivitamin syrup|Multivitamin syrup administered daily from 6 to 10 months of age.
215109518|NCT06816524|BIOLOGICAL|R21-Matrix/M Vaccine (malaria vaccine)|R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age.
215109519|NCT06816524|BIOLOGICAL|Measles-Rubella vaccine|Measles-Rubella vaccine administered at 9 months of age.
215109520|NCT02122367|OTHER|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
215109521|NCT02211456|PROCEDURE|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
215109522|NCT04199143|DRUG|Nitrous Oxide-Oxygen|The medical product used in this study is a gas for common medical use in various domains including anesthesic, consisting in the equimolar mixture of nitrous oxide and oxygen. Subjects will receive a mixture of 50% N2O / 50% O2 for 1 hour.
214509945|NCT07050732|BIOLOGICAL|Arexvy (2 doses total)|Arexvy at enrollment, Arexvy at Day 365
214509946|NCT07050732|BIOLOGICAL|Arexvy (3 doses total)|Arexvy at enrollment, Day 60, and Day 365
214509947|NCT07050732|BIOLOGICAL|Arexvy (1 dose total)|Arexvy at enrollment
214509948|NCT07050732|OTHER|Placebo|Placebo vaccine at day 60
215109523|NCT04199143|DEVICE|Tissue Pulsatility Imaging - TPI|Tissue Pulsatility Imaging (TPI) is a variation of ultrasonic Doppler strain imaging we are developing to measure the local expansion and relaxation of the brain tissue over the cardiac cycle to characterize and image perfusion.
215109524|NCT04199143|DEVICE|Magnetic Resonance Imaging - MRI|Structural and Functionnal (including BOLD and ASL) MRI will be aquired in this study
215109525|NCT00095173|DRUG|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
215109526|NCT00095173|DRUG|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
215109527|NCT00095173|DRUG|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly
214509949|NCT05675059|BEHAVIORAL|Consultations with Moffitt Dietician|Participants will have an initial consultation and then biweekly follow-up visits (in-person or virtually) with a study dietician for 12 weeks.
214509950|NCT05675059|BEHAVIORAL|Daily Food Intake Diary with Fitbit Smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone app and wearing a Fitbit for 12 weeks.
215109528|NCT06300268|DEVICE|AdvaPro Sirolimus Eluting Coronary Stent System|Cardiac Stent
215109529|NCT03563365|OTHER|Replenix Power of 3 Cream with resveratrol|Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
215109530|NCT03563365|DRUG|Adapalene and Benzoyl peroxide gel, 0.1%/2.5%|FDA approved topical agent for the treatment of acne
215109531|NCT03659877|BEHAVIORAL|Physical activity|Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
215109532|NCT01745042|OTHER|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
215109533|NCT00008528|DRUG|Enfuvirtide|
215109534|NCT00639626|DRUG|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
215109535|NCT04897178|DIAGNOSTIC_TEST|Ultrasound|Routine 2 dimensional Ultrasound used to screen fetuses for congenital anomalies
214509951|NCT05675059|BEHAVIORAL|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at 4, 8, 12 and 16 weeks.
214509952|NCT06737809|DEVICE|IP Plasmafit® Revision cup (and stem) system|Revision total hip arthroplasty (THA) due to periprosthetic joint infection
214509953|NCT07052799|DRUG|Aspirin 80mg|8-day (-5, +3) supply of aspirin 80mg before and after colonoscopy
214509954|NCT07052799|DRUG|Placebo Oral Tablet|8-day (-5, +3) supply of placebo before and after colonoscopy
215109536|NCT02089126|DRUG|Gemigliptin/Glimepiride combination|
214509955|NCT07052747|OTHER|Clinical periodontal assessment|Comprehensive site-level and full-mouth evaluations of periodontal parameters, including plaque index (PI), gingival index (GI), probing pocket depth (PPD), recession depth (RD), bleeding on probing (BOP), keratinized tissue width (KTW), mucosal phenotype, mucosal redness (MR), mucosal discomfort (MD), and torque gauge (TG) measurements.
214509956|NCT07052838|DRUG|HSK39297 tablets|200mg QD
214509957|NCT07052851|DEVICE|CCoat, Liposphere Ltd|a single IA injection of 4 ml CCoat
214509958|NCT07052851|DEVICE|Synvisc-One® (hylan G-F 20)|Group 2 (Active Comparator): a single IA Synvisc-One® (hylan G-F 20) of 6 mL, Genzyme Corporation
214509959|NCT06782178|PROCEDURE|Arthroscopic lysis and lavage|Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly.
214509960|NCT06782178|PROCEDURE|Arthrocentesis/Saline|Arthrocentesis refers to a blind irrigation of the temproromandibular joint with saline solution
214509961|NCT06890767|DEVICE|Wearable mobile device|Patients admitted due to an acute COPD exacerbation will be asked to wear the wearable mobile device for a period of 3 months. An app linked to the device will be installed on their phone, and be used to send vital parameter data to the investigators.
214509962|NCT06890767|OTHER|CAT Questionnaire|During the time of hospital admission and at the end of study, a COPD Assessment Test questionnaire will be taken.
214509963|NCT06890767|OTHER|DHRQ Questionnaire|During the time of hospital admission, the patient will be asked to fill in the Digital Health Readiness Questionnaire
215109537|NCT00897221|DRUG|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
215109538|NCT00897221|DRUG|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
215109539|NCT00315016|DRUG|eplerenone|active comparator
215109540|NCT00315016|DRUG|fosinopril|doubling of fosinopril dose
215109541|NCT00315016|DRUG|placebo|placebo (double dummy)
215109542|NCT02286232|BEHAVIORAL|Stretching exercise|This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
215109543|NCT02286232|BEHAVIORAL|Self-care book|The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
215109544|NCT06514404|OTHER|observational study|Observational study of the effects on anxiety and empathy of personality the situation of start academic year in health sciences
215109545|NCT03323801|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
215109546|NCT06191172|BEHAVIORAL|Reminiscence Therapy|Old objects and pictures of old objects that facilitate remembering about weekly topics will be taken to the institution by the researcher, and individuals within the scope of the research will be asked for their own photographs, if any.
215109547|NCT06191172|BEHAVIORAL|Montessori application|Drill toy Matching puzzle Chickpeas, rice sorting Lock, zipper Counting beans Making a tie Taking and pouring food with a scoop
215109548|NCT06191172|BEHAVIORAL|Environmental Layout|Dining place Music Lighting Heat
215109549|NCT06191172|BEHAVIORAL|Application of contrast ergonomic special equipment|White tablecloth Beveled red blue and yellow blue plate Ergonomic yellow and red fork, spoon and cup
215109550|NCT05889637|DIAGNOSTIC_TEST|Gastric ultrasound|Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.
215109551|NCT01154426|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
214509964|NCT07052721|DEVICE|Experimental Treatment|Percutaneous peripheral nerve stimulation with a frequency of 100 Hz, a pulse duration of 100 µs, and a current amplitude of 0.001-10 mA (1-10,000 µA). Participants will adjust the amplitude, as needed.
215109552|NCT01154426|DRUG|Gemcitabine Hydrochloride|Given IV
215109553|NCT01154426|OTHER|Pharmacological Study|Correlative studies
215109554|NCT01154426|DRUG|Veliparib|Given orally
215109555|NCT00005824|BIOLOGICAL|filgrastim|
215109556|NCT00005824|DRUG|busulfan|
215109557|NCT00005824|DRUG|cyclophosphamide|
215109558|NCT00005824|PROCEDURE|peripheral blood stem cell transplantation|
215109559|NCT02337881|DRUG|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
215109560|NCT02337881|DRUG|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
215109561|NCT01500668|DRUG|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
215109562|NCT01500668|DRUG|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
215109563|NCT04687371|OTHER|Proprioceptive vestibular exercise|To assess effects of proprioceptive vestibular exercises training in patients with peripheral vestibular hypofunctions
215109564|NCT04687371|OTHER|Standard vestibular rehabilitation exercises|To assess effects of standard vestibular rehabilitation exercises in patients with peripheral vestibular hypofunctions
215109565|NCT04687371|OTHER|Controlled|First and last measurement will be taken. There will be no intervention. study will include 9 patients.
215109566|NCT01574885|DEVICE|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
215109567|NCT01574885|DEVICE|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
215109568|NCT03067623|DRUG|PRP|PRP intrauterine infusion
214509965|NCT07052721|DEVICE|Sham Comparator|SHAM percutaneous peripheral nerve stimulation with a frequency of 100 Hz, a pulse duration of 100 µs, and a current amplitude of 0.001-10 mA (1-10,000 µA). Participants can adjust the amplitude, as needed; but no electrical current will ever reach the patient's body.
214509966|NCT07099950|OTHER|Low-intensity focused ultrasound|80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, administered as a single dose (1-epoch), or in multiple doses (3-epoch).
215109569|NCT03067623|DEVICE|Tomcat catheter|PRP intrauterine infusion by means Tomcat catheter
215109570|NCT02302872|DEVICE|ARTO System|
215109571|NCT04870372|DRUG|Selegiline|Subjects will receive one Selegiline tablet (5 mg) per day administered at breakfast. The initial dose of Selegiline is 5 mg/day and be up-titrated in 2-week intervals in increments of 5 mg up to 10 mg (which can be taken at breakfast or divided doses of 5 mg each taken at breakfast and lunch) according to the investigator's judgment, based on individual clinical response and tolerability.
215109572|NCT02708355|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
215109573|NCT02708355|DRUG|Placebo|Placebo capsules
215109574|NCT03052595|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
215109575|NCT03052595|DIAGNOSTIC_TEST|Testing of autonomous nervous system function|Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
215109576|NCT03052595|DIAGNOSTIC_TEST|Stroop test|Stroop test will be used to test cognitive function
215109577|NCT06526065|OTHER|no intervention|no intervention
215109578|NCT01440205|BEHAVIORAL|Easy list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy."
215109579|NCT01440205|BEHAVIORAL|Challenging list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult."
215109580|NCT01440205|BEHAVIORAL|Control|No check box element
215109581|NCT04202887|DRUG|Low Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
215109582|NCT04202887|DRUG|High Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
215109583|NCT04202887|DEVICE|Gastric Ultrasonography|"The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF."
215109584|NCT05526287|OTHER|Dual-Task Training|"Dual-task training sessions include; walking on treadmill for 10-30 minutes and half of this walking period participants will perform cognitive tasks, cognitive tasks will be repeated on tandem stance position and single leg stance position other half of the session consists of motor-motor dual task activities and gait training on firm and soft surfaces.~Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week."
215109585|NCT05526287|OTHER|Home Exercise Program|Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week.
215109586|NCT00665548|RADIATION|X-ray; magnetic resonance imaging|"Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences."
215109587|NCT03515564|BEHAVIORAL|Dance/Movement Therapy, Art Therapy, Mindful Yoga|Utilizing deep breathing, exercise modalities, and social support in all settings
215109588|NCT05188131|DRUG|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
215109589|NCT05188131|DRUG|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
215109590|NCT05681494|PROCEDURE|Root canal treatment|after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
215109591|NCT05681494|PROCEDURE|Vital pulp therapy|exposed pulp will be capped with 3 mm calcium silicate material
215109592|NCT01340573|DRUG|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
215109593|NCT01340573|DRUG|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of \<65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of \>85 kg received 1200 mg of ribavirin daily.
215109594|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
215109595|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
215109596|NCT01380834|DRUG|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
215109597|NCT01380834|DRUG|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
215109598|NCT01418079|DEVICE|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
215109599|NCT00049712|BIOLOGICAL|etaracizumab|
215109600|NCT04310566|DEVICE|JJVC Investigational Multifocal Contact Lens (senofilcon A c3)|TEST
215109601|NCT04310566|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL
215109602|NCT02657447|DRUG|Betalutin with lilotomab dose 1|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
215109603|NCT02657447|DRUG|Betalutin with lilotomab dose 2|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
215109604|NCT02735954|OTHER|Marijuana|This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
215109605|NCT03801603|BEHAVIORAL|HPV vaccination training and education|1\) Training of providers and clinic staff on the importance of providing a strong HPV vaccination program and 2) HPV vaccination education for parents and the community.
214509967|NCT07097922|DRUG|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops were instilled into the inferior conjunctival vault of both eyes
215109606|NCT06121024|PROCEDURE|Interventional Bronchoscopy|Bronchoscopy offers vital information when evaluating patients suffering from tracheal stenosis. It enables direct visualisation which identifies the lesion, determines its location and extent of airway involvement, highlights vascularity and fragility, allows for tissue diagnosis and enables the operator to assess the extent of mucosal infiltration and airway compression caused by the tumour. The technique facilitates assessment of stenosis diameter for suitable stent selection. In addition to enabling diagnostic bronchoscopy, rigid bronchoscopy offers therapeutic options such as dilatation, cryotherapy and stenting for tracheal stenosis patients. Our clinical setting employs rigid bronchoscopy for interventional procedures with both diagnostic and therapeutic aspects.
215109607|NCT01265303|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
215109608|NCT01711645|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
215109609|NCT01548066|DRUG|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
215109610|NCT01548066|DRUG|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
215109611|NCT04836884|PROCEDURE|Percutaneous Vascular Anomaly/Malformation Biopsy|US-guided percutaneous vascular anomaly core needle biopsy of up to 10 cores using an 18-gauge co-axial core needle biopsy device at the time of clinically indicated sclerotherapy, embolization or ablation treatment.
215109612|NCT03878784|DRUG|Imigran|All patients will undergo this intervention on one of two study days
215109613|NCT03878784|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
215109614|NCT02327494|DRUG|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
215109615|NCT00662116|DRUG|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
215109616|NCT00662116|DRUG|placebo|placebo tablets - two tablets taken twice daily
215109617|NCT05628909|PROCEDURE|PPV with SO tamponade|Patients randomized into silicone oil group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
215109618|NCT05628909|PROCEDURE|PPV with fovea-sparing ILMP and gas tamponade|Patients randomized into gas group 1 were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
215109619|NCT05628909|PROCEDURE|PPV with gas tamponade|Patients randomized into gas group 2 were received pars plana vitrectomy surgery without internal limiting membrane peeling and gas tamponade.
215109620|NCT03332446|OTHER|cold water immersion|10 min at 12-15°C
215109621|NCT02109809|RADIATION|total nodal irradiation|Undergo TLI
215109622|NCT02109809|OTHER|laboratory biomarker analysis|Correlative studies
215109623|NCT02109809|OTHER|questionnaire administration|Ancillary studies
215109624|NCT00637962|BIOLOGICAL|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
215109625|NCT00637962|BIOLOGICAL|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
215109626|NCT02999412|PROCEDURE|Comprehensive medication review|"* A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~* The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature \[4\]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~* Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
215109627|NCT02999412|PROCEDURE|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:~* In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~* A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~* A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
215109628|NCT02999412|PROCEDURE|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
214692195|NCT06442852|OTHER|exposure|The observed exposure factor was the expression level of synaptic associated mirna in the serum of patients with Alzheimer's disease and healthy volunteers
215109629|NCT01616368|BEHAVIORAL|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
215109630|NCT05150717|DRUG|[14C]-Jaktinib|Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.
215109631|NCT01041521|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
215109632|NCT02371408|DRUG|ravidasvir hydrochloride|200 mg
215109633|NCT02371408|DRUG|sofosbuvir|400 mg
215109634|NCT02371408|DRUG|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
215109635|NCT00627133|DRUG|levetiracetam|2 gram iv load, 500mg bid
215109636|NCT05641922|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
214509968|NCT07097922|DRUG|0.1% hyaluronic acid|0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
215109637|NCT01500486|DEVICE|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
215109638|NCT01960517|DEVICE|ACS Catheter|
215109639|NCT06204081|DEVICE|CSO_without cueing|The sole is worn without using the cueing application
215109640|NCT06204081|DEVICE|CSO_cueing|The sole is worn with using the cueing application
215109641|NCT03691662|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
215109642|NCT03691662|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
215109643|NCT02080299|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
215109644|NCT02080299|PROCEDURE|Placebo|Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
215109645|NCT05254249|DRUG|Lactobacillus Plantarum IS-10506|Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
215109646|NCT05254249|OTHER|Placebo|Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets
215109647|NCT01454765|OTHER|generation of stem cells|Collected germ cells will be cultured in medium. The germ cell cultures will be infected with reprograming factors. Rare colonies with characteristic stem cell morphologies will be expanded.
215109648|NCT01746173|DRUG|Cyclophosphamide|
215109649|NCT01746173|DRUG|Doxorubicin|
215109650|NCT01746173|DRUG|Vincristine|
215109651|NCT01746173|DRUG|Etoposide|
215109652|NCT01746173|DRUG|Prednisone|
215109653|NCT01746173|DRUG|Filgrastim|
215109654|NCT01746173|DRUG|Plerixafor|
215109655|NCT01746173|PROCEDURE|Stem Cell Collection|
215109656|NCT01746173|DRUG|Palifermin|
215109657|NCT01746173|DRUG|Gemcitabine|
215109658|NCT01746173|DRUG|Busulfan|
215109659|NCT01746173|DRUG|Melphalan|
215109660|NCT01746173|PROCEDURE|Stem Cell Transplant|
215109661|NCT00147316|DRUG|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
215109662|NCT00538070|DIETARY_SUPPLEMENT|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
215109663|NCT02983864|BEHAVIORAL|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
215109664|NCT02983864|BEHAVIORAL|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
215109665|NCT02983864|BEHAVIORAL|Relaxation|A one session intervention focused on increasing relaxation skills
215109666|NCT02983864|BEHAVIORAL|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
215109667|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
215109668|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
215109669|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
215109670|NCT01540669|DIETARY_SUPPLEMENT|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
215109671|NCT05063682|BIOLOGICAL|EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes|ICV administration
215109672|NCT01964638|PROCEDURE|Targeted Biopsy|
215109673|NCT02177474|BEHAVIORAL|Telephone based peer support|
215109674|NCT04530864|DRUG|Dextenza 0.4Mg Ophthalmic Insert|All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
215109675|NCT00691184|DRUG|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
215109676|NCT00691184|DRUG|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
215109677|NCT00691184|DRUG|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
215109678|NCT00691184|DRUG|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
215109679|NCT05557305|DEVICE|Videogame therapy|There will be 5 video game-type applications for virtual therapy, each with a specific therapeutic objective, which will be administered by trained personnel, depending on the characteristics of each patient.
215109680|NCT05557305|OTHER|Conventional therapy|Occupational therapy with different play materials
215109681|NCT04033783|OTHER|6MWT - accompanied|Assessor walks behind the patient
215109682|NCT04033783|OTHER|6MWT - not accompanied|Assessor does not walk behind the patient
215109683|NCT01601665|DEVICE|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
215109684|NCT01601665|DEVICE|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
215109685|NCT01601665|DEVICE|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
215109686|NCT01601665|DEVICE|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
214509969|NCT07099664|DIAGNOSTIC_TEST|Measurement of aortic Vmax and VTI with suprasternal doppler.|Measurement of aortic Vmax and VTI with suprasternal doppler. Measurement of VTI variation and cardiac output after general anaesthesia. After preoperative fasting compensation, measurement of cardiac output (CO). Search of a difference in the suprasternale VTI variability between the patients who have increased their CO after fasting compensation and the patient who haven't.
214509970|NCT07098481|DRUG|ACCESS+ strategy Epclusa 400/100 Oral Tablet|The ACCESS+ strategy will rely on four components: (1) same-day on-site rapid anti-HCV and HCV RNA testing (rapid diagnostic test and GeneXpert), (2) same-day on-site pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg once daily for 12 weeks), (3) minimal clinical and biological monitoring, and (4) management of patients in non-specialist services by trained general medical doctors and counselors (community health workers, nurses or social workers).
214509971|NCT07098481|DRUG|ACCESS+ Strategy Vosevi 400/100/100 Oral Tablet|The ACCESS+ strategy will rely on four components: (1) same-day on-site rapid anti-HCV and HCV RNA testing (rapid diagnostic test and GeneXpert), (2) same-day on-site pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100mg) once daily for 12 weeks, (3) minimal clinical and biological monitoring, and (4) management of patients in non-specialist services by trained general medical doctors and counselors (community health workers, nurses or social workers).
214692196|NCT02768649|DRUG|RBP-7000|Sequential dosing of each cohort
215109687|NCT01601665|DEVICE|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
215109688|NCT02646813|PROCEDURE|Intraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed intraluminally
215109689|NCT02646813|PROCEDURE|Extraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed extraluminally
215109690|NCT00567411|DRUG|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
215109691|NCT00567411|DRUG|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
215109692|NCT00268970|DRUG|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
215109693|NCT01658761|PROCEDURE|vitrectomy|Surgery
215109694|NCT05688332|DRUG|Voglibose + Metformin|"In treatment group B, 59 participants will also be randomly assigned to the voglibose 0.2/0.3mg TDS + metformin 500mg BD treatment combination to be taken orally daily, during or immediately after meals with dose titration at day 6 and 12 if the average fasting blood glucose (FBG) level is ≥7 mmol/L (126 mg/dL) and then dosage will be maintained for the remainder of the treatment period Participants in the intervention group initially receiving voglibose 0.2mg + metformin 500mg BD will be dose-titrated to voglibose 0.3mg +metformin 1g BD.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint."
215109695|NCT05688332|DRUG|Glibenclamide + Metformin|"The drugs (glibenclamide + metformin), in the control or comparator group will also be taken orally, glibenclamide once a day (OD) before meals, and metformin twice a day (BD) also before meals. These drugs will also be taken with a dose-titration at days 6 and 12 if the average is FBG level will be ≥ 7 mmol/L and the dose will be maintained for the remainder of the study period.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint. In this group, participants will initially receive glibenclamide 5mg once daily (OD) + metformin 500mg BD then will be dose-titrated to glibenclamide 10mg OD + metformin 1g BD."
215109696|NCT01748721|BIOLOGICAL|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
215109697|NCT01748721|OTHER|pharmacological study|Correlative studies
215109698|NCT01748721|OTHER|laboratory biomarker analysis|Optional correlative studies
215109699|NCT00982839|PROCEDURE|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
215109700|NCT00982839|PROCEDURE|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
215109701|NCT02400021|DRUG|Prometrium|
215109702|NCT01600937|BEHAVIORAL|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
215109703|NCT01770015|PROCEDURE|biological sampling|cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
215109704|NCT01770015|PROCEDURE|sampling blood|HLA DR antigen, cytokines (IL 6 and 10), B-glucan
215109705|NCT01770015|PROCEDURE|endotracheal aspiration|fungi and bacteria endotracheal aspiration
215109706|NCT02956941|BEHAVIORAL|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
215109707|NCT00658463|DRUG|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
215109708|NCT00658463|DRUG|Placebo|Placebo
215109709|NCT01500902|OTHER|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
215109710|NCT01500902|OTHER|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
215109711|NCT01771250|BIOLOGICAL|Insulin Peglispro|Daily doses administered SC.
215109712|NCT01771250|BIOLOGICAL|Insulin Glargine|Daily doses administered SC.
215109713|NCT03778450|DRUG|Analgesics, Opioid|"Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients."
215109714|NCT03778450|DRUG|Non-Opioid Analgesic|Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
215109715|NCT04674657|DRUG|blood drug concentration|blood drug concentration
215109716|NCT02451462|DRUG|Zoledronic acid|
215109717|NCT00307203|DRUG|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
214509972|NCT07098481|DRUG|Standard Strategy Vosevi 400/100/100 Oral Tablet|In the standard strategy based on routine medical practice in Cameroon, anti-HCV positive participants will be referred to and managed by gastroenterologists who will initiate pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100mg) once daily for 12 weeks, and the patients' management will be closer. However, the process for screening and treatment initiation will be longer.
214509973|NCT07098481|DRUG|Standard Strategy Epclusa 400/100 Oral Tablet|In the standard strategy based on routine medical practice in Cameroon, anti-HCV positive participants will be referred to and managed by gastroenterologists who will initiate pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg) once daily for 12 weeks, and the patients' management will be closer. However, the process for screening and treatment initiation will be longer.
214509974|NCT07098728|DRUG|Levetiracetam IV|Leveget injection 500mg/5ml
214509975|NCT07098728|DRUG|Phenobarbital|Phenobarbital injection 200mg/ml (BPI Insein)
214509976|NCT07099378|OTHER|Saliva and Serum|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.
214509977|NCT07099378|OTHER|Saliva and Serum|ELISA method will be used to measure TNF-α values in collected saliva and serum samples.RT-qPCR based miRNA gene expression analyses will be performed with 2-step qRT-PCR Kits (Thermofisher Scientific, MA, USA).
214509978|NCT07098026|DRUG|Shenqi Fuwei Mixture|Shenqi Fuwei Mixture
214509979|NCT07098026|DRUG|Shenqi Fuwei Mixture Placebo|Shenqi Fuwei Mixture Placebo
214509980|NCT05523505|DEVICE|Sham intervention|Use of the non-invasive brain stimulation device to simulate peripheral experience of stimulation without actually stimulating the brain.
214509981|NCT05523505|DEVICE|RLN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left angular gyrus using transcranial alternating current stimulation (tACS).
214509982|NCT05523505|DEVICE|RLN and CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left dorsolateral prefrontal cortex and left angular gyrus using transcranial alternating current stimulation (tACS).
214509983|NCT04094675|DRUG|Sirolimus|Use of sirolimus 2 mg by mouth daily for 1 year
215109718|NCT00307203|BEHAVIORAL|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
215109719|NCT00307203|DRUG|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
215109720|NCT02925624|PROCEDURE|Pulmonary vein isolation|
215109721|NCT05026203|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days
215109722|NCT05026203|DRUG|Midazolam|Midazolam
215109723|NCT03006874|DRUG|CJ-12420 100mg QD|CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
215109724|NCT03006874|DRUG|Esomeprazole 40mg|Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
215109725|NCT03006874|DRUG|CJ-12420 50mg QD|CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
215109726|NCT03111329|OTHER|No aspiration of gastric residuals|No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
215109727|NCT05360745|DIETARY_SUPPLEMENT|ARACOMPLEX®|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
215109728|NCT05360745|DIETARY_SUPPLEMENT|placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
215109729|NCT05777512|PROCEDURE|Gastric Feeds|The participant will receive nutrition via a nasogastric tube. Gastric feedings will be administered as bolus feeds every 3 hours over 1 hour. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
215109730|NCT05777512|PROCEDURE|Jejunal Feeds|The participant will receive nutrition via a nasojejunal tube. Postpyloric feedings will be administered continuously into the jejunum. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
214692197|NCT02768649|DRUG|risperidone|All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
214692198|NCT02277899|OTHER|Communication regarding overweight status|Pediatrician-patient/parent communication regarding child's high weight status
214692199|NCT02277899|OTHER|Risk-factor assessment and counseling|Counseling regarding cardiovascular risk factor assessments/results.
214692200|NCT02277899|OTHER|Lifestyle behavior assessment and counseling|Counseling regarding diet and lifestyle changes to improve weight status.
215109731|NCT04591444|DRUG|Fluoride Varnish|Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.
215109732|NCT04591444|DRUG|Glass Ionomer Sealant|Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
215109733|NCT04591444|OTHER|Placebo Group|4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.
215109734|NCT02110264|DRUG|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
215109735|NCT02110264|BEHAVIORAL|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
215109736|NCT02110264|BEHAVIORAL|ETAU|Participants assigned to the ETAU group will receive drug education.
215109737|NCT03940118|DEVICE|Catheter secretion suctioning|Catheter secretion suctioning with prior nebulization of hypertonic saline
215109738|NCT03940118|COMBINATION_PRODUCT|Secretion suctioning + hypertonic saline|Catheter secretion suctioning with prior nebulization of hypertonic saline
215109739|NCT03940118|DEVICE|Ins-exsufflation|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
215109740|NCT03940118|COMBINATION_PRODUCT|Ins-exsufflation + Hypertonic saline|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
215109741|NCT03970291|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
215109742|NCT01907425|OTHER|Blood samples|
215109743|NCT00376857|DRUG|Surgery with and without the aid of Indocyanine Green (ICG)|
215109744|NCT00958646|OTHER|Osteopathic Manipulation|Standardized rib raising protocol
215109745|NCT00958646|OTHER|Placebo|Light touch control procedure
215109746|NCT01359501|DRUG|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
215109747|NCT01359501|DRUG|Placebo|Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
215109748|NCT05476029|DIAGNOSTIC_TEST|Blood samples and alveolar lavage fluid were collected|Blood samples and alveolar lavage fluid were collected for exosome sorting and identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
215109749|NCT01665391|DRUG|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
215109750|NCT01665391|DRUG|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
215109751|NCT01665391|DRUG|Placebo|Placebo administered to match active treatment group
215109752|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
215109753|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
215109754|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
215109755|NCT01545440|DRUG|placebo|subcutaneous dose every 4 weeks
215109756|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (2 times/week)|IVES sessions were performed two times in a week, for 10 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback.
215109757|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (5 times/week)|IVES performed in the same way as Group 1, except for frequency of treatment. IVES sessions were performed five times in a week, for 4 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. Stimulation parameters were the same as Group 1.
215109758|NCT01737216|DRUG|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
215109759|NCT01737216|DRUG|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
215109760|NCT05665803|PROCEDURE|Pediatric rotary files|Mechanical preparation of primary tooth canals with pediatric rotary files
215109761|NCT05665803|PROCEDURE|Manual flare files|Mechanical preparation of primary tooth canals with manual flare files
215109762|NCT04241406|DEVICE|Transcutaneous spinal cord stimulation|Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequentl
215109763|NCT02518633|DEVICE|Continuous positive airway pressure devices|overnight use of CPAP device
215109764|NCT00544037|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
215109765|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrolyte and quality of recovery of the patients
215109766|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1.0 μg/kg, maintenance dose with 0.25 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patient
215109767|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patients
215109768|NCT04771637|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
215109769|NCT00523081|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
215109770|NCT00523081|BEHAVIORAL|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
215109771|NCT03458156|BIOLOGICAL|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
215109772|NCT03458156|BIOLOGICAL|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
215109773|NCT03458156|OTHER|the control group|The patients will be assigned to the control group.
215109774|NCT02975674|DEVICE|MT-12 dental implant|Placement of the MT-12 dental implant with Morse taper implant-abutment connection
215109775|NCT02975674|DEVICE|CON.INT dental implant|Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
215109776|NCT04703491|BEHAVIORAL|Interactive and full-featured intervention|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements. They will play games based on Cognitive Bias Modification (CBM) paradigms, practice mindfulness, and chat with an automated empathic chatbot.
215109777|NCT04703491|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features
215109778|NCT04703491|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
215109779|NCT01629758|BIOLOGICAL|Denenicokin|
215109780|NCT01629758|BIOLOGICAL|Nivolumab|
215109781|NCT00306540|DRUG|Quetiapine Fumarate|oral flexible dose
215109782|NCT00306540|DRUG|quetiapine fumarate placebo|oral 0 mg
215109783|NCT00446173|DRUG|Busulfan|130 mg/m\^2 IV Daily Over 3 Hours x 4 Days
215109784|NCT00446173|DRUG|Cyclophosphamide|60 mg/kg IV Daily Over 4 Hours x 2 Days
215109785|NCT00446173|DRUG|G-CSF|10 mcg/kg Subcutaneously Once Daily
215109786|NCT00446173|DRUG|GM-CSF|250 mcg/kg Subcutaneously Once Daily
215109787|NCT04560387|BEHAVIORAL|Physician-lead complex program of weight-reducing interventions|A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.
215109788|NCT04560387|PROCEDURE|Bariatric surgery - sleeve gastrectomy|Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
215109789|NCT04839549|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
215109790|NCT04839549|DRUG|Fluoromethalone .01%|Fluoromethalone .01%
215109791|NCT04994548|PROCEDURE|Endosocpic resection of early esophageal tumor|under general anesthesia, by mucosectomy or endoscopic submucosal dissection
215109792|NCT01894438|BEHAVIORAL|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
215109793|NCT01894438|BEHAVIORAL|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
215109794|NCT03806608|PROCEDURE|Crestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
215109795|NCT03806608|PROCEDURE|Subcrestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
215109796|NCT03294850|PROCEDURE|Bariatric surgery|Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied
214692201|NCT02277899|OTHER|Interval follow-up to readdress weight|Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.
215109797|NCT03294850|DEVICE|HepQuant SHUNT Dual Cholate Liver Diagnostic Kit|For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.
215109798|NCT01153724|DRUG|BI 1744|10 mcg solution for oral inhalation
215109799|NCT01153724|DRUG|Fluconazole|400 mg capsule
215109800|NCT01605110|DRUG|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
215109801|NCT01605110|DRUG|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
215109802|NCT05750550|OTHER|Instrument Assisted Soft Tissue Mobilization|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
215109803|NCT04223908|OTHER|observational : questionnaries for assessment of health burden|The French IN-FOCUS study was designed to capture current and retrospective data in FCS or MCS. Patients were called by the participating centers and were proposed to answer a paper questionnaire or to connect to a web-based questionnaire The questionnaire was divided into sections specifically assessing various domains of their experience: demographic data, signs, symptoms and complications of the disease, healthcare circuit, management, relationship with healthcare providers, and burden of the disease on daily life. (Details are available as supplementary material S1). The questionnaire focused on symptoms because the interest of quality of life assessment tools is debated in rare diseases with episodic manifestations. Indeed, most of these tools refer to a limited recall period.
215109804|NCT02731443|PROCEDURE|Epilepsy surgery|Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
215109805|NCT02731443|PROCEDURE|Depth electrodes insertion|Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
215109806|NCT04314674|DRUG|%3 HS bolus|After head fixation %3 HS bolus 3 ml/kg will be administered
215109807|NCT04314674|DRUG|%3 HS infusion 20 ml/h|After head fixation %3 HS 20 ml/h infusion will be administered
215109808|NCT04314674|DRUG|20% mannitol|After head fixation %20 mannitol 0.6 ml/kg will be administered
215109809|NCT01351155|DEVICE|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
215109810|NCT03295617|PROCEDURE|Thoracoscopy|Thoracoscopy surgery
215109811|NCT02619643|DEVICE|Transcranial Magnetic Stimulation (Magstim)|
215109812|NCT03850535|DRUG|Idasanutlin|Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
215109813|NCT03850535|DRUG|Cytarabine|Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m\^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m\^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
215109814|NCT03850535|DRUG|Daunorubicin|Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m\^2 QD as IV infusion.
215109815|NCT03850535|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)|After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
215109816|NCT01824433|DRUG|venlafaxine|venlafaxine 75-225mg qd
215109817|NCT01824433|DRUG|fluoxetine|fluoxetine 20-60mg qd
215109818|NCT02491606|DRUG|Tafenoquine|Tafenoquine 200mg and 400 mg
215109819|NCT02491606|OTHER|Placebo|Placebo
215109820|NCT01438606|BIOLOGICAL|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
214424732|NCT03280836|BEHAVIORAL|Exercise|"All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.~The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max."
215109821|NCT01438606|BIOLOGICAL|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
215109822|NCT00003864|DRUG|carboplatin|
214424733|NCT03522467|DRUG|MRCP001|MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
215109823|NCT00003864|DRUG|docetaxel|
215109824|NCT01742806|DEVICE|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
215109825|NCT03154749|DRUG|DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)|All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
215109826|NCT02547558|PROCEDURE|Arterial blood gases|Measured through radial arterial catheter
215109827|NCT02547558|PROCEDURE|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
215109828|NCT02547558|PROCEDURE|Vital signs|As measured in clinical practice
215109829|NCT02547558|PROCEDURE|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
215109830|NCT02547558|PROCEDURE|Spirometry|In a daily calibrated spirometer.
215109831|NCT02547558|DRUG|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
215109832|NCT01555333|DRUG|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
215109833|NCT00470925|DRUG|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
215109834|NCT05599243|DRUG|Dutasteride|The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).
215109835|NCT05599243|OTHER|Placebo|Vehicle excipient
215109836|NCT05409898|DEVICE|smart wearable device|screening masked hypertension with smart wearable devices
215109837|NCT00364143|DRUG|IHL-305 (irinotecan liposome injection)|
214424734|NCT01301196|BEHAVIORAL|Educational workshop|3h attendance at educational workshop plus self-monitoring
215109838|NCT04757545|OTHER|HM-PRO|"The intervention group will have a predetermined consultation appointment planned to assess medical status and symptom control. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients:~1. Worsening in symptoms results in a nurse-led telephone consultation within two days guided by the symptom management manual.~2. Minor changes in patient's symptom assessment result in a nurse-led telephone consultation within seven days using the symptom management manual.~3. Patients that are completely stable in the symptom assessment will receive an electronic answer via min-SP (electronic patient journal) regarding the results and a new appointment, including PRO-data prior to this."
215109839|NCT00870545|BEHAVIORAL|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
215109840|NCT01217372|DIETARY_SUPPLEMENT|Lemon supplementation|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
215109841|NCT00344422|DRUG|Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)|
215109842|NCT04248088|BEHAVIORAL|Gentle Stretching and Education|60 minutes of gentle stretching twice weekly for 6 months
215109843|NCT00242099|PROCEDURE|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
215109844|NCT03701919|DRUG|Botulinum toxin pyloroplasty|Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
215109845|NCT03701919|DRUG|Normal saline pyloric injection|Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
215109846|NCT04230213|DRUG|PF-06410293|SC injection
215109847|NCT04230213|DRUG|adalimumab|SC injection
215109848|NCT01160913|PROCEDURE|Continuous wound infusion|
215109849|NCT01160913|PROCEDURE|Continuous wound|
215109850|NCT03162237|OTHER|Porcine islets|"Porcine islets: 10000IEQ/Kg;~Tacrolimus: 0.087mg/kg, Bid;~mycophemo-latemofetil (MMF): 1g x 2/d;~NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg"
215109851|NCT03162237|OTHER|Autologous Treg|Autologous Treg: 2x10\^6/Kg
215109852|NCT00524472|OTHER|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
215109853|NCT00524472|OTHER|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
215109854|NCT02860572|OTHER|follow-up without intervention|
215109855|NCT02860572|OTHER|fluid bolus|
215109856|NCT02508428|DEVICE|Hip Replacement with crosslinked Marathon polyethylene|Comparison of Marathon and Enduron polyethylene
215109857|NCT02508428|DEVICE|Hip Replacement with noncrosslinked Enduron polyethylene|
215109858|NCT02178696|OTHER|Placebo, identified as placebo to participants|White tablets
215109859|NCT02178696|DRUG|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
215109860|NCT02178696|OTHER|"Placebo, identifed to participants as Active medication"|Blue Capsule
215109861|NCT01394913|DRUG|Reumatocept (etanercept)|50mg each week for 30 weeks
214424735|NCT03993613|BIOLOGICAL|human apotransferrin|Intravenous infusions
215109862|NCT01394913|DRUG|Enbrel (etanercept)|50mg each week for 30 weeks
215109863|NCT04833296|DRUG|Ropivacaine|all patients will receive interscalene block using same volume of ropivacaine but in different concentrations
215109864|NCT02430116|PROCEDURE|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
215109865|NCT00209300|DRUG|Pentasa|
215109866|NCT04554771|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation
215109867|NCT04554771|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29
215109868|NCT04554771|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29
215109869|NCT04554771|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy
215109870|NCT02210975|DEVICE|LES-Stimulation Device|
215109871|NCT00216216|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
215109872|NCT04230824|DIETARY_SUPPLEMENT|Pre-workout plus and Protein recovery plus|products consumed prior and after exercise
215109873|NCT04230824|OTHER|Placebo|placebo product consumed prior and after exercise
215109874|NCT04230824|OTHER|6-week resistance training program|participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)
215109875|NCT02859441|DRUG|Ranibizumab|Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5) with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 microliter, which correlates to 0.5 mg of dry ranibizumab.
215109876|NCT02859441|DRUG|E10030|E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
215109877|NCT05426941|BEHAVIORAL|Music Imagery|Up to 30 participants will be randomized to receive 8 weekly Music Imagery sessions over 8-12 weeks.
215109878|NCT05426941|BEHAVIORAL|Music Listening|Up to 15 participants will be randomized to independent music listening.
215109879|NCT03842241|DEVICE|Non-custom made foot orthoses|Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
215109880|NCT04883034|PROCEDURE|adductor canal block in outpatient clinic|perform adductor canal block in outpatient clinic for patient post total knee arthroplasty
215109881|NCT04883034|DRUG|Analgesics, etoricoxibe|anaelgetic oral intake
215109882|NCT02748070|DRUG|Prednisone|
215109883|NCT02748070|DRUG|Flonase|
215109884|NCT04031989|DEVICE|CorVista Capture|The CorVista System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms developed by CorVista Health. Data collected with the CorVista System during this study will not be used to guide treatment.
215109885|NCT02785068|DRUG|MM-151|Oligoclonal antibody
215109886|NCT02785068|DRUG|nal-IRI|Nanoliposomal irinotecan
214424736|NCT01681251|OTHER|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|"Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV."
214424737|NCT01681251|OTHER|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
214424738|NCT04893213|OTHER|Manipulation of availability of lower energy meal options|Menus provided differ in % of menu options that are higher vs. lower in energy
214424739|NCT02537704|BEHAVIORAL|Group Lifestyle Balance Program|
214424740|NCT00477776|DRUG|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
214424741|NCT00477776|DRUG|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
214424742|NCT04177017|BEHAVIORAL|Mindfulness-based intervention|"The behavioral intervention was carried out once a week during 60 minutes from May to November, and included mindfulness-based practices sought to foster self-awareness, and dyadic activities sought to awakening subtle perception of the other.~Group activities, which entailed more than two participants, were also conducted to foster empathic collaboration and prosocialness. Diverse collaborative games were carried out in which mutual help was needed for achieving shared goals in an amusing way .~Perspective-taking was encouraged within the group, by sharing each participant's experience, which included expressing how each child had felt (i.e., if neglected, ignored or cared for) and whether they had enjoyed helping their peers or no."
214424743|NCT04852432|DEVICE|high flow nasal cannula|The heated air is administered at a rate of 2L/kg/min using an Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand). Inhalation oxygen concentration starts with 50%.
214424744|NCT04852432|DEVICE|nasal prong|Oxygen is administered via nasal prong
215109887|NCT02785068|DRUG|Leucovorin|folinic acid
215109888|NCT02785068|DRUG|5-FU|Chemotherapy
215109889|NCT00928694|DRUG|fenofibrate (U.S. formulation)|Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.
215109890|NCT00928694|DRUG|fenofibrate (UK formulation)|Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
215109891|NCT01315444|DRUG|Stop PPI gradually|
215109892|NCT01315444|DRUG|Stop PPI gradually|
215109893|NCT01580202|DRUG|Entecavir|Entecavir 0.5mg daily per os
215109894|NCT01580202|DRUG|Lamivudine|lamivudine 100mg daily per os
215109895|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
215109896|NCT02215304|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
215109897|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
215109898|NCT02215304|DIETARY_SUPPLEMENT|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
215109899|NCT00534976|DRUG|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily"
215109900|NCT00534976|DRUG|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily"
215109901|NCT03799939|DEVICE|Intervention group|Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.
215109902|NCT00861471|DRUG|Docetaxel|"One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days."
215109903|NCT00861471|DRUG|Imatinib Mesylate|"One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."
215109904|NCT03981627|DRUG|ADO09 formulation|Subcutaneous injection of ADO09 formulation
215109905|NCT03981627|DRUG|NovoRapid®|Subcutaneous injection of insulin aspart
215109906|NCT04364152|BEHAVIORAL|Dual-task walking training|Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
215109907|NCT00724633|OTHER|Lowering the dialysate sodium|Please see above
215109908|NCT01281033|PROCEDURE|Manual Thrombectomy|In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.
215109909|NCT01281033|PROCEDURE|AngioJet Rheolytic Thrombectomy (RT) System|The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.
215109910|NCT05972746|DEVICE|Telemonitoring with electronic alerts|Patients assigned to this group will receive standard care plus a telemonitoring program.
215109911|NCT05972746|OTHER|Standard of care|Standard of care
215109912|NCT06183073|PROCEDURE|caudal block|bupivacaine 0.25% in a dose of (1 ml / kg)
215109913|NCT06183073|DRUG|Dexmedetomidine|dexmedetomidine 1μg/ kg.
214424745|NCT03178110|BEHAVIORAL|Physical therapy and dynasplint|Participants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased.
214424746|NCT04820439|DRUG|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|A single intravenous infusion of HS627 420mg
214424747|NCT04820439|DRUG|Perjeta ®|A single intravenous infusion of Perjeta ®420mg
215109914|NCT06183073|PROCEDURE|TAP|analgesia
215109915|NCT06183073|DRUG|Bupivacain|bupivacaine 0.25% in a dose of (0.5 ml / kg
215109916|NCT05793242|DEVICE|Hypervolt|HyperVolt Percussive Massage Device: this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a vibrating device to the back of the thigh with moderate pressure while continuously moving the device for 5 minutes.
215109917|NCT05793242|DEVICE|Body Tempering|Body Tempering:this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a moderately heavy metal device to the back of the thigh while continuously moving the device for 5 minutes.
215109918|NCT05793242|DEVICE|Dry cupping|Dry Cupping: This will be performed by a physical therapist while the participant is prone. The physical therapist will apply several negative pressure devices to the back of your thigh for 5 minutes.
215109919|NCT05793242|OTHER|Static stretching|Participants will perform a static stretch on their lower extremity. This stretch will be performed by having the participant loop a strap around their heel and grasping it with both hands followed by pulling the strap to raise the fully extended leg into hip flexion. The participant will be instructed to lift the leg until they reach their maximal tolerable point and then to hold the position for 30 seconds. They will then lower the extremity to the table and rest for 15 seconds This self-stretch sequence will be performed for 7 cycles so that the total intervention was equal to the intervention time of the other group (5 minutes).7
215109920|NCT03422965|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography images capture.
215109921|NCT03422965|DIAGNOSTIC_TEST|Blood test|Blood test, systemic markers
215109922|NCT03422965|DIAGNOSTIC_TEST|Urine test|Urine test, systemic markers
215109923|NCT03797456|DRUG|ICP-022|ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
215109924|NCT02929238|OTHER|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
215109925|NCT02929238|OTHER|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
215109926|NCT02834247|DRUG|TAK-659|TAK-659 Tablets.
215109927|NCT02834247|DRUG|Nivolumab|Nivolumab intravenous infusion.
215109928|NCT01103388|DRUG|Rituximab|375 mg/m\^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
215109929|NCT03987516|OTHER|Active exercising|Patients allocated to the experimental group were included in an active exercising program adapted to each patient
215109930|NCT03475485|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
215109931|NCT03475485|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
215109932|NCT03475485|DEVICE|Placebo|A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
215109933|NCT06196606|DRUG|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
215109934|NCT03487744|OTHER|Osmolite 1.5|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
214509984|NCT06936280|BEHAVIORAL|ACTnow|"The group-based psychological intervention consists of six bi-weekly sessions, each lasting two hours, with 6-10 participants per group, led by a psychologist and nurse.~The intervention is based on Acceptance and Commitment Therapy (ACT), an evidence-based approach shown to be effective for chronic diseases, with additional elements from cognitive behavioral therapy and health education. It is manual-based, developed by experienced clinicians at SDCO, and includes tools from an existing diabetes distress intervention (REDUCE).~Each session includes a mindfulness exercise, a review of the previous session, a new topic, individual homework assignments, and a conclusion. Participants complete an online questionnaire to track diabetes distress after each session. The group process lasts about 3 months. Preliminary results from a feasibility study showed positive outcomes in recruitment, patient satisfaction, and reduction of diabetes distress (publication in progress)."
214509985|NCT06941792|DRUG|inclisiran sodium injection|After randomization, patients in the inclisiran group will receive inclisiran sodium injection
215109935|NCT03487744|OTHER|Promote without fiber|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
215109936|NCT01354717|DRUG|Brand Carac|treatment of actinic keratosis
215109937|NCT01354717|DRUG|Generic 0.5% 5-fluorouracil cream|treatment of actinic keratosis
215109938|NCT01354717|OTHER|Placebo cream|treatment of actinic keratosis
215109939|NCT00439296|DRUG|ABT-751|"Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest."
215109940|NCT00439296|DRUG|Dexamethasone|"In Treatment Course 1 only:~* 10 mg/m2/day divided BID.~* Take dexamethasone by mouth days 1-14."
214509986|NCT06941792|COMBINATION_PRODUCT|Standard of Care|After randomization switching to or adding on another/other lipid-lowering therapies
215109941|NCT00439296|DRUG|PEG-asparaginase|"In Treatment Course 1:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on day 15."
215109942|NCT00439296|DRUG|Doxorubicin|"In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1."
215109943|NCT00439296|DRUG|Cytarabine|"* Given Intrathecally on day 1 of course 1 at the dose defined by age below.~  * 30 mg for patients age 1-1.99~ * 50 mg for patients age 2-2.99~ * 70 mg for patients \>3 years of age~* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12."
215109944|NCT00439296|DRUG|Methotrexate|"In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose"
215109945|NCT00439296|DRUG|Cyclophosphamide|Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
214509987|NCT03976323|BIOLOGICAL|Pembrolizumab|IV infusion
214509988|NCT03976323|DRUG|Pemetrexed|IV infusion
214509989|NCT03976323|DRUG|Carboplatin|IV infusion
214509990|NCT03976323|DRUG|Cisplatin|IV infusion
214509991|NCT03976323|DRUG|Olaparib|Oral Tablet
215109946|NCT00439296|DRUG|6-thioguanine|Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
215109953|NCT05111249|DRUG|Branaplam|messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.
215109954|NCT05111249|DRUG|Placebo|Matching placebo oral solution once weekly
215109955|NCT02378688|DRUG|MT-1303|
215109956|NCT02378688|DRUG|Placebo|
215109957|NCT05128578|BEHAVIORAL|Liver Education About Pain (LEAP)|LEAP is a modular 12-week pain self-management intervention with 6 individual sessions and 6 optional group sessions. Individual sessions serve the purpose of individualizing the program to the needs of the patients. Group sessions allow participants to practice skills, set goals with the group, seek social support, and learn together. The purpose of the LEAP program is to make pain better, help patients reach their personal goals (things that may be hard to do because of pain), and add to the care patients' medical team is providing.
215109958|NCT05128578|BEHAVIORAL|Usual Care|"Patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions."
215109959|NCT05725083|PROCEDURE|Lower thoracic epidural|before induction of anesthesia,first the investigators identify the correct targeted thoracic level. All epidural block will be performed under all aseptic precautions with a 17-gauge Tuohy needle and 19 G flex-tip catheters. Using the loss of resistance to saline technique, catheter will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection. Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the epidural catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15ml/h .for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1 mg bolus , 10 min lockout period . The catheter will be removed under complete aseptic precautions after 48 hrs.
215109960|NCT05725083|PROCEDURE|Erector spinae plane block|before induction of anasthesia ,highfrequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle.confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.Then the catheter placement 5cm into the space under the erector spinae muscle and suitable test dose will be administered . Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h , for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1mg bolus,10 min lockout period.The catheter will be removed under complete aseptic precautions after 48 hrs.
215109961|NCT03965741|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Follow clinical administration
215109962|NCT03965741|DRUG|Apixaban(Eliquis)|Follow clinical administration
215109963|NCT03965741|DRUG|Pradaxa (Dabigatran etexilate)|Follow clinical administration
215109964|NCT03009422|DRUG|Local application pentostam|
215109965|NCT03009422|DRUG|intra-lisional pentostam|
215109966|NCT03009422|DEVICE|fractional CO2 laser|
215109967|NCT06274047|DRUG|Apalutamide|Given by PO
215109968|NCT06274047|DRUG|Androgen Deprivation Therapy|Given by PO
215109969|NCT05078398|BEHAVIORAL|POINT Protocol|Patients will receive counseling on risks and benefits of opioids for pain control, asked to choose whether they need opioid prescription when ready for discharge.
215109970|NCT05078398|BEHAVIORAL|Usual care|Will prescribe standardized amount of opioid for postoperative pain without patient input
214424748|NCT05942963|DRUG|Empagliflozin 10 MG|10-25 mg/day
215109971|NCT02031263|PROCEDURE|bronchial thermoplasty system|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
215109972|NCT02124694|BEHAVIORAL|HTUG|HTUG is a group psychotherapy...
215109973|NCT00910780|DRUG|Aripiprazole|via oral tablets, everyday
215109974|NCT00910780|DRUG|Zyprexa|via oral tablets, taken once daily
215109975|NCT00910780|DRUG|Risperdal|via oral tablets, taken once daily
214424749|NCT05942963|DRUG|Pioglitazone 15mg|15-45 mg/day
215109976|NCT05701020|OTHER|questionnary|If agreeing to the protocol, ; patients will answered questions about sexual health during the gynecologic consultation
215109977|NCT03004911|DEVICE|ProFibro (Mobile application)|ProFibro, a mobile Android application in Brazilian Portuguese to promote self-care in patients with fibromyalgia
215109978|NCT03004911|DEVICE|Paper booklet|A 64-page booklet with content similar to the mobile application
215109979|NCT04911894|DRUG|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
215109980|NCT02638324|PROCEDURE|Renal nervous denervation|The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
215109981|NCT03152695|DEVICE|High-intensity focused ultrasound|Local tumor ablation by ArcBlate (EpiSonica, Taiwan) will be performed, and the entire procedure will be monitored by MRI
215109982|NCT00154440|DRUG|proton pump inhibitor|
215109983|NCT00154440|DRUG|clarithromycin|
215109984|NCT00154440|DRUG|amoxicillin|
215109985|NCT00154440|DRUG|metronidazole|
215109986|NCT00154440|PROCEDURE|radiation therapy|
214424750|NCT05942963|DRUG|Metformin|1000mg-2850mg/ day
214424751|NCT06176924|DEVICE|tDCS|tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.
214424752|NCT06176924|OTHER|Relaxation technique|Relaxation technique
214424753|NCT00566904|DRUG|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
214424754|NCT00566904|DRUG|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
215109987|NCT01016600|DRUG|Lenalidomide|
215109988|NCT01016600|DRUG|Azacitidine|
215109989|NCT04769570|PROCEDURE|interscalene brachial plexus block|Single shot ultrasound guided interscalene brachial plexus block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
215109990|NCT04769570|PROCEDURE|suprascapular nerve block|Single shot ultrasound guided interscalene brachial plexus block and Suprascapular nerve block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
215109991|NCT04769570|PROCEDURE|Group Control|consist of the patient group without any procedure.
215109992|NCT02679755|DRUG|Palbociclib|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
215109993|NCT02679755|DRUG|Letrozole|2.5 mg/d tablets orally on a continuous regimen
215109994|NCT04755608|OTHER|Low Intensity Exercises with Blood Flow Restriction|In the exercise protocol, people exercised resistance between 20% and 30% of 1 MaxRepetition with free weight. In addition, blood flow was restricted in 70% of the arterial occlusion pressure of the individual with the help of a cuff during exercise.
215109995|NCT04755608|OTHER|High Intensity Resistant Exercise|People included in the study did resistance exercise with free weight at 70-80% of 1 MT.
215109996|NCT03779659|DEVICE|Synapse TENS device|At the time of local anesthetic application the TENS device will be activated and placed on the buccal and lingual alveolar mucosa adjacent to the tooth receiving the restorative treatment using the pad applicator. The tip of the device with the electrodes are placed in a vertical up and down motion for approximately ten seconds. Following this, the level of pain and anxiety are measured using the Wong Baker Scale and Visual Analog Scale. The TENS device is used for achieving localized pain relief at the site of local anesthetic injection prior to injecting the anesthetic agent (such as lidocaine or articaine). Following this, once the clinician ensures that the patient is pain free then local anesthetic injection is given and following that the dental procedures are conducted.
215109997|NCT03779659|DRUG|Topical anesthetic gel|"The local anesthetic gel is typically used for achieving localized pain relief at the site of local anesthetic injection and this is part of standard care that is followed prior to dental procedures.~The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure"
214424755|NCT00566904|OTHER|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
215109998|NCT03245125|BEHAVIORAL|High-intensity interval training|Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.
215109999|NCT00725049|DEVICE|Dental Implant (Nanotite)|Root form titanium dental implant
215110000|NCT02451917|DRUG|Glargine insulin|The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained
215110001|NCT02451917|DRUG|NPH insulin|The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
215110002|NCT00493259|BEHAVIORAL|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
215110003|NCT00493259|BEHAVIORAL|Depression Scale for Children (CES-DC)|questionnaire
215110004|NCT01460134|DRUG|CDX-1127|"Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127."
215110005|NCT01460134|DRUG|CDX-1127|"Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
215110006|NCT01460134|DRUG|CDX-1127|"Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
215110007|NCT05474573|DEVICE|Combined ultrasound and fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope and performing sonography
215110008|NCT05474573|DEVICE|Fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
215110009|NCT02324283|DRUG|desflurane|"Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia."
215110010|NCT02324283|DRUG|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
215110011|NCT01316874|DRUG|Valrubicin, 800 mg|Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
215110012|NCT02432586|BEHAVIORAL|Intensive Education|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
215110013|NCT06384157|DRUG|INDV-2000|INDV-2000 is a highly potent and selective OX1R antagonist that is being developed as a therapy for the treatment of OUD.
215110014|NCT06384157|OTHER|Placebo|This is a randomized, double-blind, placebo-controlled study.
215110015|NCT02300259|DRUG|LY2623091|Administered orally
215110016|NCT02300259|DRUG|Itraconazole|Administered orally
215110017|NCT02300259|DRUG|Simvastatin|Administered orally
215110018|NCT02300259|DRUG|Tadalafil|Administered orally
215110019|NCT02300259|DRUG|Diltiazem|Administered orally
215110020|NCT03951272|DEVICE|Lyoplant® Onlay/DURAFORM™ Dural Graft Implant|Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
215110021|NCT04737278|DRUG|Cunermuspir|"Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:~Organic evaporated cane juice powder, hypromellose, titanium dioxide"
215110022|NCT04737278|OTHER|Placebo|same non-medical ingredients and encapsulation as Intervention 1
214424756|NCT01764815|DEVICE|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
215110023|NCT02737475|DRUG|BMS-986178|Specified dose on specified days
215110024|NCT02737475|DRUG|Nivolumab|Specified dose on specified days
215110025|NCT02737475|DRUG|Ipilimumab|Specified dose on specified days
215110026|NCT02737475|BIOLOGICAL|Tetanus vaccine|Specified dose on specified days
215110027|NCT02737475|BIOLOGICAL|DPV-001 vaccine|DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
215110028|NCT02737475|DRUG|Cyclophosphamide|Specified dose on specified days
215110029|NCT04867551|DRUG|KDT-3594|oral administration, dose titration
215110030|NCT06257875|DRUG|Lutikizumab Matching Placebo|SC Injection
215110031|NCT06257875|DRUG|Lutikizumab Matching Placebo|IV Infusion
214424757|NCT02808338|DEVICE|Philips BiPAP AutoSV Advanced System One|Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
214424758|NCT02808338|DEVICE|Modified Philips BiPAP ASV|This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
214424759|NCT02808338|DEVICE|ResMed S7 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
214424760|NCT02808338|DEVICE|ResMed S9 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
214424761|NCT00903266|BEHAVIORAL|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
214692202|NCT02277899|OTHER|Patient-centered communication|Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
215028404|NCT05559047|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
215110032|NCT06257875|DRUG|Adalimumab Matching Placebo|SC Injection
215110033|NCT06257875|DRUG|Lutikizumab|Subcutaneous (SC) Injection
215110034|NCT06257875|DRUG|Lutikizumab|Intravenous (IV) Infusion
215110035|NCT06257875|DRUG|Adalimumab|SC Injection
215110036|NCT05048316|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
215110037|NCT06244472|DEVICE|Experiment 1: visual and auditory attention task|We will use the FYNA Research system on 20 healthy volunteers with a visual and auditory attention task to evaluate the system's performance in recording brain signals complex frequency content.
215110038|NCT06244472|DEVICE|Experiment 2: language production and rest tasks|We will use the FYNA Research system on 20 healthy healthy volunteers with a language production task to assess the system's functional mapping capabilities and a resting task to assess the system's ability to identify resting networks.
215110039|NCT06244472|DEVICE|Experiment 3: visuo-motor task|We will use the FYNA Research system in 20 healthy volunteers with a visuo-motor task to evaluate the system's performance in recording brain signals when the subject moves, inducing perturbations that affect the classical system (loss of spatial precision) and the FYNA Research system (low-frequency artifacts).
215110040|NCT06244472|DEVICE|Experiment 4: brain activity at rest|We will be using the FYNA Research system on 20 concussed male athletes volunteers to assess the system's ability to detect modulations in the frequency content of resting brain activity.
215110041|NCT02338986|DRUG|Plasma|Plasma
215110042|NCT05147805|DRUG|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
215110043|NCT05147805|DRUG|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
215110044|NCT04227093|DRUG|Acetazolamide|Oral acetazolamide tablets of 250 mg taken twice daily.
214424762|NCT00903266|BEHAVIORAL|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
214424763|NCT00969371|DEVICE|posterior chamber IOL implantation|
214424764|NCT00969371|DEVICE|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
214424765|NCT00057837|BIOLOGICAL|G-CSF|G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery \> 10,000 dL.
214424766|NCT00057837|DRUG|Cisplatin|Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
215110045|NCT04227093|DRUG|Placebo|Matching placebo tablets taken twice daily.
215110046|NCT02741141|OTHER|New partograph based on the studies of Neal and Lowe|"The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol."
215110047|NCT02741141|OTHER|Classical partograph|Classical partograph used as standard care
215110048|NCT06146829|OTHER|no intervention|no intervention
215110049|NCT00410930|BIOLOGICAL|Subcutaneous immunotherapy - Recombinant birch pollen|
215110050|NCT04951752|DRUG|Ropivacaine injection|Transmuscular quadratus lumborum block - active
215110051|NCT00959595|DRUG|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
215110052|NCT00959595|DRUG|EMLA cream|50g applied according to description of intervention
215110053|NCT00546000|DRUG|Fluticasone propionate 0.05% lotion|Daily applications
215110054|NCT05054426|DRUG|Methotrexate|intravenous versus intrathecal methotrexate
215110055|NCT03231852|OTHER|Survey|Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey
215110056|NCT00563459|DRUG|carisbamate|400-1200 mg/day for 12 months
215110057|NCT00563459|DRUG|topiramate|200-400mg/day for 12 months
215110058|NCT00563459|DRUG|levetiracetam|1000-3000mg/day for 12 months
215110059|NCT01212393|BEHAVIORAL|reminders|In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
215110060|NCT00889824|DEVICE|balance prosthesis|vibrotactile stimulation
215110061|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
215110062|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
215110063|NCT00660179|DRUG|placebo|Matching placebo, once daily
215110064|NCT04236752|RADIATION|Stereotactic Ablative Body Radiation (SBRT)|
215110065|NCT05833997|PROCEDURE|Monopolar Transurethral resection of bladder tumor|"Patients randomized to Monopolar TURBT will be operated using a 26F continuous-flow resectoscope sheaths and a single-pole working element to exclusive use of the resection. The power will be set to cut in 80w and 60w. The technique that will be performed will be the classic endoscopic resection from the top of the tumor until reaching the base, taking a sample from the base of the lesion (muscle layer). Fragments will be removed through an Ellik evacuator, and the solution used will be 3% glycine. After the procedure, the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation.~After 30-60 days of the first procedure, all patients diagnosed with a lamina propria invasion in the uro-pathology analysis (T1) will be submitted to a new monopolar TURBT."
215110066|NCT05833997|PROCEDURE|Holmium Laser resection of bladder tumor (HoLEBT)|"It will be used a 24-26F continuous-flow resectoscope sheath with a specific working element to use with a 600µm fiber to Laser Holmium.~Patients will be operated with the Megapulse 70w (Richard Wolf) and laser will be set to deliver the energy of 0,5J and 30-40Hz frequency, 15-20W of final energy. The solution used will be 0,9% saline solution. The resection will start from the base of the lesion, reaching the muscle layer to obtain a sample and resection of the whole tumor, without fragmentation. After this, the morcellation will be performed in the apex of tumor sparing the base with a long nephroscope, and the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation. The morcellated product will be sent to the pathology lab for detailed analysis."
215110067|NCT00002357|DRUG|HBY 097|
215110068|NCT00002357|DRUG|Zidovudine|
215110069|NCT02002741|DRUG|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
215110070|NCT02002741|DRUG|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
215110071|NCT00650403|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fed
215110072|NCT00650403|DRUG|Paxil® 40 mg Tablet|40mg, single dose fed
215110073|NCT01800630|DRUG|Gemcitabine HCl Oral Formulation|
215110074|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
215110075|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
215110076|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
215110077|NCT01504412|DRUG|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
215110078|NCT01504412|DRUG|Pregabalin capsules|Pregabalin oral capsules 150 mg administered twice a day
215110079|NCT04055909|DRUG|nangibotide low dose|nangibotide 0.3 mg/kg/h
215110080|NCT04055909|DRUG|nangibotide high dose|nangibotide 1.0 mg/kg/h
215110081|NCT04055909|DRUG|placebo|matching placebo
215110082|NCT02581735|OTHER|Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
215110083|NCT02312050|DRUG|GCS-100|1 mg, 3 mg, or 9 mg IV push injections
215110084|NCT02312050|DRUG|Placebo|
215110085|NCT03326700|PROCEDURE|Inguinal Hernia Repair|Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
215110086|NCT02832635|DRUG|TMZ|TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy
215110087|NCT02832635|RADIATION|WBRT with avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.
215110088|NCT02832635|RADIATION|WBRT without avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.
215110089|NCT04729075|OTHER|ARDS and COVID19 treatments|Interventions that will be analyzed will include: immunomodulation; oxygen supplementation type, duration and level; mechanical ventilation type, duration; diuresis; inotrope/vasopressors; prone positioning
215110090|NCT00624273|DRUG|Sildenafil therapy|oral use
215110091|NCT05196191|BIOLOGICAL|VIAGENEX Max|Collagenous membrane derived from umbilical cord
215110092|NCT05196191|PROCEDURE|Hibiclens wash|Antiseptic skin cleanser
215110093|NCT01449006|DRUG|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
215110094|NCT04857580|DEVICE|CTS Device|Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
214424767|NCT00057837|DRUG|Etoposide|Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
214424768|NCT00057837|DRUG|Irinotecan|50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
215110095|NCT05104125|DRUG|ASC40 25mg|25mg of ASC40 orally once daily for 12 weeks.
215110096|NCT05104125|DRUG|ASC40 50mg|50mg of ASC40 orally once daily for 12 weeks.
215110097|NCT05104125|DRUG|ASC40 75mg|75mg of ASC40 orally once daily for 12 weeks.
215110098|NCT05104125|DRUG|Placebo|Placebo orally once daily for 12 weeks.
215110099|NCT05322720|BIOLOGICAL|EOC202|EOC202 will be SC injection
215110100|NCT05322720|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel will be Iv injection
215110101|NCT06270914|BEHAVIORAL|Inclusive Positive Behavior Interventions and Supports|The intervention is based on the Norwegian manualized program of SW-PBIS, N-PALS (Positiv Atferd, Støttende Læringsmiljø, og Sammhandling). The Norwegian model shares its core components with the original SW-PBIS model. The program's core components constitute: (a) positive behavior support strategies, including positive expectations and classroom rules, which are followed up with positive feedback and encouragement; (b) a system for monitoring student behavior, (c) school-wide corrections using consequences, (c) instruction in classroom management skills for teachers, and (e) strategies for collaboration with parents. These components are implemented through activities at school level and at classroom level.
215110102|NCT01703507|DRUG|Ipilimumab|Given IV
215110103|NCT01703507|RADIATION|Whole-Brain Radiation Therapy (WBRT)|Undergo WBRT
215110104|NCT01703507|RADIATION|Stereotactic Radiosurgery (SRS)|Undergo SRS
215110105|NCT04138446|OTHER|Altitude exposure in climate chamber|Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
215110106|NCT06444581|BEHAVIORAL|Super Skills Schools|Super Skills Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by Super Skills-trained clinical psychologists. Sessions will take place once a week for twelve weeks, with each session lasting approximately fifty minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face.
215110107|NCT00407472|DEVICE|ATS-1 needle free device|
215110108|NCT02695693|BEHAVIORAL|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
215110109|NCT02695693|BEHAVIORAL|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
215110110|NCT02695693|BEHAVIORAL|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
215110111|NCT02695693|BEHAVIORAL|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
215110112|NCT04656457|DEVICE|Treadmill|Treadmill is not used to harness power, but as exercise machines for running or walking in one place. Rather than the user powering the mill, the machine provides a moving platform with a wide conveyor belt driven by an electric motor or a flywheel. The belt moves to the rear, requiring the user to walk or run at a speed matching that of the belt. The rate at which the belt moves is the rate of walking or running. Thus, the speed of running may be controlled and measured
215110113|NCT04656457|OTHER|resisted exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting)
215110114|NCT03574636|DEVICE|OCT guidance|OCT guide stent implantation
215110115|NCT03574636|DEVICE|IVUS guidance|IVUS guide stent implantation
215110116|NCT03574636|DEVICE|QCA|QCA guide stent implantation
215110117|NCT01112787|DRUG|Tazarotene Foam|Tazarotene Foam
215110118|NCT01112787|DRUG|Vehicle Foam|Vehicle Foam
215110119|NCT01112787|DRUG|Sodium Laural Sulfate|Sodium Laural Sulfate
214424769|NCT00057837|DRUG|Topotecan|Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
214424770|NCT03573284|DIAGNOSTIC_TEST|fractional exhaled nitric oxide(FeNO)|FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
214424771|NCT03573284|DIAGNOSTIC_TEST|impulse oscillometry(IOS)|The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
214424772|NCT01382342|DRUG|Rasagiline|1 mg daily
214424773|NCT01382342|DRUG|Placebo|1 mg daily
215110120|NCT01112787|DRUG|Distilled Water|Distilled Water
215110121|NCT00297323|DRUG|Topiramate|75 patients over the age of 2 years old with epilepsy.
215110122|NCT02664506|BEHAVIORAL|Word repetition after a time delay.|This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
215110123|NCT03733613|OTHER|no intervention|no intervention
215110124|NCT03258086|DIAGNOSTIC_TEST|blood sample test|blood sample will be taken from all diabetic children for assessment of vitamin D level
215110125|NCT00330005|BEHAVIORAL|Group Psychotherapy|
215110126|NCT00002359|BIOLOGICAL|HIV-1 Immunogen|
215110127|NCT00749723|DRUG|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
215110128|NCT00749723|DRUG|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
215110129|NCT00749723|DRUG|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
215110130|NCT00749723|DRUG|thiotepa, carboplatin, etoposide|high dose chemotherapy followed by to autologous stem cell transplantation
215110131|NCT00749723|DRUG|temozolomide, thiotepa|high dose chemotherapy followed by autologous stem cell transplantation
215110132|NCT00749723|PROCEDURE|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
215110133|NCT00749723|DRUG|intraventricular etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (\>3m to \<3y 0.7 mg; \>3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
215110134|NCT00749723|DRUG|trofosfamide, etoposide|maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
215110135|NCT05176236|OTHER|Pictographic tracheostomy care handouts|The handouts were developed and validated by Clinical and inter-professional experts based on the hospital's text-based tracheostomy home care instructions.
215110136|NCT03356678|DRUG|Pralatrexate|"* Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed.~* Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed."
215110137|NCT05260268|BEHAVIORAL|TEST Intervention|The TEST intervention will include standard post-transplant care and include additional touchpoints utilizing the Way to Health system. Details on this intervention are included in the study arm description.
215110138|NCT01385241|BEHAVIORAL|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
215110139|NCT05696886|DRUG|Pethidine|Group A received Pethidine alone in the period between January 2021 and December 2021
215110140|NCT05696886|DRUG|Tramadol with pethidine|Group B got Tramadol with pethidine in the period between January 2022 and December 2022
215110141|NCT00260884|BEHAVIORAL|conventional gastrectomy or radical lymph node dissection|
215110142|NCT00542607|DRUG|levocetirizine dihydrochloride|
215110143|NCT04120961|DRUG|prolonged continuous use of bivalirudin|prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)
215110144|NCT04120961|DRUG|bivalirudin use during ePCI|bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
215110145|NCT00729963|DRUG|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.
215110146|NCT00729963|DEVICE|CPAP|
215110147|NCT05502445|OTHER|educational intervention|"In this group, the steps below are added:on the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance. On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements."
215110148|NCT00891241|DRUG|LMI 1195-101|Single dose, bolus IV injection of LMI 1195
215110149|NCT05059509|BIOLOGICAL|FB825|FB825, 5mg/kg, by 1 hour IV infusion on Day 1
215110150|NCT02177188|DEVICE|LBNP Lower Bodi Negative Pressure Chamber|
215110151|NCT05648292|BEHAVIORAL|Neuropsychological tests and psychological questionnaires|"* The clinical group will complete:~  * the BCcogSEP: a comprehensive neuropsychological examination~ * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression~* The control group will complete:~  * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression"
215110152|NCT01851629|BEHAVIORAL|Locomotor Training|Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.
215110153|NCT01851629|OTHER|Cross-Sectional Testing (No Intervention)|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
215110154|NCT04030572|DRUG|Clonidine Pill|0.1 mg tabs, one by mouth daily at bedtime for one week
215110155|NCT06310421|DIAGNOSTIC_TEST|Screening SMA test|Drops of blood from a puncture from the newborn's heel are collected, dried for 24 hours at room temperature and then sent to the laboratory for analysis. The screening test is a first-level molecular genetic test that allows the identification of patients affected by SMA who present the homozygous deletion of exon 7 of the SMN1 gene using the Real Time polymerase chain reaction (PCR) technique. This qualitative method is based on the use of specific fluorescent probes that discriminate the SMN1 gene from its survival motor neuron 2 (SMN2) homologue and also allow the quality assessment of genomic DNA through amplification of an internal control gene. When a positive testing patient is identified, the birth center is promptly notified to call the family and carry out a further blood sample aimed at confirming the possible diagnosis with a second level test.
215110156|NCT03773237|DIETARY_SUPPLEMENT|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
215110157|NCT03773237|DIETARY_SUPPLEMENT|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
215110158|NCT00317330|DRUG|Isoniazid|
215110159|NCT00317330|DRUG|Pyrazinamide|
215110160|NCT00317330|DRUG|Rifampin|
215110161|NCT04078555|DRUG|ENERGI-F703 GEL|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
215110162|NCT04078555|DRUG|ENERGI-F703 GEL matched vehicle|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
215110163|NCT00287508|DEVICE|Carotid artery stenting with filter (interventional)|
215110164|NCT02016651|BEHAVIORAL|Right side position|Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
215110165|NCT06467903|DEVICE|SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .|second AI medical device to evaluate the retinal image of the patient's eye. two AI as MD will be evaluating the retinal image
215110166|NCT04119180|DRUG|Ketamine 50 MG/ML|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
215110167|NCT04119180|DRUG|Midazolam Hcl 2Mg/Ml Syrup|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine;
214509992|NCT06944821|PROCEDURE|In-situ simulation|Each simulation session takes place over one day, with 4 scenarios recreating life-threatening emergency situations (cardiorespiratory arrest, hemorrhagic shock, etc.). Each scenario is designed to meet specific pedagogical objectives, which will be debriefed by simulation trainers: crisis resource management (communication, alerting, etc.) or organization of multi-professional teamwork
214509993|NCT06944821|OTHER|Role-playing using a simulation scenario|Team performance in critical situations, assessed during a simulation scenario for all participants. The assessment will be carried out blind by 1 examiner, trained in CRM (Crisis Resource Management) analysis in simulation and debriefing.
215110168|NCT04119180|PROCEDURE|Protective stabilization|The legal guardian or accompanying person appointed by the legal guardian should sit in the dental chair with the child and contain leg and arm movements. A dental assistant keeps the child's head contained during care.
215110169|NCT02221674|DRUG|Tapentadol|
215110170|NCT03660761|DRUG|apatinib|The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.
215110171|NCT03660761|DRUG|temodar|dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d
215110172|NCT04014985|OTHER|An extensive biological assessment|To study the morphology of red blood cells, the markers of oxidative stress and the signaling pathway of IFGF1.
215110173|NCT05704790|OTHER|Cognitive Compensatory Training|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
215110174|NCT05227430|OTHER|Educational video tutorials|Educational video tutorials (Hysterectomy, Bilateral salpingo-oophorectomy, Bilateral salpingectomy)
215110175|NCT05292131|DRUG|bimekizumab|Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.
215110176|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|32 mg
215110177|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|48 mg
215110178|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|64 mg
214424774|NCT04393246|DRUG|EDP1815|EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
214424775|NCT04393246|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
214424776|NCT04393246|DRUG|Ambrisentan|Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
214424777|NCT04393246|OTHER|Standard of care|Regular standard of care for COVID-19 patients
214424778|NCT00192491|BIOLOGICAL|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
214692203|NCT03041194|OTHER|dietary affects|Dietary affects on urine pH in relation to Interstitial cystitis symptoms
215110179|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|80mg
215110180|NCT03198494|OTHER|Acoustic 1Hz Stimulation|1Hz acoustic pulses delivered during sleep via headphones
214424779|NCT00192491|BIOLOGICAL|FluMist|Nasal sprayer of FluMist
214424780|NCT00192491|OTHER|Placebo|Nasal Sprayer of Placebo
214424781|NCT02655835|BEHAVIORAL|Internet Mindfulness Meditation|
215110181|NCT03198494|OTHER|Sham Background Noise|Background Noise used as a control
215110182|NCT06555575|DRUG|Ubiquinone 200 Mg Oral Capsule|By mouth three times daily for three months
215110183|NCT06555575|DRUG|Ubiquinol 100 MG Oral Capsule|By mouth three times daily for three months
215110184|NCT06092047|BIOLOGICAL|UTAA09 cells for infusion|Intravenous injection, dosage:1-10×10\^8 CAR+ γδT cells, Cell concentration: 2×10\^7 cells/mL.
215110185|NCT06092047|DRUG|Fludarabine|30 mg/m\^2/day×4 days
215110186|NCT06092047|DRUG|Cyclophosphamide|1000 mg/m\^2/day×3 days
215110187|NCT06506487|BEHAVIORAL|Doll Therapy|Doll therapy involves the use of lifelike dolls to provide comfort and reduce behavioral and psychological symptoms in people with dementia. The therapy includes activities such as holding, dressing, and interacting with the dolls under the guidance of trained caregivers.
215110188|NCT05882214|DIETARY_SUPPLEMENT|β-nicotinamide Mononucleotide|After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.
214692204|NCT00235651|DRUG|Amphotericin B|
214692205|NCT00100412|DRUG|Graded dobutamine infusions|
214692206|NCT00100412|DRUG|Graded phenylephrine injections|
215110189|NCT05882214|DIETARY_SUPPLEMENT|Maltodextrin|After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.
215110190|NCT04438889|OTHER|Non-interventional|Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.
215110191|NCT06170853|OTHER|Exercise with augmented reality glasses|Three days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
215110192|NCT05658484|DRUG|Dimethyl fumarate|Administered as specified in the treatment arm.
215110193|NCT04468919|BEHAVIORAL|BCI-FIT multi-modal access|Adding a personalized multi-modal access protocol to customize a BCI-FIT access method configuration for each individual end user, based on a combination of user characteristics, clinical expertise, user feedback, and system performance data in the software.
215110194|NCT04468919|BEHAVIORAL|BCI-FIT adaptive signal modeling|Adding a BCI-FIT adaptive signal modeling that employs transfer learning and on-line model adaptation techniques with noisy labels in the software of this brain-computer interface to eliminate the need for data collection exclusively for model calibration, as well as to address model drift issues associated with drowsiness, fatigue, and other human and environmental factors.
215110195|NCT04468919|BEHAVIORAL|BCI-FIT active querying|Adding BCI-FIT active querying techniques which are software-based optimal action control policies in the brain-computer interface developed with active and reinforcement learning techniques in order to perform efficient user intent inference to improve the entire speed-accuracy trade-off curve for alternative communication.
215110196|NCT04468919|BEHAVIORAL|BCI-FIT language modeling|Adding vocabulary and location information (called partner and environmental input) to the language models in the brain-computer interface from a user's communication partner.
215110197|NCT06101030|DEVICE|Signal On|InSee monitor patient signals are on.
214424782|NCT02655835|BEHAVIORAL|Access|
214424783|NCT02995096|PROCEDURE|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
214424784|NCT02995096|DRUG|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
214424785|NCT03774459|DRUG|High dose ANAVEX2-73|Active oral capsule
214424786|NCT03774459|DRUG|Mid dose ANAVEX2-73|Active oral capsule
214424787|NCT03774459|DRUG|Placebo oral capsule|Placebo oral capsule
214424788|NCT02337569|DRUG|NPC-02|
215110198|NCT04891809|DRUG|Isatuximab-Irfc 20 MG/ML [Sarclisa]|Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
215110199|NCT04891809|DRUG|Lenalidomide|"Induction: 25mg\*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~\*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) \< 50 mL/min) starting dose is 10 mg"
215110200|NCT04891809|DRUG|Dexamethasone Oral|"Induction:~Patients aged \<75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly"
215110201|NCT05588648|DRUG|Vactosertib|Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.
215110202|NCT04544111|DRUG|Trametinib|"2mg by mouth daily~\*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube"
215110203|NCT04544111|DRUG|Dabrafenib|150 mg twice daily (OR at dose the patient previously tolerated)
215110204|NCT04544111|DRUG|PDR001|400mg IV every 4 weeks
214424789|NCT02337569|DRUG|Placebos|
215110205|NCT06086626|DRUG|Cefiderocol|Administered via intravenous (IV) infusion
215110206|NCT06086626|DRUG|Standard of Care|Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards
215110207|NCT03829449|DRUG|rVA576|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).
215110208|NCT04390880|DRUG|18F-DCFPyL|Study participants will receive intravenous administration of 18F-DCFPyL and undergo a PET/CT imaging study. Patients may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
215110209|NCT02557542|OTHER|One Stop Vein Clinic|Same day diagnosis and treatment
215110210|NCT02557542|DEVICE|Radiofrequency ablation|Venous ablation
215110211|NCT02557542|DEVICE|Endovenous laser ablation|Venous ablation
214424790|NCT00952263|BIOLOGICAL|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
215110212|NCT02557542|DRUG|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
215110213|NCT05880771|OTHER|Immediate Implant Placement|Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.
215110214|NCT05600543|DEVICE|Lumbar belt|"All subjects (LBP group and healthy group) wear the belt during the two visits to perform differents tests.~The invistigator will ask the LBP patients to wear the lumbar belt between the two visits (for 4 weeks, for 4 to 8 hours per day)"
214424791|NCT00588809|DRUG|selumetinib|Given PO
214424792|NCT00106054|DRUG|Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.|
214424793|NCT03146065|BIOLOGICAL|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
214424794|NCT03146065|DRUG|Placebo|Comparison of Placebo to different doses of PF-06730512
214424795|NCT06513806|DRUG|Granisetron 1 Mg/mL Intravenous Solution|will receive granisetron 3 mg iv bolus
214424796|NCT06513806|DRUG|Pethidin|will receive pethidine 25 mg iv bolus
214509994|NCT06944821|OTHER|Questionnaires|Quality of lige questionnaire Pro-QOL, Karasek questionnaire, Satisfaction questionnaire at work : WRQoL, Work Life Balance scale, Mayo Hight Team Performance scale will be completed at baseline and at 6 months
215110215|NCT05600543|DEVICE|Lombaskin lumbar belt and the Lyne Up percko postural T-shirt.|Lombaskin lumbar belt and the Lyne Up percko postural T-shirt could be worn during the third addtional visit proposed to the healthy subject.
215110216|NCT05042076|DRUG|BK-specific T cells from Donor Lymphocytes|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis, enriched for BK-specific CD4+ and CD8+ T cells~Suspension of BK-specific T cells in approximately 7 mL (5-10 mL range for volume of IMP) of 0.9% NaCl with 2.5% HSA at a cell dose of: ≥ 300 and ≤ 5,000 BK virus-specific CD3+ T cells/kg body weight (BW).~IV bolus injection; IV push of IMP over approximately 2-4 minutes, resulting in an infusion rate of approximately 3 mL/min."
215110217|NCT03976882|DRUG|Hetrombopag|Hetrombopag
215110218|NCT03976882|DRUG|Placebo|Placebo
215110219|NCT06641791|RADIATION|Standard Radiotherapy (SRT)|2400 cGy in 3 fractions - day 0/7/21, OR, 2500 cGy in 5 fractions over 1 week
215110220|NCT06641791|RADIATION|Stereotactic Body Radiotherapy (SBRT)|4500 cGy in 5 fractions (twice a week to primary and nodal GTV, OR, 4000 cGy in 5 fractions twice a week if organs at risk.
215110221|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case Group - Tomato-free diet|Nutritional intervention without tomatoes and sauce
215110222|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case group - Diet enriched with tomatoes|Nutritional intervention enriched with tomatoes and souce
215110223|NCT06643403|DRUG|Oxygen 100% Gas for Inhalation|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for max. 45 minutes"
215110224|NCT05141721|DRUG|GRT-C901|A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
215110225|NCT05141721|DRUG|GRT-R902|A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
215110226|NCT05141721|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
215110227|NCT05141721|DRUG|Ipilimumab|Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
215110228|NCT05141721|DRUG|Fluoropyrimidine plus leucovorin|Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
215110229|NCT05141721|DRUG|Bevacizumab|Bevacizumab administered as maintenance therapy per standard of care.
215110230|NCT05196022|OTHER|Cochlear implant|G2 will receive a cochlear implant during the study
215110231|NCT06136897|PROCEDURE|Biopsy Procedure|Undergo biopsy
215110232|NCT06136897|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
215110233|NCT06136897|PROCEDURE|Echocardiography Test|Undergo ECHO
215110234|NCT06136897|BIOLOGICAL|Pertuzumab|Given IV
215110235|NCT06136897|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
214424797|NCT02886858|DEVICE|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
214424798|NCT02886858|DEVICE|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
214424799|NCT03328715|DEVICE|intraoperative OCT|before and after surgery intraoperative OCT is performed
214424800|NCT03328715|DEVICE|stand-alone OCT|before and after surgery stand-alone OCT is performed
214424801|NCT02539212|DEVICE|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
214424802|NCT02539212|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
214424803|NCT05987878|PROCEDURE|single minimal conjunctival incision|A 5-0 PGA traction suture was used near the corneal limbus corresponding to the operated muscle. A 3-4 mm single conjunctival incision posterior and parallel to the insertion in medial, lateral or superior rectus muscle was used. A hang-back recession of the muscle was done using 6-0 PGA suture. The conjunctiva was closed by an 8-0 PGA single stitch with knot burial
214424804|NCT01444235|DRUG|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
214509995|NCT06948604|BEHAVIORAL|Exercise|this exercise used to improve urine complication post TURP
215110236|NCT06136897|BIOLOGICAL|Trastuzumab|Given IV
215110237|NCT05428631|DEVICE|Implantation of the CARDIOMEMS™ HF device|The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
215110238|NCT06532565|DRUG|GS-2121|Tablet administered orally
215110239|NCT06532565|DRUG|Zimberelimab|Administered intravenously
215110240|NCT03705559|DRUG|Vaporized Marijuana|Active Marijuana administered through vaporizer
215110241|NCT03705559|DRUG|Opioid Agonist|Active Opioid Agonist administered intranasally
215110242|NCT03705559|DRUG|Placebo|Experimental, non-therapeutic administration of inactive opioid or marijuana dose(s)
215110243|NCT03559647|DRUG|Atezolizumab|Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
215110244|NCT00583063|DRUG|sunitinib|25 mg daily (oral dosing)
215110245|NCT00583063|DRUG|rapamycin|4 mg daily (oral dosing)
214509996|NCT06951945|DRUG|THDBH120 injection|Participants received THDBH120 by subcutaneous injection.
214509997|NCT06951945|DRUG|Placebo of THDBH120 injection|Participants received placebo by subcutaneous injection.
215110246|NCT04384029|OTHER|Covid-19 + patients|all the patients hospitalized in Geneva and SARS-Cov2 positive
215110247|NCT04027751|DRUG|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia induction
215110248|NCT04027751|DRUG|Placebos|Investigators administrated intravenously 0.9% saline solution as a placebo
215110249|NCT04891523|DIETARY_SUPPLEMENT|Probiotics-O (Burgerstein)|Topical oral treatment with the probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein) in form of a lozenge, daily, during 3 weeks.
215110250|NCT04891523|OTHER|Placebo [inactivated Probiotics-O (Burgerstein)]|Topical oral treatment with the placebo \[inactivated probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein)\] in form of a lozenge, daily, during 3 weeks.
215110251|NCT03357016|OTHER|Training programs|High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)
215110252|NCT01077401|DRUG|Ranibizumab|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
215110253|NCT01077401|DRUG|ranibizumab|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
215110254|NCT05727813|DEVICE|cryoablation|cryoablation of breast cancer smaller than 2 cm
215110255|NCT01581398|DRUG|Ypeginterferon alfa-2b|sc, qw, 24 weeks.
215110256|NCT01581398|DRUG|Pegasys|sc, qw, 24 weeks.
215110257|NCT01581398|DRUG|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
215110258|NCT01581398|DRUG|Pegasys|sc, qw, 48 weeks.
215110259|NCT04930900|DRUG|ARS-1 with URTI|ARS-1
215110260|NCT04930900|DRUG|ARS-1 without URTI|ARS-1 without URTI
215110261|NCT06206161|BEHAVIORAL|Indicated Prevention, Clinical Staff|Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
215110262|NCT06206161|BEHAVIORAL|Selective Prevention|Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use).
215110263|NCT06206161|BEHAVIORAL|Expanded Paraprofessional Workforce|Brief interventions delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
215110264|NCT03109639|DEVICE|Conventional EUS FNA needle|Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.
215110265|NCT03109639|DEVICE|Acquire FNB device|Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle
215110266|NCT00180765|PROCEDURE|Up to 100ml blood will be taken by venupuncture.|
215110267|NCT02399774|DEVICE|Leboride|"1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
215110268|NCT00034086|DRUG|Lopinavir/Ritonavir|
215110269|NCT00034086|DRUG|Lamivudine/Zidovudine|
215110270|NCT00034086|DRUG|Tenofovir disoproxil fumarate|
214509998|NCT06952231|DRUG|Sitagliptin + Metformin|Self administration of Sitagliptin (as phosphate monohydrate) 50 mg twice daily plus metformin HCl 1000 mg twice daily
214509999|NCT06952231|DRUG|Empagliflozin + Metformin|Self administration of Empagliflozin 12.5 mg twice daily plus metformin HCl 1000 mg twice daily.
214510000|NCT05447286|DRUG|NYX-783|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
214510001|NCT05447286|DRUG|Placebo|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
214692207|NCT00100412|BEHAVIORAL|Psychosocial challenge involving socioevaluative public speaking|
214692208|NCT01113021|DEVICE|Photon stimulation by low level laser therapy|
214692209|NCT03217578|OTHER|SMA Newborn Screening|
215110271|NCT00034086|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
215110272|NCT00034086|DRUG|Lamivudine|
215110273|NCT00034086|DRUG|Stavudine|
215110274|NCT00034086|DRUG|Zidovudine|
215110275|NCT00034086|DRUG|Didanosine|
215110276|NCT00034086|BIOLOGICAL|Lyme Disease Vaccine Recombinant OspA|
215110277|NCT00034086|BIOLOGICAL|Haemophilus B Conjugate Vaccine|
215110278|NCT05206760|PROCEDURE|Brain biopsy|Biopsy of brain tissue
215110279|NCT02134444|BEHAVIORAL|Experimental group|Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.
214424805|NCT01444235|DRUG|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
214510002|NCT05447286|DRUG|Oxycodone|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
215110280|NCT02134444|BEHAVIORAL|Control group|Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
215110281|NCT06241105|DRUG|Lenvatinib+Toripalimab.|Adjustment of Medication Dosage: Throughout the course of treatment, adjustments should be made exclusively to the dosage of the drug Lenvatinib.The starting dosage for lenvatinib is 8 mg, administered orally once a day for a period of four weeks. If no adverse reactions are observed, the dosage can be escalated to 12 mg for individuals weighing over 60 kg. However, if the patient experiences intolerable side effects, the dosage should be decreased back to 8 mg.For individuals weighing less than 60 kg, the maximum dosage is 8 mg per day. Should adverse reactions become intolerable, the dosage may be decreased to 4 mg per day.Withdrawal from the study if still intolerable.
215110282|NCT01979952|DRUG|Matching Placebo|twice daily dosing
215110283|NCT01979952|DRUG|Nintedanib|gelating capsule
215110284|NCT03661333|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
215110285|NCT05421481|OTHER|home visit, health education, mobile application, group walk, message|"Home visit: Elderly individuals will be visited once at home. During the home visit, training will be given on the slide about physical activity. A brochure will be provided for general health promotion awareness. Counseling will also be provided during the home visit process.~Google Fit Application: During the home visit, the application will be downloaded to the phone of the elderly, and a document will be given about the use of the application after the usage is explained. The researcher will support those who have problems with the application in the following weeks.~Group walking: The walk, which will be done once, will be done in a light paced manner, and the purpose of the walk is to see the number of steps in the mobile application and to increase their motivation with the group.~Message: Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be."
215110286|NCT05851820|OTHER|comparison of outcomes/exposure|analysing if diabetes mellitus have an impact on the primary outcomes: hospital stay, admission to the ICU, death.
215110287|NCT04379206|DIAGNOSTIC_TEST|HIV self-test kit|fingerprick and oral fluid HIV self-tests with optional on-site or hotline staff assistance
215110288|NCT04379206|OTHER|Graphical User Interface|Gamification or neumorphism user interface
214424806|NCT04034745|DRUG|telotristat ethyl|250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
214424807|NCT01435395|DRUG|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
214510003|NCT04742894|BEHAVIORAL|Visual Feedback Training|Participants will be trained to work with a computer setup to control the position of a visual cursor on the screen using their speech while their auditory feedback is altered. The goal of the training is to help improve speech production and motor control ability.
214424808|NCT02129049|OTHER|educational intervention|Participate in the Enhancing Connections Telephone Program
214424809|NCT02129049|BEHAVIORAL|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
214424810|NCT02129049|OTHER|questionnaire administration|Ancillary studies
214424811|NCT03408925|OTHER|Exercise program|The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
214510004|NCT00682318|DRUG|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
215110289|NCT04489199|OTHER|Questionnaire and semi-structured interview|questionnaire submitted by telephone 3 months, 6 months, 1 year, 5 years, and 10 years after the stroke/TIA. interview duration 20 to 40 minutes
215110290|NCT06149871|BEHAVIORAL|Physical activity|resistance, aerobic, and flexibility exercises
215110291|NCT05375448|OTHER|Neural mobilisation|"Participants will perform an active femoral nerve mobilisation technique. The treatment will be performed at home.~Patients will receive a video model to perform the exercise during the 8 weeks of treatment. The treatment should be performed 10 repetitions twice a day, with one set recommended in the morning and one in the evening.~The treatment will be monitored by telephone and if there are any doubts, the session will be carried out together with the patient."
215110292|NCT03560089|DEVICE|Serious game|Serious game with movements
215110293|NCT03560089|DEVICE|Placebo serious game|Serious game without movement
215110294|NCT06490133|DIETARY_SUPPLEMENT|Polyhpenol extract|Three capsules in fasting conditions 15 minutes prior breakfast
215110295|NCT06490133|DIETARY_SUPPLEMENT|Placebo|Three capsules in fasting conditions 15 minutes before breakfast
215110296|NCT05254431|BEHAVIORAL|Exercise|"Novel Moderate Intensity Interval Exercise~The Experimental Design is a randomized trial of moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls"
215110297|NCT05462574|OTHER|No Intervention|No Intervention
215110298|NCT04517344|OTHER|Initial Flow Rate|Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
215110299|NCT05438576|OTHER|Digital stethoscope electrocardiogram|Digital stethoscope artificial intelligence enabled electrocardiogram (AI-ECG). An artificial intelligence algorithm which analyses ECG data and generates prediction probabilities for a diagnosis of cardiomyopathy.
215110300|NCT01028846|DRUG|Diazoxide|4 mg/kg body weight total dosage administered orally
215110301|NCT01028846|DRUG|Placebo|Oral saline
214424812|NCT03264235|DEVICE|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.~Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
214424813|NCT03264235|OTHER|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
214424814|NCT05520086|DRUG|Single Dose|Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
215110302|NCT00391612|DEVICE|Exhale® Drug-Eluting Stent|Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
215110303|NCT00391612|DEVICE|Sham control|5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
215110304|NCT03466736|DIAGNOSTIC_TEST|[18F]flutemetamol PET scan|Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
215110305|NCT06583330|DRUG|Low Molecular Weight Heparin (dalteparin)|All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.
215110306|NCT06583902|DRUG|Intravenous iron|Patients with an absolute deficiency (ferritin ≤100 μg/L) or functional deficiency (ferritin ≤ 300 μg/L with transferrin saturation ≤20%) receive iron supplementation, through a single administration of an iron preparation for intravenous use administered according to the doses present in the technical data sheet.
215110307|NCT06583902|OTHER|Retrospective case-control analysis|the only routine clinical data collection (Hb, iron status, direct and indirect Coombs test, IL6, erythropoietin dosage, number of units of blood components possibly transfused)
215110308|NCT06583889|DRUG|Heparin|The patients randomized to standard medical care will receive (or continue) either any type of body-weight adjusted low molecular weight heparin in therapeutic dose, or intravenous adjusted dose unfractionated heparin (aPTT value kept within 1 time the normal value), according to the existing international guidelines.
215110309|NCT06583889|PROCEDURE|Endovascular treatment|Standard endovascular techniques to mechanically remove clot material, such as mechanical thrombectomy and/or balloon angioplasty and/or local application of alteplase or urokinase within the thrombosed sinuses.
215110310|NCT04281381|DIAGNOSTIC_TEST|Cross-sectional imaging|MRI with gadolinium contrast will be the imaging modality of choice. In patients with contraindications to MRI who instead undergo baseline evaluation by CT scan, tumor evaluation will be by serial CT scans with IV contrast throughout the study period.
215110311|NCT00544336|OTHER|questionnaire administration|no intervention
215110312|NCT00544336|OTHER|survey administration|no intervention
215110313|NCT00544336|PROCEDURE|quality-of-life assessment|no intervention
215110314|NCT01966835|BEHAVIORAL|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
215110315|NCT05971927|BEHAVIORAL|Simulation education|Randomly assigned experimental group students performed eight different vaginal examination scenarios in the laboratory on the fetal monitoring and labor progress model set for cervical dilatation, cervical effacement, presenting fetal part, presence of amniotic membrane and fetal descent. The researchers repeated the vaginal examination scenario and informed the students about the evaluation results after each student had performed the vaginal examination scenario prepared by the researchers. This process continued until the experimental group students completed eight different vaginal examination scenarios.
215110316|NCT01407666|PROCEDURE|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
215110317|NCT01511068|DRUG|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
215110318|NCT04278976|OTHER|Implementation of CoBaTrICE|"The implemention of CoBaTrICE will include the three following essential elements:~1. Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~2. Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~3. The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process."
215110319|NCT03616509|DRUG|Growth hormone|12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
215110320|NCT03616509|DRUG|Placebo|2 months on placebo, sodium chloride 0,9% injections
215110321|NCT00465088|DRUG|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
215110322|NCT00465088|DRUG|atorvastatin|40 mg at bedtime
215110323|NCT04035239|DEVICE|BGS goggles|BGS goggles use for 3-6 weeks
215110324|NCT06512168|BEHAVIORAL|AAC Generative Language Intervention|Aided AAC Language Input/Output Intervention
215110325|NCT02716623|OTHER|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories tha